Cancer_type	QTL_type	tag_SNP	LD	SNP	SNP_position	Alleles	Methylation_probe	Methylation_position	Probe_related_gene	Beta	t-stat	Correlation_coefficient (r)	p-value	Traits
LUAD	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg27539214	chr16:67997921	SLC12A4	-0.51	-6.92	-0.32	1.66e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.7	0.35	9.62e-14	Breast cancer;
LUAD	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg18252515	chr7:66147081	NA	-0.62	-6.89	-0.32	2.03e-11	Diabetic kidney disease;
LUAD	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg24399712	chr22:39784796	NA	-0.76	-13.11	-0.54	3.44e-33	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg08470875	chr2:26401718	FAM59B	0.76	9.57	0.42	8.89e-20	Gut microbiome composition (summer);
LUAD	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.5	-0.38	3.38e-16	Height;
LUAD	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg21138405	chr5:131827807	IRF1	0.6	13.89	0.56	2.17e-36	Asthma (sex interaction);
LUAD	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg25894440	chr7:65020034	NA	-0.64	-6.89	-0.32	2.03e-11	Diabetic kidney disease;
LUAD	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11644478	chr21:40555479	PSMG1	-0.42	-6.99	-0.32	1.05e-11	Menarche (age at onset);
LUAD	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg02158880	chr13:53174818	NA	0.55	9.59	0.42	7.52e-20	Lewy body disease;
LUAD	cis	rs897984	0.609	rs732172	chr16:31050033	C/T	cg02466173	chr16:30829666	NA	-0.55	-9.65	-0.42	4.9e-20	Dementia with Lewy bodies;
LUAD	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg11062466	chr8:58055876	NA	0.51	7.09	0.33	5.72e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg05991184	chr2:219186017	PNKD	0.37	7.14	0.33	4.16e-12	Colorectal cancer;
LUAD	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg08847533	chr14:75593920	NEK9	-0.38	-6.48	-0.3	2.54e-10	Height;
LUAD	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg27454412	chr7:1067447	C7orf50	-0.43	-8.04	-0.36	9.4e-15	Bronchopulmonary dysplasia;
LUAD	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg14092571	chr14:90743983	NA	-0.52	-9.25	-0.41	1.11e-18	Mortality in heart failure;
LUAD	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg17177755	chr1:15930204	NA	-0.44	-7.27	-0.33	1.76e-12	Systolic blood pressure;
LUAD	trans	rs4650994	1.000	rs4077194	chr1:178533832	A/C	cg05059571	chr16:84539110	KIAA1609	0.57	10.3	0.45	2.33e-22	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg05110241	chr16:68378359	PRMT7	-0.95	-10.91	-0.47	1.33e-24	Schizophrenia;
LUAD	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg15208524	chr1:10270712	KIF1B	-0.41	-6.47	-0.3	2.64e-10	Hepatocellular carcinoma;
LUAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg22535103	chr8:58192502	C8orf71	-0.59	-7.04	-0.32	7.87e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9807989	0.507	rs3755266	chr2:103042712	G/A	cg03938978	chr2:103052716	IL18RAP	0.46	10.49	0.45	4.89e-23	Asthma;
LUAD	cis	rs3784262	0.692	rs12907125	chr15:58282621	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.51	-0.34	3.63e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12859382	chr3:52445103	PHF7;BAP1	-0.43	-6.52	-0.3	1.99e-10	Height;
LUAD	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.21e-16	Prostate cancer;
LUAD	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg04944784	chr2:26401820	FAM59B	-0.92	-13.66	-0.55	1.82e-35	Gut microbiome composition (summer);
LUAD	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg14092988	chr3:52407081	DNAH1	0.45	8.87	0.4	2.1e-17	Bipolar disorder;
LUAD	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg05342682	chr7:94953680	PON1	-0.5	-7.06	-0.32	6.81e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg09035930	chr12:129282057	SLC15A4	0.72	16.65	0.63	3.1e-48	Systemic lupus erythematosus;
LUAD	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg09835421	chr16:68378352	PRMT7	-0.77	-8.22	-0.37	2.54e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1451375	0.617	rs10271341	chr7:50591583	A/C	cg18232548	chr7:50535776	DDC	0.62	8.51	0.38	3.06e-16	Malaria;
LUAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.57	-9.22	-0.41	1.37e-18	Longevity;Endometriosis;
LUAD	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg07636037	chr3:49044803	WDR6	0.64	12.38	0.52	2.98e-30	Parkinson's disease;
LUAD	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg08999081	chr20:33150536	PIGU	0.47	9.19	0.41	1.77e-18	Coronary artery disease;
LUAD	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg14668632	chr7:2872130	GNA12	-0.7	-12.33	-0.51	4.79e-30	Height;
LUAD	trans	rs11088226	0.681	rs1015047	chr21:33949423	A/G	cg09050820	chr6:167586206	TCP10L2	0.92	14.11	0.57	2.6e-37	Gastritis;
LUAD	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg18016565	chr1:150552671	MCL1	0.47	8.37	0.38	8.25e-16	Urate levels;
LUAD	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg27144592	chr16:783916	NARFL	0.36	6.63	0.31	1.01e-10	Height;
LUAD	trans	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg21659725	chr3:3221576	CRBN	-0.59	-9.5	-0.42	1.61e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg19773385	chr1:10388646	KIF1B	-0.44	-7.31	-0.34	1.32e-12	Hepatocellular carcinoma;
LUAD	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg09137382	chr11:130731461	NA	0.42	7.61	0.35	1.8e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3806843	0.608	rs246042	chr5:140330967	G/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg23887609	chr12:130822674	PIWIL1	0.41	6.89	0.32	2.07e-11	Menopause (age at onset);
LUAD	cis	rs2041840	0.538	rs7600995	chr2:37575026	C/G	cg25727520	chr2:37576821	QPCT	-0.33	-7.27	-0.33	1.8e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg06636001	chr8:8085503	FLJ10661	0.44	7.08	0.33	5.99e-12	Mood instability;
LUAD	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg02527881	chr3:46936655	PTH1R	-0.44	-8.42	-0.38	5.72e-16	Colorectal cancer;
LUAD	cis	rs6714710	0.603	rs58546246	chr2:98521823	C/A	cg26665480	chr2:98280029	ACTR1B	0.5	8.17	0.37	3.6e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs12208915	0.848	rs2321896	chr6:79509744	G/C	cg05283184	chr6:79620031	NA	0.49	6.41	0.3	3.95e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg00277334	chr10:82204260	NA	-0.58	-9.63	-0.42	5.43e-20	Post bronchodilator FEV1;
LUAD	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg15181151	chr6:150070149	PCMT1	0.38	7.68	0.35	1.12e-13	Lung cancer;
LUAD	cis	rs7714584	1.000	rs12656538	chr5:150251380	A/G	cg22134413	chr5:150180641	NA	0.62	6.72	0.31	5.73e-11	Crohn's disease;
LUAD	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg13546538	chr9:111754815	CTNNAL1	-0.46	-6.39	-0.3	4.38e-10	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs71478720	0.953	rs5744256	chr11:112022848	A/G	cg09122223	chr11:112035175	IL18	0.42	6.51	0.3	2.17e-10	Interleukin-18 levels;
LUAD	cis	rs2629540	0.847	rs12762597	chr10:126387043	G/A	cg08799069	chr10:126477246	METTL10	0.46	6.82	0.31	3.18e-11	Cocaine dependence;
LUAD	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg16479474	chr6:28041457	NA	0.46	7.65	0.35	1.41e-13	Depression;
LUAD	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg07636037	chr3:49044803	WDR6	0.64	12.27	0.51	7.9e-30	Parkinson's disease;
LUAD	cis	rs3733418	0.929	rs1401401	chr4:165927956	G/A	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.49	-6.42	-0.3	3.72e-10	Obesity-related traits;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26964202	chr12:63328896	PPM1H	-0.65	-6.59	-0.31	1.28e-10	Type 2 diabetes;
LUAD	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg24818145	chr4:99064322	C4orf37	0.41	6.7	0.31	6.73e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg26384229	chr12:38710491	ALG10B	0.42	7.13	0.33	4.28e-12	Heart rate;
LUAD	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg03929089	chr4:120376271	NA	0.68	9.84	0.43	1.02e-20	Coronary artery disease;
LUAD	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.23	-0.37	2.32e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg18335740	chr13:41363409	SLC25A15	0.48	8.46	0.38	4.26e-16	Lewy body disease;
LUAD	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.09	0.37	6.38e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	trans	rs9393777	0.920	rs13212562	chr6:27300310	A/G	cg06606381	chr12:133084897	FBRSL1	-0.64	-6.58	-0.3	1.4e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg27532560	chr4:187881888	NA	0.38	7.28	0.33	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg15117754	chr3:10150083	C3orf24	0.44	7.1	0.33	5.43e-12	Alzheimer's disease;
LUAD	cis	rs733175	0.855	rs10016075	chr4:10006663	G/T	cg02734326	chr4:10020555	SLC2A9	0.44	6.37	0.3	5.02e-10	Psychosis and Alzheimer's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00878827	chr14:75229987	YLPM1	-0.56	-6.91	-0.32	1.78e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg17063962	chr7:91808500	NA	-0.65	-11.48	-0.49	9.87e-27	Breast cancer;
LUAD	cis	rs9902453	0.934	rs7211246	chr17:28485762	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.65	0.39	1.05e-16	Coffee consumption (cups per day);
LUAD	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg12310025	chr6:25882481	NA	-0.49	-7.21	-0.33	2.55e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg14227996	chr4:17616232	MED28	0.71	7.37	0.34	9.19e-13	Opioid sensitivity;
LUAD	cis	rs13064411	0.696	rs6799610	chr3:113248748	A/C	cg18753928	chr3:113234510	CCDC52	0.73	12.09	0.51	4.34e-29	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg05044414	chr3:183734942	ABCC5	0.48	10.08	0.44	1.45e-21	Anterior chamber depth;
LUAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14893161	chr1:205819251	PM20D1	0.8	16.5	0.63	1.38e-47	Menarche (age at onset);
LUAD	cis	rs62400317	0.859	rs12201899	chr6:45298204	C/A	cg20913747	chr6:44695427	NA	-0.43	-6.98	-0.32	1.13e-11	Total body bone mineral density;
LUAD	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg19717773	chr7:2847554	GNA12	-0.53	-10.5	-0.45	4.38e-23	Height;
LUAD	cis	rs9462027	0.651	rs2395599	chr6:34641415	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-8.58	-0.38	1.86e-16	Systemic lupus erythematosus;
LUAD	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.43	0.42	2.64e-19	Tonsillectomy;
LUAD	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg23625390	chr15:77176239	SCAPER	-0.53	-8.49	-0.38	3.6e-16	Blood metabolite levels;
LUAD	cis	rs1595825	1.000	rs1304164	chr2:198877234	C/A	cg00982548	chr2:198649783	BOLL	-0.6	-8.68	-0.39	8.65e-17	Ulcerative colitis;
LUAD	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19524238	chr7:2802976	GNA12	-0.31	-6.4	-0.3	4.04e-10	Height;
LUAD	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg22535103	chr8:58192502	C8orf71	-0.61	-6.65	-0.31	9.1e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7173743	0.756	rs8032842	chr15:79125849	G/A	cg15571903	chr15:79123663	NA	0.44	8.78	0.39	4.16e-17	Coronary artery disease;
LUAD	trans	rs587242	0.956	rs602272	chr1:96893914	G/A	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs4072705	0.934	rs4838194	chr9:127342815	T/C	cg13476313	chr9:127244764	NR5A1	0.3	7.39	0.34	7.96e-13	Menarche (age at onset);
LUAD	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.58	-0.35	2.18e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs9929218	0.954	rs35444713	chr16:68824492	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-13.3	-0.54	5.99e-34	Colorectal cancer;
LUAD	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg03467027	chr4:99064603	C4orf37	0.41	6.62	0.31	1.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg26513180	chr16:89883248	FANCA	0.78	6.73	0.31	5.65e-11	Skin colour saturation;
LUAD	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg16049864	chr8:95962084	TP53INP1	0.53	10.47	0.45	5.69e-23	Type 2 diabetes;
LUAD	cis	rs7705042	0.865	rs7733850	chr5:141515564	C/T	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.67	-0.31	8.02e-11	Asthma;
LUAD	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg26850624	chr5:429559	AHRR	-0.42	-6.65	-0.31	9.24e-11	Cystic fibrosis severity;
LUAD	cis	rs12900413	0.603	rs4448912	chr15:90299690	G/A	cg24249390	chr15:90295951	MESP1	-0.35	-6.92	-0.32	1.64e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs6062509	0.965	rs2315008	chr20:62343956	T/G	cg21849932	chr20:62369462	LIME1	-0.46	-7.44	-0.34	5.61e-13	Prostate cancer;
LUAD	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg06387496	chr7:2775674	GNA12	-0.4	-6.61	-0.31	1.15e-10	Height;
LUAD	cis	rs6005807	0.843	rs7291268	chr22:28897619	T/C	cg12565055	chr22:29076175	TTC28	0.67	6.52	0.3	1.99e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs9341808	0.718	rs9352801	chr6:80817468	G/T	cg08355045	chr6:80787529	NA	0.56	10.05	0.44	1.88e-21	Sitting height ratio;
LUAD	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22857025	chr5:266934	NA	-0.96	-14.39	-0.57	1.64e-38	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11475922	chr19:12251131	ZNF20	-0.42	-6.69	-0.31	7.07e-11	Height;
LUAD	cis	rs4786125	0.596	rs12149100	chr16:6922512	T/G	cg03623568	chr16:6915990	A2BP1	-0.48	-10.35	-0.45	1.57e-22	Heart rate variability traits (SDNN);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg11342277	chr1:116915598	ATP1A1	-0.68	-6.57	-0.3	1.48e-10	Type 2 diabetes;
LUAD	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg17689763	chr4:710664	PCGF3	-0.58	-9.9	-0.43	6.64e-21	White blood cell count;
LUAD	cis	rs3007168	1.000	rs3007079	chr14:51613517	A/G	cg23942311	chr14:51606299	NA	0.55	7.55	0.34	2.61e-13	Cancer;
LUAD	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg01884057	chr2:25150051	NA	0.35	7.41	0.34	6.86e-13	Body mass index;
LUAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.31	-7.13	-0.33	4.27e-12	Lymphocyte counts;
LUAD	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg22705602	chr4:152727874	NA	-0.41	-7.16	-0.33	3.5e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg07362569	chr17:61921086	SMARCD2	0.37	6.38	0.3	4.52e-10	Prudent dietary pattern;
LUAD	trans	rs1941687	0.765	rs11877423	chr18:31390368	G/A	cg27147174	chr7:100797783	AP1S1	-0.5	-8.24	-0.37	2.22e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg10356904	chr22:49881777	NA	-0.41	-8.06	-0.36	8e-15	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg07741184	chr6:167504864	NA	0.39	9.01	0.4	7.39e-18	Primary biliary cholangitis;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg07719772	chr16:32360419	NA	-0.5	-7.88	-0.36	2.71e-14	Menopause (age at onset);
LUAD	cis	rs7291412	0.601	rs7292407	chr22:46453712	A/C	cg05468064	chr22:46423449	NA	-0.34	-7.31	-0.34	1.3e-12	Dupuytren's disease;Subjective well-being;
LUAD	cis	rs9807989	0.507	rs4851571	chr2:103019000	C/T	cg03938978	chr2:103052716	IL18RAP	0.45	10.29	0.45	2.54e-22	Asthma;
LUAD	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg24069376	chr3:38537580	EXOG	0.45	10.92	0.47	1.27e-24	Electrocardiographic conduction measures;
LUAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg13560548	chr3:10150139	C3orf24	-0.43	-6.36	-0.3	5.14e-10	Alzheimer's disease;
LUAD	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg12016809	chr21:47604291	C21orf56	0.45	7.51	0.34	3.64e-13	Testicular germ cell tumor;
LUAD	trans	rs7395662	0.713	rs11512404	chr11:48936171	T/G	cg00717180	chr2:96193071	NA	-0.4	-7.56	-0.35	2.46e-13	HDL cholesterol;
LUAD	cis	rs2070488	0.730	rs2268759	chr3:38514327	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	9.56	0.42	9.88e-20	Electrocardiographic conduction measures;
LUAD	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	14.84	0.59	2.1e-40	Smoking behavior;
LUAD	trans	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg21659725	chr3:3221576	CRBN	0.38	6.38	0.3	4.52e-10	Resting heart rate;
LUAD	cis	rs6594713	0.800	rs67320720	chr5:112761449	A/C	cg12552261	chr5:112820674	MCC	0.48	6.9	0.32	1.85e-11	Brain cytoarchitecture;
LUAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.85e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg11822812	chr5:140052017	DND1	-0.41	-7.63	-0.35	1.5700000000000001e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4409675	0.576	rs6598912	chr1:28233289	C/T	cg23691781	chr1:28212827	C1orf38	0.37	10.69	0.46	9.31e-24	Corneal astigmatism;
LUAD	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg03859395	chr2:55845619	SMEK2	0.76	14.23	0.57	7.64e-38	Metabolic syndrome;
LUAD	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg04800585	chr6:26043546	HIST1H2BB	0.43	7.02	0.32	8.87e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9341808	0.683	rs7771449	chr6:80919977	C/T	cg08355045	chr6:80787529	NA	0.58	10.54	0.46	3.25e-23	Sitting height ratio;
LUAD	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg19635926	chr16:89946313	TCF25	0.79	6.76	0.31	4.67e-11	Skin colour saturation;
LUAD	cis	rs6761276	0.635	rs4849150	chr2:113830582	A/C	cg09040174	chr2:113837401	NA	0.54	8.19	0.37	3.18e-15	Protein quantitative trait loci;
LUAD	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15541040	chr2:3486749	NA	-0.4	-6.8	-0.31	3.65e-11	Neurofibrillary tangles;
LUAD	cis	rs2274471	0.645	rs2031907	chr9:5087596	G/A	cg03390472	chr9:5043263	JAK2	-0.58	-7.88	-0.36	2.87e-14	Crohn's disease;
LUAD	cis	rs72928364	0.858	rs34645172	chr3:100709735	T/C	cg10123952	chr3:100791384	NA	0.63	7.14	0.33	4.09e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs28655083	1.000	rs11863397	chr16:77060388	T/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.4	-6.68	-0.31	7.64e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg16647868	chr5:131706066	SLC22A5	0.38	6.62	0.31	1.09e-10	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg15128208	chr22:42549153	NA	-0.37	-7.51	-0.34	3.5e-13	Cognitive function;
LUAD	cis	rs600626	0.947	rs1219549	chr11:75454622	T/C	cg24262691	chr11:75473276	NA	0.44	7.17	0.33	3.38e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg15556689	chr8:8085844	FLJ10661	0.42	6.71	0.31	6.4e-11	Mood instability;
LUAD	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.78	-13.53	-0.55	6.82e-35	Chronic sinus infection;
LUAD	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg26384229	chr12:38710491	ALG10B	0.45	7.36	0.34	9.9e-13	Bladder cancer;
LUAD	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg15704280	chr7:45808275	SEPT13	-0.78	-11.21	-0.48	1.07e-25	Coronary artery disease;
LUAD	cis	rs9341808	0.718	rs2179842	chr6:80979053	T/C	cg08355045	chr6:80787529	NA	0.55	9.9	0.43	6.21e-21	Sitting height ratio;
LUAD	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg05082376	chr22:42548792	NA	-0.39	-6.77	-0.31	4.25e-11	Cognitive function;
LUAD	cis	rs11948739	0.501	rs4254896	chr5:130363499	C/T	cg08523029	chr5:130500466	HINT1	-0.6	-7.68	-0.35	1.09e-13	Pediatric bone mineral content (hip);
LUAD	cis	rs68170813	0.652	rs7784906	chr7:107148386	C/T	cg23024343	chr7:107201750	COG5	0.53	6.68	0.31	7.35e-11	Coronary artery disease;
LUAD	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg24768116	chr2:27665128	KRTCAP3	0.25	6.37	0.3	4.85e-10	Oral cavity cancer;
LUAD	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg08761264	chr16:28874980	SH2B1	-0.44	-6.77	-0.31	4.36e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs68170813	0.617	rs117884147	chr7:107177593	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-9.09	-0.4	3.86e-18	Coronary artery disease;
LUAD	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg15448220	chr1:150897856	SETDB1	0.49	8.5	0.38	3.35e-16	Melanoma;
LUAD	cis	rs9323205	0.677	rs8014210	chr14:51709802	T/C	cg23942311	chr14:51606299	NA	-0.6	-8.99	-0.4	8.63e-18	Cancer;
LUAD	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.95	0.32	1.37e-11	Parkinson's disease;
LUAD	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg05590025	chr7:65112418	INTS4L2	-0.76	-7.97	-0.36	1.5e-14	Diabetic kidney disease;
LUAD	cis	rs6754311	0.689	rs192822	chr2:136682274	A/T	cg25344623	chr2:136566232	LCT	-0.33	-6.46	-0.3	2.92e-10	Mosquito bite size;
LUAD	cis	rs7786808	0.552	rs4909207	chr7:158187136	G/A	cg09998033	chr7:158218633	PTPRN2	-0.42	-7.37	-0.34	9.32e-13	Obesity-related traits;
LUAD	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg23758822	chr17:41437982	NA	1.0	20.92	0.71	3.2e-67	Menopause (age at onset);
LUAD	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-8.68	-0.39	8.75e-17	Gut microbiome composition (summer);
LUAD	cis	rs752010	0.806	rs4457567	chr1:42091407	C/T	cg06885757	chr1:42089581	HIVEP3	0.48	10.86	0.47	2.11e-24	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg04450456	chr4:17643702	FAM184B	0.43	8.5	0.38	3.4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7937890	0.869	rs2915404	chr11:14404825	A/G	cg02251663	chr11:14281053	SPON1	-0.35	-6.66	-0.31	8.43e-11	Mitochondrial DNA levels;
LUAD	cis	rs28595532	1.000	rs115965820	chr4:119586485	G/A	cg14228332	chr4:119757509	SEC24D	0.76	7.05	0.32	7.55e-12	Cannabis dependence symptom count;
LUAD	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg00933542	chr6:150070202	PCMT1	-0.4	-7.99	-0.36	1.27e-14	Lung cancer;
LUAD	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-9.25	-0.41	1.08e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2445762	0.659	rs55810637	chr15:51664903	G/A	cg20344442	chr15:51633704	GLDN	0.39	7.0	0.32	1.02e-11	Hormone measurements;
LUAD	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg14196790	chr5:131705035	SLC22A5	0.49	8.6	0.39	1.56e-16	Breast cancer;Mosquito bite size;
LUAD	cis	rs4948275	0.530	rs10994747	chr10:63149922	A/G	cg03237606	chr10:63212265	TMEM26	-0.33	-6.66	-0.31	8.4e-11	Night sleep phenotypes;
LUAD	cis	rs61897795	0.657	rs174589	chr11:61615803	C/G	cg21709803	chr11:61594965	FADS2	0.41	6.66	0.31	8.63e-11	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs12545109	0.800	rs2576599	chr8:57388410	G/A	cg21220214	chr8:57350948	NA	-0.65	-9.06	-0.4	4.73e-18	Obesity-related traits;
LUAD	cis	rs7851660	0.967	rs1867280	chr9:100616066	G/C	cg13688889	chr9:100608707	NA	-0.53	-9.71	-0.43	2.86e-20	Strep throat;
LUAD	cis	rs2882667	0.893	rs13180851	chr5:138290607	C/G	cg04439458	chr5:138467593	SIL1	-0.36	-6.54	-0.3	1.78e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2242073	0.935	rs12464841	chr2:208997084	C/T	cg06181187	chr2:209010896	CRYGB	0.36	6.38	0.3	4.58e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs17102423	0.661	rs45604339	chr14:65543102	C/T	cg11161011	chr14:65562177	MAX	-0.48	-7.57	-0.35	2.35e-13	Obesity-related traits;
LUAD	cis	rs4812048	1.000	rs4812048	chr20:57587771	C/T	cg14073986	chr20:57617431	SLMO2	0.54	6.82	0.31	3.1e-11	Mean platelet volume;
LUAD	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg10518543	chr12:38710700	ALG10B	-0.47	-7.74	-0.35	7.42e-14	Morning vs. evening chronotype;
LUAD	cis	rs2408955	0.568	rs12099462	chr12:48503104	T/C	cg04545296	chr12:48745243	ZNF641	-0.33	-8.56	-0.38	2.12e-16	Glycated hemoglobin levels;
LUAD	trans	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg06606381	chr12:133084897	FBRSL1	-0.49	-6.39	-0.3	4.26e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08280861	chr8:58055591	NA	0.67	8.72	0.39	6.27e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg19717773	chr7:2847554	GNA12	-0.47	-8.61	-0.39	1.41e-16	Height;
LUAD	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9929218	0.954	rs72785165	chr16:68755635	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-15.14	-0.59	1.05e-41	Colorectal cancer;
LUAD	cis	rs4372836	0.553	rs6706858	chr2:28992607	C/G	cg09522027	chr2:28974177	PPP1CB	-0.63	-11.01	-0.47	6.04e-25	Body mass index;
LUAD	cis	rs877282	0.842	rs35872126	chr10:764545	G/A	cg17470449	chr10:769945	NA	0.62	8.83	0.39	2.91e-17	Uric acid levels;
LUAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg05896524	chr21:47604654	C21orf56	0.62	10.38	0.45	1.2e-22	Testicular germ cell tumor;
LUAD	trans	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	10.61	0.46	1.77e-23	Type 2 diabetes;
LUAD	cis	rs782590	0.574	rs12991445	chr2:55675939	C/T	cg18811423	chr2:55921094	PNPT1	0.41	6.45	0.3	2.98e-10	Metabolic syndrome;
LUAD	cis	rs2795502	0.564	rs72777186	chr10:43430464	C/T	cg08461752	chr10:43522343	NA	-0.76	-8.42	-0.38	5.83e-16	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg24818145	chr4:99064322	C4orf37	-0.46	-7.68	-0.35	1.15e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg14917512	chr19:3094685	GNA11	-0.56	-6.64	-0.31	9.4e-11	Diabetic kidney disease;
LUAD	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg14228332	chr4:119757509	SEC24D	0.7	6.82	0.31	3.17e-11	Cannabis dependence symptom count;
LUAD	cis	rs25422	0.540	rs9481842	chr6:118974798	A/C	cg07617317	chr6:118971624	C6orf204	0.41	7.15	0.33	3.84e-12	Renal cell carcinoma;
LUAD	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg08999081	chr20:33150536	PIGU	0.47	8.86	0.4	2.17e-17	Coronary artery disease;
LUAD	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg02734326	chr4:10020555	SLC2A9	0.64	11.46	0.49	1.15e-26	Bone mineral density;
LUAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg01324343	chr3:183735012	ABCC5	0.95	25.38	0.78	5.24e-87	Anterior chamber depth;
LUAD	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg03354898	chr7:1950403	MAD1L1	-0.45	-8.74	-0.39	5.37e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg22875332	chr1:76189707	ACADM	0.92	18.97	0.68	1.55e-58	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs438465	1.000	rs438465	chr6:169820381	T/C	cg11181693	chr6:169825345	NA	-0.64	-7.93	-0.36	1.95e-14	Corneal astigmatism;
LUAD	trans	rs11039798	1.000	rs7102865	chr11:48458361	A/C	cg03929089	chr4:120376271	NA	0.57	6.61	0.31	1.18e-10	Axial length;
LUAD	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg00757033	chr12:89920650	WDR51B	0.7	12.14	0.51	2.6e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg12193833	chr17:30244370	NA	-0.58	-7.0	-0.32	1.03e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs9486719	1.000	rs35487471	chr6:96879715	C/T	cg06623918	chr6:96969491	KIAA0776	-0.71	-10.02	-0.44	2.32e-21	Migraine;Coronary artery disease;
LUAD	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg08742575	chr21:47604166	C21orf56	-0.48	-7.85	-0.36	3.54e-14	Testicular germ cell tumor;
LUAD	cis	rs9462027	0.959	rs205262	chr6:34563164	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.29	-6.81	-0.31	3.3e-11	Systemic lupus erythematosus;
LUAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg18621852	chr3:10150065	C3orf24	0.49	8.67	0.39	9.34e-17	Alzheimer's disease;
LUAD	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg02782426	chr3:40428986	ENTPD3	0.36	7.64	0.35	1.42e-13	Renal cell carcinoma;
LUAD	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11644478	chr21:40555479	PSMG1	0.64	10.06	0.44	1.68e-21	Cognitive function;
LUAD	cis	rs11893307	0.566	rs62179714	chr2:191567541	G/C	cg11845111	chr2:191398756	TMEM194B	-0.44	-6.36	-0.3	5.26e-10	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg18180107	chr4:99064573	C4orf37	0.4	6.44	0.3	3.19e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg04586622	chr2:25135609	ADCY3	0.36	8.32	0.37	1.25e-15	Body mass index;
LUAD	trans	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg07817883	chr1:32538562	TMEM39B	-0.56	-7.75	-0.35	7.06e-14	Monocyte percentage of white cells;
LUAD	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-8.95	-0.4	1.15e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg13385794	chr1:248469461	NA	0.24	6.55	0.3	1.63e-10	Common traits (Other);
LUAD	cis	rs1018836	0.632	rs1028255	chr8:91485578	A/T	cg16814680	chr8:91681699	NA	-0.66	-11.35	-0.48	2.91e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10781543	0.763	rs10781539	chr9:139320965	G/A	cg14019695	chr9:139328340	INPP5E	0.54	10.45	0.45	6.89e-23	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.54	0.52	6.72e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg02782426	chr3:40428986	ENTPD3	0.43	9.55	0.42	1.04e-19	Renal cell carcinoma;
LUAD	cis	rs7582720	0.945	rs72936860	chr2:203783484	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs7336332	0.547	rs9581859	chr13:28035147	A/T	cg22138327	chr13:27999177	GTF3A	0.87	9.91	0.43	5.8e-21	Weight;
LUAD	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg23018236	chr17:30244563	NA	-0.48	-6.37	-0.3	4.82e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.31	-0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs3760982	1.000	rs60184524	chr19:44294215	A/G	cg12072164	chr19:44306565	LYPD5	0.38	7.57	0.35	2.31e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg15247329	chr7:2764246	NA	-0.35	-6.48	-0.3	2.48e-10	Height;
LUAD	cis	rs12618769	0.652	rs4851146	chr2:99237439	A/G	cg10123293	chr2:99228465	UNC50	0.51	9.1	0.4	3.52e-18	Bipolar disorder;
LUAD	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg02569458	chr12:86230093	RASSF9	-0.41	-7.6	-0.35	1.95e-13	Major depressive disorder;
LUAD	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg23283495	chr1:209979779	IRF6	0.41	7.28	0.33	1.62e-12	Monobrow;
LUAD	cis	rs999737	0.960	rs17756147	chr14:69036127	G/A	cg04147497	chr14:69052728	RAD51L1	-0.44	-6.53	-0.3	1.92e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg02158880	chr13:53174818	NA	0.47	8.1	0.37	5.98e-15	Lewy body disease;
LUAD	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg04398451	chr17:18023971	MYO15A	-0.67	-12.18	-0.51	1.84e-29	Total body bone mineral density;
LUAD	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg23985595	chr17:80112537	CCDC57	0.53	9.74	0.43	2.39e-20	Life satisfaction;
LUAD	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-9.89	-0.43	6.72e-21	Life satisfaction;
LUAD	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg24818145	chr4:99064322	C4orf37	-0.42	-6.96	-0.32	1.26e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs62238980	0.614	rs116866390	chr22:32533595	G/A	cg00543991	chr22:32367038	NA	0.87	8.37	0.38	8.63e-16	Childhood ear infection;
LUAD	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.22	-0.37	2.45e-15	Bipolar disorder;
LUAD	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg12292205	chr6:26970375	C6orf41	-0.41	-7.06	-0.32	7.08e-12	Schizophrenia;
LUAD	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.76	13.18	0.54	1.84e-33	Chronic sinus infection;
LUAD	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg00814883	chr7:100076585	TSC22D4	-0.85	-12.42	-0.52	2.13e-30	Platelet count;
LUAD	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg09455208	chr3:40491958	NA	0.6	13.13	0.54	2.89e-33	Renal cell carcinoma;
LUAD	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg18230493	chr5:56204884	C5orf35	-0.85	-12.54	-0.52	6.65e-31	Initial pursuit acceleration;
LUAD	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg27539214	chr16:67997921	SLC12A4	-0.72	-9.19	-0.41	1.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2665103	0.610	rs1972460	chr15:82530630	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.41	-7.01	-0.32	9.19e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9925964	0.687	rs12917722	chr16:30948397	A/G	cg02466173	chr16:30829666	NA	0.47	8.04	0.36	9.24e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs600626	0.529	rs2004638	chr11:75471012	C/T	cg24262691	chr11:75473276	NA	0.57	8.29	0.37	1.58e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs68170813	0.559	rs80153759	chr7:106944145	C/A	cg02696742	chr7:106810147	HBP1	-0.75	-10.45	-0.45	6.74e-23	Coronary artery disease;
LUAD	cis	rs6684514	1.000	rs10908500	chr1:156280671	A/T	cg16558208	chr1:156270281	VHLL	0.52	9.54	0.42	1.15e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs7524258	0.901	rs11120884	chr1:7305361	C/A	cg07173049	chr1:7289937	CAMTA1	0.36	6.6	0.31	1.26e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg01191920	chr7:158217561	PTPRN2	-0.66	-14.12	-0.57	2.39e-37	Obesity-related traits;
LUAD	cis	rs6076065	1.000	rs6076065	chr20:23368411	C/A	cg11657817	chr20:23433608	CST11	0.44	8.66	0.39	1.03e-16	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.49	0.3	2.44e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg12062639	chr20:23401060	NAPB	1.01	10.83	0.47	2.67e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs698833	0.886	rs2053455	chr2:44550233	C/T	cg04920474	chr2:44395004	PPM1B	0.4	7.18	0.33	3.07e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	trans	rs8002861	0.905	rs12853286	chr13:44446817	A/G	cg17145862	chr1:211918768	LPGAT1	-0.67	-14.6	-0.58	2.25e-39	Leprosy;
LUAD	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg00316803	chr15:76480434	C15orf27	-0.36	-7.11	-0.33	4.84e-12	Blood metabolite levels;
LUAD	trans	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.74	-0.46	5.92e-24	Obesity-related traits;
LUAD	cis	rs727505	0.607	rs17387389	chr7:124784751	T/C	cg23710748	chr7:124431027	NA	-0.38	-7.72	-0.35	8.31e-14	Lewy body disease;
LUAD	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg14634687	chr17:47094252	IGF2BP1	0.27	6.84	0.32	2.73e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg01299579	chr2:10830716	NOL10	-0.41	-7.17	-0.33	3.38e-12	Prostate cancer;
LUAD	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg23229984	chr5:148520753	ABLIM3	-0.43	-6.95	-0.32	1.39e-11	Breast cancer;
LUAD	cis	rs10155981	0.510	rs28439106	chr7:22592349	T/C	cg05062323	chr7:22590069	NA	-0.73	-7.29	-0.33	1.49e-12	Bilirubin levels;
LUAD	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg11494091	chr17:61959527	GH2	0.41	7.33	0.34	1.2e-12	Height;
LUAD	cis	rs1957429	0.901	rs7141985	chr14:65345670	C/T	cg23373153	chr14:65346875	NA	0.61	6.46	0.3	2.9e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg11344533	chr11:111475393	SIK2	-0.34	-6.44	-0.3	3.2e-10	Primary sclerosing cholangitis;
LUAD	trans	rs8073060	0.559	rs72829925	chr17:34049778	C/A	cg19694781	chr19:47549865	TMEM160	1.21	18.83	0.68	7e-58	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg22777832	chr20:62339229	ARFRP1;ZGPAT	-0.51	-6.35	-0.3	5.63e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg11859384	chr17:80120422	CCDC57	0.48	8.68	0.39	8.7e-17	Life satisfaction;
LUAD	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg04414720	chr1:150670196	GOLPH3L	0.72	12.91	0.53	2.22e-32	Melanoma;
LUAD	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg17810781	chr1:201082982	CACNA1S	0.37	6.56	0.3	1.56e-10	Permanent tooth development;
LUAD	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-7.02	-0.32	9.11e-12	Morning vs. evening chronotype;
LUAD	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg11189052	chr15:85197271	WDR73	-0.6	-9.92	-0.43	5.28e-21	P wave terminal force;
LUAD	cis	rs853679	0.607	rs34218844	chr6:28290647	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.54	6.37	0.3	4.99e-10	Depression;
LUAD	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg08071915	chr8:12219732	FAM66A	0.45	7.33	0.34	1.21e-12	Joint mobility (Beighton score);
LUAD	cis	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg05901451	chr6:126070800	HEY2	-0.44	-6.69	-0.31	7.24e-11	Endometrial cancer;
LUAD	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg18252515	chr7:66147081	NA	0.59	6.47	0.3	2.71e-10	Diabetic kidney disease;
LUAD	cis	rs4356932	1.000	rs13130221	chr4:76955617	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.54	-0.3	1.78e-10	Blood protein levels;
LUAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg10729496	chr3:10149963	C3orf24	0.58	9.42	0.42	3.04e-19	Alzheimer's disease;
LUAD	cis	rs2017305	0.749	rs12249735	chr10:70791235	A/G	cg01024728	chr10:70782572	NA	0.65	6.61	0.31	1.17e-10	Depression (quantitative trait);
LUAD	cis	rs15676	0.783	rs4489410	chr9:131591649	A/C	cg00228799	chr9:131580591	ENDOG	-0.44	-6.89	-0.32	2.07e-11	Blood metabolite levels;
LUAD	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg09137382	chr11:130731461	NA	0.42	7.58	0.35	2.17e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg25173405	chr17:45401733	C17orf57	-0.44	-7.12	-0.33	4.6e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	8.28	0.37	1.64e-15	Mean corpuscular volume;
LUAD	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg02158880	chr13:53174818	NA	0.39	6.44	0.3	3.22e-10	Lewy body disease;
LUAD	cis	rs904251	0.523	rs2797798	chr6:37481437	C/T	cg25019722	chr6:37503610	NA	-0.33	-7.54	-0.34	2.95e-13	Cognitive performance;
LUAD	cis	rs11971779	0.648	rs66463279	chr7:139118661	A/G	cg23387468	chr7:139079360	LUC7L2	0.3	6.96	0.32	1.29e-11	Diisocyanate-induced asthma;
LUAD	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg13334819	chr7:99746414	C7orf59	0.64	9.83	0.43	1.14e-20	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.71e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg27411982	chr8:10470053	RP1L1	-0.42	-7.53	-0.34	3.19e-13	Neuroticism;
LUAD	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg20991723	chr1:152506922	NA	0.32	6.43	0.3	3.42e-10	Hair morphology;
LUAD	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22857025	chr5:266934	NA	-0.99	-14.44	-0.57	1.05e-38	Breast cancer;
LUAD	cis	rs741677	0.702	rs9893847	chr17:489043	C/G	cg15660573	chr17:549704	VPS53	-0.53	-8.72	-0.39	6.38e-17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	8.49	0.38	3.53e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs73198271	0.740	rs10110711	chr8:8650456	C/T	cg01851573	chr8:8652454	MFHAS1	0.51	9.04	0.4	5.75e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.27	-0.37	1.8e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.32	6.5	0.3	2.2e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06024111	chr6:43597558	MAD2L1BP;GTPBP2	-0.43	-6.59	-0.31	1.34e-10	Height;
LUAD	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg08470875	chr2:26401718	FAM59B	-0.63	-8.53	-0.38	2.62e-16	Gut microbiome composition (summer);
LUAD	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg02569458	chr12:86230093	RASSF9	0.43	7.68	0.35	1.15e-13	Major depressive disorder;
LUAD	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-7.64	-0.35	1.46e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg27494647	chr7:150038898	RARRES2	0.55	9.67	0.43	3.94e-20	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs757647	0.680	rs3756764	chr5:137672554	C/G	cg10676309	chr5:137685565	NA	0.4	7.12	0.33	4.78e-12	Menarche (age at onset);
LUAD	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg20307385	chr11:47447363	PSMC3	0.51	7.9	0.36	2.44e-14	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg20701182	chr2:24300061	SF3B14	0.69	7.64	0.35	1.43e-13	Lymphocyte counts;
LUAD	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg06636001	chr8:8085503	FLJ10661	0.48	7.87	0.36	3.05e-14	Mood instability;
LUAD	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg13390004	chr1:15929781	NA	0.5	8.89	0.4	1.72e-17	Systolic blood pressure;
LUAD	cis	rs4900538	0.855	rs60215817	chr14:102873886	A/G	cg18135206	chr14:102964638	TECPR2	-1.02	-21.2	-0.72	1.77e-68	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.47	-0.34	4.74e-13	Bipolar disorder;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07086847	chr8:145550618	DGAT1	-0.54	-6.89	-0.32	1.97e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs347685	0.871	rs72990266	chr3:141741960	G/A	cg02222454	chr3:141762828	NA	0.47	6.62	0.31	1.08e-10	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine);
LUAD	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg12062639	chr20:23401060	NAPB	1.07	11.39	0.48	2.14e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg11494091	chr17:61959527	GH2	0.72	17.62	0.65	1.71e-52	Prudent dietary pattern;
LUAD	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg03168497	chr17:48586147	MYCBPAP	0.56	7.01	0.32	9.41e-12	Visceral fat;
LUAD	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg10729496	chr3:10149963	C3orf24	0.47	7.0	0.32	1.02e-11	Alzheimer's disease;
LUAD	cis	rs7224314	1.000	rs62085808	chr17:65357692	G/A	cg01507342	chr17:65387096	PITPNC1	-0.5	-8.04	-0.36	9.36e-15	Diisocyanate-induced asthma;
LUAD	cis	rs447921	0.861	rs36119142	chr17:74454336	T/G	cg17201438	chr17:74438067	UBE2O	0.68	8.61	0.39	1.45e-16	Mitochondrial DNA levels;
LUAD	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4148087	1.000	rs28485452	chr21:43615131	G/A	cg08841829	chr21:43638893	ABCG1	-0.59	-7.58	-0.35	2.14e-13	Eating disorder in bipolar disorder;
LUAD	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg15468180	chr1:107600409	PRMT6	-0.39	-6.79	-0.31	3.81e-11	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg15147215	chr3:52552868	STAB1	-0.38	-7.31	-0.34	1.31e-12	Bipolar disorder;
LUAD	cis	rs7665090	0.967	rs13106304	chr4:103554975	A/G	cg07973026	chr4:103553119	MANBA	0.47	8.42	0.38	5.92e-16	Primary biliary cholangitis;
LUAD	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.19	-0.37	3.08e-15	Total cholesterol levels;
LUAD	cis	rs6545883	0.868	rs2441381	chr2:61798829	C/T	cg15711740	chr2:61764176	XPO1	-0.43	-6.77	-0.31	4.4e-11	Tuberculosis;
LUAD	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14240646	chr10:27532245	ACBD5	0.82	11.59	0.49	3.76e-27	Breast cancer;
LUAD	cis	rs1371614	0.635	rs12612619	chr2:27137671	C/T	cg00617064	chr2:27272375	NA	0.35	6.72	0.31	5.99e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg02551604	chr5:131831745	NA	0.67	10.87	0.47	1.88e-24	Asthma (sex interaction);
LUAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.72	-0.35	8.45e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs17152411	1.000	rs1065301	chr10:126616038	A/G	cg07906193	chr10:126599966	NA	0.54	7.68	0.35	1.15e-13	Height;
LUAD	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg09654669	chr8:57350985	NA	-0.65	-10.02	-0.44	2.42e-21	Obesity-related traits;
LUAD	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg23758822	chr17:41437982	NA	1.01	20.5	0.71	2.24e-65	Menopause (age at onset);
LUAD	cis	rs10927875	0.632	rs2013745	chr1:16126676	G/A	cg21385522	chr1:16154831	NA	-1.02	-20.8	-0.71	1.03e-66	Dilated cardiomyopathy;
LUAD	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.39e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7681423	1.000	rs7654093	chr4:155545072	A/T	cg20735720	chr4:155535218	FGG	-0.51	-7.5	-0.34	3.67e-13	Fibrinogen;
LUAD	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg00129232	chr17:37814104	STARD3	-0.47	-8.37	-0.38	8.7e-16	Asthma;
LUAD	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg18811423	chr2:55921094	PNPT1	0.53	8.93	0.4	1.35e-17	Metabolic syndrome;
LUAD	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg12011299	chr4:100065546	ADH4	-0.74	-13.64	-0.55	2.38e-35	Alcohol dependence;
LUAD	trans	rs629535	0.514	rs55653755	chr8:70154383	A/C	cg21567404	chr3:27674614	NA	-1.0	-16.27	-0.62	1.46e-46	Dupuytren's disease;
LUAD	cis	rs367943	0.665	rs2115210	chr5:112966125	T/C	cg12552261	chr5:112820674	MCC	0.38	6.72	0.31	5.91e-11	Type 2 diabetes;
LUAD	cis	rs1975974	1.000	rs7210944	chr17:21727476	C/T	cg18423549	chr17:21743878	NA	-0.79	-14.03	-0.56	5.4e-37	Psoriasis;
LUAD	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg12011299	chr4:100065546	ADH4	0.66	12.14	0.51	2.72e-29	Alcohol dependence;
LUAD	cis	rs11077998	0.869	rs6502123	chr17:80532170	T/C	cg10255544	chr17:80519551	FOXK2	0.34	6.66	0.31	8.42e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg02508848	chr16:68573721	ZFP90	-0.42	-6.5	-0.3	2.22e-10	Ulcerative colitis;
LUAD	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg04450456	chr4:17643702	FAM184B	0.38	7.29	0.33	1.51e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg12311346	chr5:56204834	C5orf35	-0.43	-7.13	-0.33	4.5e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs11031096	0.502	rs4910598	chr11:4101368	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.07	-0.32	6.54e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs1497828	0.956	rs2815242	chr1:217552998	C/T	cg04411442	chr1:217543379	NA	0.38	6.87	0.32	2.27e-11	Dialysis-related mortality;
LUAD	cis	rs1816752	0.870	rs73469543	chr13:24998970	T/C	cg02811702	chr13:24901961	NA	0.41	7.12	0.33	4.77e-12	Obesity-related traits;
LUAD	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.58	-10.03	-0.44	2.29e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg22907277	chr7:1156413	C7orf50	0.48	8.03	0.36	9.73e-15	Longevity;Endometriosis;
LUAD	cis	rs12505328	0.966	rs28473076	chr4:174356073	C/T	cg12145043	chr4:174357286	NA	-0.57	-9.98	-0.44	3.38e-21	Chin dimples;
LUAD	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg09945482	chr18:12777974	NA	0.52	6.63	0.31	1.05e-10	Inflammatory skin disease;
LUAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg04234412	chr22:24373322	LOC391322	-0.82	-15.19	-0.59	6.4e-42	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6484504	0.512	rs2761594	chr11:31318244	A/G	cg26647111	chr11:31128758	NA	0.46	8.02	0.36	1.01e-14	Red blood cell count;
LUAD	cis	rs870825	0.616	rs4610378	chr4:185624220	C/T	cg04058563	chr4:185651563	MLF1IP	-0.85	-13.99	-0.56	7.84e-37	Blood protein levels;
LUAD	cis	rs6489882	0.867	rs4767031	chr12:113362751	C/G	cg20102336	chr12:113376681	OAS3	-0.61	-9.4	-0.42	3.6e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs1941184	0.526	rs9956859	chr18:29030796	T/C	cg03238162	chr18:29027701	DSG3	0.36	6.52	0.3	2.04e-10	Parkinson's disease (age of onset);
LUAD	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg12034118	chr1:209979487	IRF6	0.59	6.62	0.31	1.06e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08109568	chr15:31115862	NA	-0.61	-10.13	-0.44	9.46e-22	Huntington's disease progression;
LUAD	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18876405	chr7:65276391	NA	0.47	7.52	0.34	3.39e-13	Aortic root size;
LUAD	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg23625390	chr15:77176239	SCAPER	-0.51	-7.78	-0.35	5.72e-14	Blood metabolite levels;
LUAD	cis	rs2880765	0.835	rs6497206	chr15:86029225	A/G	cg13263323	chr15:86062960	AKAP13	-0.48	-8.93	-0.4	1.32e-17	Coronary artery disease;
LUAD	cis	rs35883536	0.626	rs80052576	chr1:101039229	A/G	cg06223162	chr1:101003688	GPR88	-0.48	-9.2	-0.41	1.59e-18	Monocyte count;
LUAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg24503407	chr1:205819492	PM20D1	-0.71	-14.07	-0.56	3.59e-37	Monocyte percentage of white cells;
LUAD	cis	rs870825	0.616	rs28673855	chr4:185627416	T/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg07776626	chr8:57350775	NA	-0.62	-8.8	-0.39	3.59e-17	Obesity-related traits;
LUAD	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg17800788	chr1:21766015	NBPF3	0.36	6.98	0.32	1.18e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg21226059	chr5:178986404	RUFY1	0.6	10.39	0.45	1.15e-22	Lung cancer;
LUAD	cis	rs11585357	0.895	rs72633803	chr1:17616758	G/A	cg08277548	chr1:17600880	PADI3	-0.95	-13.88	-0.56	2.3e-36	Hair shape;
LUAD	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.33	7.68	0.35	1.15e-13	Prostate cancer;
LUAD	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg17063962	chr7:91808500	NA	0.71	12.67	0.52	2e-31	Breast cancer;
LUAD	cis	rs4849845	0.584	rs3896630	chr2:121037018	A/G	cg24070213	chr2:121070622	NA	0.4	7.63	0.35	1.62e-13	Mean platelet volume;
LUAD	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg09253696	chr17:73873529	TRIM47	-0.7	-8.87	-0.4	2.06e-17	Psoriasis;
LUAD	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg10591111	chr5:226296	SDHA	-0.55	-7.13	-0.33	4.26e-12	Breast cancer;
LUAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.73	0.31	5.53e-11	Prudent dietary pattern;
LUAD	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg24848339	chr3:12840334	CAND2	0.43	8.64	0.39	1.21e-16	QRS complex (12-leadsum);
LUAD	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg26384229	chr12:38710491	ALG10B	-0.44	-7.34	-0.34	1.09e-12	Morning vs. evening chronotype;
LUAD	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg20108693	chr8:143823809	SLURP1	0.31	7.13	0.33	4.26e-12	Urinary tract infection frequency;
LUAD	cis	rs2996428	0.561	rs12134919	chr1:3744641	G/A	cg22529645	chr1:3704559	LRRC47	0.52	9.88	0.43	7.28e-21	Red cell distribution width;
LUAD	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06505273	chr16:24850292	NA	0.47	6.8	0.31	3.65e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21582582	chr3:182698605	DCUN1D1	0.61	10.28	0.45	2.86e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs6445967	0.518	rs62259820	chr3:58438900	C/T	cg23715586	chr3:58305044	RPP14	0.39	6.36	0.3	5.33e-10	Platelet count;
LUAD	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs755249	0.501	rs661316	chr1:39631297	G/A	cg27567593	chr1:39956653	BMP8A	-0.34	-6.41	-0.3	3.83e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg22532475	chr10:104410764	TRIM8	-0.43	-8.53	-0.38	2.67e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg00129232	chr17:37814104	STARD3	-0.48	-8.07	-0.37	7.44e-15	Asthma;
LUAD	trans	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.06	17.02	0.64	7.58e-50	Exhaled nitric oxide output;
LUAD	cis	rs68170813	0.605	rs4730227	chr7:106904031	G/C	cg02696742	chr7:106810147	HBP1	-0.76	-10.71	-0.46	7.32e-24	Coronary artery disease;
LUAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08677398	chr8:58056175	NA	0.46	6.45	0.3	3.12e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg20119798	chr7:94954144	PON1	-0.49	-6.91	-0.32	1.77e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs375066	0.935	rs10414702	chr19:44380536	A/G	cg12072164	chr19:44306565	LYPD5	0.32	6.49	0.3	2.44e-10	Breast cancer;
LUAD	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg23533926	chr12:111358616	MYL2	-0.43	-7.34	-0.34	1.07e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-6.86	-0.32	2.48e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg25894440	chr7:65020034	NA	-0.67	-7.22	-0.33	2.41e-12	Diabetic kidney disease;
LUAD	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg23533926	chr12:111358616	MYL2	-0.4	-6.77	-0.31	4.23e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg06360820	chr2:242988706	NA	-0.97	-13.27	-0.54	7.51e-34	Obesity-related traits;
LUAD	cis	rs7771547	0.573	rs566742	chr6:36395668	C/T	cg04289385	chr6:36355825	ETV7	0.43	6.7	0.31	6.8e-11	Platelet distribution width;
LUAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg08132940	chr7:1081526	C7orf50	-0.73	-10.24	-0.45	3.94e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg19622623	chr12:86230825	RASSF9	-0.55	-9.96	-0.44	3.86e-21	Major depressive disorder;
LUAD	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg03929089	chr4:120376271	NA	0.57	7.13	0.33	4.42e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03352830	chr11:487213	PTDSS2	0.82	10.74	0.46	6.08e-24	Body mass index;
LUAD	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg17595323	chr11:93583763	C11orf90	-0.43	-9.06	-0.4	4.83e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	trans	rs9557635	0.766	rs4772380	chr13:102057214	C/T	cg14752429	chr2:26569594	GPR113;SELI	-0.38	-6.35	-0.3	5.61e-10	Non-small cell lung cancer;
LUAD	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg25985355	chr7:65971099	NA	0.53	6.6	0.31	1.25e-10	Diabetic kidney disease;
LUAD	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs240764	0.817	rs240143	chr6:101080621	G/A	cg09795085	chr6:101329169	ASCC3	0.43	7.52	0.34	3.23e-13	Neuroticism;
LUAD	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg03929089	chr4:120376271	NA	0.54	6.95	0.32	1.36e-11	Axial length;
LUAD	trans	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg19676328	chr12:49525230	TUBA1B	-0.59	-8.33	-0.38	1.18e-15	Total cholesterol levels;
LUAD	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg00769240	chr8:12517080	NA	-0.42	-8.13	-0.37	4.68e-15	Blood pressure (smoking interaction);
LUAD	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18876405	chr7:65276391	NA	-0.53	-9.21	-0.41	1.58e-18	Aortic root size;
LUAD	cis	rs367615	0.661	rs9326775	chr5:108836925	A/T	cg17395555	chr5:108820864	NA	0.66	14.39	0.57	1.61e-38	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg18827107	chr12:86230957	RASSF9	-0.66	-12.02	-0.5	7.72e-29	Major depressive disorder;
LUAD	trans	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg04775059	chr7:64541387	NA	0.51	6.83	0.32	2.93e-11	Aortic root size;
LUAD	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs262150	0.530	rs2730232	chr7:158784469	C/T	cg19418458	chr7:158789849	NA	0.45	6.63	0.31	9.95e-11	Facial morphology (factor 20);
LUAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg10729496	chr3:10149963	C3orf24	0.49	7.88	0.36	2.73e-14	Alzheimer's disease;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11668638	chr6:42952412	PPP2R5D	0.45	7.17	0.33	3.43e-12	Monocyte percentage of white cells;
LUAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-7.67	-0.35	1.23e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg04036182	chr15:45458818	NA	-0.42	-7.3	-0.33	1.47e-12	Glomerular filtration rate;
LUAD	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.85	-0.32	2.69e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg18876405	chr7:65276391	NA	-0.61	-10.64	-0.46	1.34e-23	Aortic root size;
LUAD	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg27572855	chr1:25598939	RHD	-0.54	-11.82	-0.5	4.62e-28	Erythrocyte sedimentation rate;
LUAD	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg07371521	chr5:154026371	NA	-0.49	-7.98	-0.36	1.41e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	trans	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.94	0.44	4.58e-21	Ulcerative colitis;
LUAD	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg12310025	chr6:25882481	NA	0.83	13.79	0.56	5.57e-36	Blood metabolite levels;
LUAD	cis	rs4285028	0.948	rs2877560	chr3:121699238	C/A	cg11130432	chr3:121712080	ILDR1	-0.58	-8.2	-0.37	2.9e-15	Multiple sclerosis;
LUAD	cis	rs3813948	0.543	rs11120218	chr1:207278451	C/T	cg26044340	chr1:207277291	C4BPA	-0.52	-7.8	-0.35	5.03e-14	C4b binding protein levels;
LUAD	trans	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg11693508	chr17:37793320	STARD3	0.71	9.11	0.4	3.19e-18	Neuroticism;
LUAD	cis	rs892961	0.867	rs1079354	chr17:75415713	C/T	cg05865280	chr17:75406074	SEPT9	0.62	18.5	0.67	2e-56	Airflow obstruction;
LUAD	cis	rs1232027	0.582	rs6151614	chr5:79961335	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg25767906	chr1:53392781	SCP2	-0.59	-10.95	-0.47	9.59e-25	Monocyte count;
LUAD	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg03433033	chr1:76189801	ACADM	0.9	18.08	0.66	1.45e-54	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6998277	0.830	rs6981007	chr8:103598257	G/C	cg10187029	chr8:103597600	NA	0.87	16.43	0.62	2.8e-47	Migraine;
LUAD	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg00981070	chr1:2046702	PRKCZ	0.36	6.97	0.32	1.25e-11	Height;
LUAD	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11890956	chr21:40555474	PSMG1	0.63	11.17	0.48	1.45e-25	Cognitive function;
LUAD	trans	rs75804782	0.581	rs13415491	chr2:239319901	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	8.62	0.39	1.33e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06505273	chr16:24850292	NA	0.48	6.92	0.32	1.66e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03264133	chr6:25882463	NA	-0.57	-9.39	-0.42	3.71e-19	Blood metabolite levels;
LUAD	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg26384229	chr12:38710491	ALG10B	-0.38	-6.35	-0.3	5.46e-10	Bladder cancer;
LUAD	cis	rs1784581	0.599	rs1789992	chr6:162401854	A/G	cg17173639	chr6:162384350	PARK2	-0.51	-9.22	-0.41	1.42e-18	Itch intensity from mosquito bite;
LUAD	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.83	12.48	0.52	1.16e-30	Schizophrenia;
LUAD	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg14668632	chr7:2872130	GNA12	-0.69	-12.61	-0.52	3.62e-31	Height;
LUAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.7	-0.39	7.63e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg04545296	chr12:48745243	ZNF641	0.39	9.89	0.43	7e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13012494	chr21:47604986	C21orf56	0.68	11.21	0.48	1.05e-25	Testicular germ cell tumor;
LUAD	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg25482853	chr8:67687455	SGK3	1.14	17.77	0.65	3.65e-53	Lung disease severity in cystic fibrosis;
LUAD	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg04756594	chr16:24857601	SLC5A11	-0.51	-10.09	-0.44	1.39e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs6558530	0.965	rs7460287	chr8:1708274	G/C	cg17159058	chr8:1704075	NA	-0.39	-6.37	-0.3	4.97e-10	Systolic blood pressure;
LUAD	cis	rs6489882	0.966	rs3937434	chr12:113406196	A/G	cg20102336	chr12:113376681	OAS3	-0.48	-6.97	-0.32	1.26e-11	Chronic lymphocytic leukemia;
LUAD	cis	rs17169635	0.601	rs4732062	chr7:134547955	G/A	cg07876788	chr7:134849633	TMEM140	-0.38	-6.42	-0.3	3.62e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	trans	rs1997103	1.000	rs12532070	chr7:55407698	A/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.33	-0.41	6.15e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg06558623	chr16:89946397	TCF25	1.18	10.88	0.47	1.76e-24	Skin colour saturation;
LUAD	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg02375832	chr11:62437615	C11orf48	-0.35	-6.76	-0.31	4.52e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3733585	0.683	rs3796839	chr4:10009917	G/A	cg11266682	chr4:10021025	SLC2A9	0.67	14.96	0.59	6.65e-41	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg11663144	chr21:46675770	NA	-0.61	-11.68	-0.49	1.64e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs17095355	1.000	rs61614979	chr10:111743994	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.66	-8.75	-0.39	5.02e-17	Biliary atresia;
LUAD	cis	rs5756813	0.661	rs2285178	chr22:38205989	T/C	cg06521852	chr22:38141419	TRIOBP	0.47	8.62	0.39	1.37e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg04414720	chr1:150670196	GOLPH3L	0.58	9.97	0.44	3.69e-21	Melanoma;
LUAD	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22857025	chr5:266934	NA	-0.96	-14.33	-0.57	2.98e-38	Breast cancer;
LUAD	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.61	-0.31	1.17e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg12940439	chr1:67600707	NA	0.42	7.96	0.36	1.65e-14	Psoriasis;
LUAD	cis	rs7809950	0.817	rs17154091	chr7:107084790	T/C	cg23024343	chr7:107201750	COG5	-0.89	-14.73	-0.58	5.98e-40	Coronary artery disease;
LUAD	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg00321850	chr1:175162397	KIAA0040	-0.54	-11.36	-0.48	2.78e-26	Alcohol dependence;
LUAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.65	0.31	8.85e-11	Prudent dietary pattern;
LUAD	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg21475434	chr5:93447410	FAM172A	0.73	7.83	0.36	4.07e-14	Diabetic retinopathy;
LUAD	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg24818145	chr4:99064322	C4orf37	-0.41	-6.87	-0.32	2.3e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35306767	0.623	rs56201968	chr10:1141666	A/G	cg26597838	chr10:835615	NA	0.6	8.86	0.4	2.18e-17	Eosinophil percentage of granulocytes;
LUAD	cis	rs3125734	0.633	rs4979773	chr10:63967731	G/C	cg19640130	chr10:64028056	RTKN2	-0.33	-6.97	-0.32	1.21e-11	Rheumatoid arthritis;
LUAD	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg03467027	chr4:99064603	C4orf37	0.41	6.7	0.31	6.5500000000000006e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg22535103	chr8:58192502	C8orf71	-0.65	-6.89	-0.32	2e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg25809561	chr17:30822961	MYO1D	0.49	9.0	0.4	7.8e-18	Schizophrenia;
LUAD	cis	rs35995292	0.963	rs10239557	chr7:38950137	C/T	cg19327137	chr7:38886074	VPS41	0.5	7.85	0.36	3.33e-14	Subjective well-being (multi-trait analysis);
LUAD	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.8	0.31	3.63e-11	Schizophrenia;
LUAD	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg15664640	chr17:80829946	TBCD	0.58	7.8	0.35	4.98e-14	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.35	-7.55	-0.34	2.68e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.36	6.41	0.3	3.83e-10	Schizophrenia;
LUAD	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.56	-0.34	2.6e-13	Blood metabolite levels;
LUAD	cis	rs7193541	0.965	rs7184423	chr16:74709737	C/A	cg01733217	chr16:74700730	RFWD3	0.54	9.29	0.41	8.52e-19	Multiple myeloma;
LUAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg13010199	chr12:38710504	ALG10B	0.41	6.46	0.3	2.83e-10	Bladder cancer;
LUAD	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg06618935	chr21:46677482	NA	-0.48	-9.84	-0.43	1.02e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs13064411	0.735	rs6778800	chr3:113149236	A/G	cg18753928	chr3:113234510	CCDC52	-0.67	-11.18	-0.48	1.29e-25	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg20587970	chr11:113659929	NA	1.11	15.17	0.59	7.85e-42	Hip circumference adjusted for BMI;
LUAD	cis	rs2742234	0.590	rs1254965	chr10:43689853	C/T	cg15436174	chr10:43711423	RASGEF1A	0.52	8.89	0.4	1.82e-17	Hirschsprung disease;
LUAD	trans	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.58	0.46	2.34e-23	Mean corpuscular volume;
LUAD	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-8.35	-0.38	9.97e-16	Alzheimer's disease (late onset);
LUAD	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg16479474	chr6:28041457	NA	0.45	7.73	0.35	7.89e-14	Parkinson's disease;
LUAD	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg23172400	chr8:95962367	TP53INP1	0.32	7.57	0.35	2.42e-13	Type 2 diabetes;
LUAD	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18404041	chr3:52824283	ITIH1	-0.61	-12.36	-0.52	3.51e-30	Bipolar disorder;
LUAD	trans	rs9393777	0.920	rs34071253	chr6:27391802	C/T	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.73	-0.35	8.13e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs72949976	1.000	rs72949976	chr2:214034104	C/T	cg08319019	chr2:214017104	IKZF2	-0.51	-7.65	-0.35	1.36e-13	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg24642844	chr7:1081250	C7orf50	-0.84	-13.37	-0.55	2.89e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg25985355	chr7:65971099	NA	0.53	6.72	0.31	6e-11	Diabetic kidney disease;
LUAD	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg15485101	chr11:133734466	NA	0.38	8.26	0.37	1.89e-15	Childhood ear infection;
LUAD	cis	rs250585	0.850	rs4968016	chr16:23530089	T/C	cg00143387	chr16:23521605	GGA2	-0.59	-7.25	-0.33	2.06e-12	Egg allergy;
LUAD	cis	rs72772090	0.539	rs72775817	chr5:96190709	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-6.76	-0.31	4.68e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg10755058	chr3:40428713	ENTPD3	-0.39	-7.48	-0.34	4.35e-13	Renal cell carcinoma;
LUAD	cis	rs1045714	0.895	rs73035504	chr7:2642878	G/A	cg24848437	chr7:2645542	IQCE	0.7	8.2	0.37	2.86e-15	Urate levels in lean individuals;
LUAD	cis	rs2505998	0.787	rs28502801	chr10:43584039	A/T	cg15436174	chr10:43711423	RASGEF1A	-0.35	-6.58	-0.3	1.4e-10	Hirschsprung disease;
LUAD	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg13642260	chr9:130955380	CIZ1	0.45	7.59	0.35	2.03e-13	Attention deficit hyperactivity disorder;
LUAD	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg15541040	chr2:3486749	NA	-0.43	-7.26	-0.33	1.86e-12	Neurofibrillary tangles;
LUAD	trans	rs8073060	0.586	rs225250	chr17:33941963	A/G	cg19694781	chr19:47549865	TMEM160	-1.26	-20.33	-0.7	1.31e-64	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg06873352	chr17:61820015	STRADA	0.42	7.13	0.33	4.29e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7274811	0.744	rs3213183	chr20:32262962	C/T	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.46	-6.75	-0.31	4.75e-11	Height;
LUAD	cis	rs7172809	0.573	rs17470952	chr15:77700916	G/T	cg11865553	chr15:77376250	NA	-0.39	-6.51	-0.3	2.18e-10	Glucose homeostasis traits;
LUAD	cis	rs62238980	0.614	rs76869058	chr22:32561375	C/T	cg00543991	chr22:32367038	NA	0.8	7.29	0.33	1.49e-12	Childhood ear infection;
LUAD	cis	rs1395	0.925	rs1659696	chr2:27407831	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.44	-8.18	-0.37	3.33e-15	Blood metabolite levels;
LUAD	cis	rs2046867	0.862	rs6549483	chr3:72805316	T/G	cg25664220	chr3:72788482	NA	-0.63	-11.78	-0.5	6.78e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg16482183	chr6:26056742	HIST1H1C	0.46	6.85	0.32	2.64e-11	Iron status biomarkers;
LUAD	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg17420585	chr12:42539391	GXYLT1	-0.37	-6.63	-0.31	1.03e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-12.18	-0.51	1.79e-29	Smoking initiation;
LUAD	cis	rs741677	0.929	rs741678	chr17:464291	T/C	cg13332499	chr17:408570	NA	0.36	7.26	0.33	1.85e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9807989	0.507	rs7605284	chr2:103044175	T/G	cg03938978	chr2:103052716	IL18RAP	0.46	10.49	0.45	4.89e-23	Asthma;
LUAD	trans	rs9354308	0.840	rs17508021	chr6:66569748	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.51	7.6	0.35	1.91e-13	Metabolite levels;
LUAD	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg06002616	chr8:101225028	SPAG1	-0.38	-7.83	-0.36	3.85e-14	Atrioventricular conduction;
LUAD	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	7.92	0.36	2.05e-14	Menopause (age at onset);
LUAD	cis	rs4006360	0.543	rs937403	chr17:39296016	A/C	cg20663846	chr17:39254439	KRTAP4-8	0.36	7.41	0.34	7.07e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg08885076	chr2:99613938	TSGA10	0.41	7.61	0.35	1.84e-13	Chronic sinus infection;
LUAD	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg19413350	chr8:57351067	NA	-0.41	-6.52	-0.3	1.95e-10	Obesity-related traits;
LUAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg05896524	chr21:47604654	C21orf56	0.63	10.76	0.46	4.84e-24	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.791	rs55655651	chr17:28244286	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.34	0.41	5.55e-19	Coffee consumption (cups per day);
LUAD	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.97	20.85	0.71	6.08e-67	Chronic sinus infection;
LUAD	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg22508957	chr16:3507546	NAT15	-0.4	-6.55	-0.3	1.72e-10	Body mass index (adult);
LUAD	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg03948781	chr1:205179583	DSTYK	0.33	6.47	0.3	2.76e-10	Red blood cell count;
LUAD	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg13319975	chr6:146136371	FBXO30	-0.59	-9.73	-0.43	2.46e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg10523679	chr1:76189770	ACADM	0.8	12.13	0.51	2.92e-29	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg20291162	chr17:40259547	DHX58	-0.68	-10.52	-0.46	3.8e-23	Fibrinogen levels;
LUAD	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg26587870	chr6:27730563	NA	-0.53	-8.17	-0.37	3.71e-15	Breast cancer;
LUAD	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	cis	rs7173743	0.756	rs8035039	chr15:79129823	A/G	cg00540400	chr15:79124168	NA	0.38	7.69	0.35	1.03e-13	Coronary artery disease;
LUAD	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg14582100	chr15:45693742	SPATA5L1	0.52	9.89	0.43	6.86e-21	Homoarginine levels;
LUAD	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.94	13.46	0.55	1.26e-34	Smoking behavior;
LUAD	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg05082376	chr22:42548792	NA	-0.42	-7.17	-0.33	3.37e-12	Schizophrenia;
LUAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg20607798	chr8:58055168	NA	0.67	8.79	0.39	3.8e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg07806771	chr7:64541737	NA	-0.46	-7.38	-0.34	8.29e-13	Calcium levels;
LUAD	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	6.45	0.3	3.05e-10	Obesity-related traits;
LUAD	cis	rs12519773	0.526	rs4869191	chr5:92525434	A/T	cg18783429	chr5:92414398	NA	-0.37	-6.5	-0.3	2.33e-10	Migraine;
LUAD	cis	rs6669072	0.647	rs1335727	chr1:91238652	C/T	cg08895590	chr1:91227319	NA	-0.31	-6.56	-0.3	1.62e-10	Cognitive function;
LUAD	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg06627628	chr2:24431161	ITSN2	-0.51	-8.54	-0.38	2.42e-16	Asthma;
LUAD	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg22491629	chr6:157744540	C6orf35	-0.71	-8.28	-0.37	1.68e-15	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs13082711	0.558	rs1844983	chr3:27370203	C/T	cg02860705	chr3:27208620	NA	-0.56	-9.66	-0.43	4.26e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg02527881	chr3:46936655	PTH1R	0.43	8.22	0.37	2.45e-15	Colorectal cancer;
LUAD	cis	rs89107	0.631	rs11758402	chr6:118620293	A/G	cg21191810	chr6:118973309	C6orf204	0.38	6.86	0.32	2.5e-11	Cardiac structure and function;
LUAD	trans	rs853679	0.607	rs72846780	chr6:28119055	T/C	cg01620082	chr3:125678407	NA	-1.1	-10.38	-0.45	1.25e-22	Depression;
LUAD	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg12140854	chr5:148520817	ABLIM3	-0.68	-10.93	-0.47	1.2e-24	Breast cancer;
LUAD	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg09658497	chr7:2847517	GNA12	-0.49	-8.86	-0.4	2.24e-17	Height;
LUAD	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg13385794	chr1:248469461	NA	0.27	7.06	0.32	6.9e-12	Common traits (Other);
LUAD	cis	rs3774749	0.565	rs1005678	chr3:50210289	C/G	cg14019146	chr3:50243930	SLC38A3	-0.37	-7.3	-0.33	1.44e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.86	0.36	3.31e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg24642844	chr7:1081250	C7orf50	-0.83	-12.67	-0.52	2.04e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2075371	0.644	rs1643041	chr7:134012211	C/T	cg20476274	chr7:133979776	SLC35B4	0.6	10.03	0.44	2.18e-21	Mean platelet volume;
LUAD	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg19318889	chr4:1322082	MAEA	-0.84	-14.39	-0.57	1.73e-38	Longevity;
LUAD	cis	rs7173743	1.000	rs4420501	chr15:79138478	A/T	cg00540400	chr15:79124168	NA	-0.33	-6.35	-0.3	5.47e-10	Coronary artery disease;
LUAD	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-7.1	-0.33	5.21e-12	Longevity;Endometriosis;
LUAD	cis	rs4268898	0.552	rs4665663	chr2:24372139	G/C	cg20701182	chr2:24300061	SF3B14	-0.4	-6.35	-0.3	5.41e-10	Asthma;
LUAD	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg23018236	chr17:30244563	NA	-0.69	-8.39	-0.38	7.53e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs4790333	0.715	rs2447110	chr17:2261677	A/G	cg02569219	chr17:2266849	SGSM2	0.63	12.26	0.51	8.67e-30	Proinsulin levels;
LUAD	cis	rs9560113	1.000	rs2104790	chr13:112177412	C/T	cg14154082	chr13:112174009	NA	0.37	6.87	0.32	2.32e-11	Menarche (age at onset);
LUAD	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg14671364	chr1:107599128	PRMT6	0.63	10.9	0.47	1.44e-24	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.37	7.92	0.36	2.06e-14	Parkinson's disease;
LUAD	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.18	-0.33	3.12e-12	Height;
LUAD	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg25838465	chr1:92012736	NA	-0.54	-10.69	-0.46	9.28e-24	Breast cancer;
LUAD	cis	rs6714710	0.603	rs17488897	chr2:98365164	G/C	cg26665480	chr2:98280029	ACTR1B	0.56	9.05	0.4	5.2e-18	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs4006360	0.547	rs9901868	chr17:39232963	A/G	cg20663846	chr17:39254439	KRTAP4-8	0.39	8.59	0.39	1.75e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs72772090	0.539	rs11743410	chr5:96124453	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-7.02	-0.32	8.82e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg15147215	chr3:52552868	STAB1	-0.39	-7.19	-0.33	2.99e-12	Bipolar disorder;
LUAD	trans	rs62458065	0.513	rs10268803	chr7:32547835	A/G	cg00845942	chr12:64062724	DPY19L2	-0.56	-8.11	-0.37	5.36e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7274811	0.625	rs169797	chr20:31926490	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.45	6.59	0.31	1.28e-10	Height;
LUAD	cis	rs6881634	0.501	rs10064024	chr5:77723497	A/T	cg11547950	chr5:77652471	NA	-0.37	-6.73	-0.31	5.45e-11	Hippocampal atrophy;
LUAD	cis	rs9467160	0.871	rs7762593	chr6:24449417	G/A	cg20631270	chr6:24437470	GPLD1	0.44	6.74	0.31	5.33e-11	Liver enzyme levels;
LUAD	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg11242978	chr22:46423387	NA	-0.36	-6.56	-0.3	1.54e-10	Dupuytren's disease;
LUAD	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.77	8.73	0.39	5.84e-17	Initial pursuit acceleration;
LUAD	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg10295955	chr4:187884368	NA	-1.06	-23.42	-0.75	2.19e-78	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2239547	0.603	rs71301807	chr3:53085475	C/G	cg18404041	chr3:52824283	ITIH1	-0.52	-8.79	-0.39	3.69e-17	Schizophrenia;
LUAD	trans	rs1493916	0.837	rs1027332	chr18:31410097	A/C	cg27147174	chr7:100797783	AP1S1	-0.62	-10.88	-0.47	1.73e-24	Life satisfaction;
LUAD	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg21890820	chr11:65308645	LTBP3	0.46	7.3	0.33	1.41e-12	Bone mineral density;
LUAD	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg11292332	chr7:45801988	SEPT13	-0.29	-6.4	-0.3	4.19e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg04731861	chr2:219085781	ARPC2	0.23	7.02	0.32	8.63e-12	Colorectal cancer;
LUAD	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.18	0.44	6.42e-22	Ileal carcinoids;
LUAD	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.04	0.32	7.98e-12	Colorectal cancer;
LUAD	cis	rs9394169	0.818	rs1547671	chr6:33777260	C/T	cg13859433	chr6:33739653	LEMD2	-0.28	-6.68	-0.31	7.39e-11	Essential tremor;
LUAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg13397359	chr6:42928475	GNMT	0.59	11.07	0.47	3.41e-25	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg08999081	chr20:33150536	PIGU	0.51	10.57	0.46	2.49e-23	Coronary artery disease;
LUAD	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg08847533	chr14:75593920	NEK9	0.42	7.3	0.33	1.4e-12	Height;
LUAD	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg18252515	chr7:66147081	NA	-0.61	-6.77	-0.31	4.44e-11	Diabetic kidney disease;
LUAD	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg19163074	chr7:65112434	INTS4L2	0.44	6.75	0.31	4.89e-11	Aortic root size;
LUAD	cis	rs7216064	1.000	rs12451511	chr17:65874861	T/G	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg26924012	chr15:45694286	SPATA5L1	0.64	10.91	0.47	1.4e-24	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg16647868	chr5:131706066	SLC22A5	-0.5	-7.8	-0.35	4.99e-14	Blood metabolite levels;
LUAD	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.55	-0.3	1.66e-10	Total body bone mineral density;
LUAD	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.78	0.31	4.01e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg09835421	chr16:68378352	PRMT7	-0.95	-11.0	-0.47	6.55e-25	Schizophrenia;
LUAD	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg10518543	chr12:38710700	ALG10B	-0.44	-7.33	-0.34	1.16e-12	Morning vs. evening chronotype;
LUAD	cis	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg12964065	chr18:77638022	KCNG2	0.55	6.84	0.32	2.85e-11	Opioid sensitivity;
LUAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg03188948	chr7:1209495	NA	0.77	10.29	0.45	2.59e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs870825	0.616	rs4437299	chr4:185643223	T/A	cg04058563	chr4:185651563	MLF1IP	0.87	14.03	0.56	5.61e-37	Blood protein levels;
LUAD	cis	rs1595825	1.000	rs1304165	chr2:198877300	G/A	cg10547527	chr2:198650123	BOLL	-0.48	-6.68	-0.31	7.67e-11	Ulcerative colitis;
LUAD	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg12927641	chr6:109611667	NA	-0.45	-7.51	-0.34	3.46e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs6840360	0.571	rs2407069	chr4:152533201	G/A	cg22705602	chr4:152727874	NA	-0.38	-6.72	-0.31	6.06e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs11885103	0.791	rs10197290	chr2:584872	A/G	cg12228919	chr15:44955936	SPG11	-0.44	-6.67	-0.31	7.89e-11	Heschl's gyrus morphology;
LUAD	cis	rs6893807	0.697	rs27774	chr5:87959033	G/A	cg02225085	chr5:87975992	LOC645323	-0.4	-6.84	-0.32	2.85e-11	Body mass index;
LUAD	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg09184832	chr6:79620586	NA	-0.53	-9.9	-0.43	6.4e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg09658497	chr7:2847517	GNA12	-0.45	-8.19	-0.37	3.12e-15	Height;
LUAD	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg00757033	chr12:89920650	WDR51B	0.71	12.14	0.51	2.56e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-14.53	-0.58	4.39e-39	Headache;
LUAD	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg01528321	chr10:82214614	TSPAN14	0.54	8.35	0.38	9.57e-16	Post bronchodilator FEV1;
LUAD	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg13768953	chr17:7114967	DLG4	-0.43	-8.18	-0.37	3.3e-15	Diastolic blood pressure;
LUAD	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg04369109	chr6:150039330	LATS1	-0.44	-7.52	-0.34	3.25e-13	Lung cancer;
LUAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg13012494	chr21:47604986	C21orf56	0.46	7.58	0.35	2.22e-13	Testicular germ cell tumor;
LUAD	cis	rs113835537	0.529	rs2279864	chr11:66247844	G/A	cg26679405	chr11:66247800	DPP3	-0.46	-6.65	-0.31	9.2e-11	Airway imaging phenotypes;
LUAD	cis	rs12949688	1.000	rs12949688	chr17:55825701	C/T	cg12582317	chr17:55822272	NA	-0.37	-7.33	-0.34	1.16e-12	Schizophrenia;
LUAD	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.69	10.6	0.46	1.95e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs2040771	0.774	rs9604935	chr22:19211665	C/T	cg02655711	chr22:19163373	SLC25A1	0.56	10.63	0.46	1.49e-23	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.57	-10.88	-0.47	1.84e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg15128208	chr22:42549153	NA	0.43	6.73	0.31	5.69e-11	Birth weight;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00748821	chr4:83932227	LIN54	-0.4	-6.35	-0.3	5.47e-10	Height;
LUAD	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.48e-10	Prostate cancer;
LUAD	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg01689657	chr7:91764605	CYP51A1	0.31	7.54	0.34	2.99e-13	Breast cancer;
LUAD	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg27211696	chr2:191398769	TMEM194B	-0.59	-7.94	-0.36	1.82e-14	Diastolic blood pressure;
LUAD	cis	rs9914544	0.545	rs57035178	chr17:18797767	C/T	cg25390199	chr17:18761479	PRPSAP2	-0.37	-6.44	-0.3	3.29e-10	Educational attainment (years of education);
LUAD	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7831492	0.564	rs57596574	chr8:41609843	G/A	cg17182837	chr8:41585554	ANK1	-0.42	-9.0	-0.4	7.88e-18	Colorectal cancer;
LUAD	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg23758822	chr17:41437982	NA	0.91	18.2	0.66	4.33e-55	Menopause (age at onset);
LUAD	cis	rs7527798	0.571	rs4844611	chr1:207827538	G/C	cg09232269	chr1:207846808	CR1L	-0.37	-7.05	-0.32	7.17e-12	Erythrocyte sedimentation rate;
LUAD	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg03714773	chr7:91764589	CYP51A1	0.28	6.47	0.3	2.65e-10	Breast cancer;
LUAD	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.59	-9.96	-0.44	3.82e-21	Electrocardiographic conduction measures;
LUAD	cis	rs7737355	0.812	rs251012	chr5:131030295	A/G	cg25547332	chr5:131281432	NA	-0.41	-6.78	-0.31	4e-11	Life satisfaction;
LUAD	cis	rs7937682	0.587	rs571594	chr11:111359334	A/G	cg09085632	chr11:111637200	PPP2R1B	0.41	6.67	0.31	7.83e-11	Primary sclerosing cholangitis;
LUAD	trans	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg11693508	chr17:37793320	STARD3	0.82	10.6	0.46	1.87e-23	Bipolar disorder;
LUAD	trans	rs7939886	0.920	rs17150102	chr11:55904382	A/C	cg15704280	chr7:45808275	SEPT13	0.66	6.38	0.3	4.79e-10	Myopia (pathological);
LUAD	cis	rs847577	0.630	rs11764933	chr7:97825188	G/A	cg21770322	chr7:97807741	LMTK2	0.35	8.33	0.38	1.16e-15	Breast cancer;
LUAD	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.35	0.34	9.99e-13	Menopause (age at onset);
LUAD	cis	rs1034435	0.723	rs713946	chr22:48891376	T/C	cg05992904	chr22:48892994	FAM19A5	-0.75	-16.61	-0.63	4.85e-48	Late-onset Alzheimer's disease;
LUAD	cis	rs4389656	0.625	rs274682	chr5:6748518	A/G	cg10857441	chr5:6722123	POLS	-0.43	-7.03	-0.32	8.22e-12	Coronary artery disease;
LUAD	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg19336497	chr11:14380999	RRAS2	0.56	11.57	0.49	4.3e-27	Vitamin D levels;
LUAD	cis	rs2908197	0.713	rs2961038	chr7:75952070	G/C	cg24580635	chr7:76178542	LOC100133091	-0.43	-6.72	-0.31	6e-11	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg06671706	chr8:8559999	CLDN23	0.64	10.95	0.47	9.59e-25	Obesity-related traits;
LUAD	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg12016809	chr21:47604291	C21orf56	0.45	7.38	0.34	8.6e-13	Testicular germ cell tumor;
LUAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg02869364	chr7:1081709	C7orf50	-0.51	-6.55	-0.3	1.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.79	-0.43	1.59e-20	Alzheimer's disease;
LUAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg08027265	chr7:2291960	NA	-0.45	-7.39	-0.34	7.75e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs3821902	0.646	rs17344716	chr3:64019744	T/A	cg22134162	chr3:63841271	THOC7	-0.42	-6.99	-0.32	1.07e-11	Breast cancer;
LUAD	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01570182	chr17:44337453	NA	1.14	17.63	0.65	1.45e-52	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg03467027	chr4:99064603	C4orf37	0.4	6.49	0.3	2.34e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18876405	chr7:65276391	NA	-0.42	-6.8	-0.31	3.49e-11	Aortic root size;
LUAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18876405	chr7:65276391	NA	0.57	9.43	0.42	2.8e-19	Aortic root size;
LUAD	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg09455208	chr3:40491958	NA	0.64	14.25	0.57	6.5e-38	Renal cell carcinoma;
LUAD	cis	rs887829	0.569	rs6711351	chr2:234634916	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-9.43	-0.42	2.7e-19	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg14664628	chr15:75095509	CSK	-0.58	-9.14	-0.41	2.66e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs654950	0.901	rs1885654	chr1:42007188	C/A	cg06885757	chr1:42089581	HIVEP3	-0.49	-10.86	-0.47	2.03e-24	Airway imaging phenotypes;
LUAD	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg14895029	chr7:2775587	GNA12	-0.45	-7.51	-0.34	3.66e-13	Height;
LUAD	cis	rs1784581	0.674	rs1784592	chr6:162387365	T/A	cg17173639	chr6:162384350	PARK2	-0.51	-9.1	-0.4	3.48e-18	Itch intensity from mosquito bite;
LUAD	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21659725	chr3:3221576	CRBN	0.66	11.38	0.48	2.28e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.51	-9.41	-0.42	3.09e-19	Longevity;Endometriosis;
LUAD	trans	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg07393940	chr7:158741817	NA	0.66	11.29	0.48	5.31e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg10518543	chr12:38710700	ALG10B	0.43	7.36	0.34	9.85e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg21984481	chr17:79567631	NPLOC4	-0.71	-17.14	-0.64	2.2e-50	Eye color traits;
LUAD	cis	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-7.07	-0.32	6.57e-12	Systolic blood pressure;
LUAD	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg17177755	chr1:15930204	NA	0.46	7.35	0.34	1e-12	Systolic blood pressure;
LUAD	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg11663144	chr21:46675770	NA	-0.48	-9.17	-0.41	2.13e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg22676075	chr6:135203613	NA	0.41	7.48	0.34	4.22e-13	Red blood cell count;
LUAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg22907277	chr7:1156413	C7orf50	0.71	8.31	0.37	1.29e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg07817883	chr1:32538562	TMEM39B	0.68	8.15	0.37	4.02e-15	Monocyte percentage of white cells;
LUAD	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg18190219	chr22:46762943	CELSR1	-0.5	-6.45	-0.3	3.12e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg22875332	chr1:76189707	ACADM	0.87	16.41	0.62	3.45e-47	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg23173402	chr1:227635558	NA	0.68	6.49	0.3	2.46e-10	Major depressive disorder;
LUAD	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg15501526	chr10:2543763	NA	0.75	17.03	0.64	6.39e-50	Age-related hearing impairment;
LUAD	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg10544611	chr16:67998164	SLC12A4	-0.54	-6.87	-0.32	2.38e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-7.32	-0.34	1.23e-12	IgG glycosylation;
LUAD	cis	rs2046867	0.862	rs62251646	chr3:72805787	T/C	cg25664220	chr3:72788482	NA	-0.67	-11.95	-0.5	1.54e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7187994	0.848	rs34139611	chr16:84772473	C/T	cg07647771	chr16:84786436	USP10	-0.37	-9.11	-0.41	3.26e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg23262073	chr20:60523788	NA	-0.65	-10.57	-0.46	2.42e-23	Obesity-related traits;
LUAD	cis	rs921968	0.541	rs2710246	chr2:219533894	C/T	cg02176678	chr2:219576539	TTLL4	0.67	13.36	0.54	3.26e-34	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.8	0.53	5.98e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg02176678	chr2:219576539	TTLL4	-0.76	-15.88	-0.61	6.84e-45	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs6558530	0.931	rs4639549	chr8:1708044	A/G	cg17159058	chr8:1704075	NA	-0.4	-6.45	-0.3	3e-10	Systolic blood pressure;
LUAD	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg00701064	chr4:6280414	WFS1	0.66	14.47	0.58	7.7e-39	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17911021	chr15:45493416	SHF	-0.4	-6.66	-0.31	8.44e-11	Cancer;
LUAD	cis	rs10821973	0.527	rs7895575	chr10:63977537	G/A	cg09941381	chr10:64027924	RTKN2	-0.34	-6.72	-0.31	5.72e-11	Hypothyroidism;
LUAD	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs9788721	0.802	rs56219465	chr15:78742579	A/G	cg18825076	chr15:78729989	IREB2	-0.56	-9.66	-0.43	4.29e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg03859395	chr2:55845619	SMEK2	-0.44	-6.74	-0.31	5.09e-11	Metabolic syndrome;
LUAD	cis	rs1950500	0.550	rs7148384	chr14:24828814	C/T	cg22990158	chr14:24802150	ADCY4	0.48	6.45	0.3	3.08e-10	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19558860	chr14:93582779	ITPK1	-0.52	-6.39	-0.3	4.31e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg05665937	chr4:1216051	CTBP1	0.46	8.27	0.37	1.75e-15	Obesity-related traits;
LUAD	cis	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.65	0.31	9.09e-11	Endometrial cancer;
LUAD	trans	rs9354308	0.899	rs2814094	chr6:66536275	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.52	-7.93	-0.36	1.96e-14	Metabolite levels;
LUAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg27588902	chr6:42928151	GNMT	-0.37	-9.79	-0.43	1.57e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg27660248	chr4:1201315	LOC100130872;LOC100130872-SPON2	-0.35	-6.37	-0.3	4.8e-10	Obesity-related traits;
LUAD	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg20607798	chr8:58055168	NA	0.58	7.77	0.35	5.99e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs2108225	0.837	rs7810937	chr7:107447500	A/G	cg18560240	chr7:107437656	SLC26A3	-0.42	-6.87	-0.32	2.35e-11	Ulcerative colitis;
LUAD	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg11494091	chr17:61959527	GH2	0.4	7.21	0.33	2.54e-12	Height;
LUAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08677398	chr8:58056175	NA	0.55	7.08	0.33	6.06e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14240646	chr10:27532245	ACBD5	-0.79	-10.99	-0.47	6.84e-25	Breast cancer;
LUAD	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg24733560	chr20:60626293	TAF4	0.47	8.35	0.38	9.770000000000001e-16	Body mass index;
LUAD	cis	rs12545109	0.800	rs2118260	chr8:57393481	T/C	cg21220214	chr8:57350948	NA	-0.66	-9.27	-0.41	9.51e-19	Obesity-related traits;
LUAD	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg21385522	chr1:16154831	NA	-0.95	-15.32	-0.6	1.85e-42	Dilated cardiomyopathy;
LUAD	cis	rs3096299	0.583	rs2965949	chr16:89520452	A/G	cg06640241	chr16:89574553	SPG7	0.54	8.11	0.37	5.47e-15	Multiple myeloma (IgH translocation);
LUAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.63	-10.33	-0.45	1.82e-22	Longevity;Endometriosis;
LUAD	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.08	-0.37	6.91e-15	Diabetic kidney disease;
LUAD	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.65	9.98	0.44	3.43e-21	Lymphocyte percentage of white cells;
LUAD	cis	rs7680126	0.536	rs4525975	chr4:10037390	T/C	cg00071950	chr4:10020882	SLC2A9	0.65	7.92	0.36	2.12e-14	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg18512352	chr11:47633146	NA	-0.48	-8.49	-0.38	3.6e-16	Subjective well-being;
LUAD	trans	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.66	-9.56	-0.42	9.43e-20	Blood trace element (Cu levels);
LUAD	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg11822812	chr5:140052017	DND1	-0.44	-7.9	-0.36	2.47e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4846217	0.915	rs7525661	chr1:10453292	C/A	cg17425144	chr1:10567563	PEX14	-0.53	-6.59	-0.31	1.28e-10	Platelet count;
LUAD	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg04539111	chr16:67997858	SLC12A4	-0.48	-6.43	-0.3	3.37e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.8	-0.5	5.61e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg18621852	chr3:10150065	C3orf24	0.48	8.45	0.38	4.89e-16	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.41e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg14893161	chr1:205819251	PM20D1	0.52	8.13	0.37	4.68e-15	Parkinson's disease;
LUAD	cis	rs9811920	0.799	rs9832134	chr3:99836722	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	10.62	0.46	1.6e-23	Axial length;
LUAD	cis	rs9372498	0.536	rs62422224	chr6:118941116	G/A	cg07617317	chr6:118971624	C6orf204	0.56	8.1	0.37	5.74e-15	Diastolic blood pressure;
LUAD	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg06784218	chr1:46089804	CCDC17	0.6	13.37	0.55	2.89e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg05368731	chr17:41323189	NBR1	0.97	20.59	0.71	9.16e-66	Menopause (age at onset);
LUAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg05896524	chr21:47604654	C21orf56	0.74	13.22	0.54	1.21e-33	Testicular germ cell tumor;
LUAD	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg18252515	chr7:66147081	NA	-0.63	-6.89	-0.32	2.01e-11	Diabetic kidney disease;
LUAD	trans	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg01620082	chr3:125678407	NA	-0.71	-7.18	-0.33	3.14e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6543140	0.964	rs4851578	chr2:103028951	T/G	cg03938978	chr2:103052716	IL18RAP	0.35	6.72	0.31	5.92e-11	Blood protein levels;
LUAD	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg18132916	chr6:79620363	NA	-0.45	-7.72	-0.35	8.48e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg06641503	chr3:48959341	ARIH2	-0.42	-8.19	-0.37	3.05e-15	Parkinson's disease;
LUAD	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg22823121	chr1:150693482	HORMAD1	0.45	9.18	0.41	1.93e-18	Tonsillectomy;
LUAD	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg12863693	chr15:85201151	NMB	0.43	8.02	0.36	1.08e-14	Schizophrenia;
LUAD	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.54	8.97	0.4	9.56e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs356992	0.915	rs76674	chr2:60749109	C/T	cg08426369	chr2:60753602	BCL11A	-0.47	-8.02	-0.36	1.03e-14	Educational attainment (years of education);
LUAD	cis	rs1595825	0.891	rs4422151	chr2:198544183	A/T	cg11031976	chr2:198649780	BOLL	-0.44	-6.63	-0.31	1e-10	Ulcerative colitis;
LUAD	cis	rs2447097	0.935	rs2447094	chr17:2294048	A/C	cg02569219	chr17:2266849	SGSM2	0.46	8.05	0.36	8.74e-15	Autism spectrum disorder;
LUAD	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg00484396	chr16:3507460	NAT15	-0.71	-11.27	-0.48	6.09e-26	Tuberculosis;
LUAD	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg23992470	chr4:843637	GAK	0.71	7.46	0.34	4.94e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11644478	chr21:40555479	PSMG1	-0.43	-7.13	-0.33	4.24e-12	Menarche (age at onset);
LUAD	cis	rs6062509	0.895	rs55946717	chr20:62363869	G/A	cg02966332	chr20:62369605	LIME1	-0.46	-7.51	-0.34	3.5e-13	Prostate cancer;
LUAD	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg08632164	chr7:65971372	NA	-0.37	-6.46	-0.3	2.83e-10	Aortic root size;
LUAD	cis	rs2997447	0.846	rs3008418	chr1:26403098	G/A	cg00147160	chr1:26503991	CNKSR1	0.36	6.69	0.31	7.26e-11	QRS complex (12-leadsum);
LUAD	cis	rs11206510	0.585	rs2495505	chr1:55484810	A/G	cg13462158	chr1:55522104	PCSK9	0.43	6.65	0.31	9.08e-11	Coronary heart disease;LDL cholesterol;Myocardial infarction (early onset);Myocardial infarction;Coronary artery disease;
LUAD	cis	rs877282	0.947	rs7923867	chr10:768094	G/A	cg06581033	chr10:766294	NA	-0.62	-8.34	-0.38	1.08e-15	Uric acid levels;
LUAD	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06028605	chr16:24865363	SLC5A11	0.56	8.44	0.38	5.13e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	6.7	0.31	6.69e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs68170813	0.617	rs17481842	chr7:107121862	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-9.06	-0.4	4.84e-18	Coronary artery disease;
LUAD	cis	rs600231	0.542	rs10896010	chr11:65246220	C/A	cg17120908	chr11:65337727	SSSCA1	-0.64	-8.48	-0.38	3.88e-16	Bone mineral density;
LUAD	trans	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg26043149	chr18:55253948	FECH	-0.48	-7.78	-0.35	5.79e-14	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg15704280	chr7:45808275	SEPT13	0.68	11.04	0.47	4.65e-25	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-16.97	-0.64	1.22e-49	Exhaled nitric oxide output;
LUAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18099408	chr3:52552593	STAB1	-0.53	-9.6	-0.42	7.07e-20	Electroencephalogram traits;
LUAD	cis	rs4308124	0.708	rs7585313	chr2:111975203	A/G	cg04571233	chr2:111982156	NA	-0.46	-6.61	-0.31	1.15e-10	Vitiligo;
LUAD	cis	rs240764	0.853	rs4461738	chr6:100977940	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-7.19	-0.33	2.99e-12	Neuroticism;
LUAD	cis	rs6663390	0.510	rs2267895	chr1:208081063	C/T	cg03990033	chr1:208084030	CD34	0.51	6.48	0.3	2.52e-10	Facial morphology (factor 18);
LUAD	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00166722	chr3:10149974	C3orf24	0.63	10.42	0.45	8.88e-23	Alzheimer's disease;
LUAD	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.34	-6.47	-0.3	2.65e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg03929089	chr4:120376271	NA	-0.82	-14.35	-0.57	2.51e-38	Height;
LUAD	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg22482690	chr17:47019901	SNF8	0.45	8.77	0.39	4.31e-17	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg08859206	chr1:53392774	SCP2	-0.47	-8.69	-0.39	8.18e-17	Monocyte count;
LUAD	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg06671706	chr8:8559999	CLDN23	0.68	11.68	0.49	1.67e-27	Obesity-related traits;
LUAD	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg26587870	chr6:27730563	NA	-0.49	-8.18	-0.37	3.27e-15	Parkinson's disease;
LUAD	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg26384229	chr12:38710491	ALG10B	-0.4	-6.8	-0.31	3.64e-11	Bladder cancer;
LUAD	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg02423579	chr7:2872169	GNA12	-0.57	-9.73	-0.43	2.43e-20	Height;
LUAD	cis	rs11585357	0.793	rs11588418	chr1:17616445	A/G	cg08277548	chr1:17600880	PADI3	-0.9	-13.34	-0.54	4.13e-34	Hair shape;
LUAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg14159672	chr1:205819179	PM20D1	0.47	7.41	0.34	6.85e-13	Parkinson's disease;
LUAD	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg15704280	chr7:45808275	SEPT13	-1.0	-20.43	-0.7	4.95e-65	Height;
LUAD	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.32	-0.45	2.07e-22	Monocyte percentage of white cells;
LUAD	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.73e-16	Neutrophil percentage of white cells;
LUAD	cis	rs7336332	0.527	rs1475219	chr13:28037415	A/G	cg22138327	chr13:27999177	GTF3A	0.6	8.8	0.39	3.56e-17	Weight;
LUAD	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg04851639	chr8:1020857	NA	-0.32	-7.64	-0.35	1.5e-13	Schizophrenia;
LUAD	trans	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg25894440	chr7:65020034	NA	-0.64	-6.84	-0.32	2.85e-11	Gout;
LUAD	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg18512352	chr11:47633146	NA	-0.56	-10.04	-0.44	2.02e-21	Subjective well-being;
LUAD	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg10560079	chr2:191398806	TMEM194B	-0.54	-7.07	-0.33	6.28e-12	Diastolic blood pressure;
LUAD	cis	rs4638749	0.677	rs9631035	chr2:108818916	C/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.27	-0.33	1.73e-12	Blood pressure;
LUAD	cis	rs6594713	0.837	rs13181732	chr5:112724778	C/T	cg12552261	chr5:112820674	MCC	-0.48	-6.99	-0.32	1.07e-11	Brain cytoarchitecture;
LUAD	cis	rs7116495	1.000	rs610041	chr11:71797968	A/G	cg07596299	chr11:71824057	C11orf51	-0.77	-6.44	-0.3	3.2e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs4846217	0.831	rs11804162	chr1:10402841	C/T	cg17425144	chr1:10567563	PEX14	-0.5	-6.5	-0.3	2.23e-10	Platelet count;
LUAD	cis	rs7587476	0.784	rs62202001	chr2:215690359	C/G	cg04004882	chr2:215674386	BARD1	0.52	6.56	0.3	1.53e-10	Neuroblastoma;
LUAD	cis	rs7809950	0.953	rs3094383	chr7:107143164	G/A	cg23024343	chr7:107201750	COG5	-0.73	-12.35	-0.51	3.95e-30	Coronary artery disease;
LUAD	cis	rs6489882	0.966	rs4238033	chr12:113378081	T/A	cg20102336	chr12:113376681	OAS3	-0.57	-8.89	-0.4	1.76e-17	Chronic lymphocytic leukemia;
LUAD	trans	rs1728785	1.000	rs1645927	chr16:68589300	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.3	0.45	2.43e-22	Ulcerative colitis;
LUAD	cis	rs9517313	0.584	rs9556974	chr13:99216302	G/C	cg20487152	chr13:99095054	FARP1	-0.5	-8.48	-0.38	3.88e-16	Neuroticism;
LUAD	cis	rs17683430	0.557	rs4821012	chr22:32387985	A/G	cg00543991	chr22:32367038	NA	0.92	8.16	0.37	3.95e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg07677032	chr17:61819896	STRADA	0.56	10.31	0.45	2.25e-22	Prudent dietary pattern;
LUAD	cis	rs72928364	1.000	rs66852780	chr3:100709222	A/C	cg10123952	chr3:100791384	NA	0.62	7.12	0.33	4.78e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs17102423	0.788	rs35176994	chr14:65596004	T/C	cg11161011	chr14:65562177	MAX	-0.47	-7.29	-0.33	1.51e-12	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg17366294	chr4:99064904	C4orf37	0.63	11.93	0.5	1.78e-28	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg21427119	chr20:30132790	HM13	-0.56	-8.81	-0.39	3.38e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg27170947	chr2:26402098	FAM59B	-0.8	-11.61	-0.49	3.02e-27	Gut microbiome composition (summer);
LUAD	cis	rs2235649	0.588	rs11863172	chr16:1909083	C/G	cg08610935	chr16:1836813	NUBP2	-0.51	-7.05	-0.32	7.38e-12	Blood metabolite levels;
LUAD	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg19875535	chr5:140030758	IK	-0.44	-7.4	-0.34	7.48e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg00280220	chr17:61926910	NA	0.36	6.99	0.32	1.07e-11	Prudent dietary pattern;
LUAD	cis	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.38	-0.34	8.66e-13	Resting heart rate;
LUAD	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg03806693	chr22:41940476	POLR3H	-0.73	-9.76	-0.43	1.98e-20	Vitiligo;
LUAD	cis	rs3018712	0.532	rs2510397	chr11:68419559	A/G	cg16797656	chr11:68205561	LRP5	-0.42	-6.47	-0.3	2.79e-10	Total body bone mineral density;
LUAD	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.63	0.31	1.04e-10	Menarche (age at onset);
LUAD	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg21017887	chr14:105400489	NA	0.73	13.88	0.56	2.22e-36	Rheumatoid arthritis;
LUAD	trans	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg19862616	chr7:65841803	NCRNA00174	1.05	25.94	0.78	1.75e-89	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg03929089	chr4:120376271	NA	-0.9	-17.14	-0.64	2.09e-50	Coronary artery disease;
LUAD	cis	rs6484504	0.532	rs2774403	chr11:31320530	A/T	cg14844989	chr11:31128820	NA	0.43	7.96	0.36	1.59e-14	Red blood cell count;
LUAD	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22857025	chr5:266934	NA	-0.95	-14.04	-0.56	5.05e-37	Breast cancer;
LUAD	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg20283391	chr11:68216788	NA	-0.4	-6.48	-0.3	2.56e-10	Total body bone mineral density;
LUAD	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.82	-0.43	1.27e-20	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg06740227	chr12:86229804	RASSF9	0.39	6.99	0.32	1.1e-11	Major depressive disorder;
LUAD	cis	rs10924309	0.889	rs10924307	chr1:245858125	C/T	cg00036263	chr1:245852353	KIF26B	-0.47	-7.2	-0.33	2.8e-12	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg18230493	chr5:56204884	C5orf35	-0.44	-7.44	-0.34	5.64e-13	Coronary artery disease;
LUAD	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg16325326	chr1:53192061	ZYG11B	-0.66	-12.49	-0.52	1.04e-30	Monocyte count;
LUAD	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg21194808	chr1:2205498	SKI	0.41	6.49	0.3	2.35e-10	Height;
LUAD	cis	rs9503598	0.502	rs17309827	chr6:3433318	A/C	cg00476032	chr6:3446245	SLC22A23	-0.32	-6.45	-0.3	3.14e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	trans	rs2262909	0.962	rs4932952	chr19:22246788	G/A	cg05197062	chr11:11642011	GALNTL4	0.59	9.15	0.41	2.43e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg15997130	chr1:24165203	NA	-0.48	-7.56	-0.35	2.53e-13	Immature fraction of reticulocytes;
LUAD	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg27494647	chr7:150038898	RARRES2	0.43	7.14	0.33	4.11e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs501916	0.604	rs616871	chr15:48058259	T/A	cg16110827	chr15:48056943	SEMA6D	-0.36	-6.56	-0.3	1.58e-10	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg01475377	chr6:109611718	NA	-0.5	-9.4	-0.42	3.39e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs679087	1.000	rs436124	chr12:29916839	C/T	cg14258853	chr12:29935411	TMTC1	0.59	10.46	0.45	6.48e-23	Schizophrenia;
LUAD	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	7.3	0.33	1.45e-12	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.07	0.37	7.55e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17092148	1.000	rs6088594	chr20:33343157	A/G	cg16810054	chr20:33298113	TP53INP2	0.52	8.26	0.37	1.86e-15	Neuroticism;
LUAD	cis	rs9649213	0.559	rs56997921	chr7:98009224	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.73	-10.62	-0.46	1.67e-23	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.83	0.36	3.99e-14	Depression;
LUAD	cis	rs741677	0.713	rs516382	chr17:486431	A/G	cg15660573	chr17:549704	VPS53	0.57	9.42	0.42	2.97e-19	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9323205	0.677	rs12587080	chr14:51723079	A/C	cg23942311	chr14:51606299	NA	-0.57	-8.63	-0.39	1.23e-16	Cancer;
LUAD	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg26384229	chr12:38710491	ALG10B	0.4	6.53	0.3	1.9e-10	Morning vs. evening chronotype;
LUAD	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg10792982	chr14:105748885	BRF1	0.38	7.83	0.36	3.99e-14	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs1018836	0.669	rs6471243	chr8:91656967	C/T	cg16814680	chr8:91681699	NA	0.91	19.05	0.68	7.45e-59	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12050794	0.671	rs8192362	chr15:72519858	G/A	cg16672083	chr15:72433130	SENP8	0.65	11.98	0.5	1.16e-28	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs12791968	0.649	rs3802785	chr11:44995441	C/T	cg11846598	chr11:44996168	LOC221122	-0.65	-9.26	-0.41	1.02e-18	Inhibitory control;
LUAD	trans	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg21659725	chr3:3221576	CRBN	0.38	6.4	0.3	4.15e-10	Resting heart rate;
LUAD	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.67	10.8	0.47	3.41e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1832871	1.000	rs827857	chr6:158706497	C/T	cg07165851	chr6:158734300	TULP4	0.37	6.36	0.3	5.3e-10	Height;
LUAD	cis	rs2294693	0.945	rs9369252	chr6:40986028	C/T	cg14769373	chr6:40998127	UNC5CL	0.53	8.03	0.36	9.55e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.66	-0.31	8.3e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg17177755	chr1:15930204	NA	0.44	7.1	0.33	5.27e-12	Systolic blood pressure;
LUAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg08132940	chr7:1081526	C7orf50	-0.77	-10.31	-0.45	2.21e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg13736514	chr6:26305472	NA	-0.69	-13.16	-0.54	2.14e-33	Educational attainment;
LUAD	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg10518543	chr12:38710700	ALG10B	0.48	8.08	0.37	6.83e-15	Heart rate;
LUAD	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg13319975	chr6:146136371	FBXO30	-0.57	-9.66	-0.43	4.46e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg01448562	chr3:133502909	NA	0.49	8.87	0.4	2.14e-17	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.06	0.32	6.7e-12	Platelet count;
LUAD	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg05725404	chr16:58534157	NDRG4	-0.7	-7.32	-0.34	1.25e-12	Schizophrenia;
LUAD	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.13	-0.37	4.73e-15	Prostate cancer;
LUAD	cis	rs62400317	0.762	rs6908606	chr6:44998888	A/G	cg18551225	chr6:44695536	NA	-0.56	-8.67	-0.39	9.07e-17	Total body bone mineral density;
LUAD	cis	rs41311933	0.706	rs41308028	chr9:123792469	T/C	cg13567360	chr9:123745713	C5	-0.75	-9.01	-0.4	7.36e-18	Coronary artery disease;
LUAD	trans	rs1493916	0.837	rs9952002	chr18:31414314	C/G	cg15819921	chr19:927150	ARID3A	-0.44	-7.21	-0.33	2.54e-12	Life satisfaction;
LUAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.76	0.31	4.72e-11	Obesity-related traits;
LUAD	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.36	-0.3	5.1e-10	Aortic root size;
LUAD	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg03929089	chr4:120376271	NA	0.58	8.94	0.4	1.24e-17	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs17155006	0.783	rs410286	chr7:107749257	A/T	cg05962710	chr7:107745446	LAMB4	-0.34	-7.31	-0.33	1.37e-12	Pneumococcal bacteremia;
LUAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.57	0.35	2.35e-13	Electroencephalogram traits;
LUAD	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg24531977	chr5:56204891	C5orf35	-0.4	-6.48	-0.3	2.61e-10	Coronary artery disease;
LUAD	cis	rs10504073	0.584	rs56078938	chr8:49940342	A/C	cg00325661	chr8:49890786	NA	0.48	10.45	0.45	6.79e-23	Blood metabolite ratios;
LUAD	cis	rs877282	1.000	rs11253362	chr10:770979	G/T	cg06581033	chr10:766294	NA	-0.55	-7.65	-0.35	1.33e-13	Uric acid levels;
LUAD	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-6.69	-0.31	7.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg08132940	chr7:1081526	C7orf50	-0.79	-10.66	-0.46	1.14e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg23978390	chr7:1156363	C7orf50	0.52	8.21	0.37	2.61e-15	Longevity;Endometriosis;
LUAD	cis	rs4389656	0.857	rs274709	chr5:6726464	T/C	cg10857441	chr5:6722123	POLS	-0.47	-8.0	-0.36	1.18e-14	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg12000995	chr2:27665139	KRTCAP3	0.35	8.91	0.4	1.58e-17	Total body bone mineral density;
LUAD	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg04034577	chr2:241836375	C2orf54	-0.48	-10.38	-0.45	1.23e-22	Urinary metabolites;
LUAD	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg17178900	chr1:205818956	PM20D1	0.41	6.77	0.31	4.37e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg26516362	chr5:178986906	RUFY1	0.59	10.48	0.45	5.24e-23	Lung cancer;
LUAD	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg01200585	chr1:228362443	C1orf69	0.42	7.57	0.35	2.41e-13	Diastolic blood pressure;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07581484	chr11:236519	SIRT3;PSMD13	-0.41	-6.7	-0.31	6.56e-11	Cancer;
LUAD	trans	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	15.3	0.6	2.33e-42	Exhaled nitric oxide levels;
LUAD	cis	rs11811982	0.793	rs11807375	chr1:227511411	A/G	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg01579765	chr21:45077557	HSF2BP	-0.53	-12.06	-0.51	5.35e-29	Mean corpuscular volume;
LUAD	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg21775007	chr8:11205619	TDH	0.38	6.41	0.3	4e-10	Mood instability;
LUAD	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg06636551	chr8:101224915	SPAG1	-0.37	-6.74	-0.31	5.36e-11	Atrioventricular conduction;
LUAD	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.52	-0.34	3.26e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.06	0.32	6.7e-12	Platelet count;
LUAD	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03264133	chr6:25882463	NA	-0.46	-6.83	-0.32	3.04e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg10518543	chr12:38710700	ALG10B	0.41	6.37	0.3	4.9e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2274273	0.870	rs7160523	chr14:55594560	G/T	cg04306507	chr14:55594613	LGALS3	0.41	8.58	0.39	1.77e-16	Protein biomarker;
LUAD	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg11871910	chr12:69753446	YEATS4	0.54	8.56	0.38	2.05e-16	Blood protein levels;
LUAD	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.67	-0.31	8.25e-11	Crohn's disease;
LUAD	cis	rs526821	0.532	rs578067	chr11:55313690	T/G	cg04317927	chr11:55418816	OR4S2	0.38	7.2	0.33	2.78e-12	Pediatric bone mineral density (spine);
LUAD	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.87	-0.36	3.09e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs113835537	0.529	rs3892818	chr11:66240191	C/T	cg24851651	chr11:66362959	CCS	0.57	10.18	0.44	6.65e-22	Airway imaging phenotypes;
LUAD	cis	rs1997103	0.765	rs55686950	chr7:55396552	A/C	cg17469321	chr7:55412551	NA	0.66	11.32	0.48	3.86e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg21385522	chr1:16154831	NA	0.67	10.71	0.46	7.88e-24	Dilated cardiomyopathy;
LUAD	trans	rs4650994	0.524	rs2811299	chr1:178586377	A/G	cg05059571	chr16:84539110	KIAA1609	0.65	11.28	0.48	5.67e-26	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs7107174	1.000	rs11237471	chr11:78082604	C/T	cg19901956	chr11:77921274	USP35	-0.49	-6.92	-0.32	1.64e-11	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg03676636	chr4:99064102	C4orf37	0.31	8.08	0.37	6.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg08132940	chr7:1081526	C7orf50	-0.78	-10.56	-0.46	2.64e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg24069376	chr3:38537580	EXOG	0.42	9.85	0.43	9.27e-21	Electrocardiographic conduction measures;
LUAD	trans	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg24644049	chr4:85504048	CDS1	0.91	7.84	0.36	3.76e-14	Skin colour saturation;
LUAD	cis	rs2067615	0.524	rs10778499	chr12:107068387	C/T	cg15890332	chr12:107067104	RFX4	0.42	8.8	0.39	3.39e-17	Heart rate;
LUAD	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.61	-0.31	1.19e-10	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs6598955	0.627	rs3924324	chr1:26616280	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.72	-9.92	-0.43	5.22e-21	Obesity-related traits;
LUAD	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.28	-0.45	2.8e-22	Total body bone mineral density;
LUAD	cis	rs76878669	0.561	rs2236679	chr11:66108894	G/C	cg18002602	chr11:66138449	SLC29A2	-0.49	-10.54	-0.46	3.18e-23	Educational attainment (years of education);
LUAD	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.6	7.54	0.34	2.95e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.24	-0.33	2.13e-12	Total cholesterol levels;
LUAD	cis	rs7830933	0.780	rs9644033	chr8:23610639	A/T	cg04349084	chr8:23602677	NA	0.48	6.82	0.31	3.11e-11	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
LUAD	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg05110241	chr16:68378359	PRMT7	-0.63	-7.41	-0.34	7e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.11e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg00255919	chr5:131827918	IRF1	-0.29	-6.58	-0.3	1.38e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg03676636	chr4:99064102	C4orf37	0.3	7.16	0.33	3.54e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg27541892	chr1:1571801	CDK11B	0.43	7.23	0.33	2.35e-12	Body mass index;
LUAD	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg02734326	chr4:10020555	SLC2A9	0.56	9.89	0.43	7.07e-21	Bone mineral density;
LUAD	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg01802117	chr1:53393560	SCP2	-0.33	-6.43	-0.3	3.43e-10	Monocyte count;
LUAD	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg10556349	chr10:835070	NA	-0.49	-6.54	-0.3	1.79e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg01884057	chr2:25150051	NA	0.3	6.53	0.3	1.89e-10	Body mass index;
LUAD	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7975161	0.671	rs7314893	chr12:104597769	C/T	cg25273343	chr12:104657179	TXNRD1	-0.5	-7.43	-0.34	6.04e-13	Toenail selenium levels;
LUAD	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg11266682	chr4:10021025	SLC2A9	0.69	15.79	0.61	1.69e-44	Bone mineral density;
LUAD	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg00852783	chr1:26633632	UBXN11	0.46	7.61	0.35	1.83e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs11229555	0.609	rs11229434	chr11:58185501	C/T	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs8112211	0.954	rs7252835	chr19:38832946	G/A	cg14299480	chr19:38876666	GGN	-0.45	-7.91	-0.36	2.29e-14	Blood protein levels;
LUAD	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg10356904	chr22:49881777	NA	-0.41	-8.7	-0.39	7.31e-17	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs13315871	1.000	rs9864824	chr3:58394835	A/G	cg12435725	chr3:58293450	RPP14	0.68	7.34	0.34	1.1e-12	Cholesterol, total;
LUAD	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg20673091	chr1:2541236	MMEL1	0.38	8.07	0.37	7.33e-15	Ulcerative colitis;
LUAD	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg10523679	chr1:76189770	ACADM	-0.75	-11.42	-0.49	1.7e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg07080864	chr8:57359956	PENK	-0.36	-6.55	-0.3	1.65e-10	Obesity-related traits;
LUAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg11062466	chr8:58055876	NA	0.45	6.45	0.3	2.99e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9658691	0.607	rs9325604	chr10:90775756	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-7.3	-0.33	1.48e-12	Mosquito bite size;
LUAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg03188948	chr7:1209495	NA	0.48	7.94	0.36	1.89e-14	Longevity;Endometriosis;
LUAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg22963979	chr7:1858916	MAD1L1	-0.62	-10.61	-0.46	1.84e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg17724175	chr1:150552817	MCL1	0.38	8.71	0.39	6.84e-17	Melanoma;
LUAD	cis	rs12545109	0.879	rs1513317	chr8:57372966	C/G	cg19413350	chr8:57351067	NA	-0.47	-7.07	-0.33	6.31e-12	Obesity-related traits;
LUAD	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.88	-0.61	7.43e-45	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg03676636	chr4:99064102	C4orf37	0.37	9.55	0.42	1.04e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg06606381	chr12:133084897	FBRSL1	-0.68	-7.1	-0.33	5.24e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg19336497	chr11:14380999	RRAS2	-0.35	-7.22	-0.33	2.49e-12	Mitochondrial DNA levels;
LUAD	cis	rs7809950	0.678	rs12672451	chr7:106853817	C/G	cg23024343	chr7:107201750	COG5	-0.8	-12.88	-0.53	2.87e-32	Coronary artery disease;
LUAD	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg10518543	chr12:38710700	ALG10B	0.44	7.45	0.34	5.2e-13	Morning vs. evening chronotype;
LUAD	cis	rs9513627	1.000	rs7317126	chr13:100119739	T/A	cg25919922	chr13:100150906	NA	-0.62	-6.39	-0.3	4.29e-10	Obesity-related traits;
LUAD	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.6	11.47	0.49	1.06e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg08470875	chr2:26401718	FAM59B	-0.64	-8.27	-0.37	1.74e-15	Gut microbiome composition (summer);
LUAD	cis	rs1524976	1.000	rs62255273	chr3:65452827	C/A	cg16238336	chr3:65465873	MAGI1	-0.67	-7.6	-0.35	1.94e-13	PR interval;
LUAD	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg16325326	chr1:53192061	ZYG11B	-0.63	-11.72	-0.5	1.12e-27	Monocyte count;
LUAD	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg09640425	chr7:158790006	NA	-0.54	-9.36	-0.41	4.76e-19	Facial morphology (factor 20);
LUAD	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg17105886	chr17:28927953	LRRC37B2	0.82	7.87	0.36	2.9e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg17509989	chr5:176798049	RGS14	0.61	9.13	0.41	2.93e-18	Urate levels in lean individuals;
LUAD	cis	rs2425143	1.000	rs6060643	chr20:34449851	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.18	-0.33	3.25e-12	Blood protein levels;
LUAD	cis	rs7586879	1.000	rs7603153	chr2:25116966	T/C	cg04586622	chr2:25135609	ADCY3	0.34	7.37	0.34	9.31e-13	Body mass index;
LUAD	cis	rs9948	0.655	rs6758151	chr2:97388884	A/G	cg20312557	chr2:97357134	FER1L5	-0.6	-7.43	-0.34	6.07e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs73198271	0.531	rs3827812	chr8:8654898	C/T	cg01851573	chr8:8652454	MFHAS1	0.72	10.89	0.47	1.64e-24	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09175582	chr1:161736000	ATF6	-0.39	-6.6	-0.31	1.2e-10	Cancer;
LUAD	cis	rs7166081	0.704	rs2414952	chr15:67724392	A/T	cg24579218	chr15:68104479	NA	-0.49	-7.98	-0.36	1.36e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	trans	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg21659725	chr3:3221576	CRBN	-0.59	-9.45	-0.42	2.36e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1113500	0.702	rs11185262	chr1:108639742	C/T	cg06207961	chr1:108661230	NA	0.45	8.45	0.38	4.75e-16	Growth-regulated protein alpha levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21887597	chr15:83419354	NA	-0.42	-6.55	-0.3	1.64e-10	Height;
LUAD	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg19318889	chr4:1322082	MAEA	0.44	6.96	0.32	1.27e-11	Obesity-related traits;
LUAD	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg00495681	chr13:53174319	NA	0.48	8.44	0.38	5.12e-16	Lewy body disease;
LUAD	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg12573674	chr2:1569213	NA	-0.58	-6.74	-0.31	5.17e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.62	7.49	0.34	3.93e-13	Body mass index;
LUAD	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg06808227	chr14:105710500	BRF1	-0.44	-6.87	-0.32	2.37e-11	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.42	-6.61	-0.31	1.16e-10	Breast cancer;
LUAD	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg09021430	chr5:549028	NA	-0.67	-13.18	-0.54	1.79e-33	Lung disease severity in cystic fibrosis;
LUAD	trans	rs11039798	0.920	rs11039940	chr11:48716316	C/T	cg03929089	chr4:120376271	NA	0.6	6.9	0.32	1.89e-11	Axial length;
LUAD	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg03467027	chr4:99064603	C4orf37	0.41	6.61	0.31	1.19e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg21918786	chr6:109611834	NA	-0.58	-10.61	-0.46	1.84e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg17328964	chr8:145687451	CYHR1	0.55	9.44	0.42	2.51e-19	Age at first birth;
LUAD	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg16083429	chr3:49237500	CCDC36	-0.34	-6.39	-0.3	4.34e-10	Menarche (age at onset);
LUAD	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg22875332	chr1:76189707	ACADM	0.6	9.69	0.43	3.38e-20	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg25767906	chr1:53392781	SCP2	-0.37	-6.72	-0.31	5.86e-11	Monocyte count;
LUAD	cis	rs3106136	0.527	rs4235050	chr4:95157156	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.19	-0.44	5.86e-22	Capecitabine sensitivity;
LUAD	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs2404602	0.655	rs10444809	chr15:77124536	G/C	cg03037974	chr15:76606532	NA	-0.33	-6.7	-0.31	6.86e-11	Blood metabolite levels;
LUAD	cis	rs62400317	0.762	rs12214794	chr6:44931465	G/A	cg20913747	chr6:44695427	NA	-0.44	-6.85	-0.32	2.54e-11	Total body bone mineral density;
LUAD	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg24848339	chr3:12840334	CAND2	0.42	8.37	0.38	8.74e-16	QRS complex (12-leadsum);
LUAD	cis	rs11741688	0.557	rs10043579	chr5:178330174	C/T	cg21944022	chr5:178288650	ZNF354B	0.5	9.28	0.41	8.92e-19	Sleep duration;
LUAD	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg26513180	chr16:89883248	FANCA	-0.67	-12.17	-0.51	2e-29	Vitiligo;
LUAD	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.01	0.36	1.11e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11496792	chr9:123477254	MEGF9	0.42	6.36	0.3	5.15e-10	Gut microbiome composition (summer);
LUAD	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg04058563	chr4:185651563	MLF1IP	0.42	7.46	0.34	4.8e-13	Kawasaki disease;
LUAD	cis	rs4523957	0.788	rs7217687	chr17:2098272	G/C	cg16513277	chr17:2031491	SMG6	-0.74	-13.6	-0.55	3.26e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	7.58	0.35	2.16e-13	Personality dimensions;
LUAD	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.4	-6.45	-0.3	3.14e-10	Longevity;Endometriosis;
LUAD	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg05665937	chr4:1216051	CTBP1	0.48	7.35	0.34	1.05e-12	Longevity;
LUAD	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg06784218	chr1:46089804	CCDC17	0.54	11.62	0.49	2.85e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg26384229	chr12:38710491	ALG10B	0.38	6.7	0.31	6.71e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.6	-8.62	-0.39	1.33e-16	Gut microbiome composition (summer);
LUAD	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.56	0.34	2.59e-13	Cannabis dependence symptom count;
LUAD	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.96	-0.47	8.76e-25	Total body bone mineral density;
LUAD	cis	rs501916	0.833	rs10519143	chr15:48055567	T/G	cg16110827	chr15:48056943	SEMA6D	-0.38	-6.74	-0.31	5.13e-11	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg10589385	chr1:150898437	SETDB1	0.41	7.49	0.34	4.17e-13	Melanoma;
LUAD	cis	rs897984	0.609	rs1108431	chr16:31054607	C/T	cg02466173	chr16:30829666	NA	-0.55	-9.63	-0.42	5.49e-20	Dementia with Lewy bodies;
LUAD	cis	rs1997103	1.000	rs10278894	chr7:55404748	A/G	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs8018808	0.936	rs10140302	chr14:77855693	C/A	cg20045696	chr14:77926864	AHSA1	-0.37	-6.59	-0.31	1.28e-10	Myeloid white cell count;
LUAD	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10802521	chr3:52805072	NEK4	-0.54	-9.17	-0.41	2.16e-18	Bipolar disorder;
LUAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg18621852	chr3:10150065	C3orf24	0.48	8.3	0.37	1.44e-15	Alzheimer's disease;
LUAD	cis	rs877282	0.891	rs34383514	chr10:800181	T/C	cg06581033	chr10:766294	NA	-0.55	-7.47	-0.34	4.5e-13	Uric acid levels;
LUAD	cis	rs6479527	0.840	rs1360429	chr9:96762314	C/T	cg14459158	chr9:96720562	NA	0.38	6.63	0.31	1.05e-10	Esophageal adenocarcinoma;
LUAD	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21028142	chr17:79581711	NPLOC4	0.44	9.46	0.42	2.09e-19	Eye color traits;
LUAD	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg23649088	chr2:200775458	C2orf69	-0.71	-10.99	-0.47	7.19e-25	LDL cholesterol to HDL cholesterol ratio;
LUAD	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.93	13.25	0.54	8.81e-34	Smoking behavior;
LUAD	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg06937882	chr20:24974362	C20orf3	-0.35	-6.92	-0.32	1.63e-11	Blood protein levels;
LUAD	trans	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg06606381	chr12:133084897	FBRSL1	-0.68	-7.11	-0.33	4.89e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg22852734	chr6:133119734	C6orf192	0.93	6.96	0.32	1.34e-11	Type 2 diabetes nephropathy;
LUAD	trans	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg07817883	chr1:32538562	TMEM39B	-0.59	-7.39	-0.34	7.7e-13	Monocyte percentage of white cells;
LUAD	cis	rs6500395	1.000	rs6500402	chr16:48687354	C/T	cg04672837	chr16:48644449	N4BP1	0.38	6.73	0.31	5.37e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg14343924	chr8:8086146	FLJ10661	0.49	8.29	0.37	1.5e-15	Mood instability;
LUAD	cis	rs7216064	1.000	rs11869819	chr17:65868669	A/C	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs4481887	0.800	rs28590733	chr1:248514978	T/C	cg00666640	chr1:248458726	OR2T12	0.28	7.03	0.32	8.49e-12	Common traits (Other);
LUAD	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.3	-6.61	-0.31	1.17e-10	Blood metabolite levels;
LUAD	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg16797656	chr11:68205561	LRP5	-0.44	-9.23	-0.41	1.3e-18	Total body bone mineral density;
LUAD	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg09184832	chr6:79620586	NA	-0.53	-9.84	-0.43	1.07e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg13047869	chr3:10149882	C3orf24	0.64	9.6	0.42	6.98e-20	Alzheimer's disease;
LUAD	cis	rs17401966	0.931	rs10864448	chr1:10277497	A/T	cg15208524	chr1:10270712	KIF1B	0.45	6.87	0.32	2.27e-11	Hepatocellular carcinoma;
LUAD	trans	rs225245	0.817	rs225302	chr17:33922396	C/T	cg19694781	chr19:47549865	TMEM160	-0.46	-7.58	-0.35	2.14e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs300703	0.935	rs300749	chr2:208143	G/T	cg24565620	chr2:194026	NA	-0.5	-6.71	-0.31	6.29e-11	Blood protein levels;
LUAD	cis	rs9863	0.861	rs7973683	chr12:124449223	C/A	cg17723958	chr12:124429295	CCDC92	-0.4	-6.68	-0.31	7.39e-11	White blood cell count;
LUAD	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg22431228	chr1:16359049	CLCNKA	0.42	7.77	0.35	6.2e-14	Systolic blood pressure;
LUAD	cis	rs7665090	1.000	rs6821119	chr4:103555233	T/C	cg07973026	chr4:103553119	MANBA	0.47	8.3	0.37	1.41e-15	Primary biliary cholangitis;
LUAD	cis	rs8060686	0.516	rs8062085	chr16:68289313	C/A	cg09835421	chr16:68378352	PRMT7	-0.55	-6.92	-0.32	1.72e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg02880119	chr16:3481970	NA	0.59	8.74	0.39	5.44e-17	Body mass index (adult);
LUAD	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg04731861	chr2:219085781	ARPC2	0.27	8.22	0.37	2.53e-15	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg14343924	chr8:8086146	FLJ10661	0.48	7.43	0.34	6.25e-13	Mood instability;
LUAD	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg24578937	chr1:2090814	PRKCZ	0.79	16.49	0.63	1.56e-47	Height;
LUAD	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.46	-8.92	-0.4	1.42e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg07719772	chr16:32360419	NA	-0.48	-7.63	-0.35	1.58e-13	Menopause (age at onset);
LUAD	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg09263875	chr16:632152	PIGQ	0.8	17.26	0.64	6.33e-51	Height;
LUAD	cis	rs2580764	0.566	rs2968793	chr2:55285024	C/T	cg09592903	chr2:55203963	RTN4	0.41	9.06	0.4	4.8e-18	Mean platelet volume;
LUAD	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg26513180	chr16:89883248	FANCA	0.72	6.83	0.32	2.98e-11	Skin colour saturation;
LUAD	cis	rs1395	0.922	rs11898114	chr2:27515527	C/T	cg23587288	chr2:27483067	SLC30A3	-0.4	-7.57	-0.35	2.32e-13	Blood metabolite levels;
LUAD	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg17757837	chr7:157058334	UBE3C	-0.49	-8.85	-0.4	2.34e-17	Body mass index;
LUAD	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg20283391	chr11:68216788	NA	-0.41	-6.79	-0.31	3.75e-11	Total body bone mineral density;
LUAD	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg10792982	chr14:105748885	BRF1	0.45	9.88	0.43	7.3e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg22764044	chr5:178986830	RUFY1	-0.71	-12.3	-0.51	6.01e-30	Lung cancer;
LUAD	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg23544223	chr18:12777786	NA	0.67	8.53	0.38	2.71e-16	Inflammatory skin disease;
LUAD	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg19468946	chr17:37922297	IKZF3	0.4	6.42	0.3	3.57e-10	Self-reported allergy;
LUAD	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg04414720	chr1:150670196	GOLPH3L	0.64	11.04	0.47	4.67e-25	Melanoma;
LUAD	cis	rs7584330	0.554	rs729389	chr2:238425118	G/A	cg14458575	chr2:238380390	NA	0.6	9.74	0.43	2.36e-20	Prostate cancer;
LUAD	trans	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg07817883	chr1:32538562	TMEM39B	1.38	11.14	0.48	1.83e-25	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs8002861	0.691	rs9525851	chr13:44402132	T/A	cg17145862	chr1:211918768	LPGAT1	-0.55	-10.83	-0.47	2.85e-24	Leprosy;
LUAD	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg19767477	chr5:127420684	SLC12A2	-0.42	-6.43	-0.3	3.38e-10	Ileal carcinoids;
LUAD	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg09184832	chr6:79620586	NA	-0.51	-9.62	-0.42	5.87e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/A	cg00383909	chr3:49044727	WDR6	0.75	8.47	0.38	4.17e-16	Parkinson's disease;
LUAD	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg06131755	chr6:160182447	ACAT2	0.44	6.55	0.3	1.68e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs1371867	0.846	rs2919471	chr8:101232701	T/C	cg06636551	chr8:101224915	SPAG1	0.41	7.37	0.34	9.13e-13	Atrioventricular conduction;
LUAD	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg20476274	chr7:133979776	SLC35B4	0.74	13.56	0.55	4.97e-35	Mean platelet volume;
LUAD	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	7.96	0.36	1.64e-14	Menarche (age at onset);
LUAD	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg22508957	chr16:3507546	NAT15	0.76	13.33	0.54	4.27e-34	Tuberculosis;
LUAD	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.08	-0.33	5.94e-12	Blood metabolite levels;
LUAD	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg13770153	chr20:60521292	NA	0.64	9.74	0.43	2.35e-20	Body mass index;
LUAD	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg05805236	chr11:65401703	PCNXL3	-0.6	-9.49	-0.42	1.68e-19	Acne (severe);
LUAD	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg26384229	chr12:38710491	ALG10B	-0.38	-6.51	-0.3	2.19e-10	Bladder cancer;
LUAD	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg01528321	chr10:82214614	TSPAN14	-0.57	-9.35	-0.41	5.17e-19	Post bronchodilator FEV1;
LUAD	cis	rs28830936	1.000	rs11637341	chr15:41955825	G/T	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.63	-0.31	1.03e-10	Diastolic blood pressure;
LUAD	cis	rs68170813	0.559	rs113211438	chr7:106969198	G/A	cg23024343	chr7:107201750	COG5	0.5	7.16	0.33	3.67e-12	Coronary artery disease;
LUAD	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg01849466	chr14:104193079	ZFYVE21	0.53	9.65	0.42	4.98e-20	Schizophrenia;
LUAD	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.56	-0.35	2.47e-13	HDL cholesterol;
LUAD	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg04287289	chr16:89883240	FANCA	0.48	7.79	0.35	5.27e-14	Vitiligo;
LUAD	trans	rs8002861	0.840	rs7989353	chr13:44438957	T/C	cg17145862	chr1:211918768	LPGAT1	0.74	17.14	0.64	2.16e-50	Leprosy;
LUAD	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg06108461	chr20:60628389	TAF4	-1.1	-19.93	-0.7	8.02e-63	Body mass index;
LUAD	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg06618935	chr21:46677482	NA	-0.49	-9.99	-0.44	3.09e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	17.17	0.64	1.65e-50	Exhaled nitric oxide output;
LUAD	cis	rs8017423	0.967	rs11626011	chr14:90693572	A/G	cg14092571	chr14:90743983	NA	-0.48	-8.22	-0.37	2.49e-15	Mortality in heart failure;
LUAD	trans	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg01620082	chr3:125678407	NA	-0.62	-7.83	-0.36	3.92e-14	Lung cancer in ever smokers;
LUAD	cis	rs367943	0.698	rs7728525	chr5:112972215	C/G	cg12552261	chr5:112820674	MCC	0.45	8.06	0.36	7.8e-15	Type 2 diabetes;
LUAD	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg12016809	chr21:47604291	C21orf56	0.46	7.18	0.33	3.12e-12	Testicular germ cell tumor;
LUAD	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg20119798	chr7:94954144	PON1	-0.49	-6.86	-0.32	2.5e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.6	-0.35	1.95e-13	Resting heart rate;
LUAD	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg03037974	chr15:76606532	NA	0.47	11.08	0.47	3.19e-25	Blood metabolite levels;
LUAD	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg16479474	chr6:28041457	NA	0.38	6.7	0.31	6.53e-11	Parkinson's disease;
LUAD	cis	rs12681288	0.550	rs59004371	chr8:962393	T/C	cg04851639	chr8:1020857	NA	-0.31	-7.23	-0.33	2.26e-12	Schizophrenia;
LUAD	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg10057126	chr4:77819792	ANKRD56	0.55	9.5	0.42	1.58e-19	Emphysema distribution in smoking;
LUAD	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.1	-24.79	-0.77	1.94e-84	Ulcerative colitis;
LUAD	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03264133	chr6:25882463	NA	-0.55	-8.84	-0.4	2.54e-17	Blood metabolite levels;
LUAD	cis	rs12760731	0.565	rs12034657	chr1:178099354	A/C	cg00404053	chr1:178313656	RASAL2	-0.73	-8.83	-0.39	2.78e-17	Obesity-related traits;
LUAD	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg14186256	chr22:23484241	RTDR1	0.46	7.8	0.35	4.73e-14	Bone mineral density;
LUAD	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22307029	chr19:49891270	CCDC155	0.68	9.74	0.43	2.28e-20	Multiple sclerosis;
LUAD	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.99e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg20933634	chr6:27740509	NA	0.46	7.27	0.33	1.77e-12	Parkinson's disease;
LUAD	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	ch.11.42038R	chr11:967971	AP2A2	0.39	6.86	0.32	2.38e-11	Alzheimer's disease (late onset);
LUAD	trans	rs2735413	0.918	rs4888731	chr16:78080418	A/G	cg01028844	chr5:122736986	CEP120	0.4	6.43	0.3	3.47e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs9443645	0.527	rs1415859	chr6:79794858	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.65	-0.31	9.12e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.45	0.3	2.98e-10	Depression;
LUAD	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg11502198	chr6:26597334	ABT1	0.54	9.14	0.41	2.55e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg15309053	chr8:964076	NA	0.42	8.81	0.39	3.17e-17	Schizophrenia;
LUAD	cis	rs790123	1.000	rs790123	chr3:122388993	T/C	cg22896480	chr3:122379438	NA	0.42	7.05	0.32	7.23e-12	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.39	-6.39	-0.3	4.43e-10	Renal function-related traits (BUN);
LUAD	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg09658497	chr7:2847517	GNA12	-0.55	-9.27	-0.41	9.75e-19	Height;
LUAD	trans	rs8002861	0.967	rs9533691	chr13:44482208	A/G	cg17145862	chr1:211918768	LPGAT1	0.75	17.73	0.65	5.14e-53	Leprosy;
LUAD	trans	rs11039798	1.000	rs11530232	chr11:48622376	C/T	cg15704280	chr7:45808275	SEPT13	0.73	7.47	0.34	4.71e-13	Axial length;
LUAD	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg00383909	chr3:49044727	WDR6	0.66	8.59	0.39	1.7e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6906287	0.647	rs3951042	chr6:118722495	C/T	cg05564266	chr6:118973597	C6orf204	0.33	7.03	0.32	8.21e-12	Electrocardiographic conduction measures;
LUAD	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg09976142	chr9:130955436	CIZ1	0.43	8.04	0.36	8.92e-15	Attention deficit hyperactivity disorder;
LUAD	cis	rs2652834	0.808	rs4775614	chr15:63351687	A/G	cg25406657	chr15:63342033	TPM1	-0.44	-7.01	-0.32	9.31e-12	HDL cholesterol;
LUAD	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.59	10.5	0.45	4.59e-23	Eosinophil percentage of white cells;
LUAD	cis	rs7017914	0.967	rs1471114	chr8:71675547	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.31	-6.41	-0.3	3.85e-10	Bone mineral density;
LUAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08677398	chr8:58056175	NA	0.45	6.45	0.3	3.07e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg04154034	chr17:28927549	LRRC37B2	0.6	7.18	0.33	3.24e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg04287289	chr16:89883240	FANCA	0.83	7.23	0.33	2.24e-12	Skin colour saturation;
LUAD	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-10.69	-0.46	9.29e-24	Hemoglobin concentration;
LUAD	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg13385794	chr1:248469461	NA	0.26	7.07	0.32	6.56e-12	Common traits (Other);
LUAD	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg20476274	chr7:133979776	SLC35B4	0.65	10.94	0.47	1.05e-24	Mean platelet volume;
LUAD	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg17644776	chr2:200775616	C2orf69	0.57	9.74	0.43	2.26e-20	Osteoporosis;
LUAD	cis	rs938554	0.806	rs4447862	chr4:9931645	C/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.61	-0.31	1.16e-10	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg05043794	chr9:111880884	C9orf5	-0.41	-6.89	-0.32	1.97e-11	Menarche (age at onset);
LUAD	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.17	-0.33	3.44e-12	Resting heart rate;
LUAD	cis	rs654950	0.783	rs639298	chr1:42001530	A/G	cg06885757	chr1:42089581	HIVEP3	-0.36	-7.86	-0.36	3.16e-14	Airway imaging phenotypes;
LUAD	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg05182265	chr7:156933206	UBE3C	-0.8	-17.3	-0.64	4.19e-51	Body mass index;
LUAD	cis	rs7943203	1.000	rs61913875	chr11:108298852	A/G	cg04873221	chr11:107992290	ACAT1	-0.43	-6.91	-0.32	1.74e-11	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg00071950	chr4:10020882	SLC2A9	0.49	7.28	0.33	1.65e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg24101359	chr6:42928495	GNMT	0.45	8.38	0.38	8.19e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg11833968	chr6:79620685	NA	-0.44	-8.36	-0.38	9.42e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg11494091	chr17:61959527	GH2	0.4	6.98	0.32	1.12e-11	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27103680	chr2:86423081	IMMT	-0.43	-6.65	-0.31	9.1e-11	Height;
LUAD	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg05110241	chr16:68378359	PRMT7	-0.84	-9.2	-0.41	1.59e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2692947	0.526	rs58719199	chr2:96578247	G/A	cg23100626	chr2:96804247	ASTL	0.32	7.74	0.35	7.63e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7072216	0.881	rs7916469	chr10:100148653	T/C	cg26618903	chr10:100175079	PYROXD2	-0.3	-6.51	-0.3	2.16e-10	Metabolite levels;
LUAD	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg20283391	chr11:68216788	NA	-0.41	-6.73	-0.31	5.45e-11	Total body bone mineral density;
LUAD	trans	rs6598955	0.671	rs3924325	chr1:26616320	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.71	-9.56	-0.42	9.61e-20	Obesity-related traits;
LUAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg10729496	chr3:10149963	C3orf24	0.61	9.87	0.43	8.12e-21	Alzheimer's disease;
LUAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-9.82	-0.43	1.22e-20	Longevity;Endometriosis;
LUAD	cis	rs8177876	0.658	rs77874075	chr16:81066339	T/G	cg08591886	chr16:81111003	C16orf46	-0.82	-7.24	-0.33	2.16e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg05966235	chr16:28915196	ATP2A1	0.46	7.44	0.34	5.86e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs1493916	0.837	rs10401087	chr18:31320716	A/G	cg27147174	chr7:100797783	AP1S1	-0.59	-10.12	-0.44	1.05e-21	Life satisfaction;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg14749448	chr11:65325872	LTBP3	-0.38	-7.54	-0.34	2.9e-13	Vertical cup-disc ratio;
LUAD	trans	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg14791747	chr16:20752902	THUMPD1	0.44	6.42	0.3	3.56e-10	Cognitive test performance;
LUAD	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg27494647	chr7:150038898	RARRES2	0.54	9.56	0.42	9.55e-20	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg03467027	chr4:99064603	C4orf37	0.41	6.64	0.31	9.55e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.71	-13.29	-0.54	6.43e-34	Menarche (age at onset);
LUAD	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg06558623	chr16:89946397	TCF25	0.96	10.5	0.45	4.41e-23	Skin colour saturation;
LUAD	cis	rs7809799	0.571	rs11978582	chr7:98915958	C/T	cg12290671	chr7:99195819	NA	0.75	6.85	0.32	2.65e-11	Ulcerative colitis;
LUAD	cis	rs4680	0.737	rs4818	chr22:19951207	C/G	cg23601416	chr22:19950040	COMT	-0.37	-7.45	-0.34	5.42e-13	Blood metabolite levels;
LUAD	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.46	-7.3	-0.33	1.45e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg14552801	chr7:65878734	NA	-0.37	-6.35	-0.3	5.43e-10	Aortic root size;
LUAD	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	7.31	0.33	1.36e-12	Platelet count;
LUAD	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06028808	chr11:68637592	NA	0.49	8.06	0.36	8.15e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4774899	0.932	rs12912868	chr15:57537199	T/C	cg14026238	chr15:57616123	NA	0.34	6.39	0.3	4.5e-10	Urinary tract infection frequency;
LUAD	trans	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg13565492	chr6:43139072	SRF	-0.58	-6.49	-0.3	2.38e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs231513	1.000	rs231526	chr17:41951277	T/C	cg26893861	chr17:41843967	DUSP3	-0.67	-7.54	-0.34	2.99e-13	Cognitive function;
LUAD	cis	rs7584330	0.666	rs1574530	chr2:238395708	A/T	cg14458575	chr2:238380390	NA	0.56	8.79	0.39	3.75e-17	Prostate cancer;
LUAD	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.34	6.82	0.31	3.16e-11	Obesity-related traits;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24078708	chr3:42846184	HIGD1A	-0.39	-6.46	-0.3	2.94e-10	Cancer;
LUAD	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15506890	chr2:3487001	NA	-0.44	-7.44	-0.34	5.76e-13	Neurofibrillary tangles;
LUAD	cis	rs11811982	0.793	rs114536396	chr1:227536087	C/G	cg24860534	chr1:227506868	CDC42BPA	0.71	7.52	0.34	3.35e-13	Optic disc area;
LUAD	trans	rs75804782	0.580	rs72987332	chr2:239362529	G/T	cg01134436	chr17:81009848	B3GNTL1	0.81	8.84	0.39	2.65e-17	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.46	0.52	1.4e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg21220214	chr8:57350948	NA	-0.6	-8.89	-0.4	1.8e-17	Obesity-related traits;
LUAD	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	11.39	0.48	2.12e-26	Colorectal cancer;
LUAD	cis	rs9323205	0.817	rs56100232	chr14:51699378	A/G	cg23942311	chr14:51606299	NA	-0.59	-9.04	-0.4	5.73e-18	Cancer;
LUAD	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg13393036	chr8:95962371	TP53INP1	-0.4	-9.57	-0.42	9.2e-20	Type 2 diabetes;
LUAD	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-7.18	-0.33	3.21e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg18305652	chr10:134549665	INPP5A	0.62	11.84	0.5	4.11e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg02891314	chr5:179741120	GFPT2	-0.74	-11.92	-0.5	1.93e-28	Height;
LUAD	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg14582100	chr15:45693742	SPATA5L1	0.64	12.57	0.52	5.2500000000000004e-31	Homoarginine levels;
LUAD	cis	rs7731657	0.537	rs2905534	chr5:130242005	C/T	cg08523029	chr5:130500466	HINT1	-0.58	-7.53	-0.34	3.05e-13	Fasting plasma glucose;
LUAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg05434287	chr7:2030229	MAD1L1	-0.4	-6.64	-0.31	9.41e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs4285028	0.747	rs9838301	chr3:121375144	G/T	cg11130432	chr3:121712080	ILDR1	-0.45	-6.37	-0.3	4.84e-10	Multiple sclerosis;
LUAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg08132940	chr7:1081526	C7orf50	-0.77	-10.29	-0.45	2.49e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg26384229	chr12:38710491	ALG10B	0.48	7.8	0.35	4.79e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10821973	0.527	rs6479793	chr10:63983295	C/A	cg09941381	chr10:64027924	RTKN2	-0.34	-6.77	-0.31	4.23e-11	Hypothyroidism;
LUAD	cis	rs2286885	1.000	rs10760439	chr9:129250830	A/C	cg15282417	chr9:129245246	FAM125B	0.46	9.25	0.41	1.15e-18	Intraocular pressure;
LUAD	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg21854759	chr1:92012499	NA	-0.52	-9.98	-0.44	3.27e-21	Breast cancer;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg15414828	chr11:71791511	LRTOMT;NUMA1	-0.53	-6.46	-0.3	2.89e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.52	-0.34	3.29e-13	Total body bone mineral density;
LUAD	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.78	0.31	4.16e-11	Cardiac Troponin-T levels;
LUAD	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg22166914	chr1:53195759	ZYG11B	0.42	6.98	0.32	1.13e-11	Monocyte count;
LUAD	cis	rs847577	0.630	rs3801294	chr7:97822210	G/A	cg24562669	chr7:97807699	LMTK2	0.34	8.06	0.37	7.68e-15	Breast cancer;
LUAD	cis	rs2278491	0.528	rs4514005	chr8:117782385	C/T	cg23513447	chr8:117778558	UTP23	-0.54	-7.5	-0.34	3.69e-13	Body mass index;
LUAD	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.33	-0.41	5.91e-19	Dilated cardiomyopathy;
LUAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14893161	chr1:205819251	PM20D1	0.82	17.29	0.64	4.94e-51	Menarche (age at onset);
LUAD	cis	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.93	-0.32	1.62e-11	Neuroticism;
LUAD	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg25358565	chr5:93447407	FAM172A	0.68	7.97	0.36	1.53e-14	Diabetic retinopathy;
LUAD	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg04398451	chr17:18023971	MYO15A	0.65	11.59	0.49	3.77e-27	Total body bone mineral density;
LUAD	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-8.72	-0.39	6.65e-17	Schizophrenia;
LUAD	cis	rs9341808	0.650	rs6909546	chr6:80869923	C/G	cg08355045	chr6:80787529	NA	0.54	9.83	0.43	1.16e-20	Sitting height ratio;
LUAD	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg12365402	chr11:9010492	NRIP3	-0.52	-10.62	-0.46	1.7e-23	Hemoglobin concentration;
LUAD	cis	rs7737355	0.947	rs3776007	chr5:130875085	C/G	cg25547332	chr5:131281432	NA	-0.42	-6.43	-0.3	3.48e-10	Life satisfaction;
LUAD	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg27144592	chr16:783916	NARFL	0.37	6.72	0.31	6.02e-11	Height;
LUAD	cis	rs910187	0.571	rs6124958	chr20:45801117	T/C	cg27589058	chr20:45804311	EYA2	-0.37	-8.4	-0.38	7.01e-16	Migraine;
LUAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg25703541	chr22:24373054	LOC391322	-0.82	-14.74	-0.58	5.83e-40	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.69	10.75	0.46	5.61e-24	Lymphocyte percentage of white cells;
LUAD	cis	rs9393692	0.557	rs12665035	chr6:26275649	T/C	cg13736514	chr6:26305472	NA	-0.51	-7.95	-0.36	1.67e-14	Educational attainment;
LUAD	cis	rs1865721	0.771	rs4410169	chr18:73138840	A/G	cg26385618	chr18:73139727	C18orf62	-0.51	-10.35	-0.45	1.51e-22	Intelligence;
LUAD	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg07570687	chr10:102243282	WNT8B	0.48	7.31	0.34	1.31e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.5	0.38	3.21e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs367615	0.704	rs11747622	chr5:108844720	G/A	cg17395555	chr5:108820864	NA	0.66	14.04	0.56	4.91e-37	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.33	-6.66	-0.31	8.43e-11	Monocyte percentage of white cells;
LUAD	cis	rs7100689	0.646	rs10749573	chr10:82136839	T/A	cg00277334	chr10:82204260	NA	-0.63	-10.54	-0.46	3.26e-23	Post bronchodilator FEV1;
LUAD	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg07741184	chr6:167504864	NA	-0.3	-7.2	-0.33	2.81e-12	Crohn's disease;
LUAD	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg21427119	chr20:30132790	HM13	-0.6	-9.27	-0.41	9.4e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg23625390	chr15:77176239	SCAPER	-0.41	-7.3	-0.33	1.45e-12	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	8.1	0.37	5.82e-15	Parkinson's disease;
LUAD	cis	rs193541	0.632	rs2407402	chr5:122107105	G/C	cg19077854	chr5:122220652	SNX24	0.36	6.44	0.3	3.17e-10	Glucose homeostasis traits;
LUAD	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg03453431	chr7:157225567	NA	-0.42	-7.16	-0.33	3.53e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg02426739	chr12:132285352	NA	0.34	6.84	0.32	2.76e-11	Migraine;
LUAD	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg25985355	chr7:65971099	NA	-0.38	-6.89	-0.32	2.02e-11	Aortic root size;
LUAD	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg15557168	chr22:42548783	NA	0.51	9.41	0.42	3.33e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg26647111	chr11:31128758	NA	-0.45	-7.83	-0.36	3.86e-14	Red blood cell count;
LUAD	cis	rs758324	0.812	rs7709934	chr5:131145210	C/T	cg06307176	chr5:131281290	NA	0.44	7.26	0.33	1.85e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg21475434	chr5:93447410	FAM172A	0.74	8.23	0.37	2.28e-15	Diabetic retinopathy;
LUAD	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-20.31	-0.7	1.58e-64	Height;
LUAD	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg17420585	chr12:42539391	GXYLT1	-0.37	-6.49	-0.3	2.36e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg02527881	chr3:46936655	PTH1R	-0.46	-8.89	-0.4	1.78e-17	Colorectal cancer;
LUAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg11416102	chr8:651193	ERICH1	0.95	9.02	0.4	6.52e-18	IgG glycosylation;
LUAD	cis	rs10189230	0.868	rs5002064	chr2:222353508	G/A	cg14652038	chr2:222343519	EPHA4	0.43	8.56	0.38	2.14e-16	Urate levels in lean individuals;
LUAD	trans	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.67	-10.31	-0.45	2.21e-22	Obesity-related traits;
LUAD	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg09455208	chr3:40491958	NA	0.55	12.11	0.51	3.51e-29	Renal cell carcinoma;
LUAD	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	6.5	0.3	2.33e-10	Aortic root size;
LUAD	cis	rs12210905	0.688	rs72845030	chr6:27532643	A/G	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	trans	rs3924048	0.574	rs11121925	chr1:12613130	A/C	cg05052031	chr3:33138450	TMPPE;GLB1	0.4	6.92	0.32	1.64e-11	Optic cup area;
LUAD	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg08807101	chr21:30365312	RNF160	-0.44	-7.58	-0.35	2.14e-13	Dental caries;
LUAD	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg11822812	chr5:140052017	DND1	-0.42	-7.89	-0.36	2.55e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg11814155	chr7:99998594	ZCWPW1	0.43	7.48	0.34	4.27e-13	Platelet count;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg25064146	chr11:111957872	TIMM8B;SDHD	-0.38	-6.36	-0.3	5.11e-10	Subcortical brain region volumes;
LUAD	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26314531	chr2:26401878	FAM59B	-0.55	-7.71	-0.35	9.38e-14	Gut microbiome composition (summer);
LUAD	cis	rs4273100	1.000	rs12602286	chr17:19236954	G/T	cg03711562	chr17:18936298	GRAP	0.36	7.28	0.33	1.62e-12	Schizophrenia;
LUAD	cis	rs727505	0.607	rs67454509	chr7:124792500	A/G	cg23710748	chr7:124431027	NA	-0.38	-7.61	-0.35	1.77e-13	Lewy body disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg13303461	chr11:57335730	UBE2L6	-0.67	-6.84	-0.32	2.82e-11	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg21724239	chr8:58056113	NA	0.82	10.14	0.44	9.29e-22	Developmental language disorder (linguistic errors);
LUAD	trans	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg14343924	chr8:8086146	FLJ10661	0.46	6.86	0.32	2.42e-11	Neuroticism;
LUAD	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.91	-0.36	2.2e-14	Diabetic kidney disease;
LUAD	cis	rs11771526	0.792	rs28394389	chr7:32298509	C/T	cg13207630	chr7:32358064	NA	0.58	7.23	0.33	2.35e-12	Body mass index;
LUAD	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg22189786	chr22:42395067	WBP2NL	0.46	6.61	0.31	1.13e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg22823121	chr1:150693482	HORMAD1	0.37	7.25	0.33	1.96e-12	Melanoma;
LUAD	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg01689657	chr7:91764605	CYP51A1	0.32	7.77	0.35	5.83e-14	Breast cancer;
LUAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.25	0.41	1.08e-18	Alzheimer's disease;
LUAD	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg09796270	chr17:17721594	SREBF1	0.37	7.16	0.33	3.52e-12	Total body bone mineral density;
LUAD	cis	rs922182	0.617	rs12324438	chr15:64243436	A/C	cg02919090	chr15:64263738	DAPK2	-0.36	-6.93	-0.32	1.55e-11	Blood protein levels;
LUAD	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg21963583	chr11:68658836	MRPL21	0.62	10.69	0.46	8.9e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs240764	0.578	rs12215909	chr6:101227598	T/C	cg09795085	chr6:101329169	ASCC3	-0.45	-8.03	-0.36	9.86e-15	Neuroticism;
LUAD	cis	rs12431939	1.000	rs12431939	chr14:51692699	A/G	cg23942311	chr14:51606299	NA	0.57	7.84	0.36	3.81e-14	Cancer;
LUAD	trans	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4242434	0.927	rs10099846	chr8:22534178	C/T	cg03733263	chr8:22462867	KIAA1967	-0.7	-11.36	-0.48	2.7e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg12573674	chr2:1569213	NA	-0.56	-8.11	-0.37	5.47e-15	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg13511324	chr14:104056883	C14orf153	0.25	6.38	0.3	4.53e-10	Coronary artery disease;
LUAD	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg11502198	chr6:26597334	ABT1	0.56	9.35	0.41	5.19e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs1497828	0.912	rs2810764	chr1:217573645	T/C	cg04411442	chr1:217543379	NA	0.38	6.77	0.31	4.28e-11	Dialysis-related mortality;
LUAD	trans	rs71327718	1	rs71327718	chr3:125592857	C/G	cg07211511	chr3:129823064	LOC729375	-0.85	-9.15	-0.41	2.4e-18	Metabolite levels (HVA/5-HIAA ratio);
LUAD	trans	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg11292332	chr7:45801988	SEPT13	0.28	6.48	0.3	2.61e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg26554054	chr8:600488	NA	0.8	8.23	0.37	2.28e-15	IgG glycosylation;
LUAD	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs56346965	0.967	rs2159819	chr2:191532737	C/G	cg27211696	chr2:191398769	TMEM194B	-0.47	-8.6	-0.39	1.59e-16	Bone mineral density (Ward's triangle area);
LUAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.58	-10.13	-0.44	1e-21	Lymphocyte counts;
LUAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4380275	0.965	rs4315562	chr2:772723	A/G	cg21665850	chr2:731073	NA	0.5	8.97	0.4	9.55e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg04234412	chr22:24373322	LOC391322	0.83	15.74	0.61	2.97e-44	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4148087	0.518	rs61207594	chr21:43610807	A/C	cg08841829	chr21:43638893	ABCG1	-0.56	-7.42	-0.34	6.6e-13	Eating disorder in bipolar disorder;
LUAD	cis	rs8064299	0.597	rs6501737	chr17:72780830	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.4	-6.51	-0.3	2.14e-10	Monocyte count;
LUAD	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.49	8.74	0.39	5.32e-17	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg16615211	chr3:44902933	MIR564;TMEM42	0.39	7.34	0.34	1.1e-12	Depressive symptoms;
LUAD	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-7.27	-0.33	1.78e-12	Retinal vascular caliber;
LUAD	cis	rs62400317	0.859	rs12191262	chr6:45227016	G/A	cg18551225	chr6:44695536	NA	-0.56	-8.68	-0.39	8.79e-17	Total body bone mineral density;
LUAD	cis	rs807669	0.903	rs2854643	chr22:19189706	T/C	cg02655711	chr22:19163373	SLC25A1	0.85	18.66	0.67	3.92e-57	Metabolite levels;
LUAD	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	8.99	0.4	8.07e-18	Tonsillectomy;
LUAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9486719	0.790	rs2499790	chr6:96845078	G/A	cg06623918	chr6:96969491	KIAA0776	0.71	9.3	0.41	7.58e-19	Migraine;Coronary artery disease;
LUAD	cis	rs12711979	0.566	rs10195076	chr2:3854501	A/G	cg17052675	chr2:3827356	NA	-0.4	-7.08	-0.33	6.13e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	7.06	0.32	6.67e-12	Menopause (age at onset);
LUAD	cis	rs68170813	0.559	rs74925723	chr7:106954536	G/C	cg23024343	chr7:107201750	COG5	0.5	7.2	0.33	2.84e-12	Coronary artery disease;
LUAD	cis	rs9560113	0.573	rs9560132	chr13:112237456	C/T	cg10483660	chr13:112241077	NA	0.46	9.51	0.42	1.48e-19	Menarche (age at onset);
LUAD	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg13012494	chr21:47604986	C21orf56	-0.43	-6.72	-0.31	5.77e-11	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg05340658	chr4:99064831	C4orf37	0.44	6.69	0.31	7.23e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg09904177	chr6:26538194	HMGN4	0.43	7.26	0.33	1.87e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2479724	0.572	rs6920885	chr6:41941169	T/C	cg17623882	chr6:41773611	USP49	-0.48	-8.34	-0.38	1.08e-15	Menarche (age at onset);
LUAD	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.33	6.57	0.3	1.53e-10	Obesity-related traits;
LUAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.79	-16.88	-0.63	2.92e-49	Longevity;Endometriosis;
LUAD	cis	rs3981351	0.797	rs12777332	chr10:115458936	A/G	cg24846397	chr10:115438155	CASP7	-0.39	-6.36	-0.3	5.31e-10	Obesity-related traits;
LUAD	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1797081	0.646	rs7090256	chr10:16851949	T/G	cg14835575	chr10:16859367	RSU1	0.52	8.16	0.37	3.91e-15	Platelet distribution width;
LUAD	cis	rs3760982	1.000	rs10421887	chr19:44294849	C/T	cg12072164	chr19:44306565	LYPD5	-0.38	-7.7	-0.35	9.77e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg05590025	chr7:65112418	INTS4L2	-0.72	-8.0	-0.36	1.22e-14	Diabetic kidney disease;
LUAD	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg27284194	chr4:1044797	NA	0.7	10.07	0.44	1.55e-21	Recombination rate (females);
LUAD	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg06781209	chr11:61594997	FADS2	-0.4	-7.4	-0.34	7.51e-13	Trans fatty acid levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26434548	chr7:129074607	FAM40B	-0.57	-6.95	-0.32	1.4e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg00631329	chr6:26305371	NA	-0.7	-13.37	-0.55	2.84e-34	Educational attainment;
LUAD	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg00277334	chr10:82204260	NA	-0.54	-8.98	-0.4	9.24e-18	Post bronchodilator FEV1;
LUAD	cis	rs910187	0.641	rs3186647	chr20:45817067	T/C	cg27589058	chr20:45804311	EYA2	-0.3	-6.92	-0.32	1.66e-11	Migraine;
LUAD	cis	rs250677	0.916	rs17109279	chr5:148416581	A/G	cg18129178	chr5:148520854	ABLIM3	-0.57	-8.61	-0.39	1.5e-16	Breast cancer;
LUAD	cis	rs7173743	0.935	rs12232282	chr15:79136525	T/C	cg15571903	chr15:79123663	NA	-0.37	-7.08	-0.33	5.91e-12	Coronary artery disease;
LUAD	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg08508325	chr11:3079039	CARS	-0.56	-11.76	-0.5	7.8e-28	Longevity;
LUAD	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg00750074	chr16:89608354	SPG7	-0.54	-8.88	-0.4	1.93e-17	Multiple myeloma (IgH translocation);
LUAD	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg03037974	chr15:76606532	NA	0.38	8.14	0.37	4.33e-15	Blood metabolite levels;
LUAD	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg00745463	chr17:30367425	LRRC37B	0.87	9.3	0.41	7.67e-19	Hip circumference adjusted for BMI;
LUAD	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg02891314	chr5:179741120	GFPT2	-0.74	-12.27	-0.51	7.8e-30	Height;
LUAD	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg17105886	chr17:28927953	LRRC37B2	0.83	7.11	0.33	4.98e-12	Body mass index;
LUAD	trans	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.59	-10.81	-0.47	3.32e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs654950	0.875	rs586055	chr1:41999076	T/C	cg06885757	chr1:42089581	HIVEP3	0.34	7.04	0.32	8.04e-12	Airway imaging phenotypes;
LUAD	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg04450456	chr4:17643702	FAM184B	0.38	7.6	0.35	1.94e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-7.62	-0.35	1.73e-13	Lung cancer;
LUAD	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg16953816	chr12:123349952	VPS37B	0.59	6.54	0.3	1.75e-10	Schizophrenia;
LUAD	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-8.46	-0.38	4.54e-16	Menarche (age at onset);
LUAD	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg21100191	chr22:23484243	RTDR1	0.65	11.45	0.49	1.25e-26	Bone mineral density;
LUAD	cis	rs10929159	0.928	rs7569558	chr2:236924309	G/A	cg14895183	chr2:236924282	AGAP1	0.37	6.36	0.3	5.19e-10	Parkinson's disease;
LUAD	cis	rs2046867	0.818	rs17010215	chr3:72886965	A/G	cg04365224	chr3:72788183	NA	-0.44	-6.55	-0.3	1.66e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14240646	chr10:27532245	ACBD5	-0.9	-11.58	-0.49	3.92e-27	Breast cancer;
LUAD	cis	rs7107174	0.892	rs2512548	chr11:77962116	A/G	cg19901956	chr11:77921274	USP35	-0.51	-6.6	-0.31	1.21e-10	Testicular germ cell tumor;
LUAD	cis	rs4713675	0.604	rs791902	chr6:33702617	G/A	cg14003231	chr6:33640908	ITPR3	-0.37	-6.97	-0.32	1.22e-11	Plateletcrit;
LUAD	cis	rs4713675	0.709	rs542441	chr6:33675851	A/C	cg13859433	chr6:33739653	LEMD2	0.31	7.13	0.33	4.45e-12	Plateletcrit;
LUAD	cis	rs7474896	0.537	rs1022449	chr10:38279467	T/A	cg25427524	chr10:38739819	LOC399744	0.6	8.52	0.38	2.75e-16	Obesity (extreme);
LUAD	cis	rs7680126	0.626	rs929575	chr4:10196886	C/G	cg02734326	chr4:10020555	SLC2A9	-0.52	-6.64	-0.31	9.81e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	7.29	0.33	1.54e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11644478	chr21:40555479	PSMG1	0.68	11.12	0.48	2.18e-25	Cognitive function;
LUAD	cis	rs4906332	0.754	rs34235720	chr14:104004968	C/T	cg19000871	chr14:103996768	TRMT61A	-0.53	-8.77	-0.39	4.53e-17	Coronary artery disease;
LUAD	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.68	12.42	0.52	2.15e-30	Cognitive ability;
LUAD	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg02079420	chr8:82753780	SNX16	-0.43	-8.69	-0.39	7.83e-17	Diastolic blood pressure;
LUAD	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg17264618	chr3:40429014	ENTPD3	0.35	7.45	0.34	5.21e-13	Renal cell carcinoma;
LUAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.13	25.9	0.78	2.81e-89	Subjective well-being;
LUAD	cis	rs9322817	0.691	rs9391244	chr6:105257690	G/A	cg02098413	chr6:105308735	HACE1	-0.42	-8.91	-0.4	1.51e-17	Thyroid stimulating hormone;
LUAD	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.46	0.38	4.36e-16	Menarche (age at onset);
LUAD	trans	rs10802346	0.545	rs4478780	chr1:246372241	T/C	cg13514129	chr1:39547527	MACF1	0.6	10.64	0.46	1.35e-23	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03264133	chr6:25882463	NA	0.82	13.52	0.55	7.05e-35	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg21724239	chr8:58056113	NA	0.79	9.7	0.43	3.33e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7100689	0.646	rs11202721	chr10:82135762	G/A	cg00277334	chr10:82204260	NA	-0.63	-10.54	-0.46	3.26e-23	Post bronchodilator FEV1;
LUAD	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg00933542	chr6:150070202	PCMT1	0.36	7.53	0.34	3.06e-13	Testicular germ cell tumor;
LUAD	cis	rs28655083	0.956	rs1485792	chr16:77100439	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.4	-6.61	-0.31	1.18e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg05368731	chr17:41323189	NBR1	0.97	19.8	0.69	3.12e-62	Menopause (age at onset);
LUAD	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg14092988	chr3:52407081	DNAH1	0.39	7.84	0.36	3.61e-14	Electroencephalogram traits;
LUAD	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg22705602	chr4:152727874	NA	-0.42	-7.23	-0.33	2.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.64	-10.72	-0.46	7.22e-24	Glomerular filtration rate;
LUAD	cis	rs11625487	0.515	rs12434419	chr14:77855617	G/A	cg20045696	chr14:77926864	AHSA1	-0.64	-10.96	-0.47	8.78e-25	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUAD	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg17911788	chr17:44343683	NA	-0.5	-7.31	-0.33	1.35e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs864537	0.676	rs2056625	chr1:167420299	G/A	cg22356347	chr1:167427500	CD247	-0.51	-10.38	-0.45	1.25e-22	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg09796270	chr17:17721594	SREBF1	-0.37	-7.22	-0.33	2.39e-12	Total body bone mineral density;
LUAD	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg03433033	chr1:76189801	ACADM	0.85	14.67	0.58	1.16e-39	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg18876405	chr7:65276391	NA	0.63	10.94	0.47	1.03e-24	Calcium levels;
LUAD	cis	rs4378999	0.800	rs6445622	chr3:51356823	T/C	cg12934382	chr3:51741135	GRM2	0.42	6.47	0.3	2.77e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs4700695	0.920	rs251303	chr5:65248753	A/C	cg21114390	chr5:65439923	SFRS12	0.62	7.49	0.34	4.12e-13	Facial morphology (factor 19);
LUAD	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg01765077	chr12:122356316	WDR66	0.41	6.94	0.32	1.5e-11	Mean corpuscular volume;
LUAD	cis	rs2573652	1.000	rs2573650	chr15:100514097	A/G	cg09918751	chr15:100517450	ADAMTS17	0.46	8.07	0.37	7.22e-15	Height;
LUAD	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.68	-0.58	1.03e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03352830	chr11:487213	PTDSS2	0.79	10.19	0.44	5.91e-22	Body mass index;
LUAD	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg17063962	chr7:91808500	NA	0.67	11.87	0.5	2.93e-28	Breast cancer;
LUAD	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg02574844	chr11:5959923	NA	-0.39	-6.74	-0.31	5.12e-11	DNA methylation (variation);
LUAD	cis	rs1784581	0.588	rs7451121	chr6:162412344	A/G	cg17173639	chr6:162384350	PARK2	0.44	7.94	0.36	1.79e-14	Itch intensity from mosquito bite;
LUAD	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg05064044	chr6:292385	DUSP22	-0.58	-9.51	-0.42	1.48e-19	Menopause (age at onset);
LUAD	trans	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg01620082	chr3:125678407	NA	-0.62	-7.86	-0.36	3.17e-14	Lung cancer in ever smokers;
LUAD	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-9.18	-0.41	1.89e-18	Life satisfaction;
LUAD	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg17063962	chr7:91808500	NA	0.62	10.41	0.45	9.85e-23	Breast cancer;
LUAD	cis	rs4888262	0.545	rs4588013	chr16:74703388	C/T	cg01733217	chr16:74700730	RFWD3	0.52	8.6	0.39	1.58e-16	Testicular germ cell tumor;
LUAD	trans	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg15704280	chr7:45808275	SEPT13	0.65	7.64	0.35	1.48e-13	Intraocular pressure;
LUAD	cis	rs7336332	0.598	rs76249173	chr13:28010445	A/G	cg22138327	chr13:27999177	GTF3A	0.77	10.1	0.44	1.22e-21	Weight;
LUAD	cis	rs6743376	0.556	rs2515399	chr2:113819451	G/T	cg09040174	chr2:113837401	NA	0.51	7.96	0.36	1.61e-14	Inflammatory biomarkers;
LUAD	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg05714579	chr10:131428358	MGMT	0.39	6.41	0.3	3.81e-10	Response to temozolomide;
LUAD	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06873352	chr17:61820015	STRADA	0.56	9.11	0.41	3.3e-18	Height;
LUAD	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg01475377	chr6:109611718	NA	-0.52	-9.96	-0.44	3.81e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	9.3	0.41	7.58e-19	Melanoma;
LUAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg04632378	chr13:21900426	NA	0.4	6.42	0.3	3.67e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs4454254	0.966	rs4631439	chr8:141059650	C/T	cg05910124	chr8:141057427	TRAPPC9	-0.31	-6.38	-0.3	4.79e-10	Pulse pressure;
LUAD	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg16988262	chr1:15930761	NA	0.44	7.4	0.34	7.63e-13	Systolic blood pressure;
LUAD	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg17063962	chr7:91808500	NA	-0.65	-11.14	-0.48	1.84e-25	Breast cancer;
LUAD	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.53	8.34	0.38	1.04e-15	Chronic sinus infection;
LUAD	cis	rs12618769	0.597	rs4851140	chr2:99079339	T/C	cg10123293	chr2:99228465	UNC50	0.47	8.33	0.38	1.11e-15	Bipolar disorder;
LUAD	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg23758822	chr17:41437982	NA	0.99	20.82	0.71	8.69e-67	Menopause (age at onset);
LUAD	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg06784218	chr1:46089804	CCDC17	0.6	13.33	0.54	4.38e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs990171	0.538	rs6741235	chr2:103117283	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	6.54	0.3	1.76e-10	Lymphocyte counts;
LUAD	trans	rs8002861	0.967	rs2166301	chr13:44473955	A/T	cg17145862	chr1:211918768	LPGAT1	0.76	17.84	0.66	1.7e-53	Leprosy;
LUAD	cis	rs7833986	0.534	rs2976022	chr8:57007843	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	1.02	18.03	0.66	2.59e-54	Height;
LUAD	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg23625390	chr15:77176239	SCAPER	0.43	7.58	0.35	2.15e-13	Blood metabolite levels;
LUAD	cis	rs3087591	0.960	rs2952995	chr17:29541061	T/C	cg24425628	chr17:29625626	OMG;NF1	0.42	6.81	0.31	3.3e-11	Hip circumference;
LUAD	trans	rs11039798	0.925	rs6485831	chr11:48455031	A/T	cg02254774	chr11:50257496	LOC441601	0.5	6.41	0.3	3.79e-10	Axial length;
LUAD	cis	rs11640533	0.901	rs2908790	chr16:53412161	T/C	cg27158636	chr16:53407423	NA	0.39	6.45	0.3	3.15e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7582720	1.000	rs72932780	chr2:203695826	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.39	0.42	3.71e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg07599136	chr5:415885	AHRR	0.75	8.4	0.38	6.86e-16	Fat distribution (HIV);
LUAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.58	-0.46	2.2e-23	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs612683	0.759	rs12722868	chr1:100956478	A/G	cg06223162	chr1:101003688	GPR88	0.5	9.55	0.42	1.1e-19	Breast cancer;
LUAD	cis	rs1997103	0.906	rs6593232	chr7:55402916	C/T	cg17469321	chr7:55412551	NA	0.67	11.39	0.48	2.05e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1535500	1.000	rs1535500	chr6:39284050	G/T	cg06347083	chr6:39282316	KCNK17	-0.37	-7.89	-0.36	2.53e-14	Type 2 diabetes;
LUAD	cis	rs12618769	0.597	rs72821946	chr2:99142411	G/C	cg10123293	chr2:99228465	UNC50	0.47	8.52	0.38	2.88e-16	Bipolar disorder;
LUAD	cis	rs10203711	0.966	rs6716938	chr2:239599283	A/G	cg14580085	chr2:239553406	NA	0.41	8.84	0.4	2.51e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9296092	0.538	rs62405953	chr6:33524760	C/T	cg13560919	chr6:33536144	NA	-0.89	-16.52	-0.63	1.19e-47	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs597583	0.806	rs11603366	chr11:117396505	G/T	cg27161313	chr11:117392002	DSCAML1	-0.49	-8.16	-0.37	3.93e-15	Putamen volume;
LUAD	cis	rs7709909	0.755	rs2035256	chr5:79996632	A/G	cg24059623	chr5:79951536	MSH3;DHFR	0.48	8.86	0.4	2.26e-17	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs2859741	0.546	rs10489413	chr1:37513906	C/T	cg09363841	chr1:37513479	NA	-0.31	-7.46	-0.34	4.83e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg08132940	chr7:1081526	C7orf50	-0.77	-10.31	-0.45	2.21e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04769218	chr7:99098020	ZNF394	-0.6	-7.43	-0.34	5.93e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg15309053	chr8:964076	NA	0.32	6.91	0.32	1.84e-11	Schizophrenia;
LUAD	cis	rs6546550	0.901	rs6546556	chr2:70139001	A/G	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.97	-0.47	8.24e-25	Prevalent atrial fibrillation;
LUAD	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg03037974	chr15:76606532	NA	0.38	8.15	0.37	4.06e-15	Blood metabolite levels;
LUAD	cis	rs4594175	0.926	rs10149006	chr14:51615265	A/C	cg23942311	chr14:51606299	NA	0.64	11.04	0.47	4.42e-25	Cancer;
LUAD	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg24069376	chr3:38537580	EXOG	0.38	8.77	0.39	4.41e-17	Electrocardiographic conduction measures;
LUAD	cis	rs6906287	0.647	rs7746778	chr6:118725871	C/A	cg05564266	chr6:118973597	C6orf204	0.33	6.98	0.32	1.18e-11	Electrocardiographic conduction measures;
LUAD	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg00255919	chr5:131827918	IRF1	0.29	6.37	0.3	4.81e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.14	0.54	2.51e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg14228332	chr4:119757509	SEC24D	0.86	7.88	0.36	2.84e-14	Cannabis dependence symptom count;
LUAD	cis	rs7937890	0.504	rs2575822	chr11:14519851	C/A	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.25e-11	Mitochondrial DNA levels;
LUAD	cis	rs9807989	0.839	rs9308857	chr2:102979624	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	6.38	0.3	4.58e-10	Asthma;
LUAD	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg07741184	chr6:167504864	NA	0.41	9.57	0.42	8.7e-20	Crohn's disease;
LUAD	cis	rs8177876	0.642	rs8052490	chr16:81111856	A/G	cg08591886	chr16:81111003	C16orf46	-0.77	-7.13	-0.33	4.34e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10802521	chr3:52805072	NEK4	-0.62	-11.08	-0.47	3.05e-25	Bipolar disorder;
LUAD	cis	rs7851660	0.967	rs1443435	chr9:100617583	T/C	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	trans	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg27411982	chr8:10470053	RP1L1	0.37	6.51	0.3	2.17e-10	Mood instability;
LUAD	cis	rs62229266	0.804	rs2835263	chr21:37430245	A/G	cg12218747	chr21:37451666	NA	0.46	7.96	0.36	1.56e-14	Mitral valve prolapse;
LUAD	cis	rs490234	0.702	rs1339499	chr9:128406453	T/C	cg14078157	chr9:128172775	NA	-0.45	-8.03	-0.36	9.66e-15	Mean arterial pressure;
LUAD	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg21605333	chr4:119757512	SEC24D	0.93	8.63	0.39	1.29e-16	Cannabis dependence symptom count;
LUAD	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg22117172	chr7:91764530	CYP51A1	0.34	7.46	0.34	5.1e-13	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19977494	chr7:128431264	CCDC136	-0.4	-6.62	-0.31	1.08e-10	Height;
LUAD	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05901451	chr6:126070800	HEY2	0.74	13.06	0.54	5.62e-33	Brugada syndrome;
LUAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg07217954	chr7:1067459	C7orf50	0.43	6.62	0.31	1.1e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6669072	0.869	rs7526803	chr1:91235725	A/G	cg08895590	chr1:91227319	NA	0.33	6.73	0.31	5.64e-11	Cognitive function;
LUAD	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg00750074	chr16:89608354	SPG7	0.39	6.47	0.3	2.75e-10	Multiple myeloma (IgH translocation);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18876494	chr12:69004196	RAP1B	-0.6	-7.16	-0.33	3.51e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.3	-0.45	2.36e-22	Platelet count;
LUAD	cis	rs4964805	0.657	rs11111781	chr12:104187440	C/T	cg02344784	chr12:104178138	NT5DC3	0.43	8.96	0.4	1.04e-17	Attention deficit hyperactivity disorder;
LUAD	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	9.11	0.41	3.28e-18	Menarche (age at onset);
LUAD	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg03467027	chr4:99064603	C4orf37	0.43	7.06	0.32	7.06e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2425143	1.000	rs55761608	chr20:34344226	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.17	-0.33	3.46e-12	Blood protein levels;
LUAD	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg01416388	chr22:39784598	NA	0.53	9.04	0.4	5.56e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08704250	chr15:31115839	NA	-0.73	-13.42	-0.55	1.81e-34	Huntington's disease progression;
LUAD	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg09658497	chr7:2847517	GNA12	-0.52	-8.58	-0.38	1.83e-16	Height;
LUAD	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg23711669	chr6:146136114	FBXO30	0.38	6.46	0.3	2.82e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs427394	0.664	rs274697	chr5:6731477	A/C	cg10857441	chr5:6722123	POLS	-0.59	-11.86	-0.5	3.23e-28	Menopause (age at onset);
LUAD	cis	rs3813948	0.505	rs17020993	chr1:207288392	A/G	cg26044340	chr1:207277291	C4BPA	-0.49	-8.05	-0.36	8.76e-15	C4b binding protein levels;
LUAD	cis	rs9512730	0.517	rs1967772	chr13:28036062	G/A	cg04070771	chr13:27998621	GTF3A	0.57	8.47	0.38	4.18e-16	Schizophrenia;
LUAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg04025307	chr7:1156635	C7orf50	0.65	9.24	0.41	1.17e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg04025307	chr7:1156635	C7orf50	0.67	9.42	0.42	3e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg07507251	chr3:52567010	NT5DC2	0.37	7.23	0.33	2.23e-12	Bipolar disorder;
LUAD	cis	rs9447004	0.583	rs28360541	chr6:74432427	T/G	cg23004174	chr6:74404879	CD109	0.46	8.37	0.38	8.32e-16	Blood protein levels;Calcium levels;
LUAD	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg10544611	chr16:67998164	SLC12A4	-0.64	-7.69	-0.35	1.07e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.54	-9.65	-0.42	4.62e-20	Lymphocyte counts;
LUAD	cis	rs2046867	0.774	rs1393585	chr3:72886722	A/G	cg25664220	chr3:72788482	NA	-0.66	-11.71	-0.49	1.24e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg17848003	chr1:3704513	LRRC47	0.53	10.7	0.46	8.46e-24	Red cell distribution width;
LUAD	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-20.5	-0.71	2.38e-65	Height;
LUAD	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24308560	chr3:49941425	MST1R	-0.59	-9.89	-0.43	7.08e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs12579753	0.917	rs7972839	chr12:82178920	C/T	cg07988820	chr12:82153109	PPFIA2	-0.44	-7.24	-0.33	2.09e-12	Resting heart rate;
LUAD	trans	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg11693508	chr17:37793320	STARD3	0.81	10.23	0.45	4.21e-22	Bipolar disorder;
LUAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg02951883	chr7:2050386	MAD1L1	-0.97	-18.83	-0.68	7e-58	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.42	-0.42	2.93e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9788682	0.747	rs2656072	chr15:78744292	A/G	cg18825076	chr15:78729989	IREB2	-0.55	-7.79	-0.35	5.1e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg02160872	chr5:212506	CCDC127	0.5	6.38	0.3	4.64e-10	Breast cancer;
LUAD	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.36	0.34	9.62e-13	Menopause (age at onset);
LUAD	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg09455208	chr3:40491958	NA	0.56	12.54	0.52	6.8e-31	Renal cell carcinoma;
LUAD	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.45	0.3	3.08e-10	Cognitive test performance;
LUAD	cis	rs35740288	0.770	rs56092539	chr15:86182512	A/G	cg13263323	chr15:86062960	AKAP13	-0.44	-7.09	-0.33	5.8e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17738503	chr17:49244158	NME2;NME1-NME2	-0.56	-6.72	-0.31	5.72e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg15117754	chr3:10150083	C3orf24	0.46	7.51	0.34	3.44e-13	Alzheimer's disease;
LUAD	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg08470875	chr2:26401718	FAM59B	-0.6	-8.2	-0.37	2.96e-15	Gut microbiome composition (summer);
LUAD	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.36	6.97	0.32	1.22e-11	Depression;
LUAD	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg18490616	chr2:88469792	THNSL2	0.62	6.55	0.3	1.64e-10	Plasma clusterin levels;
LUAD	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg12292205	chr6:26970375	C6orf41	-0.57	-9.97	-0.44	3.56e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.87	0.36	3.06e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62400317	0.859	rs12211519	chr6:45160530	C/A	cg18551225	chr6:44695536	NA	-0.56	-8.57	-0.38	1.91e-16	Total body bone mineral density;
LUAD	cis	rs2860975	0.905	rs10882516	chr10:96791217	A/C	cg09036531	chr10:96991505	NA	-0.45	-6.69	-0.31	7e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs738321	0.757	rs2284062	chr22:38544221	A/G	cg17652424	chr22:38574118	PLA2G6	-0.26	-6.84	-0.32	2.72e-11	Breast cancer;
LUAD	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg12193833	chr17:30244370	NA	-0.58	-7.0	-0.32	1.03e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs6541297	0.703	rs586712	chr1:230315242	A/G	cg20703242	chr1:230279135	GALNT2	-0.48	-7.06	-0.32	7.01e-12	Coronary artery disease;
LUAD	trans	rs9354308	0.867	rs2802051	chr6:66536403	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.53	8.1	0.37	5.85e-15	Metabolite levels;
LUAD	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.38	-6.74	-0.31	5.3e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9650657	0.707	rs6984744	chr8:10616265	A/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.53	-0.3	1.91e-10	Neuroticism;
LUAD	cis	rs9462027	0.606	rs205260	chr6:34563958	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.87	-0.4	2.04e-17	Systemic lupus erythematosus;
LUAD	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg10483660	chr13:112241077	NA	-0.32	-6.86	-0.32	2.41e-11	Hepatitis;
LUAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg22907277	chr7:1156413	C7orf50	0.68	8.0	0.36	1.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg24069376	chr3:38537580	EXOG	0.34	7.68	0.35	1.12e-13	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg03676636	chr4:99064102	C4orf37	0.32	8.34	0.38	1.06e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg14186256	chr22:23484241	RTDR1	0.48	8.1	0.37	6.04e-15	Bone mineral density;
LUAD	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06544989	chr22:39130855	UNC84B	0.43	8.03	0.36	9.95e-15	Menopause (age at onset);
LUAD	trans	rs4650994	0.593	rs6694406	chr1:178532010	C/T	cg05059571	chr16:84539110	KIAA1609	0.44	6.83	0.32	2.9e-11	HDL cholesterol levels;HDL cholesterol;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23053825	chr2:203879250	NBEAL1	-0.41	-6.69	-0.31	7.07e-11	Cancer;
LUAD	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg04731861	chr2:219085781	ARPC2	0.23	7.02	0.32	8.83e-12	Colorectal cancer;
LUAD	cis	rs6499255	0.951	rs11075728	chr16:69611582	A/G	cg15192750	chr16:69999425	NA	0.53	8.25	0.37	1.96e-15	IgE levels;
LUAD	cis	rs354225	0.544	rs7599241	chr2:54801856	G/A	cg01766943	chr2:54829624	SPTBN1	0.38	7.03	0.32	8.09e-12	Schizophrenia;
LUAD	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg02951883	chr7:2050386	MAD1L1	0.84	15.42	0.6	7.17e-43	Bipolar disorder and schizophrenia;
LUAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.71	-14.73	-0.58	6.4e-40	Longevity;Endometriosis;
LUAD	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	7.32	0.34	1.23e-12	Breast cancer;
LUAD	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg26408565	chr15:76604113	ETFA	-0.44	-6.97	-0.32	1.23e-11	Blood metabolite levels;
LUAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg16606324	chr3:10149918	C3orf24	0.68	11.37	0.48	2.59e-26	Alzheimer's disease;
LUAD	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg12698349	chr2:225449008	CUL3	0.66	10.0	0.44	2.74e-21	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs10781543	0.839	rs6560632	chr9:139371786	A/C	cg14169450	chr9:139327907	INPP5E	0.46	8.37	0.38	8.71e-16	Monocyte percentage of white cells;
LUAD	cis	rs6446731	0.593	rs2858084	chr4:3272118	A/C	cg08886695	chr4:3369023	RGS12	-0.49	-8.13	-0.37	4.84e-15	Mean platelet volume;
LUAD	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.74	-12.38	-0.52	2.93e-30	Primary sclerosing cholangitis;
LUAD	cis	rs6952808	0.964	rs10950407	chr7:1895666	T/G	cg02951883	chr7:2050386	MAD1L1	-0.74	-11.49	-0.49	8.94e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs9788721	0.900	rs4243084	chr15:78911672	G/C	cg18825076	chr15:78729989	IREB2	-0.51	-8.16	-0.37	3.74e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs73206853	0.764	rs7980838	chr12:110672978	T/A	cg12870014	chr12:110450643	ANKRD13A	0.64	7.57	0.35	2.4e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg18187862	chr3:45730750	SACM1L	0.54	8.3	0.37	1.43e-15	Primary sclerosing cholangitis;
LUAD	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg04842962	chr6:43655489	MRPS18A	1.01	25.53	0.78	1.06e-87	IgG glycosylation;
LUAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg20607798	chr8:58055168	NA	0.58	7.41	0.34	6.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs3857067	0.806	rs6857967	chr4:95112303	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.38	-6.71	-0.31	6.46e-11	QT interval;
LUAD	cis	rs7759001	0.857	rs6923108	chr6:27362109	G/A	cg18711553	chr6:27366782	ZNF391	0.39	6.54	0.3	1.81e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs6761276	0.780	rs12477867	chr2:113835919	C/A	cg09040174	chr2:113837401	NA	0.81	15.75	0.61	2.68e-44	Protein quantitative trait loci;
LUAD	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg25173405	chr17:45401733	C17orf57	-0.49	-8.13	-0.37	4.83e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12431939	1.000	rs4567626	chr14:51647640	A/T	cg23942311	chr14:51606299	NA	0.57	7.91	0.36	2.22e-14	Cancer;
LUAD	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg05340658	chr4:99064831	C4orf37	0.54	9.14	0.41	2.7e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg20368463	chr18:77673604	PQLC1	-0.49	-6.97	-0.32	1.23e-11	Opioid sensitivity;
LUAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg07217954	chr7:1067459	C7orf50	0.42	6.88	0.32	2.17e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg05304507	chr6:116381966	FRK	0.2	6.99	0.32	1.11e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg13319975	chr6:146136371	FBXO30	-0.59	-9.91	-0.43	5.83e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg17200465	chr3:40428508	ENTPD3	0.28	6.67	0.31	8.13e-11	Renal cell carcinoma;
LUAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg04267008	chr7:1944627	MAD1L1	-0.73	-11.51	-0.49	7.39e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs1298908	0.639	rs2236568	chr10:82035923	C/A	cg09936400	chr10:82049201	MAT1A	0.35	6.36	0.3	5.28e-10	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.27	0.37	1.73e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11039798	1.000	rs34044596	chr11:48527936	T/C	cg15704280	chr7:45808275	SEPT13	0.63	7.29	0.33	1.54e-12	Axial length;
LUAD	cis	rs2425143	0.730	rs6579259	chr20:34462550	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.06	-0.32	7.08e-12	Blood protein levels;
LUAD	cis	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg06360820	chr2:242988706	NA	-1.05	-12.65	-0.52	2.59e-31	Obesity-related traits;
LUAD	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg18351406	chr4:77819688	ANKRD56	0.61	9.68	0.43	3.87e-20	Emphysema distribution in smoking;
LUAD	cis	rs3774830	0.623	rs7661692	chr4:5471853	G/A	cg26943120	chr4:5472116	STK32B	0.4	8.54	0.38	2.39e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg11965913	chr1:205819406	PM20D1	0.77	15.03	0.59	3.29e-41	Monocyte percentage of white cells;
LUAD	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg15691649	chr6:25882328	NA	-0.45	-7.08	-0.33	6.08e-12	Blood metabolite levels;
LUAD	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg18252515	chr7:66147081	NA	-0.61	-6.75	-0.31	4.99e-11	Diabetic kidney disease;
LUAD	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg25985355	chr7:65971099	NA	0.38	7.07	0.33	6.27e-12	Aortic root size;
LUAD	trans	rs3779273	0.776	rs1829989	chr7:77830751	A/C	cg05596911	chr5:118502651	DMXL1	-0.38	-6.58	-0.3	1.41e-10	Body mass index;
LUAD	cis	rs15676	0.783	rs10819442	chr9:131564750	C/G	cg00228799	chr9:131580591	ENDOG	-0.47	-7.34	-0.34	1.07e-12	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07998558	chr7:150648497	KCNH2	0.51	6.59	0.31	1.35e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02475777	chr4:1388615	CRIPAK	0.65	9.13	0.41	2.75e-18	Longevity;
LUAD	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg02018176	chr4:1364513	KIAA1530	0.57	10.87	0.47	2.01e-24	Longevity;
LUAD	cis	rs1160297	0.576	rs13002328	chr2:53085447	A/C	cg07782112	chr2:53107842	NA	0.39	8.37	0.38	8.22e-16	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4650994	0.525	rs2493865	chr1:178545016	G/A	cg05059571	chr16:84539110	KIAA1609	0.73	13.47	0.55	1.11e-34	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg23018236	chr17:30244563	NA	-0.69	-8.47	-0.38	3.96e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	6.82	0.31	3.13e-11	Motion sickness;
LUAD	cis	rs10129255	0.500	rs59939897	chr14:107191651	A/G	cg07958169	chr14:107095056	NA	-0.37	-7.36	-0.34	9.91e-13	Kawasaki disease;
LUAD	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg18105134	chr13:113819100	PROZ	-0.81	-14.59	-0.58	2.35e-39	Platelet distribution width;
LUAD	cis	rs6445967	1.000	rs7622074	chr3:58312297	A/G	cg23715586	chr3:58305044	RPP14	0.43	7.61	0.35	1.81e-13	Platelet count;
LUAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg02869364	chr7:1081709	C7orf50	-0.5	-6.41	-0.3	3.81e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs67073037	0.956	rs12622122	chr2:29111060	C/A	cg09522027	chr2:28974177	PPP1CB	0.48	6.76	0.31	4.64e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
LUAD	trans	rs7395662	0.856	rs117753969	chr11:48760328	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.22	-0.33	2.48e-12	HDL cholesterol;
LUAD	trans	rs57046232	0.552	rs1887412	chr20:6340856	A/G	cg21095983	chr6:86352623	SYNCRIP	0.42	6.43	0.3	3.5e-10	Colorectal cancer;
LUAD	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg03929089	chr4:120376271	NA	-0.83	-15.25	-0.6	3.65e-42	Coronary artery disease;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg02189925	chr1:205091232	RBBP5	-0.42	-7.07	-0.33	6.45e-12	Subcortical brain region volumes;
LUAD	cis	rs1387259	0.570	rs12368659	chr12:48562299	C/A	cg04545296	chr12:48745243	ZNF641	0.31	8.04	0.36	9.15e-15	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.66	-0.31	8.32e-11	Gout;
LUAD	cis	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg07460842	chr6:66804631	NA	0.91	14.45	0.57	9.31e-39	Exhaled nitric oxide levels;
LUAD	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg08999081	chr20:33150536	PIGU	0.49	9.34	0.41	5.75e-19	Coronary artery disease;
LUAD	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.3	-0.45	2.43e-22	Total body bone mineral density;
LUAD	cis	rs953387	1.000	rs10803550	chr2:136907790	C/T	cg05194412	chr2:137003533	NA	-0.39	-6.4	-0.3	4.12e-10	Arthritis (juvenile idiopathic);
LUAD	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg02527881	chr3:46936655	PTH1R	0.43	8.22	0.37	2.45e-15	Colorectal cancer;
LUAD	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg20476274	chr7:133979776	SLC35B4	0.86	17.73	0.65	5.58e-53	Mean platelet volume;
LUAD	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg24324837	chr19:49891574	CCDC155	0.54	8.37	0.38	8.61e-16	Multiple sclerosis;
LUAD	cis	rs7731657	0.537	rs2419937	chr5:130316874	C/G	cg08523029	chr5:130500466	HINT1	-0.57	-7.33	-0.34	1.2e-12	Fasting plasma glucose;
LUAD	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg04455712	chr21:45112962	RRP1B	0.42	8.4	0.38	6.89e-16	Mean corpuscular volume;
LUAD	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.87	0.4	2.11e-17	Menopause (age at onset);
LUAD	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg12193833	chr17:30244370	NA	-0.59	-6.83	-0.32	3.03e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg17173187	chr15:85201210	NMB	-0.51	-8.9	-0.4	1.66e-17	Schizophrenia;
LUAD	cis	rs6840360	0.550	rs11723438	chr4:152531801	C/T	cg22705602	chr4:152727874	NA	0.39	6.92	0.32	1.66e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10911363	0.592	rs2702180	chr1:183517971	T/C	cg09173681	chr1:183549694	NCF2	0.55	10.32	0.45	2.06e-22	Systemic lupus erythematosus;
LUAD	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg01528321	chr10:82214614	TSPAN14	0.51	7.98	0.36	1.43e-14	Post bronchodilator FEV1;
LUAD	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg02880119	chr16:3481970	NA	-0.53	-8.18	-0.37	3.3e-15	Body mass index (adult);
LUAD	cis	rs877282	0.945	rs34367686	chr10:791868	G/C	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	cis	rs7851660	0.809	rs7032114	chr9:100656459	T/G	cg13688889	chr9:100608707	NA	-0.54	-9.08	-0.4	4.17e-18	Strep throat;
LUAD	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.65	0.31	9.27e-11	Aortic root size;
LUAD	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg17724175	chr1:150552817	MCL1	-0.33	-7.64	-0.35	1.51e-13	Melanoma;
LUAD	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.79	-0.35	5.06e-14	HDL cholesterol;
LUAD	cis	rs57920188	0.640	rs4311852	chr1:4085353	C/A	cg20703997	chr1:4087676	NA	0.47	8.35	0.38	9.64e-16	Interleukin-17 levels;
LUAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg18621852	chr3:10150065	C3orf24	0.43	6.73	0.31	5.65e-11	Alzheimer's disease;
LUAD	cis	rs3784262	0.669	rs4646597	chr15:58300768	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.52	-0.34	3.23e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs11771526	0.901	rs7357161	chr7:32302475	A/C	cg13207630	chr7:32358064	NA	0.6	7.32	0.34	1.27e-12	Body mass index;
LUAD	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-8.26	-0.37	1.94e-15	Monocyte percentage of white cells;
LUAD	cis	rs6987853	0.830	rs4737048	chr8:42359035	G/T	cg09913449	chr8:42400586	C8orf40	-0.39	-7.04	-0.32	8.01e-12	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg27539214	chr16:67997921	SLC12A4	-0.62	-8.75	-0.39	5.29e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs77956314	0.515	rs60940473	chr12:117462582	C/T	cg02017074	chr12:117425053	FBXW8	-0.64	-8.24	-0.37	2.13e-15	Subcortical brain region volumes;Hippocampal volume;
LUAD	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg20701182	chr2:24300061	SF3B14	0.68	7.64	0.35	1.51e-13	Lymphocyte counts;
LUAD	cis	rs9467773	1.000	rs1570060	chr6:26573562	A/G	cg09904177	chr6:26538194	HMGN4	0.44	7.03	0.32	8.25e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg21918786	chr6:109611834	NA	-0.54	-9.52	-0.42	1.31e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs12530845	0.945	rs73725433	chr7:135313251	C/T	cg23117316	chr7:135346802	PL-5283	-0.52	-9.5	-0.42	1.52e-19	Red blood cell traits;
LUAD	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg24308560	chr3:49941425	MST1R	-0.52	-8.59	-0.39	1.73e-16	Body mass index;
LUAD	cis	rs6988985	0.728	rs5303	chr8:143955095	A/G	cg10324643	chr8:143916377	GML	0.31	6.42	0.3	3.75e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs739496	0.843	rs638791	chr12:111989236	A/G	cg10833066	chr12:111807467	FAM109A	0.41	6.57	0.3	1.52e-10	Platelet count;
LUAD	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg00666640	chr1:248458726	OR2T12	0.34	8.22	0.37	2.58e-15	Common traits (Other);
LUAD	trans	rs45509595	0.841	rs17751184	chr6:27775028	C/T	cg06606381	chr12:133084897	FBRSL1	-1.08	-10.14	-0.44	9.28e-22	Breast cancer;
LUAD	cis	rs6076065	0.963	rs6048797	chr20:23422621	G/A	cg11657817	chr20:23433608	CST11	0.5	9.67	0.43	4.09e-20	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.75	0.53	9.8e-32	Cognitive ability;
LUAD	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19748678	chr4:122722346	EXOSC9	0.42	6.82	0.31	3.24e-11	Type 2 diabetes;
LUAD	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg18451016	chr1:38461880	NA	0.47	8.88	0.4	1.92e-17	Coronary artery disease;
LUAD	trans	rs9951602	0.512	rs9946138	chr18:76654608	A/G	cg02800362	chr5:177631904	HNRNPAB	0.92	14.62	0.58	1.88e-39	Obesity-related traits;
LUAD	cis	rs7582720	1.000	rs76461893	chr2:203865515	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.28	0.41	8.55e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg27535305	chr1:53392650	SCP2	0.46	9.12	0.41	3e-18	Monocyte count;
LUAD	trans	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg24644049	chr4:85504048	CDS1	0.84	6.88	0.32	2.23e-11	Skin colour saturation;
LUAD	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg20542592	chr8:11973495	FAM66D	0.42	6.61	0.31	1.17e-10	Joint mobility (Beighton score);
LUAD	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg00106254	chr7:1943704	MAD1L1	-0.6	-8.9	-0.4	1.61e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs1215050	0.904	rs260898	chr4:98706492	C/G	cg17366294	chr4:99064904	C4orf37	-0.44	-7.32	-0.34	1.24e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg20701182	chr2:24300061	SF3B14	0.67	7.51	0.34	3.46e-13	Lymphocyte counts;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg01973725	chr5:80608537	RNU5E;RNU5D;ZCCHC9	0.42	6.55	0.3	1.69e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg24818145	chr4:99064322	C4orf37	0.44	6.86	0.32	2.47e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg12714757	chr17:73874637	TRIM47	-0.4	-6.4	-0.3	4.08e-10	Psoriasis;
LUAD	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg10589385	chr1:150898437	SETDB1	0.45	8.35	0.38	9.9e-16	Melanoma;
LUAD	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg23950597	chr19:37808831	NA	-0.6	-7.46	-0.34	4.88e-13	Coronary artery calcification;
LUAD	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg13180566	chr4:1052158	NA	-0.38	-6.52	-0.3	1.96e-10	Recombination rate (females);
LUAD	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg14092988	chr3:52407081	DNAH1	-0.45	-9.12	-0.41	3e-18	Bipolar disorder;
LUAD	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg07617317	chr6:118971624	C6orf204	0.55	8.09	0.37	6.19e-15	Diastolic blood pressure;
LUAD	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg00757033	chr12:89920650	WDR51B	0.66	11.38	0.48	2.27e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs4237845	0.586	rs4760174	chr12:58320436	G/A	cg02175503	chr12:58329896	NA	0.43	7.34	0.34	1.14e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6688613	0.685	rs6427047	chr1:166914258	A/G	cg07049167	chr1:166818506	POGK	0.53	8.39	0.38	7.61e-16	Refractive astigmatism;
LUAD	trans	rs3857536	0.813	rs2040594	chr6:66943966	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.55	-0.3	1.66e-10	Blood trace element (Cu levels);
LUAD	trans	rs58106596	0.950	rs11695646	chr2:232584807	C/T	cg01370599	chr3:116745421	NA	-0.43	-6.62	-0.31	1.06e-10	White blood cell count;Lymphocyte counts;
LUAD	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg26924012	chr15:45694286	SPATA5L1	0.63	10.64	0.46	1.37e-23	Glomerular filtration rate;
LUAD	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	12.55	0.52	6.05e-31	Monocyte percentage of white cells;
LUAD	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg10518543	chr12:38710700	ALG10B	-0.41	-6.57	-0.3	1.47e-10	Bladder cancer;
LUAD	cis	rs921968	0.565	rs2272189	chr2:219610322	G/A	cg02176678	chr2:219576539	TTLL4	-0.57	-11.35	-0.48	2.94e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg02423579	chr7:2872169	GNA12	-0.85	-14.48	-0.58	7.06e-39	Height;
LUAD	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg23262073	chr20:60523788	NA	-0.46	-7.94	-0.36	1.81e-14	Body mass index;
LUAD	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg09509183	chr1:209979624	IRF6	0.61	7.01	0.32	9.56e-12	Coronary artery disease;
LUAD	trans	rs2735413	0.918	rs4887932	chr16:78078350	C/A	cg01028844	chr5:122736986	CEP120	0.4	6.44	0.3	3.29e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg15704280	chr7:45808275	SEPT13	-1.0	-20.9	-0.71	3.63e-67	Coronary artery disease;
LUAD	cis	rs7010267	0.596	rs6984572	chr8:120054168	G/A	cg01975934	chr8:119970761	NA	-0.33	-6.4	-0.3	4.14e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg03433033	chr1:76189801	ACADM	-0.46	-6.8	-0.31	3.61e-11	Daytime sleep phenotypes;
LUAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg24829409	chr8:58192753	C8orf71	-0.61	-7.11	-0.33	4.82e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg23795048	chr12:9217529	LOC144571	0.46	8.31	0.37	1.35e-15	Sjögren's syndrome;
LUAD	cis	rs853679	0.760	rs967005	chr6:28210688	C/T	cg16479474	chr6:28041457	NA	0.41	6.65	0.31	9.3e-11	Depression;
LUAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00149659	chr3:10157352	C3orf10	0.59	8.1	0.37	5.85e-15	Alzheimer's disease;
LUAD	cis	rs2580764	0.515	rs7570629	chr2:55255935	A/T	cg09592903	chr2:55203963	RTN4	-0.46	-10.38	-0.45	1.24e-22	Mean platelet volume;
LUAD	cis	rs438465	1.000	rs2860563	chr6:169888241	A/G	cg11181693	chr6:169825345	NA	-0.61	-7.86	-0.36	3.14e-14	Corneal astigmatism;
LUAD	cis	rs1232027	0.616	rs1677629	chr5:79961841	C/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg02733842	chr7:1102375	C7orf50	0.54	8.62	0.39	1.37e-16	Bronchopulmonary dysplasia;
LUAD	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg05182265	chr7:156933206	UBE3C	-0.79	-17.15	-0.64	1.92e-50	Body mass index;
LUAD	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg03388025	chr16:89894329	SPIRE2	0.33	7.81	0.36	4.48e-14	Vitiligo;
LUAD	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg27129171	chr3:47204927	SETD2	0.42	6.78	0.31	4.01e-11	Colorectal cancer;
LUAD	cis	rs6835098	0.520	rs2127896	chr4:174211285	G/A	cg08422745	chr4:174089978	GALNT7	-0.56	-8.92	-0.4	1.38e-17	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.84e-26	Alzheimer's disease (late onset);
LUAD	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs7851660	0.967	rs1443434	chr9:100617479	G/T	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg05340658	chr4:99064831	C4orf37	0.56	9.47	0.42	2.05e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg22852734	chr6:133119734	C6orf192	0.77	9.12	0.41	3e-18	Type 2 diabetes nephropathy;
LUAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg23958373	chr8:599963	NA	-0.97	-9.73	-0.43	2.57e-20	IgG glycosylation;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg21548813	chr6:291882	DUSP22	-0.79	-13.47	-0.55	1.19e-34	Menopause (age at onset);
LUAD	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg27284194	chr4:1044797	NA	0.69	9.91	0.43	5.79e-21	Recombination rate (females);
LUAD	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg22029157	chr1:209979665	IRF6	0.47	8.46	0.38	4.35e-16	Monobrow;
LUAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg04234412	chr22:24373322	LOC391322	-0.8	-14.43	-0.57	1.13e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg00757033	chr12:89920650	WDR51B	0.68	11.57	0.49	4.53e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg11584989	chr19:19387371	SF4	0.58	9.3	0.41	7.53e-19	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.96	0.36	1.57e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9581857	0.556	rs9581864	chr13:28041567	T/C	cg22138327	chr13:27999177	GTF3A	0.78	11.34	0.48	3.25e-26	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg10792982	chr14:105748885	BRF1	0.44	9.1	0.4	3.54e-18	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs11958404	1.000	rs72816531	chr5:157413079	A/G	cg05962755	chr5:157440814	NA	0.44	6.99	0.32	1.07e-11	IgG glycosylation;
LUAD	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg21862992	chr11:68658383	NA	-0.52	-9.59	-0.42	7.89e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.9	9.44	0.42	2.6e-19	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6842047	1.000	rs4862668	chr4:187136443	A/T	cg02012338	chr4:187126139	CYP4V2	0.92	9.51	0.42	1.51e-19	Blood protein levels;
LUAD	cis	rs73206853	0.764	rs55929416	chr12:110622543	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	8.04	0.36	9.28e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs1975974	1.000	rs4889732	chr17:21721443	T/C	cg18423549	chr17:21743878	NA	-0.76	-13.58	-0.55	4.22e-35	Psoriasis;
LUAD	cis	rs870825	0.550	rs59051283	chr4:185646476	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-6.89	-0.32	2.06e-11	Total body bone mineral density;
LUAD	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg08601574	chr20:25228251	PYGB	0.46	8.51	0.38	3.16e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs733175	0.830	rs6820756	chr4:10062849	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-7.29	-0.33	1.51e-12	Psychosis and Alzheimer's disease;
LUAD	cis	rs990171	0.538	rs4851600	chr2:103116223	C/G	cg03938978	chr2:103052716	IL18RAP	-0.33	-6.52	-0.3	2.03e-10	Lymphocyte counts;
LUAD	trans	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg04775059	chr7:64541387	NA	-0.53	-7.03	-0.32	8.24e-12	Aortic root size;
LUAD	cis	rs3823572	0.564	rs2971973	chr7:133644256	G/A	cg03336402	chr7:133662267	EXOC4	-0.4	-7.38	-0.34	8.25e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs853679	0.546	rs200977	chr6:27854301	T/C	cg01620082	chr3:125678407	NA	-0.87	-8.95	-0.4	1.13e-17	Depression;
LUAD	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg02269571	chr22:50332266	NA	-0.63	-9.35	-0.41	5.23e-19	Schizophrenia;
LUAD	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg10589385	chr1:150898437	SETDB1	-0.4	-7.55	-0.34	2.7e-13	Tonsillectomy;
LUAD	cis	rs62238980	0.614	rs76010922	chr22:32471678	G/A	cg00543991	chr22:32367038	NA	0.92	8.7	0.39	7.27e-17	Childhood ear infection;
LUAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.48	-9.07	-0.4	4.43e-18	Lymphocyte counts;
LUAD	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.5	0.3	2.31e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs1816752	0.875	rs8001187	chr13:24976414	G/A	cg02811702	chr13:24901961	NA	0.38	6.45	0.3	3.03e-10	Obesity-related traits;
LUAD	cis	rs3849570	0.732	rs11715625	chr3:81875938	A/T	cg07356753	chr3:81810745	GBE1	-0.57	-9.25	-0.41	1.08e-18	Waist circumference;Body mass index;
LUAD	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg06641503	chr3:48959341	ARIH2	-0.39	-7.35	-0.34	1.05e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.34	-0.34	1.12e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg21782813	chr7:2030301	MAD1L1	0.6	10.51	0.46	4e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs7737355	0.947	rs2021774	chr5:130920831	G/A	cg06307176	chr5:131281290	NA	0.49	7.76	0.35	6.47e-14	Life satisfaction;
LUAD	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg27211204	chr15:99791508	LRRC28	-0.49	-6.73	-0.31	5.63e-11	Testicular germ cell tumor;
LUAD	cis	rs13064411	0.518	rs9870996	chr3:113238375	A/C	cg10517650	chr3:113235015	CCDC52	-0.36	-6.65	-0.31	9.2e-11	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs4072705	1.000	rs4836988	chr9:127497573	T/C	cg13476313	chr9:127244764	NR5A1	0.28	6.71	0.31	6.28e-11	Menarche (age at onset);
LUAD	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg12062639	chr20:23401060	NAPB	1.1	11.43	0.49	1.54e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg09509183	chr1:209979624	IRF6	0.52	6.61	0.31	1.13e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg12927641	chr6:109611667	NA	-0.56	-9.73	-0.43	2.52e-20	Reticulocyte fraction of red cells;
LUAD	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg14024328	chr4:719362	PCGF3	-0.52	-8.47	-0.38	4.08e-16	White blood cell count;
LUAD	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg25985355	chr7:65971099	NA	-0.56	-6.95	-0.32	1.35e-11	Diabetic kidney disease;
LUAD	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06544989	chr22:39130855	UNC84B	0.4	7.24	0.33	2.1e-12	Menopause (age at onset);
LUAD	cis	rs4523957	0.651	rs9910413	chr17:2081419	G/A	cg16513277	chr17:2031491	SMG6	-0.95	-19.02	-0.68	9.65e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg06002616	chr8:101225028	SPAG1	-0.39	-8.14	-0.37	4.57e-15	Atrioventricular conduction;
LUAD	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg04856117	chr22:19949901	COMT	-0.29	-6.65	-0.31	9.03e-11	Blood metabolite levels;
LUAD	cis	rs526821	0.553	rs510095	chr11:55289154	T/C	cg04317927	chr11:55418816	OR4S2	0.39	7.3	0.33	1.42e-12	Pediatric bone mineral density (spine);
LUAD	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg09537434	chr19:41945824	ATP5SL	0.49	7.73	0.35	8.19e-14	Height;
LUAD	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.68	-10.38	-0.45	1.22e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs4891159	0.548	rs12454625	chr18:74128751	A/G	cg24786174	chr18:74118243	ZNF516	0.9	22.59	0.74	1.05e-74	Longevity;
LUAD	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg02683114	chr2:24398427	C2orf84	-0.42	-6.48	-0.3	2.52e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg00071950	chr4:10020882	SLC2A9	0.82	16.89	0.63	2.8e-49	Bone mineral density;
LUAD	cis	rs9473147	0.516	rs9381564	chr6:47443806	A/G	cg02130027	chr6:47444894	CD2AP	0.37	6.87	0.32	2.32e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs1448094	1.000	rs10083080	chr12:86348579	G/C	cg02569458	chr12:86230093	RASSF9	0.35	6.74	0.31	5.25e-11	Major depressive disorder;
LUAD	cis	rs13082711	0.863	rs35998108	chr3:27423427	G/A	cg02860705	chr3:27208620	NA	0.56	8.6	0.39	1.53e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg17724175	chr1:150552817	MCL1	0.35	7.98	0.36	1.4e-14	Melanoma;
LUAD	cis	rs41311933	0.656	rs41309844	chr9:123781647	A/C	cg13567360	chr9:123745713	C5	-0.68	-8.12	-0.37	5.12e-15	Coronary artery disease;
LUAD	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg23649088	chr2:200775458	C2orf69	0.62	7.77	0.35	6.15e-14	Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12522898	chr20:33891700	UQCC	-0.38	-6.66	-0.31	8.33e-11	Cancer;
LUAD	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg15962314	chr1:44399869	ARTN	0.32	6.82	0.31	3.22e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9329289	0.510	rs28579610	chr10:2546080	C/A	cg15501526	chr10:2543763	NA	0.55	11.9	0.5	2.32e-28	Age-related hearing impairment;
LUAD	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.51	0.52	9.23e-31	Tonsillectomy;
LUAD	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg02569458	chr12:86230093	RASSF9	0.47	8.49	0.38	3.45e-16	Major depressive disorder;
LUAD	cis	rs10924309	0.640	rs6700599	chr1:245854047	G/T	cg00036263	chr1:245852353	KIF26B	-0.53	-9.07	-0.4	4.35e-18	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg16681516	chr19:46297285	DMWD	0.44	8.72	0.39	6.38e-17	Coronary artery disease;
LUAD	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg26384229	chr12:38710491	ALG10B	0.4	6.46	0.3	2.81e-10	Morning vs. evening chronotype;
LUAD	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-6.87	-0.32	2.34e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg06112835	chr11:68658793	MRPL21	0.47	8.36	0.38	8.93e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.46	-0.42	2.09e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7210086	0.768	rs4395115	chr17:70640382	G/C	cg04206342	chr17:70636940	NA	-0.36	-6.94	-0.32	1.47e-11	Ulcerative colitis;
LUAD	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg21963583	chr11:68658836	MRPL21	0.64	11.45	0.49	1.21e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11644478	chr21:40555479	PSMG1	-0.59	-9.88	-0.43	7.3e-21	Cognitive function;
LUAD	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.2	-0.33	2.73e-12	Coronary artery disease;
LUAD	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.5	-7.98	-0.36	1.38e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.8	0.46	3.55e-24	Smoking behavior;
LUAD	cis	rs13064411	0.518	rs7623919	chr3:113219160	A/G	cg10517650	chr3:113235015	CCDC52	-0.38	-7.03	-0.32	8.33e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs17867775	0.623	rs12670241	chr7:126692465	G/A	cg02090654	chr7:126698344	MIR592;GRM8	0.84	9.77	0.43	1.82e-20	Anti-saccade response;
LUAD	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.43	-0.3	3.46e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg17366294	chr4:99064904	C4orf37	0.58	9.91	0.43	5.93e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9394438	0.628	rs4714078	chr6:37543852	G/A	cg00985040	chr6:37553208	NA	-0.44	-9.35	-0.41	5.16e-19	IgG glycosylation;
LUAD	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg09201001	chr11:18656081	SPTY2D1	0.37	6.36	0.3	5.19e-10	Breast cancer;
LUAD	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg11941060	chr3:133502564	NA	0.39	6.62	0.31	1.12e-10	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.37	-0.34	9.19e-13	Breast cancer;
LUAD	trans	rs9982601	0.722	rs16991453	chr21:35647104	C/T	cg12609467	chr3:49508289	DAG1	0.5	6.36	0.3	5.28e-10	Coronary artery disease;Coronary heart disease;Myocardial infarction;Myocardial infarction (early onset);
LUAD	cis	rs7187994	0.848	rs34923260	chr16:84773460	A/G	cg07647771	chr16:84786436	USP10	-0.37	-9.21	-0.41	1.49e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	trans	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg04565464	chr8:145669602	NFKBIL2	0.46	6.76	0.31	4.66e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.67	0.31	7.97e-11	Menarche (age at onset);
LUAD	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.82	-7.96	-0.36	1.61e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg13073564	chr4:8508604	NA	-0.49	-9.07	-0.4	4.52e-18	Response to antineoplastic agents;
LUAD	cis	rs16882447	0.607	rs13435967	chr5:53490881	G/T	cg06461071	chr5:53490839	ARL15	-0.42	-7.64	-0.35	1.49e-13	Systolic blood pressure (dietary potassium intake interaction);
LUAD	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg01475377	chr6:109611718	NA	-0.52	-10.18	-0.44	6.6e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg23018236	chr17:30244563	NA	-0.68	-7.93	-0.36	1.96e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs9811920	0.809	rs4928151	chr3:99767553	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	7.62	0.35	1.62e-13	Axial length;
LUAD	cis	rs2070677	0.736	rs6537612	chr10:135336717	A/T	cg20169779	chr10:135381914	SYCE1	-0.57	-6.88	-0.32	2.11e-11	Gout;
LUAD	trans	rs236907	0.859	rs2143369	chr1:171767372	A/G	cg13482142	chr2:234261155	NA	0.49	6.47	0.3	2.64e-10	Mean platelet volume;
LUAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg20891283	chr12:69753455	YEATS4	0.46	7.32	0.34	1.25e-12	Blood protein levels;
LUAD	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg08280861	chr8:58055591	NA	0.56	7.74	0.35	7.37e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs8002861	0.905	rs12429722	chr13:44412466	T/A	cg12856521	chr11:46389249	DGKZ	-0.38	-6.46	-0.3	2.89e-10	Leprosy;
LUAD	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.44	6.38	0.3	4.53e-10	Resistin levels;
LUAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.03	0.66	2.59e-54	Prudent dietary pattern;
LUAD	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg03433033	chr1:76189801	ACADM	-0.49	-7.31	-0.33	1.37e-12	Daytime sleep phenotypes;
LUAD	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg23939001	chr4:940644	TMEM175	0.76	13.52	0.55	7.46e-35	Sjögren's syndrome;
LUAD	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg00255919	chr5:131827918	IRF1	0.47	10.71	0.46	7.63e-24	Asthma (sex interaction);
LUAD	cis	rs240764	0.687	rs1336245	chr6:101197640	A/T	cg09795085	chr6:101329169	ASCC3	-0.47	-8.38	-0.38	7.87e-16	Neuroticism;
LUAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg11062466	chr8:58055876	NA	0.86	10.51	0.45	4.28e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs16866061	1.000	rs72972378	chr2:225372562	A/G	cg12698349	chr2:225449008	CUL3	0.74	12.77	0.53	7.91e-32	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg03433033	chr1:76189801	ACADM	-0.52	-7.66	-0.35	1.25e-13	Daytime sleep phenotypes;
LUAD	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg17724175	chr1:150552817	MCL1	0.38	9.43	0.42	2.66e-19	Tonsillectomy;
LUAD	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg00933542	chr6:150070202	PCMT1	0.36	7.53	0.34	3.06e-13	Testicular germ cell tumor;
LUAD	cis	rs9811920	0.931	rs7629487	chr3:99860401	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.38	-6.87	-0.32	2.26e-11	Axial length;
LUAD	cis	rs9788721	0.934	rs16969968	chr15:78882925	G/A	cg18825076	chr15:78729989	IREB2	-0.57	-9.2	-0.41	1.66e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg13770153	chr20:60521292	NA	-0.58	-9.72	-0.43	2.76e-20	Body mass index;
LUAD	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs113835537	0.866	rs59566349	chr11:66365994	A/T	cg24851651	chr11:66362959	CCS	0.58	8.05	0.36	8.49e-15	Airway imaging phenotypes;
LUAD	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg08219700	chr8:58056026	NA	0.56	7.74	0.35	7.14e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910187	0.605	rs3787239	chr20:45802729	T/C	cg27589058	chr20:45804311	EYA2	-0.36	-8.32	-0.37	1.24e-15	Migraine;
LUAD	cis	rs4638749	0.677	rs4676187	chr2:108842936	T/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.33	-0.34	1.19e-12	Blood pressure;
LUAD	cis	rs2882667	0.861	rs11959727	chr5:138396965	C/T	cg04439458	chr5:138467593	SIL1	-0.4	-7.29	-0.33	1.56e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs12545109	0.800	rs2576599	chr8:57388410	G/A	cg17761419	chr8:57350749	NA	-0.56	-8.04	-0.36	8.81e-15	Obesity-related traits;
LUAD	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.56	8.96	0.4	1.02e-17	Cognitive ability;
LUAD	cis	rs11112613	0.609	rs2374534	chr12:106047897	A/T	cg03607813	chr12:105948248	NA	0.52	6.97	0.32	1.25e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg01657329	chr11:68192670	LRP5	-0.4	-6.42	-0.3	3.57e-10	Total body bone mineral density;
LUAD	trans	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg01620082	chr3:125678407	NA	-0.62	-7.42	-0.34	6.49e-13	Depression;
LUAD	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.1	-0.4	3.56e-18	Alcohol dependence;
LUAD	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg13390004	chr1:15929781	NA	0.48	8.37	0.38	8.7e-16	Systolic blood pressure;
LUAD	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.77	-9.67	-0.43	3.97e-20	Body mass index;
LUAD	cis	rs4889911	0.544	rs1294081	chr17:77829864	T/C	cg02876276	chr17:77834299	NA	0.51	7.78	0.35	5.53e-14	Electroencephalogram traits;
LUAD	cis	rs6500395	0.925	rs12920170	chr16:48701530	A/G	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.66	0.31	8.71e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7188861	0.626	rs7193871	chr16:11455606	C/G	cg00044050	chr16:11439710	C16orf75	0.46	6.57	0.3	1.45e-10	HDL cholesterol;
LUAD	cis	rs791888	0.767	rs2255684	chr10:89419971	C/T	cg13926569	chr10:89418898	PAPSS2	-0.53	-10.02	-0.44	2.39e-21	Magnesium levels;
LUAD	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg11502198	chr6:26597334	ABT1	0.56	9.43	0.42	2.72e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg22681709	chr2:178499509	PDE11A	-0.38	-6.97	-0.32	1.21e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1448094	0.935	rs11117120	chr12:86336447	G/A	cg06740227	chr12:86229804	RASSF9	0.36	6.53	0.3	1.91e-10	Major depressive disorder;
LUAD	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg07741184	chr6:167504864	NA	0.31	7.11	0.33	5.13e-12	Crohn's disease;
LUAD	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg27144592	chr16:783916	NARFL	-0.72	-12.63	-0.52	3.12e-31	Height;
LUAD	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg07617317	chr6:118971624	C6orf204	0.55	8.33	0.38	1.14e-15	Diastolic blood pressure;
LUAD	cis	rs939658	0.875	rs2177057	chr15:79441441	G/C	cg17916960	chr15:79447300	NA	-0.53	-11.26	-0.48	6.91e-26	Refractive error;
LUAD	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg18190219	chr22:46762943	CELSR1	-0.55	-6.73	-0.31	5.49e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7192380	0.729	rs11648335	chr16:69597317	A/G	cg26679644	chr16:69762563	NA	0.38	7.14	0.33	4.08e-12	Sjögren's syndrome;
LUAD	cis	rs7927771	0.524	rs7107922	chr11:47669289	C/A	cg18512352	chr11:47633146	NA	0.37	6.66	0.31	8.42e-11	Subjective well-being;
LUAD	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg10591111	chr5:226296	SDHA	-0.56	-7.27	-0.33	1.81e-12	Breast cancer;
LUAD	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg08109568	chr15:31115862	NA	-0.63	-9.84	-0.43	1e-20	Huntington's disease progression;
LUAD	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg04414720	chr1:150670196	GOLPH3L	0.6	10.37	0.45	1.29e-22	Melanoma;
LUAD	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg04398451	chr17:18023971	MYO15A	-0.64	-11.78	-0.5	6.57e-28	Total body bone mineral density;
LUAD	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg06558623	chr16:89946397	TCF25	1.13	10.26	0.45	3.43e-22	Skin colour saturation;
LUAD	trans	rs61472021	1	rs61472021	chr6:26090025	T/C	cg06606381	chr12:133084897	FBRSL1	-0.62	-7.0	-0.32	1.02e-11	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.14e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg24768116	chr2:27665128	KRTCAP3	0.26	6.43	0.3	3.38e-10	Oral cavity cancer;
LUAD	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg21951975	chr1:209979733	IRF6	0.49	6.6	0.31	1.22e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg21775007	chr8:11205619	TDH	-0.4	-7.12	-0.33	4.73e-12	Retinal vascular caliber;
LUAD	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.33e-13	Menopause (age at onset);
LUAD	cis	rs7771547	0.519	rs12206445	chr6:36379628	G/A	cg04289385	chr6:36355825	ETV7	0.52	7.49	0.34	3.93e-13	Platelet distribution width;
LUAD	cis	rs7903847	0.620	rs2297988	chr10:99118382	A/G	cg20016023	chr10:99160130	RRP12	-0.28	-6.74	-0.31	5.14e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs72772090	0.539	rs72773932	chr5:96118148	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-7.18	-0.33	3.2e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg05042697	chr2:10830656	NOL10	-0.39	-6.73	-0.31	5.43e-11	Prostate cancer;
LUAD	cis	rs418053	0.648	rs204228	chr6:13680776	A/G	cg02206980	chr6:13574034	SIRT5	-0.35	-7.58	-0.35	2.23e-13	Breast cancer;
LUAD	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg15448220	chr1:150897856	SETDB1	0.53	8.93	0.4	1.28e-17	Melanoma;
LUAD	cis	rs9314323	0.729	rs7823021	chr8:26224958	G/T	cg13160058	chr8:26243215	BNIP3L	-0.47	-9.52	-0.42	1.39e-19	Red cell distribution width;
LUAD	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06112835	chr11:68658793	MRPL21	0.51	9.22	0.41	1.47e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg22875332	chr1:76189707	ACADM	0.89	18.09	0.66	1.36e-54	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg20587970	chr11:113659929	NA	-0.7	-10.74	-0.46	5.82e-24	Hip circumference adjusted for BMI;
LUAD	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg11494091	chr17:61959527	GH2	-0.69	-16.02	-0.61	1.69e-45	Prudent dietary pattern;
LUAD	cis	rs3784262	0.669	rs1063666	chr15:58246602	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.37	-7.3	-0.33	1.41e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg05340658	chr4:99064831	C4orf37	0.43	7.25	0.33	2.01e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg08999081	chr20:33150536	PIGU	0.48	9.27	0.41	9.32e-19	Coronary artery disease;
LUAD	cis	rs11771526	0.681	rs11767011	chr7:32420648	G/A	cg13207630	chr7:32358064	NA	0.67	6.92	0.32	1.64e-11	Body mass index;
LUAD	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs11169225	1.000	rs11169225	chr12:50345671	T/A	cg04450003	chr12:50355995	AQP5	0.76	10.17	0.44	7.02e-22	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.57	9.97	0.44	3.52e-21	Birth weight;
LUAD	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.44	0.3	3.28e-10	Depression;
LUAD	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg18721089	chr20:30220636	NA	-0.46	-6.72	-0.31	5.84e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs35146811	0.700	rs866500	chr7:99840461	A/G	cg22906224	chr7:99728672	NA	-0.63	-10.14	-0.44	8.74e-22	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg11062466	chr8:58055876	NA	0.67	9.02	0.4	6.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6712932	1.000	rs6712932	chr2:105837598	C/T	cg22878388	chr2:105853796	NA	0.38	6.63	0.31	1.01e-10	Type 2 diabetes;
LUAD	cis	rs6484504	0.625	rs672396	chr11:31386165	A/G	cg26647111	chr11:31128758	NA	0.43	7.59	0.35	2.05e-13	Red blood cell count;
LUAD	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg07157834	chr1:205819609	PM20D1	0.46	6.39	0.3	4.47e-10	Parkinson's disease;
LUAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24503407	chr1:205819492	PM20D1	0.91	20.88	0.71	4.51e-67	Menarche (age at onset);
LUAD	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg16680214	chr1:154839983	KCNN3	-0.61	-12.56	-0.52	5.52e-31	Prostate cancer;
LUAD	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.82	-0.43	1.24e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs4481887	0.639	rs10749644	chr1:248414587	A/C	cg00666640	chr1:248458726	OR2T12	0.29	7.27	0.33	1.78e-12	Common traits (Other);
LUAD	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg16099169	chr2:106886729	NA	-0.8	-15.05	-0.59	2.66e-41	Facial morphology (factor 23);
LUAD	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg25985355	chr7:65971099	NA	-0.39	-7.2	-0.33	2.8e-12	Aortic root size;
LUAD	cis	rs12618769	0.652	rs72823796	chr2:99227812	C/T	cg10123293	chr2:99228465	UNC50	0.48	8.47	0.38	3.97e-16	Bipolar disorder;
LUAD	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs7584330	0.554	rs7559057	chr2:238435306	A/T	cg14458575	chr2:238380390	NA	0.62	9.86	0.43	8.76e-21	Prostate cancer;
LUAD	cis	rs12711979	1.000	rs12711979	chr2:3869559	A/G	cg17052675	chr2:3827356	NA	-0.47	-8.67	-0.39	9.57e-17	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs3823572	0.542	rs62470443	chr7:133627499	G/A	cg03336402	chr7:133662267	EXOC4	0.42	7.55	0.34	2.7e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6424115	1.000	rs12116511	chr1:24162662	A/G	cg10978503	chr1:24200527	CNR2	-0.56	-12.02	-0.5	8.14e-29	Immature fraction of reticulocytes;
LUAD	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg27661571	chr11:113659931	NA	-0.68	-7.92	-0.36	2.05e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs420259	0.516	rs722069	chr16:23506940	A/G	cg00143387	chr16:23521605	GGA2	0.65	9.24	0.41	1.17e-18	Bipolar disorder;
LUAD	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg25324976	chr17:61989376	CSHL1	-0.34	-6.73	-0.31	5.46e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg07538946	chr5:131705188	SLC22A5	-0.49	-8.21	-0.37	2.73e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs2688608	0.647	rs2461863	chr10:75680236	C/T	cg23231163	chr10:75533350	FUT11	-0.38	-7.01	-0.32	9.7e-12	Inflammatory bowel disease;
LUAD	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg05368731	chr17:41323189	NBR1	0.96	19.15	0.68	2.53e-59	Menopause (age at onset);
LUAD	cis	rs868036	0.958	rs12593813	chr15:68036852	C/T	cg08079166	chr15:68083412	MAP2K5	0.31	6.36	0.3	5.37e-10	Restless legs syndrome;
LUAD	cis	rs1904096	0.506	rs12511433	chr4:95162425	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.29	-0.41	8.14e-19	Type 2 diabetes;
LUAD	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg18854424	chr1:2615690	NA	-0.42	-9.06	-0.4	4.75e-18	Ulcerative colitis;
LUAD	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.59	-0.49	3.54e-27	Primary sclerosing cholangitis;
LUAD	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg13944838	chr5:179740914	GFPT2	0.73	12.25	0.51	9.48e-30	Height;
LUAD	cis	rs8013055	0.846	rs35723046	chr14:105970548	C/T	cg19700328	chr14:106028568	NA	-0.45	-7.74	-0.35	7.51e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg27494647	chr7:150038898	RARRES2	0.55	9.67	0.43	3.94e-20	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg02423579	chr7:2872169	GNA12	-0.87	-15.47	-0.6	4.35e-43	Height;
LUAD	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg23939001	chr4:940644	TMEM175	0.8	15.45	0.6	5e-43	Sjögren's syndrome;
LUAD	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg18621852	chr3:10150065	C3orf24	0.42	7.46	0.34	5.08e-13	Alzheimer's disease;
LUAD	cis	rs2016266	0.859	rs11170506	chr12:53730759	G/T	cg26875137	chr12:53738046	NA	-0.38	-7.52	-0.34	3.42e-13	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg17173187	chr15:85201210	NMB	0.53	9.26	0.41	1.02e-18	Schizophrenia;
LUAD	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.98	-0.36	1.41e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg02176678	chr2:219576539	TTLL4	-0.82	-17.43	-0.65	1.1e-51	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg26384229	chr12:38710491	ALG10B	-0.4	-6.77	-0.31	4.27e-11	Morning vs. evening chronotype;
LUAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.51	-9.05	-0.4	5.24e-18	Lymphocyte counts;
LUAD	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.72	0.43	2.66e-20	Lung cancer in ever smokers;
LUAD	cis	rs2280018	0.609	rs2941253	chr16:15173746	G/A	cg07549590	chr16:15018862	NA	-0.53	-10.11	-0.44	1.15e-21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg05368731	chr17:41323189	NBR1	0.96	19.54	0.69	4.53e-61	Menopause (age at onset);
LUAD	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg27144592	chr16:783916	NARFL	0.37	6.65	0.31	8.81e-11	Height;
LUAD	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg00933542	chr6:150070202	PCMT1	0.44	9.42	0.42	3.03e-19	Lung cancer;
LUAD	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg06064525	chr11:970664	AP2A2	-0.53	-10.75	-0.46	5.28e-24	Alzheimer's disease (late onset);
LUAD	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.3	-7.65	-0.35	1.4e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs8067545	0.750	rs7208365	chr17:19998017	T/G	cg04132472	chr17:19861366	AKAP10	0.29	6.81	0.31	3.43e-11	Schizophrenia;
LUAD	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg26850624	chr5:429559	AHRR	-0.42	-6.65	-0.31	9.22e-11	Cystic fibrosis severity;
LUAD	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-6.45	-0.3	3.14e-10	Retinal vascular caliber;
LUAD	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.91	-0.32	1.79e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg19041857	chr6:27730383	NA	-0.45	-7.75	-0.35	6.67e-14	Parkinson's disease;
LUAD	cis	rs1215050	0.791	rs13107606	chr4:98823187	C/A	cg24818145	chr4:99064322	C4orf37	0.41	6.76	0.31	4.45e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00166722	chr3:10149974	C3orf24	0.74	12.65	0.52	2.48e-31	Alzheimer's disease;
LUAD	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg06532163	chr17:45867833	NA	0.49	8.55	0.38	2.24e-16	IgG glycosylation;
LUAD	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg18306943	chr3:40428807	ENTPD3	0.42	7.01	0.32	9.26e-12	Renal cell carcinoma;
LUAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg11965913	chr1:205819406	PM20D1	0.83	17.34	0.64	2.85e-51	Menarche (age at onset);
LUAD	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg07217954	chr7:1067459	C7orf50	-0.43	-7.39	-0.34	7.87e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg09835421	chr16:68378352	PRMT7	-0.82	-8.81	-0.39	3.21e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.96	0.32	1.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg14343924	chr8:8086146	FLJ10661	0.55	8.7	0.39	7.55e-17	Neuroticism;
LUAD	cis	rs2404602	0.575	rs11633309	chr15:76962349	C/A	cg23625390	chr15:77176239	SCAPER	-0.46	-6.47	-0.3	2.66e-10	Blood metabolite levels;
LUAD	cis	rs10465746	0.935	rs4258241	chr1:84437929	G/A	cg10977910	chr1:84465055	TTLL7	0.51	8.21	0.37	2.68e-15	Obesity-related traits;
LUAD	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg02551604	chr5:131831745	NA	-0.63	-10.12	-0.44	1.07e-21	Asthma (sex interaction);
LUAD	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg23649088	chr2:200775458	C2orf69	0.53	8.42	0.38	5.96e-16	Osteoporosis;
LUAD	cis	rs12208915	0.731	rs9361473	chr6:79657042	C/T	cg11833968	chr6:79620685	NA	0.53	7.59	0.35	2.09e-13	Left atrial antero-posterior diameter;
LUAD	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg06002616	chr8:101225028	SPAG1	-0.39	-7.82	-0.36	4.39e-14	Atrioventricular conduction;
LUAD	cis	rs7572644	0.679	rs17006365	chr2:28123374	T/G	cg27432699	chr2:27873401	GPN1	-0.41	-6.48	-0.3	2.54e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUAD	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg17177755	chr1:15930204	NA	0.45	7.37	0.34	9.03e-13	Systolic blood pressure;
LUAD	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg12458913	chr13:53173898	NA	-0.39	-6.99	-0.32	1.1e-11	Lewy body disease;
LUAD	cis	rs2067615	0.507	rs1922432	chr12:107077232	G/A	cg15890332	chr12:107067104	RFX4	0.42	8.75	0.39	5.06e-17	Heart rate;
LUAD	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.41	0.34	7.14e-13	Bipolar disorder;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg15286784	chr20:47895175	C20orf199;SNORD12C;ZNFX1	0.39	6.64	0.31	9.94e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-9.95	-0.44	4.29e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg12011299	chr4:100065546	ADH4	0.7	12.59	0.52	4.29e-31	Smoking initiation;
LUAD	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21659725	chr3:3221576	CRBN	0.7	11.71	0.49	1.28e-27	Resting heart rate;
LUAD	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg09117114	chr16:67998030	SLC12A4	-0.52	-6.92	-0.32	1.73e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs41278232	1.000	rs73153149	chr20:62656325	G/A	cg03065311	chr20:62601662	ZNF512B	0.53	7.04	0.32	7.79e-12	Tonsillectomy;
LUAD	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06544989	chr22:39130855	UNC84B	0.41	7.56	0.34	2.61e-13	Menopause (age at onset);
LUAD	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg11645453	chr3:52864694	ITIH4	-0.56	-10.54	-0.46	3.16e-23	Schizophrenia;
LUAD	cis	rs6987853	0.686	rs10087350	chr8:42359484	G/A	cg09913449	chr8:42400586	C8orf40	-0.44	-8.16	-0.37	3.92e-15	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg23933602	chr10:16859644	RSU1	0.86	17.6	0.65	1.96e-52	Platelet distribution width;
LUAD	cis	rs6087990	0.899	rs1883729	chr20:31363193	G/A	cg13636640	chr20:31349939	DNMT3B	0.82	15.48	0.6	3.96e-43	Ulcerative colitis;
LUAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg11062466	chr8:58055876	NA	0.8	10.1	0.44	1.27e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs9653442	0.704	rs10211595	chr2:100726476	G/C	cg07810366	chr2:100720526	AFF3	-0.38	-7.75	-0.35	6.81e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07451103	chr19:54663286	LENG1	-0.64	-6.44	-0.3	3.27e-10	Type 2 diabetes;
LUAD	cis	rs12900413	0.603	rs11629982	chr15:90300272	G/A	cg24249390	chr15:90295951	MESP1	-0.35	-6.99	-0.32	1.06e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs7599312	0.534	rs6751692	chr2:213408120	C/T	cg16329650	chr2:213403929	ERBB4	0.61	10.88	0.47	1.72e-24	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2880765	0.835	rs4842887	chr15:86035810	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.47	-0.3	2.77e-10	Coronary artery disease;
LUAD	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg03467027	chr4:99064603	C4orf37	0.42	6.85	0.32	2.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.62	-0.35	1.67e-13	Lung cancer;
LUAD	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg08280861	chr8:58055591	NA	0.62	8.23	0.37	2.34e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs853679	0.599	rs13193295	chr6:28003228	C/G	cg01620082	chr3:125678407	NA	-1.09	-10.37	-0.45	1.28e-22	Depression;
LUAD	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg01689657	chr7:91764605	CYP51A1	-0.31	-7.58	-0.35	2.25e-13	Breast cancer;
LUAD	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg23649088	chr2:200775458	C2orf69	-0.63	-8.15	-0.37	4.31e-15	Schizophrenia;
LUAD	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.1	0.47	2.73e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs8002861	0.905	rs12873099	chr13:44396247	G/A	cg17145862	chr1:211918768	LPGAT1	-0.67	-14.16	-0.57	1.5e-37	Leprosy;
LUAD	cis	rs7809615	0.901	rs10273424	chr7:99196073	T/A	cg12290671	chr7:99195819	NA	-0.65	-7.16	-0.33	3.54e-12	Blood metabolite ratios;
LUAD	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.6	10.76	0.46	4.91e-24	Birth weight;
LUAD	cis	rs813218	0.584	rs793469	chr3:99537305	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-7.76	-0.35	6.25e-14	Orofacial clefts;
LUAD	trans	rs7944735	0.832	rs7130876	chr11:48050995	A/G	cg15704280	chr7:45808275	SEPT13	0.7	8.78	0.39	4.15e-17	Intraocular pressure;
LUAD	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.61e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs10411161	0.810	rs77082285	chr19:52387583	G/A	cg22319618	chr22:45562946	NUP50	-0.66	-7.37	-0.34	8.88e-13	Breast cancer;
LUAD	cis	rs420259	0.516	rs432477	chr16:23600573	T/C	cg00143387	chr16:23521605	GGA2	0.7	9.83	0.43	1.16e-20	Bipolar disorder;
LUAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg13560548	chr3:10150139	C3orf24	0.41	6.96	0.32	1.29e-11	Alzheimer's disease;
LUAD	cis	rs2262909	0.962	rs425781	chr19:22229306	A/G	cg11619707	chr19:22235551	ZNF257	-0.48	-7.4	-0.34	7.34e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg17911788	chr17:44343683	NA	-0.52	-7.16	-0.33	3.65e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.54	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg20991723	chr1:152506922	NA	0.33	6.6	0.31	1.21e-10	Hair morphology;
LUAD	cis	rs3849570	1.000	rs9842330	chr3:81814688	G/A	cg07356753	chr3:81810745	GBE1	-0.71	-12.5	-0.52	9.59e-31	Waist circumference;Body mass index;
LUAD	cis	rs4919694	1.000	rs11191445	chr10:104651055	C/T	cg04362960	chr10:104952993	NT5C2	0.77	8.23	0.37	2.36e-15	Arsenic metabolism;
LUAD	cis	rs2686555	0.553	rs1616213	chr12:121077508	C/T	cg24292016	chr12:121087689	CABP1	0.41	6.49	0.3	2.36e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13126279	chr21:47581558	C21orf56	-0.53	-9.35	-0.41	5.12e-19	Testicular germ cell tumor;
LUAD	cis	rs2996428	0.709	rs6424052	chr1:3713746	A/G	cg13057898	chr1:3703894	LRRC47	0.64	10.91	0.47	1.44e-24	Red cell distribution width;
LUAD	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg17747265	chr1:1875780	NA	-0.6	-13.65	-0.55	2.08e-35	Body mass index;
LUAD	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg11502198	chr6:26597334	ABT1	0.67	11.79	0.5	6.23e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.08e-11	Depression;
LUAD	cis	rs9787249	0.533	rs1883649	chr1:40246549	C/T	cg19912559	chr1:40204330	PPIE	0.47	8.1	0.37	6.1e-15	Blood protein levels;
LUAD	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04267008	chr7:1944627	MAD1L1	0.65	9.97	0.44	3.69e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs6138458	0.816	rs2151463	chr20:24911819	A/C	cg06937882	chr20:24974362	C20orf3	-0.33	-6.43	-0.3	3.52e-10	Blood protein levels;
LUAD	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg01851573	chr8:8652454	MFHAS1	0.4	7.13	0.33	4.26e-12	Mood instability;
LUAD	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.42	-0.34	6.4e-13	Total body bone mineral density;
LUAD	trans	rs800082	0.690	rs2717392	chr3:144280080	T/C	cg24215973	chr2:240111563	HDAC4	0.57	9.27	0.41	9.67e-19	Smoking behavior;
LUAD	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg16988262	chr1:15930761	NA	0.42	7.16	0.33	3.64e-12	Systolic blood pressure;
LUAD	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg04287289	chr16:89883240	FANCA	0.84	7.21	0.33	2.62e-12	Skin colour saturation;
LUAD	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg26408565	chr15:76604113	ETFA	0.4	6.82	0.31	3.22e-11	Blood metabolite levels;
LUAD	cis	rs80319144	1.000	rs17808235	chr2:159123724	C/G	cg24986868	chr2:159312599	PKP4;CCDC148	-0.35	-6.41	-0.3	3.95e-10	Restless legs syndrome;
LUAD	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg00634984	chr7:65235879	NA	0.49	6.65	0.31	8.89e-11	Aortic root size;
LUAD	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg01765077	chr12:122356316	WDR66	-0.56	-9.66	-0.43	4.53e-20	Mean corpuscular volume;
LUAD	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg26408565	chr15:76604113	ETFA	-0.45	-7.21	-0.33	2.65e-12	Blood metabolite levels;
LUAD	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg19622623	chr12:86230825	RASSF9	-0.45	-7.81	-0.35	4.68e-14	Major depressive disorder;
LUAD	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-8.4	-0.38	7.08e-16	Total body bone mineral density;
LUAD	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg04369109	chr6:150039330	LATS1	-0.46	-7.74	-0.35	7.23e-14	Lung cancer;
LUAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg18131467	chr2:239335373	ASB1	-0.7	-12.02	-0.5	7.82e-29	Multiple system atrophy;
LUAD	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.59	-10.26	-0.45	3.2e-22	Melanoma;
LUAD	cis	rs1113500	0.614	rs61797342	chr1:108608385	G/A	cg06207961	chr1:108661230	NA	0.42	6.86	0.32	2.4e-11	Growth-regulated protein alpha levels;
LUAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg12419862	chr22:24373484	LOC391322	0.67	11.4	0.48	1.88e-26	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg13397359	chr6:42928475	GNMT	0.66	13.17	0.54	1.89e-33	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.78	-0.39	4.09e-17	Total body bone mineral density;
LUAD	cis	rs9814567	0.712	rs9838889	chr3:134332311	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-16.45	-0.62	2.29e-47	Schizophrenia;
LUAD	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg18827107	chr12:86230957	RASSF9	-0.69	-12.92	-0.53	2.02e-32	Major depressive disorder;
LUAD	trans	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg12400702	chr3:12838781	CAND2	0.31	6.44	0.3	3.27e-10	Parkinson's disease;
LUAD	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.36	0.3	5.2400000000000005e-10	Depression;
LUAD	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg23277830	chr1:3704460	LRRC47	0.46	9.57	0.42	8.97e-20	Red cell distribution width;
LUAD	cis	rs2066819	1.000	rs57137641	chr12:56741228	G/A	cg26714650	chr12:56694279	CS	-0.86	-6.99	-0.32	1.07e-11	Psoriasis vulgaris;
LUAD	cis	rs7017914	1.000	rs13252719	chr8:71734569	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.68	-0.31	7.6e-11	Bone mineral density;
LUAD	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg09323728	chr8:95962352	TP53INP1	0.3	7.14	0.33	4.16e-12	Type 2 diabetes;
LUAD	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg09365446	chr1:150670422	GOLPH3L	0.54	9.61	0.42	6.35e-20	Melanoma;
LUAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg05564831	chr3:52568323	NT5DC2	0.36	6.59	0.31	1.3e-10	Electroencephalogram traits;
LUAD	cis	rs977987	0.931	rs7195161	chr16:75495572	T/C	cg03315344	chr16:75512273	CHST6	0.66	14.99	0.59	4.94e-41	Dupuytren's disease;
LUAD	cis	rs2658782	0.789	rs2605580	chr11:93147054	C/T	cg15737290	chr11:93063684	CCDC67	0.48	7.48	0.34	4.27e-13	Pulmonary function decline;
LUAD	cis	rs1461503	0.966	rs7113725	chr11:122843511	G/T	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	trans	rs9784649	1.000	rs56004901	chr5:24998968	A/G	cg11038491	chr20:34638489	LOC647979	-0.65	-8.16	-0.37	3.91e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7828089	0.504	rs12676477	chr8:22266425	T/C	cg12081754	chr8:22256438	SLC39A14	0.66	10.99	0.47	7.11e-25	Verbal declarative memory;
LUAD	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.41	0.3	3.89e-10	Cognitive test performance;
LUAD	cis	rs10193935	0.901	rs62142599	chr2:42548935	G/A	cg27598129	chr2:42591480	NA	-0.73	-9.54	-0.42	1.18e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11039798	1.000	rs11039798	chr11:48540223	G/A	cg03929089	chr4:120376271	NA	0.65	6.41	0.3	3.78e-10	Axial length;
LUAD	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg01028140	chr2:1542097	TPO	-0.56	-7.49	-0.34	4.02e-13	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg05665937	chr4:1216051	CTBP1	0.41	6.72	0.31	5.9e-11	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg02782426	chr3:40428986	ENTPD3	0.39	8.34	0.38	1.06e-15	Renal cell carcinoma;
LUAD	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.34	6.73	0.31	5.62e-11	Menopause (age at onset);
LUAD	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg19500851	chr17:37840957	PGAP3	-0.33	-6.59	-0.31	1.3100000000000001e-10	Asthma;
LUAD	cis	rs12541635	0.677	rs1817939	chr8:107029820	A/G	cg10147462	chr8:107024639	NA	0.55	10.12	0.44	1.09e-21	Age of smoking initiation;
LUAD	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg13870426	chr17:30244630	NA	-0.55	-6.47	-0.3	2.65e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg12311346	chr5:56204834	C5orf35	-0.47	-7.68	-0.35	1.15e-13	Coronary artery disease;
LUAD	cis	rs9443645	0.507	rs9352633	chr6:79462623	C/G	cg18132916	chr6:79620363	NA	-0.43	-7.24	-0.33	2.1e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg24818145	chr4:99064322	C4orf37	0.42	7.02	0.32	8.66e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg06606381	chr12:133084897	FBRSL1	-0.9	-8.62	-0.39	1.3e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg12564285	chr5:131593104	PDLIM4	0.37	6.48	0.3	2.52e-10	Acylcarnitine levels;
LUAD	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg06636001	chr8:8085503	FLJ10661	0.4	6.68	0.31	7.71e-11	Mood instability;
LUAD	cis	rs10782582	0.609	rs5745547	chr1:76378275	G/C	cg03433033	chr1:76189801	ACADM	-0.45	-6.49	-0.3	2.38e-10	Daytime sleep phenotypes;
LUAD	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg20108693	chr8:143823809	SLURP1	0.3	7.08	0.33	6.06e-12	Urinary tract infection frequency;
LUAD	cis	rs713477	1.000	rs12893000	chr14:55912280	G/T	cg13175173	chr14:55914753	NA	-0.35	-7.2	-0.33	2.78e-12	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg07153921	chr17:41440717	NA	-0.4	-6.62	-0.31	1.06e-10	Menopause (age at onset);
LUAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03188948	chr7:1209495	NA	0.48	8.06	0.37	7.63e-15	Longevity;Endometriosis;
LUAD	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.64	12.97	0.53	1.24e-32	Hemoglobin concentration;
LUAD	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg22598563	chr5:131563921	P4HA2	-0.32	-8.1	-0.37	5.89e-15	Blood metabolite levels;
LUAD	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	8.74	0.39	5.55e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg09060608	chr5:178986726	RUFY1	0.73	13.38	0.55	2.64e-34	Lung cancer;
LUAD	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg10523679	chr1:76189770	ACADM	-0.47	-6.48	-0.3	2.51e-10	Daytime sleep phenotypes;
LUAD	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg17264618	chr3:40429014	ENTPD3	0.4	8.76	0.39	4.93e-17	Renal cell carcinoma;
LUAD	cis	rs34734847	0.766	rs3794214	chr12:121168245	C/T	cg13914990	chr12:121174878	ACADS	-0.39	-7.63	-0.35	1.56e-13	Mean corpuscular volume;
LUAD	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg12935359	chr14:103987150	CKB	0.52	8.12	0.37	4.99e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2979489	0.891	rs3824107	chr8:30353412	A/G	cg26383811	chr8:30366931	RBPMS	0.58	8.97	0.4	9.64e-18	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs1497828	0.956	rs1566178	chr1:217526431	G/A	cg04411442	chr1:217543379	NA	-0.35	-6.44	-0.3	3.26e-10	Dialysis-related mortality;
LUAD	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg10547527	chr2:198650123	BOLL	0.54	7.74	0.35	7.24e-14	Ulcerative colitis;
LUAD	cis	rs4919694	1.000	rs79254677	chr10:104691567	A/G	cg04362960	chr10:104952993	NT5C2	0.71	7.64	0.35	1.46e-13	Arsenic metabolism;
LUAD	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg12935359	chr14:103987150	CKB	-0.48	-7.78	-0.35	5.64e-14	Body mass index;
LUAD	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg20744362	chr22:50050164	C22orf34	0.33	6.36	0.3	5.18e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg07685180	chr8:600429	NA	0.86	8.59	0.39	1.65e-16	IgG glycosylation;
LUAD	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg15997130	chr1:24165203	NA	-0.49	-7.68	-0.35	1.09e-13	Immature fraction of reticulocytes;
LUAD	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg02527881	chr3:46936655	PTH1R	-0.55	-11.4	-0.48	1.96e-26	Colorectal cancer;
LUAD	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg05368731	chr17:41323189	NBR1	0.87	13.88	0.56	2.38e-36	Menopause (age at onset);
LUAD	trans	rs6074578	0.902	rs6033484	chr20:185926	A/G	cg12523403	chr19:12779890	MORG1;C19orf56	-0.36	-6.5	-0.3	2.24e-10	Hirschsprung disease;
LUAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18402987	chr7:1209562	NA	0.48	8.11	0.37	5.52e-15	Longevity;Endometriosis;
LUAD	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.54	0.42	1.17e-19	Lung cancer in ever smokers;
LUAD	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg05110241	chr16:68378359	PRMT7	-0.87	-9.27	-0.41	9.54e-19	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg00280220	chr17:61926910	NA	-0.33	-6.46	-0.3	2.84e-10	Prudent dietary pattern;
LUAD	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.48	-0.3	2.48e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg01236616	chr12:121019343	POP5	-1.19	-17.76	-0.65	3.78e-53	Type 1 diabetes nephropathy;
LUAD	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg01528321	chr10:82214614	TSPAN14	0.66	10.58	0.46	2.27e-23	Post bronchodilator FEV1;
LUAD	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg05110241	chr16:68378359	PRMT7	-0.83	-8.96	-0.4	1.04e-17	Schizophrenia;
LUAD	cis	rs790123	1.000	rs2650950	chr3:122382048	C/T	cg22896480	chr3:122379438	NA	0.41	6.86	0.32	2.4e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11644478	chr21:40555479	PSMG1	0.69	11.36	0.48	2.69e-26	Cognitive function;
LUAD	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03352830	chr11:487213	PTDSS2	0.82	10.64	0.46	1.36e-23	Body mass index;
LUAD	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg14725641	chr11:61582763	MIR1908;FADS1	-0.54	-6.63	-0.31	1.05e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg10018233	chr7:150070692	REPIN1	0.54	9.58	0.42	8.06e-20	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs13315871	0.722	rs3952239	chr3:58312057	G/T	cg20936604	chr3:58311152	NA	-0.78	-8.37	-0.38	8.66e-16	Cholesterol, total;
LUAD	cis	rs4786125	0.516	rs7203888	chr16:6915483	T/C	cg03623568	chr16:6915990	A2BP1	-0.49	-10.68	-0.46	9.9899999999999993e-24	Heart rate variability traits (SDNN);
LUAD	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg27411982	chr8:10470053	RP1L1	0.37	6.49	0.3	2.34e-10	Morning vs. evening chronotype;
LUAD	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg17063962	chr7:91808500	NA	0.61	10.05	0.44	1.88e-21	Breast cancer;
LUAD	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.4	-0.3	4.02e-10	Aortic root size;
LUAD	trans	rs9784649	1.000	rs6864025	chr5:24960691	G/C	cg08600765	chr20:34638493	LOC647979	-0.57	-7.64	-0.35	1.47e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg02782426	chr3:40428986	ENTPD3	0.42	8.88	0.4	1.94e-17	Renal cell carcinoma;
LUAD	cis	rs7267979	1.000	rs397119	chr20:25440187	C/A	cg08601574	chr20:25228251	PYGB	0.46	8.52	0.38	2.83e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.91	0.36	2.29e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.7e-32	Immature fraction of reticulocytes;
LUAD	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.56	7.71	0.35	9.03e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg18854424	chr1:2615690	NA	-0.42	-9.07	-0.4	4.49e-18	Ulcerative colitis;
LUAD	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg03388025	chr16:89894329	SPIRE2	0.5	13.18	0.54	1.78e-33	Vitiligo;
LUAD	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18404041	chr3:52824283	ITIH1	-0.58	-11.69	-0.49	1.48e-27	Bipolar disorder;
LUAD	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg26898376	chr11:64110657	CCDC88B	0.38	7.06	0.32	6.7e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs9473147	0.503	rs2171086	chr6:47590104	C/T	cg20196966	chr6:47445060	CD2AP	0.43	6.85	0.32	2.69e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.68	-0.43	3.62e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.03	23.29	0.75	7.93e-78	Chronic sinus infection;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg19364635	chr2:38978654	SFRS7	0.39	6.68	0.31	7.77e-11	Bipolar disorder;
LUAD	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg02228675	chr17:40259724	DHX58	-0.47	-7.61	-0.35	1.78e-13	Fibrinogen levels;
LUAD	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg05896524	chr21:47604654	C21orf56	0.56	9.24	0.41	1.17e-18	Testicular germ cell tumor;
LUAD	cis	rs2692947	0.537	rs72821437	chr2:96200799	C/T	cg23100626	chr2:96804247	ASTL	0.32	7.93	0.36	1.94e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs529866	0.500	rs918739	chr16:11439733	G/T	cg00044050	chr16:11439710	C16orf75	-0.55	-7.83	-0.36	3.99e-14	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs1941687	0.509	rs7230319	chr18:31321289	A/T	cg27147174	chr7:100797783	AP1S1	-0.65	-11.66	-0.49	1.89e-27	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	trans	rs11039798	0.920	rs8186465	chr11:48796771	T/C	cg15704280	chr7:45808275	SEPT13	0.67	7.83	0.36	3.98e-14	Axial length;
LUAD	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg22117172	chr7:91764530	CYP51A1	0.34	7.35	0.34	1.04e-12	Breast cancer;
LUAD	trans	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg14917512	chr19:3094685	GNA11	-0.55	-6.51	-0.3	2.14e-10	Diabetic kidney disease;
LUAD	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.25	-0.33	2e-12	Blood metabolite levels;
LUAD	cis	rs4699052	0.928	rs2169511	chr4:104192580	G/A	cg16532752	chr4:104119610	CENPE	-0.49	-7.32	-0.34	1.3e-12	Testicular germ cell tumor;
LUAD	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg03289416	chr15:75166202	SCAMP2	0.49	8.4	0.38	6.7e-16	Breast cancer;
LUAD	cis	rs367943	0.871	rs348940	chr5:112824530	C/A	cg12552261	chr5:112820674	MCC	-0.49	-8.99	-0.4	8.3e-18	Type 2 diabetes;
LUAD	cis	rs1448094	0.872	rs1026085	chr12:86355735	A/G	cg02569458	chr12:86230093	RASSF9	0.36	6.83	0.32	2.89e-11	Major depressive disorder;
LUAD	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg07636037	chr3:49044803	WDR6	0.51	9.35	0.41	5.29e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg20368463	chr18:77673604	PQLC1	-0.58	-9.97	-0.44	3.52e-21	Schizophrenia;
LUAD	cis	rs9581857	0.685	rs9579084	chr13:28028201	A/G	cg22138327	chr13:27999177	GTF3A	-0.8	-10.18	-0.44	6.37e-22	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg09263875	chr16:632152	PIGQ	0.78	15.82	0.61	1.31e-44	Height;
LUAD	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg18755752	chr8:142205143	DENND3	-0.46	-8.11	-0.37	5.35e-15	Immature fraction of reticulocytes;
LUAD	cis	rs13315871	1.000	rs28626602	chr3:58409786	G/C	cg20936604	chr3:58311152	NA	-0.69	-7.25	-0.33	1.94e-12	Cholesterol, total;
LUAD	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg26384229	chr12:38710491	ALG10B	0.5	8.03	0.36	9.5e-15	Bladder cancer;
LUAD	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg25036284	chr2:26402008	FAM59B	-0.67	-8.92	-0.4	1.38e-17	Gut microbiome composition (summer);
LUAD	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg26513180	chr16:89883248	FANCA	0.46	7.51	0.34	3.58e-13	Vitiligo;
LUAD	trans	rs1941687	0.527	rs12608181	chr18:31339351	T/G	cg27147174	chr7:100797783	AP1S1	-0.7	-12.7	-0.53	1.5e-31	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs4523957	0.928	rs8074850	chr17:2187931	C/A	cg16513277	chr17:2031491	SMG6	-0.78	-14.72	-0.58	7.05e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7213347	0.707	rs9898390	chr17:2177484	C/G	cg02569219	chr17:2266849	SGSM2	-0.43	-6.96	-0.32	1.29e-11	Total body bone mineral density;
LUAD	cis	rs13315871	0.929	rs9837903	chr3:58301906	A/T	cg12435725	chr3:58293450	RPP14	-0.74	-7.88	-0.36	2.86e-14	Cholesterol, total;
LUAD	trans	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg21659725	chr3:3221576	CRBN	-0.62	-10.08	-0.44	1.47e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg26566898	chr11:117069891	TAGLN	0.33	6.42	0.3	3.57e-10	Blood protein levels;
LUAD	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg16850897	chr7:100343110	ZAN	-0.66	-10.79	-0.46	3.85e-24	Other erythrocyte phenotypes;
LUAD	cis	rs2806561	0.894	rs598438	chr1:23531563	C/T	cg12483005	chr1:23474871	LUZP1	0.4	6.77	0.31	4.45e-11	Height;
LUAD	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg26384229	chr12:38710491	ALG10B	-0.45	-7.79	-0.35	5.25e-14	Heart rate;
LUAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg08742575	chr21:47604166	C21orf56	0.56	9.65	0.42	4.75e-20	Testicular germ cell tumor;
LUAD	cis	rs754466	0.651	rs10762767	chr10:79645070	C/A	cg17075019	chr10:79541650	NA	-0.85	-17.41	-0.65	1.47e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs73416724	1.000	rs111467122	chr6:43334547	C/T	cg26312998	chr6:43337775	ZNF318	0.55	6.69	0.31	7.22e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg06713675	chr4:122721982	EXOSC9	-0.81	-16.57	-0.63	7.17e-48	Type 2 diabetes;
LUAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg07362569	chr17:61921086	SMARCD2	0.39	6.74	0.31	5.18e-11	Prudent dietary pattern;
LUAD	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg25767906	chr1:53392781	SCP2	-0.34	-6.47	-0.3	2.75e-10	Monocyte count;
LUAD	cis	rs2637266	0.905	rs7076442	chr10:78360480	A/C	cg18941641	chr10:78392320	NA	-0.31	-6.45	-0.3	3.02e-10	Pulmonary function;
LUAD	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg05590025	chr7:65112418	INTS4L2	0.74	7.87	0.36	3.03e-14	Diabetic kidney disease;
LUAD	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.59	-0.35	2.09e-13	Height;
LUAD	cis	rs6445967	0.530	rs12490706	chr3:58408247	C/T	cg13750441	chr3:58318267	PXK	0.32	6.48	0.3	2.6e-10	Platelet count;
LUAD	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg12645284	chr15:79092878	ADAMTS7	-0.45	-7.56	-0.34	2.58e-13	Coronary artery disease or large artery stroke;
LUAD	cis	rs7633770	0.749	rs6442011	chr3:46685722	C/T	cg11219411	chr3:46661640	NA	0.58	12.9	0.53	2.42e-32	Coronary artery disease;
LUAD	cis	rs78487399	0.808	rs13414619	chr2:43699406	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-7.14	-0.33	4.16e-12	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg15181151	chr6:150070149	PCMT1	0.38	7.39	0.34	7.91e-13	Lung cancer;
LUAD	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg11189052	chr15:85197271	WDR73	-0.6	-9.99	-0.44	3.14e-21	P wave terminal force;
LUAD	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg00316803	chr15:76480434	C15orf27	-0.4	-7.48	-0.34	4.36e-13	Blood metabolite levels;
LUAD	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg21475434	chr5:93447410	FAM172A	0.75	8.37	0.38	8.25e-16	Diabetic retinopathy;
LUAD	trans	rs8002861	0.665	rs2065926	chr13:44422371	A/G	cg17145862	chr1:211918768	LPGAT1	-0.54	-10.65	-0.46	1.26e-23	Leprosy;
LUAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.62	-9.99	-0.44	3.02e-21	Renal function-related traits (BUN);
LUAD	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg18190219	chr22:46762943	CELSR1	-0.56	-6.47	-0.3	2.75e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	14.47	0.58	7.98e-39	Smoking behavior;
LUAD	cis	rs7937890	0.535	rs2575857	chr11:14501296	C/T	cg23387056	chr11:14280742	SPON1	-0.35	-6.82	-0.31	3.17e-11	Mitochondrial DNA levels;
LUAD	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg06547715	chr2:218990976	CXCR2	-0.28	-6.76	-0.31	4.56e-11	High light scatter reticulocyte percentage of red cells;Plateletcrit;
LUAD	cis	rs12079745	0.793	rs12071122	chr1:169191749	C/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.1	-8.0	-0.36	1.23e-14	QT interval;
LUAD	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-23.72	-0.76	1.02e-79	Height;
LUAD	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-10.98	-0.47	7.62e-25	Monocyte percentage of white cells;
LUAD	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg00484396	chr16:3507460	NAT15	0.73	9.74	0.43	2.31e-20	Tuberculosis;
LUAD	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22857025	chr5:266934	NA	-0.97	-14.37	-0.57	1.96e-38	Breast cancer;
LUAD	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg07936489	chr17:37558343	FBXL20	0.5	6.74	0.31	5.09e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg23188684	chr11:67383651	NA	-0.39	-6.88	-0.32	2.16e-11	Mean corpuscular volume;
LUAD	cis	rs6987853	0.787	rs10958722	chr8:42425487	T/C	cg09913449	chr8:42400586	C8orf40	0.48	9.36	0.41	4.67e-19	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.54	-0.3	1.81e-10	Morning vs. evening chronotype;
LUAD	cis	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg01868782	chr6:126071099	HEY2	-0.32	-6.41	-0.3	3.96e-10	Brugada syndrome;
LUAD	cis	rs7671266	0.668	rs10007416	chr4:10159457	T/C	cg02734326	chr4:10020555	SLC2A9	-0.52	-6.77	-0.31	4.39e-11	Cardiovascular disease risk factors;
LUAD	cis	rs2625529	0.701	rs12911154	chr15:72212653	G/A	cg16672083	chr15:72433130	SENP8	-0.75	-12.38	-0.52	2.95e-30	Red blood cell count;
LUAD	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.44	-0.42	2.5e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg21724239	chr8:58056113	NA	0.89	10.73	0.46	6.28e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg11941060	chr3:133502564	NA	-0.4	-6.9	-0.32	1.96e-11	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg17845761	chr1:175162550	KIAA0040	0.38	10.0	0.44	2.8e-21	Alcohol dependence;
LUAD	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.11e-12	Height;
LUAD	cis	rs58804349	0.605	rs117540287	chr10:43512040	G/T	cg15903213	chr10:43522190	NA	-0.61	-6.46	-0.3	2.9e-10	Pediatric bone mineral content (radius);
LUAD	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg23803603	chr1:2058230	PRKCZ	0.41	6.63	0.31	1.01e-10	Height;
LUAD	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg24069376	chr3:38537580	EXOG	0.46	11.18	0.48	1.29e-25	Electrocardiographic conduction measures;
LUAD	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg01579765	chr21:45077557	HSF2BP	-0.63	-14.07	-0.56	3.65e-37	Mean corpuscular volume;
LUAD	cis	rs1670533	0.932	rs13137819	chr4:1042115	T/C	cg27284194	chr4:1044797	NA	0.7	9.32	0.41	6.63e-19	Recombination rate (females);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg07633499	chr22:19467075	UFD1L;CDC45L	-0.39	-6.74	-0.31	5.08e-11	Subcortical brain region volumes;
LUAD	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.68	-11.4	-0.48	2e-26	Primary sclerosing cholangitis;
LUAD	cis	rs929596	0.785	rs17864701	chr2:234652717	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.74	-12.62	-0.52	3.3e-31	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg23758822	chr17:41437982	NA	0.92	18.83	0.68	6.82e-58	Menopause (age at onset);
LUAD	trans	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	8.73	0.39	6.06e-17	Mean corpuscular volume;
LUAD	cis	rs67072384	0.892	rs67034709	chr11:72451004	T/C	cg04827223	chr11:72435913	ARAP1	-0.62	-7.67	-0.35	1.16e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08280861	chr8:58055591	NA	0.63	8.31	0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg00784671	chr22:46762841	CELSR1	-0.58	-7.22	-0.33	2.47e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg24154853	chr7:158122151	PTPRN2	0.57	11.38	0.48	2.29e-26	Calcium levels;
LUAD	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg21153622	chr11:89784906	NA	-0.32	-6.46	-0.3	2.95e-10	Height;
LUAD	cis	rs9487051	0.735	rs1260596	chr6:109519847	T/C	cg01475377	chr6:109611718	NA	-0.38	-7.31	-0.33	1.36e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg07936489	chr17:37558343	FBXL20	-0.47	-7.54	-0.34	2.9e-13	Glomerular filtration rate (creatinine);
LUAD	trans	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg01620082	chr3:125678407	NA	-0.72	-7.91	-0.36	2.34e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg18512352	chr11:47633146	NA	0.4	7.14	0.33	4.21e-12	Subjective well-being;
LUAD	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg20476274	chr7:133979776	SLC35B4	0.72	13.03	0.54	7.11e-33	Mean platelet volume;
LUAD	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg26384229	chr12:38710491	ALG10B	0.44	7.25	0.33	2.05e-12	Morning vs. evening chronotype;
LUAD	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg23262073	chr20:60523788	NA	-0.46	-7.98	-0.36	1.37e-14	Body mass index;
LUAD	cis	rs7582720	1.000	rs114155121	chr2:203718682	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.71	8.78	0.39	3.94e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs13315871	1.000	rs11713214	chr3:58445991	C/T	cg12435725	chr3:58293450	RPP14	-0.69	-7.45	-0.34	5.2e-13	Cholesterol, total;
LUAD	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg05368731	chr17:41323189	NBR1	0.82	16.03	0.61	1.59e-45	Menopause (age at onset);
LUAD	trans	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg19862616	chr7:65841803	NCRNA00174	1.04	25.68	0.78	2.44e-88	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs735539	0.521	rs1810717	chr13:21412235	A/G	cg27499820	chr13:21296301	IL17D	0.43	7.21	0.33	2.59e-12	Dental caries;
LUAD	cis	rs250677	1.000	rs190378	chr5:148434275	G/T	cg23229984	chr5:148520753	ABLIM3	0.41	6.42	0.3	3.7e-10	Breast cancer;
LUAD	cis	rs1595825	0.891	rs77706948	chr2:198608441	T/G	cg11031976	chr2:198649780	BOLL	-0.49	-6.89	-0.32	2.06e-11	Ulcerative colitis;
LUAD	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.74	10.25	0.45	3.52e-22	Smoking behavior;
LUAD	cis	rs35740288	0.587	rs4843089	chr15:86176136	C/T	cg13263323	chr15:86062960	AKAP13	-0.45	-7.28	-0.33	1.61e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs2072438	0.503	rs2146838	chr9:123876305	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.4	-6.69	-0.31	7.18e-11	Rheumatoid arthritis;
LUAD	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg15485101	chr11:133734466	NA	0.39	8.71	0.39	6.7e-17	Childhood ear infection;
LUAD	cis	rs6867032	1.000	rs4975802	chr5:2019750	T/C	cg26168224	chr5:2018326	NA	0.79	17.73	0.65	5.37e-53	Gut microbiome composition (winter);
LUAD	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-7.07	-0.33	6.36e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2985684	0.841	rs7158577	chr14:50058633	C/T	cg04989706	chr14:50066350	PPIL5	-0.51	-7.54	-0.34	2.96e-13	Carotid intima media thickness;
LUAD	cis	rs57590327	0.508	rs4622918	chr3:81965382	A/G	cg07356753	chr3:81810745	GBE1	-0.55	-9.31	-0.41	6.92e-19	Extraversion;
LUAD	cis	rs7043114	0.525	rs2516567	chr9:95187418	C/T	cg14631576	chr9:95140430	CENPP	-0.42	-8.5	-0.38	3.2e-16	Height;
LUAD	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg19077165	chr18:44547161	KATNAL2	0.42	7.29	0.33	1.49e-12	Personality dimensions;
LUAD	cis	rs4144027	0.967	rs56126771	chr14:104361143	C/G	cg12183467	chr14:104352244	NA	0.37	7.04	0.32	7.97e-12	Blood metabolite levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg18466108	chr12:99038412	APAF1;IKBIP	-0.74	-7.22	-0.33	2.47e-12	Type 2 diabetes;
LUAD	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs59104589	0.617	rs16843671	chr2:242374358	T/C	cg08645257	chr2:242211290	HDLBP	0.45	7.33	0.34	1.21e-12	Fibrinogen levels;
LUAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg10862848	chr6:42927986	GNMT	-0.27	-7.98	-0.36	1.43e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6835098	0.924	rs2332669	chr4:174163398	G/A	cg27433088	chr4:174089019	GALNT7	0.37	7.31	0.33	1.39e-12	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23583168	chr7:148888333	NA	-0.82	-14.23	-0.57	7.99e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg10909506	chr17:38081995	ORMDL3	0.4	7.18	0.33	3.11e-12	Self-reported allergy;
LUAD	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg14345882	chr6:26364793	BTN3A2	0.69	6.97	0.32	1.23e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1595825	0.891	rs2293255	chr2:198621506	T/C	cg10547527	chr2:198650123	BOLL	-0.55	-7.76	-0.35	6.31e-14	Ulcerative colitis;
LUAD	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg25985355	chr7:65971099	NA	-0.51	-6.36	-0.3	5.25e-10	Diabetic kidney disease;
LUAD	cis	rs6906287	0.647	rs7773274	chr6:118934740	C/G	cg18833306	chr6:118973337	C6orf204	0.48	8.45	0.38	4.77e-16	Electrocardiographic conduction measures;
LUAD	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg10518543	chr12:38710700	ALG10B	0.41	6.36	0.3	5.25e-10	Bladder cancer;
LUAD	cis	rs12347191	0.500	rs925485	chr9:100619561	G/C	cg13688889	chr9:100608707	NA	-0.63	-10.21	-0.44	4.95e-22	Orofacial clefts;
LUAD	cis	rs2580764	0.541	rs2968786	chr2:55264859	C/G	cg09592903	chr2:55203963	RTN4	0.43	10.0	0.44	2.85e-21	Mean platelet volume;
LUAD	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg23262073	chr20:60523788	NA	-0.44	-7.13	-0.33	4.42e-12	Body mass index;
LUAD	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg13180566	chr4:1052158	NA	-0.4	-6.72	-0.31	5.77e-11	Recombination rate (females);
LUAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg05313129	chr8:58192883	C8orf71	-0.59	-6.6	-0.31	1.22e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22455342	chr2:225449267	CUL3	0.64	9.89	0.43	7.14e-21	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg04450456	chr4:17643702	FAM184B	-0.42	-8.24	-0.37	2.11e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.05	-0.36	8.53e-15	Cystic fibrosis severity;
LUAD	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg08885076	chr2:99613938	TSGA10	-0.4	-7.03	-0.32	8.2e-12	Chronic sinus infection;
LUAD	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg19767477	chr5:127420684	SLC12A2	-0.43	-6.66	-0.31	8.78e-11	Ileal carcinoids;
LUAD	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg06873352	chr17:61820015	STRADA	0.41	6.91	0.32	1.75e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg02869364	chr7:1081709	C7orf50	-0.35	-6.56	-0.3	1.6e-10	Longevity;Endometriosis;
LUAD	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg25894440	chr7:65020034	NA	-0.68	-7.36	-0.34	9.49e-13	Diabetic kidney disease;
LUAD	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.11	-0.33	4.87e-12	Total body bone mineral density;
LUAD	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.07	-0.44	1.66e-21	Migraine;Coronary artery disease;
LUAD	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg10792982	chr14:105748885	BRF1	0.43	9.04	0.4	5.64e-18	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg03526776	chr6:41159608	TREML2	0.33	6.85	0.32	2.58e-11	Alzheimer's disease (late onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24483304	chr1:43855122	MED8;C1orf84	-0.48	-7.4	-0.34	7.32e-13	Height;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg06768987	chr16:18572942	NOMO2	0.48	7.83	0.36	4.04e-14	Diastolic blood pressure;
LUAD	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08677398	chr8:58056175	NA	0.48	6.86	0.32	2.48e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg00129232	chr17:37814104	STARD3	-0.46	-7.87	-0.36	3.06e-14	Asthma;
LUAD	cis	rs600626	0.636	rs10899109	chr11:75451201	G/A	cg24262691	chr11:75473276	NA	0.53	6.99	0.32	1.06e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg02002194	chr4:3960332	NA	-0.28	-6.52	-0.3	2.04e-10	Mood instability;
LUAD	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg00666640	chr1:248458726	OR2T12	0.33	8.06	0.36	8.14e-15	Common traits (Other);
LUAD	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg10589385	chr1:150898437	SETDB1	0.39	7.33	0.34	1.2e-12	Tonsillectomy;
LUAD	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg07741184	chr6:167504864	NA	0.31	7.03	0.32	8.2e-12	Crohn's disease;
LUAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-9.6	-0.42	7.14e-20	Alzheimer's disease;
LUAD	trans	rs1728785	0.681	rs4783649	chr16:68558467	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-10.24	-0.45	3.79e-22	Ulcerative colitis;
LUAD	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	13.39	0.55	2.53e-34	Lung cancer in ever smokers;
LUAD	trans	rs853679	0.607	rs34765154	chr6:28130450	G/A	cg01620082	chr3:125678407	NA	-1.1	-10.38	-0.45	1.25e-22	Depression;
LUAD	trans	rs9929218	0.954	rs7186333	chr16:68815838	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.81	-0.56	4.32e-36	Colorectal cancer;
LUAD	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg05340658	chr4:99064831	C4orf37	0.45	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00722097	chr6:111195976	AMD1	-0.56	-6.82	-0.31	3.22e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg03714773	chr7:91764589	CYP51A1	0.27	6.46	0.3	2.89e-10	Breast cancer;
LUAD	cis	rs751728	0.965	rs4713681	chr6:33754817	T/C	cg13859433	chr6:33739653	LEMD2	-0.36	-8.19	-0.37	3.03e-15	Crohn's disease;
LUAD	cis	rs1451375	0.572	rs68011952	chr7:50638128	C/T	cg18232548	chr7:50535776	DDC	0.47	6.49	0.3	2.34e-10	Malaria;
LUAD	trans	rs1941687	0.797	rs8098328	chr18:31401732	A/G	cg27147174	chr7:100797783	AP1S1	0.45	7.31	0.33	1.35e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg27170947	chr2:26402098	FAM59B	-0.68	-9.38	-0.41	4.12e-19	Gut microbiome composition (summer);
LUAD	cis	rs2692947	0.832	rs2692954	chr2:96683378	T/G	cg23100626	chr2:96804247	ASTL	0.34	8.41	0.38	6.48e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg07917127	chr4:99064746	C4orf37	0.44	7.32	0.34	1.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg26373071	chr5:1325741	CLPTM1L	0.38	7.87	0.36	3.03e-14	Lung cancer;
LUAD	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.16e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg06608945	chr2:219082296	ARPC2	-0.45	-7.33	-0.34	1.18e-12	Colorectal cancer;
LUAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg11050988	chr7:1952600	MAD1L1	-0.37	-7.68	-0.35	1.15e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7089973	0.872	rs7923295	chr10:116625159	C/G	cg25233709	chr10:116636983	FAM160B1	-0.38	-7.42	-0.34	6.2800000000000005e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg25769590	chr7:158789503	NA	-0.39	-7.2	-0.33	2.75e-12	Facial morphology (factor 20);
LUAD	trans	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.44	0.49	1.34e-26	Mean corpuscular volume;
LUAD	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.61	8.39	0.38	7.34e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6738485	0.507	rs72819611	chr2:106845912	G/A	cg16099169	chr2:106886729	NA	-0.79	-11.29	-0.48	5.06e-26	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg26408565	chr15:76604113	ETFA	-0.44	-6.97	-0.32	1.23e-11	Blood metabolite levels;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	ch.21.33444458F	chr21:34522588	NA	-0.38	-6.61	-0.31	1.19e-10	Subcortical brain region volumes;
LUAD	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg23649088	chr2:200775458	C2orf69	-0.6	-7.17	-0.33	3.44e-12	Schizophrenia;
LUAD	cis	rs9296092	0.500	rs4376348	chr6:33521097	A/G	cg13560919	chr6:33536144	NA	-0.87	-15.54	-0.6	2.02e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg04414720	chr1:150670196	GOLPH3L	0.66	11.8	0.5	5.45e-28	Melanoma;
LUAD	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg03733263	chr8:22462867	KIAA1967	0.64	10.88	0.47	1.8e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs1018836	0.851	rs6986359	chr8:91643162	A/G	cg16814680	chr8:91681699	NA	-0.66	-11.56	-0.49	4.59e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg22875332	chr1:76189707	ACADM	0.92	19.14	0.68	2.82e-59	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg23277830	chr1:3704460	LRRC47	0.42	8.49	0.38	3.54e-16	Red cell distribution width;
LUAD	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg00901687	chr17:48585270	MYCBPAP	0.51	6.75	0.31	4.87e-11	Visceral fat;
LUAD	cis	rs4919694	1.000	rs7083328	chr10:104769268	G/A	cg04362960	chr10:104952993	NT5C2	0.72	7.65	0.35	1.41e-13	Arsenic metabolism;
LUAD	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.5	-0.42	1.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6256	0.929	rs56272325	chr11:13508857	C/G	cg11976911	chr11:13509032	NA	-0.52	-6.4	-0.3	4.02e-10	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
LUAD	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg09117114	chr16:67998030	SLC12A4	-0.51	-7.47	-0.34	4.65e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs72634258	0.836	rs9658012	chr1:7989022	C/T	cg26816564	chr1:7831052	VAMP3	0.53	6.8	0.31	3.52e-11	Inflammatory bowel disease;
LUAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07157834	chr1:205819609	PM20D1	0.72	13.72	0.56	1.03e-35	Menarche (age at onset);
LUAD	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg18811423	chr2:55921094	PNPT1	0.51	8.39	0.38	7.14e-16	Metabolic syndrome;
LUAD	cis	rs113835537	0.935	rs57043177	chr11:66423147	A/G	cg24851651	chr11:66362959	CCS	0.58	8.01	0.36	1.11e-14	Airway imaging phenotypes;
LUAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08439880	chr3:133502540	NA	0.5	10.6	0.46	1.96e-23	Iron status biomarkers;
LUAD	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	7.87	0.36	3.08e-14	Breast cancer;
LUAD	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg17509989	chr5:176798049	RGS14	0.61	9.15	0.41	2.47e-18	Urate levels in lean individuals;
LUAD	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01570182	chr17:44337453	NA	-0.77	-12.51	-0.52	9.15e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg14725641	chr11:61582763	MIR1908;FADS1	-0.39	-6.37	-0.3	5.05e-10	Trans fatty acid levels;
LUAD	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg22676075	chr6:135203613	NA	0.4	7.44	0.34	5.48e-13	Red blood cell count;
LUAD	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg05373962	chr22:49881684	NA	-0.48	-9.87	-0.43	7.85e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.46	-9.13	-0.41	2.82e-18	Monocyte percentage of white cells;
LUAD	cis	rs7089973	0.872	rs35622181	chr10:116631976	C/T	cg25233709	chr10:116636983	FAM160B1	0.39	7.52	0.34	3.3e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg04586622	chr2:25135609	ADCY3	0.37	8.46	0.38	4.52e-16	Body mass index;
LUAD	cis	rs6025261	0.761	rs6099360	chr20:55511902	C/T	cg04763273	chr20:55502381	NA	-0.32	-6.5	-0.3	2.23e-10	Verbal memory performance (delayed recall level);
LUAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg13560548	chr3:10150139	C3orf24	0.41	6.74	0.31	5.15e-11	Alzheimer's disease;
LUAD	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg12193833	chr17:30244370	NA	-0.58	-7.05	-0.32	7.15e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs12291225	0.877	rs2303974	chr11:14264979	G/T	cg19336497	chr11:14380999	RRAS2	-0.56	-11.27	-0.48	6.1e-26	Sense of smell;
LUAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.5	-9.07	-0.4	4.45e-18	Lymphocyte counts;
LUAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg23712970	chr14:23540735	ACIN1	-0.43	-7.04	-0.32	7.6e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg11871910	chr12:69753446	YEATS4	0.46	7.34	0.34	1.11e-12	Blood protein levels;
LUAD	cis	rs72960926	0.590	rs72952344	chr6:74800914	G/C	cg03266952	chr6:74778945	NA	-0.82	-6.49	-0.3	2.4e-10	Metabolite levels (MHPG);
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10308682	chr20:5931622	MCM8;TRMT6	0.45	7.02	0.32	8.71e-12	Monocyte percentage of white cells;
LUAD	cis	rs17818399	0.926	rs1378764	chr2:46839681	C/T	cg21681030	chr2:46777652	RHOQ	0.42	7.44	0.34	5.74e-13	Height;
LUAD	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22625903	chr11:62313283	AHNAK	-0.46	-7.18	-0.33	3.07e-12	Height;
LUAD	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.62	0.31	1.11e-10	Menarche (age at onset);
LUAD	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg23533926	chr12:111358616	MYL2	-0.41	-7.01	-0.32	9.73e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.68	-0.39	8.57e-17	Alzheimer's disease (late onset);
LUAD	cis	rs12286929	0.609	rs11602686	chr11:115100638	G/A	cg04055981	chr11:115044050	NA	0.41	7.08	0.33	6.24e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg19442545	chr10:75533431	FUT11	-0.49	-8.41	-0.38	6.44e-16	Inflammatory bowel disease;
LUAD	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.32	6.64e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6906287	0.647	rs2213856	chr6:118806793	C/T	cg21191810	chr6:118973309	C6orf204	0.49	9.67	0.43	4.1e-20	Electrocardiographic conduction measures;
LUAD	cis	rs10821973	0.597	rs3864793	chr10:64002989	T/C	cg09941381	chr10:64027924	RTKN2	-0.35	-6.85	-0.32	2.64e-11	Hypothyroidism;
LUAD	cis	rs1595825	0.838	rs57437055	chr2:198782617	A/C	cg11031976	chr2:198649780	BOLL	-0.48	-7.19	-0.33	2.89e-12	Ulcerative colitis;
LUAD	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg00981070	chr1:2046702	PRKCZ	-0.32	-6.58	-0.3	1.36e-10	Height;
LUAD	cis	rs4713675	0.584	rs2966	chr6:33689520	C/T	cg13859433	chr6:33739653	LEMD2	-0.3	-7.16	-0.33	3.68e-12	Plateletcrit;
LUAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.61	8.3	0.37	1.45e-15	Renal function-related traits (BUN);
LUAD	cis	rs72901758	0.768	rs1567237	chr17:76246294	A/G	cg25512537	chr17:76250053	NA	-0.38	-7.55	-0.34	2.79e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs62400317	0.762	rs6908606	chr6:44998888	A/G	cg20913747	chr6:44695427	NA	-0.41	-6.54	-0.3	1.81e-10	Total body bone mineral density;
LUAD	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg27170947	chr2:26402098	FAM59B	0.64	8.15	0.37	4.22e-15	Gut microbiome composition (summer);
LUAD	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.61	-11.18	-0.48	1.29e-25	Urate levels in overweight individuals;
LUAD	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg14552801	chr7:65878734	NA	0.38	6.44	0.3	3.23e-10	Aortic root size;
LUAD	cis	rs1595825	0.838	rs7603283	chr2:198517592	A/G	cg10547527	chr2:198650123	BOLL	-0.54	-7.64	-0.35	1.47e-13	Ulcerative colitis;
LUAD	trans	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.73	0.35	8.15e-14	Resting heart rate;
LUAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg15147215	chr3:52552868	STAB1	-0.49	-9.15	-0.41	2.48e-18	Electroencephalogram traits;
LUAD	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg00802000	chr16:706648	WDR90	-0.44	-8.21	-0.37	2.78e-15	Height;
LUAD	cis	rs9372498	0.536	rs62422235	chr6:118971913	G/A	cg21191810	chr6:118973309	C6orf204	-0.55	-8.24	-0.37	2.22e-15	Diastolic blood pressure;
LUAD	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.95e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs13315871	0.929	rs11717783	chr3:58267642	A/T	cg20936604	chr3:58311152	NA	-0.58	-6.51	-0.3	2.16e-10	Cholesterol, total;
LUAD	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.11	-0.37	5.52e-15	Diabetic kidney disease;
LUAD	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	trans	rs114934997	0.881	rs10473185	chr5:40375167	A/G	cg19995539	chr12:120539137	RAB35	-0.54	-6.8	-0.31	3.64e-11	Psoriasis;
LUAD	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg11189052	chr15:85197271	WDR73	0.68	8.96	0.4	1.06e-17	Schizophrenia;
LUAD	cis	rs4711336	1.000	rs2229642	chr6:33659472	C/G	cg13859433	chr6:33739653	LEMD2	-0.3	-7.02	-0.32	8.72e-12	Height;
LUAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.5e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07950158	chr19:45874032	ERCC2	-0.55	-8.7	-0.39	7.46e-17	Height;
LUAD	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg01802117	chr1:53393560	SCP2	-0.38	-7.33	-0.34	1.21e-12	Monocyte count;
LUAD	cis	rs1448094	0.785	rs6539941	chr12:86452813	G/T	cg00310523	chr12:86230176	RASSF9	-0.35	-7.39	-0.34	8.01e-13	Major depressive disorder;
LUAD	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg16797656	chr11:68205561	LRP5	0.47	9.13	0.41	2.88e-18	Total body bone mineral density;
LUAD	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg18209359	chr17:80159595	CCDC57	0.4	6.93	0.32	1.57e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08564027	chr20:61660810	NA	0.88	18.83	0.68	6.9e-58	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs6435862	0.593	rs34732883	chr2:215674371	C/T	cg04004882	chr2:215674386	BARD1	-0.66	-9.62	-0.42	5.96e-20	Neuroblastoma (high-risk);
LUAD	cis	rs6494488	0.500	rs72741319	chr15:64716977	C/G	cg08069370	chr15:64387884	SNX1	-0.75	-6.64	-0.31	9.44e-11	Coronary artery disease;
LUAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg04025307	chr7:1156635	C7orf50	0.6	10.88	0.47	1.86e-24	Longevity;Endometriosis;
LUAD	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg08470875	chr2:26401718	FAM59B	-0.75	-10.39	-0.45	1.09e-22	Gut microbiome composition (summer);
LUAD	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg22875332	chr1:76189707	ACADM	0.75	11.78	0.5	6.51e-28	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05665937	chr4:1216051	CTBP1	-0.47	-7.66	-0.35	1.27e-13	Obesity-related traits;
LUAD	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg20607287	chr7:12443886	VWDE	-0.53	-6.67	-0.31	7.88e-11	Coronary artery disease;
LUAD	cis	rs4356932	1.000	rs4309862	chr4:76945981	A/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.49	-0.3	2.36e-10	Blood protein levels;
LUAD	cis	rs738321	0.701	rs11703601	chr22:38598041	C/T	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.97	-0.32	1.24e-11	Breast cancer;
LUAD	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.21	0.37	2.61e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs977987	0.806	rs35263058	chr16:75391937	T/C	cg03315344	chr16:75512273	CHST6	0.65	14.18	0.57	1.24e-37	Dupuytren's disease;
LUAD	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg12483005	chr1:23474871	LUZP1	0.52	9.13	0.41	2.93e-18	Height;
LUAD	cis	rs7616330	0.836	rs17008114	chr3:71045000	A/C	cg20891481	chr3:71115714	FOXP1	0.5	8.18	0.37	3.37e-15	QT interval;
LUAD	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg12140854	chr5:148520817	ABLIM3	-0.68	-10.04	-0.44	2.09e-21	Breast cancer;
LUAD	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg27490568	chr2:178487706	NA	0.41	6.68	0.31	7.74e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg08888203	chr3:10149979	C3orf24	0.73	12.78	0.53	7.21e-32	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg17366294	chr4:99064904	C4orf37	0.66	12.61	0.52	3.64e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4691139	0.582	rs4133108	chr4:165952435	C/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.39	-7.23	-0.33	2.31e-12	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg02734326	chr4:10020555	SLC2A9	0.45	7.61	0.35	1.76e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg18811423	chr2:55921094	PNPT1	0.51	8.56	0.38	2.06e-16	Metabolic syndrome;
LUAD	trans	rs10248839	0.518	rs34011864	chr7:29698499	G/A	cg27349345	chr7:35225932	NA	-0.44	-6.38	-0.3	4.63e-10	Facial emotion recognition (angry faces);
LUAD	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg03806693	chr22:41940476	POLR3H	0.73	9.84	0.43	1.02e-20	Vitiligo;
LUAD	trans	rs8002861	0.664	rs2184882	chr13:44450346	C/T	cg12856521	chr11:46389249	DGKZ	0.47	8.2	0.37	2.96e-15	Leprosy;
LUAD	cis	rs432925	0.600	rs214249	chr16:348687	T/G	cg06233593	chr16:337645	AXIN1	0.31	6.88	0.32	2.19e-11	Morning vs. evening chronotype;
LUAD	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg21918786	chr6:109611834	NA	0.55	10.13	0.44	9.4e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.79e-18	Life satisfaction;
LUAD	cis	rs7274811	0.625	rs211041	chr20:31932068	A/G	cg14921437	chr20:32255988	NECAB3;C20orf134	0.44	6.53	0.3	1.91e-10	Height;
LUAD	cis	rs12681287	0.577	rs11992955	chr8:87530485	A/G	cg27223183	chr8:87520930	FAM82B	0.71	10.09	0.44	1.3e-21	Caudate activity during reward;
LUAD	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg05082376	chr22:42548792	NA	0.45	7.72	0.35	8.26e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs13082711	0.522	rs533175	chr3:27361432	A/G	cg02860705	chr3:27208620	NA	-0.53	-8.7	-0.39	7.25e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs57590327	0.503	rs17019299	chr3:81851643	A/G	cg07356753	chr3:81810745	GBE1	-0.61	-9.84	-0.43	1.03e-20	Extraversion;
LUAD	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg02734326	chr4:10020555	SLC2A9	-0.54	-9.6	-0.42	7.3e-20	Bone mineral density;
LUAD	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg08029281	chr1:67600428	NA	0.35	6.53	0.3	1.88e-10	Psoriasis;
LUAD	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg15445000	chr17:37608096	MED1	-0.45	-8.32	-0.37	1.23e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs2688608	0.839	rs2633310	chr10:75594050	G/T	cg19442545	chr10:75533431	FUT11	0.43	7.25	0.33	2.03e-12	Inflammatory bowel disease;
LUAD	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.45	-6.49	-0.3	2.44e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2274273	0.686	rs17253695	chr14:55574610	A/T	cg04306507	chr14:55594613	LGALS3	-0.36	-6.66	-0.31	8.29e-11	Protein biomarker;
LUAD	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg19302996	chr17:73780495	UNK	-0.43	-6.62	-0.31	1.06e-10	Psoriasis;
LUAD	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.59	-10.45	-0.45	6.9e-23	Melanoma;
LUAD	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.87e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg23982607	chr1:1823379	GNB1	-0.91	-18.92	-0.68	2.61e-58	Body mass index;
LUAD	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg09165964	chr15:75287851	SCAMP5	-0.48	-7.3	-0.33	1.43e-12	Blood trace element (Zn levels);
LUAD	trans	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg01620082	chr3:125678407	NA	-0.43	-6.5	-0.3	2.25e-10	Parkinson's disease;
LUAD	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg00204512	chr16:28754710	NA	0.33	6.9	0.32	1.87e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg19761014	chr17:28927070	LRRC37B2	0.79	7.9	0.36	2.51e-14	Body mass index;
LUAD	cis	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg26958806	chr6:27640298	NA	0.64	6.35	0.3	5.45e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.16	29.13	0.82	3.8e-103	Colorectal cancer;
LUAD	cis	rs3087591	0.960	rs12945157	chr17:29603631	G/A	cg24425628	chr17:29625626	OMG;NF1	0.41	6.69	0.31	7.31e-11	Hip circumference;
LUAD	trans	rs75804782	0.521	rs55973123	chr2:239416264	G/A	cg01134436	chr17:81009848	B3GNTL1	0.56	6.38	0.3	4.6e-10	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2412208	0.545	rs7414485	chr1:7121397	G/A	cg20434152	chr1:7120926	CAMTA1	-0.4	-10.27	-0.45	2.95e-22	Survival in sporadic amyotrophic lateral sclerosis;
LUAD	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg02221422	chr11:68192511	LRP5	-0.41	-6.79	-0.31	3.82e-11	Total body bone mineral density;
LUAD	cis	rs12681288	0.963	rs7822955	chr8:1029090	C/T	cg04851639	chr8:1020857	NA	0.38	9.37	0.41	4.47e-19	Schizophrenia;
LUAD	cis	rs1018836	0.923	rs6998150	chr8:91645969	A/C	cg16814680	chr8:91681699	NA	-0.7	-11.9	-0.5	2.31e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg12016809	chr21:47604291	C21orf56	0.47	7.74	0.35	7.57e-14	Testicular germ cell tumor;
LUAD	cis	rs12681288	0.644	rs2600494	chr8:1025517	C/T	cg04851639	chr8:1020857	NA	-0.45	-10.96	-0.47	8.74e-25	Schizophrenia;
LUAD	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.77	-0.35	5.94e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7224685	0.520	rs2603034	chr17:3981837	T/C	cg07607921	chr17:4047574	ZZEF1;CYB5D2	-0.42	-7.24	-0.33	2.14e-12	Type 2 diabetes;
LUAD	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg15147215	chr3:52552868	STAB1	-0.39	-7.17	-0.33	3.31e-12	Bipolar disorder;
LUAD	cis	rs1595825	0.735	rs2228135	chr2:198950029	A/G	cg00982548	chr2:198649783	BOLL	-0.66	-9.05	-0.4	5.13e-18	Ulcerative colitis;
LUAD	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg14631576	chr9:95140430	CENPP	-0.47	-9.53	-0.42	1.24e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs16866061	0.888	rs6748341	chr2:225377574	C/G	cg12698349	chr2:225449008	CUL3	0.75	12.61	0.52	3.44e-31	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg06271696	chr7:157225062	NA	-0.51	-10.71	-0.46	7.88e-24	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs2235649	0.798	rs9922462	chr16:1848011	C/T	cg08610935	chr16:1836813	NUBP2	-0.5	-7.74	-0.35	7.31e-14	Blood metabolite levels;
LUAD	trans	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg14791747	chr16:20752902	THUMPD1	-0.48	-7.21	-0.33	2.64e-12	Pancreatic cancer;
LUAD	trans	rs9393777	0.778	rs66841633	chr6:27382386	G/T	cg01620082	chr3:125678407	NA	-0.79	-8.52	-0.38	2.87e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg00784671	chr22:46762841	CELSR1	-0.58	-7.24	-0.33	2.08e-12	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16538604	chr4:2010703	WHSC2	-0.53	-6.36	-0.3	5.33e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.559	rs80212020	chr7:106957596	C/T	cg23024343	chr7:107201750	COG5	0.5	7.2	0.33	2.84e-12	Coronary artery disease;
LUAD	trans	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.51	-0.34	3.56e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06544989	chr22:39130855	UNC84B	-0.43	-8.62	-0.39	1.34e-16	Menopause (age at onset);
LUAD	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.41	0.49	1.77e-26	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs961253	0.522	rs2148813	chr20:6352470	T/C	cg21095983	chr6:86352623	SYNCRIP	0.43	6.81	0.31	3.3e-11	Colorectal cancer;
LUAD	cis	rs10465746	0.935	rs6692233	chr1:84327214	A/G	cg10977910	chr1:84465055	TTLL7	-0.5	-8.08	-0.37	6.86e-15	Obesity-related traits;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg15133313	chr6:53213956	ELOVL5	-0.43	-6.82	-0.31	3.14e-11	Vertical cup-disc ratio;
LUAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs17641971	0.662	rs10435575	chr8:49996107	C/T	cg00325661	chr8:49890786	NA	0.3	6.8	0.31	3.59e-11	Blood metabolite levels;
LUAD	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-7.24	-0.33	2.11e-12	Morning vs. evening chronotype;
LUAD	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg18932078	chr1:2524107	MMEL1	0.36	6.64	0.31	9.48e-11	Ulcerative colitis;
LUAD	trans	rs1728785	1.000	rs1645976	chr16:68563509	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.78	0.43	1.69e-20	Ulcerative colitis;
LUAD	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg04727924	chr7:799746	HEATR2	-0.53	-7.16	-0.33	3.62e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg05084668	chr3:125655381	ALG1L	-0.85	-12.84	-0.53	4.22e-32	Blood pressure (smoking interaction);
LUAD	cis	rs75920871	0.920	rs7924318	chr11:116816630	C/G	cg04087571	chr11:116723030	SIK3	-0.32	-6.5	-0.3	2.33e-10	Subjective well-being;
LUAD	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01570182	chr17:44337453	NA	-0.94	-13.85	-0.56	3.18e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg02527881	chr3:46936655	PTH1R	-0.52	-10.42	-0.45	8.81e-23	Colorectal cancer;
LUAD	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg21545522	chr1:205238299	TMCC2	0.38	6.94	0.32	1.51e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs3761847	0.622	rs1323471	chr9:123826315	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	6.49	0.3	2.38e-10	Rheumatoid arthritis;
LUAD	cis	rs2455799	0.613	rs62241264	chr3:15943471	T/C	cg16303742	chr3:15540471	COLQ	-0.47	-8.4	-0.38	7.05e-16	Mean platelet volume;
LUAD	cis	rs4660306	0.961	rs4660862	chr1:45955056	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-8.01	-0.36	1.11e-14	Homocysteine levels;
LUAD	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg18811423	chr2:55921094	PNPT1	-0.49	-7.98	-0.36	1.43e-14	Metabolic syndrome;
LUAD	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg26384229	chr12:38710491	ALG10B	0.47	7.51	0.34	3.49e-13	Heart rate;
LUAD	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.86	-0.32	2.39e-11	Retinal vascular caliber;
LUAD	cis	rs7786877	0.680	rs12532878	chr7:100212254	G/A	cg20848291	chr7:100343083	ZAN	-0.55	-7.48	-0.34	4.4e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7771547	0.574	rs9394361	chr6:36551370	A/C	cg02952361	chr6:36355661	ETV7	0.49	6.64	0.31	9.8e-11	Platelet distribution width;
LUAD	cis	rs2992756	0.663	rs3007733	chr1:18800911	C/T	cg24076588	chr1:18808559	KLHDC7A	-0.46	-7.43	-0.34	6.08e-13	Breast cancer;
LUAD	cis	rs7010267	1.000	rs7010267	chr8:119946656	A/C	cg01975934	chr8:119970761	NA	-0.38	-7.43	-0.34	6.02e-13	Total body bone mineral density (age 45-60);
LUAD	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.91	-0.32	1.78e-11	Height;
LUAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg20607798	chr8:58055168	NA	0.59	7.08	0.33	6.07e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9473147	0.516	rs10948363	chr6:47487762	A/G	cg20196966	chr6:47445060	CD2AP	0.44	6.8	0.31	3.67e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs17490626	0.568	rs12413525	chr10:71211721	C/A	cg12610070	chr10:71211762	TSPAN15	-0.41	-10.83	-0.47	2.69e-24	Thrombosis;
LUAD	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg05623727	chr3:50126028	RBM5	0.3	6.64	0.31	9.58e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg15017067	chr4:17643749	FAM184B	0.35	7.0	0.32	1.04e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg19636519	chr7:99541626	NA	0.39	7.01	0.32	9.72e-12	Coronary artery disease;
LUAD	cis	rs1232027	0.700	rs1677633	chr5:79928224	C/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs943466	0.911	rs73746509	chr6:33729825	C/T	cg16010596	chr6:33739607	LEMD2	-0.35	-6.55	-0.3	1.7e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg14895029	chr7:2775587	GNA12	-0.44	-7.0	-0.32	9.82e-12	Height;
LUAD	cis	rs2625529	0.878	rs4777478	chr15:72279085	T/C	cg16672083	chr15:72433130	SENP8	-0.76	-12.76	-0.53	9.28e-32	Red blood cell count;
LUAD	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg10518543	chr12:38710700	ALG10B	-0.48	-7.98	-0.36	1.4e-14	Morning vs. evening chronotype;
LUAD	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg13319975	chr6:146136371	FBXO30	-0.66	-11.31	-0.48	4.28e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg18721089	chr20:30220636	NA	-0.49	-7.06	-0.32	6.99e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs58804349	0.605	rs117540287	chr10:43512040	G/T	cg20628663	chr10:43360327	NA	0.55	6.57	0.3	1.5e-10	Pediatric bone mineral content (radius);
LUAD	cis	rs7116495	1.000	rs12272213	chr11:71816219	G/A	cg07596299	chr11:71824057	C11orf51	0.76	6.42	0.3	3.61e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg17757837	chr7:157058334	UBE3C	-0.47	-8.26	-0.37	1.82e-15	Body mass index;
LUAD	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg11941060	chr3:133502564	NA	-0.46	-7.71	-0.35	9.23e-14	Iron status biomarkers;
LUAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03647317	chr4:187891568	NA	0.37	7.01	0.32	9.49e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.42	0.3	3.76e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg22875332	chr1:76189707	ACADM	-0.64	-10.24	-0.45	4.04e-22	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg25894440	chr7:65020034	NA	0.63	6.74	0.31	5.21e-11	Diabetic kidney disease;
LUAD	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg09835421	chr16:68378352	PRMT7	-0.92	-10.7	-0.46	8.26e-24	Schizophrenia;
LUAD	cis	rs11811982	0.793	rs114537871	chr1:227560794	G/A	cg24860534	chr1:227506868	CDC42BPA	0.72	7.6	0.35	1.89e-13	Optic disc area;
LUAD	cis	rs3820068	0.871	rs11585808	chr1:15805662	C/T	cg13390004	chr1:15929781	NA	0.44	6.64	0.31	9.45e-11	Systolic blood pressure;
LUAD	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg06640241	chr16:89574553	SPG7	0.47	7.6	0.35	1.87e-13	Multiple myeloma (IgH translocation);
LUAD	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg25319279	chr11:5960081	NA	-0.4	-7.04	-0.32	7.7e-12	DNA methylation (variation);
LUAD	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg21724239	chr8:58056113	NA	0.6	7.88	0.36	2.85e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs73206853	0.841	rs57216167	chr12:110940748	C/T	cg12870014	chr12:110450643	ANKRD13A	0.61	6.82	0.31	3.25e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs62238980	0.614	rs12160688	chr22:32554996	C/T	cg00543991	chr22:32367038	NA	0.85	7.46	0.34	4.86e-13	Childhood ear infection;
LUAD	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg01808030	chr22:45809952	RIBC2;SMC1B	0.8	8.85	0.4	2.48e-17	Tonsillectomy;
LUAD	cis	rs13064411	0.501	rs13092925	chr3:113209375	C/G	cg18753928	chr3:113234510	CCDC52	-0.55	-9.73	-0.43	2.58e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg22681709	chr2:178499509	PDE11A	-0.5	-8.38	-0.38	7.82e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.24	-0.51	1.04e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2637266	1.000	rs6480824	chr10:78355705	G/A	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs1160297	0.609	rs1828338	chr2:53096951	T/C	cg07782112	chr2:53107842	NA	0.42	8.85	0.4	2.5e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs68170813	0.652	rs12533694	chr7:107102817	C/T	cg23024343	chr7:107201750	COG5	0.51	6.5	0.3	2.24e-10	Coronary artery disease;
LUAD	trans	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg06165179	chr7:39990544	CDK13	0.48	6.45	0.3	2.98e-10	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs174775	0.513	rs2283849	chr22:29743482	T/C	cg07256473	chr22:29710276	RASL10A	-0.53	-10.14	-0.44	8.81e-22	Immature fraction of reticulocytes;
LUAD	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg18032046	chr6:28092343	ZSCAN16	0.48	6.47	0.3	2.72e-10	Depression;
LUAD	trans	rs225245	0.694	rs321616	chr17:33882720	C/T	cg19694781	chr19:47549865	TMEM160	-0.44	-7.14	-0.33	4.19e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg00204512	chr16:28754710	NA	0.31	6.69	0.31	7.06e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs12431939	0.762	rs60294020	chr14:51704821	C/A	cg23942311	chr14:51606299	NA	-0.56	-7.7	-0.35	9.85e-14	Cancer;
LUAD	cis	rs8192282	0.739	rs4131514	chr1:154500089	A/G	cg16683920	chr1:154474344	TDRD10;SHE	-0.46	-7.08	-0.33	6.18e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg18129748	chr3:49941408	MST1R	-0.44	-7.24	-0.33	2.1e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15433164	chr3:25824899	NGLY1	-0.51	-7.07	-0.33	6.61e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg04546413	chr19:29218101	NA	0.71	10.51	0.45	4.18e-23	Methadone dose in opioid dependence;
LUAD	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg21153622	chr11:89784906	NA	-0.33	-6.51	-0.3	2.07e-10	Coronary artery disease;
LUAD	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg02176678	chr2:219576539	TTLL4	-0.81	-16.59	-0.63	5.68e-48	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg14458575	chr2:238380390	NA	0.73	11.07	0.47	3.44e-25	Prostate cancer;
LUAD	cis	rs727505	0.954	rs1525613	chr7:124658636	A/G	cg23710748	chr7:124431027	NA	-0.42	-8.32	-0.38	1.2e-15	Lewy body disease;
LUAD	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg03948781	chr1:205179583	DSTYK	0.33	6.5	0.3	2.32e-10	Red blood cell count;
LUAD	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg21775007	chr8:11205619	TDH	-0.56	-10.24	-0.45	3.83e-22	Retinal vascular caliber;
LUAD	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg20203395	chr5:56204925	C5orf35	0.61	9.43	0.42	2.84e-19	Initial pursuit acceleration;
LUAD	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg00074818	chr8:8560427	CLDN23	0.68	10.52	0.46	3.85e-23	Obesity-related traits;
LUAD	cis	rs2535633	0.631	rs2245424	chr3:53003021	G/C	cg18404041	chr3:52824283	ITIH1	0.38	6.77	0.31	4.33e-11	Body mass index;
LUAD	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg03161606	chr19:29218774	NA	0.52	7.4	0.34	7.52e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs6500395	1.000	rs9928051	chr16:48557316	T/A	cg04672837	chr16:48644449	N4BP1	0.39	6.74	0.31	5.23e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg13354988	chr2:263656	ACP1;SH3YL1	0.3	6.6	0.31	1.22e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10579408	chr7:86850525	C7orf23	0.51	7.22	0.33	2.41e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19748678	chr4:122722346	EXOSC9	0.43	6.82	0.31	3.18e-11	Type 2 diabetes;
LUAD	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg15704280	chr7:45808275	SEPT13	0.68	8.92	0.4	1.37e-17	Axial length;
LUAD	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.68	13.05	0.54	6e-33	Cognitive ability;
LUAD	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg02454025	chr1:11042201	C1orf127	1.04	17.71	0.65	6.82e-53	Ewing sarcoma;
LUAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14159672	chr1:205819179	PM20D1	0.74	14.61	0.58	2.04e-39	Monocyte percentage of white cells;
LUAD	trans	rs4942242	0.512	rs9533551	chr13:44187120	G/C	cg19169023	chr15:41853346	TYRO3	-0.75	-12.86	-0.53	3.39e-32	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg04989706	chr14:50066350	PPIL5	-0.54	-7.84	-0.36	3.6e-14	Carotid intima media thickness;
LUAD	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.83	0.43	1.09e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2637266	1.000	rs12784382	chr10:78378348	G/T	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.7e-11	Pulmonary function;
LUAD	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg03563238	chr19:33554763	RHPN2	-0.37	-8.56	-0.38	2.12e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg01849466	chr14:104193079	ZFYVE21	-0.6	-10.96	-0.47	9.29e-25	Schizophrenia;
LUAD	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg10755058	chr3:40428713	ENTPD3	0.44	8.11	0.37	5.53e-15	Renal cell carcinoma;
LUAD	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg00981070	chr1:2046702	PRKCZ	0.36	7.69	0.35	1.03e-13	Height;
LUAD	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg04450456	chr4:17643702	FAM184B	0.36	7.05	0.32	7.42e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs939658	0.805	rs34222382	chr15:79440748	C/T	cg17916960	chr15:79447300	NA	-0.53	-11.1	-0.47	2.78e-25	Refractive error;
LUAD	cis	rs859767	0.741	rs7602801	chr2:135363870	A/G	cg12500956	chr2:135428796	TMEM163	-0.31	-8.19	-0.37	3.22e-15	Neuroticism;
LUAD	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg20933634	chr6:27740509	NA	0.51	8.17	0.37	3.58e-15	Parkinson's disease;
LUAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg04234412	chr22:24373322	LOC391322	-0.92	-18.46	-0.67	3.16e-56	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs734999	0.967	rs6667605	chr1:2502780	C/T	cg18854424	chr1:2615690	NA	0.34	7.89	0.36	2.58e-14	Ulcerative colitis;
LUAD	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg14092571	chr14:90743983	NA	0.47	8.25	0.37	2.04e-15	Mortality in heart failure;
LUAD	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.2	0.37	2.91e-15	Menopause (age at onset);
LUAD	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18876405	chr7:65276391	NA	0.45	7.19	0.33	2.9e-12	Aortic root size;
LUAD	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg02423579	chr7:2872169	GNA12	-0.75	-12.89	-0.53	2.71e-32	Height;
LUAD	cis	rs6688613	0.685	rs4657613	chr1:166870878	A/G	cg07049167	chr1:166818506	POGK	0.57	9.05	0.4	5.1e-18	Refractive astigmatism;
LUAD	trans	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04565464	chr8:145669602	NFKBIL2	0.44	6.59	0.31	1.33e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs8058578	0.943	rs35629860	chr16:30671532	G/A	cg05768032	chr16:30646687	NA	0.44	7.42	0.34	6.68e-13	Multiple myeloma;
LUAD	cis	rs6424115	0.862	rs34845821	chr1:24066486	C/T	cg10978503	chr1:24200527	CNR2	-0.43	-7.9	-0.36	2.42e-14	Immature fraction of reticulocytes;
LUAD	cis	rs35264875	0.846	rs72930625	chr11:68867120	T/A	cg02660097	chr11:68866761	NA	0.52	7.27	0.33	1.8e-12	Blond vs. brown hair color;
LUAD	cis	rs2573652	1.000	rs12440866	chr15:100517010	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.55	-10.36	-0.45	1.47e-22	Height;
LUAD	trans	rs9354308	0.933	rs12203567	chr6:66589062	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.52	7.74	0.35	7.36e-14	Metabolite levels;
LUAD	cis	rs8060686	0.623	rs7205935	chr16:68152157	A/G	cg05110241	chr16:68378359	PRMT7	-0.56	-7.2	-0.33	2.72e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6489882	0.902	rs7966314	chr12:113372539	C/T	cg20102336	chr12:113376681	OAS3	0.57	9.03	0.4	6.29e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs698813	0.674	rs11680456	chr2:44497544	C/G	cg00619915	chr2:44497795	NA	-0.43	-6.4	-0.3	4.16e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUAD	cis	rs3772130	0.962	rs11706783	chr3:121534322	T/C	cg20356878	chr3:121714668	ILDR1	0.53	8.5	0.38	3.24e-16	Cognitive performance;
LUAD	trans	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg26043149	chr18:55253948	FECH	-0.48	-8.14	-0.37	4.35e-15	Bone mineral density;
LUAD	cis	rs11229555	0.645	rs11229427	chr11:58180275	A/C	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7127129	0.872	rs10898859	chr11:70054051	G/A	cg06159181	chr11:70072977	NA	-0.35	-6.71	-0.31	6.42e-11	Aortic root size;
LUAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg05834845	chr3:195489306	MUC4	0.58	7.37	0.34	8.8e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs4849845	0.637	rs4077564	chr2:121004241	C/T	cg24070213	chr2:121070622	NA	0.41	7.54	0.34	2.83e-13	Mean platelet volume;
LUAD	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg00071950	chr4:10020882	SLC2A9	0.65	10.8	0.46	3.5e-24	Blood metabolite levels;
LUAD	cis	rs2274471	0.680	rs2031903	chr9:5191297	T/C	cg03390472	chr9:5043263	JAK2	-0.55	-7.27	-0.33	1.75e-12	Crohn's disease;
LUAD	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg21951975	chr1:209979733	IRF6	0.55	7.83	0.36	3.97e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs9863	0.896	rs2130382	chr12:124484643	C/G	cg17723958	chr12:124429295	CCDC92	-0.41	-6.58	-0.3	1.38e-10	White blood cell count;
LUAD	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08677398	chr8:58056175	NA	0.47	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs12517041	1.000	rs6894144	chr5:23312635	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg02782426	chr3:40428986	ENTPD3	0.35	7.46	0.34	4.94e-13	Renal cell carcinoma;
LUAD	cis	rs3806843	0.576	rs246072	chr5:140320426	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.33	-6.8	-0.31	3.53e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1595825	0.891	rs73056840	chr2:198783466	C/A	cg00361562	chr2:198649771	BOLL	-0.47	-6.73	-0.31	5.53e-11	Ulcerative colitis;
LUAD	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg04586622	chr2:25135609	ADCY3	0.38	8.54	0.38	2.45e-16	Body mass index;
LUAD	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg00071950	chr4:10020882	SLC2A9	-0.66	-12.65	-0.52	2.44e-31	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg07169764	chr2:136633963	MCM6	0.64	7.67	0.35	1.21e-13	Corneal structure;
LUAD	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg06766960	chr11:133703094	NA	-0.37	-7.09	-0.33	5.52e-12	Childhood ear infection;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26960647	chr6:138188928	TNFAIP3	-0.4	-6.4	-0.3	4.02e-10	Cancer;
LUAD	cis	rs754466	0.580	rs10824573	chr10:79540969	T/C	cg17075019	chr10:79541650	NA	-0.92	-19.71	-0.69	8.16e-62	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg23985595	chr17:80112537	CCDC57	-0.51	-9.26	-0.41	1.04e-18	Life satisfaction;
LUAD	cis	rs4594175	0.926	rs60234748	chr14:51630102	T/C	cg23942311	chr14:51606299	NA	0.64	11.22	0.48	9.49e-26	Cancer;
LUAD	cis	rs7582720	1.000	rs72934740	chr2:203741362	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.45	0.42	2.39e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	8.0	0.36	1.18e-14	Hip circumference adjusted for BMI;
LUAD	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22968622	chr17:43663579	NA	1.37	24.87	0.77	8.73e-85	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-12.91	-0.53	2.17e-32	Breast cancer;
LUAD	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg14844989	chr11:31128820	NA	-0.46	-8.44	-0.38	5.03e-16	Red blood cell count;
LUAD	cis	rs7192380	0.964	rs6499231	chr16:69588016	A/G	cg26679644	chr16:69762563	NA	0.45	8.58	0.38	1.84e-16	Sjögren's syndrome;
LUAD	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg04155289	chr7:94953770	PON1	-0.52	-6.89	-0.32	1.99e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg06740227	chr12:86229804	RASSF9	0.38	6.8	0.31	3.58e-11	Major depressive disorder;
LUAD	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.77	-0.31	4.44e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg08601574	chr20:25228251	PYGB	-0.46	-8.72	-0.39	6.46e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.1	-0.51	3.76e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3767633	0.528	rs4417044	chr1:161888955	T/C	cg27519958	chr1:161735129	ATF6	-0.43	-7.34	-0.34	1.12e-12	IgG glycosylation;
LUAD	cis	rs2736345	0.516	rs7844858	chr8:11392659	T/A	cg27411982	chr8:10470053	RP1L1	0.36	6.35	0.3	5.46e-10	Sjögren's syndrome;Systemic lupus erythematosus;
LUAD	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg10755058	chr3:40428713	ENTPD3	-0.34	-6.41	-0.3	3.92e-10	Renal cell carcinoma;
LUAD	trans	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg26043149	chr18:55253948	FECH	0.51	8.32	0.38	1.19e-15	Bone mineral density;
LUAD	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg00204512	chr16:28754710	NA	0.33	7.06	0.32	7.07e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg23625390	chr15:77176239	SCAPER	-0.5	-7.82	-0.36	4.38e-14	Blood metabolite levels;
LUAD	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg00750074	chr16:89608354	SPG7	-0.56	-9.55	-0.42	1.05e-19	Multiple myeloma (IgH translocation);
LUAD	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg03467027	chr4:99064603	C4orf37	0.4	6.35	0.3	5.45e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs8177876	0.658	rs16954513	chr16:81077204	T/A	cg08591886	chr16:81111003	C16orf46	-0.95	-7.38	-0.34	8.27e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg06558623	chr16:89946397	TCF25	1.15	10.34	0.45	1.72e-22	Skin colour saturation;
LUAD	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg19678392	chr7:94953810	PON1	-0.6	-7.94	-0.36	1.81e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.93	-0.36	1.93e-14	Body mass index;
LUAD	cis	rs6500395	1.000	rs7201196	chr16:48674030	C/T	cg04672837	chr16:48644449	N4BP1	0.39	6.81	0.31	3.43e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs13064411	0.696	rs1486894	chr3:113211513	G/A	cg10517650	chr3:113235015	CCDC52	-0.56	-9.63	-0.42	5.58e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08677398	chr8:58056175	NA	0.47	6.57	0.3	1.52e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.68	-10.04	-0.44	2.09e-21	Platelet distribution width;
LUAD	cis	rs9322817	0.691	rs2486141	chr6:105299930	G/A	cg02098413	chr6:105308735	HACE1	0.42	9.05	0.4	5.1e-18	Thyroid stimulating hormone;
LUAD	cis	rs2554380	0.628	rs11853983	chr15:84462810	A/G	cg14598478	chr15:84363061	ADAMTSL3	0.37	6.58	0.3	1.38e-10	Height;
LUAD	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.77	-0.43	1.76e-20	Schizophrenia;
LUAD	cis	rs11677370	0.533	rs12711971	chr2:3820821	G/C	cg17052675	chr2:3827356	NA	-0.63	-10.56	-0.46	2.71e-23	Type 2 diabetes;
LUAD	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.51	-8.38	-0.38	8.2e-16	Multiple sclerosis;
LUAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	12.93	0.53	1.94e-32	Prudent dietary pattern;
LUAD	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg23758822	chr17:41437982	NA	1.0	20.52	0.71	1.84e-65	Menopause (age at onset);
LUAD	cis	rs11785400	0.890	rs13279182	chr8:143720544	A/G	cg10596483	chr8:143751796	JRK	0.42	6.62	0.31	1.08e-10	Schizophrenia;
LUAD	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg18944383	chr4:111397179	ENPEP	-0.38	-7.31	-0.33	1.33e-12	Height;
LUAD	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg23649088	chr2:200775458	C2orf69	-0.62	-7.77	-0.35	6.15e-14	Schizophrenia;
LUAD	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.84e-26	Alzheimer's disease (late onset);
LUAD	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg00277334	chr10:82204260	NA	-0.57	-9.5	-0.42	1.62e-19	Post bronchodilator FEV1;
LUAD	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg07570687	chr10:102243282	WNT8B	0.42	6.39	0.3	4.4e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg03209412	chr4:183728196	NA	0.79	10.98	0.47	7.28e-25	Pediatric autoimmune diseases;
LUAD	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg11645453	chr3:52864694	ITIH4	0.6	11.1	0.47	2.75e-25	Schizophrenia;
LUAD	cis	rs77861329	0.748	rs731684	chr3:52109841	T/C	cg08692210	chr3:52188851	WDR51A	0.55	6.94	0.32	1.51e-11	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg00898013	chr13:113819073	PROZ	-0.79	-13.96	-0.56	1.12e-36	Platelet distribution width;
LUAD	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg12311346	chr5:56204834	C5orf35	-0.85	-12.73	-0.53	1.2e-31	Initial pursuit acceleration;
LUAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg08888203	chr3:10149979	C3orf24	0.74	12.79	0.53	6.98e-32	Alzheimer's disease;
LUAD	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg11502198	chr6:26597334	ABT1	0.54	9.14	0.41	2.56e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg22535103	chr8:58192502	C8orf71	-0.74	-10.44	-0.45	7.32e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg15445000	chr17:37608096	MED1	-0.44	-8.1	-0.37	6.1e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg18230493	chr5:56204884	C5orf35	-0.86	-12.44	-0.52	1.7e-30	Initial pursuit acceleration;
LUAD	cis	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg07460842	chr6:66804631	NA	-0.43	-6.7	-0.31	6.5e-11	Blood trace element (Cu levels);
LUAD	trans	rs71537559	1	rs71537559	chr6:27309779	G/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.29	-0.37	1.48e-15	Squamous cell lung carcinoma;
LUAD	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg07917127	chr4:99064746	C4orf37	-0.42	-6.97	-0.32	1.19e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21984481	chr17:79567631	NPLOC4	0.71	17.18	0.64	1.46e-50	Eye color traits;
LUAD	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg21475434	chr5:93447410	FAM172A	-0.49	-6.66	-0.31	8.37e-11	Diabetic retinopathy;
LUAD	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg06108461	chr20:60628389	TAF4	-0.81	-13.87	-0.56	2.48e-36	Body mass index;
LUAD	cis	rs2282300	0.739	rs7926465	chr11:30333016	C/T	cg06241208	chr11:30344200	C11orf46	0.56	7.12	0.33	4.81e-12	Morning vs. evening chronotype;
LUAD	cis	rs300774	1.000	rs300772	chr2:117230	C/T	cg21211680	chr2:198530	NA	-0.48	-6.91	-0.32	1.74e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg03563238	chr19:33554763	RHPN2	-0.37	-8.56	-0.38	2.12e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg22467129	chr15:76604101	ETFA	-0.5	-8.7	-0.39	7.57e-17	Blood metabolite levels;
LUAD	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg14583973	chr4:3374767	RGS12	0.3	7.57	0.35	2.31e-13	Serum sulfate level;
LUAD	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg15557168	chr22:42548783	NA	-0.5	-9.4	-0.42	3.6e-19	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.31	0.41	7.18e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-8.0	-0.36	1.23e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs2425143	1.000	rs6058311	chr20:34321895	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.43	-0.34	6.03e-13	Blood protein levels;
LUAD	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg00383909	chr3:49044727	WDR6	0.9	10.0	0.44	2.92e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg03452623	chr4:187889614	NA	-0.81	-16.35	-0.62	6.23e-47	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.7	-12.72	-0.53	1.31e-31	Axial length;
LUAD	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.41	-8.09	-0.37	6.58e-15	Glomerular filtration rate;
LUAD	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg06784218	chr1:46089804	CCDC17	0.6	13.37	0.54	3.03e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.77e-11	Depression;
LUAD	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	7.84	0.36	3.69e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2067615	0.579	rs12312782	chr12:107135647	G/A	cg15890332	chr12:107067104	RFX4	0.38	8.17	0.37	3.7e-15	Heart rate;
LUAD	cis	rs6489882	0.703	rs10850093	chr12:113360468	C/T	cg20102336	chr12:113376681	OAS3	-0.54	-8.34	-0.38	1.08e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg04731861	chr2:219085781	ARPC2	0.27	8.22	0.37	2.53e-15	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs7107174	0.892	rs12281104	chr11:78046940	T/C	cg19901956	chr11:77921274	USP35	-0.48	-6.76	-0.31	4.68e-11	Testicular germ cell tumor;
LUAD	cis	rs68170813	0.559	rs78440378	chr7:106962782	C/A	cg23024343	chr7:107201750	COG5	0.5	7.15	0.33	3.78e-12	Coronary artery disease;
LUAD	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22307029	chr19:49891270	CCDC155	0.79	13.02	0.53	8.26e-33	Multiple sclerosis;
LUAD	cis	rs2777491	0.574	rs316611	chr15:41751678	A/G	cg18705301	chr15:41695430	NDUFAF1	1.02	20.33	0.7	1.41e-64	Ulcerative colitis;
LUAD	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg11965913	chr1:205819406	PM20D1	0.44	7.02	0.32	8.82e-12	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs9296092	0.538	rs9469486	chr6:33516849	G/A	cg13560919	chr6:33536144	NA	-0.88	-16.53	-0.63	1e-47	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.19	-0.33	2.9e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2479724	0.591	rs4526183	chr6:41829267	T/C	cg17623882	chr6:41773611	USP49	-0.46	-6.81	-0.31	3.34e-11	Menarche (age at onset);
LUAD	cis	rs6138458	0.626	rs6138473	chr20:25012155	A/G	cg26195577	chr20:24973756	C20orf3	-0.7	-12.0	-0.5	9.18e-29	Blood protein levels;
LUAD	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg21204522	chr6:27730016	NA	-0.44	-6.94	-0.32	1.51e-11	Parkinson's disease;
LUAD	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.91	-0.36	2.2e-14	Diabetic kidney disease;
LUAD	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg24450063	chr1:156163899	SLC25A44	1.0	16.15	0.62	4.84e-46	Testicular germ cell tumor;
LUAD	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg13385794	chr1:248469461	NA	0.25	6.72	0.31	5.89e-11	Common traits (Other);
LUAD	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.35	-8.91	-0.4	1.54e-17	Menopause (age at onset);
LUAD	cis	rs2657888	0.899	rs7300877	chr12:56933233	C/A	cg23002907	chr12:56915593	RBMS2	0.36	6.59	0.31	1.3100000000000001e-10	Adiponectin levels;
LUAD	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg18721089	chr20:30220636	NA	-0.45	-6.5	-0.3	2.24e-10	Mean corpuscular hemoglobin;
LUAD	trans	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg00953403	chr17:74099816	EXOC7	-0.58	-9.33	-0.41	5.98e-19	Psychosis in Alzheimer's disease;
LUAD	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.77	-0.46	4.38e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg21609526	chr1:3105151	PRDM16	-0.35	-7.1	-0.33	5.21e-12	Migraine;
LUAD	cis	rs12261331	1	rs12261331	chr10:82287527	C/T	cg01528321	chr10:82214614	TSPAN14	-0.62	-7.1	-0.33	5.39e-12	Post bronchodilator FEV1;
LUAD	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg20307385	chr11:47447363	PSMC3	0.53	7.94	0.36	1.89e-14	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs877282	0.838	rs11253374	chr10:774961	C/T	cg17470449	chr10:769945	NA	0.64	9.26	0.41	1.01e-18	Uric acid levels;
LUAD	cis	rs56283067	0.887	rs12200892	chr6:44768925	T/C	cg20913747	chr6:44695427	NA	-0.47	-7.26	-0.33	1.86e-12	Total body bone mineral density;
LUAD	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg06074448	chr4:187884817	NA	-0.36	-7.05	-0.32	7.3e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-8.56	-0.38	2.15e-16	Menarche (age at onset);
LUAD	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg01689657	chr7:91764605	CYP51A1	0.39	9.78	0.43	1.72e-20	Breast cancer;
LUAD	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.66	0.31	8.75e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4846217	1.000	rs11121548	chr1:10424252	C/T	cg17425144	chr1:10567563	PEX14	-0.49	-6.4	-0.3	4.04e-10	Platelet count;
LUAD	cis	rs10781543	0.776	rs4378078	chr9:139375962	A/G	cg14169450	chr9:139327907	INPP5E	0.44	8.02	0.36	1.03e-14	Monocyte percentage of white cells;
LUAD	trans	rs11088226	0.846	rs2154501	chr21:33926451	G/A	cg09050820	chr6:167586206	TCP10L2	0.65	9.84	0.43	1.03e-20	Gastritis;
LUAD	cis	rs2224391	0.656	rs68007503	chr6:5292616	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-8.56	-0.38	2.16e-16	Height;
LUAD	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg00666640	chr1:248458726	OR2T12	0.3	7.27	0.33	1.77e-12	Common traits (Other);
LUAD	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg07741184	chr6:167504864	NA	0.35	8.07	0.37	7.53e-15	Crohn's disease;
LUAD	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg13319975	chr6:146136371	FBXO30	-0.61	-9.83	-0.43	1.14e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg17509989	chr5:176798049	RGS14	-0.76	-14.03	-0.56	5.5e-37	Urinary electrolytes (magnesium/calcium ratio);
LUAD	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg22166914	chr1:53195759	ZYG11B	0.41	7.33	0.34	1.2e-12	Monocyte count;
LUAD	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg17911788	chr17:44343683	NA	-0.48	-6.55	-0.3	1.7e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg19875535	chr5:140030758	IK	-0.4	-6.74	-0.31	5.08e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs977987	0.806	rs11864102	chr16:75442360	C/T	cg03315344	chr16:75512273	CHST6	0.64	14.14	0.57	1.87e-37	Dupuytren's disease;
LUAD	cis	rs9814567	0.712	rs9838119	chr3:134331980	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7107174	1.000	rs10793300	chr11:78019582	T/A	cg02023728	chr11:77925099	USP35	0.52	7.85	0.36	3.49e-14	Testicular germ cell tumor;
LUAD	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg17366294	chr4:99064904	C4orf37	-0.48	-8.51	-0.38	3.16e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.8	0.31	3.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg26587870	chr6:27730563	NA	-0.43	-7.15	-0.33	3.78e-12	Parkinson's disease;
LUAD	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg09137382	chr11:130731461	NA	0.42	7.59	0.35	2.07e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg27170947	chr2:26402098	FAM59B	-0.63	-8.78	-0.39	3.98e-17	Gut microbiome composition (summer);
LUAD	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg06627628	chr2:24431161	ITSN2	-0.53	-6.46	-0.3	2.83e-10	Lymphocyte counts;
LUAD	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg25767906	chr1:53392781	SCP2	0.46	8.54	0.38	2.41e-16	Monocyte count;
LUAD	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg05966235	chr16:28915196	ATP2A1	0.46	7.48	0.34	4.21e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg13902645	chr11:5959945	NA	-0.57	-9.99	-0.44	2.95e-21	DNA methylation (variation);
LUAD	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg21770322	chr7:97807741	LMTK2	0.33	7.47	0.34	4.65e-13	Breast cancer;
LUAD	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg04772025	chr11:68637568	NA	0.56	9.01	0.4	7.08e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg12011299	chr4:100065546	ADH4	0.67	12.28	0.51	7.3e-30	Alcohol dependence;
LUAD	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg04731861	chr2:219085781	ARPC2	0.22	7.0	0.32	1.01e-11	Colorectal cancer;
LUAD	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.34	6.7	0.31	6.5500000000000006e-11	IgG glycosylation;
LUAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg22907277	chr7:1156413	C7orf50	0.68	7.97	0.36	1.49e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6594713	0.679	rs17388260	chr5:112764578	C/A	cg12552261	chr5:112820674	MCC	0.54	7.52	0.34	3.36e-13	Brain cytoarchitecture;
LUAD	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg03467027	chr4:99064603	C4orf37	0.43	6.96	0.32	1.31e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11048434	0.761	rs11494570	chr12:9127147	T/C	cg20380214	chr12:9217688	LOC144571	0.34	6.38	0.3	4.69e-10	Sjögren's syndrome;
LUAD	cis	rs7771547	0.519	rs72852340	chr6:36554804	G/A	cg04289385	chr6:36355825	ETV7	0.48	6.41	0.3	3.79e-10	Platelet distribution width;
LUAD	cis	rs2249625	0.808	rs2449422	chr6:72836766	T/C	cg18830697	chr6:72922368	RIMS1	-0.36	-6.72	-0.31	5.88e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg08601574	chr20:25228251	PYGB	0.45	8.34	0.38	1.04e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs73416724	1.000	rs75473868	chr6:43352623	A/G	cg26312998	chr6:43337775	ZNF318	0.55	6.6	0.31	1.26e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs870825	0.616	rs4519838	chr4:185628457	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	13.83	0.56	3.88e-36	Blood protein levels;
LUAD	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-7.44	-0.34	5.71e-13	Morning vs. evening chronotype;
LUAD	cis	rs9283706	0.623	rs10041624	chr5:66314861	T/A	cg11590213	chr5:66331682	MAST4	0.4	6.53	0.3	1.85e-10	Coronary artery disease;
LUAD	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18876405	chr7:65276391	NA	-0.43	-6.88	-0.32	2.22e-11	Aortic root size;
LUAD	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg11584989	chr19:19387371	SF4	0.38	6.84	0.32	2.73e-11	Tonsillectomy;
LUAD	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg06387496	chr7:2775674	GNA12	-0.39	-6.51	-0.3	2.13e-10	Height;
LUAD	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg00631329	chr6:26305371	NA	-0.68	-13.21	-0.54	1.41e-33	Educational attainment;
LUAD	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-8.15	-0.37	4.19e-15	Total cholesterol levels;
LUAD	cis	rs9837602	1.000	rs9851645	chr3:99767409	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-7.04	-0.32	7.94e-12	Breast cancer;
LUAD	cis	rs2404602	0.530	rs11072614	chr15:76967205	G/A	cg23625390	chr15:77176239	SCAPER	-0.48	-6.88	-0.32	2.12e-11	Blood metabolite levels;
LUAD	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23583168	chr7:148888333	NA	-0.87	-17.43	-0.65	1.12e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg09796270	chr17:17721594	SREBF1	0.37	7.58	0.35	2.28e-13	Total body bone mineral density;
LUAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg15117754	chr3:10150083	C3orf24	0.4	6.66	0.31	8.79e-11	Alzheimer's disease;
LUAD	cis	rs2408955	0.522	rs973398	chr12:48491048	A/G	cg04545296	chr12:48745243	ZNF641	-0.33	-8.57	-0.38	1.93e-16	Glycated hemoglobin levels;
LUAD	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg05368731	chr17:41323189	NBR1	0.98	20.62	0.71	6.67e-66	Menopause (age at onset);
LUAD	cis	rs78487399	0.808	rs13405076	chr2:43735353	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-6.41	-0.3	3.97e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs1003719	0.788	rs3787782	chr21:38462909	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.33e-16	Eye color traits;
LUAD	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg12714757	chr17:73874637	TRIM47	-0.45	-6.73	-0.31	5.68e-11	Psoriasis;
LUAD	cis	rs12681287	0.547	rs6998303	chr8:87510185	T/C	cg27223183	chr8:87520930	FAM82B	-0.71	-10.12	-0.44	1.07e-21	Caudate activity during reward;
LUAD	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg03806693	chr22:41940476	POLR3H	0.73	9.76	0.43	1.93e-20	Vitiligo;
LUAD	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.69	12.57	0.52	5.2500000000000004e-31	Cognitive ability;
LUAD	cis	rs2067615	0.524	rs9804754	chr12:107083031	G/A	cg15890332	chr12:107067104	RFX4	0.41	8.71	0.39	6.83e-17	Heart rate;
LUAD	cis	rs1113500	0.787	rs4571989	chr1:108631344	G/A	cg06207961	chr1:108661230	NA	0.34	6.47	0.3	2.68e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg21605333	chr4:119757512	SEC24D	0.93	8.76	0.39	4.9e-17	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg03676636	chr4:99064102	C4orf37	0.28	7.25	0.33	2.03e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg26384229	chr12:38710491	ALG10B	0.52	8.63	0.39	1.21e-16	Heart rate;
LUAD	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg05182265	chr7:156933206	UBE3C	-0.8	-17.24	-0.64	8.1e-51	Body mass index;
LUAD	trans	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.45	0.34	5.13e-13	Resting heart rate;
LUAD	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg13319975	chr6:146136371	FBXO30	0.63	10.87	0.47	1.95e-24	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg20542592	chr8:11973495	FAM66D	-0.41	-6.53	-0.3	1.94e-10	Mood instability;
LUAD	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.52	-0.3	2e-10	Alzheimer's disease (late onset);
LUAD	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.77	-0.31	4.33e-11	Post bronchodilator FEV1;
LUAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg22764044	chr5:178986830	RUFY1	0.71	12.28	0.51	7.49e-30	Lung cancer;
LUAD	trans	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg18187862	chr3:45730750	SACM1L	0.49	7.75	0.35	6.89e-14	Primary sclerosing cholangitis;
LUAD	cis	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.39	-0.34	7.93e-13	Resting heart rate;
LUAD	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg00071950	chr4:10020882	SLC2A9	-0.59	-11.12	-0.48	2.28e-25	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg00717180	chr2:96193071	NA	-0.47	-8.82	-0.39	3.13e-17	Coronary artery disease;
LUAD	cis	rs7830933	0.780	rs1561105	chr8:23610799	T/G	cg04349084	chr8:23602677	NA	0.49	7.03	0.32	8.17e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
LUAD	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg22676075	chr6:135203613	NA	0.54	9.63	0.42	5.42e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg14345882	chr6:26364793	BTN3A2	0.64	6.44	0.3	3.28e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12210905	0.688	rs114188783	chr6:27449604	T/C	cg08851530	chr6:28072375	NA	1.03	7.92	0.36	2.19e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.58	-0.35	2.14e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-11.32	-0.48	3.95e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.49	7.02	0.32	8.73e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-7.54	-0.34	2.89e-13	Personality dimensions;
LUAD	cis	rs7072216	0.770	rs1737	chr10:100176366	T/C	cg26618903	chr10:100175079	PYROXD2	-0.34	-7.69	-0.35	1.03e-13	Metabolite levels;
LUAD	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg02782426	chr3:40428986	ENTPD3	0.35	7.52	0.34	3.39e-13	Renal cell carcinoma;
LUAD	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg14668632	chr7:2872130	GNA12	-0.7	-12.06	-0.51	5.25e-29	Height;
LUAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08677398	chr8:58056175	NA	0.48	6.77	0.31	4.3e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg22535103	chr8:58192502	C8orf71	-0.75	-10.6	-0.46	1.93e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg13073564	chr4:8508604	NA	-0.52	-9.68	-0.43	3.83e-20	Response to antineoplastic agents;
LUAD	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24531977	chr5:56204891	C5orf35	-0.79	-12.94	-0.53	1.61e-32	Initial pursuit acceleration;
LUAD	cis	rs10465746	0.570	rs6658559	chr1:84467412	A/G	cg10977910	chr1:84465055	TTLL7	0.47	7.18	0.33	3.21e-12	Obesity-related traits;
LUAD	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg06641503	chr3:48959341	ARIH2	-0.39	-7.56	-0.34	2.61e-13	Parkinson's disease;
LUAD	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg21862992	chr11:68658383	NA	0.53	9.68	0.43	3.83e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg12140854	chr5:148520817	ABLIM3	-0.69	-10.28	-0.45	2.82e-22	Breast cancer;
LUAD	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg15395560	chr15:45543142	SLC28A2	0.37	6.36	0.3	5.22e-10	Uric acid levels;
LUAD	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg14092988	chr3:52407081	DNAH1	0.33	6.55	0.3	1.71e-10	Bipolar disorder;
LUAD	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg14584255	chr6:163149320	PACRG;PARK2	-0.36	-7.1	-0.33	5.15e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs897984	0.645	rs58726213	chr16:31044683	A/G	cg02466173	chr16:30829666	NA	-0.56	-9.84	-0.43	1.01e-20	Dementia with Lewy bodies;
LUAD	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg05304507	chr6:116381966	FRK	0.2	6.87	0.32	2.35e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs752010	0.523	rs10890160	chr1:42120011	A/G	cg06885757	chr1:42089581	HIVEP3	0.45	9.95	0.44	4.25e-21	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs2279817	0.863	rs12749985	chr1:18026004	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.53	-8.93	-0.4	1.32e-17	Neuroticism;
LUAD	cis	rs7010267	0.583	rs1485302	chr8:119976144	A/G	cg01975934	chr8:119970761	NA	0.35	6.7	0.31	6.86e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs921968	0.565	rs7594046	chr2:219624170	A/G	cg02176678	chr2:219576539	TTLL4	0.57	11.36	0.48	2.78e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2795502	0.873	rs3121282	chr10:43423626	T/A	cg20628663	chr10:43360327	NA	0.65	10.54	0.46	3.16e-23	Blood protein levels;
LUAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg16606324	chr3:10149918	C3orf24	0.67	11.05	0.47	3.95e-25	Alzheimer's disease;
LUAD	cis	rs490234	0.841	rs950534	chr9:128225881	C/G	cg14078157	chr9:128172775	NA	-0.39	-7.16	-0.33	3.62e-12	Mean arterial pressure;
LUAD	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	6.36	0.3	5.33e-10	Lung cancer in ever smokers;
LUAD	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg04450456	chr4:17643702	FAM184B	0.42	8.33	0.38	1.11e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg15704280	chr7:45808275	SEPT13	-0.6	-8.19	-0.37	3.06e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs250585	0.920	rs250556	chr16:23446396	T/C	cg00143387	chr16:23521605	GGA2	0.62	7.56	0.34	2.61e-13	Egg allergy;
LUAD	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg06623918	chr6:96969491	KIAA0776	0.84	16.03	0.61	1.55e-45	Headache;
LUAD	cis	rs7771547	0.519	rs12202691	chr6:36377820	G/A	cg07856975	chr6:36356162	ETV7	0.53	7.95	0.36	1.76e-14	Platelet distribution width;
LUAD	cis	rs34734847	1.000	rs3021338	chr12:121162989	A/G	cg21892295	chr12:121157589	UNC119B	-0.45	-8.13	-0.37	4.9e-15	Mean corpuscular volume;
LUAD	cis	rs11971779	0.680	rs12154842	chr7:139078484	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.87	0.32	2.3e-11	Diisocyanate-induced asthma;
LUAD	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg22491629	chr6:157744540	C6orf35	-0.81	-9.21	-0.41	1.58e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.55	-0.34	2.79e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7246657	0.943	rs2279148	chr19:38024683	A/G	cg23950597	chr19:37808831	NA	-0.59	-7.34	-0.34	1.07e-12	Coronary artery calcification;
LUAD	trans	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg11693508	chr17:37793320	STARD3	0.82	10.6	0.46	1.87e-23	Bipolar disorder;
LUAD	cis	rs7737355	0.812	rs116825489	chr5:131061504	C/T	cg25547332	chr5:131281432	NA	0.43	6.99	0.32	1.08e-11	Life satisfaction;
LUAD	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg09796270	chr17:17721594	SREBF1	0.38	7.51	0.34	3.43e-13	Total body bone mineral density;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg07421368	chr2:67624930	ETAA1	0.42	6.48	0.3	2.61e-10	Monocyte percentage of white cells;
LUAD	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg12310025	chr6:25882481	NA	-0.46	-7.0	-0.32	1.02e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.36	-0.38	9.02e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg21862992	chr11:68658383	NA	0.52	9.43	0.42	2.75e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg20933634	chr6:27740509	NA	0.51	8.35	0.38	9.74e-16	Parkinson's disease;
LUAD	cis	rs62238980	0.614	rs117629537	chr22:32400579	C/T	cg00543991	chr22:32367038	NA	0.95	8.87	0.4	2.05e-17	Childhood ear infection;
LUAD	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.02	0.36	1.03e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg09455208	chr3:40491958	NA	-0.54	-12.13	-0.51	2.92e-29	Renal cell carcinoma;
LUAD	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg07741184	chr6:167504864	NA	-0.33	-7.86	-0.36	3.28e-14	Primary biliary cholangitis;
LUAD	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg05425664	chr17:57184151	TRIM37	0.43	7.7	0.35	9.53e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg22683308	chr4:1340831	KIAA1530	-0.45	-7.59	-0.35	2.11e-13	Longevity;
LUAD	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg24399712	chr22:39784796	NA	0.47	6.91	0.32	1.8e-11	IgG glycosylation;
LUAD	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg17724175	chr1:150552817	MCL1	0.38	8.76	0.39	4.72e-17	Melanoma;
LUAD	cis	rs12681287	0.640	rs7007855	chr8:87429491	T/G	cg27223183	chr8:87520930	FAM82B	0.67	9.58	0.42	8.35e-20	Caudate activity during reward;
LUAD	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.7	-12.92	-0.53	1.98e-32	Axial length;
LUAD	cis	rs2652834	0.904	rs2937859	chr15:63366282	C/T	cg25406657	chr15:63342033	TPM1	-0.43	-7.08	-0.33	5.95e-12	HDL cholesterol;
LUAD	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.75	-0.31	4.88e-11	Height;
LUAD	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg06740227	chr12:86229804	RASSF9	0.39	6.93	0.32	1.62e-11	Major depressive disorder;
LUAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22442454	chr1:209979470	IRF6	0.52	7.67	0.35	1.17e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs2860975	0.501	rs602941	chr10:96961184	G/A	cg10482532	chr10:96946522	NA	-0.35	-6.4	-0.3	4.12e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs4900538	0.819	rs72698595	chr14:102863099	G/A	cg18135206	chr14:102964638	TECPR2	-1.02	-21.23	-0.72	1.22e-68	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	trans	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg19894588	chr14:64061835	NA	0.52	8.09	0.37	6.54e-15	Glioblastoma;Glioma;
LUAD	cis	rs3849570	0.961	rs3772896	chr3:81751968	C/T	cg07356753	chr3:81810745	GBE1	-0.7	-12.3	-0.51	6.15e-30	Waist circumference;Body mass index;
LUAD	cis	rs34734847	0.842	rs556001	chr12:121152967	A/G	cg21892295	chr12:121157589	UNC119B	-0.37	-6.69	-0.31	7.31e-11	Mean corpuscular volume;
LUAD	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg14343924	chr8:8086146	FLJ10661	0.51	7.82	0.36	4.25e-14	Mood instability;
LUAD	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg26384229	chr12:38710491	ALG10B	-0.48	-7.85	-0.36	3.39e-14	Bladder cancer;
LUAD	cis	rs4819852	1.000	rs4819852	chr22:19988167	G/A	cg07821417	chr22:19972146	ARVCF	0.43	7.75	0.35	7.05e-14	Pulse pressure;
LUAD	cis	rs89107	0.550	rs11758454	chr6:118848799	A/C	cg21191810	chr6:118973309	C6orf204	0.39	7.07	0.33	6.46e-12	Cardiac structure and function;
LUAD	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg22920501	chr2:26401640	FAM59B	-0.72	-10.65	-0.46	1.31e-23	Gut microbiome composition (summer);
LUAD	trans	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg02030672	chr11:45687055	CHST1	0.39	6.73	0.31	5.64e-11	Obesity-related traits;
LUAD	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg26384229	chr12:38710491	ALG10B	0.51	8.04	0.36	8.78e-15	Bladder cancer;
LUAD	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg00999904	chr2:3704751	ALLC	-0.82	-12.55	-0.52	6.24e-31	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs1973993	0.903	rs2038646	chr1:96940371	C/G	cg10631902	chr5:14652156	NA	0.56	10.6	0.46	2.01e-23	Weight;
LUAD	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg11707310	chr1:2537719	MMEL1	-0.38	-8.06	-0.36	8.04e-15	Ulcerative colitis;
LUAD	cis	rs17401966	1.000	rs35766535	chr1:10284659	T/C	cg15208524	chr1:10270712	KIF1B	0.55	7.95	0.36	1.75e-14	Hepatocellular carcinoma;
LUAD	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg09365446	chr1:150670422	GOLPH3L	0.65	11.77	0.5	7.68e-28	Melanoma;
LUAD	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg06784218	chr1:46089804	CCDC17	-0.6	-13.37	-0.54	3.01e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-7.24	-0.33	2.19e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg10468373	chr11:64009913	FKBP2	-0.53	-6.88	-0.32	2.12e-11	Mean platelet volume;
LUAD	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.68	-0.58	1.03e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg23649088	chr2:200775458	C2orf69	-0.54	-7.02	-0.32	8.81e-12	Schizophrenia;
LUAD	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg02569458	chr12:86230093	RASSF9	0.43	7.89	0.36	2.54e-14	Major depressive disorder;
LUAD	cis	rs7731657	0.537	rs10053245	chr5:130353033	G/A	cg08523029	chr5:130500466	HINT1	-0.6	-7.73	-0.35	7.92e-14	Fasting plasma glucose;
LUAD	trans	rs1178968	0.901	rs6949855	chr7:72728130	A/G	cg15428835	chr7:75027521	TRIM73;TRIM74	0.5	6.44	0.3	3.21e-10	Triglyceride levels;
LUAD	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg04539111	chr16:67997858	SLC12A4	-0.55	-6.73	-0.31	5.63e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg00204512	chr16:28754710	NA	0.34	7.51	0.34	3.59e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7216064	0.684	rs62084675	chr17:66027025	A/G	cg08758996	chr17:66097529	LOC651250	-0.42	-6.93	-0.32	1.57e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg14416269	chr4:6271139	WFS1	0.59	10.95	0.47	9.39e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03041700	chr1:1407645	ATAD3B	-0.45	-6.91	-0.32	1.77e-11	Height;
LUAD	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.45	-0.52	1.54e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg15181151	chr6:150070149	PCMT1	0.41	8.22	0.37	2.6e-15	Lung cancer;
LUAD	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg26875233	chr11:93583750	C11orf90	-0.39	-8.85	-0.4	2.36e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg22508957	chr16:3507546	NAT15	-0.4	-6.61	-0.31	1.15e-10	Body mass index (adult);
LUAD	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.54	0.3	1.81e-10	Aortic root size;
LUAD	cis	rs8017423	0.647	rs12883000	chr14:90820557	G/A	cg14092571	chr14:90743983	NA	0.39	6.63	0.31	1.04e-10	Mortality in heart failure;
LUAD	cis	rs116248771	0.739	rs73156426	chr3:158346289	G/A	cg16708174	chr3:158430962	RARRES1	0.46	6.8	0.31	3.62e-11	diarrhoeal disease at age 2;
LUAD	cis	rs3736594	1.000	rs3792252	chr2:27995931	A/G	cg27432699	chr2:27873401	GPN1	0.41	6.58	0.3	1.39e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg27494647	chr7:150038898	RARRES2	0.48	8.51	0.38	3.08e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg19774624	chr17:42201019	HDAC5	0.39	6.7	0.31	6.71e-11	Total body bone mineral density;
LUAD	cis	rs4853036	1.000	rs62134006	chr2:70050641	T/C	cg02498382	chr2:70120550	SNRNP27	-0.51	-8.19	-0.37	3.11e-15	Colorectal or endometrial cancer;
LUAD	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg00495681	chr13:53174319	NA	0.49	8.83	0.39	2.91e-17	Lewy body disease;
LUAD	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg24531977	chr5:56204891	C5orf35	0.77	12.37	0.52	3.2e-30	Initial pursuit acceleration;
LUAD	cis	rs427394	0.632	rs377137	chr5:6740468	T/G	cg12316010	chr5:6737918	POLS	0.39	7.51	0.34	3.56e-13	Menopause (age at onset);
LUAD	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.82	-14.05	-0.56	4.36e-37	Platelet distribution width;
LUAD	cis	rs262150	0.659	rs73167293	chr7:158772638	C/T	cg19418458	chr7:158789849	NA	0.63	8.63	0.39	1.28e-16	Facial morphology (factor 20);
LUAD	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg07061783	chr6:25882402	NA	0.57	8.87	0.4	2.04e-17	Blood metabolite levels;
LUAD	cis	rs8099014	0.906	rs4940696	chr18:56106596	C/T	cg12907477	chr18:56117327	MIR122	-0.5	-8.25	-0.37	2.05e-15	Platelet count;
LUAD	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg05966235	chr16:28915196	ATP2A1	0.46	7.48	0.34	4.21e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg07636037	chr3:49044803	WDR6	0.64	12.54	0.52	7.09e-31	Parkinson's disease;
LUAD	cis	rs2455601	0.882	rs11042118	chr11:8928791	T/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-7.33	-0.34	1.17e-12	Schizophrenia;
LUAD	cis	rs1113500	0.933	rs4593854	chr1:108638519	A/G	cg06207961	chr1:108661230	NA	0.44	8.36	0.38	9.21e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg16606324	chr3:10149918	C3orf24	0.68	11.41	0.49	1.78e-26	Alzheimer's disease;
LUAD	cis	rs2479724	0.901	rs33954419	chr6:41786136	A/G	cg17623882	chr6:41773611	USP49	-0.69	-12.97	-0.53	1.32e-32	Menarche (age at onset);
LUAD	cis	rs11811982	0.793	rs114087988	chr1:227532395	T/C	cg24860534	chr1:227506868	CDC42BPA	0.71	7.52	0.34	3.35e-13	Optic disc area;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg04691540	chr1:179198414	ABL2	0.38	6.4	0.3	4.24e-10	Schizophrenia;
LUAD	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg17063962	chr7:91808500	NA	0.73	13.24	0.54	9.97e-34	Breast cancer;
LUAD	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg06784218	chr1:46089804	CCDC17	0.6	13.39	0.55	2.41e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2070677	0.736	rs4529856	chr10:135414020	C/G	cg20169779	chr10:135381914	SYCE1	-0.52	-6.84	-0.32	2.83e-11	Gout;
LUAD	cis	rs758324	0.812	rs494349	chr5:131260452	C/A	cg06307176	chr5:131281290	NA	-0.46	-7.64	-0.35	1.42e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.5	-0.42	1.56e-19	Life satisfaction;
LUAD	trans	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.67	-11.13	-0.48	2.15e-25	Mean corpuscular volume;
LUAD	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.29	0.54	6.06e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.19	-0.33	2.89e-12	Triglycerides;
LUAD	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	6.98	0.32	1.16e-11	Cognitive test performance;
LUAD	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg25767906	chr1:53392781	SCP2	-0.54	-10.07	-0.44	1.56e-21	Monocyte count;
LUAD	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg00431813	chr7:1051703	C7orf50	-0.52	-10.18	-0.44	6.21e-22	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg18180107	chr4:99064573	C4orf37	0.42	6.81	0.31	3.41e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-7.04	-0.32	7.76e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg06608945	chr2:219082296	ARPC2	-0.42	-6.82	-0.31	3.06e-11	Colorectal cancer;
LUAD	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg05616858	chr17:37843591	ERBB2;PGAP3	0.32	6.39	0.3	4.33e-10	Asthma;
LUAD	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg03806693	chr22:41940476	POLR3H	0.73	9.89	0.43	6.67e-21	Vitiligo;
LUAD	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg00310523	chr12:86230176	RASSF9	0.37	7.39	0.34	7.85e-13	Major depressive disorder;
LUAD	trans	rs629535	0.814	rs55873935	chr8:70081646	G/A	cg21567404	chr3:27674614	NA	-0.99	-17.93	-0.66	6.8e-54	Dupuytren's disease;
LUAD	cis	rs2839627	0.638	rs73366794	chr21:44269180	C/T	cg03543861	chr21:44258195	NA	0.62	7.73	0.35	7.73e-14	Information processing speed;
LUAD	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.15	0.33	3.89e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs754466	0.651	rs7895188	chr10:79623378	C/G	cg17075019	chr10:79541650	NA	0.84	17.52	0.65	4.41e-52	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.11	0.37	5.44e-15	Menopause (age at onset);
LUAD	cis	rs7843479	0.544	rs7839925	chr8:21792983	G/C	cg03445287	chr8:21823731	XPO7	-0.49	-9.26	-0.41	1.05e-18	Mean corpuscular volume;
LUAD	cis	rs7020830	0.898	rs7846747	chr9:37167539	A/C	cg14294708	chr9:37120828	ZCCHC7	0.88	18.13	0.66	8.72e-55	Schizophrenia;
LUAD	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg00310523	chr12:86230176	RASSF9	0.37	7.39	0.34	7.85e-13	Major depressive disorder;
LUAD	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg12311346	chr5:56204834	C5orf35	-0.84	-12.51	-0.52	8.85e-31	Initial pursuit acceleration;
LUAD	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg22117172	chr7:91764530	CYP51A1	-0.34	-7.43	-0.34	6.19e-13	Breast cancer;
LUAD	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg00898013	chr13:113819073	PROZ	-0.64	-11.56	-0.49	4.67e-27	Platelet distribution width;
LUAD	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26314531	chr2:26401878	FAM59B	0.71	9.04	0.4	5.87e-18	Gut microbiome composition (summer);
LUAD	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg22875332	chr1:76189707	ACADM	0.86	15.32	0.6	1.82e-42	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs11098699	0.821	rs6811630	chr4:124222254	G/A	cg09941581	chr4:124220074	SPATA5	0.49	7.97	0.36	1.52e-14	Mosquito bite size;
LUAD	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg03037974	chr15:76606532	NA	0.47	10.87	0.47	1.98e-24	Blood metabolite levels;
LUAD	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg25237894	chr2:233734115	C2orf82	-0.61	-11.43	-0.49	1.48e-26	Coronary artery disease;
LUAD	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg06671706	chr8:8559999	CLDN23	0.67	11.78	0.5	6.82e-28	Obesity-related traits;
LUAD	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg14343924	chr8:8086146	FLJ10661	0.55	8.57	0.38	1.89e-16	Neuroticism;
LUAD	cis	rs1983170	0.736	rs11589162	chr1:91974743	C/G	cg02896835	chr1:92012615	NA	0.59	7.95	0.36	1.75e-14	Eosinophil percentage of white cells;
LUAD	trans	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg26043149	chr18:55253948	FECH	-0.52	-8.35	-0.38	9.8e-16	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg26043149	chr18:55253948	FECH	0.5	8.14	0.37	4.32e-15	Bone mineral density;
LUAD	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18099408	chr3:52552593	STAB1	0.44	7.79	0.35	5.11e-14	Bipolar disorder;
LUAD	trans	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.87	-0.36	3.1e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.57	0.52	5.38e-31	Tonsillectomy;
LUAD	cis	rs2455601	0.638	rs2568092	chr11:8987438	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.48	7.57	0.35	2.39e-13	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg18180107	chr4:99064573	C4orf37	-0.42	-6.74	-0.31	5.22e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg12454169	chr2:30669597	LCLAT1	0.64	8.21	0.37	2.73e-15	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg01689657	chr7:91764605	CYP51A1	-0.35	-8.67	-0.39	9.13e-17	Breast cancer;
LUAD	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1003719	0.715	rs6579	chr21:38568308	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.19	-0.37	3.12e-15	Eye color traits;
LUAD	cis	rs7177699	0.526	rs7165042	chr15:79123338	C/G	cg00540400	chr15:79124168	NA	0.44	9.73	0.43	2.48e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	trans	rs75804782	0.572	rs112551758	chr2:239299770	A/G	cg01134436	chr17:81009848	B3GNTL1	0.77	6.84	0.32	2.75e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs116095464	1.000	rs6879758	chr5:350277	G/C	cg22857025	chr5:266934	NA	-1.04	-8.7	-0.39	7.58e-17	Breast cancer;
LUAD	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg18252515	chr7:66147081	NA	-0.63	-6.89	-0.32	2.01e-11	Diabetic kidney disease;
LUAD	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg16205897	chr5:131564050	P4HA2	0.31	6.73	0.31	5.54e-11	Acylcarnitine levels;
LUAD	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08859206	chr1:53392774	SCP2	-0.71	-13.47	-0.55	1.17e-34	Monocyte count;
LUAD	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg23978390	chr7:1156363	C7orf50	0.53	8.63	0.39	1.27e-16	Longevity;Endometriosis;
LUAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg04025307	chr7:1156635	C7orf50	0.6	6.81	0.31	3.43e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00586367	chr8:74790437	UBE2W	-0.43	-6.88	-0.32	2.12e-11	Height;
LUAD	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg24450063	chr1:156163899	SLC25A44	1.18	27.58	0.8	1.52e-96	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.58	0.3	1.42e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17433780	0.964	rs10493821	chr1:89475135	C/T	cg09516651	chr1:89888402	LOC400759	0.52	9.31	0.41	7.11e-19	Carotid intima media thickness;
LUAD	trans	rs853679	0.607	rs35072899	chr6:28281541	C/T	cg01620082	chr3:125678407	NA	-1.1	-10.51	-0.46	4.29e-23	Depression;
LUAD	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg06740227	chr12:86229804	RASSF9	0.45	7.91	0.36	2.31e-14	Major depressive disorder;
LUAD	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg08645402	chr16:4508243	NA	-0.6	-11.64	-0.49	2.35e-27	Schizophrenia;
LUAD	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg03676636	chr4:99064102	C4orf37	0.26	6.49	0.3	2.46e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22655038	chr22:31477112	SMTN	-0.4	-6.36	-0.3	5.33e-10	Monocyte percentage of white cells;
LUAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	8.91	0.4	1.51e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2979489	0.891	rs2915624	chr8:30381245	T/C	cg26383811	chr8:30366931	RBPMS	-0.69	-10.45	-0.45	6.98e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg18944383	chr4:111397179	ENPEP	0.38	7.66	0.35	1.24e-13	Height;
LUAD	cis	rs6066825	0.605	rs761274	chr20:47315362	T/C	cg18078177	chr20:47281410	PREX1	0.4	6.61	0.31	1.14e-10	Colorectal cancer;
LUAD	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg18190219	chr22:46762943	CELSR1	-0.5	-6.45	-0.3	3.12e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.38	7.12	0.33	4.64e-12	Depressive symptoms;
LUAD	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg16325326	chr1:53192061	ZYG11B	0.68	13.29	0.54	6.04e-34	Monocyte count;
LUAD	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.49	7.77	0.35	6.06e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs117623576	0.680	rs740859	chr10:32361839	G/A	cg03047570	chr10:32398778	NA	-0.69	-7.9	-0.36	2.51e-14	Anti-saccade response;
LUAD	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	trans	rs7944735	0.567	rs7946766	chr11:48004369	C/T	cg15704280	chr7:45808275	SEPT13	0.61	6.66	0.31	8.62e-11	Intraocular pressure;
LUAD	trans	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.26	-0.37	1.93e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg07362569	chr17:61921086	SMARCD2	0.39	6.72	0.31	6.06e-11	Prudent dietary pattern;
LUAD	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg25767906	chr1:53392781	SCP2	-0.5	-9.46	-0.42	2.11e-19	Monocyte count;
LUAD	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg02375832	chr11:62437615	C11orf48	-0.36	-7.08	-0.33	6.04e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.68	-10.76	-0.46	4.81e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs701145	0.730	rs2666192	chr3:154004009	T/C	cg17054900	chr3:154042577	DHX36	0.64	7.08	0.33	6.18e-12	Coronary artery disease;
LUAD	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.84	0.43	1.07e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7408868	0.908	rs10416865	chr19:15277601	T/C	cg14696996	chr19:15285081	NOTCH3	0.82	10.59	0.46	2.07e-23	Pulse pressure;
LUAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg11965913	chr1:205819406	PM20D1	0.47	7.47	0.34	4.76e-13	Parkinson's disease;
LUAD	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg21204522	chr6:27730016	NA	-0.43	-6.89	-0.32	2.08e-11	Parkinson's disease;
LUAD	cis	rs2227564	0.649	rs2243610	chr10:75601653	A/T	cg00564723	chr10:75632066	CAMK2G	-0.31	-6.67	-0.31	7.9e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg26668828	chr6:292823	DUSP22	-0.57	-9.67	-0.43	4.04e-20	Menopause (age at onset);
LUAD	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.41	6.83	0.31	3.05e-11	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.33	0.41	5.85e-19	Alzheimer's disease;
LUAD	cis	rs11048434	0.736	rs1476911	chr12:9090859	C/T	cg23795048	chr12:9217529	LOC144571	0.43	7.85	0.36	3.51e-14	Sjögren's syndrome;
LUAD	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg13319975	chr6:146136371	FBXO30	-0.58	-9.67	-0.43	3.99e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10100465	0.961	rs1396354	chr8:118632412	A/G	cg09430518	chr8:118662568	NA	-0.34	-6.78	-0.31	3.93e-11	Leprosy;
LUAD	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg06108461	chr20:60628389	TAF4	-1.12	-20.36	-0.7	9.93e-65	Body mass index;
LUAD	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg03806693	chr22:41940476	POLR3H	-0.62	-9.22	-0.41	1.43e-18	Vitiligo;
LUAD	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg20500540	chr8:101228448	SPAG1	-0.35	-6.43	-0.3	3.52e-10	Atrioventricular conduction;
LUAD	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.21	0.33	2.67e-12	Motion sickness;
LUAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14893161	chr1:205819251	PM20D1	0.94	22.51	0.74	2.44e-74	Menarche (age at onset);
LUAD	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg23283495	chr1:209979779	IRF6	0.71	10.24	0.45	3.87e-22	Cleft lip with or without cleft palate;
LUAD	trans	rs587242	0.557	rs66945820	chr1:97180860	C/G	cg10631902	chr5:14652156	NA	0.38	6.38	0.3	4.63e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.54	-0.34	2.81e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs61332075	0.501	rs55706928	chr2:239445806	T/C	cg01134436	chr17:81009848	B3GNTL1	0.79	8.62	0.39	1.32e-16	Lung function (FEV1/FVC);
LUAD	trans	rs4650994	0.593	rs2811297	chr1:178551472	C/T	cg05059571	chr16:84539110	KIAA1609	0.42	6.42	0.3	3.63e-10	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg02551604	chr5:131831745	NA	-0.61	-10.08	-0.44	1.46e-21	Asthma (sex interaction);
LUAD	cis	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg01251360	chr16:68772225	CDH1	-0.3	-9.26	-0.41	1.01e-18	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.63	0.31	1.02e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg19773385	chr1:10388646	KIF1B	-0.41	-6.78	-0.31	4.13e-11	Hepatocellular carcinoma;
LUAD	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg11166453	chr1:247681781	NA	0.38	7.25	0.33	1.96e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg03433033	chr1:76189801	ACADM	0.81	14.56	0.58	3.21e-39	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2485376	1.000	rs2479548	chr10:104057688	G/T	cg20641465	chr10:103991465	PITX3	-0.58	-10.7	-0.46	8.17e-24	QT interval;
LUAD	cis	rs17095355	0.818	rs7071509	chr10:111775849	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.43	-0.34	6.26e-13	Biliary atresia;
LUAD	cis	rs59104589	0.550	rs12612038	chr2:242369685	A/G	cg08645257	chr2:242211290	HDLBP	0.44	7.02	0.32	8.92e-12	Fibrinogen levels;
LUAD	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg03806693	chr22:41940476	POLR3H	-0.5	-7.42	-0.34	6.45e-13	Vitiligo;
LUAD	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg00106254	chr7:1943704	MAD1L1	-0.59	-8.77	-0.39	4.47e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg04369109	chr6:150039330	LATS1	-0.42	-7.08	-0.33	6.16e-12	Lung cancer;
LUAD	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.12	0.33	4.59e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1816752	0.935	rs4770676	chr13:25003883	A/G	cg02811702	chr13:24901961	NA	0.44	7.17	0.33	3.38e-12	Obesity-related traits;
LUAD	trans	rs10483853	0.887	rs2269967	chr14:73738042	A/G	cg02580604	chr1:63250136	ATG4C	0.52	6.64	0.31	9.51e-11	Coronary artery calcification;
LUAD	cis	rs76878669	0.561	rs12420203	chr11:66163794	T/C	cg18002602	chr11:66138449	SLC29A2	0.48	10.35	0.45	1.6400000000000001e-22	Educational attainment (years of education);
LUAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg04025307	chr7:1156635	C7orf50	0.67	8.37	0.38	8.69e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg21659725	chr3:3221576	CRBN	0.4	6.71	0.31	6.19e-11	Resting heart rate;
LUAD	trans	rs5760842	0.538	rs1076047	chr22:25495049	T/C	cg16733866	chr21:42792609	MX1	0.66	9.15	0.41	2.45e-18	Recurrent major depressive disorder;
LUAD	cis	rs17608059	0.710	rs8080167	chr17:13949828	G/A	cg11395062	chr17:14139857	CDRT15	0.45	7.29	0.33	1.52e-12	Temperament;
LUAD	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.7	-13.39	-0.55	2.4e-34	Ulcerative colitis;
LUAD	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08704250	chr15:31115839	NA	-0.55	-9.88	-0.43	7.65e-21	Huntington's disease progression;
LUAD	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg03340356	chr1:67600835	NA	0.41	7.44	0.34	5.6e-13	Psoriasis;
LUAD	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg18811423	chr2:55921094	PNPT1	0.55	9.43	0.42	2.63e-19	Metabolic syndrome;
LUAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg13047869	chr3:10149882	C3orf24	0.66	11.13	0.48	2.15e-25	Alzheimer's disease;
LUAD	cis	rs4730250	0.707	rs257385	chr7:106807448	T/C	cg23024343	chr7:107201750	COG5	0.51	6.81	0.31	3.38e-11	Osteoarthritis;
LUAD	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06873352	chr17:61820015	STRADA	0.55	8.92	0.4	1.43e-17	Height;
LUAD	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg19163074	chr7:65112434	INTS4L2	0.45	6.83	0.32	3e-11	Aortic root size;
LUAD	trans	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg01620082	chr3:125678407	NA	-0.54	-7.08	-0.33	6.23e-12	Depression;
LUAD	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21659725	chr3:3221576	CRBN	-0.63	-10.07	-0.44	1.6e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2230307	0.572	rs621212	chr1:100559281	T/C	cg20868668	chr1:100435035	SLC35A3	0.49	7.33	0.34	1.2e-12	Carotid intima media thickness;
LUAD	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg24768116	chr2:27665128	KRTCAP3	0.26	6.42	0.3	3.73e-10	Oral cavity cancer;
LUAD	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg24399712	chr22:39784796	NA	-0.81	-15.42	-0.6	6.78e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg18132916	chr6:79620363	NA	-0.46	-8.0	-0.36	1.22e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg22117172	chr7:91764530	CYP51A1	0.31	6.7	0.31	6.75e-11	Breast cancer;
LUAD	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg03806693	chr22:41940476	POLR3H	0.74	10.02	0.44	2.42e-21	Vitiligo;
LUAD	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg02428538	chr16:24856791	SLC5A11	0.5	6.93	0.32	1.61e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs977987	0.872	rs4887825	chr16:75472422	C/A	cg03315344	chr16:75512273	CHST6	0.65	14.21	0.57	9.86e-38	Dupuytren's disease;
LUAD	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg07741184	chr6:167504864	NA	0.29	7.0	0.32	9.82e-12	Crohn's disease;
LUAD	cis	rs12545109	0.800	rs2609978	chr8:57394467	T/C	cg17761419	chr8:57350749	NA	-0.57	-8.19	-0.37	3.03e-15	Obesity-related traits;
LUAD	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg01689657	chr7:91764605	CYP51A1	0.32	8.1	0.37	5.96e-15	Breast cancer;
LUAD	cis	rs3813948	0.908	rs12057769	chr1:207279481	G/A	cg11153969	chr1:207277031	C4BPA	-0.64	-6.86	-0.32	2.46e-11	C4b binding protein levels;
LUAD	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg00277334	chr10:82204260	NA	-0.56	-9.26	-0.41	1.04e-18	Post bronchodilator FEV1;
LUAD	cis	rs62400317	0.762	rs11961316	chr6:45029598	T/C	cg18551225	chr6:44695536	NA	-0.55	-8.05	-0.36	8.7e-15	Total body bone mineral density;
LUAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08280861	chr8:58055591	NA	0.54	6.91	0.32	1.79e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7843479	0.965	rs13269198	chr8:21823025	G/A	cg10047019	chr8:21822950	XPO7	-0.37	-6.38	-0.3	4.55e-10	Mean corpuscular volume;
LUAD	cis	rs9462027	0.628	rs9462030	chr6:34831280	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-8.89	-0.4	1.75e-17	Systemic lupus erythematosus;
LUAD	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg13798912	chr7:905769	UNC84A	-0.62	-7.18	-0.33	3.22e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg05340658	chr4:99064831	C4orf37	0.55	9.46	0.42	2.24e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg08807101	chr21:30365312	RNF160	0.43	6.43	0.3	3.39e-10	Selective IgA deficiency;
LUAD	cis	rs28374715	0.783	rs11635269	chr15:41570710	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-21.25	-0.72	1.02e-68	Ulcerative colitis;
LUAD	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs4664308	1.000	rs62175515	chr2:160909524	A/T	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.75	-0.31	4.93e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs35740288	0.770	rs62022867	chr15:86173281	A/G	cg13263323	chr15:86062960	AKAP13	-0.45	-7.25	-0.33	2.05e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg12927641	chr6:109611667	NA	-0.5	-8.79	-0.39	3.94e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg05082376	chr22:42548792	NA	0.45	7.85	0.36	3.38e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs447921	1.000	rs447921	chr17:74414559	T/C	cg17201438	chr17:74438067	UBE2O	-0.53	-7.49	-0.34	3.98e-13	Mitochondrial DNA levels;
LUAD	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg18132916	chr6:79620363	NA	-0.44	-7.64	-0.35	1.47e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg06484146	chr7:12443880	VWDE	-0.6	-7.62	-0.35	1.64e-13	Coronary artery disease;
LUAD	cis	rs6665290	0.904	rs1045287	chr1:227178962	C/T	cg10327440	chr1:227177885	CDC42BPA	1.2	39.95	0.89	1.2e-145	Myeloid white cell count;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg11761572	chr19:39390455	SIRT2;NFKBIB	0.39	6.39	0.3	4.36e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9399401	0.961	rs2050157	chr6:142658162	C/T	cg03128060	chr6:142623767	GPR126	0.3	6.54	0.3	1.76e-10	Chronic obstructive pulmonary disease;
LUAD	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg20476274	chr7:133979776	SLC35B4	0.84	17.14	0.64	2.19e-50	Mean platelet volume;
LUAD	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.11	-24.32	-0.76	2.23e-82	Ulcerative colitis;
LUAD	cis	rs13315871	1.000	rs13320620	chr3:58408845	A/G	cg20936604	chr3:58311152	NA	-0.69	-7.24	-0.33	2.16e-12	Cholesterol, total;
LUAD	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg26924012	chr15:45694286	SPATA5L1	1.02	19.06	0.68	6.2e-59	Homoarginine levels;
LUAD	cis	rs68170813	0.641	rs79328953	chr7:106901557	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.53	-0.46	3.47e-23	Coronary artery disease;
LUAD	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg15017067	chr4:17643749	FAM184B	0.34	6.44	0.3	3.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs7127307	0.740	rs4144896	chr11:128182026	C/T	cg25263898	chr1:36774223	C1orf113	0.49	6.41	0.3	3.97e-10	Atopic dermatitis;
LUAD	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg02527881	chr3:46936655	PTH1R	0.52	10.26	0.45	3.38e-22	Colorectal cancer;
LUAD	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg05535760	chr7:792225	HEATR2	-0.82	-9.53	-0.42	1.24e-19	Cerebrospinal P-tau181p levels;
LUAD	cis	rs113835537	0.529	rs10896125	chr11:66288733	G/C	cg24851651	chr11:66362959	CCS	0.57	10.17	0.44	6.88e-22	Airway imaging phenotypes;
LUAD	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg11859384	chr17:80120422	CCDC57	0.51	9.2	0.41	1.59e-18	Life satisfaction;
LUAD	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg15691649	chr6:25882328	NA	-0.49	-7.09	-0.33	5.66e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs17401966	0.838	rs34636442	chr1:10427459	T/G	cg19773385	chr1:10388646	KIF1B	-0.4	-6.47	-0.3	2.64e-10	Hepatocellular carcinoma;
LUAD	cis	rs713587	0.525	rs11687089	chr2:25082926	T/C	cg04586622	chr2:25135609	ADCY3	0.37	8.36	0.38	9.04e-16	Body mass index in non-asthmatics;
LUAD	cis	rs863345	0.604	rs10908673	chr1:158503908	T/G	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg11822812	chr5:140052017	DND1	-0.44	-7.91	-0.36	2.34e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.36	0.34	9.89e-13	Menopause (age at onset);
LUAD	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg10596483	chr8:143751796	JRK	-0.44	-7.18	-0.33	3.07e-12	Schizophrenia;
LUAD	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.41	6.76	0.31	4.56e-11	Platelet count;
LUAD	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.07	0.37	7.12e-15	Menopause (age at onset);
LUAD	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg07507251	chr3:52567010	NT5DC2	0.37	7.13	0.33	4.26e-12	Bipolar disorder;
LUAD	cis	rs11048434	0.736	rs11048345	chr12:9123056	T/G	cg13575925	chr12:9217583	LOC144571	0.36	6.73	0.31	5.68e-11	Sjögren's syndrome;
LUAD	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1403694	1.000	rs2689197	chr3:186438346	C/T	cg12454167	chr3:186435060	KNG1	0.43	8.78	0.39	3.99e-17	Blood protein levels;
LUAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg03354898	chr7:1950403	MAD1L1	0.35	6.7	0.31	6.82e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg08558340	chr7:100472263	SRRT	0.51	6.39	0.3	4.37e-10	Resting heart rate;
LUAD	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg12573674	chr2:1569213	NA	-0.61	-7.2	-0.33	2.74e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg13565492	chr6:43139072	SRF	-0.68	-9.55	-0.42	1.05e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg27572855	chr1:25598939	RHD	0.53	11.36	0.48	2.78e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg15017067	chr4:17643749	FAM184B	0.34	6.77	0.31	4.23e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg02753203	chr1:228287806	NA	0.56	10.35	0.45	1.53e-22	Diastolic blood pressure;
LUAD	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.6	0.39	1.53e-16	Menarche (age at onset);
LUAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08677398	chr8:58056175	NA	0.48	6.85	0.32	2.64e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.37	-7.27	-0.33	1.76e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg13870426	chr17:30244630	NA	-0.57	-6.63	-0.31	1.05e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	7.93	0.36	1.92e-14	Menopause (age at onset);
LUAD	cis	rs116248771	0.739	rs73156478	chr3:158398716	C/T	cg16708174	chr3:158430962	RARRES1	0.47	6.78	0.31	4.16e-11	diarrhoeal disease at age 2;
LUAD	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.54	0.3	1.74e-10	Platelet count;
LUAD	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg26587870	chr6:27730563	NA	-0.48	-7.98	-0.36	1.39e-14	Parkinson's disease;
LUAD	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg01475377	chr6:109611718	NA	-0.52	-9.98	-0.44	3.39e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg07212818	chr11:638076	DRD4	-0.45	-6.74	-0.31	5.18e-11	Systemic lupus erythematosus;
LUAD	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg22868518	chr11:507468	RNH1	-0.67	-6.6	-0.31	1.26e-10	Body mass index;
LUAD	cis	rs11958404	0.932	rs72816598	chr5:157436017	G/A	cg05962755	chr5:157440814	NA	0.54	8.12	0.37	5.05e-15	IgG glycosylation;
LUAD	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg24130564	chr14:104152367	KLC1	-0.55	-9.73	-0.43	2.56e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg21699342	chr2:239360505	ASB1	0.51	9.08	0.4	4.16e-18	Multiple system atrophy;
LUAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.61	-0.31	1.16e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg14820908	chr5:178986412	RUFY1	0.54	9.15	0.41	2.37e-18	Lung cancer;
LUAD	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06022373	chr22:39101656	GTPBP1	-0.4	-6.97	-0.32	1.24e-11	Menopause (age at onset);
LUAD	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.45	0.3	2.98e-10	Depression;
LUAD	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3784262	0.669	rs4646595	chr15:58302341	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-7.17	-0.33	3.37e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs17135859	1.000	rs2416324	chr5:113009791	G/A	cg12552261	chr5:112820674	MCC	0.5	6.75	0.31	4.87e-11	F-cell distribution;
LUAD	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.1	0.37	6.12e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg02527881	chr3:46936655	PTH1R	-0.49	-9.61	-0.42	6.78e-20	Colorectal cancer;
LUAD	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg07217954	chr7:1067459	C7orf50	-0.43	-7.34	-0.34	1.12e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg01097406	chr16:89675127	NA	-0.33	-6.67	-0.31	7.88e-11	Vitiligo;
LUAD	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg11494091	chr17:61959527	GH2	0.42	8.05	0.36	8.22e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg07343612	chr16:622815	PIGQ	-0.83	-16.45	-0.62	2.37e-47	Height;
LUAD	cis	rs1032833	0.732	rs17363246	chr2:179983495	A/G	cg23883738	chr2:179974586	SESTD1	-0.7	-7.82	-0.36	4.34e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs225245	0.782	rs321599	chr17:33905745	C/T	cg05299278	chr17:33885742	SLFN14	0.52	11.91	0.5	2.13e-28	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg03233332	chr7:66118400	NA	-0.44	-6.69	-0.31	6.95e-11	Aortic root size;
LUAD	cis	rs526821	0.595	rs629948	chr11:55356448	G/A	cg04317927	chr11:55418816	OR4S2	0.39	7.51	0.34	3.52e-13	Pediatric bone mineral density (spine);
LUAD	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-12.3	-0.51	5.98e-30	Breast cancer;
LUAD	cis	rs7500321	1.000	rs7500321	chr16:28977020	G/A	cg05966235	chr16:28915196	ATP2A1	-0.5	-7.44	-0.34	5.53e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2030114	0.531	rs2173454	chr16:51598869	A/G	cg03758633	chr16:51611768	NA	-0.31	-6.36	-0.3	5.2400000000000005e-10	Blood pressure measurement (high sodium and potassium intervention);
LUAD	trans	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-10.75	-0.46	5.6e-24	Exhaled nitric oxide output;
LUAD	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg25324976	chr17:61989376	CSHL1	0.38	7.26	0.33	1.86e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs62400317	0.826	rs11970412	chr6:45037516	C/T	cg20913747	chr6:44695427	NA	-0.42	-6.64	-0.31	9.85e-11	Total body bone mineral density;
LUAD	cis	rs11048434	0.761	rs10842660	chr12:9138897	G/A	cg23795048	chr12:9217529	LOC144571	0.43	7.92	0.36	2.14e-14	Sjögren's syndrome;
LUAD	cis	rs35883536	1.000	rs11583008	chr1:101085094	A/G	cg06223162	chr1:101003688	GPR88	0.35	6.38	0.3	4.67e-10	Monocyte count;
LUAD	cis	rs6906287	0.573	rs12198461	chr6:118880640	T/G	cg18833306	chr6:118973337	C6orf204	0.5	8.85	0.4	2.44e-17	Electrocardiographic conduction measures;
LUAD	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg07636037	chr3:49044803	WDR6	0.53	10.07	0.44	1.62e-21	Menarche (age at onset);
LUAD	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25427524	chr10:38739819	LOC399744	-0.68	-12.93	-0.53	1.88e-32	Extrinsic epigenetic age acceleration;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04071446	chr10:115933849	C10orf118	0.46	6.89	0.32	2.02e-11	Monocyte percentage of white cells;
LUAD	cis	rs921968	0.565	rs2037622	chr2:219609440	T/C	cg02176678	chr2:219576539	TTLL4	-0.59	-12.08	-0.51	4.49e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9560113	0.597	rs1163644	chr13:112241223	C/T	cg10483660	chr13:112241077	NA	-0.48	-10.14	-0.44	9.28e-22	Menarche (age at onset);
LUAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.49	6.89	0.32	2.08e-11	Renal function-related traits (BUN);
LUAD	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg04414720	chr1:150670196	GOLPH3L	0.72	12.77	0.53	7.99e-32	Melanoma;
LUAD	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02788857	chr8:22132959	PIWIL2	0.54	9.98	0.44	3.45e-21	Hypertriglyceridemia;
LUAD	cis	rs4901869	0.902	rs10149194	chr14:59308198	A/G	cg02291164	chr14:59296302	NA	-0.63	-15.97	-0.61	3e-45	Panic disorder;
LUAD	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-6.72	-0.31	5.73e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg03289416	chr15:75166202	SCAMP2	0.44	7.3	0.33	1.44e-12	Caffeine consumption;
LUAD	cis	rs798766	0.830	rs8389	chr4:1746844	A/T	cg05874882	chr4:1763078	NA	-0.35	-6.41	-0.3	3.79e-10	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs7192380	0.893	rs12924052	chr16:69777246	T/C	cg26679644	chr16:69762563	NA	-0.51	-9.71	-0.43	3e-20	Sjögren's syndrome;
LUAD	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.55e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg01849466	chr14:104193079	ZFYVE21	0.5	8.2	0.37	2.82e-15	Body mass index;
LUAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.19	0.54	1.67e-33	Prudent dietary pattern;
LUAD	cis	rs59698941	0.943	rs67437142	chr5:132306722	T/C	cg14825688	chr5:132208181	LEAP2	-0.48	-6.51	-0.3	2.09e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs7737355	0.947	rs6864145	chr5:130637861	C/T	cg06307176	chr5:131281290	NA	0.46	7.32	0.34	1.25e-12	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	8.98	0.4	9e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9462027	1.000	rs9296133	chr6:34777533	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.3	-6.85	-0.32	2.68e-11	Systemic lupus erythematosus;
LUAD	cis	rs6547631	0.628	rs2886768	chr2:85927555	A/C	cg21473183	chr2:85925749	GNLY	0.33	6.95	0.32	1.37e-11	Blood protein levels;
LUAD	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg15691649	chr6:25882328	NA	-0.45	-7.12	-0.33	4.59e-12	Blood metabolite levels;
LUAD	cis	rs12545109	0.571	rs1370306	chr8:57299137	C/G	cg07776626	chr8:57350775	NA	-0.64	-8.86	-0.4	2.29e-17	Obesity-related traits;
LUAD	cis	rs939658	0.805	rs8035606	chr15:79420245	C/T	cg17916960	chr15:79447300	NA	-0.52	-11.08	-0.47	3.18e-25	Refractive error;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg23864632	chr19:47220401	PRKD2	-0.62	-6.39	-0.3	4.41e-10	Type 2 diabetes;
LUAD	cis	rs2735413	0.918	rs4887932	chr16:78078350	C/A	cg04733911	chr16:78082701	NA	-0.35	-8.3	-0.37	1.46e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs807669	0.934	rs1780643	chr22:19191725	T/C	cg24911827	chr22:19170109	CLTCL1	0.43	8.87	0.4	2.14e-17	Metabolite levels;
LUAD	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg11344533	chr11:111475393	SIK2	-0.36	-6.69	-0.31	7.26e-11	Primary sclerosing cholangitis;
LUAD	cis	rs2735413	0.918	rs2344494	chr16:78078111	C/T	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg16325326	chr1:53192061	ZYG11B	0.51	8.6	0.39	1.58e-16	Monocyte count;
LUAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg10802521	chr3:52805072	NEK4	-0.45	-7.66	-0.35	1.27e-13	Electroencephalogram traits;
LUAD	cis	rs2573652	1.000	rs2727195	chr15:100513117	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.41	-7.34	-0.34	1.12e-12	Height;
LUAD	cis	rs9902453	0.833	rs7216631	chr17:28495112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.95	0.44	4.39e-21	Coffee consumption (cups per day);
LUAD	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg03030879	chr14:75389066	RPS6KL1	-0.47	-8.41	-0.38	6.28e-16	Caffeine consumption;
LUAD	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg20469991	chr17:27169893	C17orf63	-0.53	-6.67	-0.31	8e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg26597838	chr10:835615	NA	1.3	20.16	0.7	7.85e-64	Eosinophil percentage of granulocytes;
LUAD	cis	rs11098699	0.784	rs11737129	chr4:124243421	A/T	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg09509183	chr1:209979624	IRF6	-0.45	-8.46	-0.38	4.54e-16	Monobrow;
LUAD	cis	rs35771425	0.600	rs1020336	chr1:211661016	C/T	cg10512769	chr1:211675356	NA	-0.39	-7.14	-0.33	4.22e-12	Educational attainment (years of education);
LUAD	cis	rs10193935	0.901	rs6724626	chr2:42689757	C/G	cg27598129	chr2:42591480	NA	0.73	8.97	0.4	9.9e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13082711	0.911	rs11719386	chr3:27505636	G/C	cg02860705	chr3:27208620	NA	0.61	9.24	0.41	1.25e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs427941	0.703	rs1734879	chr7:101740610	C/A	cg06246474	chr7:101738831	CUX1	0.42	7.32	0.34	1.25e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg03806693	chr22:41940476	POLR3H	0.76	10.14	0.44	9.01e-22	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg18404041	chr3:52824283	ITIH1	0.4	7.23	0.33	2.33e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg24644049	chr4:85504048	CDS1	0.89	7.33	0.34	1.17e-12	Skin colour saturation;
LUAD	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg08645402	chr16:4508243	NA	0.58	10.8	0.46	3.48e-24	Schizophrenia;
LUAD	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg22875332	chr1:76189707	ACADM	-0.43	-6.37	-0.3	5.08e-10	Daytime sleep phenotypes;
LUAD	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg01689657	chr7:91764605	CYP51A1	0.33	8.3	0.37	1.44e-15	Breast cancer;
LUAD	cis	rs1371614	0.589	rs3739086	chr2:27165202	T/C	cg00617064	chr2:27272375	NA	0.36	6.85	0.32	2.6e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs12681287	0.752	rs10112123	chr8:87302328	T/C	cg27223183	chr8:87520930	FAM82B	-0.6	-8.26	-0.37	1.95e-15	Caudate activity during reward;
LUAD	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg19875535	chr5:140030758	IK	-0.48	-8.07	-0.37	7.54e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4713675	0.584	rs6917140	chr6:33678394	C/G	cg13859433	chr6:33739653	LEMD2	-0.3	-7.11	-0.33	5.14e-12	Plateletcrit;
LUAD	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg21984481	chr17:79567631	NPLOC4	-0.55	-11.63	-0.49	2.6e-27	Eye color traits;
LUAD	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg02782426	chr3:40428986	ENTPD3	0.42	9.43	0.42	2.71e-19	Renal cell carcinoma;
LUAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.41	-6.43	-0.3	3.55e-10	Longevity;Endometriosis;
LUAD	cis	rs1232027	0.656	rs836795	chr5:80012071	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.45	-7.13	-0.33	4.43e-12	Huntington's disease progression;
LUAD	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg13770153	chr20:60521292	NA	-0.46	-7.62	-0.35	1.69e-13	Body mass index;
LUAD	cis	rs17152411	1.000	rs733402	chr10:126594152	T/C	cg07906193	chr10:126599966	NA	0.53	7.6	0.35	1.95e-13	Height;
LUAD	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg06074448	chr4:187884817	NA	-0.39	-7.83	-0.36	4.06e-14	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs758324	0.891	rs652839	chr5:131281106	G/C	cg25547332	chr5:131281432	NA	-0.42	-6.4	-0.3	4.15e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg13685833	chr1:53393034	SCP2	0.48	7.36	0.34	9.7e-13	Monocyte count;
LUAD	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg19773385	chr1:10388646	KIF1B	-0.42	-6.91	-0.32	1.81e-11	Hepatocellular carcinoma;
LUAD	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg08027265	chr7:2291960	NA	-0.41	-7.2	-0.33	2.81e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.81	0.31	3.29e-11	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.27e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22496380	chr5:211416	CCDC127	0.91	12.75	0.53	1e-31	Breast cancer;
LUAD	cis	rs4713118	0.506	rs9366697	chr6:27633018	T/C	cg20933634	chr6:27740509	NA	0.38	6.45	0.3	2.97e-10	Parkinson's disease;
LUAD	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg08029281	chr1:67600428	NA	0.35	6.66	0.31	8.38e-11	Psoriasis;
LUAD	trans	rs994533	0.928	rs7594625	chr2:218293564	A/C	cg15065069	chr1:154974120	ZBTB7B	0.41	6.67	0.31	8.05e-11	Height;
LUAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg07806771	chr7:64541737	NA	-0.52	-8.34	-0.38	1.03e-15	Calcium levels;
LUAD	cis	rs4268898	0.552	rs11125444	chr2:24367205	G/T	cg06627628	chr2:24431161	ITSN2	0.43	7.45	0.34	5.26e-13	Asthma;
LUAD	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg23018236	chr17:30244563	NA	-0.57	-6.38	-0.3	4.74e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs28493229	0.748	rs10426415	chr19:41183590	A/G	cg21869046	chr19:41225005	ITPKC	0.54	8.6	0.39	1.61e-16	Kawasaki disease;
LUAD	cis	rs7107174	1.000	rs10899476	chr11:78051794	A/G	cg19901956	chr11:77921274	USP35	-0.51	-6.62	-0.31	1.06e-10	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg21724239	chr8:58056113	NA	0.68	8.77	0.39	4.56e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg05991184	chr2:219186017	PNKD	-0.38	-7.5	-0.34	3.77e-13	Colorectal cancer;
LUAD	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg17173187	chr15:85201210	NMB	-0.41	-6.6	-0.31	1.24e-10	Schizophrenia;
LUAD	cis	rs758324	0.812	rs13170176	chr5:131138736	G/C	cg06307176	chr5:131281290	NA	0.46	7.49	0.34	4.01e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4273100	0.646	rs6587216	chr17:19224397	G/C	cg03910582	chr17:19030146	GRAPL	-0.54	-8.0	-0.36	1.18e-14	Schizophrenia;
LUAD	cis	rs2281845	0.507	rs12025414	chr1:201100496	A/G	cg06714761	chr1:201096289	NA	0.33	7.26	0.33	1.87e-12	Permanent tooth development;
LUAD	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.55	-0.34	2.69e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg14396892	chr9:96623032	NA	-0.44	-8.5	-0.38	3.34e-16	DNA methylation (variation);
LUAD	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg23649088	chr2:200775458	C2orf69	-0.6	-8.43	-0.38	5.34e-16	Schizophrenia;
LUAD	cis	rs3862260	1.000	rs3862260	chr1:120160789	G/A	cg11530693	chr1:120165357	ZNF697	0.68	13.29	0.54	6.06e-34	Systemic lupus erythematosus;
LUAD	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs6840360	0.550	rs6836343	chr4:152497564	A/G	cg22705602	chr4:152727874	NA	-0.37	-6.64	-0.31	9.65e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg07936489	chr17:37558343	FBXL20	0.5	6.79	0.31	3.74e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg21733973	chr7:65235735	NA	0.47	7.71	0.35	9.35e-14	Calcium levels;
LUAD	cis	rs3916	0.794	rs3021337	chr12:121163261	C/T	cg21892295	chr12:121157589	UNC119B	-0.41	-7.01	-0.32	9.4e-12	Urinary metabolites (H-NMR features);
LUAD	trans	rs11165623	0.564	rs11165658	chr1:96985670	A/G	cg10631902	chr5:14652156	NA	-0.42	-7.8	-0.35	4.79e-14	Hip circumference;Waist circumference;
LUAD	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg11645453	chr3:52864694	ITIH4	-0.38	-7.61	-0.35	1.78e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg22875332	chr1:76189707	ACADM	0.76	12.28	0.51	7.38e-30	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg15556689	chr8:8085844	FLJ10661	0.41	6.79	0.31	3.77e-11	Mood instability;
LUAD	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg16479474	chr6:28041457	NA	0.4	7.04	0.32	7.57e-12	Parkinson's disease;
LUAD	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg10909506	chr17:38081995	ORMDL3	0.36	6.72	0.31	6.03e-11	Self-reported allergy;
LUAD	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-15.95	-0.61	3.48e-45	Chronic sinus infection;
LUAD	cis	rs9487051	0.738	rs171272	chr6:109530094	T/C	cg21918786	chr6:109611834	NA	-0.42	-7.33	-0.34	1.21e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.15	0.33	3.89e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg09365446	chr1:150670422	GOLPH3L	0.61	10.76	0.46	4.85e-24	Melanoma;
LUAD	trans	rs10838798	0.563	rs11039516	chr11:48124157	T/A	cg15704280	chr7:45808275	SEPT13	-0.49	-7.77	-0.35	6.11e-14	Height;
LUAD	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg00071950	chr4:10020882	SLC2A9	0.74	14.93	0.59	8.69e-41	Bone mineral density;
LUAD	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg18404041	chr3:52824283	ITIH1	-0.67	-14.41	-0.57	1.41e-38	Bipolar disorder;
LUAD	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg18230493	chr5:56204884	C5orf35	-0.85	-12.54	-0.52	6.65e-31	Initial pursuit acceleration;
LUAD	cis	rs2795502	0.938	rs3121281	chr10:43400753	A/G	cg27426351	chr10:43362370	NA	0.53	8.57	0.38	1.98e-16	Blood protein levels;
LUAD	cis	rs727505	1.000	rs55964341	chr7:124517280	A/G	cg23710748	chr7:124431027	NA	-0.47	-9.56	-0.42	9.77e-20	Lewy body disease;
LUAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs595982	0.510	rs3826817	chr19:49401444	C/T	cg21252483	chr19:49399788	TULP2	-0.49	-9.2	-0.41	1.63e-18	Red cell distribution width;
LUAD	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06544989	chr22:39130855	UNC84B	0.43	8.03	0.36	9.95e-15	Menopause (age at onset);
LUAD	cis	rs1003719	0.612	rs2835652	chr21:38557408	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.22	-0.37	2.56e-15	Eye color traits;
LUAD	cis	rs68170813	0.559	rs76167266	chr7:106900664	C/T	cg02696742	chr7:106810147	HBP1	-0.77	-10.56	-0.46	2.74e-23	Coronary artery disease;
LUAD	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg04414720	chr1:150670196	GOLPH3L	0.72	13.36	0.54	3.28e-34	Tonsillectomy;
LUAD	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg05044414	chr3:183734942	ABCC5	0.46	9.59	0.42	7.73e-20	Anterior chamber depth;
LUAD	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg15335139	chr3:50242325	SLC38A3	-0.38	-6.65	-0.31	8.84e-11	Menarche (age at onset);
LUAD	trans	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg11693508	chr17:37793320	STARD3	0.5	7.34	0.34	1.08e-12	Neuroticism;
LUAD	cis	rs11048434	0.698	rs10842537	chr12:9066158	T/C	cg13575925	chr12:9217583	LOC144571	0.37	6.7	0.31	6.68e-11	Sjögren's syndrome;
LUAD	cis	rs17095355	0.818	rs57239324	chr10:111770871	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.58	-6.71	-0.31	6.09e-11	Biliary atresia;
LUAD	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg25208724	chr1:156163844	SLC25A44	1.16	26.27	0.79	6.83e-91	Testicular germ cell tumor;
LUAD	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.58	-0.3	1.38e-10	Bladder cancer;
LUAD	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg03433033	chr1:76189801	ACADM	-0.69	-10.84	-0.47	2.59e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7593730	0.945	rs6706545	chr2:161181478	T/A	cg22609984	chr2:161126801	NA	0.45	7.31	0.34	1.32e-12	Type 2 diabetes;
LUAD	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-7.12	-0.33	4.68e-12	Type 2 diabetes;
LUAD	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg00802000	chr16:706648	WDR90	-0.37	-6.94	-0.32	1.45e-11	Height;
LUAD	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.54	0.49	5.92e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg19336497	chr11:14380999	RRAS2	-0.66	-14.2	-0.57	1.05e-37	Sense of smell;
LUAD	cis	rs1483890	0.723	rs1843046	chr3:69410614	C/A	cg22125112	chr3:69402811	FRMD4B	0.46	7.66	0.35	1.26e-13	Resting heart rate;
LUAD	cis	rs7705042	0.865	rs2043280	chr5:141513691	C/G	cg23435118	chr5:141488016	NDFIP1	0.38	6.45	0.3	3.04e-10	Asthma;
LUAD	cis	rs2286503	0.780	rs2240727	chr7:22852512	C/T	cg06496272	chr7:22895283	SNORD93	-0.37	-6.42	-0.3	3.72e-10	Fibrinogen;
LUAD	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg14019695	chr9:139328340	INPP5E	0.4	6.57	0.3	1.47e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg07549590	chr16:15018862	NA	-0.41	-7.77	-0.35	5.91e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg21548813	chr6:291882	DUSP22	-0.52	-8.57	-0.38	1.94e-16	Menopause (age at onset);
LUAD	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg27170947	chr2:26402098	FAM59B	-0.63	-8.85	-0.4	2.47e-17	Gut microbiome composition (summer);
LUAD	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg08893839	chr5:154027129	NA	0.56	7.4	0.34	7.48e-13	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.29	-0.33	1.49e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg08078137	chr12:19593453	AEBP2	-0.41	-7.95	-0.36	1.72e-14	Schizophrenia;
LUAD	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg01579765	chr21:45077557	HSF2BP	-0.63	-15.3	-0.6	2.26e-42	Mean corpuscular volume;
LUAD	cis	rs921968	0.565	rs35189512	chr2:219628759	T/C	cg02176678	chr2:219576539	TTLL4	-0.58	-11.44	-0.49	1.32e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg10589385	chr1:150898437	SETDB1	0.41	7.74	0.35	7.43e-14	Melanoma;
LUAD	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg05368731	chr17:41323189	NBR1	0.95	19.81	0.69	2.86e-62	Menopause (age at onset);
LUAD	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg14324370	chr2:177042789	NA	0.4	7.31	0.33	1.36e-12	IgG glycosylation;
LUAD	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.39	6.7	0.31	6.7e-11	Body mass index (adult);
LUAD	cis	rs7072216	0.763	rs12763326	chr10:100167396	A/G	cg26618903	chr10:100175079	PYROXD2	0.35	7.64	0.35	1.44e-13	Metabolite levels;
LUAD	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg13010199	chr12:38710504	ALG10B	-0.39	-6.58	-0.3	1.43e-10	Bladder cancer;
LUAD	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg13402656	chr8:1511478	DLGAP2	-0.69	-13.92	-0.56	1.57e-36	Lung cancer;
LUAD	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg25985355	chr7:65971099	NA	-0.55	-6.82	-0.31	3.17e-11	Diabetic kidney disease;
LUAD	cis	rs2282300	0.956	rs594937	chr11:30390132	A/G	cg25418670	chr11:30344373	C11orf46	0.48	6.54	0.3	1.77e-10	Morning vs. evening chronotype;
LUAD	cis	rs2996428	0.561	rs72640913	chr1:3747023	C/G	cg17848003	chr1:3704513	LRRC47	0.48	9.76	0.43	2.01e-20	Red cell distribution width;
LUAD	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.47	-8.23	-0.37	2.41e-15	Age at first birth;
LUAD	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg02375832	chr11:62437615	C11orf48	0.32	6.68	0.31	7.73e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12893597	1.000	rs12893597	chr14:76812695	C/T	cg20290672	chr14:76816747	NA	-0.41	-6.59	-0.31	1.33e-10	Maximal oxygen uptake response;
LUAD	cis	rs17095355	1.000	rs7921609	chr10:111691599	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.78	-11.03	-0.47	4.85e-25	Biliary atresia;
LUAD	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg11814155	chr7:99998594	ZCWPW1	0.43	7.32	0.34	1.26e-12	Platelet count;
LUAD	cis	rs938554	0.542	rs7678287	chr4:10000501	A/G	cg00071950	chr4:10020882	SLC2A9	0.61	9.48	0.42	1.89e-19	Blood metabolite levels;
LUAD	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg23229984	chr5:148520753	ABLIM3	-0.44	-6.66	-0.31	8.79e-11	Breast cancer;
LUAD	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg18827107	chr12:86230957	RASSF9	-0.69	-12.77	-0.53	8.28e-32	Major depressive disorder;
LUAD	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg20129853	chr10:51489980	NA	0.35	6.88	0.32	2.14e-11	Prostate-specific antigen levels;
LUAD	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg06671706	chr8:8559999	CLDN23	0.65	11.33	0.48	3.77e-26	Obesity-related traits;
LUAD	cis	rs250585	1.000	rs4968011	chr16:23500558	C/T	cg00143387	chr16:23521605	GGA2	0.66	7.84	0.36	3.76e-14	Egg allergy;
LUAD	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg03467027	chr4:99064603	C4orf37	0.39	6.43	0.3	3.37e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.81	0.53	5.73e-32	Cognitive ability;
LUAD	cis	rs6489785	0.522	rs2701177	chr12:121344490	G/T	cg02419362	chr12:121203948	SPPL3	-0.34	-6.83	-0.32	3.01e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg18252515	chr7:66147081	NA	-0.61	-6.67	-0.31	8.16e-11	Diabetic kidney disease;
LUAD	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg10978503	chr1:24200527	CNR2	-0.48	-9.89	-0.43	6.99e-21	Immature fraction of reticulocytes;
LUAD	trans	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.26	-0.37	1.93e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg19729930	chr2:74357872	NA	1.02	18.69	0.67	2.82e-57	Gestational age at birth (maternal effect);
LUAD	cis	rs4072705	1.000	rs7874367	chr9:127377780	A/T	cg01786973	chr9:127249749	NR5A1	-0.29	-6.4	-0.3	4.1e-10	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22496380	chr5:211416	CCDC127	-0.93	-13.14	-0.54	2.51e-33	Breast cancer;
LUAD	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg21862992	chr11:68658383	NA	0.53	9.62	0.42	6.08e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg27170947	chr2:26402098	FAM59B	0.82	11.43	0.49	1.49e-26	Gut microbiome composition (summer);
LUAD	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg09455208	chr3:40491958	NA	0.55	12.2	0.51	1.47e-29	Renal cell carcinoma;
LUAD	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.64	-0.31	9.56e-11	Triglycerides;
LUAD	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg00071950	chr4:10020882	SLC2A9	0.73	14.7	0.58	8.26e-40	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2742234	0.541	rs12220534	chr10:43734306	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.49	-8.94	-0.4	1.25e-17	Hirschsprung disease;
LUAD	trans	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg26043149	chr18:55253948	FECH	0.42	6.96	0.32	1.34e-11	Bone mineral density;
LUAD	cis	rs1595825	0.891	rs7595819	chr2:198543156	A/C	cg10547527	chr2:198650123	BOLL	0.48	6.84	0.32	2.86e-11	Ulcerative colitis;
LUAD	cis	rs470119	1.000	rs470119	chr22:50966914	C/T	cg12969734	chr22:50962224	SCO2	-0.4	-7.46	-0.34	4.91e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg23625390	chr15:77176239	SCAPER	-0.58	-9.18	-0.41	1.91e-18	Blood metabolite levels;
LUAD	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg05991184	chr2:219186017	PNKD	0.37	7.14	0.33	4.21e-12	Colorectal cancer;
LUAD	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-12.86	-0.53	3.46e-32	Bone mineral density;
LUAD	cis	rs743757	1.000	rs6446206	chr3:50455470	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.43	6.62	0.31	1.08e-10	Diastolic blood pressure;
LUAD	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.6	-0.35	1.89e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg13319975	chr6:146136371	FBXO30	-0.61	-10.29	-0.45	2.66e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg11915388	chr22:42470451	FAM109B	-0.39	-6.93	-0.32	1.57e-11	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg16205897	chr5:131564050	P4HA2	-0.36	-7.7	-0.35	1e-13	Acylcarnitine levels;
LUAD	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg18016565	chr1:150552671	MCL1	-0.41	-7.48	-0.34	4.42e-13	Tonsillectomy;
LUAD	cis	rs68170813	0.559	rs1548523	chr7:106944408	G/A	cg23024343	chr7:107201750	COG5	0.49	7.05	0.32	7.57e-12	Coronary artery disease;
LUAD	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.61	0.31	1.15e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-9.02	-0.4	6.79e-18	Lymphocyte counts;
LUAD	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-8.1	-0.37	5.87e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26314531	chr2:26401878	FAM59B	-0.55	-7.66	-0.35	1.3e-13	Gut microbiome composition (summer);
LUAD	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg02891314	chr5:179741120	GFPT2	-0.7	-11.29	-0.48	5.2e-26	Height;
LUAD	cis	rs367615	0.959	rs17161951	chr5:108930590	A/G	cg17395555	chr5:108820864	NA	-0.45	-7.81	-0.35	4.56e-14	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg16262614	chr3:133464971	TF	0.34	6.39	0.3	4.43e-10	Iron status biomarkers;
LUAD	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg06740227	chr12:86229804	RASSF9	0.4	7.01	0.32	9.27e-12	Major depressive disorder;
LUAD	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg09537434	chr19:41945824	ATP5SL	-0.5	-7.93	-0.36	1.92e-14	Height;
LUAD	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg11189052	chr15:85197271	WDR73	0.59	7.61	0.35	1.84e-13	Schizophrenia;
LUAD	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2274273	0.638	rs9919921	chr14:55695505	A/G	cg04306507	chr14:55594613	LGALS3	0.43	8.06	0.36	7.9e-15	Protein biomarker;
LUAD	cis	rs6684514	1.000	rs3806409	chr1:156252291	A/G	cg16558208	chr1:156270281	VHLL	0.53	9.58	0.42	8.12e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs6993813	0.814	rs4577982	chr8:120029337	A/G	cg01975934	chr8:119970761	NA	-0.37	-7.35	-0.34	1.06e-12	Bone mineral density (hip);
LUAD	cis	rs7771547	0.607	rs632943	chr6:36469121	A/G	cg07856975	chr6:36356162	ETV7	0.43	6.62	0.31	1.12e-10	Platelet distribution width;
LUAD	cis	rs11048434	0.661	rs34791180	chr12:9110919	T/C	cg04155231	chr12:9217510	LOC144571	0.39	7.3	0.33	1.47e-12	Sjögren's syndrome;
LUAD	trans	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg03929089	chr4:120376271	NA	0.57	6.56	0.3	1.54e-10	Intraocular pressure;
LUAD	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg01802117	chr1:53393560	SCP2	0.33	6.47	0.3	2.68e-10	Monocyte count;
LUAD	cis	rs62064224	0.638	rs9748130	chr17:30739113	A/G	cg25809561	chr17:30822961	MYO1D	0.46	8.45	0.38	4.68e-16	Schizophrenia;
LUAD	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg22823121	chr1:150693482	HORMAD1	0.44	8.91	0.4	1.55e-17	Tonsillectomy;
LUAD	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg10589385	chr1:150898437	SETDB1	0.45	8.36	0.38	8.84e-16	Melanoma;
LUAD	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg00666640	chr1:248458726	OR2T12	0.29	6.79	0.31	3.81e-11	Common traits (Other);
LUAD	cis	rs12541635	0.966	rs7819043	chr8:106989783	T/C	cg10147462	chr8:107024639	NA	0.5	9.02	0.4	6.47e-18	Age of smoking initiation;
LUAD	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg27432699	chr2:27873401	GPN1	-0.67	-11.88	-0.5	2.67e-28	Oral cavity cancer;
LUAD	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.22	0.41	1.4e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910873	0.505	rs7261964	chr20:33205011	C/T	cg16810054	chr20:33298113	TP53INP2	-0.55	-7.98	-0.36	1.36e-14	Melanoma;
LUAD	cis	rs17818399	0.926	rs7590693	chr2:46823992	G/A	cg09399716	chr2:46890238	NA	-0.43	-8.44	-0.38	5.14e-16	Height;
LUAD	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg02466173	chr16:30829666	NA	-0.65	-11.41	-0.49	1.8e-26	Multiple myeloma;
LUAD	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg17372223	chr3:52568218	NT5DC2	0.34	6.55	0.3	1.69e-10	Bipolar disorder;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg17759082	chr3:122920507	SEC22A	-0.41	-6.89	-0.32	2.02e-11	Subcortical brain region volumes;
LUAD	cis	rs7246865	0.954	rs3745348	chr19:17212410	C/T	cg19418318	chr19:17219073	MYO9B	0.47	8.15	0.37	4.12e-15	Reticulocyte fraction of red cells;
LUAD	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg23587288	chr2:27483067	SLC30A3	-0.39	-6.82	-0.31	3.21e-11	Blood metabolite levels;
LUAD	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-12.85	-0.53	3.85e-32	Mean corpuscular volume;
LUAD	cis	rs34638657	0.827	rs3829548	chr16:82206238	C/A	cg09439754	chr16:82129088	HSD17B2	-0.31	-6.38	-0.3	4.56e-10	Lung adenocarcinoma;
LUAD	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.91	-0.4	1.51e-17	Total body bone mineral density;
LUAD	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg06484146	chr7:12443880	VWDE	-0.5	-7.13	-0.33	4.38e-12	Coronary artery disease;
LUAD	cis	rs710865	0.627	rs10799710	chr1:19483209	A/G	cg13387374	chr1:19411106	UBR4	0.49	8.61	0.39	1.47e-16	Brain structure;
LUAD	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg12034118	chr1:209979487	IRF6	0.55	6.5	0.3	2.24e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs7474896	0.559	rs1208779	chr10:38077729	A/C	cg25427524	chr10:38739819	LOC399744	-0.61	-8.71	-0.39	6.7e-17	Obesity (extreme);
LUAD	cis	rs244899	0.935	rs2432645	chr5:167936423	A/G	cg06604206	chr5:167912465	RARS	-0.41	-7.03	-0.32	8.52e-12	Response to platinum-based chemotherapy (carboplatin);
LUAD	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.37	-7.88	-0.36	2.87e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg10518543	chr12:38710700	ALG10B	-0.43	-7.12	-0.33	4.78e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg06641503	chr3:48959341	ARIH2	-0.4	-7.94	-0.36	1.89e-14	Menarche (age at onset);
LUAD	cis	rs68170813	0.652	rs11532774	chr7:107201579	T/C	cg02696742	chr7:106810147	HBP1	-0.76	-8.93	-0.4	1.3e-17	Coronary artery disease;
LUAD	cis	rs68170813	0.599	rs12532514	chr7:107000952	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.08	-0.44	1.42e-21	Coronary artery disease;
LUAD	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg25237894	chr2:233734115	C2orf82	0.62	11.89	0.5	2.48e-28	Coronary artery disease;
LUAD	cis	rs1816752	0.905	rs4770666	chr13:24989029	T/C	cg02811702	chr13:24901961	NA	0.41	7.07	0.32	6.63e-12	Obesity-related traits;
LUAD	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg05535760	chr7:792225	HEATR2	1.0	12.77	0.53	8.49e-32	Cerebrospinal P-tau181p levels;
LUAD	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg17724175	chr1:150552817	MCL1	0.39	9.35	0.41	5.26e-19	Tonsillectomy;
LUAD	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg02160872	chr5:212506	CCDC127	-0.5	-6.44	-0.3	3.21e-10	Breast cancer;
LUAD	cis	rs4664308	1.000	rs17341301	chr2:160902420	G/A	cg03641300	chr2:160917029	PLA2R1	-0.38	-6.59	-0.31	1.28e-10	Idiopathic membranous nephropathy;
LUAD	cis	rs2992756	0.663	rs2992732	chr1:18802825	G/A	cg24076588	chr1:18808559	KLHDC7A	-0.45	-7.37	-0.34	9e-13	Breast cancer;
LUAD	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg02002194	chr4:3960332	NA	-0.27	-6.52	-0.3	2.02e-10	Retinal vascular caliber;
LUAD	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg24578937	chr1:2090814	PRKCZ	-0.55	-10.97	-0.47	8.01e-25	Height;
LUAD	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18876405	chr7:65276391	NA	0.43	6.74	0.31	5.36e-11	Aortic root size;
LUAD	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg04414720	chr1:150670196	GOLPH3L	0.62	10.81	0.47	3.17e-24	Tonsillectomy;
LUAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-9.67	-0.43	4.19e-20	Lymphocyte counts;
LUAD	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg04586622	chr2:25135609	ADCY3	0.37	8.33	0.38	1.13e-15	Body mass index;
LUAD	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg01579765	chr21:45077557	HSF2BP	0.59	13.23	0.54	1.16e-33	Mean corpuscular volume;
LUAD	trans	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg01620082	chr3:125678407	NA	-0.44	-6.7	-0.31	6.82e-11	Parkinson's disease;
LUAD	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg15226275	chr6:116381976	FRK	0.23	7.46	0.34	4.89e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg03806693	chr22:41940476	POLR3H	0.68	9.99	0.44	2.99e-21	Vitiligo;
LUAD	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg25019722	chr6:37503610	NA	-0.3	-6.7	-0.31	6.72e-11	Cognitive performance;
LUAD	cis	rs7264396	0.563	rs2425114	chr20:34322346	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2e-15	Total cholesterol levels;
LUAD	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg19622623	chr12:86230825	RASSF9	0.42	7.49	0.34	3.93e-13	Major depressive disorder;
LUAD	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg15083037	chr5:83017644	HAPLN1	-0.43	-7.51	-0.34	3.44e-13	Prostate cancer;
LUAD	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg07404485	chr7:94953653	PON1	-0.49	-7.11	-0.33	5.11e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.08	-0.4	4.31e-18	Total body bone mineral density;
LUAD	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg04414720	chr1:150670196	GOLPH3L	0.67	11.79	0.5	6.3e-28	Melanoma;
LUAD	cis	rs7943203	0.962	rs11212636	chr11:108311965	G/A	cg04873221	chr11:107992290	ACAT1	-0.42	-6.71	-0.31	6.29e-11	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs68170813	0.559	rs58319984	chr7:106965794	G/A	cg23024343	chr7:107201750	COG5	0.45	6.45	0.3	3.02e-10	Coronary artery disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01668174	chr2:106810661	UXS1	-0.45	-7.12	-0.33	4.52e-12	Height;
LUAD	trans	rs12200782	1.000	rs6456741	chr6:26617058	C/T	cg08851530	chr6:28072375	NA	0.72	6.59	0.31	1.33e-10	Small cell lung carcinoma;
LUAD	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.16	-0.33	3.68e-12	Breast cancer;
LUAD	cis	rs7072216	0.763	rs2274243	chr10:100175267	T/C	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.7	-0.39	7.57e-17	Metabolite levels;
LUAD	cis	rs6942407	0.546	rs2108271	chr7:86805372	G/A	cg02420886	chr7:86849541	C7orf23	0.61	7.06	0.32	6.67e-12	Food allergy;
LUAD	cis	rs2996428	0.667	rs2368534	chr1:3740640	C/T	cg17848003	chr1:3704513	LRRC47	0.53	10.3	0.45	2.35e-22	Red cell distribution width;
LUAD	cis	rs11048434	0.736	rs2377673	chr12:9112551	A/G	cg23795048	chr12:9217529	LOC144571	0.42	7.77	0.35	5.88e-14	Sjögren's syndrome;
LUAD	cis	rs12505328	0.514	rs2119789	chr4:174383330	T/G	cg12145043	chr4:174357286	NA	0.42	6.65	0.31	9.17e-11	Chin dimples;
LUAD	cis	rs57920188	0.640	rs10915600	chr1:4082105	T/G	cg10510935	chr1:4059661	NA	0.48	7.2	0.33	2.75e-12	Interleukin-17 levels;
LUAD	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg07741184	chr6:167504864	NA	0.35	8.14	0.37	4.46e-15	Primary biliary cholangitis;
LUAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg12034118	chr1:209979487	IRF6	0.46	6.55	0.3	1.67e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg00321850	chr1:175162397	KIAA0040	-0.54	-11.42	-0.49	1.62e-26	Alcohol dependence;
LUAD	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg12454169	chr2:30669597	LCLAT1	0.57	7.77	0.35	6.12e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs758324	0.812	rs1875176	chr5:131202457	A/G	cg06307176	chr5:131281290	NA	-0.44	-7.41	-0.34	6.91e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg05966235	chr16:28915196	ATP2A1	0.46	7.44	0.34	5.86e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1448094	0.617	rs2221319	chr12:86468064	C/A	cg18827107	chr12:86230957	RASSF9	0.49	8.59	0.39	1.64e-16	Major depressive disorder;
LUAD	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg18944383	chr4:111397179	ENPEP	0.41	8.2	0.37	2.89e-15	Height;
LUAD	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg04414720	chr1:150670196	GOLPH3L	0.72	13.39	0.55	2.58e-34	Tonsillectomy;
LUAD	cis	rs4889911	0.544	rs2650254	chr17:77833655	A/G	cg01306824	chr17:77834118	NA	0.43	6.38	0.3	4.61e-10	Electroencephalogram traits;
LUAD	cis	rs2625529	0.775	rs35673773	chr15:72399886	C/A	cg16672083	chr15:72433130	SENP8	-0.74	-12.57	-0.52	5.03e-31	Red blood cell count;
LUAD	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.6	-0.42	7.19e-20	Life satisfaction;
LUAD	trans	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04565464	chr8:145669602	NFKBIL2	0.43	6.43	0.3	3.53e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs12540874	0.542	rs4947582	chr7:50566090	C/T	cg18232548	chr7:50535776	DDC	-0.64	-11.85	-0.5	3.53e-28	Systemic sclerosis;
LUAD	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg00933542	chr6:150070202	PCMT1	0.45	9.43	0.42	2.76e-19	Lung cancer;
LUAD	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg18490616	chr2:88469792	THNSL2	0.79	8.32	0.37	1.24e-15	Plasma clusterin levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24487784	chr11:696252	TMEM80;DEAF1	-0.46	-7.1	-0.33	5.33e-12	Height;
LUAD	cis	rs9581857	0.547	rs9581870	chr13:28083957	T/G	cg22138327	chr13:27999177	GTF3A	0.86	9.54	0.42	1.18e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg11887960	chr12:57824829	NA	0.56	7.09	0.33	5.82e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs9902453	1.000	rs12600855	chr17:28279591	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.87	0.4	2.04e-17	Coffee consumption (cups per day);
LUAD	cis	rs859767	0.501	rs12691869	chr2:135407641	T/C	cg12500956	chr2:135428796	TMEM163	-0.28	-7.3	-0.33	1.44e-12	Neuroticism;
LUAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg02951883	chr7:2050386	MAD1L1	-0.78	-13.02	-0.53	7.81e-33	Bipolar disorder and schizophrenia;
LUAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg26354017	chr1:205819088	PM20D1	0.92	22.29	0.73	2.25e-73	Menarche (age at onset);
LUAD	cis	rs11676348	0.808	rs1008563	chr2:219026888	G/A	cg06547715	chr2:218990976	CXCR2	0.3	6.9	0.32	1.92e-11	Ulcerative colitis;
LUAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.56	0.3	1.61e-10	Prudent dietary pattern;
LUAD	cis	rs899997	0.773	rs12595461	chr15:78969172	T/G	cg04896959	chr15:78267971	NA	-0.59	-9.02	-0.4	6.8e-18	Coronary artery disease or large artery stroke;
LUAD	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg09835421	chr16:68378352	PRMT7	-0.91	-9.74	-0.43	2.41e-20	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.59	-0.52	4.41e-31	Monocyte count;
LUAD	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg01579765	chr21:45077557	HSF2BP	-0.64	-14.83	-0.58	2.27e-40	Mean corpuscular volume;
LUAD	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg19678392	chr7:94953810	PON1	-0.6	-8.25	-0.37	1.96e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg21028142	chr17:79581711	NPLOC4	0.38	7.69	0.35	1.04e-13	Eye color traits;
LUAD	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18876405	chr7:65276391	NA	0.41	6.39	0.3	4.42e-10	Aortic root size;
LUAD	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg00769240	chr8:12517080	NA	-0.39	-6.53	-0.3	1.87e-10	Blood pressure (smoking interaction);
LUAD	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.04	0.32	7.98e-12	Hypertriglyceridemia;
LUAD	cis	rs941898	0.836	rs8016001	chr14:100598691	A/G	cg26002632	chr14:100625216	DEGS2	-0.38	-7.3	-0.33	1.47e-12	White matter hyperintensity burden;
LUAD	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg03806693	chr22:41940476	POLR3H	-0.45	-6.55	-0.3	1.68e-10	Vitiligo;
LUAD	cis	rs3820068	0.705	rs16851731	chr1:15860240	A/G	cg13390004	chr1:15929781	NA	0.42	6.82	0.31	3.13e-11	Systolic blood pressure;
LUAD	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.33	7.0	0.32	1.01e-11	Depression;
LUAD	cis	rs7487075	0.619	rs7134289	chr12:46838336	G/A	cg23829395	chr12:46796953	NA	0.31	6.89	0.32	1.97e-11	Itch intensity from mosquito bite;
LUAD	cis	rs9972944	0.756	rs2873818	chr17:63762867	A/T	cg07283582	chr17:63770753	CCDC46	-0.51	-11.57	-0.49	4.41e-27	Total body bone mineral density;
LUAD	cis	rs250585	0.920	rs8046051	chr16:23538666	G/A	cg00143387	chr16:23521605	GGA2	-0.65	-7.41	-0.34	6.71e-13	Egg allergy;
LUAD	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg13319975	chr6:146136371	FBXO30	-0.59	-9.91	-0.43	5.68e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg00106254	chr7:1943704	MAD1L1	0.49	7.49	0.34	4.06e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg04106633	chr4:1044584	NA	-0.56	-10.12	-0.44	1.06e-21	Recombination rate (males);
LUAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	7.54	0.34	2.97e-13	Alzheimer's disease;
LUAD	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg22823121	chr1:150693482	HORMAD1	0.44	8.91	0.4	1.55e-17	Tonsillectomy;
LUAD	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg23985595	chr17:80112537	CCDC57	0.44	7.84	0.36	3.81e-14	Life satisfaction;
LUAD	cis	rs12286929	0.576	rs2275997	chr11:115100186	A/G	cg04055981	chr11:115044050	NA	0.39	6.93	0.32	1.59e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg12927641	chr6:109611667	NA	-0.49	-8.62	-0.39	1.36e-16	Reticulocyte fraction of red cells;
LUAD	cis	rs10242455	0.557	rs73401516	chr7:99068351	C/A	cg18809830	chr7:99032528	PTCD1	-1.0	-7.35	-0.34	1.04e-12	Blood metabolite levels;
LUAD	cis	rs11126435	0.858	rs363668	chr2:74929176	G/A	cg19285774	chr2:74907978	SEMA4F	0.37	6.54	0.3	1.74e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.42	-7.65	-0.35	1.34e-13	Tonsillectomy;
LUAD	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg06191203	chr2:152266755	RIF1	-0.46	-7.08	-0.33	5.87e-12	Lung cancer;
LUAD	cis	rs9473147	0.503	rs9473123	chr6:47475339	G/A	cg02130027	chr6:47444894	CD2AP	0.36	6.93	0.32	1.55e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs977987	0.843	rs12928036	chr16:75483132	G/A	cg03315344	chr16:75512273	CHST6	0.64	13.81	0.56	4.64e-36	Dupuytren's disease;
LUAD	cis	rs9287719	0.699	rs4669602	chr2:10787967	C/T	cg02196655	chr2:10830764	NOL10	-0.39	-6.88	-0.32	2.22e-11	Prostate cancer;
LUAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg09436375	chr6:42928200	GNMT	-0.29	-8.4	-0.38	6.72e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs868036	1.000	rs6494696	chr15:68103206	C/G	cg24579218	chr15:68104479	NA	0.37	6.89	0.32	1.99e-11	Restless legs syndrome;
LUAD	cis	rs7617773	0.817	rs79310258	chr3:48259667	C/G	cg11946769	chr3:48343235	NME6	0.41	6.35	0.3	5.52e-10	Coronary artery disease;
LUAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg12432903	chr7:1882776	MAD1L1	-0.53	-8.77	-0.39	4.28e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg23982607	chr1:1823379	GNB1	-0.92	-19.31	-0.68	4.73e-60	Body mass index;
LUAD	cis	rs240764	0.658	rs11155637	chr6:101203592	A/G	cg09795085	chr6:101329169	ASCC3	-0.48	-8.35	-0.38	1.01e-15	Neuroticism;
LUAD	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg07917127	chr4:99064746	C4orf37	0.39	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-7.85	-0.36	3.54e-14	Total cholesterol levels;
LUAD	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.44	-0.3	3.21e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg08847533	chr14:75593920	NEK9	0.4	6.79	0.31	3.89e-11	Height;
LUAD	cis	rs986417	1.000	rs1262174	chr14:60887194	C/T	cg27398547	chr14:60952738	C14orf39	0.5	6.38	0.3	4.73e-10	Gut microbiota (bacterial taxa);
LUAD	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg13642260	chr9:130955380	CIZ1	0.46	7.75	0.35	6.88e-14	Attention deficit hyperactivity disorder;
LUAD	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18404041	chr3:52824283	ITIH1	-0.57	-11.92	-0.5	1.91e-28	Electroencephalogram traits;
LUAD	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg05340658	chr4:99064831	C4orf37	0.51	8.49	0.38	3.47e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg21782813	chr7:2030301	MAD1L1	-0.52	-9.2	-0.41	1.61e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.27e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12612619	0.732	rs6547355	chr2:27210205	G/A	cg00617064	chr2:27272375	NA	-0.36	-7.06	-0.32	6.76e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs344364	0.576	rs238680	chr16:1872160	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.42	6.64	0.31	9.53e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg22907277	chr7:1156413	C7orf50	0.41	7.16	0.33	3.69e-12	Longevity;Endometriosis;
LUAD	cis	rs2455799	0.613	rs6772879	chr3:15741793	G/A	cg16303742	chr3:15540471	COLQ	-0.49	-9.1	-0.4	3.68e-18	Mean platelet volume;
LUAD	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg06046430	chr4:77819534	ANKRD56	0.55	8.72	0.39	6.64e-17	Emphysema distribution in smoking;
LUAD	cis	rs7903847	0.642	rs11189172	chr10:99135215	T/C	cg20016023	chr10:99160130	RRP12	-0.34	-8.12	-0.37	5.14e-15	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg04025307	chr7:1156635	C7orf50	0.66	7.55	0.34	2.66e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg08888203	chr3:10149979	C3orf24	0.71	12.43	0.52	1.87e-30	Alzheimer's disease;
LUAD	cis	rs6748734	0.947	rs6752787	chr2:241840647	G/A	cg04034577	chr2:241836375	C2orf54	-0.48	-10.24	-0.45	3.8e-22	Urinary metabolites;
LUAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-7.78	-0.35	5.53e-14	Longevity;Endometriosis;
LUAD	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg17633681	chr16:88106987	BANP	0.41	7.1	0.33	5.15e-12	Menopause (age at onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22080472	chr1:28176762	PPP1R8	0.42	6.41	0.3	3.89e-10	Height;
LUAD	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg18811423	chr2:55921094	PNPT1	0.56	9.55	0.42	1.09e-19	Metabolic syndrome;
LUAD	cis	rs459571	0.959	rs465535	chr9:136910905	C/T	cg13789015	chr9:136890014	NCRNA00094	0.8	13.33	0.54	4.2e-34	Platelet distribution width;
LUAD	trans	rs4650994	0.593	rs2761472	chr1:178609356	C/T	cg05059571	chr16:84539110	KIAA1609	-0.4	-6.47	-0.3	2.66e-10	HDL cholesterol levels;HDL cholesterol;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg19502700	chr4:113558183	LARP7;C4orf21	-0.4	-6.7	-0.31	6.6e-11	Schizophrenia;
LUAD	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg21171335	chr12:122356390	WDR66	0.66	11.63	0.49	2.46e-27	Mean corpuscular volume;
LUAD	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-14.51	-0.58	5.36e-39	Schizophrenia;
LUAD	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg04267008	chr7:1944627	MAD1L1	-0.55	-8.2	-0.37	3e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg21918786	chr6:109611834	NA	0.6	11.19	0.48	1.17e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs868036	1.000	rs1026734	chr15:68100950	T/C	cg24579218	chr15:68104479	NA	-0.4	-7.45	-0.34	5.44e-13	Restless legs syndrome;
LUAD	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg15432903	chr11:17409602	KCNJ11	0.54	10.12	0.44	1.09e-21	Type 2 diabetes;
LUAD	cis	rs72928364	0.858	rs66598219	chr3:100779435	T/C	cg10123952	chr3:100791384	NA	0.73	7.87	0.36	3.1e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg22014379	chr2:113192561	RGPD8;RGPD5	0.51	6.54	0.3	1.8e-10	Yeast infection;
LUAD	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg23166289	chr1:210001082	C1orf107	0.48	6.84	0.32	2.8e-11	Orofacial clefts;
LUAD	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	12.54	0.52	7.14e-31	Monocyte percentage of white cells;
LUAD	cis	rs7536201	0.936	rs7532198	chr1:25294208	C/T	cg23273869	chr1:25296894	NA	-0.36	-7.01	-0.32	9.19e-12	Psoriasis vulgaris;
LUAD	trans	rs6076960	0.598	rs3905168	chr20:6226752	C/T	cg17788362	chr6:86352627	SYNCRIP	0.43	6.74	0.31	5.16e-11	Smooth-surface caries;
LUAD	cis	rs4356932	0.935	rs4129781	chr4:76959388	C/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.52	-0.3	2.05e-10	Blood protein levels;
LUAD	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg08847533	chr14:75593920	NEK9	0.39	6.61	0.31	1.15e-10	Height;
LUAD	cis	rs1032833	0.732	rs76298720	chr2:179990353	C/G	cg23883738	chr2:179974586	SESTD1	-0.7	-7.73	-0.35	8.12e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.61e-18	Life satisfaction;
LUAD	cis	rs13082711	0.911	rs67104968	chr3:27510304	A/G	cg02860705	chr3:27208620	NA	0.57	8.79	0.39	3.68e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg23815491	chr16:72088622	HP	0.58	11.06	0.47	3.66e-25	Fibrinogen levels;
LUAD	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg21033440	chr11:65409861	SIPA1	-0.45	-7.52	-0.34	3.22e-13	Blood pressure (age interaction);
LUAD	cis	rs7814319	0.700	rs7838479	chr8:97268077	G/A	cg20787634	chr8:97240163	UQCRB	-0.36	-6.6	-0.31	1.23e-10	Lung function (FVC);
LUAD	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg18230493	chr5:56204884	C5orf35	-1.02	-14.66	-0.58	1.25e-39	Initial pursuit acceleration;
LUAD	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg20703242	chr1:230279135	GALNT2	0.68	12.51	0.52	9.26e-31	Coronary artery disease;
LUAD	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg20933634	chr6:27740509	NA	0.46	7.29	0.33	1.52e-12	Parkinson's disease;
LUAD	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg04727924	chr7:799746	HEATR2	-0.53	-7.23	-0.33	2.23e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4947962	0.648	rs76692262	chr7:55089831	A/G	cg23757825	chr7:55092271	EGFR	-0.56	-7.19	-0.33	2.89e-12	Subjective response to lithium treatment;
LUAD	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.49	-0.45	4.81e-23	Monocyte percentage of white cells;
LUAD	cis	rs3772130	0.962	rs6776670	chr3:121543120	C/T	cg20356878	chr3:121714668	ILDR1	0.52	8.59	0.39	1.75e-16	Cognitive performance;
LUAD	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg14541582	chr5:601475	NA	0.35	7.68	0.35	1.11e-13	Obesity-related traits;
LUAD	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg24531977	chr5:56204891	C5orf35	-0.53	-8.38	-0.38	8.13e-16	Coronary artery disease;
LUAD	cis	rs113835537	0.529	rs2276406	chr11:66283257	C/T	cg24851651	chr11:66362959	CCS	0.57	10.1	0.44	1.25e-21	Airway imaging phenotypes;
LUAD	cis	rs9399401	0.626	rs13198644	chr6:142783233	A/G	cg03128060	chr6:142623767	GPR126	0.44	8.4	0.38	6.72e-16	Chronic obstructive pulmonary disease;
LUAD	cis	rs12760731	0.565	rs71628268	chr1:178151908	T/C	cg00404053	chr1:178313656	RASAL2	0.72	8.63	0.39	1.29e-16	Obesity-related traits;
LUAD	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg07917127	chr4:99064746	C4orf37	0.39	6.53	0.3	1.94e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg02527881	chr3:46936655	PTH1R	-0.48	-9.33	-0.41	5.81e-19	Colorectal cancer;
LUAD	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.52	-8.71	-0.39	6.87e-17	Alzheimer's disease (late onset);
LUAD	cis	rs4664304	1.000	rs55977890	chr2:160776866	C/T	cg23995753	chr2:160760732	LY75	-0.42	-7.35	-0.34	1.05e-12	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19998654	chr2:37458983	CEBPZ;C2orf56	-0.56	-6.74	-0.31	5.06e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs870825	0.616	rs7681824	chr4:185617525	A/G	cg04058563	chr4:185651563	MLF1IP	0.88	14.13	0.57	2.12e-37	Blood protein levels;
LUAD	cis	rs7680126	0.633	rs11730631	chr4:10292968	C/T	cg00071950	chr4:10020882	SLC2A9	0.59	8.72	0.39	6.43e-17	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	trans	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg08071915	chr8:12219732	FAM66A	0.43	7.18	0.33	3.16e-12	Joint mobility (Beighton score);
LUAD	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg26384229	chr12:38710491	ALG10B	0.43	7.32	0.34	1.28e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.48e-11	Crohn's disease;
LUAD	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg17264618	chr3:40429014	ENTPD3	-0.37	-8.47	-0.38	4.18e-16	Renal cell carcinoma;
LUAD	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08704250	chr15:31115839	NA	0.72	13.25	0.54	8.97e-34	Huntington's disease progression;
LUAD	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg27411982	chr8:10470053	RP1L1	0.38	6.68	0.31	7.49e-11	Retinal vascular caliber;
LUAD	cis	rs7659604	0.540	rs34445121	chr4:122710889	G/A	cg06713675	chr4:122721982	EXOSC9	0.45	8.22	0.37	2.43e-15	Type 2 diabetes;
LUAD	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg00933542	chr6:150070202	PCMT1	0.42	8.26	0.37	1.94e-15	Lung cancer;
LUAD	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg08997352	chr12:9597637	DDX12	-0.63	-10.66	-0.46	1.12e-23	Breast size;
LUAD	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg13385794	chr1:248469461	NA	0.27	7.15	0.33	3.86e-12	Common traits (Other);
LUAD	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg15448220	chr1:150897856	SETDB1	-0.44	-7.56	-0.35	2.53e-13	Tonsillectomy;
LUAD	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg14584255	chr6:163149320	PACRG;PARK2	-0.37	-7.04	-0.32	7.69e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg05110241	chr16:68378359	PRMT7	-0.82	-8.7	-0.39	7.26e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-9.36	-0.41	4.62e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs8014204	0.743	rs35809608	chr14:75254762	A/G	cg06637938	chr14:75390232	RPS6KL1	0.37	6.8	0.31	3.66e-11	Caffeine consumption;
LUAD	cis	rs3760982	0.845	rs62116962	chr19:44287234	A/G	cg12072164	chr19:44306565	LYPD5	-0.38	-7.64	-0.35	1.46e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs4919694	1.000	rs12266291	chr10:104806884	G/A	cg04362960	chr10:104952993	NT5C2	0.73	7.86	0.36	3.28e-14	Arsenic metabolism;
LUAD	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg09658497	chr7:2847517	GNA12	-0.49	-8.91	-0.4	1.49e-17	Height;
LUAD	cis	rs4664304	0.789	rs2063439	chr2:160800101	C/A	cg23995753	chr2:160760732	LY75	-0.41	-7.27	-0.33	1.8e-12	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1595825	0.891	rs112898725	chr2:198650006	C/T	cg00361562	chr2:198649771	BOLL	-0.46	-6.53	-0.3	1.93e-10	Ulcerative colitis;
LUAD	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.91	-0.36	2.23e-14	Total body bone mineral density;
LUAD	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg08508325	chr11:3079039	CARS	0.44	9.12	0.41	3.03e-18	Calcium levels;
LUAD	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg23422044	chr7:1970798	MAD1L1	-0.58	-7.24	-0.33	2.15e-12	Bipolar disorder;
LUAD	cis	rs929596	0.556	rs10168416	chr2:234597087	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.64	-10.73	-0.46	6.29e-24	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs7191700	0.601	rs243329	chr16:11352313	A/T	cg00044050	chr16:11439710	C16orf75	0.67	10.76	0.46	5.12e-24	Multiple sclerosis;
LUAD	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.29	0.33	1.54e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.29	-0.33	1.49e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs6426558	0.537	rs2492630	chr1:227286931	A/G	cg10327440	chr1:227177885	CDC42BPA	0.58	9.38	0.42	3.91e-19	Neutrophil percentage of white cells;
LUAD	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.51	-8.5	-0.38	3.4e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-9.01	-0.4	7.13e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg12311346	chr5:56204834	C5orf35	-0.93	-13.75	-0.56	8.23e-36	Initial pursuit acceleration;
LUAD	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg00701064	chr4:6280414	WFS1	0.65	14.28	0.57	5.08e-38	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg05340658	chr4:99064831	C4orf37	0.46	7.52	0.34	3.25e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg23029597	chr12:123009494	RSRC2	0.53	8.21	0.37	2.73e-15	Body mass index;
LUAD	trans	rs11039798	1.000	rs6485856	chr11:48556298	G/C	cg02254774	chr11:50257496	LOC441601	0.53	6.57	0.3	1.5e-10	Axial length;
LUAD	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg26384229	chr12:38710491	ALG10B	0.44	7.39	0.34	8e-13	Morning vs. evening chronotype;
LUAD	cis	rs11771526	0.792	rs17161104	chr7:32298582	C/T	cg27532318	chr7:32358331	NA	0.6	7.77	0.35	5.97e-14	Body mass index;
LUAD	cis	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg21775007	chr8:11205619	TDH	-0.4	-6.79	-0.31	3.84e-11	Neuroticism;
LUAD	trans	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.23e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg13319975	chr6:146136371	FBXO30	-0.54	-8.67	-0.39	9.29e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13095912	1.000	rs17523471	chr3:185304018	T/C	cg11274856	chr3:185301563	NA	0.37	7.51	0.34	3.58e-13	Systolic blood pressure;
LUAD	cis	rs713587	0.563	rs7591460	chr2:25103967	A/C	cg01884057	chr2:25150051	NA	0.32	6.69	0.31	7.2e-11	Body mass index in non-asthmatics;
LUAD	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.61	0.35	1.84e-13	Platelet count;
LUAD	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg19041857	chr6:27730383	NA	-0.38	-6.44	-0.3	3.16e-10	Parkinson's disease;
LUAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg05434287	chr7:2030229	MAD1L1	0.42	6.91	0.32	1.77e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg14598338	chr9:96623480	NA	-0.45	-9.58	-0.42	8.69e-20	DNA methylation (variation);
LUAD	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg18811423	chr2:55921094	PNPT1	0.52	8.67	0.39	9.39e-17	Metabolic syndrome;
LUAD	cis	rs4285028	0.747	rs3772126	chr3:121354583	G/A	cg11130432	chr3:121712080	ILDR1	-0.45	-6.38	-0.3	4.73e-10	Multiple sclerosis;
LUAD	cis	rs12618769	0.597	rs72819986	chr2:99045867	G/C	cg10123293	chr2:99228465	UNC50	0.45	7.92	0.36	2.19e-14	Bipolar disorder;
LUAD	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg13390004	chr1:15929781	NA	0.47	8.45	0.38	4.63e-16	Systolic blood pressure;
LUAD	cis	rs8130944	0.822	rs2839574	chr21:44107989	A/G	cg16784985	chr21:44105474	PDE9A	-0.4	-6.59	-0.31	1.33e-10	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg19761014	chr17:28927070	LRRC37B2	0.83	8.16	0.37	4e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.71	-0.31	6.43e-11	Joint mobility (Beighton score);
LUAD	cis	rs7107174	1.000	rs1893448	chr11:77969180	G/A	cg02023728	chr11:77925099	USP35	0.42	7.06	0.32	6.87e-12	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg24818145	chr4:99064322	C4orf37	0.44	7.35	0.34	1.05e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg07460842	chr6:66804631	NA	-1.04	-16.58	-0.63	6.18e-48	Exhaled nitric oxide output;
LUAD	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg00933542	chr6:150070202	PCMT1	0.44	9.68	0.43	3.63e-20	Lung cancer;
LUAD	cis	rs13095912	1.000	rs13100034	chr3:185318804	G/A	cg11274856	chr3:185301563	NA	0.37	7.48	0.34	4.23e-13	Systolic blood pressure;
LUAD	cis	rs4853036	0.629	rs34704699	chr2:70014710	G/A	cg02498382	chr2:70120550	SNRNP27	-0.49	-7.09	-0.33	5.62e-12	Colorectal or endometrial cancer;
LUAD	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg02569458	chr12:86230093	RASSF9	0.45	8.14	0.37	4.54e-15	Major depressive disorder;
LUAD	cis	rs1215050	0.791	rs13114823	chr4:98671119	G/A	cg05340658	chr4:99064831	C4orf37	-0.42	-6.89	-0.32	1.97e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg13293535	chr8:11597251	GATA4	0.27	6.38	0.3	4.53e-10	Neuroticism;
LUAD	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03264133	chr6:25882463	NA	0.83	13.82	0.56	4.24e-36	Blood metabolite levels;
LUAD	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg00745463	chr17:30367425	LRRC37B	0.81	9.48	0.42	1.85e-19	Hip circumference adjusted for BMI;
LUAD	cis	rs3785574	0.650	rs3815358	chr17:62010270	A/G	cg06873352	chr17:61820015	STRADA	-0.4	-6.4	-0.3	4.09e-10	Height;
LUAD	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.5	0.38	3.28e-16	Platelet count;
LUAD	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg21545522	chr1:205238299	TMCC2	0.36	6.59	0.31	1.3100000000000001e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg02782426	chr3:40428986	ENTPD3	0.35	7.73	0.35	7.79e-14	Renal cell carcinoma;
LUAD	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.38	-0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27286337	chr10:134555280	INPP5A	0.7	8.79	0.39	3.85e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg20503657	chr10:835505	NA	0.48	7.48	0.34	4.41e-13	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg02461776	chr11:598696	PHRF1	0.46	6.79	0.31	3.78e-11	Systemic lupus erythematosus;
LUAD	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg19635926	chr16:89946313	TCF25	0.74	6.97	0.32	1.22e-11	Skin colour saturation;
LUAD	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg00383909	chr3:49044727	WDR6	-0.77	-7.64	-0.35	1.46e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg15448220	chr1:150897856	SETDB1	-0.46	-7.98	-0.36	1.36e-14	Tonsillectomy;
LUAD	cis	rs2742234	0.955	rs1800861	chr10:43613843	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.45	-8.03	-0.36	1e-14	Hirschsprung disease;
LUAD	cis	rs6499255	1.000	rs4464069	chr16:69816284	C/T	cg00738113	chr16:70207722	CLEC18C	-0.38	-6.43	-0.3	3.55e-10	IgE levels;
LUAD	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg26677194	chr12:130822605	PIWIL1	0.57	9.12	0.41	2.99e-18	Menopause (age at onset);
LUAD	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg04414720	chr1:150670196	GOLPH3L	0.74	13.84	0.56	3.3e-36	Tonsillectomy;
LUAD	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg04450456	chr4:17643702	FAM184B	-0.39	-7.75	-0.35	6.81e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7017914	0.967	rs35115527	chr8:71643009	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg05887092	chr17:76393375	PGS1	0.56	11.45	0.49	1.3e-26	HDL cholesterol levels;
LUAD	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-20.31	-0.7	1.58e-64	Height;
LUAD	trans	rs7395662	0.963	rs7125110	chr11:48545507	G/A	cg15704280	chr7:45808275	SEPT13	-0.41	-6.37	-0.3	4.81e-10	HDL cholesterol;
LUAD	cis	rs2279817	1.000	rs1339801	chr1:18020298	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.57	9.61	0.42	6.37e-20	Neuroticism;
LUAD	cis	rs7192380	0.651	rs920191	chr16:69689120	G/A	cg26679644	chr16:69762563	NA	0.44	7.16	0.33	3.57e-12	Sjögren's syndrome;
LUAD	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg21204522	chr6:27730016	NA	-0.45	-7.38	-0.34	8.74e-13	Parkinson's disease;
LUAD	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg00933542	chr6:150070202	PCMT1	0.46	9.67	0.43	4.02e-20	Lung cancer;
LUAD	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg07169764	chr2:136633963	MCM6	0.78	9.16	0.41	2.24e-18	Corneal structure;
LUAD	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.73	-0.31	5.43e-11	Total body bone mineral density;
LUAD	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg19717773	chr7:2847554	GNA12	-0.48	-8.16	-0.37	3.99e-15	Height;
LUAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg06753367	chr22:24256600	NA	-0.38	-6.62	-0.31	1.1e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs78773383	0.505	rs10033019	chr4:39391940	A/G	cg12062995	chr4:39368212	RFC1	0.46	7.99	0.36	1.3e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg12311346	chr5:56204834	C5orf35	-0.47	-7.68	-0.35	1.12e-13	Coronary artery disease;
LUAD	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg15181151	chr6:150070149	PCMT1	0.42	8.7	0.39	7.56e-17	Lung cancer;
LUAD	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg20203395	chr5:56204925	C5orf35	-0.82	-11.85	-0.5	3.72e-28	Initial pursuit acceleration;
LUAD	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-7.54	-0.34	2.88e-13	Alzheimer's disease (late onset);
LUAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.5	-0.38	3.37e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg03806693	chr22:41940476	POLR3H	-0.49	-7.29	-0.33	1.55e-12	Vitiligo;
LUAD	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg00147160	chr1:26503991	CNKSR1	0.37	8.73	0.39	6.04e-17	Height;
LUAD	cis	rs7084921	0.608	rs4475856	chr10:101833339	G/T	cg19754520	chr10:101825118	CPN1	-0.34	-6.87	-0.32	2.26e-11	Bone mineral density;
LUAD	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg00316803	chr15:76480434	C15orf27	-0.43	-8.59	-0.39	1.74e-16	Blood metabolite levels;
LUAD	cis	rs1368882	1.000	rs1368882	chr1:55107019	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.47	-8.0	-0.36	1.18e-14	Non-substance related behavioral disinhibition;
LUAD	cis	rs12431939	0.817	rs7153408	chr14:51671492	G/A	cg23942311	chr14:51606299	NA	0.41	6.45	0.3	3.07e-10	Cancer;
LUAD	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg07527032	chr15:84868466	LOC388152	0.43	6.41	0.3	3.83e-10	Schizophrenia;
LUAD	cis	rs870825	0.616	rs7678864	chr4:185635158	C/T	cg04058563	chr4:185651563	MLF1IP	0.9	14.43	0.57	1.19e-38	Blood protein levels;
LUAD	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg06453172	chr10:134556979	INPP5A	-0.78	-11.09	-0.47	3.02e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	12.42	0.52	2.11e-30	Monocyte percentage of white cells;
LUAD	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg13180566	chr4:1052158	NA	-0.4	-6.73	-0.31	5.71e-11	Recombination rate (females);
LUAD	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg23758822	chr17:41437982	NA	1.01	21.51	0.72	7.05e-70	Menopause (age at onset);
LUAD	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7216064	1.000	rs35243555	chr17:65876477	G/C	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.23	-0.41	1.3e-18	Type 2 diabetes;
LUAD	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.69	0.49	1.46e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg27494647	chr7:150038898	RARRES2	0.54	9.56	0.42	9.55e-20	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.48	-0.3	2.48e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06544989	chr22:39130855	UNC84B	0.42	7.57	0.35	2.33e-13	Menopause (age at onset);
LUAD	cis	rs34734847	0.787	rs695948	chr12:121149596	A/G	cg21892295	chr12:121157589	UNC119B	-0.39	-6.97	-0.32	1.25e-11	Mean corpuscular volume;
LUAD	cis	rs6445967	1.000	rs6786088	chr3:58315075	T/C	cg23715586	chr3:58305044	RPP14	0.43	7.61	0.35	1.8e-13	Platelet count;
LUAD	cis	rs3784262	0.740	rs2119859	chr15:58254745	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-8.35	-0.38	9.96e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs8067287	0.762	rs62065418	chr17:16820938	G/A	cg26910001	chr17:16838321	NA	-0.48	-6.67	-0.31	8.14e-11	Diabetic kidney disease;
LUAD	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg27286337	chr10:134555280	INPP5A	0.7	9.92	0.43	5.43e-21	Migraine;
LUAD	cis	rs367615	0.840	rs113540823	chr5:108879084	C/T	cg17395555	chr5:108820864	NA	0.54	8.81	0.39	3.32e-17	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg19635926	chr16:89946313	TCF25	0.74	6.93	0.32	1.62e-11	Skin colour saturation;
LUAD	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg20607287	chr7:12443886	VWDE	-0.54	-6.83	-0.32	2.97e-11	Coronary artery disease;
LUAD	trans	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04565464	chr8:145669602	NFKBIL2	0.44	6.87	0.32	2.3e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21659725	chr3:3221576	CRBN	0.67	11.49	0.49	8.71e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs2019216	0.542	rs2221893	chr17:21930012	A/G	cg22648282	chr17:21454238	C17orf51	-0.48	-8.52	-0.38	2.91e-16	Pelvic organ prolapse;
LUAD	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-8.21	-0.37	2.77e-15	Height;
LUAD	cis	rs10979	1.000	rs11155300	chr6:143894576	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.28	-0.45	2.77e-22	Hypospadias;
LUAD	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg21427119	chr20:30132790	HM13	-0.48	-7.47	-0.34	4.68e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs9494145	0.531	rs9399136	chr6:135402339	T/C	cg22676075	chr6:135203613	NA	0.59	8.79	0.39	3.83e-17	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUAD	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg27535305	chr1:53392650	SCP2	-0.35	-7.18	-0.33	3.15e-12	Monocyte count;
LUAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg18305652	chr10:134549665	INPP5A	0.59	11.37	0.48	2.64e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg09796270	chr17:17721594	SREBF1	0.39	7.92	0.36	2.06e-14	Total body bone mineral density;
LUAD	cis	rs9473147	0.516	rs9463342	chr6:47585106	A/T	cg02130027	chr6:47444894	CD2AP	0.36	6.9	0.32	1.87e-11	Platelet distribution width;Mean platelet volume;
LUAD	trans	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg21284400	chr1:149981654	OTUD7B	-0.38	-6.54	-0.3	1.73e-10	Longevity;Endometriosis;
LUAD	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg23625390	chr15:77176239	SCAPER	0.46	7.32	0.34	1.28e-12	Blood metabolite levels;
LUAD	cis	rs4588572	0.706	rs72760906	chr5:77652457	T/C	cg11547950	chr5:77652471	NA	0.78	12.94	0.53	1.76e-32	Triglycerides;
LUAD	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg25036284	chr2:26402008	FAM59B	0.65	8.33	0.38	1.11e-15	Gut microbiome composition (summer);
LUAD	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg07741184	chr6:167504864	NA	-0.3	-7.17	-0.33	3.48e-12	Crohn's disease;
LUAD	trans	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg27411982	chr8:10470053	RP1L1	0.43	7.79	0.35	5.16e-14	Mood instability;
LUAD	cis	rs654950	0.840	rs647146	chr1:41986286	G/A	cg06885757	chr1:42089581	HIVEP3	0.36	7.66	0.35	1.25e-13	Airway imaging phenotypes;
LUAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg05434287	chr7:2030229	MAD1L1	0.4	6.66	0.31	8.75e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg15445000	chr17:37608096	MED1	-0.39	-6.52	-0.3	2.05e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs3007168	1.000	rs3007076	chr14:51605352	G/T	cg23942311	chr14:51606299	NA	0.53	7.31	0.33	1.35e-12	Cancer;
LUAD	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg15704280	chr7:45808275	SEPT13	0.91	17.57	0.65	2.88e-52	Coronary artery disease;
LUAD	trans	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg19676328	chr12:49525230	TUBA1B	-0.73	-11.47	-0.49	1.02e-26	Total cholesterol levels;
LUAD	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg14983838	chr19:29218262	NA	0.67	9.46	0.42	2.24e-19	Methadone dose in opioid dependence;
LUAD	cis	rs2019216	0.500	rs71371082	chr17:21889647	T/C	cg22648282	chr17:21454238	C17orf51	-0.47	-7.93	-0.36	2e-14	Pelvic organ prolapse;
LUAD	cis	rs9326248	0.581	rs7120706	chr11:116830087	C/T	cg20608306	chr11:116969690	SIK3	-0.31	-7.03	-0.32	8.58e-12	Blood protein levels;
LUAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.59	9.08	0.4	4.29e-18	Alzheimer's disease;
LUAD	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg13918804	chr1:2043761	PRKCZ	0.4	6.79	0.31	3.86e-11	Height;
LUAD	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	6.7	0.31	6.69e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs727505	0.721	rs56269941	chr7:124768732	T/A	cg23710748	chr7:124431027	NA	-0.38	-7.85	-0.36	3.56e-14	Lewy body disease;
LUAD	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.64	12.54	0.52	6.88e-31	Homoarginine levels;
LUAD	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg07157834	chr1:205819609	PM20D1	-0.46	-6.79	-0.31	3.93e-11	Menarche (age at onset);
LUAD	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg15133208	chr4:90757351	SNCA	-0.47	-7.09	-0.33	5.8e-12	Neuroticism;
LUAD	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg04450456	chr4:17643702	FAM184B	0.42	8.21	0.37	2.61e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs17021463	0.807	rs6532480	chr4:95277038	T/C	cg11021082	chr4:95130006	SMARCAD1	0.36	6.45	0.3	3.14e-10	Testicular germ cell tumor;
LUAD	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg13877915	chr19:58951672	ZNF132	0.73	14.25	0.57	6.34e-38	Uric acid clearance;
LUAD	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg18225595	chr11:63971243	STIP1	0.5	8.62	0.39	1.35e-16	Platelet count;
LUAD	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg10589385	chr1:150898437	SETDB1	0.43	7.93	0.36	1.97e-14	Melanoma;
LUAD	cis	rs7707921	0.957	rs2059891	chr5:81508792	G/C	cg15871215	chr5:81402204	ATG10	0.72	10.32	0.45	2.11e-22	Breast cancer;
LUAD	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg12179176	chr11:130786555	SNX19	0.64	10.67	0.46	1.07e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg15445000	chr17:37608096	MED1	-0.44	-8.21	-0.37	2.74e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg22920501	chr2:26401640	FAM59B	0.96	13.85	0.56	2.96e-36	Gut microbiome composition (summer);
LUAD	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06022373	chr22:39101656	GTPBP1	0.45	7.0	0.32	1e-11	Menopause (age at onset);
LUAD	trans	rs9693857	0.553	rs10100760	chr8:9370559	C/T	cg21775007	chr8:11205619	TDH	-0.36	-6.51	-0.3	2.17e-10	Systolic blood pressure;
LUAD	cis	rs2456568	0.771	rs2102333	chr11:93634749	G/A	cg26875233	chr11:93583750	C11orf90	-0.29	-6.39	-0.3	4.35e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg15448220	chr1:150897856	SETDB1	0.53	9.32	0.41	6.74e-19	Melanoma;
LUAD	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg14008862	chr17:28927542	LRRC37B2	0.72	7.06	0.32	6.78e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg26875233	chr11:93583750	C11orf90	-0.39	-8.81	-0.39	3.28e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg25173405	chr17:45401733	C17orf57	-0.59	-9.95	-0.44	4.13e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs62283056	0.512	rs1079215	chr4:6282393	A/G	cg25554036	chr4:6271136	WFS1	0.65	11.42	0.49	1.59e-26	Cisplatin-induced ototoxicity;
LUAD	cis	rs9633740	1.000	rs1870137	chr10:82269848	C/G	cg00277334	chr10:82204260	NA	-0.62	-8.31	-0.37	1.27e-15	Post bronchodilator FEV1;
LUAD	cis	rs6445967	0.530	rs3922711	chr3:58384243	A/C	cg13750441	chr3:58318267	PXK	-0.34	-7.03	-0.32	8.5e-12	Platelet count;
LUAD	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg24531977	chr5:56204891	C5orf35	0.45	7.31	0.33	1.34e-12	Coronary artery disease;
LUAD	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.16	0.33	3.67e-12	Prostate cancer;
LUAD	cis	rs1375194	0.582	rs13388224	chr2:33802902	T/C	cg04131969	chr2:33951647	MYADML	-0.56	-8.63	-0.39	1.29e-16	Response to antidepressants in depression;
LUAD	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs12986413	0.624	rs2108825	chr19:2136515	T/C	cg09261902	chr19:2140048	AP3D1	0.34	6.79	0.31	3.9e-11	Height;
LUAD	cis	rs9522267	0.535	rs9522284	chr13:112229343	C/T	cg10483660	chr13:112241077	NA	-0.32	-6.76	-0.31	4.51e-11	Hepatitis;
LUAD	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22307029	chr19:49891270	CCDC155	0.64	9.93	0.43	5.09e-21	Multiple sclerosis;
LUAD	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg01579765	chr21:45077557	HSF2BP	-0.63	-14.68	-0.58	1.02e-39	Mean corpuscular volume;
LUAD	cis	rs3820068	0.705	rs4646103	chr1:15819827	T/A	cg13390004	chr1:15929781	NA	0.41	6.59	0.31	1.3e-10	Systolic blood pressure;
LUAD	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg06002616	chr8:101225028	SPAG1	-0.39	-8.11	-0.37	5.42e-15	Atrioventricular conduction;
LUAD	cis	rs7809950	0.678	rs62483640	chr7:106900214	T/G	cg23024343	chr7:107201750	COG5	-0.81	-13.3	-0.54	5.62e-34	Coronary artery disease;
LUAD	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg12623918	chr2:306882	NA	0.36	7.2	0.33	2.83e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg03526776	chr6:41159608	TREML2	0.55	11.24	0.48	7.86e-26	Alzheimer's disease (late onset);
LUAD	cis	rs77106637	0.929	rs74333814	chr11:72457487	C/T	cg04827223	chr11:72435913	ARAP1	-0.5	-6.72	-0.31	5.79e-11	Type 2 diabetes;
LUAD	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg24558204	chr6:135376177	HBS1L	-0.46	-8.39	-0.38	7.46e-16	Red blood cell count;
LUAD	cis	rs1371614	0.635	rs12618836	chr2:27137616	A/G	cg00617064	chr2:27272375	NA	-0.34	-6.67	-0.31	7.85e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.8	0.76	4.34e-80	Chronic sinus infection;
LUAD	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg00383909	chr3:49044727	WDR6	0.42	6.48	0.3	2.58e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07167872	chr1:205819463	PM20D1	0.78	15.77	0.61	2.14e-44	Menarche (age at onset);
LUAD	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg20701182	chr2:24300061	SF3B14	0.91	13.81	0.56	4.56e-36	Lymphocyte counts;
LUAD	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg11941060	chr3:133502564	NA	-0.43	-7.17	-0.33	3.47e-12	Iron status biomarkers;
LUAD	cis	rs7584330	0.554	rs7598559	chr2:238435398	A/G	cg14458575	chr2:238380390	NA	-0.67	-10.2	-0.44	5.31e-22	Prostate cancer;
LUAD	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.62	-0.35	1.63e-13	Blood metabolite levels;
LUAD	cis	rs62238980	0.614	rs117586262	chr22:32406424	G/A	cg00543991	chr22:32367038	NA	0.96	9.05	0.4	5.32e-18	Childhood ear infection;
LUAD	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg11663144	chr21:46675770	NA	-0.61	-11.98	-0.5	1.13e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs68170813	0.559	rs17428126	chr7:106897037	C/T	cg02696742	chr7:106810147	HBP1	-0.77	-10.64	-0.46	1.37e-23	Coronary artery disease;
LUAD	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg23649088	chr2:200775458	C2orf69	-0.61	-8.2	-0.37	2.86e-15	Schizophrenia;
LUAD	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg06915202	chr7:98029285	BAIAP2L1	0.31	6.45	0.3	3.15e-10	Prostate cancer (SNP x SNP interaction);
LUAD	trans	rs7746199	0.736	rs35037868	chr6:27759115	G/C	cg01620082	chr3:125678407	NA	-1.08	-10.32	-0.45	2.04e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg14092571	chr14:90743983	NA	-0.49	-8.65	-0.39	1.07e-16	Mortality in heart failure;
LUAD	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.94	0.32	1.5e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg14092988	chr3:52407081	DNAH1	0.33	6.58	0.3	1.39e-10	Bipolar disorder;
LUAD	cis	rs2109514	0.542	rs17138684	chr7:116070698	G/C	cg04696780	chr7:116139425	CAV2	-0.31	-6.9	-0.32	1.96e-11	Prevalent atrial fibrillation;
LUAD	cis	rs59104589	0.617	rs60132543	chr2:242344599	T/C	cg08645257	chr2:242211290	HDLBP	0.43	6.98	0.32	1.11e-11	Fibrinogen levels;
LUAD	cis	rs9394169	0.818	rs1547671	chr6:33777260	C/T	cg07979401	chr6:33739406	LEMD2	-0.36	-7.05	-0.32	7.12e-12	Essential tremor;
LUAD	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg02975922	chr3:195473998	MUC4	-0.45	-7.4	-0.34	7.33e-13	Pancreatic cancer;
LUAD	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg21100191	chr22:23484243	RTDR1	0.67	11.55	0.49	5.02e-27	Bone mineral density;
LUAD	cis	rs1403694	0.695	rs5029970	chr3:186434491	T/C	cg12454167	chr3:186435060	KNG1	0.5	10.45	0.45	6.93e-23	Blood protein levels;
LUAD	cis	rs2997447	0.846	rs3008419	chr1:26402820	A/C	cg00147160	chr1:26503991	CNKSR1	0.34	6.52	0.3	2.01e-10	QRS complex (12-leadsum);
LUAD	trans	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-25.13	-0.77	6.16e-86	Exhaled nitric oxide output;
LUAD	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg12011299	chr4:100065546	ADH4	0.65	11.95	0.5	1.51e-28	Alcohol dependence;
LUAD	cis	rs10129255	0.500	rs6576225	chr14:107186359	G/C	cg23076370	chr14:107095027	NA	-0.44	-8.73	-0.39	6.02e-17	Kawasaki disease;
LUAD	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg21963583	chr11:68658836	MRPL21	0.66	11.7	0.49	1.39e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg20203395	chr5:56204925	C5orf35	-0.82	-11.64	-0.49	2.35e-27	Initial pursuit acceleration;
LUAD	cis	rs7737355	0.812	rs116825489	chr5:131061504	C/T	cg06307176	chr5:131281290	NA	0.46	7.73	0.35	7.79e-14	Life satisfaction;
LUAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	6.57	0.3	1.5e-10	Renal function-related traits (BUN);
LUAD	cis	rs752010	0.662	rs10890154	chr1:42106740	C/T	cg06885757	chr1:42089581	HIVEP3	0.37	7.78	0.35	5.67e-14	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-9.35	-0.41	5.18e-19	Alzheimer's disease;
LUAD	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg24558204	chr6:135376177	HBS1L	0.49	9.14	0.41	2.61e-18	Red blood cell count;
LUAD	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg08316699	chr6:150357289	NA	0.36	7.3	0.33	1.42e-12	Alopecia areata;
LUAD	cis	rs3813567	0.759	rs12148319	chr15:78956192	A/G	cg05914723	chr15:78953907	NA	0.58	7.95	0.36	1.73e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg15181151	chr6:150070149	PCMT1	0.38	7.41	0.34	6.73e-13	Lung cancer;
LUAD	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg20933634	chr6:27740509	NA	0.47	7.46	0.34	4.97e-13	Parkinson's disease;
LUAD	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg25382214	chr1:3105252	PRDM16	-0.32	-6.45	-0.3	2.99e-10	Migraine;
LUAD	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg10523679	chr1:76189770	ACADM	-1.04	-24.84	-0.77	1.17e-84	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.4	-6.91	-0.32	1.78e-11	Longevity;Endometriosis;
LUAD	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg26394196	chr10:1453818	ADARB2	-0.33	-6.36	-0.3	5.21e-10	Radiation response;
LUAD	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg11266682	chr4:10021025	SLC2A9	0.67	15.52	0.6	2.67e-43	Bone mineral density;
LUAD	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.2	15.97	0.61	3.01e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7818345	1.000	rs7823194	chr8:19292528	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.3	6.61	0.31	1.14e-10	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs35883536	0.609	rs2647327	chr1:101041766	C/T	cg06223162	chr1:101003688	GPR88	0.46	8.91	0.4	1.54e-17	Monocyte count;
LUAD	cis	rs4604732	0.631	rs1106720	chr1:247624681	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	9.21	0.41	1.59e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg13385794	chr1:248469461	NA	0.27	7.18	0.33	3.21e-12	Common traits (Other);
LUAD	cis	rs12545109	0.800	rs2118261	chr8:57393286	A/G	cg09654669	chr8:57350985	NA	0.64	9.56	0.42	1.01e-19	Obesity-related traits;
LUAD	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg13180566	chr4:1052158	NA	0.39	6.44	0.3	3.17e-10	Recombination rate (females);
LUAD	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg21798802	chr22:38057573	PDXP	0.49	9.92	0.43	5.62e-21	Fat distribution (HIV);
LUAD	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23583168	chr7:148888333	NA	-0.91	-19.0	-0.68	1.2e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6543140	0.964	rs13393175	chr2:103078849	T/G	cg04239558	chr2:103089729	SLC9A4	0.36	7.34	0.34	1.11e-12	Blood protein levels;
LUAD	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg00383909	chr3:49044727	WDR6	0.95	9.32	0.41	6.36e-19	Cognitive function;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg17338258	chr17:7533521	SHBG	-0.41	-7.33	-0.34	1.16e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg24101359	chr6:42928495	GNMT	0.52	9.95	0.44	4.1e-21	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg02869364	chr7:1081709	C7orf50	-0.5	-6.43	-0.3	3.45e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.41	-7.81	-0.36	4.55e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg09491104	chr22:46646882	C22orf40	-0.62	-10.19	-0.44	6.01e-22	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg08132940	chr7:1081526	C7orf50	-0.77	-10.35	-0.45	1.63e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.39	-7.71	-0.35	9.36e-14	Total body bone mineral density;
LUAD	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.35	6.79	0.31	3.91e-11	Depression;
LUAD	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg04025307	chr7:1156635	C7orf50	0.57	8.39	0.38	7.47e-16	Bronchopulmonary dysplasia;
LUAD	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.51	-0.42	1.51e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2274273	0.870	rs7153612	chr14:55788762	T/C	cg04306507	chr14:55594613	LGALS3	0.44	9.08	0.4	4.22e-18	Protein biomarker;
LUAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg13047869	chr3:10149882	C3orf24	0.63	10.8	0.46	3.58e-24	Alzheimer's disease;
LUAD	cis	rs12545109	0.800	rs1467125	chr8:57418638	C/T	cg21220214	chr8:57350948	NA	-0.63	-8.8	-0.39	3.55e-17	Obesity-related traits;
LUAD	cis	rs4901869	0.966	rs4901868	chr14:59333792	C/T	cg02291164	chr14:59296302	NA	-0.61	-14.86	-0.59	1.69e-40	Panic disorder;
LUAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg07685180	chr8:600429	NA	0.87	8.66	0.39	1.01e-16	IgG glycosylation;
LUAD	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg03453431	chr7:157225567	NA	-0.53	-9.58	-0.42	8.38e-20	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	trans	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg17712092	chr4:129076599	LARP1B	-0.77	-11.81	-0.5	5.01e-28	Breast cancer;
LUAD	cis	rs2286503	0.780	rs2286506	chr7:22854815	T/C	cg06496272	chr7:22895283	SNORD93	-0.38	-6.51	-0.3	2.07e-10	Fibrinogen;
LUAD	cis	rs2235642	0.592	rs743963	chr16:1657350	A/T	cg26528668	chr16:1614120	IFT140	0.43	7.24	0.33	2.1e-12	Coronary artery disease;
LUAD	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-7.81	-0.36	4.41e-14	Morning vs. evening chronotype;
LUAD	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg13685833	chr1:53393034	SCP2	-0.44	-7.22	-0.33	2.5e-12	Monocyte count;
LUAD	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg09455208	chr3:40491958	NA	0.54	11.83	0.5	4.22e-28	Renal cell carcinoma;
LUAD	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg02734326	chr4:10020555	SLC2A9	0.47	7.33	0.34	1.17e-12	Blood metabolite levels;
LUAD	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.13	-0.41	2.84e-18	Life satisfaction;
LUAD	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg20991723	chr1:152506922	NA	0.33	6.53	0.3	1.87e-10	Hair morphology;
LUAD	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-7.76	-0.35	6.64e-14	Blood metabolite levels;
LUAD	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg17644776	chr2:200775616	C2orf69	-0.51	-7.2	-0.33	2.69e-12	Schizophrenia;
LUAD	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-19.75	-0.69	5.55e-62	Height;
LUAD	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg01503450	chr10:980765	NA	-0.39	-6.87	-0.32	2.32e-11	Eosinophil percentage of granulocytes;
LUAD	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.87	-11.99	-0.5	1.02e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg21862992	chr11:68658383	NA	0.55	10.05	0.44	1.95e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg08219700	chr8:58056026	NA	0.4	6.42	0.3	3.75e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg02527881	chr3:46936655	PTH1R	0.4	7.78	0.35	5.6e-14	Colorectal cancer;
LUAD	cis	rs698833	0.741	rs2340808	chr2:44511861	T/C	cg04920474	chr2:44395004	PPM1B	0.4	7.01	0.32	9.47e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs10769966	0.515	rs2568069	chr11:8977707	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.54	9.25	0.41	1.16e-18	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs4072705	1.000	rs13283284	chr9:127516177	T/C	cg13476313	chr9:127244764	NR5A1	0.28	6.9	0.32	1.96e-11	Menarche (age at onset);
LUAD	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg00271210	chr6:167070053	RPS6KA2	0.34	6.59	0.31	1.3e-10	Crohn's disease;
LUAD	cis	rs10203711	1.000	rs907107	chr2:239565780	T/C	cg14580085	chr2:239553406	NA	0.41	8.91	0.4	1.51e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg17366294	chr4:99064904	C4orf37	0.65	12.64	0.52	2.71e-31	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8002861	0.664	rs9533662	chr13:44435988	T/A	cg17145862	chr1:211918768	LPGAT1	0.65	13.02	0.53	8e-33	Leprosy;
LUAD	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg12011299	chr4:100065546	ADH4	0.68	12.3	0.51	6.08e-30	Smoking initiation;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg10577346	chr11:8704225	RPL27A	-0.36	-6.35	-0.3	5.43e-10	Schizophrenia;
LUAD	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg18827107	chr12:86230957	RASSF9	-0.71	-13.07	-0.54	4.86e-33	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6432018	0.964	rs13415136	chr2:9729708	A/G	cg12832956	chr2:9616023	IAH1	-0.36	-6.45	-0.3	2.99e-10	Heart rate variability traits;
LUAD	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg03929089	chr4:120376271	NA	-0.97	-19.61	-0.69	2.26e-61	Height;
LUAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg08742575	chr21:47604166	C21orf56	0.61	10.67	0.46	1.09e-23	Testicular germ cell tumor;
LUAD	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg12935359	chr14:103987150	CKB	-0.44	-7.0	-0.32	1.02e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4523957	0.560	rs1994884	chr17:2084008	G/A	cg16513277	chr17:2031491	SMG6	-0.95	-18.95	-0.68	2.08e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs758324	0.853	rs6865911	chr5:131204659	A/G	cg25547332	chr5:131281432	NA	0.44	6.75	0.31	5e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg17724175	chr1:150552817	MCL1	0.35	7.93	0.36	2.01e-14	Melanoma;
LUAD	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg13770153	chr20:60521292	NA	-0.58	-9.01	-0.4	7.2e-18	Body mass index;
LUAD	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.24	0.37	2.17e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg00280220	chr17:61926910	NA	0.36	6.89	0.32	2.08e-11	Prudent dietary pattern;
LUAD	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg17346650	chr17:80929145	B3GNTL1	0.38	6.57	0.3	1.45e-10	Glycated hemoglobin levels;
LUAD	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg04450456	chr4:17643702	FAM184B	0.38	7.46	0.34	4.91e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg21285383	chr16:89894308	SPIRE2	0.4	9.68	0.43	3.71e-20	Vitiligo;
LUAD	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18876405	chr7:65276391	NA	-0.43	-6.85	-0.32	2.55e-11	Aortic root size;
LUAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg26528668	chr16:1614120	IFT140	0.57	10.35	0.45	1.55e-22	Coronary artery disease;
LUAD	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg18404041	chr3:52824283	ITIH1	0.56	9.45	0.42	2.33e-19	Schizophrenia;
LUAD	cis	rs57590327	0.503	rs6776737	chr3:81513729	T/C	cg07356753	chr3:81810745	GBE1	0.49	7.65	0.35	1.33e-13	Extraversion;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg04777052	chr13:73355909	DIS3;PIBF1	-0.38	-6.72	-0.31	5.87e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.37	0.3	4.94e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7683537	0.501	rs2171838	chr4:185667404	A/G	cg04058563	chr4:185651563	MLF1IP	-0.6	-9.2	-0.41	1.63e-18	Systemic lupus erythematosus;
LUAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00166722	chr3:10149974	C3orf24	0.71	12.27	0.51	8.39e-30	Alzheimer's disease;
LUAD	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-16.13	-0.62	5.71e-46	Schizophrenia;
LUAD	cis	rs7189233	0.955	rs16952242	chr16:53474250	C/T	cg04059762	chr16:53544020	NA	-0.41	-6.6	-0.31	1.27e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg11189052	chr15:85197271	WDR73	0.67	8.79	0.39	3.65e-17	Schizophrenia;
LUAD	cis	rs9616064	0.889	rs5767287	chr22:46996179	G/A	cg05621596	chr22:47072043	GRAMD4	-0.55	-9.07	-0.4	4.35e-18	Urate levels in obese individuals;
LUAD	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg08916839	chr5:415575	AHRR	0.82	9.51	0.42	1.49e-19	Fat distribution (HIV);
LUAD	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.47	0.3	2.78e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4638749	0.906	rs34974921	chr2:108860253	A/G	cg25838818	chr2:108905173	SULT1C2	-0.56	-8.82	-0.39	3.05e-17	Blood pressure;
LUAD	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg05340658	chr4:99064831	C4orf37	0.47	7.76	0.35	6.33e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6540559	0.543	rs664097	chr1:210422179	C/T	cg22029157	chr1:209979665	IRF6	0.64	7.23	0.33	2.34e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs939658	0.805	rs11635757	chr15:79432737	T/C	cg17916960	chr15:79447300	NA	-0.53	-11.32	-0.48	4.06e-26	Refractive error;
LUAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg00280220	chr17:61926910	NA	0.36	6.94	0.32	1.45e-11	Prudent dietary pattern;
LUAD	cis	rs7590720	0.819	rs1344694	chr2:216893637	T/G	cg12620499	chr2:216877984	MREG	0.57	9.65	0.42	4.89e-20	Alcohol dependence;
LUAD	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg17063962	chr7:91808500	NA	0.68	12.19	0.51	1.65e-29	Breast cancer;
LUAD	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12681287	0.605	rs13262672	chr8:87355812	T/C	cg27223183	chr8:87520930	FAM82B	-0.69	-9.66	-0.43	4.29e-20	Caudate activity during reward;
LUAD	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg19622623	chr12:86230825	RASSF9	0.43	7.57	0.35	2.42e-13	Major depressive disorder;
LUAD	cis	rs7210086	0.768	rs4075985	chr17:70640873	C/G	cg04206342	chr17:70636940	NA	-0.35	-6.88	-0.32	2.15e-11	Ulcerative colitis;
LUAD	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg12573674	chr2:1569213	NA	-0.56	-8.43	-0.38	5.31e-16	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg08645402	chr16:4508243	NA	0.56	10.34	0.45	1.71e-22	Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26096107	chr6:110012386	AKD1;FIG4	-0.42	-6.99	-0.32	1.08e-11	Cancer;
LUAD	cis	rs6835098	0.692	rs7657374	chr4:174065756	A/T	cg08422745	chr4:174089978	GALNT7	-0.86	-15.3	-0.6	2.26e-42	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs698833	0.926	rs786620	chr2:44595803	C/T	cg04920474	chr2:44395004	PPM1B	0.4	7.37	0.34	9.21e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.44	-0.34	5.72e-13	Triglycerides;
LUAD	cis	rs4332037	0.508	rs60238952	chr7:1914350	A/G	cg17551891	chr7:1960795	MAD1L1	-0.41	-7.1	-0.33	5.25e-12	Bipolar disorder;
LUAD	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg17366294	chr4:99064904	C4orf37	-0.48	-8.49	-0.38	3.66e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.07	0.33	6.28e-12	Platelet count;
LUAD	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg21775007	chr8:11205619	TDH	-0.51	-9.25	-0.41	1.09e-18	Retinal vascular caliber;
LUAD	cis	rs1873147	0.569	rs11636033	chr15:63311091	G/T	cg21584241	chr15:63341463	TPM1	-0.44	-6.89	-0.32	2.01e-11	Orofacial clefts;
LUAD	cis	rs6665290	0.904	rs1045252	chr1:227181555	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.38	-0.89	3.24e-147	Myeloid white cell count;
LUAD	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22857025	chr5:266934	NA	-0.97	-14.32	-0.57	3.32e-38	Breast cancer;
LUAD	cis	rs6714710	0.603	rs34974566	chr2:98552299	C/G	cg26665480	chr2:98280029	ACTR1B	0.49	8.07	0.37	7.26e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg13263323	chr15:86062960	AKAP13	-0.48	-8.92	-0.4	1.44e-17	Coronary artery disease;
LUAD	cis	rs3774830	0.748	rs58854245	chr4:5466134	G/A	cg26943120	chr4:5472116	STK32B	0.38	7.76	0.35	6.55e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg14598338	chr9:96623480	NA	0.41	8.74	0.39	5.39e-17	DNA methylation (variation);
LUAD	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg26924012	chr15:45694286	SPATA5L1	0.64	10.97	0.47	8.33e-25	Glomerular filtration rate;
LUAD	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg01689657	chr7:91764605	CYP51A1	0.31	7.45	0.34	5.16e-13	Breast cancer;
LUAD	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg11645453	chr3:52864694	ITIH4	-0.34	-6.85	-0.32	2.63e-11	Bipolar disorder;
LUAD	cis	rs17152411	0.895	rs7080475	chr10:126585767	A/G	cg07906193	chr10:126599966	NA	0.54	7.65	0.35	1.34e-13	Height;
LUAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg04025307	chr7:1156635	C7orf50	0.6	6.78	0.31	4.07e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg03433033	chr1:76189801	ACADM	-0.68	-10.54	-0.46	3.11e-23	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7010267	0.596	rs1905777	chr8:120021840	A/T	cg01975934	chr8:119970761	NA	-0.34	-6.57	-0.3	1.45e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg21918786	chr6:109611834	NA	0.57	10.69	0.46	8.68e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg06873352	chr17:61820015	STRADA	-0.74	-15.04	-0.59	2.82e-41	Prudent dietary pattern;
LUAD	cis	rs6906287	0.647	rs67832971	chr6:118832205	C/T	cg18833306	chr6:118973337	C6orf204	0.47	8.43	0.38	5.36e-16	Electrocardiographic conduction measures;
LUAD	cis	rs1566497	0.754	rs10000851	chr4:169743239	C/T	cg20607169	chr4:169750834	PALLD	0.45	7.92	0.36	2.14e-14	Pulse pressure;
LUAD	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg02733842	chr7:1102375	C7orf50	-0.85	-12.59	-0.52	4.34e-31	Bronchopulmonary dysplasia;
LUAD	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg23262073	chr20:60523788	NA	-0.37	-6.37	-0.3	4.87e-10	Body mass index;
LUAD	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg19635926	chr16:89946313	TCF25	0.69	6.52	0.3	2e-10	Skin colour saturation;
LUAD	cis	rs2274273	0.624	rs11848456	chr14:55755392	A/G	cg04306507	chr14:55594613	LGALS3	0.41	8.0	0.36	1.18e-14	Protein biomarker;
LUAD	cis	rs6500395	0.926	rs1039342	chr16:48577498	G/A	cg04672837	chr16:48644449	N4BP1	0.37	6.45	0.3	3.01e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg14186256	chr22:23484241	RTDR1	0.47	8.13	0.37	4.63e-15	Bone mineral density;
LUAD	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23221052	chr5:179740743	GFPT2	-0.66	-10.62	-0.46	1.69e-23	Height;
LUAD	cis	rs2882667	0.898	rs6867343	chr5:138374428	C/T	cg04439458	chr5:138467593	SIL1	-0.4	-7.16	-0.33	3.5e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.98	-0.5	1.09e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs9951602	0.512	rs9955812	chr18:76650954	T/A	cg02800362	chr5:177631904	HNRNPAB	0.92	14.03	0.56	5.64e-37	Obesity-related traits;
LUAD	cis	rs11650494	0.908	rs11658111	chr17:47383994	C/T	cg08112188	chr17:47440006	ZNF652	0.93	8.04	0.36	9.18e-15	Prostate cancer;
LUAD	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg18230493	chr5:56204884	C5orf35	-0.59	-9.72	-0.43	2.71e-20	Coronary artery disease;
LUAD	cis	rs2227564	0.672	rs2459449	chr10:75669013	T/C	cg23231163	chr10:75533350	FUT11	-0.44	-6.84	-0.32	2.72e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg00495681	chr13:53174319	NA	0.74	14.99	0.59	4.68e-41	Lewy body disease;
LUAD	cis	rs7172809	0.573	rs11854182	chr15:77448977	T/C	cg11865553	chr15:77376250	NA	-0.39	-6.39	-0.3	4.37e-10	Glucose homeostasis traits;
LUAD	cis	rs7187994	0.848	rs12922556	chr16:84784290	C/T	cg07647771	chr16:84786436	USP10	0.34	8.96	0.4	1.08e-17	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg14835575	chr10:16859367	RSU1	0.99	14.56	0.58	3.15e-39	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg07460842	chr6:66804631	NA	0.62	9.74	0.43	2.42e-20	Type 2 diabetes;
LUAD	cis	rs11048434	0.698	rs7300767	chr12:9123477	T/G	cg04155231	chr12:9217510	LOC144571	0.38	7.18	0.33	3.18e-12	Sjögren's syndrome;
LUAD	cis	rs3820068	0.705	rs72643683	chr1:15824905	C/A	cg17385448	chr1:15911702	AGMAT	0.39	6.36	0.3	5.39e-10	Systolic blood pressure;
LUAD	cis	rs4680	0.737	rs4818	chr22:19951207	C/G	cg06346307	chr22:19949965	COMT	-0.37	-7.24	-0.33	2.13e-12	Blood metabolite levels;
LUAD	cis	rs9863	0.827	rs7134121	chr12:124447346	T/C	cg17723958	chr12:124429295	CCDC92	-0.42	-6.91	-0.32	1.77e-11	White blood cell count;
LUAD	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg14847009	chr1:175162515	KIAA0040	0.31	7.82	0.36	4.21e-14	Alcohol dependence;
LUAD	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs1832871	0.672	rs9457345	chr6:158743098	A/G	cg07165851	chr6:158734300	TULP4	0.71	10.94	0.47	1.07e-24	Height;
LUAD	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg22117172	chr7:91764530	CYP51A1	0.34	7.52	0.34	3.42e-13	Breast cancer;
LUAD	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg01475377	chr6:109611718	NA	-0.55	-10.6	-0.46	1.93e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg09455208	chr3:40491958	NA	0.58	12.93	0.53	1.91e-32	Renal cell carcinoma;
LUAD	cis	rs76419734	0.558	rs17260183	chr4:106533196	C/A	cg05309399	chr4:106552544	FLJ20184	-0.57	-6.93	-0.32	1.54e-11	Post bronchodilator FEV1;
LUAD	trans	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.8	-15.17	-0.59	8e-42	Brugada syndrome;
LUAD	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg25894440	chr7:65020034	NA	-0.63	-6.74	-0.31	5.21e-11	Diabetic kidney disease;
LUAD	cis	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg00071950	chr4:10020882	SLC2A9	0.48	7.33	0.34	1.18e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg01874867	chr7:94954059	PON1	-0.5	-6.92	-0.32	1.69e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg11915388	chr22:42470451	FAM109B	0.41	7.28	0.33	1.64e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg14008862	chr17:28927542	LRRC37B2	0.75	7.43	0.34	6.2e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs13191362	0.573	rs9365499	chr6:163271833	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.38	6.37	0.3	5.03e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg25828334	chr19:18545568	ISYNA1	-0.38	-7.65	-0.35	1.38e-13	Breast cancer;
LUAD	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-10.99	-0.47	6.99e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg16414030	chr3:133502952	NA	-0.67	-13.04	-0.54	6.66e-33	Iron status biomarkers;
LUAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.58e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs739496	0.843	rs595529	chr12:112000648	A/T	cg10833066	chr12:111807467	FAM109A	0.41	6.57	0.3	1.52e-10	Platelet count;
LUAD	cis	rs9581857	0.556	rs1885991	chr13:28040470	G/A	cg22138327	chr13:27999177	GTF3A	0.77	11.02	0.47	5.19e-25	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs2554380	0.628	rs6602990	chr15:84452222	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.4	-7.15	-0.33	3.79e-12	Height;
LUAD	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg26373071	chr5:1325741	CLPTM1L	0.36	7.56	0.35	2.47e-13	Lung cancer;
LUAD	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg25237894	chr2:233734115	C2orf82	-0.6	-11.3	-0.48	4.7e-26	Coronary artery disease;
LUAD	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg02753203	chr1:228287806	NA	-0.47	-8.58	-0.39	1.77e-16	Diastolic blood pressure;
LUAD	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg14541582	chr5:601475	NA	-0.36	-7.58	-0.35	2.19e-13	Lung disease severity in cystic fibrosis;
LUAD	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg03929089	chr4:120376271	NA	-0.6	-9.48	-0.42	1.81e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg18721089	chr20:30220636	NA	-0.41	-6.45	-0.3	2.98e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs1784581	0.722	rs1621456	chr6:162399985	C/T	cg17173639	chr6:162384350	PARK2	-0.51	-9.18	-0.41	2e-18	Itch intensity from mosquito bite;
LUAD	cis	rs11077998	0.967	rs4789790	chr17:80510789	G/A	cg10255544	chr17:80519551	FOXK2	0.35	6.82	0.31	3.18e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg19622623	chr12:86230825	RASSF9	-0.54	-9.5	-0.42	1.6e-19	Major depressive disorder;
LUAD	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg11663144	chr21:46675770	NA	-0.61	-11.63	-0.49	2.46e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7943203	0.524	rs373759	chr11:108220657	C/T	cg04873221	chr11:107992290	ACAT1	-0.48	-7.39	-0.34	7.7e-13	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.86	0.36	3.11e-14	Depression;
LUAD	cis	rs938554	0.779	rs6449173	chr4:9966105	A/C	cg11266682	chr4:10021025	SLC2A9	-0.45	-7.95	-0.36	1.74e-14	Blood metabolite levels;
LUAD	cis	rs13082711	0.911	rs3736312	chr3:27442336	G/A	cg02860705	chr3:27208620	NA	0.6	9.26	0.41	1.05e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	trans	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg03886242	chr7:26192032	NFE2L3	0.44	7.69	0.35	1.02e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg22823121	chr1:150693482	HORMAD1	0.38	7.35	0.34	1.03e-12	Melanoma;
LUAD	cis	rs675209	0.637	rs1285879	chr6:7137363	T/C	cg23726566	chr6:7051754	NA	-0.38	-6.49	-0.3	2.47e-10	Urate levels;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg00101895	chr6:108279135	SEC63	-0.4	-6.71	-0.31	6.22e-11	Subcortical brain region volumes;
LUAD	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg06046430	chr4:77819534	ANKRD56	0.55	8.84	0.4	2.53e-17	Emphysema distribution in smoking;
LUAD	cis	rs2050392	0.931	rs2265187	chr10:30690844	C/T	cg18806716	chr10:30721971	MAP3K8	-0.55	-10.71	-0.46	7.61e-24	Inflammatory bowel disease;
LUAD	cis	rs11696501	0.688	rs6073842	chr20:44293841	G/C	cg11783356	chr20:44313418	WFDC10B	-0.49	-8.22	-0.37	2.53e-15	Brain structure;
LUAD	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg22029157	chr1:209979665	IRF6	0.47	8.39	0.38	7.36e-16	Monobrow;
LUAD	cis	rs11048434	0.698	rs7300767	chr12:9123477	T/G	cg23795048	chr12:9217529	LOC144571	0.42	7.56	0.34	2.56e-13	Sjögren's syndrome;
LUAD	cis	rs2115536	0.692	rs8036559	chr15:80170563	C/T	cg11839771	chr15:80205821	ST20	-0.37	-6.63	-0.31	1.02e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs775227	0.574	rs13083453	chr3:113096943	G/A	cg10517650	chr3:113235015	CCDC52	-0.47	-6.38	-0.3	4.68e-10	Dental caries;
LUAD	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg15485101	chr11:133734466	NA	0.34	7.69	0.35	1.05e-13	Childhood ear infection;
LUAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg05457628	chr5:178986728	RUFY1	0.76	13.6	0.55	3.51e-35	Lung cancer;
LUAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg10729496	chr3:10149963	C3orf24	0.64	9.56	0.42	9.9e-20	Alzheimer's disease;
LUAD	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg10356904	chr22:49881777	NA	-0.39	-7.22	-0.33	2.44e-12	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs783540	1.000	rs11637433	chr15:83321336	A/G	cg18393722	chr15:85113863	UBE2QP1	0.46	7.34	0.34	1.1e-12	Schizophrenia;
LUAD	cis	rs2985684	1.000	rs2224949	chr14:50096560	A/G	cg04989706	chr14:50066350	PPIL5	0.45	6.72	0.31	5.8e-11	Carotid intima media thickness;
LUAD	cis	rs15676	0.783	rs2280845	chr9:131583170	T/C	cg00228799	chr9:131580591	ENDOG	0.48	7.67	0.35	1.17e-13	Blood metabolite levels;
LUAD	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.49	-0.34	4.02e-13	Alzheimer's disease (late onset);
LUAD	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg00316803	chr15:76480434	C15orf27	0.39	6.57	0.3	1.51e-10	Blood metabolite levels;
LUAD	cis	rs6743376	0.556	rs2515391	chr2:113815997	C/T	cg09040174	chr2:113837401	NA	0.5	7.73	0.35	7.67e-14	Inflammatory biomarkers;
LUAD	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg00933542	chr6:150070202	PCMT1	0.44	9.68	0.43	3.86e-20	Lung cancer;
LUAD	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg23625390	chr15:77176239	SCAPER	0.41	7.03	0.32	8.33e-12	Blood metabolite levels;
LUAD	cis	rs6087990	0.735	rs2424906	chr20:31359109	A/G	cg13636640	chr20:31349939	DNMT3B	0.76	14.37	0.57	2.13e-38	Ulcerative colitis;
LUAD	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg23254163	chr1:152506842	NA	0.26	7.02	0.32	9.08e-12	Hair morphology;
LUAD	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg04944784	chr2:26401820	FAM59B	-0.73	-10.07	-0.44	1.65e-21	Gut microbiome composition (summer);
LUAD	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	11.05	0.47	4.11e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg01528321	chr10:82214614	TSPAN14	0.74	11.31	0.48	4.49e-26	Post bronchodilator FEV1;
LUAD	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg26769984	chr7:1090371	C7orf50	0.65	10.03	0.44	2.14e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg05082376	chr22:42548792	NA	-0.43	-7.63	-0.35	1.55e-13	Schizophrenia;
LUAD	cis	rs11048434	0.636	rs11614970	chr12:9060053	G/A	cg04155231	chr12:9217510	LOC144571	0.37	6.88	0.32	2.12e-11	Sjögren's syndrome;
LUAD	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg14834391	chr1:2537342	MMEL1	0.31	6.42	0.3	3.6e-10	Ulcerative colitis;
LUAD	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.33	0.34	1.15e-12	Menopause (age at onset);
LUAD	cis	rs790123	0.965	rs2133850	chr3:122381696	C/T	cg15604389	chr3:122379662	NA	0.48	8.4	0.38	6.77e-16	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg26384229	chr12:38710491	ALG10B	0.45	7.36	0.34	9.9e-13	Bladder cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13544184	chr9:71395167	PIP5K1B;FAM122A	-0.42	-6.75	-0.31	4.99e-11	Cancer;
LUAD	cis	rs3733418	0.929	rs1401400	chr4:165927911	G/C	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.52	-6.73	-0.31	5.67e-11	Obesity-related traits;
LUAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12711979	0.765	rs6715805	chr2:3821117	T/C	cg17052675	chr2:3827356	NA	-0.51	-10.53	-0.46	3.52e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg21475434	chr5:93447410	FAM172A	0.74	8.59	0.39	1.72e-16	Diabetic retinopathy;
LUAD	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	8.65	0.39	1.05e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg26343298	chr8:95960752	TP53INP1	0.38	8.03	0.36	9.95e-15	Type 2 diabetes;
LUAD	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg07305463	chr2:136567211	LCT	-0.36	-6.75	-0.31	5.02e-11	Mosquito bite size;
LUAD	cis	rs6499255	0.951	rs8045705	chr16:69581672	A/G	cg15192750	chr16:69999425	NA	0.51	7.98	0.36	1.39e-14	IgE levels;
LUAD	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg15448220	chr1:150897856	SETDB1	0.46	7.97	0.36	1.47e-14	Tonsillectomy;
LUAD	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg17595323	chr11:93583763	C11orf90	-0.43	-9.12	-0.41	3.11e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg18016565	chr1:150552671	MCL1	0.43	7.76	0.35	6.38e-14	Melanoma;
LUAD	cis	rs748404	0.723	rs512431	chr15:43541939	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.46	-7.37	-0.34	9.31e-13	Lung cancer;
LUAD	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg00745463	chr17:30367425	LRRC37B	-0.79	-9.72	-0.43	2.68e-20	Hip circumference adjusted for BMI;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg05489143	chr3:40498640	RPL14	-0.43	-7.31	-0.33	1.34e-12	Subcortical brain region volumes;
LUAD	cis	rs986417	1.000	rs1254298	chr14:60883842	C/T	cg27398547	chr14:60952738	C14orf39	-0.66	-7.71	-0.35	9.13e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg24846343	chr22:24311635	DDTL	0.8	17.86	0.66	1.36e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg15448220	chr1:150897856	SETDB1	0.51	8.72	0.39	6.53e-17	Melanoma;
LUAD	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg09796270	chr17:17721594	SREBF1	-0.4	-8.03	-0.36	9.77e-15	Total body bone mineral density;
LUAD	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.59	0.52	4.48e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg13535736	chr9:111863775	C9orf5	-0.42	-6.45	-0.3	3.09e-10	Menarche (age at onset);
LUAD	cis	rs9902453	0.904	rs9900974	chr17:28364456	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.62	-0.46	1.66e-23	Coffee consumption (cups per day);
LUAD	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg09065629	chr16:1709722	CRAMP1L	0.42	7.37	0.34	9.04e-13	Coronary artery disease;
LUAD	cis	rs2067615	0.579	rs10778502	chr12:107090201	T/C	cg15890332	chr12:107067104	RFX4	0.4	8.38	0.38	7.9e-16	Heart rate;
LUAD	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg01874867	chr7:94954059	PON1	-0.48	-6.48	-0.3	2.49e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg25344623	chr2:136566232	LCT	-0.34	-6.67	-0.31	8.03e-11	Mosquito bite size;
LUAD	cis	rs2286885	1.000	rs741022	chr9:129252113	C/G	cg15282417	chr9:129245246	FAM125B	0.44	9.09	0.4	3.85e-18	Intraocular pressure;
LUAD	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg13334819	chr7:99746414	C7orf59	0.66	10.57	0.46	2.57e-23	Coronary artery disease;
LUAD	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg04282206	chr17:62833786	PLEKHM1P	0.39	6.55	0.3	1.69e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg24818145	chr4:99064322	C4orf37	-0.47	-7.95	-0.36	1.7e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.84e-26	Alzheimer's disease (late onset);
LUAD	cis	rs89107	0.603	rs414091	chr6:118613398	T/C	cg21191810	chr6:118973309	C6orf204	0.53	10.58	0.46	2.34e-23	Cardiac structure and function;
LUAD	cis	rs7737355	0.947	rs6596027	chr5:130879547	A/G	cg25547332	chr5:131281432	NA	0.43	6.45	0.3	3e-10	Life satisfaction;
LUAD	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg25358565	chr5:93447407	FAM172A	0.58	6.81	0.31	3.35e-11	Diabetic retinopathy;
LUAD	cis	rs4642101	0.824	rs3889515	chr3:12844112	G/C	cg24848339	chr3:12840334	CAND2	0.39	7.91	0.36	2.29e-14	QRS complex (12-leadsum);
LUAD	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	9.54	0.42	1.16e-19	Electrocardiographic conduction measures;
LUAD	cis	rs36051895	0.659	rs72701605	chr9:5062056	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-7.17	-0.33	3.31e-12	Pediatric autoimmune diseases;
LUAD	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18404041	chr3:52824283	ITIH1	-0.53	-11.01	-0.47	5.72e-25	Bipolar disorder;
LUAD	cis	rs758324	0.947	rs1948704	chr5:131171653	A/G	cg06307176	chr5:131281290	NA	0.5	7.86	0.36	3.17e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg03929089	chr4:120376271	NA	0.71	11.45	0.49	1.29e-26	Coronary artery disease;
LUAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg22907277	chr7:1156413	C7orf50	0.8	12.22	0.51	1.29e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.76	9.49	0.42	1.75e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg23254163	chr1:152506842	NA	0.26	7.04	0.32	8.05e-12	Hair morphology;
LUAD	cis	rs67366981	1.000	rs17105547	chr14:77698358	G/A	cg22824376	chr14:77648248	TMEM63C	0.74	7.83	0.36	3.97e-14	Obsessive-compulsive symptoms;
LUAD	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg12179176	chr11:130786555	SNX19	0.45	7.24	0.33	2.16e-12	Schizophrenia;
LUAD	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.9	-0.36	2.45e-14	Total body bone mineral density;
LUAD	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg13012494	chr21:47604986	C21orf56	0.47	7.75	0.35	6.7e-14	Testicular germ cell tumor;
LUAD	cis	rs9323205	0.862	rs11629399	chr14:51612814	T/C	cg23942311	chr14:51606299	NA	-0.62	-10.11	-0.44	1.18e-21	Cancer;
LUAD	cis	rs7267979	0.586	rs6050429	chr20:25183058	G/A	cg08601574	chr20:25228251	PYGB	0.36	6.61	0.31	1.14e-10	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs889398	0.677	rs68161338	chr16:69823778	T/G	cg00738113	chr16:70207722	CLEC18C	0.34	6.8	0.31	3.63e-11	Body mass index;
LUAD	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg23992470	chr4:843637	GAK	0.69	7.48	0.34	4.31e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2386661	0.784	rs2386652	chr10:5676326	G/A	cg26603656	chr10:5671107	NA	0.43	7.22	0.33	2.44e-12	Breast cancer;
LUAD	cis	rs3087591	0.919	rs9913470	chr17:29566575	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.62	-0.31	1.1e-10	Hip circumference;
LUAD	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg06636001	chr8:8085503	FLJ10661	0.42	6.54	0.3	1.74e-10	Joint mobility (Beighton score);
LUAD	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg08798685	chr6:27730294	NA	-0.4	-6.38	-0.3	4.55e-10	Parkinson's disease;
LUAD	cis	rs4730250	0.634	rs257371	chr7:106795043	C/A	cg23024343	chr7:107201750	COG5	0.51	6.97	0.32	1.25e-11	Osteoarthritis;
LUAD	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg17724175	chr1:150552817	MCL1	0.35	7.93	0.36	2.01e-14	Melanoma;
LUAD	cis	rs7590720	0.731	rs1864253	chr2:216878008	C/G	cg12620499	chr2:216877984	MREG	0.6	10.16	0.44	7.58e-22	Alcohol dependence;
LUAD	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg27539214	chr16:67997921	SLC12A4	-0.67	-8.2	-0.37	2.93e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg16680214	chr1:154839983	KCNN3	-0.65	-13.44	-0.55	1.49e-34	Prostate cancer;
LUAD	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg22963979	chr7:1858916	MAD1L1	-0.5	-8.77	-0.39	4.39e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs7586879	0.789	rs11688754	chr2:25133885	C/T	cg04586622	chr2:25135609	ADCY3	0.37	7.53	0.34	3.02e-13	Body mass index;
LUAD	cis	rs6545883	0.929	rs1209434	chr2:61672958	G/A	cg15711740	chr2:61764176	XPO1	-0.4	-6.4	-0.3	4.2e-10	Tuberculosis;
LUAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-7.66	-0.35	1.28e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs68170813	0.605	rs2299428	chr7:107134384	A/G	cg02696742	chr7:106810147	HBP1	-0.78	-10.42	-0.45	9e-23	Coronary artery disease;
LUAD	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23583168	chr7:148888333	NA	-0.89	-17.9	-0.66	9.52e-54	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg12143784	chr7:64541923	NA	0.52	8.57	0.38	1.89e-16	Calcium levels;
LUAD	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.14	0.48	1.9e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-11.24	-0.48	7.84e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.79	0.31	3.85e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2219968	0.701	rs7015968	chr8:78995994	A/G	cg00280220	chr17:61926910	NA	-0.35	-6.36	-0.3	5.34e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26314531	chr2:26401878	FAM59B	-0.64	-8.7	-0.39	7.27e-17	Gut microbiome composition (summer);
LUAD	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg10518543	chr12:38710700	ALG10B	0.42	6.36	0.3	5.18e-10	Bladder cancer;
LUAD	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg03929089	chr4:120376271	NA	0.57	7.48	0.34	4.2e-13	Axial length;
LUAD	trans	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg21659725	chr3:3221576	CRBN	-0.57	-9.17	-0.41	2.14e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg25173405	chr17:45401733	C17orf57	-0.47	-7.78	-0.35	5.79e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12472274	0.941	rs2880131	chr2:239089151	A/C	cg17459225	chr2:239074497	NA	0.72	9.94	0.44	4.49e-21	Phospholipid levels (plasma);
LUAD	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg05304507	chr6:116381966	FRK	0.2	6.79	0.31	3.81e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg22117172	chr7:91764530	CYP51A1	0.35	7.9	0.36	2.43e-14	Breast cancer;
LUAD	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21659725	chr3:3221576	CRBN	-0.63	-9.95	-0.44	4.13e-21	Educational attainment;
LUAD	cis	rs7084921	0.552	rs7913374	chr10:101879686	C/G	cg19754520	chr10:101825118	CPN1	0.32	6.45	0.3	3.01e-10	Bone mineral density;
LUAD	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg07538946	chr5:131705188	SLC22A5	0.41	6.83	0.32	3e-11	Blood metabolite levels;
LUAD	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg19163074	chr7:65112434	INTS4L2	-0.45	-6.74	-0.31	5.32e-11	Aortic root size;
LUAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	10.69	0.46	9.31e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg27129171	chr3:47204927	SETD2	0.42	6.78	0.31	4.09e-11	Colorectal cancer;
LUAD	cis	rs35740288	0.770	rs1871285	chr15:86152487	C/T	cg13263323	chr15:86062960	AKAP13	-0.44	-7.02	-0.32	8.78e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	trans	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg05926928	chr17:57297772	GDPD1	0.63	9.52	0.42	1.32e-19	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUAD	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg20129853	chr10:51489980	NA	0.34	6.83	0.32	3.01e-11	Prostate-specific antigen levels;
LUAD	cis	rs8099014	1.000	rs4940710	chr18:56135390	C/G	cg12907477	chr18:56117327	MIR122	0.39	6.62	0.31	1.1e-10	Platelet count;
LUAD	cis	rs240764	0.621	rs4840154	chr6:101225723	A/C	cg09795085	chr6:101329169	ASCC3	-0.44	-7.72	-0.35	8.4e-14	Neuroticism;
LUAD	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg11062466	chr8:58055876	NA	0.79	9.66	0.43	4.46e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg06360820	chr2:242988706	NA	-1.05	-14.3	-0.57	4.22e-38	Obesity-related traits;
LUAD	cis	rs3815700	1.000	rs8101356	chr19:33093402	C/T	cg02997394	chr19:33096574	ANKRD27	0.66	8.7	0.39	7.31e-17	Eosinophilic esophagitis;
LUAD	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg15147215	chr3:52552868	STAB1	-0.38	-6.81	-0.31	3.42e-11	Bipolar disorder;
LUAD	cis	rs775227	0.574	rs16860849	chr3:113049993	C/T	cg18753928	chr3:113234510	CCDC52	0.64	8.52	0.38	2.92e-16	Dental caries;
LUAD	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg06197492	chr11:2016605	H19	0.42	8.38	0.38	7.68e-16	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	0.29	7.34	0.34	1.07e-12	Total body bone mineral density;
LUAD	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg03806693	chr22:41940476	POLR3H	-0.47	-6.93	-0.32	1.56e-11	Vitiligo;
LUAD	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg15432903	chr11:17409602	KCNJ11	0.52	9.91	0.43	5.8e-21	Type 2 diabetes;
LUAD	trans	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg26043149	chr18:55253948	FECH	0.51	8.3	0.37	1.4e-15	Bone mineral density;
LUAD	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg17971929	chr21:40555470	PSMG1	-0.42	-6.72	-0.31	5.86e-11	Cognitive function;
LUAD	cis	rs4722585	0.533	rs12334205	chr7:26202490	G/A	cg07876897	chr7:26191696	NFE2L3	0.45	7.32	0.34	1.3e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg14458575	chr2:238380390	NA	-0.59	-9.42	-0.42	2.87e-19	Prostate cancer;
LUAD	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.05e-19	Life satisfaction;
LUAD	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg19875535	chr5:140030758	IK	-0.48	-8.07	-0.37	7.55e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7799006	0.964	rs3757440	chr7:2272936	A/G	cg12745145	chr7:2261452	MAD1L1	-0.34	-6.82	-0.31	3.17e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg14791747	chr16:20752902	THUMPD1	0.9	16.02	0.61	1.82e-45	Cognitive test performance;
LUAD	cis	rs75920871	0.858	rs11216168	chr11:116741553	G/A	cg04087571	chr11:116723030	SIK3	-0.33	-6.48	-0.3	2.49e-10	Subjective well-being;
LUAD	trans	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg01620082	chr3:125678407	NA	-1.04	-10.23	-0.45	4.13e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6445967	0.554	rs62259769	chr3:58414382	C/T	cg23715586	chr3:58305044	RPP14	0.4	6.61	0.31	1.17e-10	Platelet count;
LUAD	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-13.84	-0.56	3.42e-36	Headache;
LUAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg25204440	chr1:209979598	IRF6	0.63	12.5	0.52	9.52e-31	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUAD	cis	rs4771122	0.728	rs1475221	chr13:28037566	C/T	cg22138327	chr13:27999177	GTF3A	-0.62	-8.94	-0.4	1.22e-17	Body mass index;
LUAD	trans	rs9929218	1.000	rs12443730	chr16:68804342	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.72	-0.55	1.11e-35	Colorectal cancer;
LUAD	cis	rs6754311	0.544	rs11693502	chr2:136808949	C/T	cg05194412	chr2:137003533	NA	0.48	7.68	0.35	1.1e-13	Mosquito bite size;
LUAD	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg25173405	chr17:45401733	C17orf57	-0.53	-9.07	-0.4	4.6e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg10518543	chr12:38710700	ALG10B	-0.42	-6.97	-0.32	1.24e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg18099408	chr3:52552593	STAB1	-0.39	-6.68	-0.31	7.6e-11	Bipolar disorder;
LUAD	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg22508957	chr16:3507546	NAT15	-0.83	-9.53	-0.42	1.26e-19	Tuberculosis;
LUAD	cis	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg07460842	chr6:66804631	NA	0.61	9.71	0.43	3.06e-20	Type 2 diabetes;
LUAD	cis	rs8077889	1.000	rs17675122	chr17:41886190	A/G	cg26893861	chr17:41843967	DUSP3	0.95	14.58	0.58	2.55e-39	Triglycerides;
LUAD	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg26597838	chr10:835615	NA	1.0	15.69	0.61	4.68e-44	Eosinophil percentage of granulocytes;
LUAD	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg24838063	chr12:130822603	PIWIL1	0.64	10.68	0.46	9.9899999999999993e-24	Menopause (age at onset);
LUAD	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg22166914	chr1:53195759	ZYG11B	0.45	7.63	0.35	1.52e-13	Monocyte count;
LUAD	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg00898013	chr13:113819073	PROZ	-0.68	-12.12	-0.51	3.13e-29	Platelet distribution width;
LUAD	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg18404041	chr3:52824283	ITIH1	0.41	7.41	0.34	6.88e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06544989	chr22:39130855	UNC84B	-0.45	-8.65	-0.39	1.09e-16	Menopause (age at onset);
LUAD	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.39	-10.09	-0.44	1.4e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7771547	0.573	rs619011	chr6:36476592	A/G	cg07856975	chr6:36356162	ETV7	0.42	6.38	0.3	4.7e-10	Platelet distribution width;
LUAD	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg11502198	chr6:26597334	ABT1	0.56	9.35	0.41	5.14e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.84	-0.43	1.03e-20	Monocyte percentage of white cells;
LUAD	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg07606381	chr6:8435919	SLC35B3	0.41	6.76	0.31	4.51e-11	Motion sickness;
LUAD	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg04287289	chr16:89883240	FANCA	-0.49	-8.12	-0.37	5.02e-15	Vitiligo;
LUAD	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg11645453	chr3:52864694	ITIH4	-0.39	-7.63	-0.35	1.56e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg11833968	chr6:79620685	NA	-0.44	-8.11	-0.37	5.42e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg22676075	chr6:135203613	NA	0.42	7.58	0.35	2.24e-13	Red blood cell count;
LUAD	cis	rs62238980	0.614	rs80321137	chr22:32460767	C/T	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs6500395	1.000	rs4517800	chr16:48677404	T/A	cg04672837	chr16:48644449	N4BP1	0.39	6.81	0.31	3.43e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs1997103	1.000	rs4947500	chr7:55407270	C/A	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2279817	0.818	rs11582250	chr1:17994234	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.47	-7.26	-0.33	1.89e-12	Neuroticism;
LUAD	cis	rs4604732	0.631	rs75600450	chr1:247625492	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.34	-0.45	1.71e-22	Total body bone mineral density;
LUAD	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg23625390	chr15:77176239	SCAPER	0.49	7.69	0.35	1.02e-13	Blood metabolite levels;
LUAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg13560548	chr3:10150139	C3orf24	0.41	6.74	0.31	5.15e-11	Alzheimer's disease;
LUAD	cis	rs4919694	1.000	rs10509758	chr10:104681710	T/C	cg04362960	chr10:104952993	NT5C2	0.72	7.75	0.35	6.87e-14	Arsenic metabolism;
LUAD	cis	rs806215	1.000	rs712698	chr7:127249098	C/T	cg25922125	chr7:127225783	GCC1	0.49	7.1	0.33	5.47e-12	Type 2 diabetes;
LUAD	cis	rs8010715	0.848	rs8009511	chr14:24593980	G/A	cg23112188	chr14:24563095	PCK2	-0.32	-6.51	-0.3	2.12e-10	IgG glycosylation;
LUAD	cis	rs8077889	1.000	rs2880329	chr17:41866168	T/A	cg26893861	chr17:41843967	DUSP3	0.96	14.72	0.58	6.5e-40	Triglycerides;
LUAD	cis	rs1160297	0.609	rs1451455	chr2:53101529	T/C	cg07782112	chr2:53107842	NA	0.42	9.04	0.4	5.77e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7084921	0.608	rs12780510	chr10:101865881	T/C	cg19754520	chr10:101825118	CPN1	-0.32	-6.45	-0.3	3.11e-10	Bone mineral density;
LUAD	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg11645453	chr3:52864694	ITIH4	-0.36	-6.96	-0.32	1.33e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs494562	0.730	rs9450271	chr6:86114837	G/A	cg21730993	chr6:86159210	NT5E	0.57	6.53	0.3	1.9e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg08439880	chr3:133502540	NA	-0.37	-7.16	-0.33	3.58e-12	Iron status biomarkers;
LUAD	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg15704280	chr7:45808275	SEPT13	-1.05	-23.66	-0.75	1.89e-79	Height;
LUAD	cis	rs617219	0.553	rs114964313	chr5:78433572	G/A	cg25119155	chr5:78426943	BHMT	0.37	6.45	0.3	3e-10	Betaine levels in individuals undergoing cardiac evaluation;
LUAD	cis	rs3087591	0.922	rs2905799	chr17:29536901	G/A	cg24425628	chr17:29625626	OMG;NF1	0.4	6.52	0.3	2.05e-10	Hip circumference;
LUAD	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.72	-12.32	-0.51	5.16e-30	Primary sclerosing cholangitis;
LUAD	cis	rs6076065	0.723	rs4815199	chr20:23347169	G/A	cg11657817	chr20:23433608	CST11	0.47	8.94	0.4	1.2e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs9473147	0.516	rs9296561	chr6:47488938	G/A	cg20196966	chr6:47445060	CD2AP	0.45	7.08	0.33	6.11e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2046867	0.908	rs2322610	chr3:72793651	C/A	cg25664220	chr3:72788482	NA	-0.63	-11.56	-0.49	4.87e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg07636037	chr3:49044803	WDR6	0.62	10.46	0.45	6.21e-23	Menarche (age at onset);
LUAD	cis	rs7264396	0.836	rs4911183	chr20:34181553	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.44	6.66	0.31	8.43e-11	Total cholesterol levels;
LUAD	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg01802117	chr1:53393560	SCP2	0.37	7.2	0.33	2.8e-12	Monocyte count;
LUAD	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg09640425	chr7:158790006	NA	-0.48	-8.17	-0.37	3.5e-15	Facial morphology (factor 20);
LUAD	cis	rs1448094	0.813	rs6539942	chr12:86452969	T/C	cg18827107	chr12:86230957	RASSF9	0.41	7.35	0.34	1.02e-12	Major depressive disorder;
LUAD	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13636640	chr20:31349939	DNMT3B	0.75	13.54	0.55	5.7e-35	Ulcerative colitis;
LUAD	cis	rs2810114	1.000	rs2810114	chr14:71395604	C/A	cg15910301	chr14:71632612	NA	-0.41	-6.45	-0.3	3.01e-10	Alcohol dependence;
LUAD	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg03526776	chr6:41159608	TREML2	0.35	7.31	0.33	1.33e-12	Alzheimer's disease (late onset);
LUAD	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg19761014	chr17:28927070	LRRC37B2	0.84	8.37	0.38	8.43e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg20703242	chr1:230279135	GALNT2	0.66	12.19	0.51	1.74e-29	Coronary artery disease;
LUAD	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg12310025	chr6:25882481	NA	0.58	9.74	0.43	2.28e-20	Blood metabolite levels;
LUAD	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg18252515	chr7:66147081	NA	0.6	6.68	0.31	7.56e-11	Diabetic kidney disease;
LUAD	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg19336497	chr11:14380999	RRAS2	-0.69	-16.34	-0.62	7.36e-47	Sense of smell;
LUAD	cis	rs62458065	0.850	rs7785659	chr7:32461015	C/T	cg20159608	chr7:32802032	NA	-0.53	-6.99	-0.32	1.1e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12667521	chr19:29218732	NA	0.61	8.61	0.39	1.49e-16	Methadone dose in opioid dependence;
LUAD	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	8.34	0.38	1.09e-15	Breast cancer;
LUAD	cis	rs1497828	0.956	rs2646833	chr1:217545039	A/G	cg04411442	chr1:217543379	NA	0.35	6.48	0.3	2.56e-10	Dialysis-related mortality;
LUAD	cis	rs3812565	0.506	rs4259518	chr9:139322503	T/C	cg14019695	chr9:139328340	INPP5E	0.57	11.67	0.49	1.73e-27	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg15448220	chr1:150897856	SETDB1	0.46	7.92	0.36	2.06e-14	Tonsillectomy;
LUAD	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.22	-0.33	2.45e-12	Bipolar disorder;
LUAD	cis	rs2274273	0.837	rs11625968	chr14:55801004	G/C	cg04306507	chr14:55594613	LGALS3	0.44	9.16	0.41	2.27e-18	Protein biomarker;
LUAD	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-6.87	-0.32	2.35e-11	Total body bone mineral density;
LUAD	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg26513180	chr16:89883248	FANCA	0.75	6.67	0.31	8.13e-11	Skin colour saturation;
LUAD	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg00666640	chr1:248458726	OR2T12	0.3	7.24	0.33	2.14e-12	Common traits (Other);
LUAD	cis	rs6499255	0.951	rs11639947	chr16:69646122	C/T	cg15192750	chr16:69999425	NA	0.54	8.5	0.38	3.38e-16	IgE levels;
LUAD	cis	rs13064411	0.542	rs11537650	chr3:113222036	G/A	cg18753928	chr3:113234510	CCDC52	-0.55	-9.71	-0.43	3e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs11585357	0.947	rs2977303	chr1:17611548	A/T	cg08277548	chr1:17600880	PADI3	-0.81	-12.23	-0.51	1.14e-29	Hair shape;
LUAD	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg26769984	chr7:1090371	C7orf50	0.57	9.6	0.42	7.15e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs1003719	0.646	rs2032063	chr21:38576657	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.2	-0.37	2.89e-15	Eye color traits;
LUAD	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg25894440	chr7:65020034	NA	-0.63	-6.65	-0.31	8.99e-11	Diabetic kidney disease;
LUAD	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg27539214	chr16:67997921	SLC12A4	-0.72	-9.18	-0.41	1.87e-18	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13904199	chr9:86594091	HNRNPK	0.47	7.25	0.33	1.99e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg06453172	chr10:134556979	INPP5A	-0.76	-10.97	-0.47	8.59e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg15557168	chr22:42548783	NA	-0.36	-6.39	-0.3	4.35e-10	Cognitive function;
LUAD	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24531977	chr5:56204891	C5orf35	-0.97	-14.57	-0.58	2.85e-39	Initial pursuit acceleration;
LUAD	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg07414643	chr4:187882934	NA	0.33	6.75	0.31	4.81e-11	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg07817883	chr1:32538562	TMEM39B	1.14	11.48	0.49	9.34e-27	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs62400317	0.859	rs10948205	chr6:45124585	T/C	cg20913747	chr6:44695427	NA	-0.42	-6.69	-0.31	7.1e-11	Total body bone mineral density;
LUAD	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg17443473	chr1:3703550	LRRC47	0.44	7.38	0.34	8.2e-13	Red cell distribution width;
LUAD	cis	rs2742234	1.000	rs1864399	chr10:43610455	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.44	-7.82	-0.36	4.32e-14	Hirschsprung disease;
LUAD	cis	rs62238980	0.614	rs75691061	chr22:32381222	G/A	cg02631450	chr22:32366979	NA	0.79	6.46	0.3	2.9e-10	Childhood ear infection;
LUAD	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg04989706	chr14:50066350	PPIL5	0.53	7.75	0.35	6.74e-14	Carotid intima media thickness;
LUAD	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg06784218	chr1:46089804	CCDC17	-0.6	-13.5	-0.55	8.36e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4660306	1.000	rs6429567	chr1:45956700	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-8.01	-0.36	1.11e-14	Homocysteine levels;
LUAD	cis	rs4812048	1.000	rs6070697	chr20:57599402	G/A	cg14073986	chr20:57617431	SLMO2	0.56	7.17	0.33	3.4e-12	Mean platelet volume;
LUAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03452623	chr4:187889614	NA	-0.82	-16.76	-0.63	9.79e-49	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg06784218	chr1:46089804	CCDC17	-0.53	-11.64	-0.49	2.27e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1847202	0.859	rs13090900	chr3:72946560	C/A	cg25664220	chr3:72788482	NA	-0.45	-7.92	-0.36	2.05e-14	Motion sickness;
LUAD	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.4	-6.36	-0.3	5.26e-10	Glycated hemoglobin levels;
LUAD	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg06740227	chr12:86229804	RASSF9	0.36	6.55	0.3	1.63e-10	Major depressive disorder;
LUAD	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06873352	chr17:61820015	STRADA	0.52	8.52	0.38	2.88e-16	Height;
LUAD	cis	rs4713675	0.510	rs1014933	chr6:33677235	A/G	cg14003231	chr6:33640908	ITPR3	0.49	9.41	0.42	3.32e-19	Plateletcrit;
LUAD	cis	rs7582720	1.000	rs72934767	chr2:203766563	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg22105103	chr4:187893119	NA	0.54	11.63	0.49	2.51e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26314531	chr2:26401878	FAM59B	-0.64	-8.73	-0.39	5.91e-17	Gut microbiome composition (summer);
LUAD	cis	rs939658	0.967	rs7171067	chr15:79452727	G/T	cg17916960	chr15:79447300	NA	0.47	9.52	0.42	1.35e-19	Refractive error;
LUAD	trans	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg21775007	chr8:11205619	TDH	0.39	7.0	0.32	9.96e-12	Mood instability;
LUAD	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg12011299	chr4:100065546	ADH4	-0.72	-13.36	-0.54	3.31e-34	Alcohol dependence;
LUAD	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg20108693	chr8:143823809	SLURP1	0.32	7.23	0.33	2.22e-12	Urinary tract infection frequency;
LUAD	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg10802521	chr3:52805072	NEK4	-0.46	-6.63	-0.31	1.01e-10	Schizophrenia;
LUAD	cis	rs2735413	0.881	rs4888732	chr16:78080505	A/G	cg04733911	chr16:78082701	NA	-0.35	-8.22	-0.37	2.48e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg18306943	chr3:40428807	ENTPD3	0.36	6.37	0.3	4.98e-10	Renal cell carcinoma;
LUAD	cis	rs11098699	0.821	rs12500715	chr4:124230078	T/C	cg09941581	chr4:124220074	SPATA5	0.46	7.3	0.33	1.42e-12	Mosquito bite size;
LUAD	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg13319975	chr6:146136371	FBXO30	-0.64	-11.14	-0.48	1.93e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs714027	1.000	rs2412970	chr22:30486826	C/T	cg11564601	chr22:30592435	NA	0.4	8.78	0.39	4.19e-17	Lymphocyte counts;
LUAD	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg07570687	chr10:102243282	WNT8B	0.44	6.79	0.31	3.72e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg13722127	chr7:150037890	RARRES2	0.48	8.37	0.38	8.59e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg00277334	chr10:82204260	NA	-0.63	-10.54	-0.46	3.23e-23	Post bronchodilator FEV1;
LUAD	trans	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg01620082	chr3:125678407	NA	-1.1	-10.56	-0.46	2.69e-23	Depression;
LUAD	trans	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.71	-0.35	8.88e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.89	-0.32	2.06e-11	Retinal vascular caliber;
LUAD	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.7	0.39	7.29e-17	Menopause (age at onset);
LUAD	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg20848291	chr7:100343083	ZAN	0.39	6.72	0.31	5.83e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs12545109	0.842	rs10958482	chr8:57389331	G/T	cg19413350	chr8:57351067	NA	-0.44	-6.85	-0.32	2.64e-11	Obesity-related traits;
LUAD	trans	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17712092	chr4:129076599	LARP1B	0.85	15.93	0.61	4.1e-45	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-9.08	-0.4	4.23e-18	Life satisfaction;
LUAD	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg05887092	chr17:76393375	PGS1	0.42	7.42	0.34	6.31e-13	HDL cholesterol levels;
LUAD	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg14926445	chr8:58193284	C8orf71	-0.48	-7.0	-0.32	1.03e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg25427524	chr10:38739819	LOC399744	-0.59	-6.62	-0.31	1.09e-10	Obesity (extreme);
LUAD	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg07936489	chr17:37558343	FBXL20	-0.56	-7.39	-0.34	7.68e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg21823605	chr1:152486609	CRCT1	0.28	6.52	0.3	2.01e-10	Hair morphology;
LUAD	cis	rs4523957	0.620	rs1565764	chr17:2074303	G/A	cg16513277	chr17:2031491	SMG6	-0.99	-20.0	-0.7	3.94e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg02569458	chr12:86230093	RASSF9	0.45	8.12	0.37	5.02e-15	Major depressive disorder;
LUAD	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg09509183	chr1:209979624	IRF6	0.57	7.8	0.35	5.05e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs3845702	0.668	rs3856415	chr2:180807367	G/A	cg01881094	chr2:180872142	CWC22	-0.82	-8.76	-0.39	4.86e-17	Schizophrenia;
LUAD	cis	rs3820068	0.705	rs4646031	chr1:15834648	A/G	cg13390004	chr1:15929781	NA	0.42	6.78	0.31	4.06e-11	Systolic blood pressure;
LUAD	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg27170947	chr2:26402098	FAM59B	-0.62	-8.7	-0.39	7.22e-17	Gut microbiome composition (summer);
LUAD	cis	rs2046867	0.862	rs62252362	chr3:72855218	A/G	cg25664220	chr3:72788482	NA	-0.61	-11.24	-0.48	8.01e-26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs62400317	0.826	rs12194682	chr6:45320520	T/A	cg18551225	chr6:44695536	NA	-0.54	-8.57	-0.38	2.01e-16	Total body bone mineral density;
LUAD	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg22431228	chr1:16359049	CLCNKA	0.61	11.7	0.49	1.34e-27	Dilated cardiomyopathy;
LUAD	cis	rs7614311	0.636	rs73130576	chr3:63890875	T/C	cg22134162	chr3:63841271	THOC7	-0.52	-8.65	-0.39	1.08e-16	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg13263323	chr15:86062960	AKAP13	-0.45	-7.46	-0.34	5e-13	Coronary artery disease;
LUAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02359409	chr6:42947317	PEX6	-0.39	-7.07	-0.32	6.63e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg21724239	chr8:58056113	NA	0.82	9.72	0.43	2.76e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg21237687	chr17:6899380	ALOX12	0.39	7.28	0.33	1.63e-12	Tonsillectomy;
LUAD	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg22753661	chr15:79092743	ADAMTS7	-0.44	-6.39	-0.3	4.5e-10	Coronary artery disease or large artery stroke;
LUAD	cis	rs6446731	0.517	rs2071667	chr4:3269926	C/A	cg08886695	chr4:3369023	RGS12	0.47	7.92	0.36	2.17e-14	Mean platelet volume;
LUAD	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg05368731	chr17:41323189	NBR1	0.97	20.55	0.71	1.44e-65	Menopause (age at onset);
LUAD	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg00071950	chr4:10020882	SLC2A9	-0.72	-14.4	-0.57	1.57e-38	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg01228410	chr5:493893	SLC9A3	0.53	7.13	0.33	4.45e-12	Cystic fibrosis severity;
LUAD	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg04539111	chr16:67997858	SLC12A4	-0.63	-7.93	-0.36	2.02e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg27279351	chr12:120934652	DYNLL1	0.43	6.44	0.3	3.32e-10	High light scatter reticulocyte count;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg08728825	chr12:44152210	PUS7L;IRAK4	0.42	6.65	0.31	9.03e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2239547	0.563	rs2581820	chr3:53020544	A/G	cg18404041	chr3:52824283	ITIH1	0.5	8.75	0.39	4.99e-17	Schizophrenia;
LUAD	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg17178900	chr1:205818956	PM20D1	0.46	7.3	0.33	1.43e-12	Menarche (age at onset);
LUAD	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg21153622	chr11:89784906	NA	-0.33	-6.51	-0.3	2.19e-10	Coronary artery disease;
LUAD	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg22117172	chr7:91764530	CYP51A1	0.35	7.67	0.35	1.18e-13	Breast cancer;
LUAD	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.56	0.52	5.93e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg15467112	chr14:75489610	MLH3	-0.36	-6.68	-0.31	7.6e-11	Height;
LUAD	trans	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg12400702	chr3:12838781	CAND2	0.31	6.42	0.3	3.73e-10	Parkinson's disease;
LUAD	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg07741184	chr6:167504864	NA	-0.3	-7.23	-0.33	2.28e-12	Crohn's disease;
LUAD	cis	rs367943	0.666	rs10074214	chr5:112702214	A/G	cg21806985	chr5:112824646	MCC	0.25	6.7	0.31	6.5500000000000006e-11	Type 2 diabetes;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg00726782	chr12:58299213	NA	-0.39	-6.51	-0.3	2.13e-10	Subcortical brain region volumes;
LUAD	cis	rs11811982	0.793	rs78220690	chr1:227297523	T/C	cg24860534	chr1:227506868	CDC42BPA	0.68	7.31	0.33	1.35e-12	Optic disc area;
LUAD	cis	rs4889609	0.834	rs72785520	chr16:31070778	C/T	cg02466173	chr16:30829666	NA	-0.54	-9.28	-0.41	9.17e-19	Response to metformin (IC50);
LUAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.85	0.32	2.64e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg15226275	chr6:116381976	FRK	0.24	7.74	0.35	7.59e-14	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs2971970	0.519	rs10246171	chr7:133633228	T/C	cg03336402	chr7:133662267	EXOC4	0.39	7.08	0.33	6.12e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg03733263	chr8:22462867	KIAA1967	0.64	10.89	0.47	1.63e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs798554	0.591	rs1636248	chr7:2882030	T/C	cg19717773	chr7:2847554	GNA12	-0.47	-8.57	-0.38	1.91e-16	Height;
LUAD	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.49	-0.34	3.99e-13	Type 2 diabetes;
LUAD	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg14583973	chr4:3374767	RGS12	0.31	7.83	0.36	4.07e-14	Serum sulfate level;
LUAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.3	-7.01	-0.32	9.56e-12	Lymphocyte counts;
LUAD	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg27068330	chr11:65405492	SIPA1	-0.76	-11.64	-0.49	2.4200000000000002e-27	Acne (severe);
LUAD	cis	rs12049351	0.774	rs6662732	chr1:229629245	A/C	cg11742688	chr1:229674241	ABCB10	0.4	6.44	0.3	3.24e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs986417	1.000	rs1254332	chr14:60916587	T/C	cg27398547	chr14:60952738	C14orf39	-0.61	-7.56	-0.34	2.6e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs791888	0.667	rs2762520	chr10:89414845	A/G	cg13926569	chr10:89418898	PAPSS2	-0.34	-6.48	-0.3	2.51e-10	Magnesium levels;
LUAD	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg18446336	chr7:2847575	GNA12	-0.39	-7.09	-0.33	5.59e-12	Height;
LUAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg08888203	chr3:10149979	C3orf24	0.63	10.73	0.46	6.56e-24	Alzheimer's disease;
LUAD	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.0	0.32	9.82e-12	Prostate cancer;
LUAD	cis	rs4072705	0.646	rs4838187	chr9:127242076	G/C	cg14219918	chr9:127249562	NR5A1	0.29	6.67	0.31	8.17e-11	Menarche (age at onset);
LUAD	cis	rs12976411	0.575	rs16966906	chr19:32823374	A/G	cg02282382	chr19:32836354	ZNF507	0.71	6.43	0.3	3.54e-10	Coronary artery disease;
LUAD	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg16680214	chr1:154839983	KCNN3	-0.62	-13.04	-0.54	6.92e-33	Prostate cancer;
LUAD	cis	rs41311933	0.901	rs76481162	chr9:123740526	A/G	cg13567360	chr9:123745713	C5	-0.84	-9.22	-0.41	1.46e-18	Coronary artery disease;
LUAD	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg02527881	chr3:46936655	PTH1R	-0.5	-10.24	-0.45	3.83e-22	Colorectal cancer;
LUAD	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg09160332	chr4:120329925	NA	-0.36	-6.45	-0.3	3.11e-10	Corneal astigmatism;
LUAD	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.12	0.37	5.31e-15	Menopause (age at onset);
LUAD	cis	rs2742234	0.759	rs12241923	chr10:43713047	T/C	cg15436174	chr10:43711423	RASGEF1A	0.37	6.7	0.31	6.7e-11	Hirschsprung disease;
LUAD	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.66	-0.35	1.32e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1448094	0.967	rs2121892	chr12:86324556	G/T	cg18827107	chr12:86230957	RASSF9	-0.44	-7.93	-0.36	1.94e-14	Major depressive disorder;
LUAD	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg27661571	chr11:113659931	NA	0.69	8.08	0.37	6.98e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg05457628	chr5:178986728	RUFY1	0.59	10.17	0.44	7.16e-22	Lung cancer;
LUAD	cis	rs11051970	0.636	rs2733705	chr12:32561564	T/C	cg24626660	chr12:32551988	NA	0.34	7.3	0.33	1.48e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg06532163	chr17:45867833	NA	-0.48	-8.72	-0.39	6.33e-17	IgG glycosylation;
LUAD	cis	rs117623576	0.941	rs72784857	chr10:32441029	C/T	cg03047570	chr10:32398778	NA	-0.8	-9.41	-0.42	3.1e-19	Anti-saccade response;
LUAD	cis	rs751728	0.585	rs9380381	chr6:33771070	C/T	cg13859433	chr6:33739653	LEMD2	-0.36	-7.29	-0.33	1.58e-12	Crohn's disease;
LUAD	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg05304507	chr6:116381966	FRK	0.2	6.79	0.31	3.75e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs4356932	1.000	rs4637430	chr4:76962223	G/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.52	-0.3	2.05e-10	Blood protein levels;
LUAD	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	6.05e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg17712092	chr4:129076599	LARP1B	1.01	21.16	0.72	2.74e-68	Eosinophil percentage of white cells;
LUAD	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg16006841	chr5:176797999	RGS14	0.56	8.99	0.4	8.64e-18	Urate levels in lean individuals;
LUAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06873352	chr17:61820015	STRADA	0.81	18.12	0.66	1.04e-54	Prudent dietary pattern;
LUAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.46	-6.8	-0.31	3.69e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs490234	0.702	rs13284572	chr9:128258270	T/C	cg14078157	chr9:128172775	NA	-0.46	-8.13	-0.37	4.75e-15	Mean arterial pressure;
LUAD	cis	rs7680126	0.580	rs6827401	chr4:10031066	G/A	cg11266682	chr4:10021025	SLC2A9	0.48	6.67	0.31	8.06e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs904251	0.504	rs2797795	chr6:37480683	T/C	cg25019722	chr6:37503610	NA	-0.33	-7.54	-0.34	2.95e-13	Cognitive performance;
LUAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg04455712	chr21:45112962	RRP1B	0.49	9.66	0.42	4.58e-20	Mean corpuscular volume;
LUAD	cis	rs3806843	0.547	rs246054	chr5:140326159	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs41311933	0.803	rs62578400	chr9:123700496	T/C	cg13567360	chr9:123745713	C5	-0.83	-7.22	-0.33	2.36e-12	Coronary artery disease;
LUAD	trans	rs9467603	0.925	rs4712969	chr6:25764192	A/G	cg06606381	chr12:133084897	FBRSL1	0.65	6.38	0.3	4.63e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs3823572	0.564	rs2971955	chr7:133665939	C/T	cg03336402	chr7:133662267	EXOC4	0.4	7.48	0.34	4.43e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg19875535	chr5:140030758	IK	-0.48	-8.0	-0.36	1.17e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs300774	0.858	rs423038	chr2:129486	A/C	cg21211680	chr2:198530	NA	-0.47	-7.41	-0.34	6.86e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs7536201	0.967	rs7542123	chr1:25299816	G/A	cg23273869	chr1:25296894	NA	-0.39	-8.07	-0.37	7.56e-15	Psoriasis vulgaris;
LUAD	trans	rs7701967	0.697	rs11948761	chr5:130370970	A/T	cg14196790	chr5:131705035	SLC22A5	-0.44	-6.87	-0.32	2.36e-11	Mosquito bite size;Itch intensity from mosquito bite adjusted by bite size;Itch intensity from mosquito bite;
LUAD	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg06532163	chr17:45867833	NA	0.48	8.47	0.38	4.02e-16	IgG glycosylation;
LUAD	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg13012494	chr21:47604986	C21orf56	0.46	7.37	0.34	9.28e-13	Testicular germ cell tumor;
LUAD	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg03929089	chr4:120376271	NA	-0.99	-20.57	-0.71	1.14e-65	Height;
LUAD	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg16797656	chr11:68205561	LRP5	0.47	9.16	0.41	2.2e-18	Total body bone mineral density;
LUAD	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.0	-0.36	1.17e-14	Diabetic kidney disease;
LUAD	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg10018233	chr7:150070692	REPIN1	0.49	7.66	0.35	1.27e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg24531977	chr5:56204891	C5orf35	-0.71	-11.47	-0.49	1.02e-26	Coronary artery disease;
LUAD	cis	rs11756438	0.572	rs2798328	chr6:119005378	C/T	cg18833306	chr6:118973337	C6orf204	0.5	9.03	0.4	6.35e-18	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs887829	0.569	rs4399719	chr2:234666461	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-8.42	-0.38	6.12e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg07423050	chr13:99094983	FARP1	0.83	16.88	0.63	2.94e-49	Neuroticism;
LUAD	cis	rs684232	0.933	rs866304	chr17:587729	T/C	cg15660573	chr17:549704	VPS53	-0.41	-6.68	-0.31	7.56e-11	Prostate cancer;
LUAD	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg27411982	chr8:10470053	RP1L1	-0.39	-6.97	-0.32	1.23e-11	Triglycerides;
LUAD	cis	rs68170813	0.559	rs1121312	chr7:106927820	C/T	cg02696742	chr7:106810147	HBP1	-0.78	-10.68	-0.46	9.7e-24	Coronary artery disease;
LUAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg24846343	chr22:24311635	DDTL	-0.55	-9.54	-0.42	1.14e-19	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg03433033	chr1:76189801	ACADM	0.75	11.54	0.49	5.52e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12620999	1.000	rs4377286	chr2:238069686	C/T	cg23555395	chr2:238036564	NA	-0.57	-8.74	-0.39	5.34e-17	Systemic lupus erythematosus;
LUAD	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg02951883	chr7:2050386	MAD1L1	-0.52	-8.34	-0.38	1.04e-15	Schizophrenia;
LUAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg18621852	chr3:10150065	C3orf24	0.42	7.46	0.34	5.08e-13	Alzheimer's disease;
LUAD	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18876405	chr7:65276391	NA	-0.42	-6.7	-0.31	6.62e-11	Aortic root size;
LUAD	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg06606381	chr12:133084897	FBRSL1	0.58	7.29	0.33	1.5e-12	Depression;
LUAD	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg02038168	chr22:39784481	NA	-0.57	-10.06	-0.44	1.72e-21	Intelligence (multi-trait analysis);
LUAD	trans	rs9467711	0.651	rs34888489	chr6:26073375	C/A	cg01620082	chr3:125678407	NA	-1.02	-8.07	-0.37	7.29e-15	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg04565464	chr8:145669602	NFKBIL2	0.44	6.44	0.3	3.3e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg23743428	chr13:21893420	NA	-0.44	-8.09	-0.37	6.53e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg14634687	chr17:47094252	IGF2BP1	0.28	7.31	0.33	1.38e-12	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg03467027	chr4:99064603	C4orf37	0.42	6.75	0.31	4.96e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.82	-0.39	3.1e-17	Initial pursuit acceleration;
LUAD	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg06263672	chr7:65235340	NA	0.48	6.48	0.3	2.58e-10	Aortic root size;
LUAD	cis	rs2996428	0.667	rs2368534	chr1:3740640	C/T	cg23277830	chr1:3704460	LRRC47	0.46	9.19	0.41	1.81e-18	Red cell distribution width;
LUAD	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg12667521	chr19:29218732	NA	0.54	7.16	0.33	3.58e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs244899	0.967	rs2445785	chr5:167924928	A/G	cg06604206	chr5:167912465	RARS	0.37	6.62	0.31	1.1e-10	Response to platinum-based chemotherapy (carboplatin);
LUAD	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg18827107	chr12:86230957	RASSF9	-0.5	-9.1	-0.4	3.7e-18	Major depressive disorder;
LUAD	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	11.59	0.49	3.6e-27	Mean platelet volume;
LUAD	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg18225595	chr11:63971243	STIP1	-0.48	-8.24	-0.37	2.19e-15	Platelet count;
LUAD	cis	rs4664304	0.629	rs3828324	chr2:160834991	C/T	cg23995753	chr2:160760732	LY75	0.39	6.83	0.32	2.97e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg09117114	chr16:67998030	SLC12A4	-0.47	-6.62	-0.31	1.12e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg22906224	chr7:99728672	NA	-0.62	-10.86	-0.47	2.08e-24	Coronary artery disease;
LUAD	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg03605463	chr16:89740564	NA	0.42	6.47	0.3	2.67e-10	Vitiligo;
LUAD	cis	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg23950597	chr19:37808831	NA	-0.58	-7.2	-0.33	2.81e-12	Coronary artery calcification;
LUAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg11766577	chr21:47581405	C21orf56	-0.63	-11.44	-0.49	1.33e-26	Testicular germ cell tumor;
LUAD	cis	rs708547	0.647	rs1718839	chr4:57827206	A/G	cg00922110	chr4:57842668	C4orf14	-0.39	-7.19	-0.33	2.99e-12	Response to bleomycin (chromatid breaks);
LUAD	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21582582	chr3:182698605	DCUN1D1	0.6	10.16	0.44	7.92e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs2485376	1.000	rs4919622	chr10:104012941	T/C	cg20641465	chr10:103991465	PITX3	0.57	10.4	0.45	1.02e-22	QT interval;
LUAD	cis	rs10746514	0.931	rs11582890	chr1:232251218	C/T	cg09506761	chr1:232265262	NA	0.38	6.97	0.32	1.26e-11	Response to statin therapy;
LUAD	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg02733842	chr7:1102375	C7orf50	-0.67	-10.21	-0.44	5.12e-22	Bronchopulmonary dysplasia;
LUAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg04234412	chr22:24373322	LOC391322	0.84	15.45	0.6	5.23e-43	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4285028	0.948	rs35902163	chr3:121649526	G/A	cg20356878	chr3:121714668	ILDR1	-0.49	-6.38	-0.3	4.64e-10	Multiple sclerosis;
LUAD	cis	rs9535307	0.929	rs9535316	chr13:50312397	G/A	cg04663916	chr13:50265991	EBPL	0.59	6.9	0.32	1.91e-11	Obesity-related traits;
LUAD	cis	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg05901451	chr6:126070800	HEY2	-0.43	-6.47	-0.3	2.77e-10	Endometrial cancer;
LUAD	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg25894440	chr7:65020034	NA	-0.63	-6.71	-0.31	6.35e-11	Gout;
LUAD	trans	rs1728785	1.000	rs1170436	chr16:68607486	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.77	0.46	4.43e-24	Ulcerative colitis;
LUAD	cis	rs4903604	0.581	rs11159278	chr14:78034001	C/G	cg18872420	chr14:78023429	SPTLC2	0.48	8.76	0.39	4.59e-17	Gut microbiome composition (winter);
LUAD	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg18932078	chr1:2524107	MMEL1	0.39	7.28	0.33	1.66e-12	Ulcerative colitis;
LUAD	cis	rs4730250	0.708	rs74983157	chr7:106823951	A/G	cg02696742	chr7:106810147	HBP1	-0.78	-10.85	-0.47	2.35e-24	Osteoarthritis;
LUAD	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg00106254	chr7:1943704	MAD1L1	-0.44	-6.57	-0.3	1.52e-10	Schizophrenia;
LUAD	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg00757033	chr12:89920650	WDR51B	0.7	11.68	0.49	1.62e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg03929089	chr4:120376271	NA	0.74	12.61	0.52	3.5e-31	Coronary artery disease;
LUAD	cis	rs4986172	0.726	rs12051846	chr17:43226887	A/G	cg10701640	chr17:43249399	NA	0.58	10.25	0.45	3.66e-22	Height;
LUAD	cis	rs9341808	0.519	rs7771593	chr6:81036127	T/C	cg08355045	chr6:80787529	NA	-0.41	-6.83	-0.32	2.97e-11	Sitting height ratio;
LUAD	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	10.14	0.44	9.21e-22	Electrocardiographic conduction measures;
LUAD	cis	rs17169635	0.601	rs3778853	chr7:134545098	A/G	cg07876788	chr7:134849633	TMEM140	-0.4	-6.56	-0.3	1.58e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs7072216	0.922	rs2296438	chr10:100146895	T/C	cg26618903	chr10:100175079	PYROXD2	-0.3	-6.55	-0.3	1.69e-10	Metabolite levels;
LUAD	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.25	-0.41	1.09e-18	Life satisfaction;
LUAD	cis	rs61990749	0.597	rs13379065	chr14:78141295	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.49	-6.51	-0.3	2.14e-10	Fibroblast growth factor basic levels;
LUAD	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg04398451	chr17:18023971	MYO15A	0.64	11.23	0.48	8.67e-26	Total body bone mineral density;
LUAD	cis	rs4851254	0.626	rs71413861	chr2:100673501	A/G	cg04109781	chr2:100722022	AFF3	0.36	6.38	0.3	4.67e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-6.71	-0.31	6.35e-11	IgG glycosylation;
LUAD	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg18944383	chr4:111397179	ENPEP	0.4	7.96	0.36	1.61e-14	Height;
LUAD	cis	rs6594713	0.679	rs34147627	chr5:112948161	G/A	cg12552261	chr5:112820674	MCC	0.52	7.13	0.33	4.4e-12	Brain cytoarchitecture;
LUAD	cis	rs6750795	0.765	rs6742387	chr2:232354832	G/T	cg19187155	chr2:232395269	NMUR1	0.51	9.64	0.42	5e-20	Height;
LUAD	cis	rs8044868	0.530	rs7185840	chr16:72102112	A/G	cg23815491	chr16:72088622	HP	0.5	9.25	0.41	1.09e-18	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs9309473	0.607	rs10196402	chr2:73572081	A/C	cg20560298	chr2:73613845	ALMS1	-0.42	-6.46	-0.3	2.86e-10	Metabolite levels;
LUAD	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg14092571	chr14:90743983	NA	-0.51	-8.95	-0.4	1.09e-17	Mortality in heart failure;
LUAD	cis	rs6752107	0.967	rs11694081	chr2:234148586	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.53	9.12	0.41	2.96e-18	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg27211696	chr2:191398769	TMEM194B	0.76	16.04	0.62	1.4e-45	Pulse pressure;
LUAD	cis	rs9807989	0.507	rs4851577	chr2:103028921	T/C	cg03938978	chr2:103052716	IL18RAP	0.44	9.94	0.44	4.72e-21	Asthma;
LUAD	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg09365446	chr1:150670422	GOLPH3L	0.53	9.24	0.41	1.25e-18	Tonsillectomy;
LUAD	cis	rs1018836	0.786	rs10086401	chr8:91572818	C/T	cg16814680	chr8:91681699	NA	-0.59	-9.9	-0.43	6.43e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	5.75e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg05340658	chr4:99064831	C4orf37	0.53	9.06	0.4	4.81e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs155346	1.000	rs265156	chr5:139386659	C/T	cg01090482	chr5:139365336	NRG2	-0.34	-6.56	-0.3	1.56e-10	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUAD	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg25237894	chr2:233734115	C2orf82	-0.58	-10.99	-0.47	7.22e-25	Coronary artery disease;
LUAD	cis	rs13064411	0.518	rs9852703	chr3:113189368	C/T	cg18753928	chr3:113234510	CCDC52	0.47	8.63	0.39	1.21e-16	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.34	6.52	0.3	1.95e-10	Sum eosinophil basophil counts;
LUAD	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.49	-0.34	4.17e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4604732	0.631	rs11490200	chr1:247625915	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg25753631	chr6:25732923	NA	-0.41	-7.2	-0.33	2.7e-12	Iron status biomarkers;
LUAD	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	0.950	rs11981299	chr7:95029701	T/A	cg05342682	chr7:94953680	PON1	-0.49	-6.77	-0.31	4.33e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2070677	0.935	rs4351775	chr10:135402200	C/T	cg20169779	chr10:135381914	SYCE1	-0.52	-8.32	-0.38	1.18e-15	Gout;
LUAD	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01570182	chr17:44337453	NA	0.78	12.73	0.53	1.15e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6840360	0.533	rs13147021	chr4:152722688	A/C	cg22705602	chr4:152727874	NA	0.46	8.74	0.39	5.43e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg27411982	chr8:10470053	RP1L1	-0.36	-6.58	-0.3	1.4e-10	Mood instability;
LUAD	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.31	6.71	0.31	6.45e-11	Parkinson's disease;
LUAD	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03934478	chr11:495069	RNH1	0.77	9.23	0.41	1.29e-18	Body mass index;
LUAD	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.51	-0.3	2.13e-10	Total body bone mineral density;
LUAD	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg02505535	chr3:195703920	SDHAP1	-0.36	-7.49	-0.34	4.04e-13	Pancreatic cancer;
LUAD	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg06781209	chr11:61594997	FADS2	-0.41	-7.62	-0.35	1.73e-13	LDL cholesterol;
LUAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg07677032	chr17:61819896	STRADA	0.5	9.06	0.4	4.7e-18	Prudent dietary pattern;
LUAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg20607798	chr8:58055168	NA	0.57	7.28	0.33	1.63e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg08847533	chr14:75593920	NEK9	0.42	7.12	0.33	4.72e-12	Height;
LUAD	cis	rs4631830	0.900	rs9787697	chr10:51533376	C/T	cg20129853	chr10:51489980	NA	-0.34	-6.74	-0.31	5.36e-11	Prostate-specific antigen levels;
LUAD	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.65	0.31	9.26e-11	Parkinson's disease;
LUAD	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg01851573	chr8:8652454	MFHAS1	0.41	7.3	0.33	1.4e-12	Mood instability;
LUAD	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg22117172	chr7:91764530	CYP51A1	-0.34	-7.44	-0.34	5.85e-13	Breast cancer;
LUAD	cis	rs4727443	0.653	rs6465759	chr7:99587980	T/C	cg22004693	chr7:99632812	ZKSCAN1	-0.4	-7.02	-0.32	8.89e-12	Interstitial lung disease;
LUAD	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg07432352	chr17:45403706	C17orf57	0.38	7.25	0.33	1.97e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg23625390	chr15:77176239	SCAPER	-0.48	-7.74	-0.35	7.51e-14	Blood metabolite levels;
LUAD	cis	rs732716	0.785	rs34080966	chr19:4417845	C/T	cg21934504	chr19:4445085	UBXN6	-0.4	-6.87	-0.32	2.26e-11	Mean corpuscular volume;
LUAD	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg02423579	chr7:2872169	GNA12	-0.85	-14.53	-0.58	4.43e-39	Height;
LUAD	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg14458575	chr2:238380390	NA	0.68	12.95	0.53	1.47e-32	Prostate cancer;
LUAD	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg18016565	chr1:150552671	MCL1	0.41	7.64	0.35	1.44e-13	Tonsillectomy;
LUAD	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	8.77	0.39	4.54e-17	Breast cancer;
LUAD	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.43	-7.33	-0.34	1.14e-12	Alzheimer's disease (late onset);
LUAD	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg17063962	chr7:91808500	NA	-0.67	-11.71	-0.49	1.27e-27	Breast cancer;
LUAD	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.62	-8.12	-0.37	4.99e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg27432699	chr2:27873401	GPN1	-0.4	-7.02	-0.32	9.11e-12	Total body bone mineral density;
LUAD	cis	rs929596	1.000	rs929596	chr2:234674476	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.7	-10.93	-0.47	1.19e-24	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg11919837	chr8:57350735	NA	-0.43	-6.41	-0.3	3.98e-10	Obesity-related traits;
LUAD	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	9.33	0.41	6.1e-19	Monocyte percentage of white cells;
LUAD	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg12935359	chr14:103987150	CKB	-0.49	-8.23	-0.37	2.41e-15	Body mass index;
LUAD	cis	rs7586879	1.000	rs7586879	chr2:25116977	C/T	cg04586622	chr2:25135609	ADCY3	0.34	7.29	0.33	1.58e-12	Body mass index;
LUAD	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg12527260	chr11:63683744	RCOR2	0.34	7.0	0.32	1.03e-11	Pulse pressure;
LUAD	cis	rs1784581	0.631	rs3016544	chr6:162393065	T/C	cg17173639	chr6:162384350	PARK2	-0.5	-9.03	-0.4	6.32e-18	Itch intensity from mosquito bite;
LUAD	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg24818145	chr4:99064322	C4orf37	0.46	7.91	0.36	2.29e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg10978503	chr1:24200527	CNR2	0.6	12.84	0.53	4.37e-32	Immature fraction of reticulocytes;
LUAD	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.68	-10.38	-0.45	1.22e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-11.68	-0.49	1.6e-27	Bipolar disorder;
LUAD	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg07636037	chr3:49044803	WDR6	0.63	12.13	0.51	2.91e-29	Parkinson's disease;
LUAD	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06558623	chr16:89946397	TCF25	0.82	8.34	0.38	1.04e-15	Skin colour saturation;
LUAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.78	14.61	0.58	1.9e-39	Lymphocyte counts;
LUAD	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg00933542	chr6:150070202	PCMT1	-0.4	-8.21	-0.37	2.7e-15	Lung cancer;
LUAD	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg20848291	chr7:100343083	ZAN	0.4	6.88	0.32	2.1e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs250585	0.920	rs631022	chr16:23410398	G/A	cg00143387	chr16:23521605	GGA2	0.55	6.91	0.32	1.81e-11	Egg allergy;
LUAD	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	trans	rs1997103	1.000	rs10279035	chr7:55412055	C/T	cg20935933	chr6:143382018	AIG1	0.53	7.42	0.34	6.65e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg01097406	chr16:89675127	NA	0.32	6.76	0.31	4.68e-11	Vitiligo;
LUAD	cis	rs7680126	0.626	rs11721501	chr4:10189135	G/A	cg00071950	chr4:10020882	SLC2A9	-0.6	-8.05	-0.36	8.67e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg11845111	chr2:191398756	TMEM194B	-0.85	-11.31	-0.48	4.45e-26	Diastolic blood pressure;
LUAD	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19346786	chr7:2764209	NA	-0.57	-12.08	-0.51	4.45e-29	Height;
LUAD	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg26513180	chr16:89883248	FANCA	0.69	12.94	0.53	1.71e-32	Vitiligo;
LUAD	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg08807101	chr21:30365312	RNF160	0.51	8.65	0.39	1.1e-16	Dental caries;
LUAD	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg04287289	chr16:89883240	FANCA	0.69	12.72	0.53	1.33e-31	Vitiligo;
LUAD	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.57	-0.3	1.45e-10	Breast cancer;
LUAD	cis	rs7274811	0.625	rs293726	chr20:31932047	A/C	cg03904042	chr20:32255491	NECAB3;C20orf134	0.45	6.69	0.31	6.95e-11	Height;
LUAD	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.31	-6.88	-0.32	2.14e-11	Dupuytren's disease;
LUAD	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg02269571	chr22:50332266	NA	-0.59	-8.95	-0.4	1.16e-17	Schizophrenia;
LUAD	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg17845761	chr1:175162550	KIAA0040	-0.34	-9.06	-0.4	4.99e-18	Alcohol dependence;
LUAD	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg13319975	chr6:146136371	FBXO30	0.66	11.45	0.49	1.27e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg20628663	chr10:43360327	NA	-0.73	-11.24	-0.48	7.87e-26	Blood protein levels;
LUAD	cis	rs10504073	0.584	rs115370638	chr8:49916452	A/G	cg00325661	chr8:49890786	NA	0.47	10.49	0.45	4.96e-23	Blood metabolite ratios;
LUAD	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg17971929	chr21:40555470	PSMG1	0.53	8.19	0.37	3.15e-15	Cognitive function;
LUAD	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-7.79	-0.35	5.21e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9341808	0.556	rs1474791	chr6:81033097	A/G	cg08355045	chr6:80787529	NA	0.5	8.69	0.39	7.92e-17	Sitting height ratio;
LUAD	trans	rs8129326	0.805	rs9984075	chr21:35784117	T/A	cg07474852	chr4:123073612	NA	0.46	7.54	0.34	2.82e-13	Cancer;
LUAD	cis	rs28595532	0.702	rs116320061	chr4:119384600	C/T	cg02775129	chr4:119771670	NA	-0.65	-6.44	-0.3	3.18e-10	Cannabis dependence symptom count;
LUAD	cis	rs929596	0.793	rs2741044	chr2:234579368	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-8.8	-0.39	3.54e-17	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg05368731	chr17:41323189	NBR1	0.87	14.48	0.58	6.74e-39	Menopause (age at onset);
LUAD	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg13607699	chr17:42295918	UBTF	0.56	9.18	0.41	1.94e-18	Total body bone mineral density;
LUAD	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg13385794	chr1:248469461	NA	0.27	7.31	0.33	1.34e-12	Common traits (Other);
LUAD	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12756686	chr19:29218302	NA	0.66	9.7	0.43	3.28e-20	Methadone dose in opioid dependence;
LUAD	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18099408	chr3:52552593	STAB1	-0.46	-8.08	-0.37	6.71e-15	Bipolar disorder;
LUAD	cis	rs829883	0.738	rs249854	chr12:98862772	G/A	cg25150519	chr12:98850993	NA	0.76	14.29	0.57	4.6e-38	Colorectal adenoma (advanced);
LUAD	trans	rs4942242	1.000	rs9594987	chr13:44230994	C/T	cg19169023	chr15:41853346	TYRO3	0.49	8.36	0.38	9.34e-16	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg15117754	chr3:10150083	C3orf24	0.41	6.59	0.31	1.3100000000000001e-10	Alzheimer's disease;
LUAD	cis	rs7264396	0.528	rs3787174	chr20:34487921	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-6.96	-0.32	1.3e-11	Total cholesterol levels;
LUAD	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg18867708	chr6:26865862	GUSBL1	0.41	6.54	0.3	1.81e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg06766960	chr11:133703094	NA	-0.46	-8.58	-0.39	1.77e-16	Childhood ear infection;
LUAD	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg25233709	chr10:116636983	FAM160B1	0.41	8.08	0.37	6.93e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg20135002	chr11:47629003	NA	-0.37	-6.56	-0.3	1.59e-10	Subjective well-being;
LUAD	cis	rs1461503	0.903	rs7124683	chr11:122834036	A/G	cg27398637	chr11:122830231	C11orf63	0.32	6.39	0.3	4.35e-10	Menarche (age at onset);
LUAD	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg18944383	chr4:111397179	ENPEP	-0.5	-9.04	-0.4	5.47e-18	Height;
LUAD	cis	rs6840360	0.593	rs11723227	chr4:152689717	G/A	cg22705602	chr4:152727874	NA	-0.48	-9.21	-0.41	1.58e-18	Intelligence (multi-trait analysis);
LUAD	trans	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg01620082	chr3:125678407	NA	-0.75	-8.24	-0.37	2.17e-15	Breast cancer;
LUAD	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg10909506	chr17:38081995	ORMDL3	0.38	6.62	0.31	1.11e-10	Self-reported allergy;
LUAD	cis	rs2004318	0.850	rs111365792	chr19:55078730	C/T	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.93e-13	Blood protein levels;
LUAD	trans	rs7200543	1.000	rs7200543	chr16:15129970	C/T	cg24683922	chr1:11983373	KIAA2013	0.46	7.79	0.35	5.27e-14	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg03806693	chr22:41940476	POLR3H	-0.76	-10.04	-0.44	2.07e-21	Vitiligo;
LUAD	trans	rs4714291	0.963	rs2395543	chr6:39965020	A/G	cg02267698	chr19:7991119	CTXN1	0.42	6.37	0.3	4.98e-10	Strep throat;
LUAD	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg24399712	chr22:39784796	NA	0.52	9.31	0.41	7.3e-19	IgG glycosylation;
LUAD	trans	rs10411161	0.810	rs60981935	chr19:52385281	C/T	cg22319618	chr22:45562946	NUP50	-0.65	-7.51	-0.34	3.55e-13	Breast cancer;
LUAD	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg06671706	chr8:8559999	CLDN23	-0.36	-6.45	-0.3	3.15e-10	Mood instability;
LUAD	cis	rs4988958	0.565	rs885088	chr2:103039044	A/G	cg03938978	chr2:103052716	IL18RAP	0.44	10.14	0.44	9.26e-22	Asthma (childhood onset);
LUAD	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.13	-0.37	4.66e-15	Total body bone mineral density;
LUAD	cis	rs73198271	0.628	rs11781258	chr8:8589758	A/G	cg01851573	chr8:8652454	MFHAS1	0.47	6.77	0.31	4.29e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg27433088	chr4:174089019	GALNT7	-0.37	-6.8	-0.31	3.55e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26398333	chr1:153895721	GATAD2B	-0.41	-6.65	-0.31	9.15e-11	Height;
LUAD	cis	rs68170813	0.559	rs76933738	chr7:106814574	T/C	cg02696742	chr7:106810147	HBP1	-0.81	-11.44	-0.49	1.44e-26	Coronary artery disease;
LUAD	trans	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg07211511	chr3:129823064	LOC729375	-0.91	-12.47	-0.52	1.32e-30	Blood pressure (smoking interaction);
LUAD	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg00310523	chr12:86230176	RASSF9	0.39	7.8	0.35	4.99e-14	Major depressive disorder;
LUAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg21782813	chr7:2030301	MAD1L1	0.6	10.51	0.46	4e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.81	-13.63	-0.55	2.51e-35	Bipolar disorder and schizophrenia;
LUAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.54	-9.65	-0.42	4.62e-20	Lymphocyte counts;
LUAD	cis	rs11051970	0.636	rs2733704	chr12:32567858	C/T	cg24626660	chr12:32551988	NA	0.34	7.47	0.34	4.49e-13	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs73198271	0.740	rs1039912	chr8:8648229	C/T	cg01851573	chr8:8652454	MFHAS1	0.47	8.06	0.36	7.74e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg11915388	chr22:42470451	FAM109B	0.41	7.37	0.34	8.84e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg07549590	chr16:15018862	NA	-0.39	-7.34	-0.34	1.14e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg17890828	chr19:36103534	HAUS5	-0.65	-6.43	-0.3	3.44e-10	Type 2 diabetes;
LUAD	cis	rs9837602	1.000	rs7620228	chr3:99790332	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	9.19	0.41	1.81e-18	Breast cancer;
LUAD	cis	rs57502260	0.915	rs75202638	chr11:68210421	C/T	cg16797656	chr11:68205561	LRP5	0.48	7.41	0.34	6.97e-13	Total body bone mineral density (age 45-60);
LUAD	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg23029597	chr12:123009494	RSRC2	-0.58	-9.28	-0.41	9.15e-19	Body mass index;
LUAD	cis	rs2797685	1.000	rs2640908	chr1:7889941	C/T	cg04725166	chr1:7887271	PER3	-0.48	-7.09	-0.33	5.75e-12	Crohn's disease;
LUAD	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg03806693	chr22:41940476	POLR3H	-0.56	-8.37	-0.38	8.73e-16	Vitiligo;
LUAD	cis	rs6484504	0.576	rs2447671	chr11:31334323	A/G	cg26647111	chr11:31128758	NA	-0.42	-7.41	-0.34	6.73e-13	Red blood cell count;
LUAD	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg08280861	chr8:58055591	NA	0.55	7.6	0.35	1.86e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg16606324	chr3:10149918	C3orf24	0.72	11.83	0.5	4.38e-28	Alzheimer's disease;
LUAD	cis	rs72949976	1.000	rs62186568	chr2:214033955	G/A	cg08319019	chr2:214017104	IKZF2	-0.5	-7.55	-0.34	2.64e-13	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg22676075	chr6:135203613	NA	0.43	7.82	0.36	4.32e-14	Red blood cell count;
LUAD	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg18230493	chr5:56204884	C5orf35	-0.85	-12.37	-0.52	3.37e-30	Initial pursuit acceleration;
LUAD	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg18446336	chr7:2847575	GNA12	-0.32	-6.42	-0.3	3.74e-10	Height;
LUAD	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg13722127	chr7:150037890	RARRES2	0.44	7.24	0.33	2.17e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6499255	0.904	rs2161631	chr16:69556948	C/A	cg26679644	chr16:69762563	NA	0.43	6.56	0.3	1.53e-10	IgE levels;
LUAD	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg25237894	chr2:233734115	C2orf82	0.62	11.7	0.49	1.44e-27	Coronary artery disease;
LUAD	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26119090	chr2:26468346	HADHA;HADHB	0.6	8.51	0.38	3.06e-16	Gut microbiome composition (summer);
LUAD	cis	rs1232027	0.656	rs844368	chr5:79976382	C/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.77	-0.31	4.44e-11	Huntington's disease progression;
LUAD	cis	rs7537052	0.669	rs475591	chr1:36642420	T/C	cg24686825	chr1:36642396	MAP7D1	-0.37	-6.7	-0.31	6.51e-11	Schizophrenia;
LUAD	cis	rs17092148	1.000	rs2378260	chr20:33374897	G/A	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.19	-0.37	3.09e-15	Neuroticism;
LUAD	cis	rs11585357	0.947	rs72646795	chr1:17612120	C/T	cg08277548	chr1:17600880	PADI3	-0.87	-12.68	-0.52	1.85e-31	Hair shape;
LUAD	cis	rs12545109	0.765	rs1960727	chr8:57411368	G/A	cg19413350	chr8:57351067	NA	-0.44	-6.61	-0.31	1.19e-10	Obesity-related traits;
LUAD	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00802000	chr16:706648	WDR90	-0.41	-7.77	-0.35	6.18e-14	Height;
LUAD	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.78	-0.43	1.63e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg27489772	chr12:121021490	NA	-0.55	-6.84	-0.32	2.79e-11	Type 1 diabetes nephropathy;
LUAD	cis	rs9487051	0.766	rs351748	chr6:109532296	C/T	cg01475377	chr6:109611718	NA	0.41	7.67	0.35	1.21e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	6.48	0.3	2.5e-10	Aortic root size;
LUAD	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg04703951	chr17:43578652	NA	0.62	8.67	0.39	9.52e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.61	-7.35	-0.34	1.01e-12	Body mass index;
LUAD	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg24308560	chr3:49941425	MST1R	-0.53	-8.63	-0.39	1.22e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg23978390	chr7:1156363	C7orf50	0.57	8.76	0.39	4.85e-17	Longevity;Endometriosis;
LUAD	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.95	13.86	0.56	2.84e-36	Smoking behavior;
LUAD	cis	rs67478160	0.643	rs6576005	chr14:104292369	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.61	-11.15	-0.48	1.67e-25	Schizophrenia;
LUAD	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06544989	chr22:39130855	UNC84B	0.41	7.35	0.34	1.05e-12	Menopause (age at onset);
LUAD	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg22571038	chr17:48585470	MYCBPAP	-0.43	-6.55	-0.3	1.71e-10	Visceral fat;
LUAD	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg06784218	chr1:46089804	CCDC17	-0.55	-11.73	-0.5	1.01e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.34	0.41	5.51e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg09222892	chr1:25734099	RHCE	-0.51	-9.34	-0.41	5.61e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg14668632	chr7:2872130	GNA12	-0.75	-13.48	-0.55	1.1e-34	Height;
LUAD	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06544989	chr22:39130855	UNC84B	-0.41	-7.37	-0.34	9.14e-13	Menopause (age at onset);
LUAD	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg10755058	chr3:40428713	ENTPD3	0.38	7.23	0.33	2.22e-12	Renal cell carcinoma;
LUAD	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg24531977	chr5:56204891	C5orf35	-0.4	-6.53	-0.3	1.84e-10	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs6138458	1.000	rs227624	chr20:24911562	T/C	cg06937882	chr20:24974362	C20orf3	-0.33	-6.43	-0.3	3.52e-10	Blood protein levels;
LUAD	cis	rs13082711	0.911	rs34422761	chr3:27513366	C/A	cg02860705	chr3:27208620	NA	0.57	8.79	0.39	3.68e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs754466	1.000	rs754466	chr10:79680434	A/T	cg17075019	chr10:79541650	NA	-0.78	-13.03	-0.54	7.11e-33	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg16405210	chr4:1374714	KIAA1530	-0.6	-9.16	-0.41	2.3e-18	Longevity;
LUAD	cis	rs494562	0.803	rs727870	chr6:86131156	A/G	cg21730993	chr6:86159210	NT5E	0.64	7.58	0.35	2.16e-13	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.58	8.07	0.37	7.59e-15	Renal function-related traits (BUN);
LUAD	trans	rs1728785	0.892	rs1617749	chr16:68580890	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.72	10.7	0.46	8.43e-24	Ulcerative colitis;
LUAD	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.0	-0.36	1.23e-14	Diabetic kidney disease;
LUAD	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg02421172	chr7:1938701	MAD1L1	0.45	6.76	0.31	4.6e-11	Bipolar disorder;
LUAD	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg09455208	chr3:40491958	NA	0.55	12.27	0.51	7.93e-30	Renal cell carcinoma;
LUAD	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg26408565	chr15:76604113	ETFA	0.42	6.94	0.32	1.46e-11	Blood metabolite levels;
LUAD	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.71	-0.31	6.16e-11	Neuroticism;
LUAD	cis	rs3087591	0.960	rs2953012	chr17:29496486	A/G	cg24425628	chr17:29625626	OMG;NF1	0.42	6.86	0.32	2.41e-11	Hip circumference;
LUAD	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.47	0.3	2.64e-10	Depression;
LUAD	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg03233332	chr7:66118400	NA	0.44	6.73	0.31	5.44e-11	Aortic root size;
LUAD	cis	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg27411982	chr8:10470053	RP1L1	0.42	7.51	0.34	3.44e-13	Neuroticism;
LUAD	cis	rs7809950	1.000	rs10234355	chr7:107086517	T/G	cg23024343	chr7:107201750	COG5	-0.72	-12.21	-0.51	1.36e-29	Coronary artery disease;
LUAD	cis	rs921968	0.643	rs832806	chr2:219473914	A/T	cg02176678	chr2:219576539	TTLL4	0.6	11.32	0.48	4.11e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg07169764	chr2:136633963	MCM6	0.66	7.82	0.36	4.26e-14	Corneal structure;
LUAD	cis	rs2046867	0.644	rs56947804	chr3:72788435	T/C	cg25664220	chr3:72788482	NA	-0.69	-12.43	-0.52	1.94e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg18490616	chr2:88469792	THNSL2	0.8	8.36	0.38	9.13e-16	Plasma clusterin levels;
LUAD	trans	rs8002861	0.727	rs9533652	chr13:44419532	A/G	cg17145862	chr1:211918768	LPGAT1	-0.54	-10.7	-0.46	7.95e-24	Leprosy;
LUAD	cis	rs6840360	0.593	rs10033405	chr4:152474489	A/G	cg22705602	chr4:152727874	NA	-0.37	-6.71	-0.31	6.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg04025307	chr7:1156635	C7orf50	0.6	6.78	0.31	4.07e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9902453	0.845	rs7209622	chr17:28256807	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	10.88	0.47	1.85e-24	Coffee consumption (cups per day);
LUAD	cis	rs698833	0.518	rs7562945	chr2:44552772	G/T	cg04920474	chr2:44395004	PPM1B	0.4	6.46	0.3	2.82e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05901451	chr6:126070800	HEY2	-0.84	-15.76	-0.61	2.32e-44	Brugada syndrome;
LUAD	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.5	7.93	0.36	1.96e-14	Homocysteine levels;
LUAD	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.47	0.3	2.67e-10	Cardiac Troponin-T levels;
LUAD	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg13798912	chr7:905769	UNC84A	-0.61	-6.95	-0.32	1.4e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4711350	0.953	rs942496	chr6:33788055	A/G	cg07979401	chr6:33739406	LEMD2	-0.43	-6.38	-0.3	4.75e-10	Schizophrenia;
LUAD	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg09365446	chr1:150670422	GOLPH3L	-0.49	-8.63	-0.39	1.29e-16	Tonsillectomy;
LUAD	cis	rs6669119	0.668	rs75088145	chr1:19092368	G/A	cg26220594	chr1:19110978	NA	0.58	7.49	0.34	4.05e-13	Percentage gas trapping;
LUAD	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg27170947	chr2:26402098	FAM59B	-0.69	-9.41	-0.42	3.19e-19	Gut microbiome composition (summer);
LUAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	8.9	0.4	1.66e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg26446133	chr18:72167187	CNDP2	-0.79	-11.39	-0.48	2.07e-26	Refractive error;
LUAD	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.76	0.35	6.46e-14	Platelet count;
LUAD	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22307029	chr19:49891270	CCDC155	0.75	12.25	0.51	1.01e-29	Multiple sclerosis;
LUAD	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg25985355	chr7:65971099	NA	-0.56	-6.85	-0.32	2.68e-11	Diabetic kidney disease;
LUAD	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg05110241	chr16:68378359	PRMT7	-0.71	-8.18	-0.37	3.42e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.33e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg18721089	chr20:30220636	NA	-0.47	-6.56	-0.3	1.59e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs11031096	0.727	rs12290828	chr11:4144867	C/G	cg18678763	chr11:4115507	RRM1	-0.42	-7.29	-0.33	1.58e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg21724239	chr8:58056113	NA	0.73	9.51	0.42	1.46e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg04703951	chr17:43578652	NA	-0.45	-7.22	-0.33	2.49e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1595825	0.945	rs73056890	chr2:198831260	A/G	cg00361562	chr2:198649771	BOLL	-0.47	-6.72	-0.31	5.79e-11	Ulcerative colitis;
LUAD	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03934478	chr11:495069	RNH1	0.75	9.12	0.41	3.11e-18	Body mass index;
LUAD	cis	rs938554	0.779	rs7680126	chr4:9985596	G/A	cg11266682	chr4:10021025	SLC2A9	0.43	7.49	0.34	4.05e-13	Blood metabolite levels;
LUAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.17	-0.41	2.17e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs420259	0.516	rs4968014	chr16:23523875	G/T	cg00143387	chr16:23521605	GGA2	-0.69	-9.91	-0.43	6e-21	Bipolar disorder;
LUAD	trans	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg01620082	chr3:125678407	NA	-0.61	-7.28	-0.33	1.65e-12	Depression;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg09996344	chr7:66093369	KCTD7	-0.45	-7.59	-0.35	2e-13	Schizophrenia;
LUAD	trans	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg07211511	chr3:129823064	LOC729375	-0.91	-13.68	-0.55	1.58e-35	Blood pressure (smoking interaction);
LUAD	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg13334819	chr7:99746414	C7orf59	0.66	10.6	0.46	2e-23	Coronary artery disease;
LUAD	cis	rs733175	0.855	rs10022499	chr4:10006537	C/A	cg11266682	chr4:10021025	SLC2A9	0.42	7.17	0.33	3.4e-12	Psychosis and Alzheimer's disease;
LUAD	trans	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg18187862	chr3:45730750	SACM1L	0.53	8.17	0.37	3.68e-15	Primary sclerosing cholangitis;
LUAD	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg11125805	chr5:150678162	SLC36A3	0.76	17.46	0.65	8.83e-52	Skin aging (microtopography measurement);
LUAD	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg19418458	chr7:158789849	NA	-0.63	-11.12	-0.48	2.2e-25	Facial morphology (factor 20);
LUAD	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.43e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg27124370	chr19:33622961	WDR88	0.45	6.88	0.32	2.12e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7551222	0.752	rs10900594	chr1:204470129	C/G	cg20240347	chr1:204465584	NA	-0.35	-6.7	-0.31	6.8e-11	Schizophrenia;
LUAD	cis	rs6545883	0.929	rs2593625	chr2:61668769	C/T	cg15711740	chr2:61764176	XPO1	-0.41	-6.4	-0.3	4.23e-10	Tuberculosis;
LUAD	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg03806693	chr22:41940476	POLR3H	0.59	8.61	0.39	1.49e-16	Vitiligo;
LUAD	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg07636037	chr3:49044803	WDR6	0.35	6.48	0.3	2.61e-10	Resting heart rate;
LUAD	cis	rs7474896	0.583	rs1208770	chr10:38044683	C/T	cg25427524	chr10:38739819	LOC399744	-0.61	-8.68	-0.39	8.4e-17	Obesity (extreme);
LUAD	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg16988262	chr1:15930761	NA	0.41	6.82	0.31	3.07e-11	Systolic blood pressure;
LUAD	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-9.24	-0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg14061069	chr19:46274453	DMPK	-0.33	-6.37	-0.3	4.96e-10	Coronary artery disease;
LUAD	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg17724175	chr1:150552817	MCL1	0.35	8.01	0.36	1.09e-14	Melanoma;
LUAD	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.25	-0.41	1.14e-18	Total body bone mineral density;
LUAD	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.45	-7.06	-0.32	6.74e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.46	0.3	2.97e-10	Depression;
LUAD	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg03609598	chr5:56110824	MAP3K1	-0.47	-7.48	-0.34	4.46e-13	Coronary artery disease;
LUAD	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg03563238	chr19:33554763	RHPN2	-0.36	-8.28	-0.37	1.63e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg15605315	chr1:45957053	TESK2	-0.42	-6.63	-0.31	1e-10	High light scatter reticulocyte count;
LUAD	cis	rs7202877	0.611	rs7187263	chr16:75308978	C/A	cg03315344	chr16:75512273	CHST6	0.49	6.76	0.31	4.72e-11	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs7827545	1.000	rs1372659	chr8:135566779	T/A	cg17885191	chr8:135476712	NA	0.5	8.04	0.36	8.88e-15	Hypertension (SNP x SNP interaction);
LUAD	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg25828334	chr19:18545568	ISYNA1	-0.36	-7.24	-0.33	2.12e-12	Breast cancer;
LUAD	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg18132916	chr6:79620363	NA	-0.45	-7.78	-0.35	5.43e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg02505535	chr3:195703920	SDHAP1	-0.36	-7.47	-0.34	4.67e-13	Pancreatic cancer;
LUAD	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.59	10.52	0.46	3.91e-23	Birth weight;
LUAD	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg13736514	chr6:26305472	NA	-0.69	-12.9	-0.53	2.55e-32	Educational attainment;
LUAD	cis	rs2479724	0.935	rs2025951	chr6:41827193	C/T	cg17623882	chr6:41773611	USP49	0.67	12.51	0.52	9.22e-31	Menarche (age at onset);
LUAD	cis	rs6545883	0.929	rs1900572	chr2:61650715	T/G	cg15711740	chr2:61764176	XPO1	0.41	6.61	0.31	1.18e-10	Tuberculosis;
LUAD	trans	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg04450456	chr4:17643702	FAM184B	0.42	8.34	0.38	1.03e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs868036	1.000	rs3784719	chr15:68098180	C/T	cg24579218	chr15:68104479	NA	-0.39	-7.41	-0.34	6.9e-13	Restless legs syndrome;
LUAD	cis	rs17608059	0.566	rs6502327	chr17:13946187	T/C	cg11395062	chr17:14139857	CDRT15	0.45	7.04	0.32	7.68e-12	Temperament;
LUAD	cis	rs3784262	0.904	rs17820823	chr15:58239358	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.44	-8.97	-0.4	9.89e-18	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs10911363	0.592	rs2702182	chr1:183516440	C/T	cg09173681	chr1:183549694	NCF2	0.56	10.65	0.46	1.22e-23	Systemic lupus erythematosus;
LUAD	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg15605315	chr1:45957053	TESK2	0.49	7.79	0.35	5.37e-14	High light scatter reticulocyte count;
LUAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08219700	chr8:58056026	NA	0.55	7.68	0.35	1.08e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg13334819	chr7:99746414	C7orf59	-0.57	-8.38	-0.38	7.96e-16	Coronary artery disease;
LUAD	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg06547715	chr2:218990976	CXCR2	0.44	10.64	0.46	1.38e-23	Ulcerative colitis;
LUAD	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg23277830	chr1:3704460	LRRC47	0.45	9.39	0.42	3.78e-19	Red cell distribution width;
LUAD	cis	rs7665090	1.000	rs7664828	chr4:103551376	C/T	cg07973026	chr4:103553119	MANBA	0.48	8.53	0.38	2.63e-16	Primary biliary cholangitis;
LUAD	trans	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	15.8	0.61	1.58e-44	Exhaled nitric oxide levels;
LUAD	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	trans	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg06606381	chr12:133084897	FBRSL1	-0.86	-9.05	-0.4	5.36e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1018836	0.828	rs10956730	chr8:91597428	T/G	cg16814680	chr8:91681699	NA	-0.58	-9.88	-0.43	7.55e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3784262	0.527	rs1441815	chr15:58274229	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-6.4	-0.3	4.06e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg01119278	chr6:110721349	DDO	0.51	9.54	0.42	1.15e-19	Platelet distribution width;
LUAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg26304593	chr6:42947056	PEX6	-0.45	-7.49	-0.34	4.16e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07923666	chr12:49932857	KCNH3	-0.49	-6.44	-0.3	3.23e-10	Resting heart rate;
LUAD	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg16479474	chr6:28041457	NA	0.46	7.65	0.35	1.41e-13	Depression;
LUAD	cis	rs10242455	0.557	rs57830676	chr7:99281363	C/T	cg18809830	chr7:99032528	PTCD1	-1.03	-8.53	-0.38	2.72e-16	Blood metabolite levels;
LUAD	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.75	-15.69	-0.61	4.48e-44	Lung cancer;
LUAD	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg14092988	chr3:52407081	DNAH1	0.42	8.11	0.37	5.72e-15	Bipolar disorder;
LUAD	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg24818145	chr4:99064322	C4orf37	0.44	7.25	0.33	2.04e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg06618935	chr21:46677482	NA	-0.49	-10.03	-0.44	2.21e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg12483801	chr4:183727862	NA	0.55	6.96	0.32	1.31e-11	Pediatric autoimmune diseases;
LUAD	cis	rs11696501	0.688	rs1013562	chr20:44310744	A/G	cg11783356	chr20:44313418	WFDC10B	-0.48	-7.62	-0.35	1.73e-13	Brain structure;
LUAD	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg15992532	chr8:142229932	SLC45A4	0.47	8.25	0.37	2e-15	Immature fraction of reticulocytes;
LUAD	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg14983838	chr19:29218262	NA	0.63	9.66	0.42	4.58e-20	Methadone dose in opioid dependence;
LUAD	cis	rs6761276	0.752	rs12477866	chr2:113835908	C/T	cg02343335	chr2:113785852	IL1F8	-0.35	-7.01	-0.32	9.26e-12	Protein quantitative trait loci;
LUAD	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg05110241	chr16:68378359	PRMT7	-0.7	-7.99	-0.36	1.26e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg04731861	chr2:219085781	ARPC2	-0.23	-7.09	-0.33	5.71e-12	Colorectal cancer;
LUAD	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg02176678	chr2:219576539	TTLL4	-0.74	-14.91	-0.59	1.03e-40	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs8073060	0.505	rs225270	chr17:33968871	A/T	cg19694781	chr19:47549865	TMEM160	-1.24	-19.51	-0.69	6.03e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21582582	chr3:182698605	DCUN1D1	0.72	14.06	0.56	3.98e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg13944838	chr5:179740914	GFPT2	-0.74	-12.13	-0.51	2.94e-29	Height;
LUAD	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg02782426	chr3:40428986	ENTPD3	0.42	8.9	0.4	1.64e-17	Renal cell carcinoma;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04272052	chr7:99662051	ZNF3;ZSCAN21	0.5	6.39	0.3	4.49e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg22166914	chr1:53195759	ZYG11B	-0.51	-8.82	-0.39	2.92e-17	Monocyte count;
LUAD	cis	rs2274273	0.837	rs10131913	chr14:55787420	A/G	cg04306507	chr14:55594613	LGALS3	0.41	8.5	0.38	3.26e-16	Protein biomarker;
LUAD	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg15445000	chr17:37608096	MED1	-0.38	-6.56	-0.3	1.58e-10	Glomerular filtration rate (creatinine);
LUAD	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg04842962	chr6:43655489	MRPS18A	-1.05	-27.29	-0.8	2.66e-95	IgG glycosylation;
LUAD	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg11344533	chr11:111475393	SIK2	-0.36	-6.56	-0.3	1.56e-10	Primary sclerosing cholangitis;
LUAD	cis	rs612683	0.517	rs3767832	chr1:100943100	A/G	cg06223162	chr1:101003688	GPR88	-0.43	-8.41	-0.38	6.37e-16	Breast cancer;
LUAD	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12923728	chr3:195709715	SDHAP1	0.74	12.73	0.53	1.19e-31	Pancreatic cancer;
LUAD	cis	rs1595825	0.945	rs1850634	chr2:198827896	T/C	cg10547527	chr2:198650123	BOLL	-0.51	-7.1	-0.33	5.43e-12	Ulcerative colitis;
LUAD	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg05590025	chr7:65112418	INTS4L2	-0.65	-7.39	-0.34	7.67e-13	Diabetic kidney disease;
LUAD	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg01475377	chr6:109611718	NA	-0.54	-10.51	-0.45	4.22e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs6541297	0.699	rs1555290	chr1:230294989	A/C	cg20703242	chr1:230279135	GALNT2	-0.56	-8.3	-0.37	1.45e-15	Coronary artery disease;
LUAD	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg13393036	chr8:95962371	TP53INP1	0.37	7.92	0.36	2.06e-14	Type 2 diabetes;
LUAD	cis	rs9611519	1.000	rs3818003	chr22:41609690	C/T	cg13813247	chr22:41461852	NA	-0.44	-7.52	-0.34	3.27e-13	Neuroticism;
LUAD	cis	rs11214589	0.651	rs11214594	chr11:113259332	G/A	cg14159747	chr11:113255604	NA	0.64	13.53	0.55	6.41e-35	Neuroticism;
LUAD	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg04756594	chr16:24857601	SLC5A11	0.77	13.35	0.54	3.66e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs10189230	0.967	rs13002861	chr2:222352859	T/G	cg14652038	chr2:222343519	EPHA4	0.43	8.59	0.39	1.73e-16	Urate levels in lean individuals;
LUAD	cis	rs6460942	1.000	rs62448562	chr7:12398785	T/C	cg20607287	chr7:12443886	VWDE	-0.55	-6.79	-0.31	3.8e-11	Coronary artery disease;
LUAD	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg25358565	chr5:93447407	FAM172A	-0.63	-7.54	-0.34	2.9e-13	Diabetic retinopathy;
LUAD	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg23625390	chr15:77176239	SCAPER	0.44	7.8	0.35	5.04e-14	Blood metabolite levels;
LUAD	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg14345882	chr6:26364793	BTN3A2	0.69	7.04	0.32	7.77e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg04414720	chr1:150670196	GOLPH3L	-0.49	-8.2	-0.37	2.92e-15	Tonsillectomy;
LUAD	cis	rs1371614	0.523	rs11904656	chr2:27173249	G/A	cg00617064	chr2:27272375	NA	-0.36	-6.85	-0.32	2.68e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs7274811	0.711	rs291700	chr20:31981849	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.45	-6.71	-0.31	6.12e-11	Height;
LUAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg15117754	chr3:10150083	C3orf24	0.42	6.75	0.31	4.97e-11	Alzheimer's disease;
LUAD	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.49	-9.77	-0.43	1.86e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1375194	0.606	rs2044644	chr2:33817559	A/G	cg04131969	chr2:33951647	MYADML	-0.53	-8.44	-0.38	5.2e-16	Response to antidepressants in depression;
LUAD	cis	rs4409675	0.576	rs10794507	chr1:28216072	T/C	cg23691781	chr1:28212827	C1orf38	0.38	11.1	0.47	2.69e-25	Corneal astigmatism;
LUAD	cis	rs859767	0.741	rs6713239	chr2:135434849	C/T	cg12500956	chr2:135428796	TMEM163	-0.31	-8.07	-0.37	7.26e-15	Neuroticism;
LUAD	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	9.17	0.41	2.15e-18	Tonsillectomy;
LUAD	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg18180107	chr4:99064573	C4orf37	0.42	6.63	0.31	1.02e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg25457927	chr22:38595422	NA	-0.53	-13.59	-0.55	3.7e-35	Cutaneous nevi;
LUAD	cis	rs1232027	1.000	rs865646	chr5:79942357	G/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.4	-6.55	-0.3	1.64e-10	Huntington's disease progression;
LUAD	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg11814155	chr7:99998594	ZCWPW1	0.45	7.82	0.36	4.35e-14	Platelet count;
LUAD	trans	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg01620082	chr3:125678407	NA	-0.8	-8.06	-0.36	8.14e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg08601574	chr20:25228251	PYGB	-0.47	-8.9	-0.4	1.69e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs3733418	0.929	rs72697952	chr4:165900928	A/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-6.76	-0.31	4.59e-11	Obesity-related traits;
LUAD	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg17757837	chr7:157058334	UBE3C	-0.49	-8.74	-0.39	5.46e-17	Body mass index;
LUAD	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs3760982	1.000	rs10405457	chr19:44296582	G/T	cg12072164	chr19:44306565	LYPD5	0.38	7.71	0.35	8.84e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg15226275	chr6:116381976	FRK	0.23	7.51	0.34	3.45e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg16988262	chr1:15930761	NA	0.42	6.88	0.32	2.13e-11	Systolic blood pressure;
LUAD	cis	rs12618769	0.597	rs12617721	chr2:99083892	G/T	cg10123293	chr2:99228465	UNC50	-0.45	-8.32	-0.38	1.19e-15	Bipolar disorder;
LUAD	cis	rs7737355	0.853	rs26005	chr5:130988029	A/G	cg25547332	chr5:131281432	NA	0.44	6.63	0.31	1.02e-10	Life satisfaction;
LUAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.67e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg14668821	chr17:77704760	ENPP7	0.33	6.61	0.31	1.18e-10	Menopause (age at onset);
LUAD	cis	rs1595825	0.735	rs16827267	chr2:198924967	G/A	cg00982548	chr2:198649783	BOLL	-0.64	-8.88	-0.4	1.87e-17	Ulcerative colitis;
LUAD	cis	rs7107174	0.681	rs3102742	chr11:77949334	G/T	cg19901956	chr11:77921274	USP35	-0.55	-6.63	-0.31	1.03e-10	Testicular germ cell tumor;
LUAD	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.84	-0.5	3.89e-28	Schizophrenia;
LUAD	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.42	0.55	1.78e-34	Tonsillectomy;
LUAD	cis	rs2797160	1.000	rs1739375	chr6:126012013	T/C	cg05901451	chr6:126070800	HEY2	0.46	7.01	0.32	9.2e-12	Endometrial cancer;
LUAD	cis	rs4523957	0.614	rs2984941	chr17:2031543	A/G	cg16513277	chr17:2031491	SMG6	-0.96	-19.29	-0.68	6.16e-60	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg07636037	chr3:49044803	WDR6	-0.49	-8.04	-0.36	9.4e-15	Menarche (age at onset);
LUAD	cis	rs7301016	0.846	rs7302094	chr12:62967430	C/T	cg11441379	chr12:63026424	NA	0.61	7.8	0.35	4.99e-14	IgG glycosylation;
LUAD	cis	rs7831492	0.564	rs7831530	chr8:41614567	G/A	cg17182837	chr8:41585554	ANK1	-0.4	-8.63	-0.39	1.22e-16	Colorectal cancer;
LUAD	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.38	6.73	0.31	5.63e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg27124370	chr19:33622961	WDR88	0.43	6.66	0.31	8.47e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs750460	0.808	rs2165241	chr15:74222202	A/G	cg23484268	chr15:74220776	LOXL1	0.35	6.69	0.31	7.2e-11	Height;
LUAD	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg07741184	chr6:167504864	NA	0.4	9.12	0.41	3.18e-18	Crohn's disease;
LUAD	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg02423579	chr7:2872169	GNA12	-0.82	-14.21	-0.57	1.01e-37	Height;
LUAD	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg03563238	chr19:33554763	RHPN2	-0.39	-8.96	-0.4	1.09e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg12483005	chr1:23474871	LUZP1	0.52	8.97	0.4	9.62e-18	Height;
LUAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg19678392	chr7:94953810	PON1	-0.72	-12.88	-0.53	3e-32	Paraoxonase activity;
LUAD	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg13126279	chr21:47581558	C21orf56	-0.44	-7.56	-0.35	2.46e-13	Testicular germ cell tumor;
LUAD	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg02269571	chr22:50332266	NA	-0.6	-9.07	-0.4	4.55e-18	Schizophrenia;
LUAD	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg07153921	chr17:41440717	NA	0.4	6.79	0.31	3.75e-11	Menopause (age at onset);
LUAD	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg16606324	chr3:10149918	C3orf24	0.67	10.97	0.47	8.41e-25	Alzheimer's disease;
LUAD	cis	rs2625529	0.938	rs8747	chr15:72115541	C/A	cg16672083	chr15:72433130	SENP8	-0.71	-10.93	-0.47	1.14e-24	Red blood cell count;
LUAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg22907277	chr7:1156413	C7orf50	0.69	8.05	0.36	8.6e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg11707310	chr1:2537719	MMEL1	0.38	8.02	0.36	1.02e-14	Ulcerative colitis;
LUAD	trans	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg03886242	chr7:26192032	NFE2L3	0.41	7.21	0.33	2.57e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg25319279	chr11:5960081	NA	-0.41	-7.63	-0.35	1.55e-13	DNA methylation (variation);
LUAD	trans	rs11885103	0.791	rs11686772	chr2:584563	C/T	cg12228919	chr15:44955936	SPG11	-0.44	-6.67	-0.31	7.88e-11	Heschl's gyrus morphology;
LUAD	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg14092988	chr3:52407081	DNAH1	0.39	7.9	0.36	2.36e-14	Bipolar disorder;
LUAD	cis	rs9473147	0.543	rs4715025	chr6:47483653	C/G	cg20196966	chr6:47445060	CD2AP	0.44	6.8	0.31	3.67e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg02176678	chr2:219576539	TTLL4	0.73	14.45	0.57	9.33e-39	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg04025307	chr7:1156635	C7orf50	0.68	7.92	0.36	2.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	7.13	0.33	4.35e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs9837602	1.000	rs9873878	chr3:99711816	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.98	-0.32	1.18e-11	Breast cancer;
LUAD	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23158103	chr7:148848205	ZNF398	-0.65	-11.77	-0.5	7.07e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg02951883	chr7:2050386	MAD1L1	-0.83	-14.21	-0.57	9.87e-38	Bipolar disorder and schizophrenia;
LUAD	cis	rs2425143	1.000	rs12480408	chr20:34234800	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.2	-0.33	2.78e-12	Blood protein levels;
LUAD	trans	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg21659725	chr3:3221576	CRBN	-0.57	-9.17	-0.41	2.14e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24531977	chr5:56204891	C5orf35	-0.99	-15.2	-0.59	6.23e-42	Initial pursuit acceleration;
LUAD	trans	rs853679	0.546	rs200990	chr6:27815823	T/G	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.86	-0.36	3.33e-14	Depression;
LUAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg14458575	chr2:238380390	NA	0.69	12.72	0.53	1.32e-31	Prostate cancer;
LUAD	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg21028142	chr17:79581711	NPLOC4	0.42	8.82	0.39	2.98e-17	Eye color traits;
LUAD	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg18180107	chr4:99064573	C4orf37	0.43	6.92	0.32	1.65e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg07741184	chr6:167504864	NA	0.36	8.17	0.37	3.66e-15	Primary biliary cholangitis;
LUAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg18621852	chr3:10150065	C3orf24	0.48	8.52	0.38	2.75e-16	Alzheimer's disease;
LUAD	cis	rs526821	0.595	rs2926309	chr11:55314219	G/A	cg04317927	chr11:55418816	OR4S2	0.38	7.2	0.33	2.78e-12	Pediatric bone mineral density (spine);
LUAD	cis	rs2625529	0.824	rs7172309	chr15:72384483	C/T	cg16672083	chr15:72433130	SENP8	-0.74	-12.5	-0.52	1.01e-30	Red blood cell count;
LUAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.53	-9.16	-0.41	2.21e-18	Longevity;Endometriosis;
LUAD	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.08	-0.33	6.19e-12	Height;
LUAD	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.83	0.53	4.8e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9929218	1.000	rs12930371	chr16:68802936	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.81	13.83	0.56	3.89e-36	Colorectal cancer;
LUAD	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg21220214	chr8:57350948	NA	-0.62	-8.66	-0.39	9.82e-17	Obesity-related traits;
LUAD	cis	rs427394	0.772	rs274689	chr5:6736215	G/C	cg10857441	chr5:6722123	POLS	-0.64	-12.37	-0.52	3.2e-30	Menopause (age at onset);
LUAD	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.88	0.36	2.71e-14	Bladder cancer;
LUAD	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg24069376	chr3:38537580	EXOG	0.36	8.4	0.38	6.82e-16	Electrocardiographic conduction measures;
LUAD	cis	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg11143507	chr3:125485238	NA	-0.44	-7.39	-0.34	7.83e-13	Blood pressure (smoking interaction);
LUAD	cis	rs6665290	0.904	rs2297415	chr1:227172903	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.2	-38.77	-0.88	2.44e-141	Myeloid white cell count;
LUAD	trans	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg27411982	chr8:10470053	RP1L1	0.39	7.05	0.32	7.36e-12	Joint mobility (Beighton score);
LUAD	cis	rs9811920	0.809	rs35422475	chr3:99711545	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	6.87	0.32	2.35e-11	Axial length;
LUAD	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg21827317	chr3:136751795	NA	0.36	6.58	0.3	1.37e-10	Neuroticism;
LUAD	cis	rs4722585	0.533	rs2237335	chr7:26200213	A/G	cg07876897	chr7:26191696	NFE2L3	0.46	7.51	0.34	3.6e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.23	-0.37	2.28e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg07708487	chr16:89387014	ANKRD11	-0.33	-6.78	-0.31	4.04e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg08514558	chr10:81106712	PPIF	0.47	9.26	0.41	9.98e-19	Height;
LUAD	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg06108461	chr20:60628389	TAF4	-0.82	-14.08	-0.56	3.37e-37	Body mass index;
LUAD	cis	rs6543140	0.964	rs6734203	chr2:103080066	G/C	cg04239558	chr2:103089729	SLC9A4	0.36	7.33	0.34	1.15e-12	Blood protein levels;
LUAD	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.2	0.44	5.63e-22	Ileal carcinoids;
LUAD	trans	rs13160161	0.533	rs13189402	chr5:38922894	G/A	cg26570867	chr16:12308181	SNX29	0.42	6.52	0.3	2e-10	Obesity-related traits;
LUAD	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27297192	chr10:134578999	INPP5A	0.39	6.67	0.31	8.11e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2425143	0.841	rs4911519	chr20:34362326	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	7.44	0.34	5.54e-13	Blood protein levels;
LUAD	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17691542	chr6:26056736	HIST1H1C	0.49	6.73	0.31	5.49e-11	Iron status biomarkers;
LUAD	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg18230493	chr5:56204884	C5orf35	-0.47	-7.93	-0.36	2.01e-14	Coronary artery disease;
LUAD	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg15556689	chr8:8085844	FLJ10661	0.47	7.9	0.36	2.48e-14	Mood instability;
LUAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg06753367	chr22:24256600	NA	-0.39	-6.9	-0.32	1.94e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.09	0.33	5.7e-12	Parkinson's disease;
LUAD	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg06784218	chr1:46089804	CCDC17	-0.53	-11.59	-0.49	3.67e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2224391	0.628	rs2773311	chr6:5250866	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.62	-9.46	-0.42	2.2e-19	Height;
LUAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.52	-9.29	-0.41	8.16e-19	Lymphocyte counts;
LUAD	cis	rs4660214	0.666	rs2256614	chr1:39824718	C/G	cg27567593	chr1:39956653	BMP8A	-0.36	-7.32	-0.34	1.27e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg02160872	chr5:212506	CCDC127	-0.51	-6.61	-0.31	1.16e-10	Breast cancer;
LUAD	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg10057126	chr4:77819792	ANKRD56	0.53	9.02	0.4	6.47e-18	Emphysema distribution in smoking;
LUAD	cis	rs3806843	0.576	rs246043	chr5:140330924	G/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7119	0.700	rs57471224	chr15:77888169	A/G	cg27398640	chr15:77910606	LINGO1	0.38	7.53	0.34	3.16e-13	Type 2 diabetes;
LUAD	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg21191810	chr6:118973309	C6orf204	-0.52	-8.2	-0.37	2.93e-15	Diastolic blood pressure;
LUAD	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg15147215	chr3:52552868	STAB1	0.4	7.35	0.34	1.01e-12	Bipolar disorder;
LUAD	cis	rs35771425	0.626	rs55761812	chr1:211653935	C/T	cg10512769	chr1:211675356	NA	-0.37	-6.42	-0.3	3.73e-10	Educational attainment (years of education);
LUAD	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg00684032	chr4:1343700	KIAA1530	0.41	6.94	0.32	1.44e-11	Obesity-related traits;
LUAD	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg23625390	chr15:77176239	SCAPER	-0.54	-8.84	-0.39	2.58e-17	Blood metabolite levels;
LUAD	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	8.26	0.37	1.84e-15	Rheumatoid arthritis;
LUAD	cis	rs12541635	0.677	rs7819501	chr8:107006962	C/T	cg10147462	chr8:107024639	NA	-0.57	-9.99	-0.44	3.05e-21	Age of smoking initiation;
LUAD	cis	rs62238980	0.614	rs117256264	chr22:32381750	T/C	cg00543991	chr22:32367038	NA	0.94	8.78	0.39	4.09e-17	Childhood ear infection;
LUAD	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.5	0.34	3.78e-13	Tonsillectomy;
LUAD	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23158103	chr7:148848205	ZNF398	-0.5	-8.8	-0.39	3.47e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg05434287	chr7:2030229	MAD1L1	-0.42	-6.88	-0.32	2.15e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg22823121	chr1:150693482	HORMAD1	0.45	9.15	0.41	2.4e-18	Tonsillectomy;
LUAD	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.36	-6.41	-0.3	3.9e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg04111992	chr7:158790115	NA	-0.51	-8.74	-0.39	5.48e-17	Facial morphology (factor 20);
LUAD	cis	rs4711336	1.000	rs3818523	chr6:33660371	G/A	cg14003231	chr6:33640908	ITPR3	0.5	9.54	0.42	1.13e-19	Height;
LUAD	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg13606994	chr1:44402422	ARTN	-0.38	-7.64	-0.35	1.43e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg17173187	chr15:85201210	NMB	0.49	8.69	0.39	8.25e-17	Schizophrenia;
LUAD	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg23887609	chr12:130822674	PIWIL1	0.41	6.83	0.32	3e-11	Menopause (age at onset);
LUAD	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg25894440	chr7:65020034	NA	-0.64	-6.89	-0.32	2.03e-11	Diabetic kidney disease;
LUAD	cis	rs2692947	0.673	rs4907299	chr2:96780122	G/T	cg23100626	chr2:96804247	ASTL	0.36	9.12	0.41	3.06e-18	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	trans	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg14917512	chr19:3094685	GNA11	-0.53	-6.53	-0.3	1.9e-10	Diabetic kidney disease;
LUAD	cis	rs713587	0.935	rs11676272	chr2:25141538	A/G	cg01884057	chr2:25150051	NA	0.39	8.24	0.37	2.26e-15	Body mass index in non-asthmatics;
LUAD	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg13319975	chr6:146136371	FBXO30	0.65	11.29	0.48	5.07e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs908922	0.523	rs4845786	chr1:152510144	A/G	cg23254163	chr1:152506842	NA	0.26	7.07	0.33	6.44e-12	Hair morphology;
LUAD	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6835098	0.962	rs4377567	chr4:174083590	C/G	cg08422745	chr4:174089978	GALNT7	0.93	18.2	0.66	4.39e-55	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-7.01	-0.32	9.56e-12	Breast cancer;
LUAD	cis	rs10979	1.000	rs9373394	chr6:143890776	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.3	-0.45	2.33e-22	Hypospadias;
LUAD	trans	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg20587970	chr11:113659929	NA	0.88	11.78	0.5	6.76e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg04287289	chr16:89883240	FANCA	0.7	6.58	0.3	1.43e-10	Skin colour saturation;
LUAD	cis	rs513349	1.000	rs210146	chr6:33549098	A/G	cg24505687	chr6:33548425	BAK1	0.45	8.72	0.39	6.5e-17	Platelet count;
LUAD	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg07870213	chr5:140052090	DND1	1.0	14.53	0.58	4.16e-39	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg04025307	chr7:1156635	C7orf50	0.66	7.49	0.34	4.17e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62458065	0.513	rs9655340	chr7:32535920	A/G	cg20159608	chr7:32802032	NA	0.66	9.85	0.43	9.63e-21	Metabolite levels (HVA/MHPG ratio);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg18488745	chr11:67141242	LOC100130987;CLCF1	-0.38	-6.48	-0.3	2.49e-10	Cancer;
LUAD	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg11915388	chr22:42470451	FAM109B	0.39	7.02	0.32	9.11e-12	Schizophrenia;
LUAD	cis	rs7843479	0.965	rs11775479	chr8:21859991	C/T	cg03445287	chr8:21823731	XPO7	-0.45	-8.21	-0.37	2.63e-15	Mean corpuscular volume;
LUAD	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg27432699	chr2:27873401	GPN1	0.52	9.01	0.4	7.07e-18	Oral cavity cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg19320564	chr1:40157253	HPCAL4	-0.67	-6.6	-0.31	1.27e-10	Type 2 diabetes;
LUAD	cis	rs2425143	1.000	rs6060639	chr20:34438183	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.17	-0.33	3.32e-12	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg05340658	chr4:99064831	C4orf37	0.56	9.53	0.42	1.29e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11039798	0.688	rs10839007	chr11:48703442	A/C	cg15704280	chr7:45808275	SEPT13	0.67	7.84	0.36	3.58e-14	Axial length;
LUAD	cis	rs7215564	0.908	rs9908112	chr17:78753455	A/G	cg09596252	chr17:78655493	RPTOR	-0.62	-6.83	-0.32	3.01e-11	Myopia (pathological);
LUAD	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg09222892	chr1:25734099	RHCE	-0.51	-9.51	-0.42	1.46e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.88	-0.5	2.72e-28	Electroencephalogram traits;
LUAD	cis	rs34658409	1	rs34658409	chr8:42433985	TC/T	cg09913449	chr8:42400586	C8orf40	0.44	8.44	0.38	5.12e-16	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg18180107	chr4:99064573	C4orf37	0.4	6.45	0.3	3.04e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg23583168	chr7:148888333	NA	-1.04	-24.47	-0.77	5.15e-83	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg15017067	chr4:17643749	FAM184B	0.35	6.83	0.32	2.88e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4343996	0.902	rs4722710	chr7:3388254	C/A	cg21248987	chr7:3385318	SDK1	-0.35	-6.54	-0.3	1.81e-10	Motion sickness;
LUAD	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg18196295	chr10:418757	DIP2C	-0.55	-9.44	-0.42	2.59e-19	Psychosis in Alzheimer's disease;
LUAD	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.25e-14	Prostate cancer;
LUAD	cis	rs7843479	0.965	rs11135741	chr8:21801091	C/T	cg03445287	chr8:21823731	XPO7	-0.47	-8.6	-0.39	1.61e-16	Mean corpuscular volume;
LUAD	cis	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg21775007	chr8:11205619	TDH	-0.37	-6.43	-0.3	3.46e-10	Retinal vascular caliber;
LUAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.84	-0.32	2.77e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.45	-8.87	-0.4	2e-17	Glomerular filtration rate;
LUAD	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg22349387	chr12:9600060	DDX12	-0.41	-7.15	-0.33	3.73e-12	Breast size;
LUAD	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.77	-0.35	6.02e-14	Monocyte count;
LUAD	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.66	0.31	8.75e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6740322	0.748	rs6720087	chr2:43468745	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.72	10.88	0.47	1.84e-24	Coronary artery disease;
LUAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg06453172	chr10:134556979	INPP5A	-0.76	-10.99	-0.47	7.11e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7043114	0.525	rs6479419	chr9:95110002	T/C	cg14631576	chr9:95140430	CENPP	-0.43	-8.63	-0.39	1.28e-16	Height;
LUAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg11062466	chr8:58055876	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg02993280	chr1:107599747	PRMT6	-0.5	-8.38	-0.38	8.02e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg05342682	chr7:94953680	PON1	-0.52	-7.41	-0.34	6.88e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg11050988	chr7:1952600	MAD1L1	-0.39	-7.97	-0.36	1.5e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg02734326	chr4:10020555	SLC2A9	-0.45	-7.47	-0.34	4.62e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11890956	chr21:40555474	PSMG1	-0.64	-11.04	-0.47	4.47e-25	Cognitive function;
LUAD	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg23758822	chr17:41437982	NA	0.96	20.13	0.7	1.09e-63	Menopause (age at onset);
LUAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.49	7.0	0.32	9.8e-12	Renal function-related traits (BUN);
LUAD	cis	rs71478720	0.729	rs75649625	chr11:112052194	G/A	cg04929355	chr11:112034997	IL18	0.41	6.8	0.31	3.63e-11	Interleukin-18 levels;
LUAD	cis	rs752010	0.806	rs1109255	chr1:42091708	C/T	cg06885757	chr1:42089581	HIVEP3	0.48	10.86	0.47	2.15e-24	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg05313129	chr8:58192883	C8orf71	-0.51	-7.71	-0.35	8.89e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg03034668	chr16:1723424	CRAMP1L	-0.41	-7.07	-0.32	6.6e-12	Coronary artery disease;
LUAD	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26314531	chr2:26401878	FAM59B	-0.55	-7.65	-0.35	1.35e-13	Gut microbiome composition (summer);
LUAD	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg00071950	chr4:10020882	SLC2A9	0.71	14.34	0.57	2.79e-38	Bone mineral density;
LUAD	cis	rs7107174	1.000	rs2510039	chr11:77944480	G/A	cg02023728	chr11:77925099	USP35	0.49	7.29	0.33	1.49e-12	Testicular germ cell tumor;
LUAD	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.36	7.18	0.33	3.14e-12	Obesity-related traits;
LUAD	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg08999081	chr20:33150536	PIGU	0.63	14.41	0.57	1.46e-38	Coronary artery disease;
LUAD	trans	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04565464	chr8:145669602	NFKBIL2	0.46	6.9	0.32	1.93e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg22963979	chr7:1858916	MAD1L1	-0.62	-10.61	-0.46	1.79e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs2880765	0.835	rs7169632	chr15:86044667	T/G	cg13263323	chr15:86062960	AKAP13	-0.5	-9.24	-0.41	1.21e-18	Coronary artery disease;
LUAD	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg24558204	chr6:135376177	HBS1L	0.45	8.08	0.37	6.71e-15	Red blood cell count;
LUAD	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg02951883	chr7:2050386	MAD1L1	-0.82	-14.3	-0.57	4.1e-38	Bipolar disorder and schizophrenia;
LUAD	cis	rs1003719	0.788	rs2006941	chr21:38467616	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.65	0.39	1.11e-16	Eye color traits;
LUAD	cis	rs4588572	0.643	rs1864173	chr5:77691158	C/T	cg11547950	chr5:77652471	NA	0.77	12.22	0.51	1.23e-29	Triglycerides;
LUAD	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg12935359	chr14:103987150	CKB	-0.48	-8.08	-0.37	6.93e-15	Body mass index;
LUAD	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg03806693	chr22:41940476	POLR3H	0.73	9.81	0.43	1.33e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg03433033	chr1:76189801	ACADM	-0.86	-17.53	-0.65	4.18e-52	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs62400317	0.859	rs12199871	chr6:45307682	C/T	cg20913747	chr6:44695427	NA	-0.44	-7.04	-0.32	7.62e-12	Total body bone mineral density;
LUAD	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg14092571	chr14:90743983	NA	-0.49	-8.63	-0.39	1.21e-16	Mortality in heart failure;
LUAD	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Parkinson's disease;
LUAD	cis	rs4372836	1.000	rs6547872	chr2:28978074	C/T	cg09522027	chr2:28974177	PPP1CB	-0.6	-9.63	-0.42	5.83e-20	Body mass index;
LUAD	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg26597838	chr10:835615	NA	-0.52	-8.27	-0.37	1.71e-15	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs3806843	0.576	rs246006	chr5:140339228	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.52	-0.3	2.03e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg26384229	chr12:38710491	ALG10B	0.49	7.9	0.36	2.47e-14	Morning vs. evening chronotype;
LUAD	cis	rs7394190	0.748	rs79936644	chr10:75545117	C/T	cg02286717	chr10:75415704	SYNPO2L	-0.36	-6.36	-0.3	5.22e-10	Incident atrial fibrillation;
LUAD	trans	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg18834416	chr8:37888184	EIF4EBP1	0.4	6.52	0.3	2.04e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12801636	0.557	rs3741378	chr11:65408937	C/T	cg24147428	chr11:65409760	SIPA1	-0.52	-7.53	-0.34	3.09e-13	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg01528321	chr10:82214614	TSPAN14	0.64	10.11	0.44	1.18e-21	Post bronchodilator FEV1;
LUAD	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg03037974	chr15:76606532	NA	0.31	6.37	0.3	5.01e-10	Blood metabolite levels;
LUAD	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg24397884	chr7:158709396	WDR60	0.43	7.16	0.33	3.6e-12	Height;
LUAD	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-11.44	-0.49	1.37e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-10.31	-0.45	2.26e-22	Lymphocyte counts;
LUAD	cis	rs9796	0.866	rs692155	chr15:41407061	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.37	-6.82	-0.31	3.21e-11	Menopause (age at onset);
LUAD	trans	rs853679	0.546	rs200989	chr6:27816442	A/G	cg01620082	chr3:125678407	NA	-0.81	-8.85	-0.4	2.4e-17	Depression;
LUAD	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.6	11.91	0.5	2.18e-28	Tonsillectomy;
LUAD	cis	rs7274811	0.634	rs4911356	chr20:32255034	T/C	cg12710480	chr20:32254216	NECAB3;C20orf134	-0.32	-6.39	-0.3	4.39e-10	Height;
LUAD	cis	rs1595825	0.945	rs16826320	chr2:198845623	T/C	cg00361562	chr2:198649771	BOLL	-0.47	-6.66	-0.31	8.73e-11	Ulcerative colitis;
LUAD	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg18833306	chr6:118973337	C6orf204	-0.52	-7.67	-0.35	1.21e-13	Diastolic blood pressure;
LUAD	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg02176678	chr2:219576539	TTLL4	-0.82	-17.48	-0.65	7.08e-52	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7705042	0.826	rs6883827	chr5:141504991	A/G	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.84	-0.32	2.75e-11	Asthma;
LUAD	cis	rs2282300	0.696	rs1222214	chr11:30347695	C/G	cg25418670	chr11:30344373	C11orf46	-0.52	-6.94	-0.32	1.5e-11	Morning vs. evening chronotype;
LUAD	cis	rs9462027	0.628	rs9469899	chr6:34793124	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.66	-0.39	1.02e-16	Systemic lupus erythematosus;
LUAD	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg04455712	chr21:45112962	RRP1B	0.47	9.37	0.41	4.38e-19	Mean corpuscular volume;
LUAD	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg11062466	chr8:58055876	NA	0.61	7.84	0.36	3.76e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-8.78	-0.39	3.96e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2262909	1.000	rs765527	chr19:22129555	A/G	cg11619707	chr19:22235551	ZNF257	0.42	6.67	0.31	8.08e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg05110241	chr16:68378359	PRMT7	-0.82	-8.9	-0.4	1.7e-17	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg04995722	chr7:26192034	NFE2L3	0.36	6.38	0.3	4.7e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg05896524	chr21:47604654	C21orf56	-0.77	-13.4	-0.55	2.32e-34	Testicular germ cell tumor;
LUAD	cis	rs67311347	0.544	rs7644181	chr3:40355665	A/G	cg02782426	chr3:40428986	ENTPD3	-0.36	-7.81	-0.36	4.55e-14	Renal cell carcinoma;
LUAD	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.98	-0.36	1.41e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs11650494	0.908	rs8076023	chr17:47399633	C/G	cg08112188	chr17:47440006	ZNF652	0.93	7.97	0.36	1.44e-14	Prostate cancer;
LUAD	cis	rs9811920	0.683	rs10936003	chr3:99667565	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-9.82	-0.43	1.23e-20	Axial length;
LUAD	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg11502198	chr6:26597334	ABT1	-0.54	-8.97	-0.4	9.5e-18	Intelligence (multi-trait analysis);
LUAD	trans	rs8002861	0.870	rs9525855	chr13:44431660	A/G	cg17145862	chr1:211918768	LPGAT1	0.74	17.04	0.64	6.28e-50	Leprosy;
LUAD	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23583168	chr7:148888333	NA	0.91	18.88	0.68	3.99e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg02773041	chr1:40204384	PPIE	0.51	8.46	0.38	4.28e-16	Blood protein levels;
LUAD	cis	rs4604732	0.631	rs34924545	chr1:247626892	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	9.02	0.4	6.67e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg07677032	chr17:61819896	STRADA	0.58	10.68	0.46	1e-23	Prudent dietary pattern;
LUAD	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	trans	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg18187862	chr3:45730750	SACM1L	-0.58	-9.03	-0.4	6.1e-18	Primary sclerosing cholangitis;
LUAD	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg20607287	chr7:12443886	VWDE	-0.49	-6.92	-0.32	1.71e-11	Coronary artery disease;
LUAD	cis	rs10489202	0.583	rs201539	chr1:167995407	A/G	cg24449463	chr1:168025552	DCAF6	-0.76	-12.39	-0.52	2.66e-30	Schizophrenia;
LUAD	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg00071950	chr4:10020882	SLC2A9	-0.6	-11.63	-0.49	2.59e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6835098	1.000	rs2332654	chr4:174088399	C/T	cg08422745	chr4:174089978	GALNT7	-0.95	-17.92	-0.66	7.37e-54	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg15445000	chr17:37608096	MED1	-0.43	-8.07	-0.37	7.45e-15	Glomerular filtration rate (creatinine);
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg18500714	chr14:100706288	YY1	-0.46	-6.38	-0.3	4.69e-10	Testicular germ cell tumor;
LUAD	cis	rs7731657	0.537	rs72801738	chr5:130207637	A/G	cg08523029	chr5:130500466	HINT1	-0.57	-7.29	-0.33	1.58e-12	Fasting plasma glucose;
LUAD	cis	rs7945705	1.000	rs7937298	chr11:8867509	G/C	cg12365402	chr11:9010492	NRIP3	0.45	8.08	0.37	7.05e-15	Hemoglobin concentration;
LUAD	cis	rs72949976	0.646	rs1441171	chr2:214033637	G/T	cg08319019	chr2:214017104	IKZF2	0.54	8.31	0.37	1.34e-15	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg25767906	chr1:53392781	SCP2	-0.48	-8.62	-0.39	1.33e-16	Monocyte count;
LUAD	cis	rs2109514	1.000	rs2270188	chr7:116140524	G/T	cg12739419	chr7:116140593	CAV2	-0.36	-7.71	-0.35	8.88e-14	Prevalent atrial fibrillation;
LUAD	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg10556349	chr10:835070	NA	0.49	6.63	0.31	1.03e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg00933542	chr6:150070202	PCMT1	0.44	9.05	0.4	5.44e-18	Lung cancer;
LUAD	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg02269571	chr22:50332266	NA	-0.61	-9.41	-0.42	3.27e-19	Schizophrenia;
LUAD	cis	rs11696501	0.739	rs6104249	chr20:44250487	C/G	cg11783356	chr20:44313418	WFDC10B	0.52	8.57	0.38	1.92e-16	Brain structure;
LUAD	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg08280861	chr8:58055591	NA	0.55	7.43	0.34	6.06e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	6.76	0.31	4.58e-11	Lung cancer in ever smokers;
LUAD	cis	rs9925964	1.000	rs9925964	chr16:31129895	A/G	cg03418659	chr16:31128414	MYST1	0.4	6.61	0.31	1.14e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg18230493	chr5:56204884	C5orf35	-0.44	-7.29	-0.33	1.51e-12	Coronary artery disease;
LUAD	cis	rs2067615	0.579	rs4964489	chr12:107171808	A/G	cg15890332	chr12:107067104	RFX4	0.39	8.38	0.38	7.72e-16	Heart rate;
LUAD	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg08470875	chr2:26401718	FAM59B	0.64	8.77	0.39	4.47e-17	Gut microbiome composition (summer);
LUAD	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg21153622	chr11:89784906	NA	-0.34	-6.6	-0.31	1.2e-10	Height;
LUAD	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg08807101	chr21:30365312	RNF160	-0.44	-7.48	-0.34	4.31e-13	Dental caries;
LUAD	cis	rs208520	0.874	rs208481	chr6:66922636	A/G	cg07460842	chr6:66804631	NA	-0.97	-13.97	-0.56	1e-36	Exhaled nitric oxide output;
LUAD	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg06636551	chr8:101224915	SPAG1	0.36	6.74	0.31	5.04e-11	Atrioventricular conduction;
LUAD	cis	rs6543140	0.964	rs1523206	chr2:103070175	A/T	cg04239558	chr2:103089729	SLC9A4	0.36	7.29	0.33	1.49e-12	Blood protein levels;
LUAD	cis	rs4776059	1.000	rs12914047	chr15:52970993	G/A	cg24008177	chr15:52972085	KIAA1370	0.26	7.28	0.33	1.66e-12	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.61	-0.31	1.19e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs72720396	0.789	rs10922910	chr1:91199862	G/T	cg13456504	chr1:91191583	NA	0.57	10.1	0.44	1.3e-21	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.73	0.31	5.55e-11	Colorectal cancer;
LUAD	cis	rs806215	0.723	rs1090682	chr7:127245159	T/C	cg25922125	chr7:127225783	GCC1	0.48	7.06	0.32	6.94e-12	Type 2 diabetes;
LUAD	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg09365446	chr1:150670422	GOLPH3L	0.62	10.69	0.46	9.36e-24	Melanoma;
LUAD	cis	rs4006360	0.629	rs2132842	chr17:39234214	G/A	cg16090541	chr17:39240343	KRTAP4-7	-0.37	-6.41	-0.3	3.98e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22857025	chr5:266934	NA	-1.06	-13.27	-0.54	7.79e-34	Breast cancer;
LUAD	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg11266682	chr4:10021025	SLC2A9	0.53	11.45	0.49	1.25e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7100689	0.622	rs10736344	chr10:82133955	T/C	cg01528321	chr10:82214614	TSPAN14	0.65	10.26	0.45	3.26e-22	Post bronchodilator FEV1;
LUAD	cis	rs6558530	0.897	rs10481354	chr8:1704030	A/G	cg19131313	chr8:1704013	NA	0.41	6.87	0.32	2.28e-11	Systolic blood pressure;
LUAD	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg18230493	chr5:56204884	C5orf35	-0.45	-7.48	-0.34	4.22e-13	Coronary artery disease;
LUAD	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg19468946	chr17:37922297	IKZF3	0.41	6.59	0.31	1.3e-10	Self-reported allergy;
LUAD	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08280861	chr8:58055591	NA	-0.76	-9.45	-0.42	2.3e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-8.7	-0.39	7.22e-17	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg18252515	chr7:66147081	NA	-0.62	-6.82	-0.31	3.21e-11	Diabetic kidney disease;
LUAD	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg21191810	chr6:118973309	C6orf204	-0.52	-7.98	-0.36	1.4e-14	Diastolic blood pressure;
LUAD	cis	rs9837602	1.000	rs6799379	chr3:99762840	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-7.68	-0.35	1.13e-13	Breast cancer;
LUAD	cis	rs4700695	0.545	rs253275	chr5:65509809	A/G	cg21114390	chr5:65439923	SFRS12	-0.81	-12.22	-0.51	1.28e-29	Facial morphology (factor 19);
LUAD	cis	rs733175	0.599	rs6856396	chr4:10031163	A/T	cg11266682	chr4:10021025	SLC2A9	0.5	7.42	0.34	6.7e-13	Psychosis and Alzheimer's disease;
LUAD	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg25838465	chr1:92012736	NA	0.5	7.33	0.34	1.15e-12	Eosinophil percentage of white cells;
LUAD	cis	rs6060717	0.536	rs6060676	chr20:34498551	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.7	-0.31	6.75e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg06784218	chr1:46089804	CCDC17	-0.51	-11.31	-0.48	4.16e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg04025307	chr7:1156635	C7orf50	0.65	8.01	0.36	1.13e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg06740227	chr12:86229804	RASSF9	0.41	7.2	0.33	2.86e-12	Major depressive disorder;
LUAD	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg01017244	chr2:74357527	NA	0.91	14.43	0.57	1.2e-38	Gestational age at birth (maternal effect);
LUAD	cis	rs4953076	0.533	rs10173126	chr2:44446492	T/C	cg04920474	chr2:44395004	PPM1B	0.54	8.06	0.36	7.99e-15	Height;
LUAD	cis	rs2485376	1.000	rs9664049	chr10:104000307	C/T	cg20641465	chr10:103991465	PITX3	0.57	10.42	0.45	8.85e-23	QT interval;
LUAD	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00149659	chr3:10157352	C3orf10	-0.62	-8.63	-0.39	1.25e-16	Alzheimer's disease;
LUAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg15117754	chr3:10150083	C3orf24	0.38	6.39	0.3	4.4e-10	Alzheimer's disease;
LUAD	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.78	0.35	5.45e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg20503657	chr10:835505	NA	0.94	14.46	0.58	8.97e-39	Eosinophil percentage of granulocytes;
LUAD	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03264133	chr6:25882463	NA	0.59	9.8	0.43	1.41e-20	Blood metabolite levels;
LUAD	cis	rs2346177	0.874	rs4953372	chr2:46651624	C/G	cg26688816	chr2:46740690	ATP6V1E2	0.4	6.47	0.3	2.66e-10	HDL cholesterol;
LUAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14893161	chr1:205819251	PM20D1	-0.75	-15.2	-0.59	6.18e-42	Monocyte percentage of white cells;
LUAD	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg11915388	chr22:42470451	FAM109B	-0.41	-7.36	-0.34	9.64e-13	Schizophrenia;
LUAD	cis	rs6558530	0.666	rs6558526	chr8:1702572	A/G	cg19131313	chr8:1704013	NA	-0.43	-6.49	-0.3	2.41e-10	Systolic blood pressure;
LUAD	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg14196790	chr5:131705035	SLC22A5	-0.37	-6.39	-0.3	4.46e-10	Blood metabolite levels;
LUAD	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg18811423	chr2:55921094	PNPT1	0.51	8.44	0.38	5.18e-16	Metabolic syndrome;
LUAD	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.39	-0.42	3.76e-19	Schizophrenia;
LUAD	cis	rs8040855	0.644	rs2342120	chr15:85728820	G/T	cg04831495	chr15:85060580	GOLGA6L5	0.42	6.87	0.32	2.3e-11	Bulimia nervosa;
LUAD	trans	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg01620082	chr3:125678407	NA	-1.1	-10.22	-0.45	4.5e-22	Depression;
LUAD	cis	rs62229266	0.804	rs2835231	chr21:37390598	C/T	cg08632701	chr21:37451849	NA	-0.44	-7.35	-0.34	1e-12	Mitral valve prolapse;
LUAD	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg26169700	chr22:42538906	CYP2D7P1	-0.58	-7.28	-0.33	1.67e-12	Birth weight;
LUAD	cis	rs738321	0.701	rs4821754	chr22:38581503	A/G	cg25457927	chr22:38595422	NA	0.53	11.61	0.49	3.14e-27	Breast cancer;
LUAD	cis	rs4853525	0.522	rs6744420	chr2:191589082	A/G	cg27211696	chr2:191398769	TMEM194B	0.4	6.7	0.31	6.53e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	trans	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.6	9.45	0.42	2.42e-19	Endometrial cancer;
LUAD	cis	rs8017423	0.608	rs12589866	chr14:90820977	T/C	cg14092571	chr14:90743983	NA	0.39	6.65	0.31	9.35e-11	Mortality in heart failure;
LUAD	cis	rs4077515	0.901	rs34826348	chr9:139281570	A/C	cg14019695	chr9:139328340	INPP5E	0.4	7.51	0.34	3.45e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg19761014	chr17:28927070	LRRC37B2	0.79	9.55	0.42	1.04e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-7.98	-0.36	1.36e-14	Diabetic kidney disease;
LUAD	cis	rs3820068	0.705	rs72645803	chr1:15868232	G/A	cg13390004	chr1:15929781	NA	0.4	6.4	0.3	4.17e-10	Systolic blood pressure;
LUAD	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg13535736	chr9:111863775	C9orf5	-0.44	-6.87	-0.32	2.33e-11	Menarche (age at onset);
LUAD	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg05340658	chr4:99064831	C4orf37	0.45	7.47	0.34	4.69e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg22009923	chr11:832065	CD151	-0.34	-6.62	-0.31	1.1e-10	Mean platelet volume;
LUAD	cis	rs62238980	0.614	rs117209345	chr22:32504935	G/C	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg25358565	chr5:93447407	FAM172A	0.6	7.69	0.35	1.04e-13	Diabetic retinopathy;
LUAD	cis	rs9462027	0.628	rs9380455	chr6:34690778	C/A	cg07306190	chr6:34760872	UHRF1BP1	0.35	9.0	0.4	7.61e-18	Systemic lupus erythematosus;
LUAD	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg00530320	chr1:46809349	NSUN4	-0.52	-8.15	-0.37	4.08e-15	Menopause (age at onset);
LUAD	cis	rs12216545	0.662	rs6972770	chr7:150240784	A/G	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.4	-0.3	4.08e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Colorectal cancer;
LUAD	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21659725	chr3:3221576	CRBN	-0.5	-8.3	-0.37	1.38e-15	Body mass index;
LUAD	cis	rs295140	0.837	rs12474914	chr2:201130210	A/G	cg23649088	chr2:200775458	C2orf69	-0.39	-6.42	-0.3	3.63e-10	QT interval;
LUAD	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg04546413	chr19:29218101	NA	0.71	10.52	0.46	3.77e-23	Methadone dose in opioid dependence;
LUAD	cis	rs9811920	0.809	rs13059754	chr3:99678490	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-11.04	-0.47	4.33e-25	Axial length;
LUAD	cis	rs57502260	0.573	rs12291008	chr11:68389072	T/C	cg02221422	chr11:68192511	LRP5	-0.45	-6.68	-0.31	7.74e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs863345	0.604	rs2317970	chr1:158504770	T/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs8077889	0.956	rs4792910	chr17:41840229	T/C	cg26893861	chr17:41843967	DUSP3	0.94	14.51	0.58	5.09e-39	Triglycerides;
LUAD	cis	rs2233152	0.520	rs56101381	chr19:41272902	T/C	cg21869046	chr19:41225005	ITPKC	0.48	8.78	0.39	4.16e-17	Kawasaki disease;
LUAD	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg13511324	chr14:104056883	C14orf153	0.26	6.53	0.3	1.92e-10	Reticulocyte count;
LUAD	trans	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg18187862	chr3:45730750	SACM1L	-0.53	-7.76	-0.35	6.46e-14	Primary sclerosing cholangitis;
LUAD	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg17264618	chr3:40429014	ENTPD3	0.39	8.61	0.39	1.43e-16	Renal cell carcinoma;
LUAD	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg25753631	chr6:25732923	NA	-0.4	-6.56	-0.3	1.59e-10	Iron status biomarkers;
LUAD	cis	rs2224391	0.628	rs766340	chr6:5243521	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-8.61	-0.39	1.5e-16	Height;
LUAD	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07343612	chr16:622815	PIGQ	-0.83	-16.83	-0.63	4.8e-49	Height;
LUAD	cis	rs7737355	0.947	rs9327620	chr5:130996451	A/G	cg25547332	chr5:131281432	NA	0.44	6.61	0.31	1.15e-10	Life satisfaction;
LUAD	cis	rs7671266	0.616	rs4320137	chr4:10072969	C/T	cg00071950	chr4:10020882	SLC2A9	0.51	6.85	0.32	2.54e-11	Cardiovascular disease risk factors;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg11759937	chr19:47729458	BBC3	-0.65	-6.39	-0.3	4.41e-10	Type 2 diabetes;
LUAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg00280220	chr17:61926910	NA	0.36	7.03	0.32	8.36e-12	Prudent dietary pattern;
LUAD	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg00316803	chr15:76480434	C15orf27	-0.39	-7.14	-0.33	4.12e-12	Blood metabolite levels;
LUAD	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg17346650	chr17:80929145	B3GNTL1	0.39	6.64	0.31	9.43e-11	Glycated hemoglobin levels;
LUAD	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.37	0.55	2.89e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6840360	0.615	rs10021407	chr4:152465002	A/G	cg22705602	chr4:152727874	NA	-0.37	-6.71	-0.31	6.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs89107	0.688	rs283088	chr6:118592191	T/C	cg18833306	chr6:118973337	C6orf204	0.52	9.49	0.42	1.73e-19	Cardiac structure and function;
LUAD	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg06784218	chr1:46089804	CCDC17	0.51	11.19	0.48	1.24e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg23173402	chr1:227635558	NA	0.67	7.69	0.35	1.04e-13	Major depressive disorder;
LUAD	cis	rs9487051	0.735	rs1260595	chr6:109519873	T/G	cg21918786	chr6:109611834	NA	-0.41	-7.53	-0.34	3.1e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg17644776	chr2:200775616	C2orf69	0.55	7.38	0.34	8.48e-13	Schizophrenia;
LUAD	cis	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.98	-0.36	1.37e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.61e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg08071915	chr8:12219732	FAM66A	0.44	7.22	0.33	2.4e-12	Joint mobility (Beighton score);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26988692	chr8:37756473	RAB11FIP1	-0.52	-6.57	-0.3	1.52e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg22105103	chr4:187893119	NA	0.56	12.19	0.51	1.72e-29	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg06917634	chr15:78832804	PSMA4	0.39	6.39	0.3	4.3e-10	Sudden cardiac arrest;
LUAD	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg09455208	chr3:40491958	NA	0.56	12.55	0.52	6.34e-31	Renal cell carcinoma;
LUAD	cis	rs9394152	0.845	rs4713632	chr6:33472990	G/T	cg13560919	chr6:33536144	NA	0.51	8.64	0.39	1.17e-16	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg08742575	chr21:47604166	C21orf56	0.41	6.37	0.3	4.83e-10	Testicular germ cell tumor;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14898140	chr17:66031871	KPNA2	-0.61	-7.52	-0.34	3.3e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2357013	0.752	rs55992015	chr2:53170717	C/T	cg07782112	chr2:53107842	NA	-0.34	-6.9	-0.32	1.93e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	5.75e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.07	12.82	0.53	5.26e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg10729496	chr3:10149963	C3orf24	0.58	9.58	0.42	8.43e-20	Alzheimer's disease;
LUAD	cis	rs12291225	0.585	rs4757250	chr11:14375683	C/A	cg19336497	chr11:14380999	RRAS2	-0.69	-16.17	-0.62	3.73e-46	Sense of smell;
LUAD	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.44	0.34	5.72e-13	Tonsillectomy;
LUAD	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg17747265	chr1:1875780	NA	-0.76	-19.01	-0.68	1.1e-58	Body mass index;
LUAD	cis	rs2859741	1.000	rs1773575	chr1:37505129	T/C	cg09363841	chr1:37513479	NA	-0.34	-8.35	-0.38	9.95e-16	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Depression;
LUAD	cis	rs4523957	0.614	rs216184	chr17:2174270	T/G	cg16513277	chr17:2031491	SMG6	0.64	8.11	0.37	5.72e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg22153745	chr1:153894579	GATAD2B	-0.5	-7.15	-0.33	3.95e-12	Total cholesterol levels;
LUAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg14789911	chr21:47582049	C21orf56	0.42	7.04	0.32	7.71e-12	Testicular germ cell tumor;
LUAD	trans	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg13565492	chr6:43139072	SRF	-0.73	-9.85	-0.43	9.59e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg12035532	chr1:1886765	KIAA1751	0.42	6.89	0.32	2.09e-11	Body mass index;
LUAD	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg24558204	chr6:135376177	HBS1L	0.46	8.51	0.38	2.99e-16	Red blood cell count;
LUAD	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg04025307	chr7:1156635	C7orf50	0.53	7.55	0.34	2.71e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs151234	0.565	rs11401	chr16:28602991	A/G	cg04643524	chr16:28609220	SULT1A2	0.42	6.96	0.32	1.32e-11	Platelet distribution width;
LUAD	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.77	-0.35	5.96e-14	Monocyte count;
LUAD	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg08632164	chr7:65971372	NA	-0.38	-6.62	-0.31	1.09e-10	Aortic root size;
LUAD	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg07741184	chr6:167504864	NA	0.35	8.09	0.37	6.43e-15	Crohn's disease;
LUAD	cis	rs1832871	0.672	rs9456295	chr6:158772078	G/A	cg07165851	chr6:158734300	TULP4	0.72	11.32	0.48	4.12e-26	Height;
LUAD	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg14092988	chr3:52407081	DNAH1	0.37	7.51	0.34	3.53e-13	Bipolar disorder;
LUAD	trans	rs875971	0.545	rs316316	chr7:65614257	C/T	cg04775059	chr7:64541387	NA	-0.49	-6.73	-0.31	5.69e-11	Aortic root size;
LUAD	cis	rs516243	0.703	rs169538	chr1:10737045	T/C	cg02903756	chr1:10750680	CASZ1	-0.5	-9.41	-0.42	3.21e-19	Migraine - clinic-based;
LUAD	cis	rs7937890	0.559	rs2597187	chr11:14517019	C/G	cg06199346	chr11:14280333	SPON1	-0.32	-6.42	-0.3	3.58e-10	Mitochondrial DNA levels;
LUAD	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg23758822	chr17:41437982	NA	0.99	20.76	0.71	1.59e-66	Menopause (age at onset);
LUAD	cis	rs9341808	0.617	rs9294170	chr6:80814080	A/G	cg08355045	chr6:80787529	NA	0.62	11.61	0.49	3e-27	Sitting height ratio;
LUAD	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.39e-13	Menopause (age at onset);
LUAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08048268	chr3:133502702	NA	-0.54	-11.08	-0.47	3.14e-25	Iron status biomarkers;
LUAD	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg05725404	chr16:58534157	NDRG4	-0.73	-7.59	-0.35	2.1e-13	Schizophrenia;
LUAD	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg11645453	chr3:52864694	ITIH4	0.53	9.84	0.43	1.04e-20	Schizophrenia;
LUAD	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg13607699	chr17:42295918	UBTF	-0.55	-9.22	-0.41	1.44e-18	Total body bone mineral density;
LUAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg23743428	chr13:21893420	NA	-0.49	-8.64	-0.39	1.17e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs76419734	0.614	rs72669979	chr4:106523289	T/C	cg05309399	chr4:106552544	FLJ20184	-0.53	-6.61	-0.31	1.14e-10	Post bronchodilator FEV1;
LUAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg13560548	chr3:10150139	C3orf24	0.45	7.33	0.34	1.22e-12	Alzheimer's disease;
LUAD	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg16262614	chr3:133464971	TF	0.43	8.8	0.39	3.46e-17	Iron status biomarkers (transferrin levels);
LUAD	cis	rs4846217	1.000	rs12135774	chr1:10386506	T/C	cg17425144	chr1:10567563	PEX14	-0.5	-6.54	-0.3	1.8e-10	Platelet count;
LUAD	cis	rs9788721	0.614	rs951984	chr15:78720915	T/A	cg18825076	chr15:78729989	IREB2	-0.54	-8.41	-0.38	6.29e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	2.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg07636037	chr3:49044803	WDR6	0.53	10.06	0.44	1.69e-21	Menarche (age at onset);
LUAD	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg02269571	chr22:50332266	NA	0.52	8.02	0.36	1.02e-14	Schizophrenia;
LUAD	cis	rs939584	1.000	rs4854349	chr2:647861	T/C	cg03444855	chr2:621920	NA	-0.39	-6.49	-0.3	2.37e-10	Body mass index;
LUAD	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg08508325	chr11:3079039	CARS	-0.6	-13.24	-0.54	1.03e-33	Longevity;
LUAD	cis	rs9394841	0.667	rs9471653	chr6:41755410	C/G	cg17623882	chr6:41773611	USP49	-0.52	-7.34	-0.34	1.1e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs7953508	0.506	rs2200160	chr12:93963873	C/T	cg18151635	chr12:93972918	NA	-0.78	-11.63	-0.49	2.66e-27	Pubertal anthropometrics;
LUAD	cis	rs1448094	0.967	rs10863118	chr12:86339232	C/G	cg00310523	chr12:86230176	RASSF9	0.36	7.73	0.35	7.93e-14	Major depressive disorder;
LUAD	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg00071950	chr4:10020882	SLC2A9	0.76	15.38	0.6	9.83e-43	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg17105886	chr17:28927953	LRRC37B2	0.75	6.71	0.31	6.45e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg03806693	chr22:41940476	POLR3H	-0.66	-9.46	-0.42	2.1e-19	Vitiligo;
LUAD	cis	rs6546550	0.901	rs6736408	chr2:70137774	C/T	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.97	-0.47	8.24e-25	Prevalent atrial fibrillation;
LUAD	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg26384229	chr12:38710491	ALG10B	0.42	6.88	0.32	2.22e-11	Morning vs. evening chronotype;
LUAD	cis	rs1595825	0.945	rs73056880	chr2:198822292	G/A	cg11031976	chr2:198649780	BOLL	-0.47	-6.94	-0.32	1.5e-11	Ulcerative colitis;
LUAD	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26314531	chr2:26401878	FAM59B	-0.7	-9.53	-0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs367943	0.688	rs1464163	chr5:112691815	A/G	cg21806985	chr5:112824646	MCC	0.25	6.48	0.3	2.5e-10	Type 2 diabetes;
LUAD	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg20991723	chr1:152506922	NA	0.35	6.91	0.32	1.79e-11	Hair morphology;
LUAD	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-10.8	-0.46	3.54e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8192282	0.739	rs6427716	chr1:154497329	G/T	cg07911225	chr1:154474108	TDRD10;SHE	-0.42	-7.22	-0.33	2.43e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg05110241	chr16:68378359	PRMT7	-0.87	-9.29	-0.41	7.97e-19	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs738322	0.804	rs4821743	chr22:38514906	A/G	cg17652424	chr22:38574118	PLA2G6	-0.28	-8.15	-0.37	4.19e-15	Cutaneous nevi;
LUAD	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg15704280	chr7:45808275	SEPT13	-0.53	-8.39	-0.38	7.17e-16	HDL cholesterol;
LUAD	cis	rs938554	0.692	rs13125209	chr4:9982044	A/C	cg11266682	chr4:10021025	SLC2A9	0.43	7.56	0.34	2.58e-13	Blood metabolite levels;
LUAD	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-20.54	-0.71	1.61e-65	Coronary artery disease;
LUAD	cis	rs11771526	0.786	rs11768318	chr7:32372965	T/G	cg27532318	chr7:32358331	NA	0.71	8.24	0.37	2.23e-15	Body mass index;
LUAD	cis	rs7659604	0.540	rs10012775	chr4:122676878	T/C	cg06713675	chr4:122721982	EXOSC9	0.42	7.67	0.35	1.17e-13	Type 2 diabetes;
LUAD	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg06387496	chr7:2775674	GNA12	-0.4	-6.79	-0.31	3.87e-11	Height;
LUAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.76e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg25703541	chr22:24373054	LOC391322	-0.63	-8.93	-0.4	1.35e-17	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg13010199	chr12:38710504	ALG10B	-0.38	-6.47	-0.3	2.67e-10	Morning vs. evening chronotype;
LUAD	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg24955955	chr5:415729	AHRR	0.79	8.85	0.4	2.34e-17	Fat distribution (HIV);
LUAD	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.21	-0.33	2.62e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7072216	0.763	rs7091709	chr10:100167605	G/A	cg26618903	chr10:100175079	PYROXD2	-0.38	-8.39	-0.38	7.22e-16	Metabolite levels;
LUAD	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg04225089	chr17:73874465	TRIM47	-0.41	-6.94	-0.32	1.47e-11	Psoriasis;
LUAD	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	9.41	0.42	3.31e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-11.14	-0.48	1.9e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg18016565	chr1:150552671	MCL1	0.44	8.01	0.36	1.09e-14	Tonsillectomy;
LUAD	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg04450456	chr4:17643702	FAM184B	0.36	6.97	0.32	1.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg09184832	chr6:79620586	NA	-0.5	-9.3	-0.41	7.54e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs4713675	0.584	rs560111	chr6:33706277	C/T	cg13859433	chr6:33739653	LEMD2	-0.29	-6.8	-0.31	3.67e-11	Plateletcrit;
LUAD	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg04398451	chr17:18023971	MYO15A	-0.77	-14.05	-0.56	4.36e-37	Total body bone mineral density;
LUAD	cis	rs4906332	0.966	rs7159665	chr14:103984616	C/T	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.19	-0.33	3.05e-12	Coronary artery disease;
LUAD	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.95	-0.36	1.67e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.33	0.38	1.1e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7809950	0.768	rs2701678	chr7:107283711	A/G	cg23024343	chr7:107201750	COG5	0.67	11.04	0.47	4.62e-25	Coronary artery disease;
LUAD	cis	rs10992471	0.603	rs7850528	chr9:95208992	A/G	cg14631576	chr9:95140430	CENPP	-0.55	-11.36	-0.48	2.78e-26	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg17366294	chr4:99064904	C4orf37	0.66	12.76	0.53	9.29e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg00776166	chr8:613548	NA	0.57	6.46	0.3	2.88e-10	IgG glycosylation;
LUAD	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg11663144	chr21:46675770	NA	-0.6	-11.77	-0.5	7.37e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg09654669	chr8:57350985	NA	-0.66	-10.06	-0.44	1.76e-21	Obesity-related traits;
LUAD	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg22105103	chr4:187893119	NA	0.53	11.45	0.49	1.22e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg25985355	chr7:65971099	NA	0.53	6.7	0.31	6.87e-11	Diabetic kidney disease;
LUAD	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.29	-6.64	-0.31	9.79e-11	Dupuytren's disease;
LUAD	cis	rs17095355	0.818	rs12571549	chr10:111770013	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.58	-6.99	-0.32	1.04e-11	Biliary atresia;
LUAD	cis	rs1878931	0.580	rs7204571	chr16:3402444	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.39	6.75	0.31	4.84e-11	Body mass index (adult);
LUAD	cis	rs4774899	0.752	rs2962991	chr15:57348776	A/G	cg14026238	chr15:57616123	NA	0.43	8.37	0.38	8.28e-16	Urinary tract infection frequency;
LUAD	cis	rs10129255	0.500	rs2105991	chr14:107138039	C/G	cg07958169	chr14:107095056	NA	-0.36	-7.04	-0.32	7.84e-12	Kawasaki disease;
LUAD	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.61	-0.31	1.13e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg11673840	chr17:47092156	IGF2BP1	-0.38	-7.29	-0.33	1.55e-12	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs6500395	0.962	rs9941275	chr16:48573428	A/G	cg04672837	chr16:48644449	N4BP1	0.37	6.45	0.3	3.1e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs9354308	0.802	rs2814102	chr6:66523230	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.48	7.1	0.33	5.46e-12	Metabolite levels;
LUAD	cis	rs6540559	0.543	rs672819	chr1:210436404	T/A	cg22029157	chr1:209979665	IRF6	0.58	6.65	0.31	9.11e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.45	-0.38	4.68e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.41	8.27	0.37	1.74e-15	Monocyte percentage of white cells;
LUAD	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg08859206	chr1:53392774	SCP2	0.63	11.73	0.5	1.01e-27	Monocyte count;
LUAD	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7793919	0.652	rs10228886	chr7:4783224	C/T	cg12434134	chr7:4767406	FOXK1	0.33	6.68	0.31	7.34e-11	Mosquito bite size;
LUAD	cis	rs796364	0.715	rs77089299	chr2:201116853	A/G	cg17644776	chr2:200775616	C2orf69	-0.62	-6.5	-0.3	2.23e-10	Schizophrenia;
LUAD	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg18512352	chr11:47633146	NA	-0.57	-10.08	-0.44	1.45e-21	Subjective well-being;
LUAD	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06028808	chr11:68637592	NA	0.49	7.98	0.36	1.34e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10744422	0.764	rs6489241	chr12:123288739	C/G	cg16953816	chr12:123349952	VPS37B	0.69	6.46	0.3	2.94e-10	Schizophrenia;
LUAD	cis	rs10788264	0.504	rs10749452	chr10:124028141	A/G	cg09507567	chr10:124027408	NA	0.53	11.97	0.5	1.23e-28	Total body bone mineral density;
LUAD	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg24069376	chr3:38537580	EXOG	0.34	7.78	0.35	5.51e-14	Electrocardiographic conduction measures;
LUAD	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg17063962	chr7:91808500	NA	0.67	11.92	0.5	1.89e-28	Breast cancer;
LUAD	trans	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg06606381	chr12:133084897	FBRSL1	-1.21	-11.17	-0.48	1.42e-25	Depression;
LUAD	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.58	0.39	1.77e-16	Menopause (age at onset);
LUAD	cis	rs72928364	1.000	rs13080859	chr3:100678060	C/T	cg10123952	chr3:100791384	NA	0.63	7.31	0.33	1.39e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.41	-7.06	-0.32	6.78e-12	Colorectal cancer;
LUAD	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.58e-12	Breast cancer;
LUAD	cis	rs80319144	1.000	rs2193701	chr2:159274227	A/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.87	0.32	2.33e-11	Restless legs syndrome;
LUAD	cis	rs73198271	0.740	rs28402110	chr8:8647249	C/A	cg01851573	chr8:8652454	MFHAS1	0.48	8.54	0.38	2.53e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg05890377	chr2:74357713	NA	0.76	12.0	0.5	9.31e-29	Gestational age at birth (maternal effect);
LUAD	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg27454412	chr7:1067447	C7orf50	-0.44	-7.76	-0.35	6.6e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs62064224	0.614	rs9916114	chr17:30766950	T/C	cg25809561	chr17:30822961	MYO1D	0.48	8.51	0.38	3.04e-16	Schizophrenia;
LUAD	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg06784218	chr1:46089804	CCDC17	0.54	11.68	0.49	1.58e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4711350	0.862	rs530614	chr6:33714781	G/A	cg07979401	chr6:33739406	LEMD2	0.49	7.83	0.36	3.96e-14	Schizophrenia;
LUAD	cis	rs2455799	0.613	rs13060772	chr3:15896795	C/T	cg16303742	chr3:15540471	COLQ	-0.51	-9.39	-0.42	3.86e-19	Mean platelet volume;
LUAD	cis	rs9283706	0.655	rs4016246	chr5:66310192	A/G	cg11590213	chr5:66331682	MAST4	0.42	6.88	0.32	2.21e-11	Coronary artery disease;
LUAD	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg00204512	chr16:28754710	NA	0.35	7.67	0.35	1.17e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs751837	0.591	rs34301396	chr14:103429420	T/C	cg10087771	chr14:103399429	CDC42BPB	0.74	7.17	0.33	3.47e-12	Large B-cell lymphoma;
LUAD	cis	rs7177699	0.550	rs4468572	chr15:79124475	C/T	cg00540400	chr15:79124168	NA	-0.44	-9.74	-0.43	2.39e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.18	0.33	3.06e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg18129748	chr3:49941408	MST1R	-0.4	-6.65	-0.31	8.92e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg01579765	chr21:45077557	HSF2BP	-0.58	-13.64	-0.55	2.25e-35	Mean corpuscular volume;
LUAD	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg12034118	chr1:209979487	IRF6	0.59	6.59	0.31	1.28e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08677398	chr8:58056175	NA	0.46	6.54	0.3	1.76e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs752010	0.571	rs10890135	chr1:42054084	G/A	cg06885757	chr1:42089581	HIVEP3	0.38	8.02	0.36	1.04e-14	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg10802521	chr3:52805072	NEK4	0.39	6.57	0.3	1.47e-10	Electroencephalogram traits;
LUAD	cis	rs35883536	0.967	rs9433740	chr1:101133985	G/A	cg06223162	chr1:101003688	GPR88	-0.37	-6.84	-0.32	2.76e-11	Monocyte count;
LUAD	trans	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg01620082	chr3:125678407	NA	-0.44	-6.48	-0.3	2.55e-10	Depression;
LUAD	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg07537917	chr2:241836409	C2orf54	-0.32	-9.09	-0.4	3.83e-18	Urinary metabolites;
LUAD	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg00757033	chr12:89920650	WDR51B	0.71	12.14	0.51	2.56e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs6541297	0.703	rs636810	chr1:230317018	C/T	cg20703242	chr1:230279135	GALNT2	-0.47	-6.99	-0.32	1.09e-11	Coronary artery disease;
LUAD	cis	rs59698941	0.527	rs1032764	chr5:132185419	A/C	cg14825688	chr5:132208181	LEAP2	-0.53	-10.72	-0.46	7.01e-24	Apolipoprotein A-IV levels;
LUAD	cis	rs73206853	0.764	rs7960705	chr12:111084540	G/A	cg12870014	chr12:110450643	ANKRD13A	0.62	7.22	0.33	2.48e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs8077889	1.000	rs2079005	chr17:41865627	T/G	cg26893861	chr17:41843967	DUSP3	0.96	14.72	0.58	6.5e-40	Triglycerides;
LUAD	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg18105139	chr6:28058856	ZSCAN12L1	0.27	6.64	0.31	9.52e-11	Parkinson's disease;
LUAD	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg20891283	chr12:69753455	YEATS4	0.42	6.49	0.3	2.41e-10	Blood protein levels;
LUAD	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg26587870	chr6:27730563	NA	-0.6	-6.75	-0.31	4.8e-11	Breast cancer;
LUAD	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg02569458	chr12:86230093	RASSF9	0.43	7.7	0.35	9.88e-14	Major depressive disorder;
LUAD	cis	rs12545109	0.765	rs2576589	chr8:57425647	C/T	cg21220214	chr8:57350948	NA	-0.58	-8.1	-0.37	5.89e-15	Obesity-related traits;
LUAD	cis	rs4698790	0.635	rs2298749	chr4:110681505	C/T	cg07850274	chr4:110748770	RRH	-0.42	-6.81	-0.31	3.29e-11	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21166756	chr11:800131	LRDD	0.37	6.44	0.3	3.17e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg14343924	chr8:8086146	FLJ10661	0.44	6.52	0.3	2.04e-10	Mean corpuscular volume;
LUAD	cis	rs2274273	1.000	rs7493394	chr14:55617755	A/T	cg04306507	chr14:55594613	LGALS3	0.37	7.49	0.34	4.04e-13	Protein biomarker;
LUAD	cis	rs3849570	0.961	rs13340130	chr3:81790970	A/T	cg07356753	chr3:81810745	GBE1	-0.7	-12.38	-0.52	2.91e-30	Waist circumference;Body mass index;
LUAD	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg18132916	chr6:79620363	NA	-0.45	-7.81	-0.36	4.49e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7665090	0.846	rs4496586	chr4:103557311	G/C	cg07973026	chr4:103553119	MANBA	0.43	7.6	0.35	1.93e-13	Primary biliary cholangitis;
LUAD	cis	rs7731657	0.537	rs6889977	chr5:130328628	G/A	cg08523029	chr5:130500466	HINT1	0.56	7.36	0.34	9.74e-13	Fasting plasma glucose;
LUAD	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg06873352	chr17:61820015	STRADA	0.43	7.06	0.32	6.88e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2692947	0.683	rs2315416	chr2:96558477	C/T	cg23100626	chr2:96804247	ASTL	0.3	7.73	0.35	7.9e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.61	-0.31	1.19e-10	Retinal vascular caliber;
LUAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.22	-0.41	1.41e-18	Alzheimer's disease;
LUAD	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.38	-6.59	-0.31	1.3e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg08916839	chr5:415575	AHRR	0.86	10.03	0.44	2.24e-21	Fat distribution (HIV);
LUAD	cis	rs9902453	0.904	rs11654983	chr17:28370042	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.5	-0.45	4.31e-23	Coffee consumption (cups per day);
LUAD	trans	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-16.95	-0.64	1.52e-49	Exhaled nitric oxide output;
LUAD	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg16615211	chr3:44902933	MIR564;TMEM42	0.37	7.03	0.32	8.35e-12	Depressive symptoms;
LUAD	cis	rs2880765	0.805	rs34598679	chr15:86042205	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.37	-6.35	-0.3	5.56e-10	Coronary artery disease;
LUAD	cis	rs2046867	0.862	rs75638790	chr3:72830502	C/T	cg25664220	chr3:72788482	NA	-0.7	-12.15	-0.51	2.34e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg19761014	chr17:28927070	LRRC37B2	0.92	9.0	0.4	7.81e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6076065	0.683	rs2424528	chr20:23361613	C/T	cg11657817	chr20:23433608	CST11	0.47	8.78	0.39	4.17e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7107174	1.000	rs10899452	chr11:77995143	A/C	cg02023728	chr11:77925099	USP35	0.49	7.57	0.35	2.36e-13	Testicular germ cell tumor;
LUAD	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg05872129	chr22:39784769	NA	-0.8	-15.04	-0.59	2.94e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.77	-16.69	-0.63	2.14e-48	Longevity;Endometriosis;
LUAD	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	7.39	0.34	7.94e-13	Menopause (age at onset);
LUAD	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg03806693	chr22:41940476	POLR3H	0.74	9.95	0.44	4.33e-21	Vitiligo;
LUAD	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg03526776	chr6:41159608	TREML2	0.55	11.23	0.48	8.63e-26	Alzheimer's disease (late onset);
LUAD	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg05874882	chr4:1763078	NA	0.35	6.43	0.3	3.45e-10	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg03806693	chr22:41940476	POLR3H	0.64	9.61	0.42	6.54e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg27572855	chr1:25598939	RHD	0.53	11.36	0.48	2.78e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg17652424	chr22:38574118	PLA2G6	-0.33	-10.13	-0.44	9.75e-22	Cutaneous nevi;
LUAD	cis	rs11811982	0.793	rs7524967	chr1:227370823	G/C	cg24860534	chr1:227506868	CDC42BPA	0.67	7.33	0.34	1.22e-12	Optic disc area;
LUAD	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06022373	chr22:39101656	GTPBP1	0.45	7.03	0.32	8.51e-12	Menopause (age at onset);
LUAD	cis	rs6546550	0.743	rs6546548	chr2:70017022	A/G	cg02498382	chr2:70120550	SNRNP27	-0.5	-8.89	-0.4	1.76e-17	Prevalent atrial fibrillation;
LUAD	cis	rs2387326	0.671	rs12256275	chr10:129947139	T/C	cg16087940	chr10:129947807	NA	-0.66	-9.21	-0.41	1.49e-18	Select biomarker traits;
LUAD	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg16850897	chr7:100343110	ZAN	-0.59	-8.17	-0.37	3.56e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg17031739	chr1:67600172	NA	-0.52	-9.26	-0.41	1.01e-18	Psoriasis;
LUAD	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.14	-0.54	2.51e-33	Breast cancer;
LUAD	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg05425664	chr17:57184151	TRIM37	0.44	7.09	0.33	5.54e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7651039	0.641	rs6773682	chr3:15676426	G/A	cg16303742	chr3:15540471	COLQ	0.6	11.3	0.48	4.53e-26	Coronary heart disease;
LUAD	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15369054	chr17:80825471	TBCD	0.58	9.51	0.42	1.4e-19	Breast cancer;
LUAD	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg10544611	chr16:67998164	SLC12A4	-0.55	-6.85	-0.32	2.66e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2688608	0.934	rs2675679	chr10:75658581	C/T	cg23231163	chr10:75533350	FUT11	-0.38	-7.07	-0.33	6.44e-12	Inflammatory bowel disease;
LUAD	cis	rs1395	0.744	rs11126929	chr2:27472027	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.39	-6.84	-0.32	2.75e-11	Blood metabolite levels;
LUAD	trans	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg04775059	chr7:64541387	NA	0.52	6.79	0.31	3.76e-11	Aortic root size;
LUAD	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg22166914	chr1:53195759	ZYG11B	0.47	7.58	0.35	2.26e-13	Monocyte count;
LUAD	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg26384229	chr12:38710491	ALG10B	0.45	7.43	0.34	5.94e-13	Morning vs. evening chronotype;
LUAD	cis	rs7107174	0.892	rs10899490	chr11:78105879	C/T	cg19901956	chr11:77921274	USP35	-0.48	-6.77	-0.31	4.32e-11	Testicular germ cell tumor;
LUAD	trans	rs10805346	0.505	rs35995899	chr4:10112862	T/C	cg26043149	chr18:55253948	FECH	0.47	7.79	0.35	5.16e-14	Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs11676348	0.772	rs12694427	chr2:218945045	C/T	cg06547715	chr2:218990976	CXCR2	0.28	6.49	0.3	2.45e-10	Ulcerative colitis;
LUAD	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.02e-13	Morning vs. evening chronotype;
LUAD	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg18016565	chr1:150552671	MCL1	-0.41	-7.33	-0.34	1.17e-12	Tonsillectomy;
LUAD	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg15557168	chr22:42548783	NA	0.51	9.48	0.42	1.92e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg02423579	chr7:2872169	GNA12	-0.86	-14.94	-0.59	8.13e-41	Height;
LUAD	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg21171335	chr12:122356390	WDR66	0.62	10.93	0.47	1.14e-24	Mean corpuscular volume;
LUAD	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg00530320	chr1:46809349	NSUN4	0.51	7.93	0.36	1.92e-14	Menopause (age at onset);
LUAD	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg11814155	chr7:99998594	ZCWPW1	0.43	7.57	0.35	2.38e-13	Platelet count;
LUAD	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg22906224	chr7:99728672	NA	0.63	10.81	0.47	3.22e-24	Coronary artery disease;
LUAD	cis	rs11247915	0.561	rs12750420	chr1:26608649	G/A	cg15628303	chr1:26608928	UBXN11	0.54	9.66	0.43	4.37e-20	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.77	0.31	4.27e-11	Depression;
LUAD	cis	rs11195062	0.766	rs7897645	chr10:112006669	C/A	cg19214408	chr10:111981687	MXI1	-0.45	-7.36	-0.34	9.43e-13	Multiple myeloma;
LUAD	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg27284194	chr4:1044797	NA	0.69	9.98	0.44	3.36e-21	Recombination rate (females);
LUAD	cis	rs790123	1.000	rs790125	chr3:122388464	A/G	cg15604389	chr3:122379662	NA	0.52	9.34	0.41	5.52e-19	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg24846343	chr22:24311635	DDTL	0.71	15.61	0.6	1.01e-43	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg26343298	chr8:95960752	TP53INP1	0.37	7.82	0.36	4.11e-14	Type 2 diabetes;
LUAD	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00475322	chr7:917719	C7orf20	0.7	12.81	0.53	5.58e-32	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg15147215	chr3:52552868	STAB1	-0.36	-6.48	-0.3	2.59e-10	Electroencephalogram traits;
LUAD	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.86	-0.36	3.31e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-7.12	-0.33	4.67e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg13319975	chr6:146136371	FBXO30	0.67	11.38	0.48	2.23e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1950500	0.550	rs7148384	chr14:24828814	C/T	cg07162820	chr14:24837146	NFATC4	0.48	9.15	0.41	2.45e-18	Height;
LUAD	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	8.81	0.39	3.3e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg18198730	chr1:247681584	NA	0.43	7.68	0.35	1.15e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg22823121	chr1:150693482	HORMAD1	-0.4	-7.76	-0.35	6.42e-14	Tonsillectomy;
LUAD	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg06627628	chr2:24431161	ITSN2	-0.48	-6.62	-0.31	1.09e-10	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg03929089	chr4:120376271	NA	-0.7	-10.54	-0.46	3.3e-23	Coronary artery disease;
LUAD	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg12573674	chr2:1569213	NA	-0.6	-8.71	-0.39	7.1e-17	IgG glycosylation;
LUAD	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg14844989	chr11:31128820	NA	-0.46	-8.45	-0.38	4.81e-16	Red blood cell count;
LUAD	cis	rs10465746	0.846	rs9700285	chr1:84336685	G/A	cg10977910	chr1:84465055	TTLL7	0.51	8.21	0.37	2.67e-15	Obesity-related traits;
LUAD	cis	rs7582720	1.000	rs75869289	chr2:203806724	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09263875	chr16:632152	PIGQ	0.81	17.52	0.65	4.52e-52	Height;
LUAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs1160297	0.576	rs10206560	chr2:53089060	G/C	cg07782112	chr2:53107842	NA	0.39	8.36	0.38	9.21e-16	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs1509123	0.609	rs17804647	chr17:6704071	A/G	cg12642237	chr17:6703447	TEKT1	0.5	7.66	0.35	1.28e-13	Blood metabolite levels;
LUAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08048268	chr3:133502702	NA	-0.52	-10.4	-0.45	1.07e-22	Iron status biomarkers;
LUAD	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg02176678	chr2:219576539	TTLL4	0.6	11.68	0.49	1.61e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	10.24	0.45	4.06e-22	Axial length;
LUAD	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg23029597	chr12:123009494	RSRC2	-0.5	-8.26	-0.37	1.86e-15	Body mass index;
LUAD	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg24308560	chr3:49941425	MST1R	-0.52	-8.65	-0.39	1.11e-16	Intelligence (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07698384	chr15:25684465	UBE3A	-0.45	-7.15	-0.33	3.75e-12	Height;
LUAD	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg09184832	chr6:79620586	NA	-0.52	-9.76	-0.43	1.91e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs34734847	0.703	rs7978125	chr12:121167039	A/G	cg21892295	chr12:121157589	UNC119B	-0.37	-6.47	-0.3	2.74e-10	Mean corpuscular volume;
LUAD	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg14598338	chr9:96623480	NA	-0.44	-9.55	-0.42	1.06e-19	DNA methylation (variation);
LUAD	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg12310025	chr6:25882481	NA	-0.46	-6.92	-0.32	1.64e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2040771	0.770	rs9605962	chr22:19233615	C/T	cg02655711	chr22:19163373	SLC25A1	0.57	10.78	0.46	4.17e-24	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg05425664	chr17:57184151	TRIM37	-0.43	-7.76	-0.35	6.53e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.16	0.41	2.29e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg09324608	chr17:30823087	MYO1D	0.38	6.89	0.32	2.02e-11	Schizophrenia;
LUAD	cis	rs7731657	0.537	rs10478956	chr5:130318514	C/G	cg08523029	chr5:130500466	HINT1	0.54	6.68	0.31	7.62e-11	Fasting plasma glucose;
LUAD	cis	rs1865721	0.771	rs6566092	chr18:73136496	C/T	cg26385618	chr18:73139727	C18orf62	-0.51	-10.47	-0.45	5.85e-23	Intelligence;
LUAD	cis	rs41311933	0.562	rs72760247	chr9:123925882	A/G	cg13567360	chr9:123745713	C5	-0.7	-8.3	-0.37	1.38e-15	Coronary artery disease;
LUAD	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg14458575	chr2:238380390	NA	0.7	12.8	0.53	6.12e-32	Prostate cancer;
LUAD	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg03388025	chr16:89894329	SPIRE2	-0.32	-7.55	-0.34	2.65e-13	Vitiligo;
LUAD	cis	rs11585357	0.895	rs877552	chr1:17631236	C/T	cg08277548	chr1:17600880	PADI3	-0.91	-13.74	-0.56	8.44e-36	Hair shape;
LUAD	cis	rs4372836	0.964	rs11683296	chr2:28925404	A/G	cg09522027	chr2:28974177	PPP1CB	0.59	9.26	0.41	1.05e-18	Body mass index;
LUAD	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.41	-0.34	7.01e-13	Menarche (age at onset);
LUAD	cis	rs6445967	1.000	rs6791748	chr3:58308519	G/A	cg23715586	chr3:58305044	RPP14	0.42	7.59	0.35	2.05e-13	Platelet count;
LUAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg21724239	chr8:58056113	NA	0.68	8.75	0.39	4.95e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg24579218	chr15:68104479	NA	-0.52	-9.0	-0.4	8e-18	Restless legs syndrome;
LUAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg00280220	chr17:61926910	NA	0.36	6.86	0.32	2.41e-11	Prudent dietary pattern;
LUAD	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg09035930	chr12:129282057	SLC15A4	0.7	15.93	0.61	4.51e-45	Systemic lupus erythematosus;
LUAD	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg24558204	chr6:135376177	HBS1L	0.48	8.91	0.4	1.54e-17	Red blood cell count;
LUAD	cis	rs986417	0.748	rs8019541	chr14:60929145	A/G	cg27398547	chr14:60952738	C14orf39	0.63	7.72	0.35	8.34e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg09796270	chr17:17721594	SREBF1	0.38	7.56	0.34	2.61e-13	Total body bone mineral density;
LUAD	cis	rs116095464	1.000	rs3936676	chr5:353677	T/C	cg22857025	chr5:266934	NA	-1.07	-8.99	-0.4	8.16e-18	Breast cancer;
LUAD	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.54	0.42	1.12e-19	Monocyte percentage of white cells;
LUAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg16031515	chr1:205743344	RAB7L1	-0.38	-7.66	-0.35	1.28e-13	Menarche (age at onset);
LUAD	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	cg06064525	chr11:970664	AP2A2	-0.46	-9.16	-0.41	2.2e-18	Alzheimer's disease (late onset);
LUAD	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.23	-0.33	2.34e-12	Height;
LUAD	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg10518543	chr12:38710700	ALG10B	-0.41	-6.48	-0.3	2.53e-10	Bladder cancer;
LUAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg00280220	chr17:61926910	NA	0.36	6.99	0.32	1.08e-11	Prudent dietary pattern;
LUAD	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg00106254	chr7:1943704	MAD1L1	-0.46	-6.84	-0.32	2.7e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03517284	chr6:25882590	NA	-0.48	-7.39	-0.34	7.96e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg21681030	chr2:46777652	RHOQ	0.42	7.04	0.32	7.68e-12	Height;
LUAD	cis	rs7809950	1.000	rs10274041	chr7:107261556	C/T	cg23024343	chr7:107201750	COG5	0.73	11.98	0.5	1.11e-28	Coronary artery disease;
LUAD	cis	rs7903847	0.620	rs17112676	chr10:99122288	G/A	cg20016023	chr10:99160130	RRP12	-0.28	-6.84	-0.32	2.8e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10849893	0.557	rs6489812	chr12:121913559	T/A	cg01154721	chr12:121881891	KDM2B	0.49	8.32	0.37	1.26e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg09029085	chr17:47094198	IGF2BP1	0.29	6.61	0.31	1.16e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg03714773	chr7:91764589	CYP51A1	-0.31	-7.02	-0.32	9.12e-12	Breast cancer;
LUAD	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg08470875	chr2:26401718	FAM59B	-0.62	-8.52	-0.38	2.89e-16	Gut microbiome composition (summer);
LUAD	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.46	-0.34	4.85e-13	Total body bone mineral density;
LUAD	trans	rs11039798	0.920	rs11500574	chr11:48713986	A/T	cg02254774	chr11:50257496	LOC441601	0.52	6.58	0.3	1.4e-10	Axial length;
LUAD	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg18451016	chr1:38461880	NA	0.37	7.34	0.34	1.13e-12	Coronary artery disease;
LUAD	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg04025307	chr7:1156635	C7orf50	0.57	8.09	0.37	6.18e-15	Bronchopulmonary dysplasia;
LUAD	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg18404041	chr3:52824283	ITIH1	0.42	7.64	0.35	1.52e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs8002861	0.692	rs9533646	chr13:44410669	T/C	cg12856521	chr11:46389249	DGKZ	-0.48	-8.34	-0.38	1.03e-15	Leprosy;
LUAD	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg19912559	chr1:40204330	PPIE	0.57	10.01	0.44	2.57e-21	Blood protein levels;
LUAD	cis	rs17253792	0.822	rs76201070	chr14:56063604	A/C	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	trans	rs6561151	0.681	rs17065161	chr13:44443723	A/T	cg17145862	chr1:211918768	LPGAT1	0.49	6.97	0.32	1.23e-11	Crohn's disease;
LUAD	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg22920501	chr2:26401640	FAM59B	-0.76	-10.97	-0.47	8.37e-25	Gut microbiome composition (summer);
LUAD	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg11859384	chr17:80120422	CCDC57	-0.5	-9.07	-0.4	4.47e-18	Life satisfaction;
LUAD	cis	rs6901250	0.807	rs1606366	chr6:117132438	C/G	cg12892004	chr6:117198278	RFX6	0.34	7.27	0.33	1.8e-12	C-reactive protein levels;
LUAD	cis	rs2367725	1	rs2367725	chr1:44215828	C/T	cg19743044	chr1:44115203	KDM4A	-0.39	-6.87	-0.32	2.26e-11	Aging (time to event);
LUAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg04025307	chr7:1156635	C7orf50	0.66	7.92	0.36	2.13e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11048434	0.761	rs1805765	chr12:9094548	A/G	cg23795048	chr12:9217529	LOC144571	0.42	7.62	0.35	1.73e-13	Sjögren's syndrome;
LUAD	cis	rs897984	0.568	rs67456613	chr16:30888295	G/A	cg05768032	chr16:30646687	NA	0.41	6.46	0.3	2.87e-10	Dementia with Lewy bodies;
LUAD	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg22532475	chr10:104410764	TRIM8	0.34	6.85	0.32	2.61e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg25985355	chr7:65971099	NA	-0.55	-6.74	-0.31	5.08e-11	Diabetic kidney disease;
LUAD	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.36	-18.27	-0.66	2.12e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg17757837	chr7:157058334	UBE3C	0.48	8.49	0.38	3.61e-16	Body mass index;
LUAD	cis	rs8017423	0.934	rs2401874	chr14:90682467	C/T	cg14092571	chr14:90743983	NA	-0.48	-8.56	-0.38	2.07e-16	Mortality in heart failure;
LUAD	trans	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg07211511	chr3:129823064	LOC729375	-0.51	-7.04	-0.32	7.87e-12	Blood pressure (smoking interaction);
LUAD	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg14169450	chr9:139327907	INPP5E	0.41	6.42	0.3	3.66e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs34638657	0.833	rs4889479	chr16:82201474	T/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.58	-0.3	1.38e-10	Lung adenocarcinoma;
LUAD	cis	rs2244613	0.706	rs7200011	chr16:55794768	C/A	cg27396498	chr16:55794478	CES4	0.46	6.59	0.31	1.27e-10	Response to dabigatran etexilate treatment;
LUAD	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg12923728	chr3:195709715	SDHAP1	0.44	6.72	0.31	6.04e-11	Mean corpuscular volume;
LUAD	cis	rs1003719	0.680	rs2835629	chr21:38521660	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.41	-0.38	6.27e-16	Eye color traits;
LUAD	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg07606381	chr6:8435919	SLC35B3	0.4	6.65	0.31	9.07e-11	Motion sickness;
LUAD	cis	rs1595825	0.891	rs73056823	chr2:198769788	T/C	cg10547527	chr2:198650123	BOLL	-0.53	-7.64	-0.35	1.45e-13	Ulcerative colitis;
LUAD	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.83	-0.36	3.92e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs791888	1.000	rs2147288	chr10:89415882	C/A	cg13926569	chr10:89418898	PAPSS2	-0.45	-8.47	-0.38	4.12e-16	Magnesium levels;
LUAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg11965913	chr1:205819406	PM20D1	0.77	15.44	0.6	5.46e-43	Menarche (age at onset);
LUAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg00280220	chr17:61926910	NA	0.37	7.18	0.33	3.08e-12	Prudent dietary pattern;
LUAD	cis	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg27411982	chr8:10470053	RP1L1	0.43	8.03	0.36	9.43e-15	Retinal vascular caliber;
LUAD	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg17173187	chr15:85201210	NMB	0.48	8.38	0.38	7.81e-16	Schizophrenia;
LUAD	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg08773314	chr2:239334832	ASB1	0.44	10.25	0.45	3.57e-22	Multiple system atrophy;
LUAD	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg06112835	chr11:68658793	MRPL21	0.53	9.47	0.42	2.04e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00552226	chr2:70475288	TIA1	-0.45	-6.94	-0.32	1.45e-11	Height;
LUAD	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.51	0.34	3.47e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg06784218	chr1:46089804	CCDC17	0.59	13.24	0.54	9.84e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	7.9	0.36	2.38e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg06453172	chr10:134556979	INPP5A	0.8	11.65	0.49	2.19e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg03474202	chr17:45855739	NA	-0.39	-9.24	-0.41	1.18e-18	IgG glycosylation;
LUAD	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg03037974	chr15:76606532	NA	0.33	6.66	0.31	8.49e-11	Blood metabolite levels;
LUAD	trans	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg19469189	chr11:128781035	KCNJ5	0.42	6.68	0.31	7.48e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6920965	0.583	rs9388456	chr6:126147197	C/T	cg05901451	chr6:126070800	HEY2	-0.43	-6.68	-0.31	7.67e-11	High light scatter reticulocyte count;
LUAD	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg21153622	chr11:89784906	NA	-0.33	-6.47	-0.3	2.78e-10	Coronary artery disease;
LUAD	cis	rs2535633	0.602	rs6801235	chr3:53009595	T/C	cg11645453	chr3:52864694	ITIH4	0.37	6.88	0.32	2.12e-11	Body mass index;
LUAD	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.89	-17.59	-0.65	2.35e-52	Ulcerative colitis;
LUAD	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg18132916	chr6:79620363	NA	-0.47	-8.13	-0.37	4.87e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg07917127	chr4:99064746	C4orf37	0.42	6.97	0.32	1.24e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg13902645	chr11:5959945	NA	-0.58	-10.25	-0.45	3.75e-22	DNA methylation (variation);
LUAD	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg27170947	chr2:26402098	FAM59B	-0.61	-8.82	-0.39	3.06e-17	Gut microbiome composition (summer);
LUAD	cis	rs62238980	0.522	rs79367011	chr22:32450245	G/T	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs7737355	0.812	rs10063264	chr5:130898197	C/G	cg06307176	chr5:131281290	NA	0.44	7.21	0.33	2.63e-12	Life satisfaction;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg09192333	chr22:38142150	TRIOBP	-0.41	-6.97	-0.32	1.21e-11	Schizophrenia;
LUAD	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg06028605	chr16:24865363	SLC5A11	0.37	6.75	0.31	4.95e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg13012494	chr21:47604986	C21orf56	-0.54	-7.84	-0.36	3.71e-14	Testicular germ cell tumor;
LUAD	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg01874867	chr7:94954059	PON1	0.49	6.66	0.31	8.35e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9644630	1.000	rs9644629	chr8:19369290	T/C	cg06699216	chr8:19333253	CSGALNACT1	-0.3	-7.04	-0.32	7.99e-12	Oropharynx cancer;
LUAD	trans	rs6076960	0.684	rs6054059	chr20:6262472	G/T	cg17788362	chr6:86352627	SYNCRIP	0.4	6.42	0.3	3.63e-10	Smooth-surface caries;
LUAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.37	-7.07	-0.33	6.47e-12	Longevity;Endometriosis;
LUAD	cis	rs1160297	0.517	rs1451462	chr2:53123412	C/T	cg07782112	chr2:53107842	NA	-0.35	-7.46	-0.34	5.08e-13	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg01475377	chr6:109611718	NA	-0.54	-10.28	-0.45	2.73e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs7089973	0.966	rs55711292	chr10:116604870	T/G	cg23260525	chr10:116636907	FAM160B1	0.42	9.07	0.4	4.38e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-7.77	-0.35	6e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg02228675	chr17:40259724	DHX58	-0.44	-6.98	-0.32	1.17e-11	Fibrinogen levels;
LUAD	cis	rs864537	0.646	rs1723018	chr1:167433420	A/G	cg22356347	chr1:167427500	CD247	-0.45	-8.99	-0.4	8.23e-18	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.17e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7180079	1.000	rs7183694	chr15:64538955	G/C	cg08069370	chr15:64387884	SNX1	-0.51	-6.56	-0.3	1.6e-10	Monocyte count;
LUAD	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg09359103	chr1:154839909	KCNN3	0.91	21.17	0.72	2.39e-68	Prostate cancer;
LUAD	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg22166914	chr1:53195759	ZYG11B	-0.51	-8.84	-0.39	2.55e-17	Monocyte count;
LUAD	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg23649088	chr2:200775458	C2orf69	-0.57	-6.48	-0.3	2.57e-10	Schizophrenia;
LUAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg22105103	chr4:187893119	NA	0.57	12.61	0.52	3.6e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6066825	0.590	rs729663	chr20:47304306	C/T	cg18078177	chr20:47281410	PREX1	-0.41	-7.05	-0.32	7.26e-12	Colorectal cancer;
LUAD	cis	rs11048434	0.761	rs10842662	chr12:9139344	G/A	cg26114124	chr12:9217669	LOC144571	0.39	7.2	0.33	2.86e-12	Sjögren's syndrome;
LUAD	cis	rs2281845	0.507	rs10800760	chr1:201100439	G/A	cg06714761	chr1:201096289	NA	0.33	7.26	0.33	1.87e-12	Permanent tooth development;
LUAD	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.56e-12	Crohn's disease;
LUAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.88	16.78	0.63	8.29e-49	Lymphocyte counts;
LUAD	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg16049864	chr8:95962084	TP53INP1	-0.6	-13.21	-0.54	1.29e-33	Type 2 diabetes;
LUAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg00989853	chr1:209979345	IRF6	0.36	7.94	0.36	1.9e-14	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUAD	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg22496339	chr2:162101262	NA	-0.42	-6.72	-0.31	6.01e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.55e-11	Crohn's disease;
LUAD	cis	rs1832871	0.711	rs9457264	chr6:158689367	G/A	cg07165851	chr6:158734300	TULP4	0.71	10.98	0.47	7.63e-25	Height;
LUAD	cis	rs2882667	0.755	rs55650316	chr5:138467292	C/G	cg04439458	chr5:138467593	SIL1	-0.56	-10.54	-0.46	3.26e-23	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs67981189	0.593	rs4147077	chr14:71454870	A/G	cg15332261	chr14:71375349	PCNX	-0.39	-6.46	-0.3	2.83e-10	Schizophrenia;
LUAD	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg03037974	chr15:76606532	NA	0.39	8.55	0.38	2.29e-16	Blood metabolite levels;
LUAD	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg10978503	chr1:24200527	CNR2	0.56	12.09	0.51	4.29e-29	Immature fraction of reticulocytes;
LUAD	cis	rs6594713	0.717	rs17331844	chr5:112914426	G/T	cg12552261	chr5:112820674	MCC	0.58	8.89	0.4	1.77e-17	Brain cytoarchitecture;
LUAD	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg15448220	chr1:150897856	SETDB1	0.56	9.76	0.43	2e-20	Melanoma;
LUAD	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg09455208	chr3:40491958	NA	0.49	10.4	0.45	1.03e-22	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg07917127	chr4:99064746	C4orf37	0.45	7.35	0.34	1.05e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7945718	0.805	rs11022510	chr11:12833262	G/A	cg25843174	chr11:12811716	TEAD1	0.22	6.62	0.31	1.08e-10	Educational attainment (years of education);
LUAD	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg26373071	chr5:1325741	CLPTM1L	0.36	7.54	0.34	2.84e-13	Lung cancer;
LUAD	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg18138036	chr10:133769891	PPP2R2D	0.4	6.45	0.3	3.01e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.41	0.34	7.09e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs2274273	0.588	rs2297816	chr14:55833038	A/G	cg04306507	chr14:55594613	LGALS3	0.41	7.96	0.36	1.64e-14	Protein biomarker;
LUAD	cis	rs8040855	0.621	rs6496796	chr15:85726848	T/C	cg04831495	chr15:85060580	GOLGA6L5	0.42	6.86	0.32	2.51e-11	Bulimia nervosa;
LUAD	trans	rs875971	0.929	rs778682	chr7:65837934	A/G	cg14917512	chr19:3094685	GNA11	-0.38	-6.61	-0.31	1.18e-10	Aortic root size;
LUAD	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg01849466	chr14:104193079	ZFYVE21	0.54	8.87	0.4	2.02e-17	Body mass index;
LUAD	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg07606381	chr6:8435919	SLC35B3	0.42	6.89	0.32	2.01e-11	Motion sickness;
LUAD	cis	rs2455799	0.574	rs2470534	chr3:15701054	C/G	cg16303742	chr3:15540471	COLQ	0.49	9.22	0.41	1.47e-18	Mean platelet volume;
LUAD	cis	rs4006360	0.657	rs7225713	chr17:39252092	T/C	cg16090541	chr17:39240343	KRTAP4-7	-0.36	-6.38	-0.3	4.62e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg20203395	chr5:56204925	C5orf35	-0.63	-9.63	-0.42	5.54e-20	Initial pursuit acceleration;
LUAD	cis	rs2046867	0.862	rs11922794	chr3:72813582	G/C	cg25664220	chr3:72788482	NA	-0.64	-11.47	-0.49	1.02e-26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg27124370	chr19:33622961	WDR88	0.46	7.08	0.33	5.86e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs2018683	0.932	rs4386882	chr7:28989270	C/T	cg19402173	chr7:128379420	CALU	-0.65	-10.97	-0.47	8.42e-25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2742234	0.794	rs17153156	chr10:43704637	C/G	cg15436174	chr10:43711423	RASGEF1A	0.38	6.9	0.32	1.87e-11	Hirschsprung disease;
LUAD	cis	rs698833	0.758	rs7586188	chr2:44544955	G/A	cg04920474	chr2:44395004	PPM1B	0.42	7.61	0.35	1.81e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs13064411	0.696	rs7622740	chr3:113206771	G/A	cg18753928	chr3:113234510	CCDC52	-0.74	-12.4	-0.52	2.46e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.11	-0.54	3.46e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs7746199	0.736	rs56405707	chr6:27640246	G/A	cg01620082	chr3:125678407	NA	-1.04	-10.21	-0.44	4.98e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg09455208	chr3:40491958	NA	0.55	12.21	0.51	1.43e-29	Renal cell carcinoma;
LUAD	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg23758822	chr17:41437982	NA	1.0	20.92	0.71	3.2e-67	Menopause (age at onset);
LUAD	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg12863693	chr15:85201151	NMB	0.36	6.47	0.3	2.73e-10	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg13047869	chr3:10149882	C3orf24	-0.67	-11.28	-0.48	5.41e-26	Alzheimer's disease;
LUAD	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg14895029	chr7:2775587	GNA12	-0.44	-7.19	-0.33	2.89e-12	Height;
LUAD	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg26343298	chr8:95960752	TP53INP1	0.38	8.09	0.37	6.57e-15	Type 2 diabetes;
LUAD	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg04218760	chr10:45406644	TMEM72	-0.32	-8.05	-0.36	8.27e-15	Mean corpuscular volume;
LUAD	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg00631329	chr6:26305371	NA	-0.7	-13.5	-0.55	9e-35	Educational attainment;
LUAD	cis	rs3020333	0.875	rs3020334	chr6:152012956	A/G	cg22157087	chr6:152012887	ESR1	0.37	6.59	0.31	1.28e-10	Total body bone mineral density;
LUAD	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg14582100	chr15:45693742	SPATA5L1	0.64	12.56	0.52	5.85e-31	Homoarginine levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23659696	chr6:39083005	C6orf64	-0.59	-7.26	-0.33	1.92e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg12863693	chr15:85201151	NMB	0.4	7.4	0.34	7.52e-13	Schizophrenia;
LUAD	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-8.11	-0.37	5.53e-15	Total cholesterol levels;
LUAD	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg24503407	chr1:205819492	PM20D1	0.76	15.5	0.6	3.11e-43	Menarche (age at onset);
LUAD	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg25894440	chr7:65020034	NA	-0.63	-6.69	-0.31	7.02e-11	Diabetic kidney disease;
LUAD	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg09455208	chr3:40491958	NA	0.51	10.66	0.46	1.19e-23	Renal cell carcinoma;
LUAD	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg18761221	chr20:60518478	NA	0.39	6.79	0.31	3.87e-11	Body mass index;
LUAD	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg10523679	chr1:76189770	ACADM	0.9	16.21	0.62	2.5e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg25804541	chr17:80189381	SLC16A3	0.33	7.19	0.33	3.05e-12	Life satisfaction;
LUAD	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21582582	chr3:182698605	DCUN1D1	0.61	9.83	0.43	1.1e-20	Resting heart rate;
LUAD	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg19436804	chr8:8560866	CLDN23	0.42	6.4	0.3	4.01e-10	Obesity-related traits;
LUAD	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg09658497	chr7:2847517	GNA12	-0.46	-7.73	-0.35	7.82e-14	Height;
LUAD	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg04944784	chr2:26401820	FAM59B	-0.75	-11.09	-0.47	2.94e-25	Gut microbiome composition (summer);
LUAD	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.61	-7.35	-0.34	1.01e-12	Body mass index;
LUAD	trans	rs9784649	0.574	rs7702369	chr5:25026602	A/G	cg11038491	chr20:34638489	LOC647979	-0.53	-7.46	-0.34	4.94e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg12016809	chr21:47604291	C21orf56	0.65	11.44	0.49	1.39e-26	Testicular germ cell tumor;
LUAD	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg00933542	chr6:150070202	PCMT1	0.43	9.03	0.4	6.3e-18	Lung cancer;
LUAD	cis	rs7107174	1.000	rs10899470	chr11:78020052	C/T	cg19901956	chr11:77921274	USP35	-0.53	-6.45	-0.3	3.15e-10	Testicular germ cell tumor;
LUAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg10544611	chr16:67998164	SLC12A4	-0.69	-8.27	-0.37	1.75e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg05896524	chr21:47604654	C21orf56	0.44	6.76	0.31	4.56e-11	Testicular germ cell tumor;
LUAD	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg08859206	chr1:53392774	SCP2	0.58	10.52	0.46	3.82e-23	Monocyte count;
LUAD	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg22431228	chr1:16359049	CLCNKA	-0.64	-13.19	-0.54	1.66e-33	Systolic blood pressure;
LUAD	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg24818145	chr4:99064322	C4orf37	-0.41	-6.84	-0.32	2.75e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10819733	chr22:24237672	NA	-0.37	-6.77	-0.31	4.45e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.35	-6.85	-0.32	2.63e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs8099014	0.731	rs4261624	chr18:56101290	T/A	cg12907477	chr18:56117327	MIR122	0.49	7.12	0.33	4.56e-12	Platelet count;
LUAD	cis	rs7000551	0.663	rs11778831	chr8:22335088	C/T	cg12081754	chr8:22256438	SLC39A14	0.47	7.77	0.35	5.97e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg14092988	chr3:52407081	DNAH1	0.44	8.87	0.4	2.08e-17	Bipolar disorder;
LUAD	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg02038168	chr22:39784481	NA	0.5	8.27	0.37	1.8e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs933688	0.532	rs2973477	chr5:90553722	C/T	cg17503389	chr5:90575422	NA	-0.44	-6.61	-0.31	1.2e-10	Smoking behavior;
LUAD	cis	rs68170813	0.559	rs79978998	chr7:106845482	C/T	cg23024343	chr7:107201750	COG5	0.49	7.08	0.33	5.97e-12	Coronary artery disease;
LUAD	cis	rs7707921	1.000	rs749401	chr5:81561369	T/C	cg15871215	chr5:81402204	ATG10	-0.7	-10.15	-0.44	8.27e-22	Breast cancer;
LUAD	cis	rs77972916	0.611	rs11693190	chr2:43602415	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-8.35	-0.38	9.67e-16	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.3	6.36	0.3	5.19e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg03161606	chr19:29218774	NA	0.61	8.75	0.39	5.32e-17	Methadone dose in opioid dependence;
LUAD	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg18944383	chr4:111397179	ENPEP	0.55	10.71	0.46	7.36e-24	Height;
LUAD	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg07527032	chr15:84868466	LOC388152	0.44	6.66	0.31	8.77e-11	Schizophrenia;
LUAD	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg08859206	chr1:53392774	SCP2	-0.63	-11.59	-0.49	3.79e-27	Monocyte count;
LUAD	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	trans	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg18187862	chr3:45730750	SACM1L	-0.46	-6.63	-0.31	1.04e-10	Primary sclerosing cholangitis;
LUAD	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.36e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg14345882	chr6:26364793	BTN3A2	0.7	7.1	0.33	5.18e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg23262073	chr20:60523788	NA	-0.44	-7.07	-0.32	6.62e-12	Body mass index;
LUAD	cis	rs7927771	0.542	rs11039336	chr11:47706141	A/G	cg18512352	chr11:47633146	NA	-0.37	-6.62	-0.31	1.06e-10	Subjective well-being;
LUAD	cis	rs4642101	0.680	rs6442330	chr3:12820501	A/G	cg24848339	chr3:12840334	CAND2	0.44	8.6	0.39	1.62e-16	QRS complex (12-leadsum);
LUAD	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg12292205	chr6:26970375	C6orf41	-0.38	-6.73	-0.31	5.6e-11	Schizophrenia;
LUAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg04025307	chr7:1156635	C7orf50	0.83	15.51	0.6	2.76e-43	Longevity;Endometriosis;
LUAD	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg04267008	chr7:1944627	MAD1L1	-0.76	-12.13	-0.51	3.02e-29	Bipolar disorder and schizophrenia;
LUAD	cis	rs62400317	0.859	rs62436779	chr6:45124911	G/A	cg18551225	chr6:44695536	NA	-0.55	-8.66	-0.39	1.02e-16	Total body bone mineral density;
LUAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg14092988	chr3:52407081	DNAH1	0.33	6.48	0.3	2.49e-10	Electroencephalogram traits;
LUAD	cis	rs758324	0.812	rs4280859	chr5:131246941	A/T	cg25547332	chr5:131281432	NA	-0.42	-6.77	-0.31	4.35e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg04450456	chr4:17643702	FAM184B	0.4	7.94	0.36	1.82e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg13057898	chr1:3703894	LRRC47	0.63	10.65	0.46	1.22e-23	Red cell distribution width;
LUAD	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg07432352	chr17:45403706	C17orf57	-0.42	-8.17	-0.37	3.7e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06074958	chr12:57118908	NACA	-0.42	-6.47	-0.3	2.78e-10	Height;
LUAD	cis	rs3924048	0.559	rs4075303	chr1:12626593	C/G	cg00291366	chr1:12616550	NA	0.32	6.47	0.3	2.74e-10	Optic cup area;
LUAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg27454412	chr7:1067447	C7orf50	0.4	6.73	0.31	5.49e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg08601574	chr20:25228251	PYGB	0.46	8.54	0.38	2.5e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.5	7.01	0.32	9.3e-12	Platelet count;
LUAD	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg11663144	chr21:46675770	NA	-0.58	-11.53	-0.49	6.03e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg11833968	chr6:79620685	NA	-0.44	-8.35	-0.38	9.52e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7020830	0.858	rs1492714	chr9:37141259	T/C	cg14294708	chr9:37120828	ZCCHC7	0.86	17.18	0.64	1.38e-50	Schizophrenia;
LUAD	cis	rs4664304	0.781	rs3828323	chr2:160808075	C/T	cg23995753	chr2:160760732	LY75	-0.41	-7.26	-0.33	1.84e-12	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7665090	1.000	rs6839064	chr4:103555676	T/C	cg07973026	chr4:103553119	MANBA	0.47	8.43	0.38	5.37e-16	Primary biliary cholangitis;
LUAD	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg04154034	chr17:28927549	LRRC37B2	0.69	6.79	0.31	3.7e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs4409675	0.619	rs12070173	chr1:28231955	G/C	cg23691781	chr1:28212827	C1orf38	0.37	10.81	0.47	3.38e-24	Corneal astigmatism;
LUAD	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.02	0.4	6.73e-18	Colorectal cancer;
LUAD	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11890956	chr21:40555474	PSMG1	-0.55	-9.56	-0.42	9.84e-20	Menarche (age at onset);
LUAD	cis	rs1448094	0.967	rs10863109	chr12:86328415	A/G	cg00310523	chr12:86230176	RASSF9	0.35	7.56	0.34	2.58e-13	Major depressive disorder;
LUAD	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg18105134	chr13:113819100	PROZ	-0.86	-15.09	-0.59	1.78e-41	Platelet distribution width;
LUAD	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg18132916	chr6:79620363	NA	-0.47	-8.23	-0.37	2.27e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg05425664	chr17:57184151	TRIM37	0.43	7.72	0.35	8.77e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.56	0.3	1.55e-10	Depression;
LUAD	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg24818145	chr4:99064322	C4orf37	0.41	6.78	0.31	4.09e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9925964	0.933	rs9929899	chr16:31062701	C/A	cg03418659	chr16:31128414	MYST1	0.4	7.09	0.33	5.73e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg06606381	chr12:133084897	FBRSL1	-0.96	-9.1	-0.4	3.45e-18	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg04944784	chr2:26401820	FAM59B	0.88	12.54	0.52	6.84e-31	Gut microbiome composition (summer);
LUAD	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg09455208	chr3:40491958	NA	-0.58	-12.73	-0.53	1.24e-31	Renal cell carcinoma;
LUAD	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.72	-0.31	5.94e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs420259	0.516	rs531805	chr16:23466035	C/T	cg00143387	chr16:23521605	GGA2	0.7	9.87	0.43	8.43e-21	Bipolar disorder;
LUAD	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.4e-12	Lung cancer;
LUAD	cis	rs17092148	1.000	rs62211617	chr20:33400355	C/G	cg16810054	chr20:33298113	TP53INP2	0.53	8.2	0.37	2.81e-15	Neuroticism;
LUAD	cis	rs12681287	0.609	rs13281414	chr8:87495254	A/C	cg27223183	chr8:87520930	FAM82B	-0.71	-10.15	-0.44	8.15e-22	Caudate activity during reward;
LUAD	cis	rs6005807	0.688	rs9625475	chr22:28841839	C/T	cg12565055	chr22:29076175	TTC28	-0.64	-6.91	-0.32	1.8e-11	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg23387056	chr11:14280742	SPON1	-0.4	-8.06	-0.36	7.88e-15	Mitochondrial DNA levels;
LUAD	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg24308560	chr3:49941425	MST1R	0.52	8.54	0.38	2.44e-16	Body mass index;
LUAD	trans	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.72	12.96	0.53	1.36e-32	Mean corpuscular volume;
LUAD	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg18190219	chr22:46762943	CELSR1	-0.59	-6.62	-0.31	1.1e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg22907277	chr7:1156413	C7orf50	0.67	8.33	0.38	1.17e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1595825	0.891	rs112898725	chr2:198650006	C/T	cg00982548	chr2:198649783	BOLL	-0.66	-9.5	-0.42	1.54e-19	Ulcerative colitis;
LUAD	trans	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg14917512	chr19:3094685	GNA11	-0.57	-6.65	-0.31	8.96e-11	Diabetic kidney disease;
LUAD	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg08219700	chr8:58056026	NA	0.53	7.71	0.35	9.23e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg25019722	chr6:37503610	NA	0.3	6.88	0.32	2.22e-11	Cognitive performance;
LUAD	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg21475434	chr5:93447410	FAM172A	0.74	8.59	0.39	1.72e-16	Diabetic retinopathy;
LUAD	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg07936489	chr17:37558343	FBXL20	0.45	7.17	0.33	3.46e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg11941060	chr3:133502564	NA	0.62	11.35	0.48	2.93e-26	Iron status biomarkers;
LUAD	cis	rs727505	1.000	rs10265763	chr7:124451514	G/A	cg23710748	chr7:124431027	NA	-0.45	-9.41	-0.42	3.28e-19	Lewy body disease;
LUAD	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.6	11.27	0.48	6e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11809207	1.000	rs55695238	chr1:26521931	C/G	cg00147160	chr1:26503991	CNKSR1	0.44	8.81	0.39	3.33e-17	Height;
LUAD	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg08859206	chr1:53392774	SCP2	-0.63	-11.42	-0.49	1.66e-26	Monocyte count;
LUAD	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg17173187	chr15:85201210	NMB	0.37	6.76	0.31	4.6e-11	Schizophrenia;
LUAD	cis	rs4594175	0.926	rs116372620	chr14:51599682	T/C	cg23942311	chr14:51606299	NA	0.64	11.04	0.47	4.6e-25	Cancer;
LUAD	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg20701182	chr2:24300061	SF3B14	0.64	7.17	0.33	3.29e-12	Lymphocyte counts;
LUAD	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg20469991	chr17:27169893	C17orf63	-0.51	-6.68	-0.31	7.64e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg18230493	chr5:56204884	C5orf35	0.71	11.33	0.48	3.55e-26	Initial pursuit acceleration;
LUAD	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg02221422	chr11:68192511	LRP5	0.42	6.92	0.32	1.65e-11	Total body bone mineral density;
LUAD	cis	rs2625529	0.824	rs7170461	chr15:72218599	C/A	cg16672083	chr15:72433130	SENP8	-0.74	-12.37	-0.52	3.32e-30	Red blood cell count;
LUAD	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.56	-9.45	-0.42	2.41e-19	Glomerular filtration rate;
LUAD	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg04016957	chr4:1044486	NA	-0.41	-6.92	-0.32	1.73e-11	Recombination rate (males);
LUAD	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg02421172	chr7:1938701	MAD1L1	0.46	6.67	0.31	7.89e-11	Bipolar disorder;
LUAD	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	11.66	0.49	1.9e-27	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg23803603	chr1:2058230	PRKCZ	-0.39	-6.56	-0.3	1.58e-10	Height;
LUAD	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg24112000	chr20:60950667	NA	-0.66	-9.26	-0.41	1.04e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg17264618	chr3:40429014	ENTPD3	0.39	8.83	0.39	2.88e-17	Renal cell carcinoma;
LUAD	trans	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg06175025	chr14:78082992	SPTLC2	-0.4	-6.51	-0.3	2.08e-10	Bone mineral density;
LUAD	cis	rs11696501	0.688	rs6104291	chr20:44323368	C/G	cg11783356	chr20:44313418	WFDC10B	-0.51	-8.34	-0.38	1.09e-15	Brain structure;
LUAD	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.56e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg13385794	chr1:248469461	NA	0.26	6.94	0.32	1.46e-11	Common traits (Other);
LUAD	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg11502198	chr6:26597334	ABT1	0.68	11.85	0.5	3.69e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-8.09	-0.37	6.26e-15	Height;Educational attainment;Head circumference (infant);
LUAD	cis	rs2357013	0.752	rs12474925	chr2:53176117	C/A	cg07782112	chr2:53107842	NA	-0.34	-6.88	-0.32	2.2e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg05896524	chr21:47604654	C21orf56	-0.74	-13.14	-0.54	2.59e-33	Testicular germ cell tumor;
LUAD	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg08601574	chr20:25228251	PYGB	0.47	8.88	0.4	1.86e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg04775059	chr7:64541387	NA	0.58	9.49	0.42	1.77e-19	Calcium levels;
LUAD	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg00310523	chr12:86230176	RASSF9	0.42	8.83	0.39	2.87e-17	Major depressive disorder;
LUAD	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22496380	chr5:211416	CCDC127	-1.23	-16.62	-0.63	4.14e-48	Breast cancer;
LUAD	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg17200465	chr3:40428508	ENTPD3	0.29	6.83	0.32	2.89e-11	Renal cell carcinoma;
LUAD	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg07167872	chr1:205819463	PM20D1	-0.53	-8.06	-0.36	8.17e-15	Menarche (age at onset);
LUAD	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.58	-9.89	-0.43	7.05e-21	Menarche (age at onset);
LUAD	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg08859206	chr1:53392774	SCP2	-0.49	-9.01	-0.4	7.42e-18	Monocyte count;
LUAD	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-8.0	-0.36	1.17e-14	Hemoglobin concentration;
LUAD	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg24818145	chr4:99064322	C4orf37	0.48	8.09	0.37	6.3e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg12016809	chr21:47604291	C21orf56	-0.66	-11.8	-0.5	5.85e-28	Testicular germ cell tumor;
LUAD	cis	rs61897795	0.657	rs174590	chr11:61616977	G/C	cg00603274	chr11:61596626	FADS2	-0.42	-6.53	-0.3	1.94e-10	Neutrophil count;Sum basophil neutrophil counts;
LUAD	trans	rs9914544	0.545	rs7222893	chr17:18811702	A/G	cg21372672	chr17:16614065	CCDC144A	-0.39	-7.0	-0.32	1.03e-11	Educational attainment (years of education);
LUAD	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08644924	chr19:14117541	RFX1	-0.38	-6.41	-0.3	3.78e-10	Schizophrenia;
LUAD	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg27284194	chr4:1044797	NA	0.41	6.67	0.31	8.06e-11	Obesity-related traits;
LUAD	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg16205897	chr5:131564050	P4HA2	-0.44	-9.81	-0.43	1.31e-20	Blood metabolite levels;
LUAD	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg00316803	chr15:76480434	C15orf27	-0.41	-7.91	-0.36	2.31e-14	Blood metabolite levels;
LUAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13732083	chr21:47605072	C21orf56	-0.62	-10.54	-0.46	3.24e-23	Testicular germ cell tumor;
LUAD	cis	rs7680126	0.586	rs7689060	chr4:10305463	C/G	cg11266682	chr4:10021025	SLC2A9	0.4	6.88	0.32	2.2e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg25985355	chr7:65971099	NA	-0.52	-6.66	-0.31	8.5e-11	Gout;
LUAD	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg13770153	chr20:60521292	NA	-0.57	-8.84	-0.4	2.53e-17	Body mass index;
LUAD	cis	rs6484504	0.576	rs208072	chr11:31141288	A/G	cg14844989	chr11:31128820	NA	0.42	7.82	0.36	4.18e-14	Red blood cell count;
LUAD	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg16988262	chr1:15930761	NA	0.41	6.82	0.31	3.07e-11	Systolic blood pressure;
LUAD	cis	rs6554196	0.693	rs2237028	chr4:55536375	T/G	cg18836493	chr4:55524333	KIT	-0.36	-6.76	-0.31	4.52e-11	Monocyte count;
LUAD	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg15017067	chr4:17643749	FAM184B	0.38	7.42	0.34	6.2800000000000005e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg15242686	chr22:24348715	GSTTP1	0.42	7.2	0.33	2.79e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg26384229	chr12:38710491	ALG10B	0.51	8.32	0.38	1.19e-15	Heart rate;
LUAD	cis	rs3789045	0.774	rs12029692	chr1:204532323	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.43	-7.2	-0.33	2.7e-12	Educational attainment (college completion);
LUAD	cis	rs3106136	0.527	rs2664872	chr4:95146952	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.04	-0.44	2.11e-21	Capecitabine sensitivity;
LUAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg19130645	chr7:65235666	NA	-0.43	-7.25	-0.33	1.96e-12	Calcium levels;
LUAD	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg03959625	chr15:84868606	LOC388152	0.41	6.57	0.3	1.49e-10	Schizophrenia;
LUAD	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg08677398	chr8:58056175	NA	0.48	6.59	0.31	1.32e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs731174	0.802	rs628492	chr1:38178277	G/A	cg06917450	chr1:38156652	C1orf109	-0.4	-6.44	-0.3	3.35e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg26384229	chr12:38710491	ALG10B	0.4	6.94	0.32	1.48e-11	Heart rate;
LUAD	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg19700328	chr14:106028568	NA	-0.41	-6.93	-0.32	1.57e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.09	0.33	5.61e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg02734326	chr4:10020555	SLC2A9	0.49	7.53	0.34	3.03e-13	Blood metabolite levels;
LUAD	cis	rs597539	0.690	rs1272609	chr11:68618182	T/C	cg06112835	chr11:68658793	MRPL21	0.5	8.82	0.39	2.94e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg22117172	chr7:91764530	CYP51A1	-0.37	-8.05	-0.36	8.19e-15	Breast cancer;
LUAD	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg20291162	chr17:40259547	DHX58	-0.68	-10.51	-0.45	4.25e-23	Fibrinogen levels;
LUAD	cis	rs738322	0.753	rs5756968	chr22:38595240	C/T	cg25457927	chr22:38595422	NA	0.7	20.86	0.71	5.57e-67	Cutaneous nevi;
LUAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00149659	chr3:10157352	C3orf10	0.86	11.57	0.49	4.56e-27	Alzheimer's disease;
LUAD	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg23758822	chr17:41437982	NA	0.99	19.89	0.7	1.25e-62	Menopause (age at onset);
LUAD	cis	rs2230307	0.536	rs684519	chr1:100604715	T/G	cg20868668	chr1:100435035	SLC35A3	-0.51	-7.67	-0.35	1.16e-13	Carotid intima media thickness;
LUAD	cis	rs35995292	0.500	rs6955677	chr7:38933942	C/T	cg19327137	chr7:38886074	VPS41	0.71	14.35	0.57	2.43e-38	Subjective well-being (multi-trait analysis);
LUAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg13560548	chr3:10150139	C3orf24	0.4	6.56	0.3	1.53e-10	Alzheimer's disease;
LUAD	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.58	-0.3	1.4e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg11663144	chr21:46675770	NA	-0.61	-11.63	-0.49	2.46e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1395	0.778	rs6749393	chr2:27451000	C/T	cg23587288	chr2:27483067	SLC30A3	-0.4	-7.57	-0.35	2.34e-13	Blood metabolite levels;
LUAD	cis	rs12612619	0.704	rs10185736	chr2:27321224	T/C	cg00617064	chr2:27272375	NA	0.36	6.58	0.3	1.36e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs72634258	0.945	rs12745223	chr1:8094978	C/T	cg26816564	chr1:7831052	VAMP3	0.52	6.65	0.31	8.86e-11	Inflammatory bowel disease;
LUAD	cis	rs12760731	0.565	rs12027723	chr1:178090271	A/T	cg00404053	chr1:178313656	RASAL2	0.72	9.23	0.41	1.34e-18	Obesity-related traits;
LUAD	cis	rs9811920	0.838	rs12488245	chr3:99835254	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-7.18	-0.33	3.07e-12	Axial length;
LUAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg07677032	chr17:61819896	STRADA	0.56	10.11	0.44	1.18e-21	Prudent dietary pattern;
LUAD	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg08999081	chr20:33150536	PIGU	-0.62	-13.96	-0.56	1.08e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg06263672	chr7:65235340	NA	0.49	6.55	0.3	1.66e-10	Aortic root size;
LUAD	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg06784218	chr1:46089804	CCDC17	0.57	12.74	0.53	1.04e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg18755752	chr8:142205143	DENND3	-0.5	-8.48	-0.38	3.86e-16	Immature fraction of reticulocytes;
LUAD	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg20290983	chr6:43655470	MRPS18A	1.07	26.7	0.79	8.83e-93	IgG glycosylation;
LUAD	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg10518543	chr12:38710700	ALG10B	0.45	7.55	0.34	2.64e-13	Heart rate;
LUAD	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg02733842	chr7:1102375	C7orf50	-0.59	-9.11	-0.41	3.24e-18	Bronchopulmonary dysplasia;
LUAD	trans	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg24644049	chr4:85504048	CDS1	0.87	7.0	0.32	9.84e-12	Skin colour saturation;
LUAD	cis	rs367943	0.901	rs171180	chr5:112817093	A/C	cg12552261	chr5:112820674	MCC	-0.58	-11.04	-0.47	4.66e-25	Type 2 diabetes;
LUAD	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg06740227	chr12:86229804	RASSF9	0.45	7.85	0.36	3.38e-14	Major depressive disorder;
LUAD	cis	rs1823874	0.962	rs12906206	chr15:100359126	A/T	cg16400843	chr15:100339927	C15orf51	0.3	7.0	0.32	1.01e-11	IgG glycosylation;
LUAD	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg21138405	chr5:131827807	IRF1	-0.6	-13.42	-0.55	1.83e-34	Asthma (sex interaction);
LUAD	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	14.97	0.59	5.96e-41	Smoking behavior;
LUAD	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.41	-7.98	-0.36	1.36e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg00717180	chr2:96193071	NA	-0.44	-8.48	-0.38	3.88e-16	Coronary artery disease;
LUAD	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg03709012	chr19:19516395	GATAD2A	0.51	6.83	0.32	3.03e-11	Nonalcoholic fatty liver disease;
LUAD	trans	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg01620082	chr3:125678407	NA	-0.45	-6.69	-0.31	7.07e-11	Depression;
LUAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.5	6.65	0.31	8.97e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7584330	0.554	rs7598035	chr2:238434942	C/T	cg14458575	chr2:238380390	NA	0.6	9.62	0.42	6.18e-20	Prostate cancer;
LUAD	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg06484146	chr7:12443880	VWDE	-0.58	-7.36	-0.34	9.91e-13	Coronary artery disease;
LUAD	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg14092988	chr3:52407081	DNAH1	0.45	9.15	0.41	2.51e-18	Bipolar disorder;
LUAD	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg08601574	chr20:25228251	PYGB	-0.46	-8.65	-0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg12667521	chr19:29218732	NA	0.6	8.12	0.37	4.98e-15	Methadone dose in opioid dependence;
LUAD	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg20203395	chr5:56204925	C5orf35	-0.5	-7.96	-0.36	1.61e-14	Coronary artery disease;
LUAD	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg05890377	chr2:74357713	NA	0.82	11.86	0.5	3.37e-28	Gestational age at birth (maternal effect);
LUAD	cis	rs4638749	1.000	rs12616140	chr2:108867728	A/G	cg25838818	chr2:108905173	SULT1C2	-0.54	-8.57	-0.38	2.02e-16	Blood pressure;
LUAD	cis	rs12291225	0.883	rs1864658	chr11:14256444	C/T	cg19336497	chr11:14380999	RRAS2	0.5	9.96	0.44	3.86e-21	Sense of smell;
LUAD	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.89	-0.5	2.59e-28	Bipolar disorder;
LUAD	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg05182265	chr7:156933206	UBE3C	-0.8	-17.28	-0.64	5.14e-51	Body mass index;
LUAD	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg25809561	chr17:30822961	MYO1D	0.75	15.73	0.61	3.06e-44	Schizophrenia;
LUAD	cis	rs11971779	0.590	rs9642120	chr7:139083971	C/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg09117114	chr16:67998030	SLC12A4	-0.54	-7.12	-0.33	4.7e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs73198271	0.531	rs17630714	chr8:8657681	C/T	cg01851573	chr8:8652454	MFHAS1	0.74	11.19	0.48	1.18e-25	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.58	0.3	1.39e-10	Depression;
LUAD	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg24324837	chr19:49891574	CCDC155	0.56	8.9	0.4	1.69e-17	Multiple sclerosis;
LUAD	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg04025307	chr7:1156635	C7orf50	0.57	8.11	0.37	5.47e-15	Bronchopulmonary dysplasia;
LUAD	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg23281280	chr6:28129359	ZNF389	0.43	6.4	0.3	4.25e-10	Depression;
LUAD	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg18105139	chr6:28058856	ZSCAN12L1	0.25	6.48	0.3	2.52e-10	Parkinson's disease;
LUAD	cis	rs2806561	0.823	rs658508	chr1:23480362	T/C	cg19743168	chr1:23544995	NA	0.36	6.56	0.3	1.6e-10	Height;
LUAD	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg08999081	chr20:33150536	PIGU	0.32	6.35	0.3	5.52e-10	Height;
LUAD	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg14092988	chr3:52407081	DNAH1	0.35	6.95	0.32	1.43e-11	Bipolar disorder;
LUAD	cis	rs41311933	0.611	rs72760216	chr9:123861014	C/T	cg13567360	chr9:123745713	C5	-0.72	-8.29	-0.37	1.5e-15	Coronary artery disease;
LUAD	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.6	-10.29	-0.45	2.59e-22	Blood protein levels;
LUAD	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.78	-0.46	4.18e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg16342193	chr10:102329863	NA	-0.37	-6.53	-0.3	1.84e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg09035930	chr12:129282057	SLC15A4	0.75	17.88	0.66	1.15e-53	Systemic lupus erythematosus;
LUAD	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg08132940	chr7:1081526	C7orf50	-0.71	-7.39	-0.34	8.04e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12900413	0.564	rs8035800	chr15:90314790	T/C	cg24249390	chr15:90295951	MESP1	-0.34	-6.83	-0.32	2.94e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs17095355	1.000	rs17095355	chr10:111735750	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.64	-8.63	-0.39	1.21e-16	Biliary atresia;
LUAD	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg03474202	chr17:45855739	NA	-0.39	-9.07	-0.4	4.55e-18	IgG glycosylation;
LUAD	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg24562669	chr7:97807699	LMTK2	0.3	7.03	0.32	8.37e-12	Breast cancer;
LUAD	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg04727924	chr7:799746	HEATR2	-0.55	-7.39	-0.34	7.85e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg00631329	chr6:26305371	NA	-0.69	-13.02	-0.53	8.36e-33	Educational attainment;
LUAD	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg15557168	chr22:42548783	NA	0.51	9.48	0.42	1.92e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg23985595	chr17:80112537	CCDC57	0.53	9.61	0.42	6.55e-20	Life satisfaction;
LUAD	cis	rs9549367	0.804	rs9549704	chr13:113885187	T/C	cg00898013	chr13:113819073	PROZ	-0.63	-10.51	-0.46	4.03e-23	Platelet distribution width;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg10605791	chr12:122242589	SETD1B;LOC338799	-0.66	-6.66	-0.31	8.49e-11	Type 2 diabetes;
LUAD	cis	rs8044868	0.886	rs12325266	chr16:72214858	C/T	cg23815491	chr16:72088622	HP	0.42	7.34	0.34	1.09e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.7	12.95	0.53	1.54e-32	Menarche (age at onset);
LUAD	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg24069376	chr3:38537580	EXOG	-0.35	-7.94	-0.36	1.83e-14	Electrocardiographic conduction measures;
LUAD	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg26168224	chr5:2018326	NA	0.73	15.35	0.6	1.33e-42	Gut microbiome composition (winter);
LUAD	cis	rs9354308	0.933	rs1938068	chr6:66607807	T/C	cg07460842	chr6:66804631	NA	0.48	7.22	0.33	2.46e-12	Metabolite levels;
LUAD	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.39	-6.62	-0.31	1.08e-10	Platelet count;
LUAD	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg10755058	chr3:40428713	ENTPD3	0.35	6.55	0.3	1.66e-10	Renal cell carcinoma;
LUAD	cis	rs743757	0.878	rs12494849	chr3:50524558	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.48	7.53	0.34	3.11e-13	Diastolic blood pressure;
LUAD	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg21204522	chr6:27730016	NA	-0.47	-7.48	-0.34	4.41e-13	Parkinson's disease;
LUAD	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg25358565	chr5:93447407	FAM172A	0.62	7.59	0.35	2.01e-13	Diabetic retinopathy;
LUAD	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11890956	chr21:40555474	PSMG1	-0.59	-9.63	-0.42	5.43e-20	Cognitive function;
LUAD	trans	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg18187862	chr3:45730750	SACM1L	0.52	8.0	0.36	1.19e-14	Primary sclerosing cholangitis;
LUAD	cis	rs7903847	0.596	rs10786340	chr10:99156563	G/C	cg20016023	chr10:99160130	RRP12	-0.32	-7.78	-0.35	5.57e-14	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg04455712	chr21:45112962	RRP1B	-0.5	-10.59	-0.46	2.04e-23	Mean corpuscular volume;
LUAD	cis	rs1160297	0.552	rs6732467	chr2:53223652	C/T	cg07782112	chr2:53107842	NA	-0.34	-6.95	-0.32	1.37e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg15309053	chr8:964076	NA	0.33	7.09	0.33	5.8e-12	Schizophrenia;
LUAD	cis	rs9341808	0.519	rs684251	chr6:80967337	G/A	cg08355045	chr6:80787529	NA	-0.47	-8.27	-0.37	1.74e-15	Sitting height ratio;
LUAD	trans	rs28735056	0.935	rs537962	chr18:77592660	C/G	cg05926928	chr17:57297772	GDPD1	0.49	7.03	0.32	8.27e-12	Schizophrenia;
LUAD	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.57	-9.47	-0.42	1.99e-19	Response to fenofibrate (adiponectin levels);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg11949866	chr1:10754891	CASZ1	-0.39	-6.91	-0.32	1.81e-11	Schizophrenia;
LUAD	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg22491629	chr6:157744540	C6orf35	-0.79	-9.06	-0.4	4.72e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg23982607	chr1:1823379	GNB1	-0.92	-19.35	-0.69	3.13e-60	Body mass index;
LUAD	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg13685833	chr1:53393034	SCP2	0.48	7.36	0.34	9.7e-13	Monocyte count;
LUAD	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg04455712	chr21:45112962	RRP1B	0.4	8.31	0.37	1.29e-15	Mean corpuscular volume;
LUAD	cis	rs6445967	1.000	rs12637163	chr3:58317692	A/G	cg23715586	chr3:58305044	RPP14	0.43	7.64	0.35	1.43e-13	Platelet count;
LUAD	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00802000	chr16:706648	WDR90	-0.4	-7.39	-0.34	8.03e-13	Height;
LUAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg27454412	chr7:1067447	C7orf50	0.47	7.46	0.34	4.92e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs4650994	1.000	rs4650993	chr1:178515187	A/G	cg05059571	chr16:84539110	KIAA1609	-0.62	-10.77	-0.46	4.6e-24	HDL cholesterol levels;HDL cholesterol;
LUAD	trans	rs75804782	0.520	rs34058921	chr2:239318665	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	8.29	0.37	1.57e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg04731861	chr2:219085781	ARPC2	0.23	7.18	0.33	3.1e-12	Colorectal cancer;
LUAD	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg00383909	chr3:49044727	WDR6	0.42	6.38	0.3	4.62e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);
LUAD	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg15790184	chr11:494944	RNH1	0.42	6.83	0.32	2.9100000000000002e-11	Systemic lupus erythematosus;
LUAD	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg11148817	chr5:312970	AHRR;PDCD6	-0.47	-6.44	-0.3	3.23e-10	Breast cancer;
LUAD	cis	rs6445967	1.000	rs14927	chr3:58305033	G/T	cg23715586	chr3:58305044	RPP14	-0.44	-8.13	-0.37	4.65e-15	Platelet count;
LUAD	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg12193833	chr17:30244370	NA	-0.59	-7.18	-0.33	3.16e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs12545109	0.800	rs1913278	chr8:57403725	T/C	cg19413350	chr8:57351067	NA	-0.43	-6.63	-0.31	1.03e-10	Obesity-related traits;
LUAD	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg26587870	chr6:27730563	NA	-0.47	-7.85	-0.36	3.36e-14	Parkinson's disease;
LUAD	trans	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.73	11.88	0.5	2.72e-28	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs138491296	1	rs138491296	chr17:27961561	GATTATT/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-9.78	-0.43	1.74e-20	White blood cell count;
LUAD	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18876405	chr7:65276391	NA	0.41	6.47	0.3	2.71e-10	Aortic root size;
LUAD	cis	rs760805	1.000	rs4649037	chr1:25258301	G/T	cg22509179	chr1:25234806	RUNX3	-0.74	-13.46	-0.55	1.27e-34	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg11494091	chr17:61959527	GH2	0.74	18.32	0.67	1.27e-55	Prudent dietary pattern;
LUAD	cis	rs3820068	0.822	rs11581917	chr1:15805722	G/A	cg13390004	chr1:15929781	NA	0.44	6.64	0.31	9.45e-11	Systolic blood pressure;
LUAD	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg27170947	chr2:26402098	FAM59B	-0.6	-8.59	-0.39	1.63e-16	Gut microbiome composition (summer);
LUAD	cis	rs4700695	0.534	rs37234	chr5:65222898	T/C	cg21114390	chr5:65439923	SFRS12	0.62	6.71	0.31	6.43e-11	Facial morphology (factor 19);
LUAD	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg00666640	chr1:248458726	OR2T12	0.32	7.86	0.36	3.31e-14	Common traits (Other);
LUAD	cis	rs6489882	0.836	rs6489878	chr12:113368125	A/G	cg20102336	chr12:113376681	OAS3	-0.58	-8.95	-0.4	1.09e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs2735413	0.958	rs1922611	chr16:78053121	C/T	cg04733911	chr16:78082701	NA	-0.29	-6.54	-0.3	1.77e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs250677	0.522	rs10038913	chr5:148354224	A/G	cg12140854	chr5:148520817	ABLIM3	0.55	8.91	0.4	1.58e-17	Breast cancer;
LUAD	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg23281280	chr6:28129359	ZNF389	0.45	6.56	0.3	1.62e-10	Parkinson's disease;
LUAD	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg14019146	chr3:50243930	SLC38A3	0.36	6.81	0.31	3.31e-11	Body mass index;
LUAD	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg10518543	chr12:38710700	ALG10B	0.53	8.64	0.39	1.16e-16	Morning vs. evening chronotype;
LUAD	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg05042697	chr2:10830656	NOL10	0.38	6.62	0.31	1.11e-10	Prostate cancer;
LUAD	cis	rs55665837	0.778	rs11023212	chr11:14431709	G/A	cg19336497	chr11:14380999	RRAS2	-0.57	-11.46	-0.49	1.14e-26	Vitamin D levels;
LUAD	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg02551604	chr5:131831745	NA	-0.61	-10.08	-0.44	1.46e-21	Asthma (sex interaction);
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg01516881	chr6:292596	DUSP22	-0.77	-13.34	-0.54	3.9e-34	Menopause (age at onset);
LUAD	cis	rs501916	0.602	rs472081	chr15:48058652	G/T	cg16110827	chr15:48056943	SEMA6D	-0.35	-6.53	-0.3	1.87e-10	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg00071950	chr4:10020882	SLC2A9	0.49	7.25	0.33	2.02e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg05805236	chr11:65401703	PCNXL3	-0.52	-8.69	-0.39	8.11e-17	Acne (severe);
LUAD	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg17757837	chr7:157058334	UBE3C	0.48	8.48	0.38	3.8e-16	Body mass index;
LUAD	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.03	-15.38	-0.6	1.01e-42	Schizophrenia;
LUAD	cis	rs6005807	0.920	rs9625433	chr22:28620996	G/A	cg12565055	chr22:29076175	TTC28	0.65	6.41	0.3	3.85e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg03526776	chr6:41159608	TREML2	0.33	6.89	0.32	1.99e-11	Alzheimer's disease (late onset);
LUAD	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg10523679	chr1:76189770	ACADM	0.9	15.41	0.6	7.8e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg25894440	chr7:65020034	NA	-0.64	-7.0	-0.32	1.02e-11	Diabetic kidney disease;
LUAD	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.69	-11.97	-0.5	1.24e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg06108461	chr20:60628389	TAF4	-0.74	-12.35	-0.51	4e-30	Body mass index;
LUAD	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-16.36	-0.62	5.58e-47	Schizophrenia;
LUAD	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg09323728	chr8:95962352	TP53INP1	-0.34	-7.45	-0.34	5.2e-13	Type 2 diabetes;
LUAD	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg07080864	chr8:57359956	PENK	-0.37	-6.58	-0.3	1.43e-10	Obesity-related traits;
LUAD	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg02782426	chr3:40428986	ENTPD3	0.42	8.87	0.4	2.07e-17	Renal cell carcinoma;
LUAD	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg06740227	chr12:86229804	RASSF9	0.47	8.25	0.37	2.1e-15	Major depressive disorder;
LUAD	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg20476274	chr7:133979776	SLC35B4	0.84	16.84	0.63	4.66e-49	Mean platelet volume;
LUAD	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg25767906	chr1:53392781	SCP2	-0.55	-10.29	-0.45	2.55e-22	Monocyte count;
LUAD	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg26169700	chr22:42538906	CYP2D7P1	-0.48	-6.42	-0.3	3.66e-10	Birth weight;
LUAD	cis	rs2882667	0.861	rs13176902	chr5:138393329	T/C	cg04439458	chr5:138467593	SIL1	-0.38	-6.97	-0.32	1.26e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg26384229	chr12:38710491	ALG10B	0.44	7.19	0.33	3.01e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg15017067	chr4:17643749	FAM184B	-0.34	-6.83	-0.32	3e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10189230	0.967	rs12990760	chr2:222354725	G/T	cg14652038	chr2:222343519	EPHA4	0.43	8.56	0.38	2.14e-16	Urate levels in lean individuals;
LUAD	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg14828511	chr1:107599125	PRMT6	0.59	10.36	0.45	1.48e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg00495681	chr13:53174319	NA	0.48	8.69	0.39	8.02e-17	Lewy body disease;
LUAD	cis	rs59104589	0.583	rs12618809	chr2:242249122	G/A	cg08645257	chr2:242211290	HDLBP	0.5	7.87	0.36	2.94e-14	Fibrinogen levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06639788	chr1:100503523	HIAT1	-0.52	-6.65	-0.31	8.92e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg09796270	chr17:17721594	SREBF1	0.37	7.58	0.35	2.28e-13	Total body bone mineral density;
LUAD	cis	rs28595532	0.688	rs116173135	chr4:119721949	C/T	cg02775129	chr4:119771670	NA	-0.86	-7.74	-0.35	7.56e-14	Cannabis dependence symptom count;
LUAD	cis	rs2735413	0.632	rs4436790	chr16:78097252	G/A	cg04733911	chr16:78082701	NA	0.37	8.33	0.38	1.13e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.78	-0.35	5.45e-14	Blood trace element (Zn levels);
LUAD	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.61	-9.91	-0.43	5.99e-21	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg05564831	chr3:52568323	NT5DC2	-0.36	-6.56	-0.3	1.57e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.48	-0.3	2.61e-10	Morning vs. evening chronotype;
LUAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06873352	chr17:61820015	STRADA	0.84	18.86	0.68	5.32e-58	Prudent dietary pattern;
LUAD	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg24069376	chr3:38537580	EXOG	0.45	11.0	0.47	6.54e-25	Electrocardiographic conduction measures;
LUAD	cis	rs17102423	0.531	rs2763888	chr14:65571493	T/C	cg11161011	chr14:65562177	MAX	-0.43	-7.24	-0.33	2.11e-12	Obesity-related traits;
LUAD	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg06494592	chr3:125709126	NA	-0.49	-6.5	-0.3	2.22e-10	Blood pressure (smoking interaction);
LUAD	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg06608945	chr2:219082296	ARPC2	-0.46	-7.9	-0.36	2.51e-14	Colorectal cancer;
LUAD	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.28	-7.41	-0.34	6.99e-13	Schizophrenia;
LUAD	cis	rs4409675	0.527	rs1884469	chr1:28239434	G/A	cg23691781	chr1:28212827	C1orf38	0.39	10.91	0.47	1.37e-24	Corneal astigmatism;
LUAD	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg27624424	chr6:160112604	SOD2	0.44	6.36	0.3	5.19e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg13319975	chr6:146136371	FBXO30	-0.59	-9.91	-0.43	5.68e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg21724239	chr8:58056113	NA	0.66	8.66	0.39	9.86e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-13.98	-0.56	8.87e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs6897795	0.680	rs9329133	chr5:177609540	C/T	cg19598605	chr2:70056955	GMCL1	-0.61	-7.96	-0.36	1.61e-14	Plateletcrit;
LUAD	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg04154034	chr17:28927549	LRRC37B2	-0.59	-6.93	-0.32	1.6e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg22105103	chr4:187893119	NA	0.53	11.17	0.48	1.41e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg22153463	chr1:85462885	MCOLN2	-0.58	-8.04	-0.36	9.05e-15	Serum sulfate level;
LUAD	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23158103	chr7:148848205	ZNF398	-0.61	-11.29	-0.48	5.21e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs12681287	1.000	rs12681287	chr8:87269536	A/C	cg27223183	chr8:87520930	FAM82B	0.62	8.85	0.4	2.34e-17	Caudate activity during reward;
LUAD	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.41	-8.24	-0.37	2.18e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs9354308	0.933	rs2802064	chr6:66564352	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.53	8.01	0.36	1.12e-14	Metabolite levels;
LUAD	cis	rs62400317	0.731	rs72867436	chr6:44975488	T/G	cg20913747	chr6:44695427	NA	-0.44	-6.95	-0.32	1.42e-11	Total body bone mineral density;
LUAD	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg07606381	chr6:8435919	SLC35B3	0.41	6.83	0.32	2.98e-11	Motion sickness;
LUAD	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg12310025	chr6:25882481	NA	-0.48	-7.1	-0.33	5.32e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.29	-0.41	8.46e-19	Alzheimer's disease;
LUAD	trans	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.74	0.46	5.74e-24	Exhaled nitric oxide output;
LUAD	trans	rs75804782	0.641	rs72987328	chr2:239360097	C/T	cg01134436	chr17:81009848	B3GNTL1	0.78	8.74	0.39	5.56e-17	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2274273	0.600	rs10131730	chr14:55840092	C/T	cg04306507	chr14:55594613	LGALS3	0.41	7.91	0.36	2.24e-14	Protein biomarker;
LUAD	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg00277334	chr10:82204260	NA	-0.57	-9.31	-0.41	7.29e-19	Post bronchodilator FEV1;
LUAD	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg17063962	chr7:91808500	NA	0.67	11.92	0.5	1.89e-28	Breast cancer;
LUAD	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.38	-6.47	-0.3	2.7e-10	HDL cholesterol;
LUAD	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg04756594	chr16:24857601	SLC5A11	0.5	9.78	0.43	1.75e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs9323205	0.871	rs2999393	chr14:51655167	G/T	cg23942311	chr14:51606299	NA	0.59	10.35	0.45	1.53e-22	Cancer;
LUAD	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs7737355	0.947	rs31585	chr5:130999082	A/G	cg25547332	chr5:131281432	NA	0.44	6.6	0.31	1.24e-10	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.27	0.37	1.73e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg18016565	chr1:150552671	MCL1	0.42	7.72	0.35	8.76e-14	Tonsillectomy;
LUAD	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.35	-0.45	1.56e-22	Monocyte percentage of white cells;
LUAD	cis	rs454510	0.542	rs10754417	chr1:120177454	G/T	cg11530693	chr1:120165357	ZNF697	0.43	7.02	0.32	8.94e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18876405	chr7:65276391	NA	-0.42	-6.76	-0.31	4.59e-11	Aortic root size;
LUAD	cis	rs68170813	0.641	rs4730228	chr7:106904077	T/C	cg02696742	chr7:106810147	HBP1	-0.78	-10.87	-0.47	1.93e-24	Coronary artery disease;
LUAD	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg19773385	chr1:10388646	KIF1B	-0.43	-7.07	-0.33	6.37e-12	Hepatocellular carcinoma;
LUAD	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg15147215	chr3:52552868	STAB1	-0.37	-6.9	-0.32	1.85e-11	Bipolar disorder;
LUAD	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg27411982	chr8:10470053	RP1L1	0.38	6.88	0.32	2.21e-11	Retinal vascular caliber;
LUAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-10.93	-0.47	1.17e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs10203711	0.866	rs66849943	chr2:239580956	T/C	cg14580085	chr2:239553406	NA	0.4	8.35	0.38	9.59e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs829883	0.659	rs4762495	chr12:98934105	C/T	cg25150519	chr12:98850993	NA	-0.5	-7.9	-0.36	2.44e-14	Colorectal adenoma (advanced);
LUAD	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg10645314	chr2:3704589	ALLC	-0.59	-9.4	-0.42	3.52e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg12575136	chr18:32820987	ZNF397	0.45	7.11	0.33	4.93e-12	White blood cell count;
LUAD	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg15208524	chr1:10270712	KIF1B	0.43	6.48	0.3	2.52e-10	Hepatocellular carcinoma;
LUAD	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg15921436	chr17:44337874	NA	0.89	11.64	0.49	2.26e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.74	10.28	0.45	2.79e-22	Smoking behavior;
LUAD	cis	rs986417	0.901	rs7157458	chr14:60999852	C/T	cg27398547	chr14:60952738	C14orf39	0.64	8.01	0.36	1.1e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg19761014	chr17:28927070	LRRC37B2	0.71	6.36	0.3	5.3e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1843834	0.898	rs2014887	chr2:225520082	A/G	cg22455342	chr2:225449267	CUL3	0.45	6.75	0.31	4.83e-11	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.4	-0.45	1.03e-22	Glomerular filtration rate;
LUAD	cis	rs9902453	0.904	rs11080115	chr17:28408070	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-9.83	-0.43	1.16e-20	Coffee consumption (cups per day);
LUAD	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg13180566	chr4:1052158	NA	-0.4	-6.73	-0.31	5.71e-11	Recombination rate (females);
LUAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08677398	chr8:58056175	NA	0.46	6.54	0.3	1.76e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26314531	chr2:26401878	FAM59B	-0.61	-8.27	-0.37	1.75e-15	Gut microbiome composition (summer);
LUAD	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg17264618	chr3:40429014	ENTPD3	0.42	8.5	0.38	3.18e-16	Renal cell carcinoma;
LUAD	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg09658497	chr7:2847517	GNA12	-0.44	-7.48	-0.34	4.22e-13	Height;
LUAD	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg26384229	chr12:38710491	ALG10B	0.4	6.67	0.31	8.05e-11	Bladder cancer;
LUAD	trans	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg16011800	chr17:1958478	HIC1	-0.56	-8.01	-0.36	1.11e-14	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.77	0.53	7.85e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg00666640	chr1:248458726	OR2T12	0.29	6.72	0.31	5.93e-11	Common traits (Other);
LUAD	cis	rs2692947	0.759	rs1917890	chr2:96672001	C/T	cg23100626	chr2:96804247	ASTL	0.3	7.86	0.36	3.21e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.84	0.32	2.73e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg12179176	chr11:130786555	SNX19	0.55	9.29	0.41	8.21e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-8.56	-0.38	2.17e-16	Neutrophil percentage of white cells;
LUAD	cis	rs1448094	0.836	rs7484454	chr12:86425576	A/G	cg00310523	chr12:86230176	RASSF9	0.35	7.33	0.34	1.16e-12	Major depressive disorder;
LUAD	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg07741184	chr6:167504864	NA	0.29	7.03	0.32	8.43e-12	Crohn's disease;
LUAD	cis	rs713477	0.967	rs12887653	chr14:55911030	T/A	cg13175173	chr14:55914753	NA	-0.33	-6.94	-0.32	1.44e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg07570687	chr10:102243282	WNT8B	0.48	7.34	0.34	1.09e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs68170813	0.559	rs3801958	chr7:106961139	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.46	-0.45	6.5e-23	Coronary artery disease;
LUAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg27454412	chr7:1067447	C7orf50	0.44	7.01	0.32	9.47e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.51	-9.06	-0.4	4.94e-18	Lymphocyte counts;
LUAD	trans	rs55986470	0.641	rs11904817	chr2:239382914	G/T	cg01134436	chr17:81009848	B3GNTL1	0.54	6.54	0.3	1.83e-10	Chronotype;
LUAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg13560548	chr3:10150139	C3orf24	0.42	6.82	0.31	3.19e-11	Alzheimer's disease;
LUAD	cis	rs3750965	0.881	rs61057353	chr11:68817050	C/G	cg06818126	chr11:68850279	TPCN2	-0.46	-6.57	-0.3	1.48e-10	Hair color;
LUAD	trans	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg19676328	chr12:49525230	TUBA1B	-0.7	-11.1	-0.47	2.69e-25	Total cholesterol levels;
LUAD	cis	rs8048589	0.603	rs2457193	chr16:12178797	C/T	cg03816625	chr16:12192430	SNX29	0.47	7.24	0.33	2.1e-12	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	trans	rs853679	0.607	rs13204012	chr6:28201531	G/A	cg01620082	chr3:125678407	NA	-1.1	-10.34	-0.45	1.67e-22	Depression;
LUAD	cis	rs6960043	0.714	rs7784091	chr7:15047637	A/G	cg19272540	chr7:15055459	NA	-0.34	-7.54	-0.34	2.96e-13	Type 2 diabetes;
LUAD	cis	rs10489202	1.000	rs7523437	chr1:168029365	A/G	cg24449463	chr1:168025552	DCAF6	-0.59	-7.36	-0.34	9.67e-13	Schizophrenia;
LUAD	trans	rs7944735	0.817	rs7101582	chr11:47714610	G/A	cg15704280	chr7:45808275	SEPT13	0.54	7.2	0.33	2.7e-12	Intraocular pressure;
LUAD	cis	rs1881396	0.891	rs2141372	chr2:27827196	G/T	cg27432699	chr2:27873401	GPN1	0.45	6.58	0.3	1.36e-10	Nonalcoholic fatty liver disease;
LUAD	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-7.85	-0.36	3.54e-14	Total cholesterol levels;
LUAD	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg04772025	chr11:68637568	NA	0.58	9.14	0.41	2.63e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-8.15	-0.37	4.14e-15	Menarche (age at onset);
LUAD	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg12908607	chr1:44402522	ARTN	-0.52	-9.95	-0.44	4.2e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7666738	0.657	rs13102002	chr4:98617794	T/C	cg17366294	chr4:99064904	C4orf37	0.61	9.62	0.42	5.92e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg06618935	chr21:46677482	NA	-0.47	-9.56	-0.42	1.01e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs16958440	0.867	rs77599321	chr18:44689642	T/C	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08219700	chr8:58056026	NA	0.56	7.72	0.35	8.46e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg21724239	chr8:58056113	NA	0.63	8.11	0.37	5.45e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg04775059	chr7:64541387	NA	-0.51	-6.97	-0.32	1.21e-11	Aortic root size;
LUAD	cis	rs7809950	0.954	rs2520242	chr7:107136320	G/T	cg23024343	chr7:107201750	COG5	0.75	12.68	0.52	1.82e-31	Coronary artery disease;
LUAD	cis	rs9462027	0.675	rs9296132	chr6:34777531	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.84	-0.39	2.6e-17	Systemic lupus erythematosus;
LUAD	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg18200150	chr17:30822561	MYO1D	0.72	15.57	0.6	1.58e-43	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1865721	1.000	rs62089508	chr18:73193344	C/T	cg26385618	chr18:73139727	C18orf62	-0.41	-7.48	-0.34	4.31e-13	Intelligence;
LUAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg22535103	chr8:58192502	C8orf71	-0.75	-8.88	-0.4	2e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs300703	0.654	rs401364	chr2:119493	G/A	cg21211680	chr2:198530	NA	-0.62	-7.79	-0.35	5.29e-14	Blood protein levels;
LUAD	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg07936489	chr17:37558343	FBXL20	-0.55	-6.85	-0.32	2.59e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg02527881	chr3:46936655	PTH1R	-0.44	-8.63	-0.39	1.27e-16	Colorectal cancer;
LUAD	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg16479474	chr6:28041457	NA	0.46	7.65	0.35	1.41e-13	Depression;
LUAD	cis	rs7833986	0.534	rs2458083	chr8:56898785	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	14.42	0.57	1.2e-38	Height;
LUAD	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.7	-0.61	4.27e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1950500	0.565	rs3181248	chr14:24808168	G/A	cg22990158	chr14:24802150	ADCY4	-0.58	-10.88	-0.47	1.81e-24	Height;
LUAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg18402987	chr7:1209562	NA	0.78	9.72	0.43	2.7e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11771526	0.786	rs11768955	chr7:32378706	T/C	cg13207630	chr7:32358064	NA	0.74	7.68	0.35	1.12e-13	Body mass index;
LUAD	trans	rs1325195	0.507	rs10798652	chr1:179061427	A/G	cg11624085	chr17:8464688	MYH10	0.49	7.67	0.35	1.19e-13	IgE grass sensitization;
LUAD	cis	rs1372520	0.684	rs356191	chr4:90688120	G/A	cg15133208	chr4:90757351	SNCA	0.48	6.99	0.32	1.09e-11	Neuroticism;
LUAD	cis	rs6906287	0.631	rs2798321	chr6:118991602	G/T	cg05564266	chr6:118973597	C6orf204	0.36	7.51	0.34	3.61e-13	Electrocardiographic conduction measures;
LUAD	cis	rs6984449	0.508	rs62496184	chr8:19319423	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.29	-6.78	-0.31	3.94e-11	Educational attainment;
LUAD	cis	rs9807989	1.000	rs9807989	chr2:102971200	T/C	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.05e-10	Asthma;
LUAD	cis	rs6906287	0.647	rs2213857	chr6:118806780	A/G	cg21191810	chr6:118973309	C6orf204	0.49	9.67	0.43	4.1e-20	Electrocardiographic conduction measures;
LUAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg07217954	chr7:1067459	C7orf50	0.46	7.12	0.33	4.76e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg04398451	chr17:18023971	MYO15A	-0.63	-11.53	-0.49	6.24e-27	Total body bone mineral density;
LUAD	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg01579765	chr21:45077557	HSF2BP	-0.56	-12.51	-0.52	9.23e-31	Mean corpuscular volume;
LUAD	trans	rs1728785	1.000	rs1099296	chr16:68588653	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.3	0.45	2.43e-22	Ulcerative colitis;
LUAD	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.28	-0.57	5.01e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg14416269	chr4:6271139	WFS1	0.61	12.79	0.53	7.02e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg06558623	chr16:89946397	TCF25	1.12	12.18	0.51	1.78e-29	Skin colour saturation;
LUAD	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.06	0.32	6.71e-12	Depression;
LUAD	trans	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.65	-0.31	9.36e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1113500	0.933	rs4517375	chr1:108638330	A/C	cg06207961	chr1:108661230	NA	-0.43	-8.03	-0.36	9.92e-15	Growth-regulated protein alpha levels;
LUAD	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	10.66	0.46	1.15e-23	Resting heart rate;
LUAD	cis	rs1448094	0.872	rs12322940	chr12:86406708	G/C	cg06740227	chr12:86229804	RASSF9	0.39	7.19	0.33	2.95e-12	Major depressive disorder;
LUAD	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.56	-10.08	-0.44	1.45e-21	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs4601821	0.823	rs4938013	chr11:113264470	A/C	cg14159747	chr11:113255604	NA	0.48	8.96	0.4	1.04e-17	Alcoholic chronic pancreatitis;
LUAD	cis	rs870825	0.616	rs1401361	chr4:185643742	G/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.06	0.56	4e-37	Blood protein levels;
LUAD	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.44	-0.42	2.51e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.66	-0.35	1.26e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg21016266	chr12:122356598	WDR66	0.62	10.8	0.47	3.44e-24	Mean corpuscular volume;
LUAD	cis	rs7937890	0.559	rs10766184	chr11:14542577	A/G	cg06199346	chr11:14280333	SPON1	-0.32	-6.43	-0.3	3.38e-10	Mitochondrial DNA levels;
LUAD	cis	rs7589342	0.894	rs7557976	chr2:106435061	C/A	cg16077055	chr2:106428750	NCK2	0.36	6.39	0.3	4.26e-10	Addiction;
LUAD	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg05283184	chr6:79620031	NA	-0.6	-11.96	-0.5	1.4e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs11971779	0.618	rs9640925	chr7:139085288	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs4285028	0.948	rs6790281	chr3:121665543	C/A	cg20356878	chr3:121714668	ILDR1	-0.49	-6.56	-0.3	1.58e-10	Multiple sclerosis;
LUAD	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06112835	chr11:68658793	MRPL21	0.53	9.38	0.41	4.1e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg01884057	chr2:25150051	NA	0.31	6.63	0.31	1.02e-10	Body mass index;
LUAD	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg04727924	chr7:799746	HEATR2	-0.59	-7.42	-0.34	6.4e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs12681287	0.640	rs4587306	chr8:87385511	T/C	cg00550725	chr8:87521180	FAM82B	-0.47	-6.73	-0.31	5.71e-11	Caudate activity during reward;
LUAD	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg09365446	chr1:150670422	GOLPH3L	-0.42	-7.17	-0.33	3.44e-12	Tonsillectomy;
LUAD	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg21963583	chr11:68658836	MRPL21	0.65	11.57	0.49	4.43e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg08645402	chr16:4508243	NA	0.58	11.04	0.47	4.43e-25	Schizophrenia;
LUAD	cis	rs2425143	1.000	rs4504072	chr20:34448773	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.18	-0.33	3.25e-12	Blood protein levels;
LUAD	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg10589385	chr1:150898437	SETDB1	0.41	7.75	0.35	6.75e-14	Tonsillectomy;
LUAD	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg27661571	chr11:113659931	NA	-0.56	-7.19	-0.33	3.05e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs4460629	0.521	rs4361977	chr1:155076079	C/T	cg23973274	chr1:155060172	NA	-0.45	-7.87	-0.36	3.01e-14	Serum magnesium levels;
LUAD	cis	rs67311347	0.544	rs2278930	chr3:40351092	C/T	cg02782426	chr3:40428986	ENTPD3	0.35	7.48	0.34	4.25e-13	Renal cell carcinoma;
LUAD	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.95	0.4	1.14e-17	Gut microbiome composition (summer);
LUAD	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg16325326	chr1:53192061	ZYG11B	-0.5	-8.01	-0.36	1.14e-14	Monocyte count;
LUAD	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.09	-23.46	-0.75	1.51e-78	Ulcerative colitis;
LUAD	cis	rs8060686	0.516	rs7197756	chr16:68275516	A/C	cg26727032	chr16:67993705	SLC12A4	-0.5	-8.36	-0.38	9.17e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg16479474	chr6:28041457	NA	0.38	6.57	0.3	1.51e-10	Parkinson's disease;
LUAD	cis	rs9807989	0.839	rs1974675	chr2:102986375	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	6.36	0.3	5.16e-10	Asthma;
LUAD	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22307029	chr19:49891270	CCDC155	0.63	10.33	0.45	1.84e-22	Multiple sclerosis;
LUAD	cis	rs6484504	0.576	rs158139	chr11:31216076	C/T	cg14844989	chr11:31128820	NA	-0.44	-8.2	-0.37	2.96e-15	Red blood cell count;
LUAD	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-23.31	-0.75	6.84e-78	Height;
LUAD	cis	rs832540	0.519	rs10940518	chr5:56270794	C/T	cg12311346	chr5:56204834	C5orf35	-0.52	-8.41	-0.38	6.21e-16	Coronary artery disease;
LUAD	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg19622623	chr12:86230825	RASSF9	0.43	7.67	0.35	1.19e-13	Major depressive disorder;
LUAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg15117754	chr3:10150083	C3orf24	0.44	7.12	0.33	4.71e-12	Alzheimer's disease;
LUAD	cis	rs7737355	0.812	rs257391	chr5:130740005	A/C	cg06307176	chr5:131281290	NA	0.4	6.55	0.3	1.66e-10	Life satisfaction;
LUAD	cis	rs9473147	0.516	rs10948367	chr6:47585615	A/G	cg20196966	chr6:47445060	CD2AP	0.43	6.99	0.32	1.1e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg22532475	chr10:104410764	TRIM8	-0.43	-7.94	-0.36	1.8e-14	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg00933542	chr6:150070202	PCMT1	0.44	9.62	0.42	6.29e-20	Lung cancer;
LUAD	cis	rs2224391	0.628	rs6913120	chr6:5260505	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.61	-9.05	-0.4	5.37e-18	Height;
LUAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg00106254	chr7:1943704	MAD1L1	-0.6	-9.05	-0.4	5.34e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22857025	chr5:266934	NA	-1.04	-13.14	-0.54	2.54e-33	Breast cancer;
LUAD	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg15704280	chr7:45808275	SEPT13	0.63	8.42	0.38	5.71e-16	Axial length;
LUAD	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg03433033	chr1:76189801	ACADM	0.46	6.74	0.31	5.33e-11	Daytime sleep phenotypes;
LUAD	cis	rs1595825	0.735	rs2164327	chr2:198726773	C/T	cg00361562	chr2:198649771	BOLL	-0.48	-6.88	-0.32	2.12e-11	Ulcerative colitis;
LUAD	trans	rs8002861	0.727	rs9525850	chr13:44402100	C/T	cg17145862	chr1:211918768	LPGAT1	-0.55	-10.83	-0.47	2.68e-24	Leprosy;
LUAD	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg15181151	chr6:150070149	PCMT1	0.39	7.8	0.35	5e-14	Lung cancer;
LUAD	cis	rs4006360	0.657	rs72625994	chr17:39253749	T/C	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.31	0.37	1.27e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7017914	0.934	rs7006615	chr8:71639807	T/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-10.47	-0.45	5.7e-23	Bipolar disorder;
LUAD	cis	rs9747201	1.000	rs67588022	chr17:80176071	G/A	cg18209359	chr17:80159595	CCDC57	-0.38	-6.4	-0.3	4.23e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs7395662	0.804	rs8186428	chr11:48734677	C/T	cg15704280	chr7:45808275	SEPT13	-0.45	-7.12	-0.33	4.67e-12	HDL cholesterol;
LUAD	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg02423579	chr7:2872169	GNA12	-0.55	-9.09	-0.4	3.93e-18	Height;
LUAD	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.49	8.05	0.36	8.71e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs4889855	0.614	rs9892081	chr17:78484484	A/C	cg16591659	chr17:78472290	NA	0.52	8.36	0.38	9.37e-16	Fractional excretion of uric acid;
LUAD	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21582582	chr3:182698605	DCUN1D1	0.6	10.15	0.44	8.01e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs55665837	1.000	rs10832256	chr11:14442875	G/A	cg19336497	chr11:14380999	RRAS2	-0.51	-10.33	-0.45	1.85e-22	Vitamin D levels;
LUAD	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.46	-0.38	4.4e-16	Bipolar disorder and schizophrenia;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg26141063	chr18:32870200	ZNF271;ZNF397OS	-0.42	-7.39	-0.34	7.99e-13	Schizophrenia;
LUAD	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg16325326	chr1:53192061	ZYG11B	0.54	9.35	0.41	5.07e-19	Monocyte count;
LUAD	cis	rs79349575	0.721	rs2291725	chr17:47039132	T/C	cg26022315	chr17:47021804	SNF8	0.41	7.27	0.33	1.81e-12	Type 2 diabetes;
LUAD	cis	rs9902453	0.715	rs2628176	chr17:28139292	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-9.75	-0.43	2.09e-20	Coffee consumption (cups per day);
LUAD	cis	rs2806561	0.964	rs1757041	chr1:23506063	G/A	cg19743168	chr1:23544995	NA	0.39	7.17	0.33	3.29e-12	Height;
LUAD	trans	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.7	13.97	0.56	1.02e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg12564285	chr5:131593104	PDLIM4	-0.39	-6.7	-0.31	6.71e-11	Breast cancer;
LUAD	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.7	14.45	0.57	9.31e-39	Myeloid white cell count;
LUAD	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg12193833	chr17:30244370	NA	0.53	6.64	0.31	9.45e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg10556349	chr10:835070	NA	0.46	7.21	0.33	2.59e-12	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs6840360	0.571	rs10007653	chr4:152524055	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.72	-0.31	5.93e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs11165623	0.602	rs4127309	chr1:97006892	T/C	cg10631902	chr5:14652156	NA	-0.42	-7.4	-0.34	7.31e-13	Hip circumference;Waist circumference;
LUAD	cis	rs4702	0.591	rs7183988	chr15:91428589	T/G	cg05469396	chr15:91419421	FURIN	0.46	7.91	0.36	2.19e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.39	0.34	7.75e-13	Bipolar disorder;
LUAD	cis	rs41311933	0.656	rs7027797	chr9:123771799	T/C	cg13567360	chr9:123745713	C5	-0.68	-8.12	-0.37	4.99e-15	Coronary artery disease;
LUAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13126279	chr21:47581558	C21orf56	-0.53	-8.71	-0.39	7.11e-17	Testicular germ cell tumor;
LUAD	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg00745463	chr17:30367425	LRRC37B	-1.06	-12.65	-0.52	2.46e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg19163074	chr7:65112434	INTS4L2	0.43	6.73	0.31	5.62e-11	Aortic root size;
LUAD	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg27432699	chr2:27873401	GPN1	-0.38	-6.49	-0.3	2.47e-10	Total body bone mineral density;
LUAD	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg00933542	chr6:150070202	PCMT1	0.45	9.56	0.42	9.62e-20	Lung cancer;
LUAD	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg09517075	chr8:22133004	PIWIL2	0.47	8.62	0.39	1.32e-16	Hypertriglyceridemia;
LUAD	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18876405	chr7:65276391	NA	-0.4	-6.4	-0.3	4.19e-10	Aortic root size;
LUAD	cis	rs17152411	1.000	rs17152448	chr10:126675645	C/G	cg07906193	chr10:126599966	NA	0.54	7.35	0.34	1.06e-12	Height;
LUAD	cis	rs12620999	0.555	rs4073396	chr2:238111471	A/C	cg23555395	chr2:238036564	NA	0.48	7.12	0.33	4.79e-12	Systemic lupus erythematosus;
LUAD	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.44	6.77	0.31	4.43e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs701145	0.585	rs357473	chr3:153895147	C/T	cg17054900	chr3:154042577	DHX36	0.59	6.43	0.3	3.46e-10	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.26e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg19622623	chr12:86230825	RASSF9	-0.36	-6.64	-0.31	9.5e-11	Major depressive disorder;
LUAD	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg05425664	chr17:57184151	TRIM37	0.44	7.85	0.36	3.4e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg16535667	chr11:65410126	SIPA1	-0.5	-7.43	-0.34	6.25e-13	Blood pressure (age interaction);
LUAD	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg11822812	chr5:140052017	DND1	-0.42	-7.53	-0.34	3.08e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	trans	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg24644049	chr4:85504048	CDS1	0.84	7.69	0.35	1.02e-13	Skin colour saturation;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24969022	chr7:6866040	C7orf28B	-0.43	-6.73	-0.31	5.47e-11	Height;
LUAD	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg23281280	chr6:28129359	ZNF389	0.46	6.65	0.31	9.18e-11	Depression;
LUAD	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg25173405	chr17:45401733	C17orf57	-0.52	-8.81	-0.39	3.2e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg18755752	chr8:142205143	DENND3	0.77	15.37	0.6	1.11e-42	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg06108461	chr20:60628389	TAF4	-1.11	-20.41	-0.7	5.84e-65	Body mass index;
LUAD	cis	rs1997103	1.000	rs10252413	chr7:55396740	C/G	cg17469321	chr7:55412551	NA	0.66	11.35	0.48	3.1e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg03929089	chr4:120376271	NA	-0.91	-16.8	-0.63	6.58e-49	Height;
LUAD	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg01802117	chr1:53393560	SCP2	-0.33	-6.47	-0.3	2.64e-10	Monocyte count;
LUAD	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21659725	chr3:3221576	CRBN	-0.61	-10.5	-0.45	4.37e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg15147215	chr3:52552868	STAB1	-0.38	-7.13	-0.33	4.3e-12	Electroencephalogram traits;
LUAD	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg03929089	chr4:120376271	NA	-0.9	-17.23	-0.64	8.92e-51	Height;
LUAD	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg05425664	chr17:57184151	TRIM37	0.39	6.68	0.31	7.56e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg21548813	chr6:291882	DUSP22	-0.52	-8.29	-0.37	1.47e-15	Menopause (age at onset);
LUAD	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg00701064	chr4:6280414	WFS1	0.67	14.65	0.58	1.3e-39	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7095607	0.813	rs10823148	chr10:69926334	C/G	cg18986048	chr10:69913749	MYPN	0.37	6.4	0.3	4.18e-10	Lung function (FVC);
LUAD	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg01200585	chr1:228362443	C1orf69	-0.4	-7.24	-0.33	2.2e-12	Diastolic blood pressure;
LUAD	cis	rs7520050	0.902	rs7514192	chr1:46248977	A/G	cg06784218	chr1:46089804	CCDC17	-0.3	-6.53	-0.3	1.87e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.36	-7.12	-0.33	4.82e-12	IgG glycosylation;
LUAD	trans	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg25482853	chr8:67687455	SGK3	0.68	10.43	0.45	7.86e-23	Obesity-related traits;
LUAD	cis	rs3823572	0.542	rs11767663	chr7:133630596	T/C	cg03336402	chr7:133662267	EXOC4	0.44	7.83	0.36	4.05e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg05283184	chr6:79620031	NA	-0.43	-7.56	-0.35	2.46e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg18277682	chr1:228362509	C1orf69	-0.38	-6.44	-0.3	3.25e-10	Diastolic blood pressure;
LUAD	trans	rs877282	0.945	rs71491311	chr10:791747	G/A	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg24515799	chr6:149867235	PPIL4	0.43	6.35	0.3	5.51e-10	QT interval;
LUAD	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg07305463	chr2:136567211	LCT	-0.37	-7.03	-0.32	8.18e-12	Mosquito bite size;
LUAD	cis	rs6577655	0.517	rs2241893	chr8:135586659	C/T	cg17885191	chr8:135476712	NA	0.64	8.5	0.38	3.26e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.76	0.31	4.45e-11	Parkinson's disease;
LUAD	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg25251562	chr2:3704773	ALLC	-0.49	-7.01	-0.32	9.28e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg02221422	chr11:68192511	LRP5	-0.43	-7.12	-0.33	4.79e-12	Total body bone mineral density;
LUAD	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg11247378	chr22:39784982	NA	-0.59	-8.15	-0.37	4.21e-15	IgG glycosylation;
LUAD	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs55823223	0.564	rs2034947	chr17:73863929	T/C	cg04225089	chr17:73874465	TRIM47	-0.39	-6.95	-0.32	1.41e-11	Psoriasis;
LUAD	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg10792982	chr14:105748885	BRF1	0.44	9.66	0.43	4.53e-20	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs11771526	1.000	rs11770367	chr7:32354319	C/T	cg27511599	chr7:32358540	NA	0.62	7.02	0.32	8.73e-12	Body mass index;
LUAD	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg04990556	chr1:26633338	UBXN11	0.46	7.23	0.33	2.26e-12	Obesity-related traits;
LUAD	cis	rs4946717	0.740	rs6941301	chr6:106472457	T/C	cg02270332	chr6:106475062	NA	0.44	8.83	0.39	2.72e-17	Inflammatory bowel disease;
LUAD	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg20283391	chr11:68216788	NA	-0.42	-6.56	-0.3	1.56e-10	Total body bone mineral density;
LUAD	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg16647868	chr5:131706066	SLC22A5	0.49	7.86	0.36	3.13e-14	Breast cancer;
LUAD	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg20203395	chr5:56204925	C5orf35	-0.82	-11.58	-0.49	4.04e-27	Initial pursuit acceleration;
LUAD	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg14582100	chr15:45693742	SPATA5L1	0.64	12.46	0.52	1.45e-30	Homoarginine levels;
LUAD	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.65	-0.31	8.93e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg23954153	chr1:44402353	ARTN	-0.37	-6.97	-0.32	1.19e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg08798685	chr6:27730294	NA	-0.68	-6.69	-0.31	7.08e-11	Depression;
LUAD	trans	rs9393777	0.920	rs13212562	chr6:27300310	A/G	cg01620082	chr3:125678407	NA	-0.64	-7.18	-0.33	3.19e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg15704280	chr7:45808275	SEPT13	-0.6	-8.09	-0.37	6.47e-15	Axial length;
LUAD	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg24818145	chr4:99064322	C4orf37	0.41	6.89	0.32	2.04e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg05215272	chr17:6899095	ALOX12	-0.43	-8.65	-0.39	1.08e-16	Tonsillectomy;
LUAD	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg15309053	chr8:964076	NA	0.42	8.83	0.39	2.88e-17	Schizophrenia;
LUAD	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg21153622	chr11:89784906	NA	-0.32	-6.44	-0.3	3.28e-10	HDL cholesterol;
LUAD	cis	rs4523957	0.928	rs216219	chr17:2147291	T/C	cg16513277	chr17:2031491	SMG6	0.77	14.59	0.58	2.5e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg12564285	chr5:131593104	PDLIM4	0.37	6.48	0.3	2.54e-10	Breast cancer;
LUAD	cis	rs13315871	0.860	rs17059098	chr3:58255739	G/A	cg20936604	chr3:58311152	NA	-0.78	-8.09	-0.37	6.39e-15	Cholesterol, total;
LUAD	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg10164272	chr16:89456328	ANKRD11	0.41	6.5	0.3	2.31e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs7737355	0.947	rs2191001	chr5:131096677	C/G	cg06307176	chr5:131281290	NA	0.51	8.07	0.37	7.09e-15	Life satisfaction;
LUAD	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg00255919	chr5:131827918	IRF1	-0.51	-12.04	-0.51	6.34e-29	Asthma (sex interaction);
LUAD	cis	rs4953076	0.573	rs6734443	chr2:44408282	G/C	cg04920474	chr2:44395004	PPM1B	0.56	8.6	0.39	1.56e-16	Height;
LUAD	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg19875535	chr5:140030758	IK	-0.39	-6.61	-0.31	1.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg06671706	chr8:8559999	CLDN23	0.66	11.4	0.48	1.87e-26	Obesity-related traits;
LUAD	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg14828511	chr1:107599125	PRMT6	0.53	8.65	0.39	1.06e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7107174	1.000	rs2244508	chr11:77948515	T/A	cg02023728	chr11:77925099	USP35	0.45	6.78	0.31	4.06e-11	Testicular germ cell tumor;
LUAD	cis	rs7089973	0.872	rs60820172	chr10:116625891	C/T	cg25233709	chr10:116636983	FAM160B1	0.39	7.56	0.35	2.48e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg13334819	chr7:99746414	C7orf59	-0.64	-9.68	-0.43	3.63e-20	Coronary artery disease;
LUAD	cis	rs9863	0.828	rs11057408	chr12:124464836	G/T	cg17723958	chr12:124429295	CCDC92	-0.42	-7.05	-0.32	7.23e-12	White blood cell count;
LUAD	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg23283495	chr1:209979779	IRF6	0.74	8.98	0.4	9.29e-18	Coronary artery disease;
LUAD	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg10589385	chr1:150898437	SETDB1	0.43	7.9	0.36	2.5e-14	Melanoma;
LUAD	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg18827107	chr12:86230957	RASSF9	-0.54	-9.68	-0.43	3.74e-20	Major depressive disorder;
LUAD	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg07010633	chr17:73824396	UNC13D	-0.33	-6.65	-0.31	9.05e-11	White matter hyperintensity burden;
LUAD	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg13319975	chr6:146136371	FBXO30	0.59	9.9	0.43	6.15e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3784262	0.565	rs4646605	chr15:58287912	C/A	cg12031962	chr15:58353849	ALDH1A2	0.38	7.26	0.33	1.87e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs8060686	0.623	rs56303487	chr16:68029739	C/T	cg26727032	chr16:67993705	SLC12A4	-0.45	-7.08	-0.33	6.07e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg23131131	chr22:24373011	LOC391322	-0.59	-9.86	-0.43	8.75e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg04989706	chr14:50066350	PPIL5	-0.51	-7.69	-0.35	1.01e-13	Carotid intima media thickness;
LUAD	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg07917127	chr4:99064746	C4orf37	0.41	6.75	0.31	4.86e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg18944383	chr4:111397179	ENPEP	0.37	7.5	0.34	3.83e-13	Height;
LUAD	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg23649088	chr2:200775458	C2orf69	0.62	7.77	0.35	6.15e-14	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.0	0.36	1.25e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4242434	0.892	rs1809452	chr8:22491397	G/A	cg03733263	chr8:22462867	KIAA1967	0.69	11.01	0.47	5.7e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.05	-0.56	4.73e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs1595825	0.891	rs2045244	chr2:198506466	C/T	cg00982548	chr2:198649783	BOLL	-0.61	-8.63	-0.39	1.29e-16	Ulcerative colitis;
LUAD	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg19610905	chr11:61596333	FADS2	-0.58	-9.84	-0.43	1.03e-20	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs72928364	0.685	rs1375513	chr3:100771291	T/G	cg10123952	chr3:100791384	NA	0.45	6.38	0.3	4.59e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg14668632	chr7:2872130	GNA12	-0.48	-8.5	-0.38	3.24e-16	Height;
LUAD	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.78	-0.39	4.22e-17	Alzheimer's disease (late onset);
LUAD	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg03929089	chr4:120376271	NA	-0.51	-8.18	-0.37	3.47e-15	HDL cholesterol;
LUAD	cis	rs7010267	0.692	rs2073618	chr8:119964052	G/C	cg01975934	chr8:119970761	NA	-0.34	-6.52	-0.3	2.02e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs8044868	0.521	rs3852782	chr16:72169023	T/G	cg23815491	chr16:72088622	HP	0.5	9.31	0.41	7.27e-19	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg15017067	chr4:17643749	FAM184B	0.36	7.08	0.33	5.85e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19717773	chr7:2847554	GNA12	-0.56	-9.83	-0.43	1.14e-20	Height;
LUAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg04287289	chr16:89883240	FANCA	0.7	6.58	0.3	1.43e-10	Skin colour saturation;
LUAD	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	8.06	0.36	8.12e-15	Rheumatoid arthritis;
LUAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.49	0.55	9.69e-35	Prudent dietary pattern;
LUAD	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg12292205	chr6:26970375	C6orf41	-0.57	-9.97	-0.44	3.56e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg18132916	chr6:79620363	NA	-0.45	-7.79	-0.35	5.37e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs35123781	0.696	rs4912756	chr5:139070780	A/T	cg10513866	chr5:139070639	NA	0.56	9.17	0.41	2.12e-18	Schizophrenia;
LUAD	cis	rs934734	0.699	rs268138	chr2:65607294	A/G	cg11674355	chr2:65610261	SPRED2	0.36	6.49	0.3	2.4e-10	Rheumatoid arthritis;
LUAD	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg04352962	chr1:209979756	IRF6	0.51	6.53	0.3	1.93e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg15468180	chr1:107600409	PRMT6	-0.46	-7.82	-0.36	4.4e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg05617483	chr15:76483344	C15orf27	0.35	6.37	0.3	4.9e-10	Blood metabolite levels;
LUAD	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg00316803	chr15:76480434	C15orf27	-0.39	-7.3	-0.33	1.48e-12	Blood metabolite levels;
LUAD	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.92	-0.32	1.67e-11	Height;
LUAD	cis	rs68170813	0.559	rs77605964	chr7:106962948	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-10.36	-0.45	1.49e-22	Coronary artery disease;
LUAD	cis	rs731174	0.959	rs7527344	chr1:38191560	C/A	cg06917450	chr1:38156652	C1orf109	-0.44	-7.29	-0.33	1.54e-12	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg22920501	chr2:26401640	FAM59B	0.97	13.78	0.56	6.06e-36	Gut microbiome composition (summer);
LUAD	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.26	-0.33	1.88e-12	Type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg17063962	chr7:91808500	NA	0.67	11.95	0.5	1.49e-28	Breast cancer;
LUAD	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.75	0.53	9.8e-32	Cognitive ability;
LUAD	cis	rs4853036	1.000	rs12614581	chr2:70079400	C/G	cg02498382	chr2:70120550	SNRNP27	-0.5	-8.11	-0.37	5.37e-15	Colorectal or endometrial cancer;
LUAD	cis	rs704	0.790	rs708100	chr17:26688663	G/A	cg10342447	chr17:26645325	TMEM97	-0.33	-6.75	-0.31	4.96e-11	Osteoprotegerin levels;
LUAD	cis	rs870825	0.616	rs2090590	chr4:185647850	A/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg01689657	chr7:91764605	CYP51A1	-0.3	-7.08	-0.33	5.97e-12	Breast cancer;
LUAD	cis	rs2281845	0.826	rs4915214	chr1:201076290	T/A	cg22815214	chr1:201083145	CACNA1S	0.48	8.11	0.37	5.51e-15	Permanent tooth development;
LUAD	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg18252515	chr7:66147081	NA	-0.62	-7.0	-0.32	9.8e-12	Gout;
LUAD	trans	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg14917512	chr19:3094685	GNA11	-0.58	-6.85	-0.32	2.54e-11	Diabetic kidney disease;
LUAD	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg15556689	chr8:8085844	FLJ10661	0.39	6.35	0.3	5.48e-10	Systolic blood pressure;
LUAD	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.78	-0.31	4.09e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs11971779	0.523	rs10279160	chr7:139090761	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg16479474	chr6:28041457	NA	0.36	6.91	0.32	1.75e-11	Parkinson's disease;
LUAD	cis	rs13144136	0.687	rs13119277	chr4:10658129	C/T	cg10242279	chr4:10666415	CLNK	-0.31	-6.44	-0.3	3.33e-10	Resistance to antihypertensive treatment in hypertension;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11437374	chr5:169010780	CCDC99	-0.57	-6.87	-0.32	2.26e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs864537	0.590	rs1214596	chr1:167427170	A/T	cg22356347	chr1:167427500	CD247	0.5	10.0	0.44	2.73e-21	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs4786125	0.665	rs6500857	chr16:6903364	C/T	cg03623568	chr16:6915990	A2BP1	-0.49	-10.65	-0.46	1.26e-23	Heart rate variability traits (SDNN);
LUAD	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg25452165	chr22:42524984	CYP2D6	-0.38	-6.42	-0.3	3.76e-10	Schizophrenia;
LUAD	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg00666640	chr1:248458726	OR2T12	0.3	7.27	0.33	1.8e-12	Common traits (Other);
LUAD	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	7.94e-19	Tonsillectomy;
LUAD	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg19622623	chr12:86230825	RASSF9	-0.45	-7.99	-0.36	1.27e-14	Major depressive disorder;
LUAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg04234412	chr22:24373322	LOC391322	-0.84	-16.25	-0.62	1.7e-46	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg25554036	chr4:6271136	WFS1	0.7	14.23	0.57	7.73e-38	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg13699009	chr12:122356056	WDR66	0.29	6.42	0.3	3.67e-10	Mean corpuscular volume;
LUAD	cis	rs933688	0.532	rs11740007	chr5:90545498	C/G	cg17503389	chr5:90575422	NA	-0.44	-6.96	-0.32	1.32e-11	Smoking behavior;
LUAD	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.02	0.36	1.04e-14	Breast cancer;
LUAD	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg26384229	chr12:38710491	ALG10B	0.49	7.77	0.35	6.07e-14	Bladder cancer;
LUAD	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg00277334	chr10:82204260	NA	-0.67	-12.06	-0.51	5.53e-29	Post bronchodilator FEV1;
LUAD	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.06	0.32	7.06e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg09455208	chr3:40491958	NA	0.56	12.34	0.51	4.41e-30	Renal cell carcinoma;
LUAD	trans	rs11671005	0.610	rs2305122	chr19:59056752	G/C	cg22037779	chr5:139682734	PFDN1	-0.65	-8.62	-0.39	1.37e-16	Mean platelet volume;
LUAD	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg23260525	chr10:116636907	FAM160B1	0.47	11.0	0.47	6.26e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9914544	0.505	rs4924774	chr17:18794920	A/C	cg25390199	chr17:18761479	PRPSAP2	-0.37	-6.43	-0.3	3.39e-10	Educational attainment (years of education);
LUAD	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.27	-6.67	-0.31	8.22e-11	Coronary artery disease;
LUAD	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-6.83	-0.32	2.9e-11	Personality dimensions;
LUAD	cis	rs9581857	0.547	rs1235848	chr13:28111559	G/T	cg22138327	chr13:27999177	GTF3A	-0.67	-8.26	-0.37	1.83e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg10207527	chr1:894257	NOC2L	-0.67	-6.53	-0.3	1.88e-10	Type 2 diabetes;
LUAD	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg21856205	chr7:94953877	PON1	-0.53	-7.44	-0.34	5.72e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg26647111	chr11:31128758	NA	-0.46	-8.02	-0.36	1.08e-14	Red blood cell count;
LUAD	cis	rs12893668	0.581	rs34843146	chr14:104079864	G/A	cg13511324	chr14:104056883	C14orf153	0.26	6.39	0.3	4.29e-10	Reticulocyte count;
LUAD	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg13180566	chr4:1052158	NA	-0.4	-6.44	-0.3	3.18e-10	Recombination rate (females);
LUAD	cis	rs6714710	0.603	rs35255677	chr2:98567820	G/A	cg26665480	chr2:98280029	ACTR1B	0.49	8.07	0.37	7.26e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs7677751	0.806	rs4864847	chr4:55071953	G/A	cg17187183	chr4:55093834	PDGFRA	0.44	6.89	0.32	1.99e-11	Corneal astigmatism;
LUAD	cis	rs66569888	0.523	rs4522599	chr2:106926004	G/C	cg15412446	chr2:106886593	NA	0.59	8.51	0.38	3.04e-16	Facial morphology (factor 23);
LUAD	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.41	-18.3	-0.66	1.57e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-15.21	-0.59	5.52e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs783540	1.000	rs11631963	chr15:83318202	T/C	cg18393722	chr15:85113863	UBE2QP1	0.45	7.19	0.33	3.02e-12	Schizophrenia;
LUAD	cis	rs4604732	0.527	rs12031949	chr1:247624463	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.4	6.94	0.32	1.44e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg04990556	chr1:26633338	UBXN11	-0.39	-6.51	-0.3	2.13e-10	Obesity-related traits;
LUAD	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg26384229	chr12:38710491	ALG10B	0.47	7.67	0.35	1.16e-13	Morning vs. evening chronotype;
LUAD	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg25985355	chr7:65971099	NA	0.38	7.15	0.33	3.73e-12	Aortic root size;
LUAD	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg03433033	chr1:76189801	ACADM	-0.84	-14.89	-0.59	1.25e-40	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg02038168	chr22:39784481	NA	-0.6	-10.59	-0.46	2.06e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg17200465	chr3:40428508	ENTPD3	0.28	7.18	0.33	3.22e-12	Renal cell carcinoma;
LUAD	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg25457927	chr22:38595422	NA	-0.54	-13.83	-0.56	3.68e-36	Cutaneous nevi;
LUAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg24101359	chr6:42928495	GNMT	0.49	9.05	0.4	5.35e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg18335740	chr13:41363409	SLC25A15	0.49	8.76	0.39	4.7e-17	Lewy body disease;
LUAD	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg12863693	chr15:85201151	NMB	0.37	6.44	0.3	3.16e-10	Schizophrenia;
LUAD	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.33	-0.34	1.16e-12	Reticulocyte count;
LUAD	cis	rs12541635	0.966	rs6469023	chr8:106989558	T/C	cg10147462	chr8:107024639	NA	0.48	8.46	0.38	4.51e-16	Age of smoking initiation;
LUAD	cis	rs9487051	0.768	rs398944	chr6:109523444	T/G	cg01475377	chr6:109611718	NA	-0.37	-6.83	-0.31	3.05e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg24642844	chr7:1081250	C7orf50	-0.93	-14.03	-0.56	5.28e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg20701182	chr2:24300061	SF3B14	0.56	6.65	0.31	8.93e-11	Lymphocyte counts;
LUAD	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-6.99	-0.32	1.11e-11	Type 2 diabetes;
LUAD	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.86	0.32	2.53e-11	Schizophrenia;
LUAD	cis	rs6445967	1.000	rs13059916	chr3:58316364	A/G	cg23715586	chr3:58305044	RPP14	0.43	7.59	0.35	2.07e-13	Platelet count;
LUAD	cis	rs9341808	0.529	rs9352826	chr6:81059371	C/T	cg08355045	chr6:80787529	NA	0.48	8.1	0.37	5.84e-15	Sitting height ratio;
LUAD	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22496380	chr5:211416	CCDC127	-0.94	-13.19	-0.54	1.7e-33	Breast cancer;
LUAD	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22968622	chr17:43663579	NA	1.36	23.96	0.76	8.67e-81	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg15448220	chr1:150897856	SETDB1	0.54	9.21	0.41	1.57e-18	Melanoma;
LUAD	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.31	-0.34	1.31e-12	Coronary artery disease;
LUAD	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03517284	chr6:25882590	NA	-0.51	-7.57	-0.35	2.35e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26314531	chr2:26401878	FAM59B	0.73	9.0	0.4	7.93e-18	Gut microbiome composition (summer);
LUAD	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg13902645	chr11:5959945	NA	-0.55	-10.65	-0.46	1.3e-23	DNA methylation (variation);
LUAD	cis	rs684232	0.602	rs445268	chr17:563338	G/A	cg12384639	chr17:618140	VPS53	0.47	7.88	0.36	2.79e-14	Prostate cancer;
LUAD	cis	rs6987853	0.761	rs2974322	chr8:42424724	T/C	cg09913449	chr8:42400586	C8orf40	0.51	10.31	0.45	2.15e-22	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs13315871	1.000	rs11715445	chr3:58343888	T/C	cg12435725	chr3:58293450	RPP14	-0.71	-7.71	-0.35	9.08e-14	Cholesterol, total;
LUAD	cis	rs1595825	0.891	rs57990618	chr2:198660838	C/T	cg00982548	chr2:198649783	BOLL	-0.67	-9.08	-0.4	4.29e-18	Ulcerative colitis;
LUAD	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg02569458	chr12:86230093	RASSF9	-0.4	-7.46	-0.34	5.01e-13	Major depressive disorder;
LUAD	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg15704280	chr7:45808275	SEPT13	-1.07	-24.89	-0.77	6.98e-85	Height;
LUAD	cis	rs2041840	0.824	rs7593932	chr2:37567226	C/T	cg25727520	chr2:37576821	QPCT	-0.33	-6.81	-0.31	3.43e-11	Chronic lymphocytic leukemia;
LUAD	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg06740227	chr12:86229804	RASSF9	0.45	7.88	0.36	2.78e-14	Major depressive disorder;
LUAD	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg26373071	chr5:1325741	CLPTM1L	0.37	7.76	0.35	6.35e-14	Lung cancer;
LUAD	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg15448220	chr1:150897856	SETDB1	0.57	9.88	0.43	7.45e-21	Melanoma;
LUAD	cis	rs6906287	0.647	rs12206329	chr6:118863789	G/T	cg05564266	chr6:118973597	C6orf204	0.35	7.43	0.34	6.24e-13	Electrocardiographic conduction measures;
LUAD	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg08999081	chr20:33150536	PIGU	0.48	9.25	0.41	1.12e-18	Coronary artery disease;
LUAD	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21582582	chr3:182698605	DCUN1D1	0.6	10.38	0.45	1.19e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs9811920	0.809	rs793464	chr3:99626028	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.54	0.49	5.5e-27	Axial length;
LUAD	cis	rs240764	0.580	rs4839789	chr6:101233235	T/A	cg09795085	chr6:101329169	ASCC3	-0.43	-7.64	-0.35	1.49e-13	Neuroticism;
LUAD	cis	rs9462027	0.628	rs6937132	chr6:34799221	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.73	-0.39	5.74e-17	Systemic lupus erythematosus;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg13214185	chr14:107219616	NA	0.43	7.48	0.34	4.45e-13	Menopause (age at onset);
LUAD	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg26384229	chr12:38710491	ALG10B	0.46	7.44	0.34	5.51e-13	Bladder cancer;
LUAD	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.95	0.32	1.43e-11	Hypertriglyceridemia;
LUAD	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg10978503	chr1:24200527	CNR2	0.46	9.37	0.41	4.53e-19	Immature fraction of reticulocytes;
LUAD	trans	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg01620082	chr3:125678407	NA	-0.96	-9.83	-0.43	1.13e-20	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs62400317	0.762	rs62436369	chr6:44867539	C/G	cg20913747	chr6:44695427	NA	-0.41	-6.43	-0.3	3.5e-10	Total body bone mineral density;
LUAD	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg21918786	chr6:109611834	NA	-0.59	-10.94	-0.47	1.02e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs72772090	0.539	rs111886458	chr5:96125047	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-7.06	-0.32	7.07e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs17102423	0.685	rs7156617	chr14:65541381	G/A	cg11161011	chr14:65562177	MAX	-0.46	-7.7	-0.35	9.87e-14	Obesity-related traits;
LUAD	cis	rs7107174	1.000	rs10899489	chr11:78095373	G/T	cg19901956	chr11:77921274	USP35	-0.48	-6.72	-0.31	6.03e-11	Testicular germ cell tumor;
LUAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg02524346	chr8:600233	NA	0.87	9.34	0.41	5.72e-19	IgG glycosylation;
LUAD	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg00106254	chr7:1943704	MAD1L1	-0.45	-6.97	-0.32	1.24e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg09826364	chr7:158789723	NA	-0.4	-7.16	-0.33	3.49e-12	Facial morphology (factor 20);
LUAD	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7680126	0.633	rs4698014	chr4:10286301	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.49	-0.3	2.39e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.64	8.44	0.38	5.29e-16	Gut microbiome composition (summer);
LUAD	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.75	0.31	5.04e-11	Aortic root size;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11846912	chr15:66797229	ZWILCH;RPL4	-0.38	-6.51	-0.3	2.07e-10	Cancer;
LUAD	trans	rs79911532	0.515	rs887579	chr7:75701640	G/A	cg19862616	chr7:65841803	NCRNA00174	0.82	8.47	0.38	4e-16	Mononucleosis;
LUAD	cis	rs9469913	0.799	rs2744955	chr6:34618958	C/G	cg14254433	chr6:34482411	PACSIN1	-0.42	-6.6	-0.31	1.24e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg12908607	chr1:44402522	ARTN	-0.53	-10.21	-0.44	4.86e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg08923669	chr16:420230	MRPL28	-0.56	-10.15	-0.44	8.14e-22	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs2235649	0.623	rs8048162	chr16:1848918	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-8.18	-0.37	3.42e-15	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00030291	chr7:8302094	ICA1	-0.55	-6.61	-0.31	1.18e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04018625	chr2:171608293	NA	0.5	7.79	0.35	5.34e-14	Hepatitis;
LUAD	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs4919694	1.000	rs11191473	chr10:104710710	C/G	cg04362960	chr10:104952993	NT5C2	0.74	7.93	0.36	1.98e-14	Arsenic metabolism;
LUAD	cis	rs758324	0.853	rs6882899	chr5:131172467	G/C	cg25547332	chr5:131281432	NA	0.43	6.62	0.31	1.07e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4006360	0.646	rs6503602	chr17:39301175	A/C	cg20663846	chr17:39254439	KRTAP4-8	0.36	7.8	0.35	4.88e-14	Bipolar disorder and schizophrenia;
LUAD	trans	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg18187862	chr3:45730750	SACM1L	0.58	9.05	0.4	5.27e-18	Primary sclerosing cholangitis;
LUAD	trans	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg18187862	chr3:45730750	SACM1L	0.5	7.89	0.36	2.55e-14	Primary sclerosing cholangitis;
LUAD	trans	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg07817883	chr1:32538562	TMEM39B	0.63	8.06	0.36	8.16e-15	Monocyte percentage of white cells;
LUAD	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21028142	chr17:79581711	NPLOC4	-0.41	-8.58	-0.38	1.84e-16	Eye color traits;
LUAD	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg22920501	chr2:26401640	FAM59B	0.78	10.15	0.44	8.55e-22	Gut microbiome composition (summer);
LUAD	cis	rs17095355	0.605	rs2273740	chr10:111637635	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.76	-0.35	6.37e-14	Biliary atresia;
LUAD	cis	rs56283067	0.847	rs12215181	chr6:44736076	C/T	cg18551225	chr6:44695536	NA	-0.58	-9.54	-0.42	1.13e-19	Total body bone mineral density;
LUAD	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg06108461	chr20:60628389	TAF4	-0.77	-13.53	-0.55	6.46e-35	Body mass index;
LUAD	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.16	0.37	3.85e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02353165	chr6:42928485	GNMT	0.41	7.29	0.33	1.54e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg18944383	chr4:111397179	ENPEP	-0.51	-9.36	-0.41	4.85e-19	Coronary artery disease;
LUAD	cis	rs17095355	0.901	rs6584964	chr10:111759160	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.0	-0.36	1.23e-14	Biliary atresia;
LUAD	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.96	0.36	1.58e-14	Morning vs. evening chronotype;
LUAD	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18876405	chr7:65276391	NA	0.61	10.39	0.45	1.09e-22	Aortic root size;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02386725	chr1:162467755	UHMK1	-0.57	-7.01	-0.32	9.28e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg23029597	chr12:123009494	RSRC2	-0.53	-8.31	-0.37	1.35e-15	Body mass index;
LUAD	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg19792802	chr11:65647270	CTSW	-0.41	-6.42	-0.3	3.72e-10	Crohn's disease;
LUAD	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.7	-10.77	-0.46	4.68e-24	Chronic sinus infection;
LUAD	cis	rs7561528	0.501	rs4663104	chr2:127890786	C/G	cg08168897	chr2:127865431	BIN1	-0.41	-6.37	-0.3	4.87e-10	Alzheimer's disease;Alzheimer's disease (late onset);
LUAD	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg09117114	chr16:67998030	SLC12A4	-0.51	-6.78	-0.31	4.01e-11	Schizophrenia;
LUAD	cis	rs9902453	0.838	rs3110495	chr17:27978455	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-9.67	-0.43	4.2e-20	Coffee consumption (cups per day);
LUAD	cis	rs4790333	0.531	rs2447107	chr17:2257864	A/G	cg27406664	chr17:2294951	MNT	0.4	8.07	0.37	7.23e-15	Proinsulin levels;
LUAD	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg24578937	chr1:2090814	PRKCZ	-0.57	-11.23	-0.48	8.75e-26	Height;
LUAD	cis	rs733175	0.544	rs4698022	chr4:10304641	C/A	cg00071950	chr4:10020882	SLC2A9	-0.64	-6.73	-0.31	5.5e-11	Psychosis and Alzheimer's disease;
LUAD	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg26168224	chr5:2018326	NA	0.76	17.11	0.64	2.93e-50	Gut microbiome composition (winter);
LUAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg08888203	chr3:10149979	C3orf24	0.75	13.13	0.54	2.98e-33	Alzheimer's disease;
LUAD	cis	rs6754311	0.551	rs313526	chr2:136445526	C/T	cg07305463	chr2:136567211	LCT	-0.34	-6.4	-0.3	4.13e-10	Mosquito bite size;
LUAD	trans	rs2797160	0.547	rs9401836	chr6:125956736	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-7.37	-0.34	9.21e-13	Endometrial cancer;
LUAD	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg09537434	chr19:41945824	ATP5SL	-0.45	-7.24	-0.33	2.18e-12	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27574168	chr18:54318782	WDR7	-0.43	-6.55	-0.3	1.7e-10	Height;
LUAD	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg26597838	chr10:835615	NA	1.3	20.16	0.7	7.85e-64	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.947	rs11242078	chr5:130792035	A/C	cg06307176	chr5:131281290	NA	-0.49	-7.69	-0.35	1.02e-13	Life satisfaction;
LUAD	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.09	-0.33	5.75e-12	Total body bone mineral density;
LUAD	trans	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg01620082	chr3:125678407	NA	-0.44	-6.48	-0.3	2.51e-10	Depression;
LUAD	cis	rs3812049	0.532	rs251216	chr5:127543280	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.48	6.41	0.3	3.88e-10	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs8099014	1.000	rs4940392	chr18:56107146	G/A	cg12907477	chr18:56117327	MIR122	0.39	6.69	0.31	6.91e-11	Platelet count;
LUAD	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg23533926	chr12:111358616	MYL2	-0.41	-7.1	-0.33	5.22e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs597583	0.715	rs11216437	chr11:117394685	A/G	cg27161313	chr11:117392002	DSCAML1	0.51	8.32	0.37	1.24e-15	Putamen volume;
LUAD	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg06873352	chr17:61820015	STRADA	-0.4	-6.63	-0.31	1e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg03909863	chr11:638404	DRD4	-0.45	-6.38	-0.3	4.64e-10	Systemic lupus erythematosus;
LUAD	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg20119798	chr7:94954144	PON1	-0.49	-6.91	-0.32	1.77e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg27539214	chr16:67997921	SLC12A4	-0.61	-8.02	-0.36	1.06e-14	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2797160	1.000	rs1578794	chr6:126015469	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.58e-17	Endometrial cancer;
LUAD	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.34	-8.56	-0.38	2.04e-16	Total body bone mineral density;
LUAD	trans	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg14791747	chr16:20752902	THUMPD1	0.9	16.02	0.61	1.82e-45	Cognitive test performance;
LUAD	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg00310523	chr12:86230176	RASSF9	0.38	7.73	0.35	7.94e-14	Major depressive disorder;
LUAD	cis	rs1497828	0.956	rs2646821	chr1:217528236	C/T	cg04411442	chr1:217543379	NA	-0.37	-6.79	-0.31	3.77e-11	Dialysis-related mortality;
LUAD	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg00666640	chr1:248458726	OR2T12	0.32	7.88	0.36	2.86e-14	Common traits (Other);
LUAD	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg19875535	chr5:140030758	IK	-0.48	-8.07	-0.37	7.46e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg08029281	chr1:67600428	NA	-0.35	-6.6	-0.31	1.23e-10	Psoriasis;
LUAD	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg02012338	chr4:187126139	CYP4V2	1.07	10.24	0.45	3.78e-22	Blood protein levels;
LUAD	cis	rs11771526	0.892	rs62457540	chr7:32372199	A/G	cg13207630	chr7:32358064	NA	0.68	7.72	0.35	8.52e-14	Body mass index;
LUAD	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg13319975	chr6:146136371	FBXO30	-0.61	-10.12	-0.44	1.1e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg23625390	chr15:77176239	SCAPER	-0.39	-6.83	-0.32	2.99e-11	Blood metabolite levels;
LUAD	cis	rs10489202	0.608	rs4657733	chr1:168086434	G/A	cg25738037	chr1:168025549	DCAF6	-0.45	-6.59	-0.3	1.35e-10	Schizophrenia;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg26755928	chr19:10363173	MRPL4	0.4	6.37	0.3	4.8e-10	Bilirubin levels;
LUAD	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg27532758	chr8:7812741	FAM66E	0.4	6.92	0.32	1.68e-11	Neuroticism;
LUAD	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg18512352	chr11:47633146	NA	0.38	6.83	0.32	2.9100000000000002e-11	Neuroticism;
LUAD	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg12140854	chr5:148520817	ABLIM3	-0.67	-10.74	-0.46	5.72e-24	Breast cancer;
LUAD	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg05187965	chr10:45406764	TMEM72	-0.46	-9.33	-0.41	6.2e-19	Mean corpuscular volume;
LUAD	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06544989	chr22:39130855	UNC84B	-0.36	-7.36	-0.34	9.98e-13	Menopause (age at onset);
LUAD	cis	rs921968	0.565	rs3731876	chr2:219602819	G/A	cg02176678	chr2:219576539	TTLL4	-0.56	-10.94	-0.47	1.06e-24	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2797160	1.000	rs2747717	chr6:126008435	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.64	0.31	9.48e-11	Endometrial cancer;
LUAD	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.77	-0.46	4.41e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg25817165	chr18:72167213	CNDP2	-0.69	-9.97	-0.44	3.5e-21	Refractive error;
LUAD	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg04117972	chr1:227635322	NA	0.8	6.64	0.31	9.65e-11	Major depressive disorder;
LUAD	cis	rs2455799	0.552	rs1472697	chr3:15750268	G/A	cg16303742	chr3:15540471	COLQ	-0.52	-9.71	-0.43	2.93e-20	Mean platelet volume;
LUAD	cis	rs12681287	0.604	rs6471316	chr8:87403587	G/C	cg00550725	chr8:87521180	FAM82B	-0.44	-6.46	-0.3	2.95e-10	Caudate activity during reward;
LUAD	cis	rs9322817	0.583	rs6571202	chr6:105182644	G/T	cg02098413	chr6:105308735	HACE1	-0.43	-9.08	-0.4	4.32e-18	Thyroid stimulating hormone;
LUAD	cis	rs2625529	0.824	rs35112434	chr15:72448326	G/T	cg16672083	chr15:72433130	SENP8	-0.78	-12.73	-0.53	1.19e-31	Red blood cell count;
LUAD	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg27489772	chr12:121021490	NA	0.55	7.05	0.32	7.52e-12	Type 1 diabetes nephropathy;
LUAD	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19717773	chr7:2847554	GNA12	-0.57	-9.7	-0.43	3.23e-20	Height;
LUAD	cis	rs1595825	0.891	rs73056840	chr2:198783466	C/A	cg10547527	chr2:198650123	BOLL	-0.53	-7.64	-0.35	1.45e-13	Ulcerative colitis;
LUAD	cis	rs62238980	0.614	rs117067740	chr22:32407944	C/A	cg00543991	chr22:32367038	NA	0.96	9.05	0.4	5.32e-18	Childhood ear infection;
LUAD	trans	rs629535	0.814	rs545720	chr8:70063370	T/C	cg21567404	chr3:27674614	NA	1.01	18.52	0.67	1.64e-56	Dupuytren's disease;
LUAD	cis	rs77861329	1.000	rs9817653	chr3:52148233	T/G	cg08692210	chr3:52188851	WDR51A	0.83	7.75	0.35	6.7e-14	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs367943	0.730	rs2914174	chr5:112978531	C/T	cg12552261	chr5:112820674	MCC	-0.52	-9.08	-0.4	4.04e-18	Type 2 diabetes;
LUAD	cis	rs3750082	0.582	rs7800883	chr7:32971282	G/A	cg05721444	chr7:32995514	FKBP9	0.44	7.36	0.34	9.58e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs4604732	0.536	rs7528219	chr1:247628307	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	9.11	0.41	3.23e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg02951883	chr7:2050386	MAD1L1	-0.79	-14.09	-0.57	3.21e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs9914988	0.619	rs9898529	chr17:27318861	A/T	cg02049041	chr17:27085579	C17orf63	0.49	6.45	0.3	3.14e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg04413180	chr2:236847057	AGAP1	-0.43	-7.46	-0.34	5.1e-13	Diastolic blood pressure;
LUAD	cis	rs11676348	0.712	rs11687434	chr2:218945143	A/G	cg06547715	chr2:218990976	CXCR2	0.29	6.61	0.31	1.15e-10	Ulcerative colitis;
LUAD	cis	rs6546550	0.935	rs4241261	chr2:70063660	A/G	cg02498382	chr2:70120550	SNRNP27	-0.55	-10.41	-0.45	9.37e-23	Prevalent atrial fibrillation;
LUAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.88	0.47	1.73e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12079745	0.590	rs35144581	chr1:169183588	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-1.06	-7.73	-0.35	7.74e-14	QT interval;
LUAD	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.54	-0.34	2.81e-13	Total cholesterol levels;
LUAD	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg16325326	chr1:53192061	ZYG11B	-0.61	-12.16	-0.51	2.13e-29	Monocyte count;
LUAD	trans	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17712092	chr4:129076599	LARP1B	0.94	18.09	0.66	1.42e-54	Eosinophil percentage of white cells;
LUAD	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg16479474	chr6:28041457	NA	0.43	7.38	0.34	8.39e-13	Depression;
LUAD	cis	rs7584330	0.554	rs13392410	chr2:238430273	G/A	cg14458575	chr2:238380390	NA	0.63	9.91	0.43	5.95e-21	Prostate cancer;
LUAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg10729496	chr3:10149963	C3orf24	0.47	6.89	0.32	2.09e-11	Alzheimer's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17103929	chr8:101225361	SPAG1	-0.48	-7.53	-0.34	3.08e-13	Height;
LUAD	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.58	8.75	0.39	5.02e-17	Platelet count;
LUAD	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg05313129	chr8:58192883	C8orf71	-0.52	-7.77	-0.35	5.86e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7187994	0.672	rs7186685	chr16:84798781	T/C	cg07647771	chr16:84786436	USP10	-0.31	-8.23	-0.37	2.35e-15	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg09127314	chr1:152161683	NA	0.41	6.71	0.31	6.29e-11	Inflammatory skin disease;
LUAD	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	6.64	0.31	9.39e-11	Schizophrenia;
LUAD	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11644478	chr21:40555479	PSMG1	-0.42	-6.95	-0.32	1.37e-11	Menarche (age at onset);
LUAD	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg01206211	chr2:36825736	FEZ2	-0.5	-9.62	-0.42	6.3e-20	Height;
LUAD	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg10523679	chr1:76189770	ACADM	0.77	11.44	0.49	1.37e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg08999081	chr20:33150536	PIGU	0.64	14.12	0.57	2.2e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg03563238	chr19:33554763	RHPN2	0.32	7.76	0.35	6.24e-14	Bone properties (heel);
LUAD	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg02951883	chr7:2050386	MAD1L1	-0.82	-15.6	-0.6	1.18e-43	Bipolar disorder and schizophrenia;
LUAD	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.25	-0.41	1.13e-18	Type 2 diabetes;
LUAD	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.79	-0.35	5.28e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6690583	0.623	rs1371143	chr1:85455532	C/T	cg22153463	chr1:85462885	MCOLN2	0.58	6.74	0.31	5.36e-11	Serum sulfate level;
LUAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg05564831	chr3:52568323	NT5DC2	0.35	6.49	0.3	2.42e-10	Electroencephalogram traits;
LUAD	cis	rs7107174	1.000	rs1385601	chr11:77936064	A/C	cg02023728	chr11:77925099	USP35	0.41	6.88	0.32	2.11e-11	Testicular germ cell tumor;
LUAD	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26314531	chr2:26401878	FAM59B	-0.57	-7.91	-0.36	2.32e-14	Gut microbiome composition (summer);
LUAD	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-7.92	-0.36	2.15e-14	Total body bone mineral density;
LUAD	cis	rs4786125	0.804	rs6500850	chr16:6896389	A/T	cg03623568	chr16:6915990	A2BP1	-0.39	-8.34	-0.38	1.02e-15	Heart rate variability traits (SDNN);
LUAD	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg05673287	chr15:77411982	SGK269	-0.43	-7.37	-0.34	9.12e-13	Type 2 diabetes;
LUAD	cis	rs1784581	0.588	rs1789988	chr6:162408472	C/T	cg17173639	chr6:162384350	PARK2	-0.44	-7.74	-0.35	7.42e-14	Itch intensity from mosquito bite;
LUAD	cis	rs7771547	0.519	rs12206445	chr6:36379628	G/A	cg02952361	chr6:36355661	ETV7	0.44	6.53	0.3	1.92e-10	Platelet distribution width;
LUAD	cis	rs1032833	0.660	rs77975658	chr2:179973354	G/A	cg23883738	chr2:179974586	SESTD1	-0.72	-8.3	-0.37	1.39e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg26597838	chr10:835615	NA	1.06	16.41	0.62	3.32e-47	Eosinophil percentage of granulocytes;
LUAD	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg25036284	chr2:26402008	FAM59B	-0.6	-8.34	-0.38	1.02e-15	Gut microbiome composition (summer);
LUAD	cis	rs2637266	1.000	rs7896831	chr10:78366649	A/T	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.72e-11	Pulmonary function;
LUAD	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg01065977	chr19:18549689	ISYNA1	-0.41	-7.85	-0.36	3.45e-14	Breast cancer;
LUAD	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06873352	chr17:61820015	STRADA	0.55	8.91	0.4	1.49e-17	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19886613	chr18:61089605	VPS4B	-0.42	-6.44	-0.3	3.25e-10	Height;
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg13214185	chr14:107219616	NA	0.41	7.17	0.33	3.37e-12	Menopause (age at onset);
LUAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg18621852	chr3:10150065	C3orf24	0.46	8.13	0.37	4.94e-15	Alzheimer's disease;
LUAD	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg05590025	chr7:65112418	INTS4L2	0.74	8.05	0.36	8.39e-15	Diabetic kidney disease;
LUAD	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24308560	chr3:49941425	MST1R	0.57	9.72	0.43	2.67e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs4711336	1.000	rs2296742	chr6:33659793	G/A	cg13859433	chr6:33739653	LEMD2	-0.3	-7.02	-0.32	8.72e-12	Height;
LUAD	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.72	0.46	7.14e-24	Smoking behavior;
LUAD	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg15448220	chr1:150897856	SETDB1	0.54	9.11	0.41	3.28e-18	Melanoma;
LUAD	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg10556349	chr10:835070	NA	0.57	7.03	0.32	8.42e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg07617317	chr6:118971624	C6orf204	0.54	8.03	0.36	9.72e-15	Diastolic blood pressure;
LUAD	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg06781209	chr11:61594997	FADS2	-0.43	-7.65	-0.35	1.36e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs739496	0.542	rs7306529	chr12:111780644	A/G	cg10833066	chr12:111807467	FAM109A	0.63	12.36	0.52	3.45e-30	Platelet count;
LUAD	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg24920358	chr1:40204285	PPIE	-0.69	-12.27	-0.51	7.79e-30	Blood protein levels;
LUAD	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg19901468	chr14:105411992	AHNAK2	-0.54	-10.68	-0.46	9.81e-24	Rheumatoid arthritis;
LUAD	trans	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	10.18	0.44	6.57e-22	Type 2 diabetes;
LUAD	cis	rs1011018	0.590	rs76304235	chr7:139456611	C/T	cg26515926	chr7:139453581	HIPK2	-0.49	-6.39	-0.3	4.45e-10	Systolic blood pressure;
LUAD	cis	rs17095355	0.748	rs17127118	chr10:111900010	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.58	-6.57	-0.3	1.47e-10	Biliary atresia;
LUAD	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg25237894	chr2:233734115	C2orf82	0.62	11.78	0.5	6.79e-28	Coronary artery disease;
LUAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg12432903	chr7:1882776	MAD1L1	-0.53	-8.5	-0.38	3.24e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg17200465	chr3:40428508	ENTPD3	0.27	6.49	0.3	2.44e-10	Renal cell carcinoma;
LUAD	cis	rs568617	0.716	rs17854357	chr11:65601560	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.65	7.25	0.33	2.06e-12	Crohn's disease;
LUAD	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25427524	chr10:38739819	LOC399744	-0.74	-13.14	-0.54	2.5e-33	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg08470875	chr2:26401718	FAM59B	-0.57	-7.84	-0.36	3.59e-14	Gut microbiome composition (summer);
LUAD	cis	rs1950626	0.750	rs72700530	chr14:101429459	G/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.55	0.34	2.79e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs3204270	0.759	rs8071492	chr17:79682650	G/A	cg18367735	chr17:79674897	NA	0.53	6.71	0.31	6.36e-11	Dental caries;
LUAD	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg00383909	chr3:49044727	WDR6	0.85	8.38	0.38	7.84e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg25208724	chr1:156163844	SLC25A44	0.98	15.38	0.6	9.93e-43	Testicular germ cell tumor;
LUAD	cis	rs1595825	0.627	rs1435567	chr2:198748726	T/C	cg00982548	chr2:198649783	BOLL	-0.64	-9.11	-0.41	3.27e-18	Ulcerative colitis;
LUAD	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg05043794	chr9:111880884	C9orf5	-0.44	-7.45	-0.34	5.23e-13	Menarche (age at onset);
LUAD	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg23887609	chr12:130822674	PIWIL1	0.4	6.68	0.31	7.57e-11	Menopause (age at onset);
LUAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg18538332	chr22:24372958	LOC391322	-0.55	-9.12	-0.41	3.13e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg25024717	chr12:54324583	NA	0.33	6.9	0.32	1.92e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.53	9.58	0.42	8.61e-20	Lymphocyte counts;
LUAD	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg07810366	chr2:100720526	AFF3	-0.36	-7.49	-0.34	4.06e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg01448562	chr3:133502909	NA	-0.66	-12.2	-0.51	1.51e-29	Iron status biomarkers;
LUAD	cis	rs472402	0.580	rs11738248	chr5:6657494	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.41	-6.37	-0.3	4.86e-10	Response to amphetamines;
LUAD	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.64	11.89	0.5	2.57e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11811982	0.793	rs75606178	chr1:227421821	A/T	cg24860534	chr1:227506868	CDC42BPA	0.7	7.58	0.35	2.27e-13	Optic disc area;
LUAD	cis	rs7737355	0.947	rs9327620	chr5:130996451	A/G	cg06307176	chr5:131281290	NA	0.53	8.34	0.38	1.06e-15	Life satisfaction;
LUAD	trans	rs4650994	1.000	rs10913572	chr1:178526718	C/T	cg05059571	chr16:84539110	KIAA1609	-0.59	-10.06	-0.44	1.73e-21	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg08470875	chr2:26401718	FAM59B	0.6	8.51	0.38	2.95e-16	Gut microbiome composition (summer);
LUAD	cis	rs9473147	0.516	rs10456570	chr6:47559451	A/G	cg20196966	chr6:47445060	CD2AP	0.43	6.86	0.32	2.39e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg05874882	chr4:1763078	NA	0.36	6.46	0.3	2.82e-10	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs12210905	0.688	rs12215386	chr6:27406877	G/T	cg08851530	chr6:28072375	NA	1.03	7.52	0.34	3.3e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg08645402	chr16:4508243	NA	0.58	10.22	0.44	4.79e-22	Schizophrenia;
LUAD	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.26e-12	Tonsillectomy;
LUAD	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg19717773	chr7:2847554	GNA12	-0.52	-8.87	-0.4	2.1e-17	Height;
LUAD	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg14403583	chr14:105418241	AHNAK2	-0.42	-7.89	-0.36	2.58e-14	Rheumatoid arthritis;
LUAD	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg06558623	chr16:89946397	TCF25	1.16	10.82	0.47	2.89e-24	Skin colour saturation;
LUAD	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg02196655	chr2:10830764	NOL10	0.46	8.39	0.38	7.24e-16	Prostate cancer;
LUAD	cis	rs89107	0.641	rs376875	chr6:118611592	C/T	cg18833306	chr6:118973337	C6orf204	0.51	9.46	0.42	2.2e-19	Cardiac structure and function;
LUAD	cis	rs2455826	0.544	rs2455841	chr3:15762120	C/A	cg16303742	chr3:15540471	COLQ	-0.38	-6.38	-0.3	4.61e-10	Inflammatory skin disease;
LUAD	cis	rs244899	0.967	rs184957	chr5:167919623	T/A	cg06604206	chr5:167912465	RARS	-0.42	-7.31	-0.33	1.38e-12	Response to platinum-based chemotherapy (carboplatin);
LUAD	cis	rs12681287	0.517	rs68008113	chr8:87520894	C/A	cg27223183	chr8:87520930	FAM82B	-0.73	-10.26	-0.45	3.31e-22	Caudate activity during reward;
LUAD	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg08999081	chr20:33150536	PIGU	0.49	9.46	0.42	2.18e-19	Coronary artery disease;
LUAD	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg18105134	chr13:113819100	PROZ	0.91	16.46	0.62	2.18e-47	Platelet distribution width;
LUAD	cis	rs6998277	0.553	rs6468837	chr8:103602767	A/G	cg10187029	chr8:103597600	NA	0.7	12.91	0.53	2.21e-32	Migraine;
LUAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg07234876	chr8:600039	NA	1.03	10.13	0.44	9.72e-22	IgG glycosylation;
LUAD	cis	rs11971779	0.585	rs3922848	chr7:139046210	T/C	cg23387468	chr7:139079360	LUC7L2	0.28	6.54	0.3	1.79e-10	Diisocyanate-induced asthma;
LUAD	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21545522	chr1:205238299	TMCC2	0.36	6.7	0.31	6.83e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs829883	0.659	rs11109521	chr12:98930809	C/A	cg25150519	chr12:98850993	NA	-0.5	-7.89	-0.36	2.61e-14	Colorectal adenoma (advanced);
LUAD	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg03609598	chr5:56110824	MAP3K1	0.59	7.2	0.33	2.82e-12	Initial pursuit acceleration;
LUAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg18621852	chr3:10150065	C3orf24	0.42	7.46	0.34	5.08e-13	Alzheimer's disease;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg20994084	chr17:79269488	SLC38A10	-0.38	-6.4	-0.3	4.08e-10	Subcortical brain region volumes;
LUAD	cis	rs3803170	0.513	rs10849941	chr12:111818487	A/T	cg10833066	chr12:111807467	FAM109A	0.44	8.17	0.37	3.7e-15	Mean corpuscular hemoglobin;
LUAD	cis	rs6499255	1.000	rs12925371	chr16:69773885	G/A	cg15192750	chr16:69999425	NA	0.57	8.85	0.4	2.43e-17	IgE levels;
LUAD	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg12034118	chr1:209979487	IRF6	0.52	6.54	0.3	1.73e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg17177755	chr1:15930204	NA	0.44	7.1	0.33	5.22e-12	Systolic blood pressure;
LUAD	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg22852734	chr6:133119734	C6orf192	0.78	9.37	0.41	4.27e-19	Type 2 diabetes nephropathy;
LUAD	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg20119798	chr7:94954144	PON1	-0.47	-6.42	-0.3	3.76e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg17063962	chr7:91808500	NA	0.73	13.25	0.54	9.24e-34	Breast cancer;
LUAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg24829409	chr8:58192753	C8orf71	-0.59	-7.91	-0.36	2.34e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.802	rs7397730	chr12:86416212	T/C	cg19622623	chr12:86230825	RASSF9	-0.37	-6.71	-0.31	6.11e-11	Major depressive disorder;
LUAD	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg21918786	chr6:109611834	NA	-0.58	-10.6	-0.46	1.97e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg04731861	chr2:219085781	ARPC2	0.24	7.19	0.33	2.97e-12	Colorectal cancer;
LUAD	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg12179176	chr11:130786555	SNX19	0.43	6.89	0.32	2e-11	Schizophrenia;
LUAD	cis	rs926938	0.618	rs1286560	chr1:115375930	C/T	cg12756093	chr1:115239321	AMPD1	-0.37	-6.55	-0.3	1.63e-10	Autism;
LUAD	trans	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg14917512	chr19:3094685	GNA11	-0.56	-6.55	-0.3	1.72e-10	Diabetic kidney disease;
LUAD	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg18932078	chr1:2524107	MMEL1	0.35	6.49	0.3	2.35e-10	Ulcerative colitis;
LUAD	cis	rs986417	1.000	rs1033733	chr14:60932438	G/T	cg27398547	chr14:60952738	C14orf39	0.67	7.88	0.36	2.74e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg13606994	chr1:44402422	ARTN	-0.33	-6.92	-0.32	1.68e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs7072216	0.763	rs2274246	chr10:100175060	C/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.7	-0.39	7.57e-17	Metabolite levels;
LUAD	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.24	-0.33	2.18e-12	Bipolar disorder;
LUAD	cis	rs13082711	0.911	rs57992391	chr3:27511567	A/C	cg02860705	chr3:27208620	NA	0.57	8.79	0.39	3.68e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.59	0.52	4.48e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4664304	0.770	rs55860731	chr2:160875437	C/T	cg23995753	chr2:160760732	LY75	-0.43	-7.33	-0.34	1.15e-12	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg19413350	chr8:57351067	NA	-0.42	-6.66	-0.31	8.42e-11	Obesity-related traits;
LUAD	cis	rs16854884	0.683	rs2053211	chr3:143774592	C/T	cg01302019	chr3:143689584	C3orf58	0.41	6.79	0.31	3.74e-11	Economic and political preferences (feminism/equality);
LUAD	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg20476274	chr7:133979776	SLC35B4	0.84	16.27	0.62	1.4e-46	Mean platelet volume;
LUAD	trans	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-15.18	-0.59	7.5e-42	Exhaled nitric oxide output;
LUAD	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg15448220	chr1:150897856	SETDB1	0.47	8.06	0.36	8.01e-15	Tonsillectomy;
LUAD	cis	rs7617773	0.780	rs7645425	chr3:48362369	A/T	cg11946769	chr3:48343235	NME6	0.45	6.89	0.32	2.05e-11	Coronary artery disease;
LUAD	cis	rs476633	0.708	rs28629856	chr15:41446950	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.6	-10.78	-0.46	4.27e-24	Glomerular filtration rate (creatinine);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg05484393	chr3:170587694	RPL22L1	0.4	6.57	0.3	1.49e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.34	0.41	5.59e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72772090	0.539	rs72773917	chr5:96111302	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.04	-0.32	7.83e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg22189786	chr22:42395067	WBP2NL	-0.44	-6.4	-0.3	4.19e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs9323205	0.765	rs2999386	chr14:51652628	G/T	cg23942311	chr14:51606299	NA	0.54	9.67	0.43	4.08e-20	Cancer;
LUAD	cis	rs1975974	0.872	rs17052352	chr17:21721972	A/G	cg18423549	chr17:21743878	NA	-0.8	-14.56	-0.58	3.37e-39	Psoriasis;
LUAD	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg12483801	chr4:183727862	NA	0.53	6.93	0.32	1.58e-11	Pediatric autoimmune diseases;
LUAD	cis	rs7224737	0.789	rs8071235	chr17:40300126	C/A	cg00647820	chr17:40259828	DHX58	-0.43	-6.67	-0.31	8.12e-11	Fibrinogen levels;
LUAD	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg00666640	chr1:248458726	OR2T12	0.33	7.8	0.35	4.84e-14	Common traits (Other);
LUAD	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg09537434	chr19:41945824	ATP5SL	-0.52	-8.19	-0.37	3.16e-15	Height;
LUAD	cis	rs62229266	1.000	rs62229266	chr21:37460271	A/T	cg12218747	chr21:37451666	NA	-0.52	-8.83	-0.39	2.89e-17	Mitral valve prolapse;
LUAD	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg09640425	chr7:158790006	NA	-0.53	-9.16	-0.41	2.26e-18	Facial morphology (factor 20);
LUAD	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01570182	chr17:44337453	NA	0.77	12.44	0.52	1.69e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs8060686	0.516	rs4567701	chr16:68163662	T/C	cg05110241	chr16:68378359	PRMT7	-0.57	-7.23	-0.33	2.32e-12	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg06606381	chr12:133084897	FBRSL1	-0.86	-9.05	-0.4	5.36e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7552167	0.925	rs3932664	chr1:24511663	G/T	cg01960748	chr1:24522592	NA	-0.75	-9.99	-0.44	3.08e-21	Psoriasis vulgaris;
LUAD	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08859206	chr1:53392774	SCP2	-0.76	-14.95	-0.59	7.27e-41	Monocyte count;
LUAD	trans	rs11039798	1.000	rs12280020	chr11:48618844	G/C	cg03929089	chr4:120376271	NA	0.56	6.6	0.31	1.24e-10	Axial length;
LUAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg04234412	chr22:24373322	LOC391322	-0.86	-16.61	-0.63	4.59e-48	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg13877915	chr19:58951672	ZNF132	0.73	13.96	0.56	1.12e-36	Uric acid clearance;
LUAD	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg00316803	chr15:76480434	C15orf27	-0.36	-6.79	-0.31	3.7e-11	Blood metabolite levels;
LUAD	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg15445000	chr17:37608096	MED1	0.48	8.88	0.4	1.95e-17	Glomerular filtration rate (creatinine);
LUAD	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.78	-13.55	-0.55	5.49e-35	Chronic sinus infection;
LUAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg13047869	chr3:10149882	C3orf24	0.67	11.48	0.49	9.3e-27	Alzheimer's disease;
LUAD	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg02782426	chr3:40428986	ENTPD3	0.35	7.59	0.35	2.11e-13	Renal cell carcinoma;
LUAD	cis	rs9807989	0.524	rs4851576	chr2:103028895	C/T	cg03938978	chr2:103052716	IL18RAP	0.44	9.94	0.44	4.72e-21	Asthma;
LUAD	cis	rs2692947	0.537	rs11685849	chr2:96243804	C/A	cg23100626	chr2:96804247	ASTL	0.34	7.71	0.35	8.89e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00166722	chr3:10149974	C3orf24	0.73	12.65	0.52	2.57e-31	Alzheimer's disease;
LUAD	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg22482690	chr17:47019901	SNF8	0.46	8.98	0.4	9.04e-18	Type 2 diabetes;
LUAD	cis	rs1569328	0.793	rs6574220	chr14:75725769	T/C	cg18117039	chr14:75741733	NA	0.51	8.36	0.38	8.96e-16	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs5756813	0.754	rs5750495	chr22:38179120	T/A	cg19894588	chr14:64061835	NA	0.48	6.93	0.32	1.57e-11	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs8017423	0.838	rs11845950	chr14:90723962	T/A	cg14092571	chr14:90743983	NA	-0.51	-8.97	-0.4	9.93e-18	Mortality in heart failure;
LUAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg21724239	chr8:58056113	NA	-0.66	-8.51	-0.38	2.98e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26314531	chr2:26401878	FAM59B	-0.57	-7.91	-0.36	2.21e-14	Gut microbiome composition (summer);
LUAD	cis	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg21775007	chr8:11205619	TDH	0.55	9.87	0.43	8.13e-21	Retinal vascular caliber;
LUAD	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg09222892	chr1:25734099	RHCE	0.51	9.5	0.42	1.52e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.24	0.33	2.1e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs12791968	1.000	rs1552301	chr11:45002551	A/G	cg11846598	chr11:44996168	LOC221122	-0.77	-13.69	-0.55	1.41e-35	Inhibitory control;
LUAD	cis	rs1847202	0.859	rs7634316	chr3:72941452	C/G	cg25664220	chr3:72788482	NA	0.41	7.16	0.33	3.52e-12	Motion sickness;
LUAD	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg04282206	chr17:62833786	PLEKHM1P	0.61	8.89	0.4	1.79e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs11077815	0.708	rs4789296	chr17:74440550	C/T	cg06840243	chr17:74442338	UBE2O	-0.4	-7.3	-0.33	1.44e-12	Lymphocyte counts;
LUAD	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg11845111	chr2:191398756	TMEM194B	-0.8	-10.59	-0.46	2.14e-23	Diastolic blood pressure;
LUAD	cis	rs7009516	0.669	rs13251418	chr8:24246832	A/T	cg01759110	chr8:24241694	ADAMDEC1	-0.44	-8.77	-0.39	4.33e-17	Hair greying;
LUAD	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.49	0.3	2.34e-10	Depression;
LUAD	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg04267008	chr7:1944627	MAD1L1	-0.53	-7.81	-0.35	4.64e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.38	-8.46	-0.38	4.39e-16	Hemoglobin concentration;
LUAD	cis	rs7827545	0.545	rs6998092	chr8:135557449	A/G	cg17885191	chr8:135476712	NA	0.61	8.21	0.37	2.65e-15	Hypertension (SNP x SNP interaction);
LUAD	trans	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.61	-0.39	1.45e-16	Endometrial cancer;
LUAD	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.59	10.5	0.45	4.59e-23	Eosinophil percentage of white cells;
LUAD	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg04944784	chr2:26401820	FAM59B	-0.89	-12.43	-0.52	1.96e-30	Gut microbiome composition (summer);
LUAD	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg07636037	chr3:49044803	WDR6	-0.49	-8.16	-0.37	3.76e-15	Menarche (age at onset);
LUAD	cis	rs34734847	0.766	rs3794214	chr12:121168245	C/T	cg27246729	chr12:121163418	ACADS	-0.35	-6.39	-0.3	4.27e-10	Mean corpuscular volume;
LUAD	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg18200150	chr17:30822561	MYO1D	0.58	11.63	0.49	2.58e-27	Schizophrenia;
LUAD	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg24069376	chr3:38537580	EXOG	0.46	11.15	0.48	1.7e-25	Electrocardiographic conduction measures;
LUAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg22535103	chr8:58192502	C8orf71	0.58	6.95	0.32	1.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg02176678	chr2:219576539	TTLL4	-0.59	-11.4	-0.48	2.01e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg00290607	chr11:67383545	NA	0.39	6.49	0.3	2.37e-10	Mean corpuscular volume;
LUAD	cis	rs3820068	0.705	rs11589076	chr1:15827027	C/T	cg13390004	chr1:15929781	NA	0.4	6.44	0.3	3.27e-10	Systolic blood pressure;
LUAD	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.31	-0.37	1.32e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03517284	chr6:25882590	NA	-0.82	-13.97	-0.56	1.02e-36	Blood metabolite levels;
LUAD	trans	rs1493916	0.905	rs1586988	chr18:31396001	G/C	cg27147174	chr7:100797783	AP1S1	-0.72	-13.25	-0.54	8.84e-34	Life satisfaction;
LUAD	cis	rs2901656	0.544	rs6658843	chr1:172399082	G/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.42	8.09	0.37	6.39e-15	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg02951883	chr7:2050386	MAD1L1	-0.69	-11.88	-0.5	2.71e-28	Bipolar disorder and schizophrenia;
LUAD	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg12884169	chr21:40033163	ERG	-0.5	-10.64	-0.46	1.38e-23	Coronary artery disease;
LUAD	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg20744362	chr22:50050164	C22orf34	0.4	8.68	0.39	8.68e-17	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.62	0.31	1.07e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9467160	0.651	rs7755403	chr6:24453447	C/G	cg20631270	chr6:24437470	GPLD1	0.41	6.46	0.3	2.93e-10	Liver enzyme levels;
LUAD	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg07636037	chr3:49044803	WDR6	0.47	7.43	0.34	6.09e-13	Menarche (age at onset);
LUAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg27454412	chr7:1067447	C7orf50	0.45	7.12	0.33	4.65e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4072705	0.615	rs4838189	chr9:127248926	C/A	cg14219918	chr9:127249562	NR5A1	0.29	6.6	0.31	1.24e-10	Menarche (age at onset);
LUAD	cis	rs6987853	0.966	rs1947297	chr8:42453023	A/G	cg09913449	chr8:42400586	C8orf40	0.42	7.65	0.35	1.33e-13	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg22875332	chr1:76189707	ACADM	-0.96	-22.89	-0.74	4.8e-76	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg27490568	chr2:178487706	NA	0.43	7.31	0.33	1.36e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg23625390	chr15:77176239	SCAPER	0.37	6.62	0.31	1.09e-10	Blood metabolite levels;
LUAD	cis	rs11048434	0.723	rs1805737	chr12:9084670	A/T	cg23795048	chr12:9217529	LOC144571	0.42	7.62	0.35	1.74e-13	Sjögren's syndrome;
LUAD	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg02018176	chr4:1364513	KIAA1530	0.47	8.72	0.39	6.33e-17	Longevity;
LUAD	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg03517284	chr6:25882590	NA	0.42	6.7	0.31	6.48e-11	Height;
LUAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg11965913	chr1:205819406	PM20D1	0.96	23.19	0.75	2.37e-77	Menarche (age at onset);
LUAD	trans	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg03929089	chr4:120376271	NA	0.57	6.69	0.31	7.09e-11	Intraocular pressure;
LUAD	cis	rs45430	1.000	rs364525	chr21:42745578	A/G	cg22778903	chr21:42741698	MX2	-0.38	-7.97	-0.36	1.44e-14	Melanoma;
LUAD	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg06221963	chr1:154839813	KCNN3	-0.87	-19.96	-0.7	5.98e-63	Prostate cancer;
LUAD	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.85	-14.75	-0.58	5.15e-40	Platelet distribution width;
LUAD	cis	rs790123	1.000	rs2650950	chr3:122382048	C/T	cg15604389	chr3:122379662	NA	0.5	8.86	0.4	2.31e-17	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs250677	0.522	rs11954893	chr5:148392362	A/G	cg12140854	chr5:148520817	ABLIM3	-0.56	-8.59	-0.39	1.73e-16	Breast cancer;
LUAD	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.39	0.38	7.27e-16	Platelet count;
LUAD	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg20933634	chr6:27740509	NA	0.47	7.33	0.34	1.15e-12	Parkinson's disease;
LUAD	cis	rs11771526	0.642	rs11762517	chr7:32336793	T/C	cg13207630	chr7:32358064	NA	0.53	6.85	0.32	2.67e-11	Body mass index;
LUAD	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg19761014	chr17:28927070	LRRC37B2	0.79	8.01	0.36	1.14e-14	Body mass index;
LUAD	cis	rs12541491	0.506	rs11250007	chr8:10285086	C/G	cg12940923	chr8:10282607	MSRA	-0.34	-6.4	-0.3	4.08e-10	Schizophrenia;
LUAD	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg01657329	chr11:68192670	LRP5	-0.47	-8.28	-0.37	1.64e-15	Total body bone mineral density;
LUAD	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22857025	chr5:266934	NA	-0.95	-14.28	-0.57	5.15e-38	Breast cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg08874598	chr8:102217901	ZNF706	-0.39	-6.42	-0.3	3.74e-10	Schizophrenia;
LUAD	cis	rs2274273	0.624	rs7150234	chr14:55802181	A/G	cg04306507	chr14:55594613	LGALS3	0.4	7.55	0.34	2.78e-13	Protein biomarker;
LUAD	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg11915388	chr22:42470451	FAM109B	-0.4	-7.06	-0.32	6.72e-12	Schizophrenia;
LUAD	cis	rs4242434	0.672	rs10113779	chr8:22485934	G/C	cg03733263	chr8:22462867	KIAA1967	0.6	9.89	0.43	7.06e-21	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs6028335	0.674	rs3752301	chr20:37654024	T/G	cg27660920	chr20:37554817	FAM83D	0.53	6.62	0.31	1.1e-10	Alcohol and nicotine co-dependence;
LUAD	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg05991184	chr2:219186017	PNKD	0.35	6.77	0.31	4.45e-11	Colorectal cancer;
LUAD	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg09936142	chr19:10668400	KRI1	-0.47	-6.69	-0.31	6.93e-11	Red cell distribution width;
LUAD	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10802521	chr3:52805072	NEK4	-0.54	-9.12	-0.41	3.09e-18	Bipolar disorder;
LUAD	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-10.5	-0.45	4.44e-23	Gut microbiome composition (summer);
LUAD	cis	rs7927771	0.542	rs6485775	chr11:47773518	A/G	cg18512352	chr11:47633146	NA	-0.35	-6.35	-0.3	5.41e-10	Subjective well-being;
LUAD	cis	rs12753569	0.748	rs1340689	chr1:76506409	T/A	cg00791851	chr1:76518896	NA	0.28	6.36	0.3	5.27e-10	Personality dimensions;
LUAD	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.01	0.32	9.52e-12	Motion sickness;
LUAD	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3789045	0.729	rs12039968	chr1:204490674	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.43	-7.28	-0.33	1.62e-12	Educational attainment (college completion);
LUAD	cis	rs300774	0.844	rs300729	chr2:131788	C/G	cg21211680	chr2:198530	NA	0.46	7.17	0.33	3.35e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.16e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1003719	0.788	rs2835582	chr21:38458773	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.59	0.39	1.73e-16	Eye color traits;
LUAD	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg25753631	chr6:25732923	NA	-0.44	-7.76	-0.35	6.26e-14	Iron status biomarkers;
LUAD	cis	rs6445967	0.530	rs67572634	chr3:58290843	T/C	cg13750441	chr3:58318267	PXK	-0.3	-6.37	-0.3	4.84e-10	Platelet count;
LUAD	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg01236616	chr12:121019343	POP5	-1.21	-19.17	-0.68	2.03e-59	Type 1 diabetes nephropathy;
LUAD	cis	rs300774	1.000	rs300799	chr2:105514	G/A	cg21211680	chr2:198530	NA	-0.45	-6.5	-0.3	2.25e-10	Suicide attempts in bipolar disorder;
LUAD	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg03609598	chr5:56110824	MAP3K1	-0.67	-9.03	-0.4	6.19e-18	Initial pursuit acceleration;
LUAD	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.36	6.98	0.32	1.18e-11	Obesity-related traits;
LUAD	cis	rs11195062	0.521	rs6584977	chr10:111954970	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.49	-7.95	-0.36	1.73e-14	Multiple myeloma;
LUAD	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.5	0.3	2.26e-10	Cardiac Troponin-T levels;
LUAD	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.99e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg06784218	chr1:46089804	CCDC17	0.5	10.92	0.47	1.22e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6484504	0.576	rs2616792	chr11:31324298	T/G	cg26647111	chr11:31128758	NA	0.44	7.81	0.36	4.51e-14	Red blood cell count;
LUAD	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.02	-0.4	6.56e-18	Total body bone mineral density;
LUAD	cis	rs10911363	0.659	rs7518244	chr1:183434807	C/T	cg09173681	chr1:183549694	NCF2	-0.55	-9.97	-0.44	3.65e-21	Systemic lupus erythematosus;
LUAD	cis	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg00071950	chr4:10020882	SLC2A9	0.48	6.85	0.32	2.63e-11	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg06784218	chr1:46089804	CCDC17	0.35	7.53	0.34	3.05e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg27454412	chr7:1067447	C7orf50	-0.34	-6.58	-0.3	1.42e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs239198	0.602	rs11755579	chr6:101322469	A/C	cg09795085	chr6:101329169	ASCC3	0.41	6.99	0.32	1.07e-11	Menarche (age at onset);
LUAD	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg23260525	chr10:116636907	FAM160B1	0.47	11.0	0.47	6.26e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs9784649	1.000	rs56004901	chr5:24998968	A/G	cg08600765	chr20:34638493	LOC647979	-0.61	-7.75	-0.35	6.91e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.41	0.42	3.12e-19	Mean corpuscular volume;
LUAD	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21582582	chr3:182698605	DCUN1D1	0.72	14.04	0.56	4.91e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg21827317	chr3:136751795	NA	0.36	6.6	0.31	1.21e-10	Neuroticism;
LUAD	cis	rs3789045	0.826	rs55979051	chr1:204567041	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.41	-7.01	-0.32	9.7e-12	Educational attainment (college completion);
LUAD	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21659725	chr3:3221576	CRBN	-0.87	-18.51	-0.67	1.91e-56	Intelligence (multi-trait analysis);
LUAD	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg16680214	chr1:154839983	KCNN3	-0.63	-13.16	-0.54	2.08e-33	Prostate cancer;
LUAD	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06873352	chr17:61820015	STRADA	0.5	8.06	0.36	7.94e-15	Height;
LUAD	trans	rs853679	0.607	rs13199772	chr6:27834085	A/G	cg01620082	chr3:125678407	NA	-1.04	-10.25	-0.45	3.6e-22	Depression;
LUAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.86	-21.53	-0.72	5.95e-70	Longevity;Endometriosis;
LUAD	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg18932078	chr1:2524107	MMEL1	-0.37	-6.95	-0.32	1.37e-11	Ulcerative colitis;
LUAD	cis	rs654384	0.866	rs13224870	chr7:4172006	C/T	cg26275264	chr7:4183598	SDK1	0.4	7.53	0.34	3.07e-13	Positive affect;
LUAD	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg03563238	chr19:33554763	RHPN2	0.38	8.92	0.4	1.46e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4372836	1.000	rs11690423	chr2:28951537	G/C	cg09522027	chr2:28974177	PPP1CB	0.62	10.05	0.44	1.86e-21	Body mass index;
LUAD	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg01657329	chr11:68192670	LRP5	-0.46	-8.17	-0.37	3.54e-15	Total body bone mineral density;
LUAD	cis	rs13064411	0.696	rs9869318	chr3:113146271	T/C	cg10517650	chr3:113235015	CCDC52	-0.54	-9.03	-0.4	6.29e-18	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7264396	0.790	rs761825	chr20:34194054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-7.17	-0.33	3.44e-12	Total cholesterol levels;
LUAD	cis	rs897984	0.542	rs4468641	chr16:31096876	A/C	cg02466173	chr16:30829666	NA	-0.57	-9.81	-0.43	1.36e-20	Dementia with Lewy bodies;
LUAD	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg05697835	chr1:2722811	NA	0.32	6.68	0.31	7.48e-11	Ulcerative colitis;
LUAD	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg16647868	chr5:131706066	SLC22A5	-0.41	-6.97	-0.32	1.24e-11	Blood metabolite levels;
LUAD	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08704250	chr15:31115839	NA	-0.57	-10.18	-0.44	6.36e-22	Huntington's disease progression;
LUAD	cis	rs2797160	1.000	rs1777195	chr6:126006861	A/C	cg05901451	chr6:126070800	HEY2	0.46	6.9	0.32	1.89e-11	Endometrial cancer;
LUAD	cis	rs6840360	0.571	rs7685697	chr4:152558849	A/G	cg22705602	chr4:152727874	NA	-0.36	-6.37	-0.3	4.98e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs757647	1.000	rs11334	chr5:137772296	G/C	cg10676309	chr5:137685565	NA	0.36	6.86	0.32	2.48e-11	Menarche (age at onset);
LUAD	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg13334819	chr7:99746414	C7orf59	-0.67	-10.12	-0.44	1.07e-21	Coronary artery disease;
LUAD	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg23158103	chr7:148848205	ZNF398	-0.47	-8.13	-0.37	4.97e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg18305652	chr10:134549665	INPP5A	0.61	12.71	0.53	1.37e-31	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.63	-11.96	-0.5	1.35e-28	Schizophrenia;
LUAD	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg06108461	chr20:60628389	TAF4	-1.12	-20.93	-0.71	2.89e-67	Body mass index;
LUAD	cis	rs4713675	0.584	rs7759668	chr6:33670406	C/T	cg13859433	chr6:33739653	LEMD2	0.29	7.03	0.32	8.39e-12	Plateletcrit;
LUAD	trans	rs11039798	1.000	rs34044596	chr11:48527936	T/C	cg02254774	chr11:50257496	LOC441601	0.53	6.59	0.31	1.3100000000000001e-10	Axial length;
LUAD	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg19700328	chr14:106028568	NA	-0.46	-7.82	-0.36	4.26e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.52	-8.48	-0.38	3.93e-16	Renal function-related traits (BUN);
LUAD	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg24531977	chr5:56204891	C5orf35	0.45	7.36	0.34	9.96e-13	Coronary artery disease;
LUAD	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg09222892	chr1:25734099	RHCE	-0.46	-8.54	-0.38	2.5e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg22683308	chr4:1340831	KIAA1530	-0.44	-7.48	-0.34	4.4e-13	Longevity;
LUAD	cis	rs4662945	0.603	rs10496678	chr2:130262209	C/T	cg05903289	chr2:130345205	NA	-0.34	-7.41	-0.34	7.1e-13	Response to cytidine analogues (gemcitabine);
LUAD	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg15704280	chr7:45808275	SEPT13	-0.71	-11.01	-0.47	5.99e-25	Coronary artery disease;
LUAD	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg05340658	chr4:99064831	C4orf37	0.45	6.92	0.32	1.66e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.5	-6.5	-0.3	2.21e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs853679	0.607	rs34765154	chr6:28130450	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.56	6.53	0.3	1.91e-10	Depression;
LUAD	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22968622	chr17:43663579	NA	-1.19	-19.87	-0.69	1.55e-62	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg00310523	chr12:86230176	RASSF9	-0.36	-7.25	-0.33	1.97e-12	Major depressive disorder;
LUAD	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg04450456	chr4:17643702	FAM184B	0.38	7.6	0.35	1.87e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs853679	0.607	rs13207345	chr6:28265572	C/T	cg06606381	chr12:133084897	FBRSL1	-1.22	-11.36	-0.48	2.72e-26	Depression;
LUAD	cis	rs6674970	1.000	rs6674970	chr1:151116279	C/T	cg11822372	chr1:151115635	SEMA6C	0.64	10.47	0.45	5.86e-23	Childhood ear infection;
LUAD	cis	rs8027181	0.839	rs11072385	chr15:73020839	A/G	cg25632853	chr15:73088954	NA	0.31	6.73	0.31	5.6e-11	Triglyceride levels;
LUAD	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.61	-0.52	3.68e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs7536201	1.000	rs11249221	chr1:25300541	T/C	cg23273869	chr1:25296894	NA	-0.39	-8.04	-0.36	9.33e-15	Psoriasis vulgaris;
LUAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg08472276	chr7:1133186	C7orf50;GPER	-0.52	-9.69	-0.43	3.59e-20	Longevity;Endometriosis;
LUAD	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg00007226	chr14:105781366	PACS2	-0.41	-6.79	-0.31	3.75e-11	Brain structure;
LUAD	cis	rs4891159	0.790	rs8098821	chr18:74140345	T/C	cg24786174	chr18:74118243	ZNF516	-0.79	-14.58	-0.58	2.74e-39	Longevity;
LUAD	trans	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.98	0.5	1.13e-28	Mean corpuscular volume;
LUAD	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg10589385	chr1:150898437	SETDB1	-0.38	-6.62	-0.31	1.09e-10	Blood protein levels;
LUAD	cis	rs2932538	0.961	rs2932539	chr1:113215786	A/G	cg22162597	chr1:113214053	CAPZA1	-0.45	-6.8	-0.31	3.6e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	trans	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg01620082	chr3:125678407	NA	-0.73	-8.18	-0.37	3.34e-15	Breast cancer;
LUAD	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg06108461	chr20:60628389	TAF4	0.97	14.86	0.59	1.72e-40	Body mass index;
LUAD	cis	rs9394841	0.692	rs9381095	chr6:41806708	T/A	cg25600774	chr6:41776562	USP49	-0.42	-6.47	-0.3	2.78e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg02569458	chr12:86230093	RASSF9	0.42	7.75	0.35	7.12e-14	Major depressive disorder;
LUAD	cis	rs72772090	0.710	rs112178674	chr5:96060355	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-6.76	-0.31	4.71e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.11	-0.41	3.28e-18	Alcohol dependence;
LUAD	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06022373	chr22:39101656	GTPBP1	0.46	7.15	0.33	3.72e-12	Menopause (age at onset);
LUAD	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06112835	chr11:68658793	MRPL21	0.53	9.57	0.42	8.88e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg01884057	chr2:25150051	NA	-0.3	-6.43	-0.3	3.41e-10	Body mass index;
LUAD	cis	rs7107174	1.000	rs2511168	chr11:77965081	T/G	cg19901956	chr11:77921274	USP35	-0.53	-6.59	-0.31	1.3100000000000001e-10	Testicular germ cell tumor;
LUAD	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg07936489	chr17:37558343	FBXL20	0.51	6.9	0.32	1.9e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs1953600	0.837	rs2819946	chr10:81951635	G/A	cg00277334	chr10:82204260	NA	0.41	6.93	0.32	1.57e-11	Sarcoidosis;
LUAD	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21545522	chr1:205238299	TMCC2	0.39	7.24	0.33	2.07e-12	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg01579765	chr21:45077557	HSF2BP	0.59	13.23	0.54	1.07e-33	Mean corpuscular volume;
LUAD	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg14895029	chr7:2775587	GNA12	-0.45	-7.17	-0.33	3.33e-12	Height;
LUAD	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg14893161	chr1:205819251	PM20D1	-0.45	-7.34	-0.34	1.08e-12	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs11249608	0.548	rs10479519	chr5:178450693	T/C	cg01312482	chr5:178451176	ZNF879	-0.44	-6.8	-0.31	3.52e-11	Pubertal anthropometrics;
LUAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.79	-0.35	5.06e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3772130	0.564	rs28760466	chr3:121601510	A/G	cg20356878	chr3:121714668	ILDR1	0.68	13.66	0.55	1.91e-35	Cognitive performance;
LUAD	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg00074818	chr8:8560427	CLDN23	0.69	10.62	0.46	1.62e-23	Obesity-related traits;
LUAD	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.78	-0.43	1.63e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs2274273	0.624	rs66464079	chr14:55766164	G/T	cg04306507	chr14:55594613	LGALS3	0.4	7.69	0.35	1.02e-13	Protein biomarker;
LUAD	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg23985595	chr17:80112537	CCDC57	0.53	9.69	0.43	3.54e-20	Life satisfaction;
LUAD	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg04731861	chr2:219085781	ARPC2	0.23	7.14	0.33	4.01e-12	Colorectal cancer;
LUAD	cis	rs8058578	0.832	rs35969813	chr16:30714417	T/C	cg02466173	chr16:30829666	NA	-0.69	-11.94	-0.5	1.58e-28	Multiple myeloma;
LUAD	cis	rs6541297	0.941	rs2180078	chr1:230280513	T/C	cg20703242	chr1:230279135	GALNT2	0.66	11.7	0.49	1.34e-27	Coronary artery disease;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg26894311	chr10:104153930	NFKB2	-0.39	-6.41	-0.3	3.9e-10	Schizophrenia;
LUAD	cis	rs490234	0.702	rs4838274	chr9:128345994	C/A	cg14078157	chr9:128172775	NA	-0.44	-7.91	-0.36	2.22e-14	Mean arterial pressure;
LUAD	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg25208724	chr1:156163844	SLC25A44	1.05	21.55	0.72	4.56e-70	Testicular germ cell tumor;
LUAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg11965913	chr1:205819406	PM20D1	0.48	7.85	0.36	3.37e-14	Parkinson's disease;
LUAD	trans	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.93	0.4	1.35e-17	Endometrial cancer;
LUAD	cis	rs907683	0.584	rs12991025	chr2:220284779	C/T	cg15015639	chr2:220282977	DES	0.48	9.01	0.4	6.88e-18	Resting heart rate;
LUAD	cis	rs7593730	0.636	rs1020731	chr2:161144055	A/G	cg22609984	chr2:161126801	NA	-0.49	-7.84	-0.36	3.83e-14	Type 2 diabetes;
LUAD	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24838063	chr12:130822603	PIWIL1	0.68	11.78	0.5	6.77e-28	Menopause (age at onset);
LUAD	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg25894440	chr7:65020034	NA	0.61	6.59	0.31	1.32e-10	Diabetic kidney disease;
LUAD	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.7	-0.39	7.46e-17	Total body bone mineral density;
LUAD	cis	rs3806843	0.576	rs246036	chr5:140331886	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.62	-0.31	1.06e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs72634258	0.519	rs35267144	chr1:7934258	G/A	cg26816564	chr1:7831052	VAMP3	0.56	7.73	0.35	7.66e-14	Inflammatory bowel disease;
LUAD	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg23231163	chr10:75533350	FUT11	0.5	9.81	0.43	1.36e-20	Inflammatory bowel disease;
LUAD	trans	rs75804782	0.630	rs55708222	chr2:239287693	C/T	cg01134436	chr17:81009848	B3GNTL1	0.7	6.53	0.3	1.93e-10	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	cis	rs12210905	1.000	rs72838266	chr6:27015052	T/C	cg11502198	chr6:26597334	ABT1	-0.79	-6.45	-0.3	3.07e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs9393692	0.557	rs62394764	chr6:26305503	T/C	cg00631329	chr6:26305371	NA	-0.57	-9.48	-0.42	1.86e-19	Educational attainment;
LUAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08280861	chr8:58055591	NA	0.55	7.16	0.33	3.53e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs300703	0.515	rs300694	chr2:182277	G/T	cg24565620	chr2:194026	NA	0.38	6.67	0.31	8.11e-11	Blood protein levels;
LUAD	cis	rs981844	0.689	rs7666762	chr4:154684197	C/T	cg10279832	chr4:154682576	RNF175	0.34	7.15	0.33	3.79e-12	Response to statins (LDL cholesterol change);
LUAD	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg09835421	chr16:68378352	PRMT7	-0.81	-8.75	-0.39	5.14e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-10.97	-0.47	8.3e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4478137	0.899	rs10857354	chr4:164239841	A/G	cg06758707	chr4:164254230	NPY1R	0.43	6.89	0.32	2.03e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg01851573	chr8:8652454	MFHAS1	0.37	6.75	0.31	4.75e-11	Mood instability;
LUAD	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg12310025	chr6:25882481	NA	-0.58	-9.55	-0.42	1.1e-19	Blood metabolite levels;
LUAD	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg27539214	chr16:67997921	SLC12A4	-0.68	-8.09	-0.37	6.58e-15	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg11693508	chr17:37793320	STARD3	0.61	7.56	0.35	2.48e-13	Neuroticism;
LUAD	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg27068330	chr11:65405492	SIPA1	-0.77	-12.47	-0.52	1.35e-30	Acne (severe);
LUAD	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg21724239	chr8:58056113	NA	0.6	7.88	0.36	2.85e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-6.53	-0.3	1.85e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg24154853	chr7:158122151	PTPRN2	0.49	8.1	0.37	5.77e-15	Response to amphetamines;
LUAD	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg07432352	chr17:45403706	C17orf57	-0.4	-7.69	-0.35	1.02e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg20503657	chr10:835505	NA	0.96	14.69	0.58	9.35e-40	Eosinophil percentage of granulocytes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23099349	chr6:26032281	HIST1H3B	-0.42	-6.79	-0.31	3.75e-11	Height;
LUAD	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg26668828	chr6:292823	DUSP22	-0.58	-9.84	-0.43	1.05e-20	Menopause (age at onset);
LUAD	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.61	-8.74	-0.39	5.36e-17	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg24644049	chr4:85504048	CDS1	0.92	8.03	0.36	9.83e-15	Skin colour saturation;
LUAD	cis	rs3204270	0.673	rs62077190	chr17:79676109	C/A	cg18367735	chr17:79674897	NA	0.59	6.92	0.32	1.66e-11	Dental caries;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg15383120	chr6:291909	DUSP22	-0.72	-12.21	-0.51	1.37e-29	Menopause (age at onset);
LUAD	cis	rs8017423	0.647	rs12882575	chr14:90820454	C/G	cg14092571	chr14:90743983	NA	0.39	6.63	0.31	1.04e-10	Mortality in heart failure;
LUAD	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.8	-0.35	4.77e-14	Neutrophil percentage of white cells;
LUAD	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-10.93	-0.47	1.12e-24	Coronary artery disease;
LUAD	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.45	0.38	4.91e-16	Parkinson's disease;
LUAD	cis	rs516243	0.807	rs578554	chr1:10741669	A/C	cg02903756	chr1:10750680	CASZ1	-0.47	-8.86	-0.4	2.16e-17	Migraine - clinic-based;
LUAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13732083	chr21:47605072	C21orf56	0.59	10.36	0.45	1.47e-22	Testicular germ cell tumor;
LUAD	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg20203395	chr5:56204925	C5orf35	-0.72	-10.36	-0.45	1.5e-22	Initial pursuit acceleration;
LUAD	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg07423050	chr13:99094983	FARP1	-0.56	-9.33	-0.41	6.13e-19	Longevity;
LUAD	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg21100191	chr22:23484243	RTDR1	0.71	12.36	0.52	3.5e-30	Bone mineral density;
LUAD	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg08859206	chr1:53392774	SCP2	0.57	10.29	0.45	2.6e-22	Monocyte count;
LUAD	cis	rs73206853	0.640	rs2098140	chr12:110726081	T/A	cg12870014	chr12:110450643	ANKRD13A	0.61	6.4	0.3	4.19e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg11766577	chr21:47581405	C21orf56	0.64	11.78	0.5	6.98e-28	Testicular germ cell tumor;
LUAD	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg22491629	chr6:157744540	C6orf35	-0.83	-9.53	-0.42	1.24e-19	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg01802117	chr1:53393560	SCP2	-0.37	-7.21	-0.33	2.6e-12	Monocyte count;
LUAD	cis	rs922182	0.557	rs7161953	chr15:64202887	C/A	cg02919090	chr15:64263738	DAPK2	-0.35	-6.62	-0.31	1.12e-10	Blood protein levels;
LUAD	cis	rs6761276	0.674	rs3811056	chr2:113831183	T/C	cg09040174	chr2:113837401	NA	0.64	9.77	0.43	1.76e-20	Protein quantitative trait loci;
LUAD	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg20503657	chr10:835505	NA	0.48	7.53	0.34	3.07e-13	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg05872129	chr22:39784769	NA	-0.77	-12.93	-0.53	1.77e-32	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg17264618	chr3:40429014	ENTPD3	0.39	8.62	0.39	1.36e-16	Renal cell carcinoma;
LUAD	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg14828511	chr1:107599125	PRMT6	0.54	9.43	0.42	2.69e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs727505	1.000	rs10230610	chr7:124425398	A/C	cg23710748	chr7:124431027	NA	-0.44	-8.75	-0.39	5.17e-17	Lewy body disease;
LUAD	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	8.99	0.4	8.07e-18	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg05340658	chr4:99064831	C4orf37	0.54	9.15	0.41	2.47e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.63	-0.31	1.02e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs8051149	0.688	rs55776570	chr16:87869516	C/G	cg10099957	chr16:87869757	SLC7A5	0.5	8.91	0.4	1.48e-17	Blood metabolite levels;
LUAD	cis	rs9902453	1.000	rs4465650	chr17:28396721	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	9.13	0.41	2.86e-18	Coffee consumption (cups per day);
LUAD	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg10755058	chr3:40428713	ENTPD3	0.46	8.46	0.38	4.35e-16	Renal cell carcinoma;
LUAD	cis	rs6543140	0.927	rs917999	chr2:103067869	G/A	cg03938978	chr2:103052716	IL18RAP	0.35	6.8	0.31	3.53e-11	Blood protein levels;
LUAD	cis	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg20476274	chr7:133979776	SLC35B4	-0.66	-10.83	-0.47	2.76e-24	Mean platelet volume;
LUAD	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg02951883	chr7:2050386	MAD1L1	-0.75	-12.72	-0.53	1.33e-31	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUAD	trans	rs7395662	0.963	rs8189076	chr11:48732975	C/T	cg00717180	chr2:96193071	NA	0.39	7.21	0.33	2.6e-12	HDL cholesterol;
LUAD	cis	rs9462027	0.628	rs58671447	chr6:34752351	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.91	-0.4	1.57e-17	Systemic lupus erythematosus;
LUAD	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg09796270	chr17:17721594	SREBF1	0.38	7.79	0.35	5.3e-14	Total body bone mineral density;
LUAD	cis	rs78773383	0.505	rs13123782	chr4:39377405	A/C	cg12062995	chr4:39368212	RFC1	0.41	6.9	0.32	1.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.41	0.34	6.76e-13	Tonsillectomy;
LUAD	cis	rs4588572	0.686	rs4470742	chr5:77657957	T/G	cg11547950	chr5:77652471	NA	0.78	11.85	0.5	3.49e-28	Triglycerides;
LUAD	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.18	16.1	0.62	8.23e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.36	7.8	0.35	4.95e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3845702	0.673	rs12468986	chr2:180862320	T/G	cg01881094	chr2:180872142	CWC22	0.81	8.67	0.39	9.63e-17	Schizophrenia;
LUAD	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg17724175	chr1:150552817	MCL1	0.39	9.4	0.42	3.51e-19	Tonsillectomy;
LUAD	cis	rs603446	0.703	rs1263151	chr11:116641028	C/T	cg08672956	chr11:116640933	BUD13	0.34	6.63	0.31	1.03e-10	Triglycerides;
LUAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00166722	chr3:10149974	C3orf24	0.75	12.74	0.53	1.05e-31	Alzheimer's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08209163	chr13:28024472	MTIF3	-0.55	-6.64	-0.31	9.87e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-6.9	-0.32	1.91e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg01657329	chr11:68192670	LRP5	-0.47	-8.18	-0.37	3.44e-15	Total body bone mineral density;
LUAD	cis	rs977987	0.902	rs34539062	chr16:75493279	C/A	cg03315344	chr16:75512273	CHST6	0.66	14.99	0.59	4.83e-41	Dupuytren's disease;
LUAD	cis	rs9322817	0.691	rs2486136	chr6:105285759	C/T	cg02098413	chr6:105308735	HACE1	0.41	8.96	0.4	1.06e-17	Thyroid stimulating hormone;
LUAD	cis	rs9309473	0.583	rs6705203	chr2:73574600	T/C	cg20560298	chr2:73613845	ALMS1	-0.43	-6.77	-0.31	4.44e-11	Metabolite levels;
LUAD	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg08859206	chr1:53392774	SCP2	0.58	10.52	0.46	3.76e-23	Monocyte count;
LUAD	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg13902645	chr11:5959945	NA	0.67	13.44	0.55	1.57e-34	DNA methylation (variation);
LUAD	cis	rs7943203	0.539	rs7946557	chr11:108284447	C/T	cg04873221	chr11:107992290	ACAT1	-0.48	-7.37	-0.34	9.13e-13	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs7937890	0.559	rs2597221	chr11:14527075	C/T	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.25e-11	Mitochondrial DNA levels;
LUAD	cis	rs4664308	0.935	rs4520993	chr2:160937673	G/A	cg03641300	chr2:160917029	PLA2R1	-0.38	-6.5	-0.3	2.21e-10	Idiopathic membranous nephropathy;
LUAD	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg06640241	chr16:89574553	SPG7	0.4	6.63	0.31	1.01e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs62400317	0.859	rs114017772	chr6:45113862	T/C	cg18551225	chr6:44695536	NA	-0.56	-8.73	-0.39	5.91e-17	Total body bone mineral density;
LUAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg27588902	chr6:42928151	GNMT	-0.37	-9.68	-0.43	3.77e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7107174	1.000	rs2510043	chr11:77977481	C/G	cg02023728	chr11:77925099	USP35	0.4	6.72	0.31	5.95e-11	Testicular germ cell tumor;
LUAD	cis	rs12545109	0.837	rs4738500	chr8:57356193	G/A	cg07776626	chr8:57350775	NA	-0.67	-9.34	-0.41	5.61e-19	Obesity-related traits;
LUAD	cis	rs7737355	0.898	rs26007	chr5:131006356	T/A	cg06307176	chr5:131281290	NA	0.54	8.34	0.38	1.03e-15	Life satisfaction;
LUAD	cis	rs9287719	0.774	rs4997811	chr2:10755538	T/C	cg03983476	chr2:10830698	NOL10	-0.45	-7.82	-0.36	4.17e-14	Prostate cancer;
LUAD	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.4	0.34	7.47e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg08645402	chr16:4508243	NA	0.51	9.19	0.41	1.79e-18	Schizophrenia;
LUAD	cis	rs807669	0.868	rs762529	chr22:19170205	C/G	cg24911827	chr22:19170109	CLTCL1	0.46	9.59	0.42	7.99e-20	Metabolite levels;
LUAD	cis	rs938554	0.736	rs4697699	chr4:9945722	T/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-7.98	-0.36	1.42e-14	Blood metabolite levels;
LUAD	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg19875535	chr5:140030758	IK	-0.41	-6.98	-0.32	1.14e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg11162385	chr20:25604740	NANP	-0.45	-6.38	-0.3	4.53e-10	Testicular germ cell tumor;
LUAD	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg21775007	chr8:11205619	TDH	0.46	8.25	0.37	2.08e-15	Retinal vascular caliber;
LUAD	cis	rs1215050	0.791	rs649866	chr4:98738826	T/C	cg17366294	chr4:99064904	C4orf37	0.48	8.67	0.39	9.57e-17	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7737355	0.947	rs9885286	chr5:130883270	C/T	cg06307176	chr5:131281290	NA	0.52	8.19	0.37	3.04e-15	Life satisfaction;
LUAD	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg06108461	chr20:60628389	TAF4	-1.11	-20.19	-0.7	5.7e-64	Body mass index;
LUAD	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg14202850	chr17:43974869	MAPT;LOC100130148	0.37	6.41	0.3	3.9e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11644478	chr21:40555479	PSMG1	0.7	11.62	0.49	2.9e-27	Cognitive function;
LUAD	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg08085267	chr17:45401833	C17orf57	-0.51	-8.52	-0.38	2.84e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11890956	chr21:40555474	PSMG1	0.79	13.9	0.56	1.87e-36	Cognitive function;
LUAD	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg03037974	chr15:76606532	NA	0.38	7.91	0.36	2.34e-14	Blood metabolite levels;
LUAD	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg15110403	chr19:17392923	ANKLE1	-0.46	-7.17	-0.33	3.35e-12	Systemic lupus erythematosus;
LUAD	cis	rs4730250	0.707	rs1981696	chr7:106794100	C/T	cg02696742	chr7:106810147	HBP1	0.76	9.96	0.44	3.97e-21	Osteoarthritis;
LUAD	cis	rs6906287	0.647	rs59671368	chr6:118911430	T/A	cg18833306	chr6:118973337	C6orf204	0.48	8.4	0.38	7.08e-16	Electrocardiographic conduction measures;
LUAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.67	-0.46	1.05e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg25036284	chr2:26402008	FAM59B	-0.83	-11.68	-0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg01200585	chr1:228362443	C1orf69	-0.39	-7.1	-0.33	5.38e-12	Diastolic blood pressure;
LUAD	cis	rs6867032	1.000	rs2129472	chr5:2016247	G/A	cg26168224	chr5:2018326	NA	0.8	18.29	0.66	1.76e-55	Gut microbiome composition (winter);
LUAD	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg01017244	chr2:74357527	NA	0.83	13.88	0.56	2.28e-36	Gestational age at birth (maternal effect);
LUAD	cis	rs61990749	0.597	rs2299930	chr14:78163722	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.5	-6.52	-0.3	2e-10	Fibroblast growth factor basic levels;
LUAD	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg27490568	chr2:178487706	NA	0.57	8.32	0.38	1.21e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.53	-0.3	1.87e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg27634071	chr22:45809740	RIBC2;SMC1B	-0.6	-6.44	-0.3	3.2e-10	Tonsillectomy;
LUAD	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.61	-7.35	-0.34	1.01e-12	Body mass index;
LUAD	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.55	0.42	1.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1832871	0.711	rs9459924	chr6:158703902	G/A	cg07165851	chr6:158734300	TULP4	0.71	11.08	0.47	3.13e-25	Height;
LUAD	trans	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg16011800	chr17:1958478	HIC1	0.58	8.07	0.37	7.45e-15	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg13385794	chr1:248469461	NA	0.27	7.17	0.33	3.46e-12	Common traits (Other);
LUAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg09033563	chr22:24373618	LOC391322	-0.55	-8.72	-0.39	6.65e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6992820	0.899	rs7013301	chr8:56688226	G/T	cg06880721	chr8:56792545	LYN	-0.45	-7.5	-0.34	3.72e-13	Mean platelet volume;
LUAD	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg23719950	chr11:63933701	MACROD1	-0.63	-7.44	-0.34	5.65e-13	Mean platelet volume;
LUAD	cis	rs6543140	1.000	rs6543140	chr2:103074274	G/T	cg04239558	chr2:103089729	SLC9A4	0.36	7.34	0.34	1.11e-12	Blood protein levels;
LUAD	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.49	7.73	0.35	8.16e-14	Total body bone mineral density;
LUAD	cis	rs10489202	0.634	rs6427119	chr1:168074145	A/G	cg24449463	chr1:168025552	DCAF6	0.62	9.42	0.42	2.86e-19	Schizophrenia;
LUAD	cis	rs9796	0.835	rs3100807	chr15:41292206	G/A	cg18705301	chr15:41695430	NDUFAF1	0.39	7.38	0.34	8.68e-13	Menopause (age at onset);
LUAD	cis	rs11031096	0.782	rs11031110	chr11:4162652	G/C	cg18678763	chr11:4115507	RRM1	-0.44	-7.57	-0.35	2.36e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs7072216	0.763	rs7910014	chr10:100172110	C/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.67	-0.39	9.52e-17	Metabolite levels;
LUAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.8	-0.31	3.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg18854424	chr1:2615690	NA	0.42	9.15	0.41	2.43e-18	Ulcerative colitis;
LUAD	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg12311346	chr5:56204834	C5orf35	-0.92	-13.7	-0.55	1.32e-35	Initial pursuit acceleration;
LUAD	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg05313129	chr8:58192883	C8orf71	-0.59	-8.7	-0.39	7.45e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4711350	1.000	rs4711350	chr6:33741716	A/G	cg13859433	chr6:33739653	LEMD2	-0.35	-6.78	-0.31	4e-11	Schizophrenia;
LUAD	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.45	-0.3	3.02e-10	Prostate cancer;
LUAD	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg13385794	chr1:248469461	NA	0.26	6.97	0.32	1.23e-11	Common traits (Other);
LUAD	cis	rs9513627	0.833	rs73556129	chr13:100113167	C/T	cg25919922	chr13:100150906	NA	-0.67	-6.37	-0.3	4.95e-10	Obesity-related traits;
LUAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg09436375	chr6:42928200	GNMT	-0.29	-8.35	-0.38	1.01e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.32	-0.34	1.22e-12	Blood metabolite levels;
LUAD	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg04990556	chr1:26633338	UBXN11	-0.43	-6.98	-0.32	1.12e-11	Obesity-related traits;
LUAD	cis	rs17102423	0.594	rs8010213	chr14:65552182	C/T	cg11161011	chr14:65562177	MAX	-0.44	-7.42	-0.34	6.52e-13	Obesity-related traits;
LUAD	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg17366294	chr4:99064904	C4orf37	0.59	10.95	0.47	9.8e-25	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs2268241	0.938	rs11088251	chr21:34770810	A/C	cg14850771	chr21:34775459	IFNGR2	0.6	7.59	0.35	2.08e-13	Obesity-related traits;
LUAD	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg19318889	chr4:1322082	MAEA	0.4	6.4	0.3	4.2e-10	Obesity-related traits;
LUAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00166722	chr3:10149974	C3orf24	0.63	10.61	0.46	1.77e-23	Alzheimer's disease;
LUAD	cis	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg00071950	chr4:10020882	SLC2A9	0.55	8.31	0.37	1.31e-15	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg20991723	chr1:152506922	NA	0.33	6.55	0.3	1.63e-10	Hair morphology;
LUAD	cis	rs1595825	0.786	rs16826740	chr2:198893927	A/G	cg11031976	chr2:198649780	BOLL	-0.45	-6.53	-0.3	1.84e-10	Ulcerative colitis;
LUAD	cis	rs9287719	0.601	rs6755281	chr2:10769855	T/C	cg02196655	chr2:10830764	NOL10	-0.38	-6.59	-0.31	1.28e-10	Prostate cancer;
LUAD	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg19418458	chr7:158789849	NA	0.66	8.8	0.39	3.63e-17	Facial morphology (factor 20);
LUAD	trans	rs879500	0.653	rs4131805	chr18:26059112	T/C	cg26154937	chr10:49674883	ARHGAP22	0.32	6.58	0.3	1.38e-10	Lung function (FVC);
LUAD	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg23018236	chr17:30244563	NA	-0.69	-8.42	-0.38	6.04e-16	Hip circumference adjusted for BMI;
LUAD	trans	rs11039798	0.925	rs7929225	chr11:48931739	G/C	cg03929089	chr4:120376271	NA	0.59	6.79	0.31	3.9e-11	Axial length;
LUAD	trans	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg00717180	chr2:96193071	NA	-0.43	-7.95	-0.36	1.72e-14	HDL cholesterol;
LUAD	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21582582	chr3:182698605	DCUN1D1	0.72	14.1	0.57	2.78e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21984481	chr17:79567631	NPLOC4	0.65	15.66	0.61	6.36e-44	Eye color traits;
LUAD	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	11.52	0.49	6.82e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg20503657	chr10:835505	NA	0.76	10.17	0.44	7.02e-22	Eosinophil percentage of granulocytes;
LUAD	cis	rs12210905	0.688	rs72845232	chr6:27428126	T/G	cg08851530	chr6:28072375	NA	1.02	7.77	0.35	6.04e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs2279817	0.863	rs11203439	chr1:18026328	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.56	8.93	0.4	1.34e-17	Neuroticism;
LUAD	cis	rs11771526	0.901	rs41519845	chr7:32315443	A/T	cg27532318	chr7:32358331	NA	0.6	7.58	0.35	2.14e-13	Body mass index;
LUAD	cis	rs3736594	0.918	rs9677663	chr2:27972445	G/A	cg27432699	chr2:27873401	GPN1	-0.47	-7.32	-0.34	1.23e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.71	-0.39	6.68e-17	Alcohol dependence;
LUAD	cis	rs61897795	0.657	rs174587	chr11:61612830	C/T	cg06781209	chr11:61594997	FADS2	-0.46	-7.3	-0.33	1.48e-12	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14159672	chr1:205819179	PM20D1	0.92	20.97	0.71	1.87e-67	Menarche (age at onset);
LUAD	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg20673091	chr1:2541236	MMEL1	0.44	9.6	0.42	7.1e-20	Ulcerative colitis;
LUAD	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg21951975	chr1:209979733	IRF6	0.56	8.03	0.36	9.6e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg11214544	chr1:2391121	NA	-0.49	-10.85	-0.47	2.31e-24	Schizophrenia;
LUAD	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.57	0.52	5.38e-31	Urate levels;
LUAD	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg06547715	chr2:218990976	CXCR2	-0.41	-9.86	-0.43	8.63e-21	Ulcerative colitis;
LUAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg10862848	chr6:42927986	GNMT	-0.31	-8.86	-0.4	2.28e-17	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg22875332	chr1:76189707	ACADM	-0.66	-10.49	-0.45	4.73e-23	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4638749	0.677	rs7568919	chr2:108832376	C/A	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.3	-0.33	1.48e-12	Blood pressure;
LUAD	cis	rs10992471	0.603	rs7033979	chr9:95223980	A/G	cg14631576	chr9:95140430	CENPP	-0.56	-11.51	-0.49	7.1e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs9287719	0.601	rs6755281	chr2:10769855	T/C	cg03983476	chr2:10830698	NOL10	-0.39	-6.48	-0.3	2.55e-10	Prostate cancer;
LUAD	cis	rs727505	0.866	rs3214004	chr7:124720929	T/C	cg23710748	chr7:124431027	NA	-0.42	-8.51	-0.38	2.97e-16	Lewy body disease;
LUAD	cis	rs6138458	1.000	rs6114988	chr20:24977586	C/T	cg06937882	chr20:24974362	C20orf3	-0.34	-6.8	-0.31	3.61e-11	Blood protein levels;
LUAD	cis	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg07460842	chr6:66804631	NA	0.93	14.85	0.59	1.95e-40	Exhaled nitric oxide levels;
LUAD	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg25809561	chr17:30822961	MYO1D	0.75	15.54	0.6	2.08e-43	Schizophrenia;
LUAD	trans	rs1422110	0.647	rs10063838	chr5:85530546	T/C	cg01787110	chr1:109008453	NBPF6	-0.75	-12.81	-0.53	5.68e-32	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19346786	chr7:2764209	NA	-0.41	-8.82	-0.39	2.93e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg17761419	chr8:57350749	NA	-0.52	-7.89	-0.36	2.64e-14	Obesity-related traits;
LUAD	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg06623918	chr6:96969491	KIAA0776	0.73	11.63	0.49	2.57e-27	Migraine;Coronary artery disease;
LUAD	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg07195577	chr17:27052828	TLCD1	0.46	6.44	0.3	3.17e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg01191920	chr7:158217561	PTPRN2	-0.74	-16.65	-0.63	3.09e-48	Obesity-related traits;
LUAD	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.61	0.31	1.14e-10	Cardiac Troponin-T levels;
LUAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg18402987	chr7:1209562	NA	0.77	9.45	0.42	2.3e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.84e-26	Alzheimer's disease (late onset);
LUAD	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg08859206	chr1:53392774	SCP2	0.6	10.8	0.46	3.62e-24	Monocyte count;
LUAD	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg18876405	chr7:65276391	NA	-0.42	-6.71	-0.31	6.18e-11	Aortic root size;
LUAD	cis	rs12760731	0.720	rs34194793	chr1:178329065	G/T	cg00404053	chr1:178313656	RASAL2	0.66	8.48	0.38	3.81e-16	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.26e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg25243455	chr2:114033360	PAX8;LOC440839	0.39	8.64	0.39	1.21e-16	Lymphocyte counts;
LUAD	cis	rs57502260	1.000	rs56312530	chr11:68219415	G/A	cg16797656	chr11:68205561	LRP5	0.52	8.11	0.37	5.47e-15	Total body bone mineral density (age 45-60);
LUAD	cis	rs6993813	0.872	rs10091277	chr8:120034387	A/G	cg01975934	chr8:119970761	NA	-0.35	-6.83	-0.32	3.03e-11	Bone mineral density (hip);
LUAD	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg25319279	chr11:5960081	NA	-0.4	-7.47	-0.34	4.71e-13	DNA methylation (variation);
LUAD	cis	rs6484504	0.576	rs158136	chr11:31220712	C/T	cg26647111	chr11:31128758	NA	-0.46	-8.24	-0.37	2.13e-15	Red blood cell count;
LUAD	cis	rs2688608	0.967	rs2688609	chr10:75658181	A/G	cg19442545	chr10:75533431	FUT11	0.43	7.25	0.33	1.98e-12	Inflammatory bowel disease;
LUAD	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg06484146	chr7:12443880	VWDE	-0.6	-7.62	-0.35	1.64e-13	Coronary artery disease;
LUAD	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6782228	0.675	rs9813845	chr3:128399623	G/C	cg16766828	chr3:128327626	NA	-0.4	-7.18	-0.33	3.16e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	trans	rs1493916	0.777	rs1493910	chr18:31318376	A/G	cg27147174	chr7:100797783	AP1S1	-0.64	-11.3	-0.48	4.87e-26	Life satisfaction;
LUAD	cis	rs863345	0.526	rs2051666	chr1:158507160	T/G	cg12129480	chr1:158549410	OR10X1	-0.24	-6.41	-0.3	3.88e-10	Pneumococcal bacteremia;
LUAD	cis	rs193541	0.586	rs11241662	chr5:122181975	A/G	cg19077854	chr5:122220652	SNX24	-0.34	-6.49	-0.3	2.34e-10	Glucose homeostasis traits;
LUAD	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg03467027	chr4:99064603	C4orf37	0.41	6.63	0.31	1.03e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.54	-0.34	2.81e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12545109	0.800	rs1437278	chr8:57357024	T/C	cg17761419	chr8:57350749	NA	-0.58	-8.13	-0.37	4.67e-15	Obesity-related traits;
LUAD	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg08027265	chr7:2291960	NA	-0.52	-9.18	-0.41	1.98e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs2625529	0.761	rs11853268	chr15:72238973	T/C	cg16672083	chr15:72433130	SENP8	-0.76	-12.75	-0.53	9.73e-32	Red blood cell count;
LUAD	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg01689657	chr7:91764605	CYP51A1	0.38	9.27	0.41	9.8e-19	Breast cancer;
LUAD	cis	rs12681287	0.547	rs6471360	chr8:87513469	C/T	cg27223183	chr8:87520930	FAM82B	0.72	10.32	0.45	2.08e-22	Caudate activity during reward;
LUAD	cis	rs4891159	0.790	rs683306	chr18:74112473	C/G	cg24786174	chr18:74118243	ZNF516	-0.81	-15.29	-0.6	2.52e-42	Longevity;
LUAD	cis	rs7119038	0.607	rs12365699	chr11:118743286	C/T	cg19308663	chr11:118741387	NA	0.63	8.18	0.37	3.26e-15	Sjögren's syndrome;
LUAD	cis	rs526821	0.595	rs517627	chr11:55356489	C/T	cg04317927	chr11:55418816	OR4S2	0.39	7.51	0.34	3.52e-13	Pediatric bone mineral density (spine);
LUAD	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.72	-0.35	8.21e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.66	0.31	8.53e-11	Cardiac Troponin-T levels;
LUAD	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg08422745	chr4:174089978	GALNT7	0.94	16.26	0.62	1.54e-46	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg15017067	chr4:17643749	FAM184B	0.35	6.83	0.32	3.01e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11971779	0.553	rs10085770	chr7:139100349	G/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.38e-10	Diisocyanate-induced asthma;
LUAD	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg03560586	chr2:239334908	ASB1	-0.3	-6.45	-0.3	3e-10	Multiple system atrophy;
LUAD	cis	rs6901250	1.000	rs615199	chr6:117113653	T/C	cg12892004	chr6:117198278	RFX6	0.33	6.94	0.32	1.47e-11	C-reactive protein levels;
LUAD	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-11.75	-0.5	8.78e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg07423050	chr13:99094983	FARP1	-0.54	-9.11	-0.4	3.37e-18	Longevity;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg11636699	chr19:13044490	FARSA	-0.57	-6.89	-0.32	1.97e-11	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02353165	chr6:42928485	GNMT	0.4	7.04	0.32	8.05e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2455601	0.608	rs16906256	chr11:8887097	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.43	-8.08	-0.37	7.07e-15	Schizophrenia;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14938410	chr1:150521562	ADAMTSL4	0.42	6.58	0.3	1.37e-10	Gut microbiome composition (summer);
LUAD	trans	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg21775007	chr8:11205619	TDH	0.39	6.71	0.31	6.32e-11	Mood instability;
LUAD	cis	rs2692947	0.759	rs2692937	chr2:96751871	G/A	cg23100626	chr2:96804247	ASTL	0.35	8.81	0.39	3.26e-17	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg13354988	chr2:263656	ACP1;SH3YL1	0.29	6.39	0.3	4.3e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg02807482	chr3:125708958	NA	-0.65	-8.65	-0.39	1.06e-16	Blood pressure (smoking interaction);
LUAD	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.49	-9.68	-0.43	3.84e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg15017067	chr4:17643749	FAM184B	0.35	6.47	0.3	2.67e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08399230	chr16:4665037	FAM100A	-0.5	-6.49	-0.3	2.44e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg04989706	chr14:50066350	PPIL5	-0.49	-7.34	-0.34	1.14e-12	Carotid intima media thickness;
LUAD	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg17366294	chr4:99064904	C4orf37	-0.5	-8.83	-0.39	2.76e-17	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19942813	chr3:187463496	BCL6	-0.54	-6.45	-0.3	3.01e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.04	0.32	7.86e-12	Prostate cancer;
LUAD	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.46	-7.33	-0.34	1.19e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	trans	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04565464	chr8:145669602	NFKBIL2	0.44	6.55	0.3	1.69e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg14343924	chr8:8086146	FLJ10661	-0.47	-7.24	-0.33	2.13e-12	Mood instability;
LUAD	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg14779329	chr11:130786720	SNX19	0.39	6.92	0.32	1.63e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7187994	0.609	rs35705630	chr16:84743372	T/C	cg07647771	chr16:84786436	USP10	-0.27	-7.39	-0.34	8.13e-13	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs739496	0.527	rs4767074	chr12:112292962	G/C	cg10833066	chr12:111807467	FAM109A	0.43	7.02	0.32	8.96e-12	Platelet count;
LUAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs2046867	0.908	rs62251650	chr3:72809823	T/C	cg25664220	chr3:72788482	NA	-0.67	-11.95	-0.5	1.54e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg09997546	chr11:8931473	C11orf17;ST5	0.39	8.11	0.37	5.5e-15	Hemoglobin concentration;
LUAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.19	-0.41	1.78e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg11845111	chr2:191398756	TMEM194B	-0.73	-9.69	-0.43	3.54e-20	Diastolic blood pressure;
LUAD	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg23803603	chr1:2058230	PRKCZ	-0.42	-7.77	-0.35	6.16e-14	Height;
LUAD	cis	rs9902453	1.000	rs9902453	chr17:28349095	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.22	-0.41	1.43e-18	Coffee consumption (cups per day);
LUAD	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03407747	chr17:6899364	ALOX12	0.39	7.37	0.34	8.84e-13	Tonsillectomy;
LUAD	cis	rs3733418	0.929	rs72697952	chr4:165900928	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.49	-6.91	-0.32	1.79e-11	Obesity-related traits;
LUAD	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg15462221	chr8:8086144	FLJ10661	-0.39	-6.39	-0.3	4.35e-10	Mood instability;
LUAD	cis	rs7408868	0.563	rs10404382	chr19:15301389	C/A	cg14696996	chr19:15285081	NOTCH3	0.64	8.52	0.38	2.82e-16	Pulse pressure;
LUAD	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.61	-0.42	6.76e-20	Life satisfaction;
LUAD	cis	rs3820068	0.871	rs2861484	chr1:15812665	G/T	cg13390004	chr1:15929781	NA	0.46	6.64	0.31	9.65e-11	Systolic blood pressure;
LUAD	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg11189052	chr15:85197271	WDR73	0.68	8.92	0.4	1.38e-17	Schizophrenia;
LUAD	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg17177755	chr1:15930204	NA	0.46	7.41	0.34	6.87e-13	Systolic blood pressure;
LUAD	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg15704280	chr7:45808275	SEPT13	-1.05	-23.49	-0.75	1.05e-78	Height;
LUAD	cis	rs938554	0.956	rs874432	chr4:9920606	A/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-7.42	-0.34	6.37e-13	Blood metabolite levels;
LUAD	cis	rs12422267	0.536	rs12303484	chr12:132609558	G/A	cg09764611	chr12:132620959	NA	-0.63	-10.65	-0.46	1.3e-23	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs6564851	0.506	rs11641342	chr16:81257588	G/A	cg00908271	chr16:81254010	PKD1L2	0.34	6.89	0.32	2.09e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg04369109	chr6:150039330	LATS1	0.44	7.25	0.33	1.95e-12	Lung cancer;
LUAD	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg15181151	chr6:150070149	PCMT1	0.38	7.68	0.35	1.12e-13	Lung cancer;
LUAD	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg02158880	chr13:53174818	NA	0.49	8.43	0.38	5.49e-16	Lewy body disease;
LUAD	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg07936489	chr17:37558343	FBXL20	0.47	7.52	0.34	3.32e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg25036284	chr2:26402008	FAM59B	-0.58	-8.17	-0.37	3.48e-15	Gut microbiome composition (summer);
LUAD	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg27411982	chr8:10470053	RP1L1	0.38	6.74	0.31	5.14e-11	Retinal vascular caliber;
LUAD	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.06e-11	Parkinson's disease;
LUAD	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.89	-0.32	2.04e-11	Retinal vascular caliber;
LUAD	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-12.45	-0.52	1.55e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	10.32	0.45	2.1e-22	Lung cancer in ever smokers;
LUAD	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	6.12e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg17633681	chr16:88106987	BANP	0.41	7.02	0.32	9.01e-12	Menopause (age at onset);
LUAD	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg21171335	chr12:122356390	WDR66	-0.74	-13.56	-0.55	4.69e-35	Mean corpuscular volume;
LUAD	cis	rs9888739	0.800	rs1143683	chr16:31336888	A/G	cg15817542	chr16:31343056	ITGAM	0.43	7.24	0.33	2.14e-12	Systemic lupus erythematosus;
LUAD	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg23803603	chr1:2058230	PRKCZ	0.43	6.84	0.32	2.84e-11	Height;
LUAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg05896524	chr21:47604654	C21orf56	-0.74	-13.37	-0.54	3.08e-34	Testicular germ cell tumor;
LUAD	cis	rs1018836	0.886	rs10112242	chr8:91642631	G/C	cg16814680	chr8:91681699	NA	-0.66	-11.46	-0.49	1.12e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg13047869	chr3:10149882	C3orf24	0.54	8.14	0.37	4.62e-15	Alzheimer's disease;
LUAD	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg20607798	chr8:58055168	NA	0.8	9.7	0.43	3.33e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11021810	chr14:89720620	FOXN3	0.53	6.46	0.3	2.85e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg18135555	chr8:22132992	PIWIL2	0.41	7.41	0.34	6.87e-13	Hypertriglyceridemia;
LUAD	cis	rs8077889	0.917	rs4793037	chr17:41914826	C/T	cg26893861	chr17:41843967	DUSP3	0.89	14.32	0.57	3.38e-38	Triglycerides;
LUAD	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.85	-0.36	3.38e-14	Diabetic kidney disease;
LUAD	cis	rs2458413	1.000	rs2458413	chr8:105359432	C/T	cg04554929	chr8:105342491	NA	0.35	6.75	0.31	4.84e-11	Paget's disease;
LUAD	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg24399712	chr22:39784796	NA	-0.82	-16.11	-0.62	7.42e-46	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg09323728	chr8:95962352	TP53INP1	-0.35	-8.51	-0.38	2.96e-16	Type 2 diabetes;
LUAD	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.14	0.33	3.99e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg26384229	chr12:38710491	ALG10B	0.46	7.52	0.34	3.2e-13	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24323328	chr12:1099998	ERC1	-0.56	-6.74	-0.31	5.32e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg12432903	chr7:1882776	MAD1L1	0.39	6.51	0.3	2.18e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs1595825	0.838	rs79381203	chr2:198573762	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-7.37	-0.34	8.92e-13	Ulcerative colitis;
LUAD	cis	rs2742417	0.565	rs2673031	chr3:45756986	A/G	cg10512202	chr3:45649293	LIMD1	0.49	9.15	0.41	2.35e-18	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg10523679	chr1:76189770	ACADM	0.69	9.52	0.42	1.35e-19	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg26384229	chr12:38710491	ALG10B	0.45	7.38	0.34	8.57e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs41311933	0.656	rs72760226	chr9:123887327	G/T	cg13567360	chr9:123745713	C5	-0.73	-8.46	-0.38	4.36e-16	Coronary artery disease;
LUAD	trans	rs208520	0.690	rs851458	chr6:66813279	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-17.88	-0.66	1.17e-53	Exhaled nitric oxide output;
LUAD	cis	rs41311933	0.656	rs72758196	chr9:123820313	G/A	cg13567360	chr9:123745713	C5	-0.73	-8.79	-0.39	3.86e-17	Coronary artery disease;
LUAD	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg21427119	chr20:30132790	HM13	-0.61	-9.12	-0.41	3.08e-18	Mean corpuscular hemoglobin;
LUAD	cis	rs977987	0.806	rs7185640	chr16:75394399	A/G	cg03315344	chr16:75512273	CHST6	0.65	14.19	0.57	1.22e-37	Dupuytren's disease;
LUAD	cis	rs7493	0.901	rs11767787	chr7:95026753	T/C	cg04871131	chr7:94954202	PON1	-0.48	-6.54	-0.3	1.79e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg11707310	chr1:2537719	MMEL1	0.38	7.86	0.36	3.23e-14	Ulcerative colitis;
LUAD	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg02782426	chr3:40428986	ENTPD3	0.35	7.59	0.35	2e-13	Renal cell carcinoma;
LUAD	cis	rs9487051	0.839	rs13196590	chr6:109561918	T/C	cg21918786	chr6:109611834	NA	-0.43	-7.22	-0.33	2.43e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs11676348	0.935	rs6716276	chr2:218962205	A/G	cg06547715	chr2:218990976	CXCR2	0.36	8.15	0.37	4.2e-15	Ulcerative colitis;
LUAD	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24308560	chr3:49941425	MST1R	0.54	9.15	0.41	2.45e-18	Body mass index;
LUAD	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.18	-0.33	3.12e-12	Height;
LUAD	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg21138405	chr5:131827807	IRF1	-0.6	-13.34	-0.54	3.82e-34	Asthma (sex interaction);
LUAD	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg02423579	chr7:2872169	GNA12	-0.84	-14.34	-0.57	2.75e-38	Height;
LUAD	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg02505535	chr3:195703920	SDHAP1	0.33	6.84	0.32	2.8e-11	Pancreatic cancer;
LUAD	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg03859395	chr2:55845619	SMEK2	0.76	14.16	0.57	1.6e-37	Metabolic syndrome;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg14114033	chr7:105752648	SYPL1	-0.65	-6.37	-0.3	5.01e-10	Type 2 diabetes;
LUAD	cis	rs55728055	0.661	rs62237791	chr22:31973124	A/G	cg01338084	chr22:32026380	PISD	0.9	6.94	0.32	1.51e-11	Age-related hearing impairment;
LUAD	cis	rs2294693	0.730	rs9369248	chr6:40959664	G/T	cg14769373	chr6:40998127	UNC5CL	0.54	8.08	0.37	7.04e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg13511324	chr14:104056883	C14orf153	0.26	6.49	0.3	2.43e-10	Coronary artery disease;
LUAD	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg22963979	chr7:1858916	MAD1L1	-0.59	-10.17	-0.44	6.84e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg11965913	chr1:205819406	PM20D1	-0.53	-8.06	-0.36	8.05e-15	Menarche (age at onset);
LUAD	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.7	-11.62	-0.49	2.79e-27	Primary sclerosing cholangitis;
LUAD	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg23029597	chr12:123009494	RSRC2	-0.57	-8.93	-0.4	1.35e-17	Body mass index;
LUAD	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03517284	chr6:25882590	NA	-0.57	-9.17	-0.41	2.07e-18	Blood metabolite levels;
LUAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.61	8.36	0.38	9.03e-16	Renal function-related traits (BUN);
LUAD	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg05342682	chr7:94953680	PON1	-0.51	-7.1	-0.33	5.45e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg15448220	chr1:150897856	SETDB1	0.5	8.62	0.39	1.35e-16	Tonsillectomy;
LUAD	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.72	-0.35	8.21e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg04414720	chr1:150670196	GOLPH3L	0.71	12.28	0.51	7.25e-30	Melanoma;
LUAD	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg18180107	chr4:99064573	C4orf37	0.41	6.67	0.31	8.2e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg03676636	chr4:99064102	C4orf37	-0.31	-8.21	-0.37	2.74e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6960043	0.818	rs10228066	chr7:15063569	C/T	cg19272540	chr7:15055459	NA	-0.36	-7.87	-0.36	2.92e-14	Type 2 diabetes;
LUAD	trans	rs6561151	0.957	rs7995004	chr13:44478820	C/T	cg12856521	chr11:46389249	DGKZ	0.64	10.06	0.44	1.72e-21	Crohn's disease;
LUAD	cis	rs2996428	0.709	rs7527973	chr1:3704041	C/T	cg23277830	chr1:3704460	LRRC47	0.49	10.13	0.44	9.6e-22	Red cell distribution width;
LUAD	cis	rs494562	0.892	rs617483	chr6:86124008	C/T	cg17966619	chr6:86160162	NT5E	0.64	7.68	0.35	1.14e-13	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1609391	0.543	rs6761993	chr3:136625902	C/T	cg15507776	chr3:136538369	TMEM22	0.5	8.93	0.4	1.36e-17	Neuroticism;
LUAD	cis	rs2286885	1.000	rs10760438	chr9:129245334	C/A	cg15282417	chr9:129245246	FAM125B	0.43	8.66	0.39	1.04e-16	Intraocular pressure;
LUAD	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.67	-0.35	1.21e-13	Total body bone mineral density;
LUAD	trans	rs7746199	0.736	rs72845070	chr6:27668300	A/C	cg06606381	chr12:133084897	FBRSL1	-1.16	-10.51	-0.46	4.1000000000000003e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs990171	0.511	rs2072509	chr2:103118337	G/C	cg03938978	chr2:103052716	IL18RAP	0.33	6.48	0.3	2.52e-10	Lymphocyte counts;
LUAD	cis	rs7267979	0.816	rs374701	chr20:25483616	A/G	cg08601574	chr20:25228251	PYGB	0.41	7.72	0.35	8.48e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10821973	0.527	rs4420157	chr10:63979105	C/T	cg09941381	chr10:64027924	RTKN2	-0.34	-6.75	-0.31	4.95e-11	Hypothyroidism;
LUAD	cis	rs10392	0.543	rs4812333	chr20:37536119	T/A	cg27552599	chr20:37590471	DHX35	0.38	6.45	0.3	2.98e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg25482853	chr8:67687455	SGK3	1.18	18.2	0.66	4.58e-55	Lung disease severity in cystic fibrosis;
LUAD	cis	rs2677744	0.626	rs12905855	chr15:91498429	G/C	cg23684204	chr15:91497937	RCCD1	0.42	7.1	0.33	5.22e-12	Attention deficit hyperactivity disorder;
LUAD	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg25919922	chr13:100150906	NA	0.68	8.96	0.4	1.07e-17	Obesity-related traits;
LUAD	cis	rs250677	0.524	rs417413	chr5:148452726	T/C	cg12140854	chr5:148520817	ABLIM3	-0.5	-8.52	-0.38	2.75e-16	Breast cancer;
LUAD	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg25554036	chr4:6271136	WFS1	0.65	11.5	0.49	8.45e-27	Cisplatin-induced ototoxicity;
LUAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg10150615	chr22:24372951	LOC391322	-0.57	-9.57	-0.42	9.38e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg16031515	chr1:205743344	RAB7L1	-0.36	-7.3	-0.33	1.45e-12	Menarche (age at onset);
LUAD	cis	rs1003719	0.762	rs6517402	chr21:38447423	A/C	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.53	0.38	2.73e-16	Eye color traits;
LUAD	cis	rs1003719	0.788	rs61701101	chr21:38450317	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.66	0.39	9.98e-17	Eye color traits;
LUAD	cis	rs2046867	0.628	rs7617996	chr3:72915315	C/T	cg25664220	chr3:72788482	NA	-0.55	-10.14	-0.44	9.26e-22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9902453	0.808	rs76039587	chr17:28233760	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.34	0.41	5.55e-19	Coffee consumption (cups per day);
LUAD	cis	rs17095355	1.000	rs2122517	chr10:111754787	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.75	-10.65	-0.46	1.3e-23	Biliary atresia;
LUAD	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg02782426	chr3:40428986	ENTPD3	0.35	7.58	0.35	2.28e-13	Renal cell carcinoma;
LUAD	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg23109721	chr2:106886537	NA	-0.48	-6.79	-0.31	3.78e-11	Facial morphology (factor 23);
LUAD	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.54	-8.86	-0.4	2.17e-17	Primary sclerosing cholangitis;
LUAD	cis	rs6988985	0.589	rs6471580	chr8:143986701	A/G	cg10324643	chr8:143916377	GML	0.32	6.75	0.31	5e-11	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs2224391	0.590	rs2773312	chr6:5251798	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-8.58	-0.38	1.83e-16	Height;
LUAD	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg00310523	chr12:86230176	RASSF9	0.4	8.19	0.37	3.06e-15	Major depressive disorder;
LUAD	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.48e-11	Crohn's disease;
LUAD	cis	rs9584850	1.000	rs9584850	chr13:99101426	G/C	cg07423050	chr13:99094983	FARP1	0.4	6.73	0.31	5.48e-11	Neuroticism;
LUAD	cis	rs868943	0.743	rs13192924	chr6:116352332	T/C	cg15226275	chr6:116381976	FRK	0.23	6.41	0.3	3.78e-10	Total cholesterol levels;
LUAD	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07256732	chr16:621771	PIGQ	-0.33	-6.95	-0.32	1.43e-11	Height;
LUAD	cis	rs6831352	0.879	rs35146617	chr4:100066686	C/T	cg12011299	chr4:100065546	ADH4	-0.72	-12.98	-0.53	1.19e-32	Alcohol dependence;
LUAD	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg02733842	chr7:1102375	C7orf50	-0.82	-11.86	-0.5	3.29e-28	Bronchopulmonary dysplasia;
LUAD	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg02461776	chr11:598696	PHRF1	0.47	6.87	0.32	2.31e-11	Systemic lupus erythematosus;
LUAD	cis	rs782590	0.721	rs1084525	chr2:55929430	C/T	cg03859395	chr2:55845619	SMEK2	0.67	11.95	0.5	1.43e-28	Metabolic syndrome;
LUAD	cis	rs56283067	0.740	rs111810959	chr6:44709460	C/A	cg18551225	chr6:44695536	NA	-0.54	-9.06	-0.4	5.03e-18	Total body bone mineral density;
LUAD	cis	rs35110281	0.540	rs55840436	chr21:45118541	G/T	cg04455712	chr21:45112962	RRP1B	0.49	9.98	0.44	3.41e-21	Mean corpuscular volume;
LUAD	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg09455208	chr3:40491958	NA	0.65	14.24	0.57	6.94e-38	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.48	-6.61	-0.31	1.19e-10	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.15e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg21782813	chr7:2030301	MAD1L1	0.6	10.52	0.46	3.89e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg09117114	chr16:67998030	SLC12A4	-0.6	-7.52	-0.34	3.4e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25427524	chr10:38739819	LOC399744	-0.78	-14.31	-0.57	3.52e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4795519	0.556	rs4889760	chr17:22231756	A/G	cg22648282	chr17:21454238	C17orf51	-0.38	-6.61	-0.31	1.15e-10	Chronic myeloid leukemia;
LUAD	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.51	-0.3	2.13e-10	Triglycerides;
LUAD	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg04586622	chr2:25135609	ADCY3	0.38	8.69	0.39	8.05e-17	Body mass index;
LUAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.82	-0.31	3.12e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1215050	0.776	rs1627946	chr4:98844416	G/A	cg17366294	chr4:99064904	C4orf37	-0.48	-8.36	-0.38	8.88e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18876405	chr7:65276391	NA	0.42	6.51	0.3	2.18e-10	Aortic root size;
LUAD	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg02158880	chr13:53174818	NA	0.47	7.95	0.36	1.72e-14	Lewy body disease;
LUAD	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg00701064	chr4:6280414	WFS1	0.58	10.91	0.47	1.33e-24	Cisplatin-induced ototoxicity;
LUAD	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg06740227	chr12:86229804	RASSF9	-0.36	-6.58	-0.3	1.39e-10	Major depressive disorder;
LUAD	cis	rs494562	0.892	rs617483	chr6:86124008	C/T	cg13315970	chr6:86159197	NT5E	0.72	8.06	0.37	7.63e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg00933542	chr6:150070202	PCMT1	0.44	9.6	0.42	6.92e-20	Lung cancer;
LUAD	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg09455208	chr3:40491958	NA	0.61	13.25	0.54	9.24e-34	Renal cell carcinoma;
LUAD	cis	rs2573652	1.000	rs11634977	chr15:100516472	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.55	-10.35	-0.45	1.59e-22	Height;
LUAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg12432903	chr7:1882776	MAD1L1	-0.5	-8.35	-0.38	1e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs4889855	0.511	rs9908700	chr17:78466594	A/G	cg16591659	chr17:78472290	NA	-0.52	-8.42	-0.38	6.03e-16	Fractional excretion of uric acid;
LUAD	cis	rs4764487	0.735	rs2072372	chr12:6344600	C/A	cg08284733	chr12:6341482	CD9	0.42	7.41	0.34	6.76e-13	Mean platelet volume;
LUAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08219700	chr8:58056026	NA	0.57	8.08	0.37	6.8e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg06131755	chr6:160182447	ACAT2	0.43	6.38	0.3	4.76e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg06740227	chr12:86229804	RASSF9	0.41	7.29	0.33	1.57e-12	Major depressive disorder;
LUAD	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg20108693	chr8:143823809	SLURP1	0.31	7.13	0.33	4.26e-12	Urinary tract infection frequency;
LUAD	cis	rs11051970	0.879	rs2651378	chr12:32581794	A/G	cg24626660	chr12:32551988	NA	0.32	6.5	0.3	2.23e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg04989706	chr14:50066350	PPIL5	-0.49	-7.29	-0.33	1.58e-12	Carotid intima media thickness;
LUAD	cis	rs3784262	0.528	rs4553566	chr15:58336319	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-7.02	-0.32	8.8e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg03030879	chr14:75389066	RPS6KL1	0.34	6.41	0.3	3.98e-10	Caffeine consumption;
LUAD	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg06740227	chr12:86229804	RASSF9	0.42	7.24	0.33	2.1e-12	Major depressive disorder;
LUAD	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.78	-0.31	4.02e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg22681709	chr2:178499509	PDE11A	-0.56	-9.72	-0.43	2.78e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10089	1.000	rs10089	chr5:127522543	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	9.13	0.41	2.94e-18	Ileal carcinoids;
LUAD	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg05342682	chr7:94953680	PON1	-0.51	-7.01	-0.32	9.46e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg11822812	chr5:140052017	DND1	0.38	6.66	0.31	8.67e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.36	7.32	0.34	1.27e-12	Parkinson's disease;
LUAD	cis	rs2425143	1.000	rs57963833	chr20:34344225	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.17	-0.33	3.46e-12	Blood protein levels;
LUAD	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg08470875	chr2:26401718	FAM59B	-0.5	-6.91	-0.32	1.81e-11	Gut microbiome composition (summer);
LUAD	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg05044414	chr3:183734942	ABCC5	0.48	9.95	0.44	4.28e-21	Anterior chamber depth;
LUAD	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg12034118	chr1:209979487	IRF6	0.58	7.73	0.35	7.68e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs2686555	0.649	rs1151874	chr12:121092555	T/C	cg24292016	chr12:121087689	CABP1	0.44	7.06	0.32	6.79e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg00603274	chr11:61596626	FADS2	-0.42	-6.68	-0.31	7.35e-11	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.62	-0.42	6.23e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg15921436	chr17:44337874	NA	-0.75	-9.72	-0.43	2.66e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9296095	1.000	rs5745582	chr6:33546498	C/T	cg14003231	chr6:33640908	ITPR3	0.52	9.43	0.42	2.79e-19	Platelet count;
LUAD	trans	rs11039798	0.614	rs11039954	chr11:48741818	A/G	cg15704280	chr7:45808275	SEPT13	0.67	7.89	0.36	2.62e-14	Axial length;
LUAD	trans	rs6076960	0.629	rs6054031	chr20:6233657	C/G	cg17788362	chr6:86352627	SYNCRIP	0.42	6.5	0.3	2.29e-10	Smooth-surface caries;
LUAD	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg21433313	chr16:3507492	NAT15	0.76	9.55	0.42	1.07e-19	Tuberculosis;
LUAD	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-8.45	-0.38	4.85e-16	Alzheimer's disease (late onset);
LUAD	cis	rs4988958	0.548	rs6543127	chr2:103028301	A/C	cg03938978	chr2:103052716	IL18RAP	0.45	10.33	0.45	1.82e-22	Asthma (childhood onset);
LUAD	cis	rs11030122	0.661	rs4910877	chr11:4062153	A/G	cg18678763	chr11:4115507	RRM1	-0.43	-7.21	-0.33	2.58e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs6761276	1.000	rs6761276	chr2:113832312	C/T	cg05240855	chr2:113734107	IL1F9	0.29	6.51	0.3	2.07e-10	Protein quantitative trait loci;
LUAD	trans	rs2840044	1.000	rs17637907	chr17:33891386	A/G	cg19694781	chr19:47549865	TMEM160	0.62	10.19	0.44	5.84e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg21191810	chr6:118973309	C6orf204	-0.49	-7.75	-0.35	7.07e-14	Diastolic blood pressure;
LUAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg00280220	chr17:61926910	NA	0.36	6.9	0.32	1.9e-11	Prudent dietary pattern;
LUAD	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg17105886	chr17:28927953	LRRC37B2	0.78	7.55	0.34	2.7e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6890695	1	rs6890695	chr5:130888424	C/G	cg25547332	chr5:131281432	NA	0.44	6.73	0.31	5.67e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg09654669	chr8:57350985	NA	-0.7	-10.28	-0.45	2.73e-22	Obesity-related traits;
LUAD	trans	rs7246760	0.867	rs73014056	chr19:9914120	G/A	cg02900749	chr2:68251473	NA	-0.7	-6.5	-0.3	2.31e-10	Pursuit maintenance gain;
LUAD	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.26	0.33	1.87e-12	Tonsillectomy;
LUAD	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.89	-0.36	2.67e-14	Personality dimensions;
LUAD	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15664640	chr17:80829946	TBCD	-0.84	-17.06	-0.64	5.15e-50	Breast cancer;
LUAD	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg14196790	chr5:131705035	SLC22A5	0.47	8.66	0.39	1.02e-16	Blood metabolite levels;
LUAD	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg13010199	chr12:38710504	ALG10B	0.4	6.79	0.31	3.74e-11	Bladder cancer;
LUAD	cis	rs59698941	0.943	rs72799498	chr5:132291157	G/A	cg14825688	chr5:132208181	LEAP2	-0.48	-6.46	-0.3	2.82e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs2455799	0.593	rs2047852	chr3:15732539	T/G	cg16303742	chr3:15540471	COLQ	-0.51	-9.37	-0.41	4.29e-19	Mean platelet volume;
LUAD	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg12310025	chr6:25882481	NA	0.59	9.85	0.43	9.5e-21	Blood metabolite levels;
LUAD	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg22105103	chr4:187893119	NA	0.58	12.81	0.53	5.75e-32	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg02493740	chr2:85810744	VAMP5	-0.39	-7.08	-0.33	5.94e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.68	12.96	0.53	1.39e-32	Cognitive ability;
LUAD	cis	rs11811982	0.793	rs77464064	chr1:227301610	C/T	cg24860534	chr1:227506868	CDC42BPA	0.65	7.07	0.33	6.48e-12	Optic disc area;
LUAD	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg11062466	chr8:58055876	NA	0.61	7.84	0.36	3.76e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg13722127	chr7:150037890	RARRES2	0.48	8.44	0.38	5.24e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.36	0.34	9.62e-13	Menopause (age at onset);
LUAD	trans	rs225245	0.817	rs1049379	chr17:33998802	G/C	cg19694781	chr19:47549865	TMEM160	-0.47	-7.69	-0.35	1.07e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs6138458	1.000	rs6707	chr20:24944166	C/T	cg06937882	chr20:24974362	C20orf3	-0.35	-6.92	-0.32	1.67e-11	Blood protein levels;
LUAD	trans	rs2262909	0.962	rs73021832	chr19:22316144	G/C	cg17074339	chr11:11642133	GALNTL4	0.47	7.56	0.35	2.57e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3772130	0.961	rs1573819	chr3:121469646	A/C	cg20356878	chr3:121714668	ILDR1	0.52	7.96	0.36	1.64e-14	Cognitive performance;
LUAD	cis	rs2839627	0.608	rs2001521	chr21:44232180	T/A	cg03543861	chr21:44258195	NA	0.64	7.66	0.35	1.27e-13	Information processing speed;
LUAD	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03264133	chr6:25882463	NA	-0.55	-8.96	-0.4	1.04e-17	Blood metabolite levels;
LUAD	trans	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg26043149	chr18:55253948	FECH	1.08	19.18	0.68	1.9e-59	Gout;Urate levels;Serum uric acid levels;
LUAD	trans	rs800082	0.668	rs9856190	chr3:144288547	G/C	cg24215973	chr2:240111563	HDAC4	-0.59	-9.44	-0.42	2.62e-19	Smoking behavior;
LUAD	cis	rs12208915	0.848	rs9350786	chr6:79517306	G/T	cg05283184	chr6:79620031	NA	0.49	6.39	0.3	4.34e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg15448220	chr1:150897856	SETDB1	0.46	7.96	0.36	1.63e-14	Tonsillectomy;
LUAD	trans	rs7395662	0.963	rs4882094	chr11:48532460	T/C	cg00717180	chr2:96193071	NA	-0.4	-7.48	-0.34	4.34e-13	HDL cholesterol;
LUAD	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg01851573	chr8:8652454	MFHAS1	-0.45	-8.02	-0.36	1.06e-14	Neuroticism;
LUAD	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg03929089	chr4:120376271	NA	-0.93	-17.47	-0.65	7.35e-52	Height;
LUAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg13047869	chr3:10149882	C3orf24	0.64	11.03	0.47	4.89e-25	Alzheimer's disease;
LUAD	cis	rs7274811	0.688	rs56234419	chr20:32086447	C/T	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.46	-6.88	-0.32	2.19e-11	Height;
LUAD	cis	rs612683	0.894	rs10875290	chr1:100853755	G/T	cg06223162	chr1:101003688	GPR88	0.4	7.61	0.35	1.75e-13	Breast cancer;
LUAD	cis	rs9796	0.516	rs28473405	chr15:41293170	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.51	-9.39	-0.42	3.64e-19	Menopause (age at onset);
LUAD	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg19346786	chr7:2764209	NA	-0.53	-11.46	-0.49	1.19e-26	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13402217	chr1:151584375	SNX27	-0.55	-6.65	-0.31	9.28e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg24818145	chr4:99064322	C4orf37	0.44	7.25	0.33	2.02e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2387326	1.000	rs34558168	chr10:129932106	T/C	cg16087940	chr10:129947807	NA	-0.49	-6.56	-0.3	1.6e-10	Select biomarker traits;
LUAD	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg08805041	chr16:621841	PIGQ	-0.31	-6.37	-0.3	4.87e-10	Height;
LUAD	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg19825600	chr2:3704501	ALLC	-0.4	-7.59	-0.35	2.08e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg05887092	chr17:76393375	PGS1	0.41	7.25	0.33	2.01e-12	HDL cholesterol levels;
LUAD	cis	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-7.07	-0.33	6.47e-12	Bipolar disorder;
LUAD	cis	rs6430585	0.527	rs1438303	chr2:136429857	C/T	cg07169764	chr2:136633963	MCM6	0.59	6.89	0.32	2e-11	Corneal structure;
LUAD	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg18230493	chr5:56204884	C5orf35	-0.86	-12.63	-0.52	3.11e-31	Initial pursuit acceleration;
LUAD	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.94	-0.4	1.21e-17	Total body bone mineral density;
LUAD	cis	rs669446	0.529	rs6697354	chr1:44151015	T/G	cg12908607	chr1:44402522	ARTN	-0.34	-6.68	-0.31	7.53e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	trans	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg18335740	chr13:41363409	SLC25A15	0.5	8.62	0.39	1.39e-16	Lewy body disease;
LUAD	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.22	-0.37	2.52e-15	Bipolar disorder;
LUAD	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg23281280	chr6:28129359	ZNF389	0.46	6.45	0.3	3e-10	Depression;
LUAD	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.39	-6.89	-0.32	2.03e-11	Tonsillectomy;
LUAD	cis	rs68092024	0.731	rs793479	chr3:99488232	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-9.41	-0.42	3.1400000000000002e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs7512552	0.839	rs17596326	chr1:150433819	A/G	cg15654264	chr1:150340011	RPRD2	0.59	11.47	0.49	1.06e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs73198271	0.530	rs113160067	chr8:8654521	A/C	cg01851573	chr8:8652454	MFHAS1	0.7	11.29	0.48	5.04e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg20135002	chr11:47629003	NA	-0.41	-7.19	-0.33	3.02e-12	Subjective well-being;
LUAD	cis	rs1472147	0.955	rs3736614	chr7:128509048	T/G	cg00260937	chr7:128520193	KCP	0.42	6.55	0.3	1.66e-10	Calcium levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00106501	chr15:41186668	VPS18	-0.38	-6.44	-0.3	3.29e-10	Cancer;
LUAD	trans	rs877282	0.947	rs957642	chr10:773966	C/T	cg22713356	chr15:30763199	NA	1.14	16.62	0.63	4.41e-48	Uric acid levels;
LUAD	cis	rs7432375	0.610	rs28458819	chr3:136522314	A/G	cg15507776	chr3:136538369	TMEM22	0.39	6.96	0.32	1.3e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg16988262	chr1:15930761	NA	0.44	7.42	0.34	6.38e-13	Systolic blood pressure;
LUAD	cis	rs3733418	1.000	rs3733419	chr4:165878170	A/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.53	-6.92	-0.32	1.67e-11	Obesity-related traits;
LUAD	cis	rs11722228	0.893	rs6449144	chr4:9944650	T/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.63	-0.35	1.6e-13	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs11811982	0.793	rs78292385	chr1:227295064	T/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.4	0.34	7.23e-13	Optic disc area;
LUAD	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg16486109	chr11:613632	IRF7	0.47	7.12	0.33	4.75e-12	Systemic lupus erythematosus;
LUAD	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg09117114	chr16:67998030	SLC12A4	-0.46	-6.42	-0.3	3.57e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs77741769	0.569	rs10774572	chr12:121309561	A/G	cg02419362	chr12:121203948	SPPL3	0.42	8.59	0.39	1.64e-16	Mean corpuscular volume;
LUAD	cis	rs11048434	0.661	rs34791180	chr12:9110919	T/C	cg13575925	chr12:9217583	LOC144571	0.36	6.79	0.31	3.71e-11	Sjögren's syndrome;
LUAD	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg12310025	chr6:25882481	NA	-0.62	-9.14	-0.41	2.6e-18	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00408597	chr11:9685941	SWAP70	-0.55	-6.75	-0.31	4.75e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg08999081	chr20:33150536	PIGU	0.64	14.3	0.57	4.02e-38	Coronary artery disease;
LUAD	cis	rs9786986	0.665	rs12402210	chr1:235701708	T/A	cg08848088	chr1:235714526	GNG4	0.52	6.88	0.32	2.19e-11	Body mass index;
LUAD	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22857025	chr5:266934	NA	-0.97	-14.68	-0.58	1.01e-39	Breast cancer;
LUAD	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg07211511	chr3:129823064	LOC729375	-0.84	-12.36	-0.52	3.64e-30	Blood pressure (smoking interaction);
LUAD	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg04944784	chr2:26401820	FAM59B	0.88	12.18	0.51	1.8e-29	Gut microbiome composition (summer);
LUAD	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg02782426	chr3:40428986	ENTPD3	0.42	8.88	0.4	1.94e-17	Renal cell carcinoma;
LUAD	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg19875535	chr5:140030758	IK	-0.48	-8.07	-0.37	7.46e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg08085267	chr17:45401833	C17orf57	-0.65	-11.66	-0.49	1.96e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg20701182	chr2:24300061	SF3B14	0.57	6.8	0.31	3.69e-11	Lymphocyte counts;
LUAD	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.52	-0.52	8.44e-31	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.3	-7.66	-0.35	1.31e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs34115320	1	rs34115320	chr7:148783936	CT/C	cg23158103	chr7:148848205	ZNF398	-0.59	-10.67	-0.46	1.11e-23	Sum basophil neutrophil counts;Neutrophil count;
LUAD	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg13944838	chr5:179740914	GFPT2	-0.74	-12.27	-0.51	7.98e-30	Height;
LUAD	cis	rs4711350	0.953	rs1547668	chr6:33775446	A/G	cg07979401	chr6:33739406	LEMD2	-0.49	-7.76	-0.35	6.56e-14	Schizophrenia;
LUAD	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.55	9.69	0.43	3.49e-20	Eosinophil percentage of white cells;
LUAD	cis	rs7903847	0.673	rs61861870	chr10:99154339	G/T	cg20016023	chr10:99160130	RRP12	-0.34	-7.44	-0.34	5.52e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg12365402	chr11:9010492	NRIP3	0.43	8.02	0.36	1.03e-14	Hemoglobin concentration;
LUAD	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg26022315	chr17:47021804	SNF8	0.4	7.27	0.33	1.77e-12	Type 2 diabetes;
LUAD	trans	rs11650494	0.908	rs117853079	chr17:47421593	G/C	cg11430096	chr6:110968061	CDK19	0.86	6.55	0.3	1.63e-10	Prostate cancer;
LUAD	trans	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-9.89	-0.43	7.15e-21	Brugada syndrome;
LUAD	cis	rs7937890	0.561	rs2575849	chr11:14539639	T/A	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.15e-12	Mitochondrial DNA levels;
LUAD	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg22875332	chr1:76189707	ACADM	-0.63	-10.26	-0.45	3.27e-22	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg27411982	chr8:10470053	RP1L1	0.4	6.99	0.32	1.11e-11	Retinal vascular caliber;
LUAD	cis	rs10193935	0.901	rs62142596	chr2:42529339	C/T	cg27598129	chr2:42591480	NA	-0.66	-8.66	-0.39	1.03e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg03233332	chr7:66118400	NA	-0.45	-6.69	-0.31	7.26e-11	Aortic root size;
LUAD	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg25769590	chr7:158789503	NA	-0.38	-6.99	-0.32	1.08e-11	Facial morphology (factor 20);
LUAD	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg09796270	chr17:17721594	SREBF1	0.42	8.74	0.39	5.45e-17	Total body bone mineral density;
LUAD	cis	rs656319	0.607	rs35437983	chr8:10005053	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-6.93	-0.32	1.59e-11	Myopia (pathological);
LUAD	cis	rs2839627	0.513	rs7282879	chr21:44286525	C/T	cg03543861	chr21:44258195	NA	0.65	8.92	0.4	1.37e-17	Information processing speed;
LUAD	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.45	-7.81	-0.35	4.66e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg07167872	chr1:205819463	PM20D1	-0.51	-7.8	-0.35	4.83e-14	Menarche (age at onset);
LUAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	12.75	0.53	9.68e-32	Prudent dietary pattern;
LUAD	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.9	0.4	1.71e-17	Parkinson's disease;
LUAD	cis	rs11771526	1.000	rs6462350	chr7:32342000	G/A	cg27511599	chr7:32358540	NA	0.59	7.07	0.33	6.37e-12	Body mass index;
LUAD	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg15181151	chr6:150070149	PCMT1	0.37	6.82	0.31	3.07e-11	Lung cancer;
LUAD	cis	rs367943	1.000	rs1057827	chr5:112823768	T/C	cg12552261	chr5:112820674	MCC	0.59	11.17	0.48	1.49e-25	Type 2 diabetes;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg02591199	chr4:113066609	C4orf32	0.42	6.44	0.3	3.17e-10	QT interval;
LUAD	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg24634471	chr8:143751801	JRK	0.48	7.84	0.36	3.79e-14	Schizophrenia;
LUAD	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.0	-0.4	7.79e-18	Aortic root size;
LUAD	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg10802521	chr3:52805072	NEK4	-0.48	-7.97	-0.36	1.52e-14	Electroencephalogram traits;
LUAD	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.81	-12.4	-0.52	2.44e-30	Chronic sinus infection;
LUAD	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg06417478	chr19:12876846	HOOK2	0.43	6.92	0.32	1.64e-11	Bipolar disorder;
LUAD	trans	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.72	-12.98	-0.53	1.15e-32	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg11941060	chr3:133502564	NA	-0.53	-8.57	-0.38	1.98e-16	Iron status biomarkers;
LUAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg15117754	chr3:10150083	C3orf24	0.42	7.0	0.32	1.03e-11	Alzheimer's disease;
LUAD	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22968622	chr17:43663579	NA	-0.88	-15.31	-0.6	2.07e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1983170	0.799	rs2063055	chr1:92020835	G/T	cg02896835	chr1:92012615	NA	0.39	6.57	0.3	1.46e-10	Eosinophil percentage of white cells;
LUAD	cis	rs62238980	0.522	rs77418985	chr22:32380919	C/G	cg02631450	chr22:32366979	NA	0.79	6.46	0.3	2.9e-10	Childhood ear infection;
LUAD	cis	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg07460842	chr6:66804631	NA	1.07	16.8	0.63	7.16e-49	Exhaled nitric oxide output;
LUAD	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.95	-0.36	1.78e-14	Monocyte percentage of white cells;
LUAD	cis	rs2041840	1.000	rs2540977	chr2:37462228	T/A	cg25727520	chr2:37576821	QPCT	-0.37	-7.49	-0.34	4e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs7927771	0.524	rs7942074	chr11:47720509	T/C	cg18512352	chr11:47633146	NA	0.37	6.55	0.3	1.63e-10	Subjective well-being;
LUAD	trans	rs7395662	0.655	rs2202458	chr11:48856547	T/G	cg00717180	chr2:96193071	NA	0.36	6.73	0.31	5.41e-11	HDL cholesterol;
LUAD	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.26	0.33	1.86e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg14092988	chr3:52407081	DNAH1	0.39	7.84	0.36	3.61e-14	Electroencephalogram traits;
LUAD	cis	rs7267979	0.932	rs367666	chr20:25449818	T/C	cg08601574	chr20:25228251	PYGB	0.44	7.94	0.36	1.79e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.44	0.3	3.17e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1595825	0.891	rs73058876	chr2:198895022	A/G	cg11031976	chr2:198649780	BOLL	-0.45	-6.58	-0.3	1.4e-10	Ulcerative colitis;
LUAD	cis	rs7009516	0.625	rs1907754	chr8:24259027	A/C	cg01759110	chr8:24241694	ADAMDEC1	-0.39	-7.99	-0.36	1.25e-14	Hair greying;
LUAD	cis	rs7584330	0.554	rs10176035	chr2:238433449	T/C	cg14458575	chr2:238380390	NA	0.6	9.5	0.42	1.5700000000000001e-19	Prostate cancer;
LUAD	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.98	-0.32	1.15e-11	Height;
LUAD	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-8.03	-0.36	9.63e-15	Body mass index;
LUAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg27454412	chr7:1067447	C7orf50	0.44	7.01	0.32	9.47e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6496044	0.568	rs11632326	chr15:86079834	A/C	cg13263323	chr15:86062960	AKAP13	-0.41	-7.37	-0.34	9.19e-13	Interstitial lung disease;
LUAD	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg16988262	chr1:15930761	NA	0.42	6.78	0.31	4.01e-11	Systolic blood pressure;
LUAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00149659	chr3:10157352	C3orf10	0.54	7.61	0.35	1.82e-13	Alzheimer's disease;
LUAD	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.13	-0.33	4.29e-12	Blood metabolite levels;
LUAD	cis	rs2554380	0.943	rs2585042	chr15:84341748	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.57	-8.77	-0.39	4.28e-17	Height;
LUAD	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg14092988	chr3:52407081	DNAH1	0.45	9.1	0.4	3.54e-18	Bipolar disorder;
LUAD	cis	rs2224391	0.656	rs17140096	chr6:5287255	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-7.96	-0.36	1.6e-14	Height;
LUAD	cis	rs1440088	0.732	rs13386066	chr2:198371687	C/T	cg00982548	chr2:198649783	BOLL	0.48	6.82	0.31	3.18e-11	Ulcerative colitis;
LUAD	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg26597838	chr10:835615	NA	0.98	15.35	0.6	1.32e-42	Eosinophil percentage of granulocytes;
LUAD	cis	rs4604732	0.631	rs76761880	chr1:247626377	T/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs3803170	0.513	rs10849942	chr12:111818637	T/C	cg10833066	chr12:111807467	FAM109A	0.47	8.67	0.39	9.3e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-8.99	-0.4	8.04e-18	Gut microbiome composition (summer);
LUAD	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.57	-10.28	-0.45	2.91e-22	Eosinophil percentage of white cells;
LUAD	cis	rs10465746	0.809	rs2389617	chr1:84437652	A/T	cg10977910	chr1:84465055	TTLL7	0.59	9.74	0.43	2.24e-20	Obesity-related traits;
LUAD	cis	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg06360820	chr2:242988706	NA	-0.89	-9.64	-0.42	5.01e-20	Obesity-related traits;
LUAD	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg11645453	chr3:52864694	ITIH4	0.51	9.89	0.43	7.01e-21	Bipolar disorder;
LUAD	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg08807101	chr21:30365312	RNF160	0.53	9.07	0.4	4.54e-18	Dental caries;
LUAD	cis	rs2902440	0.502	rs58621044	chr1:67664840	G/C	cg03340356	chr1:67600835	NA	0.37	6.62	0.31	1.08e-10	Crohn's disease;
LUAD	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-9.5	-0.42	1.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-23.35	-0.75	4.27e-78	Height;
LUAD	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg24531977	chr5:56204891	C5orf35	-0.4	-6.55	-0.3	1.71e-10	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs17655565	1.000	rs17126640	chr12:52704991	C/T	cg08257133	chr12:52711352	KRT83	0.38	6.61	0.31	1.16e-10	Plasma amyloid beta peptide concentrations (ABx-42);
LUAD	cis	rs4964805	0.632	rs9706225	chr12:104188086	T/C	cg02344784	chr12:104178138	NT5DC3	0.45	9.07	0.4	4.65e-18	Attention deficit hyperactivity disorder;
LUAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg04025307	chr7:1156635	C7orf50	0.65	7.41	0.34	6.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg20891283	chr12:69753455	YEATS4	0.45	7.35	0.34	1.06e-12	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs1113500	0.614	rs12565953	chr1:108607087	C/T	cg06207961	chr1:108661230	NA	0.43	6.94	0.32	1.48e-11	Growth-regulated protein alpha levels;
LUAD	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg08470875	chr2:26401718	FAM59B	-0.57	-7.78	-0.35	5.42e-14	Gut microbiome composition (summer);
LUAD	cis	rs62400317	0.826	rs62438867	chr6:45049787	G/A	cg20913747	chr6:44695427	NA	-0.42	-6.61	-0.31	1.13e-10	Total body bone mineral density;
LUAD	cis	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg23950597	chr19:37808831	NA	-0.61	-7.7	-0.35	9.78e-14	Coronary artery calcification;
LUAD	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.19	0.33	2.91e-12	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.39	0.38	7.09e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11644478	chr21:40555479	PSMG1	0.71	12.01	0.5	8.29e-29	Cognitive function;
LUAD	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg10802521	chr3:52805072	NEK4	-0.45	-6.52	-0.3	1.97e-10	Schizophrenia;
LUAD	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg12062639	chr20:23401060	NAPB	1.08	11.35	0.48	2.96e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg08847533	chr14:75593920	NEK9	-0.38	-6.46	-0.3	2.96e-10	Height;
LUAD	cis	rs9296095	0.607	rs10947409	chr6:33515191	G/C	cg14003231	chr6:33640908	ITPR3	0.47	8.63	0.39	1.24e-16	Platelet count;
LUAD	cis	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.36	-0.34	9.85e-13	Triglycerides;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07333738	chr16:765560	METRN	-0.67	-6.99	-0.32	1.11e-11	Type 2 diabetes;
LUAD	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg07636037	chr3:49044803	WDR6	0.48	8.19	0.37	3.13e-15	Menarche (age at onset);
LUAD	cis	rs6987853	0.787	rs2974314	chr8:42457043	C/T	cg09913449	chr8:42400586	C8orf40	0.44	8.14	0.37	4.36e-15	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-9.02	-0.4	6.79e-18	Lymphocyte counts;
LUAD	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	9.07	0.4	4.47e-18	Tonsillectomy;
LUAD	cis	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg27411982	chr8:10470053	RP1L1	-0.46	-8.29	-0.37	1.47e-15	Neuroticism;
LUAD	cis	rs6688613	0.685	rs742048	chr1:166910145	A/C	cg07049167	chr1:166818506	POGK	-0.56	-8.34	-0.38	1.03e-15	Refractive astigmatism;
LUAD	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg01689657	chr7:91764605	CYP51A1	0.32	8.04	0.36	8.84e-15	Breast cancer;
LUAD	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg12292205	chr6:26970375	C6orf41	0.5	8.48	0.38	3.94e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg05535760	chr7:792225	HEATR2	0.84	11.25	0.48	7.56e-26	Cerebrospinal P-tau181p levels;
LUAD	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.75	0.39	5.08e-17	Menopause (age at onset);
LUAD	cis	rs6543140	0.964	rs2141781	chr2:103082906	G/A	cg03938978	chr2:103052716	IL18RAP	0.35	6.72	0.31	5.97e-11	Blood protein levels;
LUAD	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg21399703	chr1:247681439	NA	0.37	7.22	0.33	2.36e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs735539	1.000	rs9579929	chr13:21282724	C/T	cg27499820	chr13:21296301	IL17D	-0.4	-6.88	-0.32	2.1e-11	Dental caries;
LUAD	cis	rs7213347	0.707	rs216215	chr17:2140668	C/T	cg02569219	chr17:2266849	SGSM2	-0.41	-6.68	-0.31	7.69e-11	Total body bone mineral density;
LUAD	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03264133	chr6:25882463	NA	0.58	9.61	0.42	6.41e-20	Blood metabolite levels;
LUAD	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.1	0.33	5.43e-12	Menopause (age at onset);
LUAD	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg25358565	chr5:93447407	FAM172A	0.61	7.34	0.34	1.08e-12	Diabetic retinopathy;
LUAD	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg25894440	chr7:65020034	NA	-0.59	-6.36	-0.3	5.16e-10	Diabetic kidney disease;
LUAD	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.04	-0.32	7.97e-12	Lung cancer;
LUAD	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg14893161	chr1:205819251	PM20D1	-0.5	-7.68	-0.35	1.09e-13	Menarche (age at onset);
LUAD	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg00666640	chr1:248458726	OR2T12	0.33	8.09	0.37	6.15e-15	Common traits (Other);
LUAD	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg27068330	chr11:65405492	SIPA1	0.56	8.87	0.4	2.11e-17	Acne (severe);
LUAD	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11890956	chr21:40555474	PSMG1	-0.5	-8.54	-0.38	2.53e-16	Menarche (age at onset);
LUAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg05896524	chr21:47604654	C21orf56	0.66	11.83	0.5	4.46e-28	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg03809021	chr16:89831123	FANCA	0.77	11.87	0.5	3.14e-28	Vitiligo;
LUAD	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.68	0.39	8.68e-17	Menopause (age at onset);
LUAD	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg25804541	chr17:80189381	SLC16A3	0.3	6.75	0.31	4.97e-11	Life satisfaction;
LUAD	cis	rs4601790	1.000	rs4601790	chr11:65353906	C/T	cg24147428	chr11:65409760	SIPA1	0.43	7.1	0.33	5.39e-12	Blood pressure (age interaction);
LUAD	cis	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg00086871	chr4:6988644	TBC1D14	0.75	6.5	0.3	2.22e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2425143	1.000	rs7273668	chr20:34442731	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.17	-0.33	3.32e-12	Blood protein levels;
LUAD	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg02574844	chr11:5959923	NA	0.38	6.99	0.32	1.08e-11	DNA methylation (variation);
LUAD	cis	rs11025523	1.000	rs11025523	chr11:20378124	A/G	cg02900213	chr11:20385756	HTATIP2	-0.46	-7.05	-0.32	7.41e-12	Obesity-related traits;
LUAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.29	0.41	8.04e-19	Alzheimer's disease;
LUAD	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg02696790	chr15:75250997	RPP25	0.37	7.31	0.33	1.35e-12	Breast cancer;
LUAD	cis	rs7116495	1.000	rs6592448	chr11:71670044	C/T	cg07596299	chr11:71824057	C11orf51	0.74	6.37	0.3	4.81e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6840360	0.571	rs62327274	chr4:152548012	C/T	cg22705602	chr4:152727874	NA	-0.43	-7.31	-0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg26384229	chr12:38710491	ALG10B	0.47	7.78	0.35	5.79e-14	Bladder cancer;
LUAD	cis	rs3790645	1.000	rs34062688	chr1:26887150	A/G	cg23229016	chr1:26872525	RPS6KA1	0.21	6.93	0.32	1.53e-11	Glucose homeostasis traits;
LUAD	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg26076054	chr5:421317	AHRR	-0.43	-6.42	-0.3	3.73e-10	Cystic fibrosis severity;
LUAD	cis	rs17102423	0.723	rs8181939	chr14:65555758	G/A	cg11161011	chr14:65562177	MAX	-0.51	-8.12	-0.37	5.08e-15	Obesity-related traits;
LUAD	cis	rs8060686	0.858	rs7196789	chr16:67927124	C/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-8.93	-0.4	1.29e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg23544223	chr18:12777786	NA	0.67	8.53	0.38	2.71e-16	Inflammatory skin disease;
LUAD	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg07917127	chr4:99064746	C4orf37	-0.42	-7.07	-0.33	6.38e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg21856205	chr7:94953877	PON1	-0.53	-7.18	-0.33	3.23e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7737355	0.773	rs9327616	chr5:130902196	C/T	cg06307176	chr5:131281290	NA	0.44	7.18	0.33	3.16e-12	Life satisfaction;
LUAD	cis	rs1864400	0.690	rs2565200	chr10:43622933	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.46	-7.87	-0.36	3.09e-14	Hirschsprung disease;
LUAD	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg21475434	chr5:93447410	FAM172A	0.74	8.23	0.37	2.29e-15	Diabetic retinopathy;
LUAD	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg01528321	chr10:82214614	TSPAN14	0.55	8.92	0.4	1.42e-17	Post bronchodilator FEV1;
LUAD	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg14893161	chr1:205819251	PM20D1	-0.5	-7.7	-0.35	9.98e-14	Menarche (age at onset);
LUAD	cis	rs231513	0.954	rs231514	chr17:41964516	C/T	cg26893861	chr17:41843967	DUSP3	-0.66	-7.52	-0.34	3.27e-13	Cognitive function;
LUAD	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg13332499	chr17:408570	NA	0.44	10.06	0.44	1.78e-21	Hip circumference adjusted for BMI;
LUAD	cis	rs6906287	0.669	rs2184402	chr6:118935341	T/C	cg05564266	chr6:118973597	C6orf204	0.37	7.76	0.35	6.42e-14	Electrocardiographic conduction measures;
LUAD	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg01017244	chr2:74357527	NA	0.89	13.49	0.55	9.66e-35	Gestational age at birth (maternal effect);
LUAD	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg27494647	chr7:150038898	RARRES2	0.44	7.22	0.33	2.51e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.56	-0.3	1.58e-10	Aortic root size;
LUAD	cis	rs7809950	1.000	rs2066735	chr7:107188719	G/T	cg23024343	chr7:107201750	COG5	-0.74	-12.57	-0.52	5.43e-31	Coronary artery disease;
LUAD	cis	rs9309473	0.687	rs6747145	chr2:73609177	C/T	cg20560298	chr2:73613845	ALMS1	-0.43	-6.61	-0.31	1.16e-10	Metabolite levels;
LUAD	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg18512352	chr11:47633146	NA	-0.55	-9.74	-0.43	2.37e-20	Subjective well-being;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg14302662	chr12:113623332	C12orf52;DDX54	-0.65	-6.64	-0.31	9.78e-11	Type 2 diabetes;
LUAD	cis	rs7943203	1.000	rs7934719	chr11:108341864	C/T	cg04873221	chr11:107992290	ACAT1	-0.4	-6.48	-0.3	2.49e-10	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg25985355	chr7:65971099	NA	-0.37	-6.82	-0.31	3.07e-11	Aortic root size;
LUAD	cis	rs7771547	0.519	rs6917489	chr6:36368169	C/T	cg04289385	chr6:36355825	ETV7	0.54	7.74	0.35	7.57e-14	Platelet distribution width;
LUAD	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg15383120	chr6:291909	DUSP22	-0.49	-7.98	-0.36	1.35e-14	Menopause (age at onset);
LUAD	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg09873201	chr16:3507582	NAT15	0.51	7.85	0.36	3.49e-14	Tuberculosis;
LUAD	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg10978503	chr1:24200527	CNR2	0.46	9.36	0.41	4.75e-19	Immature fraction of reticulocytes;
LUAD	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg26536354	chr8:144654954	C8orf73	0.62	6.71	0.31	6.36e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs4372836	0.541	rs6710080	chr2:28989975	A/G	cg09522027	chr2:28974177	PPP1CB	-0.63	-11.02	-0.47	5.32e-25	Body mass index;
LUAD	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21659725	chr3:3221576	CRBN	-0.84	-17.75	-0.65	4.31e-53	Intelligence (multi-trait analysis);
LUAD	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg19052272	chr2:3704530	ALLC	0.57	9.65	0.42	4.7e-20	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg07917127	chr4:99064746	C4orf37	0.42	7.03	0.32	8.37e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs943466	1.000	rs11755593	chr6:33740325	G/C	cg16010596	chr6:33739607	LEMD2	-0.42	-7.85	-0.36	3.55e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg06221963	chr1:154839813	KCNN3	-0.89	-21.1	-0.72	5.03e-68	Prostate cancer;
LUAD	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg23254163	chr1:152506842	NA	0.25	6.96	0.32	1.31e-11	Hair morphology;
LUAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg02951883	chr7:2050386	MAD1L1	-0.64	-10.26	-0.45	3.2800000000000002e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg18105134	chr13:113819100	PROZ	-0.8	-14.0	-0.56	7.16e-37	Platelet distribution width;
LUAD	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg06641503	chr3:48959341	ARIH2	-0.39	-6.79	-0.31	3.87e-11	Menarche (age at onset);
LUAD	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03517284	chr6:25882590	NA	-0.58	-9.56	-0.42	1.02e-19	Blood metabolite levels;
LUAD	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg17724175	chr1:150552817	MCL1	0.39	8.81	0.39	3.25e-17	Melanoma;
LUAD	cis	rs7809615	0.792	rs45618033	chr7:99046617	G/A	cg03133378	chr7:99195931	NA	-0.55	-6.51	-0.3	2.16e-10	Blood metabolite ratios;
LUAD	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.57	-8.88	-0.4	1.97e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7818345	0.967	rs13255946	chr8:19275354	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.79	0.31	3.76e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg26384229	chr12:38710491	ALG10B	0.42	7.19	0.33	2.99e-12	Morning vs. evening chronotype;
LUAD	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23158103	chr7:148848205	ZNF398	-0.61	-11.02	-0.47	5.36e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs41311933	0.803	rs62578394	chr9:123695233	C/T	cg13567360	chr9:123745713	C5	-0.83	-7.22	-0.33	2.36e-12	Coronary artery disease;
LUAD	trans	rs8073060	0.505	rs225276	chr17:33973034	T/C	cg19694781	chr19:47549865	TMEM160	-1.24	-19.47	-0.69	9.31e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7809950	0.817	rs2237671	chr7:107131528	A/T	cg23024343	chr7:107201750	COG5	-0.87	-14.46	-0.58	8.84e-39	Coronary artery disease;
LUAD	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg18436788	chr1:3704244	LRRC47	0.31	6.38	0.3	4.7e-10	Red cell distribution width;
LUAD	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg12179176	chr11:130786555	SNX19	0.53	8.71	0.39	7.05e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg17074396	chr22:49843754	NA	-0.33	-6.82	-0.31	3.22e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg02428538	chr16:24856791	SLC5A11	0.49	6.86	0.32	2.52e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.67	-0.31	8.19e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg09455208	chr3:40491958	NA	0.59	12.89	0.53	2.74e-32	Renal cell carcinoma;
LUAD	trans	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs8192282	0.739	rs4518898	chr1:154492432	T/C	cg16683920	chr1:154474344	TDRD10;SHE	-0.45	-6.99	-0.32	1.09e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs9644630	0.813	rs4922036	chr8:19328219	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.36	6.78	0.31	4.09e-11	Oropharynx cancer;
LUAD	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.59	7.81	0.36	4.44e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg18827107	chr12:86230957	RASSF9	-0.48	-8.48	-0.38	3.9e-16	Major depressive disorder;
LUAD	cis	rs7614311	0.681	rs73117036	chr3:63892725	G/C	cg22134162	chr3:63841271	THOC7	-0.53	-8.75	-0.39	5.12e-17	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg20476274	chr7:133979776	SLC35B4	0.85	17.23	0.64	8.75e-51	Mean platelet volume;
LUAD	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg17724175	chr1:150552817	MCL1	0.4	9.86	0.43	9.09e-21	Tonsillectomy;
LUAD	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg11344533	chr11:111475393	SIK2	-0.35	-6.64	-0.31	9.9e-11	Primary sclerosing cholangitis;
LUAD	cis	rs1003719	0.715	rs1981432	chr21:38541356	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.34	-0.38	1.04e-15	Eye color traits;
LUAD	cis	rs28595532	0.545	rs17516512	chr4:119258491	T/C	cg02775129	chr4:119771670	NA	-0.58	-6.44	-0.3	3.23e-10	Cannabis dependence symptom count;
LUAD	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg11901034	chr3:128598214	ACAD9	-0.5	-7.82	-0.36	4.36e-14	IgG glycosylation;
LUAD	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg21427119	chr20:30132790	HM13	-0.6	-9.1	-0.4	3.7e-18	Mean corpuscular hemoglobin;
LUAD	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg04036182	chr15:45458818	NA	-0.4	-6.96	-0.32	1.31e-11	Glomerular filtration rate;
LUAD	cis	rs7903847	0.656	rs61861861	chr10:99143619	C/T	cg20016023	chr10:99160130	RRP12	-0.34	-7.44	-0.34	5.79e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs344364	0.602	rs7188401	chr16:1876949	G/C	cg07386859	chr16:1872102	HAGH	0.51	7.59	0.35	1.99e-13	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7630877	0.962	rs17748709	chr3:179642526	A/T	cg18765712	chr3:179670323	PEX5L	0.34	6.42	0.3	3.59e-10	Type 2 diabetes;
LUAD	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg06558623	chr16:89946397	TCF25	1.22	12.43	0.52	1.95e-30	Skin colour saturation;
LUAD	cis	rs12144309	0.576	rs7515189	chr1:114197693	C/T	cg03325407	chr1:114423726	BCL2L15	0.45	6.74	0.31	5.2e-11	Coronary artery disease;
LUAD	cis	rs4372836	0.543	rs11686412	chr2:28992405	A/G	cg09522027	chr2:28974177	PPP1CB	-0.63	-11.01	-0.47	6.04e-25	Body mass index;
LUAD	cis	rs4409675	0.576	rs2295367	chr1:28224312	C/T	cg23691781	chr1:28212827	C1orf38	0.39	11.11	0.48	2.45e-25	Corneal astigmatism;
LUAD	cis	rs12900413	0.687	rs28752094	chr15:90311645	G/A	cg24249390	chr15:90295951	MESP1	-0.34	-6.64	-0.31	9.63e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	9.35	0.41	4.99e-19	Colorectal cancer;
LUAD	cis	rs17401966	1.000	rs12117765	chr1:10268170	A/G	cg15208524	chr1:10270712	KIF1B	0.53	7.72	0.35	8.51e-14	Hepatocellular carcinoma;
LUAD	cis	rs4711350	0.734	rs4713676	chr6:33722098	G/T	cg18005901	chr6:33739558	LEMD2	0.45	7.27	0.33	1.73e-12	Schizophrenia;
LUAD	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06022373	chr22:39101656	GTPBP1	0.46	7.21	0.33	2.6e-12	Menopause (age at onset);
LUAD	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg15358701	chr1:161410459	NA	-0.69	-7.17	-0.33	3.3e-12	Rheumatoid arthritis;
LUAD	cis	rs17095355	1.000	rs55717725	chr10:111666629	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.71	-9.44	-0.42	2.54e-19	Biliary atresia;
LUAD	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs12681287	0.640	rs7460342	chr8:87475137	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-9.65	-0.42	4.67e-20	Caudate activity during reward;
LUAD	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11890956	chr21:40555474	PSMG1	0.82	14.74	0.58	5.43e-40	Cognitive function;
LUAD	cis	rs986417	0.901	rs1015119	chr14:61027510	G/T	cg27398547	chr14:60952738	C14orf39	0.56	6.77	0.31	4.22e-11	Gut microbiota (bacterial taxa);
LUAD	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg10909506	chr17:38081995	ORMDL3	0.4	6.91	0.32	1.75e-11	Self-reported allergy;
LUAD	cis	rs9863	0.861	rs4405410	chr12:124435788	T/A	cg17723958	chr12:124429295	CCDC92	-0.41	-6.69	-0.31	7.1e-11	White blood cell count;
LUAD	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg22467129	chr15:76604101	ETFA	-0.5	-8.81	-0.39	3.19e-17	Blood metabolite levels;
LUAD	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-7.53	-0.34	3.07e-13	Blood metabolite levels;
LUAD	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26314531	chr2:26401878	FAM59B	-0.72	-9.81	-0.43	1.37e-20	Gut microbiome composition (summer);
LUAD	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg22963979	chr7:1858916	MAD1L1	-0.47	-8.15	-0.37	4.22e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs3739034	0.877	rs13001022	chr2:135520614	G/C	cg12500956	chr2:135428796	TMEM163	0.38	6.8	0.31	3.63e-11	Gut microbiome composition (winter);
LUAD	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg15133208	chr4:90757351	SNCA	-0.46	-7.05	-0.32	7.14e-12	Neuroticism;
LUAD	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg10518543	chr12:38710700	ALG10B	0.47	7.91	0.36	2.2e-14	Morning vs. evening chronotype;
LUAD	cis	rs887829	0.570	rs45615240	chr2:234599296	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.69	-0.43	3.53e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs11893307	0.509	rs12612904	chr2:191534847	A/G	cg11845111	chr2:191398756	TMEM194B	-0.48	-6.94	-0.32	1.51e-11	Mean platelet volume;
LUAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-9.86	-0.43	8.95e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs295140	0.506	rs295136	chr2:201141002	G/C	cg23649088	chr2:200775458	C2orf69	0.5	8.43	0.38	5.53e-16	QT interval;
LUAD	cis	rs7274811	0.744	rs209677	chr20:32140287	C/T	cg00478435	chr20:32254706	NECAB3;C20orf134	0.4	6.41	0.3	4.01e-10	Height;
LUAD	cis	rs7927771	0.524	rs11039415	chr11:47845814	A/G	cg18512352	chr11:47633146	NA	0.36	6.38	0.3	4.61e-10	Subjective well-being;
LUAD	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg18230493	chr5:56204884	C5orf35	-0.85	-12.54	-0.52	6.65e-31	Initial pursuit acceleration;
LUAD	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg14752069	chr8:11977206	FAM66D	-0.3	-6.85	-0.32	2.69e-11	Retinal vascular caliber;
LUAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg21782813	chr7:2030301	MAD1L1	-0.45	-7.84	-0.36	3.62e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs7680126	0.633	rs11730631	chr4:10292968	C/T	cg11266682	chr4:10021025	SLC2A9	0.47	7.73	0.35	7.89e-14	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs8180040	0.553	rs7620997	chr3:47214122	C/T	cg02527881	chr3:46936655	PTH1R	0.39	7.18	0.33	3.26e-12	Colorectal cancer;
LUAD	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg26597838	chr10:835615	NA	-0.53	-8.42	-0.38	6e-16	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs2880765	0.743	rs8032488	chr15:86012768	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.36	-0.3	5.32e-10	Coronary artery disease;
LUAD	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg02569458	chr12:86230093	RASSF9	-0.42	-7.75	-0.35	6.86e-14	Major depressive disorder;
LUAD	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg22676075	chr6:135203613	NA	0.52	9.42	0.42	3.03e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg23625390	chr15:77176239	SCAPER	-0.57	-9.15	-0.41	2.49e-18	Blood metabolite levels;
LUAD	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg14828511	chr1:107599125	PRMT6	-0.56	-10.12	-0.44	1.04e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.25	-0.33	2.01e-12	Breast cancer;
LUAD	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg14558114	chr2:88469736	THNSL2	-0.42	-6.71	-0.31	6.45e-11	Response to metformin (IC50);
LUAD	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg05340658	chr4:99064831	C4orf37	0.54	9.18	0.41	1.91e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg21231944	chr12:82153410	PPFIA2	-0.36	-6.59	-0.31	1.33e-10	Resting heart rate;
LUAD	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg03037974	chr15:76606532	NA	0.39	8.3	0.37	1.37e-15	Blood metabolite levels;
LUAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg00280220	chr17:61926910	NA	-0.35	-6.69	-0.31	7.06e-11	Prudent dietary pattern;
LUAD	cis	rs7582720	1.000	rs72928608	chr2:203836507	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12379764	chr21:47803548	PCNT	-0.43	-7.05	-0.32	7.41e-12	Testicular germ cell tumor;
LUAD	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg19622623	chr12:86230825	RASSF9	0.44	7.88	0.36	2.73e-14	Major depressive disorder;
LUAD	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg06608945	chr2:219082296	ARPC2	-0.43	-7.11	-0.33	4.88e-12	Colorectal cancer;
LUAD	trans	rs1728785	1.000	rs12918865	chr16:68566546	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.71	0.43	2.85e-20	Ulcerative colitis;
LUAD	cis	rs2932538	0.922	rs61818800	chr1:113148571	A/G	cg22162597	chr1:113214053	CAPZA1	0.44	6.69	0.31	7.11e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.84	9.06	0.4	4.76e-18	Body mass index;
LUAD	cis	rs1595825	0.891	rs1030796	chr2:198674673	A/G	cg11031976	chr2:198649780	BOLL	-0.48	-7.01	-0.32	9.33e-12	Ulcerative colitis;
LUAD	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.15	0.37	4.18e-15	Rheumatoid arthritis;
LUAD	cis	rs1003719	0.762	rs2835598	chr21:38466669	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.31e-16	Eye color traits;
LUAD	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.52	-0.42	1.36e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg02423579	chr7:2872169	GNA12	-0.78	-13.39	-0.55	2.42e-34	Height;
LUAD	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg18876405	chr7:65276391	NA	0.4	6.36	0.3	5.4e-10	Aortic root size;
LUAD	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.37	0.34	9.32e-13	Breast cancer;
LUAD	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg09796270	chr17:17721594	SREBF1	0.41	8.39	0.38	7.34e-16	Total body bone mineral density;
LUAD	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg02527881	chr3:46936655	PTH1R	-0.48	-9.42	-0.42	3.01e-19	Colorectal cancer;
LUAD	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg00933542	chr6:150070202	PCMT1	0.44	9.61	0.42	6.77e-20	Lung cancer;
LUAD	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg25985355	chr7:65971099	NA	-0.54	-6.73	-0.31	5.5e-11	Diabetic kidney disease;
LUAD	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg16049864	chr8:95962084	TP53INP1	-0.6	-13.2	-0.54	1.51e-33	Type 2 diabetes;
LUAD	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg20503657	chr10:835505	NA	0.66	9.15	0.41	2.34e-18	Eosinophil percentage of granulocytes;
LUAD	trans	rs9951602	0.512	rs8098115	chr18:76653986	G/T	cg02800362	chr5:177631904	HNRNPAB	0.91	14.57	0.58	3.06e-39	Obesity-related traits;
LUAD	cis	rs16958440	0.867	rs77348110	chr18:44674167	T/C	cg17192377	chr18:44677553	HDHD2	0.84	8.02	0.36	1.05e-14	Sitting height ratio;
LUAD	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg25036284	chr2:26402008	FAM59B	-0.64	-9.02	-0.4	6.78e-18	Gut microbiome composition (summer);
LUAD	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg21153622	chr11:89784906	NA	-0.32	-6.36	-0.3	5.26e-10	Height;
LUAD	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg18446336	chr7:2847575	GNA12	-0.32	-6.56	-0.3	1.53e-10	Height;
LUAD	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.64	-0.35	1.47e-13	Monocyte count;
LUAD	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.08	0.33	6.15e-12	Motion sickness;
LUAD	trans	rs9929218	1.000	rs13339591	chr16:68809273	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.93	-0.56	1.47e-36	Colorectal cancer;
LUAD	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg20119798	chr7:94954144	PON1	-0.49	-6.91	-0.32	1.77e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg18944383	chr4:111397179	ENPEP	-0.37	-7.03	-0.32	8.21e-12	Coronary artery disease;
LUAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-10.31	-0.45	2.26e-22	Lymphocyte counts;
LUAD	cis	rs4953076	0.573	rs6544746	chr2:44407985	C/T	cg04920474	chr2:44395004	PPM1B	0.54	8.45	0.38	4.71e-16	Height;
LUAD	cis	rs62238980	0.614	rs76853252	chr22:32455857	T/C	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-6.84	-0.32	2.84e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1232027	0.656	rs1677647	chr5:79964816	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.45	-7.39	-0.34	7.89e-13	Huntington's disease progression;
LUAD	cis	rs2274273	0.686	rs66782529	chr14:55587867	C/T	cg04306507	chr14:55594613	LGALS3	0.38	7.03	0.32	8.12e-12	Protein biomarker;
LUAD	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22496380	chr5:211416	CCDC127	-0.95	-13.32	-0.54	4.88e-34	Breast cancer;
LUAD	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7208859	0.614	rs216474	chr17:28865091	C/T	cg17105886	chr17:28927953	LRRC37B2	-0.7	-6.95	-0.32	1.36e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2046867	0.908	rs6771413	chr3:72790308	G/A	cg25664220	chr3:72788482	NA	-0.62	-11.28	-0.48	5.44e-26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg16680214	chr1:154839983	KCNN3	-0.64	-13.27	-0.54	7.9e-34	Prostate cancer;
LUAD	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg04450456	chr4:17643702	FAM184B	0.39	7.53	0.34	3.09e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	14.2	0.57	1.05e-37	Lung cancer in ever smokers;
LUAD	cis	rs9811920	0.809	rs4577503	chr3:99657922	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.59	-11.34	-0.48	3.27e-26	Axial length;
LUAD	cis	rs7582720	1.000	rs72934510	chr2:203925360	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.83	0.43	1.1e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg02569458	chr12:86230093	RASSF9	0.41	7.61	0.35	1.81e-13	Major depressive disorder;
LUAD	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.66	-0.35	1.32e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs2971970	0.519	rs6968008	chr7:133632324	C/T	cg03336402	chr7:133662267	EXOC4	0.39	7.09	0.33	5.68e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6586163	0.509	rs2031610	chr10:90754487	T/C	cg03111039	chr10:90751583	FAS;ACTA2	0.67	11.16	0.48	1.63e-25	Chronic lymphocytic leukemia;
LUAD	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg26408565	chr15:76604113	ETFA	-0.43	-6.96	-0.32	1.33e-11	Blood metabolite levels;
LUAD	cis	rs2996428	0.667	rs2368534	chr1:3740640	C/T	cg22529645	chr1:3704559	LRRC47	0.56	10.14	0.44	9.02e-22	Red cell distribution width;
LUAD	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg05368731	chr17:41323189	NBR1	0.96	19.54	0.69	4.53e-61	Menopause (age at onset);
LUAD	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg14671364	chr1:107599128	PRMT6	0.55	9.2	0.41	1.72e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs10992471	0.528	rs3780347	chr9:95266812	A/G	cg14631576	chr9:95140430	CENPP	-0.49	-10.1	-0.44	1.29e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg02466173	chr16:30829666	NA	-0.68	-12.07	-0.51	4.85e-29	Multiple myeloma;
LUAD	cis	rs62238980	0.614	rs117628874	chr22:32452970	T/C	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg00101154	chr16:420108	MRPL28	0.43	7.45	0.34	5.33e-13	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs12681287	0.547	rs9297922	chr8:87542317	A/G	cg27223183	chr8:87520930	FAM82B	0.72	10.23	0.45	4.23e-22	Caudate activity during reward;
LUAD	cis	rs9788682	0.694	rs10851906	chr15:78774676	A/G	cg18825076	chr15:78729989	IREB2	0.54	7.52	0.34	3.32e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07636037	chr3:49044803	WDR6	0.47	7.88	0.36	2.79e-14	Menarche (age at onset);
LUAD	cis	rs1550582	1.000	rs1550582	chr8:135542084	A/G	cg17885191	chr8:135476712	NA	-0.66	-9.48	-0.42	1.86e-19	Educational attainment;
LUAD	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg22189786	chr22:42395067	WBP2NL	0.45	6.49	0.3	2.42e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg25554036	chr4:6271136	WFS1	0.65	12.65	0.52	2.39e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg01657329	chr11:68192670	LRP5	-0.4	-6.45	-0.3	3.08e-10	Total body bone mineral density;
LUAD	cis	rs75920871	0.640	rs61903395	chr11:116931907	A/G	cg04087571	chr11:116723030	SIK3	-0.32	-6.79	-0.31	3.78e-11	Subjective well-being;
LUAD	trans	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg18187862	chr3:45730750	SACM1L	0.5	7.81	0.36	4.45e-14	Primary sclerosing cholangitis;
LUAD	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg06740227	chr12:86229804	RASSF9	0.41	7.29	0.33	1.57e-12	Major depressive disorder;
LUAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	9.07	0.4	4.44e-18	Alzheimer's disease;
LUAD	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg26677194	chr12:130822605	PIWIL1	0.57	9.41	0.42	3.11e-19	Menopause (age at onset);
LUAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg22907277	chr7:1156413	C7orf50	0.53	8.89	0.4	1.72e-17	Longevity;Endometriosis;
LUAD	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg21471580	chr8:22132874	PIWIL2	0.46	8.28	0.37	1.59e-15	Hypertriglyceridemia;
LUAD	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10802521	chr3:52805072	NEK4	-0.53	-9.07	-0.4	4.38e-18	Bipolar disorder;
LUAD	trans	rs3858145	0.588	rs115455464	chr10:70038498	T/C	cg04882175	chr6:131122610	NA	-0.59	-7.1	-0.33	5.39e-12	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUAD	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg06002616	chr8:101225028	SPAG1	-0.34	-6.8	-0.31	3.65e-11	Atrioventricular conduction;
LUAD	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg14343924	chr8:8086146	FLJ10661	0.44	6.92	0.32	1.63e-11	Mood instability;
LUAD	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg01312482	chr5:178451176	ZNF879	-0.44	-7.02	-0.32	9.17e-12	Pubertal anthropometrics;
LUAD	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.46	7.7	0.35	9.92e-14	Body mass index (adult);
LUAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg24642844	chr7:1081250	C7orf50	-0.85	-13.32	-0.54	4.97e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-8.3	-0.37	1.44e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs10805346	0.558	rs12506562	chr4:10106954	G/T	cg26043149	chr18:55253948	FECH	0.43	6.83	0.32	2.98e-11	Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg07828340	chr4:882639	GAK	1.07	10.85	0.47	2.29e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.68	0.52	1.86e-31	Cognitive ability;
LUAD	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg02176678	chr2:219576539	TTLL4	0.67	13.04	0.54	6.57e-33	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg22117172	chr7:91764530	CYP51A1	-0.35	-7.6	-0.35	1.99e-13	Breast cancer;
LUAD	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg03563238	chr19:33554763	RHPN2	-0.39	-9.13	-0.41	2.87e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6445967	1.000	rs62259324	chr3:58291107	T/C	cg23715586	chr3:58305044	RPP14	0.42	7.57	0.35	2.44e-13	Platelet count;
LUAD	trans	rs853679	0.607	rs35072899	chr6:28281541	C/T	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.16	-0.48	1.54e-25	Depression;
LUAD	cis	rs4964805	0.626	rs869993	chr12:104175138	A/T	cg02344784	chr12:104178138	NT5DC3	0.36	6.42	0.3	3.77e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs7264396	0.779	rs6087723	chr20:34175783	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.44	6.67	0.31	8.09e-11	Total cholesterol levels;
LUAD	cis	rs62400317	0.859	rs11966878	chr6:45328265	C/T	cg20913747	chr6:44695427	NA	0.39	6.41	0.3	3.9e-10	Total body bone mineral density;
LUAD	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.54e-15	Bipolar disorder;
LUAD	cis	rs77861329	0.748	rs4687810	chr3:52169095	T/C	cg08692210	chr3:52188851	WDR51A	0.55	7.0	0.32	1.01e-11	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg20608306	chr11:116969690	SIK3	0.29	6.58	0.3	1.42e-10	Blood protein levels;
LUAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg00280220	chr17:61926910	NA	0.36	6.9	0.32	1.95e-11	Prudent dietary pattern;
LUAD	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg15557168	chr22:42548783	NA	0.51	9.49	0.42	1.7e-19	Schizophrenia;
LUAD	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg18932078	chr1:2524107	MMEL1	0.39	7.25	0.33	1.99e-12	Ulcerative colitis;
LUAD	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs9462027	0.606	rs3777752	chr6:34772212	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.71	-0.39	7.17e-17	Systemic lupus erythematosus;
LUAD	cis	rs7665090	1.000	rs7677509	chr4:103550006	T/C	cg07973026	chr4:103553119	MANBA	0.47	8.4	0.38	6.94e-16	Primary biliary cholangitis;
LUAD	cis	rs11030122	0.702	rs10767715	chr11:3951409	G/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.2	-0.33	2.7e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg18827107	chr12:86230957	RASSF9	0.54	9.74	0.43	2.24e-20	Major depressive disorder;
LUAD	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg00999904	chr2:3704751	ALLC	-0.51	-8.95	-0.4	1.15e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg12564285	chr5:131593104	PDLIM4	0.37	6.48	0.3	2.52e-10	Breast cancer;
LUAD	cis	rs870825	0.655	rs28726376	chr4:185638954	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.97	0.56	9.31e-37	Blood protein levels;
LUAD	cis	rs6060717	0.536	rs11697024	chr20:34546500	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-6.86	-0.32	2.52e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	7.9	0.36	2.38e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg00981070	chr1:2046702	PRKCZ	0.36	6.89	0.32	2.05e-11	Height;
LUAD	cis	rs13315871	1.000	rs13327709	chr3:58408767	C/T	cg20936604	chr3:58311152	NA	-0.69	-7.24	-0.33	2.16e-12	Cholesterol, total;
LUAD	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	24.03	0.76	4.5e-81	Chronic sinus infection;
LUAD	cis	rs11671005	0.696	rs73066211	chr19:58997079	C/T	cg13877915	chr19:58951672	ZNF132	0.56	6.89	0.32	2.08e-11	Mean platelet volume;
LUAD	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg01579765	chr21:45077557	HSF2BP	-0.63	-14.68	-0.58	1.02e-39	Mean corpuscular volume;
LUAD	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.24	-0.51	1.04e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3916	0.641	rs2393749	chr12:121131891	C/T	cg27246729	chr12:121163418	ACADS	0.36	6.63	0.31	1.01e-10	Urinary metabolites (H-NMR features);
LUAD	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.4e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4588572	0.570	rs2362832	chr5:77795843	A/G	cg11547950	chr5:77652471	NA	-0.75	-11.78	-0.5	6.62e-28	Triglycerides;
LUAD	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg03433033	chr1:76189801	ACADM	-0.51	-7.42	-0.34	6.41e-13	Daytime sleep phenotypes;
LUAD	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg27454412	chr7:1067447	C7orf50	-0.39	-7.41	-0.34	7.13e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs2797160	1.000	rs1739371	chr6:126011291	G/A	cg05901451	chr6:126070800	HEY2	0.44	6.46	0.3	2.89e-10	Endometrial cancer;
LUAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg13560548	chr3:10150139	C3orf24	0.45	7.66	0.35	1.27e-13	Alzheimer's disease;
LUAD	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg13736514	chr6:26305472	NA	-0.52	-9.53	-0.42	1.24e-19	Educational attainment;
LUAD	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg22166914	chr1:53195759	ZYG11B	-0.48	-7.9	-0.36	2.51e-14	Monocyte count;
LUAD	cis	rs367615	0.918	rs10067984	chr5:108872684	C/T	cg17395555	chr5:108820864	NA	0.54	8.81	0.39	3.32e-17	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg25324976	chr17:61989376	CSHL1	0.44	8.34	0.38	1.05e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg12756686	chr19:29218302	NA	0.65	8.95	0.4	1.15e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg26893861	chr17:41843967	DUSP3	0.9	14.25	0.57	6.83e-38	Triglycerides;
LUAD	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.39	-0.3	4.48e-10	Breast cancer;
LUAD	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-14.51	-0.58	5.23e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.57	-10.16	-0.44	7.66e-22	Longevity;Endometriosis;
LUAD	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg24803719	chr17:45855879	NA	-0.32	-7.0	-0.32	9.78e-12	IgG glycosylation;
LUAD	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.05	-0.32	7.36e-12	Height;
LUAD	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg11663144	chr21:46675770	NA	-0.57	-11.36	-0.48	2.73e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs733175	0.855	rs9291641	chr4:10007259	C/T	cg02734326	chr4:10020555	SLC2A9	0.44	6.45	0.3	2.98e-10	Psychosis and Alzheimer's disease;
LUAD	cis	rs12024301	0.557	rs12042646	chr1:183614282	C/T	cg19264170	chr1:183622470	APOBEC4;RGL1	-0.68	-7.02	-0.32	9.05e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg22963979	chr7:1858916	MAD1L1	-0.54	-9.28	-0.41	8.56e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs2425143	0.822	rs6060677	chr20:34499368	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.6	7.15	0.33	3.94e-12	Blood protein levels;
LUAD	cis	rs300774	0.925	rs300710	chr2:139574	C/T	cg21211680	chr2:198530	NA	0.48	7.42	0.34	6.58e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg15468180	chr1:107600409	PRMT6	0.4	6.42	0.3	3.59e-10	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs747782	0.639	rs61649224	chr11:48057640	G/A	cg15704280	chr7:45808275	SEPT13	0.65	6.89	0.32	2.02e-11	Intraocular pressure;
LUAD	cis	rs10746514	1.000	rs1576618	chr1:232244331	A/G	cg09506761	chr1:232265262	NA	-0.37	-6.85	-0.32	2.6e-11	Response to statin therapy;
LUAD	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg11645453	chr3:52864694	ITIH4	0.37	7.38	0.34	8.5e-13	Bipolar disorder;
LUAD	cis	rs7124681	0.565	rs2904127	chr11:47817290	A/G	cg18512352	chr11:47633146	NA	0.36	6.38	0.3	4.61e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6993813	0.805	rs4327884	chr8:120019593	A/G	cg01975934	chr8:119970761	NA	-0.34	-6.52	-0.3	1.98e-10	Bone mineral density (hip);
LUAD	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg26673648	chr5:177209285	NA	0.48	8.35	0.38	9.91e-16	Methadone dose in opioid dependence;
LUAD	cis	rs2692947	0.537	rs11677429	chr2:96193061	C/T	cg23100626	chr2:96804247	ASTL	0.34	8.47	0.38	4.2e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03934478	chr11:495069	RNH1	0.76	8.91	0.4	1.55e-17	Body mass index;
LUAD	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	0.29	7.33	0.34	1.14e-12	Total body bone mineral density;
LUAD	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg14345882	chr6:26364793	BTN3A2	0.7	7.1	0.33	5.18e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10242455	0.571	rs45593341	chr7:99304911	C/A	cg18809830	chr7:99032528	PTCD1	-0.96	-8.12	-0.37	5.18e-15	Blood metabolite levels;
LUAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg13397359	chr6:42928475	GNMT	0.59	11.2	0.48	1.12e-25	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg08999081	chr20:33150536	PIGU	-0.62	-13.72	-0.55	1.07e-35	Glomerular filtration rate (creatinine);
LUAD	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg13870426	chr17:30244630	NA	-0.57	-6.62	-0.31	1.12e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.09	0.33	5.52e-12	Parkinson's disease;
LUAD	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23158103	chr7:148848205	ZNF398	-0.62	-10.74	-0.46	6.02e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.28e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg06453172	chr10:134556979	INPP5A	-0.64	-10.39	-0.45	1.14e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg09526685	chr4:187126073	CYP4V2	0.99	10.54	0.46	3.14e-23	Blood protein levels;
LUAD	cis	rs6906287	0.647	rs11753128	chr6:118853514	C/T	cg18833306	chr6:118973337	C6orf204	0.46	8.12	0.37	5.19e-15	Electrocardiographic conduction measures;
LUAD	cis	rs2274273	0.682	rs7151224	chr14:55517262	G/A	cg04306507	chr14:55594613	LGALS3	0.33	6.73	0.31	5.53e-11	Protein biomarker;
LUAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg16606324	chr3:10149918	C3orf24	0.68	11.41	0.49	1.78e-26	Alzheimer's disease;
LUAD	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg21951975	chr1:209979733	IRF6	0.56	7.11	0.33	5.01e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg11189052	chr15:85197271	WDR73	0.65	8.76	0.39	4.82e-17	Schizophrenia;
LUAD	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg04944784	chr2:26401820	FAM59B	-0.7	-9.93	-0.43	5.07e-21	Gut microbiome composition (summer);
LUAD	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11644478	chr21:40555479	PSMG1	0.66	10.96	0.47	8.91e-25	Cognitive function;
LUAD	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs8038465	0.568	rs62004592	chr15:73878019	A/G	cg15420318	chr15:73925796	NPTN	0.45	7.5	0.34	3.71e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg15181151	chr6:150070149	PCMT1	0.42	8.71	0.39	6.76e-17	Lung cancer;
LUAD	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg21475434	chr5:93447410	FAM172A	0.72	8.49	0.38	3.54e-16	Diabetic retinopathy;
LUAD	cis	rs9341808	0.558	rs3805911	chr6:80933996	A/C	cg08355045	chr6:80787529	NA	0.48	8.49	0.38	3.66e-16	Sitting height ratio;
LUAD	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	6.64	0.31	9.66e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg26408565	chr15:76604113	ETFA	-0.55	-9.62	-0.42	6.1e-20	Blood metabolite levels;
LUAD	cis	rs13394619	0.875	rs9287734	chr2:11724475	A/G	cg07314298	chr2:11723111	GREB1	-0.53	-9.84	-0.43	1.07e-20	Endometriosis;
LUAD	cis	rs4077515	0.967	rs3829110	chr9:139269198	A/G	cg14019695	chr9:139328340	INPP5E	0.4	7.64	0.35	1.44e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1003719	0.788	rs60447195	chr21:38448600	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.54	0.38	2.42e-16	Eye color traits;
LUAD	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg03209412	chr4:183728196	NA	0.85	11.6	0.49	3.28e-27	Pediatric autoimmune diseases;
LUAD	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg02569458	chr12:86230093	RASSF9	0.43	7.89	0.36	2.68e-14	Major depressive disorder;
LUAD	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.44	6.81	0.31	3.29e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs13315871	0.929	rs79813245	chr3:58318475	G/A	cg12435725	chr3:58293450	RPP14	-0.73	-7.69	-0.35	1.08e-13	Cholesterol, total;
LUAD	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg01657329	chr11:68192670	LRP5	0.47	8.43	0.38	5.45e-16	Total body bone mineral density;
LUAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg20607798	chr8:58055168	NA	-0.58	-7.34	-0.34	1.08e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg14917512	chr19:3094685	GNA11	-0.57	-6.77	-0.31	4.22e-11	Diabetic kidney disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23285320	chr19:36546349	THAP8;WDR62	-0.46	-7.18	-0.33	3.14e-12	Height;
LUAD	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg21951975	chr1:209979733	IRF6	0.56	8.12	0.37	5.19e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs12049351	0.719	rs10916493	chr1:229634397	G/T	cg11742688	chr1:229674241	ABCB10	-0.42	-6.42	-0.3	3.7e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg26769984	chr7:1090371	C7orf50	0.58	9.42	0.42	2.97e-19	Bronchopulmonary dysplasia;
LUAD	cis	rs1941023	0.606	rs7926219	chr11:60180335	C/T	cg08716584	chr11:60157161	MS4A7	-0.35	-6.49	-0.3	2.34e-10	Congenital heart disease (maternal effect);
LUAD	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg20203395	chr5:56204925	C5orf35	-0.81	-11.63	-0.49	2.51e-27	Initial pursuit acceleration;
LUAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-8.83	-0.39	2.74e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02669656	chr8:104033463	ATP6V1C1	-0.39	-6.43	-0.3	3.4e-10	Cancer;
LUAD	cis	rs4746822	0.559	rs4746826	chr10:70985650	G/A	cg14418922	chr10:70824840	NA	-0.37	-7.15	-0.33	3.97e-12	Glycemic traits (pregnancy);
LUAD	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg02423579	chr7:2872169	GNA12	-0.91	-16.41	-0.62	3.49e-47	Height;
LUAD	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg25173405	chr17:45401733	C17orf57	0.52	8.94	0.4	1.18e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg16325326	chr1:53192061	ZYG11B	-0.67	-12.79	-0.53	6.55e-32	Monocyte count;
LUAD	cis	rs6445967	0.530	rs56041256	chr3:58391678	G/A	cg13750441	chr3:58318267	PXK	-0.33	-6.73	-0.31	5.46e-11	Platelet count;
LUAD	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg18527919	chr2:24398170	C2orf84	0.4	6.71	0.31	6.15e-11	Asthma;
LUAD	trans	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg04775059	chr7:64541387	NA	0.51	6.98	0.32	1.12e-11	Aortic root size;
LUAD	cis	rs7909074	0.651	rs10900127	chr10:45390103	C/A	cg04218760	chr10:45406644	TMEM72	-0.26	-6.59	-0.31	1.29e-10	Mean corpuscular volume;
LUAD	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg13180566	chr4:1052158	NA	-0.38	-6.52	-0.3	2.04e-10	Recombination rate (females);
LUAD	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18876405	chr7:65276391	NA	0.57	9.49	0.42	1.75e-19	Aortic root size;
LUAD	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg15309053	chr8:964076	NA	0.42	9.27	0.41	9.71e-19	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.38e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72845660	0.550	rs6584499	chr10:104188259	A/C	cg20641465	chr10:103991465	PITX3	-0.52	-9.25	-0.41	1.14e-18	Intelligence (multi-trait analysis);
LUAD	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	15.15	0.59	9.79e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg08132940	chr7:1081526	C7orf50	-0.76	-10.33	-0.45	1.8e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-11.01	-0.47	5.86e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7187994	0.848	rs34179694	chr16:84776522	A/G	cg07647771	chr16:84786436	USP10	-0.37	-9.53	-0.42	1.21e-19	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg08085267	chr17:45401833	C17orf57	-0.63	-11.2	-0.48	1.09e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg08558340	chr7:100472263	SRRT	0.51	6.39	0.3	4.37e-10	Resting heart rate;
LUAD	cis	rs2041840	1.000	rs6544065	chr2:37497417	C/T	cg25727520	chr2:37576821	QPCT	-0.33	-6.68	-0.31	7.73e-11	Chronic lymphocytic leukemia;
LUAD	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12292205	chr6:26970375	C6orf41	-0.48	-6.71	-0.31	6.2e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg25554036	chr4:6271136	WFS1	0.65	11.5	0.49	8.45e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6494488	0.500	rs72744740	chr15:65050491	C/G	cg08069370	chr15:64387884	SNX1	-0.74	-6.64	-0.31	9.68e-11	Coronary artery disease;
LUAD	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg08514558	chr10:81106712	PPIF	0.51	10.09	0.44	1.35e-21	Height;
LUAD	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.31	-0.45	2.13e-22	Platelet count;
LUAD	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg22508957	chr16:3507546	NAT15	0.44	6.92	0.32	1.68e-11	Body mass index (adult);
LUAD	cis	rs35883536	1.000	rs871151	chr1:101123737	G/A	cg06223162	chr1:101003688	GPR88	0.37	6.95	0.32	1.36e-11	Monocyte count;
LUAD	cis	rs3772130	0.962	rs9812228	chr3:121495682	C/G	cg20356878	chr3:121714668	ILDR1	0.51	8.1	0.37	5.81e-15	Cognitive performance;
LUAD	cis	rs4389656	0.857	rs2279657	chr5:6737571	A/G	cg10857441	chr5:6722123	POLS	-0.47	-7.87	-0.36	3.03e-14	Coronary artery disease;
LUAD	cis	rs9535307	0.719	rs10492591	chr13:50385256	C/T	cg04663916	chr13:50265991	EBPL	-0.65	-7.01	-0.32	9.62e-12	Obesity-related traits;
LUAD	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg08847533	chr14:75593920	NEK9	0.43	7.36	0.34	9.37e-13	Height;
LUAD	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg21153622	chr11:89784906	NA	-0.33	-6.54	-0.3	1.75e-10	Coronary artery disease;
LUAD	cis	rs752010	0.619	rs10736421	chr1:42106230	G/A	cg06885757	chr1:42089581	HIVEP3	0.59	13.35	0.54	3.67e-34	Lupus nephritis in systemic lupus erythematosus;
LUAD	trans	rs9929218	0.911	rs4783686	chr16:68834156	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-12.61	-0.52	3.47e-31	Colorectal cancer;
LUAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg03354898	chr7:1950403	MAD1L1	-0.45	-8.72	-0.39	6.35e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg03233332	chr7:66118400	NA	0.44	6.75	0.31	4.95e-11	Aortic root size;
LUAD	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.49	-0.52	1.08e-30	Breast cancer;
LUAD	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	9.53	0.42	1.21e-19	Hip circumference adjusted for BMI;
LUAD	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg24801067	chr17:62843696	NA	0.64	8.84	0.39	2.59e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs208520	0.874	rs208515	chr6:66945749	A/G	cg07460842	chr6:66804631	NA	-1.0	-14.54	-0.58	4.06e-39	Exhaled nitric oxide output;
LUAD	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg03690763	chr11:133734501	NA	-0.35	-8.1	-0.37	5.76e-15	Childhood ear infection;
LUAD	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg22349387	chr12:9600060	DDX12	-0.37	-6.4	-0.3	4.14e-10	Breast size;
LUAD	cis	rs1881396	0.891	rs62131879	chr2:27755112	T/G	cg27432699	chr2:27873401	GPN1	0.47	6.45	0.3	3.12e-10	Nonalcoholic fatty liver disease;
LUAD	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg17757837	chr7:157058334	UBE3C	0.48	8.47	0.38	4.2e-16	Body mass index;
LUAD	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	10.45	0.45	6.79e-23	Post bronchodilator FEV1;
LUAD	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg03467027	chr4:99064603	C4orf37	0.41	6.7	0.31	6.61e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7187994	0.848	rs3751759	chr16:84778222	G/A	cg07647771	chr16:84786436	USP10	-0.37	-9.39	-0.42	3.62e-19	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19748678	chr4:122722346	EXOSC9	0.44	6.94	0.32	1.5e-11	Type 2 diabetes;
LUAD	cis	rs10504073	0.647	rs56057508	chr8:49982793	G/T	cg00325661	chr8:49890786	NA	0.45	10.31	0.45	2.27e-22	Blood metabolite ratios;
LUAD	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg25358565	chr5:93447407	FAM172A	-0.59	-7.52	-0.34	3.37e-13	Diabetic retinopathy;
LUAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg02136620	chr5:178986620	RUFY1	0.5	8.38	0.38	8.01e-16	Lung cancer;
LUAD	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.05	-0.36	8.53e-15	Cystic fibrosis severity;
LUAD	cis	rs686320	1.000	rs679643	chr11:65250590	C/A	cg21890820	chr11:65308645	LTBP3	0.75	8.27	0.37	1.73e-15	Hip circumference adjusted for BMI;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13099106	chr12:120525172	CCDC64	0.42	6.62	0.31	1.1e-10	Monocyte percentage of white cells;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg18042851	chr5:128431096	ISOC1	-0.39	-6.39	-0.3	4.4e-10	Cancer;
LUAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13732083	chr21:47605072	C21orf56	-0.59	-10.34	-0.45	1.68e-22	Testicular germ cell tumor;
LUAD	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.64	-0.35	1.5e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg09658066	chr6:35995354	MAPK14	-0.42	-6.43	-0.3	3.55e-10	Vertical cup-disc ratio;
LUAD	cis	rs977987	0.843	rs4888427	chr16:75478447	A/G	cg03315344	chr16:75512273	CHST6	0.64	13.92	0.56	1.53e-36	Dupuytren's disease;
LUAD	cis	rs751728	0.965	rs9394168	chr6:33759701	T/A	cg13859433	chr6:33739653	LEMD2	-0.39	-9.21	-0.41	1.55e-18	Crohn's disease;
LUAD	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.26e-12	Tonsillectomy;
LUAD	cis	rs2274273	0.840	rs2341622	chr14:55737243	C/A	cg04306507	chr14:55594613	LGALS3	0.4	8.4	0.38	6.76e-16	Protein biomarker;
LUAD	trans	rs10805346	0.501	rs4604059	chr4:10115065	C/T	cg26043149	chr18:55253948	FECH	-0.49	-8.07	-0.37	7.59e-15	Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs62400317	0.859	rs10456549	chr6:45225761	C/T	cg18551225	chr6:44695536	NA	-0.51	-7.98	-0.36	1.43e-14	Total body bone mineral density;
LUAD	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg23758822	chr17:41437982	NA	0.9	18.49	0.67	2.25e-56	Menopause (age at onset);
LUAD	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.94	-0.32	1.44e-11	Heart rate;
LUAD	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg02569458	chr12:86230093	RASSF9	0.44	8.05	0.36	8.3e-15	Major depressive disorder;
LUAD	cis	rs315934	0.739	rs315920	chr2:113873018	A/G	cg09040174	chr2:113837401	NA	0.55	6.8	0.31	3.64e-11	Dysmenorrheic pain;
LUAD	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-11.17	-0.48	1.46e-25	Hemoglobin concentration;
LUAD	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg06108461	chr20:60628389	TAF4	-0.83	-14.15	-0.57	1.71e-37	Body mass index;
LUAD	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg20503657	chr10:835505	NA	0.8	12.32	0.51	5.22e-30	Eosinophil percentage of granulocytes;
LUAD	cis	rs4588572	0.602	rs10059672	chr5:77673317	G/C	cg11547950	chr5:77652471	NA	0.77	11.86	0.5	3.41e-28	Triglycerides;
LUAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg20607798	chr8:58055168	NA	0.66	8.57	0.38	2.01e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg14895029	chr7:2775587	GNA12	-0.45	-7.3	-0.33	1.48e-12	Height;
LUAD	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg04944784	chr2:26401820	FAM59B	-0.89	-12.57	-0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg06453172	chr10:134556979	INPP5A	-0.77	-10.93	-0.47	1.16e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11644478	chr21:40555479	PSMG1	-0.4	-6.65	-0.31	8.88e-11	Menarche (age at onset);
LUAD	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg27454412	chr7:1067447	C7orf50	-0.4	-7.63	-0.35	1.55e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs7178572	0.568	rs8030074	chr15:77654232	C/T	cg15453836	chr15:77711506	NA	-0.37	-6.54	-0.3	1.76e-10	Type 2 diabetes;
LUAD	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg12311346	chr5:56204834	C5orf35	-0.53	-8.32	-0.38	1.19e-15	Coronary artery disease;
LUAD	cis	rs16958440	0.867	rs58061761	chr18:44686165	T/C	cg17192377	chr18:44677553	HDHD2	0.84	8.07	0.37	7.19e-15	Sitting height ratio;
LUAD	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs11077998	0.844	rs8064433	chr17:80501046	A/T	cg10255544	chr17:80519551	FOXK2	0.35	6.9	0.32	1.96e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg09021430	chr5:549028	NA	-0.69	-13.45	-0.55	1.43e-34	Lung disease severity in cystic fibrosis;
LUAD	cis	rs89107	0.967	rs4946333	chr6:118565665	A/G	cg21191810	chr6:118973309	C6orf204	-0.46	-8.9	-0.4	1.68e-17	Cardiac structure and function;
LUAD	cis	rs1018836	0.663	rs56784954	chr8:91505094	C/T	cg16814680	chr8:91681699	NA	-0.66	-10.8	-0.46	3.47e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2224391	0.590	rs72813693	chr6:5273464	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.63	-8.16	-0.37	3.98e-15	Height;
LUAD	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg02158880	chr13:53174818	NA	0.42	7.28	0.33	1.59e-12	Lewy body disease;
LUAD	cis	rs9796	0.621	rs537244	chr15:41469313	G/T	cg18705301	chr15:41695430	NDUFAF1	0.48	8.63	0.39	1.28e-16	Menopause (age at onset);
LUAD	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg22105103	chr4:187893119	NA	0.51	11.06	0.47	3.93e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg08470875	chr2:26401718	FAM59B	-0.62	-8.17	-0.37	3.53e-15	Gut microbiome composition (summer);
LUAD	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg18005901	chr6:33739558	LEMD2	-0.59	-9.48	-0.42	1.82e-19	Schizophrenia;
LUAD	cis	rs9902453	0.904	rs8078638	chr17:28290358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	10.05	0.44	1.84e-21	Coffee consumption (cups per day);
LUAD	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg08989290	chr16:615782	NHLRC4	0.31	6.8	0.31	3.6e-11	Height;
LUAD	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg04450456	chr4:17643702	FAM184B	0.39	7.63	0.35	1.58e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12545109	0.800	rs1371936	chr8:57422715	A/G	cg07776626	chr8:57350775	NA	-0.63	-8.86	-0.4	2.3e-17	Obesity-related traits;
LUAD	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg12935359	chr14:103987150	CKB	-0.47	-7.89	-0.36	2.66e-14	Body mass index;
LUAD	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.14	-0.33	4.08e-12	Bipolar disorder;
LUAD	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06544989	chr22:39130855	UNC84B	0.42	8.0	0.36	1.24e-14	Menopause (age at onset);
LUAD	cis	rs1232027	0.656	rs1677682	chr5:79956593	C/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.09	-0.33	5.7e-12	Huntington's disease progression;
LUAD	trans	rs7395662	1.000	rs11039851	chr11:48600839	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.57	-0.3	1.53e-10	HDL cholesterol;
LUAD	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg25554036	chr4:6271136	WFS1	0.67	13.38	0.55	2.61e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg11189052	chr15:85197271	WDR73	0.66	8.93	0.4	1.29e-17	Schizophrenia;
LUAD	cis	rs903263	0.512	rs1325602	chr1:84505777	C/T	cg10977910	chr1:84465055	TTLL7	0.5	7.43	0.34	6.13e-13	Breast cancer (male);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10141844	chr2:238473847	PRLH	0.44	6.39	0.3	4.43e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg07741184	chr6:167504864	NA	0.3	7.2	0.33	2.8e-12	Crohn's disease;
LUAD	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg15133208	chr4:90757351	SNCA	-0.45	-6.89	-0.32	2e-11	Neuroticism;
LUAD	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg13647721	chr17:30228624	UTP6	-0.49	-6.66	-0.31	8.29e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.93	-0.43	4.85e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs9826463	0.582	rs73238148	chr3:142061446	G/A	cg20824294	chr3:142316082	PLS1	0.42	7.14	0.33	4.21e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	trans	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg04995722	chr7:26192034	NFE2L3	-0.37	-6.51	-0.3	2.17e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.79	-0.35	5.24e-14	Blood metabolite levels;
LUAD	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg00129232	chr17:37814104	STARD3	-0.45	-7.48	-0.34	4.25e-13	Asthma;
LUAD	cis	rs4711336	0.967	rs4711338	chr6:33660188	T/C	cg13859433	chr6:33739653	LEMD2	-0.3	-7.02	-0.32	8.72e-12	Height;
LUAD	cis	rs887829	0.570	rs10175809	chr2:234596865	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.67	-0.43	4e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg17173187	chr15:85201210	NMB	0.47	8.12	0.37	5.27e-15	Schizophrenia;
LUAD	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg13699009	chr12:122356056	WDR66	0.31	6.89	0.32	1.99e-11	Mean corpuscular volume;
LUAD	cis	rs673604	1.000	rs7543044	chr1:35674311	A/G	cg12633102	chr1:35676489	NA	-0.71	-10.21	-0.44	4.87e-22	Endometrial cancer;
LUAD	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg22823121	chr1:150693482	HORMAD1	0.39	7.5	0.34	3.72e-13	Melanoma;
LUAD	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg23029597	chr12:123009494	RSRC2	-0.44	-7.0	-0.32	9.84e-12	Body mass index;
LUAD	trans	rs1493916	0.905	rs1586988	chr18:31396001	G/C	cg13755796	chr4:20253514	NA	-0.45	-7.6	-0.35	1.91e-13	Life satisfaction;
LUAD	trans	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg07211511	chr3:129823064	LOC729375	-0.87	-9.7	-0.43	3.28e-20	Blood pressure (smoking interaction);
LUAD	cis	rs2455799	1.000	rs7612540	chr3:15899177	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-6.57	-0.3	1.52e-10	Mean platelet volume;
LUAD	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg25036284	chr2:26402008	FAM59B	-0.68	-9.2	-0.41	1.7e-18	Gut microbiome composition (summer);
LUAD	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-14.51	-0.58	5.23e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.66	-0.39	9.95e-17	Total body bone mineral density;
LUAD	trans	rs4650994	0.525	rs17361286	chr1:178521916	C/G	cg05059571	chr16:84539110	KIAA1609	-0.72	-12.77	-0.53	8.3e-32	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg03709012	chr19:19516395	GATAD2A	0.51	6.89	0.32	2.09e-11	Nonalcoholic fatty liver disease;
LUAD	cis	rs1847202	0.762	rs13093504	chr3:72949855	T/C	cg25664220	chr3:72788482	NA	-0.42	-7.37	-0.34	9.09e-13	Motion sickness;
LUAD	cis	rs10821973	0.527	rs2393867	chr10:64021749	T/A	cg09941381	chr10:64027924	RTKN2	-0.36	-7.13	-0.33	4.46e-12	Hypothyroidism;
LUAD	cis	rs7586879	0.828	rs7597157	chr2:25089166	C/T	cg04586622	chr2:25135609	ADCY3	0.36	7.2	0.33	2.72e-12	Body mass index;
LUAD	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg08085267	chr17:45401833	C17orf57	-0.65	-11.75	-0.5	8.81e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg26384229	chr12:38710491	ALG10B	-0.42	-7.22	-0.33	2.36e-12	Heart rate;
LUAD	trans	rs61931739	0.513	rs10743833	chr12:33897481	C/T	cg10518543	chr12:38710700	ALG10B	0.42	6.67	0.31	7.8e-11	Morning vs. evening chronotype;
LUAD	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg27411982	chr8:10470053	RP1L1	-0.46	-8.8	-0.39	3.46e-17	Retinal vascular caliber;
LUAD	trans	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg18187862	chr3:45730750	SACM1L	0.5	7.95	0.36	1.68e-14	Primary sclerosing cholangitis;
LUAD	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21659725	chr3:3221576	CRBN	-0.63	-11.06	-0.47	3.93e-25	Intelligence (multi-trait analysis);
LUAD	trans	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg04565464	chr8:145669602	NFKBIL2	0.45	6.49	0.3	2.37e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg09359103	chr1:154839909	KCNN3	-0.91	-20.91	-0.71	3.28e-67	Prostate cancer;
LUAD	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11890956	chr21:40555474	PSMG1	-0.51	-8.71	-0.39	7.13e-17	Menarche (age at onset);
LUAD	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg08316699	chr6:150357289	NA	0.34	7.14	0.33	4.03e-12	Alopecia areata;
LUAD	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg00383909	chr3:49044727	WDR6	0.44	6.87	0.32	2.24e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg00271210	chr6:167070053	RPS6KA2	0.34	6.47	0.3	2.8e-10	Crohn's disease;
LUAD	cis	rs7274811	0.744	rs6119395	chr20:32244711	G/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.48	-7.05	-0.32	7.29e-12	Height;
LUAD	cis	rs4853036	0.857	rs1048139	chr2:70131791	T/A	cg02498382	chr2:70120550	SNRNP27	-0.55	-8.85	-0.4	2.44e-17	Colorectal or endometrial cancer;
LUAD	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg01689657	chr7:91764605	CYP51A1	0.32	7.88	0.36	2.88e-14	Breast cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg25798026	chr22:32149910	DEPDC5	-0.41	-7.08	-0.33	5.93e-12	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg01689657	chr7:91764605	CYP51A1	0.38	9.44	0.42	2.5e-19	Breast cancer;
LUAD	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg14196790	chr5:131705035	SLC22A5	0.37	6.52	0.3	1.97e-10	Blood metabolite levels;
LUAD	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg16647868	chr5:131706066	SLC22A5	0.39	6.39	0.3	4.41e-10	Blood metabolite levels;
LUAD	cis	rs8025790	0.508	rs12902812	chr15:67909279	C/T	cg27219399	chr15:67835830	MAP2K5	0.45	7.99	0.36	1.33e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.51	-0.34	3.61e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs12568771	1.000	rs12568771	chr1:17613809	A/G	cg08277548	chr1:17600880	PADI3	0.35	6.51	0.3	2.15e-10	IgA nephropathy;
LUAD	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	9.55	0.42	1.04e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg26384229	chr12:38710491	ALG10B	0.4	6.48	0.3	2.52e-10	Morning vs. evening chronotype;
LUAD	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.1	-0.51	3.68e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12505328	0.552	rs12645814	chr4:174383584	C/T	cg12145043	chr4:174357286	NA	-0.46	-7.05	-0.32	7.21e-12	Chin dimples;
LUAD	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg22875332	chr1:76189707	ACADM	-0.85	-16.25	-0.62	1.69e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg23649088	chr2:200775458	C2orf69	0.58	8.22	0.37	2.51e-15	Schizophrenia;
LUAD	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	7.22	0.33	2.42e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7084921	0.521	rs12782269	chr10:101875210	T/C	cg19754520	chr10:101825118	CPN1	-0.32	-6.81	-0.31	3.4e-11	Bone mineral density;
LUAD	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg04944784	chr2:26401820	FAM59B	0.81	10.01	0.44	2.54e-21	Gut microbiome composition (summer);
LUAD	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.32	-7.87	-0.36	3e-14	Total body bone mineral density;
LUAD	cis	rs9972944	0.729	rs7224482	chr17:63777949	C/A	cg07283582	chr17:63770753	CCDC46	0.49	10.6	0.46	1.98e-23	Total body bone mineral density;
LUAD	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg14196790	chr5:131705035	SLC22A5	0.5	8.76	0.39	4.6e-17	Breast cancer;Mosquito bite size;
LUAD	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg00933542	chr6:150070202	PCMT1	0.45	9.67	0.43	3.95e-20	Lung cancer;
LUAD	trans	rs11989744	0.500	rs7826517	chr8:23568841	G/A	cg03492747	chr16:86543808	FOXF1	-0.53	-11.19	-0.48	1.18e-25	Waist-hip ratio;
LUAD	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg06627628	chr2:24431161	ITSN2	-0.47	-8.0	-0.36	1.25e-14	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs13064411	0.660	rs11916690	chr3:113012343	A/C	cg18753928	chr3:113234510	CCDC52	-0.57	-9.1	-0.4	3.47e-18	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.38	-0.34	8.46e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg25985355	chr7:65971099	NA	-0.39	-7.11	-0.33	4.92e-12	Aortic root size;
LUAD	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg16405210	chr4:1374714	KIAA1530	0.48	7.79	0.35	5.09e-14	Obesity-related traits;
LUAD	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg19318889	chr4:1322082	MAEA	0.55	9.36	0.41	4.73e-19	Longevity;
LUAD	cis	rs9581857	0.579	rs75326986	chr13:27997758	C/T	cg22138327	chr13:27999177	GTF3A	0.94	11.44	0.49	1.41e-26	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg23625390	chr15:77176239	SCAPER	-0.5	-7.83	-0.36	4.03e-14	Blood metabolite levels;
LUAD	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg26513180	chr16:89883248	FANCA	-0.46	-7.68	-0.35	1.08e-13	Vitiligo;
LUAD	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg24801067	chr17:62843696	NA	0.66	8.76	0.39	4.86e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg04731861	chr2:219085781	ARPC2	0.23	7.04	0.32	7.7e-12	Colorectal cancer;
LUAD	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg23711669	chr6:146136114	FBXO30	0.39	6.56	0.3	1.6e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg22823121	chr1:150693482	HORMAD1	0.46	8.77	0.39	4.49e-17	Melanoma;
LUAD	cis	rs9393692	0.557	rs9379845	chr6:26291601	C/T	cg13736514	chr6:26305472	NA	-0.53	-8.36	-0.38	9.47e-16	Educational attainment;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06096824	chr1:51443952	NA	-0.68	-6.72	-0.31	6.01e-11	Type 2 diabetes;
LUAD	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg25319279	chr11:5960081	NA	-0.4	-7.04	-0.32	7.7e-12	DNA methylation (variation);
LUAD	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.4	-0.6	8.3e-43	Chronic sinus infection;
LUAD	trans	rs75804782	0.641	rs72985397	chr2:239341354	A/G	cg01134436	chr17:81009848	B3GNTL1	0.75	8.24	0.37	2.25e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg05754148	chr16:3507555	NAT15	0.38	6.5	0.3	2.3e-10	Body mass index (adult);
LUAD	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg01689657	chr7:91764605	CYP51A1	0.37	9.24	0.41	1.2e-18	Breast cancer;
LUAD	cis	rs113835537	0.559	rs74933537	chr11:66274958	A/C	cg24851651	chr11:66362959	CCS	0.55	9.82	0.43	1.19e-20	Airway imaging phenotypes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00088033	chr17:35969707	SYNRG	-0.42	-6.47	-0.3	2.72e-10	Height;
LUAD	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg09035930	chr12:129282057	SLC15A4	0.75	18.02	0.66	2.82e-54	Systemic lupus erythematosus;
LUAD	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg25985355	chr7:65971099	NA	-0.55	-6.84	-0.32	2.8e-11	Diabetic kidney disease;
LUAD	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	7.05	0.32	7.46e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs68170813	0.559	rs75154004	chr7:106903326	C/T	cg23024343	chr7:107201750	COG5	0.48	6.99	0.32	1.11e-11	Coronary artery disease;
LUAD	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg00717180	chr2:96193071	NA	-0.41	-7.68	-0.35	1.15e-13	HDL cholesterol;
LUAD	cis	rs6993813	0.593	rs10086835	chr8:120040181	C/T	cg01975934	chr8:119970761	NA	-0.34	-6.44	-0.3	3.34e-10	Bone mineral density (hip);
LUAD	cis	rs1232027	0.666	rs13161245	chr5:79944733	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-7.9	-0.36	2.46e-14	Huntington's disease progression;
LUAD	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg05872129	chr22:39784769	NA	-0.82	-15.92	-0.61	4.65e-45	Intelligence (multi-trait analysis);
LUAD	cis	rs9948	0.655	rs57582887	chr2:97406354	A/C	cg20312557	chr2:97357134	FER1L5	-0.73	-8.12	-0.37	5.3e-15	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg16988262	chr1:15930761	NA	0.42	7.01	0.32	9.56e-12	Systolic blood pressure;
LUAD	cis	rs2046867	0.908	rs868336	chr3:72818165	A/C	cg25664220	chr3:72788482	NA	-0.64	-11.74	-0.5	9.93e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg17724175	chr1:150552817	MCL1	-0.33	-7.73	-0.35	8.16e-14	Melanoma;
LUAD	trans	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	12.41	0.52	2.33e-30	Mean corpuscular volume;
LUAD	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg06064525	chr11:970664	AP2A2	-0.43	-8.32	-0.38	1.18e-15	Alzheimer's disease (late onset);
LUAD	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-8.56	-0.38	2.17e-16	Neutrophil percentage of white cells;
LUAD	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg22823121	chr1:150693482	HORMAD1	0.45	8.99	0.4	8.07e-18	Tonsillectomy;
LUAD	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg16325326	chr1:53192061	ZYG11B	0.52	8.79	0.39	3.76e-17	Monocyte count;
LUAD	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg02569458	chr12:86230093	RASSF9	0.43	7.82	0.36	4.19e-14	Major depressive disorder;
LUAD	cis	rs35883536	0.647	rs2783703	chr1:101040794	T/C	cg06223162	chr1:101003688	GPR88	0.47	9.14	0.41	2.68e-18	Monocyte count;
LUAD	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg02569458	chr12:86230093	RASSF9	0.37	7.2	0.33	2.75e-12	Major depressive disorder;
LUAD	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg08999081	chr20:33150536	PIGU	0.47	9.16	0.41	2.17e-18	Coronary artery disease;
LUAD	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg24397884	chr7:158709396	WDR60	-0.74	-13.46	-0.55	1.22e-34	Height;
LUAD	cis	rs62238980	0.522	rs76859275	chr22:32515891	G/A	cg00543991	chr22:32367038	NA	0.88	8.51	0.38	3.06e-16	Childhood ear infection;
LUAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg10295955	chr4:187884368	NA	1.09	25.94	0.78	1.75e-89	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg21226059	chr5:178986404	RUFY1	0.68	11.63	0.49	2.6e-27	Lung cancer;
LUAD	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	9.55	0.42	1.08e-19	Axial length;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg02572448	chr1:8763403	RERE	-0.49	-6.53	-0.3	1.86e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs7932354	0.528	rs4752952	chr11:47082858	T/C	cg19486271	chr11:47235900	DDB2	-0.47	-7.5	-0.34	3.89e-13	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg17264618	chr3:40429014	ENTPD3	0.37	7.81	0.36	4.47e-14	Renal cell carcinoma;
LUAD	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg16342193	chr10:102329863	NA	-0.37	-6.58	-0.3	1.36e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	7.01	0.32	9.49e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07141622	chr14:70193793	NA	-0.55	-6.74	-0.31	5.07e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs4714291	0.832	rs1923462	chr6:39976100	T/C	cg02267698	chr19:7991119	CTXN1	-0.47	-7.37	-0.34	9.3e-13	Strep throat;
LUAD	trans	rs208520	0.690	rs207108	chr6:66794096	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.32	-0.64	3.48e-51	Exhaled nitric oxide output;
LUAD	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.2	0.33	2.68e-12	Blood metabolite levels;
LUAD	cis	rs367943	0.901	rs463167	chr5:112799369	C/A	cg12552261	chr5:112820674	MCC	-0.59	-11.1	-0.47	2.72e-25	Type 2 diabetes;
LUAD	trans	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.65	0.49	2.18e-27	Mean corpuscular volume;
LUAD	cis	rs10089	0.953	rs114881127	chr5:127369661	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	9.79	0.43	1.52e-20	Ileal carcinoids;
LUAD	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg00316803	chr15:76480434	C15orf27	0.39	7.27	0.33	1.76e-12	Blood metabolite levels;
LUAD	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg04842962	chr6:43655489	MRPS18A	1.06	27.01	0.8	4.26e-94	IgG glycosylation;
LUAD	cis	rs12579753	0.917	rs7954438	chr12:82184419	T/C	cg07988820	chr12:82153109	PPFIA2	-0.45	-7.24	-0.33	2.1e-12	Resting heart rate;
LUAD	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg15181151	chr6:150070149	PCMT1	0.37	7.51	0.34	3.61e-13	Lung cancer;
LUAD	cis	rs10489202	0.513	rs4657731	chr1:168081255	C/T	cg25738037	chr1:168025549	DCAF6	-0.44	-6.52	-0.3	2.06e-10	Schizophrenia;
LUAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg14820908	chr5:178986412	RUFY1	-0.53	-8.84	-0.39	2.56e-17	Lung cancer;
LUAD	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.46	-8.01	-0.36	1.09e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	8.06	0.36	7.85e-15	Parkinson's disease;
LUAD	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.95	0.4	1.14e-17	Menopause (age at onset);
LUAD	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg25237894	chr2:233734115	C2orf82	-0.61	-11.36	-0.48	2.79e-26	Coronary artery disease;
LUAD	trans	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.12	0.44	1.02e-21	Mean corpuscular volume;
LUAD	trans	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg19862616	chr7:65841803	NCRNA00174	1.05	26.66	0.79	1.38e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg17105886	chr17:28927953	LRRC37B2	0.67	7.3	0.33	1.46e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3752645	1.000	rs2237653	chr7:106760048	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-6.46	-0.3	2.91e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg17757837	chr7:157058334	UBE3C	0.48	8.53	0.38	2.66e-16	Body mass index;
LUAD	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg04455712	chr21:45112962	RRP1B	0.47	9.58	0.42	8.31e-20	Mean corpuscular volume;
LUAD	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg13575925	chr12:9217583	LOC144571	0.39	7.34	0.34	1.08e-12	Sjögren's syndrome;
LUAD	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg08798685	chr6:27730294	NA	-0.4	-6.46	-0.3	2.88e-10	Parkinson's disease;
LUAD	cis	rs76419734	0.558	rs10032269	chr4:106525703	A/G	cg05309399	chr4:106552544	FLJ20184	-0.53	-6.67	-0.31	7.85e-11	Post bronchodilator FEV1;
LUAD	cis	rs2067615	0.560	rs10431462	chr12:107106546	G/A	cg15890332	chr12:107067104	RFX4	0.4	8.5	0.38	3.37e-16	Heart rate;
LUAD	cis	rs6500395	1.000	rs7191028	chr16:48626023	T/C	cg04672837	chr16:48644449	N4BP1	0.38	6.59	0.31	1.32e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg07404485	chr7:94953653	PON1	-0.49	-7.14	-0.33	4.08e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg11645453	chr3:52864694	ITIH4	0.52	9.29	0.41	8.31e-19	Schizophrenia;
LUAD	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg18129178	chr5:148520854	ABLIM3	-0.64	-9.87	-0.43	8.41e-21	Breast cancer;
LUAD	cis	rs57502260	1.000	rs57502260	chr11:68220905	A/G	cg16797656	chr11:68205561	LRP5	0.52	8.29	0.37	1.53e-15	Total body bone mineral density (age 45-60);
LUAD	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg15383120	chr6:291909	DUSP22	-0.49	-7.96	-0.36	1.6e-14	Menopause (age at onset);
LUAD	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg15704280	chr7:45808275	SEPT13	-0.65	-9.97	-0.44	3.52e-21	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg02524346	chr8:600233	NA	-0.88	-8.47	-0.38	4.06e-16	IgG glycosylation;
LUAD	cis	rs760794	0.791	rs6938760	chr6:19802104	C/A	cg02404759	chr6:19790362	NA	-0.34	-6.41	-0.3	3.98e-10	Endometriosis;
LUAD	cis	rs2979489	0.891	rs7822839	chr8:30354453	A/G	cg26383811	chr8:30366931	RBPMS	0.69	10.71	0.46	7.42e-24	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg18402987	chr7:1209562	NA	0.8	9.84	0.43	1.03e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.49	0.55	9.69e-35	Prudent dietary pattern;
LUAD	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	6.68	0.31	7.75e-11	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg07936489	chr17:37558343	FBXL20	-0.47	-7.5	-0.34	3.76e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs240764	0.658	rs9322212	chr6:101248474	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-7.56	-0.34	2.53e-13	Neuroticism;
LUAD	trans	rs4894410	1.000	rs4894410	chr3:139043236	C/G	cg03297192	chr17:32611642	CCL11	0.6	6.92	0.32	1.68e-11	Kawasaki disease;
LUAD	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08564027	chr20:61660810	NA	0.88	18.83	0.68	6.9e-58	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg06002616	chr8:101225028	SPAG1	-0.39	-7.92	-0.36	2.06e-14	Atrioventricular conduction;
LUAD	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg03874509	chr1:107600012	PRMT6	0.5	8.75	0.39	5.13e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13126279	chr21:47581558	C21orf56	0.54	9.09	0.4	4.01e-18	Testicular germ cell tumor;
LUAD	trans	rs941408	0.515	rs759067	chr19:2775668	C/T	cg19676328	chr12:49525230	TUBA1B	-0.61	-8.44	-0.38	4.99e-16	Total cholesterol levels;
LUAD	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg27572855	chr1:25598939	RHD	-0.54	-11.75	-0.5	8.44e-28	Erythrocyte sedimentation rate;
LUAD	cis	rs2224391	0.590	rs9405813	chr6:5251850	G/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-7.86	-0.36	3.32e-14	Height;
LUAD	cis	rs939658	0.805	rs11638004	chr15:79425765	A/C	cg17916960	chr15:79447300	NA	-0.51	-10.93	-0.47	1.17e-24	Refractive error;
LUAD	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg11494091	chr17:61959527	GH2	0.43	8.15	0.37	4.19e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7707921	0.752	rs2406909	chr5:81276087	T/C	cg15871215	chr5:81402204	ATG10	0.68	11.07	0.47	3.35e-25	Breast cancer;
LUAD	cis	rs1451375	0.698	rs1839740	chr7:50646280	C/T	cg18232548	chr7:50535776	DDC	0.5	8.23	0.37	2.27e-15	Malaria;
LUAD	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg12458913	chr13:53173898	NA	0.42	7.53	0.34	3.1400000000000003e-13	Lewy body disease;
LUAD	trans	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg01620082	chr3:125678407	NA	-0.83	-8.59	-0.39	1.73e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg22823121	chr1:150693482	HORMAD1	0.43	8.28	0.37	1.69e-15	Melanoma;
LUAD	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg00684032	chr4:1343700	KIAA1530	0.48	7.77	0.35	5.86e-14	Obesity-related traits;
LUAD	cis	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.39	-0.34	8.03e-13	Resting heart rate;
LUAD	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg17863274	chr19:49399704	TULP2	-0.56	-8.56	-0.38	2.19e-16	Red cell distribution width;
LUAD	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23978390	chr7:1156363	C7orf50	0.59	9.44	0.42	2.57e-19	Longevity;Endometriosis;
LUAD	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.74	-13.45	-0.55	1.43e-34	Axial length;
LUAD	cis	rs12946454	0.668	rs4792867	chr17:43249444	C/T	cg10701640	chr17:43249399	NA	0.57	11.49	0.49	8.69e-27	Systolic blood pressure;
LUAD	cis	rs6484504	0.512	rs7940020	chr11:31366453	T/G	cg26647111	chr11:31128758	NA	0.45	7.84	0.36	3.6e-14	Red blood cell count;
LUAD	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg13319975	chr6:146136371	FBXO30	0.62	10.58	0.46	2.27e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg16606324	chr3:10149918	C3orf24	0.59	9.56	0.42	1.01e-19	Alzheimer's disease;
LUAD	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg27529037	chr20:44575021	PCIF1	0.46	8.05	0.36	8.4e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg13732083	chr21:47605072	C21orf56	0.43	7.09	0.33	5.84e-12	Testicular germ cell tumor;
LUAD	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg02423579	chr7:2872169	GNA12	-0.42	-6.96	-0.32	1.32e-11	Height;
LUAD	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg25173405	chr17:45401733	C17orf57	-0.48	-7.99	-0.36	1.25e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg20701182	chr2:24300061	SF3B14	0.64	7.46	0.34	5.07e-13	Lymphocyte counts;
LUAD	cis	rs9473147	0.543	rs4711878	chr6:47456118	A/G	cg20196966	chr6:47445060	CD2AP	0.45	6.99	0.32	1.04e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	5.75e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg08798685	chr6:27730294	NA	-0.43	-7.05	-0.32	7.18e-12	Parkinson's disease;
LUAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg04025307	chr7:1156635	C7orf50	0.73	13.37	0.55	2.98e-34	Longevity;Endometriosis;
LUAD	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg03605463	chr16:89740564	NA	0.6	10.96	0.47	8.93e-25	Hemoglobin concentration;
LUAD	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg07343612	chr16:622815	PIGQ	-0.79	-15.58	-0.6	1.46e-43	Height;
LUAD	cis	rs300703	0.542	rs443419	chr2:189800	C/T	cg21211680	chr2:198530	NA	-0.51	-7.64	-0.35	1.51e-13	Blood protein levels;
LUAD	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg17757837	chr7:157058334	UBE3C	0.47	8.46	0.38	4.4e-16	Body mass index;
LUAD	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg05182265	chr7:156933206	UBE3C	0.68	13.26	0.54	8.62e-34	Body mass index;
LUAD	cis	rs7809950	1.000	rs2293658	chr7:107270567	C/T	cg23024343	chr7:107201750	COG5	-0.77	-12.98	-0.53	1.14e-32	Coronary artery disease;
LUAD	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg17863274	chr19:49399704	TULP2	-0.57	-9.03	-0.4	6.12e-18	Red cell distribution width;
LUAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg18305652	chr10:134549665	INPP5A	0.6	11.74	0.5	9.85e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1595825	0.891	rs73058876	chr2:198895022	A/G	cg00982548	chr2:198649783	BOLL	-0.65	-9.2	-0.41	1.65e-18	Ulcerative colitis;
LUAD	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.15	-0.41	2.44e-18	Life satisfaction;
LUAD	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg10518543	chr12:38710700	ALG10B	0.5	8.39	0.38	7.38e-16	Morning vs. evening chronotype;
LUAD	cis	rs7786808	0.527	rs62478405	chr7:158188528	G/A	cg09998033	chr7:158218633	PTPRN2	-0.42	-7.37	-0.34	9.32e-13	Obesity-related traits;
LUAD	cis	rs7428	0.527	rs4832164	chr2:85546932	A/C	cg24342717	chr2:85555507	TGOLN2	-0.49	-7.99	-0.36	1.26e-14	Ear protrusion;
LUAD	cis	rs755249	0.508	rs12023553	chr1:39671492	C/A	cg27567593	chr1:39956653	BMP8A	0.38	7.35	0.34	1.03e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7147624	1.000	rs7147624	chr14:65865625	G/T	cg03016385	chr14:66212404	NA	0.54	6.52	0.3	2e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08704250	chr15:31115839	NA	-0.73	-13.79	-0.56	5.37e-36	Huntington's disease progression;
LUAD	cis	rs727505	0.909	rs7810427	chr7:124645103	C/T	cg23710748	chr7:124431027	NA	-0.43	-8.43	-0.38	5.33e-16	Lewy body disease;
LUAD	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.37	0.57	2.12e-38	Schizophrenia;
LUAD	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg20587970	chr11:113659929	NA	-1.2	-18.25	-0.66	2.76e-55	Hip circumference adjusted for BMI;
LUAD	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg13334819	chr7:99746414	C7orf59	0.66	10.57	0.46	2.57e-23	Coronary artery disease;
LUAD	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg19875535	chr5:140030758	IK	0.44	7.35	0.34	1.04e-12	Schizophrenia;
LUAD	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06022373	chr22:39101656	GTPBP1	0.47	7.81	0.36	4.42e-14	Menopause (age at onset);
LUAD	cis	rs4988958	0.565	rs1420100	chr2:103037002	C/A	cg03938978	chr2:103052716	IL18RAP	0.45	10.33	0.45	1.82e-22	Asthma (childhood onset);
LUAD	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg05110241	chr16:68378359	PRMT7	-0.81	-8.75	-0.39	5.05e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2274273	0.745	rs8005399	chr14:55542845	A/G	cg04306507	chr14:55594613	LGALS3	0.33	6.68	0.31	7.59e-11	Protein biomarker;
LUAD	cis	rs73198271	0.960	rs17154702	chr8:8609880	C/T	cg01851573	chr8:8652454	MFHAS1	0.51	8.43	0.38	5.49e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9393692	0.620	rs9358918	chr6:26286744	C/T	cg13736514	chr6:26305472	NA	-0.54	-9.35	-0.41	5.29e-19	Educational attainment;
LUAD	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg18180107	chr4:99064573	C4orf37	0.4	6.44	0.3	3.25e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg02880119	chr16:3481970	NA	0.47	7.0	0.32	1e-11	Body mass index (adult);
LUAD	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg00898013	chr13:113819073	PROZ	-0.64	-11.53	-0.49	6.29e-27	Platelet distribution width;
LUAD	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2625529	0.590	rs2856929	chr15:72496762	T/C	cg16672083	chr15:72433130	SENP8	-0.75	-12.66	-0.52	2.25e-31	Red blood cell count;
LUAD	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg02423579	chr7:2872169	GNA12	-0.82	-13.67	-0.55	1.65e-35	Height;
LUAD	cis	rs7107174	1.000	rs57738705	chr11:77994489	A/G	cg19901956	chr11:77921274	USP35	-0.53	-6.8	-0.31	3.56e-11	Testicular germ cell tumor;
LUAD	cis	rs2274273	0.686	rs2296489	chr14:55624977	T/C	cg04306507	chr14:55594613	LGALS3	0.42	7.64	0.35	1.47e-13	Protein biomarker;
LUAD	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg13685833	chr1:53393034	SCP2	-0.46	-7.42	-0.34	6.69e-13	Monocyte count;
LUAD	cis	rs4604732	0.631	rs80319072	chr1:247626835	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg06640241	chr16:89574553	SPG7	0.47	7.44	0.34	5.68e-13	Multiple myeloma (IgH translocation);
LUAD	cis	rs2692947	0.673	rs1168965	chr2:96787899	C/G	cg23100626	chr2:96804247	ASTL	-0.36	-9.73	-0.43	2.49e-20	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7731657	0.537	rs2107334	chr5:130292773	T/C	cg08523029	chr5:130500466	HINT1	-0.57	-7.43	-0.34	5.98e-13	Fasting plasma glucose;
LUAD	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg24955955	chr5:415729	AHRR	0.77	8.58	0.39	1.78e-16	Fat distribution (HIV);
LUAD	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg17063962	chr7:91808500	NA	-0.66	-11.47	-0.49	1.07e-26	Breast cancer;
LUAD	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg13813247	chr22:41461852	NA	-0.45	-7.35	-0.34	1.05e-12	Neuroticism;
LUAD	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg12407791	chr17:73824354	UNC13D	-0.32	-6.7	-0.31	6.48e-11	White matter hyperintensity burden;
LUAD	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.47	-0.34	4.51e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg26043149	chr18:55253948	FECH	1.03	17.14	0.64	2.24e-50	Gout;Urate levels;Serum uric acid levels;
LUAD	trans	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg21051086	chr3:73046214	PPP4R2	-0.46	-6.99	-0.32	1.07e-11	Pancreatic cancer;
LUAD	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg22681709	chr2:178499509	PDE11A	-0.46	-7.69	-0.35	1.02e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg27494647	chr7:150038898	RARRES2	-0.53	-9.34	-0.41	5.56e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs56283067	0.887	rs4644056	chr6:44776136	G/T	cg18551225	chr6:44695536	NA	0.54	8.33	0.38	1.15e-15	Total body bone mineral density;
LUAD	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg02696790	chr15:75250997	RPP25	-0.35	-6.97	-0.32	1.19e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs7727544	0.506	rs10040809	chr5:131343017	A/C	cg16205897	chr5:131564050	P4HA2	-0.32	-7.0	-0.32	1.04e-11	Blood metabolite levels;
LUAD	cis	rs2853333	0.622	rs2519962	chr19:35752691	A/G	cg08833636	chr19:35715976	FAM187B	0.34	6.37	0.3	4.91e-10	Red blood cell count;
LUAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00149659	chr3:10157352	C3orf10	0.56	7.19	0.33	2.87e-12	Alzheimer's disease;
LUAD	cis	rs1448094	0.872	rs7300073	chr12:86393513	A/C	cg02569458	chr12:86230093	RASSF9	0.37	7.15	0.33	3.94e-12	Major depressive disorder;
LUAD	cis	rs2742234	0.541	rs10899778	chr10:43718509	G/C	cg15436174	chr10:43711423	RASGEF1A	0.55	9.02	0.4	6.55e-18	Hirschsprung disease;
LUAD	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg00310523	chr12:86230176	RASSF9	0.41	8.71	0.39	6.76e-17	Major depressive disorder;
LUAD	cis	rs79243044	0.695	rs6578654	chr11:5540613	C/T	cg24229750	chr11:5531283	UBQLN3	0.29	6.36	0.3	5.36e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg07936489	chr17:37558343	FBXL20	0.51	6.95	0.32	1.37e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs10979	1.000	rs9376762	chr6:143887248	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.18	-0.44	6.7e-22	Hypospadias;
LUAD	cis	rs78761021	0.867	rs74449008	chr17:9782376	C/T	cg26853458	chr17:9805074	RCVRN	0.36	7.0	0.32	1.02e-11	Type 2 diabetes;
LUAD	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	6.61	0.31	1.16e-10	Cognitive test performance;
LUAD	cis	rs4356932	1.000	rs10017431	chr4:76955406	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.54	-0.3	1.78e-10	Blood protein levels;
LUAD	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg17031739	chr1:67600172	NA	0.52	9.16	0.41	2.25e-18	Psoriasis;
LUAD	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg00484396	chr16:3507460	NAT15	0.76	9.7	0.43	3.2e-20	Tuberculosis;
LUAD	cis	rs977987	0.836	rs7199062	chr16:75474827	G/A	cg03315344	chr16:75512273	CHST6	0.64	13.92	0.56	1.65e-36	Dupuytren's disease;
LUAD	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg21427119	chr20:30132790	HM13	-0.66	-10.12	-0.44	1.03e-21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUAD	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.36	7.04	0.32	7.85e-12	Monocyte percentage of white cells;
LUAD	cis	rs7274811	0.711	rs184110	chr20:31981432	G/A	cg13403462	chr20:32256071	NECAB3;C20orf134	0.46	7.01	0.32	9.56e-12	Height;
LUAD	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg01416388	chr22:39784598	NA	-0.51	-8.32	-0.37	1.24e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.688	rs116566508	chr4:119619195	G/A	cg14228332	chr4:119757509	SEC24D	0.77	7.07	0.32	6.56e-12	Cannabis dependence symptom count;
LUAD	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg20019720	chr6:154832845	CNKSR3	0.66	12.93	0.53	1.8e-32	Lipoprotein (a) levels;
LUAD	cis	rs6005807	0.719	rs73430168	chr22:28985428	C/T	cg12565055	chr22:29076175	TTC28	0.71	7.98	0.36	1.41e-14	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg01251360	chr16:68772225	CDH1	-0.28	-8.86	-0.4	2.27e-17	Colorectal cancer;
LUAD	cis	rs7709909	0.553	rs32960	chr5:80041918	C/T	cg24059623	chr5:79951536	MSH3;DHFR	0.49	7.43	0.34	5.93e-13	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg14324370	chr2:177042789	NA	0.39	7.29	0.33	1.54e-12	IgG glycosylation;
LUAD	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.66	10.69	0.46	8.68e-24	Height;
LUAD	cis	rs72720396	0.789	rs12022460	chr1:91202257	A/G	cg13456504	chr1:91191583	NA	-0.57	-9.99	-0.44	3.19e-21	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg15181151	chr6:150070149	PCMT1	0.41	8.53	0.38	2.57e-16	Lung cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21110052	chr7:29234262	CHN2	-0.5	-6.48	-0.3	2.52e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.95	-0.32	1.4e-11	Total cholesterol levels;
LUAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg00280220	chr17:61926910	NA	0.37	7.18	0.33	3.23e-12	Prudent dietary pattern;
LUAD	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg12193833	chr17:30244370	NA	-0.58	-6.8	-0.31	3.55e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg16235748	chr6:149772707	ZC3H12D	0.29	6.43	0.3	3.36e-10	Dupuytren's disease;
LUAD	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg10591111	chr5:226296	SDHA	-0.55	-7.17	-0.33	3.27e-12	Breast cancer;
LUAD	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg00101154	chr16:420108	MRPL28	-0.62	-8.94	-0.4	1.22e-17	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs7394190	0.748	rs2306325	chr10:75506674	T/C	cg02286717	chr10:75415704	SYNPO2L	-0.37	-6.51	-0.3	2.11e-10	Incident atrial fibrillation;
LUAD	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06544989	chr22:39130855	UNC84B	-0.43	-7.66	-0.35	1.29e-13	Menopause (age at onset);
LUAD	cis	rs2859741	0.565	rs12031540	chr1:37513757	C/T	cg09363841	chr1:37513479	NA	-0.29	-7.08	-0.33	5.91e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg03563238	chr19:33554763	RHPN2	-0.35	-8.39	-0.38	7.2e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg15128208	chr22:42549153	NA	0.43	6.72	0.31	5.77e-11	Birth weight;
LUAD	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg00666640	chr1:248458726	OR2T12	0.3	7.24	0.33	2.14e-12	Common traits (Other);
LUAD	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg06784218	chr1:46089804	CCDC17	-0.6	-13.37	-0.54	3.04e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs758324	0.947	rs1875177	chr5:131202625	T/C	cg06307176	chr5:131281290	NA	0.52	8.26	0.37	1.86e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg05283184	chr6:79620031	NA	-0.58	-11.51	-0.49	7.71e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg02428538	chr16:24856791	SLC5A11	0.48	6.62	0.31	1.1e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg24848339	chr3:12840334	CAND2	0.49	10.43	0.45	7.82e-23	QRS complex (12-leadsum);
LUAD	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg22467129	chr15:76604101	ETFA	0.48	8.1	0.37	6.13e-15	Blood metabolite levels;
LUAD	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-8.16	-0.37	3.74e-15	Monocyte percentage of white cells;
LUAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03188948	chr7:1209495	NA	0.49	8.02	0.36	1.03e-14	Longevity;Endometriosis;
LUAD	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg23262073	chr20:60523788	NA	-0.46	-7.41	-0.34	7.12e-13	Body mass index;
LUAD	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg18016565	chr1:150552671	MCL1	-0.4	-6.95	-0.32	1.36e-11	Tonsillectomy;
LUAD	cis	rs2455799	0.574	rs2455798	chr3:15700505	G/C	cg16303742	chr3:15540471	COLQ	-0.5	-9.32	-0.41	6.73e-19	Mean platelet volume;
LUAD	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg01324343	chr3:183735012	ABCC5	0.8	17.69	0.65	7.72e-53	Anterior chamber depth;
LUAD	trans	rs7712671	0.840	rs11241418	chr5:116527405	C/T	cg27506889	chr16:67970774	PSMB10	0.41	6.75	0.31	4.74e-11	Schizophrenia;
LUAD	cis	rs35883536	0.647	rs17402630	chr1:101046587	C/T	cg06223162	chr1:101003688	GPR88	-0.48	-9.32	-0.41	6.57e-19	Monocyte count;
LUAD	trans	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg24644049	chr4:85504048	CDS1	0.88	7.14	0.33	4.18e-12	Skin colour saturation;
LUAD	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg26513180	chr16:89883248	FANCA	0.78	6.74	0.31	5.14e-11	Skin colour saturation;
LUAD	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg19041857	chr6:27730383	NA	-0.43	-7.44	-0.34	5.57e-13	Parkinson's disease;
LUAD	cis	rs7586879	0.609	rs7608976	chr2:25075281	G/A	cg04586622	chr2:25135609	ADCY3	0.37	8.37	0.38	8.78e-16	Body mass index;
LUAD	cis	rs7512552	0.839	rs1627235	chr1:150358858	C/T	cg15654264	chr1:150340011	RPRD2	0.61	11.64	0.49	2.4e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.29	0.37	1.55e-15	Alzheimer's disease;
LUAD	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg17971929	chr21:40555470	PSMG1	0.5	7.6	0.35	1.89e-13	Cognitive function;
LUAD	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg04034577	chr2:241836375	C2orf54	-0.54	-12.49	-0.52	1.08e-30	Urinary metabolites;
LUAD	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.45	0.34	5.2e-13	Tonsillectomy;
LUAD	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg03806693	chr22:41940476	POLR3H	-0.58	-8.35	-0.38	9.94e-16	Vitiligo;
LUAD	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.21	-0.41	1.58e-18	Total body bone mineral density;
LUAD	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg14196790	chr5:131705035	SLC22A5	0.36	6.54	0.3	1.77e-10	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg24818145	chr4:99064322	C4orf37	0.48	8.2	0.37	2.9e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7264396	0.623	rs2425123	chr20:34329547	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.28	-0.37	1.67e-15	Total cholesterol levels;
LUAD	cis	rs2882667	0.858	rs13170388	chr5:138436865	A/G	cg04439458	chr5:138467593	SIL1	-0.54	-9.75	-0.43	2.23e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs62400317	0.859	rs10456542	chr6:45107579	G/A	cg20913747	chr6:44695427	NA	-0.42	-6.69	-0.31	7.02e-11	Total body bone mineral density;
LUAD	cis	rs4947962	0.590	rs6969537	chr7:55082418	C/T	cg23757825	chr7:55092271	EGFR	-0.48	-6.47	-0.3	2.71e-10	Subjective response to lithium treatment;
LUAD	cis	rs236352	0.576	rs3778017	chr6:36842183	C/T	cg10099585	chr6:36853529	C6orf89	-0.39	-6.38	-0.3	4.55e-10	Heart rate;
LUAD	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg13902645	chr11:5959945	NA	-0.58	-10.28	-0.45	2.92e-22	DNA methylation (variation);
LUAD	cis	rs7945705	0.875	rs4929914	chr11:8824388	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.32	-6.79	-0.31	3.83e-11	Hemoglobin concentration;
LUAD	cis	rs7665090	0.806	rs413967	chr4:103583196	G/A	cg07973026	chr4:103553119	MANBA	-0.41	-7.1	-0.33	5.2e-12	Primary biliary cholangitis;
LUAD	cis	rs12545109	0.800	rs1440747	chr8:57417924	G/T	cg09654669	chr8:57350985	NA	0.65	9.15	0.41	2.41e-18	Obesity-related traits;
LUAD	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg06608945	chr2:219082296	ARPC2	-0.42	-6.99	-0.32	1.05e-11	Colorectal cancer;
LUAD	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg26513180	chr16:89883248	FANCA	0.73	6.99	0.32	1.06e-11	Skin colour saturation;
LUAD	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg09184832	chr6:79620586	NA	0.46	8.18	0.37	3.37e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs12681287	0.927	rs7003059	chr8:87330713	C/T	cg27223183	chr8:87520930	FAM82B	-0.63	-8.84	-0.39	2.63e-17	Caudate activity during reward;
LUAD	cis	rs17067123	0.708	rs72712835	chr4:180053338	T/C	cg26610307	chr4:180072759	NA	-0.53	-6.45	-0.3	3.13e-10	Response to hepatitis C treatment;
LUAD	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg00310523	chr12:86230176	RASSF9	-0.34	-6.87	-0.32	2.38e-11	Major depressive disorder;
LUAD	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-13.0	-0.53	9.72e-33	Chronic sinus infection;
LUAD	cis	rs1950626	0.623	rs61991083	chr14:101436435	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.37	7.44	0.34	5.54e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs6028335	0.610	rs73110616	chr20:37552943	C/T	cg27660920	chr20:37554817	FAM83D	0.58	7.49	0.34	3.95e-13	Alcohol and nicotine co-dependence;
LUAD	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg04455712	chr21:45112962	RRP1B	0.49	9.53	0.42	1.23e-19	Mean corpuscular volume;
LUAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.12	-0.33	4.69e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs9616064	0.853	rs7284865	chr22:46996529	C/T	cg05621596	chr22:47072043	GRAMD4	-0.54	-9.03	-0.4	6e-18	Urate levels in obese individuals;
LUAD	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.62	-0.35	1.65e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg02782426	chr3:40428986	ENTPD3	-0.41	-8.91	-0.4	1.5e-17	Renal cell carcinoma;
LUAD	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.52	8.09	0.37	6.21e-15	Electrocardiographic conduction measures;
LUAD	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg22482690	chr17:47019901	SNF8	0.45	8.58	0.38	1.86e-16	Type 2 diabetes;
LUAD	cis	rs6545883	0.929	rs6707830	chr2:61749472	G/A	cg15711740	chr2:61764176	XPO1	-0.41	-6.74	-0.31	5.09e-11	Tuberculosis;
LUAD	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg00933542	chr6:150070202	PCMT1	0.43	9.12	0.41	3.15e-18	Lung cancer;
LUAD	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.55	7.81	0.35	4.57e-14	Platelet count;
LUAD	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg15445000	chr17:37608096	MED1	0.45	8.31	0.37	1.32e-15	Glomerular filtration rate (creatinine);
LUAD	trans	rs258892	0.894	rs155435	chr5:72200093	G/A	cg14879065	chr14:104662468	NA	-0.35	-6.39	-0.3	4.45e-10	Small cell lung carcinoma;
LUAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08439880	chr3:133502540	NA	-0.44	-9.04	-0.4	5.76e-18	Iron status biomarkers;
LUAD	cis	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg08601574	chr20:25228251	PYGB	-0.44	-8.17	-0.37	3.48e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs17401966	0.838	rs4529713	chr1:10307295	A/G	cg15208524	chr1:10270712	KIF1B	0.42	6.43	0.3	3.45e-10	Hepatocellular carcinoma;
LUAD	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg21918786	chr6:109611834	NA	-0.57	-10.37	-0.45	1.35e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs7737355	0.898	rs31590	chr5:131005181	A/G	cg06307176	chr5:131281290	NA	0.54	8.34	0.38	1.03e-15	Life satisfaction;
LUAD	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg25358565	chr5:93447407	FAM172A	0.64	7.65	0.35	1.34e-13	Diabetic retinopathy;
LUAD	cis	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg08601574	chr20:25228251	PYGB	0.47	8.81	0.39	3.35e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.32	-18.25	-0.66	2.7e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.37	6.7	0.31	6.8e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.53	7.96	0.36	1.59e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg18944383	chr4:111397179	ENPEP	0.38	6.91	0.32	1.74e-11	Coronary artery disease;
LUAD	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg23503501	chr22:45809793	SMC1B;RIBC2	0.71	7.4	0.34	7.31e-13	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg03676636	chr4:99064102	C4orf37	0.31	8.03	0.36	1.01e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs735539	0.521	rs9552278	chr13:21352318	C/T	cg27499820	chr13:21296301	IL17D	0.5	7.56	0.35	2.5e-13	Dental caries;
LUAD	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg20476274	chr7:133979776	SLC35B4	0.64	10.87	0.47	1.91e-24	Mean platelet volume;
LUAD	cis	rs6906287	0.647	rs2213857	chr6:118806780	A/G	cg18833306	chr6:118973337	C6orf204	0.46	8.29	0.37	1.54e-15	Electrocardiographic conduction measures;
LUAD	trans	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg15704280	chr7:45808275	SEPT13	-0.6	-8.15	-0.37	4.04e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg14196790	chr5:131705035	SLC22A5	0.48	8.65	0.39	1.1e-16	Blood metabolite levels;
LUAD	trans	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	10.33	0.45	1.9e-22	Type 2 diabetes;
LUAD	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg15147215	chr3:52552868	STAB1	-0.4	-7.28	-0.33	1.61e-12	Bipolar disorder;
LUAD	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg23172400	chr8:95962367	TP53INP1	0.31	6.62	0.31	1.11e-10	Type 2 diabetes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22036233	chr14:68283005	ZFYVE26	-0.39	-6.6	-0.31	1.24e-10	Cancer;
LUAD	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.58	0.49	3.93e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs1160297	0.576	rs1376569	chr2:53087260	C/T	cg07782112	chr2:53107842	NA	0.39	8.29	0.37	1.55e-15	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg02753203	chr1:228287806	NA	-0.48	-8.7	-0.39	7.68e-17	Diastolic blood pressure;
LUAD	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.63	0.31	1.05e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-10.76	-0.46	4.9e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg25456477	chr12:86230367	RASSF9	0.34	6.41	0.3	3.92e-10	Major depressive disorder;
LUAD	cis	rs2658782	1.000	rs2019814	chr11:93168885	A/G	cg15737290	chr11:93063684	CCDC67	0.52	7.19	0.33	3.01e-12	Pulmonary function decline;
LUAD	cis	rs1697139	0.563	rs6859520	chr5:66529020	C/T	cg11553311	chr5:66541588	NA	0.42	7.81	0.35	4.58e-14	Breast cancer;
LUAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-9.63	-0.42	5.64e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1881797	0.527	rs74227706	chr1:247638315	A/C	cg14830002	chr1:247616686	OR2B11	0.51	6.98	0.32	1.12e-11	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg02049041	chr17:27085579	C17orf63	0.66	8.72	0.39	6.27e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.7e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6446731	0.593	rs2157090	chr4:3273110	C/T	cg08886695	chr4:3369023	RGS12	-0.5	-8.42	-0.38	5.94e-16	Mean platelet volume;
LUAD	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg00982548	chr2:198649783	BOLL	-0.64	-9.02	-0.4	6.88e-18	Ulcerative colitis;
LUAD	cis	rs6076065	0.548	rs6048740	chr20:23325047	G/A	cg11657817	chr20:23433608	CST11	0.55	11.46	0.49	1.16e-26	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg21782813	chr7:2030301	MAD1L1	0.55	9.68	0.43	3.8e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs2404602	0.684	rs2454451	chr15:76861461	G/T	cg23625390	chr15:77176239	SCAPER	0.56	8.87	0.4	2.12e-17	Blood metabolite levels;
LUAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.49	7.03	0.32	8.46e-12	Renal function-related traits (BUN);
LUAD	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.22e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg19683494	chr5:74908142	NA	0.5	7.16	0.33	3.5e-12	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LUAD	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg04586622	chr2:25135609	ADCY3	0.37	8.46	0.38	4.56e-16	Body mass index;
LUAD	cis	rs1395	1.000	rs1659685	chr2:27420690	C/T	cg23587288	chr2:27483067	SLC30A3	0.39	7.99	0.36	1.31e-14	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg17366294	chr4:99064904	C4orf37	0.63	12.2	0.51	1.59e-29	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.49	-0.34	4.13e-13	Bipolar disorder;
LUAD	trans	rs360929	0.935	rs168629	chr4:152895947	C/T	cg22822647	chr19:16771056	TMEM38A;C19orf42	0.53	6.59	0.31	1.33e-10	Volumetric brain MRI;
LUAD	cis	rs16910800	0.953	rs73481423	chr11:23205302	T/C	cg20040320	chr11:23191996	NA	-0.5	-7.38	-0.34	8.25e-13	Cancer;
LUAD	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg05110241	chr16:68378359	PRMT7	-0.83	-8.73	-0.39	6.16e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg04369109	chr6:150039330	LATS1	0.44	7.59	0.35	2.1e-13	Lung cancer;
LUAD	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.53e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg18944383	chr4:111397179	ENPEP	0.4	8.16	0.37	3.75e-15	Height;
LUAD	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg21028142	chr17:79581711	NPLOC4	-0.42	-8.87	-0.4	2.1e-17	Eye color traits;
LUAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg18402987	chr7:1209562	NA	0.8	9.9	0.43	6.26e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg04546413	chr19:29218101	NA	0.67	10.41	0.45	9.91e-23	Methadone dose in opioid dependence;
LUAD	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg11766577	chr21:47581405	C21orf56	-0.46	-7.93	-0.36	1.92e-14	Testicular germ cell tumor;
LUAD	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.61	-11.53	-0.49	6e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg02527881	chr3:46936655	PTH1R	0.38	7.08	0.33	5.99e-12	Colorectal cancer;
LUAD	cis	rs1595825	1.000	rs73058834	chr2:198873779	T/G	cg10547527	chr2:198650123	BOLL	-0.49	-6.74	-0.31	5.22e-11	Ulcerative colitis;
LUAD	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg19717773	chr7:2847554	GNA12	-0.43	-7.13	-0.33	4.26e-12	Height;
LUAD	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg14345882	chr6:26364793	BTN3A2	0.7	7.14	0.33	4.13e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs494562	0.892	rs573892	chr6:86118189	A/C	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg00666640	chr1:248458726	OR2T12	0.33	7.98	0.36	1.37e-14	Common traits (Other);
LUAD	trans	rs2797160	0.967	rs2747715	chr6:126007719	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.55	8.57	0.38	1.92e-16	Endometrial cancer;
LUAD	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg25036284	chr2:26402008	FAM59B	-0.55	-7.8	-0.35	4.95e-14	Gut microbiome composition (summer);
LUAD	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg03929089	chr4:120376271	NA	-0.93	-17.14	-0.64	2.18e-50	Height;
LUAD	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11890956	chr21:40555474	PSMG1	0.72	11.96	0.5	1.29e-28	Cognitive function;
LUAD	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg20701182	chr2:24300061	SF3B14	0.9	13.48	0.55	1.06e-34	Lymphocyte counts;
LUAD	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg01448562	chr3:133502909	NA	-0.52	-8.99	-0.4	8.36e-18	Iron status biomarkers;
LUAD	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg02527881	chr3:46936655	PTH1R	0.54	10.61	0.46	1.78e-23	Colorectal cancer;
LUAD	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.64	-0.39	1.17e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.38e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg24818145	chr4:99064322	C4orf37	0.49	8.26	0.37	1.88e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg21285383	chr16:89894308	SPIRE2	0.36	7.75	0.35	6.74e-14	Vitiligo;
LUAD	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg07570687	chr10:102243282	WNT8B	0.44	6.77	0.31	4.4e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg20203395	chr5:56204925	C5orf35	-0.72	-10.94	-0.47	1.03e-24	Initial pursuit acceleration;
LUAD	trans	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg06606381	chr12:133084897	FBRSL1	-0.66	-7.62	-0.35	1.66e-13	Depression;
LUAD	cis	rs713587	0.935	rs4430895	chr2:25161386	C/T	cg01884057	chr2:25150051	NA	0.35	7.54	0.34	2.94e-13	Body mass index in non-asthmatics;
LUAD	cis	rs2274273	0.905	rs10134800	chr14:55635209	A/G	cg04306507	chr14:55594613	LGALS3	0.41	8.37	0.38	8.46e-16	Protein biomarker;
LUAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg27454412	chr7:1067447	C7orf50	0.48	7.72	0.35	8.28e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg11663144	chr21:46675770	NA	-0.58	-10.73	-0.46	6.23e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg06606381	chr12:133084897	FBRSL1	-0.52	-7.05	-0.32	7.36e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg10589385	chr1:150898437	SETDB1	0.4	7.47	0.34	4.65e-13	Melanoma;
LUAD	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg00083206	chr6:110721305	DDO	-0.44	-8.11	-0.37	5.59e-15	Platelet distribution width;
LUAD	cis	rs7809950	1.000	rs17154077	chr7:107077941	C/T	cg23024343	chr7:107201750	COG5	0.7	12.06	0.51	5.41e-29	Coronary artery disease;
LUAD	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg27661571	chr11:113659931	NA	-0.52	-6.49	-0.3	2.37e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg25797454	chr6:150327115	RAET1K	0.36	7.78	0.35	5.43e-14	Alopecia areata;
LUAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-9.9	-0.43	6.4e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs11696501	0.588	rs6073831	chr20:44279550	A/T	cg11783356	chr20:44313418	WFDC10B	-0.49	-8.09	-0.37	6.42e-15	Brain structure;
LUAD	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg07432352	chr17:45403706	C17orf57	-0.41	-7.96	-0.36	1.56e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg18252515	chr7:66147081	NA	-0.63	-6.96	-0.32	1.28e-11	Gout;
LUAD	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08704250	chr15:31115839	NA	-0.73	-13.66	-0.55	1.91e-35	Huntington's disease progression;
LUAD	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg22868518	chr11:507468	RNH1	0.63	6.45	0.3	3.04e-10	Body mass index;
LUAD	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg05887092	chr17:76393375	PGS1	0.54	10.75	0.46	5.21e-24	HDL cholesterol levels;
LUAD	cis	rs757647	0.723	rs2240330	chr5:137780631	C/T	cg10676309	chr5:137685565	NA	0.42	7.42	0.34	6.6e-13	Menarche (age at onset);
LUAD	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06544989	chr22:39130855	UNC84B	0.45	8.82	0.39	3.11e-17	Menopause (age at onset);
LUAD	cis	rs2235649	0.828	rs9936486	chr16:1849888	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.47	-7.73	-0.35	7.72e-14	Blood metabolite levels;
LUAD	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.21	-0.37	2.73e-15	Total body bone mineral density;
LUAD	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg25173405	chr17:45401733	C17orf57	0.49	7.86	0.36	3.21e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg25358565	chr5:93447407	FAM172A	0.64	7.62	0.35	1.63e-13	Diabetic retinopathy;
LUAD	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-11.75	-0.5	8.58e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg09491104	chr22:46646882	C22orf40	-0.53	-6.78	-0.31	4.08e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs12348691	0.503	rs6478423	chr9:100592030	C/T	cg13688889	chr9:100608707	NA	-0.62	-10.11	-0.44	1.14e-21	Alopecia areata;
LUAD	cis	rs35740288	0.742	rs4843087	chr15:86172855	A/G	cg13263323	chr15:86062960	AKAP13	-0.45	-7.25	-0.33	2.05e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg27539214	chr16:67997921	SLC12A4	-0.68	-8.52	-0.38	2.74e-16	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08555112	chr17:48942811	TOB1	-0.44	-7.04	-0.32	7.79e-12	Height;
LUAD	cis	rs8027181	0.839	rs62017600	chr15:73072236	T/A	cg25632853	chr15:73088954	NA	0.32	7.03	0.32	8.49e-12	Triglyceride levels;
LUAD	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg03526776	chr6:41159608	TREML2	0.33	6.98	0.32	1.18e-11	Alzheimer's disease (late onset);
LUAD	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.91	-0.43	5.82e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg08888203	chr3:10149979	C3orf24	0.73	13.17	0.54	1.99e-33	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.91	0.36	2.29e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs941408	0.515	rs878893	chr19:2781325	A/G	cg19676328	chr12:49525230	TUBA1B	-0.59	-8.34	-0.38	1.09e-15	Total cholesterol levels;
LUAD	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	7.79	0.35	5.2e-14	Rheumatoid arthritis;
LUAD	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg03806693	chr22:41940476	POLR3H	0.69	9.83	0.43	1.09e-20	Vitiligo;
LUAD	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg04944784	chr2:26401820	FAM59B	-0.88	-12.6	-0.52	4.12e-31	Gut microbiome composition (summer);
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg20774646	chr1:149858164	HIST2H2BE;HIST2H2AC	0.38	6.46	0.3	2.82e-10	Anger;
LUAD	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.36	7.28	0.33	1.64e-12	Depression;
LUAD	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.48	0.3	2.6200000000000003e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1062746	0.711	rs8056833	chr16:87378388	G/C	cg02258303	chr16:87377426	FBXO31	-0.43	-7.54	-0.34	2.94e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg25427524	chr10:38739819	LOC399744	-0.6	-7.42	-0.34	6.2800000000000005e-13	Obesity (extreme);
LUAD	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg26384229	chr12:38710491	ALG10B	0.44	7.26	0.33	1.91e-12	Bladder cancer;
LUAD	cis	rs12893668	0.581	rs34843146	chr14:104079864	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.51	-8.15	-0.37	4.05e-15	Reticulocyte count;
LUAD	trans	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs2840044	1.000	rs225259	chr17:33958168	A/G	cg05299278	chr17:33885742	SLFN14	0.43	8.71	0.39	7.03e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg13319975	chr6:146136371	FBXO30	0.65	11.11	0.48	2.53e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg27411982	chr8:10470053	RP1L1	0.42	7.25	0.33	1.94e-12	Retinal vascular caliber;
LUAD	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22496380	chr5:211416	CCDC127	-1.23	-16.08	-0.62	9.79e-46	Breast cancer;
LUAD	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg12011299	chr4:100065546	ADH4	0.66	12.17	0.51	2.06e-29	Alcohol dependence;
LUAD	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg17971929	chr21:40555470	PSMG1	0.53	8.38	0.38	7.88e-16	Cognitive function;
LUAD	cis	rs7100689	0.646	rs11202725	chr10:82136276	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	10.26	0.45	3.26e-22	Post bronchodilator FEV1;
LUAD	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg26384229	chr12:38710491	ALG10B	0.5	8.08	0.37	6.86e-15	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg13397359	chr6:42928475	GNMT	0.57	10.99	0.47	7.18e-25	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg08027265	chr7:2291960	NA	-0.43	-7.07	-0.33	6.44e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs11626933	1.000	rs61986782	chr14:90751344	C/T	cg14092571	chr14:90743983	NA	-0.96	-18.13	-0.66	8.77e-55	Gut microbiota (bacterial taxa);
LUAD	cis	rs7177699	0.525	rs7402376	chr15:79113570	A/G	cg00540400	chr15:79124168	NA	-0.46	-9.72	-0.43	2.76e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg12483005	chr1:23474871	LUZP1	0.52	9.0	0.4	7.99e-18	Height;
LUAD	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg00999904	chr2:3704751	ALLC	-0.53	-9.19	-0.41	1.72e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg07677032	chr17:61819896	STRADA	0.59	10.83	0.47	2.83e-24	Prudent dietary pattern;
LUAD	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs78472555	1.000	rs11247124	chr15:100265725	C/T	cg18869061	chr15:100272053	LYSMD4	-0.4	-6.51	-0.3	2.1e-10	Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg26897989	chr16:1907736	C16orf73	0.51	6.69	0.31	6.9e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs7098414	0.531	rs4120852	chr10:82018594	G/T	cg00277334	chr10:82204260	NA	-0.38	-6.52	-0.3	2.04e-10	Post bronchodilator FEV1;
LUAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.43	-0.34	6.16e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs738322	0.555	rs6001027	chr22:38545619	A/G	cg25457927	chr22:38595422	NA	-0.57	-13.34	-0.54	3.96e-34	Cutaneous nevi;
LUAD	trans	rs3857536	0.813	rs7771569	chr6:66946717	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	cis	rs73206853	0.563	rs34378671	chr12:111163204	C/T	cg12870014	chr12:110450643	ANKRD13A	0.6	7.0	0.32	1.02e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg00106254	chr7:1943704	MAD1L1	-0.62	-9.55	-0.42	1.05e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg06074448	chr4:187884817	NA	-0.35	-6.9	-0.32	1.87e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6138458	0.828	rs6132785	chr20:24993414	T/C	cg26195577	chr20:24973756	C20orf3	0.78	13.69	0.55	1.43e-35	Blood protein levels;
LUAD	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg14092988	chr3:52407081	DNAH1	0.43	8.51	0.38	3.08e-16	Bipolar disorder;
LUAD	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.91	-0.36	2.23e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg23758822	chr17:41437982	NA	0.99	19.85	0.69	1.99e-62	Menopause (age at onset);
LUAD	cis	rs656319	0.638	rs670044	chr8:9892529	G/T	cg27411982	chr8:10470053	RP1L1	0.41	7.32	0.34	1.28e-12	Myopia (pathological);
LUAD	cis	rs739496	0.843	rs688812	chr12:111962581	C/T	cg10833066	chr12:111807467	FAM109A	0.41	6.51	0.3	2.19e-10	Platelet count;
LUAD	cis	rs11167764	0.945	rs4912619	chr5:141471847	G/A	cg23435118	chr5:141488016	NDFIP1	-0.48	-7.23	-0.33	2.24e-12	Crohn's disease;
LUAD	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg15017067	chr4:17643749	FAM184B	0.37	7.3	0.33	1.45e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg15556689	chr8:8085844	FLJ10661	0.41	6.51	0.3	2.08e-10	Mood instability;
LUAD	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg24399712	chr22:39784796	NA	-0.8	-15.31	-0.6	2.03e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.56e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg02002194	chr4:3960332	NA	-0.32	-7.51	-0.34	3.53e-13	Neuroticism;
LUAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg27454412	chr7:1067447	C7orf50	0.43	7.38	0.34	8.25e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-10.39	-0.45	1.14e-22	Gut microbiome composition (summer);
LUAD	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-7.31	-0.33	1.38e-12	Morning vs. evening chronotype;
LUAD	cis	rs11671005	0.571	rs56243535	chr19:59006150	C/T	cg13877915	chr19:58951672	ZNF132	0.51	6.44	0.3	3.2e-10	Mean platelet volume;
LUAD	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27286337	chr10:134555280	INPP5A	0.68	9.15	0.41	2.46e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg22535103	chr8:58192502	C8orf71	-0.58	-7.49	-0.34	4.18e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs1160297	0.576	rs13030509	chr2:53110287	T/A	cg07782112	chr2:53107842	NA	0.36	7.77	0.35	5.98e-14	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg27454412	chr7:1067447	C7orf50	0.44	7.04	0.32	7.84e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg18854424	chr1:2615690	NA	0.42	9.24	0.41	1.21e-18	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.55	0.42	1.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12760731	0.565	rs12048698	chr1:178136792	T/C	cg00404053	chr1:178313656	RASAL2	0.71	8.91	0.4	1.5e-17	Obesity-related traits;
LUAD	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg02734326	chr4:10020555	SLC2A9	0.64	11.33	0.48	3.73e-26	Bone mineral density;
LUAD	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03352830	chr11:487213	PTDSS2	0.77	9.56	0.42	9.84e-20	Body mass index;
LUAD	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg04842962	chr6:43655489	MRPS18A	1.06	26.25	0.79	8.22e-91	IgG glycosylation;
LUAD	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.45	-6.88	-0.32	2.18e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs4604732	0.536	rs7528219	chr1:247628307	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.05	0.32	7.27e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg02136620	chr5:178986620	RUFY1	0.39	6.46	0.3	2.92e-10	Lung cancer;
LUAD	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg18016565	chr1:150552671	MCL1	0.41	7.49	0.34	4.02e-13	Tonsillectomy;
LUAD	cis	rs11650494	0.908	rs73340392	chr17:47358308	G/A	cg08112188	chr17:47440006	ZNF652	0.91	7.83	0.36	3.96e-14	Prostate cancer;
LUAD	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24308560	chr3:49941425	MST1R	0.55	9.3	0.41	7.57e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg14092988	chr3:52407081	DNAH1	0.45	8.88	0.4	1.95e-17	Bipolar disorder;
LUAD	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.06	0.32	6.96e-12	Motion sickness;
LUAD	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg15412446	chr2:106886593	NA	-0.69	-10.18	-0.44	6.48e-22	Facial morphology (factor 23);
LUAD	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg27394845	chr17:28928406	LRRC37B2	0.5	6.37	0.3	4.96e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg02951883	chr7:2050386	MAD1L1	-0.85	-14.55	-0.58	3.61e-39	Bipolar disorder and schizophrenia;
LUAD	cis	rs1595825	0.838	rs73058883	chr2:198896255	C/T	cg11031976	chr2:198649780	BOLL	-0.45	-6.53	-0.3	1.84e-10	Ulcerative colitis;
LUAD	cis	rs62238980	0.614	rs33954397	chr22:32506143	C/T	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	trans	rs783540	0.609	rs803686	chr15:83219340	G/A	cg16105309	chr15:79090380	ADAMTS7	0.4	6.85	0.32	2.6e-11	Schizophrenia;
LUAD	cis	rs10129255	0.500	rs10131875	chr14:107201036	T/C	cg07958169	chr14:107095056	NA	-0.37	-7.45	-0.34	5.47e-13	Kawasaki disease;
LUAD	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg07211511	chr3:129823064	LOC729375	-0.44	-6.51	-0.3	2.14e-10	Blood pressure (smoking interaction);
LUAD	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg08027265	chr7:2291960	NA	-0.45	-7.49	-0.34	4.1e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs10899021	0.920	rs61901540	chr11:74314865	A/G	cg25880958	chr11:74394337	NA	-0.62	-8.5	-0.38	3.34e-16	Response to metformin (IC50);
LUAD	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg07828340	chr4:882639	GAK	1.05	10.84	0.47	2.47e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg08888203	chr3:10149979	C3orf24	0.63	9.77	0.43	1.8899999999999998e-20	Alzheimer's disease;
LUAD	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg13393036	chr8:95962371	TP53INP1	-0.44	-10.49	-0.45	4.75e-23	Type 2 diabetes;
LUAD	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg06784218	chr1:46089804	CCDC17	0.51	11.18	0.48	1.29e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg16606324	chr3:10149918	C3orf24	0.58	9.46	0.42	2.23e-19	Alzheimer's disease;
LUAD	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg10518543	chr12:38710700	ALG10B	-0.44	-7.08	-0.33	6.07e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs494562	1.000	rs527670	chr6:86115779	T/C	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg07305463	chr2:136567211	LCT	-0.35	-6.56	-0.3	1.6e-10	Mosquito bite size;
LUAD	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg25894440	chr7:65020034	NA	-0.68	-7.36	-0.34	9.49e-13	Diabetic kidney disease;
LUAD	cis	rs7845219	0.555	rs1129152	chr8:95888307	C/T	cg26343298	chr8:95960752	TP53INP1	0.37	7.58	0.35	2.17e-13	Type 2 diabetes;
LUAD	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.37	-0.57	2.05e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.56	9.59	0.42	7.89e-20	Birth weight;
LUAD	cis	rs7116495	1.000	rs3018302	chr11:71790942	A/C	cg07596299	chr11:71824057	C11orf51	-0.78	-6.64	-0.31	9.61e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg06753367	chr22:24256600	NA	-0.38	-6.63	-0.31	1e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.4	7.81	0.36	4.4e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6076065	0.723	rs6137905	chr20:23340938	G/A	cg11657817	chr20:23433608	CST11	0.5	9.18	0.41	1.96e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1232027	0.656	rs861372	chr5:79976322	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.77	-0.31	4.37e-11	Huntington's disease progression;
LUAD	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg06740227	chr12:86229804	RASSF9	-0.41	-7.32	-0.34	1.23e-12	Major depressive disorder;
LUAD	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg13319975	chr6:146136371	FBXO30	-0.82	-14.34	-0.57	2.65e-38	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3820068	0.705	rs4646083	chr1:15825564	G/A	cg13390004	chr1:15929781	NA	0.4	6.41	0.3	3.8e-10	Systolic blood pressure;
LUAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.49	6.76	0.31	4.49e-11	Renal function-related traits (BUN);
LUAD	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs870825	1.000	rs870825	chr4:185588045	A/G	cg04058563	chr4:185651563	MLF1IP	0.71	8.94	0.4	1.19e-17	Blood protein levels;
LUAD	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg17200465	chr3:40428508	ENTPD3	0.27	6.71	0.31	6.44e-11	Renal cell carcinoma;
LUAD	cis	rs12210905	0.800	rs12201890	chr6:26662626	A/C	cg11502198	chr6:26597334	ABT1	-0.76	-6.54	-0.3	1.77e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22825116	chr2:88991018	RPIA	-0.4	-6.36	-0.3	5.14e-10	Cancer;
LUAD	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg09359103	chr1:154839909	KCNN3	-0.91	-21.24	-0.72	1.09e-68	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.54	0.52	6.97e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2554380	0.843	rs2098904	chr15:84406255	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.48	-7.36	-0.34	9.47e-13	Height;
LUAD	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg22139774	chr2:100720529	AFF3	-0.34	-6.52	-0.3	2.03e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg25894440	chr7:65020034	NA	-0.64	-6.83	-0.32	2.96e-11	Diabetic kidney disease;
LUAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.53	0.3	1.88e-10	Prudent dietary pattern;
LUAD	cis	rs9902453	0.765	rs3102562	chr17:28040403	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.36	0.45	1.45e-22	Coffee consumption (cups per day);
LUAD	cis	rs1997103	0.863	rs2140916	chr7:55403154	A/C	cg17469321	chr7:55412551	NA	0.67	11.39	0.48	2.05e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg16606324	chr3:10149918	C3orf24	0.54	8.02	0.36	1.06e-14	Alzheimer's disease;
LUAD	cis	rs62064224	0.554	rs9894877	chr17:30679517	T/A	cg25809561	chr17:30822961	MYO1D	0.48	8.65	0.39	1.07e-16	Schizophrenia;
LUAD	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg06781209	chr11:61594997	FADS2	0.34	6.66	0.31	8.62e-11	Trans fatty acid levels;
LUAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg08132940	chr7:1081526	C7orf50	-0.45	-6.9	-0.32	1.92e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg14196790	chr5:131705035	SLC22A5	0.52	9.55	0.42	1.06e-19	Blood metabolite levels;
LUAD	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg08472276	chr7:1133186	C7orf50;GPER	0.51	9.73	0.43	2.48e-20	Longevity;Endometriosis;
LUAD	cis	rs9837602	1.000	rs9837602	chr3:99824685	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	9.22	0.41	1.4e-18	Breast cancer;
LUAD	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg18825076	chr15:78729989	IREB2	0.49	6.67	0.31	8.19e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg03233332	chr7:66118400	NA	-0.43	-6.49	-0.3	2.38e-10	Aortic root size;
LUAD	cis	rs887829	0.569	rs3806596	chr2:234637707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.48	8.01	0.36	1.11e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs7192380	0.825	rs3811348	chr16:69782855	C/T	cg26679644	chr16:69762563	NA	-0.5	-9.37	-0.41	4.25e-19	Sjögren's syndrome;
LUAD	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg02423579	chr7:2872169	GNA12	-0.56	-9.47	-0.42	1.96e-19	Height;
LUAD	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg10295955	chr4:187884368	NA	-1.11	-27.75	-0.8	2.67e-97	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9951602	0.512	rs9958376	chr18:76655167	G/T	cg02800362	chr5:177631904	HNRNPAB	0.91	14.4	0.57	1.57e-38	Obesity-related traits;
LUAD	cis	rs3784262	0.679	rs11071366	chr15:58334244	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.5	-9.75	-0.43	2.09e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07930192	chr7:1003750	NA	0.4	7.71	0.35	9.19e-14	Longevity;Endometriosis;
LUAD	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.7	-0.35	9.52e-14	Blood metabolite levels;
LUAD	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg22532475	chr10:104410764	TRIM8	-0.48	-9.21	-0.41	1.53e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.83	-0.5	4.3e-28	Mean corpuscular volume;
LUAD	cis	rs4988958	0.527	rs11465641	chr2:103000868	T/G	cg03938978	chr2:103052716	IL18RAP	0.45	10.24	0.45	3.99e-22	Asthma (childhood onset);
LUAD	cis	rs36051895	0.664	rs10815154	chr9:5095538	G/A	cg02405213	chr9:5042618	JAK2	-0.44	-6.6	-0.31	1.23e-10	Pediatric autoimmune diseases;
LUAD	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg25251562	chr2:3704773	ALLC	0.47	7.32	0.34	1.27e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7017914	0.934	rs2639921	chr8:71874834	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.42	-0.3	3.69e-10	Bone mineral density;
LUAD	trans	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg01620082	chr3:125678407	NA	0.46	6.47	0.3	2.76e-10	Depression;
LUAD	cis	rs4711336	0.935	rs3818529	chr6:33661106	T/C	cg14003231	chr6:33640908	ITPR3	0.49	9.47	0.42	2.03e-19	Height;
LUAD	cis	rs7819412	0.522	rs13276708	chr8:10989206	T/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.55	-0.3	1.72e-10	Triglycerides;
LUAD	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg11871910	chr12:69753446	YEATS4	0.71	12.36	0.52	3.57e-30	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs1595825	0.945	rs7581202	chr2:198836777	A/G	cg00361562	chr2:198649771	BOLL	-0.47	-6.66	-0.31	8.63e-11	Ulcerative colitis;
LUAD	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.61	11.96	0.5	1.36e-28	Hemoglobin concentration;
LUAD	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs2040771	0.804	rs1340958	chr22:19253332	A/G	cg24911827	chr22:19170109	CLTCL1	-0.31	-6.39	-0.3	4.3e-10	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs494562	0.892	rs7753711	chr6:86130699	G/T	cg17966619	chr6:86160162	NT5E	-0.63	-7.92	-0.36	2.07e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg06627628	chr2:24431161	ITSN2	-0.68	-10.93	-0.47	1.12e-24	Asthma;
LUAD	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg12365402	chr11:9010492	NRIP3	-0.47	-8.99	-0.4	8.2e-18	Hemoglobin concentration;
LUAD	trans	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04565464	chr8:145669602	NFKBIL2	0.46	6.91	0.32	1.8e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6835098	0.962	rs4377567	chr4:174083590	C/G	cg27433088	chr4:174089019	GALNT7	-0.38	-7.43	-0.34	6.18e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs9535307	0.719	rs1570353	chr13:50385967	G/T	cg04663916	chr13:50265991	EBPL	-0.63	-6.96	-0.32	1.33e-11	Obesity-related traits;
LUAD	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg14092988	chr3:52407081	DNAH1	0.37	7.43	0.34	5.91e-13	Bipolar disorder;
LUAD	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.42	-0.34	6.68e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg14668632	chr7:2872130	GNA12	-0.75	-13.38	-0.55	2.74e-34	Height;
LUAD	cis	rs7937890	0.706	rs7115393	chr11:14268378	T/A	cg23387056	chr11:14280742	SPON1	0.36	7.29	0.33	1.54e-12	Mitochondrial DNA levels;
LUAD	cis	rs2996428	0.709	rs6424052	chr1:3713746	A/G	cg17848003	chr1:3704513	LRRC47	0.52	10.44	0.45	7.47e-23	Red cell distribution width;
LUAD	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg18138036	chr10:133769891	PPP2R2D	0.4	6.46	0.3	2.85e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg08859206	chr1:53392774	SCP2	-0.48	-8.64	-0.39	1.21e-16	Monocyte count;
LUAD	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg24069376	chr3:38537580	EXOG	0.45	10.91	0.47	1.35e-24	Electrocardiographic conduction measures;
LUAD	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg08885076	chr2:99613938	TSGA10	0.36	6.53	0.3	1.86e-10	Chronic sinus infection;
LUAD	cis	rs7512552	0.803	rs9435997	chr1:150289496	G/A	cg15654264	chr1:150340011	RPRD2	-0.61	-11.53	-0.49	6.12e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.53	9.17	0.41	2.04e-18	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7177699	0.557	rs55870734	chr15:79117917	A/T	cg00540400	chr15:79124168	NA	-0.46	-9.76	-0.43	1.96e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs1403694	0.695	rs3774292	chr3:186433574	A/T	cg12454167	chr3:186435060	KNG1	0.51	10.6	0.46	1.96e-23	Blood protein levels;
LUAD	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg05182265	chr7:156933206	UBE3C	-0.81	-17.25	-0.64	6.87e-51	Body mass index;
LUAD	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.58	0.52	4.73e-31	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg07480495	chr12:109748034	FOXN4	-0.34	-6.45	-0.3	2.98e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg03037974	chr15:76606532	NA	0.37	7.93	0.36	2e-14	Blood metabolite levels;
LUAD	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.57e-13	Tonsillectomy;
LUAD	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.56	-0.35	2.47e-13	Blood metabolite levels;
LUAD	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.38	-8.38	-0.38	7.76e-16	Hemoglobin concentration;
LUAD	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg01851573	chr8:8652454	MFHAS1	0.37	6.46	0.3	2.84e-10	Mood instability;
LUAD	cis	rs11048434	0.612	rs7299653	chr12:9058993	A/T	cg23795048	chr12:9217529	LOC144571	0.4	7.18	0.33	3.24e-12	Sjögren's syndrome;
LUAD	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	7.92	0.36	2.07e-14	Breast cancer;
LUAD	cis	rs6942407	0.592	rs886787	chr7:86850210	C/T	cg02420886	chr7:86849541	C7orf23	0.65	7.51	0.34	3.64e-13	Food allergy;
LUAD	trans	rs7395662	1.000	rs12365220	chr11:48555957	T/C	cg15704280	chr7:45808275	SEPT13	-0.41	-6.37	-0.3	4.81e-10	HDL cholesterol;
LUAD	cis	rs1448094	0.842	rs7309725	chr12:86440612	T/C	cg02569458	chr12:86230093	RASSF9	0.35	6.77	0.31	4.25e-11	Major depressive disorder;
LUAD	cis	rs854765	0.693	rs4924822	chr17:17748013	A/G	cg04398451	chr17:18023971	MYO15A	0.64	11.31	0.48	4.47e-26	Total body bone mineral density;
LUAD	trans	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg07393940	chr7:158741817	NA	-0.67	-11.45	-0.49	1.23e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs58106596	0.605	rs58212470	chr2:232561579	C/T	cg01370599	chr3:116745421	NA	0.62	9.0	0.4	7.5e-18	White blood cell count;Lymphocyte counts;
LUAD	trans	rs7395662	1.000	rs12421159	chr11:48624841	C/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.48	-0.3	2.57e-10	HDL cholesterol;
LUAD	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg08999081	chr20:33150536	PIGU	0.64	14.58	0.58	2.69e-39	Coronary artery disease;
LUAD	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg25753631	chr6:25732923	NA	-0.37	-6.43	-0.3	3.49e-10	Iron status biomarkers;
LUAD	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg04450456	chr4:17643702	FAM184B	-0.42	-8.08	-0.37	6.74e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg22764044	chr5:178986830	RUFY1	0.55	8.32	0.38	1.22e-15	Lung cancer;
LUAD	cis	rs7192380	0.571	rs10852456	chr16:69605613	G/T	cg00738113	chr16:70207722	CLEC18C	-0.33	-6.72	-0.31	5.83e-11	Sjögren's syndrome;
LUAD	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg10518543	chr12:38710700	ALG10B	0.47	7.81	0.35	4.69e-14	Morning vs. evening chronotype;
LUAD	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg12311346	chr5:56204834	C5orf35	-0.92	-13.81	-0.56	4.38e-36	Initial pursuit acceleration;
LUAD	cis	rs9394841	0.667	rs9471653	chr6:41755410	C/G	cg25600774	chr6:41776562	USP49	-0.44	-6.7	-0.31	6.63e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.07	-22.83	-0.74	9.06e-76	Ulcerative colitis;
LUAD	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg20673091	chr1:2541236	MMEL1	-0.44	-9.49	-0.42	1.67e-19	Ulcerative colitis;
LUAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03188948	chr7:1209495	NA	0.49	8.6	0.39	1.6e-16	Longevity;Endometriosis;
LUAD	trans	rs853679	0.607	rs72854513	chr6:28265954	A/T	cg06606381	chr12:133084897	FBRSL1	-1.22	-11.36	-0.48	2.72e-26	Depression;
LUAD	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg16647868	chr5:131706066	SLC22A5	0.39	6.7	0.31	6.85e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg06766960	chr11:133703094	NA	-0.34	-6.49	-0.3	2.4e-10	Childhood ear infection;
LUAD	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg25838465	chr1:92012736	NA	0.72	15.72	0.61	3.61e-44	Breast cancer;
LUAD	cis	rs1018836	0.851	rs7014073	chr8:91618548	T/C	cg16814680	chr8:91681699	NA	-0.69	-11.84	-0.5	3.82e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs2797160	0.967	rs28629380	chr6:126004197	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-8.27	-0.37	1.71e-15	Endometrial cancer;
LUAD	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg18132916	chr6:79620363	NA	-0.44	-7.57	-0.35	2.42e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs225245	0.817	rs225290	chr17:33927904	C/G	cg05299278	chr17:33885742	SLFN14	0.52	12.0	0.5	9.31e-29	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs10106298	0.846	rs1076030	chr8:103676345	T/C	cg10187029	chr8:103597600	NA	0.39	6.49	0.3	2.39e-10	Schizophrenia;
LUAD	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg02734326	chr4:10020555	SLC2A9	-0.5	-8.82	-0.39	2.94e-17	Bone mineral density;
LUAD	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-9.21	-0.41	1.51e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg05901451	chr6:126070800	HEY2	-0.57	-9.11	-0.4	3.44e-18	Brugada syndrome;
LUAD	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.77	-10.15	-0.44	8.59e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7737355	0.947	rs6875058	chr5:130882702	C/G	cg25547332	chr5:131281432	NA	0.43	6.45	0.3	3.02e-10	Life satisfaction;
LUAD	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg13319975	chr6:146136371	FBXO30	-0.64	-11.06	-0.47	3.65e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg13334819	chr7:99746414	C7orf59	-0.58	-8.65	-0.39	1.1e-16	Coronary artery disease;
LUAD	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg15017067	chr4:17643749	FAM184B	-0.36	-6.83	-0.32	2.95e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg23803603	chr1:2058230	PRKCZ	-0.38	-6.73	-0.31	5.7e-11	Height;
LUAD	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg18138036	chr10:133769891	PPP2R2D	0.41	6.76	0.31	4.6e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg25809561	chr17:30822961	MYO1D	0.46	8.31	0.37	1.32e-15	Schizophrenia;
LUAD	cis	rs367943	0.665	rs6889298	chr5:112965011	C/T	cg12552261	chr5:112820674	MCC	0.37	6.41	0.3	3.91e-10	Type 2 diabetes;
LUAD	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg02423579	chr7:2872169	GNA12	-0.89	-15.94	-0.61	3.71e-45	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08874598	chr8:102217901	ZNF706	-0.6	-7.39	-0.34	7.96e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs55665837	1.000	rs34382046	chr11:14451318	C/T	cg19336497	chr11:14380999	RRAS2	-0.5	-10.21	-0.44	5.12e-22	Vitamin D levels;
LUAD	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.5	-0.3	2.3e-10	Total body bone mineral density;
LUAD	cis	rs10089	0.953	rs2190797	chr5:127352875	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	9.5	0.42	1.59e-19	Ileal carcinoids;
LUAD	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg04455712	chr21:45112962	RRP1B	0.39	7.28	0.33	1.67e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs9863	0.896	rs7307053	chr12:124494540	A/G	cg17723958	chr12:124429295	CCDC92	0.4	6.66	0.31	8.54e-11	White blood cell count;
LUAD	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg00204512	chr16:28754710	NA	0.31	6.76	0.31	4.56e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs34638657	0.673	rs62045961	chr16:82199723	A/G	cg09439754	chr16:82129088	HSD17B2	-0.37	-7.07	-0.33	6.52e-12	Lung adenocarcinoma;
LUAD	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg09455208	chr3:40491958	NA	0.65	14.14	0.57	1.95e-37	Renal cell carcinoma;
LUAD	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-9.26	-0.41	1.02e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg02773041	chr1:40204384	PPIE	0.52	8.48	0.38	3.9e-16	Blood protein levels;
LUAD	cis	rs8067545	0.750	rs4570919	chr17:20000815	C/T	cg04132472	chr17:19861366	AKAP10	0.31	7.3	0.33	1.44e-12	Schizophrenia;
LUAD	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg18225595	chr11:63971243	STIP1	-0.45	-7.68	-0.35	1.13e-13	Platelet count;
LUAD	cis	rs220324	0.647	rs55877840	chr21:43560383	T/C	cg08841829	chr21:43638893	ABCG1	-0.47	-6.47	-0.3	2.73e-10	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.56	-9.52	-0.42	1.38e-19	Glomerular filtration rate;
LUAD	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg22852734	chr6:133119734	C6orf192	0.78	9.39	0.42	3.71e-19	Type 2 diabetes nephropathy;
LUAD	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.68	-12.91	-0.53	2.29e-32	Ulcerative colitis;
LUAD	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg23435118	chr5:141488016	NDFIP1	-0.5	-7.7	-0.35	9.47e-14	Crohn's disease;
LUAD	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	8.11	0.37	5.36e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62238980	0.614	rs77949114	chr22:32453504	T/C	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs7903847	0.620	rs17112674	chr10:99122178	C/T	cg20016023	chr10:99160130	RRP12	0.28	6.67	0.31	8.08e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.58	7.75	0.35	6.71e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2262909	0.962	rs2017521	chr19:22126138	T/C	cg11619707	chr19:22235551	ZNF257	-0.44	-6.8	-0.31	3.61e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg05283184	chr6:79620031	NA	-0.61	-12.41	-0.52	2.33e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg02176678	chr2:219576539	TTLL4	0.61	12.04	0.51	6.82e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg04414720	chr1:150670196	GOLPH3L	0.69	12.32	0.51	5.33e-30	Melanoma;
LUAD	cis	rs7107174	1.000	rs4245459	chr11:78065959	T/G	cg19901956	chr11:77921274	USP35	-0.5	-6.41	-0.3	3.94e-10	Testicular germ cell tumor;
LUAD	trans	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.51	-8.19	-0.37	3.07e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg05368731	chr17:41323189	NBR1	0.98	20.49	0.71	2.59e-65	Menopause (age at onset);
LUAD	cis	rs13064411	0.518	rs1552433	chr3:113225730	C/A	cg10517650	chr3:113235015	CCDC52	-0.38	-7.22	-0.33	2.35e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs597583	1.000	rs597583	chr11:117421799	C/G	cg27161313	chr11:117392002	DSCAML1	-0.44	-7.53	-0.34	3.06e-13	Putamen volume;
LUAD	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg11663144	chr21:46675770	NA	-0.5	-9.11	-0.4	3.43e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg24818145	chr4:99064322	C4orf37	0.39	6.43	0.3	3.46e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg01620082	chr3:125678407	NA	-0.71	-7.87	-0.36	2.94e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg03929089	chr4:120376271	NA	-0.89	-17.06	-0.64	5.1e-50	Height;
LUAD	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg18721089	chr20:30220636	NA	-0.41	-6.41	-0.3	3.87e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg04287289	chr16:89883240	FANCA	-0.49	-8.0	-0.36	1.19e-14	Vitiligo;
LUAD	cis	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg07460842	chr6:66804631	NA	0.96	12.74	0.53	1.06e-31	Exhaled nitric oxide output;
LUAD	cis	rs904251	0.523	rs1757191	chr6:37482871	C/T	cg25019722	chr6:37503610	NA	-0.33	-7.65	-0.35	1.34e-13	Cognitive performance;
LUAD	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.98	0.36	1.41e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7178375	0.607	rs7171212	chr15:31207711	C/T	cg03767031	chr15:31195708	MTMR15	0.78	7.99	0.36	1.28e-14	Hypertriglyceridemia;
LUAD	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg10755058	chr3:40428713	ENTPD3	0.39	7.43	0.34	6.13e-13	Renal cell carcinoma;
LUAD	cis	rs9902453	0.765	rs9890747	chr17:28007442	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.31	0.45	2.17e-22	Coffee consumption (cups per day);
LUAD	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg18129178	chr5:148520854	ABLIM3	0.6	9.59	0.42	7.5599999999999994e-20	Breast cancer;
LUAD	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg14186256	chr22:23484241	RTDR1	0.46	7.86	0.36	3.19e-14	Bone mineral density;
LUAD	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg15704280	chr7:45808275	SEPT13	0.64	8.21	0.37	2.64e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg27170947	chr2:26402098	FAM59B	0.65	8.26	0.37	1.82e-15	Gut microbiome composition (summer);
LUAD	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.25	-0.37	2.04e-15	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg18404041	chr3:52824283	ITIH1	0.53	8.87	0.4	2.02e-17	Schizophrenia;
LUAD	cis	rs57590327	0.504	rs11712243	chr3:81840674	T/G	cg07356753	chr3:81810745	GBE1	-0.63	-10.18	-0.44	6.23e-22	Extraversion;
LUAD	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg07636037	chr3:49044803	WDR6	0.56	10.6	0.46	1.87e-23	Menarche (age at onset);
LUAD	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg06641503	chr3:48959341	ARIH2	-0.39	-7.65	-0.35	1.37e-13	Parkinson's disease;
LUAD	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg16049864	chr8:95962084	TP53INP1	-0.44	-8.45	-0.38	4.88e-16	Type 2 diabetes;
LUAD	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg20203395	chr5:56204925	C5orf35	-0.82	-11.97	-0.5	1.2e-28	Initial pursuit acceleration;
LUAD	cis	rs977987	0.806	rs2865531	chr16:75390316	T/A	cg03315344	chr16:75512273	CHST6	0.65	14.22	0.57	8.77e-38	Dupuytren's disease;
LUAD	trans	rs75804782	0.625	rs13430702	chr2:239467349	G/A	cg01134436	chr17:81009848	B3GNTL1	0.71	7.28	0.33	1.64e-12	Morning vs. evening chronotype;Chronotype;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg15067401	chr12:88536400	TMTC3;CEP290	0.37	6.35	0.3	5.63e-10	Bipolar disorder;
LUAD	cis	rs4372836	0.504	rs62131973	chr2:29044437	T/G	cg09522027	chr2:28974177	PPP1CB	-0.61	-11.0	-0.47	6.34e-25	Body mass index;
LUAD	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg06002616	chr8:101225028	SPAG1	-0.42	-8.44	-0.38	5.26e-16	Atrioventricular conduction;
LUAD	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg25828334	chr19:18545568	ISYNA1	-0.36	-7.23	-0.33	2.35e-12	Breast cancer;
LUAD	cis	rs2455601	0.786	rs3763913	chr11:8951230	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-7.51	-0.34	3.45e-13	Schizophrenia;
LUAD	cis	rs35883536	1.000	rs2282253	chr1:101094383	C/G	cg06223162	chr1:101003688	GPR88	0.35	6.47	0.3	2.75e-10	Monocyte count;
LUAD	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg17366294	chr4:99064904	C4orf37	0.65	12.41	0.52	2.19e-30	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg15704280	chr7:45808275	SEPT13	0.78	12.67	0.52	2.05e-31	Coronary artery disease;
LUAD	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg11062466	chr8:58055876	NA	0.76	9.59	0.42	7.63e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg00277334	chr10:82204260	NA	-0.6	-9.97	-0.44	3.48e-21	Post bronchodilator FEV1;
LUAD	cis	rs12200560	0.505	rs211178	chr6:97074094	T/A	cg06623918	chr6:96969491	KIAA0776	0.47	7.21	0.33	2.64e-12	Coronary heart disease;
LUAD	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg04800585	chr6:26043546	HIST1H2BB	0.43	7.63	0.35	1.56e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.06	-0.32	6.83e-12	Blood metabolite levels;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10179684	chr2:96874394	STARD7	0.42	6.49	0.3	2.46e-10	Gut microbiome composition (summer);
LUAD	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.44	0.3	3.28e-10	Parkinson's disease;
LUAD	cis	rs1403694	0.695	rs1836860	chr3:186436604	C/T	cg12454167	chr3:186435060	KNG1	-0.5	-10.69	-0.46	8.79e-24	Blood protein levels;
LUAD	cis	rs72949976	0.646	rs4673731	chr2:214028544	C/T	cg08319019	chr2:214017104	IKZF2	0.53	7.94	0.36	1.87e-14	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg19774624	chr17:42201019	HDAC5	-0.38	-6.46	-0.3	2.88e-10	Total body bone mineral density;
LUAD	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg06784218	chr1:46089804	CCDC17	0.56	12.39	0.52	2.71e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg06641503	chr3:48959341	ARIH2	-0.42	-7.07	-0.33	6.4e-12	Menarche (age at onset);
LUAD	cis	rs4917833	0.789	rs1060446	chr10:100218721	C/G	cg25691326	chr10:100228212	HPSE2	0.36	6.44	0.3	3.26e-10	Pediatric bone mineral density (femoral neck);
LUAD	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.55	0.3	1.7e-10	Colorectal cancer;
LUAD	cis	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg26958806	chr6:27640298	NA	0.65	6.41	0.3	3.9e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg21823605	chr1:152486609	CRCT1	0.28	6.52	0.3	2.01e-10	Hair morphology;
LUAD	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg04414720	chr1:150670196	GOLPH3L	0.72	12.66	0.52	2.16e-31	Urate levels;
LUAD	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg14343924	chr8:8086146	FLJ10661	0.51	8.07	0.37	7.6e-15	Mood instability;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05910615	chr19:36248877	HSPB6;C19orf55	-0.53	-6.41	-0.3	3.88e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.96	0.36	1.57e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4692589	0.965	rs733672	chr4:170950243	C/A	cg19918862	chr4:170955249	NA	0.3	7.11	0.33	4.95e-12	Anxiety disorder;
LUAD	cis	rs9300255	0.510	rs1727322	chr12:123699520	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-6.52	-0.3	1.99e-10	Neutrophil percentage of white cells;
LUAD	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg17173187	chr15:85201210	NMB	0.48	8.23	0.37	2.35e-15	Schizophrenia;
LUAD	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.73	15.58	0.6	1.34e-43	Myeloid white cell count;
LUAD	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg07936489	chr17:37558343	FBXL20	-0.46	-7.31	-0.33	1.38e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg01579765	chr21:45077557	HSF2BP	0.62	13.81	0.56	4.41e-36	Mean corpuscular volume;
LUAD	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.16	0.48	1.59e-25	Height;
LUAD	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg14019695	chr9:139328340	INPP5E	-0.41	-8.08	-0.37	7.06e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg13319975	chr6:146136371	FBXO30	-0.59	-9.91	-0.43	6.12e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg04827223	chr11:72435913	ARAP1	-0.55	-8.25	-0.37	1.96e-15	Type 2 diabetes;
LUAD	cis	rs35995292	1.000	rs35995292	chr7:38913017	T/G	cg19327137	chr7:38886074	VPS41	0.5	8.24	0.37	2.18e-15	Subjective well-being (multi-trait analysis);
LUAD	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.57	12.01	0.5	8.19e-29	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9393692	0.620	rs9358927	chr6:26330492	T/G	cg13736514	chr6:26305472	NA	-0.49	-8.35	-0.38	9.51e-16	Educational attainment;
LUAD	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.06	24.67	0.77	6.49e-84	Chronic sinus infection;
LUAD	cis	rs6594713	0.921	rs13181534	chr5:112724641	A/G	cg12552261	chr5:112820674	MCC	0.54	8.51	0.38	3e-16	Brain cytoarchitecture;
LUAD	cis	rs72901758	0.768	rs1567237	chr17:76246294	A/G	cg26068271	chr17:76253126	NA	-0.45	-7.71	-0.35	8.87e-14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg26647111	chr11:31128758	NA	0.48	8.5	0.38	3.39e-16	Red blood cell count;
LUAD	cis	rs6558530	0.965	rs730377	chr8:1707951	G/A	cg19131313	chr8:1704013	NA	-0.45	-7.25	-0.33	1.98e-12	Systolic blood pressure;
LUAD	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg21100191	chr22:23484243	RTDR1	0.72	12.48	0.52	1.18e-30	Bone mineral density;
LUAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg21724239	chr8:58056113	NA	0.61	7.75	0.35	6.69e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg00071950	chr4:10020882	SLC2A9	0.81	17.14	0.64	2.18e-50	Bone mineral density;
LUAD	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg15704280	chr7:45808275	SEPT13	-0.53	-8.38	-0.38	7.95e-16	HDL cholesterol;
LUAD	trans	rs6561151	0.681	rs10507521	chr13:44441834	C/G	cg17145862	chr1:211918768	LPGAT1	-0.5	-7.73	-0.35	8.15e-14	Crohn's disease;
LUAD	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg10589385	chr1:150898437	SETDB1	0.43	7.93	0.36	1.98e-14	Melanoma;
LUAD	cis	rs16866061	0.962	rs16866045	chr2:225413020	G/A	cg12698349	chr2:225449008	CUL3	0.78	13.57	0.55	4.62e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg10523679	chr1:76189770	ACADM	0.66	10.2	0.44	5.42e-22	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.41	-0.38	6.33e-16	Total body bone mineral density;
LUAD	cis	rs6782228	0.606	rs9828893	chr3:128332925	T/C	cg16766828	chr3:128327626	NA	-0.39	-7.21	-0.33	2.57e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg27068330	chr11:65405492	SIPA1	-0.7	-11.2	-0.48	1.08e-25	Non-alcoholic fatty liver disease histology (lobular);
LUAD	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg14186256	chr22:23484241	RTDR1	-0.43	-7.51	-0.34	3.48e-13	Bone mineral density;
LUAD	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg13319975	chr6:146136371	FBXO30	-0.62	-10.77	-0.46	4.7e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6496044	1.000	rs6496044	chr15:86067306	G/A	cg13263323	chr15:86062960	AKAP13	-0.55	-9.54	-0.42	1.13e-19	Interstitial lung disease;
LUAD	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08109568	chr15:31115862	NA	-0.51	-8.89	-0.4	1.72e-17	Huntington's disease progression;
LUAD	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg06108461	chr20:60628389	TAF4	-1.12	-20.41	-0.7	5.66e-65	Body mass index;
LUAD	cis	rs7918232	0.567	rs11015463	chr10:27319258	A/G	cg14240646	chr10:27532245	ACBD5	-0.62	-9.25	-0.41	1.15e-18	Breast cancer;
LUAD	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg03733263	chr8:22462867	KIAA1967	0.73	12.26	0.51	8.88e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.78	-0.43	1.63e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs4683142	0.518	rs4682811	chr3:46164795	A/G	cg11211486	chr3:46033800	FYCO1	-0.43	-6.47	-0.3	2.69e-10	Methadone dose in opioid dependence;
LUAD	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg00071950	chr4:10020882	SLC2A9	0.6	11.49	0.49	9.21e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2637266	1.000	rs2395394	chr10:78360679	G/C	cg18941641	chr10:78392320	NA	0.33	6.8	0.31	3.57e-11	Pulmonary function;
LUAD	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.23	-0.41	1.27e-18	Life satisfaction;
LUAD	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg17264618	chr3:40429014	ENTPD3	0.4	9.05	0.4	5.07e-18	Renal cell carcinoma;
LUAD	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg08859206	chr1:53392774	SCP2	0.6	10.69	0.46	8.81e-24	Monocyte count;
LUAD	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg01689657	chr7:91764605	CYP51A1	0.34	8.32	0.38	1.18e-15	Breast cancer;
LUAD	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg06766960	chr11:133703094	NA	-0.44	-8.21	-0.37	2.65e-15	Childhood ear infection;
LUAD	cis	rs57502260	0.704	rs41478448	chr11:68181621	A/G	cg16797656	chr11:68205561	LRP5	0.41	6.36	0.3	5.31e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs9309473	0.687	rs11126399	chr2:73613341	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-6.94	-0.32	1.48e-11	Metabolite levels;
LUAD	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg20203395	chr5:56204925	C5orf35	0.65	9.95	0.44	4.31e-21	Initial pursuit acceleration;
LUAD	cis	rs6906287	0.647	rs6938226	chr6:118852561	C/A	cg18833306	chr6:118973337	C6orf204	0.46	8.12	0.37	5.19e-15	Electrocardiographic conduction measures;
LUAD	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg15704280	chr7:45808275	SEPT13	0.63	8.6	0.39	1.59e-16	Axial length;
LUAD	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg27284194	chr4:1044797	NA	0.71	10.44	0.45	7.55e-23	Recombination rate (females);
LUAD	cis	rs71403859	0.502	rs34766979	chr16:71475511	G/A	cg08717414	chr16:71523259	ZNF19	-0.6	-7.28	-0.33	1.65e-12	Post bronchodilator FEV1;
LUAD	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg22532475	chr10:104410764	TRIM8	-0.48	-9.29	-0.41	8.48e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs977987	0.778	rs34222958	chr16:75398252	C/T	cg03315344	chr16:75512273	CHST6	0.64	13.98	0.56	9.05e-37	Dupuytren's disease;
LUAD	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.45	-7.61	-0.35	1.78e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg08989290	chr16:615782	NHLRC4	0.31	6.72	0.31	5.75e-11	Height;
LUAD	cis	rs4072705	0.967	rs10818979	chr9:127336913	G/A	cg13476313	chr9:127244764	NR5A1	0.32	7.56	0.35	2.51e-13	Menarche (age at onset);
LUAD	cis	rs870825	0.616	rs35818632	chr4:185649661	G/T	cg04058563	chr4:185651563	MLF1IP	0.85	12.54	0.52	6.89e-31	Blood protein levels;
LUAD	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg02493740	chr2:85810744	VAMP5	-0.61	-11.04	-0.47	4.52e-25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg21226059	chr5:178986404	RUFY1	0.71	12.91	0.53	2.15e-32	Lung cancer;
LUAD	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11890956	chr21:40555474	PSMG1	0.81	14.4	0.57	1.47e-38	Cognitive function;
LUAD	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg02423579	chr7:2872169	GNA12	-0.77	-13.14	-0.54	2.55e-33	Height;
LUAD	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg19635926	chr16:89946313	TCF25	0.74	6.93	0.32	1.62e-11	Skin colour saturation;
LUAD	cis	rs6842047	0.563	rs6843711	chr4:187212953	T/C	cg02012338	chr4:187126139	CYP4V2	0.73	6.86	0.32	2.51e-11	Blood protein levels;
LUAD	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg06636551	chr8:101224915	SPAG1	-0.37	-6.75	-0.31	4.75e-11	Atrioventricular conduction;
LUAD	trans	rs3857536	0.813	rs1029401	chr6:66952268	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.52	-0.3	2.04e-10	Blood trace element (Cu levels);
LUAD	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg21963583	chr11:68658836	MRPL21	0.65	11.45	0.49	1.27e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.7	0.39	7.29e-17	Menopause (age at onset);
LUAD	cis	rs7119038	0.818	rs76704408	chr11:118683327	G/T	cg19308663	chr11:118741387	NA	0.43	6.43	0.3	3.53e-10	Sjögren's syndrome;
LUAD	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg21475434	chr5:93447410	FAM172A	0.61	7.69	0.35	1.07e-13	Diabetic retinopathy;
LUAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-9.0	-0.4	7.48e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.66	0.31	8.61e-11	Breast cancer;
LUAD	cis	rs62027291	0.605	rs62030413	chr15:76878201	A/G	cg22467129	chr15:76604101	ETFA	0.71	6.45	0.3	2.97e-10	Plateletcrit;
LUAD	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg15181151	chr6:150070149	PCMT1	0.32	6.51	0.3	2.17e-10	Testicular germ cell tumor;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16046673	chr13:51483748	RNASEH2B	-0.46	-7.49	-0.34	3.98e-13	Cancer;
LUAD	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg11822812	chr5:140052017	DND1	-0.44	-8.24	-0.37	2.11e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg05340658	chr4:99064831	C4orf37	0.55	9.33	0.41	5.87e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7614311	0.596	rs2888013	chr3:64005226	A/G	cg22134162	chr3:63841271	THOC7	-0.39	-7.34	-0.34	1.14e-12	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg26343298	chr8:95960752	TP53INP1	0.37	7.82	0.36	4.12e-14	Type 2 diabetes;
LUAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08439880	chr3:133502540	NA	-0.49	-9.97	-0.44	3.58e-21	Iron status biomarkers;
LUAD	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-7.39	-0.34	8.12e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7680126	0.596	rs10020887	chr4:10140751	C/G	cg00071950	chr4:10020882	SLC2A9	-0.6	-8.79	-0.39	3.75e-17	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs367943	0.666	rs6594704	chr5:112692834	A/T	cg12552261	chr5:112820674	MCC	0.46	9.05	0.4	5.42e-18	Type 2 diabetes;
LUAD	cis	rs78761021	0.867	rs8077037	chr17:9788746	G/A	cg26853458	chr17:9805074	RCVRN	0.34	6.88	0.32	2.21e-11	Type 2 diabetes;
LUAD	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg10167378	chr1:228756711	NA	0.67	9.07	0.4	4.47e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs7180079	1.000	rs28550147	chr15:64517028	C/T	cg08069370	chr15:64387884	SNX1	-0.5	-6.39	-0.3	4.44e-10	Monocyte count;
LUAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08280861	chr8:58055591	NA	0.66	8.63	0.39	1.25e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.28	-0.51	7.17e-30	Primary sclerosing cholangitis;
LUAD	cis	rs367943	1.000	rs367943	chr5:112809728	C/T	cg12552261	chr5:112820674	MCC	0.58	10.89	0.47	1.6e-24	Type 2 diabetes;
LUAD	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg06784218	chr1:46089804	CCDC17	0.5	11.11	0.48	2.56e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1997103	0.954	rs6593236	chr7:55410992	C/T	cg17469321	chr7:55412551	NA	0.68	11.48	0.49	9.66e-27	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg05313129	chr8:58192883	C8orf71	-0.55	-7.25	-0.33	2.05e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg02683114	chr2:24398427	C2orf84	-0.51	-7.56	-0.35	2.47e-13	Asthma;
LUAD	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.04	-0.32	7.72e-12	HDL cholesterol;
LUAD	trans	rs4714291	0.832	rs7764688	chr6:40115442	G/T	cg02267698	chr19:7991119	CTXN1	-0.45	-7.15	-0.33	3.76e-12	Strep throat;
LUAD	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg17425144	chr1:10567563	PEX14	0.61	12.84	0.53	4.29e-32	Breast cancer;
LUAD	cis	rs494562	0.892	rs573892	chr6:86118189	A/C	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.6	11.51	0.49	7.61e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18876405	chr7:65276391	NA	-0.41	-6.43	-0.3	3.53e-10	Aortic root size;
LUAD	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg04511125	chr2:88470314	THNSL2	1.0	11.01	0.47	6.06e-25	Plasma clusterin levels;
LUAD	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg26769984	chr7:1090371	C7orf50	0.64	9.99	0.44	3.18e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg09904177	chr6:26538194	HMGN4	0.44	7.36	0.34	9.71e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.31	-0.34	1.31e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg20744362	chr22:50050164	C22orf34	0.43	9.4	0.42	3.5e-19	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.5	7.01	0.32	9.3e-12	Platelet count;
LUAD	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg26384229	chr12:38710491	ALG10B	0.44	7.32	0.34	1.28e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg04398451	chr17:18023971	MYO15A	-0.65	-11.71	-0.49	1.3e-27	Total body bone mineral density;
LUAD	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg06784218	chr1:46089804	CCDC17	-0.53	-11.59	-0.49	3.71e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs6561151	0.957	rs2121034	chr13:44473866	G/T	cg17145862	chr1:211918768	LPGAT1	0.55	9.22	0.41	1.46e-18	Crohn's disease;
LUAD	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg10589385	chr1:150898437	SETDB1	0.44	8.16	0.37	3.97e-15	Tonsillectomy;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg03324837	chr17:61044407	NA	0.4	6.45	0.3	3.03e-10	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg20597908	chr12:110888290	ARPC3	0.41	6.52	0.3	2.04e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.45	-9.11	-0.41	3.22e-18	Monocyte percentage of white cells;
LUAD	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg11901034	chr3:128598214	ACAD9	-0.49	-7.32	-0.34	1.28e-12	IgG glycosylation;
LUAD	cis	rs7267979	0.844	rs6076343	chr20:25376663	C/T	cg08601574	chr20:25228251	PYGB	-0.41	-7.72	-0.35	8.28e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.59	-10.25	-0.45	3.75e-22	Menarche (age at onset);
LUAD	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg17105886	chr17:28927953	LRRC37B2	0.77	7.74	0.35	7.31e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs295140	0.526	rs295114	chr2:201195602	C/T	cg23649088	chr2:200775458	C2orf69	0.47	8.09	0.37	6.24e-15	QT interval;
LUAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg21724239	chr8:58056113	NA	0.65	8.41	0.38	6.32e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1847202	0.826	rs11922892	chr3:72952186	T/G	cg25664220	chr3:72788482	NA	-0.41	-7.2	-0.33	2.8e-12	Motion sickness;
LUAD	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.87	-12.63	-0.52	2.85e-31	Red cell distribution width;
LUAD	cis	rs12701220	0.595	rs12532837	chr7:1122851	T/A	cg27454412	chr7:1067447	C7orf50	-0.38	-6.9	-0.32	1.93e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs6445967	0.569	rs2885869	chr3:58284799	G/A	cg13750441	chr3:58318267	PXK	-0.3	-6.41	-0.3	3.8e-10	Platelet count;
LUAD	cis	rs11048434	0.687	rs12814670	chr12:9060025	C/T	cg23795048	chr12:9217529	LOC144571	0.41	7.4	0.34	7.33e-13	Sjögren's syndrome;
LUAD	cis	rs3774830	0.714	rs73212742	chr4:5464915	A/G	cg26943120	chr4:5472116	STK32B	0.38	7.73	0.35	8.01e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg23985595	chr17:80112537	CCDC57	-0.53	-9.51	-0.42	1.43e-19	Life satisfaction;
LUAD	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-6.82	-0.31	3.22e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9902453	0.845	rs2628165	chr17:28121166	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.46	0.38	4.4e-16	Coffee consumption (cups per day);
LUAD	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg01475377	chr6:109611718	NA	-0.54	-10.49	-0.45	4.92e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs1153858	0.562	rs8025019	chr15:45735865	C/T	cg26924012	chr15:45694286	SPATA5L1	0.82	7.64	0.35	1.48e-13	Homoarginine levels;
LUAD	trans	rs11039798	0.920	rs8186465	chr11:48796771	T/C	cg03929089	chr4:120376271	NA	0.59	6.8	0.31	3.56e-11	Axial length;
LUAD	cis	rs7264396	0.623	rs78949029	chr20:34384964	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.63	-0.35	1.6e-13	Total cholesterol levels;
LUAD	cis	rs7512552	0.780	rs1260411	chr1:150382088	G/A	cg15654264	chr1:150340011	RPRD2	0.59	11.24	0.48	7.63e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs354225	0.544	rs13403284	chr2:54805749	A/G	cg26097391	chr2:54893211	SPTBN1	0.42	6.42	0.3	3.73e-10	Schizophrenia;
LUAD	trans	rs7395662	0.864	rs11039872	chr11:48629533	C/T	cg15704280	chr7:45808275	SEPT13	-0.41	-6.37	-0.3	4.8e-10	HDL cholesterol;
LUAD	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg06781209	chr11:61594997	FADS2	-0.39	-7.18	-0.33	3.16e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs727505	0.909	rs1031958	chr7:124627309	C/T	cg23710748	chr7:124431027	NA	-0.42	-8.3	-0.37	1.44e-15	Lewy body disease;
LUAD	cis	rs12995491	1.000	rs12995491	chr2:88527414	C/T	cg14558114	chr2:88469736	THNSL2	0.4	6.41	0.3	3.99e-10	Response to metformin (IC50);
LUAD	trans	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg03929089	chr4:120376271	NA	0.57	6.45	0.3	3.15e-10	Axial length;
LUAD	trans	rs564343	0.898	rs576740	chr11:65852571	G/A	cg26701943	chr11:108369231	KDELC2	-0.43	-7.16	-0.33	3.68e-12	Obesity (early onset extreme);
LUAD	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg05922057	chr17:4047571	ZZEF1;CYB5D2	-0.37	-6.42	-0.3	3.57e-10	Type 2 diabetes;
LUAD	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg06873352	chr17:61820015	STRADA	0.43	7.06	0.32	6.88e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7665090	1.000	rs3733202	chr4:103556861	A/G	cg07973026	chr4:103553119	MANBA	0.45	8.13	0.37	4.68e-15	Primary biliary cholangitis;
LUAD	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.41	-0.34	7.02e-13	Bipolar disorder;
LUAD	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg07741184	chr6:167504864	NA	-0.31	-7.35	-0.34	1.03e-12	Lung cancer;
LUAD	trans	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg01620082	chr3:125678407	NA	-0.85	-8.82	-0.39	2.99e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg21017887	chr14:105400489	NA	0.75	14.4	0.57	1.48e-38	Rheumatoid arthritis;
LUAD	cis	rs6908034	0.607	rs80355837	chr6:19808343	C/G	cg02682789	chr6:19804855	NA	0.84	8.71	0.39	6.87e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg24558204	chr6:135376177	HBS1L	0.45	8.28	0.37	1.67e-15	Red blood cell count;
LUAD	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg18404041	chr3:52824283	ITIH1	0.41	7.55	0.34	2.65e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg18335740	chr13:41363409	SLC25A15	0.5	8.57	0.38	2.03e-16	Lewy body disease;
LUAD	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg23758822	chr17:41437982	NA	0.98	20.04	0.7	2.77e-63	Menopause (age at onset);
LUAD	cis	rs17539620	0.534	rs76931320	chr6:154833508	G/A	cg20019720	chr6:154832845	CNKSR3	0.64	12.16	0.51	2.27e-29	Lipoprotein (a) levels;
LUAD	cis	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg27411982	chr8:10470053	RP1L1	0.41	7.69	0.35	1.02e-13	Neuroticism;
LUAD	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg14416269	chr4:6271139	WFS1	0.6	11.58	0.49	3.89e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg20503657	chr10:835505	NA	0.8	10.43	0.45	7.76e-23	Eosinophil percentage of granulocytes;
LUAD	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.72	0.39	6.32e-17	Menopause (age at onset);
LUAD	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg16989719	chr2:238392110	NA	-0.36	-6.5	-0.3	2.21e-10	Prostate cancer;
LUAD	cis	rs240764	0.817	rs239226	chr6:101107969	G/C	cg09795085	chr6:101329169	ASCC3	0.44	7.51	0.34	3.56e-13	Neuroticism;
LUAD	cis	rs57590327	0.716	rs3772891	chr3:81776760	A/G	cg07356753	chr3:81810745	GBE1	0.58	8.54	0.38	2.43e-16	Extraversion;
LUAD	cis	rs7927592	0.513	rs607887	chr11:68196961	C/T	cg16797656	chr11:68205561	LRP5	0.52	11.22	0.48	9.57e-26	Total body bone mineral density;
LUAD	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg06611532	chr13:114900021	NA	0.37	8.62	0.39	1.31e-16	Schizophrenia;
LUAD	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.77	-0.5	7.32e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.28	-0.57	5.01e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs10465746	0.901	rs17475760	chr1:84398435	A/T	cg10977910	chr1:84465055	TTLL7	0.5	8.09	0.37	6.58e-15	Obesity-related traits;
LUAD	cis	rs16910800	0.731	rs7125729	chr11:23181637	A/G	cg20040320	chr11:23191996	NA	-0.75	-10.02	-0.44	2.32e-21	Cancer;
LUAD	cis	rs62238980	0.614	rs75321866	chr22:32460707	C/T	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg10819733	chr22:24237672	NA	-0.43	-8.13	-0.37	4.93e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg03929089	chr4:120376271	NA	0.54	7.15	0.33	3.89e-12	Axial length;
LUAD	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg10518543	chr12:38710700	ALG10B	-0.47	-8.05	-0.36	8.53e-15	Morning vs. evening chronotype;
LUAD	cis	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg07460842	chr6:66804631	NA	-0.98	-14.72	-0.58	7.02e-40	Exhaled nitric oxide output;
LUAD	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg25985355	chr7:65971099	NA	-0.56	-6.91	-0.32	1.79e-11	Gout;
LUAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.41	-0.38	6.26e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg06606381	chr12:133084897	FBRSL1	-1.04	-9.86	-0.43	8.65e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg15790184	chr11:494944	RNH1	0.56	6.88	0.32	2.12e-11	Body mass index;
LUAD	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18404041	chr3:52824283	ITIH1	-0.58	-12.06	-0.51	5.62e-29	Bipolar disorder;
LUAD	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg07741184	chr6:167504864	NA	-0.31	-7.23	-0.33	2.31e-12	Crohn's disease;
LUAD	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg00290607	chr11:67383545	NA	0.4	6.59	0.31	1.32e-10	Mean corpuscular volume;
LUAD	cis	rs12369635	1.000	rs12372807	chr12:129561332	C/T	cg01909103	chr12:129572610	TMEM132D	-0.57	-6.47	-0.3	2.69e-10	Schizophrenia (inflammation and infection response interaction);
LUAD	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.08e-11	Parkinson's disease;
LUAD	cis	rs490234	0.934	rs571675	chr9:128297692	C/T	cg14078157	chr9:128172775	NA	0.38	6.97	0.32	1.2e-11	Mean arterial pressure;
LUAD	cis	rs28595532	0.764	rs115916994	chr4:119688758	A/G	cg02775129	chr4:119771670	NA	-0.84	-8.0	-0.36	1.2e-14	Cannabis dependence symptom count;
LUAD	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg17644776	chr2:200775616	C2orf69	0.53	7.23	0.33	2.21e-12	Schizophrenia;
LUAD	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.19	-0.33	3.02e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg12140854	chr5:148520817	ABLIM3	-0.61	-10.18	-0.44	6.33e-22	Breast cancer;
LUAD	cis	rs73206853	0.609	rs61582364	chr12:110967847	T/G	cg12870014	chr12:110450643	ANKRD13A	0.63	7.35	0.34	1.05e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg00280220	chr17:61926910	NA	0.36	6.98	0.32	1.17e-11	Prudent dietary pattern;
LUAD	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg06640241	chr16:89574553	SPG7	0.59	8.69	0.39	7.88e-17	Multiple myeloma (IgH translocation);
LUAD	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg04450456	chr4:17643702	FAM184B	0.4	7.84	0.36	3.69e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs62238980	0.614	rs117195584	chr22:32390013	C/A	cg00543991	chr22:32367038	NA	0.92	8.16	0.37	3.95e-15	Childhood ear infection;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg00286450	chr13:42622831	DGKH	-0.65	-6.69	-0.31	7.12e-11	Type 2 diabetes;
LUAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg14159672	chr1:205819179	PM20D1	0.46	7.43	0.34	6.13e-13	Parkinson's disease;
LUAD	trans	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg27661571	chr11:113659931	NA	-0.63	-6.42	-0.3	3.76e-10	Height;
LUAD	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg20487152	chr13:99095054	FARP1	0.47	8.66	0.39	1.02e-16	Educational attainment (years of education);
LUAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-7.97	-0.36	1.48e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs494562	0.892	rs638745	chr6:86115587	C/G	cg21730993	chr6:86159210	NT5E	0.71	8.06	0.36	7.76e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs236352	0.576	rs3756905	chr6:36843777	C/T	cg10099585	chr6:36853529	C6orf89	-0.39	-6.39	-0.3	4.51e-10	Heart rate;
LUAD	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg26597838	chr10:835615	NA	0.68	9.58	0.42	8.59e-20	Eosinophil percentage of granulocytes;
LUAD	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.6	-0.35	1.96e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg07404485	chr7:94953653	PON1	-0.5	-7.24	-0.33	2.14e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg02896835	chr1:92012615	NA	-0.63	-13.15	-0.54	2.37e-33	Breast cancer;
LUAD	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg16988262	chr1:15930761	NA	0.41	6.88	0.32	2.12e-11	Systolic blood pressure;
LUAD	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg04369109	chr6:150039330	LATS1	-0.46	-7.82	-0.36	4.34e-14	Lung cancer;
LUAD	trans	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg20587970	chr11:113659929	NA	-1.12	-15.45	-0.6	5.27e-43	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg21724239	chr8:58056113	NA	0.78	9.33	0.41	6.04e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg16989719	chr2:238392110	NA	-0.37	-7.96	-0.36	1.62e-14	Prostate cancer;
LUAD	cis	rs7107174	1.000	rs2511178	chr11:77923220	C/T	cg19901956	chr11:77921274	USP35	-0.51	-6.52	-0.3	2.07e-10	Testicular germ cell tumor;
LUAD	cis	rs6479527	0.806	rs12351292	chr9:96763271	G/A	cg14459158	chr9:96720562	NA	0.37	6.61	0.31	1.13e-10	Esophageal adenocarcinoma;
LUAD	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg25894440	chr7:65020034	NA	0.61	6.56	0.3	1.55e-10	Diabetic kidney disease;
LUAD	cis	rs3803170	0.513	rs7302763	chr12:111827569	C/T	cg10833066	chr12:111807467	FAM109A	0.49	8.78	0.39	4e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg03806693	chr22:41940476	POLR3H	-0.48	-7.28	-0.33	1.6e-12	Neuroticism;
LUAD	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	9.89	0.43	6.86e-21	Total body bone mineral density;
LUAD	cis	rs1595825	0.891	rs996427	chr2:198685609	G/A	cg00361562	chr2:198649771	BOLL	-0.49	-7.03	-0.32	8.11e-12	Ulcerative colitis;
LUAD	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg02049041	chr17:27085579	C17orf63	-0.61	-8.24	-0.37	2.22e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg04511125	chr2:88470314	THNSL2	0.77	9.06	0.4	4.77e-18	Plasma clusterin levels;
LUAD	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg11189052	chr15:85197271	WDR73	0.61	7.59	0.35	2.06e-13	Schizophrenia;
LUAD	trans	rs2735413	0.881	rs4888727	chr16:78077038	T/C	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6987853	0.761	rs2974321	chr8:42424727	A/G	cg09913449	chr8:42400586	C8orf40	0.51	10.31	0.45	2.15e-22	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs986417	1.000	rs4901995	chr14:61090629	C/G	cg27398547	chr14:60952738	C14orf39	0.64	7.34	0.34	1.07e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg27454412	chr7:1067447	C7orf50	-0.45	-7.91	-0.36	2.33e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg24069376	chr3:38537580	EXOG	0.37	8.39	0.38	7.29e-16	Electrocardiographic conduction measures;
LUAD	cis	rs7945718	0.905	rs6486032	chr11:12723693	G/A	cg25843174	chr11:12811716	TEAD1	0.21	6.42	0.3	3.64e-10	Educational attainment (years of education);
LUAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg05457628	chr5:178986728	RUFY1	0.62	10.06	0.44	1.75e-21	Lung cancer;
LUAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg22535103	chr8:58192502	C8orf71	-0.74	-10.44	-0.45	7.32e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg07741184	chr6:167504864	NA	0.31	7.19	0.33	2.94e-12	Crohn's disease;
LUAD	cis	rs295137	0.798	rs1900706	chr2:201214071	A/C	cg23649088	chr2:200775458	C2orf69	0.44	7.19	0.33	2.96e-12	Asthma (bronchodilator response);
LUAD	cis	rs8067545	0.641	rs203479	chr17:19829311	T/C	cg04132472	chr17:19861366	AKAP10	0.39	9.3	0.41	7.79e-19	Schizophrenia;
LUAD	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg22920501	chr2:26401640	FAM59B	0.97	13.4	0.55	2.33e-34	Gut microbiome composition (summer);
LUAD	cis	rs7909074	0.531	rs879343	chr10:45400707	G/T	cg05187965	chr10:45406764	TMEM72	-0.42	-7.52	-0.34	3.32e-13	Mean corpuscular volume;
LUAD	cis	rs2046867	0.818	rs62251647	chr3:72805789	G/A	cg04365224	chr3:72788183	NA	-0.48	-7.31	-0.33	1.38e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2658782	0.951	rs72972357	chr11:93118840	T/C	cg15737290	chr11:93063684	CCDC67	-0.49	-6.79	-0.31	3.92e-11	Pulmonary function decline;
LUAD	cis	rs9796	0.717	rs476633	chr15:41392134	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.43	-7.88	-0.36	2.84e-14	Menopause (age at onset);
LUAD	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg27211696	chr2:191398769	TMEM194B	-0.59	-7.94	-0.36	1.82e-14	Diastolic blood pressure;
LUAD	trans	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg05590025	chr7:65112418	INTS4L2	0.75	7.94	0.36	1.83e-14	Gout;
LUAD	cis	rs2637266	0.783	rs11001866	chr10:78486774	C/T	cg18941641	chr10:78392320	NA	0.33	6.85	0.32	2.63e-11	Pulmonary function;
LUAD	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.73	0.35	8.02e-14	Breast cancer;
LUAD	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.48	-8.8	-0.39	3.46e-17	Menarche (age at onset);
LUAD	cis	rs7528419	1.000	rs7528419	chr1:109817192	A/G	cg00908766	chr1:109817496	CELSR2	-0.74	-14.06	-0.56	4.03e-37	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUAD	cis	rs2795502	0.564	rs3004259	chr10:43486041	A/G	cg15903213	chr10:43522190	NA	0.62	6.62	0.31	1.1e-10	Blood protein levels;
LUAD	cis	rs9487051	0.834	rs6919423	chr6:109558471	C/T	cg21918786	chr6:109611834	NA	-0.42	-7.38	-0.34	8.38e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg11247378	chr22:39784982	NA	-0.56	-8.22	-0.37	2.46e-15	IgG glycosylation;
LUAD	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg04036182	chr15:45458818	NA	0.41	7.15	0.33	3.84e-12	Glomerular filtration rate;
LUAD	cis	rs9341808	0.600	rs590641	chr6:80966483	A/G	cg08355045	chr6:80787529	NA	0.48	8.39	0.38	7.54e-16	Sitting height ratio;
LUAD	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg13722127	chr7:150037890	RARRES2	0.45	7.98	0.36	1.42e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs12976411	0.575	rs55679515	chr19:32823044	G/A	cg02282382	chr19:32836354	ZNF507	0.71	6.43	0.3	3.54e-10	Coronary artery disease;
LUAD	cis	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg08601574	chr20:25228251	PYGB	0.49	8.99	0.4	8.08e-18	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.74	-0.46	5.85e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs877282	0.898	rs10904547	chr10:766283	C/T	cg22713356	chr15:30763199	NA	1.26	17.37	0.65	2.05e-51	Uric acid levels;
LUAD	cis	rs9296092	0.517	rs9461877	chr6:33516667	C/T	cg13560919	chr6:33536144	NA	-0.87	-15.37	-0.6	1.19e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg03037974	chr15:76606532	NA	0.4	8.82	0.39	3.04e-17	Blood metabolite levels;
LUAD	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg21153622	chr11:89784906	NA	-0.33	-6.56	-0.3	1.57e-10	Coronary artery disease;
LUAD	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg00316803	chr15:76480434	C15orf27	-0.41	-7.88	-0.36	2.88e-14	Blood metabolite levels;
LUAD	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.82	-0.43	1.23e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.47e-11	Crohn's disease;
LUAD	cis	rs10865541	1.000	rs11684337	chr2:3395287	A/G	cg13173536	chr2:3403300	TTC15	0.34	6.66	0.31	8.6e-11	Obesity-related traits;
LUAD	cis	rs58799304	0.618	rs35997354	chr1:156071806	G/A	cg25208724	chr1:156163844	SLC25A44	0.52	6.43	0.3	3.53e-10	Ischemic stroke;
LUAD	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.5	-0.34	3.89e-13	Coronary artery disease;
LUAD	cis	rs12216545	0.737	rs4725910	chr7:150237268	A/G	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.4	-0.3	4.08e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg17366294	chr4:99064904	C4orf37	0.65	12.52	0.52	7.98e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg08645402	chr16:4508243	NA	0.49	7.93	0.36	1.97e-14	Schizophrenia;
LUAD	cis	rs6445967	0.554	rs12634453	chr3:58434593	A/G	cg23715586	chr3:58305044	RPP14	0.39	6.35	0.3	5.48e-10	Platelet count;
LUAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg11905131	chr22:24372483	LOC391322	-0.57	-9.52	-0.42	1.3e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg13685833	chr1:53393034	SCP2	-0.5	-8.22	-0.37	2.56e-15	Monocyte count;
LUAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg07677032	chr17:61819896	STRADA	0.57	10.38	0.45	1.24e-22	Prudent dietary pattern;
LUAD	cis	rs12545109	0.879	rs893234	chr8:57363885	G/A	cg21220214	chr8:57350948	NA	-0.67	-9.17	-0.41	2.17e-18	Obesity-related traits;
LUAD	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	8.74	0.39	5.55e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs760805	0.900	rs1005733	chr1:25261960	T/A	cg22509179	chr1:25234806	RUNX3	-0.78	-14.24	-0.57	6.99e-38	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg14917512	chr19:3094685	GNA11	-0.57	-6.7	-0.31	6.66e-11	Diabetic kidney disease;
LUAD	cis	rs2073300	1.000	rs79255223	chr20:23443559	G/T	cg12062639	chr20:23401060	NAPB	0.98	8.35	0.38	9.91e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.11	-0.37	5.5e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg00204512	chr16:28754710	NA	0.36	7.8	0.35	4.72e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.44	0.57	1.08e-38	Schizophrenia;
LUAD	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg24768116	chr2:27665128	KRTCAP3	0.27	6.7	0.31	6.51e-11	Oral cavity cancer;
LUAD	cis	rs9354308	0.933	rs2814131	chr6:66562051	T/A	cg07460842	chr6:66804631	NA	0.51	7.59	0.35	2.06e-13	Metabolite levels;
LUAD	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg26677194	chr12:130822605	PIWIL1	-0.56	-9.2	-0.41	1.63e-18	Menopause (age at onset);
LUAD	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg11979294	chr10:103880575	LDB1	0.38	6.71	0.31	6.18e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs11676348	0.873	rs10210012	chr2:219013334	G/A	cg06547715	chr2:218990976	CXCR2	0.32	7.36	0.34	9.43e-13	Ulcerative colitis;
LUAD	cis	rs4888262	0.508	rs4887779	chr16:74647795	A/G	cg01733217	chr16:74700730	RFWD3	-0.52	-8.69	-0.39	7.96e-17	Testicular germ cell tumor;
LUAD	cis	rs6761276	0.899	rs11891557	chr2:113835319	G/A	cg10479672	chr2:113810641	IL1F8	-0.38	-7.65	-0.35	1.39e-13	Protein quantitative trait loci;
LUAD	cis	rs3806843	0.583	rs408652	chr5:140330013	T/G	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.41	-0.3	3.93e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22857025	chr5:266934	NA	-0.97	-14.47	-0.58	7.55e-39	Breast cancer;
LUAD	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg06046430	chr4:77819534	ANKRD56	0.54	8.63	0.39	1.22e-16	Emphysema distribution in smoking;
LUAD	cis	rs1904096	0.506	rs7439869	chr4:95173779	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-8.87	-0.4	2e-17	Type 2 diabetes;
LUAD	cis	rs7493	0.950	rs11977702	chr7:95029767	C/T	cg01874867	chr7:94954059	PON1	-0.5	-6.8	-0.31	3.63e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg25036284	chr2:26402008	FAM59B	0.84	11.84	0.5	3.81e-28	Gut microbiome composition (summer);
LUAD	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.59	-0.58	2.43e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7177699	0.557	rs9920968	chr15:79118747	G/A	cg15571903	chr15:79123663	NA	0.38	7.6	0.35	1.98e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs1983170	0.736	rs12127718	chr1:91997490	A/T	cg02896835	chr1:92012615	NA	0.54	7.34	0.34	1.1e-12	Eosinophil percentage of white cells;
LUAD	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg00484396	chr16:3507460	NAT15	0.75	9.94	0.44	4.49e-21	Tuberculosis;
LUAD	cis	rs17095355	1.000	rs7083619	chr10:111755762	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.76	-10.46	-0.45	6.22e-23	Biliary atresia;
LUAD	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06544989	chr22:39130855	UNC84B	0.45	9.05	0.4	5.13e-18	Menopause (age at onset);
LUAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg26513180	chr16:89883248	FANCA	0.66	12.17	0.51	2.01e-29	Vitiligo;
LUAD	cis	rs7737355	0.947	rs31584	chr5:130993124	A/G	cg06307176	chr5:131281290	NA	0.53	8.34	0.38	1.06e-15	Life satisfaction;
LUAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08219700	chr8:58056026	NA	0.65	9.16	0.41	2.28e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7737355	0.645	rs7731071	chr5:130973483	A/G	cg06307176	chr5:131281290	NA	0.53	8.02	0.36	1.05e-14	Life satisfaction;
LUAD	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg25985355	chr7:65971099	NA	-0.55	-6.76	-0.31	4.56e-11	Diabetic kidney disease;
LUAD	cis	rs77741769	0.571	rs11065311	chr12:121324115	A/T	cg02419362	chr12:121203948	SPPL3	-0.39	-8.0	-0.36	1.2e-14	Mean corpuscular volume;
LUAD	cis	rs367943	0.966	rs348945	chr5:112822889	C/T	cg12552261	chr5:112820674	MCC	-0.59	-11.17	-0.48	1.49e-25	Type 2 diabetes;
LUAD	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg19302996	chr17:73780495	UNK	-0.43	-6.5	-0.3	2.24e-10	Psoriasis;
LUAD	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.27	-0.41	9.24e-19	Life satisfaction;
LUAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg03433033	chr1:76189801	ACADM	0.79	12.51	0.52	9.04e-31	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1881797	0.527	rs78398999	chr1:247686970	G/A	cg21399703	chr1:247681439	NA	0.5	6.85	0.32	2.57e-11	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg16797656	chr11:68205561	LRP5	0.53	11.38	0.48	2.41e-26	Total body bone mineral density;
LUAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg04234412	chr22:24373322	LOC391322	-0.92	-18.88	-0.68	4.04e-58	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg27454412	chr7:1067447	C7orf50	0.48	7.73	0.35	7.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6500395	1.000	rs1872655	chr16:48670883	A/C	cg04672837	chr16:48644449	N4BP1	0.38	6.69	0.31	7.06e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg09365446	chr1:150670422	GOLPH3L	0.67	12.71	0.53	1.44e-31	Tonsillectomy;
LUAD	cis	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg27411982	chr8:10470053	RP1L1	0.38	7.06	0.32	6.75e-12	Morning vs. evening chronotype;
LUAD	trans	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg26811252	chr16:29126840	RRN3P2	0.62	10.38	0.45	1.18e-22	Menopause (age at onset);
LUAD	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg09365446	chr1:150670422	GOLPH3L	0.54	9.26	0.41	1.04e-18	Melanoma;
LUAD	trans	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg07211511	chr3:129823064	LOC729375	-0.53	-6.73	-0.31	5.7e-11	Blood pressure (smoking interaction);
LUAD	cis	rs921968	0.541	rs72965147	chr2:219341827	A/G	cg02176678	chr2:219576539	TTLL4	-0.82	-16.17	-0.62	3.81e-46	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2637266	0.935	rs12772269	chr10:78394292	C/A	cg18941641	chr10:78392320	NA	0.34	7.1	0.33	5.39e-12	Pulmonary function;
LUAD	cis	rs7116495	1.000	rs4945426	chr11:71748146	A/C	cg07596299	chr11:71824057	C11orf51	0.74	6.66	0.31	8.31e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg15557168	chr22:42548783	NA	0.5	9.12	0.41	3.1e-18	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17095355	1.000	rs55897175	chr10:111699190	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.71	-9.74	-0.43	2.35e-20	Biliary atresia;
LUAD	cis	rs3007168	0.904	rs12884159	chr14:51661855	G/C	cg23942311	chr14:51606299	NA	0.56	7.5	0.34	3.75e-13	Cancer;
LUAD	cis	rs72634258	0.554	rs4908705	chr1:7926401	C/T	cg26816564	chr1:7831052	VAMP3	0.56	8.2	0.37	3e-15	Inflammatory bowel disease;
LUAD	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg13334819	chr7:99746414	C7orf59	-0.65	-10.47	-0.45	5.66e-23	Coronary artery disease;
LUAD	cis	rs1524976	1.000	rs62255282	chr3:65485422	C/T	cg16238336	chr3:65465873	MAGI1	-0.68	-7.54	-0.34	2.91e-13	PR interval;
LUAD	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg20933634	chr6:27740509	NA	-0.47	-7.34	-0.34	1.11e-12	Parkinson's disease;
LUAD	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg17971929	chr21:40555470	PSMG1	0.52	8.15	0.37	4.08e-15	Cognitive function;
LUAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg11766577	chr21:47581405	C21orf56	-0.53	-9.19	-0.41	1.73e-18	Testicular germ cell tumor;
LUAD	trans	rs7395662	1.000	rs10838943	chr11:48557442	T/G	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.1e-12	HDL cholesterol;
LUAD	cis	rs7512552	0.839	rs1260459	chr1:150348253	T/G	cg15654264	chr1:150340011	RPRD2	0.58	11.07	0.47	3.61e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg16414030	chr3:133502952	NA	-0.55	-9.62	-0.42	5.86e-20	Iron status biomarkers;
LUAD	trans	rs3960554	0.741	rs10232162	chr7:75702505	C/T	cg19862616	chr7:65841803	NCRNA00174	0.82	11.17	0.48	1.45e-25	Eotaxin levels;
LUAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06873352	chr17:61820015	STRADA	0.81	18.0	0.66	3.52e-54	Prudent dietary pattern;
LUAD	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg23625390	chr15:77176239	SCAPER	-0.53	-8.14	-0.37	4.46e-15	Blood metabolite levels;
LUAD	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg03929089	chr4:120376271	NA	-0.9	-16.7	-0.63	1.96e-48	Coronary artery disease;
LUAD	cis	rs3204270	0.714	rs7189	chr17:79668897	C/T	cg18367735	chr17:79674897	NA	0.6	7.16	0.33	3.52e-12	Dental caries;
LUAD	cis	rs494562	1.000	rs495469	chr6:86117025	C/T	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.43	-8.1	-0.37	5.73e-15	Longevity;Endometriosis;
LUAD	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg26384229	chr12:38710491	ALG10B	0.51	8.43	0.38	5.35e-16	Heart rate;
LUAD	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03264133	chr6:25882463	NA	-0.57	-9.39	-0.42	3.71e-19	Blood metabolite levels;
LUAD	trans	rs1493916	0.601	rs7237379	chr18:31322540	C/T	cg15819921	chr19:927150	ARID3A	0.45	7.48	0.34	4.34e-13	Life satisfaction;
LUAD	trans	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.73	-0.35	7.65e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7187994	0.848	rs16974535	chr16:84783473	G/A	cg07647771	chr16:84786436	USP10	-0.37	-9.47	-0.42	2.05e-19	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg12432903	chr7:1882776	MAD1L1	-0.4	-6.46	-0.3	2.95e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00166722	chr3:10149974	C3orf24	-0.74	-12.58	-0.52	4.94e-31	Alzheimer's disease;
LUAD	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg09491104	chr22:46646882	C22orf40	-0.59	-7.9	-0.36	2.35e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.52	-0.42	1.3e-19	Life satisfaction;
LUAD	trans	rs4650994	0.905	rs12753251	chr1:178529898	G/A	cg05059571	chr16:84539110	KIAA1609	-0.59	-10.13	-0.44	9.9e-22	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.84	-0.32	2.75e-11	Lung cancer;
LUAD	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.59	-10.31	-0.45	2.19e-22	Menarche (age at onset);
LUAD	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs78707713	0.841	rs76628955	chr10:71208625	C/T	cg12610070	chr10:71211762	TSPAN15	-0.41	-7.38	-0.34	8.46e-13	Venous thromboembolism;
LUAD	cis	rs17401966	1.000	rs7520651	chr1:10329872	G/A	cg15208524	chr1:10270712	KIF1B	0.57	8.68	0.39	8.62e-17	Hepatocellular carcinoma;
LUAD	trans	rs9354308	0.899	rs2814099	chr6:66555130	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.54	8.27	0.37	1.7e-15	Metabolite levels;
LUAD	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11756438	0.572	rs2638545	chr6:119000203	G/C	cg18833306	chr6:118973337	C6orf204	0.54	9.67	0.43	4.03e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg03030879	chr14:75389066	RPS6KL1	0.34	6.47	0.3	2.73e-10	Caffeine consumption;
LUAD	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	6.44	0.3	3.31e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg13685833	chr1:53393034	SCP2	-0.4	-6.71	-0.31	6.39e-11	Monocyte count;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg25327839	chr11:73308997	FAM168A	-0.42	-6.87	-0.32	2.35e-11	Schizophrenia;
LUAD	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg23262073	chr20:60523788	NA	-0.45	-7.76	-0.35	6.41e-14	Body mass index;
LUAD	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg03929089	chr4:120376271	NA	-0.68	-10.28	-0.45	2.83e-22	Coronary artery disease;
LUAD	cis	rs9329221	0.655	rs4316191	chr8:10259229	G/A	cg21775007	chr8:11205619	TDH	-0.37	-6.42	-0.3	3.77e-10	Neuroticism;
LUAD	cis	rs8014204	0.836	rs7150254	chr14:75299101	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.35	-6.68	-0.31	7.32e-11	Caffeine consumption;
LUAD	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.91	-17.97	-0.66	4.71e-54	Ulcerative colitis;
LUAD	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg09117114	chr16:67998030	SLC12A4	-0.53	-6.98	-0.32	1.12e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	trans	rs11039798	1.000	rs3902927	chr11:48581457	C/T	cg15704280	chr7:45808275	SEPT13	0.64	7.58	0.35	2.27e-13	Axial length;
LUAD	cis	rs3784262	0.740	rs4646582	chr15:58307381	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-8.29	-0.37	1.52e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg16325326	chr1:53192061	ZYG11B	0.66	13.1	0.54	3.63e-33	Monocyte count;
LUAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg27454412	chr7:1067447	C7orf50	0.48	7.73	0.35	7.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05901451	chr6:126070800	HEY2	0.82	15.41	0.6	7.78e-43	Brugada syndrome;
LUAD	cis	rs977987	0.931	rs11641430	chr16:75495276	T/C	cg03315344	chr16:75512273	CHST6	0.66	14.99	0.59	4.94e-41	Dupuytren's disease;
LUAD	cis	rs6546550	0.935	rs4853027	chr2:70039224	A/G	cg02498382	chr2:70120550	SNRNP27	0.55	10.35	0.45	1.52e-22	Prevalent atrial fibrillation;
LUAD	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.78e-19	Life satisfaction;
LUAD	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg11822812	chr5:140052017	DND1	0.38	6.66	0.31	8.67e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs250677	0.522	rs1432801	chr5:148390979	T/C	cg12140854	chr5:148520817	ABLIM3	-0.56	-8.54	-0.38	2.45e-16	Breast cancer;
LUAD	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg11766577	chr21:47581405	C21orf56	-0.46	-7.88	-0.36	2.83e-14	Testicular germ cell tumor;
LUAD	cis	rs1784581	0.651	rs3016568	chr6:162388158	G/A	cg17173639	chr6:162384350	PARK2	-0.52	-9.35	-0.41	4.96e-19	Itch intensity from mosquito bite;
LUAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg24642844	chr7:1081250	C7orf50	-0.9	-13.88	-0.56	2.28e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.22e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08330117	chr8:90770456	RIPK2	0.42	6.47	0.3	2.69e-10	Gut microbiome composition (summer);
LUAD	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg10876282	chr6:28092338	ZSCAN16	0.47	7.23	0.33	2.26e-12	Cardiac Troponin-T levels;
LUAD	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.68	13.33	0.54	4.2e-34	Cognitive ability;
LUAD	trans	rs11700980	0.636	rs116306600	chr21:30232542	T/C	cg14791747	chr16:20752902	THUMPD1	0.6	6.6	0.31	1.22e-10	QRS complex (12-leadsum);
LUAD	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg12756686	chr19:29218302	NA	0.67	9.55	0.42	1.07e-19	Methadone dose in opioid dependence;
LUAD	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12256311	chr17:685750	GLOD4;RNMTL1	-0.52	-6.46	-0.3	2.97e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg16988262	chr1:15930761	NA	0.41	6.85	0.32	2.61e-11	Systolic blood pressure;
LUAD	cis	rs1595825	0.786	rs74652956	chr2:198754247	C/T	cg00982548	chr2:198649783	BOLL	-0.63	-9.1	-0.4	3.47e-18	Ulcerative colitis;
LUAD	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg23803603	chr1:2058230	PRKCZ	0.39	7.16	0.33	3.69e-12	Height;
LUAD	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.31	-0.51	5.5e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg14196790	chr5:131705035	SLC22A5	0.38	6.95	0.32	1.42e-11	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4728302	0.583	rs12707091	chr7:133185749	A/G	cg10665199	chr7:133106180	EXOC4	0.62	10.76	0.46	5.15e-24	Intelligence;Intelligence (multi-trait analysis);
LUAD	cis	rs240764	0.717	rs10872622	chr6:101165017	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-7.19	-0.33	2.96e-12	Neuroticism;
LUAD	cis	rs6782228	0.675	rs6806687	chr3:128391789	C/T	cg16766828	chr3:128327626	NA	0.35	6.49	0.3	2.34e-10	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs796825	0.548	rs12494395	chr3:119987430	G/A	cg21790991	chr3:120137480	FSTL1	-0.47	-8.09	-0.37	6.47e-15	HIV-1 susceptibility;
LUAD	cis	rs6484504	0.625	rs672396	chr11:31386165	A/G	cg14844989	chr11:31128820	NA	0.43	7.94	0.36	1.79e-14	Red blood cell count;
LUAD	cis	rs11153730	0.503	rs283040	chr6:118631934	A/G	cg18833306	chr6:118973337	C6orf204	0.52	9.61	0.42	6.67e-20	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs6484504	0.600	rs2616815	chr11:31327316	C/T	cg26647111	chr11:31128758	NA	0.44	7.81	0.36	4.51e-14	Red blood cell count;
LUAD	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.66	-0.31	8.51e-11	Crohn's disease;
LUAD	cis	rs2004318	1.000	rs111992790	chr19:55078751	C/A	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.93e-13	Blood protein levels;
LUAD	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg17177755	chr1:15930204	NA	0.49	7.73	0.35	7.76e-14	Systolic blood pressure;
LUAD	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg27129171	chr3:47204927	SETD2	0.43	6.96	0.32	1.27e-11	Colorectal cancer;
LUAD	cis	rs7851660	0.809	rs3824495	chr9:100663700	A/C	cg13688889	chr9:100608707	NA	0.52	8.98	0.4	9.31e-18	Strep throat;
LUAD	cis	rs490234	0.841	rs476819	chr9:128362737	C/T	cg14078157	chr9:128172775	NA	-0.39	-7.42	-0.34	6.3e-13	Mean arterial pressure;
LUAD	cis	rs1032833	0.732	rs75749465	chr2:180012005	T/C	cg23883738	chr2:179974586	SESTD1	-0.65	-7.3	-0.33	1.46e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs13223928	0.536	rs12700594	chr7:3156701	G/A	cg19214707	chr7:3157722	NA	0.53	9.66	0.43	4.43e-20	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg26516362	chr5:178986906	RUFY1	0.58	10.38	0.45	1.2e-22	Lung cancer;
LUAD	cis	rs7937890	0.559	rs2597188	chr11:14516906	G/A	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.12e-10	Mitochondrial DNA levels;
LUAD	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg10518543	chr12:38710700	ALG10B	0.42	6.47	0.3	2.73e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.99	-0.36	1.32e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs59698941	0.943	rs56927472	chr5:132226038	T/A	cg14825688	chr5:132208181	LEAP2	-0.47	-6.65	-0.31	8.85e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg07423050	chr13:99094983	FARP1	-0.56	-9.31	-0.41	7.13e-19	Longevity;
LUAD	cis	rs7737355	0.947	rs32110	chr5:131045835	T/C	cg25547332	chr5:131281432	NA	0.45	6.6	0.31	1.26e-10	Life satisfaction;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26495864	chr1:29064146	YTHDF2	0.45	6.77	0.31	4.35e-11	Gut microbiome composition (summer);
LUAD	cis	rs6489882	0.836	rs2384071	chr12:113367343	A/G	cg20102336	chr12:113376681	OAS3	-0.59	-9.08	-0.4	4.13e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11644478	chr21:40555479	PSMG1	0.7	11.81	0.5	5.1e-28	Cognitive function;
LUAD	cis	rs459571	0.959	rs378740	chr9:136890876	C/A	cg13789015	chr9:136890014	NCRNA00094	0.84	14.07	0.56	3.8e-37	Platelet distribution width;
LUAD	cis	rs7027203	1.000	rs7864114	chr9:96551954	A/G	cg14598338	chr9:96623480	NA	0.38	7.6	0.35	1.91e-13	DNA methylation (variation);
LUAD	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.68	-10.41	-0.45	9.25e-23	Chronic sinus infection;
LUAD	cis	rs6782228	0.565	rs2811496	chr3:128359958	A/T	cg16766828	chr3:128327626	NA	-0.38	-7.07	-0.33	6.37e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg09365446	chr1:150670422	GOLPH3L	0.63	11.15	0.48	1.76e-25	Melanoma;
LUAD	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg13607699	chr17:42295918	UBTF	0.54	8.85	0.4	2.48e-17	Total body bone mineral density;
LUAD	cis	rs10203711	0.933	rs12692238	chr2:239553940	T/C	cg14580085	chr2:239553406	NA	0.38	7.9	0.36	2.37e-14	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17253792	0.822	rs75897560	chr14:56090965	C/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg07828340	chr4:882639	GAK	0.98	9.96	0.44	4.05e-21	Parkinson's disease;
LUAD	cis	rs6831256	1.000	rs6831256	chr4:3473139	A/G	cg04192923	chr4:3473232	DOK7	0.34	6.35	0.3	5.56e-10	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LUAD	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg10729496	chr3:10149963	C3orf24	0.57	7.47	0.34	4.78e-13	Alzheimer's disease;
LUAD	cis	rs7043114	0.525	rs7863406	chr9:95053381	T/C	cg14631576	chr9:95140430	CENPP	-0.42	-8.45	-0.38	4.8e-16	Height;
LUAD	cis	rs7633770	0.841	rs11130100	chr3:46679198	A/T	cg11219411	chr3:46661640	NA	-0.61	-13.33	-0.54	4.39e-34	Coronary artery disease;
LUAD	cis	rs990171	0.538	rs6705272	chr2:103106569	A/C	cg03938978	chr2:103052716	IL18RAP	0.34	6.63	0.31	1.04e-10	Lymphocyte counts;
LUAD	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.46	0.52	1.4e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs62064224	0.714	rs4795692	chr17:30636688	G/T	cg25809561	chr17:30822961	MYO1D	0.46	8.29	0.37	1.56e-15	Schizophrenia;
LUAD	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg23587288	chr2:27483067	SLC30A3	-0.4	-7.12	-0.33	4.69e-12	Blood metabolite levels;
LUAD	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg17279839	chr7:150038598	RARRES2	0.39	6.45	0.3	3.04e-10	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg08293367	chr22:22089752	YPEL1	0.39	6.37	0.3	5.04e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.76	0.31	4.49e-11	Platelet count;
LUAD	trans	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg26043149	chr18:55253948	FECH	1.04	18.17	0.66	6.26e-55	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs6066825	0.555	rs717709	chr20:47305959	G/A	cg18078177	chr20:47281410	PREX1	0.42	7.09	0.33	5.6e-12	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.55	0.42	1.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2130392	0.926	rs7680323	chr4:185652871	A/T	cg04058563	chr4:185651563	MLF1IP	-0.39	-6.9	-0.32	1.93e-11	Kawasaki disease;
LUAD	trans	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1595825	0.732	rs74885211	chr2:198419911	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.93	-0.32	1.58e-11	Ulcerative colitis;
LUAD	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.27	6.59	0.31	1.3100000000000001e-10	Parkinson's disease;
LUAD	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.67	10.91	0.47	1.35e-24	Height;
LUAD	cis	rs4594175	0.926	rs113095693	chr14:51600511	G/C	cg23942311	chr14:51606299	NA	0.64	11.09	0.47	3e-25	Cancer;
LUAD	cis	rs9560113	0.573	rs61955236	chr13:112242861	G/A	cg10483660	chr13:112241077	NA	0.47	9.6	0.42	7.18e-20	Menarche (age at onset);
LUAD	cis	rs11214589	0.651	rs11214596	chr11:113264511	C/G	cg14159747	chr11:113255604	NA	0.66	13.95	0.56	1.14e-36	Neuroticism;
LUAD	cis	rs10979	0.964	rs12526234	chr6:143898680	A/T	cg25407410	chr6:143891975	LOC285740	-0.65	-10.29	-0.45	2.7e-22	Hypospadias;
LUAD	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg03929089	chr4:120376271	NA	-0.92	-17.5	-0.65	5.39e-52	Height;
LUAD	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg13319975	chr6:146136371	FBXO30	-0.55	-9.2	-0.41	1.59e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg16479474	chr6:28041457	NA	0.46	7.67	0.35	1.2e-13	Depression;
LUAD	cis	rs367943	0.666	rs6594705	chr5:112692851	T/G	cg21806985	chr5:112824646	MCC	0.25	6.41	0.3	3.83e-10	Type 2 diabetes;
LUAD	cis	rs9549328	0.520	rs36144023	chr13:113616592	T/C	cg17524180	chr13:113633600	MCF2L	0.3	6.41	0.3	3.88e-10	Systolic blood pressure;
LUAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg00280220	chr17:61926910	NA	0.35	6.77	0.31	4.4e-11	Prudent dietary pattern;
LUAD	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.32	-0.34	1.28e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg06641503	chr3:48959341	ARIH2	-0.4	-7.99	-0.36	1.33e-14	Parkinson's disease;
LUAD	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg22482690	chr17:47019901	SNF8	0.44	8.37	0.38	8.39e-16	Type 2 diabetes;
LUAD	cis	rs9905704	0.681	rs8081247	chr17:56557837	G/A	cg19466818	chr17:56409534	MIR142	0.33	6.57	0.3	1.48e-10	Testicular germ cell tumor;
LUAD	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg19077165	chr18:44547161	KATNAL2	-0.44	-7.51	-0.34	3.61e-13	Personality dimensions;
LUAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg06753367	chr22:24256600	NA	-0.38	-6.96	-0.32	1.33e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs57920188	0.535	rs77116992	chr1:4095498	T/A	cg10510935	chr1:4059661	NA	0.45	6.8	0.31	3.56e-11	Interleukin-17 levels;
LUAD	cis	rs10129255	0.518	rs12590732	chr14:107187851	C/T	cg07958169	chr14:107095056	NA	0.36	7.23	0.33	2.32e-12	Kawasaki disease;
LUAD	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-8.54	-0.38	2.42e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg13565492	chr6:43139072	SRF	-0.75	-10.16	-0.44	7.78e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7027203	1.000	rs7854820	chr9:96526027	A/G	cg14598338	chr9:96623480	NA	0.38	7.51	0.34	3.43e-13	DNA methylation (variation);
LUAD	trans	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg07211511	chr3:129823064	LOC729375	-0.52	-7.04	-0.32	7.79e-12	Blood pressure (smoking interaction);
LUAD	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.38	6.85	0.32	2.61e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg01475377	chr6:109611718	NA	-0.49	-9.27	-0.41	9.37e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg11301795	chr4:187892539	NA	-0.77	-15.68	-0.61	5.23e-44	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-12.26	-0.51	8.58e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11890956	chr21:40555474	PSMG1	0.83	14.92	0.59	9.48e-41	Cognitive function;
LUAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg21733973	chr7:65235735	NA	0.45	7.1	0.33	5.27e-12	Calcium levels;
LUAD	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg12310025	chr6:25882481	NA	0.55	9.32	0.41	6.72e-19	Blood metabolite levels;
LUAD	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg00814883	chr7:100076585	TSC22D4	-0.78	-10.39	-0.45	1.13e-22	Platelet count;
LUAD	cis	rs10465746	0.570	rs11163886	chr1:84473445	C/A	cg10977910	chr1:84465055	TTLL7	0.49	7.46	0.34	4.97e-13	Obesity-related traits;
LUAD	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg01097406	chr16:89675127	NA	0.37	8.26	0.37	1.88e-15	Hemoglobin concentration;
LUAD	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg12292205	chr6:26970375	C6orf41	-0.57	-9.97	-0.44	3.56e-21	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg01620082	chr3:125678407	NA	-0.72	-7.28	-0.33	1.62e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg18944383	chr4:111397179	ENPEP	0.39	7.67	0.35	1.18e-13	Height;
LUAD	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.42	7.1	0.33	5.14e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	10.08	0.44	1.48e-21	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg18129748	chr3:49941408	MST1R	0.43	7.15	0.33	3.73e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2637266	0.685	rs7098713	chr10:78452828	C/T	cg18941641	chr10:78392320	NA	0.33	6.75	0.31	4.77e-11	Pulmonary function;
LUAD	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg02466173	chr16:30829666	NA	-0.71	-12.88	-0.53	3.03e-32	Multiple myeloma;
LUAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06873352	chr17:61820015	STRADA	0.83	18.6	0.67	7.24e-57	Prudent dietary pattern;
LUAD	cis	rs7107174	1.000	rs10899468	chr11:78016650	C/T	cg19901956	chr11:77921274	USP35	-0.53	-6.52	-0.3	2e-10	Testicular germ cell tumor;
LUAD	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg00071950	chr4:10020882	SLC2A9	0.85	18.22	0.66	3.53e-55	Bone mineral density;
LUAD	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg05966235	chr16:28915196	ATP2A1	0.47	7.66	0.35	1.31e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg10556349	chr10:835070	NA	0.66	7.65	0.35	1.41e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg24399712	chr22:39784796	NA	-0.7	-11.67	-0.49	1.88e-27	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg21252483	chr19:49399788	TULP2	-0.88	-14.31	-0.57	3.61e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	trans	rs7395662	0.963	rs11499897	chr11:48717866	G/A	cg15704280	chr7:45808275	SEPT13	0.43	6.75	0.31	5.04e-11	HDL cholesterol;
LUAD	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg21798802	chr22:38057573	PDXP	0.35	7.25	0.33	2e-12	Fat distribution (HIV);
LUAD	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg06784218	chr1:46089804	CCDC17	0.51	11.21	0.48	1.05e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.55	0.42	1.1e-19	Cognitive ability;
LUAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg23131131	chr22:24373011	LOC391322	-0.59	-9.84	-0.43	1.06e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4664308	1.000	rs1511218	chr2:160906390	T/C	cg03641300	chr2:160917029	PLA2R1	-0.4	-6.91	-0.32	1.76e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg04850045	chr2:105853200	NA	-0.35	-6.4	-0.3	4.13e-10	Type 2 diabetes;
LUAD	cis	rs11112613	0.653	rs2374533	chr12:106047891	A/G	cg03607813	chr12:105948248	NA	0.51	6.94	0.32	1.46e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg04234412	chr22:24373322	LOC391322	-0.83	-15.71	-0.61	3.75e-44	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg08632164	chr7:65971372	NA	-0.55	-6.38	-0.3	4.53e-10	Diabetic kidney disease;
LUAD	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg20203395	chr5:56204925	C5orf35	-0.83	-11.84	-0.5	4.11e-28	Initial pursuit acceleration;
LUAD	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg10518543	chr12:38710700	ALG10B	-0.44	-7.23	-0.33	2.34e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-9.11	-0.41	3.3e-18	Bipolar disorder;
LUAD	cis	rs11681884	0.892	rs2121327	chr2:113852193	A/G	cg12858261	chr2:113808755	IL1F8	0.57	6.39	0.3	4.35e-10	Stroke;
LUAD	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.58	0.3	1.36e-10	Cardiac Troponin-T levels;
LUAD	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	6.56	0.3	1.55e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs11893307	0.509	rs12618075	chr2:191545821	A/G	cg11845111	chr2:191398756	TMEM194B	-0.44	-6.64	-0.31	9.71e-11	Mean platelet volume;
LUAD	trans	rs1997103	1.000	rs2877284	chr7:55408778	A/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1003719	0.788	rs3787783	chr21:38462959	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.33e-16	Eye color traits;
LUAD	trans	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg24644049	chr4:85504048	CDS1	0.89	7.33	0.34	1.17e-12	Skin colour saturation;
LUAD	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg27661571	chr11:113659931	NA	-0.54	-6.58	-0.3	1.35e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2456568	0.802	rs11020585	chr11:93638493	A/C	cg26875233	chr11:93583750	C11orf90	0.3	6.63	0.31	1.04e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs2230307	0.536	rs534252	chr1:100472604	A/G	cg20868668	chr1:100435035	SLC35A3	0.54	7.78	0.35	5.7e-14	Carotid intima media thickness;
LUAD	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg02733842	chr7:1102375	C7orf50	-0.42	-7.23	-0.33	2.31e-12	Longevity;Endometriosis;
LUAD	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.73	-0.46	6.41e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs11811982	0.793	rs115273856	chr1:227393091	G/C	cg24860534	chr1:227506868	CDC42BPA	0.67	7.38	0.34	8.3e-13	Optic disc area;
LUAD	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg02569458	chr12:86230093	RASSF9	0.39	7.18	0.33	3.14e-12	Major depressive disorder;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16116313	chr12:122255002	SETD1B	0.53	6.4	0.3	4.07e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs17253792	0.822	rs17747083	chr14:56110594	T/C	cg01858014	chr14:56050164	KTN1	-0.61	-6.41	-0.3	3.85e-10	Putamen volume;
LUAD	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.51	0.34	3.46e-13	Breast cancer;
LUAD	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg17366294	chr4:99064904	C4orf37	0.57	8.61	0.39	1.41e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08677398	chr8:58056175	NA	0.5	7.02	0.32	9.1e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs17433780	0.964	rs12121223	chr1:89481583	C/T	cg09516651	chr1:89888402	LOC400759	0.53	9.45	0.42	2.33e-19	Carotid intima media thickness;
LUAD	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg03477792	chr4:77819574	ANKRD56	0.49	7.42	0.34	6.57e-13	Emphysema distribution in smoking;
LUAD	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg12935359	chr14:103987150	CKB	-0.48	-8.0	-0.36	1.24e-14	Body mass index;
LUAD	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg08085267	chr17:45401833	C17orf57	0.66	12.01	0.5	8.62e-29	Multiple sclerosis or amyotrophic lateral sclerosis;
LUAD	cis	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg21775007	chr8:11205619	TDH	0.56	9.86	0.43	8.97e-21	Retinal vascular caliber;
LUAD	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.24	-0.37	2.19e-15	Breast cancer;
LUAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg03188948	chr7:1209495	NA	0.76	9.31	0.41	6.83e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1476679	1.000	rs34919929	chr7:100012334	G/A	cg22906224	chr7:99728672	NA	-0.45	-7.35	-0.34	1.06e-12	Alzheimer's disease (late onset);
LUAD	cis	rs9309473	0.607	rs7567343	chr2:73596605	C/A	cg20560298	chr2:73613845	ALMS1	-0.44	-6.81	-0.31	3.29e-11	Metabolite levels;
LUAD	trans	rs7395662	0.963	rs11039870	chr11:48626478	C/T	cg15704280	chr7:45808275	SEPT13	-0.41	-6.47	-0.3	2.71e-10	HDL cholesterol;
LUAD	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg07936489	chr17:37558343	FBXL20	-0.44	-6.85	-0.32	2.57e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-6.87	-0.32	2.35e-11	Total body bone mineral density;
LUAD	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg26513180	chr16:89883248	FANCA	0.79	7.27	0.33	1.76e-12	Skin colour saturation;
LUAD	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg18230493	chr5:56204884	C5orf35	-0.9	-12.94	-0.53	1.65e-32	Initial pursuit acceleration;
LUAD	cis	rs10821973	0.527	rs7089059	chr10:64034274	C/T	cg19640130	chr10:64028056	RTKN2	-0.36	-6.39	-0.3	4.39e-10	Hypothyroidism;
LUAD	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg06808227	chr14:105710500	BRF1	-0.42	-6.54	-0.3	1.81e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs1595825	0.838	rs16823400	chr2:198603229	A/G	cg11031976	chr2:198649780	BOLL	-0.47	-6.97	-0.32	1.22e-11	Ulcerative colitis;
LUAD	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg07212818	chr11:638076	DRD4	-0.45	-6.73	-0.31	5.64e-11	Systemic lupus erythematosus;
LUAD	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.15	0.33	3.89e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9517313	0.554	rs3809366	chr13:99230266	C/T	cg20487152	chr13:99095054	FARP1	-0.48	-8.13	-0.37	4.68e-15	Neuroticism;
LUAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg02869364	chr7:1081709	C7orf50	-0.5	-6.46	-0.3	2.85e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg17724175	chr1:150552817	MCL1	0.37	8.42	0.38	6.02e-16	Melanoma;
LUAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.57	-10.16	-0.44	7.37e-22	Longevity;Endometriosis;
LUAD	cis	rs6987853	0.933	rs6980507	chr8:42383084	A/G	cg09913449	chr8:42400586	C8orf40	0.36	6.88	0.32	2.19e-11	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg23978390	chr7:1156363	C7orf50	0.44	6.78	0.31	4.04e-11	Longevity;Endometriosis;
LUAD	trans	rs2840044	1.000	rs225262	chr17:33959697	A/G	cg19694781	chr19:47549865	TMEM160	-0.63	-10.17	-0.44	6.74e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.38	-0.42	4e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg08213375	chr14:104286397	PPP1R13B	0.26	6.87	0.32	2.32e-11	Schizophrenia;
LUAD	cis	rs4774899	0.752	rs2464429	chr15:57348302	C/T	cg14026238	chr15:57616123	NA	0.43	8.37	0.38	8.28e-16	Urinary tract infection frequency;
LUAD	cis	rs243505	0.528	rs740951	chr7:148470160	C/A	cg09806900	chr7:148480153	CUL1	0.46	7.83	0.36	4.05e-14	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg00634984	chr7:65235879	NA	0.49	6.59	0.31	1.33e-10	Aortic root size;
LUAD	cis	rs6752107	0.503	rs2304776	chr2:234227693	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	7.87	0.36	2.96e-14	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs4523957	0.890	rs432200	chr17:2191960	A/G	cg16513277	chr17:2031491	SMG6	0.76	14.2	0.57	1.08e-37	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01510332	chr19:59087201	MGC2752	0.46	7.31	0.33	1.35e-12	Gut microbiome composition (summer);
LUAD	cis	rs4372836	0.964	rs4665432	chr2:28952026	G/A	cg09522027	chr2:28974177	PPP1CB	0.62	10.05	0.44	1.86e-21	Body mass index;
LUAD	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg08514558	chr10:81106712	PPIF	0.48	9.21	0.41	1.57e-18	Height;
LUAD	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg21963583	chr11:68658836	MRPL21	0.65	11.36	0.48	2.75e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg13010344	chr12:123464640	ARL6IP4	-0.38	-6.41	-0.3	3.83e-10	Platelet count;
LUAD	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg23933602	chr10:16859644	RSU1	0.66	9.89	0.43	6.89e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg21798802	chr22:38057573	PDXP	0.34	6.98	0.32	1.16e-11	Fat distribution (HIV);
LUAD	cis	rs367943	1.000	rs348925	chr5:112817533	T/A	cg12552261	chr5:112820674	MCC	-0.58	-11.04	-0.47	4.66e-25	Type 2 diabetes;
LUAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg16414030	chr3:133502952	NA	-0.68	-12.98	-0.53	1.18e-32	Iron status biomarkers;
LUAD	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg00495681	chr13:53174319	NA	0.6	11.29	0.48	5.02e-26	Lewy body disease;
LUAD	cis	rs2637266	0.967	rs2579748	chr10:78328313	T/C	cg18941641	chr10:78392320	NA	0.33	6.84	0.32	2.75e-11	Pulmonary function;
LUAD	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg11965913	chr1:205819406	PM20D1	-0.54	-8.25	-0.37	2e-15	Menarche (age at onset);
LUAD	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Depression;
LUAD	trans	rs1493916	0.748	rs2040203	chr18:31307420	G/T	cg15819921	chr19:927150	ARID3A	-0.41	-6.65	-0.31	9.08e-11	Life satisfaction;
LUAD	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg18225595	chr11:63971243	STIP1	0.53	8.94	0.4	1.25e-17	Platelet count;
LUAD	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03934478	chr11:495069	RNH1	0.78	9.36	0.41	4.83e-19	Body mass index;
LUAD	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	9.78	0.43	1.73e-20	Total body bone mineral density;
LUAD	cis	rs2067615	0.579	rs1073261	chr12:107135942	A/G	cg15890332	chr12:107067104	RFX4	0.39	8.39	0.38	7.41e-16	Heart rate;
LUAD	trans	rs7395662	1.000	rs11039800	chr11:48542579	C/T	cg15704280	chr7:45808275	SEPT13	0.41	6.39	0.3	4.31e-10	HDL cholesterol;
LUAD	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.47	0.3	2.69e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg12927641	chr6:109611667	NA	-0.43	-7.2	-0.33	2.85e-12	Reticulocyte fraction of red cells;
LUAD	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg03929089	chr4:120376271	NA	0.56	6.99	0.32	1.06e-11	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-9.02	-0.4	6.41e-18	Total body bone mineral density;
LUAD	cis	rs9487051	0.834	rs436880	chr6:109553069	C/T	cg21918786	chr6:109611834	NA	-0.4	-6.91	-0.32	1.81e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg10518543	chr12:38710700	ALG10B	-0.42	-6.88	-0.32	2.16e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg16479474	chr6:28041457	NA	0.46	7.62	0.35	1.72e-13	Depression;
LUAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg02869364	chr7:1081709	C7orf50	-0.51	-6.61	-0.31	1.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs68170813	0.641	rs74524528	chr7:107090979	G/A	cg23024343	chr7:107201750	COG5	0.51	7.05	0.32	7.13e-12	Coronary artery disease;
LUAD	cis	rs6543140	0.865	rs6760275	chr2:103079607	C/T	cg03938978	chr2:103052716	IL18RAP	0.36	6.92	0.32	1.66e-11	Blood protein levels;
LUAD	cis	rs56283067	0.847	rs60328783	chr6:44693099	C/G	cg20913747	chr6:44695427	NA	-0.44	-7.54	-0.34	2.83e-13	Total body bone mineral density;
LUAD	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg09367891	chr1:107599246	PRMT6	0.59	9.96	0.44	4.04e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.81	0.35	4.6e-14	Depression;
LUAD	cis	rs73058052	1.000	rs73058052	chr19:50099422	C/T	cg21913888	chr19:50084626	PRRG2;NOSIP	0.35	7.07	0.32	6.61e-12	Fibrinogen levels;
LUAD	trans	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg04995722	chr7:26192034	NFE2L3	0.37	6.5	0.3	2.27e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4730250	0.707	rs257375	chr7:106799043	A/G	cg02696742	chr7:106810147	HBP1	-0.78	-10.75	-0.46	5.54e-24	Osteoarthritis;
LUAD	cis	rs3087591	0.959	rs9893872	chr17:29571195	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.76	-0.31	4.69e-11	Hip circumference;
LUAD	cis	rs7210086	0.768	rs4072716	chr17:70640933	T/C	cg04206342	chr17:70636940	NA	-0.35	-6.88	-0.32	2.15e-11	Ulcerative colitis;
LUAD	cis	rs17401966	0.838	rs1013952	chr1:10319247	G/A	cg19773385	chr1:10388646	KIF1B	-0.39	-6.46	-0.3	2.89e-10	Hepatocellular carcinoma;
LUAD	cis	rs807669	0.835	rs698423	chr22:19197896	T/C	cg24911827	chr22:19170109	CLTCL1	0.42	8.65	0.39	1.06e-16	Metabolite levels;
LUAD	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg15147215	chr3:52552868	STAB1	-0.4	-7.48	-0.34	4.38e-13	Electroencephalogram traits;
LUAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.73	-0.46	6.49e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg06221963	chr1:154839813	KCNN3	-0.85	-20.05	-0.7	2.38e-63	Prostate cancer;
LUAD	cis	rs9473147	0.516	rs1931837	chr6:47442377	C/T	cg20196966	chr6:47445060	CD2AP	0.43	6.55	0.3	1.69e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg21775007	chr8:11205619	TDH	-0.46	-8.2	-0.37	2.95e-15	Retinal vascular caliber;
LUAD	trans	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg02030672	chr11:45687055	CHST1	0.36	6.4	0.3	4.23e-10	Obesity-related traits;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05226292	chr8:71520850	TRAM1	-0.57	-7.1	-0.33	5.37e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07590406	chr3:58292066	RPP14	-0.42	-6.69	-0.31	6.95e-11	Height;
LUAD	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg03676636	chr4:99064102	C4orf37	-0.31	-8.27	-0.37	1.77e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg21433313	chr16:3507492	NAT15	0.74	9.66	0.43	4.42e-20	Tuberculosis;
LUAD	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg18198730	chr1:247681584	NA	0.44	7.62	0.35	1.71e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg01579765	chr21:45077557	HSF2BP	0.55	12.51	0.52	8.76e-31	Mean corpuscular volume;
LUAD	cis	rs4253772	0.515	rs9615968	chr22:46772695	A/G	cg00784671	chr22:46762841	CELSR1	-0.68	-7.47	-0.34	4.68e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2108225	0.872	rs6980029	chr7:107446127	T/C	cg18560240	chr7:107437656	SLC26A3	-0.42	-6.85	-0.32	2.62e-11	Ulcerative colitis;
LUAD	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg01097406	chr16:89675127	NA	0.42	9.1	0.4	3.62e-18	Vitiligo;
LUAD	cis	rs12545109	0.800	rs2582404	chr8:57387368	C/T	cg09654669	chr8:57350985	NA	-0.68	-9.76	-0.43	2.02e-20	Obesity-related traits;
LUAD	cis	rs4660214	0.666	rs4660550	chr1:39688459	A/T	cg27567593	chr1:39956653	BMP8A	0.33	6.56	0.3	1.56e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6906287	0.625	rs7764272	chr6:118692498	A/C	cg05564266	chr6:118973597	C6orf204	0.36	7.82	0.36	4.3e-14	Electrocardiographic conduction measures;
LUAD	cis	rs4604732	0.631	rs76761880	chr1:247626377	T/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7536201	1.000	rs7523328	chr1:25294195	G/A	cg23273869	chr1:25296894	NA	-0.36	-7.01	-0.32	9.19e-12	Psoriasis vulgaris;
LUAD	cis	rs6445967	0.530	rs62258104	chr3:58379984	G/C	cg13750441	chr3:58318267	PXK	-0.33	-6.84	-0.32	2.87e-11	Platelet count;
LUAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg13047869	chr3:10149882	C3orf24	0.66	11.38	0.48	2.34e-26	Alzheimer's disease;
LUAD	cis	rs6500395	0.928	rs7199206	chr16:48702538	A/G	cg04672837	chr16:48644449	N4BP1	-0.38	-6.68	-0.31	7.53e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg11494091	chr17:61959527	GH2	-0.69	-15.73	-0.61	3.11e-44	Prudent dietary pattern;
LUAD	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg20673091	chr1:2541236	MMEL1	0.45	9.82	0.43	1.24e-20	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.13e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3125734	0.719	rs10821972	chr10:64043735	G/A	cg09941381	chr10:64027924	RTKN2	-0.31	-7.23	-0.33	2.32e-12	Rheumatoid arthritis;
LUAD	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.4	-0.45	1.06e-22	Total body bone mineral density;
LUAD	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg11663144	chr21:46675770	NA	-0.57	-11.23	-0.48	8.96e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg17372223	chr3:52568218	NT5DC2	-0.39	-7.04	-0.32	7.67e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs55665837	1.000	rs12295723	chr11:14450201	T/C	cg19336497	chr11:14380999	RRAS2	-0.51	-10.3	-0.45	2.45e-22	Vitamin D levels;
LUAD	cis	rs6087990	0.965	rs742630	chr20:31350664	C/G	cg13636640	chr20:31349939	DNMT3B	0.84	16.12	0.62	6.42e-46	Ulcerative colitis;
LUAD	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.44	-0.42	2.56e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06873352	chr17:61820015	STRADA	0.82	17.99	0.66	3.94e-54	Prudent dietary pattern;
LUAD	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-20.27	-0.7	2.41e-64	Height;
LUAD	cis	rs35995292	0.963	rs2392609	chr7:38952595	C/T	cg19327137	chr7:38886074	VPS41	0.5	7.85	0.36	3.33e-14	Subjective well-being (multi-trait analysis);
LUAD	cis	rs67311347	0.544	rs13097602	chr3:40339247	T/C	cg09455208	chr3:40491958	NA	-0.47	-9.76	-0.43	1.97e-20	Renal cell carcinoma;
LUAD	cis	rs1595825	0.891	rs78835808	chr2:198669110	G/A	cg00361562	chr2:198649771	BOLL	-0.5	-6.73	-0.31	5.4e-11	Ulcerative colitis;
LUAD	trans	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg11693508	chr17:37793320	STARD3	0.55	7.64	0.35	1.52e-13	Bipolar disorder;
LUAD	cis	rs59698941	0.550	rs60042615	chr5:132193220	A/G	cg16419906	chr5:132167176	NA	-0.33	-6.54	-0.3	1.77e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03264133	chr6:25882463	NA	-0.58	-9.45	-0.42	2.38e-19	Blood metabolite levels;
LUAD	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg01475377	chr6:109611718	NA	-0.54	-10.21	-0.44	5e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg09835421	chr16:68378352	PRMT7	-0.74	-8.48	-0.38	3.69e-16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
LUAD	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg02683114	chr2:24398427	C2orf84	-0.53	-7.83	-0.36	4.01e-14	Asthma;
LUAD	cis	rs9914988	0.943	rs7224870	chr17:27102620	A/G	cg02049041	chr17:27085579	C17orf63	0.61	8.24	0.37	2.2e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs5756813	0.635	rs4820301	chr22:38126364	G/A	cg06521852	chr22:38141419	TRIOBP	0.5	8.72	0.39	6.32e-17	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg04944784	chr2:26401820	FAM59B	-0.89	-12.57	-0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	trans	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg04565464	chr8:145669602	NFKBIL2	0.47	7.01	0.32	9.51e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6987853	0.933	rs2974355	chr8:42414117	C/T	cg09913449	chr8:42400586	C8orf40	0.42	7.72	0.35	8.69e-14	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg18187862	chr3:45730750	SACM1L	0.51	8.04	0.36	9.17e-15	Primary sclerosing cholangitis;
LUAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg18621852	chr3:10150065	C3orf24	-0.47	-7.4	-0.34	7.26e-13	Alzheimer's disease;
LUAD	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg06627628	chr2:24431161	ITSN2	-0.56	-6.55	-0.3	1.63e-10	Lymphocyte counts;
LUAD	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg23758822	chr17:41437982	NA	0.9	18.3	0.66	1.56e-55	Menopause (age at onset);
LUAD	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg09117114	chr16:67998030	SLC12A4	-0.49	-6.97	-0.32	1.24e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg27124370	chr19:33622961	WDR88	-0.43	-6.62	-0.31	1.09e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs11811982	0.793	rs116647640	chr1:227408696	A/G	cg24860534	chr1:227506868	CDC42BPA	0.71	7.66	0.35	1.26e-13	Optic disc area;
LUAD	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg18230493	chr5:56204884	C5orf35	0.66	10.51	0.46	4e-23	Initial pursuit acceleration;
LUAD	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22496380	chr5:211416	CCDC127	-0.91	-12.8	-0.53	6.14e-32	Breast cancer;
LUAD	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg06199346	chr11:14280333	SPON1	-0.32	-6.41	-0.3	3.93e-10	Mitochondrial DNA levels;
LUAD	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg13319975	chr6:146136371	FBXO30	0.64	10.65	0.46	1.32e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg22117172	chr7:91764530	CYP51A1	-0.35	-7.6	-0.35	1.99e-13	Breast cancer;
LUAD	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4711336	0.935	rs3818525	chr6:33660779	A/G	cg13859433	chr6:33739653	LEMD2	-0.3	-7.18	-0.33	3.23e-12	Height;
LUAD	cis	rs7474896	0.559	rs1212108	chr10:38094322	A/C	cg25427524	chr10:38739819	LOC399744	-0.62	-8.71	-0.39	7.17e-17	Obesity (extreme);
LUAD	cis	rs8060686	0.516	rs8044995	chr16:68189340	G/A	cg26727032	chr16:67993705	SLC12A4	-0.47	-7.75	-0.35	6.91e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg26384229	chr12:38710491	ALG10B	0.49	7.86	0.36	3.33e-14	Bladder cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11011602	chr9:136215029	SNORD24;MED22;RPL7A	-0.48	-7.47	-0.34	4.6e-13	Height;
LUAD	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg05110241	chr16:68378359	PRMT7	-0.68	-7.7	-0.35	9.98e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.63	0.31	1.05e-10	Prudent dietary pattern;
LUAD	cis	rs71478720	1.000	rs71478720	chr11:112009605	C/T	cg04929355	chr11:112034997	IL18	0.45	6.88	0.32	2.12e-11	Interleukin-18 levels;
LUAD	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg11766577	chr21:47581405	C21orf56	-0.46	-7.88	-0.36	2.83e-14	Testicular germ cell tumor;
LUAD	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg07305463	chr2:136567211	LCT	-0.36	-6.92	-0.32	1.63e-11	Mosquito bite size;
LUAD	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg06387496	chr7:2775674	GNA12	-0.39	-6.48	-0.3	2.61e-10	Height;
LUAD	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.46	-8.25	-0.37	2.09e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs1395	0.571	rs114507490	chr2:27527246	T/A	cg24768116	chr2:27665128	KRTCAP3	-0.33	-6.93	-0.32	1.61e-11	Blood metabolite levels;
LUAD	cis	rs12912251	0.948	rs34141940	chr15:38989657	G/A	cg01338139	chr15:38987640	C15orf53	-0.57	-8.92	-0.4	1.47e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs11030122	0.702	rs12286710	chr11:3967171	T/G	cg18678763	chr11:4115507	RRM1	-0.45	-7.47	-0.34	4.49e-13	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg21862992	chr11:68658383	NA	0.51	9.56	0.42	9.52e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg00684032	chr4:1343700	KIAA1530	0.41	6.89	0.32	2.07e-11	Obesity-related traits;
LUAD	cis	rs36051895	0.659	rs3780367	chr9:5068755	T/G	cg02405213	chr9:5042618	JAK2	-0.5	-6.83	-0.32	2.93e-11	Pediatric autoimmune diseases;
LUAD	cis	rs3764563	1.000	rs8107240	chr19:15737392	A/G	cg20725493	chr19:15740067	CYP4F8	-0.72	-7.99	-0.36	1.34e-14	Inflammatory biomarkers;
LUAD	trans	rs79911532	0.515	rs117892182	chr7:75805689	C/A	cg19862616	chr7:65841803	NCRNA00174	0.85	8.56	0.38	2.05e-16	Mononucleosis;
LUAD	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg10589385	chr1:150898437	SETDB1	0.4	7.49	0.34	4.08e-13	Melanoma;
LUAD	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg13334819	chr7:99746414	C7orf59	0.66	10.57	0.46	2.57e-23	Coronary artery disease;
LUAD	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.6	-0.35	1.92e-13	Blood metabolite levels;
LUAD	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.4	0.42	3.51e-19	Tonsillectomy;
LUAD	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18876405	chr7:65276391	NA	0.41	6.39	0.3	4.42e-10	Aortic root size;
LUAD	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.11	-24.65	-0.77	7.94e-84	Ulcerative colitis;
LUAD	cis	rs17601876	0.814	rs12050767	chr15:51557257	T/C	cg19946085	chr15:51559439	CYP19A1	-0.36	-6.5	-0.3	2.21e-10	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LUAD	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg26924012	chr15:45694286	SPATA5L1	0.99	18.29	0.66	1.8e-55	Homoarginine levels;
LUAD	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg25894440	chr7:65020034	NA	0.69	7.34	0.34	1.11e-12	Diabetic kidney disease;
LUAD	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg11189052	chr15:85197271	WDR73	0.66	9.07	0.4	4.35e-18	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg06552810	chr11:31128660	NA	-0.33	-6.45	-0.3	3.02e-10	Red blood cell count;
LUAD	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg11859384	chr17:80120422	CCDC57	-0.48	-8.61	-0.39	1.41e-16	Life satisfaction;
LUAD	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg09835421	chr16:68378352	PRMT7	-0.84	-9.07	-0.4	4.45e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg19318889	chr4:1322082	MAEA	0.48	8.4	0.38	6.96e-16	Obesity-related traits;
LUAD	cis	rs6541297	1.000	rs6681042	chr1:230278979	G/A	cg20703242	chr1:230279135	GALNT2	0.66	12.26	0.51	8.85e-30	Coronary artery disease;
LUAD	trans	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg11693508	chr17:37793320	STARD3	0.6	7.63	0.35	1.53e-13	Neuroticism;
LUAD	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	7.65	0.35	1.36e-13	Menarche (age at onset);
LUAD	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg27490568	chr2:178487706	NA	0.57	8.62	0.39	1.34e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs3820068	0.705	rs41270255	chr1:15892980	G/A	cg13390004	chr1:15929781	NA	0.43	6.89	0.32	2.04e-11	Systolic blood pressure;
LUAD	cis	rs2230307	0.518	rs2810425	chr1:100665072	G/C	cg20868668	chr1:100435035	SLC35A3	-0.54	-8.02	-0.36	1.07e-14	Carotid intima media thickness;
LUAD	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg22598563	chr5:131563921	P4HA2	-0.32	-7.83	-0.36	3.89e-14	Blood metabolite levels;
LUAD	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg12000995	chr2:27665139	KRTCAP3	-0.32	-8.23	-0.37	2.27e-15	Total body bone mineral density;
LUAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg21724239	chr8:58056113	NA	0.66	8.66	0.39	9.86e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-15.23	-0.6	4.39e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg01620082	chr3:125678407	NA	-0.46	-6.76	-0.31	4.61e-11	Depression;
LUAD	cis	rs1395	0.626	rs72817537	chr2:27497549	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.08	-0.33	6.07e-12	Blood metabolite levels;
LUAD	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg08632164	chr7:65971372	NA	-0.37	-6.35	-0.3	5.44e-10	Aortic root size;
LUAD	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg00933542	chr6:150070202	PCMT1	0.34	6.85	0.32	2.54e-11	Testicular germ cell tumor;
LUAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg16606324	chr3:10149918	C3orf24	0.59	9.65	0.42	4.73e-20	Alzheimer's disease;
LUAD	cis	rs13064411	0.696	rs3732803	chr3:113211957	T/C	cg18753928	chr3:113234510	CCDC52	-0.73	-12.37	-0.52	3.33e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg27286337	chr10:134555280	INPP5A	0.44	7.43	0.34	6.02e-13	Gait speed in old age;
LUAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg08132940	chr7:1081526	C7orf50	-0.44	-6.77	-0.31	4.45e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7107174	0.681	rs3102742	chr11:77949334	G/T	cg02023728	chr11:77925099	USP35	0.49	7.18	0.33	3.09e-12	Testicular germ cell tumor;
LUAD	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.06	24.42	0.76	8.45e-83	Chronic sinus infection;
LUAD	cis	rs926938	0.584	rs6689326	chr1:115369112	T/A	cg12756093	chr1:115239321	AMPD1	-0.36	-6.43	-0.3	3.4e-10	Autism;
LUAD	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg03929089	chr4:120376271	NA	-0.74	-12.1	-0.51	3.64e-29	Coronary artery disease;
LUAD	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.1	0.33	5.48e-12	Motion sickness;
LUAD	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg07917127	chr4:99064746	C4orf37	0.42	7.02	0.32	9.15e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg27266060	chr8:22091797	NA	0.45	8.34	0.38	1.08e-15	Hypertriglyceridemia;
LUAD	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg01802117	chr1:53393560	SCP2	-0.37	-7.17	-0.33	3.29e-12	Monocyte count;
LUAD	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg05991184	chr2:219186017	PNKD	0.37	7.02	0.32	8.88e-12	Colorectal cancer;
LUAD	cis	rs17401966	0.838	rs946503	chr1:10308631	C/G	cg19773385	chr1:10388646	KIF1B	0.38	6.36	0.3	5.32e-10	Hepatocellular carcinoma;
LUAD	cis	rs7539409	0.651	rs979757	chr1:84296605	T/C	cg10977910	chr1:84465055	TTLL7	0.71	8.37	0.38	8.54e-16	Alzheimer's disease;
LUAD	cis	rs4631830	0.863	rs2249986	chr10:51521684	T/G	cg20129853	chr10:51489980	NA	-0.33	-6.58	-0.3	1.37e-10	Prostate-specific antigen levels;
LUAD	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg19635926	chr16:89946313	TCF25	0.74	6.53	0.3	1.91e-10	Skin colour saturation;
LUAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg05896524	chr21:47604654	C21orf56	0.61	9.77	0.43	1.81e-20	Testicular germ cell tumor;
LUAD	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg22823121	chr1:150693482	HORMAD1	0.41	7.88	0.36	2.81e-14	Melanoma;
LUAD	trans	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg01620082	chr3:125678407	NA	-0.45	-6.77	-0.31	4.26e-11	Parkinson's disease;
LUAD	cis	rs758324	0.947	rs2896961	chr5:131165006	C/T	cg06307176	chr5:131281290	NA	0.5	8.03	0.36	9.81e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg07460842	chr6:66804631	NA	1.15	26.56	0.79	3.76e-92	Exhaled nitric oxide output;
LUAD	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg18833306	chr6:118973337	C6orf204	-0.49	-7.27	-0.33	1.75e-12	Diastolic blood pressure;
LUAD	cis	rs11650494	0.908	rs118099826	chr17:47447836	G/T	cg08112188	chr17:47440006	ZNF652	0.98	8.25	0.37	1.99e-15	Prostate cancer;
LUAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.83	0.43	1.16e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg25256661	chr17:7137939	DVL2	0.65	12.79	0.53	6.56e-32	Diastolic blood pressure;
LUAD	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.62	12.05	0.51	5.75e-29	Hemoglobin concentration;
LUAD	cis	rs989128	0.600	rs9913677	chr17:48628581	T/A	cg24438145	chr17:48624694	SPATA20	0.37	6.51	0.3	2.13e-10	Type 2 diabetes;
LUAD	cis	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg07460842	chr6:66804631	NA	0.9	12.21	0.51	1.44e-29	Exhaled nitric oxide output;
LUAD	cis	rs72928364	1.000	rs4060963	chr3:100624561	A/G	cg10123952	chr3:100791384	NA	-0.55	-6.83	-0.32	3.01e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg00933542	chr6:150070202	PCMT1	0.43	8.89	0.4	1.8e-17	Lung cancer;
LUAD	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.59	0.42	7.83e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg00316803	chr15:76480434	C15orf27	0.38	6.44	0.3	3.16e-10	Blood metabolite levels;
LUAD	trans	rs7395662	0.864	rs11039917	chr11:48695428	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	1.98e-12	HDL cholesterol;
LUAD	cis	rs7072216	0.763	rs3750601	chr10:100174561	C/A	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.7	-0.39	7.57e-17	Metabolite levels;
LUAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.7	-0.35	9.93e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs961253	0.522	rs6085496	chr20:6315656	C/T	cg21095983	chr6:86352623	SYNCRIP	0.43	6.65	0.31	8.97e-11	Colorectal cancer;
LUAD	cis	rs10242455	0.702	rs73405247	chr7:99159174	C/G	cg18809830	chr7:99032528	PTCD1	-1.04	-7.8	-0.35	4.81e-14	Blood metabolite levels;
LUAD	cis	rs9902453	0.817	rs2628170	chr17:28056612	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-9.9	-0.43	6.6e-21	Coffee consumption (cups per day);
LUAD	trans	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04565464	chr8:145669602	NFKBIL2	0.46	6.81	0.31	3.41e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18864164	chr10:115934049	MIR2110;C10orf118	0.4	6.35	0.3	5.55e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg09365446	chr1:150670422	GOLPH3L	0.58	10.26	0.45	3.31e-22	Melanoma;
LUAD	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg21028142	chr17:79581711	NPLOC4	0.43	8.85	0.4	2.48e-17	Eye color traits;
LUAD	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg09904177	chr6:26538194	HMGN4	0.43	7.21	0.33	2.51e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg15691649	chr6:25882328	NA	0.46	7.52	0.34	3.25e-13	Blood metabolite levels;
LUAD	cis	rs4414128	0.832	rs4601655	chr10:5680738	A/G	cg12223502	chr10:5658492	NA	0.44	6.86	0.32	2.41e-11	Breast cancer;
LUAD	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.33	7.11	0.33	5e-12	Cardiac Troponin-T levels;
LUAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg05457628	chr5:178986728	RUFY1	0.67	11.77	0.5	7.13e-28	Lung cancer;
LUAD	trans	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg06606381	chr12:133084897	FBRSL1	-0.8	-6.73	-0.31	5.41e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.32e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg08888203	chr3:10149979	C3orf24	0.69	11.79	0.5	6.15e-28	Alzheimer's disease;
LUAD	trans	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg26043149	chr18:55253948	FECH	-0.42	-6.71	-0.31	6.46e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg09184832	chr6:79620586	NA	-0.39	-6.52	-0.3	2.04e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs10504073	0.647	rs62507246	chr8:50013449	G/A	cg00325661	chr8:49890786	NA	0.44	9.99	0.44	3.13e-21	Blood metabolite ratios;
LUAD	cis	rs7043114	0.525	rs10283572	chr9:95133074	G/A	cg14631576	chr9:95140430	CENPP	-0.4	-8.14	-0.37	4.55e-15	Height;
LUAD	cis	rs11048434	0.736	rs1049925	chr12:9086898	A/G	cg04155231	chr12:9217510	LOC144571	0.4	7.43	0.34	6.04e-13	Sjögren's syndrome;
LUAD	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg20203395	chr5:56204925	C5orf35	-0.43	-6.6	-0.31	1.23e-10	Coronary artery disease;
LUAD	trans	rs4650994	0.593	rs12096732	chr1:178523164	C/T	cg05059571	chr16:84539110	KIAA1609	0.41	6.43	0.3	3.38e-10	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg25985355	chr7:65971099	NA	-0.53	-6.58	-0.3	1.41e-10	Diabetic kidney disease;
LUAD	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg16647868	chr5:131706066	SLC22A5	0.4	6.91	0.32	1.79e-11	Blood metabolite levels;
LUAD	cis	rs10788264	0.716	rs7091348	chr10:124016160	C/T	cg09507567	chr10:124027408	NA	0.49	10.81	0.47	3.26e-24	Total body bone mineral density;
LUAD	cis	rs12801636	0.512	rs2075660	chr11:65414709	C/A	cg16535667	chr11:65410126	SIPA1	-0.48	-6.81	-0.31	3.37e-11	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs7527798	0.637	rs7515149	chr1:207838352	T/G	cg09232269	chr1:207846808	CR1L	-0.37	-7.19	-0.33	2.93e-12	Erythrocyte sedimentation rate;
LUAD	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg18721089	chr20:30220636	NA	-0.48	-6.91	-0.32	1.82e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.22	0.37	2.59e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.21e-16	Prostate cancer;
LUAD	cis	rs2731664	0.792	rs335432	chr5:176866258	G/A	cg23176889	chr5:176863531	GRK6	-0.74	-14.44	-0.57	1.05e-38	Intelligence (multi-trait analysis);
LUAD	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg23301539	chr8:142222248	SLC45A4	-0.47	-8.6	-0.39	1.62e-16	Immature fraction of reticulocytes;
LUAD	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.7	13.16	0.54	2.06e-33	Axial length;
LUAD	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.53	0.52	7.54e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4906332	1.000	rs35771849	chr14:103981942	A/G	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.0	-0.32	9.96e-12	Coronary artery disease;
LUAD	trans	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.42e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17712092	chr4:129076599	LARP1B	-0.85	-16.43	-0.62	2.83e-47	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg16325326	chr1:53192061	ZYG11B	0.65	12.77	0.53	8.43e-32	Monocyte count;
LUAD	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg01657329	chr11:68192670	LRP5	-0.55	-9.77	-0.43	1.81e-20	Total body bone mineral density;
LUAD	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.69	0.31	6.95e-11	Depression;
LUAD	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06022373	chr22:39101656	GTPBP1	0.39	6.63	0.31	1.04e-10	Menopause (age at onset);
LUAD	trans	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-8.89	-0.4	1.84e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg17911788	chr17:44343683	NA	-0.51	-7.21	-0.33	2.58e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10489202	0.954	rs12403023	chr1:168086999	A/G	cg24449463	chr1:168025552	DCAF6	-0.57	-7.68	-0.35	1.15e-13	Schizophrenia;
LUAD	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg19336497	chr11:14380999	RRAS2	0.65	14.0	0.56	7.43e-37	Sense of smell;
LUAD	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg17366294	chr4:99064904	C4orf37	0.53	9.77	0.43	1.77e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg21475434	chr5:93447410	FAM172A	-0.5	-6.83	-0.32	2.93e-11	Diabetic retinopathy;
LUAD	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg21204522	chr6:27730016	NA	-0.47	-7.53	-0.34	3.07e-13	Parkinson's disease;
LUAD	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg02269571	chr22:50332266	NA	0.59	8.91	0.4	1.49e-17	Schizophrenia;
LUAD	cis	rs16958440	0.867	rs28587821	chr18:44687906	G/A	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-6.94	-0.32	1.49e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg17860381	chr5:142783569	NR3C1	-0.39	-6.81	-0.31	3.33e-11	Schizophrenia;
LUAD	cis	rs1032833	0.732	rs17454164	chr2:179995839	T/G	cg23883738	chr2:179974586	SESTD1	-0.7	-7.73	-0.35	8.12e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg13047869	chr3:10149882	C3orf24	0.66	11.09	0.47	2.88e-25	Alzheimer's disease;
LUAD	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg08514558	chr10:81106712	PPIF	0.49	9.35	0.41	4.99e-19	Height;
LUAD	cis	rs7010267	0.681	rs7842942	chr8:120008587	T/C	cg01975934	chr8:119970761	NA	-0.37	-7.02	-0.32	9.01e-12	Total body bone mineral density (age 45-60);
LUAD	cis	rs4372836	0.658	rs56178008	chr2:29098543	T/A	cg09522027	chr2:28974177	PPP1CB	0.65	11.39	0.48	2.05e-26	Body mass index;
LUAD	cis	rs62238980	0.614	rs74534759	chr22:32383419	T/G	cg02631450	chr22:32366979	NA	0.81	6.56	0.3	1.61e-10	Childhood ear infection;
LUAD	cis	rs6960043	0.818	rs10244051	chr7:15063833	T/G	cg19272540	chr7:15055459	NA	-0.36	-7.86	-0.36	3.22e-14	Type 2 diabetes;
LUAD	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg21775007	chr8:11205619	TDH	-0.38	-6.56	-0.3	1.56e-10	Triglycerides;
LUAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg10150615	chr22:24372951	LOC391322	-0.49	-8.12	-0.37	5.32e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4253772	0.626	rs12169526	chr22:46763846	C/T	cg09491104	chr22:46646882	C22orf40	-0.55	-6.7	-0.31	6.63e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7843479	1.000	rs67385415	chr8:21853733	T/C	cg03445287	chr8:21823731	XPO7	-0.45	-8.27	-0.37	1.79e-15	Mean corpuscular volume;
LUAD	cis	rs9300255	0.722	rs11830103	chr12:123823546	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.39	6.83	0.32	2.87e-11	Neutrophil percentage of white cells;
LUAD	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.6	-0.39	1.62e-16	Alzheimer's disease (late onset);
LUAD	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg18252515	chr7:66147081	NA	-0.62	-6.91	-0.32	1.84e-11	Diabetic kidney disease;
LUAD	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg03714773	chr7:91764589	CYP51A1	0.27	6.49	0.3	2.46e-10	Breast cancer;
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg12122041	chr4:3234814	HTT	0.4	6.47	0.3	2.78e-10	Hepatitis;
LUAD	cis	rs11671005	0.695	rs12972898	chr19:58956888	A/G	cg13877915	chr19:58951672	ZNF132	0.59	7.5	0.34	3.92e-13	Mean platelet volume;
LUAD	cis	rs7107174	1.000	rs10899460	chr11:78010080	A/G	cg19901956	chr11:77921274	USP35	-0.55	-6.8	-0.31	3.66e-11	Testicular germ cell tumor;
LUAD	cis	rs7737355	0.812	rs251015	chr5:131029683	A/G	cg25547332	chr5:131281432	NA	0.43	7.04	0.32	7.64e-12	Life satisfaction;
LUAD	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg17252645	chr8:143867129	LY6D	-0.35	-6.56	-0.3	1.54e-10	Urinary tract infection frequency;
LUAD	trans	rs79911532	0.515	rs112615204	chr7:75760909	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	8.66	0.39	1.01e-16	Mononucleosis;
LUAD	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.53	1.39e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg18252515	chr7:66147081	NA	-0.62	-6.68	-0.31	7.75e-11	Diabetic kidney disease;
LUAD	cis	rs6669072	0.703	rs3843306	chr1:91288130	A/T	cg08895590	chr1:91227319	NA	0.32	6.52	0.3	2e-10	Cognitive function;
LUAD	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00864171	chr11:67383662	NA	0.39	6.87	0.32	2.3e-11	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.39e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg02527881	chr3:46936655	PTH1R	0.44	8.37	0.38	8.72e-16	Colorectal cancer;
LUAD	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.8	-13.62	-0.55	2.88e-35	Chronic sinus infection;
LUAD	cis	rs4253772	0.530	rs11090875	chr22:46785301	C/T	cg00784671	chr22:46762841	CELSR1	-0.62	-7.34	-0.34	1.14e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg16205897	chr5:131564050	P4HA2	-0.42	-9.58	-0.42	8.6e-20	Blood metabolite levels;
LUAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg10411590	chr13:21900810	NA	0.45	7.04	0.32	7.83e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs8099014	1.000	rs7234602	chr18:56111593	G/T	cg12907477	chr18:56117327	MIR122	0.39	6.71	0.31	6.24e-11	Platelet count;
LUAD	cis	rs9341808	0.667	rs7745301	chr6:80922561	G/T	cg08355045	chr6:80787529	NA	0.48	8.62	0.39	1.35e-16	Sitting height ratio;
LUAD	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg26769984	chr7:1090371	C7orf50	0.59	9.61	0.42	6.56e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.09	-0.33	5.65e-12	Lung cancer;
LUAD	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24308560	chr3:49941425	MST1R	0.55	9.37	0.41	4.35e-19	Body mass index;
LUAD	trans	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg06606381	chr12:133084897	FBRSL1	-0.55	-7.35	-0.34	1.02e-12	Depression;
LUAD	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-11.37	-0.48	2.5e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9399401	0.626	rs1928528	chr6:142779109	T/G	cg04461802	chr6:142623433	GPR126	0.39	7.11	0.33	4.83e-12	Chronic obstructive pulmonary disease;
LUAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.6	0.31	1.26e-10	Prudent dietary pattern;
LUAD	cis	rs10193935	0.901	rs2286701	chr2:42555636	T/C	cg27598129	chr2:42591480	NA	-0.8	-10.31	-0.45	2.26e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg05340658	chr4:99064831	C4orf37	0.54	9.14	0.41	2.7e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg22482690	chr17:47019901	SNF8	0.46	8.98	0.4	9.25e-18	Type 2 diabetes;
LUAD	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg25894440	chr7:65020034	NA	0.64	6.92	0.32	1.65e-11	Diabetic kidney disease;
LUAD	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg07570687	chr10:102243282	WNT8B	0.45	7.01	0.32	9.3e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9341808	0.718	rs2322630	chr6:80841033	A/G	cg08355045	chr6:80787529	NA	0.56	10.08	0.44	1.52e-21	Sitting height ratio;
LUAD	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg06092702	chr1:163392909	NA	0.41	8.79	0.39	3.87e-17	Motion sickness;
LUAD	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg07538946	chr5:131705188	SLC22A5	0.49	7.97	0.36	1.45e-14	Breast cancer;Mosquito bite size;
LUAD	cis	rs7737355	0.947	rs6596029	chr5:130899079	T/C	cg06307176	chr5:131281290	NA	0.52	8.17	0.37	3.49e-15	Life satisfaction;
LUAD	cis	rs116248771	0.739	rs12185969	chr3:158360880	C/T	cg16708174	chr3:158430962	RARRES1	0.47	6.82	0.31	3.18e-11	diarrhoeal disease at age 2;
LUAD	cis	rs4285028	0.747	rs7647351	chr3:121422109	T/C	cg11130432	chr3:121712080	ILDR1	-0.47	-6.82	-0.31	3.11e-11	Multiple sclerosis;
LUAD	cis	rs4148087	0.860	rs9980310	chr21:43607858	C/T	cg08841829	chr21:43638893	ABCG1	-0.55	-7.25	-0.33	1.98e-12	Eating disorder in bipolar disorder;
LUAD	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg15605315	chr1:45957053	TESK2	0.47	7.38	0.34	8.5e-13	High light scatter reticulocyte count;
LUAD	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg13010199	chr12:38710504	ALG10B	0.38	6.48	0.3	2.6e-10	Bladder cancer;
LUAD	cis	rs9788721	0.836	rs17484524	chr15:78772676	A/G	cg18825076	chr15:78729989	IREB2	-0.59	-9.79	-0.43	1.6e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg14343924	chr8:8086146	FLJ10661	-0.44	-7.14	-0.33	4.1e-12	Neuroticism;
LUAD	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03264133	chr6:25882463	NA	-0.5	-7.52	-0.34	3.28e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs10089	0.953	rs6887674	chr5:127531183	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	8.95	0.4	1.11e-17	Ileal carcinoids;
LUAD	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.09	-0.4	3.9e-18	Total body bone mineral density;
LUAD	cis	rs6906287	0.647	rs11153752	chr6:118834771	A/T	cg18833306	chr6:118973337	C6orf204	0.47	8.43	0.38	5.36e-16	Electrocardiographic conduction measures;
LUAD	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-8.0	-0.36	1.2e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2046867	0.908	rs67967166	chr3:72794198	A/G	cg04365224	chr3:72788183	NA	-0.43	-6.73	-0.31	5.42e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11971779	0.715	rs6954219	chr7:139065110	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.76	0.31	4.63e-11	Diisocyanate-induced asthma;
LUAD	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg03477792	chr4:77819574	ANKRD56	0.49	7.55	0.34	2.64e-13	Emphysema distribution in smoking;
LUAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg18621852	chr3:10150065	C3orf24	0.42	6.68	0.31	7.33e-11	Alzheimer's disease;
LUAD	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg10518543	chr12:38710700	ALG10B	-0.5	-8.32	-0.38	1.22e-15	Morning vs. evening chronotype;
LUAD	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg17063962	chr7:91808500	NA	-0.68	-12.36	-0.52	3.59e-30	Breast cancer;
LUAD	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg14092988	chr3:52407081	DNAH1	0.45	9.0	0.4	7.89e-18	Bipolar disorder;
LUAD	cis	rs116248771	0.739	rs2291595	chr3:158378847	A/G	cg16708174	chr3:158430962	RARRES1	0.47	6.83	0.32	3.03e-11	diarrhoeal disease at age 2;
LUAD	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg22875332	chr1:76189707	ACADM	-0.68	-10.76	-0.46	4.79e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg09835421	chr16:68378352	PRMT7	-0.81	-8.75	-0.39	5.07e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6500395	0.963	rs2883642	chr16:48685146	C/T	cg04672837	chr16:48644449	N4BP1	-0.39	-6.81	-0.31	3.4e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6684514	1.000	rs12038217	chr1:156248297	C/T	cg16558208	chr1:156270281	VHLL	0.53	9.52	0.42	1.36e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.98	0.32	1.18e-11	Colorectal cancer;
LUAD	cis	rs17401966	0.838	rs61775887	chr1:10284733	T/C	cg15208524	chr1:10270712	KIF1B	0.43	6.54	0.3	1.75e-10	Hepatocellular carcinoma;
LUAD	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26314531	chr2:26401878	FAM59B	-0.55	-7.71	-0.35	9.38e-14	Gut microbiome composition (summer);
LUAD	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg20607287	chr7:12443886	VWDE	-0.53	-6.73	-0.31	5.58e-11	Coronary artery disease;
LUAD	cis	rs11078597	0.731	rs2070863	chr17:1648502	C/T	cg18436246	chr17:1640651	WDR81	0.8	12.56	0.52	5.6e-31	Serum albumin level;
LUAD	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg18404041	chr3:52824283	ITIH1	0.4	7.3	0.33	1.46e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg20607798	chr8:58055168	NA	0.72	9.44	0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg05865280	chr17:75406074	SEPT9	0.61	19.29	0.68	5.77e-60	Airflow obstruction;
LUAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg02869364	chr7:1081709	C7orf50	-0.35	-6.61	-0.31	1.17e-10	Longevity;Endometriosis;
LUAD	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg02049041	chr17:27085579	C17orf63	0.65	8.54	0.38	2.41e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg10589385	chr1:150898437	SETDB1	0.45	8.44	0.38	5.11e-16	Melanoma;
LUAD	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24308560	chr3:49941425	MST1R	-0.57	-9.44	-0.42	2.51e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22331096	chr8:128749328	MYC	-0.54	-6.41	-0.3	3.81e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg15557168	chr22:42548783	NA	0.51	9.41	0.42	3.33e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10911363	0.592	rs10911354	chr1:183489278	G/A	cg09173681	chr1:183549694	NCF2	0.55	10.19	0.44	6.02e-22	Systemic lupus erythematosus;
LUAD	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg06784218	chr1:46089804	CCDC17	0.6	13.37	0.55	2.89e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg09065629	chr16:1709722	CRAMP1L	0.41	7.16	0.33	3.54e-12	Coronary artery disease;
LUAD	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	7.08	0.33	5.97e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg17173187	chr15:85201210	NMB	0.5	8.7	0.39	7.52e-17	Schizophrenia;
LUAD	cis	rs7923452	0.938	rs34560372	chr10:30773831	G/A	cg18806716	chr10:30721971	MAP3K8	0.57	7.87	0.36	2.91e-14	Itch intensity from mosquito bite;
LUAD	cis	rs9644630	0.841	rs6984449	chr8:19327959	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.32	-7.9	-0.36	2.51e-14	Oropharynx cancer;
LUAD	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg01416388	chr22:39784598	NA	0.53	8.39	0.38	7.23e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg00071950	chr4:10020882	SLC2A9	-0.74	-14.76	-0.58	4.49e-40	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg15744005	chr10:104629667	AS3MT	-0.33	-6.59	-0.31	1.3e-10	Arsenic metabolism;
LUAD	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	6.76	0.31	4.6e-11	Mood instability;
LUAD	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.03	-0.36	9.69e-15	Diabetic kidney disease;
LUAD	cis	rs6489882	0.902	rs757405	chr12:113406945	T/A	cg20102336	chr12:113376681	OAS3	-0.48	-6.97	-0.32	1.26e-11	Chronic lymphocytic leukemia;
LUAD	trans	rs11671005	0.504	rs3794964	chr19:59070916	T/C	cg22037779	chr5:139682734	PFDN1	-0.66	-10.46	-0.45	6.19e-23	Mean platelet volume;
LUAD	cis	rs4629710	0.617	rs28360555	chr6:131538952	C/A	cg12606694	chr6:131520996	AKAP7	0.47	6.95	0.32	1.42e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs7000551	0.725	rs1075534	chr8:22374074	A/G	cg12081754	chr8:22256438	SLC39A14	0.39	6.49	0.3	2.41e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.46	0.52	1.4e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg16606324	chr3:10149918	C3orf24	0.61	9.96	0.44	3.77e-21	Alzheimer's disease;
LUAD	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg15704280	chr7:45808275	SEPT13	0.74	10.8	0.46	3.66e-24	Coronary artery disease;
LUAD	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg13319975	chr6:146136371	FBXO30	0.67	11.57	0.49	4.41e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg12599982	chr1:44399894	ARTN	-0.35	-7.0	-0.32	1.04e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg25358565	chr5:93447407	FAM172A	0.66	7.75	0.35	6.74e-14	Diabetic retinopathy;
LUAD	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg24675056	chr1:15929824	NA	0.49	8.48	0.38	3.92e-16	Systolic blood pressure;
LUAD	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg15128208	chr22:42549153	NA	0.42	6.73	0.31	5.37e-11	Birth weight;
LUAD	cis	rs7119	0.671	rs10152850	chr15:77904426	G/A	cg27398640	chr15:77910606	LINGO1	0.4	7.53	0.34	3.18e-13	Type 2 diabetes;
LUAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10150615	chr22:24372951	LOC391322	0.57	9.41	0.42	3.12e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs870825	0.929	rs72689265	chr4:185590982	A/G	cg04058563	chr4:185651563	MLF1IP	0.74	9.52	0.42	1.37e-19	Blood protein levels;
LUAD	cis	rs1595825	0.891	rs73054819	chr2:198625744	G/T	cg10547527	chr2:198650123	BOLL	-0.57	-8.09	-0.37	6.29e-15	Ulcerative colitis;
LUAD	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg07741184	chr6:167504864	NA	0.31	7.42	0.34	6.31e-13	Crohn's disease;
LUAD	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg02390115	chr1:21767211	NBPF3	0.41	6.84	0.32	2.7e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg12311346	chr5:56204834	C5orf35	0.9	13.62	0.55	2.78e-35	Initial pursuit acceleration;
LUAD	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.17	-0.48	1.5e-25	Type 2 diabetes;
LUAD	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.66	-0.43	4.48e-20	Schizophrenia;
LUAD	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg22705602	chr4:152727874	NA	-0.4	-7.07	-0.33	6.3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg27426351	chr10:43362370	NA	0.52	8.36	0.38	9.33e-16	Blood protein levels;
LUAD	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg19700328	chr14:106028568	NA	-0.51	-8.41	-0.38	6.13e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs2637266	1.000	rs7098929	chr10:78361194	T/G	cg18941641	chr10:78392320	NA	0.33	6.84	0.32	2.74e-11	Pulmonary function;
LUAD	cis	rs9972944	0.902	rs9972947	chr17:63771088	G/A	cg07283582	chr17:63770753	CCDC46	0.53	11.91	0.5	2.08e-28	Total body bone mineral density;
LUAD	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg18761221	chr20:60518478	NA	0.37	6.63	0.31	1.03e-10	Body mass index;
LUAD	trans	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg06606381	chr12:133084897	FBRSL1	-0.95	-8.28	-0.37	1.68e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg03467027	chr4:99064603	C4orf37	-0.43	-7.12	-0.33	4.64e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg08859206	chr1:53392774	SCP2	0.59	10.6	0.46	1.98e-23	Monocyte count;
LUAD	cis	rs35883536	0.647	rs34195036	chr1:101040429	C/A	cg06223162	chr1:101003688	GPR88	-0.44	-8.48	-0.38	3.9e-16	Monocyte count;
LUAD	cis	rs35771425	0.619	rs7538812	chr1:211442186	A/G	cg26515805	chr1:211431828	RCOR3	-0.44	-8.6	-0.39	1.58e-16	Educational attainment (years of education);
LUAD	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg02269571	chr22:50332266	NA	-0.68	-9.9	-0.43	6.32e-21	Schizophrenia;
LUAD	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg14530993	chr4:882597	GAK	0.69	6.46	0.3	2.8e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg26384229	chr12:38710491	ALG10B	0.46	7.44	0.34	5.51e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs559928	0.553	rs4930168	chr11:64173058	A/G	cg05555928	chr11:63887634	MACROD1	-0.48	-8.02	-0.36	1.04e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUAD	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg06221963	chr1:154839813	KCNN3	-0.84	-19.43	-0.69	1.4e-60	Prostate cancer;
LUAD	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg09222892	chr1:25734099	RHCE	0.5	9.21	0.41	1.53e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg15017067	chr4:17643749	FAM184B	0.35	6.81	0.31	3.38e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs11039798	0.920	rs11040013	chr11:48782862	G/A	cg03929089	chr4:120376271	NA	0.57	6.43	0.3	3.5e-10	Axial length;
LUAD	cis	rs2235642	0.533	rs9922661	chr16:1605163	C/A	cg03034668	chr16:1723424	CRAMP1L	-0.54	-8.47	-0.38	4.21e-16	Coronary artery disease;
LUAD	cis	rs727505	0.721	rs56069273	chr7:124768604	G/A	cg23710748	chr7:124431027	NA	-0.36	-7.54	-0.34	2.87e-13	Lewy body disease;
LUAD	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	trans	rs6711606	0.697	rs17020684	chr2:101904107	C/T	cg08201736	chr15:79298769	RASGRF1	0.4	6.51	0.3	2.08e-10	Pancreatic cancer;
LUAD	cis	rs11958404	0.932	rs61478293	chr5:157426299	G/A	cg05962755	chr5:157440814	NA	0.5	7.73	0.35	8.04e-14	IgG glycosylation;
LUAD	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg24558204	chr6:135376177	HBS1L	-0.46	-7.63	-0.35	1.62e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs68170813	0.652	rs116894096	chr7:107178477	G/A	cg23024343	chr7:107201750	COG5	0.52	6.61	0.31	1.15e-10	Coronary artery disease;
LUAD	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg07169764	chr2:136633963	MCM6	0.79	9.33	0.41	5.91e-19	Corneal structure;
LUAD	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg00383909	chr3:49044727	WDR6	0.92	8.67	0.39	9.07e-17	Blood protein levels;
LUAD	cis	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg27411982	chr8:10470053	RP1L1	-0.37	-6.58	-0.3	1.41e-10	Retinal vascular caliber;
LUAD	cis	rs12681288	0.550	rs73176529	chr8:962283	G/C	cg15309053	chr8:964076	NA	0.5	11.31	0.48	4.22e-26	Schizophrenia;
LUAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.57	-10.12	-0.44	1.05e-21	Lymphocyte counts;
LUAD	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg03713592	chr11:72463424	ARAP1	0.6	7.68	0.35	1.13e-13	Type 2 diabetes;
LUAD	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg21951975	chr1:209979733	IRF6	0.52	6.49	0.3	2.44e-10	Coronary artery disease;
LUAD	cis	rs754466	0.580	rs10762765	chr10:79566407	T/C	cg17075019	chr10:79541650	NA	-0.88	-18.68	-0.67	3.27e-57	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg25985355	chr7:65971099	NA	0.39	7.1	0.33	5.3e-12	Aortic root size;
LUAD	cis	rs758324	0.947	rs600661	chr5:131290894	T/C	cg06307176	chr5:131281290	NA	-0.5	-7.83	-0.36	3.87e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6969780	0.915	rs3801320	chr7:27164364	C/A	cg05579037	chr7:27184853	NA	-0.46	-6.65	-0.31	8.84e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg16031515	chr1:205743344	RAB7L1	-0.38	-7.47	-0.34	4.72e-13	Menarche (age at onset);
LUAD	cis	rs295137	0.798	rs295142	chr2:201211716	C/T	cg23649088	chr2:200775458	C2orf69	-0.43	-7.18	-0.33	3.06e-12	Asthma (bronchodilator response);
LUAD	cis	rs6750795	0.569	rs1667308	chr2:232406344	T/C	cg19187155	chr2:232395269	NMUR1	0.48	8.84	0.39	2.61e-17	Height;
LUAD	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23583168	chr7:148888333	NA	-0.93	-19.3	-0.68	5.33e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg05234568	chr11:5960015	NA	-0.52	-9.15	-0.41	2.42e-18	DNA methylation (variation);
LUAD	cis	rs7120118	0.517	rs2290149	chr11:47345916	T/C	cg13308137	chr11:47528955	CUGBP1	0.41	7.21	0.33	2.53e-12	HDL cholesterol;
LUAD	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg11871910	chr12:69753446	YEATS4	0.7	11.96	0.5	1.39e-28	Blood protein levels;
LUAD	cis	rs7536201	0.846	rs6600250	chr1:25305172	C/T	cg23273869	chr1:25296894	NA	-0.37	-7.48	-0.34	4.43e-13	Psoriasis vulgaris;
LUAD	cis	rs1941023	0.503	rs12798266	chr11:60118851	G/A	cg08716584	chr11:60157161	MS4A7	-0.46	-8.96	-0.4	1.07e-17	Congenital heart disease (maternal effect);
LUAD	cis	rs113835537	0.529	rs7950407	chr11:66258006	A/G	cg24851651	chr11:66362959	CCS	0.54	9.69	0.43	3.61e-20	Airway imaging phenotypes;
LUAD	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg09367891	chr1:107599246	PRMT6	0.54	9.0	0.4	7.92e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg01874867	chr7:94954059	PON1	-0.48	-6.48	-0.3	2.49e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg15117754	chr3:10150083	C3orf24	0.4	6.53	0.3	1.85e-10	Alzheimer's disease;
LUAD	cis	rs981844	0.714	rs2405202	chr4:154705132	A/G	cg10279832	chr4:154682576	RNF175	0.34	7.06	0.32	6.74e-12	Response to statins (LDL cholesterol change);
LUAD	cis	rs7084921	0.608	rs11596883	chr10:101861622	T/C	cg19754520	chr10:101825118	CPN1	-0.33	-6.48	-0.3	2.5e-10	Bone mineral density;
LUAD	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-15.6	-0.6	1.11e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg19717773	chr7:2847554	GNA12	0.5	9.31	0.41	6.94e-19	Plateletcrit;
LUAD	cis	rs11971779	0.680	rs10085902	chr7:139109105	G/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.38e-10	Diisocyanate-induced asthma;
LUAD	cis	rs56283067	0.847	rs2128543	chr6:44685552	G/A	cg18551225	chr6:44695536	NA	-0.6	-10.0	-0.44	2.72e-21	Total body bone mineral density;
LUAD	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg12011299	chr4:100065546	ADH4	0.72	13.64	0.55	2.31e-35	Alcohol dependence;
LUAD	trans	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg01620082	chr3:125678407	NA	-0.46	-7.02	-0.32	8.71e-12	Parkinson's disease;
LUAD	cis	rs151234	0.676	rs554206	chr16:28576369	G/A	cg04609801	chr16:28609176	SULT1A2	0.62	9.03	0.4	6.14e-18	Platelet distribution width;
LUAD	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg07741184	chr6:167504864	NA	0.29	7.03	0.32	8.43e-12	Crohn's disease;
LUAD	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg15691649	chr6:25882328	NA	-0.44	-7.05	-0.32	7.32e-12	Blood metabolite levels;
LUAD	cis	rs2735413	0.881	rs12923218	chr16:78080274	C/G	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg04414720	chr1:150670196	GOLPH3L	0.73	13.42	0.55	1.78e-34	Tonsillectomy;
LUAD	cis	rs2882667	0.898	rs12719519	chr5:138375687	G/A	cg04439458	chr5:138467593	SIL1	-0.4	-7.26	-0.33	1.91e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.64	-11.44	-0.49	1.36e-26	Urate levels in overweight individuals;
LUAD	cis	rs67072384	1.000	rs67809272	chr11:72450941	T/A	cg04827223	chr11:72435913	ARAP1	-0.63	-7.29	-0.33	1.54e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg22014379	chr2:113192561	RGPD8;RGPD5	0.51	6.37	0.3	4.9e-10	Yeast infection;
LUAD	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg19980929	chr12:42632907	YAF2	-0.34	-6.56	-0.3	1.58e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs4372836	0.729	rs4132617	chr2:29031312	C/A	cg09522027	chr2:28974177	PPP1CB	-0.67	-12.04	-0.51	6.48e-29	Body mass index;
LUAD	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg01444801	chr10:135216882	MTG1	-0.52	-6.92	-0.32	1.71e-11	Systemic lupus erythematosus;
LUAD	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg20891558	chr2:74357851	NA	1.01	15.59	0.6	1.24e-43	Gestational age at birth (maternal effect);
LUAD	cis	rs12900413	0.687	rs28650972	chr15:90311941	C/T	cg24249390	chr15:90295951	MESP1	-0.33	-6.58	-0.3	1.44e-10	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg21385522	chr1:16154831	NA	-0.69	-10.86	-0.47	2.13e-24	Dilated cardiomyopathy;
LUAD	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	10.55	0.46	2.89e-23	Blood metabolite levels;
LUAD	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg01312482	chr5:178451176	ZNF879	-0.46	-7.03	-0.32	8.48e-12	Pubertal anthropometrics;
LUAD	cis	rs28595532	1.000	rs28600971	chr4:119712728	G/T	cg21605333	chr4:119757512	SEC24D	0.87	8.24	0.37	2.2e-15	Cannabis dependence symptom count;
LUAD	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.36	-7.15	-0.33	3.85e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg02993280	chr1:107599747	PRMT6	0.46	7.56	0.34	2.56e-13	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg04851639	chr8:1020857	NA	-0.4	-9.75	-0.43	2.08e-20	Schizophrenia;
LUAD	cis	rs231513	0.954	rs231498	chr17:41975251	C/G	cg26893861	chr17:41843967	DUSP3	-0.55	-6.65	-0.31	9.21e-11	Cognitive function;
LUAD	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg01579765	chr21:45077557	HSF2BP	-0.58	-13.67	-0.55	1.79e-35	Mean corpuscular volume;
LUAD	cis	rs11650494	1.000	rs11650494	chr17:47345186	G/A	cg08112188	chr17:47440006	ZNF652	0.71	6.44	0.3	3.3e-10	Prostate cancer;
LUAD	cis	rs1348850	0.526	rs10930802	chr2:178460095	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-6.53	-0.3	1.92e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg07617317	chr6:118971624	C6orf204	0.55	8.24	0.37	2.23e-15	Diastolic blood pressure;
LUAD	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg04800585	chr6:26043546	HIST1H2BB	0.37	6.64	0.31	9.84e-11	Blood metabolite levels;
LUAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg11062466	chr8:58055876	NA	0.65	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs12545109	0.800	rs2670028	chr8:57423673	G/A	cg17761419	chr8:57350749	NA	-0.51	-7.54	-0.34	2.82e-13	Obesity-related traits;
LUAD	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg17063962	chr7:91808500	NA	0.7	12.76	0.53	8.9e-32	Breast cancer;
LUAD	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	12.12	0.51	3.09e-29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg15181151	chr6:150070149	PCMT1	0.42	8.61	0.39	1.48e-16	Lung cancer;
LUAD	cis	rs7575217	0.670	rs2592392	chr2:101723343	A/G	cg23907051	chr2:101730305	TBC1D8	0.27	6.55	0.3	1.63e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg05313129	chr8:58192883	C8orf71	0.55	7.14	0.33	4.06e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg02569458	chr12:86230093	RASSF9	0.41	7.69	0.35	1.05e-13	Major depressive disorder;
LUAD	cis	rs57994353	0.598	rs72775768	chr9:139324574	C/T	cg14019695	chr9:139328340	INPP5E	0.42	7.33	0.34	1.16e-12	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06112835	chr11:68658793	MRPL21	0.52	9.26	0.41	1.04e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg07234876	chr8:600039	NA	1.03	10.51	0.46	4.12e-23	IgG glycosylation;
LUAD	cis	rs28595532	0.841	rs115233595	chr4:119744214	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs1788820	0.917	rs1624695	chr18:21142992	A/T	cg14672496	chr18:21087552	C18orf8	0.36	6.91	0.32	1.81e-11	Body mass index;
LUAD	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg21775007	chr8:11205619	TDH	-0.37	-6.56	-0.3	1.56e-10	Neuroticism;
LUAD	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg02998240	chr1:16508668	NA	-0.23	-6.91	-0.32	1.81e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg03959625	chr15:84868606	LOC388152	0.42	6.61	0.31	1.19e-10	Schizophrenia;
LUAD	trans	rs2735413	0.846	rs12923290	chr16:78079956	A/G	cg01028844	chr5:122736986	CEP120	0.41	6.52	0.3	2.07e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs2797685	1.000	rs1689904	chr1:7890801	C/T	cg04725166	chr1:7887271	PER3	-0.48	-7.09	-0.33	5.75e-12	Crohn's disease;
LUAD	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	7.47	0.34	4.65e-13	Tonsillectomy;
LUAD	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg02569458	chr12:86230093	RASSF9	-0.41	-7.6	-0.35	1.95e-13	Major depressive disorder;
LUAD	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg17063962	chr7:91808500	NA	0.67	11.15	0.48	1.73e-25	Breast cancer;
LUAD	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg10518543	chr12:38710700	ALG10B	0.48	8.1	0.37	5.78e-15	Morning vs. evening chronotype;
LUAD	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg16989719	chr2:238392110	NA	0.34	6.94	0.32	1.47e-11	Prostate cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14569778	chr17:28952111	LRRC37B2	0.46	6.38	0.3	4.68e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18876405	chr7:65276391	NA	0.41	6.47	0.3	2.68e-10	Aortic root size;
LUAD	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg16374910	chr1:201084995	NA	-0.35	-6.7	-0.31	6.71e-11	Permanent tooth development;
LUAD	cis	rs7178572	0.568	rs12905951	chr15:77649431	G/A	cg15453836	chr15:77711506	NA	-0.37	-6.53	-0.3	1.92e-10	Type 2 diabetes;
LUAD	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg24813613	chr7:1882135	MAD1L1	-0.4	-6.38	-0.3	4.6e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs1696756	0.816	rs2650242	chr17:77827360	A/T	cg00646381	chr17:77835854	NA	0.47	7.62	0.35	1.71e-13	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg09365446	chr1:150670422	GOLPH3L	0.55	9.62	0.42	6.27e-20	Melanoma;
LUAD	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg26513180	chr16:89883248	FANCA	0.75	6.84	0.32	2.71e-11	Skin colour saturation;
LUAD	cis	rs13095912	0.785	rs6444076	chr3:185321405	T/C	cg11274856	chr3:185301563	NA	0.49	9.32	0.41	6.71e-19	Systolic blood pressure;
LUAD	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg21385522	chr1:16154831	NA	-1.08	-23.3	-0.75	7.18e-78	Dilated cardiomyopathy;
LUAD	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg15110403	chr19:17392923	ANKLE1	-0.46	-7.5	-0.34	3.91e-13	Systemic lupus erythematosus;
LUAD	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg12863693	chr15:85201151	NMB	0.41	7.67	0.35	1.21e-13	Schizophrenia;
LUAD	cis	rs7731657	0.537	rs6595983	chr5:130335755	A/G	cg08523029	chr5:130500466	HINT1	0.57	7.54	0.34	2.95e-13	Fasting plasma glucose;
LUAD	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-7.49	-0.34	4.01e-13	Tonsillectomy;
LUAD	cis	rs999943	0.810	rs62407648	chr6:33622436	C/G	cg14003231	chr6:33640908	ITPR3	0.94	19.41	0.69	1.72e-60	Obesity (extreme);
LUAD	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg06558623	chr16:89946397	TCF25	1.16	10.95	0.47	9.98e-25	Skin colour saturation;
LUAD	trans	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg04775059	chr7:64541387	NA	0.5	6.72	0.31	5.94e-11	Aortic root size;
LUAD	cis	rs847851	0.958	rs7753949	chr6:34882394	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-7.16	-0.33	3.62e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.66	-9.8	-0.43	1.43e-20	Platelet distribution width;
LUAD	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg08916839	chr5:415575	AHRR	0.87	9.97	0.44	3.74e-21	Fat distribution (HIV);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg12475106	chr4:503275	PIGG	-0.39	-6.35	-0.3	5.69e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg04036182	chr15:45458818	NA	-0.4	-6.84	-0.32	2.77e-11	Glomerular filtration rate;
LUAD	cis	rs7809950	0.678	rs982447	chr7:106973534	T/C	cg23024343	chr7:107201750	COG5	-0.81	-13.82	-0.56	3.97e-36	Coronary artery disease;
LUAD	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg04450456	chr4:17643702	FAM184B	-0.39	-7.34	-0.34	1.09e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4888262	0.526	rs6564145	chr16:74621129	G/A	cg01733217	chr16:74700730	RFWD3	0.51	8.57	0.38	1.95e-16	Testicular germ cell tumor;
LUAD	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18876405	chr7:65276391	NA	-0.45	-7.09	-0.33	5.5e-12	Aortic root size;
LUAD	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg25173405	chr17:45401733	C17orf57	-0.53	-9.09	-0.4	3.92e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.45	-7.5	-0.34	3.78e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs494562	0.730	rs9450270	chr6:86114766	A/G	cg21730993	chr6:86159210	NT5E	0.56	6.72	0.31	5.77e-11	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg04000281	chr11:63949212	NA	0.27	6.44	0.3	3.23e-10	Platelet count;
LUAD	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg14458575	chr2:238380390	NA	0.65	12.23	0.51	1.13e-29	Prostate cancer;
LUAD	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg02931644	chr1:25747376	RHCE	-0.41	-8.45	-0.38	4.78e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs6906287	0.573	rs12205899	chr6:118699928	C/G	cg05564266	chr6:118973597	C6orf204	0.33	7.06	0.32	6.9e-12	Electrocardiographic conduction measures;
LUAD	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg20673091	chr1:2541236	MMEL1	-0.4	-8.52	-0.38	2.81e-16	Ulcerative colitis;
LUAD	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg21171335	chr12:122356390	WDR66	0.69	12.02	0.5	7.55e-29	Mean corpuscular volume;
LUAD	cis	rs7617773	0.780	rs77044321	chr3:48349314	C/T	cg11946769	chr3:48343235	NME6	0.44	6.73	0.31	5.56e-11	Coronary artery disease;
LUAD	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg18138036	chr10:133769891	PPP2R2D	0.4	6.53	0.3	1.9e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg09796270	chr17:17721594	SREBF1	0.37	7.58	0.35	2.18e-13	Total body bone mineral density;
LUAD	cis	rs13082711	0.522	rs4973760	chr3:27349047	G/A	cg02860705	chr3:27208620	NA	0.5	8.29	0.37	1.49e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg18252515	chr7:66147081	NA	-0.61	-6.73	-0.31	5.63e-11	Diabetic kidney disease;
LUAD	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg06046430	chr4:77819534	ANKRD56	0.55	8.74	0.39	5.68e-17	Emphysema distribution in smoking;
LUAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-7.0	-0.32	1.01e-11	Longevity;Endometriosis;
LUAD	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg23950597	chr19:37808831	NA	-0.62	-7.68	-0.35	1.15e-13	Coronary artery calcification;
LUAD	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg06108461	chr20:60628389	TAF4	-0.75	-12.89	-0.53	2.66e-32	Body mass index;
LUAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg07217954	chr7:1067459	C7orf50	0.38	6.37	0.3	5.06e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg17863274	chr19:49399704	TULP2	-0.58	-9.09	-0.4	3.86e-18	Red cell distribution width;
LUAD	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg04025307	chr7:1156635	C7orf50	0.52	6.9	0.32	1.97e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs113835537	0.529	rs11227499	chr11:66272824	A/G	cg10315249	chr11:66235081	PELI3	0.31	6.35	0.3	5.5e-10	Airway imaging phenotypes;
LUAD	trans	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg19862616	chr7:65841803	NCRNA00174	1.06	27.08	0.8	1.99e-94	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.55	0.3	1.63e-10	Depression;
LUAD	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg08885076	chr2:99613938	TSGA10	-0.4	-7.25	-0.33	1.99e-12	Chronic sinus infection;
LUAD	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg09117114	chr16:67998030	SLC12A4	-0.48	-6.81	-0.31	3.33e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg02734326	chr4:10020555	SLC2A9	-0.51	-8.66	-0.39	1.04e-16	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1232027	0.622	rs1650659	chr5:79963537	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.15	-0.33	3.76e-12	Huntington's disease progression;
LUAD	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg18404041	chr3:52824283	ITIH1	-0.42	-7.82	-0.36	4.2e-14	Electroencephalogram traits;
LUAD	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg16647868	chr5:131706066	SLC22A5	0.5	7.99	0.36	1.25e-14	Breast cancer;
LUAD	cis	rs3821902	0.646	rs17344653	chr3:64015989	C/T	cg22134162	chr3:63841271	THOC7	-0.41	-6.76	-0.31	4.47e-11	Breast cancer;
LUAD	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg09998033	chr7:158218633	PTPRN2	-0.54	-9.89	-0.43	6.69e-21	Obesity-related traits;
LUAD	trans	rs877282	0.583	rs12358255	chr10:828626	C/T	cg22713356	chr15:30763199	NA	0.91	11.03	0.47	4.85e-25	Uric acid levels;
LUAD	cis	rs1032833	0.732	rs17363393	chr2:180006052	C/T	cg23883738	chr2:179974586	SESTD1	-0.62	-7.2	-0.33	2.75e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg13302166	chr17:8534048	MYH10	-0.67	-6.45	-0.3	3.03e-10	Type 2 diabetes;
LUAD	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg07917127	chr4:99064746	C4orf37	0.5	8.1	0.37	5.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg12756686	chr19:29218302	NA	0.53	6.85	0.32	2.57e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg08754654	chr5:154026448	NA	0.47	7.92	0.36	2.05e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.71e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs829883	0.934	rs249814	chr12:98892964	A/G	cg25150519	chr12:98850993	NA	0.67	11.08	0.47	3.26e-25	Colorectal adenoma (advanced);
LUAD	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06558623	chr16:89946397	TCF25	0.82	8.34	0.38	1.04e-15	Skin colour saturation;
LUAD	cis	rs11585357	0.671	rs2501776	chr1:17619279	C/T	cg08277548	chr1:17600880	PADI3	0.55	9.33	0.41	6e-19	Hair shape;
LUAD	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.14	0.33	4.2e-12	Parkinson's disease;
LUAD	cis	rs3087591	0.919	rs2018624	chr17:29560777	T/G	cg24425628	chr17:29625626	OMG;NF1	-0.39	-6.35	-0.3	5.43e-10	Hip circumference;
LUAD	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	7.45	0.34	5.15e-13	Platelet count;
LUAD	cis	rs1395	0.922	rs11693052	chr2:27484620	A/G	cg23587288	chr2:27483067	SLC30A3	-0.4	-8.15	-0.37	4.02e-15	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg04944784	chr2:26401820	FAM59B	-0.89	-12.57	-0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	trans	rs17685	0.925	rs1057868	chr7:75615006	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	15.34	0.6	1.54e-42	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg24818145	chr4:99064322	C4orf37	0.47	7.96	0.36	1.62e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg20703242	chr1:230279135	GALNT2	0.68	12.64	0.52	2.7e-31	Coronary artery disease;
LUAD	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg24558204	chr6:135376177	HBS1L	0.48	8.16	0.37	3.84e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg27170947	chr2:26402098	FAM59B	0.8	11.31	0.48	4.23e-26	Gut microbiome composition (summer);
LUAD	cis	rs7828089	0.542	rs7332050	chr8:22265294	G/T	cg12081754	chr8:22256438	SLC39A14	0.65	10.63	0.46	1.47e-23	Verbal declarative memory;
LUAD	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg27068330	chr11:65405492	SIPA1	-0.75	-11.23	-0.48	8.39e-26	Acne (severe);
LUAD	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg16049864	chr8:95962084	TP53INP1	-0.54	-11.5	-0.49	8.19e-27	Type 2 diabetes;
LUAD	cis	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg08071915	chr8:12219732	FAM66A	0.38	6.49	0.3	2.39e-10	Monocyte count;
LUAD	cis	rs7107174	1.000	rs901103	chr11:77931346	C/T	cg02023728	chr11:77925099	USP35	0.53	8.04	0.36	9.11e-15	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg11062466	chr8:58055876	NA	0.7	9.24	0.41	1.18e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6445967	0.530	rs56267535	chr3:58397399	A/G	cg23715586	chr3:58305044	RPP14	0.41	6.74	0.31	5.33e-11	Platelet count;
LUAD	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg17757837	chr7:157058334	UBE3C	0.48	8.47	0.38	4.2e-16	Body mass index;
LUAD	cis	rs847577	0.569	rs2394817	chr7:97690438	C/T	cg24562669	chr7:97807699	LMTK2	0.29	6.91	0.32	1.78e-11	Breast cancer;
LUAD	cis	rs7582720	1.000	rs115400054	chr2:203676105	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.18	0.41	1.96e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6752107	0.935	rs11688431	chr2:234147175	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.53	9.14	0.41	2.73e-18	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg03929089	chr4:120376271	NA	-0.97	-19.67	-0.69	1.2e-61	Height;
LUAD	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg25237894	chr2:233734115	C2orf82	0.61	11.65	0.49	2.22e-27	Coronary artery disease;
LUAD	cis	rs9868809	0.881	rs2276850	chr3:48669648	G/A	cg00383909	chr3:49044727	WDR6	0.65	7.09	0.33	5.56e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1957429	0.901	rs1467569	chr14:65347986	T/C	cg23373153	chr14:65346875	NA	0.55	6.45	0.3	2.99e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg15445000	chr17:37608096	MED1	0.44	8.14	0.37	4.43e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg04772025	chr11:68637568	NA	-0.54	-8.76	-0.39	4.79e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg17200465	chr3:40428508	ENTPD3	0.28	6.79	0.31	3.75e-11	Renal cell carcinoma;
LUAD	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24308560	chr3:49941425	MST1R	0.54	9.25	0.41	1.14e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg18180107	chr4:99064573	C4orf37	0.4	6.48	0.3	2.6200000000000003e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg19767477	chr5:127420684	SLC12A2	-0.41	-6.4	-0.3	4.09e-10	Ileal carcinoids;
LUAD	cis	rs9039	0.959	rs12925781	chr16:9216914	A/G	cg08831531	chr16:9218945	NA	0.42	7.01	0.32	9.32e-12	Menopause (age at onset);
LUAD	cis	rs1232027	0.700	rs1677634	chr5:79928324	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs16854884	0.586	rs7634145	chr3:143754150	G/A	cg01302019	chr3:143689584	C3orf58	-0.37	-6.65	-0.31	9.18e-11	Economic and political preferences (feminism/equality);
LUAD	cis	rs9560113	1.000	rs9555806	chr13:112179954	G/A	cg14154082	chr13:112174009	NA	0.36	6.75	0.31	4.77e-11	Menarche (age at onset);
LUAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08280861	chr8:58055591	NA	0.67	8.72	0.39	6.27e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27539746	chr10:118764201	KIAA1598	-0.58	-7.1	-0.33	5.33e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.5e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.39	7.13	0.33	4.51e-12	Blood metabolite levels;
LUAD	trans	rs877282	0.629	rs78997110	chr10:764388	A/G	cg22713356	chr15:30763199	NA	1.26	16.45	0.62	2.42e-47	Uric acid levels;
LUAD	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg18827107	chr12:86230957	RASSF9	0.54	9.74	0.43	2.24e-20	Major depressive disorder;
LUAD	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg06112835	chr11:68658793	MRPL21	0.5	8.97	0.4	9.61e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs754466	0.651	rs10824584	chr10:79625947	G/A	cg17075019	chr10:79541650	NA	-0.85	-17.56	-0.65	3.08e-52	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6426558	0.537	rs10799381	chr1:227239746	G/T	cg10327440	chr1:227177885	CDC42BPA	0.56	9.13	0.41	2.82e-18	Neutrophil percentage of white cells;
LUAD	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.22	-0.54	1.18e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.95	-0.36	1.78e-14	Diabetic kidney disease;
LUAD	cis	rs2658782	0.951	rs2608214	chr11:93148665	C/T	cg15737290	chr11:93063684	CCDC67	0.49	6.93	0.32	1.56e-11	Pulmonary function decline;
LUAD	cis	rs73198271	0.740	rs10100066	chr8:8650393	T/G	cg01851573	chr8:8652454	MFHAS1	0.51	9.04	0.4	5.75e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg21681030	chr2:46777652	RHOQ	0.4	6.58	0.3	1.39e-10	Height;
LUAD	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.74e-11	Parkinson's disease;
LUAD	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg25753631	chr6:25732923	NA	-0.37	-6.43	-0.3	3.49e-10	Iron status biomarkers;
LUAD	cis	rs1395	0.922	rs6547521	chr2:27488432	G/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.41	7.71	0.35	9.02e-14	Blood metabolite levels;
LUAD	cis	rs13315871	1.000	rs9849482	chr3:58422087	G/T	cg20936604	chr3:58311152	NA	-0.69	-6.92	-0.32	1.68e-11	Cholesterol, total;
LUAD	cis	rs727505	1.000	rs720614	chr7:124452790	T/C	cg23710748	chr7:124431027	NA	-0.45	-9.32	-0.41	6.6e-19	Lewy body disease;
LUAD	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg05110241	chr16:68378359	PRMT7	-0.83	-9.03	-0.4	6.05e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg04287289	chr16:89883240	FANCA	0.74	6.53	0.3	1.93e-10	Skin colour saturation;
LUAD	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg11062466	chr8:58055876	NA	0.45	6.42	0.3	3.56e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7759001	0.857	rs9468101	chr6:27352938	G/A	cg18711553	chr6:27366782	ZNF391	0.39	6.43	0.3	3.36e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs59698941	0.943	rs67462411	chr5:132220031	C/T	cg14825688	chr5:132208181	LEAP2	-0.47	-6.65	-0.31	8.85e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg25319279	chr11:5960081	NA	-0.38	-6.74	-0.31	5.23e-11	DNA methylation (variation);
LUAD	cis	rs13064411	0.518	rs1471883	chr3:113211828	C/T	cg18753928	chr3:113234510	CCDC52	-0.48	-8.75	-0.39	5.23e-17	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs1669338	0.588	rs7629889	chr3:3187643	C/T	cg18224492	chr9:123636988	PHF19	0.49	6.74	0.31	5.33e-11	White matter integrity;
LUAD	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg11879182	chr18:77439856	CTDP1	0.39	6.35	0.3	5.46e-10	Monocyte count;
LUAD	cis	rs68170813	0.559	rs77185844	chr7:106812916	A/C	cg02696742	chr7:106810147	HBP1	-0.79	-11.0	-0.47	6.4e-25	Coronary artery disease;
LUAD	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.37	7.84	0.36	3.79e-14	Parkinson's disease;
LUAD	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.8	0.35	5e-14	Lung cancer;
LUAD	cis	rs11971779	0.616	rs10278377	chr7:139103071	G/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.38e-10	Diisocyanate-induced asthma;
LUAD	cis	rs9837602	0.872	rs35154249	chr3:99738230	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.53	-0.3	1.86e-10	Breast cancer;
LUAD	cis	rs7680126	0.596	rs4698030	chr4:10315850	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.64	-0.31	9.79e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg23711669	chr6:146136114	FBXO30	-0.39	-6.52	-0.3	2.05e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.08	-0.37	7.05e-15	Diabetic kidney disease;
LUAD	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg21918786	chr6:109611834	NA	-0.53	-9.24	-0.41	1.2e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs56283067	0.847	rs56172130	chr6:44696262	G/A	cg20913747	chr6:44695427	NA	-0.42	-7.25	-0.33	1.99e-12	Total body bone mineral density;
LUAD	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg01579765	chr21:45077557	HSF2BP	0.59	13.6	0.55	3.34e-35	Mean corpuscular volume;
LUAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg22963979	chr7:1858916	MAD1L1	-0.68	-12.0	-0.5	9.2e-29	Bipolar disorder and schizophrenia;
LUAD	cis	rs757647	0.723	rs34747207	chr5:137778338	A/G	cg10676309	chr5:137685565	NA	0.42	7.43	0.34	5.91e-13	Menarche (age at onset);
LUAD	cis	rs68170813	0.641	rs75639044	chr7:107092631	A/C	cg23024343	chr7:107201750	COG5	0.51	7.05	0.32	7.13e-12	Coronary artery disease;
LUAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	8.68	0.39	8.78e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs4937291	0.966	rs2103173	chr11:112210052	A/G	cg26894311	chr10:104153930	NFKB2	-0.44	-6.69	-0.31	7.17e-11	Interleukin-18 levels;
LUAD	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg15445000	chr17:37608096	MED1	-0.4	-6.69	-0.31	7.03e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg23029597	chr12:123009494	RSRC2	-0.53	-8.15	-0.37	4.18e-15	Body mass index;
LUAD	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg17330251	chr7:94953956	PON1	0.52	6.96	0.32	1.33e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00166722	chr3:10149974	C3orf24	-0.72	-12.33	-0.51	4.52e-30	Alzheimer's disease;
LUAD	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg25324976	chr17:61989376	CSHL1	0.34	6.7	0.31	6.52e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg18621852	chr3:10150065	C3orf24	0.49	8.83	0.39	2.72e-17	Alzheimer's disease;
LUAD	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.44	6.67	0.31	8.18e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.44e-10	Prostate cancer;
LUAD	trans	rs800082	0.698	rs1178943	chr3:144391772	T/G	cg24215973	chr2:240111563	HDAC4	-0.68	-10.78	-0.46	4.03e-24	Smoking behavior;
LUAD	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg02734326	chr4:10020555	SLC2A9	0.42	7.12	0.33	4.57e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs9747201	1.000	rs8082212	chr17:80175100	G/C	cg07393940	chr7:158741817	NA	0.69	11.46	0.49	1.12e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg21226059	chr5:178986404	RUFY1	0.53	9.0	0.4	7.81e-18	Lung cancer;
LUAD	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.58	0.52	4.9e-31	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.13e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7851660	0.805	rs10759981	chr9:100635780	A/G	cg13688889	chr9:100608707	NA	-0.49	-8.45	-0.38	4.81e-16	Strep throat;
LUAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.47	0.3	2.71e-10	Depression;
LUAD	cis	rs12348691	0.503	rs907576	chr9:100615359	C/T	cg13688889	chr9:100608707	NA	-0.63	-10.31	-0.45	2.22e-22	Alopecia areata;
LUAD	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg16486109	chr11:613632	IRF7	0.55	8.07	0.37	7.3e-15	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs12545109	0.837	rs1437277	chr8:57356734	T/C	cg17761419	chr8:57350749	NA	-0.58	-8.1	-0.37	6.09e-15	Obesity-related traits;
LUAD	cis	rs3935685	0.874	rs4477663	chr15:78007254	A/G	cg25212270	chr15:78015279	NA	-0.31	-6.87	-0.32	2.3e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs863345	0.565	rs10908671	chr1:158502160	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	trans	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-10.87	-0.47	1.97e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2688608	0.967	rs9971038	chr10:75661149	C/T	cg23231163	chr10:75533350	FUT11	-0.38	-7.01	-0.32	9.23e-12	Inflammatory bowel disease;
LUAD	cis	rs9837602	1.000	rs1688772	chr3:99503366	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-8.73	-0.39	6.04e-17	Breast cancer;
LUAD	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg01324343	chr3:183735012	ABCC5	0.91	24.31	0.76	2.46e-82	Anterior chamber depth;
LUAD	cis	rs62238980	0.614	rs117534689	chr22:32392350	T/C	cg00543991	chr22:32367038	NA	0.92	8.16	0.37	3.95e-15	Childhood ear infection;
LUAD	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.56	-0.3	1.61e-10	Coronary artery disease;
LUAD	cis	rs4072705	0.615	rs4838189	chr9:127248926	C/A	cg01786973	chr9:127249749	NR5A1	0.31	6.71	0.31	6.16e-11	Menarche (age at onset);
LUAD	cis	rs775227	0.574	rs34049435	chr3:113099499	C/T	cg18753928	chr3:113234510	CCDC52	-0.69	-9.07	-0.4	4.41e-18	Dental caries;
LUAD	cis	rs31251	0.903	rs11746464	chr5:130857727	T/G	cg06307176	chr5:131281290	NA	0.36	6.49	0.3	2.47e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs76878669	0.538	rs2282530	chr11:66177952	C/T	cg10616300	chr11:66138557	SLC29A2	-0.37	-7.51	-0.34	3.63e-13	Educational attainment (years of education);
LUAD	cis	rs7843479	0.965	rs4636204	chr8:21823206	T/G	cg10047019	chr8:21822950	XPO7	-0.38	-6.45	-0.3	2.98e-10	Mean corpuscular volume;
LUAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg11301795	chr4:187892539	NA	-0.76	-15.47	-0.6	4.33e-43	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7264396	0.790	rs761826	chr20:34194243	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.52	-0.3	2.02e-10	Total cholesterol levels;
LUAD	cis	rs7178375	0.607	rs12903674	chr15:31194552	G/C	cg15020726	chr15:31196382	MTMR15	0.65	6.77	0.31	4.35e-11	Hypertriglyceridemia;
LUAD	trans	rs11039798	0.920	rs12417899	chr11:49017552	G/A	cg15704280	chr7:45808275	SEPT13	0.74	7.47	0.34	4.73e-13	Axial length;
LUAD	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg26384229	chr12:38710491	ALG10B	0.42	7.04	0.32	7.82e-12	Morning vs. evening chronotype;
LUAD	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.4	-0.45	1.06e-22	Total body bone mineral density;
LUAD	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg08470875	chr2:26401718	FAM59B	-0.6	-8.23	-0.37	2.27e-15	Gut microbiome composition (summer);
LUAD	trans	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg26043149	chr18:55253948	FECH	-0.49	-8.15	-0.37	4.19e-15	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7582720	0.887	rs72934589	chr2:204017937	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.59	0.42	7.76e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	trans	rs2262909	0.962	rs73019889	chr19:22277826	C/G	cg05197062	chr11:11642011	GALNTL4	0.58	8.99	0.4	8.5e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg11098525	chr4:1320231	MAEA	-0.39	-6.39	-0.3	4.29e-10	Obesity-related traits;
LUAD	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg07930552	chr6:133119739	C6orf192	0.86	6.59	0.3	1.35e-10	Type 2 diabetes nephropathy;
LUAD	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg04450456	chr4:17643702	FAM184B	0.39	7.48	0.34	4.43e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.81	0.35	4.65e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg21951975	chr1:209979733	IRF6	-0.49	-6.63	-0.31	1.02e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs2249625	0.874	rs1852705	chr6:72875512	G/T	cg18830697	chr6:72922368	RIMS1	-0.36	-6.77	-0.31	4.28e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg18200150	chr17:30822561	MYO1D	0.44	8.16	0.37	3.77e-15	Schizophrenia;
LUAD	trans	rs3219090	1.000	rs2666428	chr1:226589709	C/T	cg27539482	chr13:111589090	NA	0.43	7.31	0.33	1.32e-12	Melanoma;
LUAD	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg27170947	chr2:26402098	FAM59B	0.82	11.32	0.48	3.99e-26	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg08280861	chr8:58055591	NA	0.64	8.29	0.37	1.49e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6494488	0.500	rs116857608	chr15:64798168	C/T	cg08069370	chr15:64387884	SNX1	-0.75	-6.73	-0.31	5.69e-11	Coronary artery disease;
LUAD	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg11062466	chr8:58055876	NA	0.75	9.21	0.41	1.52e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg06214716	chr4:10118677	WDR1	-0.42	-6.7	-0.31	6.65e-11	Bone mineral density;
LUAD	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg18180107	chr4:99064573	C4orf37	0.42	6.74	0.31	5.29e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9811920	0.555	rs9850382	chr3:99915939	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.44	8.42	0.38	6.04e-16	Axial length;
LUAD	cis	rs870825	0.616	rs7680639	chr4:185652915	C/T	cg04058563	chr4:185651563	MLF1IP	-0.85	-13.61	-0.55	3.09e-35	Blood protein levels;
LUAD	cis	rs9469890	0.604	rs11756280	chr6:34503439	T/C	cg17674042	chr6:34482479	PACSIN1	-0.52	-7.26	-0.33	1.93e-12	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg10426581	chr7:100472382	SRRT	0.75	9.96	0.44	3.89e-21	Resting heart rate;
LUAD	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg05283184	chr6:79620031	NA	-0.61	-12.41	-0.52	2.33e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.17	-0.33	3.28e-12	Glomerular filtration rate;
LUAD	cis	rs2686555	0.576	rs2686553	chr12:121077389	A/C	cg18477009	chr12:121087777	CABP1	0.45	7.6	0.35	1.86e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg11416102	chr8:651193	ERICH1	-0.88	-8.68	-0.39	8.46e-17	IgG glycosylation;
LUAD	cis	rs17095355	0.818	rs6584970	chr10:111847820	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.55	-6.99	-0.32	1.08e-11	Biliary atresia;
LUAD	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.08	-0.51	4.49e-29	Primary sclerosing cholangitis;
LUAD	cis	rs2573652	1.000	rs2573651	chr15:100514109	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.49	-8.73	-0.39	6.05e-17	Height;
LUAD	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg23625390	chr15:77176239	SCAPER	0.35	6.35	0.3	5.5e-10	Blood metabolite levels;
LUAD	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg13397359	chr6:42928475	GNMT	0.53	7.93	0.36	2e-14	Blood protein levels;
LUAD	cis	rs8068544	0.818	rs79892925	chr17:40171819	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.2	-12.26	-0.51	9.08e-30	Reticulocyte fraction of red cells;Reticulocyte count;
LUAD	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg08027265	chr7:2291960	NA	-0.41	-6.53	-0.3	1.91e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03934478	chr11:495069	RNH1	0.71	8.66	0.39	1e-16	Body mass index;
LUAD	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-13.64	-0.55	2.39e-35	Chronic sinus infection;
LUAD	cis	rs28595532	0.641	rs72670220	chr4:119300053	A/G	cg02775129	chr4:119771670	NA	-0.63	-6.55	-0.3	1.66e-10	Cannabis dependence symptom count;
LUAD	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg12311346	chr5:56204834	C5orf35	0.46	7.56	0.34	2.57e-13	Coronary artery disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08920773	chr3:38207524	OXSR1	-0.63	-6.52	-0.3	1.96e-10	Type 2 diabetes;
LUAD	cis	rs4638749	0.906	rs34974921	chr2:108860253	A/G	cg06795125	chr2:108905320	SULT1C2	-0.42	-6.62	-0.31	1.1e-10	Blood pressure;
LUAD	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-8.26	-0.37	1.87e-15	Gut microbiome composition (summer);
LUAD	trans	rs9929218	0.954	rs1981871	chr16:68819007	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.68	-0.55	1.55e-35	Colorectal cancer;
LUAD	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg21433313	chr16:3507492	NAT15	0.74	9.7	0.43	3.09e-20	Tuberculosis;
LUAD	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg07527032	chr15:84868466	LOC388152	0.44	6.63	0.31	1.04e-10	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs10950821	0.734	rs11772926	chr7:20685900	T/C	cg02470904	chr7:20686108	ABCB5	0.38	6.44	0.3	3.16e-10	Response to statin therapy;
LUAD	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg03714773	chr7:91764589	CYP51A1	-0.3	-6.84	-0.32	2.71e-11	Breast cancer;
LUAD	cis	rs225245	0.755	rs226441	chr17:34033072	C/T	cg05299278	chr17:33885742	SLFN14	0.5	11.26	0.48	6.45e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg25985355	chr7:65971099	NA	-0.34	-6.41	-0.3	3.93e-10	Aortic root size;
LUAD	cis	rs4853036	0.951	rs10496175	chr2:70153848	A/G	cg02498382	chr2:70120550	SNRNP27	-0.53	-8.68	-0.39	8.73e-17	Colorectal or endometrial cancer;
LUAD	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.46e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.757	rs12453308	chr17:28441604	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.47	0.38	4.21e-16	Coffee consumption (cups per day);
LUAD	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg00999904	chr2:3704751	ALLC	-0.51	-8.95	-0.4	1.15e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.14	0.37	4.52e-15	Menopause (age at onset);
LUAD	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg11766577	chr21:47581405	C21orf56	0.51	8.7	0.39	7.49e-17	Testicular germ cell tumor;
LUAD	cis	rs9394152	0.817	rs4428487	chr6:33468394	G/A	cg13560919	chr6:33536144	NA	0.5	8.32	0.38	1.22e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs1003719	0.708	rs3787788	chr21:38502804	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-9.06	-0.4	4.8e-18	Eye color traits;
LUAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg21782813	chr7:2030301	MAD1L1	0.42	6.92	0.32	1.68e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg21775007	chr8:11205619	TDH	-0.5	-9.08	-0.4	4.26e-18	Retinal vascular caliber;
LUAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08219700	chr8:58056026	NA	0.61	7.95	0.36	1.68e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg05800723	chr4:79103126	FRAS1	-0.37	-6.58	-0.3	1.43e-10	Anger;
LUAD	cis	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.98	-0.36	1.37e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs17490626	0.568	rs12416520	chr10:71211945	A/G	cg12610070	chr10:71211762	TSPAN15	-0.41	-10.97	-0.47	8.59e-25	Thrombosis;
LUAD	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg05754148	chr16:3507555	NAT15	0.45	6.81	0.31	3.32e-11	Body mass index (adult);
LUAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13732083	chr21:47605072	C21orf56	-0.6	-10.6	-0.46	1.94e-23	Testicular germ cell tumor;
LUAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg21226059	chr5:178986404	RUFY1	-0.68	-11.44	-0.49	1.4e-26	Lung cancer;
LUAD	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg21963583	chr11:68658836	MRPL21	0.65	11.46	0.49	1.16e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs28374715	0.617	rs16971735	chr15:41563970	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.57	-10.18	-0.44	6.25e-22	Ulcerative colitis;
LUAD	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg23954153	chr1:44402353	ARTN	-0.36	-6.69	-0.31	6.92e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.82	-0.39	2.94e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1232027	0.656	rs836794	chr5:80012251	C/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.48	-7.59	-0.35	2.04e-13	Huntington's disease progression;
LUAD	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg07527032	chr15:84868466	LOC388152	0.44	6.48	0.3	2.58e-10	Schizophrenia;
LUAD	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg24112000	chr20:60950667	NA	0.67	11.03	0.47	4.92e-25	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs2274273	0.522	rs2251366	chr14:55518156	A/G	cg04306507	chr14:55594613	LGALS3	0.33	6.73	0.31	5.5e-11	Protein biomarker;
LUAD	cis	rs4930561	0.714	rs7950452	chr11:67962407	C/A	cg04465784	chr11:67976953	SUV420H1	-0.28	-8.26	-0.37	1.91e-15	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs12210905	0.688	rs12191373	chr6:27484330	C/T	cg08851530	chr6:28072375	NA	1.0	7.67	0.35	1.21e-13	Hip circumference adjusted for BMI;
LUAD	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg11292332	chr7:45801988	SEPT13	-0.29	-6.53	-0.3	1.91e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.77	-0.31	4.27e-11	Diabetic kidney disease;
LUAD	trans	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.53	-0.3	1.84e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7267979	1.000	rs6107045	chr20:25441936	G/A	cg08601574	chr20:25228251	PYGB	0.43	7.95	0.36	1.72e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.06	0.37	7.64e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.627	rs1435567	chr2:198748726	T/C	cg10547527	chr2:198650123	BOLL	-0.54	-7.56	-0.34	2.56e-13	Ulcerative colitis;
LUAD	cis	rs1018836	0.663	rs4735190	chr8:91509601	A/G	cg16814680	chr8:91681699	NA	-0.66	-10.79	-0.46	3.84e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg18538332	chr22:24372958	LOC391322	-0.54	-8.91	-0.4	1.51e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1483890	1.000	rs1483890	chr3:69410725	A/G	cg22125112	chr3:69402811	FRMD4B	0.4	7.13	0.33	4.23e-12	Resting heart rate;
LUAD	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg15468180	chr1:107600409	PRMT6	-0.44	-7.59	-0.35	2.05e-13	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18876405	chr7:65276391	NA	-0.44	-6.96	-0.32	1.3e-11	Aortic root size;
LUAD	cis	rs11118844	0.843	rs11118847	chr1:221922614	A/G	cg04222084	chr1:221915650	DUSP10	-0.68	-7.62	-0.35	1.69e-13	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg02733842	chr7:1102375	C7orf50	-0.39	-6.86	-0.32	2.39e-11	Longevity;Endometriosis;
LUAD	cis	rs7527798	0.592	rs11118282	chr1:207832402	G/A	cg09232269	chr1:207846808	CR1L	-0.37	-7.13	-0.33	4.34e-12	Erythrocyte sedimentation rate;
LUAD	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-9.83	-0.43	1.16e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs909002	0.819	rs2292989	chr1:32135773	A/G	cg13919466	chr1:32135498	COL16A1	0.31	6.89	0.32	2.08e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg00071950	chr4:10020882	SLC2A9	0.49	7.02	0.32	9.03e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-7.09	-0.33	5.76e-12	Systolic blood pressure;
LUAD	cis	rs2806561	0.964	rs683052	chr1:23514953	T/C	cg19743168	chr1:23544995	NA	0.41	7.75	0.35	7.1e-14	Height;
LUAD	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.98	-0.4	9.06e-18	Bipolar disorder;
LUAD	trans	rs8002861	0.935	rs9533672	chr13:44451180	C/T	cg12856521	chr11:46389249	DGKZ	0.38	6.41	0.3	3.96e-10	Leprosy;
LUAD	cis	rs8177876	0.749	rs2278024	chr16:81079233	C/G	cg08591886	chr16:81111003	C16orf46	-0.76	-7.07	-0.33	6.35e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg25233709	chr10:116636983	FAM160B1	0.42	8.24	0.37	2.12e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1509123	0.609	rs118144554	chr17:6721816	C/A	cg12642237	chr17:6703447	TEKT1	-0.49	-7.02	-0.32	9.15e-12	Blood metabolite levels;
LUAD	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg04398451	chr17:18023971	MYO15A	0.78	14.08	0.56	3.28e-37	Total body bone mineral density;
LUAD	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg22676075	chr6:135203613	NA	0.42	7.84	0.36	3.62e-14	Red blood cell count;
LUAD	cis	rs4077468	0.927	rs1342063	chr1:205912859	C/T	cg14159672	chr1:205819179	PM20D1	-0.38	-6.75	-0.31	4.88e-11	Cystic fibrosis-related diabetes;
LUAD	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg11189052	chr15:85197271	WDR73	-0.58	-9.61	-0.42	6.66e-20	P wave terminal force;
LUAD	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg00981070	chr1:2046702	PRKCZ	0.37	6.9	0.32	1.86e-11	Height;
LUAD	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg22868518	chr11:507468	RNH1	-0.67	-6.55	-0.3	1.65e-10	Body mass index;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg16232842	chr15:74286823	PML	-0.37	-6.36	-0.3	5.18e-10	Subcortical brain region volumes;
LUAD	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg18132916	chr6:79620363	NA	0.44	7.58	0.35	2.22e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.79	0.56	5.59e-36	Tonsillectomy;
LUAD	cis	rs68170813	0.559	rs3801963	chr7:106898036	C/T	cg23024343	chr7:107201750	COG5	0.44	6.57	0.3	1.44e-10	Coronary artery disease;
LUAD	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg18854424	chr1:2615690	NA	-0.41	-8.84	-0.39	2.67e-17	Ulcerative colitis;
LUAD	cis	rs1348850	0.526	rs4243391	chr2:178468089	A/T	cg27490568	chr2:178487706	NA	0.53	8.05	0.36	8.64e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.06	-0.36	7.95e-15	Total body bone mineral density;
LUAD	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg25457927	chr22:38595422	NA	-0.5	-12.04	-0.51	6.5e-29	Cutaneous nevi;
LUAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.25	0.41	1.08e-18	Alzheimer's disease;
LUAD	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg23758822	chr17:41437982	NA	0.87	14.0	0.56	7.26e-37	Menopause (age at onset);
LUAD	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg19000871	chr14:103996768	TRMT61A	0.51	8.99	0.4	8.49e-18	Coronary artery disease;
LUAD	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.87	-0.4	2.13e-17	Total body bone mineral density;
LUAD	cis	rs1448094	0.967	rs2121892	chr12:86324556	G/T	cg02569458	chr12:86230093	RASSF9	0.37	7.07	0.33	6.27e-12	Major depressive disorder;
LUAD	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg12311346	chr5:56204834	C5orf35	-0.47	-7.75	-0.35	6.79e-14	Coronary artery disease;
LUAD	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	11.8	0.5	5.61e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg15117754	chr3:10150083	C3orf24	0.44	7.09	0.33	5.76e-12	Alzheimer's disease;
LUAD	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg24579218	chr15:68104479	NA	-0.52	-9.0	-0.4	8e-18	Restless legs syndrome;
LUAD	cis	rs9715521	0.719	rs11936702	chr4:59849081	G/A	cg11281224	chr4:60001000	NA	-0.6	-10.24	-0.45	3.85e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg08999081	chr20:33150536	PIGU	0.63	14.03	0.56	5.5e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg02158880	chr13:53174818	NA	0.6	10.83	0.47	2.75e-24	Lewy body disease;
LUAD	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg06713675	chr4:122721982	EXOSC9	-0.85	-18.45	-0.67	3.51e-56	Type 2 diabetes;
LUAD	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg23188684	chr11:67383651	NA	0.39	6.67	0.31	7.81e-11	Mean corpuscular volume;
LUAD	cis	rs7582720	1.000	rs72936830	chr2:203769803	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs11023332	0.800	rs12271890	chr11:14934686	A/G	cg19336497	chr11:14380999	RRAS2	-0.39	-7.38	-0.34	8.57e-13	Adiponectin levels;Vitamin D levels;
LUAD	cis	rs16854884	0.586	rs2011080	chr3:143756149	T/G	cg01302019	chr3:143689584	C3orf58	-0.39	-6.95	-0.32	1.38e-11	Economic and political preferences (feminism/equality);
LUAD	cis	rs679087	1.000	rs302315	chr12:29919054	G/C	cg14258853	chr12:29935411	TMTC1	-0.6	-10.37	-0.45	1.35e-22	Schizophrenia;
LUAD	cis	rs2617583	0.530	rs1478435	chr5:1454612	T/C	cg13982541	chr5:1466431	LPCAT1	0.59	9.41	0.42	3.23e-19	Breast cancer;
LUAD	cis	rs9863	0.861	rs7958691	chr12:124440743	G/T	cg17723958	chr12:124429295	CCDC92	-0.39	-6.46	-0.3	2.9e-10	White blood cell count;
LUAD	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg13736514	chr6:26305472	NA	-0.68	-12.88	-0.53	3.05e-32	Educational attainment;
LUAD	trans	rs11039798	0.844	rs11040177	chr11:48976211	G/C	cg03929089	chr4:120376271	NA	0.59	6.79	0.31	3.9e-11	Axial length;
LUAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08280861	chr8:58055591	NA	0.6	7.67	0.35	1.18e-13	Developmental language disorder (linguistic errors);
LUAD	trans	rs853679	0.607	rs200489	chr6:27798257	T/C	cg01620082	chr3:125678407	NA	-0.81	-8.76	-0.39	4.58e-17	Depression;
LUAD	cis	rs68170813	0.522	rs12535814	chr7:107038432	A/T	cg02696742	chr7:106810147	HBP1	-0.78	-10.88	-0.47	1.81e-24	Coronary artery disease;
LUAD	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg02196655	chr2:10830764	NOL10	0.41	7.61	0.35	1.81e-13	Prostate cancer;
LUAD	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs11650494	0.710	rs77653195	chr17:47468868	A/T	cg08112188	chr17:47440006	ZNF652	0.78	6.43	0.3	3.41e-10	Prostate cancer;
LUAD	trans	rs12517041	1.000	rs2081950	chr5:23287505	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.51	-0.3	2.11e-10	Calcium levels;
LUAD	cis	rs225245	0.817	rs225284	chr17:33933006	A/C	cg05299278	chr17:33885742	SLFN14	0.51	11.65	0.49	2.05e-27	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs225245	0.791	rs7406966	chr17:34013636	A/C	cg05299278	chr17:33885742	SLFN14	0.5	11.34	0.48	3.37e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg21770322	chr7:97807741	LMTK2	-0.33	-7.68	-0.35	1.11e-13	Breast cancer;
LUAD	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	8.72	0.39	6.23e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg04218760	chr10:45406644	TMEM72	-0.32	-7.96	-0.36	1.56e-14	Mean corpuscular volume;
LUAD	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg07211511	chr3:129823064	LOC729375	-0.84	-12.26	-0.51	8.5e-30	Blood pressure (smoking interaction);
LUAD	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg17264618	chr3:40429014	ENTPD3	0.42	9.06	0.4	4.72e-18	Renal cell carcinoma;
LUAD	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg09835421	chr16:68378352	PRMT7	0.63	7.41	0.34	6.95e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg17063962	chr7:91808500	NA	-0.61	-9.93	-0.43	4.98e-21	Breast cancer;
LUAD	trans	rs1406428	0.573	rs12613632	chr2:51705755	C/G	cg01078248	chr7:123197661	NDUFA5	0.44	6.55	0.3	1.71e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg22598563	chr5:131563921	P4HA2	-0.34	-8.78	-0.39	4.03e-17	Blood metabolite levels;
LUAD	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg19336497	chr11:14380999	RRAS2	-0.66	-14.2	-0.57	1.05e-37	Sense of smell;
LUAD	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10802521	chr3:52805072	NEK4	-0.58	-10.3	-0.45	2.43e-22	Electroencephalogram traits;
LUAD	cis	rs4853036	0.903	rs13021969	chr2:70117602	T/C	cg02498382	chr2:70120550	SNRNP27	-0.5	-8.24	-0.37	2.24e-15	Colorectal or endometrial cancer;
LUAD	cis	rs10193935	0.901	rs6733464	chr2:42563597	A/G	cg27598129	chr2:42591480	NA	-0.79	-10.38	-0.45	1.22e-22	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg06606381	chr12:133084897	FBRSL1	-0.88	-8.43	-0.38	5.63e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg00495681	chr13:53174319	NA	0.53	10.0	0.44	2.85e-21	Lewy body disease;
LUAD	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg24838063	chr12:130822603	PIWIL1	0.65	10.67	0.46	1.03e-23	Menopause (age at onset);
LUAD	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg09365446	chr1:150670422	GOLPH3L	0.55	9.66	0.43	4.29e-20	Melanoma;
LUAD	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg19761014	chr17:28927070	LRRC37B2	0.7	6.41	0.3	3.83e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg11344533	chr11:111475393	SIK2	0.38	7.15	0.33	3.88e-12	Primary sclerosing cholangitis;
LUAD	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg17063962	chr7:91808500	NA	-0.68	-11.8	-0.5	5.66e-28	Breast cancer;
LUAD	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg08601574	chr20:25228251	PYGB	0.43	7.84	0.36	3.76e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg10755058	chr3:40428713	ENTPD3	0.43	8.31	0.37	1.29e-15	Renal cell carcinoma;
LUAD	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg02527881	chr3:46936655	PTH1R	-0.51	-10.46	-0.45	6.24e-23	Colorectal cancer;
LUAD	cis	rs7094131	0.523	rs10828322	chr10:22876002	G/A	cg19500236	chr10:22911537	PIP4K2A	0.39	7.13	0.33	4.5e-12	Obesity-related traits;
LUAD	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg25237894	chr2:233734115	C2orf82	-0.59	-11.8	-0.5	5.71e-28	Coronary artery disease;
LUAD	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.56	0.35	2.51e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg22532475	chr10:104410764	TRIM8	-0.45	-8.83	-0.39	2.7e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg23958373	chr8:599963	NA	1.18	10.95	0.47	9.81e-25	IgG glycosylation;
LUAD	cis	rs7493	0.901	rs13226149	chr7:95025600	G/A	cg21856205	chr7:94953877	PON1	-0.55	-7.89	-0.36	2.53e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg13319975	chr6:146136371	FBXO30	-0.67	-11.84	-0.5	4.09e-28	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg20476274	chr7:133979776	SLC35B4	0.58	9.41	0.42	3.2e-19	Mean platelet volume;
LUAD	trans	rs9393777	0.920	rs13207689	chr6:27369704	C/G	cg01620082	chr3:125678407	NA	-0.98	-9.38	-0.41	3.91e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19733847	chr19:8571072	NA	0.42	6.57	0.3	1.52e-10	Monocyte percentage of white cells;
LUAD	cis	rs3806843	0.576	rs246030	chr5:140333154	C/G	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11644478	chr21:40555479	PSMG1	-0.6	-10.01	-0.44	2.54e-21	Cognitive function;
LUAD	cis	rs11585357	0.501	rs72646770	chr1:17580767	T/C	cg08277548	chr1:17600880	PADI3	-0.66	-7.06	-0.32	6.85e-12	Hair shape;
LUAD	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg15997130	chr1:24165203	NA	-0.58	-10.34	-0.45	1.71e-22	Immature fraction of reticulocytes;
LUAD	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.57e-13	Urate levels;
LUAD	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg02079420	chr8:82753780	SNX16	-0.41	-8.24	-0.37	2.24e-15	Diastolic blood pressure;
LUAD	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg09165964	chr15:75287851	SCAMP5	-0.47	-7.12	-0.33	4.53e-12	Blood trace element (Zn levels);
LUAD	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg22862634	chr11:62369728	EML3;MTA2	0.58	11.16	0.48	1.57e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg05434287	chr7:2030229	MAD1L1	0.43	6.93	0.32	1.61e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg11416102	chr8:651193	ERICH1	0.84	8.01	0.36	1.11e-14	IgG glycosylation;
LUAD	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg22875332	chr1:76189707	ACADM	0.87	16.54	0.63	9.6e-48	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2004318	1.000	rs45479893	chr19:55086169	A/G	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.85e-13	Blood protein levels;
LUAD	cis	rs12210905	0.688	rs12374649	chr6:27343726	C/T	cg08851530	chr6:28072375	NA	1.09	7.97	0.36	1.45e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg21033440	chr11:65409861	SIPA1	-0.49	-7.8	-0.35	4.98e-14	Blood pressure (age interaction);
LUAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg14926445	chr8:58193284	C8orf71	-0.53	-7.58	-0.35	2.27e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg09060608	chr5:178986726	RUFY1	-0.57	-9.68	-0.43	3.69e-20	Lung cancer;
LUAD	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg12011299	chr4:100065546	ADH4	0.7	12.86	0.53	3.66e-32	Alcohol dependence;
LUAD	cis	rs1595825	0.735	rs2164327	chr2:198726773	C/T	cg00982548	chr2:198649783	BOLL	-0.64	-9.26	-0.41	1.06e-18	Ulcerative colitis;
LUAD	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.85	-0.32	2.56e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1595825	0.891	rs3851979	chr2:198707638	A/T	cg10547527	chr2:198650123	BOLL	0.56	8.02	0.36	1.08e-14	Ulcerative colitis;
LUAD	cis	rs11992162	0.569	rs35283519	chr8:11831661	C/T	cg08071915	chr8:12219732	FAM66A	0.43	6.51	0.3	2.08e-10	Monocyte count;
LUAD	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg21427119	chr20:30132790	HM13	-0.62	-9.46	-0.42	2.24e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg09650180	chr20:62225654	GMEB2	-0.48	-6.84	-0.32	2.87e-11	Glioma;Non-glioblastoma glioma;Glioblastoma;
LUAD	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg02228675	chr17:40259724	DHX58	-0.44	-7.09	-0.33	5.79e-12	Fibrinogen levels;
LUAD	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.52	-10.76	-0.46	4.86e-24	Monocyte percentage of white cells;
LUAD	cis	rs17767294	0.803	rs59701161	chr6:27646117	T/C	cg08851530	chr6:28072375	NA	0.97	7.31	0.34	1.31e-12	Parkinson's disease;
LUAD	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg21399703	chr1:247681439	NA	-0.45	-8.53	-0.38	2.58e-16	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.32	-0.38	1.21e-15	Total body bone mineral density;
LUAD	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg26384229	chr12:38710491	ALG10B	0.48	7.82	0.36	4.31e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg02158880	chr13:53174818	NA	-0.44	-7.49	-0.34	4.1e-13	Lewy body disease;
LUAD	cis	rs1873147	0.569	rs11636033	chr15:63311091	G/T	cg12160578	chr15:63334699	TPM1	-0.45	-6.77	-0.31	4.28e-11	Orofacial clefts;
LUAD	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg20848291	chr7:100343083	ZAN	-0.63	-9.96	-0.44	3.8e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg23649088	chr2:200775458	C2orf69	-0.48	-8.29	-0.37	1.48e-15	QT interval;
LUAD	cis	rs17685	0.753	rs10476	chr7:75696420	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.41	7.92	0.36	2.17e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4594175	0.926	rs4243570	chr14:51624243	C/T	cg23942311	chr14:51606299	NA	0.65	11.71	0.49	1.25e-27	Cancer;
LUAD	cis	rs7671266	0.611	rs10939833	chr4:10309537	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.9	-0.32	1.96e-11	Cardiovascular disease risk factors;
LUAD	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.75	-0.71	1.82e-66	Height;
LUAD	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-11.33	-0.48	3.51e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg09491104	chr22:46646882	C22orf40	-0.59	-7.72	-0.35	8.2e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2227631	0.505	rs6955537	chr7:100759727	A/G	cg18465962	chr7:100767262	NA	-0.4	-6.77	-0.31	4.35e-11	Plasminogen activator inhibitor type 1 levels (PAI-1);
LUAD	cis	rs8064299	0.597	rs4789097	chr17:72781208	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.4	-6.46	-0.3	2.84e-10	Monocyte count;
LUAD	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	8.03	0.36	9.75e-15	Schizophrenia;
LUAD	cis	rs897984	0.609	rs11862744	chr16:31057800	G/A	cg02466173	chr16:30829666	NA	-0.56	-9.82	-0.43	1.25e-20	Dementia with Lewy bodies;
LUAD	cis	rs17193922	0.876	rs17194040	chr16:53550898	C/T	cg04059762	chr16:53544020	NA	-0.4	-6.35	-0.3	5.44e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg13319975	chr6:146136371	FBXO30	0.66	11.31	0.48	4.24e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs986417	1.000	rs8004736	chr14:61053061	T/C	cg27398547	chr14:60952738	C14orf39	0.65	7.13	0.33	4.36e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs2412208	0.795	rs4074964	chr1:7105079	A/G	cg20434152	chr1:7120926	CAMTA1	-0.31	-6.71	-0.31	6.18e-11	Survival in sporadic amyotrophic lateral sclerosis;
LUAD	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg09365446	chr1:150670422	GOLPH3L	0.61	10.75	0.46	5.64e-24	Melanoma;
LUAD	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg26924012	chr15:45694286	SPATA5L1	1.02	18.78	0.67	1.16e-57	Homoarginine levels;
LUAD	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg18240062	chr17:79603768	NPLOC4	0.36	6.35	0.3	5.42e-10	Eye color traits;
LUAD	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg13319975	chr6:146136371	FBXO30	-0.61	-10.3	-0.45	2.29e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06544989	chr22:39130855	UNC84B	0.34	6.97	0.32	1.23e-11	Menopause (age at onset);
LUAD	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.45	-7.53	-0.34	3.05e-13	Lymphocyte percentage of white cells;
LUAD	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.47	-7.54	-0.34	2.94e-13	Hematocrit;
LUAD	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17197710	0.673	rs61897361	chr11:47346378	G/A	cg13308137	chr11:47528955	CUGBP1	0.45	7.22	0.33	2.5e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18876405	chr7:65276391	NA	-0.42	-6.76	-0.31	4.59e-11	Aortic root size;
LUAD	cis	rs36051895	0.589	rs7038763	chr9:5076399	T/C	cg02405213	chr9:5042618	JAK2	-0.46	-6.67	-0.31	8.09e-11	Pediatric autoimmune diseases;
LUAD	cis	rs7707921	0.757	rs226198	chr5:81573992	C/T	cg15871215	chr5:81402204	ATG10	0.68	9.57	0.42	9.1e-20	Breast cancer;
LUAD	cis	rs89107	0.641	rs431115	chr6:118612615	C/T	cg21191810	chr6:118973309	C6orf204	0.54	10.86	0.47	2.2e-24	Cardiac structure and function;
LUAD	cis	rs7833986	0.501	rs72653967	chr8:56999432	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	1.02	18.08	0.66	1.43e-54	Height;
LUAD	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg16414030	chr3:133502952	NA	-0.69	-12.99	-0.53	1.1e-32	Iron status biomarkers;
LUAD	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg20307385	chr11:47447363	PSMC3	0.53	7.87	0.36	3.1e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg23254163	chr1:152506842	NA	0.25	6.96	0.32	1.31e-11	Hair morphology;
LUAD	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-7.47	-0.34	4.67e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg26384229	chr12:38710491	ALG10B	0.47	7.58	0.35	2.23e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs240764	0.717	rs239215	chr6:101147426	A/G	cg09795085	chr6:101329169	ASCC3	0.41	7.14	0.33	4.12e-12	Neuroticism;
LUAD	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.76	0.46	4.92e-24	Smoking behavior;
LUAD	cis	rs10089	1.000	rs72794392	chr5:127490061	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	9.22	0.41	1.44e-18	Ileal carcinoids;
LUAD	cis	rs240764	0.555	rs11967951	chr6:101231905	G/A	cg09795085	chr6:101329169	ASCC3	0.41	7.17	0.33	3.39e-12	Neuroticism;
LUAD	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg10560079	chr2:191398806	TMEM194B	0.44	7.9	0.36	2.45e-14	Pulse pressure;
LUAD	trans	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg06606381	chr12:133084897	FBRSL1	-1.14	-9.6	-0.42	6.85e-20	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.28	0.37	1.62e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg00106254	chr7:1943704	MAD1L1	-0.59	-8.99	-0.4	8.18e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg00750074	chr16:89608354	SPG7	-0.62	-10.61	-0.46	1.81e-23	Multiple myeloma (IgH translocation);
LUAD	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg07917127	chr4:99064746	C4orf37	-0.4	-6.4	-0.3	4.21e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62238980	0.614	rs734092	chr22:32462167	C/G	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs4711350	0.862	rs597723	chr6:33694079	C/T	cg07979401	chr6:33739406	LEMD2	0.43	7.15	0.33	3.93e-12	Schizophrenia;
LUAD	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg10792982	chr14:105748885	BRF1	-0.44	-9.47	-0.42	2.07e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg02371401	chr5:676784	TPPP	0.45	7.46	0.34	4.85e-13	Obesity-related traits;
LUAD	cis	rs6840360	0.571	rs17275536	chr4:152498625	C/T	cg22705602	chr4:152727874	NA	-0.38	-6.68	-0.31	7.45e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg04111992	chr7:158790115	NA	-0.42	-6.91	-0.32	1.83e-11	Facial morphology (factor 20);
LUAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg06753367	chr22:24256600	NA	-0.41	-7.42	-0.34	6.32e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs859767	0.501	rs10171371	chr2:135372159	C/T	cg12500956	chr2:135428796	TMEM163	-0.27	-7.03	-0.32	8.38e-12	Neuroticism;
LUAD	cis	rs7000551	0.689	rs6996872	chr8:22316753	T/C	cg12081754	chr8:22256438	SLC39A14	0.46	7.71	0.35	9.32e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg26304593	chr6:42947056	PEX6	-0.47	-7.98	-0.36	1.39e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg23815491	chr16:72088622	HP	0.44	7.09	0.33	5.66e-12	Blood protein levels;
LUAD	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg06641503	chr3:48959341	ARIH2	-0.4	-7.99	-0.36	1.33e-14	Parkinson's disease;
LUAD	cis	rs36051895	0.658	rs7030260	chr9:5008070	C/A	cg02405213	chr9:5042618	JAK2	-0.48	-7.31	-0.33	1.37e-12	Pediatric autoimmune diseases;
LUAD	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg02569458	chr12:86230093	RASSF9	0.37	7.1	0.33	5.38e-12	Major depressive disorder;
LUAD	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg25753631	chr6:25732923	NA	-0.37	-6.43	-0.3	3.49e-10	Iron status biomarkers;
LUAD	cis	rs8010715	0.636	rs2277480	chr14:24587515	G/A	cg23112188	chr14:24563095	PCK2	-0.35	-6.97	-0.32	1.26e-11	IgG glycosylation;
LUAD	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg06784218	chr1:46089804	CCDC17	-0.61	-13.46	-0.55	1.22e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg09399716	chr2:46890238	NA	-0.37	-6.43	-0.3	3.43e-10	Height;
LUAD	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg02018176	chr4:1364513	KIAA1530	0.55	10.4	0.45	1.05e-22	Longevity;
LUAD	cis	rs2455799	1.000	rs9815283	chr3:15867375	A/G	cg16303742	chr3:15540471	COLQ	-0.37	-6.4	-0.3	4.16e-10	Mean platelet volume;
LUAD	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg20476274	chr7:133979776	SLC35B4	0.79	15.24	0.6	4.06e-42	Mean platelet volume;
LUAD	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.87	0.36	2.95e-14	Parkinson's disease;
LUAD	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21659725	chr3:3221576	CRBN	0.67	11.55	0.49	5.05e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.57	-9.49	-0.42	1.74e-19	Glomerular filtration rate;
LUAD	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06544989	chr22:39130855	UNC84B	0.43	7.97	0.36	1.45e-14	Menopause (age at onset);
LUAD	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg19500851	chr17:37840957	PGAP3	-0.33	-6.46	-0.3	2.88e-10	Asthma;
LUAD	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg07212818	chr11:638076	DRD4	-0.45	-6.63	-0.31	1e-10	Systemic lupus erythematosus;
LUAD	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.94	-0.4	1.26e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs68170813	0.641	rs75254991	chr7:106938903	C/T	cg23024343	chr7:107201750	COG5	0.47	7.09	0.33	5.54e-12	Coronary artery disease;
LUAD	cis	rs9400271	0.527	rs4946954	chr6:109639656	A/G	cg21918786	chr6:109611834	NA	-0.39	-6.5	-0.3	2.24e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg03538708	chr1:25844672	NA	-0.37	-6.42	-0.3	3.74e-10	Erythrocyte sedimentation rate;
LUAD	cis	rs8177876	0.822	rs9925943	chr16:81111007	T/C	cg08591886	chr16:81111003	C16orf46	-0.76	-7.09	-0.33	5.65e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11890956	chr21:40555474	PSMG1	-0.52	-8.8	-0.39	3.63e-17	Menarche (age at onset);
LUAD	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg27490568	chr2:178487706	NA	0.61	8.83	0.39	2.79e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg20673091	chr1:2541236	MMEL1	0.44	9.49	0.42	1.71e-19	Ulcerative colitis;
LUAD	cis	rs11677416	1.000	rs3783514	chr2:113547425	A/G	cg27083787	chr2:113543245	IL1A	0.4	6.78	0.31	3.96e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg21724239	chr8:58056113	NA	0.61	7.97	0.36	1.51e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.802	rs12369634	chr12:86406792	C/G	cg02569458	chr12:86230093	RASSF9	0.4	7.6	0.35	1.9e-13	Major depressive disorder;
LUAD	cis	rs2742234	0.590	rs2565201	chr10:43618484	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.5	-8.5	-0.38	3.39e-16	Hirschsprung disease;
LUAD	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg22676075	chr6:135203613	NA	0.4	7.32	0.34	1.25e-12	Red blood cell count;
LUAD	cis	rs1595825	0.891	rs16825917	chr2:198805185	C/T	cg10547527	chr2:198650123	BOLL	-0.52	-7.05	-0.32	7.5e-12	Ulcerative colitis;
LUAD	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg22868518	chr11:507468	RNH1	-0.63	-6.41	-0.3	3.9e-10	Body mass index;
LUAD	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg22117172	chr7:91764530	CYP51A1	0.35	7.49	0.34	3.98e-13	Breast cancer;
LUAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg10729496	chr3:10149963	C3orf24	0.58	9.5	0.42	1.63e-19	Alzheimer's disease;
LUAD	cis	rs73206853	0.925	rs12318836	chr12:110642190	A/C	cg12870014	chr12:110450643	ANKRD13A	0.57	8.04	0.36	8.79e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs752010	0.967	rs10890151	chr1:42101843	C/A	cg06885757	chr1:42089581	HIVEP3	0.4	8.23	0.37	2.26e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs2227564	0.620	rs4746148	chr10:75534488	C/T	cg23231163	chr10:75533350	FUT11	-0.43	-6.69	-0.31	6.92e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg25767906	chr1:53392781	SCP2	0.54	10.25	0.45	3.5e-22	Monocyte count;
LUAD	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18876405	chr7:65276391	NA	-0.44	-6.98	-0.32	1.16e-11	Aortic root size;
LUAD	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.91	0.36	2.29e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg15921436	chr17:44337874	NA	0.88	11.49	0.49	8.82e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg25767906	chr1:53392781	SCP2	0.46	8.54	0.38	2.41e-16	Monocyte count;
LUAD	cis	rs113835537	0.529	rs11227515	chr11:66287383	C/T	cg24851651	chr11:66362959	CCS	0.55	9.95	0.44	4.35e-21	Airway imaging phenotypes;
LUAD	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.66	-0.61	6.61e-44	Eye color traits;
LUAD	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.39	7.83	0.36	4.03e-14	Neutrophil percentage of white cells;
LUAD	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	ch.11.42038R	chr11:967971	AP2A2	0.42	7.34	0.34	1.14e-12	Alzheimer's disease (late onset);
LUAD	trans	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg03886242	chr7:26192032	NFE2L3	-0.44	-7.65	-0.35	1.42e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7776786	0.934	rs13243526	chr7:18812917	C/T	cg13420273	chr7:18810212	HDAC9	-0.33	-6.9	-0.32	1.89e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg17063962	chr7:91808500	NA	0.7	12.76	0.53	8.88e-32	Breast cancer;
LUAD	cis	rs9399401	0.593	rs262117	chr6:142807093	G/A	cg04461802	chr6:142623433	GPR126	0.38	6.68	0.31	7.6e-11	Chronic obstructive pulmonary disease;
LUAD	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg15704280	chr7:45808275	SEPT13	-0.62	-9.34	-0.41	5.63e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg20607287	chr7:12443886	VWDE	-0.51	-6.68	-0.31	7.47e-11	Coronary artery disease;
LUAD	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg27490568	chr2:178487706	NA	0.74	10.96	0.47	8.96e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg26384229	chr12:38710491	ALG10B	0.48	8.01	0.36	1.16e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg06558623	chr16:89946397	TCF25	1.15	10.16	0.44	7.69e-22	Skin colour saturation;
LUAD	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.81	11.74	0.5	9.87e-28	Smoking behavior;
LUAD	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg19318889	chr4:1322082	MAEA	0.51	8.56	0.38	2.03e-16	Longevity;
LUAD	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg02951883	chr7:2050386	MAD1L1	-0.71	-11.89	-0.5	2.48e-28	Schizophrenia;
LUAD	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg05182265	chr7:156933206	UBE3C	-0.8	-17.28	-0.64	5.14e-51	Body mass index;
LUAD	cis	rs72634258	0.503	rs2794666	chr1:7822009	A/G	cg26816564	chr1:7831052	VAMP3	0.62	8.12	0.37	4.99e-15	Inflammatory bowel disease;
LUAD	cis	rs4380275	1.000	rs4380275	chr2:773278	C/T	cg21665850	chr2:731073	NA	0.5	8.94	0.4	1.24e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUAD	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg21963583	chr11:68658836	MRPL21	0.64	11.49	0.49	8.92e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg01689657	chr7:91764605	CYP51A1	0.29	6.92	0.32	1.69e-11	Breast cancer;
LUAD	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	7.55	0.34	2.72e-13	Parkinson's disease;
LUAD	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg27284194	chr4:1044797	NA	0.68	9.44	0.42	2.47e-19	Recombination rate (females);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg05296608	chr10:134537282	INPP5A	-0.44	-7.3	-0.33	1.45e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1232027	0.656	rs1677698	chr5:79957483	A/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.01	-0.32	9.29e-12	Huntington's disease progression;
LUAD	cis	rs75920871	0.925	rs61905716	chr11:116919067	C/T	cg04087571	chr11:116723030	SIK3	-0.33	-6.76	-0.31	4.53e-11	Subjective well-being;
LUAD	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg05425664	chr17:57184151	TRIM37	0.42	7.57	0.35	2.44e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg24818145	chr4:99064322	C4orf37	0.4	6.76	0.31	4.57e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs36096196	0.891	rs12082516	chr1:2251160	C/T	cg06784691	chr1:2245988	NA	0.34	7.16	0.33	3.59e-12	Coronary artery disease;
LUAD	trans	rs8073060	0.586	rs6505485	chr17:33996102	C/T	cg19694781	chr19:47549865	TMEM160	-1.16	-17.96	-0.66	5.09e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg24642844	chr7:1081250	C7orf50	-0.88	-9.68	-0.43	3.87e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg24733560	chr20:60626293	TAF4	0.45	8.85	0.4	2.44e-17	Body mass index;
LUAD	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg18944383	chr4:111397179	ENPEP	0.39	7.84	0.36	3.75e-14	Height;
LUAD	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-14.76	-0.58	4.51e-40	Schizophrenia;
LUAD	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg09904177	chr6:26538194	HMGN4	0.4	6.53	0.3	1.86e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.44	-9.4	-0.42	3.58e-19	Total body bone mineral density;
LUAD	trans	rs7395662	0.929	rs12363679	chr11:48556023	G/C	cg15704280	chr7:45808275	SEPT13	-0.41	-6.37	-0.3	4.81e-10	HDL cholesterol;
LUAD	cis	rs11626933	1.000	rs11626016	chr14:90747979	C/T	cg14092571	chr14:90743983	NA	-0.96	-18.18	-0.66	5.55e-55	Gut microbiota (bacterial taxa);
LUAD	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg11871910	chr12:69753446	YEATS4	0.7	12.04	0.51	6.52e-29	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg22166914	chr1:53195759	ZYG11B	0.46	7.39	0.34	7.83e-13	Monocyte count;
LUAD	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg23422044	chr7:1970798	MAD1L1	-0.58	-7.24	-0.33	2.15e-12	Bipolar disorder;
LUAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg23978390	chr7:1156363	C7orf50	0.43	6.72	0.31	5.8200000000000003e-11	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg13565492	chr6:43139072	SRF	-0.61	-6.47	-0.3	2.76e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg14019146	chr3:50243930	SLC38A3	-0.54	-10.79	-0.46	3.89e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg02269571	chr22:50332266	NA	-0.59	-8.88	-0.4	1.86e-17	Schizophrenia;
LUAD	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg08219700	chr8:58056026	NA	0.41	6.39	0.3	4.44e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg02734326	chr4:10020555	SLC2A9	-0.42	-7.33	-0.34	1.17e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8046696	1	rs8046696	chr16:75442143	T/G	cg03315344	chr16:75512273	CHST6	0.64	13.72	0.55	1.11e-35	Coronary artery disease;
LUAD	cis	rs6750795	0.542	rs1797388	chr2:232415981	T/G	cg19187155	chr2:232395269	NMUR1	0.49	8.97	0.4	9.79e-18	Height;
LUAD	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg23719950	chr11:63933701	MACROD1	-0.58	-6.9	-0.32	1.85e-11	Mean platelet volume;
LUAD	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg11645453	chr3:52864694	ITIH4	-0.34	-7.12	-0.33	4.64e-12	Bipolar disorder;
LUAD	cis	rs4077515	0.874	rs4498662	chr9:139290251	C/G	cg14019695	chr9:139328340	INPP5E	0.39	7.43	0.34	6.01e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg18944383	chr4:111397179	ENPEP	0.39	6.98	0.32	1.17e-11	Coronary artery disease;
LUAD	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg02158880	chr13:53174818	NA	0.54	9.5	0.42	1.5700000000000001e-19	Lewy body disease;
LUAD	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg13390004	chr1:15929781	NA	0.48	8.47	0.38	3.95e-16	Systolic blood pressure;
LUAD	cis	rs11112613	0.609	rs11112585	chr12:105933442	A/G	cg03607813	chr12:105948248	NA	-0.85	-11.98	-0.5	1.09e-28	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	trans	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg03886242	chr7:26192032	NFE2L3	-0.46	-8.04	-0.36	9.18e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg06484146	chr7:12443880	VWDE	-0.6	-7.62	-0.35	1.64e-13	Coronary artery disease;
LUAD	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21659725	chr3:3221576	CRBN	-0.63	-10.05	-0.44	1.87e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs1493916	1.000	rs9964702	chr18:31390427	A/C	cg13755796	chr4:20253514	NA	-0.41	-6.89	-0.32	2.1e-11	Life satisfaction;
LUAD	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg04414720	chr1:150670196	GOLPH3L	-0.47	-7.37	-0.34	8.8e-13	Tonsillectomy;
LUAD	trans	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg04995722	chr7:26192034	NFE2L3	-0.41	-7.15	-0.33	3.79e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4523957	0.855	rs9897160	chr17:2121566	A/G	cg16513277	chr17:2031491	SMG6	-0.82	-15.38	-0.6	1.05e-42	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	cis	rs3761218	1.000	rs4815603	chr20:3772527	A/T	cg02737268	chr20:3780182	CDC25B	0.29	6.75	0.31	4.92e-11	Bipolar disorder;
LUAD	trans	rs7395662	0.926	rs12288788	chr11:48686863	A/G	cg15704280	chr7:45808275	SEPT13	-0.41	-6.4	-0.3	4.17e-10	HDL cholesterol;
LUAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg25703541	chr22:24373054	LOC391322	-0.84	-16.03	-0.61	1.59e-45	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs863345	0.604	rs11264997	chr1:158485482	C/T	cg12129480	chr1:158549410	OR10X1	-0.25	-6.63	-0.31	1.02e-10	Pneumococcal bacteremia;
LUAD	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg14228332	chr4:119757509	SEC24D	0.8	7.56	0.34	2.57e-13	Cannabis dependence symptom count;
LUAD	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg14668632	chr7:2872130	GNA12	-0.6	-9.99	-0.44	3.16e-21	Height;
LUAD	cis	rs4006360	0.601	rs7501863	chr17:39249898	A/G	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.05	0.36	8.74e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg08601574	chr20:25228251	PYGB	0.46	8.8	0.39	3.41e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18876405	chr7:65276391	NA	-0.58	-9.91	-0.43	5.74e-21	Aortic root size;
LUAD	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.49	0.34	3.93e-13	Bipolar disorder;
LUAD	cis	rs722864	0.627	rs62175799	chr2:173935026	G/C	cg09210666	chr2:173941575	ZAK	0.51	6.75	0.31	4.96e-11	Lung cancer;
LUAD	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg02773041	chr1:40204384	PPIE	0.51	8.48	0.38	3.67e-16	Blood protein levels;
LUAD	cis	rs11048434	0.649	rs11613650	chr12:9060396	T/C	cg23795048	chr12:9217529	LOC144571	0.41	7.32	0.34	1.24e-12	Sjögren's syndrome;
LUAD	cis	rs9584850	0.834	rs7334078	chr13:99120484	C/T	cg20750642	chr13:99100586	FARP1	0.33	7.02	0.32	8.94e-12	Neuroticism;
LUAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08677398	chr8:58056175	NA	0.45	6.45	0.3	3.07e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs367943	0.666	rs12332129	chr5:112977983	A/G	cg12552261	chr5:112820674	MCC	0.47	8.72	0.39	6.56e-17	Type 2 diabetes;
LUAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2839627	0.638	rs7281701	chr21:44277296	C/T	cg03543861	chr21:44258195	NA	0.64	7.95	0.36	1.77e-14	Information processing speed;
LUAD	cis	rs4930561	0.739	rs10896303	chr11:67974292	C/A	cg04465784	chr11:67976953	SUV420H1	-0.28	-8.28	-0.37	1.59e-15	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg20503657	chr10:835505	NA	1.25	18.96	0.68	1.73e-58	Eosinophil percentage of granulocytes;
LUAD	cis	rs12216545	0.686	rs2373811	chr7:150251651	A/G	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.43	-0.3	3.43e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.75	-0.31	4.86e-11	Height;
LUAD	cis	rs11771526	0.901	rs13438711	chr7:32297310	G/A	cg13207630	chr7:32358064	NA	0.57	7.11	0.33	5.07e-12	Body mass index;
LUAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.51e-10	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg26513180	chr16:89883248	FANCA	0.78	6.99	0.32	1.09e-11	Skin colour saturation;
LUAD	cis	rs9394438	0.593	rs10947679	chr6:37543524	C/G	cg00985040	chr6:37553208	NA	0.44	9.29	0.41	7.93e-19	IgG glycosylation;
LUAD	cis	rs2688608	0.869	rs2633308	chr10:75653904	A/T	cg19442545	chr10:75533431	FUT11	-0.37	-6.36	-0.3	5.35e-10	Inflammatory bowel disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10833826	chr17:76837038	USP36	-0.53	-6.35	-0.3	5.6e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs748404	0.697	rs574065	chr15:43550655	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.52	-8.75	-0.39	5e-17	Lung cancer;
LUAD	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg21775007	chr8:11205619	TDH	0.47	8.21	0.37	2.75e-15	Retinal vascular caliber;
LUAD	cis	rs1559088	0.744	rs12462426	chr19:33536683	A/C	cg03563238	chr19:33554763	RHPN2	-0.31	-6.99	-0.32	1.11e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg21280719	chr6:42927975	GNMT	-0.38	-11.22	-0.48	9.18e-26	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg01657329	chr11:68192670	LRP5	-0.42	-6.7	-0.31	6.59e-11	Total body bone mineral density;
LUAD	cis	rs2688608	0.905	rs2633300	chr10:75656647	A/C	cg19442545	chr10:75533431	FUT11	-0.4	-6.92	-0.32	1.67e-11	Inflammatory bowel disease;
LUAD	cis	rs7809950	0.954	rs2712193	chr7:107125885	A/C	cg23024343	chr7:107201750	COG5	-0.69	-11.75	-0.5	8.77e-28	Coronary artery disease;
LUAD	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg13770153	chr20:60521292	NA	-1.0	-17.97	-0.66	4.73e-54	Obesity-related traits;
LUAD	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg13334819	chr7:99746414	C7orf59	0.63	9.9	0.43	6.48e-21	Coronary artery disease;
LUAD	cis	rs6076065	0.723	rs2424550	chr20:23394669	C/T	cg11657817	chr20:23433608	CST11	0.46	8.59	0.39	1.65e-16	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2274273	0.624	rs10143136	chr14:55743528	G/A	cg04306507	chr14:55594613	LGALS3	0.43	8.15	0.37	4.19e-15	Protein biomarker;
LUAD	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg17652424	chr22:38574118	PLA2G6	-0.33	-9.94	-0.44	4.62e-21	Cutaneous nevi;
LUAD	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg04705435	chr11:17411270	KCNJ11	0.41	6.79	0.31	3.78e-11	Type 2 diabetes;
LUAD	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg06618935	chr21:46677482	NA	-0.49	-9.99	-0.44	3.09e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg20476274	chr7:133979776	SLC35B4	0.87	17.67	0.65	9.85e-53	Mean platelet volume;
LUAD	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg09904177	chr6:26538194	HMGN4	0.43	7.26	0.33	1.87e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg17724175	chr1:150552817	MCL1	0.35	8.1	0.37	6.01e-15	Melanoma;
LUAD	cis	rs6005807	0.764	rs12169595	chr22:28966474	G/A	cg12565055	chr22:29076175	TTC28	0.67	6.63	0.31	1.01e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg06131755	chr6:160182447	ACAT2	0.44	6.54	0.3	1.81e-10	Age-related macular degeneration (geographic atrophy);
LUAD	trans	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.87	-0.32	2.35e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg03676636	chr4:99064102	C4orf37	0.32	8.34	0.38	1.05e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10899021	1.000	rs10899021	chr11:74338054	C/T	cg25880958	chr11:74394337	NA	0.52	7.19	0.33	3.01e-12	Response to metformin (IC50);
LUAD	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.4	0.45	1.05e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg03714773	chr7:91764589	CYP51A1	0.28	6.7	0.31	6.49e-11	Breast cancer;
LUAD	cis	rs1624802	0.638	rs1696431	chr12:130498408	C/T	cg15444478	chr12:130494697	NA	0.31	6.84	0.32	2.74e-11	Obesity-related traits;
LUAD	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06022373	chr22:39101656	GTPBP1	0.46	7.21	0.33	2.6e-12	Menopause (age at onset);
LUAD	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs887829	0.570	rs6753569	chr2:234595817	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.67	-0.43	4e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg00204512	chr16:28754710	NA	0.35	7.65	0.35	1.39e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.77	-9.43	-0.42	2.82e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06112835	chr11:68658793	MRPL21	0.54	9.68	0.43	3.74e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg03959625	chr15:84868606	LOC388152	0.4	6.48	0.3	2.6200000000000003e-10	Schizophrenia;
LUAD	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg16950941	chr11:66035639	RAB1B	0.45	7.61	0.35	1.82e-13	Gout;
LUAD	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg13770153	chr20:60521292	NA	-0.47	-7.88	-0.36	2.86e-14	Body mass index;
LUAD	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg14926445	chr8:58193284	C8orf71	-0.53	-7.83	-0.36	4e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg25456477	chr12:86230367	RASSF9	0.33	6.38	0.3	4.68e-10	Major depressive disorder;
LUAD	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg17063962	chr7:91808500	NA	0.68	12.37	0.52	3.29e-30	Breast cancer;
LUAD	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg27284194	chr4:1044797	NA	0.71	10.3	0.45	2.3e-22	Recombination rate (females);
LUAD	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg16647868	chr5:131706066	SLC22A5	0.49	7.8	0.35	4.83e-14	Blood metabolite levels;
LUAD	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg14092988	chr3:52407081	DNAH1	0.37	7.53	0.34	3.1e-13	Bipolar disorder;
LUAD	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg05368731	chr17:41323189	NBR1	0.97	20.52	0.71	1.85e-65	Menopause (age at onset);
LUAD	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg06608945	chr2:219082296	ARPC2	-0.43	-7.09	-0.33	5.5e-12	Colorectal cancer;
LUAD	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg24399712	chr22:39784796	NA	-0.79	-15.3	-0.6	2.15e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24531977	chr5:56204891	C5orf35	-0.97	-14.86	-0.59	1.78e-40	Initial pursuit acceleration;
LUAD	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg04876069	chr12:132293656	NA	-0.39	-6.8	-0.31	3.55e-11	Migraine;
LUAD	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg00634984	chr7:65235879	NA	-0.5	-6.55	-0.3	1.65e-10	Aortic root size;
LUAD	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.38	6.53	0.3	1.91e-10	Menarche (age at onset);
LUAD	trans	rs7395662	0.711	rs11512405	chr11:48936357	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.43	-0.34	5.93e-13	HDL cholesterol;
LUAD	cis	rs2554380	0.891	rs2562782	chr15:84300081	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.52	-7.76	-0.35	6.63e-14	Height;
LUAD	cis	rs735539	0.521	rs2762996	chr13:21373908	A/C	cg27499820	chr13:21296301	IL17D	0.46	7.71	0.35	9.21e-14	Dental caries;
LUAD	trans	rs11039798	0.841	rs10839174	chr11:48931185	G/A	cg15704280	chr7:45808275	SEPT13	0.67	7.8	0.35	4.95e-14	Axial length;
LUAD	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg06558623	chr16:89946397	TCF25	1.15	10.14	0.44	9e-22	Skin colour saturation;
LUAD	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg20503657	chr10:835505	NA	0.83	12.69	0.53	1.64e-31	Eosinophil percentage of granulocytes;
LUAD	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg01503450	chr10:980765	NA	-0.39	-6.87	-0.32	2.28e-11	Eosinophil percentage of granulocytes;
LUAD	trans	rs9914544	0.564	rs7223173	chr17:18805887	A/G	cg21372672	chr17:16614065	CCDC144A	-0.37	-6.5	-0.3	2.23e-10	Educational attainment (years of education);
LUAD	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg17173187	chr15:85201210	NMB	0.38	6.38	0.3	4.76e-10	Schizophrenia;
LUAD	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg25769590	chr7:158789503	NA	-0.38	-7.04	-0.32	7.62e-12	Facial morphology (factor 20);
LUAD	cis	rs501916	0.634	rs531596	chr15:48058214	C/T	cg16110827	chr15:48056943	SEMA6D	-0.36	-6.56	-0.3	1.58e-10	Inflammatory bowel disease;Ulcerative colitis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23709988	chr14:23772096	PPP1R3E	-0.57	-7.0	-0.32	9.84e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs701145	0.938	rs701138	chr3:154063609	T/C	cg17054900	chr3:154042577	DHX36	0.63	7.05	0.32	7.4e-12	Coronary artery disease;
LUAD	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg09491104	chr22:46646882	C22orf40	-0.68	-12.5	-0.52	9.71e-31	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs367943	0.712	rs26961	chr5:112736779	A/G	cg12552261	chr5:112820674	MCC	0.46	8.86	0.4	2.22e-17	Type 2 diabetes;
LUAD	cis	rs2073016	0.925	rs2073014	chr6:41029109	C/T	cg14769373	chr6:40998127	UNC5CL	0.59	8.34	0.38	1.03e-15	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);
LUAD	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.37	6.46	0.3	2.87e-10	Blood metabolite levels;
LUAD	cis	rs13064411	0.696	rs1552432	chr3:113225660	G/C	cg18753928	chr3:113234510	CCDC52	-0.73	-12.43	-0.52	1.93e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg08888203	chr3:10149979	C3orf24	0.73	11.17	0.48	1.44e-25	Alzheimer's disease;
LUAD	cis	rs13315871	1.000	rs71311858	chr3:58323793	G/C	cg12435725	chr3:58293450	RPP14	-0.73	-7.68	-0.35	1.1e-13	Cholesterol, total;
LUAD	cis	rs13064411	0.696	rs9836396	chr3:113184282	T/C	cg18753928	chr3:113234510	CCDC52	-0.67	-11.61	-0.49	3.15e-27	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs897984	0.609	rs732173	chr16:31050023	C/A	cg02466173	chr16:30829666	NA	-0.55	-9.63	-0.42	5.49e-20	Dementia with Lewy bodies;
LUAD	trans	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg07393940	chr7:158741817	NA	0.68	11.63	0.49	2.59e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg20290983	chr6:43655470	MRPS18A	1.07	27.14	0.8	1.12e-94	IgG glycosylation;
LUAD	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg17328964	chr8:145687451	CYHR1	-0.56	-9.68	-0.43	3.87e-20	Age at first birth;
LUAD	cis	rs2050392	1.000	rs2480280	chr10:30696092	A/G	cg18806716	chr10:30721971	MAP3K8	-0.53	-10.54	-0.46	3.34e-23	Inflammatory bowel disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07172558	chr13:111365483	ING1	-0.42	-6.72	-0.31	5.92e-11	Cancer;
LUAD	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.45	-7.82	-0.36	4.35e-14	Body mass index (adult);
LUAD	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.42	7.38	0.34	8.68e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2286885	1.000	rs2286885	chr9:129246487	A/C	cg15282417	chr9:129245246	FAM125B	0.45	9.13	0.41	2.87e-18	Intraocular pressure;
LUAD	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg15997130	chr1:24165203	NA	0.54	9.43	0.42	2.81e-19	Immature fraction of reticulocytes;
LUAD	cis	rs7536201	1.000	rs7536201	chr1:25293084	T/C	cg23273869	chr1:25296894	NA	-0.35	-6.93	-0.32	1.6e-11	Psoriasis vulgaris;
LUAD	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg02896835	chr1:92012615	NA	-0.58	-11.91	-0.5	2.03e-28	Breast cancer;
LUAD	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	7.09	0.33	5.67e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs4714291	0.963	rs1743969	chr6:40096918	A/G	cg02267698	chr19:7991119	CTXN1	0.42	6.38	0.3	4.66e-10	Strep throat;
LUAD	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg03929089	chr4:120376271	NA	-0.71	-10.8	-0.46	3.53e-24	Height;
LUAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg22963979	chr7:1858916	MAD1L1	-0.69	-12.28	-0.51	7.07e-30	Bipolar disorder and schizophrenia;
LUAD	trans	rs2262909	0.924	rs11085509	chr19:22204573	T/C	cg05197062	chr11:11642011	GALNTL4	-0.54	-8.08	-0.37	6.75e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg19622623	chr12:86230825	RASSF9	-0.39	-7.02	-0.32	9.09e-12	Major depressive disorder;
LUAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg18621852	chr3:10150065	C3orf24	0.42	6.74	0.31	5.34e-11	Alzheimer's disease;
LUAD	cis	rs13095912	0.962	rs6785918	chr3:185330631	A/G	cg11274856	chr3:185301563	NA	0.38	7.59	0.35	2.08e-13	Systolic blood pressure;
LUAD	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.77	10.4	0.45	1.01e-22	Schizophrenia;
LUAD	cis	rs5756813	0.754	rs11705616	chr22:38180487	G/T	cg06521852	chr22:38141419	TRIOBP	0.49	9.28	0.41	9.12e-19	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg25703541	chr22:24373054	LOC391322	-0.86	-15.83	-0.61	1.18e-44	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg03732007	chr1:2071316	PRKCZ	-0.35	-6.66	-0.31	8.63e-11	Height;
LUAD	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg23018236	chr17:30244563	NA	-0.69	-8.48	-0.38	3.69e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg02569458	chr12:86230093	RASSF9	0.45	8.24	0.37	2.25e-15	Major depressive disorder;
LUAD	cis	rs7241530	0.636	rs4799271	chr18:75898539	C/T	cg14642773	chr18:75888474	NA	0.35	6.35	0.3	5.46e-10	Educational attainment (years of education);
LUAD	cis	rs1829883	1.000	rs2460683	chr5:98778568	A/G	cg08333243	chr5:99726346	NA	-0.37	-7.1	-0.33	5.33e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg04896959	chr15:78267971	NA	0.63	12.05	0.51	6.23e-29	Coronary artery disease or large artery stroke;
LUAD	cis	rs240764	0.817	rs240146	chr6:101078718	G/A	cg09795085	chr6:101329169	ASCC3	0.43	7.52	0.34	3.23e-13	Neuroticism;
LUAD	cis	rs2282300	0.739	rs1616223	chr11:30338783	A/C	cg25418670	chr11:30344373	C11orf46	-0.52	-7.14	-0.33	4.16e-12	Morning vs. evening chronotype;
LUAD	cis	rs72772090	0.539	rs11748519	chr5:96119328	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-7.18	-0.33	3.2e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg17366294	chr4:99064904	C4orf37	0.67	12.81	0.53	5.57e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9503598	0.714	rs7758776	chr6:3452245	C/T	cg00476032	chr6:3446245	SLC22A23	0.39	8.86	0.4	2.31e-17	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg14345882	chr6:26364793	BTN3A2	0.7	7.14	0.33	4.13e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg13319975	chr6:146136371	FBXO30	-0.65	-11.35	-0.48	3.08e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2692947	0.589	rs810057	chr2:97015073	T/C	cg23100626	chr2:96804247	ASTL	0.36	8.77	0.39	4.39e-17	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs990171	0.538	rs2075190	chr2:103118559	A/T	cg03938978	chr2:103052716	IL18RAP	0.33	6.55	0.3	1.71e-10	Lymphocyte counts;
LUAD	cis	rs7258465	1.000	rs34010330	chr19:18559657	G/C	cg25828334	chr19:18545568	ISYNA1	-0.4	-7.97	-0.36	1.46e-14	Breast cancer;
LUAD	cis	rs9837602	1.000	rs793472	chr3:99546110	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.6	-8.5	-0.38	3.37e-16	Breast cancer;
LUAD	cis	rs28595532	0.920	rs17257945	chr4:119666465	T/A	cg21605333	chr4:119757512	SEC24D	0.83	7.46	0.34	5.06e-13	Cannabis dependence symptom count;
LUAD	cis	rs1198430	0.789	rs1198423	chr1:23735241	G/T	cg12023170	chr1:23751761	TCEA3	-0.47	-6.36	-0.3	5.32e-10	Total cholesterol levels;
LUAD	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg22920501	chr2:26401640	FAM59B	-0.76	-10.97	-0.47	8.37e-25	Gut microbiome composition (summer);
LUAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg18765753	chr7:1198926	ZFAND2A	-0.42	-7.58	-0.35	2.21e-13	Longevity;Endometriosis;
LUAD	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg00981070	chr1:2046702	PRKCZ	-0.36	-7.39	-0.34	7.71e-13	Height;
LUAD	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.94	0.4	1.19e-17	Gut microbiome composition (summer);
LUAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg08888203	chr3:10149979	C3orf24	0.74	12.97	0.53	1.25e-32	Alzheimer's disease;
LUAD	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.6	-0.31	1.21e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9296095	0.747	rs12206050	chr6:33564296	A/T	cg24505687	chr6:33548425	BAK1	0.42	6.63	0.31	1.04e-10	Platelet count;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg19155557	chr3:41240643	CTNNB1	-0.41	-7.26	-0.33	1.89e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg27588902	chr6:42928151	GNMT	-0.36	-9.64	-0.42	5.07e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7586879	0.796	rs916486	chr2:25082629	C/A	cg04586622	chr2:25135609	ADCY3	0.34	6.89	0.32	2.09e-11	Body mass index;
LUAD	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg05304507	chr6:116381966	FRK	0.2	6.66	0.31	8.34e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12618769	0.597	rs3754885	chr2:99121708	G/T	cg10123293	chr2:99228465	UNC50	0.46	8.12	0.37	5.1e-15	Bipolar disorder;
LUAD	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg08989290	chr16:615782	NHLRC4	0.31	6.72	0.31	5.75e-11	Height;
LUAD	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg09365446	chr1:150670422	GOLPH3L	0.65	12.15	0.51	2.52e-29	Tonsillectomy;
LUAD	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg13319975	chr6:146136371	FBXO30	-0.65	-11.28	-0.48	5.54e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg04267008	chr7:1944627	MAD1L1	-0.71	-10.81	-0.47	3.15e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs2455799	1.000	rs9873472	chr3:15867596	T/A	cg16303742	chr3:15540471	COLQ	-0.38	-6.58	-0.3	1.39e-10	Mean platelet volume;
LUAD	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg21951975	chr1:209979733	IRF6	0.56	7.14	0.33	4.03e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08219700	chr8:58056026	NA	0.6	8.3	0.37	1.45e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg02527881	chr3:46936655	PTH1R	0.41	7.78	0.35	5.77e-14	Colorectal cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10902427	chr5:176944034	DDX41	-0.57	-7.38	-0.34	8.31e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.6	0.31	1.22e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg09263875	chr16:632152	PIGQ	0.81	17.39	0.65	1.66e-51	Height;
LUAD	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.4	7.13	0.33	4.23e-12	Menarche (age at onset);
LUAD	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg00339695	chr16:24857497	SLC5A11	0.55	9.72	0.43	2.63e-20	Intelligence (multi-trait analysis);
LUAD	trans	rs7127307	0.740	rs4144896	chr11:128182026	C/T	cg17548431	chr4:160024475	NA	-0.51	-6.48	-0.3	2.54e-10	Atopic dermatitis;
LUAD	cis	rs2249625	0.564	rs2496496	chr6:72884053	A/G	cg18830697	chr6:72922368	RIMS1	-0.45	-8.13	-0.37	4.91e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	7.09	0.33	5.79e-12	Tonsillectomy;
LUAD	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg22875332	chr1:76189707	ACADM	-0.69	-11.34	-0.48	3.42e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23583168	chr7:148888333	NA	-0.91	-18.99	-0.68	1.27e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.93	-0.36	2.03e-14	Depression;
LUAD	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.82	-12.76	-0.53	8.95e-32	Chronic sinus infection;
LUAD	cis	rs11048434	0.736	rs1049925	chr12:9086898	A/G	cg23795048	chr12:9217529	LOC144571	0.43	7.78	0.35	5.5e-14	Sjögren's syndrome;
LUAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg08132940	chr7:1081526	C7orf50	-0.44	-6.69	-0.31	7.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg07917127	chr4:99064746	C4orf37	0.5	8.13	0.37	4.76e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg22823121	chr1:150693482	HORMAD1	0.45	9.17	0.41	2.15e-18	Tonsillectomy;
LUAD	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06544989	chr22:39130855	UNC84B	0.45	8.46	0.38	4.49e-16	Menopause (age at onset);
LUAD	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg21214613	chr1:16344536	HSPB7	0.57	10.01	0.44	2.68e-21	Dilated cardiomyopathy;
LUAD	cis	rs11048434	0.698	rs10842537	chr12:9066158	T/C	cg26114124	chr12:9217669	LOC144571	0.36	6.5	0.3	2.23e-10	Sjögren's syndrome;
LUAD	cis	rs7177699	0.557	rs7176187	chr15:79121373	A/G	cg00540400	chr15:79124168	NA	0.41	8.93	0.4	1.29e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg08470875	chr2:26401718	FAM59B	-0.77	-10.37	-0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg23750338	chr8:142222470	SLC45A4	0.32	6.43	0.3	3.41e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs12824058	0.737	rs873663	chr12:130816316	C/T	cg26677194	chr12:130822605	PIWIL1	0.54	8.76	0.39	4.92e-17	Menopause (age at onset);
LUAD	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg22166914	chr1:53195759	ZYG11B	0.4	6.72	0.31	5.8200000000000003e-11	Monocyte count;
LUAD	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg26384229	chr12:38710491	ALG10B	-0.41	-6.67	-0.31	7.94e-11	Morning vs. evening chronotype;
LUAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.49	8.82	0.39	3.06e-17	Lymphocyte counts;
LUAD	cis	rs654950	0.934	rs653369	chr1:42002376	A/T	cg06885757	chr1:42089581	HIVEP3	-0.49	-10.7	-0.46	8.04e-24	Airway imaging phenotypes;
LUAD	cis	rs11650494	0.908	rs73324308	chr17:47405338	T/G	cg08112188	chr17:47440006	ZNF652	0.93	7.97	0.36	1.44e-14	Prostate cancer;
LUAD	cis	rs1461503	0.966	rs10892936	chr11:122841720	G/A	cg27398637	chr11:122830231	C11orf63	-0.36	-6.85	-0.32	2.55e-11	Menarche (age at onset);
LUAD	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg01616529	chr11:638424	DRD4	-0.44	-6.43	-0.3	3.42e-10	Systemic lupus erythematosus;
LUAD	cis	rs2692947	0.695	rs12464148	chr2:96596710	G/C	cg23100626	chr2:96804247	ASTL	0.3	7.73	0.35	8.18e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.37	-0.48	2.61e-26	Bipolar disorder and schizophrenia;
LUAD	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg17077180	chr1:38461687	NA	-0.44	-8.01	-0.36	1.14e-14	Coronary artery disease;
LUAD	cis	rs7771547	0.855	rs9368942	chr6:36566513	C/G	cg07856975	chr6:36356162	ETV7	0.43	6.65	0.31	9.29e-11	Platelet distribution width;
LUAD	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg21475434	chr5:93447410	FAM172A	0.73	8.31	0.37	1.28e-15	Diabetic retinopathy;
LUAD	cis	rs8014204	0.836	rs12888998	chr14:75292662	G/T	cg06637938	chr14:75390232	RPS6KL1	0.4	7.31	0.33	1.37e-12	Caffeine consumption;
LUAD	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg17173187	chr15:85201210	NMB	0.42	6.84	0.32	2.81e-11	Schizophrenia;
LUAD	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg10978503	chr1:24200527	CNR2	0.55	12.05	0.51	6.15e-29	Immature fraction of reticulocytes;
LUAD	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	7.24	0.33	2.12e-12	Body mass index;
LUAD	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg02421172	chr7:1938701	MAD1L1	0.44	6.39	0.3	4.28e-10	Bipolar disorder;
LUAD	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg17173187	chr15:85201210	NMB	0.54	9.43	0.42	2.67e-19	Schizophrenia;
LUAD	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-10.49	-0.45	4.71e-23	Gut microbiome composition (summer);
LUAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg23131131	chr22:24373011	LOC391322	-0.59	-9.99	-0.44	3.07e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg08508325	chr11:3079039	CARS	-0.64	-14.35	-0.57	2.56e-38	Longevity;
LUAD	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.69	-0.43	3.44e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg09359103	chr1:154839909	KCNN3	-0.91	-20.92	-0.71	2.94e-67	Prostate cancer;
LUAD	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg10483660	chr13:112241077	NA	-0.32	-6.88	-0.32	2.23e-11	Hepatitis;
LUAD	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg27426351	chr10:43362370	NA	-0.5	-7.71	-0.35	9.18e-14	Blood protein levels;
LUAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.6	-8.83	-0.39	2.83e-17	Alzheimer's disease;
LUAD	cis	rs12618769	0.597	rs3769727	chr2:99103318	C/T	cg10123293	chr2:99228465	UNC50	0.46	8.39	0.38	7.48e-16	Bipolar disorder;
LUAD	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.32	-6.48	-0.3	2.61e-10	Personality dimensions;
LUAD	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg22508957	chr16:3507546	NAT15	-0.81	-9.08	-0.4	4.15e-18	Tuberculosis;
LUAD	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg17333051	chr19:2783644	SGTA	0.46	7.14	0.33	4.17e-12	Total cholesterol levels;
LUAD	cis	rs4356932	1.000	rs4456983	chr4:76958688	A/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.52	-0.3	2.05e-10	Blood protein levels;
LUAD	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg25251562	chr2:3704773	ALLC	-0.5	-8.23	-0.37	2.29e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11890956	chr21:40555474	PSMG1	-0.67	-11.61	-0.49	2.96e-27	Cognitive function;
LUAD	cis	rs73206853	0.841	rs73191828	chr12:110946121	G/A	cg12870014	chr12:110450643	ANKRD13A	0.62	7.01	0.32	9.52e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg18350739	chr11:68623251	NA	-0.37	-6.4	-0.3	4.21e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg10518543	chr12:38710700	ALG10B	-0.47	-7.79	-0.35	5.16e-14	Morning vs. evening chronotype;
LUAD	trans	rs3960554	0.808	rs78478514	chr7:75655896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.82	11.08	0.47	3.15e-25	Eotaxin levels;
LUAD	cis	rs7193541	0.965	rs4402594	chr16:74701360	C/T	cg01733217	chr16:74700730	RFWD3	0.52	8.89	0.4	1.74e-17	Multiple myeloma;
LUAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg19626725	chr5:178986131	RUFY1	-0.43	-7.72	-0.35	8.28e-14	Lung cancer;
LUAD	cis	rs2742417	1.000	rs2673067	chr3:45770087	A/C	cg10512202	chr3:45649293	LIMD1	0.37	6.51	0.3	2.1e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs9902453	0.874	rs62070271	chr17:28268358	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.5	0.45	4.43e-23	Coffee consumption (cups per day);
LUAD	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	6.66	0.31	8.4e-11	Obesity-related traits;
LUAD	cis	rs71403859	0.502	rs71403847	chr16:71468226	T/C	cg08717414	chr16:71523259	ZNF19	-0.57	-7.14	-0.33	4.12e-12	Post bronchodilator FEV1;
LUAD	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg20701182	chr2:24300061	SF3B14	0.53	6.48	0.3	2.63e-10	Lymphocyte counts;
LUAD	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg20744362	chr22:50050164	C22orf34	0.42	9.23	0.41	1.28e-18	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	6.82	0.31	3.13e-11	Motion sickness;
LUAD	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg02228675	chr17:40259724	DHX58	-0.44	-7.27	-0.33	1.8e-12	Fibrinogen levels;
LUAD	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-14.84	-0.59	2.04e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg10755058	chr3:40428713	ENTPD3	-0.42	-8.04	-0.36	8.95e-15	Renal cell carcinoma;
LUAD	cis	rs3750082	0.889	rs3750081	chr7:32930876	T/G	cg05721444	chr7:32995514	FKBP9	0.38	6.82	0.31	3.15e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs4711350	0.871	rs1998949	chr6:33721457	T/C	cg07979401	chr6:33739406	LEMD2	-0.4	-6.71	-0.31	6.33e-11	Schizophrenia;
LUAD	cis	rs2797160	1.000	rs6934435	chr6:126017481	T/G	cg05901451	chr6:126070800	HEY2	0.46	6.79	0.31	3.79e-11	Endometrial cancer;
LUAD	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg09455208	chr3:40491958	NA	0.65	14.4	0.57	1.52e-38	Renal cell carcinoma;
LUAD	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.56	7.92	0.36	2.14e-14	Platelet count;
LUAD	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-13.74	-0.56	9.23e-36	Total body bone mineral density;
LUAD	cis	rs698833	0.926	rs1067342	chr2:44622256	A/C	cg04920474	chr2:44395004	PPM1B	0.38	6.8	0.31	3.5e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg20701182	chr2:24300061	SF3B14	0.88	13.43	0.55	1.71e-34	Lymphocyte counts;
LUAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08219700	chr8:58056026	NA	0.57	8.08	0.37	6.8e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg23029597	chr12:123009494	RSRC2	-0.58	-9.22	-0.41	1.45e-18	Body mass index;
LUAD	cis	rs10908458	0.808	rs11264322	chr1:155087933	G/A	cg23973274	chr1:155060172	NA	-0.46	-8.09	-0.37	6.32e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg06609049	chr19:2785107	THOP1	0.73	11.86	0.5	3.17e-28	Total cholesterol levels;
LUAD	cis	rs11756438	0.607	rs1688631	chr6:119019064	A/T	cg18833306	chr6:118973337	C6orf204	0.4	6.86	0.32	2.43e-11	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs300774	0.748	rs413523	chr2:131203	C/G	cg21211680	chr2:198530	NA	-0.48	-7.53	-0.34	3.12e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg16647868	chr5:131706066	SLC22A5	-0.39	-6.65	-0.31	8.95e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19346786	chr7:2764209	NA	-0.58	-12.61	-0.52	3.66e-31	Height;
LUAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg22907277	chr7:1156413	C7orf50	0.71	8.31	0.37	1.29e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg06606381	chr12:133084897	FBRSL1	-0.64	-6.73	-0.31	5.42e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2764208	0.770	rs112283401	chr6:34797756	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.36	-0.38	9.43e-16	Systemic lupus erythematosus;
LUAD	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg17747265	chr1:1875780	NA	-0.75	-18.71	-0.67	2.38e-57	Body mass index;
LUAD	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg02018176	chr4:1364513	KIAA1530	0.57	10.81	0.47	3.12e-24	Longevity;
LUAD	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg13402656	chr8:1511478	DLGAP2	-0.73	-15.52	-0.6	2.52e-43	Lung cancer;
LUAD	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg24675056	chr1:15929824	NA	0.48	8.34	0.38	1.08e-15	Systolic blood pressure;
LUAD	cis	rs6960043	0.714	rs4719430	chr7:15047280	C/G	cg19272540	chr7:15055459	NA	-0.38	-8.35	-0.38	9.5e-16	Type 2 diabetes;
LUAD	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg16647868	chr5:131706066	SLC22A5	-0.37	-6.41	-0.3	3.8e-10	Breast cancer;
LUAD	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg08645402	chr16:4508243	NA	0.58	10.8	0.46	3.48e-24	Schizophrenia;
LUAD	cis	rs10129255	0.500	rs11627315	chr14:107210420	T/C	cg23076370	chr14:107095027	NA	-0.43	-8.52	-0.38	2.84e-16	Kawasaki disease;
LUAD	cis	rs9341808	0.718	rs3805920	chr6:80892745	T/C	cg08355045	chr6:80787529	NA	0.58	10.49	0.45	4.9e-23	Sitting height ratio;
LUAD	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.46	-0.34	5.1e-13	Electroencephalogram traits;
LUAD	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg18944383	chr4:111397179	ENPEP	0.39	7.84	0.36	3.75e-14	Height;
LUAD	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg17264618	chr3:40429014	ENTPD3	0.41	8.83	0.39	2.84e-17	Renal cell carcinoma;
LUAD	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg11292332	chr7:45801988	SEPT13	-0.3	-6.64	-0.31	9.44e-11	Extrinsic epigenetic age acceleration;
LUAD	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg07870213	chr5:140052090	DND1	-0.66	-10.01	-0.44	2.6e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg21724239	chr8:58056113	NA	0.66	8.13	0.37	4.93e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg20257096	chr14:21851954	SUPT16H	0.41	7.03	0.32	8.14e-12	Anger;
LUAD	cis	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.68	-0.31	7.77e-11	Neuroticism;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg22119580	chr3:140951301	ACPL2	-0.7	-6.91	-0.32	1.78e-11	Type 2 diabetes;
LUAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg04025307	chr7:1156635	C7orf50	0.71	9.84	0.43	1.06e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.91	0.36	2.28e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs117623576	0.941	rs72778716	chr10:32370541	G/A	cg03047570	chr10:32398778	NA	-0.9	-10.34	-0.45	1.68e-22	Anti-saccade response;
LUAD	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-15.6	-0.6	1.18e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs516243	0.871	rs3748687	chr1:10736216	G/A	cg02903756	chr1:10750680	CASZ1	-0.47	-8.79	-0.39	3.9e-17	Migraine - clinic-based;
LUAD	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.3	6.38	0.3	4.64e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7617773	0.744	rs2125482	chr3:48323133	T/G	cg11946769	chr3:48343235	NME6	0.43	6.62	0.31	1.12e-10	Coronary artery disease;
LUAD	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg10876282	chr6:28092338	ZSCAN16	0.46	7.45	0.34	5.43e-13	Parkinson's disease;
LUAD	trans	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-17.07	-0.64	4.55e-50	Exhaled nitric oxide output;
LUAD	cis	rs7274811	0.595	rs13045068	chr20:32133484	G/C	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.45	-6.64	-0.31	9.54e-11	Height;
LUAD	cis	rs5758511	0.689	rs11913578	chr22:42347391	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.38	6.62	0.31	1.09e-10	Birth weight;
LUAD	trans	rs853679	0.505	rs35781323	chr6:28144832	T/C	cg06606381	chr12:133084897	FBRSL1	-1.22	-10.86	-0.47	2.15e-24	Depression;
LUAD	cis	rs2070997	0.586	rs7851994	chr9:133749848	C/T	cg03924115	chr9:133768966	QRFP	0.49	6.78	0.31	3.98e-11	Response to amphetamines;
LUAD	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg11915388	chr22:42470451	FAM109B	0.41	7.28	0.33	1.64e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg19717773	chr7:2847554	GNA12	-0.44	-7.56	-0.34	2.55e-13	Height;
LUAD	trans	rs8002861	0.870	rs2121030	chr13:44444574	C/T	cg17145862	chr1:211918768	LPGAT1	-0.73	-16.89	-0.63	2.71e-49	Leprosy;
LUAD	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.86	-0.36	3.11e-14	Total body bone mineral density;
LUAD	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg25251562	chr2:3704773	ALLC	-0.5	-8.3	-0.37	1.46e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.15	0.33	3.78e-12	Motion sickness;
LUAD	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg26597838	chr10:835615	NA	1.05	16.74	0.63	1.29e-48	Eosinophil percentage of granulocytes;
LUAD	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg17761419	chr8:57350749	NA	-0.52	-7.89	-0.36	2.64e-14	Obesity-related traits;
LUAD	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-10.91	-0.47	1.4e-24	Hemoglobin concentration;
LUAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg18621852	chr3:10150065	C3orf24	0.43	6.88	0.32	2.17e-11	Alzheimer's disease;
LUAD	cis	rs2274273	0.662	rs67958555	chr14:55670866	G/A	cg04306507	chr14:55594613	LGALS3	0.43	8.01	0.36	1.14e-14	Protein biomarker;
LUAD	cis	rs7705042	0.865	rs9324866	chr5:141497650	A/G	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.78	-0.31	4.05e-11	Asthma;
LUAD	cis	rs16910800	0.731	rs16910738	chr11:23189455	C/T	cg20040320	chr11:23191996	NA	-0.75	-10.02	-0.44	2.32e-21	Cancer;
LUAD	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg03289416	chr15:75166202	SCAMP2	-0.37	-6.52	-0.3	1.96e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs4409675	0.576	rs6691656	chr1:28221130	C/G	cg23691781	chr1:28212827	C1orf38	0.39	11.33	0.48	3.76e-26	Corneal astigmatism;
LUAD	cis	rs12681287	0.640	rs7820234	chr8:87350950	A/C	cg27223183	chr8:87520930	FAM82B	-0.69	-9.66	-0.43	4.38e-20	Caudate activity during reward;
LUAD	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	7.07	0.32	6.63e-12	Schizophrenia;
LUAD	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg08085267	chr17:45401833	C17orf57	-0.49	-8.13	-0.37	4.74e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg18944383	chr4:111397179	ENPEP	0.37	7.62	0.35	1.68e-13	Height;
LUAD	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01570182	chr17:44337453	NA	-0.65	-10.35	-0.45	1.57e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg21659725	chr3:3221576	CRBN	-0.57	-9.06	-0.4	4.79e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17270561	0.609	rs9379778	chr6:25687579	T/C	cg25753631	chr6:25732923	NA	-0.39	-6.92	-0.32	1.66e-11	Iron status biomarkers;
LUAD	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg08027265	chr7:2291960	NA	-0.4	-6.76	-0.31	4.68e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg21138405	chr5:131827807	IRF1	0.43	9.62	0.42	6.09e-20	Breast cancer;Mosquito bite size;
LUAD	trans	rs2018683	0.600	rs6948880	chr7:29003478	C/T	cg19402173	chr7:128379420	CALU	-0.55	-8.93	-0.4	1.28e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg01191920	chr7:158217561	PTPRN2	-0.66	-14.24	-0.57	7.45e-38	Obesity-related traits;
LUAD	cis	rs9837602	0.938	rs1021341	chr3:99786289	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.58	-0.3	1.37e-10	Breast cancer;
LUAD	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.58	-0.35	2.24e-13	Platelet count;
LUAD	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg13126279	chr21:47581558	C21orf56	-0.5	-8.27	-0.37	1.71e-15	Testicular germ cell tumor;
LUAD	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.19	-0.33	2.94e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13631	0.728	rs7466635	chr9:139980417	T/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	-0.38	-6.65	-0.31	8.81e-11	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs9323205	0.677	rs61987261	chr14:51723879	G/A	cg23942311	chr14:51606299	NA	-0.57	-8.69	-0.39	8.18e-17	Cancer;
LUAD	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg08807101	chr21:30365312	RNF160	0.5	8.49	0.38	3.58e-16	Dental caries;
LUAD	cis	rs17433780	0.808	rs7541867	chr1:89513537	G/A	cg09516651	chr1:89888402	LOC400759	0.57	10.76	0.46	4.99e-24	Carotid intima media thickness;
LUAD	cis	rs354225	0.544	rs4616509	chr2:54807982	T/C	cg01766943	chr2:54829624	SPTBN1	0.39	7.34	0.34	1.1e-12	Schizophrenia;
LUAD	trans	rs11039798	0.698	rs6485805	chr11:48101723	C/T	cg15704280	chr7:45808275	SEPT13	0.69	7.43	0.34	5.9e-13	Axial length;
LUAD	cis	rs10924309	0.737	rs1122734	chr1:245853336	A/T	cg00036263	chr1:245852353	KIF26B	-0.53	-9.15	-0.41	2.49e-18	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs8067545	1.000	rs7211535	chr17:19922364	A/G	cg04132472	chr17:19861366	AKAP10	0.27	6.5	0.3	2.25e-10	Schizophrenia;
LUAD	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg27129171	chr3:47204927	SETD2	-0.4	-6.36	-0.3	5.39e-10	Colorectal cancer;
LUAD	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.68	-11.36	-0.48	2.74e-26	Primary sclerosing cholangitis;
LUAD	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg12310025	chr6:25882481	NA	0.49	7.89	0.36	2.7e-14	Blood metabolite levels;
LUAD	cis	rs9948	0.708	rs116121826	chr2:97441914	A/G	cg20312557	chr2:97357134	FER1L5	-0.63	-7.36	-0.34	9.71e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs9392556	0.829	rs9328220	chr6:4120181	A/C	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.42	-7.27	-0.33	1.8e-12	Blood metabolite levels;
LUAD	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg04414720	chr1:150670196	GOLPH3L	0.6	10.27	0.45	2.97e-22	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg06074448	chr4:187884817	NA	-0.4	-8.05	-0.36	8.38e-15	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3733418	0.929	rs7657444	chr4:165886559	G/C	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.53	-6.8	-0.31	3.62e-11	Obesity-related traits;
LUAD	cis	rs524023	0.914	rs555456	chr11:64418259	T/C	cg19131476	chr11:64387923	NRXN2	-0.42	-8.46	-0.38	4.51e-16	Urate levels in obese individuals;
LUAD	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg07700843	chr1:2391317	NA	-0.5	-11.69	-0.49	1.45e-27	Schizophrenia;
LUAD	cis	rs4006360	0.686	rs1848814	chr17:39240281	A/G	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.29	0.37	1.54e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg21724239	chr8:58056113	NA	0.72	9.53	0.42	1.24e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6906287	0.647	rs12197337	chr6:118884092	C/T	cg05564266	chr6:118973597	C6orf204	0.36	7.49	0.34	4.06e-13	Electrocardiographic conduction measures;
LUAD	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.9	-0.36	2.45e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.45	0.3	3.03e-10	Menarche (age at onset);
LUAD	cis	rs116095464	1.000	rs56095714	chr5:311256	C/T	cg22496380	chr5:211416	CCDC127	-1.08	-8.39	-0.38	7.25e-16	Breast cancer;
LUAD	cis	rs7010267	0.570	rs1485295	chr8:120039462	A/G	cg01975934	chr8:119970761	NA	-0.34	-6.43	-0.3	3.5e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg26384229	chr12:38710491	ALG10B	-0.4	-6.84	-0.32	2.86e-11	Heart rate;
LUAD	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg04154034	chr17:28927549	LRRC37B2	0.66	6.45	0.3	3.01e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs11811982	0.793	rs41270147	chr1:227406908	G/A	cg24860534	chr1:227506868	CDC42BPA	0.64	7.2	0.33	2.79e-12	Optic disc area;
LUAD	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.64	7.95	0.36	1.76e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12545109	0.800	rs1437278	chr8:57357024	T/C	cg11919837	chr8:57350735	NA	-0.48	-6.61	-0.31	1.14e-10	Obesity-related traits;
LUAD	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg13180566	chr4:1052158	NA	-0.4	-6.72	-0.31	5.8e-11	Recombination rate (females);
LUAD	cis	rs9902453	0.904	rs4994353	chr17:28386280	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.22	-0.41	1.43e-18	Coffee consumption (cups per day);
LUAD	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18876405	chr7:65276391	NA	-0.57	-9.51	-0.42	1.4e-19	Aortic root size;
LUAD	cis	rs7843479	0.965	rs4636204	chr8:21823206	T/G	cg03445287	chr8:21823731	XPO7	-0.46	-8.52	-0.38	2.74e-16	Mean corpuscular volume;
LUAD	cis	rs4713675	0.565	rs4713665	chr6:33674419	T/G	cg13859433	chr6:33739653	LEMD2	-0.3	-7.07	-0.33	6.5e-12	Plateletcrit;
LUAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg23958373	chr8:599963	NA	1.04	10.01	0.44	2.52e-21	IgG glycosylation;
LUAD	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18876405	chr7:65276391	NA	0.57	9.42	0.42	2.86e-19	Aortic root size;
LUAD	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg21856205	chr7:94953877	PON1	-0.56	-7.94	-0.36	1.84e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19960880	chr10:97050830	PDLIM1	-0.54	-6.48	-0.3	2.57e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs68170813	0.559	rs77150993	chr7:106817100	G/T	cg02696742	chr7:106810147	HBP1	-0.79	-11.09	-0.47	3.01e-25	Coronary artery disease;
LUAD	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.41	-7.88	-0.36	2.76e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2797685	0.898	rs2071987	chr1:7834026	G/A	cg04725166	chr1:7887271	PER3	-0.49	-7.13	-0.33	4.44e-12	Crohn's disease;
LUAD	cis	rs9595066	0.712	rs4391951	chr13:44755071	C/T	cg04068111	chr13:44716778	NA	0.5	8.49	0.38	3.48e-16	Schizophrenia;
LUAD	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg27539214	chr16:67997921	SLC12A4	-0.68	-8.43	-0.38	5.39e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.78	-13.53	-0.55	6.82e-35	Chronic sinus infection;
LUAD	trans	rs9784649	1.000	rs56156666	chr5:24999440	A/T	cg08600765	chr20:34638493	LOC647979	-0.61	-7.75	-0.35	6.91e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg05425664	chr17:57184151	TRIM37	-0.42	-7.61	-0.35	1.82e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg18129748	chr3:49941408	MST1R	0.41	6.88	0.32	2.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7737355	0.812	rs13158295	chr5:130629392	G/A	cg06307176	chr5:131281290	NA	0.39	6.6	0.31	1.24e-10	Life satisfaction;
LUAD	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg16950941	chr11:66035639	RAB1B	0.43	7.25	0.33	2e-12	Gout;
LUAD	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-8.96	-0.4	1.02e-17	Schizophrenia;
LUAD	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg06873352	chr17:61820015	STRADA	-0.66	-12.94	-0.53	1.65e-32	Prudent dietary pattern;
LUAD	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg00484396	chr16:3507460	NAT15	0.79	8.17	0.37	3.64e-15	Tuberculosis;
LUAD	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg08470875	chr2:26401718	FAM59B	0.78	10.37	0.45	1.28e-22	Gut microbiome composition (summer);
LUAD	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.5	-0.34	3.89e-13	Coronary artery disease;
LUAD	cis	rs7707921	0.679	rs150934	chr5:81600339	G/A	cg15871215	chr5:81402204	ATG10	0.46	6.5	0.3	2.26e-10	Breast cancer;
LUAD	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg20290983	chr6:43655470	MRPS18A	1.08	27.02	0.8	3.88e-94	IgG glycosylation;
LUAD	cis	rs4950928	0.823	rs4950929	chr1:203160126	A/C	cg17014757	chr1:203156097	CHI3L1	0.6	8.64	0.39	1.19e-16	YKL-40 levels;
LUAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.66	-12.66	-0.52	2.2e-31	Longevity;Endometriosis;
LUAD	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06544989	chr22:39130855	UNC84B	0.48	9.56	0.42	9.49e-20	Menopause (age at onset);
LUAD	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg03732007	chr1:2071316	PRKCZ	0.34	6.71	0.31	6.38e-11	Height;
LUAD	cis	rs2274273	0.870	rs11851169	chr14:55815932	G/A	cg04306507	chr14:55594613	LGALS3	0.44	9.18	0.41	1.87e-18	Protein biomarker;
LUAD	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	8.61	0.39	1.48e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs870825	0.860	rs55974219	chr4:185600733	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	11.51	0.49	7.31e-27	Blood protein levels;
LUAD	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg22681709	chr2:178499509	PDE11A	-0.44	-7.3	-0.33	1.46e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9811920	0.965	rs9289981	chr3:99868104	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.62	11.25	0.48	7.08e-26	Axial length;
LUAD	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg12311346	chr5:56204834	C5orf35	0.73	11.6	0.49	3.39e-27	Initial pursuit acceleration;
LUAD	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg11266682	chr4:10021025	SLC2A9	0.69	15.76	0.61	2.27e-44	Bone mineral density;
LUAD	cis	rs7216064	1.000	rs4791212	chr17:65975385	C/T	cg08758996	chr17:66097529	LOC651250	0.46	7.07	0.33	6.38e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	trans	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.42e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs758324	0.947	rs1500115	chr5:131216427	G/T	cg06307176	chr5:131281290	NA	0.52	8.26	0.37	1.86e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg09658497	chr7:2847517	GNA12	-0.54	-9.11	-0.41	3.29e-18	Height;
LUAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg11766577	chr21:47581405	C21orf56	0.64	11.67	0.49	1.85e-27	Testicular germ cell tumor;
LUAD	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11890956	chr21:40555474	PSMG1	-0.55	-9.49	-0.42	1.76e-19	Menarche (age at onset);
LUAD	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg17724175	chr1:150552817	MCL1	0.39	9.39	0.42	3.82e-19	Tonsillectomy;
LUAD	cis	rs11031096	0.811	rs4910599	chr11:4156040	T/A	cg18678763	chr11:4115507	RRM1	-0.43	-7.45	-0.34	5.21e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg06002616	chr8:101225028	SPAG1	0.38	7.75	0.35	7.14e-14	Atrioventricular conduction;
LUAD	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg25173405	chr17:45401733	C17orf57	0.51	8.36	0.38	9.41e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg02196655	chr2:10830764	NOL10	0.47	8.49	0.38	3.51e-16	Prostate cancer;
LUAD	cis	rs6840360	0.615	rs7695412	chr4:152488075	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.77	-0.31	4.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.77	-0.31	4.38e-11	Mood instability;
LUAD	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10802521	chr3:52805072	NEK4	-0.53	-9.07	-0.4	4.38e-18	Bipolar disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19229622	chr11:47291485	MADD	-0.48	-7.38	-0.34	8.52e-13	Height;
LUAD	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg17849569	chr6:28058911	ZSCAN12L1	-0.33	-7.01	-0.32	9.56e-12	Depression;
LUAD	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg21475434	chr5:93447410	FAM172A	-0.58	-7.36	-0.34	9.8e-13	Diabetic retinopathy;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg17841782	chr1:59762205	FGGY	-0.69	-6.61	-0.31	1.16e-10	Type 2 diabetes;
LUAD	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.74	-13.29	-0.54	6.23e-34	Breast cancer;
LUAD	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg03037974	chr15:76606532	NA	0.38	8.02	0.36	1.06e-14	Blood metabolite levels;
LUAD	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg17279839	chr7:150038598	RARRES2	0.43	7.49	0.34	4.1e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg11766577	chr21:47581405	C21orf56	-0.44	-7.62	-0.35	1.65e-13	Testicular germ cell tumor;
LUAD	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg23625390	chr15:77176239	SCAPER	-0.54	-8.23	-0.37	2.37e-15	Blood metabolite levels;
LUAD	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg08470875	chr2:26401718	FAM59B	0.64	7.97	0.36	1.49e-14	Gut microbiome composition (summer);
LUAD	trans	rs12246027	0.580	rs74332769	chr10:260044	T/C	cg00953403	chr17:74099816	EXOC7	0.52	6.6	0.31	1.23e-10	Blood metabolite levels;
LUAD	cis	rs6714710	0.603	rs13034929	chr2:98402772	G/C	cg26665480	chr2:98280029	ACTR1B	0.55	8.92	0.4	1.44e-17	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg15181151	chr6:150070149	PCMT1	0.39	7.57	0.35	2.41e-13	Lung cancer;
LUAD	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.76	-0.31	4.65e-11	Aortic root size;
LUAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.71e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg23950597	chr19:37808831	NA	0.62	7.65	0.35	1.4e-13	Coronary artery calcification;
LUAD	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.42	-0.3	3.76e-10	Triglycerides;
LUAD	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.55	-0.3	1.69e-10	Obesity-related traits;
LUAD	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg05283184	chr6:79620031	NA	-0.61	-12.2	-0.51	1.59e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg17173187	chr15:85201210	NMB	0.52	9.24	0.41	1.25e-18	Schizophrenia;
LUAD	cis	rs6541297	0.631	rs641038	chr1:230324801	G/A	cg20703242	chr1:230279135	GALNT2	-0.42	-6.73	-0.31	5.4e-11	Coronary artery disease;
LUAD	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06022373	chr22:39101656	GTPBP1	-0.47	-7.84	-0.36	3.7e-14	Menopause (age at onset);
LUAD	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.11	0.48	2.37e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7172809	0.573	rs11854466	chr15:77584733	T/C	cg11865553	chr15:77376250	NA	-0.39	-6.46	-0.3	2.97e-10	Glucose homeostasis traits;
LUAD	cis	rs600550	0.528	rs56661806	chr11:59848438	T/G	cg02771260	chr11:59836817	MS4A3	0.31	6.5	0.3	2.23e-10	Lipoprotein-associated phospholipase A2 activity and mass;
LUAD	trans	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg18187862	chr3:45730750	SACM1L	0.55	8.85	0.4	2.41e-17	Primary sclerosing cholangitis;
LUAD	cis	rs16882447	0.651	rs1664668	chr5:53488282	T/C	cg06461071	chr5:53490839	ARL15	0.39	6.53	0.3	1.89e-10	Systolic blood pressure (dietary potassium intake interaction);
LUAD	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11890956	chr21:40555474	PSMG1	-0.64	-11.13	-0.48	2.1e-25	Cognitive function;
LUAD	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg05234568	chr11:5960015	NA	-0.57	-10.15	-0.44	8.52e-22	DNA methylation (variation);
LUAD	cis	rs12681287	0.673	rs2976178	chr8:87332552	C/G	cg00550725	chr8:87521180	FAM82B	0.46	6.4	0.3	4.03e-10	Caudate activity during reward;
LUAD	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg10978503	chr1:24200527	CNR2	0.59	12.81	0.53	5.87e-32	Immature fraction of reticulocytes;
LUAD	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg26597838	chr10:835615	NA	0.51	8.04	0.36	9.26e-15	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg12365402	chr11:9010492	NRIP3	-0.52	-10.62	-0.46	1.7e-23	Hemoglobin concentration;
LUAD	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg21724239	chr8:58056113	NA	-0.54	-7.15	-0.33	3.83e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg13560548	chr3:10150139	C3orf24	0.42	6.78	0.31	4.03e-11	Alzheimer's disease;
LUAD	cis	rs2637266	0.967	rs6480826	chr10:78356154	A/G	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg22753661	chr15:79092743	ADAMTS7	0.54	8.38	0.38	7.66e-16	Coronary artery disease or large artery stroke;
LUAD	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.89	0.36	2.58e-14	Parkinson's disease;
LUAD	cis	rs35883536	0.647	rs17411209	chr1:101046734	A/G	cg06223162	chr1:101003688	GPR88	-0.48	-9.23	-0.41	1.3e-18	Monocyte count;
LUAD	trans	rs4799710	0.643	rs9954233	chr18:31298923	C/T	cg27147174	chr7:100797783	AP1S1	0.45	7.3	0.33	1.4e-12	Pulmonary function;
LUAD	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg00383909	chr3:49044727	WDR6	0.75	8.62	0.39	1.37e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.42	-0.34	6.34e-13	Platelet count;
LUAD	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg23950597	chr19:37808831	NA	-0.57	-6.97	-0.32	1.23e-11	Coronary artery calcification;
LUAD	cis	rs73198271	0.531	rs3748142	chr8:8655355	G/A	cg01851573	chr8:8652454	MFHAS1	0.73	11.08	0.47	3.17e-25	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4638749	0.677	rs7370742	chr2:108815385	T/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.27	-0.33	1.7e-12	Blood pressure;
LUAD	trans	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg18187862	chr3:45730750	SACM1L	-0.45	-6.46	-0.3	2.84e-10	Primary sclerosing cholangitis;
LUAD	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg14582100	chr15:45693742	SPATA5L1	0.42	8.51	0.38	3.07e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.07	0.37	7.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-6.99	-0.32	1.1e-11	Lung cancer;
LUAD	cis	rs12545109	0.842	rs2582379	chr8:57395243	C/T	cg21220214	chr8:57350948	NA	0.61	8.09	0.37	6.53e-15	Obesity-related traits;
LUAD	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-18.36	-0.67	8.84e-56	Coronary artery disease;
LUAD	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg01416388	chr22:39784598	NA	-0.53	-9.0	-0.4	7.79e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs9394169	0.514	rs1886355	chr6:33776877	C/T	cg07979401	chr6:33739406	LEMD2	-0.33	-6.39	-0.3	4.26e-10	Essential tremor;
LUAD	cis	rs6426558	0.514	rs3754418	chr1:227348473	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.56	-8.95	-0.4	1.12e-17	Neutrophil percentage of white cells;
LUAD	cis	rs3806843	0.576	rs246047	chr5:140328337	C/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7137828	0.837	rs653178	chr12:112007756	A/G	cg10833066	chr12:111807467	FAM109A	-0.33	-6.63	-0.31	1.06e-10	Glaucoma (primary open-angle);Coronary artery disease;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg04455712	chr21:45112962	RRP1B	0.4	7.77	0.35	5.85e-14	Mean corpuscular volume;
LUAD	cis	rs62400317	0.859	rs12191566	chr6:45160002	T/C	cg18551225	chr6:44695536	NA	-0.55	-8.44	-0.38	5.14e-16	Total body bone mineral density;
LUAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00149659	chr3:10157352	C3orf10	0.63	8.82	0.39	2.97e-17	Alzheimer's disease;
LUAD	cis	rs113835537	0.529	rs7928882	chr11:66234765	C/T	cg24851651	chr11:66362959	CCS	0.58	10.55	0.46	2.93e-23	Airway imaging phenotypes;
LUAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg11494091	chr17:61959527	GH2	0.74	18.58	0.67	9.11e-57	Prudent dietary pattern;
LUAD	trans	rs701145	0.640	rs896016	chr3:153929902	C/T	cg14299572	chr10:34021103	NA	-0.39	-6.47	-0.3	2.71e-10	Coronary artery disease;
LUAD	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg20476274	chr7:133979776	SLC35B4	0.76	13.08	0.54	4.73e-33	Mean platelet volume;
LUAD	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg07828340	chr4:882639	GAK	1.05	10.84	0.47	2.47e-24	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-20.24	-0.7	3.41e-64	Height;
LUAD	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.79	-15.26	-0.6	3.22e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs13082711	0.522	rs515402	chr3:27331022	G/T	cg02860705	chr3:27208620	NA	0.52	8.56	0.38	2.12e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.81	0.43	1.32e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg21028142	chr17:79581711	NPLOC4	0.35	6.89	0.32	2.06e-11	Eye color traits;
LUAD	cis	rs8099014	0.814	rs7227488	chr18:56113233	A/G	cg12907477	chr18:56117327	MIR122	0.49	8.22	0.37	2.51e-15	Platelet count;
LUAD	cis	rs748404	0.697	rs555001	chr15:43545728	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.12	0.37	5.09e-15	Lung cancer;
LUAD	cis	rs2067615	0.542	rs10861654	chr12:107122896	A/G	cg15890332	chr12:107067104	RFX4	0.4	8.6	0.39	1.59e-16	Heart rate;
LUAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg11965913	chr1:205819406	PM20D1	0.83	17.34	0.64	2.85e-51	Menarche (age at onset);
LUAD	cis	rs6499255	0.951	rs9788837	chr16:69688413	A/G	cg15192750	chr16:69999425	NA	0.54	8.27	0.37	1.7e-15	IgE levels;
LUAD	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg02782426	chr3:40428986	ENTPD3	-0.38	-8.18	-0.37	3.41e-15	Renal cell carcinoma;
LUAD	cis	rs870825	0.616	rs6810600	chr4:185616814	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.09	0.57	3.19e-37	Blood protein levels;
LUAD	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg19912559	chr1:40204330	PPIE	0.56	9.52	0.42	1.29e-19	Blood protein levels;
LUAD	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg26597838	chr10:835615	NA	0.99	14.99	0.59	4.75e-41	Eosinophil percentage of granulocytes;
LUAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.16	-0.41	2.34e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg04414720	chr1:150670196	GOLPH3L	0.66	11.36	0.48	2.67e-26	Melanoma;
LUAD	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg01191920	chr7:158217561	PTPRN2	-0.69	-15.12	-0.59	1.39e-41	Obesity-related traits;
LUAD	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg23533926	chr12:111358616	MYL2	-0.43	-7.39	-0.34	8.09e-13	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6446731	0.517	rs2071671	chr4:3269787	C/G	cg08886695	chr4:3369023	RGS12	0.47	7.92	0.36	2.17e-14	Mean platelet volume;
LUAD	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	trans	rs2797160	1.000	rs1739352	chr6:126005310	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-8.89	-0.4	1.78e-17	Endometrial cancer;
LUAD	cis	rs59698941	0.943	rs67952459	chr5:132297902	C/T	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs300703	0.576	rs3791216	chr2:237142	C/A	cg21211680	chr2:198530	NA	0.61	6.35	0.3	5.41e-10	Blood protein levels;
LUAD	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg08213375	chr14:104286397	PPP1R13B	0.26	6.85	0.32	2.6e-11	Schizophrenia;
LUAD	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15541040	chr2:3486749	NA	-0.43	-7.43	-0.34	6.1e-13	Neurofibrillary tangles;
LUAD	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg06641503	chr3:48959341	ARIH2	-0.37	-7.34	-0.34	1.14e-12	Parkinson's disease;
LUAD	cis	rs10193935	0.901	rs12622153	chr2:42598386	C/A	cg27598129	chr2:42591480	NA	-0.76	-9.9	-0.43	6.32e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.37	0.55	2.89e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs853679	0.607	rs201002	chr6:27808192	A/G	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.35	-0.34	1.06e-12	Depression;
LUAD	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg03233332	chr7:66118400	NA	-0.46	-6.88	-0.32	2.2e-11	Aortic root size;
LUAD	cis	rs2050392	0.771	rs303446	chr10:30728489	C/T	cg18806716	chr10:30721971	MAP3K8	-0.56	-11.05	-0.47	4.19e-25	Inflammatory bowel disease;
LUAD	cis	rs2455601	0.786	rs10279	chr11:8969309	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.44	-7.45	-0.34	5.22e-13	Schizophrenia;
LUAD	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	13.08	0.54	4.38e-33	Monocyte percentage of white cells;
LUAD	cis	rs62400317	0.859	rs12214885	chr6:45197731	C/G	cg20913747	chr6:44695427	NA	-0.42	-6.49	-0.3	2.44e-10	Total body bone mineral density;
LUAD	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg00898013	chr13:113819073	PROZ	0.73	13.19	0.54	1.55e-33	Platelet distribution width;
LUAD	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg07432352	chr17:45403706	C17orf57	-0.39	-7.58	-0.35	2.26e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg04546413	chr19:29218101	NA	0.67	10.28	0.45	2.88e-22	Methadone dose in opioid dependence;
LUAD	cis	rs804280	0.662	rs11784764	chr8:11610874	C/T	cg23972785	chr8:11611189	GATA4	-0.46	-7.5	-0.34	3.91e-13	Myopia (pathological);
LUAD	cis	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-6.75	-0.31	4.8e-11	Triglycerides;
LUAD	cis	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.76	-0.31	4.56e-11	Morning vs. evening chronotype;
LUAD	cis	rs10404486	1.000	rs10404486	chr19:53284135	A/G	cg18671199	chr19:53289524	ZNF600	-0.46	-6.98	-0.32	1.13e-11	Phospholipid levels (plasma);
LUAD	cis	rs1595825	0.735	rs113834557	chr2:198611624	A/G	cg11031976	chr2:198649780	BOLL	-0.47	-6.86	-0.32	2.5e-11	Ulcerative colitis;
LUAD	trans	rs783540	0.592	rs2567632	chr15:83284804	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.56	-8.69	-0.39	8.05e-17	Schizophrenia;
LUAD	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	8.34	0.38	1.04e-15	Lung cancer in ever smokers;
LUAD	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs7289126	1.000	rs7290372	chr22:38628388	T/G	cg17652424	chr22:38574118	PLA2G6	-0.25	-7.27	-0.33	1.77e-12	Mammographic density (dense area);Percent mammographic density;
LUAD	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg03929089	chr4:120376271	NA	0.67	9.61	0.42	6.37e-20	Coronary artery disease;
LUAD	trans	rs4714291	0.928	rs761799	chr6:39990050	T/A	cg02267698	chr19:7991119	CTXN1	0.43	6.47	0.3	2.69e-10	Strep throat;
LUAD	trans	rs11885103	0.543	rs1320362	chr2:564079	G/T	cg12228919	chr15:44955936	SPG11	-0.42	-6.51	-0.3	2.19e-10	Heschl's gyrus morphology;
LUAD	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.38	-6.66	-0.31	8.77e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg02176678	chr2:219576539	TTLL4	0.68	13.43	0.55	1.69e-34	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.75	-0.35	6.79e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs17641971	0.684	rs10957363	chr8:49999175	T/A	cg00325661	chr8:49890786	NA	0.31	6.84	0.32	2.78e-11	Blood metabolite levels;
LUAD	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.66	-0.35	1.24e-13	Bipolar disorder;
LUAD	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg09455208	chr3:40491958	NA	0.52	10.29	0.45	2.64e-22	Renal cell carcinoma;
LUAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg24829409	chr8:58192753	C8orf71	-0.66	-7.51	-0.34	3.51e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs494562	0.892	rs1322404	chr6:86126912	T/A	cg13315970	chr6:86159197	NT5E	0.71	7.86	0.36	3.15e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg16680214	chr1:154839983	KCNN3	-0.63	-13.15	-0.54	2.3e-33	Prostate cancer;
LUAD	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg00316803	chr15:76480434	C15orf27	-0.4	-7.52	-0.34	3.35e-13	Blood metabolite levels;
LUAD	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg10327440	chr1:227177885	CDC42BPA	1.1	30.91	0.83	1.41e-110	Myeloid white cell count;
LUAD	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg16988262	chr1:15930761	NA	0.41	6.88	0.32	2.12e-11	Systolic blood pressure;
LUAD	trans	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.39	-0.3	4.33e-10	Aortic root size;
LUAD	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.36	7.29	0.33	1.51e-12	Monocyte percentage of white cells;
LUAD	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg02221422	chr11:68192511	LRP5	-0.39	-6.61	-0.31	1.14e-10	Total body bone mineral density;
LUAD	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg21605333	chr4:119757512	SEC24D	0.93	8.68	0.39	8.38e-17	Cannabis dependence symptom count;
LUAD	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg21918786	chr6:109611834	NA	-0.54	-9.5	-0.42	1.53e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.54	0.34	2.8e-13	Tonsillectomy;
LUAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03452623	chr4:187889614	NA	-0.82	-17.23	-0.64	8.99e-51	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1018836	0.923	rs7833025	chr8:91568470	G/C	cg16814680	chr8:91681699	NA	-0.71	-12.25	-0.51	9.82e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13315871	0.790	rs9825431	chr3:58406694	G/C	cg20936604	chr3:58311152	NA	-0.69	-6.9	-0.32	1.86e-11	Cholesterol, total;
LUAD	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg13180566	chr4:1052158	NA	-0.39	-6.79	-0.31	3.78e-11	Recombination rate (females);
LUAD	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg02903104	chr8:1507517	DLGAP2	0.35	7.88	0.36	2.82e-14	Lung cancer;
LUAD	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14829155	chr15:31115871	NA	-0.79	-13.45	-0.55	1.38e-34	Huntington's disease progression;
LUAD	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg24558204	chr6:135376177	HBS1L	0.48	8.74	0.39	5.36e-17	Red blood cell count;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg22886512	chr19:8408083	KANK3	0.37	6.35	0.3	5.58e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs78761021	0.651	rs731540	chr17:9799127	G/A	cg26853458	chr17:9805074	RCVRN	0.43	8.24	0.37	2.15e-15	Type 2 diabetes;
LUAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg03354898	chr7:1950403	MAD1L1	-0.41	-7.38	-0.34	8.64e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs9902453	0.967	rs4493117	chr17:28489770	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.95	0.44	4.39e-21	Coffee consumption (cups per day);
LUAD	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg21918786	chr6:109611834	NA	-0.6	-11.28	-0.48	5.8e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs3026401	0.562	rs762972	chr11:31797603	A/G	cg26647111	chr11:31128758	NA	0.42	7.03	0.32	8.32e-12	Body mass index;
LUAD	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg03806693	chr22:41940476	POLR3H	-0.61	-8.96	-0.4	1.05e-17	Vitiligo;
LUAD	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.61	-0.31	1.16e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg21214613	chr1:16344536	HSPB7	0.34	6.44	0.3	3.34e-10	Systolic blood pressure;
LUAD	cis	rs7589728	0.844	rs2363010	chr2:88496399	G/C	cg04511125	chr2:88470314	THNSL2	0.79	8.13	0.37	4.96e-15	Plasma clusterin levels;
LUAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg26354017	chr1:205819088	PM20D1	0.81	17.4	0.65	1.56e-51	Menarche (age at onset);
LUAD	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03517284	chr6:25882590	NA	-0.58	-8.51	-0.38	3.15e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg07677032	chr17:61819896	STRADA	0.57	10.34	0.45	1.78e-22	Prudent dietary pattern;
LUAD	cis	rs514406	0.734	rs581118	chr1:53311324	T/C	cg16325326	chr1:53192061	ZYG11B	0.63	11.03	0.47	4.74e-25	Monocyte count;
LUAD	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg12573674	chr2:1569213	NA	-0.54	-6.72	-0.31	5.77e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg13319975	chr6:146136371	FBXO30	0.63	10.69	0.46	9.01e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7771547	0.603	rs9357218	chr6:36549858	G/A	cg04289385	chr6:36355825	ETV7	0.5	6.63	0.31	1.01e-10	Platelet distribution width;
LUAD	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg00634984	chr7:65235879	NA	0.49	6.55	0.3	1.67e-10	Aortic root size;
LUAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg26304593	chr6:42947056	PEX6	-0.44	-7.25	-0.33	1.98e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs679087	0.606	rs302344	chr12:29940953	A/G	cg14258853	chr12:29935411	TMTC1	0.54	7.85	0.36	3.53e-14	Schizophrenia;
LUAD	cis	rs2230307	0.536	rs834278	chr1:100510882	T/C	cg20868668	chr1:100435035	SLC35A3	0.54	7.87	0.36	3.02e-14	Carotid intima media thickness;
LUAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg21951975	chr1:209979733	IRF6	0.58	9.14	0.41	2.69e-18	Cleft lip with or without cleft palate;
LUAD	cis	rs11622475	1.000	rs10136440	chr14:104397367	C/A	cg12183467	chr14:104352244	NA	0.4	7.09	0.33	5.69e-12	Bipolar disorder;
LUAD	cis	rs2629540	0.806	rs10901812	chr10:126419384	A/G	cg08799069	chr10:126477246	METTL10	-0.43	-6.38	-0.3	4.58e-10	Cocaine dependence;
LUAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg08132940	chr7:1081526	C7orf50	-0.78	-10.55	-0.46	2.93e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg23978390	chr7:1156363	C7orf50	0.66	9.23	0.41	1.34e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.97	0.32	1.25e-11	Hypertriglyceridemia;
LUAD	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg10296153	chr3:3168554	TRNT1	-0.36	-6.6	-0.31	1.2e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
LUAD	trans	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-9.76	-0.43	2.01e-20	Brugada syndrome;
LUAD	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26314531	chr2:26401878	FAM59B	-0.7	-9.53	-0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs10795433	0.541	rs6602163	chr10:16966766	A/G	cg00939682	chr10:16933505	CUBN	0.48	6.9	0.32	1.91e-11	Urinary albumin-to-creatinine ratio;Microalbuminuria;
LUAD	cis	rs3743162	0.553	rs12915656	chr15:85415580	G/C	cg11189052	chr15:85197271	WDR73	0.56	6.83	0.32	2.94e-11	Alzheimer's disease (age of onset);
LUAD	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg21214613	chr1:16344536	HSPB7	-0.39	-7.06	-0.32	6.93e-12	Systolic blood pressure;
LUAD	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg06064525	chr11:970664	AP2A2	0.55	11.51	0.49	7.56e-27	Alzheimer's disease (late onset);
LUAD	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg03396347	chr1:1875803	NA	-0.62	-16.03	-0.61	1.64e-45	Body mass index;
LUAD	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.68e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg16325326	chr1:53192061	ZYG11B	-0.73	-14.21	-0.57	9.36e-38	Monocyte count;
LUAD	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg18806716	chr10:30721971	MAP3K8	-0.78	-16.56	-0.63	7.85e-48	Inflammatory bowel disease;
LUAD	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg09085632	chr11:111637200	PPP2R1B	0.67	11.29	0.48	5.18e-26	Primary sclerosing cholangitis;
LUAD	cis	rs9308433	0.529	rs4655246	chr1:214502898	G/C	cg06198575	chr1:214491504	SMYD2	0.44	7.47	0.34	4.73e-13	IgG glycosylation;
LUAD	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg11822812	chr5:140052017	DND1	0.38	6.66	0.31	8.67e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg18944383	chr4:111397179	ENPEP	0.48	8.96	0.4	1.04e-17	Height;
LUAD	cis	rs10992471	0.603	rs10820968	chr9:95106443	A/G	cg14631576	chr9:95140430	CENPP	-0.56	-11.49	-0.49	8.85e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg08999081	chr20:33150536	PIGU	-0.37	-7.27	-0.33	1.78e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg03452623	chr4:187889614	NA	-0.81	-15.77	-0.61	2.21e-44	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-7.98	-0.36	1.44e-14	Total cholesterol levels;
LUAD	cis	rs6835098	0.692	rs6553679	chr4:174072292	C/T	cg08422745	chr4:174089978	GALNT7	-0.83	-14.12	-0.57	2.31e-37	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs9581857	0.547	rs9581882	chr13:28110682	C/G	cg22138327	chr13:27999177	GTF3A	0.79	8.05	0.36	8.38e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7274811	0.681	rs291674	chr20:31954890	C/G	cg13403462	chr20:32256071	NECAB3;C20orf134	0.45	6.74	0.31	5.36e-11	Height;
LUAD	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg27211696	chr2:191398769	TMEM194B	0.8	17.12	0.64	2.7e-50	Pulse pressure;
LUAD	cis	rs2230307	0.706	rs564562	chr1:100471566	T/C	cg20868668	chr1:100435035	SLC35A3	0.63	7.58	0.35	2.23e-13	Carotid intima media thickness;
LUAD	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg18129178	chr5:148520854	ABLIM3	-0.61	-9.42	-0.42	2.97e-19	Breast cancer;
LUAD	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg01528321	chr10:82214614	TSPAN14	0.55	8.93	0.4	1.34e-17	Post bronchodilator FEV1;
LUAD	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg23260525	chr10:116636907	FAM160B1	0.54	13.03	0.54	7.21e-33	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg15242686	chr22:24348715	GSTTP1	0.43	7.29	0.33	1.49e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.38	-0.38	7.69e-16	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs7395662	1.000	rs9645642	chr11:48705455	G/T	cg00717180	chr2:96193071	NA	-0.39	-7.23	-0.33	2.27e-12	HDL cholesterol;
LUAD	cis	rs240764	0.817	rs239230	chr6:101105862	C/A	cg09795085	chr6:101329169	ASCC3	0.44	7.51	0.34	3.56e-13	Neuroticism;
LUAD	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg01657329	chr11:68192670	LRP5	-0.4	-6.35	-0.3	5.49e-10	Total body bone mineral density;
LUAD	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.34	0.34	1.11e-12	Bladder cancer;
LUAD	cis	rs57920188	0.584	rs12080562	chr1:4089697	C/A	cg20703997	chr1:4087676	NA	0.48	9.06	0.4	4.84e-18	Interleukin-17 levels;
LUAD	cis	rs6500395	1.000	rs1486411	chr16:48587083	T/C	cg04672837	chr16:48644449	N4BP1	0.38	6.51	0.3	2.14e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg10518543	chr12:38710700	ALG10B	-0.43	-7.11	-0.33	5.07e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg10544611	chr16:67998164	SLC12A4	0.53	6.96	0.32	1.34e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7100689	0.646	rs10736347	chr10:82134465	G/A	cg00277334	chr10:82204260	NA	-0.63	-10.54	-0.46	3.26e-23	Post bronchodilator FEV1;
LUAD	cis	rs870825	0.616	rs4386643	chr4:185624281	A/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.41	-8.0	-0.36	1.2e-14	Cystic fibrosis severity;
LUAD	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg15147215	chr3:52552868	STAB1	-0.41	-7.43	-0.34	6.14e-13	Bipolar disorder;
LUAD	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg05590025	chr7:65112418	INTS4L2	0.72	7.5	0.34	3.84e-13	Diabetic kidney disease;
LUAD	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg23262073	chr20:60523788	NA	-0.46	-7.96	-0.36	1.65e-14	Body mass index;
LUAD	cis	rs7527798	0.592	rs12411037	chr1:207857158	T/C	cg09232269	chr1:207846808	CR1L	-0.37	-7.01	-0.32	9.44e-12	Erythrocyte sedimentation rate;
LUAD	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg11494091	chr17:61959527	GH2	0.42	7.83	0.36	4.06e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.96	-0.32	1.32e-11	Lung cancer;
LUAD	cis	rs11696501	0.637	rs6104298	chr20:44327774	A/G	cg11783356	chr20:44313418	WFDC10B	-0.51	-8.38	-0.38	8.12e-16	Brain structure;
LUAD	cis	rs9811920	0.535	rs704572	chr3:99482314	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.64	-0.39	1.18e-16	Axial length;
LUAD	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg26893861	chr17:41843967	DUSP3	-1.19	-28.2	-0.81	3.43e-99	Triglycerides;
LUAD	trans	rs1997103	0.911	rs6945663	chr7:55407011	C/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg07423050	chr13:99094983	FARP1	-0.55	-9.28	-0.41	8.99e-19	Longevity;
LUAD	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg09509183	chr1:209979624	IRF6	0.51	6.98	0.32	1.12e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg23172400	chr8:95962367	TP53INP1	0.34	7.35	0.34	1.04e-12	Type 2 diabetes;
LUAD	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg14092988	chr3:52407081	DNAH1	0.57	11.38	0.48	2.28e-26	Bipolar disorder;
LUAD	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg21028142	chr17:79581711	NPLOC4	0.42	8.83	0.39	2.71e-17	Eye color traits;
LUAD	cis	rs7095607	0.813	rs7903493	chr10:69931156	C/A	cg18986048	chr10:69913749	MYPN	0.37	6.39	0.3	4.51e-10	Lung function (FVC);
LUAD	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg05304507	chr6:116381966	FRK	0.19	6.69	0.31	7.28e-11	Cholesterol, total;LDL cholesterol;
LUAD	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg03929089	chr4:120376271	NA	-0.45	-7.01	-0.32	9.19e-12	Coronary artery disease;
LUAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg03188948	chr7:1209495	NA	0.81	9.73	0.43	2.42e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.19	0.54	1.68e-33	Prudent dietary pattern;
LUAD	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg10755058	chr3:40428713	ENTPD3	0.43	8.37	0.38	8.78e-16	Renal cell carcinoma;
LUAD	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg21475434	chr5:93447410	FAM172A	0.75	8.61	0.39	1.42e-16	Diabetic retinopathy;
LUAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg27094323	chr7:1216898	NA	-0.39	-7.13	-0.33	4.44e-12	Longevity;Endometriosis;
LUAD	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.46	-0.34	4.88e-13	Bipolar disorder;
LUAD	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.59	0.52	4.48e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg04730925	chr18:51795821	POLI	0.4	6.52	0.3	2.03e-10	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.06e-19	Life satisfaction;
LUAD	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg20673091	chr1:2541236	MMEL1	0.39	8.2	0.37	2.87e-15	Ulcerative colitis;
LUAD	cis	rs2806561	0.929	rs627304	chr1:23537555	A/G	cg19743168	chr1:23544995	NA	0.46	8.49	0.38	3.53e-16	Height;
LUAD	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-24.39	-0.76	1.13e-82	Height;
LUAD	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg19767477	chr5:127420684	SLC12A2	-0.44	-6.49	-0.3	2.41e-10	Ileal carcinoids;
LUAD	trans	rs4650994	1.000	rs17276527	chr1:178520680	G/A	cg05059571	chr16:84539110	KIAA1609	-0.6	-10.24	-0.45	4.02e-22	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg24818145	chr4:99064322	C4orf37	0.41	6.89	0.32	2.04e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4888262	0.545	rs4888270	chr16:74698576	A/G	cg01733217	chr16:74700730	RFWD3	0.52	8.51	0.38	2.95e-16	Testicular germ cell tumor;
LUAD	cis	rs2224391	0.910	rs2875979	chr6:5275243	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.54	9.03	0.4	6.17e-18	Height;
LUAD	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg14092988	chr3:52407081	DNAH1	0.45	8.89	0.4	1.72e-17	Bipolar disorder;
LUAD	cis	rs2109514	1.000	rs6466579	chr7:116151155	T/C	cg12739419	chr7:116140593	CAV2	-0.37	-7.94	-0.36	1.87e-14	Prevalent atrial fibrillation;
LUAD	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg11344533	chr11:111475393	SIK2	-0.35	-6.64	-0.31	9.9e-11	Primary sclerosing cholangitis;
LUAD	cis	rs11048434	0.736	rs12823100	chr12:9108908	C/A	cg23795048	chr12:9217529	LOC144571	0.41	7.62	0.35	1.72e-13	Sjögren's syndrome;
LUAD	cis	rs12142240	1.000	rs12142240	chr1:46747301	T/C	cg00530320	chr1:46809349	NSUN4	0.43	6.77	0.31	4.42e-11	Menopause (age at onset);
LUAD	cis	rs7119167	0.636	rs75721806	chr11:73013876	A/G	cg03470933	chr11:73073008	ARHGEF17	0.35	6.41	0.3	3.8e-10	Blood protein levels;
LUAD	cis	rs2279817	0.863	rs2354291	chr1:18027554	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.49	-8.39	-0.38	7.11e-16	Neuroticism;
LUAD	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg24818145	chr4:99064322	C4orf37	0.42	7.03	0.32	8.35e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg02869364	chr7:1081709	C7orf50	-0.51	-6.61	-0.31	1.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg26314531	chr2:26401878	FAM59B	-0.56	-7.75	-0.35	6.96e-14	Gut microbiome composition (summer);
LUAD	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs11112613	0.775	rs10507194	chr12:105959488	G/A	cg03607813	chr12:105948248	NA	0.81	12.83	0.53	4.72e-32	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg13385794	chr1:248469461	NA	0.25	6.95	0.32	1.35e-11	Common traits (Other);
LUAD	cis	rs11166629	1.000	rs7818331	chr8:135639653	C/T	cg27224718	chr8:135614730	ZFAT	0.59	10.53	0.46	3.49e-23	Smoking quantity;
LUAD	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg01788221	chr16:89496183	ANKRD11	-0.37	-7.19	-0.33	3.05e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg17264618	chr3:40429014	ENTPD3	-0.39	-8.51	-0.38	3.14e-16	Renal cell carcinoma;
LUAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg16590910	chr6:42928470	GNMT	0.35	6.63	0.31	1e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs77972916	0.609	rs13414381	chr2:43567218	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-7.34	-0.34	1.13e-12	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs853679	0.607	rs35902873	chr6:28058949	G/C	cg01620082	chr3:125678407	NA	-1.1	-10.56	-0.46	2.69e-23	Depression;
LUAD	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.17	15.54	0.6	2.05e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs490234	0.702	rs2416964	chr9:128360413	C/T	cg14078157	chr9:128172775	NA	-0.44	-7.85	-0.36	3.45e-14	Mean arterial pressure;
LUAD	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg19318889	chr4:1322082	MAEA	0.42	7.13	0.33	4.45e-12	Obesity-related traits;
LUAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg11494091	chr17:61959527	GH2	0.75	18.64	0.67	4.84e-57	Prudent dietary pattern;
LUAD	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10802521	chr3:52805072	NEK4	-0.53	-9.07	-0.4	4.38e-18	Bipolar disorder;
LUAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg12419862	chr22:24373484	LOC391322	0.66	12.25	0.51	9.97e-30	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4680	1.000	rs4680	chr22:19951271	C/T	cg23601416	chr22:19950040	COMT	0.31	6.58	0.3	1.37e-10	Blood metabolite levels;
LUAD	cis	rs9902453	0.967	rs12150261	chr17:28320473	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.51	-8.62	-0.39	1.33e-16	Coffee consumption (cups per day);
LUAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.52	-0.3	1.98e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg26924012	chr15:45694286	SPATA5L1	1.02	18.91	0.68	3.04e-58	Homoarginine levels;
LUAD	trans	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.66	-11.19	-0.48	1.21e-25	Blood trace element (Cu levels);
LUAD	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-6.81	-0.31	3.41e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg06713675	chr4:122721982	EXOSC9	-0.77	-15.32	-0.6	1.94e-42	Type 2 diabetes;
LUAD	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18099408	chr3:52552593	STAB1	-0.46	-8.11	-0.37	5.63e-15	Bipolar disorder;
LUAD	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg17633681	chr16:88106987	BANP	0.39	6.9	0.32	1.94e-11	Menopause (age at onset);
LUAD	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-7.76	-0.35	6.36e-14	Morning vs. evening chronotype;
LUAD	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	ch.11.42038R	chr11:967971	AP2A2	0.42	7.32	0.34	1.26e-12	Alzheimer's disease (late onset);
LUAD	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.12	-0.33	4.66e-12	Coronary artery disease;
LUAD	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg22029157	chr1:209979665	IRF6	0.79	11.51	0.49	7.33e-27	Cleft lip with or without cleft palate;
LUAD	cis	rs57920188	0.535	rs10915658	chr1:4092921	T/C	cg20703997	chr1:4087676	NA	0.48	9.01	0.4	7.22e-18	Interleukin-17 levels;
LUAD	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	12.82	0.53	5.16e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg22920501	chr2:26401640	FAM59B	-0.76	-10.97	-0.47	8.37e-25	Gut microbiome composition (summer);
LUAD	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg03396347	chr1:1875803	NA	-0.6	-15.47	-0.6	4.17e-43	Body mass index;
LUAD	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-9.35	-0.41	5.01e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg20368463	chr18:77673604	PQLC1	0.6	10.06	0.44	1.77e-21	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg17178900	chr1:205818956	PM20D1	0.54	10.28	0.45	2.76e-22	Menarche (age at onset);
LUAD	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg27446573	chr6:127587934	RNF146	0.45	6.73	0.31	5.66e-11	Breast cancer;
LUAD	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19346786	chr7:2764209	NA	-0.55	-11.87	-0.5	3.04e-28	Height;
LUAD	cis	rs1030268	0.651	rs35711160	chr7:133595233	A/G	cg10665199	chr7:133106180	EXOC4	0.48	6.52	0.3	1.96e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg18621852	chr3:10150065	C3orf24	0.45	8.1	0.37	5.96e-15	Alzheimer's disease;
LUAD	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg17346650	chr17:80929145	B3GNTL1	0.41	7.25	0.33	2.04e-12	Glycated hemoglobin levels;
LUAD	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg09509183	chr1:209979624	IRF6	0.59	7.28	0.33	1.62e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg19717773	chr7:2847554	GNA12	-0.46	-7.75	-0.35	6.71e-14	Height;
LUAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08439880	chr3:133502540	NA	-0.45	-8.84	-0.4	2.51e-17	Iron status biomarkers;
LUAD	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.52	0.3	1.97e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg02734326	chr4:10020555	SLC2A9	0.54	9.48	0.42	1.86e-19	Bone mineral density;
LUAD	cis	rs7737355	0.947	rs9327619	chr5:130921781	A/G	cg06307176	chr5:131281290	NA	0.49	7.62	0.35	1.73e-13	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg05340658	chr4:99064831	C4orf37	0.53	9.05	0.4	5.32e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.34	-8.45	-0.38	4.63e-16	Total body bone mineral density;
LUAD	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg18105134	chr13:113819100	PROZ	0.73	12.94	0.53	1.65e-32	Platelet distribution width;
LUAD	cis	rs2479724	0.846	rs1536702	chr6:41869950	T/A	cg17623882	chr6:41773611	USP49	-0.62	-11.36	-0.48	2.77e-26	Menarche (age at onset);
LUAD	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg15448220	chr1:150897856	SETDB1	0.46	7.97	0.36	1.47e-14	Tonsillectomy;
LUAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg04025307	chr7:1156635	C7orf50	0.66	7.55	0.34	2.66e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2274273	0.870	rs1952087	chr14:55683211	A/C	cg04306507	chr14:55594613	LGALS3	0.4	8.19	0.37	3.19e-15	Protein biomarker;
LUAD	cis	rs8017423	0.967	rs11627429	chr14:90689232	G/A	cg14092571	chr14:90743983	NA	0.46	7.86	0.36	3.28e-14	Mortality in heart failure;
LUAD	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18876405	chr7:65276391	NA	-0.44	-7.05	-0.32	7.32e-12	Aortic root size;
LUAD	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg09873201	chr16:3507582	NAT15	0.52	7.8	0.35	4.91e-14	Tuberculosis;
LUAD	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.15	0.44	8.6e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs67072384	1.000	rs2365442	chr11:72450218	G/A	cg04827223	chr11:72435913	ARAP1	-0.63	-7.29	-0.33	1.54e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg24768116	chr2:27665128	KRTCAP3	0.27	6.66	0.31	8.35e-11	Oral cavity cancer;
LUAD	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg17971929	chr21:40555470	PSMG1	-0.53	-8.35	-0.38	9.52e-16	Cognitive function;
LUAD	cis	rs7707921	0.522	rs10065463	chr5:81500280	A/G	cg15871215	chr5:81402204	ATG10	-0.65	-11.57	-0.49	4.4e-27	Breast cancer;
LUAD	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg06627628	chr2:24431161	ITSN2	-0.7	-11.28	-0.48	5.81e-26	Asthma;
LUAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg21280719	chr6:42927975	GNMT	-0.39	-11.73	-0.5	1.06e-27	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6906287	0.647	rs11153753	chr6:118836153	T/C	cg05564266	chr6:118973597	C6orf204	0.36	7.66	0.35	1.26e-13	Electrocardiographic conduction measures;
LUAD	cis	rs11958404	0.932	rs56065211	chr5:157439386	C/T	cg05962755	chr5:157440814	NA	0.71	9.95	0.44	4.36e-21	IgG glycosylation;
LUAD	trans	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg04565464	chr8:145669602	NFKBIL2	0.47	6.68	0.31	7.42e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9297145	0.585	rs10953283	chr7:98782750	A/G	cg05967295	chr7:98741636	SMURF1	0.72	13.14	0.54	2.69e-33	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg09184832	chr6:79620586	NA	-0.38	-6.41	-0.3	3.95e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.74	-0.58	5.84e-40	Schizophrenia;
LUAD	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg00204512	chr16:28754710	NA	0.35	7.6	0.35	1.99e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs17685	0.712	rs869805	chr7:75688596	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.91	-0.36	2.21e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg00071950	chr4:10020882	SLC2A9	0.75	15.01	0.59	3.78e-41	Bone mineral density;
LUAD	cis	rs2455601	1.000	rs12418190	chr11:8899818	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-6.65	-0.31	9e-11	Schizophrenia;
LUAD	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg23711669	chr6:146136114	FBXO30	0.38	6.58	0.3	1.4e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg23649088	chr2:200775458	C2orf69	0.62	8.31	0.37	1.32e-15	Schizophrenia;
LUAD	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg07617317	chr6:118971624	C6orf204	0.55	8.54	0.38	2.38e-16	Renal cell carcinoma;
LUAD	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg05340658	chr4:99064831	C4orf37	0.44	6.73	0.31	5.53e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg25019722	chr6:37503610	NA	-0.31	-7.09	-0.33	5.59e-12	Cognitive performance;
LUAD	cis	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg27411982	chr8:10470053	RP1L1	-0.45	-8.03	-0.36	9.72e-15	Neuroticism;
LUAD	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg10645314	chr2:3704589	ALLC	-0.59	-9.41	-0.42	3.31e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg24644049	chr4:85504048	CDS1	0.88	7.4	0.34	7.44e-13	Skin colour saturation;
LUAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02359409	chr6:42947317	PEX6	0.39	6.98	0.32	1.14e-11	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs354225	0.584	rs6749802	chr2:54824146	A/G	cg01766943	chr2:54829624	SPTBN1	0.39	7.24	0.33	2.12e-12	Schizophrenia;
LUAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.61	0.31	1.19e-10	Prudent dietary pattern;
LUAD	cis	rs6840360	0.533	rs11099829	chr4:152727299	A/G	cg22705602	chr4:152727874	NA	0.47	8.96	0.4	1.05e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	7.43	0.34	6.15e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8018808	1.000	rs4903577	chr14:77847258	C/T	cg20045696	chr14:77926864	AHSA1	-0.39	-6.99	-0.32	1.11e-11	Myeloid white cell count;
LUAD	cis	rs9487051	0.735	rs455839	chr6:109524221	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.81	-0.31	3.45e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg03609598	chr5:56110824	MAP3K1	-0.68	-9.22	-0.41	1.44e-18	Initial pursuit acceleration;
LUAD	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg25809561	chr17:30822961	MYO1D	0.48	8.6	0.39	1.61e-16	Schizophrenia;
LUAD	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg23649088	chr2:200775458	C2orf69	0.62	8.33	0.38	1.11e-15	Schizophrenia;
LUAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg17178900	chr1:205818956	PM20D1	0.56	10.56	0.46	2.62e-23	Menarche (age at onset);
LUAD	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg08999081	chr20:33150536	PIGU	0.63	14.11	0.57	2.58e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs2479724	0.755	rs4318867	chr6:41753670	G/T	cg17623882	chr6:41773611	USP49	0.67	12.57	0.52	5.15e-31	Menarche (age at onset);
LUAD	cis	rs6489785	0.562	rs494632	chr12:121189116	C/T	cg02419362	chr12:121203948	SPPL3	0.39	7.92	0.36	2.06e-14	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs243505	1.000	rs243521	chr7:148421571	T/C	cg09806900	chr7:148480153	CUL1	-0.44	-7.46	-0.34	4.83e-13	Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg18944383	chr4:111397179	ENPEP	0.39	7.88	0.36	2.86e-14	Height;
LUAD	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg06873352	chr17:61820015	STRADA	0.41	6.83	0.32	2.88e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg13047869	chr3:10149882	C3orf24	0.66	11.09	0.47	2.88e-25	Alzheimer's disease;
LUAD	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.45	7.6	0.35	1.87e-13	Body mass index (adult);
LUAD	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg08601574	chr20:25228251	PYGB	0.47	8.88	0.4	1.9e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1448094	0.872	rs12322940	chr12:86406708	G/C	cg02569458	chr12:86230093	RASSF9	0.38	7.36	0.34	9.41e-13	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6445967	0.569	rs57078778	chr3:58289947	T/C	cg13750441	chr3:58318267	PXK	-0.31	-6.5	-0.3	2.27e-10	Platelet count;
LUAD	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg05340658	chr4:99064831	C4orf37	-0.45	-7.39	-0.34	8.14e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504073	0.669	rs818558	chr8:50030855	A/G	cg00325661	chr8:49890786	NA	0.4	9.22	0.41	1.43e-18	Blood metabolite ratios;
LUAD	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg06640241	chr16:89574553	SPG7	0.68	11.93	0.5	1.78e-28	Multiple myeloma (IgH translocation);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg04043873	chr17:80303714	NA	-0.4	-6.52	-0.3	2e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1816752	0.905	rs13428	chr13:25009441	C/G	cg02811702	chr13:24901961	NA	0.44	7.41	0.34	7.04e-13	Obesity-related traits;
LUAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg01448562	chr3:133502909	NA	-0.69	-12.59	-0.52	4.19e-31	Iron status biomarkers;
LUAD	cis	rs735539	1.000	rs6490605	chr13:21285009	C/T	cg27499820	chr13:21296301	IL17D	0.41	7.3	0.33	1.42e-12	Dental caries;
LUAD	cis	rs7927771	0.839	rs3817334	chr11:47650993	C/T	cg18512352	chr11:47633146	NA	-0.38	-6.81	-0.31	3.46e-11	Subjective well-being;
LUAD	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08280861	chr8:58055591	NA	0.74	8.99	0.4	8.26e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-8.45	-0.38	4.76e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg06781209	chr11:61594997	FADS2	-0.4	-7.44	-0.34	5.67e-13	Trans fatty acid levels;
LUAD	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg04398451	chr17:18023971	MYO15A	-0.78	-14.18	-0.57	1.31e-37	Total body bone mineral density;
LUAD	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg03959625	chr15:84868606	LOC388152	0.4	6.37	0.3	4.98e-10	Schizophrenia;
LUAD	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg20933634	chr6:27740509	NA	0.45	7.07	0.33	6.34e-12	Parkinson's disease;
LUAD	cis	rs1595825	1.000	rs1440090	chr2:198879297	T/G	cg00982548	chr2:198649783	BOLL	-0.6	-8.69	-0.39	8.27e-17	Ulcerative colitis;
LUAD	cis	rs12760731	0.565	rs11583144	chr1:178222070	C/G	cg00404053	chr1:178313656	RASAL2	0.73	9.21	0.41	1.48e-18	Obesity-related traits;
LUAD	cis	rs4642101	0.694	rs12631514	chr3:12838293	G/C	cg24848339	chr3:12840334	CAND2	0.49	10.35	0.45	1.52e-22	QRS complex (12-leadsum);
LUAD	trans	rs7395662	0.791	rs12273724	chr11:48845710	G/A	cg00717180	chr2:96193071	NA	0.36	6.65	0.31	9.3e-11	HDL cholesterol;
LUAD	cis	rs71636778	0.543	rs12749822	chr1:27221963	T/C	cg12203394	chr1:27248618	NUDC	0.51	6.48	0.3	2.52e-10	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6445967	0.530	rs1126737	chr3:58413405	T/C	cg23715586	chr3:58305044	RPP14	0.4	6.61	0.31	1.17e-10	Platelet count;
LUAD	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18404041	chr3:52824283	ITIH1	-0.61	-12.43	-0.52	1.88e-30	Bipolar disorder;
LUAD	cis	rs62400317	0.793	rs12210230	chr6:45344854	T/A	cg18551225	chr6:44695536	NA	-0.52	-8.12	-0.37	5e-15	Total body bone mineral density;
LUAD	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg23985595	chr17:80112537	CCDC57	-0.53	-9.53	-0.42	1.29e-19	Life satisfaction;
LUAD	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.6	0.31	1.22e-10	Parkinson's disease;
LUAD	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs3540	0.960	rs8040585	chr15:91026477	T/C	cg10434728	chr15:90938212	IQGAP1	0.36	6.81	0.31	3.26e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs1535500	0.967	rs12663159	chr6:39282277	C/A	cg03252829	chr6:39282164	KCNK17	-0.32	-6.78	-0.31	4.02e-11	Type 2 diabetes;
LUAD	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg21733973	chr7:65235735	NA	0.48	6.4	0.3	4.07e-10	Aortic root size;
LUAD	trans	rs17689437	0.647	rs820799	chr16:68559537	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.4	6.36	0.3	5.09e-10	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LUAD	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg24838063	chr12:130822603	PIWIL1	0.64	10.65	0.46	1.25e-23	Menopause (age at onset);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg20332866	chr1:100678932	DBT	-0.4	-6.56	-0.3	1.6e-10	Cancer;
LUAD	cis	rs4372836	0.580	rs6718662	chr2:29048758	G/C	cg09522027	chr2:28974177	PPP1CB	-0.68	-11.87	-0.5	3.06e-28	Body mass index;
LUAD	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg20790798	chr5:1857306	NA	-0.46	-7.82	-0.36	4.28e-14	Cardiovascular disease risk factors;
LUAD	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.18	-0.33	3.26e-12	Breast cancer;
LUAD	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg02423579	chr7:2872169	GNA12	-0.84	-14.53	-0.58	4.17e-39	Height;
LUAD	cis	rs990171	0.538	rs12995030	chr2:103116466	C/G	cg03938978	chr2:103052716	IL18RAP	0.33	6.53	0.3	1.84e-10	Lymphocyte counts;
LUAD	cis	rs1594829	0.553	rs2046225	chr8:26151802	A/C	cg13160058	chr8:26243215	BNIP3L	0.33	7.36	0.34	9.46e-13	Height;
LUAD	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10802521	chr3:52805072	NEK4	-0.61	-11.04	-0.47	4.61e-25	Electroencephalogram traits;
LUAD	cis	rs7937890	0.559	rs2597201	chr11:14485404	T/C	cg02886208	chr11:14281011	SPON1	-0.34	-6.51	-0.3	2.12e-10	Mitochondrial DNA levels;
LUAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.42	0.3	3.6e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2004318	1.000	rs77812912	chr19:55078054	T/C	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.93e-13	Blood protein levels;
LUAD	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg03526776	chr6:41159608	TREML2	0.32	6.78	0.31	4.08e-11	Alzheimer's disease (late onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15813570	chr14:64854563	MTHFD1	-0.43	-6.89	-0.32	2.07e-11	Height;
LUAD	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg16479474	chr6:28041457	NA	0.45	7.73	0.35	7.89e-14	Depression;
LUAD	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.86	-0.53	3.5e-32	Dilated cardiomyopathy;
LUAD	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg25566285	chr7:158114605	PTPRN2	-0.52	-11.09	-0.47	2.8e-25	Calcium levels;
LUAD	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg18306943	chr3:40428807	ENTPD3	0.4	6.99	0.32	1.1e-11	Renal cell carcinoma;
LUAD	cis	rs10744422	1.000	rs2135014	chr12:123333065	C/T	cg16953816	chr12:123349952	VPS37B	0.59	6.64	0.31	9.46e-11	Schizophrenia;
LUAD	cis	rs9837602	1.000	rs13323143	chr3:99811553	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-6.85	-0.32	2.59e-11	Breast cancer;
LUAD	cis	rs4604732	0.631	rs75320597	chr1:247626751	T/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg14983838	chr19:29218262	NA	0.52	7.41	0.34	7.12e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18876405	chr7:65276391	NA	0.4	6.43	0.3	3.42e-10	Aortic root size;
LUAD	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.66	-0.61	6.36e-44	Eye color traits;
LUAD	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg17724175	chr1:150552817	MCL1	0.32	7.48	0.34	4.45e-13	Melanoma;
LUAD	cis	rs13223928	0.651	rs4722435	chr7:3152962	C/T	cg19214707	chr7:3157722	NA	0.51	9.32	0.41	6.62e-19	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg17757837	chr7:157058334	UBE3C	0.46	8.15	0.37	4.14e-15	Body mass index;
LUAD	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg07741184	chr6:167504864	NA	0.36	8.24	0.37	2.11e-15	Primary biliary cholangitis;
LUAD	cis	rs7258465	1.000	rs34010330	chr19:18559657	G/C	cg01065977	chr19:18549689	ISYNA1	-0.35	-6.51	-0.3	2.1e-10	Breast cancer;
LUAD	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg16060761	chr17:80687452	NA	0.45	6.77	0.31	4.41e-11	Breast cancer;
LUAD	cis	rs6542838	0.611	rs7588441	chr2:99518858	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.36	-0.34	9.94e-13	Fear of minor pain;
LUAD	cis	rs2224391	1.000	rs9504370	chr6:5261601	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-9.76	-0.43	2.05e-20	Height;
LUAD	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg15445000	chr17:37608096	MED1	0.43	7.94	0.36	1.84e-14	Urinary metabolites;
LUAD	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.57	7.92	0.36	2.06e-14	Platelet count;
LUAD	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg05468064	chr22:46423449	NA	-0.5	-11.3	-0.48	4.83e-26	Dupuytren's disease;
LUAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg07677032	chr17:61819896	STRADA	0.54	9.8	0.43	1.39e-20	Prudent dietary pattern;
LUAD	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg13012494	chr21:47604986	C21orf56	0.46	7.57	0.35	2.37e-13	Testicular germ cell tumor;
LUAD	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg23719950	chr11:63933701	MACROD1	-0.58	-6.92	-0.32	1.63e-11	Mean platelet volume;
LUAD	cis	rs8060686	0.668	rs8048034	chr16:68210604	A/G	cg26727032	chr16:67993705	SLC12A4	-0.46	-7.59	-0.35	1.99e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg00898013	chr13:113819073	PROZ	-0.69	-12.21	-0.51	1.45e-29	Platelet distribution width;
LUAD	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.57	-9.42	-0.42	2.93e-19	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs4523957	0.890	rs62069332	chr17:2112720	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-14.95	-0.59	6.83e-41	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-8.35	-0.38	1e-15	Longevity;Endometriosis;
LUAD	cis	rs11811982	0.793	rs77599485	chr1:227352195	T/C	cg24860534	chr1:227506868	CDC42BPA	0.66	7.22	0.33	2.41e-12	Optic disc area;
LUAD	cis	rs2425143	0.908	rs11697087	chr20:34427583	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.59	-0.31	1.32e-10	Blood protein levels;
LUAD	cis	rs9462027	0.628	rs9469886	chr6:34758824	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.91	-0.4	1.53e-17	Systemic lupus erythematosus;
LUAD	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	8.79	0.39	3.68e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs4919694	1.000	rs58317752	chr10:104799267	T/A	cg04362960	chr10:104952993	NT5C2	0.73	7.86	0.36	3.28e-14	Arsenic metabolism;
LUAD	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg00431813	chr7:1051703	C7orf50	-0.66	-13.88	-0.56	2.32e-36	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08219700	chr8:58056026	NA	0.63	8.82	0.39	2.92e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs727505	1.000	rs66513837	chr7:124492763	A/G	cg23710748	chr7:124431027	NA	-0.49	-9.79	-0.43	1.5e-20	Lewy body disease;
LUAD	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg22532475	chr10:104410764	TRIM8	-0.43	-8.53	-0.38	2.67e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	7.89	0.36	2.59e-14	Schizophrenia;
LUAD	trans	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg11693508	chr17:37793320	STARD3	0.6	8.11	0.37	5.41e-15	Bipolar disorder;
LUAD	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg15123519	chr2:136567270	LCT	0.38	6.99	0.32	1.04e-11	Mosquito bite size;
LUAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg02869364	chr7:1081709	C7orf50	-0.51	-6.67	-0.31	7.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00149659	chr3:10157352	C3orf10	0.62	8.51	0.38	3.07e-16	Alzheimer's disease;
LUAD	trans	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.16	-28.51	-0.81	1.55e-100	Colorectal cancer;
LUAD	cis	rs10484885	0.680	rs72921943	chr6:90581542	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.7	-10.0	-0.44	2.9e-21	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg02428538	chr16:24856791	SLC5A11	-0.51	-7.15	-0.33	3.75e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg20456055	chr7:150725256	ABCB8	-0.45	-6.38	-0.3	4.75e-10	Blood protein levels;
LUAD	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06022373	chr22:39101656	GTPBP1	0.47	7.37	0.34	9.13e-13	Menopause (age at onset);
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg14280569	chr7:102004775	NA	-0.41	-7.23	-0.33	2.21e-12	Schizophrenia;
LUAD	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.9	-0.36	2.46e-14	Diabetic kidney disease;
LUAD	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23158103	chr7:148848205	ZNF398	-0.67	-12.51	-0.52	9.4e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs3818285	1.000	rs3818285	chr10:111635212	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.42	-0.38	6.01e-16	Superior crus of antihelix expression;
LUAD	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg14558114	chr2:88469736	THNSL2	0.86	9.28	0.41	9.13e-19	Plasma clusterin levels;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg15317945	chr6:22569543	HDGFL1	-0.36	-6.59	-0.31	1.3e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg05425664	chr17:57184151	TRIM37	0.44	7.87	0.36	2.94e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg20607798	chr8:58055168	NA	0.67	8.77	0.39	4.44e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.0	-0.32	1.01e-11	Height;
LUAD	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg04016957	chr4:1044486	NA	0.41	6.86	0.32	2.44e-11	Recombination rate (males);
LUAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg22907277	chr7:1156413	C7orf50	0.48	7.49	0.34	4.03e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-6.95	-0.32	1.36e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.57	-0.46	2.5e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs758324	0.947	rs4705835	chr5:131116899	T/C	cg25547332	chr5:131281432	NA	0.45	6.76	0.31	4.47e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1595825	0.891	rs79745588	chr2:198516835	G/A	cg00982548	chr2:198649783	BOLL	-0.61	-8.57	-0.38	1.92e-16	Ulcerative colitis;
LUAD	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg03474202	chr17:45855739	NA	-0.37	-8.71	-0.39	7.04e-17	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg06606381	chr12:133084897	FBRSL1	-0.67	-7.37	-0.34	8.94e-13	Breast cancer;
LUAD	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.52	-8.63	-0.39	1.25e-16	Glomerular filtration rate;
LUAD	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	1.95e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12760731	0.565	rs12049568	chr1:178154345	A/G	cg00404053	chr1:178313656	RASAL2	0.72	9.1	0.4	3.67e-18	Obesity-related traits;
LUAD	cis	rs999943	0.846	rs9348923	chr6:33617924	C/T	cg14003231	chr6:33640908	ITPR3	0.89	17.85	0.66	1.52e-53	Obesity (extreme);
LUAD	cis	rs863345	0.565	rs2051665	chr1:158507157	A/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.41	-0.3	3.88e-10	Pneumococcal bacteremia;
LUAD	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg15226275	chr6:116381976	FRK	-0.23	-7.52	-0.34	3.35e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg23583168	chr7:148888333	NA	-1.0	-22.71	-0.74	3.13e-75	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg27588902	chr6:42928151	GNMT	-0.38	-10.09	-0.44	1.38e-21	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg22823121	chr1:150693482	HORMAD1	0.45	9.09	0.4	3.97e-18	Melanoma;
LUAD	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	trans	rs7555117	0.794	rs2989476	chr1:61059259	C/G	cg01111842	chr9:140444966	PNPLA7;MRPL41	-0.39	-6.41	-0.3	3.96e-10	Facial morphology (factor 19);
LUAD	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.41	-19.53	-0.69	5.13e-61	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg21138405	chr5:131827807	IRF1	0.6	13.77	0.56	6.51e-36	Asthma (sex interaction);
LUAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.7	-0.39	7.63e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg06028808	chr11:68637592	NA	0.5	8.27	0.37	1.71e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg01475377	chr6:109611718	NA	-0.51	-9.43	-0.42	2.71e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs17270561	0.609	rs4711094	chr6:25706174	T/A	cg25753631	chr6:25732923	NA	-0.37	-6.59	-0.31	1.28e-10	Iron status biomarkers;
LUAD	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg00631329	chr6:26305371	NA	-0.73	-14.1	-0.57	2.92e-37	Educational attainment;
LUAD	trans	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg13565492	chr6:43139072	SRF	-0.74	-10.08	-0.44	1.42e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.34	7.09	0.33	5.71e-12	Parkinson's disease;
LUAD	trans	rs7615952	0.611	rs79405914	chr3:125723623	C/T	cg07211511	chr3:129823064	LOC729375	-0.82	-7.73	-0.35	7.79e-14	Blood pressure (smoking interaction);
LUAD	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg09359103	chr1:154839909	KCNN3	-0.91	-21.24	-0.72	1.09e-68	Prostate cancer;
LUAD	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg10435618	chr10:838112	NA	0.47	6.41	0.3	3.95e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs3820068	0.734	rs72645830	chr1:15889910	A/G	cg24675056	chr1:15929824	NA	0.43	6.79	0.31	3.76e-11	Systolic blood pressure;
LUAD	cis	rs12200560	0.505	rs172425	chr6:97075299	A/T	cg06623918	chr6:96969491	KIAA0776	0.47	7.28	0.33	1.64e-12	Coronary heart disease;
LUAD	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg17074396	chr22:49843754	NA	-0.33	-6.77	-0.31	4.31e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg03714773	chr7:91764589	CYP51A1	0.28	6.53	0.3	1.86e-10	Breast cancer;
LUAD	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg03467027	chr4:99064603	C4orf37	0.4	6.43	0.3	3.45e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24308560	chr3:49941425	MST1R	-0.56	-9.31	-0.41	6.76e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs8072100	0.869	rs4439799	chr17:45781599	C/T	cg25173405	chr17:45401733	C17orf57	-0.47	-7.85	-0.36	3.51e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.27	0.37	1.73e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.33	6.42	0.3	3.56e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.93	-0.43	4.9e-21	Bipolar disorder and schizophrenia;
LUAD	trans	rs208520	0.874	rs208517	chr6:66947040	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-14.84	-0.59	2.01e-40	Exhaled nitric oxide output;
LUAD	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg14458575	chr2:238380390	NA	0.66	12.34	0.51	4.28e-30	Prostate cancer;
LUAD	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg27411982	chr8:10470053	RP1L1	0.38	6.64	0.31	9.49e-11	Retinal vascular caliber;
LUAD	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg21475434	chr5:93447410	FAM172A	0.74	8.22	0.37	2.58e-15	Diabetic retinopathy;
LUAD	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg15900387	chr1:150738905	CTSS	-0.37	-6.71	-0.31	6.41e-11	Melanoma;
LUAD	cis	rs73198271	0.740	rs10092600	chr8:8649023	A/G	cg01851573	chr8:8652454	MFHAS1	0.49	8.53	0.38	2.58e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7809950	0.954	rs2189839	chr7:107230026	A/G	cg23024343	chr7:107201750	COG5	0.67	11.21	0.48	1.05e-25	Coronary artery disease;
LUAD	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg12698349	chr2:225449008	CUL3	0.7	10.46	0.45	6.25e-23	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs9326248	0.559	rs1269329	chr11:116755041	T/C	cg20608306	chr11:116969690	SIK3	0.3	6.56	0.3	1.58e-10	Blood protein levels;
LUAD	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg14403583	chr14:105418241	AHNAK2	-0.46	-8.97	-0.4	1e-17	Rheumatoid arthritis;
LUAD	cis	rs13315871	0.929	rs71311852	chr3:58298843	G/A	cg20936604	chr3:58311152	NA	-0.75	-7.61	-0.35	1.82e-13	Cholesterol, total;
LUAD	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg00106254	chr7:1943704	MAD1L1	-0.52	-8.26	-0.37	1.85e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg17063962	chr7:91808500	NA	0.67	11.92	0.5	1.89e-28	Breast cancer;
LUAD	trans	rs7395662	0.927	rs2135690	chr11:48733601	A/G	cg15704280	chr7:45808275	SEPT13	0.41	6.4	0.3	4.17e-10	HDL cholesterol;
LUAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg02869364	chr7:1081709	C7orf50	-0.49	-6.59	-0.31	1.3e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg22029157	chr1:209979665	IRF6	0.7	9.36	0.41	4.71e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs17532515	0.652	rs17005942	chr4:141378000	C/T	cg03645522	chr4:141391200	NA	0.4	6.41	0.3	3.85e-10	Select biomarker traits;
LUAD	cis	rs13040088	1.000	rs2295000	chr20:61536938	A/G	cg23096297	chr20:61557774	DIDO1	-0.74	-10.46	-0.45	6.32e-23	Menopause (age at onset);
LUAD	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg04450456	chr4:17643702	FAM184B	0.4	7.84	0.36	3.76e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10465746	0.780	rs7550413	chr1:84423891	T/A	cg10977910	chr1:84465055	TTLL7	0.59	9.64	0.42	5.11e-20	Obesity-related traits;
LUAD	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg17177755	chr1:15930204	NA	0.45	7.37	0.34	9.03e-13	Systolic blood pressure;
LUAD	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg08493051	chr2:3487164	NA	-0.45	-7.81	-0.35	4.64e-14	Neurofibrillary tangles;
LUAD	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg02269571	chr22:50332266	NA	0.59	8.96	0.4	1.05e-17	Schizophrenia;
LUAD	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg11822812	chr5:140052017	DND1	-0.37	-6.63	-0.31	1.02e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg21724239	chr8:58056113	NA	0.74	9.62	0.42	5.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26314531	chr2:26401878	FAM59B	-0.55	-7.62	-0.35	1.64e-13	Gut microbiome composition (summer);
LUAD	cis	rs35740288	0.770	rs36044792	chr15:86146551	A/G	cg13263323	chr15:86062960	AKAP13	-0.43	-6.99	-0.32	1.11e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs1232027	0.700	rs1650695	chr5:79951382	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.9	-0.36	2.36e-14	Huntington's disease progression;
LUAD	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg10909506	chr17:38081995	ORMDL3	0.39	7.06	0.32	6.7e-12	Self-reported allergy;
LUAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06873352	chr17:61820015	STRADA	0.83	18.55	0.67	1.2e-56	Prudent dietary pattern;
LUAD	cis	rs2067615	0.524	rs4246257	chr12:107062329	C/T	cg15890332	chr12:107067104	RFX4	0.41	8.8	0.39	3.44e-17	Heart rate;
LUAD	cis	rs220324	0.688	rs9980786	chr21:43562535	C/T	cg09727148	chr21:43560719	UMODL1	0.6	9.1	0.4	3.66e-18	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg02631126	chr6:28058918	ZSCAN12L1	-0.38	-7.48	-0.34	4.45e-13	Depression;
LUAD	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.47	-9.78	-0.43	1.64e-20	Total body bone mineral density;
LUAD	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22857025	chr5:266934	NA	-1.01	-12.74	-0.53	1.11e-31	Breast cancer;
LUAD	cis	rs1595825	0.945	rs61184128	chr2:198843659	C/T	cg11031976	chr2:198649780	BOLL	-0.47	-7.02	-0.32	9.13e-12	Ulcerative colitis;
LUAD	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg17031739	chr1:67600172	NA	0.5	8.84	0.39	2.7e-17	Psoriasis;
LUAD	cis	rs10899021	0.920	rs7112384	chr11:74348205	T/G	cg25880958	chr11:74394337	NA	-0.64	-8.6	-0.39	1.54e-16	Response to metformin (IC50);
LUAD	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg19622623	chr12:86230825	RASSF9	0.47	8.22	0.37	2.53e-15	Major depressive disorder;
LUAD	cis	rs11690462	0.528	rs6710942	chr2:26636390	A/G	cg22920501	chr2:26401640	FAM59B	0.44	6.42	0.3	3.69e-10	Coronary artery disease;
LUAD	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg14689365	chr7:158441557	NCAPG2	0.38	6.44	0.3	3.3e-10	Height;
LUAD	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06112835	chr11:68658793	MRPL21	0.49	8.83	0.39	2.91e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.48	7.73	0.35	7.88e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1003719	0.788	rs9981226	chr21:38452127	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.55	0.38	2.27e-16	Eye color traits;
LUAD	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-7.04	-0.32	7.97e-12	Lung cancer;
LUAD	cis	rs813218	0.625	rs793484	chr3:99491508	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-8.51	-0.38	3.03e-16	Orofacial clefts;
LUAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg11965913	chr1:205819406	PM20D1	0.81	16.55	0.63	8.16e-48	Menarche (age at onset);
LUAD	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg12011299	chr4:100065546	ADH4	0.7	12.59	0.52	4.29e-31	Smoking initiation;
LUAD	cis	rs938554	0.779	rs7680126	chr4:9985596	G/A	cg00071950	chr4:10020882	SLC2A9	0.52	8.02	0.36	1.01e-14	Blood metabolite levels;
LUAD	cis	rs67072384	0.901	rs7936972	chr11:72479692	T/C	cg04827223	chr11:72435913	ARAP1	-0.65	-7.02	-0.32	8.68e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg20744362	chr22:50050164	C22orf34	0.4	8.48	0.38	3.88e-16	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg02631126	chr6:28058918	ZSCAN12L1	-0.33	-6.59	-0.31	1.28e-10	Parkinson's disease;
LUAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg20607798	chr8:58055168	NA	0.67	8.79	0.39	3.8e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.51	-0.38	3.12e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00149659	chr3:10157352	C3orf10	0.61	8.68	0.39	8.54e-17	Alzheimer's disease;
LUAD	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.42	-0.34	6.4e-13	Glomerular filtration rate;
LUAD	cis	rs7809950	0.861	rs10264412	chr7:107183877	G/A	cg23024343	chr7:107201750	COG5	-0.86	-14.46	-0.58	8.95e-39	Coronary artery disease;
LUAD	cis	rs9837602	0.882	rs9875664	chr3:99729130	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.62	9.35	0.41	5.16e-19	Breast cancer;
LUAD	cis	rs438034	1.000	rs369801	chr1:214829916	A/C	cg16144317	chr1:214725524	PTPN14	-0.36	-6.78	-0.31	4.17e-11	Response to antineoplastic agents;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09637004	chr1:41483537	SLFNL1	0.45	6.36	0.3	5.35e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg06784218	chr1:46089804	CCDC17	0.6	13.4	0.55	2.3e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg03433033	chr1:76189801	ACADM	-0.51	-7.34	-0.34	1.12e-12	Daytime sleep phenotypes;
LUAD	cis	rs9560113	1.000	rs4773379	chr13:112176088	G/C	cg14154082	chr13:112174009	NA	0.37	6.87	0.32	2.34e-11	Menarche (age at onset);
LUAD	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg11344533	chr11:111475393	SIK2	0.37	6.35	0.3	5.52e-10	Primary sclerosing cholangitis;
LUAD	cis	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg19041857	chr6:27730383	NA	-0.46	-7.18	-0.33	3.16e-12	Parkinson's disease;
LUAD	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg08847533	chr14:75593920	NEK9	0.38	6.58	0.3	1.41e-10	Height;
LUAD	trans	rs8002861	0.901	rs9525867	chr13:44463557	G/A	cg17145862	chr1:211918768	LPGAT1	0.76	18.05	0.66	2.07e-54	Leprosy;
LUAD	cis	rs11756438	0.572	rs1844964	chr6:119002528	C/T	cg18833306	chr6:118973337	C6orf204	0.52	9.35	0.41	5.16e-19	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg04450456	chr4:17643702	FAM184B	0.37	6.84	0.32	2.84e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg11062466	chr8:58055876	NA	0.46	6.69	0.31	7.1e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs981844	0.740	rs10024619	chr4:154684441	A/T	cg10279832	chr4:154682576	RNF175	0.34	7.15	0.33	3.79e-12	Response to statins (LDL cholesterol change);
LUAD	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.76	-0.31	4.58e-11	Retinal vascular caliber;
LUAD	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg05425664	chr17:57184151	TRIM37	-0.43	-7.48	-0.34	4.48e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg15448220	chr1:150897856	SETDB1	0.53	8.97	0.4	9.86e-18	Melanoma;
LUAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg22907277	chr7:1156413	C7orf50	0.52	8.31	0.37	1.29e-15	Longevity;Endometriosis;
LUAD	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23583168	chr7:148888333	NA	-0.93	-19.1	-0.68	4.37e-59	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg02269571	chr22:50332266	NA	-0.67	-9.44	-0.42	2.46e-19	Schizophrenia;
LUAD	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg12863693	chr15:85201151	NMB	0.4	7.34	0.34	1.09e-12	Schizophrenia;
LUAD	cis	rs239198	0.578	rs11155708	chr6:101292189	G/A	cg09795085	chr6:101329169	ASCC3	0.41	6.87	0.32	2.36e-11	Menarche (age at onset);
LUAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11905131	chr22:24372483	LOC391322	0.55	9.65	0.42	4.74e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs751728	1.000	rs9394166	chr6:33751122	G/C	cg13859433	chr6:33739653	LEMD2	-0.38	-8.71	-0.39	7.15e-17	Crohn's disease;
LUAD	cis	rs4642101	0.824	rs11717013	chr3:12843862	A/C	cg24848339	chr3:12840334	CAND2	0.39	7.91	0.36	2.29e-14	QRS complex (12-leadsum);
LUAD	cis	rs859767	0.741	rs1516991	chr2:135370052	G/A	cg12500956	chr2:135428796	TMEM163	-0.3	-7.99	-0.36	1.28e-14	Neuroticism;
LUAD	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7851660	0.809	rs12550872	chr9:100653128	G/A	cg13688889	chr9:100608707	NA	-0.54	-9.08	-0.4	4.17e-18	Strep throat;
LUAD	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.83	-0.61	1.19e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg07362569	chr17:61921086	SMARCD2	0.39	6.73	0.31	5.52e-11	Prudent dietary pattern;
LUAD	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg14541582	chr5:601475	NA	-0.36	-7.66	-0.35	1.31e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg04827223	chr11:72435913	ARAP1	-0.65	-12.26	-0.51	8.65e-30	Type 2 diabetes;
LUAD	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg00495681	chr13:53174319	NA	-0.51	-9.09	-0.4	3.8e-18	Lewy body disease;
LUAD	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.9	0.32	1.95e-11	Depression;
LUAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg20607798	chr8:58055168	NA	0.78	9.58	0.42	8.67e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg05457628	chr5:178986728	RUFY1	-0.63	-10.76	-0.46	4.89e-24	Lung cancer;
LUAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08280861	chr8:58055591	NA	0.65	10.79	0.46	3.94e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7186908	0.711	rs9923344	chr16:72190653	T/C	cg23815491	chr16:72088622	HP	0.5	7.98	0.36	1.42e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.08	0.37	6.84e-15	Breast cancer;
LUAD	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg00666640	chr1:248458726	OR2T12	0.3	7.24	0.33	2.14e-12	Common traits (Other);
LUAD	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg17178900	chr1:205818956	PM20D1	-0.41	-6.86	-0.32	2.51e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg18252515	chr7:66147081	NA	-0.59	-6.55	-0.3	1.7e-10	Diabetic kidney disease;
LUAD	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg11663144	chr21:46675770	NA	0.51	8.94	0.4	1.26e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg19436804	chr8:8560866	CLDN23	0.42	6.41	0.3	3.88e-10	Obesity-related traits;
LUAD	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg13334819	chr7:99746414	C7orf59	-0.56	-8.26	-0.37	1.89e-15	Coronary artery disease;
LUAD	cis	rs7680126	0.596	rs10939835	chr4:10313750	A/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-7.32	-0.34	1.28e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22590775	chr19:49891494	CCDC155	0.74	11.75	0.5	9.19e-28	Multiple sclerosis;
LUAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg01448562	chr3:133502909	NA	-0.77	-15.5	-0.6	3.13e-43	Iron status biomarkers;
LUAD	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg05234568	chr11:5960015	NA	0.35	6.46	0.3	2.85e-10	DNA methylation (variation);
LUAD	cis	rs68170813	0.559	rs3779498	chr7:106923158	C/G	cg02696742	chr7:106810147	HBP1	-0.76	-10.53	-0.46	3.44e-23	Coronary artery disease;
LUAD	cis	rs6426558	0.559	rs2813947	chr1:227459413	G/T	cg10327440	chr1:227177885	CDC42BPA	0.56	9.07	0.4	4.36e-18	Neutrophil percentage of white cells;
LUAD	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg00717180	chr2:96193071	NA	-0.35	-6.41	-0.3	3.91e-10	Coronary artery disease;
LUAD	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg06484146	chr7:12443880	VWDE	-0.6	-7.65	-0.35	1.33e-13	Coronary artery disease;
LUAD	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg01200585	chr1:228362443	C1orf69	0.42	7.57	0.35	2.41e-13	Diastolic blood pressure;
LUAD	cis	rs892961	1.000	rs11653743	chr17:75401923	C/A	cg05865280	chr17:75406074	SEPT9	0.61	18.22	0.66	3.75e-55	Airflow obstruction;
LUAD	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg06766960	chr11:133703094	NA	-0.45	-8.59	-0.39	1.67e-16	Childhood ear infection;
LUAD	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg11822812	chr5:140052017	DND1	0.38	6.74	0.31	5.29e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6993813	0.872	rs10955924	chr8:120053343	A/C	cg01975934	chr8:119970761	NA	0.35	6.93	0.32	1.55e-11	Bone mineral density (hip);
LUAD	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.39	-6.5	-0.3	2.22e-10	Total body bone mineral density;
LUAD	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10802521	chr3:52805072	NEK4	-0.62	-11.07	-0.47	3.45e-25	Bipolar disorder;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg19565306	chr22:51222011	RPL23AP82;RABL2B	-0.39	-6.93	-0.32	1.62e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg19193384	chr17:30244184	NA	-0.51	-6.44	-0.3	3.32e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.39	0.55	2.41e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08704250	chr15:31115839	NA	-0.56	-10.33	-0.45	1.87e-22	Huntington's disease progression;
LUAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg07167872	chr1:205819463	PM20D1	0.73	14.18	0.57	1.27e-37	Monocyte percentage of white cells;
LUAD	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22857025	chr5:266934	NA	-0.96	-14.33	-0.57	2.98e-38	Breast cancer;
LUAD	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg12863693	chr15:85201151	NMB	0.42	7.59	0.35	2.09e-13	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg20790798	chr5:1857306	NA	-0.45	-7.77	-0.35	6.1e-14	Cardiovascular disease risk factors;
LUAD	cis	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.41	-0.34	7e-13	Resting heart rate;
LUAD	cis	rs9625935	0.748	rs12537	chr22:30423460	C/T	cg11564601	chr22:30592435	NA	-0.32	-6.72	-0.31	5.85e-11	Tonsillectomy;
LUAD	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03878208	chr11:72483293	STARD10	0.61	8.78	0.39	3.96e-17	Type 2 diabetes;
LUAD	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg10518543	chr12:38710700	ALG10B	-0.4	-6.62	-0.31	1.11e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg06740227	chr12:86229804	RASSF9	0.4	7.14	0.33	4.15e-12	Major depressive disorder;
LUAD	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg05182265	chr7:156933206	UBE3C	0.81	17.09	0.64	3.51e-50	Body mass index;
LUAD	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg24399712	chr22:39784796	NA	-0.74	-12.29	-0.51	6.64e-30	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	trans	rs1941687	0.797	rs1493917	chr18:31392833	G/A	cg27147174	chr7:100797783	AP1S1	-0.5	-8.26	-0.37	1.93e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.12	-0.37	5.13e-15	Reticulocyte count;
LUAD	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg05110241	chr16:68378359	PRMT7	-0.79	-8.59	-0.39	1.68e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg05697835	chr1:2722811	NA	-0.3	-6.43	-0.3	3.5e-10	Ulcerative colitis;
LUAD	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg26587870	chr6:27730563	NA	-0.49	-8.19	-0.37	3.04e-15	Parkinson's disease;
LUAD	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-7.97	-0.36	1.5e-14	Diabetic kidney disease;
LUAD	trans	rs3857536	0.776	rs9342535	chr6:66932963	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.35	-0.3	5.66e-10	Blood trace element (Cu levels);
LUAD	cis	rs7100689	0.646	rs10736346	chr10:82134281	A/C	cg01528321	chr10:82214614	TSPAN14	0.65	10.26	0.45	3.26e-22	Post bronchodilator FEV1;
LUAD	cis	rs2455826	0.500	rs2455852	chr3:15688688	C/T	cg16303742	chr3:15540471	COLQ	-0.58	-10.95	-0.47	9.72e-25	Inflammatory skin disease;
LUAD	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg02733842	chr7:1102375	C7orf50	-0.59	-9.22	-0.41	1.36e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg06766960	chr11:133703094	NA	-0.36	-6.92	-0.32	1.66e-11	Childhood ear infection;
LUAD	cis	rs17362650	0.960	rs13031491	chr2:9642521	C/T	cg12832956	chr2:9616023	IAH1	-0.47	-7.42	-0.34	6.45e-13	Alcohol dependence (age at onset);
LUAD	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.85	0.53	3.78e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg06191203	chr2:152266755	RIF1	-0.61	-9.4	-0.42	3.51e-19	Lung cancer;
LUAD	cis	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.52	6.36	0.3	5.11e-10	Depression;
LUAD	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.76	-13.31	-0.54	5.09e-34	Axial length;
LUAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg27588902	chr6:42928151	GNMT	-0.36	-9.7	-0.43	3.09e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg21238619	chr17:78079768	GAA	-0.38	-6.98	-0.32	1.13e-11	Yeast infection;
LUAD	cis	rs2220004	0.533	rs10444367	chr11:55718299	C/T	cg22937354	chr11:55606216	OR5D16	-0.37	-6.51	-0.3	2.1e-10	Odorant perception (&beta-damascenone);
LUAD	cis	rs12149202	0.627	rs393793	chr16:85728152	T/C	cg26571870	chr16:85723150	GINS2	-0.34	-6.66	-0.31	8.55e-11	Blood pressure traits (multi-trait analysis);
LUAD	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg07080864	chr8:57359956	PENK	-0.38	-6.81	-0.31	3.37e-11	Obesity-related traits;
LUAD	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.69	-0.39	8.26e-17	Glomerular filtration rate;
LUAD	cis	rs757647	0.638	rs12519732	chr5:137757377	A/C	cg10676309	chr5:137685565	NA	0.43	7.54	0.34	2.98e-13	Menarche (age at onset);
LUAD	cis	rs17401966	1.000	rs11121532	chr1:10277898	G/T	cg15208524	chr1:10270712	KIF1B	0.55	7.95	0.36	1.75e-14	Hepatocellular carcinoma;
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg14668821	chr17:77704760	ENPP7	0.33	6.68	0.31	7.42e-11	Menopause (age at onset);
LUAD	cis	rs447921	0.861	rs452868	chr17:74421483	C/A	cg17201438	chr17:74438067	UBE2O	-0.62	-8.49	-0.38	3.46e-16	Mitochondrial DNA levels;
LUAD	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg01657329	chr11:68192670	LRP5	-0.41	-6.56	-0.3	1.62e-10	Total body bone mineral density;
LUAD	trans	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg05926928	chr17:57297772	GDPD1	0.73	9.06	0.4	5.03e-18	Opioid sensitivity;
LUAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg08132940	chr7:1081526	C7orf50	-0.67	-9.2	-0.41	1.69e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg00495681	chr13:53174319	NA	0.48	8.61	0.39	1.42e-16	Lewy body disease;
LUAD	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23221052	chr5:179740743	GFPT2	-0.72	-12.01	-0.5	8.47e-29	Height;
LUAD	cis	rs7727544	0.526	rs4705908	chr5:131347520	G/A	cg16205897	chr5:131564050	P4HA2	-0.32	-6.8	-0.31	3.51e-11	Blood metabolite levels;
LUAD	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg24112000	chr20:60950667	NA	0.74	12.4	0.52	2.51e-30	Colorectal cancer;
LUAD	cis	rs7193541	0.691	rs3851728	chr16:74480660	C/T	cg01733217	chr16:74700730	RFWD3	0.42	7.15	0.33	3.81e-12	Multiple myeloma;
LUAD	cis	rs6684514	1.000	rs2270291	chr1:156244992	G/C	cg16558208	chr1:156270281	VHLL	0.53	9.58	0.42	8.12e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs7428	0.527	rs1061782	chr2:85546615	A/G	cg24342717	chr2:85555507	TGOLN2	0.48	7.9	0.36	2.4e-14	Ear protrusion;
LUAD	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg22532475	chr10:104410764	TRIM8	-0.47	-9.15	-0.41	2.39e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs2262909	0.925	rs73019838	chr19:22247732	T/A	cg17074339	chr11:11642133	GALNTL4	0.47	7.71	0.35	8.96e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12976411	0.575	rs59290294	chr19:32827336	T/C	cg18253629	chr19:32836317	ZNF507	0.65	6.81	0.31	3.31e-11	Coronary artery disease;
LUAD	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg11062466	chr8:58055876	NA	0.56	7.54	0.34	2.86e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg15445000	chr17:37608096	MED1	-0.45	-8.31	-0.37	1.27e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg01416388	chr22:39784598	NA	0.51	8.81	0.39	3.32e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg09455208	chr3:40491958	NA	0.51	10.5	0.45	4.36e-23	Renal cell carcinoma;
LUAD	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg09658497	chr7:2847517	GNA12	-0.55	-9.14	-0.41	2.54e-18	Height;
LUAD	cis	rs7584330	0.518	rs74003103	chr2:238446699	G/A	cg14458575	chr2:238380390	NA	0.75	11.04	0.47	4.5e-25	Prostate cancer;
LUAD	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs10129255	0.518	rs8004895	chr14:107193377	T/C	cg07958169	chr14:107095056	NA	-0.37	-7.36	-0.34	9.91e-13	Kawasaki disease;
LUAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg22907277	chr7:1156413	C7orf50	0.68	8.0	0.36	1.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11955175	1.000	rs75728011	chr5:40797505	A/C	cg04002187	chr5:40835754	RPL37	0.8	6.46	0.3	2.96e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg25809561	chr17:30822961	MYO1D	0.46	8.39	0.38	7.42e-16	Schizophrenia;
LUAD	cis	rs17532515	0.652	rs6844879	chr4:141380434	C/A	cg03645522	chr4:141391200	NA	0.39	6.41	0.3	3.92e-10	Select biomarker traits;
LUAD	cis	rs7737355	0.812	rs994453	chr5:130872520	G/T	cg06307176	chr5:131281290	NA	-0.44	-7.27	-0.33	1.79e-12	Life satisfaction;
LUAD	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-8.07	-0.37	7.4e-15	Blood metabolite levels;
LUAD	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg08085267	chr17:45401833	C17orf57	0.59	10.77	0.46	4.7e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs524023	0.958	rs3825016	chr11:64359286	C/T	cg19131476	chr11:64387923	NRXN2	-0.35	-6.58	-0.3	1.37e-10	Urate levels in obese individuals;
LUAD	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg04414720	chr1:150670196	GOLPH3L	0.67	11.52	0.49	6.71e-27	Melanoma;
LUAD	cis	rs751728	1.000	rs6920075	chr6:33731797	C/T	cg13859433	chr6:33739653	LEMD2	-0.4	-9.56	-0.42	9.45e-20	Crohn's disease;
LUAD	cis	rs377457	0.893	rs451871	chr16:85736429	A/G	cg02758499	chr16:85682440	KIAA0182	0.37	7.12	0.33	4.78e-12	Type 2 diabetes;
LUAD	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg01200585	chr1:228362443	C1orf69	-0.4	-7.36	-0.34	9.56e-13	Diastolic blood pressure;
LUAD	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg12599982	chr1:44399894	ARTN	0.36	7.02	0.32	8.67e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg23719950	chr11:63933701	MACROD1	-0.59	-7.01	-0.32	9.19e-12	Mean platelet volume;
LUAD	cis	rs6831352	0.879	rs4699717	chr4:100066137	C/T	cg12011299	chr4:100065546	ADH4	-0.74	-13.41	-0.55	1.94e-34	Alcohol dependence;
LUAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg21951975	chr1:209979733	IRF6	0.55	8.91	0.4	1.48e-17	Cleft lip with or without cleft palate;
LUAD	cis	rs9811920	0.666	rs793456	chr3:99525631	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.53	-9.65	-0.42	4.68e-20	Axial length;
LUAD	cis	rs986417	1.000	rs1254254	chr14:60831146	G/A	cg27398547	chr14:60952738	C14orf39	-0.61	-7.33	-0.34	1.16e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg22920501	chr2:26401640	FAM59B	-0.82	-11.51	-0.49	7.66e-27	Gut microbiome composition (summer);
LUAD	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11644478	chr21:40555479	PSMG1	-0.39	-6.51	-0.3	2.11e-10	Menarche (age at onset);
LUAD	cis	rs977987	0.843	rs12443904	chr16:75438770	C/T	cg03315344	chr16:75512273	CHST6	0.63	13.93	0.56	1.5e-36	Dupuytren's disease;
LUAD	cis	rs7000551	0.680	rs28546543	chr8:22314872	A/C	cg12081754	chr8:22256438	SLC39A14	0.44	7.22	0.33	2.46e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs58106596	0.517	rs17271845	chr2:232653173	G/T	cg26500773	chr2:232646331	PDE6D	-0.54	-7.57	-0.35	2.38e-13	White blood cell count;Lymphocyte counts;
LUAD	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg14159672	chr1:205819179	PM20D1	-0.51	-7.68	-0.35	1.12e-13	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.56	-7.64	-0.35	1.46e-13	Body mass index;
LUAD	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg26587870	chr6:27730563	NA	-0.69	-7.01	-0.32	9.28e-12	Depression;
LUAD	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg17105886	chr17:28927953	LRRC37B2	0.76	7.18	0.33	3.14e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1113500	0.933	rs1414674	chr1:108625947	A/G	cg06207961	chr1:108661230	NA	0.46	8.65	0.39	1.06e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg22532475	chr10:104410764	TRIM8	0.36	7.28	0.33	1.62e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg09365446	chr1:150670422	GOLPH3L	0.65	12.19	0.51	1.63e-29	Urate levels;
LUAD	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg12564285	chr5:131593104	PDLIM4	0.37	6.94	0.32	1.48e-11	Acylcarnitine levels;
LUAD	trans	rs1268789	0.571	rs949507	chr4:79394086	C/T	cg14078059	chr12:65174660	NA	-0.41	-6.73	-0.31	5.59e-11	Hair shape;Hair morphology;
LUAD	cis	rs773506	0.628	rs10733739	chr9:93929515	C/T	cg14446406	chr9:93919335	NA	-0.36	-6.59	-0.31	1.3100000000000001e-10	Type 2 diabetes nephropathy;
LUAD	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg00981070	chr1:2046702	PRKCZ	0.36	7.71	0.35	9.33e-14	Height;
LUAD	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg05872129	chr22:39784769	NA	-0.82	-15.62	-0.6	9.78e-44	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	0.544	rs6804545	chr3:40354040	G/C	cg09455208	chr3:40491958	NA	0.52	10.87	0.47	2.03e-24	Renal cell carcinoma;
LUAD	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg18854424	chr1:2615690	NA	0.4	8.5	0.38	3.18e-16	Ulcerative colitis;
LUAD	cis	rs231513	1.000	rs231513	chr17:41965200	C/G	cg26893861	chr17:41843967	DUSP3	-0.64	-7.38	-0.34	8.5e-13	Cognitive function;
LUAD	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg15790184	chr11:494944	RNH1	0.55	7.15	0.33	3.88e-12	Body mass index;
LUAD	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18404041	chr3:52824283	ITIH1	-0.57	-11.92	-0.5	1.91e-28	Bipolar disorder;
LUAD	cis	rs12681287	0.752	rs10956786	chr8:87301237	T/C	cg27223183	chr8:87520930	FAM82B	-0.6	-8.26	-0.37	1.95e-15	Caudate activity during reward;
LUAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08219700	chr8:58056026	NA	0.57	7.89	0.36	2.64e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg04450456	chr4:17643702	FAM184B	-0.42	-8.11	-0.37	5.69e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg11494091	chr17:61959527	GH2	0.74	18.37	0.67	7.72e-56	Prudent dietary pattern;
LUAD	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg25233709	chr10:116636983	FAM160B1	0.46	9.19	0.41	1.77e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04565464	chr8:145669602	NFKBIL2	0.43	6.67	0.31	8.08e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs66569888	0.523	rs4522599	chr2:106926004	G/C	cg16099169	chr2:106886729	NA	0.63	9.2	0.41	1.71e-18	Facial morphology (factor 23);
LUAD	cis	rs68170813	0.559	rs78440378	chr7:106962782	C/A	cg02696742	chr7:106810147	HBP1	-0.75	-10.12	-0.44	1.02e-21	Coronary artery disease;
LUAD	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18876405	chr7:65276391	NA	0.57	9.43	0.42	2.73e-19	Aortic root size;
LUAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg02951883	chr7:2050386	MAD1L1	-0.97	-19.21	-0.68	1.46e-59	Bipolar disorder and schizophrenia;
LUAD	trans	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	25.66	0.78	2.91e-88	Colorectal cancer;
LUAD	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.48	-8.67	-0.39	9.18e-17	Menarche (age at onset);
LUAD	cis	rs3820068	0.524	rs34094056	chr1:15824154	G/T	cg24675056	chr1:15929824	NA	0.41	6.41	0.3	3.91e-10	Systolic blood pressure;
LUAD	cis	rs7119	0.717	rs11630916	chr15:77821331	G/A	cg27398640	chr15:77910606	LINGO1	-0.35	-6.53	-0.3	1.9e-10	Type 2 diabetes;
LUAD	cis	rs68170813	0.617	rs10464499	chr7:107137571	C/T	cg23024343	chr7:107201750	COG5	0.53	6.71	0.31	6.13e-11	Coronary artery disease;
LUAD	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg02733842	chr7:1102375	C7orf50	-0.53	-8.5	-0.38	3.3e-16	Bronchopulmonary dysplasia;
LUAD	cis	rs9972944	0.756	rs6416948	chr17:63767131	T/G	cg07283582	chr17:63770753	CCDC46	-0.5	-11.18	-0.48	1.28e-25	Total body bone mineral density;
LUAD	cis	rs908922	0.605	rs3753448	chr1:152486407	A/C	cg23254163	chr1:152506842	NA	0.26	7.11	0.33	4.89e-12	Hair morphology;
LUAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg06873352	chr17:61820015	STRADA	-0.72	-14.65	-0.58	1.31e-39	Prudent dietary pattern;
LUAD	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg07527032	chr15:84868466	LOC388152	0.44	6.63	0.31	1.04e-10	Schizophrenia;
LUAD	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg23815491	chr16:72088622	HP	0.51	9.19	0.41	1.75e-18	Fibrinogen levels;
LUAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-7.74	-0.35	7.49e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22307029	chr19:49891270	CCDC155	0.81	13.04	0.54	6.89e-33	Multiple sclerosis;
LUAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.01	-0.32	9.55e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7503807	1.000	rs7503807	chr17:78591111	G/T	cg09596252	chr17:78655493	RPTOR	-0.39	-7.79	-0.35	5.06e-14	Obesity;
LUAD	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.7	-14.2	-0.57	1.04e-37	Urate levels in overweight individuals;
LUAD	cis	rs9843304	0.528	rs9880421	chr3:149183359	C/T	cg08667024	chr3:149219783	TM4SF4	0.39	7.22	0.33	2.36e-12	Gallstone disease;
LUAD	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg10518543	chr12:38710700	ALG10B	-0.41	-6.59	-0.31	1.32e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.8	0.76	4.34e-80	Chronic sinus infection;
LUAD	cis	rs1032833	0.732	rs879539	chr2:180003331	A/G	cg23883738	chr2:179974586	SESTD1	-0.7	-7.65	-0.35	1.39e-13	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs7707921	0.958	rs6452447	chr5:81482522	A/G	cg15871215	chr5:81402204	ATG10	0.71	10.24	0.45	4.03e-22	Breast cancer;
LUAD	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg15704280	chr7:45808275	SEPT13	-0.79	-13.34	-0.54	3.9e-34	Coronary artery disease;
LUAD	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg08712631	chr7:1960676	MAD1L1	-0.41	-6.58	-0.3	1.42e-10	Neuroticism;
LUAD	cis	rs877282	1.000	rs11253370	chr10:773712	G/A	cg06581033	chr10:766294	NA	-0.48	-6.7	-0.31	6.56e-11	Uric acid levels;
LUAD	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg26536354	chr8:144654954	C8orf73	0.62	6.71	0.31	6.36e-11	Attention deficit hyperactivity disorder;
LUAD	trans	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-10.37	-0.45	1.37e-22	Obesity-related traits;
LUAD	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg01884057	chr2:25150051	NA	0.32	6.81	0.31	3.36e-11	Body mass index;
LUAD	cis	rs4481887	0.927	rs4427440	chr1:248480337	T/A	cg13385794	chr1:248469461	NA	0.26	7.0	0.32	1.01e-11	Common traits (Other);
LUAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg13047869	chr3:10149882	C3orf24	0.62	10.1	0.44	1.22e-21	Alzheimer's disease;
LUAD	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.14	0.37	4.52e-15	Menopause (age at onset);
LUAD	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-17.27	-0.64	5.55e-51	Exhaled nitric oxide output;
LUAD	cis	rs6546550	0.901	rs13028508	chr2:70118427	A/T	cg02498382	chr2:70120550	SNRNP27	0.58	11.03	0.47	4.86e-25	Prevalent atrial fibrillation;
LUAD	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	8.88e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2882667	0.628	rs13173618	chr5:138139780	T/G	cg04439458	chr5:138467593	SIL1	-0.41	-6.66	-0.31	8.35e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg09835421	chr16:68378352	PRMT7	-0.82	-8.75	-0.39	5.13e-17	Schizophrenia;
LUAD	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg08601574	chr20:25228251	PYGB	-0.47	-8.8	-0.39	3.43e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg18811423	chr2:55921094	PNPT1	0.51	8.53	0.38	2.56e-16	Metabolic syndrome;
LUAD	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg00383909	chr3:49044727	WDR6	0.98	10.42	0.45	8.57e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs11809207	1.000	rs41284333	chr1:26517267	A/G	cg00147160	chr1:26503991	CNKSR1	0.42	8.55	0.38	2.3e-16	Height;
LUAD	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg23958373	chr8:599963	NA	0.8	7.45	0.34	5.14e-13	IgG glycosylation;
LUAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg22105103	chr4:187893119	NA	0.53	11.34	0.48	3.19e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3862030	0.720	rs7341995	chr10:104223831	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.93	-0.36	2.02e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	trans	rs747782	0.528	rs11039669	chr11:48328818	C/T	cg03929089	chr4:120376271	NA	0.56	6.48	0.3	2.6e-10	Intraocular pressure;
LUAD	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg01579765	chr21:45077557	HSF2BP	-0.62	-13.78	-0.56	5.79e-36	Mean corpuscular volume;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg01585723	chr16:33734837	NA	0.35	6.42	0.3	3.75e-10	Menopause (age at onset);
LUAD	cis	rs7326068	0.610	rs9578316	chr13:21340088	C/T	cg27499820	chr13:21296301	IL17D	0.56	8.36	0.38	9.3e-16	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg12940439	chr1:67600707	NA	0.47	8.65	0.39	1.07e-16	Psoriasis;
LUAD	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03264133	chr6:25882463	NA	-0.55	-8.95	-0.4	1.15e-17	Blood metabolite levels;
LUAD	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg03714773	chr7:91764589	CYP51A1	0.27	6.54	0.3	1.83e-10	Breast cancer;
LUAD	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg09117114	chr16:67998030	SLC12A4	-0.48	-6.82	-0.31	3.06e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs7944735	0.817	rs747782	chr11:47940925	A/G	cg03929089	chr4:120376271	NA	0.6	7.96	0.36	1.55e-14	Intraocular pressure;
LUAD	trans	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg24644049	chr4:85504048	CDS1	0.87	6.99	0.32	1.05e-11	Skin colour saturation;
LUAD	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg23422044	chr7:1970798	MAD1L1	-0.5	-6.36	-0.3	5.38e-10	Bipolar disorder;
LUAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08280861	chr8:58055591	NA	0.63	8.24	0.37	2.25e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4919694	1.000	rs74749600	chr10:104732996	T/C	cg04362960	chr10:104952993	NT5C2	0.82	8.58	0.38	1.86e-16	Arsenic metabolism;
LUAD	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg22467129	chr15:76604101	ETFA	-0.49	-8.5	-0.38	3.2e-16	Blood metabolite levels;
LUAD	cis	rs1448094	0.872	rs10863147	chr12:86408441	G/C	cg19622623	chr12:86230825	RASSF9	-0.37	-6.74	-0.31	5.25e-11	Major depressive disorder;
LUAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg18402987	chr7:1209562	NA	0.78	9.54	0.42	1.19e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs89107	1.000	rs89107	chr6:118578043	G/A	cg18833306	chr6:118973337	C6orf204	0.48	8.71	0.39	7.13e-17	Cardiac structure and function;
LUAD	cis	rs4691139	0.619	rs2139218	chr4:165922427	T/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.42	-7.76	-0.35	6.34e-14	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs4481887	0.893	rs28451623	chr1:248509783	G/A	cg00666640	chr1:248458726	OR2T12	0.28	7.13	0.33	4.34e-12	Common traits (Other);
LUAD	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg06637938	chr14:75390232	RPS6KL1	0.37	6.88	0.32	2.1e-11	Caffeine consumption;
LUAD	cis	rs6500395	1.000	rs11076578	chr16:48714520	C/G	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs208520	0.802	rs851600	chr6:66893754	T/C	cg07460842	chr6:66804631	NA	-0.98	-14.59	-0.58	2.37e-39	Exhaled nitric oxide output;
LUAD	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg10589385	chr1:150898437	SETDB1	0.43	7.99	0.36	1.27e-14	Melanoma;
LUAD	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18404041	chr3:52824283	ITIH1	-0.59	-11.92	-0.5	1.99e-28	Bipolar disorder;
LUAD	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg09537434	chr19:41945824	ATP5SL	-0.53	-8.48	-0.38	3.82e-16	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05360402	chr5:110848191	STARD4	-0.41	-6.43	-0.3	3.55e-10	Height;
LUAD	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg00495681	chr13:53174319	NA	0.47	7.88	0.36	2.86e-14	Lewy body disease;
LUAD	cis	rs6545883	0.929	rs7561229	chr2:61737990	A/T	cg15711740	chr2:61764176	XPO1	-0.39	-6.39	-0.3	4.31e-10	Tuberculosis;
LUAD	cis	rs59104589	0.617	rs111937035	chr2:242212177	C/T	cg08645257	chr2:242211290	HDLBP	0.51	8.02	0.36	1.03e-14	Fibrinogen levels;
LUAD	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg09796270	chr17:17721594	SREBF1	-0.37	-7.28	-0.33	1.69e-12	Total body bone mineral density;
LUAD	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.44	-0.42	2.44e-19	Life satisfaction;
LUAD	cis	rs7824557	0.650	rs2572406	chr8:11092252	C/G	cg21775007	chr8:11205619	TDH	0.37	6.67	0.31	8.05e-11	Retinal vascular caliber;
LUAD	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.59	-10.49	-0.45	5.01e-23	Melanoma;
LUAD	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.46	7.62	0.35	1.63e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs3818285	0.959	rs35420248	chr10:111643074	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.1	-0.37	5.99e-15	Superior crus of antihelix expression;
LUAD	cis	rs6906287	0.647	rs12660455	chr6:118717382	C/T	cg18833306	chr6:118973337	C6orf204	0.48	8.45	0.38	4.7e-16	Electrocardiographic conduction measures;
LUAD	cis	rs2985684	1.000	rs2985687	chr14:50100386	T/C	cg04989706	chr14:50066350	PPIL5	-0.47	-6.9	-0.32	1.93e-11	Carotid intima media thickness;
LUAD	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.46	-8.01	-0.36	1.09e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs887829	0.570	rs4553819	chr2:234594083	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.67	-0.43	4e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg18000306	chr6:288505	NA	0.43	8.02	0.36	1.05e-14	Menopause (age at onset);
LUAD	trans	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg22431228	chr1:16359049	CLCNKA	-0.43	-8.01	-0.36	1.11e-14	Systolic blood pressure;
LUAD	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.63	-0.39	1.26e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18876405	chr7:65276391	NA	0.56	9.42	0.42	2.99e-19	Aortic root size;
LUAD	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg25344623	chr2:136566232	LCT	0.35	6.87	0.32	2.27e-11	Mosquito bite size;
LUAD	cis	rs1881396	0.945	rs1881395	chr2:27838549	G/A	cg27432699	chr2:27873401	GPN1	0.46	6.67	0.31	7.8e-11	Nonalcoholic fatty liver disease;
LUAD	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg14844989	chr11:31128820	NA	-0.45	-8.23	-0.37	2.4e-15	Red blood cell count;
LUAD	cis	rs1451375	0.572	rs896309	chr7:50545022	A/G	cg18232548	chr7:50535776	DDC	-0.65	-9.05	-0.4	5.3e-18	Malaria;
LUAD	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.31	6.5	0.3	2.23e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	7.8	0.35	4.75e-14	Menopause (age at onset);
LUAD	trans	rs7395662	0.864	rs10838951	chr11:48571088	T/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.8e-10	HDL cholesterol;
LUAD	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6543140	0.964	rs13393175	chr2:103078849	T/G	cg03938978	chr2:103052716	IL18RAP	0.35	6.8	0.31	3.6e-11	Blood protein levels;
LUAD	cis	rs730566	1.000	rs730566	chr3:48487048	G/T	cg07636037	chr3:49044803	WDR6	-0.42	-6.75	-0.31	5.01e-11	Prion diseases;
LUAD	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg15017067	chr4:17643749	FAM184B	-0.36	-6.75	-0.31	4.75e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg18944383	chr4:111397179	ENPEP	0.38	6.56	0.3	1.58e-10	Coronary artery disease;
LUAD	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg19622623	chr12:86230825	RASSF9	-0.4	-7.1	-0.33	5.31e-12	Major depressive disorder;
LUAD	cis	rs41271473	0.526	rs10916337	chr1:228714902	C/T	cg16512390	chr1:228756714	NA	0.68	9.1	0.4	3.47e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs3816788	0.620	rs11783414	chr8:21773384	A/G	cg03445287	chr8:21823731	XPO7	0.39	7.18	0.33	3.14e-12	Lung cancer in ever smokers;
LUAD	cis	rs2073300	1.000	rs17830565	chr20:23444805	G/A	cg12062639	chr20:23401060	NAPB	0.98	8.35	0.38	9.91e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-8.07	-0.37	7.12e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg17178900	chr1:205818956	PM20D1	0.68	13.61	0.55	3.12e-35	Menarche (age at onset);
LUAD	cis	rs847577	0.630	rs11764933	chr7:97825188	G/A	cg24562669	chr7:97807699	LMTK2	0.34	8.06	0.37	7.68e-15	Breast cancer;
LUAD	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg13126279	chr21:47581558	C21orf56	-0.43	-7.41	-0.34	6.74e-13	Testicular germ cell tumor;
LUAD	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg09165964	chr15:75287851	SCAMP5	-0.44	-6.72	-0.31	5.95e-11	Blood trace element (Zn levels);
LUAD	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.6	0.31	1.22e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs240764	0.578	rs1414734	chr6:101201823	T/C	cg09795085	chr6:101329169	ASCC3	0.44	7.64	0.35	1.43e-13	Neuroticism;
LUAD	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.32	6.47	0.3	2.78e-10	Bipolar disorder;
LUAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg24813613	chr7:1882135	MAD1L1	-0.49	-7.68	-0.35	1.13e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg15605315	chr1:45957053	TESK2	0.49	7.71	0.35	9.03e-14	High light scatter reticulocyte count;
LUAD	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.3	-7.91	-0.36	2.27e-14	Total body bone mineral density;
LUAD	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg08085267	chr17:45401833	C17orf57	-0.65	-11.76	-0.5	8.23e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6743376	0.556	rs957201	chr2:113821200	T/C	cg09040174	chr2:113837401	NA	0.47	7.31	0.33	1.34e-12	Inflammatory biomarkers;
LUAD	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg22532475	chr10:104410764	TRIM8	-0.39	-7.04	-0.32	7.58e-12	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg16479474	chr6:28041457	NA	0.41	6.89	0.32	1.99e-11	Parkinson's disease;
LUAD	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg08999081	chr20:33150536	PIGU	0.62	13.94	0.56	1.28e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg22676075	chr6:135203613	NA	0.56	9.95	0.44	4.34e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.53	-9.39	-0.42	3.89e-19	Axial length;
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg12277888	chr11:35723985	TRIM44	0.43	6.63	0.31	1.05e-10	Hepatitis;
LUAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18099408	chr3:52552593	STAB1	-0.51	-9.32	-0.41	6.74e-19	Electroencephalogram traits;
LUAD	cis	rs4072705	0.933	rs10760376	chr9:127554070	A/G	cg13476313	chr9:127244764	NR5A1	-0.29	-6.75	-0.31	5e-11	Menarche (age at onset);
LUAD	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg12034118	chr1:209979487	IRF6	0.45	6.4	0.3	4.23e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs2880765	0.835	rs6497202	chr15:86021375	T/C	cg13263323	chr15:86062960	AKAP13	-0.48	-8.92	-0.4	1.44e-17	Coronary artery disease;
LUAD	cis	rs2882667	1.000	rs10064201	chr5:138309405	C/T	cg04439458	chr5:138467593	SIL1	-0.42	-7.58	-0.35	2.15e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg05913198	chr10:21822977	MLLT10	-0.33	-6.48	-0.3	2.56e-10	Schizophrenia;
LUAD	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg08213375	chr14:104286397	PPP1R13B	0.28	7.2	0.33	2.69e-12	Schizophrenia;
LUAD	trans	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg26043149	chr18:55253948	FECH	-0.43	-7.03	-0.32	8.17e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12286929	0.637	rs3802858	chr11:115078492	T/C	cg04055981	chr11:115044050	NA	-0.45	-7.76	-0.35	6.53e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-8.69	-0.39	7.98e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.62	-11.83	-0.5	4.33e-28	Longevity;Endometriosis;
LUAD	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	12.56	0.52	5.89e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2455799	0.573	rs62243672	chr3:15937200	C/T	cg16303742	chr3:15540471	COLQ	-0.47	-8.43	-0.38	5.63e-16	Mean platelet volume;
LUAD	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.48	-8.05	-0.36	8.29e-15	Tonsillectomy;
LUAD	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.9	0.4	1.62e-17	Schizophrenia;
LUAD	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	6.2e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg14917512	chr19:3094685	GNA11	-0.37	-6.37	-0.3	4.98e-10	Aortic root size;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg22080472	chr1:28176762	PPP1R8	-0.4	-6.41	-0.3	3.81e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg26384229	chr12:38710491	ALG10B	0.48	7.8	0.35	4.88e-14	Bladder cancer;
LUAD	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.42	-7.5	-0.34	3.75e-13	Longevity;Endometriosis;
LUAD	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg11879182	chr18:77439856	CTDP1	0.4	6.35	0.3	5.52e-10	Monocyte count;
LUAD	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg00634984	chr7:65235879	NA	0.52	6.97	0.32	1.21e-11	Aortic root size;
LUAD	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg18045461	chr22:29601862	EMID1	0.34	6.35	0.3	5.72e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg13902645	chr11:5959945	NA	-0.48	-8.06	-0.36	8.01e-15	DNA methylation (variation);
LUAD	trans	rs7395662	0.864	rs10839201	chr11:48989417	A/G	cg00717180	chr2:96193071	NA	0.43	8.35	0.38	9.87e-16	HDL cholesterol;
LUAD	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs34375054	0.660	rs58624919	chr12:125596458	G/A	cg06287003	chr12:125626642	AACS	-0.44	-6.55	-0.3	1.7e-10	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg00280220	chr17:61926910	NA	0.36	6.83	0.32	2.9e-11	Prudent dietary pattern;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26230390	chr2:203130314	NOP58	-0.54	-6.76	-0.31	4.6e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg24503407	chr1:205819492	PM20D1	0.44	7.05	0.32	7.46e-12	Parkinson's disease;
LUAD	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg19875535	chr5:140030758	IK	-0.42	-7.05	-0.32	7.56e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4711350	0.906	rs3957165	chr6:33784864	A/G	cg07979401	chr6:33739406	LEMD2	0.41	6.87	0.32	2.3e-11	Schizophrenia;
LUAD	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg06641503	chr3:48959341	ARIH2	-0.4	-7.85	-0.36	3.56e-14	Parkinson's disease;
LUAD	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg07917127	chr4:99064746	C4orf37	0.41	6.72	0.31	6.05e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg15117754	chr3:10150083	C3orf24	0.42	6.67	0.31	8e-11	Alzheimer's disease;
LUAD	cis	rs9487051	0.768	rs371960	chr6:109525082	A/G	cg21918786	chr6:109611834	NA	-0.39	-6.89	-0.32	2.03e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.32	7.43	0.34	6.22e-13	Prostate cancer;
LUAD	cis	rs758324	0.947	rs1500115	chr5:131216427	G/T	cg25547332	chr5:131281432	NA	0.44	6.75	0.31	5e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs500891	0.525	rs1144177	chr6:84029793	A/G	cg08257003	chr6:84140564	ME1	0.34	6.43	0.3	3.49e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg02773041	chr1:40204384	PPIE	0.52	8.49	0.38	3.42e-16	Blood protein levels;
LUAD	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg19875535	chr5:140030758	IK	0.47	7.71	0.35	8.78e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.76	0.35	6.5e-14	Platelet count;
LUAD	cis	rs847851	1.000	rs57951780	chr6:34852891	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-7.28	-0.33	1.63e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.44	-7.89	-0.36	2.59e-14	Age at first birth;
LUAD	cis	rs7274811	0.744	rs55651102	chr20:32188068	A/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.5	-7.26	-0.33	1.88e-12	Height;
LUAD	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.74	0.31	5.24e-11	Cognitive test performance;
LUAD	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.3	1.35e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg19875535	chr5:140030758	IK	0.45	7.45	0.34	5.43e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg20849893	chr7:64541193	NA	0.47	7.59	0.35	2.02e-13	Calcium levels;
LUAD	cis	rs3087591	1.000	rs2905795	chr17:29547601	A/G	cg24425628	chr17:29625626	OMG;NF1	0.41	6.76	0.31	4.53e-11	Hip circumference;
LUAD	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg16647868	chr5:131706066	SLC22A5	0.36	6.4	0.3	4.21e-10	Blood metabolite levels;
LUAD	cis	rs4594175	0.926	rs7493621	chr14:51623665	C/T	cg23942311	chr14:51606299	NA	0.65	11.25	0.48	7.24e-26	Cancer;
LUAD	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07343612	chr16:622815	PIGQ	-0.83	-17.07	-0.64	4.54e-50	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05787931	chr3:52232012	ALAS1	-0.54	-6.58	-0.3	1.38e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg26811252	chr16:29126840	RRN3P2	0.6	10.29	0.45	2.64e-22	Menopause (age at onset);
LUAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27286337	chr10:134555280	INPP5A	0.72	9.58	0.42	8.08e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.15e-13	Heart rate;
LUAD	cis	rs587080	0.559	rs12364730	chr11:65228278	C/T	cg17120908	chr11:65337727	SSSCA1	-0.64	-8.21	-0.37	2.73e-15	Plateletcrit;
LUAD	cis	rs11677416	1.000	rs1516790	chr2:113531291	G/A	cg27083787	chr2:113543245	IL1A	0.38	6.46	0.3	2.8e-10	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs9902453	0.904	rs12951836	chr17:28410277	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.31	-0.45	2.2e-22	Coffee consumption (cups per day);
LUAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg12016809	chr21:47604291	C21orf56	0.65	11.26	0.48	6.72e-26	Testicular germ cell tumor;
LUAD	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg10755058	chr3:40428713	ENTPD3	-0.44	-8.46	-0.38	4.37e-16	Renal cell carcinoma;
LUAD	cis	rs11893307	0.509	rs62182902	chr2:191502767	G/C	cg11845111	chr2:191398756	TMEM194B	-0.45	-6.44	-0.3	3.18e-10	Mean platelet volume;
LUAD	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg04586622	chr2:25135609	ADCY3	0.36	8.16	0.37	3.95e-15	Body mass index;
LUAD	cis	rs3087591	1.000	rs12939853	chr17:29455021	G/A	cg24425628	chr17:29625626	OMG;NF1	0.41	6.66	0.31	8.51e-11	Hip circumference;
LUAD	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg01802117	chr1:53393560	SCP2	-0.37	-7.13	-0.33	4.27e-12	Monocyte count;
LUAD	cis	rs886126	0.684	rs10744769	chr12:111650780	G/T	cg10833066	chr12:111807467	FAM109A	0.5	9.28	0.41	8.54e-19	Coronary heart disease;
LUAD	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg04287289	chr16:89883240	FANCA	0.7	6.58	0.3	1.43e-10	Skin colour saturation;
LUAD	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.81	0.35	4.6e-14	Depression;
LUAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg17178900	chr1:205818956	PM20D1	0.74	15.46	0.6	4.86e-43	Menarche (age at onset);
LUAD	cis	rs10193935	1.000	rs13424523	chr2:42413562	T/G	cg27598129	chr2:42591480	NA	-0.71	-9.44	-0.42	2.54e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	1.000	rs115965820	chr4:119586485	G/A	cg21605333	chr4:119757512	SEC24D	0.86	7.93	0.36	1.98e-14	Cannabis dependence symptom count;
LUAD	trans	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04565464	chr8:145669602	NFKBIL2	0.48	7.19	0.33	3.03e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs11971779	0.680	rs6962637	chr7:139051350	G/A	cg23387468	chr7:139079360	LUC7L2	0.28	6.49	0.3	2.47e-10	Diisocyanate-induced asthma;
LUAD	trans	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg18187862	chr3:45730750	SACM1L	0.49	7.74	0.35	7.53e-14	Primary sclerosing cholangitis;
LUAD	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg03806693	chr22:41940476	POLR3H	-0.56	-8.48	-0.38	3.67e-16	Vitiligo;
LUAD	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.45	-8.0	-0.36	1.24e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.6	8.44	0.38	4.94e-16	Mean corpuscular hemoglobin;
LUAD	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg20203395	chr5:56204925	C5orf35	-0.64	-9.97	-0.44	3.48e-21	Initial pursuit acceleration;
LUAD	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-6.38	-0.3	4.61e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs669446	0.562	rs10890275	chr1:44194216	T/G	cg12908607	chr1:44402522	ARTN	-0.36	-7.12	-0.33	4.63e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg11822812	chr5:140052017	DND1	0.37	6.46	0.3	2.95e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs422249	0.819	rs174611	chr11:61627881	T/C	cg19610905	chr11:61596333	FADS2	-0.5	-7.51	-0.34	3.45e-13	Trans fatty acid levels;
LUAD	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.4	-0.3	4.09e-10	Alzheimer's disease (late onset);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg05124756	chr4:2263820	MXD4	-0.33	-6.41	-0.3	3.95e-10	Schizophrenia;
LUAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg13047869	chr3:10149882	C3orf24	0.65	9.68	0.43	3.81e-20	Alzheimer's disease;
LUAD	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg17761419	chr8:57350749	NA	-0.58	-8.39	-0.38	7.52e-16	Obesity-related traits;
LUAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg04025307	chr7:1156635	C7orf50	0.65	7.48	0.34	4.41e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2070677	0.935	rs12245492	chr10:135419727	A/G	cg20169779	chr10:135381914	SYCE1	-0.52	-8.14	-0.37	4.47e-15	Gout;
LUAD	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg09455208	chr3:40491958	NA	0.53	11.8	0.5	5.81e-28	Renal cell carcinoma;
LUAD	cis	rs494562	1.000	rs495469	chr6:86117025	C/T	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.59	-8.54	-0.38	2.38e-16	Alzheimer's disease;
LUAD	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg18512352	chr11:47633146	NA	-0.4	-6.96	-0.32	1.27e-11	Subjective well-being;
LUAD	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.54	-0.34	2.82e-13	Height;
LUAD	trans	rs877282	1.000	rs10904552	chr10:774326	A/G	cg22713356	chr15:30763199	NA	1.17	16.74	0.63	1.23e-48	Uric acid levels;
LUAD	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg03806693	chr22:41940476	POLR3H	0.57	8.42	0.38	5.83e-16	Vitiligo;
LUAD	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg24733560	chr20:60626293	TAF4	0.45	8.76	0.39	4.77e-17	Body mass index;
LUAD	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-12.0	-0.5	9.56e-29	Bipolar disorder;
LUAD	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg26958806	chr6:27640298	NA	0.57	6.47	0.3	2.73e-10	Breast cancer;
LUAD	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg25985355	chr7:65971099	NA	-0.56	-6.85	-0.32	2.68e-11	Diabetic kidney disease;
LUAD	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-8.7	-0.39	7.22e-17	Gut microbiome composition (summer);
LUAD	trans	rs2797160	0.547	rs1418645	chr6:125946476	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-7.4	-0.34	7.64e-13	Endometrial cancer;
LUAD	cis	rs220324	0.688	rs2017391	chr21:43588394	C/T	cg09727148	chr21:43560719	UMODL1	0.46	6.83	0.32	2.98e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05665937	chr4:1216051	CTBP1	0.42	6.37	0.3	4.92e-10	Longevity;
LUAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg03806693	chr22:41940476	POLR3H	-0.82	-11.63	-0.49	2.67e-27	Vitiligo;
LUAD	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.42	-8.25	-0.37	2.02e-15	Glomerular filtration rate;
LUAD	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg19163074	chr7:65112434	INTS4L2	0.46	7.07	0.33	6.41e-12	Aortic root size;
LUAD	cis	rs13095912	1.000	rs2034344	chr3:185337788	T/C	cg11274856	chr3:185301563	NA	0.39	7.84	0.36	3.65e-14	Systolic blood pressure;
LUAD	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg02696790	chr15:75250997	RPP25	-0.33	-6.57	-0.3	1.49e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.65	9.11	0.41	3.3e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2230307	0.536	rs12733952	chr1:100611571	A/G	cg20868668	chr1:100435035	SLC35A3	0.51	7.72	0.35	8.37e-14	Carotid intima media thickness;
LUAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08280861	chr8:58055591	NA	-0.51	-6.41	-0.3	3.93e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs3784262	0.692	rs12914388	chr15:58283843	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.45	-0.34	5.39e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg17252645	chr8:143867129	LY6D	-0.35	-6.6	-0.31	1.2e-10	Urinary tract infection frequency;
LUAD	cis	rs7428	0.545	rs1053561	chr2:85546052	A/G	cg24342717	chr2:85555507	TGOLN2	-0.49	-8.1	-0.37	6.05e-15	Ear protrusion;
LUAD	cis	rs887829	0.569	rs3821242	chr2:234637803	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-9.17	-0.41	2.07e-18	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.5	0.3	2.24e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4523957	0.651	rs9908373	chr17:2086534	G/A	cg16513277	chr17:2031491	SMG6	-0.97	-19.28	-0.68	6.69e-60	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg27426351	chr10:43362370	NA	-0.55	-8.4	-0.38	6.59e-16	Blood protein levels;
LUAD	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg00631329	chr6:26305371	NA	0.52	9.11	0.4	3.38e-18	Educational attainment;
LUAD	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.25	0.37	2.08e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.27e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg00981070	chr1:2046702	PRKCZ	0.33	6.86	0.32	2.42e-11	Height;
LUAD	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.94	-0.44	4.76e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs4493873	1.000	rs7014578	chr8:92077568	C/G	cg16814680	chr8:91681699	NA	0.41	6.52	0.3	2.04e-10	Migraine - clinic-based;
LUAD	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg22117172	chr7:91764530	CYP51A1	0.35	7.8	0.35	4.93e-14	Breast cancer;
LUAD	cis	rs9902453	0.765	rs2169810	chr17:28167941	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	11.07	0.47	3.56e-25	Coffee consumption (cups per day);
LUAD	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg13390004	chr1:15929781	NA	0.47	8.5	0.38	3.29e-16	Systolic blood pressure;
LUAD	cis	rs490234	0.702	rs12553311	chr9:128398996	T/C	cg14078157	chr9:128172775	NA	-0.46	-8.14	-0.37	4.53e-15	Mean arterial pressure;
LUAD	cis	rs6987853	0.814	rs1947296	chr8:42452999	T/C	cg09913449	chr8:42400586	C8orf40	0.46	8.57	0.38	1.94e-16	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	17.85	0.66	1.61e-53	Exhaled nitric oxide output;
LUAD	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.58	9.14	0.41	2.59e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.36	0.41	4.65e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.58	-9.73	-0.43	2.5e-20	Mean corpuscular volume;
LUAD	cis	rs55788414	1.000	rs55788414	chr16:81184939	C/T	cg06400318	chr16:81190750	PKD1L2	-0.75	-8.74	-0.39	5.35e-17	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs113835537	0.597	rs2305534	chr11:66313203	T/C	cg24851651	chr11:66362959	CCS	0.59	10.34	0.45	1.68e-22	Airway imaging phenotypes;
LUAD	trans	rs6561151	0.681	rs17462017	chr13:44472235	C/T	cg12856521	chr11:46389249	DGKZ	0.98	12.7	0.53	1.5e-31	Crohn's disease;
LUAD	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.28	6.64	0.31	9.63e-11	Prostate cancer;
LUAD	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg25753631	chr6:25732923	NA	0.45	7.98	0.36	1.36e-14	Iron status biomarkers;
LUAD	cis	rs939658	0.805	rs35484723	chr15:79441032	A/G	cg17916960	chr15:79447300	NA	-0.53	-11.2	-0.48	1.08e-25	Refractive error;
LUAD	cis	rs2880765	0.527	rs35184622	chr15:86073035	A/G	cg13263323	chr15:86062960	AKAP13	-0.51	-8.68	-0.39	8.73e-17	Coronary artery disease;
LUAD	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg00339695	chr16:24857497	SLC5A11	0.51	9.14	0.41	2.64e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg24690094	chr11:67383802	NA	-0.54	-10.22	-0.44	4.78e-22	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.24	0.37	2.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.46	-6.96	-0.32	1.32e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs727505	0.865	rs10253613	chr7:124508929	G/A	cg23710748	chr7:124431027	NA	-0.47	-9.56	-0.42	9.77e-20	Lewy body disease;
LUAD	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg22444338	chr7:1054449	C7orf50	0.46	7.83	0.36	4.03e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.61	-11.13	-0.48	2.04e-25	Schizophrenia;
LUAD	trans	rs783540	1.000	rs6603033	chr15:83335875	A/C	cg18393722	chr15:85113863	UBE2QP1	0.47	7.64	0.35	1.48e-13	Schizophrenia;
LUAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg02524346	chr8:600233	NA	1.1	10.73	0.46	6.35e-24	IgG glycosylation;
LUAD	cis	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg27411982	chr8:10470053	RP1L1	0.43	7.86	0.36	3.22e-14	Neuroticism;
LUAD	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg12927641	chr6:109611667	NA	-0.51	-8.81	-0.39	3.22e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg08999081	chr20:33150536	PIGU	0.62	13.98	0.56	9.28e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs17818399	0.781	rs4952837	chr2:46865734	T/C	cg09399716	chr2:46890238	NA	-0.43	-8.08	-0.37	7.04e-15	Height;
LUAD	cis	rs8025790	0.508	rs4776943	chr15:67836069	T/C	cg24579218	chr15:68104479	NA	-0.5	-7.98	-0.36	1.42e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs2224391	0.628	rs2753238	chr6:5252795	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-8.77	-0.39	4.43e-17	Height;
LUAD	cis	rs4638749	0.734	rs6542756	chr2:108865629	C/G	cg25838818	chr2:108905173	SULT1C2	-0.38	-6.62	-0.31	1.07e-10	Blood pressure;
LUAD	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.99	0.32	1.1e-11	Hypertriglyceridemia;
LUAD	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	9.13	0.41	2.95e-18	Tonsillectomy;
LUAD	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg04036182	chr15:45458818	NA	-0.37	-6.59	-0.31	1.28e-10	Glomerular filtration rate;
LUAD	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	8.54	0.38	2.45e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03452623	chr4:187889614	NA	-0.84	-17.83	-0.66	1.91e-53	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg06002616	chr8:101225028	SPAG1	-0.41	-8.27	-0.37	1.71e-15	Atrioventricular conduction;
LUAD	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.1	0.33	5.14e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.39	-6.58	-0.3	1.43e-10	HDL cholesterol;
LUAD	trans	rs7746199	0.611	rs17750747	chr6:27730334	T/C	cg01620082	chr3:125678407	NA	-1.0	-10.23	-0.45	4.43e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10979	0.782	rs9390108	chr6:143892722	A/T	cg25407410	chr6:143891975	LOC285740	-0.63	-9.76	-0.43	1.94e-20	Hypospadias;
LUAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg16606324	chr3:10149918	C3orf24	0.68	11.12	0.48	2.21e-25	Alzheimer's disease;
LUAD	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.69	-0.61	4.77e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6500395	0.963	rs961951	chr16:48716720	A/G	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs977987	0.815	rs1364078	chr16:75396881	T/C	cg03315344	chr16:75512273	CHST6	0.64	13.9	0.56	1.89e-36	Dupuytren's disease;
LUAD	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg13918804	chr1:2043761	PRKCZ	0.41	6.87	0.32	2.28e-11	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19760249	chr17:79254595	SLC38A10	0.51	6.43	0.3	3.53e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11771526	0.901	rs11771230	chr7:32315546	C/T	cg13207630	chr7:32358064	NA	-0.64	-7.71	-0.35	9.06e-14	Body mass index;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00940809	chr21:44312947	NDUFV3	-0.57	-6.9	-0.32	1.92e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7923837	1.000	rs7923866	chr10:94482076	C/T	cg25093409	chr10:94429542	NA	0.36	6.39	0.3	4.29e-10	Body mass index;Multiple sclerosis;
LUAD	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg26343298	chr8:95960752	TP53INP1	0.4	8.51	0.38	3.04e-16	Type 2 diabetes;
LUAD	cis	rs7089973	0.872	rs11818114	chr10:116634878	G/C	cg25233709	chr10:116636983	FAM160B1	0.39	7.55	0.34	2.67e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2274273	0.967	rs2340931	chr14:55616937	T/G	cg04306507	chr14:55594613	LGALS3	0.4	8.35	0.38	9.61e-16	Protein biomarker;
LUAD	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.51	6.79	0.31	3.8e-11	Platelet count;
LUAD	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.2	0.33	2.86e-12	Lung cancer;
LUAD	cis	rs2220004	0.507	rs11231796	chr11:55766709	A/G	cg22937354	chr11:55606216	OR5D16	-0.37	-6.4	-0.3	4.19e-10	Odorant perception (&beta-damascenone);
LUAD	cis	rs7647973	1.000	rs11130189	chr3:49347357	C/A	cg07636037	chr3:49044803	WDR6	0.46	7.64	0.35	1.43e-13	Menarche (age at onset);
LUAD	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-10.09	-0.44	1.32e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7584330	0.554	rs114331205	chr2:238432559	A/C	cg14458575	chr2:238380390	NA	0.61	9.71	0.43	2.92e-20	Prostate cancer;
LUAD	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg05665937	chr4:1216051	CTBP1	0.42	7.01	0.32	9.46e-12	Obesity-related traits;
LUAD	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.06	24.23	0.76	5.86e-82	Chronic sinus infection;
LUAD	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg16482183	chr6:26056742	HIST1H1C	0.56	7.77	0.35	6.14e-14	Iron status biomarkers;
LUAD	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg18512352	chr11:47633146	NA	-0.43	-7.5	-0.34	3.83e-13	Subjective well-being;
LUAD	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.95	0.36	1.74e-14	Depression;
LUAD	cis	rs9768139	0.683	rs7779781	chr7:158115071	T/C	cg25566285	chr7:158114605	PTPRN2	0.54	11.65	0.49	2.07e-27	Calcium levels;
LUAD	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg18811423	chr2:55921094	PNPT1	0.54	9.08	0.4	4.17e-18	Metabolic syndrome;
LUAD	trans	rs9929218	0.559	rs11642362	chr16:68811307	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.0	21.09	0.72	5.42e-68	Colorectal cancer;
LUAD	cis	rs11951515	0.508	rs10065689	chr5:43604258	T/C	cg01983248	chr5:43482804	C5orf28	-0.39	-8.45	-0.38	4.69e-16	Metabolite levels  (X-11787);
LUAD	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg27426351	chr10:43362370	NA	-0.54	-8.32	-0.38	1.18e-15	Blood protein levels;
LUAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.17	-0.41	2.17e-18	Bipolar disorder and schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22769031	chr20:35580195	SAMHD1	-0.41	-6.48	-0.3	2.49e-10	Height;
LUAD	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.55	-7.92	-0.36	2.07e-14	IgG glycosylation;
LUAD	cis	rs13082711	0.522	rs6551192	chr3:27343376	C/T	cg02860705	chr3:27208620	NA	0.48	8.04	0.36	9.37e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg09359103	chr1:154839909	KCNN3	-0.91	-21.24	-0.72	1.09e-68	Prostate cancer;
LUAD	cis	rs9788721	0.836	rs17483548	chr15:78730313	G/A	cg18825076	chr15:78729989	IREB2	-0.59	-10.07	-0.44	1.6e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg18811423	chr2:55921094	PNPT1	0.57	9.59	0.42	7.68e-20	Metabolic syndrome;
LUAD	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11890956	chr21:40555474	PSMG1	0.61	10.13	0.44	1.01e-21	Cognitive function;
LUAD	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg09263875	chr16:632152	PIGQ	0.8	17.18	0.64	1.51e-50	Height;
LUAD	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg18527919	chr2:24398170	C2orf84	0.38	6.4	0.3	4.11e-10	Asthma;
LUAD	trans	rs2270927	0.510	rs34596551	chr5:75577143	C/T	cg13563193	chr19:33072644	PDCD5	1.04	9.47	0.42	2.02e-19	Mean corpuscular volume;
LUAD	cis	rs2816062	0.813	rs2816044	chr1:18892826	A/G	cg18795169	chr1:18902165	NA	-0.93	-21.94	-0.73	8.17e-72	Urate levels in lean individuals;
LUAD	cis	rs4853036	1.000	rs13025205	chr2:70044159	C/G	cg02498382	chr2:70120550	SNRNP27	-0.51	-8.15	-0.37	4.14e-15	Colorectal or endometrial cancer;
LUAD	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.57	8.32	0.37	1.23e-15	Platelet count;
LUAD	cis	rs899997	0.862	rs8032552	chr15:78971136	T/C	cg04896959	chr15:78267971	NA	-0.48	-8.62	-0.39	1.4e-16	Coronary artery disease or large artery stroke;
LUAD	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg14668632	chr7:2872130	GNA12	-0.46	-8.12	-0.37	5.21e-15	Height;
LUAD	trans	rs9467711	0.591	rs41266779	chr6:26021872	C/T	cg01620082	chr3:125678407	NA	-1.02	-8.07	-0.37	7.29e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7177699	0.557	rs4073322	chr15:79122541	G/C	cg15571903	chr15:79123663	NA	0.38	7.81	0.35	4.64e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs9296092	0.517	rs55963187	chr6:33523778	G/C	cg13560919	chr6:33536144	NA	-0.87	-15.58	-0.6	1.35e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs2274273	0.624	rs66551709	chr14:55791022	A/T	cg04306507	chr14:55594613	LGALS3	0.43	8.33	0.38	1.11e-15	Protein biomarker;
LUAD	trans	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.5	0.55	8.49e-35	Exhaled nitric oxide output;
LUAD	cis	rs853679	0.585	rs201001	chr6:27808899	T/C	cg26587870	chr6:27730563	NA	-0.51	-7.97	-0.36	1.48e-14	Depression;
LUAD	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg07570687	chr10:102243282	WNT8B	0.48	7.37	0.34	9.16e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg00933542	chr6:150070202	PCMT1	0.46	9.45	0.42	2.39e-19	Lung cancer;
LUAD	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg15147215	chr3:52552868	STAB1	-0.38	-7.13	-0.33	4.3e-12	Electroencephalogram traits;
LUAD	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg26384229	chr12:38710491	ALG10B	0.4	6.94	0.32	1.48e-11	Heart rate;
LUAD	cis	rs1461503	0.934	rs7113330	chr11:122843358	C/T	cg27398637	chr11:122830231	C11orf63	-0.37	-7.05	-0.32	7.53e-12	Menarche (age at onset);
LUAD	cis	rs751837	0.591	rs34440792	chr14:103426095	C/T	cg10087771	chr14:103399429	CDC42BPB	0.73	6.5	0.3	2.31e-10	Large B-cell lymphoma;
LUAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg20637647	chr7:64974828	NA	-0.38	-6.41	-0.3	3.88e-10	Calcium levels;
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg02738677	chr3:133265129	NA	-0.43	-6.62	-0.31	1.1e-10	Height;
LUAD	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00166722	chr3:10149974	C3orf24	0.75	12.77	0.53	7.92e-32	Alzheimer's disease;
LUAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg13047869	chr3:10149882	C3orf24	0.52	7.92	0.36	2.12e-14	Alzheimer's disease;
LUAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg17178900	chr1:205818956	PM20D1	-0.69	-14.52	-0.58	5.01e-39	Menarche (age at onset);
LUAD	cis	rs6089584	0.586	rs2296087	chr20:60584328	T/A	cg06108461	chr20:60628389	TAF4	-0.72	-12.18	-0.51	1.85e-29	Body mass index;
LUAD	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg03433313	chr16:819064	MIR662	-0.62	-10.75	-0.46	5.32e-24	Mean corpuscular volume;
LUAD	cis	rs7301826	0.966	rs4759795	chr12:131300900	G/A	cg11011512	chr12:131303247	STX2	0.37	6.35	0.3	5.5e-10	Plasma plasminogen activator levels;
LUAD	cis	rs250677	0.522	rs4562031	chr5:148368451	A/G	cg12140854	chr5:148520817	ABLIM3	0.56	8.62	0.39	1.37e-16	Breast cancer;
LUAD	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.53	-0.42	1.2e-19	Life satisfaction;
LUAD	cis	rs2455799	0.613	rs2654654	chr3:15789242	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-9.72	-0.43	2.83e-20	Mean platelet volume;
LUAD	cis	rs9649213	0.614	rs9641236	chr7:97998124	T/A	cg09267113	chr7:98030324	BAIAP2L1	-0.76	-11.14	-0.48	1.88e-25	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7677751	0.767	rs890205	chr4:55063373	C/A	cg17187183	chr4:55093834	PDGFRA	0.42	7.03	0.32	8.57e-12	Corneal astigmatism;
LUAD	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.72	-0.31	5.8e-11	Bladder cancer;
LUAD	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg14343924	chr8:8086146	FLJ10661	0.45	6.92	0.32	1.65e-11	Neuroticism;
LUAD	trans	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg01620082	chr3:125678407	NA	-1.04	-10.25	-0.45	3.6e-22	Depression;
LUAD	cis	rs7027203	0.964	rs7853688	chr9:96523254	C/A	cg14598338	chr9:96623480	NA	0.38	7.51	0.34	3.64e-13	DNA methylation (variation);
LUAD	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg25985355	chr7:65971099	NA	-0.52	-6.45	-0.3	3.12e-10	Gout;
LUAD	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25427524	chr10:38739819	LOC399744	0.76	14.2	0.57	1.03e-37	Extrinsic epigenetic age acceleration;
LUAD	cis	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg00071950	chr4:10020882	SLC2A9	0.48	7.22	0.33	2.37e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg18827107	chr12:86230957	RASSF9	-0.61	-10.95	-0.47	1.01e-24	Major depressive disorder;
LUAD	cis	rs7707921	0.548	rs80356261	chr5:81667964	T/C	cg15871215	chr5:81402204	ATG10	-0.52	-7.07	-0.33	6.36e-12	Breast cancer;
LUAD	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg05368731	chr17:41323189	NBR1	-0.84	-16.91	-0.64	2.23e-49	Menopause (age at onset);
LUAD	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.92	-0.32	1.66e-11	Triglycerides;
LUAD	cis	rs6993813	0.620	rs12056346	chr8:120042191	T/C	cg01975934	chr8:119970761	NA	-0.34	-6.44	-0.3	3.34e-10	Bone mineral density (hip);
LUAD	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.26	-0.45	3.42e-22	Menopause (age at onset);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16497277	chr3:49208875	KLHDC8B	-0.44	-7.17	-0.33	3.36e-12	Cancer;
LUAD	cis	rs2692947	0.599	rs7561198	chr2:96774981	C/G	cg23100626	chr2:96804247	ASTL	-0.38	-10.06	-0.44	1.74e-21	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg20607798	chr8:58055168	NA	0.57	7.69	0.35	1.01e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg19163074	chr7:65112434	INTS4L2	0.43	6.74	0.31	5.14e-11	Aortic root size;
LUAD	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg01616529	chr11:638424	DRD4	-0.44	-6.47	-0.3	2.66e-10	Systemic lupus erythematosus;
LUAD	trans	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg01620082	chr3:125678407	NA	-0.7	-7.98	-0.36	1.38e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg15448220	chr1:150897856	SETDB1	-0.53	-9.29	-0.41	8.42e-19	Melanoma;
LUAD	cis	rs4955124	0.558	rs78465094	chr3:32019016	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.64	6.43	0.3	3.45e-10	Schizophrenia;
LUAD	cis	rs3125734	0.653	rs1007976	chr10:63970144	C/T	cg09941381	chr10:64027924	RTKN2	0.28	6.46	0.3	2.85e-10	Rheumatoid arthritis;
LUAD	cis	rs12711979	0.765	rs10208316	chr2:3827630	T/C	cg17052675	chr2:3827356	NA	-0.55	-11.47	-0.49	1.06e-26	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg18825076	chr15:78729989	IREB2	0.46	6.44	0.3	3.16e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	trans	rs9393777	0.920	rs72839445	chr6:27249686	G/A	cg01620082	chr3:125678407	NA	-1.01	-9.71	-0.43	2.96e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg02136620	chr5:178986620	RUFY1	0.47	7.55	0.34	2.76e-13	Lung cancer;
LUAD	cis	rs9486719	0.948	rs2092095	chr6:96870864	T/G	cg06623918	chr6:96969491	KIAA0776	0.71	10.01	0.44	2.62e-21	Migraine;Coronary artery disease;
LUAD	cis	rs6761276	0.899	rs13398125	chr2:113834835	G/A	cg09040174	chr2:113837401	NA	0.8	15.65	0.61	7.33e-44	Protein quantitative trait loci;
LUAD	cis	rs56283067	0.887	rs62437968	chr6:44729495	G/A	cg18551225	chr6:44695536	NA	-0.58	-9.59	-0.42	7.96e-20	Total body bone mineral density;
LUAD	cis	rs10227331	0.846	rs10237006	chr7:157298250	A/G	cg04156418	chr7:157293606	NA	0.36	7.64	0.35	1.5e-13	Inattentive symptoms;
LUAD	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05665937	chr4:1216051	CTBP1	-0.45	-6.7	-0.31	6.73e-11	Longevity;
LUAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg24829409	chr8:58192753	C8orf71	-0.55	-7.04	-0.32	7.69e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg03340356	chr1:67600835	NA	0.41	7.25	0.33	1.96e-12	Psoriasis;
LUAD	cis	rs6542838	0.611	rs13006398	chr2:99522323	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.21	-0.33	2.57e-12	Fear of minor pain;
LUAD	cis	rs2688608	0.839	rs2675662	chr10:75599127	A/G	cg23231163	chr10:75533350	FUT11	0.47	8.77	0.39	4.31e-17	Inflammatory bowel disease;
LUAD	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg08999081	chr20:33150536	PIGU	-0.46	-8.99	-0.4	8.17e-18	Coronary artery disease;
LUAD	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg05872129	chr22:39784769	NA	-0.84	-16.21	-0.62	2.58e-46	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg11062466	chr8:58055876	NA	0.55	7.53	0.34	3.1400000000000003e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg24642844	chr7:1081250	C7orf50	-0.97	-14.71	-0.58	7.38e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg07167872	chr1:205819463	PM20D1	0.51	7.27	0.33	1.8e-12	Parkinson's disease;
LUAD	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.97	0.32	1.24e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg04731861	chr2:219085781	ARPC2	-0.26	-8.17	-0.37	3.61e-15	Colorectal cancer;
LUAD	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.77	-0.31	4.45e-11	Breast cancer;
LUAD	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg19761014	chr17:28927070	LRRC37B2	0.67	6.37	0.3	5.06e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg26409978	chr12:56511862	ZC3H10	0.41	6.38	0.3	4.79e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs7582720	1.000	rs72932776	chr2:203688300	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.3	0.41	7.37e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs11771526	1.000	rs11770367	chr7:32354319	C/T	cg13207630	chr7:32358064	NA	0.71	7.92	0.36	2.05e-14	Body mass index;
LUAD	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg11062466	chr8:58055876	NA	0.45	6.43	0.3	3.53e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1451375	0.785	rs6593010	chr7:50629888	A/G	cg18232548	chr7:50535776	DDC	0.55	8.91	0.4	1.5e-17	Malaria;
LUAD	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg06873352	chr17:61820015	STRADA	0.4	6.73	0.31	5.5e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg26587870	chr6:27730563	NA	-0.64	-7.0	-0.32	9.92e-12	Breast cancer;
LUAD	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg06636551	chr8:101224915	SPAG1	0.37	6.68	0.31	7.44e-11	Atrioventricular conduction;
LUAD	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	9.17	0.41	2.15e-18	Tonsillectomy;
LUAD	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg06781209	chr11:61594997	FADS2	-0.65	-9.64	-0.42	5.36e-20	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	trans	rs6074578	0.902	rs6033484	chr20:185926	A/G	cg11297934	chr3:12705869	RAF1	-0.38	-6.56	-0.3	1.55e-10	Hirschsprung disease;
LUAD	cis	rs847577	0.609	rs7791463	chr7:97819047	G/A	cg24562669	chr7:97807699	LMTK2	0.33	7.98	0.36	1.35e-14	Breast cancer;
LUAD	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	7.94	0.36	1.82e-14	Tonsillectomy;
LUAD	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg05340658	chr4:99064831	C4orf37	0.42	7.16	0.33	3.6e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg05926928	chr17:57297772	GDPD1	1.39	19.28	0.68	6.57e-60	Opioid sensitivity;
LUAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg24813613	chr7:1882135	MAD1L1	-0.45	-7.17	-0.33	3.35e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg24578937	chr1:2090814	PRKCZ	-0.55	-10.93	-0.47	1.17e-24	Height;
LUAD	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg12179176	chr11:130786555	SNX19	0.66	11.02	0.47	5.16e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg05283184	chr6:79620031	NA	0.58	11.4	0.48	2.03e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs12425451	0.552	rs10848765	chr12:3141495	C/T	cg05389053	chr12:3131226	TEAD4	0.44	7.15	0.33	3.86e-12	Narcolepsy with cataplexy;
LUAD	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg20503657	chr10:835505	NA	1.27	18.55	0.67	1.17e-56	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12406019	0.510	rs12126464	chr1:78608215	T/C	cg20826526	chr3:156266748	SSR3	-0.53	-8.83	-0.39	2.78e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.81	-0.36	4.47e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg11584989	chr19:19387371	SF4	0.57	9.33	0.41	6.01e-19	Tonsillectomy;
LUAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg12419862	chr22:24373484	LOC391322	-0.66	-10.91	-0.47	1.37e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs806795	0.525	rs12661552	chr6:26265200	G/A	cg00631329	chr6:26305371	NA	-0.54	-9.02	-0.4	6.8e-18	Mosquito bite size;
LUAD	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg14416269	chr4:6271139	WFS1	0.61	12.56	0.52	5.48e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg21214613	chr1:16344536	HSPB7	-0.43	-7.41	-0.34	7.11e-13	Dilated cardiomyopathy;
LUAD	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg11189052	chr15:85197271	WDR73	0.65	8.76	0.39	4.67e-17	Schizophrenia;
LUAD	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg18306943	chr3:40428807	ENTPD3	0.43	7.28	0.33	1.67e-12	Renal cell carcinoma;
LUAD	cis	rs1003719	0.762	rs11701556	chr21:38455153	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.42	0.38	5.76e-16	Eye color traits;
LUAD	cis	rs4660306	0.961	rs937290	chr1:45961955	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-8.01	-0.36	1.09e-14	Homocysteine levels;
LUAD	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08219700	chr8:58056026	NA	0.7	9.12	0.41	3.03e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg03859395	chr2:55845619	SMEK2	0.74	13.79	0.56	5.62e-36	Metabolic syndrome;
LUAD	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.39	-0.38	7.35e-16	Menopause (age at onset);
LUAD	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.95	-0.36	1.76e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4730250	0.554	rs17428504	chr7:106914944	T/C	cg23024343	chr7:107201750	COG5	0.5	6.79	0.31	3.89e-11	Osteoarthritis;
LUAD	cis	rs11651000	0.625	rs4794063	chr17:45804494	C/T	cg03474202	chr17:45855739	NA	-0.35	-7.41	-0.34	6.77e-13	IgG glycosylation;
LUAD	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg14835575	chr10:16859367	RSU1	0.95	13.83	0.56	3.84e-36	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg14631576	chr9:95140430	CENPP	0.46	9.43	0.42	2.75e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.83	-0.36	4.04e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs72634258	0.554	rs35123409	chr1:7878568	C/T	cg26816564	chr1:7831052	VAMP3	0.78	9.76	0.43	2e-20	Inflammatory bowel disease;
LUAD	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg05187965	chr10:45406764	TMEM72	-0.48	-9.91	-0.43	5.77e-21	Mean corpuscular volume;
LUAD	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg26441486	chr22:50317300	CRELD2	0.44	6.68	0.31	7.35e-11	Schizophrenia;
LUAD	cis	rs17102423	0.826	rs10873182	chr14:65605408	C/T	cg11161011	chr14:65562177	MAX	-0.48	-7.68	-0.35	1.09e-13	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.76	0.53	9e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg00431813	chr7:1051703	C7orf50	0.53	10.44	0.45	7.35e-23	Longevity;Endometriosis;
LUAD	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18876405	chr7:65276391	NA	0.41	6.51	0.3	2.16e-10	Aortic root size;
LUAD	cis	rs7759001	0.857	rs980963	chr6:27360937	C/T	cg18711553	chr6:27366782	ZNF391	0.39	6.37	0.3	5.08e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.76	-0.35	6.43e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4372836	0.658	rs7579321	chr2:28983166	T/C	cg09522027	chr2:28974177	PPP1CB	-0.7	-12.72	-0.53	1.35e-31	Body mass index;
LUAD	cis	rs757647	0.723	rs1052648	chr5:137684732	A/G	cg10676309	chr5:137685565	NA	-0.4	-7.02	-0.32	9.08e-12	Menarche (age at onset);
LUAD	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg08645402	chr16:4508243	NA	0.58	10.42	0.45	8.91e-23	Schizophrenia;
LUAD	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg14008862	chr17:28927542	LRRC37B2	0.62	6.39	0.3	4.44e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.6	-0.42	7.19e-20	Life satisfaction;
LUAD	cis	rs4862307	0.733	rs28631204	chr4:184996363	T/G	cg06737308	chr4:185021514	ENPP6	0.57	9.27	0.41	9.28e-19	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg02389323	chr16:88786976	FAM38A	1.26	11.91	0.5	2.1e-28	Plateletcrit;
LUAD	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.35e-11	Breast cancer;
LUAD	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg17173187	chr15:85201210	NMB	0.53	9.33	0.41	6.09e-19	Schizophrenia;
LUAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.66	0.31	8.36e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg25233709	chr10:116636983	FAM160B1	0.41	8.26	0.37	1.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9914988	0.832	rs34901720	chr17:27179518	A/G	cg07195577	chr17:27052828	TLCD1	0.45	6.43	0.3	3.52e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg15199754	chr20:37064006	LOC388796;SNORA71D	-0.43	-7.15	-0.33	3.81e-12	Cancer;
LUAD	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.83	0.32	2.98e-11	Motion sickness;
LUAD	cis	rs13315871	1.000	rs11710058	chr3:58383048	G/A	cg20936604	chr3:58311152	NA	-0.68	-7.09	-0.33	5.75e-12	Cholesterol, total;
LUAD	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg00933542	chr6:150070202	PCMT1	0.35	7.37	0.34	8.91e-13	Testicular germ cell tumor;
LUAD	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg07741184	chr6:167504864	NA	0.4	9.13	0.41	2.74e-18	Crohn's disease;
LUAD	cis	rs2235649	0.592	rs8051883	chr16:1958978	G/A	cg07386859	chr16:1872102	HAGH	0.45	6.5	0.3	2.26e-10	Blood metabolite levels;
LUAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg16606324	chr3:10149918	C3orf24	0.67	11.03	0.47	4.93e-25	Alzheimer's disease;
LUAD	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg10327440	chr1:227177885	CDC42BPA	1.12	30.03	0.83	6.37e-107	Myeloid white cell count;
LUAD	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.05	-0.32	7.52e-12	Height;
LUAD	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg21496419	chr19:44306685	LYPD5	0.33	7.15	0.33	3.91e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg02734326	chr4:10020555	SLC2A9	-0.51	-8.85	-0.4	2.36e-17	Bone mineral density;
LUAD	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg09658497	chr7:2847517	GNA12	-0.54	-9.18	-0.41	1.92e-18	Height;
LUAD	cis	rs17095355	1.000	rs1376111	chr10:111707255	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.72	-9.8	-0.43	1.43e-20	Biliary atresia;
LUAD	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg26102564	chr10:131424627	MGMT	0.34	6.4	0.3	4.08e-10	Response to temozolomide;
LUAD	cis	rs11756438	0.547	rs1343287	chr6:119001805	T/C	cg21191810	chr6:118973309	C6orf204	0.5	9.59	0.42	7.77e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs599083	0.829	rs314751	chr11:68179560	C/T	cg16797656	chr11:68205561	LRP5	-0.46	-9.05	-0.4	5.08e-18	Bone mineral density (spine);
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg27074720	chr19:45843894	KLC3	-0.46	-6.5	-0.3	2.31e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs5756931	0.503	rs2076112	chr22:38538822	A/G	cg25457927	chr22:38595422	NA	-0.4	-9.38	-0.41	4.07e-19	Triglycerides;
LUAD	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg00339695	chr16:24857497	SLC5A11	0.53	9.7	0.43	3.23e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2070997	0.517	rs9762	chr9:133762553	A/G	cg13397898	chr9:133768931	QRFP	0.42	6.81	0.31	3.47e-11	Response to amphetamines;
LUAD	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.41	-7.92	-0.36	2.15e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	0.61	10.79	0.46	3.77e-24	Menarche (age at onset);
LUAD	cis	rs12618769	0.625	rs3769733	chr2:99100716	A/G	cg10123293	chr2:99228465	UNC50	0.46	8.12	0.37	5.1e-15	Bipolar disorder;
LUAD	cis	rs2554380	0.628	rs2081541	chr15:84443686	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.4	-7.14	-0.33	3.99e-12	Height;
LUAD	cis	rs4700695	0.841	rs152933	chr5:65359530	A/G	cg21114390	chr5:65439923	SFRS12	-0.62	-7.52	-0.34	3.23e-13	Facial morphology (factor 19);
LUAD	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg01802117	chr1:53393560	SCP2	0.37	7.2	0.33	2.8e-12	Monocyte count;
LUAD	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	6.42	0.3	3.68e-10	Menarche (age at onset);
LUAD	cis	rs7107174	0.892	rs4945265	chr11:78027458	G/A	cg02023728	chr11:77925099	USP35	0.52	7.75	0.35	7.04e-14	Testicular germ cell tumor;
LUAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg17330251	chr7:94953956	PON1	-0.75	-14.26	-0.57	5.8e-38	Paraoxonase activity;
LUAD	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg10518543	chr12:38710700	ALG10B	0.42	6.41	0.3	3.94e-10	Heart rate;
LUAD	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg26924012	chr15:45694286	SPATA5L1	1.02	18.85	0.68	5.65e-58	Homoarginine levels;
LUAD	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg15691649	chr6:25882328	NA	-0.45	-6.39	-0.3	4.41e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2425143	1.000	rs17093026	chr20:34318911	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.6	6.63	0.31	1.01e-10	Blood protein levels;
LUAD	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg13535736	chr9:111863775	C9orf5	-0.44	-6.93	-0.32	1.59e-11	Menarche (age at onset);
LUAD	cis	rs10916814	1.000	rs7365904	chr1:20904528	G/A	cg24502330	chr1:20914028	CDA	-0.36	-6.41	-0.3	3.85e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg26818010	chr10:134567672	INPP5A	-0.87	-15.07	-0.59	2.28e-41	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs68170813	0.559	rs2189501	chr7:106942766	A/T	cg23024343	chr7:107201750	COG5	0.5	7.25	0.33	2.06e-12	Coronary artery disease;
LUAD	trans	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg15704280	chr7:45808275	SEPT13	-0.59	-7.93	-0.36	2.02e-14	Axial length;
LUAD	cis	rs9341808	0.754	rs3805907	chr6:80973665	A/G	cg08355045	chr6:80787529	NA	-0.55	-10.27	-0.45	2.97e-22	Sitting height ratio;
LUAD	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg23719950	chr11:63933701	MACROD1	-0.6	-6.8	-0.31	3.62e-11	Mean platelet volume;
LUAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg26338869	chr17:61819248	STRADA	-0.39	-6.58	-0.3	1.37e-10	Prudent dietary pattern;
LUAD	cis	rs1395	0.778	rs72810794	chr2:27401260	C/T	cg23587288	chr2:27483067	SLC30A3	-0.41	-7.62	-0.35	1.7e-13	Blood metabolite levels;
LUAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg12373951	chr3:133503437	NA	0.38	7.41	0.34	7.16e-13	Iron status biomarkers;
LUAD	cis	rs7274811	0.625	rs293726	chr20:31932047	A/C	cg14921437	chr20:32255988	NECAB3;C20orf134	0.43	6.56	0.3	1.57e-10	Height;
LUAD	cis	rs2764208	0.599	rs9368828	chr6:34661449	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.34	8.48	0.38	3.82e-16	Systemic lupus erythematosus;
LUAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11905131	chr22:24372483	LOC391322	0.58	9.78	0.43	1.65e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-38.97	-0.88	4.62e-142	Myeloid white cell count;
LUAD	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg11871910	chr12:69753446	YEATS4	0.65	10.89	0.47	1.61e-24	Blood protein levels;
LUAD	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-9.02	-0.4	6.41e-18	Total body bone mineral density;
LUAD	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg11494091	chr17:61959527	GH2	0.44	8.37	0.38	8.23e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs8067545	0.750	rs9897246	chr17:19965702	T/G	cg04132472	chr17:19861366	AKAP10	0.27	6.37	0.3	4.87e-10	Schizophrenia;
LUAD	cis	rs89107	0.602	rs72967533	chr6:118655020	T/C	cg21191810	chr6:118973309	C6orf204	0.39	7.24	0.33	2.07e-12	Cardiac structure and function;
LUAD	trans	rs8105895	0.735	rs17554694	chr19:22317148	A/G	cg17074339	chr11:11642133	GALNTL4	0.41	6.47	0.3	2.64e-10	Body mass index (change over time);
LUAD	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7100689	0.646	rs10749573	chr10:82136839	T/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.26	0.45	3.26e-22	Post bronchodilator FEV1;
LUAD	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03517284	chr6:25882590	NA	-0.58	-9.54	-0.42	1.17e-19	Blood metabolite levels;
LUAD	cis	rs220324	0.688	rs2236703	chr21:43562525	G/A	cg08841829	chr21:43638893	ABCG1	-0.51	-6.81	-0.31	3.38e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg12034118	chr1:209979487	IRF6	0.55	6.48	0.3	2.6e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg14186256	chr22:23484241	RTDR1	0.48	8.08	0.37	6.68e-15	Bone mineral density;
LUAD	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg20487152	chr13:99095054	FARP1	-0.45	-7.93	-0.36	1.97e-14	Longevity;
LUAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg18402987	chr7:1209562	NA	0.73	9.04	0.4	5.86e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg08601574	chr20:25228251	PYGB	-0.47	-8.9	-0.4	1.66e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2933343	1.000	rs789213	chr3:128616359	C/G	cg11901034	chr3:128598214	ACAD9	0.45	6.45	0.3	3.07e-10	IgG glycosylation;
LUAD	cis	rs9796	0.745	rs2947493	chr15:41375694	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.43	-7.98	-0.36	1.4e-14	Menopause (age at onset);
LUAD	cis	rs28374715	0.733	rs9568	chr15:41573612	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.94	-18.21	-0.66	3.89e-55	Ulcerative colitis;
LUAD	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg15704280	chr7:45808275	SEPT13	0.92	17.7	0.65	7.28e-53	Coronary artery disease;
LUAD	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg15147215	chr3:52552868	STAB1	-0.41	-7.49	-0.34	4.08e-13	Bipolar disorder;
LUAD	cis	rs4444235	0.564	rs9323252	chr14:54404121	G/A	cg16720578	chr14:54410717	NA	0.49	9.1	0.4	3.55e-18	Colorectal cancer;
LUAD	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.98	-0.32	1.15e-11	Height;
LUAD	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg01689657	chr7:91764605	CYP51A1	0.3	7.3	0.33	1.48e-12	Breast cancer;
LUAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg05564831	chr3:52568323	NT5DC2	0.35	6.48	0.3	2.48e-10	Electroencephalogram traits;
LUAD	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg03929089	chr4:120376271	NA	-0.92	-17.61	-0.65	1.82e-52	Height;
LUAD	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg03037974	chr15:76606532	NA	0.39	8.38	0.38	8e-16	Blood metabolite levels;
LUAD	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.5	-7.77	-0.35	6.05e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg13870426	chr17:30244630	NA	-0.55	-6.58	-0.3	1.43e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg18854424	chr1:2615690	NA	0.43	9.36	0.41	4.59e-19	Ulcerative colitis;
LUAD	cis	rs12208915	0.848	rs955765	chr6:79532610	C/T	cg09184832	chr6:79620586	NA	0.47	6.39	0.3	4.27e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs7953508	0.750	rs7977788	chr12:93982332	G/A	cg18151635	chr12:93972918	NA	-0.59	-9.58	-0.42	8.63e-20	Pubertal anthropometrics;
LUAD	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.65e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg26597838	chr10:835615	NA	0.95	14.07	0.56	3.86e-37	Eosinophil percentage of granulocytes;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11467262	chr20:57607340	ATP5E	-0.63	-8.47	-0.38	3.98e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg06637938	chr14:75390232	RPS6KL1	0.37	6.57	0.3	1.53e-10	Caffeine consumption;
LUAD	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.45	-0.3	2.99e-10	Prostate cancer;
LUAD	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22857025	chr5:266934	NA	-0.99	-14.78	-0.58	3.85e-40	Breast cancer;
LUAD	cis	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg21775007	chr8:11205619	TDH	0.57	10.13	0.44	9.85e-22	Retinal vascular caliber;
LUAD	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg12119029	chr16:89752879	CDK10	0.34	7.69	0.35	1.03e-13	Hemoglobin concentration;
LUAD	cis	rs113835537	0.529	rs2279865	chr11:66203025	A/C	cg24851651	chr11:66362959	CCS	0.58	10.46	0.45	6.1e-23	Airway imaging phenotypes;
LUAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00149659	chr3:10157352	C3orf10	0.55	7.57	0.35	2.41e-13	Alzheimer's disease;
LUAD	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg13319975	chr6:146136371	FBXO30	0.59	10.2	0.44	5.31e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11153730	0.503	rs283057	chr6:118625734	T/C	cg18833306	chr6:118973337	C6orf204	0.52	9.61	0.42	6.56e-20	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg00049323	chr5:472564	LOC25845	0.46	7.58	0.35	2.24e-13	Cystic fibrosis severity;
LUAD	cis	rs1865721	1.000	rs62089507	chr18:73179019	C/T	cg26385618	chr18:73139727	C18orf62	-0.43	-7.93	-0.36	1.96e-14	Intelligence;
LUAD	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg27411982	chr8:10470053	RP1L1	-0.43	-7.99	-0.36	1.3e-14	Retinal vascular caliber;
LUAD	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg12564285	chr5:131593104	PDLIM4	0.39	6.72	0.31	5.94e-11	Acylcarnitine levels;
LUAD	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg11645453	chr3:52864694	ITIH4	0.54	10.01	0.44	2.54e-21	Schizophrenia;
LUAD	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg03709012	chr19:19516395	GATAD2A	0.48	6.38	0.3	4.53e-10	Nonalcoholic fatty liver disease;
LUAD	cis	rs6494488	0.500	rs72741357	chr15:64783452	C/G	cg08069370	chr15:64387884	SNX1	-0.75	-6.73	-0.31	5.69e-11	Coronary artery disease;
LUAD	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.6	-0.39	1.54e-16	Neutrophil percentage of white cells;
LUAD	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg25456477	chr12:86230367	RASSF9	0.32	6.48	0.3	2.59e-10	Major depressive disorder;
LUAD	cis	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg14752069	chr8:11977206	FAM66D	-0.3	-6.46	-0.3	2.9e-10	Triglycerides;
LUAD	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.76	-0.31	4.59e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg06784218	chr1:46089804	CCDC17	-0.61	-13.59	-0.55	3.56e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	7.93	0.36	2.02e-14	Menopause (age at onset);
LUAD	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg05535760	chr7:792225	HEATR2	0.83	11.11	0.48	2.47e-25	Cerebrospinal P-tau181p levels;
LUAD	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg14895029	chr7:2775587	GNA12	-0.39	-6.37	-0.3	4.81e-10	Height;
LUAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.59	-10.26	-0.45	3.23e-22	Lymphocyte counts;
LUAD	cis	rs78761021	0.720	rs874306	chr17:9797994	G/A	cg26853458	chr17:9805074	RCVRN	0.41	7.94	0.36	1.89e-14	Type 2 diabetes;
LUAD	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg02176678	chr2:219576539	TTLL4	0.61	11.85	0.5	3.54e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs736801	0.964	rs17622656	chr5:131820997	A/G	cg00255919	chr5:131827918	IRF1	0.31	7.08	0.33	5.93e-12	Breast cancer;Mosquito bite size;
LUAD	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg03037974	chr15:76606532	NA	0.38	8.02	0.36	1.04e-14	Blood metabolite levels;
LUAD	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	8.63	0.39	1.25e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3784262	0.669	rs12595180	chr15:58332541	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.58	-0.35	2.16e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg12311346	chr5:56204834	C5orf35	0.43	7.15	0.33	3.88e-12	Coronary artery disease;
LUAD	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18404041	chr3:52824283	ITIH1	-0.59	-12.34	-0.51	4.22e-30	Bipolar disorder;
LUAD	cis	rs6992820	0.592	rs3808391	chr8:56790649	A/G	cg06880721	chr8:56792545	LYN	-0.49	-8.2	-0.37	2.95e-15	Mean platelet volume;
LUAD	cis	rs3007168	1.000	rs3007168	chr14:51608293	G/A	cg23942311	chr14:51606299	NA	0.54	7.39	0.34	8.02e-13	Cancer;
LUAD	cis	rs13040088	1.000	rs910831	chr20:61558775	T/C	cg23096297	chr20:61557774	DIDO1	0.74	10.13	0.44	9.89e-22	Menopause (age at onset);
LUAD	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg22920501	chr2:26401640	FAM59B	-0.96	-14.21	-0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21659725	chr3:3221576	CRBN	0.67	11.58	0.49	4.09e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-7.57	-0.35	2.43e-13	Alzheimer's disease (late onset);
LUAD	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.36	7.78	0.35	5.63e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.83	-0.36	4.06e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7593730	1.000	rs6718070	chr2:161170153	A/C	cg22609984	chr2:161126801	NA	0.45	7.25	0.33	1.93e-12	Type 2 diabetes;
LUAD	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg12935359	chr14:103987150	CKB	-0.49	-7.95	-0.36	1.74e-14	Body mass index;
LUAD	cis	rs4372836	1.000	rs7598876	chr2:28974466	T/C	cg09522027	chr2:28974177	PPP1CB	-0.62	-10.01	-0.44	2.57e-21	Body mass index;
LUAD	cis	rs977987	0.806	rs1895490	chr16:75392806	G/A	cg03315344	chr16:75512273	CHST6	0.65	14.15	0.57	1.77e-37	Dupuytren's disease;
LUAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.42	-0.3	3.66e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs12530845	0.623	rs73721681	chr7:135361917	A/G	cg23117316	chr7:135346802	PL-5283	-0.59	-8.94	-0.4	1.19e-17	Red blood cell traits;
LUAD	cis	rs9302065	0.565	rs2992910	chr13:95962216	T/A	cg24476569	chr13:95954382	ABCC4	-0.6	-11.12	-0.48	2.18e-25	Blood metabolite levels;
LUAD	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg00666640	chr1:248458726	OR2T12	0.32	7.88	0.36	2.86e-14	Common traits (Other);
LUAD	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg06064525	chr11:970664	AP2A2	-0.54	-11.1	-0.48	2.57e-25	Alzheimer's disease (late onset);
LUAD	cis	rs10848704	0.637	rs11062351	chr12:2881763	C/T	cg19995117	chr12:2880862	NA	0.57	12.78	0.53	7.51e-32	Quantitative traits;
LUAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.58	-0.42	8.04e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg18721089	chr20:30220636	NA	-0.45	-6.76	-0.31	4.71e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs12900413	0.687	rs6496599	chr15:90314582	C/T	cg24249390	chr15:90295951	MESP1	-0.34	-6.82	-0.31	3.07e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.88	-0.32	2.12e-11	Neuroticism;
LUAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08219700	chr8:58056026	NA	0.6	8.34	0.38	1.02e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg11166453	chr1:247681781	NA	0.38	7.28	0.33	1.68e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs889398	0.802	rs12921407	chr16:69860933	T/C	cg00738113	chr16:70207722	CLEC18C	0.36	7.12	0.33	4.63e-12	Body mass index;
LUAD	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg21028142	chr17:79581711	NPLOC4	0.35	6.86	0.32	2.52e-11	Eye color traits;
LUAD	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	8.75	0.39	5.08e-17	Breast cancer;
LUAD	trans	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg01620082	chr3:125678407	NA	-1.04	-10.34	-0.45	1.67e-22	Urinary tract infection frequency;
LUAD	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg04607235	chr12:12878440	APOLD1	-0.49	-7.83	-0.36	3.93e-14	Lymphocyte counts;
LUAD	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg16479474	chr6:28041457	NA	0.44	7.44	0.34	5.75e-13	Parkinson's disease;
LUAD	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg15017067	chr4:17643749	FAM184B	0.35	6.78	0.31	4.14e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg15017067	chr4:17643749	FAM184B	0.36	6.92	0.32	1.65e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg19041857	chr6:27730383	NA	-0.45	-6.95	-0.32	1.37e-11	Breast cancer;
LUAD	cis	rs7680126	0.633	rs4697975	chr4:10209966	A/T	cg11266682	chr4:10021025	SLC2A9	-0.45	-6.87	-0.32	2.35e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs8063160	0.799	rs1805007	chr16:89986117	A/G	cg07984980	chr16:89898383	SPIRE2	-0.73	-7.48	-0.34	4.23e-13	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LUAD	cis	rs3784262	0.967	rs4646612	chr15:58265077	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.46	-9.41	-0.42	3.27e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.81	-14.16	-0.57	1.63e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs10899021	0.512	rs2186955	chr11:74375475	C/T	cg25880958	chr11:74394337	NA	0.47	7.85	0.36	3.44e-14	Response to metformin (IC50);
LUAD	cis	rs2688608	0.869	rs2250140	chr10:75612881	T/C	cg19442545	chr10:75533431	FUT11	-0.43	-7.2	-0.33	2.69e-12	Inflammatory bowel disease;
LUAD	cis	rs7487075	0.619	rs7311504	chr12:46830776	G/A	cg23829395	chr12:46796953	NA	0.32	7.09	0.33	5.64e-12	Itch intensity from mosquito bite;
LUAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg05313129	chr8:58192883	C8orf71	-0.6	-7.4	-0.34	7.48e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7937890	0.559	rs2597200	chr11:14485600	A/G	cg06199346	chr11:14280333	SPON1	-0.33	-6.53	-0.3	1.94e-10	Mitochondrial DNA levels;
LUAD	cis	rs7524258	0.868	rs4908451	chr1:7299618	C/G	cg07173049	chr1:7289937	CAMTA1	-0.52	-10.04	-0.44	1.96e-21	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg17366294	chr4:99064904	C4orf37	0.68	12.86	0.53	3.53e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg25358565	chr5:93447407	FAM172A	0.65	7.69	0.35	1.07e-13	Diabetic retinopathy;
LUAD	cis	rs12519773	0.562	rs6557066	chr5:92499467	T/A	cg18783429	chr5:92414398	NA	0.46	8.24	0.37	2.21e-15	Migraine;
LUAD	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	15.35	0.6	1.41e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg05425664	chr17:57184151	TRIM37	-0.43	-7.58	-0.35	2.15e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg11189052	chr15:85197271	WDR73	0.59	7.61	0.35	1.84e-13	Schizophrenia;
LUAD	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg06713675	chr4:122721982	EXOSC9	-0.79	-15.92	-0.61	4.62e-45	Type 2 diabetes;
LUAD	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg12432903	chr7:1882776	MAD1L1	-0.43	-6.99	-0.32	1.06e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2735413	0.918	rs11646244	chr16:78082453	T/C	cg04733911	chr16:78082701	NA	-0.35	-8.21	-0.37	2.74e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg16988262	chr1:15930761	NA	0.41	6.85	0.32	2.61e-11	Systolic blood pressure;
LUAD	cis	rs56283067	0.847	rs12198153	chr6:44691878	T/C	cg20913747	chr6:44695427	NA	-0.44	-7.45	-0.34	5.16e-13	Total body bone mineral density;
LUAD	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.98	-0.36	1.34e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg07741184	chr6:167504864	NA	0.34	7.88	0.36	2.76e-14	Crohn's disease;
LUAD	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg22681709	chr2:178499509	PDE11A	-0.42	-7.05	-0.32	7.46e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.44	-0.34	5.76e-13	Breast cancer;
LUAD	cis	rs9826463	0.877	rs73228788	chr3:142351463	C/T	cg20824294	chr3:142316082	PLS1	0.49	6.84	0.32	2.72e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg03188948	chr7:1209495	NA	0.81	9.85	0.43	9.7e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11153730	0.503	rs283040	chr6:118631934	A/G	cg21191810	chr6:118973309	C6orf204	0.5	9.95	0.44	4.13e-21	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg08125733	chr17:73851984	WBP2	0.67	7.06	0.32	6.99e-12	Psoriasis;
LUAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg22907277	chr7:1156413	C7orf50	0.68	8.0	0.36	1.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg02228675	chr17:40259724	DHX58	-0.45	-7.14	-0.33	3.98e-12	Fibrinogen levels;
LUAD	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg10518543	chr12:38710700	ALG10B	-0.43	-7.06	-0.32	6.84e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06544989	chr22:39130855	UNC84B	0.44	8.27	0.37	1.7e-15	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.32e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg27446573	chr6:127587934	RNF146	0.41	6.36	0.3	5.35e-10	Breast cancer;
LUAD	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg19622623	chr12:86230825	RASSF9	-0.42	-7.36	-0.34	9.55e-13	Major depressive disorder;
LUAD	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.43	-0.38	5.67e-16	Total body bone mineral density;
LUAD	trans	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg21659725	chr3:3221576	CRBN	0.4	6.71	0.31	6.2e-11	Resting heart rate;
LUAD	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg22442454	chr1:209979470	IRF6	0.56	6.55	0.3	1.67e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs9462027	0.628	rs9462023	chr6:34769410	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.71	-0.39	7.17e-17	Systemic lupus erythematosus;
LUAD	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg18306943	chr3:40428807	ENTPD3	0.39	6.73	0.31	5.63e-11	Renal cell carcinoma;
LUAD	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg23260525	chr10:116636907	FAM160B1	0.46	10.48	0.45	5.45e-23	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg17063962	chr7:91808500	NA	-0.62	-10.83	-0.47	2.79e-24	Breast cancer;
LUAD	cis	rs16858210	0.837	rs11716104	chr3:183581999	G/C	cg01324343	chr3:183735012	ABCC5	0.41	6.47	0.3	2.76e-10	Menopause (age at onset);
LUAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08677398	chr8:58056175	NA	0.52	6.95	0.32	1.37e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs9929218	1.000	rs67359183	chr16:68814204	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-14.01	-0.56	6.75e-37	Colorectal cancer;
LUAD	cis	rs12618769	0.652	rs3754872	chr2:99223925	A/T	cg10123293	chr2:99228465	UNC50	0.48	8.78	0.39	4.12e-17	Bipolar disorder;
LUAD	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg09796270	chr17:17721594	SREBF1	0.36	6.98	0.32	1.11e-11	Total body bone mineral density;
LUAD	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.98	-0.4	8.9e-18	Total body bone mineral density;
LUAD	trans	rs1997103	1.000	rs9649781	chr7:55411809	A/G	cg20935933	chr6:143382018	AIG1	0.54	7.41	0.34	6.99e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg06532163	chr17:45867833	NA	0.48	8.5	0.38	3.38e-16	IgG glycosylation;
LUAD	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg24818145	chr4:99064322	C4orf37	0.44	6.86	0.32	2.47e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg02049041	chr17:27085579	C17orf63	0.66	8.7	0.39	7.59e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg00802000	chr16:706648	WDR90	-0.38	-7.14	-0.33	4.15e-12	Height;
LUAD	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg03929089	chr4:120376271	NA	-0.51	-8.13	-0.37	4.64e-15	HDL cholesterol;
LUAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg17178900	chr1:205818956	PM20D1	0.72	14.68	0.58	1.02e-39	Menarche (age at onset);
LUAD	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg11814155	chr7:99998594	ZCWPW1	0.45	7.75	0.35	7.02e-14	Platelet count;
LUAD	cis	rs752010	0.749	rs12141084	chr1:42117737	C/T	cg06885757	chr1:42089581	HIVEP3	0.37	7.74	0.35	7.3e-14	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.9	9.44	0.42	2.6e-19	Initial pursuit acceleration;
LUAD	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg23887609	chr12:130822674	PIWIL1	0.41	6.69	0.31	7.3e-11	Menopause (age at onset);
LUAD	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg18761221	chr20:60518478	NA	0.39	6.66	0.31	8.63e-11	Body mass index;
LUAD	cis	rs1448094	0.558	rs7485285	chr12:86483641	G/A	cg19622623	chr12:86230825	RASSF9	0.41	7.23	0.33	2.29e-12	Major depressive disorder;
LUAD	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg09035930	chr12:129282057	SLC15A4	0.75	17.84	0.66	1.72e-53	Systemic lupus erythematosus;
LUAD	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.33	7.18	0.33	3.17e-12	Prostate cancer;
LUAD	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg07570687	chr10:102243282	WNT8B	0.44	6.8	0.31	3.5e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs977987	0.806	rs4888404	chr16:75428097	G/A	cg03315344	chr16:75512273	CHST6	0.64	13.99	0.56	8.36e-37	Dupuytren's disease;
LUAD	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg24813613	chr7:1882135	MAD1L1	-0.4	-6.47	-0.3	2.7e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs746627	0.614	rs1421028	chr17:63822041	A/G	cg07283582	chr17:63770753	CCDC46	-0.53	-8.73	-0.39	5.92e-17	Total body bone mineral density;
LUAD	cis	rs2840044	0.534	rs167691	chr17:33885826	G/A	cg05299278	chr17:33885742	SLFN14	0.55	12.93	0.53	1.82e-32	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs11771526	0.686	rs62457463	chr7:32289856	C/T	cg27532318	chr7:32358331	NA	0.64	7.88	0.36	2.79e-14	Body mass index;
LUAD	cis	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg07460842	chr6:66804631	NA	0.97	12.96	0.53	1.35e-32	Exhaled nitric oxide output;
LUAD	cis	rs11756438	0.572	rs2638529	chr6:119006459	T/C	cg21191810	chr6:118973309	C6orf204	0.47	9.07	0.4	4.51e-18	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg13319975	chr6:146136371	FBXO30	-0.79	-13.85	-0.56	3.17e-36	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg07167872	chr1:205819463	PM20D1	-0.41	-6.49	-0.3	2.41e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.85	-0.32	2.69e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg04154034	chr17:28927549	LRRC37B2	0.69	6.79	0.31	3.7e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05901451	chr6:126070800	HEY2	-0.67	-10.99	-0.47	6.79e-25	Brugada syndrome;
LUAD	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg11871910	chr12:69753446	YEATS4	0.69	11.86	0.5	3.21e-28	Blood protein levels;
LUAD	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg23887609	chr12:130822674	PIWIL1	0.4	6.66	0.31	8.62e-11	Menopause (age at onset);
LUAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12016809	chr21:47604291	C21orf56	-0.65	-11.03	-0.47	5.06e-25	Testicular germ cell tumor;
LUAD	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg08798685	chr6:27730294	NA	-0.69	-7.3	-0.33	1.47e-12	Depression;
LUAD	cis	rs7119	0.635	rs2667767	chr15:77876031	T/C	cg27398640	chr15:77910606	LINGO1	0.4	7.73	0.35	7.93e-14	Type 2 diabetes;
LUAD	trans	rs7570971	1.000	rs6730157	chr2:135907088	C/T	cg05194412	chr2:137003533	NA	0.42	6.42	0.3	3.64e-10	Blood metabolite levels;Body mass index;Cholesterol, total;
LUAD	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg18827107	chr12:86230957	RASSF9	-0.54	-9.58	-0.42	8.58e-20	Major depressive disorder;
LUAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07157834	chr1:205819609	PM20D1	-0.62	-11.17	-0.48	1.49e-25	Menarche (age at onset);
LUAD	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.55	-9.26	-0.41	1.06e-18	Glomerular filtration rate;
LUAD	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg18129178	chr5:148520854	ABLIM3	-0.62	-9.52	-0.42	1.32e-19	Breast cancer;
LUAD	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18876405	chr7:65276391	NA	0.44	7.08	0.33	6.08e-12	Aortic root size;
LUAD	cis	rs2274273	0.870	rs8021583	chr14:55749607	G/A	cg04306507	chr14:55594613	LGALS3	0.44	9.11	0.4	3.41e-18	Protein biomarker;
LUAD	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg18854424	chr1:2615690	NA	0.4	8.57	0.38	1.95e-16	Multiple sclerosis;
LUAD	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg25664220	chr3:72788482	NA	-0.67	-11.72	-0.5	1.14e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg07305463	chr2:136567211	LCT	0.37	6.88	0.32	2.11e-11	Mosquito bite size;
LUAD	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg09256556	chr8:142187200	DENND3	-0.42	-7.0	-0.32	1.03e-11	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs11039798	0.698	rs78553793	chr11:48947336	C/A	cg03929089	chr4:120376271	NA	0.66	6.57	0.3	1.49e-10	Axial length;
LUAD	cis	rs9902453	0.845	rs72823935	chr17:28008595	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.25	0.41	1.08e-18	Coffee consumption (cups per day);
LUAD	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg12923728	chr3:195709715	SDHAP1	0.45	6.83	0.32	2.99e-11	Mean corpuscular volume;
LUAD	cis	rs4604732	0.536	rs12074913	chr1:247631607	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.18	0.33	3.16e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs859767	0.679	rs4954158	chr2:135426618	T/C	cg12500956	chr2:135428796	TMEM163	-0.32	-8.55	-0.38	2.33e-16	Neuroticism;
LUAD	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg10544611	chr16:67998164	SLC12A4	-0.55	-6.94	-0.32	1.44e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg22491629	chr6:157744540	C6orf35	-0.78	-9.04	-0.4	5.73e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg11822812	chr5:140052017	DND1	-0.37	-6.64	-0.31	9.92e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9341808	0.905	rs3805903	chr6:80975829	T/C	cg08355045	chr6:80787529	NA	0.54	10.08	0.44	1.51e-21	Sitting height ratio;
LUAD	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-6.53	-0.3	1.84e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs4824093	0.610	rs7410534	chr22:50289925	C/T	cg09872104	chr7:134855509	C7orf49	-0.85	-6.81	-0.31	3.33e-11	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg08798685	chr6:27730294	NA	-0.47	-7.07	-0.33	6.25e-12	Breast cancer;
LUAD	cis	rs7267979	1.000	rs453329	chr20:25440593	G/A	cg08601574	chr20:25228251	PYGB	0.46	8.54	0.38	2.37e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs829883	0.966	rs249853	chr12:98864908	A/C	cg25150519	chr12:98850993	NA	0.67	11.15	0.48	1.8e-25	Colorectal adenoma (advanced);
LUAD	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg07617317	chr6:118971624	C6orf204	0.55	8.33	0.38	1.14e-15	Diastolic blood pressure;
LUAD	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg10523679	chr1:76189770	ACADM	0.9	15.88	0.61	7.19e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.32	-8.16	-0.37	3.81e-15	Total body bone mineral density;
LUAD	cis	rs28595532	1.000	rs114912871	chr4:119697004	G/C	cg02775129	chr4:119771670	NA	-0.84	-8.0	-0.36	1.2e-14	Cannabis dependence symptom count;
LUAD	cis	rs364477	0.762	rs12238866	chr9:1001309	G/T	cg13952963	chr9:998547	NA	-0.52	-7.05	-0.32	7.3e-12	Major depressive disorder;
LUAD	cis	rs1448094	0.935	rs11117120	chr12:86336447	G/A	cg02569458	chr12:86230093	RASSF9	0.37	7.15	0.33	3.76e-12	Major depressive disorder;
LUAD	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.48	-0.3	2.52e-10	Aortic root size;
LUAD	cis	rs9914544	0.545	rs2892015	chr17:18786849	C/T	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.49	-0.3	2.45e-10	Educational attainment (years of education);
LUAD	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg16647868	chr5:131706066	SLC22A5	-0.46	-7.48	-0.34	4.23e-13	Breast cancer;
LUAD	cis	rs1555895	0.611	rs2892159	chr10:855061	G/A	cg20503657	chr10:835505	NA	0.41	6.5	0.3	2.22e-10	Survival in rectal cancer;
LUAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.52	-9.82	-0.43	1.17e-20	Longevity;Endometriosis;
LUAD	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.53	0.3	1.85e-10	Colorectal cancer;
LUAD	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09263875	chr16:632152	PIGQ	0.8	17.31	0.64	3.85e-51	Height;
LUAD	cis	rs9902453	0.904	rs9897794	chr17:28296327	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	10.29	0.45	2.65e-22	Coffee consumption (cups per day);
LUAD	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg05340658	chr4:99064831	C4orf37	0.46	7.68	0.35	1.08e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs2018683	0.677	rs12531456	chr7:28970611	A/C	cg19402173	chr7:128379420	CALU	-0.51	-8.13	-0.37	4.96e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9354308	0.933	rs2802063	chr6:66564148	T/C	cg07460842	chr6:66804631	NA	0.51	7.59	0.35	2.06e-13	Metabolite levels;
LUAD	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.36	0.3	5.2400000000000005e-10	Depression;
LUAD	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6499255	1.000	rs6499253	chr16:69802672	C/T	cg15192750	chr16:69999425	NA	0.56	8.84	0.39	2.69e-17	IgE levels;
LUAD	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg25358565	chr5:93447407	FAM172A	0.64	7.57	0.35	2.3e-13	Diabetic retinopathy;
LUAD	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.94	0.32	1.49e-11	Cognitive test performance;
LUAD	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg19163074	chr7:65112434	INTS4L2	-0.45	-6.87	-0.32	2.37e-11	Aortic root size;
LUAD	cis	rs9814567	0.752	rs6779326	chr3:134330027	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.49e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7119	0.635	rs59745219	chr15:77884130	A/G	cg27398640	chr15:77910606	LINGO1	0.39	7.74	0.35	7.55e-14	Type 2 diabetes;
LUAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.64	-10.68	-0.46	1e-23	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08280861	chr8:58055591	NA	0.8	9.65	0.42	4.69e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs3760982	0.585	rs61013802	chr19:44292142	A/T	cg21496419	chr19:44306685	LYPD5	0.34	7.41	0.34	7.13e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs9923856	0.570	rs9888873	chr16:11082874	T/G	cg04616529	chr16:11181986	CLEC16A	-0.41	-6.44	-0.3	3.29e-10	Atopic dermatitis;Adult asthma;
LUAD	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7945718	1.000	rs7945719	chr11:12748820	A/C	cg25843174	chr11:12811716	TEAD1	0.23	6.87	0.32	2.36e-11	Educational attainment (years of education);
LUAD	trans	rs1422110	0.513	rs1422105	chr5:85448371	A/C	cg01787110	chr1:109008453	NBPF6	0.51	8.67	0.39	9.43e-17	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg00922110	chr4:57842668	C4orf14	-0.41	-7.11	-0.33	5e-12	Response to bleomycin (chromatid breaks);
LUAD	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg26384229	chr12:38710491	ALG10B	0.41	7.0	0.32	1.01e-11	Morning vs. evening chronotype;
LUAD	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg02269571	chr22:50332266	NA	-0.66	-9.56	-0.42	9.63e-20	Schizophrenia;
LUAD	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg16325326	chr1:53192061	ZYG11B	-0.62	-11.02	-0.47	5.19e-25	Monocyte count;
LUAD	trans	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	7.51	0.34	3.47e-13	Resting heart rate;
LUAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg02951883	chr7:2050386	MAD1L1	-0.9	-16.42	-0.62	3.01e-47	Bipolar disorder and schizophrenia;
LUAD	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg14829155	chr15:31115871	NA	-0.51	-8.88	-0.4	1.89e-17	Huntington's disease progression;
LUAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	cis	rs6908034	0.607	rs78402429	chr6:19811690	C/A	cg02682789	chr6:19804855	NA	0.91	9.09	0.4	3.9e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg27661571	chr11:113659931	NA	-0.68	-7.92	-0.36	2.05e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-7.37	-0.34	9.25e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9462027	0.628	rs3734264	chr6:34831866	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-8.97	-0.4	1e-17	Systemic lupus erythematosus;
LUAD	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg03983476	chr2:10830698	NOL10	-0.47	-8.1	-0.37	5.86e-15	Prostate cancer;
LUAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg05896524	chr21:47604654	C21orf56	-0.74	-13.23	-0.54	1.1e-33	Testicular germ cell tumor;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg24357026	chr19:36705589	ZNF565;ZNF146	-0.39	-6.58	-0.3	1.38e-10	Schizophrenia;
LUAD	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg01475377	chr6:109611718	NA	0.49	9.08	0.4	4.33e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs2735413	0.794	rs55951868	chr16:78078804	C/A	cg04733911	chr16:78082701	NA	-0.32	-7.37	-0.34	9.28e-13	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg06740227	chr12:86229804	RASSF9	0.4	7.01	0.32	9.27e-12	Major depressive disorder;
LUAD	trans	rs8002861	0.967	rs2325071	chr13:44476793	T/C	cg17145862	chr1:211918768	LPGAT1	0.75	17.72	0.65	6.03e-53	Leprosy;
LUAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08677398	chr8:58056175	NA	0.52	6.78	0.31	3.94e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs701145	0.640	rs357495	chr3:153939099	A/G	cg14299572	chr10:34021103	NA	-0.39	-6.49	-0.3	2.35e-10	Coronary artery disease;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg11235426	chr6:292522	DUSP22	-0.81	-13.83	-0.56	3.85e-36	Menopause (age at onset);
LUAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg02524346	chr8:600233	NA	1.07	10.66	0.46	1.18e-23	IgG glycosylation;
LUAD	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	7.43	0.34	6.08e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7659604	0.540	rs10001092	chr4:122677177	C/T	cg06713675	chr4:122721982	EXOSC9	0.42	7.68	0.35	1.08e-13	Type 2 diabetes;
LUAD	trans	rs4650994	0.593	rs7540745	chr1:178529757	C/T	cg05059571	chr16:84539110	KIAA1609	0.41	6.49	0.3	2.45e-10	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs300774	0.925	rs441469	chr2:129028	C/T	cg21211680	chr2:198530	NA	-0.46	-7.21	-0.33	2.52e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg26647111	chr11:31128758	NA	-0.46	-7.98	-0.36	1.36e-14	Red blood cell count;
LUAD	trans	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg01620082	chr3:125678407	NA	0.83	9.1	0.4	3.49e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg24503407	chr1:205819492	PM20D1	0.77	15.41	0.6	7.24e-43	Menarche (age at onset);
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07892879	chr17:79845984	THOC4	0.48	6.4	0.3	4.04e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21477317	chr3:48488082	ATRIP	-0.41	-6.8	-0.31	3.62e-11	Cancer;
LUAD	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg04731861	chr2:219085781	ARPC2	-0.24	-7.41	-0.34	7.08e-13	Colorectal cancer;
LUAD	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg03983476	chr2:10830698	NOL10	-0.45	-7.87	-0.36	3.08e-14	Prostate cancer;
LUAD	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg16329650	chr2:213403929	ERBB4	0.6	10.75	0.46	5.32e-24	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg03929089	chr4:120376271	NA	-0.6	-8.04	-0.36	9.23e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg03388025	chr16:89894329	SPIRE2	0.48	12.3	0.51	6.36e-30	Vitiligo;
LUAD	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg19635926	chr16:89946313	TCF25	0.64	6.57	0.3	1.48e-10	Skin colour saturation;
LUAD	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg07217954	chr7:1067459	C7orf50	-0.44	-7.56	-0.35	2.48e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs7512552	0.839	rs1260405	chr1:150304781	A/G	cg15654264	chr1:150340011	RPRD2	0.59	11.14	0.48	1.97e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2688608	0.934	rs2675679	chr10:75658581	C/T	cg19442545	chr10:75533431	FUT11	-0.41	-7.06	-0.32	6.72e-12	Inflammatory bowel disease;
LUAD	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.54	-9.1	-0.4	3.65e-18	Glomerular filtration rate;
LUAD	cis	rs9467773	1.000	rs1977201	chr6:26573674	T/C	cg09904177	chr6:26538194	HMGN4	0.44	7.03	0.32	8.25e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg24642844	chr7:1081250	C7orf50	-0.98	-14.87	-0.59	1.54e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg17178900	chr1:205818956	PM20D1	0.84	19.21	0.68	1.34e-59	Menarche (age at onset);
LUAD	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.5	-0.34	3.78e-13	Neutrophil percentage of white cells;
LUAD	cis	rs733175	0.951	rs6826764	chr4:10030794	C/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-8.41	-0.38	6.57e-16	Psychosis and Alzheimer's disease;
LUAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg11062466	chr8:58055876	NA	0.66	8.63	0.39	1.3e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs494562	0.892	rs490079	chr6:86117599	T/C	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg16479474	chr6:28041457	NA	0.44	7.4	0.34	7.22e-13	Depression;
LUAD	cis	rs300774	0.858	rs300718	chr2:136579	G/A	cg21211680	chr2:198530	NA	-0.47	-7.38	-0.34	8.37e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs939658	0.805	rs35832166	chr15:79417994	G/T	cg17916960	chr15:79447300	NA	-0.53	-11.18	-0.48	1.29e-25	Refractive error;
LUAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.44	-8.74	-0.39	5.58e-17	Longevity;Endometriosis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21601059	chr12:56122983	CD63	-0.57	-6.83	-0.32	2.93e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.46	0.34	5.05e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.1	-0.51	3.68e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-6.83	-0.32	3.01e-11	Body mass index;
LUAD	cis	rs1461503	0.932	rs56778812	chr11:122840491	C/T	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg18825076	chr15:78729989	IREB2	0.49	6.76	0.31	4.5e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg04546413	chr19:29218101	NA	0.7	10.37	0.45	1.3e-22	Methadone dose in opioid dependence;
LUAD	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg26769984	chr7:1090371	C7orf50	0.58	9.74	0.43	2.3e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs4899554	0.640	rs72719914	chr14:75708305	G/A	cg18117039	chr14:75741733	NA	0.63	8.72	0.39	6.21e-17	Inflammatory bowel disease;
LUAD	cis	rs7274811	0.711	rs291689	chr20:32003974	A/G	cg13403462	chr20:32256071	NECAB3;C20orf134	0.42	6.44	0.3	3.33e-10	Height;
LUAD	cis	rs7818345	0.967	rs4554480	chr8:19284072	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.33	7.21	0.33	2.65e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12145550	chr20:44600942	ZNF335	-0.54	-6.65	-0.31	9.1e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg03714773	chr7:91764589	CYP51A1	0.29	6.59	0.31	1.33e-10	Breast cancer;
LUAD	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg02569458	chr12:86230093	RASSF9	0.42	7.75	0.35	7.12e-14	Major depressive disorder;
LUAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.74	-0.35	7.33e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg08807101	chr21:30365312	RNF160	0.51	8.74	0.39	5.43e-17	Dental caries;
LUAD	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg23018236	chr17:30244563	NA	-0.61	-7.91	-0.36	2.24e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg11494091	chr17:61959527	GH2	0.43	8.3	0.37	1.4e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg14458575	chr2:238380390	NA	-0.71	-13.6	-0.55	3.34e-35	Prostate cancer;
LUAD	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg01868782	chr6:126071099	HEY2	0.31	6.38	0.3	4.65e-10	Brugada syndrome;
LUAD	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg02782426	chr3:40428986	ENTPD3	0.35	7.51	0.34	3.44e-13	Renal cell carcinoma;
LUAD	cis	rs6500395	1.000	rs2355297	chr16:48685338	T/C	cg04672837	chr16:48644449	N4BP1	-0.39	-6.81	-0.31	3.4e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7617773	0.817	rs3731555	chr3:48206102	G/A	cg11946769	chr3:48343235	NME6	0.41	6.36	0.3	5.11e-10	Coronary artery disease;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg06529459	chr11:67397595	NUDT8	0.4	6.99	0.32	1.05e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg04267008	chr7:1944627	MAD1L1	-0.68	-10.7	-0.46	8.56e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs2882667	0.898	rs6882526	chr5:138382368	A/G	cg04439458	chr5:138467593	SIL1	-0.4	-7.27	-0.33	1.8e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10150615	chr22:24372951	LOC391322	0.49	8.02	0.36	1.07e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg09455208	chr3:40491958	NA	-0.55	-12.13	-0.51	3.02e-29	Renal cell carcinoma;
LUAD	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	7.73	0.35	7.67e-14	Menopause (age at onset);
LUAD	cis	rs13064411	0.518	rs7623919	chr3:113219160	A/G	cg18753928	chr3:113234510	CCDC52	-0.48	-8.6	-0.39	1.62e-16	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg24503407	chr1:205819492	PM20D1	-0.52	-7.86	-0.36	3.11e-14	Menarche (age at onset);
LUAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg07167872	chr1:205819463	PM20D1	-0.54	-8.4	-0.38	6.9e-16	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.45	-6.74	-0.31	5.18e-11	Total body bone mineral density;
LUAD	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg26769984	chr7:1090371	C7orf50	0.62	9.84	0.43	9.98e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs9788682	0.747	rs2656071	chr15:78745343	A/T	cg18825076	chr15:78729989	IREB2	-0.55	-7.9	-0.36	2.41e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs7932354	0.502	rs11600668	chr11:47193566	G/A	cg19486271	chr11:47235900	DDB2	0.44	6.89	0.32	1.99e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg15691649	chr6:25882328	NA	0.44	7.06	0.32	7.06e-12	Blood metabolite levels;
LUAD	cis	rs73206853	0.563	rs73194026	chr12:111140219	G/T	cg12870014	chr12:110450643	ANKRD13A	0.59	6.54	0.3	1.82e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7095607	0.538	rs2634706	chr10:69917590	A/C	cg18986048	chr10:69913749	MYPN	0.44	7.59	0.35	2.13e-13	Lung function (FVC);
LUAD	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg16049864	chr8:95962084	TP53INP1	-0.47	-9.45	-0.42	2.26e-19	Type 2 diabetes;
LUAD	cis	rs117623576	0.941	rs7924082	chr10:32429126	A/G	cg03047570	chr10:32398778	NA	0.72	8.49	0.38	3.43e-16	Anti-saccade response;
LUAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg04234412	chr22:24373322	LOC391322	-0.73	-12.27	-0.51	8.43e-30	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.43	8.28	0.37	1.69e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg07936489	chr17:37558343	FBXL20	0.51	6.98	0.32	1.14e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs6494488	0.500	rs72744751	chr15:65064657	C/T	cg08069370	chr15:64387884	SNX1	-0.72	-6.64	-0.31	9.61e-11	Coronary artery disease;
LUAD	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg00603274	chr11:61596626	FADS2	-0.37	-6.42	-0.3	3.69e-10	Trans fatty acid levels;
LUAD	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-8.23	-0.37	2.28e-15	Type 2 diabetes;
LUAD	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-10.0	-0.44	2.89e-21	Gut microbiome composition (summer);
LUAD	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg00784671	chr22:46762841	CELSR1	-0.59	-7.76	-0.35	6.5e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg18538332	chr22:24372958	LOC391322	0.48	7.82	0.36	4.39e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21659725	chr3:3221576	CRBN	-0.86	-18.32	-0.67	1.29e-55	Intelligence (multi-trait analysis);
LUAD	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-15.16	-0.59	8.76e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg18016565	chr1:150552671	MCL1	0.42	7.72	0.35	8.76e-14	Tonsillectomy;
LUAD	cis	rs4846217	1.000	rs4846215	chr1:10412636	A/T	cg17425144	chr1:10567563	PEX14	-0.49	-6.46	-0.3	2.89e-10	Platelet count;
LUAD	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg14558114	chr2:88469736	THNSL2	0.69	6.96	0.32	1.34e-11	Plasma clusterin levels;
LUAD	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.88	0.36	2.75e-14	Depression;
LUAD	cis	rs1997103	1.000	rs6593238	chr7:55411048	A/G	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9467160	1.000	rs7762901	chr6:24449639	G/A	cg16211469	chr6:24423932	MRS2	0.42	6.63	0.31	1.04e-10	Liver enzyme levels;
LUAD	cis	rs367943	0.933	rs451453	chr5:112808970	G/C	cg12552261	chr5:112820674	MCC	-0.59	-11.1	-0.47	2.72e-25	Type 2 diabetes;
LUAD	cis	rs7180079	0.620	rs8036775	chr15:64844372	G/T	cg08069370	chr15:64387884	SNX1	-0.53	-6.68	-0.31	7.45e-11	Monocyte count;
LUAD	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg06636001	chr8:8085503	FLJ10661	0.42	6.72	0.31	5.8e-11	Mood instability;
LUAD	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg05340658	chr4:99064831	C4orf37	0.46	7.56	0.34	2.56e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg05754148	chr16:3507555	NAT15	-0.5	-8.17	-0.37	3.62e-15	Body mass index (adult);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02159610	chr16:29822716	PRRT2	-0.5	-7.67	-0.35	1.16e-13	Height;
LUAD	trans	rs7712671	0.840	rs11241418	chr5:116527405	C/T	cg24539604	chr2:191184750	HIBCH	0.44	6.83	0.32	2.92e-11	Schizophrenia;
LUAD	trans	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.5	-8.0	-0.36	1.18e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs13315871	0.929	rs7628038	chr3:58313813	T/C	cg20936604	chr3:58311152	NA	-0.78	-8.44	-0.38	5.28e-16	Cholesterol, total;
LUAD	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg26384229	chr12:38710491	ALG10B	-0.4	-6.83	-0.32	3.01e-11	Morning vs. evening chronotype;
LUAD	trans	rs9503551	0.642	rs9503548	chr6:3332617	A/G	cg13915676	chr9:139305538	SDCCAG3;PMPCA	0.49	6.49	0.3	2.36e-10	Nicotine dependence;
LUAD	cis	rs6543140	0.964	rs4851593	chr2:103089227	C/T	cg03938978	chr2:103052716	IL18RAP	-0.34	-6.6	-0.31	1.26e-10	Blood protein levels;
LUAD	cis	rs3820068	0.734	rs72645830	chr1:15889910	A/G	cg13390004	chr1:15929781	NA	0.43	6.8	0.31	3.67e-11	Systolic blood pressure;
LUAD	cis	rs7809615	0.901	rs17161761	chr7:99156934	C/T	cg03133378	chr7:99195931	NA	-0.58	-6.55	-0.3	1.65e-10	Blood metabolite ratios;
LUAD	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg21709803	chr11:61594965	FADS2	-0.4	-7.34	-0.34	1.07e-12	LDL cholesterol;
LUAD	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg08999081	chr20:33150536	PIGU	-0.63	-14.32	-0.57	3.24e-38	Glomerular filtration rate (creatinine);
LUAD	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg12035532	chr1:1886765	KIAA1751	0.41	6.95	0.32	1.36e-11	Body mass index;
LUAD	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.28	-0.54	7.08e-34	Chronic sinus infection;
LUAD	trans	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg14917512	chr19:3094685	GNA11	0.55	6.65	0.31	9.22e-11	Diabetic kidney disease;
LUAD	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00149659	chr3:10157352	C3orf10	-0.56	-7.79	-0.35	5.3e-14	Alzheimer's disease;
LUAD	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg22117172	chr7:91764530	CYP51A1	0.36	7.77	0.35	5.9e-14	Breast cancer;
LUAD	cis	rs73086581	1.000	rs2326289	chr20:3952300	T/C	cg02187196	chr20:3869020	PANK2	0.46	6.49	0.3	2.34e-10	Response to antidepressants in depression;
LUAD	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg18827107	chr12:86230957	RASSF9	-0.62	-10.9	-0.47	1.45e-24	Major depressive disorder;
LUAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	cis	rs4378999	0.668	rs9864443	chr3:51656376	C/G	cg12934382	chr3:51741135	GRM2	0.42	7.34	0.34	1.08e-12	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg17971929	chr21:40555470	PSMG1	-0.57	-8.97	-0.4	1e-17	Cognitive function;
LUAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.33	0.54	4.28e-34	Prudent dietary pattern;
LUAD	cis	rs35740288	0.770	rs11634707	chr15:86151867	A/G	cg13263323	chr15:86062960	AKAP13	-0.44	-7.13	-0.33	4.51e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg14530993	chr4:882597	GAK	-0.75	-7.63	-0.35	1.59e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg22681709	chr2:178499509	PDE11A	-0.4	-7.44	-0.34	5.64e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.2	-0.37	2.81e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg01689657	chr7:91764605	CYP51A1	0.38	9.55	0.42	1.04e-19	Breast cancer;
LUAD	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg06547715	chr2:218990976	CXCR2	-0.27	-6.49	-0.3	2.44e-10	Colorectal cancer;
LUAD	cis	rs17818399	0.815	rs17768138	chr2:46868217	A/G	cg09399716	chr2:46890238	NA	-0.42	-7.9	-0.36	2.48e-14	Height;
LUAD	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg04772025	chr11:68637568	NA	0.54	8.51	0.38	2.95e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1784581	0.651	rs1784588	chr6:162390027	T/A	cg17173639	chr6:162384350	PARK2	-0.51	-9.21	-0.41	1.5e-18	Itch intensity from mosquito bite;
LUAD	cis	rs2882667	0.858	rs4643949	chr5:138372345	C/T	cg04439458	chr5:138467593	SIL1	-0.4	-7.25	-0.33	2.06e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.86	-0.5	3.36e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06873352	chr17:61820015	STRADA	0.83	18.55	0.67	1.2e-56	Prudent dietary pattern;
LUAD	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg09359103	chr1:154839909	KCNN3	-0.92	-21.21	-0.72	1.59e-68	Prostate cancer;
LUAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg03396347	chr1:1875803	NA	-0.6	-15.32	-0.6	1.88e-42	Body mass index;
LUAD	cis	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg07460842	chr6:66804631	NA	0.95	15.06	0.59	2.43e-41	Exhaled nitric oxide levels;
LUAD	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg15921436	chr17:44337874	NA	-0.58	-8.84	-0.39	2.65e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.37	0.38	8.75e-16	Lymphocyte percentage of white cells;
LUAD	cis	rs9902453	0.868	rs7212162	chr17:28321328	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.45	0.45	6.95e-23	Coffee consumption (cups per day);
LUAD	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg05182265	chr7:156933206	UBE3C	-0.8	-17.26	-0.64	6.54e-51	Body mass index;
LUAD	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.13	-0.33	4.35e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg18827107	chr12:86230957	RASSF9	-0.53	-9.31	-0.41	7.2e-19	Major depressive disorder;
LUAD	trans	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg00717180	chr2:96193071	NA	-0.37	-6.83	-0.32	3.04e-11	Height;
LUAD	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg18132916	chr6:79620363	NA	-0.46	-7.84	-0.36	3.72e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg23758822	chr17:41437982	NA	0.99	20.74	0.71	1.89e-66	Menopause (age at onset);
LUAD	trans	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.01	-0.5	8.8e-29	Primary sclerosing cholangitis;
LUAD	cis	rs4953076	0.613	rs11124981	chr2:44462133	A/T	cg04920474	chr2:44395004	PPM1B	0.55	8.38	0.38	8.12e-16	Height;
LUAD	cis	rs9581857	0.579	rs75872792	chr13:27996064	G/T	cg22138327	chr13:27999177	GTF3A	0.97	11.64	0.49	2.31e-27	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg04756594	chr16:24857601	SLC5A11	0.51	9.89	0.43	7.06e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs6087990	1.000	rs6087990	chr20:31349908	T/C	cg13636640	chr20:31349939	DNMT3B	0.86	17.03	0.64	6.65e-50	Ulcerative colitis;
LUAD	cis	rs1550582	0.662	rs7812708	chr8:135500832	C/T	cg17885191	chr8:135476712	NA	0.91	14.22	0.57	8.66e-38	Educational attainment;
LUAD	cis	rs10465746	0.725	rs10127737	chr1:84368642	G/A	cg10977910	chr1:84465055	TTLL7	0.61	9.92	0.43	5.3e-21	Obesity-related traits;
LUAD	trans	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.19	-0.33	2.98e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg26513180	chr16:89883248	FANCA	0.78	6.75	0.31	5.04e-11	Skin colour saturation;
LUAD	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg11833968	chr6:79620685	NA	-0.44	-8.26	-0.37	1.92e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs968567	0.689	rs61897795	chr11:61618169	A/G	cg06781209	chr11:61594997	FADS2	-0.62	-8.45	-0.38	4.65e-16	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg08632164	chr7:65971372	NA	-0.54	-6.41	-0.3	3.81e-10	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg05340658	chr4:99064831	C4orf37	0.54	9.12	0.41	2.96e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34734847	0.842	rs7308648	chr12:121144144	C/G	cg27246729	chr12:121163418	ACADS	0.37	6.87	0.32	2.34e-11	Mean corpuscular volume;
LUAD	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg11859384	chr17:80120422	CCDC57	0.49	8.88	0.4	1.9e-17	Life satisfaction;
LUAD	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg00321850	chr1:175162397	KIAA0040	0.55	11.91	0.5	2.19e-28	Alcohol dependence;
LUAD	cis	rs13315871	1.000	rs9824965	chr3:58433505	T/A	cg20936604	chr3:58311152	NA	-0.67	-7.07	-0.33	6.51e-12	Cholesterol, total;
LUAD	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs6688613	0.649	rs2294195	chr1:166838281	T/C	cg07049167	chr1:166818506	POGK	0.57	8.8	0.39	3.5e-17	Refractive astigmatism;
LUAD	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.82	-0.36	4.26e-14	Blood metabolite levels;
LUAD	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11644478	chr21:40555479	PSMG1	-0.54	-8.66	-0.39	9.96e-17	Cognitive function;
LUAD	trans	rs853679	0.546	rs200948	chr6:27835272	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.08	-0.37	6.63e-15	Depression;
LUAD	cis	rs6545883	0.899	rs1562309	chr2:61770126	C/A	cg15711740	chr2:61764176	XPO1	-0.43	-6.79	-0.31	3.85e-11	Tuberculosis;
LUAD	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg03929089	chr4:120376271	NA	-0.98	-20.37	-0.7	8.58e-65	Height;
LUAD	trans	rs75804782	0.630	rs113725999	chr2:239287651	C/T	cg01134436	chr17:81009848	B3GNTL1	0.76	6.82	0.31	3.2e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.04	0.32	7.98e-12	Colorectal cancer;
LUAD	cis	rs6484504	0.532	rs2761589	chr11:31311429	C/G	cg26647111	chr11:31128758	NA	0.46	8.01	0.36	1.15e-14	Red blood cell count;
LUAD	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg10591111	chr5:226296	SDHA	-0.57	-6.84	-0.32	2.87e-11	Breast cancer;
LUAD	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.6	0.31	1.21e-10	Schizophrenia;
LUAD	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.72	-14.76	-0.58	4.71e-40	Urate levels in overweight individuals;
LUAD	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.46	-0.34	4.94e-13	Resting heart rate;
LUAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2066819	1.000	rs117683816	chr12:56638267	T/C	cg26714650	chr12:56694279	CS	-0.83	-6.99	-0.32	1.05e-11	Psoriasis vulgaris;
LUAD	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg08640252	chr16:1820949	NME3	-0.48	-9.0	-0.4	7.78e-18	Insulin-like growth factors;
LUAD	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg08085267	chr17:45401833	C17orf57	-0.5	-8.24	-0.37	2.21e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.76e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.59	-9.81	-0.43	1.36e-20	Electrocardiographic conduction measures;
LUAD	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18099408	chr3:52552593	STAB1	-0.44	-8.19	-0.37	3.06e-15	Bipolar disorder;
LUAD	cis	rs6490294	0.799	rs6489819	chr12:112328230	C/A	cg10833066	chr12:111807467	FAM109A	0.44	7.16	0.33	3.57e-12	Mean platelet volume;
LUAD	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg20203395	chr5:56204925	C5orf35	-0.81	-11.51	-0.49	7.61e-27	Initial pursuit acceleration;
LUAD	cis	rs240764	0.782	rs239235	chr6:101100528	A/G	cg09795085	chr6:101329169	ASCC3	0.44	7.56	0.35	2.5e-13	Neuroticism;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg23186294	chr19:59070531	UBE2M;LOC100131691	-0.43	-7.22	-0.33	2.46e-12	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg23711669	chr6:146136114	FBXO30	0.38	6.53	0.3	1.87e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg25767906	chr1:53392781	SCP2	0.41	7.53	0.34	3e-13	Monocyte count;
LUAD	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg10544611	chr16:67998164	SLC12A4	-0.69	-8.23	-0.37	2.28e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6714710	0.603	rs1875699	chr2:98580724	G/T	cg26665480	chr2:98280029	ACTR1B	0.5	8.18	0.37	3.28e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs9323205	0.765	rs2999390	chr14:51654944	C/G	cg23942311	chr14:51606299	NA	-0.52	-9.52	-0.42	1.33e-19	Cancer;
LUAD	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg06060754	chr5:176797920	RGS14	0.56	10.72	0.46	6.99e-24	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs80319144	0.521	rs55873205	chr2:159311576	C/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.41	8.0	0.36	1.17e-14	Restless legs syndrome;
LUAD	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg10518543	chr12:38710700	ALG10B	0.41	6.37	0.3	5.02e-10	Bladder cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09418283	chr12:80084718	PAWR	-0.64	-6.61	-0.31	1.15e-10	Type 2 diabetes;
LUAD	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg02527881	chr3:46936655	PTH1R	0.44	8.65	0.39	1.1e-16	Colorectal cancer;
LUAD	cis	rs686320	1.000	rs3132770	chr11:65251317	G/A	cg21890820	chr11:65308645	LTBP3	0.76	8.35	0.38	1.01e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg09165964	chr15:75287851	SCAMP5	-0.44	-6.72	-0.31	5.95e-11	Blood trace element (Zn levels);
LUAD	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.61	-10.23	-0.45	4.27e-22	Glomerular filtration rate;
LUAD	cis	rs877282	0.853	rs11595507	chr10:756703	C/T	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg24562669	chr7:97807699	LMTK2	0.29	6.89	0.32	2.09e-11	Breast cancer;
LUAD	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08109568	chr15:31115862	NA	-0.79	-13.95	-0.56	1.19e-36	Huntington's disease progression;
LUAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg00280220	chr17:61926910	NA	0.37	7.06	0.32	6.84e-12	Prudent dietary pattern;
LUAD	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg08999081	chr20:33150536	PIGU	0.35	6.75	0.31	4.86e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs2692947	0.508	rs2216793	chr2:96196322	A/G	cg23100626	chr2:96804247	ASTL	0.34	8.45	0.38	4.89e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg09915433	chr19:53449742	NA	-0.56	-9.87	-0.43	8.39e-21	Psoriasis;
LUAD	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.3	0.51	6.42e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg21252483	chr19:49399788	TULP2	0.6	9.32	0.41	6.56e-19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg19717773	chr7:2847554	GNA12	0.41	6.58	0.3	1.39e-10	Height;
LUAD	cis	rs6500395	0.962	rs9927888	chr16:48557764	A/T	cg04672837	chr16:48644449	N4BP1	0.38	6.69	0.31	7.05e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg25036284	chr2:26402008	FAM59B	0.85	10.79	0.46	3.98e-24	Gut microbiome composition (summer);
LUAD	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg20291162	chr17:40259547	DHX58	-0.68	-10.72	-0.46	6.7e-24	Fibrinogen levels;
LUAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	12.52	0.52	8.34e-31	Prudent dietary pattern;
LUAD	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg08632164	chr7:65971372	NA	0.38	6.68	0.31	7.72e-11	Aortic root size;
LUAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg11494091	chr17:61959527	GH2	0.74	18.54	0.67	1.31e-56	Prudent dietary pattern;
LUAD	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg04369109	chr6:150039330	LATS1	-0.46	-7.81	-0.35	4.67e-14	Lung cancer;
LUAD	cis	rs7789940	0.904	rs56919252	chr7:75937520	T/C	cg10167463	chr7:75959203	YWHAG	-0.68	-11.82	-0.5	4.82e-28	Multiple sclerosis;
LUAD	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg25344623	chr2:136566232	LCT	0.34	6.75	0.31	4.79e-11	Mosquito bite size;
LUAD	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg21775007	chr8:11205619	TDH	-0.5	-8.94	-0.4	1.23e-17	Retinal vascular caliber;
LUAD	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.11	0.33	5.07e-12	Bladder cancer;
LUAD	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg08219700	chr8:58056026	NA	0.57	7.82	0.36	4.3e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs427394	0.582	rs274665	chr5:6707981	C/T	cg12316010	chr5:6737918	POLS	0.36	6.87	0.32	2.26e-11	Menopause (age at onset);
LUAD	cis	rs9581857	0.725	rs117947621	chr13:28022267	T/C	cg22138327	chr13:27999177	GTF3A	0.9	10.53	0.46	3.61e-23	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7107174	0.901	rs2450140	chr11:77924388	T/C	cg19901956	chr11:77921274	USP35	-0.55	-6.97	-0.32	1.23e-11	Testicular germ cell tumor;
LUAD	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg19875535	chr5:140030758	IK	-0.48	-8.07	-0.37	7.54e-15	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs2235573	0.594	rs4821730	chr22:38441587	A/G	cg19894588	chr14:64061835	NA	0.45	6.99	0.32	1.09e-11	Glioblastoma;Glioma;
LUAD	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-7.79	-0.35	5.3e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7246657	1.000	rs34544865	chr19:37801242	G/C	cg23950597	chr19:37808831	NA	-0.65	-7.0	-0.32	9.94e-12	Coronary artery calcification;
LUAD	cis	rs117623576	0.941	rs72778747	chr10:32421518	G/T	cg03047570	chr10:32398778	NA	-0.73	-8.82	-0.39	3.13e-17	Anti-saccade response;
LUAD	cis	rs76878669	0.561	rs7115577	chr11:66172258	G/T	cg18002602	chr11:66138449	SLC29A2	-0.47	-10.1	-0.44	1.29e-21	Educational attainment (years of education);
LUAD	cis	rs1395	0.778	rs34618115	chr2:27418289	G/A	cg23587288	chr2:27483067	SLC30A3	-0.42	-7.88	-0.36	2.88e-14	Blood metabolite levels;
LUAD	cis	rs17270561	0.583	rs6908407	chr6:25703656	A/T	cg25753631	chr6:25732923	NA	0.4	7.05	0.32	7.29e-12	Iron status biomarkers;
LUAD	cis	rs12541635	0.739	rs10955412	chr8:107075592	T/C	cg10147462	chr8:107024639	NA	-0.51	-8.81	-0.39	3.18e-17	Age of smoking initiation;
LUAD	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg11833968	chr6:79620685	NA	-0.43	-8.05	-0.36	8.45e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg09021430	chr5:549028	NA	-0.69	-13.45	-0.55	1.43e-34	Lung disease severity in cystic fibrosis;
LUAD	cis	rs2806561	0.929	rs628096	chr1:23537676	C/G	cg19743168	chr1:23544995	NA	0.46	8.49	0.38	3.49e-16	Height;
LUAD	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg10556349	chr10:835070	NA	0.49	6.35	0.3	5.4e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.94e-11	Hepatitis;
LUAD	cis	rs909341	0.537	rs6011098	chr20:62398935	C/T	cg14758556	chr20:62440591	NA	-0.46	-6.79	-0.31	3.86e-11	Atopic dermatitis;
LUAD	cis	rs9560113	1.000	rs9560109	chr13:112180468	C/T	cg14154082	chr13:112174009	NA	0.37	6.92	0.32	1.64e-11	Menarche (age at onset);
LUAD	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg22681709	chr2:178499509	PDE11A	-0.41	-6.72	-0.31	5.9e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg04248312	chr19:17393744	ANKLE1	0.98	18.45	0.67	3.41e-56	Systemic lupus erythematosus;
LUAD	cis	rs7487075	0.619	rs10785629	chr12:46854727	G/A	cg23829395	chr12:46796953	NA	0.31	6.91	0.32	1.74e-11	Itch intensity from mosquito bite;
LUAD	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19717773	chr7:2847554	GNA12	-0.57	-9.65	-0.42	4.71e-20	Height;
LUAD	trans	rs8073060	0.586	rs226084	chr17:34019582	T/A	cg19694781	chr19:47549865	TMEM160	-1.22	-19.42	-0.69	1.67e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs2131877	0.956	rs57750973	chr3:194870093	T/C	cg19760965	chr3:194868843	C3orf21	0.41	6.83	0.31	3.05e-11	Non-small cell lung cancer;
LUAD	cis	rs10100465	0.961	rs7817912	chr8:118644565	C/G	cg09430518	chr8:118662568	NA	-0.31	-6.38	-0.3	4.65e-10	Leprosy;
LUAD	cis	rs300774	0.925	rs397911	chr2:147317	A/G	cg21211680	chr2:198530	NA	-0.48	-7.45	-0.34	5.44e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg11189052	chr15:85197271	WDR73	0.59	7.48	0.34	4.22e-13	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs3823572	0.564	rs2346273	chr7:133659764	A/T	cg03336402	chr7:133662267	EXOC4	-0.41	-7.59	-0.35	2.08e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.16	-0.41	2.23e-18	Life satisfaction;
LUAD	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg09065629	chr16:1709722	CRAMP1L	0.41	7.13	0.33	4.47e-12	Coronary artery disease;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11141692	chr4:111866916	NA	0.47	7.59	0.35	2.09e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg00745463	chr17:30367425	LRRC37B	-0.86	-8.53	-0.38	2.67e-16	Height;
LUAD	trans	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg07393940	chr7:158741817	NA	0.69	11.46	0.49	1.2e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.91	-0.5	2.11e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6835098	0.924	rs13125240	chr4:174151619	T/C	cg27433088	chr4:174089019	GALNT7	-0.39	-7.03	-0.32	8.49e-12	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg04756594	chr16:24857601	SLC5A11	0.66	11.0	0.47	6.45e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg10792982	chr14:105748885	BRF1	0.41	8.93	0.4	1.32e-17	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7193541	0.662	rs8058133	chr16:74657485	A/T	cg01733217	chr16:74700730	RFWD3	0.67	12.59	0.52	4.45e-31	Multiple myeloma;
LUAD	trans	rs7395662	0.963	rs11499897	chr11:48717866	G/A	cg00717180	chr2:96193071	NA	0.39	7.23	0.33	2.27e-12	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg05340658	chr4:99064831	C4orf37	0.54	9.12	0.41	2.96e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg25894440	chr7:65020034	NA	-0.63	-6.71	-0.31	6.35e-11	Gout;
LUAD	cis	rs758324	0.898	rs11958749	chr5:131166014	T/C	cg25547332	chr5:131281432	NA	0.43	6.64	0.31	9.74e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs2067615	0.560	rs2044304	chr12:107184363	T/G	cg15890332	chr12:107067104	RFX4	0.39	8.42	0.38	6.02e-16	Heart rate;
LUAD	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg27535305	chr1:53392650	SCP2	-0.42	-8.63	-0.39	1.25e-16	Monocyte count;
LUAD	cis	rs4852324	0.536	rs71418714	chr2:74219886	G/C	cg01017244	chr2:74357527	NA	0.8	7.31	0.33	1.35e-12	Systemic lupus erythematosus;
LUAD	cis	rs2294693	0.945	rs9394755	chr6:41006680	C/T	cg14769373	chr6:40998127	UNC5CL	0.52	8.16	0.37	3.79e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11112613	0.713	rs11112587	chr12:105941285	G/A	cg03607813	chr12:105948248	NA	0.81	13.49	0.55	9.76e-35	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg06060754	chr5:176797920	RGS14	-0.56	-9.53	-0.42	1.24e-19	Urate levels in lean individuals;
LUAD	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg27170947	chr2:26402098	FAM59B	0.81	10.66	0.46	1.15e-23	Gut microbiome composition (summer);
LUAD	cis	rs6545883	0.929	rs1186700	chr2:61663372	A/C	cg15711740	chr2:61764176	XPO1	-0.41	-6.48	-0.3	2.51e-10	Tuberculosis;
LUAD	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.33	-17.62	-0.65	1.66e-52	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2797160	1.000	rs1612249	chr6:126014916	C/A	cg05901451	chr6:126070800	HEY2	0.45	6.71	0.31	6.22e-11	Endometrial cancer;
LUAD	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg14835575	chr10:16859367	RSU1	0.53	8.07	0.37	7.44e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg13047869	chr3:10149882	C3orf24	0.6	9.35	0.41	5.31e-19	Alzheimer's disease;
LUAD	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg08807101	chr21:30365312	RNF160	-0.43	-7.53	-0.34	3.18e-13	Dental caries;
LUAD	cis	rs1018836	0.663	rs2205151	chr8:91483468	A/C	cg16814680	chr8:91681699	NA	-0.65	-10.88	-0.47	1.82e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs79976124	0.837	rs10498840	chr6:66658513	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	10.9	0.47	1.52e-24	Type 2 diabetes;
LUAD	cis	rs447921	0.861	rs66686654	chr17:74430310	A/T	cg17201438	chr17:74438067	UBE2O	0.69	8.85	0.4	2.48e-17	Mitochondrial DNA levels;
LUAD	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg21252483	chr19:49399788	TULP2	-0.88	-14.31	-0.57	3.61e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg00933542	chr6:150070202	PCMT1	0.43	9.24	0.41	1.26e-18	Lung cancer;
LUAD	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg08885076	chr2:99613938	TSGA10	0.36	6.46	0.3	2.91e-10	Chronic sinus infection;
LUAD	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg14403583	chr14:105418241	AHNAK2	-0.43	-8.01	-0.36	1.12e-14	Rheumatoid arthritis;
LUAD	cis	rs938554	0.571	rs12509955	chr4:10024303	C/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-9.69	-0.43	3.47e-20	Blood metabolite levels;
LUAD	cis	rs873917	0.577	rs784599	chr1:40138507	A/G	cg00990022	chr1:40138052	NT5C1A	-0.44	-6.69	-0.31	7.13e-11	Amyotrophic lateral sclerosis;
LUAD	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg03609598	chr5:56110824	MAP3K1	-0.62	-8.43	-0.38	5.34e-16	Initial pursuit acceleration;
LUAD	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg06784218	chr1:46089804	CCDC17	0.53	11.49	0.49	8.58e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-9.23	-0.41	1.35e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg22117172	chr7:91764530	CYP51A1	0.35	7.91	0.36	2.29e-14	Breast cancer;
LUAD	cis	rs12431939	0.948	rs67116854	chr14:51670464	G/A	cg23942311	chr14:51606299	NA	-0.55	-7.79	-0.35	5.26e-14	Cancer;
LUAD	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg17063962	chr7:91808500	NA	0.71	12.75	0.53	9.64e-32	Breast cancer;
LUAD	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.53	-0.34	3.1e-13	Resting heart rate;
LUAD	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg23752985	chr2:85803571	VAMP8	0.34	6.54	0.3	1.74e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4824093	0.610	rs9627799	chr22:50317989	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-7.29	-0.33	1.52e-12	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18099408	chr3:52552593	STAB1	-0.45	-7.98	-0.36	1.35e-14	Electroencephalogram traits;
LUAD	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg18404041	chr3:52824283	ITIH1	0.55	9.33	0.41	6.09e-19	Schizophrenia;
LUAD	cis	rs1448094	0.802	rs7397730	chr12:86416212	T/C	cg06740227	chr12:86229804	RASSF9	0.39	7.11	0.33	4.85e-12	Major depressive disorder;
LUAD	cis	rs758324	0.947	rs6861174	chr5:131156129	A/G	cg06307176	chr5:131281290	NA	0.49	7.76	0.35	6.4e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1847202	0.826	rs13063441	chr3:72952400	A/G	cg25664220	chr3:72788482	NA	-0.42	-7.36	-0.34	9.35e-13	Motion sickness;
LUAD	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg21775007	chr8:11205619	TDH	0.49	8.53	0.38	2.7e-16	Retinal vascular caliber;
LUAD	trans	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.7	-0.39	7.5e-17	Endometrial cancer;
LUAD	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs9462027	0.628	rs9296129	chr6:34774414	C/G	cg07306190	chr6:34760872	UHRF1BP1	0.35	8.67	0.39	9.25e-17	Systemic lupus erythematosus;
LUAD	cis	rs684232	0.666	rs2657629	chr17:602261	G/T	cg12384639	chr17:618140	VPS53	0.48	8.49	0.38	3.55e-16	Prostate cancer;
LUAD	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg06112835	chr11:68658793	MRPL21	0.5	8.85	0.4	2.36e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg06453172	chr10:134556979	INPP5A	-0.67	-10.05	-0.44	1.87e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.73	0.31	5.43e-11	Menarche (age at onset);
LUAD	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26314531	chr2:26401878	FAM59B	0.76	10.12	0.44	1.1e-21	Gut microbiome composition (summer);
LUAD	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg11859384	chr17:80120422	CCDC57	-0.5	-9.12	-0.41	3.08e-18	Life satisfaction;
LUAD	cis	rs80207740	0.838	rs17581959	chr8:21807757	A/G	cg25597362	chr8:21767310	DOK2	-0.64	-8.02	-0.36	1.06e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg00280220	chr17:61926910	NA	0.37	7.17	0.33	3.39e-12	Prudent dietary pattern;
LUAD	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg10468373	chr11:64009913	FKBP2	0.54	6.71	0.31	6.09e-11	Mean platelet volume;
LUAD	cis	rs9487051	0.735	rs1761608	chr6:109517706	G/A	cg01475377	chr6:109611718	NA	-0.39	-7.33	-0.34	1.14e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg02038168	chr22:39784481	NA	-0.52	-8.93	-0.4	1.31e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg22683308	chr4:1340831	KIAA1530	-0.4	-6.52	-0.3	2e-10	Longevity;
LUAD	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg23245007	chr3:195682326	NA	0.39	6.58	0.3	1.37e-10	Pancreatic cancer;
LUAD	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg07080864	chr8:57359956	PENK	-0.37	-6.61	-0.31	1.14e-10	Obesity-related traits;
LUAD	trans	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.91	-0.36	2.22e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7043114	0.507	rs10992291	chr9:95033009	T/C	cg14631576	chr9:95140430	CENPP	-0.41	-8.33	-0.38	1.16e-15	Height;
LUAD	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg05966235	chr16:28915196	ATP2A1	0.47	7.63	0.35	1.52e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg12016809	chr21:47604291	C21orf56	0.66	11.67	0.49	1.79e-27	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08219700	chr8:58056026	NA	0.62	8.82	0.39	3.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg25251562	chr2:3704773	ALLC	0.41	7.09	0.33	5.75e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.14	0.37	4.46e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7833986	1.000	rs72654002	chr8:57095939	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.76	10.2	0.44	5.57e-22	Height;
LUAD	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.75	-12.51	-0.52	8.92e-31	Primary sclerosing cholangitis;
LUAD	cis	rs2046867	0.818	rs7620212	chr3:72778610	C/T	cg25664220	chr3:72788482	NA	-0.7	-12.58	-0.52	4.89e-31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg21427119	chr20:30132790	HM13	-0.6	-9.06	-0.4	4.94e-18	Mean corpuscular hemoglobin;
LUAD	cis	rs7833986	0.534	rs17813240	chr8:56925791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.96	15.95	0.61	3.56e-45	Height;
LUAD	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg03806693	chr22:41940476	POLR3H	0.53	7.57	0.35	2.3e-13	Vitiligo;
LUAD	cis	rs593982	0.920	rs487264	chr11:65481465	A/C	cg08755490	chr11:65554678	OVOL1	1.16	13.95	0.56	1.2e-36	Atopic dermatitis;
LUAD	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-10.43	-0.45	7.97e-23	Schizophrenia;
LUAD	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg02428538	chr16:24856791	SLC5A11	-0.49	-6.92	-0.32	1.71e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg23533926	chr12:111358616	MYL2	-0.4	-6.88	-0.32	2.22e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg27446573	chr6:127587934	RNF146	0.43	6.39	0.3	4.35e-10	Breast cancer;
LUAD	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg07570687	chr10:102243282	WNT8B	-0.43	-6.66	-0.31	8.34e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.21	-0.41	1.53e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg07828340	chr4:882639	GAK	1.06	10.89	0.47	1.66e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg03433033	chr1:76189801	ACADM	0.77	12.16	0.51	2.26e-29	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg11189052	chr15:85197271	WDR73	0.68	8.92	0.4	1.38e-17	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs80319144	1.000	rs75006818	chr2:159263874	C/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.96	0.32	1.28e-11	Restless legs syndrome;
LUAD	cis	rs250677	0.522	rs10040598	chr5:148365720	C/A	cg12140854	chr5:148520817	ABLIM3	0.57	9.0	0.4	7.58e-18	Breast cancer;
LUAD	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-23.47	-0.75	1.31e-78	Height;
LUAD	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg01657329	chr11:68192670	LRP5	0.48	8.61	0.39	1.48e-16	Total body bone mineral density;
LUAD	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.19	-0.33	3.02e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00149659	chr3:10157352	C3orf10	0.61	8.68	0.39	8.54e-17	Alzheimer's disease;
LUAD	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.15	-0.33	3.81e-12	Total cholesterol levels;
LUAD	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.45	8.43	0.38	5.49e-16	Hemoglobin concentration;
LUAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg11062466	chr8:58055876	NA	0.65	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs5771069	0.931	rs137864	chr22:50446988	C/T	cg27467552	chr22:50353597	PIM3	-0.45	-8.1	-0.37	6e-15	Ulcerative colitis;
LUAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs72634258	0.554	rs12092614	chr1:7865710	C/T	cg26816564	chr1:7831052	VAMP3	0.65	8.94	0.4	1.22e-17	Inflammatory bowel disease;
LUAD	cis	rs4853525	0.522	rs10490538	chr2:191590066	C/T	cg11845111	chr2:191398756	TMEM194B	0.46	7.39	0.34	7.89e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	trans	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-8.93	-0.4	1.27e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg06558623	chr16:89946397	TCF25	1.18	10.68	0.46	1e-23	Skin colour saturation;
LUAD	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg13722127	chr7:150037890	RARRES2	0.43	7.02	0.32	8.72e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg07195577	chr17:27052828	TLCD1	-0.45	-6.37	-0.3	4.95e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2742234	0.590	rs2503863	chr10:43667398	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.52	-8.9	-0.4	1.67e-17	Hirschsprung disease;
LUAD	cis	rs7851660	0.935	rs10818124	chr9:100603008	C/T	cg13688889	chr9:100608707	NA	-0.52	-9.61	-0.42	6.33e-20	Strep throat;
LUAD	cis	rs67311347	0.594	rs12629111	chr3:40285351	T/C	cg09455208	chr3:40491958	NA	0.43	8.58	0.39	1.82e-16	Renal cell carcinoma;
LUAD	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg15128208	chr22:42549153	NA	0.43	6.85	0.32	2.63e-11	Birth weight;
LUAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg04082016	chr2:20871401	NA	-0.46	-8.51	-0.38	3.11e-16	Abdominal aortic aneurysm;
LUAD	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg23840854	chr1:161414152	NA	-0.87	-11.31	-0.48	4.33e-26	Rheumatoid arthritis;
LUAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-7.25	-0.33	2.05e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg11502198	chr6:26597334	ABT1	0.66	11.38	0.48	2.33e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs16866061	1.000	rs16866061	chr2:225439844	A/G	cg12698349	chr2:225449008	CUL3	0.78	13.91	0.56	1.66e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg18200150	chr17:30822561	MYO1D	0.44	8.24	0.37	2.22e-15	Schizophrenia;
LUAD	cis	rs2040771	0.804	rs2073754	chr22:19221406	G/T	cg02655711	chr22:19163373	SLC25A1	-0.55	-10.29	-0.45	2.57e-22	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs1559088	1.000	rs28803235	chr19:33561804	G/A	cg27124370	chr19:33622961	WDR88	0.45	6.89	0.32	1.99e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2901656	0.934	rs2285170	chr1:172425529	C/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.46	8.73	0.39	6.04e-17	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs250585	0.850	rs6497673	chr16:23545711	G/A	cg00143387	chr16:23521605	GGA2	-0.64	-7.82	-0.36	4.12e-14	Egg allergy;
LUAD	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg01884057	chr2:25150051	NA	0.33	6.99	0.32	1.07e-11	Body mass index;
LUAD	cis	rs2985684	0.894	rs4900927	chr14:50018741	G/T	cg04989706	chr14:50066350	PPIL5	-0.51	-7.64	-0.35	1.45e-13	Carotid intima media thickness;
LUAD	trans	rs8073060	0.586	rs7214742	chr17:33981969	C/A	cg19694781	chr19:47549865	TMEM160	-1.23	-19.31	-0.68	4.77e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01570182	chr17:44337453	NA	0.77	12.67	0.52	1.97e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs490234	0.966	rs569408	chr9:128304824	G/A	cg14078157	chr9:128172775	NA	0.38	7.09	0.33	5.68e-12	Mean arterial pressure;
LUAD	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.73	0.35	7.81e-14	Bladder cancer;
LUAD	cis	rs367943	1.000	rs348963	chr5:112819027	A/G	cg12552261	chr5:112820674	MCC	-0.58	-10.99	-0.47	6.72e-25	Type 2 diabetes;
LUAD	cis	rs1816752	0.783	rs7317439	chr13:24985077	A/T	cg02811702	chr13:24901961	NA	0.43	7.37	0.34	9.06e-13	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12144309	0.580	rs2040041	chr1:114312623	T/C	cg03325407	chr1:114423726	BCL2L15	-0.39	-6.8	-0.31	3.63e-11	Coronary artery disease;
LUAD	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg15704280	chr7:45808275	SEPT13	-0.53	-8.33	-0.38	1.14e-15	HDL cholesterol;
LUAD	cis	rs7937890	0.810	rs10734224	chr11:14424124	G/T	cg22961513	chr11:14280813	SPON1	-0.42	-8.42	-0.38	5.98e-16	Mitochondrial DNA levels;
LUAD	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg15704280	chr7:45808275	SEPT13	-1.0	-20.02	-0.7	3.34e-63	Height;
LUAD	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg00814883	chr7:100076585	TSC22D4	-0.86	-13.06	-0.54	5.26e-33	Platelet count;
LUAD	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg15445000	chr17:37608096	MED1	0.45	8.31	0.37	1.32e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs1448094	0.617	rs1502799	chr12:86474921	T/C	cg02569458	chr12:86230093	RASSF9	-0.35	-6.44	-0.3	3.17e-10	Major depressive disorder;
LUAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg08132940	chr7:1081526	C7orf50	-0.76	-10.34	-0.45	1.73e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg00898013	chr13:113819073	PROZ	-0.68	-12.2	-0.51	1.55e-29	Platelet distribution width;
LUAD	cis	rs11023332	0.706	rs11023379	chr11:14929960	C/T	cg19336497	chr11:14380999	RRAS2	-0.38	-7.21	-0.33	2.52e-12	Adiponectin levels;Vitamin D levels;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg18762849	chr10:81741832	NA	0.39	6.69	0.31	7.27e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs9905704	0.645	rs17175543	chr17:56803598	G/T	cg19466818	chr17:56409534	MIR142	-0.36	-6.89	-0.32	2.03e-11	Testicular germ cell tumor;
LUAD	trans	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-8.82	-0.39	3.07e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4523957	0.928	rs4790072	chr17:2173497	A/G	cg16513277	chr17:2031491	SMG6	-0.77	-14.65	-0.58	1.36e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	9.19	0.41	1.74e-18	Platelet count;
LUAD	cis	rs12681287	0.752	rs9283958	chr8:87253048	T/C	cg00550725	chr8:87521180	FAM82B	0.45	6.52	0.3	1.97e-10	Caudate activity during reward;
LUAD	cis	rs1395	0.813	rs11685326	chr2:27453679	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	8.59	0.39	1.66e-16	Blood metabolite levels;
LUAD	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg17747265	chr1:1875780	NA	-0.75	-18.58	-0.67	8.79e-57	Body mass index;
LUAD	trans	rs1864729	1.000	rs1431891	chr8:98282716	A/G	cg08679828	chr8:102218111	ZNF706	-0.83	-8.79	-0.39	3.88e-17	Estradiol plasma levels (breast cancer);
LUAD	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25427524	chr10:38739819	LOC399744	-0.75	-13.33	-0.54	4.25e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg06611532	chr13:114900021	NA	0.38	8.98	0.4	9.08e-18	Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03471705	chr14:81686966	GTF2A1	-0.4	-6.76	-0.31	4.63e-11	Cancer;
LUAD	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg23758822	chr17:41437982	NA	0.91	18.63	0.67	5.14e-57	Menopause (age at onset);
LUAD	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg03929089	chr4:120376271	NA	0.57	7.41	0.34	6.91e-13	Axial length;
LUAD	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg16680214	chr1:154839983	KCNN3	-0.63	-13.23	-0.54	1.11e-33	Prostate cancer;
LUAD	cis	rs1461503	0.934	rs7107560	chr11:122845380	T/C	cg27398637	chr11:122830231	C11orf63	-0.35	-6.65	-0.31	9.35e-11	Menarche (age at onset);
LUAD	cis	rs2979489	0.945	rs2979472	chr8:30291704	G/C	cg26383811	chr8:30366931	RBPMS	0.65	10.04	0.44	2.05e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs300774	0.844	rs1810329	chr2:176395	A/T	cg21211680	chr2:198530	NA	0.55	8.35	0.38	9.770000000000001e-16	Suicide attempts in bipolar disorder;
LUAD	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03934478	chr11:495069	RNH1	0.77	9.23	0.41	1.29e-18	Body mass index;
LUAD	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.47	0.3	2.68e-10	Aortic root size;
LUAD	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	7.79	0.35	5.12e-14	Parkinson's disease;
LUAD	cis	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg21775007	chr8:11205619	TDH	-0.4	-6.79	-0.31	3.86e-11	Retinal vascular caliber;
LUAD	cis	rs7640424	0.819	rs162070	chr3:107835448	G/A	cg09227934	chr3:107805635	CD47	0.49	8.62	0.39	1.36e-16	Body mass index;
LUAD	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21659725	chr3:3221576	CRBN	-0.63	-11.0	-0.47	6.25e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs7177699	0.557	rs6495333	chr15:79113215	G/A	cg00540400	chr15:79124168	NA	0.44	9.48	0.42	1.83e-19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg17724175	chr1:150552817	MCL1	0.34	7.87	0.36	3.01e-14	Melanoma;
LUAD	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg11098525	chr4:1320231	MAEA	-0.41	-6.91	-0.32	1.77e-11	Obesity-related traits;
LUAD	cis	rs73198271	0.628	rs76079102	chr8:8591553	A/T	cg01851573	chr8:8652454	MFHAS1	0.47	6.79	0.31	3.7e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg11919837	chr8:57350735	NA	-0.43	-6.52	-0.3	1.99e-10	Obesity-related traits;
LUAD	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.81	-12.29	-0.51	6.52e-30	Ankle injury;
LUAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg11062466	chr8:58055876	NA	0.67	9.01	0.4	7.2e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs3833788	1	rs3833788	chr12:121151062	CTCTCTTG/C	cg21892295	chr12:121157589	UNC119B	-0.45	-8.23	-0.37	2.29e-15	Mean corpuscular hemoglobin;
LUAD	cis	rs4711350	1.000	rs2395401	chr6:33759471	T/C	cg07979401	chr6:33739406	LEMD2	-0.51	-8.39	-0.38	7.13e-16	Schizophrenia;
LUAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg09509183	chr1:209979624	IRF6	0.53	7.9	0.36	2.42e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg08213375	chr14:104286397	PPP1R13B	0.28	7.22	0.33	2.4e-12	Schizophrenia;
LUAD	cis	rs11072804	1	rs11072804	chr15:79078486	T/G	cg22753661	chr15:79092743	ADAMTS7	0.5	8.09	0.37	6.33e-15	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs6714710	0.603	rs7583868	chr2:98588372	C/A	cg26665480	chr2:98280029	ACTR1B	0.5	8.16	0.37	3.83e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg06558623	chr16:89946397	TCF25	0.71	8.07	0.37	7.5e-15	Skin colour saturation;
LUAD	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg23887609	chr12:130822674	PIWIL1	0.41	6.92	0.32	1.68e-11	Menopause (age at onset);
LUAD	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.41	0.45	9.69e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg12016809	chr21:47604291	C21orf56	0.53	9.03	0.4	6.07e-18	Testicular germ cell tumor;
LUAD	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg09065629	chr16:1709722	CRAMP1L	0.42	7.37	0.34	8.83e-13	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.55	-0.3	1.69e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg25985355	chr7:65971099	NA	-0.52	-6.56	-0.3	1.57e-10	Diabetic kidney disease;
LUAD	cis	rs367943	0.665	rs6877548	chr5:112970054	C/T	cg12552261	chr5:112820674	MCC	0.39	6.92	0.32	1.65e-11	Type 2 diabetes;
LUAD	cis	rs1997103	1.000	rs6949244	chr7:55411301	C/G	cg17469321	chr7:55412551	NA	0.67	11.39	0.48	2.05e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg02775129	chr4:119771670	NA	-0.86	-8.15	-0.37	4.09e-15	Cannabis dependence symptom count;
LUAD	cis	rs2279817	0.780	rs71644065	chr1:18001669	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.57	-8.07	-0.37	7.37e-15	Neuroticism;
LUAD	cis	rs7520050	0.966	rs785464	chr1:46523089	T/C	cg06784218	chr1:46089804	CCDC17	-0.3	-6.48	-0.3	2.57e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14019695	chr9:139328340	INPP5E	-0.53	-10.61	-0.46	1.73e-23	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs12122100	0.837	rs12142004	chr1:146506676	T/C	cg03526459	chr1:146549940	NA	-0.36	-6.83	-0.32	3.03e-11	HIV-1 control;
LUAD	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg01097406	chr16:89675127	NA	0.38	8.35	0.38	9.55e-16	Hemoglobin concentration;
LUAD	cis	rs2281845	0.791	rs1325313	chr1:201076167	C/T	cg22815214	chr1:201083145	CACNA1S	0.48	8.04	0.36	9.33e-15	Permanent tooth development;
LUAD	cis	rs727505	1.000	rs10241173	chr7:124453258	A/G	cg23710748	chr7:124431027	NA	-0.43	-9.35	-0.41	5.31e-19	Lewy body disease;
LUAD	cis	rs7851660	0.967	rs7043885	chr9:100596439	C/T	cg13688889	chr9:100608707	NA	-0.52	-9.6	-0.42	6.95e-20	Strep throat;
LUAD	cis	rs7771547	0.573	rs664370	chr6:36393816	A/G	cg07856975	chr6:36356162	ETV7	0.48	7.61	0.35	1.82e-13	Platelet distribution width;
LUAD	cis	rs9512730	0.906	rs4771136	chr13:28070769	C/A	cg04070771	chr13:27998621	GTF3A	0.49	7.15	0.33	3.96e-12	Schizophrenia;
LUAD	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.89e-14	Depression;
LUAD	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg17366294	chr4:99064904	C4orf37	0.48	8.4	0.38	7.08e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs5756391	0.568	rs2075940	chr22:37318446	G/A	cg16356956	chr22:37317934	CSF2RB	0.31	6.5	0.3	2.22e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.18	0.33	3.1e-12	Obesity-related traits;
LUAD	cis	rs56161922	1.000	rs72468035	chr1:207812405	C/T	cg11752769	chr1:207818423	CR1L	-0.62	-6.38	-0.3	4.77e-10	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg06808227	chr14:105710500	BRF1	-0.42	-6.51	-0.3	2.09e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.51	9.04	0.4	5.62e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.58e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2235649	0.798	rs9932875	chr16:1848012	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.43	-6.95	-0.32	1.4e-11	Blood metabolite levels;
LUAD	cis	rs938554	0.571	rs12509955	chr4:10024303	C/T	cg00071950	chr4:10020882	SLC2A9	-0.6	-9.81	-0.43	1.35e-20	Blood metabolite levels;
LUAD	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg18232548	chr7:50535776	DDC	-0.7	-12.32	-0.51	5.29e-30	Systemic sclerosis;
LUAD	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg14092988	chr3:52407081	DNAH1	0.36	7.41	0.34	6.83e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg13319975	chr6:146136371	FBXO30	-0.66	-11.21	-0.48	1.04e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2625529	0.824	rs7183749	chr15:72377278	G/A	cg16672083	chr15:72433130	SENP8	-0.75	-12.56	-0.52	5.84e-31	Red blood cell count;
LUAD	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.98	0.32	1.18e-11	Colorectal cancer;
LUAD	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg12740337	chr6:28058973	ZSCAN12L1	0.25	6.42	0.3	3.66e-10	Parkinson's disease;
LUAD	cis	rs7731657	0.537	rs10478958	chr5:130333536	C/A	cg08523029	chr5:130500466	HINT1	0.56	7.35	0.34	1.03e-12	Fasting plasma glucose;
LUAD	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg13319975	chr6:146136371	FBXO30	-0.61	-10.41	-0.45	9.87e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg27535305	chr1:53392650	SCP2	0.46	9.12	0.41	3e-18	Monocyte count;
LUAD	cis	rs17401966	1.000	rs12118323	chr1:10469641	A/G	cg19773385	chr1:10388646	KIF1B	-0.41	-6.64	-0.31	9.67e-11	Hepatocellular carcinoma;
LUAD	cis	rs7589728	0.748	rs35051888	chr2:88482258	G/A	cg18490616	chr2:88469792	THNSL2	0.74	7.57	0.35	2.35e-13	Plasma clusterin levels;
LUAD	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.39	8.04	0.36	9.22e-15	Hemoglobin concentration;
LUAD	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg11189052	chr15:85197271	WDR73	0.68	8.98	0.4	8.85e-18	Schizophrenia;
LUAD	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg14582100	chr15:45693742	SPATA5L1	0.64	12.5	0.52	9.64e-31	Homoarginine levels;
LUAD	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg02428538	chr16:24856791	SLC5A11	0.48	6.99	0.32	1.08e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg22442454	chr1:209979470	IRF6	0.55	6.57	0.3	1.46e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.6	0.52	3.99e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg16797656	chr11:68205561	LRP5	0.47	9.23	0.41	1.31e-18	Total body bone mineral density;
LUAD	cis	rs9858542	0.537	rs9818758	chr3:49382925	G/A	cg00383909	chr3:49044727	WDR6	0.66	8.2	0.37	2.96e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg03733263	chr8:22462867	KIAA1967	0.72	11.49	0.49	8.56e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg27490568	chr2:178487706	NA	0.39	6.41	0.3	3.96e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg09085632	chr11:111637200	PPP2R1B	0.63	9.31	0.41	6.78e-19	Primary sclerosing cholangitis;
LUAD	cis	rs9796	0.558	rs11855102	chr15:41513257	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.44	-7.94	-0.36	1.89e-14	Menopause (age at onset);
LUAD	cis	rs6761276	0.649	rs3827763	chr2:113831289	C/T	cg09040174	chr2:113837401	NA	-0.64	-10.1	-0.44	1.3e-21	Protein quantitative trait loci;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg02796970	chr10:39023768	NA	-0.47	-7.53	-0.34	3.18e-13	Menopause (age at onset);
LUAD	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.21e-19	Life satisfaction;
LUAD	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg12311346	chr5:56204834	C5orf35	0.72	11.43	0.49	1.54e-26	Initial pursuit acceleration;
LUAD	cis	rs10899021	1.000	rs11236186	chr11:74362865	G/A	cg25880958	chr11:74394337	NA	-0.62	-8.26	-0.37	1.84e-15	Response to metformin (IC50);
LUAD	cis	rs17253792	0.731	rs74829671	chr14:56112759	G/C	cg01858014	chr14:56050164	KTN1	-0.61	-6.45	-0.3	3.13e-10	Putamen volume;
LUAD	cis	rs7149337	0.836	rs34953083	chr14:51672432	A/G	cg23942311	chr14:51606299	NA	0.85	19.57	0.69	3.33e-61	Cancer;
LUAD	cis	rs1451375	0.617	rs2060763	chr7:50542359	G/A	cg18232548	chr7:50535776	DDC	-0.65	-9.16	-0.41	2.21e-18	Malaria;
LUAD	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg24154853	chr7:158122151	PTPRN2	0.59	11.83	0.5	4.37e-28	Calcium levels;
LUAD	cis	rs714027	0.967	rs193477	chr22:30451486	C/T	cg00539347	chr22:30592296	NA	-0.29	-6.87	-0.32	2.32e-11	Lymphocyte counts;
LUAD	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.5	0.3	2.26e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs6906287	0.647	rs67832971	chr6:118832205	C/T	cg05564266	chr6:118973597	C6orf204	0.35	7.43	0.34	6.24e-13	Electrocardiographic conduction measures;
LUAD	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg17200465	chr3:40428508	ENTPD3	0.27	6.47	0.3	2.76e-10	Renal cell carcinoma;
LUAD	cis	rs12208915	0.559	rs4706738	chr6:79514153	A/G	cg05283184	chr6:79620031	NA	0.42	7.38	0.34	8.6e-13	Left atrial antero-posterior diameter;
LUAD	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg07570687	chr10:102243282	WNT8B	0.45	6.92	0.32	1.68e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9487051	0.724	rs11966072	chr6:109634828	A/G	cg01475377	chr6:109611718	NA	-0.4	-6.45	-0.3	3.03e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs7731657	0.537	rs1018948	chr5:130290958	C/A	cg08523029	chr5:130500466	HINT1	-0.58	-7.53	-0.34	3.18e-13	Fasting plasma glucose;
LUAD	cis	rs4372836	0.729	rs7567861	chr2:29035849	C/T	cg09522027	chr2:28974177	PPP1CB	-0.69	-12.66	-0.52	2.35e-31	Body mass index;
LUAD	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg17911788	chr17:44343683	NA	-0.48	-6.9	-0.32	1.9e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg02527881	chr3:46936655	PTH1R	-0.51	-10.39	-0.45	1.11e-22	Colorectal cancer;
LUAD	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.8	-0.53	6.09e-32	Breast cancer;
LUAD	cis	rs68170813	0.641	rs77397573	chr7:107006892	G/A	cg02696742	chr7:106810147	HBP1	-0.78	-10.57	-0.46	2.4e-23	Coronary artery disease;
LUAD	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.73	-11.96	-0.5	1.39e-28	Primary sclerosing cholangitis;
LUAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.61	8.07	0.37	7.33e-15	Renal function-related traits (BUN);
LUAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08280861	chr8:58055591	NA	0.61	8.0	0.36	1.18e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg25894440	chr7:65020034	NA	-0.65	-7.05	-0.32	7.26e-12	Diabetic kidney disease;
LUAD	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg25456477	chr12:86230367	RASSF9	0.31	6.38	0.3	4.57e-10	Major depressive disorder;
LUAD	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg10639395	chr11:8710044	RPL27A	0.34	6.62	0.31	1.1e-10	Hemoglobin concentration;
LUAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg15242686	chr22:24348715	GSTTP1	-0.44	-7.63	-0.35	1.62e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg03929089	chr4:120376271	NA	-0.91	-17.14	-0.64	2.21e-50	Coronary artery disease;
LUAD	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg16797656	chr11:68205561	LRP5	0.52	11.19	0.48	1.17e-25	Total body bone mineral density;
LUAD	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg01851573	chr8:8652454	MFHAS1	0.43	7.88	0.36	2.89e-14	Mood instability;
LUAD	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg11915388	chr22:42470451	FAM109B	0.41	7.36	0.34	9.67e-13	Schizophrenia;
LUAD	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg01689657	chr7:91764605	CYP51A1	-0.3	-7.29	-0.33	1.58e-12	Breast cancer;
LUAD	cis	rs6500395	1.000	rs55671623	chr16:48631154	A/G	cg04672837	chr16:48644449	N4BP1	0.39	6.69	0.31	6.99e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.69	11.4	0.48	1.99e-26	Mean corpuscular volume;
LUAD	cis	rs13190036	0.551	rs11957608	chr5:176655345	T/C	cg06733329	chr5:176740039	MXD3	0.45	6.67	0.31	8.01e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	cis	rs240764	0.817	rs240113	chr6:101058886	G/A	cg09795085	chr6:101329169	ASCC3	0.44	7.69	0.35	1.04e-13	Neuroticism;
LUAD	cis	rs315934	0.664	rs11693683	chr2:113850653	T/A	cg09040174	chr2:113837401	NA	0.61	7.09	0.33	5.76e-12	Dysmenorrheic pain;
LUAD	cis	rs10465746	0.935	rs11580836	chr1:84333310	C/T	cg10977910	chr1:84465055	TTLL7	0.5	8.19	0.37	3.05e-15	Obesity-related traits;
LUAD	cis	rs17095355	1.000	rs13377046	chr10:111729228	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.65	-8.88	-0.4	1.91e-17	Biliary atresia;
LUAD	cis	rs7737355	0.947	rs244736	chr5:130816178	T/C	cg06307176	chr5:131281290	NA	0.51	8.22	0.37	2.45e-15	Life satisfaction;
LUAD	cis	rs9341808	0.718	rs9352803	chr6:80864667	G/T	cg08355045	chr6:80787529	NA	0.55	9.81	0.43	1.3e-20	Sitting height ratio;
LUAD	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg08601574	chr20:25228251	PYGB	0.47	8.67	0.39	9.07e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs735539	0.645	rs9552253	chr13:21202350	T/C	cg27499820	chr13:21296301	IL17D	0.52	8.66	0.39	1.04e-16	Dental caries;
LUAD	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg00603274	chr11:61596626	FADS2	0.41	7.01	0.32	9.29e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.4	0.3	4.19e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs62238980	0.614	rs117161237	chr22:32501630	C/T	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg11833968	chr6:79620685	NA	-0.42	-7.87	-0.36	2.92e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	0.892	rs9667579	chr11:48730148	C/T	cg00717180	chr2:96193071	NA	0.39	7.23	0.33	2.27e-12	HDL cholesterol;
LUAD	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg14582100	chr15:45693742	SPATA5L1	0.63	12.28	0.51	7.24e-30	Homoarginine levels;
LUAD	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg25985355	chr7:65971099	NA	-0.38	-6.89	-0.32	2.02e-11	Aortic root size;
LUAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg18402987	chr7:1209562	NA	0.81	9.91	0.43	6.12e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg07636037	chr3:49044803	WDR6	0.57	10.75	0.46	5.56e-24	Parkinson's disease;
LUAD	trans	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg06437703	chr8:37914619	EIF4EBP1	0.56	9.83	0.43	1.15e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg27572855	chr1:25598939	RHD	0.55	12.21	0.51	1.36e-29	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.67	-8.82	-0.39	2.98e-17	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs738321	0.762	rs5995543	chr22:38579026	G/A	cg17652424	chr22:38574118	PLA2G6	-0.29	-7.65	-0.35	1.35e-13	Breast cancer;
LUAD	cis	rs714027	1.000	rs714027	chr22:30577771	A/G	cg11564601	chr22:30592435	NA	0.38	8.24	0.37	2.13e-15	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg17105886	chr17:28927953	LRRC37B2	0.78	7.76	0.35	6.35e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs9354308	0.866	rs2802054	chr6:66544766	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.52	8.07	0.37	7.58e-15	Metabolite levels;
LUAD	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg00981070	chr1:2046702	PRKCZ	-0.34	-6.82	-0.31	3.08e-11	Height;
LUAD	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg17366294	chr4:99064904	C4orf37	0.66	12.76	0.53	9.29e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4820539	1.000	rs1051875	chr22:23466031	G/A	cg14186256	chr22:23484241	RTDR1	0.47	8.2	0.37	3e-15	Bone mineral density;
LUAD	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs2412208	0.609	rs10746465	chr1:7107231	C/A	cg20434152	chr1:7120926	CAMTA1	-0.34	-7.74	-0.35	7.43e-14	Survival in sporadic amyotrophic lateral sclerosis;
LUAD	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg07636037	chr3:49044803	WDR6	0.63	12.37	0.52	3.32e-30	Parkinson's disease;
LUAD	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg04824913	chr4:887549	GAK	0.43	6.38	0.3	4.67e-10	Systemic sclerosis;
LUAD	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21659725	chr3:3221576	CRBN	0.67	11.44	0.49	1.33e-26	Intelligence (multi-trait analysis);
LUAD	trans	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg03886242	chr7:26192032	NFE2L3	0.44	7.38	0.34	8.45e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7072216	0.770	rs1061115	chr10:100177049	G/A	cg26618903	chr10:100175079	PYROXD2	-0.34	-7.58	-0.35	2.21e-13	Metabolite levels;
LUAD	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg07741184	chr6:167504864	NA	0.31	7.47	0.34	4.74e-13	Crohn's disease;
LUAD	cis	rs4356932	1.000	rs4619915	chr4:76955201	A/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.37	-6.63	-0.31	1.03e-10	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	9.84	0.43	1.06e-20	Ileal carcinoids;
LUAD	cis	rs1975974	0.511	rs66766425	chr17:21755307	G/T	cg18423549	chr17:21743878	NA	-0.84	-14.09	-0.57	3.11e-37	Psoriasis;
LUAD	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.02e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11048434	0.636	rs12815310	chr12:9059934	A/G	cg23795048	chr12:9217529	LOC144571	0.41	7.33	0.34	1.14e-12	Sjögren's syndrome;
LUAD	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg15704280	chr7:45808275	SEPT13	-0.53	-8.33	-0.38	1.12e-15	HDL cholesterol;
LUAD	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg05425664	chr17:57184151	TRIM37	0.43	7.8	0.35	4.89e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg14343924	chr8:8086146	FLJ10661	0.41	6.54	0.3	1.74e-10	Systemic lupus erythematosus;
LUAD	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg15997130	chr1:24165203	NA	-0.42	-7.1	-0.33	5.33e-12	Immature fraction of reticulocytes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23939166	chr14:55032812	NA	-0.4	-6.55	-0.3	1.63e-10	Cancer;
LUAD	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg00316803	chr15:76480434	C15orf27	0.41	6.4	0.3	4.2e-10	Blood metabolite levels;
LUAD	cis	rs55665837	0.922	rs12287212	chr11:14449861	C/A	cg19336497	chr11:14380999	RRAS2	-0.5	-10.17	-0.44	6.84e-22	Vitamin D levels;
LUAD	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg18806716	chr10:30721971	MAP3K8	0.63	12.41	0.52	2.23e-30	Inflammatory bowel disease;
LUAD	cis	rs708547	0.671	rs1718863	chr4:57887586	G/T	cg00922110	chr4:57842668	C4orf14	-0.44	-8.13	-0.37	4.7e-15	Response to bleomycin (chromatid breaks);
LUAD	trans	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg01620082	chr3:125678407	NA	-0.45	-6.71	-0.31	6.45e-11	Depression;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18491775	chr10:76586186	MYST4	-0.46	-7.17	-0.33	3.3e-12	Height;
LUAD	cis	rs12208915	0.848	rs9359351	chr6:79492533	A/G	cg05283184	chr6:79620031	NA	0.51	6.8	0.31	3.55e-11	Left atrial antero-posterior diameter;
LUAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg22907277	chr7:1156413	C7orf50	0.68	8.04	0.36	9.36e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11229555	0.574	rs11229454	chr11:58203682	T/C	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-14.84	-0.59	2.04e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg08999081	chr20:33150536	PIGU	0.6	12.74	0.53	1.12e-31	Glomerular filtration rate (creatinine);
LUAD	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.74	0.31	5.34e-11	Mood instability;
LUAD	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.43	-0.34	5.94e-13	Type 2 diabetes;
LUAD	cis	rs7582720	1.000	rs72932574	chr2:203866336	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.28	0.41	8.55e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg20203395	chr5:56204925	C5orf35	-0.83	-11.88	-0.5	2.64e-28	Initial pursuit acceleration;
LUAD	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg01689657	chr7:91764605	CYP51A1	-0.3	-7.29	-0.33	1.58e-12	Breast cancer;
LUAD	cis	rs4523957	0.583	rs7212589	chr17:2042393	A/G	cg16513277	chr17:2031491	SMG6	-0.98	-20.08	-0.7	1.79e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.21	0.33	2.6e-12	Menopause (age at onset);
LUAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11051970	0.589	rs2931550	chr12:32542033	T/C	cg24626660	chr12:32551988	NA	0.3	6.39	0.3	4.47e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg20126980	chr7:130080915	TSGA14	-0.72	-6.8	-0.31	3.55e-11	Type 2 diabetes;
LUAD	cis	rs3736594	0.722	rs12993377	chr2:27952767	G/C	cg27432699	chr2:27873401	GPN1	-0.43	-6.69	-0.31	7.24e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs7671266	0.589	rs10938772	chr4:10375328	A/G	cg00071950	chr4:10020882	SLC2A9	-0.42	-6.41	-0.3	3.86e-10	Cardiovascular disease risk factors;
LUAD	cis	rs17092148	0.636	rs6058107	chr20:33288546	T/C	cg16810054	chr20:33298113	TP53INP2	-0.44	-7.78	-0.35	5.42e-14	Neuroticism;
LUAD	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06028808	chr11:68637592	NA	0.49	8.08	0.37	6.96e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg12310025	chr6:25882481	NA	-0.53	-7.94	-0.36	1.8e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg19622623	chr12:86230825	RASSF9	-0.44	-7.81	-0.35	4.68e-14	Major depressive disorder;
LUAD	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03517284	chr6:25882590	NA	-0.4	-6.53	-0.3	1.93e-10	Height;
LUAD	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg18105134	chr13:113819100	PROZ	-0.86	-15.04	-0.59	3.06e-41	Platelet distribution width;
LUAD	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-7.8	-0.35	4.98e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs9348721	0.562	rs9393716	chr6:26376868	A/G	cg01620082	chr3:125678407	NA	-0.54	-6.76	-0.31	4.46e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg06753367	chr22:24256600	NA	-0.41	-7.6	-0.35	1.92e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg25437947	chr8:17941982	ASAH1	-0.68	-6.84	-0.32	2.82e-11	Type 2 diabetes;
LUAD	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg02018176	chr4:1364513	KIAA1530	-0.58	-10.44	-0.45	7.59e-23	Obesity-related traits;
LUAD	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg06671706	chr8:8559999	CLDN23	0.66	11.3	0.48	4.72e-26	Obesity-related traits;
LUAD	trans	rs12200782	1.000	rs3800304	chr6:26598798	G/A	cg08851530	chr6:28072375	NA	0.72	6.59	0.31	1.28e-10	Small cell lung carcinoma;
LUAD	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg13770153	chr20:60521292	NA	-0.58	-9.09	-0.4	3.91e-18	Body mass index;
LUAD	cis	rs6062509	0.895	rs55946717	chr20:62363869	G/A	cg21849932	chr20:62369462	LIME1	-0.46	-7.29	-0.33	1.54e-12	Prostate cancer;
LUAD	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg11189052	chr15:85197271	WDR73	-0.63	-10.39	-0.45	1.11e-22	P wave terminal force;
LUAD	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06028808	chr11:68637592	NA	0.45	7.33	0.34	1.16e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg13319975	chr6:146136371	FBXO30	0.63	10.65	0.46	1.24e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1975974	1.000	rs4889703	chr17:21721663	T/C	cg18423549	chr17:21743878	NA	-0.77	-13.55	-0.55	5.19e-35	Psoriasis;
LUAD	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06112835	chr11:68658793	MRPL21	0.51	9.24	0.41	1.23e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg18932078	chr1:2524107	MMEL1	-0.37	-7.03	-0.32	8.42e-12	Ulcerative colitis;
LUAD	trans	rs3857536	0.813	rs7771716	chr6:66946769	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	trans	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg04775059	chr7:64541387	NA	0.5	6.72	0.31	5.9e-11	Aortic root size;
LUAD	cis	rs6495367	0.803	rs2870111	chr15:79403585	C/T	cg17916960	chr15:79447300	NA	0.37	7.01	0.32	9.66e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs4285028	0.948	rs12497349	chr3:121708517	T/C	cg11130432	chr3:121712080	ILDR1	-0.58	-8.41	-0.38	6.48e-16	Multiple sclerosis;
LUAD	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg08219700	chr8:58056026	NA	0.62	7.79	0.35	5.25e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs76419734	0.558	rs17035915	chr4:106520435	T/A	cg05309399	chr4:106552544	FLJ20184	-0.54	-6.57	-0.3	1.44e-10	Post bronchodilator FEV1;
LUAD	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg02221750	chr19:17393354	ANKLE1	0.76	12.4	0.52	2.44e-30	Systemic lupus erythematosus;
LUAD	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg21605333	chr4:119757512	SEC24D	0.78	7.6	0.35	1.95e-13	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg07677032	chr17:61819896	STRADA	-0.52	-9.23	-0.41	1.28e-18	Prudent dietary pattern;
LUAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg23131131	chr22:24373011	LOC391322	0.57	9.51	0.42	1.45e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12144309	0.580	rs1217403	chr1:114388804	T/C	cg03325407	chr1:114423726	BCL2L15	0.39	6.8	0.31	3.51e-11	Coronary artery disease;
LUAD	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg25554036	chr4:6271136	WFS1	0.65	12.33	0.51	4.9e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.45	6.96	0.32	1.33e-11	Schizophrenia;
LUAD	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-6.91	-0.32	1.75e-11	Schizophrenia;
LUAD	cis	rs78761021	0.829	rs55973554	chr17:9793756	G/A	cg26853458	chr17:9805074	RCVRN	0.36	6.79	0.31	3.86e-11	Type 2 diabetes;
LUAD	cis	rs17102423	0.530	rs4902359	chr14:65542790	G/A	cg11161011	chr14:65562177	MAX	-0.42	-6.91	-0.32	1.76e-11	Obesity-related traits;
LUAD	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg14834391	chr1:2537342	MMEL1	-0.31	-6.56	-0.3	1.61e-10	Ulcerative colitis;
LUAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.57	-10.02	-0.44	2.34e-21	Lymphocyte counts;
LUAD	trans	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg14791747	chr16:20752902	THUMPD1	-0.49	-7.23	-0.33	2.33e-12	Pancreatic cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02942644	chr3:119217190	C3orf1	-0.38	-6.37	-0.3	4.97e-10	Cancer;
LUAD	cis	rs68170813	0.559	rs74584447	chr7:106944755	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.45	-0.45	6.74e-23	Coronary artery disease;
LUAD	cis	rs2692947	1.000	rs2692947	chr2:96674116	T/C	cg23100626	chr2:96804247	ASTL	0.3	7.78	0.35	5.54e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.44	-0.42	2.55e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06028605	chr16:24865363	SLC5A11	-0.55	-8.51	-0.38	3.01e-16	Intelligence (multi-trait analysis);
LUAD	trans	rs8129326	0.664	rs2834479	chr21:35783219	A/G	cg07474852	chr4:123073612	NA	0.51	8.19	0.37	3.1e-15	Cancer;
LUAD	cis	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05901451	chr6:126070800	HEY2	0.45	6.65	0.31	9.09e-11	Endometrial cancer;
LUAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg23131131	chr22:24373011	LOC391322	-0.59	-9.88	-0.43	7.63e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9517313	0.591	rs17574543	chr13:99172893	G/A	cg20487152	chr13:99095054	FARP1	-0.54	-9.01	-0.4	7.1e-18	Neuroticism;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11123972	chr11:68228042	SAPS3	-0.59	-7.15	-0.33	3.73e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.59	-0.31	1.29e-10	Breast cancer;
LUAD	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.14	0.33	4.2e-12	Parkinson's disease;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg18845578	chr2:240003174	HDAC4	-0.44	-7.29	-0.33	1.57e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg18252515	chr7:66147081	NA	-0.56	-6.69	-0.31	7.09e-11	Diabetic kidney disease;
LUAD	trans	rs2262909	1.000	rs2078089	chr19:22209753	A/T	cg05197062	chr11:11642011	GALNTL4	-0.54	-8.09	-0.37	6.21e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg25358565	chr5:93447407	FAM172A	0.59	6.9	0.32	1.97e-11	Diabetic retinopathy;
LUAD	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg03806693	chr22:41940476	POLR3H	-0.79	-11.15	-0.48	1.76e-25	Vitiligo;
LUAD	cis	rs939658	0.683	rs8041222	chr15:79465549	A/G	cg17916960	chr15:79447300	NA	-0.36	-6.81	-0.31	3.36e-11	Refractive error;
LUAD	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg01475377	chr6:109611718	NA	-0.55	-10.6	-0.46	1.93e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs6840360	0.615	rs12647616	chr4:152607662	G/A	cg22705602	chr4:152727874	NA	-0.48	-8.94	-0.4	1.22e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7851660	0.809	rs7044799	chr9:100665393	A/T	cg13688889	chr9:100608707	NA	-0.54	-9.16	-0.41	2.34e-18	Strep throat;
LUAD	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg11833968	chr6:79620685	NA	0.42	7.85	0.36	3.38e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg07917127	chr4:99064746	C4orf37	0.42	6.96	0.32	1.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg22868518	chr11:507468	RNH1	-0.65	-6.52	-0.3	1.99e-10	Body mass index;
LUAD	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg05434287	chr7:2030229	MAD1L1	0.41	6.62	0.31	1.12e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg24558204	chr6:135376177	HBS1L	0.45	8.32	0.38	1.21e-15	Red blood cell count;
LUAD	cis	rs1816752	0.870	rs7998797	chr13:25014988	A/C	cg02811702	chr13:24901961	NA	0.45	7.88	0.36	2.72e-14	Obesity-related traits;
LUAD	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg21709803	chr11:61594965	FADS2	-0.38	-6.9	-0.32	1.89e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs9549367	0.588	rs9549360	chr13:113893032	C/G	cg00898013	chr13:113819073	PROZ	-0.58	-7.73	-0.35	7.83e-14	Platelet distribution width;
LUAD	cis	rs9807989	0.507	rs1420105	chr2:103035119	A/G	cg03938978	chr2:103052716	IL18RAP	0.45	10.4	0.45	1.08e-22	Asthma;
LUAD	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg19901468	chr14:105411992	AHNAK2	-0.51	-9.92	-0.43	5.59e-21	Rheumatoid arthritis;
LUAD	trans	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg06606381	chr12:133084897	FBRSL1	-1.23	-10.79	-0.46	3.73e-24	Depression;
LUAD	trans	rs1997103	0.954	rs6953004	chr7:55411919	G/A	cg20935933	chr6:143382018	AIG1	0.53	7.42	0.34	6.65e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg13902645	chr11:5959945	NA	-0.52	-9.21	-0.41	1.54e-18	DNA methylation (variation);
LUAD	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-7.81	-0.36	4.49e-14	Lung cancer;
LUAD	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg01416388	chr22:39784598	NA	-0.51	-8.66	-0.39	1.01e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg22683308	chr4:1340831	KIAA1530	-0.41	-6.66	-0.31	8.72e-11	Longevity;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05886006	chr1:161359784	NA	-0.42	-7.22	-0.33	2.42e-12	Height;
LUAD	cis	rs1451375	0.607	rs7807335	chr7:50631862	A/C	cg18232548	chr7:50535776	DDC	-0.49	-6.9	-0.32	1.86e-11	Malaria;
LUAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg10729496	chr3:10149963	C3orf24	0.64	9.65	0.42	4.77e-20	Alzheimer's disease;
LUAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.62	8.39	0.38	7.53e-16	Renal function-related traits (BUN);
LUAD	trans	rs7712671	0.840	rs11241418	chr5:116527405	C/T	cg13247069	chr12:49961998	MCRS1	0.41	6.68	0.31	7.46e-11	Schizophrenia;
LUAD	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg25767906	chr1:53392781	SCP2	0.41	7.53	0.34	3e-13	Monocyte count;
LUAD	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg21918786	chr6:109611834	NA	-0.57	-10.72	-0.46	7.24e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs10857712	0.904	rs36118799	chr10:135222369	T/G	cg01444801	chr10:135216882	MTG1	-0.56	-7.48	-0.34	4.24e-13	Systemic lupus erythematosus;
LUAD	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.59	-0.31	1.33e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg11645453	chr3:52864694	ITIH4	-0.38	-7.44	-0.34	5.66e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg20135002	chr11:47629003	NA	-0.4	-7.02	-0.32	9.17e-12	Subjective well-being;
LUAD	cis	rs2115630	0.936	rs6496318	chr15:85215229	C/T	cg11189052	chr15:85197271	WDR73	-0.64	-10.63	-0.46	1.46e-23	P wave terminal force;
LUAD	cis	rs10089	0.552	rs11955148	chr5:127557814	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.47	6.45	0.3	3.09e-10	Ileal carcinoids;
LUAD	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg05673287	chr15:77411982	SGK269	-0.42	-7.2	-0.33	2.86e-12	Type 2 diabetes;
LUAD	cis	rs17169635	0.524	rs10231387	chr7:134545091	T/G	cg07876788	chr7:134849633	TMEM140	-0.4	-6.8	-0.31	3.6e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.02	0.32	8.9e-12	Hypertriglyceridemia;
LUAD	trans	rs587242	1.000	rs722155	chr1:96906374	A/G	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-7.79	-0.35	5.38e-14	Neuroticism;
LUAD	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg08798685	chr6:27730294	NA	-0.4	-6.49	-0.3	2.38e-10	Parkinson's disease;
LUAD	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg24397884	chr7:158709396	WDR60	-0.69	-9.04	-0.4	5.53e-18	Height;
LUAD	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.64	-0.52	2.77e-31	Breast cancer;
LUAD	cis	rs2880765	0.835	rs11638498	chr15:86023018	T/C	cg13263323	chr15:86062960	AKAP13	-0.48	-8.92	-0.4	1.38e-17	Coronary artery disease;
LUAD	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg12935359	chr14:103987150	CKB	-0.46	-7.42	-0.34	6.67e-13	Body mass index;
LUAD	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg05590025	chr7:65112418	INTS4L2	0.74	7.87	0.36	3.03e-14	Diabetic kidney disease;
LUAD	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg02018176	chr4:1364513	KIAA1530	0.36	6.37	0.3	5.04e-10	Obesity-related traits;
LUAD	cis	rs12579753	0.827	rs7958100	chr12:82200782	G/A	cg07988820	chr12:82153109	PPFIA2	-0.45	-7.09	-0.33	5.72e-12	Resting heart rate;
LUAD	cis	rs11048434	0.761	rs12827988	chr12:9130287	A/G	cg13575925	chr12:9217583	LOC144571	0.38	7.01	0.32	9.25e-12	Sjögren's syndrome;
LUAD	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.54	-0.3	1.79e-10	Breast cancer;
LUAD	cis	rs2742234	0.910	rs2505505	chr10:43648221	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.44	-7.97	-0.36	1.5e-14	Hirschsprung disease;
LUAD	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg11494091	chr17:61959527	GH2	0.43	8.08	0.37	7.09e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1476679	0.830	rs6971558	chr7:100079857	A/T	cg22906224	chr7:99728672	NA	-0.44	-6.86	-0.32	2.44e-11	Alzheimer's disease (late onset);
LUAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.55	-8.82	-0.39	2.95e-17	Longevity;Endometriosis;
LUAD	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg09184832	chr6:79620586	NA	-0.51	-9.57	-0.42	9.14e-20	Intelligence (multi-trait analysis);
LUAD	trans	rs853679	0.607	rs34878803	chr6:28250179	T/C	cg01620082	chr3:125678407	NA	-1.05	-10.6	-0.46	2e-23	Depression;
LUAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg24503407	chr1:205819492	PM20D1	-0.68	-13.42	-0.55	1.93e-34	Monocyte percentage of white cells;
LUAD	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg05132306	chr1:1846340	CALML6	0.31	6.82	0.31	3.06e-11	Body mass index;
LUAD	cis	rs77861329	0.748	rs749995	chr3:52176701	C/T	cg08692210	chr3:52188851	WDR51A	0.55	6.93	0.32	1.54e-11	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11644478	chr21:40555479	PSMG1	-0.42	-6.92	-0.32	1.67e-11	Menarche (age at onset);
LUAD	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg13180566	chr4:1052158	NA	-0.39	-6.71	-0.31	6.2e-11	Recombination rate (females);
LUAD	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.31	7.27	0.33	1.75e-12	Prostate cancer;
LUAD	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.77	-9.63	-0.42	5.42e-20	Lung cancer in ever smokers;
LUAD	trans	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg16724585	chr3:197361211	NA	-0.51	-7.59	-0.35	2.01e-13	Pancreatic cancer;
LUAD	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg07917127	chr4:99064746	C4orf37	0.41	6.71	0.31	6.1e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg26043149	chr18:55253948	FECH	-0.42	-6.99	-0.32	1.11e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18402987	chr7:1209562	NA	0.39	6.59	0.31	1.28e-10	Longevity;Endometriosis;
LUAD	cis	rs11958404	1.000	rs72816523	chr5:157403168	G/C	cg05962755	chr5:157440814	NA	0.61	8.48	0.38	3.74e-16	IgG glycosylation;
LUAD	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg18811423	chr2:55921094	PNPT1	0.51	8.39	0.38	7.57e-16	Metabolic syndrome;
LUAD	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg18876405	chr7:65276391	NA	-0.63	-10.97	-0.47	7.98e-25	Calcium levels;
LUAD	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg00277334	chr10:82204260	NA	-0.67	-12.15	-0.51	2.34e-29	Post bronchodilator FEV1;
LUAD	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.72	0.31	5.78e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.01	0.36	1.11e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-7.33	-0.34	1.17e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg26513180	chr16:89883248	FANCA	0.75	6.76	0.31	4.55e-11	Skin colour saturation;
LUAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg23131131	chr22:24373011	LOC391322	-0.47	-7.97	-0.36	1.47e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg25173405	chr17:45401733	C17orf57	-0.59	-9.86	-0.43	9.04e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg04414720	chr1:150670196	GOLPH3L	0.72	13.36	0.54	3.28e-34	Tonsillectomy;
LUAD	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	14.41	0.57	1.39e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs11771526	0.901	rs62457494	chr7:32312299	T/G	cg13207630	chr7:32358064	NA	0.59	7.46	0.34	4.92e-13	Body mass index;
LUAD	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg09365446	chr1:150670422	GOLPH3L	0.66	12.58	0.52	4.9e-31	Tonsillectomy;
LUAD	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg23533926	chr12:111358616	MYL2	-0.4	-6.91	-0.32	1.76e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg13813247	chr22:41461852	NA	-0.49	-7.82	-0.36	4.29e-14	Neuroticism;
LUAD	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg08632164	chr7:65971372	NA	-0.55	-6.37	-0.3	4.93e-10	Diabetic kidney disease;
LUAD	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg05110241	chr16:68378359	PRMT7	-0.81	-8.62	-0.39	1.31e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg09998033	chr7:158218633	PTPRN2	0.38	6.64	0.31	9.54e-11	Obesity-related traits;
LUAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg21724239	chr8:58056113	NA	0.65	8.41	0.38	6.32e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg04851639	chr8:1020857	NA	-0.39	-9.77	-0.43	1.86e-20	Schizophrenia;
LUAD	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg14668632	chr7:2872130	GNA12	-0.46	-8.09	-0.37	6.22e-15	Height;
LUAD	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg25767906	chr1:53392781	SCP2	-0.35	-6.6	-0.31	1.21e-10	Monocyte count;
LUAD	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg19622623	chr12:86230825	RASSF9	-0.44	-7.86	-0.36	3.14e-14	Major depressive disorder;
LUAD	cis	rs889398	0.651	rs1566455	chr16:69900164	G/T	cg00738113	chr16:70207722	CLEC18C	-0.35	-7.01	-0.32	9.74e-12	Body mass index;
LUAD	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg02228675	chr17:40259724	DHX58	0.46	7.45	0.34	5.13e-13	Fibrinogen levels;
LUAD	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg04944784	chr2:26401820	FAM59B	0.73	9.29	0.41	8.26e-19	Gut microbiome composition (summer);
LUAD	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg22166914	chr1:53195759	ZYG11B	0.47	7.56	0.35	2.47e-13	Monocyte count;
LUAD	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg08807101	chr21:30365312	RNF160	0.51	8.79	0.39	3.93e-17	Dental caries;
LUAD	trans	rs1493916	0.837	rs4997493	chr18:31407302	C/T	cg15819921	chr19:927150	ARID3A	-0.42	-6.86	-0.32	2.44e-11	Life satisfaction;
LUAD	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg25767906	chr1:53392781	SCP2	-0.42	-7.48	-0.34	4.37e-13	Monocyte count;
LUAD	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg25482853	chr8:67687455	SGK3	1.18	18.25	0.66	2.68e-55	Lung disease severity in cystic fibrosis;
LUAD	cis	rs9814567	0.752	rs7623567	chr3:134330976	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.62	-8.15	-0.37	4.22e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs4824093	0.544	rs73443951	chr22:50301251	C/T	cg09872104	chr7:134855509	C7orf49	-0.78	-7.32	-0.34	1.3e-12	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg25767906	chr1:53392781	SCP2	-0.49	-8.8	-0.39	3.52e-17	Monocyte count;
LUAD	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg17330251	chr7:94953956	PON1	-0.53	-7.17	-0.33	3.36e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg07936489	chr17:37558343	FBXL20	0.51	6.98	0.32	1.14e-11	Glomerular filtration rate (creatinine);
LUAD	trans	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.51	7.77	0.35	5.99e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9948	0.748	rs62156223	chr2:97412167	T/C	cg20312557	chr2:97357134	FER1L5	-0.67	-7.62	-0.35	1.65e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg18932078	chr1:2524107	MMEL1	-0.36	-6.86	-0.32	2.51e-11	Ulcerative colitis;
LUAD	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg26818010	chr10:134567672	INPP5A	-0.86	-14.47	-0.58	7.58e-39	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg25754956	chr12:51612065	POU6F1	0.55	7.32	0.34	1.29e-12	Cisplatin-induced ototoxicity;
LUAD	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg22906224	chr7:99728672	NA	0.61	10.04	0.44	2.07e-21	Coronary artery disease;
LUAD	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg04703951	chr17:43578652	NA	0.45	7.15	0.33	3.96e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.55	-0.38	2.29e-16	Total body bone mineral density;
LUAD	cis	rs9910055	0.593	rs58392387	chr17:42297889	A/G	cg13607699	chr17:42295918	UBTF	0.57	9.09	0.4	3.91e-18	Total body bone mineral density;
LUAD	cis	rs11167764	0.638	rs7729747	chr5:141478055	C/A	cg08523384	chr5:141488047	NDFIP1	-0.49	-7.1	-0.33	5.34e-12	Crohn's disease;
LUAD	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg18876405	chr7:65276391	NA	0.46	7.54	0.34	2.82e-13	Aortic root size;
LUAD	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs3845702	0.736	rs259810	chr2:180787821	T/C	cg01881094	chr2:180872142	CWC22	-0.64	-6.89	-0.32	2.06e-11	Schizophrenia;
LUAD	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg23625390	chr15:77176239	SCAPER	-0.46	-7.29	-0.33	1.52e-12	Blood metabolite levels;
LUAD	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg18138036	chr10:133769891	PPP2R2D	0.41	6.69	0.31	7.09e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs1997103	1.000	rs4947504	chr7:55409428	T/C	cg17469321	chr7:55412551	NA	0.62	10.54	0.46	3.15e-23	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs10746514	0.833	rs2356925	chr1:232261769	G/A	cg09506761	chr1:232265262	NA	-0.38	-7.13	-0.33	4.42e-12	Response to statin therapy;
LUAD	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg00745463	chr17:30367425	LRRC37B	0.81	9.48	0.42	1.85e-19	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg13560548	chr3:10150139	C3orf24	0.42	6.44	0.3	3.15e-10	Alzheimer's disease;
LUAD	cis	rs4144027	0.967	rs12879686	chr14:104360741	C/T	cg12183467	chr14:104352244	NA	0.37	6.96	0.32	1.27e-11	Blood metabolite levels;
LUAD	cis	rs3736594	0.649	rs867282	chr2:27951658	A/G	cg27432699	chr2:27873401	GPN1	-0.42	-6.41	-0.3	3.79e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27297192	chr10:134578999	INPP5A	0.39	6.8	0.31	3.49e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02463440	chr8:22132932	PIWIL2	0.57	10.25	0.45	3.63e-22	Hypertriglyceridemia;
LUAD	cis	rs713587	0.967	rs6749422	chr2:25150011	C/G	cg01884057	chr2:25150051	NA	0.39	8.32	0.37	1.25e-15	Body mass index in non-asthmatics;
LUAD	cis	rs11771526	0.892	rs62457504	chr7:32336097	G/A	cg27511599	chr7:32358540	NA	0.61	7.17	0.33	3.47e-12	Body mass index;
LUAD	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11644478	chr21:40555479	PSMG1	0.38	6.38	0.3	4.58e-10	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg04287289	chr16:89883240	FANCA	0.63	6.63	0.31	1.03e-10	Skin colour saturation;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg03067462	chr11:2422131	TSSC4	-0.37	-6.66	-0.31	8.79e-11	Schizophrenia;
LUAD	cis	rs59104589	0.617	rs6672	chr2:242293021	A/G	cg08645257	chr2:242211290	HDLBP	0.46	7.43	0.34	6.23e-13	Fibrinogen levels;
LUAD	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg13319975	chr6:146136371	FBXO30	-0.63	-10.84	-0.47	2.44e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg09455208	chr3:40491958	NA	0.56	12.24	0.51	1.08e-29	Renal cell carcinoma;
LUAD	cis	rs829883	0.624	rs829881	chr12:98881228	T/G	cg25150519	chr12:98850993	NA	0.42	6.88	0.32	2.1e-11	Colorectal adenoma (advanced);
LUAD	cis	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg06521852	chr22:38141419	TRIOBP	-0.51	-9.38	-0.41	4.2e-19	Optic cup area;Vertical cup-disc ratio;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg14693487	chr11:117198998	CEP164	0.35	6.37	0.3	4.86e-10	Bipolar disorder;
LUAD	cis	rs4919694	1.000	rs12258551	chr10:104767892	C/G	cg04362960	chr10:104952993	NT5C2	0.72	7.65	0.35	1.41e-13	Arsenic metabolism;
LUAD	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg03714773	chr7:91764589	CYP51A1	0.32	7.42	0.34	6.49e-13	Breast cancer;
LUAD	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.01	0.36	1.12e-14	Breast cancer;
LUAD	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg21918786	chr6:109611834	NA	-0.61	-11.26	-0.48	6.8e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg20578329	chr17:80767326	TBCD	-0.62	-7.18	-0.33	3.12e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg02421172	chr7:1938701	MAD1L1	0.46	6.71	0.31	6.18e-11	Bipolar disorder;
LUAD	cis	rs7707921	0.881	rs73134747	chr5:81378294	C/T	cg15871215	chr5:81402204	ATG10	-0.68	-9.59	-0.42	7.49e-20	Breast cancer;
LUAD	cis	rs2233152	0.572	rs10411008	chr19:41297241	T/C	cg21869046	chr19:41225005	ITPKC	0.4	7.22	0.33	2.51e-12	Kawasaki disease;
LUAD	cis	rs7737355	0.898	rs10079359	chr5:130758283	A/G	cg06307176	chr5:131281290	NA	-0.42	-7.1	-0.33	5.22e-12	Life satisfaction;
LUAD	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg13385794	chr1:248469461	NA	0.25	6.77	0.31	4.45e-11	Common traits (Other);
LUAD	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg02176678	chr2:219576539	TTLL4	0.59	11.55	0.49	5.38e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg10468373	chr11:64009913	FKBP2	0.54	6.8	0.31	3.51e-11	Mean platelet volume;
LUAD	cis	rs938554	1.000	rs938552	chr4:9925524	T/C	cg00071950	chr4:10020882	SLC2A9	0.54	8.54	0.38	2.48e-16	Blood metabolite levels;
LUAD	cis	rs7523050	0.558	rs35926243	chr1:109407712	T/A	cg08274380	chr1:109419600	GPSM2	0.78	6.71	0.31	6.11e-11	Fat distribution (HIV);
LUAD	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.19	16.5	0.63	1.39e-47	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg16989719	chr2:238392110	NA	-0.34	-7.25	-0.33	1.94e-12	Prostate cancer;
LUAD	cis	rs71403859	0.730	rs12922775	chr16:71584354	C/T	cg08717414	chr16:71523259	ZNF19	-0.63	-7.59	-0.35	2.08e-13	Post bronchodilator FEV1;
LUAD	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg14541582	chr5:601475	NA	-0.37	-7.82	-0.36	4.25e-14	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7681423	1.000	rs2066854	chr4:155535181	T/A	cg20735720	chr4:155535218	FGG	-0.49	-7.02	-0.32	8.83e-12	Fibrinogen;
LUAD	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg10596483	chr8:143751796	JRK	0.46	7.34	0.34	1.08e-12	Schizophrenia;
LUAD	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg01200585	chr1:228362443	C1orf69	-0.37	-6.35	-0.3	5.44e-10	Parkinson's disease;
LUAD	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg27068330	chr11:65405492	SIPA1	-0.57	-9.13	-0.41	2.79e-18	Acne (severe);
LUAD	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg25767906	chr1:53392781	SCP2	0.39	7.19	0.33	2.87e-12	Monocyte count;
LUAD	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg02951883	chr7:2050386	MAD1L1	-0.64	-10.41	-0.45	9.87e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.01	-0.44	2.63e-21	Monocyte percentage of white cells;
LUAD	cis	rs28719689	0.655	rs17063833	chr8:1275384	A/G	cg22761795	chr8:1265118	NA	0.58	7.91	0.36	2.23e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg05805236	chr11:65401703	PCNXL3	-0.48	-7.94	-0.36	1.89e-14	Acne (severe);
LUAD	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.8	-0.39	3.43e-17	Alzheimer's disease (late onset);
LUAD	cis	rs62400317	0.859	rs10948223	chr6:45273921	A/C	cg18551225	chr6:44695536	NA	-0.55	-8.54	-0.38	2.49e-16	Total body bone mineral density;
LUAD	trans	rs7939886	0.920	rs11227158	chr11:55843795	A/G	cg15704280	chr7:45808275	SEPT13	0.66	6.47	0.3	2.67e-10	Myopia (pathological);
LUAD	cis	rs4791641	0.743	rs2270445	chr17:8219478	A/G	cg08322244	chr17:8066669	VAMP2	-0.34	-6.78	-0.31	4.04e-11	LDL cholesterol levels;Hematocrit;Hemoglobin concentration;Red blood cell count;LDL cholesterol;
LUAD	cis	rs12995491	0.902	rs6737641	chr2:88529471	A/T	cg04511125	chr2:88470314	THNSL2	-0.45	-7.6	-0.35	1.87e-13	Response to metformin (IC50);
LUAD	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg07169764	chr2:136633963	MCM6	0.81	9.52	0.42	1.38e-19	Corneal structure;
LUAD	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18404041	chr3:52824283	ITIH1	0.6	12.18	0.51	1.92e-29	Bipolar disorder;
LUAD	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.51	0.38	3.08e-16	Platelet count;
LUAD	cis	rs12155623	0.603	rs2203065	chr8:49881987	A/G	cg22283653	chr8:49824208	NA	-0.36	-7.13	-0.33	4.43e-12	Sudden cardiac arrest;
LUAD	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	9.07	0.4	4.4e-18	Tonsillectomy;
LUAD	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg11189052	chr15:85197271	WDR73	0.61	7.59	0.35	2.06e-13	Schizophrenia;
LUAD	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg20991723	chr1:152506922	NA	0.35	6.81	0.31	3.32e-11	Hair morphology;
LUAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs863345	0.584	rs11265018	chr1:158506409	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.6	-0.31	1.21e-10	Pneumococcal bacteremia;
LUAD	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg26384229	chr12:38710491	ALG10B	0.46	7.58	0.35	2.24e-13	Bladder cancer;
LUAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg12419862	chr22:24373484	LOC391322	-0.69	-12.12	-0.51	3.11e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11650494	0.831	rs8065389	chr17:47456064	G/T	cg08112188	chr17:47440006	ZNF652	-0.77	-7.57	-0.35	2.31e-13	Prostate cancer;
LUAD	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	8.37	0.38	8.59e-16	Parkinson's disease;
LUAD	cis	rs597539	0.690	rs1272609	chr11:68618182	T/C	cg04772025	chr11:68637568	NA	0.59	9.35	0.41	4.95e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg07167872	chr1:205819463	PM20D1	0.48	7.72	0.35	8.37e-14	Parkinson's disease;
LUAD	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg18825076	chr15:78729989	IREB2	0.49	6.71	0.31	6.4e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	trans	rs208520	0.690	rs207107	chr6:66794385	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.32	-0.64	3.48e-51	Exhaled nitric oxide output;
LUAD	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg05835009	chr4:710272	PCGF3	0.59	8.82	0.39	3.05e-17	White blood cell count;
LUAD	cis	rs8060686	0.516	rs8048364	chr16:68253324	T/G	cg05110241	chr16:68378359	PRMT7	-0.58	-7.49	-0.34	4e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg26811252	chr16:29126840	RRN3P2	0.67	11.27	0.48	6.32e-26	Menopause (age at onset);
LUAD	cis	rs3931	0.607	rs11676084	chr2:169703974	C/T	cg22278106	chr2:169746720	SPC25	0.52	7.37	0.34	9.17e-13	Monocyte count;
LUAD	cis	rs870825	0.929	rs55880126	chr4:185591237	T/G	cg04058563	chr4:185651563	MLF1IP	0.79	10.04	0.44	1.99e-21	Blood protein levels;
LUAD	cis	rs3125734	0.660	rs10733769	chr10:63974255	G/T	cg19640130	chr10:64028056	RTKN2	-0.34	-7.13	-0.33	4.51e-12	Rheumatoid arthritis;
LUAD	cis	rs6717918	0.884	rs67163108	chr2:233183967	A/G	ch.2.233013039R	chr2:233304795	NA	0.51	6.99	0.32	1.06e-11	Height;
LUAD	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg24308560	chr3:49941425	MST1R	0.53	8.77	0.39	4.42e-17	Body mass index;
LUAD	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg24838063	chr12:130822603	PIWIL1	0.64	10.67	0.46	1.03e-23	Menopause (age at onset);
LUAD	cis	rs1555895	0.611	rs3763722	chr10:859270	C/T	cg20503657	chr10:835505	NA	0.41	6.52	0.3	2.06e-10	Survival in rectal cancer;
LUAD	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg11098525	chr4:1320231	MAEA	-0.4	-6.38	-0.3	4.55e-10	Obesity-related traits;
LUAD	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg18129178	chr5:148520854	ABLIM3	-0.64	-9.8	-0.43	1.42e-20	Breast cancer;
LUAD	cis	rs16866061	0.517	rs7594223	chr2:225472985	T/C	cg12698349	chr2:225449008	CUL3	0.55	8.71	0.39	6.99e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	10.34	0.45	1.78e-22	Smoking behavior;
LUAD	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg05340658	chr4:99064831	C4orf37	0.46	7.48	0.34	4.25e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07959896	chr2:39005451	GEMIN6	0.4	6.5	0.3	2.2e-10	Survival in pancreatic cancer;
LUAD	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg11645453	chr3:52864694	ITIH4	0.37	7.37	0.34	9.16e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg25173405	chr17:45401733	C17orf57	-0.53	-8.99	-0.4	8.22e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11890956	chr21:40555474	PSMG1	-0.52	-8.8	-0.39	3.63e-17	Menarche (age at onset);
LUAD	cis	rs3091242	0.933	rs9645452	chr1:25668326	C/T	cg02931644	chr1:25747376	RHCE	-0.44	-9.04	-0.4	5.69e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs7917772	0.715	rs7077678	chr10:104438565	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-6.94	-0.32	1.46e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg06623918	chr6:96969491	KIAA0776	-0.71	-9.93	-0.43	4.94e-21	Migraine;Coronary artery disease;
LUAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.31	-7.03	-0.32	8.22e-12	Lymphocyte counts;
LUAD	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg16405210	chr4:1374714	KIAA1530	-0.5	-8.72	-0.39	6.47e-17	Longevity;
LUAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg11766577	chr21:47581405	C21orf56	0.47	6.96	0.32	1.31e-11	Testicular germ cell tumor;
LUAD	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg27572855	chr1:25598939	RHD	0.59	13.3	0.54	5.56e-34	Erythrocyte sedimentation rate;
LUAD	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg14668632	chr7:2872130	GNA12	-0.75	-13.67	-0.55	1.74e-35	Height;
LUAD	cis	rs2692947	0.727	rs749459	chr2:96795714	G/A	cg23100626	chr2:96804247	ASTL	0.34	9.06	0.4	4.85e-18	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7213347	0.707	rs4790323	chr17:2181658	A/G	cg02569219	chr17:2266849	SGSM2	-0.44	-7.17	-0.33	3.47e-12	Total body bone mineral density;
LUAD	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg19000871	chr14:103996768	TRMT61A	0.52	9.07	0.4	4.43e-18	Coronary artery disease;
LUAD	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg11663144	chr21:46675770	NA	-0.6	-11.83	-0.5	4.19e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26314531	chr2:26401878	FAM59B	-0.6	-8.29	-0.37	1.47e-15	Gut microbiome composition (summer);
LUAD	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg14186256	chr22:23484241	RTDR1	0.47	8.02	0.36	1.06e-14	Bone mineral density;
LUAD	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg06618935	chr21:46677482	NA	-0.5	-10.01	-0.44	2.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs783540	0.521	rs1259176	chr15:83270898	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.51	-7.5	-0.34	3.71e-13	Schizophrenia;
LUAD	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg03929089	chr4:120376271	NA	-0.6	-9.38	-0.41	3.95e-19	Height;
LUAD	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg07757535	chr4:1339547	NA	0.29	6.53	0.3	1.93e-10	Longevity;
LUAD	trans	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.53	8.02	0.36	1.04e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs1395	1.000	rs1275530	chr2:27432547	A/G	cg23587288	chr2:27483067	SLC30A3	0.4	8.19	0.37	3.04e-15	Blood metabolite levels;
LUAD	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg02527881	chr3:46936655	PTH1R	-0.48	-9.42	-0.42	3.01e-19	Colorectal cancer;
LUAD	cis	rs67366981	0.778	rs3952319	chr14:77684379	A/T	cg22824376	chr14:77648248	TMEM63C	0.82	9.9	0.43	6.38e-21	Obsessive-compulsive symptoms;
LUAD	cis	rs12940923	1.000	rs12949848	chr17:56362067	A/G	cg19466818	chr17:56409534	MIR142	-0.36	-6.38	-0.3	4.61e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg03714773	chr7:91764589	CYP51A1	0.27	6.42	0.3	3.59e-10	Breast cancer;
LUAD	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg06214716	chr4:10118677	WDR1	-0.44	-6.86	-0.32	2.48e-11	Bone mineral density;
LUAD	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg00071950	chr4:10020882	SLC2A9	0.85	18.69	0.67	2.76e-57	Bone mineral density;
LUAD	cis	rs1160297	0.609	rs10164868	chr2:53095923	G/T	cg07782112	chr2:53107842	NA	0.42	8.84	0.4	2.53e-17	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.67	-0.39	9.48e-17	Depression;
LUAD	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.75	0.31	4.75e-11	Parkinson's disease;
LUAD	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.49	-0.52	1.08e-30	Breast cancer;
LUAD	cis	rs12989701	0.877	rs7557280	chr2:127873161	T/A	cg08168897	chr2:127865431	BIN1	0.46	7.17	0.33	3.41e-12	Alzheimer's disease (late onset);
LUAD	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg25233709	chr10:116636983	FAM160B1	0.41	8.21	0.37	2.64e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1190552	0.846	rs3742437	chr14:102965047	G/A	cg18135206	chr14:102964638	TECPR2	0.47	6.69	0.31	6.89e-11	Blood protein levels;
LUAD	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg05665937	chr4:1216051	CTBP1	0.38	6.41	0.3	3.9e-10	Obesity-related traits;
LUAD	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg15017067	chr4:17643749	FAM184B	-0.36	-7.05	-0.32	7.46e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2692947	0.727	rs1657502	chr2:96795608	A/C	cg23100626	chr2:96804247	ASTL	0.35	9.43	0.42	2.68e-19	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs4372836	0.729	rs4665436	chr2:29090227	T/C	cg09522027	chr2:28974177	PPP1CB	0.67	11.83	0.5	4.41e-28	Body mass index;
LUAD	trans	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg07211511	chr3:129823064	LOC729375	-0.55	-7.31	-0.33	1.39e-12	Blood pressure (smoking interaction);
LUAD	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06544989	chr22:39130855	UNC84B	0.44	8.27	0.37	1.74e-15	Menopause (age at onset);
LUAD	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg27129171	chr3:47204927	SETD2	0.41	6.5	0.3	2.32e-10	Colorectal cancer;
LUAD	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	7.95	0.36	1.74e-14	Menopause (age at onset);
LUAD	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.83	-0.32	2.95e-11	Type 2 diabetes;
LUAD	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg27432699	chr2:27873401	GPN1	0.6	10.67	0.46	1.05e-23	Oral cavity cancer;
LUAD	cis	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05901451	chr6:126070800	HEY2	-0.61	-9.93	-0.43	5.12e-21	Brugada syndrome;
LUAD	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg10544611	chr16:67998164	SLC12A4	-0.63	-7.41	-0.34	6.7e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7707921	0.829	rs226204	chr5:81610680	G/A	cg15871215	chr5:81402204	ATG10	0.56	8.24	0.37	2.2e-15	Breast cancer;
LUAD	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg00933542	chr6:150070202	PCMT1	0.43	9.18	0.41	1.91e-18	Lung cancer;
LUAD	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg06740227	chr12:86229804	RASSF9	0.47	8.24	0.37	2.21e-15	Major depressive disorder;
LUAD	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.12e-14	Prostate cancer;
LUAD	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg12311346	chr5:56204834	C5orf35	0.99	14.5	0.58	5.62e-39	Initial pursuit acceleration;
LUAD	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	9.4e-15	Tonsillectomy;
LUAD	cis	rs7301826	0.651	rs12228959	chr12:131296068	T/G	cg11011512	chr12:131303247	STX2	0.44	7.41	0.34	6.76e-13	Plasma plasminogen activator levels;
LUAD	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	8.13	0.37	4.65e-15	Blood metabolite levels;
LUAD	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg06784218	chr1:46089804	CCDC17	0.58	12.93	0.53	1.93e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg15445000	chr17:37608096	MED1	-0.44	-8.13	-0.37	4.78e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg21427119	chr20:30132790	HM13	-0.48	-7.68	-0.35	1.12e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs4853036	0.672	rs12474858	chr2:70027802	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-6.51	-0.3	2.08e-10	Colorectal or endometrial cancer;
LUAD	cis	rs1941023	0.584	rs6591578	chr11:60158649	G/A	cg08716584	chr11:60157161	MS4A7	-0.47	-8.87	-0.4	2.13e-17	Congenital heart disease (maternal effect);
LUAD	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg13722127	chr7:150037890	RARRES2	0.44	7.53	0.34	3e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg10589385	chr1:150898437	SETDB1	-0.39	-7.29	-0.33	1.52e-12	Melanoma;
LUAD	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg13385794	chr1:248469461	NA	0.25	6.95	0.32	1.35e-11	Common traits (Other);
LUAD	cis	rs731174	0.797	rs678511	chr1:38156427	T/C	cg06917450	chr1:38156652	C1orf109	-0.41	-6.62	-0.31	1.08e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg07917127	chr4:99064746	C4orf37	0.39	6.42	0.3	3.65e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg23387056	chr11:14280742	SPON1	0.47	10.12	0.44	1.04e-21	Mitochondrial DNA levels;
LUAD	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg10792982	chr14:105748885	BRF1	0.43	9.38	0.42	3.95e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs501916	0.796	rs75186419	chr15:48043934	G/A	cg16110827	chr15:48056943	SEMA6D	-0.38	-6.9	-0.32	1.88e-11	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg12311346	chr5:56204834	C5orf35	-1.1	-17.35	-0.64	2.56e-51	Initial pursuit acceleration;
LUAD	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg21475434	chr5:93447410	FAM172A	0.7	8.36	0.38	8.84e-16	Diabetic retinopathy;
LUAD	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg24596788	chr1:163392923	NA	-0.33	-7.48	-0.34	4.4e-13	Motion sickness;
LUAD	cis	rs6496044	0.507	rs62022863	chr15:86162053	C/G	cg13263323	chr15:86062960	AKAP13	0.4	6.82	0.31	3.21e-11	Interstitial lung disease;
LUAD	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg23254163	chr1:152506842	NA	0.26	7.13	0.33	4.42e-12	Hair morphology;
LUAD	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg13736514	chr6:26305472	NA	0.58	10.33	0.45	1.8e-22	Mosquito bite size;
LUAD	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg03676636	chr4:99064102	C4orf37	0.3	7.2	0.33	2.71e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs55788414	1.000	rs28395434	chr16:81182222	G/A	cg06400318	chr16:81190750	PKD1L2	-0.64	-8.28	-0.37	1.61e-15	Left ventricular obstructive tract defect (maternal effect);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg10055505	chr1:246582035	SMYD3	-0.42	-7.11	-0.33	5.11e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg09367891	chr1:107599246	PRMT6	-0.59	-9.88	-0.43	7.28e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.26	0.37	1.82e-15	Rheumatoid arthritis;
LUAD	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg11247378	chr22:39784982	NA	0.6	9.94	0.44	4.64e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg00316803	chr15:76480434	C15orf27	-0.43	-8.53	-0.38	2.62e-16	Blood metabolite levels;
LUAD	cis	rs78761021	0.720	rs79348078	chr17:9795771	T/A	cg26853458	chr17:9805074	RCVRN	0.4	7.63	0.35	1.59e-13	Type 2 diabetes;
LUAD	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg18230493	chr5:56204884	C5orf35	0.96	14.07	0.56	3.86e-37	Initial pursuit acceleration;
LUAD	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.44	6.78	0.31	4.12e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs11811982	0.793	rs111996994	chr1:227567209	A/G	cg24860534	chr1:227506868	CDC42BPA	0.66	7.2	0.33	2.8e-12	Optic disc area;
LUAD	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg03467027	chr4:99064603	C4orf37	0.47	7.38	0.34	8.26e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs60154123	0.730	rs4844987	chr1:210458190	G/T	cg22029157	chr1:209979665	IRF6	0.56	6.59	0.31	1.33e-10	Coronary artery disease;
LUAD	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg02569458	chr12:86230093	RASSF9	0.36	6.82	0.31	3.14e-11	Major depressive disorder;
LUAD	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg21775007	chr8:11205619	TDH	-0.5	-9.08	-0.4	4.26e-18	Retinal vascular caliber;
LUAD	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg05887092	chr17:76393375	PGS1	0.39	6.89	0.32	1.99e-11	HDL cholesterol levels;
LUAD	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg10018233	chr7:150070692	REPIN1	0.48	7.54	0.34	2.9e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4711350	0.734	rs9380379	chr6:33766131	A/G	cg18005901	chr6:33739558	LEMD2	-0.53	-8.46	-0.38	4.36e-16	Schizophrenia;
LUAD	cis	rs684232	0.649	rs838369	chr17:578180	T/C	cg15660573	chr17:549704	VPS53	-0.77	-14.78	-0.58	3.71e-40	Prostate cancer;
LUAD	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg14541582	chr5:601475	NA	-0.38	-8.15	-0.37	4.15e-15	Obesity-related traits;
LUAD	cis	rs3857067	0.506	rs282450	chr4:95139598	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.13	-0.44	9.77e-22	QT interval;
LUAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22857025	chr5:266934	NA	-0.96	-14.39	-0.57	1.75e-38	Breast cancer;
LUAD	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg25985355	chr7:65971099	NA	-0.4	-7.38	-0.34	8.44e-13	Aortic root size;
LUAD	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg12311346	chr5:56204834	C5orf35	-0.48	-7.9	-0.36	2.51e-14	Coronary artery disease;
LUAD	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg19418458	chr7:158789849	NA	0.58	10.09	0.44	1.39e-21	Facial morphology (factor 20);
LUAD	cis	rs7267979	0.932	rs4280527	chr20:25544014	A/G	cg08601574	chr20:25228251	PYGB	0.42	7.7	0.35	1.01e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs8060686	0.516	rs2290700	chr16:68288983	T/G	cg09835421	chr16:68378352	PRMT7	-0.55	-6.92	-0.32	1.72e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs62400317	0.723	rs12196188	chr6:44976426	G/C	cg18551225	chr6:44695536	NA	-0.59	-8.95	-0.4	1.11e-17	Total body bone mineral density;
LUAD	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg11502198	chr6:26597334	ABT1	0.48	7.78	0.35	5.58e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs739496	0.615	rs3809274	chr12:112044333	G/C	cg10833066	chr12:111807467	FAM109A	0.44	7.1	0.33	5.23e-12	Platelet count;
LUAD	cis	rs12618769	0.597	rs72819996	chr2:99059983	G/A	cg10123293	chr2:99228465	UNC50	0.46	8.11	0.37	5.48e-15	Bipolar disorder;
LUAD	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-7.0	-0.32	9.84e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs17092148	1.000	rs6060040	chr20:33359054	G/C	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.05	-0.36	8.3e-15	Neuroticism;
LUAD	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg00666640	chr1:248458726	OR2T12	0.35	8.31	0.37	1.33e-15	Common traits (Other);
LUAD	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06028808	chr11:68637592	NA	0.5	8.37	0.38	8.81e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2637266	0.935	rs2579771	chr10:78407544	A/G	cg18941641	chr10:78392320	NA	0.36	7.5	0.34	3.91e-13	Pulmonary function;
LUAD	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg11189052	chr15:85197271	WDR73	0.66	8.9	0.4	1.61e-17	Schizophrenia;
LUAD	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg18512352	chr11:47633146	NA	-0.54	-9.6	-0.42	6.87e-20	Subjective well-being;
LUAD	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg20703242	chr1:230279135	GALNT2	-0.62	-10.68	-0.46	9.59e-24	Coronary artery disease;
LUAD	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.53	0.3	1.86e-10	Breast cancer;
LUAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.9	0.47	1.51e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6138458	1.000	rs227631	chr20:24913653	A/G	cg26195577	chr20:24973756	C20orf3	0.96	16.3	0.62	1.07e-46	Blood protein levels;
LUAD	cis	rs6733011	0.578	rs10181972	chr2:99497284	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.83	-0.32	2.89e-11	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg02734326	chr4:10020555	SLC2A9	0.6	10.52	0.46	3.69e-23	Bone mineral density;
LUAD	trans	rs10411161	0.810	rs57171871	chr19:52385332	T/C	cg22319618	chr22:45562946	NUP50	-0.66	-7.58	-0.35	2.13e-13	Breast cancer;
LUAD	cis	rs490234	0.702	rs4838275	chr9:128352785	C/T	cg14078157	chr9:128172775	NA	-0.45	-8.05	-0.36	8.45e-15	Mean arterial pressure;
LUAD	cis	rs10129255	0.536	rs10142951	chr14:107190574	A/G	cg07958169	chr14:107095056	NA	-0.37	-7.36	-0.34	9.55e-13	Kawasaki disease;
LUAD	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg04369109	chr6:150039330	LATS1	-0.44	-7.49	-0.34	3.95e-13	Lung cancer;
LUAD	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11890956	chr21:40555474	PSMG1	-0.64	-10.98	-0.47	7.79e-25	Cognitive function;
LUAD	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg02176678	chr2:219576539	TTLL4	0.6	11.69	0.49	1.5e-27	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg17712092	chr4:129076599	LARP1B	-0.77	-11.77	-0.5	7.11e-28	Breast cancer;
LUAD	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-7.09	-0.33	5.68e-12	IgG glycosylation;
LUAD	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg05283184	chr6:79620031	NA	-0.61	-12.19	-0.51	1.7e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-7.42	-0.34	6.52e-13	Major depressive disorder;
LUAD	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg01802117	chr1:53393560	SCP2	0.33	6.62	0.31	1.12e-10	Monocyte count;
LUAD	cis	rs3784262	0.565	rs2642630	chr15:58316960	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.36	-6.88	-0.32	2.12e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.66	0.31	8.74e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg23587288	chr2:27483067	SLC30A3	-0.43	-8.45	-0.38	4.69e-16	Blood metabolite levels;
LUAD	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-15.3	-0.6	2.31e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg04455712	chr21:45112962	RRP1B	0.47	9.35	0.41	5.15e-19	Mean corpuscular volume;
LUAD	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.48	-8.55	-0.38	2.32e-16	Tonsillectomy;
LUAD	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg17366294	chr4:99064904	C4orf37	0.57	9.67	0.43	4.09e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7953508	0.659	rs1316739	chr12:93968256	G/A	cg18151635	chr12:93972918	NA	-0.74	-11.97	-0.5	1.18e-28	Pubertal anthropometrics;
LUAD	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg00147160	chr1:26503991	CNKSR1	0.38	8.84	0.39	2.66e-17	Height;
LUAD	cis	rs1385374	0.858	rs3741615	chr12:129298848	G/A	cg09035930	chr12:129282057	SLC15A4	-0.63	-6.83	-0.32	2.88e-11	Systemic lupus erythematosus;
LUAD	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg21427119	chr20:30132790	HM13	-0.48	-7.68	-0.35	1.12e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs7809799	0.826	rs66674233	chr7:98882356	G/A	cg12290671	chr7:99195819	NA	-0.79	-6.53	-0.3	1.87e-10	Ulcerative colitis;
LUAD	trans	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg01620082	chr3:125678407	NA	-0.63	-7.26	-0.33	1.87e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.67	-10.44	-0.45	7.26e-23	Chronic sinus infection;
LUAD	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg15181151	chr6:150070149	PCMT1	0.39	7.8	0.35	5e-14	Lung cancer;
LUAD	cis	rs11771526	1.000	rs10231440	chr7:32299435	C/A	cg27532318	chr7:32358331	NA	0.56	7.21	0.33	2.54e-12	Body mass index;
LUAD	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg18477163	chr1:228402036	OBSCN	-0.38	-7.49	-0.34	4.18e-13	Diastolic blood pressure;
LUAD	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg22482690	chr17:47019901	SNF8	0.43	8.06	0.36	7.91e-15	Type 2 diabetes;
LUAD	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg12444411	chr7:2802554	GNA12	-0.36	-6.38	-0.3	4.73e-10	Height;
LUAD	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg22676075	chr6:135203613	NA	-0.74	-14.33	-0.57	2.96e-38	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-12.59	-0.52	4.32e-31	Mean corpuscular volume;
LUAD	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg03859395	chr2:55845619	SMEK2	0.76	14.13	0.57	2.19e-37	Metabolic syndrome;
LUAD	cis	rs829883	0.724	rs11109508	chr12:98905985	T/C	cg25150519	chr12:98850993	NA	-0.53	-8.24	-0.37	2.2e-15	Colorectal adenoma (advanced);
LUAD	trans	rs1406428	0.573	rs12613632	chr2:51705755	C/G	cg26847850	chr2:172380409	CYBRD1	0.33	6.64	0.31	9.64e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg08999081	chr20:33150536	PIGU	0.48	9.18	0.41	1.91e-18	Coronary artery disease;
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg15383120	chr6:291909	DUSP22	-0.71	-12.03	-0.5	7.33e-29	Menopause (age at onset);
LUAD	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg02734326	chr4:10020555	SLC2A9	0.57	9.81	0.43	1.27e-20	Bone mineral density;
LUAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg00106254	chr7:1943704	MAD1L1	-0.59	-8.62	-0.39	1.4e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs2836950	0.805	rs62223042	chr21:40683740	A/G	cg11890956	chr21:40555474	PSMG1	-0.48	-7.58	-0.35	2.2e-13	Menarche (age at onset);
LUAD	cis	rs1953600	0.870	rs12770550	chr10:81953451	G/T	cg00277334	chr10:82204260	NA	0.43	7.28	0.33	1.67e-12	Sarcoidosis;
LUAD	cis	rs2004318	1.000	rs73614626	chr19:55139399	T/C	cg03320607	chr19:54800032	LILRA3	-0.68	-7.19	-0.33	3.01e-12	Blood protein levels;
LUAD	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg23992470	chr4:843637	GAK	0.58	7.03	0.32	8.59e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs490234	0.841	rs7863341	chr9:128449085	A/G	cg14078157	chr9:128172775	NA	0.41	7.61	0.35	1.79e-13	Mean arterial pressure;
LUAD	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg24768116	chr2:27665128	KRTCAP3	0.27	6.74	0.31	5.12e-11	Oral cavity cancer;
LUAD	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.63	-0.31	1.01e-10	Height;
LUAD	cis	rs1696756	0.638	rs1285274	chr17:77829907	G/A	cg01306824	chr17:77834118	NA	0.46	7.01	0.32	9.29e-12	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg16205897	chr5:131564050	P4HA2	-0.33	-7.47	-0.34	4.62e-13	Blood metabolite levels;
LUAD	cis	rs1816752	0.905	rs9511262	chr13:25012023	C/T	cg02811702	chr13:24901961	NA	0.46	7.93	0.36	2.03e-14	Obesity-related traits;
LUAD	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg24920358	chr1:40204285	PPIE	0.71	12.98	0.53	1.21e-32	Blood protein levels;
LUAD	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg25811766	chr13:21894605	NA	-0.62	-7.54	-0.34	2.91e-13	White matter hyperintensity burden;
LUAD	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg18129748	chr3:49941408	MST1R	0.44	7.34	0.34	1.09e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.56	10.5	0.45	4.45e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg08470875	chr2:26401718	FAM59B	-0.62	-8.49	-0.38	3.51e-16	Gut microbiome composition (summer);
LUAD	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg02527881	chr3:46936655	PTH1R	0.42	8.09	0.37	6.2e-15	Colorectal cancer;
LUAD	cis	rs859767	1.000	rs859767	chr2:135341200	A/G	cg12500956	chr2:135428796	TMEM163	0.3	7.99	0.36	1.32e-14	Neuroticism;
LUAD	cis	rs4691139	1.000	rs7693977	chr4:165903050	C/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.43	-8.45	-0.38	4.78e-16	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg09184832	chr6:79620586	NA	-0.5	-9.3	-0.41	7.54e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs8077889	0.871	rs11079838	chr17:41898971	G/A	cg26893861	chr17:41843967	DUSP3	0.92	15.52	0.6	2.46e-43	Triglycerides;
LUAD	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-9.02	-0.4	6.51e-18	Menopause (age at onset);
LUAD	cis	rs4285028	0.948	rs12488334	chr3:121702526	T/C	cg11130432	chr3:121712080	ILDR1	-0.58	-8.2	-0.37	2.81e-15	Multiple sclerosis;
LUAD	trans	rs11039798	0.925	rs12277669	chr11:48925316	A/T	cg02254774	chr11:50257496	LOC441601	0.52	6.56	0.3	1.62e-10	Axial length;
LUAD	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg27432699	chr2:27873401	GPN1	-0.37	-6.37	-0.3	4.84e-10	Total body bone mineral density;
LUAD	trans	rs11039798	0.557	rs683180	chr11:48463949	A/G	cg15704280	chr7:45808275	SEPT13	-0.59	-7.89	-0.36	2.65e-14	Axial length;
LUAD	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg26769984	chr7:1090371	C7orf50	0.63	8.96	0.4	1.06e-17	Bronchopulmonary dysplasia;
LUAD	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg25753631	chr6:25732923	NA	0.37	6.57	0.3	1.47e-10	Iron status biomarkers;
LUAD	cis	rs4243830	0.522	rs10157142	chr1:6618785	A/T	cg05709478	chr1:6581295	PLEKHG5	-0.52	-6.54	-0.3	1.73e-10	Body mass index;
LUAD	cis	rs7180079	1.000	rs7175456	chr15:64534620	C/G	cg08069370	chr15:64387884	SNX1	-0.51	-6.56	-0.3	1.6e-10	Monocyte count;
LUAD	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24308560	chr3:49941425	MST1R	0.55	9.39	0.42	3.82e-19	Body mass index;
LUAD	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg01788221	chr16:89496183	ANKRD11	-0.36	-6.92	-0.32	1.66e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg06636551	chr8:101224915	SPAG1	-0.37	-6.67	-0.31	8.11e-11	Atrioventricular conduction;
LUAD	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.44	0.38	5.18e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg15017067	chr4:17643749	FAM184B	-0.36	-6.91	-0.32	1.79e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7584330	0.554	rs10190935	chr2:238435482	G/A	cg14458575	chr2:238380390	NA	0.63	9.98	0.44	3.31e-21	Prostate cancer;
LUAD	cis	rs9443645	0.527	rs10943588	chr6:79510994	A/C	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-6.64	-0.31	9.45e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg04155289	chr7:94953770	PON1	-0.54	-7.36	-0.34	9.74e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs73206853	0.764	rs7960988	chr12:110749918	G/A	cg12870014	chr12:110450643	ANKRD13A	0.65	7.52	0.34	3.34e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg06641503	chr3:48959341	ARIH2	-0.38	-7.58	-0.35	2.23e-13	Menarche (age at onset);
LUAD	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08280861	chr8:58055591	NA	0.73	8.83	0.39	2.82e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg13565492	chr6:43139072	SRF	-0.61	-7.05	-0.32	7.51e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13082711	0.911	rs57317249	chr3:27515854	A/C	cg02860705	chr3:27208620	NA	0.57	8.79	0.39	3.72e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14001360	chr2:28113654	BRE;LOC100302650;RBKS	-0.55	-6.72	-0.31	5.87e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg06074448	chr4:187884817	NA	-0.41	-8.29	-0.37	1.52e-15	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg27394845	chr17:28928406	LRRC37B2	-0.52	-6.69	-0.31	6.99e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg07460842	chr6:66804631	NA	0.95	12.61	0.52	3.58e-31	Exhaled nitric oxide output;
LUAD	cis	rs11048434	0.761	rs10842662	chr12:9139344	G/A	cg04155231	chr12:9217510	LOC144571	0.42	8.01	0.36	1.09e-14	Sjögren's syndrome;
LUAD	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg12062639	chr20:23401060	NAPB	1.08	11.36	0.48	2.76e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.87	-0.32	2.31e-11	Crohn's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21951679	chr5:178977648	RUFY1	-0.5	-6.59	-0.31	1.33e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.87	-0.32	2.27e-11	Bipolar disorder;
LUAD	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg03806693	chr22:41940476	POLR3H	-0.48	-7.23	-0.33	2.34e-12	Vitiligo;
LUAD	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg09021430	chr5:549028	NA	-0.59	-13.11	-0.54	3.51e-33	Obesity-related traits;
LUAD	trans	rs4718428	0.924	rs6971897	chr7:66412774	T/A	cg18876405	chr7:65276391	NA	0.49	7.89	0.36	2.64e-14	Corneal structure;
LUAD	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg03859395	chr2:55845619	SMEK2	0.76	14.06	0.56	4.06e-37	Metabolic syndrome;
LUAD	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg27432699	chr2:27873401	GPN1	-0.38	-6.41	-0.3	3.85e-10	Total body bone mineral density;
LUAD	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.47	-9.79	-0.43	1.49e-20	Total body bone mineral density;
LUAD	cis	rs926938	0.618	rs6693491	chr1:115371061	A/G	cg12756093	chr1:115239321	AMPD1	-0.37	-6.45	-0.3	3.07e-10	Autism;
LUAD	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-15.6	-0.6	1.18e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg16060761	chr17:80687452	NA	0.46	6.92	0.32	1.69e-11	Breast cancer;
LUAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11905131	chr22:24372483	LOC391322	-0.57	-9.67	-0.43	4.23e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3125734	0.633	rs6479791	chr10:63980341	T/C	cg09941381	chr10:64027924	RTKN2	-0.3	-6.92	-0.32	1.7e-11	Rheumatoid arthritis;
LUAD	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	6.95	0.32	1.39e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg26528668	chr16:1614120	IFT140	0.5	8.91	0.4	1.56e-17	Coronary artery disease;
LUAD	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg02782426	chr3:40428986	ENTPD3	-0.38	-8.31	-0.37	1.28e-15	Renal cell carcinoma;
LUAD	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg11266682	chr4:10021025	SLC2A9	0.67	14.78	0.58	3.91e-40	Bone mineral density;
LUAD	cis	rs17253792	0.822	rs8009608	chr14:56062590	C/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.99	-0.36	1.34e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs739496	0.542	rs10219736	chr12:111788402	C/T	cg10833066	chr12:111807467	FAM109A	0.66	13.12	0.54	3.13e-33	Platelet count;
LUAD	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg06766960	chr11:133703094	NA	-0.44	-8.26	-0.37	1.85e-15	Childhood ear infection;
LUAD	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg13685833	chr1:53393034	SCP2	-0.4	-6.66	-0.31	8.28e-11	Monocyte count;
LUAD	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg07432352	chr17:45403706	C17orf57	-0.43	-8.42	-0.38	5.76e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3784262	0.669	rs4646564	chr15:58351797	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.77	-0.35	6.03e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg18876405	chr7:65276391	NA	-0.42	-7.12	-0.33	4.73e-12	Calcium levels;
LUAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg11062466	chr8:58055876	NA	0.67	9.02	0.4	6.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs870825	0.616	rs6825561	chr4:185615532	A/T	cg04058563	chr4:185651563	MLF1IP	0.88	14.09	0.57	3.19e-37	Blood protein levels;
LUAD	cis	rs68170813	0.559	rs79564258	chr7:107059803	C/A	cg02696742	chr7:106810147	HBP1	-0.77	-10.57	-0.46	2.54e-23	Coronary artery disease;
LUAD	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg22618164	chr12:122356400	WDR66	0.75	13.72	0.55	1.12e-35	Mean corpuscular volume;
LUAD	cis	rs7116495	0.786	rs10736784	chr11:71718911	T/A	cg07596299	chr11:71824057	C11orf51	-0.76	-6.5	-0.3	2.22e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs2692947	0.740	rs60452119	chr2:96420050	T/C	cg23100626	chr2:96804247	ASTL	0.31	7.72	0.35	8.66e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg25985355	chr7:65971099	NA	-0.38	-6.93	-0.32	1.59e-11	Aortic root size;
LUAD	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg07917127	chr4:99064746	C4orf37	-0.42	-6.99	-0.32	1.1e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg24119722	chr22:42347272	LOC339674	-0.28	-6.39	-0.3	4.4e-10	Cognitive function;
LUAD	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg03233332	chr7:66118400	NA	-0.45	-6.64	-0.31	9.75e-11	Aortic root size;
LUAD	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg02807482	chr3:125708958	NA	-0.66	-8.85	-0.4	2.44e-17	Blood pressure (smoking interaction);
LUAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg16606324	chr3:10149918	C3orf24	0.67	11.16	0.48	1.57e-25	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	6.87	0.32	2.25e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg14844989	chr11:31128820	NA	-0.47	-8.55	-0.38	2.31e-16	Red blood cell count;
LUAD	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.41	8.14	0.37	4.36e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1983170	1.000	rs10874785	chr1:92015243	G/A	cg21854759	chr1:92012499	NA	0.45	6.82	0.31	3.23e-11	Eosinophil percentage of white cells;
LUAD	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg17747265	chr1:1875780	NA	-0.76	-19.02	-0.68	9.74e-59	Body mass index;
LUAD	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-8.53	-0.38	2.62e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4711350	1.000	rs10947436	chr6:33739960	A/G	cg07979401	chr6:33739406	LEMD2	-0.52	-8.64	-0.39	1.13e-16	Schizophrenia;
LUAD	cis	rs73086581	1.000	rs17215340	chr20:3970173	C/G	cg02187196	chr20:3869020	PANK2	-0.42	-6.39	-0.3	4.49e-10	Response to antidepressants in depression;
LUAD	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg21153622	chr11:89784906	NA	-0.32	-6.43	-0.3	3.53e-10	Height;
LUAD	cis	rs2455799	0.613	rs3856830	chr3:15806520	A/C	cg16303742	chr3:15540471	COLQ	-0.52	-9.61	-0.42	6.5e-20	Mean platelet volume;
LUAD	cis	rs6430585	0.528	rs309133	chr2:136751842	A/C	cg07169764	chr2:136633963	MCM6	0.71	8.77	0.39	4.41e-17	Corneal structure;
LUAD	cis	rs8177876	0.822	rs1563075	chr16:81107748	T/C	cg08591886	chr16:81111003	C16orf46	-0.77	-7.25	-0.33	1.95e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg11062466	chr8:58055876	NA	0.65	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg24818145	chr4:99064322	C4orf37	0.46	7.81	0.36	4.46e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10203711	1.000	rs7582256	chr2:239587446	C/T	cg14580085	chr2:239553406	NA	0.42	9.05	0.4	5.22e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg26587870	chr6:27730563	NA	-0.54	-8.58	-0.38	1.85e-16	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
LUAD	trans	rs8002861	0.664	rs2218497	chr13:44428793	G/A	cg17145862	chr1:211918768	LPGAT1	0.65	13.02	0.53	8e-33	Leprosy;
LUAD	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.77	-0.35	6.02e-14	Monocyte count;
LUAD	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg13393036	chr8:95962371	TP53INP1	-0.43	-10.37	-0.45	1.32e-22	Type 2 diabetes;
LUAD	cis	rs7818345	0.967	rs11787230	chr8:19280982	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.29	6.42	0.3	3.6e-10	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-15.27	-0.6	2.95e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs877282	0.583	rs11253428	chr10:823233	C/T	cg22713356	chr15:30763199	NA	0.9	10.7	0.46	8.23e-24	Uric acid levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg00846720	chr4:170533756	NEK1	-0.63	-6.7	-0.31	6.6e-11	Type 2 diabetes;
LUAD	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg19163074	chr7:65112434	INTS4L2	0.42	6.64	0.31	9.58e-11	Aortic root size;
LUAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg09509183	chr1:209979624	IRF6	-0.58	-8.8	-0.39	3.59e-17	Cleft lip with or without cleft palate;
LUAD	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg11266682	chr4:10021025	SLC2A9	0.64	14.89	0.59	1.31e-40	Bone mineral density;
LUAD	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg26727032	chr16:67993705	SLC12A4	-0.49	-8.13	-0.37	4.91e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg19761014	chr17:28927070	LRRC37B2	0.86	8.34	0.38	1.07e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs17532515	0.652	rs67200893	chr4:141377690	G/A	cg03645522	chr4:141391200	NA	0.4	6.41	0.3	3.85e-10	Select biomarker traits;
LUAD	cis	rs1451375	0.617	rs12671474	chr7:50591395	C/A	cg18232548	chr7:50535776	DDC	0.62	8.47	0.38	3.99e-16	Malaria;
LUAD	trans	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.94	-0.32	1.52e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs698833	0.852	rs2241870	chr2:44549204	A/G	cg04920474	chr2:44395004	PPM1B	0.38	6.62	0.31	1.08e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg05084668	chr3:125655381	ALG1L	-0.89	-11.78	-0.5	6.55e-28	Blood pressure (smoking interaction);
LUAD	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg00981070	chr1:2046702	PRKCZ	0.36	6.95	0.32	1.37e-11	Height;
LUAD	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg00857998	chr1:205179979	DSTYK	0.4	6.51	0.3	2.18e-10	Red blood cell count;
LUAD	cis	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg08601574	chr20:25228251	PYGB	-0.46	-8.74	-0.39	5.71e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg03929089	chr4:120376271	NA	-0.46	-7.05	-0.32	7.37e-12	HDL cholesterol;
LUAD	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.42	-8.33	-0.38	1.1e-15	Glomerular filtration rate;
LUAD	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg13736514	chr6:26305472	NA	-0.68	-12.88	-0.53	3.05e-32	Educational attainment;
LUAD	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	7.24	0.33	2.09e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg00898013	chr13:113819073	PROZ	-0.69	-12.16	-0.51	2.16e-29	Platelet distribution width;
LUAD	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg16797656	chr11:68205561	LRP5	0.46	9.71	0.43	2.87e-20	Total body bone mineral density;
LUAD	trans	rs1493916	0.748	rs1845386	chr18:31318256	C/G	cg27147174	chr7:100797783	AP1S1	-0.65	-10.95	-0.47	9.67e-25	Life satisfaction;
LUAD	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg16486109	chr11:613632	IRF7	0.49	7.61	0.35	1.76e-13	Systemic lupus erythematosus;
LUAD	cis	rs6076065	0.548	rs6048742	chr20:23327584	T/C	cg11657817	chr20:23433608	CST11	0.54	11.31	0.48	4.34e-26	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg25535316	chr11:579198	PHRF1	-0.41	-6.64	-0.31	9.49e-11	Systemic lupus erythematosus;
LUAD	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg20587970	chr11:113659929	NA	-1.38	-20.87	-0.71	4.98e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg27124370	chr19:33622961	WDR88	0.45	7.33	0.34	1.17e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs8077889	1.000	rs2342310	chr17:41866199	T/C	cg26893861	chr17:41843967	DUSP3	0.96	14.72	0.58	6.5e-40	Triglycerides;
LUAD	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg03517284	chr6:25882590	NA	-0.4	-6.44	-0.3	3.29e-10	Height;
LUAD	cis	rs7216064	0.953	rs58141639	chr17:65864902	C/T	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs813218	0.565	rs6805884	chr3:99684808	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.3	-0.37	1.4e-15	Orofacial clefts;
LUAD	cis	rs1865721	0.771	rs8093397	chr18:73136217	C/G	cg26385618	chr18:73139727	C18orf62	-0.51	-10.47	-0.45	5.85e-23	Intelligence;
LUAD	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg05340658	chr4:99064831	C4orf37	0.53	8.98	0.4	8.92e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8073060	0.544	rs17550716	chr17:33893208	A/G	cg19694781	chr19:47549865	TMEM160	1.2	19.85	0.69	1.97e-62	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg13012494	chr21:47604986	C21orf56	-0.5	-7.64	-0.35	1.45e-13	Testicular germ cell tumor;
LUAD	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21545522	chr1:205238299	TMCC2	0.38	7.06	0.32	6.87e-12	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs7119038	0.818	rs10892286	chr11:118642085	A/C	cg19308663	chr11:118741387	NA	0.48	6.69	0.31	7.14e-11	Sjögren's syndrome;
LUAD	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg00071950	chr4:10020882	SLC2A9	0.85	18.22	0.66	3.53e-55	Bone mineral density;
LUAD	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18404041	chr3:52824283	ITIH1	-0.6	-12.6	-0.52	3.8e-31	Electroencephalogram traits;
LUAD	cis	rs9486719	0.947	rs2472893	chr6:96870048	G/C	cg06623918	chr6:96969491	KIAA0776	0.71	10.01	0.44	2.62e-21	Migraine;Coronary artery disease;
LUAD	cis	rs7172809	0.643	rs4886874	chr15:77838086	A/C	cg11865553	chr15:77376250	NA	0.37	6.51	0.3	2.08e-10	Glucose homeostasis traits;
LUAD	cis	rs7737355	0.812	rs798414	chr5:130696450	C/T	cg06307176	chr5:131281290	NA	-0.39	-6.57	-0.3	1.46e-10	Life satisfaction;
LUAD	cis	rs427394	0.659	rs175594	chr5:6729885	T/G	cg10857441	chr5:6722123	POLS	-0.62	-11.04	-0.47	4.32e-25	Menopause (age at onset);
LUAD	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg09367891	chr1:107599246	PRMT6	-0.58	-9.62	-0.42	6.03e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg03806693	chr22:41940476	POLR3H	0.68	9.35	0.41	5.23e-19	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg13334819	chr7:99746414	C7orf59	0.64	9.98	0.44	3.3e-21	Coronary artery disease;
LUAD	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24308560	chr3:49941425	MST1R	0.53	9.0	0.4	7.84e-18	Body mass index;
LUAD	cis	rs113835537	0.529	rs4930183	chr11:66255732	C/T	cg24851651	chr11:66362959	CCS	0.56	9.85	0.43	9.57e-21	Airway imaging phenotypes;
LUAD	cis	rs6539288	0.513	rs7977247	chr12:107259470	T/C	cg15890332	chr12:107067104	RFX4	0.37	7.77	0.35	5.93e-14	Total body bone mineral density;
LUAD	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg10518543	chr12:38710700	ALG10B	-0.44	-7.28	-0.33	1.66e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs3125734	0.607	rs7923556	chr10:64024648	A/G	cg09941381	chr10:64027924	RTKN2	-0.32	-7.49	-0.34	4.04e-13	Rheumatoid arthritis;
LUAD	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg19717773	chr7:2847554	GNA12	0.53	10.08	0.44	1.45e-21	Height;
LUAD	cis	rs17095355	0.710	rs2150211	chr10:111855414	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.78	-0.39	4.19e-17	Biliary atresia;
LUAD	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg07395648	chr5:131743802	NA	-0.37	-6.37	-0.3	5e-10	Breast cancer;
LUAD	cis	rs11031096	0.727	rs7932702	chr11:4124372	C/T	cg18678763	chr11:4115507	RRM1	-0.43	-7.42	-0.34	6.4e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27054308	chr14:20922865	APEX1;OSGEP	0.42	6.69	0.31	6.94e-11	Gut microbiome composition (summer);
LUAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.52	-8.21	-0.37	2.63e-15	Longevity;Endometriosis;
LUAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg13560548	chr3:10150139	C3orf24	0.4	6.56	0.3	1.53e-10	Alzheimer's disease;
LUAD	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg07606381	chr6:8435919	SLC35B3	0.44	7.22	0.33	2.48e-12	Motion sickness;
LUAD	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg19163074	chr7:65112434	INTS4L2	0.44	6.75	0.31	5.04e-11	Aortic root size;
LUAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg12373951	chr3:133503437	NA	0.4	7.98	0.36	1.36e-14	Iron status biomarkers;
LUAD	cis	rs7584330	0.554	rs79213383	chr2:238426890	A/G	cg14458575	chr2:238380390	NA	0.61	9.85	0.43	9.8e-21	Prostate cancer;
LUAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.34	0.34	1.13e-12	Tonsillectomy;
LUAD	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg13319975	chr6:146136371	FBXO30	0.57	9.61	0.42	6.51e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.53	0.34	3.1e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs2762353	0.574	rs4409177	chr6:25694491	T/G	cg03517284	chr6:25882590	NA	0.85	14.15	0.57	1.66e-37	Blood metabolite levels;
LUAD	cis	rs7408868	0.706	rs7257550	chr19:15292088	C/G	cg14696996	chr19:15285081	NOTCH3	0.67	9.04	0.4	5.62e-18	Pulse pressure;
LUAD	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg22482690	chr17:47019901	SNF8	0.47	9.19	0.41	1.75e-18	Type 2 diabetes;
LUAD	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg23505145	chr19:12996616	KLF1	0.61	9.97	0.44	3.56e-21	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs116095464	1.000	rs56095714	chr5:311256	C/T	cg22857025	chr5:266934	NA	-1.07	-8.6	-0.39	1.56e-16	Breast cancer;
LUAD	cis	rs2294693	0.579	rs10947939	chr6:40947618	C/G	cg14769373	chr6:40998127	UNC5CL	-0.5	-6.95	-0.32	1.43e-11	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg09253696	chr17:73873529	TRIM47	-0.41	-7.19	-0.33	3.04e-12	Psoriasis;
LUAD	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg12940439	chr1:67600707	NA	0.43	8.44	0.38	5.11e-16	Psoriasis;
LUAD	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg18240062	chr17:79603768	NPLOC4	0.36	6.43	0.3	3.43e-10	Eye color traits;
LUAD	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg11814155	chr7:99998594	ZCWPW1	0.45	7.65	0.35	1.32e-13	Platelet count;
LUAD	cis	rs714027	1.000	rs2412975	chr22:30540590	T/C	cg11564601	chr22:30592435	NA	-0.39	-8.33	-0.38	1.13e-15	Lymphocyte counts;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13948074	chr1:178511686	C1orf220	-0.45	-7.15	-0.33	3.77e-12	Height;
LUAD	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg27535305	chr1:53392650	SCP2	0.31	6.59	0.31	1.33e-10	Monocyte count;
LUAD	cis	rs7707921	1.000	rs7707921	chr5:81538046	T/A	cg15871215	chr5:81402204	ATG10	0.7	10.03	0.44	2.14e-21	Breast cancer;
LUAD	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21171335	chr12:122356390	WDR66	0.68	12.56	0.52	5.57e-31	Mean corpuscular volume;
LUAD	cis	rs7503807	1.000	rs12939613	chr17:78588202	A/G	cg09596252	chr17:78655493	RPTOR	0.36	6.77	0.31	4.19e-11	Obesity;
LUAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg04775059	chr7:64541387	NA	-0.51	-8.21	-0.37	2.65e-15	Calcium levels;
LUAD	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg04586622	chr2:25135609	ADCY3	0.37	8.36	0.38	9.25e-16	Body mass index;
LUAD	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg05110241	chr16:68378359	PRMT7	-0.84	-9.76	-0.43	2.02e-20	Schizophrenia;
LUAD	cis	rs754466	0.914	rs4595491	chr10:79685833	G/A	cg17075019	chr10:79541650	NA	-0.83	-13.86	-0.56	2.73e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1113500	0.933	rs11185255	chr1:108633191	T/A	cg06207961	chr1:108661230	NA	0.45	8.49	0.38	3.65e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg00701064	chr4:6280414	WFS1	0.58	10.78	0.46	4.09e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7818345	0.967	rs6999786	chr8:19277817	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.68	0.31	7.71e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs7614311	0.552	rs73117078	chr3:63942084	G/A	cg22134162	chr3:63841271	THOC7	-0.51	-8.06	-0.36	7.79e-15	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs8177876	0.822	rs8056972	chr16:81112422	C/A	cg08591886	chr16:81111003	C16orf46	-0.76	-7.04	-0.32	8.03e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg21984481	chr17:79567631	NPLOC4	0.71	17.17	0.64	1.6e-50	Eye color traits;
LUAD	cis	rs3791556	0.581	rs6543514	chr2:240096690	T/C	cg03281426	chr2:240109471	HDAC4	0.46	7.98	0.36	1.41e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg09029085	chr17:47094198	IGF2BP1	0.3	6.67	0.31	7.93e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg25894440	chr7:65020034	NA	-0.69	-7.27	-0.33	1.73e-12	Diabetic kidney disease;
LUAD	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg20290983	chr6:43655470	MRPS18A	1.06	26.88	0.79	1.46e-93	IgG glycosylation;
LUAD	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg12908607	chr1:44402522	ARTN	-0.45	-8.95	-0.4	1.1e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg16405210	chr4:1374714	KIAA1530	-0.6	-9.29	-0.41	8.06e-19	Longevity;
LUAD	cis	rs3823572	0.564	rs10272270	chr7:133636174	A/T	cg03336402	chr7:133662267	EXOC4	0.43	7.71	0.35	8.88e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26314531	chr2:26401878	FAM59B	-0.57	-8.0	-0.36	1.17e-14	Gut microbiome composition (summer);
LUAD	cis	rs12681288	0.676	rs935819	chr8:1021814	T/C	cg15309053	chr8:964076	NA	0.38	8.0	0.36	1.2e-14	Schizophrenia;
LUAD	cis	rs73198271	0.960	rs11776546	chr8:8609181	T/G	cg01851573	chr8:8652454	MFHAS1	0.51	8.07	0.37	7.36e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs476633	0.708	rs8031159	chr15:41445199	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.6	-10.78	-0.46	4.17e-24	Glomerular filtration rate (creatinine);
LUAD	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg18129748	chr3:49941408	MST1R	0.39	6.4	0.3	4.09e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6430585	0.527	rs76380759	chr2:136438517	G/A	cg07169764	chr2:136633963	MCM6	0.58	6.83	0.32	2.9e-11	Corneal structure;
LUAD	cis	rs4700695	0.841	rs251610	chr5:65278481	G/T	cg21114390	chr5:65439923	SFRS12	-0.6	-7.25	-0.33	1.98e-12	Facial morphology (factor 19);
LUAD	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg04800585	chr6:26043546	HIST1H2BB	0.5	8.59	0.39	1.68e-16	Intelligence (multi-trait analysis);
LUAD	trans	rs867371	0.502	rs1846908	chr15:82522526	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.41	-6.84	-0.32	2.76e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LUAD	cis	rs2274273	0.554	rs3742564	chr14:55530120	C/T	cg04306507	chr14:55594613	LGALS3	-0.33	-6.47	-0.3	2.76e-10	Protein biomarker;
LUAD	cis	rs34421088	0.585	rs10101661	chr8:11593504	C/T	cg13293535	chr8:11597251	GATA4	0.29	6.62	0.31	1.08e-10	Neuroticism;
LUAD	cis	rs2281636	1.000	rs2804417	chr10:101516215	G/A	cg17885402	chr10:101492224	COX15;CUTC	0.39	6.61	0.31	1.15e-10	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg07917127	chr4:99064746	C4orf37	0.44	7.23	0.33	2.35e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7828089	0.582	rs3817445	chr8:22266054	G/T	cg12081754	chr8:22256438	SLC39A14	0.68	11.34	0.48	3.24e-26	Verbal declarative memory;
LUAD	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg09035930	chr12:129282057	SLC15A4	0.71	15.79	0.61	1.73e-44	Systemic lupus erythematosus;
LUAD	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg17644776	chr2:200775616	C2orf69	-0.52	-6.53	-0.3	1.9e-10	Schizophrenia;
LUAD	cis	rs9837602	0.688	rs9839910	chr3:99907945	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.55	7.46	0.34	4.84e-13	Breast cancer;
LUAD	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg17480646	chr11:65405466	SIPA1	0.44	6.67	0.31	8.08e-11	Acne (severe);
LUAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg06937882	chr20:24974362	C20orf3	0.34	7.02	0.32	8.86e-12	Blood protein levels;
LUAD	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg13870426	chr17:30244630	NA	-0.57	-6.63	-0.31	1.05e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs10097731	0.901	rs10464931	chr8:82042664	A/G	cg25230327	chr8:82042993	NA	0.66	11.7	0.49	1.43e-27	Serum total protein level;
LUAD	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg00049323	chr5:472564	LOC25845	0.41	6.61	0.31	1.16e-10	Cystic fibrosis severity;
LUAD	cis	rs4845570	0.850	rs4504897	chr1:151766851	T/A	cg07092448	chr1:151763213	TDRKH	0.79	10.73	0.46	6.38e-24	Coronary artery disease;
LUAD	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg03233332	chr7:66118400	NA	-0.45	-6.64	-0.31	9.75e-11	Aortic root size;
LUAD	cis	rs7843479	0.965	rs3816786	chr8:21860425	A/T	cg03445287	chr8:21823731	XPO7	-0.45	-8.35	-0.38	9.84e-16	Mean corpuscular volume;
LUAD	cis	rs877282	1.000	rs71494928	chr10:769134	A/G	cg06581033	chr10:766294	NA	-0.6	-8.09	-0.37	6.22e-15	Uric acid levels;
LUAD	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.51e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-11.18	-0.48	1.31e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.76	0.35	6.46e-14	Platelet count;
LUAD	cis	rs4700695	0.719	rs27079	chr5:65443966	C/T	cg21114390	chr5:65439923	SFRS12	-0.93	-14.5	-0.58	6.06e-39	Facial morphology (factor 19);
LUAD	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg06108461	chr20:60628389	TAF4	-0.82	-13.96	-0.56	1.03e-36	Body mass index;
LUAD	trans	rs877282	1.000	rs12219807	chr10:772870	A/C	cg22713356	chr15:30763199	NA	1.17	16.73	0.63	1.35e-48	Uric acid levels;
LUAD	cis	rs3784262	0.740	rs4646600	chr15:58295616	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.42	-8.33	-0.38	1.11e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg02018176	chr4:1364513	KIAA1530	0.38	6.52	0.3	1.95e-10	Obesity-related traits;
LUAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg11062466	chr8:58055876	NA	0.67	9.02	0.4	6.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs11811982	0.793	rs80237401	chr1:227441012	G/A	cg24860534	chr1:227506868	CDC42BPA	0.62	6.84	0.32	2.78e-11	Optic disc area;
LUAD	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.81	0.36	4.47e-14	Bladder cancer;
LUAD	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg01689657	chr7:91764605	CYP51A1	0.32	7.64	0.35	1.43e-13	Breast cancer;
LUAD	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg10426581	chr7:100472382	SRRT	0.73	9.59	0.42	7.86e-20	Resting heart rate;
LUAD	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg25036284	chr2:26402008	FAM59B	-0.81	-11.66	-0.49	2e-27	Gut microbiome composition (summer);
LUAD	cis	rs1444418	1.000	rs12262796	chr10:64558740	T/C	cg14943953	chr10:64564468	ADO	-0.58	-6.92	-0.32	1.67e-11	Atopic dermatitis;
LUAD	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg25237894	chr2:233734115	C2orf82	0.63	11.92	0.5	2.01e-28	Coronary artery disease;
LUAD	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.02	0.32	8.9e-12	Hypertriglyceridemia;
LUAD	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg02782426	chr3:40428986	ENTPD3	0.43	9.01	0.4	7.19e-18	Renal cell carcinoma;
LUAD	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg17633681	chr16:88106987	BANP	0.39	6.93	0.32	1.57e-11	Menopause (age at onset);
LUAD	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg13606994	chr1:44402422	ARTN	-0.34	-7.02	-0.32	8.66e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.62	-0.35	1.63e-13	Lung cancer;
LUAD	trans	rs62458065	0.568	rs62466415	chr7:32518254	C/T	cg00845942	chr12:64062724	DPY19L2	-0.57	-7.55	-0.34	2.74e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg04989706	chr14:50066350	PPIL5	-0.53	-7.72	-0.35	8.41e-14	Carotid intima media thickness;
LUAD	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg24558204	chr6:135376177	HBS1L	-0.45	-8.32	-0.38	1.18e-15	Red blood cell count;
LUAD	trans	rs877282	0.842	rs12357963	chr10:757562	C/T	cg22713356	chr15:30763199	NA	1.23	15.56	0.6	1.71e-43	Uric acid levels;
LUAD	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg24558204	chr6:135376177	HBS1L	0.48	8.88	0.4	1.94e-17	Red blood cell count;
LUAD	cis	rs6906287	0.647	rs2356492	chr6:118809437	C/G	cg21191810	chr6:118973309	C6orf204	0.5	9.79	0.43	1.52e-20	Electrocardiographic conduction measures;
LUAD	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg26384229	chr12:38710491	ALG10B	0.53	8.54	0.38	2.36e-16	Heart rate;
LUAD	cis	rs6714710	0.603	rs55776387	chr2:98405034	T/C	cg26665480	chr2:98280029	ACTR1B	0.49	8.15	0.37	4.2e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg15017067	chr4:17643749	FAM184B	0.37	7.3	0.33	1.45e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg19743168	chr1:23544995	NA	0.36	6.44	0.3	3.23e-10	Height;
LUAD	cis	rs6494488	0.500	rs72743002	chr15:65011195	G/A	cg08069370	chr15:64387884	SNX1	-0.76	-6.77	-0.31	4.43e-11	Coronary artery disease;
LUAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg04025307	chr7:1156635	C7orf50	0.6	6.77	0.31	4.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg06753367	chr22:24256600	NA	-0.38	-6.87	-0.32	2.36e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13837895	chr19:50145301	SCAF1	-0.39	-6.43	-0.3	3.44e-10	Height;
LUAD	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg22963979	chr7:1858916	MAD1L1	-0.5	-8.56	-0.38	2.14e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs68170813	0.559	rs12537011	chr7:107027833	G/A	cg23024343	chr7:107201750	COG5	0.52	7.2	0.33	2.84e-12	Coronary artery disease;
LUAD	trans	rs3857536	0.741	rs2097679	chr6:66937994	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg07936489	chr17:37558343	FBXL20	0.46	7.33	0.34	1.21e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	7.4	0.34	7.46e-13	Platelet count;
LUAD	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg12615879	chr12:58013172	SLC26A10	0.48	10.35	0.45	1.52e-22	Multiple sclerosis;
LUAD	cis	rs367943	0.608	rs6898912	chr5:112989978	C/T	cg12552261	chr5:112820674	MCC	0.42	7.58	0.35	2.16e-13	Type 2 diabetes;
LUAD	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg22681709	chr2:178499509	PDE11A	-0.49	-8.3	-0.37	1.44e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	9.24	0.41	1.2e-18	Total body bone mineral density;
LUAD	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03517284	chr6:25882590	NA	-0.86	-12.22	-0.51	1.28e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg25894440	chr7:65020034	NA	-0.68	-7.32	-0.34	1.29e-12	Diabetic kidney disease;
LUAD	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg09650180	chr20:62225654	GMEB2	-0.48	-6.93	-0.32	1.53e-11	Glioma;Non-glioblastoma glioma;Glioblastoma;
LUAD	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.58	-0.35	2.13e-13	Lung cancer;
LUAD	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg23387056	chr11:14280742	SPON1	0.47	9.99	0.44	2.95e-21	Mitochondrial DNA levels;
LUAD	trans	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04565464	chr8:145669602	NFKBIL2	-0.43	-6.59	-0.31	1.3100000000000001e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg19682962	chr22:31796123	DRG1	0.39	6.48	0.3	2.54e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg12292205	chr6:26970375	C6orf41	-0.6	-10.35	-0.45	1.54e-22	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs240764	0.817	rs240115	chr6:101053069	T/C	cg09795085	chr6:101329169	ASCC3	0.44	7.69	0.35	1.04e-13	Neuroticism;
LUAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg18621852	chr3:10150065	C3orf24	0.49	8.47	0.38	3.98e-16	Alzheimer's disease;
LUAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg05313129	chr8:58192883	C8orf71	-0.6	-7.15	-0.33	3.8e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg04775059	chr7:64541387	NA	-0.52	-8.4	-0.38	6.8e-16	Calcium levels;
LUAD	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg11062466	chr8:58055876	NA	0.58	7.85	0.36	3.46e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg10295955	chr4:187884368	NA	-1.09	-25.81	-0.78	6.81e-89	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg10755058	chr3:40428713	ENTPD3	-0.36	-6.68	-0.31	7.6e-11	Renal cell carcinoma;
LUAD	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg02734326	chr4:10020555	SLC2A9	0.63	11.33	0.48	3.46e-26	Bone mineral density;
LUAD	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs4253772	0.744	rs9627278	chr22:46643432	C/G	cg09491104	chr22:46646882	C22orf40	-0.52	-9.61	-0.42	6.84e-20	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg06221963	chr1:154839813	KCNN3	0.83	19.46	0.69	1.01e-60	Prostate cancer;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg08793459	chr17:57784647	PTRH2;TMEM49	-0.49	-6.72	-0.31	5.89e-11	Testicular germ cell tumor;
LUAD	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg01579765	chr21:45077557	HSF2BP	-0.59	-13.49	-0.55	9.93e-35	Mean corpuscular volume;
LUAD	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.09	15.22	0.59	4.94e-42	Lung cancer in ever smokers;
LUAD	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg04727924	chr7:799746	HEATR2	-0.54	-7.51	-0.34	3.55e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg00784671	chr22:46762841	CELSR1	-0.53	-7.3	-0.33	1.41e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg18016565	chr1:150552671	MCL1	0.41	7.5	0.34	3.86e-13	Tonsillectomy;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07374247	chr6:27860935	HIST1H2AM;HIST1H2BO	-0.43	-6.6	-0.31	1.2e-10	Height;
LUAD	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	7.25	0.33	1.97e-12	Iron status biomarkers;
LUAD	trans	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg18187862	chr3:45730750	SACM1L	0.53	8.17	0.37	3.68e-15	Primary sclerosing cholangitis;
LUAD	cis	rs1137	1.000	rs1137	chr2:74939176	A/G	cg19285774	chr2:74907978	SEMA4F	-0.37	-7.0	-0.32	1.03e-11	Myopia (pathological);
LUAD	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg16535667	chr11:65410126	SIPA1	-0.49	-7.3	-0.33	1.47e-12	Blood pressure (age interaction);
LUAD	trans	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg07211511	chr3:129823064	LOC729375	-0.56	-7.24	-0.33	2.14e-12	Blood pressure (smoking interaction);
LUAD	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18404041	chr3:52824283	ITIH1	-0.57	-12.02	-0.5	7.99e-29	Electroencephalogram traits;
LUAD	cis	rs72901758	0.696	rs72909029	chr17:76249451	A/G	cg26068271	chr17:76253126	NA	0.48	8.09	0.37	6.38e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg05709478	chr1:6581295	PLEKHG5	0.6	7.82	0.36	4.24e-14	Body mass index;
LUAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg10729496	chr3:10149963	C3orf24	0.6	10.05	0.44	1.82e-21	Alzheimer's disease;
LUAD	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg13535736	chr9:111863775	C9orf5	-0.42	-6.45	-0.3	3.09e-10	Menarche (age at onset);
LUAD	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg11530693	chr1:120165357	ZNF697	0.87	18.35	0.67	9.12e-56	Systemic lupus erythematosus;
LUAD	cis	rs4730250	0.654	rs6947857	chr7:106787266	T/G	cg02696742	chr7:106810147	HBP1	0.82	10.9	0.47	1.49e-24	Osteoarthritis;
LUAD	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg05340658	chr4:99064831	C4orf37	0.47	6.64	0.31	9.88e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12200782	1.000	rs72844495	chr6:26610640	T/C	cg08851530	chr6:28072375	NA	0.72	6.59	0.31	1.28e-10	Small cell lung carcinoma;
LUAD	cis	rs11229555	0.609	rs12273517	chr11:58201094	C/T	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg25894440	chr7:65020034	NA	0.63	6.73	0.31	5.63e-11	Gout;
LUAD	cis	rs7827545	1.000	rs4909481	chr8:135564555	A/G	cg17885191	chr8:135476712	NA	0.49	7.78	0.35	5.77e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg18621852	chr3:10150065	C3orf24	0.49	8.83	0.39	2.72e-17	Alzheimer's disease;
LUAD	cis	rs4454254	1.000	rs4440615	chr8:141057641	G/A	cg06693505	chr8:141057453	TRAPPC9	-0.32	-6.69	-0.31	6.96e-11	Pulse pressure;
LUAD	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.45	-8.18	-0.37	3.27e-15	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg01579765	chr21:45077557	HSF2BP	-0.59	-13.68	-0.55	1.5e-35	Mean corpuscular volume;
LUAD	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg15962314	chr1:44399869	ARTN	0.31	6.93	0.32	1.54e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs637571	0.524	rs674363	chr11:65699134	G/A	cg17712092	chr4:129076599	LARP1B	-0.89	-16.95	-0.64	1.43e-49	Eosinophil percentage of white cells;
LUAD	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg04414720	chr1:150670196	GOLPH3L	-0.7	-11.65	-0.49	2.17e-27	Blood protein levels;
LUAD	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.88	-0.47	1.79e-24	Total body bone mineral density;
LUAD	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg17366294	chr4:99064904	C4orf37	-0.66	-12.76	-0.53	8.75e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1003719	0.680	rs3992	chr21:38505969	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-9.06	-0.4	4.8e-18	Eye color traits;
LUAD	cis	rs8192282	0.739	rs6656395	chr1:154500016	T/C	cg16683920	chr1:154474344	TDRD10;SHE	-0.46	-7.08	-0.33	6.18e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg07404485	chr7:94953653	PON1	-0.49	-7.05	-0.32	7.28e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs986417	0.892	rs11622577	chr14:60814981	A/T	cg27398547	chr14:60952738	C14orf39	-0.62	-7.37	-0.34	8.82e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs11126435	0.858	rs75141469	chr2:74933617	G/A	cg19285774	chr2:74907978	SEMA4F	0.36	6.4	0.3	4.14e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg25358565	chr5:93447407	FAM172A	0.58	7.2	0.33	2.69e-12	Diabetic retinopathy;
LUAD	cis	rs11945232	1.000	rs10027786	chr4:88347512	A/G	cg23841344	chr4:88312519	HSD17B11	-0.54	-8.06	-0.36	7.8e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7593730	1.000	rs11693602	chr2:161224658	A/G	cg22609984	chr2:161126801	NA	-0.43	-7.07	-0.33	6.3e-12	Type 2 diabetes;
LUAD	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg02569458	chr12:86230093	RASSF9	0.43	7.86	0.36	3.32e-14	Major depressive disorder;
LUAD	trans	rs853679	1.000	rs1679709	chr6:28228342	A/G	cg01620082	chr3:125678407	NA	0.48	6.48	0.3	2.55e-10	Depression;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg03701779	chr10:74927978	FAM149B1;ECD	-0.39	-6.77	-0.31	4.39e-11	Schizophrenia;
LUAD	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs62229266	0.804	rs2835259	chr21:37425302	T/C	cg12218747	chr21:37451666	NA	-0.47	-8.08	-0.37	7.09e-15	Mitral valve prolapse;
LUAD	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04856096	chr8:68255097	ARFGEF1	0.44	6.4	0.3	4.2e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs909002	0.819	rs4949457	chr1:32140053	C/T	cg13919466	chr1:32135498	COL16A1	0.31	6.9	0.32	1.88e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg23260525	chr10:116636907	FAM160B1	0.47	11.0	0.47	6.26e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg15448220	chr1:150897856	SETDB1	-0.46	-7.97	-0.36	1.49e-14	Tonsillectomy;
LUAD	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg17443473	chr1:3703550	LRRC47	0.45	7.59	0.35	2.02e-13	Red cell distribution width;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11490987	chr7:149535717	ZNF862	-0.54	-6.55	-0.3	1.72e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs8064299	0.584	rs2384957	chr17:72784630	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.43	7.11	0.33	4.99e-12	Monocyte count;
LUAD	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.67e-15	Bipolar disorder;
LUAD	trans	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	26.66	0.79	1.38e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs11118844	0.793	rs10863654	chr1:221946787	G/A	cg04222084	chr1:221915650	DUSP10	-0.68	-7.56	-0.34	2.58e-13	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	cis	rs41311933	1.000	rs41311863	chr9:123757620	G/C	cg13567360	chr9:123745713	C5	-0.76	-8.44	-0.38	4.99e-16	Coronary artery disease;
LUAD	cis	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg05084668	chr3:125655381	ALG1L	-0.66	-8.86	-0.4	2.19e-17	Blood pressure (smoking interaction);
LUAD	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg14092988	chr3:52407081	DNAH1	0.45	9.08	0.4	4.18e-18	Bipolar disorder;
LUAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg22963979	chr7:1858916	MAD1L1	-0.62	-10.75	-0.46	5.62e-24	Bipolar disorder and schizophrenia;
LUAD	trans	rs28595532	0.557	rs4359977	chr4:119314055	T/C	cg26518628	chr1:97050305	NA	-0.47	-6.41	-0.3	3.98e-10	Cannabis dependence symptom count;
LUAD	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg18944383	chr4:111397179	ENPEP	0.37	7.43	0.34	5.9e-13	Height;
LUAD	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg13699009	chr12:122356056	WDR66	0.32	6.98	0.32	1.14e-11	Mean corpuscular volume;
LUAD	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg10434728	chr15:90938212	IQGAP1	-0.36	-6.95	-0.32	1.42e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs533581	0.866	rs488251	chr16:88972554	G/A	cg16701003	chr16:89028210	CBFA2T3	0.54	10.55	0.46	3.04e-23	Social autistic-like traits;
LUAD	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg00814883	chr7:100076585	TSC22D4	-0.8	-11.59	-0.49	3.55e-27	Platelet count;
LUAD	cis	rs28830936	0.966	rs2303518	chr15:42109975	T/G	cg17847044	chr15:42102381	MAPKBP1	-0.38	-8.05	-0.36	8.29e-15	Diastolic blood pressure;
LUAD	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg05182265	chr7:156933206	UBE3C	-0.8	-17.28	-0.64	5.14e-51	Body mass index;
LUAD	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg27631724	chr1:11040367	C1orf127	0.53	8.98	0.4	8.82e-18	Ewing sarcoma;
LUAD	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06022373	chr22:39101656	GTPBP1	0.44	6.96	0.32	1.33e-11	Menopause (age at onset);
LUAD	cis	rs13315871	0.929	rs4560319	chr3:58386274	C/T	cg20936604	chr3:58311152	NA	-0.68	-7.11	-0.33	4.88e-12	Cholesterol, total;
LUAD	cis	rs8060686	0.516	rs8048364	chr16:68253324	T/G	cg26727032	chr16:67993705	SLC12A4	-0.48	-7.92	-0.36	2.14e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6499255	0.904	rs7190652	chr16:69616292	C/G	cg15192750	chr16:69999425	NA	0.54	8.4	0.38	6.84e-16	IgE levels;
LUAD	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg05368731	chr17:41323189	NBR1	0.97	20.67	0.71	3.87e-66	Menopause (age at onset);
LUAD	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg11057378	chr10:81107060	PPIF	0.37	6.99	0.32	1.11e-11	Height;
LUAD	cis	rs2294693	0.679	rs4317403	chr6:40971173	C/T	cg14769373	chr6:40998127	UNC5CL	-0.53	-7.41	-0.34	7.09e-13	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg04218760	chr10:45406644	TMEM72	-0.3	-7.5	-0.34	3.91e-13	Mean corpuscular volume;
LUAD	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg19717773	chr7:2847554	GNA12	-0.52	-9.78	-0.43	1.63e-20	Height;
LUAD	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg04450456	chr4:17643702	FAM184B	0.36	6.97	0.32	1.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs243505	0.898	rs243532	chr7:148412371	A/G	cg09806900	chr7:148480153	CUL1	-0.45	-7.48	-0.34	4.19e-13	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9283706	0.641	rs1990894	chr5:66331685	C/T	cg11590213	chr5:66331682	MAST4	0.39	6.68	0.31	7.61e-11	Coronary artery disease;
LUAD	cis	rs4891159	0.790	rs9950025	chr18:74113596	C/G	cg24786174	chr18:74118243	ZNF516	0.8	15.12	0.59	1.36e-41	Longevity;
LUAD	cis	rs9868809	0.881	rs6773261	chr3:48675064	A/G	cg00383909	chr3:49044727	WDR6	0.61	6.81	0.31	3.44e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg21095983	chr6:86352623	SYNCRIP	0.46	7.23	0.33	2.31e-12	Smooth-surface caries;
LUAD	cis	rs939658	0.805	rs11634903	chr15:79436192	C/T	cg17916960	chr15:79447300	NA	0.51	10.59	0.46	2.15e-23	Refractive error;
LUAD	cis	rs7100689	0.556	rs10788541	chr10:82016530	T/G	cg01528321	chr10:82214614	TSPAN14	0.49	7.65	0.35	1.34e-13	Post bronchodilator FEV1;
LUAD	cis	rs7927771	0.524	rs11039402	chr11:47826090	A/C	cg18512352	chr11:47633146	NA	0.36	6.38	0.3	4.61e-10	Subjective well-being;
LUAD	trans	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg03886242	chr7:26192032	NFE2L3	-0.48	-8.43	-0.38	5.39e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.31	6.45	0.3	3.11e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs853679	0.607	rs13217984	chr6:28139710	A/T	cg06606381	chr12:133084897	FBRSL1	-1.22	-10.86	-0.47	2.15e-24	Depression;
LUAD	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	8.03e-16	Body mass index;
LUAD	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.15	0.33	3.72e-12	Menopause (age at onset);
LUAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg14789911	chr21:47582049	C21orf56	-0.46	-8.2	-0.37	2.92e-15	Testicular germ cell tumor;
LUAD	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg16405210	chr4:1374714	KIAA1530	-0.43	-7.18	-0.33	3.15e-12	Longevity;
LUAD	cis	rs7561273	0.609	rs6720226	chr2:24295853	A/G	cg20701182	chr2:24300061	SF3B14	0.41	6.83	0.32	2.96e-11	Quantitative traits;
LUAD	cis	rs7428	0.527	rs7608892	chr2:85542718	G/A	cg24342717	chr2:85555507	TGOLN2	-0.5	-8.2	-0.37	2.9e-15	Ear protrusion;
LUAD	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-6.54	-0.3	1.79e-10	IgG glycosylation;
LUAD	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg00316803	chr15:76480434	C15orf27	0.39	6.41	0.3	3.95e-10	Blood metabolite levels;
LUAD	cis	rs10426930	0.700	rs7253212	chr19:5021391	G/A	cg25246084	chr19:4971487	KDM4B	-0.44	-7.83	-0.36	3.96e-14	Monocyte percentage of white cells;
LUAD	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg08296037	chr16:1584118	IFT140;TMEM204	-0.27	-6.76	-0.31	4.64e-11	Coronary artery disease;
LUAD	cis	rs7166081	0.672	rs12441715	chr15:67860587	G/A	cg24579218	chr15:68104479	NA	-0.49	-7.99	-0.36	1.29e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs6011002	0.590	rs1298721	chr20:62352319	T/C	cg01176363	chr20:62369445	LIME1	-0.79	-6.64	-0.31	9.47e-11	Dental caries;
LUAD	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg24531977	chr5:56204891	C5orf35	-0.66	-10.82	-0.47	3.08e-24	Coronary artery disease;
LUAD	cis	rs7474896	0.559	rs1208560	chr10:38221618	A/T	cg25427524	chr10:38739819	LOC399744	0.58	8.4	0.38	6.82e-16	Obesity (extreme);
LUAD	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg11070056	chr1:107600091	PRMT6	-0.64	-11.02	-0.47	5.19e-25	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs68170813	0.559	rs75154004	chr7:106903326	C/T	cg02696742	chr7:106810147	HBP1	-0.78	-10.87	-0.47	1.93e-24	Coronary artery disease;
LUAD	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg05042697	chr2:10830656	NOL10	-0.37	-6.38	-0.3	4.72e-10	Prostate cancer;
LUAD	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg02782426	chr3:40428986	ENTPD3	0.43	9.18	0.41	1.91e-18	Renal cell carcinoma;
LUAD	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21582582	chr3:182698605	DCUN1D1	0.59	10.06	0.44	1.73e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg08508325	chr11:3079039	CARS	-0.61	-13.14	-0.54	2.66e-33	Longevity;
LUAD	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg21775007	chr8:11205619	TDH	-0.53	-9.71	-0.43	2.96e-20	Retinal vascular caliber;
LUAD	cis	rs524023	0.914	rs11607663	chr11:64368670	G/C	cg19131476	chr11:64387923	NRXN2	-0.43	-8.34	-0.38	1.06e-15	Urate levels in obese individuals;
LUAD	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.4	0.55	2.27e-34	Tonsillectomy;
LUAD	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg04036182	chr15:45458818	NA	-0.4	-6.91	-0.32	1.78e-11	Glomerular filtration rate;
LUAD	cis	rs4700695	1.000	rs4700696	chr5:65412634	G/C	cg21114390	chr5:65439923	SFRS12	-0.57	-6.48	-0.3	2.54e-10	Facial morphology (factor 19);
LUAD	trans	rs3756407	1.000	rs267977	chr5:10720879	A/T	cg10835083	chr2:222395101	EPHA4	0.76	6.36	0.3	5.19e-10	Metabolite levels (Pyroglutamine);
LUAD	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg07538946	chr5:131705188	SLC22A5	-0.49	-8.21	-0.37	2.73e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs1018836	0.527	rs13268721	chr8:91481549	G/A	cg16814680	chr8:91681699	NA	-0.68	-11.34	-0.48	3.27e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg14396892	chr9:96623032	NA	-0.44	-8.54	-0.38	2.37e-16	DNA methylation (variation);
LUAD	cis	rs1595825	0.891	rs16826873	chr2:198898222	A/C	cg10547527	chr2:198650123	BOLL	0.52	7.1	0.33	5.41e-12	Ulcerative colitis;
LUAD	cis	rs6500395	1.000	rs9936467	chr16:48677983	T/C	cg04672837	chr16:48644449	N4BP1	0.39	6.81	0.31	3.43e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg11901034	chr3:128598214	ACAD9	-0.55	-8.79	-0.39	3.75e-17	IgG glycosylation;
LUAD	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg19318889	chr4:1322082	MAEA	0.46	7.57	0.35	2.38e-13	Obesity-related traits;
LUAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08280861	chr8:58055591	NA	0.65	8.49	0.38	3.63e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg20578329	chr17:80767326	TBCD	-0.65	-7.41	-0.34	7.04e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs2625529	0.652	rs2034879	chr15:72429989	A/G	cg16672083	chr15:72433130	SENP8	-0.64	-11.91	-0.5	2.04e-28	Red blood cell count;
LUAD	cis	rs4730250	0.707	rs6977868	chr7:106790555	T/G	cg02696742	chr7:106810147	HBP1	0.83	10.68	0.46	9.52e-24	Osteoarthritis;
LUAD	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg09455208	chr3:40491958	NA	0.56	12.36	0.51	3.7e-30	Renal cell carcinoma;
LUAD	cis	rs6710529	1	rs6710529	chr2:219645553	G/A	cg02176678	chr2:219576539	TTLL4	-0.59	-11.75	-0.5	8.62e-28	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3789045	0.685	rs12036042	chr1:204469314	T/C	cg17419461	chr1:204415978	PIK3C2B	-0.42	-7.14	-0.33	4.18e-12	Educational attainment (college completion);
LUAD	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg06002616	chr8:101225028	SPAG1	-0.39	-7.92	-0.36	2.06e-14	Atrioventricular conduction;
LUAD	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg07917127	chr4:99064746	C4orf37	0.41	6.72	0.31	6.05e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6669119	0.668	rs17352385	chr1:19087695	A/G	cg26220594	chr1:19110978	NA	0.58	7.31	0.34	1.32e-12	Percentage gas trapping;
LUAD	cis	rs3820068	0.705	rs4645983	chr1:15850603	G/A	cg13390004	chr1:15929781	NA	0.41	6.74	0.31	5.37e-11	Systolic blood pressure;
LUAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs7944735	0.817	rs2305983	chr11:47858755	C/T	cg15704280	chr7:45808275	SEPT13	0.53	7.09	0.33	5.62e-12	Intraocular pressure;
LUAD	cis	rs863345	0.564	rs10908667	chr1:158500121	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.49	-0.3	2.34e-10	Pneumococcal bacteremia;
LUAD	cis	rs4481233	0.528	rs115776655	chr4:10381329	C/T	cg00071950	chr4:10020882	SLC2A9	-0.59	-8.18	-0.37	3.4e-15	Metabolic traits;
LUAD	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg00666640	chr1:248458726	OR2T12	0.3	7.22	0.33	2.47e-12	Common traits (Other);
LUAD	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg15704280	chr7:45808275	SEPT13	-1.0	-20.58	-0.71	1.06e-65	Height;
LUAD	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg21775007	chr8:11205619	TDH	0.38	6.41	0.3	4e-10	Mood instability;
LUAD	cis	rs4700695	0.719	rs27077	chr5:65445342	C/T	cg21114390	chr5:65439923	SFRS12	0.89	14.58	0.58	2.64e-39	Facial morphology (factor 19);
LUAD	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-8.22	-0.37	2.45e-15	Major depressive disorder;
LUAD	cis	rs6076065	0.683	rs2424556	chr20:23419556	C/T	cg11657817	chr20:23433608	CST11	0.48	9.37	0.41	4.35e-19	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg23422044	chr7:1970798	MAD1L1	-0.58	-7.19	-0.33	2.99e-12	Bipolar disorder;
LUAD	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg11459648	chr5:138714337	SLC23A1	-0.41	-7.16	-0.33	3.65e-12	Esophageal squamous cell carcinoma;
LUAD	cis	rs9902453	0.726	rs3115092	chr17:28036350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.28	0.45	2.74e-22	Coffee consumption (cups per day);
LUAD	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg19077165	chr18:44547161	KATNAL2	-0.44	-7.62	-0.35	1.72e-13	Personality dimensions;
LUAD	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18876405	chr7:65276391	NA	-0.6	-10.1	-0.44	1.24e-21	Aortic root size;
LUAD	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg00129232	chr17:37814104	STARD3	-0.45	-7.43	-0.34	6.19e-13	Asthma;
LUAD	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg15147215	chr3:52552868	STAB1	-0.41	-7.49	-0.34	4.08e-13	Bipolar disorder;
LUAD	cis	rs755383	0.545	rs13295058	chr9:858735	A/G	cg14021170	chr9:826657	NA	0.46	7.65	0.35	1.39e-13	Testicular germ cell tumor;Testicular germ cell cancer;Testicular cancer;
LUAD	cis	rs11650494	0.908	rs73340399	chr17:47372743	G/C	cg08112188	chr17:47440006	ZNF652	0.93	8.07	0.37	7.58e-15	Prostate cancer;
LUAD	cis	rs4953076	0.573	rs920519	chr2:44452344	T/C	cg04920474	chr2:44395004	PPM1B	0.54	8.53	0.38	2.71e-16	Height;
LUAD	cis	rs4953318	0.619	rs13406901	chr2:46363066	T/G	cg12428440	chr2:46370979	PRKCE	0.42	6.81	0.31	3.38e-11	Red blood cell count;Hematocrit;Red blood cell traits;
LUAD	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg22117172	chr7:91764530	CYP51A1	0.34	7.63	0.35	1.58e-13	Breast cancer;
LUAD	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg10523679	chr1:76189770	ACADM	0.94	18.49	0.67	2.18e-56	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg07636037	chr3:49044803	WDR6	0.54	10.35	0.45	1.52e-22	Menarche (age at onset);
LUAD	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg03929089	chr4:120376271	NA	-0.66	-10.76	-0.46	5.18e-24	Coronary artery disease;
LUAD	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg00814883	chr7:100076585	TSC22D4	-0.81	-11.48	-0.49	9.75e-27	Platelet count;
LUAD	cis	rs2625529	0.824	rs12439900	chr15:72373640	A/G	cg16672083	chr15:72433130	SENP8	-0.75	-12.7	-0.53	1.61e-31	Red blood cell count;
LUAD	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg23018236	chr17:30244563	NA	-0.63	-8.21	-0.37	2.66e-15	Hip circumference adjusted for BMI;
LUAD	trans	rs80264589	1	rs80264589	chr6:26927602	G/A	cg01620082	chr3:125678407	NA	-0.95	-9.07	-0.4	4.48e-18	Lung cancer;Intelligence (multi-trait analysis);
LUAD	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.83	11.38	0.48	2.37e-26	Smoking behavior;
LUAD	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg07195577	chr17:27052828	TLCD1	0.46	6.45	0.3	3.07e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.42	-0.34	6.62e-13	Coronary artery disease;
LUAD	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-13.48	-0.55	1.04e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs17095355	1.000	rs9630102	chr10:111738662	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.67	-9.1	-0.4	3.56e-18	Biliary atresia;
LUAD	cis	rs11741688	0.557	rs6897783	chr5:178330574	G/A	cg21944022	chr5:178288650	ZNF354B	0.5	9.28	0.41	8.92e-19	Sleep duration;
LUAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg10729496	chr3:10149963	C3orf24	0.55	8.96	0.4	1.06e-17	Alzheimer's disease;
LUAD	cis	rs6743376	0.509	rs3180234	chr2:113820655	A/T	cg09040174	chr2:113837401	NA	0.46	7.2	0.33	2.7e-12	Inflammatory biomarkers;
LUAD	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.4	-0.34	7.21e-13	Breast cancer;
LUAD	cis	rs9487051	0.735	rs352837	chr6:109521806	C/T	cg21918786	chr6:109611834	NA	0.43	7.84	0.36	3.69e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs3849570	1.000	rs11915016	chr3:81833966	G/A	cg07356753	chr3:81810745	GBE1	-0.71	-12.74	-0.53	1.11e-31	Waist circumference;Body mass index;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26261793	chr1:171810543	DNM3	-0.63	-6.52	-0.3	1.99e-10	Type 2 diabetes;
LUAD	cis	rs28785552	0.769	rs7253672	chr19:53243212	G/C	cg10871876	chr19:53194124	ZNF83	0.41	6.45	0.3	2.99e-10	Response to paliperidone in schizophrenia (PANSS score);
LUAD	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg04154034	chr17:28927549	LRRC37B2	0.68	6.78	0.31	4.08e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs12540874	0.542	rs4947581	chr7:50565967	G/A	cg18232548	chr7:50535776	DDC	-0.67	-12.42	-0.52	1.97e-30	Systemic sclerosis;
LUAD	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08280861	chr8:58055591	NA	0.55	7.16	0.33	3.53e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg00280220	chr17:61926910	NA	0.37	7.05	0.32	7.26e-12	Prudent dietary pattern;
LUAD	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.88	-0.5	2.72e-28	Electroencephalogram traits;
LUAD	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg02549819	chr16:58548995	SETD6	0.8	6.55	0.3	1.69e-10	Schizophrenia;
LUAD	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg03806693	chr22:41940476	POLR3H	-0.56	-8.08	-0.37	6.76e-15	Vitiligo;
LUAD	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg11344533	chr11:111475393	SIK2	-0.37	-6.77	-0.31	4.23e-11	Primary sclerosing cholangitis;
LUAD	cis	rs41311933	1.000	rs16910255	chr9:123756983	C/T	cg13567360	chr9:123745713	C5	-0.75	-9.06	-0.4	5.04e-18	Coronary artery disease;
LUAD	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg23018236	chr17:30244563	NA	-0.68	-8.26	-0.37	1.93e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg03609598	chr5:56110824	MAP3K1	-0.57	-7.9	-0.36	2.36e-14	Initial pursuit acceleration;
LUAD	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg00814883	chr7:100076585	TSC22D4	-0.85	-12.48	-0.52	1.24e-30	Platelet count;
LUAD	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg09253696	chr17:73873529	TRIM47	0.4	6.98	0.32	1.17e-11	Psoriasis;
LUAD	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg13180566	chr4:1052158	NA	-0.4	-6.72	-0.31	5.87e-11	Recombination rate (females);
LUAD	cis	rs2637266	1.000	rs12413656	chr10:78379666	A/C	cg18941641	chr10:78392320	NA	0.34	7.09	0.33	5.52e-12	Pulmonary function;
LUAD	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg08132940	chr7:1081526	C7orf50	-0.56	-6.36	-0.3	5.21e-10	Longevity;Endometriosis;
LUAD	cis	rs59698941	0.891	rs59707248	chr5:132267535	C/T	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.62	0.31	1.12e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg12310025	chr6:25882481	NA	0.89	14.85	0.59	1.9e-40	Blood metabolite levels;
LUAD	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg24813613	chr7:1882135	MAD1L1	-0.4	-6.41	-0.3	3.88e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.05e-19	Life satisfaction;
LUAD	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.34	6.61	0.31	1.18e-10	IgG glycosylation;
LUAD	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg22875332	chr1:76189707	ACADM	0.89	18.19	0.66	4.78e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs11971779	0.590	rs4732374	chr7:139091453	G/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg17031739	chr1:67600172	NA	0.5	8.92	0.4	1.47e-17	Psoriasis;
LUAD	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.23	-0.37	2.38e-15	Bipolar disorder;
LUAD	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg25817165	chr18:72167213	CNDP2	-0.69	-9.97	-0.44	3.5e-21	Refractive error;
LUAD	cis	rs11893307	0.537	rs1558473	chr2:191504064	A/C	cg11845111	chr2:191398756	TMEM194B	-0.44	-6.51	-0.3	2.12e-10	Mean platelet volume;
LUAD	cis	rs863345	0.604	rs2054992	chr1:158506015	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.6	-0.31	1.25e-10	Pneumococcal bacteremia;
LUAD	cis	rs8017423	0.967	rs11627528	chr14:90719697	C/A	cg14092571	chr14:90743983	NA	0.45	7.79	0.35	5.12e-14	Mortality in heart failure;
LUAD	trans	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.42	0.52	1.99e-30	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-6.54	-0.3	1.79e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg25358565	chr5:93447407	FAM172A	0.59	6.86	0.32	2.44e-11	Diabetic retinopathy;
LUAD	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg21724239	chr8:58056113	NA	0.69	7.32	0.34	1.3e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg26811252	chr16:29126840	RRN3P2	0.6	10.29	0.45	2.64e-22	Menopause (age at onset);
LUAD	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg00383909	chr3:49044727	WDR6	0.91	10.07	0.44	1.62e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg07195577	chr17:27052828	TLCD1	0.46	6.42	0.3	3.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg00071950	chr4:10020882	SLC2A9	0.85	18.61	0.67	6.8e-57	Bone mineral density;
LUAD	trans	rs11165623	0.792	rs9437609	chr1:96977961	A/C	cg10631902	chr5:14652156	NA	-0.56	-11.08	-0.47	3.31e-25	Hip circumference;Waist circumference;
LUAD	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	7.92	0.36	2.17e-14	Parkinson's disease;
LUAD	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.31	7.01	0.32	9.47e-12	Parkinson's disease;
LUAD	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg26384229	chr12:38710491	ALG10B	0.4	6.94	0.32	1.48e-11	Heart rate;
LUAD	cis	rs7681423	1.000	rs7659024	chr4:155520930	G/A	cg20735720	chr4:155535218	FGG	-0.52	-7.59	-0.35	2.06e-13	Fibrinogen;
LUAD	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg02389323	chr16:88786976	FAM38A	1.04	10.02	0.44	2.42e-21	Plateletcrit;
LUAD	cis	rs2692947	0.644	rs772175	chr2:96944553	G/A	cg23100626	chr2:96804247	ASTL	0.37	9.41	0.42	3.18e-19	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15664640	chr17:80829946	TBCD	-0.84	-17.01	-0.64	8.18e-50	Breast cancer;
LUAD	cis	rs10097731	0.901	rs10464892	chr8:82042991	A/G	cg25230327	chr8:82042993	NA	0.63	11.04	0.47	4.34e-25	Serum total protein level;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg25568561	chr14:102276087	PPP2R5C	-0.38	-6.48	-0.3	2.55e-10	Subcortical brain region volumes;
LUAD	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg15790184	chr11:494944	RNH1	0.56	6.83	0.32	2.9e-11	Body mass index;
LUAD	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg00204512	chr16:28754710	NA	0.33	7.12	0.33	4.52e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.41	6.71	0.31	6.26e-11	Platelet count;
LUAD	cis	rs6740322	0.643	rs13390381	chr2:43534414	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-9.8	-0.43	1.45e-20	Coronary artery disease;
LUAD	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg18277682	chr1:228362509	C1orf69	-0.39	-6.58	-0.3	1.37e-10	Diastolic blood pressure;
LUAD	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.89	-17.48	-0.65	6.61e-52	Headache;
LUAD	cis	rs877282	1.000	rs11253362	chr10:770979	G/T	cg17470449	chr10:769945	NA	0.66	9.9	0.43	6.45e-21	Uric acid levels;
LUAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02353165	chr6:42928485	GNMT	-0.43	-7.76	-0.35	6.53e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg05665937	chr4:1216051	CTBP1	0.4	7.27	0.33	1.79e-12	Obesity-related traits;
LUAD	cis	rs427394	0.659	rs274717	chr5:6721067	C/T	cg12316010	chr5:6737918	POLS	-0.4	-7.68	-0.35	1.08e-13	Menopause (age at onset);
LUAD	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg19635926	chr16:89946313	TCF25	0.64	6.44	0.3	3.18e-10	Skin colour saturation;
LUAD	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg20135002	chr11:47629003	NA	-0.42	-7.32	-0.34	1.22e-12	Subjective well-being;
LUAD	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.48e-10	Prostate cancer;
LUAD	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	6.41	0.3	3.96e-10	Schizophrenia;
LUAD	cis	rs9487051	0.676	rs11964178	chr6:109562035	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.17	-0.33	3.42e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg08439880	chr3:133502540	NA	-0.37	-7.15	-0.33	3.89e-12	Iron status biomarkers;
LUAD	trans	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.23	-0.33	2.35e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg02132458	chr4:57333267	SRP72	-0.4	-6.5	-0.3	2.28e-10	Subcortical brain region volumes;
LUAD	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	6.73	0.31	5.43e-11	Tonsillectomy;
LUAD	cis	rs11771526	0.901	rs10271047	chr7:32289660	A/C	cg13207630	chr7:32358064	NA	-0.55	-7.04	-0.32	7.62e-12	Body mass index;
LUAD	cis	rs1953600	0.870	rs2788295	chr10:81941007	C/G	cg04850286	chr10:81895943	PLAC9	0.36	6.44	0.3	3.25e-10	Sarcoidosis;
LUAD	cis	rs2286885	0.965	rs4836548	chr9:129255456	G/A	cg15282417	chr9:129245246	FAM125B	0.43	8.82	0.39	2.95e-17	Intraocular pressure;
LUAD	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg07507251	chr3:52567010	NT5DC2	0.41	8.64	0.39	1.15e-16	Bipolar disorder;
LUAD	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	10.52	0.46	3.66e-23	Smoking behavior;
LUAD	trans	rs1728785	0.901	rs698711	chr16:68561955	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	9.51	0.42	1.44e-19	Ulcerative colitis;
LUAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg08027265	chr7:2291960	NA	-0.42	-6.75	-0.31	4.79e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg17386466	chr2:87035620	CD8A	-0.41	-6.71	-0.31	6.37e-11	Subcortical brain region volumes;
LUAD	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg23758822	chr17:41437982	NA	1.01	20.96	0.71	1.96e-67	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.24	0.37	2.13e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg11693508	chr17:37793320	STARD3	0.76	9.99	0.44	3.03e-21	Bipolar disorder;
LUAD	trans	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg26043149	chr18:55253948	FECH	0.51	8.31	0.37	1.35e-15	Bone mineral density;
LUAD	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-6.92	-0.32	1.65e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs142483589	1	rs142483589	chr9:139320323	CCG/C	cg14019695	chr9:139328340	INPP5E	0.41	6.76	0.31	4.58e-11	White blood cell count;
LUAD	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg12935359	chr14:103987150	CKB	-0.47	-7.43	-0.34	6.21e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.86	-11.72	-0.5	1.14e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg15704280	chr7:45808275	SEPT13	0.65	8.69	0.39	8.21e-17	Axial length;
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg21581312	chr15:35529473	LOC723972	-0.43	-6.55	-0.3	1.67e-10	Height;
LUAD	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.56	-0.34	2.59e-13	Lung cancer;
LUAD	cis	rs6138458	1.000	rs6114984	chr20:24976610	A/G	cg06937882	chr20:24974362	C20orf3	-0.34	-6.81	-0.31	3.26e-11	Blood protein levels;
LUAD	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg22532475	chr10:104410764	TRIM8	-0.42	-8.31	-0.37	1.32e-15	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg02931644	chr1:25747376	RHCE	-0.41	-8.52	-0.38	2.79e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg05887092	chr17:76393375	PGS1	0.42	7.41	0.34	7.1e-13	HDL cholesterol levels;
LUAD	cis	rs300774	0.858	rs1829220	chr2:118383	A/C	cg21211680	chr2:198530	NA	-0.46	-6.76	-0.31	4.61e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg01579765	chr21:45077557	HSF2BP	-0.58	-13.6	-0.55	3.3e-35	Mean corpuscular volume;
LUAD	cis	rs7818345	0.595	rs58551730	chr8:19316627	T/A	cg06699216	chr8:19333253	CSGALNACT1	-0.3	-6.58	-0.3	1.42e-10	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs877282	0.945	rs11253390	chr10:788678	A/G	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg15557168	chr22:42548783	NA	0.51	9.41	0.42	3.33e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg26924012	chr15:45694286	SPATA5L1	1.03	19.3	0.68	5.41e-60	Homoarginine levels;
LUAD	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg18129748	chr3:49941408	MST1R	-0.4	-6.62	-0.31	1.06e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4481887	0.830	rs28581861	chr1:248506028	T/G	cg00666640	chr1:248458726	OR2T12	0.28	7.05	0.32	7.15e-12	Common traits (Other);
LUAD	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg11502198	chr6:26597334	ABT1	0.56	9.32	0.41	6.74e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg12419862	chr22:24373484	LOC391322	-0.86	-16.18	-0.62	3.5e-46	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg25319279	chr11:5960081	NA	0.4	7.66	0.35	1.28e-13	DNA methylation (variation);
LUAD	cis	rs9297145	0.958	rs11975761	chr7:98766688	G/A	cg05967295	chr7:98741636	SMURF1	-0.88	-16.11	-0.62	7.23e-46	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs62103177	0.564	rs55867755	chr18:77723434	C/T	cg02751453	chr18:77725136	HSBP1L1	-0.42	-7.34	-0.34	1.1e-12	Opioid sensitivity;
LUAD	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg01765077	chr12:122356316	WDR66	0.58	10.13	0.44	9.85e-22	Mean corpuscular volume;
LUAD	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.04	-0.32	7.86e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg13010199	chr12:38710504	ALG10B	0.41	6.75	0.31	4.95e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg11494091	chr17:61959527	GH2	0.4	7.1	0.33	5.48e-12	Height;
LUAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs877282	0.898	rs36064821	chr10:760952	C/T	cg06581033	chr10:766294	NA	-0.58	-7.97	-0.36	1.45e-14	Uric acid levels;
LUAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.79	-16.64	-0.63	3.5e-48	Longevity;Endometriosis;
LUAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-6.96	-0.32	1.26e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11098699	0.784	rs4833900	chr4:124243995	A/G	cg09941581	chr4:124220074	SPATA5	0.42	6.66	0.31	8.48e-11	Mosquito bite size;
LUAD	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.08	0.33	5.93e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4900538	0.927	rs2403058	chr14:102964654	A/G	cg18135206	chr14:102964638	TECPR2	1.06	23.7	0.76	1.28e-79	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg09491104	chr22:46646882	C22orf40	-0.6	-7.88	-0.36	2.86e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg23758822	chr17:41437982	NA	0.99	19.85	0.69	1.99e-62	Menopause (age at onset);
LUAD	cis	rs1267303	0.716	rs942255	chr1:46989792	C/T	cg16387850	chr1:46982889	NA	-0.43	-6.92	-0.32	1.63e-11	Monobrow;
LUAD	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19346786	chr7:2764209	NA	-0.55	-12.05	-0.51	6.19e-29	Height;
LUAD	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg04369109	chr6:150039330	LATS1	-0.44	-7.52	-0.34	3.25e-13	Lung cancer;
LUAD	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg06558623	chr16:89946397	TCF25	1.13	10.21	0.44	5.12e-22	Skin colour saturation;
LUAD	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg03467027	chr4:99064603	C4orf37	0.41	6.62	0.31	1.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg10755058	chr3:40428713	ENTPD3	0.38	7.33	0.34	1.16e-12	Renal cell carcinoma;
LUAD	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.7	-0.31	6.69e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs12997796	0.556	rs35129240	chr2:86929217	G/A	cg23743911	chr2:86949715	RMND5A	0.45	6.55	0.3	1.63e-10	Schizophrenia;
LUAD	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg12310025	chr6:25882481	NA	0.83	13.79	0.56	5.57e-36	Blood metabolite levels;
LUAD	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg21782813	chr7:2030301	MAD1L1	0.43	7.32	0.34	1.3e-12	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg25894440	chr7:65020034	NA	-0.68	-7.24	-0.33	2.14e-12	Diabetic kidney disease;
LUAD	cis	rs684232	0.602	rs4968057	chr17:517521	T/A	cg12384639	chr17:618140	VPS53	0.49	8.28	0.37	1.64e-15	Prostate cancer;
LUAD	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg17757837	chr7:157058334	UBE3C	0.47	8.45	0.38	4.62e-16	Body mass index;
LUAD	cis	rs6445967	0.593	rs7644457	chr3:58417190	G/C	cg13750441	chr3:58318267	PXK	-0.31	-6.48	-0.3	2.55e-10	Platelet count;
LUAD	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.92	13.33	0.54	4.24e-34	Smoking behavior;
LUAD	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-15.27	-0.6	2.95e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg07967210	chr17:47022446	SNF8	0.36	6.48	0.3	2.56e-10	Type 2 diabetes;
LUAD	trans	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.91	-0.32	1.8e-11	Gout;
LUAD	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg18854424	chr1:2615690	NA	0.41	9.15	0.41	2.43e-18	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs9807989	0.524	rs7591246	chr2:102999403	C/A	cg03938978	chr2:103052716	IL18RAP	0.45	10.24	0.45	3.99e-22	Asthma;
LUAD	cis	rs4638749	0.677	rs1563111	chr2:108845717	A/G	cg25838818	chr2:108905173	SULT1C2	-0.43	-7.54	-0.34	2.96e-13	Blood pressure;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17502267	chr15:59981239	BNIP2	0.41	6.41	0.3	3.91e-10	Height;
LUAD	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg17724175	chr1:150552817	MCL1	-0.37	-9.02	-0.4	6.67e-18	Tonsillectomy;
LUAD	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	6.55	0.3	1.72e-10	Cognitive test performance;
LUAD	cis	rs2932538	0.922	rs6663922	chr1:113095948	T/C	cg22162597	chr1:113214053	CAPZA1	0.41	6.49	0.3	2.37e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg02423579	chr7:2872169	GNA12	-0.82	-14.21	-0.57	1.01e-37	Height;
LUAD	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg26597838	chr10:835615	NA	0.77	10.32	0.45	2e-22	Eosinophil percentage of granulocytes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17979863	chr2:231852034	NA	-0.44	-6.73	-0.31	5.7e-11	Height;
LUAD	cis	rs9633740	1.000	rs1902660	chr10:82263683	G/C	cg00277334	chr10:82204260	NA	-0.63	-8.7	-0.39	7.32e-17	Post bronchodilator FEV1;
LUAD	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11644478	chr21:40555479	PSMG1	0.6	9.44	0.42	2.62e-19	Cognitive function;
LUAD	trans	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg13565492	chr6:43139072	SRF	-0.75	-10.17	-0.44	6.84e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs933688	0.532	rs10072084	chr5:90539203	A/G	cg00335715	chr5:90575459	NA	0.41	6.77	0.31	4.2e-11	Smoking behavior;
LUAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg10755058	chr3:40428713	ENTPD3	0.43	8.32	0.37	1.26e-15	Renal cell carcinoma;
LUAD	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg18833306	chr6:118973337	C6orf204	-0.5	-7.34	-0.34	1.08e-12	Diastolic blood pressure;
LUAD	cis	rs7408868	0.520	rs1043994	chr19:15302844	T/C	cg14696996	chr19:15285081	NOTCH3	0.64	8.51	0.38	2.94e-16	Pulse pressure;
LUAD	cis	rs758324	0.947	rs683749	chr5:131283376	C/T	cg25547332	chr5:131281432	NA	-0.43	-6.55	-0.3	1.7e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg09858108	chr8:58055024	NA	0.59	10.22	0.44	4.78e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs7617773	0.815	rs9825637	chr3:48372282	T/C	cg11946769	chr3:48343235	NME6	0.44	6.83	0.32	2.93e-11	Coronary artery disease;
LUAD	cis	rs7737355	0.947	rs56228197	chr5:130805475	C/T	cg06307176	chr5:131281290	NA	-0.52	-8.24	-0.37	2.21e-15	Life satisfaction;
LUAD	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg07917127	chr4:99064746	C4orf37	0.46	7.42	0.34	6.4e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg23950597	chr19:37808831	NA	-0.62	-7.32	-0.34	1.23e-12	Coronary artery calcification;
LUAD	cis	rs11048434	0.687	rs12814670	chr12:9060025	C/T	cg04155231	chr12:9217510	LOC144571	0.38	6.96	0.32	1.3e-11	Sjögren's syndrome;
LUAD	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg15997130	chr1:24165203	NA	0.55	9.5	0.42	1.54e-19	Immature fraction of reticulocytes;
LUAD	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg13319975	chr6:146136371	FBXO30	0.59	9.96	0.44	4.08e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg11266682	chr4:10021025	SLC2A9	0.47	8.63	0.39	1.23e-16	Blood metabolite levels;
LUAD	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg19678392	chr7:94953810	PON1	-0.57	-7.78	-0.35	5.51e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2997447	0.846	rs3008232	chr1:26402621	A/G	cg00147160	chr1:26503991	CNKSR1	0.35	6.48	0.3	2.54e-10	QRS complex (12-leadsum);
LUAD	cis	rs2658782	0.694	rs3019221	chr11:93079700	C/G	cg15737290	chr11:93063684	CCDC67	0.52	7.86	0.36	3.11e-14	Pulmonary function decline;
LUAD	cis	rs953387	1.000	rs4954567	chr2:136901587	G/T	cg05194412	chr2:137003533	NA	-0.44	-7.21	-0.33	2.57e-12	Arthritis (juvenile idiopathic);
LUAD	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.82	0.53	5.17e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg09117114	chr16:67998030	SLC12A4	-0.48	-6.82	-0.31	3.06e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg20290983	chr6:43655470	MRPS18A	0.94	17.72	0.65	5.99e-53	IgG glycosylation;
LUAD	cis	rs752092	1.000	rs752092	chr15:101781934	C/T	cg19997662	chr15:101784653	CHSY1	0.55	10.23	0.45	4.27e-22	Corneal structure;
LUAD	cis	rs1983170	0.735	rs963910	chr1:92014136	T/C	cg21854759	chr1:92012499	NA	-0.45	-7.12	-0.33	4.69e-12	Eosinophil percentage of white cells;
LUAD	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg02269571	chr22:50332266	NA	-0.66	-10.0	-0.44	2.9e-21	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg20203395	chr5:56204925	C5orf35	0.64	9.84	0.43	1.02e-20	Initial pursuit acceleration;
LUAD	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg24130564	chr14:104152367	KLC1	-0.52	-9.32	-0.41	6.33e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg00530320	chr1:46809349	NSUN4	0.53	8.23	0.37	2.33e-15	Menopause (age at onset);
LUAD	trans	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg26043149	chr18:55253948	FECH	0.48	7.75	0.35	6.84e-14	Bone mineral density;
LUAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg07217954	chr7:1067459	C7orf50	0.43	6.68	0.31	7.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4953404	0.613	rs6734725	chr2:46897570	G/A	cg09399716	chr2:46890238	NA	-0.34	-6.53	-0.3	1.84e-10	Pulse pressure (alcohol consumption interaction);
LUAD	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg09537434	chr19:41945824	ATP5SL	-0.52	-8.15	-0.37	4.16e-15	Height;
LUAD	trans	rs8073060	0.859	rs17550268	chr17:33874678	T/C	cg19694781	chr19:47549865	TMEM160	0.94	14.44	0.57	1.03e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs9323205	0.723	rs61987304	chr14:51741213	A/G	cg23942311	chr14:51606299	NA	-0.55	-7.73	-0.35	8.01e-14	Cancer;
LUAD	trans	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg07211511	chr3:129823064	LOC729375	-0.69	-9.75	-0.43	2.18e-20	Blood pressure (smoking interaction);
LUAD	trans	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg26043149	chr18:55253948	FECH	0.43	7.02	0.32	8.76e-12	Bone mineral density;
LUAD	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg14092988	chr3:52407081	DNAH1	0.45	8.84	0.39	2.62e-17	Bipolar disorder;
LUAD	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10802521	chr3:52805072	NEK4	-0.61	-11.14	-0.48	1.83e-25	Electroencephalogram traits;
LUAD	cis	rs7072216	0.763	rs7914401	chr10:100163928	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-8.97	-0.4	9.81e-18	Metabolite levels;
LUAD	cis	rs68170813	0.521	rs61673847	chr7:106892431	A/G	cg23024343	chr7:107201750	COG5	0.49	7.05	0.32	7.57e-12	Coronary artery disease;
LUAD	cis	rs1949733	0.635	rs4358384	chr4:8536913	C/T	cg13073564	chr4:8508604	NA	0.45	7.66	0.35	1.31e-13	Response to antineoplastic agents;
LUAD	cis	rs9581857	0.547	rs927579	chr13:28075079	A/G	cg22138327	chr13:27999177	GTF3A	0.89	9.27	0.41	9.26e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg22676075	chr6:135203613	NA	-0.38	-7.01	-0.32	9.58e-12	Red blood cell count;
LUAD	cis	rs12348691	0.503	rs7046645	chr9:100617375	T/C	cg13688889	chr9:100608707	NA	-0.63	-10.23	-0.45	4.25e-22	Alopecia areata;
LUAD	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg07936489	chr17:37558343	FBXL20	0.44	6.98	0.32	1.16e-11	Glomerular filtration rate (creatinine);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08180934	chr12:16035177	STRAP	-0.65	-6.76	-0.31	4.56e-11	Type 2 diabetes;
LUAD	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg22139774	chr2:100720529	AFF3	0.33	6.45	0.3	3.14e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs3784262	0.742	rs28379349	chr15:58202494	A/G	cg12031962	chr15:58353849	ALDH1A2	0.41	8.01	0.36	1.09e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs295140	0.566	rs295141	chr2:201163556	C/T	cg23649088	chr2:200775458	C2orf69	-0.45	-7.8	-0.35	4.76e-14	QT interval;
LUAD	trans	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg01620082	chr3:125678407	NA	-0.71	-7.15	-0.33	3.79e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg27124370	chr19:33622961	WDR88	0.47	7.33	0.34	1.21e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg19717773	chr7:2847554	GNA12	-0.54	-10.45	-0.45	7.04e-23	Plateletcrit;
LUAD	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg23985595	chr17:80112537	CCDC57	-0.51	-9.35	-0.41	5.07e-19	Life satisfaction;
LUAD	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg17401720	chr7:158221031	PTPRN2	0.32	6.42	0.3	3.7e-10	Obesity-related traits;
LUAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg00080972	chr5:178986291	RUFY1	0.54	9.47	0.42	1.96e-19	Lung cancer;
LUAD	cis	rs10504073	0.647	rs4348510	chr8:50016027	C/A	cg00325661	chr8:49890786	NA	0.43	9.83	0.43	1.12e-20	Blood metabolite ratios;
LUAD	cis	rs11048434	0.636	rs11047953	chr12:9064923	A/C	cg26114124	chr12:9217669	LOC144571	0.36	6.36	0.3	5.09e-10	Sjögren's syndrome;
LUAD	cis	rs701145	0.938	rs242117	chr3:154026467	T/C	cg17054900	chr3:154042577	DHX36	0.66	7.36	0.34	9.69e-13	Coronary artery disease;
LUAD	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg12623918	chr2:306882	NA	0.34	6.79	0.31	3.86e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg02421172	chr7:1938701	MAD1L1	0.4	6.36	0.3	5.21e-10	Bipolar disorder;
LUAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg08355456	chr11:67383691	NA	0.37	6.5	0.3	2.27e-10	Mean corpuscular volume;
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg14576294	chr17:7307495	C17orf61	-0.36	-6.43	-0.3	3.35e-10	Migraine with aura;
LUAD	cis	rs12208915	0.848	rs9343834	chr6:79517671	G/A	cg05283184	chr6:79620031	NA	0.49	6.39	0.3	4.33e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs11771526	0.901	rs78065961	chr7:32300967	C/T	cg27532318	chr7:32358331	NA	0.56	7.21	0.33	2.54e-12	Body mass index;
LUAD	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg09455208	chr3:40491958	NA	0.54	11.84	0.5	4.04e-28	Renal cell carcinoma;
LUAD	trans	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg06606381	chr12:133084897	FBRSL1	-0.94	-8.88	-0.4	1.91e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg18306943	chr3:40428807	ENTPD3	0.38	6.51	0.3	2.18e-10	Renal cell carcinoma;
LUAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.69	-8.83	-0.39	2.74e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10078	0.615	rs2720997	chr5:433654	A/G	cg07599136	chr5:415885	AHRR	0.72	7.95	0.36	1.7e-14	Fat distribution (HIV);
LUAD	cis	rs11971779	0.616	rs7779314	chr7:139112696	G/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.38	-0.3	4.74e-10	Diisocyanate-induced asthma;
LUAD	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg09117114	chr16:67998030	SLC12A4	-0.6	-7.52	-0.34	3.4e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg18811423	chr2:55921094	PNPT1	0.51	8.58	0.39	1.78e-16	Metabolic syndrome;
LUAD	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.91	0.4	1.48e-17	Cognitive ability;
LUAD	cis	rs7680126	0.627	rs9291642	chr4:10007275	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	8.35	0.38	1e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg04287289	chr16:89883240	FANCA	0.67	12.08	0.51	4.49e-29	Vitiligo;
LUAD	trans	rs8002861	0.810	rs7334812	chr13:44445538	C/T	cg17145862	chr1:211918768	LPGAT1	0.75	17.32	0.64	3.56e-51	Leprosy;
LUAD	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg17279839	chr7:150038598	RARRES2	0.47	7.52	0.34	3.23e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg27632911	chr20:34205182	SPAG4	0.38	6.48	0.3	2.48e-10	Total cholesterol levels;
LUAD	cis	rs2997447	0.846	rs2997445	chr1:26390154	C/T	cg00147160	chr1:26503991	CNKSR1	0.36	6.79	0.31	3.89e-11	QRS complex (12-leadsum);
LUAD	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg03676636	chr4:99064102	C4orf37	0.32	8.34	0.38	1.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.36	-0.3	5.36e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg21775007	chr8:11205619	TDH	-0.5	-9.06	-0.4	4.85e-18	Retinal vascular caliber;
LUAD	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg00933542	chr6:150070202	PCMT1	0.45	9.85	0.43	9.93e-21	Lung cancer;
LUAD	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg02527881	chr3:46936655	PTH1R	0.46	8.87	0.4	2.07e-17	Colorectal cancer;
LUAD	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg00484396	chr16:3507460	NAT15	0.75	9.96	0.44	3.93e-21	Tuberculosis;
LUAD	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg04851639	chr8:1020857	NA	-0.33	-7.51	-0.34	3.47e-13	Schizophrenia;
LUAD	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg02683114	chr2:24398427	C2orf84	0.42	6.94	0.32	1.49e-11	Asthma;
LUAD	cis	rs6499255	0.951	rs11641233	chr16:69734563	C/T	cg15192750	chr16:69999425	NA	0.5	7.81	0.35	4.61e-14	IgE levels;
LUAD	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg18721089	chr20:30220636	NA	-0.45	-6.84	-0.32	2.78e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs12765878	1.000	rs3814220	chr10:105647300	A/G	cg11005552	chr10:105648138	OBFC1	0.44	8.26	0.37	1.91e-15	Coronary artery disease;
LUAD	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg17849569	chr6:28058911	ZSCAN12L1	0.31	6.68	0.31	7.55e-11	Parkinson's disease;
LUAD	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg00149659	chr3:10157352	C3orf10	0.85	10.5	0.45	4.35e-23	Alzheimer's disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17169333	chr8:96281960	C8orf37	-0.4	-6.54	-0.3	1.82e-10	Cancer;
LUAD	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg10802521	chr3:52805072	NEK4	-0.48	-7.91	-0.36	2.34e-14	Bipolar disorder;
LUAD	cis	rs909002	0.849	rs10798879	chr1:32096815	T/C	cg13919466	chr1:32135498	COL16A1	-0.36	-8.18	-0.37	3.35e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2286503	1.000	rs2286501	chr7:22856785	G/C	cg06496272	chr7:22895283	SNORD93	-0.4	-7.13	-0.33	4.27e-12	Fibrinogen;
LUAD	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg06623918	chr6:96969491	KIAA0776	-0.7	-9.8	-0.43	1.4e-20	Migraine;Coronary artery disease;
LUAD	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.34e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12901634	chr17:34091205	C17orf50	0.4	6.43	0.3	3.5e-10	Gut microbiome composition (summer);
LUAD	trans	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg06606381	chr12:133084897	FBRSL1	-0.62	-7.52	-0.34	3.3e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.68	-8.18	-0.37	3.28e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1045714	0.895	rs17833498	chr7:2647007	A/G	cg20813462	chr7:2646259	IQCE	-0.64	-7.23	-0.33	2.27e-12	Urate levels in lean individuals;
LUAD	trans	rs7395662	1.000	rs7481880	chr11:48609347	C/T	cg00717180	chr2:96193071	NA	-0.38	-7.14	-0.33	4e-12	HDL cholesterol;
LUAD	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg25251562	chr2:3704773	ALLC	-0.49	-8.14	-0.37	4.54e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg12935359	chr14:103987150	CKB	0.52	8.14	0.37	4.57e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg15704280	chr7:45808275	SEPT13	0.67	9.13	0.41	2.86e-18	Axial length;
LUAD	trans	rs4650994	0.525	rs2493848	chr1:178547838	T/A	cg05059571	chr16:84539110	KIAA1609	0.72	13.37	0.55	2.94e-34	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs500891	0.525	rs1145902	chr6:84038531	A/G	cg08257003	chr6:84140564	ME1	0.34	6.35	0.3	5.54e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg05590025	chr7:65112418	INTS4L2	-0.72	-7.66	-0.35	1.32e-13	Diabetic kidney disease;
LUAD	cis	rs34286592	0.929	rs9923649	chr16:29832138	G/A	cg08218971	chr16:29826754	C16orf53;PRRT2	0.4	6.44	0.3	3.26e-10	Multiple sclerosis;
LUAD	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg13535736	chr9:111863775	C9orf5	-0.42	-6.47	-0.3	2.77e-10	Menarche (age at onset);
LUAD	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg01065977	chr19:18549689	ISYNA1	0.41	7.95	0.36	1.73e-14	Breast cancer;
LUAD	cis	rs11971779	0.553	rs10269108	chr7:139106332	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	7.16e-11	Diisocyanate-induced asthma;
LUAD	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-7.81	-0.36	4.4e-14	Schizophrenia;
LUAD	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg12311346	chr5:56204834	C5orf35	-0.93	-13.68	-0.55	1.58e-35	Initial pursuit acceleration;
LUAD	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg02079420	chr8:82753780	SNX16	0.4	8.11	0.37	5.36e-15	Diastolic blood pressure;
LUAD	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03647317	chr4:187891568	NA	0.34	6.41	0.3	3.96e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg06718696	chr17:78121285	EIF4A3	0.6	8.94	0.4	1.26e-17	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10216189	0.785	rs4352753	chr7:5527223	A/C	cg11800390	chr7:5515995	FBXL18	0.35	7.41	0.34	7.13e-13	Relative hand skill in reading disability;
LUAD	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg07606381	chr6:8435919	SLC35B3	0.4	6.85	0.32	2.65e-11	Motion sickness;
LUAD	cis	rs2971970	0.519	rs28566817	chr7:133628668	A/G	cg03336402	chr7:133662267	EXOC4	0.39	7.08	0.33	6.15e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg06074448	chr4:187884817	NA	-0.37	-7.3	-0.33	1.47e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg24955955	chr5:415729	AHRR	0.79	8.97	0.4	9.64e-18	Fat distribution (HIV);
LUAD	cis	rs1816752	0.792	rs7330956	chr13:24987312	A/G	cg02811702	chr13:24901961	NA	0.43	7.36	0.34	9.39e-13	Obesity-related traits;
LUAD	cis	rs3761847	0.622	rs10818500	chr9:123810883	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.4	-6.8	-0.31	3.63e-11	Rheumatoid arthritis;
LUAD	cis	rs2244613	0.882	rs7200877	chr16:55794882	A/T	cg27396498	chr16:55794478	CES4	0.52	7.37	0.34	9.06e-13	Response to dabigatran etexilate treatment;
LUAD	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg04772025	chr11:68637568	NA	0.56	8.94	0.4	1.24e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg17420585	chr12:42539391	GXYLT1	-0.38	-6.74	-0.31	5.25e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-7.29	-0.33	1.54e-12	Longevity;Endometriosis;
LUAD	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06022373	chr22:39101656	GTPBP1	0.46	7.11	0.33	5.06e-12	Menopause (age at onset);
LUAD	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg00106254	chr7:1943704	MAD1L1	-0.49	-7.49	-0.34	3.98e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg03609598	chr5:56110824	MAP3K1	0.51	6.48	0.3	2.57e-10	Initial pursuit acceleration;
LUAD	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg21862992	chr11:68658383	NA	0.52	9.55	0.42	1.05e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10489202	0.634	rs11582396	chr1:168077636	C/T	cg24449463	chr1:168025552	DCAF6	-0.61	-9.36	-0.41	4.75e-19	Schizophrenia;
LUAD	cis	rs4523957	0.620	rs9912385	chr17:2062591	T/G	cg16513277	chr17:2031491	SMG6	-0.96	-18.89	-0.68	3.82e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg02574844	chr11:5959923	NA	-0.43	-7.36	-0.34	9.66e-13	DNA methylation (variation);
LUAD	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.82	0.31	3.12e-11	Depression;
LUAD	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg15557168	chr22:42548783	NA	-0.51	-9.37	-0.41	4.48e-19	Schizophrenia;
LUAD	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-9.29	-0.41	8.35e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg02931644	chr1:25747376	RHCE	0.43	9.06	0.4	4.83e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg05342682	chr7:94953680	PON1	-0.51	-7.11	-0.33	4.86e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg03609598	chr5:56110824	MAP3K1	0.49	7.26	0.33	1.92e-12	Initial pursuit acceleration;
LUAD	cis	rs3789045	0.615	rs11240748	chr1:204453320	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.45	-8.38	-0.38	8.09e-16	Educational attainment (college completion);
LUAD	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg14092988	chr3:52407081	DNAH1	0.45	8.98	0.4	9.3e-18	Bipolar disorder;
LUAD	cis	rs738322	0.804	rs4821743	chr22:38514906	A/G	cg25457927	chr22:38595422	NA	-0.46	-10.84	-0.47	2.42e-24	Cutaneous nevi;
LUAD	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.47	7.23	0.33	2.31e-12	Schizophrenia;
LUAD	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg12310025	chr6:25882481	NA	-0.59	-9.64	-0.42	5.33e-20	Blood metabolite levels;
LUAD	cis	rs9362426	0.672	rs12663865	chr6:88103149	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.41	7.07	0.33	6.4e-12	Depressive episodes in bipolar disorder;
LUAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg12432903	chr7:1882776	MAD1L1	-0.43	-6.96	-0.32	1.27e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg05805236	chr11:65401703	PCNXL3	-0.61	-9.83	-0.43	1.11e-20	Acne (severe);
LUAD	cis	rs2734839	1.000	rs2734839	chr11:113286490	C/T	cg14159747	chr11:113255604	NA	0.53	9.89	0.43	6.96e-21	Information processing speed;
LUAD	cis	rs7301826	0.585	rs6486600	chr12:131292977	C/T	cg11011512	chr12:131303247	STX2	0.4	6.54	0.3	1.83e-10	Plasma plasminogen activator levels;
LUAD	cis	rs13315871	1.000	rs71311857	chr3:58323377	A/G	cg12435725	chr3:58293450	RPP14	-0.73	-7.68	-0.35	1.1e-13	Cholesterol, total;
LUAD	cis	rs877282	1.000	rs11253367	chr10:773389	G/A	cg17470449	chr10:769945	NA	0.7	11.01	0.47	5.9e-25	Uric acid levels;
LUAD	cis	rs1167827	0.805	rs809439	chr7:75161318	T/A	cg16384552	chr7:74938386	SPDYE8P	0.69	11.51	0.49	7.5e-27	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26314531	chr2:26401878	FAM59B	-0.72	-10.54	-0.46	3.16e-23	Gut microbiome composition (summer);
LUAD	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg02807482	chr3:125708958	NA	-0.66	-8.74	-0.39	5.32e-17	Blood pressure (smoking interaction);
LUAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg11416102	chr8:651193	ERICH1	0.96	9.22	0.41	1.43e-18	IgG glycosylation;
LUAD	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg23840854	chr1:161414152	NA	-0.9	-11.68	-0.49	1.62e-27	Rheumatoid arthritis;
LUAD	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg18944383	chr4:111397179	ENPEP	0.37	7.68	0.35	1.12e-13	Height;
LUAD	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12379764	chr21:47803548	PCNT	-0.42	-6.83	-0.32	2.96e-11	Testicular germ cell tumor;
LUAD	cis	rs4356932	1.000	rs4859587	chr4:76943296	A/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.5	-0.3	2.23e-10	Blood protein levels;
LUAD	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg03929089	chr4:120376271	NA	-0.53	-7.78	-0.35	5.72e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg00745463	chr17:30367425	LRRC37B	-1.06	-12.64	-0.52	2.85e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg09263875	chr16:632152	PIGQ	0.82	17.7	0.65	7.01e-53	Height;
LUAD	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg00129232	chr17:37814104	STARD3	-0.45	-7.56	-0.35	2.47e-13	Asthma;
LUAD	cis	rs4774899	0.767	rs13329616	chr15:57430242	A/T	cg14026238	chr15:57616123	NA	-0.43	-8.36	-0.38	9.15e-16	Urinary tract infection frequency;
LUAD	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg15664640	chr17:80829946	TBCD	-0.69	-8.36	-0.38	9.05e-16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs7731657	0.509	rs916956	chr5:130331705	C/G	cg08523029	chr5:130500466	HINT1	-0.59	-7.65	-0.35	1.34e-13	Fasting plasma glucose;
LUAD	cis	rs10744422	0.920	rs897393	chr12:123312051	A/G	cg16953816	chr12:123349952	VPS37B	-0.6	-7.01	-0.32	9.4e-12	Schizophrenia;
LUAD	cis	rs4930561	0.765	rs4930564	chr11:67983281	C/T	cg04465784	chr11:67976953	SUV420H1	0.28	8.32	0.38	1.21e-15	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs4389656	0.857	rs416847	chr5:6739567	A/G	cg10857441	chr5:6722123	POLS	-0.46	-7.78	-0.35	5.69e-14	Coronary artery disease;
LUAD	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg06108461	chr20:60628389	TAF4	-1.11	-20.45	-0.71	4.01e-65	Body mass index;
LUAD	cis	rs4711350	0.953	rs1951930	chr6:33782655	C/A	cg18005901	chr6:33739558	LEMD2	-0.46	-6.37	-0.3	4.82e-10	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.05	0.36	8.47e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.9	-18.41	-0.67	5.28e-56	Ulcerative colitis;
LUAD	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg25452165	chr22:42524984	CYP2D6	-0.38	-6.39	-0.3	4.27e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1595825	0.786	rs79490184	chr2:198894219	T/A	cg00982548	chr2:198649783	BOLL	-0.65	-9.18	-0.41	1.88e-18	Ulcerative colitis;
LUAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg12016809	chr21:47604291	C21orf56	0.45	7.56	0.35	2.47e-13	Testicular germ cell tumor;
LUAD	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg23649088	chr2:200775458	C2orf69	0.53	8.43	0.38	5.6e-16	Osteoporosis;
LUAD	cis	rs3774830	0.846	rs11731730	chr4:5454545	C/T	cg26943120	chr4:5472116	STK32B	0.34	7.04	0.32	8.01e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7107174	0.892	rs2510033	chr11:77941771	T/G	cg19901956	chr11:77921274	USP35	-0.53	-6.53	-0.3	1.83e-10	Testicular germ cell tumor;
LUAD	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg26384229	chr12:38710491	ALG10B	-0.42	-7.17	-0.33	3.48e-12	Morning vs. evening chronotype;
LUAD	cis	rs225245	0.610	rs321608	chr17:33880636	A/G	cg05299278	chr17:33885742	SLFN14	0.48	10.93	0.47	1.21e-24	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg06627628	chr2:24431161	ITSN2	-0.7	-11.06	-0.47	3.63e-25	Asthma;
LUAD	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.13	-0.41	2.85e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg15557168	chr22:42548783	NA	-0.5	-9.4	-0.42	3.39e-19	Schizophrenia;
LUAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.58e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.53	-0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg12179176	chr11:130786555	SNX19	0.55	9.29	0.41	8.21e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg21433313	chr16:3507492	NAT15	0.76	13.88	0.56	2.32e-36	Tuberculosis;
LUAD	cis	rs877282	1.000	rs71494928	chr10:769134	A/G	cg17470449	chr10:769945	NA	0.63	8.9	0.4	1.66e-17	Uric acid levels;
LUAD	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg09365446	chr1:150670422	GOLPH3L	-0.49	-8.46	-0.38	4.47e-16	Tonsillectomy;
LUAD	cis	rs11971779	0.680	rs7795520	chr7:139079207	A/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.4	-0.3	4.05e-10	Diisocyanate-induced asthma;
LUAD	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg11859384	chr17:80120422	CCDC57	0.48	8.65	0.39	1.09e-16	Life satisfaction;
LUAD	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg15181151	chr6:150070149	PCMT1	0.38	7.68	0.35	1.12e-13	Lung cancer;
LUAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg13397359	chr6:42928475	GNMT	0.62	11.66	0.49	1.94e-27	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1045714	0.895	rs73043180	chr7:2645972	C/T	cg24848437	chr7:2645542	IQCE	0.71	8.33	0.38	1.15e-15	Urate levels in lean individuals;
LUAD	cis	rs9914544	0.545	rs4924945	chr17:18813160	A/G	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.58	-0.3	1.43e-10	Educational attainment (years of education);
LUAD	trans	rs2262909	0.924	rs11085509	chr19:22204573	T/C	cg17074339	chr11:11642133	GALNTL4	-0.43	-6.8	-0.31	3.51e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs938554	0.657	rs7660895	chr4:9985445	A/G	cg11266682	chr4:10021025	SLC2A9	0.4	7.44	0.34	5.51e-13	Blood metabolite levels;
LUAD	cis	rs6062509	0.630	rs6011058	chr20:62356627	C/T	cg01176363	chr20:62369445	LIME1	-0.47	-7.51	-0.34	3.45e-13	Prostate cancer;
LUAD	cis	rs6691722	0.506	rs11587667	chr1:24715435	C/G	cg02336364	chr1:24764700	NIPAL3	0.38	8.16	0.37	3.93e-15	Response to interferon beta in multiple sclerosis;
LUAD	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg27572855	chr1:25598939	RHD	0.54	11.55	0.49	5.26e-27	Erythrocyte sedimentation rate;
LUAD	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg10356904	chr22:49881777	NA	-0.41	-8.06	-0.36	8e-15	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs11048434	0.636	rs11614970	chr12:9060053	G/A	cg26114124	chr12:9217669	LOC144571	0.36	6.47	0.3	2.69e-10	Sjögren's syndrome;
LUAD	cis	rs4692589	0.556	rs13133562	chr4:170965709	C/T	cg19918862	chr4:170955249	NA	0.32	6.47	0.3	2.65e-10	Anxiety disorder;
LUAD	cis	rs6981523	0.553	rs2409730	chr8:11060638	C/A	cg27411982	chr8:10470053	RP1L1	-0.36	-6.56	-0.3	1.57e-10	Neuroticism;
LUAD	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02018176	chr4:1364513	KIAA1530	0.69	12.07	0.51	5.02e-29	Longevity;
LUAD	cis	rs7737355	0.947	rs56228197	chr5:130805475	C/T	cg25547332	chr5:131281432	NA	-0.43	-6.64	-0.31	9.38e-11	Life satisfaction;
LUAD	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-8.63	-0.39	1.26e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg08219700	chr8:58056026	NA	0.63	8.81	0.39	3.2e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg12564285	chr5:131593104	PDLIM4	-0.38	-6.46	-0.3	2.84e-10	Acylcarnitine levels;
LUAD	trans	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg14917512	chr19:3094685	GNA11	-0.56	-6.64	-0.31	9.4e-11	Diabetic kidney disease;
LUAD	cis	rs2274273	0.600	rs10134317	chr14:55793448	C/T	cg04306507	chr14:55594613	LGALS3	0.41	8.02	0.36	1.08e-14	Protein biomarker;
LUAD	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg19825600	chr2:3704501	ALLC	-0.41	-7.72	-0.35	8.4e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg11247378	chr22:39784982	NA	0.5	8.89	0.4	1.83e-17	IgG glycosylation;
LUAD	cis	rs3812111	0.510	rs17077755	chr6:116592033	C/T	cg18828861	chr6:116576566	TSPYL4	0.37	7.15	0.33	3.81e-12	Age-related macular degeneration;
LUAD	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg17063962	chr7:91808500	NA	0.6	10.31	0.45	2.21e-22	Breast cancer;
LUAD	trans	rs7939886	0.920	rs12223067	chr11:55915420	C/A	cg15704280	chr7:45808275	SEPT13	0.66	6.38	0.3	4.79e-10	Myopia (pathological);
LUAD	cis	rs9392556	0.509	rs588158	chr6:4079592	G/C	cg10424681	chr6:4079350	C6orf201;C6orf146	0.31	7.45	0.34	5.22e-13	Blood metabolite levels;
LUAD	trans	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	8.8	0.39	3.4e-17	Mean corpuscular volume;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07399355	chr1:155163013	MUC1	-0.42	-6.37	-0.3	4.81e-10	Height;
LUAD	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg21204522	chr6:27730016	NA	-0.48	-7.65	-0.35	1.38e-13	Parkinson's disease;
LUAD	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.66	-0.35	1.31e-13	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7107174	0.892	rs4291702	chr11:78001248	C/T	cg02023728	chr11:77925099	USP35	0.39	6.45	0.3	2.97e-10	Testicular germ cell tumor;
LUAD	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg10560079	chr2:191398806	TMEM194B	-0.53	-6.72	-0.31	5.72e-11	Diastolic blood pressure;
LUAD	cis	rs4148883	0.898	rs4699726	chr4:100099513	T/C	cg12011299	chr4:100065546	ADH4	0.44	8.3	0.37	1.4e-15	Alcohol dependence;
LUAD	cis	rs11696501	0.738	rs6104294	chr20:44326850	T/C	cg11783356	chr20:44313418	WFDC10B	-0.51	-8.38	-0.38	8.12e-16	Brain structure;
LUAD	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg18932078	chr1:2524107	MMEL1	-0.37	-6.99	-0.32	1.09e-11	Ulcerative colitis;
LUAD	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg12564285	chr5:131593104	PDLIM4	0.37	6.72	0.31	5.97e-11	Acylcarnitine levels;
LUAD	cis	rs58799304	0.618	rs35997354	chr1:156071806	G/A	cg15685922	chr1:156045208	MEX3A	-0.38	-6.75	-0.31	4.98e-11	Ischemic stroke;
LUAD	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg00271210	chr6:167070053	RPS6KA2	0.34	6.59	0.31	1.33e-10	Crohn's disease;
LUAD	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg02466173	chr16:30829666	NA	-0.67	-12.15	-0.51	2.37e-29	Multiple myeloma;
LUAD	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg14582100	chr15:45693742	SPATA5L1	0.64	12.48	0.52	1.23e-30	Homoarginine levels;
LUAD	cis	rs8192282	0.646	rs4288587	chr1:154492357	A/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.45	-6.99	-0.32	1.09e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs300703	0.719	rs423314	chr2:195372	A/G	cg24565620	chr2:194026	NA	-0.45	-7.19	-0.33	2.96e-12	Blood protein levels;
LUAD	cis	rs4986172	0.690	rs11657325	chr17:43242694	C/T	cg10701640	chr17:43249399	NA	0.58	10.83	0.47	2.64e-24	Height;
LUAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.22	0.54	1.26e-33	Prudent dietary pattern;
LUAD	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg00310523	chr12:86230176	RASSF9	0.42	8.76	0.39	4.89e-17	Major depressive disorder;
LUAD	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg21028142	chr17:79581711	NPLOC4	0.37	7.48	0.34	4.42e-13	Eye color traits;
LUAD	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg01788221	chr16:89496183	ANKRD11	-0.35	-6.66	-0.31	8.57e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg13770153	chr20:60521292	NA	-0.47	-8.22	-0.37	2.52e-15	Body mass index;
LUAD	cis	rs4711336	1.000	rs764754	chr6:33658310	C/T	cg13859433	chr6:33739653	LEMD2	-0.3	-6.85	-0.32	2.65e-11	Height;
LUAD	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg10518543	chr12:38710700	ALG10B	-0.45	-7.27	-0.33	1.71e-12	Morning vs. evening chronotype;
LUAD	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.51	0.38	2.96e-16	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06819704	chr5:159707559	CCNJL	-0.45	-6.55	-0.3	1.63e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg04731861	chr2:219085781	ARPC2	-0.23	-7.16	-0.33	3.69e-12	Colorectal cancer;
LUAD	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.37	7.5	0.34	3.83e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg16797656	chr11:68205561	LRP5	0.45	8.68	0.39	8.8e-17	Total body bone mineral density;
LUAD	trans	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg24644049	chr4:85504048	CDS1	0.86	7.78	0.35	5.78e-14	Skin colour saturation;
LUAD	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06028605	chr16:24865363	SLC5A11	0.52	8.02	0.36	1.05e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg21775007	chr8:11205619	TDH	-0.52	-9.46	-0.42	2.09e-19	Retinal vascular caliber;
LUAD	cis	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.4	-6.96	-0.32	1.33e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg11814155	chr7:99998594	ZCWPW1	0.43	7.37	0.34	9.23e-13	Platelet count;
LUAD	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg10596483	chr8:143751796	JRK	0.44	7.1	0.33	5.23e-12	Schizophrenia;
LUAD	trans	rs629535	0.734	rs542288	chr8:70057149	G/T	cg21567404	chr3:27674614	NA	-1.01	-18.76	-0.67	1.43e-57	Dupuytren's disease;
LUAD	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	cis	rs7582720	1.000	rs72936834	chr2:203771260	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9868809	0.881	rs34368826	chr3:48670827	G/T	cg00383909	chr3:49044727	WDR6	0.65	7.09	0.33	5.56e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7737355	0.898	rs13164236	chr5:131079808	C/T	cg25547332	chr5:131281432	NA	0.44	6.74	0.31	5.19e-11	Life satisfaction;
LUAD	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg03859395	chr2:55845619	SMEK2	0.76	14.58	0.58	2.59e-39	Metabolic syndrome;
LUAD	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg22875332	chr1:76189707	ACADM	-0.45	-6.6	-0.31	1.24e-10	Daytime sleep phenotypes;
LUAD	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.25	0.41	1.16e-18	Colorectal cancer;
LUAD	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.01	-0.36	1.14e-14	Diabetic kidney disease;
LUAD	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg12310025	chr6:25882481	NA	-0.52	-7.81	-0.35	4.59e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg15017067	chr4:17643749	FAM184B	0.33	6.38	0.3	4.72e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	6.59	0.31	1.27e-10	Rheumatoid arthritis;
LUAD	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg27170947	chr2:26402098	FAM59B	-0.81	-12.23	-0.51	1.19e-29	Gut microbiome composition (summer);
LUAD	cis	rs7771547	0.519	rs6917489	chr6:36368169	C/T	cg02952361	chr6:36355661	ETV7	0.46	6.64	0.31	9.82e-11	Platelet distribution width;
LUAD	cis	rs6847149	0.714	rs7687956	chr4:110810224	A/T	cg07850274	chr4:110748770	RRH	0.42	6.66	0.31	8.64e-11	Exercise treadmill test traits;
LUAD	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg02951883	chr7:2050386	MAD1L1	-0.81	-13.6	-0.55	3.22e-35	Bipolar disorder and schizophrenia;
LUAD	cis	rs73198271	0.531	rs112930476	chr8:8671551	G/A	cg01851573	chr8:8652454	MFHAS1	0.68	10.17	0.44	6.73e-22	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs6678622	0.931	rs9729667	chr1:78349214	C/T	cg20826526	chr3:156266748	SSR3	-0.44	-6.76	-0.31	4.55e-11	Hip circumference;
LUAD	cis	rs7267979	0.844	rs2474780	chr20:25285835	G/A	cg08601574	chr20:25228251	PYGB	0.41	7.63	0.35	1.54e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs800082	0.501	rs9873732	chr3:144191665	C/T	cg24215973	chr2:240111563	HDAC4	0.48	7.42	0.34	6.69e-13	Smoking behavior;
LUAD	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19507727	chr1:233086292	C1orf57	-0.52	-6.45	-0.3	3.08e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg05340658	chr4:99064831	C4orf37	0.55	9.36	0.41	4.65e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7809950	0.678	rs62482507	chr7:107024488	T/G	cg23024343	chr7:107201750	COG5	-0.83	-14.31	-0.57	3.64e-38	Coronary artery disease;
LUAD	trans	rs11885103	0.543	rs2724925	chr2:562458	G/A	cg12228919	chr15:44955936	SPG11	-0.41	-6.35	-0.3	5.55e-10	Heschl's gyrus morphology;
LUAD	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg21475434	chr5:93447410	FAM172A	0.71	8.45	0.38	4.79e-16	Diabetic retinopathy;
LUAD	cis	rs17095355	0.818	rs12268462	chr10:111775047	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.01	-0.36	1.14e-14	Biliary atresia;
LUAD	cis	rs76878669	0.561	rs12416747	chr11:66135614	A/G	cg18002602	chr11:66138449	SLC29A2	0.47	10.18	0.44	6.58e-22	Educational attainment (years of education);
LUAD	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg18230493	chr5:56204884	C5orf35	-0.85	-12.91	-0.53	2.19e-32	Initial pursuit acceleration;
LUAD	cis	rs921968	0.529	rs6729341	chr2:219611434	T/G	cg02176678	chr2:219576539	TTLL4	-0.59	-12.08	-0.51	4.49e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7536201	1.000	rs1609996	chr1:25301869	T/C	cg23273869	chr1:25296894	NA	-0.38	-7.83	-0.36	3.94e-14	Psoriasis vulgaris;
LUAD	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg06618935	chr21:46677482	NA	-0.46	-9.33	-0.41	6e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg11822812	chr5:140052017	DND1	0.38	6.76	0.31	4.56e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg09835421	chr16:68378352	PRMT7	-0.81	-8.86	-0.4	2.2e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg04545296	chr12:48745243	ZNF641	0.38	9.68	0.43	3.63e-20	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.55	-0.6	1.9e-43	Chronic sinus infection;
LUAD	cis	rs10465746	0.746	rs6699501	chr1:84389993	A/G	cg10977910	chr1:84465055	TTLL7	0.59	9.65	0.42	4.93e-20	Obesity-related traits;
LUAD	cis	rs9644630	0.841	rs4292704	chr8:19329303	G/C	cg06562184	chr8:19319451	CSGALNACT1	0.35	6.46	0.3	2.85e-10	Oropharynx cancer;
LUAD	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg24675056	chr1:15929824	NA	0.48	8.44	0.38	5.23e-16	Systolic blood pressure;
LUAD	cis	rs2688608	0.780	rs2688619	chr10:75682176	A/G	cg19442545	chr10:75533431	FUT11	-0.37	-6.38	-0.3	4.78e-10	Inflammatory bowel disease;
LUAD	cis	rs2004318	1.000	rs2004318	chr19:55138232	C/T	cg03320607	chr19:54800032	LILRA3	-0.68	-7.19	-0.33	3.01e-12	Blood protein levels;
LUAD	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg00958927	chr1:175162553	KIAA0040	-0.24	-6.4	-0.3	4.21e-10	Alcohol dependence;
LUAD	cis	rs7589342	0.929	rs7562054	chr2:106433513	G/C	cg16077055	chr2:106428750	NCK2	0.36	6.39	0.3	4.26e-10	Addiction;
LUAD	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg14668632	chr7:2872130	GNA12	-0.48	-8.53	-0.38	2.72e-16	Height;
LUAD	cis	rs6499255	0.951	rs8052086	chr16:69692468	A/C	cg15192750	chr16:69999425	NA	0.54	8.22	0.37	2.49e-15	IgE levels;
LUAD	cis	rs1448094	0.935	rs4919775	chr12:86339985	T/C	cg02569458	chr12:86230093	RASSF9	0.37	7.15	0.33	3.76e-12	Major depressive disorder;
LUAD	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg02527881	chr3:46936655	PTH1R	0.44	8.39	0.38	7.37e-16	Colorectal cancer;
LUAD	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.46e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2816062	0.786	rs2745317	chr1:18896552	G/A	cg18795169	chr1:18902165	NA	-0.93	-22.42	-0.74	6.42e-74	Urate levels in lean individuals;
LUAD	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.35	-0.34	1.06e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6684514	1.000	rs12122180	chr1:156244559	G/A	cg16558208	chr1:156270281	VHLL	0.53	9.52	0.42	1.36e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.98	10.62	0.46	1.57e-23	Initial pursuit acceleration;
LUAD	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg21724239	chr8:58056113	NA	0.78	9.31	0.41	6.78e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg16479474	chr6:28041457	NA	0.39	6.99	0.32	1.1e-11	Parkinson's disease;
LUAD	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg18944383	chr4:111397179	ENPEP	0.39	7.84	0.36	3.75e-14	Height;
LUAD	cis	rs2235649	0.828	rs9936486	chr16:1849888	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.4	-6.42	-0.3	3.7e-10	Blood metabolite levels;
LUAD	trans	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg04775059	chr7:64541387	NA	0.51	6.96	0.32	1.34e-11	Aortic root size;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg23260799	chr11:451101	PTDSS2	0.45	7.31	0.33	1.35e-12	Diastolic blood pressure;
LUAD	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.96	0.36	1.57e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg00280220	chr17:61926910	NA	0.37	7.15	0.33	3.85e-12	Prudent dietary pattern;
LUAD	trans	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg26043149	chr18:55253948	FECH	-0.48	-8.2	-0.37	2.87e-15	Bone mineral density;
LUAD	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22857025	chr5:266934	NA	-0.97	-14.44	-0.57	1.07e-38	Breast cancer;
LUAD	trans	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.65	-0.31	8.96e-11	Diabetic kidney disease;
LUAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg14092988	chr3:52407081	DNAH1	0.41	8.1	0.37	6.13e-15	Electroencephalogram traits;
LUAD	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg12927641	chr6:109611667	NA	-0.52	-9.3	-0.41	7.77e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg26408565	chr15:76604113	ETFA	-0.43	-6.96	-0.32	1.32e-11	Blood metabolite levels;
LUAD	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg05535760	chr7:792225	HEATR2	-0.83	-9.91	-0.43	5.69e-21	Cerebrospinal P-tau181p levels;
LUAD	trans	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.26	-0.37	1.93e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs35883536	0.609	rs10783142	chr1:101043902	C/G	cg06223162	chr1:101003688	GPR88	-0.47	-9.18	-0.41	1.88e-18	Monocyte count;
LUAD	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg23933602	chr10:16859644	RSU1	0.96	19.61	0.69	2.21e-61	Platelet distribution width;
LUAD	cis	rs11811982	0.793	rs77755024	chr1:227357784	T/A	cg24860534	chr1:227506868	CDC42BPA	0.66	7.22	0.33	2.41e-12	Optic disc area;
LUAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg13397359	chr6:42928475	GNMT	0.66	13.1	0.54	3.83e-33	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg04234412	chr22:24373322	LOC391322	-0.79	-14.31	-0.57	3.59e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.08	25.63	0.78	4.02e-88	Colorectal cancer;
LUAD	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg07636037	chr3:49044803	WDR6	0.61	11.98	0.5	1.1e-28	Parkinson's disease;
LUAD	cis	rs11690462	0.926	rs11689086	chr2:26549127	C/T	cg13255216	chr2:26625047	C2orf39	0.37	6.37	0.3	4.9e-10	Coronary artery disease;
LUAD	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg06108461	chr20:60628389	TAF4	-1.13	-20.62	-0.71	6.5e-66	Body mass index;
LUAD	cis	rs6460942	1.000	rs73053527	chr7:12313008	C/A	cg06484146	chr7:12443880	VWDE	-0.54	-6.41	-0.3	3.88e-10	Coronary artery disease;
LUAD	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg09509183	chr1:209979624	IRF6	0.57	7.97	0.36	1.53e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg04025307	chr7:1156635	C7orf50	0.84	16.05	0.62	1.29e-45	Longevity;Endometriosis;
LUAD	cis	rs11771526	0.901	rs7357136	chr7:32302338	G/T	cg27532318	chr7:32358331	NA	0.59	7.42	0.34	6.66e-13	Body mass index;
LUAD	cis	rs1215050	0.791	rs10856931	chr4:98819306	C/T	cg24818145	chr4:99064322	C4orf37	0.41	6.76	0.31	4.45e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg08071915	chr8:12219732	FAM66A	0.46	7.45	0.34	5.23e-13	Joint mobility (Beighton score);
LUAD	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg25237894	chr2:233734115	C2orf82	-0.48	-9.03	-0.4	6.21e-18	Coronary artery disease;
LUAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22029157	chr1:209979665	IRF6	0.85	20.07	0.7	2.06e-63	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUAD	cis	rs4604732	0.631	rs10802509	chr1:247627158	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg25985355	chr7:65971099	NA	0.36	6.47	0.3	2.68e-10	Aortic root size;
LUAD	cis	rs41311933	0.803	rs41312871	chr9:123733630	C/T	cg13567360	chr9:123745713	C5	-0.85	-9.2	-0.41	1.71e-18	Coronary artery disease;
LUAD	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg26343298	chr8:95960752	TP53INP1	0.4	8.4	0.38	6.83e-16	Type 2 diabetes;
LUAD	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg21194808	chr1:2205498	SKI	0.41	6.44	0.3	3.21e-10	Height;
LUAD	cis	rs11229555	0.609	rs12273635	chr11:58186327	T/C	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.73	10.57	0.46	2.46e-23	Ulcerative colitis;
LUAD	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg09658497	chr7:2847517	GNA12	-0.48	-8.86	-0.4	2.28e-17	Height;
LUAD	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg00316803	chr15:76480434	C15orf27	-0.4	-7.78	-0.35	5.49e-14	Blood metabolite levels;
LUAD	cis	rs2046867	0.818	rs62249875	chr3:72911858	G/A	cg25664220	chr3:72788482	NA	-0.59	-10.41	-0.45	9.79e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.67	0.31	8.2e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg15910685	chr13:79980098	RBM26	-0.44	-6.88	-0.32	2.17e-11	Vertical cup-disc ratio;
LUAD	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg06671706	chr8:8559999	CLDN23	0.66	11.48	0.49	9.6800000000000007e-27	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.9	0.36	2.44e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17269548	chr7:44836290	PPIA	-0.52	-6.88	-0.32	2.14e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.85e-14	Depression;
LUAD	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg08847533	chr14:75593920	NEK9	0.43	7.37	0.34	9.13e-13	Height;
LUAD	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg13180566	chr4:1052158	NA	-0.38	-6.5	-0.3	2.2e-10	Recombination rate (females);
LUAD	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg10518543	chr12:38710700	ALG10B	-0.5	-8.49	-0.38	3.41e-16	Morning vs. evening chronotype;
LUAD	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg21138405	chr5:131827807	IRF1	0.45	9.71	0.43	2.99e-20	Breast cancer;Mosquito bite size;
LUAD	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.25	0.54	9.08e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7709909	0.553	rs26782	chr5:80052419	G/A	cg24059623	chr5:79951536	MSH3;DHFR	0.48	7.19	0.33	2.89e-12	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg27446573	chr6:127587934	RNF146	0.43	6.66	0.31	8.73e-11	Breast cancer;
LUAD	cis	rs977987	0.778	rs1109341	chr16:75445605	G/A	cg03315344	chr16:75512273	CHST6	0.63	13.89	0.56	2.05e-36	Dupuytren's disease;
LUAD	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937890	0.559	rs2575853	chr11:14533963	T/C	cg22961513	chr11:14280813	SPON1	-0.38	-7.36	-0.34	9.79e-13	Mitochondrial DNA levels;
LUAD	cis	rs34734847	0.933	rs998727	chr12:121149064	T/G	cg21892295	chr12:121157589	UNC119B	-0.47	-8.57	-0.38	1.9e-16	Mean corpuscular volume;
LUAD	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg18827107	chr12:86230957	RASSF9	-0.54	-9.52	-0.42	1.35e-19	Major depressive disorder;
LUAD	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg04287289	chr16:89883240	FANCA	0.78	6.92	0.32	1.73e-11	Skin colour saturation;
LUAD	trans	rs194045	0.609	rs252344	chr16:29184882	G/A	cg17334114	chr3:133646504	NA	0.54	7.04	0.32	7.59e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.64	11.93	0.5	1.78e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg03605463	chr16:89740564	NA	-0.47	-7.43	-0.34	5.91e-13	Hemoglobin concentration;
LUAD	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.52	8.42	0.38	6.05e-16	Total body bone mineral density;
LUAD	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg00677455	chr12:58241039	CTDSP2	-0.44	-7.43	-0.34	5.96e-13	Multiple sclerosis;
LUAD	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg21171335	chr12:122356390	WDR66	0.66	11.56	0.49	4.73e-27	Mean corpuscular volume;
LUAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.41	-6.44	-0.3	3.31e-10	Longevity;Endometriosis;
LUAD	cis	rs7680126	0.672	rs10939819	chr4:10290661	T/C	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.11	-0.33	5.04e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg10755058	chr3:40428713	ENTPD3	0.43	8.5	0.38	3.23e-16	Renal cell carcinoma;
LUAD	cis	rs7508679	1.000	rs10410204	chr19:7224350	C/T	cg00428638	chr19:7224713	INSR	0.74	15.92	0.61	4.84e-45	Hypothyroidism;
LUAD	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.29	6.35	0.3	5.52e-10	Parkinson's disease;
LUAD	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24308560	chr3:49941425	MST1R	-0.58	-9.9	-0.43	6.3e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs7178375	0.607	rs7171212	chr15:31207711	C/T	cg15020726	chr15:31196382	MTMR15	0.67	7.0	0.32	9.88e-12	Hypertriglyceridemia;
LUAD	cis	rs73086581	1.000	rs14047	chr20:3914215	G/A	cg02187196	chr20:3869020	PANK2	0.48	6.77	0.31	4.26e-11	Response to antidepressants in depression;
LUAD	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg15309053	chr8:964076	NA	0.37	7.92	0.36	2.14e-14	Schizophrenia;
LUAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg10729496	chr3:10149963	C3orf24	0.58	9.34	0.41	5.58e-19	Alzheimer's disease;
LUAD	cis	rs2657888	1.000	rs2657890	chr12:56938577	C/T	cg23002907	chr12:56915593	RBMS2	0.37	6.97	0.32	1.26e-11	Adiponectin levels;
LUAD	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg22875332	chr1:76189707	ACADM	-0.84	-15.26	-0.6	3.25e-42	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs41311933	0.656	rs72758197	chr9:123820360	G/A	cg13567360	chr9:123745713	C5	-0.65	-7.94	-0.36	1.81e-14	Coronary artery disease;
LUAD	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg10518543	chr12:38710700	ALG10B	0.41	6.39	0.3	4.29e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7843479	0.506	rs7818430	chr8:21798429	C/T	cg03445287	chr8:21823731	XPO7	-0.49	-9.33	-0.41	5.89e-19	Mean corpuscular volume;
LUAD	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg15181151	chr6:150070149	PCMT1	0.32	6.51	0.3	2.17e-10	Testicular germ cell tumor;
LUAD	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg11915388	chr22:42470451	FAM109B	0.39	6.93	0.32	1.56e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08677398	chr8:58056175	NA	0.48	6.77	0.31	4.3e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.76	-9.6	-0.42	7.19e-20	Body mass index;
LUAD	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg14092988	chr3:52407081	DNAH1	0.37	7.25	0.33	1.95e-12	Electroencephalogram traits;
LUAD	cis	rs12893597	0.715	rs4624098	chr14:76826256	G/A	cg20290672	chr14:76816747	NA	-0.46	-7.28	-0.33	1.66e-12	Maximal oxygen uptake response;
LUAD	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg07936489	chr17:37558343	FBXL20	-0.57	-7.94	-0.36	1.8e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs1137	0.904	rs205639	chr2:74948981	T/C	cg19285774	chr2:74907978	SEMA4F	-0.35	-6.53	-0.3	1.84e-10	Myopia (pathological);
LUAD	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg21171335	chr12:122356390	WDR66	0.77	14.32	0.57	3.44e-38	Mean corpuscular volume;
LUAD	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg11266682	chr4:10021025	SLC2A9	0.67	15.01	0.59	4.03e-41	Bone mineral density;
LUAD	cis	rs739496	0.843	rs616559	chr12:112003350	C/T	cg10833066	chr12:111807467	FAM109A	-0.37	-6.38	-0.3	4.56e-10	Platelet count;
LUAD	cis	rs11671005	0.735	rs11668789	chr19:58928309	C/T	cg13877915	chr19:58951672	ZNF132	0.56	7.42	0.34	6.67e-13	Mean platelet volume;
LUAD	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg11822812	chr5:140052017	DND1	-0.38	-7.03	-0.32	8.08e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg04450456	chr4:17643702	FAM184B	0.36	6.83	0.32	2.94e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg27494647	chr7:150038898	RARRES2	0.5	8.41	0.38	6.26e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4700695	0.668	rs166180	chr5:65499225	C/T	cg21114390	chr5:65439923	SFRS12	-0.91	-14.0	-0.56	7.02e-37	Facial morphology (factor 19);
LUAD	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.16	-0.41	2.28e-18	Life satisfaction;
LUAD	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg04450456	chr4:17643702	FAM184B	0.41	8.13	0.37	4.71e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-7.17	-0.33	3.34e-12	Major depressive disorder;
LUAD	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.56	-0.35	2.52e-13	Menarche (age at onset);
LUAD	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02018176	chr4:1364513	KIAA1530	-0.57	-10.21	-0.44	4.96e-22	Obesity-related traits;
LUAD	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg21699342	chr2:239360505	ASB1	-0.6	-11.79	-0.5	5.95e-28	Multiple system atrophy;
LUAD	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg11859384	chr17:80120422	CCDC57	0.5	9.05	0.4	5.37e-18	Life satisfaction;
LUAD	trans	rs3960554	0.740	rs10216079	chr7:75690988	A/C	cg19862616	chr7:65841803	NCRNA00174	0.81	10.99	0.47	6.93e-25	Eotaxin levels;
LUAD	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	12.71	0.53	1.44e-31	Monocyte percentage of white cells;
LUAD	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.53	1.39e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg25838465	chr1:92012736	NA	0.53	10.53	0.46	3.53e-23	Breast cancer;
LUAD	cis	rs1865721	0.682	rs7242637	chr18:73147492	A/C	cg26385618	chr18:73139727	C18orf62	-0.5	-10.01	-0.44	2.66e-21	Intelligence;
LUAD	cis	rs4713675	0.565	rs4711341	chr6:33690797	A/G	cg14003231	chr6:33640908	ITPR3	0.48	9.4	0.42	3.43e-19	Plateletcrit;
LUAD	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg06784218	chr1:46089804	CCDC17	0.54	11.66	0.49	2.02e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg12927641	chr6:109611667	NA	-0.52	-9.12	-0.41	2.96e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs62400317	0.859	rs56283067	chr6:45100330	T/C	cg18551225	chr6:44695536	NA	-0.57	-8.83	-0.39	2.73e-17	Total body bone mineral density;
LUAD	cis	rs9900062	0.507	rs7225993	chr17:62708284	C/G	cg02097616	chr17:62675921	NA	0.6	9.79	0.43	1.54e-20	QT interval;
LUAD	trans	rs877282	1.000	rs2004479	chr10:770854	G/A	cg22713356	chr15:30763199	NA	1.26	17.64	0.65	1.4e-52	Uric acid levels;
LUAD	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.51e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	7.11	0.33	4.9e-12	Cognitive test performance;
LUAD	cis	rs11229555	0.645	rs11229445	chr11:58199458	G/A	cg15696309	chr11:58395628	NA	-0.72	-10.17	-0.44	6.95e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg05340658	chr4:99064831	C4orf37	0.45	7.36	0.34	9.65e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7258465	1.000	rs10413237	chr19:18548249	A/C	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.51	-0.34	3.56e-13	Breast cancer;
LUAD	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.38	6.76	0.31	4.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.68	-8.14	-0.37	4.38e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7937890	0.559	rs2575852	chr11:14533368	G/A	cg06199346	chr11:14280333	SPON1	-0.32	-6.42	-0.3	3.58e-10	Mitochondrial DNA levels;
LUAD	cis	rs4953076	0.573	rs67537903	chr2:44422111	G/A	cg04920474	chr2:44395004	PPM1B	0.54	8.34	0.38	1.05e-15	Height;
LUAD	cis	rs2806561	0.754	rs10917337	chr1:23300723	G/A	cg19743168	chr1:23544995	NA	-0.36	-6.41	-0.3	3.87e-10	Height;
LUAD	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.02	0.36	1.02e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg05295671	chr13:79234353	RNF219	0.48	7.07	0.33	6.49e-12	Large artery stroke;
LUAD	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg26384229	chr12:38710491	ALG10B	0.46	7.35	0.34	1.05e-12	Heart rate;
LUAD	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-7.01	-0.32	9.57e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg23985595	chr17:80112537	CCDC57	0.53	9.67	0.43	3.98e-20	Life satisfaction;
LUAD	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.65e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg05754148	chr16:3507555	NAT15	-0.43	-6.71	-0.31	6.2e-11	Body mass index (adult);
LUAD	cis	rs13082711	0.595	rs34453788	chr3:27330153	T/C	cg02860705	chr3:27208620	NA	0.77	11.89	0.5	2.42e-28	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7116495	1.000	rs4338555	chr11:71755696	T/C	cg07596299	chr11:71824057	C11orf51	-0.78	-6.65	-0.31	8.84e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs2274273	0.588	rs9323285	chr14:55863829	A/C	cg04306507	chr14:55594613	LGALS3	-0.39	-7.41	-0.34	6.88e-13	Protein biomarker;
LUAD	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg09491104	chr22:46646882	C22orf40	-0.53	-6.95	-0.32	1.38e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs11209185	0.602	rs12034179	chr1:68433212	T/C	cg22082780	chr1:68452167	NA	-0.38	-7.53	-0.34	3.18e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg17366294	chr4:99064904	C4orf37	0.66	12.62	0.52	3.36e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg04727924	chr7:799746	HEATR2	-0.57	-7.08	-0.33	5.91e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs10992471	0.651	rs10124058	chr9:95522882	G/A	cg14631576	chr9:95140430	CENPP	-0.48	-9.82	-0.43	1.23e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg09117114	chr16:67998030	SLC12A4	-0.48	-6.82	-0.31	3.06e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs151234	0.741	rs151229	chr16:28584937	G/A	cg04643524	chr16:28609220	SULT1A2	0.64	8.96	0.4	1.01e-17	Platelet distribution width;
LUAD	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg13535736	chr9:111863775	C9orf5	-0.44	-6.95	-0.32	1.4e-11	Menarche (age at onset);
LUAD	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg16049864	chr8:95962084	TP53INP1	-0.54	-11.6	-0.49	3.33e-27	Type 2 diabetes;
LUAD	cis	rs12200560	0.505	rs9400166	chr6:97077101	G/A	cg06623918	chr6:96969491	KIAA0776	0.47	7.35	0.34	1.01e-12	Coronary heart disease;
LUAD	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg23978390	chr7:1156363	C7orf50	0.56	7.64	0.35	1.45e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24308560	chr3:49941425	MST1R	0.55	9.3	0.41	7.56e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs17092148	0.887	rs6059931	chr20:33175338	A/G	cg16810054	chr20:33298113	TP53INP2	-0.54	-8.21	-0.37	2.77e-15	Neuroticism;
LUAD	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg19041857	chr6:27730383	NA	-0.43	-7.29	-0.33	1.52e-12	Parkinson's disease;
LUAD	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg10518543	chr12:38710700	ALG10B	-0.52	-8.43	-0.38	5.37e-16	Morning vs. evening chronotype;
LUAD	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg04450456	chr4:17643702	FAM184B	0.4	7.89	0.36	2.6e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.57	-7.16	-0.33	3.61e-12	Alzheimer's disease;
LUAD	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg17724175	chr1:150552817	MCL1	0.36	8.19	0.37	3.1e-15	Melanoma;
LUAD	trans	rs629535	0.590	rs62513427	chr8:70138891	A/T	cg21567404	chr3:27674614	NA	-1.01	-16.48	-0.63	1.65e-47	Dupuytren's disease;
LUAD	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg07212818	chr11:638076	DRD4	-0.45	-6.63	-0.31	1e-10	Systemic lupus erythematosus;
LUAD	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg01448562	chr3:133502909	NA	-0.53	-8.96	-0.4	1.03e-17	Iron status biomarkers;
LUAD	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg09365446	chr1:150670422	GOLPH3L	0.55	9.62	0.42	6.27e-20	Tonsillectomy;
LUAD	cis	rs11264213	0.591	rs399393	chr1:36553673	A/G	cg27506609	chr1:36549197	TEKT2	-0.67	-6.4	-0.3	4.01e-10	Schizophrenia;
LUAD	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg22823121	chr1:150693482	HORMAD1	0.41	7.9	0.36	2.46e-14	Melanoma;
LUAD	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg26513180	chr16:89883248	FANCA	0.65	6.65	0.31	9.32e-11	Interleukin-17 levels;
LUAD	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06873352	chr17:61820015	STRADA	0.57	9.22	0.41	1.37e-18	Height;
LUAD	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg07741184	chr6:167504864	NA	0.29	7.03	0.32	8.39e-12	Crohn's disease;
LUAD	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg26924012	chr15:45694286	SPATA5L1	0.99	18.22	0.66	3.45e-55	Homoarginine levels;
LUAD	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg00106254	chr7:1943704	MAD1L1	-0.61	-9.25	-0.41	1.16e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs6604026	0.698	rs4847384	chr1:93382279	T/C	cg17283838	chr1:93427260	FAM69A	-0.43	-6.71	-0.31	6.22e-11	Multiple sclerosis;
LUAD	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg21862992	chr11:68658383	NA	-0.46	-8.35	-0.38	9.66e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs7746199	0.736	rs13193480	chr6:27702561	A/G	cg06606381	chr12:133084897	FBRSL1	-1.07	-10.05	-0.44	1.88e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg13393036	chr8:95962371	TP53INP1	0.37	8.9	0.4	1.71e-17	Type 2 diabetes;
LUAD	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg05043794	chr9:111880884	C9orf5	-0.43	-7.51	-0.34	3.52e-13	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg18180107	chr4:99064573	C4orf37	0.44	7.05	0.32	7.4e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9796	0.870	rs2925345	chr15:41311799	T/C	cg18705301	chr15:41695430	NDUFAF1	0.38	6.89	0.32	1.98e-11	Menopause (age at onset);
LUAD	cis	rs12681287	0.752	rs12677470	chr8:87260559	G/A	cg00550725	chr8:87521180	FAM82B	0.44	6.37	0.3	4.98e-10	Caudate activity during reward;
LUAD	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	12.52	0.52	8.34e-31	Monocyte percentage of white cells;
LUAD	cis	rs9467773	1.000	rs9467798	chr6:26575697	G/A	cg11502198	chr6:26597334	ABT1	0.61	10.06	0.44	1.76e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs17152411	0.793	rs12569669	chr10:126592671	A/G	cg07906193	chr10:126599966	NA	0.55	7.76	0.35	6.5e-14	Height;
LUAD	cis	rs68170813	0.559	rs77185844	chr7:106812916	A/C	cg23024343	chr7:107201750	COG5	0.49	7.03	0.32	8.26e-12	Coronary artery disease;
LUAD	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.68	-0.35	1.08e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10901296	0.660	rs11991	chr9:133762558	T/C	cg13397898	chr9:133768931	QRFP	0.52	6.61	0.31	1.15e-10	Bilirubin levels;
LUAD	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.69	-12.56	-0.52	5.49e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.53	-0.34	3.18e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13064411	0.735	rs2614191	chr3:113269201	C/T	cg18753928	chr3:113234510	CCDC52	-0.46	-7.37	-0.34	9.3e-13	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	12.93	0.53	1.94e-32	Prudent dietary pattern;
LUAD	cis	rs10129255	0.518	rs10136903	chr14:107187105	T/C	cg23076370	chr14:107095027	NA	-0.43	-8.7	-0.39	7.62e-17	Kawasaki disease;
LUAD	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg18404041	chr3:52824283	ITIH1	0.4	7.24	0.33	2.09e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg06547715	chr2:218990976	CXCR2	-0.28	-6.72	-0.31	5.73e-11	Colorectal cancer;
LUAD	cis	rs10899021	0.790	rs12280434	chr11:74332827	C/T	cg25880958	chr11:74394337	NA	-0.53	-7.17	-0.33	3.36e-12	Response to metformin (IC50);
LUAD	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg14847009	chr1:175162515	KIAA0040	0.34	8.98	0.4	9.29e-18	Alcohol dependence;
LUAD	cis	rs1448094	0.645	rs12301701	chr12:86472798	C/T	cg19622623	chr12:86230825	RASSF9	0.41	7.37	0.34	9.12e-13	Major depressive disorder;
LUAD	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24838063	chr12:130822603	PIWIL1	0.64	10.7	0.46	8.19e-24	Menopause (age at onset);
LUAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg18621852	chr3:10150065	C3orf24	-0.51	-9.2	-0.41	1.61e-18	Alzheimer's disease;
LUAD	cis	rs10203711	1.000	rs4663328	chr2:239574103	A/G	cg14580085	chr2:239553406	NA	-0.42	-9.06	-0.4	4.87e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg21220214	chr8:57350948	NA	-0.6	-8.9	-0.4	1.68e-17	Obesity-related traits;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg23837253	chr19:47759802	CCDC9	-0.67	-6.46	-0.3	2.8e-10	Type 2 diabetes;
LUAD	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg02269571	chr22:50332266	NA	-0.68	-9.74	-0.43	2.37e-20	Schizophrenia;
LUAD	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg26587870	chr6:27730563	NA	-0.43	-6.98	-0.32	1.17e-11	Parkinson's disease;
LUAD	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-14.78	-0.58	3.82e-40	Schizophrenia;
LUAD	cis	rs113835537	0.597	rs3737525	chr11:66306355	A/G	cg24851651	chr11:66362959	CCS	0.59	9.94	0.44	4.72e-21	Airway imaging phenotypes;
LUAD	cis	rs74417235	0.610	rs13178134	chr5:154063032	A/T	cg08893839	chr5:154027129	NA	-0.54	-7.18	-0.33	3.22e-12	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg10523679	chr1:76189770	ACADM	0.97	19.57	0.69	3.44e-61	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg01200585	chr1:228362443	C1orf69	0.43	7.89	0.36	2.63e-14	Diastolic blood pressure;
LUAD	cis	rs73058052	0.867	rs57940349	chr19:50097607	C/T	cg21913888	chr19:50084626	PRRG2;NOSIP	0.33	6.92	0.32	1.7e-11	Fibrinogen levels;
LUAD	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg07776626	chr8:57350775	NA	-0.6	-8.85	-0.4	2.45e-17	Obesity-related traits;
LUAD	cis	rs7017914	0.967	rs12680166	chr8:71678638	G/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.67e-10	Bone mineral density;
LUAD	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg03885332	chr11:832357	CD151	-0.41	-7.64	-0.35	1.43e-13	Mean platelet volume;
LUAD	cis	rs113835537	0.529	rs11824771	chr11:66262550	T/C	cg24851651	chr11:66362959	CCS	0.55	9.84	0.43	1.05e-20	Airway imaging phenotypes;
LUAD	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg09835421	chr16:68378352	PRMT7	-0.85	-9.1	-0.4	3.55e-18	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.64	-0.31	9.9e-11	Coronary artery disease;
LUAD	cis	rs1018836	0.632	rs2879361	chr8:91481909	C/T	cg16814680	chr8:91681699	NA	0.6	10.21	0.44	4.91e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7301016	0.846	rs12367878	chr12:63027483	C/T	cg11441379	chr12:63026424	NA	0.62	7.41	0.34	7.04e-13	IgG glycosylation;
LUAD	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg04414720	chr1:150670196	GOLPH3L	0.74	13.18	0.54	1.74e-33	Melanoma;
LUAD	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg13770153	chr20:60521292	NA	-0.56	-9.28	-0.41	8.69e-19	Body mass index;
LUAD	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg18404041	chr3:52824283	ITIH1	-0.6	-12.18	-0.51	1.78e-29	Bipolar disorder;
LUAD	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg12011299	chr4:100065546	ADH4	0.73	13.72	0.55	1.1e-35	Alcohol dependence;
LUAD	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg06558623	chr16:89946397	TCF25	1.14	9.96	0.44	4e-21	Skin colour saturation;
LUAD	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg27432699	chr2:27873401	GPN1	0.55	9.6	0.42	6.89e-20	Oral cavity cancer;
LUAD	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg24154853	chr7:158122151	PTPRN2	0.59	11.86	0.5	3.3e-28	Calcium levels;
LUAD	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg03690763	chr11:133734501	NA	-0.34	-8.23	-0.37	2.42e-15	Childhood ear infection;
LUAD	cis	rs2692947	0.794	rs2692893	chr2:96756547	C/T	cg23100626	chr2:96804247	ASTL	0.35	8.88	0.4	1.88e-17	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg12310025	chr6:25882481	NA	-0.41	-6.67	-0.31	7.87e-11	Height;
LUAD	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg17652424	chr22:38574118	PLA2G6	-0.33	-10.13	-0.44	9.75e-22	Cutaneous nevi;
LUAD	trans	rs7246760	0.867	rs66464474	chr19:9795149	T/C	cg02900749	chr2:68251473	NA	-0.59	-6.56	-0.3	1.59e-10	Pursuit maintenance gain;
LUAD	cis	rs8077889	0.871	rs16940243	chr17:41900003	C/G	cg26893861	chr17:41843967	DUSP3	0.91	15.56	0.6	1.65e-43	Triglycerides;
LUAD	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	9.63	0.42	5.79e-20	Electrocardiographic conduction measures;
LUAD	cis	rs4148087	0.673	rs9981792	chr21:43598637	C/T	cg08841829	chr21:43638893	ABCG1	0.46	6.42	0.3	3.75e-10	Eating disorder in bipolar disorder;
LUAD	cis	rs2455799	0.573	rs924753	chr3:15706124	C/T	cg16303742	chr3:15540471	COLQ	-0.43	-7.93	-0.36	2.03e-14	Mean platelet volume;
LUAD	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18876405	chr7:65276391	NA	-0.41	-6.45	-0.3	3.13e-10	Aortic root size;
LUAD	cis	rs2535633	0.631	rs2581819	chr3:53016552	C/A	cg11645453	chr3:52864694	ITIH4	-0.38	-7.08	-0.33	6.05e-12	Body mass index;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg23869335	chr2:220159595	PTPRN;MIR153-1	-0.62	-6.43	-0.3	3.43e-10	Type 2 diabetes;
LUAD	cis	rs9837602	1.000	rs9841186	chr3:99795651	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.64	-9.9	-0.43	6.55e-21	Breast cancer;
LUAD	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.41	0.34	6.91e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.92	-0.32	1.65e-11	Mood instability;
LUAD	cis	rs9287719	0.649	rs10186984	chr2:10734192	C/G	cg03983476	chr2:10830698	NOL10	0.39	6.42	0.3	3.68e-10	Prostate cancer;
LUAD	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-6.96	-0.32	1.32e-11	Lung cancer;
LUAD	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.38	-6.37	-0.3	4.91e-10	Neutrophil percentage of white cells;
LUAD	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg18016565	chr1:150552671	MCL1	0.4	7.49	0.34	4.12e-13	Tonsillectomy;
LUAD	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg04450456	chr4:17643702	FAM184B	0.4	7.95	0.36	1.76e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs1448094	0.785	rs6539941	chr12:86452813	G/T	cg18827107	chr12:86230957	RASSF9	0.43	7.74	0.35	7.6e-14	Major depressive disorder;
LUAD	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg05665937	chr4:1216051	CTBP1	0.48	7.15	0.33	3.73e-12	Longevity;
LUAD	cis	rs3744061	0.557	rs9889902	chr17:74648034	T/C	cg27546012	chr17:74684504	MXRA7	-0.4	-7.08	-0.33	5.96e-12	Retinal arteriolar caliber;
LUAD	cis	rs12618769	0.652	rs17033813	chr2:99196483	A/G	cg10123293	chr2:99228465	UNC50	-0.48	-8.45	-0.38	4.63e-16	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg18944383	chr4:111397179	ENPEP	0.41	8.26	0.37	1.87e-15	Height;
LUAD	cis	rs754466	0.874	rs10430531	chr10:79660125	T/C	cg17075019	chr10:79541650	NA	-0.85	-14.09	-0.57	3.07e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	8.73	0.39	6.16e-17	Hip circumference adjusted for BMI;
LUAD	trans	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg24644049	chr4:85504048	CDS1	0.84	7.46	0.34	4.94e-13	Skin colour saturation;
LUAD	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg25985355	chr7:65971099	NA	-0.4	-7.38	-0.34	8.44e-13	Aortic root size;
LUAD	cis	rs4444359	0.679	rs7190014	chr16:11551515	C/T	cg08104224	chr16:11588532	NA	0.37	6.48	0.3	2.53e-10	Facial morphology (factor 17, height of vermillion upper lip);
LUAD	cis	rs7680126	0.595	rs17251963	chr4:10142561	A/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-8.32	-0.38	1.21e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03517284	chr6:25882590	NA	-0.49	-7.48	-0.34	4.35e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1595825	0.945	rs6756641	chr2:198849672	T/G	cg11031976	chr2:198649780	BOLL	-0.45	-6.74	-0.31	5.28e-11	Ulcerative colitis;
LUAD	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg26446133	chr18:72167187	CNDP2	-0.92	-16.12	-0.62	6.42e-46	Refractive error;
LUAD	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Colorectal cancer;
LUAD	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg15181151	chr6:150070149	PCMT1	0.39	7.91	0.36	2.31e-14	Lung cancer;
LUAD	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg09184832	chr6:79620586	NA	-0.5	-9.46	-0.42	2.24e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs3960554	0.674	rs113848658	chr7:75791858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.82	10.75	0.46	5.33e-24	Eotaxin levels;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg22956410	chr19:58281117	ZNF586	-0.49	-6.53	-0.3	1.85e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg09365446	chr1:150670422	GOLPH3L	0.63	11.15	0.48	1.79e-25	Melanoma;
LUAD	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg08761264	chr16:28874980	SH2B1	-0.45	-6.93	-0.32	1.58e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.33	0.38	1.13e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.891	rs79845692	chr2:198523541	T/C	cg10547527	chr2:198650123	BOLL	-0.54	-7.66	-0.35	1.3e-13	Ulcerative colitis;
LUAD	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18876405	chr7:65276391	NA	-0.53	-9.16	-0.41	2.18e-18	Aortic root size;
LUAD	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.98	-0.32	1.15e-11	Height;
LUAD	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg02951883	chr7:2050386	MAD1L1	-0.81	-13.5	-0.55	8.4e-35	Bipolar disorder and schizophrenia;
LUAD	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg26597838	chr10:835615	NA	0.69	9.82	0.43	1.21e-20	Eosinophil percentage of granulocytes;
LUAD	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg09835421	chr16:68378352	PRMT7	-0.96	-10.8	-0.46	3.68e-24	Magnesium levels;
LUAD	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1572072	1.000	rs9510769	chr13:24121482	A/G	cg25639084	chr13:24133513	NA	-0.22	-6.45	-0.3	3.02e-10	Nasopharyngeal carcinoma;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg10532262	chr3:172428426	NCEH1	-0.48	-6.73	-0.31	5.69e-11	Testicular germ cell tumor;
LUAD	cis	rs10465746	0.967	rs6670658	chr1:84461268	A/G	cg10977910	chr1:84465055	TTLL7	0.51	8.25	0.37	2e-15	Obesity-related traits;
LUAD	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg17971929	chr21:40555470	PSMG1	0.5	7.6	0.35	1.89e-13	Cognitive function;
LUAD	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg01236616	chr12:121019343	POP5	-1.16	-17.03	-0.64	6.7e-50	Type 1 diabetes nephropathy;
LUAD	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.39	-0.38	7.54e-16	Neutrophil percentage of white cells;
LUAD	cis	rs240764	0.645	rs454747	chr6:101055566	T/C	cg09795085	chr6:101329169	ASCC3	0.4	6.99	0.32	1.11e-11	Neuroticism;
LUAD	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg13385794	chr1:248469461	NA	0.25	6.46	0.3	2.84e-10	Common traits (Other);
LUAD	cis	rs1997103	1.000	rs1997102	chr7:55399322	A/C	cg17469321	chr7:55412551	NA	-0.67	-11.77	-0.5	7.33e-28	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs859767	0.501	rs1123184	chr2:135431057	C/G	cg12500956	chr2:135428796	TMEM163	-0.27	-7.36	-0.34	9.92e-13	Neuroticism;
LUAD	cis	rs2274273	0.774	rs9323278	chr14:55541574	C/G	cg04306507	chr14:55594613	LGALS3	0.31	6.53	0.3	1.85e-10	Protein biomarker;
LUAD	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg20933634	chr6:27740509	NA	0.45	6.99	0.32	1.11e-11	Parkinson's disease;
LUAD	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.71	-0.39	7.02e-17	Menopause (age at onset);
LUAD	cis	rs2658782	0.756	rs2658777	chr11:93148423	C/T	cg15737290	chr11:93063684	CCDC67	0.48	6.85	0.32	2.6e-11	Pulmonary function decline;
LUAD	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg13057898	chr1:3703894	LRRC47	0.62	10.39	0.45	1.16e-22	Red cell distribution width;
LUAD	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg14196790	chr5:131705035	SLC22A5	0.38	6.76	0.31	4.52e-11	Blood metabolite levels;
LUAD	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs12681287	0.640	rs61106663	chr8:87477081	G/C	cg27223183	chr8:87520930	FAM82B	-0.67	-9.61	-0.42	6.38e-20	Caudate activity during reward;
LUAD	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg19413350	chr8:57351067	NA	-0.41	-6.54	-0.3	1.75e-10	Obesity-related traits;
LUAD	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.75	0.31	4.86e-11	Breast cancer;
LUAD	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg23231163	chr10:75533350	FUT11	-0.54	-10.24	-0.45	3.84e-22	Inflammatory bowel disease;
LUAD	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.73	9.91	0.43	6e-21	Smoking behavior;
LUAD	trans	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg21659725	chr3:3221576	CRBN	0.39	6.58	0.3	1.4e-10	Resting heart rate;
LUAD	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.4	6.85	0.32	2.6e-11	Total body bone mineral density;
LUAD	cis	rs6684514	1.000	rs12038481	chr1:156284815	T/C	cg16558208	chr1:156270281	VHLL	0.53	9.71	0.43	2.95e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg11494091	chr17:61959527	GH2	0.42	8.18	0.37	3.33e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18702234	chr17:40985921	PSME3	-0.44	-6.82	-0.31	3.17e-11	Height;
LUAD	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg23587288	chr2:27483067	SLC30A3	-0.43	-8.45	-0.38	4.69e-16	Blood metabolite levels;
LUAD	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg00255919	chr5:131827918	IRF1	-0.29	-6.68	-0.31	7.43e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg13390004	chr1:15929781	NA	0.49	8.61	0.39	1.49e-16	Systolic blood pressure;
LUAD	cis	rs57590327	0.555	rs13099615	chr3:81729101	T/A	cg07356753	chr3:81810745	GBE1	-0.63	-10.12	-0.44	1.03e-21	Extraversion;
LUAD	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg02782426	chr3:40428986	ENTPD3	0.35	7.59	0.35	2e-13	Renal cell carcinoma;
LUAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg02951883	chr7:2050386	MAD1L1	-0.93	-17.91	-0.66	8.43e-54	Bipolar disorder and schizophrenia;
LUAD	cis	rs72928364	1.000	rs35509049	chr3:100660764	C/T	cg10123952	chr3:100791384	NA	0.65	7.51	0.34	3.55e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6906287	0.647	rs11153752	chr6:118834771	A/T	cg21191810	chr6:118973309	C6orf204	0.5	9.77	0.43	1.85e-20	Electrocardiographic conduction measures;
LUAD	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg06618935	chr21:46677482	NA	-0.49	-10.03	-0.44	2.19e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg04450456	chr4:17643702	FAM184B	-0.4	-7.66	-0.35	1.26e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg06263672	chr7:65235340	NA	0.49	6.46	0.3	2.96e-10	Aortic root size;
LUAD	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.64	0.52	2.71e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4786125	0.801	rs8057091	chr16:6902148	A/G	cg03623568	chr16:6915990	A2BP1	-0.45	-9.59	-0.42	7.97e-20	Heart rate variability traits (SDNN);
LUAD	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-7.21	-0.33	2.66e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg10295955	chr4:187884368	NA	1.07	23.24	0.75	1.31e-77	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1595825	0.945	rs1850634	chr2:198827896	T/C	cg00982548	chr2:198649783	BOLL	-0.63	-8.93	-0.4	1.34e-17	Ulcerative colitis;
LUAD	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg17863274	chr19:49399704	TULP2	-0.63	-9.52	-0.42	1.37e-19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	14.18	0.57	1.34e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg17177755	chr1:15930204	NA	0.44	7.02	0.32	8.92e-12	Systolic blood pressure;
LUAD	cis	rs300774	0.925	rs300723	chr2:134131	C/T	cg21211680	chr2:198530	NA	-0.47	-7.38	-0.34	8.37e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs1509123	0.609	rs74520150	chr17:6703929	T/G	cg12642237	chr17:6703447	TEKT1	-0.5	-7.53	-0.34	3.06e-13	Blood metabolite levels;
LUAD	cis	rs62400317	0.859	rs11965706	chr6:45141441	T/A	cg18551225	chr6:44695536	NA	-0.53	-8.31	-0.37	1.3e-15	Total body bone mineral density;
LUAD	trans	rs12517041	1.000	rs1428618	chr5:23282263	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.47	-0.3	2.73e-10	Calcium levels;
LUAD	trans	rs877282	0.838	rs34778553	chr10:796865	T/C	cg22713356	chr15:30763199	NA	1.3	19.52	0.69	5.48e-61	Uric acid levels;
LUAD	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg11494091	chr17:61959527	GH2	0.39	6.87	0.32	2.34e-11	Height;
LUAD	cis	rs4900538	0.855	rs72698597	chr14:102868633	C/T	cg18135206	chr14:102964638	TECPR2	-1.02	-21.2	-0.72	1.77e-68	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg24397884	chr7:158709396	WDR60	0.63	8.63	0.39	1.22e-16	Height;
LUAD	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg24578937	chr1:2090814	PRKCZ	-0.51	-9.96	-0.44	3.83e-21	Height;
LUAD	cis	rs10489202	0.954	rs3820399	chr1:168062053	C/T	cg24449463	chr1:168025552	DCAF6	-0.56	-7.02	-0.32	8.67e-12	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.01	0.36	1.12e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3764563	1.000	rs4646530	chr19:15735238	A/T	cg20725493	chr19:15740067	CYP4F8	0.76	8.24	0.37	2.23e-15	Inflammatory biomarkers;
LUAD	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.2	0.48	1.13e-25	Height;
LUAD	cis	rs7584330	0.554	rs76605518	chr2:238425992	G/A	cg14458575	chr2:238380390	NA	0.61	9.83	0.43	1.1e-20	Prostate cancer;
LUAD	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg17330251	chr7:94953956	PON1	-0.51	-6.79	-0.31	3.91e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs62064224	0.589	rs2041306	chr17:30665675	T/C	cg25809561	chr17:30822961	MYO1D	0.48	8.56	0.38	2.14e-16	Schizophrenia;
LUAD	cis	rs7607369	0.536	rs7566656	chr2:219664519	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-10.41	-0.45	9.57e-23	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg02527881	chr3:46936655	PTH1R	-0.43	-8.59	-0.39	1.66e-16	Colorectal cancer;
LUAD	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs1595825	0.891	rs1851779	chr2:198647108	C/T	cg10547527	chr2:198650123	BOLL	-0.54	-7.52	-0.34	3.24e-13	Ulcerative colitis;
LUAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.49	6.69	0.31	7.26e-11	Renal function-related traits (BUN);
LUAD	cis	rs758324	0.947	rs422291	chr5:131320942	A/T	cg06307176	chr5:131281290	NA	-0.53	-7.63	-0.35	1.55e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg23982607	chr1:1823379	GNB1	-0.9	-18.78	-0.67	1.16e-57	Body mass index;
LUAD	cis	rs4730250	0.707	rs257387	chr7:106808480	G/A	cg23024343	chr7:107201750	COG5	0.5	6.81	0.31	3.35e-11	Osteoarthritis;
LUAD	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg00431813	chr7:1051703	C7orf50	-0.65	-13.97	-0.56	9.53e-37	Longevity;Endometriosis;
LUAD	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg15181151	chr6:150070149	PCMT1	0.41	8.55	0.38	2.2e-16	Lung cancer;
LUAD	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg00933542	chr6:150070202	PCMT1	0.45	9.78	0.43	1.62e-20	Lung cancer;
LUAD	cis	rs6866614	0.608	rs17132288	chr5:131336105	C/T	cg16205897	chr5:131564050	P4HA2	-0.32	-7.04	-0.32	7.93e-12	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg04025307	chr7:1156635	C7orf50	0.65	7.58	0.35	2.14e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12216545	0.711	rs6960291	chr7:150250577	G/T	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.39	-0.3	4.27e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs2665103	0.632	rs3902959	chr15:82544927	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.42	-7.01	-0.32	9.48e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg05425664	chr17:57184151	TRIM37	-0.45	-7.99	-0.36	1.33e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg07817883	chr1:32538562	TMEM39B	1.34	12.95	0.53	1.47e-32	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg22482690	chr17:47019901	SNF8	0.45	8.51	0.38	3.15e-16	Type 2 diabetes;
LUAD	cis	rs4588572	0.643	rs1019803	chr5:77739154	A/G	cg11547950	chr5:77652471	NA	-0.74	-11.63	-0.49	2.66e-27	Triglycerides;
LUAD	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg17848003	chr1:3704513	LRRC47	0.53	10.5	0.45	4.47e-23	Red cell distribution width;
LUAD	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.9	0.53	2.54e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2274273	1.000	rs2147972	chr14:55598030	T/C	cg04306507	chr14:55594613	LGALS3	0.38	7.69	0.35	1.07e-13	Protein biomarker;
LUAD	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg23982607	chr1:1823379	GNB1	-0.9	-18.33	-0.67	1.18e-55	Body mass index;
LUAD	cis	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg27411982	chr8:10470053	RP1L1	-0.41	-7.29	-0.33	1.51e-12	Triglycerides;
LUAD	cis	rs732716	0.719	rs56088814	chr19:4422178	T/A	cg21934504	chr19:4445085	UBXN6	0.41	6.74	0.31	5.07e-11	Mean corpuscular volume;
LUAD	cis	rs476633	0.595	rs11857726	chr15:41530359	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.59	-10.82	-0.47	3.11e-24	Glomerular filtration rate (creatinine);
LUAD	cis	rs11771526	0.901	rs2191000	chr7:32275098	C/A	cg13207630	chr7:32358064	NA	0.63	7.53	0.34	2.99e-13	Body mass index;
LUAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg24813613	chr7:1882135	MAD1L1	-0.45	-7.13	-0.33	4.23e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs3820068	0.580	rs61169376	chr1:16003832	A/G	cg17177755	chr1:15930204	NA	0.5	7.82	0.36	4.2e-14	Systolic blood pressure;
LUAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03762994	chr17:6899332	ALOX12	0.35	6.56	0.3	1.57e-10	Tonsillectomy;
LUAD	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg05621596	chr22:47072043	GRAMD4	-0.66	-10.96	-0.47	9.25e-25	Urate levels in obese individuals;
LUAD	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg25817165	chr18:72167213	CNDP2	-0.69	-9.97	-0.44	3.5e-21	Refractive error;
LUAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg03188948	chr7:1209495	NA	0.81	9.78	0.43	1.65e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8177876	0.822	rs9929586	chr16:81113021	A/G	cg08591886	chr16:81111003	C16orf46	-0.76	-7.01	-0.32	9.76e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg04772025	chr11:68637568	NA	0.58	9.19	0.41	1.84e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg27535305	chr1:53392650	SCP2	-0.39	-8.11	-0.37	5.41e-15	Monocyte count;
LUAD	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg26384229	chr12:38710491	ALG10B	0.48	7.8	0.35	4.88e-14	Bladder cancer;
LUAD	cis	rs4900538	0.855	rs1209151	chr14:102893756	C/T	cg18135206	chr14:102964638	TECPR2	-1.02	-21.07	-0.72	6.56e-68	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs713477	0.935	rs7147968	chr14:55909040	G/A	cg13175173	chr14:55914753	NA	-0.34	-7.08	-0.33	6.16e-12	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.18	-0.37	3.36e-15	Total body bone mineral density;
LUAD	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg24308560	chr3:49941425	MST1R	-0.52	-8.27	-0.37	1.76e-15	Body mass index;
LUAD	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.43	-0.42	2.64e-19	Life satisfaction;
LUAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg20607798	chr8:58055168	NA	0.55	6.43	0.3	3.45e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg19163074	chr7:65112434	INTS4L2	-0.45	-6.85	-0.32	2.54e-11	Aortic root size;
LUAD	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg08601574	chr20:25228251	PYGB	-0.46	-8.65	-0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg03676636	chr4:99064102	C4orf37	0.29	7.69	0.35	1.03e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4356932	1.000	rs11097212	chr4:76952879	A/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.35	-6.43	-0.3	3.45e-10	Blood protein levels;
LUAD	cis	rs68170813	0.559	rs75203426	chr7:107017589	G/C	cg02696742	chr7:106810147	HBP1	-0.79	-10.73	-0.46	6.22e-24	Coronary artery disease;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg20555477	chr9:86594889	HNRNPK;RMI1	0.4	6.73	0.31	5.65e-11	Anger;
LUAD	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	2.92e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7809950	0.678	rs17154040	chr7:107005246	C/T	cg23024343	chr7:107201750	COG5	0.81	14.1	0.57	2.91e-37	Coronary artery disease;
LUAD	cis	rs9902453	0.578	rs8073217	chr17:28164263	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	10.38	0.45	1.26e-22	Coffee consumption (cups per day);
LUAD	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg10792982	chr14:105748885	BRF1	0.46	10.02	0.44	2.49e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.77	0.31	4.27e-11	Depression;
LUAD	cis	rs6835098	0.924	rs12639929	chr4:174156538	C/T	cg27433088	chr4:174089019	GALNT7	0.4	7.47	0.34	4.72e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg06074448	chr4:187884817	NA	0.35	7.02	0.32	8.79e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs9341808	0.718	rs10943696	chr6:80901272	C/G	cg08355045	chr6:80787529	NA	0.58	10.52	0.46	3.89e-23	Sitting height ratio;
LUAD	trans	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg15704280	chr7:45808275	SEPT13	0.68	9.3	0.41	7.32e-19	Axial length;
LUAD	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg14668632	chr7:2872130	GNA12	-0.49	-8.77	-0.39	4.54e-17	Height;
LUAD	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.54	-9.58	-0.42	8.2e-20	Prudent dietary pattern;
LUAD	cis	rs7584330	0.704	rs60079197	chr2:238358584	A/T	cg14458575	chr2:238380390	NA	0.99	17.55	0.65	3.48e-52	Prostate cancer;
LUAD	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg17105886	chr17:28927953	LRRC37B2	0.66	7.53	0.34	3.01e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs12912251	0.947	rs7171233	chr15:38988760	T/A	cg01338139	chr15:38987640	C15orf53	-0.59	-9.29	-0.41	7.95e-19	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg18806716	chr10:30721971	MAP3K8	-0.79	-17.01	-0.64	7.85e-50	Inflammatory bowel disease;
LUAD	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.46	7.64	0.35	1.52e-13	Lung cancer in ever smokers;
LUAD	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg19041857	chr6:27730383	NA	0.41	6.61	0.31	1.17e-10	Parkinson's disease;
LUAD	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.36	-0.34	9.67e-13	Bipolar disorder;
LUAD	cis	rs7680126	0.644	rs62288518	chr4:10087464	T/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-8.64	-0.39	1.14e-16	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08677398	chr8:58056175	NA	0.48	6.84	0.32	2.87e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg12935359	chr14:103987150	CKB	0.5	7.8	0.35	4.94e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs62238980	0.614	rs75526838	chr22:32451830	A/G	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs28595532	0.545	rs13101451	chr4:119253427	A/G	cg02775129	chr4:119771670	NA	-0.58	-6.44	-0.3	3.23e-10	Cannabis dependence symptom count;
LUAD	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg00431813	chr7:1051703	C7orf50	-0.51	-10.1	-0.44	1.22e-21	Longevity;Endometriosis;
LUAD	trans	rs783540	1.000	rs783531	chr15:83249119	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.43	-7.04	-0.32	7.68e-12	Schizophrenia;
LUAD	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg18932078	chr1:2524107	MMEL1	0.38	7.13	0.33	4.5e-12	Ulcerative colitis;
LUAD	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg07708487	chr16:89387014	ANKRD11	-0.34	-6.84	-0.32	2.86e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-7.39	-0.34	7.98e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs2018683	0.707	rs1021691	chr7:28974496	C/T	cg19402173	chr7:128379420	CALU	-0.52	-8.41	-0.38	6.43e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg04539111	chr16:67997858	SLC12A4	-0.63	-7.69	-0.35	1.03e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1595825	0.786	rs79490184	chr2:198894219	T/A	cg11031976	chr2:198649780	BOLL	-0.45	-6.53	-0.3	1.84e-10	Ulcerative colitis;
LUAD	cis	rs7799006	0.606	rs12669625	chr7:2315950	C/T	cg08027265	chr7:2291960	NA	-0.72	-14.61	-0.58	1.96e-39	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs72772090	0.539	rs11747148	chr5:96112863	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-7.36	-0.34	9.41e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.43	-6.9	-0.32	1.91e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg02782426	chr3:40428986	ENTPD3	0.35	7.61	0.35	1.77e-13	Renal cell carcinoma;
LUAD	cis	rs7843479	0.965	rs11785657	chr8:21859485	G/A	cg03445287	chr8:21823731	XPO7	-0.44	-8.02	-0.36	1.06e-14	Mean corpuscular volume;
LUAD	cis	rs1232027	0.700	rs1643638	chr5:79930256	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs10203711	0.901	rs907104	chr2:239564564	T/G	cg14580085	chr2:239553406	NA	0.41	8.63	0.39	1.26e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg10802521	chr3:52805072	NEK4	0.52	8.77	0.39	4.33e-17	Bipolar disorder;
LUAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg05434287	chr7:2030229	MAD1L1	0.4	6.56	0.3	1.54e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs11165623	0.602	rs942904	chr1:97025708	C/T	cg10631902	chr5:14652156	NA	-0.4	-6.99	-0.32	1.06e-11	Hip circumference;Waist circumference;
LUAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg03188948	chr7:1209495	NA	0.83	10.13	0.44	9.87e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg00717180	chr2:96193071	NA	-0.38	-7.01	-0.32	9.62e-12	HDL cholesterol;
LUAD	cis	rs2479724	0.811	rs8393	chr6:41757836	C/A	cg17623882	chr6:41773611	USP49	0.67	12.57	0.52	5.15e-31	Menarche (age at onset);
LUAD	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22590775	chr19:49891494	CCDC155	0.58	9.5	0.42	1.62e-19	Multiple sclerosis;
LUAD	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg17480646	chr11:65405466	SIPA1	-0.46	-6.84	-0.32	2.8e-11	Acne (severe);
LUAD	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg20290983	chr6:43655470	MRPS18A	1.07	27.14	0.8	1.12e-94	IgG glycosylation;
LUAD	trans	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17712092	chr4:129076599	LARP1B	0.84	15.56	0.6	1.72e-43	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs6558530	0.965	rs7460287	chr8:1708274	G/C	cg19131313	chr8:1704013	NA	-0.46	-7.35	-0.34	1.02e-12	Systolic blood pressure;
LUAD	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg08885076	chr2:99613938	TSGA10	0.35	6.46	0.3	2.9e-10	Chronic sinus infection;
LUAD	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg22823121	chr1:150693482	HORMAD1	0.37	7.25	0.33	1.96e-12	Tonsillectomy;
LUAD	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg04944784	chr2:26401820	FAM59B	-0.71	-10.02	-0.44	2.37e-21	Gut microbiome composition (summer);
LUAD	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.54	-0.42	1.12e-19	Schizophrenia;
LUAD	cis	rs2932538	0.961	rs3013441	chr1:113192605	C/T	cg22162597	chr1:113214053	CAPZA1	-0.5	-6.92	-0.32	1.67e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg22823121	chr1:150693482	HORMAD1	0.36	6.79	0.31	3.79e-11	Melanoma;
LUAD	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-7.49	-0.34	4.01e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg20203395	chr5:56204925	C5orf35	-0.81	-11.67	-0.49	1.73e-27	Initial pursuit acceleration;
LUAD	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg02734326	chr4:10020555	SLC2A9	0.64	11.37	0.48	2.51e-26	Bone mineral density;
LUAD	cis	rs459571	0.959	rs410876	chr9:136893867	C/A	cg13789015	chr9:136890014	NCRNA00094	0.85	14.46	0.58	8.89e-39	Platelet distribution width;
LUAD	cis	rs1595825	0.891	rs73054827	chr2:198649905	G/A	cg11031976	chr2:198649780	BOLL	-0.47	-7.0	-0.32	1.02e-11	Ulcerative colitis;
LUAD	cis	rs73206853	0.764	rs73191817	chr12:110918673	G/A	cg12870014	chr12:110450643	ANKRD13A	0.6	6.61	0.31	1.14e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs595018	0.505	rs11230501	chr11:60598075	G/A	cg07268726	chr11:60701918	TMEM132A	-0.52	-6.81	-0.31	3.35e-11	Wegener's granulomatosis;
LUAD	cis	rs9652601	0.959	rs7200940	chr16:11164567	G/C	cg04616529	chr16:11181986	CLEC16A	-0.38	-6.66	-0.31	8.67e-11	Systemic lupus erythematosus;
LUAD	cis	rs6758955	0.850	rs6735172	chr2:10475013	A/G	cg15773312	chr2:10472214	HPCAL1	-0.49	-6.98	-0.32	1.13e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg13319975	chr6:146136371	FBXO30	-0.59	-10.11	-0.44	1.14e-21	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20136959	chr13:49821950	CDADC1	-0.45	-7.05	-0.32	7.56e-12	Height;
LUAD	cis	rs4523957	0.786	rs9897624	chr17:2121745	A/G	cg16513277	chr17:2031491	SMG6	-0.81	-15.06	-0.59	2.36e-41	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg24562669	chr7:97807699	LMTK2	0.29	7.01	0.32	9.2e-12	Breast cancer;
LUAD	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6430585	0.528	rs309142	chr2:136715324	T/C	cg07169764	chr2:136633963	MCM6	0.69	8.51	0.38	2.96e-16	Corneal structure;
LUAD	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg19635926	chr16:89946313	TCF25	0.73	6.8	0.31	3.48e-11	Skin colour saturation;
LUAD	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg20135002	chr11:47629003	NA	-0.41	-7.19	-0.33	3.02e-12	Subjective well-being;
LUAD	cis	rs17401966	0.838	rs12738317	chr1:10419663	C/T	cg19773385	chr1:10388646	KIF1B	-0.4	-6.47	-0.3	2.64e-10	Hepatocellular carcinoma;
LUAD	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.0	0.32	9.82e-12	Prostate cancer;
LUAD	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg05425664	chr17:57184151	TRIM37	0.42	7.69	0.35	1.01e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs758324	0.947	rs4493667	chr5:131247218	G/T	cg25547332	chr5:131281432	NA	-0.44	-6.76	-0.31	4.67e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.56	0.3	1.54e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg21782813	chr7:2030301	MAD1L1	0.5	8.71	0.39	7.12e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs9427116	0.502	rs6699825	chr1:154582970	A/G	cg17218026	chr1:154582156	ADAR	0.5	10.0	0.44	2.89e-21	Blood protein levels;
LUAD	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg08847533	chr14:75593920	NEK9	0.43	7.52	0.34	3.39e-13	Height;
LUAD	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.86	-0.32	2.42e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26314531	chr2:26401878	FAM59B	0.72	9.72	0.43	2.76e-20	Gut microbiome composition (summer);
LUAD	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg14092571	chr14:90743983	NA	0.45	7.66	0.35	1.31e-13	Mortality in heart failure;
LUAD	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg06547715	chr2:218990976	CXCR2	-0.29	-6.79	-0.31	3.71e-11	Colorectal cancer;
LUAD	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg13319975	chr6:146136371	FBXO30	-0.61	-10.25	-0.45	3.6e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4268898	0.722	rs34565113	chr2:24423076	G/T	cg02683114	chr2:24398427	C2orf84	0.4	6.77	0.31	4.22e-11	Asthma;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11214243	chr11:65405388	SIPA1	-0.41	-6.47	-0.3	2.68e-10	Height;
LUAD	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg13126279	chr21:47581558	C21orf56	0.4	7.01	0.32	9.72e-12	Testicular germ cell tumor;
LUAD	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.48e-10	Prostate cancer;
LUAD	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	7.4	0.34	7.46e-13	Platelet count;
LUAD	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg01689657	chr7:91764605	CYP51A1	0.34	8.63	0.39	1.27e-16	Breast cancer;
LUAD	cis	rs758324	0.947	rs804059	chr5:131270136	T/C	cg06307176	chr5:131281290	NA	-0.52	-8.23	-0.37	2.27e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03264133	chr6:25882463	NA	-0.55	-8.96	-0.4	1.04e-17	Blood metabolite levels;
LUAD	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.6	-0.35	1.98e-13	Coronary artery disease;
LUAD	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14240646	chr10:27532245	ACBD5	-0.89	-12.01	-0.5	8.41e-29	Breast cancer;
LUAD	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg05340658	chr4:99064831	C4orf37	0.53	8.78	0.39	4.23e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg09915433	chr19:53449742	NA	0.57	10.07	0.44	1.62e-21	Psoriasis;
LUAD	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03517284	chr6:25882590	NA	-0.57	-9.33	-0.41	5.8e-19	Blood metabolite levels;
LUAD	cis	rs4631830	0.900	rs4630241	chr10:51532751	G/A	cg20129853	chr10:51489980	NA	-0.34	-6.7	-0.31	6.57e-11	Prostate-specific antigen levels;
LUAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08677398	chr8:58056175	NA	0.48	6.84	0.32	2.87e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7680126	0.596	rs4698029	chr4:10312798	C/G	cg11266682	chr4:10021025	SLC2A9	0.44	6.79	0.31	3.73e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9314323	0.693	rs13264882	chr8:26224240	G/T	cg13160058	chr8:26243215	BNIP3L	-0.46	-9.43	-0.42	2.77e-19	Red cell distribution width;
LUAD	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-8.17	-0.37	3.62e-15	Alzheimer's disease (late onset);
LUAD	cis	rs3007168	1.000	rs2999362	chr14:51605265	A/G	cg23942311	chr14:51606299	NA	0.53	7.31	0.33	1.35e-12	Cancer;
LUAD	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.57	0.3	1.5e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11126435	0.858	rs11126440	chr2:74929490	C/T	cg19285774	chr2:74907978	SEMA4F	-0.37	-6.51	-0.3	2.1e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg09455208	chr3:40491958	NA	-0.5	-10.72	-0.46	7.02e-24	Renal cell carcinoma;
LUAD	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg05234568	chr11:5960015	NA	-0.5	-8.8	-0.39	3.55e-17	DNA methylation (variation);
LUAD	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg18252515	chr7:66147081	NA	0.6	6.66	0.31	8.3e-11	Diabetic kidney disease;
LUAD	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg27446573	chr6:127587934	RNF146	0.43	6.47	0.3	2.72e-10	Breast cancer;
LUAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.19	-0.41	1.77e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	12.04	0.51	6.83e-29	Hip circumference adjusted for BMI;
LUAD	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg03609598	chr5:56110824	MAP3K1	-0.69	-9.32	-0.41	6.72e-19	Initial pursuit acceleration;
LUAD	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg20135002	chr11:47629003	NA	-0.42	-7.32	-0.34	1.22e-12	Subjective well-being;
LUAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg02524346	chr8:600233	NA	-0.99	-10.01	-0.44	2.6e-21	IgG glycosylation;
LUAD	cis	rs868036	1.000	rs1871307	chr15:68100623	C/T	cg24579218	chr15:68104479	NA	-0.4	-7.45	-0.34	5.44e-13	Restless legs syndrome;
LUAD	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00934597	chr7:893267	UNC84A	0.5	8.42	0.38	5.78e-16	Perceived unattractiveness to mosquitoes;
LUAD	trans	rs853679	0.546	rs200996	chr6:27811828	G/A	cg06606381	chr12:133084897	FBRSL1	-0.8	-7.93	-0.36	2.04e-14	Depression;
LUAD	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.38	6.58	0.3	1.42e-10	Type 2 diabetes;
LUAD	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg03874509	chr1:107600012	PRMT6	-0.58	-10.08	-0.44	1.48e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg26043149	chr18:55253948	FECH	0.49	8.47	0.38	4.01e-16	Bone mineral density;
LUAD	trans	rs1493916	1.000	rs11081827	chr18:31390228	C/A	cg27147174	chr7:100797783	AP1S1	-0.7	-12.43	-0.52	1.82e-30	Life satisfaction;
LUAD	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21582582	chr3:182698605	DCUN1D1	0.55	9.5	0.42	1.56e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.48	-0.38	3.82e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg06784218	chr1:46089804	CCDC17	0.56	12.64	0.52	2.68e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg06074448	chr4:187884817	NA	-0.35	-6.87	-0.32	2.26e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs73206853	0.563	rs73194040	chr12:111181106	C/T	cg12870014	chr12:110450643	ANKRD13A	0.6	6.48	0.3	2.49e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg14895029	chr7:2775587	GNA12	-0.42	-6.91	-0.32	1.82e-11	Height;
LUAD	cis	rs6867032	0.527	rs13190594	chr5:2012474	T/C	cg26168224	chr5:2018326	NA	0.54	11.01	0.47	5.72e-25	Gut microbiome composition (winter);
LUAD	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg22532475	chr10:104410764	TRIM8	-0.36	-6.74	-0.31	5.11e-11	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2742234	0.578	rs2435354	chr10:43652445	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.53	-8.94	-0.4	1.2e-17	Hirschsprung disease;
LUAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg00024416	chr22:24240387	NA	0.5	9.34	0.41	5.63e-19	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg21191810	chr6:118973309	C6orf204	-0.52	-8.1	-0.37	5.88e-15	Diastolic blood pressure;
LUAD	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg07432352	chr17:45403706	C17orf57	-0.42	-8.2	-0.37	2.92e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg03563238	chr19:33554763	RHPN2	-0.34	-8.02	-0.36	1.07e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23583168	chr7:148888333	NA	-0.89	-17.67	-0.65	9.99e-53	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg17264618	chr3:40429014	ENTPD3	0.4	8.77	0.39	4.5e-17	Renal cell carcinoma;
LUAD	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-7.96	-0.36	1.6e-14	Total body bone mineral density;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17037329	chr17:73285700	SLC25A19	-0.45	-7.02	-0.32	9.16e-12	Height;
LUAD	cis	rs4700695	0.841	rs251325	chr5:65269618	A/G	cg21114390	chr5:65439923	SFRS12	0.56	6.37	0.3	4.95e-10	Facial morphology (factor 19);
LUAD	cis	rs11048434	0.698	rs10842537	chr12:9066158	T/C	cg23795048	chr12:9217529	LOC144571	0.41	7.36	0.34	9.48e-13	Sjögren's syndrome;
LUAD	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg01528321	chr10:82214614	TSPAN14	0.45	7.17	0.33	3.47e-12	Post bronchodilator FEV1;
LUAD	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg20673091	chr1:2541236	MMEL1	0.29	6.56	0.3	1.59e-10	Ulcerative colitis;
LUAD	cis	rs2997447	0.846	rs3008430	chr1:26390328	A/G	cg00147160	chr1:26503991	CNKSR1	0.37	6.95	0.32	1.41e-11	QRS complex (12-leadsum);
LUAD	cis	rs10089	0.903	rs6862701	chr5:127391249	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	10.09	0.44	1.35e-21	Ileal carcinoids;
LUAD	cis	rs738321	0.794	rs5756940	chr22:38558842	C/T	cg17652424	chr22:38574118	PLA2G6	-0.26	-6.59	-0.31	1.3e-10	Breast cancer;
LUAD	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg19977408	chr4:129209103	PGRMC2	-0.36	-6.48	-0.3	2.53e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
LUAD	cis	rs9787249	0.533	rs1883648	chr1:40246535	T/G	cg02773041	chr1:40204384	PPIE	0.45	7.69	0.35	1.06e-13	Blood protein levels;
LUAD	cis	rs3106136	0.546	rs183993	chr4:95130025	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.2	-0.44	5.33e-22	Capecitabine sensitivity;
LUAD	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg11766577	chr21:47581405	C21orf56	-0.46	-7.88	-0.36	2.83e-14	Testicular germ cell tumor;
LUAD	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg17105886	chr17:28927953	LRRC37B2	0.81	7.84	0.36	3.63e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg19318889	chr4:1322082	MAEA	0.48	7.92	0.36	2.05e-14	Obesity-related traits;
LUAD	cis	rs1555895	0.566	rs11253451	chr10:852885	C/T	cg20503657	chr10:835505	NA	0.4	6.36	0.3	5.18e-10	Survival in rectal cancer;
LUAD	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg15485101	chr11:133734466	NA	0.34	7.66	0.35	1.26e-13	Childhood ear infection;
LUAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg11062466	chr8:58055876	NA	0.65	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.02	0.36	1.05e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	8.01	0.36	1.14e-14	Parkinson's disease;
LUAD	cis	rs13315871	0.929	rs4560319	chr3:58386274	C/T	cg12435725	chr3:58293450	RPP14	-0.67	-7.36	-0.34	9.57e-13	Cholesterol, total;
LUAD	cis	rs11048434	0.736	rs7302417	chr12:9091116	G/T	cg26114124	chr12:9217669	LOC144571	0.37	6.79	0.31	3.84e-11	Sjögren's syndrome;
LUAD	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg01788221	chr16:89496183	ANKRD11	-0.36	-6.93	-0.32	1.57e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg17410650	chr12:54324560	NA	-0.58	-12.71	-0.53	1.44e-31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUAD	cis	rs2652834	0.718	rs2414811	chr15:63397725	C/T	cg25406657	chr15:63342033	TPM1	-0.39	-6.47	-0.3	2.74e-10	HDL cholesterol;
LUAD	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg19336497	chr11:14380999	RRAS2	-0.61	-12.74	-0.53	1.03e-31	Vitamin D levels;
LUAD	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-11.68	-0.49	1.65e-27	Schizophrenia;
LUAD	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg05340658	chr4:99064831	C4orf37	0.46	6.99	0.32	1.05e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs71386921	1	rs71386921	chr10:27478698	AAT/A	cg14240646	chr10:27532245	ACBD5	-0.87	-12.99	-0.53	1.02e-32	Breast cancer;
LUAD	cis	rs113835537	0.529	rs4930183	chr11:66255732	C/T	cg26679405	chr11:66247800	DPP3	-0.46	-6.7	-0.31	6.49e-11	Airway imaging phenotypes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18968306	chr11:134093878	NCAPD3;VPS26B	-0.53	-6.43	-0.3	3.47e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.49	10.06	0.44	1.69e-21	Monocyte percentage of white cells;
LUAD	cis	rs57590327	0.555	rs11127740	chr3:81743062	A/C	cg07356753	chr3:81810745	GBE1	-0.56	-8.92	-0.4	1.37e-17	Extraversion;
LUAD	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg07432352	chr17:45403706	C17orf57	-0.43	-8.23	-0.37	2.34e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20595394	chr12:7080011	PHB2;EMG1	-0.45	-7.01	-0.32	9.3e-12	Height;
LUAD	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg04036182	chr15:45458818	NA	-0.36	-6.37	-0.3	4.83e-10	Glomerular filtration rate;
LUAD	cis	rs9902453	0.845	rs12602426	chr17:28158815	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	9.05	0.4	5.25e-18	Coffee consumption (cups per day);
LUAD	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg15181151	chr6:150070149	PCMT1	0.36	7.07	0.32	6.62e-12	Lung cancer;
LUAD	cis	rs2840044	1.000	rs1671656	chr17:33939661	C/T	cg05299278	chr17:33885742	SLFN14	0.43	8.72	0.39	6.19e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs12760731	0.565	rs12037429	chr1:178224741	C/T	cg00404053	chr1:178313656	RASAL2	0.73	9.21	0.41	1.48e-18	Obesity-related traits;
LUAD	cis	rs12824058	0.707	rs2398509	chr12:130816464	T/C	cg24838063	chr12:130822603	PIWIL1	0.63	10.58	0.46	2.27e-23	Menopause (age at onset);
LUAD	cis	rs9323205	0.773	rs4334206	chr14:51702414	G/C	cg23942311	chr14:51606299	NA	-0.59	-9.04	-0.4	5.73e-18	Cancer;
LUAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg18402987	chr7:1209562	NA	0.78	9.48	0.42	1.81e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2688608	1.000	rs2675680	chr10:75658864	T/C	cg23231163	chr10:75533350	FUT11	-0.4	-7.34	-0.34	1.09e-12	Inflammatory bowel disease;
LUAD	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg23815491	chr16:72088622	HP	0.55	9.97	0.44	3.49e-21	Fibrinogen levels;
LUAD	cis	rs12519773	0.501	rs10428523	chr5:92536365	G/A	cg18783429	chr5:92414398	NA	0.43	7.6	0.35	1.93e-13	Migraine;
LUAD	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg03929089	chr4:120376271	NA	0.57	7.13	0.33	4.42e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-8.96	-0.4	1.02e-17	Lymphocyte counts;
LUAD	cis	rs9914988	0.832	rs34901720	chr17:27179518	A/G	cg02049041	chr17:27085579	C17orf63	0.62	8.36	0.38	9.43e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg24531977	chr5:56204891	C5orf35	-0.48	-8.08	-0.37	7e-15	Coronary artery disease;
LUAD	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg26408565	chr15:76604113	ETFA	-0.44	-7.13	-0.33	4.45e-12	Blood metabolite levels;
LUAD	trans	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.93	0.4	1.35e-17	Endometrial cancer;
LUAD	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg11833968	chr6:79620685	NA	-0.44	-8.1	-0.37	5.88e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs758324	0.812	rs116369002	chr5:131242055	G/A	cg25547332	chr5:131281432	NA	-0.42	-6.88	-0.32	2.14e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg18099408	chr3:52552593	STAB1	-0.39	-6.9	-0.32	1.93e-11	Bipolar disorder;
LUAD	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-7.69	-0.35	1.02e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.32e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg27284194	chr4:1044797	NA	0.54	8.9	0.4	1.71e-17	Recombination rate (males);
LUAD	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg04287289	chr16:89883240	FANCA	0.71	13.01	0.53	8.37e-33	Vitiligo;
LUAD	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg24579218	chr15:68104479	NA	-0.6	-9.46	-0.42	2.22e-19	Restless legs syndrome;
LUAD	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg09945482	chr18:12777974	NA	-0.56	-6.53	-0.3	1.94e-10	Inflammatory skin disease;
LUAD	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22857025	chr5:266934	NA	-1.03	-13.12	-0.54	3.11e-33	Breast cancer;
LUAD	cis	rs3764563	1.000	rs4808326	chr19:15726147	A/G	cg20725493	chr19:15740067	CYP4F8	-0.67	-7.68	-0.35	1.13e-13	Inflammatory biomarkers;
LUAD	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg04450456	chr4:17643702	FAM184B	0.37	6.95	0.32	1.37e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.61	0.31	1.14e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg24579218	chr15:68104479	NA	-0.52	-9.0	-0.4	8e-18	Restless legs syndrome;
LUAD	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg07606381	chr6:8435919	SLC35B3	0.4	6.64	0.31	9.59e-11	Motion sickness;
LUAD	cis	rs12540874	0.895	rs4245556	chr7:50661661	C/T	cg18232548	chr7:50535776	DDC	-0.55	-9.35	-0.41	5.02e-19	Systemic sclerosis;
LUAD	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg02734326	chr4:10020555	SLC2A9	0.65	11.56	0.49	4.66e-27	Bone mineral density;
LUAD	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.88	0.32	2.13e-11	Colorectal cancer;
LUAD	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg16989719	chr2:238392110	NA	-0.33	-6.63	-0.31	1.05e-10	Prostate cancer;
LUAD	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.54	-9.12	-0.41	2.96e-18	Electrocardiographic conduction measures;
LUAD	cis	rs7107174	0.901	rs2450138	chr11:77924870	C/T	cg02023728	chr11:77925099	USP35	0.51	8.01	0.36	1.11e-14	Testicular germ cell tumor;
LUAD	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg18240062	chr17:79603768	NPLOC4	0.36	6.35	0.3	5.42e-10	Eye color traits;
LUAD	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg00530320	chr1:46809349	NSUN4	0.51	7.86	0.36	3.16e-14	Menopause (age at onset);
LUAD	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06112835	chr11:68658793	MRPL21	0.54	10.1	0.44	1.3e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg09065629	chr16:1709722	CRAMP1L	0.42	7.35	0.34	1.01e-12	Coronary artery disease;
LUAD	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg03806693	chr22:41940476	POLR3H	0.77	10.28	0.45	2.78e-22	Vitiligo;
LUAD	cis	rs220324	0.688	rs8134831	chr21:43568380	G/A	cg08841829	chr21:43638893	ABCG1	-0.47	-6.78	-0.31	3.99e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg25319279	chr11:5960081	NA	-0.38	-6.74	-0.31	5.29e-11	DNA methylation (variation);
LUAD	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg18833306	chr6:118973337	C6orf204	-0.5	-7.34	-0.34	1.08e-12	Diastolic blood pressure;
LUAD	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg03929089	chr4:120376271	NA	-0.99	-20.65	-0.71	4.76e-66	Height;
LUAD	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg13180566	chr4:1052158	NA	-0.4	-6.78	-0.31	4.04e-11	Recombination rate (females);
LUAD	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg02527881	chr3:46936655	PTH1R	-0.48	-9.35	-0.41	5.04e-19	Colorectal cancer;
LUAD	cis	rs908922	0.676	rs7518654	chr1:152517845	C/G	cg21823605	chr1:152486609	CRCT1	0.29	6.54	0.3	1.8e-10	Hair morphology;
LUAD	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.37	-0.45	1.34e-22	Monocyte percentage of white cells;
LUAD	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.61	0.39	1.49e-16	Parkinson's disease;
LUAD	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-10.2	-0.44	5.27e-22	Chronic sinus infection;
LUAD	cis	rs2282300	0.739	rs1933343	chr11:30310992	T/C	cg06241208	chr11:30344200	C11orf46	0.58	7.5	0.34	3.72e-13	Morning vs. evening chronotype;
LUAD	trans	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg14917512	chr19:3094685	GNA11	0.38	6.66	0.31	8.52e-11	Aortic root size;
LUAD	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg03467027	chr4:99064603	C4orf37	0.41	6.75	0.31	4.98e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg11909912	chr17:43974919	MAPT;LOC100130148	0.41	6.88	0.32	2.19e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg18230493	chr5:56204884	C5orf35	-0.85	-12.28	-0.51	7.56e-30	Initial pursuit acceleration;
LUAD	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.03	-0.32	8.44e-12	Total body bone mineral density;
LUAD	cis	rs9826463	0.582	rs73238145	chr3:142060559	G/A	cg20824294	chr3:142316082	PLS1	0.41	6.92	0.32	1.65e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg20991723	chr1:152506922	NA	0.34	6.66	0.31	8.76e-11	Hair morphology;
LUAD	cis	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg02951883	chr7:2050386	MAD1L1	0.53	7.66	0.35	1.32e-13	Neuroticism;
LUAD	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg06740227	chr12:86229804	RASSF9	0.45	7.89	0.36	2.69e-14	Major depressive disorder;
LUAD	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg25554036	chr4:6271136	WFS1	0.67	13.4	0.55	2.34e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg02782426	chr3:40428986	ENTPD3	0.35	7.19	0.33	2.93e-12	Renal cell carcinoma;
LUAD	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg08601574	chr20:25228251	PYGB	0.46	8.82	0.39	2.94e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg06108461	chr20:60628389	TAF4	-0.83	-14.48	-0.58	6.93e-39	Body mass index;
LUAD	cis	rs12472274	0.529	rs11683094	chr2:239118057	G/A	cg17459225	chr2:239074497	NA	0.59	6.81	0.31	3.39e-11	Phospholipid levels (plasma);
LUAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.12	0.41	3.16e-18	Alzheimer's disease;
LUAD	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg16988262	chr1:15930761	NA	0.42	7.01	0.32	9.42e-12	Systolic blood pressure;
LUAD	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	9.32	0.41	6.62e-19	Total body bone mineral density;
LUAD	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg13722127	chr7:150037890	RARRES2	0.45	7.62	0.35	1.63e-13	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.87	-0.32	2.37e-11	Height;
LUAD	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg24397884	chr7:158709396	WDR60	0.47	8.05	0.36	8.49e-15	Height;
LUAD	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg22823121	chr1:150693482	HORMAD1	0.45	9.17	0.41	2.15e-18	Tonsillectomy;
LUAD	cis	rs11229555	0.609	rs34133416	chr11:58184720	T/C	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	15.51	0.6	2.92e-43	Bone mineral density;
LUAD	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg15181151	chr6:150070149	PCMT1	0.38	7.69	0.35	1.08e-13	Lung cancer;
LUAD	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg06766960	chr11:133703094	NA	-0.46	-8.56	-0.38	2.17e-16	Childhood ear infection;
LUAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07157834	chr1:205819609	PM20D1	0.75	14.61	0.58	1.97e-39	Menarche (age at onset);
LUAD	cis	rs62238980	0.521	rs80342684	chr22:32380494	G/A	cg02631450	chr22:32366979	NA	0.79	6.46	0.3	2.9e-10	Childhood ear infection;
LUAD	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23583168	chr7:148888333	NA	1.0	22.71	0.74	3.2700000000000002e-75	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-10.87	-0.47	1.87e-24	Bone mineral density;
LUAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg07217954	chr7:1067459	C7orf50	0.45	7.1	0.33	5.28e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.66	-0.35	1.26e-13	Breast cancer;
LUAD	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-7.9	-0.36	2.42e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs72634258	0.838	rs10489450	chr1:8079301	C/T	cg26816564	chr1:7831052	VAMP3	0.54	6.95	0.32	1.4e-11	Inflammatory bowel disease;
LUAD	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg14634687	chr17:47094252	IGF2BP1	0.29	7.48	0.34	4.29e-13	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs17152411	0.895	rs66531168	chr10:126586908	T/A	cg07906193	chr10:126599966	NA	0.54	7.67	0.35	1.16e-13	Height;
LUAD	cis	rs2294693	0.634	rs4714425	chr6:41012916	A/G	cg14769373	chr6:40998127	UNC5CL	0.44	7.2	0.33	2.73e-12	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg22676075	chr6:135203613	NA	0.43	7.73	0.35	7.88e-14	Red blood cell count;
LUAD	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg25894440	chr7:65020034	NA	-0.66	-7.14	-0.33	4.11e-12	Diabetic kidney disease;
LUAD	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg02880119	chr16:3481970	NA	0.63	9.35	0.41	5.12e-19	Body mass index (adult);
LUAD	cis	rs13315871	0.790	rs28502788	chr3:58296208	A/T	cg20936604	chr3:58311152	NA	-0.77	-8.41	-0.38	6.3e-16	Cholesterol, total;
LUAD	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg16486109	chr11:613632	IRF7	0.49	8.15	0.37	4.18e-15	Systemic lupus erythematosus;
LUAD	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-15.51	-0.6	2.84e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs7000551	0.700	rs2461480	chr8:22381839	C/T	cg12081754	chr8:22256438	SLC39A14	0.45	7.41	0.34	6.7e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs10911251	0.508	rs2296297	chr1:183105324	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.05	0.32	7.17e-12	Colorectal cancer;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg04481126	chr16:423872	TMEM8A	-0.37	-6.93	-0.32	1.53e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg06784218	chr1:46089804	CCDC17	0.5	11.01	0.47	5.95e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4604732	0.527	rs79329288	chr1:247626513	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22455342	chr2:225449267	CUL3	-0.68	-10.26	-0.45	3.3e-22	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.46	-0.34	5.1e-13	Electroencephalogram traits;
LUAD	trans	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg01620082	chr3:125678407	NA	-0.77	-8.42	-0.38	6.03e-16	Breast cancer;
LUAD	cis	rs2235649	0.753	rs4316755	chr16:1849916	T/G	cg08610935	chr16:1836813	NUBP2	-0.48	-7.49	-0.34	4.18e-13	Blood metabolite levels;
LUAD	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg19318889	chr4:1322082	MAEA	0.91	15.63	0.6	8.86e-44	Longevity;
LUAD	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg05425664	chr17:57184151	TRIM37	-0.43	-7.76	-0.35	6.57e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg21153622	chr11:89784906	NA	0.33	6.43	0.3	3.36e-10	Coronary artery disease;
LUAD	cis	rs59698941	0.943	rs10900812	chr5:132268567	G/A	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg13010199	chr12:38710504	ALG10B	0.39	6.4	0.3	4.02e-10	Bladder cancer;
LUAD	cis	rs3823572	0.564	rs2953620	chr7:133666388	T/C	cg03336402	chr7:133662267	EXOC4	-0.43	-7.76	-0.35	6.28e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg02221422	chr11:68192511	LRP5	0.4	6.65	0.31	9.28e-11	Total body bone mineral density;
LUAD	cis	rs1595825	0.786	rs75619425	chr2:198537281	A/G	cg10547527	chr2:198650123	BOLL	-0.53	-7.42	-0.34	6.67e-13	Ulcerative colitis;
LUAD	cis	rs1003719	0.680	rs1034357	chr21:38571482	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.2	-0.37	2.89e-15	Eye color traits;
LUAD	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	8.85	0.4	2.41e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg00071950	chr4:10020882	SLC2A9	0.7	13.26	0.54	8.19e-34	Bone mineral density;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26034150	chr2:201936608	FAM126B;NDUFB3	-0.45	-7.59	-0.35	2.11e-13	Cancer;
LUAD	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.1	0.37	5.93e-15	Menopause (age at onset);
LUAD	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg14396892	chr9:96623032	NA	-0.44	-8.38	-0.38	7.8e-16	DNA methylation (variation);
LUAD	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg27490568	chr2:178487706	NA	0.41	7.05	0.32	7.32e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg15691649	chr6:25882328	NA	-0.44	-6.92	-0.32	1.72e-11	Blood metabolite levels;
LUAD	cis	rs13082711	0.554	rs13087873	chr3:27392326	C/T	cg02860705	chr3:27208620	NA	0.71	10.81	0.47	3.37e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.38	6.35	0.3	5.49e-10	Total body bone mineral density;
LUAD	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg02990361	chr1:107599529	PRMT6	0.6	9.98	0.44	3.3e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg12599982	chr1:44399894	ARTN	0.35	6.73	0.31	5.4e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg12964065	chr18:77638022	KCNG2	0.55	6.8	0.31	3.66e-11	Opioid sensitivity;
LUAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04267008	chr7:1944627	MAD1L1	-0.69	-10.53	-0.46	3.5e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07167872	chr1:205819463	PM20D1	0.77	15.74	0.61	2.88e-44	Menarche (age at onset);
LUAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg07507251	chr3:52567010	NT5DC2	0.37	7.15	0.33	3.84e-12	Bipolar disorder;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg00670742	chr2:87034831	CD8A	-0.6	-6.51	-0.3	2.12e-10	Type 2 diabetes;
LUAD	cis	rs7799006	0.691	rs10447541	chr7:2301578	T/G	cg08027265	chr7:2291960	NA	-0.73	-14.91	-0.59	1.01e-40	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs11638815	0.626	rs11635624	chr15:83315731	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.48	-7.43	-0.34	5.93e-13	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg26384229	chr12:38710491	ALG10B	0.42	7.04	0.32	7.92e-12	Morning vs. evening chronotype;
LUAD	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg23625390	chr15:77176239	SCAPER	0.42	7.2	0.33	2.86e-12	Blood metabolite levels;
LUAD	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg07332563	chr6:291687	DUSP22	-0.47	-7.93	-0.36	1.95e-14	Menopause (age at onset);
LUAD	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg08807101	chr21:30365312	RNF160	-0.43	-7.4	-0.34	7.32e-13	Dental caries;
LUAD	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg11584989	chr19:19387371	SF4	-0.36	-6.43	-0.3	3.54e-10	Tonsillectomy;
LUAD	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg24818145	chr4:99064322	C4orf37	0.47	7.97	0.36	1.49e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg21385522	chr1:16154831	NA	-1.08	-23.15	-0.75	3.58e-77	Dilated cardiomyopathy;
LUAD	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg25811766	chr13:21894605	NA	-0.64	-7.41	-0.34	6.71e-13	White matter hyperintensity burden;
LUAD	cis	rs877282	0.898	rs12359731	chr10:759497	A/G	cg06581033	chr10:766294	NA	-0.56	-7.97	-0.36	1.48e-14	Uric acid levels;
LUAD	cis	rs8177876	0.822	rs7203546	chr16:81116922	A/G	cg08591886	chr16:81111003	C16orf46	0.65	6.53	0.3	1.91e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg12908607	chr1:44402522	ARTN	-0.45	-8.79	-0.39	3.71e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg18944383	chr4:111397179	ENPEP	0.34	6.67	0.31	7.88e-11	Coronary artery disease;
LUAD	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.91	0.4	1.5e-17	Cognitive ability;
LUAD	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg23992470	chr4:843637	GAK	0.7	7.29	0.33	1.51e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4273100	0.834	rs59415593	chr17:19223224	T/G	cg03711562	chr17:18936298	GRAP	-0.42	-8.07	-0.37	7.57e-15	Schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10651637	chr15:45315642	SORD	-0.52	-6.38	-0.3	4.79e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs8060686	0.516	rs9938020	chr16:68251784	C/G	cg09835421	chr16:68378352	PRMT7	-0.54	-6.76	-0.31	4.54e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg10591111	chr5:226296	SDHA	-0.55	-7.0	-0.32	1.04e-11	Breast cancer;
LUAD	cis	rs17818399	0.502	rs1451152	chr2:46800150	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.4	-6.65	-0.31	8.82e-11	Height;
LUAD	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg23939001	chr4:940644	TMEM175	0.77	15.18	0.59	7.51e-42	Sjögren's syndrome;
LUAD	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.88	0.53	2.99e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-12.78	-0.53	7.71e-32	Migraine;Coronary artery disease;
LUAD	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg03609598	chr5:56110824	MAP3K1	-0.42	-6.66	-0.31	8.57e-11	Coronary artery disease;
LUAD	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg22705602	chr4:152727874	NA	-0.42	-7.3	-0.33	1.43e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg25173405	chr17:45401733	C17orf57	0.45	7.75	0.35	6.91e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg09455208	chr3:40491958	NA	0.66	14.5	0.58	6.03e-39	Renal cell carcinoma;
LUAD	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	24.46	0.77	5.54e-83	Chronic sinus infection;
LUAD	cis	rs9796	0.553	rs2925343	chr15:41306493	T/C	cg18705301	chr15:41695430	NDUFAF1	0.49	9.06	0.4	4.71e-18	Menopause (age at onset);
LUAD	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.43	-0.3	3.52e-10	Calcium levels;
LUAD	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.39	-6.86	-0.32	2.45e-11	Platelet count;
LUAD	trans	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg25482853	chr8:67687455	SGK3	1.06	16.65	0.63	2.99e-48	Obesity-related traits;
LUAD	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg05805236	chr11:65401703	PCNXL3	-0.55	-8.77	-0.39	4.4e-17	Acne (severe);
LUAD	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg23283495	chr1:209979779	IRF6	0.75	9.11	0.4	3.4e-18	Cleft lip with or without cleft palate;
LUAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg15840638	chr15:79298691	RASGRF1	-0.49	-6.49	-0.3	2.34e-10	Lung function (FEV1/FVC);
LUAD	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg06453172	chr10:134556979	INPP5A	-0.65	-10.23	-0.45	4.2e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg14092988	chr3:52407081	DNAH1	0.6	12.04	0.51	6.34e-29	Bipolar disorder;
LUAD	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg15123519	chr2:136567270	LCT	-0.39	-7.04	-0.32	7.99e-12	Mosquito bite size;
LUAD	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg03714773	chr7:91764589	CYP51A1	0.3	6.76	0.31	4.57e-11	Breast cancer;
LUAD	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg19077165	chr18:44547161	KATNAL2	0.47	8.17	0.37	3.69e-15	Personality dimensions;
LUAD	cis	rs701145	0.550	rs450115	chr3:153923418	A/C	cg17054900	chr3:154042577	DHX36	0.66	7.08	0.33	6.13e-12	Coronary artery disease;
LUAD	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg21709803	chr11:61594965	FADS2	-0.37	-6.45	-0.3	2.98e-10	Trans fatty acid levels;
LUAD	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg12573674	chr2:1569213	NA	-0.58	-8.53	-0.38	2.69e-16	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg02569458	chr12:86230093	RASSF9	0.39	7.57	0.35	2.36e-13	Major depressive disorder;
LUAD	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg04539111	chr16:67997858	SLC12A4	-0.55	-6.88	-0.32	2.11e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2857891	1.000	rs2857891	chr11:6962957	C/T	cg04053776	chr11:6947353	ZNF215	0.5	7.19	0.33	2.95e-12	Response to cytadine analogues (cytosine arabinoside);
LUAD	cis	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg08601574	chr20:25228251	PYGB	-0.45	-8.21	-0.37	2.73e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4243830	1.000	rs41278014	chr1:6579653	G/C	cg04093404	chr1:6614507	TAS1R1;NOL9	0.68	7.18	0.33	3.25e-12	Body mass index;
LUAD	cis	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg24289452	chr6:170231220	NA	-0.61	-6.6	-0.31	1.23e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08677398	chr8:58056175	NA	0.5	7.03	0.32	8.33e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg02176678	chr2:219576539	TTLL4	0.68	13.66	0.55	1.94e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg17063962	chr7:91808500	NA	0.68	12.07	0.51	4.9e-29	Breast cancer;
LUAD	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.31	-0.45	2.13e-22	Platelet count;
LUAD	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09872104	chr7:134855509	C7orf49	-0.52	-6.36	-0.3	5.17e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg20933634	chr6:27740509	NA	-0.38	-6.38	-0.3	4.64e-10	Parkinson's disease;
LUAD	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.18	-0.41	1.96e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11126435	0.858	rs363621	chr2:74928965	G/A	cg19285774	chr2:74907978	SEMA4F	0.36	6.41	0.3	3.99e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg12940439	chr1:67600707	NA	0.43	8.25	0.37	2.03e-15	Psoriasis;
LUAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg04851639	chr8:1020857	NA	-0.39	-9.82	-0.43	1.25e-20	Schizophrenia;
LUAD	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-7.08	-0.33	6e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg17063962	chr7:91808500	NA	0.64	10.94	0.47	1.08e-24	Breast cancer;
LUAD	cis	rs4604732	0.631	rs74154675	chr1:247625836	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.48	-0.3	2.55e-10	Depression;
LUAD	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg11645453	chr3:52864694	ITIH4	0.58	10.19	0.44	6.07e-22	Schizophrenia;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg12873305	chr11:65626984	MUS81;CFL1	-0.39	-6.48	-0.3	2.58e-10	Schizophrenia;
LUAD	cis	rs2742234	1.000	rs1864399	chr10:43610455	T/C	cg02780029	chr10:43622663	RET	-0.41	-6.57	-0.3	1.49e-10	Hirschsprung disease;
LUAD	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg19193384	chr17:30244184	NA	-0.51	-6.63	-0.31	1.01e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg23602478	chr1:26503979	CNKSR1	0.28	7.02	0.32	8.65e-12	Height;
LUAD	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg19052272	chr2:3704530	ALLC	-0.42	-7.35	-0.34	1.01e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg08508325	chr11:3079039	CARS	0.44	9.09	0.4	3.9e-18	Calcium levels;
LUAD	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-9.0	-0.4	8e-18	Hemoglobin concentration;
LUAD	cis	rs733175	0.855	rs10023068	chr4:10004832	C/T	cg00071950	chr4:10020882	SLC2A9	-0.6	-9.59	-0.42	7.43e-20	Psychosis and Alzheimer's disease;
LUAD	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg14092988	chr3:52407081	DNAH1	0.45	9.15	0.41	2.51e-18	Bipolar disorder;
LUAD	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg05368731	chr17:41323189	NBR1	0.83	16.42	0.62	3.01e-47	Menopause (age at onset);
LUAD	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg17757837	chr7:157058334	UBE3C	-0.5	-8.73	-0.39	6.06e-17	Body mass index;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg18035301	chr10:30722695	MAP3K8	-0.38	-6.67	-0.31	7.83e-11	Schizophrenia;
LUAD	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg25828334	chr19:18545568	ISYNA1	-0.36	-7.16	-0.33	3.55e-12	Breast cancer;
LUAD	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg05368731	chr17:41323189	NBR1	0.97	20.87	0.71	5.27e-67	Menopause (age at onset);
LUAD	trans	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg14917512	chr19:3094685	GNA11	0.36	6.5	0.3	2.29e-10	Aortic root size;
LUAD	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg12863693	chr15:85201151	NMB	0.37	6.8	0.31	3.5e-11	Schizophrenia;
LUAD	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg23422044	chr7:1970798	MAD1L1	-0.57	-8.0	-0.36	1.23e-14	Bipolar disorder;
LUAD	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.68	0.31	7.42e-11	Motion sickness;
LUAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.22	0.44	4.66e-22	Prudent dietary pattern;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg11871820	chr6:131949485	MED23	-0.4	-6.92	-0.32	1.72e-11	Schizophrenia;
LUAD	trans	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg12400702	chr3:12838781	CAND2	0.31	6.46	0.3	2.91e-10	Parkinson's disease;
LUAD	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg06131755	chr6:160182447	ACAT2	0.43	6.56	0.3	1.55e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs11048434	0.736	rs1805732	chr12:9090892	A/G	cg26114124	chr12:9217669	LOC144571	-0.38	-7.03	-0.32	8.14e-12	Sjögren's syndrome;
LUAD	cis	rs4409675	0.576	rs12062621	chr1:28230404	A/G	cg23691781	chr1:28212827	C1orf38	0.37	10.81	0.47	3.38e-24	Corneal astigmatism;
LUAD	cis	rs750460	1.000	rs11631579	chr15:74235704	A/G	cg23484268	chr15:74220776	LOXL1	-0.35	-6.69	-0.31	6.89e-11	Height;
LUAD	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg23262073	chr20:60523788	NA	-0.44	-7.61	-0.35	1.78e-13	Body mass index;
LUAD	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg17366294	chr4:99064904	C4orf37	0.53	9.69	0.43	3.58e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg14196790	chr5:131705035	SLC22A5	0.55	9.9	0.43	6.53e-21	Blood metabolite levels;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03205495	chr19:14640249	TECR;MIR639	0.43	6.6	0.31	1.22e-10	Gut microbiome composition (summer);
LUAD	cis	rs1232027	0.523	rs1650657	chr5:79964249	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.45	-7.36	-0.34	9.57e-13	Huntington's disease progression;
LUAD	cis	rs2688608	1.000	rs2688610	chr10:75654931	A/G	cg23231163	chr10:75533350	FUT11	0.35	6.36	0.3	5.21e-10	Inflammatory bowel disease;
LUAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17019866	chr8:121457656	MTBP;MRPL13	-0.39	-6.35	-0.3	5.42e-10	Cancer;
LUAD	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.39	0.34	7.87e-13	Hypertriglyceridemia;
LUAD	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg06697600	chr4:7070879	GRPEL1	0.48	7.01	0.32	9.4e-12	Monocyte percentage of white cells;
LUAD	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg09537434	chr19:41945824	ATP5SL	0.54	8.52	0.38	2.8e-16	Height;
LUAD	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg17279839	chr7:150038598	RARRES2	0.43	7.5	0.34	3.83e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg11189052	chr15:85197271	WDR73	0.71	9.51	0.42	1.48e-19	Schizophrenia;
LUAD	cis	rs7000551	0.556	rs6998780	chr8:22254639	C/T	cg12081754	chr8:22256438	SLC39A14	0.91	15.47	0.6	4.25e-43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg07371521	chr5:154026371	NA	0.48	7.78	0.35	5.43e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.61	-8.85	-0.4	2.39e-17	Gut microbiome composition (summer);
LUAD	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.25	-0.33	1.96e-12	Height;
LUAD	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	8.88	0.4	1.87e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg26516362	chr5:178986906	RUFY1	0.54	8.72	0.39	6.4e-17	Lung cancer;
LUAD	cis	rs7588746	0.521	rs73054585	chr2:201144386	T/A	cg23649088	chr2:200775458	C2orf69	-0.54	-7.76	-0.35	6.37e-14	Bipolar disorder lithium response (continuous) or schizophrenia;
LUAD	cis	rs17818399	0.926	rs1378764	chr2:46839681	C/T	cg09399716	chr2:46890238	NA	-0.4	-7.42	-0.34	6.57e-13	Height;
LUAD	cis	rs10899021	0.920	rs11236171	chr11:74317518	C/T	cg25880958	chr11:74394337	NA	-0.6	-8.17	-0.37	3.73e-15	Response to metformin (IC50);
LUAD	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.37	0.38	8.27e-16	Platelet count;
LUAD	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.79	0.31	3.78e-11	Rheumatoid arthritis;
LUAD	cis	rs17197710	0.673	rs12576690	chr11:47321509	T/C	cg13308137	chr11:47528955	CUGBP1	0.45	7.14	0.33	4.22e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7705042	0.828	rs6877864	chr5:141503839	A/G	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.59	-0.31	1.29e-10	Asthma;
LUAD	cis	rs12545109	0.879	rs2670015	chr8:57376607	T/A	cg07776626	chr8:57350775	NA	-0.67	-9.28	-0.41	8.66e-19	Obesity-related traits;
LUAD	cis	rs10504073	0.669	rs12548464	chr8:50023867	C/T	cg00325661	chr8:49890786	NA	0.44	10.3	0.45	2.47e-22	Blood metabolite ratios;
LUAD	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg23625390	chr15:77176239	SCAPER	0.39	6.83	0.32	3.02e-11	Blood metabolite levels;
LUAD	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg14582100	chr15:45693742	SPATA5L1	0.42	8.65	0.39	1.05e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs6445967	0.554	rs58361427	chr3:58434164	A/G	cg13750441	chr3:58318267	PXK	-0.31	-6.42	-0.3	3.73e-10	Platelet count;
LUAD	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs877282	0.898	rs11253341	chr10:765008	G/C	cg17470449	chr10:769945	NA	0.63	9.0	0.4	7.54e-18	Uric acid levels;
LUAD	cis	rs17169635	0.601	rs993034	chr7:134546809	T/A	cg07876788	chr7:134849633	TMEM140	-0.39	-6.62	-0.31	1.07e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg08859206	chr1:53392774	SCP2	0.58	10.52	0.46	3.79e-23	Monocyte count;
LUAD	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.9	-0.32	1.94e-11	Obesity-related traits;
LUAD	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg10544611	chr16:67998164	SLC12A4	-0.69	-8.08	-0.37	6.85e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg08999081	chr20:33150536	PIGU	0.64	14.31	0.57	3.55e-38	Coronary artery disease;
LUAD	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.6	-0.31	1.21e-10	Breast cancer;
LUAD	cis	rs4077515	0.874	rs4498662	chr9:139290251	C/G	cg14169450	chr9:139327907	INPP5E	0.38	7.06	0.32	6.86e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg10755058	chr3:40428713	ENTPD3	0.46	8.54	0.38	2.44e-16	Renal cell carcinoma;
LUAD	cis	rs68170813	0.652	rs7807154	chr7:107161391	T/G	cg02696742	chr7:106810147	HBP1	-0.74	-8.77	-0.39	4.46e-17	Coronary artery disease;
LUAD	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg04450456	chr4:17643702	FAM184B	0.41	8.27	0.37	1.7e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg11693508	chr17:37793320	STARD3	0.53	7.2	0.33	2.81e-12	Bipolar disorder;
LUAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg04160749	chr8:58172571	NA	-0.37	-6.84	-0.32	2.85e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg02038168	chr22:39784481	NA	-0.56	-9.86	-0.43	8.65e-21	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg15704280	chr7:45808275	SEPT13	-1.06	-23.72	-0.76	1.02e-79	Height;
LUAD	cis	rs9503598	0.636	rs6596977	chr6:3466254	G/A	cg00476032	chr6:3446245	SLC22A23	0.32	6.75	0.31	4.84e-11	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg09085632	chr11:111637200	PPP2R1B	0.64	9.63	0.42	5.68e-20	Primary sclerosing cholangitis;
LUAD	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-14.51	-0.58	5.23e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg00684032	chr4:1343700	KIAA1530	0.42	7.05	0.32	7.5e-12	Obesity-related traits;
LUAD	cis	rs4722404	0.592	rs7791687	chr7:3119643	G/A	cg19214707	chr7:3157722	NA	-0.43	-6.85	-0.32	2.7e-11	Atopic dermatitis;
LUAD	cis	rs7000551	0.715	rs1879793	chr8:22313986	G/A	cg12081754	chr8:22256438	SLC39A14	0.43	7.17	0.33	3.37e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.54	0.38	2.46e-16	Platelet count;
LUAD	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg11833968	chr6:79620685	NA	-0.43	-8.18	-0.37	3.43e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg24690094	chr11:67383802	NA	-0.44	-7.13	-0.33	4.25e-12	Mean corpuscular volume;
LUAD	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg07211511	chr3:129823064	LOC729375	-0.82	-12.04	-0.51	6.52e-29	Blood pressure (smoking interaction);
LUAD	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg18404041	chr3:52824283	ITIH1	0.52	8.99	0.4	8.16e-18	Schizophrenia;
LUAD	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg00933542	chr6:150070202	PCMT1	0.46	9.82	0.43	1.26e-20	Lung cancer;
LUAD	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg20203395	chr5:56204925	C5orf35	0.98	13.82	0.56	4.06e-36	Initial pursuit acceleration;
LUAD	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg02753203	chr1:228287806	NA	-0.46	-8.34	-0.38	1.08e-15	Diastolic blood pressure;
LUAD	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.39	-6.46	-0.3	2.9e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg13334819	chr7:99746414	C7orf59	0.58	8.65	0.39	1.1e-16	Coronary artery disease;
LUAD	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.61	0.31	1.15e-10	Fuchs's corneal dystrophy;
LUAD	trans	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg14791747	chr16:20752902	THUMPD1	0.49	7.1	0.33	5.24e-12	Pancreatic cancer;
LUAD	cis	rs854765	0.624	rs11657423	chr17:17728574	T/C	cg04398451	chr17:18023971	MYO15A	0.61	10.6	0.46	1.93e-23	Total body bone mineral density;
LUAD	cis	rs2239547	0.522	rs2581779	chr3:53056199	T/C	cg18404041	chr3:52824283	ITIH1	0.51	8.4	0.38	6.6e-16	Schizophrenia;
LUAD	cis	rs62238980	0.614	rs76592979	chr22:32413239	G/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg13319975	chr6:146136371	FBXO30	-0.59	-9.89	-0.43	7.11e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7524258	0.868	rs4243824	chr1:7289777	G/A	cg04342483	chr1:7259290	CAMTA1	-0.28	-6.38	-0.3	4.77e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.82	-0.47	3.08e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg19875535	chr5:140030758	IK	0.45	7.54	0.34	2.92e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg08085267	chr17:45401833	C17orf57	-0.51	-8.54	-0.38	2.42e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2046867	0.908	rs62251649	chr3:72809610	A/C	cg04365224	chr3:72788183	NA	-0.48	-7.31	-0.33	1.38e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg19336497	chr11:14380999	RRAS2	0.68	16.27	0.62	1.4300000000000001e-46	Sense of smell;
LUAD	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	8.06	0.36	8.12e-15	Rheumatoid arthritis;
LUAD	trans	rs1973993	0.745	rs56119386	chr1:96962215	C/T	cg10631902	chr5:14652156	NA	-0.45	-7.8	-0.35	4.91e-14	Weight;
LUAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg13271783	chr10:134563150	INPP5A	-0.41	-6.6	-0.31	1.24e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg12311346	chr5:56204834	C5orf35	-0.44	-7.23	-0.33	2.22e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg12311346	chr5:56204834	C5orf35	-0.42	-7.02	-0.32	8.88e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs2455601	0.786	rs2568070	chr11:8976893	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-6.45	-0.3	3.08e-10	Schizophrenia;
LUAD	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg10589385	chr1:150898437	SETDB1	0.45	8.29	0.37	1.57e-15	Melanoma;
LUAD	cis	rs9948	0.786	rs62156226	chr2:97417108	G/A	cg20312557	chr2:97357134	FER1L5	-0.62	-7.3	-0.33	1.44e-12	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg00280220	chr17:61926910	NA	0.36	6.9	0.32	1.89e-11	Prudent dietary pattern;
LUAD	cis	rs11168351	0.926	rs10875719	chr12:48411158	T/C	cg04545296	chr12:48745243	ZNF641	0.32	8.01	0.36	1.15e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg12140854	chr5:148520817	ABLIM3	-0.67	-10.68	-0.46	1.02e-23	Breast cancer;
LUAD	cis	rs3784262	0.669	rs2414530	chr15:58356362	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.35	-0.34	1.03e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg26384229	chr12:38710491	ALG10B	0.4	6.49	0.3	2.46e-10	Morning vs. evening chronotype;
LUAD	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-14.84	-0.59	2.04e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg25324976	chr17:61989376	CSHL1	0.34	6.78	0.31	4.04e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg12193833	chr17:30244370	NA	-0.58	-7.04	-0.32	7.63e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg27394845	chr17:28928406	LRRC37B2	0.49	6.39	0.3	4.46e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4642101	0.640	rs7629354	chr3:12827746	T/G	cg24848339	chr3:12840334	CAND2	0.43	8.55	0.38	2.22e-16	QRS complex (12-leadsum);
LUAD	cis	rs698833	0.852	rs2241869	chr2:44549229	A/G	cg04920474	chr2:44395004	PPM1B	-0.37	-6.6	-0.31	1.27e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg00701064	chr4:6280414	WFS1	0.6	12.62	0.52	3.21e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7937890	0.559	rs2597197	chr11:14489832	G/A	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.18e-12	Mitochondrial DNA levels;
LUAD	cis	rs7149337	0.836	rs35345236	chr14:51671817	T/C	cg23942311	chr14:51606299	NA	0.86	19.75	0.69	5.56e-62	Cancer;
LUAD	cis	rs17362650	1.000	rs13032333	chr2:9620701	T/A	cg12832956	chr2:9616023	IAH1	-0.48	-7.54	-0.34	2.97e-13	Alcohol dependence (age at onset);
LUAD	cis	rs427394	0.659	rs274678	chr5:6752385	A/G	cg14682080	chr5:6737778	POLS	-0.36	-7.83	-0.36	4.05e-14	Menopause (age at onset);
LUAD	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg17971929	chr21:40555470	PSMG1	0.45	7.11	0.33	5.11e-12	Cognitive function;
LUAD	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg01874867	chr7:94954059	PON1	-0.5	-6.96	-0.32	1.28e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg03453431	chr7:157225567	NA	-0.4	-6.88	-0.32	2.14e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg07061783	chr6:25882402	NA	0.57	8.85	0.4	2.4e-17	Blood metabolite levels;
LUAD	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.39	-6.75	-0.31	4.95e-11	Age at first birth;
LUAD	cis	rs1018836	0.892	rs5005585	chr8:91581975	A/G	cg16814680	chr8:91681699	NA	-0.56	-9.37	-0.41	4.37e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs17401966	1.000	rs58549151	chr1:10314657	A/C	cg15208524	chr1:10270712	KIF1B	0.56	8.21	0.37	2.64e-15	Hepatocellular carcinoma;
LUAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg07167872	chr1:205819463	PM20D1	0.5	8.15	0.37	4.31e-15	Parkinson's disease;
LUAD	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg16060761	chr17:80687452	NA	-0.7	-11.45	-0.49	1.23e-26	Glycated hemoglobin levels;
LUAD	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg17845761	chr1:175162550	KIAA0040	0.37	9.83	0.43	1.17e-20	Alcohol dependence;
LUAD	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg27539214	chr16:67997921	SLC12A4	-0.69	-8.76	-0.39	4.71e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3087591	0.960	rs10512433	chr17:29600564	T/C	cg24425628	chr17:29625626	OMG;NF1	0.42	6.92	0.32	1.66e-11	Hip circumference;
LUAD	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg23533926	chr12:111358616	MYL2	-0.42	-7.27	-0.33	1.78e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg18306943	chr3:40428807	ENTPD3	-0.38	-6.49	-0.3	2.44e-10	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg24818145	chr4:99064322	C4orf37	0.48	7.97	0.36	1.45e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg15448220	chr1:150897856	SETDB1	0.46	8.01	0.36	1.15e-14	Tonsillectomy;
LUAD	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.75	-12.57	-0.52	5.15e-31	Primary sclerosing cholangitis;
LUAD	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.76	0.31	4.64e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg22105103	chr4:187893119	NA	-0.44	-9.62	-0.42	6.18e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg05373962	chr22:49881684	NA	-0.48	-9.99	-0.44	3.08e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7246657	0.943	rs6508732	chr19:38000468	C/T	cg23950597	chr19:37808831	NA	-0.54	-6.88	-0.32	2.14e-11	Coronary artery calcification;
LUAD	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg22535103	chr8:58192502	C8orf71	-0.75	-10.78	-0.46	4.3e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs1997103	0.911	rs11238361	chr7:55395981	A/G	cg20935933	chr6:143382018	AIG1	0.52	7.33	0.34	1.19e-12	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs7395662	0.895	rs1827971	chr11:48718502	C/G	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	2.03e-12	HDL cholesterol;
LUAD	cis	rs9392556	0.829	rs853416	chr6:4113047	A/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.36	-6.41	-0.3	3.96e-10	Blood metabolite levels;
LUAD	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.47	-0.6	4.07e-43	Eye color traits;
LUAD	cis	rs751728	1.000	rs3793079	chr6:33767788	T/A	cg13859433	chr6:33739653	LEMD2	-0.4	-9.44	-0.42	2.5e-19	Crohn's disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg21097105	chr17:19265900	B9D1	-0.75	-7.22	-0.33	2.43e-12	Type 2 diabetes;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg11728900	chr10:13203459	MCM10	0.43	6.88	0.32	2.1e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs250677	0.522	rs10042466	chr5:148393634	T/C	cg18129178	chr5:148520854	ABLIM3	-0.57	-8.5	-0.38	3.39e-16	Breast cancer;
LUAD	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.21e-19	Life satisfaction;
LUAD	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg04398451	chr17:18023971	MYO15A	0.76	13.78	0.56	6.05e-36	Total body bone mineral density;
LUAD	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg24848339	chr3:12840334	CAND2	0.42	8.55	0.38	2.22e-16	QRS complex (12-leadsum);
LUAD	cis	rs10465746	0.967	rs6703382	chr1:84435700	G/A	cg10977910	chr1:84465055	TTLL7	0.51	8.21	0.37	2.71e-15	Obesity-related traits;
LUAD	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg25358565	chr5:93447407	FAM172A	0.62	7.01	0.32	9.39e-12	Diabetic retinopathy;
LUAD	cis	rs11048434	0.736	rs2377673	chr12:9112551	A/G	cg04155231	chr12:9217510	LOC144571	0.39	7.45	0.34	5.24e-13	Sjögren's syndrome;
LUAD	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg15704280	chr7:45808275	SEPT13	0.79	12.52	0.52	8.55e-31	Height;
LUAD	cis	rs807669	0.903	rs1780642	chr22:19170604	T/C	cg02655711	chr22:19163373	SLC25A1	0.87	19.33	0.68	4.09e-60	Metabolite levels;
LUAD	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg25324976	chr17:61989376	CSHL1	0.38	7.39	0.34	7.83e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7147624	1.000	rs10873192	chr14:66110653	A/G	cg03016385	chr14:66212404	NA	-0.6	-6.99	-0.32	1.1e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs2197308	0.549	rs10785517	chr12:38577992	G/T	cg10518543	chr12:38710700	ALG10B	0.45	7.57	0.35	2.29e-13	Morning vs. evening chronotype;
LUAD	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.43	-8.7	-0.39	7.43e-17	Response to fenofibrate (adiponectin levels);
LUAD	trans	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg04565464	chr8:145669602	NFKBIL2	0.42	6.36	0.3	5.16e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20732367	chr2:238601467	LRRFIP1	0.43	6.65	0.31	8.98e-11	Gut microbiome composition (summer);
LUAD	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg14668632	chr7:2872130	GNA12	-0.75	-13.51	-0.55	7.83e-35	Height;
LUAD	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg25344623	chr2:136566232	LCT	0.34	6.67	0.31	7.91e-11	Mosquito bite size;
LUAD	cis	rs863345	0.604	rs6666805	chr1:158498305	G/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.61	-0.31	1.18e-10	Pneumococcal bacteremia;
LUAD	cis	rs7943203	0.568	rs179110	chr11:108254999	T/C	cg04873221	chr11:107992290	ACAT1	-0.5	-7.51	-0.34	3.62e-13	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs4006360	0.520	rs4986664	chr17:39250248	C/T	cg16090541	chr17:39240343	KRTAP4-7	-0.36	-6.44	-0.3	3.32e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs68170813	0.559	rs79026644	chr7:107031803	A/G	cg23024343	chr7:107201750	COG5	0.52	7.36	0.34	9.97e-13	Coronary artery disease;
LUAD	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs2235573	0.657	rs4821731	chr22:38445214	C/A	cg19894588	chr14:64061835	NA	0.45	6.91	0.32	1.74e-11	Glioblastoma;Glioma;
LUAD	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg09826364	chr7:158789723	NA	-0.4	-7.16	-0.33	3.49e-12	Facial morphology (factor 20);
LUAD	cis	rs9462027	0.628	rs2814961	chr6:34706951	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.02	-0.4	6.62e-18	Systemic lupus erythematosus;
LUAD	cis	rs62238980	0.614	rs41430344	chr22:32381973	C/T	cg02631450	chr22:32366979	NA	0.8	6.64	0.31	9.47e-11	Childhood ear infection;
LUAD	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs62400317	0.826	rs12205642	chr6:45331765	T/C	cg20913747	chr6:44695427	NA	-0.39	-6.39	-0.3	4.4e-10	Total body bone mineral density;
LUAD	cis	rs7520050	0.966	rs1707340	chr1:46514942	T/C	cg06784218	chr1:46089804	CCDC17	-0.31	-6.58	-0.3	1.4e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs57502260	0.790	rs7129320	chr11:68388220	G/A	cg16797656	chr11:68205561	LRP5	0.47	7.26	0.33	1.84e-12	Total body bone mineral density (age 45-60);
LUAD	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg08885076	chr2:99613938	TSGA10	0.38	6.88	0.32	2.2e-11	Chronic sinus infection;
LUAD	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg14584255	chr6:163149320	PACRG;PARK2	-0.37	-7.11	-0.33	5.07e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs599083	0.793	rs471966	chr11:68173861	C/T	cg01657329	chr11:68192670	LRP5	0.5	8.43	0.38	5.62e-16	Bone mineral density (spine);
LUAD	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.43	-7.35	-0.34	1.06e-12	Longevity;Endometriosis;
LUAD	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg22823121	chr1:150693482	HORMAD1	0.44	8.91	0.4	1.55e-17	Tonsillectomy;
LUAD	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.48	-6.43	-0.3	3.43e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12210905	0.688	rs12199806	chr6:27435943	A/C	cg08851530	chr6:28072375	NA	1.03	7.92	0.36	2.19e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs73198271	0.628	rs11783707	chr8:8589609	C/T	cg01851573	chr8:8652454	MFHAS1	0.47	6.7	0.31	6.82e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2668423	0.922	rs266805	chr19:1376723	C/T	cg02639931	chr19:1387894	NDUFS7	-0.49	-8.64	-0.39	1.16e-16	Nonalcoholic fatty liver disease;
LUAD	cis	rs2455799	0.613	rs4467435	chr3:15791671	A/G	cg16303742	chr3:15540471	COLQ	-0.52	-9.72	-0.43	2.83e-20	Mean platelet volume;
LUAD	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg02527881	chr3:46936655	PTH1R	0.42	7.88	0.36	2.85e-14	Colorectal cancer;
LUAD	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg05991184	chr2:219186017	PNKD	0.37	7.11	0.33	4.91e-12	Colorectal cancer;
LUAD	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg02782426	chr3:40428986	ENTPD3	0.35	7.5	0.34	3.86e-13	Renal cell carcinoma;
LUAD	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg08645402	chr16:4508243	NA	0.56	10.18	0.44	6.32e-22	Schizophrenia;
LUAD	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.5	8.03	0.36	9.94e-15	Total body bone mineral density;
LUAD	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg22431228	chr1:16359049	CLCNKA	0.41	6.74	0.31	5.1e-11	Dilated cardiomyopathy;
LUAD	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg24690094	chr11:67383802	NA	0.4	7.18	0.33	3.11e-12	Mean corpuscular volume;
LUAD	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg17971929	chr21:40555470	PSMG1	0.54	8.35	0.38	9.96e-16	Cognitive function;
LUAD	trans	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.65	-0.46	1.24e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.45	-7.37	-0.34	9.04e-13	Tonsillectomy;
LUAD	cis	rs1965732	0.563	rs13390724	chr2:3721632	G/A	cg10645314	chr2:3704589	ALLC	-0.44	-7.68	-0.35	1.14e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14029663	chr14:50582909	C14orf138	-0.48	-6.51	-0.3	2.18e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg13565492	chr6:43139072	SRF	-0.73	-9.74	-0.43	2.24e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg19875535	chr5:140030758	IK	-0.41	-6.99	-0.32	1.06e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg15921436	chr17:44337874	NA	0.63	9.42	0.42	2.9e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg06671706	chr8:8559999	CLDN23	0.68	11.68	0.49	1.67e-27	Obesity-related traits;
LUAD	cis	rs8130944	0.828	rs2284962	chr21:44111032	A/G	cg16784985	chr21:44105474	PDE9A	-0.4	-6.79	-0.31	3.84e-11	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19748678	chr4:122722346	EXOSC9	0.43	6.79	0.31	3.77e-11	Type 2 diabetes;
LUAD	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg03609598	chr5:56110824	MAP3K1	-0.68	-9.27	-0.41	9.92e-19	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg12699174	chr1:156024477	ROBLD3;UBQLN4	-0.39	-6.42	-0.3	3.58e-10	Schizophrenia;
LUAD	cis	rs701145	0.938	rs355770	chr3:154040273	G/A	cg17054900	chr3:154042577	DHX36	0.66	7.32	0.34	1.29e-12	Coronary artery disease;
LUAD	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg13385794	chr1:248469461	NA	0.25	6.66	0.31	8.74e-11	Common traits (Other);
LUAD	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg19875535	chr5:140030758	IK	0.47	7.81	0.36	4.45e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	6.4	0.3	4.19e-10	Menarche (age at onset);
LUAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	0.31	7.06	0.32	6.92e-12	Lymphocyte counts;
LUAD	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.69	-13.4	-0.55	2.18e-34	Ulcerative colitis;
LUAD	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg02569458	chr12:86230093	RASSF9	0.46	8.33	0.38	1.16e-15	Major depressive disorder;
LUAD	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12756686	chr19:29218302	NA	-0.63	-8.24	-0.37	2.17e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg07828340	chr4:882639	GAK	1.05	10.84	0.47	2.47e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.552	rs4886823	chr15:76965402	A/G	cg23625390	chr15:77176239	SCAPER	-0.48	-7.28	-0.33	1.63e-12	Blood metabolite levels;
LUAD	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg12927641	chr6:109611667	NA	-0.54	-9.48	-0.42	1.83e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs2067615	0.579	rs10861657	chr12:107131314	A/G	cg15890332	chr12:107067104	RFX4	0.38	8.15	0.37	4.12e-15	Heart rate;
LUAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg13047869	chr3:10149882	C3orf24	0.67	11.48	0.49	9.3e-27	Alzheimer's disease;
LUAD	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg02176678	chr2:219576539	TTLL4	0.61	11.71	0.49	1.27e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg14530993	chr4:882597	GAK	0.81	7.96	0.36	1.6e-14	Parkinson's disease;
LUAD	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg13699009	chr12:122356056	WDR66	0.31	6.83	0.32	2.9e-11	Mean corpuscular volume;
LUAD	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg27432699	chr2:27873401	GPN1	0.58	10.32	0.45	2.1e-22	Oral cavity cancer;
LUAD	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg17264618	chr3:40429014	ENTPD3	0.43	8.92	0.4	1.39e-17	Renal cell carcinoma;
LUAD	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg19318889	chr4:1322082	MAEA	-0.43	-7.46	-0.34	4.85e-13	Obesity-related traits;
LUAD	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg16512390	chr1:228756714	NA	0.49	8.29	0.37	1.49e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs909002	0.849	rs6664789	chr1:32072406	C/G	cg13919466	chr1:32135498	COL16A1	-0.34	-7.77	-0.35	5.87e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7173743	0.756	rs8034804	chr15:79129600	C/T	cg15571903	chr15:79123663	NA	0.4	7.85	0.36	3.55e-14	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.82	0.31	3.12e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9393692	0.557	rs62394769	chr6:26326182	C/T	cg00631329	chr6:26305371	NA	-0.54	-8.61	-0.39	1.42e-16	Educational attainment;
LUAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg23978390	chr7:1156363	C7orf50	0.44	6.71	0.31	6.22e-11	Longevity;Endometriosis;
LUAD	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.8	0.31	3.69e-11	Parkinson's disease;
LUAD	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg13699009	chr12:122356056	WDR66	0.3	6.41	0.3	3.83e-10	Mean corpuscular volume;
LUAD	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg07395648	chr5:131743802	NA	0.38	6.51	0.3	2.17e-10	Breast cancer;
LUAD	cis	rs9826463	0.757	rs66597875	chr3:142264782	T/C	cg20824294	chr3:142316082	PLS1	0.41	7.39	0.34	7.81e-13	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10979	1.000	rs9390113	chr6:143896205	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.28	-0.45	2.77e-22	Hypospadias;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg07332563	chr6:291687	DUSP22	-0.69	-11.96	-0.5	1.36e-28	Menopause (age at onset);
LUAD	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg08219700	chr8:58056026	NA	0.6	8.47	0.38	3.98e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg08514558	chr10:81106712	PPIF	0.48	9.52	0.42	1.39e-19	Height;
LUAD	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg11266682	chr4:10021025	SLC2A9	0.67	15.46	0.6	4.49e-43	Bone mineral density;
LUAD	cis	rs7095607	0.813	rs1873111	chr10:69922446	T/C	cg18986048	chr10:69913749	MYPN	0.38	6.57	0.3	1.49e-10	Lung function (FVC);
LUAD	cis	rs11723261	0.582	rs6814287	chr4:122323	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	7.57	0.35	2.38e-13	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg17724175	chr1:150552817	MCL1	-0.41	-9.26	-0.41	1.08e-18	Urate levels;
LUAD	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg04155289	chr7:94953770	PON1	-0.54	-7.36	-0.34	9.74e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.47	8.61	0.39	1.48e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4380275	0.965	rs4375894	chr2:772567	G/C	cg21665850	chr2:731073	NA	0.5	9.03	0.4	5.91e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUAD	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg10560079	chr2:191398806	TMEM194B	-0.54	-7.03	-0.32	8.26e-12	Diastolic blood pressure;
LUAD	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg18944383	chr4:111397179	ENPEP	0.41	8.19	0.37	3.15e-15	Height;
LUAD	cis	rs2932538	0.922	rs2273369	chr1:113072477	A/G	cg22162597	chr1:113214053	CAPZA1	0.45	6.72	0.31	5.95e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg11062466	chr8:58055876	NA	0.54	7.41	0.34	6.86e-13	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg18944383	chr4:111397179	ENPEP	0.36	7.31	0.33	1.35e-12	Height;
LUAD	trans	rs8073060	0.519	rs8065286	chr17:33864479	A/G	cg19694781	chr19:47549865	TMEM160	0.52	8.35	0.38	9.71e-16	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	14.28	0.57	5.1e-38	Lung cancer in ever smokers;
LUAD	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg05665937	chr4:1216051	CTBP1	0.42	7.04	0.32	7.61e-12	Obesity-related traits;
LUAD	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg25324976	chr17:61989376	CSHL1	0.34	6.66	0.31	8.52e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs62229266	0.804	rs2835241	chr21:37411380	G/T	cg08632701	chr21:37451849	NA	0.44	7.38	0.34	8.64e-13	Mitral valve prolapse;
LUAD	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg07636037	chr3:49044803	WDR6	0.54	8.76	0.39	4.84e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg09033563	chr22:24373618	LOC391322	-0.49	-7.51	-0.34	3.49e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.48	6.83	0.32	2.93e-11	Platelet count;
LUAD	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg06623918	chr6:96969491	KIAA0776	0.72	9.83	0.43	1.1e-20	Migraine;Coronary artery disease;
LUAD	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	7.9	0.36	2.4e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg23625390	chr15:77176239	SCAPER	0.39	6.79	0.31	3.8e-11	Blood metabolite levels;
LUAD	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg18252515	chr7:66147081	NA	-0.63	-6.84	-0.32	2.86e-11	Diabetic kidney disease;
LUAD	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	9.4e-15	Tonsillectomy;
LUAD	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg03929089	chr4:120376271	NA	0.57	7.13	0.33	4.42e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg24399712	chr22:39784796	NA	-0.79	-14.92	-0.59	9.14e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg06002616	chr8:101225028	SPAG1	-0.41	-8.42	-0.38	6.01e-16	Atrioventricular conduction;
LUAD	cis	rs7043114	0.525	rs7869742	chr9:95256174	A/G	cg14631576	chr9:95140430	CENPP	-0.4	-8.11	-0.37	5.65e-15	Height;
LUAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23978390	chr7:1156363	C7orf50	0.63	10.04	0.44	2.08e-21	Longevity;Endometriosis;
LUAD	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg07741184	chr6:167504864	NA	-0.3	-7.07	-0.32	6.55e-12	Primary biliary cholangitis;
LUAD	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-10.61	-0.46	1.78e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg02493740	chr2:85810744	VAMP5	-0.62	-10.91	-0.47	1.42e-24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg17173187	chr15:85201210	NMB	0.4	6.37	0.3	4.93e-10	Schizophrenia;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg21117678	chr7:101459024	CUX1	-0.4	-6.54	-0.3	1.73e-10	Schizophrenia;
LUAD	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg25024717	chr12:54324583	NA	-0.32	-7.09	-0.33	5.77e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUAD	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg13902645	chr11:5959945	NA	0.54	9.93	0.43	5.08e-21	DNA methylation (variation);
LUAD	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.32	-0.34	1.26e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.36e-12	Lung cancer;
LUAD	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg19318889	chr4:1322082	MAEA	-0.73	-12.56	-0.52	5.44e-31	Obesity-related traits;
LUAD	trans	rs8002861	0.664	rs4941474	chr13:44450289	C/T	cg17145862	chr1:211918768	LPGAT1	0.65	13.35	0.54	3.7e-34	Leprosy;
LUAD	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg17644776	chr2:200775616	C2orf69	0.55	7.29	0.33	1.57e-12	Schizophrenia;
LUAD	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg13180566	chr4:1052158	NA	-0.39	-6.69	-0.31	7.15e-11	Recombination rate (females);
LUAD	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg18306943	chr3:40428807	ENTPD3	0.43	7.27	0.33	1.81e-12	Renal cell carcinoma;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg01458961	chr4:102269425	PPP3CA	0.38	6.59	0.31	1.33e-10	Anger;
LUAD	cis	rs11112613	0.595	rs871219	chr12:105938519	C/A	cg03607813	chr12:105948248	NA	0.87	13.09	0.54	4.09e-33	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs7274811	0.711	rs373618	chr20:31992639	C/A	cg14921437	chr20:32255988	NECAB3;C20orf134	0.45	6.75	0.31	5.03e-11	Height;
LUAD	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg14582100	chr15:45693742	SPATA5L1	0.64	12.58	0.52	4.61e-31	Homoarginine levels;
LUAD	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg22823121	chr1:150693482	HORMAD1	0.44	8.84	0.39	2.69e-17	Tonsillectomy;
LUAD	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg17863274	chr19:49399704	TULP2	-0.64	-9.78	-0.43	1.74e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg01868782	chr6:126071099	HEY2	-0.32	-6.75	-0.31	4.81e-11	Brugada syndrome;
LUAD	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.33	6.67	0.31	8.2e-11	Obesity-related traits;
LUAD	cis	rs9302635	0.678	rs8054585	chr16:72225314	G/A	cg23815491	chr16:72088622	HP	0.44	6.93	0.32	1.56e-11	Blood protein levels;
LUAD	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg22906224	chr7:99728672	NA	-0.64	-11.13	-0.48	2e-25	Coronary artery disease;
LUAD	cis	rs9826463	0.582	rs73238140	chr3:142046665	T/G	cg20824294	chr3:142316082	PLS1	0.4	6.93	0.32	1.54e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg25985355	chr7:65971099	NA	-0.36	-6.66	-0.31	8.79e-11	Aortic root size;
LUAD	cis	rs116248771	0.739	rs12633674	chr3:158368217	G/T	cg16708174	chr3:158430962	RARRES1	0.46	6.8	0.31	3.58e-11	diarrhoeal disease at age 2;
LUAD	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg06740227	chr12:86229804	RASSF9	0.42	7.29	0.33	1.55e-12	Major depressive disorder;
LUAD	cis	rs73198271	0.595	rs55874147	chr8:8591954	T/C	cg01851573	chr8:8652454	MFHAS1	0.47	6.8	0.31	3.6e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg11494091	chr17:61959527	GH2	0.74	18.31	0.66	1.5e-55	Prudent dietary pattern;
LUAD	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg18305652	chr10:134549665	INPP5A	0.59	11.59	0.49	3.5e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg15448220	chr1:150897856	SETDB1	0.53	9.06	0.4	4.81e-18	Tonsillectomy;
LUAD	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs4764487	0.687	rs3181300	chr12:6345199	C/T	cg08284733	chr12:6341482	CD9	0.37	6.71	0.31	6.14e-11	Mean platelet volume;
LUAD	cis	rs7536201	1.000	rs10903121	chr1:25300042	G/A	cg23273869	chr1:25296894	NA	-0.39	-8.07	-0.37	7.56e-15	Psoriasis vulgaris;
LUAD	cis	rs60871478	0.730	rs73042471	chr7:927762	G/A	cg05535760	chr7:792225	HEATR2	-0.72	-7.72	-0.35	8.21e-14	Cerebrospinal P-tau181p levels;
LUAD	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-7.53	-0.34	3.01e-13	Bladder cancer;
LUAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.47e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1018836	0.886	rs7817954	chr8:91535105	G/A	cg16814680	chr8:91681699	NA	-0.75	-12.99	-0.53	1.02e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg11766577	chr21:47581405	C21orf56	0.54	9.22	0.41	1.39e-18	Testicular germ cell tumor;
LUAD	cis	rs7274811	0.625	rs293734	chr20:31924680	T/A	cg14921437	chr20:32255988	NECAB3;C20orf134	0.44	6.45	0.3	3.03e-10	Height;
LUAD	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg20991723	chr1:152506922	NA	0.36	7.05	0.32	7.14e-12	Hair morphology;
LUAD	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06873352	chr17:61820015	STRADA	0.82	18.12	0.66	9.67e-55	Prudent dietary pattern;
LUAD	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg04414720	chr1:150670196	GOLPH3L	0.74	13.82	0.56	4.22e-36	Tonsillectomy;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05065690	chr12:49246007	DDX23	-0.42	-6.54	-0.3	1.73e-10	Height;
LUAD	cis	rs1594829	0.553	rs2046226	chr8:26152050	G/A	cg13160058	chr8:26243215	BNIP3L	-0.33	-7.38	-0.34	8.27e-13	Height;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08531998	chr19:2819857	ZNF554	-0.53	-7.12	-0.33	4.72e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2455601	0.882	rs11042115	chr11:8926679	A/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.53	-8.48	-0.38	3.71e-16	Schizophrenia;
LUAD	cis	rs757110	0.868	rs5219	chr11:17409572	T/C	cg15432903	chr11:17409602	KCNJ11	0.6	11.36	0.48	2.72e-26	Type 2 diabetes;
LUAD	cis	rs7731657	0.537	rs6595973	chr5:130327126	C/A	cg08523029	chr5:130500466	HINT1	0.56	7.36	0.34	9.74e-13	Fasting plasma glucose;
LUAD	trans	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.62	0.31	1.11e-10	Neuroticism;
LUAD	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.34e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4523957	0.579	rs57130712	chr17:2089035	A/G	cg16513277	chr17:2031491	SMG6	-0.87	-16.74	-0.63	1.29e-48	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg09323728	chr8:95962352	TP53INP1	-0.32	-7.77	-0.35	5.88e-14	Type 2 diabetes;
LUAD	cis	rs7527798	0.592	rs12022909	chr1:207859743	T/C	cg09232269	chr1:207846808	CR1L	-0.41	-7.79	-0.35	5.17e-14	Erythrocyte sedimentation rate;
LUAD	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg05342682	chr7:94953680	PON1	0.51	7.34	0.34	1.08e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.94	-0.36	1.83e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg01028140	chr2:1542097	TPO	-0.6	-7.71	-0.35	9.02e-14	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs2625529	0.526	rs7179942	chr15:72563074	C/G	cg16672083	chr15:72433130	SENP8	0.65	11.98	0.5	1.17e-28	Red blood cell count;
LUAD	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg09526685	chr4:187126073	CYP4V2	0.88	9.33	0.41	5.81e-19	Activated partial thromboplastin time;
LUAD	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg23281280	chr6:28129359	ZNF389	0.48	6.71	0.31	6.44e-11	Depression;
LUAD	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg27454412	chr7:1067447	C7orf50	-0.4	-7.65	-0.35	1.4e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg24558204	chr6:135376177	HBS1L	0.49	9.14	0.41	2.59e-18	Red blood cell count;
LUAD	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-7.57	-0.35	2.3e-13	Blood metabolite levels;
LUAD	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg06608945	chr2:219082296	ARPC2	-0.42	-6.97	-0.32	1.23e-11	Colorectal cancer;
LUAD	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg17105886	chr17:28927953	LRRC37B2	0.8	7.7	0.35	9.93e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10979	0.964	rs9496682	chr6:143898805	A/G	cg25407410	chr6:143891975	LOC285740	-0.65	-10.28	-0.45	2.91e-22	Hypospadias;
LUAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg27532560	chr4:187881888	NA	-0.37	-7.07	-0.32	6.64e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.83	-0.36	4.08e-14	Neutrophil percentage of white cells;
LUAD	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg07741184	chr6:167504864	NA	-0.29	-6.89	-0.32	2.06e-11	Rheumatoid arthritis;
LUAD	cis	rs2688608	0.836	rs2675668	chr10:75636148	G/A	cg23231163	chr10:75533350	FUT11	-0.44	-7.98	-0.36	1.42e-14	Inflammatory bowel disease;
LUAD	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18099408	chr3:52552593	STAB1	-0.45	-8.09	-0.37	6.29e-15	Bipolar disorder;
LUAD	cis	rs76878669	0.561	rs3177514	chr11:66130358	T/G	cg18002602	chr11:66138449	SLC29A2	0.46	9.8	0.43	1.38e-20	Educational attainment (years of education);
LUAD	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs427394	0.796	rs274683	chr5:6747950	T/A	cg14682080	chr5:6737778	POLS	0.33	7.12	0.33	4.69e-12	Menopause (age at onset);
LUAD	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg04450456	chr4:17643702	FAM184B	0.42	8.22	0.37	2.56e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3087591	0.922	rs2905879	chr17:29545431	T/A	cg24425628	chr17:29625626	OMG;NF1	0.42	6.81	0.31	3.3e-11	Hip circumference;
LUAD	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-23.44	-0.75	1.76e-78	Height;
LUAD	cis	rs8099014	1.000	rs4637007	chr18:56126282	G/A	cg12907477	chr18:56117327	MIR122	0.39	6.61	0.31	1.14e-10	Platelet count;
LUAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.44	-7.43	-0.34	6.03e-13	Longevity;Endometriosis;
LUAD	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg17264618	chr3:40429014	ENTPD3	0.39	8.74	0.39	5.46e-17	Renal cell carcinoma;
LUAD	cis	rs7326068	0.596	rs4505167	chr13:21341096	T/C	cg27499820	chr13:21296301	IL17D	0.55	8.37	0.38	8.79e-16	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg07402062	chr16:89894098	SPIRE2	-0.49	-6.81	-0.31	3.3e-11	Caffeine consumption;
LUAD	cis	rs1003719	0.667	rs3753073	chr21:38466615	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.45	7.5	0.34	3.77e-13	Eye color traits;
LUAD	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg19000871	chr14:103996768	TRMT61A	-0.39	-6.91	-0.32	1.83e-11	Coronary artery disease;
LUAD	cis	rs796825	0.530	rs751799	chr3:120016964	G/A	cg21790991	chr3:120137480	FSTL1	-0.46	-7.67	-0.35	1.18e-13	HIV-1 susceptibility;
LUAD	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg22963979	chr7:1858916	MAD1L1	-0.51	-8.5	-0.38	3.34e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg25237894	chr2:233734115	C2orf82	0.6	11.3	0.48	4.57e-26	Coronary artery disease;
LUAD	cis	rs11723261	0.582	rs114199753	chr4:163520	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	7.91	0.36	2.26e-14	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10802521	chr3:52805072	NEK4	0.49	8.38	0.38	8.05e-16	Bipolar disorder;
LUAD	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg18138036	chr10:133769891	PPP2R2D	0.41	6.77	0.31	4.45e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg01788221	chr16:89496183	ANKRD11	-0.38	-7.42	-0.34	6.69e-13	Multiple myeloma (IgH translocation);
LUAD	trans	rs10411161	0.702	rs10424202	chr19:52387297	G/A	cg22319618	chr22:45562946	NUP50	-0.64	-8.99	-0.4	8.63e-18	Breast cancer;
LUAD	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg00316803	chr15:76480434	C15orf27	-0.4	-7.58	-0.35	2.19e-13	Blood metabolite levels;
LUAD	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg13770153	chr20:60521292	NA	-0.65	-10.09	-0.44	1.34e-21	Body mass index;
LUAD	cis	rs9858542	0.543	rs2230929	chr3:49343175	G/A	cg00383909	chr3:49044727	WDR6	0.62	7.94	0.36	1.85e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs3106136	0.933	rs35718240	chr4:95164030	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.94	-0.32	1.47e-11	Capecitabine sensitivity;
LUAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg08888203	chr3:10149979	C3orf24	0.68	11.55	0.49	5.01e-27	Alzheimer's disease;
LUAD	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg24088639	chr11:34937564	PDHX;APIP	0.42	6.98	0.32	1.12e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg02880119	chr16:3481970	NA	-0.54	-8.3	-0.37	1.4e-15	Body mass index (adult);
LUAD	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg12458913	chr13:53173898	NA	0.48	8.51	0.38	3e-16	Lewy body disease;
LUAD	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg07507251	chr3:52567010	NT5DC2	0.37	7.32	0.34	1.26e-12	Bipolar disorder;
LUAD	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg16325326	chr1:53192061	ZYG11B	-0.63	-11.82	-0.5	4.73e-28	Monocyte count;
LUAD	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.55e-11	Crohn's disease;
LUAD	cis	rs4638749	0.677	rs10185270	chr2:108838692	A/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.42	-0.34	6.49e-13	Blood pressure;
LUAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg06263672	chr7:65235340	NA	0.48	7.74	0.35	7.35e-14	Calcium levels;
LUAD	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg16988262	chr1:15930761	NA	0.43	7.0	0.32	1e-11	Systolic blood pressure;
LUAD	cis	rs3744061	0.520	rs9908979	chr17:74645486	T/G	cg27546012	chr17:74684504	MXRA7	-0.38	-6.84	-0.32	2.85e-11	Retinal arteriolar caliber;
LUAD	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg16060761	chr17:80687452	NA	-0.56	-8.17	-0.37	3.72e-15	Glycated hemoglobin levels;
LUAD	cis	rs938554	0.736	rs4475146	chr4:9946656	C/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.31	-0.33	1.34e-12	Blood metabolite levels;
LUAD	cis	rs55665837	0.540	rs10128681	chr11:14701576	T/C	cg19336497	chr11:14380999	RRAS2	-0.41	-7.91	-0.36	2.21e-14	Vitamin D levels;
LUAD	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03264133	chr6:25882463	NA	-0.57	-9.36	-0.41	4.79e-19	Blood metabolite levels;
LUAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg11766577	chr21:47581405	C21orf56	0.56	9.45	0.42	2.32e-19	Testicular germ cell tumor;
LUAD	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg22676075	chr6:135203613	NA	0.4	7.46	0.34	4.95e-13	Reticulocyte count;High light scatter reticulocyte count;
LUAD	cis	rs9394841	0.692	rs2395795	chr6:41802354	G/A	cg25600774	chr6:41776562	USP49	-0.42	-6.47	-0.3	2.78e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.19	0.41	1.83e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2735413	0.918	rs12918959	chr16:78081719	T/C	cg04733911	chr16:78082701	NA	-0.35	-8.22	-0.37	2.53e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs2712431	0.554	rs9864772	chr3:128316939	A/G	cg16766828	chr3:128327626	NA	-0.41	-7.67	-0.35	1.21e-13	Monocyte chemoattractant protein-1 levels;
LUAD	cis	rs4842666	0.831	rs11105337	chr12:89993507	A/T	cg00757033	chr12:89920650	WDR51B	0.51	6.72	0.31	6e-11	Blood pressure;
LUAD	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg11502198	chr6:26597334	ABT1	0.66	11.38	0.48	2.33e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.72	-0.35	8.21e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4824093	0.610	rs73443974	chr22:50314316	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-7.78	-0.35	5.68e-14	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg05835009	chr4:710272	PCGF3	0.59	8.57	0.38	1.97e-16	White blood cell count;
LUAD	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg24768116	chr2:27665128	KRTCAP3	0.26	6.36	0.3	5.2400000000000005e-10	Oral cavity cancer;
LUAD	cis	rs6960043	0.738	rs10950548	chr7:15057728	G/A	cg19272540	chr7:15055459	NA	0.4	8.93	0.4	1.32e-17	Type 2 diabetes;
LUAD	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.75	11.89	0.5	2.44e-28	Platelet distribution width;
LUAD	cis	rs494562	0.892	rs9353310	chr6:86126199	C/T	cg21730993	chr6:86159210	NT5E	0.72	7.92	0.36	2.05e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg17971929	chr21:40555470	PSMG1	0.43	6.87	0.32	2.32e-11	Cognitive function;
LUAD	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg11693508	chr17:37793320	STARD3	0.83	10.46	0.45	6.53e-23	Bipolar disorder;
LUAD	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg11814155	chr7:99998594	ZCWPW1	0.37	6.37	0.3	4.82e-10	Platelet count;
LUAD	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-11.96	-0.5	1.32e-28	Bipolar disorder;
LUAD	cis	rs62400317	0.859	rs12214885	chr6:45197731	C/G	cg18551225	chr6:44695536	NA	-0.56	-8.35	-0.38	1.01e-15	Total body bone mineral density;
LUAD	cis	rs9560113	0.959	rs4771756	chr13:112176083	T/G	cg14154082	chr13:112174009	NA	0.37	6.85	0.32	2.54e-11	Menarche (age at onset);
LUAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg07677032	chr17:61819896	STRADA	0.57	10.48	0.45	5.49e-23	Prudent dietary pattern;
LUAD	cis	rs10489202	0.632	rs149912	chr1:167957803	A/T	cg24449463	chr1:168025552	DCAF6	-0.74	-12.23	-0.51	1.15e-29	Schizophrenia;
LUAD	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg05110241	chr16:68378359	PRMT7	-0.93	-10.37	-0.45	1.3e-22	Schizophrenia;
LUAD	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg23283495	chr1:209979779	IRF6	0.73	10.64	0.46	1.43e-23	Cleft lip with or without cleft palate;
LUAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg20607798	chr8:58055168	NA	0.66	8.74	0.39	5.66e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg04800585	chr6:26043546	HIST1H2BB	0.52	8.94	0.4	1.18e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs870825	0.587	rs35845099	chr4:185639762	A/G	cg04058563	chr4:185651563	MLF1IP	0.88	14.12	0.57	2.26e-37	Blood protein levels;
LUAD	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.48	-0.3	2.52e-10	Aortic root size;
LUAD	trans	rs6076960	0.564	rs3852935	chr20:6143180	C/G	cg21095983	chr6:86352623	SYNCRIP	0.46	7.68	0.35	1.1e-13	Smooth-surface caries;
LUAD	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg06263672	chr7:65235340	NA	0.48	6.36	0.3	5.28e-10	Aortic root size;
LUAD	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.49	6.61	0.31	1.14e-10	Platelet count;
LUAD	cis	rs79518236	1	rs79518236	chr7:98026554	ACT/A	cg09267113	chr7:98030324	BAIAP2L1	-0.77	-11.13	-0.48	2.1e-25	Breast cancer;
LUAD	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg01884057	chr2:25150051	NA	0.34	7.24	0.33	2.13e-12	Body mass index;
LUAD	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg02569458	chr12:86230093	RASSF9	0.44	7.81	0.36	4.49e-14	Major depressive disorder;
LUAD	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.73	0.31	5.44e-11	Motion sickness;
LUAD	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg27665823	chr16:460516	DECR2	0.55	6.69	0.31	7.1e-11	Colorectal cancer;
LUAD	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg22875332	chr1:76189707	ACADM	-0.7	-11.55	-0.49	5.2e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08280861	chr8:58055591	NA	0.67	8.68	0.39	8.64e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4072705	0.967	rs10760369	chr9:127397400	A/G	cg13476313	chr9:127244764	NR5A1	0.34	8.14	0.37	4.57e-15	Menarche (age at onset);
LUAD	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10802521	chr3:52805072	NEK4	-0.54	-9.32	-0.41	6.73e-19	Electroencephalogram traits;
LUAD	trans	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg18187862	chr3:45730750	SACM1L	0.51	7.92	0.36	2.08e-14	Primary sclerosing cholangitis;
LUAD	cis	rs208520	0.874	rs208518	chr6:66948501	C/G	cg07460842	chr6:66804631	NA	0.99	14.2	0.57	1.08e-37	Exhaled nitric oxide output;
LUAD	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	trans	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg14917512	chr19:3094685	GNA11	0.58	6.84	0.32	2.72e-11	Diabetic kidney disease;
LUAD	trans	rs11638815	0.626	rs1313492	chr15:83272955	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.49	-7.38	-0.34	8.21e-13	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg12927641	chr6:109611667	NA	-0.5	-8.35	-0.38	9.62e-16	Reticulocyte fraction of red cells;
LUAD	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.98	-0.32	1.12e-11	Type 2 diabetes;
LUAD	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg23985595	chr17:80112537	CCDC57	-0.41	-7.44	-0.34	5.51e-13	Life satisfaction;
LUAD	trans	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg01620082	chr3:125678407	NA	-0.45	-6.79	-0.31	3.9e-11	Parkinson's disease;
LUAD	trans	rs1493916	0.837	rs9952002	chr18:31414314	C/G	cg27147174	chr7:100797783	AP1S1	-0.64	-11.3	-0.48	4.71e-26	Life satisfaction;
LUAD	trans	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg27411982	chr8:10470053	RP1L1	0.4	6.93	0.32	1.57e-11	Neuroticism;
LUAD	cis	rs4920343	0.890	rs4920531	chr1:19095746	A/G	cg26220594	chr1:19110978	NA	-0.4	-6.75	-0.31	4.78e-11	Knee osteoarthritis;
LUAD	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg27490568	chr2:178487706	NA	0.65	9.51	0.42	1.41e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg16800975	chr8:17434541	PDGFRL	-0.44	-7.62	-0.35	1.7e-13	Schizophrenia;
LUAD	cis	rs929596	0.517	rs1875263	chr2:234625622	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-10.81	-0.47	3.19e-24	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg22681709	chr2:178499509	PDE11A	-0.43	-6.8	-0.31	3.66e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg27572855	chr1:25598939	RHD	0.59	13.3	0.54	5.56e-34	Plateletcrit;Mean corpuscular volume;
LUAD	trans	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-10.84	-0.47	2.49e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg25535316	chr11:579198	PHRF1	-0.45	-7.26	-0.33	1.88e-12	Systemic lupus erythematosus;
LUAD	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg09998033	chr7:158218633	PTPRN2	-0.42	-7.4	-0.34	7.47e-13	Obesity-related traits;
LUAD	cis	rs1595825	0.945	rs73058818	chr2:198862600	C/T	cg00982548	chr2:198649783	BOLL	-0.59	-8.54	-0.38	2.4e-16	Ulcerative colitis;
LUAD	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg02038168	chr22:39784481	NA	-0.58	-9.68	-0.43	3.91e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg19912559	chr1:40204330	PPIE	0.57	9.94	0.44	4.64e-21	Blood protein levels;
LUAD	cis	rs6840360	0.615	rs2120098	chr4:152457180	T/A	cg22705602	chr4:152727874	NA	-0.41	-7.45	-0.34	5.2e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.15	-33.19	-0.85	7.61e-120	Myeloid white cell count;
LUAD	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg06544989	chr22:39130855	UNC84B	-0.39	-7.83	-0.36	3.98e-14	Menopause (age at onset);
LUAD	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.38	0.55	2.81e-34	Tonsillectomy;
LUAD	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg04287289	chr16:89883240	FANCA	0.65	6.64	0.31	9.54e-11	Skin colour saturation;
LUAD	cis	rs922182	0.763	rs1380841	chr15:64261912	T/C	cg02919090	chr15:64263738	DAPK2	0.34	6.53	0.3	1.89e-10	Blood protein levels;
LUAD	cis	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.33e-10	Ulcerative colitis;
LUAD	trans	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg11693508	chr17:37793320	STARD3	0.69	9.36	0.41	4.91e-19	Bipolar disorder;
LUAD	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg21798802	chr22:38057573	PDXP	-0.49	-10.03	-0.44	2.28e-21	Fat distribution (HIV);
LUAD	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg20135002	chr11:47629003	NA	-0.41	-7.14	-0.33	4.04e-12	Subjective well-being;
LUAD	cis	rs7127900	0.583	rs11043147	chr11:2234169	C/G	cg25635251	chr11:2234043	NA	1.05	22.12	0.73	1.33e-72	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
LUAD	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03517284	chr6:25882590	NA	-0.58	-8.51	-0.38	2.95e-16	Intelligence (multi-trait analysis);
LUAD	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg03929089	chr4:120376271	NA	0.82	14.92	0.59	9.97e-41	Coronary artery disease;
LUAD	cis	rs113835537	0.529	rs60358007	chr11:66222353	G/A	cg24851651	chr11:66362959	CCS	0.61	10.58	0.46	2.33e-23	Airway imaging phenotypes;
LUAD	trans	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg27211696	chr2:191398769	TMEM194B	0.77	16.48	0.63	1.78e-47	Pulse pressure;
LUAD	cis	rs4280164	0.945	rs2224122	chr14:24783414	G/C	cg07162820	chr14:24837146	NFATC4	0.35	6.55	0.3	1.63e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg09873201	chr16:3507582	NAT15	-0.51	-8.3	-0.37	1.38e-15	Tuberculosis;
LUAD	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.27	-6.54	-0.3	1.76e-10	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	2.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11048434	0.636	rs7306165	chr12:9059081	T/C	cg23795048	chr12:9217529	LOC144571	0.41	7.43	0.34	6.06e-13	Sjögren's syndrome;
LUAD	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg15445000	chr17:37608096	MED1	0.44	8.0	0.36	1.22e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs11048434	0.698	rs1805784	chr12:9065172	G/T	cg23795048	chr12:9217529	LOC144571	0.41	7.22	0.33	2.36e-12	Sjögren's syndrome;
LUAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg04455712	chr21:45112962	RRP1B	0.41	8.27	0.37	1.7e-15	Mean corpuscular volume;
LUAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg16606324	chr3:10149918	C3orf24	0.63	10.17	0.44	7.09e-22	Alzheimer's disease;
LUAD	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg05082376	chr22:42548792	NA	-0.49	-9.02	-0.4	6.63e-18	Schizophrenia;
LUAD	cis	rs77741769	0.571	rs989986	chr12:121274178	A/C	cg02419362	chr12:121203948	SPPL3	0.41	8.31	0.37	1.33e-15	Mean corpuscular volume;
LUAD	cis	rs2046867	0.908	rs4677206	chr3:72780052	A/T	cg04365224	chr3:72788183	NA	0.42	6.48	0.3	2.57e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg26513180	chr16:89883248	FANCA	0.66	12.17	0.51	2.01e-29	Vitiligo;
LUAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg13047869	chr3:10149882	C3orf24	0.67	10.02	0.44	2.37e-21	Alzheimer's disease;
LUAD	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg10755058	chr3:40428713	ENTPD3	0.46	8.28	0.37	1.64e-15	Renal cell carcinoma;
LUAD	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg17177755	chr1:15930204	NA	0.45	7.26	0.33	1.92e-12	Systolic blood pressure;
LUAD	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23583168	chr7:148888333	NA	-0.91	-18.26	-0.66	2.27e-55	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs13064411	0.696	rs6808394	chr3:113122524	T/G	cg18753928	chr3:113234510	CCDC52	-0.72	-11.66	-0.49	2.03e-27	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg05434287	chr7:2030229	MAD1L1	0.42	6.91	0.32	1.81e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg14008862	chr17:28927542	LRRC37B2	0.66	6.41	0.3	3.86e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7000551	0.689	rs6984908	chr8:22316901	A/G	cg12081754	chr8:22256438	SLC39A14	-0.42	-6.87	-0.32	2.29e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs1692580	0.807	rs12138597	chr1:2189477	T/C	cg24578937	chr1:2090814	PRKCZ	0.54	10.58	0.46	2.37e-23	Coronary artery disease;
LUAD	cis	rs68170813	0.522	rs12154818	chr7:107074515	G/C	cg23024343	chr7:107201750	COG5	0.44	6.42	0.3	3.7e-10	Coronary artery disease;
LUAD	cis	rs877282	1.000	rs12219807	chr10:772870	A/C	cg17470449	chr10:769945	NA	0.68	10.67	0.46	1.06e-23	Uric acid levels;
LUAD	cis	rs7582720	0.561	rs114407963	chr2:204154677	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.02	0.4	6.6e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs4698036	0.601	rs4698050	chr4:10410748	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-7.44	-0.34	5.52e-13	Cardiovascular disease risk factors;
LUAD	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg05368731	chr17:41323189	NBR1	0.95	19.46	0.69	1.02e-60	Menopause (age at onset);
LUAD	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg01868782	chr6:126071099	HEY2	-0.32	-6.52	-0.3	2.02e-10	Brugada syndrome;
LUAD	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg04398451	chr17:18023971	MYO15A	0.62	10.47	0.45	5.76e-23	Total body bone mineral density;
LUAD	cis	rs9309473	0.687	rs6706235	chr2:73613558	C/G	cg20560298	chr2:73613845	ALMS1	-0.45	-7.06	-0.32	6.83e-12	Metabolite levels;
LUAD	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg07538946	chr5:131705188	SLC22A5	-0.39	-6.5	-0.3	2.25e-10	Breast cancer;
LUAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg08132940	chr7:1081526	C7orf50	-0.76	-10.26	-0.45	3.25e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg26384229	chr12:38710491	ALG10B	0.48	7.78	0.35	5.55e-14	Bladder cancer;
LUAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg11062466	chr8:58055876	NA	0.67	9.01	0.4	7.2e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.42	-0.42	2.85e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg07606381	chr6:8435919	SLC35B3	-0.44	-7.4	-0.34	7.57e-13	Motion sickness;
LUAD	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg02176678	chr2:219576539	TTLL4	-0.83	-17.6	-0.65	2.12e-52	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg09365446	chr1:150670422	GOLPH3L	0.63	11.12	0.48	2.34e-25	Melanoma;
LUAD	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg15181151	chr6:150070149	PCMT1	0.38	7.02	0.32	8.9e-12	Lung cancer;
LUAD	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg06784218	chr1:46089804	CCDC17	0.6	13.55	0.55	5.61e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07044724	chr16:30406465	ZNF48	-0.44	-6.99	-0.32	1.1e-11	Height;
LUAD	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03517284	chr6:25882590	NA	-1.03	-18.67	-0.67	3.43e-57	Urate levels;
LUAD	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg20891283	chr12:69753455	YEATS4	0.43	7.05	0.32	7.21e-12	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs9649213	0.586	rs55648546	chr7:97960800	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.74	-11.0	-0.47	6.15e-25	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg07952391	chr2:88470173	THNSL2	-0.41	-6.64	-0.31	9.83e-11	Response to metformin (IC50);
LUAD	cis	rs6066835	1.000	rs6122720	chr20:47351095	G/A	cg18078177	chr20:47281410	PREX1	0.7	6.58	0.3	1.37e-10	Multiple myeloma;
LUAD	cis	rs7665090	1.000	rs7665659	chr4:103551818	C/T	cg07973026	chr4:103553119	MANBA	0.48	8.53	0.38	2.63e-16	Primary biliary cholangitis;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg00306198	chr8:109455451	TTC35	-0.4	-6.72	-0.31	5.81e-11	Subcortical brain region volumes;
LUAD	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.54	7.61	0.35	1.75e-13	Platelet count;
LUAD	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg25894440	chr7:65020034	NA	-0.64	-7.55	-0.34	2.72e-13	Diabetic kidney disease;
LUAD	cis	rs9560113	1.000	rs9560105	chr13:112175363	A/T	cg14154082	chr13:112174009	NA	-0.39	-7.33	-0.34	1.2e-12	Menarche (age at onset);
LUAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg18402987	chr7:1209562	NA	0.8	9.85	0.43	9.51e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg25797454	chr6:150327115	RAET1K	0.33	7.23	0.33	2.25e-12	Alopecia areata;
LUAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg24829409	chr8:58192753	C8orf71	-0.61	-9.22	-0.41	1.37e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26314531	chr2:26401878	FAM59B	-0.7	-9.81	-0.43	1.33e-20	Gut microbiome composition (summer);
LUAD	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg18016565	chr1:150552671	MCL1	0.41	7.5	0.34	3.86e-13	Tonsillectomy;
LUAD	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg02018176	chr4:1364513	KIAA1530	0.57	10.68	0.46	1.02e-23	Longevity;
LUAD	cis	rs1003719	0.715	rs1981433	chr21:38542223	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.43	-0.38	5.44e-16	Eye color traits;
LUAD	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg20119798	chr7:94954144	PON1	-0.48	-6.77	-0.31	4.36e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2686555	0.649	rs503667	chr12:121088750	A/G	cg13504434	chr12:121088311	CABP1	0.37	6.43	0.3	3.36e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg07153921	chr17:41440717	NA	-0.42	-7.12	-0.33	4.81e-12	Menopause (age at onset);
LUAD	trans	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.96	-0.32	1.33e-11	Mood instability;
LUAD	cis	rs1448094	0.842	rs10863155	chr12:86446416	T/C	cg02569458	chr12:86230093	RASSF9	-0.37	-7.12	-0.33	4.69e-12	Major depressive disorder;
LUAD	cis	rs11671005	0.735	rs56292587	chr19:58919066	A/T	cg13877915	chr19:58951672	ZNF132	0.55	7.27	0.33	1.75e-12	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	6.46	0.3	2.89e-10	Schizophrenia;
LUAD	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg19622623	chr12:86230825	RASSF9	-0.37	-6.67	-0.31	8.13e-11	Major depressive disorder;
LUAD	cis	rs11958404	0.789	rs72818150	chr5:157484121	A/G	cg05962755	chr5:157440814	NA	0.65	8.75	0.39	4.95e-17	IgG glycosylation;
LUAD	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg02018176	chr4:1364513	KIAA1530	0.37	6.44	0.3	3.21e-10	Obesity-related traits;
LUAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg13397359	chr6:42928475	GNMT	0.6	11.48	0.49	9.58e-27	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg17971929	chr21:40555470	PSMG1	0.54	8.59	0.39	1.68e-16	Cognitive function;
LUAD	trans	rs2797160	1.000	rs1777222	chr6:126021030	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.54	8.82	0.39	3e-17	Endometrial cancer;
LUAD	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.25	-0.33	2.03e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg00933542	chr6:150070202	PCMT1	0.46	10.35	0.45	1.63e-22	Lung cancer;
LUAD	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg09491104	chr22:46646882	C22orf40	-0.63	-10.55	-0.46	2.94e-23	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21582582	chr3:182698605	DCUN1D1	0.6	9.74	0.43	2.35e-20	Resting heart rate;
LUAD	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg00933542	chr6:150070202	PCMT1	0.43	9.24	0.41	1.26e-18	Lung cancer;
LUAD	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg15017067	chr4:17643749	FAM184B	0.36	6.89	0.32	2.08e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7027203	1.000	rs13288708	chr9:96509653	T/C	cg14598338	chr9:96623480	NA	0.38	7.65	0.35	1.33e-13	DNA methylation (variation);
LUAD	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06022373	chr22:39101656	GTPBP1	0.42	6.53	0.3	1.92e-10	Menopause (age at onset);
LUAD	trans	rs1493916	0.837	rs11876492	chr18:31413804	T/C	cg15819921	chr19:927150	ARID3A	-0.43	-7.15	-0.33	3.95e-12	Life satisfaction;
LUAD	cis	rs9535307	0.860	rs1127021	chr13:50296115	C/T	cg04663916	chr13:50265991	EBPL	0.58	6.89	0.32	2.03e-11	Obesity-related traits;
LUAD	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg02951883	chr7:2050386	MAD1L1	-0.71	-12.45	-0.52	1.57e-30	Schizophrenia;
LUAD	cis	rs10540	0.584	rs10751658	chr11:437401	C/G	cg08200582	chr11:442649	ANO9	0.58	8.09	0.37	6.25e-15	Body mass index;
LUAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg04025307	chr7:1156635	C7orf50	0.71	12.79	0.53	6.72e-32	Longevity;Endometriosis;
LUAD	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg20587970	chr11:113659929	NA	-1.38	-20.92	-0.71	3.05e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg24558204	chr6:135376177	HBS1L	0.45	8.37	0.38	8.58e-16	Red blood cell count;
LUAD	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg05754148	chr16:3507555	NAT15	-0.42	-6.44	-0.3	3.17e-10	Body mass index (adult);
LUAD	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.62	-11.89	-0.5	2.56e-28	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs853679	0.607	rs35749575	chr6:28114818	G/T	cg12623302	chr6:28058802	ZSCAN12L1	0.56	6.53	0.3	1.91e-10	Depression;
LUAD	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg27490568	chr2:178487706	NA	-0.4	-6.72	-0.31	5.8200000000000003e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg00666640	chr1:248458726	OR2T12	0.29	7.04	0.32	7.71e-12	Common traits (Other);
LUAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	trans	rs75804782	0.641	rs72983861	chr2:239326126	G/A	cg01134436	chr17:81009848	B3GNTL1	0.79	8.32	0.38	1.21e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03647317	chr4:187891568	NA	-0.37	-6.99	-0.32	1.05e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg16049864	chr8:95962084	TP53INP1	-0.51	-10.73	-0.46	6.56e-24	Type 2 diabetes;
LUAD	cis	rs7582720	1.000	rs72936846	chr2:203774734	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg12310025	chr6:25882481	NA	-0.5	-7.47	-0.34	4.6e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs2544390	1.000	rs2673172	chr2:170204800	A/C	cg15382669	chr21:34697036	IFNAR1	-0.37	-6.36	-0.3	5.17e-10	Urate levels;
LUAD	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.6	-0.35	1.96e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.61	0.31	1.15e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg18827107	chr12:86230957	RASSF9	-0.62	-11.0	-0.47	6.1e-25	Major depressive disorder;
LUAD	cis	rs9473147	0.516	rs7754971	chr6:47590476	C/T	cg12968598	chr6:47444699	CD2AP	0.35	6.38	0.3	4.65e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg07404485	chr7:94953653	PON1	-0.49	-7.08	-0.33	6.01e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9392556	0.765	rs613709	chr6:4120683	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.42	-7.28	-0.33	1.63e-12	Blood metabolite levels;
LUAD	cis	rs8017423	0.967	rs7151776	chr14:90724803	A/G	cg14092571	chr14:90743983	NA	-0.48	-8.39	-0.38	7.54e-16	Mortality in heart failure;
LUAD	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg18621852	chr3:10150065	C3orf24	0.5	9.06	0.4	5.05e-18	Alzheimer's disease;
LUAD	trans	rs564343	0.563	rs493320	chr11:65832367	C/A	cg26701943	chr11:108369231	KDELC2	-0.51	-8.22	-0.37	2.51e-15	Obesity (early onset extreme);
LUAD	trans	rs877282	0.898	rs11253344	chr10:765162	C/T	cg22713356	chr15:30763199	NA	1.27	17.4	0.65	1.56e-51	Uric acid levels;
LUAD	cis	rs9392556	0.600	rs661404	chr6:4126097	C/T	cg10424681	chr6:4079350	C6orf201;C6orf146	0.28	7.03	0.32	8.32e-12	Blood metabolite levels;
LUAD	cis	rs250585	1.000	rs426674	chr16:23460152	C/T	cg00143387	chr16:23521605	GGA2	0.67	7.96	0.36	1.57e-14	Egg allergy;
LUAD	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg23992470	chr4:843637	GAK	0.7	7.52	0.34	3.27e-13	Parkinson's disease;
LUAD	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.63	-11.77	-0.5	7.2e-28	Prudent dietary pattern;
LUAD	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg08885076	chr2:99613938	TSGA10	0.4	7.55	0.34	2.78e-13	Chronic sinus infection;
LUAD	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg23598886	chr18:12777645	NA	0.63	7.93	0.36	2.03e-14	Inflammatory skin disease;
LUAD	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg02527881	chr3:46936655	PTH1R	0.68	15.09	0.59	1.82e-41	Birth weight;
LUAD	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26314531	chr2:26401878	FAM59B	-0.55	-7.71	-0.35	9.38e-14	Gut microbiome composition (summer);
LUAD	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg21138405	chr5:131827807	IRF1	0.6	13.77	0.56	6.51e-36	Asthma (sex interaction);
LUAD	cis	rs7647973	1.000	rs11130189	chr3:49347357	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.49	0.38	3.45e-16	Menarche (age at onset);
LUAD	cis	rs497273	0.511	rs1151862	chr12:121331285	G/A	cg02419362	chr12:121203948	SPPL3	-0.38	-7.68	-0.35	1.14e-13	Systemic lupus erythematosus;
LUAD	cis	rs877282	0.898	rs2004478	chr10:770709	C/A	cg06581033	chr10:766294	NA	-0.56	-7.65	-0.35	1.35e-13	Uric acid levels;
LUAD	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg18351406	chr4:77819688	ANKRD56	0.62	10.0	0.44	2.87e-21	Emphysema distribution in smoking;
LUAD	cis	rs354225	0.544	rs10208225	chr2:54806049	G/A	cg26097391	chr2:54893211	SPTBN1	0.42	6.43	0.3	3.48e-10	Schizophrenia;
LUAD	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg06641503	chr3:48959341	ARIH2	-0.4	-7.74	-0.35	7.29e-14	Parkinson's disease;
LUAD	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06544989	chr22:39130855	UNC84B	0.44	8.88	0.4	1.86e-17	Menopause (age at onset);
LUAD	cis	rs12200560	0.505	rs1334318	chr6:97079610	A/G	cg06623918	chr6:96969491	KIAA0776	-0.45	-6.98	-0.32	1.13e-11	Coronary heart disease;
LUAD	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.36	-6.58	-0.3	1.43e-10	Caffeine consumption;
LUAD	cis	rs7731657	0.537	rs973901	chr5:130362623	G/T	cg08523029	chr5:130500466	HINT1	-0.59	-7.61	-0.35	1.84e-13	Fasting plasma glucose;
LUAD	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg14895029	chr7:2775587	GNA12	-0.42	-6.81	-0.31	3.39e-11	Height;
LUAD	cis	rs2070677	0.935	rs12261048	chr10:135407923	A/G	cg20169779	chr10:135381914	SYCE1	-0.52	-8.36	-0.38	9.37e-16	Gout;
LUAD	cis	rs6458375	1.000	rs6458375	chr6:44202352	C/T	cg04609694	chr6:44204009	NA	0.52	8.57	0.38	1.94e-16	Interleukin-10 levels;
LUAD	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg10356904	chr22:49881777	NA	-0.41	-8.06	-0.36	8e-15	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs1232027	0.656	rs1677630	chr5:79983108	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.42	-6.5	-0.3	2.27e-10	Huntington's disease progression;
LUAD	cis	rs7587476	0.822	rs6726763	chr2:215681580	T/G	cg04004882	chr2:215674386	BARD1	0.51	6.46	0.3	2.97e-10	Neuroblastoma;
LUAD	cis	rs7252981	0.632	rs8101679	chr19:19733877	T/C	cg11584989	chr19:19387371	SF4	-0.49	-7.94	-0.36	1.84e-14	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg05313129	chr8:58192883	C8orf71	-0.5	-7.57	-0.35	2.42e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs6669119	0.668	rs79187116	chr1:19091297	G/A	cg19637330	chr1:19110922	NA	0.61	7.11	0.33	5.06e-12	Percentage gas trapping;
LUAD	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg02527881	chr3:46936655	PTH1R	0.51	10.13	0.44	9.48e-22	Colorectal cancer;
LUAD	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg20503657	chr10:835505	NA	0.93	14.24	0.57	7.46e-38	Eosinophil percentage of granulocytes;
LUAD	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.49	-8.62	-0.39	1.39e-16	Menarche (age at onset);
LUAD	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg03433033	chr1:76189801	ACADM	-0.45	-6.6	-0.31	1.24e-10	Daytime sleep phenotypes;
LUAD	cis	rs877282	1.000	rs71491304	chr10:772982	C/T	cg06581033	chr10:766294	NA	-0.48	-6.77	-0.31	4.2e-11	Uric acid levels;
LUAD	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg13385794	chr1:248469461	NA	0.25	6.95	0.32	1.35e-11	Common traits (Other);
LUAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg00280220	chr17:61926910	NA	0.36	7.03	0.32	8.58e-12	Prudent dietary pattern;
LUAD	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.76	-0.31	4.56e-11	Breast cancer;
LUAD	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg22166914	chr1:53195759	ZYG11B	-0.45	-7.56	-0.34	2.55e-13	Monocyte count;
LUAD	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg02734326	chr4:10020555	SLC2A9	-0.56	-9.7	-0.43	3.09e-20	Bone mineral density;
LUAD	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07343612	chr16:622815	PIGQ	-0.82	-16.35	-0.62	6.12e-47	Height;
LUAD	cis	rs870825	0.550	rs28525282	chr4:185631468	T/C	cg04058563	chr4:185651563	MLF1IP	0.9	14.37	0.57	2.08e-38	Blood protein levels;
LUAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.05	0.54	6.1e-33	Prudent dietary pattern;
LUAD	trans	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg00953403	chr17:74099816	EXOC7	-0.47	-6.97	-0.32	1.23e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg03354898	chr7:1950403	MAD1L1	-0.45	-8.52	-0.38	2.74e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.27	-0.33	1.78e-12	Total cholesterol levels;
LUAD	cis	rs13088645	0.532	rs9835166	chr3:134166224	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	8.62	0.39	1.37e-16	Coronary artery disease;
LUAD	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg26769984	chr7:1090371	C7orf50	0.64	9.15	0.41	2.37e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs3789045	0.560	rs3747634	chr1:204411063	C/T	cg17419461	chr1:204415978	PIK3C2B	0.55	8.93	0.4	1.33e-17	Educational attainment (college completion);
LUAD	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg09365446	chr1:150670422	GOLPH3L	0.59	10.39	0.45	1.11e-22	Melanoma;
LUAD	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg15383120	chr6:291909	DUSP22	-0.45	-7.46	-0.34	4.82e-13	Menopause (age at onset);
LUAD	cis	rs7020830	0.867	rs55845273	chr9:37362219	C/T	cg14294708	chr9:37120828	ZCCHC7	0.88	17.82	0.65	2.14e-53	Schizophrenia;
LUAD	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg26022315	chr17:47021804	SNF8	0.4	7.1	0.33	5.31e-12	Type 2 diabetes;
LUAD	cis	rs7094131	0.549	rs10219113	chr10:22875788	T/C	cg19500236	chr10:22911537	PIP4K2A	0.39	7.11	0.33	5.11e-12	Obesity-related traits;
LUAD	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg19436804	chr8:8560866	CLDN23	0.42	6.41	0.3	3.88e-10	Obesity-related traits;
LUAD	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg23758822	chr17:41437982	NA	0.99	19.91	0.7	9.89e-63	Menopause (age at onset);
LUAD	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg02734326	chr4:10020555	SLC2A9	-0.5	-8.82	-0.39	2.99e-17	Bone mineral density;
LUAD	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.35e-11	Breast cancer;
LUAD	cis	rs2734839	0.964	rs7131440	chr11:113299910	A/G	cg14159747	chr11:113255604	NA	-0.52	-9.76	-0.43	1.92e-20	Information processing speed;
LUAD	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg14779329	chr11:130786720	SNX19	0.37	6.48	0.3	2.53e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.11	-0.51	3.58e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg13385794	chr1:248469461	NA	0.26	7.12	0.33	4.74e-12	Common traits (Other);
LUAD	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg09365446	chr1:150670422	GOLPH3L	-0.4	-6.45	-0.3	3.01e-10	Tonsillectomy;
LUAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg03188948	chr7:1209495	NA	0.65	9.31	0.41	6.88e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Hypertriglyceridemia;
LUAD	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg16325326	chr1:53192061	ZYG11B	-0.6	-10.84	-0.47	2.6e-24	Monocyte count;
LUAD	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.53	-0.3	1.87e-10	Total body bone mineral density;
LUAD	cis	rs11811982	0.793	rs11803651	chr1:227471650	C/G	cg24860534	chr1:227506868	CDC42BPA	0.63	7.11	0.33	4.92e-12	Optic disc area;
LUAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg13560548	chr3:10150139	C3orf24	0.43	6.43	0.3	3.54e-10	Alzheimer's disease;
LUAD	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg10356904	chr22:49881777	NA	-0.42	-9.16	-0.41	2.18e-18	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg15448220	chr1:150897856	SETDB1	-0.42	-6.72	-0.31	5.74e-11	Urate levels;
LUAD	cis	rs8067545	0.616	rs203470	chr17:19858626	C/T	cg04132472	chr17:19861366	AKAP10	0.4	9.33	0.41	5.84e-19	Schizophrenia;
LUAD	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg17971929	chr21:40555470	PSMG1	-0.4	-6.47	-0.3	2.75e-10	Cognitive function;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg01222684	chr5:159435961	TTC1	-0.4	-6.92	-0.32	1.65e-11	Subcortical brain region volumes;
LUAD	cis	rs367615	0.959	rs4957830	chr5:108911758	G/T	cg17395555	chr5:108820864	NA	0.45	7.62	0.35	1.72e-13	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg05966235	chr16:28915196	ATP2A1	0.47	7.71	0.35	8.82e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.72	-0.61	3.57e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg06558623	chr16:89946397	TCF25	1.12	9.76	0.43	2.05e-20	Skin colour saturation;
LUAD	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg10792982	chr14:105748885	BRF1	0.47	9.75	0.43	2.06e-20	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg18944383	chr4:111397179	ENPEP	-0.35	-6.51	-0.3	2.15e-10	Coronary artery disease;
LUAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg20607798	chr8:58055168	NA	0.58	7.41	0.34	6.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs754466	0.606	rs3740250	chr10:79580101	C/T	cg17075019	chr10:79541650	NA	-0.92	-19.68	-0.69	1.12e-61	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10504737	chr1:27226971	GPATCH3	-0.41	-6.37	-0.3	5.01e-10	Height;
LUAD	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg11502198	chr6:26597334	ABT1	0.56	9.43	0.42	2.82e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg19678392	chr7:94953810	PON1	-0.59	-8.27	-0.37	1.72e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg08508325	chr11:3079039	CARS	0.44	9.08	0.4	4.28e-18	Calcium levels;
LUAD	cis	rs10141207	0.531	rs1547213	chr14:32678646	C/A	cg23627301	chr14:32673368	NA	0.46	8.19	0.37	3.01e-15	Asthma;
LUAD	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.34	6.92	0.32	1.69e-11	Lung cancer in ever smokers;
LUAD	cis	rs7593730	0.945	rs2925762	chr2:161117051	A/C	cg22609984	chr2:161126801	NA	0.46	7.3	0.33	1.47e-12	Type 2 diabetes;
LUAD	trans	rs10411161	0.640	rs7252303	chr19:52389357	G/A	cg22319618	chr22:45562946	NUP50	-0.64	-9.14	-0.41	2.58e-18	Breast cancer;
LUAD	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg13606994	chr1:44402422	ARTN	-0.33	-6.79	-0.31	3.82e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07580707	chr3:14220061	XPC;LSM3	-0.62	-7.55	-0.34	2.62e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs4714291	0.963	rs2475496	chr6:39963850	A/G	cg02267698	chr19:7991119	CTXN1	0.41	6.38	0.3	4.52e-10	Strep throat;
LUAD	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg25985355	chr7:65971099	NA	0.55	6.84	0.32	2.8e-11	Diabetic kidney disease;
LUAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg07507251	chr3:52567010	NT5DC2	-0.46	-9.41	-0.42	3.17e-19	Electroencephalogram traits;
LUAD	cis	rs193541	0.632	rs1903260	chr5:122135188	T/C	cg19077854	chr5:122220652	SNX24	0.37	6.48	0.3	2.53e-10	Glucose homeostasis traits;
LUAD	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg22823121	chr1:150693482	HORMAD1	-0.38	-7.5	-0.34	3.78e-13	Tonsillectomy;
LUAD	cis	rs7107174	0.901	rs866901	chr11:77926309	C/T	cg19901956	chr11:77921274	USP35	-0.54	-6.69	-0.31	7.08e-11	Testicular germ cell tumor;
LUAD	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg12863693	chr15:85201151	NMB	0.37	6.35	0.3	5.57e-10	Schizophrenia;
LUAD	cis	rs9287719	0.649	rs58633964	chr2:10736382	T/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.05	-0.36	8.46e-15	Prostate cancer;
LUAD	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg14847009	chr1:175162515	KIAA0040	-0.38	-10.41	-0.45	9.88e-23	Diastolic blood pressure;
LUAD	cis	rs11190604	1.000	rs28522614	chr10:102323141	T/A	cg07570687	chr10:102243282	WNT8B	0.45	6.78	0.31	4.02e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg26513180	chr16:89883248	FANCA	-0.47	-7.88	-0.36	2.83e-14	Vitiligo;
LUAD	cis	rs10489202	1.000	rs11587594	chr1:167989180	A/T	cg24449463	chr1:168025552	DCAF6	-0.57	-7.21	-0.33	2.65e-12	Schizophrenia;
LUAD	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.33	0.34	1.19e-12	Tonsillectomy;
LUAD	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-8.15	-0.37	4.09e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.23	-0.33	2.32e-12	Blood metabolite levels;
LUAD	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs9905704	0.633	rs2526368	chr17:56470310	G/T	cg19466818	chr17:56409534	MIR142	0.35	7.08	0.33	6.17e-12	Testicular germ cell tumor;
LUAD	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg11189052	chr15:85197271	WDR73	0.61	7.59	0.35	2.06e-13	Schizophrenia;
LUAD	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg19418458	chr7:158789849	NA	-0.63	-11.05	-0.47	4.1e-25	Facial morphology (factor 20);
LUAD	cis	rs2625529	0.590	rs8023703	chr15:72504059	G/A	cg16672083	chr15:72433130	SENP8	0.68	11.86	0.5	3.18e-28	Red blood cell count;
LUAD	trans	rs11700980	0.636	rs77555990	chr21:30229776	C/A	cg14791747	chr16:20752902	THUMPD1	0.6	6.59	0.31	1.3e-10	QRS complex (12-leadsum);
LUAD	cis	rs754466	0.580	rs10824571	chr10:79531931	G/A	cg17075019	chr10:79541650	NA	-0.91	-19.01	-0.68	1.11e-58	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg03929089	chr4:120376271	NA	-0.72	-10.77	-0.46	4.42e-24	Coronary artery disease;
LUAD	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg05579598	chr16:88989069	CBFA2T3	0.33	7.07	0.33	6.24e-12	Social autistic-like traits;
LUAD	cis	rs62400317	0.762	rs12212190	chr6:44926271	T/C	cg20913747	chr6:44695427	NA	-0.44	-6.95	-0.32	1.37e-11	Total body bone mineral density;
LUAD	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.55	0.3	1.71e-10	Lung cancer in ever smokers;
LUAD	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.09	0.33	5.82e-12	Depression;
LUAD	cis	rs12936587	0.564	rs7208561	chr17:17615528	C/T	cg04398451	chr17:18023971	MYO15A	-0.42	-6.86	-0.32	2.45e-11	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08101139	chr19:21579953	ZNF493	-0.57	-6.91	-0.32	1.81e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg23649088	chr2:200775458	C2orf69	-0.59	-8.41	-0.38	6.53e-16	Schizophrenia;
LUAD	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3750082	0.889	rs12154586	chr7:32923371	T/C	cg05721444	chr7:32995514	FKBP9	0.37	6.75	0.31	4.76e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg05373962	chr22:49881684	NA	-0.5	-9.94	-0.44	4.7e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg22532475	chr10:104410764	TRIM8	-0.48	-9.21	-0.41	1.53e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3087591	0.853	rs2953003	chr17:29502731	T/C	cg24425628	chr17:29625626	OMG;NF1	0.41	6.64	0.31	9.62e-11	Hip circumference;
LUAD	cis	rs3791556	0.661	rs3791539	chr2:240102327	C/T	cg03281426	chr2:240109471	HDAC4	0.51	10.01	0.44	2.58e-21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg16099169	chr2:106886729	NA	0.77	12.37	0.52	3.2e-30	Facial morphology (factor 23);
LUAD	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg06263672	chr7:65235340	NA	0.47	6.42	0.3	3.58e-10	Aortic root size;
LUAD	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-6.51	-0.3	2.12e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg07636037	chr3:49044803	WDR6	0.63	12.1	0.51	3.69e-29	Parkinson's disease;
LUAD	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-16.01	-0.61	1.89e-45	Chronic sinus infection;
LUAD	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg19622623	chr12:86230825	RASSF9	-0.55	-9.87	-0.43	7.98e-21	Major depressive disorder;
LUAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.49	-8.32	-0.38	1.21e-15	Renal function-related traits (BUN);
LUAD	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg13511324	chr14:104056883	C14orf153	0.25	6.39	0.3	4.41e-10	Coronary artery disease;
LUAD	cis	rs35995292	1.000	rs3779119	chr7:38942248	C/G	cg19327137	chr7:38886074	VPS41	0.51	8.36	0.38	9.12e-16	Subjective well-being (multi-trait analysis);
LUAD	cis	rs4638749	1.000	rs2219078	chr2:108875198	C/T	cg06795125	chr2:108905320	SULT1C2	-0.4	-6.37	-0.3	4.87e-10	Blood pressure;
LUAD	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	7.5	0.34	3.77e-13	Rheumatoid arthritis;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08984405	chr17:685103	RNMTL1;GLOD4	-0.41	-6.97	-0.32	1.2e-11	Cancer;
LUAD	cis	rs1385374	0.858	rs10847692	chr12:129289679	A/T	cg09035930	chr12:129282057	SLC15A4	-0.65	-6.91	-0.32	1.79e-11	Systemic lupus erythematosus;
LUAD	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg11189052	chr15:85197271	WDR73	0.58	7.31	0.34	1.31e-12	Schizophrenia;
LUAD	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg25838465	chr1:92012736	NA	0.5	7.29	0.33	1.55e-12	Eosinophil percentage of white cells;
LUAD	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg08632164	chr7:65971372	NA	0.55	6.47	0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7189233	0.911	rs8057808	chr16:53520613	G/A	cg04059762	chr16:53544020	NA	-0.39	-6.38	-0.3	4.64e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg08027265	chr7:2291960	NA	-0.43	-7.0	-0.32	1e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg14196790	chr5:131705035	SLC22A5	0.38	6.85	0.32	2.56e-11	Breast cancer;
LUAD	trans	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	1.04e-10	Diabetic kidney disease;
LUAD	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.7	-0.35	1e-13	Bipolar disorder;
LUAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg26516362	chr5:178986906	RUFY1	0.67	12.05	0.51	6.05e-29	Lung cancer;
LUAD	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg03929089	chr4:120376271	NA	-0.99	-20.65	-0.71	4.76e-66	Height;
LUAD	cis	rs7809950	0.817	rs2701679	chr7:107283908	A/G	cg23024343	chr7:107201750	COG5	0.67	11.07	0.47	3.44e-25	Coronary artery disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09077332	chr16:595794	SOLH	0.46	6.88	0.32	2.18e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg15133208	chr4:90757351	SNCA	-0.47	-7.54	-0.34	2.98e-13	Neuroticism;
LUAD	cis	rs73206853	0.764	rs3026425	chr12:110688168	A/G	cg12870014	chr12:110450643	ANKRD13A	0.65	7.52	0.34	3.23e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg14829155	chr15:31115871	NA	0.51	8.89	0.4	1.78e-17	Huntington's disease progression;
LUAD	cis	rs73198271	1.000	rs11784958	chr8:8607781	C/A	cg01851573	chr8:8652454	MFHAS1	0.51	8.22	0.37	2.52e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.99	-0.32	1.05e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg02782426	chr3:40428986	ENTPD3	0.43	9.12	0.41	3.03e-18	Renal cell carcinoma;
LUAD	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg12935359	chr14:103987150	CKB	0.47	7.7	0.35	1e-13	Body mass index;
LUAD	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	8.07	0.37	7.25e-15	Rheumatoid arthritis;
LUAD	trans	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg07211511	chr3:129823064	LOC729375	-0.94	-10.48	-0.45	5.21e-23	Blood pressure (smoking interaction);
LUAD	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg07395648	chr5:131743802	NA	-0.39	-6.77	-0.31	4.23e-11	Breast cancer;
LUAD	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg02733842	chr7:1102375	C7orf50	-0.41	-7.14	-0.33	3.99e-12	Longevity;Endometriosis;
LUAD	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.5	8.43	0.38	5.34e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg07741184	chr6:167504864	NA	0.29	7.03	0.32	8.43e-12	Crohn's disease;
LUAD	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06544989	chr22:39130855	UNC84B	0.44	8.78	0.39	4.04e-17	Menopause (age at onset);
LUAD	cis	rs877282	0.853	rs10904544	chr10:756966	A/G	cg17470449	chr10:769945	NA	0.59	8.05	0.36	8.47e-15	Uric acid levels;
LUAD	cis	rs2952156	1.000	rs4252627	chr17:37868715	C/T	cg00129232	chr17:37814104	STARD3	-0.45	-7.44	-0.34	5.66e-13	Asthma;
LUAD	cis	rs2625529	0.617	rs2957365	chr15:72348106	C/T	cg16672083	chr15:72433130	SENP8	0.65	12.13	0.51	2.81e-29	Red blood cell count;
LUAD	cis	rs4730250	0.669	rs6466160	chr7:106793175	T/A	cg23024343	chr7:107201750	COG5	-0.5	-6.87	-0.32	2.3e-11	Osteoarthritis;
LUAD	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.05	-0.32	7.19e-12	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937890	0.559	rs2597196	chr11:14491601	C/T	cg22961513	chr11:14280813	SPON1	0.36	6.89	0.32	2.09e-11	Mitochondrial DNA levels;
LUAD	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg05872129	chr22:39784769	NA	-0.81	-15.11	-0.59	1.41e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	10.7	0.46	8.45e-24	Height;
LUAD	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg13877915	chr19:58951672	ZNF132	0.72	13.61	0.55	3.09e-35	Uric acid clearance;
LUAD	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg11645453	chr3:52864694	ITIH4	-0.39	-7.62	-0.35	1.73e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg09835421	chr16:68378352	PRMT7	-0.74	-8.48	-0.38	3.69e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg00814883	chr7:100076585	TSC22D4	-0.87	-13.06	-0.54	5.53e-33	Platelet count;
LUAD	cis	rs7289126	0.966	rs2267378	chr22:38630956	G/A	cg17652424	chr22:38574118	PLA2G6	-0.24	-6.87	-0.32	2.3e-11	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.15	-10.13	-0.44	9.92e-22	Acne (severe);
LUAD	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18876405	chr7:65276391	NA	0.54	8.85	0.4	2.36e-17	Aortic root size;
LUAD	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.42	0.38	5.75e-16	Platelet count;
LUAD	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.67	-10.32	-0.45	1.96e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg11645453	chr3:52864694	ITIH4	-0.39	-7.64	-0.35	1.48e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12286929	0.699	rs1048932	chr11:115044850	C/A	cg04055981	chr11:115044050	NA	-0.42	-7.24	-0.33	2.15e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22496380	chr5:211416	CCDC127	-0.94	-13.19	-0.54	1.7e-33	Breast cancer;
LUAD	cis	rs427394	0.802	rs274718	chr5:6720988	G/T	cg10857441	chr5:6722123	POLS	-0.63	-12.47	-0.52	1.25e-30	Menopause (age at onset);
LUAD	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg10295955	chr4:187884368	NA	-1.08	-23.54	-0.75	6.16e-79	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6942407	0.546	rs10228392	chr7:86799673	A/T	cg02420886	chr7:86849541	C7orf23	0.64	7.36	0.34	9.79e-13	Food allergy;
LUAD	cis	rs2302190	0.882	rs8073754	chr17:56618030	C/T	cg25885038	chr17:56607967	SEPT4	-0.52	-8.36	-0.38	9.1e-16	Vitamin D levels;
LUAD	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg00277334	chr10:82204260	NA	-0.57	-9.33	-0.41	5.84e-19	Post bronchodilator FEV1;
LUAD	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21659725	chr3:3221576	CRBN	-0.61	-10.7	-0.46	8.6e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg09455208	chr3:40491958	NA	0.52	11.09	0.47	2.96e-25	Renal cell carcinoma;
LUAD	trans	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg26043149	chr18:55253948	FECH	1.03	18.28	0.66	1.99e-55	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.41	-0.34	6.99e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg07917127	chr4:99064746	C4orf37	0.43	7.04	0.32	7.93e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11031096	0.782	rs2284450	chr11:4149214	A/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.64	-0.35	1.52e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg26354017	chr1:205819088	PM20D1	0.51	8.3	0.37	1.42e-15	Parkinson's disease;
LUAD	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg19875535	chr5:140030758	IK	0.47	7.71	0.35	8.78e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6437061	0.764	rs6437055	chr2:233094365	G/T	ch.2.233013039R	chr2:233304795	NA	-0.39	-6.47	-0.3	2.68e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg25324976	chr17:61989376	CSHL1	-0.34	-6.42	-0.3	3.77e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4843185	0.646	rs35953313	chr16:85710476	T/A	cg26571870	chr16:85723150	GINS2	-0.35	-6.88	-0.32	2.13e-11	Platelet distribution width;
LUAD	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg22823121	chr1:150693482	HORMAD1	0.45	9.17	0.41	2.15e-18	Tonsillectomy;
LUAD	cis	rs7771547	0.723	rs7741888	chr6:36552304	T/C	cg07856975	chr6:36356162	ETV7	0.45	6.39	0.3	4.41e-10	Platelet distribution width;
LUAD	cis	rs11048434	0.636	rs11047953	chr12:9064923	A/C	cg04155231	chr12:9217510	LOC144571	0.37	6.87	0.32	2.28e-11	Sjögren's syndrome;
LUAD	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg21399703	chr1:247681439	NA	0.43	7.77	0.35	5.82e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs17067123	0.539	rs75564322	chr4:180066838	A/G	cg26610307	chr4:180072759	NA	-0.52	-6.75	-0.31	4.86e-11	Response to hepatitis C treatment;
LUAD	cis	rs12681287	0.547	rs9942823	chr8:87509177	A/G	cg27223183	chr8:87520930	FAM82B	-0.71	-10.12	-0.44	1.07e-21	Caudate activity during reward;
LUAD	cis	rs9419702	0.538	rs9419625	chr10:133534954	T/G	cg04492858	chr10:133558786	NA	0.36	6.88	0.32	2.12e-11	Survival in rectal cancer;
LUAD	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg10645314	chr2:3704589	ALLC	0.57	8.83	0.39	2.71e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg08798685	chr6:27730294	NA	-0.58	-6.78	-0.31	4.06e-11	Breast cancer;
LUAD	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg20503657	chr10:835505	NA	-0.45	-6.85	-0.32	2.62e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg24531977	chr5:56204891	C5orf35	0.74	12.06	0.51	5.61e-29	Initial pursuit acceleration;
LUAD	cis	rs7737355	0.947	rs3776004	chr5:130879431	G/C	cg06307176	chr5:131281290	NA	0.53	8.21	0.37	2.78e-15	Life satisfaction;
LUAD	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg14582100	chr15:45693742	SPATA5L1	0.64	12.38	0.52	2.84e-30	Homoarginine levels;
LUAD	cis	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg27411982	chr8:10470053	RP1L1	-0.41	-7.35	-0.34	1.06e-12	Triglycerides;
LUAD	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	9.76	0.43	1.97e-20	Prudent dietary pattern;
LUAD	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg19761014	chr17:28927070	LRRC37B2	0.76	7.8	0.35	4.79e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg23229984	chr5:148520753	ABLIM3	0.49	7.59	0.35	2.01e-13	Breast cancer;
LUAD	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg06740227	chr12:86229804	RASSF9	0.45	7.91	0.36	2.31e-14	Major depressive disorder;
LUAD	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg11502198	chr6:26597334	ABT1	0.66	11.38	0.48	2.33e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs6005807	0.719	rs6005809	chr22:28942227	C/T	cg12565055	chr22:29076175	TTC28	-0.73	-8.61	-0.39	1.5e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg09137382	chr11:130731461	NA	0.42	7.63	0.35	1.62e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21659725	chr3:3221576	CRBN	-0.86	-18.04	-0.66	2.33e-54	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.12	-0.41	3.07e-18	Life satisfaction;
LUAD	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg04842962	chr6:43655489	MRPS18A	0.77	14.79	0.58	3.58e-40	IgG glycosylation;
LUAD	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg27170947	chr2:26402098	FAM59B	-0.62	-8.7	-0.39	7.22e-17	Gut microbiome composition (summer);
LUAD	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg06263672	chr7:65235340	NA	-0.5	-6.62	-0.31	1.06e-10	Aortic root size;
LUAD	trans	rs637571	0.676	rs634534	chr11:65665256	A/G	cg17712092	chr4:129076599	LARP1B	-0.92	-17.75	-0.65	4.54e-53	Eosinophil percentage of white cells;
LUAD	trans	rs7395662	0.963	rs7951432	chr11:48591280	T/A	cg00717180	chr2:96193071	NA	-0.4	-7.54	-0.34	2.98e-13	HDL cholesterol;
LUAD	cis	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg14752069	chr8:11977206	FAM66D	0.29	6.53	0.3	1.91e-10	Neuroticism;
LUAD	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg03733263	chr8:22462867	KIAA1967	0.71	11.29	0.48	5.22e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs2115536	0.640	rs934134	chr15:80168218	T/C	cg11839771	chr15:80205821	ST20	-0.37	-6.65	-0.31	8.96e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2227564	0.649	rs2242258	chr10:75607168	T/C	cg00564723	chr10:75632066	CAMK2G	0.32	6.77	0.31	4.42e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg12863693	chr15:85201151	NMB	0.36	6.51	0.3	2.09e-10	Schizophrenia;
LUAD	cis	rs10489202	1.000	rs17485889	chr1:168018840	G/T	cg24449463	chr1:168025552	DCAF6	-0.58	-7.38	-0.34	8.62e-13	Schizophrenia;
LUAD	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.78	0.35	5.52e-14	Lung cancer;
LUAD	cis	rs59698941	0.550	rs12652469	chr5:132182765	A/G	cg16419906	chr5:132167176	NA	-0.32	-6.41	-0.3	3.83e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs6489785	0.735	rs12825746	chr12:121268033	A/C	cg02419362	chr12:121203948	SPPL3	0.36	7.39	0.34	7.92e-13	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg03806693	chr22:41940476	POLR3H	-0.48	-7.06	-0.32	6.92e-12	Vitiligo;
LUAD	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg24803719	chr17:45855879	NA	-0.35	-7.96	-0.36	1.57e-14	IgG glycosylation;
LUAD	cis	rs6840360	0.571	rs17360371	chr4:152565374	C/T	cg22705602	chr4:152727874	NA	-0.41	-7.06	-0.32	6.97e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs938554	0.744	rs7675964	chr4:9941434	C/T	cg11266682	chr4:10021025	SLC2A9	-0.34	-6.36	-0.3	5.1e-10	Blood metabolite levels;
LUAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg10862848	chr6:42927986	GNMT	-0.32	-9.21	-0.41	1.53e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg22868518	chr11:507468	RNH1	-0.65	-6.39	-0.3	4.5e-10	Body mass index;
LUAD	cis	rs6714710	0.603	rs11692010	chr2:98397301	C/T	cg26665480	chr2:98280029	ACTR1B	0.5	8.16	0.37	3.83e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg04398451	chr17:18023971	MYO15A	-0.75	-13.84	-0.56	3.39e-36	Total body bone mineral density;
LUAD	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg06808227	chr14:105710500	BRF1	-0.42	-6.46	-0.3	2.81e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7180079	1.000	rs62021590	chr15:64521349	A/T	cg08069370	chr15:64387884	SNX1	-0.52	-6.56	-0.3	1.56e-10	Monocyte count;
LUAD	cis	rs735539	0.521	rs9552282	chr13:21365721	C/T	cg27499820	chr13:21296301	IL17D	0.48	7.93	0.36	2.03e-14	Dental caries;
LUAD	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.76	0.31	4.64e-11	Depression;
LUAD	cis	rs9323205	0.798	rs2999392	chr14:51655145	A/G	cg23942311	chr14:51606299	NA	-0.58	-10.19	-0.44	6.05e-22	Cancer;
LUAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg13560548	chr3:10150139	C3orf24	0.39	6.47	0.3	2.71e-10	Alzheimer's disease;
LUAD	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg17971929	chr21:40555470	PSMG1	0.53	8.38	0.38	8.16e-16	Cognitive function;
LUAD	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg23978390	chr7:1156363	C7orf50	0.57	7.63	0.35	1.54e-13	Bronchopulmonary dysplasia;
LUAD	trans	rs7395662	0.889	rs11039972	chr11:48759252	A/G	cg15704280	chr7:45808275	SEPT13	0.43	6.68	0.31	7.36e-11	HDL cholesterol;
LUAD	trans	rs564343	0.688	rs539046	chr11:65843778	A/T	cg26701943	chr11:108369231	KDELC2	-0.48	-7.98	-0.36	1.41e-14	Obesity (early onset extreme);
LUAD	cis	rs13315871	0.929	rs2056120	chr3:58309436	A/T	cg12435725	chr3:58293450	RPP14	-0.73	-8.36	-0.38	9.22e-16	Cholesterol, total;
LUAD	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg22535103	chr8:58192502	C8orf71	-0.65	-9.26	-0.41	1.06e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg27588902	chr6:42928151	GNMT	-0.36	-9.53	-0.42	1.27e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg23109721	chr2:106886537	NA	-0.46	-6.63	-0.31	1.05e-10	Facial morphology (factor 23);
LUAD	cis	rs877282	0.891	rs34652870	chr10:772218	T/C	cg17470449	chr10:769945	NA	0.66	9.52	0.42	1.31e-19	Uric acid levels;
LUAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg09060608	chr5:178986726	RUFY1	0.7	12.53	0.52	7.8e-31	Lung cancer;
LUAD	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11890956	chr21:40555474	PSMG1	0.78	13.8	0.56	5.15e-36	Cognitive function;
LUAD	cis	rs1003719	0.582	rs2835634	chr21:38528270	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.48	-0.38	3.71e-16	Eye color traits;
LUAD	cis	rs17095355	0.605	rs41291880	chr10:111635785	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.69	-0.35	1.03e-13	Biliary atresia;
LUAD	cis	rs10465746	0.780	rs7529293	chr1:84331981	A/G	cg10977910	chr1:84465055	TTLL7	0.6	9.79	0.43	1.59e-20	Obesity-related traits;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03965620	chr10:12238232	CDC123;NUDT5	-0.44	-6.98	-0.32	1.14e-11	Height;
LUAD	cis	rs2274273	0.662	rs4040064	chr14:55678088	G/T	cg04306507	chr14:55594613	LGALS3	0.43	8.02	0.36	1.06e-14	Protein biomarker;
LUAD	cis	rs12791968	0.765	rs12794846	chr11:44998943	C/T	cg11846598	chr11:44996168	LOC221122	0.59	9.01	0.4	7.41e-18	Inhibitory control;
LUAD	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.61	-0.31	1.15e-10	Neuroticism;
LUAD	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg10876282	chr6:28092338	ZSCAN16	0.43	6.58	0.3	1.4e-10	Parkinson's disease;
LUAD	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg07493874	chr5:1342172	CLPTM1L	0.31	6.77	0.31	4.42e-11	Lung cancer;
LUAD	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg13736514	chr6:26305472	NA	-0.43	-7.15	-0.33	3.73e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08207256	chr19:10828848	DNM2;MIR638	-0.52	-6.44	-0.3	3.23e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg06002616	chr8:101225028	SPAG1	-0.38	-7.83	-0.36	3.97e-14	Atrioventricular conduction;
LUAD	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg11707310	chr1:2537719	MMEL1	0.4	8.48	0.38	3.84e-16	Ulcerative colitis;
LUAD	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg06046430	chr4:77819534	ANKRD56	0.55	8.87	0.4	2.12e-17	Emphysema distribution in smoking;
LUAD	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg21699342	chr2:239360505	ASB1	0.54	10.54	0.46	3.21e-23	Multiple system atrophy;
LUAD	cis	rs7512552	0.803	rs9436125	chr1:150487961	C/G	cg15654264	chr1:150340011	RPRD2	0.6	11.4	0.48	2.02e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg18105134	chr13:113819100	PROZ	-0.87	-15.14	-0.59	1.1e-41	Platelet distribution width;
LUAD	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.41	0.3	3.84e-10	Depression;
LUAD	cis	rs1975974	1.000	rs111981054	chr17:21725592	C/G	cg18423549	chr17:21743878	NA	-0.79	-13.97	-0.56	9.92e-37	Psoriasis;
LUAD	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg16701003	chr16:89028210	CBFA2T3	0.53	10.34	0.45	1.7e-22	Social autistic-like traits;
LUAD	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.73	13.06	0.54	5.46e-33	Axial length;
LUAD	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg01868782	chr6:126071099	HEY2	0.31	6.38	0.3	4.65e-10	Brugada syndrome;
LUAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-7.25	-0.33	2.05e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs11989744	0.597	rs11135768	chr8:23573278	A/G	cg03492747	chr16:86543808	FOXF1	0.49	10.57	0.46	2.48e-23	Waist-hip ratio;
LUAD	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg12292205	chr6:26970375	C6orf41	0.38	6.69	0.31	6.97e-11	Schizophrenia;
LUAD	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg08873628	chr1:175162347	KIAA0040	-0.39	-6.77	-0.31	4.42e-11	Alcohol dependence;
LUAD	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg15445000	chr17:37608096	MED1	-0.44	-8.07	-0.37	7.45e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg07917127	chr4:99064746	C4orf37	0.5	8.06	0.37	7.7e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8112211	0.911	rs2286475	chr19:38847431	T/C	cg14299480	chr19:38876666	GGN	-0.45	-7.46	-0.34	4.82e-13	Blood protein levels;
LUAD	cis	rs2658782	0.789	rs2658773	chr11:93126914	A/G	cg15737290	chr11:93063684	CCDC67	0.48	6.78	0.31	4.07e-11	Pulmonary function decline;
LUAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg11494091	chr17:61959527	GH2	0.74	18.58	0.67	9.11e-57	Prudent dietary pattern;
LUAD	cis	rs12474201	0.928	rs12998753	chr2:46938385	A/G	cg09399716	chr2:46890238	NA	-0.36	-6.62	-0.31	1.09e-10	Height;
LUAD	trans	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg14791747	chr16:20752902	THUMPD1	-0.46	-6.87	-0.32	2.35e-11	Pancreatic cancer;
LUAD	cis	rs6908034	0.607	rs34109983	chr6:19808042	G/A	cg02682789	chr6:19804855	NA	0.84	8.71	0.39	6.87e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg10150615	chr22:24372951	LOC391322	-0.52	-8.26	-0.37	1.95e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg02221750	chr19:17393354	ANKLE1	0.76	12.53	0.52	7.85e-31	Systemic lupus erythematosus;
LUAD	cis	rs6854137	0.758	rs10005789	chr4:169740931	A/G	cg20607169	chr4:169750834	PALLD	0.47	8.36	0.38	9.34e-16	Vein graft stenosis in coronary artery bypass grafting;
LUAD	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg07169764	chr2:136633963	MCM6	0.76	8.92	0.4	1.41e-17	Corneal structure;
LUAD	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.03	-0.36	9.93e-15	Diabetic kidney disease;
LUAD	cis	rs4072705	0.617	rs10283445	chr9:127243637	A/G	cg01786973	chr9:127249749	NR5A1	0.3	6.78	0.31	4.06e-11	Menarche (age at onset);
LUAD	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg23803603	chr1:2058230	PRKCZ	0.44	7.02	0.32	8.7e-12	Height;
LUAD	cis	rs7224314	1.000	rs62084077	chr17:65386837	G/A	cg01507342	chr17:65387096	PITPNC1	-0.55	-9.34	-0.41	5.58e-19	Diisocyanate-induced asthma;
LUAD	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.69	-0.35	1.05e-13	Blood metabolite levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg03044510	chr21:27107978	ATP5J;GABPA	-0.41	-6.68	-0.31	7.42e-11	Schizophrenia;
LUAD	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg22482690	chr17:47019901	SNF8	0.45	8.78	0.39	4.19e-17	Type 2 diabetes;
LUAD	cis	rs1403694	0.695	rs3821815	chr3:186434262	A/G	cg12454167	chr3:186435060	KNG1	0.5	10.51	0.46	4.16e-23	Blood protein levels;
LUAD	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg03526776	chr6:41159608	TREML2	0.51	11.32	0.48	3.88e-26	Alzheimer's disease (late onset);
LUAD	cis	rs7177699	0.557	rs7176187	chr15:79121373	A/G	cg15571903	chr15:79123663	NA	0.36	7.39	0.34	8.04e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs1065852	0.510	rs5758666	chr22:42632833	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.39	7.02	0.32	8.63e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg21951975	chr1:209979733	IRF6	0.36	6.56	0.3	1.55e-10	Monobrow;
LUAD	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18876405	chr7:65276391	NA	-0.41	-6.52	-0.3	1.99e-10	Aortic root size;
LUAD	cis	rs1997103	1.000	rs4948012	chr7:55412578	A/C	cg17469321	chr7:55412551	NA	0.66	11.31	0.48	4.49e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs4280164	0.943	rs2516564	chr14:24778643	C/T	cg22990158	chr14:24802150	ADCY4	0.47	6.76	0.31	4.51e-11	Parent of origin effect on language impairment (paternal);
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg13214185	chr14:107219616	NA	0.4	7.02	0.32	8.99e-12	Menopause (age at onset);
LUAD	cis	rs7953508	0.711	rs10492321	chr12:93980088	T/A	cg18151635	chr12:93972918	NA	-0.71	-10.99	-0.47	6.66e-25	Pubertal anthropometrics;
LUAD	cis	rs7432375	0.641	rs835649	chr3:136671890	G/A	cg15507776	chr3:136538369	TMEM22	0.38	6.76	0.31	4.67e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg25797454	chr6:150327115	RAET1K	0.36	7.61	0.35	1.8e-13	Alopecia areata;
LUAD	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg15468180	chr1:107600409	PRMT6	0.39	6.62	0.31	1.07e-10	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg18252515	chr7:66147081	NA	-0.61	-6.75	-0.31	4.99e-11	Diabetic kidney disease;
LUAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg20607798	chr8:58055168	NA	-0.57	-7.21	-0.33	2.67e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs490234	0.576	rs3104554	chr9:128152615	C/T	cg14078157	chr9:128172775	NA	-0.38	-6.93	-0.32	1.61e-11	Mean arterial pressure;
LUAD	cis	rs7481584	1.000	rs3814964	chr11:2999507	G/T	cg11201177	chr11:2961805	NA	0.38	6.46	0.3	2.86e-10	Calcium levels;
LUAD	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg24069376	chr3:38537580	EXOG	0.37	8.39	0.38	7.29e-16	Electrocardiographic conduction measures;
LUAD	cis	rs11585357	0.895	rs72633814	chr1:17626456	T/C	cg08277548	chr1:17600880	PADI3	-0.98	-14.22	-0.57	9.09e-38	Hair shape;
LUAD	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg21385522	chr1:16154831	NA	0.44	6.66	0.31	8.42e-11	Dilated cardiomyopathy;
LUAD	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg02461776	chr11:598696	PHRF1	0.48	6.94	0.32	1.47e-11	Systemic lupus erythematosus;
LUAD	trans	rs9929218	1.000	rs13334471	chr16:68800452	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.69	-0.55	1.48e-35	Colorectal cancer;
LUAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10819733	chr22:24237672	NA	-0.38	-7.13	-0.33	4.38e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12612619	0.732	rs13020526	chr2:27204650	C/T	cg00617064	chr2:27272375	NA	-0.38	-7.5	-0.34	3.68e-13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.44	7.74	0.35	7.53e-14	Tonsillectomy;
LUAD	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg17200465	chr3:40428508	ENTPD3	0.27	6.51	0.3	2.11e-10	Renal cell carcinoma;
LUAD	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg20578329	chr17:80767326	TBCD	-0.64	-7.93	-0.36	1.95e-14	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs7224314	1.000	rs57672368	chr17:65358688	G/C	cg01507342	chr17:65387096	PITPNC1	-0.51	-8.09	-0.37	6.28e-15	Diisocyanate-induced asthma;
LUAD	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg20991723	chr1:152506922	NA	0.32	6.45	0.3	3.12e-10	Hair morphology;
LUAD	cis	rs6445967	0.530	rs12486031	chr3:58409679	G/A	cg23715586	chr3:58305044	RPP14	0.41	6.75	0.31	4.8e-11	Platelet count;
LUAD	cis	rs7216064	0.953	rs11871285	chr17:65840809	G/T	cg08758996	chr17:66097529	LOC651250	0.46	6.98	0.32	1.15e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs4588572	0.643	rs10440686	chr5:77688331	A/G	cg11547950	chr5:77652471	NA	0.74	11.61	0.49	3.05e-27	Triglycerides;
LUAD	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg10792982	chr14:105748885	BRF1	0.45	9.81	0.43	1.35e-20	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs986417	1.000	rs1254270	chr14:60843134	G/T	cg27398547	chr14:60952738	C14orf39	-0.61	-7.3	-0.33	1.43e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.51	-8.56	-0.38	2.11e-16	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg03467027	chr4:99064603	C4orf37	0.45	7.33	0.34	1.16e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg07460842	chr6:66804631	NA	0.96	12.87	0.53	3.14e-32	Exhaled nitric oxide output;
LUAD	trans	rs11227306	0.934	rs10896056	chr11:65587905	A/G	cg17712092	chr4:129076599	LARP1B	0.67	10.38	0.45	1.21e-22	DNA methylation (variation);
LUAD	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg03929089	chr4:120376271	NA	-0.97	-19.76	-0.69	5e-62	Height;
LUAD	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25427524	chr10:38739819	LOC399744	-0.76	-13.67	-0.55	1.66e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.99	17.37	0.65	2.12e-51	IgG glycosylation;
LUAD	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg21775007	chr8:11205619	TDH	0.54	9.75	0.43	2.11e-20	Retinal vascular caliber;
LUAD	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg14343924	chr8:8086146	FLJ10661	0.47	7.42	0.34	6.69e-13	Neuroticism;
LUAD	trans	rs629535	0.814	rs604254	chr8:70059164	A/G	cg21567404	chr3:27674614	NA	1.01	18.56	0.67	1.07e-56	Dupuytren's disease;
LUAD	cis	rs870825	0.616	rs28582728	chr4:185646920	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg04287289	chr16:89883240	FANCA	0.66	11.93	0.5	1.76e-28	Vitiligo;
LUAD	trans	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg07776626	chr8:57350775	NA	-0.6	-9.01	-0.4	7.35e-18	Obesity-related traits;
LUAD	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21659725	chr3:3221576	CRBN	0.52	8.28	0.37	1.67e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg12011299	chr4:100065546	ADH4	-0.76	-14.83	-0.58	2.32e-40	Alcohol dependence;
LUAD	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.64	-0.35	1.47e-13	Bipolar disorder;
LUAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg18402987	chr7:1209562	NA	0.77	9.5	0.42	1.58e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg21770322	chr7:97807741	LMTK2	0.34	8.17	0.37	3.67e-15	Breast cancer;
LUAD	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg04731861	chr2:219085781	ARPC2	-0.24	-7.26	-0.33	1.86e-12	Colorectal cancer;
LUAD	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg12588279	chr6:26043732	HIST1H2BB	0.35	6.37	0.3	4.97e-10	Blood metabolite levels;
LUAD	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg05754148	chr16:3507555	NAT15	-0.68	-11.19	-0.48	1.25e-25	Tuberculosis;
LUAD	cis	rs870825	0.929	rs72689254	chr4:185589941	C/T	cg04058563	chr4:185651563	MLF1IP	0.74	9.42	0.42	2.91e-19	Blood protein levels;
LUAD	cis	rs420259	0.516	rs9927961	chr16:23514525	G/A	cg00143387	chr16:23521605	GGA2	-0.71	-9.75	-0.43	2.23e-20	Bipolar disorder;
LUAD	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg03609598	chr5:56110824	MAP3K1	-0.68	-9.23	-0.41	1.26e-18	Initial pursuit acceleration;
LUAD	cis	rs28655083	0.828	rs9938028	chr16:77127830	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.46	7.82	0.36	4.23e-14	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg05082376	chr22:42548792	NA	-0.4	-7.04	-0.32	7.9e-12	Cognitive function;
LUAD	cis	rs7937890	0.559	rs2597221	chr11:14527075	C/T	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.12e-10	Mitochondrial DNA levels;
LUAD	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg11502198	chr6:26597334	ABT1	0.54	9.08	0.4	4.13e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7681423	0.951	rs13130318	chr4:155538470	T/G	cg20735720	chr4:155535218	FGG	-0.47	-6.71	-0.31	6.11e-11	Fibrinogen;
LUAD	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.98	-0.4	8.67e-18	Total body bone mineral density;
LUAD	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg14169450	chr9:139327907	INPP5E	0.49	9.08	0.4	4.13e-18	Monocyte percentage of white cells;
LUAD	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg15997130	chr1:24165203	NA	0.56	10.0	0.44	2.76e-21	Immature fraction of reticulocytes;
LUAD	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg19875535	chr5:140030758	IK	0.44	7.32	0.34	1.29e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg10578991	chr7:12443926	VWDE	-0.46	-6.48	-0.3	2.63e-10	Coronary artery disease;
LUAD	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg07917127	chr4:99064746	C4orf37	0.5	8.06	0.37	7.69e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16816226	chr3:5228848	EDEM1	-0.41	-6.91	-0.32	1.8e-11	Cancer;
LUAD	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.8	-0.35	4.82e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9399137	0.507	rs7772031	chr6:135259734	G/A	cg24558204	chr6:135376177	HBS1L	-0.39	-6.55	-0.3	1.72e-10	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	9.2	0.41	1.65e-18	Electrocardiographic conduction measures;
LUAD	cis	rs10089	1.000	rs62373701	chr5:127416294	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.22	0.45	4.63e-22	Ileal carcinoids;
LUAD	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg06618935	chr21:46677482	NA	-0.51	-10.35	-0.45	1.55e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg11502198	chr6:26597334	ABT1	0.54	9.08	0.4	4.13e-18	Intelligence (multi-trait analysis);
LUAD	trans	rs10838798	0.523	rs11039543	chr11:48168103	G/A	cg03929089	chr4:120376271	NA	-0.46	-7.04	-0.32	7.82e-12	Height;
LUAD	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg17724175	chr1:150552817	MCL1	0.39	9.27	0.41	9.76e-19	Tonsillectomy;
LUAD	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg09835421	chr16:68378352	PRMT7	-0.91	-9.69	-0.43	3.52e-20	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg07936489	chr17:37558343	FBXL20	0.51	6.89	0.32	2.04e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg21028142	chr17:79581711	NPLOC4	0.37	7.54	0.34	2.95e-13	Eye color traits;
LUAD	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg01874867	chr7:94954059	PON1	-0.49	-6.64	-0.31	9.8e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg01181863	chr3:195395398	SDHAP2	-0.58	-8.82	-0.39	2.99e-17	Pancreatic cancer;
LUAD	cis	rs593982	0.764	rs55796623	chr11:65411714	G/A	cg08755490	chr11:65554678	OVOL1	-1.19	-12.21	-0.51	1.44e-29	Atopic dermatitis;
LUAD	cis	rs6499255	0.951	rs74026882	chr16:69635059	A/G	cg15192750	chr16:69999425	NA	0.53	8.39	0.38	7.44e-16	IgE levels;
LUAD	cis	rs7614311	0.681	rs6809100	chr3:63901180	A/G	cg22134162	chr3:63841271	THOC7	-0.53	-8.78	-0.39	4.13e-17	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs68170813	0.617	rs17486	chr7:107112890	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-8.99	-0.4	8.04e-18	Coronary artery disease;
LUAD	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg01528321	chr10:82214614	TSPAN14	0.65	10.19	0.44	6.12e-22	Post bronchodilator FEV1;
LUAD	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10802521	chr3:52805072	NEK4	-0.62	-11.2	-0.48	1.12e-25	Bipolar disorder;
LUAD	cis	rs796825	0.530	rs4676676	chr3:119987645	C/T	cg21790991	chr3:120137480	FSTL1	-0.47	-8.09	-0.37	6.47e-15	HIV-1 susceptibility;
LUAD	cis	rs1595825	0.891	rs73056859	chr2:198801720	A/G	cg11031976	chr2:198649780	BOLL	-0.47	-6.89	-0.32	1.97e-11	Ulcerative colitis;
LUAD	cis	rs71403859	0.803	rs7203606	chr16:71590511	A/C	cg08717414	chr16:71523259	ZNF19	-0.6	-7.25	-0.33	2.02e-12	Post bronchodilator FEV1;
LUAD	cis	rs317865	0.737	rs73234648	chr4:16193602	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.87	8.45	0.38	4.6e-16	Kidney disease (early stage) in type 1 diabetes;
LUAD	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.53	-0.34	3.18e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18876405	chr7:65276391	NA	-0.45	-7.22	-0.33	2.41e-12	Aortic root size;
LUAD	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg27211696	chr2:191398769	TMEM194B	-0.66	-8.46	-0.38	4.45e-16	Diastolic blood pressure;
LUAD	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg12923728	chr3:195709715	SDHAP1	-0.67	-10.0	-0.44	2.83e-21	Pancreatic cancer;
LUAD	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg05617483	chr15:76483344	C15orf27	0.35	6.39	0.3	4.29e-10	Blood metabolite levels;
LUAD	cis	rs7707921	0.752	rs34981833	chr5:81272732	T/C	cg15871215	chr5:81402204	ATG10	-0.7	-9.86	-0.43	8.87e-21	Breast cancer;
LUAD	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg23281280	chr6:28129359	ZNF389	0.46	6.63	0.31	1.03e-10	Depression;
LUAD	cis	rs9535307	0.696	rs9535305	chr13:50290415	A/T	cg04663916	chr13:50265991	EBPL	0.58	6.82	0.31	3.1e-11	Obesity-related traits;
LUAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg11766577	chr21:47581405	C21orf56	-0.57	-10.4	-0.45	1.02e-22	Testicular germ cell tumor;
LUAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-9.41	-0.42	3.26e-19	Alzheimer's disease;
LUAD	cis	rs2859741	0.967	rs575939	chr1:37513854	T/C	cg09363841	chr1:37513479	NA	-0.37	-9.48	-0.42	1.86e-19	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg00666640	chr1:248458726	OR2T12	0.33	8.11	0.37	5.41e-15	Common traits (Other);
LUAD	cis	rs2041840	0.961	rs6742641	chr2:37531523	G/T	cg25727520	chr2:37576821	QPCT	-0.37	-7.52	-0.34	3.21e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs8060686	0.641	rs7204192	chr16:68039309	A/G	cg27539214	chr16:67997921	SLC12A4	-0.51	-7.11	-0.33	5.12e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8067545	0.750	rs4925080	chr17:19991838	T/A	cg04132472	chr17:19861366	AKAP10	0.29	6.93	0.32	1.59e-11	Schizophrenia;
LUAD	trans	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.69	11.8	0.5	5.42e-28	Mean corpuscular volume;
LUAD	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg23254163	chr1:152506842	NA	0.27	7.34	0.34	1.14e-12	Hair morphology;
LUAD	cis	rs3125734	0.633	rs4979754	chr10:64048959	G/A	cg19640130	chr10:64028056	RTKN2	-0.36	-7.79	-0.35	5.36e-14	Rheumatoid arthritis;
LUAD	cis	rs367943	0.712	rs13188946	chr5:112722855	C/T	cg12552261	chr5:112820674	MCC	0.47	9.21	0.41	1.58e-18	Type 2 diabetes;
LUAD	cis	rs243505	1.000	rs243515	chr7:148426672	A/C	cg09806900	chr7:148480153	CUL1	-0.4	-6.68	-0.31	7.37e-11	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg25324976	chr17:61989376	CSHL1	0.37	7.26	0.33	1.82e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg07636037	chr3:49044803	WDR6	0.35	6.45	0.3	3.01e-10	Resting heart rate;
LUAD	trans	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg14343924	chr8:8086146	FLJ10661	0.48	7.44	0.34	5.59e-13	Neuroticism;
LUAD	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg06627628	chr2:24431161	ITSN2	-0.48	-6.62	-0.31	1.09e-10	Lymphocyte counts;
LUAD	cis	rs2882667	0.898	rs6890272	chr5:138371116	G/A	cg04439458	chr5:138467593	SIL1	-0.39	-7.14	-0.33	4.22e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs55788414	0.932	rs12103303	chr16:81181497	A/G	cg06400318	chr16:81190750	PKD1L2	-0.66	-8.21	-0.37	2.63e-15	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg07460842	chr6:66804631	NA	1.08	16.88	0.63	3.11e-49	Exhaled nitric oxide output;
LUAD	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg13319975	chr6:146136371	FBXO30	0.63	10.85	0.47	2.25e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11229555	0.645	rs7116847	chr11:58178478	C/A	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	5.75e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2235649	0.833	rs4335769	chr16:1849376	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-8.15	-0.37	4.02e-15	Blood metabolite levels;
LUAD	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03647317	chr4:187891568	NA	0.34	6.47	0.3	2.64e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs11039798	1.000	rs12225599	chr11:48755868	T/C	cg15704280	chr7:45808275	SEPT13	0.67	7.84	0.36	3.58e-14	Axial length;
LUAD	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg06618935	chr21:46677482	NA	-0.42	-7.39	-0.34	7.66e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs754466	0.580	rs2579176	chr10:79529350	A/G	cg17075019	chr10:79541650	NA	-0.92	-19.47	-0.69	9.63e-61	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg14917512	chr19:3094685	GNA11	-0.57	-6.65	-0.31	8.96e-11	Diabetic kidney disease;
LUAD	cis	rs7551222	0.716	rs10494852	chr1:204457786	A/G	cg20240347	chr1:204465584	NA	0.35	6.98	0.32	1.18e-11	Schizophrenia;
LUAD	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.4	6.65	0.31	9.03e-11	Total body bone mineral density;
LUAD	cis	rs9653442	1.000	rs11676922	chr2:100806940	T/A	cg22139774	chr2:100720529	AFF3	-0.34	-6.49	-0.3	2.47e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.56	9.27	0.41	9.56e-19	Multiple sclerosis;
LUAD	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg01028140	chr2:1542097	TPO	-0.53	-8.08	-0.37	6.9e-15	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.15	0.33	3.89e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.705	rs11587541	chr1:15899478	T/C	cg24675056	chr1:15929824	NA	0.41	6.54	0.3	1.77e-10	Systolic blood pressure;
LUAD	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg12062639	chr20:23401060	NAPB	1.09	11.27	0.48	6.24e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.68	-11.26	-0.48	6.75e-26	Primary sclerosing cholangitis;
LUAD	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg21475434	chr5:93447410	FAM172A	0.72	8.1	0.37	6.1e-15	Diabetic retinopathy;
LUAD	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg02196655	chr2:10830764	NOL10	-0.46	-8.39	-0.38	7.39e-16	Prostate cancer;
LUAD	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg04851639	chr8:1020857	NA	-0.38	-8.81	-0.39	3.29e-17	Schizophrenia;
LUAD	cis	rs859767	0.887	rs842362	chr2:135341120	C/T	cg12500956	chr2:135428796	TMEM163	0.32	8.34	0.38	1.07e-15	Neuroticism;
LUAD	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg00666640	chr1:248458726	OR2T12	0.33	7.82	0.36	4.29e-14	Common traits (Other);
LUAD	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg22467129	chr15:76604101	ETFA	-0.49	-8.5	-0.38	3.18e-16	Blood metabolite levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11429632	chr9:123964581	RAB14	-0.4	-6.74	-0.31	5.36e-11	Cancer;
LUAD	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.71	0.31	6.29e-11	Parkinson's disease;
LUAD	cis	rs4737010	0.536	rs6474365	chr8:41662940	G/T	cg08923054	chr8:41654455	ANK1	0.4	6.47	0.3	2.64e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4523957	0.620	rs8064309	chr17:2059961	T/C	cg16513277	chr17:2031491	SMG6	-0.96	-18.89	-0.68	3.82e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg00701064	chr4:6280414	WFS1	0.64	13.97	0.56	9.77e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.69	-0.35	1.07e-13	Alzheimer's disease (late onset);
LUAD	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg23985595	chr17:80112537	CCDC57	-0.53	-9.74	-0.43	2.25e-20	Life satisfaction;
LUAD	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg19000871	chr14:103996768	TRMT61A	-0.54	-9.18	-0.41	1.89e-18	Coronary artery disease;
LUAD	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.95	-13.92	-0.56	1.59e-36	Schizophrenia;
LUAD	trans	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg18335740	chr13:41363409	SLC25A15	0.71	13.56	0.55	4.95e-35	Lewy body disease;
LUAD	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg01849466	chr14:104193079	ZFYVE21	0.51	8.33	0.38	1.11e-15	Body mass index;
LUAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-7.76	-0.35	6.65e-14	Tonsillectomy;
LUAD	cis	rs12545109	0.732	rs1973629	chr8:57429583	A/G	cg17761419	chr8:57350749	NA	-0.58	-7.97	-0.36	1.52e-14	Obesity-related traits;
LUAD	cis	rs72634258	0.503	rs697674	chr1:7837878	C/G	cg26816564	chr1:7831052	VAMP3	0.66	9.18	0.41	1.98e-18	Inflammatory bowel disease;
LUAD	cis	rs2425143	1.000	rs79035779	chr20:34343004	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.96	-0.32	1.33e-11	Blood protein levels;
LUAD	cis	rs11696501	0.688	rs6065866	chr20:44323440	G/A	cg11783356	chr20:44313418	WFDC10B	-0.51	-8.34	-0.38	1.09e-15	Brain structure;
LUAD	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg05768032	chr16:30646687	NA	0.44	7.63	0.35	1.5700000000000001e-13	Multiple myeloma;
LUAD	cis	rs2882667	0.858	rs13176497	chr5:138446074	T/C	cg04439458	chr5:138467593	SIL1	-0.55	-9.78	-0.43	1.66e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg11502198	chr6:26597334	ABT1	0.56	9.39	0.42	3.75e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg16205897	chr5:131564050	P4HA2	-0.33	-7.52	-0.34	3.38e-13	Blood metabolite levels;
LUAD	cis	rs7215564	0.730	rs34579757	chr17:78700077	G/A	cg09596252	chr17:78655493	RPTOR	0.68	6.84	0.32	2.85e-11	Myopia (pathological);
LUAD	cis	rs73198271	0.653	rs10099808	chr8:8659873	A/G	cg01851573	chr8:8652454	MFHAS1	-0.45	-8.1	-0.37	6.11e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs5756813	0.635	rs12160750	chr22:38199054	A/G	cg19894588	chr14:64061835	NA	-0.55	-7.76	-0.35	6.61e-14	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg22920501	chr2:26401640	FAM59B	-0.76	-10.88	-0.47	1.74e-24	Gut microbiome composition (summer);
LUAD	cis	rs2274273	0.662	rs4525413	chr14:55661138	A/T	cg04306507	chr14:55594613	LGALS3	0.39	7.32	0.34	1.23e-12	Protein biomarker;
LUAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg12373951	chr3:133503437	NA	-0.36	-7.38	-0.34	8.37e-13	Iron status biomarkers;
LUAD	cis	rs12908161	0.515	rs12907646	chr15:85403496	G/A	cg11189052	chr15:85197271	WDR73	0.57	6.89	0.32	2.06e-11	Schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13834670	chr9:129677390	RALGPS1	-0.54	-6.64	-0.31	9.46e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg01802117	chr1:53393560	SCP2	-0.41	-7.95	-0.36	1.71e-14	Monocyte count;
LUAD	cis	rs7089973	0.872	rs3180654	chr10:116615045	T/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.8	0.43	1.46e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.46e-11	Depression;
LUAD	cis	rs7665090	1.000	rs11724614	chr4:103550248	A/G	cg07973026	chr4:103553119	MANBA	0.47	8.4	0.38	6.94e-16	Primary biliary cholangitis;
LUAD	trans	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg01620082	chr3:125678407	NA	-0.43	-6.62	-0.31	1.08e-10	Parkinson's disease;
LUAD	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.46	-7.71	-0.35	9.21e-14	Schizophrenia;
LUAD	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-11.32	-0.48	3.86e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs76878669	0.515	rs12576299	chr11:66132286	T/C	cg18002602	chr11:66138449	SLC29A2	0.47	10.16	0.44	7.74e-22	Educational attainment (years of education);
LUAD	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg03467027	chr4:99064603	C4orf37	0.39	6.37	0.3	5.05e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg22875332	chr1:76189707	ACADM	0.84	16.87	0.63	3.34e-49	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4356932	1.000	rs4241578	chr4:76944491	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.49	-0.3	2.36e-10	Blood protein levels;
LUAD	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg07606381	chr6:8435919	SLC35B3	0.42	6.88	0.32	2.12e-11	Motion sickness;
LUAD	cis	rs2688608	0.672	rs2688622	chr10:75688981	C/A	cg23231163	chr10:75533350	FUT11	-0.36	-6.5	-0.3	2.25e-10	Inflammatory bowel disease;
LUAD	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg15017067	chr4:17643749	FAM184B	0.36	6.89	0.32	2.08e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs367615	0.506	rs1428932	chr5:108792479	A/G	cg17395555	chr5:108820864	NA	-0.64	-13.78	-0.56	5.92e-36	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.39	-10.09	-0.44	1.4e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs490234	0.966	rs530628	chr9:128325934	C/G	cg14078157	chr9:128172775	NA	-0.39	-7.25	-0.33	2.01e-12	Mean arterial pressure;
LUAD	trans	rs9393777	0.502	rs3823427	chr6:27256346	G/C	cg06606381	chr12:133084897	FBRSL1	-0.5	-6.8	-0.31	3.47e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg01528321	chr10:82214614	TSPAN14	0.65	9.92	0.43	5.22e-21	Post bronchodilator FEV1;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg25433267	chr10:77161647	C10orf41;ZNF503	-0.38	-6.47	-0.3	2.75e-10	Schizophrenia;
LUAD	trans	rs7944735	0.817	rs6485788	chr11:47873883	C/T	cg03929089	chr4:120376271	NA	-0.48	-6.5	-0.3	2.2e-10	Intraocular pressure;
LUAD	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg17757837	chr7:157058334	UBE3C	-0.47	-8.31	-0.37	1.36e-15	Body mass index;
LUAD	cis	rs6005807	0.843	rs9620804	chr22:28919200	G/A	cg12565055	chr22:29076175	TTC28	0.67	6.52	0.3	1.99e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs4953076	0.573	rs7602070	chr2:44388614	G/A	cg04920474	chr2:44395004	PPM1B	0.56	8.56	0.38	2.09e-16	Height;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16458170	chr11:36311174	COMMD9	-0.42	-7.0	-0.32	1.04e-11	Cancer;
LUAD	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg19610905	chr11:61596333	FADS2	0.6	10.31	0.45	2.14e-22	Trans fatty acid levels;
LUAD	cis	rs6547741	0.752	rs7562863	chr2:27892694	T/A	cg27432699	chr2:27873401	GPN1	-0.64	-11.22	-0.48	9.29e-26	Oral cavity cancer;
LUAD	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg07570687	chr10:102243282	WNT8B	0.48	7.28	0.33	1.63e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs113835537	0.529	rs11550299	chr11:66254085	G/T	cg24851651	chr11:66362959	CCS	0.56	9.85	0.43	9.57e-21	Airway imaging phenotypes;
LUAD	cis	rs67311347	0.544	rs12635762	chr3:40332759	C/T	cg09455208	chr3:40491958	NA	-0.47	-10.03	-0.44	2.2e-21	Renal cell carcinoma;
LUAD	cis	rs1595825	0.891	rs60582020	chr2:198520555	A/C	cg10547527	chr2:198650123	BOLL	-0.54	-7.61	-0.35	1.75e-13	Ulcerative colitis;
LUAD	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg26384229	chr12:38710491	ALG10B	0.51	8.04	0.36	8.78e-15	Bladder cancer;
LUAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg13560548	chr3:10150139	C3orf24	0.45	7.33	0.34	1.22e-12	Alzheimer's disease;
LUAD	cis	rs986417	0.748	rs1955700	chr14:61046481	A/G	cg27398547	chr14:60952738	C14orf39	0.52	6.64	0.31	9.65e-11	Gut microbiota (bacterial taxa);
LUAD	cis	rs738322	0.555	rs6001029	chr22:38555193	C/A	cg25457927	chr22:38595422	NA	-0.58	-13.68	-0.55	1.51e-35	Cutaneous nevi;
LUAD	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-6.39	-0.3	4.33e-10	Cognitive test performance;
LUAD	cis	rs9287719	0.601	rs1861299	chr2:10763757	C/G	cg03983476	chr2:10830698	NOL10	-0.39	-6.45	-0.3	2.99e-10	Prostate cancer;
LUAD	cis	rs9875589	0.509	rs1586514	chr3:14050157	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	7.37	0.34	9.23e-13	Ovarian reserve;
LUAD	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg14159672	chr1:205819179	PM20D1	-0.53	-7.91	-0.36	2.33e-14	Menarche (age at onset);
LUAD	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg02493740	chr2:85810744	VAMP5	-0.45	-8.11	-0.37	5.48e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs11229555	0.874	rs11605297	chr11:58296806	G/A	cg15696309	chr11:58395628	NA	-0.72	-10.28	-0.45	2.93e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2286503	0.839	rs2240728	chr7:22852499	C/T	cg06496272	chr7:22895283	SNORD93	-0.39	-6.88	-0.32	2.22e-11	Fibrinogen;
LUAD	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg13319975	chr6:146136371	FBXO30	0.57	9.46	0.42	2.1e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.64	-0.35	1.48e-13	Personality dimensions;
LUAD	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.94e-11	Hepatitis;
LUAD	cis	rs7680126	0.500	rs4697933	chr4:10146493	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-7.62	-0.35	1.7e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	9.19	0.41	1.83e-18	Tonsillectomy;
LUAD	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg16482183	chr6:26056742	HIST1H1C	0.45	6.61	0.31	1.16e-10	Iron status biomarkers;
LUAD	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg22508957	chr16:3507546	NAT15	0.43	6.6	0.31	1.27e-10	Body mass index (adult);
LUAD	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg08999081	chr20:33150536	PIGU	0.62	13.94	0.56	1.28e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs9837602	0.872	rs35154249	chr3:99738230	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	8.5	0.38	3.23e-16	Breast cancer;
LUAD	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg05368731	chr17:41323189	NBR1	0.97	20.33	0.7	1.39e-64	Menopause (age at onset);
LUAD	cis	rs8058578	0.945	rs34480360	chr16:30798689	G/A	cg05768032	chr16:30646687	NA	0.42	7.08	0.33	5.92e-12	Multiple myeloma;
LUAD	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg17177755	chr1:15930204	NA	0.46	7.4	0.34	7.19e-13	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.72	-0.35	8.67e-14	Systolic blood pressure;
LUAD	cis	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg13789015	chr9:136890014	NCRNA00094	0.85	14.31	0.57	3.52e-38	Platelet distribution width;
LUAD	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.33	7.17	0.33	3.37e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs55788414	0.932	rs7185658	chr16:81189336	A/G	cg06400318	chr16:81190750	PKD1L2	-0.75	-9.67	-0.43	4.16e-20	Left ventricular obstructive tract defect (maternal effect);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03495688	chr9:6007586	KIAA2026	-0.46	-7.31	-0.33	1.38e-12	Height;
LUAD	cis	rs503341	0.756	rs10897450	chr11:63593219	G/C	cg04850017	chr11:63683019	RCOR2	0.35	7.8	0.35	4.85e-14	Pulse pressure;
LUAD	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21582582	chr3:182698605	DCUN1D1	0.5	7.38	0.34	8.65e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg04990556	chr1:26633338	UBXN11	-0.39	-6.54	-0.3	1.78e-10	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg21775007	chr8:11205619	TDH	0.38	6.43	0.3	3.42e-10	Mood instability;
LUAD	trans	rs853679	0.607	rs35098436	chr6:28134221	T/C	cg06606381	chr12:133084897	FBRSL1	-1.22	-10.86	-0.47	2.15e-24	Depression;
LUAD	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12286929	0.515	rs6589486	chr11:115084297	T/C	cg04055981	chr11:115044050	NA	0.41	7.27	0.33	1.72e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg05283184	chr6:79620031	NA	-0.57	-11.27	-0.48	6.3e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs9314323	0.692	rs6557914	chr8:26208744	G/C	cg13160058	chr8:26243215	BNIP3L	-0.47	-9.7	-0.43	3.33e-20	Red cell distribution width;
LUAD	cis	rs3925075	0.531	rs9673519	chr16:31347557	T/C	cg10451425	chr16:31478370	ARMC5	0.4	6.38	0.3	4.53e-10	IgA nephropathy;
LUAD	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg01028140	chr2:1542097	TPO	-0.42	-7.14	-0.33	4.2e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg12365402	chr11:9010492	NRIP3	-0.41	-7.24	-0.33	2.12e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg19729930	chr2:74357872	NA	1.04	17.35	0.64	2.48e-51	Gestational age at birth (maternal effect);
LUAD	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg11645453	chr3:52864694	ITIH4	-0.39	-7.61	-0.35	1.75e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6543140	0.964	rs2160200	chr2:103033963	G/T	cg04239558	chr2:103089729	SLC9A4	0.35	7.01	0.32	9.26e-12	Blood protein levels;
LUAD	trans	rs7395662	0.963	rs11039773	chr11:48513931	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.29	-0.33	1.5e-12	HDL cholesterol;
LUAD	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Depression;
LUAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.61	0.31	1.14e-10	Prudent dietary pattern;
LUAD	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg09491104	chr22:46646882	C22orf40	-0.64	-11.68	-0.49	1.68e-27	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs938554	0.501	rs7671266	chr4:10056376	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-8.81	-0.39	3.3e-17	Blood metabolite levels;
LUAD	cis	rs813218	0.523	rs1708167	chr3:99459236	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.43	-7.95	-0.36	1.67e-14	Orofacial clefts;
LUAD	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg11859384	chr17:80120422	CCDC57	-0.49	-8.85	-0.4	2.42e-17	Life satisfaction;
LUAD	cis	rs9309473	0.579	rs6728128	chr2:73595982	T/C	cg20560298	chr2:73613845	ALMS1	-0.44	-6.81	-0.31	3.29e-11	Metabolite levels;
LUAD	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg03878208	chr11:72483293	STARD10	0.46	6.56	0.3	1.61e-10	Type 2 diabetes;
LUAD	cis	rs454510	0.816	rs347904	chr1:120177620	C/T	cg16322792	chr1:120165303	ZNF697	0.46	8.57	0.38	1.95e-16	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08109568	chr15:31115862	NA	-0.6	-10.03	-0.44	2.26e-21	Huntington's disease progression;
LUAD	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg14345882	chr6:26364793	BTN3A2	0.7	7.54	0.34	2.88e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg21775007	chr8:11205619	TDH	-0.49	-9.03	-0.4	5.96e-18	Retinal vascular caliber;
LUAD	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg16647868	chr5:131706066	SLC22A5	0.48	7.67	0.35	1.18e-13	Breast cancer;
LUAD	trans	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs6087990	0.806	rs6141814	chr20:31368960	C/A	cg13636640	chr20:31349939	DNMT3B	0.75	13.63	0.55	2.5e-35	Ulcerative colitis;
LUAD	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg02896835	chr1:92012615	NA	-0.59	-12.04	-0.51	6.65e-29	Breast cancer;
LUAD	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg15900387	chr1:150738905	CTSS	-0.35	-6.37	-0.3	5.09e-10	Melanoma;
LUAD	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg12292205	chr6:26970375	C6orf41	0.39	6.86	0.32	2.42e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg20607798	chr8:58055168	NA	0.68	8.88	0.4	1.87e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg19318889	chr4:1322082	MAEA	0.52	8.64	0.39	1.2e-16	Longevity;
LUAD	cis	rs7937890	0.559	rs2597206	chr11:14477538	A/C	cg06199346	chr11:14280333	SPON1	-0.33	-6.53	-0.3	1.91e-10	Mitochondrial DNA levels;
LUAD	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg00593900	chr19:10206746	ANGPTL6	-0.39	-8.11	-0.37	5.44e-15	Narcolepsy;
LUAD	trans	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg07923666	chr12:49932857	KCNH3	0.51	6.42	0.3	3.65e-10	Resting heart rate;
LUAD	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg15105011	chr4:940614	TMEM175	-0.41	-6.48	-0.3	2.5e-10	Parkinson's disease;
LUAD	cis	rs62458065	1.000	rs10275978	chr7:32466719	G/T	cg20159608	chr7:32802032	NA	-0.48	-6.92	-0.32	1.7e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg16479474	chr6:28041457	NA	0.41	6.98	0.32	1.16e-11	Parkinson's disease;
LUAD	cis	rs225245	0.610	rs321607	chr17:33880584	A/G	cg05299278	chr17:33885742	SLFN14	0.48	10.93	0.47	1.21e-24	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs1215050	0.904	rs9307215	chr4:98813965	A/G	cg05340658	chr4:99064831	C4orf37	0.42	6.81	0.31	3.29e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg11814155	chr7:99998594	ZCWPW1	0.43	7.37	0.34	9.23e-13	Platelet count;
LUAD	cis	rs1232027	0.656	rs1650652	chr5:79965365	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.33	-0.34	1.16e-12	Huntington's disease progression;
LUAD	cis	rs933688	0.532	rs868557	chr5:90550379	G/A	cg00335715	chr5:90575459	NA	-0.44	-6.75	-0.31	4.9e-11	Smoking behavior;
LUAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg20607798	chr8:58055168	NA	0.57	8.07	0.37	7.33e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs62400317	0.859	rs10948205	chr6:45124585	T/C	cg18551225	chr6:44695536	NA	-0.56	-8.78	-0.39	4.2e-17	Total body bone mineral density;
LUAD	trans	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg27411982	chr8:10470053	RP1L1	0.39	6.83	0.32	2.93e-11	Neuroticism;
LUAD	trans	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg04775059	chr7:64541387	NA	0.5	6.8	0.31	3.53e-11	Aortic root size;
LUAD	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18404041	chr3:52824283	ITIH1	-0.61	-12.21	-0.51	1.39e-29	Bipolar disorder;
LUAD	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg20744362	chr22:50050164	C22orf34	0.43	9.34	0.41	5.61e-19	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7107174	0.892	rs4944196	chr11:78008731	G/A	cg02023728	chr11:77925099	USP35	0.49	7.24	0.33	2.14e-12	Testicular germ cell tumor;
LUAD	cis	rs4629710	0.592	rs11154622	chr6:131547578	C/T	cg12606694	chr6:131520996	AKAP7	0.47	6.93	0.32	1.58e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs17095355	0.892	rs1571617	chr10:111732025	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.72	-10.29	-0.45	2.57e-22	Biliary atresia;
LUAD	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	7.18	0.33	3.22e-12	Schizophrenia;
LUAD	cis	rs10788264	0.621	rs9633734	chr10:124057667	T/C	cg09507567	chr10:124027408	NA	0.49	10.54	0.46	3.11e-23	Total body bone mineral density;
LUAD	cis	rs1595825	0.735	rs57603546	chr2:198918524	C/A	cg10547527	chr2:198650123	BOLL	-0.51	-6.93	-0.32	1.57e-11	Ulcerative colitis;
LUAD	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg03929089	chr4:120376271	NA	-0.43	-6.7	-0.31	6.83e-11	HDL cholesterol;
LUAD	cis	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg27411982	chr8:10470053	RP1L1	0.42	8.05	0.36	8.51e-15	Neuroticism;
LUAD	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.96	-0.36	1.63e-14	Personality dimensions;
LUAD	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg03929089	chr4:120376271	NA	-0.82	-14.48	-0.58	7.1e-39	Height;
LUAD	trans	rs4650994	0.593	rs12568310	chr1:178514622	C/T	cg05059571	chr16:84539110	KIAA1609	0.47	7.33	0.34	1.14e-12	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg02221422	chr11:68192511	LRP5	-0.41	-6.65	-0.31	8.89e-11	Total body bone mineral density;
LUAD	cis	rs4523957	0.928	rs8066372	chr17:2180968	A/G	cg16513277	chr17:2031491	SMG6	-0.77	-14.57	-0.58	2.9e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg20203395	chr5:56204925	C5orf35	-0.84	-11.94	-0.5	1.55e-28	Initial pursuit acceleration;
LUAD	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg07636037	chr3:49044803	WDR6	0.63	12.19	0.51	1.67e-29	Parkinson's disease;
LUAD	cis	rs2835872	0.759	rs2835895	chr21:39066353	C/T	cg06728970	chr21:39037746	KCNJ6	-0.41	-7.0	-0.32	1.03e-11	Electroencephalographic traits in alcoholism;
LUAD	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg05665937	chr4:1216051	CTBP1	0.38	6.41	0.3	3.8e-10	Obesity-related traits;
LUAD	cis	rs7607369	0.648	rs7599984	chr2:219656713	T/G	cg02176678	chr2:219576539	TTLL4	-0.7	-14.0	-0.56	7.25e-37	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg02569458	chr12:86230093	RASSF9	0.41	7.47	0.34	4.76e-13	Major depressive disorder;
LUAD	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg22338127	chr1:209979572	IRF6	0.51	6.52	0.3	2.01e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs7107174	1.000	rs2511187	chr11:77985849	T/A	cg19901956	chr11:77921274	USP35	-0.51	-6.48	-0.3	2.58e-10	Testicular germ cell tumor;
LUAD	cis	rs7822232	1.000	rs7822232	chr8:145145687	A/C	cg07195118	chr8:145162905	KIAA1875	-0.64	-6.57	-0.3	1.49e-10	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg20607798	chr8:58055168	NA	0.79	9.76	0.43	1.93e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg26384229	chr12:38710491	ALG10B	0.49	7.93	0.36	1.99e-14	Bladder cancer;
LUAD	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.33	0.34	1.18e-12	Bipolar disorder;
LUAD	cis	rs7584330	0.554	rs74449293	chr2:238426458	G/A	cg14458575	chr2:238380390	NA	0.61	9.85	0.43	9.8e-21	Prostate cancer;
LUAD	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg17971929	chr21:40555470	PSMG1	-0.4	-6.37	-0.3	4.81e-10	Cognitive function;
LUAD	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17152411	0.895	rs7094381	chr10:126585848	G/A	cg07906193	chr10:126599966	NA	0.54	7.65	0.35	1.34e-13	Height;
LUAD	trans	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs593982	1.000	rs56257941	chr11:65505641	C/T	cg08755490	chr11:65554678	OVOL1	-1.35	-16.29	-0.62	1.2e-46	Atopic dermatitis;
LUAD	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg18827107	chr12:86230957	RASSF9	0.54	9.63	0.42	5.64e-20	Major depressive disorder;
LUAD	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.49	0.45	5.05e-23	Post bronchodilator FEV1;
LUAD	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg26818010	chr10:134567672	INPP5A	-0.87	-14.98	-0.59	5.29e-41	Migraine;
LUAD	cis	rs6445967	0.554	rs12629206	chr3:58434380	G/T	cg13750441	chr3:58318267	PXK	-0.31	-6.42	-0.3	3.73e-10	Platelet count;
LUAD	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg23254163	chr1:152506842	NA	0.27	7.5	0.34	3.81e-13	Hair morphology;
LUAD	cis	rs12681287	0.608	rs13270090	chr8:87553297	T/A	cg27223183	chr8:87520930	FAM82B	0.66	9.27	0.41	9.32e-19	Caudate activity during reward;
LUAD	trans	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.2	-0.33	2.83e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg03609598	chr5:56110824	MAP3K1	0.48	7.74	0.35	7.57e-14	Coronary artery disease;
LUAD	cis	rs6543140	0.890	rs61122764	chr2:102999520	A/G	cg04239558	chr2:103089729	SLC9A4	0.33	6.65	0.31	9.13e-11	Blood protein levels;
LUAD	trans	rs877282	0.853	rs12779017	chr10:763619	T/C	cg22713356	chr15:30763199	NA	1.26	17.41	0.65	1.4e-51	Uric acid levels;
LUAD	cis	rs73206853	0.563	rs73194043	chr12:111188782	G/A	cg12870014	chr12:110450643	ANKRD13A	0.57	6.4	0.3	4.11e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs8073060	0.586	rs35542792	chr17:33903886	A/G	cg19694781	chr19:47549865	TMEM160	1.23	19.77	0.69	4.47e-62	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs35883536	0.669	rs1932352	chr1:101161251	G/A	cg06223162	chr1:101003688	GPR88	-0.42	-7.61	-0.35	1.82e-13	Monocyte count;
LUAD	cis	rs13315871	1.000	rs28489489	chr3:58443755	C/A	cg20936604	chr3:58311152	NA	-0.67	-7.05	-0.32	7.39e-12	Cholesterol, total;
LUAD	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg02551604	chr5:131831745	NA	0.64	10.44	0.45	7.53e-23	Asthma (sex interaction);
LUAD	cis	rs7116495	0.786	rs678193	chr11:71770273	A/C	cg07596299	chr11:71824057	C11orf51	-0.79	-6.69	-0.31	7.12e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.27	-0.45	2.97e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4006360	0.579	rs1510075	chr17:39236452	C/T	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.05	0.36	8.39e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26350286	chr8:95652691	ESRP1	-0.39	-6.38	-0.3	4.79e-10	Cancer;
LUAD	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg03354898	chr7:1950403	MAD1L1	-0.37	-7.16	-0.33	3.54e-12	Schizophrenia;
LUAD	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg19622623	chr12:86230825	RASSF9	-0.43	-7.61	-0.35	1.81e-13	Major depressive disorder;
LUAD	cis	rs2637266	0.967	rs4608018	chr10:78376110	T/C	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg26597838	chr10:835615	NA	1.0	15.74	0.61	2.95e-44	Eosinophil percentage of granulocytes;
LUAD	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg17173187	chr15:85201210	NMB	0.47	8.18	0.37	3.36e-15	Schizophrenia;
LUAD	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg07741184	chr6:167504864	NA	0.36	8.12	0.37	5.12e-15	Primary biliary cholangitis;
LUAD	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg11247378	chr22:39784982	NA	-0.61	-9.63	-0.42	5.41e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg07169764	chr2:136633963	MCM6	0.63	7.67	0.35	1.22e-13	Corneal structure;
LUAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-9.12	-0.41	3.17e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7301826	0.627	rs10773823	chr12:131294501	C/T	cg11011512	chr12:131303247	STX2	0.44	7.41	0.34	6.76e-13	Plasma plasminogen activator levels;
LUAD	cis	rs1215050	0.791	rs6813619	chr4:98830768	C/T	cg17366294	chr4:99064904	C4orf37	-0.47	-8.33	-0.38	1.14e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs733175	0.857	rs10018663	chr4:10004797	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	6.72	0.31	5.77e-11	Psychosis and Alzheimer's disease;
LUAD	trans	rs87938	1.000	rs428510	chr3:41138172	G/T	cg11224624	chr8:145049280	PLEC1	0.41	6.73	0.31	5.45e-11	Bone mineral density (hip);
LUAD	cis	rs926938	0.584	rs1286561	chr1:115375428	T/C	cg12756093	chr1:115239321	AMPD1	-0.37	-6.52	-0.3	2e-10	Autism;
LUAD	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg13385794	chr1:248469461	NA	0.25	6.45	0.3	3.09e-10	Common traits (Other);
LUAD	cis	rs68170813	0.559	rs2107319	chr7:106863744	T/C	cg02696742	chr7:106810147	HBP1	-0.76	-10.83	-0.47	2.67e-24	Coronary artery disease;
LUAD	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg23029597	chr12:123009494	RSRC2	-0.51	-7.71	-0.35	8.94e-14	Body mass index;
LUAD	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg02176678	chr2:219576539	TTLL4	0.75	15.16	0.59	8.94e-42	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg19318889	chr4:1322082	MAEA	0.6	10.2	0.44	5.44e-22	Longevity;
LUAD	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.6	-0.49	3.4e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs258892	0.947	rs266436	chr5:72174553	G/A	cg14879065	chr14:104662468	NA	-0.35	-6.39	-0.3	4.45e-10	Small cell lung carcinoma;
LUAD	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg04287289	chr16:89883240	FANCA	0.54	8.17	0.37	3.64e-15	Vitiligo;
LUAD	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.01	0.36	1.15e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg01448562	chr3:133502909	NA	-0.7	-12.68	-0.52	1.96e-31	Iron status biomarkers;
LUAD	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg22823121	chr1:150693482	HORMAD1	0.41	7.88	0.36	2.81e-14	Melanoma;
LUAD	trans	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg24644049	chr4:85504048	CDS1	0.84	7.46	0.34	4.94e-13	Skin colour saturation;
LUAD	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg09904177	chr6:26538194	HMGN4	0.43	7.12	0.33	4.62e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11644478	chr21:40555479	PSMG1	0.7	11.78	0.5	6.5e-28	Cognitive function;
LUAD	cis	rs225245	0.755	rs6505491	chr17:34026335	A/G	cg05299278	chr17:33885742	SLFN14	0.5	11.24	0.48	7.65e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg15181151	chr6:150070149	PCMT1	0.41	8.36	0.38	8.92e-16	Lung cancer;
LUAD	cis	rs1472147	0.696	rs1532222	chr7:128516945	A/C	cg00260937	chr7:128520193	KCP	-0.47	-7.23	-0.33	2.23e-12	Calcium levels;
LUAD	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23583168	chr7:148888333	NA	-1.05	-26.32	-0.79	3.93e-91	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs72928364	1.000	rs67946790	chr3:100688682	T/A	cg10123952	chr3:100791384	NA	0.64	7.47	0.34	4.74e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3820068	0.906	rs72865183	chr1:15795380	C/T	cg13390004	chr1:15929781	NA	0.45	6.85	0.32	2.69e-11	Systolic blood pressure;
LUAD	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg02782426	chr3:40428986	ENTPD3	-0.36	-7.91	-0.36	2.27e-14	Renal cell carcinoma;
LUAD	cis	rs11696501	0.792	rs2227290	chr20:44176142	G/T	cg11783356	chr20:44313418	WFDC10B	-0.39	-6.84	-0.32	2.73e-11	Brain structure;
LUAD	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg09835421	chr16:68378352	PRMT7	-0.81	-8.71	-0.39	6.77e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.27	0.45	3.12e-22	Lymphocyte percentage of white cells;
LUAD	trans	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg02002194	chr4:3960332	NA	-0.28	-6.69	-0.31	6.92e-11	Mood instability;
LUAD	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg07917127	chr4:99064746	C4orf37	0.44	7.14	0.33	4.08e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg21153622	chr11:89784906	NA	-0.34	-6.78	-0.31	4.11e-11	Height;
LUAD	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg23625390	chr15:77176239	SCAPER	-0.45	-7.21	-0.33	2.6e-12	Blood metabolite levels;
LUAD	cis	rs8177876	0.822	rs56119129	chr16:81118266	C/T	cg08591886	chr16:81111003	C16orf46	-0.8	-7.39	-0.34	7.72e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs757081	0.738	rs1073443	chr11:17350394	C/T	cg15432903	chr11:17409602	KCNJ11	-0.43	-6.86	-0.32	2.4e-11	Systolic blood pressure;
LUAD	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-20.39	-0.7	7.58e-65	Coronary artery disease;
LUAD	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg22508957	chr16:3507546	NAT15	-0.87	-9.84	-0.43	1.06e-20	Tuberculosis;
LUAD	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg06547715	chr2:218990976	CXCR2	0.28	6.68	0.31	7.44e-11	Colorectal cancer;
LUAD	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12923728	chr3:195709715	SDHAP1	-0.78	-13.16	-0.54	2.19e-33	Pancreatic cancer;
LUAD	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg18225595	chr11:63971243	STIP1	0.49	8.32	0.37	1.23e-15	Platelet count;
LUAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06873352	chr17:61820015	STRADA	0.81	18.01	0.66	2.94e-54	Prudent dietary pattern;
LUAD	trans	rs7395662	1.000	rs4882019	chr11:48598748	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.33	-0.34	1.14e-12	HDL cholesterol;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg21548813	chr6:291882	DUSP22	-0.79	-13.36	-0.54	3.27e-34	Menopause (age at onset);
LUAD	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.34	-0.41	5.75e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28595532	0.516	rs17594740	chr4:119246754	C/T	cg02775129	chr4:119771670	NA	-0.75	-6.99	-0.32	1.09e-11	Cannabis dependence symptom count;
LUAD	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg15147215	chr3:52552868	STAB1	0.4	7.28	0.33	1.65e-12	Bipolar disorder;
LUAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg18621852	chr3:10150065	C3orf24	0.42	7.46	0.34	5.08e-13	Alzheimer's disease;
LUAD	cis	rs354225	0.544	rs4641979	chr2:54811917	G/A	cg01766943	chr2:54829624	SPTBN1	0.37	7.05	0.32	7.33e-12	Schizophrenia;
LUAD	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg08859206	chr1:53392774	SCP2	0.59	10.45	0.45	6.72e-23	Monocyte count;
LUAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg21951975	chr1:209979733	IRF6	0.58	9.03	0.4	6.26e-18	Cleft lip with or without cleft palate;
LUAD	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg19346786	chr7:2764209	NA	-0.52	-11.39	-0.48	2.09e-26	Height;
LUAD	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg15900387	chr1:150738905	CTSS	-0.36	-6.56	-0.3	1.56e-10	Melanoma;
LUAD	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18099408	chr3:52552593	STAB1	-0.47	-8.07	-0.37	7.33e-15	Bipolar disorder;
LUAD	cis	rs6906287	0.647	rs3734381	chr6:118887303	A/G	cg18833306	chr6:118973337	C6orf204	0.46	7.9	0.36	2.43e-14	Electrocardiographic conduction measures;
LUAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.99	0.47	7.04e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg01620082	chr3:125678407	NA	-0.8	-8.08	-0.37	6.7e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg03808351	chr9:123631620	PHF19	-0.41	-6.78	-0.31	4.13e-11	Birth weight;
LUAD	cis	rs6445967	0.530	rs12629939	chr3:58396163	T/C	cg13750441	chr3:58318267	PXK	-0.33	-6.76	-0.31	4.66e-11	Platelet count;
LUAD	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.13	15.22	0.59	4.98e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg12034118	chr1:209979487	IRF6	0.51	6.73	0.31	5.4e-11	Cleft lip with or without cleft palate;
LUAD	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg15704280	chr7:45808275	SEPT13	-0.76	-11.2	-0.48	1.1e-25	Coronary artery disease;
LUAD	cis	rs2692947	0.759	rs2949885	chr2:96662415	A/G	cg23100626	chr2:96804247	ASTL	0.31	8.0	0.36	1.21e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	trans	rs1941687	0.509	rs7238029	chr18:31317755	A/G	cg27147174	chr7:100797783	AP1S1	-0.64	-11.21	-0.48	1.01e-25	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs2066819	1.000	rs78495928	chr12:56635080	G/C	cg26714650	chr12:56694279	CS	-0.83	-6.99	-0.32	1.05e-11	Psoriasis vulgaris;
LUAD	cis	rs11229555	0.645	rs34530191	chr11:58200854	A/G	cg15696309	chr11:58395628	NA	-0.77	-10.52	-0.46	3.94e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1757171	0.504	rs11969056	chr6:37484285	C/T	cg25019722	chr6:37503610	NA	-0.33	-7.75	-0.35	6.98e-14	Cognitive performance;
LUAD	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.51	-10.65	-0.46	1.3e-23	Monocyte percentage of white cells;
LUAD	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg20283391	chr11:68216788	NA	-0.41	-6.49	-0.3	2.46e-10	Total body bone mineral density;
LUAD	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg06623918	chr6:96969491	KIAA0776	-0.88	-17.41	-0.65	1.33e-51	Headache;
LUAD	cis	rs6499129	0.558	rs7191281	chr16:67655133	T/C	cg26727032	chr16:67993705	SLC12A4	-0.42	-6.57	-0.3	1.45e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10493773	1.000	rs7523292	chr1:86134992	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.53	-8.76	-0.39	4.58e-17	Urate levels in overweight individuals;
LUAD	cis	rs7737355	0.812	rs13167908	chr5:131083829	T/C	cg06307176	chr5:131281290	NA	0.47	7.77	0.35	5.86e-14	Life satisfaction;
LUAD	cis	rs886126	1.000	rs7973104	chr12:111670774	C/G	cg10833066	chr12:111807467	FAM109A	0.55	10.82	0.47	3.05e-24	Coronary heart disease;
LUAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg24829409	chr8:58192753	C8orf71	0.56	7.69	0.35	1.04e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1594829	0.535	rs11784209	chr8:26170246	T/C	cg13160058	chr8:26243215	BNIP3L	-0.34	-7.61	-0.35	1.79e-13	Height;
LUAD	cis	rs727505	0.954	rs1014163	chr7:124443604	G/A	cg23710748	chr7:124431027	NA	-0.46	-9.42	-0.42	3.05e-19	Lewy body disease;
LUAD	cis	rs7180079	1.000	rs6494477	chr15:64667334	T/C	cg08069370	chr15:64387884	SNX1	0.5	6.38	0.3	4.63e-10	Monocyte count;
LUAD	cis	rs11893307	0.537	rs61345672	chr2:191507014	A/C	cg11845111	chr2:191398756	TMEM194B	-0.46	-6.66	-0.31	8.61e-11	Mean platelet volume;
LUAD	cis	rs6961069	0.806	rs11770907	chr7:80258630	G/A	cg04458919	chr7:80252533	CD36	0.37	7.12	0.33	4.53e-12	Platelet count;
LUAD	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.84	0.36	3.66e-14	Bladder cancer;
LUAD	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg25173405	chr17:45401733	C17orf57	0.45	7.7	0.35	9.65e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08467595	chr3:13009117	IQSEC1	-0.53	-6.56	-0.3	1.58e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg07917127	chr4:99064746	C4orf37	0.42	6.83	0.32	3e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2224391	0.628	rs9504365	chr6:5256116	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-8.9	-0.4	1.6e-17	Height;
LUAD	trans	rs1493916	0.748	rs4799355	chr18:31313124	G/T	cg27147174	chr7:100797783	AP1S1	-0.59	-10.18	-0.44	6.44e-22	Life satisfaction;
LUAD	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg06636551	chr8:101224915	SPAG1	-0.37	-6.76	-0.31	4.62e-11	Atrioventricular conduction;
LUAD	cis	rs7851660	0.809	rs7037324	chr9:100658318	A/G	cg13688889	chr9:100608707	NA	-0.54	-9.11	-0.41	3.24e-18	Strep throat;
LUAD	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg06784218	chr1:46089804	CCDC17	0.6	13.57	0.55	4.32e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg05082376	chr22:42548792	NA	0.44	7.65	0.35	1.38e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg13722127	chr7:150037890	RARRES2	0.51	8.37	0.38	8.46e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26314531	chr2:26401878	FAM59B	-0.7	-9.53	-0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	trans	rs2262909	0.925	rs404822	chr19:22215967	A/C	cg17074339	chr11:11642133	GALNTL4	-0.43	-6.88	-0.32	2.17e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.63	9.63	0.42	5.75e-20	IgG glycosylation;
LUAD	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg18569988	chr3:195679450	NA	0.43	6.51	0.3	2.1e-10	Pancreatic cancer;
LUAD	cis	rs12900413	0.562	rs11631438	chr15:90300620	C/T	cg24249390	chr15:90295951	MESP1	-0.35	-6.83	-0.32	2.98e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs10788264	0.504	rs4751886	chr10:124020396	T/C	cg09507567	chr10:124027408	NA	0.54	12.27	0.51	7.98e-30	Total body bone mineral density;
LUAD	cis	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg27411982	chr8:10470053	RP1L1	0.41	7.73	0.35	8.05e-14	Systolic blood pressure;
LUAD	cis	rs2637266	0.783	rs846642	chr10:78522318	A/G	cg18941641	chr10:78392320	NA	-0.32	-6.8	-0.31	3.59e-11	Pulmonary function;
LUAD	cis	rs6908034	0.505	rs76391302	chr6:19819116	G/A	cg02682789	chr6:19804855	NA	0.94	8.83	0.39	2.74e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs3733585	0.683	rs3796839	chr4:10009917	G/A	cg00071950	chr4:10020882	SLC2A9	0.83	17.21	0.64	1.06e-50	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6782228	0.606	rs2001950	chr3:128419756	A/G	cg16766828	chr3:128327626	NA	-0.39	-7.28	-0.33	1.6e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08280861	chr8:58055591	NA	0.65	8.42	0.38	5.93e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06022373	chr22:39101656	GTPBP1	0.44	6.59	0.31	1.28e-10	Menopause (age at onset);
LUAD	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg19717773	chr7:2847554	GNA12	-0.54	-10.64	-0.46	1.4e-23	Height;
LUAD	cis	rs77861329	1.000	rs9809254	chr3:52111474	T/C	cg08692210	chr3:52188851	WDR51A	0.87	8.69	0.39	8.14e-17	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.76	-0.39	4.75e-17	Total body bone mineral density;
LUAD	cis	rs11756438	0.572	rs1771756	chr6:119018502	C/T	cg18833306	chr6:118973337	C6orf204	0.5	8.95	0.4	1.1e-17	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg23029597	chr12:123009494	RSRC2	0.53	8.3	0.37	1.37e-15	Body mass index;
LUAD	cis	rs55823223	0.564	rs2034947	chr17:73863929	T/C	cg09253696	chr17:73873529	TRIM47	-0.42	-7.17	-0.33	3.47e-12	Psoriasis;
LUAD	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg08989290	chr16:615782	NHLRC4	0.32	6.87	0.32	2.27e-11	Height;
LUAD	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg24011408	chr12:48396354	COL2A1	-0.43	-9.6	-0.42	7.13e-20	Plateletcrit;
LUAD	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg21475434	chr5:93447410	FAM172A	0.78	8.63	0.39	1.23e-16	Diabetic retinopathy;
LUAD	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg20848291	chr7:100343083	ZAN	-0.61	-9.76	-0.43	1.9e-20	Other erythrocyte phenotypes;
LUAD	cis	rs12618769	0.597	rs17033136	chr2:99149404	C/T	cg10123293	chr2:99228465	UNC50	-0.46	-8.41	-0.38	6.14e-16	Bipolar disorder;
LUAD	cis	rs684232	0.623	rs12601935	chr17:519325	G/A	cg12384639	chr17:618140	VPS53	0.49	8.28	0.37	1.64e-15	Prostate cancer;
LUAD	trans	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	1.04e-10	Diabetic kidney disease;
LUAD	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg04414720	chr1:150670196	GOLPH3L	0.6	10.27	0.45	3.11e-22	Melanoma;
LUAD	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg25894440	chr7:65020034	NA	-0.61	-6.58	-0.3	1.39e-10	Diabetic kidney disease;
LUAD	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg03806693	chr22:41940476	POLR3H	0.64	8.93	0.4	1.27e-17	Vitiligo;
LUAD	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	9.24	0.41	1.22e-18	Colorectal cancer;
LUAD	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg09365446	chr1:150670422	GOLPH3L	0.56	9.64	0.42	5.23e-20	Melanoma;
LUAD	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg02254774	chr11:50257496	LOC441601	-0.41	-6.4	-0.3	4.24e-10	Height;
LUAD	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	5.84e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg02002194	chr4:3960332	NA	-0.29	-7.01	-0.32	9.67e-12	Mood instability;
LUAD	cis	rs2456568	0.802	rs7115629	chr11:93635477	G/A	cg26875233	chr11:93583750	C11orf90	-0.29	-6.39	-0.3	4.35e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs9296092	0.517	rs56206922	chr6:33522567	C/T	cg13560919	chr6:33536144	NA	-0.88	-16.8	-0.63	6.99e-49	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg02450064	chr17:40260053	DHX58	-0.42	-7.21	-0.33	2.56e-12	Fibrinogen levels;
LUAD	cis	rs10129255	0.536	rs6576223	chr14:107184687	C/T	cg23076370	chr14:107095027	NA	-0.43	-8.68	-0.39	8.58e-17	Kawasaki disease;
LUAD	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg17971929	chr21:40555470	PSMG1	-0.41	-6.71	-0.31	6.33e-11	Cognitive function;
LUAD	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg04756594	chr16:24857601	SLC5A11	-0.76	-13.29	-0.54	6.44e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs4642101	0.597	rs9865624	chr3:12822786	T/A	cg24848339	chr3:12840334	CAND2	0.43	8.61	0.39	1.48e-16	QRS complex (12-leadsum);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg24924243	chr11:27528430	LIN7C;BDNFOS	-0.42	-7.42	-0.34	6.32e-13	Schizophrenia;
LUAD	cis	rs11811982	0.793	rs116732179	chr1:227526671	A/G	cg24860534	chr1:227506868	CDC42BPA	0.67	7.3	0.33	1.43e-12	Optic disc area;
LUAD	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg14500267	chr11:67383377	NA	0.38	6.78	0.31	4.12e-11	Mean corpuscular volume;
LUAD	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg13732083	chr21:47605072	C21orf56	0.42	6.95	0.32	1.39e-11	Testicular germ cell tumor;
LUAD	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg20701182	chr2:24300061	SF3B14	0.61	6.91	0.32	1.84e-11	Birth weight;
LUAD	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.63	11.81	0.5	5.28e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg17330251	chr7:94953956	PON1	0.54	7.56	0.34	2.58e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7870753	0.628	rs2406001	chr9:99188970	C/G	cg13563390	chr9:99253610	HABP4	-0.38	-6.36	-0.3	5.38e-10	Height;
LUAD	cis	rs7127129	0.549	rs10793035	chr11:70051966	A/G	cg06159181	chr11:70072977	NA	-0.43	-8.41	-0.38	6.35e-16	Aortic root size;
LUAD	cis	rs2019216	0.521	rs12449447	chr17:21888786	C/T	cg22648282	chr17:21454238	C17orf51	-0.48	-8.32	-0.37	1.24e-15	Pelvic organ prolapse;
LUAD	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.38	0.38	8.02e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs986417	0.818	rs6573319	chr14:61091913	C/G	cg27398547	chr14:60952738	C14orf39	0.56	6.48	0.3	2.55e-10	Gut microbiota (bacterial taxa);
LUAD	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.6	-0.42	6.86e-20	Life satisfaction;
LUAD	cis	rs4356932	1.000	rs13130018	chr4:76955519	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.54	-0.3	1.78e-10	Blood protein levels;
LUAD	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg17724175	chr1:150552817	MCL1	-0.32	-7.39	-0.34	7.74e-13	Melanoma;
LUAD	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.25e-13	Tonsillectomy;
LUAD	cis	rs7180079	1.000	rs2062249	chr15:64672159	C/A	cg08069370	chr15:64387884	SNX1	0.5	6.45	0.3	3.12e-10	Monocyte count;
LUAD	cis	rs76878669	0.561	rs4244813	chr11:66129488	G/C	cg18002602	chr11:66138449	SLC29A2	0.47	10.16	0.44	7.74e-22	Educational attainment (years of education);
LUAD	cis	rs6500395	1.000	rs11649236	chr16:48632478	C/T	cg04672837	chr16:48644449	N4BP1	0.38	6.57	0.3	1.46e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7326068	0.610	rs9552265	chr13:21311695	C/T	cg27499820	chr13:21296301	IL17D	0.41	6.93	0.32	1.59e-11	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.7e-15	Prostate cancer;
LUAD	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg14689365	chr7:158441557	NCAPG2	0.4	6.72	0.31	5.98e-11	Height;
LUAD	trans	rs6601327	0.775	rs12156017	chr8:9406837	C/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.81	-0.36	4.43e-14	Multiple myeloma (hyperdiploidy);
LUAD	cis	rs867529	0.620	rs335121	chr2:89084327	G/C	cg26627705	chr2:89060884	NA	0.45	6.63	0.31	1.05e-10	Height;
LUAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.61	0.31	1.17e-10	Prudent dietary pattern;
LUAD	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.56	-0.3	1.62e-10	Breast cancer;
LUAD	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg14169450	chr9:139327907	INPP5E	0.44	7.92	0.36	2.08e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11644478	chr21:40555479	PSMG1	0.61	10.48	0.45	5.24e-23	Cognitive function;
LUAD	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg26384229	chr12:38710491	ALG10B	0.47	7.55	0.34	2.72e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs3744061	0.569	rs2240769	chr17:74718155	C/T	cg27546012	chr17:74684504	MXRA7	-0.46	-7.79	-0.35	5.24e-14	Retinal arteriolar caliber;
LUAD	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg04731861	chr2:219085781	ARPC2	-0.22	-6.83	-0.32	3e-11	Colorectal cancer;
LUAD	cis	rs113835537	0.529	rs11227512	chr11:66281291	T/C	cg26679405	chr11:66247800	DPP3	-0.46	-6.71	-0.31	6.26e-11	Airway imaging phenotypes;
LUAD	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg14895029	chr7:2775587	GNA12	-0.44	-7.11	-0.33	4.91e-12	Height;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg20591167	chr15:99602178	NA	0.39	6.56	0.3	1.61e-10	Bilirubin levels;
LUAD	cis	rs7264396	0.563	rs2425131	chr20:34337074	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.05	-0.36	8.75e-15	Total cholesterol levels;
LUAD	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.81	0.35	4.6e-14	Parkinson's disease;
LUAD	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg06784218	chr1:46089804	CCDC17	-0.61	-13.8	-0.56	5.03e-36	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg02660097	chr11:68866761	NA	0.47	6.52	0.3	1.96e-10	Blond vs. brown hair color;
LUAD	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg03806693	chr22:41940476	POLR3H	-0.58	-8.47	-0.38	4.23e-16	Vitiligo;
LUAD	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg05590025	chr7:65112418	INTS4L2	0.74	7.87	0.36	3.01e-14	Diabetic kidney disease;
LUAD	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-6.46	-0.3	2.89e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg03651054	chr13:50194643	NA	-0.37	-7.62	-0.35	1.66e-13	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.8	0.31	3.54e-11	Colorectal cancer;
LUAD	cis	rs13064411	0.696	rs7631082	chr3:113208913	C/G	cg18753928	chr3:113234510	CCDC52	-0.73	-12.4	-0.52	2.41e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.45	-7.47	-0.34	4.63e-13	Body mass index;
LUAD	cis	rs12431939	1.000	rs7140375	chr14:51637242	T/G	cg23942311	chr14:51606299	NA	-0.59	-8.16	-0.37	3.89e-15	Cancer;
LUAD	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg04414720	chr1:150670196	GOLPH3L	0.65	11.0	0.47	6.31e-25	Melanoma;
LUAD	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg27539214	chr16:67997921	SLC12A4	-0.68	-8.09	-0.37	6.58e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.61	0.35	1.75e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg21204522	chr6:27730016	NA	-0.66	-6.82	-0.31	3.09e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10788972	1.000	rs10788972	chr1:54572243	C/A	cg25741118	chr1:54482237	LDLRAD1	-0.24	-6.83	-0.32	3.02e-11	Parkinson disease and lewy body pathology;
LUAD	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg09650180	chr20:62225654	GMEB2	0.45	6.59	0.3	1.34e-10	Glioblastoma;
LUAD	cis	rs12431939	0.947	rs56026555	chr14:51649066	G/T	cg23942311	chr14:51606299	NA	-0.62	-8.4	-0.38	7.08e-16	Cancer;
LUAD	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg17845761	chr1:175162550	KIAA0040	-0.34	-8.96	-0.4	1.07e-17	Alcohol dependence;
LUAD	cis	rs35740288	0.770	rs12906580	chr15:86155287	C/T	cg13263323	chr15:86062960	AKAP13	0.43	6.94	0.32	1.52e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs72802342	0.510	rs12932952	chr16:75365486	C/T	cg03315344	chr16:75512273	CHST6	0.49	6.92	0.32	1.73e-11	Advanced age-related macular degeneration;
LUAD	trans	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg01620082	chr3:125678407	NA	-0.99	-9.58	-0.42	8.69e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg08742575	chr21:47604166	C21orf56	0.52	8.86	0.4	2.32e-17	Testicular germ cell tumor;
LUAD	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg11859384	chr17:80120422	CCDC57	-0.52	-9.47	-0.42	1.99e-19	Life satisfaction;
LUAD	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg22431228	chr1:16359049	CLCNKA	-0.54	-9.65	-0.42	4.63e-20	Dilated cardiomyopathy;
LUAD	cis	rs11650494	0.908	rs111834333	chr17:47411814	C/T	cg08112188	chr17:47440006	ZNF652	0.91	7.89	0.36	2.53e-14	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg05340658	chr4:99064831	C4orf37	0.55	9.35	0.41	5.28e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg22482690	chr17:47019901	SNF8	0.44	8.55	0.38	2.25e-16	Type 2 diabetes;
LUAD	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg23352942	chr3:46931381	PTH1R	-0.39	-7.92	-0.36	2.09e-14	Birth weight;
LUAD	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg12311346	chr5:56204834	C5orf35	-0.44	-7.27	-0.33	1.71e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs76878669	0.561	rs10896112	chr11:66116836	G/C	cg18002602	chr11:66138449	SLC29A2	-0.49	-10.64	-0.46	1.4e-23	Educational attainment (years of education);
LUAD	cis	rs7552167	0.925	rs7546025	chr1:24510252	T/C	cg01960748	chr1:24522592	NA	-0.8	-10.31	-0.45	2.22e-22	Psoriasis vulgaris;
LUAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg20607798	chr8:58055168	NA	0.78	9.69	0.43	3.45e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.33e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg13560548	chr3:10150139	C3orf24	0.45	7.33	0.34	1.22e-12	Alzheimer's disease;
LUAD	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg20503657	chr10:835505	NA	1.05	15.91	0.61	5.38e-45	Eosinophil percentage of granulocytes;
LUAD	cis	rs11958404	1.000	rs11958404	chr5:157410278	A/T	cg05962755	chr5:157440814	NA	0.44	6.59	0.3	1.34e-10	IgG glycosylation;
LUAD	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg17063962	chr7:91808500	NA	0.7	12.45	0.52	1.63e-30	Breast cancer;
LUAD	cis	rs741677	0.963	rs8064649	chr17:472610	T/C	cg13332499	chr17:408570	NA	0.34	6.74	0.31	5.24e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22029157	chr1:209979665	IRF6	0.78	12.43	0.52	1.87e-30	Cleft lip with or without cleft palate;
LUAD	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg01802117	chr1:53393560	SCP2	-0.34	-6.73	-0.31	5.63e-11	Monocyte count;
LUAD	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg04287289	chr16:89883240	FANCA	0.48	7.75	0.35	6.72e-14	Vitiligo;
LUAD	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg17971929	chr21:40555470	PSMG1	0.53	8.38	0.38	7.85e-16	Cognitive function;
LUAD	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg15557168	chr22:42548783	NA	0.5	9.29	0.41	8.21e-19	Schizophrenia;
LUAD	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg00898013	chr13:113819073	PROZ	-0.69	-12.16	-0.51	2.2e-29	Platelet distribution width;
LUAD	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg27539214	chr16:67997921	SLC12A4	-0.72	-9.19	-0.41	1.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs921968	0.613	rs6436066	chr2:219578361	T/G	cg02176678	chr2:219576539	TTLL4	-0.61	-12.24	-0.51	1.07e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs790123	0.933	rs1092556	chr3:122387354	T/G	cg15604389	chr3:122379662	NA	0.58	10.54	0.46	3.22e-23	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg07776626	chr8:57350775	NA	-0.6	-8.95	-0.4	1.13e-17	Obesity-related traits;
LUAD	cis	rs13315871	1.000	rs11717423	chr3:58330177	C/G	cg12435725	chr3:58293450	RPP14	-0.74	-7.9	-0.36	2.35e-14	Cholesterol, total;
LUAD	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg08885076	chr2:99613938	TSGA10	-0.41	-7.21	-0.33	2.63e-12	Chronic sinus infection;
LUAD	cis	rs12200560	0.505	rs211165	chr6:97068520	A/T	cg06623918	chr6:96969491	KIAA0776	0.45	6.77	0.31	4.24e-11	Coronary heart disease;
LUAD	cis	rs847577	0.609	rs705308	chr7:97695363	C/A	cg24562669	chr7:97807699	LMTK2	-0.3	-7.16	-0.33	3.71e-12	Breast cancer;
LUAD	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg19302996	chr17:73780495	UNK	0.42	6.45	0.3	2.98e-10	Psoriasis;
LUAD	cis	rs17102423	0.594	rs1124751	chr14:65567601	C/A	cg16583315	chr14:65563665	MAX	-0.35	-6.58	-0.3	1.42e-10	Obesity-related traits;
LUAD	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg13902645	chr11:5959945	NA	-0.57	-10.01	-0.44	2.65e-21	DNA methylation (variation);
LUAD	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg21862992	chr11:68658383	NA	0.53	9.62	0.42	6.22e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg05373962	chr22:49881684	NA	-0.46	-10.25	-0.45	3.76e-22	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg04827223	chr11:72435913	ARAP1	0.47	7.21	0.33	2.58e-12	Type 2 diabetes;
LUAD	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg11663144	chr21:46675770	NA	-0.38	-6.57	-0.3	1.51e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22338127	chr1:209979572	IRF6	-0.46	-6.49	-0.3	2.41e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18404041	chr3:52824283	ITIH1	-0.59	-11.8	-0.5	5.55e-28	Bipolar disorder;
LUAD	cis	rs7582720	1.000	rs72926769	chr2:203798318	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	trans	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.68	-12.18	-0.51	1.85e-29	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg18252515	chr7:66147081	NA	-0.61	-6.8	-0.31	3.52e-11	Diabetic kidney disease;
LUAD	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg16988262	chr1:15930761	NA	0.41	6.87	0.32	2.34e-11	Systolic blood pressure;
LUAD	cis	rs939658	0.728	rs12904789	chr15:79412589	G/A	cg17916960	chr15:79447300	NA	-0.49	-9.67	-0.43	3.92e-20	Refractive error;
LUAD	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.57	9.36	0.41	4.85e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg13385794	chr1:248469461	NA	0.27	7.01	0.32	9.68e-12	Common traits (Other);
LUAD	trans	rs5756813	0.754	rs8136757	chr22:38185971	A/G	cg19894588	chr14:64061835	NA	-0.46	-6.68	-0.31	7.43e-11	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg04450456	chr4:17643702	FAM184B	0.37	7.26	0.33	1.91e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3752962	0.588	rs903164	chr17:1939502	G/A	cg24156229	chr17:1948635	NA	-0.47	-8.21	-0.37	2.8e-15	Itch intensity from mosquito bite;
LUAD	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg18827107	chr12:86230957	RASSF9	-0.49	-8.7	-0.39	7.35e-17	Major depressive disorder;
LUAD	cis	rs1215050	0.846	rs783923	chr4:98968686	C/T	cg17366294	chr4:99064904	C4orf37	-0.42	-7.22	-0.33	2.47e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg14668632	chr7:2872130	GNA12	-0.56	-9.9	-0.43	6.28e-21	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.95	-0.4	1.16e-17	Gut microbiome composition (summer);
LUAD	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg21153622	chr11:89784906	NA	-0.34	-6.77	-0.31	4.4e-11	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg18180107	chr4:99064573	C4orf37	0.4	6.51	0.3	2.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg18190219	chr22:46762943	CELSR1	-0.57	-6.59	-0.31	1.3e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg07460842	chr6:66804631	NA	0.62	9.77	0.43	1.8899999999999998e-20	Type 2 diabetes;
LUAD	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg02527881	chr3:46936655	PTH1R	-0.48	-9.63	-0.42	5.74e-20	Colorectal cancer;
LUAD	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg12310025	chr6:25882481	NA	0.47	7.04	0.32	7.69e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg06064525	chr11:970664	AP2A2	-0.56	-11.49	-0.49	8.88e-27	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg14092988	chr3:52407081	DNAH1	0.37	7.4	0.34	7.47e-13	Bipolar disorder;
LUAD	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg11266682	chr4:10021025	SLC2A9	0.46	8.39	0.38	7.24e-16	Blood metabolite levels;
LUAD	cis	rs2224391	0.590	rs72813697	chr6:5274266	T/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.61	-7.87	-0.36	3.09e-14	Height;
LUAD	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.88	0.53	2.99e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs80207740	1.000	rs17296501	chr8:21849566	C/T	cg25597362	chr8:21767310	DOK2	-0.61	-7.69	-0.35	1.04e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg19761014	chr17:28927070	LRRC37B2	0.86	8.36	0.38	9.21e-16	Body mass index;
LUAD	trans	rs7395662	1.000	rs12419576	chr11:48581644	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.14e-12	HDL cholesterol;
LUAD	cis	rs2230307	0.656	rs6662945	chr1:100584746	A/C	cg20868668	chr1:100435035	SLC35A3	0.61	7.17	0.33	3.38e-12	Carotid intima media thickness;
LUAD	trans	rs6076960	0.652	rs3852945	chr20:6254118	T/C	cg21095983	chr6:86352623	SYNCRIP	0.39	6.35	0.3	5.7e-10	Smooth-surface caries;
LUAD	cis	rs7705042	0.865	rs6580229	chr5:141510754	A/G	cg08523384	chr5:141488047	NDFIP1	-0.38	-6.52	-0.3	1.99e-10	Asthma;
LUAD	cis	rs6445967	0.530	rs67549097	chr3:58346893	C/T	cg23715586	chr3:58305044	RPP14	0.4	6.36	0.3	5.3e-10	Platelet count;
LUAD	cis	rs57920188	0.535	rs10915658	chr1:4092921	T/C	cg10510935	chr1:4059661	NA	0.45	6.91	0.32	1.77e-11	Interleukin-17 levels;
LUAD	cis	rs36051895	0.664	rs4593605	chr9:5107278	C/A	cg02405213	chr9:5042618	JAK2	-0.47	-6.52	-0.3	2.05e-10	Pediatric autoimmune diseases;
LUAD	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg24578937	chr1:2090814	PRKCZ	0.47	9.16	0.41	2.19e-18	Coronary artery disease;
LUAD	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg02733842	chr7:1102375	C7orf50	-0.68	-10.14	-0.44	9.08e-22	Bronchopulmonary dysplasia;
LUAD	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.01e-10	Skin colour saturation;
LUAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.25	-0.37	2.05e-15	Alzheimer's disease;
LUAD	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg05709478	chr1:6581295	PLEKHG5	0.55	7.56	0.35	2.44e-13	Body mass index;
LUAD	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-7.21	-0.33	2.65e-12	Lung cancer;
LUAD	cis	rs2050392	0.792	rs9338188	chr10:30721963	G/C	cg18806716	chr10:30721971	MAP3K8	-0.54	-10.72	-0.46	7.26e-24	Inflammatory bowel disease;
LUAD	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg10518543	chr12:38710700	ALG10B	-0.41	-6.87	-0.32	2.28e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4493873	1.000	rs4493873	chr8:92075643	A/C	cg16814680	chr8:91681699	NA	0.41	6.51	0.3	2.16e-10	Migraine - clinic-based;
LUAD	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg15704280	chr7:45808275	SEPT13	-0.62	-8.34	-0.38	1.07e-15	Axial length;
LUAD	trans	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg03886242	chr7:26192032	NFE2L3	0.36	6.44	0.3	3.23e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24531977	chr5:56204891	C5orf35	-0.98	-14.71	-0.58	7.48e-40	Initial pursuit acceleration;
LUAD	cis	rs16854884	0.586	rs7650172	chr3:143729408	G/C	cg01302019	chr3:143689584	C3orf58	-0.38	-6.73	-0.31	5.54e-11	Economic and political preferences (feminism/equality);
LUAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg10862848	chr6:42927986	GNMT	-0.32	-9.3	-0.41	7.68e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs642803	1.000	rs642803	chr11:65560620	C/T	cg27068330	chr11:65405492	SIPA1	0.45	7.27	0.33	1.74e-12	Urate levels;
LUAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg17330251	chr7:94953956	PON1	-0.71	-12.83	-0.53	4.48e-32	Paraoxonase activity;
LUAD	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg02038168	chr22:39784481	NA	-0.53	-8.46	-0.38	4.35e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg18944383	chr4:111397179	ENPEP	0.39	7.84	0.36	3.72e-14	Height;
LUAD	cis	rs262150	0.501	rs1017034	chr7:158820460	A/G	cg09640425	chr7:158790006	NA	-0.56	-9.56	-0.42	9.48e-20	Facial morphology (factor 20);
LUAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg16606324	chr3:10149918	C3orf24	-0.61	-10.07	-0.44	1.58e-21	Alzheimer's disease;
LUAD	cis	rs10419226	0.533	rs6510996	chr19:18788208	A/G	cg22001208	chr19:18782374	NA	-0.47	-7.92	-0.36	2.1e-14	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg15549821	chr19:49342101	PLEKHA4	0.86	13.11	0.54	3.48e-33	Red cell distribution width;
LUAD	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.07	15.11	0.59	1.46e-41	Lung cancer in ever smokers;
LUAD	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg04369109	chr6:150039330	LATS1	-0.49	-8.34	-0.38	1.06e-15	Lung cancer;
LUAD	cis	rs6840360	1.000	rs6846114	chr4:152604558	A/G	cg22705602	chr4:152727874	NA	0.32	6.42	0.3	3.75e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg14092571	chr14:90743983	NA	-0.49	-8.69	-0.39	7.97e-17	Mortality in heart failure;
LUAD	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg19635926	chr16:89946313	TCF25	0.74	6.55	0.3	1.7e-10	Skin colour saturation;
LUAD	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg00495681	chr13:53174319	NA	0.47	8.62	0.39	1.34e-16	Lewy body disease;
LUAD	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg21100191	chr22:23484243	RTDR1	0.68	11.97	0.5	1.23e-28	Bone mineral density;
LUAD	cis	rs4006360	0.535	rs2173202	chr17:39235235	C/T	cg20663846	chr17:39254439	KRTAP4-8	-0.37	-8.37	-0.38	8.31e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg18105134	chr13:113819100	PROZ	0.91	16.04	0.62	1.4e-45	Platelet distribution width;
LUAD	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.89	0.36	2.63e-14	Morning vs. evening chronotype;
LUAD	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg05283184	chr6:79620031	NA	-0.59	-11.84	-0.5	4.02e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs2242073	0.660	rs12464752	chr2:208996677	G/A	cg06181187	chr2:209010896	CRYGB	0.34	6.68	0.31	7.33e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg08508325	chr11:3079039	CARS	0.44	8.97	0.4	9.4e-18	Calcium levels;
LUAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg07217954	chr7:1067459	C7orf50	0.43	6.7	0.31	6.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg26384229	chr12:38710491	ALG10B	-0.46	-7.82	-0.36	4.32e-14	Morning vs. evening chronotype;
LUAD	cis	rs6087990	0.899	rs6087999	chr20:31363774	A/G	cg13636640	chr20:31349939	DNMT3B	0.82	15.52	0.6	2.48e-43	Ulcerative colitis;
LUAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03452623	chr4:187889614	NA	-0.82	-16.76	-0.63	9.79e-49	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg22535103	chr8:58192502	C8orf71	-0.6	-7.04	-0.32	7.74e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg12193833	chr17:30244370	NA	-0.57	-6.93	-0.32	1.58e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.51	-9.06	-0.4	4.92e-18	Lymphocyte counts;
LUAD	cis	rs9811920	0.516	rs793485	chr3:99492383	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-8.51	-0.38	3.03e-16	Axial length;
LUAD	cis	rs3750082	0.852	rs10260000	chr7:32898234	T/C	cg05721444	chr7:32995514	FKBP9	0.36	6.47	0.3	2.7e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs3087591	1.000	rs7214792	chr17:29460673	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	6.73	0.31	5.54e-11	Hip circumference;
LUAD	cis	rs13064411	0.696	rs6799610	chr3:113248748	A/C	cg10517650	chr3:113235015	CCDC52	0.54	9.07	0.4	4.47e-18	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg07636037	chr3:49044803	WDR6	0.57	10.33	0.45	1.81e-22	Parkinson's disease;
LUAD	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg10589385	chr1:150898437	SETDB1	0.39	7.31	0.34	1.31e-12	Urate levels;
LUAD	trans	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg18187862	chr3:45730750	SACM1L	0.57	9.07	0.4	4.5e-18	Primary sclerosing cholangitis;
LUAD	cis	rs9341808	0.754	rs9294173	chr6:80991630	T/A	cg08355045	chr6:80787529	NA	0.53	9.42	0.42	2.97e-19	Sitting height ratio;
LUAD	cis	rs7177699	0.557	rs9920493	chr15:79113846	A/C	cg15571903	chr15:79123663	NA	0.37	7.44	0.34	5.71e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs6750795	0.569	rs1667305	chr2:232403829	A/G	cg19187155	chr2:232395269	NMUR1	0.48	8.71	0.39	6.79e-17	Height;
LUAD	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg15704280	chr7:45808275	SEPT13	-0.54	-8.5	-0.38	3.18e-16	Height;
LUAD	cis	rs2421770	0.530	rs11033084	chr11:35367408	T/G	cg13971030	chr11:35366721	SLC1A2	-0.45	-7.84	-0.36	3.63e-14	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs11671005	0.735	rs34152946	chr19:58923263	C/T	cg13877915	chr19:58951672	ZNF132	0.55	7.27	0.33	1.75e-12	Mean platelet volume;
LUAD	cis	rs2286885	0.965	rs741024	chr9:129251821	A/G	cg15282417	chr9:129245246	FAM125B	-0.43	-8.85	-0.4	2.43e-17	Intraocular pressure;
LUAD	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.48	8.51	0.38	3.06e-16	Alzheimer's disease (late onset);
LUAD	cis	rs3784262	0.631	rs3742961	chr15:58247977	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.37	-7.08	-0.33	5.89e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg07936489	chr17:37558343	FBXL20	-0.47	-7.41	-0.34	6.94e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg21724239	chr8:58056113	NA	0.71	9.11	0.4	3.34e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9394841	0.667	rs12661667	chr6:41792545	C/T	cg17623882	chr6:41773611	USP49	-0.53	-7.5	-0.34	3.9e-13	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs4285028	0.948	rs12630486	chr3:121685267	C/T	cg11130432	chr3:121712080	ILDR1	-0.59	-8.44	-0.38	5.05e-16	Multiple sclerosis;
LUAD	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg18404041	chr3:52824283	ITIH1	0.52	8.76	0.39	4.75e-17	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg11814155	chr7:99998594	ZCWPW1	0.41	6.54	0.3	1.8e-10	Platelet count;
LUAD	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1865721	0.682	rs1561080	chr18:73145847	A/G	cg26385618	chr18:73139727	C18orf62	-0.48	-9.72	-0.43	2.68e-20	Intelligence;
LUAD	trans	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg27411982	chr8:10470053	RP1L1	-0.36	-6.58	-0.3	1.36e-10	Mood instability;
LUAD	cis	rs977987	0.742	rs12928898	chr16:75462081	G/A	cg03315344	chr16:75512273	CHST6	0.65	14.01	0.56	6.59e-37	Dupuytren's disease;
LUAD	cis	rs9905704	0.633	rs2680707	chr17:56455641	T/C	cg19466818	chr17:56409534	MIR142	0.35	6.92	0.32	1.64e-11	Testicular germ cell tumor;
LUAD	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.74	0.43	2.28e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25418748	chr5:178977236	RUFY1	0.48	6.37	0.3	5.05e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg26039829	chr8:22132926	PIWIL2	-0.57	-10.48	-0.45	5.25e-23	Hypertriglyceridemia;
LUAD	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12756686	chr19:29218302	NA	0.6	8.8	0.39	3.61e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg05535760	chr7:792225	HEATR2	0.86	11.25	0.48	7.07e-26	Cerebrospinal P-tau181p levels;
LUAD	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg10556349	chr10:835070	NA	0.68	8.13	0.37	4.75e-15	Eosinophil percentage of granulocytes;
LUAD	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg15181151	chr6:150070149	PCMT1	0.39	7.68	0.35	1.12e-13	Lung cancer;
LUAD	cis	rs2067615	0.579	rs3782709	chr12:107205753	A/G	cg15890332	chr12:107067104	RFX4	0.36	7.41	0.34	7.05e-13	Heart rate;
LUAD	cis	rs2652834	0.861	rs4774472	chr15:63353760	C/A	cg25406657	chr15:63342033	TPM1	-0.42	-6.76	-0.31	4.52e-11	HDL cholesterol;
LUAD	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg05665937	chr4:1216051	CTBP1	-0.44	-7.89	-0.36	2.62e-14	Obesity-related traits;
LUAD	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-6.62	-0.31	1.1e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.5	-0.34	3.89e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg06641503	chr3:48959341	ARIH2	-0.41	-8.03	-0.36	9.54e-15	Parkinson's disease;
LUAD	cis	rs9560113	1.000	rs4773387	chr13:112180955	T/C	cg14154082	chr13:112174009	NA	0.36	6.64	0.31	9.5e-11	Menarche (age at onset);
LUAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14893161	chr1:205819251	PM20D1	0.51	8.24	0.37	2.23e-15	Parkinson's disease;
LUAD	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg18827107	chr12:86230957	RASSF9	-0.54	-9.34	-0.41	5.41e-19	Major depressive disorder;
LUAD	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg23625390	chr15:77176239	SCAPER	0.46	7.41	0.34	6.79e-13	Blood metabolite levels;
LUAD	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg15790184	chr11:494944	RNH1	0.55	6.87	0.32	2.32e-11	Body mass index;
LUAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg10351095	chr21:47802916	PCNT	-0.4	-6.5	-0.3	2.3e-10	Testicular germ cell tumor;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08450409	chr12:53342662	KRT18	-0.46	-7.02	-0.32	8.68e-12	Height;
LUAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg15242686	chr22:24348715	GSTTP1	0.45	7.85	0.36	3.37e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4843185	0.763	rs9534	chr16:85711502	C/T	cg26571870	chr16:85723150	GINS2	0.32	6.83	0.32	3e-11	Platelet distribution width;
LUAD	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg17279839	chr7:150038598	RARRES2	0.44	7.46	0.34	5.04e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7107174	1.000	rs2511177	chr11:77922960	C/T	cg19901956	chr11:77921274	USP35	-0.49	-6.8	-0.31	3.57e-11	Testicular germ cell tumor;
LUAD	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg00277334	chr10:82204260	NA	-0.57	-9.47	-0.42	2.07e-19	Post bronchodilator FEV1;
LUAD	cis	rs3849570	0.615	rs1851918	chr3:81980557	C/T	cg07356753	chr3:81810745	GBE1	-0.49	-8.21	-0.37	2.61e-15	Waist circumference;Body mass index;
LUAD	cis	rs9486719	1.000	rs2142653	chr6:96871520	C/A	cg06623918	chr6:96969491	KIAA0776	0.71	9.98	0.44	3.33e-21	Migraine;Coronary artery disease;
LUAD	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg16797656	chr11:68205561	LRP5	0.45	8.73	0.39	5.98e-17	Total body bone mineral density;
LUAD	cis	rs2109514	0.902	rs717957	chr7:116113107	G/C	cg12739419	chr7:116140593	CAV2	-0.33	-6.82	-0.31	3.22e-11	Prevalent atrial fibrillation;
LUAD	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg19774624	chr17:42201019	HDAC5	-0.41	-7.11	-0.33	5.01e-12	Total body bone mineral density;
LUAD	cis	rs7975161	0.640	rs10735394	chr12:104687142	C/A	cg25273343	chr12:104657179	TXNRD1	-0.64	-7.66	-0.35	1.25e-13	Toenail selenium levels;
LUAD	cis	rs9814567	0.574	rs7650509	chr3:134170971	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.53	9.06	0.4	4.9e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2816062	0.710	rs2816052	chr1:18895536	T/C	cg18795169	chr1:18902165	NA	-0.94	-22.53	-0.74	2.07e-74	Urate levels in lean individuals;
LUAD	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.2	0.44	5.36e-22	Ileal carcinoids;
LUAD	cis	rs10493773	0.928	rs12751296	chr1:86176968	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.55	-9.09	-0.4	3.93e-18	Urate levels in overweight individuals;
LUAD	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg10057126	chr4:77819792	ANKRD56	0.55	9.62	0.42	6.09e-20	Emphysema distribution in smoking;
LUAD	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg05865280	chr17:75406074	SEPT9	-0.61	-19.25	-0.68	9.53e-60	Airflow obstruction;
LUAD	cis	rs3820068	0.705	rs57971278	chr1:15838604	G/A	cg13390004	chr1:15929781	NA	0.41	6.71	0.31	6.1e-11	Systolic blood pressure;
LUAD	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg26597838	chr10:835615	NA	1.03	15.78	0.61	1.83e-44	Eosinophil percentage of granulocytes;
LUAD	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg19717773	chr7:2847554	GNA12	-0.53	-10.04	-0.44	2.06e-21	Height;
LUAD	cis	rs7267979	0.844	rs6083845	chr20:25388090	G/C	cg08601574	chr20:25228251	PYGB	-0.42	-7.91	-0.36	2.34e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg08645402	chr16:4508243	NA	0.52	8.85	0.4	2.38e-17	Schizophrenia;
LUAD	cis	rs17095355	1.000	rs7073969	chr10:111753798	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.64	-7.33	-0.34	1.17e-12	Biliary atresia;
LUAD	cis	rs62458065	0.713	rs62463967	chr7:32498329	G/A	cg20159608	chr7:32802032	NA	-0.6	-8.19	-0.37	3.02e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2637266	1.000	rs2130795	chr10:78333892	C/G	cg18941641	chr10:78392320	NA	0.33	6.9	0.32	1.91e-11	Pulmonary function;
LUAD	cis	rs747650	0.892	rs1976142	chr11:47225694	T/C	cg19486271	chr11:47235900	DDB2	-0.44	-7.22	-0.33	2.42e-12	Acne (severe);
LUAD	cis	rs3087591	0.960	rs12940303	chr17:29604862	C/T	cg24425628	chr17:29625626	OMG;NF1	0.41	6.66	0.31	8.45e-11	Hip circumference;
LUAD	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg12365402	chr11:9010492	NRIP3	-0.46	-8.93	-0.4	1.29e-17	Hemoglobin concentration;
LUAD	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg25985355	chr7:65971099	NA	0.38	7.08	0.33	5.9e-12	Aortic root size;
LUAD	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg02807482	chr3:125708958	NA	-0.65	-8.39	-0.38	7.15e-16	Blood pressure (smoking interaction);
LUAD	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	10.69	0.46	8.71e-24	Hip circumference adjusted for BMI;
LUAD	trans	rs453301	0.653	rs7853	chr8:8890814	A/G	cg27411982	chr8:10470053	RP1L1	0.38	6.47	0.3	2.77e-10	Joint mobility (Beighton score);
LUAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg00106254	chr7:1943704	MAD1L1	0.54	7.75	0.35	6.71e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.56	0.3	1.55e-10	Menarche (age at onset);
LUAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.31	-0.41	6.92e-19	Alzheimer's disease;
LUAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg20607798	chr8:58055168	NA	0.58	7.0	0.32	1.03e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1595825	0.945	rs73056883	chr2:198824638	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-7.1	-0.33	5.43e-12	Ulcerative colitis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05290708	chr7:140372864	ADCK2	-0.45	-6.91	-0.32	1.76e-11	Height;
LUAD	cis	rs7617773	0.780	rs13090538	chr3:48370769	A/C	cg11946769	chr3:48343235	NME6	0.45	7.05	0.32	7.55e-12	Coronary artery disease;
LUAD	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg05872129	chr22:39784769	NA	-0.56	-8.12	-0.37	5.29e-15	IgG glycosylation;
LUAD	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg23625390	chr15:77176239	SCAPER	0.37	6.56	0.3	1.56e-10	Blood metabolite levels;
LUAD	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.43	-0.34	5.94e-13	Type 2 diabetes;
LUAD	cis	rs454510	1.000	rs454510	chr1:120195042	C/T	cg11530693	chr1:120165357	ZNF697	-0.54	-8.13	-0.37	4.92e-15	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg04455712	chr21:45112962	RRP1B	0.43	8.78	0.39	4.2e-17	Mean corpuscular volume;
LUAD	cis	rs9914988	1.000	rs901975	chr17:27189774	A/G	cg20469991	chr17:27169893	C17orf63	0.51	6.65	0.31	8.82e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1524976	1.000	rs11719771	chr3:65481987	G/T	cg16238336	chr3:65465873	MAGI1	-0.7	-8.0	-0.36	1.18e-14	PR interval;
LUAD	trans	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg24644049	chr4:85504048	CDS1	0.84	7.69	0.35	1.02e-13	Skin colour saturation;
LUAD	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg18944383	chr4:111397179	ENPEP	0.39	7.81	0.36	4.43e-14	Height;
LUAD	cis	rs4819852	0.958	rs2238792	chr22:19983213	C/T	cg07821417	chr22:19972146	ARVCF	0.42	7.9	0.36	2.46e-14	Pulse pressure;
LUAD	cis	rs72634258	0.554	rs4908699	chr1:7905274	G/A	cg26816564	chr1:7831052	VAMP3	0.69	9.46	0.42	2.11e-19	Inflammatory bowel disease;
LUAD	cis	rs89107	1.000	rs283077	chr6:118569679	T/G	cg18833306	chr6:118973337	C6orf204	0.48	8.7	0.39	7.51e-17	Cardiac structure and function;
LUAD	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg20608306	chr11:116969690	SIK3	0.28	6.39	0.3	4.46e-10	Blood protein levels;
LUAD	cis	rs12711979	0.509	rs10178286	chr2:3823821	A/G	cg17052675	chr2:3827356	NA	0.82	18.09	0.66	1.34e-54	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs4253772	0.938	rs10154348	chr22:46638159	C/A	cg09491104	chr22:46646882	C22orf40	-0.54	-7.83	-0.36	4.09e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.31	0.33	1.37e-12	Tonsillectomy;
LUAD	cis	rs1865721	1.000	rs62089503	chr18:73177766	C/T	cg26385618	chr18:73139727	C18orf62	-0.43	-7.93	-0.36	1.96e-14	Intelligence;
LUAD	cis	rs7737355	0.755	rs12519233	chr5:130960093	C/A	cg06307176	chr5:131281290	NA	0.5	7.68	0.35	1.11e-13	Life satisfaction;
LUAD	cis	rs9584850	0.915	rs7983438	chr13:99103317	T/C	cg17380943	chr13:99100506	FARP1	-0.35	-6.61	-0.31	1.14e-10	Neuroticism;
LUAD	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23158103	chr7:148848205	ZNF398	-0.67	-12.58	-0.52	4.64e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg16479474	chr6:28041457	NA	0.46	7.94	0.36	1.8e-14	Depression;
LUAD	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg19052272	chr2:3704530	ALLC	-0.42	-7.35	-0.34	1.04e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs3540	0.960	rs2238327	chr15:91012949	G/A	cg10434728	chr15:90938212	IQGAP1	0.37	6.82	0.31	3.18e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs1018836	0.923	rs12545279	chr8:91636373	C/G	cg16814680	chr8:91681699	NA	-0.66	-10.95	-0.47	9.51e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg17105886	chr17:28927953	LRRC37B2	0.76	7.6	0.35	1.97e-13	Body mass index;
LUAD	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.82	9.53	0.42	1.22e-19	Yeast infection;
LUAD	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.77	-0.31	4.33e-11	Post bronchodilator FEV1;
LUAD	trans	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg04565464	chr8:145669602	NFKBIL2	-0.44	-6.77	-0.31	4.25e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.58	8.42	0.38	5.84e-16	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg20607798	chr8:58055168	NA	0.64	8.11	0.37	5.45e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg07167872	chr1:205819463	PM20D1	0.51	8.67	0.39	9e-17	Menarche (age at onset);
LUAD	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg03806693	chr22:41940476	POLR3H	-0.58	-8.35	-0.38	9.94e-16	Vitiligo;
LUAD	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg21427119	chr20:30132790	HM13	-0.62	-9.41	-0.42	3.2e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg06784218	chr1:46089804	CCDC17	0.52	11.43	0.49	1.47e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs472402	0.560	rs10065299	chr5:6654489	T/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.41	-6.37	-0.3	4.93e-10	Response to amphetamines;
LUAD	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg25894440	chr7:65020034	NA	-0.68	-7.31	-0.34	1.31e-12	Diabetic kidney disease;
LUAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg05457628	chr5:178986728	RUFY1	0.68	11.85	0.5	3.72e-28	Lung cancer;
LUAD	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg07061783	chr6:25882402	NA	0.52	8.24	0.37	2.24e-15	Blood metabolite levels;
LUAD	cis	rs3087591	0.960	rs2905869	chr17:29519016	C/A	cg24425628	chr17:29625626	OMG;NF1	0.4	6.51	0.3	2.14e-10	Hip circumference;
LUAD	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg13699009	chr12:122356056	WDR66	0.39	8.66	0.39	1.03e-16	Mean corpuscular volume;
LUAD	cis	rs1448094	0.842	rs12809288	chr12:86455427	C/T	cg06740227	chr12:86229804	RASSF9	-0.37	-6.79	-0.31	3.82e-11	Major depressive disorder;
LUAD	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg04800585	chr6:26043546	HIST1H2BB	0.41	6.59	0.31	1.33e-10	Urate levels;
LUAD	cis	rs6701037	0.875	rs1057301	chr1:175126524	T/C	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.38	-0.41	4.19e-19	Alcohol dependence;
LUAD	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg03929089	chr4:120376271	NA	-0.44	-6.76	-0.31	4.61e-11	HDL cholesterol;
LUAD	cis	rs1865721	0.682	rs3745081	chr18:73142923	A/G	cg26385618	chr18:73139727	C18orf62	-0.5	-10.02	-0.44	2.33e-21	Intelligence;
LUAD	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg09222892	chr1:25734099	RHCE	0.5	9.32	0.41	6.63e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg16205897	chr5:131564050	P4HA2	-0.34	-7.77	-0.35	5.94e-14	Blood metabolite levels;
LUAD	cis	rs1003719	1.000	rs2835608	chr21:38493455	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.24	0.37	2.17e-15	Eye color traits;
LUAD	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg07195577	chr17:27052828	TLCD1	0.47	6.53	0.3	1.88e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.68	12.53	0.52	7.54e-31	Lymphocyte counts;
LUAD	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg02751453	chr18:77725136	HSBP1L1	0.36	6.83	0.32	3e-11	Opioid sensitivity;
LUAD	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg17366294	chr4:99064904	C4orf37	0.57	9.68	0.43	3.64e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8077889	0.917	rs72836553	chr17:41909851	A/G	cg26893861	chr17:41843967	DUSP3	0.94	14.64	0.58	1.42e-39	Triglycerides;
LUAD	trans	rs2008242	0.593	rs985222	chr4:5229884	A/G	cg26099876	chr8:141644609	EIF2C2	-0.43	-7.1	-0.33	5.37e-12	Electrocardiographic conduction measures;
LUAD	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.54	-8.86	-0.4	2.17e-17	Primary sclerosing cholangitis;
LUAD	cis	rs220324	0.688	rs9637294	chr21:43571540	G/A	cg08841829	chr21:43638893	ABCG1	-0.52	-6.96	-0.32	1.33e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg27284194	chr4:1044797	NA	0.55	9.0	0.4	7.74e-18	Recombination rate (males);
LUAD	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg07936489	chr17:37558343	FBXL20	0.51	6.71	0.31	6.19e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs4638749	0.677	rs12712014	chr2:108812044	A/G	cg25838818	chr2:108905173	SULT1C2	0.4	7.1	0.33	5.27e-12	Blood pressure;
LUAD	cis	rs6993813	0.843	rs4401893	chr8:120044383	C/T	cg01975934	chr8:119970761	NA	-0.37	-7.22	-0.33	2.41e-12	Bone mineral density (hip);
LUAD	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg22117172	chr7:91764530	CYP51A1	0.33	7.16	0.33	3.62e-12	Breast cancer;
LUAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg22907277	chr7:1156413	C7orf50	0.7	8.24	0.37	2.2e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg13918804	chr1:2043761	PRKCZ	0.41	6.92	0.32	1.72e-11	Height;
LUAD	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg25173405	chr17:45401733	C17orf57	-0.44	-7.52	-0.34	3.31e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.21	-0.64	1.11e-50	Exhaled nitric oxide output;
LUAD	trans	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg01620082	chr3:125678407	NA	-0.81	-8.18	-0.37	3.36e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg12573674	chr2:1569213	NA	-0.56	-8.25	-0.37	2.01e-15	IgG glycosylation;
LUAD	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg10556349	chr10:835070	NA	-0.47	-7.31	-0.33	1.35e-12	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg06558623	chr16:89946397	TCF25	1.14	9.96	0.44	4.02e-21	Skin colour saturation;
LUAD	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg01097406	chr16:89675127	NA	0.44	9.5	0.42	1.58e-19	Vitiligo;
LUAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg10729496	chr3:10149963	C3orf24	0.57	9.22	0.41	1.37e-18	Alzheimer's disease;
LUAD	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg11871910	chr12:69753446	YEATS4	0.54	8.38	0.38	7.82e-16	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs62400317	0.859	rs12193812	chr6:45140761	C/T	cg18551225	chr6:44695536	NA	-0.52	-8.2	-0.37	2.96e-15	Total body bone mineral density;
LUAD	cis	rs7833986	1.000	rs66553445	chr8:57096781	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.76	10.2	0.44	5.57e-22	Height;
LUAD	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg21385522	chr1:16154831	NA	-0.68	-12.25	-0.51	1e-29	Dilated cardiomyopathy;
LUAD	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg12317470	chr15:67143691	NA	0.51	7.72	0.35	8.4e-14	Lung cancer (smoking interaction);
LUAD	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg17120908	chr11:65337727	SSSCA1	-0.62	-9.84	-0.43	1.08e-20	Bone mineral density;
LUAD	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg02421172	chr7:1938701	MAD1L1	0.46	6.46	0.3	2.83e-10	Bipolar disorder;
LUAD	cis	rs7000551	0.725	rs2248987	chr8:22399002	C/G	cg12081754	chr8:22256438	SLC39A14	0.46	7.59	0.35	2.06e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7799006	0.723	rs33922585	chr7:2285178	C/T	cg02951883	chr7:2050386	MAD1L1	-0.43	-6.54	-0.3	1.77e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg03886242	chr7:26192032	NFE2L3	-0.47	-8.19	-0.37	3.15e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg11645453	chr3:52864694	ITIH4	0.6	11.23	0.48	8.49e-26	Schizophrenia;
LUAD	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg27490568	chr2:178487706	NA	0.41	6.86	0.32	2.39e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.8	-0.31	3.59e-11	Neuroticism;
LUAD	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg23758822	chr17:41437982	NA	1.02	20.97	0.71	1.82e-67	Menopause (age at onset);
LUAD	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg10591111	chr5:226296	SDHA	-0.54	-6.95	-0.32	1.4e-11	Breast cancer;
LUAD	cis	rs737008	0.922	rs11074957	chr16:11378151	G/A	cg00044050	chr16:11439710	C16orf75	-0.44	-6.49	-0.3	2.4e-10	Obesity-related traits;
LUAD	cis	rs939658	0.683	rs1474256	chr15:79463847	C/T	cg17916960	chr15:79447300	NA	0.37	6.93	0.32	1.57e-11	Refractive error;
LUAD	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg15704280	chr7:45808275	SEPT13	-1.05	-23.8	-0.76	4.6e-80	Height;
LUAD	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg11965913	chr1:205819406	PM20D1	0.46	7.42	0.34	6.69e-13	Parkinson's disease;
LUAD	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg06636551	chr8:101224915	SPAG1	-0.38	-6.88	-0.32	2.15e-11	Atrioventricular conduction;
LUAD	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg16205897	chr5:131564050	P4HA2	-0.32	-7.0	-0.32	1.02e-11	Blood metabolite levels;
LUAD	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg04398451	chr17:18023971	MYO15A	0.78	14.15	0.57	1.76e-37	Total body bone mineral density;
LUAD	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg20129853	chr10:51489980	NA	-0.36	-7.16	-0.33	3.64e-12	Prostate-specific antigen levels;
LUAD	cis	rs1371614	0.611	rs3910615	chr2:27131022	A/G	cg00617064	chr2:27272375	NA	0.34	6.61	0.31	1.15e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs113835537	0.529	rs11227509	chr11:66281194	T/C	cg26679405	chr11:66247800	DPP3	-0.46	-6.67	-0.31	8.26e-11	Airway imaging phenotypes;
LUAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.93	-0.36	1.98e-14	Alzheimer's disease;
LUAD	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg17063962	chr7:91808500	NA	0.7	12.65	0.52	2.58e-31	Breast cancer;
LUAD	trans	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg00769240	chr8:12517080	NA	-0.43	-7.29	-0.33	1.53e-12	Blood pressure (smoking interaction);
LUAD	cis	rs8077889	0.619	rs1230399	chr17:41845403	C/T	cg26893861	chr17:41843967	DUSP3	-1.14	-26.6	-0.79	2.51e-92	Triglycerides;
LUAD	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg21153622	chr11:89784906	NA	-0.35	-6.95	-0.32	1.35e-11	HDL cholesterol;
LUAD	trans	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg07393940	chr7:158741817	NA	0.68	11.45	0.49	1.28e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.65	-10.44	-0.45	7.41e-23	IgG glycosylation;
LUAD	cis	rs2579519	0.547	rs11683523	chr2:96544855	T/C	cg23100626	chr2:96804247	ASTL	0.31	7.56	0.34	2.6e-13	Diastolic blood pressure;
LUAD	trans	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg01620082	chr3:125678407	NA	-0.84	-8.08	-0.37	6.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg18854424	chr1:2615690	NA	0.42	9.1	0.4	3.71e-18	Ulcerative colitis;
LUAD	trans	rs7395662	1.000	rs4882130	chr11:48588954	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.12e-12	HDL cholesterol;
LUAD	trans	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg04775059	chr7:64541387	NA	0.53	7.03	0.32	8.43e-12	Aortic root size;
LUAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg11062466	chr8:58055876	NA	0.68	8.47	0.38	4.11e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs11800820	0.557	rs12735611	chr1:246660197	G/T	cg16700716	chr1:246684329	NA	0.36	6.64	0.31	9.81e-11	Obesity-related traits;
LUAD	cis	rs16910800	1.000	rs2468655	chr11:23197060	G/A	cg20040320	chr11:23191996	NA	0.48	7.21	0.33	2.62e-12	Cancer;
LUAD	cis	rs12681288	0.550	rs12674921	chr8:957969	A/C	cg04851639	chr8:1020857	NA	-0.34	-7.97	-0.36	1.5e-14	Schizophrenia;
LUAD	cis	rs4702	0.611	rs7177338	chr15:91428636	G/A	cg05469396	chr15:91419421	FURIN	0.46	7.87	0.36	2.95e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg01416388	chr22:39784598	NA	-0.45	-6.78	-0.31	4.18e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg07936489	chr17:37558343	FBXL20	-0.52	-7.05	-0.32	7.41e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs11249608	0.548	rs11958355	chr5:178451640	T/C	cg01312482	chr5:178451176	ZNF879	-0.44	-6.81	-0.31	3.46e-11	Pubertal anthropometrics;
LUAD	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg09165964	chr15:75287851	SCAMP5	-0.47	-7.12	-0.33	4.53e-12	Blood trace element (Zn levels);
LUAD	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-8.22	-0.37	2.44e-15	Monocyte percentage of white cells;
LUAD	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.85	12.07	0.51	5.21e-29	Smoking behavior;
LUAD	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg11645453	chr3:52864694	ITIH4	0.58	10.69	0.46	9.13e-24	Schizophrenia;
LUAD	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	12.72	0.53	1.25e-31	Monocyte percentage of white cells;
LUAD	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg03806693	chr22:41940476	POLR3H	-0.81	-11.46	-0.49	1.15e-26	Vitiligo;
LUAD	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg15448220	chr1:150897856	SETDB1	0.53	8.97	0.4	9.86e-18	Melanoma;
LUAD	trans	rs877282	0.755	rs11253399	chr10:790030	T/A	cg22713356	chr15:30763199	NA	1.11	15.92	0.61	4.58e-45	Uric acid levels;
LUAD	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg26513180	chr16:89883248	FANCA	0.69	12.99	0.53	1.1e-32	Vitiligo;
LUAD	cis	rs57994353	0.897	rs3812594	chr9:139368953	G/A	cg14169450	chr9:139327907	INPP5E	0.41	6.42	0.3	3.59e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03620551	chr4:128886807	MFSD8;C4orf29	-0.4	-6.66	-0.31	8.75e-11	Cancer;
LUAD	cis	rs1595825	0.891	rs7592344	chr2:198572461	C/T	cg11031976	chr2:198649780	BOLL	-0.45	-6.92	-0.32	1.71e-11	Ulcerative colitis;
LUAD	cis	rs1018836	0.786	rs4734237	chr8:91533361	A/C	cg16814680	chr8:91681699	NA	0.45	7.71	0.35	9.2e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs375066	0.935	rs11673020	chr19:44374631	A/G	cg12072164	chr19:44306565	LYPD5	0.32	6.53	0.3	1.86e-10	Breast cancer;
LUAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.63	-11.14	-0.48	1.83e-25	Lymphocyte counts;
LUAD	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg22139774	chr2:100720529	AFF3	-0.35	-6.69	-0.31	7.31e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs7680126	0.536	rs4484299	chr4:10050451	A/G	cg00071950	chr4:10020882	SLC2A9	0.58	7.48	0.34	4.41e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	trans	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg18335740	chr13:41363409	SLC25A15	0.56	9.5	0.42	1.61e-19	Lewy body disease;
LUAD	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg12863693	chr15:85201151	NMB	0.36	6.49	0.3	2.37e-10	Schizophrenia;
LUAD	cis	rs7193541	0.859	rs12598791	chr16:74500745	A/C	cg01733217	chr16:74700730	RFWD3	0.54	8.75	0.39	5.17e-17	Multiple myeloma;
LUAD	trans	rs5756813	0.688	rs5995498	chr22:38196573	T/G	cg19894588	chr14:64061835	NA	-0.55	-7.77	-0.35	5.91e-14	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.57	-0.3	1.45e-10	Breast cancer;
LUAD	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg13393036	chr8:95962371	TP53INP1	-0.4	-9.74	-0.43	2.33e-20	Type 2 diabetes;
LUAD	cis	rs12893668	0.703	rs2403197	chr14:104053764	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.94	-0.36	1.85e-14	Reticulocyte count;
LUAD	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg25324976	chr17:61989376	CSHL1	-0.34	-6.81	-0.31	3.31e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg07936489	chr17:37558343	FBXL20	0.54	7.97	0.36	1.49e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg05665937	chr4:1216051	CTBP1	0.42	7.04	0.32	7.61e-12	Obesity-related traits;
LUAD	cis	rs686320	1.000	rs1194758	chr11:65238085	A/T	cg21890820	chr11:65308645	LTBP3	-0.64	-7.18	-0.33	3.25e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg05887092	chr17:76393375	PGS1	0.41	7.28	0.33	1.65e-12	HDL cholesterol levels;
LUAD	trans	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg13698153	chr12:118541722	VSIG10	0.43	6.58	0.3	1.43e-10	Hemoglobin concentration;
LUAD	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg25894440	chr7:65020034	NA	-0.69	-7.33	-0.34	1.21e-12	Diabetic kidney disease;
LUAD	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg10544611	chr16:67998164	SLC12A4	-0.69	-8.21	-0.37	2.79e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07157834	chr1:205819609	PM20D1	-0.52	-9.12	-0.41	3.15e-18	Menarche (age at onset);
LUAD	trans	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.06	-25.37	-0.78	5.3e-87	Colorectal cancer;
LUAD	cis	rs713477	1.000	rs7149622	chr14:55909402	T/C	cg13175173	chr14:55914753	NA	-0.33	-6.95	-0.32	1.41e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg07217954	chr7:1067459	C7orf50	0.4	6.54	0.3	1.78e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg15448220	chr1:150897856	SETDB1	-0.43	-6.89	-0.32	2e-11	Urate levels;
LUAD	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg00129232	chr17:37814104	STARD3	-0.44	-7.45	-0.34	5.14e-13	Asthma;
LUAD	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg25036284	chr2:26402008	FAM59B	-0.56	-7.93	-0.36	2.01e-14	Gut microbiome composition (summer);
LUAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.41	0.34	6.94e-13	Electroencephalogram traits;
LUAD	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg15997130	chr1:24165203	NA	0.55	9.44	0.42	2.63e-19	Immature fraction of reticulocytes;
LUAD	cis	rs2692947	0.644	rs1168968	chr2:96825363	C/T	cg23100626	chr2:96804247	ASTL	0.38	10.03	0.44	2.19e-21	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.74	0.31	5.33e-11	Motion sickness;
LUAD	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg17063962	chr7:91808500	NA	0.67	11.92	0.5	1.89e-28	Breast cancer;
LUAD	trans	rs3857536	0.813	rs9354405	chr6:66948575	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.67	-0.31	7.9e-11	Blood trace element (Cu levels);
LUAD	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18099408	chr3:52552593	STAB1	-0.46	-8.07	-0.37	7.46e-15	Bipolar disorder;
LUAD	cis	rs6076065	0.748	rs6137933	chr20:23383103	A/T	cg11657817	chr20:23433608	CST11	0.57	12.07	0.51	4.8e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs9972944	0.899	rs9972954	chr17:63771050	T/C	cg07283582	chr17:63770753	CCDC46	0.52	11.77	0.5	7.19e-28	Total body bone mineral density;
LUAD	trans	rs4471463	1	rs4471463	chr11:112983595	C/T	cg01289020	chr16:71323706	FTSJD1	-0.38	-6.44	-0.3	3.24e-10	Cannabis use;
LUAD	cis	rs4072705	0.967	rs4838209	chr9:127528842	C/T	cg13476313	chr9:127244764	NR5A1	0.33	7.94	0.36	1.84e-14	Menarche (age at onset);
LUAD	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg23301539	chr8:142222248	SLC45A4	0.48	8.75	0.39	5.18e-17	Immature fraction of reticulocytes;
LUAD	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.59	11.09	0.47	2.97e-25	Eosinophil percentage of white cells;
LUAD	cis	rs2573652	0.723	rs4577068	chr15:100515959	T/A	cg09918751	chr15:100517450	ADAMTS17	-0.63	-11.35	-0.48	3.1e-26	Height;
LUAD	trans	rs7395662	0.658	rs8189235	chr11:48740064	G/A	cg00717180	chr2:96193071	NA	0.35	6.46	0.3	2.81e-10	HDL cholesterol;
LUAD	cis	rs7326068	0.558	rs8002588	chr13:21339386	A/G	cg27499820	chr13:21296301	IL17D	0.57	8.55	0.38	2.3e-16	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs7020830	0.861	rs13289001	chr9:37311592	A/G	cg14294708	chr9:37120828	ZCCHC7	0.88	17.78	0.65	3.34e-53	Schizophrenia;
LUAD	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg18833306	chr6:118973337	C6orf204	-0.49	-7.22	-0.33	2.39e-12	Diastolic blood pressure;
LUAD	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg15181151	chr6:150070149	PCMT1	0.33	6.56	0.3	1.62e-10	Testicular germ cell tumor;
LUAD	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg14092988	chr3:52407081	DNAH1	0.45	8.94	0.4	1.19e-17	Bipolar disorder;
LUAD	trans	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.52	9.73	0.43	2.52e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg04287289	chr16:89883240	FANCA	0.67	12.16	0.51	2.18e-29	Vitiligo;
LUAD	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14829155	chr15:31115871	NA	-0.59	-9.66	-0.43	4.5e-20	Huntington's disease progression;
LUAD	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.02	0.32	8.88e-12	Parkinson's disease;
LUAD	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.77e-11	Depression;
LUAD	cis	rs12545109	1.000	rs1975284	chr8:57314663	A/G	cg09654669	chr8:57350985	NA	-0.61	-8.59	-0.39	1.71e-16	Obesity-related traits;
LUAD	cis	rs4889855	0.530	rs9901467	chr17:78574008	G/A	cg16591659	chr17:78472290	NA	-0.43	-7.62	-0.35	1.62e-13	Fractional excretion of uric acid;
LUAD	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg25427524	chr10:38739819	LOC399744	0.56	9.89	0.43	6.99e-21	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg27411982	chr8:10470053	RP1L1	-0.39	-7.12	-0.33	4.65e-12	Systolic blood pressure;
LUAD	cis	rs68170813	0.559	rs113422695	chr7:107070208	T/A	cg23024343	chr7:107201750	COG5	0.5	6.84	0.32	2.85e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg24818145	chr4:99064322	C4orf37	0.45	7.12	0.33	4.55e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7665090	1.000	rs13112557	chr4:103552253	T/C	cg07973026	chr4:103553119	MANBA	0.48	8.61	0.39	1.41e-16	Primary biliary cholangitis;
LUAD	cis	rs2294693	1.000	rs2294693	chr6:41005502	T/C	cg14769373	chr6:40998127	UNC5CL	-0.54	-8.39	-0.38	7.14e-16	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.32	6.84	0.32	2.86e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg00666640	chr1:248458726	OR2T12	0.29	6.74	0.31	5.05e-11	Common traits (Other);
LUAD	trans	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.97	0.44	3.58e-21	Ulcerative colitis;
LUAD	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg21605333	chr4:119757512	SEC24D	0.97	8.73	0.39	6.15e-17	Cannabis dependence symptom count;
LUAD	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg07606381	chr6:8435919	SLC35B3	0.42	6.82	0.31	3.13e-11	Motion sickness;
LUAD	cis	rs2880765	0.546	rs11637726	chr15:86059271	C/T	cg13263323	chr15:86062960	AKAP13	0.51	8.59	0.39	1.71e-16	Coronary artery disease;
LUAD	cis	rs11681884	1.000	rs72950839	chr2:113846794	G/T	cg12858261	chr2:113808755	IL1F8	0.53	6.53	0.3	1.84e-10	Stroke;
LUAD	cis	rs17152411	1.000	rs11245423	chr10:126588435	C/A	cg07906193	chr10:126599966	NA	0.53	7.55	0.34	2.67e-13	Height;
LUAD	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-8.51	-0.38	3.04e-16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg08621418	chr6:79944414	HMGN3	-0.49	-6.62	-0.31	1.06e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg22875332	chr1:76189707	ACADM	0.87	15.98	0.61	2.64e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs864537	0.646	rs2995091	chr1:167434277	T/C	cg22356347	chr1:167427500	CD247	-0.5	-9.88	-0.43	7.35e-21	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs68170813	0.559	rs17427849	chr7:106864237	A/G	cg23024343	chr7:107201750	COG5	0.5	7.25	0.33	2.01e-12	Coronary artery disease;
LUAD	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg12458913	chr13:53173898	NA	0.42	7.51	0.34	3.44e-13	Lewy body disease;
LUAD	cis	rs1232027	0.622	rs1677652	chr5:79967954	G/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.82	-0.31	3.06e-11	Huntington's disease progression;
LUAD	cis	rs10896135	0.526	rs12795774	chr11:66381517	T/C	cg15964523	chr11:66469143	SPTBN2	0.42	6.86	0.32	2.46e-11	Bipolar disorder;
LUAD	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.71	-12.31	-0.51	5.41e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.04e-13	Morning vs. evening chronotype;
LUAD	cis	rs921968	0.565	rs12611632	chr2:219621258	C/T	cg02176678	chr2:219576539	TTLL4	-0.59	-12.0	-0.5	9.65e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg19729930	chr2:74357872	NA	0.91	16.56	0.63	7.9e-48	Gestational age at birth (maternal effect);
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg00832928	chr3:150329458	SELT	-0.45	-7.13	-0.33	4.32e-12	Height;
LUAD	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.57	-0.38	2.01e-16	Total body bone mineral density;
LUAD	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg05368731	chr17:41323189	NBR1	-0.97	-20.53	-0.71	1.7e-65	Menopause (age at onset);
LUAD	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.82	-0.58	2.65e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7095607	0.538	rs2255027	chr10:69920911	T/C	cg18986048	chr10:69913749	MYPN	0.46	7.83	0.36	3.87e-14	Lung function (FVC);
LUAD	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg18230493	chr5:56204884	C5orf35	-0.64	-10.23	-0.45	4.34e-22	Coronary artery disease;
LUAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg05434287	chr7:2030229	MAD1L1	0.39	6.5	0.3	2.26e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2279817	0.863	rs6586569	chr1:18027377	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.52	8.66	0.39	9.87e-17	Neuroticism;
LUAD	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg08999081	chr20:33150536	PIGU	-0.63	-14.12	-0.57	2.25e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg25838465	chr1:92012736	NA	-0.54	-10.69	-0.46	9.28e-24	Breast cancer;
LUAD	cis	rs7586879	0.828	rs10195271	chr2:25108650	A/C	cg04586622	chr2:25135609	ADCY3	-0.35	-7.19	-0.33	3.01e-12	Body mass index;
LUAD	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg21890820	chr11:65308645	LTBP3	0.47	7.56	0.35	2.47e-13	Bone mineral density;
LUAD	cis	rs6908034	0.660	rs12525506	chr6:19794234	G/T	cg02682789	chr6:19804855	NA	0.92	9.05	0.4	5.23e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg26587870	chr6:27730563	NA	-0.64	-6.95	-0.32	1.43e-11	Breast cancer;
LUAD	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg26818010	chr10:134567672	INPP5A	-0.87	-14.96	-0.59	6.53e-41	Migraine;
LUAD	cis	rs62229266	0.773	rs878606	chr21:37406692	G/A	cg08632701	chr21:37451849	NA	-0.46	-7.61	-0.35	1.84e-13	Mitral valve prolapse;
LUAD	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg13393036	chr8:95962371	TP53INP1	-0.44	-10.49	-0.45	4.75e-23	Type 2 diabetes;
LUAD	cis	rs8014204	0.806	rs11159104	chr14:75293374	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.35	-6.6	-0.31	1.26e-10	Caffeine consumption;
LUAD	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg01616529	chr11:638424	DRD4	-0.45	-6.55	-0.3	1.7e-10	Systemic lupus erythematosus;
LUAD	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg00898013	chr13:113819073	PROZ	-0.65	-11.84	-0.5	4.1e-28	Platelet distribution width;
LUAD	cis	rs36715	1.000	rs2617621	chr5:127546266	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	6.83	0.32	2.88e-11	Breast cancer;
LUAD	cis	rs4664304	0.903	rs72957578	chr2:160754133	G/C	cg23995753	chr2:160760732	LY75	-0.47	-8.38	-0.38	7.91e-16	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs73206853	0.841	rs16940933	chr12:111102574	C/A	cg12870014	chr12:110450643	ANKRD13A	0.61	6.79	0.31	3.77e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg09455208	chr3:40491958	NA	-0.59	-13.13	-0.54	2.72e-33	Renal cell carcinoma;
LUAD	cis	rs17685	0.767	rs10954732	chr7:75611149	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.42	8.15	0.37	4.27e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01913188	chr2:44223249	LRPPRC	-0.44	-7.21	-0.33	2.61e-12	Cancer;
LUAD	cis	rs7771547	0.692	rs9380580	chr6:36551396	T/C	cg07856975	chr6:36356162	ETV7	0.45	6.39	0.3	4.41e-10	Platelet distribution width;
LUAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-9.52	-0.42	1.32e-19	Longevity;Endometriosis;
LUAD	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg17279839	chr7:150038598	RARRES2	0.46	7.53	0.34	3.17e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg17644776	chr2:200775616	C2orf69	0.54	7.32	0.34	1.29e-12	Schizophrenia;
LUAD	cis	rs12155623	0.803	rs6987879	chr8:49808062	T/C	cg22283653	chr8:49824208	NA	-0.48	-8.6	-0.39	1.55e-16	Sudden cardiac arrest;
LUAD	trans	rs7944735	0.507	rs7396592	chr11:48100837	T/C	cg03929089	chr4:120376271	NA	-0.65	-9.28	-0.41	8.86e-19	Intraocular pressure;
LUAD	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.2	0.37	2.92e-15	Menopause (age at onset);
LUAD	cis	rs151234	0.741	rs11074908	chr16:28608356	C/T	cg04609801	chr16:28609176	SULT1A2	0.58	7.91	0.36	2.26e-14	Platelet distribution width;
LUAD	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg11250194	chr11:61601937	FADS2	-0.62	-8.3	-0.37	1.41e-15	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs9863	0.804	rs80270210	chr12:124447397	G/T	cg17723958	chr12:124429295	CCDC92	-0.42	-6.72	-0.31	5.8200000000000003e-11	White blood cell count;
LUAD	cis	rs7326068	0.504	rs7983020	chr13:21239941	C/T	cg27499820	chr13:21296301	IL17D	-0.44	-7.97	-0.36	1.48e-14	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs12545109	0.571	rs4237014	chr8:57284479	C/A	cg21220214	chr8:57350948	NA	-0.68	-9.29	-0.41	8.51e-19	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg14343924	chr8:8086146	FLJ10661	-0.49	-7.64	-0.35	1.47e-13	Joint mobility (Beighton score);
LUAD	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg20300514	chr1:2120985	C1orf86;LOC100128003	0.37	6.45	0.3	3.07e-10	Height;
LUAD	cis	rs9796	0.835	rs2927062	chr15:41302687	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.4	-7.57	-0.35	2.39e-13	Menopause (age at onset);
LUAD	cis	rs2455799	0.613	rs3924773	chr3:15796853	G/A	cg16303742	chr3:15540471	COLQ	-0.52	-9.72	-0.43	2.83e-20	Mean platelet volume;
LUAD	cis	rs4074961	0.527	rs10908356	chr1:38038388	G/A	cg12696750	chr1:38022466	DNALI1	0.38	6.61	0.31	1.16e-10	Axial length;
LUAD	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06028808	chr11:68637592	NA	0.5	8.37	0.38	8.81e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg19875535	chr5:140030758	IK	0.42	6.87	0.32	2.27e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg06221963	chr1:154839813	KCNN3	-0.82	-18.75	-0.67	1.6e-57	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg06618935	chr21:46677482	NA	-0.51	-10.16	-0.44	7.88e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11644478	chr21:40555479	PSMG1	0.71	11.9	0.5	2.28e-28	Cognitive function;
LUAD	cis	rs34638657	0.574	rs4143216	chr16:82216491	G/A	cg09439754	chr16:82129088	HSD17B2	-0.35	-6.65	-0.31	9.25e-11	Lung adenocarcinoma;
LUAD	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg00634984	chr7:65235879	NA	0.49	6.52	0.3	2.02e-10	Aortic root size;
LUAD	cis	rs4660214	0.666	rs1984143	chr1:39756317	G/A	cg27567593	chr1:39956653	BMP8A	0.35	6.92	0.32	1.69e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs12753569	0.967	rs6696116	chr1:76483732	C/T	cg00791851	chr1:76518896	NA	-0.29	-6.48	-0.3	2.52e-10	Personality dimensions;
LUAD	cis	rs7937890	0.507	rs4463820	chr11:14556342	A/G	cg23387056	chr11:14280742	SPON1	-0.35	-6.85	-0.32	2.68e-11	Mitochondrial DNA levels;
LUAD	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg18209359	chr17:80159595	CCDC57	-0.4	-6.93	-0.32	1.59e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs17095355	1.000	rs12570230	chr10:111691614	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.71	-9.6	-0.42	7.07e-20	Biliary atresia;
LUAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg11494091	chr17:61959527	GH2	-0.75	-18.75	-0.67	1.53e-57	Prudent dietary pattern;
LUAD	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg09835421	chr16:68378352	PRMT7	-0.83	-8.89	-0.4	1.82e-17	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs7395662	0.890	rs1847652	chr11:48975013	A/G	cg00717180	chr2:96193071	NA	0.37	6.86	0.32	2.4e-11	HDL cholesterol;
LUAD	cis	rs2274273	0.870	rs7158768	chr14:55763612	A/C	cg04306507	chr14:55594613	LGALS3	0.41	8.44	0.38	4.94e-16	Protein biomarker;
LUAD	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.62	-0.39	1.38e-16	Height;
LUAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00166722	chr3:10149974	C3orf24	0.67	11.22	0.48	9.86e-26	Alzheimer's disease;
LUAD	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg21775007	chr8:11205619	TDH	0.47	8.19	0.37	3.06e-15	Retinal vascular caliber;
LUAD	cis	rs9902453	1.000	rs60967688	chr17:28437052	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	9.02	0.4	6.54e-18	Coffee consumption (cups per day);
LUAD	cis	rs6961069	0.777	rs4545029	chr7:80252518	T/G	cg04458919	chr7:80252533	CD36	0.38	7.29	0.33	1.55e-12	Platelet count;
LUAD	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12923728	chr3:195709715	SDHAP1	-0.77	-13.01	-0.53	8.46e-33	Pancreatic cancer;
LUAD	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg09537434	chr19:41945824	ATP5SL	-0.53	-8.43	-0.38	5.49e-16	Height;
LUAD	cis	rs10865541	0.902	rs12474836	chr2:3418874	A/G	cg22182287	chr2:3452347	TTC15	0.46	8.04	0.36	9.09e-15	Obesity-related traits;
LUAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03188948	chr7:1209495	NA	0.5	8.51	0.38	3.07e-16	Longevity;Endometriosis;
LUAD	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21582582	chr3:182698605	DCUN1D1	0.72	13.54	0.55	5.83e-35	Intelligence (multi-trait analysis);
LUAD	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg04117972	chr1:227635322	NA	0.66	6.73	0.31	5.49e-11	Major depressive disorder;
LUAD	cis	rs62238980	0.614	rs77949114	chr22:32453504	T/C	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18404041	chr3:52824283	ITIH1	-0.6	-12.47	-0.52	1.29e-30	Electroencephalogram traits;
LUAD	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg25767906	chr1:53392781	SCP2	-0.49	-9.1	-0.4	3.58e-18	Monocyte count;
LUAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg17178900	chr1:205818956	PM20D1	0.72	14.93	0.59	8.27e-41	Menarche (age at onset);
LUAD	cis	rs807669	0.903	rs1018764	chr22:19172006	T/C	cg02655711	chr22:19163373	SLC25A1	0.87	19.29	0.68	6.2e-60	Metabolite levels;
LUAD	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg07507251	chr3:52567010	NT5DC2	0.39	7.46	0.34	4.85e-13	Bipolar disorder;
LUAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.41	-7.53	-0.34	3.17e-13	Longevity;Endometriosis;
LUAD	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg00814883	chr7:100076585	TSC22D4	-0.85	-12.42	-0.52	2.13e-30	Platelet count;
LUAD	cis	rs13191362	0.573	rs9365499	chr6:163271833	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.71	10.17	0.44	6.88e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4604732	0.631	rs34330532	chr1:247626844	G/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg26408565	chr15:76604113	ETFA	-0.49	-8.16	-0.37	3.82e-15	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27286337	chr10:134555280	INPP5A	0.72	9.72	0.43	2.76e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg27284194	chr4:1044797	NA	0.71	10.27	0.45	2.96e-22	Recombination rate (females);
LUAD	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	7.59	0.35	2.12e-13	Personality dimensions;
LUAD	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg02753203	chr1:228287806	NA	-0.51	-9.38	-0.42	4e-19	Diastolic blood pressure;
LUAD	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.49	6.66	0.31	8.62e-11	Gut microbiome composition (summer);
LUAD	cis	rs7851660	0.527	rs7859751	chr9:100575888	C/T	cg13688889	chr9:100608707	NA	-0.6	-10.53	-0.46	3.4e-23	Strep throat;
LUAD	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg00071950	chr4:10020882	SLC2A9	-0.59	-11.2	-0.48	1.15e-25	Bone mineral density;
LUAD	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11890956	chr21:40555474	PSMG1	0.78	13.41	0.55	1.95e-34	Cognitive function;
LUAD	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg04546413	chr19:29218101	NA	0.64	8.11	0.37	5.67e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-8.99	-0.4	8.6e-18	Life satisfaction;
LUAD	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg15691649	chr6:25882328	NA	-0.5	-7.16	-0.33	3.66e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg10518543	chr12:38710700	ALG10B	0.42	6.48	0.3	2.59e-10	Bladder cancer;
LUAD	cis	rs12760731	0.720	rs12026110	chr1:178410984	G/A	cg00404053	chr1:178313656	RASAL2	0.61	7.84	0.36	3.65e-14	Obesity-related traits;
LUAD	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	11.85	0.5	3.72e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.26	-0.54	8.48e-34	Chronic sinus infection;
LUAD	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg23533926	chr12:111358616	MYL2	-0.43	-7.3	-0.33	1.45e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg06627628	chr2:24431161	ITSN2	-0.68	-10.85	-0.47	2.35e-24	Asthma;
LUAD	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg07870213	chr5:140052090	DND1	-0.72	-11.11	-0.48	2.43e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg27454412	chr7:1067447	C7orf50	0.43	6.93	0.32	1.55e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7617773	0.780	rs11706277	chr3:48360433	A/G	cg11946769	chr3:48343235	NME6	0.43	6.52	0.3	2.01e-10	Coronary artery disease;
LUAD	cis	rs12681287	0.752	rs10086569	chr8:87247209	C/T	cg27223183	chr8:87520930	FAM82B	-0.59	-8.3	-0.37	1.41e-15	Caudate activity during reward;
LUAD	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	trans	rs3960554	0.808	rs57721466	chr7:75710049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.82	11.13	0.48	2.14e-25	Eotaxin levels;
LUAD	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	12.15	0.51	2.46e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs11214589	0.747	rs2155462	chr11:113206799	A/C	cg14159747	chr11:113255604	NA	0.62	12.64	0.52	2.82e-31	Neuroticism;
LUAD	cis	rs9843304	0.526	rs9850213	chr3:149202590	C/T	cg08667024	chr3:149219783	TM4SF4	0.38	7.01	0.32	9.34e-12	Gallstone disease;
LUAD	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg24818145	chr4:99064322	C4orf37	0.49	8.09	0.37	6.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs754466	0.580	rs2289311	chr10:79565655	G/A	cg17075019	chr10:79541650	NA	-0.89	-18.85	-0.68	5.44e-58	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9826463	0.759	rs56161530	chr3:142332376	C/A	cg20824294	chr3:142316082	PLS1	0.46	6.92	0.32	1.63e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.25	-0.33	2.06e-12	Total cholesterol levels;
LUAD	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg04944784	chr2:26401820	FAM59B	-0.76	-10.5	-0.45	4.4e-23	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.5e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs1395	0.744	rs1122227	chr2:27544285	C/T	cg23587288	chr2:27483067	SLC30A3	-0.39	-7.11	-0.33	5.09e-12	Blood metabolite levels;
LUAD	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg04181038	chr4:183730758	NA	0.73	10.72	0.46	6.71e-24	Pediatric autoimmune diseases;
LUAD	cis	rs17739794	0.517	rs35856917	chr8:774395	C/G	cg01971667	chr8:817044	NA	-0.34	-6.75	-0.31	4.81e-11	Clozapine-induced cytotoxicity;
LUAD	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg17264618	chr3:40429014	ENTPD3	0.41	9.02	0.4	6.87e-18	Renal cell carcinoma;
LUAD	cis	rs9549328	0.699	rs2993345	chr13:113617086	C/T	cg17524180	chr13:113633600	MCF2L	0.3	6.48	0.3	2.48e-10	Systolic blood pressure;
LUAD	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg19318889	chr4:1322082	MAEA	0.5	8.37	0.38	8.26e-16	Obesity-related traits;
LUAD	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg04369109	chr6:150039330	LATS1	-0.44	-7.54	-0.34	2.93e-13	Lung cancer;
LUAD	cis	rs7737355	0.947	rs31253	chr5:130833011	A/C	cg25547332	chr5:131281432	NA	0.43	6.64	0.31	9.7e-11	Life satisfaction;
LUAD	cis	rs4631830	0.832	rs2611513	chr10:51515457	A/G	cg20129853	chr10:51489980	NA	0.33	6.81	0.31	3.31e-11	Prostate-specific antigen levels;
LUAD	cis	rs7677751	0.848	rs4635872	chr4:55099041	C/A	cg17187183	chr4:55093834	PDGFRA	0.51	8.59	0.39	1.67e-16	Corneal astigmatism;
LUAD	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg11062466	chr8:58055876	NA	0.44	6.54	0.3	1.74e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg18402987	chr7:1209562	NA	0.51	7.6	0.35	1.94e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs76878669	0.561	rs11227465	chr11:66115879	T/A	cg18002602	chr11:66138449	SLC29A2	-0.48	-10.23	-0.45	4.43e-22	Educational attainment (years of education);
LUAD	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs4650994	1.000	rs6660445	chr1:178528871	C/T	cg05059571	chr16:84539110	KIAA1609	-0.59	-10.06	-0.44	1.73e-21	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.72	0.31	5.85e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5758659	0.633	rs762995	chr22:42672124	A/G	cg15128208	chr22:42549153	NA	-0.38	-7.57	-0.35	2.28e-13	Cognitive function;
LUAD	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg05865280	chr17:75406074	SEPT9	0.61	18.33	0.67	1.2e-55	Airflow obstruction;
LUAD	cis	rs494562	0.892	rs521005	chr6:86116542	A/G	cg13315970	chr6:86159197	NT5E	0.71	7.97	0.36	1.52e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7187994	0.848	rs12933228	chr16:84770691	G/A	cg07647771	chr16:84786436	USP10	-0.37	-9.08	-0.4	4.25e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs7172809	0.573	rs78481361	chr15:77654784	C/T	cg11865553	chr15:77376250	NA	-0.39	-6.7	-0.31	6.75e-11	Glucose homeostasis traits;
LUAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg12419862	chr22:24373484	LOC391322	0.67	9.92	0.43	5.39e-21	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg06558623	chr16:89946397	TCF25	0.95	10.5	0.45	4.43e-23	Skin colour saturation;
LUAD	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.4	8.03	0.36	9.71e-15	Depression;
LUAD	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg20673091	chr1:2541236	MMEL1	0.44	9.69	0.43	3.41e-20	Ulcerative colitis;
LUAD	trans	rs8002861	0.935	rs9533672	chr13:44451180	C/T	cg17145862	chr1:211918768	LPGAT1	0.77	17.96	0.66	4.93e-54	Leprosy;
LUAD	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg06064525	chr11:970664	AP2A2	-0.43	-8.37	-0.38	8.23e-16	Alzheimer's disease (late onset);
LUAD	cis	rs4711350	0.765	rs2182658	chr6:33748831	G/T	cg16010596	chr6:33739607	LEMD2	0.4	7.49	0.34	4.18e-13	Schizophrenia;
LUAD	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg03874509	chr1:107600012	PRMT6	0.56	9.75	0.43	2.15e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg17346650	chr17:80929145	B3GNTL1	0.4	6.8	0.31	3.59e-11	Glycated hemoglobin levels;
LUAD	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg06064525	chr11:970664	AP2A2	-0.54	-10.96	-0.47	9.27e-25	Alzheimer's disease (late onset);
LUAD	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg03929089	chr4:120376271	NA	-0.89	-17.25	-0.64	7.07e-51	Height;
LUAD	cis	rs11690462	0.963	rs12471804	chr2:26559717	C/G	cg04726446	chr2:26624865	C2orf39	0.35	6.36	0.3	5.34e-10	Coronary artery disease;
LUAD	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	7.08	0.33	5.91e-12	Tonsillectomy;
LUAD	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg10755058	chr3:40428713	ENTPD3	0.39	7.56	0.35	2.48e-13	Renal cell carcinoma;
LUAD	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg09873201	chr16:3507582	NAT15	-0.5	-7.43	-0.34	5.98e-13	Tuberculosis;
LUAD	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg10596483	chr8:143751796	JRK	0.46	7.32	0.34	1.25e-12	Schizophrenia;
LUAD	cis	rs13082711	0.911	rs34316374	chr3:27437385	G/C	cg02860705	chr3:27208620	NA	0.59	9.11	0.4	3.39e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-10.92	-0.47	1.25e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6684514	1.000	rs2277871	chr1:156246742	A/G	cg16558208	chr1:156270281	VHLL	0.53	9.58	0.42	8.12e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs6684514	1.000	rs11264464	chr1:156250887	T/G	cg16558208	chr1:156270281	VHLL	0.53	9.58	0.42	8.12e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg22117172	chr7:91764530	CYP51A1	-0.31	-6.42	-0.3	3.56e-10	Breast cancer;
LUAD	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg06627628	chr2:24431161	ITSN2	-0.4	-6.91	-0.32	1.82e-11	Asthma;
LUAD	trans	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg19862616	chr7:65841803	NCRNA00174	1.05	25.05	0.77	1.34e-85	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg18538332	chr22:24372958	LOC391322	0.53	9.04	0.4	5.9e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg22681709	chr2:178499509	PDE11A	-0.44	-7.37	-0.34	9.06e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg22563815	chr15:78856949	CHRNA5	-0.32	-6.49	-0.3	2.44e-10	Sudden cardiac arrest;
LUAD	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.86	0.36	3.32e-14	Parkinson's disease;
LUAD	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03352830	chr11:487213	PTDSS2	0.68	8.37	0.38	8.44e-16	Body mass index;
LUAD	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg12016809	chr21:47604291	C21orf56	0.45	7.53	0.34	3.17e-13	Testicular germ cell tumor;
LUAD	cis	rs12681288	0.748	rs2701935	chr8:1028618	T/A	cg15309053	chr8:964076	NA	0.39	8.1	0.37	6.06e-15	Schizophrenia;
LUAD	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg06671706	chr8:8559999	CLDN23	0.65	11.35	0.48	2.99e-26	Obesity-related traits;
LUAD	cis	rs3774830	0.967	rs1004375	chr4:5438478	G/A	cg26943120	chr4:5472116	STK32B	0.32	6.4	0.3	4.25e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg01874867	chr7:94954059	PON1	-0.52	-6.93	-0.32	1.55e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg12311346	chr5:56204834	C5orf35	-0.64	-9.91	-0.43	6.1e-21	Coronary artery disease;
LUAD	cis	rs7937890	0.559	rs2575853	chr11:14533963	T/C	cg23387056	chr11:14280742	SPON1	-0.35	-6.85	-0.32	2.65e-11	Mitochondrial DNA levels;
LUAD	cis	rs6484504	0.600	rs972714	chr11:31358875	T/G	cg14844989	chr11:31128820	NA	0.45	8.36	0.38	9.13e-16	Red blood cell count;
LUAD	trans	rs6601327	1.000	rs6601327	chr8:9395532	C/T	cg27411982	chr8:10470053	RP1L1	-0.36	-6.44	-0.3	3.18e-10	Multiple myeloma (hyperdiploidy);
LUAD	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg03948781	chr1:205179583	DSTYK	0.35	6.43	0.3	3.38e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs4795519	0.922	rs8070275	chr17:22142172	T/C	cg22648282	chr17:21454238	C17orf51	-0.38	-6.52	-0.3	2.04e-10	Chronic myeloid leukemia;
LUAD	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg17173187	chr15:85201210	NMB	0.44	7.38	0.34	8.27e-13	Schizophrenia;
LUAD	cis	rs15676	0.679	rs6478853	chr9:131588813	C/G	cg00228799	chr9:131580591	ENDOG	-0.44	-6.98	-0.32	1.16e-11	Blood metabolite levels;
LUAD	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg14668632	chr7:2872130	GNA12	-0.75	-13.13	-0.54	2.75e-33	Height;
LUAD	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg00530320	chr1:46809349	NSUN4	0.54	8.08	0.37	6.7e-15	Menopause (age at onset);
LUAD	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg09365446	chr1:150670422	GOLPH3L	0.61	10.91	0.47	1.39e-24	Melanoma;
LUAD	trans	rs11976180	0.569	rs12703565	chr7:143754401	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.67	-10.42	-0.45	8.74e-23	Obesity-related traits;
LUAD	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg11189052	chr15:85197271	WDR73	0.59	7.61	0.35	1.84e-13	Schizophrenia;
LUAD	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg27068330	chr11:65405492	SIPA1	0.56	8.87	0.4	2.11e-17	Acne (severe);
LUAD	cis	rs7301826	0.932	rs1007246	chr12:131280130	T/A	cg11011512	chr12:131303247	STX2	0.39	6.67	0.31	8.24e-11	Plasma plasminogen activator levels;
LUAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13012494	chr21:47604986	C21orf56	0.65	11.49	0.49	8.57e-27	Testicular germ cell tumor;
LUAD	cis	rs8067545	0.750	rs4267380	chr17:19971564	A/G	cg04132472	chr17:19861366	AKAP10	0.27	6.45	0.3	2.99e-10	Schizophrenia;
LUAD	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.19	0.33	3.05e-12	Tonsillectomy;
LUAD	cis	rs7156960	0.540	rs4903393	chr14:76734188	A/C	cg13981132	chr14:76734493	NA	-0.45	-7.15	-0.33	3.89e-12	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs10411161	0.702	rs8100716	chr19:52384061	T/C	cg22319618	chr22:45562946	NUP50	-0.59	-8.2	-0.37	2.84e-15	Breast cancer;
LUAD	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg05283184	chr6:79620031	NA	-0.56	-11.21	-0.48	1.06e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs6594499	0.500	rs10491424	chr5:110453806	T/C	cg04450332	chr5:110408780	TSLP	0.33	6.54	0.3	1.73e-10	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6960043	0.818	rs10264063	chr7:15053193	G/C	cg19272540	chr7:15055459	NA	0.36	8.18	0.37	3.29e-15	Type 2 diabetes;
LUAD	trans	rs28735056	1.000	rs4798923	chr18:77629373	G/A	cg05926928	chr17:57297772	GDPD1	-0.48	-6.57	-0.3	1.48e-10	Schizophrenia;
LUAD	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg07741184	chr6:167504864	NA	0.34	7.8	0.35	4.78e-14	Crohn's disease;
LUAD	cis	rs28493229	0.708	rs111410535	chr19:41158441	C/T	cg21869046	chr19:41225005	ITPKC	0.52	9.16	0.41	2.18e-18	Kawasaki disease;
LUAD	trans	rs931812	0.757	rs34988706	chr8:101907062	C/T	cg20993868	chr7:22813445	NA	0.57	12.11	0.51	3.44e-29	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg26338869	chr17:61819248	STRADA	-0.39	-6.58	-0.3	1.37e-10	Prudent dietary pattern;
LUAD	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg05991184	chr2:219186017	PNKD	0.35	6.6	0.31	1.26e-10	Colorectal cancer;
LUAD	cis	rs240764	0.781	rs12212736	chr6:101151410	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-7.8	-0.35	5.01e-14	Neuroticism;
LUAD	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg06784218	chr1:46089804	CCDC17	-0.6	-13.33	-0.54	4.15e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.38	6.38	0.3	4.66e-10	Systemic lupus erythematosus;
LUAD	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg26384229	chr12:38710491	ALG10B	0.5	8.03	0.36	9.71e-15	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs3125734	0.633	rs3902162	chr10:64041817	C/T	cg19640130	chr10:64028056	RTKN2	-0.36	-7.81	-0.35	4.7e-14	Rheumatoid arthritis;
LUAD	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg15557168	chr22:42548783	NA	0.51	9.3	0.41	7.31e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9486719	0.948	rs11152952	chr6:96894303	A/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.11	-0.44	1.18e-21	Migraine;Coronary artery disease;
LUAD	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg00316803	chr15:76480434	C15orf27	-0.42	-8.03	-0.36	9.61e-15	Blood metabolite levels;
LUAD	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg15556689	chr8:8085844	FLJ10661	0.42	6.8	0.31	3.58e-11	Mood instability;
LUAD	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg07393940	chr7:158741817	NA	-0.69	-11.75	-0.5	8.43e-28	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7851660	0.967	rs10046805	chr9:100613956	G/A	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg12016809	chr21:47604291	C21orf56	0.47	7.78	0.35	5.47e-14	Testicular germ cell tumor;
LUAD	trans	rs877282	0.945	rs11253391	chr10:788752	G/A	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	trans	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg01620082	chr3:125678407	NA	-0.75	-8.11	-0.37	5.34e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg16590910	chr6:42928470	GNMT	0.37	6.71	0.31	6.36e-11	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs5771069	0.933	rs137845	chr22:50439430	A/G	cg27467552	chr22:50353597	PIM3	-0.42	-7.37	-0.34	9.15e-13	Ulcerative colitis;
LUAD	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg10556349	chr10:835070	NA	0.58	7.26	0.33	1.82e-12	Eosinophil percentage of granulocytes;
LUAD	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg23533926	chr12:111358616	MYL2	-0.39	-6.82	-0.31	3.23e-11	Extrinsic epigenetic age acceleration;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04811762	chr6:150039439	LATS1	-0.43	-6.64	-0.31	9.53e-11	Height;
LUAD	cis	rs929596	0.556	rs10202865	chr2:234587707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.63	-10.43	-0.45	8.04e-23	Total bilirubin levels in HIV-1 infection;
LUAD	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.41	-19.53	-0.69	5.13e-61	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.81	0.31	3.33e-11	Parkinson's disease;
LUAD	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.68	-12.56	-0.52	5.71e-31	Axial length;
LUAD	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.29	6.51	0.3	2.09e-10	Parkinson's disease;
LUAD	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg00310523	chr12:86230176	RASSF9	0.4	8.01	0.36	1.13e-14	Major depressive disorder;
LUAD	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg08798685	chr6:27730294	NA	-0.69	-7.29	-0.33	1.57e-12	Depression;
LUAD	cis	rs2019216	0.500	rs7502283	chr17:21878561	G/C	cg22648282	chr17:21454238	C17orf51	-0.47	-7.95	-0.36	1.68e-14	Pelvic organ prolapse;
LUAD	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg13385794	chr1:248469461	NA	0.27	7.28	0.33	1.63e-12	Common traits (Other);
LUAD	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg08807101	chr21:30365312	RNF160	-0.52	-8.89	-0.4	1.76e-17	Dental caries;
LUAD	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg25237894	chr2:233734115	C2orf82	0.63	11.83	0.5	4.5e-28	Coronary artery disease;
LUAD	cis	rs8060686	0.623	rs58388686	chr16:68075439	A/G	cg09835421	chr16:68378352	PRMT7	-0.52	-6.65	-0.31	9.17e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8077889	0.672	rs3785810	chr17:41850689	C/G	cg26893861	chr17:41843967	DUSP3	1.13	25.61	0.78	5.13e-88	Triglycerides;
LUAD	cis	rs1232027	0.700	rs1643659	chr5:79934836	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.4	0.38	6.67e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs986417	0.901	rs10139995	chr14:60947177	G/T	cg27398547	chr14:60952738	C14orf39	0.68	8.11	0.37	5.65e-15	Gut microbiota (bacterial taxa);
LUAD	cis	rs9902453	0.845	rs7222842	chr17:28246943	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.26	0.41	1.02e-18	Coffee consumption (cups per day);
LUAD	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-13.3	-0.54	5.8e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg00666640	chr1:248458726	OR2T12	0.33	8.06	0.36	8.14e-15	Common traits (Other);
LUAD	cis	rs10540	0.584	rs10751658	chr11:437401	C/G	cg19913688	chr11:428466	ANO9	0.57	7.68	0.35	1.12e-13	Body mass index;
LUAD	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg07343612	chr16:622815	PIGQ	-0.82	-15.59	-0.6	1.29e-43	Height;
LUAD	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg11292332	chr7:45801988	SEPT13	-0.3	-6.63	-0.31	1.05e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg02782426	chr3:40428986	ENTPD3	0.45	9.34	0.41	5.69e-19	Renal cell carcinoma;
LUAD	trans	rs11088226	0.709	rs55860967	chr21:33880018	G/A	cg09050820	chr6:167586206	TCP10L2	0.54	7.13	0.33	4.44e-12	Gastritis;
LUAD	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg20991723	chr1:152506922	NA	-0.34	-6.79	-0.31	3.76e-11	Hair morphology;
LUAD	cis	rs12681287	0.640	rs13258126	chr8:87453378	G/T	cg27223183	chr8:87520930	FAM82B	-0.68	-9.59	-0.42	7.69e-20	Caudate activity during reward;
LUAD	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg18944383	chr4:111397179	ENPEP	0.41	8.26	0.37	1.87e-15	Height;
LUAD	cis	rs636291	0.517	rs2781233	chr1:10529194	T/C	cg17425144	chr1:10567563	PEX14	0.56	11.2	0.48	1.12e-25	Prostate cancer;
LUAD	cis	rs9892942	1	rs9892942	chr17:27178761	C/T	cg02049041	chr17:27085579	C17orf63	0.62	8.36	0.38	9.17e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25427524	chr10:38739819	LOC399744	-0.76	-13.56	-0.55	4.99e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs853679	0.546	rs200953	chr6:27837267	T/C	cg01620082	chr3:125678407	NA	-0.83	-8.93	-0.4	1.3e-17	Depression;
LUAD	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg17330251	chr7:94953956	PON1	-0.53	-7.16	-0.33	3.63e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg07570687	chr10:102243282	WNT8B	0.45	6.95	0.32	1.4e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.68	-0.43	3.8e-20	Schizophrenia;
LUAD	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg23985595	chr17:80112537	CCDC57	0.44	7.87	0.36	2.91e-14	Life satisfaction;
LUAD	cis	rs2275731	1.000	rs1411875	chr10:16527890	C/G	cg04254609	chr10:16479192	PTER	-0.44	-6.64	-0.31	9.36e-11	Bone fracture in osteoporosis;
LUAD	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg18827107	chr12:86230957	RASSF9	-0.52	-9.26	-0.41	9.99e-19	Major depressive disorder;
LUAD	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg09904177	chr6:26538194	HMGN4	0.42	6.94	0.32	1.51e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-7.32	-0.34	1.23e-12	Morning vs. evening chronotype;
LUAD	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-6.8	-0.31	3.59e-11	IgG glycosylation;
LUAD	cis	rs4964805	0.672	rs4964823	chr12:104181420	A/T	cg02344784	chr12:104178138	NT5DC3	0.39	6.63	0.31	1.03e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg17177755	chr1:15930204	NA	0.45	7.27	0.33	1.8e-12	Systolic blood pressure;
LUAD	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg12011299	chr4:100065546	ADH4	0.67	12.43	0.52	1.92e-30	Alcohol dependence;
LUAD	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg27432699	chr2:27873401	GPN1	-0.69	-12.19	-0.51	1.65e-29	Oral cavity cancer;
LUAD	cis	rs3931020	0.566	rs1409782	chr1:75272935	T/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.42	6.62	0.31	1.11e-10	Resistin levels;
LUAD	cis	rs7274811	0.681	rs158676	chr20:31974395	G/A	cg13403462	chr20:32256071	NECAB3;C20orf134	0.45	6.78	0.31	4.11e-11	Height;
LUAD	cis	rs907683	0.584	rs12920	chr2:220285666	C/G	cg15015639	chr2:220282977	DES	0.47	8.7	0.39	7.37e-17	Resting heart rate;
LUAD	cis	rs72634258	0.945	rs12753070	chr1:8114319	C/G	cg26816564	chr1:7831052	VAMP3	0.52	6.65	0.31	8.86e-11	Inflammatory bowel disease;
LUAD	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg04586622	chr2:25135609	ADCY3	0.37	8.34	0.38	1.05e-15	Body mass index;
LUAD	cis	rs9768139	0.935	rs10434944	chr7:158116911	C/T	cg24154853	chr7:158122151	PTPRN2	-0.54	-10.91	-0.47	1.33e-24	Calcium levels;
LUAD	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg02734326	chr4:10020555	SLC2A9	0.63	11.27	0.48	6.1e-26	Bone mineral density;
LUAD	cis	rs7759001	0.857	rs4504471	chr6:27372242	C/T	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs76878669	0.561	rs7115577	chr11:66172258	G/T	cg10616300	chr11:66138557	SLC29A2	-0.35	-7.36	-0.34	9.62e-13	Educational attainment (years of education);
LUAD	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg22117172	chr7:91764530	CYP51A1	0.31	6.7	0.31	6.75e-11	Breast cancer;
LUAD	cis	rs12681287	0.547	rs10956873	chr8:87547028	T/C	cg27223183	chr8:87520930	FAM82B	0.72	10.3	0.45	2.33e-22	Caudate activity during reward;
LUAD	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg21028142	chr17:79581711	NPLOC4	0.38	7.58	0.35	2.17e-13	Eye color traits;
LUAD	cis	rs6906287	0.559	rs7751467	chr6:118893861	T/A	cg05564266	chr6:118973597	C6orf204	0.36	7.55	0.34	2.67e-13	Electrocardiographic conduction measures;
LUAD	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg18105139	chr6:28058856	ZSCAN12L1	0.25	6.49	0.3	2.45e-10	Cardiac Troponin-T levels;
LUAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg03188948	chr7:1209495	NA	0.81	9.93	0.43	5.2e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg15557168	chr22:42548783	NA	-0.44	-8.1	-0.37	6.11e-15	Cognitive function;
LUAD	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg17264618	chr3:40429014	ENTPD3	0.4	9.15	0.41	2.42e-18	Renal cell carcinoma;
LUAD	cis	rs3772130	0.962	rs13065245	chr3:121566729	C/A	cg20356878	chr3:121714668	ILDR1	0.53	8.27	0.37	1.77e-15	Cognitive performance;
LUAD	trans	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg27600084	chr12:12264075	NA	0.41	7.57	0.35	2.31e-13	Breast size;
LUAD	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg18230493	chr5:56204884	C5orf35	-0.46	-7.62	-0.35	1.65e-13	Coronary artery disease;
LUAD	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg14343924	chr8:8086146	FLJ10661	0.5	7.98	0.36	1.37e-14	Mood instability;
LUAD	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.43	6.74	0.31	5.24e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg18180107	chr4:99064573	C4orf37	0.47	7.28	0.33	1.65e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.623	rs7204208	chr16:68069416	A/G	cg26727032	chr16:67993705	SLC12A4	-0.47	-7.97	-0.36	1.48e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2985684	0.948	rs2985685	chr14:50101370	G/A	cg04989706	chr14:50066350	PPIL5	-0.47	-6.9	-0.32	1.93e-11	Carotid intima media thickness;
LUAD	trans	rs7939886	0.920	rs11227180	chr11:55855611	G/C	cg15704280	chr7:45808275	SEPT13	0.66	6.47	0.3	2.67e-10	Myopia (pathological);
LUAD	cis	rs3862030	0.533	rs715440	chr10:104258095	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-8.47	-0.38	4.08e-16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg02733842	chr7:1102375	C7orf50	-0.84	-12.37	-0.52	3.22e-30	Bronchopulmonary dysplasia;
LUAD	cis	rs11112613	0.775	rs7299470	chr12:105961773	G/A	cg03607813	chr12:105948248	NA	0.75	12.46	0.52	1.48e-30	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg21427119	chr20:30132790	HM13	-0.54	-8.66	-0.39	9.77e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg10544611	chr16:67998164	SLC12A4	-0.57	-7.12	-0.33	4.72e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg11502198	chr6:26597334	ABT1	0.55	9.17	0.41	2.12e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg23758822	chr17:41437982	NA	1.0	20.95	0.71	2.27e-67	Menopause (age at onset);
LUAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg17178900	chr1:205818956	PM20D1	0.72	14.95	0.59	7.03e-41	Menarche (age at onset);
LUAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg00280220	chr17:61926910	NA	0.36	6.98	0.32	1.18e-11	Prudent dietary pattern;
LUAD	cis	rs9826463	0.582	rs73238186	chr3:142141180	A/C	cg20824294	chr3:142316082	PLS1	0.39	6.7	0.31	6.53e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.08	0.33	6.03e-12	Motion sickness;
LUAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg17178900	chr1:205818956	PM20D1	0.55	10.39	0.45	1.09e-22	Menarche (age at onset);
LUAD	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg06608945	chr2:219082296	ARPC2	0.52	8.92	0.4	1.38e-17	Colorectal cancer;
LUAD	trans	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.14	-0.37	4.36e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg12311346	chr5:56204834	C5orf35	-0.52	-8.29	-0.37	1.53e-15	Coronary artery disease;
LUAD	cis	rs9786986	0.764	rs75753504	chr1:235697380	C/T	cg08848088	chr1:235714526	GNG4	0.52	6.66	0.31	8.32e-11	Body mass index;
LUAD	cis	rs1784581	1.000	rs1618170	chr6:162400337	C/T	cg17173639	chr6:162384350	PARK2	-0.57	-10.38	-0.45	1.24e-22	Itch intensity from mosquito bite;
LUAD	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg04111992	chr7:158790115	NA	-0.49	-8.21	-0.37	2.73e-15	Facial morphology (factor 20);
LUAD	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg14343924	chr8:8086146	FLJ10661	-0.46	-7.36	-0.34	9.69e-13	Mood instability;
LUAD	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg19901468	chr14:105411992	AHNAK2	-0.54	-10.67	-0.46	1.07e-23	Rheumatoid arthritis;
LUAD	cis	rs6674176	0.932	rs12410334	chr1:44442521	A/C	cg23954153	chr1:44402353	ARTN	-0.37	-6.62	-0.31	1.09e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg02753203	chr1:228287806	NA	-0.49	-8.85	-0.4	2.41e-17	Diastolic blood pressure;
LUAD	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22857025	chr5:266934	NA	-0.96	-14.33	-0.57	2.98e-38	Breast cancer;
LUAD	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg18016565	chr1:150552671	MCL1	0.37	6.39	0.3	4.36e-10	Melanoma;
LUAD	cis	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.43	8.22	0.37	2.58e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg07211511	chr3:129823064	LOC729375	-0.44	-6.52	-0.3	2.05e-10	Blood pressure (smoking interaction);
LUAD	cis	rs4970988	0.607	rs7548516	chr1:150980281	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.54	-8.27	-0.37	1.81e-15	Urate levels;
LUAD	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg24562669	chr7:97807699	LMTK2	0.3	7.17	0.33	3.3e-12	Breast cancer;
LUAD	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.34	-6.56	-0.3	1.56e-10	Glomerular filtration rate;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15951691	chr7:150065937	REPIN1	-0.44	-6.79	-0.31	3.72e-11	Height;
LUAD	trans	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg07817883	chr1:32538562	TMEM39B	0.65	7.83	0.36	3.86e-14	Monocyte percentage of white cells;
LUAD	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg15704280	chr7:45808275	SEPT13	-0.84	-13.72	-0.55	1.05e-35	Coronary artery disease;
LUAD	cis	rs7584330	0.541	rs10202181	chr2:238352099	A/G	cg14458575	chr2:238380390	NA	0.7	12.8	0.53	6.12e-32	Prostate cancer;
LUAD	cis	rs7640424	0.589	rs7612356	chr3:107811037	C/G	cg09227934	chr3:107805635	CD47	-0.66	-10.47	-0.45	5.63e-23	Body mass index;
LUAD	cis	rs7216064	1.000	rs12602912	chr17:65870073	C/T	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg17178900	chr1:205818956	PM20D1	0.84	19.25	0.68	8.88e-60	Menarche (age at onset);
LUAD	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.51	0.34	3.46e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg00898013	chr13:113819073	PROZ	-0.82	-14.98	-0.59	5.18e-41	Platelet distribution width;
LUAD	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg08601574	chr20:25228251	PYGB	-0.47	-8.84	-0.39	2.66e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2932538	0.883	rs6701351	chr1:113139196	G/A	cg22162597	chr1:113214053	CAPZA1	0.41	6.45	0.3	3.01e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg21775007	chr8:11205619	TDH	0.38	6.49	0.3	2.43e-10	Neuroticism;
LUAD	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg26752003	chr8:145688521	CYHR1	-0.46	-7.95	-0.36	1.75e-14	Age at first birth;
LUAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-7.05	-0.32	7.18e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs790123	1.000	rs790123	chr3:122388993	T/C	cg17380795	chr3:122379686	NA	0.5	8.58	0.39	1.8e-16	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg26039829	chr8:22132926	PIWIL2	0.59	10.86	0.47	2.16e-24	Hypertriglyceridemia;
LUAD	cis	rs17362650	0.694	rs62118851	chr2:9566878	C/T	cg12832956	chr2:9616023	IAH1	-0.5	-8.68	-0.39	8.95e-17	Alcohol dependence (age at onset);
LUAD	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg15704280	chr7:45808275	SEPT13	-0.75	-10.99	-0.47	6.85e-25	Coronary artery disease;
LUAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00149659	chr3:10157352	C3orf10	0.61	8.68	0.39	8.54e-17	Alzheimer's disease;
LUAD	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22968622	chr17:43663579	NA	1.34	23.8	0.76	4.67e-80	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs258892	0.947	rs9885319	chr5:72179404	T/G	cg14879065	chr14:104662468	NA	-0.35	-6.39	-0.3	4.45e-10	Small cell lung carcinoma;
LUAD	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.68	0.31	7.77e-11	Rheumatoid arthritis;
LUAD	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg17757837	chr7:157058334	UBE3C	0.48	8.53	0.38	2.66e-16	Body mass index;
LUAD	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg05283184	chr6:79620031	NA	-0.43	-7.49	-0.34	4.14e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg14828511	chr1:107599125	PRMT6	-0.51	-8.47	-0.38	3.99e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg21138405	chr5:131827807	IRF1	0.6	13.88	0.56	2.35e-36	Asthma (sex interaction);
LUAD	cis	rs73206853	0.609	rs55833146	chr12:110872335	A/G	cg12870014	chr12:110450643	ANKRD13A	0.61	6.84	0.32	2.78e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs55823223	0.680	rs3744017	chr17:73871467	G/A	cg04225089	chr17:73874465	TRIM47	-0.47	-8.04	-0.36	8.99e-15	Psoriasis;
LUAD	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg06740227	chr12:86229804	RASSF9	0.47	8.17	0.37	3.53e-15	Major depressive disorder;
LUAD	cis	rs7432375	0.610	rs56163507	chr3:136516056	C/T	cg15507776	chr3:136538369	TMEM22	0.39	7.03	0.32	8.47e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg26597838	chr10:835615	NA	1.01	15.61	0.6	1.03e-43	Eosinophil percentage of granulocytes;
LUAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00166722	chr3:10149974	C3orf24	0.64	9.58	0.42	8.07e-20	Alzheimer's disease;
LUAD	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-7.28	-0.33	1.65e-12	Morning vs. evening chronotype;
LUAD	cis	rs3739034	0.701	rs62171377	chr2:135439752	G/A	cg12500956	chr2:135428796	TMEM163	0.36	6.42	0.3	3.74e-10	Gut microbiome composition (winter);
LUAD	cis	rs4711350	0.734	rs4713676	chr6:33722098	G/T	cg13859433	chr6:33739653	LEMD2	0.31	6.55	0.3	1.68e-10	Schizophrenia;
LUAD	cis	rs2908197	0.765	rs2098205	chr7:75938888	A/G	cg24580635	chr7:76178542	LOC100133091	-0.42	-6.53	-0.3	1.9e-10	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	trans	rs9393777	0.920	rs34953377	chr6:27381660	T/C	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.78	-0.35	5.67e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg27539214	chr16:67997921	SLC12A4	-0.69	-9.04	-0.4	5.87e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12976411	0.575	rs7252058	chr19:32827391	G/A	cg02282382	chr19:32836354	ZNF507	0.71	6.38	0.3	4.75e-10	Coronary artery disease;
LUAD	cis	rs938554	0.956	rs6838021	chr4:9927620	T/C	cg00071950	chr4:10020882	SLC2A9	0.54	8.63	0.39	1.23e-16	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg17366294	chr4:99064904	C4orf37	0.67	13.0	0.53	9.66e-33	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9462027	0.651	rs7752390	chr6:34790624	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.84	-0.4	2.52e-17	Systemic lupus erythematosus;
LUAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg12432903	chr7:1882776	MAD1L1	-0.54	-8.69	-0.39	7.96e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.27	-0.37	1.71e-15	Breast cancer;
LUAD	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg20290983	chr6:43655470	MRPS18A	0.92	17.23	0.64	9.16e-51	IgG glycosylation;
LUAD	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg18876405	chr7:65276391	NA	0.46	7.44	0.34	5.5e-13	Aortic root size;
LUAD	cis	rs1595825	0.945	rs59553483	chr2:198855201	T/C	cg00982548	chr2:198649783	BOLL	-0.58	-8.45	-0.38	4.64e-16	Ulcerative colitis;
LUAD	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12756686	chr19:29218302	NA	0.66	9.69	0.43	3.49e-20	Methadone dose in opioid dependence;
LUAD	cis	rs4680	1.000	rs4633	chr22:19950235	C/T	cg22546130	chr22:19950026	COMT	0.35	7.51	0.34	3.5e-13	Blood metabolite levels;
LUAD	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg15445000	chr17:37608096	MED1	0.45	8.27	0.37	1.8e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg26924012	chr15:45694286	SPATA5L1	0.66	11.02	0.47	5.24e-25	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs7945718	0.934	rs10831907	chr11:12790875	C/T	cg25843174	chr11:12811716	TEAD1	-0.25	-7.6	-0.35	1.93e-13	Educational attainment (years of education);
LUAD	cis	rs2742540	0.505	rs2742493	chr11:8967592	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.51	8.83	0.39	2.91e-17	Hematocrit;
LUAD	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg05966235	chr16:28915196	ATP2A1	0.46	7.44	0.34	5.86e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg17757837	chr7:157058334	UBE3C	-0.45	-7.97	-0.36	1.54e-14	Body mass index;
LUAD	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg06784218	chr1:46089804	CCDC17	0.6	13.62	0.55	2.74e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08677398	chr8:58056175	NA	0.47	6.55	0.3	1.65e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg14668632	chr7:2872130	GNA12	-0.7	-12.27	-0.51	8.17e-30	Height;
LUAD	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.15	-0.37	4.24e-15	Cannabis dependence symptom count;
LUAD	cis	rs7582720	1.000	rs72926767	chr2:203796814	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.42	0.42	2.89e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs55788414	0.932	rs12102691	chr16:81181460	G/T	cg06400318	chr16:81190750	PKD1L2	-0.66	-8.21	-0.37	2.63e-15	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg26343298	chr8:95960752	TP53INP1	0.37	7.81	0.35	4.61e-14	Type 2 diabetes;
LUAD	cis	rs1232027	0.666	rs1677666	chr5:79921825	C/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.81	-0.36	4.41e-14	Huntington's disease progression;
LUAD	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.56	-9.65	-0.42	4.75e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs89107	0.576	rs6906287	chr6:118962740	T/C	cg21191810	chr6:118973309	C6orf204	0.4	7.31	0.33	1.34e-12	Cardiac structure and function;
LUAD	cis	rs9296092	0.560	rs17627049	chr6:33537802	G/T	cg13560919	chr6:33536144	NA	-0.91	-16.12	-0.62	6.17e-46	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.63	-7.85	-0.36	3.53e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7536201	0.936	rs7414934	chr1:25293216	A/C	cg23273869	chr1:25296894	NA	-0.35	-6.93	-0.32	1.6e-11	Psoriasis vulgaris;
LUAD	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg08999081	chr20:33150536	PIGU	-0.37	-7.26	-0.33	1.9e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs79349575	0.655	rs62078384	chr17:47044463	C/T	cg26022315	chr17:47021804	SNF8	0.41	7.29	0.33	1.57e-12	Type 2 diabetes;
LUAD	cis	rs6723108	0.591	rs13399952	chr2:135394404	A/G	cg12500956	chr2:135428796	TMEM163	-0.28	-7.26	-0.33	1.93e-12	Type 2 diabetes;
LUAD	cis	rs2795502	0.515	rs116848302	chr10:43367783	G/A	cg20628663	chr10:43360327	NA	0.62	6.85	0.32	2.65e-11	Blood protein levels;
LUAD	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg20848291	chr7:100343083	ZAN	0.45	7.29	0.33	1.56e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs713587	0.563	rs11686663	chr2:25107759	C/T	cg04586622	chr2:25135609	ADCY3	0.38	8.82	0.39	3.1e-17	Body mass index in non-asthmatics;
LUAD	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg02269571	chr22:50332266	NA	-0.61	-9.22	-0.41	1.46e-18	Schizophrenia;
LUAD	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg14092571	chr14:90743983	NA	-0.51	-9.09	-0.4	3.74e-18	Mortality in heart failure;
LUAD	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg15309053	chr8:964076	NA	0.41	8.75	0.39	5.12e-17	Schizophrenia;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg04726800	chr3:128598191	ACAD9	-0.47	-6.64	-0.31	9.82e-11	Testicular germ cell tumor;
LUAD	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-14.78	-0.58	3.82e-40	Schizophrenia;
LUAD	cis	rs4638749	1.000	rs12477202	chr2:108867112	G/A	cg25838818	chr2:108905173	SULT1C2	-0.54	-8.48	-0.38	3.74e-16	Blood pressure;
LUAD	cis	rs490234	0.966	rs1250737	chr9:128428813	G/A	cg14078157	chr9:128172775	NA	0.36	6.38	0.3	4.61e-10	Mean arterial pressure;
LUAD	cis	rs354225	0.544	rs11892443	chr2:54805776	A/G	cg26097391	chr2:54893211	SPTBN1	0.42	6.48	0.3	2.59e-10	Schizophrenia;
LUAD	cis	rs9902453	0.845	rs2259855	chr17:28097860	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.23	-0.41	1.29e-18	Coffee consumption (cups per day);
LUAD	trans	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg21051086	chr3:73046214	PPP4R2	-0.45	-7.23	-0.33	2.26e-12	Pancreatic cancer;
LUAD	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg07404485	chr7:94953653	PON1	-0.58	-10.94	-0.47	1.03e-24	Paraoxonase activity;
LUAD	cis	rs10746514	0.804	rs1854822	chr1:232262270	G/C	cg09506761	chr1:232265262	NA	-0.38	-7.25	-0.33	1.94e-12	Response to statin therapy;
LUAD	trans	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg00953403	chr17:74099816	EXOC7	0.48	7.59	0.35	2.1e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg07741184	chr6:167504864	NA	0.31	7.47	0.34	4.74e-13	Crohn's disease;
LUAD	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg07167872	chr1:205819463	PM20D1	-0.55	-9.85	-0.43	9.48e-21	Menarche (age at onset);
LUAD	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.68	-0.58	1.03e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-6.69	-0.31	7.01e-11	Tonsillectomy;
LUAD	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg27490568	chr2:178487706	NA	-0.41	-6.72	-0.31	5.93e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg07211511	chr3:129823064	LOC729375	-0.71	-9.93	-0.43	5.08e-21	Blood pressure (smoking interaction);
LUAD	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.2	0.33	2.76e-12	Obesity-related traits;
LUAD	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg12310025	chr6:25882481	NA	-0.5	-7.3	-0.33	1.47e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.57	-9.77	-0.43	1.84e-20	Menarche (age at onset);
LUAD	cis	rs7680126	0.633	rs4698023	chr4:10304726	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-6.76	-0.31	4.47e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg10755058	chr3:40428713	ENTPD3	0.47	8.63	0.39	1.29e-16	Renal cell carcinoma;
LUAD	trans	rs208520	0.690	rs207091	chr6:66799847	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-17.73	-0.65	5.21e-53	Exhaled nitric oxide output;
LUAD	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg00933542	chr6:150070202	PCMT1	0.46	10.15	0.44	8.55e-22	Lung cancer;
LUAD	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg02004499	chr7:4244250	SDK1	0.45	7.17	0.33	3.34e-12	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
LUAD	cis	rs7771547	0.723	rs9394360	chr6:36550370	A/G	cg07856975	chr6:36356162	ETV7	0.45	6.39	0.3	4.41e-10	Platelet distribution width;
LUAD	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	7.17	0.33	3.32e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.42	-6.7	-0.31	6.64e-11	Schizophrenia;
LUAD	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg19318889	chr4:1322082	MAEA	0.44	6.99	0.32	1.08e-11	Obesity-related traits;
LUAD	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg02993280	chr1:107599747	PRMT6	0.47	7.69	0.35	1.03e-13	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2637266	0.935	rs7909808	chr10:78392318	A/G	cg18941641	chr10:78392320	NA	0.34	7.04	0.32	7.89e-12	Pulmonary function;
LUAD	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg00316803	chr15:76480434	C15orf27	-0.41	-7.59	-0.35	2.03e-13	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.84	0.39	2.6e-17	Cannabis dependence symptom count;
LUAD	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg08470875	chr2:26401718	FAM59B	-0.75	-10.26	-0.45	3.2e-22	Gut microbiome composition (summer);
LUAD	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg00757033	chr12:89920650	WDR51B	0.7	12.28	0.51	7.71e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.66	0.31	8.73e-11	Menarche (age at onset);
LUAD	cis	rs8099014	0.911	rs8092394	chr18:56127755	A/T	cg12907477	chr18:56117327	MIR122	0.41	7.01	0.32	9.42e-12	Platelet count;
LUAD	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.53	-0.3	1.87e-10	Total body bone mineral density;
LUAD	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg15997130	chr1:24165203	NA	0.55	9.5	0.42	1.54e-19	Immature fraction of reticulocytes;
LUAD	cis	rs12612619	0.732	rs7585410	chr2:27202120	A/G	cg00617064	chr2:27272375	NA	-0.36	-6.98	-0.32	1.13e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.68	-0.35	1.12e-13	Monocyte percentage of white cells;
LUAD	cis	rs68170813	0.652	rs4730250	chr7:107207695	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-9.03	-0.4	6.3e-18	Coronary artery disease;
LUAD	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg11707310	chr1:2537719	MMEL1	0.37	7.85	0.36	3.39e-14	Ulcerative colitis;
LUAD	cis	rs9296092	0.538	rs75082458	chr6:33524792	C/T	cg13560919	chr6:33536144	NA	-0.87	-15.42	-0.6	6.74e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs5758511	0.773	rs9623482	chr22:42360574	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.38	6.56	0.3	1.56e-10	Birth weight;
LUAD	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.59	11.48	0.49	9.26e-27	Hemoglobin concentration;
LUAD	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg27284194	chr4:1044797	NA	0.43	6.88	0.32	2.22e-11	Obesity-related traits;
LUAD	trans	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg03886242	chr7:26192032	NFE2L3	-0.44	-7.64	-0.35	1.51e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg06108461	chr20:60628389	TAF4	-1.11	-20.54	-0.71	1.5e-65	Body mass index;
LUAD	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg11901034	chr3:128598214	ACAD9	-0.54	-8.58	-0.39	1.82e-16	IgG glycosylation;
LUAD	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-8.43	-0.38	5.52e-16	Monocyte percentage of white cells;
LUAD	trans	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg26043149	chr18:55253948	FECH	-0.41	-6.78	-0.31	4.11e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg04365224	chr3:72788183	NA	-0.44	-6.56	-0.3	1.55e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs868036	0.681	rs28376010	chr15:68063739	G/T	cg24579218	chr15:68104479	NA	-0.56	-9.24	-0.41	1.22e-18	Restless legs syndrome;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08292080	chr16:56398010	AMFR	0.52	6.72	0.31	6.01e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg05340658	chr4:99064831	C4orf37	0.53	8.93	0.4	1.31e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg02012338	chr4:187126139	CYP4V2	0.92	9.11	0.41	3.3e-18	Activated partial thromboplastin time;
LUAD	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.22	-0.54	1.24e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg22963979	chr7:1858916	MAD1L1	-0.55	-9.62	-0.42	6.31e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg03806693	chr22:41940476	POLR3H	0.69	9.84	0.43	1.08e-20	Vitiligo;
LUAD	cis	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg27411982	chr8:10470053	RP1L1	0.4	7.62	0.35	1.71e-13	Neuroticism;
LUAD	trans	rs9467711	0.591	rs16891315	chr6:26111756	T/C	cg06606381	chr12:133084897	FBRSL1	-0.67	-6.71	-0.31	6.27e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg16797656	chr11:68205561	LRP5	0.47	9.02	0.4	6.51e-18	Total body bone mineral density;
LUAD	cis	rs9359856	0.517	rs11962350	chr6:90592406	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.69	-6.79	-0.31	3.74e-11	Bipolar disorder;
LUAD	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg18827107	chr12:86230957	RASSF9	-0.48	-8.67	-0.39	9.58e-17	Major depressive disorder;
LUAD	cis	rs1067327	1	rs1067327	chr2:44628529	C/G	cg04920474	chr2:44395004	PPM1B	0.43	7.74	0.35	7.36e-14	Anxiety disorder (factor score);
LUAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg26354017	chr1:205819088	PM20D1	0.8	17.08	0.64	3.8300000000000002e-50	Menarche (age at onset);
LUAD	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg11859384	chr17:80120422	CCDC57	-0.47	-8.54	-0.38	2.49e-16	Life satisfaction;
LUAD	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg01028140	chr2:1542097	TPO	-0.49	-6.63	-0.31	1.03e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs2227564	0.678	rs2242256	chr10:75597546	C/G	cg00564723	chr10:75632066	CAMK2G	0.32	6.62	0.31	1.09e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg21681030	chr2:46777652	RHOQ	0.38	7.06	0.32	6.68e-12	Height;
LUAD	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg12310025	chr6:25882481	NA	0.51	8.51	0.38	3.07e-16	Blood metabolite levels;
LUAD	cis	rs41311933	0.656	rs72758183	chr9:123786336	C/T	cg13567360	chr9:123745713	C5	-0.73	-8.57	-0.38	1.94e-16	Coronary artery disease;
LUAD	trans	rs9951602	1.000	rs9949784	chr18:76649994	A/G	cg02800362	chr5:177631904	HNRNPAB	0.98	11.57	0.49	4.32e-27	Obesity-related traits;
LUAD	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06022373	chr22:39101656	GTPBP1	0.46	7.11	0.33	4.84e-12	Menopause (age at onset);
LUAD	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg17845761	chr1:175162550	KIAA0040	0.35	9.26	0.41	1.05e-18	Alcohol dependence;
LUAD	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg04944784	chr2:26401820	FAM59B	-0.76	-10.48	-0.45	5.53e-23	Gut microbiome composition (summer);
LUAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg24813613	chr7:1882135	MAD1L1	0.41	6.61	0.31	1.13e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02353165	chr6:42928485	GNMT	0.41	7.18	0.33	3.16e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg20291162	chr17:40259547	DHX58	-0.68	-10.5	-0.45	4.51e-23	Fibrinogen levels;
LUAD	cis	rs1832886	1	rs1832886	chr10:94477539	G/A	cg25093409	chr10:94429542	NA	0.37	6.53	0.3	1.9e-10	Body mass index;
LUAD	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg17724175	chr1:150552817	MCL1	0.38	9.6	0.42	6.92e-20	Tonsillectomy;
LUAD	cis	rs11048434	0.636	rs11047953	chr12:9064923	A/C	cg13575925	chr12:9217583	LOC144571	0.36	6.62	0.31	1.09e-10	Sjögren's syndrome;
LUAD	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.42	-0.34	6.68e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg03188948	chr7:1209495	NA	0.39	6.46	0.3	2.86e-10	Longevity;Endometriosis;
LUAD	cis	rs6489882	0.934	rs1859330	chr12:113376388	G/A	cg20102336	chr12:113376681	OAS3	-0.49	-7.58	-0.35	2.27e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg07917127	chr4:99064746	C4orf37	0.41	6.85	0.32	2.55e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.967	rs3813034	chr17:28524804	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	8.23	0.37	2.38e-15	Coffee consumption (cups per day);
LUAD	cis	rs11722228	0.893	rs6449144	chr4:9944650	T/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-9.27	-0.41	9.29e-19	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg06618935	chr21:46677482	NA	-0.5	-10.01	-0.44	2.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7264396	0.563	rs2425116	chr20:34323553	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2e-15	Total cholesterol levels;
LUAD	cis	rs35883536	1.000	rs2297712	chr1:101092813	C/T	cg06223162	chr1:101003688	GPR88	0.34	6.43	0.3	3.36e-10	Monocyte count;
LUAD	cis	rs7432375	0.610	rs6793936	chr3:136509793	A/C	cg15507776	chr3:136538369	TMEM22	0.39	7.07	0.33	6.39e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs57994353	0.659	rs76259794	chr9:139377405	C/A	cg13856295	chr9:139396418	NOTCH1	-0.42	-6.62	-0.31	1.08e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.93	-0.5	1.76e-28	Bipolar disorder;
LUAD	cis	rs11168351	0.927	rs10875716	chr12:48389023	C/T	cg04545296	chr12:48745243	ZNF641	0.34	8.4	0.38	6.73e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs34638657	0.732	rs2967359	chr16:82202968	G/C	cg09439754	chr16:82129088	HSD17B2	-0.34	-6.4	-0.3	4.09e-10	Lung adenocarcinoma;
LUAD	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.63	0.42	5.44e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg12292205	chr6:26970375	C6orf41	0.39	6.98	0.32	1.17e-11	Schizophrenia;
LUAD	cis	rs2979489	0.699	rs62508370	chr8:30417026	G/A	cg26383811	chr8:30366931	RBPMS	-0.62	-9.38	-0.42	3.91e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg14169450	chr9:139327907	INPP5E	0.46	8.57	0.38	1.89e-16	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg00316803	chr15:76480434	C15orf27	-0.4	-7.55	-0.34	2.74e-13	Blood metabolite levels;
LUAD	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg23625390	chr15:77176239	SCAPER	0.51	8.09	0.37	6.39e-15	Blood metabolite levels;
LUAD	trans	rs7395662	0.963	rs11039774	chr11:48513959	G/C	cg00717180	chr2:96193071	NA	-0.4	-7.4	-0.34	7.36e-13	HDL cholesterol;
LUAD	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg20933634	chr6:27740509	NA	0.53	8.03	0.36	9.56e-15	Parkinson's disease;
LUAD	cis	rs13315871	1.000	rs11708590	chr3:58336635	A/G	cg12435725	chr3:58293450	RPP14	0.71	7.82	0.36	4.38e-14	Cholesterol, total;
LUAD	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.559	rs7793594	chr7:106891829	C/T	cg02696742	chr7:106810147	HBP1	-0.78	-10.8	-0.46	3.69e-24	Coronary artery disease;
LUAD	cis	rs7827545	1.000	rs6578238	chr8:135569490	A/C	cg17885191	chr8:135476712	NA	0.47	7.49	0.34	4.11e-13	Hypertension (SNP x SNP interaction);
LUAD	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg06784218	chr1:46089804	CCDC17	0.6	13.45	0.55	1.43e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg27432699	chr2:27873401	GPN1	0.6	10.5	0.45	4.58e-23	Oral cavity cancer;
LUAD	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22857025	chr5:266934	NA	-0.97	-14.47	-0.58	7.55e-39	Breast cancer;
LUAD	cis	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg05084668	chr3:125655381	ALG1L	-0.68	-9.07	-0.4	4.44e-18	Blood pressure (smoking interaction);
LUAD	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg16205897	chr5:131564050	P4HA2	-0.3	-6.49	-0.3	2.43e-10	Acylcarnitine levels;
LUAD	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg02886208	chr11:14281011	SPON1	0.4	8.2	0.37	2.93e-15	Mitochondrial DNA levels;
LUAD	cis	rs4077515	0.934	rs78428995	chr9:139281847	T/C	cg14019695	chr9:139328340	INPP5E	0.4	7.61	0.35	1.85e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg14791747	chr16:20752902	THUMPD1	0.74	10.13	0.44	9.59e-22	Cognitive test performance;
LUAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg21724239	chr8:58056113	NA	0.65	8.41	0.38	6.32e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.59	0.39	1.66e-16	Menopause (age at onset);
LUAD	cis	rs6758955	0.850	rs77216765	chr2:10475706	C/T	cg15773312	chr2:10472214	HPCAL1	-0.54	-7.44	-0.34	5.51e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg14227996	chr4:17616232	MED28	0.74	8.27	0.37	1.7e-15	Opioid sensitivity;
LUAD	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg00074818	chr8:8560427	CLDN23	0.69	10.62	0.46	1.64e-23	Obesity-related traits;
LUAD	cis	rs7927592	0.546	rs497261	chr11:68192244	T/C	cg16797656	chr11:68205561	LRP5	0.5	10.18	0.44	6.19e-22	Total body bone mineral density;
LUAD	cis	rs735539	0.521	rs2585897	chr13:21398979	A/G	cg27499820	chr13:21296301	IL17D	-0.47	-7.23	-0.33	2.34e-12	Dental caries;
LUAD	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg04450456	chr4:17643702	FAM184B	0.4	7.85	0.36	3.39e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg05234568	chr11:5960015	NA	-0.55	-9.91	-0.43	6.02e-21	DNA methylation (variation);
LUAD	cis	rs57920188	0.535	rs112660254	chr1:4089921	T/G	cg20703997	chr1:4087676	NA	0.48	9.15	0.41	2.45e-18	Interleukin-17 levels;
LUAD	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg19318889	chr4:1322082	MAEA	0.82	13.77	0.56	6.92e-36	Longevity;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg26781437	chr19:42807043	PAFAH1B3;PRR19	0.38	6.65	0.31	9.25e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs7744392	0.557	rs6919334	chr6:35341875	G/A	cg03355690	chr6:35265616	DEF6	0.63	6.36	0.3	5.32e-10	Cataracts in type 2 diabetes;
LUAD	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.48	-0.3	2.55e-10	Depression;
LUAD	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15369054	chr17:80825471	TBCD	0.64	10.68	0.46	1.02e-23	Breast cancer;
LUAD	trans	rs55986470	0.646	rs112559043	chr2:239446187	A/G	cg01134436	chr17:81009848	B3GNTL1	0.8	8.14	0.37	4.5e-15	Chronotype;
LUAD	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.51	-8.24	-0.37	2.19e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg16797656	chr11:68205561	LRP5	0.46	8.93	0.4	1.29e-17	Total body bone mineral density;
LUAD	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg08798685	chr6:27730294	NA	-0.43	-6.97	-0.32	1.23e-11	Parkinson's disease;
LUAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg11494091	chr17:61959527	GH2	0.74	18.54	0.67	1.31e-56	Prudent dietary pattern;
LUAD	cis	rs28595532	1.000	rs115915387	chr4:119640854	C/T	cg02775129	chr4:119771670	NA	-0.82	-7.63	-0.35	1.59e-13	Cannabis dependence symptom count;
LUAD	trans	rs7069733	1.000	rs6584555	chr10:105299611	T/C	cg23983269	chr5:175815749	HIGD2A;NOP16	-0.51	-6.55	-0.3	1.63e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg26028573	chr6:26043587	HIST1H2BB	0.39	6.39	0.3	4.35e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4481887	0.893	rs1339991	chr1:248509363	C/T	cg00666640	chr1:248458726	OR2T12	0.28	7.05	0.32	7.54e-12	Common traits (Other);
LUAD	cis	rs6138458	1.000	rs7268095	chr20:24972333	C/T	cg26195577	chr20:24973756	C20orf3	0.96	17.25	0.64	6.85e-51	Blood protein levels;
LUAD	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg13271783	chr10:134563150	INPP5A	-0.44	-7.77	-0.35	5.86e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg18827107	chr12:86230957	RASSF9	-0.56	-9.83	-0.43	1.13e-20	Major depressive disorder;
LUAD	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg08999081	chr20:33150536	PIGU	0.47	9.17	0.41	2.11e-18	Coronary artery disease;
LUAD	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg20291162	chr17:40259547	DHX58	-0.7	-10.99	-0.47	6.82e-25	Fibrinogen levels;
LUAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg07677032	chr17:61819896	STRADA	0.57	10.33	0.45	1.87e-22	Prudent dietary pattern;
LUAD	cis	rs17092148	0.790	rs6087602	chr20:33170689	G/A	cg16810054	chr20:33298113	TP53INP2	-0.49	-7.41	-0.34	7.03e-13	Neuroticism;
LUAD	cis	rs1595825	0.891	rs73056877	chr2:198816724	A/C	cg00361562	chr2:198649771	BOLL	-0.47	-6.72	-0.31	5.79e-11	Ulcerative colitis;
LUAD	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.52	-0.38	2.84e-16	Neutrophil percentage of white cells;
LUAD	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11890956	chr21:40555474	PSMG1	0.82	14.8	0.58	3e-40	Cognitive function;
LUAD	cis	rs8112211	0.953	rs61160177	chr19:38819463	C/G	cg14299480	chr19:38876666	GGN	-0.45	-7.75	-0.35	7.1e-14	Blood protein levels;
LUAD	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg21211367	chr2:162094118	NA	0.45	7.97	0.36	1.46e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg25324976	chr17:61989376	CSHL1	0.36	6.97	0.32	1.2e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.5	0.42	1.62e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs427394	0.632	rs377137	chr5:6740468	T/G	cg14682080	chr5:6737778	POLS	0.35	7.56	0.35	2.45e-13	Menopause (age at onset);
LUAD	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg25985355	chr7:65971099	NA	-0.54	-6.63	-0.31	1.05e-10	Diabetic kidney disease;
LUAD	cis	rs977987	0.966	rs6564261	chr16:75492242	C/T	cg03315344	chr16:75512273	CHST6	0.66	15.13	0.59	1.16e-41	Dupuytren's disease;
LUAD	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.74	15.76	0.61	2.38e-44	White blood cell count;
LUAD	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg07636037	chr3:49044803	WDR6	0.56	8.72	0.39	6.58e-17	Menarche (age at onset);
LUAD	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg17757837	chr7:157058334	UBE3C	0.48	8.47	0.38	4.2e-16	Body mass index;
LUAD	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg00106254	chr7:1943704	MAD1L1	-0.53	-7.91	-0.36	2.27e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg03874509	chr1:107600012	PRMT6	0.52	9.13	0.41	2.9e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg03859395	chr2:55845619	SMEK2	0.75	13.92	0.56	1.64e-36	Metabolic syndrome;
LUAD	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg08125733	chr17:73851984	WBP2	0.66	9.73	0.43	2.56e-20	Psoriasis;
LUAD	cis	rs870825	0.616	rs28416641	chr4:185617999	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg12311346	chr5:56204834	C5orf35	-0.75	-11.88	-0.5	2.73e-28	Initial pursuit acceleration;
LUAD	cis	rs11229555	0.874	rs7102852	chr11:58358348	G/A	cg15696309	chr11:58395628	NA	-0.72	-10.3	-0.45	2.35e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg03806693	chr22:41940476	POLR3H	0.73	9.89	0.43	7.14e-21	Vitiligo;
LUAD	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg11901034	chr3:128598214	ACAD9	-0.46	-7.16	-0.33	3.59e-12	IgG glycosylation;
LUAD	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.41	0.3	3.96e-10	Cognitive test performance;
LUAD	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg17173187	chr15:85201210	NMB	0.51	8.68	0.39	8.86e-17	Schizophrenia;
LUAD	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg20476274	chr7:133979776	SLC35B4	0.57	9.95	0.44	4.18e-21	Mean platelet volume;
LUAD	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg05887092	chr17:76393375	PGS1	0.4	6.9	0.32	1.91e-11	HDL cholesterol levels;
LUAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg02869364	chr7:1081709	C7orf50	-0.51	-6.55	-0.3	1.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs72949976	0.564	rs4673730	chr2:214024836	G/T	cg08319019	chr2:214017104	IKZF2	0.58	9.03	0.4	6.34e-18	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs11971779	0.680	rs6960876	chr7:139112176	C/T	cg23387468	chr7:139079360	LUC7L2	-0.29	-6.65	-0.31	9.34e-11	Diisocyanate-induced asthma;
LUAD	cis	rs9715521	0.645	rs13134207	chr4:59848379	G/T	cg11281224	chr4:60001000	NA	-0.48	-7.63	-0.35	1.55e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg09365446	chr1:150670422	GOLPH3L	0.65	12.3	0.51	6.36e-30	Tonsillectomy;
LUAD	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg20991723	chr1:152506922	NA	0.35	7.03	0.32	8.47e-12	Hair morphology;
LUAD	trans	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.52	8.67	0.39	9.47e-17	Endometrial cancer;
LUAD	cis	rs12474201	0.572	rs7596521	chr2:46918665	A/G	cg09399716	chr2:46890238	NA	-0.51	-10.13	-0.44	9.69e-22	Height;
LUAD	cis	rs9584850	0.794	rs9630321	chr13:99106979	C/G	cg20750642	chr13:99100586	FARP1	-0.32	-6.8	-0.31	3.59e-11	Neuroticism;
LUAD	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg12863693	chr15:85201151	NMB	0.36	6.49	0.3	2.4e-10	Schizophrenia;
LUAD	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg01028140	chr2:1542097	TPO	-0.53	-6.97	-0.32	1.21e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22496380	chr5:211416	CCDC127	-1.21	-15.84	-0.61	1.08e-44	Breast cancer;
LUAD	trans	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg11693508	chr17:37793320	STARD3	0.47	6.93	0.32	1.58e-11	Neuroticism;
LUAD	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.32	6.49	0.3	2.4e-10	Parkinson's disease;
LUAD	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.84	0.5	3.86e-28	Colorectal cancer;
LUAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg08132940	chr7:1081526	C7orf50	-0.76	-10.26	-0.45	3.25e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg10518543	chr12:38710700	ALG10B	0.41	6.37	0.3	5.02e-10	Bladder cancer;
LUAD	cis	rs909002	0.772	rs7525618	chr1:32073766	C/T	cg13919466	chr1:32135498	COL16A1	-0.38	-8.75	-0.39	5.24e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg07757535	chr4:1339547	NA	0.3	6.81	0.31	3.4e-11	Longevity;
LUAD	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.3	6.36	0.3	5.19e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg08859206	chr1:53392774	SCP2	0.59	10.6	0.46	1.98e-23	Monocyte count;
LUAD	trans	rs4942242	0.663	rs17460812	chr13:44215504	A/G	cg19169023	chr15:41853346	TYRO3	-0.6	-10.36	-0.45	1.45e-22	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg14345882	chr6:26364793	BTN3A2	0.66	6.88	0.32	2.12e-11	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg01620082	chr3:125678407	NA	-0.71	-7.18	-0.33	3.14e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg08645402	chr16:4508243	NA	-0.58	-11.02	-0.47	5.32e-25	Schizophrenia;
LUAD	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg17279839	chr7:150038598	RARRES2	0.47	7.57	0.35	2.4e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23158103	chr7:148848205	ZNF398	-0.65	-12.04	-0.51	6.26e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg23815491	chr16:72088622	HP	0.53	9.69	0.43	3.4e-20	Fibrinogen levels;
LUAD	trans	rs7395662	1.000	rs11039745	chr11:48463811	G/C	cg00717180	chr2:96193071	NA	-0.4	-7.41	-0.34	7.11e-13	HDL cholesterol;
LUAD	cis	rs8018808	1.000	rs4575469	chr14:77860543	G/A	cg20045696	chr14:77926864	AHSA1	-0.37	-6.63	-0.31	1.05e-10	Myeloid white cell count;
LUAD	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.95	-0.36	1.75e-14	Body mass index;
LUAD	cis	rs2456568	0.503	rs11020603	chr11:93667439	A/G	cg17595323	chr11:93583763	C11orf90	0.44	8.82	0.39	2.93e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs7107174	1.000	rs2450123	chr11:77952771	T/C	cg19901956	chr11:77921274	USP35	-0.55	-6.9	-0.32	1.96e-11	Testicular germ cell tumor;
LUAD	cis	rs240764	0.658	rs7746961	chr6:101215244	A/G	cg09795085	chr6:101329169	ASCC3	-0.42	-7.37	-0.34	9.31e-13	Neuroticism;
LUAD	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg13010199	chr12:38710504	ALG10B	0.38	6.36	0.3	5.09e-10	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21582582	chr3:182698605	DCUN1D1	0.46	7.71	0.35	9.1e-14	Body mass index;
LUAD	cis	rs7017914	0.934	rs7830550	chr8:71570431	C/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.41	-0.3	3.96e-10	Bone mineral density;
LUAD	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg04772025	chr11:68637568	NA	-0.51	-7.95	-0.36	1.74e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-9.85	-0.43	9.6e-21	Brugada syndrome;
LUAD	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg06784218	chr1:46089804	CCDC17	0.6	13.53	0.55	6.66e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg22153745	chr1:153894579	GATAD2B	-0.56	-8.55	-0.38	2.35e-16	Total cholesterol levels;
LUAD	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg07169764	chr2:136633963	MCM6	0.83	9.65	0.42	4.85e-20	Corneal structure;
LUAD	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg03806693	chr22:41940476	POLR3H	0.73	9.89	0.43	7.14e-21	Vitiligo;
LUAD	cis	rs11626933	0.959	rs17799226	chr14:90754538	C/T	cg14092571	chr14:90743983	NA	-0.95	-17.89	-0.66	1.01e-53	Gut microbiota (bacterial taxa);
LUAD	cis	rs1003719	0.715	rs2835659	chr21:38567902	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.19	-0.37	3.12e-15	Eye color traits;
LUAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg04450456	chr4:17643702	FAM184B	0.43	8.45	0.38	4.86e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10193935	1.000	rs57883795	chr2:42387926	C/T	cg27598129	chr2:42591480	NA	-0.77	-9.25	-0.41	1.15e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg02951883	chr7:2050386	MAD1L1	0.81	14.32	0.57	3.21e-38	Bipolar disorder and schizophrenia;
LUAD	cis	rs9325144	0.836	rs7489197	chr12:38750065	C/T	cg10518543	chr12:38710700	ALG10B	-0.44	-6.35	-0.3	5.44e-10	Morning vs. evening chronotype;
LUAD	trans	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.58	-9.62	-0.42	6.24e-20	Mean corpuscular volume;
LUAD	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-8.15	-0.37	4.13e-15	Alzheimer's disease (late onset);
LUAD	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-8.49	-0.38	3.66e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10911363	0.592	rs2702177	chr1:183450622	G/C	cg09173681	chr1:183549694	NCF2	0.53	9.93	0.43	4.87e-21	Systemic lupus erythematosus;
LUAD	cis	rs714027	1.000	rs5763821	chr22:30549071	A/C	cg11564601	chr22:30592435	NA	-0.37	-7.85	-0.36	3.5e-14	Lymphocyte counts;
LUAD	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.59	0.31	1.3e-10	Depression;
LUAD	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg08989290	chr16:615782	NHLRC4	0.31	6.72	0.31	5.75e-11	Height;
LUAD	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg05340658	chr4:99064831	C4orf37	0.54	9.18	0.41	1.86e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg15704280	chr7:45808275	SEPT13	-0.6	-9.71	-0.43	2.86e-20	HDL cholesterol;
LUAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00149659	chr3:10157352	C3orf10	0.55	7.74	0.35	7.39e-14	Alzheimer's disease;
LUAD	cis	rs9902453	0.967	rs6505155	chr17:28372783	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.33	-0.41	6.06e-19	Coffee consumption (cups per day);
LUAD	cis	rs9392556	0.734	rs648900	chr6:4109422	T/G	cg10424681	chr6:4079350	C6orf201;C6orf146	0.27	6.76	0.31	4.5e-11	Blood metabolite levels;
LUAD	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg25237894	chr2:233734115	C2orf82	-0.47	-8.89	-0.4	1.73e-17	Coronary artery disease;
LUAD	trans	rs10802346	0.545	rs10924545	chr1:246364592	C/T	cg22732515	chr19:44031385	ETHE1	-0.57	-9.27	-0.41	9.73e-19	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs2485376	0.842	rs7077329	chr10:104161967	T/C	cg20641465	chr10:103991465	PITX3	0.54	9.17	0.41	2.07e-18	QT interval;
LUAD	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.47	-7.47	-0.34	4.78e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg20744362	chr22:50050164	C22orf34	-0.36	-7.67	-0.35	1.17e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18876405	chr7:65276391	NA	0.43	6.75	0.31	4.89e-11	Aortic root size;
LUAD	cis	rs6693567	0.565	rs497128	chr1:150269952	A/G	cg15654264	chr1:150340011	RPRD2	-0.35	-6.4	-0.3	4.13e-10	Migraine;
LUAD	cis	rs9394841	0.692	rs13193235	chr6:41792659	T/C	cg17623882	chr6:41773611	USP49	-0.52	-7.24	-0.33	2.06e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg10729496	chr3:10149963	C3orf24	0.6	10.05	0.44	1.82e-21	Alzheimer's disease;
LUAD	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg01689657	chr7:91764605	CYP51A1	0.39	9.86	0.43	8.97e-21	Breast cancer;
LUAD	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg05754148	chr16:3507555	NAT15	0.78	8.05	0.36	8.46e-15	Tuberculosis;
LUAD	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg14668632	chr7:2872130	GNA12	-0.47	-8.39	-0.38	7.19e-16	Height;
LUAD	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg15445000	chr17:37608096	MED1	-0.45	-8.35	-0.38	9.73e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs10493773	1.000	rs12754358	chr1:86248431	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.52	-8.53	-0.38	2.63e-16	Urate levels in overweight individuals;
LUAD	cis	rs965513	0.627	rs7848973	chr9:100588839	A/G	cg13688889	chr9:100608707	NA	-0.41	-7.19	-0.33	2.95e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUAD	cis	rs3820068	0.705	rs4646063	chr1:15829813	G/A	cg24675056	chr1:15929824	NA	0.44	6.68	0.31	7.42e-11	Systolic blood pressure;
LUAD	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg12140854	chr5:148520817	ABLIM3	-0.69	-11.11	-0.48	2.35e-25	Breast cancer;
LUAD	cis	rs4072705	1.000	rs721862	chr9:127535992	C/T	cg13476313	chr9:127244764	NR5A1	0.26	6.47	0.3	2.74e-10	Menarche (age at onset);
LUAD	trans	rs7395662	0.929	rs10838959	chr11:48584732	T/A	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.12e-12	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs427941	0.655	rs2734782	chr7:101749667	T/C	cg06246474	chr7:101738831	CUX1	0.37	6.44	0.3	3.28e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg13607699	chr17:42295918	UBTF	-0.51	-8.05	-0.36	8.54e-15	Red cell distribution width;Reticulocyte count;
LUAD	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg06618935	chr21:46677482	NA	-0.48	-9.69	-0.43	3.37e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6740322	0.748	rs13432574	chr2:43544328	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-11.04	-0.47	4.55e-25	Coronary artery disease;
LUAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.25	0.41	1.08e-18	Alzheimer's disease;
LUAD	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg11915388	chr22:42470451	FAM109B	0.41	7.28	0.33	1.64e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg14039649	chr22:38352398	POLR2F	0.35	6.4	0.3	4.14e-10	Glioblastoma;Glioma;
LUAD	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg17063962	chr7:91808500	NA	0.67	11.96	0.5	1.32e-28	Breast cancer;
LUAD	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg18854424	chr1:2615690	NA	0.42	9.19	0.41	1.78e-18	Ulcerative colitis;
LUAD	cis	rs11153730	0.503	rs283066	chr6:118620064	A/G	cg18833306	chr6:118973337	C6orf204	0.55	10.17	0.44	7.18e-22	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.48	0.52	1.17e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs684232	0.602	rs448465	chr17:559888	A/T	cg15660573	chr17:549704	VPS53	-0.87	-18.05	-0.66	1.97e-54	Prostate cancer;
LUAD	trans	rs1728785	0.892	rs1103955	chr16:68588488	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.3	0.45	2.33e-22	Ulcerative colitis;
LUAD	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23158103	chr7:148848205	ZNF398	-0.58	-9.63	-0.42	5.59e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.13	-0.37	4.95e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs2806561	1.000	rs2776822	chr1:23492782	A/G	cg08575399	chr20:60719638	PSMA7;SS18L1	0.39	6.67	0.31	7.79e-11	Height;
LUAD	cis	rs250677	0.522	rs4705302	chr5:148354962	G/C	cg12140854	chr5:148520817	ABLIM3	0.57	9.2	0.41	1.63e-18	Breast cancer;
LUAD	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg21475434	chr5:93447410	FAM172A	0.59	7.49	0.34	4.05e-13	Diabetic retinopathy;
LUAD	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs4077515	0.967	rs3812558	chr9:139269135	A/G	cg14169450	chr9:139327907	INPP5E	0.35	6.37	0.3	4.82e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6596100	0.538	rs56157864	chr5:132267859	A/T	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Breast cancer;
LUAD	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg09323728	chr8:95962352	TP53INP1	-0.32	-7.62	-0.35	1.74e-13	Type 2 diabetes;
LUAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg00450029	chr8:599525	NA	0.8	7.97	0.36	1.49e-14	IgG glycosylation;
LUAD	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg06623918	chr6:96969491	KIAA0776	0.75	12.4	0.52	2.41e-30	Migraine;Coronary artery disease;
LUAD	cis	rs11771526	0.901	rs11767695	chr7:32315960	G/A	cg13207630	chr7:32358064	NA	0.62	7.48	0.34	4.36e-13	Body mass index;
LUAD	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg00981070	chr1:2046702	PRKCZ	-0.33	-6.58	-0.3	1.41e-10	Height;
LUAD	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg14343924	chr8:8086146	FLJ10661	-0.4	-6.35	-0.3	5.47e-10	Neuroticism;
LUAD	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.61	0.39	1.49e-16	Menarche (age at onset);
LUAD	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg04287289	chr16:89883240	FANCA	0.75	6.37	0.3	5.01e-10	Skin colour saturation;
LUAD	cis	rs7147624	1.000	rs7150233	chr14:66200816	A/G	cg03016385	chr14:66212404	NA	-0.59	-6.89	-0.32	2.08e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg00981070	chr1:2046702	PRKCZ	0.36	6.8	0.31	3.56e-11	Height;
LUAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg26354017	chr1:205819088	PM20D1	0.5	8.17	0.37	3.6e-15	Parkinson's disease;
LUAD	cis	rs10908458	0.584	rs10908455	chr1:155067283	C/T	cg23973274	chr1:155060172	NA	0.42	7.36	0.34	9.37e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10992471	0.580	rs10992304	chr9:95085365	G/A	cg14631576	chr9:95140430	CENPP	-0.57	-11.58	-0.49	3.94e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs8060686	0.858	rs6499143	chr16:67874264	T/C	cg26727032	chr16:67993705	SLC12A4	-0.51	-8.64	-0.39	1.18e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg00277334	chr10:82204260	NA	-0.96	-22.01	-0.73	4.33e-72	Post bronchodilator FEV1;
LUAD	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg08645402	chr16:4508243	NA	0.52	9.74	0.43	2.42e-20	Schizophrenia;
LUAD	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg12454169	chr2:30669597	LCLAT1	0.67	8.34	0.38	1.06e-15	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg19717773	chr7:2847554	GNA12	-0.5	-8.51	-0.38	3.04e-16	Height;
LUAD	cis	rs6906287	0.647	rs11153753	chr6:118836153	T/C	cg21191810	chr6:118973309	C6orf204	0.51	9.92	0.43	5.34e-21	Electrocardiographic conduction measures;
LUAD	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg00316803	chr15:76480434	C15orf27	0.39	6.4	0.3	4.19e-10	Blood metabolite levels;
LUAD	trans	rs853679	0.607	rs34788973	chr6:27879200	C/A	cg01620082	chr3:125678407	NA	-1.09	-10.17	-0.44	7.24e-22	Depression;
LUAD	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-9.12	-0.41	3.09e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg08048268	chr3:133502702	NA	-0.38	-7.13	-0.33	4.28e-12	Iron status biomarkers;
LUAD	cis	rs8060686	0.516	rs2290700	chr16:68288983	T/G	cg26727032	chr16:67993705	SLC12A4	-0.49	-8.13	-0.37	4.91e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg13770153	chr20:60521292	NA	-0.46	-7.53	-0.34	3.06e-13	Body mass index;
LUAD	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.97	0.32	1.24e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg21856205	chr7:94953877	PON1	-0.59	-11.13	-0.48	2.03e-25	Paraoxonase activity;
LUAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.57	-10.49	-0.45	4.93e-23	Longevity;Endometriosis;
LUAD	cis	rs12681287	0.640	rs67123356	chr8:87453992	A/C	cg27223183	chr8:87520930	FAM82B	-0.69	-9.62	-0.42	5.9e-20	Caudate activity during reward;
LUAD	trans	rs1493916	0.870	rs1389531	chr18:31386616	C/T	cg13755796	chr4:20253514	NA	-0.41	-6.97	-0.32	1.23e-11	Life satisfaction;
LUAD	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.42	0.34	6.41e-13	Menopause (age at onset);
LUAD	cis	rs6500395	1.000	rs3817029	chr16:48584942	C/T	cg04672837	chr16:48644449	N4BP1	0.37	6.48	0.3	2.51e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9902453	0.765	rs2729436	chr17:28120670	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.61	-0.46	1.8e-23	Coffee consumption (cups per day);
LUAD	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg21775007	chr8:11205619	TDH	-0.37	-6.42	-0.3	3.66e-10	Triglycerides;
LUAD	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg11919837	chr8:57350735	NA	-0.43	-6.35	-0.3	5.49e-10	Obesity-related traits;
LUAD	cis	rs4253772	0.515	rs8142080	chr22:46647429	G/T	cg00784671	chr22:46762841	CELSR1	-0.59	-7.21	-0.33	2.66e-12	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg04727924	chr7:799746	HEATR2	-0.52	-7.07	-0.33	6.47e-12	Cerebrospinal P-tau181p levels;
LUAD	trans	rs75804782	0.581	rs55931535	chr2:239372632	A/G	cg01134436	chr17:81009848	B3GNTL1	0.78	8.57	0.38	1.89e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg02931644	chr1:25747376	RHCE	0.44	9.16	0.41	2.27e-18	Plateletcrit;Mean corpuscular volume;
LUAD	trans	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg20587970	chr11:113659929	NA	0.87	11.45	0.49	1.3e-26	Hip circumference adjusted for BMI;
LUAD	cis	rs11209185	0.545	rs11209184	chr1:68421069	C/T	cg22082780	chr1:68452167	NA	0.48	10.2	0.44	5.41e-22	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs17818399	0.926	rs7590693	chr2:46823992	G/A	cg21681030	chr2:46777652	RHOQ	0.38	6.85	0.32	2.59e-11	Height;
LUAD	trans	rs7395662	0.781	rs11499902	chr11:48742731	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.2	-0.33	2.73e-12	HDL cholesterol;
LUAD	cis	rs28374715	0.532	rs28477406	chr15:41642036	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.11	-22.91	-0.74	4.23e-76	Ulcerative colitis;
LUAD	trans	rs372883	0.600	rs407712	chr21:30722531	G/A	cg14791747	chr16:20752902	THUMPD1	0.48	7.01	0.32	9.28e-12	Pancreatic cancer;
LUAD	cis	rs17433780	0.860	rs61798916	chr1:89493957	G/A	cg09516651	chr1:89888402	LOC400759	0.55	9.83	0.43	1.09e-20	Carotid intima media thickness;
LUAD	cis	rs2046867	0.818	rs62249879	chr3:72917171	A/G	cg04365224	chr3:72788183	NA	-0.46	-6.7	-0.31	6.63e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12541635	1.000	rs1366969	chr8:107092851	A/T	cg10147462	chr8:107024639	NA	-0.42	-7.51	-0.34	3.57e-13	Age of smoking initiation;
LUAD	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg15557168	chr22:42548783	NA	-0.37	-6.7	-0.31	6.61e-11	Cognitive function;
LUAD	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg21890820	chr11:65308645	LTBP3	1.25	10.3	0.45	2.44e-22	Height;
LUAD	trans	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.98	-0.36	1.4e-14	Gout;
LUAD	cis	rs755249	0.546	rs7533743	chr1:39957169	C/T	cg27567593	chr1:39956653	BMP8A	0.36	7.32	0.34	1.29e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs606458	0.920	rs76355571	chr11:64450566	T/A	cg27243166	chr11:64479496	NRXN2	0.51	6.35	0.3	5.43e-10	Urate levels;
LUAD	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg26384229	chr12:38710491	ALG10B	0.42	7.34	0.34	1.09e-12	Morning vs. evening chronotype;
LUAD	trans	rs587242	0.955	rs12566597	chr1:96978626	A/G	cg10631902	chr5:14652156	NA	-0.4	-6.55	-0.3	1.65e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs2880765	0.835	rs4360875	chr15:86040394	A/G	cg13263323	chr15:86062960	AKAP13	-0.5	-9.29	-0.41	8.43e-19	Coronary artery disease;
LUAD	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg22598563	chr5:131563921	P4HA2	-0.28	-6.63	-0.31	1.02e-10	Blood metabolite levels;
LUAD	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg13511324	chr14:104056883	C14orf153	0.27	6.41	0.3	3.88e-10	Reticulocyte count;
LUAD	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg04450456	chr4:17643702	FAM184B	0.41	8.15	0.37	4.09e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg08027265	chr7:2291960	NA	-0.48	-8.47	-0.38	4.22e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg03433033	chr1:76189801	ACADM	0.94	19.31	0.68	4.72e-60	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.91	0.32	1.82e-11	Hypertriglyceridemia;
LUAD	cis	rs7224314	1.000	rs7219229	chr17:65380171	C/T	cg01507342	chr17:65387096	PITPNC1	-0.53	-8.57	-0.38	1.98e-16	Diisocyanate-induced asthma;
LUAD	cis	rs34638657	0.656	rs1134847	chr16:82203742	C/T	cg09439754	chr16:82129088	HSD17B2	0.35	6.6	0.31	1.23e-10	Lung adenocarcinoma;
LUAD	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg21918786	chr6:109611834	NA	-0.57	-10.54	-0.46	3.23e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.57	10.03	0.44	2.2e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg05922057	chr17:4047571	ZZEF1;CYB5D2	-0.38	-6.59	-0.31	1.28e-10	Type 2 diabetes;
LUAD	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg22166914	chr1:53195759	ZYG11B	0.45	7.81	0.35	4.67e-14	Monocyte count;
LUAD	cis	rs732716	0.785	rs9973266	chr19:4392715	G/A	cg21934504	chr19:4445085	UBXN6	0.46	7.61	0.35	1.78e-13	Mean corpuscular volume;
LUAD	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg07741184	chr6:167504864	NA	0.32	7.31	0.34	1.32e-12	Crohn's disease;
LUAD	trans	rs5756813	0.661	rs6000898	chr22:38202399	T/C	cg19894588	chr14:64061835	NA	-0.55	-7.79	-0.35	5.28e-14	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs1950626	0.716	rs34158896	chr14:101447373	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.42	7.71	0.35	8.98e-14	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.71	-13.05	-0.54	6.14e-33	Menarche (age at onset);
LUAD	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg14668632	chr7:2872130	GNA12	0.74	13.49	0.55	9.17e-35	Height;
LUAD	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg06532163	chr17:45867833	NA	0.46	8.25	0.37	1.99e-15	IgG glycosylation;
LUAD	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg02176678	chr2:219576539	TTLL4	0.74	14.73	0.58	6.1e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg08798685	chr6:27730294	NA	-0.41	-6.63	-0.31	1.01e-10	Parkinson's disease;
LUAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg10729496	chr3:10149963	C3orf24	0.52	8.52	0.38	2.88e-16	Alzheimer's disease;
LUAD	cis	rs9467160	1.000	rs6922631	chr6:24438734	G/A	cg20631270	chr6:24437470	GPLD1	0.47	6.78	0.31	4e-11	Liver enzyme levels;
LUAD	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg08859206	chr1:53392774	SCP2	-0.81	-15.5	-0.6	3.04e-43	Monocyte count;
LUAD	trans	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.0	-0.4	7.63e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs3750082	0.817	rs3750078	chr7:32969489	G/A	cg05721444	chr7:32995514	FKBP9	-0.41	-7.58	-0.35	2.16e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg04990556	chr1:26633338	UBXN11	-0.4	-6.54	-0.3	1.73e-10	Obesity-related traits;
LUAD	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg03037974	chr15:76606532	NA	0.48	11.25	0.48	7.58e-26	Blood metabolite levels;
LUAD	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg03037974	chr15:76606532	NA	0.38	8.18	0.37	3.38e-15	Blood metabolite levels;
LUAD	cis	rs10908458	0.584	rs10908454	chr1:155066416	C/T	cg23973274	chr1:155060172	NA	-0.43	-7.59	-0.35	2.08e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs11585357	0.689	rs2977293	chr1:17599444	C/T	cg08277548	chr1:17600880	PADI3	-0.77	-11.75	-0.5	8.46e-28	Hair shape;
LUAD	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg17063962	chr7:91808500	NA	-0.66	-11.23	-0.48	9e-26	Breast cancer;
LUAD	cis	rs12760731	0.565	rs10913520	chr1:178200760	A/T	cg00404053	chr1:178313656	RASAL2	0.72	9.09	0.4	4.02e-18	Obesity-related traits;
LUAD	trans	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.6	-10.38	-0.45	1.2e-22	Mean corpuscular volume;
LUAD	cis	rs1832871	0.672	rs9457344	chr6:158742043	C/T	cg07165851	chr6:158734300	TULP4	0.72	11.09	0.47	2.99e-25	Height;
LUAD	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg23933602	chr10:16859644	RSU1	1.01	22.54	0.74	1.81e-74	Platelet distribution width;
LUAD	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg01765077	chr12:122356316	WDR66	0.54	9.47	0.42	2.07e-19	Mean corpuscular volume;
LUAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg12034118	chr1:209979487	IRF6	0.51	7.44	0.34	5.58e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs7216064	0.655	rs8078543	chr17:66037251	G/T	cg08758996	chr17:66097529	LOC651250	-0.41	-6.82	-0.31	3.23e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	trans	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg26043149	chr18:55253948	FECH	0.49	7.86	0.36	3.15e-14	Bone mineral density;
LUAD	cis	rs11640533	0.901	rs2908790	chr16:53412161	T/C	cg08681685	chr16:53407594	NA	0.45	7.65	0.35	1.4e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs748404	0.697	rs471122	chr15:43558574	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.52	-8.7	-0.39	7.54e-17	Lung cancer;
LUAD	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.9	0.53	2.48e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg17105886	chr17:28927953	LRRC37B2	0.79	7.88	0.36	2.81e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg10729496	chr3:10149963	C3orf24	0.58	9.34	0.41	5.58e-19	Alzheimer's disease;
LUAD	cis	rs7737355	0.812	rs32107	chr5:131039633	C/A	cg25547332	chr5:131281432	NA	0.43	7.05	0.32	7.36e-12	Life satisfaction;
LUAD	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.7e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6076065	0.676	rs6083084	chr20:23335582	A/G	cg11657817	chr20:23433608	CST11	-0.47	-8.66	-0.39	9.71e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg11189052	chr15:85197271	WDR73	-0.73	-12.5	-0.52	9.53e-31	P wave terminal force;
LUAD	cis	rs2688608	0.933	rs2688614	chr10:75652876	G/A	cg19442545	chr10:75533431	FUT11	-0.4	-6.79	-0.31	3.9e-11	Inflammatory bowel disease;
LUAD	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg08508325	chr11:3079039	CARS	-0.59	-12.96	-0.53	1.35e-32	Longevity;
LUAD	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.4	0.55	2.3e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg07332563	chr6:291687	DUSP22	-0.68	-11.78	-0.5	6.74e-28	Menopause (age at onset);
LUAD	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg05110241	chr16:68378359	PRMT7	-0.81	-8.75	-0.39	5.05e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs62400317	0.859	rs12203558	chr6:45244423	C/G	cg20913747	chr6:44695427	NA	-0.41	-6.57	-0.3	1.44e-10	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg18180107	chr4:99064573	C4orf37	0.4	6.48	0.3	2.61e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg19610905	chr11:61596333	FADS2	-0.81	-10.34	-0.45	1.67e-22	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-7.98	-0.36	1.42e-14	Total body bone mineral density;
LUAD	cis	rs1843834	0.898	rs12623277	chr2:225548072	T/G	cg22455342	chr2:225449267	CUL3	0.45	6.72	0.31	5.8e-11	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs12681287	0.640	rs7820234	chr8:87350950	A/C	cg00550725	chr8:87521180	FAM82B	0.47	6.74	0.31	5.32e-11	Caudate activity during reward;
LUAD	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg13918804	chr1:2043761	PRKCZ	0.4	6.68	0.31	7.78e-11	Height;
LUAD	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.59	-9.28	-0.41	8.62e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg02240030	chr7:2089880	MAD1L1	0.38	6.4	0.3	4.24e-10	Neuroticism;
LUAD	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg11814155	chr7:99998594	ZCWPW1	0.46	7.78	0.35	5.71e-14	Platelet count;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05369920	chr2:44223589	LRPPRC	-0.54	-6.55	-0.3	1.64e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg03226245	chr19:36486125	SDHAF1	0.43	6.92	0.32	1.69e-11	Monocyte percentage of white cells;
LUAD	cis	rs3096299	0.967	rs2965937	chr16:89488779	A/T	cg06640241	chr16:89574553	SPG7	0.47	7.53	0.34	3e-13	Multiple myeloma (IgH translocation);
LUAD	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg19318889	chr4:1322082	MAEA	0.55	9.39	0.42	3.66e-19	Longevity;
LUAD	cis	rs62400317	0.859	rs4479922	chr6:45248371	T/C	cg20913747	chr6:44695427	NA	-0.43	-6.9	-0.32	1.93e-11	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg18180107	chr4:99064573	C4orf37	0.42	6.72	0.31	5.75e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.48	-0.34	4.19e-13	Personality dimensions;
LUAD	cis	rs597539	0.690	rs1272609	chr11:68618182	T/C	cg21862992	chr11:68658383	NA	0.52	9.41	0.42	3.16e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.33e-10	Ulcerative colitis;
LUAD	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	6.53	0.3	1.84e-10	Schizophrenia;
LUAD	trans	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1595825	0.838	rs57437055	chr2:198782617	A/C	cg00982548	chr2:198649783	BOLL	-0.63	-9.1	-0.4	3.47e-18	Ulcerative colitis;
LUAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg24846343	chr22:24311635	DDTL	0.8	17.87	0.66	1.28e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	7.65	0.35	1.35e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs10193935	0.792	rs13423729	chr2:42492874	C/T	cg27598129	chr2:42591480	NA	-0.57	-7.84	-0.36	3.8e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.637	rs3087501	chr22:46647909	A/G	cg09491104	chr22:46646882	C22orf40	-0.73	-12.74	-0.53	1.1e-31	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg12863693	chr15:85201151	NMB	0.4	7.41	0.34	7e-13	Schizophrenia;
LUAD	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg04154034	chr17:28927549	LRRC37B2	0.55	6.51	0.3	2.16e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg08508325	chr11:3079039	CARS	0.44	8.9	0.4	1.64e-17	Calcium levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19777771	chr17:30676863	ZNF207;MIR632	-0.43	-7.1	-0.33	5.22e-12	Height;
LUAD	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.53	-0.42	1.2e-19	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg27411982	chr8:10470053	RP1L1	-0.36	-6.39	-0.3	4.46e-10	Retinal vascular caliber;
LUAD	trans	rs2797160	0.547	rs9388442	chr6:125972608	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.48	-7.68	-0.35	1.08e-13	Endometrial cancer;
LUAD	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23583168	chr7:148888333	NA	-0.99	-22.15	-0.73	9.34e-73	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-11.41	-0.48	1.85e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.68	-0.31	7.58e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	ch.11.42038R	chr11:967971	AP2A2	0.42	7.34	0.34	1.12e-12	Alzheimer's disease (late onset);
LUAD	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg18252515	chr7:66147081	NA	0.63	6.96	0.32	1.29e-11	Gout;
LUAD	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs6558530	0.932	rs4370560	chr8:1708194	G/A	cg19131313	chr8:1704013	NA	-0.46	-7.37	-0.34	8.77e-13	Systolic blood pressure;
LUAD	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg01579765	chr21:45077557	HSF2BP	-0.57	-12.51	-0.52	9.36e-31	Mean corpuscular volume;
LUAD	cis	rs1371614	0.502	rs4572551	chr2:27194013	T/C	cg00617064	chr2:27272375	NA	-0.39	-7.47	-0.34	4.68e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs6541297	0.703	rs628035	chr1:230324145	G/T	cg20703242	chr1:230279135	GALNT2	-0.46	-6.97	-0.32	1.2e-11	Coronary artery disease;
LUAD	cis	rs939584	0.799	rs2867105	chr2:601905	A/C	cg03444855	chr2:621920	NA	-0.4	-6.41	-0.3	3.96e-10	Body mass index;
LUAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg13012494	chr21:47604986	C21orf56	0.54	8.59	0.39	1.68e-16	Testicular germ cell tumor;
LUAD	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg10876282	chr6:28092338	ZSCAN16	0.42	6.42	0.3	3.74e-10	Parkinson's disease;
LUAD	trans	rs7395662	1.000	rs12366208	chr11:48563128	T/A	cg00717180	chr2:96193071	NA	-0.4	-7.42	-0.34	6.44e-13	HDL cholesterol;
LUAD	cis	rs9462027	0.606	rs2814979	chr6:34578425	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.9	-0.4	1.63e-17	Systemic lupus erythematosus;
LUAD	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.75	-13.27	-0.54	7.4e-34	Axial length;
LUAD	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg07776626	chr8:57350775	NA	-0.59	-8.93	-0.4	1.27e-17	Obesity-related traits;
LUAD	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.66	-0.35	1.28e-13	Platelet count;
LUAD	cis	rs4889855	0.530	rs78012645	chr17:78550939	C/T	cg16591659	chr17:78472290	NA	0.44	7.73	0.35	7.67e-14	Fractional excretion of uric acid;
LUAD	cis	rs9314323	0.708	rs1594829	chr8:26206077	C/T	cg13160058	chr8:26243215	BNIP3L	0.39	6.53	0.3	1.86e-10	Red cell distribution width;
LUAD	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg05535760	chr7:792225	HEATR2	0.89	11.76	0.5	8.12e-28	Cerebrospinal P-tau181p levels;
LUAD	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg25436886	chr3:127056972	NA	-0.57	-7.87	-0.36	2.95e-14	Interleukin-10 levels;Interleukin-13 levels;
LUAD	cis	rs1448094	0.872	rs7311150	chr12:86435989	A/T	cg06740227	chr12:86229804	RASSF9	0.35	6.48	0.3	2.53e-10	Major depressive disorder;
LUAD	cis	rs2742417	0.603	rs2742458	chr3:45767602	C/T	cg10512202	chr3:45649293	LIMD1	0.47	8.85	0.4	2.46e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg22663859	chr13:21900854	NA	0.49	7.79	0.35	5.39e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs7659604	0.502	rs4516738	chr4:122669177	T/C	cg06713675	chr4:122721982	EXOSC9	0.41	7.39	0.34	8.01e-13	Type 2 diabetes;
LUAD	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-10.31	-0.45	2.22e-22	Electroencephalogram traits;
LUAD	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg13770153	chr20:60521292	NA	-0.56	-9.28	-0.41	8.69e-19	Body mass index;
LUAD	cis	rs3931020	0.688	rs455032	chr1:75196488	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.48	-6.36	-0.3	5.26e-10	Resistin levels;
LUAD	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg07741184	chr6:167504864	NA	0.31	7.43	0.34	6.25e-13	Crohn's disease;
LUAD	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	6.05e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg14343924	chr8:8086146	FLJ10661	0.47	7.27	0.33	1.79e-12	Neuroticism;
LUAD	cis	rs68170813	0.559	rs7800443	chr7:106910723	G/A	cg23024343	chr7:107201750	COG5	0.5	7.25	0.33	1.98e-12	Coronary artery disease;
LUAD	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg17971929	chr21:40555470	PSMG1	0.55	8.66	0.39	1.03e-16	Cognitive function;
LUAD	cis	rs877282	0.898	rs12356709	chr10:763365	A/G	cg06581033	chr10:766294	NA	-0.59	-7.98	-0.36	1.39e-14	Uric acid levels;
LUAD	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg16647868	chr5:131706066	SLC22A5	0.39	6.42	0.3	3.57e-10	Blood metabolite levels;
LUAD	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.13	-0.37	4.78e-15	Cystic fibrosis severity;
LUAD	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg10755058	chr3:40428713	ENTPD3	0.43	8.55	0.38	2.33e-16	Renal cell carcinoma;
LUAD	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs912057	0.560	rs1294416	chr6:6741327	A/G	cg06612196	chr6:6737390	NA	0.65	15.94	0.61	4.05e-45	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs1832871	0.711	rs12525147	chr6:158683509	A/G	cg07165851	chr6:158734300	TULP4	0.69	10.31	0.45	2.2e-22	Height;
LUAD	cis	rs9341808	0.519	rs59232999	chr6:81018783	T/C	cg08355045	chr6:80787529	NA	-0.42	-7.1	-0.33	5.16e-12	Sitting height ratio;
LUAD	cis	rs116248771	0.793	rs12494750	chr3:158298411	T/G	cg16708174	chr3:158430962	RARRES1	0.46	6.57	0.3	1.46e-10	diarrhoeal disease at age 2;
LUAD	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.71	-0.31	6.16e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg14917512	chr19:3094685	GNA11	-0.39	-6.8	-0.31	3.58e-11	Aortic root size;
LUAD	cis	rs9788682	0.642	rs2568483	chr15:78752343	A/G	cg18825076	chr15:78729989	IREB2	0.55	7.78	0.35	5.46e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2046867	0.568	rs1553376	chr3:72828151	T/C	cg25664220	chr3:72788482	NA	-0.67	-11.83	-0.5	4.37e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs15676	0.783	rs7033070	chr9:131586374	G/A	cg00228799	chr9:131580591	ENDOG	-0.45	-6.99	-0.32	1.08e-11	Blood metabolite levels;
LUAD	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg04842962	chr6:43655489	MRPS18A	0.92	13.27	0.54	7.96e-34	IgG glycosylation;
LUAD	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg14541582	chr5:601475	NA	-0.37	-7.91	-0.36	2.23e-14	Lung disease severity in cystic fibrosis;
LUAD	trans	rs800082	0.501	rs10935507	chr3:144214631	A/T	cg24215973	chr2:240111563	HDAC4	0.52	8.39	0.38	7.59e-16	Smoking behavior;
LUAD	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg14343924	chr8:8086146	FLJ10661	0.47	7.26	0.33	1.89e-12	Mood instability;
LUAD	cis	rs1595825	0.945	rs73058813	chr2:198858268	A/G	cg10547527	chr2:198650123	BOLL	-0.5	-7.13	-0.33	4.47e-12	Ulcerative colitis;
LUAD	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg08632164	chr7:65971372	NA	-0.38	-6.62	-0.31	1.09e-10	Aortic root size;
LUAD	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg02782426	chr3:40428986	ENTPD3	0.35	7.52	0.34	3.39e-13	Renal cell carcinoma;
LUAD	cis	rs656900	0.647	rs668641	chr15:80118624	C/T	cg02196730	chr15:80188777	MTHFS	-0.43	-7.15	-0.33	3.72e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg02493740	chr2:85810744	VAMP5	-0.46	-8.51	-0.38	3.07e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs59698941	0.943	rs55746968	chr5:132298188	T/C	cg14825688	chr5:132208181	LEAP2	-0.47	-6.39	-0.3	4.28e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs4409675	0.548	rs1000432	chr1:28225119	T/C	cg23691781	chr1:28212827	C1orf38	0.38	10.99	0.47	6.78e-25	Corneal astigmatism;
LUAD	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	6.66	0.31	8.67e-11	Tonsillectomy;
LUAD	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg11266682	chr4:10021025	SLC2A9	0.65	14.66	0.58	1.19e-39	Bone mineral density;
LUAD	trans	rs783540	0.500	rs783541	chr15:83255061	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.6	-8.97	-0.4	9.79e-18	Schizophrenia;
LUAD	cis	rs72781680	1.000	rs55773155	chr2:24255081	A/G	cg06627628	chr2:24431161	ITSN2	-0.57	-6.52	-0.3	1.96e-10	Lymphocyte counts;
LUAD	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18404041	chr3:52824283	ITIH1	-0.59	-11.89	-0.5	2.44e-28	Bipolar disorder;
LUAD	cis	rs17102423	0.768	rs2151755	chr14:65578874	T/C	cg16583315	chr14:65563665	MAX	0.35	6.59	0.31	1.33e-10	Obesity-related traits;
LUAD	cis	rs55665837	0.540	rs10219313	chr11:14749849	C/T	cg19336497	chr11:14380999	RRAS2	-0.41	-7.8	-0.35	4.76e-14	Vitamin D levels;
LUAD	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg07936489	chr17:37558343	FBXL20	0.44	6.93	0.32	1.55e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg05887092	chr17:76393375	PGS1	0.41	7.47	0.34	4.76e-13	HDL cholesterol levels;
LUAD	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg10167378	chr1:228756711	NA	0.67	9.51	0.42	1.41e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs684232	0.649	rs838369	chr17:578180	T/C	cg12384639	chr17:618140	VPS53	0.45	7.66	0.35	1.3e-13	Prostate cancer;
LUAD	cis	rs9837602	1.000	rs1688766	chr3:99647850	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-7.14	-0.33	4e-12	Breast cancer;
LUAD	cis	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg24308560	chr3:49941425	MST1R	0.44	7.4	0.34	7.5e-13	Menarche (age at onset);
LUAD	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg10792982	chr14:105748885	BRF1	0.45	9.84	0.43	1.04e-20	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg10729496	chr3:10149963	C3orf24	0.58	9.5	0.42	1.63e-19	Alzheimer's disease;
LUAD	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg06641503	chr3:48959341	ARIH2	-0.4	-7.94	-0.36	1.86e-14	Parkinson's disease;
LUAD	cis	rs3784262	1.000	rs12908953	chr15:58277812	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.47	-9.57	-0.42	8.82e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs17197710	0.673	rs12575296	chr11:47320985	A/G	cg13308137	chr11:47528955	CUGBP1	-0.44	-7.22	-0.33	2.42e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg11833968	chr6:79620685	NA	-0.45	-8.32	-0.38	1.2e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg21724239	chr8:58056113	NA	0.82	10.14	0.44	9.01e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00149659	chr3:10157352	C3orf10	-0.56	-7.92	-0.36	2.12e-14	Alzheimer's disease;
LUAD	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg19318889	chr4:1322082	MAEA	-0.91	-15.44	-0.6	5.68e-43	Longevity;
LUAD	trans	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg00953403	chr17:74099816	EXOC7	0.44	6.88	0.32	2.13e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg09417038	chr21:47716443	C21orf57	0.42	6.89	0.32	1.97e-11	Testicular germ cell tumor;
LUAD	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg05110241	chr16:68378359	PRMT7	-0.94	-10.59	-0.46	2.07e-23	Schizophrenia;
LUAD	trans	rs75804782	0.810	rs55694368	chr2:239317692	G/T	cg01134436	chr17:81009848	B3GNTL1	0.8	8.5	0.38	3.37e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg18196295	chr10:418757	DIP2C	0.5	8.52	0.38	2.93e-16	Psychosis in Alzheimer's disease;
LUAD	cis	rs208520	1.000	rs208536	chr6:66963440	T/C	cg07460842	chr6:66804631	NA	-0.97	-13.15	-0.54	2.47e-33	Exhaled nitric oxide output;
LUAD	trans	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.94	0.44	4.58e-21	Ulcerative colitis;
LUAD	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg08999081	chr20:33150536	PIGU	0.48	9.03	0.4	5.94e-18	Coronary artery disease;
LUAD	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg00316803	chr15:76480434	C15orf27	-0.39	-7.14	-0.33	4.12e-12	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs239198	0.602	rs11758174	chr6:101322595	G/A	cg09795085	chr6:101329169	ASCC3	0.41	6.99	0.32	1.11e-11	Menarche (age at onset);
LUAD	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg19875535	chr5:140030758	IK	-0.48	-8.0	-0.36	1.18e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504073	0.527	rs118032023	chr8:49926296	A/T	cg00325661	chr8:49890786	NA	0.45	10.29	0.45	2.58e-22	Blood metabolite ratios;
LUAD	cis	rs2041840	1.000	rs2160392	chr2:37527393	A/G	cg25727520	chr2:37576821	QPCT	-0.36	-7.53	-0.34	3.09e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.42	0.34	6.53e-13	Menopause (age at onset);
LUAD	cis	rs7809950	1.000	rs4727680	chr7:107087407	T/G	cg23024343	chr7:107201750	COG5	-0.73	-12.51	-0.52	8.68e-31	Coronary artery disease;
LUAD	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg13319975	chr6:146136371	FBXO30	0.56	9.34	0.41	5.67e-19	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21659725	chr3:3221576	CRBN	-0.62	-9.97	-0.44	3.48e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs438465	1.000	rs9371135	chr6:169850264	G/A	cg11181693	chr6:169825345	NA	0.64	7.87	0.36	2.91e-14	Corneal astigmatism;
LUAD	trans	rs11039798	1.000	rs7942284	chr11:48520424	A/G	cg03929089	chr4:120376271	NA	-0.57	-6.47	-0.3	2.71e-10	Axial length;
LUAD	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg12667521	chr19:29218732	NA	0.54	7.15	0.33	3.9e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.54	-14.83	-0.58	2.41e-40	Schizophrenia;
LUAD	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg25208724	chr1:156163844	SLC25A44	1.0	17.95	0.66	5.52e-54	Testicular germ cell tumor;
LUAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg23978390	chr7:1156363	C7orf50	0.56	8.88	0.4	1.89e-17	Longevity;Endometriosis;
LUAD	trans	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg14791747	chr16:20752902	THUMPD1	0.66	10.12	0.44	1.04e-21	Cognitive test performance;
LUAD	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg06641503	chr3:48959341	ARIH2	-0.37	-6.73	-0.31	5.68e-11	Menarche (age at onset);
LUAD	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg09021430	chr5:549028	NA	-0.66	-14.73	-0.58	5.92e-40	Lung disease severity in cystic fibrosis;
LUAD	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.33e-13	Menopause (age at onset);
LUAD	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs57920188	0.640	rs4478781	chr1:4086827	C/T	cg10510935	chr1:4059661	NA	0.47	6.65	0.31	8.92e-11	Interleukin-17 levels;
LUAD	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg23625390	chr15:77176239	SCAPER	-0.52	-8.0	-0.36	1.17e-14	Blood metabolite levels;
LUAD	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg12311346	chr5:56204834	C5orf35	0.55	8.54	0.38	2.38e-16	Coronary artery disease;
LUAD	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg01181863	chr3:195395398	SDHAP2	-0.59	-8.86	-0.4	2.25e-17	Pancreatic cancer;
LUAD	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg22105103	chr4:187893119	NA	0.56	11.69	0.49	1.53e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg16325326	chr1:53192061	ZYG11B	-0.65	-11.95	-0.5	1.49e-28	Monocyte count;
LUAD	cis	rs4954585	0.683	rs10221893	chr2:137013606	C/T	cg05194412	chr2:137003533	NA	0.62	11.2	0.48	1.12e-25	Colorectal cancer;
LUAD	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg14186256	chr22:23484241	RTDR1	0.46	7.99	0.36	1.28e-14	Bone mineral density;
LUAD	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg15395560	chr15:45543142	SLC28A2	0.37	6.36	0.3	5.22e-10	Uric acid levels;
LUAD	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg06636001	chr8:8085503	FLJ10661	0.42	6.55	0.3	1.67e-10	Joint mobility (Beighton score);
LUAD	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg05342682	chr7:94953680	PON1	-0.52	-7.47	-0.34	4.57e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs752010	0.695	rs10890156	chr1:42108090	T/C	cg06885757	chr1:42089581	HIVEP3	0.39	8.26	0.37	1.82e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs897984	0.511	rs7196726	chr16:31092075	G/A	cg02466173	chr16:30829666	NA	-0.56	-9.73	-0.43	2.6e-20	Dementia with Lewy bodies;
LUAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08219700	chr8:58056026	NA	0.61	8.64	0.39	1.18e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4356932	1.000	rs10000130	chr4:76939335	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.38	-0.3	4.6e-10	Blood protein levels;
LUAD	trans	rs7395662	0.791	rs11040136	chr11:48939791	T/G	cg00717180	chr2:96193071	NA	0.39	7.45	0.34	5.46e-13	HDL cholesterol;
LUAD	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg02753203	chr1:228287806	NA	-0.64	-12.47	-0.52	1.29e-30	Diastolic blood pressure;
LUAD	cis	rs11048434	0.666	rs12371786	chr12:9090086	G/A	cg26114124	chr12:9217669	LOC144571	0.38	7.05	0.32	7.43e-12	Sjögren's syndrome;
LUAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.61	-10.67	-0.46	1.06e-23	Lymphocyte counts;
LUAD	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.85e-14	Parkinson's disease;
LUAD	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg27661571	chr11:113659931	NA	-0.69	-8.12	-0.37	5.29e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs6547631	0.622	rs10180445	chr2:85926218	C/G	cg21473183	chr2:85925749	GNLY	-0.35	-7.36	-0.34	9.75e-13	Blood protein levels;
LUAD	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg00310523	chr12:86230176	RASSF9	0.4	7.98	0.36	1.43e-14	Major depressive disorder;
LUAD	cis	rs11098699	0.769	rs6812009	chr4:124215392	A/G	cg09941581	chr4:124220074	SPATA5	0.49	8.01	0.36	1.1e-14	Mosquito bite size;
LUAD	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.21	0.33	2.67e-12	Motion sickness;
LUAD	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.31	6.41	0.3	3.97e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg11693508	chr17:37793320	STARD3	0.81	10.49	0.45	4.99e-23	Bipolar disorder;
LUAD	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	6.48	0.3	2.58e-10	Schizophrenia;
LUAD	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.66	-0.31	8.79e-11	Breast cancer;
LUAD	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg08885076	chr2:99613938	TSGA10	-0.39	-6.82	-0.31	3.18e-11	Chronic sinus infection;
LUAD	cis	rs758324	0.812	rs4705840	chr5:131206624	C/T	cg06307176	chr5:131281290	NA	0.46	7.68	0.35	1.08e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg05754148	chr16:3507555	NAT15	-0.47	-7.75	-0.35	6.9e-14	Body mass index (adult);
LUAD	cis	rs7677751	0.806	rs60806423	chr4:55086816	C/T	cg17187183	chr4:55093834	PDGFRA	0.51	8.54	0.38	2.46e-16	Corneal astigmatism;
LUAD	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg06784218	chr1:46089804	CCDC17	0.51	11.23	0.48	8.7e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg16590910	chr6:42928470	GNMT	0.41	7.72	0.35	8.28e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg00684032	chr4:1343700	KIAA1530	0.41	6.77	0.31	4.32e-11	Obesity-related traits;
LUAD	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg18932078	chr1:2524107	MMEL1	0.39	7.26	0.33	1.82e-12	Ulcerative colitis;
LUAD	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg15181151	chr6:150070149	PCMT1	0.35	6.66	0.31	8.32e-11	Lung cancer;
LUAD	cis	rs10781543	0.845	rs10781542	chr9:139327439	A/G	cg14169450	chr9:139327907	INPP5E	0.49	9.08	0.4	4.12e-18	Monocyte percentage of white cells;
LUAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg00106254	chr7:1943704	MAD1L1	-0.56	-8.71	-0.39	7.14e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs4650994	0.593	rs16853043	chr1:178545926	A/G	cg05059571	chr16:84539110	KIAA1609	0.46	7.01	0.32	9.68e-12	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs2070488	0.560	rs1381798	chr3:38437471	C/T	cg24069376	chr3:38537580	EXOG	-0.32	-6.62	-0.31	1.1e-10	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.62e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6993813	0.843	rs1485310	chr8:120051656	A/T	cg01975934	chr8:119970761	NA	-0.35	-6.81	-0.31	3.32e-11	Bone mineral density (hip);
LUAD	cis	rs698813	0.851	rs698807	chr2:44701659	G/C	cg00619915	chr2:44497795	NA	-0.44	-6.66	-0.31	8.61e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUAD	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.34	0.51	4.22e-30	Tonsillectomy;
LUAD	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg07507251	chr3:52567010	NT5DC2	0.33	6.39	0.3	4.47e-10	Bipolar disorder;
LUAD	cis	rs1595825	0.786	rs75415672	chr2:198535679	G/A	cg10547527	chr2:198650123	BOLL	-0.55	-7.69	-0.35	1.05e-13	Ulcerative colitis;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg20228512	chr17:36904069	PCGF2	-0.63	-6.43	-0.3	3.4e-10	Type 2 diabetes;
LUAD	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.04	23.44	0.75	1.77e-78	Chronic sinus infection;
LUAD	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg09976142	chr9:130955436	CIZ1	0.46	8.46	0.38	4.44e-16	Attention deficit hyperactivity disorder;
LUAD	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg09998033	chr7:158218633	PTPRN2	-0.55	-10.11	-0.44	1.13e-21	Obesity-related traits;
LUAD	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg00071950	chr4:10020882	SLC2A9	0.86	18.37	0.67	7.73e-56	Bone mineral density;
LUAD	cis	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.93	-0.32	1.61e-11	Triglycerides;
LUAD	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg04369109	chr6:150039330	LATS1	-0.42	-6.95	-0.32	1.43e-11	Lung cancer;
LUAD	cis	rs11118844	0.793	rs11118854	chr1:221943678	T/C	cg04222084	chr1:221915650	DUSP10	-0.6	-7.0	-0.32	9.88e-12	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg23533926	chr12:111358616	MYL2	-0.41	-7.01	-0.32	9.73e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg02551604	chr5:131831745	NA	-0.64	-10.62	-0.46	1.61e-23	Asthma (sex interaction);
LUAD	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18404041	chr3:52824283	ITIH1	-0.59	-11.82	-0.5	4.62e-28	Bipolar disorder;
LUAD	cis	rs2795502	0.873	rs1815716	chr10:43410200	G/A	cg27426351	chr10:43362370	NA	0.52	8.47	0.38	3.99e-16	Blood protein levels;
LUAD	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg24112000	chr20:60950667	NA	-0.88	-13.71	-0.55	1.2e-35	Colorectal cancer;
LUAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs11696501	0.688	rs6065859	chr20:44302697	C/T	cg11783356	chr20:44313418	WFDC10B	-0.48	-8.11	-0.37	5.7e-15	Brain structure;
LUAD	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg03354898	chr7:1950403	MAD1L1	0.35	6.57	0.3	1.48e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg07917127	chr4:99064746	C4orf37	-0.42	-6.95	-0.32	1.41e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9486719	1.000	rs2472890	chr6:96867646	C/T	cg06623918	chr6:96969491	KIAA0776	0.71	9.98	0.44	3.33e-21	Migraine;Coronary artery disease;
LUAD	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg18240062	chr17:79603768	NPLOC4	0.46	8.12	0.37	5.26e-15	Eye color traits;
LUAD	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg05535760	chr7:792225	HEATR2	1.0	12.51	0.52	8.84e-31	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7737355	1.000	rs12654593	chr5:130756867	C/T	cg25547332	chr5:131281432	NA	-0.43	-6.46	-0.3	2.88e-10	Life satisfaction;
LUAD	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg23018236	chr17:30244563	NA	-0.59	-7.78	-0.35	5.64e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg12935359	chr14:103987150	CKB	-0.49	-8.23	-0.37	2.41e-15	Body mass index;
LUAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg03188948	chr7:1209495	NA	0.44	6.93	0.32	1.59e-11	Longevity;Endometriosis;
LUAD	trans	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.15	-0.41	2.45e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7665090	0.528	rs4235405	chr4:103516811	T/C	cg07973026	chr4:103553119	MANBA	0.41	6.59	0.31	1.3100000000000001e-10	Primary biliary cholangitis;
LUAD	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg23985595	chr17:80112537	CCDC57	-0.5	-9.06	-0.4	4.87e-18	Life satisfaction;
LUAD	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg18252515	chr7:66147081	NA	-0.61	-6.76	-0.31	4.72e-11	Diabetic kidney disease;
LUAD	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg24130564	chr14:104152367	KLC1	-0.52	-9.03	-0.4	5.96e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg05805236	chr11:65401703	PCNXL3	-0.61	-9.83	-0.43	1.11e-20	Acne (severe);
LUAD	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg13319975	chr6:146136371	FBXO30	-0.58	-9.74	-0.43	2.4e-20	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg07211511	chr3:129823064	LOC729375	-0.89	-10.66	-0.46	1.2e-23	Blood pressure (smoking interaction);
LUAD	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg26924012	chr15:45694286	SPATA5L1	0.86	14.7	0.58	8.06e-40	Homoarginine levels;
LUAD	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg25036284	chr2:26402008	FAM59B	-0.56	-7.88	-0.36	2.82e-14	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg23758822	chr17:41437982	NA	0.9	18.44	0.67	3.58e-56	Menopause (age at onset);
LUAD	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg13385794	chr1:248469461	NA	0.26	7.07	0.33	6.48e-12	Common traits (Other);
LUAD	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-8.21	-0.37	2.77e-15	Height;
LUAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg27588902	chr6:42928151	GNMT	-0.31	-8.26	-0.37	1.91e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7759001	0.857	rs9461378	chr6:27360245	A/G	cg18711553	chr6:27366782	ZNF391	0.4	6.55	0.3	1.64e-10	Glomerular filtration rate (creatinine);
LUAD	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg23533926	chr12:111358616	MYL2	-0.42	-7.31	-0.33	1.39e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg12311346	chr5:56204834	C5orf35	0.47	7.77	0.35	5.93e-14	Coronary artery disease;
LUAD	cis	rs11083475	0.681	rs62121377	chr19:39257296	G/A	cg07905965	chr19:39260460	NA	0.46	8.54	0.38	2.47e-16	Heart rate;
LUAD	cis	rs11098699	0.821	rs4833890	chr4:124217864	G/C	cg09941581	chr4:124220074	SPATA5	0.49	7.95	0.36	1.7e-14	Mosquito bite size;
LUAD	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg08645402	chr16:4508243	NA	0.55	9.88	0.43	7.6e-21	Schizophrenia;
LUAD	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg19052272	chr2:3704530	ALLC	-0.63	-10.74	-0.46	5.9e-24	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg05991184	chr2:219186017	PNKD	-0.37	-7.21	-0.33	2.64e-12	Colorectal cancer;
LUAD	trans	rs11039798	0.920	rs116109043	chr11:48976940	C/T	cg03929089	chr4:120376271	NA	0.59	6.79	0.31	3.9e-11	Axial length;
LUAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg00280220	chr17:61926910	NA	0.36	6.98	0.32	1.18e-11	Prudent dietary pattern;
LUAD	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg04248312	chr19:17393744	ANKLE1	-0.99	-18.3	-0.66	1.63e-55	Systemic lupus erythematosus;
LUAD	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg10518543	chr12:38710700	ALG10B	-0.44	-7.11	-0.33	5.12e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg16647868	chr5:131706066	SLC22A5	0.39	6.67	0.31	7.82e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg15181151	chr6:150070149	PCMT1	0.36	6.95	0.32	1.43e-11	Lung cancer;
LUAD	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01570182	chr17:44337453	NA	-0.95	-14.84	-0.59	2.19e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg03433033	chr1:76189801	ACADM	0.84	14.51	0.58	5.08e-39	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg19622623	chr12:86230825	RASSF9	-0.54	-9.67	-0.43	4.01e-20	Major depressive disorder;
LUAD	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.25	0.48	7.03e-26	Height;
LUAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08677398	chr8:58056175	NA	0.49	6.77	0.31	4.32e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs758324	0.947	rs6861732	chr5:131156462	A/C	cg25547332	chr5:131281432	NA	0.43	6.49	0.3	2.34e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.56	-0.34	2.55e-13	Mood instability;
LUAD	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg05991184	chr2:219186017	PNKD	0.36	7.0	0.32	1.02e-11	Colorectal cancer;
LUAD	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.14	-0.41	2.59e-18	Total body bone mineral density;
LUAD	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg24634471	chr8:143751801	JRK	0.48	7.62	0.35	1.72e-13	Schizophrenia;
LUAD	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg07708487	chr16:89387014	ANKRD11	-0.35	-6.89	-0.32	2.06e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.21	-0.41	1.53e-18	Bipolar disorder;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg10552472	chr12:94071778	CRADD	-0.42	-7.11	-0.33	5.05e-12	Subcortical brain region volumes;
LUAD	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.69	-0.31	7.31e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs921968	0.613	rs2710250	chr2:219543277	A/G	cg02176678	chr2:219576539	TTLL4	-0.59	-11.83	-0.5	4.21e-28	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg09155575	chr17:38084037	ORMDL3	-0.53	-7.54	-0.34	2.99e-13	Testicular germ cell tumor;
LUAD	cis	rs17433780	0.857	rs12140979	chr1:89467242	C/G	cg09516651	chr1:89888402	LOC400759	0.5	8.88	0.4	1.87e-17	Carotid intima media thickness;
LUAD	cis	rs6594713	0.684	rs7708831	chr5:112933202	A/G	cg12552261	chr5:112820674	MCC	0.51	6.9	0.32	1.91e-11	Brain cytoarchitecture;
LUAD	cis	rs9341808	0.538	rs7747327	chr6:81035774	G/T	cg08355045	chr6:80787529	NA	-0.39	-6.65	-0.31	8.98e-11	Sitting height ratio;
LUAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08280861	chr8:58055591	NA	0.63	8.31	0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4006360	0.577	rs4986669	chr17:39250341	C/A	cg16090541	chr17:39240343	KRTAP4-7	-0.36	-6.44	-0.3	3.32e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg12623302	chr6:28058802	ZSCAN12L1	0.3	6.57	0.3	1.45e-10	Cardiac Troponin-T levels;
LUAD	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg23281280	chr6:28129359	ZNF389	0.46	6.56	0.3	1.55e-10	Depression;
LUAD	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.94	13.66	0.55	1.95e-35	Smoking behavior;
LUAD	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg27170947	chr2:26402098	FAM59B	-0.82	-11.49	-0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs758324	0.947	rs7734536	chr5:131162124	C/T	cg25547332	chr5:131281432	NA	0.42	6.51	0.3	2.18e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4919694	1.000	rs77318450	chr10:104733098	A/G	cg04362960	chr10:104952993	NT5C2	0.79	8.23	0.37	2.27e-15	Arsenic metabolism;
LUAD	cis	rs1003719	0.788	rs1543748	chr21:38446581	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.44	0.38	5.15e-16	Eye color traits;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg24975666	chr17:80416629	NARF	-0.73	-6.95	-0.32	1.43e-11	Type 2 diabetes;
LUAD	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg11494091	chr17:61959527	GH2	0.45	8.14	0.37	4.48e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Body mass index;
LUAD	cis	rs36051895	0.623	rs62541543	chr9:5042082	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-6.64	-0.31	9.72e-11	Pediatric autoimmune diseases;
LUAD	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg10909506	chr17:38081995	ORMDL3	0.39	6.82	0.31	3.11e-11	Lymphocyte counts;
LUAD	cis	rs55665837	0.701	rs12787709	chr11:14639257	G/A	cg19336497	chr11:14380999	RRAS2	-0.38	-6.77	-0.31	4.38e-11	Vitamin D levels;
LUAD	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg08601574	chr20:25228251	PYGB	0.47	8.9	0.4	1.59e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs7395662	0.895	rs2221553	chr11:48688784	C/T	cg15704280	chr7:45808275	SEPT13	-0.41	-6.35	-0.3	5.43e-10	HDL cholesterol;
LUAD	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg01017244	chr2:74357527	NA	0.88	14.35	0.57	2.4e-38	Gestational age at birth (maternal effect);
LUAD	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg02423579	chr7:2872169	GNA12	-0.81	-14.1	-0.57	2.76e-37	Height;
LUAD	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg06092702	chr1:163392909	NA	-0.41	-8.99	-0.4	8.1e-18	Motion sickness;
LUAD	cis	rs1784581	0.500	rs9355379	chr6:162421466	C/T	cg17173639	chr6:162384350	PARK2	0.54	8.9	0.4	1.6e-17	Itch intensity from mosquito bite;
LUAD	cis	rs7937890	0.559	rs2597187	chr11:14517019	C/G	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.25e-11	Mitochondrial DNA levels;
LUAD	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg06108461	chr20:60628389	TAF4	-0.82	-14.19	-0.57	1.12e-37	Body mass index;
LUAD	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2658782	0.951	rs117384439	chr11:93111478	T/G	cg15737290	chr11:93063684	CCDC67	-0.49	-6.79	-0.31	3.83e-11	Pulmonary function decline;
LUAD	cis	rs2041840	0.640	rs2300880	chr2:37537485	G/A	cg25727520	chr2:37576821	QPCT	-0.36	-7.81	-0.35	4.57e-14	Chronic lymphocytic leukemia;
LUAD	cis	rs6743376	0.556	rs1530551	chr2:113817566	C/T	cg09040174	chr2:113837401	NA	-0.52	-8.12	-0.37	5.16e-15	Inflammatory biomarkers;
LUAD	cis	rs7289126	1.000	rs8142686	chr22:38634266	C/T	cg17652424	chr22:38574118	PLA2G6	-0.24	-6.76	-0.31	4.72e-11	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg00530320	chr1:46809349	NSUN4	0.53	8.29	0.37	1.53e-15	Menopause (age at onset);
LUAD	cis	rs2579500	0.768	rs11676886	chr2:97249011	A/G	cg23100626	chr2:96804247	ASTL	-0.29	-7.15	-0.33	3.89e-12	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg27426351	chr10:43362370	NA	0.53	8.52	0.38	2.89e-16	Blood protein levels;
LUAD	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg08893839	chr5:154027129	NA	0.56	7.41	0.34	6.75e-13	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs877282	0.945	rs71491311	chr10:791747	G/A	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg13535736	chr9:111863775	C9orf5	-0.42	-6.59	-0.31	1.3100000000000001e-10	Menarche (age at onset);
LUAD	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg04450456	chr4:17643702	FAM184B	0.39	7.83	0.36	3.93e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.76	0.31	4.7e-11	Schizophrenia;
LUAD	cis	rs1595825	0.891	rs16823385	chr2:198602101	G/A	cg10547527	chr2:198650123	BOLL	-0.53	-7.01	-0.32	9.36e-12	Ulcerative colitis;
LUAD	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg09658497	chr7:2847517	GNA12	0.6	10.63	0.46	1.49e-23	Loneliness (linear analysis);
LUAD	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg11502198	chr6:26597334	ABT1	0.56	9.32	0.41	6.74e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs8077889	0.917	rs1859048	chr17:41892039	A/C	cg26893861	chr17:41843967	DUSP3	-0.88	-14.44	-0.57	9.96e-39	Triglycerides;
LUAD	cis	rs12545109	0.876	rs1992120	chr8:57337112	G/A	cg11919837	chr8:57350735	NA	-0.47	-6.38	-0.3	4.63e-10	Obesity-related traits;
LUAD	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg12179176	chr11:130786555	SNX19	-0.53	-8.98	-0.4	8.91e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.97	-0.32	1.23e-11	Bipolar disorder;
LUAD	trans	rs931812	0.825	rs34235568	chr8:101895761	C/T	cg20993868	chr7:22813445	NA	0.63	12.44	0.52	1.71e-30	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs6499255	1.000	rs4580150	chr16:69814953	G/A	cg15192750	chr16:69999425	NA	0.56	8.74	0.39	5.5e-17	IgE levels;
LUAD	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg22920501	chr2:26401640	FAM59B	-0.96	-14.61	-0.58	1.97e-39	Gut microbiome composition (summer);
LUAD	cis	rs1395	1.000	rs1275522	chr2:27426878	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.42	-7.97	-0.36	1.49e-14	Blood metabolite levels;
LUAD	cis	rs11098699	0.784	rs11947137	chr4:124205966	C/G	cg09941581	chr4:124220074	SPATA5	0.49	8.02	0.36	1.05e-14	Mosquito bite size;
LUAD	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg08742575	chr21:47604166	C21orf56	0.49	7.99	0.36	1.33e-14	Testicular germ cell tumor;
LUAD	cis	rs1448094	0.842	rs12318815	chr12:86452281	T/C	cg18827107	chr12:86230957	RASSF9	0.43	7.66	0.35	1.24e-13	Major depressive disorder;
LUAD	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.7e-32	Immature fraction of reticulocytes;
LUAD	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg19610905	chr11:61596333	FADS2	-0.61	-10.04	-0.44	2.11e-21	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-7.52	-0.34	3.27e-13	Tonsillectomy;
LUAD	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg16988262	chr1:15930761	NA	0.42	6.95	0.32	1.37e-11	Systolic blood pressure;
LUAD	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg25324976	chr17:61989376	CSHL1	0.36	7.01	0.32	9.71e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9837602	0.938	rs9873709	chr3:99711687	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-7.68	-0.35	1.08e-13	Breast cancer;
LUAD	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg02423579	chr7:2872169	GNA12	-0.52	-8.69	-0.39	8.14e-17	Height;
LUAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg22535103	chr8:58192502	C8orf71	-0.75	-9.08	-0.4	4.17e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.88	-0.36	2.81e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg11189052	chr15:85197271	WDR73	0.64	8.74	0.39	5.58e-17	Schizophrenia;
LUAD	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg10483660	chr13:112241077	NA	-0.45	-9.48	-0.42	1.86e-19	Menarche (age at onset);
LUAD	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg00383909	chr3:49044727	WDR6	0.91	10.55	0.46	2.92e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg12311346	chr5:56204834	C5orf35	-0.43	-7.22	-0.33	2.48e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg26408565	chr15:76604113	ETFA	-0.48	-8.05	-0.36	8.59e-15	Blood metabolite levels;
LUAD	cis	rs7301826	0.651	rs7971046	chr12:131286807	G/A	cg11011512	chr12:131303247	STX2	0.43	7.3	0.33	1.46e-12	Plasma plasminogen activator levels;
LUAD	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg01416388	chr22:39784598	NA	-0.52	-8.68	-0.39	8.4e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg00080972	chr5:178986291	RUFY1	-0.57	-9.96	-0.44	3.78e-21	Lung cancer;
LUAD	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg13319975	chr6:146136371	FBXO30	0.66	11.4	0.48	2.02e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg16405210	chr4:1374714	KIAA1530	-0.43	-7.43	-0.34	5.89e-13	Obesity-related traits;
LUAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg20607798	chr8:58055168	NA	0.57	7.24	0.33	2.1e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg05234568	chr11:5960015	NA	-0.58	-11.12	-0.48	2.24e-25	DNA methylation (variation);
LUAD	cis	rs68170813	0.559	rs7798223	chr7:106829223	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-11.09	-0.47	3.01e-25	Coronary artery disease;
LUAD	cis	rs6738485	0.601	rs13011900	chr2:106845059	G/C	cg16099169	chr2:106886729	NA	-0.42	-7.37	-0.34	8.82e-13	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg26338869	chr17:61819248	STRADA	-0.38	-6.35	-0.3	5.48e-10	Prudent dietary pattern;
LUAD	trans	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg06875740	chr19:51307921	C19orf48	-0.55	-7.68	-0.35	1.12e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs10979	0.965	rs7754452	chr6:143889028	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.3	-0.45	2.33e-22	Hypospadias;
LUAD	cis	rs2806561	0.664	rs55764475	chr1:23318983	C/T	cg19743168	chr1:23544995	NA	0.38	6.56	0.3	1.53e-10	Height;
LUAD	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18404041	chr3:52824283	ITIH1	0.62	12.69	0.53	1.71e-31	Bipolar disorder;
LUAD	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg26384229	chr12:38710491	ALG10B	0.52	8.53	0.38	2.64e-16	Heart rate;
LUAD	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg24818145	chr4:99064322	C4orf37	0.47	7.64	0.35	1.45e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg07362569	chr17:61921086	SMARCD2	0.39	6.67	0.31	8.16e-11	Prudent dietary pattern;
LUAD	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg02221750	chr19:17393354	ANKLE1	-0.76	-12.41	-0.52	2.27e-30	Systemic lupus erythematosus;
LUAD	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg08382946	chr5:1082689	SLC12A7	0.47	8.39	0.38	7.38e-16	QT interval;
LUAD	cis	rs1451375	0.583	rs3779078	chr7:50610918	C/T	cg18232548	chr7:50535776	DDC	0.63	8.67	0.39	9.27e-17	Malaria;
LUAD	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg02423579	chr7:2872169	GNA12	-0.87	-15.06	-0.59	2.33e-41	Height;
LUAD	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg13535736	chr9:111863775	C9orf5	0.44	6.91	0.32	1.76e-11	Menarche (age at onset);
LUAD	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg17724175	chr1:150552817	MCL1	0.39	9.42	0.42	2.91e-19	Tonsillectomy;
LUAD	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg04546413	chr19:29218101	NA	0.71	10.51	0.45	4.18e-23	Methadone dose in opioid dependence;
LUAD	trans	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg04995722	chr7:26192034	NFE2L3	-0.44	-7.62	-0.35	1.68e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4604732	0.536	rs12074913	chr1:247631607	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.17	0.33	3.47e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9341808	0.667	rs2322632	chr6:80845608	G/A	cg08355045	chr6:80787529	NA	0.46	8.09	0.37	6.43e-15	Sitting height ratio;
LUAD	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg04586622	chr2:25135609	ADCY3	0.37	8.34	0.38	1.06e-15	Body mass index;
LUAD	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg15123519	chr2:136567270	LCT	-0.38	-6.96	-0.32	1.27e-11	Mosquito bite size;
LUAD	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg27631724	chr1:11040367	C1orf127	0.5	8.77	0.39	4.4e-17	Ewing sarcoma;
LUAD	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-8.2	-0.37	2.81e-15	Monocyte percentage of white cells;
LUAD	cis	rs12681288	0.723	rs35425201	chr8:971062	C/T	cg04851639	chr8:1020857	NA	-0.33	-7.98	-0.36	1.35e-14	Schizophrenia;
LUAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.55	-6.98	-0.32	1.14e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62238980	0.614	rs4821021	chr22:32414170	T/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs713587	0.521	rs6545766	chr2:25077856	C/T	cg04586622	chr2:25135609	ADCY3	0.39	8.89	0.4	1.72e-17	Body mass index in non-asthmatics;
LUAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg27532560	chr4:187881888	NA	-0.38	-7.24	-0.33	2.19e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs877282	1.000	rs10904552	chr10:774326	A/G	cg06581033	chr10:766294	NA	-0.47	-6.64	-0.31	9.46e-11	Uric acid levels;
LUAD	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg10356904	chr22:49881777	NA	-0.33	-6.89	-0.32	1.98e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.48	-0.38	3.74e-16	Height;
LUAD	cis	rs714027	1.000	rs2412975	chr22:30540590	T/C	cg00539347	chr22:30592296	NA	-0.29	-6.73	-0.31	5.53e-11	Lymphocyte counts;
LUAD	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg18105134	chr13:113819100	PROZ	0.72	12.83	0.53	4.53e-32	Platelet distribution width;
LUAD	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg07917127	chr4:99064746	C4orf37	0.41	6.66	0.31	8.75e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg08859206	chr1:53392774	SCP2	0.6	11.16	0.48	1.53e-25	Monocyte count;
LUAD	cis	rs9302690	1.000	rs62037100	chr16:57430934	T/G	cg27017172	chr16:57497170	POLR2C	0.96	7.6	0.35	1.92e-13	Blood protein levels;
LUAD	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg22823121	chr1:150693482	HORMAD1	0.48	9.34	0.41	5.46e-19	Melanoma;
LUAD	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg09455208	chr3:40491958	NA	0.52	11.19	0.48	1.21e-25	Renal cell carcinoma;
LUAD	cis	rs13064411	0.735	rs7631138	chr3:113231925	A/T	cg18753928	chr3:113234510	CCDC52	-0.73	-12.4	-0.52	2.48e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7937890	0.559	rs2575830	chr11:14485602	C/A	cg06199346	chr11:14280333	SPON1	-0.33	-6.53	-0.3	1.94e-10	Mitochondrial DNA levels;
LUAD	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg10523679	chr1:76189770	ACADM	0.93	18.51	0.67	1.85e-56	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg00310523	chr12:86230176	RASSF9	0.4	7.91	0.36	2.27e-14	Major depressive disorder;
LUAD	cis	rs2658782	0.756	rs3019223	chr11:93084182	G/A	cg15737290	chr11:93063684	CCDC67	0.54	7.51	0.34	3.49e-13	Pulmonary function decline;
LUAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg21951975	chr1:209979733	IRF6	0.56	9.04	0.4	5.64e-18	Cleft lip with or without cleft palate;
LUAD	trans	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.7	-9.32	-0.41	6.74e-19	Obesity-related traits;
LUAD	trans	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg20542592	chr8:11973495	FAM66D	-0.43	-6.89	-0.32	2e-11	Mood instability;
LUAD	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg03467027	chr4:99064603	C4orf37	0.44	7.2	0.33	2.78e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6684514	0.961	rs72710222	chr1:156285995	T/C	cg16558208	chr1:156270281	VHLL	0.53	9.62	0.42	6.29e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg01324343	chr3:183735012	ABCC5	0.82	18.44	0.67	3.8e-56	Anterior chamber depth;
LUAD	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg05425664	chr17:57184151	TRIM37	-0.43	-7.72	-0.35	8.67e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.58	-0.3	1.37e-10	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg04842962	chr6:43655489	MRPS18A	1.05	26.56	0.79	3.65e-92	IgG glycosylation;
LUAD	cis	rs7474896	0.515	rs2749582	chr10:38275284	A/G	cg25427524	chr10:38739819	LOC399744	0.58	8.36	0.38	8.84e-16	Obesity (extreme);
LUAD	cis	rs17152411	0.895	rs7079416	chr10:126587312	C/G	cg07906193	chr10:126599966	NA	0.53	7.47	0.34	4.69e-13	Height;
LUAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.64	-0.42	4.99e-20	Alzheimer's disease;
LUAD	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21659725	chr3:3221576	CRBN	0.86	18.67	0.67	3.5e-57	Intelligence (multi-trait analysis);
LUAD	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg23158103	chr7:148848205	ZNF398	-0.47	-8.18	-0.37	3.47e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg00495681	chr13:53174319	NA	0.47	8.62	0.39	1.34e-16	Lewy body disease;
LUAD	cis	rs7737355	0.947	rs58991576	chr5:130589540	T/C	cg06307176	chr5:131281290	NA	-0.43	-7.0	-0.32	1.02e-11	Life satisfaction;
LUAD	cis	rs9392556	0.829	rs619873	chr6:4107455	A/G	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.41	-7.29	-0.33	1.52e-12	Blood metabolite levels;
LUAD	cis	rs11924390	0.800	rs1648698	chr3:186449582	G/C	cg12454167	chr3:186435060	KNG1	0.41	8.5	0.38	3.18e-16	Adiponectin levels;
LUAD	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg06873352	chr17:61820015	STRADA	0.53	8.64	0.39	1.15e-16	Height;
LUAD	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg13385794	chr1:248469461	NA	0.24	6.51	0.3	2.08e-10	Common traits (Other);
LUAD	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg27170947	chr2:26402098	FAM59B	-0.63	-8.82	-0.39	2.99e-17	Gut microbiome composition (summer);
LUAD	cis	rs17253792	0.822	rs74720318	chr14:56099828	G/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.39	-0.3	4.48e-10	Putamen volume;
LUAD	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg21138405	chr5:131827807	IRF1	0.6	13.85	0.56	3.04e-36	Asthma (sex interaction);
LUAD	cis	rs2625529	0.730	rs35713471	chr15:72459971	C/A	cg16672083	chr15:72433130	SENP8	-0.75	-12.81	-0.53	5.78e-32	Red blood cell count;
LUAD	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg25358565	chr5:93447407	FAM172A	0.55	6.53	0.3	1.86e-10	Diabetic retinopathy;
LUAD	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg18811423	chr2:55921094	PNPT1	0.52	8.72	0.39	6.4e-17	Metabolic syndrome;
LUAD	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg18016565	chr1:150552671	MCL1	-0.36	-6.47	-0.3	2.74e-10	Melanoma;
LUAD	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg24675056	chr1:15929824	NA	0.48	8.35	0.38	9.85e-16	Systolic blood pressure;
LUAD	trans	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.51	8.16	0.37	3.77e-15	Endometrial cancer;
LUAD	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg15226275	chr6:116381976	FRK	0.24	7.35	0.34	1.02e-12	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs3125734	0.633	rs1368157	chr10:64001114	T/C	cg19640130	chr10:64028056	RTKN2	-0.34	-7.24	-0.33	2.18e-12	Rheumatoid arthritis;
LUAD	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg16989719	chr2:238392110	NA	-0.35	-7.49	-0.34	4.03e-13	Prostate cancer;
LUAD	trans	rs2797160	0.967	rs1739355	chr6:126018114	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.86	0.4	2.17e-17	Endometrial cancer;
LUAD	cis	rs4629710	0.568	rs67021539	chr6:131552900	A/G	cg12606694	chr6:131520996	AKAP7	0.5	7.27	0.33	1.78e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg18402987	chr7:1209562	NA	0.46	7.3	0.33	1.45e-12	Longevity;Endometriosis;
LUAD	cis	rs11626933	1.000	rs4559843	chr14:90747488	T/C	cg14092571	chr14:90743983	NA	-0.96	-18.18	-0.66	5.55e-55	Gut microbiota (bacterial taxa);
LUAD	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg10518543	chr12:38710700	ALG10B	-0.51	-8.31	-0.37	1.35e-15	Morning vs. evening chronotype;
LUAD	cis	rs67072384	0.584	rs12275279	chr11:72437296	C/A	cg04827223	chr11:72435913	ARAP1	-0.68	-8.35	-0.38	9.61e-16	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.57	-9.71	-0.43	2.89e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg20701182	chr2:24300061	SF3B14	0.53	6.44	0.3	3.28e-10	Lymphocyte counts;
LUAD	trans	rs7944735	0.671	rs7106731	chr11:48003392	T/G	cg03929089	chr4:120376271	NA	0.57	7.92	0.36	2.13e-14	Intraocular pressure;
LUAD	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg12908607	chr1:44402522	ARTN	-0.52	-10.3	-0.45	2.37e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs11771526	0.901	rs11773754	chr7:32304801	A/G	cg27511599	chr7:32358540	NA	0.51	6.45	0.3	3.08e-10	Body mass index;
LUAD	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.68	-0.43	3.82e-20	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs2880765	0.743	rs12906308	chr15:86008059	C/T	cg13263323	chr15:86062960	AKAP13	0.48	8.66	0.39	9.83e-17	Coronary artery disease;
LUAD	cis	rs6750795	0.641	rs10933375	chr2:232367296	A/T	cg19187155	chr2:232395269	NMUR1	-0.41	-6.47	-0.3	2.78e-10	Height;
LUAD	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg25985355	chr7:65971099	NA	-0.55	-6.75	-0.31	4.77e-11	Diabetic kidney disease;
LUAD	cis	rs2637266	1.000	rs6480827	chr10:78356333	T/G	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	trans	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg24644049	chr4:85504048	CDS1	0.89	7.23	0.33	2.21e-12	Skin colour saturation;
LUAD	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg25809561	chr17:30822961	MYO1D	0.72	14.5	0.58	5.59e-39	Schizophrenia;
LUAD	trans	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.77	0.35	6.2e-14	Resting heart rate;
LUAD	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg17279839	chr7:150038598	RARRES2	0.47	7.82	0.36	4.27e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7536201	0.738	rs11249220	chr1:25300436	T/C	cg23273869	chr1:25296894	NA	-0.34	-6.41	-0.3	3.87e-10	Psoriasis vulgaris;
LUAD	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg22618164	chr12:122356400	WDR66	-0.72	-13.34	-0.54	3.86e-34	Mean corpuscular volume;
LUAD	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg00339695	chr16:24857497	SLC5A11	-0.52	-9.58	-0.42	8.36e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg23719950	chr11:63933701	MACROD1	-0.56	-6.69	-0.31	7.07e-11	Mean platelet volume;
LUAD	cis	rs12208915	0.945	rs12190108	chr6:79562655	T/C	cg09184832	chr6:79620586	NA	0.53	6.42	0.3	3.56e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs9595066	0.627	rs4941486	chr13:44749157	G/A	cg04068111	chr13:44716778	NA	-0.5	-8.36	-0.38	9.39e-16	Schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg03559817	chr5:135468621	SMAD5;SMAD5OS	-0.63	-6.36	-0.3	5.33e-10	Type 2 diabetes;
LUAD	cis	rs897984	0.762	rs4889599	chr16:30968589	C/T	cg02466173	chr16:30829666	NA	0.65	12.11	0.51	3.63e-29	Dementia with Lewy bodies;
LUAD	cis	rs1232027	0.622	rs1677708	chr5:79958039	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.02	-0.32	8.67e-12	Huntington's disease progression;
LUAD	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-8.93	-0.4	1.28e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs921968	0.565	rs6757772	chr2:219618497	T/G	cg02176678	chr2:219576539	TTLL4	-0.59	-12.08	-0.51	4.49e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg14343924	chr8:8086146	FLJ10661	-0.48	-7.45	-0.34	5.27e-13	Joint mobility (Beighton score);
LUAD	cis	rs11671005	0.779	rs3752112	chr19:58992220	T/G	cg13877915	chr19:58951672	ZNF132	0.55	6.98	0.32	1.13e-11	Mean platelet volume;
LUAD	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg26898376	chr11:64110657	CCDC88B	0.4	7.29	0.33	1.53e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg04450456	chr4:17643702	FAM184B	0.35	6.7	0.31	6.6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs31872	1.000	rs31872	chr5:140372222	A/G	cg19650706	chr5:140594406	PCDHB13	-0.47	-7.53	-0.34	3e-13	Visceral adipose tissue adjusted for BMI;
LUAD	cis	rs3862030	0.720	rs7081467	chr10:104231662	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-8.02	-0.36	1.08e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs6906287	0.669	rs6913012	chr6:118973137	G/A	cg21191810	chr6:118973309	C6orf204	0.5	9.61	0.42	6.38e-20	Electrocardiographic conduction measures;
LUAD	cis	rs12079745	0.793	rs12561922	chr1:169265794	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.11	-8.07	-0.37	7.41e-15	QT interval;
LUAD	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg04450456	chr4:17643702	FAM184B	0.36	6.81	0.31	3.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg05425664	chr17:57184151	TRIM37	0.43	7.72	0.35	8.68e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.16	0.48	1.59e-25	Height;
LUAD	cis	rs7301826	0.651	rs7295705	chr12:131301885	C/T	cg11011512	chr12:131303247	STX2	0.44	7.47	0.34	4.63e-13	Plasma plasminogen activator levels;
LUAD	cis	rs6066825	0.644	rs4810864	chr20:47319142	G/C	cg18078177	chr20:47281410	PREX1	0.39	6.49	0.3	2.44e-10	Colorectal cancer;
LUAD	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg25482853	chr8:67687455	SGK3	1.13	17.37	0.65	2.16e-51	Lung disease severity in cystic fibrosis;
LUAD	cis	rs34734847	1.000	rs56179458	chr12:121157535	G/A	cg27246729	chr12:121163418	ACADS	0.39	7.41	0.34	6.75e-13	Mean corpuscular volume;
LUAD	trans	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg26043149	chr18:55253948	FECH	-0.42	-6.87	-0.32	2.26e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7607369	0.536	rs6436091	chr2:219669141	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-10.22	-0.45	4.61e-22	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs8044868	0.586	rs6499557	chr16:72082654	A/G	cg23815491	chr16:72088622	HP	0.53	9.67	0.43	4.22e-20	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg22683308	chr4:1340831	KIAA1530	-0.44	-7.28	-0.33	1.64e-12	Longevity;
LUAD	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg19622623	chr12:86230825	RASSF9	-0.47	-8.04	-0.36	9.08e-15	Major depressive disorder;
LUAD	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg04756594	chr16:24857601	SLC5A11	0.53	9.92	0.43	5.46e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg00666640	chr1:248458726	OR2T12	0.29	6.86	0.32	2.41e-11	Common traits (Other);
LUAD	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg26513180	chr16:89883248	FANCA	-0.47	-7.95	-0.36	1.67e-14	Vitiligo;
LUAD	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg05044414	chr3:183734942	ABCC5	0.47	9.93	0.43	5.1e-21	Anterior chamber depth;
LUAD	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg07423050	chr13:99094983	FARP1	-0.45	-7.74	-0.35	7.43e-14	Longevity;
LUAD	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg11766577	chr21:47581405	C21orf56	-0.46	-7.88	-0.36	2.83e-14	Testicular germ cell tumor;
LUAD	cis	rs17155006	0.655	rs94604	chr7:107733856	C/T	cg05962710	chr7:107745446	LAMB4	-0.3	-6.53	-0.3	1.93e-10	Pneumococcal bacteremia;
LUAD	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-8.21	-0.37	2.77e-15	Height;
LUAD	trans	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04565464	chr8:145669602	NFKBIL2	0.48	7.17	0.33	3.46e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg22764044	chr5:178986830	RUFY1	0.41	7.09	0.33	5.8e-12	Lung cancer;
LUAD	trans	rs1422110	0.515	rs1155791	chr5:85417582	A/C	cg01787110	chr1:109008453	NBPF6	0.61	10.15	0.44	8.17e-22	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg22920501	chr2:26401640	FAM59B	-0.96	-14.21	-0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg02423579	chr7:2872169	GNA12	-0.59	-10.13	-0.44	9.98e-22	Height;
LUAD	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22857025	chr5:266934	NA	-0.97	-14.53	-0.58	4.25e-39	Breast cancer;
LUAD	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg14671364	chr1:107599128	PRMT6	0.57	9.82	0.43	1.19e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg19570723	chr19:47220176	PRKD2	-0.64	-6.46	-0.3	2.88e-10	Type 2 diabetes;
LUAD	cis	rs7010267	0.596	rs7013203	chr8:120017159	C/T	cg01975934	chr8:119970761	NA	0.34	6.49	0.3	2.37e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg10518543	chr12:38710700	ALG10B	-0.4	-6.59	-0.31	1.32e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9394841	0.667	rs3747749	chr6:41770604	G/A	cg25600774	chr6:41776562	USP49	-0.44	-6.73	-0.31	5.46e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg08132940	chr7:1081526	C7orf50	-0.77	-10.31	-0.45	2.21e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs67385638	1.000	rs10837697	chr11:5281018	G/C	cg12559170	chr11:5275217	HBG2	0.32	6.67	0.31	8.07e-11	Hemoglobin levels;
LUAD	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg14598338	chr9:96623480	NA	-0.45	-9.62	-0.42	6.1e-20	DNA methylation (variation);
LUAD	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	10.35	0.45	1.6400000000000001e-22	Colorectal cancer;
LUAD	cis	rs3820068	0.580	rs61169376	chr1:16003832	A/G	cg16988262	chr1:15930761	NA	0.41	6.47	0.3	2.64e-10	Systolic blood pressure;
LUAD	cis	rs7536201	1.000	rs12407074	chr1:25299432	T/A	cg23273869	chr1:25296894	NA	-0.39	-8.07	-0.37	7.56e-15	Psoriasis vulgaris;
LUAD	trans	rs12200782	1.000	rs6456742	chr6:26617075	T/C	cg08851530	chr6:28072375	NA	0.72	6.59	0.31	1.33e-10	Small cell lung carcinoma;
LUAD	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg13732083	chr21:47605072	C21orf56	0.42	6.95	0.32	1.39e-11	Testicular germ cell tumor;
LUAD	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg23254163	chr1:152506842	NA	0.26	7.29	0.33	1.59e-12	Hair morphology;
LUAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg11494091	chr17:61959527	GH2	0.73	17.91	0.66	8.84e-54	Prudent dietary pattern;
LUAD	cis	rs12765878	1.000	rs7100920	chr10:105640978	A/G	cg11005552	chr10:105648138	OBFC1	-0.41	-7.85	-0.36	3.57e-14	Coronary artery disease;
LUAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg22907277	chr7:1156413	C7orf50	0.48	8.16	0.37	3.83e-15	Longevity;Endometriosis;
LUAD	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg27446573	chr6:127587934	RNF146	0.45	6.52	0.3	2e-10	Breast cancer;
LUAD	trans	rs11039798	1.000	rs7125559	chr11:48984207	C/G	cg02254774	chr11:50257496	LOC441601	0.52	6.48	0.3	2.56e-10	Axial length;
LUAD	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg07636037	chr3:49044803	WDR6	0.35	6.4	0.3	4.12e-10	Resting heart rate;
LUAD	trans	rs12517041	1.000	rs6452112	chr5:23313498	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg27535305	chr1:53392650	SCP2	0.34	6.83	0.32	2.98e-11	Monocyte count;
LUAD	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.09	0.37	6.38e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08280861	chr8:58055591	NA	0.67	8.72	0.39	6.27e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.44	-0.45	7.67e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg16205897	chr5:131564050	P4HA2	-0.45	-10.65	-0.46	1.22e-23	Blood metabolite levels;
LUAD	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	7.07	0.33	6.39e-12	Tonsillectomy;
LUAD	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg20203395	chr5:56204925	C5orf35	-0.82	-11.8	-0.5	5.55e-28	Initial pursuit acceleration;
LUAD	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.54	8.26	0.37	1.85e-15	Platelet count;
LUAD	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05890377	chr2:74357713	NA	0.82	12.74	0.53	1.06e-31	Gestational age at birth (maternal effect);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02602480	chr2:62422689	B3GNT2	-0.4	-6.69	-0.31	7.2e-11	Height;
LUAD	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03647317	chr4:187891568	NA	-0.37	-7.16	-0.33	3.63e-12	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg21548813	chr6:291882	DUSP22	-0.54	-8.92	-0.4	1.37e-17	Menopause (age at onset);
LUAD	cis	rs909002	0.720	rs4949459	chr1:32142354	G/T	cg13919466	chr1:32135498	COL16A1	-0.38	-9.14	-0.41	2.54e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs89107	0.688	rs283085	chr6:118603267	C/A	cg21191810	chr6:118973309	C6orf204	0.49	9.74	0.43	2.23e-20	Cardiac structure and function;
LUAD	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg22431228	chr1:16359049	CLCNKA	0.42	7.99	0.36	1.31e-14	Systolic blood pressure;
LUAD	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.49	-0.42	1.66e-19	Life satisfaction;
LUAD	cis	rs10992471	0.603	rs12342019	chr9:95192508	C/T	cg14631576	chr9:95140430	CENPP	-0.56	-11.38	-0.48	2.42e-26	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs9378688	0.654	rs35224259	chr6:2363505	G/A	cg12303981	chr6:2244766	GMDS	0.43	6.58	0.3	1.41e-10	Caudate nucleus volume;
LUAD	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg16988262	chr1:15930761	NA	0.41	6.87	0.32	2.34e-11	Systolic blood pressure;
LUAD	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-8.0	-0.36	1.2e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	12.73	0.53	1.18e-31	Prudent dietary pattern;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg15257469	chr19:7069202	ZNF557	-0.39	-6.47	-0.3	2.65e-10	Cancer;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg15677368	chr1:245133209	EFCAB2	-0.44	-7.09	-0.33	5.71e-12	Vertical cup-disc ratio;
LUAD	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg09085632	chr11:111637200	PPP2R1B	0.64	9.85	0.43	9.28e-21	Primary sclerosing cholangitis;
LUAD	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.41	-0.34	6.98e-13	Coronary artery disease;
LUAD	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg17063962	chr7:91808500	NA	0.68	12.13	0.51	3.02e-29	Breast cancer;
LUAD	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.575	rs9615983	chr22:46793314	G/A	cg18190219	chr22:46762943	CELSR1	-0.58	-6.7	-0.31	6.87e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg16797656	chr11:68205561	LRP5	-0.39	-7.41	-0.34	7.05e-13	Bone mineral density (spine);
LUAD	trans	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.62	10.12	0.44	1.09e-21	Endometrial cancer;
LUAD	cis	rs9487051	0.768	rs458185	chr6:109524074	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.26	-0.33	1.85e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs9811920	0.809	rs793475	chr3:99543764	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	7.06	0.32	6.67e-12	Axial length;
LUAD	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg12863693	chr15:85201151	NMB	0.44	8.23	0.37	2.26e-15	Schizophrenia;
LUAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg04025307	chr7:1156635	C7orf50	0.65	11.58	0.49	3.99e-27	Longevity;Endometriosis;
LUAD	cis	rs12155623	1.000	rs12155623	chr8:49812201	A/T	cg22283653	chr8:49824208	NA	-0.45	-8.75	-0.39	5.26e-17	Sudden cardiac arrest;
LUAD	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg24154853	chr7:158122151	PTPRN2	0.57	11.38	0.48	2.29e-26	Calcium levels;
LUAD	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg22676075	chr6:135203613	NA	0.57	10.18	0.44	6.27e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.4	-0.42	3.46e-19	Schizophrenia;
LUAD	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16405210	chr4:1374714	KIAA1530	-0.39	-6.42	-0.3	3.68e-10	Longevity;
LUAD	cis	rs35740288	0.703	rs10520598	chr15:86173381	T/G	cg13263323	chr15:86062960	AKAP13	-0.45	-7.28	-0.33	1.61e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg06713675	chr4:122721982	EXOSC9	-0.84	-18.16	-0.66	6.49e-55	Type 2 diabetes;
LUAD	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg23166289	chr1:210001082	C1orf107	0.5	6.86	0.32	2.49e-11	Orofacial clefts;
LUAD	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg11584989	chr19:19387371	SF4	-0.4	-6.9	-0.32	1.97e-11	Tonsillectomy;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg10693065	chr11:8008448	EIF3F	0.45	7.28	0.33	1.61e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg21427119	chr20:30132790	HM13	-0.48	-7.63	-0.35	1.54e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg07677032	chr17:61819896	STRADA	0.57	10.46	0.45	6.53e-23	Prudent dietary pattern;
LUAD	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg03467027	chr4:99064603	C4orf37	0.39	6.37	0.3	5.05e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9902453	0.584	rs3809790	chr17:27955540	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-8.74	-0.39	5.34e-17	Coffee consumption (cups per day);
LUAD	cis	rs6669919	0.553	rs11587632	chr1:211668437	T/C	cg10512769	chr1:211675356	NA	-0.42	-8.24	-0.37	2.14e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs1006703	0.544	rs35299172	chr17:3834598	C/T	cg06463185	chr17:3833770	ATP2A3	0.64	7.96	0.36	1.57e-14	Glucose homeostasis traits;
LUAD	cis	rs10992471	0.603	rs987553	chr9:95298694	G/T	cg14631576	chr9:95140430	CENPP	-0.52	-10.44	-0.45	7.13e-23	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21582582	chr3:182698605	DCUN1D1	0.61	10.28	0.45	2.91e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg00784671	chr22:46762841	CELSR1	-0.58	-7.68	-0.35	1.13e-13	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg02030672	chr11:45687055	CHST1	-0.38	-6.88	-0.32	2.21e-11	Obesity-related traits;
LUAD	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg27284194	chr4:1044797	NA	0.69	9.84	0.43	1.03e-20	Recombination rate (females);
LUAD	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg21153622	chr11:89784906	NA	-0.35	-6.86	-0.32	2.53e-11	HDL cholesterol;
LUAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.58e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.2	-0.37	2.88e-15	Total cholesterol levels;
LUAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-9.43	-0.42	2.83e-19	Alzheimer's disease;
LUAD	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg07917127	chr4:99064746	C4orf37	0.39	6.44	0.3	3.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg10560079	chr2:191398806	TMEM194B	-0.52	-6.44	-0.3	3.33e-10	Diastolic blood pressure;
LUAD	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg03563238	chr19:33554763	RHPN2	-0.33	-8.03	-0.36	1e-14	Bone properties (heel);
LUAD	cis	rs243505	1.000	rs1019058	chr7:148424243	A/G	cg09806900	chr7:148480153	CUL1	-0.44	-7.38	-0.34	8.7e-13	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.39	-0.34	8.12e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7705042	0.865	rs7709361	chr5:141513854	T/C	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.67	-0.31	8.02e-11	Asthma;
LUAD	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.59	9.48	0.42	1.81e-19	Cognitive ability;
LUAD	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-14.36	-0.57	2.26e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg00981070	chr1:2046702	PRKCZ	0.32	6.95	0.32	1.42e-11	Height;
LUAD	trans	rs991427	1.000	rs991427	chr12:91474422	C/T	cg11428724	chr1:18957632	PAX7	0.42	6.53	0.3	1.87e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg16447950	chr5:562315	NA	-0.44	-7.09	-0.33	5.74e-12	Obesity-related traits;
LUAD	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg14343924	chr8:8086146	FLJ10661	0.4	6.38	0.3	4.58e-10	Retinal vascular caliber;
LUAD	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg04398451	chr17:18023971	MYO15A	0.71	12.86	0.53	3.7e-32	Total body bone mineral density;
LUAD	cis	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg26751094	chr13:95954534	ABCC4	-0.53	-11.21	-0.48	1.06e-25	Blood metabolite levels;
LUAD	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg03885332	chr11:832357	CD151	-0.42	-8.01	-0.36	1.11e-14	Mean platelet volume;
LUAD	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg27284194	chr4:1044797	NA	0.69	10.04	0.44	2.06e-21	Recombination rate (females);
LUAD	trans	rs236907	0.859	rs3891278	chr1:171756248	A/C	cg13482142	chr2:234261155	NA	0.51	6.55	0.3	1.63e-10	Mean platelet volume;
LUAD	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg01097406	chr16:89675127	NA	0.33	6.56	0.3	1.56e-10	Vitiligo;
LUAD	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg18306943	chr3:40428807	ENTPD3	0.43	7.19	0.33	2.95e-12	Renal cell carcinoma;
LUAD	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	8.73	0.39	5.97e-17	Menarche (age at onset);
LUAD	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg08085267	chr17:45401833	C17orf57	0.58	10.61	0.46	1.74e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg12524338	chr4:183729343	NA	0.62	7.37	0.34	8.95e-13	Pediatric autoimmune diseases;
LUAD	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg11859384	chr17:80120422	CCDC57	0.51	9.26	0.41	1e-18	Life satisfaction;
LUAD	trans	rs11039798	0.764	rs1121450	chr11:48897476	C/T	cg02254774	chr11:50257496	LOC441601	0.54	6.73	0.31	5.7e-11	Axial length;
LUAD	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg06453172	chr10:134556979	INPP5A	-0.66	-9.9	-0.43	6.49e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg11707310	chr1:2537719	MMEL1	0.38	7.94	0.36	1.89e-14	Ulcerative colitis;
LUAD	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg13319975	chr6:146136371	FBXO30	0.63	10.77	0.46	4.76e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs775227	0.574	rs13067967	chr3:113265215	C/G	cg18753928	chr3:113234510	CCDC52	-0.65	-9.07	-0.4	4.39e-18	Dental caries;
LUAD	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg17264618	chr3:40429014	ENTPD3	0.39	8.73	0.39	6.13e-17	Renal cell carcinoma;
LUAD	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg06484146	chr7:12443880	VWDE	-0.58	-7.33	-0.34	1.17e-12	Coronary artery disease;
LUAD	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg02896835	chr1:92012615	NA	0.45	8.91	0.4	1.48e-17	Breast cancer;
LUAD	cis	rs3106136	0.527	rs2664894	chr4:95153831	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.24	-0.45	4.01e-22	Capecitabine sensitivity;
LUAD	cis	rs3087591	1.000	rs2953015	chr17:29495341	A/G	cg24425628	chr17:29625626	OMG;NF1	0.4	6.58	0.3	1.41e-10	Hip circumference;
LUAD	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg20701182	chr2:24300061	SF3B14	0.56	6.83	0.31	3.04e-11	Lymphocyte counts;
LUAD	cis	rs9902453	0.868	rs8066602	chr17:28523085	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	9.41	0.42	3.17e-19	Coffee consumption (cups per day);
LUAD	trans	rs10802346	0.545	rs4607841	chr1:246373295	T/C	cg13514129	chr1:39547527	MACF1	0.62	10.95	0.47	9.79e-25	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs3857067	0.806	rs4693375	chr4:95133241	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.38	-6.82	-0.31	3.24e-11	QT interval;
LUAD	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg05665937	chr4:1216051	CTBP1	0.38	6.41	0.3	3.9e-10	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7927771	0.524	rs7933184	chr11:47682402	C/T	cg18512352	chr11:47633146	NA	0.37	6.52	0.3	1.99e-10	Subjective well-being;
LUAD	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg17788362	chr6:86352627	SYNCRIP	0.43	6.73	0.31	5.59e-11	Smooth-surface caries;
LUAD	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.3	6.36	0.3	5.19e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21214613	chr1:16344536	HSPB7	0.56	9.85	0.43	9.79e-21	Dilated cardiomyopathy;
LUAD	cis	rs55788414	0.725	rs13339333	chr16:81189028	C/A	cg06400318	chr16:81190750	PKD1L2	-0.79	-10.72	-0.46	7.13e-24	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg23982607	chr1:1823379	GNB1	-0.91	-19.3	-0.68	5.21e-60	Body mass index;
LUAD	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.69	-0.35	1.01e-13	Breast cancer;
LUAD	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg08219700	chr8:58056026	NA	0.58	6.59	0.31	1.29e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg03233332	chr7:66118400	NA	-0.46	-6.93	-0.32	1.63e-11	Aortic root size;
LUAD	cis	rs1873147	1.000	rs2130165	chr15:63314519	C/T	cg12160578	chr15:63334699	TPM1	-0.36	-6.67	-0.31	8.24e-11	Orofacial clefts;
LUAD	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg15181151	chr6:150070149	PCMT1	0.42	8.59	0.39	1.74e-16	Lung cancer;
LUAD	cis	rs679087	1.000	rs672107	chr12:29917266	T/A	cg14258853	chr12:29935411	TMTC1	-0.6	-10.36	-0.45	1.44e-22	Schizophrenia;
LUAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg22764044	chr5:178986830	RUFY1	0.63	10.75	0.46	5.6e-24	Lung cancer;
LUAD	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.23	-0.37	2.38e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.33	0.34	1.15e-12	Menopause (age at onset);
LUAD	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg07153921	chr17:41440717	NA	-0.4	-6.78	-0.31	4.07e-11	Menopause (age at onset);
LUAD	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg07677032	chr17:61819896	STRADA	0.56	10.07	0.44	1.6e-21	Prudent dietary pattern;
LUAD	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg14092988	chr3:52407081	DNAH1	0.37	7.49	0.34	4.02e-13	Bipolar disorder;
LUAD	cis	rs2692947	0.655	rs4605406	chr2:96583735	A/C	cg23100626	chr2:96804247	ASTL	0.32	7.85	0.36	3.49e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03517284	chr6:25882590	NA	0.53	7.73	0.35	8.07e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg11062466	chr8:58055876	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9323205	0.577	rs9672038	chr14:51724856	A/G	cg23942311	chr14:51606299	NA	-0.62	-11.61	-0.49	3.09e-27	Cancer;
LUAD	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg08859206	chr1:53392774	SCP2	-0.65	-11.77	-0.5	7.1e-28	Monocyte count;
LUAD	cis	rs12541635	0.966	rs7839195	chr8:107020193	G/A	cg10147462	chr8:107024639	NA	0.51	9.28	0.41	8.9e-19	Age of smoking initiation;
LUAD	cis	rs3823572	0.564	rs2346274	chr7:133660841	G/A	cg03336402	chr7:133662267	EXOC4	-0.41	-7.59	-0.35	2.08e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg22676075	chr6:135203613	NA	0.39	7.08	0.33	5.87e-12	Red blood cell count;
LUAD	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-8.7	-0.39	7.3e-17	Monocyte percentage of white cells;
LUAD	cis	rs6426558	0.537	rs6682642	chr1:227244600	G/T	cg10327440	chr1:227177885	CDC42BPA	0.51	8.55	0.38	2.32e-16	Neutrophil percentage of white cells;
LUAD	cis	rs11229555	0.645	rs11229442	chr11:58196790	C/T	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7010267	0.570	rs6469794	chr8:120016099	C/T	cg01975934	chr8:119970761	NA	-0.35	-6.67	-0.31	7.84e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg23625390	chr15:77176239	SCAPER	-0.46	-7.44	-0.34	5.69e-13	Blood metabolite levels;
LUAD	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg14092988	chr3:52407081	DNAH1	0.45	8.84	0.39	2.62e-17	Bipolar disorder;
LUAD	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs9443645	0.611	rs10943616	chr6:79823541	G/A	cg05283184	chr6:79620031	NA	-0.39	-6.56	-0.3	1.56e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.43	-7.58	-0.35	2.23e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg25358565	chr5:93447407	FAM172A	0.66	7.75	0.35	6.74e-14	Diabetic retinopathy;
LUAD	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg06636001	chr8:8085503	FLJ10661	0.4	6.41	0.3	3.88e-10	Mood instability;
LUAD	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg18131467	chr2:239335373	ASB1	0.7	11.87	0.5	2.9e-28	Multiple system atrophy;
LUAD	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg20476274	chr7:133979776	SLC35B4	0.74	13.66	0.55	1.94e-35	Mean platelet volume;
LUAD	trans	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg06606381	chr12:133084897	FBRSL1	-1.0	-9.42	-0.42	2.91e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12612619	0.732	rs13032100	chr2:27233859	T/C	cg00617064	chr2:27272375	NA	-0.36	-6.83	-0.32	2.98e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03517284	chr6:25882590	NA	-0.6	-8.9	-0.4	1.69e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg24550644	chr17:30846204	MYO1D	-0.37	-6.76	-0.31	4.67e-11	Schizophrenia;
LUAD	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg10589385	chr1:150898437	SETDB1	0.41	7.74	0.35	7.34e-14	Tonsillectomy;
LUAD	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg09835421	chr16:68378352	PRMT7	0.91	9.88	0.43	7.69e-21	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg22431228	chr1:16359049	CLCNKA	0.47	8.52	0.38	2.89e-16	Dilated cardiomyopathy;
LUAD	cis	rs7192380	0.767	rs11641686	chr16:69580399	A/G	cg26679644	chr16:69762563	NA	0.38	6.97	0.32	1.2e-11	Sjögren's syndrome;
LUAD	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.84	0.47	2.51e-24	Smoking behavior;
LUAD	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg06064525	chr11:970664	AP2A2	-0.53	-10.86	-0.47	2.03e-24	Alzheimer's disease (late onset);
LUAD	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg11707310	chr1:2537719	MMEL1	-0.39	-8.21	-0.37	2.71e-15	Ulcerative colitis;
LUAD	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18876405	chr7:65276391	NA	-0.44	-6.91	-0.32	1.83e-11	Aortic root size;
LUAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg11494091	chr17:61959527	GH2	0.74	18.43	0.67	3.97e-56	Prudent dietary pattern;
LUAD	cis	rs4774899	0.966	rs4774910	chr15:57410217	T/C	cg14026238	chr15:57616123	NA	0.35	6.61	0.31	1.14e-10	Urinary tract infection frequency;
LUAD	cis	rs1451375	1.000	rs921450	chr7:50623260	A/G	cg18232548	chr7:50535776	DDC	-0.57	-9.33	-0.41	6.19e-19	Malaria;
LUAD	cis	rs501916	1.000	rs3743276	chr15:48055119	C/T	cg16110827	chr15:48056943	SEMA6D	0.34	6.75	0.31	4.76e-11	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg18132916	chr6:79620363	NA	-0.44	-7.64	-0.35	1.52e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg18854424	chr1:2615690	NA	-0.42	-9.07	-0.4	4.63e-18	Ulcerative colitis;
LUAD	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.46	8.16	0.37	3.74e-15	Alzheimer's disease (late onset);
LUAD	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg01579765	chr21:45077557	HSF2BP	-0.6	-13.27	-0.54	7.92e-34	Mean corpuscular volume;
LUAD	trans	rs7395662	0.791	rs11040136	chr11:48939791	T/G	cg15704280	chr7:45808275	SEPT13	0.41	6.53	0.3	1.94e-10	HDL cholesterol;
LUAD	cis	rs11809207	0.859	rs61776644	chr1:26505548	T/C	cg00147160	chr1:26503991	CNKSR1	0.46	9.3	0.41	7.56e-19	Height;
LUAD	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg21724239	chr8:58056113	NA	0.52	7.03	0.32	8.51e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4638749	0.677	rs12329189	chr2:108812855	T/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.36	-0.34	9.91e-13	Blood pressure;
LUAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg11766577	chr21:47581405	C21orf56	-0.52	-9.19	-0.41	1.79e-18	Testicular germ cell tumor;
LUAD	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg02423579	chr7:2872169	GNA12	0.85	15.19	0.59	6.49e-42	Height;
LUAD	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg14728415	chr7:32535168	LSM5;AVL9	0.69	12.71	0.53	1.42e-31	Cognitive ability;
LUAD	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.22	0.33	2.45e-12	Blood metabolite levels;
LUAD	cis	rs3845702	0.736	rs6733426	chr2:180830958	A/G	cg01881094	chr2:180872142	CWC22	-0.74	-7.93	-0.36	1.91e-14	Schizophrenia;
LUAD	cis	rs3736594	0.559	rs1919129	chr2:27818721	C/G	cg27432699	chr2:27873401	GPN1	0.45	6.53	0.3	1.88e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs6499255	0.951	rs75815213	chr16:69702854	C/T	cg15192750	chr16:69999425	NA	0.54	8.39	0.38	7.49e-16	IgE levels;
LUAD	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg04365224	chr3:72788183	NA	-0.46	-6.85	-0.32	2.6e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	7.4	0.34	7.36e-13	Schizophrenia;
LUAD	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg23029597	chr12:123009494	RSRC2	-0.58	-9.18	-0.41	1.98e-18	Body mass index;
LUAD	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg08885076	chr2:99613938	TSGA10	-0.37	-6.48	-0.3	2.52e-10	Chronic sinus infection;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22162225	chr2:62932835	EHBP1	-0.54	-6.41	-0.3	3.98e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2455601	0.638	rs2742485	chr11:8986787	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-7.7	-0.35	9.72e-14	Schizophrenia;
LUAD	cis	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg02508848	chr16:68573721	ZFP90	-0.42	-6.55	-0.3	1.72e-10	Ulcerative colitis;
LUAD	cis	rs62238980	0.614	rs117655982	chr22:32461141	T/C	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs9796	0.674	rs6492978	chr15:41317702	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.38	-7.16	-0.33	3.64e-12	Menopause (age at onset);
LUAD	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg16235748	chr6:149772707	ZC3H12D	-0.31	-6.9	-0.32	1.95e-11	Dupuytren's disease;
LUAD	cis	rs2839627	0.683	rs6586259	chr21:44315266	G/A	cg03543861	chr21:44258195	NA	0.67	8.07	0.37	7.34e-15	Information processing speed;
LUAD	cis	rs3760982	1.000	rs11665924	chr19:44286982	G/A	cg11993925	chr19:44307056	LYPD5	0.43	8.41	0.38	6.31e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27297192	chr10:134578999	INPP5A	0.38	6.7	0.31	6.64e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg06558623	chr16:89946397	TCF25	1.12	9.76	0.43	2.05e-20	Skin colour saturation;
LUAD	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	cis	rs9925964	0.967	rs14235	chr16:31121793	G/A	cg03418659	chr16:31128414	MYST1	0.39	6.58	0.3	1.39e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg10876282	chr6:28092338	ZSCAN16	0.41	6.38	0.3	4.73e-10	Parkinson's disease;
LUAD	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-25.04	-0.77	1.57e-85	Height;
LUAD	cis	rs859767	0.741	rs883964	chr2:135436200	G/C	cg12500956	chr2:135428796	TMEM163	-0.31	-8.1	-0.37	5.83e-15	Neuroticism;
LUAD	cis	rs1182180	0.538	rs4722006	chr7:2765723	A/G	cg13137809	chr7:2768988	GNA12	0.4	6.54	0.3	1.73e-10	Platelet count;
LUAD	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg19767477	chr5:127420684	SLC12A2	-0.41	-6.4	-0.3	4.09e-10	Ileal carcinoids;
LUAD	cis	rs7267979	0.545	rs6050426	chr20:25178265	C/G	cg08601574	chr20:25228251	PYGB	0.37	6.73	0.31	5.37e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.69	0.31	7.18e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs7186908	0.761	rs34714490	chr16:72177099	G/T	cg23815491	chr16:72088622	HP	0.47	7.51	0.34	3.48e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7582720	0.806	rs72926770	chr2:203798585	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.36	0.41	4.87e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	6.51	0.3	2.14e-10	Obesity-related traits;
LUAD	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg13736514	chr6:26305472	NA	0.44	7.23	0.33	2.31e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg26668828	chr6:292823	DUSP22	-0.78	-13.78	-0.56	5.79e-36	Menopause (age at onset);
LUAD	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg26513180	chr16:89883248	FANCA	0.78	7.19	0.33	2.95e-12	Skin colour saturation;
LUAD	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg02931644	chr1:25747376	RHCE	0.42	8.72	0.39	6.48e-17	Erythrocyte sedimentation rate;
LUAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg07362569	chr17:61921086	SMARCD2	0.39	6.73	0.31	5.37e-11	Prudent dietary pattern;
LUAD	trans	rs877282	0.945	rs11253397	chr10:789774	A/G	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs3857067	0.806	rs7654919	chr4:95136164	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.36	-6.53	-0.3	1.9e-10	QT interval;
LUAD	cis	rs4862307	0.720	rs12650935	chr4:184989565	G/A	cg06737308	chr4:185021514	ENPP6	0.58	9.25	0.41	1.15e-18	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-6.5	-0.3	2.31e-10	Height;
LUAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07167872	chr1:205819463	PM20D1	0.73	14.36	0.57	2.16e-38	Monocyte percentage of white cells;
LUAD	trans	rs5756813	0.635	rs11089856	chr22:38205784	A/C	cg19894588	chr14:64061835	NA	-0.54	-7.7	-0.35	9.97e-14	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs922182	0.663	rs55929105	chr15:64265804	C/T	cg02919090	chr15:64263738	DAPK2	0.36	6.88	0.32	2.13e-11	Blood protein levels;
LUAD	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg20291162	chr17:40259547	DHX58	-0.7	-10.99	-0.47	7.02e-25	Fibrinogen levels;
LUAD	cis	rs62400317	0.731	rs12214435	chr6:44906717	G/A	cg20913747	chr6:44695427	NA	-0.45	-6.97	-0.32	1.24e-11	Total body bone mineral density;
LUAD	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26314531	chr2:26401878	FAM59B	0.74	10.54	0.46	3.2e-23	Gut microbiome composition (summer);
LUAD	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.05	0.32	7.2e-12	Menopause (age at onset);
LUAD	cis	rs7593730	0.945	rs12622664	chr2:161179356	C/G	cg22609984	chr2:161126801	NA	0.45	7.31	0.34	1.32e-12	Type 2 diabetes;
LUAD	cis	rs9487051	0.735	rs419106	chr6:109520067	C/G	cg01475377	chr6:109611718	NA	-0.41	-7.82	-0.36	4.17e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs77861329	0.748	rs6786592	chr3:52196241	T/C	cg08692210	chr3:52188851	WDR51A	0.54	6.89	0.32	1.98e-11	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg14598338	chr9:96623480	NA	-0.42	-8.94	-0.4	1.21e-17	DNA methylation (variation);
LUAD	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg12193833	chr17:30244370	NA	-0.58	-7.16	-0.33	3.71e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg16797656	chr11:68205561	LRP5	-0.37	-7.03	-0.32	8.07e-12	Bone mineral density (spine);
LUAD	cis	rs9399401	0.601	rs262120	chr6:142842360	C/A	cg03128060	chr6:142623767	GPR126	0.43	7.91	0.36	2.29e-14	Chronic obstructive pulmonary disease;
LUAD	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg05887092	chr17:76393375	PGS1	0.42	7.41	0.34	7.1e-13	HDL cholesterol levels;
LUAD	cis	rs2455799	0.634	rs1345160	chr3:15862026	C/T	cg16303742	chr3:15540471	COLQ	-0.51	-9.39	-0.42	3.67e-19	Mean platelet volume;
LUAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg11062466	chr8:58055876	NA	0.48	6.73	0.31	5.55e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.95	-0.36	1.78e-14	Monocyte percentage of white cells;
LUAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11060661	chr22:24314208	DDT;DDTL	0.35	6.49	0.3	2.43e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg17551891	chr7:1960795	MAD1L1	-0.43	-7.44	-0.34	5.78e-13	Neuroticism;
LUAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.4	-0.45	1.06e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs4660214	0.724	rs7554301	chr1:39643464	C/T	cg27567593	chr1:39956653	BMP8A	0.36	7.16	0.33	3.64e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	17.44	0.65	9.9e-52	Exhaled nitric oxide output;
LUAD	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg15147215	chr3:52552868	STAB1	-0.39	-6.93	-0.32	1.55e-11	Bipolar disorder;
LUAD	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg14926445	chr8:58193284	C8orf71	-0.48	-7.0	-0.32	1.03e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03518390	chr14:105792853	PACS2	0.5	7.54	0.34	2.91e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs72960926	0.590	rs72955123	chr6:74760355	C/T	cg03266952	chr6:74778945	NA	-0.85	-7.56	-0.34	2.56e-13	Metabolite levels (MHPG);
LUAD	cis	rs7937890	0.559	rs2597208	chr11:14472329	A/C	cg22961513	chr11:14280813	SPON1	-0.37	-7.09	-0.33	5.68e-12	Mitochondrial DNA levels;
LUAD	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg13902645	chr11:5959945	NA	-0.57	-10.69	-0.46	8.94e-24	DNA methylation (variation);
LUAD	cis	rs9972944	0.756	rs7220733	chr17:63764890	A/T	cg07283582	chr17:63770753	CCDC46	-0.47	-10.56	-0.46	2.79e-23	Total body bone mineral density;
LUAD	trans	rs6964492	0.510	rs6956766	chr7:134436349	C/T	cg25001845	chr14:75201709	FCF1	-0.42	-6.72	-0.31	5.99e-11	Tonsillectomy;
LUAD	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg24399712	chr22:39784796	NA	-0.74	-12.2	-0.51	1.54e-29	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-20.31	-0.7	1.58e-64	Height;
LUAD	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg06618935	chr21:46677482	NA	-0.5	-9.58	-0.42	8.54e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg22852734	chr6:133119734	C6orf192	0.78	9.36	0.41	4.78e-19	Type 2 diabetes nephropathy;
LUAD	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg12311346	chr5:56204834	C5orf35	-0.45	-7.33	-0.34	1.16e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs2656056	1	rs2656056	chr15:78722519	T/C	cg18825076	chr15:78729989	IREB2	-0.55	-7.6	-0.35	1.91e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg08029281	chr1:67600428	NA	0.36	7.13	0.33	4.24e-12	Psoriasis;
LUAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg03354898	chr7:1950403	MAD1L1	-0.39	-7.12	-0.33	4.69e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg21951975	chr1:209979733	IRF6	0.58	8.36	0.38	8.91e-16	Cleft lip with or without cleft palate;
LUAD	cis	rs2637266	1.000	rs2894337	chr10:78344871	C/T	cg18941641	chr10:78392320	NA	0.33	6.82	0.31	3.24e-11	Pulmonary function;
LUAD	cis	rs11671005	0.779	rs731259	chr19:58989424	C/T	cg13877915	chr19:58951672	ZNF132	0.57	6.95	0.32	1.43e-11	Mean platelet volume;
LUAD	cis	rs4454254	0.901	rs10088129	chr8:141060242	A/G	cg06693505	chr8:141057453	TRAPPC9	0.32	6.4	0.3	4.18e-10	Pulse pressure;
LUAD	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg23018236	chr17:30244563	NA	-0.62	-8.19	-0.37	3.03e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.57e-13	Tonsillectomy;
LUAD	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs16958440	0.867	rs79285649	chr18:44699019	A/T	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg09197432	chr4:183729176	NA	0.61	7.93	0.36	1.94e-14	Pediatric autoimmune diseases;
LUAD	trans	rs783540	0.846	rs2099259	chr15:83323688	C/T	cg18393722	chr15:85113863	UBE2QP1	0.43	6.76	0.31	4.46e-11	Schizophrenia;
LUAD	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg24803719	chr17:45855879	NA	-0.34	-6.7	-0.31	6.5500000000000006e-11	IgG glycosylation;
LUAD	cis	rs4948275	0.550	rs7904815	chr10:63136612	G/A	cg02461363	chr10:63212496	TMEM26	-0.34	-7.23	-0.33	2.25e-12	Night sleep phenotypes;
LUAD	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg12935359	chr14:103987150	CKB	-0.45	-7.56	-0.35	2.5e-13	Body mass index;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05452345	chr5:102455768	GIN1	-0.39	-6.59	-0.31	1.3e-10	Height;
LUAD	cis	rs3820068	0.705	rs4646072	chr1:15827711	G/A	cg13390004	chr1:15929781	NA	0.4	6.44	0.3	3.27e-10	Systolic blood pressure;
LUAD	cis	rs35771425	0.619	rs7529900	chr1:211442661	C/T	cg26515805	chr1:211431828	RCOR3	-0.41	-7.51	-0.34	3.55e-13	Educational attainment (years of education);
LUAD	trans	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg07817883	chr1:32538562	TMEM39B	-0.56	-6.79	-0.31	3.73e-11	Monocyte percentage of white cells;
LUAD	cis	rs2573652	1.000	rs12441080	chr15:100516968	A/G	cg09918751	chr15:100517450	ADAMTS17	0.5	9.16	0.41	2.25e-18	Height;
LUAD	cis	rs6835098	0.692	rs6553679	chr4:174072292	C/T	cg27433088	chr4:174089019	GALNT7	0.4	7.54	0.34	2.85e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg15242686	chr22:24348715	GSTTP1	-0.46	-8.0	-0.36	1.23e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg27411982	chr8:10470053	RP1L1	0.38	6.91	0.32	1.82e-11	Retinal vascular caliber;
LUAD	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg10295955	chr4:187884368	NA	-1.15	-28.99	-0.82	1.52e-102	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg15704280	chr7:45808275	SEPT13	-0.92	-17.21	-0.64	1.04e-50	Height;
LUAD	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.41	0.49	1.8e-26	Eosinophil percentage of white cells;
LUAD	cis	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.83	-0.32	2.94e-11	Neuroticism;
LUAD	cis	rs7809615	0.901	rs1581492	chr7:99186826	C/T	cg12290671	chr7:99195819	NA	-0.63	-7.32	-0.34	1.27e-12	Blood metabolite ratios;
LUAD	cis	rs2279817	0.735	rs11203432	chr1:17991196	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.42	-6.36	-0.3	5.37e-10	Neuroticism;
LUAD	cis	rs926938	0.765	rs12407408	chr1:115234275	A/G	cg12756093	chr1:115239321	AMPD1	0.39	6.77	0.31	4.44e-11	Autism;
LUAD	cis	rs9902453	0.808	rs62068617	chr17:28144728	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	9.05	0.4	5.08e-18	Coffee consumption (cups per day);
LUAD	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.41	7.81	0.35	4.56e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg06618935	chr21:46677482	NA	-0.44	-8.39	-0.38	7.42e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg16797656	chr11:68205561	LRP5	0.48	10.05	0.44	1.95e-21	Total body bone mineral density;
LUAD	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg18240062	chr17:79603768	NPLOC4	0.46	8.14	0.37	4.54e-15	Eye color traits;
LUAD	cis	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg07460842	chr6:66804631	NA	0.96	12.88	0.53	2.96e-32	Exhaled nitric oxide output;
LUAD	cis	rs4638749	1.000	rs2123694	chr2:108857505	A/G	cg25838818	chr2:108905173	SULT1C2	-0.54	-8.45	-0.38	4.75e-16	Blood pressure;
LUAD	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg06784218	chr1:46089804	CCDC17	0.6	13.33	0.54	4.38e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg24579218	chr15:68104479	NA	-0.52	-8.54	-0.38	2.42e-16	Obesity;
LUAD	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg04218760	chr10:45406644	TMEM72	0.3	7.64	0.35	1.49e-13	Mean corpuscular volume;
LUAD	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg11814155	chr7:99998594	ZCWPW1	0.43	7.34	0.34	1.12e-12	Platelet count;
LUAD	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg02428538	chr16:24856791	SLC5A11	0.54	7.48	0.34	4.26e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg15147215	chr3:52552868	STAB1	0.36	6.54	0.3	1.77e-10	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.17	0.37	3.51e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	8.96	0.4	1.08e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg04990556	chr1:26633338	UBXN11	-0.4	-6.6	-0.31	1.26e-10	Obesity-related traits;
LUAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-10.4	-0.45	1.05e-22	Lymphocyte counts;
LUAD	cis	rs859767	0.812	rs842360	chr2:135347885	T/C	cg12500956	chr2:135428796	TMEM163	0.3	7.66	0.35	1.27e-13	Neuroticism;
LUAD	cis	rs4372836	0.504	rs13025081	chr2:29083850	C/A	cg09522027	chr2:28974177	PPP1CB	-0.59	-10.6	-0.46	1.85e-23	Body mass index;
LUAD	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg18404041	chr3:52824283	ITIH1	0.4	7.1	0.33	5.4e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg03388025	chr16:89894329	SPIRE2	0.5	13.25	0.54	8.91e-34	Vitiligo;
LUAD	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg17372223	chr3:52568218	NT5DC2	0.4	7.27	0.33	1.77e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	ch.11.42038R	chr11:967971	AP2A2	0.4	7.06	0.32	6.81e-12	Alzheimer's disease (late onset);
LUAD	cis	rs2996428	0.561	rs2275833	chr1:3745721	C/T	cg13057898	chr1:3703894	LRRC47	0.57	9.85	0.43	9.21e-21	Red cell distribution width;
LUAD	trans	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17712092	chr4:129076599	LARP1B	0.92	17.29	0.64	4.59e-51	Eosinophil percentage of white cells;
LUAD	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg25554036	chr4:6271136	WFS1	0.67	12.99	0.53	1.02e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1476679	1.000	rs1476679	chr7:100004446	C/T	cg22906224	chr7:99728672	NA	-0.45	-7.19	-0.33	3e-12	Alzheimer's disease (late onset);
LUAD	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg08219700	chr8:58056026	NA	0.41	6.39	0.3	4.44e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs377457	0.856	rs11117268	chr16:85738269	A/T	cg02758499	chr16:85682440	KIAA0182	0.39	7.16	0.33	3.67e-12	Type 2 diabetes;
LUAD	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.45	-0.34	5.19e-13	Heart rate;
LUAD	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21659725	chr3:3221576	CRBN	0.67	11.7	0.49	1.33e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.57e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg24399712	chr22:39784796	NA	-0.69	-11.16	-0.48	1.57e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg26516362	chr5:178986906	RUFY1	0.48	8.2	0.37	2.86e-15	Lung cancer;
LUAD	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg03709012	chr19:19516395	GATAD2A	0.52	6.85	0.32	2.69e-11	Nonalcoholic fatty liver disease;
LUAD	cis	rs7659604	0.540	rs4455438	chr4:122669550	G/A	cg06713675	chr4:122721982	EXOSC9	0.41	7.48	0.34	4.2e-13	Type 2 diabetes;
LUAD	cis	rs354225	0.584	rs11898032	chr2:54821515	G/A	cg01766943	chr2:54829624	SPTBN1	0.38	7.18	0.33	3.16e-12	Schizophrenia;
LUAD	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.41	-0.3	3.9e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg14458575	chr2:238380390	NA	0.99	19.75	0.69	5.2e-62	Prostate cancer;
LUAD	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.18	-0.33	3.12e-12	Height;
LUAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg02869364	chr7:1081709	C7orf50	-0.5	-6.46	-0.3	2.85e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs829883	0.659	rs11109520	chr12:98928646	C/T	cg25150519	chr12:98850993	NA	0.51	8.03	0.36	9.5e-15	Colorectal adenoma (advanced);
LUAD	cis	rs10821973	0.527	rs6479796	chr10:64016250	C/T	cg09941381	chr10:64027924	RTKN2	-0.36	-7.15	-0.33	3.85e-12	Hypothyroidism;
LUAD	cis	rs6495122	0.662	rs11072508	chr15:75062397	C/T	cg14664628	chr15:75095509	CSK	-0.5	-8.3	-0.37	1.43e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs4072705	1.000	rs4072705	chr9:127373463	C/A	cg13476313	chr9:127244764	NR5A1	0.31	7.5	0.34	3.84e-13	Menarche (age at onset);
LUAD	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg20503657	chr10:835505	NA	0.78	10.5	0.45	4.43e-23	Eosinophil percentage of granulocytes;
LUAD	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.49	0.42	1.76e-19	Tonsillectomy;
LUAD	trans	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.61	0.46	1.75e-23	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6500395	1.000	rs1420701	chr16:48730873	C/T	cg04672837	chr16:48644449	N4BP1	-0.39	-6.78	-0.31	4.07e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg18230493	chr5:56204884	C5orf35	-0.47	-7.81	-0.35	4.66e-14	Coronary artery disease;
LUAD	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg11645453	chr3:52864694	ITIH4	0.59	11.28	0.48	5.73e-26	Schizophrenia;
LUAD	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg08280861	chr8:58055591	NA	0.69	8.27	0.37	1.7e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg23625390	chr15:77176239	SCAPER	0.6	9.53	0.42	1.2e-19	Blood metabolite levels;
LUAD	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	2.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg27411982	chr8:10470053	RP1L1	-0.4	-7.12	-0.33	4.75e-12	Systolic blood pressure;
LUAD	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-10.38	-0.45	1.2e-22	Electroencephalogram traits;
LUAD	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg18132916	chr6:79620363	NA	-0.45	-7.81	-0.36	4.49e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9902453	1.000	rs7207021	chr17:28400516	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-8.92	-0.4	1.41e-17	Coffee consumption (cups per day);
LUAD	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	8.43	0.38	5.31e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7107174	0.688	rs2063725	chr11:78133452	T/G	cg19901956	chr11:77921274	USP35	-0.46	-6.37	-0.3	4.91e-10	Testicular germ cell tumor;
LUAD	cis	rs654384	0.836	rs13224986	chr7:4172109	C/T	cg26275264	chr7:4183598	SDK1	0.4	7.59	0.35	2.13e-13	Positive affect;
LUAD	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg24813613	chr7:1882135	MAD1L1	-0.4	-6.47	-0.3	2.67e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg16479474	chr6:28041457	NA	0.36	6.49	0.3	2.45e-10	Parkinson's disease;
LUAD	trans	rs7944735	0.507	rs7396592	chr11:48100837	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-10.05	-0.44	1.95e-21	Intraocular pressure;
LUAD	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg01579765	chr21:45077557	HSF2BP	-0.59	-13.2	-0.54	1.54e-33	Mean corpuscular volume;
LUAD	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg07936489	chr17:37558343	FBXL20	-0.51	-6.72	-0.31	5.85e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs9826463	0.582	rs73238152	chr3:142071081	C/T	cg20824294	chr3:142316082	PLS1	0.41	6.87	0.32	2.35e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.47	-7.85	-0.36	3.5e-14	Longevity;Endometriosis;
LUAD	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg20701182	chr2:24300061	SF3B14	0.65	7.6	0.35	1.92e-13	Lymphocyte counts;
LUAD	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.41	-0.34	7.13e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.53	-0.34	3.1400000000000003e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.82	-0.47	3.09e-24	Total body bone mineral density;
LUAD	cis	rs6545883	0.965	rs778752	chr2:61776902	C/G	cg15711740	chr2:61764176	XPO1	-0.43	-6.86	-0.32	2.44e-11	Tuberculosis;
LUAD	trans	rs783540	0.967	rs783523	chr15:83283555	A/G	cg18393722	chr15:85113863	UBE2QP1	0.44	7.11	0.33	4.92e-12	Schizophrenia;
LUAD	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg19041857	chr6:27730383	NA	-0.45	-7.79	-0.35	5.41e-14	Parkinson's disease;
LUAD	cis	rs654950	0.783	rs668359	chr1:42003425	A/C	cg06885757	chr1:42089581	HIVEP3	-0.4	-8.92	-0.4	1.43e-17	Airway imaging phenotypes;
LUAD	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg05044414	chr3:183734942	ABCC5	0.47	9.57	0.42	8.75e-20	Anterior chamber depth;
LUAD	cis	rs1395	1.000	rs4665958	chr2:27443196	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	7.77	0.35	5.99e-14	Blood metabolite levels;
LUAD	cis	rs7027203	1.000	rs13288708	chr9:96509653	T/C	cg14396892	chr9:96623032	NA	0.38	6.89	0.32	1.98e-11	DNA methylation (variation);
LUAD	cis	rs513349	1.000	rs210145	chr6:33547440	G/C	cg07679836	chr6:33548423	BAK1	0.44	8.4	0.38	7.01e-16	Platelet count;
LUAD	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg15704280	chr7:45808275	SEPT13	0.67	9.03	0.4	6.07e-18	Axial length;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg19314403	chr19:35225114	ZNF181	-0.7	-6.88	-0.32	2.19e-11	Type 2 diabetes;
LUAD	cis	rs62238980	0.522	rs79367011	chr22:32450245	G/T	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.52	-8.18	-0.37	3.34e-15	Reticulocyte count;
LUAD	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg17644776	chr2:200775616	C2orf69	-0.55	-7.26	-0.33	1.82e-12	Schizophrenia;
LUAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg08219700	chr8:58056026	NA	0.44	6.49	0.3	2.37e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs11716531	0.512	rs7612312	chr3:27230230	C/A	cg02860705	chr3:27208620	NA	0.46	7.71	0.35	9.06e-14	Diastolic blood pressure;
LUAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg06263672	chr7:65235340	NA	-0.56	-9.24	-0.41	1.22e-18	Calcium levels;
LUAD	cis	rs11048434	0.736	rs7302417	chr12:9091116	G/T	cg23795048	chr12:9217529	LOC144571	0.43	8.04	0.36	9.1e-15	Sjögren's syndrome;
LUAD	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg22442454	chr1:209979470	IRF6	0.5	6.38	0.3	4.67e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs938554	0.657	rs9994216	chr4:9984541	G/T	cg00071950	chr4:10020882	SLC2A9	0.61	10.45	0.45	6.89e-23	Blood metabolite levels;
LUAD	cis	rs7017914	0.967	rs1493198	chr8:71851957	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.31	-6.39	-0.3	4.48e-10	Bone mineral density;
LUAD	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg06784218	chr1:46089804	CCDC17	0.51	11.23	0.48	8.7e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg17644776	chr2:200775616	C2orf69	-0.54	-6.7	-0.31	6.52e-11	Schizophrenia;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg15090714	chr17:60142985	MED13	-0.52	-6.66	-0.31	8.62e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs921968	0.565	rs35358516	chr2:219625723	A/C	cg02176678	chr2:219576539	TTLL4	-0.6	-12.18	-0.51	1.91e-29	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21659725	chr3:3221576	CRBN	-0.86	-18.31	-0.66	1.4e-55	Intelligence (multi-trait analysis);
LUAD	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg05058121	chr16:23569099	EARS2;UBFD1	-0.41	-6.95	-0.32	1.37e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg09436375	chr6:42928200	GNMT	-0.29	-8.29	-0.37	1.54e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs13064411	0.591	rs7628945	chr3:113201754	A/T	cg18753928	chr3:113234510	CCDC52	-0.55	-9.74	-0.43	2.32e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg06064525	chr11:970664	AP2A2	-0.41	-8.04	-0.36	9.41e-15	Alzheimer's disease (late onset);
LUAD	cis	rs7223966	0.810	rs2665838	chr17:61966465	C/G	cg06873352	chr17:61820015	STRADA	0.41	6.51	0.3	2.18e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs1451375	0.698	rs11489736	chr7:50645372	G/A	cg18232548	chr7:50535776	DDC	0.5	8.23	0.37	2.27e-15	Malaria;
LUAD	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8180040	0.835	rs6780013	chr3:47452118	G/A	cg02527881	chr3:46936655	PTH1R	0.39	7.52	0.34	3.24e-13	Colorectal cancer;
LUAD	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg07169764	chr2:136633963	MCM6	0.55	7.07	0.33	6.28e-12	Corneal structure;
LUAD	cis	rs3790645	0.958	rs7543005	chr1:26879376	T/C	cg23229016	chr1:26872525	RPS6KA1	0.2	6.81	0.31	3.45e-11	Glucose homeostasis traits;
LUAD	cis	rs6489882	1.000	rs6489882	chr12:113381376	G/A	cg20102336	chr12:113376681	OAS3	-0.56	-8.41	-0.38	6.18e-16	Chronic lymphocytic leukemia;
LUAD	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg13390004	chr1:15929781	NA	0.48	8.4	0.38	6.89e-16	Systolic blood pressure;
LUAD	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg15017067	chr4:17643749	FAM184B	0.35	6.88	0.32	2.22e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.18	-0.37	3.36e-15	Total body bone mineral density;
LUAD	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg05665937	chr4:1216051	CTBP1	0.48	7.09	0.33	5.5e-12	Longevity;
LUAD	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13082711	0.911	rs11716531	chr3:27457208	G/A	cg02860705	chr3:27208620	NA	0.61	9.33	0.41	6.12e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg16647868	chr5:131706066	SLC22A5	0.48	7.62	0.35	1.66e-13	Breast cancer;
LUAD	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg11766577	chr21:47581405	C21orf56	0.51	8.38	0.38	7.93e-16	Testicular germ cell tumor;
LUAD	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg17749961	chr2:30669863	LCLAT1	0.49	6.6	0.31	1.21e-10	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg12615879	chr12:58013172	SLC26A10	0.48	10.28	0.45	2.87e-22	Multiple sclerosis;
LUAD	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg14582100	chr15:45693742	SPATA5L1	-0.34	-6.79	-0.31	3.72e-11	Glomerular filtration rate;
LUAD	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25427524	chr10:38739819	LOC399744	-0.8	-14.45	-0.57	9.57e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg25358565	chr5:93447407	FAM172A	0.66	7.76	0.35	6.45e-14	Diabetic retinopathy;
LUAD	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg10518543	chr12:38710700	ALG10B	-0.54	-8.81	-0.39	3.19e-17	Morning vs. evening chronotype;
LUAD	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg20848291	chr7:100343083	ZAN	-0.61	-9.85	-0.43	9.78e-21	Other erythrocyte phenotypes;
LUAD	trans	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg14917512	chr19:3094685	GNA11	-0.58	-6.84	-0.32	2.83e-11	Diabetic kidney disease;
LUAD	cis	rs41311933	0.803	rs41312901	chr9:123726029	A/G	cg13567360	chr9:123745713	C5	-0.76	-6.95	-0.32	1.4e-11	Coronary artery disease;
LUAD	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	8.99	0.4	8.07e-18	Tonsillectomy;
LUAD	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.93	-0.5	1.76e-28	Bipolar disorder;
LUAD	cis	rs62238980	0.614	rs2899174	chr22:32458789	T/C	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs6138458	0.701	rs6050255	chr20:25007089	A/G	cg26195577	chr20:24973756	C20orf3	0.71	11.8	0.5	5.42e-28	Blood protein levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13625205	chr1:151584902	SNX27	-0.52	-6.48	-0.3	2.63e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg11189052	chr15:85197271	WDR73	0.65	8.57	0.38	1.98e-16	Schizophrenia;
LUAD	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg07507251	chr3:52567010	NT5DC2	0.38	7.53	0.34	3.03e-13	Bipolar disorder;
LUAD	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.38	0.3	4.79e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg07386859	chr16:1872102	HAGH	0.52	7.8	0.35	4.97e-14	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg16010596	chr6:33739607	LEMD2	-0.42	-7.74	-0.35	7.27e-14	Schizophrenia;
LUAD	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg06618935	chr21:46677482	NA	-0.5	-10.01	-0.44	2.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg20587970	chr11:113659929	NA	-1.42	-21.48	-0.72	9.51e-70	Hip circumference adjusted for BMI;
LUAD	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.91	0.36	2.27e-14	Bladder cancer;
LUAD	trans	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg04565464	chr8:145669602	NFKBIL2	0.43	6.53	0.3	1.84e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.58	-9.84	-0.43	1.04e-20	Cognitive ability;
LUAD	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg03929089	chr4:120376271	NA	-0.97	-20.29	-0.7	2.14e-64	Height;
LUAD	cis	rs8018808	0.902	rs176773	chr14:77882456	C/T	cg20045696	chr14:77926864	AHSA1	0.36	6.4	0.3	4.19e-10	Myeloid white cell count;
LUAD	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg08601574	chr20:25228251	PYGB	0.44	8.05	0.36	8.28e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg11645453	chr3:52864694	ITIH4	-0.53	-10.03	-0.44	2.17e-21	Schizophrenia;
LUAD	cis	rs240764	0.554	rs723742	chr6:101237174	T/A	cg09795085	chr6:101329169	ASCC3	0.41	7.17	0.33	3.39e-12	Neuroticism;
LUAD	trans	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg11693508	chr17:37793320	STARD3	0.81	10.49	0.45	4.99e-23	Bipolar disorder;
LUAD	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg13606994	chr1:44402422	ARTN	-0.34	-6.95	-0.32	1.36e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.51e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72928364	1.000	rs73137256	chr3:100601339	T/C	cg10123952	chr3:100791384	NA	0.6	6.7	0.31	6.78e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11958404	0.860	rs72818136	chr5:157462866	C/T	cg05962755	chr5:157440814	NA	0.65	9.07	0.4	4.59e-18	IgG glycosylation;
LUAD	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg05110241	chr16:68378359	PRMT7	-0.84	-9.13	-0.41	2.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs34638657	0.687	rs2303261	chr16:82203768	G/T	cg09439754	chr16:82129088	HSD17B2	-0.34	-6.46	-0.3	2.95e-10	Lung adenocarcinoma;
LUAD	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.42	6.6	0.31	1.2e-10	Platelet count;
LUAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.41	0.55	2.06e-34	Prudent dietary pattern;
LUAD	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg24558204	chr6:135376177	HBS1L	0.49	9.05	0.4	5.45e-18	Red blood cell count;
LUAD	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.41	-6.78	-0.31	4.03e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7937890	0.559	rs2575831	chr11:14486194	A/T	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.18e-12	Mitochondrial DNA levels;
LUAD	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg14895029	chr7:2775587	GNA12	-0.43	-7.29	-0.33	1.52e-12	Height;
LUAD	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.9e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg15448220	chr1:150897856	SETDB1	-0.46	-7.52	-0.34	3.21e-13	Blood protein levels;
LUAD	cis	rs62064224	0.675	rs4795693	chr17:30636727	A/G	cg18200150	chr17:30822561	MYO1D	0.44	8.18	0.37	3.46e-15	Schizophrenia;
LUAD	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg13319975	chr6:146136371	FBXO30	0.63	10.93	0.47	1.15e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6964587	0.507	rs12539439	chr7:91917365	A/C	cg22117172	chr7:91764530	CYP51A1	0.32	6.81	0.31	3.32e-11	Breast cancer;
LUAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.29	0.41	8.04e-19	Alzheimer's disease;
LUAD	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg02038168	chr22:39784481	NA	-0.5	-7.97	-0.36	1.45e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.96	0.32	1.31e-11	Schizophrenia;
LUAD	cis	rs8044868	0.586	rs7190994	chr16:72099241	T/A	cg23815491	chr16:72088622	HP	0.55	10.22	0.44	4.67e-22	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs1190552	0.846	rs1044503	chr14:102965996	A/G	cg18135206	chr14:102964638	TECPR2	0.47	6.69	0.31	6.89e-11	Blood protein levels;
LUAD	cis	rs68170813	0.559	rs4730229	chr7:106925353	A/G	cg23024343	chr7:107201750	COG5	0.5	7.2	0.33	2.85e-12	Coronary artery disease;
LUAD	trans	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.85	0.43	9.44e-21	Ulcerative colitis;
LUAD	cis	rs12286929	0.617	rs12800807	chr11:115101353	T/C	cg04055981	chr11:115044050	NA	0.41	7.14	0.33	4.12e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4663969	0.733	rs6741669	chr2:234653192	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-8.38	-0.38	8.07e-16	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.35	7.01	0.32	9.42e-12	Obesity-related traits;
LUAD	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07923305	chr1:46598507	PIK3R3	-0.52	-8.16	-0.37	3.88e-15	Height;
LUAD	cis	rs240764	0.658	rs12194255	chr6:101168439	G/A	cg09795085	chr6:101329169	ASCC3	-0.4	-6.97	-0.32	1.2e-11	Neuroticism;
LUAD	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg11833968	chr6:79620685	NA	-0.45	-8.35	-0.38	1e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg11062466	chr8:58055876	NA	0.44	6.4	0.3	4.04e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.47	0.3	2.64e-10	Breast cancer;
LUAD	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.9	-0.36	2.47e-14	Diabetic kidney disease;
LUAD	cis	rs36051895	0.659	rs7046511	chr9:5045695	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-6.43	-0.3	3.42e-10	Pediatric autoimmune diseases;
LUAD	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg03289416	chr15:75166202	SCAMP2	0.5	8.55	0.38	2.3e-16	Breast cancer;
LUAD	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg22878388	chr2:105853796	NA	-0.45	-8.08	-0.37	6.9e-15	Type 2 diabetes;
LUAD	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.09	0.33	5.62e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs72799341	0.706	rs59735493	chr16:31133100	G/A	cg05768032	chr16:30646687	NA	0.39	6.88	0.32	2.13e-11	Diastolic blood pressure;
LUAD	cis	rs7180079	0.620	rs7162324	chr15:64736287	A/G	cg08069370	chr15:64387884	SNX1	0.5	6.58	0.3	1.39e-10	Monocyte count;
LUAD	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg21963583	chr11:68658836	MRPL21	0.63	11.06	0.47	3.68e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs9393777	0.844	rs28360634	chr6:27332891	T/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.22	-0.37	2.6e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs41311933	1.000	rs10514838	chr9:123746796	T/C	cg13567360	chr9:123745713	C5	-0.78	-9.06	-0.4	4.89e-18	Coronary artery disease;
LUAD	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg04414720	chr1:150670196	GOLPH3L	0.71	12.69	0.53	1.68e-31	Melanoma;
LUAD	trans	rs12517041	1.000	rs4701363	chr5:23301008	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.48	-0.3	2.57e-10	Calcium levels;
LUAD	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.43	-6.55	-0.3	1.63e-10	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs68170813	0.523	rs111590023	chr7:107055323	T/C	cg23024343	chr7:107201750	COG5	0.47	6.81	0.31	3.41e-11	Coronary artery disease;
LUAD	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg14828511	chr1:107599125	PRMT6	0.55	9.56	0.42	9.74e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs654950	0.807	rs941970	chr1:41990867	G/A	cg06885757	chr1:42089581	HIVEP3	-0.38	-7.86	-0.36	3.13e-14	Airway imaging phenotypes;
LUAD	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06544989	chr22:39130855	UNC84B	0.45	9.0	0.4	7.87e-18	Menopause (age at onset);
LUAD	cis	rs6499255	0.904	rs7187653	chr16:69562838	G/C	cg15192750	chr16:69999425	NA	0.53	8.07	0.37	7.1e-15	IgE levels;
LUAD	cis	rs4852324	0.536	rs17009553	chr2:74220035	A/G	cg19729930	chr2:74357872	NA	-0.81	-7.59	-0.35	2.1e-13	Systemic lupus erythematosus;
LUAD	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg18512352	chr11:47633146	NA	-0.55	-9.77	-0.43	1.86e-20	Subjective well-being;
LUAD	cis	rs9811920	0.683	rs4928230	chr3:99661963	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-9.96	-0.44	3.9e-21	Axial length;
LUAD	cis	rs4700695	0.534	rs153373	chr5:65426159	G/A	cg21114390	chr5:65439923	SFRS12	-0.74	-7.01	-0.32	9.77e-12	Facial morphology (factor 19);
LUAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg05564831	chr3:52568323	NT5DC2	0.44	8.39	0.38	7.35e-16	Electroencephalogram traits;
LUAD	cis	rs17021463	0.934	rs28403447	chr4:95257753	G/A	cg11021082	chr4:95130006	SMARCAD1	0.48	8.81	0.39	3.37e-17	Testicular germ cell tumor;
LUAD	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23583168	chr7:148888333	NA	-0.89	-18.59	-0.67	8.2e-57	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs1941687	0.669	rs7243220	chr18:31408110	T/G	cg27147174	chr7:100797783	AP1S1	-0.51	-8.8	-0.39	3.57e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs1595825	0.891	rs16866940	chr2:198509058	C/T	cg10547527	chr2:198650123	BOLL	-0.54	-7.74	-0.35	7.64e-14	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.17	0.37	3.51e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	9.66	0.43	4.47e-20	Electrocardiographic conduction measures;
LUAD	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03264133	chr6:25882463	NA	0.82	13.64	0.55	2.37e-35	Blood metabolite levels;
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg02592596	chr15:30919014	ARHGAP11B	-0.38	-6.59	-0.31	1.28e-10	Migraine with aura;
LUAD	cis	rs909002	1.000	rs1474182	chr1:32136398	C/T	cg13919466	chr1:32135498	COL16A1	-0.42	-10.1	-0.44	1.24e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg18538332	chr22:24372958	LOC391322	-0.55	-9.25	-0.41	1.15e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs739496	0.615	rs640783	chr12:112168050	A/G	cg10833066	chr12:111807467	FAM109A	0.41	6.42	0.3	3.59e-10	Platelet count;
LUAD	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg09517075	chr8:22133004	PIWIL2	0.48	9.07	0.4	4.55e-18	Hypertriglyceridemia;
LUAD	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg12311346	chr5:56204834	C5orf35	-1.1	-17.09	-0.64	3.59e-50	Initial pursuit acceleration;
LUAD	cis	rs9469913	0.799	rs2814994	chr6:34620153	T/A	cg14254433	chr6:34482411	PACSIN1	-0.44	-6.81	-0.31	3.39e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg16205897	chr5:131564050	P4HA2	-0.44	-10.35	-0.45	1.62e-22	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12227505	chr17:78194145	SLC26A11;SGSH	-0.59	-7.55	-0.34	2.75e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2637266	0.745	rs241	chr10:78444456	G/T	cg18941641	chr10:78392320	NA	0.33	6.69	0.31	7.15e-11	Pulmonary function;
LUAD	cis	rs11048434	0.736	rs11048195	chr12:9105923	A/G	cg13575925	chr12:9217583	LOC144571	0.37	7.01	0.32	9.26e-12	Sjögren's syndrome;
LUAD	cis	rs3790645	1.000	rs188158	chr1:26898142	A/G	cg23229016	chr1:26872525	RPS6KA1	0.2	6.4	0.3	4.25e-10	Glucose homeostasis traits;
LUAD	cis	rs2286503	0.839	rs2240726	chr7:22853135	C/T	cg06496272	chr7:22895283	SNORD93	-0.39	-6.95	-0.32	1.4e-11	Fibrinogen;
LUAD	cis	rs9283706	0.608	rs10053537	chr5:66332543	T/C	cg11590213	chr5:66331682	MAST4	0.41	6.83	0.32	2.9100000000000002e-11	Coronary artery disease;
LUAD	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg26597838	chr10:835615	NA	0.96	15.02	0.59	3.51e-41	Eosinophil percentage of granulocytes;
LUAD	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg21252483	chr19:49399788	TULP2	-0.88	-14.31	-0.57	3.61e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg18876405	chr7:65276391	NA	0.43	7.22	0.33	2.38e-12	Calcium levels;
LUAD	cis	rs12286929	0.583	rs10458966	chr11:115102758	T/C	cg04055981	chr11:115044050	NA	0.42	7.33	0.34	1.17e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg09936400	chr10:82049201	MAT1A	0.38	6.53	0.3	1.93e-10	Post bronchodilator FEV1;
LUAD	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg18129178	chr5:148520854	ABLIM3	-0.61	-9.49	-0.42	1.66e-19	Breast cancer;
LUAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg00080972	chr5:178986291	RUFY1	0.71	12.83	0.53	4.63e-32	Lung cancer;
LUAD	cis	rs4889855	0.505	rs8077626	chr17:78600552	G/C	cg16591659	chr17:78472290	NA	-0.43	-7.48	-0.34	4.38e-13	Fractional excretion of uric acid;
LUAD	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg05754148	chr16:3507555	NAT15	0.82	10.71	0.46	7.85e-24	Tuberculosis;
LUAD	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg05340658	chr4:99064831	C4orf37	0.45	7.42	0.34	6.47e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10821973	0.550	rs10761614	chr10:63975930	C/G	cg09941381	chr10:64027924	RTKN2	-0.34	-6.74	-0.31	5.22e-11	Hypothyroidism;
LUAD	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg23422044	chr7:1970798	MAD1L1	-0.58	-7.16	-0.33	3.5e-12	Bipolar disorder;
LUAD	cis	rs300774	0.925	rs300801	chr2:105259	C/T	cg21211680	chr2:198530	NA	-0.46	-6.71	-0.31	6.34e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs6484504	0.576	rs158136	chr11:31220712	C/T	cg06552810	chr11:31128660	NA	-0.32	-6.38	-0.3	4.77e-10	Red blood cell count;
LUAD	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg04398451	chr17:18023971	MYO15A	0.64	11.59	0.49	3.71e-27	Total body bone mineral density;
LUAD	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.98	0.53	1.2e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs738322	0.901	rs132941	chr22:38545942	T/C	cg25457927	chr22:38595422	NA	-0.54	-13.53	-0.55	6.65e-35	Cutaneous nevi;
LUAD	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.49	0.38	3.48e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg19761014	chr17:28927070	LRRC37B2	-0.73	-8.61	-0.39	1.44e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8040855	0.599	rs4643289	chr15:85726714	C/T	cg04831495	chr15:85060580	GOLGA6L5	0.44	7.68	0.35	1.1e-13	Bulimia nervosa;
LUAD	cis	rs208520	1.000	rs208535	chr6:66962286	G/A	cg07460842	chr6:66804631	NA	-0.97	-13.16	-0.54	2.25e-33	Exhaled nitric oxide output;
LUAD	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	7.43	0.34	5.92e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg22963979	chr7:1858916	MAD1L1	-0.54	-8.89	-0.4	1.81e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg03597347	chr6:28058909	ZSCAN12L1	0.36	6.36	0.3	5.2e-10	Lung cancer in ever smokers;
LUAD	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg13511324	chr14:104056883	C14orf153	0.26	6.5	0.3	2.29e-10	Reticulocyte count;
LUAD	cis	rs642803	0.527	rs1647570	chr11:65568256	A/T	cg08755490	chr11:65554678	OVOL1	-0.44	-6.88	-0.32	2.22e-11	Urate levels;
LUAD	trans	rs79911532	0.515	rs17148983	chr7:75649821	C/G	cg19862616	chr7:65841803	NCRNA00174	0.79	8.51	0.38	3.06e-16	Mononucleosis;
LUAD	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-6.97	-0.32	1.24e-11	Systemic lupus erythematosus;
LUAD	trans	rs11039798	1.000	rs7125559	chr11:48984207	C/G	cg03929089	chr4:120376271	NA	0.58	6.57	0.3	1.44e-10	Axial length;
LUAD	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.47	-0.38	4.12e-16	Height;
LUAD	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg23719950	chr11:63933701	MACROD1	-0.62	-6.78	-0.31	4.17e-11	Mean platelet volume;
LUAD	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg17849569	chr6:28058911	ZSCAN12L1	0.3	6.36	0.3	5.15e-10	Parkinson's disease;
LUAD	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-7.95	-0.36	1.76e-14	Electroencephalogram traits;
LUAD	cis	rs2932538	0.846	rs7546203	chr1:113154529	C/A	cg22162597	chr1:113214053	CAPZA1	0.46	6.89	0.32	2.04e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.11e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.69	0.35	1.06e-13	Depression;
LUAD	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00149659	chr3:10157352	C3orf10	0.57	8.06	0.36	7.87e-15	Alzheimer's disease;
LUAD	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg23985595	chr17:80112537	CCDC57	0.53	9.67	0.43	3.98e-20	Life satisfaction;
LUAD	trans	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg18187862	chr3:45730750	SACM1L	0.49	7.75	0.35	6.89e-14	Primary sclerosing cholangitis;
LUAD	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg26818010	chr10:134567672	INPP5A	0.53	9.23	0.41	1.33e-18	Migraine;
LUAD	trans	rs208520	0.690	rs176289	chr6:66766522	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-17.11	-0.64	3e-50	Exhaled nitric oxide output;
LUAD	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg26384229	chr12:38710491	ALG10B	0.46	7.49	0.34	4.03e-13	Morning vs. evening chronotype;
LUAD	cis	rs9308433	0.529	rs4655333	chr1:214493549	A/G	cg06198575	chr1:214491504	SMYD2	0.43	7.42	0.34	6.3e-13	IgG glycosylation;
LUAD	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg02655711	chr22:19163373	SLC25A1	0.69	14.08	0.56	3.38e-37	Metabolite levels;
LUAD	cis	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg21775007	chr8:11205619	TDH	-0.36	-6.42	-0.3	3.63e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg23625390	chr15:77176239	SCAPER	-0.47	-7.26	-0.33	1.86e-12	Blood metabolite levels;
LUAD	cis	rs13315871	0.929	rs35004361	chr3:58313394	T/C	cg12435725	chr3:58293450	RPP14	-0.73	-8.36	-0.38	9.22e-16	Cholesterol, total;
LUAD	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg25173405	chr17:45401733	C17orf57	0.45	7.32	0.34	1.29e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg04282206	chr17:62833786	PLEKHM1P	-0.45	-7.37	-0.34	8.92e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg19901468	chr14:105411992	AHNAK2	0.5	9.41	0.42	3.25e-19	Rheumatoid arthritis;
LUAD	cis	rs2297797	0.660	rs464218	chr1:109856306	G/A	cg08367326	chr1:110052010	AMIGO1	0.38	6.44	0.3	3.28e-10	Cognitive function;
LUAD	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg23649088	chr2:200775458	C2orf69	0.64	8.44	0.38	5.1e-16	Schizophrenia;
LUAD	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg20933634	chr6:27740509	NA	0.46	7.27	0.33	1.77e-12	Parkinson's disease;
LUAD	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg11901034	chr3:128598214	ACAD9	-0.5	-7.82	-0.36	4.36e-14	IgG glycosylation;
LUAD	cis	rs921968	0.519	rs62191659	chr2:219630510	C/T	cg02176678	chr2:219576539	TTLL4	-0.59	-12.15	-0.51	2.32e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs654950	0.875	rs881719	chr1:41991427	C/T	cg06885757	chr1:42089581	HIVEP3	-0.37	-7.75	-0.35	6.87e-14	Airway imaging phenotypes;
LUAD	cis	rs11030122	0.673	rs10835601	chr11:4106416	G/A	cg18678763	chr11:4115507	RRM1	-0.48	-7.8	-0.35	4.73e-14	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs977987	0.778	rs4888412	chr16:75443196	A/G	cg03315344	chr16:75512273	CHST6	0.64	14.07	0.56	3.87e-37	Dupuytren's disease;
LUAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg04267008	chr7:1944627	MAD1L1	-0.71	-11.01	-0.47	5.97e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs943466	1.000	rs12524768	chr6:33760478	G/A	cg16010596	chr6:33739607	LEMD2	-0.4	-7.8	-0.35	4.75e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs4150161	0.591	rs3785036	chr16:84219810	T/G	cg10106505	chr16:84220380	TAF1C	-1.07	-10.55	-0.46	2.86e-23	Systolic blood pressure response to hydrochlorothiazide in hypertension;
LUAD	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg08847533	chr14:75593920	NEK9	0.4	6.77	0.31	4.44e-11	Height;
LUAD	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg17644776	chr2:200775616	C2orf69	-0.52	-6.53	-0.3	1.9e-10	Schizophrenia;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg00084687	chr7:92076896	GATAD1	0.42	6.35	0.3	5.42e-10	QT interval;
LUAD	cis	rs10950821	0.519	rs56080217	chr7:20661323	C/T	cg02470904	chr7:20686108	ABCB5	0.37	6.74	0.31	5.07e-11	Response to statin therapy;
LUAD	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23583168	chr7:148888333	NA	-0.88	-17.53	-0.65	4.3e-52	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg00071950	chr4:10020882	SLC2A9	0.72	14.79	0.58	3.57e-40	Bone mineral density;
LUAD	cis	rs7224314	1.000	rs7221926	chr17:65352181	A/T	cg01507342	chr17:65387096	PITPNC1	-0.5	-8.15	-0.37	4.12e-15	Diisocyanate-induced asthma;
LUAD	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg05754148	chr16:3507555	NAT15	-0.48	-7.81	-0.35	4.66e-14	Body mass index (adult);
LUAD	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg11871910	chr12:69753446	YEATS4	0.53	7.98	0.36	1.35e-14	Response to diuretic therapy;
LUAD	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg09455208	chr3:40491958	NA	-0.48	-10.2	-0.44	5.61e-22	Renal cell carcinoma;
LUAD	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg06221963	chr1:154839813	KCNN3	-0.85	-20.44	-0.7	4.47e-65	Prostate cancer;
LUAD	cis	rs7274811	0.744	rs6141411	chr20:32157934	G/A	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.48	-7.38	-0.34	8.52e-13	Height;
LUAD	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg12564285	chr5:131593104	PDLIM4	-0.38	-6.69	-0.31	7.09e-11	Breast cancer;
LUAD	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg04731861	chr2:219085781	ARPC2	0.23	7.03	0.32	8.35e-12	Colorectal cancer;
LUAD	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg16797656	chr11:68205561	LRP5	0.53	11.34	0.48	3.29e-26	Total body bone mineral density;
LUAD	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.79	0.31	3.77e-11	Motion sickness;
LUAD	cis	rs9393692	0.557	rs9358924	chr6:26322473	G/A	cg00631329	chr6:26305371	NA	-0.54	-8.67	-0.39	9.46e-17	Educational attainment;
LUAD	cis	rs6494488	0.500	rs72741386	chr15:64812083	T/A	cg08069370	chr15:64387884	SNX1	-0.76	-6.74	-0.31	5.17e-11	Coronary artery disease;
LUAD	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg25358565	chr5:93447407	FAM172A	0.6	7.55	0.34	2.63e-13	Diabetic retinopathy;
LUAD	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs11088226	0.681	rs74779447	chr21:33929013	G/A	cg09050820	chr6:167586206	TCP10L2	0.9	12.89	0.53	2.61e-32	Gastritis;
LUAD	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg17173187	chr15:85201210	NMB	-0.41	-6.73	-0.31	5.47e-11	Schizophrenia;
LUAD	cis	rs4233802	1.000	rs4366927	chr2:151138525	T/C	cg25300694	chr2:151184358	NA	0.81	6.98	0.32	1.12e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg25894440	chr7:65020034	NA	0.59	6.84	0.32	2.87e-11	Diabetic kidney disease;
LUAD	cis	rs11958404	0.932	rs12517979	chr5:157428918	T/C	cg05962755	chr5:157440814	NA	0.62	8.95	0.4	1.14e-17	IgG glycosylation;
LUAD	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg22508957	chr16:3507546	NAT15	0.42	6.59	0.31	1.33e-10	Body mass index (adult);
LUAD	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg11189052	chr15:85197271	WDR73	0.67	8.87	0.4	2.05e-17	Schizophrenia;
LUAD	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg06784218	chr1:46089804	CCDC17	0.53	11.27	0.48	5.9e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg18854424	chr1:2615690	NA	-0.42	-9.11	-0.41	3.27e-18	Ulcerative colitis;
LUAD	trans	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.74	-0.35	7.48e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg02475777	chr4:1388615	CRIPAK	0.65	9.03	0.4	6.13e-18	Longevity;
LUAD	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg02196655	chr2:10830764	NOL10	0.44	8.08	0.37	7.09e-15	Prostate cancer;
LUAD	cis	rs72781680	0.752	rs72796116	chr2:23913769	C/T	cg20701182	chr2:24300061	SF3B14	0.61	6.55	0.3	1.69e-10	Lymphocyte counts;
LUAD	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg21862992	chr11:68658383	NA	0.53	9.53	0.42	1.22e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.26	0.37	1.84e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs2034088	0.965	rs11651340	chr17:425099	A/C	cg13332499	chr17:408570	NA	-0.45	-10.06	-0.44	1.71e-21	Hip circumference adjusted for BMI;
LUAD	trans	rs9951602	0.512	rs8085719	chr18:76649111	A/G	cg02800362	chr5:177631904	HNRNPAB	0.92	14.03	0.56	5.5e-37	Obesity-related traits;
LUAD	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06544989	chr22:39130855	UNC84B	0.43	8.03	0.36	9.95e-15	Menopause (age at onset);
LUAD	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg11050988	chr7:1952600	MAD1L1	-0.39	-7.93	-0.36	1.91e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg11833968	chr6:79620685	NA	0.44	8.27	0.37	1.72e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2242073	0.598	rs62192821	chr2:208968050	G/A	cg24664470	chr2:208976933	NA	0.48	6.63	0.31	1.05e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg22139774	chr2:100720529	AFF3	0.38	7.78	0.35	5.59e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg10544611	chr16:67998164	SLC12A4	-0.64	-7.63	-0.35	1.5700000000000001e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7274811	0.595	rs13045068	chr20:32133484	G/C	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.51	-7.36	-0.34	9.74e-13	Height;
LUAD	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg11247378	chr22:39784982	NA	-0.74	-13.54	-0.55	5.78e-35	Intelligence (multi-trait analysis);
LUAD	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg21028142	chr17:79581711	NPLOC4	0.37	7.54	0.34	2.8e-13	Eye color traits;
LUAD	cis	rs12949688	0.934	rs12449409	chr17:55822467	G/A	cg12582317	chr17:55822272	NA	0.36	7.32	0.34	1.29e-12	Schizophrenia;
LUAD	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg07432352	chr17:45403706	C17orf57	-0.44	-8.31	-0.37	1.34e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7173743	0.756	rs12903613	chr15:79129076	G/T	cg15571903	chr15:79123663	NA	0.39	7.82	0.36	4.16e-14	Coronary artery disease;
LUAD	cis	rs7668190	0.924	rs6554162	chr4:55093955	G/A	cg17187183	chr4:55093834	PDGFRA	0.37	6.51	0.3	2.12e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17095355	1.000	rs17095350	chr10:111701708	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.71	-9.76	-0.43	1.95e-20	Biliary atresia;
LUAD	cis	rs2046867	0.862	rs62251645	chr3:72805733	T/C	cg25664220	chr3:72788482	NA	-0.68	-12.25	-0.51	9.31e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2933343	0.621	rs4927921	chr3:128568868	A/G	cg11901034	chr3:128598214	ACAD9	0.5	7.99	0.36	1.33e-14	IgG glycosylation;
LUAD	cis	rs6738485	0.763	rs11681976	chr2:106841591	C/A	cg16099169	chr2:106886729	NA	-0.46	-7.9	-0.36	2.44e-14	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg20933634	chr6:27740509	NA	0.46	7.18	0.33	3.06e-12	Parkinson's disease;
LUAD	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg20607287	chr7:12443886	VWDE	-0.53	-6.67	-0.31	8.26e-11	Coronary artery disease;
LUAD	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg01884057	chr2:25150051	NA	0.32	6.69	0.31	7e-11	Body mass index;
LUAD	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.57	-11.03	-0.47	4.76e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.49	0.45	4.89e-23	Mean corpuscular volume;
LUAD	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg04756594	chr16:24857601	SLC5A11	0.51	10.1	0.44	1.25e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.57	-8.24	-0.37	2.13e-15	Gut microbiome composition (summer);
LUAD	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.16	-0.57	1.61e-37	Schizophrenia;
LUAD	cis	rs62229266	0.835	rs998384	chr21:37445526	G/C	cg12218747	chr21:37451666	NA	-0.51	-8.71	-0.39	6.9e-17	Mitral valve prolapse;
LUAD	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg01324343	chr3:183735012	ABCC5	0.94	25.63	0.78	4.1e-88	Anterior chamber depth;
LUAD	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg09137382	chr11:130731461	NA	0.4	7.42	0.34	6.48e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1232027	0.700	rs13185915	chr5:79905411	C/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.48	-7.43	-0.34	5.98e-13	Huntington's disease progression;
LUAD	cis	rs2425143	0.547	rs6141583	chr20:34572834	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-6.64	-0.31	9.45e-11	Blood protein levels;
LUAD	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg15208524	chr1:10270712	KIF1B	0.43	6.49	0.3	2.44e-10	Hepatocellular carcinoma;
LUAD	cis	rs938554	0.956	rs6828184	chr4:9936400	G/A	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.63	-0.35	1.61e-13	Blood metabolite levels;
LUAD	cis	rs7680126	0.671	rs7663044	chr4:10023939	C/G	cg11266682	chr4:10021025	SLC2A9	0.55	8.11	0.37	5.45e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19346786	chr7:2764209	NA	-0.56	-12.02	-0.5	7.53e-29	Height;
LUAD	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg12011299	chr4:100065546	ADH4	-0.73	-13.72	-0.55	1.1e-35	Alcohol dependence;
LUAD	cis	rs4523957	0.651	rs8068642	chr17:2060353	T/C	cg16513277	chr17:2031491	SMG6	-0.96	-18.89	-0.68	3.82e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg11693508	chr17:37793320	STARD3	0.52	7.58	0.35	2.18e-13	Neuroticism;
LUAD	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg00383909	chr3:49044727	WDR6	1.0	9.41	0.42	3.27e-19	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs2835872	0.733	rs2850124	chr21:39036763	T/A	cg06728970	chr21:39037746	KCNJ6	0.4	7.6	0.35	1.92e-13	Electroencephalographic traits in alcoholism;
LUAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg09737314	chr17:6899359	ALOX12	-0.43	-8.2	-0.37	2.84e-15	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg20991723	chr1:152506922	NA	-0.34	-6.71	-0.31	6.23e-11	Hair morphology;
LUAD	cis	rs4730250	0.707	rs257373	chr7:106798290	G/A	cg23024343	chr7:107201750	COG5	0.51	6.97	0.32	1.25e-11	Osteoarthritis;
LUAD	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7017914	0.967	rs34508469	chr8:71628463	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs73086581	0.787	rs67202952	chr20:3869099	A/C	cg02187196	chr20:3869020	PANK2	0.54	7.64	0.35	1.44e-13	Response to antidepressants in depression;
LUAD	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg12863693	chr15:85201151	NMB	-0.38	-6.66	-0.31	8.37e-11	Schizophrenia;
LUAD	cis	rs7267979	0.899	rs2179459	chr20:25456141	C/A	cg08601574	chr20:25228251	PYGB	0.42	7.64	0.35	1.51e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg10518543	chr12:38710700	ALG10B	-0.47	-7.87	-0.36	2.96e-14	Morning vs. evening chronotype;
LUAD	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21582582	chr3:182698605	DCUN1D1	0.59	9.67	0.43	4e-20	Resting heart rate;
LUAD	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg23587288	chr2:27483067	SLC30A3	-0.4	-7.22	-0.33	2.4e-12	Blood metabolite levels;
LUAD	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg17724175	chr1:150552817	MCL1	0.31	7.16	0.33	3.56e-12	Melanoma;
LUAD	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs55823223	0.680	rs3744017	chr17:73871467	G/A	cg09253696	chr17:73873529	TRIM47	-0.5	-8.42	-0.38	5.87e-16	Psoriasis;
LUAD	trans	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg18187862	chr3:45730750	SACM1L	0.54	8.3	0.37	1.43e-15	Primary sclerosing cholangitis;
LUAD	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.85	0.4	2.38e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg13770153	chr20:60521292	NA	-0.58	-9.06	-0.4	5.03e-18	Body mass index;
LUAD	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.83	-0.32	3e-11	Retinal vascular caliber;
LUAD	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg02421172	chr7:1938701	MAD1L1	0.45	6.53	0.3	1.91e-10	Bipolar disorder;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg18891615	chr8:101962925	YWHAZ	0.38	6.38	0.3	4.59e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg09365446	chr1:150670422	GOLPH3L	-0.4	-6.45	-0.3	3.01e-10	Tonsillectomy;
LUAD	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg24768116	chr2:27665128	KRTCAP3	0.26	6.49	0.3	2.4e-10	Oral cavity cancer;
LUAD	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg15128208	chr22:42549153	NA	0.42	6.5	0.3	2.21e-10	Birth weight;
LUAD	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.34	6.8	0.31	3.69e-11	Obesity-related traits;
LUAD	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06873352	chr17:61820015	STRADA	0.5	8.17	0.37	3.63e-15	Height;
LUAD	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs7524258	0.900	rs7551574	chr1:7314363	G/T	cg07173049	chr1:7289937	CAMTA1	0.39	6.94	0.32	1.5e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-8.09	-0.37	6.56e-15	Alzheimer's disease;
LUAD	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg05665937	chr4:1216051	CTBP1	0.44	7.45	0.34	5.17e-13	Obesity-related traits;
LUAD	cis	rs6489785	0.710	rs2393717	chr12:121220375	G/C	cg02419362	chr12:121203948	SPPL3	0.35	7.15	0.33	3.72e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg07460842	chr6:66804631	NA	1.06	16.74	0.63	1.25e-48	Exhaled nitric oxide output;
LUAD	cis	rs8099014	0.906	rs4940692	chr18:56099715	A/G	cg12907477	chr18:56117327	MIR122	0.51	8.35	0.38	9.52e-16	Platelet count;
LUAD	cis	rs12753569	0.934	rs10430051	chr1:76491628	T/G	cg00791851	chr1:76518896	NA	-0.28	-6.39	-0.3	4.44e-10	Personality dimensions;
LUAD	cis	rs15676	0.783	rs11515530	chr9:131576367	C/T	cg00228799	chr9:131580591	ENDOG	-0.47	-7.39	-0.34	7.87e-13	Blood metabolite levels;
LUAD	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg05082376	chr22:42548792	NA	0.45	7.8	0.35	4.73e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg20469991	chr17:27169893	C17orf63	-0.52	-6.58	-0.3	1.37e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2908197	0.662	rs917423	chr7:75984717	A/G	cg24580635	chr7:76178542	LOC100133091	-0.43	-6.84	-0.32	2.8e-11	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg15790184	chr11:494944	RNH1	0.55	7.14	0.33	4.06e-12	Body mass index;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02664216	chr12:19592651	AEBP2	-0.43	-6.89	-0.32	2.05e-11	Height;
LUAD	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg21984481	chr17:79567631	NPLOC4	-0.54	-11.54	-0.49	5.62e-27	Eye color traits;
LUAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.58e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs853679	1.000	rs853679	chr6:28296863	C/A	cg01620082	chr3:125678407	NA	-0.53	-7.01	-0.32	9.23e-12	Depression;
LUAD	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg22823121	chr1:150693482	HORMAD1	-0.39	-7.73	-0.35	7.99e-14	Tonsillectomy;
LUAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.47	-0.3	2.77e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg05340658	chr4:99064831	C4orf37	-0.47	-7.82	-0.36	4.17e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg10729496	chr3:10149963	C3orf24	0.63	9.38	0.41	4.17e-19	Alzheimer's disease;
LUAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg26818010	chr10:134567672	INPP5A	-0.96	-15.8	-0.61	1.63e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg21100191	chr22:23484243	RTDR1	0.66	11.38	0.48	2.28e-26	Bone mineral density;
LUAD	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg19761014	chr17:28927070	LRRC37B2	0.7	6.61	0.31	1.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs494562	0.892	rs522915	chr6:86116321	A/G	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	trans	rs10411161	0.702	rs11879319	chr19:52389592	C/T	cg22319618	chr22:45562946	NUP50	-0.61	-8.88	-0.4	1.91e-17	Breast cancer;
LUAD	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg23254163	chr1:152506842	NA	0.27	7.25	0.33	1.99e-12	Hair morphology;
LUAD	cis	rs758324	0.812	rs11954609	chr5:131165738	A/G	cg06307176	chr5:131281290	NA	-0.44	-7.33	-0.34	1.16e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs478304	0.530	rs11568300	chr11:65425167	C/G	cg27068330	chr11:65405492	SIPA1	-0.76	-12.07	-0.51	5.06e-29	Acne (severe);
LUAD	trans	rs3942852	0.606	rs10734561	chr11:48097480	C/T	cg03929089	chr4:120376271	NA	-0.61	-8.63	-0.39	1.25e-16	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs71478720	0.953	rs7121554	chr11:112048051	C/T	cg26534425	chr11:112034925	IL18	0.43	6.57	0.3	1.47e-10	Interleukin-18 levels;
LUAD	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg07936489	chr17:37558343	FBXL20	0.46	7.13	0.33	4.42e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs11650175	0.964	rs12948946	chr17:63739352	A/G	cg07283582	chr17:63770753	CCDC46	0.38	7.26	0.33	1.92e-12	Chin dimples;
LUAD	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg16486109	chr11:613632	IRF7	0.54	9.0	0.4	7.62e-18	Systemic lupus erythematosus;
LUAD	trans	rs9747201	1.000	rs67588022	chr17:80176071	G/A	cg07393940	chr7:158741817	NA	0.68	11.32	0.48	3.78e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06544989	chr22:39130855	UNC84B	0.38	7.57	0.35	2.39e-13	Menopause (age at onset);
LUAD	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg09491104	chr22:46646882	C22orf40	0.67	12.08	0.51	4.5e-29	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg00204512	chr16:28754710	NA	0.33	7.12	0.33	4.52e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg11266682	chr4:10021025	SLC2A9	0.69	15.79	0.61	1.69e-44	Bone mineral density;
LUAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-10.75	-0.46	5.49e-24	Lymphocyte counts;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg26187342	chr17:65713858	NOL11	-0.43	-6.92	-0.32	1.63e-11	Vertical cup-disc ratio;
LUAD	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.47	7.11	0.33	5.12e-12	Schizophrenia;
LUAD	cis	rs1595825	0.838	rs6742343	chr2:198666752	C/T	cg00982548	chr2:198649783	BOLL	-0.67	-9.07	-0.4	4.43e-18	Ulcerative colitis;
LUAD	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg13393036	chr8:95962371	TP53INP1	0.37	8.09	0.37	6.37e-15	Type 2 diabetes;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg21425749	chr1:59369792	NA	-0.37	-6.36	-0.3	5.16e-10	Schizophrenia;
LUAD	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12667521	chr19:29218732	NA	0.59	8.45	0.38	4.9e-16	Methadone dose in opioid dependence;
LUAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg21475434	chr5:93447410	FAM172A	-0.74	-8.37	-0.38	8.69e-16	Diabetic retinopathy;
LUAD	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg16405210	chr4:1374714	KIAA1530	-0.62	-9.77	-0.43	1.86e-20	Longevity;
LUAD	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg21204522	chr6:27730016	NA	-0.44	-6.94	-0.32	1.51e-11	Parkinson's disease;
LUAD	cis	rs2839627	0.561	rs2839601	chr21:44317381	A/G	cg03543861	chr21:44258195	NA	0.6	8.7	0.39	7.68e-17	Information processing speed;
LUAD	cis	rs7107174	0.681	rs10793301	chr11:78020913	G/T	cg19901956	chr11:77921274	USP35	-0.53	-6.45	-0.3	3.15e-10	Testicular germ cell tumor;
LUAD	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg14828511	chr1:107599125	PRMT6	-0.59	-10.44	-0.45	7.72e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg07527032	chr15:84868466	LOC388152	0.44	6.63	0.31	1.04e-10	Schizophrenia;
LUAD	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.03	0.36	9.52e-15	Menopause (age at onset);
LUAD	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg16479474	chr6:28041457	NA	0.38	6.57	0.3	1.51e-10	Parkinson's disease;
LUAD	cis	rs73198271	0.740	rs67766414	chr8:8649533	C/T	cg01851573	chr8:8652454	MFHAS1	0.48	8.28	0.37	1.67e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2224391	0.656	rs66646775	chr6:5284395	C/A	cg26704043	chr6:5282702	FARS2	0.38	6.5	0.3	2.28e-10	Height;
LUAD	cis	rs8044868	0.502	rs9927526	chr16:72189184	C/G	cg23815491	chr16:72088622	HP	0.47	8.67	0.39	9.48e-17	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg02733842	chr7:1102375	C7orf50	-0.83	-12.02	-0.5	8e-29	Bronchopulmonary dysplasia;
LUAD	trans	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg04450456	chr4:17643702	FAM184B	0.4	7.84	0.36	3.78e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg25324976	chr17:61989376	CSHL1	0.38	7.46	0.34	5.08e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg21028142	chr17:79581711	NPLOC4	-0.38	-7.72	-0.35	8.23e-14	Eye color traits;
LUAD	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	9.18	0.41	1.93e-18	Tonsillectomy;
LUAD	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg17173187	chr15:85201210	NMB	0.4	6.53	0.3	1.87e-10	Schizophrenia;
LUAD	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg18209359	chr17:80159595	CCDC57	0.4	6.85	0.32	2.59e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4072705	0.646	rs2416933	chr9:127245529	C/T	cg01786973	chr9:127249749	NR5A1	-0.28	-6.44	-0.3	3.16e-10	Menarche (age at onset);
LUAD	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg10518543	chr12:38710700	ALG10B	-0.4	-6.35	-0.3	5.49e-10	Morning vs. evening chronotype;
LUAD	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00166722	chr3:10149974	C3orf24	0.7	12.15	0.51	2.46e-29	Alzheimer's disease;
LUAD	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg02891314	chr5:179741120	GFPT2	-0.73	-12.36	-0.52	3.49e-30	Height;
LUAD	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg10523679	chr1:76189770	ACADM	0.92	18.39	0.67	6.1e-56	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg19000871	chr14:103996768	TRMT61A	-0.41	-6.95	-0.32	1.36e-11	Coronary artery disease;
LUAD	cis	rs9341808	0.935	rs942381	chr6:80880150	T/G	cg08355045	chr6:80787529	NA	0.47	8.53	0.38	2.67e-16	Sitting height ratio;
LUAD	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg09085632	chr11:111637200	PPP2R1B	0.62	9.24	0.41	1.25e-18	Primary sclerosing cholangitis;
LUAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00166722	chr3:10149974	C3orf24	0.69	11.56	0.49	4.72e-27	Alzheimer's disease;
LUAD	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg25237894	chr2:233734115	C2orf82	0.62	11.84	0.5	3.84e-28	Coronary artery disease;
LUAD	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg13385794	chr1:248469461	NA	0.27	7.28	0.33	1.63e-12	Common traits (Other);
LUAD	cis	rs2731664	0.792	rs466256	chr5:176875956	C/A	cg23176889	chr5:176863531	GRK6	-0.7	-13.12	-0.54	3.13e-33	Intelligence (multi-trait analysis);
LUAD	cis	rs1816752	0.783	rs7139527	chr13:24985512	G/A	cg02811702	chr13:24901961	NA	0.43	7.37	0.34	9.06e-13	Obesity-related traits;
LUAD	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg12564285	chr5:131593104	PDLIM4	0.37	6.39	0.3	4.32e-10	Breast cancer;
LUAD	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg27446573	chr6:127587934	RNF146	0.45	6.66	0.31	8.44e-11	Breast cancer;
LUAD	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg14541582	chr5:601475	NA	-0.36	-7.58	-0.35	2.19e-13	Lung disease severity in cystic fibrosis;
LUAD	trans	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg26043149	chr18:55253948	FECH	0.51	8.31	0.37	1.34e-15	Bone mineral density;
LUAD	cis	rs2073300	1.000	rs6132626	chr20:23444672	T/C	cg12062639	chr20:23401060	NAPB	0.98	8.35	0.38	9.91e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg23815491	chr16:72088622	HP	0.58	10.99	0.47	7.13e-25	Fibrinogen levels;
LUAD	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg13902645	chr11:5959945	NA	0.56	10.81	0.47	3.33e-24	DNA methylation (variation);
LUAD	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg19622623	chr12:86230825	RASSF9	-0.44	-7.62	-0.35	1.63e-13	Major depressive disorder;
LUAD	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg03474202	chr17:45855739	NA	-0.39	-9.46	-0.42	2.19e-19	IgG glycosylation;
LUAD	cis	rs9826463	0.582	rs73238150	chr3:142062457	C/A	cg20824294	chr3:142316082	PLS1	0.43	7.07	0.33	6.24e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg18016565	chr1:150552671	MCL1	0.41	7.51	0.34	3.51e-13	Tonsillectomy;
LUAD	cis	rs9914544	0.545	rs8078993	chr17:18797126	A/G	cg25390199	chr17:18761479	PRPSAP2	-0.37	-6.44	-0.3	3.29e-10	Educational attainment (years of education);
LUAD	cis	rs1127311	0.905	rs6699729	chr1:154582896	A/T	cg17218026	chr1:154582156	ADAR	0.5	10.0	0.44	2.89e-21	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg06784218	chr1:46089804	CCDC17	0.5	11.13	0.48	2.11e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2274273	0.662	rs67092614	chr14:55672055	G/A	cg04306507	chr14:55594613	LGALS3	0.43	8.01	0.36	1.14e-14	Protein biomarker;
LUAD	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg18132916	chr6:79620363	NA	-0.45	-7.8	-0.35	4.87e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg23442198	chr4:187126114	CYP4V2	0.93	9.77	0.43	1.85e-20	Blood protein levels;
LUAD	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg14092571	chr14:90743983	NA	0.48	8.39	0.38	7.36e-16	Mortality in heart failure;
LUAD	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22496380	chr5:211416	CCDC127	-0.89	-11.25	-0.48	7e-26	Breast cancer;
LUAD	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg17644776	chr2:200775616	C2orf69	0.45	7.14	0.33	4.05e-12	Osteoporosis;
LUAD	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg26924012	chr15:45694286	SPATA5L1	0.57	9.58	0.42	8.41e-20	Glomerular filtration rate;
LUAD	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg07080864	chr8:57359956	PENK	-0.37	-6.61	-0.31	1.14e-10	Obesity-related traits;
LUAD	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg08885076	chr2:99613938	TSGA10	0.37	6.77	0.31	4.38e-11	Chronic sinus infection;
LUAD	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg06453172	chr10:134556979	INPP5A	-0.77	-11.12	-0.48	2.16e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg11062466	chr8:58055876	NA	0.68	9.01	0.4	7.05e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg20019720	chr6:154832845	CNKSR3	0.65	12.43	0.52	1.86e-30	Lipoprotein (a) levels;
LUAD	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.49	7.35	0.34	1.05e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.61	-11.42	-0.49	1.69e-26	Prudent dietary pattern;
LUAD	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg10523679	chr1:76189770	ACADM	0.97	19.6	0.69	2.44e-61	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg25036284	chr2:26402008	FAM59B	-0.83	-11.54	-0.49	5.85e-27	Gut microbiome composition (summer);
LUAD	cis	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.98	-0.36	1.35e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7107174	0.892	rs12284390	chr11:78103902	C/A	cg02023728	chr11:77925099	USP35	0.47	7.25	0.33	1.95e-12	Testicular germ cell tumor;
LUAD	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg05717871	chr11:638507	DRD4	-0.45	-6.58	-0.3	1.38e-10	Systemic lupus erythematosus;
LUAD	trans	rs11054731	1.000	rs10845501	chr12:12415697	A/G	cg26149032	chr3:158519514	MFSD1	0.38	6.39	0.3	4.36e-10	Coronary artery calcification;
LUAD	cis	rs35306767	0.623	rs36062650	chr10:1142571	T/C	cg26597838	chr10:835615	NA	0.61	8.88	0.4	1.89e-17	Eosinophil percentage of granulocytes;
LUAD	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg25237894	chr2:233734115	C2orf82	0.6	11.43	0.49	1.55e-26	Coronary artery disease;
LUAD	cis	rs2816062	0.813	rs2745321	chr1:18889198	G/C	cg18795169	chr1:18902165	NA	-0.94	-22.4	-0.74	7.79e-74	Urate levels in lean individuals;
LUAD	cis	rs6665290	0.904	rs1186	chr1:227177731	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.9	-0.89	4.52e-149	Myeloid white cell count;
LUAD	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg13535736	chr9:111863775	C9orf5	-0.43	-6.66	-0.31	8.37e-11	Menarche (age at onset);
LUAD	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg08470875	chr2:26401718	FAM59B	0.77	10.1	0.44	1.21e-21	Mean corpuscular hemoglobin;
LUAD	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg06671706	chr8:8559999	CLDN23	0.66	11.41	0.49	1.75e-26	Obesity-related traits;
LUAD	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg07402062	chr16:89894098	SPIRE2	0.44	11.24	0.48	8.01e-26	Vitiligo;
LUAD	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg04731861	chr2:219085781	ARPC2	0.27	8.15	0.37	4.09e-15	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg00316803	chr15:76480434	C15orf27	-0.41	-7.7	-0.35	9.55e-14	Blood metabolite levels;
LUAD	cis	rs7301826	1.000	rs4759524	chr12:131315610	G/A	cg11011512	chr12:131303247	STX2	0.38	6.56	0.3	1.58e-10	Plasma plasminogen activator levels;
LUAD	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg18306943	chr3:40428807	ENTPD3	0.38	6.73	0.31	5.57e-11	Renal cell carcinoma;
LUAD	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	25.4	0.78	4.02e-87	Chronic sinus infection;
LUAD	cis	rs12216545	0.765	rs6962518	chr7:150245938	G/C	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.37	-0.3	4.99e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg26043149	chr18:55253948	FECH	0.41	6.63	0.31	1.01e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg20248458	chr2:21022587	C2orf43	-0.7	-6.68	-0.31	7.39e-11	Type 2 diabetes;
LUAD	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg02807482	chr3:125708958	NA	-0.67	-9.21	-0.41	1.57e-18	Blood pressure (smoking interaction);
LUAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg04025307	chr7:1156635	C7orf50	-0.75	-13.3	-0.54	5.82e-34	Longevity;Endometriosis;
LUAD	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg21475434	chr5:93447410	FAM172A	0.78	8.77	0.39	4.36e-17	Diabetic retinopathy;
LUAD	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg23719950	chr11:63933701	MACROD1	-0.58	-6.92	-0.32	1.67e-11	Mean platelet volume;
LUAD	cis	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-8.29	-0.37	1.5e-15	Neuroticism;
LUAD	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.898	rs13164236	chr5:131079808	C/T	cg06307176	chr5:131281290	NA	0.52	8.16	0.37	3.77e-15	Life satisfaction;
LUAD	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg06623918	chr6:96969491	KIAA0776	-0.7	-9.66	-0.43	4.31e-20	Migraine;Coronary artery disease;
LUAD	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg14893161	chr1:205819251	PM20D1	0.44	7.02	0.32	8.97e-12	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg00933542	chr6:150070202	PCMT1	0.43	8.47	0.38	4.16e-16	Lung cancer;
LUAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.51	-0.38	3.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7189233	0.955	rs8058684	chr16:53515118	G/A	cg04059762	chr16:53544020	NA	-0.41	-6.55	-0.3	1.65e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg05425664	chr17:57184151	TRIM37	0.44	7.88	0.36	2.83e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.7	-8.94	-0.4	1.25e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg13560548	chr3:10150139	C3orf24	-0.43	-7.25	-0.33	2.02e-12	Alzheimer's disease;
LUAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg14780466	chr2:20870812	GDF7	-0.44	-8.02	-0.36	1.02e-14	Abdominal aortic aneurysm;
LUAD	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg16447950	chr5:562315	NA	-0.4	-6.5	-0.3	2.3e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08280861	chr8:58055591	NA	0.64	8.34	0.38	1.09e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2479724	0.805	rs11756454	chr6:41798578	T/A	cg17623882	chr6:41773611	USP49	0.63	11.55	0.49	5.06e-27	Menarche (age at onset);
LUAD	cis	rs12541635	0.966	rs62525736	chr8:107000638	G/C	cg10147462	chr8:107024639	NA	0.48	8.41	0.38	6.28e-16	Age of smoking initiation;
LUAD	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg06766960	chr11:133703094	NA	-0.45	-8.47	-0.38	4.24e-16	Childhood ear infection;
LUAD	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-11.05	-0.47	4.27e-25	Asthma;
LUAD	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg19442545	chr10:75533431	FUT11	-0.49	-8.09	-0.37	6.18e-15	Inflammatory bowel disease;
LUAD	cis	rs11048434	0.736	rs2377673	chr12:9112551	A/G	cg13575925	chr12:9217583	LOC144571	0.37	7.03	0.32	8.36e-12	Sjögren's syndrome;
LUAD	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.09	0.33	5.8e-12	Rheumatoid arthritis;
LUAD	cis	rs16910800	1.000	rs2468649	chr11:23200963	T/C	cg20040320	chr11:23191996	NA	0.48	7.26	0.33	1.9e-12	Cancer;
LUAD	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	6.53	0.3	1.91e-10	Aortic root size;
LUAD	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg15445000	chr17:37608096	MED1	0.45	8.22	0.37	2.5e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg06784218	chr1:46089804	CCDC17	0.57	12.98	0.53	1.21e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs17092148	1.000	rs6058112	chr20:33322006	G/C	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.19	-0.37	3.09e-15	Neuroticism;
LUAD	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg11247378	chr22:39784982	NA	-0.71	-13.27	-0.54	7.53e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg11707310	chr1:2537719	MMEL1	0.38	8.11	0.37	5.69e-15	Ulcerative colitis;
LUAD	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg17279839	chr7:150038598	RARRES2	0.43	7.2	0.33	2.77e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.9	-0.32	1.85e-11	Type 2 diabetes;
LUAD	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg09184832	chr6:79620586	NA	-0.39	-6.59	-0.31	1.32e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg02782426	chr3:40428986	ENTPD3	-0.44	-9.97	-0.44	3.61e-21	Renal cell carcinoma;
LUAD	cis	rs7937890	0.559	rs2597217	chr11:14532883	A/G	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.01e-10	Mitochondrial DNA levels;
LUAD	cis	rs7107174	1.000	rs2510045	chr11:77920563	G/T	cg02023728	chr11:77925099	USP35	0.53	7.98	0.36	1.41e-14	Testicular germ cell tumor;
LUAD	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg15691649	chr6:25882328	NA	-0.49	-6.9	-0.32	1.96e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.31	-0.41	6.92e-19	Alzheimer's disease;
LUAD	cis	rs1032833	0.732	rs113603559	chr2:180022064	C/T	cg23883738	chr2:179974586	SESTD1	-0.65	-7.3	-0.33	1.46e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07636037	chr3:49044803	WDR6	0.51	8.91	0.4	1.59e-17	Menarche (age at onset);
LUAD	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14019695	chr9:139328340	INPP5E	-0.48	-9.61	-0.42	6.78e-20	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg22823121	chr1:150693482	HORMAD1	0.45	9.09	0.4	3.95e-18	Tonsillectomy;
LUAD	cis	rs6754311	0.593	rs10928542	chr2:136410299	G/A	cg07305463	chr2:136567211	LCT	-0.34	-6.42	-0.3	3.67e-10	Mosquito bite size;
LUAD	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg26587870	chr6:27730563	NA	-0.49	-8.18	-0.37	3.36e-15	Parkinson's disease;
LUAD	cis	rs89107	0.576	rs11965985	chr6:118789834	T/C	cg21191810	chr6:118973309	C6orf204	0.41	7.54	0.34	2.8e-13	Cardiac structure and function;
LUAD	cis	rs6906287	0.647	rs35962656	chr6:118919593	G/T	cg18833306	chr6:118973337	C6orf204	0.48	8.36	0.38	9e-16	Electrocardiographic conduction measures;
LUAD	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg27454412	chr7:1067447	C7orf50	-0.35	-6.89	-0.32	2.02e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg20891283	chr12:69753455	YEATS4	0.44	6.87	0.32	2.25e-11	Blood protein levels;
LUAD	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.61	0.39	1.46e-16	Menarche (age at onset);
LUAD	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.7	0.35	9.81e-14	Bladder cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14653225	chr1:228003938	PRSS38	0.43	6.45	0.3	3.06e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg09517075	chr8:22133004	PIWIL2	0.47	8.71	0.39	6.77e-17	Hypertriglyceridemia;
LUAD	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.0	-0.36	1.17e-14	Diabetic kidney disease;
LUAD	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg17757837	chr7:157058334	UBE3C	0.46	8.14	0.37	4.43e-15	Body mass index;
LUAD	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.13	0.37	4.82e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg24399712	chr22:39784796	NA	0.67	11.46	0.49	1.13e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg21699342	chr2:239360505	ASB1	0.54	10.35	0.45	1.52e-22	Multiple system atrophy;
LUAD	cis	rs73198271	0.603	rs777705	chr8:8586868	C/T	cg01851573	chr8:8652454	MFHAS1	0.43	7.85	0.36	3.38e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs9929218	0.581	rs4783676	chr16:68801077	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.99	20.69	0.71	3.24e-66	Colorectal cancer;
LUAD	cis	rs11958404	0.932	rs72816572	chr5:157429818	T/C	cg05962755	chr5:157440814	NA	0.69	9.52	0.42	1.31e-19	IgG glycosylation;
LUAD	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.52	-8.66	-0.39	9.73e-17	Electrocardiographic conduction measures;
LUAD	cis	rs13394619	1.000	rs2358040	chr2:11731774	G/T	cg07314298	chr2:11723111	GREB1	0.48	9.14	0.41	2.66e-18	Endometriosis;
LUAD	cis	rs80319144	0.951	rs11684127	chr2:159190841	G/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.72	0.31	5.89e-11	Restless legs syndrome;
LUAD	cis	rs9807989	0.524	rs7594402	chr2:103021267	A/T	cg03938978	chr2:103052716	IL18RAP	0.45	10.32	0.45	2.05e-22	Asthma;
LUAD	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg19717773	chr7:2847554	GNA12	-0.49	-8.43	-0.38	5.68e-16	Height;
LUAD	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg06784218	chr1:46089804	CCDC17	-0.54	-11.66	-0.49	1.91e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg05042697	chr2:10830656	NOL10	0.38	6.68	0.31	7.77e-11	Prostate cancer;
LUAD	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg13319975	chr6:146136371	FBXO30	-0.59	-10.11	-0.44	1.14e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg12573674	chr2:1569213	NA	-0.61	-8.77	-0.39	4.4e-17	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg04025307	chr7:1156635	C7orf50	0.48	6.38	0.3	4.59e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs7586879	0.789	rs13428763	chr2:25132855	T/G	cg04586622	chr2:25135609	ADCY3	0.36	7.28	0.33	1.64e-12	Body mass index;
LUAD	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg03161606	chr19:29218774	NA	0.61	7.6	0.35	1.88e-13	Methadone dose in opioid dependence;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg22986084	chr14:39901328	FBXO33	-0.58	-6.88	-0.32	2.21e-11	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.72	-0.31	5.79e-11	Bladder cancer;
LUAD	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg25036284	chr2:26402008	FAM59B	-0.68	-9.24	-0.41	1.2e-18	Gut microbiome composition (summer);
LUAD	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg10645314	chr2:3704589	ALLC	-0.46	-7.63	-0.35	1.5700000000000001e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg19052272	chr2:3704530	ALLC	-0.63	-10.75	-0.46	5.2e-24	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.94	-0.36	1.78e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.45	-0.34	5.15e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2281845	0.929	rs2057579	chr1:201099275	T/C	cg22815214	chr1:201083145	CACNA1S	0.56	9.38	0.42	3.97e-19	Permanent tooth development;
LUAD	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg10755058	chr3:40428713	ENTPD3	0.38	6.9	0.32	1.94e-11	Renal cell carcinoma;
LUAD	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg03676636	chr4:99064102	C4orf37	0.31	8.27	0.37	1.72e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg24733560	chr20:60626293	TAF4	0.47	9.25	0.41	1.14e-18	Body mass index;
LUAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg22444338	chr7:1054449	C7orf50	0.45	7.66	0.35	1.25e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg01200585	chr1:228362443	C1orf69	0.46	7.58	0.35	2.22e-13	Diastolic blood pressure;
LUAD	cis	rs1387259	0.790	rs2732445	chr12:48645533	C/T	cg04545296	chr12:48745243	ZNF641	0.42	10.56	0.46	2.63e-23	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	trans	rs12517041	1.000	rs1366454	chr5:23319172	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.73	-0.31	5.37e-11	Calcium levels;
LUAD	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg03037974	chr15:76606532	NA	0.38	8.14	0.37	4.43e-15	Blood metabolite levels;
LUAD	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.41	-6.8	-0.31	3.5e-11	Rheumatoid arthritis;
LUAD	cis	rs877282	1.000	rs12773872	chr10:771939	T/C	cg17470449	chr10:769945	NA	0.66	9.52	0.42	1.31e-19	Uric acid levels;
LUAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.11	-0.4	3.36e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6920965	0.509	rs654213	chr6:126149127	C/T	cg05901451	chr6:126070800	HEY2	0.43	6.89	0.32	2.09e-11	High light scatter reticulocyte count;
LUAD	cis	rs4409675	0.576	rs10751724	chr1:28215631	C/T	cg23691781	chr1:28212827	C1orf38	0.39	11.33	0.48	3.76e-26	Corneal astigmatism;
LUAD	cis	rs7799006	0.929	rs35791351	chr7:2269248	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-7.96	-0.36	1.61e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg18944383	chr4:111397179	ENPEP	0.37	7.68	0.35	1.12e-13	Height;
LUAD	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22496380	chr5:211416	CCDC127	-0.94	-13.19	-0.54	1.7e-33	Breast cancer;
LUAD	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.66	-0.31	8.75e-11	Neutrophil percentage of white cells;
LUAD	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg18129178	chr5:148520854	ABLIM3	-0.69	-9.99	-0.44	3.08e-21	Breast cancer;
LUAD	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.7	-0.31	6.77e-11	Menopause (age at onset);
LUAD	cis	rs6489882	0.867	rs6489870	chr12:113363972	G/A	cg20102336	chr12:113376681	OAS3	-0.6	-9.34	-0.41	5.52e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg06028605	chr16:24865363	SLC5A11	0.4	6.95	0.32	1.39e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg09399716	chr2:46890238	NA	-0.45	-9.1	-0.4	3.46e-18	Height;
LUAD	cis	rs4919694	0.711	rs113361908	chr10:104978126	T/C	cg04362960	chr10:104952993	NT5C2	0.71	7.31	0.33	1.33e-12	Arsenic metabolism;
LUAD	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19346786	chr7:2764209	NA	-0.57	-12.6	-0.52	3.92e-31	Height;
LUAD	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg04287289	chr16:89883240	FANCA	0.71	13.12	0.54	3.06e-33	Vitiligo;
LUAD	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg22431228	chr1:16359049	CLCNKA	-0.43	-7.94	-0.36	1.83e-14	Systolic blood pressure;
LUAD	cis	rs8017423	0.647	rs12882973	chr14:90820502	G/A	cg14092571	chr14:90743983	NA	0.39	6.63	0.31	1.04e-10	Mortality in heart failure;
LUAD	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg05340658	chr4:99064831	C4orf37	0.53	9.07	0.4	4.46e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8067545	0.750	rs7223305	chr17:19990986	A/G	cg04132472	chr17:19861366	AKAP10	0.29	7.02	0.32	8.77e-12	Schizophrenia;
LUAD	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg02038168	chr22:39784481	NA	-0.55	-10.07	-0.44	1.62e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg18854424	chr1:2615690	NA	0.34	7.53	0.34	3.01e-13	Ulcerative colitis;
LUAD	cis	rs877282	0.853	rs12779017	chr10:763619	T/C	cg06581033	chr10:766294	NA	-0.59	-7.98	-0.36	1.39e-14	Uric acid levels;
LUAD	trans	rs2262909	0.962	rs401424	chr19:22232023	A/G	cg05197062	chr11:11642011	GALNTL4	-0.5	-7.95	-0.36	1.75e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2455601	1.000	rs72632952	chr11:8917976	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-7.25	-0.33	1.97e-12	Schizophrenia;
LUAD	cis	rs7493	0.901	rs11767787	chr7:95026753	T/C	cg17330251	chr7:94953956	PON1	-0.58	-8.22	-0.37	2.59e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.5	6.88	0.32	2.22e-11	Platelet count;
LUAD	cis	rs7809615	0.792	rs45618033	chr7:99046617	G/A	cg12290671	chr7:99195819	NA	-0.69	-8.15	-0.37	4.29e-15	Blood metabolite ratios;
LUAD	cis	rs13082711	0.554	rs66854845	chr3:27387008	C/T	cg02860705	chr3:27208620	NA	0.71	10.87	0.47	1.9e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs17433780	0.897	rs17434151	chr1:89500526	G/T	cg09516651	chr1:89888402	LOC400759	0.52	9.21	0.41	1.54e-18	Carotid intima media thickness;
LUAD	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg03929089	chr4:120376271	NA	0.58	7.59	0.35	2.02e-13	Axial length;
LUAD	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22857025	chr5:266934	NA	-0.98	-14.37	-0.57	2.04e-38	Breast cancer;
LUAD	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.62	0.52	3.42e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg14668632	chr7:2872130	GNA12	-0.75	-13.4	-0.55	2.17e-34	Height;
LUAD	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg24449463	chr1:168025552	DCAF6	-0.75	-12.34	-0.51	4.12e-30	Schizophrenia;
LUAD	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg00684032	chr4:1343700	KIAA1530	0.42	7.1	0.33	5.29e-12	Obesity-related traits;
LUAD	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg14671364	chr1:107599128	PRMT6	-0.54	-9.42	-0.42	2.94e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs8078723	0.510	rs9898547	chr17:38136026	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.47	9.31	0.41	7.17e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	trans	rs1406428	0.573	rs12613632	chr2:51705755	C/G	cg18151858	chr13:21635991	LATS2	0.38	6.5	0.3	2.2e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs735539	0.645	rs1411038	chr13:21248431	A/G	cg27499820	chr13:21296301	IL17D	0.53	8.92	0.4	1.46e-17	Dental caries;
LUAD	cis	rs6881634	0.501	rs10065805	chr5:77769002	C/G	cg11547950	chr5:77652471	NA	0.36	6.79	0.31	3.86e-11	Hippocampal atrophy;
LUAD	cis	rs2281636	1.000	rs2804418	chr10:101512094	A/C	cg17885402	chr10:101492224	COX15;CUTC	0.39	6.66	0.31	8.54e-11	Obesity-related traits;
LUAD	cis	rs5758659	0.716	rs86669	chr22:42680800	C/T	cg15128208	chr22:42549153	NA	-0.37	-7.32	-0.34	1.23e-12	Cognitive function;
LUAD	cis	rs7072216	0.922	rs7097824	chr10:100151799	A/T	cg26618903	chr10:100175079	PYROXD2	-0.3	-6.48	-0.3	2.53e-10	Metabolite levels;
LUAD	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg00933542	chr6:150070202	PCMT1	0.43	9.24	0.41	1.17e-18	Lung cancer;
LUAD	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.18	-0.33	3.12e-12	Height;
LUAD	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg04827223	chr11:72435913	ARAP1	-0.68	-13.08	-0.54	4.73e-33	Body mass index;
LUAD	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.09	13.25	0.54	9.13e-34	Lung cancer in ever smokers;
LUAD	cis	rs1847202	0.717	rs13063437	chr3:72952388	A/G	cg25664220	chr3:72788482	NA	-0.42	-7.41	-0.34	6.81e-13	Motion sickness;
LUAD	cis	rs2652834	1.000	rs2729788	chr15:63400378	G/C	cg25406657	chr15:63342033	TPM1	-0.4	-6.38	-0.3	4.56e-10	HDL cholesterol;
LUAD	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg10053473	chr17:62856997	LRRC37A3	0.71	11.44	0.49	1.38e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.42	-0.38	6.04e-16	Prostate cancer;
LUAD	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg25173405	chr17:45401733	C17orf57	0.46	7.47	0.34	4.66e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1451375	0.657	rs12672526	chr7:50657695	C/T	cg18232548	chr7:50535776	DDC	0.49	7.7	0.35	9.41e-14	Malaria;
LUAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg11494091	chr17:61959527	GH2	0.75	18.44	0.67	3.82e-56	Prudent dietary pattern;
LUAD	cis	rs56283067	0.887	rs9463043	chr6:44771114	T/C	cg18551225	chr6:44695536	NA	-0.48	-7.32	-0.34	1.23e-12	Total body bone mineral density;
LUAD	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg20307385	chr11:47447363	PSMC3	0.67	11.68	0.49	1.62e-27	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.62	11.01	0.47	5.7e-25	Birth weight;
LUAD	cis	rs7617773	0.743	rs11715876	chr3:48377922	G/A	cg11946769	chr3:48343235	NME6	0.46	6.87	0.32	2.31e-11	Coronary artery disease;
LUAD	cis	rs11893307	0.509	rs12618075	chr2:191545821	A/G	cg27211696	chr2:191398769	TMEM194B	-0.41	-6.41	-0.3	3.86e-10	Mean platelet volume;
LUAD	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg12923728	chr3:195709715	SDHAP1	0.45	6.83	0.32	2.99e-11	Mean corpuscular volume;
LUAD	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg22906224	chr7:99728672	NA	0.63	10.5	0.45	4.54e-23	Coronary artery disease;
LUAD	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg16325326	chr1:53192061	ZYG11B	0.47	7.66	0.35	1.3e-13	Monocyte count;
LUAD	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg18932078	chr1:2524107	MMEL1	0.38	7.13	0.33	4.42e-12	Ulcerative colitis;
LUAD	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.46	0.38	4.5e-16	Platelet count;
LUAD	trans	rs6940116	1	rs6940116	chr6:27708732	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.4	-0.3	4.19e-10	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg17105886	chr17:28927953	LRRC37B2	0.8	7.82	0.36	4.29e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs13112683	0.638	rs11731414	chr4:140783662	A/G	cg02876341	chr4:140783585	MAML3	0.31	6.7	0.31	6.66e-11	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LUAD	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg27539214	chr16:67997921	SLC12A4	-0.72	-9.19	-0.41	1.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18876405	chr7:65276391	NA	-0.41	-6.45	-0.3	3.13e-10	Aortic root size;
LUAD	cis	rs4523957	0.647	rs12950603	chr17:2194937	T/A	cg16513277	chr17:2031491	SMG6	0.77	14.27	0.57	5.33e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg14895029	chr7:2775587	GNA12	-0.44	-7.11	-0.33	4.95e-12	Height;
LUAD	cis	rs11209185	0.509	rs9436357	chr1:68452488	C/T	cg22082780	chr1:68452167	NA	0.53	11.41	0.49	1.75e-26	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg20503657	chr10:835505	NA	0.99	15.05	0.59	2.62e-41	Eosinophil percentage of granulocytes;
LUAD	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.39	6.36	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg03563238	chr19:33554763	RHPN2	-0.37	-8.56	-0.38	2.12e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg20503657	chr10:835505	NA	0.99	14.7	0.58	8.55e-40	Eosinophil percentage of granulocytes;
LUAD	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg08029281	chr1:67600428	NA	0.35	6.63	0.31	1.01e-10	Psoriasis;
LUAD	cis	rs7274811	0.744	rs6120309	chr20:32169600	A/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.49	-7.58	-0.35	2.15e-13	Height;
LUAD	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg15017067	chr4:17643749	FAM184B	0.37	7.2	0.33	2.73e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg07343612	chr16:622815	PIGQ	-0.79	-15.58	-0.6	1.46e-43	Height;
LUAD	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg27170947	chr2:26402098	FAM59B	-0.81	-11.48	-0.49	1e-26	Gut microbiome composition (summer);
LUAD	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.6	0.31	1.22e-10	Parkinson's disease;
LUAD	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg04727924	chr7:799746	HEATR2	-0.56	-7.31	-0.34	1.32e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg00814883	chr7:100076585	TSC22D4	-0.77	-10.8	-0.46	3.67e-24	Platelet count;
LUAD	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg21681030	chr2:46777652	RHOQ	0.38	6.62	0.31	1.11e-10	Height;
LUAD	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.88	-0.32	2.19e-11	Retinal vascular caliber;
LUAD	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg02551604	chr5:131831745	NA	-0.61	-10.08	-0.44	1.46e-21	Asthma (sex interaction);
LUAD	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg18252515	chr7:66147081	NA	-0.61	-6.66	-0.31	8.66e-11	Diabetic kidney disease;
LUAD	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg13319975	chr6:146136371	FBXO30	-0.54	-8.92	-0.4	1.37e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg24813613	chr7:1882135	MAD1L1	-0.42	-6.75	-0.31	5.03e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2404602	0.622	rs1567671	chr15:77209200	C/G	cg23625390	chr15:77176239	SCAPER	-0.49	-7.22	-0.33	2.43e-12	Blood metabolite levels;
LUAD	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg09835421	chr16:68378352	PRMT7	-0.74	-8.37	-0.38	8.39e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	cis	rs113835537	0.529	rs17580784	chr11:66214859	T/A	cg24851651	chr11:66362959	CCS	0.61	10.58	0.46	2.33e-23	Airway imaging phenotypes;
LUAD	cis	rs3087591	0.960	rs2952984	chr17:29469614	T/C	cg24425628	chr17:29625626	OMG;NF1	0.42	6.93	0.32	1.53e-11	Hip circumference;
LUAD	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg17747265	chr1:1875780	NA	0.4	8.04	0.36	9.24e-15	Body mass index;
LUAD	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg09365446	chr1:150670422	GOLPH3L	0.62	10.81	0.47	3.19e-24	Melanoma;
LUAD	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg09654669	chr8:57350985	NA	-0.65	-10.02	-0.44	2.42e-21	Obesity-related traits;
LUAD	cis	rs490234	0.805	rs517064	chr9:128348486	C/T	cg14078157	chr9:128172775	NA	0.41	7.76	0.35	6.45e-14	Mean arterial pressure;
LUAD	cis	rs654950	0.875	rs633297	chr1:41985453	A/C	cg06885757	chr1:42089581	HIVEP3	0.33	7.01	0.32	9.32e-12	Airway imaging phenotypes;
LUAD	cis	rs2455601	1.000	rs56336128	chr11:8908299	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.46	-6.66	-0.31	8.67e-11	Schizophrenia;
LUAD	trans	rs970548	0.688	rs2082110	chr10:45931070	A/G	cg14222797	chr10:16859974	RSU1	-0.54	-6.65	-0.31	9.25e-11	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs6545883	0.965	rs12713439	chr2:61752154	G/A	cg15711740	chr2:61764176	XPO1	-0.4	-6.38	-0.3	4.71e-10	Tuberculosis;
LUAD	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg11189052	chr15:85197271	WDR73	-0.61	-9.99	-0.44	3.04e-21	P wave terminal force;
LUAD	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg11189052	chr15:85197271	WDR73	0.61	7.87	0.36	2.95e-14	Schizophrenia;
LUAD	cis	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg21775007	chr8:11205619	TDH	0.37	6.61	0.31	1.18e-10	Neuroticism;
LUAD	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg03929089	chr4:120376271	NA	0.57	7.41	0.34	6.91e-13	Axial length;
LUAD	cis	rs34638657	0.500	rs7405197	chr16:82169833	C/A	cg09439754	chr16:82129088	HSD17B2	-0.33	-6.76	-0.31	4.47e-11	Lung adenocarcinoma;
LUAD	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-7.63	-0.35	1.53e-13	Neutrophil percentage of white cells;
LUAD	cis	rs7727544	0.547	rs10076758	chr5:131524299	A/G	cg14196790	chr5:131705035	SLC22A5	0.42	7.19	0.33	3.02e-12	Blood metabolite levels;
LUAD	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg23260525	chr10:116636907	FAM160B1	0.47	10.91	0.47	1.41e-24	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6490294	0.607	rs2339907	chr12:112418146	C/A	cg10833066	chr12:111807467	FAM109A	0.36	6.68	0.31	7.32e-11	Mean platelet volume;
LUAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg10295955	chr4:187884368	NA	-1.1	-25.98	-0.78	1.24e-89	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg26924012	chr15:45694286	SPATA5L1	1.02	18.85	0.68	5.65e-58	Homoarginine levels;
LUAD	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg14779329	chr11:130786720	SNX19	0.42	7.13	0.33	4.32e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1949733	0.675	rs2010758	chr4:8475623	G/A	cg13073564	chr4:8508604	NA	-0.49	-9.02	-0.4	6.5e-18	Response to antineoplastic agents;
LUAD	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg27490568	chr2:178487706	NA	0.51	8.45	0.38	4.88e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg05564831	chr3:52568323	NT5DC2	-0.37	-6.71	-0.31	6.24e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg13535736	chr9:111863775	C9orf5	-0.43	-6.67	-0.31	7.88e-11	Menarche (age at onset);
LUAD	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg00757033	chr12:89920650	WDR51B	0.69	12.14	0.51	2.56e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg07917127	chr4:99064746	C4orf37	0.39	6.53	0.3	1.93e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg12935359	chr14:103987150	CKB	0.51	7.9	0.36	2.47e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7843479	0.509	rs3758156	chr8:21770796	A/G	cg03445287	chr8:21823731	XPO7	-0.44	-8.04	-0.36	8.96e-15	Mean corpuscular volume;
LUAD	cis	rs9392556	0.829	rs633290	chr6:4114788	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	0.37	6.63	0.31	1.03e-10	Blood metabolite levels;
LUAD	cis	rs10489202	1.000	rs12408205	chr1:167982332	A/G	cg24449463	chr1:168025552	DCAF6	-0.55	-7.02	-0.32	8.68e-12	Schizophrenia;
LUAD	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg05340658	chr4:99064831	C4orf37	0.45	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg04703951	chr17:43578652	NA	0.44	7.1	0.33	5.3e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg03037974	chr15:76606532	NA	0.37	7.83	0.36	4e-14	Blood metabolite levels;
LUAD	cis	rs7975161	1.000	rs7975161	chr12:104645405	C/T	cg25273343	chr12:104657179	TXNRD1	0.66	8.2	0.37	3e-15	Toenail selenium levels;
LUAD	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg17264618	chr3:40429014	ENTPD3	0.43	9.2	0.41	1.66e-18	Renal cell carcinoma;
LUAD	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg05872129	chr22:39784769	NA	-0.76	-12.89	-0.53	2.75e-32	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9826463	0.757	rs73238195	chr3:142171525	A/C	cg20824294	chr3:142316082	PLS1	0.4	7.09	0.33	5.51e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-7.89	-0.36	2.67e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg20790798	chr5:1857306	NA	-0.46	-7.95	-0.36	1.69e-14	Cardiovascular disease risk factors;
LUAD	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg13319975	chr6:146136371	FBXO30	-0.55	-9.18	-0.41	1.95e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11809207	0.953	rs17163666	chr1:26525383	A/G	cg00300879	chr1:26503847	CNKSR1	0.28	6.88	0.32	2.11e-11	Height;
LUAD	cis	rs1232027	0.700	rs1643650	chr5:79940143	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.48	-8.02	-0.36	1.02e-14	Huntington's disease progression;
LUAD	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg06064525	chr11:970664	AP2A2	-0.54	-11.1	-0.48	2.57e-25	Alzheimer's disease (late onset);
LUAD	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg08645402	chr16:4508243	NA	0.57	10.68	0.46	1e-23	Schizophrenia;
LUAD	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg26528668	chr16:1614120	IFT140	0.57	10.39	0.45	1.12e-22	Coronary artery disease;
LUAD	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg23803603	chr1:2058230	PRKCZ	0.36	6.59	0.31	1.32e-10	Height;
LUAD	cis	rs4629710	0.545	rs11154621	chr6:131547341	A/G	cg12606694	chr6:131520996	AKAP7	0.45	6.84	0.32	2.82e-11	Multiple myeloma (IgH translocation);
LUAD	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg15704280	chr7:45808275	SEPT13	-0.73	-10.58	-0.46	2.24e-23	Coronary artery disease;
LUAD	cis	rs981844	0.740	rs10009844	chr4:154681576	C/T	cg10279832	chr4:154682576	RNF175	0.32	6.71	0.31	6.29e-11	Response to statins (LDL cholesterol change);
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg11454606	chr11:67888949	CHKA	-0.42	-6.71	-0.31	6.37e-11	Vertical cup-disc ratio;
LUAD	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg02038168	chr22:39784481	NA	-0.59	-10.44	-0.45	7.7e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs11671005	0.737	rs11671033	chr19:58963669	G/T	cg13877915	chr19:58951672	ZNF132	0.59	7.38	0.34	8.32e-13	Mean platelet volume;
LUAD	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg02869364	chr7:1081709	C7orf50	-0.49	-6.74	-0.31	5.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg26513180	chr16:89883248	FANCA	0.72	6.9	0.32	1.86e-11	Skin colour saturation;
LUAD	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg08989290	chr16:615782	NHLRC4	0.31	6.52	0.3	2.01e-10	Height;
LUAD	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg03467027	chr4:99064603	C4orf37	0.41	6.61	0.31	1.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.19	0.33	2.91e-12	Rheumatoid arthritis;
LUAD	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg11845111	chr2:191398756	TMEM194B	-0.84	-10.78	-0.46	4.36e-24	Diastolic blood pressure;
LUAD	cis	rs7274811	0.625	rs293722	chr20:31927361	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.47	-6.89	-0.32	2e-11	Height;
LUAD	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg18827107	chr12:86230957	RASSF9	-0.56	-9.89	-0.43	6.65e-21	Major depressive disorder;
LUAD	cis	rs2249625	0.523	rs2496552	chr6:72853042	T/C	cg18830697	chr6:72922368	RIMS1	-0.39	-7.47	-0.34	4.54e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs6714710	0.603	rs12104810	chr2:98443658	C/T	cg26665480	chr2:98280029	ACTR1B	0.5	8.19	0.37	3.04e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08677398	chr8:58056175	NA	0.48	6.45	0.3	2.97e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg20556744	chr2:9614537	IAH1	0.65	6.36	0.3	5.14e-10	Opioid sensitivity;
LUAD	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.73	0.53	1.14e-31	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs867371	0.722	rs8033050	chr15:82561989	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.35	-0.3	5.5e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
LUAD	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg09165964	chr15:75287851	SCAMP5	0.48	7.26	0.33	1.89e-12	Blood trace element (Zn levels);
LUAD	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg00310523	chr12:86230176	RASSF9	0.35	7.1	0.33	5.41e-12	Major depressive disorder;
LUAD	trans	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg11693508	chr17:37793320	STARD3	0.68	9.61	0.42	6.34e-20	Bipolar disorder;
LUAD	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg06784218	chr1:46089804	CCDC17	0.51	11.21	0.48	1.05e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg21475434	chr5:93447410	FAM172A	0.74	8.32	0.37	1.26e-15	Diabetic retinopathy;
LUAD	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg00634984	chr7:65235879	NA	-0.53	-6.94	-0.32	1.47e-11	Aortic root size;
LUAD	cis	rs4845570	1.000	rs4845356	chr1:151759223	T/A	cg07092448	chr1:151763213	TDRKH	0.72	8.69	0.39	8.17e-17	Coronary artery disease;
LUAD	cis	rs11229555	0.645	rs10896785	chr11:58233395	G/A	cg15696309	chr11:58395628	NA	-0.79	-10.86	-0.47	2.14e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg10556349	chr10:835070	NA	0.58	7.31	0.34	1.3e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg05373962	chr22:49881684	NA	-0.48	-11.04	-0.47	4.55e-25	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg06784218	chr1:46089804	CCDC17	0.51	11.23	0.48	8.7e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg15445000	chr17:37608096	MED1	-0.44	-8.16	-0.37	3.77e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.61	-7.17	-0.33	3.29e-12	Body mass index;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg23097277	chr12:27676539	PPFIBP1	-0.39	-6.71	-0.31	6.46e-11	Subcortical brain region volumes;
LUAD	cis	rs775227	0.528	rs775231	chr3:113027214	A/C	cg18753928	chr3:113234510	CCDC52	0.57	8.06	0.36	7.8e-15	Dental caries;
LUAD	cis	rs58106596	0.517	rs56272010	chr2:232664963	T/G	cg26500773	chr2:232646331	PDE6D	-0.55	-7.86	-0.36	3.24e-14	White blood cell count;Lymphocyte counts;
LUAD	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg15133208	chr4:90757351	SNCA	-0.47	-7.11	-0.33	4.85e-12	Neuroticism;
LUAD	cis	rs3774830	0.714	rs7688517	chr4:5466392	A/C	cg26943120	chr4:5472116	STK32B	0.37	7.74	0.35	7.41e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2652834	1.000	rs2729780	chr15:63404639	C/G	cg25406657	chr15:63342033	TPM1	-0.39	-6.38	-0.3	4.61e-10	HDL cholesterol;
LUAD	cis	rs2882667	1.000	rs2060222	chr5:138308466	C/T	cg04439458	chr5:138467593	SIL1	-0.42	-7.54	-0.34	2.84e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-6.4	-0.3	4.1e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg14196790	chr5:131705035	SLC22A5	-0.48	-8.41	-0.38	6.17e-16	Breast cancer;Mosquito bite size;
LUAD	cis	rs6840360	0.615	rs12647462	chr4:152607278	C/T	cg22705602	chr4:152727874	NA	-0.47	-8.7	-0.39	7.46e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg16479474	chr6:28041457	NA	0.37	6.77	0.31	4.29e-11	Cardiac Troponin-T levels;
LUAD	trans	rs2235573	0.594	rs12157609	chr22:38432277	C/T	cg19894588	chr14:64061835	NA	0.44	6.86	0.32	2.5e-11	Glioblastoma;Glioma;
LUAD	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-9.5	-0.42	1.63e-19	Gut microbiome composition (summer);
LUAD	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg03929089	chr4:120376271	NA	-0.96	-19.71	-0.69	8.34e-62	Height;
LUAD	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg21171335	chr12:122356390	WDR66	0.73	13.52	0.55	6.86e-35	Mean corpuscular volume;
LUAD	cis	rs7264396	0.563	rs59064961	chr20:34307950	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2.04e-15	Total cholesterol levels;
LUAD	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7953508	0.506	rs2053196	chr12:93962959	T/C	cg18151635	chr12:93972918	NA	-0.78	-11.69	-0.49	1.5e-27	Pubertal anthropometrics;
LUAD	cis	rs9788721	0.806	rs4887056	chr15:78734585	A/G	cg18825076	chr15:78729989	IREB2	-0.57	-10.01	-0.44	2.55e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	trans	rs747782	0.639	rs17198985	chr11:48183565	T/C	cg03929089	chr4:120376271	NA	0.6	6.58	0.3	1.35e-10	Intraocular pressure;
LUAD	cis	rs7119	0.623	rs11637932	chr15:77847353	T/G	cg27398640	chr15:77910606	LINGO1	-0.37	-6.72	-0.31	5.84e-11	Type 2 diabetes;
LUAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg26750617	chr12:132293702	NA	-0.45	-8.04	-0.36	8.97e-15	Migraine;
LUAD	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11644478	chr21:40555479	PSMG1	-0.54	-8.66	-0.39	1.02e-16	Cognitive function;
LUAD	cis	rs7177699	0.557	rs7165075	chr15:79115965	G/A	cg15571903	chr15:79123663	NA	0.38	7.6	0.35	1.87e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02447287	chr2:238707023	RBM44	0.49	6.37	0.3	4.91e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg06608945	chr2:219082296	ARPC2	-0.42	-7.01	-0.32	9.55e-12	Colorectal cancer;
LUAD	cis	rs7737355	0.947	rs10054733	chr5:130989426	C/T	cg06307176	chr5:131281290	NA	0.53	8.34	0.38	1.06e-15	Life satisfaction;
LUAD	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg01475377	chr6:109611718	NA	-0.53	-10.35	-0.45	1.52e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.08	0.37	7.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg04034577	chr2:241836375	C2orf54	-0.51	-11.41	-0.49	1.73e-26	Urinary metabolites;
LUAD	cis	rs72634258	0.503	rs34177663	chr1:7833228	A/G	cg26816564	chr1:7831052	VAMP3	0.8	10.49	0.45	5.08e-23	Inflammatory bowel disease;
LUAD	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg17063962	chr7:91808500	NA	0.68	12.05	0.51	5.84e-29	Breast cancer;
LUAD	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21028142	chr17:79581711	NPLOC4	-0.43	-8.91	-0.4	1.48e-17	Eye color traits;
LUAD	cis	rs2302190	0.882	rs7213415	chr17:56672433	C/G	cg25885038	chr17:56607967	SEPT4	-0.51	-8.12	-0.37	5.11e-15	Vitamin D levels;
LUAD	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	6.71	0.31	6.45e-11	Lung cancer in ever smokers;
LUAD	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg07930552	chr6:133119739	C6orf192	-0.56	-7.09	-0.33	5.52e-12	Type 2 diabetes nephropathy;
LUAD	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg21427119	chr20:30132790	HM13	-0.59	-8.82	-0.39	3.09e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs1997103	1.000	rs2177802	chr7:55410789	G/A	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.49	7.96	0.36	1.55e-14	Lymphocyte percentage of white cells;
LUAD	cis	rs7737355	0.947	rs10478980	chr5:130618247	C/T	cg06307176	chr5:131281290	NA	0.46	7.33	0.34	1.21e-12	Life satisfaction;
LUAD	cis	rs6541297	0.938	rs7551742	chr1:230290118	A/G	cg20703242	chr1:230279135	GALNT2	0.68	12.4	0.52	2.37e-30	Coronary artery disease;
LUAD	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg03563238	chr19:33554763	RHPN2	-0.37	-8.77	-0.39	4.55e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg06608945	chr2:219082296	ARPC2	0.52	8.93	0.4	1.35e-17	Colorectal cancer;
LUAD	cis	rs2282300	0.702	rs2211018	chr11:30330079	C/T	cg06241208	chr11:30344200	C11orf46	0.57	7.31	0.33	1.33e-12	Morning vs. evening chronotype;
LUAD	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg16680214	chr1:154839983	KCNN3	0.62	13.14	0.54	2.58e-33	Prostate cancer;
LUAD	trans	rs2018683	0.649	rs221193	chr7:29015784	G/T	cg19402173	chr7:128379420	CALU	-0.48	-7.66	-0.35	1.31e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs714027	0.967	rs4823077	chr22:30545149	A/G	cg00539347	chr22:30592296	NA	-0.29	-6.73	-0.31	5.53e-11	Lymphocyte counts;
LUAD	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg08508325	chr11:3079039	CARS	0.44	8.99	0.4	8.25e-18	Calcium levels;
LUAD	cis	rs7582720	0.943	rs115827549	chr2:203725678	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.12	0.41	3.09e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-10.49	-0.45	4.71e-23	Gut microbiome composition (summer);
LUAD	cis	rs10899021	0.790	rs7932194	chr11:74327378	C/G	cg25880958	chr11:74394337	NA	-0.52	-7.11	-0.33	4.95e-12	Response to metformin (IC50);
LUAD	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg13390004	chr1:15929781	NA	0.47	8.33	0.38	1.17e-15	Systolic blood pressure;
LUAD	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg15208524	chr1:10270712	KIF1B	-0.51	-7.61	-0.35	1.86e-13	Hepatocellular carcinoma;
LUAD	cis	rs68170813	0.559	rs78553765	chr7:106930787	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.45	-0.45	6.85e-23	Coronary artery disease;
LUAD	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg12311346	chr5:56204834	C5orf35	0.72	11.21	0.48	1.04e-25	Initial pursuit acceleration;
LUAD	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg05283184	chr6:79620031	NA	-0.62	-12.39	-0.52	2.64e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg12923728	chr3:195709715	SDHAP1	0.45	6.8	0.31	3.49e-11	Mean corpuscular volume;
LUAD	trans	rs148734725	1	rs148734725	chr3:49406708	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.21	-0.41	1.52e-18	Educational attainment (college completion);
LUAD	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg08999081	chr20:33150536	PIGU	0.47	9.19	0.41	1.84e-18	Coronary artery disease;
LUAD	cis	rs9914988	0.619	rs12451955	chr17:27314224	A/G	cg02049041	chr17:27085579	C17orf63	0.49	6.37	0.3	4.86e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg03467027	chr4:99064603	C4orf37	0.4	6.44	0.3	3.24e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2637266	0.783	rs846645	chr10:78516000	A/G	cg18941641	chr10:78392320	NA	0.31	6.38	0.3	4.77e-10	Pulmonary function;
LUAD	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.78	-0.31	4.03e-11	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg24818145	chr4:99064322	C4orf37	-0.47	-7.9	-0.36	2.43e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg15445000	chr17:37608096	MED1	0.44	8.2	0.37	2.82e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs7680126	0.596	rs10489070	chr4:10276352	C/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-7.06	-0.32	6.73e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs2882667	0.858	rs17207870	chr5:138387737	T/C	cg04439458	chr5:138467593	SIL1	-0.51	-9.25	-0.41	1.1e-18	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.54	-0.34	2.94e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs1941687	0.563	rs2032189	chr18:31332200	T/A	cg13755796	chr4:20253514	NA	-0.4	-6.89	-0.32	2.04e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	trans	rs3924048	0.574	rs3923904	chr1:12616535	T/C	cg05052031	chr3:33138450	TMPPE;GLB1	0.41	6.93	0.32	1.54e-11	Optic cup area;
LUAD	cis	rs3806843	0.551	rs246018	chr5:140335043	T/C	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10489202	1.000	rs3767474	chr1:168062398	C/T	cg24449463	chr1:168025552	DCAF6	-0.56	-6.95	-0.32	1.35e-11	Schizophrenia;
LUAD	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg04450456	chr4:17643702	FAM184B	0.4	7.84	0.36	3.69e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22733357	chr5:93906294	C5orf36;MIR1974	0.45	7.23	0.33	2.25e-12	Height;
LUAD	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg23933602	chr10:16859644	RSU1	0.58	7.82	0.36	4.31e-14	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs11214589	0.875	rs10891540	chr11:113239082	A/G	cg14159747	chr11:113255604	NA	-0.62	-13.26	-0.54	8.22e-34	Neuroticism;
LUAD	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg04455712	chr21:45112962	RRP1B	0.48	9.98	0.44	3.22e-21	Mean corpuscular volume;
LUAD	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-8.5	-0.38	3.3e-16	Reticulocyte count;
LUAD	cis	rs62238980	0.522	rs79152613	chr22:32413707	G/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.7e-32	Immature fraction of reticulocytes;
LUAD	trans	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.91	-0.32	1.82e-11	Diabetic kidney disease;
LUAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg21724239	chr8:58056113	NA	0.6	8.25	0.37	1.99e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs3750082	0.748	rs10248427	chr7:32898969	C/G	cg05721444	chr7:32995514	FKBP9	0.36	6.35	0.3	5.42e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg00750074	chr16:89608354	SPG7	-0.39	-6.44	-0.3	3.2e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg00933542	chr6:150070202	PCMT1	0.45	9.71	0.43	3.01e-20	Lung cancer;
LUAD	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.7	-0.31	6.58e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg13319975	chr6:146136371	FBXO30	-0.54	-8.92	-0.4	1.37e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg26354017	chr1:205819088	PM20D1	0.74	15.1	0.59	1.66e-41	Monocyte percentage of white cells;
LUAD	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg21214613	chr1:16344536	HSPB7	-0.35	-6.38	-0.3	4.55e-10	Systolic blood pressure;
LUAD	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg02450064	chr17:40260053	DHX58	-0.45	-7.52	-0.34	3.39e-13	Fibrinogen levels;
LUAD	cis	rs4493873	1.000	rs10110267	chr8:92073814	G/A	cg16814680	chr8:91681699	NA	0.43	6.86	0.32	2.48e-11	Migraine - clinic-based;
LUAD	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-8.44	-0.38	5.01e-16	Reticulocyte count;
LUAD	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	trans	rs7200543	1.000	rs6498541	chr16:15140657	A/G	cg24683922	chr1:11983373	KIAA2013	-0.45	-7.5	-0.34	3.77e-13	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs2816062	0.735	rs2816045	chr1:18892999	A/G	cg18795169	chr1:18902165	NA	-0.91	-21.52	-0.72	6.37e-70	Urate levels in lean individuals;
LUAD	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg07570687	chr10:102243282	WNT8B	0.44	6.51	0.3	2.18e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs4795519	0.592	rs34035904	chr17:22170381	T/C	cg22648282	chr17:21454238	C17orf51	-0.39	-6.62	-0.31	1.1e-10	Chronic myeloid leukemia;
LUAD	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg21918786	chr6:109611834	NA	-0.61	-11.21	-0.48	1.02e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg04586622	chr2:25135609	ADCY3	0.36	8.41	0.38	6.26e-16	Body mass index;
LUAD	cis	rs6840360	0.593	rs4696286	chr4:152606547	G/A	cg22705602	chr4:152727874	NA	-0.46	-8.49	-0.38	3.41e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg09998033	chr7:158218633	PTPRN2	-0.47	-8.29	-0.37	1.51e-15	Obesity-related traits;
LUAD	cis	rs13082711	0.555	rs7627508	chr3:27252495	A/C	cg02860705	chr3:27208620	NA	0.64	9.78	0.43	1.69e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg16031515	chr1:205743344	RAB7L1	-0.38	-7.58	-0.35	2.14e-13	Menarche (age at onset);
LUAD	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg07570687	chr10:102243282	WNT8B	0.48	7.34	0.34	1.09e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11890956	chr21:40555474	PSMG1	0.75	12.55	0.52	6.24e-31	Cognitive function;
LUAD	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg17652424	chr22:38574118	PLA2G6	-0.33	-9.88	-0.43	7.46e-21	Cutaneous nevi;
LUAD	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg25457927	chr22:38595422	NA	-0.53	-13.87	-0.56	2.48e-36	Cutaneous nevi;
LUAD	trans	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg27411982	chr8:10470053	RP1L1	-0.4	-7.35	-0.34	1.05e-12	Morning vs. evening chronotype;
LUAD	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg12927641	chr6:109611667	NA	0.51	8.99	0.4	8.18e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs2294693	0.581	rs13191323	chr6:41038845	C/T	cg14769373	chr6:40998127	UNC5CL	-0.45	-7.13	-0.33	4.3e-12	Gastric cancer;Non-cardia gastric cancer;
LUAD	trans	rs12517041	1.000	rs6875447	chr5:23305303	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.57	-0.3	1.48e-10	Calcium levels;
LUAD	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg15445000	chr17:37608096	MED1	0.43	7.94	0.36	1.84e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg06221963	chr1:154839813	KCNN3	-0.85	-20.05	-0.7	2.36e-63	Prostate cancer;
LUAD	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06544989	chr22:39130855	UNC84B	0.44	8.28	0.37	1.68e-15	Menopause (age at onset);
LUAD	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06022373	chr22:39101656	GTPBP1	0.48	7.89	0.36	2.68e-14	Menopause (age at onset);
LUAD	trans	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.71	-0.35	9.07e-14	Breast cancer;
LUAD	cis	rs7172809	0.573	rs7182221	chr15:77589535	C/T	cg11865553	chr15:77376250	NA	0.4	6.66	0.31	8.31e-11	Glucose homeostasis traits;
LUAD	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg04000281	chr11:63949212	NA	-0.28	-6.72	-0.31	5.88e-11	Platelet count;
LUAD	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg18225595	chr11:63971243	STIP1	0.51	8.69	0.39	8.04e-17	Platelet count;
LUAD	cis	rs1018836	0.544	rs2339154	chr8:91459316	T/C	cg16814680	chr8:91681699	NA	-0.53	-8.37	-0.38	8.28e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs922182	0.569	rs72752984	chr15:64264082	G/T	cg02919090	chr15:64263738	DAPK2	0.42	8.31	0.37	1.34e-15	Blood protein levels;
LUAD	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg14092571	chr14:90743983	NA	0.47	8.12	0.37	5.31e-15	Mortality in heart failure;
LUAD	cis	rs7267979	0.932	rs6115214	chr20:25557426	C/T	cg08601574	chr20:25228251	PYGB	-0.43	-7.77	-0.35	6.09e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06873352	chr17:61820015	STRADA	0.82	18.41	0.67	5.35e-56	Prudent dietary pattern;
LUAD	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg27170947	chr2:26402098	FAM59B	0.65	8.35	0.38	9.86e-16	Gut microbiome composition (summer);
LUAD	cis	rs16882447	0.641	rs6871446	chr5:53496587	T/C	cg06461071	chr5:53490839	ARL15	0.41	7.16	0.33	3.57e-12	Systolic blood pressure (dietary potassium intake interaction);
LUAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg07217954	chr7:1067459	C7orf50	0.43	6.62	0.31	1.1e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9892942	1	rs9892942	chr17:27178761	C/T	cg20469991	chr17:27169893	C17orf63	-0.52	-6.74	-0.31	5.15e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg10518543	chr12:38710700	ALG10B	0.42	6.47	0.3	2.65e-10	Heart rate;
LUAD	cis	rs1953600	1.000	rs2573346	chr10:81918041	G/A	cg00277334	chr10:82204260	NA	-0.42	-7.13	-0.33	4.23e-12	Sarcoidosis;
LUAD	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.37	0.38	8.27e-16	Platelet count;
LUAD	cis	rs243505	0.898	rs243528	chr7:148415740	T/C	cg09806900	chr7:148480153	CUL1	-0.39	-6.5	-0.3	2.21e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-6.51	-0.3	2.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs807669	0.770	rs807458	chr22:19220648	G/T	cg02655711	chr22:19163373	SLC25A1	0.58	10.59	0.46	2.1e-23	Metabolite levels;
LUAD	cis	rs704	0.523	rs11080054	chr17:26645991	G/A	cg10342447	chr17:26645325	TMEM97	-0.39	-7.77	-0.35	6.09e-14	Osteoprotegerin levels;
LUAD	cis	rs7193541	0.508	rs7188581	chr16:74672901	T/A	cg01733217	chr16:74700730	RFWD3	0.7	13.72	0.56	1.04e-35	Multiple myeloma;
LUAD	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg01851573	chr8:8652454	MFHAS1	0.38	6.44	0.3	3.24e-10	Mood instability;
LUAD	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg00933542	chr6:150070202	PCMT1	0.43	9.18	0.41	1.91e-18	Lung cancer;
LUAD	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg11266682	chr4:10021025	SLC2A9	-0.55	-12.09	-0.51	4.19e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg26384229	chr12:38710491	ALG10B	0.47	7.65	0.35	1.4e-13	Morning vs. evening chronotype;
LUAD	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg10518543	chr12:38710700	ALG10B	0.41	6.39	0.3	4.29e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg11871910	chr12:69753446	YEATS4	0.55	8.44	0.38	5.03e-16	Blood protein levels;
LUAD	cis	rs9309473	0.528	rs2091022	chr2:73564570	G/A	cg20560298	chr2:73613845	ALMS1	-0.42	-6.51	-0.3	2.09e-10	Metabolite levels;
LUAD	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg22166914	chr1:53195759	ZYG11B	0.4	6.66	0.31	8.58e-11	Monocyte count;
LUAD	trans	rs7944735	0.545	rs4752805	chr11:48018355	A/G	cg15704280	chr7:45808275	SEPT13	0.64	9.07	0.4	4.46e-18	Intraocular pressure;
LUAD	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.8	-0.31	3.48e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.42	6.97	0.32	1.21e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9486719	1.000	rs12213426	chr6:96896035	T/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.01	-0.44	2.63e-21	Migraine;Coronary artery disease;
LUAD	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg00666640	chr1:248458726	OR2T12	0.3	7.24	0.33	2.14e-12	Common traits (Other);
LUAD	cis	rs28595532	1.000	rs56000725	chr4:119637675	G/A	cg21605333	chr4:119757512	SEC24D	0.86	7.93	0.36	2e-14	Cannabis dependence symptom count;
LUAD	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg22875332	chr1:76189707	ACADM	0.84	16.83	0.63	4.9e-49	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg26441486	chr22:50317300	CRELD2	0.44	6.53	0.3	1.89e-10	Schizophrenia;
LUAD	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg00933542	chr6:150070202	PCMT1	0.44	9.42	0.42	3.08e-19	Lung cancer;
LUAD	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg25324976	chr17:61989376	CSHL1	0.38	7.31	0.33	1.34e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg17644776	chr2:200775616	C2orf69	0.44	6.96	0.32	1.26e-11	Osteoporosis;
LUAD	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg05283184	chr6:79620031	NA	-0.61	-12.41	-0.52	2.32e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg03037974	chr15:76606532	NA	-0.38	-8.01	-0.36	1.15e-14	Blood metabolite levels;
LUAD	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg03676636	chr4:99064102	C4orf37	0.29	6.96	0.32	1.3e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.74	13.36	0.54	3.21e-34	Axial length;
LUAD	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg09184832	chr6:79620586	NA	-0.51	-9.62	-0.42	5.91e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs13031619	0.607	rs13001751	chr2:3695870	A/G	cg25251562	chr2:3704773	ALLC	-0.41	-7.21	-0.33	2.61e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.16	15.35	0.6	1.32e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg27211696	chr2:191398769	TMEM194B	-0.67	-9.06	-0.4	4.99e-18	Diastolic blood pressure;
LUAD	trans	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg06606381	chr12:133084897	FBRSL1	-0.66	-6.99	-0.32	1.09e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg24562669	chr7:97807699	LMTK2	0.29	6.96	0.32	1.29e-11	Breast cancer;
LUAD	cis	rs7027203	0.759	rs10761282	chr9:96586175	G/A	cg14396892	chr9:96623032	NA	-0.39	-7.5	-0.34	3.87e-13	DNA methylation (variation);
LUAD	cis	rs10129255	0.500	rs6576226	chr14:107186374	G/A	cg07958169	chr14:107095056	NA	-0.37	-7.35	-0.34	1.03e-12	Kawasaki disease;
LUAD	cis	rs11167764	0.945	rs7720832	chr5:141473097	T/G	cg08523384	chr5:141488047	NDFIP1	-0.47	-7.17	-0.33	3.41e-12	Crohn's disease;
LUAD	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg22705602	chr4:152727874	NA	-0.44	-8.27	-0.37	1.8e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg23281280	chr6:28129359	ZNF389	-0.46	-6.7	-0.31	6.59e-11	Depression;
LUAD	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg12193833	chr17:30244370	NA	-0.57	-6.89	-0.32	2e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg13902645	chr11:5959945	NA	-0.56	-10.43	-0.45	8.14e-23	DNA methylation (variation);
LUAD	trans	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg18187862	chr3:45730750	SACM1L	0.58	9.14	0.41	2.71e-18	Primary sclerosing cholangitis;
LUAD	cis	rs7000551	0.715	rs1879792	chr8:22314029	C/A	cg12081754	chr8:22256438	SLC39A14	0.43	7.15	0.33	3.89e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02359409	chr6:42947317	PEX6	-0.37	-6.52	-0.3	2.03e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.79	-0.31	3.84e-11	Height;
LUAD	cis	rs11696501	0.688	rs6073854	chr20:44309605	A/G	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.32	-0.38	1.22e-15	Brain structure;
LUAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg01448562	chr3:133502909	NA	-0.66	-12.15	-0.51	2.41e-29	Iron status biomarkers;
LUAD	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg23982607	chr1:1823379	GNB1	-0.89	-18.21	-0.66	4.1e-55	Body mass index;
LUAD	cis	rs62238980	0.614	rs78078590	chr22:32370487	G/A	cg00543991	chr22:32367038	NA	0.91	8.21	0.37	2.8e-15	Childhood ear infection;
LUAD	cis	rs4523957	0.583	rs8068508	chr17:2047624	A/G	cg16513277	chr17:2031491	SMG6	-0.98	-19.64	-0.69	1.65e-61	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg18404041	chr3:52824283	ITIH1	0.38	7.3	0.33	1.46e-12	Electroencephalogram traits;
LUAD	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.13	0.33	4.42e-12	Menopause (age at onset);
LUAD	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg14500267	chr11:67383377	NA	0.37	6.64	0.31	9.42e-11	Mean corpuscular volume;
LUAD	cis	rs1232027	0.656	rs1650653	chr5:79965257	A/G	cg24059623	chr5:79951536	MSH3;DHFR	0.45	7.35	0.34	1.05e-12	Huntington's disease progression;
LUAD	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg08085267	chr17:45401833	C17orf57	-0.54	-9.41	-0.42	3.28e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12541635	0.833	rs4734130	chr8:107096458	A/G	cg10147462	chr8:107024639	NA	-0.4	-7.07	-0.33	6.38e-12	Age of smoking initiation;
LUAD	cis	rs701145	1.000	rs701145	chr3:154054799	T/C	cg17054900	chr3:154042577	DHX36	0.64	7.1	0.33	5.21e-12	Coronary artery disease;
LUAD	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg05132306	chr1:1846340	CALML6	-0.35	-7.4	-0.34	7.19e-13	Body mass index;
LUAD	cis	rs524023	0.914	rs4930556	chr11:64377726	G/C	cg19131476	chr11:64387923	NRXN2	-0.41	-8.15	-0.37	4.28e-15	Urate levels in obese individuals;
LUAD	cis	rs7932354	0.528	rs11039074	chr11:47081732	C/T	cg19486271	chr11:47235900	DDB2	-0.44	-6.96	-0.32	1.27e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg26513180	chr16:89883248	FANCA	0.68	12.74	0.53	1.08e-31	Vitiligo;
LUAD	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg09835421	chr16:68378352	PRMT7	-0.82	-8.61	-0.39	1.42e-16	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg14343924	chr8:8086146	FLJ10661	-0.46	-7.26	-0.33	1.83e-12	Neuroticism;
LUAD	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg20891283	chr12:69753455	YEATS4	0.44	7.29	0.33	1.58e-12	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg22532475	chr10:104410764	TRIM8	-0.43	-8.53	-0.38	2.67e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs11640533	0.901	rs2908790	chr16:53412161	T/C	cg10144400	chr16:53407678	NA	0.42	7.18	0.33	3.2e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07157834	chr1:205819609	PM20D1	0.55	9.84	0.43	1.04e-20	Menarche (age at onset);
LUAD	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg18180107	chr4:99064573	C4orf37	0.4	6.48	0.3	2.6200000000000003e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg21138405	chr5:131827807	IRF1	0.6	13.77	0.56	6.51e-36	Asthma (sex interaction);
LUAD	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg12062639	chr20:23401060	NAPB	-1.01	-10.62	-0.46	1.62e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19717773	chr7:2847554	GNA12	-0.55	-9.44	-0.42	2.48e-19	Height;
LUAD	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg15448220	chr1:150897856	SETDB1	0.56	9.71	0.43	2.99e-20	Melanoma;
LUAD	cis	rs727505	0.721	rs67277928	chr7:124776704	G/T	cg23710748	chr7:124431027	NA	-0.36	-7.58	-0.35	2.18e-13	Lewy body disease;
LUAD	cis	rs6665290	0.868	rs2183836	chr1:227199404	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.2	-34.04	-0.86	3.3e-123	Myeloid white cell count;
LUAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg00280220	chr17:61926910	NA	0.37	7.06	0.32	7.05e-12	Prudent dietary pattern;
LUAD	cis	rs6087990	0.806	rs4911254	chr20:31357579	C/A	cg13636640	chr20:31349939	DNMT3B	0.82	15.53	0.6	2.41e-43	Ulcerative colitis;
LUAD	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.56	7.92	0.36	2.14e-14	Platelet count;
LUAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg11062466	chr8:58055876	NA	0.67	8.82	0.39	3.01e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs68170813	0.652	rs74374590	chr7:107172470	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-9.09	-0.4	3.86e-18	Coronary artery disease;
LUAD	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg13902645	chr11:5959945	NA	-0.49	-8.29	-0.37	1.51e-15	DNA methylation (variation);
LUAD	trans	rs11039798	0.925	rs12277669	chr11:48925316	A/T	cg03929089	chr4:120376271	NA	0.59	6.79	0.31	3.9e-11	Axial length;
LUAD	cis	rs698833	0.798	rs1067391	chr2:44639434	T/G	cg04920474	chr2:44395004	PPM1B	0.42	7.5	0.34	3.88e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	trans	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg03886242	chr7:26192032	NFE2L3	0.45	7.82	0.36	4.2e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1997103	0.871	rs1997101	chr7:55399652	A/T	cg17469321	chr7:55412551	NA	0.67	11.41	0.49	1.73e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.37	0.34	9.32e-13	Breast cancer;
LUAD	trans	rs9329221	0.509	rs3088186	chr8:10226355	C/T	cg14343924	chr8:8086146	FLJ10661	0.46	6.7	0.31	6.82e-11	Neuroticism;
LUAD	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg09904177	chr6:26538194	HMGN4	0.42	6.73	0.31	5.51e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	9.44	0.42	2.51e-19	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg08885076	chr2:99613938	TSGA10	0.37	6.77	0.31	4.38e-11	Chronic sinus infection;
LUAD	cis	rs12618769	0.597	rs3754886	chr2:99107677	A/G	cg10123293	chr2:99228465	UNC50	0.46	8.12	0.37	5.1e-15	Bipolar disorder;
LUAD	cis	rs4853036	0.723	rs3732268	chr2:70046262	G/A	cg02498382	chr2:70120550	SNRNP27	-0.5	-7.16	-0.33	3.55e-12	Colorectal or endometrial cancer;
LUAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08677398	chr8:58056175	NA	0.45	6.45	0.3	3.07e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.08	-0.33	6.15e-12	Blood metabolite levels;
LUAD	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.72	-13.23	-0.54	1.17e-33	Menarche (age at onset);
LUAD	cis	rs4700695	0.698	rs416369	chr5:65231058	C/T	cg21114390	chr5:65439923	SFRS12	0.63	8.36	0.38	8.96e-16	Facial morphology (factor 19);
LUAD	cis	rs7084921	0.579	rs11596253	chr10:101849411	C/A	cg19754520	chr10:101825118	CPN1	-0.36	-7.25	-0.33	2.01e-12	Bone mineral density;
LUAD	cis	rs7760535	0.597	rs9320368	chr6:111904737	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.36	-6.46	-0.3	2.8e-10	Metabolic traits;
LUAD	cis	rs59698941	0.943	rs67160603	chr5:132285618	G/C	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg16145915	chr7:1198662	ZFAND2A	0.42	7.49	0.34	4.13e-13	Longevity;Endometriosis;
LUAD	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg15123519	chr2:136567270	LCT	0.39	7.25	0.33	1.93e-12	Mosquito bite size;
LUAD	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg17747265	chr1:1875780	NA	0.75	18.77	0.67	1.24e-57	Body mass index;
LUAD	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg25452165	chr22:42524984	CYP2D6	0.39	6.42	0.3	3.77e-10	Schizophrenia;
LUAD	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg05340658	chr4:99064831	C4orf37	0.42	6.92	0.32	1.73e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.76	0.31	4.64e-11	Depression;
LUAD	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg10053473	chr17:62856997	LRRC37A3	0.79	11.2	0.48	1.1e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg24733560	chr20:60626293	TAF4	0.4	7.74	0.35	7.45e-14	Body mass index;
LUAD	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-15.1	-0.59	1.61e-41	Chronic sinus infection;
LUAD	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg02782426	chr3:40428986	ENTPD3	0.35	7.56	0.35	2.49e-13	Renal cell carcinoma;
LUAD	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.69	-11.08	-0.47	3.14e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg11901034	chr3:128598214	ACAD9	-0.5	-7.62	-0.35	1.65e-13	IgG glycosylation;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12679980	chr5:43557583	PAIP1	-0.53	-6.4	-0.3	4.08e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg02269571	chr22:50332266	NA	-1.07	-10.98	-0.47	7.82e-25	Acne (severe);
LUAD	cis	rs16866061	1.000	rs10933068	chr2:225418360	G/A	cg12698349	chr2:225449008	CUL3	0.78	13.83	0.56	3.78e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg06092702	chr1:163392909	NA	-0.39	-8.55	-0.38	2.3e-16	Motion sickness;
LUAD	cis	rs3087591	0.960	rs2905872	chr17:29525027	C/A	cg24425628	chr17:29625626	OMG;NF1	0.4	6.51	0.3	2.14e-10	Hip circumference;
LUAD	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg17105886	chr17:28927953	LRRC37B2	0.84	7.75	0.35	6.72e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.79	-0.35	5.18e-14	Blood metabolite levels;
LUAD	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg08645402	chr16:4508243	NA	-0.52	-9.02	-0.4	6.5e-18	Schizophrenia;
LUAD	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg08885076	chr2:99613938	TSGA10	0.4	7.49	0.34	4.15e-13	Chronic sinus infection;
LUAD	cis	rs28374715	0.562	rs8036686	chr15:41550333	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.6	-10.89	-0.47	1.61e-24	Ulcerative colitis;
LUAD	cis	rs10419226	0.555	rs876982	chr19:18782377	C/T	cg22001208	chr19:18782374	NA	0.49	8.51	0.38	2.95e-16	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg26924012	chr15:45694286	SPATA5L1	1.02	18.92	0.68	2.86e-58	Homoarginine levels;
LUAD	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg23260525	chr10:116636907	FAM160B1	0.47	11.0	0.47	6.26e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs8067287	0.696	rs62065422	chr17:16828570	G/A	cg26910001	chr17:16838321	NA	-0.49	-6.9	-0.32	1.91e-11	Diabetic kidney disease;
LUAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00166722	chr3:10149974	C3orf24	0.64	9.76	0.43	1.92e-20	Alzheimer's disease;
LUAD	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg16479474	chr6:28041457	NA	0.44	7.4	0.34	7.22e-13	Depression;
LUAD	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg11645453	chr3:52864694	ITIH4	0.37	7.03	0.32	8.45e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg06917634	chr15:78832804	PSMA4	-0.39	-6.7	-0.31	6.74e-11	Sudden cardiac arrest;
LUAD	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg05340658	chr4:99064831	C4orf37	0.54	8.71	0.39	6.8e-17	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg07211511	chr3:129823064	LOC729375	-0.87	-10.58	-0.46	2.2e-23	Blood pressure (smoking interaction);
LUAD	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	21.77	0.73	4.91e-71	Chronic sinus infection;
LUAD	cis	rs1003719	0.762	rs8130846	chr21:38480242	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.5	0.38	3.25e-16	Eye color traits;
LUAD	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg24675056	chr1:15929824	NA	0.49	8.5	0.38	3.39e-16	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17401966	0.894	rs11587309	chr1:10446596	G/T	cg19773385	chr1:10388646	KIF1B	-0.41	-6.67	-0.31	7.97e-11	Hepatocellular carcinoma;
LUAD	cis	rs12681287	0.640	rs13282351	chr8:87484669	C/T	cg27223183	chr8:87520930	FAM82B	-0.67	-9.61	-0.42	6.38e-20	Caudate activity during reward;
LUAD	cis	rs3806843	0.898	rs3756335	chr5:140213510	A/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.86	-0.32	2.53e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs151234	0.800	rs231972	chr16:28538336	A/C	cg04609801	chr16:28609176	SULT1A2	0.55	7.35	0.34	1e-12	Platelet distribution width;
LUAD	cis	rs2742234	0.910	rs2505513	chr10:43633537	C/G	cg15436174	chr10:43711423	RASGEF1A	-0.44	-7.94	-0.36	1.9e-14	Hirschsprung disease;
LUAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.71e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.05	0.36	8.46e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2235649	0.552	rs8056773	chr16:1959432	G/A	cg08610935	chr16:1836813	NUBP2	-0.51	-7.39	-0.34	7.83e-13	Blood metabolite levels;
LUAD	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg26924012	chr15:45694286	SPATA5L1	1.0	17.71	0.65	6.74e-53	Homoarginine levels;
LUAD	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg12927641	chr6:109611667	NA	-0.48	-8.08	-0.37	6.64e-15	Reticulocyte fraction of red cells;
LUAD	cis	rs17641971	0.662	rs13268440	chr8:50000873	C/T	cg00325661	chr8:49890786	NA	0.3	6.67	0.31	7.87e-11	Blood metabolite levels;
LUAD	cis	rs11696501	0.739	rs978778	chr20:44243376	C/A	cg11783356	chr20:44313418	WFDC10B	-0.49	-7.14	-0.33	4.1e-12	Brain structure;
LUAD	cis	rs7289126	1.000	rs4820328	chr22:38635679	C/T	cg25457927	chr22:38595422	NA	-0.42	-9.98	-0.44	3.29e-21	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg23985595	chr17:80112537	CCDC57	0.52	9.49	0.42	1.73e-19	Life satisfaction;
LUAD	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg09127314	chr1:152161683	NA	0.39	6.5	0.3	2.23e-10	Inflammatory skin disease;
LUAD	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg16102102	chr5:83017553	HAPLN1	-0.77	-13.31	-0.54	5.25e-34	Prostate cancer;
LUAD	cis	rs12079745	0.793	rs11806445	chr1:169219029	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-1.1	-8.06	-0.36	7.95e-15	QT interval;
LUAD	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg17264618	chr3:40429014	ENTPD3	0.38	7.93	0.36	2.04e-14	Renal cell carcinoma;
LUAD	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.97	-0.32	1.19e-11	Type 2 diabetes;
LUAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg10802521	chr3:52805072	NEK4	-0.46	-7.57	-0.35	2.35e-13	Electroencephalogram traits;
LUAD	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-20.62	-0.71	7.09e-66	Height;
LUAD	cis	rs12618769	0.652	rs72823788	chr2:99213080	C/T	cg10123293	chr2:99228465	UNC50	0.5	8.54	0.38	2.53e-16	Bipolar disorder;
LUAD	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03517284	chr6:25882590	NA	-0.4	-6.55	-0.3	1.67e-10	Height;
LUAD	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg20476274	chr7:133979776	SLC35B4	0.83	16.23	0.62	2.15e-46	Mean platelet volume;
LUAD	cis	rs6446731	0.614	rs6446727	chr4:3274488	T/A	cg08886695	chr4:3369023	RGS12	-0.5	-8.35	-0.38	9.91e-16	Mean platelet volume;
LUAD	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg21951975	chr1:209979733	IRF6	0.55	7.19	0.33	3.03e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg07217954	chr7:1067459	C7orf50	0.46	7.16	0.33	3.62e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6596100	0.500	rs58840150	chr5:132248041	A/G	cg14825688	chr5:132208181	LEAP2	-0.47	-6.41	-0.3	3.91e-10	Breast cancer;
LUAD	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg03806693	chr22:41940476	POLR3H	0.69	9.84	0.43	1.08e-20	Vitiligo;
LUAD	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg14364472	chr9:139394549	NOTCH1	-0.44	-6.6	-0.31	1.22e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg25894440	chr7:65020034	NA	0.63	6.74	0.31	5.21e-11	Diabetic kidney disease;
LUAD	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg05283184	chr6:79620031	NA	-0.62	-12.47	-0.52	1.34e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg04155289	chr7:94953770	PON1	-0.52	-6.89	-0.32	1.99e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3764563	0.660	rs8107923	chr19:15737899	A/T	cg20725493	chr19:15740067	CYP4F8	-0.72	-7.99	-0.36	1.34e-14	Inflammatory biomarkers;
LUAD	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg06108461	chr20:60628389	TAF4	-1.0	-18.38	-0.67	7.16e-56	Body mass index;
LUAD	cis	rs1395	1.000	rs4665958	chr2:27443196	A/G	cg23587288	chr2:27483067	SLC30A3	-0.38	-7.66	-0.35	1.32e-13	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.24	-0.37	2.22e-15	Prostate cancer;
LUAD	cis	rs2839627	0.561	rs7281655	chr21:44269743	A/G	cg03543861	chr21:44258195	NA	0.65	9.4	0.42	3.45e-19	Information processing speed;
LUAD	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg25894440	chr7:65020034	NA	-0.63	-6.7	-0.31	6.86e-11	Diabetic kidney disease;
LUAD	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.79	-15.26	-0.6	3.36e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs669446	0.562	rs6429636	chr1:44183540	G/T	cg12908607	chr1:44402522	ARTN	-0.36	-7.15	-0.33	3.9e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg02569458	chr12:86230093	RASSF9	0.44	8.09	0.37	6.46e-15	Major depressive disorder;
LUAD	trans	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	25.53	0.78	1.11e-87	Colorectal cancer;
LUAD	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg13180566	chr4:1052158	NA	-0.4	-6.77	-0.31	4.25e-11	Recombination rate (females);
LUAD	cis	rs6138458	1.000	rs2387361	chr20:24899905	C/T	cg06937882	chr20:24974362	C20orf3	0.34	6.51	0.3	2.16e-10	Blood protein levels;
LUAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg11766577	chr21:47581405	C21orf56	-0.42	-6.86	-0.32	2.47e-11	Testicular germ cell tumor;
LUAD	trans	rs12517041	1.000	rs6868335	chr5:23316641	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.44	-6.42	-0.3	3.61e-10	Calcium levels;
LUAD	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg04450456	chr4:17643702	FAM184B	0.42	8.23	0.37	2.38e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7539409	0.833	rs2057083	chr1:84269942	T/G	cg10977910	chr1:84465055	TTLL7	0.69	6.89	0.32	1.97e-11	Alzheimer's disease;
LUAD	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg26384229	chr12:38710491	ALG10B	0.42	6.89	0.32	2.04e-11	Morning vs. evening chronotype;
LUAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg21724239	chr8:58056113	NA	0.8	10.06	0.44	1.67e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg16342193	chr10:102329863	NA	0.36	6.4	0.3	4.02e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1018836	0.632	rs6995399	chr8:91481629	T/C	cg16814680	chr8:91681699	NA	-0.66	-11.01	-0.47	5.97e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4072705	0.615	rs6478666	chr9:127249343	C/G	cg13476313	chr9:127244764	NR5A1	-0.37	-9.01	-0.4	7.4e-18	Menarche (age at onset);
LUAD	cis	rs494562	0.730	rs313204	chr6:86114296	C/A	cg17966619	chr6:86160162	NT5E	0.61	7.88	0.36	2.79e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg23719950	chr11:63933701	MACROD1	-0.58	-6.87	-0.32	2.32e-11	Mean platelet volume;
LUAD	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg02951883	chr7:2050386	MAD1L1	-0.83	-15.38	-0.6	1.01e-42	Bipolar disorder and schizophrenia;
LUAD	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01570182	chr17:44337453	NA	0.77	12.44	0.52	1.69e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-10.93	-0.47	1.15e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.62	-12.88	-0.53	2.92e-32	Hemoglobin concentration;
LUAD	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	cis	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg21775007	chr8:11205619	TDH	0.55	9.87	0.43	8.13e-21	Retinal vascular caliber;
LUAD	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg25324976	chr17:61989376	CSHL1	0.37	7.17	0.33	3.28e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs853679	1.000	rs853685	chr6:28288785	C/T	cg01620082	chr3:125678407	NA	-0.54	-7.12	-0.33	4.61e-12	Depression;
LUAD	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg18944383	chr4:111397179	ENPEP	0.34	6.7	0.31	6.75e-11	Coronary artery disease;
LUAD	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11890956	chr21:40555474	PSMG1	0.76	12.8	0.53	6.02e-32	Cognitive function;
LUAD	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08704250	chr15:31115839	NA	0.71	13.04	0.54	6.42e-33	Huntington's disease progression;
LUAD	cis	rs61897795	0.628	rs174579	chr11:61605613	C/T	cg11250194	chr11:61601937	FADS2	-0.46	-6.66	-0.31	8.64e-11	Neutrophil count;Sum basophil neutrophil counts;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12311644	chr22:31687046	PIK3IP1	-0.43	-6.63	-0.31	1e-10	Height;
LUAD	cis	rs62238980	0.521	rs733907	chr22:32462564	T/C	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs7177699	0.557	rs4073322	chr15:79122541	G/C	cg00540400	chr15:79124168	NA	0.45	9.77	0.43	1.78e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg03388025	chr16:89894329	SPIRE2	0.51	13.31	0.54	5.05e-34	Vitiligo;
LUAD	cis	rs2274471	0.699	rs73395341	chr9:5085549	A/G	cg03390472	chr9:5043263	JAK2	-0.55	-7.75	-0.35	6.67e-14	Crohn's disease;
LUAD	trans	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg02002194	chr4:3960332	NA	-0.32	-7.44	-0.34	5.76e-13	Mood instability;
LUAD	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22857025	chr5:266934	NA	-0.97	-14.47	-0.58	7.55e-39	Breast cancer;
LUAD	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg20703242	chr1:230279135	GALNT2	0.68	12.47	0.52	1.29e-30	Coronary artery disease;
LUAD	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg06784218	chr1:46089804	CCDC17	0.54	11.65	0.49	2.11e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg25237894	chr2:233734115	C2orf82	-0.61	-11.43	-0.49	1.48e-26	Coronary artery disease;
LUAD	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg06623918	chr6:96969491	KIAA0776	-0.7	-9.59	-0.42	7.63e-20	Migraine;Coronary artery disease;
LUAD	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg01528321	chr10:82214614	TSPAN14	-0.55	-8.44	-0.38	4.92e-16	Post bronchodilator FEV1;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02942142	chr4:169401797	DDX60L	-0.39	-6.42	-0.3	3.58e-10	Cancer;
LUAD	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg00717180	chr2:96193071	NA	-0.42	-7.74	-0.35	7.48e-14	HDL cholesterol;
LUAD	cis	rs6714710	0.580	rs35564270	chr2:98602165	A/G	cg26665480	chr2:98280029	ACTR1B	0.5	8.16	0.37	3.85e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg25237894	chr2:233734115	C2orf82	-0.48	-8.94	-0.4	1.24e-17	Coronary artery disease;
LUAD	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-18.63	-0.67	5.56e-57	Height;
LUAD	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.87	-0.36	3.07e-14	Diabetic kidney disease;
LUAD	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg01579765	chr21:45077557	HSF2BP	0.65	15.03	0.59	3.14e-41	Mean corpuscular volume;
LUAD	cis	rs713477	0.967	rs8009706	chr14:55914756	A/G	cg13175173	chr14:55914753	NA	-0.35	-7.4	-0.34	7.41e-13	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg03983476	chr2:10830698	NOL10	-0.45	-7.87	-0.36	3.08e-14	Prostate cancer;
LUAD	trans	rs2262909	0.962	rs2017521	chr19:22126138	T/C	cg05197062	chr11:11642011	GALNTL4	-0.54	-8.34	-0.38	1.05e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs68170813	0.559	rs12533767	chr7:106860245	A/C	cg23024343	chr7:107201750	COG5	0.49	7.08	0.33	5.96e-12	Coronary artery disease;
LUAD	cis	rs61897795	0.628	rs93923	chr11:61613745	C/T	cg21709803	chr11:61594965	FADS2	-0.45	-6.95	-0.32	1.42e-11	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-6.46	-0.3	2.89e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg23172400	chr8:95962367	TP53INP1	-0.34	-8.03	-0.36	9.96e-15	Type 2 diabetes;
LUAD	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg20673091	chr1:2541236	MMEL1	0.39	8.42	0.38	6.1e-16	Ulcerative colitis;
LUAD	cis	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.58	6.51	0.3	2.19e-10	Schizophrenia;
LUAD	cis	rs9863	0.861	rs10846580	chr12:124415453	T/C	cg17723958	chr12:124429295	CCDC92	-0.4	-6.37	-0.3	4.94e-10	White blood cell count;
LUAD	cis	rs2274273	0.840	rs943590	chr14:55738596	T/C	cg04306507	chr14:55594613	LGALS3	0.42	8.87	0.4	2.14e-17	Protein biomarker;
LUAD	cis	rs739496	0.615	rs634389	chr12:112164715	C/G	cg10833066	chr12:111807467	FAM109A	0.42	6.76	0.31	4.46e-11	Platelet count;
LUAD	trans	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg06606381	chr12:133084897	FBRSL1	-0.87	-9.18	-0.41	1.88e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg09455208	chr3:40491958	NA	-0.54	-11.91	-0.5	2.09e-28	Renal cell carcinoma;
LUAD	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg07936489	chr17:37558343	FBXL20	-0.48	-7.57	-0.35	2.31e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs367615	0.506	rs2963021	chr5:108800365	C/T	cg17395555	chr5:108820864	NA	0.62	13.43	0.55	1.61e-34	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg18099408	chr3:52552593	STAB1	-0.46	-8.32	-0.38	1.22e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.27e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13064411	0.696	rs9839921	chr3:113199093	G/C	cg10517650	chr3:113235015	CCDC52	-0.56	-9.72	-0.43	2.67e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs977987	0.624	rs59867374	chr16:75432682	G/A	cg03315344	chr16:75512273	CHST6	0.64	14.08	0.56	3.36e-37	Dupuytren's disease;
LUAD	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.57	0.42	9.27e-20	Menarche (age at onset);
LUAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg12419862	chr22:24373484	LOC391322	0.59	8.83	0.39	2.76e-17	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg20607798	chr8:58055168	NA	0.58	7.41	0.34	6.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg18016565	chr1:150552671	MCL1	0.41	7.58	0.35	2.14e-13	Tonsillectomy;
LUAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14893161	chr1:205819251	PM20D1	0.48	8.07	0.37	7.1e-15	Parkinson's disease;
LUAD	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg22532475	chr10:104410764	TRIM8	0.36	7.27	0.33	1.71e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg26924012	chr15:45694286	SPATA5L1	1.02	19.06	0.68	6.2e-59	Homoarginine levels;
LUAD	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg06641503	chr3:48959341	ARIH2	-0.35	-6.5	-0.3	2.3e-10	Menarche (age at onset);
LUAD	cis	rs7786808	0.530	rs6459875	chr7:158186141	C/T	cg01191920	chr7:158217561	PTPRN2	0.58	11.73	0.5	1.07e-27	Obesity-related traits;
LUAD	cis	rs13082711	0.863	rs13062327	chr3:27495573	G/A	cg02860705	chr3:27208620	NA	0.57	8.83	0.39	2.84e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg13319975	chr6:146136371	FBXO30	-0.59	-9.99	-0.44	2.95e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.51e-10	Prudent dietary pattern;
LUAD	trans	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg14917512	chr19:3094685	GNA11	-0.57	-6.65	-0.31	8.96e-11	Diabetic kidney disease;
LUAD	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg18306943	chr3:40428807	ENTPD3	-0.38	-6.53	-0.3	1.92e-10	Renal cell carcinoma;
LUAD	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg22906224	chr7:99728672	NA	0.53	8.57	0.38	1.91e-16	Coronary artery disease;
LUAD	cis	rs6484504	0.600	rs942272	chr11:31364368	C/T	cg26647111	chr11:31128758	NA	0.45	7.84	0.36	3.6e-14	Red blood cell count;
LUAD	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.13e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11167764	0.895	rs6882824	chr5:141474300	A/G	cg23435118	chr5:141488016	NDFIP1	-0.48	-7.21	-0.33	2.59e-12	Crohn's disease;
LUAD	trans	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg27411982	chr8:10470053	RP1L1	0.43	7.57	0.35	2.29e-13	Mood instability;
LUAD	trans	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.68	-0.39	8.93e-17	Endometrial cancer;
LUAD	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg04586622	chr2:25135609	ADCY3	0.37	8.54	0.38	2.43e-16	Body mass index;
LUAD	cis	rs7786808	0.508	rs896765	chr7:158182809	G/A	cg01191920	chr7:158217561	PTPRN2	0.56	11.27	0.48	6.09e-26	Obesity-related traits;
LUAD	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	7.65	0.35	1.41e-13	Rheumatoid arthritis;
LUAD	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg11502198	chr6:26597334	ABT1	0.68	11.78	0.5	6.88e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg11965913	chr1:205819406	PM20D1	0.82	17.21	0.64	1.12e-50	Menarche (age at onset);
LUAD	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-7.97	-0.36	1.53e-14	Myeloid white cell count;
LUAD	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.72	-0.31	5.79e-11	Bladder cancer;
LUAD	cis	rs2637266	0.783	rs864676	chr10:78509385	A/G	cg18941641	chr10:78392320	NA	0.31	6.39	0.3	4.29e-10	Pulmonary function;
LUAD	cis	rs12545109	0.800	rs2582401	chr8:57401656	A/G	cg21220214	chr8:57350948	NA	-0.63	-8.73	-0.39	5.9e-17	Obesity-related traits;
LUAD	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg15128208	chr22:42549153	NA	0.37	7.55	0.34	2.71e-13	Cognitive function;
LUAD	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg24690094	chr11:67383802	NA	0.4	7.12	0.33	4.63e-12	Mean corpuscular volume;
LUAD	trans	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg18187862	chr3:45730750	SACM1L	-0.54	-8.84	-0.39	2.54e-17	Primary sclerosing cholangitis;
LUAD	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg23533926	chr12:111358616	MYL2	-0.41	-7.01	-0.32	9.73e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg00666640	chr1:248458726	OR2T12	0.31	7.47	0.34	4.75e-13	Common traits (Other);
LUAD	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg15704280	chr7:45808275	SEPT13	0.63	8.08	0.37	6.77e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2050392	0.894	rs2480277	chr10:30703513	G/T	cg18806716	chr10:30721971	MAP3K8	0.5	10.07	0.44	1.57e-21	Inflammatory bowel disease;
LUAD	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-7.38	-0.34	8.37e-13	Total cholesterol levels;
LUAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg04025307	chr7:1156635	C7orf50	0.76	10.19	0.44	6.06e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg14917512	chr19:3094685	GNA11	-0.37	-6.45	-0.3	2.97e-10	Aortic root size;
LUAD	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg02421172	chr7:1938701	MAD1L1	0.47	6.74	0.31	5.05e-11	Bipolar disorder;
LUAD	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg15664640	chr17:80829946	TBCD	0.51	9.72	0.43	2.63e-20	Breast cancer;
LUAD	trans	rs4131805	0.594	rs8091116	chr18:26097809	G/A	cg26154937	chr10:49674883	ARHGAP22	0.3	6.46	0.3	2.92e-10	Hip geometry;
LUAD	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.43	-8.28	-0.37	1.58e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg06671706	chr8:8559999	CLDN23	0.6	10.33	0.45	1.82e-22	Obesity-related traits;
LUAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg05434287	chr7:2030229	MAD1L1	0.42	7.08	0.33	6.22e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs12210905	0.688	rs72841399	chr6:27489832	T/G	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	trans	rs7246760	0.867	rs16981648	chr19:9804424	A/C	cg02900749	chr2:68251473	NA	-0.58	-6.63	-0.31	1.04e-10	Pursuit maintenance gain;
LUAD	trans	rs9354308	0.868	rs9453450	chr6:66545431	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.87	-0.32	2.3e-11	Metabolite levels;
LUAD	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21659725	chr3:3221576	CRBN	0.87	18.73	0.67	1.97e-57	Intelligence (multi-trait analysis);
LUAD	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg05697835	chr1:2722811	NA	0.31	6.49	0.3	2.37e-10	Multiple sclerosis;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg12114392	chr11:77899896	KCTD21;USP35	-0.69	-6.66	-0.31	8.68e-11	Type 2 diabetes;
LUAD	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg09359103	chr1:154839909	KCNN3	-0.9	-20.49	-0.71	2.53e-65	Prostate cancer;
LUAD	cis	rs9863	0.896	rs12824567	chr12:124495203	G/C	cg17723958	chr12:124429295	CCDC92	-0.41	-6.77	-0.31	4.29e-11	White blood cell count;
LUAD	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg16989719	chr2:238392110	NA	-0.38	-8.11	-0.37	5.66e-15	Prostate cancer;
LUAD	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg12311346	chr5:56204834	C5orf35	-0.92	-13.36	-0.54	3.34e-34	Initial pursuit acceleration;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg26567249	chr8:97247842	UQCRB	-0.39	-6.71	-0.31	6.38e-11	Subcortical brain region volumes;
LUAD	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg16647868	chr5:131706066	SLC22A5	0.51	8.13	0.37	4.78e-15	Acylcarnitine levels;
LUAD	cis	rs12620999	0.878	rs7593514	chr2:237980691	A/G	cg23555395	chr2:238036564	NA	0.55	8.46	0.38	4.35e-16	Systemic lupus erythematosus;
LUAD	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg14668632	chr7:2872130	GNA12	-0.73	-13.5	-0.55	8.3e-35	Height;
LUAD	cis	rs892961	0.932	rs7216116	chr17:75405078	C/T	cg05865280	chr17:75406074	SEPT9	0.63	18.92	0.68	2.64e-58	Airflow obstruction;
LUAD	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg12458913	chr13:53173898	NA	0.38	6.8	0.31	3.61e-11	Lewy body disease;
LUAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03452623	chr4:187889614	NA	-0.82	-16.71	-0.63	1.74e-48	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs77861329	1.000	rs28659792	chr3:52107966	G/C	cg08692210	chr3:52188851	WDR51A	0.79	6.39	0.3	4.42e-10	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg13319975	chr6:146136371	FBXO30	-0.66	-11.43	-0.49	1.44e-26	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26561342	chr1:45241260	SNORD55;RPS8;SNORD46	-0.53	-6.38	-0.3	4.57e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg11859384	chr17:80120422	CCDC57	-0.47	-8.42	-0.38	6.01e-16	Life satisfaction;
LUAD	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08439880	chr3:133502540	NA	-0.44	-8.55	-0.38	2.24e-16	Iron status biomarkers;
LUAD	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg07570687	chr10:102243282	WNT8B	-0.48	-7.46	-0.34	4.96e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg24920358	chr1:40204285	PPIE	0.7	12.53	0.52	7.23e-31	Blood protein levels;
LUAD	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg07305463	chr2:136567211	LCT	-0.37	-7.1	-0.33	5.47e-12	Mosquito bite size;
LUAD	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg07570687	chr10:102243282	WNT8B	0.43	6.45	0.3	3e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6754311	0.589	rs2011724	chr2:136818006	A/G	cg05194412	chr2:137003533	NA	0.42	6.47	0.3	2.79e-10	Mosquito bite size;
LUAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg19536664	chr17:6899085	ALOX12	-0.56	-11.29	-0.48	5.07e-26	Tonsillectomy;
LUAD	cis	rs7072216	0.763	rs10748730	chr10:100171440	C/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.67	-0.39	9.52e-17	Metabolite levels;
LUAD	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11890956	chr21:40555474	PSMG1	-0.64	-11.28	-0.48	5.53e-26	Cognitive function;
LUAD	cis	rs68170813	0.559	rs2023892	chr7:106847686	C/T	cg23024343	chr7:107201750	COG5	-0.47	-6.87	-0.32	2.33e-11	Coronary artery disease;
LUAD	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.17	-0.33	3.4e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1595825	0.891	rs114426561	chr2:198698891	A/G	cg00361562	chr2:198649771	BOLL	-0.49	-7.08	-0.33	6.03e-12	Ulcerative colitis;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg02010894	chr19:16653629	CHERP	0.41	6.39	0.3	4.35e-10	Diastolic blood pressure;
LUAD	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg00271210	chr6:167070053	RPS6KA2	-0.34	-6.57	-0.3	1.52e-10	Crohn's disease;
LUAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-10.21	-0.44	4.89e-22	Electroencephalogram traits;
LUAD	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18876405	chr7:65276391	NA	-0.43	-6.82	-0.31	3.18e-11	Aortic root size;
LUAD	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg14008862	chr17:28927542	LRRC37B2	0.66	6.42	0.3	3.71e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg16205897	chr5:131564050	P4HA2	-0.3	-6.37	-0.3	5.01e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs9467773	1.000	rs1570059	chr6:26573325	C/T	cg11502198	chr6:26597334	ABT1	0.62	10.14	0.44	8.61e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.55	-0.3	1.67e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.96	0.4	1.02e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg21204522	chr6:27730016	NA	-0.48	-7.59	-0.35	2.08e-13	Parkinson's disease;
LUAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.67	-0.31	8.19e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg23950597	chr19:37808831	NA	-0.64	-7.65	-0.35	1.34e-13	Coronary artery calcification;
LUAD	cis	rs1816752	0.837	rs4769355	chr13:25015197	G/A	cg02811702	chr13:24901961	NA	0.45	7.9	0.36	2.5e-14	Obesity-related traits;
LUAD	cis	rs113835537	0.877	rs77239910	chr11:66329639	G/A	cg24851651	chr11:66362959	CCS	0.59	8.14	0.37	4.38e-15	Airway imaging phenotypes;
LUAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg26354017	chr1:205819088	PM20D1	0.62	11.69	0.49	1.47e-27	Menarche (age at onset);
LUAD	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23583168	chr7:148888333	NA	-0.91	-18.28	-0.66	1.86e-55	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs250677	0.958	rs36078	chr5:148430567	G/A	cg12140854	chr5:148520817	ABLIM3	-0.59	-8.83	-0.39	2.76e-17	Breast cancer;
LUAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg07217954	chr7:1067459	C7orf50	0.43	6.62	0.31	1.06e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg04539111	chr16:67997858	SLC12A4	-0.47	-6.67	-0.31	8.03e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg26384229	chr12:38710491	ALG10B	0.39	6.77	0.31	4.31e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	6.61	0.31	1.18e-10	Neutrophil percentage of white cells;
LUAD	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg14227996	chr4:17616232	MED28	0.7	7.46	0.34	5.01e-13	Opioid sensitivity;
LUAD	cis	rs250585	0.748	rs2106455	chr16:23550938	T/C	cg00143387	chr16:23521605	GGA2	-0.68	-8.1	-0.37	6.11e-15	Egg allergy;
LUAD	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-8.54	-0.38	2.42e-16	Major depressive disorder;
LUAD	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg26408565	chr15:76604113	ETFA	-0.45	-7.31	-0.34	1.31e-12	Blood metabolite levels;
LUAD	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg04756594	chr16:24857601	SLC5A11	-0.53	-10.43	-0.45	8.14e-23	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg03929089	chr4:120376271	NA	-0.51	-8.03	-0.36	9.71e-15	HDL cholesterol;
LUAD	cis	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg07460842	chr6:66804631	NA	0.58	9.34	0.41	5.59e-19	Type 2 diabetes;
LUAD	cis	rs17253792	0.822	rs9323289	chr14:56106784	G/C	cg01858014	chr14:56050164	KTN1	-0.61	-6.38	-0.3	4.79e-10	Putamen volume;
LUAD	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg22166914	chr1:53195759	ZYG11B	0.41	7.32	0.34	1.25e-12	Monocyte count;
LUAD	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg09137382	chr11:130731461	NA	0.44	8.16	0.37	3.81e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23583168	chr7:148888333	NA	-0.93	-19.38	-0.69	2.4e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg27490568	chr2:178487706	NA	0.43	7.22	0.33	2.36e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs72781680	1.000	rs72781689	chr2:24256349	C/T	cg20701182	chr2:24300061	SF3B14	0.69	7.39	0.34	8.16e-13	Lymphocyte counts;
LUAD	cis	rs7737355	0.699	rs7711311	chr5:130781339	G/A	cg25547332	chr5:131281432	NA	-0.43	-7.0	-0.32	9.92e-12	Life satisfaction;
LUAD	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg07917127	chr4:99064746	C4orf37	0.5	8.14	0.37	4.54e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.7	-0.35	1e-13	Bipolar disorder;
LUAD	cis	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg21775007	chr8:11205619	TDH	-0.39	-6.71	-0.31	6.34e-11	Neuroticism;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg02624704	chr1:173446429	PRDX6	-0.39	-6.6	-0.31	1.27e-10	Vertical cup-disc ratio;
LUAD	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg18230493	chr5:56204884	C5orf35	-0.44	-7.43	-0.34	5.92e-13	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg06641503	chr3:48959341	ARIH2	-0.36	-6.75	-0.31	4.79e-11	Menarche (age at onset);
LUAD	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.52	7.0	0.32	1.02e-11	Platelet count;
LUAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg07157834	chr1:205819609	PM20D1	-0.49	-7.96	-0.36	1.65e-14	Parkinson's disease;
LUAD	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg11845111	chr2:191398756	TMEM194B	-0.71	-9.44	-0.42	2.48e-19	Diastolic blood pressure;
LUAD	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg19163074	chr7:65112434	INTS4L2	0.44	6.76	0.31	4.62e-11	Aortic root size;
LUAD	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg10755058	chr3:40428713	ENTPD3	-0.39	-7.62	-0.35	1.73e-13	Renal cell carcinoma;
LUAD	cis	rs8051149	0.688	rs12444533	chr16:87869711	C/T	cg01412419	chr16:87856264	NA	0.47	8.37	0.38	8.58e-16	Blood metabolite levels;
LUAD	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg23992470	chr4:843637	GAK	0.7	7.54	0.34	2.8e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg20933634	chr6:27740509	NA	-0.53	-8.32	-0.37	1.26e-15	Parkinson's disease;
LUAD	cis	rs4372836	0.518	rs12472549	chr2:28992004	T/C	cg09522027	chr2:28974177	PPP1CB	-0.63	-11.02	-0.47	5.32e-25	Body mass index;
LUAD	cis	rs7621025	0.500	rs16844241	chr3:136635171	A/G	cg15507776	chr3:136538369	TMEM22	-0.59	-9.12	-0.41	3.03e-18	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUAD	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14169450	chr9:139327907	INPP5E	0.4	7.28	0.33	1.65e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg16797656	chr11:68205561	LRP5	0.45	8.64	0.39	1.15e-16	Total body bone mineral density;
LUAD	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg03609598	chr5:56110824	MAP3K1	-0.43	-6.74	-0.31	5.21e-11	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08677398	chr8:58056175	NA	0.49	6.94	0.32	1.5e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24519157	chr20:54987662	CASS4	0.38	6.61	0.31	1.19e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg11663144	chr21:46675770	NA	-0.48	-9.21	-0.41	1.56e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7187994	0.836	rs16974519	chr16:84782750	A/C	cg07647771	chr16:84786436	USP10	-0.37	-9.59	-0.42	7.66e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs12545109	0.879	rs1581129	chr8:57377476	T/C	cg11919837	chr8:57350735	NA	-0.49	-6.81	-0.31	3.28e-11	Obesity-related traits;
LUAD	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg05340658	chr4:99064831	C4orf37	0.45	7.36	0.34	9.65e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg01620082	chr3:125678407	NA	-0.88	-8.81	-0.39	3.38e-17	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg03395511	chr6:291903	DUSP22	-0.74	-12.7	-0.53	1.51e-31	Menopause (age at onset);
LUAD	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg15017067	chr4:17643749	FAM184B	0.37	7.45	0.34	5.31e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7527798	0.592	rs10863461	chr1:207840776	C/T	cg09232269	chr1:207846808	CR1L	-0.37	-7.47	-0.34	4.63e-13	Erythrocyte sedimentation rate;
LUAD	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21582582	chr3:182698605	DCUN1D1	0.6	10.15	0.44	8.01e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.04	0.32	7.85e-12	Colorectal cancer;
LUAD	cis	rs2882667	0.931	rs10077796	chr5:138356775	A/C	cg04439458	chr5:138467593	SIL1	0.41	7.5	0.34	3.76e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs7246760	1.000	rs56754106	chr19:9937789	T/A	cg02900749	chr2:68251473	NA	-0.63	-6.76	-0.31	4.67e-11	Pursuit maintenance gain;
LUAD	cis	rs7084921	0.579	rs11597870	chr10:101847857	T/C	cg19754520	chr10:101825118	CPN1	-0.36	-7.21	-0.33	2.6e-12	Bone mineral density;
LUAD	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06022373	chr22:39101656	GTPBP1	0.47	7.9	0.36	2.39e-14	Menopause (age at onset);
LUAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-10.12	-0.44	1.02e-21	Electroencephalogram traits;
LUAD	cis	rs7107174	1.000	rs11601196	chr11:78043431	A/C	cg02023728	chr11:77925099	USP35	0.45	7.12	0.33	4.58e-12	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4372836	1.000	rs2169751	chr2:28966758	G/C	cg09522027	chr2:28974177	PPP1CB	-0.62	-10.05	-0.44	1.86e-21	Body mass index;
LUAD	cis	rs654384	0.898	rs1077472	chr7:4175323	G/A	cg26275264	chr7:4183598	SDK1	0.4	7.64	0.35	1.45e-13	Positive affect;
LUAD	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23158103	chr7:148848205	ZNF398	-0.66	-12.59	-0.52	4.15e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg16479474	chr6:28041457	NA	0.4	7.03	0.32	8.52e-12	Parkinson's disease;
LUAD	cis	rs4700695	0.841	rs152996	chr5:65256506	A/G	cg21114390	chr5:65439923	SFRS12	0.62	7.48	0.34	4.4e-13	Facial morphology (factor 19);
LUAD	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg04450456	chr4:17643702	FAM184B	0.36	6.84	0.32	2.82e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2806561	0.695	rs67238799	chr1:23335012	G/A	cg19743168	chr1:23544995	NA	0.37	6.46	0.3	2.96e-10	Height;
LUAD	cis	rs13126513	0.519	rs959247	chr4:100556984	A/G	cg05468953	chr4:100565104	NA	0.39	7.92	0.36	2.09e-14	Metabolite levels (MHPG);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg07192240	chr11:3829780	PGAP2	-0.35	-6.52	-0.3	2.07e-10	Schizophrenia;
LUAD	cis	rs12618769	0.597	rs3769716	chr2:99133305	G/A	cg10123293	chr2:99228465	UNC50	0.46	8.21	0.37	2.77e-15	Bipolar disorder;
LUAD	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg22105103	chr4:187893119	NA	0.52	11.32	0.48	3.9e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	trans	rs7781370	1.000	rs7781370	chr7:96133531	A/G	cg25621096	chr1:151032116	CDC42SE1;MLLT11	-0.39	-6.41	-0.3	3.89e-10	Bone mineral density (hip);
LUAD	cis	rs6539288	0.674	rs4964494	chr12:107284460	A/G	cg15890332	chr12:107067104	RFX4	0.34	7.5	0.34	3.91e-13	Total body bone mineral density;
LUAD	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg18512352	chr11:47633146	NA	-0.57	-10.07	-0.44	1.58e-21	Neuroticism;
LUAD	cis	rs2235642	0.582	rs2235637	chr16:1567694	G/A	cg26528668	chr16:1614120	IFT140	0.39	6.35	0.3	5.41e-10	Coronary artery disease;
LUAD	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg03929089	chr4:120376271	NA	-0.92	-17.44	-0.65	9.82e-52	Height;
LUAD	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg09826364	chr7:158789723	NA	0.37	6.71	0.31	6.46e-11	Facial morphology (factor 20);
LUAD	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg08999081	chr20:33150536	PIGU	-0.6	-13.35	-0.54	3.75e-34	Glomerular filtration rate (creatinine);
LUAD	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg22676075	chr6:135203613	NA	0.41	7.59	0.35	2.13e-13	Red blood cell count;
LUAD	cis	rs4356932	1.000	rs6820370	chr4:76952278	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.5	-0.3	2.22e-10	Blood protein levels;
LUAD	cis	rs3007168	0.953	rs35556623	chr14:51679717	T/A	cg23942311	chr14:51606299	NA	0.57	7.7	0.35	9.6e-14	Cancer;
LUAD	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg05368731	chr17:41323189	NBR1	-0.96	-20.71	-0.71	2.7e-66	Menopause (age at onset);
LUAD	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	8.01	0.36	1.15e-14	Parkinson's disease;
LUAD	cis	rs9487051	0.768	rs461487	chr6:109525504	A/G	cg01475377	chr6:109611718	NA	-0.38	-6.96	-0.32	1.3e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg03213289	chr20:61660250	NA	0.69	14.76	0.58	4.6e-40	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg14671364	chr1:107599128	PRMT6	0.6	10.27	0.45	3.01e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg03929089	chr4:120376271	NA	-0.68	-9.72	-0.43	2.74e-20	Coronary artery disease;
LUAD	cis	rs7731657	0.537	rs7735161	chr5:130324105	C/T	cg08523029	chr5:130500466	HINT1	0.55	7.33	0.34	1.19e-12	Fasting plasma glucose;
LUAD	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg25237894	chr2:233734115	C2orf82	-0.59	-11.8	-0.5	5.71e-28	Coronary artery disease;
LUAD	trans	rs1997103	0.954	rs10246216	chr7:55390479	C/T	cg20935933	chr6:143382018	AIG1	0.54	7.51	0.34	3.44e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg22907277	chr7:1156413	C7orf50	0.75	11.22	0.48	9.12e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg02733842	chr7:1102375	C7orf50	-0.59	-9.2	-0.41	1.63e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg07741184	chr6:167504864	NA	0.29	7.03	0.32	8.43e-12	Crohn's disease;
LUAD	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg05590025	chr7:65112418	INTS4L2	0.77	8.19	0.37	3.22e-15	Diabetic kidney disease;
LUAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg04013093	chr6:42928303	GNMT	-0.28	-6.61	-0.31	1.15e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg12623918	chr2:306882	NA	0.34	6.79	0.31	3.72e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7845219	0.555	rs1129152	chr8:95888307	C/T	cg16049864	chr8:95962084	TP53INP1	-0.47	-9.5	-0.42	1.6e-19	Type 2 diabetes;
LUAD	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg17173187	chr15:85201210	NMB	0.38	6.38	0.3	4.76e-10	Schizophrenia;
LUAD	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg18854424	chr1:2615690	NA	0.42	9.18	0.41	1.95e-18	Ulcerative colitis;
LUAD	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg08470875	chr2:26401718	FAM59B	-0.62	-8.52	-0.38	2.89e-16	Gut microbiome composition (summer);
LUAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg08027265	chr7:2291960	NA	-0.41	-6.45	-0.3	3.05e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2535633	0.588	rs2564930	chr3:53017307	T/C	cg05564831	chr3:52568323	NT5DC2	-0.36	-6.37	-0.3	4.91e-10	Body mass index;
LUAD	trans	rs75804782	0.641	rs55844289	chr2:239323207	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	8.29	0.37	1.57e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs4819852	0.958	rs2238784	chr22:19972559	G/A	cg07821417	chr22:19972146	ARVCF	0.41	7.64	0.35	1.5e-13	Pulse pressure;
LUAD	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg14895029	chr7:2775587	GNA12	-0.4	-6.35	-0.3	5.56e-10	Height;
LUAD	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg27068330	chr11:65405492	SIPA1	-0.76	-11.38	-0.48	2.3e-26	Acne (severe);
LUAD	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg11766577	chr21:47581405	C21orf56	-0.46	-7.85	-0.36	3.34e-14	Testicular germ cell tumor;
LUAD	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg25319279	chr11:5960081	NA	-0.39	-6.87	-0.32	2.27e-11	DNA methylation (variation);
LUAD	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg21028142	chr17:79581711	NPLOC4	0.45	9.74	0.43	2.39e-20	Eye color traits;
LUAD	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg03037974	chr15:76606532	NA	0.48	11.28	0.48	5.66e-26	Blood metabolite levels;
LUAD	cis	rs743757	1.000	rs2236979	chr3:50486895	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.43	6.79	0.31	3.78e-11	Diastolic blood pressure;
LUAD	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21028142	chr17:79581711	NPLOC4	0.45	9.79	0.43	1.54e-20	Eye color traits;
LUAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg09177884	chr7:1199841	ZFAND2A	-0.45	-7.42	-0.34	6.29e-13	Longevity;Endometriosis;
LUAD	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg00204512	chr16:28754710	NA	0.32	6.91	0.32	1.78e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg25919922	chr13:100150906	NA	0.73	10.27	0.45	3.1e-22	Obesity-related traits;
LUAD	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7512552	0.966	rs10788873	chr1:150250534	T/A	cg15654264	chr1:150340011	RPRD2	-0.38	-6.93	-0.32	1.57e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs10129255	0.536	rs6576223	chr14:107184687	C/T	cg07958169	chr14:107095056	NA	-0.37	-7.24	-0.33	2.07e-12	Kawasaki disease;
LUAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.86	-21.53	-0.72	5.95e-70	Longevity;Endometriosis;
LUAD	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg10556349	chr10:835070	NA	0.68	8.17	0.37	3.54e-15	Eosinophil percentage of granulocytes;
LUAD	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg20503657	chr10:835505	NA	0.82	11.16	0.48	1.6e-25	Eosinophil percentage of granulocytes;
LUAD	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg14895029	chr7:2775587	GNA12	-0.41	-6.58	-0.3	1.39e-10	Height;
LUAD	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg19041857	chr6:27730383	NA	-0.41	-7.06	-0.32	6.8e-12	Parkinson's disease;
LUAD	trans	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs62400317	0.859	rs12205379	chr6:45215074	G/A	cg20913747	chr6:44695427	NA	-0.4	-6.43	-0.3	3.41e-10	Total body bone mineral density;
LUAD	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg12403142	chr1:92012408	NA	-0.37	-6.77	-0.31	4.37e-11	Breast cancer;
LUAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06873352	chr17:61820015	STRADA	0.83	18.31	0.67	1.36e-55	Prudent dietary pattern;
LUAD	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.58	-0.3	1.41e-10	Height;
LUAD	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-7.64	-0.35	1.51e-13	Tonsillectomy;
LUAD	cis	rs3760982	1.000	rs3760982	chr19:44286513	A/G	cg11993925	chr19:44307056	LYPD5	0.42	8.25	0.37	2.04e-15	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg25797454	chr6:150327115	RAET1K	0.36	7.58	0.35	2.23e-13	Alopecia areata;
LUAD	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg24450063	chr1:156163899	SLC25A44	1.03	18.33	0.67	1.21e-55	Intracerebral hemorrhage;White matter hyperintensity burden;
LUAD	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg17551891	chr7:1960795	MAD1L1	-0.39	-6.68	-0.31	7.47e-11	Neuroticism;
LUAD	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg04154034	chr17:28927549	LRRC37B2	0.71	7.05	0.32	7.52e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg05697835	chr1:2722811	NA	-0.31	-6.46	-0.3	2.93e-10	Ulcerative colitis;
LUAD	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg00823993	chr13:113535758	ATP11A	0.58	8.97	0.4	9.43e-18	Interstitial lung disease;
LUAD	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.06	0.32	6.85e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-7.08	-0.33	6.16e-12	Lung cancer;
LUAD	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg03806693	chr22:41940476	POLR3H	0.66	9.03	0.4	6.01e-18	Vitiligo;
LUAD	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg18240062	chr17:79603768	NPLOC4	-0.46	-8.11	-0.37	5.41e-15	Eye color traits;
LUAD	cis	rs12541635	0.967	rs4734896	chr8:107075454	T/C	cg10147462	chr8:107024639	NA	-0.42	-7.6	-0.35	1.95e-13	Age of smoking initiation;
LUAD	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg13319975	chr6:146136371	FBXO30	-0.58	-9.72	-0.43	2.67e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2637266	1.000	rs10824429	chr10:78346196	G/T	cg18941641	chr10:78392320	NA	0.33	6.87	0.32	2.37e-11	Pulmonary function;
LUAD	cis	rs1232027	0.622	rs1346464	chr5:79967618	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.82	-0.31	3.13e-11	Huntington's disease progression;
LUAD	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg14092988	chr3:52407081	DNAH1	0.45	9.04	0.4	5.62e-18	Bipolar disorder;
LUAD	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.41	-7.65	-0.35	1.35e-13	IgG glycosylation;
LUAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg13560548	chr3:10150139	C3orf24	0.43	7.09	0.33	5.72e-12	Alzheimer's disease;
LUAD	cis	rs2882667	0.931	rs3749665	chr5:138357211	A/G	cg04439458	chr5:138467593	SIL1	-0.4	-7.17	-0.33	3.38e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6688613	0.679	rs12116418	chr1:166944273	T/A	cg07049167	chr1:166818506	POGK	0.39	6.47	0.3	2.72e-10	Refractive astigmatism;
LUAD	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg08601574	chr20:25228251	PYGB	-0.46	-8.73	-0.39	5.86e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg13354988	chr2:263656	ACP1;SH3YL1	0.29	6.4	0.3	4.1e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21028142	chr17:79581711	NPLOC4	-0.45	-9.74	-0.43	2.38e-20	Eye color traits;
LUAD	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.02	-0.4	6.56e-18	Total body bone mineral density;
LUAD	trans	rs2840044	1.000	rs225277	chr17:33973311	G/A	cg19694781	chr19:47549865	TMEM160	-0.63	-10.18	-0.44	6.57e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs68170813	0.559	rs2395880	chr7:107074264	A/G	cg23024343	chr7:107201750	COG5	0.5	7.35	0.34	1.05e-12	Coronary artery disease;
LUAD	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.79	-0.35	5.18e-14	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs4332037	0.508	rs60238952	chr7:1914350	A/G	cg11693508	chr17:37793320	STARD3	0.49	7.24	0.33	2.09e-12	Bipolar disorder;
LUAD	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11644478	chr21:40555479	PSMG1	0.42	7.01	0.32	9.73e-12	Menarche (age at onset);
LUAD	cis	rs13082711	0.911	rs7650165	chr3:27462440	C/T	cg02860705	chr3:27208620	NA	0.58	9.08	0.4	4.02e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs892961	0.932	rs11657961	chr17:75405407	C/T	cg05865280	chr17:75406074	SEPT9	0.63	18.92	0.68	2.65e-58	Airflow obstruction;
LUAD	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg06873352	chr17:61820015	STRADA	0.41	6.92	0.32	1.64e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.58	0.3	1.39e-10	Parkinson's disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg15083964	chr4:56212371	SRD5A3	-0.64	-6.35	-0.3	5.71e-10	Type 2 diabetes;
LUAD	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.71	-0.35	8.94e-14	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg25173405	chr17:45401733	C17orf57	0.52	9.01	0.4	6.95e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6062302	0.540	rs2281926	chr20:62384309	G/C	cg14758556	chr20:62440591	NA	0.45	6.61	0.31	1.18e-10	Glioblastoma;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15309264	chr2:58274034	VRK2	-0.45	-7.22	-0.33	2.46e-12	Height;
LUAD	cis	rs1595825	0.891	rs76450397	chr2:198786112	T/C	cg00982548	chr2:198649783	BOLL	-0.63	-9.1	-0.4	3.47e-18	Ulcerative colitis;
LUAD	cis	rs4604732	0.631	rs60311891	chr1:247623127	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.4	6.84	0.32	2.76e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg12623918	chr2:306882	NA	0.36	7.22	0.33	2.48e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.43	-0.45	7.96e-23	Monocyte percentage of white cells;
LUAD	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg07741184	chr6:167504864	NA	0.4	9.17	0.41	2.11e-18	Crohn's disease;
LUAD	trans	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg01620082	chr3:125678407	NA	-0.69	-7.39	-0.34	7.84e-13	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.51	-0.38	3.12e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg24813613	chr7:1882135	MAD1L1	-0.52	-8.53	-0.38	2.55e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg02931644	chr1:25747376	RHCE	0.41	8.5	0.38	3.27e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs4774899	0.698	rs2585088	chr15:57328867	T/A	cg14026238	chr15:57616123	NA	-0.4	-7.42	-0.34	6.42e-13	Urinary tract infection frequency;
LUAD	cis	rs7089973	0.872	rs35622181	chr10:116631976	C/T	cg23260525	chr10:116636907	FAM160B1	0.43	9.53	0.42	1.25e-19	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24531977	chr5:56204891	C5orf35	0.77	12.41	0.52	2.19e-30	Initial pursuit acceleration;
LUAD	cis	rs68170813	0.559	rs2299422	chr7:106959832	A/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.21	-0.44	4.94e-22	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg08761264	chr16:28874980	SH2B1	-0.43	-6.38	-0.3	4.74e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4072705	0.900	rs4836993	chr9:127558370	G/C	cg13476313	chr9:127244764	NR5A1	0.29	6.66	0.31	8.73e-11	Menarche (age at onset);
LUAD	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg26384229	chr12:38710491	ALG10B	0.47	7.8	0.35	5.01e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs7759001	0.857	rs980961	chr6:27361019	A/G	cg18711553	chr6:27366782	ZNF391	0.39	6.53	0.3	1.94e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg12365402	chr11:9010492	NRIP3	-0.44	-8.28	-0.37	1.62e-15	Hemoglobin concentration;
LUAD	cis	rs735539	1.000	rs3000676	chr13:21286442	A/T	cg27499820	chr13:21296301	IL17D	0.43	7.23	0.33	2.21e-12	Dental caries;
LUAD	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg25024717	chr12:54324583	NA	-0.32	-6.77	-0.31	4.37e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg26554054	chr8:600488	NA	0.81	8.04	0.36	9.21e-15	IgG glycosylation;
LUAD	cis	rs6740322	0.948	rs6722694	chr2:43569798	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-10.89	-0.47	1.66e-24	Coronary artery disease;
LUAD	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg14582100	chr15:45693742	SPATA5L1	-0.42	-8.25	-0.37	2.02e-15	Glomerular filtration rate;
LUAD	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg22532475	chr10:104410764	TRIM8	-0.48	-9.21	-0.41	1.53e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg12016809	chr21:47604291	C21orf56	0.44	7.37	0.34	8.84e-13	Testicular germ cell tumor;
LUAD	cis	rs2742417	0.603	rs2253979	chr3:45773320	A/G	cg10512202	chr3:45649293	LIMD1	0.48	8.89	0.4	1.72e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg09085632	chr11:111637200	PPP2R1B	0.67	10.47	0.45	5.77e-23	Primary sclerosing cholangitis;
LUAD	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg06766960	chr11:133703094	NA	-0.44	-8.41	-0.38	6.26e-16	Childhood ear infection;
LUAD	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.79	-0.35	5.27e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg20476274	chr7:133979776	SLC35B4	0.84	16.4	0.62	3.75e-47	Mean platelet volume;
LUAD	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-8.73	-0.39	6.08e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg05966235	chr16:28915196	ATP2A1	0.51	8.17	0.37	3.61e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg26924012	chr15:45694286	SPATA5L1	0.98	16.69	0.63	2.09e-48	Homoarginine levels;
LUAD	cis	rs11229555	0.645	rs11229431	chr11:58181253	A/G	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg13047869	chr3:10149882	C3orf24	0.64	11.03	0.47	4.89e-25	Alzheimer's disease;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg23065468	chr2:136288564	R3HDM1;ZRANB3	-0.41	-6.61	-0.31	1.13e-10	Subcortical brain region volumes;
LUAD	cis	rs752010	0.523	rs10890159	chr1:42118282	A/G	cg06885757	chr1:42089581	HIVEP3	0.47	10.32	0.45	1.99e-22	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs317865	0.737	rs73234642	chr4:16186730	G/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.87	8.52	0.38	2.82e-16	Kidney disease (early stage) in type 1 diabetes;
LUAD	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs3760982	0.585	rs62116964	chr19:44291986	T/C	cg21496419	chr19:44306685	LYPD5	0.34	7.61	0.35	1.77e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.34	6.85	0.32	2.56e-11	Depression;
LUAD	cis	rs490234	0.841	rs536861	chr9:128313444	A/C	cg14078157	chr9:128172775	NA	0.43	8.02	0.36	1.07e-14	Mean arterial pressure;
LUAD	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg23985595	chr17:80112537	CCDC57	-0.53	-9.51	-0.42	1.43e-19	Life satisfaction;
LUAD	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-8.06	-0.36	7.83e-15	Height;
LUAD	cis	rs2806561	1.000	rs1757044	chr1:23515631	T/C	cg19743168	chr1:23544995	NA	0.41	7.75	0.35	7.1e-14	Height;
LUAD	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg12403142	chr1:92012408	NA	-0.4	-7.34	-0.34	1.1e-12	Breast cancer;
LUAD	cis	rs4711336	0.527	rs28651968	chr6:33717424	T/C	cg14003231	chr6:33640908	ITPR3	0.39	7.19	0.33	2.93e-12	Height;
LUAD	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.98	-0.36	1.34e-14	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg03676636	chr4:99064102	C4orf37	0.31	8.1	0.37	6.15e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62238980	0.614	rs117112619	chr22:32508140	G/A	cg00543991	chr22:32367038	NA	0.88	8.51	0.38	3.06e-16	Childhood ear infection;
LUAD	cis	rs7932354	0.528	rs2018527	chr11:47175809	A/G	cg19486271	chr11:47235900	DDB2	0.41	6.55	0.3	1.71e-10	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg23583168	chr7:148888333	NA	-1.04	-24.42	-0.76	8.31e-83	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg27572855	chr1:25598939	RHD	-0.53	-11.36	-0.48	2.83e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg17063962	chr7:91808500	NA	-0.6	-9.89	-0.43	7.02e-21	Breast cancer;
LUAD	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg06558623	chr16:89946397	TCF25	1.14	10.58	0.46	2.2e-23	Skin colour saturation;
LUAD	cis	rs17067123	0.539	rs79352031	chr4:180066810	C/T	cg26610307	chr4:180072759	NA	-0.52	-6.75	-0.31	4.86e-11	Response to hepatitis C treatment;
LUAD	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg13770153	chr20:60521292	NA	-0.46	-7.99	-0.36	1.27e-14	Body mass index;
LUAD	cis	rs62400317	0.859	rs10948211	chr6:45156767	G/A	cg18551225	chr6:44695536	NA	-0.56	-8.61	-0.39	1.45e-16	Total body bone mineral density;
LUAD	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg02030672	chr11:45687055	CHST1	0.41	7.46	0.34	4.82e-13	Obesity-related traits;
LUAD	cis	rs7843479	0.601	rs4422769	chr8:21844265	A/G	cg03445287	chr8:21823731	XPO7	-0.49	-9.18	-0.41	1.9e-18	Mean corpuscular volume;
LUAD	cis	rs2408955	0.522	rs4760612	chr12:48421856	C/T	cg04545296	chr12:48745243	ZNF641	-0.34	-8.72	-0.39	6.56e-17	Glycated hemoglobin levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05332869	chr20:39658073	TOP1	-0.47	-7.39	-0.34	7.85e-13	Height;
LUAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs55665837	0.539	rs10766196	chr11:14913131	A/G	cg19336497	chr11:14380999	RRAS2	-0.38	-7.11	-0.33	5.13e-12	Vitamin D levels;
LUAD	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.33	0.38	1.13e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06873352	chr17:61820015	STRADA	-0.81	-18.1	-0.66	1.22e-54	Prudent dietary pattern;
LUAD	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg25036284	chr2:26402008	FAM59B	-0.81	-11.44	-0.49	1.39e-26	Gut microbiome composition (summer);
LUAD	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg13319975	chr6:146136371	FBXO30	0.68	11.79	0.5	6.09e-28	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4280164	0.887	rs12886362	chr14:24791571	A/C	cg22990158	chr14:24802150	ADCY4	-0.45	-6.36	-0.3	5.15e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg12935359	chr14:103987150	CKB	-0.46	-7.67	-0.35	1.17e-13	Body mass index;
LUAD	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg26343298	chr8:95960752	TP53INP1	0.37	7.82	0.36	4.12e-14	Type 2 diabetes;
LUAD	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg01475377	chr6:109611718	NA	-0.5	-9.41	-0.42	3.19e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs10916814	0.632	rs10799646	chr1:20903985	G/T	cg24502330	chr1:20914028	CDA	-0.35	-6.87	-0.32	2.35e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg02524346	chr8:600233	NA	1.05	9.93	0.43	5.12e-21	IgG glycosylation;
LUAD	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23583168	chr7:148888333	NA	-0.9	-18.52	-0.67	1.58e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs35740288	0.731	rs11638407	chr15:86094655	A/C	cg13263323	chr15:86062960	AKAP13	-0.43	-7.06	-0.32	6.76e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg25767906	chr1:53392781	SCP2	0.41	7.3	0.33	1.45e-12	Monocyte count;
LUAD	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.87	-0.36	3.09e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg08508325	chr11:3079039	CARS	0.57	12.67	0.52	2.14e-31	Longevity;
LUAD	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg08999081	chr20:33150536	PIGU	0.54	11.37	0.48	2.56e-26	Coronary artery disease;
LUAD	cis	rs17641971	0.684	rs4873310	chr8:49990006	A/T	cg00325661	chr8:49890786	NA	0.3	6.8	0.31	3.68e-11	Blood metabolite levels;
LUAD	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg04727924	chr7:799746	HEATR2	-0.53	-7.23	-0.33	2.23e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg16325326	chr1:53192061	ZYG11B	0.48	8.14	0.37	4.52e-15	Monocyte count;
LUAD	cis	rs912057	0.601	rs1294413	chr6:6739924	C/A	cg06612196	chr6:6737390	NA	0.66	16.31	0.62	9.22e-47	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs2073300	1.000	rs6048803	chr20:23438889	A/G	cg12062639	chr20:23401060	NAPB	0.71	6.97	0.32	1.23e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg26419957	chr12:122252518	SETD1B	-0.44	-6.98	-0.32	1.12e-11	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs412658	0.504	rs369128	chr19:22107866	A/T	cg05197062	chr11:11642011	GALNTL4	-0.41	-6.93	-0.32	1.61e-11	Telomere length;
LUAD	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg26587870	chr6:27730563	NA	-0.38	-6.64	-0.31	9.91e-11	Parkinson's disease;
LUAD	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	11.95	0.5	1.43e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg23260525	chr10:116636907	FAM160B1	0.52	12.31	0.51	5.77e-30	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4708431	0.539	rs35108423	chr6:168491898	A/G	cg02770688	chr6:168491649	NA	0.37	7.45	0.34	5.38e-13	Attention deficit hyperactivity disorder (combined symptoms);
LUAD	trans	rs9951602	0.512	rs4799245	chr18:76653397	T/C	cg02800362	chr5:177631904	HNRNPAB	0.91	14.5	0.58	5.82e-39	Obesity-related traits;
LUAD	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.45	0.42	2.41e-19	Tonsillectomy;
LUAD	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg03289416	chr15:75166202	SCAMP2	-0.41	-7.17	-0.33	3.43e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs68170813	0.559	rs80212020	chr7:106957596	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.41	-0.45	9.42e-23	Coronary artery disease;
LUAD	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg13535736	chr9:111863775	C9orf5	-0.42	-6.5	-0.3	2.25e-10	Menarche (age at onset);
LUAD	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg26850624	chr5:429559	AHRR	-0.42	-6.65	-0.31	9.24e-11	Cystic fibrosis severity;
LUAD	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg21214613	chr1:16344536	HSPB7	0.57	10.25	0.45	3.63e-22	Dilated cardiomyopathy;
LUAD	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg21153622	chr11:89784906	NA	0.34	6.63	0.31	1.06e-10	Coronary artery disease;
LUAD	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg20587970	chr11:113659929	NA	-1.15	-17.2	-0.64	1.17e-50	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg13560548	chr3:10150139	C3orf24	0.43	6.94	0.32	1.44e-11	Alzheimer's disease;
LUAD	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg21856205	chr7:94953877	PON1	-0.56	-7.98	-0.36	1.39e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg22618164	chr12:122356400	WDR66	0.75	13.61	0.55	3.07e-35	Mean corpuscular volume;
LUAD	cis	rs17253792	0.822	rs28681420	chr14:56088403	G/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs11811982	0.793	rs116628261	chr1:227555669	A/G	cg24860534	chr1:227506868	CDC42BPA	0.7	7.44	0.34	5.81e-13	Optic disc area;
LUAD	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg01528321	chr10:82214614	TSPAN14	0.54	8.64	0.39	1.16e-16	Post bronchodilator FEV1;
LUAD	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg25535316	chr11:579198	PHRF1	-0.38	-6.66	-0.31	8.35e-11	Systemic lupus erythematosus;
LUAD	cis	rs7512552	0.803	rs59898460	chr1:150493004	T/C	cg15654264	chr1:150340011	RPRD2	0.6	11.44	0.49	1.34e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg14598338	chr9:96623480	NA	-0.43	-9.02	-0.4	6.57e-18	DNA methylation (variation);
LUAD	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg11266682	chr4:10021025	SLC2A9	0.66	14.85	0.59	1.95e-40	Bone mineral density;
LUAD	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg18225595	chr11:63971243	STIP1	0.52	8.65	0.39	1.09e-16	Platelet count;
LUAD	cis	rs4523957	0.671	rs4790070	chr17:2158094	C/G	cg16513277	chr17:2031491	SMG6	0.67	10.5	0.45	4.32e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg03563238	chr19:33554763	RHPN2	-0.33	-7.86	-0.36	3.11e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13342387	chr11:60681305	TMEM109	-0.42	-6.92	-0.32	1.64e-11	Cancer;
LUAD	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg02574844	chr11:5959923	NA	-0.38	-6.62	-0.31	1.07e-10	DNA methylation (variation);
LUAD	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	ch.11.42038R	chr11:967971	AP2A2	0.41	7.24	0.33	2.13e-12	Alzheimer's disease (late onset);
LUAD	cis	rs981844	0.666	rs7691303	chr4:154684198	T/C	cg10279832	chr4:154682576	RNF175	0.34	7.15	0.33	3.79e-12	Response to statins (LDL cholesterol change);
LUAD	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg07266350	chr3:49460521	AMT;NICN1	-0.37	-6.6	-0.31	1.25e-10	Menarche (age at onset);
LUAD	trans	rs783540	0.967	rs1269134	chr15:83282628	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.44	-7.08	-0.33	6.03e-12	Schizophrenia;
LUAD	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg03161606	chr19:29218774	NA	0.59	8.83	0.39	2.91e-17	Methadone dose in opioid dependence;
LUAD	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg01579765	chr21:45077557	HSF2BP	-0.6	-13.34	-0.54	3.81e-34	Mean corpuscular volume;
LUAD	cis	rs9902453	0.740	rs2254414	chr17:28061130	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.45	-0.45	6.92e-23	Coffee consumption (cups per day);
LUAD	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg24818145	chr4:99064322	C4orf37	0.42	7.03	0.32	8.6e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg13770153	chr20:60521292	NA	-0.57	-9.6	-0.42	7.26e-20	Body mass index;
LUAD	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg09998033	chr7:158218633	PTPRN2	0.55	10.17	0.44	7e-22	Obesity-related traits;
LUAD	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg03929089	chr4:120376271	NA	-0.93	-17.89	-0.66	1.08e-53	Height;
LUAD	cis	rs7833986	0.501	rs72653951	chr8:56961837	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	16.01	0.61	1.84e-45	Height;
LUAD	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg02423579	chr7:2872169	GNA12	-0.76	-12.91	-0.53	2.2e-32	Height;
LUAD	cis	rs4372836	1.000	rs11688129	chr2:28952581	T/C	cg09522027	chr2:28974177	PPP1CB	0.62	10.04	0.44	2.05e-21	Body mass index;
LUAD	cis	rs7633770	0.786	rs1520488	chr3:46677459	C/T	cg11219411	chr3:46661640	NA	0.55	12.23	0.51	1.21e-29	Coronary artery disease;
LUAD	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.62	-0.35	1.7e-13	Blood metabolite levels;
LUAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg13012494	chr21:47604986	C21orf56	0.48	6.66	0.31	8.73e-11	Testicular germ cell tumor;
LUAD	cis	rs9863	0.828	rs7975482	chr12:124481690	A/G	cg17723958	chr12:124429295	CCDC92	-0.42	-6.93	-0.32	1.57e-11	White blood cell count;
LUAD	cis	rs12530845	0.573	rs56411048	chr7:135364748	A/T	cg23117316	chr7:135346802	PL-5283	-0.55	-7.81	-0.35	4.69e-14	Red blood cell traits;
LUAD	cis	rs4919694	1.000	rs111622998	chr10:104953021	C/A	cg04362960	chr10:104952993	NT5C2	0.73	7.72	0.35	8.42e-14	Arsenic metabolism;
LUAD	cis	rs11048434	0.736	rs2377674	chr12:9112761	A/G	cg23795048	chr12:9217529	LOC144571	0.43	7.91	0.36	2.3e-14	Sjögren's syndrome;
LUAD	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg18105134	chr13:113819100	PROZ	-0.78	-13.89	-0.56	2.05e-36	Platelet distribution width;
LUAD	cis	rs6499255	0.904	rs10852458	chr16:69672410	G/A	cg26679644	chr16:69762563	NA	0.42	6.45	0.3	3.07e-10	IgE levels;
LUAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg08219700	chr8:58056026	NA	0.59	7.1	0.33	5.46e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9796	0.870	rs3900905	chr15:41260801	G/A	cg18705301	chr15:41695430	NDUFAF1	0.4	7.57	0.35	2.35e-13	Menopause (age at onset);
LUAD	cis	rs1843834	0.838	rs6436506	chr2:225558242	T/C	cg22455342	chr2:225449267	CUL3	0.46	6.67	0.31	7.98e-11	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg21475434	chr5:93447410	FAM172A	0.74	8.57	0.38	1.96e-16	Diabetic retinopathy;
LUAD	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg15309053	chr8:964076	NA	0.48	10.73	0.46	6.63e-24	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.61e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2070488	0.662	rs7652475	chr3:38481341	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.49	7.68	0.35	1.13e-13	Electrocardiographic conduction measures;
LUAD	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22496380	chr5:211416	CCDC127	-0.93	-13.03	-0.54	6.94e-33	Breast cancer;
LUAD	cis	rs7705042	0.793	rs10463348	chr5:141502035	G/T	cg08523384	chr5:141488047	NDFIP1	-0.38	-6.38	-0.3	4.54e-10	Asthma;
LUAD	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg07169764	chr2:136633963	MCM6	0.82	9.49	0.42	1.64e-19	Corneal structure;
LUAD	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg09658497	chr7:2847517	GNA12	-0.43	-7.22	-0.33	2.48e-12	Height;
LUAD	cis	rs2046867	0.818	rs6789061	chr3:72888690	C/T	cg25664220	chr3:72788482	NA	-0.66	-11.75	-0.5	8.69e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg18187862	chr3:45730750	SACM1L	0.54	8.3	0.37	1.43e-15	Primary sclerosing cholangitis;
LUAD	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg08885076	chr2:99613938	TSGA10	0.36	6.54	0.3	1.77e-10	Chronic sinus infection;
LUAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg07677032	chr17:61819896	STRADA	-0.57	-10.32	-0.45	2.08e-22	Prudent dietary pattern;
LUAD	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg14458575	chr2:238380390	NA	0.64	11.86	0.5	3.37e-28	Prostate cancer;
LUAD	cis	rs11771526	0.901	rs62457494	chr7:32312299	T/G	cg27511599	chr7:32358540	NA	0.51	6.59	0.31	1.27e-10	Body mass index;
LUAD	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg05991184	chr2:219186017	PNKD	0.37	7.1	0.33	5.22e-12	Colorectal cancer;
LUAD	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg09835421	chr16:68378352	PRMT7	-0.85	-9.1	-0.4	3.55e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg01802117	chr1:53393560	SCP2	0.37	7.18	0.33	3.08e-12	Monocyte count;
LUAD	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg13722127	chr7:150037890	RARRES2	-0.43	-7.1	-0.33	5.26e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7630877	0.962	rs56395499	chr3:179644270	T/C	cg18765712	chr3:179670323	PEX5L	0.34	6.42	0.3	3.59e-10	Type 2 diabetes;
LUAD	trans	rs875971	0.571	rs160647	chr7:65554352	C/T	cg04775059	chr7:64541387	NA	-0.52	-6.78	-0.31	4.11e-11	Aortic root size;
LUAD	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg06387496	chr7:2775674	GNA12	-0.39	-6.57	-0.3	1.47e-10	Height;
LUAD	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg07936489	chr17:37558343	FBXL20	-0.51	-6.87	-0.32	2.29e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg16325326	chr1:53192061	ZYG11B	0.69	12.44	0.52	1.75e-30	Monocyte count;
LUAD	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg24450063	chr1:156163899	SLC25A44	1.15	22.69	0.74	3.87e-75	Testicular germ cell tumor;
LUAD	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg01689657	chr7:91764605	CYP51A1	0.36	8.67	0.39	9.12e-17	Breast cancer;
LUAD	cis	rs798554	0.591	rs1636248	chr7:2882030	T/C	cg14668632	chr7:2872130	GNA12	-0.5	-8.83	-0.39	2.7e-17	Height;
LUAD	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg07305463	chr2:136567211	LCT	-0.39	-7.45	-0.34	5.28e-13	Mosquito bite size;
LUAD	trans	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg06606381	chr12:133084897	FBRSL1	-1.13	-10.1	-0.44	1.2e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg00280220	chr17:61926910	NA	0.37	7.05	0.32	7.33e-12	Prudent dietary pattern;
LUAD	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg18721089	chr20:30220636	NA	-0.49	-7.08	-0.33	6.02e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs1018836	0.923	rs13262354	chr8:91635731	G/A	cg16814680	chr8:91681699	NA	-0.69	-11.69	-0.49	1.5e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg02734326	chr4:10020555	SLC2A9	-0.54	-9.38	-0.41	4.16e-19	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs932287	0.666	rs10840161	chr11:9053824	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.31	6.4	0.3	4.16e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-1.01	-13.7	-0.55	1.25e-35	Lung cancer in ever smokers;
LUAD	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg21252483	chr19:49399788	TULP2	-0.88	-14.31	-0.57	3.61e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	11.56	0.49	4.62e-27	Lung cancer in ever smokers;
LUAD	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg04225089	chr17:73874465	TRIM47	-0.39	-6.71	-0.31	6.14e-11	Psoriasis;
LUAD	cis	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg05084668	chr3:125655381	ALG1L	-0.9	-11.96	-0.5	1.39e-28	Blood pressure (smoking interaction);
LUAD	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.82	-0.36	4.19e-14	Schizophrenia;
LUAD	cis	rs113835537	0.529	rs4930379	chr11:66255674	G/A	cg26679405	chr11:66247800	DPP3	-0.46	-6.7	-0.31	6.49e-11	Airway imaging phenotypes;
LUAD	cis	rs15676	0.783	rs7044955	chr9:131567152	C/T	cg00228799	chr9:131580591	ENDOG	-0.48	-7.41	-0.34	7.14e-13	Blood metabolite levels;
LUAD	cis	rs7116495	0.588	rs547208	chr11:71779668	A/G	cg07596299	chr11:71824057	C11orf51	-0.77	-6.55	-0.3	1.69e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-13.39	-0.55	2.38e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg00933542	chr6:150070202	PCMT1	-0.47	-10.02	-0.44	2.37e-21	Lung cancer;
LUAD	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg27286337	chr10:134555280	INPP5A	-0.95	-19.2	-0.68	1.56e-59	Migraine;
LUAD	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06112835	chr11:68658793	MRPL21	0.5	9.08	0.4	4.28e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg00316803	chr15:76480434	C15orf27	-0.41	-7.59	-0.35	2.03e-13	Blood metabolite levels;
LUAD	cis	rs3540	0.513	rs2601154	chr15:90894284	T/C	cg10434728	chr15:90938212	IQGAP1	0.37	7.06	0.32	7.06e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg24578937	chr1:2090814	PRKCZ	-0.58	-11.3	-0.48	4.57e-26	Height;
LUAD	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg00310523	chr12:86230176	RASSF9	0.4	7.86	0.36	3.16e-14	Major depressive disorder;
LUAD	cis	rs2735413	0.781	rs11649473	chr16:78077238	C/T	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	trans	rs11650494	0.908	rs73340399	chr17:47372743	G/C	cg11430096	chr6:110968061	CDK19	0.88	6.92	0.32	1.69e-11	Prostate cancer;
LUAD	cis	rs7072216	0.666	rs2274248	chr10:100148542	C/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-6.39	-0.3	4.46e-10	Metabolite levels;
LUAD	cis	rs7809950	1.000	rs7786801	chr7:107085889	C/T	cg23024343	chr7:107201750	COG5	-0.72	-12.18	-0.51	1.91e-29	Coronary artery disease;
LUAD	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg08859206	chr1:53392774	SCP2	0.63	11.54	0.49	5.76e-27	Monocyte count;
LUAD	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg05340658	chr4:99064831	C4orf37	0.53	9.05	0.4	5.17e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg15181151	chr6:150070149	PCMT1	0.38	7.58	0.35	2.24e-13	Lung cancer;
LUAD	cis	rs1915146	0.656	rs10794201	chr10:126846531	C/T	cg00406319	chr10:126851303	NA	0.34	6.47	0.3	2.75e-10	Menarche (age at onset);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26943708	chr13:35516454	NBEA	-0.69	-7.02	-0.32	9.05e-12	Type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg13047869	chr3:10149882	C3orf24	0.64	11.02	0.47	5.16e-25	Alzheimer's disease;
LUAD	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg02527881	chr3:46936655	PTH1R	-0.69	-14.89	-0.59	1.29e-40	Birth weight;
LUAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06873352	chr17:61820015	STRADA	0.83	18.35	0.67	9.75e-56	Prudent dietary pattern;
LUAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg20607798	chr8:58055168	NA	0.79	9.76	0.43	1.93e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg04398451	chr17:18023971	MYO15A	-0.81	-15.03	-0.59	3.33e-41	Total body bone mineral density;
LUAD	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg19717773	chr7:2847554	GNA12	-0.51	-9.44	-0.42	2.57e-19	Height;
LUAD	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg10544611	chr16:67998164	SLC12A4	-0.53	-6.66	-0.31	8.69e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.99	14.15	0.57	1.79e-37	Schizophrenia;
LUAD	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg23954153	chr1:44402353	ARTN	-0.36	-6.68	-0.31	7.6e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.48	0.38	3.74e-16	Menopause (age at onset);
LUAD	cis	rs7289126	1.000	rs5750571	chr22:38640312	A/G	cg17652424	chr22:38574118	PLA2G6	-0.23	-6.48	-0.3	2.58e-10	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs2625529	0.652	rs2957734	chr15:72261385	A/G	cg16672083	chr15:72433130	SENP8	0.65	12.23	0.51	1.21e-29	Red blood cell count;
LUAD	cis	rs12286929	0.600	rs4445669	chr11:115045237	C/T	cg04055981	chr11:115044050	NA	-0.45	-8.55	-0.38	2.35e-16	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs11229555	0.574	rs72919749	chr11:58323467	T/C	cg15696309	chr11:58395628	NA	-0.62	-7.06	-0.32	7.04e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg13870426	chr17:30244630	NA	-0.56	-6.62	-0.31	1.1e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg08601574	chr20:25228251	PYGB	0.47	8.88	0.4	1.93e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.5	-8.98	-0.4	8.71e-18	Longevity;Endometriosis;
LUAD	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg24690094	chr11:67383802	NA	-0.44	-7.19	-0.33	2.93e-12	Mean corpuscular volume;
LUAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg20607798	chr8:58055168	NA	0.58	7.41	0.34	6.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg18135555	chr8:22132992	PIWIL2	0.44	7.91	0.36	2.34e-14	Hypertriglyceridemia;
LUAD	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-12.57	-0.52	4.97e-31	Menarche (age at onset);
LUAD	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26314531	chr2:26401878	FAM59B	0.61	7.75	0.35	6.74e-14	Gut microbiome composition (summer);
LUAD	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg02475777	chr4:1388615	CRIPAK	0.59	8.22	0.37	2.6e-15	Longevity;
LUAD	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg00106254	chr7:1943704	MAD1L1	-0.45	-6.56	-0.3	1.55e-10	Schizophrenia;
LUAD	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg06627628	chr2:24431161	ITSN2	-0.72	-11.3	-0.48	4.87e-26	Asthma;
LUAD	cis	rs524023	0.914	rs526338	chr11:64418900	G/A	cg19131476	chr11:64387923	NRXN2	-0.43	-8.46	-0.38	4.57e-16	Urate levels in obese individuals;
LUAD	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg27631724	chr1:11040367	C1orf127	0.52	8.93	0.4	1.32e-17	Male-pattern baldness;
LUAD	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg09065629	chr16:1709722	CRAMP1L	0.42	7.29	0.33	1.54e-12	Coronary artery disease;
LUAD	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg09945482	chr18:12777974	NA	0.53	6.64	0.31	9.65e-11	Inflammatory skin disease;
LUAD	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg01097406	chr16:89675127	NA	0.34	6.96	0.32	1.3e-11	Vitiligo;
LUAD	cis	rs2637266	1.000	rs34483246	chr10:78342790	G/A	cg18941641	chr10:78392320	NA	0.33	6.87	0.32	2.37e-11	Pulmonary function;
LUAD	trans	rs9929218	1.000	rs12596061	chr16:68807828	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-13.97	-0.56	9.34e-37	Colorectal cancer;
LUAD	cis	rs490234	0.783	rs28729336	chr9:128405488	T/G	cg14078157	chr9:128172775	NA	-0.38	-6.74	-0.31	5.04e-11	Mean arterial pressure;
LUAD	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg17063962	chr7:91808500	NA	0.68	12.08	0.51	4.36e-29	Breast cancer;
LUAD	cis	rs10924309	0.889	rs884987	chr1:245860076	G/C	cg00036263	chr1:245852353	KIF26B	-0.49	-7.55	-0.34	2.76e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.8	10.82	0.47	3.03e-24	Smoking behavior;
LUAD	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.62	-0.35	1.67e-13	Lung cancer;
LUAD	cis	rs3931020	0.657	rs277369	chr1:75234661	T/C	cg10128416	chr1:75198403	TYW3;CRYZ	-0.5	-6.58	-0.3	1.42e-10	Resistin levels;
LUAD	trans	rs7746199	0.736	rs34543938	chr6:27624640	A/G	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.65	-0.46	1.24e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg26168224	chr5:2018326	NA	-0.69	-13.39	-0.55	2.39e-34	Gut microbiome composition (winter);
LUAD	cis	rs34734847	1.000	rs35360964	chr12:121156290	T/C	cg27246729	chr12:121163418	ACADS	0.39	7.41	0.34	6.85e-13	Mean corpuscular volume;
LUAD	cis	rs7737355	0.947	rs244736	chr5:130816178	T/C	cg25547332	chr5:131281432	NA	0.42	6.42	0.3	3.57e-10	Life satisfaction;
LUAD	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10802521	chr3:52805072	NEK4	-0.62	-11.08	-0.47	3.05e-25	Bipolar disorder;
LUAD	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg04851639	chr8:1020857	NA	-0.33	-8.17	-0.37	3.72e-15	Schizophrenia;
LUAD	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg18138036	chr10:133769891	PPP2R2D	0.41	6.76	0.31	4.5e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg26566898	chr11:117069891	TAGLN	0.33	6.39	0.3	4.34e-10	Blood protein levels;
LUAD	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg17330251	chr7:94953956	PON1	-0.55	-7.62	-0.35	1.64e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4478137	0.839	rs3967763	chr4:164239273	G/C	cg06758707	chr4:164254230	NPY1R	0.43	6.89	0.32	2.03e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg11822812	chr5:140052017	DND1	-0.38	-6.84	-0.32	2.73e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12760731	0.565	rs16852576	chr1:178192371	C/T	cg00404053	chr1:178313656	RASAL2	0.72	9.09	0.4	4.02e-18	Obesity-related traits;
LUAD	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.55	9.56	0.42	9.56e-20	Axial length;
LUAD	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg04476341	chr5:669733	TPPP	0.41	8.01	0.36	1.16e-14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs4919694	0.901	rs113541728	chr10:104716771	A/T	cg04362960	chr10:104952993	NT5C2	0.74	7.93	0.36	1.98e-14	Arsenic metabolism;
LUAD	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg09658497	chr7:2847517	GNA12	-0.39	-6.96	-0.32	1.34e-11	Height;
LUAD	cis	rs7833986	0.501	rs2953897	chr8:56980569	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	1.01	18.4	0.67	5.68e-56	Height;
LUAD	cis	rs6761276	0.899	rs11678375	chr2:113835691	T/C	cg10479672	chr2:113810641	IL1F8	-0.38	-7.65	-0.35	1.39e-13	Protein quantitative trait loci;
LUAD	cis	rs55788414	0.932	rs11649028	chr16:81185326	G/A	cg06400318	chr16:81190750	PKD1L2	0.64	8.79	0.39	3.74e-17	Left ventricular obstructive tract defect (maternal effect);
LUAD	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg15704280	chr7:45808275	SEPT13	-0.53	-8.37	-0.38	8.71e-16	HDL cholesterol;
LUAD	cis	rs2625529	0.668	rs34487006	chr15:72462350	G/T	cg16672083	chr15:72433130	SENP8	-0.75	-12.83	-0.53	4.5e-32	Red blood cell count;
LUAD	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg24399712	chr22:39784796	NA	0.78	15.01	0.59	3.87e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs9467773	1.000	rs1570059	chr6:26573325	C/T	cg09904177	chr6:26538194	HMGN4	0.43	6.98	0.32	1.16e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7582720	1.000	rs114110842	chr2:203823400	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24531977	chr5:56204891	C5orf35	-1.05	-15.98	-0.61	2.69e-45	Initial pursuit acceleration;
LUAD	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.25	-0.51	1.01e-29	Platelet count;
LUAD	trans	rs8073060	0.586	rs225257	chr17:33956625	G/A	cg19694781	chr19:47549865	TMEM160	-1.24	-19.53	-0.69	5.39e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg03676636	chr4:99064102	C4orf37	0.32	8.33	0.38	1.17e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.19	-0.33	3.02e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs12216545	0.765	rs10238068	chr7:150249758	G/T	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.39	-0.3	4.27e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg10645314	chr2:3704589	ALLC	-0.57	-9.12	-0.41	3.12e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs863345	0.504	rs857707	chr1:158564383	A/G	cg12129480	chr1:158549410	OR10X1	-0.24	-6.5	-0.3	2.25e-10	Pneumococcal bacteremia;
LUAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg21724239	chr8:58056113	NA	0.81	10.15	0.44	8.05e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs600231	0.508	rs11227202	chr11:65242717	G/A	cg17120908	chr11:65337727	SSSCA1	-0.63	-8.26	-0.37	1.86e-15	Bone mineral density;
LUAD	cis	rs4523957	0.690	rs11078855	chr17:2091308	A/G	cg16513277	chr17:2031491	SMG6	0.94	18.57	0.67	9.92e-57	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg16354688	chr1:16370265	CLCNKB	0.27	6.39	0.3	4.48e-10	Systolic blood pressure;
LUAD	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg04450456	chr4:17643702	FAM184B	0.39	7.65	0.35	1.35e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs986417	0.818	rs1950315	chr14:61000031	A/C	cg27398547	chr14:60952738	C14orf39	0.66	8.07	0.37	7.54e-15	Gut microbiota (bacterial taxa);
LUAD	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.73	-0.31	5.7e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs1941687	0.583	rs8091977	chr18:31359414	T/C	cg27147174	chr7:100797783	AP1S1	-0.68	-12.25	-0.51	9.68e-30	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.68	-11.39	-0.48	2.13e-26	Primary sclerosing cholangitis;
LUAD	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg08859206	chr1:53392774	SCP2	0.58	10.31	0.45	2.11e-22	Monocyte count;
LUAD	trans	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg18335740	chr13:41363409	SLC25A15	0.76	14.39	0.57	1.76e-38	Lewy body disease;
LUAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg09509183	chr1:209979624	IRF6	0.59	8.79	0.39	3.92e-17	Cleft lip with or without cleft palate;
LUAD	trans	rs2797160	0.967	rs8180614	chr6:126000599	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.79	-0.39	3.9e-17	Endometrial cancer;
LUAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg18621852	chr3:10150065	C3orf24	0.42	7.37	0.34	8.75e-13	Alzheimer's disease;
LUAD	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg04944784	chr2:26401820	FAM59B	-0.87	-12.33	-0.51	4.49e-30	Gut microbiome composition (summer);
LUAD	cis	rs8067545	1.000	rs2108979	chr17:19928566	G/A	cg04132472	chr17:19861366	AKAP10	0.27	6.5	0.3	2.25e-10	Schizophrenia;
LUAD	cis	rs72772090	0.634	rs72773912	chr5:96107801	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.45	-0.34	5.19e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05901451	chr6:126070800	HEY2	-0.44	-6.7	-0.31	6.73e-11	Endometrial cancer;
LUAD	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg15839431	chr19:19639596	YJEFN3	-0.53	-7.93	-0.36	2.02e-14	Bipolar disorder;
LUAD	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg20701182	chr2:24300061	SF3B14	0.91	13.61	0.55	3.03e-35	Lymphocyte counts;
LUAD	cis	rs12976411	0.575	rs8101983	chr19:32825147	T/G	cg02282382	chr19:32836354	ZNF507	0.71	6.44	0.3	3.24e-10	Coronary artery disease;
LUAD	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg14671364	chr1:107599128	PRMT6	-0.63	-10.84	-0.47	2.51e-24	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg11693508	chr17:37793320	STARD3	0.51	7.65	0.35	1.38e-13	Neuroticism;
LUAD	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg27144592	chr16:783916	NARFL	0.35	6.47	0.3	2.75e-10	Height;
LUAD	cis	rs7771547	0.603	rs7743396	chr6:36579252	C/T	cg04289385	chr6:36355825	ETV7	0.49	6.52	0.3	2.03e-10	Platelet distribution width;
LUAD	cis	rs2274273	0.840	rs28568813	chr14:55794114	C/G	cg04306507	chr14:55594613	LGALS3	0.41	8.54	0.38	2.52e-16	Protein biomarker;
LUAD	cis	rs701145	0.938	rs355749	chr3:153972500	T/C	cg17054900	chr3:154042577	DHX36	0.65	6.92	0.32	1.73e-11	Coronary artery disease;
LUAD	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg21605333	chr4:119757512	SEC24D	0.73	7.41	0.34	7.1e-13	Cannabis dependence symptom count;
LUAD	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg17177755	chr1:15930204	NA	0.44	7.11	0.33	5.05e-12	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	7.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13082711	0.954	rs34772035	chr3:27468872	C/G	cg02860705	chr3:27208620	NA	0.66	9.82	0.43	1.17e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg17330251	chr7:94953956	PON1	-0.55	-7.62	-0.35	1.64e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg05234568	chr11:5960015	NA	-0.51	-9.8	-0.43	1.42e-20	DNA methylation (variation);
LUAD	cis	rs9296092	0.517	rs7743064	chr6:33470529	C/T	cg13560919	chr6:33536144	NA	-0.78	-12.25	-0.51	9.84e-30	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs6028335	0.674	rs66513266	chr20:37597410	G/T	cg27660920	chr20:37554817	FAM83D	0.51	6.45	0.3	3.08e-10	Alcohol and nicotine co-dependence;
LUAD	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg10589385	chr1:150898437	SETDB1	0.39	7.42	0.34	6.51e-13	Tonsillectomy;
LUAD	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg16989719	chr2:238392110	NA	-0.38	-7.22	-0.33	2.38e-12	Prostate cancer;
LUAD	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg01689657	chr7:91764605	CYP51A1	-0.35	-8.67	-0.39	9.13e-17	Breast cancer;
LUAD	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19346786	chr7:2764209	NA	-0.58	-12.46	-0.52	1.47e-30	Height;
LUAD	trans	rs10411161	0.702	rs10402630	chr19:52384570	G/A	cg22319618	chr22:45562946	NUP50	-0.59	-8.35	-0.38	9.98e-16	Breast cancer;
LUAD	cis	rs7731657	0.537	rs973900	chr5:130362467	G/T	cg08523029	chr5:130500466	HINT1	-0.55	-7.3	-0.33	1.41e-12	Fasting plasma glucose;
LUAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg11494091	chr17:61959527	GH2	0.71	17.59	0.65	2.15e-52	Prudent dietary pattern;
LUAD	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg22868518	chr11:507468	RNH1	-0.63	-6.45	-0.3	3.15e-10	Body mass index;
LUAD	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg15147215	chr3:52552868	STAB1	-0.41	-7.52	-0.34	3.41e-13	Bipolar disorder;
LUAD	cis	rs2625529	0.526	rs6494997	chr15:72560642	C/T	cg16672083	chr15:72433130	SENP8	0.63	11.69	0.49	1.51e-27	Red blood cell count;
LUAD	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg25358565	chr5:93447407	FAM172A	0.65	7.68	0.35	1.11e-13	Diabetic retinopathy;
LUAD	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg20891558	chr2:74357851	NA	0.97	17.27	0.64	6.11e-51	Gestational age at birth (maternal effect);
LUAD	cis	rs2880765	0.743	rs7168345	chr15:86013601	A/G	cg13263323	chr15:86062960	AKAP13	0.47	8.56	0.38	2.11e-16	Coronary artery disease;
LUAD	trans	rs877282	0.898	rs11253347	chr10:765769	A/G	cg22713356	chr15:30763199	NA	1.28	17.3	0.64	4.19e-51	Uric acid levels;
LUAD	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.01	10.93	0.47	1.13e-24	Initial pursuit acceleration;
LUAD	cis	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg05084668	chr3:125655381	ALG1L	-0.63	-10.24	-0.45	3.94e-22	Blood pressure (smoking interaction);
LUAD	cis	rs2387326	0.717	rs10829335	chr10:129943515	A/G	cg16087940	chr10:129947807	NA	-0.65	-9.09	-0.4	3.81e-18	Select biomarker traits;
LUAD	cis	rs4862307	0.808	rs7666346	chr4:185000657	G/A	cg06737308	chr4:185021514	ENPP6	-0.55	-8.85	-0.4	2.47e-17	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-12.88	-0.53	2.95e-32	Breast cancer;
LUAD	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg05340658	chr4:99064831	C4orf37	0.42	7.01	0.32	9.65e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11809207	0.501	rs3762460	chr1:26495550	A/G	cg23602478	chr1:26503979	CNKSR1	0.27	6.53	0.3	1.91e-10	Height;
LUAD	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg09904177	chr6:26538194	HMGN4	0.42	6.98	0.32	1.18e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg02228675	chr17:40259724	DHX58	-0.45	-7.44	-0.34	5.8e-13	Fibrinogen levels;
LUAD	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg10057126	chr4:77819792	ANKRD56	0.54	9.31	0.41	6.89e-19	Emphysema distribution in smoking;
LUAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg24503407	chr1:205819492	PM20D1	0.81	16.79	0.63	7.39e-49	Menarche (age at onset);
LUAD	cis	rs394563	0.559	rs7753269	chr6:149671360	G/A	cg07828024	chr6:149772892	ZC3H12D	0.29	6.37	0.3	4.8e-10	Dupuytren's disease;
LUAD	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9644630	0.862	rs7830404	chr8:19357346	A/T	cg06699216	chr8:19333253	CSGALNACT1	-0.29	-6.87	-0.32	2.32e-11	Oropharynx cancer;
LUAD	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.45	-0.42	2.28e-19	Schizophrenia;
LUAD	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg00802000	chr16:706648	WDR90	-0.41	-7.72	-0.35	8.7e-14	Height;
LUAD	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.31	-6.89	-0.32	1.99e-11	Dupuytren's disease;
LUAD	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.64	0.31	9.9e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg08847533	chr14:75593920	NEK9	0.41	6.94	0.32	1.5e-11	Height;
LUAD	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg12062639	chr20:23401060	NAPB	1.11	11.58	0.49	3.94e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07930192	chr7:1003750	NA	0.4	7.76	0.35	6.58e-14	Longevity;Endometriosis;
LUAD	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.82	-0.36	4.31e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs754466	0.580	rs2289308	chr10:79579251	G/A	cg17075019	chr10:79541650	NA	-0.91	-19.19	-0.68	1.64e-59	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2242073	0.559	rs2121268	chr2:209029142	A/T	cg06181187	chr2:209010896	CRYGB	-0.41	-7.02	-0.32	9.14e-12	Attention deficit hyperactivity disorder;
LUAD	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg27490568	chr2:178487706	NA	0.51	7.97	0.36	1.46e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg27490568	chr2:178487706	NA	0.5	7.9	0.36	2.48e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg20283391	chr11:68216788	NA	-0.41	-6.6	-0.31	1.21e-10	Total body bone mineral density;
LUAD	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg03563238	chr19:33554763	RHPN2	-0.39	-9.11	-0.41	3.21e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs8008758	0.963	rs10132271	chr14:101688874	C/T	cg26224664	chr14:101693935	NA	-0.33	-6.82	-0.31	3.19e-11	Body mass index (alcohol intake interaction);
LUAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg18621852	chr3:10150065	C3orf24	0.47	8.19	0.37	3.1e-15	Alzheimer's disease;
LUAD	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg14196790	chr5:131705035	SLC22A5	0.54	9.69	0.43	3.5e-20	Blood metabolite levels;
LUAD	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.63	13.35	0.54	3.6e-34	Monocyte percentage of white cells;
LUAD	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.84	0.36	3.66e-14	Parkinson's disease;
LUAD	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	11.28	0.48	5.78e-26	Resting heart rate;
LUAD	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.41	-0.42	3.26e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg04455712	chr21:45112962	RRP1B	0.48	9.93	0.43	5.02e-21	Mean corpuscular volume;
LUAD	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.21	-0.33	2.59e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg00857998	chr1:205179979	DSTYK	0.4	6.54	0.3	1.79e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg16447950	chr5:562315	NA	-0.41	-6.41	-0.3	3.89e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7771547	0.642	rs595954	chr6:36464834	C/G	cg07856975	chr6:36356162	ETV7	0.44	6.77	0.31	4.28e-11	Platelet distribution width;
LUAD	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg17724175	chr1:150552817	MCL1	0.35	7.96	0.36	1.65e-14	Melanoma;
LUAD	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg01657329	chr11:68192670	LRP5	-0.42	-6.72	-0.31	6.03e-11	Total body bone mineral density;
LUAD	cis	rs11771526	0.901	rs62457503	chr7:32330980	A/C	cg27532318	chr7:32358331	NA	0.66	8.22	0.37	2.43e-15	Body mass index;
LUAD	cis	rs62238980	0.614	rs17682583	chr22:32401495	G/A	cg00543991	chr22:32367038	NA	0.95	8.87	0.4	2.05e-17	Childhood ear infection;
LUAD	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg23719950	chr11:63933701	MACROD1	-0.61	-6.61	-0.31	1.15e-10	Mean platelet volume;
LUAD	cis	rs12760731	0.641	rs10494513	chr1:178252377	C/G	cg00404053	chr1:178313656	RASAL2	0.63	8.72	0.39	6.39e-17	Obesity-related traits;
LUAD	cis	rs9644630	0.930	rs6586840	chr8:19365832	C/T	cg06699216	chr8:19333253	CSGALNACT1	0.32	7.6	0.35	1.92e-13	Oropharynx cancer;
LUAD	cis	rs1476679	0.830	rs6971558	chr7:100079857	A/T	cg19116668	chr7:99932089	PMS2L1	0.33	6.8	0.31	3.59e-11	Alzheimer's disease (late onset);
LUAD	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.6	1.41e-42	Chronic sinus infection;
LUAD	trans	rs1728785	0.901	rs6499186	chr16:68660565	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.01	0.44	2.67e-21	Ulcerative colitis;
LUAD	trans	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.36	-0.3	5.17e-10	Breast cancer;
LUAD	cis	rs17095355	0.901	rs10884919	chr10:111757791	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.26	-0.37	1.95e-15	Biliary atresia;
LUAD	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg27490568	chr2:178487706	NA	-0.37	-6.46	-0.3	2.83e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9300255	0.679	rs4759420	chr12:123794871	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.45	-0.3	3.07e-10	Neutrophil percentage of white cells;
LUAD	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg15467112	chr14:75489610	MLH3	0.35	6.41	0.3	3.86e-10	Height;
LUAD	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.7	0.35	9.97e-14	Breast cancer;
LUAD	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg27124370	chr19:33622961	WDR88	0.46	7.15	0.33	3.92e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03517284	chr6:25882590	NA	-0.57	-9.3	-0.41	7.84e-19	Blood metabolite levels;
LUAD	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg23533926	chr12:111358616	MYL2	-0.45	-7.63	-0.35	1.54e-13	Breast cancer;
LUAD	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg14228332	chr4:119757509	SEC24D	0.7	6.72	0.31	5.72e-11	Cannabis dependence symptom count;
LUAD	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.65	-0.31	8.93e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs6921919	0.887	rs7766356	chr6:28400538	T/C	cg01620082	chr3:125678407	NA	-0.49	-6.4	-0.3	4.08e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg08807101	chr21:30365312	RNF160	0.52	8.87	0.4	2.05e-17	Dental caries;
LUAD	cis	rs4713675	0.546	rs2296739	chr6:33656969	G/A	cg14003231	chr6:33640908	ITPR3	0.5	9.61	0.42	6.84e-20	Plateletcrit;
LUAD	cis	rs4774899	0.869	rs12900874	chr15:57358997	T/A	cg14026238	chr15:57616123	NA	0.44	8.32	0.38	1.22e-15	Urinary tract infection frequency;
LUAD	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg21856205	chr7:94953877	PON1	-0.54	-7.47	-0.34	4.66e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg12927641	chr6:109611667	NA	-0.54	-9.64	-0.42	5.05e-20	Reticulocyte fraction of red cells;
LUAD	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg19163074	chr7:65112434	INTS4L2	0.45	6.83	0.32	3e-11	Aortic root size;
LUAD	cis	rs9394438	0.529	rs10947681	chr6:37547073	C/A	cg00985040	chr6:37553208	NA	-0.51	-10.68	-0.46	9.44e-24	IgG glycosylation;
LUAD	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg23625390	chr15:77176239	SCAPER	-0.51	-7.75	-0.35	6.79e-14	Blood metabolite levels;
LUAD	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	7.29	0.33	1.57e-12	Menarche (age at onset);
LUAD	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.99	0.32	1.07e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7680126	0.531	rs11732007	chr4:10363994	G/A	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.61	-0.31	1.19e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6714710	0.603	rs6757357	chr2:98491750	T/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.25	0.37	2.05e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	trans	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg02030672	chr11:45687055	CHST1	-0.38	-6.82	-0.31	3.09e-11	Obesity-related traits;
LUAD	cis	rs4743820	0.651	rs10733738	chr9:93929352	G/A	cg14446406	chr9:93919335	NA	-0.53	-8.82	-0.39	3.01e-17	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs2795502	0.873	rs3121282	chr10:43423626	T/A	cg27426351	chr10:43362370	NA	0.47	7.58	0.35	2.23e-13	Blood protein levels;
LUAD	cis	rs7584330	0.737	rs6758246	chr2:238359891	G/C	cg16989719	chr2:238392110	NA	-0.36	-7.53	-0.34	3.08e-13	Prostate cancer;
LUAD	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.42	0.52	2.02e-30	Tonsillectomy;
LUAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg26769984	chr7:1090371	C7orf50	0.61	8.79	0.39	3.78e-17	Bronchopulmonary dysplasia;
LUAD	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg20203395	chr5:56204925	C5orf35	0.83	11.57	0.49	4.29e-27	Initial pursuit acceleration;
LUAD	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg03806693	chr22:41940476	POLR3H	-0.56	-8.08	-0.37	6.76e-15	Vitiligo;
LUAD	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.64	-0.42	5.01e-20	Schizophrenia;
LUAD	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg02574844	chr11:5959923	NA	-0.42	-7.32	-0.34	1.23e-12	DNA methylation (variation);
LUAD	trans	rs4650994	0.544	rs11579513	chr1:178496092	T/C	cg05059571	chr16:84539110	KIAA1609	-0.73	-13.43	-0.55	1.64e-34	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg12310025	chr6:25882481	NA	-0.52	-8.65	-0.39	1.05e-16	Blood metabolite levels;
LUAD	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg10523679	chr1:76189770	ACADM	0.83	16.37	0.62	5e-47	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg09365446	chr1:150670422	GOLPH3L	0.6	10.49	0.45	4.72e-23	Melanoma;
LUAD	cis	rs7659604	0.540	rs116452657	chr4:122674147	A/G	cg06713675	chr4:122721982	EXOSC9	0.42	7.68	0.35	1.11e-13	Type 2 diabetes;
LUAD	cis	rs2046867	0.908	rs2322613	chr3:72819453	A/C	cg25664220	chr3:72788482	NA	-0.62	-11.43	-0.49	1.52e-26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg13732083	chr21:47605072	C21orf56	0.42	6.93	0.32	1.55e-11	Testicular germ cell tumor;
LUAD	cis	rs15676	0.783	rs10988121	chr9:131564926	A/T	cg00228799	chr9:131580591	ENDOG	-0.47	-7.34	-0.34	1.07e-12	Blood metabolite levels;
LUAD	cis	rs7116495	1.000	rs679926	chr11:71769936	A/G	cg07596299	chr11:71824057	C11orf51	0.8	6.95	0.32	1.38e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23583168	chr7:148888333	NA	-0.9	-18.13	-0.66	8.8e-55	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg26446133	chr18:72167187	CNDP2	-0.79	-11.94	-0.5	1.59e-28	Refractive error;
LUAD	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg01765077	chr12:122356316	WDR66	0.49	8.45	0.38	4.73e-16	Mean corpuscular volume;
LUAD	cis	rs2041840	0.662	rs7605677	chr2:37540574	A/G	cg25727520	chr2:37576821	QPCT	0.34	7.11	0.33	4.93e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs7216064	0.906	rs78452260	chr17:65848522	G/T	cg08758996	chr17:66097529	LOC651250	0.48	7.35	0.34	1.04e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg03388025	chr16:89894329	SPIRE2	0.31	7.28	0.33	1.6e-12	Vitiligo;
LUAD	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.688	rs116173135	chr4:119721949	C/T	cg14228332	chr4:119757509	SEC24D	0.89	8.15	0.37	4.2e-15	Cannabis dependence symptom count;
LUAD	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.02	-0.44	2.44e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11971779	0.774	rs6467838	chr7:139043501	A/G	cg23387468	chr7:139079360	LUC7L2	0.28	6.49	0.3	2.47e-10	Diisocyanate-induced asthma;
LUAD	cis	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg07460842	chr6:66804631	NA	-0.99	-14.76	-0.58	4.38e-40	Exhaled nitric oxide output;
LUAD	cis	rs62400317	0.859	rs72869118	chr6:45064626	T/C	cg20913747	chr6:44695427	NA	-0.42	-6.7	-0.31	6.76e-11	Total body bone mineral density;
LUAD	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg18105134	chr13:113819100	PROZ	0.84	14.82	0.58	2.54e-40	Platelet distribution width;
LUAD	cis	rs354225	0.544	rs10193692	chr2:54808340	A/T	cg01766943	chr2:54829624	SPTBN1	0.38	7.21	0.33	2.56e-12	Schizophrenia;
LUAD	cis	rs10916814	0.632	rs6701759	chr1:20898400	G/T	cg24502330	chr1:20914028	CDA	-0.36	-7.18	-0.33	3.14e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23158103	chr7:148848205	ZNF398	-0.63	-11.3	-0.48	4.8e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg00204512	chr16:28754710	NA	0.33	7.35	0.34	1.01e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-10.35	-0.45	1.6400000000000001e-22	Gut microbiome composition (summer);
LUAD	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg07936489	chr17:37558343	FBXL20	-0.52	-7.17	-0.33	3.46e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-6.68	-0.31	7.66e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs2262909	0.745	rs1989120	chr19:22205528	T/C	cg05197062	chr11:11642011	GALNTL4	-0.5	-7.6	-0.35	1.87e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08113034	chr14:59655386	DAAM1	-0.42	-6.73	-0.31	5.46e-11	Height;
LUAD	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg03188948	chr7:1209495	NA	0.71	6.46	0.3	2.84e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8040855	0.557	rs9744503	chr15:85724217	T/C	cg04831495	chr15:85060580	GOLGA6L5	0.45	7.71	0.35	9.37e-14	Bulimia nervosa;
LUAD	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21659725	chr3:3221576	CRBN	-0.49	-8.15	-0.37	4.23e-15	Body mass index;
LUAD	cis	rs698833	0.886	rs8886	chr2:44547909	C/T	cg04920474	chr2:44395004	PPM1B	-0.4	-7.3	-0.33	1.44e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs10465746	0.780	rs11163865	chr1:84366917	C/T	cg10977910	chr1:84465055	TTLL7	0.6	9.75	0.43	2.23e-20	Obesity-related traits;
LUAD	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22496380	chr5:211416	CCDC127	-0.95	-13.54	-0.55	6.17e-35	Breast cancer;
LUAD	cis	rs909341	0.537	rs12481497	chr20:62385541	G/A	cg14758556	chr20:62440591	NA	0.45	6.67	0.31	8.14e-11	Atopic dermatitis;
LUAD	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.0	-0.36	1.23e-14	Diabetic kidney disease;
LUAD	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg03388025	chr16:89894329	SPIRE2	0.5	13.34	0.54	3.91e-34	Vitiligo;
LUAD	cis	rs78456975	0.506	rs10206900	chr2:1552841	T/C	cg01028140	chr2:1542097	TPO	-0.47	-7.6	-0.35	1.98e-13	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs9467773	1.000	rs12665431	chr6:26577308	T/A	cg09904177	chr6:26538194	HMGN4	0.44	7.08	0.33	6.2e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10802521	chr3:52805072	NEK4	-0.61	-11.04	-0.47	4.61e-25	Electroencephalogram traits;
LUAD	cis	rs2063714	1.000	rs2063714	chr6:157195980	C/G	cg23222435	chr6:157204239	ARID1B	-0.36	-6.53	-0.3	1.91e-10	Sitting height ratio;
LUAD	cis	rs11098699	0.784	rs12510530	chr4:124241079	A/C	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg14784868	chr12:69753453	YEATS4	0.45	7.38	0.34	8.24e-13	Blood protein levels;
LUAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg02725872	chr8:58115012	NA	-0.33	-6.47	-0.3	2.69e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg03929089	chr4:120376271	NA	-0.98	-20.96	-0.71	1.99e-67	Height;
LUAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg24829409	chr8:58192753	C8orf71	-0.53	-7.46	-0.34	4.82e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-15.21	-0.59	5.41e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2249625	0.584	rs2463744	chr6:72875936	C/T	cg18830697	chr6:72922368	RIMS1	-0.46	-8.41	-0.38	6.42e-16	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg18105134	chr13:113819100	PROZ	-0.81	-14.44	-0.57	1.02e-38	Platelet distribution width;
LUAD	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg06547715	chr2:218990976	CXCR2	0.28	6.64	0.31	9.81e-11	Colorectal cancer;
LUAD	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.61	0.31	1.15e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs6005807	0.719	rs12169460	chr22:29042079	A/G	cg12565055	chr22:29076175	TTC28	0.74	8.71	0.39	6.98e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs4713675	0.584	rs7770465	chr6:33674156	G/C	cg13859433	chr6:33739653	LEMD2	-0.29	-6.92	-0.32	1.71e-11	Plateletcrit;
LUAD	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg17200465	chr3:40428508	ENTPD3	0.27	6.46	0.3	2.91e-10	Renal cell carcinoma;
LUAD	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg07936489	chr17:37558343	FBXL20	-0.43	-6.73	-0.31	5.65e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs2386661	0.826	rs1317517	chr10:5672580	T/G	cg26603656	chr10:5671107	NA	0.41	7.09	0.33	5.76e-12	Breast cancer;
LUAD	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg10518543	chr12:38710700	ALG10B	-0.43	-7.09	-0.33	5.81e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.04	0.32	7.78e-12	Menopause (age at onset);
LUAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg27532560	chr4:187881888	NA	0.38	7.33	0.34	1.19e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2882667	0.898	rs2351465	chr5:138363851	A/C	cg04439458	chr5:138467593	SIL1	-0.39	-7.19	-0.33	3.05e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg06740227	chr12:86229804	RASSF9	0.37	6.6	0.31	1.21e-10	Major depressive disorder;
LUAD	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg06108461	chr20:60628389	TAF4	-1.12	-20.86	-0.71	5.49e-67	Body mass index;
LUAD	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg13319975	chr6:146136371	FBXO30	0.6	10.09	0.44	1.31e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg26898376	chr11:64110657	CCDC88B	0.38	7.08	0.33	6.23e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs208520	0.802	rs208496	chr6:66930786	G/C	cg07460842	chr6:66804631	NA	-0.98	-14.11	-0.57	2.65e-37	Exhaled nitric oxide output;
LUAD	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg04727924	chr7:799746	HEATR2	-0.52	-7.07	-0.33	6.47e-12	Cerebrospinal P-tau181p levels;
LUAD	trans	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.49	0.45	5.05e-23	Mean corpuscular volume;
LUAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg27454412	chr7:1067447	C7orf50	0.44	7.07	0.33	6.35e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg04703951	chr17:43578652	NA	0.63	8.74	0.39	5.62e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg22676075	chr6:135203613	NA	0.39	7.2	0.33	2.84e-12	Red blood cell count;
LUAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2742234	0.541	rs12416428	chr10:43708998	G/A	cg15436174	chr10:43711423	RASGEF1A	0.55	9.07	0.4	4.43e-18	Hirschsprung disease;
LUAD	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg15017067	chr4:17643749	FAM184B	0.33	6.39	0.3	4.4e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3784262	0.643	rs2453280	chr15:58368379	C/T	cg12031962	chr15:58353849	ALDH1A2	0.36	7.23	0.33	2.24e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1864400	0.605	rs12360493	chr10:43718613	A/G	cg15436174	chr10:43711423	RASGEF1A	0.44	7.58	0.35	2.26e-13	Hirschsprung disease;
LUAD	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg13010199	chr12:38710504	ALG10B	0.4	6.51	0.3	2.18e-10	Bladder cancer;
LUAD	trans	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg07211511	chr3:129823064	LOC729375	-0.54	-6.98	-0.32	1.14e-11	Blood pressure (smoking interaction);
LUAD	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9914544	0.545	rs4924940	chr17:18800092	T/C	cg25390199	chr17:18761479	PRPSAP2	-0.37	-6.42	-0.3	3.66e-10	Educational attainment (years of education);
LUAD	cis	rs3806843	0.576	rs246066	chr5:140323147	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.33	-6.69	-0.31	7.15e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	9.12	0.41	3.13e-18	Ileal carcinoids;
LUAD	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg22920501	chr2:26401640	FAM59B	-0.73	-10.49	-0.45	4.71e-23	Gut microbiome composition (summer);
LUAD	cis	rs9715521	0.935	rs6818912	chr4:59834738	A/G	cg11281224	chr4:60001000	NA	-0.55	-9.37	-0.41	4.56e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.58	-0.3	1.38e-10	Schizophrenia;
LUAD	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg12927641	chr6:109611667	NA	-0.53	-9.3	-0.41	7.32e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs1569175	0.522	rs2202923	chr2:200879804	C/T	cg23649088	chr2:200775458	C2orf69	-0.61	-6.71	-0.31	6.2e-11	Response to treatment for acute lymphoblastic leukemia;
LUAD	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg18944383	chr4:111397179	ENPEP	0.34	6.44	0.3	3.34e-10	Height;
LUAD	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.39	-8.01	-0.36	1.16e-14	Lung cancer;
LUAD	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg07936489	chr17:37558343	FBXL20	-0.41	-6.52	-0.3	1.96e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg00484396	chr16:3507460	NAT15	-0.75	-8.51	-0.38	3.08e-16	Tuberculosis;
LUAD	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg11822812	chr5:140052017	DND1	-0.44	-7.92	-0.36	2.17e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1712517	0.771	rs11191672	chr10:105138961	C/T	cg05636881	chr10:105038444	INA	0.33	6.41	0.3	4e-10	Migraine;
LUAD	cis	rs7336332	0.598	rs9581852	chr13:28013748	A/G	cg22138327	chr13:27999177	GTF3A	0.77	9.96	0.44	3.91e-21	Weight;
LUAD	cis	rs4691139	1.000	rs7692919	chr4:165902781	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.44	-8.8	-0.39	3.64e-17	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg15181151	chr6:150070149	PCMT1	0.36	6.87	0.32	2.33e-11	Lung cancer;
LUAD	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg06092702	chr1:163392909	NA	-0.39	-8.88	-0.4	1.85e-17	Motion sickness;
LUAD	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg11663144	chr21:46675770	NA	-0.51	-9.16	-0.41	2.34e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2067615	0.524	rs10467029	chr12:107078448	C/T	cg15890332	chr12:107067104	RFX4	0.42	8.76	0.39	4.64e-17	Heart rate;
LUAD	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg24578937	chr1:2090814	PRKCZ	-0.77	-16.4	-0.62	3.98e-47	Height;
LUAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg00080972	chr5:178986291	RUFY1	-0.63	-10.85	-0.47	2.33e-24	Lung cancer;
LUAD	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9581857	0.519	rs9581880	chr13:28105850	C/A	cg22138327	chr13:27999177	GTF3A	0.82	8.9	0.4	1.7e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg04414720	chr1:150670196	GOLPH3L	0.73	13.64	0.55	2.2e-35	Tonsillectomy;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04582473	chr10:89622060	PTEN;KILLIN	0.44	6.67	0.31	8.15e-11	Monocyte percentage of white cells;
LUAD	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg08508325	chr11:3079039	CARS	0.44	9.16	0.41	2.26e-18	Calcium levels;
LUAD	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg07537917	chr2:241836409	C2orf54	-0.32	-9.18	-0.41	1.92e-18	Urinary metabolites;
LUAD	cis	rs2579519	0.515	rs4907278	chr2:96392196	C/T	cg23100626	chr2:96804247	ASTL	0.34	8.41	0.38	6.49e-16	Diastolic blood pressure;
LUAD	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg27490568	chr2:178487706	NA	0.56	9.22	0.41	1.43e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6484504	0.576	rs158146	chr11:31210433	G/A	cg14844989	chr11:31128820	NA	-0.42	-7.79	-0.35	5.17e-14	Red blood cell count;
LUAD	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg14895029	chr7:2775587	GNA12	-0.43	-7.08	-0.33	6.06e-12	Height;
LUAD	cis	rs34929064	0.536	rs2961278	chr7:22634779	C/G	cg23521230	chr7:22704884	NA	0.47	7.04	0.32	8.02e-12	Major depression and alcohol dependence;
LUAD	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.07	0.32	6.56e-12	Rheumatoid arthritis;
LUAD	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg22852734	chr6:133119734	C6orf192	0.73	8.56	0.38	2.14e-16	Type 2 diabetes nephropathy;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23075327	chr3:46746779	TMIE	0.41	6.58	0.3	1.38e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs7590720	1.000	rs4674051	chr2:216907512	G/C	cg12620499	chr2:216877984	MREG	0.57	9.03	0.4	6.35e-18	Alcohol dependence;
LUAD	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-8.46	-0.38	4.39e-16	Alzheimer's disease (late onset);
LUAD	cis	rs73206853	0.764	rs56128816	chr12:110775609	T/C	cg12870014	chr12:110450643	ANKRD13A	0.64	7.19	0.33	3.04e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg06636551	chr8:101224915	SPAG1	-0.37	-6.67	-0.31	8.12e-11	Atrioventricular conduction;
LUAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg07234876	chr8:600039	NA	1.06	10.4	0.45	1.06e-22	IgG glycosylation;
LUAD	trans	rs4714291	0.963	rs940352	chr6:40113614	C/T	cg02267698	chr19:7991119	CTXN1	-0.44	-6.72	-0.31	5.79e-11	Strep throat;
LUAD	cis	rs7119	0.651	rs12904208	chr15:77845911	C/T	cg27398640	chr15:77910606	LINGO1	-0.36	-6.61	-0.31	1.13e-10	Type 2 diabetes;
LUAD	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg27535305	chr1:53392650	SCP2	-0.34	-6.96	-0.32	1.3e-11	Monocyte count;
LUAD	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg15181151	chr6:150070149	PCMT1	0.41	8.44	0.38	5.07e-16	Lung cancer;
LUAD	cis	rs7617773	0.817	rs9834095	chr3:48327751	G/A	cg11946769	chr3:48343235	NME6	0.43	6.65	0.31	8.89e-11	Coronary artery disease;
LUAD	cis	rs12410462	0.502	rs114121935	chr1:227959336	A/G	cg04117972	chr1:227635322	NA	0.66	6.56	0.3	1.53e-10	Major depressive disorder;
LUAD	cis	rs2455799	0.613	rs2455813	chr3:15735051	C/G	cg16303742	chr3:15540471	COLQ	-0.48	-8.91	-0.4	1.52e-17	Mean platelet volume;
LUAD	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg05805236	chr11:65401703	PCNXL3	-0.55	-8.77	-0.39	4.4e-17	Acne (severe);
LUAD	cis	rs6750795	0.507	rs1667320	chr2:232418314	G/T	cg19187155	chr2:232395269	NMUR1	0.49	8.7	0.39	7.68e-17	Height;
LUAD	cis	rs9807989	0.507	rs1592459	chr2:103031569	A/G	cg03938978	chr2:103052716	IL18RAP	0.44	10.14	0.44	8.64e-22	Asthma;
LUAD	cis	rs16866061	1.000	rs17480230	chr2:225399864	G/A	cg12698349	chr2:225449008	CUL3	0.77	13.46	0.55	1.23e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	trans	rs7246760	0.867	rs56377135	chr19:9820116	C/T	cg02900749	chr2:68251473	NA	-0.6	-6.64	-0.31	9.52e-11	Pursuit maintenance gain;
LUAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.78	-9.45	-0.42	2.38e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9906155	1.000	rs8080918	chr17:75738935	A/G	cg21700863	chr16:15069460	PDXDC1	0.77	6.6	0.31	1.22e-10	Body mass index;
LUAD	cis	rs877282	0.853	rs7079450	chr10:755932	T/A	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg07636037	chr3:49044803	WDR6	0.64	12.53	0.52	7.64e-31	Parkinson's disease;
LUAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.62	-10.76	-0.46	4.92e-24	Lymphocyte counts;
LUAD	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg06784218	chr1:46089804	CCDC17	0.51	11.26	0.48	6.76e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg03690763	chr11:133734501	NA	-0.34	-7.74	-0.35	7.18e-14	Childhood ear infection;
LUAD	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21659725	chr3:3221576	CRBN	0.87	18.73	0.67	1.97e-57	Intelligence (multi-trait analysis);
LUAD	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-7.54	-0.34	2.89e-13	Alzheimer's disease (late onset);
LUAD	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-7.48	-0.34	4.35e-13	Morning vs. evening chronotype;
LUAD	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg03929089	chr4:120376271	NA	-0.9	-16.76	-0.63	1.07e-48	Coronary artery disease;
LUAD	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-11.4	-0.48	1.89e-26	Mean corpuscular volume;
LUAD	cis	rs314370	0.570	rs314314	chr7:100423841	C/T	cg10426581	chr7:100472382	SRRT	0.47	7.25	0.33	2.05e-12	Resting heart rate;
LUAD	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg11919837	chr8:57350735	NA	-0.43	-6.53	-0.3	1.83e-10	Obesity-related traits;
LUAD	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg09365446	chr1:150670422	GOLPH3L	0.66	12.58	0.52	4.9e-31	Tonsillectomy;
LUAD	cis	rs11971779	0.680	rs6978680	chr7:139112048	A/G	cg23387468	chr7:139079360	LUC7L2	-0.27	-6.4	-0.3	4.09e-10	Diisocyanate-induced asthma;
LUAD	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg23625390	chr15:77176239	SCAPER	0.37	6.59	0.31	1.33e-10	Blood metabolite levels;
LUAD	cis	rs7903847	0.667	rs3818787	chr10:99145179	T/C	cg20016023	chr10:99160130	RRP12	-0.3	-7.19	-0.33	2.97e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg23029597	chr12:123009494	RSRC2	-0.57	-9.14	-0.41	2.6e-18	Body mass index;
LUAD	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg06360820	chr2:242988706	NA	-0.85	-9.2	-0.41	1.62e-18	Obesity-related traits;
LUAD	trans	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg04775059	chr7:64541387	NA	0.53	6.99	0.32	1.09e-11	Aortic root size;
LUAD	cis	rs2992756	0.663	rs3007733	chr1:18800911	C/T	cg14356550	chr1:18808102	KLHDC7A	-0.57	-9.69	-0.43	3.47e-20	Breast cancer;
LUAD	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg03929089	chr4:120376271	NA	-0.97	-20.29	-0.7	2.1e-64	Height;
LUAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg13560548	chr3:10150139	C3orf24	-0.43	-6.39	-0.3	4.36e-10	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1997103	1.000	rs6976824	chr7:55396115	A/C	cg17469321	chr7:55412551	NA	0.61	10.21	0.44	4.88e-22	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.88	0.32	2.13e-11	Motion sickness;
LUAD	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg03433033	chr1:76189801	ACADM	-0.45	-6.6	-0.31	1.24e-10	Daytime sleep phenotypes;
LUAD	cis	rs7943203	1.000	rs11212620	chr11:108290959	A/G	cg04873221	chr11:107992290	ACAT1	-0.43	-6.91	-0.32	1.82e-11	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs68170813	0.523	rs75999022	chr7:107017135	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-10.5	-0.45	4.33e-23	Coronary artery disease;
LUAD	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg02176678	chr2:219576539	TTLL4	0.74	14.93	0.59	8.38e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	12.82	0.53	5.16e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg03714773	chr7:91764589	CYP51A1	-0.3	-6.96	-0.32	1.3e-11	Breast cancer;
LUAD	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg23260525	chr10:116636907	FAM160B1	0.53	12.29	0.51	6.53e-30	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.63	-0.35	1.6e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg01200585	chr1:228362443	C1orf69	0.44	7.99	0.36	1.34e-14	Diastolic blood pressure;
LUAD	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg04369109	chr6:150039330	LATS1	-0.44	-7.19	-0.33	3.04e-12	Lung cancer;
LUAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23978390	chr7:1156363	C7orf50	0.63	10.23	0.45	4.36e-22	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.65	-0.31	8.81e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7119	0.651	rs12902948	chr15:77849254	T/C	cg27398640	chr15:77910606	LINGO1	-0.37	-6.8	-0.31	3.5e-11	Type 2 diabetes;
LUAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg16606324	chr3:10149918	C3orf24	0.67	10.95	0.47	9.69e-25	Alzheimer's disease;
LUAD	cis	rs4242434	0.819	rs2291230	chr8:22463697	C/G	cg03733263	chr8:22462867	KIAA1967	0.69	12.31	0.51	5.87e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg05340658	chr4:99064831	C4orf37	0.53	8.98	0.4	8.92e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6062509	0.965	rs2315007	chr20:62343845	T/C	cg02966332	chr20:62369605	LIME1	-0.46	-7.6	-0.35	1.87e-13	Prostate cancer;
LUAD	trans	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg04995722	chr7:26192034	NFE2L3	-0.41	-7.07	-0.33	6.54e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9522267	0.535	rs9522291	chr13:112233761	T/C	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.93e-11	Hepatitis;
LUAD	trans	rs7395662	0.963	rs2089209	chr11:48987120	C/T	cg00717180	chr2:96193071	NA	-0.4	-7.6	-0.35	1.96e-13	HDL cholesterol;
LUAD	cis	rs9660992	0.762	rs1172137	chr1:205246061	G/T	cg21545522	chr1:205238299	TMCC2	0.36	6.86	0.32	2.41e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	trans	rs877282	1.000	rs34257857	chr10:772993	C/A	cg22713356	chr15:30763199	NA	1.17	16.73	0.63	1.35e-48	Uric acid levels;
LUAD	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg26528668	chr16:1614120	IFT140	0.59	10.66	0.46	1.14e-23	Coronary artery disease;
LUAD	cis	rs57920188	0.703	rs10915642	chr1:4089244	T/C	cg10510935	chr1:4059661	NA	0.46	7.15	0.33	3.86e-12	Interleukin-17 levels;
LUAD	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg09835421	chr16:68378352	PRMT7	-0.83	-8.99	-0.4	8.54e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg21984481	chr17:79567631	NPLOC4	-0.71	-17.13	-0.64	2.47e-50	Eye color traits;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg15340526	chr3:50648891	CISH	-0.37	-6.49	-0.3	2.36e-10	Cancer;
LUAD	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-12.83	-0.53	4.89e-32	Breast cancer;
LUAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg11494091	chr17:61959527	GH2	0.75	18.54	0.67	1.39e-56	Prudent dietary pattern;
LUAD	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18099408	chr3:52552593	STAB1	-0.43	-7.7	-0.35	1e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.44	-0.49	1.38e-26	Primary sclerosing cholangitis;
LUAD	cis	rs7582720	1.000	rs75166090	chr2:203692760	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.45	0.42	2.34e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg20503657	chr10:835505	NA	0.99	15.19	0.59	6.91e-42	Eosinophil percentage of granulocytes;
LUAD	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg20701182	chr2:24300061	SF3B14	0.53	6.42	0.3	3.66e-10	Lymphocyte counts;
LUAD	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg00277334	chr10:82204260	NA	-0.96	-21.96	-0.73	6.62e-72	Post bronchodilator FEV1;
LUAD	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg16989719	chr2:238392110	NA	-0.36	-7.61	-0.35	1.85e-13	Prostate cancer;
LUAD	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.15	0.41	2.39e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg17063962	chr7:91808500	NA	0.66	11.32	0.48	3.79e-26	Breast cancer;
LUAD	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.79	-0.31	3.81e-11	Subjective well-being;
LUAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg15112475	chr7:1198522	ZFAND2A	-0.38	-7.14	-0.33	4.1e-12	Longevity;Endometriosis;
LUAD	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg02527881	chr3:46936655	PTH1R	-0.49	-9.89	-0.43	7.19e-21	Colorectal cancer;
LUAD	cis	rs2004318	1.000	rs6509884	chr19:55080431	T/C	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.96e-13	Blood protein levels;
LUAD	cis	rs11811982	0.793	rs55643926	chr1:227575629	C/T	cg24860534	chr1:227506868	CDC42BPA	0.55	6.5	0.3	2.21e-10	Optic disc area;
LUAD	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.97	-0.36	1.51e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs877282	0.583	rs7072970	chr10:822757	G/A	cg22713356	chr15:30763199	NA	0.9	11.18	0.48	1.35e-25	Uric acid levels;
LUAD	cis	rs2455601	0.608	rs11042104	chr11:8890924	C/G	cg12365402	chr11:9010492	NRIP3	0.39	6.41	0.3	3.84e-10	Schizophrenia;
LUAD	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg26597838	chr10:835615	NA	1.02	16.15	0.62	4.79e-46	Eosinophil percentage of granulocytes;
LUAD	cis	rs7103648	0.735	rs3824869	chr11:47378245	T/C	cg20307385	chr11:47447363	PSMC3	-0.64	-10.68	-0.46	9.59e-24	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.37	-0.34	8.86e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg03806693	chr22:41940476	POLR3H	0.68	9.95	0.44	4.24e-21	Vitiligo;
LUAD	trans	rs1422110	0.513	rs1363264	chr5:85450380	G/C	cg01787110	chr1:109008453	NBPF6	0.5	8.62	0.39	1.32e-16	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs9581857	0.685	rs9319369	chr13:28042323	A/T	cg22138327	chr13:27999177	GTF3A	0.85	9.63	0.42	5.4e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg10755058	chr3:40428713	ENTPD3	0.46	8.67	0.39	9.2e-17	Renal cell carcinoma;
LUAD	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	9.23	0.41	1.29e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg06191203	chr2:152266755	RIF1	-0.6	-8.94	-0.4	1.2e-17	Lung cancer;
LUAD	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09263875	chr16:632152	PIGQ	0.82	17.74	0.65	4.76e-53	Height;
LUAD	cis	rs7937890	0.559	rs2597200	chr11:14485600	A/G	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.44e-11	Mitochondrial DNA levels;
LUAD	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg24399712	chr22:39784796	NA	-0.74	-12.89	-0.53	2.7e-32	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	trans	rs208520	1.000	rs208535	chr6:66962286	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-13.5	-0.55	8.62e-35	Exhaled nitric oxide output;
LUAD	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.41	-0.34	6.99e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.4	8.94	0.4	1.23e-17	Hemoglobin concentration;
LUAD	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg19622623	chr12:86230825	RASSF9	-0.55	-9.96	-0.44	3.86e-21	Major depressive disorder;
LUAD	cis	rs743757	1.000	rs743757	chr3:50476378	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.45	-6.85	-0.32	2.63e-11	Diastolic blood pressure;
LUAD	cis	rs1497828	0.956	rs2646819	chr1:217525691	T/G	cg04411442	chr1:217543379	NA	-0.38	-6.83	-0.32	3.02e-11	Dialysis-related mortality;
LUAD	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg02527881	chr3:46936655	PTH1R	-0.46	-8.89	-0.4	1.78e-17	Colorectal cancer;
LUAD	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.43	-0.34	6.08e-13	Bipolar disorder;
LUAD	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg14582100	chr15:45693742	SPATA5L1	0.61	10.71	0.46	7.64e-24	Homoarginine levels;
LUAD	cis	rs2625529	0.878	rs71395051	chr15:72239789	C/T	cg16672083	chr15:72433130	SENP8	-0.76	-12.46	-0.52	1.44e-30	Red blood cell count;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg18603276	chr17:8023961	HES7	-0.4	-6.74	-0.31	5.31e-11	Schizophrenia;
LUAD	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg11822812	chr5:140052017	DND1	-0.44	-7.89	-0.36	2.55e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg00539368	chr18:74514137	NA	0.55	7.69	0.35	1.05e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LUAD	cis	rs863345	0.526	rs2051067	chr1:158507398	G/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.6	-0.31	1.21e-10	Pneumococcal bacteremia;
LUAD	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-16.02	-0.61	1.79e-45	Chronic sinus infection;
LUAD	cis	rs6076065	0.723	rs6137949	chr20:23418217	T/G	cg11657817	chr20:23433608	CST11	0.49	8.87	0.4	2.13e-17	Facial morphology (factor 15, philtrum width);
LUAD	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21659725	chr3:3221576	CRBN	0.64	11.06	0.47	3.75e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs2046867	0.862	rs75638790	chr3:72830502	C/T	cg04365224	chr3:72788183	NA	-0.47	-6.89	-0.32	2.04e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-6.49	-0.3	2.44e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg06957130	chr22:46933231	CELSR1	0.36	6.44	0.3	3.16e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg17177755	chr1:15930204	NA	0.45	7.32	0.34	1.28e-12	Systolic blood pressure;
LUAD	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg22535103	chr8:58192502	C8orf71	-0.64	-8.7	-0.39	7.67e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs10411161	0.702	rs7251755	chr19:52388948	G/A	cg22319618	chr22:45562946	NUP50	-0.64	-9.14	-0.41	2.58e-18	Breast cancer;
LUAD	cis	rs12942207	1	rs12942207	chr17:45968294	C/T	cg02219949	chr17:45927392	SP6	0.45	6.88	0.32	2.11e-11	Birth weight;
LUAD	trans	rs11039798	0.925	rs6485831	chr11:48455031	A/T	cg03929089	chr4:120376271	NA	0.58	6.72	0.31	5.75e-11	Axial length;
LUAD	cis	rs11811982	0.793	rs78061959	chr1:227303004	T/C	cg24860534	chr1:227506868	CDC42BPA	0.65	7.07	0.33	6.48e-12	Optic disc area;
LUAD	cis	rs9902453	0.726	rs3115088	chr17:28031275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.3	0.45	2.46e-22	Coffee consumption (cups per day);
LUAD	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg00495681	chr13:53174319	NA	-0.58	-10.81	-0.47	3.31e-24	Lewy body disease;
LUAD	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg02734326	chr4:10020555	SLC2A9	-0.54	-9.47	-0.42	2.04e-19	Bone mineral density;
LUAD	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg02423579	chr7:2872169	GNA12	-0.83	-14.23	-0.57	7.78e-38	Height;
LUAD	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg23018236	chr17:30244563	NA	-0.68	-8.24	-0.37	2.2e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs6499255	0.951	rs76407217	chr16:69690355	A/T	cg15192750	chr16:69999425	NA	0.49	7.68	0.35	1.15e-13	IgE levels;
LUAD	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg22963979	chr7:1858916	MAD1L1	-0.59	-10.22	-0.44	4.74e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03517284	chr6:25882590	NA	-0.57	-9.3	-0.41	7.32e-19	Blood metabolite levels;
LUAD	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10802521	chr3:52805072	NEK4	-0.59	-10.38	-0.45	1.21e-22	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.52	0.3	2.05e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg23158103	chr7:148848205	ZNF398	-0.57	-9.24	-0.41	1.22e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs1873147	0.569	rs58819603	chr15:63310866	T/A	cg21584241	chr15:63341463	TPM1	0.42	6.38	0.3	4.72e-10	Orofacial clefts;
LUAD	cis	rs1003719	0.715	rs9980353	chr21:38558812	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.22	-0.37	2.54e-15	Eye color traits;
LUAD	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg27661571	chr11:113659931	NA	-0.7	-8.14	-0.37	4.58e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg27170947	chr2:26402098	FAM59B	-0.64	-9.0	-0.4	7.46e-18	Gut microbiome composition (summer);
LUAD	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg16049864	chr8:95962084	TP53INP1	0.51	11.06	0.47	3.63e-25	Type 2 diabetes;
LUAD	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08704250	chr15:31115839	NA	-0.61	-10.56	-0.46	2.74e-23	Huntington's disease progression;
LUAD	cis	rs9486719	0.895	rs11152960	chr6:96900398	A/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.17	-0.44	6.77e-22	Migraine;Coronary artery disease;
LUAD	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg18944383	chr4:111397179	ENPEP	0.41	8.2	0.37	2.89e-15	Height;
LUAD	cis	rs17092148	0.887	rs6059936	chr20:33184249	C/T	cg16810054	chr20:33298113	TP53INP2	-0.49	-7.57	-0.35	2.33e-13	Neuroticism;
LUAD	cis	rs73206853	0.841	rs74728497	chr12:111020179	T/C	cg12870014	chr12:110450643	ANKRD13A	0.61	6.63	0.31	1.03e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs2908197	0.663	rs7802264	chr7:75985782	T/C	cg24580635	chr7:76178542	LOC100133091	-0.43	-6.84	-0.32	2.8e-11	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg06263672	chr7:65235340	NA	0.48	6.46	0.3	2.82e-10	Aortic root size;
LUAD	cis	rs6445967	0.530	rs62258105	chr3:58381262	C/T	cg13750441	chr3:58318267	PXK	-0.33	-6.74	-0.31	5.23e-11	Platelet count;
LUAD	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg08508325	chr11:3079039	CARS	0.44	9.06	0.4	5.05e-18	Calcium levels;
LUAD	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg20203395	chr5:56204925	C5orf35	-0.44	-6.91	-0.32	1.82e-11	Coronary artery disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10200820	chr5:102090930	NA	-0.55	-6.67	-0.31	8.25e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg03806693	chr22:41940476	POLR3H	0.52	7.66	0.35	1.24e-13	Vitiligo;
LUAD	cis	rs68170813	0.562	rs17429825	chr7:107050731	C/T	cg23024343	chr7:107201750	COG5	0.51	7.21	0.33	2.65e-12	Coronary artery disease;
LUAD	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg15208524	chr1:10270712	KIF1B	0.43	6.49	0.3	2.44e-10	Hepatocellular carcinoma;
LUAD	cis	rs6062509	1.000	rs6011066	chr20:62364180	G/A	cg21849932	chr20:62369462	LIME1	-0.46	-7.3	-0.33	1.41e-12	Prostate cancer;
LUAD	cis	rs10203711	1.000	rs907099	chr2:239559769	G/C	cg14580085	chr2:239553406	NA	0.4	8.42	0.38	5.94e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4786125	0.639	rs7200754	chr16:6897636	A/G	cg03623568	chr16:6915990	A2BP1	0.33	7.41	0.34	6.9e-13	Heart rate variability traits (SDNN);
LUAD	cis	rs9487051	0.768	rs351752	chr6:109536034	C/A	cg21918786	chr6:109611834	NA	-0.42	-7.27	-0.33	1.8e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg08219700	chr8:58056026	NA	0.6	8.47	0.38	3.98e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg17095167	chr13:21833918	NA	-0.43	-6.51	-0.3	2.1e-10	Height;
LUAD	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg20607798	chr8:58055168	NA	0.57	7.73	0.35	7.98e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg15017067	chr4:17643749	FAM184B	0.35	6.99	0.32	1.08e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg05110241	chr16:68378359	PRMT7	-0.82	-8.89	-0.4	1.79e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg14196790	chr5:131705035	SLC22A5	0.46	8.41	0.38	6.17e-16	Blood metabolite levels;
LUAD	trans	rs8073060	0.586	rs72829923	chr17:34045089	T/A	cg19694781	chr19:47549865	TMEM160	1.2	18.62	0.67	6e-57	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs36051895	0.632	rs12352022	chr9:5161836	T/G	cg02405213	chr9:5042618	JAK2	-0.49	-6.47	-0.3	2.74e-10	Pediatric autoimmune diseases;
LUAD	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg10556349	chr10:835070	NA	0.47	6.43	0.3	3.45e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg05182265	chr7:156933206	UBE3C	-0.8	-17.28	-0.64	5.14e-51	Body mass index;
LUAD	cis	rs7737355	1.000	rs248652	chr5:130654837	A/T	cg06307176	chr5:131281290	NA	-0.46	-7.32	-0.34	1.25e-12	Life satisfaction;
LUAD	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg23711669	chr6:146136114	FBXO30	-0.38	-6.39	-0.3	4.5e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs191220855	1	rs191220855	chr2:200778130	A/G	cg23649088	chr2:200775458	C2orf69	-0.68	-7.5	-0.34	3.83e-13	Chickenpox;
LUAD	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.36e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35883536	0.647	rs12023028	chr1:101042717	C/T	cg06223162	chr1:101003688	GPR88	-0.47	-9.0	-0.4	7.76e-18	Monocyte count;
LUAD	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18404041	chr3:52824283	ITIH1	-0.6	-12.48	-0.52	1.2e-30	Bipolar disorder;
LUAD	cis	rs2742417	0.935	rs2673028	chr3:45759654	A/G	cg10512202	chr3:45649293	LIMD1	0.39	6.99	0.32	1.1e-11	Response to anti-depressant treatment in major depressive disorder;
LUAD	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg15704280	chr7:45808275	SEPT13	-1.07	-25.01	-0.77	2.01e-85	Height;
LUAD	cis	rs7107174	1.000	rs2450131	chr11:77944568	A/C	cg19901956	chr11:77921274	USP35	-0.54	-6.7	-0.31	6.76e-11	Testicular germ cell tumor;
LUAD	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg20673091	chr1:2541236	MMEL1	0.46	10.01	0.44	2.68e-21	Ulcerative colitis;
LUAD	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg01324343	chr3:183735012	ABCC5	0.89	18.5	0.67	2.12e-56	Anterior chamber depth;
LUAD	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg09222892	chr1:25734099	RHCE	-0.5	-9.28	-0.41	8.61e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs10979	1.000	rs9399447	chr6:143896163	T/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.28	-0.45	2.77e-22	Hypospadias;
LUAD	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg03874509	chr1:107600012	PRMT6	0.57	9.96	0.44	3.79e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg27489772	chr12:121021490	NA	-0.56	-7.08	-0.33	6.19e-12	Type 1 diabetes nephropathy;
LUAD	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18404041	chr3:52824283	ITIH1	-0.6	-12.12	-0.51	3.18e-29	Bipolar disorder;
LUAD	cis	rs75229567	0.618	rs77168443	chr12:70208563	G/A	cg10114359	chr12:70132523	RAB3IP	0.85	6.63	0.31	1.02e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08138571	chr1:203309432	NA	0.45	7.52	0.34	3.36e-13	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.81	0.31	3.27e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.26e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg13126279	chr21:47581558	C21orf56	-0.44	-7.56	-0.35	2.46e-13	Testicular germ cell tumor;
LUAD	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.73	0.31	5.44e-11	Motion sickness;
LUAD	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg14664628	chr15:75095509	CSK	-0.52	-8.39	-0.38	7.25e-16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs910187	0.678	rs1046659	chr20:45817068	G/A	cg27589058	chr20:45804311	EYA2	-0.32	-7.58	-0.35	2.28e-13	Migraine;
LUAD	cis	rs9473147	0.543	rs1004173	chr6:47445017	C/T	cg20196966	chr6:47445060	CD2AP	0.42	6.39	0.3	4.49e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg10556349	chr10:835070	NA	0.46	6.4	0.3	4.17e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34734847	1.000	rs35360964	chr12:121156290	T/C	cg21892295	chr12:121157589	UNC119B	-0.45	-8.14	-0.37	4.43e-15	Mean corpuscular volume;
LUAD	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.04	-0.36	8.88e-15	Prostate cancer;
LUAD	cis	rs113835537	0.597	rs4576	chr11:66331000	A/G	cg24851651	chr11:66362959	CCS	0.59	10.73	0.46	6.26e-24	Airway imaging phenotypes;
LUAD	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg25237894	chr2:233734115	C2orf82	-0.56	-10.73	-0.46	6.27e-24	Coronary artery disease;
LUAD	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.5	-8.33	-0.38	1.18e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg24829409	chr8:58192753	C8orf71	-0.53	-8.38	-0.38	7.74e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4601821	0.789	rs7123797	chr11:113262571	A/G	cg14159747	chr11:113255604	NA	0.48	9.24	0.41	1.17e-18	Alcoholic chronic pancreatitis;
LUAD	cis	rs6541297	0.703	rs619899	chr1:230310069	A/G	cg20703242	chr1:230279135	GALNT2	-0.47	-6.99	-0.32	1.08e-11	Coronary artery disease;
LUAD	cis	rs17155006	0.746	rs425623	chr7:107747465	C/T	cg05962710	chr7:107745446	LAMB4	-0.34	-7.31	-0.33	1.37e-12	Pneumococcal bacteremia;
LUAD	cis	rs8044868	0.586	rs6499564	chr16:72189655	G/A	cg23815491	chr16:72088622	HP	0.47	8.74	0.39	5.6e-17	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg26384229	chr12:38710491	ALG10B	0.48	7.78	0.35	5.55e-14	Bladder cancer;
LUAD	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.22	-0.33	2.49e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg27411982	chr8:10470053	RP1L1	0.4	7.3	0.33	1.45e-12	Neuroticism;
LUAD	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs11674184	0.686	rs2358039	chr2:11729606	A/G	cg07314298	chr2:11723111	GREB1	-0.74	-13.64	-0.55	2.36e-35	Endometriosis;
LUAD	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg15309053	chr8:964076	NA	0.33	7.09	0.33	5.52e-12	Schizophrenia;
LUAD	cis	rs2658782	0.547	rs3020064	chr11:93060851	A/G	cg15737290	chr11:93063684	CCDC67	0.59	9.91	0.43	5.98e-21	Pulmonary function decline;
LUAD	cis	rs2692947	0.770	rs58730124	chr2:96413338	T/C	cg23100626	chr2:96804247	ASTL	0.32	7.71	0.35	9.34e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2425143	0.558	rs7274724	chr20:34539466	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-6.88	-0.32	2.13e-11	Blood protein levels;
LUAD	trans	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg04995722	chr7:26192034	NFE2L3	0.42	7.28	0.33	1.66e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2505998	0.868	rs7092603	chr10:43552931	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.36	-6.47	-0.3	2.7e-10	Hirschsprung disease;
LUAD	cis	rs367943	0.673	rs7708084	chr5:112732692	G/T	cg12552261	chr5:112820674	MCC	0.48	9.41	0.42	3.16e-19	Type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs12976411	0.575	rs34398998	chr19:32820820	C/A	cg02282382	chr19:32836354	ZNF507	0.71	6.43	0.3	3.54e-10	Coronary artery disease;
LUAD	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg18825076	chr15:78729989	IREB2	0.5	6.89	0.32	2e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg12714757	chr17:73874637	TRIM47	-0.41	-6.41	-0.3	3.96e-10	Psoriasis;
LUAD	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg18230493	chr5:56204884	C5orf35	-0.85	-12.28	-0.51	7.32e-30	Initial pursuit acceleration;
LUAD	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06544989	chr22:39130855	UNC84B	0.45	9.0	0.4	7.87e-18	Menopause (age at onset);
LUAD	cis	rs4077515	0.874	rs35670379	chr9:139270606	T/C	cg14169450	chr9:139327907	INPP5E	0.39	7.09	0.33	5.58e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg08885076	chr2:99613938	TSGA10	0.35	6.44	0.3	3.19e-10	Chronic sinus infection;
LUAD	cis	rs7937890	0.559	rs2575829	chr11:14485021	C/T	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.44e-11	Mitochondrial DNA levels;
LUAD	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg23954153	chr1:44402353	ARTN	-0.36	-6.68	-0.31	7.6e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg00310523	chr12:86230176	RASSF9	0.39	7.77	0.35	5.93e-14	Major depressive disorder;
LUAD	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg21191810	chr6:118973309	C6orf204	-0.48	-7.66	-0.35	1.28e-13	Renal cell carcinoma;
LUAD	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg15485101	chr11:133734466	NA	0.34	7.69	0.35	1.05e-13	Childhood ear infection;
LUAD	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg19622623	chr12:86230825	RASSF9	0.42	7.49	0.34	3.93e-13	Major depressive disorder;
LUAD	cis	rs7665090	1.000	rs5026472	chr4:103554773	C/G	cg07973026	chr4:103553119	MANBA	0.47	8.43	0.38	5.5e-16	Primary biliary cholangitis;
LUAD	trans	rs7395662	0.963	rs7952491	chr11:48663295	T/A	cg15704280	chr7:45808275	SEPT13	-0.41	-6.4	-0.3	4.17e-10	HDL cholesterol;
LUAD	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg25173405	chr17:45401733	C17orf57	0.43	7.41	0.34	6.86e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs701145	0.585	rs398512	chr3:153909988	T/C	cg17054900	chr3:154042577	DHX36	0.61	6.73	0.31	5.57e-11	Coronary artery disease;
LUAD	cis	rs3125734	0.633	rs6479804	chr10:64048327	T/C	cg09941381	chr10:64027924	RTKN2	-0.3	-6.92	-0.32	1.68e-11	Rheumatoid arthritis;
LUAD	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg13385794	chr1:248469461	NA	0.26	6.88	0.32	2.12e-11	Common traits (Other);
LUAD	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg17863274	chr19:49399704	TULP2	-0.54	-8.95	-0.4	1.16e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg07685180	chr8:600429	NA	0.88	8.61	0.39	1.41e-16	IgG glycosylation;
LUAD	cis	rs41311933	0.708	rs41313607	chr9:123722195	A/G	cg13567360	chr9:123745713	C5	-0.79	-6.91	-0.32	1.75e-11	Coronary artery disease;
LUAD	cis	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg08601574	chr20:25228251	PYGB	-0.45	-8.22	-0.37	2.49e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.41	-18.3	-0.66	1.57e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs62400317	0.826	rs11963924	chr6:45306562	C/T	cg20913747	chr6:44695427	NA	-0.41	-6.66	-0.31	8.61e-11	Total body bone mineral density;
LUAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg24642844	chr7:1081250	C7orf50	-0.59	-9.72	-0.43	2.84e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2387326	0.951	rs7919668	chr10:129931541	A/C	cg16087940	chr10:129947807	NA	-0.51	-7.17	-0.33	3.43e-12	Select biomarker traits;
LUAD	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.96	20.72	0.71	2.41e-66	Chronic sinus infection;
LUAD	cis	rs4891159	0.548	rs2554830	chr18:74127702	A/G	cg24786174	chr18:74118243	ZNF516	0.9	22.81	0.74	1.09e-75	Longevity;
LUAD	cis	rs807669	0.525	rs9605955	chr22:19181557	C/T	cg02655711	chr22:19163373	SLC25A1	0.59	11.22	0.48	9.55e-26	Metabolite levels;
LUAD	cis	rs4589502	0.800	rs2035150	chr15:67201794	A/C	cg09911534	chr15:67153556	NA	0.39	7.05	0.32	7.45e-12	Lung cancer (smoking interaction);
LUAD	cis	rs897984	0.553	rs2335013	chr16:30877346	T/G	cg02466173	chr16:30829666	NA	0.69	11.3	0.48	4.7e-26	Dementia with Lewy bodies;
LUAD	trans	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.27	0.45	3.04e-22	Mean corpuscular volume;
LUAD	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg07432352	chr17:45403706	C17orf57	0.39	7.45	0.34	5.43e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13012494	chr21:47604986	C21orf56	-0.7	-12.0	-0.5	9.39e-29	Testicular germ cell tumor;
LUAD	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06544989	chr22:39130855	UNC84B	0.45	8.7	0.39	7.23e-17	Menopause (age at onset);
LUAD	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.49	0.34	4e-13	Menopause (age at onset);
LUAD	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.76	0.35	6.5e-14	Platelet count;
LUAD	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg24069376	chr3:38537580	EXOG	0.46	11.0	0.47	6.25e-25	Electrocardiographic conduction measures;
LUAD	cis	rs8192282	0.739	rs4131514	chr1:154500089	A/G	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.37	-0.34	8.86e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg10523679	chr1:76189770	ACADM	0.81	12.77	0.53	8.21e-32	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg00280220	chr17:61926910	NA	0.37	7.14	0.33	4.17e-12	Prudent dietary pattern;
LUAD	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.73	-0.46	6.54e-24	Total body bone mineral density;
LUAD	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg21823605	chr1:152486609	CRCT1	0.28	6.52	0.3	2.01e-10	Hair morphology;
LUAD	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg27433088	chr4:174089019	GALNT7	-0.37	-6.8	-0.31	3.55e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs6840360	0.571	rs72730104	chr4:152543857	A/G	cg22705602	chr4:152727874	NA	-0.4	-6.89	-0.32	1.97e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.78	-0.43	1.63e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg17366294	chr4:99064904	C4orf37	0.64	12.39	0.52	2.71e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg13354988	chr2:263656	ACP1;SH3YL1	0.29	6.39	0.3	4.45e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7759001	0.857	rs2223464	chr6:27356216	G/A	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.83e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs243505	0.965	rs243503	chr7:148436106	G/C	cg09806900	chr7:148480153	CUL1	-0.43	-7.18	-0.33	3.08e-12	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg08847533	chr14:75593920	NEK9	0.42	7.14	0.33	4e-12	Height;
LUAD	cis	rs220324	0.688	rs56184115	chr21:43560554	G/T	cg09727148	chr21:43560719	UMODL1	0.57	8.73	0.39	6.15e-17	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg20129853	chr10:51489980	NA	0.34	6.76	0.31	4.49e-11	Prostate-specific antigen levels;
LUAD	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg16479474	chr6:28041457	NA	0.44	7.4	0.34	7.22e-13	Depression;
LUAD	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg17063962	chr7:91808500	NA	-0.66	-11.4	-0.48	2e-26	Breast cancer;
LUAD	cis	rs71403859	0.614	rs12447033	chr16:71583655	G/T	cg08717414	chr16:71523259	ZNF19	-0.58	-7.49	-0.34	4.17e-13	Post bronchodilator FEV1;
LUAD	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg26169700	chr22:42538906	CYP2D7P1	-0.54	-7.03	-0.32	8.36e-12	Birth weight;
LUAD	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg15921436	chr17:44337874	NA	0.81	10.98	0.47	7.86e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3823572	0.564	rs2953621	chr7:133662403	C/G	cg03336402	chr7:133662267	EXOC4	-0.43	-7.76	-0.35	6.28e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg22431228	chr1:16359049	CLCNKA	0.42	7.77	0.35	5.96e-14	Systolic blood pressure;
LUAD	cis	rs1816752	0.819	rs7988388	chr13:24986813	C/A	cg02811702	chr13:24901961	NA	0.43	7.37	0.34	9.06e-13	Obesity-related traits;
LUAD	cis	rs2548003	0.518	rs1833823	chr5:28741723	A/G	cg22863700	chr5:28928346	NA	0.45	6.84	0.32	2.85e-11	Hip geometry;
LUAD	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg06263672	chr7:65235340	NA	0.47	6.4	0.3	4.25e-10	Aortic root size;
LUAD	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.66	-0.39	1e-16	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.19e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg16606324	chr3:10149918	C3orf24	0.59	9.65	0.42	4.73e-20	Alzheimer's disease;
LUAD	cis	rs6494488	0.500	rs72742925	chr15:64863303	G/A	cg08069370	chr15:64387884	SNX1	-0.76	-6.77	-0.31	4.45e-11	Coronary artery disease;
LUAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.21	0.54	1.33e-33	Prudent dietary pattern;
LUAD	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.52	-8.78	-0.39	3.96e-17	Alzheimer's disease (late onset);
LUAD	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg22705602	chr4:152727874	NA	-0.49	-9.55	-0.42	1.02e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg23533926	chr12:111358616	MYL2	-0.4	-6.77	-0.31	4.23e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg02807482	chr3:125708958	NA	-0.57	-7.73	-0.35	8.11e-14	Blood pressure (smoking interaction);
LUAD	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg06131755	chr6:160182447	ACAT2	0.43	6.48	0.3	2.57e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs11249608	0.548	rs6860309	chr5:178451428	T/C	cg01312482	chr5:178451176	ZNF879	-0.44	-6.8	-0.31	3.68e-11	Pubertal anthropometrics;
LUAD	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg27170947	chr2:26402098	FAM59B	-0.62	-8.99	-0.4	8.04e-18	Gut microbiome composition (summer);
LUAD	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg08798685	chr6:27730294	NA	-0.7	-7.38	-0.34	8.45e-13	Depression;
LUAD	trans	rs8073060	0.586	rs225256	chr17:33955756	C/T	cg19694781	chr19:47549865	TMEM160	-1.24	-19.53	-0.69	5.39e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs4889855	0.585	rs72855201	chr17:78530597	A/G	cg16591659	chr17:78472290	NA	0.44	7.79	0.35	5.25e-14	Fractional excretion of uric acid;
LUAD	trans	rs1337391	0.649	rs12002673	chr9:16574319	C/T	cg08976687	chr2:85515537	TCF7L1	0.4	6.41	0.3	3.89e-10	Heschl's gyrus morphology;
LUAD	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg15790184	chr11:494944	RNH1	0.52	6.59	0.3	1.35e-10	Body mass index;
LUAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06873352	chr17:61820015	STRADA	0.83	18.59	0.67	8.47e-57	Prudent dietary pattern;
LUAD	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg16680214	chr1:154839983	KCNN3	-0.63	-13.26	-0.54	8.05e-34	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg05340658	chr4:99064831	C4orf37	0.53	9.07	0.4	4.48e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg25985355	chr7:65971099	NA	-0.55	-6.85	-0.32	2.54e-11	Gout;
LUAD	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg24558204	chr6:135376177	HBS1L	0.42	7.14	0.33	4.08e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg23029597	chr12:123009494	RSRC2	0.53	8.21	0.37	2.73e-15	Body mass index;
LUAD	cis	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg21775007	chr8:11205619	TDH	-0.4	-7.1	-0.33	5.15e-12	Triglycerides;
LUAD	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.92	-0.32	1.66e-11	Height;
LUAD	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg04731861	chr2:219085781	ARPC2	-0.24	-7.55	-0.34	2.72e-13	Colorectal cancer;
LUAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg14789911	chr21:47582049	C21orf56	0.45	8.04	0.36	8.93e-15	Testicular germ cell tumor;
LUAD	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg03878208	chr11:72483293	STARD10	0.46	6.58	0.3	1.42e-10	Type 2 diabetes;
LUAD	cis	rs6543140	0.964	rs1035126	chr2:103019981	C/T	cg04239558	chr2:103089729	SLC9A4	0.34	6.77	0.31	4.37e-11	Blood protein levels;
LUAD	cis	rs9837602	0.935	rs9810235	chr3:99736538	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.98	-0.32	1.12e-11	Breast cancer;
LUAD	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg00603274	chr11:61596626	FADS2	-0.71	-10.09	-0.44	1.3e-21	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs1595825	0.945	rs6736825	chr2:198854224	C/T	cg11031976	chr2:198649780	BOLL	-0.48	-7.08	-0.33	6e-12	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg03467027	chr4:99064603	C4orf37	0.39	6.4	0.3	4.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.59	0.42	7.97e-20	Cognitive ability;
LUAD	cis	rs35883536	0.647	rs55728953	chr1:101046863	T/C	cg06223162	chr1:101003688	GPR88	-0.48	-9.32	-0.41	6.57e-19	Monocyte count;
LUAD	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg04944784	chr2:26401820	FAM59B	-0.67	-9.64	-0.42	5.14e-20	Gut microbiome composition (summer);
LUAD	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg13390004	chr1:15929781	NA	0.47	8.34	0.38	1.09e-15	Systolic blood pressure;
LUAD	cis	rs7584330	0.554	rs13390883	chr2:238432619	A/T	cg14458575	chr2:238380390	NA	0.61	9.71	0.43	2.92e-20	Prostate cancer;
LUAD	cis	rs4891159	0.513	rs35534021	chr18:74130523	G/A	cg24786174	chr18:74118243	ZNF516	0.86	20.39	0.7	7.35e-65	Longevity;
LUAD	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg22117172	chr7:91764530	CYP51A1	0.33	7.37	0.34	9.07e-13	Breast cancer;
LUAD	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg22139774	chr2:100720529	AFF3	-0.35	-6.76	-0.31	4.65e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg00634984	chr7:65235879	NA	-0.44	-7.09	-0.33	5.84e-12	Calcium levels;
LUAD	cis	rs9902453	0.868	rs9896012	chr17:28470091	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.85	0.43	9.36e-21	Coffee consumption (cups per day);
LUAD	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg03929089	chr4:120376271	NA	-0.98	-20.51	-0.71	2.1e-65	Height;
LUAD	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg02018176	chr4:1364513	KIAA1530	0.37	7.03	0.32	8.27e-12	Obesity-related traits;
LUAD	cis	rs9796	0.649	rs8035828	chr15:41467287	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.61	-0.39	1.41e-16	Menopause (age at onset);
LUAD	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg21724239	chr8:58056113	NA	0.62	7.89	0.36	2.56e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg15017067	chr4:17643749	FAM184B	0.38	7.45	0.34	5.26e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.76	14.67	0.58	1.11e-39	Intelligence (multi-trait analysis);
LUAD	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg03453431	chr7:157225567	NA	-0.42	-7.2	-0.33	2.78e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg00071950	chr4:10020882	SLC2A9	0.71	13.62	0.55	2.73e-35	Bone mineral density;
LUAD	cis	rs250677	0.522	rs2895837	chr5:148357535	C/T	cg18129178	chr5:148520854	ABLIM3	0.51	7.72	0.35	8.46e-14	Breast cancer;
LUAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12210905	0.688	rs12196452	chr6:27344415	A/T	cg08851530	chr6:28072375	NA	1.09	7.97	0.36	1.45e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg13010199	chr12:38710504	ALG10B	0.38	6.37	0.3	4.94e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg09455208	chr3:40491958	NA	0.52	10.95	0.47	9.98e-25	Renal cell carcinoma;
LUAD	cis	rs2154427	0.872	rs76446596	chr21:34098391	T/C	cg21871883	chr21:34145043	C21orf49;C21orf66	0.65	6.77	0.31	4.36e-11	Bilirubin levels;
LUAD	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg13385794	chr1:248469461	NA	-0.25	-6.83	-0.32	2.94e-11	Common traits (Other);
LUAD	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg00074818	chr8:8560427	CLDN23	0.65	10.1	0.44	1.23e-21	Obesity-related traits;
LUAD	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg27535305	chr1:53392650	SCP2	0.35	7.34	0.34	1.12e-12	Monocyte count;
LUAD	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg20469991	chr17:27169893	C17orf63	-0.51	-6.5	-0.3	2.33e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg08219700	chr8:58056026	NA	0.6	7.98	0.36	1.35e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg06873352	chr17:61820015	STRADA	0.43	6.88	0.32	2.12e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg12575136	chr18:32820987	ZNF397	0.45	6.92	0.32	1.72e-11	White blood cell count;
LUAD	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg14458575	chr2:238380390	NA	0.75	11.22	0.48	9.18e-26	Prostate cancer;
LUAD	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg01191920	chr7:158217561	PTPRN2	-0.74	-16.5	-0.63	1.42e-47	Obesity-related traits;
LUAD	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg17644776	chr2:200775616	C2orf69	0.56	7.41	0.34	6.87e-13	Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13878641	chr1:110090951	GNAI3	-0.38	-6.53	-0.3	1.92e-10	Cancer;
LUAD	cis	rs9863	0.861	rs3802999	chr12:124414098	C/T	cg17723958	chr12:124429295	CCDC92	-0.42	-6.61	-0.31	1.15e-10	White blood cell count;
LUAD	cis	rs1167827	0.805	rs809439	chr7:75161318	T/A	cg04681579	chr7:75027559	TRIM73;TRIM74	0.46	6.94	0.32	1.52e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg05110241	chr16:68378359	PRMT7	-0.94	-10.59	-0.46	2.15e-23	Schizophrenia;
LUAD	cis	rs12347191	0.500	rs907578	chr9:100622883	A/G	cg13688889	chr9:100608707	NA	-0.61	-9.98	-0.44	3.24e-21	Orofacial clefts;
LUAD	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26314531	chr2:26401878	FAM59B	0.72	10.28	0.45	2.84e-22	Gut microbiome composition (summer);
LUAD	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg14196790	chr5:131705035	SLC22A5	0.48	8.56	0.38	2.18e-16	Breast cancer;Mosquito bite size;
LUAD	cis	rs6665290	0.904	rs3795451	chr1:227181923	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.2	-39.32	-0.89	2.41e-143	Myeloid white cell count;
LUAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.6	8.11	0.37	5.58e-15	Renal function-related traits (BUN);
LUAD	cis	rs912057	0.932	rs1294406	chr6:6737737	A/G	cg06612196	chr6:6737390	NA	0.54	12.23	0.51	1.2e-29	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg16006841	chr5:176797999	RGS14	-0.59	-9.16	-0.41	2.31e-18	Urate levels in lean individuals;
LUAD	cis	rs3096299	0.934	rs9927904	chr16:89462847	G/A	cg01788221	chr16:89496183	ANKRD11	-0.37	-7.04	-0.32	7.76e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.85	0.53	3.74e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg09537434	chr19:41945824	ATP5SL	-0.51	-8.09	-0.37	6.52e-15	Height;
LUAD	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.68	-0.35	1.15e-13	Alzheimer's disease (late onset);
LUAD	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg15128208	chr22:42549153	NA	0.42	6.5	0.3	2.21e-10	Birth weight;
LUAD	cis	rs7582720	1.000	rs72934573	chr2:204005072	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.59	0.42	7.57e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1267303	0.798	rs1267302	chr1:46990545	G/C	cg16387850	chr1:46982889	NA	0.4	6.39	0.3	4.34e-10	Monobrow;
LUAD	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg08999081	chr20:33150536	PIGU	0.6	13.33	0.54	4.48e-34	Glomerular filtration rate (creatinine);
LUAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg08132940	chr7:1081526	C7orf50	-0.79	-10.65	-0.46	1.25e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg17264618	chr3:40429014	ENTPD3	-0.39	-8.83	-0.39	2.87e-17	Renal cell carcinoma;
LUAD	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg16680214	chr1:154839983	KCNN3	-0.61	-12.95	-0.53	1.48e-32	Prostate cancer;
LUAD	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.32	-0.34	1.27e-12	Total body bone mineral density;
LUAD	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06022373	chr22:39101656	GTPBP1	-0.46	-7.05	-0.32	7.25e-12	Menopause (age at onset);
LUAD	cis	rs12760731	0.641	rs12036834	chr1:178236583	G/A	cg00404053	chr1:178313656	RASAL2	0.69	8.9	0.4	1.63e-17	Obesity-related traits;
LUAD	trans	rs61332075	0.501	rs56387323	chr2:239387399	T/C	cg01134436	chr17:81009848	B3GNTL1	0.8	8.77	0.39	4.27e-17	Lung function (FEV1/FVC);
LUAD	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg00071950	chr4:10020882	SLC2A9	0.58	11.11	0.48	2.55e-25	Bone mineral density;
LUAD	trans	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	19.06	0.68	6.33e-59	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4889911	0.544	rs1285273	chr17:77830885	A/G	cg02876276	chr17:77834299	NA	0.5	7.79	0.35	5.26e-14	Electroencephalogram traits;
LUAD	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg15110403	chr19:17392923	ANKLE1	-0.46	-7.44	-0.34	5.65e-13	Systemic lupus erythematosus;
LUAD	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg21918786	chr6:109611834	NA	-0.54	-9.49	-0.42	1.76e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg03690763	chr11:133734501	NA	-0.34	-7.74	-0.35	7.46e-14	Childhood ear infection;
LUAD	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.74	-12.14	-0.51	2.74e-29	Primary sclerosing cholangitis;
LUAD	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg21823605	chr1:152486609	CRCT1	0.3	6.85	0.32	2.6e-11	Hair morphology;
LUAD	cis	rs813218	0.585	rs9860561	chr3:99917434	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.45	8.58	0.39	1.76e-16	Orofacial clefts;
LUAD	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg00666640	chr1:248458726	OR2T12	0.31	7.62	0.35	1.64e-13	Common traits (Other);
LUAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg18621852	chr3:10150065	C3orf24	0.48	8.48	0.38	3.87e-16	Alzheimer's disease;
LUAD	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg00071950	chr4:10020882	SLC2A9	0.85	18.22	0.66	3.52e-55	Bone mineral density;
LUAD	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg05368731	chr17:41323189	NBR1	0.96	19.64	0.69	1.69e-61	Menopause (age at onset);
LUAD	cis	rs11640533	1.000	rs11640533	chr16:53412862	A/G	cg08681685	chr16:53407594	NA	-0.4	-6.82	-0.31	3.1e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4604732	0.536	rs78019731	chr1:247626430	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg22467129	chr15:76604101	ETFA	-0.49	-8.5	-0.38	3.2e-16	Blood metabolite levels;
LUAD	trans	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.56	-0.46	2.69e-23	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.29	6.48	0.3	2.59e-10	Systemic lupus erythematosus;
LUAD	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg07636037	chr3:49044803	WDR6	0.5	8.28	0.37	1.62e-15	Menarche (age at onset);
LUAD	cis	rs7945718	0.967	rs10831906	chr11:12783042	C/T	cg25843174	chr11:12811716	TEAD1	0.25	7.32	0.34	1.23e-12	Educational attainment (years of education);
LUAD	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.8	0.35	4.77e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg22907277	chr7:1156413	C7orf50	0.47	7.87	0.36	2.94e-14	Longevity;Endometriosis;
LUAD	cis	rs7584330	0.554	rs77380873	chr2:238426551	C/T	cg14458575	chr2:238380390	NA	0.86	13.22	0.54	1.19e-33	Prostate cancer;
LUAD	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06505273	chr16:24850292	NA	0.48	6.92	0.32	1.66e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg27170947	chr2:26402098	FAM59B	-0.8	-11.62	-0.49	2.91e-27	Gut microbiome composition (summer);
LUAD	cis	rs4356932	1.000	rs10014837	chr4:76941818	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.35	-6.4	-0.3	4.13e-10	Blood protein levels;
LUAD	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15664640	chr17:80829946	TBCD	0.8	16.07	0.62	1.05e-45	Breast cancer;
LUAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg18305652	chr10:134549665	INPP5A	0.61	11.82	0.5	4.88e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs62238980	0.614	rs117160277	chr22:32417939	A/G	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg20607798	chr8:58055168	NA	0.59	7.82	0.36	4.25e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg25894440	chr7:65020034	NA	-0.67	-7.22	-0.33	2.48e-12	Diabetic kidney disease;
LUAD	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg21138405	chr5:131827807	IRF1	-0.31	-6.43	-0.3	3.42e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg14196790	chr5:131705035	SLC22A5	0.38	6.73	0.31	5.55e-11	Blood metabolite levels;
LUAD	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg06627628	chr2:24431161	ITSN2	-0.53	-6.47	-0.3	2.77e-10	Lymphocyte counts;
LUAD	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg21100191	chr22:23484243	RTDR1	0.71	12.76	0.53	8.89e-32	Bone mineral density;
LUAD	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg19729930	chr2:74357872	NA	1.0	18.59	0.67	8.27e-57	Gestational age at birth (maternal effect);
LUAD	cis	rs4285028	0.699	rs12637968	chr3:121599976	C/T	cg11130432	chr3:121712080	ILDR1	-0.56	-7.83	-0.36	4.03e-14	Multiple sclerosis;
LUAD	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg26384229	chr12:38710491	ALG10B	-0.38	-6.54	-0.3	1.81e-10	Bladder cancer;
LUAD	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg16049864	chr8:95962084	TP53INP1	0.41	8.24	0.37	2.18e-15	Alzheimer's disease (late onset);
LUAD	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg07708487	chr16:89387014	ANKRD11	-0.33	-6.7	-0.31	6.72e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg24813613	chr7:1882135	MAD1L1	-0.4	-6.4	-0.3	4.03e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13933409	chr20:43150562	SERINC3	-0.42	-6.63	-0.31	1.06e-10	Height;
LUAD	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg09835421	chr16:68378352	PRMT7	-0.84	-8.89	-0.4	1.74e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg21782813	chr7:2030301	MAD1L1	0.53	9.42	0.42	3.05e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs1975974	0.935	rs41361749	chr17:21732693	A/G	cg18423549	chr17:21743878	NA	0.79	14.06	0.56	3.93e-37	Psoriasis;
LUAD	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg22491629	chr6:157744540	C6orf35	-0.79	-9.05	-0.4	5.3e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7737355	0.738	rs40990	chr5:130994429	G/A	cg25547332	chr5:131281432	NA	0.42	6.75	0.31	4.81e-11	Life satisfaction;
LUAD	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg04414720	chr1:150670196	GOLPH3L	0.74	13.84	0.56	3.3e-36	Tonsillectomy;
LUAD	trans	rs62458065	1.000	rs6462364	chr7:32464776	C/T	cg00845942	chr12:64062724	DPY19L2	-0.45	-6.55	-0.3	1.7e-10	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs9581857	0.685	rs78595793	chr13:28031881	C/T	cg22138327	chr13:27999177	GTF3A	0.89	10.06	0.44	1.74e-21	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg04546413	chr19:29218101	NA	0.58	8.27	0.37	1.73e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg06618935	chr21:46677482	NA	0.45	8.44	0.38	5.02e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs62458065	0.850	rs62458066	chr7:32464484	C/T	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.47	-0.34	4.66e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg17279839	chr7:150038598	RARRES2	0.44	7.37	0.34	9.15e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg02696790	chr15:75250997	RPP25	0.39	7.5	0.34	3.7e-13	Caffeine consumption;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08429159	chr1:6663269	KLHL21	-0.44	-6.88	-0.32	2.13e-11	Height;
LUAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg11494091	chr17:61959527	GH2	0.74	18.33	0.67	1.11e-55	Prudent dietary pattern;
LUAD	cis	rs1595825	1.000	rs1440087	chr2:198871476	G/C	cg10547527	chr2:198650123	BOLL	-0.5	-6.86	-0.32	2.52e-11	Ulcerative colitis;
LUAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg02524346	chr8:600233	NA	0.82	8.34	0.38	1.07e-15	IgG glycosylation;
LUAD	cis	rs4372836	0.729	rs12475612	chr2:29030006	T/G	cg09522027	chr2:28974177	PPP1CB	0.67	12.04	0.51	6.63e-29	Body mass index;
LUAD	cis	rs55728055	0.661	rs62237765	chr22:31956981	A/G	cg01338084	chr22:32026380	PISD	0.9	6.84	0.32	2.78e-11	Age-related hearing impairment;
LUAD	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.55	-0.34	2.74e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7264396	0.623	rs11698601	chr20:34205035	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-7.39	-0.34	7.7e-13	Total cholesterol levels;
LUAD	cis	rs977987	0.843	rs11641801	chr16:75455448	A/C	cg03315344	chr16:75512273	CHST6	0.64	14.15	0.57	1.66e-37	Dupuytren's disease;
LUAD	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.83	0.32	2.93e-11	Hypertriglyceridemia;
LUAD	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg05340658	chr4:99064831	C4orf37	0.56	9.46	0.42	2.13e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6076065	0.723	rs2051093	chr20:23371349	G/A	cg11657817	chr20:23433608	CST11	0.48	8.94	0.4	1.23e-17	Facial morphology (factor 15, philtrum width);
LUAD	trans	rs637571	0.726	rs689274	chr11:65665988	A/G	cg17712092	chr4:129076599	LARP1B	-0.93	-18.6	-0.67	7.66e-57	Eosinophil percentage of white cells;
LUAD	trans	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.49	-0.3	2.36e-10	Joint mobility (Beighton score);
LUAD	cis	rs7094131	0.650	rs1750775	chr10:22938848	T/C	cg19500236	chr10:22911537	PIP4K2A	-0.39	-6.55	-0.3	1.67e-10	Obesity-related traits;
LUAD	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg05425664	chr17:57184151	TRIM37	0.43	7.5	0.34	3.8e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg04756594	chr16:24857601	SLC5A11	0.76	13.37	0.55	2.93e-34	Intelligence (multi-trait analysis);
LUAD	trans	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg07817883	chr1:32538562	TMEM39B	0.6	7.21	0.33	2.54e-12	Monocyte percentage of white cells;
LUAD	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg12935359	chr14:103987150	CKB	0.46	7.15	0.33	3.87e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs11771526	0.818	rs17161140	chr7:32324199	T/C	cg27532318	chr7:32358331	NA	0.62	7.79	0.35	5.39e-14	Body mass index;
LUAD	cis	rs12928939	0.517	rs71384782	chr16:71978591	A/G	cg03805757	chr16:71968109	PKD1L3	-0.53	-8.1	-0.37	5.87e-15	Post bronchodilator FEV1;
LUAD	cis	rs12681287	0.640	rs8635	chr8:87479810	C/T	cg27223183	chr8:87520930	FAM82B	-0.67	-9.61	-0.42	6.38e-20	Caudate activity during reward;
LUAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg12419862	chr22:24373484	LOC391322	-0.69	-11.77	-0.5	7.63e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11696501	0.895	rs6130855	chr20:44148515	T/C	cg11783356	chr20:44313418	WFDC10B	-0.41	-6.77	-0.31	4.34e-11	Brain structure;
LUAD	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.61	-8.73	-0.39	6.08e-17	Gut microbiome composition (summer);
LUAD	cis	rs7737355	0.947	rs10041744	chr5:130860852	C/T	cg25547332	chr5:131281432	NA	0.43	6.51	0.3	2.19e-10	Life satisfaction;
LUAD	trans	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg06165179	chr7:39990544	CDK13	0.48	6.56	0.3	1.58e-10	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.17	-0.37	3.71e-15	Personality dimensions;
LUAD	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg21231944	chr12:82153410	PPFIA2	-0.35	-6.49	-0.3	2.35e-10	Resting heart rate;
LUAD	cis	rs11214589	0.774	rs7107223	chr11:113255574	A/T	cg14159747	chr11:113255604	NA	0.68	14.82	0.58	2.66e-40	Neuroticism;
LUAD	cis	rs7264396	0.511	rs2425102	chr20:34312303	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.29	-0.37	1.56e-15	Total cholesterol levels;
LUAD	cis	rs7119	0.623	rs12905318	chr15:77845873	T/C	cg27398640	chr15:77910606	LINGO1	-0.36	-6.61	-0.31	1.13e-10	Type 2 diabetes;
LUAD	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg14582100	chr15:45693742	SPATA5L1	0.63	12.28	0.51	7.24e-30	Homoarginine levels;
LUAD	cis	rs17155006	0.664	rs448342	chr7:107739727	A/G	cg05962710	chr7:107745446	LAMB4	-0.35	-7.32	-0.34	1.29e-12	Pneumococcal bacteremia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18234533	chr7:218310	FAM20C	0.45	6.37	0.3	4.98e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7737355	0.947	rs13163091	chr5:130836041	A/G	cg06307176	chr5:131281290	NA	-0.49	-7.91	-0.36	2.22e-14	Life satisfaction;
LUAD	cis	rs2279817	1.000	rs10788681	chr1:18019524	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.6	10.02	0.44	2.49e-21	Neuroticism;
LUAD	cis	rs9473147	0.516	rs9296561	chr6:47488938	G/A	cg02130027	chr6:47444894	CD2AP	0.36	6.96	0.32	1.3e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs8112211	0.731	rs8101488	chr19:38825094	A/G	cg14299480	chr19:38876666	GGN	-0.44	-6.47	-0.3	2.77e-10	Blood protein levels;
LUAD	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg27446573	chr6:127587934	RNF146	0.44	6.52	0.3	2.02e-10	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22091798	chr11:62446605	UBXN1	-0.45	-7.02	-0.32	9.07e-12	Height;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08511440	chr3:46923503	PTH1R	-0.61	-6.81	-0.31	3.45e-11	Type 2 diabetes;
LUAD	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	8.65	0.39	1.07e-16	Melanoma;
LUAD	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg16006841	chr5:176797999	RGS14	-0.6	-9.57	-0.42	9.35e-20	Urate levels in lean individuals;
LUAD	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg04218760	chr10:45406644	TMEM72	-0.29	-7.32	-0.34	1.25e-12	Mean corpuscular volume;
LUAD	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg24848339	chr3:12840334	CAND2	0.42	8.52	0.38	2.76e-16	QRS complex (12-leadsum);
LUAD	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg02869364	chr7:1081709	C7orf50	-0.45	-6.55	-0.3	1.62e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg18196295	chr10:418757	DIP2C	0.48	8.18	0.37	3.42e-15	Psychosis in Alzheimer's disease;
LUAD	cis	rs2637266	0.783	rs2395436	chr10:78488513	G/T	cg18941641	chr10:78392320	NA	0.33	6.85	0.32	2.65e-11	Pulmonary function;
LUAD	cis	rs6545883	0.811	rs2921718	chr2:61795267	C/A	cg15711740	chr2:61764176	XPO1	-0.41	-6.58	-0.3	1.43e-10	Tuberculosis;
LUAD	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.75	7.87	0.36	3.07e-14	Longevity;Endometriosis;
LUAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.47	-0.38	3.96e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg15181151	chr6:150070149	PCMT1	0.42	8.19	0.37	3.13e-15	Lung cancer;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17848531	chr2:182756352	SSFA2	0.4	6.37	0.3	4.91e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	trans	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.21	-0.41	1.52e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg12016809	chr21:47604291	C21orf56	-0.66	-11.66	-0.49	2e-27	Testicular germ cell tumor;
LUAD	cis	rs240764	0.782	rs12216199	chr6:101152723	C/A	cg09795085	chr6:101329169	ASCC3	-0.45	-7.8	-0.35	4.98e-14	Neuroticism;
LUAD	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg17372223	chr3:52568218	NT5DC2	-0.41	-7.47	-0.34	4.56e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg18490616	chr2:88469792	THNSL2	0.68	6.79	0.31	3.76e-11	Plasma clusterin levels;
LUAD	cis	rs11077998	0.933	rs7215465	chr17:80532532	C/T	cg10255544	chr17:80519551	FOXK2	0.34	6.71	0.31	6.23e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg02428538	chr16:24856791	SLC5A11	0.5	6.99	0.32	1.09e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	0.819	rs1473579	chr11:48901553	A/G	cg00717180	chr2:96193071	NA	-0.44	-8.51	-0.38	2.95e-16	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.63	0.31	1.03e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg20703242	chr1:230279135	GALNT2	0.65	11.13	0.48	2.07e-25	Coronary artery disease;
LUAD	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg14092988	chr3:52407081	DNAH1	0.44	8.83	0.39	2.77e-17	Bipolar disorder;
LUAD	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg16006841	chr5:176797999	RGS14	-0.51	-9.14	-0.41	2.62e-18	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs1113500	0.933	rs3909076	chr1:108631760	T/C	cg06207961	chr1:108661230	NA	0.45	8.49	0.38	3.65e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg09654669	chr8:57350985	NA	-0.65	-10.02	-0.44	2.42e-21	Obesity-related traits;
LUAD	cis	rs2455799	0.613	rs2166759	chr3:15856285	A/G	cg16303742	chr3:15540471	COLQ	0.47	8.75	0.39	4.94e-17	Mean platelet volume;
LUAD	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg11833968	chr6:79620685	NA	-0.42	-7.92	-0.36	2.16e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3106136	0.527	rs10016806	chr4:95158495	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.19	-0.44	5.86e-22	Capecitabine sensitivity;
LUAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13012494	chr21:47604986	C21orf56	0.56	9.46	0.42	2.24e-19	Testicular germ cell tumor;
LUAD	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg18854424	chr1:2615690	NA	0.42	9.24	0.41	1.26e-18	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg06558623	chr16:89946397	TCF25	0.63	7.1	0.33	5.27e-12	Skin colour saturation;
LUAD	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.8	-0.31	3.58e-11	Post bronchodilator FEV1;
LUAD	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg23229984	chr5:148520753	ABLIM3	0.47	6.62	0.31	1.07e-10	Breast cancer;
LUAD	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg08316699	chr6:150357289	NA	0.35	7.14	0.33	4.03e-12	Alopecia areata;
LUAD	cis	rs7000551	0.508	rs11780977	chr8:22245028	G/A	cg12081754	chr8:22256438	SLC39A14	0.87	13.81	0.56	4.48e-36	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	8.16	0.37	3.88e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg24450063	chr1:156163899	SLC25A44	1.23	30.09	0.83	3.59e-107	Testicular germ cell tumor;
LUAD	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg25358565	chr5:93447407	FAM172A	0.55	6.63	0.31	1.06e-10	Diabetic retinopathy;
LUAD	cis	rs9323205	0.531	rs3007082	chr14:51556581	T/C	cg23942311	chr14:51606299	NA	-0.43	-6.51	-0.3	2.16e-10	Cancer;
LUAD	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg06131755	chr6:160182447	ACAT2	0.43	6.59	0.31	1.28e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg01579765	chr21:45077557	HSF2BP	-0.58	-12.16	-0.51	2.16e-29	Mean corpuscular hemoglobin;
LUAD	cis	rs2988277	0.737	rs2949668	chr1:167434721	T/C	cg22356347	chr1:167427500	CD247	-0.36	-6.86	-0.32	2.48e-11	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg02660097	chr11:68866761	NA	0.46	6.45	0.3	3.01e-10	Blond vs. brown hair color;
LUAD	cis	rs10752881	0.652	rs10911262	chr1:183114956	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.79	0.31	3.78e-11	Colorectal cancer;
LUAD	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.85	-0.5	3.7e-28	Bipolar disorder;
LUAD	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg06641503	chr3:48959341	ARIH2	-0.36	-6.47	-0.3	2.67e-10	Menarche (age at onset);
LUAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg09436375	chr6:42928200	GNMT	-0.3	-8.42	-0.38	5.9e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02207496	chr22:18894280	DGCR6	-0.53	-6.65	-0.31	9.03e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10242455	0.702	rs45461000	chr7:99052710	A/G	cg18809830	chr7:99032528	PTCD1	-0.99	-7.18	-0.33	3.17e-12	Blood metabolite levels;
LUAD	cis	rs9322817	0.691	rs2499667	chr6:105319125	G/A	cg02098413	chr6:105308735	HACE1	0.4	8.75	0.39	5.07e-17	Thyroid stimulating hormone;
LUAD	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.99	-21.55	-0.72	4.85e-70	Chronic sinus infection;
LUAD	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.11e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg22529645	chr1:3704559	LRRC47	0.57	10.64	0.46	1.42e-23	Red cell distribution width;
LUAD	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg11189052	chr15:85197271	WDR73	0.68	8.96	0.4	1.06e-17	Schizophrenia;
LUAD	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg04000281	chr11:63949212	NA	-0.29	-6.78	-0.31	4.01e-11	Platelet count;
LUAD	trans	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.05	25.05	0.77	1.46e-85	Colorectal cancer;
LUAD	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg09526685	chr4:187126073	CYP4V2	1.02	10.75	0.46	5.23e-24	Blood protein levels;
LUAD	cis	rs3750965	0.920	rs10896420	chr11:68863047	G/A	cg06818126	chr11:68850279	TPCN2	-0.45	-6.68	-0.31	7.78e-11	Hair color;
LUAD	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg03676636	chr4:99064102	C4orf37	0.35	8.96	0.4	1.04e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg16031515	chr1:205743344	RAB7L1	-0.35	-6.93	-0.32	1.61e-11	Menarche (age at onset);
LUAD	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg14668632	chr7:2872130	GNA12	-0.75	-13.29	-0.54	6.17e-34	Height;
LUAD	trans	rs2898857	0.545	rs12942379	chr17:47358733	C/T	cg11430096	chr6:110968061	CDK19	0.53	8.19	0.37	3.04e-15	Cancer;
LUAD	trans	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg07211511	chr3:129823064	LOC729375	-0.9	-13.84	-0.56	3.55e-36	Blood pressure (smoking interaction);
LUAD	cis	rs7100689	0.890	rs4934169	chr10:82203663	A/G	cg01528321	chr10:82214614	TSPAN14	0.89	13.45	0.55	1.44e-34	Post bronchodilator FEV1;
LUAD	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg12927641	chr6:109611667	NA	-0.47	-7.85	-0.36	3.42e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs7940866	0.804	rs3910266	chr11:130814272	A/C	cg12179176	chr11:130786555	SNX19	0.43	6.88	0.32	2.17e-11	Schizophrenia;
LUAD	cis	rs1595825	0.891	rs112898725	chr2:198650006	C/T	cg10547527	chr2:198650123	BOLL	-0.57	-8.09	-0.37	6.29e-15	Ulcerative colitis;
LUAD	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.09e-16	Prostate cancer;
LUAD	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg06873352	chr17:61820015	STRADA	0.42	7.05	0.32	7.1e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg22875332	chr1:76189707	ACADM	0.88	16.59	0.63	5.78e-48	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs3936840	0.647	rs942024	chr14:102979463	C/T	cg18135206	chr14:102964638	TECPR2	0.46	7.13	0.33	4.32e-12	Plateletcrit;
LUAD	cis	rs17867775	0.623	rs11563761	chr7:126695508	A/G	cg02090654	chr7:126698344	MIR592;GRM8	0.84	9.77	0.43	1.82e-20	Anti-saccade response;
LUAD	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-10.93	-0.47	1.19e-24	Asthma;
LUAD	trans	rs10411161	0.721	rs10401778	chr19:52384315	C/T	cg22319618	chr22:45562946	NUP50	-0.59	-8.35	-0.38	9.98e-16	Breast cancer;
LUAD	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg22823121	chr1:150693482	HORMAD1	0.37	7.25	0.33	1.96e-12	Melanoma;
LUAD	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg14092988	chr3:52407081	DNAH1	-0.32	-6.37	-0.3	4.97e-10	Electroencephalogram traits;
LUAD	cis	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg24308560	chr3:49941425	MST1R	-0.53	-8.6	-0.39	1.52e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg25233709	chr10:116636983	FAM160B1	0.41	8.25	0.37	2.07e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1030268	0.715	rs13235840	chr7:133505091	A/T	cg10665199	chr7:133106180	EXOC4	0.47	6.45	0.3	3.04e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg25358565	chr5:93447407	FAM172A	0.63	7.5	0.34	3.84e-13	Diabetic retinopathy;
LUAD	trans	rs9929218	0.817	rs3114405	chr16:68722377	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.96	-16.73	-0.63	1.45e-48	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg11062466	chr8:58055876	NA	0.81	9.98	0.44	3.2e-21	Developmental language disorder (linguistic errors);
LUAD	trans	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.92	-16.45	-0.62	2.28e-47	Colorectal cancer;
LUAD	cis	rs7707921	0.914	rs4081859	chr5:81466669	G/A	cg15871215	chr5:81402204	ATG10	0.69	10.07	0.44	1.64e-21	Breast cancer;
LUAD	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg12035532	chr1:1886765	KIAA1751	0.41	6.81	0.31	3.35e-11	Body mass index;
LUAD	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.18	0.54	1.73e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg27454412	chr7:1067447	C7orf50	-0.43	-8.08	-0.37	6.71e-15	Bronchopulmonary dysplasia;
LUAD	cis	rs236352	0.515	rs9380610	chr6:36805885	A/C	cg10099585	chr6:36853529	C6orf89	-0.39	-6.67	-0.31	8.27e-11	Heart rate;
LUAD	cis	rs750460	0.966	rs11638944	chr15:74234082	C/G	cg23484268	chr15:74220776	LOXL1	-0.35	-6.66	-0.31	8.65e-11	Height;
LUAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg16414030	chr3:133502952	NA	-0.7	-13.53	-0.55	6.37e-35	Iron status biomarkers;
LUAD	trans	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg21659725	chr3:3221576	CRBN	0.38	6.4	0.3	4.15e-10	Resting heart rate;
LUAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg15117754	chr3:10150083	C3orf24	0.43	7.11	0.33	5.07e-12	Alzheimer's disease;
LUAD	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg24640516	chr1:210004059	C1orf107	0.35	6.4	0.3	4.24e-10	Orofacial clefts;
LUAD	cis	rs35991856	0.597	rs10070734	chr5:87940026	T/C	cg02225085	chr5:87975992	LOC645323	0.4	6.76	0.31	4.57e-11	Neuroticism (multi-trait analysis);
LUAD	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg05082376	chr22:42548792	NA	0.44	7.63	0.35	1.53e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg24154853	chr7:158122151	PTPRN2	0.58	11.6	0.49	3.48e-27	Calcium levels;
LUAD	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg18180107	chr4:99064573	C4orf37	0.43	6.97	0.32	1.24e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg24531977	chr5:56204891	C5orf35	-0.54	-8.5	-0.38	3.32e-16	Coronary artery disease;
LUAD	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.39	-0.38	7.35e-16	Total body bone mineral density;
LUAD	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg01097406	chr16:89675127	NA	0.33	6.8	0.31	3.48e-11	Vitiligo;
LUAD	trans	rs10102274	0.744	rs73305518	chr8:91725916	G/T	cg22978025	chr10:2308972	NA	0.58	6.37	0.3	4.85e-10	Cerebrospinal fluid clusterin levels;
LUAD	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg05340658	chr4:99064831	C4orf37	0.45	6.89	0.32	2.06e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6929812	0.651	rs4516940	chr6:27374818	C/G	cg18711553	chr6:27366782	ZNF391	0.38	6.65	0.31	9.31e-11	Neuroticism (multi-trait analysis);
LUAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg25811766	chr13:21894605	NA	0.6	9.69	0.43	3.42e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs7737355	0.773	rs31252	chr5:130833433	T/C	cg06307176	chr5:131281290	NA	0.42	6.98	0.32	1.17e-11	Life satisfaction;
LUAD	cis	rs67981189	0.579	rs2240533	chr14:71541026	T/C	cg15910301	chr14:71632612	NA	0.4	6.36	0.3	5.15e-10	Schizophrenia;
LUAD	cis	rs7945718	0.870	rs3890065	chr11:12758767	C/G	cg25843174	chr11:12811716	TEAD1	0.24	6.94	0.32	1.43e-11	Educational attainment (years of education);
LUAD	cis	rs28595532	0.702	rs72670256	chr4:119391043	G/A	cg02775129	chr4:119771670	NA	-0.65	-6.44	-0.3	3.18e-10	Cannabis dependence symptom count;
LUAD	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg19761014	chr17:28927070	LRRC37B2	0.87	8.64	0.39	1.19e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1595825	0.945	rs76877032	chr2:198840000	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-7.11	-0.33	5.06e-12	Ulcerative colitis;
LUAD	cis	rs123509	0.687	rs73077220	chr3:42842340	T/C	cg12982090	chr3:42733453	KBTBD5	-0.53	-9.04	-0.4	5.85e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs5756813	1.000	rs1074407	chr22:38156183	T/A	cg19894588	chr14:64061835	NA	0.57	9.02	0.4	6.76e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg24690094	chr11:67383802	NA	-0.51	-7.53	-0.34	3.13e-13	Mean corpuscular volume;
LUAD	cis	rs6987853	0.830	rs2272685	chr8:42354102	C/T	cg09913449	chr8:42400586	C8orf40	-0.39	-7.12	-0.33	4.58e-12	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13410877	chr18:55712976	NEDD4L	-0.43	-6.78	-0.31	4.03e-11	Height;
LUAD	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg20607287	chr7:12443886	VWDE	-0.53	-6.67	-0.31	8.01e-11	Coronary artery disease;
LUAD	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg03188948	chr7:1209495	NA	0.79	9.5	0.42	1.62e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05347473	chr6:146136440	FBXO30	-0.66	-6.51	-0.3	2.1e-10	Type 2 diabetes;
LUAD	cis	rs4462272	0.503	rs34236122	chr10:101845547	C/T	cg19754520	chr10:101825118	CPN1	-0.34	-7.33	-0.34	1.17e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9354308	0.774	rs10155672	chr6:66538447	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.86	-0.32	2.42e-11	Metabolite levels;
LUAD	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	6.92	0.32	1.64e-11	Platelet count;
LUAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg20607798	chr8:58055168	NA	0.71	9.27	0.41	9.3e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg14092571	chr14:90743983	NA	-0.95	-18.2	-0.66	4.51e-55	Gut microbiota (bacterial taxa);
LUAD	cis	rs870825	0.655	rs28604350	chr4:185638723	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	14.12	0.57	2.26e-37	Blood protein levels;
LUAD	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.18	-0.37	3.36e-15	Total body bone mineral density;
LUAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	13.2	0.54	1.46e-33	Lymphocyte counts;
LUAD	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.72	-0.35	8.37e-14	Height;
LUAD	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.62	-0.35	1.69e-13	Blood metabolite levels;
LUAD	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg06697600	chr4:7070879	GRPEL1	0.56	7.76	0.35	6.42e-14	Monocyte percentage of white cells;
LUAD	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	6.93	0.32	1.58e-11	Schizophrenia;
LUAD	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Body mass index;
LUAD	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg21918786	chr6:109611834	NA	-0.6	-11.08	-0.47	3.13e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg16988262	chr1:15930761	NA	0.41	6.86	0.32	2.45e-11	Systolic blood pressure;
LUAD	cis	rs9902453	0.868	rs8066731	chr17:28523121	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.42	0.42	3e-19	Coffee consumption (cups per day);
LUAD	cis	rs6842047	1.000	rs9995366	chr4:187131384	T/C	cg02012338	chr4:187126139	CYP4V2	0.92	9.64	0.42	5.18e-20	Blood protein levels;
LUAD	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg06873352	chr17:61820015	STRADA	0.42	6.81	0.31	3.39e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.44	-0.42	2.56e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1594829	0.553	rs7003030	chr8:26172699	G/T	cg13160058	chr8:26243215	BNIP3L	-0.34	-7.56	-0.35	2.48e-13	Height;
LUAD	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg08859206	chr1:53392774	SCP2	-0.57	-10.23	-0.45	4.21e-22	Monocyte count;
LUAD	cis	rs7814319	0.966	rs10112328	chr8:97254372	C/T	cg20787634	chr8:97240163	UQCRB	0.36	7.01	0.32	9.53e-12	Lung function (FVC);
LUAD	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg19980929	chr12:42632907	YAF2	-0.34	-6.5	-0.3	2.33e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs1018836	0.923	rs7826178	chr8:91649592	C/A	cg16814680	chr8:91681699	NA	-0.68	-11.82	-0.5	4.74e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg18944383	chr4:111397179	ENPEP	0.5	9.06	0.4	4.77e-18	Coronary artery disease;
LUAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg07685180	chr8:600429	NA	0.75	8.21	0.37	2.68e-15	IgG glycosylation;
LUAD	cis	rs735539	0.645	rs9552250	chr13:21175217	C/G	cg27499820	chr13:21296301	IL17D	0.51	8.48	0.38	3.92e-16	Dental caries;
LUAD	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	9.93	0.43	4.83e-21	Electrocardiographic conduction measures;
LUAD	trans	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg01620082	chr3:125678407	NA	-0.65	-6.89	-0.32	2.1e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg05110241	chr16:68378359	PRMT7	0.8	8.61	0.39	1.51e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg25233709	chr10:116636983	FAM160B1	0.44	8.72	0.39	6.56e-17	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg15017067	chr4:17643749	FAM184B	0.38	7.45	0.34	5.26e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.61	8.88	0.4	1.91e-17	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg24829409	chr8:58192753	C8orf71	-0.53	-7.42	-0.34	6.54e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg25427524	chr10:38739819	LOC399744	0.62	10.08	0.44	1.48e-21	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg05665937	chr4:1216051	CTBP1	0.4	7.24	0.33	2.19e-12	Obesity-related traits;
LUAD	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg23229984	chr5:148520753	ABLIM3	0.5	7.78	0.35	5.55e-14	Breast cancer;
LUAD	cis	rs367943	0.698	rs7718310	chr5:112970628	A/G	cg12552261	chr5:112820674	MCC	0.45	8.06	0.36	7.8e-15	Type 2 diabetes;
LUAD	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg19163074	chr7:65112434	INTS4L2	0.43	6.52	0.3	2.04e-10	Aortic root size;
LUAD	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg00933542	chr6:150070202	PCMT1	0.43	8.45	0.38	4.74e-16	Lung cancer;
LUAD	cis	rs12541635	0.739	rs7833595	chr8:107089603	G/T	cg10147462	chr8:107024639	NA	-0.5	-8.67	-0.39	9.44e-17	Age of smoking initiation;
LUAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg27588902	chr6:42928151	GNMT	-0.36	-9.61	-0.42	6.39e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg03732007	chr1:2071316	PRKCZ	-0.34	-6.67	-0.31	7.86e-11	Height;
LUAD	cis	rs7809950	0.954	rs2520245	chr7:107137428	G/C	cg23024343	chr7:107201750	COG5	-0.75	-12.73	-0.53	1.23e-31	Coronary artery disease;
LUAD	cis	rs6546550	0.901	rs10205487	chr2:70151471	C/T	cg02498382	chr2:70120550	SNRNP27	0.6	11.4	0.48	1.95e-26	Prevalent atrial fibrillation;
LUAD	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg25319279	chr11:5960081	NA	-0.4	-7.04	-0.32	7.7e-12	DNA methylation (variation);
LUAD	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7215564	0.908	rs2315922	chr17:78695127	C/T	cg09596252	chr17:78655493	RPTOR	0.68	6.91	0.32	1.76e-11	Myopia (pathological);
LUAD	cis	rs9302065	1.000	rs2389236	chr13:95971477	G/A	cg24476569	chr13:95954382	ABCC4	-0.47	-8.73	-0.39	6.04e-17	Blood metabolite levels;
LUAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.26	0.41	1.06e-18	Alzheimer's disease;
LUAD	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg15017067	chr4:17643749	FAM184B	0.36	7.16	0.33	3.49e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11890956	chr21:40555474	PSMG1	-0.51	-8.71	-0.39	7.13e-17	Menarche (age at onset);
LUAD	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.2	-0.51	1.55e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg26043149	chr18:55253948	FECH	0.4	6.63	0.31	1.01e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs243505	1.000	rs243507	chr7:148434600	G/A	cg09806900	chr7:148480153	CUL1	-0.43	-7.32	-0.34	1.27e-12	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg17173187	chr15:85201210	NMB	0.4	6.53	0.3	1.87e-10	Schizophrenia;
LUAD	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg00666640	chr1:248458726	OR2T12	0.3	7.27	0.33	1.77e-12	Common traits (Other);
LUAD	cis	rs4523957	0.893	rs11078018	chr17:2162119	A/G	cg16513277	chr17:2031491	SMG6	-0.76	-14.68	-0.58	1.05e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7100689	0.646	rs9804233	chr10:82134667	T/C	cg01528321	chr10:82214614	TSPAN14	0.65	10.26	0.45	3.26e-22	Post bronchodilator FEV1;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg10636391	chr1:45672074	ZSWIM5	-0.42	-7.01	-0.32	9.41e-12	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg20607798	chr8:58055168	NA	0.67	8.79	0.39	3.8e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs250585	0.850	rs394908	chr16:23463305	C/G	cg00143387	chr16:23521605	GGA2	-0.64	-7.83	-0.36	3.88e-14	Egg allergy;
LUAD	cis	rs7659604	0.540	rs7698889	chr4:122671324	G/T	cg06713675	chr4:122721982	EXOSC9	0.41	7.49	0.34	4.07e-13	Type 2 diabetes;
LUAD	cis	rs6446731	0.734	rs7675084	chr4:3273908	C/T	cg08886695	chr4:3369023	RGS12	-0.42	-6.79	-0.31	3.73e-11	Mean platelet volume;
LUAD	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg03806693	chr22:41940476	POLR3H	0.59	8.5	0.38	3.28e-16	Vitiligo;
LUAD	cis	rs28655083	1.000	rs7198870	chr16:77072963	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-7.0	-0.32	9.97e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs558133	0.964	rs6860725	chr5:78419809	C/T	cg25119155	chr5:78426943	BHMT	-0.51	-9.12	-0.41	3.04e-18	Blood and toenail selenium levels;
LUAD	cis	rs1232027	0.656	rs1677654	chr5:79968330	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.82	-0.31	3.06e-11	Huntington's disease progression;
LUAD	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22968622	chr17:43663579	NA	0.96	16.88	0.63	3.12e-49	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs525592	1	rs525592	chr11:68195104	C/T	cg01657329	chr11:68192670	LRP5	-0.55	-9.67	-0.43	4.09e-20	Bone mineral density;
LUAD	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg14345882	chr6:26364793	BTN3A2	0.69	6.91	0.32	1.79e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg19610905	chr11:61596333	FADS2	-0.73	-11.93	-0.5	1.78e-28	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg14227996	chr4:17616232	MED28	0.71	7.38	0.34	8.62e-13	Opioid sensitivity;
LUAD	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg16325326	chr1:53192061	ZYG11B	-0.6	-10.74	-0.46	5.74e-24	Monocyte count;
LUAD	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg15556689	chr8:8085844	FLJ10661	0.43	6.75	0.31	4.77e-11	Mood instability;
LUAD	cis	rs67180937	0.553	rs2936020	chr1:222829096	T/C	cg09820183	chr1:222886073	C1orf58;AIDA	0.51	6.69	0.31	7.11e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LUAD	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.45	7.9	0.36	2.4e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs76878669	0.561	rs2279862	chr11:66135179	C/T	cg18002602	chr11:66138449	SLC29A2	0.47	10.18	0.44	6.58e-22	Educational attainment (years of education);
LUAD	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.45	6.79	0.31	3.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg24578937	chr1:2090814	PRKCZ	-0.58	-12.14	-0.51	2.58e-29	Height;
LUAD	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg11833968	chr6:79620685	NA	-0.44	-8.22	-0.37	2.46e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs9296092	0.522	rs62405955	chr6:33527176	T/C	cg13560919	chr6:33536144	NA	-0.9	-16.72	-0.63	1.49e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg05110241	chr16:68378359	PRMT7	-0.84	-9.12	-0.41	2.99e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg07636037	chr3:49044803	WDR6	0.57	9.06	0.4	4.92e-18	Menarche (age at onset);
LUAD	cis	rs11811982	0.793	rs115847858	chr1:227578235	T/C	cg24860534	chr1:227506868	CDC42BPA	0.63	7.0	0.32	1e-11	Optic disc area;
LUAD	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg26384229	chr12:38710491	ALG10B	0.5	8.38	0.38	8.13e-16	Heart rate;
LUAD	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg10164272	chr16:89456328	ANKRD11	0.43	6.81	0.31	3.3e-11	Multiple myeloma (IgH translocation);
LUAD	trans	rs9929218	1.000	rs28450087	chr16:68803726	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.76	-0.56	7.41e-36	Colorectal cancer;
LUAD	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.7	-0.31	6.64e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-10.85	-0.47	2.3e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.85	0.32	2.62e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.25	0.33	2.06e-12	Menopause (age at onset);
LUAD	cis	rs7709909	0.553	rs245336	chr5:80028301	G/T	cg24059623	chr5:79951536	MSH3;DHFR	0.49	7.44	0.34	5.8e-13	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg27494647	chr7:150038898	RARRES2	-0.53	-9.45	-0.42	2.41e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.41	8.24	0.37	2.13e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs853679	0.607	rs34691223	chr6:28258208	C/A	cg12623302	chr6:28058802	ZSCAN12L1	0.52	6.44	0.3	3.19e-10	Depression;
LUAD	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg15485101	chr11:133734466	NA	0.39	8.84	0.4	2.51e-17	Childhood ear infection;
LUAD	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg04455712	chr21:45112962	RRP1B	0.44	8.81	0.39	3.3e-17	Mean corpuscular volume;
LUAD	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg04731861	chr2:219085781	ARPC2	0.23	7.06	0.32	7.02e-12	Colorectal cancer;
LUAD	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.35	6.96	0.32	1.31e-11	Depression;
LUAD	cis	rs9392556	0.829	rs693953	chr6:4120565	A/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.4	-6.89	-0.32	2.08e-11	Blood metabolite levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg15781316	chr7:96339267	SHFM1	-0.39	-6.69	-0.31	7.17e-11	Cancer;
LUAD	cis	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-6.63	-0.31	1.05e-10	Triglycerides;
LUAD	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg19717773	chr7:2847554	GNA12	-0.51	-9.69	-0.43	3.51e-20	Height;
LUAD	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg21475434	chr5:93447410	FAM172A	0.73	8.45	0.38	4.63e-16	Diabetic retinopathy;
LUAD	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-6.73	-0.31	5.39e-11	Bipolar disorder;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26346718	chr17:79482045	NA	-0.68	-6.96	-0.32	1.3e-11	Type 2 diabetes;
LUAD	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg00290607	chr11:67383545	NA	0.4	6.58	0.3	1.38e-10	Mean corpuscular volume;
LUAD	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg24675658	chr1:53192096	ZYG11B	-0.41	-6.83	-0.32	3.04e-11	Monocyte count;
LUAD	cis	rs11231629	1	rs11231629	chr11:63648573	C/T	cg04850017	chr11:63683019	RCOR2	0.44	9.78	0.43	1.67e-20	Schizophrenia;
LUAD	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.37	0.38	8.26e-16	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1493916	0.905	rs4239383	chr18:31401066	T/C	cg15819921	chr19:927150	ARID3A	-0.49	-8.1	-0.37	6.04e-15	Life satisfaction;
LUAD	trans	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	6.07e-11	Parkinson's disease;
LUAD	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg19442545	chr10:75533431	FUT11	-0.48	-7.99	-0.36	1.28e-14	Inflammatory bowel disease;
LUAD	trans	rs11650494	0.808	rs76366926	chr17:47396628	T/C	cg11430096	chr6:110968061	CDK19	0.87	6.51	0.3	2.12e-10	Prostate cancer;
LUAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg08132940	chr7:1081526	C7orf50	-0.79	-10.67	-0.46	1.04e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg19761014	chr17:28927070	LRRC37B2	0.73	7.99	0.36	1.3e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.36	-0.34	9.76e-13	Resting heart rate;
LUAD	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16744531	chr19:17905626	B3GNT3	0.49	8.94	0.4	1.2e-17	Tumor biomarkers;
LUAD	cis	rs2235649	0.789	rs9929803	chr16:1852748	A/G	cg08610935	chr16:1836813	NUBP2	-0.49	-7.33	-0.34	1.14e-12	Blood metabolite levels;
LUAD	cis	rs7903847	0.642	rs10786344	chr10:99165975	T/C	cg20016023	chr10:99160130	RRP12	-0.28	-6.78	-0.31	4.08e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.8	-0.39	3.47e-17	Alzheimer's disease (late onset);
LUAD	cis	rs10504073	0.647	rs9643395	chr8:50014500	A/C	cg00325661	chr8:49890786	NA	0.43	9.72	0.43	2.64e-20	Blood metabolite ratios;
LUAD	trans	rs1904173	0.740	rs4701479	chr5:25350332	G/T	cg08850729	chr1:60036715	FGGY	0.63	6.75	0.31	4.77e-11	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg00814883	chr7:100076585	TSC22D4	-0.52	-7.05	-0.32	7.47e-12	Lung function (FEV1/FVC);
LUAD	cis	rs12545109	0.879	rs2670015	chr8:57376607	T/A	cg11919837	chr8:57350735	NA	-0.49	-6.81	-0.31	3.28e-11	Obesity-related traits;
LUAD	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg04414720	chr1:150670196	GOLPH3L	0.62	10.73	0.46	6.63e-24	Melanoma;
LUAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.3	-0.33	1.44e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18876405	chr7:65276391	NA	0.55	9.22	0.41	1.46e-18	Aortic root size;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg14037413	chr11:9482594	ZNF143	-0.38	-6.66	-0.31	8.67e-11	Subcortical brain region volumes;
LUAD	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg11822812	chr5:140052017	DND1	0.38	6.7	0.31	6.85e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg00020340	chr7:910388	UNC84A	0.55	6.38	0.3	4.74e-10	Initial pursuit acceleration;
LUAD	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.8	-10.68	-0.46	1.01e-23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2041840	1.000	rs12712530	chr2:37505561	A/G	cg25727520	chr2:37576821	QPCT	-0.35	-7.16	-0.33	3.49e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg27494647	chr7:150038898	RARRES2	0.51	8.84	0.39	2.69e-17	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4700695	0.614	rs371246	chr5:65209126	G/A	cg21114390	chr5:65439923	SFRS12	0.65	7.35	0.34	1.06e-12	Facial morphology (factor 19);
LUAD	cis	rs57590327	0.503	rs12497231	chr3:81519291	A/G	cg07356753	chr3:81810745	GBE1	0.49	7.7	0.35	9.5e-14	Extraversion;
LUAD	cis	rs11153730	0.503	rs283045	chr6:118628476	C/G	cg21191810	chr6:118973309	C6orf204	0.49	9.58	0.42	8.67e-20	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs4786125	0.622	rs1492372	chr16:6920965	C/T	cg03623568	chr16:6915990	A2BP1	-0.49	-10.29	-0.45	2.65e-22	Heart rate variability traits (SDNN);
LUAD	cis	rs7107174	0.901	rs1046780	chr11:77926769	A/G	cg02023728	chr11:77925099	USP35	0.44	7.33	0.34	1.15e-12	Testicular germ cell tumor;
LUAD	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg23758822	chr17:41437982	NA	1.02	20.97	0.71	1.82e-67	Menopause (age at onset);
LUAD	cis	rs9515201	0.859	rs9521732	chr13:111033821	G/T	cg05272587	chr13:111038400	COL4A2	-0.35	-6.78	-0.31	4.1e-11	White matter hyperintensity burden;
LUAD	cis	rs1448094	0.802	rs56391398	chr12:86424114	C/T	cg06740227	chr12:86229804	RASSF9	0.36	6.41	0.3	3.98e-10	Major depressive disorder;
LUAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg13047869	chr3:10149882	C3orf24	0.64	9.6	0.42	6.98e-20	Alzheimer's disease;
LUAD	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg07606381	chr6:8435919	SLC35B3	0.4	6.58	0.3	1.39e-10	Motion sickness;
LUAD	cis	rs41311933	0.803	rs41312903	chr9:123725776	C/T	cg13567360	chr9:123745713	C5	-0.76	-6.95	-0.32	1.4e-11	Coronary artery disease;
LUAD	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg20534287	chr10:135191450	PAOX	0.65	7.53	0.34	3.1e-13	Lifespan;
LUAD	trans	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg11693508	chr17:37793320	STARD3	0.61	7.72	0.35	8.5e-14	Neuroticism;
LUAD	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg21963583	chr11:68658836	MRPL21	0.65	11.95	0.5	1.5e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg09640425	chr7:158790006	NA	-0.52	-8.91	-0.4	1.53e-17	Facial morphology (factor 20);
LUAD	cis	rs10465746	0.780	rs1324486	chr1:84384825	A/G	cg10977910	chr1:84465055	TTLL7	-0.55	-8.94	-0.4	1.18e-17	Obesity-related traits;
LUAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg07234876	chr8:600039	NA	1.03	10.12	0.44	1.02e-21	IgG glycosylation;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26313349	chr1:145589328	NUDT17	-0.57	-6.93	-0.32	1.53e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg18028711	chr13:45150028	TSC22D1	-0.38	-6.53	-0.3	1.91e-10	Schizophrenia;
LUAD	cis	rs2637266	0.935	rs1866890	chr10:78397073	C/T	cg18941641	chr10:78392320	NA	0.34	7.01	0.32	9.71e-12	Pulmonary function;
LUAD	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg07917127	chr4:99064746	C4orf37	0.41	6.72	0.31	6.05e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs736408	0.812	rs9881468	chr3:52828628	C/T	cg11645453	chr3:52864694	ITIH4	0.37	7.04	0.32	7.89e-12	Bipolar disorder;
LUAD	cis	rs11625487	0.609	rs74063385	chr14:77966859	C/T	cg20045696	chr14:77926864	AHSA1	-0.54	-6.41	-0.3	3.85e-10	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUAD	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.11	-0.33	5.12e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg00933542	chr6:150070202	PCMT1	0.41	8.52	0.38	2.88e-16	Lung cancer;
LUAD	cis	rs6504663	0.558	rs2412325	chr17:48546232	G/C	cg03611598	chr17:48586076	MYCBPAP	0.67	9.54	0.42	1.16e-19	Visceral fat;
LUAD	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg17031739	chr1:67600172	NA	0.45	8.18	0.37	3.35e-15	Psoriasis;
LUAD	cis	rs4713675	0.709	rs542441	chr6:33675851	A/C	cg14003231	chr6:33640908	ITPR3	-0.39	-7.03	-0.32	8.22e-12	Plateletcrit;
LUAD	cis	rs1395	1.000	rs2014252	chr2:27462405	T/A	cg23587288	chr2:27483067	SLC30A3	-0.39	-7.97	-0.36	1.44e-14	Blood metabolite levels;
LUAD	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg13732083	chr21:47605072	C21orf56	0.42	6.95	0.32	1.39e-11	Testicular germ cell tumor;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg22212156	chr20:32031449	SNTA1	-0.42	-6.63	-0.31	1.03e-10	Vertical cup-disc ratio;
LUAD	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-7.39	-0.34	8.02e-13	Retinal vascular caliber;
LUAD	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	9.4e-15	Tonsillectomy;
LUAD	cis	rs7187994	0.672	rs12932018	chr16:84796603	A/G	cg07647771	chr16:84786436	USP10	-0.3	-7.91	-0.36	2.2e-14	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg10755058	chr3:40428713	ENTPD3	0.43	8.29	0.37	1.53e-15	Renal cell carcinoma;
LUAD	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg09035930	chr12:129282057	SLC15A4	-0.7	-16.02	-0.61	1.7e-45	Systemic lupus erythematosus;
LUAD	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg21204522	chr6:27730016	NA	-0.66	-6.82	-0.31	3.09e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg05834845	chr3:195489306	MUC4	-0.62	-7.49	-0.34	4.04e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg04455712	chr21:45112962	RRP1B	0.45	9.04	0.4	5.82e-18	Mean corpuscular volume;
LUAD	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	7.86	0.36	3.22e-14	Rheumatoid arthritis;
LUAD	cis	rs62064224	0.638	rs9748130	chr17:30739113	A/G	cg18200150	chr17:30822561	MYO1D	0.39	7.29	0.33	1.5e-12	Schizophrenia;
LUAD	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg15448220	chr1:150897856	SETDB1	0.58	9.88	0.43	7.78e-21	Melanoma;
LUAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg11905131	chr22:24372483	LOC391322	-0.57	-9.5	-0.42	1.63e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg12935359	chr14:103987150	CKB	0.4	6.79	0.31	3.81e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg02176678	chr2:219576539	TTLL4	-0.8	-16.86	-0.63	3.88e-49	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg04539111	chr16:67997858	SLC12A4	-0.59	-6.92	-0.32	1.67e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg06606381	chr12:133084897	FBRSL1	-1.01	-9.71	-0.43	2.87e-20	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1448094	1.000	rs10083080	chr12:86348579	G/C	cg18827107	chr12:86230957	RASSF9	-0.46	-8.28	-0.37	1.63e-15	Major depressive disorder;
LUAD	cis	rs17095355	1.000	rs72828241	chr10:111744704	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.65	-7.72	-0.35	8.31e-14	Biliary atresia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27279652	chr12:26986506	ITPR2	-0.42	-6.43	-0.3	3.52e-10	Height;
LUAD	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg18306943	chr3:40428807	ENTPD3	0.42	7.0	0.32	1.01e-11	Renal cell carcinoma;
LUAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg07414643	chr4:187882934	NA	-0.33	-6.75	-0.31	5e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg05717871	chr11:638507	DRD4	-0.42	-6.42	-0.3	3.62e-10	Systemic lupus erythematosus;
LUAD	cis	rs9394438	0.628	rs4714080	chr6:37544618	A/G	cg00985040	chr6:37553208	NA	0.43	8.96	0.4	1.04e-17	IgG glycosylation;
LUAD	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg11822812	chr5:140052017	DND1	-0.44	-7.92	-0.36	2.18e-14	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg18944383	chr4:111397179	ENPEP	0.38	7.59	0.35	2.06e-13	Height;
LUAD	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg16325326	chr1:53192061	ZYG11B	0.51	8.78	0.39	4.07e-17	Monocyte count;
LUAD	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg03037974	chr15:76606532	NA	0.39	8.54	0.38	2.51e-16	Blood metabolite levels;
LUAD	cis	rs999943	0.846	rs10947422	chr6:33611351	G/A	cg14003231	chr6:33640908	ITPR3	0.84	16.98	0.64	1.08e-49	Obesity (extreme);
LUAD	trans	rs7395662	0.963	rs7120743	chr11:48922645	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.43	-0.34	5.88e-13	HDL cholesterol;
LUAD	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg26924012	chr15:45694286	SPATA5L1	0.98	15.63	0.61	8.31e-44	Homoarginine levels;
LUAD	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg09998033	chr7:158218633	PTPRN2	-0.48	-8.79	-0.39	3.86e-17	Obesity-related traits;
LUAD	cis	rs427394	0.659	rs175594	chr5:6729885	T/G	cg12316010	chr5:6737918	POLS	0.39	7.46	0.34	4.92e-13	Menopause (age at onset);
LUAD	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg15309053	chr8:964076	NA	0.35	7.54	0.34	2.82e-13	Schizophrenia;
LUAD	trans	rs1973993	0.967	rs11165643	chr1:96924097	C/T	cg10631902	chr5:14652156	NA	0.53	9.91	0.43	6.05e-21	Weight;
LUAD	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03264133	chr6:25882463	NA	-0.51	-8.57	-0.38	1.94e-16	Blood metabolite levels;
LUAD	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-11.75	-0.5	8.58e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs17095355	1.000	rs12265204	chr10:111752163	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.67	-8.54	-0.38	2.46e-16	Biliary atresia;
LUAD	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg07636037	chr3:49044803	WDR6	-0.45	-7.35	-0.34	1.01e-12	Menarche (age at onset);
LUAD	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg14345882	chr6:26364793	BTN3A2	0.7	7.1	0.33	5.18e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg23602478	chr1:26503979	CNKSR1	0.28	6.99	0.32	1.1e-11	Height;
LUAD	cis	rs7945718	0.967	rs10741602	chr11:12761699	A/T	cg25843174	chr11:12811716	TEAD1	0.25	7.32	0.34	1.23e-12	Educational attainment (years of education);
LUAD	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg23262073	chr20:60523788	NA	-0.47	-7.61	-0.35	1.83e-13	Body mass index;
LUAD	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg21770322	chr7:97807741	LMTK2	0.3	7.22	0.33	2.43e-12	Breast cancer;
LUAD	cis	rs4691139	0.903	rs10434177	chr4:165915531	A/T	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.53	-7.09	-0.33	5.54e-12	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.64	-0.35	1.5e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs201673768	1	rs201673768	chr12:48699606	TGTTTTGTTTTG/T	cg24011408	chr12:48396354	COL2A1	0.34	7.19	0.33	2.9e-12	Platelet count;
LUAD	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg09021430	chr5:549028	NA	-0.69	-13.3	-0.54	5.59e-34	Lung disease severity in cystic fibrosis;
LUAD	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg06221963	chr1:154839813	KCNN3	-0.84	-18.9	-0.68	3.51e-58	Prostate cancer;
LUAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg22963979	chr7:1858916	MAD1L1	-0.7	-12.36	-0.52	3.66e-30	Bipolar disorder and schizophrenia;
LUAD	cis	rs7586879	0.765	rs11683429	chr2:25120733	T/A	cg04586622	chr2:25135609	ADCY3	0.36	7.28	0.33	1.63e-12	Body mass index;
LUAD	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg15412446	chr2:106886593	NA	0.73	11.56	0.49	4.87e-27	Facial morphology (factor 23);
LUAD	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg04756594	chr16:24857601	SLC5A11	0.54	10.37	0.45	1.35e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg09117114	chr16:67998030	SLC12A4	-0.47	-6.75	-0.31	4.8e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11811982	0.793	rs115229735	chr1:227556337	T/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.44	0.34	5.81e-13	Optic disc area;
LUAD	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.15	15.04	0.59	3.01e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2131877	0.830	rs62285219	chr3:194871480	A/T	cg19760965	chr3:194868843	C3orf21	0.4	6.53	0.3	1.89e-10	Non-small cell lung cancer;
LUAD	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.27	-0.33	1.77e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg07685180	chr8:600429	NA	0.86	8.22	0.37	2.51e-15	IgG glycosylation;
LUAD	trans	rs9929218	0.954	rs9923925	chr16:68819444	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.6	-0.55	3.21e-35	Colorectal cancer;
LUAD	cis	rs6738485	0.531	rs72819612	chr2:106846316	T/C	cg16099169	chr2:106886729	NA	-0.81	-11.61	-0.49	2.99e-27	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs10979	1.000	rs9496671	chr6:143884742	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-9.24	-0.41	1.25e-18	Hypospadias;
LUAD	cis	rs78487399	0.614	rs13422551	chr2:43724682	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.42	-0.3	3.58e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg14227996	chr4:17616232	MED28	0.71	7.38	0.34	8.62e-13	Opioid sensitivity;
LUAD	cis	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg07460842	chr6:66804631	NA	0.93	14.85	0.59	1.95e-40	Exhaled nitric oxide levels;
LUAD	cis	rs9296092	0.538	rs9461880	chr6:33518714	C/T	cg13560919	chr6:33536144	NA	-0.87	-15.45	-0.6	4.9e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs2625529	0.761	rs972029	chr15:72172986	C/T	cg16672083	chr15:72433130	SENP8	-0.72	-12.54	-0.52	6.57e-31	Red blood cell count;
LUAD	cis	rs9467773	0.967	rs1321482	chr6:26575154	T/C	cg09904177	chr6:26538194	HMGN4	0.44	7.03	0.32	8.25e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.05	-0.36	8.53e-15	Cystic fibrosis severity;
LUAD	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg01657329	chr11:68192670	LRP5	0.48	8.42	0.38	5.76e-16	Total body bone mineral density;
LUAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg07677032	chr17:61819896	STRADA	0.57	10.47	0.45	5.92e-23	Prudent dietary pattern;
LUAD	cis	rs3764563	1.000	rs1022413	chr19:15741984	G/A	cg20725493	chr19:15740067	CYP4F8	-0.76	-8.82	-0.39	2.92e-17	Inflammatory biomarkers;
LUAD	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06873352	chr17:61820015	STRADA	0.57	9.22	0.41	1.37e-18	Height;
LUAD	cis	rs1595825	0.891	rs16826895	chr2:198901642	A/G	cg00361562	chr2:198649771	BOLL	-0.49	-6.82	-0.31	3.1e-11	Ulcerative colitis;
LUAD	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg05042697	chr2:10830656	NOL10	-0.37	-6.46	-0.3	2.95e-10	Prostate cancer;
LUAD	cis	rs886126	0.684	rs3858704	chr12:111705893	A/G	cg10833066	chr12:111807467	FAM109A	0.63	12.41	0.52	2.24e-30	Coronary heart disease;
LUAD	cis	rs9323205	0.677	rs4264315	chr14:51728356	G/A	cg23942311	chr14:51606299	NA	-0.57	-8.6	-0.39	1.53e-16	Cancer;
LUAD	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg09359103	chr1:154839909	KCNN3	-0.87	-18.74	-0.67	1.78e-57	Prostate cancer;
LUAD	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg22823121	chr1:150693482	HORMAD1	0.44	8.9	0.4	1.69e-17	Tonsillectomy;
LUAD	cis	rs57994353	0.897	rs66477686	chr9:139372224	T/C	cg13856295	chr9:139396418	NOTCH1	-0.43	-6.82	-0.31	3.24e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	trans	rs6076960	0.629	rs6054008	chr20:6212370	C/T	cg17788362	chr6:86352627	SYNCRIP	0.42	6.55	0.3	1.69e-10	Smooth-surface caries;
LUAD	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg23625390	chr15:77176239	SCAPER	0.39	6.78	0.31	3.97e-11	Blood metabolite levels;
LUAD	cis	rs3806701	0.619	rs6442008	chr3:46645753	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.36	-6.71	-0.31	6.44e-11	Blood protein levels;
LUAD	cis	rs870825	0.616	rs6833858	chr4:185639961	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	13.76	0.56	7.24e-36	Blood protein levels;
LUAD	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.99	14.55	0.58	3.63e-39	Schizophrenia;
LUAD	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg00981070	chr1:2046702	PRKCZ	0.37	7.92	0.36	2.05e-14	Height;
LUAD	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12923728	chr3:195709715	SDHAP1	-0.77	-12.91	-0.53	2.14e-32	Pancreatic cancer;
LUAD	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg01475377	chr6:109611718	NA	-0.51	-9.43	-0.42	2.74e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19717773	chr7:2847554	GNA12	0.53	8.95	0.4	1.15e-17	Height;
LUAD	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.65	-7.22	-0.33	2.35e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg23758822	chr17:41437982	NA	1.0	20.5	0.71	2.41e-65	Menopause (age at onset);
LUAD	cis	rs17253792	0.908	rs74354306	chr14:56065778	T/G	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs13315871	0.932	rs35741271	chr3:58323091	A/G	cg12435725	chr3:58293450	RPP14	-0.73	-7.68	-0.35	1.1e-13	Cholesterol, total;
LUAD	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg00129232	chr17:37814104	STARD3	-0.47	-7.81	-0.36	4.52e-14	Asthma;
LUAD	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg14668632	chr7:2872130	GNA12	-0.75	-14.17	-0.57	1.44e-37	Height;
LUAD	cis	rs9346649	0.630	rs4235913	chr6:168491697	T/C	cg02770688	chr6:168491649	NA	0.54	10.17	0.44	7.16e-22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg09263875	chr16:632152	PIGQ	0.82	17.84	0.66	1.69e-53	Height;
LUAD	cis	rs1784581	0.894	rs1790000	chr6:162388707	A/G	cg17173639	chr6:162384350	PARK2	0.57	10.6	0.46	1.87e-23	Itch intensity from mosquito bite;
LUAD	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg24818145	chr4:99064322	C4orf37	0.42	7.03	0.32	8.42e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11644478	chr21:40555479	PSMG1	-0.53	-8.54	-0.38	2.4e-16	Cognitive function;
LUAD	cis	rs300703	0.719	rs437853	chr2:196973	C/T	cg24565620	chr2:194026	NA	0.43	7.08	0.33	6.16e-12	Blood protein levels;
LUAD	cis	rs12545109	0.800	rs2582404	chr8:57387368	C/T	cg17761419	chr8:57350749	NA	-0.57	-8.24	-0.37	2.22e-15	Obesity-related traits;
LUAD	cis	rs7089973	0.872	rs7072364	chr10:116620840	G/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.72	0.43	2.84e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg04414720	chr1:150670196	GOLPH3L	-0.5	-8.31	-0.37	1.28e-15	Tonsillectomy;
LUAD	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.62	-0.39	1.39e-16	Total body bone mineral density;
LUAD	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg06671706	chr8:8559999	CLDN23	0.62	10.37	0.45	1.3e-22	Obesity-related traits;
LUAD	cis	rs9914988	0.943	rs28847895	chr17:27172520	T/C	cg20469991	chr17:27169893	C17orf63	-0.51	-6.56	-0.3	1.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg11494091	chr17:61959527	GH2	0.74	18.61	0.67	6.63e-57	Prudent dietary pattern;
LUAD	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg05340658	chr4:99064831	C4orf37	0.54	8.8	0.39	3.61e-17	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg11693508	chr17:37793320	STARD3	0.44	6.47	0.3	2.73e-10	Neuroticism;
LUAD	cis	rs240764	0.579	rs240151	chr6:101067720	A/T	cg09795085	chr6:101329169	ASCC3	0.39	6.74	0.31	5.28e-11	Neuroticism;
LUAD	cis	rs6594713	0.679	rs9326890	chr5:112859994	C/T	cg12552261	chr5:112820674	MCC	0.59	8.92	0.4	1.45e-17	Brain cytoarchitecture;
LUAD	cis	rs3540	0.554	rs12443252	chr15:91064690	C/T	cg10434728	chr15:90938212	IQGAP1	-0.35	-6.57	-0.3	1.47e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs10744422	1.000	rs7959441	chr12:123363825	C/T	cg16953816	chr12:123349952	VPS37B	0.61	6.96	0.32	1.28e-11	Schizophrenia;
LUAD	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.52	-8.18	-0.37	3.34e-15	Reticulocyte count;
LUAD	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg22482690	chr17:47019901	SNF8	0.47	9.1	0.4	3.6e-18	Type 2 diabetes;
LUAD	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg18854424	chr1:2615690	NA	-0.42	-9.07	-0.4	4.63e-18	Ulcerative colitis;
LUAD	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg20701182	chr2:24300061	SF3B14	0.56	6.65	0.31	8.87e-11	Lymphocyte counts;
LUAD	cis	rs8027181	1.000	rs12900863	chr15:73094671	C/T	cg25632853	chr15:73088954	NA	0.35	7.66	0.35	1.26e-13	Triglyceride levels;
LUAD	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg15962314	chr1:44399869	ARTN	0.32	7.12	0.33	4.69e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4664304	0.966	rs7601374	chr2:160754050	T/C	cg06573604	chr2:160760825	LY75	-0.4	-6.64	-0.31	9.86e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs295140	0.585	rs4233996	chr2:201131228	A/T	cg23649088	chr2:200775458	C2orf69	-0.49	-8.63	-0.39	1.21e-16	QT interval;
LUAD	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg05283184	chr6:79620031	NA	0.48	8.68	0.39	8.49e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg09455208	chr3:40491958	NA	-0.6	-13.31	-0.54	5.14e-34	Renal cell carcinoma;
LUAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-7.91	-0.36	2.34e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg03433033	chr1:76189801	ACADM	-0.49	-6.95	-0.32	1.37e-11	Daytime sleep phenotypes;
LUAD	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.27	-0.33	1.77e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg05044414	chr3:183734942	ABCC5	0.47	10.13	0.44	1.01e-21	Anterior chamber depth;
LUAD	cis	rs6674176	0.932	rs4660761	chr1:44440146	G/A	cg15962314	chr1:44399869	ARTN	0.32	6.63	0.31	1.06e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg17074396	chr22:49843754	NA	-0.32	-6.75	-0.31	4.91e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs556990	0.570	rs5960	chr13:113801737	C/T	cg00898013	chr13:113819073	PROZ	0.48	7.09	0.33	5.84e-12	Blood protein levels;
LUAD	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	9.25	0.41	1.11e-18	Platelet count;
LUAD	cis	rs2425143	0.818	rs2378414	chr20:34534374	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-6.82	-0.31	3.08e-11	Blood protein levels;
LUAD	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg05340658	chr4:99064831	C4orf37	-0.47	-7.8	-0.35	4.93e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg22079354	chr11:130786696	SNX19	0.38	6.57	0.3	1.49e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg23533926	chr12:111358616	MYL2	-0.43	-7.34	-0.34	1.07e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg03676636	chr4:99064102	C4orf37	0.33	8.58	0.39	1.77e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7945705	0.806	rs12224436	chr11:8815825	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.49	8.66	0.39	9.89e-17	Hemoglobin concentration;
LUAD	cis	rs9644630	0.932	rs4273861	chr8:19352703	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.3	-7.11	-0.33	4.88e-12	Oropharynx cancer;
LUAD	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg27433088	chr4:174089019	GALNT7	0.39	7.27	0.33	1.73e-12	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg22491629	chr6:157744540	C6orf35	0.77	8.9	0.4	1.62e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2274273	0.624	rs7147247	chr14:55777713	A/T	cg04306507	chr14:55594613	LGALS3	0.37	7.32	0.34	1.23e-12	Protein biomarker;
LUAD	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg00129232	chr17:37814104	STARD3	-0.44	-7.63	-0.35	1.58e-13	Asthma;
LUAD	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg25324976	chr17:61989376	CSHL1	0.37	7.1	0.33	5.24e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs2235573	0.625	rs3026677	chr22:38432725	C/G	cg19894588	chr14:64061835	NA	0.43	6.75	0.31	4.8e-11	Glioblastoma;Glioma;
LUAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg07362569	chr17:61921086	SMARCD2	0.39	6.74	0.31	5.12e-11	Prudent dietary pattern;
LUAD	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg08847533	chr14:75593920	NEK9	0.42	7.14	0.33	4e-12	Height;
LUAD	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.23	0.33	2.25e-12	Blood metabolite levels;
LUAD	cis	rs9535307	0.719	rs9535341	chr13:50363304	C/T	cg04663916	chr13:50265991	EBPL	-0.62	-6.99	-0.32	1.1e-11	Obesity-related traits;
LUAD	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.88	12.82	0.53	5.16e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg06784218	chr1:46089804	CCDC17	0.59	13.05	0.54	6.17e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4853525	0.522	rs62179717	chr2:191590813	T/G	cg27211696	chr2:191398769	TMEM194B	-0.41	-6.76	-0.31	4.55e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs427394	0.735	rs416689	chr5:6740855	C/T	cg10857441	chr5:6722123	POLS	-0.63	-12.34	-0.51	4.35e-30	Menopause (age at onset);
LUAD	trans	rs853679	0.607	rs34662244	chr6:28073881	G/A	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.09	-0.47	3.02e-25	Depression;
LUAD	cis	rs11229555	0.874	rs11229505	chr11:58274155	T/C	cg15696309	chr11:58395628	NA	-0.73	-10.32	-0.45	2.07e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg00666640	chr1:248458726	OR2T12	0.31	7.6	0.35	1.96e-13	Common traits (Other);
LUAD	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg12365402	chr11:9010492	NRIP3	0.44	7.38	0.34	8.26e-13	Hemoglobin concentration;
LUAD	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg06713675	chr4:122721982	EXOSC9	0.46	8.49	0.38	3.48e-16	Type 2 diabetes;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19531713	chr17:41277059	BRCA1;NBR2	0.44	6.82	0.31	3.16e-11	Monocyte percentage of white cells;
LUAD	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14240646	chr10:27532245	ACBD5	-0.93	-12.34	-0.51	4.42e-30	Breast cancer;
LUAD	cis	rs738321	0.725	rs9622738	chr22:38542346	G/A	cg25457927	chr22:38595422	NA	-0.55	-12.11	-0.51	3.38e-29	Breast cancer;
LUAD	cis	rs863345	0.526	rs10908669	chr1:158501938	C/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg23805780	chr6:130342187	L3MBTL3	-0.38	-6.54	-0.3	1.83e-10	Subcortical brain region volumes;
LUAD	cis	rs593982	0.925	rs3953806	chr11:65505153	C/T	cg08755490	chr11:65554678	OVOL1	-1.35	-16.29	-0.62	1.2e-46	Atopic dermatitis;
LUAD	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs654950	0.875	rs689076	chr1:41999127	C/T	cg06885757	chr1:42089581	HIVEP3	0.34	7.04	0.32	8.04e-12	Airway imaging phenotypes;
LUAD	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.09e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12205742	chr18:68097929	NA	0.53	6.38	0.3	4.72e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs977987	0.806	rs4888391	chr16:75400746	C/T	cg03315344	chr16:75512273	CHST6	0.65	14.03	0.56	5.38e-37	Dupuytren's disease;
LUAD	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg22467129	chr15:76604101	ETFA	-0.49	-8.56	-0.38	2.15e-16	Blood metabolite levels;
LUAD	trans	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg01620082	chr3:125678407	NA	-0.44	-6.67	-0.31	7.84e-11	Depression;
LUAD	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.21	0.51	1.43e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03264133	chr6:25882463	NA	-0.57	-9.38	-0.41	4.16e-19	Blood metabolite levels;
LUAD	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.94	-0.4	1.22e-17	Initial pursuit acceleration;
LUAD	cis	rs7582720	1.000	rs72926781	chr2:203808835	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg22532475	chr10:104410764	TRIM8	0.35	7.1	0.33	5.18e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs78761021	0.838	rs62066054	chr17:9782028	G/A	cg26853458	chr17:9805074	RCVRN	0.37	7.23	0.33	2.28e-12	Type 2 diabetes;
LUAD	cis	rs2573652	1.000	rs2581341	chr15:100514494	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.49	-8.6	-0.39	1.51e-16	Height;
LUAD	cis	rs10129255	0.557	rs4043727	chr14:107105823	C/T	cg23076370	chr14:107095027	NA	-0.39	-6.83	-0.32	2.99e-11	Kawasaki disease;
LUAD	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg04851639	chr8:1020857	NA	-0.4	-9.82	-0.43	1.23e-20	Schizophrenia;
LUAD	cis	rs1595825	0.891	rs16825188	chr2:198741134	G/C	cg13379983	chr2:198649727	BOLL	-0.48	-6.57	-0.3	1.48e-10	Ulcerative colitis;
LUAD	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.15	0.37	4.06e-15	Menopause (age at onset);
LUAD	cis	rs727505	0.754	rs56012154	chr7:124781250	A/G	cg23710748	chr7:124431027	NA	-0.39	-7.97	-0.36	1.51e-14	Lewy body disease;
LUAD	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg04287289	chr16:89883240	FANCA	0.8	7.02	0.32	9.05e-12	Skin colour saturation;
LUAD	cis	rs77741769	0.529	rs3213572	chr12:121205078	A/G	cg02419362	chr12:121203948	SPPL3	-0.36	-7.47	-0.34	4.54e-13	Mean corpuscular volume;
LUAD	cis	rs9329289	0.550	rs11251294	chr10:2562328	C/T	cg15501526	chr10:2543763	NA	-0.45	-8.65	-0.39	1.09e-16	Age-related hearing impairment;
LUAD	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg18944383	chr4:111397179	ENPEP	0.4	8.09	0.37	6.55e-15	Height;
LUAD	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg02931644	chr1:25747376	RHCE	0.41	8.5	0.38	3.27e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs4900538	0.963	rs4906205	chr14:102932447	A/G	cg18135206	chr14:102964638	TECPR2	1.05	24.32	0.76	2.19e-82	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	trans	rs877282	0.797	rs7079164	chr10:756363	A/G	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg20607287	chr7:12443886	VWDE	-0.54	-6.93	-0.32	1.62e-11	Coronary artery disease;
LUAD	cis	rs67073037	0.915	rs12622793	chr2:29111106	C/T	cg09522027	chr2:28974177	PPP1CB	0.48	6.76	0.31	4.64e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
LUAD	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.6	-9.08	-0.4	4.18e-18	Platelet count;
LUAD	trans	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg11693508	chr17:37793320	STARD3	0.73	9.72	0.43	2.65e-20	Bipolar disorder;
LUAD	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg13606994	chr1:44402422	ARTN	-0.38	-7.41	-0.34	7.16e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg03233332	chr7:66118400	NA	0.44	6.82	0.31	3.09e-11	Aortic root size;
LUAD	trans	rs9784649	0.760	rs17343923	chr5:25052414	G/A	cg11038491	chr20:34638489	LOC647979	-0.83	-11.19	-0.48	1.21e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2235649	0.833	rs2011088	chr16:1850091	T/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.4	-6.44	-0.3	3.26e-10	Blood metabolite levels;
LUAD	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-8.07	-0.37	7.4e-15	HDL cholesterol;
LUAD	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.9	0.36	2.43e-14	Breast cancer;
LUAD	cis	rs7103648	0.618	rs11039284	chr11:47564785	A/G	cg20307385	chr11:47447363	PSMC3	0.52	7.62	0.35	1.7e-13	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs2050392	0.829	rs306589	chr10:30723831	A/G	cg18806716	chr10:30721971	MAP3K8	-0.56	-11.09	-0.47	2.93e-25	Inflammatory bowel disease;
LUAD	cis	rs524023	0.874	rs7105665	chr11:64396568	T/C	cg19131476	chr11:64387923	NRXN2	-0.41	-7.94	-0.36	1.87e-14	Urate levels in obese individuals;
LUAD	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg17328964	chr8:145687451	CYHR1	-0.73	-13.3	-0.54	6.02e-34	Age at first birth;
LUAD	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01570182	chr17:44337453	NA	-0.95	-13.97	-0.56	9.69e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg21475434	chr5:93447410	FAM172A	0.74	8.33	0.38	1.17e-15	Diabetic retinopathy;
LUAD	cis	rs57920188	0.658	rs7548273	chr1:4078945	G/C	cg20703997	chr1:4087676	NA	0.45	8.34	0.38	1.08e-15	Interleukin-17 levels;
LUAD	cis	rs12986413	0.619	rs1859954	chr19:2145481	G/T	cg09261902	chr19:2140048	AP3D1	-0.33	-6.74	-0.31	5.27e-11	Height;
LUAD	cis	rs7487075	0.619	rs7959731	chr12:46839657	A/C	cg23829395	chr12:46796953	NA	-0.3	-6.66	-0.31	8.78e-11	Itch intensity from mosquito bite;
LUAD	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg20487152	chr13:99095054	FARP1	-0.49	-8.31	-0.37	1.34e-15	Longevity;
LUAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg11416102	chr8:651193	ERICH1	0.97	8.53	0.38	2.73e-16	IgG glycosylation;
LUAD	cis	rs62400317	0.762	rs62436411	chr6:44940706	T/G	cg18551225	chr6:44695536	NA	-0.55	-8.31	-0.37	1.27e-15	Total body bone mineral density;
LUAD	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg23758822	chr17:41437982	NA	0.99	20.44	0.7	4.46e-65	Menopause (age at onset);
LUAD	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg11663144	chr21:46675770	NA	-0.55	-10.66	-0.46	1.13e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg13560548	chr3:10150139	C3orf24	0.4	6.56	0.3	1.53e-10	Alzheimer's disease;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg19452060	chr12:57914632	DDIT3	-0.4	-6.38	-0.3	4.59e-10	Vertical cup-disc ratio;
LUAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg07167872	chr1:205819463	PM20D1	0.52	8.04	0.36	9.27e-15	Parkinson's disease;
LUAD	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11644478	chr21:40555479	PSMG1	-0.69	-11.7	-0.49	1.36e-27	Cognitive function;
LUAD	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg27147174	chr7:100797783	AP1S1	-0.71	-13.17	-0.54	1.87e-33	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg06547715	chr2:218990976	CXCR2	0.42	10.0	0.44	2.74e-21	Ulcerative colitis;
LUAD	trans	rs10411161	0.702	rs10423835	chr19:52387322	A/G	cg22319618	chr22:45562946	NUP50	-0.64	-8.99	-0.4	8.63e-18	Breast cancer;
LUAD	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg00933542	chr6:150070202	PCMT1	0.4	8.54	0.38	2.48e-16	Lung cancer;
LUAD	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg05926928	chr17:57297772	GDPD1	-0.58	-7.94	-0.36	1.82e-14	Opioid sensitivity;
LUAD	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg17372223	chr3:52568218	NT5DC2	-0.41	-7.47	-0.34	4.56e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2816062	0.786	rs2745316	chr1:18896830	G/A	cg18795169	chr1:18902165	NA	-0.94	-22.76	-0.74	1.87e-75	Urate levels in lean individuals;
LUAD	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg24818145	chr4:99064322	C4orf37	0.49	8.06	0.36	7.95e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg03433033	chr1:76189801	ACADM	-0.49	-7.31	-0.33	1.37e-12	Daytime sleep phenotypes;
LUAD	cis	rs11771526	0.901	rs17161124	chr7:32307324	A/T	cg13207630	chr7:32358064	NA	-0.59	-7.58	-0.35	2.2e-13	Body mass index;
LUAD	cis	rs7771547	0.519	rs4713972	chr6:36371316	C/A	cg04289385	chr6:36355825	ETV7	0.49	7.18	0.33	3.09e-12	Platelet distribution width;
LUAD	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg23992470	chr4:843637	GAK	0.7	7.28	0.33	1.65e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6782228	0.509	rs2811495	chr3:128359957	A/G	cg16766828	chr3:128327626	NA	-0.38	-7.07	-0.33	6.37e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.74	-9.39	-0.42	3.7e-19	Body mass index;
LUAD	cis	rs10170310	1.000	rs12691947	chr2:139264471	A/G	cg03782584	chr2:139258740	SPOPL	0.32	6.66	0.31	8.37e-11	Response to antipsychotic treatment;
LUAD	cis	rs73206853	0.534	rs13313211	chr12:110509616	A/T	cg12870014	chr12:110450643	ANKRD13A	0.8	8.02	0.36	1.03e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10979	0.838	rs12208649	chr6:143893321	G/T	cg25407410	chr6:143891975	LOC285740	-0.65	-10.3	-0.45	2.3e-22	Hypospadias;
LUAD	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg06671706	chr8:8559999	CLDN23	0.68	11.68	0.49	1.67e-27	Obesity-related traits;
LUAD	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg02423579	chr7:2872169	GNA12	-0.86	-14.72	-0.58	6.88e-40	Height;
LUAD	cis	rs8040855	0.576	rs62022528	chr15:85535261	C/T	cg08123816	chr15:85640762	PDE8A	-0.35	-6.35	-0.3	5.52e-10	Bulimia nervosa;
LUAD	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg12011299	chr4:100065546	ADH4	-0.58	-12.2	-0.51	1.59e-29	Alcohol dependence;
LUAD	cis	rs1278769	0.786	rs7998551	chr13:113540649	G/T	cg00823993	chr13:113535758	ATP11A	0.56	8.56	0.38	2.13e-16	Interstitial lung disease;
LUAD	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg04756594	chr16:24857601	SLC5A11	0.72	12.31	0.51	5.58e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg13535736	chr9:111863775	C9orf5	-0.43	-6.71	-0.31	6.46e-11	Menarche (age at onset);
LUAD	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06028808	chr11:68637592	NA	0.45	7.32	0.34	1.29e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-8.25	-0.37	2.03e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs738321	0.757	rs12329956	chr22:38535946	G/A	cg25457927	chr22:38595422	NA	-0.46	-10.03	-0.44	2.24e-21	Breast cancer;
LUAD	cis	rs11098699	0.821	rs13110588	chr4:124220676	A/G	cg09941581	chr4:124220074	SPATA5	-0.48	-7.82	-0.36	4.18e-14	Mosquito bite size;
LUAD	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg23229984	chr5:148520753	ABLIM3	0.5	7.7	0.35	9.72e-14	Breast cancer;
LUAD	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.88	0.32	2.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg02782426	chr3:40428986	ENTPD3	0.35	7.67	0.35	1.22e-13	Renal cell carcinoma;
LUAD	cis	rs220324	0.647	rs9981668	chr21:43559780	G/T	cg08841829	chr21:43638893	ABCG1	-0.49	-6.71	-0.31	6.38e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs6540559	0.543	rs650728	chr1:210433351	C/T	cg22029157	chr1:209979665	IRF6	0.58	6.64	0.31	9.82e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg16342193	chr10:102329863	NA	-0.36	-6.63	-0.31	1.04e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg00071950	chr4:10020882	SLC2A9	0.49	7.02	0.32	8.88e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.35	-0.51	3.79e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs2108225	0.967	rs6466189	chr7:107448516	C/T	cg18560240	chr7:107437656	SLC26A3	-0.39	-6.4	-0.3	4.03e-10	Ulcerative colitis;
LUAD	cis	rs68170813	0.559	rs7800443	chr7:106910723	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-10.66	-0.46	1.2e-23	Coronary artery disease;
LUAD	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg01028140	chr2:1542097	TPO	-0.5	-7.0	-0.32	1.01e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg09085632	chr11:111637200	PPP2R1B	0.73	11.58	0.49	4.17e-27	Primary sclerosing cholangitis;
LUAD	cis	rs7593730	0.767	rs28510864	chr2:161162662	G/A	cg22609984	chr2:161126801	NA	0.44	7.24	0.33	2.15e-12	Type 2 diabetes;
LUAD	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg23803603	chr1:2058230	PRKCZ	-0.42	-7.71	-0.35	8.85e-14	Height;
LUAD	cis	rs7408868	1.000	rs7254269	chr19:15277429	A/T	cg14696996	chr19:15285081	NOTCH3	-0.82	-10.63	-0.46	1.53e-23	Pulse pressure;
LUAD	trans	rs9929218	0.501	rs12448999	chr16:68815549	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.01	21.16	0.72	2.74e-68	Colorectal cancer;
LUAD	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg02269571	chr22:50332266	NA	-0.67	-9.57	-0.42	9.14e-20	Schizophrenia;
LUAD	cis	rs71403859	0.502	rs35394108	chr16:71540639	T/C	cg08717414	chr16:71523259	ZNF19	-0.64	-8.02	-0.36	1.02e-14	Post bronchodilator FEV1;
LUAD	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg06060754	chr5:176797920	RGS14	0.55	8.49	0.38	3.58e-16	Urate levels in lean individuals;
LUAD	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.2	0.33	2.69e-12	Cardiac Troponin-T levels;
LUAD	cis	rs1865721	0.771	rs7235563	chr18:73139335	C/G	cg26385618	chr18:73139727	C18orf62	-0.49	-10.01	-0.44	2.66e-21	Intelligence;
LUAD	cis	rs1385374	0.858	rs11059933	chr12:129303593	T/C	cg09035930	chr12:129282057	SLC15A4	-0.62	-6.7	-0.31	6.79e-11	Systemic lupus erythematosus;
LUAD	cis	rs7932354	0.528	rs10769234	chr11:47084061	G/C	cg19486271	chr11:47235900	DDB2	-0.44	-6.96	-0.32	1.27e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg02423579	chr7:2872169	GNA12	-0.92	-17.37	-0.65	2.07e-51	Height;
LUAD	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg12373951	chr3:133503437	NA	0.32	6.68	0.31	7.41e-11	Alcohol consumption (transferrin glycosylation);
LUAD	trans	rs7615952	0.546	rs2922194	chr3:125332263	G/A	cg17147758	chr8:6949321	NA	-0.49	-7.44	-0.34	5.69e-13	Blood pressure (smoking interaction);
LUAD	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg15448220	chr1:150897856	SETDB1	0.46	7.98	0.36	1.4e-14	Tonsillectomy;
LUAD	cis	rs1595825	0.786	rs77218291	chr2:198565011	A/G	cg00982548	chr2:198649783	BOLL	-0.61	-8.49	-0.38	3.42e-16	Ulcerative colitis;
LUAD	cis	rs1003719	0.708	rs2000417	chr21:38502868	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-9.06	-0.4	4.8e-18	Eye color traits;
LUAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg22907277	chr7:1156413	C7orf50	0.71	8.33	0.38	1.15e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg24130564	chr14:104152367	KLC1	-0.52	-9.32	-0.41	6.27e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs9443645	0.507	rs9352633	chr6:79462623	C/G	cg09184832	chr6:79620586	NA	-0.4	-7.15	-0.33	3.95e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg17757837	chr7:157058334	UBE3C	0.47	8.45	0.38	4.62e-16	Body mass index;
LUAD	cis	rs2637266	1.000	rs7476937	chr10:78357692	A/T	cg18941641	chr10:78392320	NA	0.34	7.2	0.33	2.77e-12	Pulmonary function;
LUAD	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg24733560	chr20:60626293	TAF4	0.47	8.35	0.38	9.770000000000001e-16	Body mass index;
LUAD	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.43	0.3	3.53e-10	Parkinson's disease;
LUAD	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg11822812	chr5:140052017	DND1	-0.44	-7.79	-0.35	5.26e-14	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg07870213	chr5:140052090	DND1	0.73	11.34	0.48	3.21e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg20503657	chr10:835505	NA	1.24	18.44	0.67	3.83e-56	Eosinophil percentage of granulocytes;
LUAD	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg06608945	chr2:219082296	ARPC2	-0.41	-6.78	-0.31	4.08e-11	Colorectal cancer;
LUAD	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg11901034	chr3:128598214	ACAD9	-0.49	-7.61	-0.35	1.8e-13	IgG glycosylation;
LUAD	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg03806693	chr22:41940476	POLR3H	-0.45	-6.55	-0.3	1.68e-10	Neuroticism;
LUAD	cis	rs684232	0.623	rs2543779	chr17:576362	C/A	cg12384639	chr17:618140	VPS53	0.48	8.37	0.38	8.78e-16	Prostate cancer;
LUAD	cis	rs1483890	0.723	rs6783070	chr3:69411596	A/C	cg22125112	chr3:69402811	FRMD4B	-0.47	-7.91	-0.36	2.27e-14	Resting heart rate;
LUAD	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.41	7.06	0.32	6.81e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg20607798	chr8:58055168	NA	0.78	9.69	0.43	3.45e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs612683	0.862	rs12760924	chr1:100898600	A/T	cg06223162	chr1:101003688	GPR88	0.43	8.01	0.36	1.15e-14	Breast cancer;
LUAD	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg19318889	chr4:1322082	MAEA	0.45	7.86	0.36	3.19e-14	Obesity-related traits;
LUAD	trans	rs8073060	0.586	rs2523116	chr17:34025460	T/C	cg19694781	chr19:47549865	TMEM160	-1.23	-19.63	-0.69	1.8e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.62	0.31	1.09e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2286503	0.780	rs981792	chr7:22861639	C/A	cg06496272	chr7:22895283	SNORD93	-0.41	-7.25	-0.33	1.99e-12	Fibrinogen;
LUAD	trans	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg14791747	chr16:20752902	THUMPD1	-0.53	-7.93	-0.36	2e-14	Pancreatic cancer;
LUAD	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.47	-0.34	4.78e-13	Neutrophil percentage of white cells;
LUAD	cis	rs9972944	0.651	rs9909246	chr17:63791547	C/G	cg07283582	chr17:63770753	CCDC46	-0.46	-9.88	-0.43	7.76e-21	Total body bone mineral density;
LUAD	cis	rs6586111	0.765	rs11186273	chr10:82371312	C/T	cg03086067	chr10:82368399	SH2D4B	-0.3	-7.13	-0.33	4.29e-12	Capecitabine sensitivity;
LUAD	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg18705301	chr15:41695430	NDUFAF1	0.68	13.05	0.54	5.99e-33	Ulcerative colitis;
LUAD	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg08893839	chr5:154027129	NA	0.51	6.79	0.31	3.85e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg00750074	chr16:89608354	SPG7	-0.53	-8.95	-0.4	1.11e-17	Multiple myeloma (IgH translocation);
LUAD	cis	rs11676348	0.772	rs12471105	chr2:218950209	G/A	cg06547715	chr2:218990976	CXCR2	0.34	7.74	0.35	7.42e-14	Ulcerative colitis;
LUAD	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg09365446	chr1:150670422	GOLPH3L	0.62	10.9	0.47	1.52e-24	Melanoma;
LUAD	cis	rs7659604	0.540	rs28394772	chr4:122678543	C/T	cg06713675	chr4:122721982	EXOSC9	0.42	7.73	0.35	7.8e-14	Type 2 diabetes;
LUAD	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg03929089	chr4:120376271	NA	-0.98	-20.58	-0.71	1.01e-65	Height;
LUAD	cis	rs1816752	0.905	rs1050112	chr13:25009297	G/T	cg02811702	chr13:24901961	NA	0.43	7.35	0.34	1.05e-12	Obesity-related traits;
LUAD	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg26384229	chr12:38710491	ALG10B	0.48	7.85	0.36	3.55e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs600626	0.529	rs58411334	chr11:75467350	G/T	cg24262691	chr11:75473276	NA	0.59	7.45	0.34	5.31e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.22	0.41	1.38e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs513349	1.000	rs513349	chr6:33541719	A/G	cg07679836	chr6:33548423	BAK1	0.44	8.47	0.38	4.01e-16	Platelet count;
LUAD	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.73	0.31	5.48e-11	Schizophrenia;
LUAD	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.53	0.52	7.6e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs225245	0.782	rs321599	chr17:33905745	C/T	cg19694781	chr19:47549865	TMEM160	-0.46	-7.55	-0.34	2.71e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg20362242	chr5:692897	TPPP	0.62	7.49	0.34	3.98e-13	Obesity-related traits;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg24515799	chr6:149867235	PPIL4	-0.41	-7.16	-0.33	3.62e-12	Schizophrenia;
LUAD	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg08601574	chr20:25228251	PYGB	0.46	8.82	0.39	2.94e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.58	-0.35	2.22e-13	Personality dimensions;
LUAD	cis	rs9324022	0.584	rs72698722	chr14:101181881	C/T	cg18089426	chr14:101175970	NA	0.53	7.55	0.34	2.79e-13	Plateletcrit;
LUAD	cis	rs250585	0.736	rs250584	chr16:23403031	A/T	cg00143387	chr16:23521605	GGA2	0.48	6.78	0.31	4.08e-11	Egg allergy;
LUAD	cis	rs6906287	0.573	rs12198461	chr6:118880640	T/G	cg05564266	chr6:118973597	C6orf204	0.36	7.67	0.35	1.24e-13	Electrocardiographic conduction measures;
LUAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg18305652	chr10:134549665	INPP5A	0.6	11.74	0.5	9.85e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg07936489	chr17:37558343	FBXL20	-0.46	-7.26	-0.33	1.82e-12	Lung function (FEV1);
LUAD	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg04455712	chr21:45112962	RRP1B	0.39	7.75	0.35	6.72e-14	Mean corpuscular volume;
LUAD	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	10.32	0.45	2.01e-22	Colorectal cancer;
LUAD	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-7.98	-0.36	1.35e-14	Electroencephalogram traits;
LUAD	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg04025307	chr7:1156635	C7orf50	0.6	9.21	0.41	1.49e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs68170813	0.523	rs10253172	chr7:106786474	C/T	cg23024343	chr7:107201750	COG5	-0.5	-6.79	-0.31	3.73e-11	Coronary artery disease;
LUAD	cis	rs7779181	0.953	rs215607	chr7:32338337	G/A	cg27532318	chr7:32358331	NA	-0.46	-7.39	-0.34	7.69e-13	Body mass index;
LUAD	cis	rs10193935	0.901	rs17029344	chr2:42444287	T/C	cg27598129	chr2:42591480	NA	-0.77	-10.12	-0.44	1.02e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.57	-7.12	-0.33	4.67e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2294693	0.786	rs10456497	chr6:40989057	T/C	cg14769373	chr6:40998127	UNC5CL	-0.58	-8.38	-0.38	7.63e-16	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs89107	0.651	rs283084	chr6:118603999	G/A	cg21191810	chr6:118973309	C6orf204	0.51	10.02	0.44	2.47e-21	Cardiac structure and function;
LUAD	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.02	0.36	1.02e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.77	-0.35	5.95e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg24531977	chr5:56204891	C5orf35	-0.44	-7.28	-0.33	1.65e-12	Coronary artery disease;
LUAD	cis	rs31251	0.900	rs11953786	chr5:131071440	A/T	cg06307176	chr5:131281290	NA	0.37	6.7	0.31	6.8e-11	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs10489202	0.632	rs202265	chr1:167990231	G/C	cg24449463	chr1:168025552	DCAF6	-0.75	-12.29	-0.51	6.9e-30	Schizophrenia;
LUAD	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg16414030	chr3:133502952	NA	-0.63	-10.72	-0.46	6.73e-24	Iron status biomarkers;
LUAD	cis	rs2281845	0.507	rs1536127	chr1:201086894	C/A	cg06714761	chr1:201096289	NA	0.35	7.42	0.34	6.53e-13	Permanent tooth development;
LUAD	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg00277334	chr10:82204260	NA	-0.69	-10.87	-0.47	1.88e-24	Post bronchodilator FEV1;
LUAD	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg09184832	chr6:79620586	NA	-0.5	-9.1	-0.4	3.5e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7584330	0.554	rs13395743	chr2:238437554	C/T	cg14458575	chr2:238380390	NA	0.63	9.61	0.42	6.38e-20	Prostate cancer;
LUAD	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18876405	chr7:65276391	NA	-0.44	-6.98	-0.32	1.16e-11	Aortic root size;
LUAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg02353165	chr6:42928485	GNMT	0.44	7.92	0.36	2.18e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg13944838	chr5:179740914	GFPT2	-0.8	-13.82	-0.56	4.15e-36	Height;
LUAD	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg21153622	chr11:89784906	NA	-0.36	-7.32	-0.34	1.27e-12	HDL cholesterol;
LUAD	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg03948781	chr1:205179583	DSTYK	-0.36	-6.56	-0.3	1.58e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs13315871	1.000	rs36097398	chr3:58367330	G/A	cg12435725	chr3:58293450	RPP14	-0.67	-7.3	-0.33	1.42e-12	Cholesterol, total;
LUAD	cis	rs6594713	0.921	rs7729269	chr5:112720394	A/G	cg12552261	chr5:112820674	MCC	0.53	8.31	0.37	1.31e-15	Brain cytoarchitecture;
LUAD	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg11266682	chr4:10021025	SLC2A9	0.52	11.42	0.49	1.58e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9462027	0.628	rs2744944	chr6:34658080	A/C	cg07306190	chr6:34760872	UHRF1BP1	0.33	8.44	0.38	5.27e-16	Systemic lupus erythematosus;
LUAD	cis	rs12989701	0.877	rs34745987	chr2:127875384	C/T	cg08168897	chr2:127865431	BIN1	0.46	7.18	0.33	3.24e-12	Alzheimer's disease (late onset);
LUAD	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg07636037	chr3:49044803	WDR6	0.63	12.11	0.51	3.3600000000000003e-29	Parkinson's disease;
LUAD	cis	rs7009516	0.934	rs13279576	chr8:24222025	A/C	cg01759110	chr8:24241694	ADAMDEC1	0.35	7.04	0.32	7.92e-12	Hair greying;
LUAD	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg04944784	chr2:26401820	FAM59B	-0.71	-9.94	-0.43	4.77e-21	Gut microbiome composition (summer);
LUAD	cis	rs1003719	0.713	rs2835594	chr21:38466064	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.31e-16	Eye color traits;
LUAD	cis	rs9902453	0.868	rs12944395	chr17:28323499	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-10.17	-0.44	7.22e-22	Coffee consumption (cups per day);
LUAD	trans	rs853679	0.607	rs66886492	chr6:28089731	C/T	cg06606381	chr12:133084897	FBRSL1	-1.21	-10.65	-0.46	1.27e-23	Depression;
LUAD	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.37	6.64	0.31	9.43e-11	Blood metabolite levels;
LUAD	cis	rs7119	0.700	rs4886519	chr15:77893885	A/G	cg27398640	chr15:77910606	LINGO1	0.4	7.76	0.35	6.26e-14	Type 2 diabetes;
LUAD	cis	rs11031096	0.502	rs1442726	chr11:4094748	G/C	cg18678763	chr11:4115507	RRM1	-0.44	-7.05	-0.32	7.51e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg25566285	chr7:158114605	PTPRN2	0.54	11.56	0.49	4.93e-27	Calcium levels;
LUAD	cis	rs10992471	0.627	rs10820980	chr9:95253342	C/T	cg14631576	chr9:95140430	CENPP	-0.56	-11.54	-0.49	5.9e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.32	-0.34	1.24e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg25208724	chr1:156163844	SLC25A44	0.83	12.18	0.51	1.78e-29	Testicular germ cell tumor;
LUAD	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg12645284	chr15:79092878	ADAMTS7	0.48	7.53	0.34	3.03e-13	Coronary artery disease or large artery stroke;
LUAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13012494	chr21:47604986	C21orf56	-0.7	-12.04	-0.51	6.46e-29	Testicular germ cell tumor;
LUAD	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg12444411	chr7:2802554	GNA12	-0.37	-6.66	-0.31	8.66e-11	Height;
LUAD	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg17173187	chr15:85201210	NMB	0.48	8.39	0.38	7.41e-16	Schizophrenia;
LUAD	cis	rs9341808	0.718	rs910266	chr6:80921170	A/T	cg08355045	chr6:80787529	NA	0.58	10.53	0.46	3.5e-23	Sitting height ratio;
LUAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.56	7.63	0.35	1.5700000000000001e-13	Renal function-related traits (BUN);
LUAD	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08704250	chr15:31115839	NA	-0.56	-10.35	-0.45	1.6e-22	Huntington's disease progression;
LUAD	trans	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg04565464	chr8:145669602	NFKBIL2	0.45	6.68	0.31	7.67e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg06873352	chr17:61820015	STRADA	0.41	6.83	0.32	2.88e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg15133208	chr4:90757351	SNCA	-0.45	-6.74	-0.31	5.36e-11	Neuroticism;
LUAD	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11644478	chr21:40555479	PSMG1	-0.4	-6.65	-0.31	8.89e-11	Menarche (age at onset);
LUAD	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg20203395	chr5:56204925	C5orf35	-0.49	-7.76	-0.35	6.35e-14	Coronary artery disease;
LUAD	cis	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg11143507	chr3:125485238	NA	-0.44	-7.39	-0.34	7.83e-13	Blood pressure (smoking interaction);
LUAD	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg08085267	chr17:45401833	C17orf57	-0.45	-7.29	-0.33	1.56e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7909074	0.691	rs11239274	chr10:45393219	A/C	cg05187965	chr10:45406764	TMEM72	0.39	7.95	0.36	1.7e-14	Mean corpuscular volume;
LUAD	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05901451	chr6:126070800	HEY2	0.56	8.87	0.4	2.15e-17	Endometrial cancer;
LUAD	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.72	13.16	0.54	2.17e-33	Menarche (age at onset);
LUAD	cis	rs8017423	0.967	rs8022531	chr14:90729931	T/C	cg14092571	chr14:90743983	NA	-0.47	-8.26	-0.37	1.88e-15	Mortality in heart failure;
LUAD	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.71	-0.39	6.72e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg03929089	chr4:120376271	NA	-0.98	-20.05	-0.7	2.47e-63	Height;
LUAD	cis	rs9905704	0.596	rs2526367	chr17:56470750	C/T	cg19466818	chr17:56409534	MIR142	0.35	7.08	0.33	6.17e-12	Testicular germ cell tumor;
LUAD	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg06092702	chr1:163392909	NA	-0.4	-8.58	-0.39	1.77e-16	Motion sickness;
LUAD	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg06453172	chr10:134556979	INPP5A	-0.77	-11.1	-0.47	2.7e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg21782813	chr7:2030301	MAD1L1	0.6	10.53	0.46	3.42e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg05697835	chr1:2722811	NA	0.29	6.59	0.31	1.29e-10	Ulcerative colitis;
LUAD	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.43	-0.34	5.94e-13	Type 2 diabetes;
LUAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg27454412	chr7:1067447	C7orf50	0.48	7.71	0.35	8.96e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg07636037	chr3:49044803	WDR6	0.61	11.63	0.49	2.57e-27	Parkinson's disease;
LUAD	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg14092571	chr14:90743983	NA	0.48	8.13	0.37	4.64e-15	Mortality in heart failure;
LUAD	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg04851639	chr8:1020857	NA	-0.4	-9.21	-0.41	1.59e-18	Schizophrenia;
LUAD	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg06740227	chr12:86229804	RASSF9	0.47	8.09	0.37	6.55e-15	Major depressive disorder;
LUAD	cis	rs62400317	0.762	rs857601	chr6:44805214	G/T	cg18551225	chr6:44695536	NA	0.46	7.15	0.33	3.8e-12	Total body bone mineral density;
LUAD	trans	rs994533	0.928	rs7594625	chr2:218293564	A/C	cg13696300	chr17:18162128	FLII	0.4	6.44	0.3	3.35e-10	Height;
LUAD	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg11822812	chr5:140052017	DND1	-0.42	-7.64	-0.35	1.47e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6987853	0.933	rs1343875	chr8:42424749	C/T	cg09913449	chr8:42400586	C8orf40	0.42	7.66	0.35	1.31e-13	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs11039798	0.841	rs7950737	chr11:48590678	T/G	cg03929089	chr4:120376271	NA	0.56	6.47	0.3	2.67e-10	Axial length;
LUAD	cis	rs36051895	0.659	rs7046077	chr9:5045328	C/G	cg02405213	chr9:5042618	JAK2	-0.44	-6.37	-0.3	4.95e-10	Pediatric autoimmune diseases;
LUAD	cis	rs4948275	0.530	rs2393853	chr10:63167688	C/G	cg03237606	chr10:63212265	TMEM26	-0.37	-7.62	-0.35	1.65e-13	Night sleep phenotypes;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10387901	chr3:15106641	MRPS25	0.42	6.35	0.3	5.69e-10	Gut microbiome composition (summer);
LUAD	cis	rs16866061	1.000	rs72974267	chr2:225454209	T/C	cg12698349	chr2:225449008	CUL3	0.77	13.46	0.55	1.28e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08677398	chr8:58056175	NA	0.47	6.57	0.3	1.52e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7116495	1.000	rs517837	chr11:71802359	A/G	cg07596299	chr11:71824057	C11orf51	-0.77	-6.68	-0.31	7.51e-11	Severe influenza A (H1N1) infection;
LUAD	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.77	-14.8	-0.58	3.19e-40	Intelligence (multi-trait analysis);
LUAD	trans	rs2735413	0.837	rs4888735	chr16:78083742	C/T	cg01028844	chr5:122736986	CEP120	0.41	6.46	0.3	2.87e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg08888203	chr3:10149979	C3orf24	0.63	10.73	0.46	6.56e-24	Alzheimer's disease;
LUAD	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg11663144	chr21:46675770	NA	-0.59	-11.73	-0.5	1.04e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg19761014	chr17:28927070	LRRC37B2	0.86	8.34	0.38	1.07e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg07923666	chr12:49932857	KCNH3	-0.54	-6.43	-0.3	3.47e-10	Resting heart rate;
LUAD	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	24.72	0.77	4.03e-84	Chronic sinus infection;
LUAD	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.55	8.14	0.37	4.56e-15	Gut microbiome composition (summer);
LUAD	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg15445000	chr17:37608096	MED1	-0.45	-8.41	-0.38	6.46e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs1878931	0.615	rs6501171	chr16:3402610	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.4	6.78	0.31	4.12e-11	Body mass index (adult);
LUAD	cis	rs7213347	1.000	rs7213347	chr17:2153257	G/C	cg16513277	chr17:2031491	SMG6	-0.45	-7.2	-0.33	2.84e-12	Total body bone mineral density;
LUAD	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg11494091	chr17:61959527	GH2	0.43	8.16	0.37	3.86e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6005807	0.719	rs2144922	chr22:28923317	A/G	cg12565055	chr22:29076175	TTC28	0.74	8.64	0.39	1.15e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs933688	0.532	rs868557	chr5:90550379	G/A	cg17503389	chr5:90575422	NA	-0.44	-6.61	-0.31	1.2e-10	Smoking behavior;
LUAD	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-9.13	-0.41	2.89e-18	Life satisfaction;
LUAD	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg18721089	chr20:30220636	NA	-0.43	-6.68	-0.31	7.69e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg02734326	chr4:10020555	SLC2A9	0.65	11.56	0.49	4.62e-27	Bone mineral density;
LUAD	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	6.92	0.32	1.64e-11	Platelet count;
LUAD	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg00666640	chr1:248458726	OR2T12	0.32	7.88	0.36	2.86e-14	Common traits (Other);
LUAD	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.02	0.36	1.02e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg25767906	chr1:53392781	SCP2	0.41	7.3	0.33	1.45e-12	Monocyte count;
LUAD	cis	rs713587	0.776	rs1172294	chr2:25169200	A/G	cg01884057	chr2:25150051	NA	0.33	6.75	0.31	5.01e-11	Body mass index in non-asthmatics;
LUAD	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.95	-0.36	1.68e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs8113142	0.550	rs66459748	chr19:29131294	T/G	cg04546413	chr19:29218101	NA	0.44	6.85	0.32	2.58e-11	Femoral neck bone geometry and menarche (age at onset);
LUAD	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg25566285	chr7:158114605	PTPRN2	0.54	11.61	0.49	3.07e-27	Calcium levels;
LUAD	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg04398451	chr17:18023971	MYO15A	-0.88	-16.81	-0.63	6.08e-49	Total body bone mineral density;
LUAD	cis	rs6060717	0.536	rs6060664	chr20:34478884	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.06	-0.32	7.08e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs67981189	0.542	rs17109053	chr14:71609698	G/C	cg15910301	chr14:71632612	NA	0.44	6.74	0.31	5.1e-11	Schizophrenia;
LUAD	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg01475377	chr6:109611718	NA	-0.55	-10.6	-0.46	1.93e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg26893861	chr17:41843967	DUSP3	1.12	25.11	0.77	7.9e-86	Triglycerides;
LUAD	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg15704280	chr7:45808275	SEPT13	-0.76	-11.77	-0.5	7.14e-28	Coronary artery disease;
LUAD	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	7.9	0.36	2.42e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs829883	0.664	rs1096148	chr12:98851005	A/G	cg25150519	chr12:98850993	NA	0.75	13.97	0.56	9.78e-37	Colorectal adenoma (advanced);
LUAD	cis	rs1595825	0.786	rs16826740	chr2:198893927	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-7.0	-0.32	1.02e-11	Ulcerative colitis;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg05959577	chr3:48129425	MAP4	0.4	6.46	0.3	2.92e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg15448220	chr1:150897856	SETDB1	0.5	8.61	0.39	1.48e-16	Melanoma;
LUAD	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg09365446	chr1:150670422	GOLPH3L	0.66	12.37	0.52	3.3e-30	Tonsillectomy;
LUAD	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg15704280	chr7:45808275	SEPT13	-0.79	-12.96	-0.53	1.36e-32	Coronary artery disease;
LUAD	cis	rs9297145	0.761	rs112155177	chr7:98747963	C/T	cg05967295	chr7:98741636	SMURF1	0.91	14.37	0.57	2.05e-38	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg15448220	chr1:150897856	SETDB1	0.53	9.32	0.41	6.74e-19	Melanoma;
LUAD	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg25894440	chr7:65020034	NA	0.61	6.47	0.3	2.63e-10	Diabetic kidney disease;
LUAD	cis	rs15676	0.783	rs7860949	chr9:131586883	C/T	cg00228799	chr9:131580591	ENDOG	-0.43	-6.82	-0.31	3.07e-11	Blood metabolite levels;
LUAD	cis	rs870825	0.616	rs14969	chr4:185615764	C/A	cg04058563	chr4:185651563	MLF1IP	0.88	14.09	0.57	3.19e-37	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg21475434	chr5:93447410	FAM172A	0.66	7.29	0.33	1.57e-12	Diabetic retinopathy;
LUAD	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg17063962	chr7:91808500	NA	-0.67	-11.71	-0.49	1.27e-27	Breast cancer;
LUAD	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08704250	chr15:31115839	NA	0.71	12.78	0.53	7.73e-32	Huntington's disease progression;
LUAD	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg21823605	chr1:152486609	CRCT1	0.3	6.85	0.32	2.6e-11	Hair morphology;
LUAD	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg22532475	chr10:104410764	TRIM8	0.35	7.0	0.32	1.02e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg02574844	chr11:5959923	NA	-0.43	-8.28	-0.37	1.58e-15	DNA methylation (variation);
LUAD	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg05623727	chr3:50126028	RBM5	-0.31	-6.75	-0.31	4.91e-11	Body mass index;
LUAD	cis	rs10540	0.584	rs10751659	chr11:437559	C/T	cg03934478	chr11:495069	RNH1	-0.49	-6.64	-0.31	9.7e-11	Body mass index;
LUAD	cis	rs593982	0.858	rs537385	chr11:65504900	G/A	cg08755490	chr11:65554678	OVOL1	1.32	20.4	0.7	6.24e-65	Atopic dermatitis;
LUAD	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.08	-0.33	6.17e-12	Total cholesterol levels;
LUAD	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.4e-15	Prostate cancer;
LUAD	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg09537434	chr19:41945824	ATP5SL	0.45	7.23	0.33	2.28e-12	Height;
LUAD	trans	rs60787346	0.883	rs2838334	chr21:45064961	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	7.32	0.34	1.29e-12	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08219700	chr8:58056026	NA	0.58	8.03	0.36	9.71e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7017914	0.935	rs35564237	chr8:71600474	G/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.61	-0.31	1.13e-10	Bone mineral density;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03857673	chr11:65769520	EIF1AD;BANF1	-0.39	-6.58	-0.3	1.38e-10	Cancer;
LUAD	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg25535316	chr11:579198	PHRF1	-0.4	-6.56	-0.3	1.56e-10	Systemic lupus erythematosus;
LUAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.41	0.3	4e-10	Platelet count;
LUAD	trans	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg07211511	chr3:129823064	LOC729375	-0.58	-7.64	-0.35	1.51e-13	Blood pressure (smoking interaction);
LUAD	cis	rs6558530	0.897	rs7838456	chr8:1707591	T/G	cg19131313	chr8:1704013	NA	-0.47	-7.69	-0.35	1.01e-13	Systolic blood pressure;
LUAD	cis	rs701145	0.585	rs447429	chr3:153909946	T/C	cg17054900	chr3:154042577	DHX36	0.61	6.73	0.31	5.57e-11	Coronary artery disease;
LUAD	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg08916839	chr5:415575	AHRR	-0.56	-7.77	-0.35	6.19e-14	Fat distribution (HIV);
LUAD	trans	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg01620082	chr3:125678407	NA	-0.76	-7.65	-0.35	1.38e-13	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg14917512	chr19:3094685	GNA11	-0.56	-6.55	-0.3	1.72e-10	Diabetic kidney disease;
LUAD	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg23750338	chr8:142222470	SLC45A4	-0.6	-13.77	-0.56	6.72e-36	Immature fraction of reticulocytes;
LUAD	cis	rs7737355	0.773	rs7720194	chr5:130837077	T/C	cg25547332	chr5:131281432	NA	0.4	6.46	0.3	2.82e-10	Life satisfaction;
LUAD	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.28	0.37	1.61e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg07169764	chr2:136633963	MCM6	0.66	8.23	0.37	2.29e-15	Corneal structure;
LUAD	cis	rs2742417	0.603	rs2742456	chr3:45767176	C/T	cg10512202	chr3:45649293	LIMD1	0.45	8.22	0.37	2.56e-15	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02359409	chr6:42947317	PEX6	-0.38	-6.77	-0.31	4.19e-11	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg17366294	chr4:99064904	C4orf37	0.65	12.47	0.52	1.31e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11677370	0.574	rs10209122	chr2:3871186	C/A	cg17052675	chr2:3827356	NA	-0.61	-10.18	-0.44	6.52e-22	Type 2 diabetes;
LUAD	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg05590025	chr7:65112418	INTS4L2	-0.77	-8.16	-0.37	3.81e-15	Diabetic kidney disease;
LUAD	cis	rs1595825	0.891	rs1016883	chr2:198881668	A/G	cg00361562	chr2:198649771	BOLL	0.46	6.41	0.3	4e-10	Ulcerative colitis;
LUAD	cis	rs600231	0.665	rs1626021	chr11:65226187	A/G	cg17120908	chr11:65337727	SSSCA1	-0.6	-9.22	-0.41	1.44e-18	Bone mineral density;
LUAD	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg00071950	chr4:10020882	SLC2A9	0.85	18.61	0.67	6.8e-57	Bone mineral density;
LUAD	trans	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg06606381	chr12:133084897	FBRSL1	-1.13	-10.48	-0.45	5.16e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4343996	0.719	rs885011	chr7:3484778	T/C	cg21248987	chr7:3385318	SDK1	0.35	6.61	0.31	1.18e-10	Motion sickness;
LUAD	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg18944383	chr4:111397179	ENPEP	0.33	6.35	0.3	5.51e-10	Height;
LUAD	cis	rs12681287	0.752	rs2917557	chr8:87314071	C/T	cg00550725	chr8:87521180	FAM82B	0.45	6.5	0.3	2.27e-10	Caudate activity during reward;
LUAD	cis	rs513349	1.000	rs513349	chr6:33541719	A/G	cg24505687	chr6:33548425	BAK1	0.44	8.59	0.39	1.65e-16	Platelet count;
LUAD	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11644478	chr21:40555479	PSMG1	0.61	9.76	0.43	2.02e-20	Cognitive function;
LUAD	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg19318889	chr4:1322082	MAEA	0.53	8.69	0.39	7.9e-17	Longevity;
LUAD	cis	rs727505	0.866	rs66852389	chr7:124724348	T/A	cg23710748	chr7:124431027	NA	-0.42	-8.51	-0.38	2.97e-16	Lewy body disease;
LUAD	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg24531977	chr5:56204891	C5orf35	-0.48	-7.88	-0.36	2.82e-14	Coronary artery disease;
LUAD	cis	rs490234	0.966	rs638168	chr9:128435256	G/A	cg14078157	chr9:128172775	NA	0.37	6.44	0.3	3.26e-10	Mean arterial pressure;
LUAD	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg17366294	chr4:99064904	C4orf37	0.6	10.05	0.44	1.9e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg20307385	chr11:47447363	PSMC3	0.64	10.72	0.46	6.95e-24	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg00684032	chr4:1343700	KIAA1530	0.42	7.04	0.32	7.89e-12	Obesity-related traits;
LUAD	cis	rs35883536	1.000	rs17403857	chr1:101105216	A/C	cg06223162	chr1:101003688	GPR88	0.37	6.9	0.32	1.96e-11	Monocyte count;
LUAD	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.71	-0.39	7.02e-17	Menopause (age at onset);
LUAD	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg27535305	chr1:53392650	SCP2	0.47	9.21	0.41	1.56e-18	Monocyte count;
LUAD	cis	rs9341808	0.558	rs2490234	chr6:80816966	G/C	cg08355045	chr6:80787529	NA	0.5	8.69	0.39	8.22e-17	Sitting height ratio;
LUAD	cis	rs9487051	0.698	rs35757653	chr6:109644599	A/C	cg21918786	chr6:109611834	NA	-0.44	-6.78	-0.31	4.16e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.4	0.55	2.3e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12095720	chr17:72978304	NA	-0.54	-6.53	-0.3	1.94e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg04155289	chr7:94953770	PON1	-0.52	-6.89	-0.32	2.09e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs89107	0.688	rs372237	chr6:118608979	G/T	cg21191810	chr6:118973309	C6orf204	0.48	9.34	0.41	5.37e-19	Cardiac structure and function;
LUAD	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg00321850	chr1:175162397	KIAA0040	-0.51	-10.8	-0.46	3.6e-24	Alcohol dependence;
LUAD	cis	rs747650	0.926	rs11039119	chr11:47201924	G/A	cg19486271	chr11:47235900	DDB2	0.41	6.55	0.3	1.64e-10	Acne (severe);
LUAD	cis	rs11771526	0.901	rs1530823	chr7:32311420	G/T	cg13207630	chr7:32358064	NA	-0.54	-7.14	-0.33	4.08e-12	Body mass index;
LUAD	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg07677032	chr17:61819896	STRADA	-0.5	-8.76	-0.39	4.87e-17	Prudent dietary pattern;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15559938	chr1:206837731	NA	-0.47	-7.32	-0.34	1.22e-12	Height;
LUAD	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg24531977	chr5:56204891	C5orf35	0.74	11.79	0.5	6.11e-28	Initial pursuit acceleration;
LUAD	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg14634687	chr17:47094252	IGF2BP1	0.27	6.76	0.31	4.52e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg02734326	chr4:10020555	SLC2A9	0.63	11.28	0.48	5.66e-26	Bone mineral density;
LUAD	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg11235426	chr6:292522	DUSP22	-0.56	-9.21	-0.41	1.51e-18	Menopause (age at onset);
LUAD	cis	rs12612619	0.659	rs12997235	chr2:27229079	A/C	cg00617064	chr2:27272375	NA	0.34	6.4	0.3	4.03e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs2996428	0.709	rs7527973	chr1:3704041	C/T	cg13057898	chr1:3703894	LRRC47	0.67	11.49	0.49	8.57e-27	Red cell distribution width;
LUAD	trans	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg01620082	chr3:125678407	NA	-0.71	-7.15	-0.33	3.79e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28493229	0.708	rs78900506	chr19:41160096	T/C	cg21869046	chr19:41225005	ITPKC	0.52	9.11	0.41	3.19e-18	Kawasaki disease;
LUAD	cis	rs36051895	0.659	rs12339666	chr9:5063296	A/C	cg02405213	chr9:5042618	JAK2	0.47	7.0	0.32	1.04e-11	Pediatric autoimmune diseases;
LUAD	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg06028605	chr16:24865363	SLC5A11	0.4	6.95	0.32	1.39e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg04989706	chr14:50066350	PPIL5	-0.54	-7.69	-0.35	1.07e-13	Carotid intima media thickness;
LUAD	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-7.58	-0.35	2.17e-13	Lung cancer;
LUAD	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg11062466	chr8:58055876	NA	0.45	6.42	0.3	3.62e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.56	-8.86	-0.4	2.21e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7301016	0.846	rs17732089	chr12:63023658	A/G	cg11441379	chr12:63026424	NA	-0.62	-7.78	-0.35	5.43e-14	IgG glycosylation;
LUAD	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg23533926	chr12:111358616	MYL2	-0.4	-6.9	-0.32	1.97e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs11971779	0.680	rs7779900	chr7:139082987	G/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.92	0.32	1.69e-11	Diisocyanate-induced asthma;
LUAD	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.38	6.39	0.3	4.49e-10	Total body bone mineral density;
LUAD	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg12667521	chr19:29218732	NA	0.54	7.44	0.34	5.72e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg05373962	chr22:49881684	NA	-0.49	-11.22	-0.48	9.52e-26	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg23116180	chr11:45167805	PRDM11	0.42	6.38	0.3	4.73e-10	QT interval;
LUAD	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	6.8	0.31	3.47e-11	Platelet count;
LUAD	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg20891558	chr2:74357851	NA	-0.89	-13.26	-0.54	8.42e-34	Gestational age at birth (maternal effect);
LUAD	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg07677032	chr17:61819896	STRADA	0.43	6.49	0.3	2.47e-10	Height;
LUAD	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.52	-0.38	2.74e-16	Neutrophil percentage of white cells;
LUAD	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg23587288	chr2:27483067	SLC30A3	-0.43	-8.45	-0.38	4.69e-16	Blood metabolite levels;
LUAD	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg09491104	chr22:46646882	C22orf40	-0.53	-7.41	-0.34	7.12e-13	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11050527	chr8:54755511	ATP6V1H	-0.41	-6.53	-0.3	1.9e-10	Height;
LUAD	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg09085632	chr11:111637200	PPP2R1B	0.64	10.73	0.46	6.26e-24	Primary sclerosing cholangitis;
LUAD	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03352830	chr11:487213	PTDSS2	0.68	8.37	0.38	8.44e-16	Body mass index;
LUAD	cis	rs6761276	0.868	rs12468224	chr2:113834434	G/C	cg09040174	chr2:113837401	NA	0.8	15.65	0.61	7.33e-44	Protein quantitative trait loci;
LUAD	cis	rs669446	0.561	rs568639	chr1:44086080	T/C	cg12908607	chr1:44402522	ARTN	-0.37	-6.78	-0.31	4.18e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg04944784	chr2:26401820	FAM59B	0.7	9.87	0.43	8.27e-21	Gut microbiome composition (summer);
LUAD	cis	rs1003719	0.788	rs2251161	chr21:38467857	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.46	0.38	4.25e-16	Eye color traits;
LUAD	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg02527881	chr3:46936655	PTH1R	-0.45	-8.67	-0.39	9.52e-17	Colorectal cancer;
LUAD	cis	rs10746514	0.833	rs10864720	chr1:232271232	C/T	cg09506761	chr1:232265262	NA	-0.39	-7.39	-0.34	8.02e-13	Response to statin therapy;
LUAD	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg23018236	chr17:30244563	NA	-0.67	-7.87	-0.36	3.04e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg04450456	chr4:17643702	FAM184B	0.37	7.03	0.32	8.49e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11051970	0.679	rs2733696	chr12:32554635	A/G	cg24626660	chr12:32551988	NA	0.34	7.22	0.33	2.39e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	9.38	0.41	4.07e-19	Melanoma;
LUAD	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.18e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg22467129	chr15:76604101	ETFA	-0.5	-8.59	-0.39	1.73e-16	Blood metabolite levels;
LUAD	cis	rs929596	0.501	rs4530361	chr2:234590041	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-9.76	-0.43	1.97e-20	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg12011299	chr4:100065546	ADH4	0.66	12.17	0.51	2.06e-29	Alcohol dependence;
LUAD	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg22117172	chr7:91764530	CYP51A1	0.37	7.87	0.36	3.06e-14	Breast cancer;
LUAD	cis	rs11214589	0.807	rs2155463	chr11:113242301	T/C	cg14159747	chr11:113255604	NA	0.62	13.35	0.54	3.51e-34	Neuroticism;
LUAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg11062466	chr8:58055876	NA	0.48	6.69	0.31	6.95e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4849845	0.598	rs4848586	chr2:121061291	C/T	cg24070213	chr2:121070622	NA	0.41	7.62	0.35	1.64e-13	Mean platelet volume;
LUAD	cis	rs2404602	0.552	rs11636612	chr15:76959530	C/T	cg00316803	chr15:76480434	C15orf27	0.44	6.46	0.3	2.8e-10	Blood metabolite levels;
LUAD	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg03806693	chr22:41940476	POLR3H	-0.64	-8.6	-0.39	1.55e-16	Vitiligo;
LUAD	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg26384229	chr12:38710491	ALG10B	-0.38	-6.48	-0.3	2.56e-10	Bladder cancer;
LUAD	trans	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.19	-30.23	-0.83	9.24e-108	Exhaled nitric oxide output;
LUAD	cis	rs4588572	0.644	rs6882191	chr5:77743098	G/A	cg11547950	chr5:77652471	NA	-0.62	-10.5	-0.45	4.64e-23	Triglycerides;
LUAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14159672	chr1:205819179	PM20D1	0.6	10.86	0.47	2.11e-24	Menarche (age at onset);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05985164	chr12:57881757	MARS	-0.56	-6.83	-0.32	2.89e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg06611532	chr13:114900021	NA	0.38	8.89	0.4	1.84e-17	Schizophrenia;
LUAD	trans	rs1997103	1.000	rs6973337	chr7:55411534	T/C	cg20935933	chr6:143382018	AIG1	0.52	7.33	0.34	1.15e-12	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg03806693	chr22:41940476	POLR3H	0.55	8.3	0.37	1.44e-15	Vitiligo;
LUAD	cis	rs13064411	0.696	rs9808893	chr3:113228444	G/A	cg10517650	chr3:113235015	CCDC52	-0.56	-9.59	-0.42	7.81e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg02176678	chr2:219576539	TTLL4	-0.81	-16.78	-0.63	8.46e-49	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg09658497	chr7:2847517	GNA12	-0.54	-9.36	-0.41	4.78e-19	Height;
LUAD	cis	rs6732160	0.613	rs10179063	chr2:73385111	T/A	cg01422370	chr2:73384389	NA	0.34	6.35	0.3	5.43e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs76419734	0.558	rs7698817	chr4:106532500	T/C	cg05309399	chr4:106552544	FLJ20184	-0.54	-6.76	-0.31	4.7e-11	Post bronchodilator FEV1;
LUAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg07362569	chr17:61921086	SMARCD2	0.39	6.74	0.31	5.22e-11	Prudent dietary pattern;
LUAD	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg00999904	chr2:3704751	ALLC	-0.52	-8.94	-0.4	1.18e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs490234	0.676	rs4838263	chr9:128225199	G/A	cg14078157	chr9:128172775	NA	-0.47	-8.37	-0.38	8.44e-16	Mean arterial pressure;
LUAD	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg24531977	chr5:56204891	C5orf35	-0.39	-6.35	-0.3	5.56e-10	Breast cancer;Breast cancer (early onset);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg27594834	chr19:11708137	ZNF627	-0.42	-7.04	-0.32	7.58e-12	Cancer;
LUAD	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg12863693	chr15:85201151	NMB	0.45	8.33	0.38	1.17e-15	Schizophrenia;
LUAD	cis	rs9972944	0.729	rs7222147	chr17:63774100	C/T	cg07283582	chr17:63770753	CCDC46	0.46	10.03	0.44	2.28e-21	Total body bone mineral density;
LUAD	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg00933542	chr6:150070202	PCMT1	0.44	9.68	0.43	3.63e-20	Lung cancer;
LUAD	cis	rs13395090	1.000	rs11687349	chr2:3717496	A/C	cg19052272	chr2:3704530	ALLC	-0.34	-6.47	-0.3	2.71e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs1728785	1.000	rs7205960	chr16:68565604	G/C	cg02508848	chr16:68573721	ZFP90	-0.42	-6.53	-0.3	1.94e-10	Ulcerative colitis;
LUAD	cis	rs1043515	0.748	rs11653487	chr17:36942631	A/G	cg20826740	chr17:37024042	NA	-0.37	-6.4	-0.3	4.08e-10	Height;
LUAD	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg17063962	chr7:91808500	NA	0.63	10.89	0.47	1.6e-24	Breast cancer;
LUAD	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg17366294	chr4:99064904	C4orf37	-0.65	-12.62	-0.52	3.2e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg01097406	chr16:89675127	NA	-0.34	-6.72	-0.31	6.06e-11	Vitiligo;
LUAD	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.48	7.79	0.35	5.09e-14	Platelet count;
LUAD	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg07538946	chr5:131705188	SLC22A5	0.45	7.38	0.34	8.63e-13	Blood metabolite levels;
LUAD	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.47	-0.34	4.68e-13	Schizophrenia;
LUAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.58e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7617773	0.851	rs7647817	chr3:48236507	G/A	cg11946769	chr3:48343235	NME6	0.41	6.41	0.3	3.78e-10	Coronary artery disease;
LUAD	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg07507251	chr3:52567010	NT5DC2	0.36	7.22	0.33	2.43e-12	Bipolar disorder;
LUAD	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg27170947	chr2:26402098	FAM59B	0.84	12.29	0.51	6.81e-30	Gut microbiome composition (summer);
LUAD	cis	rs738321	0.701	rs2413506	chr22:38593128	T/C	cg17652424	chr22:38574118	PLA2G6	-0.27	-7.04	-0.32	7.81e-12	Breast cancer;
LUAD	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg07936489	chr17:37558343	FBXL20	0.45	7.12	0.33	4.57e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg14728415	chr7:32535168	LSM5;AVL9	0.57	9.3	0.41	7.88e-19	Cognitive ability;
LUAD	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg24531977	chr5:56204891	C5orf35	-0.48	-7.92	-0.36	2.09e-14	Coronary artery disease;
LUAD	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg26924012	chr15:45694286	SPATA5L1	-0.53	-8.81	-0.39	3.32e-17	Glomerular filtration rate;
LUAD	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.64	-0.31	9.89e-11	Personality dimensions;
LUAD	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg27284194	chr4:1044797	NA	0.69	9.93	0.43	4.92e-21	Recombination rate (females);
LUAD	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg14668632	chr7:2872130	GNA12	0.48	8.55	0.38	2.2e-16	Height;
LUAD	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs2535633	0.661	rs4515041	chr3:52996032	T/A	cg18404041	chr3:52824283	ITIH1	0.39	6.68	0.31	7.57e-11	Body mass index;
LUAD	cis	rs1018836	0.884	rs13279263	chr8:91648780	T/C	cg16814680	chr8:91681699	NA	-0.63	-10.61	-0.46	1.71e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.61	-0.31	1.13e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs34734847	0.842	rs696337	chr12:121159380	T/C	cg27246729	chr12:121163418	ACADS	0.38	6.97	0.32	1.21e-11	Mean corpuscular volume;
LUAD	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg19743168	chr1:23544995	NA	0.36	6.44	0.3	3.23e-10	Height;
LUAD	cis	rs11585357	0.947	rs3003441	chr1:17611869	C/T	cg08277548	chr1:17600880	PADI3	0.84	12.74	0.53	1.07e-31	Hair shape;
LUAD	cis	rs68170813	0.562	rs17429825	chr7:107050731	C/T	cg02696742	chr7:106810147	HBP1	-0.8	-10.68	-0.46	9.78e-24	Coronary artery disease;
LUAD	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg03733263	chr8:22462867	KIAA1967	0.75	12.95	0.53	1.51e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07234876	chr8:600039	NA	-0.94	-9.43	-0.42	2.77e-19	IgG glycosylation;
LUAD	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.3	-0.45	2.43e-22	Total body bone mineral density;
LUAD	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-10.78	-0.46	4.02e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9473147	0.516	rs1485780	chr6:47556630	A/C	cg20196966	chr6:47445060	CD2AP	0.43	6.86	0.32	2.39e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg05110241	chr16:68378359	PRMT7	-0.81	-8.84	-0.4	2.51e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9715521	0.803	rs62301188	chr4:59840423	A/G	cg11281224	chr4:60001000	NA	-0.55	-9.35	-0.41	5.26e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26314531	chr2:26401878	FAM59B	0.75	10.73	0.46	6.7e-24	Gut microbiome composition (summer);
LUAD	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.9	-0.32	1.86e-11	Retinal vascular caliber;
LUAD	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg06547715	chr2:218990976	CXCR2	0.43	10.34	0.45	1.68e-22	Ulcerative colitis;
LUAD	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg12011299	chr4:100065546	ADH4	0.83	19.86	0.69	1.78e-62	Alcohol dependence;
LUAD	cis	rs72928364	1.000	rs2576391	chr3:100677010	C/G	cg10123952	chr3:100791384	NA	-0.54	-6.74	-0.31	5.33e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs17253792	0.822	rs76557162	chr14:56064701	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg06532163	chr17:45867833	NA	0.48	8.44	0.38	5.19e-16	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs656900	0.874	rs622506	chr15:80139195	A/C	cg02196730	chr15:80188777	MTHFS	-0.44	-7.0	-0.32	9.91e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.66	-10.22	-0.45	4.6e-22	Chronic sinus infection;
LUAD	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg26384229	chr12:38710491	ALG10B	0.46	7.47	0.34	4.57e-13	Bladder cancer;
LUAD	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg13770153	chr20:60521292	NA	-0.59	-9.1	-0.4	3.56e-18	Body mass index;
LUAD	trans	rs62103177	0.564	rs59188178	chr18:77723435	T/C	cg05926928	chr17:57297772	GDPD1	0.78	9.73	0.43	2.59e-20	Opioid sensitivity;
LUAD	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg10518543	chr12:38710700	ALG10B	0.49	8.34	0.38	1.05e-15	Morning vs. evening chronotype;
LUAD	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.89e-14	Depression;
LUAD	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.14	-0.41	2.57e-18	Life satisfaction;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19106087	chr17:422481	VPS53	0.52	6.43	0.3	3.54e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg10518543	chr12:38710700	ALG10B	0.41	6.35	0.3	5.46e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.95	0.36	1.74e-14	Depression;
LUAD	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg17105886	chr17:28927953	LRRC37B2	0.84	8.13	0.37	4.96e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg03929089	chr4:120376271	NA	0.57	7.13	0.33	4.49e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9323205	0.911	rs12587611	chr14:51641399	C/T	cg23942311	chr14:51606299	NA	-0.6	-10.33	-0.45	1.84e-22	Cancer;
LUAD	cis	rs59104589	0.570	rs73006397	chr2:242415523	C/T	cg08645257	chr2:242211290	HDLBP	0.39	6.57	0.3	1.46e-10	Fibrinogen levels;
LUAD	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.44	-0.42	2.5e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg04546413	chr19:29218101	NA	0.71	10.08	0.44	1.5e-21	Methadone dose in opioid dependence;
LUAD	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg25036284	chr2:26402008	FAM59B	-0.68	-9.24	-0.41	1.26e-18	Gut microbiome composition (summer);
LUAD	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg23815491	chr16:72088622	HP	0.53	9.94	0.44	4.68e-21	Fibrinogen levels;
LUAD	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7640424	0.691	rs13075747	chr3:107830164	T/A	cg09227934	chr3:107805635	CD47	-0.36	-6.6	-0.31	1.21e-10	Body mass index;
LUAD	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg21471580	chr8:22132874	PIWIL2	0.48	8.66	0.39	9.78e-17	Hypertriglyceridemia;
LUAD	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg24579218	chr15:68104479	NA	-0.53	-8.49	-0.38	3.49e-16	Obesity;
LUAD	cis	rs2286885	1.000	rs10733677	chr9:129242209	A/G	cg15282417	chr9:129245246	FAM125B	0.41	8.24	0.37	2.17e-15	Intraocular pressure;
LUAD	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg00666640	chr1:248458726	OR2T12	0.29	7.19	0.33	2.93e-12	Common traits (Other);
LUAD	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.29	-0.37	1.53e-15	Total body bone mineral density;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg01516881	chr6:292596	DUSP22	-0.76	-13.15	-0.54	2.36e-33	Menopause (age at onset);
LUAD	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg26384229	chr12:38710491	ALG10B	0.41	6.52	0.3	2.02e-10	Morning vs. evening chronotype;
LUAD	cis	rs3845702	0.866	rs818659	chr2:180870893	G/A	cg01881094	chr2:180872142	CWC22	0.61	7.83	0.36	3.89e-14	Schizophrenia;
LUAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg08888203	chr3:10149979	C3orf24	0.63	10.82	0.47	3.02e-24	Alzheimer's disease;
LUAD	cis	rs11792861	0.566	rs11792635	chr9:111848819	A/G	cg05043794	chr9:111880884	C9orf5	-0.38	-7.24	-0.33	2.2e-12	Menarche (age at onset);
LUAD	cis	rs698813	0.674	rs6544753	chr2:44501895	A/T	cg00619915	chr2:44497795	NA	-0.43	-6.35	-0.3	5.51e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUAD	trans	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg07211511	chr3:129823064	LOC729375	-0.55	-7.26	-0.33	1.86e-12	Blood pressure (smoking interaction);
LUAD	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg25753631	chr6:25732923	NA	-0.45	-7.96	-0.36	1.59e-14	Iron status biomarkers;
LUAD	trans	rs9393777	0.513	rs67540232	chr6:27140866	T/A	cg06606381	chr12:133084897	FBRSL1	-0.65	-7.73	-0.35	8.05e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4604732	0.631	rs74154673	chr1:247625629	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg03709012	chr19:19516395	GATAD2A	0.51	6.84	0.32	2.82e-11	Nonalcoholic fatty liver disease;
LUAD	cis	rs12545109	0.837	rs6474063	chr8:57355545	C/T	cg17761419	chr8:57350749	NA	-0.58	-8.39	-0.38	7.17e-16	Obesity-related traits;
LUAD	cis	rs74417235	0.528	rs9324789	chr5:154074362	C/T	cg08754654	chr5:154026448	NA	-0.37	-6.53	-0.3	1.89e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4780355	0.776	rs9936459	chr16:11437779	C/T	cg00044050	chr16:11439710	C16orf75	-0.52	-7.35	-0.34	1e-12	Crohn's disease and psoriasis;
LUAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg13047869	chr3:10149882	C3orf24	0.66	11.09	0.47	2.88e-25	Alzheimer's disease;
LUAD	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg08213375	chr14:104286397	PPP1R13B	-0.28	-7.23	-0.33	2.22e-12	Schizophrenia;
LUAD	cis	rs1018836	0.923	rs2187982	chr8:91556317	G/T	cg16814680	chr8:91681699	NA	-0.73	-13.18	-0.54	1.76e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2639990	1.000	rs632157	chr18:72911548	G/A	cg03972071	chr18:72917163	ZADH2	0.6	6.64	0.31	9.66e-11	Vascular endothelial growth factor levels;
LUAD	trans	rs877282	0.786	rs10904558	chr10:797509	C/T	cg22713356	chr15:30763199	NA	1.27	19.18	0.68	1.93e-59	Uric acid levels;
LUAD	cis	rs60154123	0.614	rs645890	chr1:210459801	A/C	cg22029157	chr1:209979665	IRF6	0.5	6.37	0.3	4.95e-10	Coronary artery disease;
LUAD	trans	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg07211511	chr3:129823064	LOC729375	-0.8	-9.98	-0.44	3.47e-21	Blood pressure (smoking interaction);
LUAD	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg11301795	chr4:187892539	NA	-0.76	-15.15	-0.59	1.04e-41	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7192380	0.965	rs9938213	chr16:69640590	T/C	cg00738113	chr16:70207722	CLEC18C	-0.34	-6.95	-0.32	1.42e-11	Sjögren's syndrome;
LUAD	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg14668632	chr7:2872130	GNA12	-0.68	-12.42	-0.52	2.11e-30	Height;
LUAD	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18876405	chr7:65276391	NA	-0.45	-7.21	-0.33	2.53e-12	Aortic root size;
LUAD	cis	rs870825	0.616	rs4519834	chr4:185633865	A/G	cg04058563	chr4:185651563	MLF1IP	-0.9	-14.57	-0.58	2.84e-39	Blood protein levels;
LUAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.61	-7.54	-0.34	2.95e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.34	6.82	0.31	3.16e-11	Obesity-related traits;
LUAD	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg27170947	chr2:26402098	FAM59B	-0.64	-8.92	-0.4	1.38e-17	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03352830	chr11:487213	PTDSS2	0.8	10.56	0.46	2.62e-23	Body mass index;
LUAD	cis	rs12711979	0.584	rs11694096	chr2:3868113	G/A	cg17052675	chr2:3827356	NA	-0.65	-13.2	-0.54	1.51e-33	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.33	6.58	0.3	1.39e-10	Parkinson's disease;
LUAD	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg12573674	chr2:1569213	NA	-0.61	-7.2	-0.33	2.74e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg25985355	chr7:65971099	NA	-0.51	-6.36	-0.3	5.25e-10	Diabetic kidney disease;
LUAD	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg05616858	chr17:37843591	ERBB2;PGAP3	0.34	6.91	0.32	1.81e-11	Asthma;
LUAD	trans	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg14917512	chr19:3094685	GNA11	0.56	6.69	0.31	7e-11	Diabetic kidney disease;
LUAD	cis	rs77741769	0.507	rs11065264	chr12:121218380	T/G	cg02419362	chr12:121203948	SPPL3	0.38	7.79	0.35	5.19e-14	Mean corpuscular volume;
LUAD	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg14844989	chr11:31128820	NA	-0.45	-8.26	-0.37	1.92e-15	Bone mineral density (spine);
LUAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg23131131	chr22:24373011	LOC391322	-0.58	-9.83	-0.43	1.09e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.97	-0.36	1.52e-14	Body mass index;
LUAD	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg21984481	chr17:79567631	NPLOC4	-0.6	-12.97	-0.53	1.27e-32	Eye color traits;
LUAD	cis	rs4481887	0.893	rs10158180	chr1:248481423	C/T	cg00666640	chr1:248458726	OR2T12	0.31	7.6	0.35	1.96e-13	Common traits (Other);
LUAD	cis	rs68170813	0.652	rs7807154	chr7:107161391	T/G	cg23024343	chr7:107201750	COG5	0.54	6.89	0.32	2.07e-11	Coronary artery disease;
LUAD	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg03929089	chr4:120376271	NA	0.68	9.83	0.43	1.14e-20	Coronary artery disease;
LUAD	cis	rs8044868	0.586	rs12917999	chr16:72089451	T/C	cg23815491	chr16:72088622	HP	0.56	10.62	0.46	1.7e-23	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg10518543	chr12:38710700	ALG10B	-0.42	-6.9	-0.32	1.93e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9463078	0.665	rs9472339	chr6:44711791	A/G	cg25276700	chr6:44698697	NA	0.34	6.52	0.3	2.06e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUAD	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg07169764	chr2:136633963	MCM6	0.76	8.84	0.39	2.57e-17	Corneal structure;
LUAD	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg19622623	chr12:86230825	RASSF9	0.43	7.59	0.35	2e-13	Major depressive disorder;
LUAD	cis	rs1160297	0.609	rs1839770	chr2:53104091	G/A	cg07782112	chr2:53107842	NA	0.38	8.47	0.38	4.05e-16	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04565464	chr8:145669602	NFKBIL2	0.45	6.86	0.32	2.39e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-6.61	-0.31	1.17e-10	Hematocrit;
LUAD	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg21427119	chr20:30132790	HM13	-0.37	-6.72	-0.31	5.89e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg08027265	chr7:2291960	NA	-0.4	-6.66	-0.31	8.6e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg15985400	chr11:76091674	PRKRIR	-0.49	-6.48	-0.3	2.54e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs7119038	0.818	rs10892293	chr11:118665575	A/T	cg19308663	chr11:118741387	NA	0.46	6.66	0.31	8.38e-11	Sjögren's syndrome;
LUAD	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg22920501	chr2:26401640	FAM59B	-0.73	-10.44	-0.45	7.12e-23	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7191700	0.673	rs12325495	chr16:11418328	C/T	cg00044050	chr16:11439710	C16orf75	0.72	11.91	0.5	2.08e-28	Multiple sclerosis;
LUAD	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg11266682	chr4:10021025	SLC2A9	0.51	10.19	0.44	6.05e-22	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg23254163	chr1:152506842	NA	0.26	7.29	0.33	1.53e-12	Hair morphology;
LUAD	cis	rs9549328	0.643	rs4907567	chr13:113617533	C/T	cg17524180	chr13:113633600	MCF2L	0.31	6.61	0.31	1.16e-10	Systolic blood pressure;
LUAD	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg07305463	chr2:136567211	LCT	-0.37	-7.16	-0.33	3.69e-12	Mosquito bite size;
LUAD	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg21770322	chr7:97807741	LMTK2	0.3	7.15	0.33	3.72e-12	Breast cancer;
LUAD	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	7.05	0.32	7.15e-12	Tonsillectomy;
LUAD	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg26597838	chr10:835615	NA	1.3	19.93	0.7	8.39e-63	Eosinophil percentage of granulocytes;
LUAD	trans	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg24644049	chr4:85504048	CDS1	0.88	7.16	0.33	3.55e-12	Skin colour saturation;
LUAD	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	7.17	0.33	3.35e-12	Rheumatoid arthritis;
LUAD	cis	rs11924390	0.749	rs822363	chr3:186452991	C/G	cg12454167	chr3:186435060	KNG1	0.4	8.34	0.38	1.09e-15	Adiponectin levels;
LUAD	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg03714773	chr7:91764589	CYP51A1	0.29	6.83	0.32	2.92e-11	Breast cancer;
LUAD	cis	rs7072216	0.727	rs10748728	chr10:100171198	C/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.68	-0.39	8.56e-17	Metabolite levels;
LUAD	cis	rs113835537	0.502	rs7104378	chr11:66216675	A/G	cg24851651	chr11:66362959	CCS	0.58	10.46	0.45	6.1e-23	Airway imaging phenotypes;
LUAD	cis	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05901451	chr6:126070800	HEY2	0.59	9.29	0.41	8.51e-19	Endometrial cancer;
LUAD	cis	rs332507	0.830	rs879535	chr3:124400107	A/G	cg05980111	chr3:124395277	KALRN	0.45	7.11	0.33	4.86e-12	Plateletcrit;
LUAD	cis	rs208520	0.837	rs208489	chr6:66927584	G/A	cg07460842	chr6:66804631	NA	-0.96	-13.64	-0.55	2.33e-35	Exhaled nitric oxide output;
LUAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg10729496	chr3:10149963	C3orf24	0.57	9.51	0.42	1.49e-19	Alzheimer's disease;
LUAD	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.64	-10.35	-0.45	1.56e-22	Birth weight;
LUAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg27297192	chr10:134578999	INPP5A	0.37	6.38	0.3	4.68e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7274811	0.681	rs291670	chr20:31945861	G/A	cg07470512	chr20:32255052	NECAB3;C20orf134	0.44	6.68	0.31	7.71e-11	Height;
LUAD	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg10978503	chr1:24200527	CNR2	-0.43	-7.89	-0.36	2.59e-14	Immature fraction of reticulocytes;
LUAD	cis	rs12541635	0.677	rs7846149	chr8:107053417	T/C	cg10147462	chr8:107024639	NA	0.52	9.31	0.41	6.85e-19	Age of smoking initiation;
LUAD	cis	rs1904096	0.506	rs10024642	chr4:95179295	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-8.77	-0.39	4.37e-17	Type 2 diabetes;
LUAD	cis	rs6906287	0.537	rs13192336	chr6:118875162	A/T	cg05564266	chr6:118973597	C6orf204	0.36	7.68	0.35	1.11e-13	Electrocardiographic conduction measures;
LUAD	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg12310025	chr6:25882481	NA	-0.57	-9.18	-0.41	1.98e-18	Blood metabolite levels;
LUAD	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg25019722	chr6:37503610	NA	-0.3	-6.98	-0.32	1.12e-11	Cognitive performance;
LUAD	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.73	0.31	5.67e-11	Aortic root size;
LUAD	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg04851639	chr8:1020857	NA	0.4	9.54	0.42	1.15e-19	Schizophrenia;
LUAD	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs62103177	0.564	rs3930042	chr18:77723843	G/A	cg20368463	chr18:77673604	PQLC1	0.52	6.71	0.31	6.25e-11	Opioid sensitivity;
LUAD	cis	rs4889855	0.530	rs4477776	chr17:78581765	G/A	cg16591659	chr17:78472290	NA	-0.43	-7.6	-0.35	1.96e-13	Fractional excretion of uric acid;
LUAD	cis	rs1461503	0.932	rs6589962	chr11:122843535	G/A	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs2839627	0.638	rs9974287	chr21:44317003	T/G	cg03543861	chr21:44258195	NA	0.66	8.06	0.36	8.06e-15	Information processing speed;
LUAD	cis	rs7084921	0.608	rs12780514	chr10:101865884	T/C	cg19754520	chr10:101825118	CPN1	-0.32	-6.45	-0.3	3.11e-10	Bone mineral density;
LUAD	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg02527881	chr3:46936655	PTH1R	-0.56	-10.19	-0.44	6.02e-22	Birth weight;
LUAD	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg20891283	chr12:69753455	YEATS4	0.43	7.05	0.32	7.19e-12	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg19318450	chr21:34852305	TMEM50B	-0.4	-6.43	-0.3	3.38e-10	Vertical cup-disc ratio;
LUAD	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg06558623	chr16:89946397	TCF25	1.15	10.41	0.45	9.62e-23	Skin colour saturation;
LUAD	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	8.35	0.38	9.6e-16	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.55	0.52	6.47e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00149659	chr3:10157352	C3orf10	0.58	8.02	0.36	1.06e-14	Alzheimer's disease;
LUAD	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.27	0.37	1.77e-15	Body mass index;
LUAD	cis	rs225245	0.817	rs225273	chr17:33970935	A/T	cg05299278	chr17:33885742	SLFN14	0.51	11.73	0.5	1.01e-27	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20409636	chr12:58146180	CDK4	-0.5	-6.49	-0.3	2.36e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6489785	0.710	rs3213566	chr12:121222578	T/C	cg02419362	chr12:121203948	SPPL3	0.35	7.16	0.33	3.72e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6733011	0.531	rs13004923	chr2:99497561	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.4	-6.42	-0.3	3.68e-10	Bipolar disorder;
LUAD	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg18132916	chr6:79620363	NA	-0.45	-7.8	-0.35	4.84e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6594713	0.570	rs35926701	chr5:112898969	A/G	cg12552261	chr5:112820674	MCC	0.52	7.19	0.33	2.99e-12	Brain cytoarchitecture;
LUAD	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg06627628	chr2:24431161	ITSN2	-0.46	-6.49	-0.3	2.42e-10	Lymphocyte counts;
LUAD	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg15704280	chr7:45808275	SEPT13	-1.06	-25.09	-0.77	8.9e-86	Height;
LUAD	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg07212818	chr11:638076	DRD4	-0.46	-6.69	-0.31	6.97e-11	Systemic lupus erythematosus;
LUAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg08132940	chr7:1081526	C7orf50	-0.76	-10.26	-0.45	3.23e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.02	0.32	8.86e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg00300879	chr1:26503847	CNKSR1	0.27	7.73	0.35	7.83e-14	Height;
LUAD	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.51e-15	Bipolar disorder;
LUAD	cis	rs11958404	0.929	rs72816508	chr5:157356031	G/T	cg05962755	chr5:157440814	NA	0.62	8.2	0.37	2.86e-15	IgG glycosylation;
LUAD	trans	rs8073060	0.586	rs9649	chr17:34050934	C/T	cg19694781	chr19:47549865	TMEM160	1.2	18.62	0.67	6e-57	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg26384229	chr12:38710491	ALG10B	0.46	7.52	0.34	3.2e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg00933542	chr6:150070202	PCMT1	0.47	9.71	0.43	2.93e-20	Lung cancer;
LUAD	trans	rs8002861	0.664	rs4942247	chr13:44405107	A/G	cg17145862	chr1:211918768	LPGAT1	0.65	13.1	0.54	3.69e-33	Leprosy;
LUAD	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg21963583	chr11:68658836	MRPL21	0.63	11.05	0.47	4.29e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg24846343	chr22:24311635	DDTL	-0.76	-16.54	-0.63	9.27e-48	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs75804782	0.641	rs72987304	chr2:239345532	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	8.44	0.38	5.07e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs73198271	1.000	rs73198279	chr8:8608504	A/G	cg01851573	chr8:8652454	MFHAS1	0.51	8.3	0.37	1.38e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg04455712	chr21:45112962	RRP1B	0.43	8.74	0.39	5.37e-17	Mean corpuscular volume;
LUAD	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg02569458	chr12:86230093	RASSF9	0.41	7.6	0.35	1.94e-13	Major depressive disorder;
LUAD	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03264133	chr6:25882463	NA	0.57	9.67	0.43	3.99e-20	Blood metabolite levels;
LUAD	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg23283495	chr1:209979779	IRF6	0.67	8.34	0.38	1.05e-15	Coronary artery disease;
LUAD	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.56	-0.3	1.61e-10	Alzheimer's disease (late onset);
LUAD	cis	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.72	-0.31	6.03e-11	Morning vs. evening chronotype;
LUAD	cis	rs4845570	1.000	rs7416415	chr1:151757798	C/T	cg07092448	chr1:151763213	TDRKH	0.75	8.52	0.38	2.76e-16	Coronary artery disease;
LUAD	cis	rs859767	0.779	rs6430528	chr2:135395348	A/G	cg12500956	chr2:135428796	TMEM163	-0.29	-7.8	-0.35	4.74e-14	Neuroticism;
LUAD	trans	rs4942242	0.663	rs1472330	chr13:44209628	A/G	cg19169023	chr15:41853346	TYRO3	0.66	11.72	0.5	1.14e-27	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-7.47	-0.34	4.54e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg17063962	chr7:91808500	NA	0.7	12.6	0.52	4.02e-31	Breast cancer;
LUAD	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg07080864	chr8:57359956	PENK	-0.37	-6.61	-0.31	1.14e-10	Obesity-related traits;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13427717	chr2:43822965	THADA	0.43	6.67	0.31	7.82e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.49	-8.94	-0.4	1.26e-17	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.08	-0.44	1.49e-21	Bipolar disorder and schizophrenia;
LUAD	trans	rs9467711	0.651	rs17526722	chr6:25918855	G/A	cg06606381	chr12:133084897	FBRSL1	-1.09	-7.91	-0.36	2.34e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg03563238	chr19:33554763	RHPN2	-0.34	-8.1	-0.37	5.94e-15	Bone properties (heel);
LUAD	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.25	0.51	1.02e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	ch.7.140705775R	chr7:141059306	NA	-0.39	-6.45	-0.3	3.13e-10	Cancer;
LUAD	cis	rs9309473	0.607	rs6716776	chr2:73587713	T/C	cg20560298	chr2:73613845	ALMS1	-0.43	-6.68	-0.31	7.33e-11	Metabolite levels;
LUAD	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg04731861	chr2:219085781	ARPC2	0.23	7.11	0.33	5.07e-12	Colorectal cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg14280964	chr1:37940281	ZC3H12A	-0.62	-6.55	-0.3	1.71e-10	Type 2 diabetes;
LUAD	cis	rs11811982	0.793	rs9660532	chr1:227515679	A/G	cg24860534	chr1:227506868	CDC42BPA	-0.61	-6.85	-0.32	2.58e-11	Optic disc area;
LUAD	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg02176678	chr2:219576539	TTLL4	0.62	12.27	0.51	7.94e-30	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1003719	0.788	rs4572679	chr21:38453227	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.45	0.38	4.62e-16	Eye color traits;
LUAD	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg03859395	chr2:55845619	SMEK2	0.61	10.54	0.46	3.16e-23	Metabolic syndrome;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01947585	chr15:59225861	SLTM	-0.49	-6.49	-0.3	2.34e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9902453	0.868	rs11080118	chr17:28475379	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.46	-0.42	2.17e-19	Coffee consumption (cups per day);
LUAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06873352	chr17:61820015	STRADA	0.83	18.55	0.67	1.24e-56	Prudent dietary pattern;
LUAD	trans	rs11039798	1.000	rs7479655	chr11:48576714	G/T	cg02254774	chr11:50257496	LOC441601	0.52	6.53	0.3	1.89e-10	Axial length;
LUAD	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg06271696	chr7:157225062	NA	-0.51	-10.79	-0.46	3.74e-24	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.37	-10.03	-0.44	2.28e-21	Total body bone mineral density;
LUAD	trans	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.86	-0.32	2.53e-11	Gout;
LUAD	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg11266682	chr4:10021025	SLC2A9	0.66	15.42	0.6	6.61e-43	Bone mineral density;
LUAD	cis	rs1881797	0.527	rs79724455	chr1:247646957	T/C	cg14830002	chr1:247616686	OR2B11	0.51	6.88	0.32	2.1e-11	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs752010	0.523	rs10890158	chr1:42117985	C/T	cg06885757	chr1:42089581	HIVEP3	0.53	11.95	0.5	1.48e-28	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs3772130	1.000	rs2070180	chr3:121351338	A/G	cg20356878	chr3:121714668	ILDR1	-0.51	-7.83	-0.36	3.99e-14	Cognitive performance;
LUAD	cis	rs727505	1.000	rs2402751	chr7:124434760	C/T	cg23710748	chr7:124431027	NA	-0.45	-8.84	-0.39	2.68e-17	Lewy body disease;
LUAD	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21582582	chr3:182698605	DCUN1D1	0.49	8.13	0.37	4.96e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg18867708	chr6:26865862	GUSBL1	0.43	6.86	0.32	2.44e-11	Schizophrenia;
LUAD	cis	rs7582720	1.000	rs72934518	chr2:203937908	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.83	0.43	1.1e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg07741184	chr6:167504864	NA	0.29	7.05	0.32	7.17e-12	Crohn's disease;
LUAD	cis	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg21775007	chr8:11205619	TDH	-0.4	-6.73	-0.31	5.66e-11	Neuroticism;
LUAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg18099408	chr3:52552593	STAB1	-0.51	-9.31	-0.41	7.02e-19	Electroencephalogram traits;
LUAD	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg20673091	chr1:2541236	MMEL1	-0.4	-8.77	-0.39	4.4e-17	Ulcerative colitis;
LUAD	cis	rs12612619	0.732	rs13032059	chr2:27233789	T/C	cg00617064	chr2:27272375	NA	-0.36	-6.83	-0.32	2.98e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-7.7	-0.35	9.43e-14	Heart rate;
LUAD	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg22482690	chr17:47019901	SNF8	0.43	8.21	0.37	2.64e-15	Type 2 diabetes;
LUAD	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg18105134	chr13:113819100	PROZ	-0.87	-15.15	-0.59	9.93e-42	Platelet distribution width;
LUAD	cis	rs62238980	0.614	rs75348576	chr22:32395467	A/C	cg00543991	chr22:32367038	NA	0.92	8.16	0.37	3.95e-15	Childhood ear infection;
LUAD	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.28	0.33	1.66e-12	Tonsillectomy;
LUAD	cis	rs7705042	0.865	rs7709361	chr5:141513854	T/C	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.9	-0.32	1.97e-11	Asthma;
LUAD	cis	rs4378999	0.800	rs1480354	chr3:51364458	G/A	cg12934382	chr3:51741135	GRM2	0.42	6.49	0.3	2.34e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg19748678	chr4:122722346	EXOSC9	0.45	7.08	0.33	6.08e-12	Type 2 diabetes;
LUAD	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg27210415	chr4:713949	PCGF3	0.62	9.18	0.41	1.95e-18	White blood cell count;
LUAD	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.49	-0.3	2.47e-10	Aortic root size;
LUAD	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg18477163	chr1:228402036	OBSCN	-0.35	-7.05	-0.32	7.43e-12	Diastolic blood pressure;
LUAD	trans	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg26043149	chr18:55253948	FECH	0.43	6.97	0.32	1.24e-11	Bone mineral density;
LUAD	cis	rs3087591	0.922	rs12939969	chr17:29463577	A/G	cg24425628	chr17:29625626	OMG;NF1	0.41	6.69	0.31	7.03e-11	Hip circumference;
LUAD	cis	rs11195062	0.766	rs7897645	chr10:112006669	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.45	-7.0	-0.32	9.93e-12	Multiple myeloma;
LUAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg04025307	chr7:1156635	C7orf50	0.66	7.48	0.34	4.22e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg10591111	chr5:226296	SDHA	-0.55	-7.17	-0.33	3.48e-12	Breast cancer;
LUAD	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg25554036	chr4:6271136	WFS1	0.69	11.29	0.48	5.08e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs73206853	0.841	rs28404862	chr12:110850241	C/G	cg12870014	chr12:110450643	ANKRD13A	0.62	6.82	0.31	3.14e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs6782228	0.651	rs9289332	chr3:128387884	C/G	cg16766828	chr3:128327626	NA	-0.39	-7.19	-0.33	2.87e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs494562	0.773	rs6919207	chr6:86129271	C/T	cg17966619	chr6:86160162	NT5E	0.66	7.88	0.36	2.78e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs35343117	1	rs35343117	chr15:86079115	C/G	cg13263323	chr15:86062960	AKAP13	-0.51	-8.52	-0.38	2.75e-16	Psoriasis;
LUAD	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-7.01	-0.32	9.64e-12	Tonsillectomy;
LUAD	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.5	6.9	0.32	1.95e-11	Platelet count;
LUAD	cis	rs7246865	0.813	rs13346655	chr19:17176757	C/G	cg19418318	chr19:17219073	MYO9B	0.4	6.55	0.3	1.63e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs7094131	0.556	rs4748818	chr10:22877953	T/G	cg19500236	chr10:22911537	PIP4K2A	0.4	7.3	0.33	1.45e-12	Obesity-related traits;
LUAD	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg20503657	chr10:835505	NA	1.25	18.96	0.68	1.73e-58	Eosinophil percentage of granulocytes;
LUAD	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg17264618	chr3:40429014	ENTPD3	-0.41	-9.13	-0.41	2.75e-18	Renal cell carcinoma;
LUAD	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg20476274	chr7:133979776	SLC35B4	0.83	16.07	0.62	1.09e-45	Mean platelet volume;
LUAD	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg22681709	chr2:178499509	PDE11A	-0.43	-7.02	-0.32	8.98e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg18512352	chr11:47633146	NA	-0.57	-10.09	-0.44	1.32e-21	Subjective well-being;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04421424	chr19:57791681	ZNF460	-0.42	-6.39	-0.3	4.32e-10	Height;
LUAD	trans	rs7395662	1.000	rs7949348	chr11:48493801	G/C	cg00717180	chr2:96193071	NA	-0.39	-7.36	-0.34	9.44e-13	HDL cholesterol;
LUAD	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg04586622	chr2:25135609	ADCY3	0.37	8.4	0.38	7.02e-16	Body mass index in non-asthmatics;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24738006	chr20:60717729	PSMA7;SS18L1	0.43	6.5	0.3	2.2e-10	Gut microbiome composition (summer);
LUAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00149659	chr3:10157352	C3orf10	0.58	7.91	0.36	2.32e-14	Alzheimer's disease;
LUAD	cis	rs9787249	0.533	rs1883648	chr1:40246535	T/G	cg24920358	chr1:40204285	PPIE	0.57	10.22	0.45	4.56e-22	Blood protein levels;
LUAD	cis	rs921968	0.565	rs7580147	chr2:219643036	A/G	cg02176678	chr2:219576539	TTLL4	-0.6	-12.27	-0.51	8.33e-30	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg26408565	chr15:76604113	ETFA	-0.48	-8.04	-0.36	9.32e-15	Blood metabolite levels;
LUAD	cis	rs1448094	0.967	rs2044617	chr12:86324089	T/C	cg00310523	chr12:86230176	RASSF9	0.35	7.56	0.34	2.58e-13	Major depressive disorder;
LUAD	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg08601574	chr20:25228251	PYGB	0.46	8.47	0.38	4.13e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg21471580	chr8:22132874	PIWIL2	0.45	7.93	0.36	1.92e-14	Hypertriglyceridemia;
LUAD	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.35	-6.53	-0.3	1.84e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg22491629	chr6:157744540	C6orf35	-0.68	-8.2	-0.37	2.98e-15	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg17063962	chr7:91808500	NA	0.68	12.31	0.51	5.78e-30	Breast cancer;
LUAD	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg08125733	chr17:73851984	WBP2	0.55	8.2	0.37	2.9e-15	Psoriasis;
LUAD	cis	rs2224391	0.590	rs17140068	chr6:5282227	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.61	-7.93	-0.36	1.96e-14	Height;
LUAD	cis	rs9486719	1.000	rs34209750	chr6:96882215	G/T	cg06623918	chr6:96969491	KIAA0776	-0.71	-10.02	-0.44	2.32e-21	Migraine;Coronary artery disease;
LUAD	cis	rs9807989	0.507	rs3213732	chr2:102998279	A/G	cg03938978	chr2:103052716	IL18RAP	0.45	10.24	0.45	3.99e-22	Asthma;
LUAD	cis	rs28595532	0.920	rs56303276	chr4:119723514	C/T	cg14228332	chr4:119757509	SEC24D	0.86	7.91	0.36	2.29e-14	Cannabis dependence symptom count;
LUAD	cis	rs2996428	0.536	rs12126653	chr1:3773815	C/G	cg22529645	chr1:3704559	LRRC47	0.56	10.03	0.44	2.14e-21	Red cell distribution width;
LUAD	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg27535305	chr1:53392650	SCP2	-0.34	-6.94	-0.32	1.44e-11	Monocyte count;
LUAD	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg11707310	chr1:2537719	MMEL1	0.39	8.18	0.37	3.33e-15	Ulcerative colitis;
LUAD	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg06784218	chr1:46089804	CCDC17	0.5	11.15	0.48	1.76e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg00071950	chr4:10020882	SLC2A9	0.63	10.56	0.46	2.62e-23	Blood metabolite levels;
LUAD	cis	rs2040771	0.804	rs1340958	chr22:19253332	A/G	cg02655711	chr22:19163373	SLC25A1	-0.57	-10.86	-0.47	2.05e-24	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.56	8.54	0.38	2.38e-16	Total cholesterol levels;
LUAD	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.38	6.71	0.31	6.13e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4601821	0.823	rs4938015	chr11:113264644	C/T	cg14159747	chr11:113255604	NA	-0.49	-9.54	-0.42	1.14e-19	Alcoholic chronic pancreatitis;
LUAD	trans	rs7395662	1.000	rs4882010	chr11:48559173	T/G	cg00717180	chr2:96193071	NA	-0.39	-7.32	-0.34	1.25e-12	HDL cholesterol;
LUAD	cis	rs7095607	0.813	rs4745947	chr10:69931840	A/C	cg18986048	chr10:69913749	MYPN	0.37	6.44	0.3	3.19e-10	Lung function (FVC);
LUAD	cis	rs11840576	0.588	rs331976	chr13:110317769	G/T	cg16896868	chr13:110319562	NA	-0.47	-6.42	-0.3	3.63e-10	Paclitaxel disposition in epithelial ovarian cancer;
LUAD	cis	rs354033	0.837	rs59347948	chr7:149193933	T/A	cg24335155	chr7:149193227	ZNF746	0.39	6.52	0.3	2.04e-10	Multiple sclerosis;
LUAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06873352	chr17:61820015	STRADA	0.82	18.21	0.66	3.8e-55	Prudent dietary pattern;
LUAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08677398	chr8:58056175	NA	0.55	7.03	0.32	8.59e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg23216685	chr1:86174607	ZNHIT6	-0.4	-7.31	-0.33	1.37e-12	Urate levels in overweight individuals;
LUAD	cis	rs6541297	0.703	rs638097	chr1:230310728	C/T	cg20703242	chr1:230279135	GALNT2	-0.48	-6.99	-0.32	1.08e-11	Coronary artery disease;
LUAD	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg13180566	chr4:1052158	NA	-0.39	-6.7	-0.31	6.65e-11	Recombination rate (females);
LUAD	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg10057126	chr4:77819792	ANKRD56	0.53	9.1	0.4	3.54e-18	Emphysema distribution in smoking;
LUAD	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.69	-0.35	1.05e-13	Platelet count;
LUAD	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg19761014	chr17:28927070	LRRC37B2	0.87	8.6	0.39	1.52e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.6	8.95	0.4	1.15e-17	Platelet count;
LUAD	cis	rs7107174	1.000	rs10899467	chr11:78014057	G/T	cg02023728	chr11:77925099	USP35	0.48	7.25	0.33	2.04e-12	Testicular germ cell tumor;
LUAD	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	12.22	0.51	1.22e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7665090	0.870	rs34349956	chr4:103559633	G/T	cg07973026	chr4:103553119	MANBA	0.47	8.23	0.37	2.31e-15	Primary biliary cholangitis;
LUAD	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg04450456	chr4:17643702	FAM184B	0.43	8.45	0.38	4.86e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.11	-0.33	4.83e-12	Bipolar disorder;
LUAD	cis	rs59104589	0.617	rs56663202	chr2:242262311	A/G	cg08645257	chr2:242211290	HDLBP	0.49	7.7	0.35	9.43e-14	Fibrinogen levels;
LUAD	cis	rs9948	1.000	rs62152790	chr2:97478579	G/A	cg20312557	chr2:97357134	FER1L5	-0.62	-7.34	-0.34	1.12e-12	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.28	-0.45	2.81e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6024905	0.587	rs1579101	chr20:36966334	C/T	cg07053727	chr20:36965646	BPI	0.38	7.59	0.35	2.11e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg11494091	chr17:61959527	GH2	0.74	18.32	0.67	1.27e-55	Prudent dietary pattern;
LUAD	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg13606994	chr1:44402422	ARTN	-0.33	-6.79	-0.31	3.82e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs7043114	0.525	rs7045409	chr9:95201540	A/T	cg14631576	chr9:95140430	CENPP	-0.41	-8.38	-0.38	7.64e-16	Height;
LUAD	trans	rs7939886	0.920	rs11231821	chr11:55777052	C/G	cg15704280	chr7:45808275	SEPT13	0.68	6.74	0.31	5.23e-11	Myopia (pathological);
LUAD	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4280164	0.551	rs3181251	chr14:24805824	C/T	cg07162820	chr14:24837146	NFATC4	0.32	6.43	0.3	3.52e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-7.92	-0.36	2.08e-14	Alzheimer's disease;
LUAD	trans	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg13565492	chr6:43139072	SRF	-0.65	-7.36	-0.34	9.73e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs72634258	0.945	rs36016881	chr1:8051241	A/G	cg26816564	chr1:7831052	VAMP3	0.52	6.84	0.32	2.78e-11	Inflammatory bowel disease;
LUAD	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg00310523	chr12:86230176	RASSF9	0.42	8.36	0.38	9.17e-16	Major depressive disorder;
LUAD	cis	rs8060686	0.623	rs2418736	chr16:68154862	A/G	cg05110241	chr16:68378359	PRMT7	0.49	6.48	0.3	2.56e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg22907277	chr7:1156413	C7orf50	0.62	7.63	0.35	1.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg14784868	chr12:69753453	YEATS4	0.46	7.59	0.35	2.02e-13	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs1595825	0.945	rs73058818	chr2:198862600	C/T	cg10547527	chr2:198650123	BOLL	-0.48	-6.91	-0.32	1.84e-11	Ulcerative colitis;
LUAD	trans	rs17685	0.753	rs869806	chr7:75688623	C/T	cg19862616	chr7:65841803	NCRNA00174	1.07	27.55	0.8	2.07e-96	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg10057126	chr4:77819792	ANKRD56	0.54	9.31	0.41	6.89e-19	Emphysema distribution in smoking;
LUAD	trans	rs8002861	0.905	rs6561150	chr13:44460470	C/T	cg17145862	chr1:211918768	LPGAT1	0.69	15.3	0.6	2.25e-42	Leprosy;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg16860267	chr18:11908803	MPPE1	-0.66	-6.4	-0.3	4.17e-10	Type 2 diabetes;
LUAD	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg10560079	chr2:191398806	TMEM194B	-0.53	-6.75	-0.31	4.87e-11	Diastolic blood pressure;
LUAD	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg11663144	chr21:46675770	NA	-0.61	-12.29	-0.51	6.85e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6752107	0.503	rs13002340	chr2:234234959	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	7.77	0.35	6.18e-14	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9837602	1.000	rs17379739	chr3:99724792	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	9.14	0.41	2.56e-18	Breast cancer;
LUAD	cis	rs9899728	0.539	rs56267297	chr17:73046996	T/C	cg27626185	chr17:73056755	KCTD2	-0.99	-11.39	-0.48	2.23e-26	Alzheimer's disease or small vessel stroke;
LUAD	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg05234568	chr11:5960015	NA	-0.56	-10.92	-0.47	1.31e-24	DNA methylation (variation);
LUAD	cis	rs2637266	1.000	rs2395386	chr10:78341623	C/T	cg18941641	chr10:78392320	NA	0.33	6.97	0.32	1.22e-11	Pulmonary function;
LUAD	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg18305652	chr10:134549665	INPP5A	0.6	11.08	0.47	3.14e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	7.94e-19	Tonsillectomy;
LUAD	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg14689365	chr7:158441557	NCAPG2	0.46	7.91	0.36	2.34e-14	Height;
LUAD	trans	rs8002861	0.810	rs2275252	chr13:44454374	A/C	cg17145862	chr1:211918768	LPGAT1	0.74	17.32	0.64	3.63e-51	Leprosy;
LUAD	cis	rs78456975	0.550	rs111467480	chr2:1569154	A/G	cg12573674	chr2:1569213	NA	-0.62	-8.84	-0.39	2.7e-17	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs6669919	0.553	rs1122745	chr1:211663261	C/T	cg10512769	chr1:211675356	NA	-0.35	-6.9	-0.32	1.93e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7301826	0.610	rs9668291	chr12:131296908	C/G	cg11011512	chr12:131303247	STX2	0.44	7.41	0.34	6.76e-13	Plasma plasminogen activator levels;
LUAD	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.46	-7.84	-0.36	3.63e-14	Rheumatoid arthritis;
LUAD	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.77	-0.35	6.02e-14	Monocyte count;
LUAD	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.93	0.76	1.24e-80	Chronic sinus infection;
LUAD	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg11266682	chr4:10021025	SLC2A9	0.66	14.37	0.57	2.04e-38	Bone mineral density;
LUAD	cis	rs9296092	0.560	rs9469502	chr6:33526648	G/A	cg13560919	chr6:33536144	NA	-0.9	-16.72	-0.63	1.49e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs6076065	1.000	rs2424538	chr20:23382076	A/G	cg11657817	chr20:23433608	CST11	0.45	8.73	0.39	5.81e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7520050	0.807	rs3013594	chr1:46138000	T/C	cg06784218	chr1:46089804	CCDC17	0.35	7.62	0.35	1.67e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08677398	chr8:58056175	NA	0.45	6.45	0.3	3.07e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs315934	0.664	rs315928	chr2:113868263	C/T	cg09040174	chr2:113837401	NA	-0.63	-7.39	-0.34	7.77e-13	Dysmenorrheic pain;
LUAD	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg24838063	chr12:130822603	PIWIL1	0.62	10.47	0.45	5.94e-23	Menopause (age at onset);
LUAD	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg15744005	chr10:104629667	AS3MT	-0.33	-6.53	-0.3	1.87e-10	Immature fraction of reticulocytes;Schizophrenia;
LUAD	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg03948781	chr1:205179583	DSTYK	0.33	6.41	0.3	3.78e-10	Red blood cell count;
LUAD	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg24397884	chr7:158709396	WDR60	0.64	8.82	0.39	3.03e-17	Height;
LUAD	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg20701182	chr2:24300061	SF3B14	0.58	6.99	0.32	1.05e-11	Lymphocyte counts;
LUAD	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg21153622	chr11:89784906	NA	-0.34	-6.8	-0.31	3.66e-11	HDL cholesterol;
LUAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03647317	chr4:187891568	NA	-0.36	-6.7	-0.31	6.6e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg18099408	chr3:52552593	STAB1	-0.42	-7.1	-0.33	5.33e-12	Electroencephalogram traits;
LUAD	trans	rs8002861	0.664	rs4942247	chr13:44405107	A/G	cg12856521	chr11:46389249	DGKZ	0.46	7.69	0.35	1.06e-13	Leprosy;
LUAD	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg15181151	chr6:150070149	PCMT1	0.38	7.68	0.35	1.12e-13	Lung cancer;
LUAD	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.28	-0.51	7.17e-30	Primary sclerosing cholangitis;
LUAD	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg25208724	chr1:156163844	SLC25A44	0.79	7.36	0.34	9.86e-13	Paclitaxel disposition in epithelial ovarian cancer;
LUAD	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	trans	rs3858145	0.588	rs2305083	chr10:70044937	C/A	cg04882175	chr6:131122610	NA	-0.57	-6.77	-0.31	4.42e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUAD	cis	rs62238980	0.614	rs79110727	chr22:32377455	A/G	cg00543991	chr22:32367038	NA	0.93	8.61	0.39	1.42e-16	Childhood ear infection;
LUAD	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg23283495	chr1:209979779	IRF6	0.73	10.7	0.46	8.52e-24	Cleft lip with or without cleft palate;
LUAD	cis	rs7731657	0.537	rs13165574	chr5:130354079	G/C	cg08523029	chr5:130500466	HINT1	0.58	7.65	0.35	1.34e-13	Fasting plasma glucose;
LUAD	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg07741184	chr6:167504864	NA	0.32	7.45	0.34	5.36e-13	Crohn's disease;
LUAD	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg00666640	chr1:248458726	OR2T12	0.33	8.1	0.37	5.83e-15	Common traits (Other);
LUAD	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03264133	chr6:25882463	NA	0.51	7.36	0.34	9.42e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg14092988	chr3:52407081	DNAH1	0.37	7.31	0.33	1.38e-12	Electroencephalogram traits;
LUAD	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg09796270	chr17:17721594	SREBF1	-0.4	-7.89	-0.36	2.53e-14	Total body bone mineral density;
LUAD	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg20587970	chr11:113659929	NA	-1.38	-20.47	-0.71	3.08e-65	Hip circumference adjusted for BMI;
LUAD	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg25894440	chr7:65020034	NA	-0.62	-6.63	-0.31	1.05e-10	Diabetic kidney disease;
LUAD	cis	rs2657888	0.529	rs118166110	chr12:56887783	G/A	cg23002907	chr12:56915593	RBMS2	-0.4	-6.91	-0.32	1.74e-11	Adiponectin levels;
LUAD	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg13906792	chr15:75199810	C15orf17	-0.35	-6.56	-0.3	1.58e-10	Breast cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg23927983	chr2:179315956	PRKRA;MIR548N;DFNB59	-0.38	-6.43	-0.3	3.39e-10	Schizophrenia;
LUAD	cis	rs11626933	1.000	rs3742669	chr14:90767746	C/A	cg14092571	chr14:90743983	NA	0.88	17.12	0.64	2.61e-50	Gut microbiota (bacterial taxa);
LUAD	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1232027	0.656	rs836808	chr5:79974570	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.42	-6.74	-0.31	5.2e-11	Huntington's disease progression;
LUAD	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg13642260	chr9:130955380	CIZ1	0.43	7.43	0.34	6.03e-13	Attention deficit hyperactivity disorder;
LUAD	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4730250	0.707	rs257387	chr7:106808480	G/A	cg02696742	chr7:106810147	HBP1	-0.87	-11.5	-0.49	8.46e-27	Osteoarthritis;
LUAD	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg06671706	chr8:8559999	CLDN23	0.65	11.27	0.48	5.94e-26	Obesity-related traits;
LUAD	cis	rs889398	0.741	rs3790076	chr16:69907445	A/C	cg00738113	chr16:70207722	CLEC18C	0.32	6.43	0.3	3.46e-10	Body mass index;
LUAD	cis	rs17401966	1.000	rs11121533	chr1:10292888	G/C	cg15208524	chr1:10270712	KIF1B	0.55	8.28	0.37	1.63e-15	Hepatocellular carcinoma;
LUAD	cis	rs7680126	0.626	rs11723388	chr4:10195802	G/A	cg00071950	chr4:10020882	SLC2A9	-0.58	-7.7	-0.35	9.86e-14	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg10589385	chr1:150898437	SETDB1	0.41	7.59	0.35	2.04e-13	Melanoma;
LUAD	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg21951975	chr1:209979733	IRF6	0.54	8.62	0.39	1.4e-16	Cleft lip with or without cleft palate;
LUAD	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg26354017	chr1:205819088	PM20D1	0.43	6.97	0.32	1.25e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs2839627	0.564	rs2839595	chr21:44298966	G/A	cg03543861	chr21:44258195	NA	0.67	8.08	0.37	6.96e-15	Information processing speed;
LUAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg22105103	chr4:187893119	NA	0.58	12.77	0.53	7.88e-32	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08439880	chr3:133502540	NA	0.45	9.12	0.41	3.01e-18	Iron status biomarkers;
LUAD	cis	rs1298062	0.663	rs1274685	chr19:50997828	G/A	cg11430371	chr19:50961752	MYBPC2	0.32	6.57	0.3	1.51e-10	Age of smoking initiation;
LUAD	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg06608945	chr2:219082296	ARPC2	-0.42	-6.77	-0.31	4.31e-11	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg04398451	chr17:18023971	MYO15A	-0.86	-16.23	-0.62	2.12e-46	Total body bone mineral density;
LUAD	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg03714773	chr7:91764589	CYP51A1	0.31	7.16	0.33	3.55e-12	Breast cancer;
LUAD	cis	rs9972944	0.729	rs10083875	chr17:63773303	T/C	cg07283582	chr17:63770753	CCDC46	0.46	10.03	0.44	2.28e-21	Total body bone mineral density;
LUAD	cis	rs117623576	0.680	rs211415	chr10:32397358	C/T	cg03047570	chr10:32398778	NA	0.67	8.48	0.38	3.88e-16	Anti-saccade response;
LUAD	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg07507251	chr3:52567010	NT5DC2	-0.36	-7.2	-0.33	2.83e-12	Bipolar disorder;
LUAD	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg11266682	chr4:10021025	SLC2A9	0.67	15.52	0.6	2.67e-43	Bone mineral density;
LUAD	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg24154853	chr7:158122151	PTPRN2	-0.56	-11.37	-0.48	2.6e-26	Calcium levels;
LUAD	cis	rs4243830	0.737	rs925744	chr1:6615695	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.77	-9.88	-0.43	7.45e-21	Body mass index;
LUAD	trans	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg26043149	chr18:55253948	FECH	-0.42	-6.82	-0.31	3.1e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg04450456	chr4:17643702	FAM184B	0.4	7.79	0.35	5.1e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg06547715	chr2:218990976	CXCR2	0.29	7.16	0.33	3.62e-12	Colorectal cancer;
LUAD	trans	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg12400702	chr3:12838781	CAND2	0.3	6.35	0.3	5.49e-10	Parkinson's disease;
LUAD	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg17366294	chr4:99064904	C4orf37	0.66	10.36	0.45	1.4e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-8.35	-0.38	1.01e-15	Fear of minor pain;
LUAD	trans	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.2	-30.96	-0.83	8.65e-111	Exhaled nitric oxide output;
LUAD	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg23933602	chr10:16859644	RSU1	0.56	7.27	0.33	1.75e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07636037	chr3:49044803	WDR6	0.49	8.48	0.38	3.94e-16	Menarche (age at onset);
LUAD	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg08085267	chr17:45401833	C17orf57	0.59	10.55	0.46	3.03e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs877282	0.842	rs12357963	chr10:757562	C/T	cg06581033	chr10:766294	NA	-0.56	-7.21	-0.33	2.57e-12	Uric acid levels;
LUAD	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg04455712	chr21:45112962	RRP1B	-0.35	-6.65	-0.31	8.86e-11	Mean corpuscular volume;
LUAD	cis	rs4481887	0.893	rs10158180	chr1:248481423	C/T	cg13385794	chr1:248469461	NA	0.26	7.0	0.32	1.01e-11	Common traits (Other);
LUAD	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg10755058	chr3:40428713	ENTPD3	0.42	8.3	0.37	1.39e-15	Renal cell carcinoma;
LUAD	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg02551604	chr5:131831745	NA	-0.61	-10.08	-0.44	1.46e-21	Asthma (sex interaction);
LUAD	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg27087555	chr16:88793112	FAM38A	-1.19	-10.95	-0.47	9.57e-25	Plateletcrit;
LUAD	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.44	-6.73	-0.31	5.46e-11	Breast cancer;
LUAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg11062466	chr8:58055876	NA	0.67	8.85	0.4	2.37e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs73206853	0.563	rs80044246	chr12:111133535	C/A	cg12870014	chr12:110450643	ANKRD13A	0.61	6.74	0.31	5.25e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs12765878	0.934	rs58543155	chr10:105643244	G/A	cg11005552	chr10:105648138	OBFC1	0.44	8.26	0.37	1.91e-15	Coronary artery disease;
LUAD	trans	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg00953403	chr17:74099816	EXOC7	-0.51	-7.44	-0.34	5.61e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg16006841	chr5:176797999	RGS14	0.79	13.23	0.54	1.16e-33	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg14784868	chr12:69753453	YEATS4	0.47	7.75	0.35	6.73e-14	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg00280220	chr17:61926910	NA	0.37	7.07	0.33	6.3e-12	Prudent dietary pattern;
LUAD	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg08470875	chr2:26401718	FAM59B	-0.67	-8.92	-0.4	1.43e-17	Gut microbiome composition (summer);
LUAD	cis	rs7241530	0.636	rs35311649	chr18:75898456	G/T	cg14642773	chr18:75888474	NA	0.35	6.35	0.3	5.46e-10	Educational attainment (years of education);
LUAD	cis	rs7937890	0.810	rs10734224	chr11:14424124	G/T	cg02251663	chr11:14281053	SPON1	-0.39	-7.56	-0.34	2.56e-13	Mitochondrial DNA levels;
LUAD	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08704250	chr15:31115839	NA	-0.56	-10.15	-0.44	8.52e-22	Huntington's disease progression;
LUAD	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg14343924	chr8:8086146	FLJ10661	0.49	7.92	0.36	2.11e-14	Mood instability;
LUAD	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg03690763	chr11:133734501	NA	-0.29	-7.04	-0.32	7.7e-12	Childhood ear infection;
LUAD	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg19346786	chr7:2764209	NA	-0.32	-6.91	-0.32	1.78e-11	Height;
LUAD	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg25358565	chr5:93447407	FAM172A	0.6	7.52	0.34	3.38e-13	Diabetic retinopathy;
LUAD	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17691542	chr6:26056736	HIST1H1C	0.46	6.37	0.3	4.96e-10	Iron status biomarkers;
LUAD	cis	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg07460842	chr6:66804631	NA	-0.65	-9.3	-0.41	7.5e-19	Blood trace element (Cu levels);
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg05881034	chr3:42623675	SEC22C	0.4	6.44	0.3	3.25e-10	Optic cup area;
LUAD	cis	rs9462027	0.517	rs2744973	chr6:34580221	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-7.91	-0.36	2.26e-14	Systemic lupus erythematosus;
LUAD	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.52e-10	Prostate cancer;
LUAD	cis	rs1941023	0.584	rs4938941	chr11:60173360	C/T	cg08716584	chr11:60157161	MS4A7	0.46	8.69	0.39	8.29e-17	Congenital heart disease (maternal effect);
LUAD	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-7.79	-0.35	5.12e-14	Menarche (age at onset);
LUAD	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06022373	chr22:39101656	GTPBP1	0.45	6.81	0.31	3.29e-11	Menopause (age at onset);
LUAD	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg22482690	chr17:47019901	SNF8	0.44	8.37	0.38	8.71e-16	Type 2 diabetes;
LUAD	trans	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg19862616	chr7:65841803	NCRNA00174	1.04	24.91	0.77	5.8e-85	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.48	8.17	0.37	3.58e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs78487399	0.808	rs72865267	chr2:43726328	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.46	-0.3	2.91e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg12407791	chr17:73824354	UNC13D	-0.33	-6.76	-0.31	4.59e-11	White matter hyperintensity burden;
LUAD	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg25036284	chr2:26402008	FAM59B	-0.81	-11.64	-0.49	2.38e-27	Gut microbiome composition (summer);
LUAD	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg03433033	chr1:76189801	ACADM	0.85	15.43	0.6	6.32e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	12.53	0.52	7.73e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg07936489	chr17:37558343	FBXL20	-0.58	-7.32	-0.34	1.27e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08564027	chr20:61660810	NA	0.88	19.47	0.69	9.35e-61	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg21856205	chr7:94953877	PON1	-0.54	-7.42	-0.34	6.56e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg06627628	chr2:24431161	ITSN2	-0.68	-10.81	-0.47	3.33e-24	Asthma;
LUAD	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg06627628	chr2:24431161	ITSN2	-0.55	-6.52	-0.3	2.05e-10	Lymphocyte counts;
LUAD	cis	rs41311933	0.656	rs875593	chr9:123887087	G/T	cg13567360	chr9:123745713	C5	-0.74	-8.57	-0.38	1.89e-16	Coronary artery disease;
LUAD	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg26924012	chr15:45694286	SPATA5L1	0.63	10.92	0.47	1.31e-24	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs9487051	0.676	rs13211313	chr6:109562074	G/C	cg21918786	chr6:109611834	NA	-0.42	-7.2	-0.33	2.71e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19717773	chr7:2847554	GNA12	0.55	9.5	0.42	1.55e-19	Height;
LUAD	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg22676075	chr6:135203613	NA	0.41	7.69	0.35	1.08e-13	Red blood cell count;
LUAD	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg20203395	chr5:56204925	C5orf35	-0.82	-11.8	-0.5	5.55e-28	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.21e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg08085267	chr17:45401833	C17orf57	-0.59	-10.33	-0.45	1.86e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg24818145	chr4:99064322	C4orf37	0.45	7.64	0.35	1.49e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs36051895	0.632	rs12340617	chr9:5164492	G/C	cg02405213	chr9:5042618	JAK2	-0.5	-6.69	-0.31	7.28e-11	Pediatric autoimmune diseases;
LUAD	cis	rs4144027	0.904	rs10438243	chr14:104345822	A/G	cg12183467	chr14:104352244	NA	-0.39	-7.61	-0.35	1.85e-13	Blood metabolite levels;
LUAD	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg21427119	chr20:30132790	HM13	0.5	7.91	0.36	2.34e-14	Mean corpuscular hemoglobin;
LUAD	trans	rs2797160	1.000	rs1739373	chr6:126011509	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.55	8.58	0.39	1.8e-16	Endometrial cancer;
LUAD	cis	rs7089973	0.836	rs1046492	chr10:116624067	C/T	cg23260525	chr10:116636907	FAM160B1	0.43	9.69	0.43	3.5e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg22681709	chr2:178499509	PDE11A	-0.45	-7.62	-0.35	1.69e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg08807101	chr21:30365312	RNF160	0.52	8.89	0.4	1.78e-17	Dental caries;
LUAD	cis	rs6594713	0.837	rs34682492	chr5:112752087	C/G	cg12552261	chr5:112820674	MCC	0.49	7.13	0.33	4.34e-12	Brain cytoarchitecture;
LUAD	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg14092988	chr3:52407081	DNAH1	0.44	8.95	0.4	1.14e-17	Bipolar disorder;
LUAD	cis	rs9837602	1.000	rs13064704	chr3:99767541	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.97	-0.32	1.25e-11	Breast cancer;
LUAD	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.33	-0.34	1.14e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg01528321	chr10:82214614	TSPAN14	0.55	8.93	0.4	1.34e-17	Post bronchodilator FEV1;
LUAD	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg19622623	chr12:86230825	RASSF9	-0.44	-7.62	-0.35	1.65e-13	Major depressive disorder;
LUAD	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg20701182	chr2:24300061	SF3B14	0.57	6.83	0.32	2.9e-11	Lymphocyte counts;
LUAD	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg03034668	chr16:1723424	CRAMP1L	0.37	6.56	0.3	1.54e-10	Coronary artery disease;
LUAD	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg18306943	chr3:40428807	ENTPD3	0.4	6.83	0.32	3.02e-11	Renal cell carcinoma;
LUAD	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18099408	chr3:52552593	STAB1	-0.46	-8.04	-0.36	9.27e-15	Bipolar disorder;
LUAD	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg01475377	chr6:109611718	NA	-0.51	-9.49	-0.42	1.75e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg06096015	chr1:231504339	EGLN1	0.33	6.39	0.3	4.33e-10	Hemoglobin concentration;
LUAD	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg05110241	chr16:68378359	PRMT7	-0.58	-7.41	-0.34	6.73e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg18854424	chr1:2615690	NA	0.43	9.43	0.42	2.73e-19	Ulcerative colitis;
LUAD	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg07952391	chr2:88470173	THNSL2	0.78	8.44	0.38	5.29e-16	Plasma clusterin levels;
LUAD	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23158103	chr7:148848205	ZNF398	-0.66	-12.26	-0.51	8.52e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs986417	0.901	rs1955697	chr14:61028435	T/C	cg27398547	chr14:60952738	C14orf39	0.66	7.92	0.36	2.17e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg06263672	chr7:65235340	NA	-0.47	-6.4	-0.3	4.15e-10	Aortic root size;
LUAD	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg08847533	chr14:75593920	NEK9	0.39	6.62	0.31	1.06e-10	Height;
LUAD	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg09324608	chr17:30823087	MYO1D	0.45	8.51	0.38	3.03e-16	Schizophrenia;
LUAD	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg11292332	chr7:45801988	SEPT13	-0.28	-6.36	-0.3	5.26e-10	Extrinsic epigenetic age acceleration;
LUAD	trans	rs258892	0.846	rs266441	chr5:72197677	A/G	cg14879065	chr14:104662468	NA	-0.36	-6.45	-0.3	3.08e-10	Small cell lung carcinoma;
LUAD	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg09658497	chr7:2847517	GNA12	-0.54	-9.26	-0.41	1.05e-18	Height;
LUAD	cis	rs6906287	0.647	rs2213856	chr6:118806793	C/T	cg18833306	chr6:118973337	C6orf204	0.46	8.29	0.37	1.54e-15	Electrocardiographic conduction measures;
LUAD	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg11814155	chr7:99998594	ZCWPW1	0.43	7.48	0.34	4.27e-13	Platelet count;
LUAD	cis	rs7119038	0.818	rs11217033	chr11:118673706	T/C	cg19308663	chr11:118741387	NA	0.45	6.46	0.3	2.82e-10	Sjögren's syndrome;
LUAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg04025307	chr7:1156635	C7orf50	0.65	11.93	0.5	1.72e-28	Longevity;Endometriosis;
LUAD	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg02527881	chr3:46936655	PTH1R	-0.56	-11.41	-0.49	1.74e-26	Colorectal cancer;
LUAD	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg12365402	chr11:9010492	NRIP3	-0.44	-8.29	-0.37	1.5e-15	Hemoglobin concentration;
LUAD	cis	rs7149337	0.805	rs4350491	chr14:51675798	A/G	cg23942311	chr14:51606299	NA	0.86	19.82	0.69	2.73e-62	Cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06717492	chr7:65447339	GUSB	-0.55	-6.65	-0.31	9.27e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg25427524	chr10:38739819	LOC399744	-0.58	-6.54	-0.3	1.82e-10	Obesity (extreme);
LUAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg05434287	chr7:2030229	MAD1L1	0.39	6.6	0.31	1.23e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9902453	0.780	rs7210991	chr17:28190961	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.51	0.42	1.41e-19	Coffee consumption (cups per day);
LUAD	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg17063962	chr7:91808500	NA	0.68	12.44	0.52	1.69e-30	Breast cancer;
LUAD	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg23803603	chr1:2058230	PRKCZ	-0.4	-7.06	-0.32	6.8e-12	Height;
LUAD	cis	rs367615	0.704	rs7704824	chr5:108850278	A/G	cg17395555	chr5:108820864	NA	0.61	12.94	0.53	1.63e-32	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs72634258	0.945	rs12727642	chr1:8046672	C/A	cg26816564	chr1:7831052	VAMP3	0.53	6.94	0.32	1.47e-11	Inflammatory bowel disease;
LUAD	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg21138405	chr5:131827807	IRF1	0.48	9.03	0.4	6.06e-18	Asthma (sex interaction);
LUAD	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg27170947	chr2:26402098	FAM59B	0.59	8.69	0.39	8.25e-17	Gut microbiome composition (summer);
LUAD	cis	rs7771547	0.542	rs597153	chr6:36395997	C/T	cg07856975	chr6:36356162	ETV7	0.49	7.77	0.35	6.21e-14	Platelet distribution width;
LUAD	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg26818010	chr10:134567672	INPP5A	-0.92	-15.17	-0.59	8.08e-42	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg07917127	chr4:99064746	C4orf37	0.42	6.98	0.32	1.11e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2637266	0.935	rs2583055	chr10:78400029	C/T	cg18941641	chr10:78392320	NA	0.34	7.04	0.32	7.75e-12	Pulmonary function;
LUAD	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg26384229	chr12:38710491	ALG10B	0.52	8.54	0.38	2.46e-16	Heart rate;
LUAD	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.77	-9.72	-0.43	2.76e-20	Body mass index;
LUAD	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg21385522	chr1:16154831	NA	1.04	21.92	0.73	1.06e-71	Dilated cardiomyopathy;
LUAD	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg14227996	chr4:17616232	MED28	0.71	7.38	0.34	8.62e-13	Opioid sensitivity;
LUAD	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg20469991	chr17:27169893	C17orf63	0.52	6.66	0.31	8.4e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.4	0.45	1.06e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs7300001	0.596	rs11064924	chr12:110510301	G/T	cg12870014	chr12:110450643	ANKRD13A	0.8	8.05	0.36	8.19e-15	Headache;
LUAD	cis	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.23	-0.33	2.24e-12	Resting heart rate;
LUAD	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg15445000	chr17:37608096	MED1	-0.45	-8.45	-0.38	4.85e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs6426558	0.537	rs498020	chr1:227304180	G/A	cg10327440	chr1:227177885	CDC42BPA	0.54	8.71	0.39	6.96e-17	Neutrophil percentage of white cells;
LUAD	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.58	-0.52	4.8e-31	Hip circumference adjusted for BMI;
LUAD	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22968622	chr17:43663579	NA	0.96	16.78	0.63	8.72e-49	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.96	-0.32	1.29e-11	Mood instability;
LUAD	cis	rs6500395	1.000	rs7195684	chr16:48710750	G/A	cg04672837	chr16:48644449	N4BP1	-0.39	-6.85	-0.32	2.67e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg06558623	chr16:89946397	TCF25	1.15	10.16	0.44	7.69e-22	Skin colour saturation;
LUAD	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg00074818	chr8:8560427	CLDN23	0.64	9.89	0.43	7.04e-21	Obesity-related traits;
LUAD	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg11663144	chr21:46675770	NA	-0.61	-12.21	-0.51	1.37e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7119	0.717	rs16968835	chr15:77734261	G/A	cg05673287	chr15:77411982	SGK269	-0.41	-7.04	-0.32	7.66e-12	Type 2 diabetes;
LUAD	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg05340658	chr4:99064831	C4orf37	0.42	7.11	0.33	4.84e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1459104	0.759	rs7939392	chr11:55257285	C/T	cg03929089	chr4:120376271	NA	0.57	6.67	0.31	7.96e-11	Body mass index;
LUAD	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg04450456	chr4:17643702	FAM184B	-0.4	-7.72	-0.35	8.47e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	6.5	0.3	2.21e-10	Personality dimensions;
LUAD	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21385522	chr1:16154831	NA	0.59	8.72	0.39	6.58e-17	Dilated cardiomyopathy;
LUAD	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg04181038	chr4:183730758	NA	0.62	9.64	0.42	5.39e-20	Pediatric autoimmune diseases;
LUAD	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg02788857	chr8:22132959	PIWIL2	0.54	10.04	0.44	2.11e-21	Hypertriglyceridemia;
LUAD	cis	rs1150668	0.768	rs1150709	chr6:28207363	C/T	cg10876282	chr6:28092338	ZSCAN16	-0.39	-6.54	-0.3	1.81e-10	Pubertal anthropometrics;
LUAD	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg13770153	chr20:60521292	NA	-0.59	-9.29	-0.41	8.21e-19	Body mass index;
LUAD	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg24675056	chr1:15929824	NA	0.49	8.06	0.36	8.02e-15	Systolic blood pressure;
LUAD	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.5	0.3	2.31e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23158103	chr7:148848205	ZNF398	-0.65	-12.35	-0.51	3.78e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg18105134	chr13:113819100	PROZ	-1.04	-18.99	-0.68	1.4e-58	Platelet distribution width;
LUAD	cis	rs6500395	0.962	rs9936883	chr16:48676443	G/A	cg04672837	chr16:48644449	N4BP1	0.39	6.81	0.31	3.43e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs11048434	0.687	rs12814670	chr12:9060025	C/T	cg13575925	chr12:9217583	LOC144571	0.37	6.86	0.32	2.47e-11	Sjögren's syndrome;
LUAD	cis	rs754466	0.580	rs12354903	chr10:79536465	T/C	cg17075019	chr10:79541650	NA	-0.93	-20.32	-0.7	1.49e-64	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.84	-11.68	-0.49	1.64e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg00376283	chr12:123451042	ABCB9	0.42	6.69	0.31	7.19e-11	Platelet count;
LUAD	cis	rs2458413	0.563	rs2458422	chr8:105332817	C/T	cg04554929	chr8:105342491	NA	-0.46	-9.13	-0.41	2.84e-18	Paget's disease;
LUAD	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	8.18	0.37	3.44e-15	Breast cancer;
LUAD	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg19743168	chr1:23544995	NA	0.36	6.44	0.3	3.23e-10	Height;
LUAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg05665937	chr4:1216051	CTBP1	0.41	7.08	0.33	5.91e-12	Obesity-related traits;
LUAD	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg19622623	chr12:86230825	RASSF9	-0.44	-7.77	-0.35	6.07e-14	Major depressive disorder;
LUAD	cis	rs68170813	0.652	rs8180747	chr7:107106308	T/C	cg23024343	chr7:107201750	COG5	0.51	6.5	0.3	2.24e-10	Coronary artery disease;
LUAD	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg03354898	chr7:1950403	MAD1L1	-0.45	-8.68	-0.39	8.34e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08219700	chr8:58056026	NA	0.71	9.44	0.42	2.43e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.18	0.44	6.41e-22	Mean corpuscular volume;
LUAD	cis	rs7107174	0.681	rs10751288	chr11:78072658	A/T	cg02023728	chr11:77925099	USP35	0.46	7.31	0.34	1.3e-12	Testicular germ cell tumor;
LUAD	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.08	0.37	6.91e-15	Rheumatoid arthritis;
LUAD	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg14092988	chr3:52407081	DNAH1	-0.44	-8.77	-0.39	4.42e-17	Bipolar disorder;
LUAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg11905131	chr22:24372483	LOC391322	-0.58	-9.83	-0.43	1.1e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6987853	0.761	rs2923391	chr8:42415942	G/A	cg09913449	chr8:42400586	C8orf40	0.51	10.23	0.45	4.27e-22	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg06608945	chr2:219082296	ARPC2	0.48	8.26	0.37	1.84e-15	Colorectal cancer;
LUAD	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg22676075	chr6:135203613	NA	0.41	7.59	0.35	2.13e-13	Red blood cell count;
LUAD	cis	rs6546550	0.901	rs10167142	chr2:70062360	T/C	cg02498382	chr2:70120550	SNRNP27	-0.57	-10.69	-0.46	9.03e-24	Prevalent atrial fibrillation;
LUAD	trans	rs9929218	1.000	rs13334326	chr16:68809207	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.93	-0.56	1.47e-36	Colorectal cancer;
LUAD	trans	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg01620082	chr3:125678407	NA	-0.7	-7.98	-0.36	1.38e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.64	-0.35	1.48e-13	Personality dimensions;
LUAD	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg00852783	chr1:26633632	UBXN11	-0.4	-7.09	-0.33	5.73e-12	Obesity-related traits;
LUAD	trans	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg07817883	chr1:32538562	TMEM39B	1.05	10.36	0.45	1.5e-22	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg17279839	chr7:150038598	RARRES2	0.42	7.13	0.33	4.32e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg06618935	chr21:46677482	NA	-0.49	-10.03	-0.44	2.21e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg26384229	chr12:38710491	ALG10B	0.49	7.88	0.36	2.74e-14	Bladder cancer;
LUAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-9.74	-0.43	2.39e-20	Lymphocyte counts;
LUAD	cis	rs62027291	0.654	rs56402836	chr15:77081967	A/C	cg22467129	chr15:76604101	ETFA	0.71	6.38	0.3	4.55e-10	Plateletcrit;
LUAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg11941060	chr3:133502564	NA	-0.65	-11.49	-0.49	8.61e-27	Iron status biomarkers;
LUAD	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.04e-13	Morning vs. evening chronotype;
LUAD	trans	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.19	-0.64	1.31e-50	Exhaled nitric oxide output;
LUAD	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg12573674	chr2:1569213	NA	-0.59	-6.95	-0.32	1.36e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs12431939	0.598	rs7144511	chr14:51740243	A/G	cg23942311	chr14:51606299	NA	0.45	6.98	0.32	1.16e-11	Cancer;
LUAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.03	-0.4	6.13e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs698833	0.926	rs786419	chr2:44685153	G/T	cg04920474	chr2:44395004	PPM1B	0.37	6.69	0.31	7.11e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs2996428	0.709	rs7527973	chr1:3704041	C/T	cg17443473	chr1:3703550	LRRC47	0.45	7.55	0.34	2.75e-13	Red cell distribution width;
LUAD	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.37	-0.3	4.83e-10	Depression;
LUAD	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg16797656	chr11:68205561	LRP5	0.45	8.47	0.38	4.1e-16	Total body bone mineral density;
LUAD	cis	rs62238980	0.614	rs117960638	chr22:32417569	C/T	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	trans	rs3824867	0.738	rs1228024	chr11:47951353	C/A	cg15704280	chr7:45808275	SEPT13	-0.49	-7.38	-0.34	8.41e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs4700695	0.697	rs251319	chr5:65239468	A/G	cg21114390	chr5:65439923	SFRS12	0.62	8.1	0.37	5.88e-15	Facial morphology (factor 19);
LUAD	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg06550200	chr5:1325588	CLPTM1L	-0.7	-13.3	-0.54	5.52e-34	Lung cancer;
LUAD	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.33	6.67	0.31	8.17e-11	Obesity-related traits;
LUAD	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg20701182	chr2:24300061	SF3B14	0.56	6.71	0.31	6.14e-11	Lymphocyte counts;
LUAD	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg27539214	chr16:67997921	SLC12A4	-0.73	-9.16	-0.41	2.25e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4523957	0.651	rs9906968	chr17:2077493	G/C	cg16513277	chr17:2031491	SMG6	-0.95	-19.07	-0.68	5.82e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg00339695	chr16:24857497	SLC5A11	-0.67	-10.8	-0.46	3.5e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg24818145	chr4:99064322	C4orf37	0.47	7.33	0.34	1.19e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg26769984	chr7:1090371	C7orf50	0.6	9.75	0.43	2.21e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.32	0.34	1.3e-12	Obesity-related traits;
LUAD	cis	rs4711336	1.000	rs2296736	chr6:33656250	T/C	cg14003231	chr6:33640908	ITPR3	0.53	10.04	0.44	2.03e-21	Height;
LUAD	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg14668632	chr7:2872130	GNA12	-0.45	-8.11	-0.37	5.57e-15	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08809542	chr4:146858263	ZNF827	-0.47	-7.39	-0.34	7.91e-13	Height;
LUAD	cis	rs9814567	1.000	rs6766897	chr3:134191303	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.43	-0.57	1.18e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg14532720	chr14:102771657	RAGE	0.44	7.26	0.33	1.85e-12	Bipolar disorder;
LUAD	cis	rs9837602	0.938	rs28503408	chr3:99794842	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-7.46	-0.34	4.9e-13	Breast cancer;
LUAD	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.78e-11	Crohn's disease;
LUAD	trans	rs62458065	1.000	rs79538247	chr7:32467792	A/G	cg00845942	chr12:64062724	DPY19L2	-0.46	-6.64	-0.31	9.5e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg27454412	chr7:1067447	C7orf50	0.42	6.76	0.31	4.59e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg07967210	chr17:47022446	SNF8	0.35	6.4	0.3	4.22e-10	Type 2 diabetes;
LUAD	cis	rs6500395	1.000	rs12598514	chr16:48689319	T/C	cg04672837	chr16:48644449	N4BP1	-0.38	-6.69	-0.31	7.31e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg20578329	chr17:80767326	TBCD	-0.57	-6.8	-0.31	3.56e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.38	0.57	1.9e-38	Schizophrenia;
LUAD	cis	rs7119	0.700	rs4886883	chr15:77888924	C/T	cg27398640	chr15:77910606	LINGO1	-0.4	-7.79	-0.35	5.35e-14	Type 2 diabetes;
LUAD	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg18477163	chr1:228402036	OBSCN	0.4	7.19	0.33	3e-12	Diastolic blood pressure;
LUAD	trans	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg01620082	chr3:125678407	NA	-0.71	-7.22	-0.33	2.44e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.33	-7.25	-0.33	1.94e-12	Lung cancer;
LUAD	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-9.3	-0.41	7.66e-19	Bipolar disorder;
LUAD	cis	rs61990749	0.597	rs2267761	chr14:78147849	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.49	-6.37	-0.3	5.07e-10	Fibroblast growth factor basic levels;
LUAD	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg01145583	chr6:160211477	TCP1;MRPL18	-0.44	-6.39	-0.3	4.45e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	9.58	0.42	8.59e-20	Lung cancer in ever smokers;
LUAD	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.02	-0.36	1.08e-14	Diabetic kidney disease;
LUAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08048268	chr3:133502702	NA	0.49	9.82	0.43	1.17e-20	Iron status biomarkers;
LUAD	trans	rs1973993	0.691	rs1989141	chr1:96898520	C/T	cg10631902	chr5:14652156	NA	0.73	15.36	0.6	1.3e-42	Weight;
LUAD	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg15628303	chr1:26608928	UBXN11	-0.36	-6.4	-0.3	4.04e-10	Height;
LUAD	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg03959625	chr15:84868606	LOC388152	0.4	6.48	0.3	2.6200000000000003e-10	Schizophrenia;
LUAD	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg21399703	chr1:247681439	NA	0.42	7.86	0.36	3.29e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7937890	0.559	rs2575837	chr11:14498001	A/G	cg06199346	chr11:14280333	SPON1	-0.32	-6.41	-0.3	3.86e-10	Mitochondrial DNA levels;
LUAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-9.43	-0.42	2.7e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg02569458	chr12:86230093	RASSF9	0.42	7.82	0.36	4.23e-14	Major depressive disorder;
LUAD	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg10802521	chr3:52805072	NEK4	-0.47	-7.95	-0.36	1.77e-14	Electroencephalogram traits;
LUAD	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.06	0.36	7.9e-15	Menopause (age at onset);
LUAD	cis	rs7665090	1.000	rs2272695	chr4:103555803	G/C	cg07973026	chr4:103553119	MANBA	0.47	8.43	0.38	5.37e-16	Primary biliary cholangitis;
LUAD	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs7072216	0.727	rs7913541	chr10:100172479	A/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.71	-0.39	6.77e-17	Metabolite levels;
LUAD	cis	rs6445967	0.530	rs4273385	chr3:58452867	C/G	cg13750441	chr3:58318267	PXK	-0.32	-6.48	-0.3	2.5e-10	Platelet count;
LUAD	cis	rs9399401	0.710	rs7765770	chr6:142687305	C/T	cg03128060	chr6:142623767	GPR126	0.5	9.81	0.43	1.35e-20	Chronic obstructive pulmonary disease;
LUAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08219700	chr8:58056026	NA	0.68	8.66	0.39	9.97e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.38	6.85	0.32	2.61e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7786808	0.527	rs62478405	chr7:158188528	G/A	cg01191920	chr7:158217561	PTPRN2	-0.63	-12.98	-0.53	1.11e-32	Obesity-related traits;
LUAD	cis	rs12431939	0.762	rs12435765	chr14:51702128	A/G	cg23942311	chr14:51606299	NA	-0.55	-7.45	-0.34	5.28e-13	Cancer;
LUAD	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.12	-0.37	5.33e-15	Prostate cancer;
LUAD	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	ch.11.42038R	chr11:967971	AP2A2	0.39	6.9	0.32	1.87e-11	Alzheimer's disease (late onset);
LUAD	cis	rs56283067	0.887	rs12215095	chr6:44756910	T/C	cg18551225	chr6:44695536	NA	-0.48	-7.36	-0.34	9.5e-13	Total body bone mineral density;
LUAD	cis	rs13315871	1.000	rs71311865	chr3:58372423	G/A	cg20936604	chr3:58311152	NA	-0.68	-7.09	-0.33	5.62e-12	Cholesterol, total;
LUAD	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg22823121	chr1:150693482	HORMAD1	0.46	8.76	0.39	4.59e-17	Melanoma;
LUAD	cis	rs73195822	0.614	rs11065717	chr12:111208823	A/C	cg12870014	chr12:110450643	ANKRD13A	0.57	6.58	0.3	1.36e-10	Itch intensity from mosquito bite;
LUAD	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18876405	chr7:65276391	NA	-0.4	-6.41	-0.3	3.82e-10	Aortic root size;
LUAD	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg01181863	chr3:195395398	SDHAP2	-0.66	-9.69	-0.43	3.34e-20	Pancreatic cancer;
LUAD	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg12035532	chr1:1886765	KIAA1751	0.4	6.73	0.31	5.39e-11	Body mass index;
LUAD	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg15128208	chr22:42549153	NA	0.41	6.46	0.3	2.88e-10	Birth weight;
LUAD	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg15448220	chr1:150897856	SETDB1	0.52	8.9	0.4	1.7e-17	Melanoma;
LUAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg13560548	chr3:10150139	C3orf24	0.4	6.56	0.3	1.53e-10	Alzheimer's disease;
LUAD	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg05425664	chr17:57184151	TRIM37	-0.43	-7.61	-0.35	1.84e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg15017067	chr4:17643749	FAM184B	0.35	6.88	0.32	2.21e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.42	-0.34	6.4e-13	Total body bone mineral density;
LUAD	cis	rs5756813	0.688	rs5995498	chr22:38196573	T/G	cg06521852	chr22:38141419	TRIOBP	0.47	8.45	0.38	4.61e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg00814883	chr7:100076585	TSC22D4	-0.8	-11.65	-0.49	2.13e-27	Platelet count;
LUAD	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg24733560	chr20:60626293	TAF4	0.47	8.18	0.37	3.39e-15	Body mass index;
LUAD	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg15557168	chr22:42548783	NA	-0.5	-9.31	-0.41	7.18e-19	Schizophrenia;
LUAD	cis	rs1044826	0.642	rs186103	chr3:139211942	C/A	cg00490450	chr3:139108681	COPB2	0.41	6.48	0.3	2.63e-10	Obesity-related traits;
LUAD	cis	rs8192282	0.739	rs4585969	chr1:154498957	C/T	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.37	-0.34	8.86e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	trans	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.4	-6.4	-0.3	4.03e-10	Obesity-related traits;
LUAD	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10802521	chr3:52805072	NEK4	-0.53	-9.0	-0.4	7.89e-18	Bipolar disorder;
LUAD	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg15691649	chr6:25882328	NA	0.63	9.69	0.43	3.38e-20	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg05340658	chr4:99064831	C4orf37	0.56	9.61	0.42	6.82e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg03609598	chr5:56110824	MAP3K1	0.61	8.35	0.38	9.87e-16	Initial pursuit acceleration;
LUAD	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg02527881	chr3:46936655	PTH1R	-0.55	-11.22	-0.48	9.3e-26	Colorectal cancer;
LUAD	cis	rs2485376	1.000	rs772012	chr10:104063367	A/G	cg20641465	chr10:103991465	PITX3	-0.58	-10.7	-0.46	8.17e-24	QT interval;
LUAD	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg27427491	chr17:78079615	GAA	-0.41	-7.72	-0.35	8.43e-14	Yeast infection;
LUAD	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg00530320	chr1:46809349	NSUN4	0.52	8.16	0.37	3.96e-15	Menopause (age at onset);
LUAD	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg23649088	chr2:200775458	C2orf69	0.64	8.42	0.38	6.03e-16	Schizophrenia;
LUAD	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg17724175	chr1:150552817	MCL1	-0.4	-9.09	-0.4	3.98e-18	Blood protein levels;
LUAD	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg09035930	chr12:129282057	SLC15A4	0.75	17.33	0.64	3.2e-51	Systemic lupus erythematosus;
LUAD	cis	rs11048434	0.736	rs2377674	chr12:9112761	A/G	cg13575925	chr12:9217583	LOC144571	0.38	7.22	0.33	2.49e-12	Sjögren's syndrome;
LUAD	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg23649088	chr2:200775458	C2orf69	-0.62	-7.77	-0.35	6.15e-14	Schizophrenia;
LUAD	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg05043794	chr9:111880884	C9orf5	-0.44	-7.64	-0.35	1.47e-13	Menarche (age at onset);
LUAD	cis	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg08601574	chr20:25228251	PYGB	-0.45	-8.21	-0.37	2.73e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2242073	0.660	rs11678616	chr2:209004548	C/T	cg06181187	chr2:209010896	CRYGB	-0.34	-6.63	-0.31	9.97e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg00020340	chr7:910388	UNC84A	0.65	7.05	0.32	7.43e-12	Initial pursuit acceleration;
LUAD	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.58	0.35	2.21e-13	Menopause (age at onset);
LUAD	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg10518543	chr12:38710700	ALG10B	-0.49	-8.19	-0.37	3.21e-15	Morning vs. evening chronotype;
LUAD	cis	rs7587476	0.822	rs13018304	chr2:215682218	T/G	cg04004882	chr2:215674386	BARD1	0.51	6.51	0.3	2.1e-10	Neuroblastoma;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg07190450	chr5:154320539	MRPL22	0.41	6.37	0.3	4.88e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg01358551	chr19:47353761	AP2S1	0.4	6.6	0.31	1.24e-10	Anger;
LUAD	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg03188948	chr7:1209495	NA	0.74	6.96	0.32	1.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg03983476	chr2:10830698	NOL10	-0.47	-8.14	-0.37	4.48e-15	Prostate cancer;
LUAD	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg18200150	chr17:30822561	MYO1D	0.44	8.23	0.37	2.39e-15	Schizophrenia;
LUAD	cis	rs16958440	0.867	rs80106524	chr18:44676639	G/A	cg17192377	chr18:44677553	HDHD2	0.84	8.03	0.36	1e-14	Sitting height ratio;
LUAD	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg17173187	chr15:85201210	NMB	-0.41	-7.01	-0.32	9.32e-12	Schizophrenia;
LUAD	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg03929089	chr4:120376271	NA	-0.92	-17.08	-0.64	3.99e-50	Height;
LUAD	cis	rs757647	0.723	rs3822837	chr5:137718687	T/C	cg10676309	chr5:137685565	NA	0.41	7.24	0.33	2.08e-12	Menarche (age at onset);
LUAD	trans	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg11887960	chr12:57824829	NA	0.55	6.78	0.31	4.13e-11	Obesity-related traits;
LUAD	trans	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg26043149	chr18:55253948	FECH	1.02	18.86	0.68	5.14e-58	Gout;Urate levels;Serum uric acid levels;
LUAD	trans	rs7395662	0.963	rs11040016	chr11:48783497	A/G	cg00717180	chr2:96193071	NA	0.37	7.05	0.32	7.12e-12	HDL cholesterol;
LUAD	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg07507251	chr3:52567010	NT5DC2	0.37	7.31	0.34	1.31e-12	Bipolar disorder;
LUAD	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.1	-0.33	5.25e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7301826	0.610	rs36051740	chr12:131292722	G/A	cg11011512	chr12:131303247	STX2	-0.4	-6.49	-0.3	2.39e-10	Plasma plasminogen activator levels;
LUAD	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg03983476	chr2:10830698	NOL10	-0.46	-8.0	-0.36	1.18e-14	Prostate cancer;
LUAD	cis	rs751728	1.000	rs2296747	chr6:33744882	C/G	cg13859433	chr6:33739653	LEMD2	-0.35	-8.13	-0.37	4.76e-15	Crohn's disease;
LUAD	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg27124370	chr19:33622961	WDR88	-0.45	-7.04	-0.32	8.04e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg26384229	chr12:38710491	ALG10B	0.39	6.7	0.31	6.73e-11	Morning vs. evening chronotype;
LUAD	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg08422745	chr4:174089978	GALNT7	-0.93	-16.52	-0.63	1.15e-47	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg23277830	chr1:3704460	LRRC47	0.45	9.39	0.42	3.73e-19	Red cell distribution width;
LUAD	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	7.21	0.33	2.58e-12	Hypertriglyceridemia;
LUAD	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg24397884	chr7:158709396	WDR60	0.66	9.07	0.4	4.4e-18	Height;
LUAD	cis	rs4594175	0.926	rs11157800	chr14:51615502	A/T	cg23942311	chr14:51606299	NA	0.59	10.22	0.44	4.75e-22	Cancer;
LUAD	cis	rs2046867	0.583	rs13316962	chr3:72911994	T/C	cg25664220	chr3:72788482	NA	-0.55	-9.95	-0.44	4.38e-21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg15664640	chr17:80829946	TBCD	-0.49	-9.11	-0.41	3.27e-18	Breast cancer;
LUAD	cis	rs62238980	0.522	rs76599991	chr22:32495779	G/A	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs4006360	0.575	rs7503162	chr17:39233899	A/G	cg16090541	chr17:39240343	KRTAP4-7	-0.37	-6.49	-0.3	2.47e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9039	0.921	rs9929699	chr16:9218270	A/G	cg08831531	chr16:9218945	NA	-0.41	-7.35	-0.34	1.05e-12	Menopause (age at onset);
LUAD	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg14784868	chr12:69753453	YEATS4	-0.43	-7.07	-0.33	6.38e-12	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg11292332	chr7:45801988	SEPT13	-0.3	-6.66	-0.31	8.76e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.41	7.06	0.32	6.78e-12	Body mass index (adult);
LUAD	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03264133	chr6:25882463	NA	0.58	9.52	0.42	1.33e-19	Blood metabolite levels;
LUAD	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg00769240	chr8:12517080	NA	-0.4	-6.64	-0.31	9.48e-11	Blood pressure (smoking interaction);
LUAD	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.37	-10.27	-0.45	3.18e-22	Total body bone mineral density;
LUAD	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg15467112	chr14:75489610	MLH3	0.35	6.41	0.3	3.86e-10	Height;
LUAD	cis	rs10493773	0.674	rs414618	chr1:86220418	G/A	cg17807903	chr1:86174739	ZNHIT6	0.49	9.08	0.4	4.34e-18	Urate levels in overweight individuals;
LUAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg03188948	chr7:1209495	NA	0.38	6.43	0.3	3.48e-10	Longevity;Endometriosis;
LUAD	cis	rs59698941	0.550	rs11748737	chr5:132201070	C/T	cg14825688	chr5:132208181	LEAP2	-0.53	-10.81	-0.47	3.29e-24	Apolipoprotein A-IV levels;
LUAD	cis	rs999737	1.000	rs999737	chr14:69034682	C/T	cg04147497	chr14:69052728	RAD51L1	-0.45	-6.55	-0.3	1.63e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg18932078	chr1:2524107	MMEL1	-0.35	-6.63	-0.31	1.04e-10	Ulcerative colitis;
LUAD	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg10518543	chr12:38710700	ALG10B	-0.43	-7.13	-0.33	4.24e-12	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg03929089	chr4:120376271	NA	-0.96	-19.52	-0.69	5.95e-61	Height;
LUAD	cis	rs9902453	0.838	rs7217638	chr17:28336772	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-9.06	-0.4	5.02e-18	Coffee consumption (cups per day);
LUAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg11062466	chr8:58055876	NA	0.65	8.63	0.39	1.21e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.28	0.33	1.63e-12	Obesity-related traits;
LUAD	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg12573674	chr2:1569213	NA	-0.61	-7.04	-0.32	7.87e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.75	0.31	4.94e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.41	0.55	2.09e-34	Prudent dietary pattern;
LUAD	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg11814155	chr7:99998594	ZCWPW1	0.42	7.41	0.34	7.08e-13	Platelet count;
LUAD	cis	rs1030268	0.640	rs12707092	chr7:133188145	C/G	cg10665199	chr7:133106180	EXOC4	0.46	6.43	0.3	3.35e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs807669	0.835	rs1780639	chr22:19174603	T/C	cg02655711	chr22:19163373	SLC25A1	0.87	19.19	0.68	1.73e-59	Metabolite levels;
LUAD	cis	rs17685	0.753	rs869806	chr7:75688623	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.96	-0.36	1.59e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7524102	0.636	rs6695165	chr1:22710602	T/C	cg18560010	chr1:22690912	NA	0.5	6.42	0.3	3.76e-10	Bone mineral density;Bone mineral density (spine);Ulcerative colitis;Bone mineral density (hip);Dupuytren's disease;
LUAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg21724239	chr8:58056113	NA	0.66	8.35	0.38	9.5e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg24397884	chr7:158709396	WDR60	0.65	9.0	0.4	7.53e-18	Height;
LUAD	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg22920501	chr2:26401640	FAM59B	-0.96	-13.95	-0.56	1.22e-36	Gut microbiome composition (summer);
LUAD	cis	rs367943	0.603	rs1864066	chr5:112997865	C/T	cg12552261	chr5:112820674	MCC	0.5	9.0	0.4	7.43e-18	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs2262909	0.853	rs56207853	chr19:22292357	C/T	cg05197062	chr11:11642011	GALNTL4	0.58	9.06	0.4	4.7e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg13393036	chr8:95962371	TP53INP1	-0.42	-9.86	-0.43	9.15e-21	Type 2 diabetes;
LUAD	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg17757837	chr7:157058334	UBE3C	0.47	8.41	0.38	6.28e-16	Body mass index;
LUAD	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/G	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.71	9.93	0.43	5.13e-21	Type 2 diabetes;
LUAD	cis	rs300703	0.515	rs300695	chr2:182644	C/A	cg24565620	chr2:194026	NA	0.38	6.67	0.31	8.11e-11	Blood protein levels;
LUAD	cis	rs6674176	0.932	rs4660761	chr1:44440146	G/A	cg23954153	chr1:44402353	ARTN	-0.37	-6.58	-0.3	1.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2479724	0.846	rs2254474	chr6:41843044	T/G	cg17623882	chr6:41773611	USP49	-0.62	-11.57	-0.49	4.36e-27	Menarche (age at onset);
LUAD	trans	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs79911532	0.515	rs78827697	chr7:75687725	C/G	cg19862616	chr7:65841803	NCRNA00174	0.84	8.71	0.39	7.15e-17	Mononucleosis;
LUAD	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg20203395	chr5:56204925	C5orf35	-0.7	-10.19	-0.44	5.83e-22	Initial pursuit acceleration;
LUAD	cis	rs6754311	0.689	rs192822	chr2:136682274	A/T	cg07305463	chr2:136567211	LCT	-0.35	-6.79	-0.31	3.7e-11	Mosquito bite size;
LUAD	cis	rs9487051	0.698	rs35849756	chr6:109644610	G/A	cg01475377	chr6:109611718	NA	-0.41	-6.41	-0.3	3.91e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs7677751	0.806	rs6554163	chr4:55102559	A/T	cg17187183	chr4:55093834	PDGFRA	0.49	8.44	0.38	5.27e-16	Corneal astigmatism;
LUAD	cis	rs11671005	0.735	rs12986387	chr19:58927215	C/T	cg13877915	chr19:58951672	ZNF132	0.56	7.42	0.34	6.67e-13	Mean platelet volume;
LUAD	cis	rs4711336	1.000	rs2296740	chr6:33659536	A/G	cg14003231	chr6:33640908	ITPR3	0.48	8.92	0.4	1.43e-17	Height;
LUAD	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg26513180	chr16:89883248	FANCA	0.73	13.98	0.56	9.05e-37	Vitiligo;
LUAD	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg18306943	chr3:40428807	ENTPD3	0.36	6.41	0.3	3.96e-10	Renal cell carcinoma;
LUAD	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg12714757	chr17:73874637	TRIM47	-0.44	-6.71	-0.31	6.13e-11	Psoriasis;
LUAD	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.54e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11958404	0.719	rs72818153	chr5:157487035	T/C	cg05962755	chr5:157440814	NA	0.65	8.75	0.39	4.95e-17	IgG glycosylation;
LUAD	cis	rs6546550	0.935	rs2872075	chr2:70068635	G/T	cg02498382	chr2:70120550	SNRNP27	-0.57	-10.8	-0.46	3.54e-24	Prevalent atrial fibrillation;
LUAD	cis	rs4280164	0.945	rs4374085	chr14:24771080	T/C	cg22990158	chr14:24802150	ADCY4	0.44	6.38	0.3	4.66e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.44	0.34	5.59e-13	Bladder cancer;
LUAD	cis	rs1832871	0.672	rs111782080	chr6:158765385	G/A	cg07165851	chr6:158734300	TULP4	0.72	10.98	0.47	7.47e-25	Height;
LUAD	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg18335740	chr13:41363409	SLC25A15	-0.57	-10.19	-0.44	5.87e-22	Lewy body disease;
LUAD	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg09117114	chr16:67998030	SLC12A4	-0.48	-6.82	-0.31	3.06e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.69	-9.0	-0.4	7.98e-18	Body mass index;
LUAD	cis	rs77972916	0.611	rs6709988	chr2:43601317	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-8.28	-0.37	1.63e-15	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26314531	chr2:26401878	FAM59B	-0.6	-8.31	-0.37	1.35e-15	Gut microbiome composition (summer);
LUAD	trans	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.02	-0.32	8.97e-12	Dental caries;
LUAD	cis	rs11153730	0.503	rs283062	chr6:118621456	A/G	cg18833306	chr6:118973337	C6orf204	-0.5	-9.03	-0.4	6e-18	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs427394	0.664	rs274696	chr5:6732213	A/C	cg10857441	chr5:6722123	POLS	-0.59	-11.86	-0.5	3.23e-28	Menopause (age at onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12439463	chr17:79848761	ANAPC11;THOC4	-0.42	-6.6	-0.31	1.2e-10	Height;
LUAD	cis	rs7178572	0.568	rs28584877	chr15:77599003	C/A	cg15453836	chr15:77711506	NA	0.37	6.4	0.3	4.24e-10	Type 2 diabetes;
LUAD	cis	rs12545109	0.879	rs2609994	chr8:57365844	A/G	cg09654669	chr8:57350985	NA	-0.7	-9.91	-0.43	5.83e-21	Obesity-related traits;
LUAD	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02788857	chr8:22132959	PIWIL2	0.53	9.9	0.43	6.5e-21	Hypertriglyceridemia;
LUAD	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg23131131	chr22:24373011	LOC391322	0.5	8.35	0.38	9.88e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2274471	0.730	rs3780379	chr9:5112519	G/A	cg03390472	chr9:5043263	JAK2	-0.56	-7.04	-0.32	7.6e-12	Crohn's disease;
LUAD	cis	rs6564851	0.545	rs8044334	chr16:81248935	T/G	cg00908271	chr16:81254010	PKD1L2	-0.41	-8.74	-0.39	5.47e-17	Carotenoid and tocopherol levels;
LUAD	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg06784218	chr1:46089804	CCDC17	-0.35	-7.65	-0.35	1.34e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.67	0.31	8.13e-11	Menarche (age at onset);
LUAD	cis	rs490234	0.812	rs13286111	chr9:128429951	A/T	cg14078157	chr9:128172775	NA	-0.44	-7.98	-0.36	1.39e-14	Mean arterial pressure;
LUAD	trans	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg21659725	chr3:3221576	CRBN	0.5	8.17	0.37	3.56e-15	Body mass index;
LUAD	cis	rs6929812	0.651	rs2076305	chr6:27375611	A/C	cg18711553	chr6:27366782	ZNF391	0.38	6.7	0.31	6.82e-11	Neuroticism (multi-trait analysis);
LUAD	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg03732007	chr1:2071316	PRKCZ	0.35	6.99	0.32	1.11e-11	Height;
LUAD	cis	rs240764	0.621	rs11155636	chr6:101201243	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.39	-0.38	7.58e-16	Neuroticism;
LUAD	cis	rs7665090	0.870	rs228616	chr4:103579691	G/A	cg07973026	chr4:103553119	MANBA	-0.4	-6.89	-0.32	2.03e-11	Primary biliary cholangitis;
LUAD	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.41	0.55	2.13e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs501916	0.727	rs12439630	chr15:48035191	C/T	cg16110827	chr15:48056943	SEMA6D	-0.35	-6.48	-0.3	2.49e-10	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs13315871	0.790	rs13066409	chr3:58428444	A/G	cg12435725	chr3:58293450	RPP14	-0.67	-7.44	-0.34	5.6e-13	Cholesterol, total;
LUAD	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg08999081	chr20:33150536	PIGU	0.61	13.51	0.55	8.27e-35	Glomerular filtration rate (creatinine);
LUAD	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg10523679	chr1:76189770	ACADM	-0.74	-11.35	-0.48	3.11e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg13565492	chr6:43139072	SRF	-0.6	-6.43	-0.3	3.42e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs3219090	0.962	rs1865222	chr1:226601884	A/C	cg27539482	chr13:111589090	NA	0.41	6.94	0.32	1.44e-11	Melanoma;
LUAD	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg22875332	chr1:76189707	ACADM	0.87	16.35	0.62	6.19e-47	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.53	6.52	0.3	1.99e-10	Depression;
LUAD	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg21475434	chr5:93447410	FAM172A	0.72	8.52	0.38	2.93e-16	Diabetic retinopathy;
LUAD	cis	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg25834613	chr7:1915315	MAD1L1	-0.4	-6.55	-0.3	1.71e-10	Bipolar disorder;
LUAD	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg04398451	chr17:18023971	MYO15A	0.77	14.08	0.56	3.36e-37	Total body bone mineral density;
LUAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg13271783	chr10:134563150	INPP5A	-0.4	-6.52	-0.3	2.02e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg02869364	chr7:1081709	C7orf50	-0.51	-6.57	-0.3	1.48e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.13	-0.37	4.77e-15	Total body bone mineral density;
LUAD	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg22823121	chr1:150693482	HORMAD1	0.37	7.27	0.33	1.7e-12	Melanoma;
LUAD	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.92	0.36	2.07e-14	Depression;
LUAD	cis	rs72799341	1.000	rs35675346	chr16:30936081	G/A	cg02466173	chr16:30829666	NA	-0.54	-8.22	-0.37	2.59e-15	Diastolic blood pressure;
LUAD	cis	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg20368463	chr18:77673604	PQLC1	-0.48	-6.9	-0.32	1.91e-11	Opioid sensitivity;
LUAD	cis	rs4711336	0.583	rs10672	chr6:33662265	T/C	cg14003231	chr6:33640908	ITPR3	0.37	6.36	0.3	5.28e-10	Height;
LUAD	cis	rs12530845	0.623	rs73721669	chr7:135347107	C/G	cg23117316	chr7:135346802	PL-5283	-0.59	-8.94	-0.4	1.21e-17	Red blood cell traits;
LUAD	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg21153622	chr11:89784906	NA	0.34	6.73	0.31	5.53e-11	Height;
LUAD	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg02176678	chr2:219576539	TTLL4	0.74	14.86	0.59	1.68e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.52	-8.35	-0.38	9.74e-16	Renal function-related traits (BUN);
LUAD	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg15704280	chr7:45808275	SEPT13	-0.91	-17.28	-0.64	5.17e-51	Coronary artery disease;
LUAD	cis	rs7274811	0.711	rs184110	chr20:31981432	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	0.48	7.41	0.34	7.03e-13	Height;
LUAD	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg11502198	chr6:26597334	ABT1	0.68	11.85	0.5	3.69e-28	Intelligence (multi-trait analysis);
LUAD	trans	rs62458065	0.513	rs10268149	chr7:32575499	T/C	cg00845942	chr12:64062724	DPY19L2	-0.56	-8.24	-0.37	2.23e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg03676636	chr4:99064102	C4orf37	0.32	8.38	0.38	7.67e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg20607798	chr8:58055168	NA	0.67	8.71	0.39	7.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1870323	0.527	rs675775	chr11:86179542	G/A	cg01663953	chr11:86133777	CCDC81	0.36	6.54	0.3	1.79e-10	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule);
LUAD	cis	rs7771547	0.603	rs7344	chr6:36570366	A/G	cg07856975	chr6:36356162	ETV7	0.52	7.14	0.33	4.21e-12	Platelet distribution width;
LUAD	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg00071950	chr4:10020882	SLC2A9	0.85	18.34	0.67	1.09e-55	Bone mineral density;
LUAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg14926445	chr8:58193284	C8orf71	-0.46	-6.82	-0.31	3.25e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg13685833	chr1:53393034	SCP2	-0.4	-6.66	-0.31	8.28e-11	Monocyte count;
LUAD	cis	rs4853036	0.723	rs35690619	chr2:70053619	A/T	cg02498382	chr2:70120550	SNRNP27	-0.51	-7.21	-0.33	2.57e-12	Colorectal or endometrial cancer;
LUAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-8.07	-0.37	7.12e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs853679	1.000	rs853678	chr6:28297313	T/A	cg01620082	chr3:125678407	NA	-0.53	-7.01	-0.32	9.23e-12	Depression;
LUAD	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03452623	chr4:187889614	NA	-0.76	-14.99	-0.59	4.62e-41	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg19302996	chr17:73780495	UNK	-0.4	-6.73	-0.31	5.5e-11	White matter hyperintensity burden;
LUAD	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg25767906	chr1:53392781	SCP2	-0.51	-9.57	-0.42	9.36e-20	Monocyte count;
LUAD	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg13606994	chr1:44402422	ARTN	-0.33	-6.79	-0.31	3.82e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs8018808	0.935	rs8005759	chr14:77880493	C/T	cg20045696	chr14:77926864	AHSA1	0.36	6.4	0.3	4.05e-10	Myeloid white cell count;
LUAD	cis	rs7149337	0.773	rs3007067	chr14:51596420	G/A	cg23942311	chr14:51606299	NA	0.86	19.61	0.69	2.25e-61	Cancer;
LUAD	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg24818145	chr4:99064322	C4orf37	0.43	7.24	0.33	2.14e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg05725404	chr16:58534157	NDRG4	-0.74	-7.86	-0.36	3.27e-14	Schizophrenia;
LUAD	cis	rs9976767	0.608	rs11909987	chr21:43822402	C/A	cg23042151	chr21:43824109	UBASH3A	-0.31	-6.57	-0.3	1.44e-10	Type 1 diabetes;
LUAD	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg08601574	chr20:25228251	PYGB	-0.44	-8.04	-0.36	8.91e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg27539214	chr16:67997921	SLC12A4	-0.68	-8.09	-0.37	6.58e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6594713	0.648	rs36023163	chr5:112891009	A/G	cg12552261	chr5:112820674	MCC	0.52	7.19	0.33	2.99e-12	Brain cytoarchitecture;
LUAD	cis	rs17739167	0.550	rs4924589	chr15:42229632	C/T	cg20935245	chr15:42234343	EHD4	0.43	7.56	0.35	2.46e-13	Monocyte count;
LUAD	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg04800585	chr6:26043546	HIST1H2BB	0.38	6.76	0.31	4.72e-11	Blood metabolite levels;
LUAD	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg24450063	chr1:156163899	SLC25A44	1.01	18.71	0.67	2.3e-57	Testicular germ cell tumor;
LUAD	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg20291162	chr17:40259547	DHX58	-0.7	-11.01	-0.47	5.66e-25	Fibrinogen levels;
LUAD	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.11	-0.37	5.34e-15	Total body bone mineral density;
LUAD	cis	rs13315871	0.929	rs77178267	chr3:58320657	T/G	cg20936604	chr3:58311152	NA	-0.72	-7.25	-0.33	2.03e-12	Cholesterol, total;
LUAD	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.61	-0.35	1.84e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03517284	chr6:25882590	NA	0.48	6.89	0.32	2.01e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08219700	chr8:58056026	NA	0.69	9.02	0.4	6.38e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg17252645	chr8:143867129	LY6D	-0.36	-6.66	-0.31	8.32e-11	Urinary tract infection frequency;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg23016472	chr19:49217901	MAMSTR	-0.65	-6.5	-0.3	2.22e-10	Type 2 diabetes;
LUAD	cis	rs2046867	0.644	rs56947804	chr3:72788435	T/C	cg04365224	chr3:72788183	NA	-0.47	-7.13	-0.33	4.4e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg10589385	chr1:150898437	SETDB1	0.45	8.28	0.37	1.65e-15	Melanoma;
LUAD	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg11502198	chr6:26597334	ABT1	-0.45	-7.03	-0.32	8.09e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7020830	0.861	rs13295981	chr9:37330067	C/T	cg14294708	chr9:37120828	ZCCHC7	0.88	17.8	0.65	2.68e-53	Schizophrenia;
LUAD	cis	rs9341808	0.754	rs9352808	chr6:80997342	G/T	cg08355045	chr6:80787529	NA	0.52	9.36	0.41	4.62e-19	Sitting height ratio;
LUAD	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg18811423	chr2:55921094	PNPT1	-0.41	-6.65	-0.31	8.89e-11	Metabolic syndrome;
LUAD	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg01416388	chr22:39784598	NA	-0.44	-6.78	-0.31	4e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg16479474	chr6:28041457	NA	0.41	7.23	0.33	2.33e-12	Parkinson's disease;
LUAD	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg15997130	chr1:24165203	NA	0.55	9.3	0.41	7.81e-19	Immature fraction of reticulocytes;
LUAD	cis	rs921968	0.565	rs692049	chr2:219622778	G/A	cg02176678	chr2:219576539	TTLL4	-0.55	-10.67	-0.46	1.06e-23	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1448094	0.842	rs12318815	chr12:86452281	T/C	cg02569458	chr12:86230093	RASSF9	-0.38	-7.26	-0.33	1.9e-12	Major depressive disorder;
LUAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6840360	0.550	rs6816471	chr4:152494869	A/G	cg22705602	chr4:152727874	NA	-0.4	-7.01	-0.32	9.72e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg22532475	chr10:104410764	TRIM8	0.32	6.35	0.3	5.5e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14893161	chr1:205819251	PM20D1	0.89	20.9	0.71	3.93e-67	Menarche (age at onset);
LUAD	cis	rs56283067	0.847	rs62435998	chr6:44695206	C/T	cg18551225	chr6:44695536	NA	-0.6	-10.03	-0.44	2.22e-21	Total body bone mineral density;
LUAD	cis	rs6782228	0.585	rs9841161	chr3:128331870	A/G	cg16766828	chr3:128327626	NA	-0.37	-6.87	-0.32	2.37e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg02371401	chr5:676784	TPPP	-0.48	-7.89	-0.36	2.57e-14	Lung disease severity in cystic fibrosis;
LUAD	cis	rs2637266	1.000	rs10219023	chr10:78364537	G/A	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.72e-11	Pulmonary function;
LUAD	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg15704280	chr7:45808275	SEPT13	0.86	16.44	0.62	2.67e-47	Coronary artery disease;
LUAD	trans	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg14917512	chr19:3094685	GNA11	0.58	6.84	0.32	2.72e-11	Diabetic kidney disease;
LUAD	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.42	-6.83	-0.32	2.98e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs4776059	1.000	rs35372377	chr15:52882281	G/A	cg24008177	chr15:52972085	KIAA1370	0.25	6.93	0.32	1.58e-11	Schizophrenia;
LUAD	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg18827107	chr12:86230957	RASSF9	-0.53	-9.45	-0.42	2.41e-19	Major depressive disorder;
LUAD	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg11941060	chr3:133502564	NA	-0.56	-8.83	-0.39	2.75e-17	Iron status biomarkers;
LUAD	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12541635	0.653	rs7014265	chr8:107026412	G/A	cg10147462	chr8:107024639	NA	0.55	9.7	0.43	3.25e-20	Age of smoking initiation;
LUAD	cis	rs977987	0.806	rs35683383	chr16:75479277	G/T	cg03315344	chr16:75512273	CHST6	0.64	13.77	0.56	6.57e-36	Dupuytren's disease;
LUAD	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg13722127	chr7:150037890	RARRES2	0.45	7.78	0.35	5.7e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs13064411	0.542	rs7631335	chr3:113209166	C/T	cg10517650	chr3:113235015	CCDC52	-0.45	-8.25	-0.37	2.01e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs13082711	0.911	rs7640957	chr3:27514015	C/A	cg02860705	chr3:27208620	NA	0.62	9.32	0.41	6.29e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.41	7.91	0.36	2.33e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg22676075	chr6:135203613	NA	0.52	9.37	0.41	4.46e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7551222	0.749	rs6682208	chr1:204566183	T/C	cg20240347	chr1:204465584	NA	-0.33	-6.43	-0.3	3.35e-10	Schizophrenia;
LUAD	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.65	-7.06	-0.32	6.68e-12	Smoking behavior;
LUAD	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg18230493	chr5:56204884	C5orf35	-0.53	-8.6	-0.39	1.54e-16	Coronary artery disease;
LUAD	cis	rs4280164	1.000	rs4280164	chr14:24771285	G/A	cg22990158	chr14:24802150	ADCY4	0.44	6.42	0.3	3.65e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.62	0.31	1.09e-10	Depression;
LUAD	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.5	0.42	1.62e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7927771	0.524	rs4752798	chr11:47886364	T/C	cg18512352	chr11:47633146	NA	-0.36	-6.5	-0.3	2.29e-10	Subjective well-being;
LUAD	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg18477163	chr1:228402036	OBSCN	-0.36	-7.27	-0.33	1.74e-12	Diastolic blood pressure;
LUAD	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg17366294	chr4:99064904	C4orf37	0.67	13.03	0.54	7.43e-33	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg06623918	chr6:96969491	KIAA0776	0.7	10.62	0.46	1.64e-23	Migraine;Coronary artery disease;
LUAD	cis	rs62238980	0.614	rs117692225	chr22:32421806	A/G	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg23283495	chr1:209979779	IRF6	0.68	9.8	0.43	1.39e-20	Cleft lip with or without cleft palate;
LUAD	cis	rs600231	0.508	rs11227201	chr11:65242548	G/A	cg17120908	chr11:65337727	SSSCA1	-0.64	-8.48	-0.38	3.88e-16	Bone mineral density;
LUAD	cis	rs10746514	1.000	rs9724948	chr1:232248244	C/T	cg09506761	chr1:232265262	NA	0.38	6.84	0.32	2.86e-11	Response to statin therapy;
LUAD	cis	rs870825	0.616	rs7678949	chr4:185635018	G/C	cg04058563	chr4:185651563	MLF1IP	0.9	14.43	0.57	1.19e-38	Blood protein levels;
LUAD	cis	rs2625529	0.652	rs2930069	chr15:72226977	G/A	cg16672083	chr15:72433130	SENP8	0.58	10.72	0.46	6.75e-24	Red blood cell count;
LUAD	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18876405	chr7:65276391	NA	-0.4	-6.4	-0.3	4.19e-10	Aortic root size;
LUAD	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-10.26	-0.45	3.21e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs9494145	1.000	rs9494145	chr6:135432552	T/C	cg22676075	chr6:135203613	NA	0.53	7.22	0.33	2.45e-12	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUAD	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg23245007	chr3:195682326	NA	-0.4	-6.67	-0.31	7.85e-11	Pancreatic cancer;
LUAD	cis	rs208520	0.609	rs208436	chr6:66897470	G/A	cg07460842	chr6:66804631	NA	-0.67	-9.92	-0.43	5.57e-21	Exhaled nitric oxide output;
LUAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg08888203	chr3:10149979	C3orf24	0.74	12.92	0.53	2e-32	Alzheimer's disease;
LUAD	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg21605333	chr4:119757512	SEC24D	0.96	8.38	0.38	7.69e-16	Cannabis dependence symptom count;
LUAD	cis	rs9902453	0.933	rs1532042	chr17:28504389	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	8.75	0.39	5.07e-17	Coffee consumption (cups per day);
LUAD	cis	rs714515	0.868	rs4916253	chr1:172361032	G/T	cg14508705	chr1:172360182	DNM3	-0.37	-6.4	-0.3	4.02e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg00316803	chr15:76480434	C15orf27	0.41	6.63	0.31	1.04e-10	Blood metabolite levels;
LUAD	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg09835421	chr16:68378352	PRMT7	-1.03	-12.02	-0.5	8.1e-29	Schizophrenia;
LUAD	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg03609598	chr5:56110824	MAP3K1	-0.68	-9.32	-0.41	6.4e-19	Initial pursuit acceleration;
LUAD	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg08999081	chr20:33150536	PIGU	0.62	13.92	0.56	1.54e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs11126435	0.858	rs363623	chr2:74930040	A/G	cg19285774	chr2:74907978	SEMA4F	0.37	6.49	0.3	2.45e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg22535103	chr8:58192502	C8orf71	-0.67	-7.28	-0.33	1.66e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg05283184	chr6:79620031	NA	-0.61	-12.24	-0.51	1.05e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs9948	0.655	rs62156210	chr2:97393736	A/T	cg20312557	chr2:97357134	FER1L5	-0.71	-7.97	-0.36	1.51e-14	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg08807101	chr21:30365312	RNF160	-0.42	-7.29	-0.33	1.57e-12	Dental caries;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg26087862	chr1:150602029	ENSA	0.37	6.95	0.32	1.39e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	trans	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	17.5	0.65	5.84e-52	Exhaled nitric oxide output;
LUAD	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18876405	chr7:65276391	NA	0.43	6.81	0.31	3.44e-11	Aortic root size;
LUAD	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.32	-0.37	1.27e-15	Schizophrenia;
LUAD	cis	rs10979	0.597	rs9321927	chr6:143913295	A/G	cg25407410	chr6:143891975	LOC285740	0.51	7.11	0.33	4.89e-12	Hypospadias;
LUAD	cis	rs62238980	0.614	rs4821001	chr22:32344403	T/C	cg00543991	chr22:32367038	NA	0.87	8.08	0.37	7.07e-15	Childhood ear infection;
LUAD	cis	rs427394	0.582	rs274661	chr5:6704848	C/T	cg12316010	chr5:6737918	POLS	0.36	6.9	0.32	1.85e-11	Menopause (age at onset);
LUAD	trans	rs13128441	0.554	rs3806721	chr4:5167917	A/G	cg26099876	chr8:141644609	EIF2C2	-0.51	-6.55	-0.3	1.64e-10	Celiac disease;
LUAD	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg00631329	chr6:26305371	NA	0.55	9.82	0.43	1.18e-20	Educational attainment;
LUAD	cis	rs6740322	0.895	rs9309097	chr2:43554397	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.78	-11.45	-0.49	1.27e-26	Coronary artery disease;
LUAD	cis	rs889398	0.741	rs6499269	chr16:69908918	T/C	cg00738113	chr16:70207722	CLEC18C	-0.34	-6.75	-0.31	4.84e-11	Body mass index;
LUAD	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg13736514	chr6:26305472	NA	-0.69	-12.81	-0.53	5.6e-32	Educational attainment;
LUAD	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18404041	chr3:52824283	ITIH1	-0.58	-11.68	-0.49	1.6e-27	Bipolar disorder;
LUAD	cis	rs3936840	0.539	rs3742445	chr14:102975552	T/A	cg18135206	chr14:102964638	TECPR2	0.46	6.85	0.32	2.64e-11	Plateletcrit;
LUAD	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg06671706	chr8:8559999	CLDN23	0.36	6.38	0.3	4.57e-10	Mood instability;
LUAD	cis	rs7833986	0.534	rs17814089	chr8:56965563	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.98	-17.98	-0.66	4.18e-54	Height;
LUAD	cis	rs17155006	0.655	rs380046	chr7:107728315	A/G	cg05962710	chr7:107745446	LAMB4	-0.3	-6.53	-0.3	1.85e-10	Pneumococcal bacteremia;
LUAD	cis	rs11971779	0.584	rs7786469	chr7:139094621	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs7107174	0.688	rs2063724	chr11:78133077	T/C	cg19901956	chr11:77921274	USP35	-0.47	-6.38	-0.3	4.68e-10	Testicular germ cell tumor;
LUAD	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg17264618	chr3:40429014	ENTPD3	0.41	8.81	0.39	3.22e-17	Renal cell carcinoma;
LUAD	cis	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.87	-7.49	-0.34	3.97e-13	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg26924012	chr15:45694286	SPATA5L1	0.63	10.92	0.47	1.31e-24	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.06e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg20587970	chr11:113659929	NA	0.87	12.6	0.52	3.98e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-11.42	-0.49	1.63e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg18404041	chr3:52824283	ITIH1	-0.73	-15.87	-0.61	7.94e-45	Bipolar disorder;
LUAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.62	-7.78	-0.35	5.52e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg15017067	chr4:17643749	FAM184B	-0.37	-6.94	-0.32	1.44e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2932538	0.961	rs6537746	chr1:113163529	C/T	cg22162597	chr1:113214053	CAPZA1	-0.46	-6.81	-0.31	3.45e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg13047869	chr3:10149882	C3orf24	0.59	9.99	0.44	2.95e-21	Alzheimer's disease;
LUAD	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg10755058	chr3:40428713	ENTPD3	0.38	7.2	0.33	2.83e-12	Renal cell carcinoma;
LUAD	trans	rs1493916	0.837	rs9945976	chr18:31409314	C/T	cg27147174	chr7:100797783	AP1S1	-0.62	-10.88	-0.47	1.73e-24	Life satisfaction;
LUAD	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg00106254	chr7:1943704	MAD1L1	-0.45	-6.52	-0.3	2.04e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg06640241	chr16:89574553	SPG7	0.45	7.21	0.33	2.64e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.53	6.65	0.31	8.91e-11	Body mass index;
LUAD	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg14668632	chr7:2872130	GNA12	-0.7	-12.71	-0.53	1.39e-31	Height;
LUAD	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg23758822	chr17:41437982	NA	-0.9	-18.58	-0.67	8.93e-57	Menopause (age at onset);
LUAD	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.59	0.42	7.97e-20	Cognitive ability;
LUAD	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6690583	0.623	rs893620	chr1:85425821	T/C	cg22153463	chr1:85462885	MCOLN2	0.57	6.4	0.3	4.2e-10	Serum sulfate level;
LUAD	trans	rs66573146	1.000	rs73088528	chr4:6967747	G/C	cg07817883	chr1:32538562	TMEM39B	1.5	12.86	0.53	3.54e-32	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs8177876	0.749	rs11865207	chr16:81089660	T/G	cg08591886	chr16:81111003	C16orf46	-0.61	-6.59	-0.31	1.28e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg21475434	chr5:93447410	FAM172A	0.76	8.51	0.38	3.16e-16	Diabetic retinopathy;
LUAD	cis	rs6076065	0.509	rs2000261	chr20:23311090	G/T	cg11657817	chr20:23433608	CST11	0.48	8.8	0.39	3.52e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg26384229	chr12:38710491	ALG10B	0.44	7.11	0.33	5.06e-12	Bladder cancer;
LUAD	cis	rs7107174	1.000	rs2511186	chr11:77984306	C/G	cg19901956	chr11:77921274	USP35	-0.52	-6.58	-0.3	1.37e-10	Testicular germ cell tumor;
LUAD	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.7	0.31	6.81e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs1595825	0.891	rs41468149	chr2:198910107	C/G	cg00982548	chr2:198649783	BOLL	0.66	9.29	0.41	8.11e-19	Ulcerative colitis;
LUAD	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg08885076	chr2:99613938	TSGA10	0.36	6.48	0.3	2.56e-10	Chronic sinus infection;
LUAD	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg20607798	chr8:58055168	NA	0.8	9.71	0.43	3.05e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg08219700	chr8:58056026	NA	0.42	6.35	0.3	5.53e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.52	0.34	3.42e-13	Breast cancer;
LUAD	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg25767906	chr1:53392781	SCP2	-0.54	-10.04	-0.44	2.08e-21	Monocyte count;
LUAD	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg21963583	chr11:68658836	MRPL21	-0.4	-7.1	-0.33	5.2e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	7.08	0.33	6.17e-12	Breast cancer;
LUAD	trans	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg04565464	chr8:145669602	NFKBIL2	0.46	7.37	0.34	9.19e-13	Schizophrenia;
LUAD	cis	rs748404	0.697	rs530188	chr15:43545314	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.45	0.34	5.29e-13	Lung cancer;
LUAD	cis	rs6543140	0.929	rs7602207	chr2:103032366	C/G	cg03938978	chr2:103052716	IL18RAP	0.35	6.86	0.32	2.5e-11	Blood protein levels;
LUAD	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg25894440	chr7:65020034	NA	-0.64	-6.83	-0.32	2.96e-11	Diabetic kidney disease;
LUAD	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg02493740	chr2:85810744	VAMP5	-0.42	-7.55	-0.34	2.72e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.4e-15	Prostate cancer;
LUAD	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg09455208	chr3:40491958	NA	0.58	12.78	0.53	7.5e-32	Renal cell carcinoma;
LUAD	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg02428538	chr16:24856791	SLC5A11	0.5	6.92	0.32	1.64e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.62	-11.03	-0.47	4.96e-25	Urate levels in overweight individuals;
LUAD	cis	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg07460842	chr6:66804631	NA	0.91	14.28	0.57	5.07e-38	Exhaled nitric oxide levels;
LUAD	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg09365446	chr1:150670422	GOLPH3L	-0.46	-7.32	-0.34	1.26e-12	Tonsillectomy;
LUAD	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg15448220	chr1:150897856	SETDB1	0.47	8.09	0.37	6.35e-15	Tonsillectomy;
LUAD	cis	rs68170813	0.599	rs77878465	chr7:106890996	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-10.58	-0.46	2.2e-23	Coronary artery disease;
LUAD	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg11965913	chr1:205819406	PM20D1	-0.44	-7.19	-0.33	2.99e-12	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs1595825	0.891	rs60484833	chr2:198812181	C/T	cg00361562	chr2:198649771	BOLL	-0.47	-6.72	-0.31	5.88e-11	Ulcerative colitis;
LUAD	cis	rs6489882	0.807	rs10774677	chr12:113362421	G/A	cg20102336	chr12:113376681	OAS3	-0.59	-9.09	-0.4	3.97e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg19052272	chr2:3704530	ALLC	-0.42	-7.78	-0.35	5.68e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg06387496	chr7:2775674	GNA12	-0.39	-6.5	-0.3	2.23e-10	Height;
LUAD	cis	rs11792861	0.566	rs966466	chr9:111851333	T/A	cg05043794	chr9:111880884	C9orf5	-0.38	-7.25	-0.33	1.94e-12	Menarche (age at onset);
LUAD	cis	rs904251	0.600	rs2270687	chr6:37418263	A/G	cg25019722	chr6:37503610	NA	-0.31	-6.96	-0.32	1.32e-11	Cognitive performance;
LUAD	cis	rs68170813	0.876	rs34523267	chr7:107226156	C/T	cg02696742	chr7:106810147	HBP1	-0.5	-6.81	-0.31	3.27e-11	Coronary artery disease;
LUAD	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg14186256	chr22:23484241	RTDR1	-0.47	-8.26	-0.37	1.86e-15	Bone mineral density;
LUAD	trans	rs11039798	1.000	rs7123704	chr11:48580535	G/A	cg03929089	chr4:120376271	NA	0.55	6.48	0.3	2.53e-10	Axial length;
LUAD	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg03161606	chr19:29218774	NA	0.6	8.65	0.39	1.05e-16	Methadone dose in opioid dependence;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg11454606	chr11:67888949	CHKA	-0.44	-7.5	-0.34	3.68e-13	Schizophrenia;
LUAD	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg20135002	chr11:47629003	NA	-0.41	-7.26	-0.33	1.86e-12	Subjective well-being;
LUAD	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg20673091	chr1:2541236	MMEL1	-0.41	-8.61	-0.39	1.43e-16	Ulcerative colitis;
LUAD	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg11861562	chr11:117069780	TAGLN	-0.34	-6.64	-0.31	9.72e-11	Blood protein levels;
LUAD	trans	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg11887960	chr12:57824829	NA	0.55	6.91	0.32	1.82e-11	Obesity-related traits;
LUAD	cis	rs6922632	0.867	rs1343625	chr6:24112737	C/G	cg26194775	chr6:24126114	NRSN1	-0.47	-8.4	-0.38	6.75e-16	Information processing speed;
LUAD	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs6992820	0.900	rs12678930	chr8:56726277	A/G	cg06880721	chr8:56792545	LYN	-0.45	-7.39	-0.34	8.17e-13	Mean platelet volume;
LUAD	cis	rs6740322	0.748	rs13420649	chr2:43463637	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-11.35	-0.48	3.1e-26	Coronary artery disease;
LUAD	cis	rs910187	0.678	rs6018330	chr20:45813216	C/T	cg27589058	chr20:45804311	EYA2	-0.31	-6.93	-0.32	1.54e-11	Migraine;
LUAD	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg15790184	chr11:494944	RNH1	0.56	6.61	0.31	1.13e-10	Body mass index;
LUAD	cis	rs12049351	0.524	rs4925495	chr1:229624424	C/T	cg11742688	chr1:229674241	ABCB10	-0.42	-6.68	-0.31	7.66e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs813218	0.565	rs2449106	chr3:99602087	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.47	8.35	0.38	9.69e-16	Orofacial clefts;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21354621	chr12:46384284	SFRS2IP	-0.43	-6.5	-0.3	2.25e-10	Height;
LUAD	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg09184832	chr6:79620586	NA	-0.4	-6.72	-0.31	5.86e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10950821	0.519	rs1476484	chr7:20669553	C/G	cg02470904	chr7:20686108	ABCB5	0.38	7.1	0.33	5.27e-12	Response to statin therapy;
LUAD	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg22029157	chr1:209979665	IRF6	0.78	11.57	0.49	4.44e-27	Cleft lip with or without cleft palate;
LUAD	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg05665937	chr4:1216051	CTBP1	0.43	7.31	0.34	1.3e-12	Obesity-related traits;
LUAD	trans	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg18187862	chr3:45730750	SACM1L	0.5	7.89	0.36	2.55e-14	Primary sclerosing cholangitis;
LUAD	cis	rs12208915	0.708	rs9361481	chr6:79726750	T/A	cg18132916	chr6:79620363	NA	0.54	7.23	0.33	2.23e-12	Left atrial antero-posterior diameter;
LUAD	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09263875	chr16:632152	PIGQ	0.82	18.41	0.67	4.93e-56	Height;
LUAD	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg04703951	chr17:43578652	NA	0.6	8.36	0.38	9.08e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3772130	0.962	rs9822949	chr3:121541239	T/G	cg20356878	chr3:121714668	ILDR1	0.53	8.57	0.38	2e-16	Cognitive performance;
LUAD	cis	rs9486719	1.000	rs13207333	chr6:96882254	T/C	cg06623918	chr6:96969491	KIAA0776	-0.71	-10.02	-0.44	2.32e-21	Migraine;Coronary artery disease;
LUAD	cis	rs2421770	0.530	rs4755396	chr11:35370624	G/A	cg13971030	chr11:35366721	SLC1A2	-0.47	-8.23	-0.37	2.35e-15	Staphylococcus aureus nasal carriage (persistent);
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg18071532	chr12:48357234	TMEM106C	-0.55	-6.56	-0.3	1.53e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.78	-0.31	4.07e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg23625390	chr15:77176239	SCAPER	0.45	7.12	0.33	4.58e-12	Blood metabolite levels;
LUAD	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg22823121	chr1:150693482	HORMAD1	-0.4	-8.1	-0.37	6.04e-15	Tonsillectomy;
LUAD	cis	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.22	-0.33	2.38e-12	Resting heart rate;
LUAD	trans	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg20587970	chr11:113659929	NA	1.11	15.17	0.59	7.85e-42	Hip circumference adjusted for BMI;
LUAD	cis	rs1595825	0.838	rs73058883	chr2:198896255	C/T	cg00982548	chr2:198649783	BOLL	-0.65	-9.18	-0.41	1.88e-18	Ulcerative colitis;
LUAD	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg12311346	chr5:56204834	C5orf35	0.73	11.74	0.5	9.5e-28	Initial pursuit acceleration;
LUAD	cis	rs1832871	0.711	rs6906854	chr6:158695000	C/T	cg07165851	chr6:158734300	TULP4	0.7	10.88	0.47	1.85e-24	Height;
LUAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg24503407	chr1:205819492	PM20D1	-0.74	-15.29	-0.6	2.58e-42	Menarche (age at onset);
LUAD	cis	rs12545109	0.679	rs1973628	chr8:57429360	T/C	cg09654669	chr8:57350985	NA	-0.65	-7.6	-0.35	1.94e-13	Obesity-related traits;
LUAD	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05165339	chr4:1420672	NA	0.27	6.39	0.3	4.27e-10	Longevity;
LUAD	cis	rs68170813	0.523	rs111590023	chr7:107055323	T/C	cg02696742	chr7:106810147	HBP1	-0.76	-10.56	-0.46	2.72e-23	Coronary artery disease;
LUAD	cis	rs701145	0.585	rs357476	chr3:153892844	A/G	cg17054900	chr3:154042577	DHX36	-0.6	-6.46	-0.3	2.83e-10	Coronary artery disease;
LUAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg20607798	chr8:58055168	NA	0.56	6.99	0.32	1.05e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg13736514	chr6:26305472	NA	0.45	7.39	0.34	7.83e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18876405	chr7:65276391	NA	-0.42	-6.72	-0.31	5.87e-11	Aortic root size;
LUAD	cis	rs10504073	0.669	rs818559	chr8:50035806	C/T	cg00325661	chr8:49890786	NA	0.4	9.02	0.4	6.66e-18	Blood metabolite ratios;
LUAD	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg16262614	chr3:133464971	TF	-0.42	-8.72	-0.39	6.56e-17	Iron status biomarkers (transferrin levels);
LUAD	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18876405	chr7:65276391	NA	-0.41	-6.47	-0.3	2.68e-10	Aortic root size;
LUAD	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.91	9.76	0.43	1.96e-20	Initial pursuit acceleration;
LUAD	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg24920358	chr1:40204285	PPIE	0.71	12.73	0.53	1.16e-31	Blood protein levels;
LUAD	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg02734326	chr4:10020555	SLC2A9	-0.45	-7.72	-0.35	8.55e-14	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2030746	0.521	rs6750309	chr2:121332191	A/G	cg03661458	chr2:121334411	NA	-0.39	-6.63	-0.31	1.03e-10	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LUAD	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09263875	chr16:632152	PIGQ	0.77	16.36	0.62	5.73e-47	Height;
LUAD	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.03	-0.44	2.24e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2505675	0.665	rs234932	chr6:2220520	C/T	cg12303981	chr6:2244766	GMDS	-0.34	-6.56	-0.3	1.57e-10	Tuberculosis;
LUAD	cis	rs7677751	0.806	rs6836215	chr4:55102741	T/C	cg17187183	chr4:55093834	PDGFRA	0.5	8.51	0.38	3.14e-16	Corneal astigmatism;
LUAD	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg15083037	chr5:83017644	HAPLN1	-0.53	-7.79	-0.35	5.4e-14	Prostate cancer;
LUAD	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg02782426	chr3:40428986	ENTPD3	0.35	7.5	0.34	3.87e-13	Renal cell carcinoma;
LUAD	cis	rs7188697	0.646	rs7184114	chr16:58585369	C/A	cg05725404	chr16:58534157	NDRG4	0.35	6.95	0.32	1.41e-11	QT interval;
LUAD	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.1	0.44	1.3e-21	Ileal carcinoids;
LUAD	cis	rs877282	0.898	rs35743076	chr10:758991	C/T	cg17470449	chr10:769945	NA	0.6	8.43	0.38	5.44e-16	Uric acid levels;
LUAD	trans	rs7555117	0.794	rs2989476	chr1:61059259	C/G	cg00810351	chr2:99552261	C2orf55	-0.36	-6.55	-0.3	1.71e-10	Facial morphology (factor 19);
LUAD	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg23711669	chr6:146136114	FBXO30	0.37	6.37	0.3	4.85e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-9.72	-0.43	2.65e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs59698941	0.709	rs58237345	chr5:132266351	T/A	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg18827107	chr12:86230957	RASSF9	0.65	11.94	0.5	1.67e-28	Major depressive disorder;
LUAD	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg06784218	chr1:46089804	CCDC17	0.5	11.13	0.48	2.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg07234876	chr8:600039	NA	1.04	9.73	0.43	2.48e-20	IgG glycosylation;
LUAD	trans	rs11039798	0.920	rs7478904	chr11:48630323	C/T	cg15704280	chr7:45808275	SEPT13	0.73	7.45	0.34	5.22e-13	Axial length;
LUAD	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs4888262	0.545	rs12716768	chr16:74556486	A/G	cg01733217	chr16:74700730	RFWD3	-0.4	-6.45	-0.3	3.03e-10	Testicular germ cell tumor;
LUAD	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.34	0.51	4.22e-30	Tonsillectomy;
LUAD	cis	rs62229266	0.839	rs11702763	chr21:37470704	A/G	cg12218747	chr21:37451666	NA	-0.46	-7.88	-0.36	2.7e-14	Mitral valve prolapse;
LUAD	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg11301795	chr4:187892539	NA	-0.77	-15.54	-0.6	2.05e-43	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	8.09	0.37	6.22e-15	Schizophrenia;
LUAD	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg04287289	chr16:89883240	FANCA	0.49	8.04	0.36	9.12e-15	Vitiligo;
LUAD	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	10.58	0.46	2.27e-23	Smoking behavior;
LUAD	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg14019146	chr3:50243930	SLC38A3	-0.42	-6.92	-0.32	1.72e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg12193833	chr17:30244370	NA	-0.57	-6.93	-0.32	1.58e-11	Hip circumference adjusted for BMI;
LUAD	trans	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg20556744	chr2:9614537	IAH1	0.64	6.49	0.3	2.46e-10	Opioid sensitivity;
LUAD	trans	rs7395662	0.963	rs115181013	chr11:48575801	T/C	cg15704280	chr7:45808275	SEPT13	-0.42	-6.55	-0.3	1.71e-10	HDL cholesterol;
LUAD	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03264133	chr6:25882463	NA	-0.87	-14.39	-0.57	1.72e-38	Blood metabolite levels;
LUAD	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg03161606	chr19:29218774	NA	0.56	7.13	0.33	4.33e-12	Methadone dose in opioid dependence;
LUAD	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg25358565	chr5:93447407	FAM172A	0.65	7.78	0.35	5.63e-14	Diabetic retinopathy;
LUAD	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg20503657	chr10:835505	NA	1.02	15.73	0.61	3.17e-44	Eosinophil percentage of granulocytes;
LUAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18099408	chr3:52552593	STAB1	-0.52	-9.53	-0.42	1.2e-19	Electroencephalogram traits;
LUAD	cis	rs427941	0.632	rs201500	chr7:101757806	G/C	cg06246474	chr7:101738831	CUX1	0.38	6.54	0.3	1.76e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	14.03	0.56	5.74e-37	Smoking behavior;
LUAD	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg01528321	chr10:82214614	TSPAN14	0.46	7.38	0.34	8.42e-13	Post bronchodilator FEV1;
LUAD	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg09835421	chr16:68378352	PRMT7	-0.83	-8.62	-0.39	1.35e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.39	0.34	7.75e-13	Bipolar disorder;
LUAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18402987	chr7:1209562	NA	0.4	6.55	0.3	1.69e-10	Longevity;Endometriosis;
LUAD	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07233135	chr10:33623121	NRP1	0.4	6.68	0.31	7.55e-11	Survival in pancreatic cancer;
LUAD	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg03929089	chr4:120376271	NA	-0.97	-19.75	-0.69	5.18e-62	Height;
LUAD	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg08493051	chr2:3487164	NA	-0.48	-8.36	-0.38	9.37e-16	Neurofibrillary tangles;
LUAD	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg03714773	chr7:91764589	CYP51A1	0.28	6.58	0.3	1.37e-10	Breast cancer;
LUAD	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.83	0.32	2.93e-11	Hypertriglyceridemia;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg12697442	chr11:101981167	YAP1	-0.43	-7.31	-0.33	1.35e-12	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg10729496	chr3:10149963	C3orf24	0.57	9.52	0.42	1.35e-19	Alzheimer's disease;
LUAD	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-11.75	-0.5	8.58e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg16060761	chr17:80687452	NA	0.49	7.4	0.34	7.57e-13	Breast cancer;
LUAD	cis	rs9487051	0.676	rs9320278	chr6:109562589	T/C	cg21918786	chr6:109611834	NA	-0.4	-6.85	-0.32	2.57e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg07402062	chr16:89894098	SPIRE2	0.45	11.36	0.48	2.71e-26	Vitiligo;
LUAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.26	0.41	1.03e-18	Alzheimer's disease;
LUAD	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.599	rs11769901	chr7:106958505	G/A	cg23024343	chr7:107201750	COG5	0.5	7.2	0.33	2.84e-12	Coronary artery disease;
LUAD	cis	rs7043114	0.525	rs2274966	chr9:95155563	C/A	cg14631576	chr9:95140430	CENPP	-0.41	-8.3	-0.37	1.37e-15	Height;
LUAD	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg16325326	chr1:53192061	ZYG11B	0.56	9.84	0.43	1.06e-20	Monocyte count;
LUAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg21970626	chr13:21893289	NA	-0.49	-8.72	-0.39	6.2e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-11.03	-0.47	5.04e-25	Bone mineral density;
LUAD	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg19622623	chr12:86230825	RASSF9	-0.49	-8.42	-0.38	5.88e-16	Major depressive disorder;
LUAD	cis	rs6881634	0.501	rs2885615	chr5:77697359	G/A	cg11547950	chr5:77652471	NA	-0.37	-6.53	-0.3	1.92e-10	Hippocampal atrophy;
LUAD	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg02527881	chr3:46936655	PTH1R	-0.48	-9.37	-0.41	4.26e-19	Colorectal cancer;
LUAD	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg13319975	chr6:146136371	FBXO30	-0.61	-10.52	-0.46	3.91e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8099014	0.861	rs6566974	chr18:56131156	A/G	cg12907477	chr18:56117327	MIR122	0.49	8.11	0.37	5.67e-15	Platelet count;
LUAD	cis	rs922182	0.617	rs55694045	chr15:64245943	T/C	cg02919090	chr15:64263738	DAPK2	0.34	6.56	0.3	1.55e-10	Blood protein levels;
LUAD	cis	rs80319144	0.521	rs75690826	chr2:159324696	C/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.41	7.98	0.36	1.38e-14	Restless legs syndrome;
LUAD	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg19767477	chr5:127420684	SLC12A2	-0.41	-6.39	-0.3	4.3e-10	Ileal carcinoids;
LUAD	cis	rs13082711	0.595	rs13075389	chr3:27339586	C/T	cg02860705	chr3:27208620	NA	0.78	12.17	0.51	1.94e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs11718455	0.960	rs11920021	chr3:44000856	T/C	cg08738300	chr3:44038990	NA	0.42	6.43	0.3	3.45e-10	Coronary artery disease;
LUAD	cis	rs1912483	0.545	rs35161461	chr17:45401757	A/G	cg25173405	chr17:45401733	C17orf57	-0.59	-9.34	-0.41	5.63e-19	Coronary artery disease;
LUAD	cis	rs2387326	0.767	rs11016094	chr10:129942423	G/A	cg16087940	chr10:129947807	NA	-0.63	-8.55	-0.38	2.19e-16	Select biomarker traits;
LUAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	10.11	0.44	1.18e-21	Lymphocyte counts;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg18854735	chr1:1822972	GNB1	-0.44	-8.01	-0.36	1.09e-14	Cancer;
LUAD	cis	rs41311933	0.803	rs62578397	chr9:123700338	A/C	cg13567360	chr9:123745713	C5	-0.83	-7.22	-0.33	2.36e-12	Coronary artery disease;
LUAD	trans	rs783540	0.867	rs10906984	chr15:83366296	A/C	cg18393722	chr15:85113863	UBE2QP1	0.4	6.39	0.3	4.44e-10	Schizophrenia;
LUAD	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	trans	rs7395662	0.927	rs8188938	chr11:48690866	C/T	cg15704280	chr7:45808275	SEPT13	0.41	6.38	0.3	4.53e-10	HDL cholesterol;
LUAD	cis	rs4713118	1.000	rs13215072	chr6:27677728	A/G	cg20933634	chr6:27740509	NA	0.41	6.37	0.3	4.93e-10	Parkinson's disease;
LUAD	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg17366294	chr4:99064904	C4orf37	0.52	9.69	0.43	3.55e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg11845111	chr2:191398756	TMEM194B	-0.74	-9.84	-0.43	1.08e-20	Diastolic blood pressure;
LUAD	cis	rs3823572	0.542	rs10224226	chr7:133626662	G/A	cg03336402	chr7:133662267	EXOC4	0.44	7.83	0.36	3.86e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg10518543	chr12:38710700	ALG10B	-0.42	-6.94	-0.32	1.5e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs977987	0.806	rs35552529	chr16:75405879	G/C	cg03315344	chr16:75512273	CHST6	0.65	14.18	0.57	1.32e-37	Dupuytren's disease;
LUAD	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg26513180	chr16:89883248	FANCA	0.78	7.14	0.33	4.13e-12	Skin colour saturation;
LUAD	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.7e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.33e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg06221963	chr1:154839813	KCNN3	-0.84	-17.58	-0.65	2.43e-52	Prostate cancer;
LUAD	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg02696790	chr15:75250997	RPP25	0.39	7.27	0.33	1.73e-12	Breast cancer;
LUAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs863345	0.565	rs10908668	chr1:158501933	C/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg17264618	chr3:40429014	ENTPD3	0.38	8.66	0.39	9.96e-17	Renal cell carcinoma;
LUAD	cis	rs853679	0.760	rs9393910	chr6:28208192	C/G	cg16479474	chr6:28041457	NA	0.41	6.68	0.31	7.73e-11	Depression;
LUAD	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg10556349	chr10:835070	NA	0.62	7.9	0.36	2.49e-14	Eosinophil percentage of granulocytes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13108601	chr6:41748242	FRS3;PRICKLE4	-0.42	-6.86	-0.32	2.42e-11	Height;
LUAD	trans	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	7.65	0.35	1.35e-13	Resting heart rate;
LUAD	cis	rs220324	0.688	rs2017391	chr21:43588394	C/T	cg08841829	chr21:43638893	ABCG1	-0.5	-6.92	-0.32	1.66e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs4523957	0.583	rs2641444	chr17:2037402	T/C	cg16513277	chr17:2031491	SMG6	-0.98	-20.08	-0.7	1.79e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3784262	0.869	rs4646628	chr15:58255282	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.43	-8.85	-0.4	2.32e-17	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg20744362	chr22:50050164	C22orf34	0.39	8.37	0.38	8.7e-16	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6554196	0.508	rs2237038	chr4:55525833	C/T	cg18836493	chr4:55524333	KIT	0.37	6.92	0.32	1.7e-11	Monocyte count;
LUAD	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg11189052	chr15:85197271	WDR73	-0.61	-10.04	-0.44	2.05e-21	P wave terminal force;
LUAD	cis	rs250585	0.790	rs437647	chr16:23462055	G/A	cg00143387	chr16:23521605	GGA2	0.69	9.7	0.43	3.13e-20	Egg allergy;
LUAD	trans	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.41	-6.76	-0.31	4.52e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.99e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg20891558	chr2:74357851	NA	0.98	15.69	0.61	4.66e-44	Gestational age at birth (maternal effect);
LUAD	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg22532475	chr10:104410764	TRIM8	-0.45	-8.52	-0.38	2.75e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9302065	1.000	rs9302065	chr13:95971016	C/T	cg26751094	chr13:95954534	ABCC4	0.34	7.06	0.32	7.01e-12	Blood metabolite levels;
LUAD	cis	rs877282	0.741	rs35865720	chr10:753022	G/A	cg17470449	chr10:769945	NA	0.58	7.81	0.35	4.56e-14	Uric acid levels;
LUAD	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg12311346	chr5:56204834	C5orf35	-0.92	-13.64	-0.55	2.32e-35	Initial pursuit acceleration;
LUAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg17372223	chr3:52568218	NT5DC2	0.42	7.77	0.35	6.12e-14	Electroencephalogram traits;
LUAD	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg11645453	chr3:52864694	ITIH4	0.38	7.48	0.34	4.3e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6906287	0.631	rs9320665	chr6:118986309	G/A	cg05564266	chr6:118973597	C6orf204	0.36	7.58	0.35	2.28e-13	Electrocardiographic conduction measures;
LUAD	cis	rs10129255	0.500	rs8022547	chr14:107190222	A/T	cg07958169	chr14:107095056	NA	-0.37	-7.37	-0.34	8.9e-13	Kawasaki disease;
LUAD	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg14343924	chr8:8086146	FLJ10661	0.46	7.3	0.33	1.42e-12	Mood instability;
LUAD	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg10589385	chr1:150898437	SETDB1	0.4	7.67	0.35	1.2e-13	Tonsillectomy;
LUAD	trans	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg01620082	chr3:125678407	NA	-0.81	-8.1	-0.37	6.15e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg02450064	chr17:40260053	DHX58	-0.44	-7.39	-0.34	8.11e-13	Fibrinogen levels;
LUAD	cis	rs12989701	0.877	rs36085158	chr2:127869982	C/T	cg08168897	chr2:127865431	BIN1	0.43	6.86	0.32	2.5e-11	Alzheimer's disease (late onset);
LUAD	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg00339695	chr16:24857497	SLC5A11	0.47	8.76	0.39	4.75e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg13732083	chr21:47605072	C21orf56	-0.4	-6.69	-0.31	6.92e-11	Testicular germ cell tumor;
LUAD	cis	rs7586879	1.000	rs10207698	chr2:25117672	C/T	cg04586622	chr2:25135609	ADCY3	0.34	7.38	0.34	8.71e-13	Body mass index;
LUAD	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs977987	0.836	rs11646044	chr16:75312548	G/T	cg03315344	chr16:75512273	CHST6	0.59	12.37	0.52	3.24e-30	Dupuytren's disease;
LUAD	cis	rs6138458	1.000	rs227624	chr20:24911562	T/C	cg26195577	chr20:24973756	C20orf3	0.96	16.32	0.62	8.79e-47	Blood protein levels;
LUAD	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.36	7.6	0.35	1.92e-13	Parkinson's disease;
LUAD	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg17063962	chr7:91808500	NA	0.65	10.72	0.46	7.22e-24	Breast cancer;
LUAD	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.22	0.33	2.47e-12	Heart rate;
LUAD	cis	rs2262909	0.962	rs390730	chr19:22233509	C/A	cg11619707	chr19:22235551	ZNF257	-0.48	-7.49	-0.34	4.04e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg14820908	chr5:178986412	RUFY1	0.42	7.14	0.33	4.03e-12	Lung cancer;
LUAD	cis	rs12760731	0.720	rs12039605	chr1:178433368	C/T	cg00404053	chr1:178313656	RASAL2	0.66	8.34	0.38	1.06e-15	Obesity-related traits;
LUAD	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg14092988	chr3:52407081	DNAH1	0.37	7.47	0.34	4.74e-13	Bipolar disorder;
LUAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg20607798	chr8:58055168	NA	0.58	7.41	0.34	6.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg08132940	chr7:1081526	C7orf50	-0.77	-10.31	-0.45	2.21e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.3	-0.41	7.8e-19	Life satisfaction;
LUAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg24642844	chr7:1081250	C7orf50	-0.83	-13.41	-0.55	2.03e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg00634984	chr7:65235879	NA	-0.47	-6.45	-0.3	3.11e-10	Aortic root size;
LUAD	trans	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.09	-0.33	5.6e-12	Neuroticism;
LUAD	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg00933542	chr6:150070202	PCMT1	0.45	10.06	0.44	1.79e-21	Lung cancer;
LUAD	cis	rs10465746	0.780	rs4907190	chr1:84409168	T/C	cg10977910	chr1:84465055	TTLL7	0.59	9.72	0.43	2.76e-20	Obesity-related traits;
LUAD	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg13385794	chr1:248469461	NA	0.24	6.44	0.3	3.25e-10	Common traits (Other);
LUAD	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-7.87	-0.36	2.94e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06873352	chr17:61820015	STRADA	0.82	18.18	0.66	5.66e-55	Prudent dietary pattern;
LUAD	cis	rs7172809	0.524	rs4886852	chr15:77417173	A/T	cg11865553	chr15:77376250	NA	-0.39	-6.43	-0.3	3.53e-10	Glucose homeostasis traits;
LUAD	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.48	0.45	5.26e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs7680126	0.595	rs17251963	chr4:10142561	A/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-7.17	-0.33	3.34e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg19980929	chr12:42632907	YAF2	-0.34	-6.52	-0.3	1.98e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg10729496	chr3:10149963	C3orf24	0.59	9.7	0.43	3.2e-20	Alzheimer's disease;
LUAD	cis	rs62238980	0.614	rs1967470	chr22:32424480	A/G	cg00543991	chr22:32367038	NA	0.81	7.87	0.36	2.91e-14	Childhood ear infection;
LUAD	cis	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.37	-6.76	-0.31	4.49e-11	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9826463	0.582	rs11720762	chr3:142140511	T/G	cg20824294	chr3:142316082	PLS1	0.36	6.42	0.3	3.58e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.35	7.22	0.33	2.35e-12	Hemoglobin concentration;
LUAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg07685180	chr8:600429	NA	-0.75	-8.16	-0.37	3.94e-15	IgG glycosylation;
LUAD	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg15017067	chr4:17643749	FAM184B	-0.38	-7.44	-0.34	5.75e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7192380	0.928	rs12933210	chr16:69742048	A/T	cg26679644	chr16:69762563	NA	-0.51	-9.76	-0.43	1.97e-20	Sjögren's syndrome;
LUAD	cis	rs758324	0.947	rs2404778	chr5:131172886	T/C	cg06307176	chr5:131281290	NA	0.51	8.16	0.37	3.83e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg00981070	chr1:2046702	PRKCZ	-0.35	-7.07	-0.32	6.6e-12	Height;
LUAD	cis	rs1143633	0.662	rs12990810	chr2:113642532	G/T	cg12858261	chr2:113808755	IL1F8	-0.39	-6.75	-0.31	4.94e-11	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg25554036	chr4:6271136	WFS1	0.62	11.26	0.48	6.91e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg01017244	chr2:74357527	NA	0.89	14.5	0.58	5.84e-39	Gestational age at birth (maternal effect);
LUAD	trans	rs1864729	1.000	rs2583506	chr8:98281847	G/A	cg08679828	chr8:102218111	ZNF706	-0.83	-8.79	-0.39	3.88e-17	Estradiol plasma levels (breast cancer);
LUAD	cis	rs68170813	0.559	rs76208112	chr7:106964222	C/T	cg23024343	chr7:107201750	COG5	0.5	7.18	0.33	3.21e-12	Coronary artery disease;
LUAD	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg03526776	chr6:41159608	TREML2	0.34	7.24	0.33	2.13e-12	Alzheimer's disease (late onset);
LUAD	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg10578991	chr7:12443926	VWDE	0.46	6.64	0.31	9.45e-11	Coronary artery disease;
LUAD	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg20503657	chr10:835505	NA	0.99	15.0	0.59	4.54e-41	Eosinophil percentage of granulocytes;
LUAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg00280220	chr17:61926910	NA	0.36	6.92	0.32	1.63e-11	Prudent dietary pattern;
LUAD	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18404041	chr3:52824283	ITIH1	-0.72	-16.26	-0.62	1.65e-46	Bipolar disorder;
LUAD	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	9.4e-15	Tonsillectomy;
LUAD	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg16329650	chr2:213403929	ERBB4	0.6	10.88	0.47	1.72e-24	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14893161	chr1:205819251	PM20D1	0.62	11.69	0.49	1.55e-27	Menarche (age at onset);
LUAD	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18404041	chr3:52824283	ITIH1	-0.58	-12.0	-0.5	9.42e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs870825	0.616	rs4623061	chr4:185643161	A/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.03	0.56	5.61e-37	Blood protein levels;
LUAD	cis	rs2479724	0.840	rs6925777	chr6:41750822	C/T	cg17623882	chr6:41773611	USP49	0.7	13.09	0.54	4.05e-33	Menarche (age at onset);
LUAD	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg13010199	chr12:38710504	ALG10B	0.4	6.56	0.3	1.6e-10	Bladder cancer;
LUAD	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg24399712	chr22:39784796	NA	0.82	15.72	0.61	3.36e-44	Intelligence (multi-trait analysis);
LUAD	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg18016565	chr1:150552671	MCL1	0.41	7.42	0.34	6.65e-13	Tonsillectomy;
LUAD	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg15017067	chr4:17643749	FAM184B	0.33	6.38	0.3	4.72e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg13770153	chr20:60521292	NA	-0.47	-8.18	-0.37	3.41e-15	Body mass index;
LUAD	cis	rs7072216	0.763	rs6584205	chr10:100173806	C/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.7	-0.39	7.57e-17	Metabolite levels;
LUAD	cis	rs9323205	0.723	rs55980461	chr14:51737434	G/A	cg23942311	chr14:51606299	NA	-0.56	-7.96	-0.36	1.6e-14	Cancer;
LUAD	cis	rs593982	0.925	rs585272	chr11:65505289	A/G	cg08755490	chr11:65554678	OVOL1	1.32	20.39	0.7	7.08e-65	Atopic dermatitis;
LUAD	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg03433033	chr1:76189801	ACADM	0.9	18.17	0.66	5.75e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg15557168	chr22:42548783	NA	-0.45	-8.34	-0.38	1.03e-15	Cognitive function;
LUAD	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg08632164	chr7:65971372	NA	-0.55	-6.37	-0.3	4.93e-10	Diabetic kidney disease;
LUAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg18402987	chr7:1209562	NA	0.5	7.42	0.34	6.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06544989	chr22:39130855	UNC84B	0.43	8.03	0.36	9.95e-15	Menopause (age at onset);
LUAD	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg18190219	chr22:46762943	CELSR1	-0.44	-6.48	-0.3	2.54e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg17366294	chr4:99064904	C4orf37	-0.48	-8.35	-0.38	9.53e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6906287	0.647	rs2213857	chr6:118806780	A/G	cg05564266	chr6:118973597	C6orf204	0.34	7.28	0.33	1.63e-12	Electrocardiographic conduction measures;
LUAD	cis	rs9875589	0.509	rs4685051	chr3:13981760	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.35	6.42	0.3	3.61e-10	Ovarian reserve;
LUAD	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg12365402	chr11:9010492	NRIP3	0.49	9.2	0.41	1.69e-18	Hemoglobin concentration;
LUAD	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg03929089	chr4:120376271	NA	-0.97	-19.5	-0.69	6.71e-61	Height;
LUAD	cis	rs11249608	0.548	rs35568336	chr5:178451854	A/G	cg01312482	chr5:178451176	ZNF879	-0.42	-6.53	-0.3	1.91e-10	Pubertal anthropometrics;
LUAD	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg04586622	chr2:25135609	ADCY3	0.32	7.17	0.33	3.33e-12	Body mass index in non-asthmatics;
LUAD	cis	rs2625529	0.938	rs2625530	chr15:72126034	G/A	cg16672083	chr15:72433130	SENP8	-0.72	-11.32	-0.48	3.9e-26	Red blood cell count;
LUAD	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg23252815	chr20:44420276	WFDC3;DNTTIP1	0.39	6.45	0.3	3.12e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08219700	chr8:58056026	NA	0.6	8.58	0.38	1.86e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7680126	0.596	rs714436	chr4:10314667	A/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.69	-0.31	7.29e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7737355	0.738	rs55955246	chr5:131078498	C/G	cg25547332	chr5:131281432	NA	0.42	6.7	0.31	6.8e-11	Life satisfaction;
LUAD	cis	rs12760731	0.720	rs11805590	chr1:178308911	A/G	cg00404053	chr1:178313656	RASAL2	0.58	8.29	0.37	1.49e-15	Obesity-related traits;
LUAD	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg13319975	chr6:146136371	FBXO30	-0.65	-11.26	-0.48	6.65e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11951515	0.899	rs6883936	chr5:43399164	T/C	cg01983248	chr5:43482804	C5orf28	-0.35	-6.78	-0.31	4.08e-11	Metabolite levels  (X-11787);
LUAD	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.8	0.35	4.77e-14	Breast cancer;
LUAD	cis	rs11249608	0.636	rs13359572	chr5:178449276	T/C	cg01312482	chr5:178451176	ZNF879	-0.45	-6.98	-0.32	1.14e-11	Pubertal anthropometrics;
LUAD	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg16797656	chr11:68205561	LRP5	-0.46	-9.87	-0.43	7.92e-21	Total body bone mineral density;
LUAD	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27286337	chr10:134555280	INPP5A	0.65	9.53	0.42	1.23e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg00204512	chr16:28754710	NA	0.32	6.89	0.32	1.98e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs12545109	0.837	rs6474063	chr8:57355545	C/T	cg11919837	chr8:57350735	NA	-0.49	-7.0	-0.32	1.04e-11	Obesity-related traits;
LUAD	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg27490568	chr2:178487706	NA	0.41	6.92	0.32	1.7e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.92	0.4	1.44e-17	Gut microbiome composition (summer);
LUAD	trans	rs258892	0.947	rs266448	chr5:72182229	G/A	cg14879065	chr14:104662468	NA	-0.35	-6.39	-0.3	4.45e-10	Small cell lung carcinoma;
LUAD	cis	rs9925964	0.967	rs12716981	chr16:31118024	C/A	cg03418659	chr16:31128414	MYST1	0.45	7.82	0.36	4.29e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1950626	0.743	rs1956734	chr14:101399830	A/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.35	-6.71	-0.31	6.11e-11	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg25237894	chr2:233734115	C2orf82	-0.48	-9.18	-0.41	1.86e-18	Coronary artery disease;
LUAD	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg23719950	chr11:63933701	MACROD1	-0.6	-7.09	-0.33	5.83e-12	Mean platelet volume;
LUAD	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.42	-0.38	6.04e-16	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.16	0.37	3.85e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11214589	0.870	rs10789942	chr11:113236199	C/T	cg14159747	chr11:113255604	NA	-0.67	-14.65	-0.58	1.3e-39	Neuroticism;
LUAD	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2479724	1.000	rs1536703	chr6:41852755	C/T	cg17623882	chr6:41773611	USP49	-0.59	-10.82	-0.47	2.9e-24	Menarche (age at onset);
LUAD	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg02743256	chr7:2109353	MAD1L1	-0.48	-6.62	-0.31	1.12e-10	Bipolar disorder;
LUAD	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg04287289	chr16:89883240	FANCA	0.71	12.97	0.53	1.33e-32	Vitiligo;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg15260365	chr11:67771606	UNC93B1	0.4	6.4	0.3	4.2e-10	Optic cup area;
LUAD	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.69	10.57	0.46	2.58e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg00318621	chr2:106887213	NA	-0.44	-6.8	-0.31	3.5e-11	Facial morphology (factor 23);
LUAD	trans	rs9784649	1.000	rs11738315	chr5:24967891	T/C	cg11038491	chr20:34638489	LOC647979	-0.62	-7.98	-0.36	1.38e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6446731	0.517	rs2071668	chr4:3269905	A/G	cg08886695	chr4:3369023	RGS12	0.46	7.68	0.35	1.08e-13	Mean platelet volume;
LUAD	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg03806693	chr22:41940476	POLR3H	-0.74	-9.79	-0.43	1.55e-20	Vitiligo;
LUAD	cis	rs738322	0.577	rs6001034	chr22:38558459	A/G	cg25457927	chr22:38595422	NA	-0.54	-12.79	-0.53	7.03e-32	Cutaneous nevi;
LUAD	cis	rs7512552	0.839	rs698919	chr1:150387000	A/G	cg15654264	chr1:150340011	RPRD2	0.58	11.15	0.48	1.81e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2625529	0.730	rs6494975	chr15:72177825	T/A	cg16672083	chr15:72433130	SENP8	0.66	12.13	0.51	2.82e-29	Red blood cell count;
LUAD	trans	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg26043149	chr18:55253948	FECH	-0.41	-6.71	-0.31	6.4e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg12365402	chr11:9010492	NRIP3	-0.44	-8.47	-0.38	4.02e-16	Hemoglobin concentration;
LUAD	cis	rs4786125	0.636	rs9932626	chr16:6917014	C/G	cg03623568	chr16:6915990	A2BP1	-0.48	-10.29	-0.45	2.6e-22	Heart rate variability traits (SDNN);
LUAD	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg04511125	chr2:88470314	THNSL2	0.8	8.64	0.39	1.2e-16	Plasma clusterin levels;
LUAD	trans	rs7395662	0.963	rs11039937	chr11:48712582	G/A	cg15704280	chr7:45808275	SEPT13	-0.41	-6.35	-0.3	5.43e-10	HDL cholesterol;
LUAD	cis	rs13190036	0.551	rs7732930	chr5:176548594	C/T	cg06733329	chr5:176740039	MXD3	0.47	6.95	0.32	1.4e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	cis	rs13064411	0.696	rs11921931	chr3:113015091	G/A	cg18753928	chr3:113234510	CCDC52	-0.55	-8.17	-0.37	3.7e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.41	-0.34	6.84e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg20476274	chr7:133979776	SLC35B4	-0.55	-9.24	-0.41	1.22e-18	Mean platelet volume;
LUAD	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.42	6.96	0.32	1.32e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg25324976	chr17:61989376	CSHL1	0.38	7.36	0.34	9.74e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg18252515	chr7:66147081	NA	-0.61	-6.62	-0.31	1.11e-10	Diabetic kidney disease;
LUAD	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg00898013	chr13:113819073	PROZ	-0.65	-11.96	-0.5	1.32e-28	Platelet distribution width;
LUAD	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg03433033	chr1:76189801	ACADM	-0.45	-6.52	-0.3	1.98e-10	Daytime sleep phenotypes;
LUAD	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.85	-0.4	2.47e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7116495	1.000	rs2511079	chr11:71804154	C/T	cg07596299	chr11:71824057	C11orf51	-0.73	-6.62	-0.31	1.1e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.43	8.25	0.37	2e-15	Total body bone mineral density;
LUAD	cis	rs57994353	0.897	rs3812594	chr9:139368953	G/A	cg14364472	chr9:139394549	NOTCH1	-0.45	-6.73	-0.31	5.57e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg04756594	chr16:24857601	SLC5A11	0.72	12.22	0.51	1.32e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs6496044	0.527	rs7163068	chr15:86072466	T/C	cg13263323	chr15:86062960	AKAP13	-0.57	-10.7	-0.46	8.06e-24	Interstitial lung disease;
LUAD	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.53	0.42	1.28e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg18446336	chr7:2847575	GNA12	-0.32	-6.47	-0.3	2.68e-10	Height;
LUAD	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg00933542	chr6:150070202	PCMT1	0.41	8.69	0.39	8.09e-17	Lung cancer;
LUAD	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg24112000	chr20:60950667	NA	-0.88	-13.88	-0.56	2.37e-36	Colorectal cancer;
LUAD	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg06784218	chr1:46089804	CCDC17	-0.53	-11.84	-0.5	3.99e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2455799	0.593	rs13078487	chr3:15929590	G/T	cg16303742	chr3:15540471	COLQ	-0.46	-8.45	-0.38	4.72e-16	Mean platelet volume;
LUAD	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg12458913	chr13:53173898	NA	0.51	9.04	0.4	5.58e-18	Lewy body disease;
LUAD	cis	rs796364	0.589	rs55700082	chr2:201135669	G/A	cg17644776	chr2:200775616	C2orf69	-0.49	-6.75	-0.31	4.9e-11	Schizophrenia;
LUAD	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg26408565	chr15:76604113	ETFA	0.43	7.15	0.33	3.79e-12	Blood metabolite levels;
LUAD	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.57	9.68	0.43	3.91e-20	Cognitive ability;
LUAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02359409	chr6:42947317	PEX6	-0.37	-6.6	-0.31	1.26e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg06627628	chr2:24431161	ITSN2	0.69	11.63	0.49	2.58e-27	Asthma;
LUAD	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15506890	chr2:3487001	NA	-0.41	-6.99	-0.32	1.07e-11	Neurofibrillary tangles;
LUAD	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.9	-0.36	2.45e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg07362569	chr17:61921086	SMARCD2	0.39	6.74	0.31	5.12e-11	Prudent dietary pattern;
LUAD	trans	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.7	-0.31	6.5500000000000006e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3806843	0.576	rs251370	chr5:140246287	C/T	cg18668511	chr5:140557227	PCDHB8	0.4	7.34	0.34	1.1e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	6.91	0.32	1.76e-11	Platelet count;
LUAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg13397359	chr6:42928475	GNMT	0.65	13.04	0.54	6.83e-33	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg02734326	chr4:10020555	SLC2A9	0.64	11.33	0.48	3.73e-26	Bone mineral density;
LUAD	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg04287289	chr16:89883240	FANCA	0.71	6.66	0.31	8.69e-11	Skin colour saturation;
LUAD	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg02228675	chr17:40259724	DHX58	-0.43	-6.91	-0.32	1.83e-11	Fibrinogen levels;
LUAD	cis	rs28655083	0.636	rs1485793	chr16:77101836	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.47	-7.16	-0.33	3.64e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg09491104	chr22:46646882	C22orf40	-0.59	-7.8	-0.35	5e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg22920501	chr2:26401640	FAM59B	-0.98	-15.3	-0.6	2.34e-42	Gut microbiome composition (summer);
LUAD	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg11266682	chr4:10021025	SLC2A9	0.56	12.11	0.51	3.46e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9902453	1.000	rs9896062	chr17:28357047	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.26	-0.41	1e-18	Coffee consumption (cups per day);
LUAD	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg05182265	chr7:156933206	UBE3C	0.81	17.44	0.65	1.03e-51	Body mass index;
LUAD	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg12310025	chr6:25882481	NA	-0.58	-9.55	-0.42	1.06e-19	Blood metabolite levels;
LUAD	cis	rs9341808	0.667	rs742833	chr6:80921446	C/T	cg08355045	chr6:80787529	NA	0.49	8.75	0.39	4.98e-17	Sitting height ratio;
LUAD	cis	rs7493	0.901	rs11767787	chr7:95026753	T/C	cg19678392	chr7:94953810	PON1	-0.61	-8.71	-0.39	6.95e-17	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs829883	0.664	rs829874	chr12:98840615	G/A	cg25150519	chr12:98850993	NA	0.72	13.4	0.55	2.22e-34	Colorectal adenoma (advanced);
LUAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg15117754	chr3:10150083	C3orf24	0.41	6.63	0.31	1.02e-10	Alzheimer's disease;
LUAD	cis	rs12545109	0.879	rs1513317	chr8:57372966	C/G	cg21220214	chr8:57350948	NA	-0.66	-9.13	-0.41	2.89e-18	Obesity-related traits;
LUAD	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg26384229	chr12:38710491	ALG10B	0.42	7.04	0.32	7.82e-12	Heart rate;
LUAD	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.3	-6.79	-0.31	3.87e-11	Dupuytren's disease;
LUAD	cis	rs7216064	0.906	rs1976052	chr17:65830578	C/T	cg08758996	chr17:66097529	LOC651250	0.46	6.62	0.31	1.09e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs977987	0.778	rs4888409	chr16:75436231	A/T	cg03315344	chr16:75512273	CHST6	0.64	14.14	0.57	1.96e-37	Dupuytren's disease;
LUAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08219700	chr8:58056026	NA	0.61	8.59	0.39	1.64e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6543140	0.964	rs4851578	chr2:103028951	T/G	cg04239558	chr2:103089729	SLC9A4	0.35	6.95	0.32	1.41e-11	Blood protein levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg18331880	chr14:102991394	NA	-0.42	-6.97	-0.32	1.19e-11	Cancer;
LUAD	trans	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg11693508	chr17:37793320	STARD3	0.49	7.2	0.33	2.69e-12	Neuroticism;
LUAD	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg04539111	chr16:67997858	SLC12A4	0.52	6.44	0.3	3.2e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1444418	1.000	rs10995309	chr10:64560878	A/G	cg14943953	chr10:64564468	ADO	0.58	7.03	0.32	8.34e-12	Atopic dermatitis;
LUAD	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg17595323	chr11:93583763	C11orf90	-0.43	-9.09	-0.4	3.96e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	trans	rs991427	1.000	rs73197056	chr12:91473658	A/C	cg11428724	chr1:18957632	PAX7	0.42	6.49	0.3	2.37e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs375066	0.592	rs349045	chr19:44299892	A/G	cg11993925	chr19:44307056	LYPD5	-0.37	-7.41	-0.34	6.76e-13	Breast cancer;
LUAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg27532560	chr4:187881888	NA	-0.35	-6.66	-0.31	8.44e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.6	8.5	0.38	3.33e-16	Gut microbiome composition (summer);
LUAD	cis	rs3125734	0.572	rs7896627	chr10:64046354	T/G	cg09941381	chr10:64027924	RTKN2	-0.31	-7.19	-0.33	3.05e-12	Rheumatoid arthritis;
LUAD	cis	rs870825	0.616	rs2130393	chr4:185642335	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.7	0.55	1.26e-35	Blood protein levels;
LUAD	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg26384229	chr12:38710491	ALG10B	0.52	8.22	0.37	2.48e-15	Bladder cancer;
LUAD	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg15704280	chr7:45808275	SEPT13	-1.06	-23.72	-0.76	1.02e-79	Height;
LUAD	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg04703951	chr17:43578652	NA	-0.56	-8.07	-0.37	7.36e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg22920501	chr2:26401640	FAM59B	-0.76	-10.96	-0.47	8.8e-25	Gut microbiome composition (summer);
LUAD	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg11663144	chr21:46675770	NA	-0.57	-11.21	-0.48	1.02e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.43	-7.93	-0.36	1.96e-14	Systemic lupus erythematosus;
LUAD	cis	rs494562	0.892	rs522129	chr6:86116381	A/G	cg13315970	chr6:86159197	NT5E	0.73	8.25	0.37	2e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg18306943	chr3:40428807	ENTPD3	0.43	7.3	0.33	1.46e-12	Renal cell carcinoma;
LUAD	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg13010199	chr12:38710504	ALG10B	-0.39	-6.58	-0.3	1.4e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg26114124	chr12:9217669	LOC144571	0.4	7.22	0.33	2.48e-12	Sjögren's syndrome;
LUAD	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg16325326	chr1:53192061	ZYG11B	0.67	12.98	0.53	1.14e-32	Monocyte count;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22015966	chr11:47198573	ARFGAP2	-0.54	-6.53	-0.3	1.94e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2979489	0.786	rs1106352	chr8:30404671	C/T	cg26383811	chr8:30366931	RBPMS	-0.69	-10.97	-0.47	8.34e-25	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg11494091	chr17:61959527	GH2	0.45	8.54	0.38	2.38e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4148087	0.860	rs4148102	chr21:43641347	A/G	cg08841829	chr21:43638893	ABCG1	0.53	7.37	0.34	8.89e-13	Eating disorder in bipolar disorder;
LUAD	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg08470875	chr2:26401718	FAM59B	-0.62	-8.45	-0.38	4.6e-16	Gut microbiome composition (summer);
LUAD	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg14343924	chr8:8086146	FLJ10661	0.46	6.95	0.32	1.4e-11	Joint mobility (Beighton score);
LUAD	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26314531	chr2:26401878	FAM59B	-0.58	-7.99	-0.36	1.33e-14	Gut microbiome composition (summer);
LUAD	trans	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg26043149	chr18:55253948	FECH	0.5	8.12	0.37	5.02e-15	Bone mineral density;
LUAD	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg01200585	chr1:228362443	C1orf69	-0.39	-7.1	-0.33	5.38e-12	Diastolic blood pressure;
LUAD	cis	rs7180079	1.000	rs28444557	chr15:64549993	A/G	cg08069370	chr15:64387884	SNX1	-0.51	-6.54	-0.3	1.81e-10	Monocyte count;
LUAD	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg08859206	chr1:53392774	SCP2	0.65	11.91	0.5	2.01e-28	Monocyte count;
LUAD	cis	rs829883	0.646	rs249838	chr12:98874749	C/G	cg25150519	chr12:98850993	NA	0.39	6.45	0.3	2.98e-10	Colorectal adenoma (advanced);
LUAD	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg24642844	chr7:1081250	C7orf50	-0.64	-7.74	-0.35	7.41e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg07741184	chr6:167504864	NA	0.35	8.35	0.38	1.02e-15	Primary biliary cholangitis;
LUAD	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg23262073	chr20:60523788	NA	-0.65	-10.44	-0.45	7.32e-23	Obesity-related traits;
LUAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg08219700	chr8:58056026	NA	0.54	7.57	0.35	2.44e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs55665837	1.000	rs12295888	chr11:14450531	T/C	cg19336497	chr11:14380999	RRAS2	-0.51	-10.3	-0.45	2.45e-22	Vitamin D levels;
LUAD	cis	rs68170813	0.599	rs12532849	chr7:106959226	A/C	cg23024343	chr7:107201750	COG5	0.5	7.18	0.33	3.24e-12	Coronary artery disease;
LUAD	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg27529037	chr20:44575021	PCIF1	0.48	8.51	0.38	2.96e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7737355	0.947	rs7720339	chr5:130837134	T/C	cg25547332	chr5:131281432	NA	0.42	6.36	0.3	5.27e-10	Life satisfaction;
LUAD	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg17177755	chr1:15930204	NA	0.48	7.58	0.35	2.22e-13	Systolic blood pressure;
LUAD	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg26566898	chr11:117069891	TAGLN	0.35	6.85	0.32	2.65e-11	Blood protein levels;
LUAD	cis	rs11048434	0.761	rs12827988	chr12:9130287	A/G	cg23795048	chr12:9217529	LOC144571	0.44	7.9	0.36	2.43e-14	Sjögren's syndrome;
LUAD	cis	rs9323205	0.798	rs4465517	chr14:51673715	C/A	cg23942311	chr14:51606299	NA	0.54	9.18	0.41	1.89e-18	Cancer;
LUAD	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg22823121	chr1:150693482	HORMAD1	0.45	8.55	0.38	2.31e-16	Melanoma;
LUAD	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg25036284	chr2:26402008	FAM59B	-0.68	-9.24	-0.41	1.26e-18	Gut microbiome composition (summer);
LUAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.29	0.41	7.9e-19	Alzheimer's disease;
LUAD	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg26408565	chr15:76604113	ETFA	-0.58	-10.48	-0.45	5.32e-23	Blood metabolite levels;
LUAD	cis	rs41311933	0.561	rs41309866	chr9:123774889	T/C	cg13567360	chr9:123745713	C5	-0.73	-8.48	-0.38	3.67e-16	Coronary artery disease;
LUAD	cis	rs6684514	1.000	rs12040868	chr1:156284803	G/T	cg16558208	chr1:156270281	VHLL	0.56	10.1	0.44	1.3e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	trans	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs7020830	0.898	rs506981	chr9:37351348	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.77	-15.3	-0.6	2.27e-42	Schizophrenia;
LUAD	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.23	-0.37	2.3e-15	Breast cancer;
LUAD	cis	rs3784262	0.669	rs3742959	chr15:58249113	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.45	-0.34	5.14e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs6674176	0.932	rs4660761	chr1:44440146	G/A	cg13606994	chr1:44402422	ARTN	-0.4	-7.46	-0.34	4.95e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg25985355	chr7:65971099	NA	-0.53	-6.58	-0.3	1.41e-10	Diabetic kidney disease;
LUAD	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg11859384	chr17:80120422	CCDC57	-0.48	-8.61	-0.39	1.41e-16	Life satisfaction;
LUAD	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg10295955	chr4:187884368	NA	-1.1	-27.79	-0.8	1.8299999999999999e-97	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg05084668	chr3:125655381	ALG1L	-0.69	-11.12	-0.48	2.33e-25	Blood pressure (smoking interaction);
LUAD	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg10755058	chr3:40428713	ENTPD3	0.46	8.7	0.39	7.56e-17	Renal cell carcinoma;
LUAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.3	-0.33	1.47e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg07570687	chr10:102243282	WNT8B	0.48	7.34	0.34	1.09e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg00080972	chr5:178986291	RUFY1	-0.65	-11.22	-0.48	9.75e-26	Lung cancer;
LUAD	cis	rs11190604	0.832	rs2489041	chr10:102333635	G/C	cg07570687	chr10:102243282	WNT8B	0.48	6.59	0.31	1.33e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs28595532	0.748	rs17594978	chr4:119336398	T/C	cg21605333	chr4:119757512	SEC24D	0.69	6.75	0.31	4.86e-11	Cannabis dependence symptom count;
LUAD	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9595066	0.627	rs4432167	chr13:44752361	C/G	cg04068111	chr13:44716778	NA	0.42	7.43	0.34	5.95e-13	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs731174	0.797	rs565316	chr1:38157624	T/C	cg06917450	chr1:38156652	C1orf109	-0.43	-6.64	-0.31	9.62e-11	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg26354017	chr1:205819088	PM20D1	0.81	17.06	0.64	5.12e-50	Menarche (age at onset);
LUAD	cis	rs977987	0.778	rs12929908	chr16:75462071	C/T	cg03315344	chr16:75512273	CHST6	0.65	14.01	0.56	6.59e-37	Dupuytren's disease;
LUAD	cis	rs62229266	0.771	rs11701590	chr21:37384730	A/C	cg12218747	chr21:37451666	NA	-0.48	-8.23	-0.37	2.31e-15	Mitral valve prolapse;
LUAD	cis	rs4964805	0.657	rs4964813	chr12:104189554	T/C	cg02344784	chr12:104178138	NT5DC3	0.45	9.28	0.41	8.83e-19	Attention deficit hyperactivity disorder;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg15216925	chr5:179921655	CNOT6	0.36	6.48	0.3	2.55e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs733175	0.855	rs10023068	chr4:10004832	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.13	-0.33	4.29e-12	Psychosis and Alzheimer's disease;
LUAD	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-6.78	-0.31	4e-11	Daytime sleep phenotypes;
LUAD	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg05340658	chr4:99064831	C4orf37	0.53	9.01	0.4	7.06e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg19163074	chr7:65112434	INTS4L2	0.42	6.36	0.3	5.19e-10	Aortic root size;
LUAD	cis	rs9902453	1.000	rs4328498	chr17:28344276	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.21	-0.41	1.49e-18	Coffee consumption (cups per day);
LUAD	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg14343924	chr8:8086146	FLJ10661	-0.44	-7.14	-0.33	4.07e-12	Mood instability;
LUAD	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg16049864	chr8:95962084	TP53INP1	-0.4	-7.22	-0.33	2.39e-12	Type 2 diabetes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22127215	chr17:4613552	ARRB2	-0.44	-6.74	-0.31	5.33e-11	Height;
LUAD	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg12311346	chr5:56204834	C5orf35	-0.61	-10.04	-0.44	1.97e-21	Coronary artery disease;
LUAD	cis	rs4589502	0.925	rs57729347	chr15:67136438	G/A	cg09911534	chr15:67153556	NA	-0.4	-6.44	-0.3	3.25e-10	Lung cancer (smoking interaction);
LUAD	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.78	-0.43	1.63e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00149659	chr3:10157352	C3orf10	0.56	7.18	0.33	3.21e-12	Alzheimer's disease;
LUAD	trans	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg10208301	chr11:6592745	DNHD1	0.5	6.42	0.3	3.67e-10	Coronary artery calcification;
LUAD	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.33	0.54	4.38e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg00047079	chr13:79188975	RNF219	-0.45	-7.2	-0.33	2.86e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg14416269	chr4:6271139	WFS1	0.64	13.13	0.54	2.81e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs73206853	0.841	rs73206894	chr12:110876328	C/T	cg12870014	chr12:110450643	ANKRD13A	0.59	6.4	0.3	4.03e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.43	-8.01	-0.36	1.15e-14	Cystic fibrosis severity;
LUAD	cis	rs7258465	0.896	rs8103660	chr19:18566395	T/C	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.48	-0.34	4.2e-13	Breast cancer;
LUAD	cis	rs11893307	0.537	rs57780226	chr2:191547865	C/G	cg27211696	chr2:191398769	TMEM194B	-0.41	-6.44	-0.3	3.19e-10	Mean platelet volume;
LUAD	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg27144592	chr16:783916	NARFL	0.37	6.76	0.31	4.58e-11	Height;
LUAD	cis	rs12612619	0.704	rs3769139	chr2:27315714	C/T	cg00617064	chr2:27272375	NA	-0.37	-7.05	-0.32	7.32e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs909002	0.886	rs10798880	chr1:32097088	G/T	cg13919466	chr1:32135498	COL16A1	-0.35	-8.11	-0.37	5.71e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.71	-0.31	6.45e-11	Depression;
LUAD	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg16701003	chr16:89028210	CBFA2T3	0.51	10.53	0.46	3.4e-23	Social autistic-like traits;
LUAD	trans	rs6074578	0.902	rs6033484	chr20:185926	A/G	cg00926192	chr17:42297085	UBTF	-0.36	-6.47	-0.3	2.78e-10	Hirschsprung disease;
LUAD	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg18225595	chr11:63971243	STIP1	0.51	8.67	0.39	9.61e-17	Platelet count;
LUAD	cis	rs4953076	0.533	rs1551315	chr2:44407618	G/A	cg04920474	chr2:44395004	PPM1B	0.56	8.74	0.39	5.5e-17	Height;
LUAD	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg08470875	chr2:26401718	FAM59B	-0.6	-8.2	-0.37	2.96e-15	Gut microbiome composition (summer);
LUAD	cis	rs7072216	1.000	rs7072216	chr10:100156853	A/G	cg26618903	chr10:100175079	PYROXD2	-0.3	-6.66	-0.31	8.54e-11	Metabolite levels;
LUAD	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg08807101	chr21:30365312	RNF160	0.52	8.95	0.4	1.12e-17	Dental caries;
LUAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.49	6.52	0.3	2.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.46	7.73	0.35	7.88e-14	Blood metabolite levels;
LUAD	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg11584989	chr19:19387371	SF4	0.35	6.39	0.3	4.28e-10	Tonsillectomy;
LUAD	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg27535305	chr1:53392650	SCP2	0.31	6.64	0.31	9.69e-11	Monocyte count;
LUAD	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg21214613	chr1:16344536	HSPB7	0.55	9.76	0.43	2.03e-20	Dilated cardiomyopathy;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02842104	chr19:12251201	ZNF20	-0.53	-6.39	-0.3	4.49e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg18512352	chr11:47633146	NA	0.46	8.17	0.37	3.69e-15	Subjective well-being;
LUAD	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg17200465	chr3:40428508	ENTPD3	0.27	6.4	0.3	4.22e-10	Renal cell carcinoma;
LUAD	cis	rs17102423	0.740	rs35520739	chr14:65577612	T/C	cg11161011	chr14:65562177	MAX	0.39	6.55	0.3	1.68e-10	Obesity-related traits;
LUAD	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg13319975	chr6:146136371	FBXO30	0.59	9.83	0.43	1.11e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	7.07	0.33	6.36e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	9.72	0.43	2.82e-20	Axial length;
LUAD	cis	rs16866061	1.000	rs12470077	chr2:225334971	T/C	cg12698349	chr2:225449008	CUL3	0.75	13.18	0.54	1.75e-33	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs7010267	0.870	rs7014574	chr8:119977077	C/T	cg01975934	chr8:119970761	NA	-0.37	-7.21	-0.33	2.63e-12	Total body bone mineral density (age 45-60);
LUAD	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg23533926	chr12:111358616	MYL2	-0.4	-6.8	-0.31	3.48e-11	Extrinsic epigenetic age acceleration;
LUAD	trans	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.4	0.45	1.02e-22	Mean corpuscular volume;
LUAD	cis	rs8049603	0.754	rs5721	chr16:23194250	C/G	cg09552652	chr16:23197569	SCNN1G	0.37	6.4	0.3	4.14e-10	Multiple sclerosis;
LUAD	trans	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.59	-10.02	-0.44	2.43e-21	Mean corpuscular volume;
LUAD	cis	rs300774	0.925	rs12233125	chr2:118611	A/T	cg21211680	chr2:198530	NA	-0.49	-7.05	-0.32	7.44e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs4148087	0.932	rs2839476	chr21:43609680	A/T	cg08841829	chr21:43638893	ABCG1	-0.56	-7.44	-0.34	5.77e-13	Eating disorder in bipolar disorder;
LUAD	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg22823121	chr1:150693482	HORMAD1	0.39	7.57	0.35	2.33e-13	Melanoma;
LUAD	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg22532475	chr10:104410764	TRIM8	-0.42	-8.31	-0.37	1.32e-15	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs977987	0.806	rs1364077	chr16:75396991	C/T	cg03315344	chr16:75512273	CHST6	0.64	13.98	0.56	9.05e-37	Dupuytren's disease;
LUAD	cis	rs13082711	0.689	rs34641383	chr3:27320210	G/A	cg02860705	chr3:27208620	NA	0.82	12.28	0.51	7.74e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg07169764	chr2:136633963	MCM6	-0.59	-7.33	-0.34	1.15e-12	Corneal structure;
LUAD	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg23711669	chr6:146136114	FBXO30	-0.37	-6.41	-0.3	3.98e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.63	-0.31	1.02e-10	Systolic blood pressure;
LUAD	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg17761419	chr8:57350749	NA	-0.51	-7.91	-0.36	2.29e-14	Obesity-related traits;
LUAD	cis	rs1595825	0.891	rs1968488	chr2:198721827	C/A	cg11031976	chr2:198649780	BOLL	-0.49	-7.21	-0.33	2.52e-12	Ulcerative colitis;
LUAD	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg14092988	chr3:52407081	DNAH1	0.39	7.82	0.36	4.21e-14	Electroencephalogram traits;
LUAD	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs9581857	0.547	rs9581876	chr13:28101113	T/C	cg22138327	chr13:27999177	GTF3A	0.89	9.29	0.41	8.01e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg05623727	chr3:50126028	RBM5	0.34	7.66	0.35	1.28e-13	Body mass index;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26433777	chr5:178157346	ZNF354A	-0.51	-6.44	-0.3	3.3e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg11901034	chr3:128598214	ACAD9	0.5	7.73	0.35	7.72e-14	IgG glycosylation;
LUAD	cis	rs4713118	1.000	rs1139226	chr6:27675290	A/T	cg20933634	chr6:27740509	NA	0.41	6.38	0.3	4.55e-10	Parkinson's disease;
LUAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg04025307	chr7:1156635	C7orf50	0.66	8.05	0.36	8.39e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg04414720	chr1:150670196	GOLPH3L	-0.47	-7.49	-0.34	3.94e-13	Tonsillectomy;
LUAD	cis	rs1865721	0.761	rs36002108	chr18:73220472	C/T	cg26385618	chr18:73139727	C18orf62	-0.36	-6.66	-0.31	8.28e-11	Intelligence;
LUAD	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-11.56	-0.49	4.8400000000000004e-27	Hemoglobin concentration;
LUAD	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg00129232	chr17:37814104	STARD3	-0.46	-8.29	-0.37	1.47e-15	Asthma;
LUAD	cis	rs6558530	0.965	rs4372027	chr8:1707958	T/C	cg17159058	chr8:1704075	NA	-0.4	-6.45	-0.3	3.04e-10	Systolic blood pressure;
LUAD	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg17200465	chr3:40428508	ENTPD3	0.27	6.35	0.3	5.42e-10	Renal cell carcinoma;
LUAD	cis	rs6594713	0.717	rs9326891	chr5:112873928	C/T	cg12552261	chr5:112820674	MCC	0.6	8.93	0.4	1.34e-17	Brain cytoarchitecture;
LUAD	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg09085632	chr11:111637200	PPP2R1B	0.61	9.14	0.41	2.57e-18	Primary sclerosing cholangitis;
LUAD	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.61	-0.35	1.78e-13	Menarche (age at onset);
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg01419084	chr19:36236615	PSENEN;U2AF1L4	0.36	6.44	0.3	3.32e-10	Bipolar disorder;
LUAD	cis	rs4691139	0.967	rs4588418	chr4:165902288	A/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.44	-8.79	-0.39	3.7e-17	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs7809950	0.773	rs9791733	chr7:107041730	T/C	cg23024343	chr7:107201750	COG5	-0.88	-14.35	-0.57	2.49e-38	Coronary artery disease;
LUAD	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg27490568	chr2:178487706	NA	0.41	6.93	0.32	1.62e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7215564	0.908	rs80183474	chr17:78655070	T/A	cg09596252	chr17:78655493	RPTOR	0.56	6.91	0.32	1.81e-11	Myopia (pathological);
LUAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg04025307	chr7:1156635	C7orf50	0.66	7.5	0.34	3.68e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg14582100	chr15:45693742	SPATA5L1	0.63	12.4	0.52	2.48e-30	Homoarginine levels;
LUAD	cis	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg07460842	chr6:66804631	NA	-0.71	-12.58	-0.52	4.89e-31	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.56	-8.93	-0.4	1.33e-17	Glomerular filtration rate;
LUAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.68	0.31	7.6e-11	Prudent dietary pattern;
LUAD	cis	rs12431939	1.000	rs11850391	chr14:51639759	A/G	cg23942311	chr14:51606299	NA	-0.58	-8.06	-0.36	8.12e-15	Cancer;
LUAD	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg14582100	chr15:45693742	SPATA5L1	0.61	11.67	0.49	1.75e-27	Homoarginine levels;
LUAD	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg12016809	chr21:47604291	C21orf56	0.45	7.51	0.34	3.64e-13	Testicular germ cell tumor;
LUAD	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg08999081	chr20:33150536	PIGU	0.6	13.24	0.54	1.05e-33	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg18180107	chr4:99064573	C4orf37	0.43	6.93	0.32	1.53e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.56	-0.35	2.47e-13	Blood metabolite levels;
LUAD	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg09455208	chr3:40491958	NA	0.52	10.85	0.47	2.22e-24	Renal cell carcinoma;
LUAD	cis	rs2742417	0.603	rs2673032	chr3:45756927	C/T	cg10512202	chr3:45649293	LIMD1	0.49	9.23	0.41	1.33e-18	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs2235649	0.833	rs9929185	chr16:1852070	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.48	-7.89	-0.36	2.58e-14	Blood metabolite levels;
LUAD	cis	rs4604732	0.631	rs1106721	chr1:247624676	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	9.21	0.41	1.59e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.79	-0.31	3.8e-11	Fear of minor pain;
LUAD	cis	rs1113500	0.862	rs3853494	chr1:108637334	G/A	cg06207961	chr1:108661230	NA	0.44	8.35	0.38	1.01e-15	Growth-regulated protein alpha levels;
LUAD	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg07936489	chr17:37558343	FBXL20	-0.52	-6.94	-0.32	1.47e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs1232027	0.700	rs1650715	chr5:79930741	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg27170947	chr2:26402098	FAM59B	-0.63	-8.92	-0.4	1.46e-17	Gut microbiome composition (summer);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17602823	chr1:28586543	SESN2	-0.53	-6.37	-0.3	4.97e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg03714773	chr7:91764589	CYP51A1	0.3	6.97	0.32	1.24e-11	Breast cancer;
LUAD	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg01689657	chr7:91764605	CYP51A1	0.28	6.75	0.31	4.92e-11	Breast cancer;
LUAD	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg26924012	chr15:45694286	SPATA5L1	-0.57	-9.42	-0.42	2.98e-19	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs7192380	0.965	rs9938213	chr16:69640590	T/C	cg26679644	chr16:69762563	NA	0.48	9.43	0.42	2.8e-19	Sjögren's syndrome;
LUAD	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg00757033	chr12:89920650	WDR51B	0.69	11.94	0.5	1.55e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg05340658	chr4:99064831	C4orf37	0.45	6.85	0.32	2.66e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7709909	0.532	rs73132417	chr5:79957038	T/C	cg24059623	chr5:79951536	MSH3;DHFR	0.47	6.9	0.32	1.92e-11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg26587870	chr6:27730563	NA	-0.44	-7.18	-0.33	3.15e-12	Parkinson's disease;
LUAD	cis	rs877282	0.838	rs11253374	chr10:774961	C/T	cg06581033	chr10:766294	NA	-0.5	-6.79	-0.31	3.93e-11	Uric acid levels;
LUAD	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg25427524	chr10:38739819	LOC399744	-0.77	-14.58	-0.58	2.79e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.36	7.34	0.34	1.09e-12	Hemoglobin concentration;
LUAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg22823121	chr1:150693482	HORMAD1	-0.34	-6.42	-0.3	3.65e-10	Monocyte chemoattractant protein-1 levels;
LUAD	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.39	-6.36	-0.3	5.28e-10	Bipolar disorder;
LUAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9560113	0.806	rs9560112	chr13:112183320	A/G	cg14154082	chr13:112174009	NA	0.36	6.74	0.31	5.3e-11	Menarche (age at onset);
LUAD	cis	rs76878669	0.561	rs4930177	chr11:66120784	T/C	cg18002602	chr11:66138449	SLC29A2	0.47	10.16	0.44	7.75e-22	Educational attainment (years of education);
LUAD	cis	rs938554	1.000	rs6832439	chr4:9924319	A/G	cg00071950	chr4:10020882	SLC2A9	0.54	8.44	0.38	5.12e-16	Blood metabolite levels;
LUAD	cis	rs11971779	0.680	rs4077889	chr7:139033914	A/G	cg23387468	chr7:139079360	LUC7L2	0.28	6.42	0.3	3.57e-10	Diisocyanate-induced asthma;
LUAD	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.06	-0.36	8.09e-15	Personality dimensions;
LUAD	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg21709803	chr11:61594965	FADS2	-0.42	-7.35	-0.34	1.04e-12	Trans fatty acid levels;
LUAD	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg02734326	chr4:10020555	SLC2A9	0.64	11.33	0.48	3.71e-26	Bone mineral density;
LUAD	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg05697835	chr1:2722811	NA	0.28	6.54	0.3	1.74e-10	Ulcerative colitis;
LUAD	cis	rs7705042	0.865	rs249642	chr5:141524980	G/C	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.69	-0.31	7.2e-11	Asthma;
LUAD	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg04369109	chr6:150039330	LATS1	-0.47	-7.57	-0.35	2.42e-13	Lung cancer;
LUAD	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg08999081	chr20:33150536	PIGU	0.62	13.93	0.56	1.39e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs2637266	1.000	rs7905033	chr10:78368212	A/C	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	cis	rs714515	0.934	rs7517737	chr1:172341975	C/A	cg14508705	chr1:172360182	DNM3	-0.37	-6.47	-0.3	2.74e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs752010	0.715	rs4660551	chr1:42099979	T/C	cg06885757	chr1:42089581	HIVEP3	0.63	13.68	0.55	1.56e-35	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.61	-7.17	-0.33	3.29e-12	Body mass index;
LUAD	cis	rs4711336	1.000	rs2296738	chr6:33656850	C/T	cg14003231	chr6:33640908	ITPR3	0.53	10.02	0.44	2.49e-21	Height;
LUAD	cis	rs57590327	0.508	rs9820349	chr3:81958587	A/G	cg07356753	chr3:81810745	GBE1	-0.55	-9.32	-0.41	6.46e-19	Extraversion;
LUAD	cis	rs3812565	0.506	rs4259518	chr9:139322503	T/C	cg14169450	chr9:139327907	INPP5E	0.45	8.48	0.38	3.82e-16	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs12900413	0.562	rs2118849	chr15:90302399	G/T	cg24249390	chr15:90295951	MESP1	-0.35	-6.85	-0.32	2.66e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs1448094	0.935	rs10746355	chr12:86330227	A/T	cg02569458	chr12:86230093	RASSF9	0.35	6.73	0.31	5.43e-11	Major depressive disorder;
LUAD	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg22705602	chr4:152727874	NA	-0.37	-6.58	-0.3	1.37e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs16854884	0.526	rs7643341	chr3:143726980	C/T	cg01302019	chr3:143689584	C3orf58	-0.43	-7.45	-0.34	5.32e-13	Economic and political preferences (feminism/equality);
LUAD	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg03676636	chr4:99064102	C4orf37	0.3	7.19	0.33	2.99e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg17366294	chr4:99064904	C4orf37	0.66	12.58	0.52	4.89e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg20673091	chr1:2541236	MMEL1	0.43	9.17	0.41	2.02e-18	Ulcerative colitis;
LUAD	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg27490568	chr2:178487706	NA	0.42	7.01	0.32	9.43e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg18016565	chr1:150552671	MCL1	0.42	7.75	0.35	7.08e-14	Tonsillectomy;
LUAD	cis	rs7192380	0.639	rs2917666	chr16:69763960	C/G	cg26679644	chr16:69762563	NA	-0.45	-8.27	-0.37	1.82e-15	Sjögren's syndrome;
LUAD	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Parkinson's disease;
LUAD	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-9.74	-0.43	2.36e-20	Gut microbiome composition (summer);
LUAD	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.22	-0.33	2.45e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg05084668	chr3:125655381	ALG1L	0.87	11.91	0.5	2.11e-28	Blood pressure (smoking interaction);
LUAD	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12756686	chr19:29218302	NA	0.67	9.84	0.43	1.04e-20	Methadone dose in opioid dependence;
LUAD	cis	rs6688613	0.840	rs6669886	chr1:166956710	T/C	cg07049167	chr1:166818506	POGK	0.45	6.66	0.31	8.3e-11	Refractive astigmatism;
LUAD	cis	rs11048434	0.736	rs12423746	chr12:9113002	G/T	cg04155231	chr12:9217510	LOC144571	0.38	7.16	0.33	3.71e-12	Sjögren's syndrome;
LUAD	cis	rs921968	0.565	rs7562426	chr2:219605118	G/A	cg02176678	chr2:219576539	TTLL4	-0.6	-12.09	-0.51	3.98e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg15247329	chr7:2764246	NA	-0.36	-6.52	-0.3	2.06e-10	Height;
LUAD	cis	rs2249625	0.874	rs2463697	chr6:72838760	A/G	cg18830697	chr6:72922368	RIMS1	-0.36	-6.74	-0.31	5.16e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06022373	chr22:39101656	GTPBP1	0.45	6.81	0.31	3.29e-11	Menopause (age at onset);
LUAD	cis	rs1448094	0.967	rs10047659	chr12:86338278	C/A	cg00310523	chr12:86230176	RASSF9	0.36	7.73	0.35	7.93e-14	Major depressive disorder;
LUAD	cis	rs11771526	0.681	rs76949995	chr7:32414431	G/A	cg13207630	chr7:32358064	NA	0.66	6.81	0.31	3.46e-11	Body mass index;
LUAD	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg11915388	chr22:42470451	FAM109B	-0.37	-6.8	-0.31	3.56e-11	Schizophrenia;
LUAD	cis	rs2625529	0.730	rs7403191	chr15:72160964	C/T	cg16672083	chr15:72433130	SENP8	-0.67	-12.25	-0.51	9.88e-30	Red blood cell count;
LUAD	cis	rs2692947	0.696	rs2576437	chr2:96800417	T/C	cg23100626	chr2:96804247	ASTL	0.34	9.14	0.41	2.63e-18	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.54	0.38	2.46e-16	Platelet count;
LUAD	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg12483005	chr1:23474871	LUZP1	0.54	9.12	0.41	3.06e-18	Height;
LUAD	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg15226275	chr6:116381976	FRK	-0.24	-7.82	-0.36	4.16e-14	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg16325326	chr1:53192061	ZYG11B	0.72	14.06	0.56	3.94e-37	Monocyte count;
LUAD	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg27539214	chr16:67997921	SLC12A4	-0.69	-8.87	-0.4	2.12e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.08	-0.33	6.17e-12	Total cholesterol levels;
LUAD	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	11.28	0.48	5.78e-26	Resting heart rate;
LUAD	cis	rs9879311	1.000	rs9879311	chr3:10415343	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.37	6.44	0.3	3.29e-10	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg06671706	chr8:8559999	CLDN23	-0.59	-10.23	-0.45	4.26e-22	Obesity-related traits;
LUAD	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg20283391	chr11:68216788	NA	-0.42	-6.56	-0.3	1.56e-10	Total body bone mineral density;
LUAD	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg22963979	chr7:1858916	MAD1L1	-0.5	-8.85	-0.4	2.48e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs6906287	0.647	rs4946350	chr6:118945433	A/C	cg21191810	chr6:118973309	C6orf204	0.5	9.55	0.42	1.08e-19	Electrocardiographic conduction measures;
LUAD	cis	rs6500395	1.000	rs7206647	chr16:48709220	G/C	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7289126	1.000	rs5995558	chr22:38647639	A/G	cg25457927	chr22:38595422	NA	-0.45	-10.29	-0.45	2.56e-22	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg19346786	chr7:2764209	NA	-0.31	-6.59	-0.31	1.3e-10	Height;
LUAD	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg05283184	chr6:79620031	NA	-0.61	-12.24	-0.51	1.05e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-7.47	-0.34	4.72e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg20476274	chr7:133979776	SLC35B4	0.82	16.34	0.62	6.73e-47	Mean platelet volume;
LUAD	cis	rs870825	0.616	rs4444873	chr4:185628406	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	13.69	0.55	1.45e-35	Blood protein levels;
LUAD	trans	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	25.53	0.78	1.11e-87	Colorectal cancer;
LUAD	cis	rs7215564	0.730	rs34484282	chr17:78684663	G/A	cg09596252	chr17:78655493	RPTOR	0.51	6.36	0.3	5.28e-10	Myopia (pathological);
LUAD	cis	rs4819852	1.000	rs1034565	chr22:19984211	A/G	cg07821417	chr22:19972146	ARVCF	-0.38	-7.41	-0.34	7.05e-13	Pulse pressure;
LUAD	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg05791153	chr7:19748676	TWISTNB	0.8	8.97	0.4	9.88e-18	Thyroid stimulating hormone;
LUAD	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg20291162	chr17:40259547	DHX58	-0.66	-10.42	-0.45	9.08e-23	Fibrinogen levels;
LUAD	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg09365446	chr1:150670422	GOLPH3L	0.55	9.33	0.41	6.23e-19	Melanoma;
LUAD	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.81	-0.36	4.45e-14	Diabetic kidney disease;
LUAD	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg27446573	chr6:127587934	RNF146	0.44	6.72	0.31	5.8e-11	Breast cancer;
LUAD	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.76	0.43	1.91e-20	Monocyte percentage of white cells;
LUAD	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg11663144	chr21:46675770	NA	-0.59	-11.7	-0.49	1.39e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg16205897	chr5:131564050	P4HA2	-0.45	-10.72	-0.46	7.11e-24	Blood metabolite levels;
LUAD	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.48	-0.34	4.27e-13	Coronary artery disease;
LUAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg27454412	chr7:1067447	C7orf50	0.48	7.64	0.35	1.43e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs494562	1.000	rs7763191	chr6:86118317	A/T	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg08632164	chr7:65971372	NA	-0.37	-6.42	-0.3	3.69e-10	Aortic root size;
LUAD	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg04155289	chr7:94953770	PON1	-0.55	-7.39	-0.34	7.68e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg07167872	chr1:205819463	PM20D1	-0.53	-8.09	-0.37	6.4e-15	Menarche (age at onset);
LUAD	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.67	-0.43	3.94e-20	Bone mineral density;
LUAD	cis	rs7274811	0.625	rs169797	chr20:31926490	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	0.43	6.47	0.3	2.78e-10	Height;
LUAD	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.35	6.79	0.31	3.91e-11	Depression;
LUAD	cis	rs9487051	0.708	rs378447	chr6:109526823	G/A	cg01475377	chr6:109611718	NA	-0.38	-6.75	-0.31	5.02e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.28	-0.54	7.08e-34	Chronic sinus infection;
LUAD	cis	rs35883536	0.647	rs12046413	chr1:101047430	T/C	cg06223162	chr1:101003688	GPR88	-0.48	-9.31	-0.41	7.1e-19	Monocyte count;
LUAD	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg01191920	chr7:158217561	PTPRN2	-0.63	-13.5	-0.55	8.55e-35	Obesity-related traits;
LUAD	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg17849569	chr6:28058911	ZSCAN12L1	0.31	7.03	0.32	8.36e-12	Parkinson's disease;
LUAD	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg17366294	chr4:99064904	C4orf37	0.71	13.37	0.54	3.05e-34	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1493916	1.000	rs990882	chr18:31398180	T/G	cg13755796	chr4:20253514	NA	-0.42	-6.93	-0.32	1.6e-11	Life satisfaction;
LUAD	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg15556689	chr8:8085844	FLJ10661	0.43	6.94	0.32	1.47e-11	Mood instability;
LUAD	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg23758822	chr17:41437982	NA	1.01	21.18	0.72	2.19e-68	Menopause (age at onset);
LUAD	cis	rs709400	1.000	rs861538	chr14:104166733	C/T	cg01849466	chr14:104193079	ZFYVE21	0.47	7.7	0.35	9.95e-14	Body mass index;
LUAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg20607798	chr8:58055168	NA	0.66	8.72	0.39	6.3e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs3018712	0.532	rs2513282	chr11:68418311	A/C	cg16797656	chr11:68205561	LRP5	-0.42	-6.5	-0.3	2.32e-10	Total body bone mineral density;
LUAD	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg20933634	chr6:27740509	NA	0.46	7.27	0.33	1.77e-12	Parkinson's disease;
LUAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg21385606	chr21:47601150	C21orf56	-0.36	-6.59	-0.31	1.3e-10	Testicular germ cell tumor;
LUAD	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg06532163	chr17:45867833	NA	0.47	8.25	0.37	2.07e-15	IgG glycosylation;
LUAD	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg18132916	chr6:79620363	NA	-0.46	-7.77	-0.35	6.19e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg22532475	chr10:104410764	TRIM8	-0.44	-8.56	-0.38	2.09e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg03340356	chr1:67600835	NA	0.41	7.35	0.34	1e-12	Psoriasis;
LUAD	cis	rs7818345	1.000	rs12675717	chr8:19293177	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.29	6.54	0.3	1.77e-10	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs6908034	0.607	rs12527834	chr6:19821781	A/G	cg02682789	chr6:19804855	NA	0.91	8.27	0.37	1.77e-15	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02784696	chr2:24270586	C2orf44	-0.48	-7.45	-0.34	5.27e-13	Height;
LUAD	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.57	-0.35	2.39e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	12.46	0.52	1.39e-30	Monocyte percentage of white cells;
LUAD	cis	rs11031096	0.782	rs10835684	chr11:4168308	G/T	cg18678763	chr11:4115507	RRM1	-0.43	-7.49	-0.34	3.99e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg12373951	chr3:133503437	NA	-0.37	-7.56	-0.34	2.55e-13	Iron status biomarkers;
LUAD	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg08470875	chr2:26401718	FAM59B	0.76	9.99	0.44	2.96e-21	Gut microbiome composition (summer);
LUAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg21951975	chr1:209979733	IRF6	0.59	9.47	0.42	1.98e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs6714710	0.535	rs3192177	chr2:98354511	G/A	cg26665480	chr2:98280029	ACTR1B	0.59	9.39	0.42	3.64e-19	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg21782813	chr7:2030301	MAD1L1	0.41	6.65	0.31	9.23e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg19743168	chr1:23544995	NA	0.39	6.84	0.32	2.72e-11	Height;
LUAD	cis	rs8049603	0.739	rs4073290	chr16:23196127	A/G	cg09552652	chr16:23197569	SCNN1G	0.36	6.41	0.3	3.81e-10	Multiple sclerosis;
LUAD	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg02176678	chr2:219576539	TTLL4	-0.79	-16.68	-0.63	2.26e-48	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08048268	chr3:133502702	NA	-0.53	-10.69	-0.46	9.37e-24	Iron status biomarkers;
LUAD	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg23933602	chr10:16859644	RSU1	0.62	9.35	0.41	5.19e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs4285028	0.796	rs12638492	chr3:121711763	G/A	cg20356878	chr3:121714668	ILDR1	-0.49	-6.5	-0.3	2.21e-10	Multiple sclerosis;
LUAD	cis	rs494562	0.892	rs619299	chr6:86121482	A/T	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg01528321	chr10:82214614	TSPAN14	0.54	8.72	0.39	6.3e-17	Post bronchodilator FEV1;
LUAD	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg03676636	chr4:99064102	C4orf37	0.34	8.89	0.4	1.83e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg13722127	chr7:150037890	RARRES2	0.49	8.16	0.37	3.8e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg06784218	chr1:46089804	CCDC17	0.47	9.69	0.43	3.51e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08219700	chr8:58056026	NA	0.71	9.38	0.41	4.11e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	8.77	0.39	4.26e-17	Breast cancer;
LUAD	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg11189052	chr15:85197271	WDR73	0.65	8.73	0.39	6.11e-17	Schizophrenia;
LUAD	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.64	0.31	9.58e-11	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg02527881	chr3:46936655	PTH1R	0.42	8.0	0.36	1.2e-14	Colorectal cancer;
LUAD	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg21153622	chr11:89784906	NA	0.33	6.58	0.3	1.42e-10	Coronary artery disease;
LUAD	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg21724239	chr8:58056113	NA	0.78	9.37	0.41	4.37e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg04414720	chr1:150670196	GOLPH3L	0.72	13.36	0.54	3.28e-34	Tonsillectomy;
LUAD	cis	rs59698941	0.709	rs12163973	chr5:132226664	G/A	cg14825688	chr5:132208181	LEAP2	-0.47	-6.65	-0.31	8.85e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18404041	chr3:52824283	ITIH1	-0.58	-12.0	-0.5	9.42e-29	Electroencephalogram traits;
LUAD	cis	rs2882667	0.929	rs17207828	chr5:138299835	A/G	cg04439458	chr5:138467593	SIL1	-0.45	-8.15	-0.37	4.06e-15	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg08601574	chr20:25228251	PYGB	-0.46	-8.72	-0.39	6.46e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg11502198	chr6:26597334	ABT1	0.56	9.35	0.41	5.23e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs12200782	1.000	rs12199239	chr6:26432570	G/C	cg08851530	chr6:28072375	NA	0.72	6.5	0.3	2.27e-10	Small cell lung carcinoma;
LUAD	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	18.61	0.67	6.8e-57	Bone mineral density;
LUAD	cis	rs796825	0.530	rs55861253	chr3:119986807	A/G	cg21790991	chr3:120137480	FSTL1	-0.47	-8.09	-0.37	6.17e-15	HIV-1 susceptibility;
LUAD	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg22920501	chr2:26401640	FAM59B	-0.77	-11.0	-0.47	6.27e-25	Gut microbiome composition (summer);
LUAD	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.52	-0.3	2.01e-10	Alzheimer's disease (late onset);
LUAD	cis	rs7301826	0.651	rs4759525	chr12:131316281	T/C	cg11011512	chr12:131303247	STX2	0.43	7.37	0.34	9.07e-13	Plasma plasminogen activator levels;
LUAD	cis	rs7809799	0.571	rs17161687	chr7:98941909	A/G	cg12290671	chr7:99195819	NA	0.78	7.19	0.33	2.98e-12	Ulcerative colitis;
LUAD	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg14092988	chr3:52407081	DNAH1	0.44	8.58	0.39	1.76e-16	Bipolar disorder;
LUAD	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg19980929	chr12:42632907	YAF2	-0.35	-6.7	-0.31	6.48e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg19622623	chr12:86230825	RASSF9	0.55	9.89	0.43	6.97e-21	Major depressive disorder;
LUAD	cis	rs1881797	1.000	rs55852476	chr1:247696173	G/A	cg18198730	chr1:247681584	NA	0.45	7.85	0.36	3.55e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg20362242	chr5:692897	TPPP	0.5	6.8	0.31	3.51e-11	Ulcerative colitis;
LUAD	cis	rs2625529	0.668	rs12591338	chr15:72556847	T/A	cg16672083	chr15:72433130	SENP8	-0.79	-13.65	-0.55	2.06e-35	Red blood cell count;
LUAD	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21659725	chr3:3221576	CRBN	-0.86	-18.31	-0.66	1.4e-55	Intelligence (multi-trait analysis);
LUAD	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.23	0.33	2.25e-12	Blood metabolite levels;
LUAD	cis	rs2625529	0.668	rs12591313	chr15:72556746	T/C	cg16672083	chr15:72433130	SENP8	-0.79	-13.65	-0.55	2.06e-35	Red blood cell count;
LUAD	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	ch.11.42038R	chr11:967971	AP2A2	0.4	7.01	0.32	9.49e-12	Alzheimer's disease (late onset);
LUAD	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg18755752	chr8:142205143	DENND3	0.48	8.12	0.37	5.06e-15	Immature fraction of reticulocytes;
LUAD	cis	rs6782228	0.675	rs56141228	chr3:128386042	C/T	cg16766828	chr3:128327626	NA	-0.39	-7.16	-0.33	3.5e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg14019146	chr3:50243930	SLC38A3	0.36	6.81	0.31	3.34e-11	Body mass index;
LUAD	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg21028142	chr17:79581711	NPLOC4	-0.42	-8.78	-0.39	4.11e-17	Eye color traits;
LUAD	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg05805236	chr11:65401703	PCNXL3	-0.59	-9.6	-0.42	7.34e-20	Acne (severe);
LUAD	cis	rs7923837	1.000	rs10748582	chr10:94477219	A/T	cg25093409	chr10:94429542	NA	0.36	6.44	0.3	3.18e-10	Body mass index;Multiple sclerosis;
LUAD	trans	rs4332037	0.722	rs4721140	chr7:1917635	A/T	cg11693508	chr17:37793320	STARD3	0.56	7.8	0.35	4.81e-14	Bipolar disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08810106	chr16:18936940	SMG1	-0.44	-6.91	-0.32	1.76e-11	Height;
LUAD	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg25985355	chr7:65971099	NA	-0.53	-6.57	-0.3	1.46e-10	Diabetic kidney disease;
LUAD	cis	rs4888262	0.526	rs8057279	chr16:74627303	C/T	cg01733217	chr16:74700730	RFWD3	0.5	8.5	0.38	3.34e-16	Testicular germ cell tumor;
LUAD	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-9.2	-0.41	1.62e-18	Schizophrenia;
LUAD	cis	rs2275731	0.636	rs2000200	chr10:16522568	C/A	cg04254609	chr10:16479192	PTER	-0.42	-6.77	-0.31	4.2e-11	Bone fracture in osteoporosis;
LUAD	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg12432903	chr7:1882776	MAD1L1	-0.41	-6.56	-0.3	1.6e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg13736514	chr6:26305472	NA	-0.69	-13.44	-0.55	1.52e-34	Educational attainment;
LUAD	cis	rs7737355	0.812	rs28610	chr5:130832382	T/C	cg06307176	chr5:131281290	NA	0.42	7.01	0.32	9.36e-12	Life satisfaction;
LUAD	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg14664628	chr15:75095509	CSK	-0.49	-8.06	-0.36	7.91e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.9	-0.36	2.43e-14	Menopause (age at onset);
LUAD	trans	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-9.8	-0.43	1.39e-20	Brugada syndrome;
LUAD	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17095355	0.818	rs12261598	chr10:111872175	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.64	-8.94	-0.4	1.23e-17	Biliary atresia;
LUAD	trans	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.2	-0.33	2.83e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg12011299	chr4:100065546	ADH4	0.63	13.05	0.54	5.85e-33	Alcohol dependence;
LUAD	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg09491104	chr22:46646882	C22orf40	-0.55	-7.78	-0.35	5.51e-14	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg05604720	chr8:90769698	RIPK2	-0.37	-6.41	-0.3	3.9e-10	Schizophrenia;
LUAD	trans	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	7.6	0.35	1.88e-13	Resting heart rate;
LUAD	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11644478	chr21:40555479	PSMG1	0.69	11.69	0.49	1.53e-27	Cognitive function;
LUAD	trans	rs11700980	0.748	rs17734876	chr21:30260144	C/T	cg14791747	chr16:20752902	THUMPD1	0.61	6.43	0.3	3.46e-10	QRS complex (12-leadsum);
LUAD	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg24579218	chr15:68104479	NA	-0.52	-8.31	-0.37	1.32e-15	Obesity;
LUAD	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg08219700	chr8:58056026	NA	0.6	8.25	0.37	2.04e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg18240062	chr17:79603768	NPLOC4	0.46	8.08	0.37	6.63e-15	Eye color traits;
LUAD	cis	rs3806843	0.576	rs246059	chr5:140325010	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg01788221	chr16:89496183	ANKRD11	-0.34	-6.53	-0.3	1.92e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg05084668	chr3:125655381	ALG1L	-0.63	-10.1	-0.44	1.2e-21	Blood pressure (smoking interaction);
LUAD	cis	rs4343996	0.714	rs10268837	chr7:3467366	T/C	cg21248987	chr7:3385318	SDK1	0.37	6.81	0.31	3.29e-11	Motion sickness;
LUAD	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg08761264	chr16:28874980	SH2B1	-0.44	-6.62	-0.31	1.09e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs758324	0.947	rs2088719	chr5:131184439	C/T	cg25547332	chr5:131281432	NA	0.44	6.7	0.31	6.85e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs2554380	0.628	rs2401130	chr15:84470735	A/C	cg14598478	chr15:84363061	ADAMTSL3	-0.39	-6.71	-0.31	6.27e-11	Height;
LUAD	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.41	-0.6	7.47e-43	Chronic sinus infection;
LUAD	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg24579218	chr15:68104479	NA	-0.54	-9.4	-0.42	3.44e-19	Restless legs syndrome;
LUAD	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg23229984	chr5:148520753	ABLIM3	0.5	7.7	0.35	9.72e-14	Breast cancer;
LUAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg07507251	chr3:52567010	NT5DC2	0.39	7.66	0.35	1.24e-13	Electroencephalogram traits;
LUAD	cis	rs1595825	0.735	rs1866665	chr2:198925980	A/G	cg00361562	chr2:198649771	BOLL	-0.5	-6.83	-0.32	3.04e-11	Ulcerative colitis;
LUAD	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg02018176	chr4:1364513	KIAA1530	0.37	6.45	0.3	3.07e-10	Obesity-related traits;
LUAD	cis	rs4767364	0.922	rs7300252	chr12:112430346	C/T	cg10833066	chr12:111807467	FAM109A	0.36	6.7	0.31	6.83e-11	Oral cavity and pharyngeal cancer;
LUAD	cis	rs72928364	0.872	rs2713787	chr3:100624438	G/C	cg10123952	chr3:100791384	NA	-0.54	-6.74	-0.31	5.11e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs45430	1.000	rs443099	chr21:42743327	G/T	cg22778903	chr21:42741698	MX2	0.39	8.32	0.37	1.23e-15	Melanoma;
LUAD	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg01851573	chr8:8652454	MFHAS1	-0.38	-6.58	-0.3	1.36e-10	Neuroticism;
LUAD	cis	rs4280164	0.551	rs3181251	chr14:24805824	C/T	cg22990158	chr14:24802150	ADCY4	0.57	8.61	0.39	1.44e-16	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs8060686	0.516	rs8044995	chr16:68189340	G/A	cg05110241	chr16:68378359	PRMT7	-0.57	-7.25	-0.33	2e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg11494091	chr17:61959527	GH2	0.74	18.57	0.67	1.04e-56	Prudent dietary pattern;
LUAD	cis	rs7582720	1.000	rs1541853	chr2:203835177	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18099408	chr3:52552593	STAB1	-0.47	-8.07	-0.37	7.36e-15	Bipolar disorder;
LUAD	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg07157834	chr1:205819609	PM20D1	-0.47	-6.94	-0.32	1.46e-11	Menarche (age at onset);
LUAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.97	-0.44	3.48e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.23	0.48	8.73e-26	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs922182	0.557	rs6494452	chr15:64199208	G/A	cg02919090	chr15:64263738	DAPK2	0.36	6.74	0.31	5.15e-11	Blood protein levels;
LUAD	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg15448220	chr1:150897856	SETDB1	0.5	8.73	0.39	5.85e-17	Tonsillectomy;
LUAD	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg02734326	chr4:10020555	SLC2A9	-0.42	-7.31	-0.33	1.33e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9649213	0.614	rs3944111	chr7:98005766	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.73	-10.66	-0.46	1.2e-23	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg00634984	chr7:65235879	NA	-0.5	-6.77	-0.31	4.43e-11	Aortic root size;
LUAD	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg17652424	chr22:38574118	PLA2G6	-0.33	-10.13	-0.44	9.75e-22	Cutaneous nevi;
LUAD	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg20119798	chr7:94954144	PON1	-0.48	-6.54	-0.3	1.76e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg26043149	chr18:55253948	FECH	0.51	8.31	0.37	1.35e-15	Bone mineral density;
LUAD	cis	rs12549902	0.871	rs4736819	chr8:41509915	C/T	cg17182837	chr8:41585554	ANK1	-0.31	-6.43	-0.3	3.39e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUAD	trans	rs9784649	0.891	rs57355285	chr5:25016384	C/G	cg11038491	chr20:34638489	LOC647979	-0.65	-8.13	-0.37	4.77e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg01958934	chr19:45449099	APOC2	0.36	7.06	0.32	6.67e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg18827107	chr12:86230957	RASSF9	-0.7	-13.04	-0.54	6.65e-33	Major depressive disorder;
LUAD	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg01299579	chr2:10830716	NOL10	0.44	7.79	0.35	5.28e-14	Prostate cancer;
LUAD	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg02038168	chr22:39784481	NA	-0.52	-8.93	-0.4	1.31e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg17063962	chr7:91808500	NA	0.68	12.35	0.51	4.08e-30	Breast cancer;
LUAD	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg06784218	chr1:46089804	CCDC17	0.6	13.37	0.55	2.89e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs1178968	0.748	rs10271751	chr7:72752062	T/C	cg15428835	chr7:75027521	TRIM73;TRIM74	0.5	6.38	0.3	4.77e-10	Triglyceride levels;
LUAD	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg10518543	chr12:38710700	ALG10B	0.42	6.43	0.3	3.47e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05901451	chr6:126070800	HEY2	-0.84	-16.58	-0.63	6.12e-48	Brugada syndrome;
LUAD	cis	rs7100689	0.725	rs10749574	chr10:82136856	T/C	cg00277334	chr10:82204260	NA	-0.59	-9.4	-0.42	3.39e-19	Post bronchodilator FEV1;
LUAD	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg24768116	chr2:27665128	KRTCAP3	0.26	6.36	0.3	5.3e-10	Oral cavity cancer;
LUAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg07157834	chr1:205819609	PM20D1	0.53	9.21	0.41	1.59e-18	Prostate cancer;
LUAD	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg20503657	chr10:835505	NA	0.75	9.88	0.43	7.23e-21	Eosinophil percentage of granulocytes;
LUAD	cis	rs7020830	0.830	rs308499	chr9:37348059	C/G	cg14294708	chr9:37120828	ZCCHC7	0.85	17.27	0.64	5.72e-51	Schizophrenia;
LUAD	cis	rs7072216	0.763	rs9787550	chr10:100169051	C/T	cg26618903	chr10:100175079	PYROXD2	-0.37	-8.11	-0.37	5.56e-15	Metabolite levels;
LUAD	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg26343298	chr8:95960752	TP53INP1	0.37	7.72	0.35	8.39e-14	Type 2 diabetes;
LUAD	cis	rs3125734	0.633	rs3852412	chr10:64050288	C/T	cg19640130	chr10:64028056	RTKN2	-0.35	-7.46	-0.34	4.81e-13	Rheumatoid arthritis;
LUAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.49	-8.19	-0.37	3.17e-15	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg17366294	chr4:99064904	C4orf37	0.65	12.64	0.52	2.81e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.812	rs2189645	chr5:130804979	A/G	cg25547332	chr5:131281432	NA	-0.41	-6.66	-0.31	8.44e-11	Life satisfaction;
LUAD	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24400517	chr7:139876520	LOC100134229;JHDM1D	-0.41	-6.71	-0.31	6.18e-11	Cancer;
LUAD	cis	rs13064411	0.696	rs6783965	chr3:113198722	C/T	cg10517650	chr3:113235015	CCDC52	-0.54	-9.27	-0.41	9.7e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs12545109	0.800	rs2576599	chr8:57388410	G/A	cg09654669	chr8:57350985	NA	-0.7	-10.0	-0.44	2.83e-21	Obesity-related traits;
LUAD	cis	rs7773004	0.875	rs9393700	chr6:26309380	G/A	cg00631329	chr6:26305371	NA	-0.54	-9.28	-0.41	9.16e-19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs250585	0.920	rs39815	chr16:23420006	G/C	cg00143387	chr16:23521605	GGA2	0.59	7.44	0.34	5.64e-13	Egg allergy;
LUAD	cis	rs9323205	0.834	rs12434435	chr14:51667524	G/T	cg23942311	chr14:51606299	NA	0.56	9.48	0.42	1.79e-19	Cancer;
LUAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg22963979	chr7:1858916	MAD1L1	-0.69	-12.31	-0.51	5.6e-30	Bipolar disorder and schizophrenia;
LUAD	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg09455208	chr3:40491958	NA	0.55	12.18	0.51	1.78e-29	Renal cell carcinoma;
LUAD	cis	rs500891	0.525	rs12524968	chr6:84076466	C/G	cg08257003	chr6:84140564	ME1	0.35	6.7	0.31	6.63e-11	Platelet-derived growth factor BB levels;
LUAD	trans	rs2770228	1.000	rs9582143	chr13:98166750	A/G	cg13787782	chr2:239161568	PER2	-0.79	-6.55	-0.3	1.68e-10	Metabolite levels (Dihydroxy docosatrienoic acid);
LUAD	cis	rs1232027	0.656	rs1650650	chr5:79965775	G/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.33	-0.34	1.16e-12	Huntington's disease progression;
LUAD	cis	rs10129255	0.536	rs10142951	chr14:107190574	A/G	cg23076370	chr14:107095027	NA	-0.44	-8.72	-0.39	6.36e-17	Kawasaki disease;
LUAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg02136620	chr5:178986620	RUFY1	-0.43	-6.92	-0.32	1.67e-11	Lung cancer;
LUAD	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.53	0.34	3.09e-13	Bipolar disorder;
LUAD	cis	rs7614311	0.636	rs73117057	chr3:63915689	A/G	cg22134162	chr3:63841271	THOC7	-0.51	-8.18	-0.37	3.42e-15	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs12681288	0.550	rs76893867	chr8:962618	G/C	cg04851639	chr8:1020857	NA	-0.31	-7.15	-0.33	3.89e-12	Schizophrenia;
LUAD	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg02018176	chr4:1364513	KIAA1530	0.36	6.37	0.3	5.04e-10	Obesity-related traits;
LUAD	trans	rs1973993	0.745	rs6683508	chr1:96955038	T/C	cg10631902	chr5:14652156	NA	-0.46	-7.9	-0.36	2.39e-14	Weight;
LUAD	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg08847533	chr14:75593920	NEK9	0.38	6.48	0.3	2.55e-10	Height;
LUAD	cis	rs3087591	0.922	rs2905788	chr17:29480295	C/T	cg24425628	chr17:29625626	OMG;NF1	0.41	6.66	0.31	8.45e-11	Hip circumference;
LUAD	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06022373	chr22:39101656	GTPBP1	-0.45	-6.81	-0.31	3.27e-11	Menopause (age at onset);
LUAD	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg12011299	chr4:100065546	ADH4	0.67	14.3	0.57	4.14e-38	Alcohol dependence;
LUAD	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg21699342	chr2:239360505	ASB1	0.59	11.53	0.49	6.38e-27	Multiple system atrophy;
LUAD	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg25036284	chr2:26402008	FAM59B	-0.83	-11.78	-0.5	6.58e-28	Gut microbiome composition (summer);
LUAD	cis	rs2235649	0.789	rs9929803	chr16:1852748	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.48	-7.9	-0.36	2.46e-14	Blood metabolite levels;
LUAD	trans	rs2018683	0.649	rs12536605	chr7:28970500	C/T	cg19402173	chr7:128379420	CALU	-0.52	-8.43	-0.38	5.62e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	8.08	0.37	7.04e-15	Schizophrenia;
LUAD	cis	rs7267979	0.727	rs2474765	chr20:25245950	G/T	cg08601574	chr20:25228251	PYGB	0.42	7.88	0.36	2.87e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg10411590	chr13:21900810	NA	0.45	7.05	0.32	7.25e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg08989290	chr16:615782	NHLRC4	0.31	6.72	0.31	5.75e-11	Height;
LUAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg09737314	chr17:6899359	ALOX12	0.4	7.65	0.35	1.36e-13	Tonsillectomy;
LUAD	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg19318889	chr4:1322082	MAEA	0.42	6.86	0.32	2.48e-11	Obesity-related traits;
LUAD	trans	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg14343924	chr8:8086146	FLJ10661	0.46	7.0	0.32	1.04e-11	Neuroticism;
LUAD	cis	rs7851660	0.967	rs7049054	chr9:100599969	T/G	cg13688889	chr9:100608707	NA	-0.52	-9.61	-0.42	6.33e-20	Strep throat;
LUAD	cis	rs62238980	0.614	rs116829978	chr22:32547785	C/T	cg00543991	chr22:32367038	NA	0.88	7.68	0.35	1.13e-13	Childhood ear infection;
LUAD	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.54	-9.16	-0.41	2.28e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg13047869	chr3:10149882	C3orf24	0.65	10.9	0.47	1.44e-24	Alzheimer's disease;
LUAD	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg01200585	chr1:228362443	C1orf69	-0.38	-7.18	-0.33	3.07e-12	Diastolic blood pressure;
LUAD	trans	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg14917512	chr19:3094685	GNA11	-0.56	-6.5	-0.3	2.21e-10	Diabetic kidney disease;
LUAD	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg18305652	chr10:134549665	INPP5A	0.6	11.08	0.47	3.14e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg15017067	chr4:17643749	FAM184B	0.37	7.07	0.33	6.33e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg17366294	chr4:99064904	C4orf37	0.53	9.72	0.43	2.8e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9469913	0.604	rs11755266	chr6:35162141	A/G	cg17674042	chr6:34482479	PACSIN1	0.56	7.22	0.33	2.42e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs7215564	0.818	rs4889881	chr17:78664157	T/C	cg09596252	chr17:78655493	RPTOR	0.52	6.54	0.3	1.75e-10	Myopia (pathological);
LUAD	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg09654669	chr8:57350985	NA	-0.65	-9.96	-0.44	3.92e-21	Obesity-related traits;
LUAD	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg09796270	chr17:17721594	SREBF1	0.37	6.96	0.32	1.34e-11	Total body bone mineral density;
LUAD	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg25985355	chr7:65971099	NA	-0.56	-6.91	-0.32	1.79e-11	Gout;
LUAD	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg26513180	chr16:89883248	FANCA	-0.69	-13.13	-0.54	2.78e-33	Vitiligo;
LUAD	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg09796270	chr17:17721594	SREBF1	0.38	7.64	0.35	1.42e-13	Total body bone mineral density;
LUAD	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg17644776	chr2:200775616	C2orf69	0.55	7.32	0.34	1.26e-12	Schizophrenia;
LUAD	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg02176678	chr2:219576539	TTLL4	0.6	11.69	0.49	1.54e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.63	11.87	0.5	2.97e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg07828024	chr6:149772892	ZC3H12D	-0.31	-6.78	-0.31	3.96e-11	Dupuytren's disease;
LUAD	cis	rs10242455	0.571	rs11734	chr7:99229768	C/G	cg18809830	chr7:99032528	PTCD1	0.81	6.97	0.32	1.22e-11	Blood metabolite levels;
LUAD	cis	rs870825	0.616	rs7680779	chr4:185652830	G/C	cg04058563	chr4:185651563	MLF1IP	-0.85	-13.61	-0.55	3.09e-35	Blood protein levels;
LUAD	cis	rs5756813	0.727	rs4239889	chr22:38140352	T/G	cg06521852	chr22:38141419	TRIOBP	0.49	8.83	0.39	2.71e-17	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg17191109	chr10:126851326	NA	-0.36	-7.27	-0.33	1.7e-12	Menarche (age at onset);
LUAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-8.02	-0.36	1.06e-14	Longevity;Endometriosis;
LUAD	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg17173187	chr15:85201210	NMB	0.44	7.33	0.34	1.2e-12	Schizophrenia;
LUAD	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg26597838	chr10:835615	NA	0.83	11.28	0.48	5.7e-26	Eosinophil percentage of granulocytes;
LUAD	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg14458575	chr2:238380390	NA	0.98	20.15	0.7	8.77e-64	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg04111992	chr7:158790115	NA	-0.5	-8.55	-0.38	2.27e-16	Facial morphology (factor 20);
LUAD	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	9.09	0.4	3.98e-18	Tonsillectomy;
LUAD	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs8112211	0.773	rs45437199	chr19:38795250	G/A	cg01275006	chr19:38876250	GGN	-0.5	-6.4	-0.3	4.17e-10	Blood protein levels;
LUAD	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg22906224	chr7:99728672	NA	-0.62	-10.86	-0.47	2.08e-24	Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg03676636	chr4:99064102	C4orf37	0.35	8.97	0.4	9.49e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10465746	0.967	rs4907191	chr1:84444165	A/G	cg10977910	chr1:84465055	TTLL7	-0.5	-8.15	-0.37	4.3e-15	Obesity-related traits;
LUAD	cis	rs3784262	0.669	rs7180059	chr15:58288172	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.69	-0.35	1.02e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.58	10.39	0.45	1.1e-22	Eosinophil percentage of white cells;
LUAD	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg19700328	chr14:106028568	NA	-0.46	-7.86	-0.36	3.25e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg15549821	chr19:49342101	PLEKHA4	-1.03	-15.57	-0.6	1.53e-43	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs4965006	1.000	rs4965006	chr12:132419533	A/G	cg00588090	chr12:132412438	PUS1	-0.58	-8.5	-0.38	3.4e-16	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs6906287	0.647	rs6569020	chr6:118795522	C/T	cg18833306	chr6:118973337	C6orf204	0.45	8.14	0.37	4.38e-15	Electrocardiographic conduction measures;
LUAD	cis	rs2816062	0.775	rs2816048	chr1:18893763	T/C	cg18795169	chr1:18902165	NA	-0.94	-22.53	-0.74	1.96e-74	Urate levels in lean individuals;
LUAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.57	7.83	0.36	3.96e-14	Renal function-related traits (BUN);
LUAD	cis	rs9837602	0.935	rs56233205	chr3:99821679	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	7.91	0.36	2.25e-14	Breast cancer;
LUAD	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.41	-6.69	-0.31	6.9e-11	Tonsillectomy;
LUAD	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg12935359	chr14:103987150	CKB	0.48	7.41	0.34	7.14e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg00310523	chr12:86230176	RASSF9	0.43	8.62	0.39	1.4e-16	Major depressive disorder;
LUAD	cis	rs513349	0.964	rs210139	chr6:33543409	A/C	cg24505687	chr6:33548425	BAK1	0.44	8.52	0.38	2.74e-16	Platelet count;
LUAD	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.74	-13.45	-0.55	1.43e-34	Axial length;
LUAD	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg27661571	chr11:113659931	NA	-0.7	-8.14	-0.37	4.58e-15	Hip circumference adjusted for BMI;
LUAD	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg15704280	chr7:45808275	SEPT13	-1.0	-20.58	-0.71	1.06e-65	Height;
LUAD	trans	rs7395662	0.895	rs11039869	chr11:48622312	C/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.48	-0.3	2.57e-10	HDL cholesterol;
LUAD	cis	rs758324	0.812	rs13165154	chr5:131155020	C/T	cg06307176	chr5:131281290	NA	0.44	7.31	0.33	1.36e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1267303	0.675	rs1267313	chr1:46986322	G/T	cg16387850	chr1:46982889	NA	0.46	7.74	0.35	7.19e-14	Monobrow;
LUAD	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg06547715	chr2:218990976	CXCR2	-0.42	-10.06	-0.44	1.74e-21	Ulcerative colitis;
LUAD	cis	rs8077889	1.000	rs113919636	chr17:41877740	A/C	cg26893861	chr17:41843967	DUSP3	0.89	14.19	0.57	1.21e-37	Triglycerides;
LUAD	cis	rs1595825	0.838	rs6742343	chr2:198666752	C/T	cg00361562	chr2:198649771	BOLL	-0.5	-6.73	-0.31	5.4e-11	Ulcerative colitis;
LUAD	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg02734326	chr4:10020555	SLC2A9	0.56	9.91	0.43	5.81e-21	Bone mineral density;
LUAD	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg26384229	chr12:38710491	ALG10B	0.42	7.02	0.32	8.76e-12	Morning vs. evening chronotype;
LUAD	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15369054	chr17:80825471	TBCD	-0.52	-8.76	-0.39	4.59e-17	Breast cancer;
LUAD	cis	rs9905704	0.633	rs2680697	chr17:56478711	T/A	cg19466818	chr17:56409534	MIR142	0.34	6.91	0.32	1.8e-11	Testicular germ cell tumor;
LUAD	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg23992470	chr4:843637	GAK	-0.63	-6.99	-0.32	1.06e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs897984	0.806	rs11640534	chr16:30949515	G/A	cg02466173	chr16:30829666	NA	0.67	12.47	0.52	1.35e-30	Dementia with Lewy bodies;
LUAD	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg24450063	chr1:156163899	SLC25A44	1.01	16.34	0.62	7.24e-47	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.9	0.36	2.44e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27620946	chr8:42011116	AP3M2	-0.44	-6.92	-0.32	1.66e-11	Height;
LUAD	cis	rs6062509	0.929	rs55791529	chr20:62363858	C/T	cg01176363	chr20:62369445	LIME1	-0.47	-7.61	-0.35	1.8e-13	Prostate cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25307277	chr6:26124601	HIST1H2AC;HIST1H2BC	-0.49	-6.44	-0.3	3.2e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-9.28	-0.41	8.57e-19	Renal function-related traits (BUN);
LUAD	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg05044414	chr3:183734942	ABCC5	0.49	10.25	0.45	3.65e-22	Anterior chamber depth;
LUAD	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg04476341	chr5:669733	TPPP	0.41	7.97	0.36	1.44e-14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg20701182	chr2:24300061	SF3B14	0.67	7.42	0.34	6.54e-13	Lymphocyte counts;
LUAD	cis	rs13315871	1.000	rs71311858	chr3:58323793	G/C	cg20936604	chr3:58311152	NA	-0.72	-7.22	-0.33	2.51e-12	Cholesterol, total;
LUAD	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg13319975	chr6:146136371	FBXO30	-0.54	-8.84	-0.39	2.55e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.32	-7.95	-0.36	1.76e-14	Total body bone mineral density;
LUAD	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.53	-0.3	1.89e-10	Retinal vascular caliber;
LUAD	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg07617317	chr6:118971624	C6orf204	0.55	8.1	0.37	5.98e-15	Diastolic blood pressure;
LUAD	cis	rs62238980	0.521	rs78249378	chr22:32409893	C/G	cg00543991	chr22:32367038	NA	0.96	9.05	0.4	5.32e-18	Childhood ear infection;
LUAD	trans	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg06606381	chr12:133084897	FBRSL1	-1.24	-10.96	-0.47	9.01e-25	Lung cancer in ever smokers;
LUAD	cis	rs4691139	0.634	rs4583719	chr4:165924657	G/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.42	-7.78	-0.35	5.48e-14	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg02527881	chr3:46936655	PTH1R	-0.54	-11.14	-0.48	1.92e-25	Colorectal cancer;
LUAD	cis	rs2742417	1.000	rs2742417	chr3:45731451	C/T	cg10512202	chr3:45649293	LIMD1	0.36	6.38	0.3	4.78e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7119038	0.774	rs7945144	chr11:118608716	A/G	cg19308663	chr11:118741387	NA	0.44	6.5	0.3	2.31e-10	Sjögren's syndrome;
LUAD	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg15900387	chr1:150738905	CTSS	-0.36	-6.65	-0.31	9.17e-11	Melanoma;
LUAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.62	-10.75	-0.46	5.42e-24	Longevity;Endometriosis;
LUAD	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg18755752	chr8:142205143	DENND3	-0.46	-7.99	-0.36	1.28e-14	Immature fraction of reticulocytes;
LUAD	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-11.12	-0.48	2.26e-25	Bone mineral density;
LUAD	cis	rs4889855	0.530	rs8072592	chr17:78615361	A/C	cg16591659	chr17:78472290	NA	0.44	7.71	0.35	9.12e-14	Fractional excretion of uric acid;
LUAD	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg00495681	chr13:53174319	NA	0.49	9.06	0.4	4.98e-18	Lewy body disease;
LUAD	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.51e-15	Bipolar disorder;
LUAD	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg16405210	chr4:1374714	KIAA1530	-0.43	-7.25	-0.33	2.05e-12	Longevity;
LUAD	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg05368731	chr17:41323189	NBR1	0.82	16.58	0.63	6.16e-48	Menopause (age at onset);
LUAD	cis	rs7487075	0.619	rs10785627	chr12:46824229	G/A	cg23829395	chr12:46796953	NA	0.32	7.1	0.33	5.34e-12	Itch intensity from mosquito bite;
LUAD	cis	rs11671005	0.651	rs35117909	chr19:58912906	G/A	cg13877915	chr19:58951672	ZNF132	0.55	6.99	0.32	1.1e-11	Mean platelet volume;
LUAD	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg25233709	chr10:116636983	FAM160B1	0.41	8.07	0.37	7.48e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1160297	0.609	rs12713231	chr2:53105695	C/G	cg07782112	chr2:53107842	NA	0.4	8.75	0.39	5.13e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.12	15.5	0.6	3.05e-43	Lung cancer in ever smokers;
LUAD	cis	rs3760982	1.000	rs3760982	chr19:44286513	A/G	cg12072164	chr19:44306565	LYPD5	0.39	7.9	0.36	2.46e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	trans	rs8073060	0.855	rs12150450	chr17:33868896	A/T	cg19694781	chr19:47549865	TMEM160	0.79	12.27	0.51	8.3e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	trans	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.38	-0.38	7.69e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg15181151	chr6:150070149	PCMT1	0.39	7.91	0.36	2.31e-14	Lung cancer;
LUAD	cis	rs599083	0.744	rs603129	chr11:68186669	A/T	cg01657329	chr11:68192670	LRP5	0.51	8.37	0.38	8.24e-16	Bone mineral density (spine);
LUAD	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg26513180	chr16:89883248	FANCA	0.79	7.19	0.33	2.92e-12	Skin colour saturation;
LUAD	cis	rs870825	0.929	rs72689262	chr4:185590950	C/G	cg04058563	chr4:185651563	MLF1IP	0.74	9.52	0.42	1.37e-19	Blood protein levels;
LUAD	cis	rs1816752	0.805	rs4769353	chr13:25000456	A/G	cg02811702	chr13:24901961	NA	0.39	6.73	0.31	5.45e-11	Obesity-related traits;
LUAD	cis	rs6743376	0.509	rs1530552	chr2:113818120	G/T	cg09040174	chr2:113837401	NA	0.52	7.99	0.36	1.32e-14	Inflammatory biomarkers;
LUAD	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg23387056	chr11:14280742	SPON1	0.46	9.63	0.42	5.45e-20	Mitochondrial DNA levels;
LUAD	cis	rs6426558	0.515	rs7412928	chr1:227332148	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.54	-8.61	-0.39	1.42e-16	Neutrophil percentage of white cells;
LUAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg22907277	chr7:1156413	C7orf50	0.69	8.06	0.37	7.69e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg21051086	chr3:73046214	PPP4R2	-0.44	-7.26	-0.33	1.87e-12	Pancreatic cancer;
LUAD	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg21699342	chr2:239360505	ASB1	0.58	11.25	0.48	7.52e-26	Multiple system atrophy;
LUAD	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.35	-6.71	-0.31	6.21e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	trans	rs7395662	1.000	rs6485872	chr11:48579710	A/C	cg00717180	chr2:96193071	NA	-0.4	-7.51	-0.34	3.57e-13	HDL cholesterol;
LUAD	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg23950597	chr19:37808831	NA	-0.6	-7.52	-0.34	3.32e-13	Coronary artery calcification;
LUAD	cis	rs62400317	0.859	rs11967630	chr6:45128524	G/C	cg18551225	chr6:44695536	NA	-0.56	-8.73	-0.39	5.77e-17	Total body bone mineral density;
LUAD	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg10729496	chr3:10149963	C3orf24	0.56	7.6	0.35	1.93e-13	Alzheimer's disease;
LUAD	cis	rs80319144	0.521	rs3796106	chr2:159312777	A/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.41	8.04	0.36	8.89e-15	Restless legs syndrome;
LUAD	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg03929089	chr4:120376271	NA	0.54	7.13	0.33	4.32e-12	Axial length;
LUAD	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg07636037	chr3:49044803	WDR6	0.48	8.05	0.36	8.47e-15	Menarche (age at onset);
LUAD	cis	rs9837602	1.000	rs9864437	chr3:99764754	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	9.22	0.41	1.46e-18	Breast cancer;
LUAD	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg13606994	chr1:44402422	ARTN	0.33	6.74	0.31	5.33e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg05044414	chr3:183734942	ABCC5	-0.4	-8.05	-0.36	8.52e-15	Anterior chamber depth;
LUAD	cis	rs12618769	0.652	rs3754875	chr2:99202747	C/G	cg10123293	chr2:99228465	UNC50	0.5	8.6	0.39	1.55e-16	Bipolar disorder;
LUAD	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg11344533	chr11:111475393	SIK2	-0.34	-6.36	-0.3	5.18e-10	Primary sclerosing cholangitis;
LUAD	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.42	-0.3	3.68e-10	Mood instability;
LUAD	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg19610905	chr11:61596333	FADS2	0.63	10.59	0.46	2.02e-23	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	trans	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg14917512	chr19:3094685	GNA11	0.57	6.77	0.31	4.22e-11	Diabetic kidney disease;
LUAD	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg21775007	chr8:11205619	TDH	0.44	7.82	0.36	4.37e-14	Retinal vascular caliber;
LUAD	cis	rs7177699	0.557	rs8026598	chr15:79112938	A/G	cg00540400	chr15:79124168	NA	0.44	9.42	0.42	2.93e-19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.1	0.33	5.2e-12	Parkinson's disease;
LUAD	cis	rs7759001	0.857	rs10807021	chr6:27356925	T/G	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.83e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	11.37	0.48	2.46e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg15704280	chr7:45808275	SEPT13	-0.93	-18.17	-0.66	5.74e-55	Coronary artery disease;
LUAD	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg18876405	chr7:65276391	NA	-0.6	-10.4	-0.45	1.07e-22	Aortic root size;
LUAD	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg00049323	chr5:472564	LOC25845	-0.46	-7.81	-0.35	4.58e-14	Cystic fibrosis severity;
LUAD	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg02176678	chr2:219576539	TTLL4	-0.82	-17.23	-0.64	8.75e-51	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.01	10.95	0.47	9.38e-25	Initial pursuit acceleration;
LUAD	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs2046867	0.908	rs2679208	chr3:72787440	G/A	cg25664220	chr3:72788482	NA	0.65	12.05	0.51	5.98e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2652834	1.000	rs2652838	chr15:63396088	A/G	cg25406657	chr15:63342033	TPM1	-0.44	-7.35	-0.34	1.03e-12	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg23260525	chr10:116636907	FAM160B1	0.46	10.17	0.44	7.08e-22	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg05084668	chr3:125655381	ALG1L	-0.48	-7.38	-0.34	8.5e-13	Blood pressure (smoking interaction);
LUAD	cis	rs926938	0.618	rs1286555	chr1:115361896	C/T	cg12756093	chr1:115239321	AMPD1	-0.36	-6.53	-0.3	1.93e-10	Autism;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg20029123	chr22:30783486	RNF215	-0.65	-6.35	-0.3	5.43e-10	Type 2 diabetes;
LUAD	cis	rs17102423	0.755	rs8009396	chr14:65573438	C/G	cg11161011	chr14:65562177	MAX	-0.53	-8.31	-0.37	1.28e-15	Obesity-related traits;
LUAD	cis	rs57590327	0.503	rs4856350	chr3:81503374	G/A	cg07356753	chr3:81810745	GBE1	0.47	7.32	0.34	1.27e-12	Extraversion;
LUAD	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg02269571	chr22:50332266	NA	-0.65	-9.55	-0.42	1.05e-19	Schizophrenia;
LUAD	cis	rs62238980	0.614	rs4820061	chr22:32378359	G/T	cg02631450	chr22:32366979	NA	0.79	6.46	0.3	2.9e-10	Childhood ear infection;
LUAD	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg27572855	chr1:25598939	RHD	0.55	11.74	0.5	9.69e-28	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs931127	0.719	rs11227259	chr11:65459404	T/C	cg27068330	chr11:65405492	SIPA1	-0.41	-6.63	-0.31	1.01e-10	Systemic lupus erythematosus;
LUAD	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg23625390	chr15:77176239	SCAPER	0.37	6.46	0.3	2.95e-10	Blood metabolite levels;
LUAD	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg11494091	chr17:61959527	GH2	0.44	8.3	0.37	1.4e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08280861	chr8:58055591	NA	0.63	8.2	0.37	2.81e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg24069376	chr3:38537580	EXOG	-0.43	-10.71	-0.46	7.33e-24	Electrocardiographic conduction measures;
LUAD	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg24531977	chr5:56204891	C5orf35	0.72	11.59	0.49	3.7e-27	Coronary artery disease;
LUAD	cis	rs2070488	0.662	rs7375040	chr3:38469116	A/G	cg24069376	chr3:38537580	EXOG	0.31	6.66	0.31	8.3e-11	Electrocardiographic conduction measures;
LUAD	cis	rs250677	0.522	rs4705302	chr5:148354962	G/C	cg18129178	chr5:148520854	ABLIM3	0.53	8.32	0.37	1.25e-15	Breast cancer;
LUAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg16606324	chr3:10149918	C3orf24	0.67	9.8	0.43	1.38e-20	Alzheimer's disease;
LUAD	cis	rs7202877	0.706	rs37599	chr16:75502132	C/T	cg03315344	chr16:75512273	CHST6	-0.48	-6.6	-0.31	1.27e-10	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg01874867	chr7:94954059	PON1	-0.51	-7.01	-0.32	9.54e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg04731861	chr2:219085781	ARPC2	-0.24	-7.3	-0.33	1.41e-12	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9354308	0.899	rs2802055	chr6:66545756	T/C	cg07460842	chr6:66804631	NA	0.49	7.5	0.34	3.78e-13	Metabolite levels;
LUAD	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg25985355	chr7:65971099	NA	-0.55	-6.76	-0.31	4.56e-11	Diabetic kidney disease;
LUAD	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg00757033	chr12:89920650	WDR51B	0.71	12.27	0.51	8.07e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7493	0.901	rs17882539	chr7:95026408	G/A	cg07404485	chr7:94953653	PON1	-0.52	-7.78	-0.35	5.46e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg16797656	chr11:68205561	LRP5	0.46	8.74	0.39	5.56e-17	Total body bone mineral density;
LUAD	cis	rs1950500	1.000	rs1950500	chr14:24830850	T/C	cg22990158	chr14:24802150	ADCY4	-0.41	-6.44	-0.3	3.16e-10	Height;
LUAD	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.3	6.93	0.32	1.56e-11	Prostate cancer;
LUAD	cis	rs12681287	0.605	rs13262672	chr8:87355812	T/C	cg00550725	chr8:87521180	FAM82B	0.46	6.63	0.31	1.01e-10	Caudate activity during reward;
LUAD	cis	rs4285028	0.948	rs13089878	chr3:121703895	T/C	cg20356878	chr3:121714668	ILDR1	-0.49	-6.55	-0.3	1.66e-10	Multiple sclerosis;
LUAD	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg22532475	chr10:104410764	TRIM8	-0.42	-8.09	-0.37	6.58e-15	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs300774	1.000	rs300773	chr2:115035	C/T	cg21211680	chr2:198530	NA	-0.47	-6.92	-0.32	1.69e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg24634471	chr8:143751801	JRK	0.49	7.89	0.36	2.53e-14	Schizophrenia;
LUAD	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg20503657	chr10:835505	NA	0.95	14.57	0.58	2.92e-39	Eosinophil percentage of granulocytes;
LUAD	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg24818145	chr4:99064322	C4orf37	0.47	7.79	0.35	5.1e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs78761021	0.720	rs874175	chr17:9798595	T/G	cg26853458	chr17:9805074	RCVRN	0.42	8.12	0.37	5.11e-15	Type 2 diabetes;
LUAD	cis	rs11112613	0.713	rs73184084	chr12:105952615	T/A	cg03607813	chr12:105948248	NA	0.74	12.78	0.53	7.56e-32	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs7224737	0.750	rs13380830	chr17:40297658	C/G	cg20291162	chr17:40259547	DHX58	-0.57	-7.54	-0.34	2.88e-13	Fibrinogen levels;
LUAD	cis	rs806794	1.000	rs806794	chr6:26200677	A/G	cg13736514	chr6:26305472	NA	-0.46	-7.54	-0.34	2.86e-13	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUAD	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg09904177	chr6:26538194	HMGN4	0.43	7.21	0.33	2.52e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9486719	0.843	rs2472875	chr6:96844691	G/A	cg06623918	chr6:96969491	KIAA0776	0.71	9.3	0.41	7.58e-19	Migraine;Coronary artery disease;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg15420318	chr15:73925796	NPTN	-0.37	-6.72	-0.31	5.79e-11	Schizophrenia;
LUAD	cis	rs7851660	0.679	rs4297160	chr9:100585506	G/A	cg13688889	chr9:100608707	NA	-0.4	-7.29	-0.33	1.5e-12	Strep throat;
LUAD	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg20991723	chr1:152506922	NA	0.32	6.4	0.3	4.24e-10	Hair morphology;
LUAD	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11644478	chr21:40555479	PSMG1	0.64	10.22	0.44	4.67e-22	Cognitive function;
LUAD	cis	rs9486719	1.000	rs2472884	chr6:96863965	C/T	cg06623918	chr6:96969491	KIAA0776	0.72	9.93	0.43	4.9e-21	Migraine;Coronary artery disease;
LUAD	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11890956	chr21:40555474	PSMG1	0.65	11.23	0.48	8.29e-26	Cognitive function;
LUAD	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg05966235	chr16:28915196	ATP2A1	0.45	7.38	0.34	8.73e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg06108461	chr20:60628389	TAF4	0.58	7.53	0.34	3.16e-13	Obesity-related traits;
LUAD	cis	rs7107174	1.000	rs2256051	chr11:77920457	G/A	cg02023728	chr11:77925099	USP35	0.42	6.85	0.32	2.68e-11	Testicular germ cell tumor;
LUAD	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18876405	chr7:65276391	NA	0.42	6.7	0.31	6.8e-11	Aortic root size;
LUAD	cis	rs1941023	0.584	rs950803	chr11:60152563	A/T	cg08716584	chr11:60157161	MS4A7	0.48	9.72	0.43	2.8e-20	Congenital heart disease (maternal effect);
LUAD	cis	rs6696239	0.513	rs2999744	chr1:227787368	C/T	cg12133451	chr1:227746453	NA	-0.36	-6.39	-0.3	4.51e-10	Height;
LUAD	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.64	11.2	0.48	1.17e-25	Birth weight;
LUAD	cis	rs739496	0.843	rs610769	chr12:111999570	G/A	cg10833066	chr12:111807467	FAM109A	0.41	6.57	0.3	1.52e-10	Platelet count;
LUAD	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10802521	chr3:52805072	NEK4	-0.61	-11.11	-0.48	2.49e-25	Bipolar disorder;
LUAD	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg18827107	chr12:86230957	RASSF9	-0.52	-9.26	-0.41	9.99e-19	Major depressive disorder;
LUAD	cis	rs72949976	1.000	rs6747328	chr2:214032156	C/G	cg08319019	chr2:214017104	IKZF2	-0.5	-7.6	-0.35	1.95e-13	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs7737355	0.947	rs6883034	chr5:130920415	T/C	cg06307176	chr5:131281290	NA	0.51	7.84	0.36	3.7e-14	Life satisfaction;
LUAD	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.68e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.19	-0.41	1.85e-18	Total body bone mineral density;
LUAD	trans	rs6011368	0.840	rs2427638	chr20:62900717	C/T	cg13869341	chr1:15865	WASH5P	0.45	8.05	0.36	8.67e-15	Clozapine-induced cytotoxicity;
LUAD	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.62	-0.35	1.63e-13	Lung cancer;
LUAD	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg07570687	chr10:102243282	WNT8B	0.45	7.04	0.32	7.59e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00166722	chr3:10149974	C3orf24	0.73	10.94	0.47	1.1e-24	Alzheimer's disease;
LUAD	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg21963583	chr11:68658836	MRPL21	0.65	11.41	0.48	1.86e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg02002194	chr4:3960332	NA	0.27	6.4	0.3	4.15e-10	Neuroticism;
LUAD	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.99	11.01	0.47	5.75e-25	Initial pursuit acceleration;
LUAD	cis	rs10950821	0.770	rs7783959	chr7:20682513	A/C	cg02470904	chr7:20686108	ABCB5	0.44	7.11	0.33	5.04e-12	Response to statin therapy;
LUAD	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg10523679	chr1:76189770	ACADM	0.94	18.54	0.67	1.41e-56	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2479724	0.905	rs2274578	chr6:41888827	C/G	cg17623882	chr6:41773611	USP49	-0.65	-11.85	-0.5	3.61e-28	Menarche (age at onset);
LUAD	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg23649088	chr2:200775458	C2orf69	-0.57	-7.04	-0.32	7.66e-12	Schizophrenia;
LUAD	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19346786	chr7:2764209	NA	-0.55	-12.01	-0.5	8.33e-29	Height;
LUAD	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg08048268	chr3:133502702	NA	0.42	8.17	0.37	3.54e-15	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg00316803	chr15:76480434	C15orf27	-0.4	-7.59	-0.35	2e-13	Blood metabolite levels;
LUAD	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg00933542	chr6:150070202	PCMT1	0.43	8.88	0.4	1.98e-17	Lung cancer;
LUAD	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.42	0.34	6.41e-13	Menopause (age at onset);
LUAD	cis	rs68170813	0.559	rs77829121	chr7:106968470	A/G	cg23024343	chr7:107201750	COG5	0.5	7.18	0.33	3.14e-12	Coronary artery disease;
LUAD	cis	rs7731657	0.537	rs971700	chr5:130361575	T/G	cg08523029	chr5:130500466	HINT1	-0.6	-7.7	-0.35	9.69e-14	Fasting plasma glucose;
LUAD	cis	rs12368653	0.534	rs923828	chr12:58015494	G/A	cg12615879	chr12:58013172	SLC26A10	0.59	12.69	0.53	1.72e-31	Multiple sclerosis;
LUAD	cis	rs1509123	0.609	rs75140264	chr17:6713675	C/T	cg12642237	chr17:6703447	TEKT1	-0.48	-7.01	-0.32	9.45e-12	Blood metabolite levels;
LUAD	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg21984481	chr17:79567631	NPLOC4	-0.71	-17.22	-0.64	1e-50	Eye color traits;
LUAD	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg01416388	chr22:39784598	NA	-0.43	-6.56	-0.3	1.61e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg22907277	chr7:1156413	C7orf50	0.52	8.69	0.39	8.1e-17	Longevity;Endometriosis;
LUAD	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg15358701	chr1:161410459	NA	-0.67	-6.97	-0.32	1.23e-11	Rheumatoid arthritis;
LUAD	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.52	-8.16	-0.37	3.99e-15	Cognitive ability;
LUAD	cis	rs9361491	0.543	rs1507153	chr6:79484386	C/A	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.45	-0.3	3.1e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg19875535	chr5:140030758	IK	0.45	7.6	0.35	1.88e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg10792982	chr14:105748885	BRF1	0.46	9.72	0.43	2.75e-20	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg06558623	chr16:89946397	TCF25	0.64	7.39	0.34	8.18e-13	Skin colour saturation;
LUAD	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.42	6.59	0.31	1.28e-10	Platelet count;
LUAD	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg03233332	chr7:66118400	NA	-0.45	-6.67	-0.31	8.2e-11	Aortic root size;
LUAD	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg07917127	chr4:99064746	C4orf37	0.5	8.06	0.37	7.69e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg18105134	chr13:113819100	PROZ	-0.87	-15.14	-0.59	1.1e-41	Platelet distribution width;
LUAD	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg11494091	chr17:61959527	GH2	-0.38	-7.13	-0.33	4.31e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.71	-0.43	2.84e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.91e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg03037974	chr15:76606532	NA	0.38	8.21	0.37	2.8e-15	Blood metabolite levels;
LUAD	trans	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg19894588	chr14:64061835	NA	0.51	7.97	0.36	1.52e-14	Glioblastoma;Glioma;
LUAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg07677032	chr17:61819896	STRADA	0.57	10.39	0.45	1.14e-22	Prudent dietary pattern;
LUAD	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg08508325	chr11:3079039	CARS	0.43	8.88	0.4	1.87e-17	Calcium levels;
LUAD	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	7.48	0.34	4.2e-13	Schizophrenia;
LUAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg14820908	chr5:178986412	RUFY1	0.64	11.3	0.48	4.89e-26	Lung cancer;
LUAD	cis	rs9814567	0.727	rs7641798	chr3:134345719	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.19	-0.51	1.6800000000000001e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4812048	1.000	rs6070692	chr20:57586374	A/G	cg14073986	chr20:57617431	SLMO2	0.54	6.52	0.3	1.97e-10	Mean platelet volume;
LUAD	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.84	-0.53	4.15e-32	Breast cancer;
LUAD	cis	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg07460842	chr6:66804631	NA	-0.94	-14.96	-0.59	6.64e-41	Exhaled nitric oxide levels;
LUAD	cis	rs7119038	0.818	rs73003215	chr11:118649512	G/A	cg19308663	chr11:118741387	NA	0.44	6.54	0.3	1.82e-10	Sjögren's syndrome;
LUAD	trans	rs9914544	0.689	rs8073236	chr17:18787182	C/G	cg21372672	chr17:16614065	CCDC144A	-0.45	-8.06	-0.36	7.97e-15	Educational attainment (years of education);
LUAD	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg14343924	chr8:8086146	FLJ10661	0.44	7.17	0.33	3.47e-12	Neuroticism;
LUAD	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg18477163	chr1:228402036	OBSCN	-0.37	-7.38	-0.34	8.55e-13	Diastolic blood pressure;
LUAD	cis	rs1172822	0.828	rs11668344	chr19:55833664	A/G	cg04391588	chr19:55832610	TMEM150B	0.35	6.78	0.31	4.05e-11	Menarche and menopause (age at onset);Menopause (age at onset);
LUAD	cis	rs9787249	0.533	rs1883649	chr1:40246549	C/T	cg24920358	chr1:40204285	PPIE	0.57	10.22	0.45	4.56e-22	Blood protein levels;
LUAD	cis	rs7589342	0.831	rs6714861	chr2:106518893	C/T	cg16077055	chr2:106428750	NCK2	-0.36	-6.39	-0.3	4.32e-10	Addiction;
LUAD	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.33	7.0	0.32	1.03e-11	Cardiac Troponin-T levels;
LUAD	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg20587970	chr11:113659929	NA	-1.38	-20.5	-0.71	2.42e-65	Hip circumference adjusted for BMI;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04025889	chr20:32891089	AHCY	-0.45	-7.0	-0.32	1.03e-11	Height;
LUAD	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg07395648	chr5:131743802	NA	0.38	6.54	0.3	1.79e-10	Breast cancer;
LUAD	cis	rs877282	0.898	rs11253346	chr10:765313	A/G	cg17470449	chr10:769945	NA	0.63	9.0	0.4	7.54e-18	Uric acid levels;
LUAD	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg22166914	chr1:53195759	ZYG11B	0.54	9.43	0.42	2.74e-19	Monocyte count;
LUAD	cis	rs7746199	0.736	rs35037868	chr6:27759115	G/C	cg12623302	chr6:28058802	ZSCAN12L1	0.54	6.41	0.3	3.93e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg08316699	chr6:150357289	NA	0.37	7.84	0.36	3.65e-14	Alopecia areata;
LUAD	cis	rs8017423	0.647	rs12883844	chr14:90820519	T/C	cg14092571	chr14:90743983	NA	0.39	6.63	0.31	1.04e-10	Mortality in heart failure;
LUAD	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg02493740	chr2:85810744	VAMP5	-0.43	-7.9	-0.36	2.36e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg20962211	chr2:183580829	DNAJC10	-0.72	-7.32	-0.34	1.27e-12	Type 2 diabetes;
LUAD	cis	rs11958404	0.546	rs10475647	chr5:157443489	A/G	cg05962755	chr5:157440814	NA	0.48	8.81	0.39	3.38e-17	IgG glycosylation;
LUAD	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg22508957	chr16:3507546	NAT15	0.48	7.37	0.34	9.09e-13	Body mass index (adult);
LUAD	cis	rs1595825	0.891	rs7592344	chr2:198572461	C/T	cg00982548	chr2:198649783	BOLL	-0.63	-9.16	-0.41	2.28e-18	Ulcerative colitis;
LUAD	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg18230493	chr5:56204884	C5orf35	-0.86	-12.49	-0.52	1.06e-30	Initial pursuit acceleration;
LUAD	cis	rs4523957	0.855	rs12601834	chr17:2112431	C/T	cg16513277	chr17:2031491	SMG6	-0.79	-14.94	-0.59	7.77e-41	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg11494091	chr17:61959527	GH2	0.44	8.62	0.39	1.36e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7759001	0.857	rs766092	chr6:27368031	T/C	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs1003719	0.788	rs2835600	chr21:38468958	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.65	0.39	1.11e-16	Eye color traits;
LUAD	cis	rs7759001	0.948	rs6456781	chr6:27386057	G/A	cg18711553	chr6:27366782	ZNF391	0.4	6.48	0.3	2.6e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs12545109	0.800	rs1440747	chr8:57417924	G/T	cg17761419	chr8:57350749	NA	0.52	7.42	0.34	6.27e-13	Obesity-related traits;
LUAD	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg24558204	chr6:135376177	HBS1L	0.48	8.14	0.37	4.6e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg27279351	chr12:120934652	DYNLL1	0.41	6.36	0.3	5.32e-10	High light scatter reticulocyte count;
LUAD	cis	rs9902453	0.765	rs3102555	chr17:28044101	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.36	0.45	1.4e-22	Coffee consumption (cups per day);
LUAD	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg21854759	chr1:92012499	NA	-0.54	-10.15	-0.44	8.04e-22	Breast cancer;
LUAD	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg04450456	chr4:17643702	FAM184B	0.37	6.94	0.32	1.44e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12900413	0.687	rs28435184	chr15:90306732	T/C	cg24249390	chr15:90295951	MESP1	-0.34	-6.57	-0.3	1.47e-10	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs4917300	0.605	rs1388800	chr8:143106264	C/T	cg25363559	chr8:143086065	NA	0.47	9.38	0.41	4.22e-19	Amyotrophic lateral sclerosis;
LUAD	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg19622623	chr12:86230825	RASSF9	-0.55	-9.82	-0.43	1.17e-20	Major depressive disorder;
LUAD	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.34	-0.41	5.41e-19	Total body bone mineral density;
LUAD	cis	rs733175	0.857	rs751092	chr4:10005897	C/T	cg00071950	chr4:10020882	SLC2A9	0.6	9.03	0.4	6.32e-18	Psychosis and Alzheimer's disease;
LUAD	cis	rs16958440	0.867	rs76922914	chr18:44688454	T/C	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.67	-0.49	1.85e-27	Bone mineral density;
LUAD	trans	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg04775059	chr7:64541387	NA	0.54	7.15	0.33	3.86e-12	Aortic root size;
LUAD	cis	rs10823500	0.777	rs10762348	chr10:71952322	C/A	cg02100629	chr10:71892760	AIFM2	-0.37	-7.58	-0.35	2.19e-13	Blood protein levels;
LUAD	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg04756594	chr16:24857601	SLC5A11	0.67	11.04	0.47	4.64e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.36	-7.09	-0.33	5.68e-12	IgG glycosylation;
LUAD	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg12119029	chr16:89752879	CDK10	0.35	7.26	0.33	1.85e-12	Vitiligo;
LUAD	cis	rs113835537	0.529	rs57691879	chr11:66236604	C/T	cg24851651	chr11:66362959	CCS	0.58	10.55	0.46	2.93e-23	Airway imaging phenotypes;
LUAD	trans	rs7395662	0.759	rs4347397	chr11:48895946	T/C	cg00717180	chr2:96193071	NA	0.39	7.42	0.34	6.66e-13	HDL cholesterol;
LUAD	cis	rs7254114	0.578	rs35248735	chr19:11312238	G/A	cg02815516	chr19:11306319	KANK2	-0.32	-6.93	-0.32	1.6e-11	Immature fraction of reticulocytes;
LUAD	trans	rs875971	1.000	rs778694	chr7:65871558	A/G	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs2952156	0.959	rs11653998	chr17:37877447	C/G	cg00129232	chr17:37814104	STARD3	-0.44	-7.3	-0.33	1.41e-12	Asthma;
LUAD	cis	rs733175	0.855	rs9291641	chr4:10007259	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	9.78	0.43	1.66e-20	Psychosis and Alzheimer's disease;
LUAD	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg03605463	chr16:89740564	NA	0.67	11.71	0.49	1.28e-27	Vitiligo;
LUAD	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg09323728	chr8:95962352	TP53INP1	-0.35	-8.36	-0.38	9.11e-16	Type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1696756	0.816	rs2650242	chr17:77827360	A/T	cg02876276	chr17:77834299	NA	0.48	7.17	0.33	3.31e-12	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg08807101	chr21:30365312	RNF160	0.44	7.58	0.35	2.22e-13	Dental caries;
LUAD	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18099408	chr3:52552593	STAB1	-0.47	-8.08	-0.37	6.72e-15	Bipolar disorder;
LUAD	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg17173187	chr15:85201210	NMB	0.47	8.32	0.37	1.24e-15	Schizophrenia;
LUAD	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg19163074	chr7:65112434	INTS4L2	0.43	6.59	0.31	1.29e-10	Aortic root size;
LUAD	cis	rs6499255	0.904	rs74029403	chr16:69710472	A/C	cg15192750	chr16:69999425	NA	0.53	7.72	0.35	8.43e-14	IgE levels;
LUAD	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.32	-0.34	1.22e-12	Coronary artery disease;
LUAD	cis	rs12208915	0.731	rs9448581	chr6:79553378	A/G	cg09184832	chr6:79620586	NA	-0.49	-7.09	-0.33	5.53e-12	Left atrial antero-posterior diameter;
LUAD	cis	rs12530845	0.887	rs6948382	chr7:135323576	G/A	cg23117316	chr7:135346802	PL-5283	-0.5	-8.69	-0.39	8.22e-17	Red blood cell traits;
LUAD	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-8.94	-0.4	1.19e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg22529645	chr1:3704559	LRRC47	0.57	10.65	0.46	1.3e-23	Red cell distribution width;
LUAD	cis	rs7512552	0.839	rs3820544	chr1:150457876	A/T	cg15654264	chr1:150340011	RPRD2	0.59	11.32	0.48	3.98e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08280861	chr8:58055591	NA	0.67	8.72	0.39	6.27e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg05966235	chr16:28915196	ATP2A1	0.51	8.12	0.37	5.11e-15	Tonsillectomy;Mean corpuscular volume;
LUAD	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg00255919	chr5:131827918	IRF1	0.48	10.99	0.47	6.81e-25	Asthma (sex interaction);
LUAD	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg06640241	chr16:89574553	SPG7	0.72	12.97	0.53	1.28e-32	Multiple myeloma (IgH translocation);
LUAD	cis	rs877282	0.853	rs7069720	chr10:754487	A/G	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg15992532	chr8:142229932	SLC45A4	-0.47	-8.5	-0.38	3.36e-16	Immature fraction of reticulocytes;
LUAD	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg06387496	chr7:2775674	GNA12	-0.4	-6.63	-0.31	1.02e-10	Height;
LUAD	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg09323728	chr8:95962352	TP53INP1	0.35	7.7	0.35	9.87e-14	Type 2 diabetes;
LUAD	trans	rs629535	1.000	rs644951	chr8:70009082	C/T	cg21567404	chr3:27674614	NA	-0.99	-17.3	-0.64	4.16e-51	Dupuytren's disease;
LUAD	cis	rs6840360	0.593	rs7654294	chr4:152690975	T/C	cg22705602	chr4:152727874	NA	-0.48	-9.13	-0.41	2.75e-18	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg15704280	chr7:45808275	SEPT13	-0.89	-16.51	-0.63	1.3e-47	Height;
LUAD	trans	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg03886242	chr7:26192032	NFE2L3	-0.44	-7.58	-0.35	2.23e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.62	0.35	1.73e-13	Platelet count;
LUAD	cis	rs2880765	0.835	rs4281668	chr15:86047286	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.4	-6.58	-0.3	1.43e-10	Coronary artery disease;
LUAD	cis	rs2294693	0.680	rs4714423	chr6:41012483	C/A	cg14769373	chr6:40998127	UNC5CL	-0.46	-7.4	-0.34	7.63e-13	Gastric cancer;Non-cardia gastric cancer;
LUAD	trans	rs2797160	1.000	rs1630556	chr6:126013155	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.54	8.7	0.39	7.72e-17	Endometrial cancer;
LUAD	cis	rs12519773	0.501	rs4293897	chr5:92500822	T/G	cg18783429	chr5:92414398	NA	0.46	8.24	0.37	2.21e-15	Migraine;
LUAD	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg10596483	chr8:143751796	JRK	0.44	7.11	0.33	5e-12	Schizophrenia;
LUAD	cis	rs9346649	0.630	rs4708641	chr6:168491416	G/A	cg02770688	chr6:168491649	NA	0.53	10.16	0.44	7.7e-22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg18196295	chr10:418757	DIP2C	-0.43	-6.56	-0.3	1.56e-10	Psychosis in Alzheimer's disease;
LUAD	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg24801067	chr17:62843696	NA	-0.54	-7.55	-0.34	2.78e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7833986	1.000	rs36088882	chr8:57092914	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	10.04	0.44	2.03e-21	Height;
LUAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg09033563	chr22:24373618	LOC391322	-0.53	-8.31	-0.37	1.31e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3784262	1.000	rs4646640	chr15:58247563	C/G	cg12031962	chr15:58353849	ALDH1A2	0.43	8.54	0.38	2.52e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg12454169	chr2:30669597	LCLAT1	0.59	8.07	0.37	7.3e-15	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg20362242	chr5:692897	TPPP	0.57	6.98	0.32	1.15e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs877282	0.945	rs11253388	chr10:787852	A/G	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg19767477	chr5:127420684	SLC12A2	-0.44	-6.75	-0.31	4.94e-11	Ileal carcinoids;
LUAD	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg03806693	chr22:41940476	POLR3H	-0.81	-11.46	-0.49	1.15e-26	Vitiligo;
LUAD	trans	rs10411161	0.810	rs17778711	chr19:52385300	A/G	cg22319618	chr22:45562946	NUP50	-0.58	-7.04	-0.32	7.84e-12	Breast cancer;
LUAD	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg19761014	chr17:28927070	LRRC37B2	0.86	8.32	0.38	1.22e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3813948	0.543	rs2808468	chr1:207280703	A/G	cg11070419	chr1:207277210	C4BPA	-0.48	-7.02	-0.32	9.03e-12	C4b binding protein levels;
LUAD	cis	rs11958404	0.615	rs10044900	chr5:157451580	C/T	cg05962755	chr5:157440814	NA	-0.45	-8.52	-0.38	2.86e-16	IgG glycosylation;
LUAD	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg15017067	chr4:17643749	FAM184B	0.37	7.17	0.33	3.4e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg18721089	chr20:30220636	NA	-0.5	-7.11	-0.33	5.07e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg15128208	chr22:42549153	NA	0.43	6.76	0.31	4.67e-11	Birth weight;
LUAD	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg23711669	chr6:146136114	FBXO30	-0.4	-6.7	-0.31	6.54e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg00933542	chr6:150070202	PCMT1	0.46	9.8	0.43	1.46e-20	Lung cancer;
LUAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg17971929	chr21:40555470	PSMG1	0.53	8.02	0.36	1.07e-14	Cognitive function;
LUAD	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg07936489	chr17:37558343	FBXL20	-0.46	-7.29	-0.33	1.52e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs6980507	0.524	rs4568607	chr8:42364354	T/C	cg09913449	chr8:42400586	C8orf40	-0.34	-6.39	-0.3	4.38e-10	Glycated hemoglobin levels;
LUAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18402987	chr7:1209562	NA	0.46	7.61	0.35	1.82e-13	Longevity;Endometriosis;
LUAD	trans	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg19862616	chr7:65841803	NCRNA00174	1.06	27.31	0.8	2.21e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9486719	1.000	rs12190508	chr6:96898269	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.17	-0.44	6.77e-22	Migraine;Coronary artery disease;
LUAD	cis	rs9644630	0.841	rs7018210	chr8:19327643	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.32	-7.82	-0.36	4.39e-14	Oropharynx cancer;
LUAD	cis	rs870825	0.616	rs6552804	chr4:185637699	A/G	cg04058563	chr4:185651563	MLF1IP	0.88	14.04	0.56	4.87e-37	Blood protein levels;
LUAD	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg13902645	chr11:5959945	NA	-0.52	-8.99	-0.4	8.55e-18	DNA methylation (variation);
LUAD	cis	rs989128	0.600	rs916978	chr17:48630452	T/C	cg24438145	chr17:48624694	SPATA20	0.38	6.58	0.3	1.37e-10	Type 2 diabetes;
LUAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg21226059	chr5:178986404	RUFY1	0.69	12.28	0.51	7.19e-30	Lung cancer;
LUAD	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.22	-0.33	2.4e-12	Total body bone mineral density;
LUAD	cis	rs7394190	0.748	rs11000764	chr10:75506864	A/G	cg02286717	chr10:75415704	SYNPO2L	-0.37	-6.51	-0.3	2.11e-10	Incident atrial fibrillation;
LUAD	cis	rs9443645	0.507	rs1475046	chr6:79461801	G/A	cg11833968	chr6:79620685	NA	-0.38	-7.04	-0.32	7.82e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.56	-7.64	-0.35	1.46e-13	Body mass index;
LUAD	cis	rs9863	0.828	rs11057409	chr12:124479331	A/G	cg17723958	chr12:124429295	CCDC92	0.42	6.96	0.32	1.31e-11	White blood cell count;
LUAD	cis	rs8040855	0.579	rs6496797	chr15:85726855	T/C	cg04831495	chr15:85060580	GOLGA6L5	0.45	7.6	0.35	1.94e-13	Bulimia nervosa;
LUAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-10.5	-0.45	4.48e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	3.98e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7010267	0.570	rs6469804	chr8:120044829	G/A	cg01975934	chr8:119970761	NA	-0.34	-6.42	-0.3	3.66e-10	Total body bone mineral density (age 45-60);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01143145	chr6:33547969	BAK1	-0.42	-6.51	-0.3	2.12e-10	Height;
LUAD	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg17063962	chr7:91808500	NA	0.68	12.16	0.51	2.19e-29	Breast cancer;
LUAD	cis	rs7107174	1.000	rs2512538	chr11:77972461	T/G	cg02023728	chr11:77925099	USP35	0.52	7.96	0.36	1.61e-14	Testicular germ cell tumor;
LUAD	cis	rs1448094	0.872	rs4919777	chr12:86358491	C/T	cg19622623	chr12:86230825	RASSF9	-0.4	-7.44	-0.34	5.78e-13	Major depressive disorder;
LUAD	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs1816752	1.000	rs1816752	chr13:24980949	A/G	cg02811702	chr13:24901961	NA	0.41	6.7	0.31	6.51e-11	Obesity-related traits;
LUAD	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12667521	chr19:29218732	NA	0.61	8.57	0.38	1.89e-16	Methadone dose in opioid dependence;
LUAD	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg10518543	chr12:38710700	ALG10B	0.42	6.46	0.3	2.83e-10	Bladder cancer;
LUAD	trans	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg01620082	chr3:125678407	NA	0.48	6.53	0.3	1.87e-10	Depression;
LUAD	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg10544611	chr16:67998164	SLC12A4	-0.54	-7.19	-0.33	3.05e-12	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg18187862	chr3:45730750	SACM1L	0.54	8.3	0.37	1.43e-15	Primary sclerosing cholangitis;
LUAD	cis	rs1609391	0.561	rs9817967	chr3:136629490	G/A	cg15507776	chr3:136538369	TMEM22	0.49	8.74	0.39	5.64e-17	Neuroticism;
LUAD	cis	rs2637266	0.756	rs2245335	chr10:78553265	T/C	cg18941641	chr10:78392320	NA	0.31	6.41	0.3	3.92e-10	Pulmonary function;
LUAD	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg05890377	chr2:74357713	NA	0.79	11.13	0.48	2.01e-25	Gestational age at birth (maternal effect);
LUAD	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg20933634	chr6:27740509	NA	0.49	7.78	0.35	5.56e-14	Parkinson's disease;
LUAD	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg19622623	chr12:86230825	RASSF9	-0.55	-9.87	-0.43	7.98e-21	Major depressive disorder;
LUAD	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg26597838	chr10:835615	NA	1.31	20.55	0.71	1.41e-65	Eosinophil percentage of granulocytes;
LUAD	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg11915388	chr22:42470451	FAM109B	-0.41	-7.35	-0.34	9.99e-13	Schizophrenia;
LUAD	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg10426581	chr7:100472382	SRRT	0.77	10.26	0.45	3.32e-22	Resting heart rate;
LUAD	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg00631329	chr6:26305371	NA	-0.7	-13.35	-0.54	3.64e-34	Educational attainment;
LUAD	cis	rs1448094	0.967	rs7312144	chr12:86328256	T/C	cg02569458	chr12:86230093	RASSF9	0.37	7.07	0.33	6.27e-12	Major depressive disorder;
LUAD	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg23954153	chr1:44402353	ARTN	-0.34	-6.73	-0.31	5.62e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg07817883	chr1:32538562	TMEM39B	0.59	7.07	0.33	6.24e-12	Monocyte percentage of white cells;
LUAD	cis	rs457162	0.588	rs281870	chr6:118572150	A/C	cg18833306	chr6:118973337	C6orf204	0.65	6.37	0.3	4.92e-10	QT interval;
LUAD	trans	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg06606381	chr12:133084897	FBRSL1	-0.66	-6.9	-0.32	1.87e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17362650	1.000	rs1056204	chr2:9647091	A/C	cg12832956	chr2:9616023	IAH1	-0.47	-7.43	-0.34	6.16e-13	Alcohol dependence (age at onset);
LUAD	cis	rs9788721	0.836	rs2656065	chr15:78750549	G/A	cg18825076	chr15:78729989	IREB2	-0.55	-9.91	-0.43	6.05e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs2019216	0.542	rs3829569	chr17:21909222	T/C	cg05591447	chr17:21909280	FLJ36000	-0.26	-6.53	-0.3	1.89e-10	Pelvic organ prolapse;
LUAD	trans	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg21659725	chr3:3221576	CRBN	-0.58	-9.32	-0.41	6.52e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg02574844	chr11:5959923	NA	-0.43	-7.36	-0.34	9.66e-13	DNA methylation (variation);
LUAD	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg03948781	chr1:205179583	DSTYK	0.35	6.7	0.31	6.58e-11	Red blood cell count;
LUAD	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg17724175	chr1:150552817	MCL1	0.33	7.65	0.35	1.4e-13	Melanoma;
LUAD	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.2	-0.37	2.83e-15	Type 2 diabetes;
LUAD	trans	rs4650994	0.816	rs1074896	chr1:178591190	A/G	cg05059571	chr16:84539110	KIAA1609	0.5	8.24	0.37	2.19e-15	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs9039	0.918	rs12933086	chr16:9225494	A/G	cg08831531	chr16:9218945	NA	-0.4	-6.51	-0.3	2.07e-10	Menopause (age at onset);
LUAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg07677032	chr17:61819896	STRADA	0.57	10.47	0.45	5.72e-23	Prudent dietary pattern;
LUAD	cis	rs7107174	1.000	rs72931642	chr11:78037862	A/T	cg02023728	chr11:77925099	USP35	0.44	6.73	0.31	5.63e-11	Testicular germ cell tumor;
LUAD	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg04455712	chr21:45112962	RRP1B	-0.46	-9.35	-0.41	5.03e-19	Mean corpuscular volume;
LUAD	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg25233709	chr10:116636983	FAM160B1	0.41	8.11	0.37	5.39e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg00981070	chr1:2046702	PRKCZ	-0.36	-7.39	-0.34	7.71e-13	Height;
LUAD	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg07617317	chr6:118971624	C6orf204	0.55	8.54	0.38	2.38e-16	Diastolic blood pressure;
LUAD	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg23625390	chr15:77176239	SCAPER	0.38	7.0	0.32	1.01e-11	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.38	0.38	7.67e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7524258	0.903	rs4908449	chr1:7292700	T/C	cg07173049	chr1:7289937	CAMTA1	0.55	10.37	0.45	1.34e-22	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs2485376	1.000	rs3808938	chr10:103993689	C/G	cg20641465	chr10:103991465	PITX3	0.55	9.99	0.44	3.18e-21	QT interval;
LUAD	cis	rs68170813	0.641	rs12534124	chr7:107119047	G/A	cg23024343	chr7:107201750	COG5	0.48	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs13315871	0.929	rs13075746	chr3:58293867	G/A	cg12435725	chr3:58293450	RPP14	-0.74	-7.88	-0.36	2.86e-14	Cholesterol, total;
LUAD	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg24733560	chr20:60626293	TAF4	0.46	8.11	0.37	5.66e-15	Body mass index;
LUAD	cis	rs2302190	0.882	rs12942018	chr17:56613277	C/T	cg25885038	chr17:56607967	SEPT4	-0.52	-8.36	-0.38	9.1e-16	Vitamin D levels;
LUAD	cis	rs6426558	0.537	rs648877	chr1:227283614	A/G	cg10327440	chr1:227177885	CDC42BPA	0.58	9.41	0.42	3.15e-19	Neutrophil percentage of white cells;
LUAD	cis	rs9807989	0.839	rs4851565	chr2:102971481	C/A	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.05e-10	Asthma;
LUAD	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg09503522	chr19:53445286	ZNF321	-0.37	-6.36	-0.3	5.28e-10	Psoriasis;
LUAD	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	7.52	0.34	3.39e-13	Tonsillectomy;
LUAD	cis	rs870825	0.616	rs57086463	chr4:185639525	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	14.12	0.57	2.26e-37	Blood protein levels;
LUAD	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg25894440	chr7:65020034	NA	-0.63	-6.64	-0.31	9.72e-11	Diabetic kidney disease;
LUAD	cis	rs1044826	0.642	rs4607068	chr3:139162994	A/G	cg00490450	chr3:139108681	COPB2	0.44	7.04	0.32	7.74e-12	Obesity-related traits;
LUAD	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06022373	chr22:39101656	GTPBP1	0.48	8.11	0.37	5.5e-15	Menopause (age at onset);
LUAD	cis	rs4604732	0.588	rs6677477	chr1:247629411	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	9.03	0.4	6.19e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg04703951	chr17:43578652	NA	0.55	8.01	0.36	1.13e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg07460842	chr6:66804631	NA	-1.19	-29.92	-0.82	1.82e-106	Exhaled nitric oxide output;
LUAD	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg00898013	chr13:113819073	PROZ	0.68	12.41	0.52	2.34e-30	Platelet distribution width;
LUAD	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg14092988	chr3:52407081	DNAH1	0.36	7.41	0.34	6.79e-13	Electroencephalogram traits;
LUAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg02725872	chr8:58115012	NA	-0.33	-6.46	-0.3	2.9e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg14343924	chr8:8086146	FLJ10661	0.55	8.77	0.39	4.54e-17	Mood instability;
LUAD	cis	rs8192282	0.739	rs12118074	chr1:154477585	G/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.45	-7.58	-0.35	2.21e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg08601574	chr20:25228251	PYGB	-0.47	-8.9	-0.4	1.66e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs62400317	0.859	rs12193030	chr6:45175210	G/A	cg18551225	chr6:44695536	NA	-0.54	-8.44	-0.38	5.21e-16	Total body bone mineral density;
LUAD	cis	rs7100689	0.516	rs3862532	chr10:82015725	A/C	cg00277334	chr10:82204260	NA	-0.45	-7.38	-0.34	8.4e-13	Post bronchodilator FEV1;
LUAD	cis	rs2070677	0.935	rs12256349	chr10:135409632	G/A	cg20169779	chr10:135381914	SYCE1	-0.52	-8.39	-0.38	7.56e-16	Gout;
LUAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg26354017	chr1:205819088	PM20D1	0.79	16.29	0.62	1.2e-46	Menarche (age at onset);
LUAD	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg04155289	chr7:94953770	PON1	-0.55	-7.42	-0.34	6.66e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg20607798	chr8:58055168	NA	0.79	9.56	0.42	9.77e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg02683114	chr2:24398427	C2orf84	-0.41	-6.57	-0.3	1.48e-10	Asthma;
LUAD	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg15208524	chr1:10270712	KIF1B	0.42	6.38	0.3	4.54e-10	Hepatocellular carcinoma;
LUAD	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg07828340	chr4:882639	GAK	0.99	10.24	0.45	4.05e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg26513180	chr16:89883248	FANCA	-0.64	-6.66	-0.31	8.59e-11	Skin colour saturation;
LUAD	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg22906224	chr7:99728672	NA	0.55	9.5	0.42	1.5700000000000001e-19	Coronary artery disease;
LUAD	cis	rs863345	0.604	rs7518708	chr1:158504274	C/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs72949976	0.646	rs1441169	chr2:214033530	A/G	cg08319019	chr2:214017104	IKZF2	0.47	7.05	0.32	7.36e-12	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg16325326	chr1:53192061	ZYG11B	0.59	10.79	0.46	3.97e-24	Monocyte count;
LUAD	cis	rs6594713	0.717	rs2972689	chr5:112945966	C/T	cg12552261	chr5:112820674	MCC	0.5	7.49	0.34	4.03e-13	Brain cytoarchitecture;
LUAD	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	9.38	0.41	4.18e-19	Colorectal cancer;
LUAD	cis	rs427394	0.632	rs2279656	chr5:6737576	G/A	cg12316010	chr5:6737918	POLS	0.39	7.31	0.33	1.35e-12	Menopause (age at onset);
LUAD	cis	rs1816752	0.837	rs9318530	chr13:24998557	A/G	cg02811702	chr13:24901961	NA	-0.4	-6.95	-0.32	1.41e-11	Obesity-related traits;
LUAD	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg09796270	chr17:17721594	SREBF1	0.34	6.49	0.3	2.41e-10	Total body bone mineral density;
LUAD	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg11148817	chr5:312970	AHRR;PDCD6	-0.47	-6.44	-0.3	3.23e-10	Breast cancer;
LUAD	cis	rs4588572	0.643	rs10043115	chr5:77692019	T/C	cg11547950	chr5:77652471	NA	0.77	12.79	0.53	6.5e-32	Triglycerides;
LUAD	cis	rs4660306	1.000	rs4660870	chr1:45995231	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-6.57	-0.3	1.52e-10	Homocysteine levels;
LUAD	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	9.12	0.41	3.05e-18	Breast cancer;
LUAD	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg03037974	chr15:76606532	NA	0.38	8.03	0.36	9.49e-15	Blood metabolite levels;
LUAD	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg09491104	chr22:46646882	C22orf40	-0.56	-7.82	-0.36	4.16e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg23978390	chr7:1156363	C7orf50	0.48	6.58	0.3	1.43e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9863	0.862	rs6488912	chr12:124442752	T/C	cg17723958	chr12:124429295	CCDC92	-0.4	-6.5	-0.3	2.27e-10	White blood cell count;
LUAD	trans	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg25894440	chr7:65020034	NA	-0.63	-6.71	-0.31	6.35e-11	Gout;
LUAD	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg09904177	chr6:26538194	HMGN4	0.44	7.45	0.34	5.15e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-8.69	-0.39	8.33e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7759001	0.857	rs980962	chr6:27361008	G/A	cg18711553	chr6:27366782	ZNF391	0.39	6.53	0.3	1.94e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs10129255	0.500	rs34326748	chr14:107190760	G/C	cg07958169	chr14:107095056	NA	-0.37	-7.25	-0.33	1.94e-12	Kawasaki disease;
LUAD	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg17644776	chr2:200775616	C2orf69	-0.52	-6.53	-0.3	1.9e-10	Schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09915932	chr17:235713	NA	-0.69	-6.83	-0.32	2.95e-11	Type 2 diabetes;
LUAD	trans	rs6561151	0.681	rs17653353	chr13:44421746	A/G	cg17145862	chr1:211918768	LPGAT1	0.55	7.52	0.34	3.41e-13	Crohn's disease;
LUAD	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg15445000	chr17:37608096	MED1	0.45	8.21	0.37	2.65e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1448094	0.706	rs10863149	chr12:86425498	A/T	cg19622623	chr12:86230825	RASSF9	-0.36	-6.42	-0.3	3.77e-10	Major depressive disorder;
LUAD	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg25767906	chr1:53392781	SCP2	-0.59	-10.92	-0.47	1.32e-24	Monocyte count;
LUAD	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg18827107	chr12:86230957	RASSF9	0.46	8.17	0.37	3.58e-15	Major depressive disorder;
LUAD	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg13770153	chr20:60521292	NA	-0.62	-9.81	-0.43	1.37e-20	Body mass index;
LUAD	cis	rs7124681	0.528	rs74608150	chr11:47696214	A/T	cg18512352	chr11:47633146	NA	0.37	6.59	0.3	1.35e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs300774	1.000	rs300774	chr2:112496	G/T	cg21211680	chr2:198530	NA	0.44	6.54	0.3	1.83e-10	Suicide attempts in bipolar disorder;
LUAD	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg11502198	chr6:26597334	ABT1	0.55	9.09	0.4	3.73e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs9826463	0.582	rs11708870	chr3:142070013	A/G	cg20824294	chr3:142316082	PLS1	0.43	7.29	0.33	1.54e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg00277334	chr10:82204260	NA	-0.67	-12.25	-0.51	9.88e-30	Post bronchodilator FEV1;
LUAD	cis	rs7799006	0.782	rs2159044	chr7:2262941	C/A	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.41	-0.3	3.83e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.07	0.32	6.64e-12	Cardiac Troponin-T levels;
LUAD	cis	rs4588572	0.643	rs1019739	chr5:77770241	G/C	cg11547950	chr5:77652471	NA	-0.78	-12.61	-0.52	3.72e-31	Triglycerides;
LUAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg06263672	chr7:65235340	NA	0.49	7.98	0.36	1.42e-14	Calcium levels;
LUAD	trans	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg06606381	chr12:133084897	FBRSL1	-1.07	-10.05	-0.44	1.88e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg26752003	chr8:145688521	CYHR1	0.46	8.22	0.37	2.48e-15	Age at first birth;
LUAD	cis	rs9400271	0.527	rs57749539	chr6:109640667	T/C	cg21918786	chr6:109611834	NA	0.39	6.41	0.3	3.91e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.66	0.31	8.56e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg01620082	chr3:125678407	NA	-0.72	-7.28	-0.33	1.62e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg12432903	chr7:1882776	MAD1L1	-0.53	-8.83	-0.39	2.77e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs17092148	0.731	rs35507767	chr20:33361364	A/T	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.19	-0.37	3.21e-15	Neuroticism;
LUAD	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg15147215	chr3:52552868	STAB1	-0.41	-7.52	-0.34	3.41e-13	Bipolar disorder;
LUAD	trans	rs4332037	0.722	rs28705934	chr7:1916116	T/A	cg11693508	chr17:37793320	STARD3	0.55	7.66	0.35	1.32e-13	Bipolar disorder;
LUAD	cis	rs807669	0.525	rs2282684	chr22:19184244	C/T	cg02655711	chr22:19163373	SLC25A1	0.59	11.15	0.48	1.67e-25	Metabolite levels;
LUAD	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg03714773	chr7:91764589	CYP51A1	0.31	7.0	0.32	1.04e-11	Breast cancer;
LUAD	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-6.73	-0.31	5.39e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.61	8.15	0.37	4.11e-15	Renal function-related traits (BUN);
LUAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-9.13	-0.41	2.82e-18	Alzheimer's disease;
LUAD	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg21427119	chr20:30132790	HM13	-0.56	-8.42	-0.38	5.92e-16	Mean corpuscular hemoglobin;
LUAD	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.54	7.74	0.35	7.4e-14	Platelet count;
LUAD	cis	rs977987	0.778	rs35415181	chr16:75403124	T/C	cg03315344	chr16:75512273	CHST6	0.65	14.07	0.56	3.79e-37	Dupuytren's disease;
LUAD	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.07	-0.37	7.22e-15	Diabetic kidney disease;
LUAD	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.8	-0.39	3.48e-17	Alzheimer's disease (late onset);
LUAD	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	15.35	0.6	1.41e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg03433033	chr1:76189801	ACADM	0.83	14.5	0.58	5.62e-39	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1832871	0.711	rs9459769	chr6:158666493	T/C	cg07165851	chr6:158734300	TULP4	0.7	10.57	0.46	2.44e-23	Height;
LUAD	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg18129178	chr5:148520854	ABLIM3	-0.64	-9.8	-0.43	1.42e-20	Breast cancer;
LUAD	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg15448220	chr1:150897856	SETDB1	0.46	7.98	0.36	1.39e-14	Tonsillectomy;
LUAD	cis	rs1003719	0.613	rs9978998	chr21:38535848	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.43	-0.38	5.42e-16	Eye color traits;
LUAD	trans	rs2018683	0.711	rs2158788	chr7:28971958	G/A	cg19402173	chr7:128379420	CALU	-0.56	-9.0	-0.4	7.55e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1113500	0.933	rs2077259	chr1:108629551	T/C	cg06207961	chr1:108661230	NA	0.45	8.52	0.38	2.83e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12618769	0.652	rs76525766	chr2:99221088	A/G	cg10123293	chr2:99228465	UNC50	0.5	8.87	0.4	2.09e-17	Bipolar disorder;
LUAD	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg00310523	chr12:86230176	RASSF9	-0.4	-7.87	-0.36	2.9e-14	Major depressive disorder;
LUAD	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg07570687	chr10:102243282	WNT8B	0.46	7.09	0.33	5.53e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg18721089	chr20:30220636	NA	-0.49	-7.06	-0.32	6.99e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs3784262	1.000	rs12903474	chr15:58276747	A/C	cg12031962	chr15:58353849	ALDH1A2	0.48	9.74	0.43	2.37e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg03806693	chr22:41940476	POLR3H	-0.66	-9.74	-0.43	2.33e-20	Vitiligo;
LUAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg11766577	chr21:47581405	C21orf56	-0.45	-6.46	-0.3	2.96e-10	Testicular germ cell tumor;
LUAD	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.45	6.95	0.32	1.39e-11	Height;
LUAD	cis	rs11771526	1.000	rs11764617	chr7:32339102	T/C	cg27511599	chr7:32358540	NA	0.61	7.15	0.33	3.84e-12	Body mass index;
LUAD	cis	rs1784581	1.000	rs1784581	chr6:162401127	A/C	cg17173639	chr6:162384350	PARK2	-0.57	-10.42	-0.45	8.52e-23	Itch intensity from mosquito bite;
LUAD	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg02753203	chr1:228287806	NA	-0.46	-8.41	-0.38	6.15e-16	Diastolic blood pressure;
LUAD	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.76	0.39	4.58e-17	Cannabis dependence symptom count;
LUAD	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg06002616	chr8:101225028	SPAG1	-0.39	-7.9	-0.36	2.35e-14	Atrioventricular conduction;
LUAD	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg15147215	chr3:52552868	STAB1	-0.4	-7.49	-0.34	3.92e-13	Electroencephalogram traits;
LUAD	cis	rs2239547	0.603	rs71301807	chr3:53085475	C/G	cg11645453	chr3:52864694	ITIH4	0.54	9.9	0.43	6.49e-21	Schizophrenia;
LUAD	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg14458575	chr2:238380390	NA	0.99	18.99	0.68	1.39e-58	Prostate cancer;
LUAD	trans	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg21659725	chr3:3221576	CRBN	-0.57	-9.17	-0.41	2.14e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.04	0.32	7.83e-12	Colorectal cancer;
LUAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg00106254	chr7:1943704	MAD1L1	-0.6	-9.05	-0.4	5.15e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs6500395	0.962	rs3743780	chr16:48647480	A/G	cg04672837	chr16:48644449	N4BP1	0.39	6.82	0.31	3.1e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9902453	0.765	rs2628191	chr17:28051140	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.33	-0.45	1.79e-22	Coffee consumption (cups per day);
LUAD	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg13319975	chr6:146136371	FBXO30	-0.67	-11.67	-0.49	1.81e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.52	7.52	0.34	3.27e-13	Total cholesterol levels;
LUAD	cis	rs116248771	0.739	rs4680448	chr3:158349978	C/A	cg16708174	chr3:158430962	RARRES1	0.47	6.92	0.32	1.71e-11	diarrhoeal disease at age 2;
LUAD	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg25767906	chr1:53392781	SCP2	0.45	8.27	0.37	1.81e-15	Monocyte count;
LUAD	cis	rs57994353	0.897	rs66477686	chr9:139372224	T/C	cg14019695	chr9:139328340	INPP5E	0.39	6.36	0.3	5.1e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06873352	chr17:61820015	STRADA	0.82	18.18	0.66	5.3e-55	Prudent dietary pattern;
LUAD	cis	rs7659604	0.540	rs28615388	chr4:122678418	C/T	cg06713675	chr4:122721982	EXOSC9	0.42	7.73	0.35	7.8e-14	Type 2 diabetes;
LUAD	cis	rs17102423	0.723	rs55658675	chr14:65554638	C/T	cg11161011	chr14:65562177	MAX	-0.51	-8.12	-0.37	5.18e-15	Obesity-related traits;
LUAD	cis	rs3981351	0.797	rs34293126	chr10:115465925	G/T	cg24846397	chr10:115438155	CASP7	-0.44	-6.69	-0.31	7.05e-11	Obesity-related traits;
LUAD	cis	rs4523957	0.671	rs7223161	chr17:2176181	G/A	cg16513277	chr17:2031491	SMG6	-0.68	-10.57	-0.46	2.48e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.48e-10	Prostate cancer;
LUAD	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg22482690	chr17:47019901	SNF8	0.46	8.88	0.4	1.87e-17	Type 2 diabetes;
LUAD	trans	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg03886242	chr7:26192032	NFE2L3	-0.39	-6.39	-0.3	4.34e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.05	-0.32	7.52e-12	Height;
LUAD	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg23260525	chr10:116636907	FAM160B1	0.47	11.0	0.47	6.26e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg24644049	chr4:85504048	CDS1	0.91	7.81	0.36	4.5e-14	Skin colour saturation;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05038977	chr17:7476167	EIF4A1	-0.45	-6.95	-0.32	1.42e-11	Height;
LUAD	cis	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg12964065	chr18:77638022	KCNG2	0.56	6.84	0.32	2.75e-11	Opioid sensitivity;
LUAD	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.59e-12	Breast cancer;
LUAD	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg14196790	chr5:131705035	SLC22A5	-0.58	-10.84	-0.47	2.62e-24	Blood metabolite levels;
LUAD	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg06784218	chr1:46089804	CCDC17	-0.59	-12.98	-0.53	1.14e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg12573674	chr2:1569213	NA	-0.57	-7.93	-0.36	2.02e-14	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg18404041	chr3:52824283	ITIH1	-0.59	-10.23	-0.45	4.44e-22	Schizophrenia;
LUAD	cis	rs2115630	0.754	rs12595321	chr15:85331269	G/A	cg11189052	chr15:85197271	WDR73	-0.46	-7.38	-0.34	8.21e-13	P wave terminal force;
LUAD	cis	rs7326068	0.610	rs2314719	chr13:21313282	G/A	cg27499820	chr13:21296301	IL17D	0.53	7.91	0.36	2.2e-14	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg07677032	chr17:61819896	STRADA	0.54	9.92	0.43	5.64e-21	Prudent dietary pattern;
LUAD	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg12458913	chr13:53173898	NA	0.35	6.4	0.3	4.24e-10	Lewy body disease;
LUAD	trans	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg01620082	chr3:125678407	NA	-1.04	-10.25	-0.45	3.6e-22	Depression;
LUAD	cis	rs10744422	0.925	rs2061098	chr12:123349410	T/C	cg16953816	chr12:123349952	VPS37B	0.64	6.87	0.32	2.35e-11	Schizophrenia;
LUAD	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg25344623	chr2:136566232	LCT	0.34	6.61	0.31	1.17e-10	Mosquito bite size;
LUAD	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg15128208	chr22:42549153	NA	0.42	6.61	0.31	1.15e-10	Birth weight;
LUAD	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	6.92	0.32	1.64e-11	Platelet count;
LUAD	cis	rs2544523	0.511	rs10929387	chr2:15912926	A/G	cg26669897	chr2:15909070	NA	0.49	8.56	0.38	2.16e-16	Asthma or chronic obstructive pulmonary disease;
LUAD	trans	rs1941687	0.563	rs7232237	chr18:31324934	C/T	cg13755796	chr4:20253514	NA	0.41	6.96	0.32	1.31e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs2625529	0.526	rs8032222	chr15:72479178	C/G	cg16672083	chr15:72433130	SENP8	0.64	11.68	0.49	1.58e-27	Red blood cell count;
LUAD	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.66	-7.32	-0.34	1.28e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.75e-11	Crohn's disease;
LUAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg00106254	chr7:1943704	MAD1L1	0.47	7.24	0.33	2.08e-12	Schizophrenia;
LUAD	cis	rs9372498	0.536	rs62422235	chr6:118971913	G/A	cg18833306	chr6:118973337	C6orf204	-0.55	-7.72	-0.35	8.32e-14	Diastolic blood pressure;
LUAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg07414643	chr4:187882934	NA	0.33	6.73	0.31	5.55e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08045932	chr20:61659980	NA	0.51	9.67	0.43	4.09e-20	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs4970988	0.607	rs7548516	chr1:150980281	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.57	-8.36	-0.38	8.82e-16	Urate levels;
LUAD	trans	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg02030672	chr11:45687055	CHST1	0.45	8.21	0.37	2.63e-15	Obesity-related traits;
LUAD	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.32	6.63e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11118844	0.793	rs10218652	chr1:221947406	T/C	cg04222084	chr1:221915650	DUSP10	-0.69	-7.63	-0.35	1.58e-13	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	trans	rs7395662	1.000	rs10838931	chr11:48540973	G/A	cg00717180	chr2:96193071	NA	-0.41	-7.59	-0.35	2.06e-13	HDL cholesterol;
LUAD	cis	rs752010	1.000	rs6664724	chr1:42093821	G/A	cg06885757	chr1:42089581	HIVEP3	0.44	9.41	0.42	3.2e-19	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg03388025	chr16:89894329	SPIRE2	0.49	11.16	0.48	1.65e-25	Vitiligo;
LUAD	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg03676636	chr4:99064102	C4orf37	0.37	9.64	0.42	5.05e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg14926445	chr8:58193284	C8orf71	-0.46	-6.74	-0.31	5.21e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg17063962	chr7:91808500	NA	0.71	12.58	0.52	4.85e-31	Breast cancer;
LUAD	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.33	7.12	0.33	4.54e-12	Cardiac Troponin-T levels;
LUAD	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg09455208	chr3:40491958	NA	0.53	11.73	0.5	1.09e-27	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937890	0.531	rs2575859	chr11:14510736	C/T	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.12e-10	Mitochondrial DNA levels;
LUAD	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg07936489	chr17:37558343	FBXL20	0.51	6.9	0.32	1.9e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07256732	chr16:621771	PIGQ	-0.33	-6.84	-0.32	2.81e-11	Height;
LUAD	cis	rs151234	0.565	rs11401	chr16:28602991	A/G	cg04609801	chr16:28609176	SULT1A2	0.42	7.01	0.32	9.32e-12	Platelet distribution width;
LUAD	trans	rs7395662	0.963	rs8189397	chr11:48711870	A/T	cg00717180	chr2:96193071	NA	-0.39	-7.24	-0.33	2.16e-12	HDL cholesterol;
LUAD	cis	rs2425143	1.000	rs1056196	chr20:34327159	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.43	-0.34	5.89e-13	Blood protein levels;
LUAD	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg00383909	chr3:49044727	WDR6	0.67	8.49	0.38	3.58e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6554196	0.525	rs6554194	chr4:55499810	T/G	cg18836493	chr4:55524333	KIT	-0.37	-6.66	-0.31	8.41e-11	Monocyte count;
LUAD	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg18129178	chr5:148520854	ABLIM3	-0.6	-8.99	-0.4	8.2e-18	Breast cancer;
LUAD	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg01236616	chr12:121019343	POP5	-1.23	-19.1	-0.68	4.09e-59	Type 1 diabetes nephropathy;
LUAD	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.6	11.58	0.49	3.91e-27	Hemoglobin concentration;
LUAD	trans	rs17054480	0.614	rs57368940	chr4:169622925	A/G	cg23372723	chr17:1015100	ABR	0.54	6.44	0.3	3.21e-10	Advanced glycation end-product levels;
LUAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg17178900	chr1:205818956	PM20D1	0.45	7.68	0.35	1.08e-13	Parkinson's disease;
LUAD	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg22868518	chr11:507468	RNH1	-0.67	-6.6	-0.31	1.26e-10	Body mass index;
LUAD	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg07607921	chr17:4047574	ZZEF1;CYB5D2	-0.46	-8.18	-0.37	3.25e-15	Type 2 diabetes;
LUAD	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg26597838	chr10:835615	NA	-1.05	-16.27	-0.62	1.46e-46	Eosinophil percentage of granulocytes;
LUAD	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg07741184	chr6:167504864	NA	0.31	7.17	0.33	3.36e-12	Crohn's disease;
LUAD	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg11645453	chr3:52864694	ITIH4	-0.34	-6.45	-0.3	3.09e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg00933542	chr6:150070202	PCMT1	0.44	9.03	0.4	5.98e-18	Lung cancer;
LUAD	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg13390004	chr1:15929781	NA	0.47	8.34	0.38	1.09e-15	Systolic blood pressure;
LUAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg24813613	chr7:1882135	MAD1L1	-0.43	-7.04	-0.32	7.84e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs750460	1.000	rs12440667	chr15:74231439	C/T	cg23484268	chr15:74220776	LOXL1	-0.35	-6.69	-0.31	7.08e-11	Height;
LUAD	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg18512352	chr11:47633146	NA	-0.54	-9.69	-0.43	3.38e-20	Subjective well-being;
LUAD	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	8.77	0.39	4.54e-17	Breast cancer;
LUAD	cis	rs4268898	0.735	rs34125395	chr2:24558242	C/T	cg06627628	chr2:24431161	ITSN2	0.39	6.93	0.32	1.57e-11	Asthma;
LUAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.22	-0.41	1.38e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg15704280	chr7:45808275	SEPT13	0.65	8.39	0.38	7.38e-16	D-dimer levels;
LUAD	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg21918786	chr6:109611834	NA	-0.58	-10.61	-0.46	1.8e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs1403694	0.669	rs10440056	chr3:186433822	C/T	cg12454167	chr3:186435060	KNG1	0.51	10.6	0.46	1.96e-23	Blood protein levels;
LUAD	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg03467027	chr4:99064603	C4orf37	0.45	6.95	0.32	1.39e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg26513180	chr16:89883248	FANCA	0.78	7.17	0.33	3.47e-12	Skin colour saturation;
LUAD	trans	rs11039798	0.614	rs11039954	chr11:48741818	A/G	cg03929089	chr4:120376271	NA	0.6	6.9	0.32	1.89e-11	Axial length;
LUAD	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.98	-0.36	1.42e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.65	-0.46	1.24e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7582720	0.945	rs2351524	chr2:203880992	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.75	-9.68	-0.43	3.8e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs11048434	0.673	rs2159961	chr12:9061456	G/T	cg13575925	chr12:9217583	LOC144571	0.37	6.79	0.31	3.81e-11	Sjögren's syndrome;
LUAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg26338869	chr17:61819248	STRADA	-0.38	-6.38	-0.3	4.65e-10	Prudent dietary pattern;
LUAD	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg01028140	chr2:1542097	TPO	-0.52	-7.27	-0.33	1.73e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg16615211	chr3:44902933	MIR564;TMEM42	0.38	6.99	0.32	1.1e-11	Depressive symptoms;
LUAD	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03352830	chr11:487213	PTDSS2	0.8	10.56	0.46	2.68e-23	Body mass index;
LUAD	cis	rs7487075	0.619	rs7485580	chr12:46830374	A/C	cg23829395	chr12:46796953	NA	0.32	7.11	0.33	5e-12	Itch intensity from mosquito bite;
LUAD	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg15369054	chr17:80825471	TBCD	0.57	6.52	0.3	1.95e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02576381	chr5:159827164	C5orf54	-0.39	-6.68	-0.31	7.35e-11	Cancer;
LUAD	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg00784671	chr22:46762841	CELSR1	-0.53	-7.43	-0.34	6.01e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg25358565	chr5:93447407	FAM172A	0.56	6.78	0.31	3.96e-11	Diabetic retinopathy;
LUAD	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg17366294	chr4:99064904	C4orf37	-0.51	-9.13	-0.41	2.88e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6138458	1.000	rs227616	chr20:24908811	T/C	cg26195577	chr20:24973756	C20orf3	0.96	16.32	0.62	8.79e-47	Blood protein levels;
LUAD	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg21153622	chr11:89784906	NA	-0.34	-6.69	-0.31	7.23e-11	Coronary artery disease;
LUAD	cis	rs12505328	0.966	rs10034374	chr4:174356389	T/C	cg12145043	chr4:174357286	NA	-0.57	-9.91	-0.43	5.91e-21	Chin dimples;
LUAD	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.9	0.53	2.48e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg16479474	chr6:28041457	NA	0.37	6.5	0.3	2.22e-10	Parkinson's disease;
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg16942681	chr18:21032779	RIOK3	-0.37	-6.37	-0.3	4.9e-10	Migraine with aura;
LUAD	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg22920501	chr2:26401640	FAM59B	0.78	10.27	0.45	3.04e-22	Gut microbiome composition (summer);
LUAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg00106254	chr7:1943704	MAD1L1	-0.55	-8.12	-0.37	5.2e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs2806561	1.000	rs2776819	chr1:23470116	A/T	cg19743168	chr1:23544995	NA	0.36	6.56	0.3	1.6e-10	Height;
LUAD	cis	rs8048589	1.000	rs11648816	chr16:12184107	T/G	cg03816625	chr16:12192430	SNX29	0.55	8.2	0.37	2.86e-15	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.43	-7.58	-0.35	2.23e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.43	-6.98	-0.32	1.17e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs601339	0.938	rs1696344	chr12:123183059	C/T	cg11919336	chr12:123188078	GPR109A	0.46	6.92	0.32	1.65e-11	Adiponectin levels;
LUAD	cis	rs62025270	0.547	rs338520	chr15:86214798	A/G	cg13263323	chr15:86062960	AKAP13	-0.44	-7.07	-0.33	6.46e-12	Idiopathic pulmonary fibrosis;
LUAD	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg18944383	chr4:111397179	ENPEP	0.37	7.41	0.34	6.86e-13	Height;
LUAD	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg04944784	chr2:26401820	FAM59B	-0.69	-9.76	-0.43	1.96e-20	Gut microbiome composition (summer);
LUAD	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg00530320	chr1:46809349	NSUN4	0.52	8.16	0.37	3.96e-15	Menopause (age at onset);
LUAD	trans	rs2797160	1.000	rs1739354	chr6:126017808	G/C	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.86	0.4	2.17e-17	Endometrial cancer;
LUAD	trans	rs8073060	0.671	rs9894813	chr17:33873848	C/T	cg19694781	chr19:47549865	TMEM160	0.94	14.05	0.56	4.46e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	trans	rs8073060	0.586	rs225264	chr17:33961335	A/G	cg19694781	chr19:47549865	TMEM160	-1.24	-19.59	-0.69	2.7e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12541635	1.000	rs1864320	chr8:107088979	C/T	cg10147462	chr8:107024639	NA	0.4	7.29	0.33	1.55e-12	Age of smoking initiation;
LUAD	cis	rs77741769	0.571	rs12371178	chr12:121309129	T/C	cg02419362	chr12:121203948	SPPL3	0.4	8.18	0.37	3.43e-15	Mean corpuscular volume;
LUAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg18621852	chr3:10150065	C3orf24	0.42	6.74	0.31	5.34e-11	Alzheimer's disease;
LUAD	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg19622623	chr12:86230825	RASSF9	-0.55	-9.8	-0.43	1.46e-20	Major depressive disorder;
LUAD	cis	rs367615	0.513	rs11741087	chr5:108807760	G/A	cg17395555	chr5:108820864	NA	0.67	13.9	0.56	1.93e-36	Colorectal cancer (SNP x SNP interaction);
LUAD	trans	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg25894440	chr7:65020034	NA	-0.63	-6.67	-0.31	8.15e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.52	0.42	1.39e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9652601	0.845	rs7184615	chr16:11165542	G/C	cg04616529	chr16:11181986	CLEC16A	0.41	7.52	0.34	3.38e-13	Systemic lupus erythematosus;
LUAD	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	6.93	0.32	1.58e-11	Schizophrenia;
LUAD	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg08859206	chr1:53392774	SCP2	0.59	10.45	0.45	6.72e-23	Monocyte count;
LUAD	trans	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.74	0.46	5.74e-24	Exhaled nitric oxide output;
LUAD	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg11822812	chr5:140052017	DND1	-0.4	-7.4	-0.34	7.61e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4481887	0.676	rs946761	chr1:248521032	T/C	cg00666640	chr1:248458726	OR2T12	0.29	7.29	0.33	1.49e-12	Common traits (Other);
LUAD	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg26343298	chr8:95960752	TP53INP1	0.37	7.82	0.36	4.12e-14	Type 2 diabetes;
LUAD	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg00204512	chr16:28754710	NA	0.34	7.28	0.33	1.66e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Depression;
LUAD	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg14725641	chr11:61582763	MIR1908;FADS1	-0.44	-6.86	-0.32	2.52e-11	Trans fatty acid levels;
LUAD	trans	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg14917512	chr19:3094685	GNA11	-0.55	-6.44	-0.3	3.28e-10	Diabetic kidney disease;
LUAD	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg17105886	chr17:28927953	LRRC37B2	0.83	8.16	0.37	3.87e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1873147	0.569	rs59418037	chr15:63310871	A/G	cg21584241	chr15:63341463	TPM1	0.42	6.38	0.3	4.72e-10	Orofacial clefts;
LUAD	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg13393036	chr8:95962371	TP53INP1	-0.34	-7.59	-0.35	2.03e-13	Type 2 diabetes;
LUAD	trans	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.0	21.43	0.72	1.67e-69	Colorectal cancer;
LUAD	cis	rs4072705	1.000	rs3739760	chr9:127453204	T/C	cg13476313	chr9:127244764	NR5A1	0.31	7.61	0.35	1.83e-13	Menarche (age at onset);
LUAD	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.41	0.34	7.03e-13	Menopause (age at onset);
LUAD	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.81	-0.36	4.44e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs10504073	0.669	rs55948643	chr8:50026403	C/G	cg00325661	chr8:49890786	NA	0.42	9.42	0.42	2.97e-19	Blood metabolite ratios;
LUAD	cis	rs4601821	0.858	rs2298489	chr11:113235419	C/T	cg14159747	chr11:113255604	NA	-0.49	-9.24	-0.41	1.26e-18	Alcoholic chronic pancreatitis;
LUAD	cis	rs684232	0.602	rs35206514	chr17:519859	T/C	cg15660573	chr17:549704	VPS53	-0.88	-17.95	-0.66	5.87e-54	Prostate cancer;
LUAD	trans	rs7395662	0.791	rs7945791	chr11:48936340	C/T	cg00717180	chr2:96193071	NA	0.39	7.43	0.34	6.09e-13	HDL cholesterol;
LUAD	cis	rs9462027	0.606	rs9394248	chr6:34739875	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-8.84	-0.39	2.57e-17	Systemic lupus erythematosus;
LUAD	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg26343298	chr8:95960752	TP53INP1	0.35	6.85	0.32	2.61e-11	Type 2 diabetes;
LUAD	cis	rs367615	0.731	rs58241713	chr5:108853664	G/A	cg17395555	chr5:108820864	NA	0.59	12.09	0.51	4.12e-29	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg05731713	chr7:157510257	PTPRN2	0.35	7.19	0.33	2.99e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg17366294	chr4:99064904	C4orf37	-0.72	-13.46	-0.55	1.21e-34	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4343996	0.902	rs4336505	chr7:3373740	A/C	cg21248987	chr7:3385318	SDK1	-0.35	-6.57	-0.3	1.47e-10	Motion sickness;
LUAD	cis	rs240764	0.594	rs9403997	chr6:101163433	A/C	cg09795085	chr6:101329169	ASCC3	0.38	6.36	0.3	5.23e-10	Neuroticism;
LUAD	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg13390004	chr1:15929781	NA	0.49	8.55	0.38	2.28e-16	Systolic blood pressure;
LUAD	cis	rs713587	0.806	rs6737082	chr2:25138040	A/C	cg01884057	chr2:25150051	NA	0.35	7.47	0.34	4.65e-13	Body mass index in non-asthmatics;
LUAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg24829409	chr8:58192753	C8orf71	-0.5	-6.48	-0.3	2.51e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs897984	0.762	rs11150601	chr16:30977799	G/A	cg02466173	chr16:30829666	NA	0.65	12.19	0.51	1.75e-29	Dementia with Lewy bodies;
LUAD	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg00981070	chr1:2046702	PRKCZ	0.36	6.95	0.32	1.42e-11	Height;
LUAD	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg15017067	chr4:17643749	FAM184B	0.36	7.08	0.33	6.12e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg10150615	chr22:24372951	LOC391322	-0.49	-7.92	-0.36	2.05e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg17366294	chr4:99064904	C4orf37	0.47	8.37	0.38	8.37e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg26043149	chr18:55253948	FECH	-0.42	-6.92	-0.32	1.64e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.79	0.39	3.86e-17	Menopause (age at onset);
LUAD	cis	rs739496	0.793	rs655107	chr12:111996557	T/C	cg10833066	chr12:111807467	FAM109A	0.42	6.58	0.3	1.39e-10	Platelet count;
LUAD	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.93	-0.5	1.81e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg22963979	chr7:1858916	MAD1L1	-0.62	-10.96	-0.47	9.34e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.49	-8.57	-0.38	1.97e-16	Alzheimer's disease (late onset);
LUAD	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-7.78	-0.35	5.47e-14	Total cholesterol levels;
LUAD	trans	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg07817883	chr1:32538562	TMEM39B	1.26	11.95	0.5	1.53e-28	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg17971929	chr21:40555470	PSMG1	0.55	8.61	0.39	1.48e-16	Cognitive function;
LUAD	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg25535316	chr11:579198	PHRF1	-0.4	-6.54	-0.3	1.77e-10	Systemic lupus erythematosus;
LUAD	cis	rs13223928	0.651	rs4722426	chr7:3150697	C/T	cg19214707	chr7:3157722	NA	0.5	9.34	0.41	5.6e-19	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg25237894	chr2:233734115	C2orf82	0.63	11.97	0.5	1.28e-28	Coronary artery disease;
LUAD	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg13271783	chr10:134563150	INPP5A	-0.41	-7.18	-0.33	3.19e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7927771	0.793	rs3740686	chr11:47376363	A/G	cg18512352	chr11:47633146	NA	0.43	7.34	0.34	1.12e-12	Subjective well-being;
LUAD	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg25985355	chr7:65971099	NA	-0.55	-6.85	-0.32	2.55e-11	Diabetic kidney disease;
LUAD	cis	rs6005807	0.719	rs9625523	chr22:29045745	T/C	cg12565055	chr22:29076175	TTC28	0.74	8.71	0.39	6.98e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs6693567	0.565	rs543179	chr1:150274610	G/A	cg15654264	chr1:150340011	RPRD2	-0.36	-6.61	-0.31	1.14e-10	Migraine;
LUAD	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg20673091	chr1:2541236	MMEL1	0.45	9.95	0.44	4.18e-21	Ulcerative colitis;
LUAD	trans	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg21582582	chr3:182698605	DCUN1D1	0.46	7.56	0.35	2.47e-13	Body mass index;
LUAD	cis	rs4285028	0.747	rs6791882	chr3:121373058	T/C	cg11130432	chr3:121712080	ILDR1	-0.47	-6.46	-0.3	2.88e-10	Multiple sclerosis;
LUAD	cis	rs10979	1.000	rs7774497	chr6:143889033	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-10.3	-0.45	2.33e-22	Hypospadias;
LUAD	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg18827107	chr12:86230957	RASSF9	-0.45	-8.07	-0.37	7.34e-15	Major depressive disorder;
LUAD	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg02734326	chr4:10020555	SLC2A9	-0.53	-9.14	-0.41	2.7e-18	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.09	-0.44	1.33e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg19729930	chr2:74357872	NA	0.89	16.25	0.62	1.81e-46	Gestational age at birth (maternal effect);
LUAD	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08677398	chr8:58056175	NA	0.51	6.56	0.3	1.61e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2004318	1.000	rs113405276	chr19:55065801	G/A	cg03320607	chr19:54800032	LILRA3	-0.73	-7.76	-0.35	6.42e-14	Blood protein levels;
LUAD	cis	rs4280164	0.551	rs8008406	chr14:24811159	C/T	cg07162820	chr14:24837146	NFATC4	-0.32	-6.62	-0.31	1.11e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs4711350	0.765	rs2182658	chr6:33748831	G/T	cg07979401	chr6:33739406	LEMD2	0.53	9.72	0.43	2.63e-20	Schizophrenia;
LUAD	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg11189052	chr15:85197271	WDR73	-0.6	-10.18	-0.44	6.39e-22	P wave terminal force;
LUAD	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg15017067	chr4:17643749	FAM184B	0.35	6.88	0.32	2.22e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg19336497	chr11:14380999	RRAS2	-0.7	-16.4	-0.62	3.78e-47	Sense of smell;
LUAD	trans	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-9.5	-0.42	1.64e-19	Brugada syndrome;
LUAD	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg05042697	chr2:10830656	NOL10	0.37	6.39	0.3	4.46e-10	Prostate cancer;
LUAD	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg27129171	chr3:47204927	SETD2	0.41	6.5	0.3	2.32e-10	Colorectal cancer;
LUAD	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg11663144	chr21:46675770	NA	-0.59	-11.41	-0.49	1.75e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs41298997	1	rs41298997	chr1:206655331	C/T	cg11166312	chr1:206654246	IKBKE	0.54	8.36	0.38	8.94e-16	Psoriasis;
LUAD	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg15921436	chr17:44337874	NA	0.63	9.48	0.42	1.8e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10899021	0.790	rs59958321	chr11:74354614	G/A	cg25880958	chr11:74394337	NA	-0.61	-8.07	-0.37	7.21e-15	Response to metformin (IC50);
LUAD	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg25036284	chr2:26402008	FAM59B	-0.83	-12.42	-0.52	1.98e-30	Gut microbiome composition (summer);
LUAD	cis	rs4233802	1.000	rs11895581	chr2:151125904	A/G	cg25300694	chr2:151184358	NA	0.78	6.66	0.31	8.61e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18402987	chr7:1209562	NA	0.45	7.35	0.34	1.06e-12	Longevity;Endometriosis;
LUAD	cis	rs9462027	0.606	rs2235569	chr6:34570070	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.73	-0.39	6.17e-17	Systemic lupus erythematosus;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg15076023	chr2:175260335	CIR1;SCRN3	-0.37	-6.38	-0.3	4.75e-10	Subcortical brain region volumes;
LUAD	cis	rs798766	1.000	rs11732213	chr4:1704244	T/C	cg03947459	chr4:1685442	FAM53A	-0.5	-6.45	-0.3	3.09e-10	Bladder cancer;Urinary bladder cancer;
LUAD	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg24801067	chr17:62843696	NA	0.65	8.88	0.4	1.87e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.06	-0.44	1.8e-21	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.54	-0.42	1.14e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs68170813	0.605	rs10464620	chr7:107135653	A/G	cg23024343	chr7:107201750	COG5	-0.51	-7.12	-0.33	4.73e-12	Coronary artery disease;
LUAD	trans	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00149659	chr3:10157352	C3orf10	0.86	11.57	0.49	4.56e-27	Alzheimer's disease;
LUAD	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02018176	chr4:1364513	KIAA1530	0.67	11.87	0.5	2.99e-28	Longevity;
LUAD	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg22906224	chr7:99728672	NA	0.56	9.73	0.43	2.45e-20	Coronary artery disease;
LUAD	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg23625390	chr15:77176239	SCAPER	-0.6	-9.45	-0.42	2.39e-19	Blood metabolite levels;
LUAD	cis	rs494562	0.892	rs7750970	chr6:86128570	A/T	cg21730993	chr6:86159210	NT5E	0.71	7.84	0.36	3.82e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg05717871	chr11:638507	DRD4	-0.41	-6.45	-0.3	3.11e-10	Systemic lupus erythematosus;
LUAD	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg18209359	chr17:80159595	CCDC57	0.4	6.91	0.32	1.79e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10203711	0.789	rs6431616	chr2:239540279	A/G	cg07725849	chr2:239542273	NA	-0.33	-6.56	-0.3	1.53e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs76878669	0.561	rs2279861	chr11:66133336	A/G	cg18002602	chr11:66138449	SLC29A2	0.47	10.14	0.44	9.16e-22	Educational attainment (years of education);
LUAD	cis	rs10788264	0.569	rs3901289	chr10:124027433	T/C	cg09507567	chr10:124027408	NA	0.55	12.7	0.53	1.51e-31	Total body bone mineral density;
LUAD	cis	rs17021463	0.872	rs34181160	chr4:95275157	T/G	cg11021082	chr4:95130006	SMARCAD1	0.42	7.5	0.34	3.75e-13	Testicular germ cell tumor;
LUAD	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg05182265	chr7:156933206	UBE3C	0.81	17.02	0.64	7.48e-50	Body mass index;
LUAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg08132940	chr7:1081526	C7orf50	-0.44	-6.69	-0.31	7.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.65	0.31	8.98e-11	Menarche (age at onset);
LUAD	cis	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg23950597	chr19:37808831	NA	-0.63	-7.38	-0.34	8.58e-13	Coronary artery calcification;
LUAD	cis	rs1865721	0.761	rs62089540	chr18:73218332	G/A	cg26385618	chr18:73139727	C18orf62	-0.36	-6.68	-0.31	7.77e-11	Intelligence;
LUAD	cis	rs10193935	0.901	rs10202848	chr2:42515661	A/G	cg27598129	chr2:42591480	NA	-0.73	-9.39	-0.42	3.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg19717773	chr7:2847554	GNA12	-0.51	-9.69	-0.43	3.55e-20	Height;
LUAD	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg24818145	chr4:99064322	C4orf37	0.47	7.96	0.36	1.57e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9473147	0.516	rs1931837	chr6:47442377	C/T	cg02130027	chr6:47444894	CD2AP	0.38	7.13	0.33	4.41e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg06521852	chr22:38141419	TRIOBP	0.5	9.24	0.41	1.18e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs10242455	0.867	rs73410654	chr7:99326663	A/G	cg18809830	chr7:99032528	PTCD1	-0.62	-6.43	-0.3	3.51e-10	Blood metabolite levels;
LUAD	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg19700328	chr14:106028568	NA	-0.46	-7.87	-0.36	2.95e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg19318889	chr4:1322082	MAEA	0.48	8.26	0.37	1.84e-15	Obesity-related traits;
LUAD	cis	rs2404602	0.598	rs71405204	chr15:76635305	C/G	cg00316803	chr15:76480434	C15orf27	0.43	6.71	0.31	6.42e-11	Blood metabolite levels;
LUAD	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg05425664	chr17:57184151	TRIM37	-0.42	-7.62	-0.35	1.65e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg15790184	chr11:494944	RNH1	0.4	6.6	0.31	1.24e-10	Systemic lupus erythematosus;
LUAD	trans	rs6940638	1.000	rs12215241	chr6:27023081	G/A	cg01620082	chr3:125678407	NA	-0.49	-6.59	-0.31	1.3100000000000001e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg26513180	chr16:89883248	FANCA	0.74	6.38	0.3	4.77e-10	Skin colour saturation;
LUAD	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg22875332	chr1:76189707	ACADM	0.81	14.84	0.59	2.19e-40	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg21385522	chr1:16154831	NA	0.44	6.67	0.31	8.08e-11	Dilated cardiomyopathy;
LUAD	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg18944383	chr4:111397179	ENPEP	0.37	7.42	0.34	6.2800000000000005e-13	Height;
LUAD	trans	rs11165623	0.792	rs12132069	chr1:96918809	A/C	cg10631902	chr5:14652156	NA	-0.63	-12.26	-0.51	8.51e-30	Hip circumference;Waist circumference;
LUAD	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg17105886	chr17:28927953	LRRC37B2	0.83	8.0	0.36	1.18e-14	Body mass index;
LUAD	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.3	0.41	7.47e-19	Colorectal cancer;
LUAD	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18876405	chr7:65276391	NA	0.61	10.17	0.44	6.72e-22	Aortic root size;
LUAD	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg11214544	chr1:2391121	NA	-0.49	-10.93	-0.47	1.2e-24	Schizophrenia;
LUAD	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg03806693	chr22:41940476	POLR3H	-0.75	-10.1	-0.44	1.28e-21	Vitiligo;
LUAD	cis	rs240764	0.817	rs12207086	chr6:101150463	G/A	cg09795085	chr6:101329169	ASCC3	-0.44	-7.51	-0.34	3.63e-13	Neuroticism;
LUAD	trans	rs587242	1.000	rs12758621	chr1:96898421	C/T	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.79e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg07217954	chr7:1067459	C7orf50	0.43	6.63	0.31	1.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs977987	0.835	rs3863445	chr16:75371744	C/G	cg03315344	chr16:75512273	CHST6	0.64	13.69	0.55	1.49e-35	Dupuytren's disease;
LUAD	cis	rs11229555	0.574	rs12292024	chr11:58186716	C/T	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6901250	0.851	rs6938235	chr6:117147946	G/T	cg12892004	chr6:117198278	RFX6	0.33	7.22	0.33	2.45e-12	C-reactive protein levels;
LUAD	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg03929089	chr4:120376271	NA	-0.56	-8.27	-0.37	1.78e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7665090	1.000	rs2866409	chr4:103554261	T/G	cg07973026	chr4:103553119	MANBA	0.5	8.82	0.39	3.09e-17	Primary biliary cholangitis;
LUAD	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg13770153	chr20:60521292	NA	-0.45	-7.39	-0.34	7.91e-13	Body mass index;
LUAD	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg11822812	chr5:140052017	DND1	-0.36	-6.56	-0.3	1.6e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg17178900	chr1:205818956	PM20D1	0.46	8.09	0.37	6.29e-15	Menarche (age at onset);
LUAD	cis	rs12681287	0.927	rs2953517	chr8:87332013	C/T	cg27223183	chr8:87520930	FAM82B	-0.65	-9.05	-0.4	5.26e-18	Caudate activity during reward;
LUAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg21724239	chr8:58056113	NA	0.52	6.52	0.3	2.04e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg03929089	chr4:120376271	NA	-0.94	-17.65	-0.65	1.19e-52	Height;
LUAD	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg22431228	chr1:16359049	CLCNKA	0.41	7.94	0.36	1.84e-14	Systolic blood pressure;
LUAD	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg25456477	chr12:86230367	RASSF9	0.35	6.66	0.31	8.58e-11	Major depressive disorder;
LUAD	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg13535736	chr9:111863775	C9orf5	-0.43	-6.58	-0.3	1.39e-10	Menarche (age at onset);
LUAD	cis	rs10242455	0.571	rs45532337	chr7:99310319	A/G	cg18809830	chr7:99032528	PTCD1	-0.76	-6.67	-0.31	8.03e-11	Blood metabolite levels;
LUAD	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg00277334	chr10:82204260	NA	-0.6	-10.02	-0.44	2.48e-21	Post bronchodilator FEV1;
LUAD	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.65	-0.31	9.15e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg22467129	chr15:76604101	ETFA	-0.4	-6.57	-0.3	1.5e-10	Blood metabolite levels;
LUAD	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg21823605	chr1:152486609	CRCT1	0.28	6.42	0.3	3.56e-10	Hair morphology;
LUAD	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.44	0.3	3.28e-10	Depression;
LUAD	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg21475434	chr5:93447410	FAM172A	0.78	8.54	0.38	2.53e-16	Diabetic retinopathy;
LUAD	cis	rs798766	1.000	rs798741	chr4:1712413	A/G	cg03947459	chr4:1685442	FAM53A	0.46	6.35	0.3	5.44e-10	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs3849570	0.961	rs11915042	chr3:81834060	G/A	cg07356753	chr3:81810745	GBE1	-0.71	-12.74	-0.53	1.11e-31	Waist circumference;Body mass index;
LUAD	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg02423579	chr7:2872169	GNA12	-0.57	-9.54	-0.42	1.17e-19	Height;
LUAD	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg18230493	chr5:56204884	C5orf35	-0.44	-7.38	-0.34	8.61e-13	Coronary artery disease;
LUAD	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg03433033	chr1:76189801	ACADM	0.83	14.39	0.57	1.65e-38	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg18404041	chr3:52824283	ITIH1	-0.6	-12.18	-0.51	1.78e-29	Bipolar disorder;
LUAD	cis	rs4604732	0.631	rs34924545	chr1:247626892	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.45	7.33	0.34	1.16e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg23815491	chr16:72088622	HP	-0.52	-9.69	-0.43	3.46e-20	Fibrinogen levels;
LUAD	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg19875535	chr5:140030758	IK	0.4	6.81	0.31	3.37e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg16325326	chr1:53192061	ZYG11B	0.54	9.35	0.41	5.07e-19	Monocyte count;
LUAD	cis	rs2019216	0.500	rs7210996	chr17:21917331	G/A	cg05591447	chr17:21909280	FLJ36000	-0.27	-6.41	-0.3	3.84e-10	Pelvic organ prolapse;
LUAD	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg01475377	chr6:109611718	NA	0.51	9.78	0.43	1.74e-20	Reticulocyte fraction of red cells;
LUAD	cis	rs7771547	0.603	rs72852338	chr6:36554240	A/C	cg12173498	chr6:36355764	ETV7	0.47	6.35	0.3	5.47e-10	Platelet distribution width;
LUAD	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg19761014	chr17:28927070	LRRC37B2	0.94	8.9	0.4	1.71e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.95	-0.4	1.13e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg10556349	chr10:835070	NA	-0.45	-6.85	-0.32	2.64e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs713477	0.901	rs1572612	chr14:55909939	C/T	cg13175173	chr14:55914753	NA	-0.33	-6.91	-0.32	1.8e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg08601574	chr20:25228251	PYGB	-0.46	-8.74	-0.39	5.71e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	8.05	0.36	8.68e-15	Breast cancer;
LUAD	cis	rs12210905	0.688	rs72845028	chr6:27528408	T/C	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs62229266	0.618	rs11088334	chr21:37466829	A/T	cg08632701	chr21:37451849	NA	-0.47	-7.92	-0.36	2.06e-14	Mitral valve prolapse;
LUAD	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg23029597	chr12:123009494	RSRC2	-0.58	-9.01	-0.4	7.37e-18	Body mass index;
LUAD	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg06197492	chr11:2016605	H19	0.42	8.31	0.37	1.29e-15	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg17063962	chr7:91808500	NA	-0.61	-10.15	-0.44	8.45e-22	Breast cancer;
LUAD	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg24818145	chr4:99064322	C4orf37	0.42	6.98	0.32	1.18e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg04414720	chr1:150670196	GOLPH3L	0.68	11.88	0.5	2.87e-28	Melanoma;
LUAD	cis	rs62400317	0.826	rs17209769	chr6:45321205	C/A	cg18551225	chr6:44695536	NA	-0.54	-8.45	-0.38	4.72e-16	Total body bone mineral density;
LUAD	cis	rs713587	1.000	rs2384054	chr2:25156773	T/C	cg04586622	chr2:25135609	ADCY3	0.32	7.1	0.33	5.35e-12	Body mass index in non-asthmatics;
LUAD	cis	rs1215050	0.669	rs783962	chr4:98884473	G/A	cg05340658	chr4:99064831	C4orf37	-0.44	-7.1	-0.33	5.48e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg16205897	chr5:131564050	P4HA2	0.34	7.44	0.34	5.56e-13	Acylcarnitine levels;
LUAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg04025307	chr7:1156635	C7orf50	0.64	7.94	0.36	1.8e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg23018236	chr17:30244563	NA	-0.63	-8.16	-0.37	3.76e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg04944784	chr2:26401820	FAM59B	-0.69	-9.78	-0.43	1.66e-20	Gut microbiome composition (summer);
LUAD	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg23029597	chr12:123009494	RSRC2	-0.5	-7.68	-0.35	1.09e-13	Body mass index;
LUAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg07362569	chr17:61921086	SMARCD2	0.39	6.69	0.31	6.91e-11	Prudent dietary pattern;
LUAD	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg11645453	chr3:52864694	ITIH4	-0.34	-6.6	-0.31	1.26e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg20135002	chr11:47629003	NA	-0.42	-7.36	-0.34	9.42e-13	Subjective well-being;
LUAD	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg04450456	chr4:17643702	FAM184B	0.4	7.84	0.36	3.69e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg10518543	chr12:38710700	ALG10B	-0.51	-8.59	-0.39	1.65e-16	Morning vs. evening chronotype;
LUAD	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg07917127	chr4:99064746	C4orf37	0.4	6.65	0.31	8.98e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg05084668	chr3:125655381	ALG1L	-0.63	-10.22	-0.44	4.7e-22	Blood pressure (smoking interaction);
LUAD	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg01528321	chr10:82214614	TSPAN14	0.68	10.41	0.45	9.4e-23	Post bronchodilator FEV1;
LUAD	cis	rs17761864	0.887	rs1885987	chr17:2203025	A/C	cg16513277	chr17:2031491	SMG6	0.4	6.37	0.3	4.99e-10	Esophageal cancer (squamous cell);
LUAD	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg19761014	chr17:28927070	LRRC37B2	0.7	6.61	0.31	1.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg17063962	chr7:91808500	NA	-0.69	-12.11	-0.51	3.38e-29	Breast cancer;
LUAD	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.65	-0.35	1.37e-13	Monocyte count;
LUAD	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21582582	chr3:182698605	DCUN1D1	0.44	7.08	0.33	5.91e-12	Body mass index;
LUAD	cis	rs4774899	0.752	rs2439919	chr15:57368459	T/C	cg14026238	chr15:57616123	NA	0.43	8.15	0.37	4.25e-15	Urinary tract infection frequency;
LUAD	cis	rs904251	0.523	rs2776871	chr6:37481759	A/G	cg25019722	chr6:37503610	NA	-0.33	-7.54	-0.34	2.95e-13	Cognitive performance;
LUAD	cis	rs10733682	0.659	rs1887970	chr9:129464827	C/T	cg00232160	chr9:129468157	NA	0.5	8.97	0.4	9.56e-18	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.4e-15	Prostate cancer;
LUAD	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg03929089	chr4:120376271	NA	-0.83	-15.07	-0.59	2.26e-41	Coronary artery disease;
LUAD	cis	rs11971779	0.584	rs17613864	chr7:139095587	C/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.35	6.96	0.32	1.31e-11	Depression;
LUAD	cis	rs7267979	0.586	rs6050439	chr20:25192331	T/C	cg08601574	chr20:25228251	PYGB	0.36	6.74	0.31	5.29e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6664467	1	rs6664467	chr1:151738403	G/A	cg07092448	chr1:151763213	TDRKH	-0.72	-7.88	-0.36	2.87e-14	Carotid plaque burden;
LUAD	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg18200150	chr17:30822561	MYO1D	0.42	7.95	0.36	1.72e-14	Schizophrenia;
LUAD	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg15467112	chr14:75489610	MLH3	-0.36	-6.66	-0.31	8.4e-11	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00297737	chr8:97273749	MTERFD1;PTDSS1	-0.46	-7.25	-0.33	2.01e-12	Height;
LUAD	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg20991723	chr1:152506922	NA	0.33	6.53	0.3	1.87e-10	Hair morphology;
LUAD	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg18944383	chr4:111397179	ENPEP	0.34	6.59	0.31	1.29e-10	Coronary artery disease;
LUAD	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg04287289	chr16:89883240	FANCA	0.64	6.39	0.3	4.45e-10	Skin colour saturation;
LUAD	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg26384229	chr12:38710491	ALG10B	0.49	7.91	0.36	2.31e-14	Morning vs. evening chronotype;
LUAD	cis	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg02951883	chr7:2050386	MAD1L1	0.53	7.48	0.34	4.26e-13	Neuroticism;
LUAD	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg09835421	chr16:68378352	PRMT7	-0.83	-8.96	-0.4	1.01e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg17724175	chr1:150552817	MCL1	0.39	9.43	0.42	2.64e-19	Tonsillectomy;
LUAD	cis	rs2425143	1.000	rs6060524	chr20:34221155	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.63	-0.31	1.02e-10	Blood protein levels;
LUAD	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg15704280	chr7:45808275	SEPT13	-1.0	-19.92	-0.7	9.21e-63	Height;
LUAD	cis	rs16854884	0.586	rs6796460	chr3:143756367	G/A	cg01302019	chr3:143689584	C3orf58	-0.38	-6.75	-0.31	4.99e-11	Economic and political preferences (feminism/equality);
LUAD	cis	rs9462027	0.628	rs2477507	chr6:34703599	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-9.0	-0.4	7.74e-18	Systemic lupus erythematosus;
LUAD	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg06641503	chr3:48959341	ARIH2	-0.43	-7.65	-0.35	1.41e-13	Menarche (age at onset);
LUAD	trans	rs970548	0.730	rs61854093	chr10:45934881	C/A	cg14222797	chr10:16859974	RSU1	-0.54	-6.7	-0.31	6.8e-11	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs9658691	0.607	rs34891735	chr10:90779212	A/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.58	-7.22	-0.33	2.46e-12	Mosquito bite size;
LUAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	8.93	0.4	1.3e-17	Alzheimer's disease;
LUAD	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg03233332	chr7:66118400	NA	-0.44	-6.72	-0.31	5.73e-11	Aortic root size;
LUAD	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg26929925	chr5:138714136	SLC23A1	-0.44	-8.04	-0.36	9.3e-15	Esophageal squamous cell carcinoma;
LUAD	trans	rs7181230	1.000	rs7181230	chr15:40360741	A/G	cg22705835	chr10:65332833	REEP3	-0.36	-7.24	-0.33	2.16e-12	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs1524976	1.000	rs1917531	chr3:65503221	A/G	cg16238336	chr3:65465873	MAGI1	0.64	7.55	0.34	2.64e-13	PR interval;
LUAD	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg20203395	chr5:56204925	C5orf35	-0.51	-7.68	-0.35	1.1e-13	Type 2 diabetes;
LUAD	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg16797656	chr11:68205561	LRP5	0.47	8.91	0.4	1.53e-17	Total body bone mineral density;
LUAD	cis	rs921968	0.565	rs4674330	chr2:219595710	T/C	cg02176678	chr2:219576539	TTLL4	-0.58	-11.81	-0.5	5.1e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-8.8	-0.39	3.44e-17	Alzheimer's disease;
LUAD	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg00021532	chr16:4324280	TFAP4	0.76	15.9	0.61	5.73e-45	Prostate-specific antigen levels;
LUAD	trans	rs1973993	0.967	rs2181375	chr1:96940119	A/G	cg10631902	chr5:14652156	NA	0.56	10.6	0.46	2.01e-23	Weight;
LUAD	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.37	-6.43	-0.3	3.52e-10	Caffeine consumption;
LUAD	cis	rs367615	0.660	rs10061221	chr5:108839038	C/T	cg17395555	chr5:108820864	NA	0.67	14.34	0.57	2.66e-38	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.07e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.79	0.39	3.8e-17	Menarche (age at onset);
LUAD	cis	rs4073416	0.542	rs12433597	chr14:66028847	T/C	cg10998611	chr14:65879393	FUT8;LOC645431	-0.42	-6.41	-0.3	3.87e-10	N-glycan levels;
LUAD	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.6	-0.39	1.62e-16	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg03467027	chr4:99064603	C4orf37	0.44	7.21	0.33	2.67e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg20578329	chr17:80767326	TBCD	-0.64	-7.57	-0.35	2.36e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs11048434	0.761	rs1805765	chr12:9094548	A/G	cg13575925	chr12:9217583	LOC144571	0.36	6.77	0.31	4.43e-11	Sjögren's syndrome;
LUAD	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg23000734	chr10:126850823	CTBP2	0.54	10.85	0.47	2.27e-24	Menarche (age at onset);
LUAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14893161	chr1:205819251	PM20D1	0.82	17.24	0.64	7.99e-51	Menarche (age at onset);
LUAD	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg18230493	chr5:56204884	C5orf35	-0.84	-12.53	-0.52	7.21e-31	Initial pursuit acceleration;
LUAD	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg15017067	chr4:17643749	FAM184B	0.38	7.42	0.34	6.2800000000000005e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg12432903	chr7:1882776	MAD1L1	-0.45	-7.19	-0.33	2.89e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg18200150	chr17:30822561	MYO1D	0.44	8.16	0.37	3.77e-15	Schizophrenia;
LUAD	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg03929089	chr4:120376271	NA	-0.98	-20.96	-0.71	1.99e-67	Height;
LUAD	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg00078996	chr12:132293329	NA	-0.39	-6.57	-0.3	1.5e-10	Migraine;
LUAD	cis	rs877282	0.853	rs7079299	chr10:756455	A/G	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg19825600	chr2:3704501	ALLC	-0.59	-9.59	-0.42	7.83e-20	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs1595825	1.000	rs1440088	chr2:198871417	A/C	cg00982548	chr2:198649783	BOLL	-0.6	-8.54	-0.38	2.49e-16	Ulcerative colitis;
LUAD	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.83	0.36	4.03e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs367943	0.660	rs9632462	chr5:112697801	T/C	cg12552261	chr5:112820674	MCC	0.48	9.36	0.41	4.84e-19	Type 2 diabetes;
LUAD	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg05535760	chr7:792225	HEATR2	-0.58	-7.47	-0.34	4.63e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.43e-19	Life satisfaction;
LUAD	cis	rs55788414	0.505	rs7190543	chr16:81189320	T/C	cg06400318	chr16:81190750	PKD1L2	-0.65	-10.29	-0.45	2.61e-22	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg16647868	chr5:131706066	SLC22A5	-0.4	-6.95	-0.32	1.41e-11	Blood metabolite levels;
LUAD	cis	rs76878669	0.561	rs10896112	chr11:66116836	G/C	cg10616300	chr11:66138557	SLC29A2	-0.36	-7.51	-0.34	3.46e-13	Educational attainment (years of education);
LUAD	trans	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg18187862	chr3:45730750	SACM1L	0.49	7.74	0.35	7.53e-14	Primary sclerosing cholangitis;
LUAD	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg02696790	chr15:75250997	RPP25	0.36	6.96	0.32	1.29e-11	Breast cancer;
LUAD	cis	rs7705042	0.865	rs6882226	chr5:141503870	T/A	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.92	-0.32	1.65e-11	Asthma;
LUAD	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.44	0.57	1.08e-38	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg02176678	chr2:219576539	TTLL4	0.61	11.81	0.5	5.35e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7180079	1.000	rs62024569	chr15:64496926	T/C	cg08069370	chr15:64387884	SNX1	-0.51	-6.39	-0.3	4.36e-10	Monocyte count;
LUAD	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg03605463	chr16:89740564	NA	-0.69	-11.67	-0.49	1.81e-27	Vitiligo;
LUAD	cis	rs4664308	1.000	rs16844715	chr2:160915106	A/G	cg03641300	chr2:160917029	PLA2R1	0.39	6.79	0.31	3.87e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg00071950	chr4:10020882	SLC2A9	0.83	17.75	0.65	4.37e-53	Bone mineral density;
LUAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.61	-10.67	-0.46	1.06e-23	Lymphocyte counts;
LUAD	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg03806693	chr22:41940476	POLR3H	-0.5	-7.51	-0.34	3.56e-13	Vitiligo;
LUAD	trans	rs783540	0.500	rs1313494	chr15:83274279	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.51	-7.49	-0.34	4.12e-13	Schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15065069	chr1:154974120	ZBTB7B	-0.47	-7.72	-0.35	8.49e-14	Height;
LUAD	cis	rs7326068	0.610	rs7995798	chr13:21338432	C/T	cg27499820	chr13:21296301	IL17D	0.56	8.34	0.38	1.09e-15	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg03676636	chr4:99064102	C4orf37	0.29	7.05	0.32	7.2e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg11965913	chr1:205819406	PM20D1	0.77	15.47	0.6	4.16e-43	Monocyte percentage of white cells;
LUAD	cis	rs4819852	0.958	rs9606203	chr22:19972118	C/A	cg07821417	chr22:19972146	ARVCF	0.41	7.62	0.35	1.67e-13	Pulse pressure;
LUAD	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.02	-0.32	8.96e-12	Reticulocyte count;
LUAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg22907277	chr7:1156413	C7orf50	0.7	8.29	0.37	1.53e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs10802346	0.545	rs10924568	chr1:246385482	C/A	cg22732515	chr19:44031385	ETHE1	0.58	9.41	0.42	3.16e-19	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs73206853	0.702	rs7960516	chr12:110529238	T/A	cg12870014	chr12:110450643	ANKRD13A	0.58	8.18	0.37	3.34e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg06784218	chr1:46089804	CCDC17	-0.57	-12.66	-0.52	2.2e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg23649088	chr2:200775458	C2orf69	-0.62	-7.77	-0.35	6.15e-14	Schizophrenia;
LUAD	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg16615211	chr3:44902933	MIR564;TMEM42	-0.37	-7.06	-0.32	6.9e-12	Depressive symptoms;
LUAD	cis	rs56346965	0.506	rs2159818	chr2:191532789	A/G	cg11845111	chr2:191398756	TMEM194B	-0.51	-8.48	-0.38	3.85e-16	Bone mineral density (Ward's triangle area);
LUAD	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg18854424	chr1:2615690	NA	0.42	9.06	0.4	4.87e-18	Ulcerative colitis;
LUAD	cis	rs2996428	0.629	rs12135894	chr1:3728061	C/T	cg22529645	chr1:3704559	LRRC47	0.56	10.47	0.45	5.58e-23	Red cell distribution width;
LUAD	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.09	-0.33	5.65e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.38	-6.5	-0.3	2.31e-10	Longevity;Endometriosis;
LUAD	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg09365446	chr1:150670422	GOLPH3L	0.61	10.91	0.47	1.39e-24	Melanoma;
LUAD	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs13082711	0.911	rs17019721	chr3:27424799	A/G	cg02860705	chr3:27208620	NA	0.55	8.55	0.38	2.34e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs9826463	0.757	rs73240318	chr3:142277427	A/G	cg20824294	chr3:142316082	PLS1	0.44	7.7	0.35	9.55e-14	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg09455208	chr3:40491958	NA	0.56	12.36	0.52	3.6e-30	Renal cell carcinoma;
LUAD	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	7.25	0.33	2.05e-12	Iron status biomarkers;
LUAD	cis	rs1595825	0.891	rs75373125	chr2:198657044	G/A	cg00361562	chr2:198649771	BOLL	-0.5	-6.54	-0.3	1.75e-10	Ulcerative colitis;
LUAD	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg23978390	chr7:1156363	C7orf50	0.57	7.84	0.36	3.63e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs9581857	0.547	rs4612914	chr13:28049128	A/G	cg22138327	chr13:27999177	GTF3A	0.85	9.42	0.42	2.86e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg26384229	chr12:38710491	ALG10B	0.46	7.37	0.34	8.92e-13	Bladder cancer;
LUAD	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg25554036	chr4:6271136	WFS1	-0.69	-13.76	-0.56	7.03e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg09455208	chr3:40491958	NA	0.51	10.71	0.46	7.84e-24	Renal cell carcinoma;
LUAD	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg20503657	chr10:835505	NA	1.25	19.11	0.68	3.73e-59	Eosinophil percentage of granulocytes;
LUAD	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg01475377	chr6:109611718	NA	-0.52	-10.16	-0.44	7.9e-22	Reticulocyte fraction of red cells;
LUAD	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg15704280	chr7:45808275	SEPT13	0.74	10.89	0.47	1.69e-24	Coronary artery disease;
LUAD	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg13385794	chr1:248469461	NA	0.26	6.9	0.32	1.89e-11	Common traits (Other);
LUAD	cis	rs6500395	1.000	rs9937610	chr16:48671274	C/G	cg04672837	chr16:48644449	N4BP1	0.41	7.05	0.32	7.12e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs10129255	0.500	rs9324092	chr14:107139823	A/G	cg07958169	chr14:107095056	NA	0.37	7.3	0.33	1.42e-12	Kawasaki disease;
LUAD	trans	rs6921919	0.789	rs6456814	chr6:28305812	C/A	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.4	-0.3	4.06e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg08027265	chr7:2291960	NA	-0.42	-7.24	-0.33	2.18e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.58	-0.38	1.87e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.66	0.31	8.75e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	11.64	0.49	2.36e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg03676636	chr4:99064102	C4orf37	0.37	9.62	0.42	6.06e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4660306	1.000	rs2077808	chr1:45988115	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.5	-7.98	-0.36	1.36e-14	Homocysteine levels;
LUAD	trans	rs10411161	0.748	rs78410648	chr19:52399401	G/A	cg22319618	chr22:45562946	NUP50	-0.69	-7.76	-0.35	6.42e-14	Breast cancer;
LUAD	cis	rs12949688	0.967	rs1990231	chr17:55821002	G/C	cg12582317	chr17:55822272	NA	0.36	7.26	0.33	1.9e-12	Schizophrenia;
LUAD	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg17063962	chr7:91808500	NA	-0.68	-12.47	-0.52	1.33e-30	Breast cancer;
LUAD	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg22676075	chr6:135203613	NA	0.49	8.66	0.39	1.03e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg26408565	chr15:76604113	ETFA	-0.45	-7.49	-0.34	4.12e-13	Blood metabolite levels;
LUAD	cis	rs9399401	0.677	rs11155241	chr6:142664439	T/A	cg03128060	chr6:142623767	GPR126	0.49	9.52	0.42	1.31e-19	Chronic obstructive pulmonary disease;
LUAD	trans	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg11693508	chr17:37793320	STARD3	0.54	7.66	0.35	1.28e-13	Bipolar disorder;
LUAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00149659	chr3:10157352	C3orf10	0.58	8.1	0.37	5.92e-15	Alzheimer's disease;
LUAD	trans	rs7404843	0.778	rs72774864	chr16:15512322	A/G	cg02716450	chr16:28638775	NA	0.78	8.35	0.38	9.88e-16	Testicular germ cell tumor;
LUAD	cis	rs7677751	0.806	rs17084051	chr4:55087581	C/A	cg17187183	chr4:55093834	PDGFRA	0.52	8.78	0.39	3.95e-17	Corneal astigmatism;
LUAD	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08439880	chr3:133502540	NA	-0.45	-8.78	-0.39	3.96e-17	Iron status biomarkers;
LUAD	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg19163074	chr7:65112434	INTS4L2	0.43	6.56	0.3	1.59e-10	Aortic root size;
LUAD	cis	rs11696845	0.761	rs11698203	chr20:43357899	C/T	cg25301532	chr20:43378953	KCNK15	-0.38	-6.74	-0.31	5.12e-11	Obesity-related traits;
LUAD	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg22676075	chr6:135203613	NA	0.42	7.71	0.35	9.24e-14	Red blood cell count;
LUAD	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.41	6.82	0.31	3.21e-11	Total body bone mineral density;
LUAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg13126279	chr21:47581558	C21orf56	-0.45	-7.75	-0.35	7.01e-14	Testicular germ cell tumor;
LUAD	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg14228332	chr4:119757509	SEC24D	0.85	7.83	0.36	3.85e-14	Cannabis dependence symptom count;
LUAD	cis	rs2422052	0.729	rs967252	chr2:118643492	T/G	cg22545206	chr2:118617499	NA	0.4	6.83	0.32	2.88e-11	Mosquito bite size;
LUAD	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg26850624	chr5:429559	AHRR	-0.42	-6.65	-0.31	9.24e-11	Cystic fibrosis severity;
LUAD	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg02683114	chr2:24398427	C2orf84	-0.41	-6.55	-0.3	1.65e-10	Asthma;
LUAD	cis	rs16866061	1.000	rs3768886	chr2:225450161	G/C	cg12698349	chr2:225449008	CUL3	0.77	13.46	0.55	1.28e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg02734326	chr4:10020555	SLC2A9	0.63	11.3	0.48	4.78e-26	Bone mineral density;
LUAD	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg26587870	chr6:27730563	NA	-0.44	-7.18	-0.33	3.15e-12	Parkinson's disease;
LUAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg07677032	chr17:61819896	STRADA	0.56	10.3	0.45	2.48e-22	Prudent dietary pattern;
LUAD	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg06740227	chr12:86229804	RASSF9	0.46	7.96	0.36	1.62e-14	Major depressive disorder;
LUAD	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg00071950	chr4:10020882	SLC2A9	-0.77	-15.16	-0.59	8.98e-42	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2070488	1.000	rs3792528	chr3:38493303	T/C	cg24069376	chr3:38537580	EXOG	0.45	10.89	0.47	1.58e-24	Electrocardiographic conduction measures;
LUAD	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg13385794	chr1:248469461	NA	0.26	7.02	0.32	9.12e-12	Common traits (Other);
LUAD	cis	rs736408	0.812	rs9881468	chr3:52828628	C/T	cg14092988	chr3:52407081	DNAH1	0.42	7.95	0.36	1.67e-14	Bipolar disorder;
LUAD	cis	rs10129255	0.500	rs1974468	chr14:107142166	A/G	cg23076370	chr14:107095027	NA	-0.45	-9.04	-0.4	5.82e-18	Kawasaki disease;
LUAD	cis	rs6484504	0.576	rs169623	chr11:31184157	T/C	cg14844989	chr11:31128820	NA	-0.44	-8.08	-0.37	6.68e-15	Red blood cell count;
LUAD	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.6	-0.42	7.19e-20	Life satisfaction;
LUAD	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg04851639	chr8:1020857	NA	-0.33	-7.39	-0.34	8.03e-13	Schizophrenia;
LUAD	cis	rs939658	0.805	rs35291410	chr15:79438660	C/T	cg17916960	chr15:79447300	NA	-0.53	-11.13	-0.48	1.99e-25	Refractive error;
LUAD	trans	rs587242	0.557	rs11165704	chr1:97181359	T/A	cg10631902	chr5:14652156	NA	0.38	6.38	0.3	4.63e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.51	-0.34	3.62e-13	Bipolar disorder;
LUAD	cis	rs1595825	0.891	rs111340803	chr2:198612877	A/G	cg00361562	chr2:198649771	BOLL	-0.47	-6.66	-0.31	8.32e-11	Ulcerative colitis;
LUAD	cis	rs62238980	0.614	rs117338064	chr22:32447147	A/C	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs4849845	0.704	rs4848580	chr2:121001117	A/G	cg24070213	chr2:121070622	NA	-0.39	-7.47	-0.34	4.77e-13	Mean platelet volume;
LUAD	cis	rs13082711	0.911	rs17682229	chr3:27443067	T/C	cg02860705	chr3:27208620	NA	0.6	9.26	0.41	1.05e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs2274273	0.837	rs6573017	chr14:55802243	G/A	cg04306507	chr14:55594613	LGALS3	0.42	8.65	0.39	1.07e-16	Protein biomarker;
LUAD	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg06046430	chr4:77819534	ANKRD56	0.53	8.59	0.39	1.66e-16	Emphysema distribution in smoking;
LUAD	cis	rs2795502	0.564	rs11239826	chr10:43403097	T/C	cg20628663	chr10:43360327	NA	0.64	7.46	0.34	4.83e-13	Blood protein levels;
LUAD	cis	rs2274273	0.905	rs8007944	chr14:55576816	A/C	cg04306507	chr14:55594613	LGALS3	0.39	8.16	0.37	3.96e-15	Protein biomarker;
LUAD	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	8.29	0.37	1.55e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg27490568	chr2:178487706	NA	0.54	8.29	0.37	1.49e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg17971929	chr21:40555470	PSMG1	0.54	8.35	0.38	9.67e-16	Cognitive function;
LUAD	cis	rs2073300	1.000	rs6132628	chr20:23446734	G/A	cg12062639	chr20:23401060	NAPB	1.01	8.92	0.4	1.44e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg05991184	chr2:219186017	PNKD	-0.35	-6.72	-0.31	5.99e-11	Colorectal cancer;
LUAD	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.35	6.95	0.32	1.41e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg07460842	chr6:66804631	NA	0.62	9.71	0.43	3.03e-20	Type 2 diabetes;
LUAD	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg17425144	chr1:10567563	PEX14	0.62	12.86	0.53	3.65e-32	Breast size;
LUAD	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06022373	chr22:39101656	GTPBP1	0.46	7.09	0.33	5.74e-12	Menopause (age at onset);
LUAD	cis	rs11650175	0.835	rs35472390	chr17:63757081	C/T	cg07283582	chr17:63770753	CCDC46	0.39	7.82	0.36	4.22e-14	Chin dimples;
LUAD	cis	rs8044868	0.586	rs3844425	chr16:72194325	T/C	cg23815491	chr16:72088622	HP	0.48	9.04	0.4	5.5e-18	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs751728	0.717	rs3763258	chr6:33773744	A/G	cg13859433	chr6:33739653	LEMD2	-0.32	-6.59	-0.31	1.33e-10	Crohn's disease;
LUAD	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg25985355	chr7:65971099	NA	-0.53	-6.58	-0.3	1.41e-10	Diabetic kidney disease;
LUAD	cis	rs12620999	0.774	rs2875726	chr2:237954576	T/C	cg23555395	chr2:238036564	NA	0.53	8.31	0.37	1.33e-15	Systemic lupus erythematosus;
LUAD	cis	rs240764	0.817	rs151573	chr6:101086333	T/C	cg09795085	chr6:101329169	ASCC3	0.43	7.37	0.34	9.09e-13	Neuroticism;
LUAD	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.56e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2033711	0.503	rs7254299	chr19:58884965	A/G	cg13877915	chr19:58951672	ZNF132	0.45	7.94	0.36	1.89e-14	Uric acid clearance;
LUAD	cis	rs4700695	0.719	rs27586	chr5:65445873	G/A	cg21114390	chr5:65439923	SFRS12	-0.93	-14.51	-0.58	5.5e-39	Facial morphology (factor 19);
LUAD	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg12311346	chr5:56204834	C5orf35	-0.92	-13.64	-0.55	2.32e-35	Initial pursuit acceleration;
LUAD	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg17330251	chr7:94953956	PON1	-0.56	-7.71	-0.35	9.32e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4343996	0.934	rs6959232	chr7:3376530	A/G	cg21248987	chr7:3385318	SDK1	-0.34	-6.44	-0.3	3.19e-10	Motion sickness;
LUAD	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg03388025	chr16:89894329	SPIRE2	-0.32	-7.33	-0.34	1.16e-12	Vitiligo;
LUAD	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg27529037	chr20:44575021	PCIF1	0.45	7.81	0.36	4.43e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.29	6.35	0.3	5.52e-10	Parkinson's disease;
LUAD	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg04036182	chr15:45458818	NA	-0.4	-7.01	-0.32	9.48e-12	Glomerular filtration rate;
LUAD	cis	rs2072499	0.966	rs887953	chr1:156191149	T/C	cg24450063	chr1:156163899	SLC25A44	1.13	22.91	0.74	4.04e-76	Testicular germ cell tumor;
LUAD	cis	rs17021463	0.844	rs17311008	chr4:95274653	A/G	cg11021082	chr4:95130006	SMARCAD1	0.42	7.5	0.34	3.77e-13	Testicular germ cell tumor;
LUAD	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.31	7.12	0.33	4.61e-12	Prostate cancer;
LUAD	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg13556452	chr1:2391241	NA	-0.39	-7.57	-0.35	2.28e-13	Non-obstructive azoospermia;
LUAD	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg22618164	chr12:122356400	WDR66	0.72	12.89	0.53	2.72e-32	Mean corpuscular volume;
LUAD	cis	rs250677	0.958	rs17109282	chr5:148416677	A/G	cg18129178	chr5:148520854	ABLIM3	0.52	8.28	0.37	1.63e-15	Breast cancer;
LUAD	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg23422044	chr7:1970798	MAD1L1	-0.58	-7.17	-0.33	3.33e-12	Bipolar disorder;
LUAD	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg27490568	chr2:178487706	NA	0.41	6.7	0.31	6.63e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.88	-0.43	7.79e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs7614311	0.636	rs66818634	chr3:63913222	G/A	cg22134162	chr3:63841271	THOC7	-0.46	-7.79	-0.35	5.15e-14	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg17366294	chr4:99064904	C4orf37	0.71	13.32	0.54	4.57e-34	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2046867	0.908	rs11927126	chr3:72806622	A/G	cg25664220	chr3:72788482	NA	-0.62	-11.51	-0.49	7.55e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10423674	0.526	rs2023878	chr19:18834124	A/G	cg14292368	chr19:18793705	CRTC1	0.41	7.01	0.32	9.67e-12	Menarche (age at onset);
LUAD	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg07700843	chr1:2391317	NA	-0.49	-9.13	-0.41	2.84e-18	Non-obstructive azoospermia;
LUAD	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg11919837	chr8:57350735	NA	-0.43	-6.57	-0.3	1.52e-10	Obesity-related traits;
LUAD	cis	rs6076065	0.594	rs6048755	chr20:23337233	A/G	cg11657817	chr20:23433608	CST11	0.6	12.3	0.51	6.3e-30	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg22823121	chr1:150693482	HORMAD1	0.47	9.12	0.41	3.17e-18	Melanoma;
LUAD	cis	rs7809950	1.000	rs17154104	chr7:107090698	C/T	cg23024343	chr7:107201750	COG5	-0.73	-12.31	-0.51	5.53e-30	Coronary artery disease;
LUAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg06138931	chr13:21896616	NA	0.41	6.79	0.31	3.89e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.79	-0.39	3.71e-17	Alzheimer's disease (late onset);
LUAD	trans	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg01620082	chr3:125678407	NA	-0.63	-7.29	-0.33	1.58e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg06640241	chr16:89574553	SPG7	-0.48	-7.95	-0.36	1.67e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg06671706	chr8:8559999	CLDN23	0.62	10.63	0.46	1.5e-23	Obesity-related traits;
LUAD	cis	rs2046867	0.818	rs62249866	chr3:72878632	T/C	cg04365224	chr3:72788183	NA	-0.44	-6.51	-0.3	2.13e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg22166914	chr1:53195759	ZYG11B	-0.51	-8.82	-0.39	2.92e-17	Monocyte count;
LUAD	cis	rs1032833	0.732	rs17363323	chr2:179996977	T/C	cg23883738	chr2:179974586	SESTD1	-0.7	-7.67	-0.35	1.2e-13	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg03874509	chr1:107600012	PRMT6	0.51	8.74	0.39	5.4e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs735539	0.574	rs10870743	chr13:21258756	C/A	cg27499820	chr13:21296301	IL17D	0.58	9.69	0.43	3.44e-20	Dental caries;
LUAD	cis	rs2046867	0.862	rs57396880	chr3:72844785	G/A	cg04365224	chr3:72788183	NA	-0.49	-7.25	-0.33	1.97e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg18827107	chr12:86230957	RASSF9	-0.7	-12.85	-0.53	3.72e-32	Major depressive disorder;
LUAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg13047869	chr3:10149882	C3orf24	0.63	10.8	0.46	3.58e-24	Alzheimer's disease;
LUAD	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg12564285	chr5:131593104	PDLIM4	0.37	6.42	0.3	3.73e-10	Breast cancer;
LUAD	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg24562669	chr7:97807699	LMTK2	0.33	7.98	0.36	1.35e-14	Breast cancer;
LUAD	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.85e-14	Depression;
LUAD	cis	rs28595532	0.748	rs72670249	chr4:119336823	G/T	cg02775129	chr4:119771670	NA	-0.66	-6.5	-0.3	2.2e-10	Cannabis dependence symptom count;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21350283	chr14:69445743	ACTN1	-0.39	-6.37	-0.3	4.96e-10	Cancer;
LUAD	cis	rs863345	0.584	rs10908676	chr1:158506163	C/G	cg12129480	chr1:158549410	OR10X1	-0.24	-6.57	-0.3	1.46e-10	Pneumococcal bacteremia;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg16103275	chr6:290800	DUSP22	0.35	6.54	0.3	1.8e-10	Menopause (age at onset);
LUAD	cis	rs763121	0.849	rs12004	chr22:38877461	T/G	cg06022373	chr22:39101656	GTPBP1	0.44	6.77	0.31	4.2e-11	Menopause (age at onset);
LUAD	cis	rs6961069	0.745	rs13233631	chr7:80270822	A/G	cg04458919	chr7:80252533	CD36	0.37	7.25	0.33	2.04e-12	Platelet count;
LUAD	trans	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg07393940	chr7:158741817	NA	-0.69	-11.96	-0.5	1.36e-28	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs600626	0.947	rs1219550	chr11:75453877	A/G	cg24262691	chr11:75473276	NA	0.43	6.98	0.32	1.15e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg07460842	chr6:66804631	NA	-1.04	-16.19	-0.62	3.25e-46	Exhaled nitric oxide output;
LUAD	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.43	7.59	0.35	2.08e-13	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08280861	chr8:58055591	NA	0.62	8.17	0.37	3.68e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg13126279	chr21:47581558	C21orf56	-0.44	-7.54	-0.34	2.94e-13	Testicular germ cell tumor;
LUAD	cis	rs6881634	0.501	rs10942851	chr5:77698490	T/C	cg11547950	chr5:77652471	NA	-0.37	-6.63	-0.31	1.04e-10	Hippocampal atrophy;
LUAD	cis	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.4	-7.57	-0.35	2.39e-13	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg03563238	chr19:33554763	RHPN2	-0.39	-9.06	-0.4	4.91e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg03609598	chr5:56110824	MAP3K1	0.66	8.46	0.38	4.44e-16	Initial pursuit acceleration;
LUAD	cis	rs76878669	0.561	rs7940980	chr11:66172910	C/T	cg10616300	chr11:66138557	SLC29A2	-0.37	-7.56	-0.35	2.47e-13	Educational attainment (years of education);
LUAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg02136620	chr5:178986620	RUFY1	0.41	6.62	0.31	1.12e-10	Lung cancer;
LUAD	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg07636037	chr3:49044803	WDR6	0.64	12.59	0.52	4.27e-31	Parkinson's disease;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg27565719	chr19:52490069	ZNF350	-0.39	-6.52	-0.3	1.98e-10	Subcortical brain region volumes;
LUAD	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg07708487	chr16:89387014	ANKRD11	-0.31	-6.51	-0.3	2.08e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg11494091	chr17:61959527	GH2	-0.64	-15.01	-0.59	3.91e-41	Prudent dietary pattern;
LUAD	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg03526776	chr6:41159608	TREML2	0.33	6.95	0.32	1.4e-11	Alzheimer's disease (late onset);
LUAD	cis	rs9644630	0.932	rs4921653	chr8:19359853	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.29	-7.08	-0.33	6.02e-12	Oropharynx cancer;
LUAD	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg22166914	chr1:53195759	ZYG11B	-0.4	-6.61	-0.31	1.17e-10	Monocyte count;
LUAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg18402987	chr7:1209562	NA	0.75	9.89	0.43	7.12e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35995292	0.927	rs4720308	chr7:38914285	A/C	cg19327137	chr7:38886074	VPS41	0.5	8.23	0.37	2.41e-15	Subjective well-being (multi-trait analysis);
LUAD	cis	rs12912251	0.500	rs2643204	chr15:39007171	C/T	cg01338139	chr15:38987640	C15orf53	0.51	6.7	0.31	6.5e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs12760731	0.517	rs34437852	chr1:178228721	T/C	cg00404053	chr1:178313656	RASAL2	0.74	9.26	0.41	1.02e-18	Obesity-related traits;
LUAD	cis	rs11030122	0.569	rs11030781	chr11:4083258	T/C	cg18678763	chr11:4115507	RRM1	-0.41	-6.56	-0.3	1.58e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg09509183	chr1:209979624	IRF6	0.59	8.12	0.37	5.31e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg14784868	chr12:69753453	YEATS4	0.47	7.86	0.36	3.2e-14	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg23752985	chr2:85803571	VAMP8	0.34	6.64	0.31	9.57e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg03433033	chr1:76189801	ACADM	0.83	14.6	0.58	2.18e-39	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7089973	0.872	rs7074729	chr10:116632257	C/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.53	0.42	1.25e-19	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg10978503	chr1:24200527	CNR2	-0.53	-11.83	-0.5	4.16e-28	Immature fraction of reticulocytes;
LUAD	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.81	0.35	4.6e-14	Parkinson's disease;
LUAD	cis	rs6494488	0.500	rs72744734	chr15:65042312	C/A	cg08069370	chr15:64387884	SNX1	-0.73	-6.47	-0.3	2.78e-10	Coronary artery disease;
LUAD	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg25324976	chr17:61989376	CSHL1	0.37	7.26	0.33	1.9e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs250585	0.736	rs30012	chr16:23420943	A/G	cg00143387	chr16:23521605	GGA2	0.63	9.15	0.41	2.4e-18	Egg allergy;
LUAD	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.3	7.65	0.35	1.32e-13	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg26043149	chr18:55253948	FECH	1.05	17.66	0.65	1.06e-52	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs6546550	0.901	rs6750488	chr2:70146125	C/T	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.92	-0.47	1.29e-24	Prevalent atrial fibrillation;
LUAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg22963979	chr7:1858916	MAD1L1	-0.49	-8.17	-0.37	3.67e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg08805041	chr16:621841	PIGQ	-0.32	-6.41	-0.3	3.94e-10	Height;
LUAD	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg11941060	chr3:133502564	NA	-0.66	-11.82	-0.5	4.67e-28	Iron status biomarkers;
LUAD	cis	rs68170813	0.641	rs12532953	chr7:106865920	C/T	cg02696742	chr7:106810147	HBP1	-0.78	-10.71	-0.46	7.76e-24	Coronary artery disease;
LUAD	cis	rs977987	0.806	rs11865004	chr16:75395777	C/T	cg03315344	chr16:75512273	CHST6	0.64	14.02	0.56	5.88e-37	Dupuytren's disease;
LUAD	trans	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg26043149	chr18:55253948	FECH	-0.49	-7.93	-0.36	2.03e-14	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25595571	chr14:104029029	BAG5;C14orf153	-0.53	-6.35	-0.3	5.57e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg14784868	chr12:69753453	YEATS4	0.46	7.58	0.35	2.25e-13	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs9393777	0.920	rs13207689	chr6:27369704	C/G	cg06606381	chr12:133084897	FBRSL1	-1.01	-9.01	-0.4	6.89e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7927771	0.507	rs7119517	chr11:47675316	T/C	cg18512352	chr11:47633146	NA	0.37	6.61	0.31	1.15e-10	Subjective well-being;
LUAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg16414030	chr3:133502952	NA	-0.67	-12.95	-0.53	1.54e-32	Iron status biomarkers;
LUAD	cis	rs16882447	0.514	rs27677	chr5:53484164	C/G	cg06461071	chr5:53490839	ARL15	-0.37	-6.6	-0.31	1.25e-10	Systolic blood pressure (dietary potassium intake interaction);
LUAD	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg05187965	chr10:45406764	TMEM72	-0.49	-9.75	-0.43	2.22e-20	Mean corpuscular volume;
LUAD	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg21100191	chr22:23484243	RTDR1	0.71	12.73	0.53	1.21e-31	Bone mineral density;
LUAD	cis	rs7712401	0.623	rs30032	chr5:122238387	G/T	cg19077854	chr5:122220652	SNX24	0.34	6.43	0.3	3.48e-10	Mean platelet volume;
LUAD	cis	rs11958404	0.789	rs7736318	chr5:157477593	A/G	cg05962755	chr5:157440814	NA	0.65	8.73	0.39	5.78e-17	IgG glycosylation;
LUAD	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.31	-8.46	-0.38	4.37e-16	Total body bone mineral density;
LUAD	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.18	-0.33	3.23e-12	Blood metabolite levels;
LUAD	cis	rs6748734	1.000	rs6739772	chr2:241840711	A/G	cg04034577	chr2:241836375	C2orf54	-0.48	-10.28	-0.45	2.82e-22	Urinary metabolites;
LUAD	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg19413350	chr8:57351067	NA	-0.42	-6.7	-0.31	6.48e-11	Obesity-related traits;
LUAD	cis	rs4820318	1	rs4820318	chr22:38570313	G/A	cg17652424	chr22:38574118	PLA2G6	-0.31	-8.65	-0.39	1.07e-16	Breast cancer;
LUAD	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.77	0.39	4.31e-17	Menarche (age at onset);
LUAD	cis	rs2422052	0.654	rs1433530	chr2:118649083	G/A	cg22545206	chr2:118617499	NA	0.38	6.6	0.31	1.2e-10	Mosquito bite size;
LUAD	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg01200585	chr1:228362443	C1orf69	0.46	7.83	0.36	4.06e-14	Diastolic blood pressure;
LUAD	cis	rs77741769	0.571	rs34009825	chr12:121326183	A/G	cg02419362	chr12:121203948	SPPL3	0.43	8.66	0.39	1.02e-16	Mean corpuscular volume;
LUAD	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg22823121	chr1:150693482	HORMAD1	0.41	7.96	0.36	1.57e-14	Melanoma;
LUAD	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg21100191	chr22:23484243	RTDR1	0.73	13.35	0.54	3.53e-34	Bone mineral density;
LUAD	cis	rs7731657	0.537	rs2419756	chr5:130259779	T/C	cg08523029	chr5:130500466	HINT1	0.58	7.49	0.34	4.01e-13	Fasting plasma glucose;
LUAD	cis	rs6717918	0.620	rs76788222	chr2:233152479	T/G	ch.2.233013039R	chr2:233304795	NA	0.49	6.49	0.3	2.41e-10	Height;
LUAD	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg04369109	chr6:150039330	LATS1	-0.44	-7.43	-0.34	5.91e-13	Lung cancer;
LUAD	cis	rs2408955	0.522	rs10875721	chr12:48413593	A/G	cg04545296	chr12:48745243	ZNF641	-0.32	-8.11	-0.37	5.63e-15	Glycated hemoglobin levels;
LUAD	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg02807482	chr3:125708958	NA	-0.66	-8.57	-0.38	1.91e-16	Blood pressure (smoking interaction);
LUAD	cis	rs6554196	0.508	rs11727273	chr4:55509748	C/T	cg18836493	chr4:55524333	KIT	-0.36	-6.65	-0.31	9.13e-11	Monocyte count;
LUAD	trans	rs9393777	0.920	rs35716472	chr6:27406607	C/G	cg01620082	chr3:125678407	NA	-0.84	-8.95	-0.4	1.14e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs73416724	1.000	rs17209400	chr6:43328062	A/G	cg26312998	chr6:43337775	ZNF318	0.55	6.69	0.31	7.26e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg22482690	chr17:47019901	SNF8	0.45	8.67	0.39	9.59e-17	Type 2 diabetes;
LUAD	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg27170947	chr2:26402098	FAM59B	-0.76	-11.6	-0.49	3.33e-27	Gut microbiome composition (summer);
LUAD	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg02269571	chr22:50332266	NA	-0.65	-9.92	-0.43	5.47e-21	Schizophrenia;
LUAD	cis	rs847577	0.569	rs35101190	chr7:97695888	G/A	cg21770322	chr7:97807741	LMTK2	0.31	7.2	0.33	2.69e-12	Breast cancer;
LUAD	cis	rs2274273	0.623	rs1187877	chr14:55495161	T/C	cg04306507	chr14:55594613	LGALS3	-0.34	-6.84	-0.32	2.71e-11	Protein biomarker;
LUAD	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg25251562	chr2:3704773	ALLC	-0.81	-12.53	-0.52	7.42e-31	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs4523957	0.583	rs2984943	chr17:2030135	T/C	cg16513277	chr17:2031491	SMG6	-0.98	-20.08	-0.7	1.79e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs747650	0.798	rs11039086	chr11:47116033	G/C	cg19486271	chr11:47235900	DDB2	-0.41	-6.59	-0.31	1.32e-10	Acne (severe);
LUAD	cis	rs870825	0.616	rs6810635	chr4:185616859	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	13.67	0.55	1.71e-35	Blood protein levels;
LUAD	cis	rs17401966	1.000	rs7520935	chr1:10354271	G/T	cg15208524	chr1:10270712	KIF1B	0.56	8.47	0.38	3.96e-16	Hepatocellular carcinoma;
LUAD	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg07343612	chr16:622815	PIGQ	0.45	6.37	0.3	5.07e-10	Height;
LUAD	cis	rs10821973	0.527	rs2116584	chr10:63979938	A/C	cg09941381	chr10:64027924	RTKN2	-0.34	-6.76	-0.31	4.48e-11	Hypothyroidism;
LUAD	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg24818145	chr4:99064322	C4orf37	0.47	7.95	0.36	1.71e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg09085632	chr11:111637200	PPP2R1B	0.68	10.93	0.47	1.15e-24	Primary sclerosing cholangitis;
LUAD	cis	rs9826463	0.582	rs73238130	chr3:142004004	G/A	cg20824294	chr3:142316082	PLS1	0.41	6.8	0.31	3.64e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg12292205	chr6:26970375	C6orf41	0.51	8.91	0.4	1.5e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6840360	0.550	rs6853955	chr4:152510806	G/A	cg22705602	chr4:152727874	NA	-0.43	-7.44	-0.34	5.83e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg03806693	chr22:41940476	POLR3H	0.59	8.54	0.38	2.43e-16	Vitiligo;
LUAD	trans	rs6921919	0.832	rs17312661	chr6:28300336	A/G	cg01620082	chr3:125678407	NA	-0.52	-6.53	-0.3	1.91e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs72928364	1.000	rs34315591	chr3:100649083	A/C	cg10123952	chr3:100791384	NA	0.65	7.37	0.34	8.86e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11696501	0.688	rs6124726	chr20:44307866	T/A	cg11783356	chr20:44313418	WFDC10B	-0.49	-8.19	-0.37	3.2e-15	Brain structure;
LUAD	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg11266682	chr4:10021025	SLC2A9	0.68	15.49	0.6	3.29e-43	Bone mineral density;
LUAD	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg02158880	chr13:53174818	NA	0.6	10.55	0.46	3e-23	Lewy body disease;
LUAD	cis	rs4711336	0.638	rs4713664	chr6:33674198	A/G	cg14003231	chr6:33640908	ITPR3	0.5	9.68	0.43	3.82e-20	Height;
LUAD	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg17971929	chr21:40555470	PSMG1	-0.43	-6.98	-0.32	1.15e-11	Cognitive function;
LUAD	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.12	0.33	4.65e-12	Motion sickness;
LUAD	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg17971929	chr21:40555470	PSMG1	0.56	8.91	0.4	1.51e-17	Cognitive function;
LUAD	trans	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg14791747	chr16:20752902	THUMPD1	-0.82	-13.65	-0.55	1.99e-35	Cognitive test performance;
LUAD	cis	rs151234	0.676	rs151320	chr16:28568678	A/G	cg04643524	chr16:28609220	SULT1A2	-0.62	-9.01	-0.4	7.23e-18	Platelet distribution width;
LUAD	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg22166914	chr1:53195759	ZYG11B	0.41	7.32	0.34	1.28e-12	Monocyte count;
LUAD	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.65	7.56	0.35	2.5e-13	Crohn's disease;
LUAD	cis	rs6687430	0.562	rs6676491	chr1:10633421	A/C	cg17425144	chr1:10567563	PEX14	0.54	10.56	0.46	2.69e-23	Hand grip strength;
LUAD	cis	rs1950626	0.750	rs34144313	chr14:101431216	C/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.57	0.35	2.35e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg06558623	chr16:89946397	TCF25	0.95	11.02	0.47	5.37e-25	Skin colour saturation;
LUAD	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-8.42	-0.38	5.96e-16	Monocyte percentage of white cells;
LUAD	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.86	0.32	2.49e-11	Depression;
LUAD	cis	rs73198271	0.515	rs78790772	chr8:8634367	A/G	cg01851573	chr8:8652454	MFHAS1	0.6	8.0	0.36	1.2e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg26022315	chr17:47021804	SNF8	0.41	7.36	0.34	9.59e-13	Type 2 diabetes;
LUAD	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg27661571	chr11:113659931	NA	-0.68	-7.92	-0.36	2.05e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.5	-0.45	4.42e-23	Menopause (age at onset);
LUAD	cis	rs12049351	0.774	rs6704265	chr1:229633056	C/A	cg11742688	chr1:229674241	ABCB10	-0.42	-6.44	-0.3	3.18e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg09658497	chr7:2847517	GNA12	-0.43	-7.7	-0.35	9.57e-14	Height;
LUAD	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.53	-0.3	1.91e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4243830	0.737	rs4908926	chr1:6617041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.58	-6.79	-0.31	3.83e-11	Body mass index;
LUAD	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg15208524	chr1:10270712	KIF1B	-0.42	-6.48	-0.3	2.63e-10	Hepatocellular carcinoma;
LUAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg14983838	chr19:29218262	NA	0.66	9.7	0.43	3.13e-20	Methadone dose in opioid dependence;
LUAD	trans	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg07211511	chr3:129823064	LOC729375	-0.58	-7.67	-0.35	1.16e-13	Blood pressure (smoking interaction);
LUAD	cis	rs13082711	0.522	rs11927257	chr3:27334294	C/T	cg02860705	chr3:27208620	NA	0.51	8.46	0.38	4.44e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27343303	chr11:34380546	NA	-0.46	-7.44	-0.34	5.74e-13	Height;
LUAD	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.27	6.64	0.31	9.52e-11	Cardiac Troponin-T levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16691477	chr11:64889790	FAU;MRPL49	-0.41	-6.38	-0.3	4.56e-10	Height;
LUAD	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg09537434	chr19:41945824	ATP5SL	-0.54	-8.55	-0.38	2.35e-16	Height;
LUAD	cis	rs7937890	0.559	rs4369365	chr11:14444515	C/G	cg22961513	chr11:14280813	SPON1	-0.37	-7.12	-0.33	4.79e-12	Mitochondrial DNA levels;
LUAD	cis	rs1215050	0.904	rs2903153	chr4:99057457	C/T	cg17366294	chr4:99064904	C4orf37	0.42	7.18	0.33	3.23e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7520050	0.807	rs72688483	chr1:46149209	A/G	cg06784218	chr1:46089804	CCDC17	0.35	7.56	0.34	2.55e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg00280220	chr17:61926910	NA	0.36	6.96	0.32	1.34e-11	Prudent dietary pattern;
LUAD	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg08601574	chr20:25228251	PYGB	-0.47	-8.96	-0.4	1.05e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg07570687	chr10:102243282	WNT8B	0.48	7.37	0.34	9.16e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs68170813	0.559	rs6967638	chr7:106929356	T/G	cg02696742	chr7:106810147	HBP1	-0.76	-10.57	-0.46	2.41e-23	Coronary artery disease;
LUAD	trans	rs877282	0.898	rs12357995	chr10:765739	T/C	cg22713356	chr15:30763199	NA	1.28	17.3	0.64	4.19e-51	Uric acid levels;
LUAD	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg19336497	chr11:14380999	RRAS2	-0.63	-13.61	-0.55	2.96e-35	Sense of smell;
LUAD	trans	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg24644049	chr4:85504048	CDS1	0.85	7.61	0.35	1.77e-13	Skin colour saturation;
LUAD	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg11822812	chr5:140052017	DND1	0.38	6.64	0.31	9.37e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg11062466	chr8:58055876	NA	0.45	6.4	0.3	4.04e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs17253792	0.822	rs28754619	chr14:56088394	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00166722	chr3:10149974	C3orf24	0.74	12.64	0.52	2.77e-31	Alzheimer's disease;
LUAD	cis	rs7937890	0.559	rs2034480	chr11:14466923	G/A	cg23387056	chr11:14280742	SPON1	-0.34	-6.66	-0.31	8.6e-11	Mitochondrial DNA levels;
LUAD	cis	rs2070677	0.935	rs4300354	chr10:135415890	C/T	cg20169779	chr10:135381914	SYCE1	-0.51	-8.2	-0.37	2.99e-15	Gout;
LUAD	cis	rs2735413	0.918	rs1922621	chr16:78075015	A/G	cg04733911	chr16:78082701	NA	-0.35	-8.43	-0.38	5.61e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs3764563	1.000	rs11673070	chr19:15746095	A/G	cg20725493	chr19:15740067	CYP4F8	-0.78	-8.69	-0.39	7.8e-17	Inflammatory biomarkers;
LUAD	cis	rs7671266	0.668	rs10002562	chr4:10159736	C/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-7.53	-0.34	3.16e-13	Cardiovascular disease risk factors;
LUAD	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.6	11.33	0.48	3.6e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1997103	1.000	rs4947503	chr7:55409427	G/T	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg05727186	chr17:43697356	MGC57346	-0.56	-6.96	-0.32	1.3e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1566497	0.791	rs4235021	chr4:169744567	A/G	cg20607169	chr4:169750834	PALLD	-0.43	-7.78	-0.35	5.76e-14	Pulse pressure;
LUAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg21733973	chr7:65235735	NA	0.52	8.45	0.38	4.7e-16	Calcium levels;
LUAD	cis	rs3806843	0.576	rs246034	chr5:140332064	A/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.66	-0.31	8.76e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg17063962	chr7:91808500	NA	0.64	10.96	0.47	8.94e-25	Breast cancer;
LUAD	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg09796270	chr17:17721594	SREBF1	0.37	6.96	0.32	1.34e-11	Total body bone mineral density;
LUAD	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg22681709	chr2:178499509	PDE11A	0.47	7.73	0.35	7.86e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs56133113	0.710	rs17131839	chr11:72830496	C/T	cg01847441	chr14:69431073	ACTN1	0.55	6.39	0.3	4.28e-10	Mean platelet volume;
LUAD	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg12193833	chr17:30244370	NA	-0.54	-7.01	-0.32	9.48e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs3789045	0.560	rs1008833	chr1:204426295	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.58	-9.18	-0.41	1.93e-18	Educational attainment (college completion);
LUAD	cis	rs4700695	0.719	rs27587	chr5:65444163	C/T	cg21114390	chr5:65439923	SFRS12	-0.93	-14.44	-0.57	1e-38	Facial morphology (factor 19);
LUAD	cis	rs9512730	0.911	rs9512720	chr13:28069056	T/A	cg04070771	chr13:27998621	GTF3A	0.45	6.59	0.31	1.28e-10	Schizophrenia;
LUAD	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11644478	chr21:40555479	PSMG1	0.68	11.34	0.48	3.21e-26	Cognitive function;
LUAD	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg12119029	chr16:89752879	CDK10	0.31	6.75	0.31	5.01e-11	Hemoglobin concentration;
LUAD	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.46	0.38	4.49e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7727544	0.508	rs10900804	chr5:131401845	C/T	cg14196790	chr5:131705035	SLC22A5	0.47	8.2	0.37	2.87e-15	Blood metabolite levels;
LUAD	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg23029597	chr12:123009494	RSRC2	-0.53	-8.24	-0.37	2.21e-15	Body mass index;
LUAD	cis	rs790123	1.000	rs790117	chr3:122380888	C/T	cg24850323	chr3:122379709	NA	0.37	6.61	0.31	1.16e-10	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg00414561	chr15:23034473	NIPA2	-0.39	-6.48	-0.3	2.6e-10	Schizophrenia;
LUAD	cis	rs977987	0.815	rs4887829	chr16:75488935	C/T	cg03315344	chr16:75512273	CHST6	0.65	14.08	0.57	3.24e-37	Dupuytren's disease;
LUAD	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg23018236	chr17:30244563	NA	-0.68	-8.33	-0.38	1.14e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs1018836	0.923	rs13267989	chr8:91581648	C/T	cg16814680	chr8:91681699	NA	-0.71	-11.95	-0.5	1.42e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg20607798	chr8:58055168	NA	0.66	8.64	0.39	1.18e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg25173405	chr17:45401733	C17orf57	-0.46	-7.62	-0.35	1.72e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12347191	0.500	rs907579	chr9:100622723	G/T	cg13688889	chr9:100608707	NA	-0.61	-9.98	-0.44	3.24e-21	Orofacial clefts;
LUAD	trans	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg14917512	chr19:3094685	GNA11	-0.56	-6.63	-0.31	1.04e-10	Diabetic kidney disease;
LUAD	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-7.83	-0.36	4.06e-14	Total body bone mineral density;
LUAD	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.21	0.33	2.6e-12	Menopause (age at onset);
LUAD	cis	rs7937890	0.593	rs2597189	chr11:14512060	C/T	cg23387056	chr11:14280742	SPON1	-0.35	-6.6	-0.31	1.24e-10	Mitochondrial DNA levels;
LUAD	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.51	0.38	3.02e-16	Menopause (age at onset);
LUAD	cis	rs11630290	1.000	rs72750986	chr15:63996338	C/A	cg12036633	chr15:63758958	NA	-0.51	-6.86	-0.32	2.47e-11	Iris characteristics;
LUAD	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.31	0.41	6.89e-19	Colorectal cancer;
LUAD	cis	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg21775007	chr8:11205619	TDH	-0.37	-6.38	-0.3	4.71e-10	Myopia (pathological);
LUAD	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg04218760	chr10:45406644	TMEM72	-0.32	-8.02	-0.36	1.05e-14	Mean corpuscular volume;
LUAD	cis	rs6761276	0.899	rs11677088	chr2:113835603	A/G	cg06383401	chr2:113825234	IL1F10	-0.3	-6.41	-0.3	3.97e-10	Protein quantitative trait loci;
LUAD	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg13180566	chr4:1052158	NA	-0.4	-6.72	-0.31	5.87e-11	Recombination rate (females);
LUAD	cis	rs12472274	0.646	rs11677736	chr2:239087198	A/T	cg17459225	chr2:239074497	NA	0.66	7.96	0.36	1.61e-14	Phospholipid levels (plasma);
LUAD	cis	rs1595825	0.945	rs76510735	chr2:198823095	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-7.1	-0.33	5.43e-12	Ulcerative colitis;
LUAD	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg11663144	chr21:46675770	NA	-0.59	-11.64	-0.49	2.27e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg20673091	chr1:2541236	MMEL1	0.4	8.51	0.38	3.16e-16	Ulcerative colitis;
LUAD	cis	rs3096299	0.781	rs3102381	chr16:89409720	G/C	cg06640241	chr16:89574553	SPG7	0.42	6.96	0.32	1.33e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg12432903	chr7:1882776	MAD1L1	-0.45	-7.21	-0.33	2.65e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg17757837	chr7:157058334	UBE3C	-0.5	-8.98	-0.4	9.22e-18	Body mass index;
LUAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg00149659	chr3:10157352	C3orf10	0.57	7.91	0.36	2.24e-14	Alzheimer's disease;
LUAD	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.63	0.39	1.23e-16	Gut microbiome composition (summer);
LUAD	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.46	8.04	0.36	9.16e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7773004	1.000	rs7773004	chr6:26267755	A/G	cg13736514	chr6:26305472	NA	-0.53	-8.82	-0.39	2.93e-17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg18854424	chr1:2615690	NA	-0.42	-9.07	-0.4	4.49e-18	Ulcerative colitis;
LUAD	cis	rs4588572	0.643	rs13155648	chr5:77755343	A/G	cg11547950	chr5:77652471	NA	-0.77	-12.43	-0.52	1.96e-30	Triglycerides;
LUAD	cis	rs2109514	0.542	rs4540346	chr7:116067883	T/C	cg04696780	chr7:116139425	CAV2	-0.33	-7.47	-0.34	4.56e-13	Prevalent atrial fibrillation;
LUAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg17178900	chr1:205818956	PM20D1	0.4	6.66	0.31	8.41e-11	Parkinson's disease;
LUAD	trans	rs225245	0.765	rs226428	chr17:34049950	C/T	cg19694781	chr19:47549865	TMEM160	0.47	7.69	0.35	1.03e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg23978390	chr7:1156363	C7orf50	0.5	6.39	0.3	4.41e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.68	-12.91	-0.53	2.22e-32	Lymphocyte counts;
LUAD	cis	rs754466	0.580	rs11002301	chr10:79574078	G/A	cg17075019	chr10:79541650	NA	-0.92	-19.98	-0.7	4.78e-63	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7707921	1.000	rs1543911	chr5:81504841	C/T	cg15871215	chr5:81402204	ATG10	0.72	10.35	0.45	1.54e-22	Breast cancer;
LUAD	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg03526776	chr6:41159608	TREML2	0.31	6.56	0.3	1.59e-10	Alzheimer's disease (late onset);
LUAD	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg04111992	chr7:158790115	NA	-0.53	-8.99	-0.4	8.56e-18	Facial morphology (factor 20);
LUAD	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg22906224	chr7:99728672	NA	0.55	9.54	0.42	1.11e-19	Coronary artery disease;
LUAD	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg23625390	chr15:77176239	SCAPER	-0.56	-8.68	-0.39	8.43e-17	Blood metabolite levels;
LUAD	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg06131755	chr6:160182447	ACAT2	0.43	6.38	0.3	4.76e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg22117172	chr7:91764530	CYP51A1	0.37	8.2	0.37	2.87e-15	Breast cancer;
LUAD	cis	rs6499255	0.857	rs11643926	chr16:69807282	A/G	cg15192750	chr16:69999425	NA	0.56	8.89	0.4	1.78e-17	IgE levels;
LUAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.61	0.31	1.19e-10	Prudent dietary pattern;
LUAD	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	7.44	0.34	5.55e-13	Rheumatoid arthritis;
LUAD	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg01689657	chr7:91764605	CYP51A1	0.38	9.5	0.42	1.63e-19	Breast cancer;
LUAD	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg11822812	chr5:140052017	DND1	-0.37	-6.64	-0.31	9.41e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg20587970	chr11:113659929	NA	-1.38	-20.91	-0.71	3.42e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg05368731	chr17:41323189	NBR1	0.96	20.2	0.7	5.37e-64	Menopause (age at onset);
LUAD	trans	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg04565464	chr8:145669602	NFKBIL2	0.44	6.6	0.31	1.27e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.89	0.53	2.7e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg08847533	chr14:75593920	NEK9	-0.4	-6.86	-0.32	2.4e-11	Height;
LUAD	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg12160578	chr15:63334699	TPM1	-0.36	-6.63	-0.31	1.05e-10	Platelet count;
LUAD	cis	rs6961069	0.777	rs6961024	chr7:80249671	G/T	cg04458919	chr7:80252533	CD36	0.38	7.2	0.33	2.76e-12	Platelet count;
LUAD	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.15	-0.33	3.81e-12	Total cholesterol levels;
LUAD	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg26513180	chr16:89883248	FANCA	0.47	7.63	0.35	1.54e-13	Vitiligo;
LUAD	cis	rs977987	0.806	rs56343285	chr16:75409797	A/G	cg03315344	chr16:75512273	CHST6	0.65	14.18	0.57	1.32e-37	Dupuytren's disease;
LUAD	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg05313129	chr8:58192883	C8orf71	-0.57	-8.41	-0.38	6.38e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg13390004	chr1:15929781	NA	0.49	8.61	0.39	1.49e-16	Systolic blood pressure;
LUAD	cis	rs41311933	0.656	rs72758201	chr9:123828217	G/C	cg13567360	chr9:123745713	C5	-0.72	-8.54	-0.38	2.52e-16	Coronary artery disease;
LUAD	cis	rs758324	0.947	rs58016983	chr5:131235275	T/C	cg06307176	chr5:131281290	NA	-0.54	-8.59	-0.39	1.67e-16	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.65	0.31	8.96e-11	Breast cancer;
LUAD	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg23982607	chr1:1823379	GNB1	-0.9	-18.55	-0.67	1.21e-56	Body mass index;
LUAD	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg22508957	chr16:3507546	NAT15	0.74	13.3	0.54	6.03e-34	Tuberculosis;
LUAD	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg12863693	chr15:85201151	NMB	0.44	8.03	0.36	1e-14	Schizophrenia;
LUAD	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg23985595	chr17:80112537	CCDC57	0.53	9.73	0.43	2.45e-20	Life satisfaction;
LUAD	trans	rs225245	0.817	rs225269	chr17:33967931	G/T	cg19694781	chr19:47549865	TMEM160	-0.44	-7.24	-0.33	2.09e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg21100191	chr22:23484243	RTDR1	0.67	11.56	0.49	4.92e-27	Bone mineral density;
LUAD	cis	rs7258465	0.931	rs34053595	chr19:18556749	T/C	cg25828334	chr19:18545568	ISYNA1	-0.4	-7.96	-0.36	1.56e-14	Breast cancer;
LUAD	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg13180566	chr4:1052158	NA	-0.38	-6.41	-0.3	3.87e-10	Recombination rate (females);
LUAD	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg14458575	chr2:238380390	NA	0.65	12.13	0.51	2.93e-29	Prostate cancer;
LUAD	trans	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.51	0.46	4.12e-23	Mean corpuscular volume;
LUAD	cis	rs981844	0.689	rs6835372	chr4:154682056	T/C	cg10279832	chr4:154682576	RNF175	0.34	6.98	0.32	1.15e-11	Response to statins (LDL cholesterol change);
LUAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg23131131	chr22:24373011	LOC391322	-0.48	-8.1	-0.37	6.12e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg14008862	chr17:28927542	LRRC37B2	0.75	7.47	0.34	4.61e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9837602	0.938	rs793457	chr3:99518987	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	7.31	0.33	1.35e-12	Breast cancer;
LUAD	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.6	0.31	1.26e-10	Aortic root size;
LUAD	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg07606381	chr6:8435919	SLC35B3	0.44	7.24	0.33	2.18e-12	Motion sickness;
LUAD	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg21204522	chr6:27730016	NA	-0.63	-6.5	-0.3	2.28e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2992756	0.663	rs2992753	chr1:18808292	A/C	cg14356550	chr1:18808102	KLHDC7A	0.55	9.66	0.43	4.3e-20	Breast cancer;
LUAD	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg13770153	chr20:60521292	NA	-0.47	-7.82	-0.36	4.29e-14	Body mass index;
LUAD	trans	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.09	-0.47	3.02e-25	Depression;
LUAD	cis	rs76878669	0.538	rs1546358	chr11:66175261	G/C	cg10616300	chr11:66138557	SLC29A2	0.35	7.35	0.34	1.02e-12	Educational attainment (years of education);
LUAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg09060608	chr5:178986726	RUFY1	0.57	9.68	0.43	3.71e-20	Lung cancer;
LUAD	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.58	-0.39	1.81e-16	Height;
LUAD	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg17425144	chr1:10567563	PEX14	-0.57	-11.88	-0.5	2.64e-28	Prostate cancer;
LUAD	cis	rs4372836	1.000	rs34409160	chr2:28943865	C/T	cg09522027	chr2:28974177	PPP1CB	0.62	9.65	0.42	4.91e-20	Body mass index;
LUAD	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg00999904	chr2:3704751	ALLC	-0.51	-8.73	-0.39	5.93e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.37e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg19318889	chr4:1322082	MAEA	0.91	15.64	0.61	8.11e-44	Longevity;
LUAD	cis	rs12545109	0.643	rs1119707	chr8:57411548	T/C	cg19413350	chr8:57351067	NA	-0.44	-6.66	-0.31	8.75e-11	Obesity-related traits;
LUAD	trans	rs11039798	0.764	rs4357721	chr11:48354907	G/A	cg03929089	chr4:120376271	NA	-0.57	-6.61	-0.31	1.16e-10	Axial length;
LUAD	cis	rs250585	1.000	rs2369007	chr16:23560205	G/T	cg00143387	chr16:23521605	GGA2	-0.69	-8.21	-0.37	2.8e-15	Egg allergy;
LUAD	cis	rs7213347	0.707	rs2038677	chr17:2178092	C/G	cg16513277	chr17:2031491	SMG6	-0.44	-6.72	-0.31	5.88e-11	Total body bone mineral density;
LUAD	cis	rs72928364	1.000	rs2245556	chr3:100615550	C/T	cg10123952	chr3:100791384	NA	0.55	7.1	0.33	5.37e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2548003	0.541	rs2014310	chr5:28723589	T/C	cg22863700	chr5:28928346	NA	0.43	6.46	0.3	2.81e-10	Hip geometry;
LUAD	cis	rs11723261	0.582	rs6599293	chr4:133027	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.45	8.03	0.36	9.6e-15	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-7.13	-0.33	4.31e-12	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg00158530	chr16:69966973	MIR140;WWP2	-0.49	-7.38	-0.34	8.66e-13	Menarche (age at onset);
LUAD	cis	rs9287719	0.745	rs4997810	chr2:10755540	T/A	cg03983476	chr2:10830698	NOL10	-0.45	-7.82	-0.36	4.17e-14	Prostate cancer;
LUAD	cis	rs7731657	0.537	rs13355897	chr5:130360622	G/A	cg08523029	chr5:130500466	HINT1	-0.59	-7.57	-0.35	2.34e-13	Fasting plasma glucose;
LUAD	cis	rs67311347	0.544	rs2278929	chr3:40351008	C/G	cg02782426	chr3:40428986	ENTPD3	-0.36	-7.84	-0.36	3.8e-14	Renal cell carcinoma;
LUAD	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg13319975	chr6:146136371	FBXO30	-0.59	-9.98	-0.44	3.4e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6060717	0.536	rs8125393	chr20:34496162	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.06	-0.32	6.88e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg10207240	chr12:122356781	WDR66	0.46	7.89	0.36	2.56e-14	Mean corpuscular volume;
LUAD	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg07636037	chr3:49044803	WDR6	-0.46	-7.39	-0.34	7.91e-13	Menarche (age at onset);
LUAD	cis	rs9910055	0.550	rs113844752	chr17:42297631	C/A	cg13607699	chr17:42295918	UBTF	0.57	9.09	0.4	3.91e-18	Total body bone mineral density;
LUAD	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg03433033	chr1:76189801	ACADM	0.84	15.13	0.59	1.17e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs354225	0.544	rs12713267	chr2:54805607	T/C	cg26097391	chr2:54893211	SPTBN1	0.42	6.42	0.3	3.73e-10	Schizophrenia;
LUAD	cis	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg11143507	chr3:125485238	NA	-0.44	-7.36	-0.34	9.72e-13	Blood pressure (smoking interaction);
LUAD	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg18209359	chr17:80159595	CCDC57	0.4	6.97	0.32	1.24e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9302635	0.745	rs35909200	chr16:72156666	T/G	cg23815491	chr16:72088622	HP	0.51	7.1	0.33	5.22e-12	Blood protein levels;
LUAD	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg04455712	chr21:45112962	RRP1B	0.47	9.23	0.41	1.3e-18	Mean corpuscular volume;
LUAD	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg14689365	chr7:158441557	NCAPG2	0.49	8.39	0.38	7.51e-16	Height;
LUAD	cis	rs12545109	0.959	rs12546307	chr8:57314790	T/A	cg21220214	chr8:57350948	NA	-0.61	-8.62	-0.39	1.36e-16	Obesity-related traits;
LUAD	cis	rs11677416	0.677	rs2856840	chr2:113538604	T/A	cg27083787	chr2:113543245	IL1A	0.38	6.61	0.31	1.16e-10	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs4462272	0.503	rs7477551	chr10:101827619	G/A	cg02250046	chr10:101825185	CPN1	-0.33	-6.55	-0.3	1.68e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg27490568	chr2:178487706	NA	0.62	9.91	0.43	6.02e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs2018683	0.621	rs10261556	chr7:28976636	G/T	cg19402173	chr7:128379420	CALU	-0.54	-8.75	-0.39	5.3e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9283706	0.689	rs1030231	chr5:66317265	A/G	cg11590213	chr5:66331682	MAST4	0.4	6.62	0.31	1.11e-10	Coronary artery disease;
LUAD	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg21475434	chr5:93447410	FAM172A	0.78	8.59	0.39	1.66e-16	Diabetic retinopathy;
LUAD	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg18490616	chr2:88469792	THNSL2	0.79	8.32	0.38	1.19e-15	Plasma clusterin levels;
LUAD	cis	rs3784262	0.757	rs74655564	chr15:58325512	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.51	-10.41	-0.45	9.7e-23	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg15181151	chr6:150070149	PCMT1	0.34	6.79	0.31	3.84e-11	Lung cancer;
LUAD	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg22546130	chr22:19950026	COMT	-0.46	-9.86	-0.43	8.73e-21	Blood metabolite levels;
LUAD	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg09640425	chr7:158790006	NA	-0.53	-9.01	-0.4	7.18e-18	Facial morphology (factor 20);
LUAD	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg24818145	chr4:99064322	C4orf37	0.47	7.96	0.36	1.57e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	12.56	0.52	5.69e-31	Lymphocyte counts;
LUAD	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg12179176	chr11:130786555	SNX19	0.43	6.84	0.32	2.8e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24531977	chr5:56204891	C5orf35	-0.98	-14.88	-0.59	1.36e-40	Initial pursuit acceleration;
LUAD	cis	rs35883536	0.967	rs1981134	chr1:101111205	G/T	cg06223162	chr1:101003688	GPR88	-0.38	-7.06	-0.32	6.7e-12	Monocyte count;
LUAD	cis	rs7903847	0.642	rs9887991	chr10:99159634	T/C	cg20016023	chr10:99160130	RRP12	-0.32	-7.66	-0.35	1.24e-13	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg07515662	chr12:56435880	RPS26	-0.46	-6.39	-0.3	4.42e-10	Blood protein levels;
LUAD	cis	rs11626933	1.000	rs59905513	chr14:90749638	T/C	cg14092571	chr14:90743983	NA	-0.95	-17.89	-0.66	1.01e-53	Gut microbiota (bacterial taxa);
LUAD	cis	rs8071789	1.000	rs8071789	chr17:38006333	C/T	cg10909506	chr17:38081995	ORMDL3	0.37	6.71	0.31	6.13e-11	Selective IgA deficiency;
LUAD	cis	rs250677	1.000	rs40525	chr5:148432932	G/T	cg18129178	chr5:148520854	ABLIM3	0.5	7.99	0.36	1.3e-14	Breast cancer;
LUAD	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg16325326	chr1:53192061	ZYG11B	-0.73	-14.27	-0.57	5.34e-38	Monocyte count;
LUAD	cis	rs7945718	0.875	rs9888179	chr11:12782601	G/T	cg25843174	chr11:12811716	TEAD1	0.25	7.36	0.34	9.88e-13	Educational attainment (years of education);
LUAD	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02475777	chr4:1388615	CRIPAK	-0.61	-8.8	-0.39	3.52e-17	Longevity;
LUAD	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg13180566	chr4:1052158	NA	-0.4	-6.72	-0.31	5.87e-11	Recombination rate (females);
LUAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg05313129	chr8:58192883	C8orf71	-0.59	-7.22	-0.33	2.43e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg19610905	chr11:61596333	FADS2	-0.61	-10.4	-0.45	1.08e-22	Trans fatty acid levels;
LUAD	cis	rs9326248	0.559	rs12808524	chr11:116890993	T/C	cg20608306	chr11:116969690	SIK3	0.31	6.94	0.32	1.45e-11	Blood protein levels;
LUAD	cis	rs4523957	0.928	rs8065650	chr17:2180823	A/G	cg16513277	chr17:2031491	SMG6	0.74	13.99	0.56	8.1e-37	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg02176678	chr2:219576539	TTLL4	0.69	13.93	0.56	1.41e-36	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs72829446	0.556	rs10048219	chr17:7403792	C/T	cg07168214	chr17:7380112	ZBTB4	-0.39	-6.61	-0.31	1.15e-10	Androgen levels;
LUAD	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.68	8.92	0.4	1.38e-17	Body mass index;
LUAD	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18876405	chr7:65276391	NA	-0.52	-8.96	-0.4	1.06e-17	Aortic root size;
LUAD	cis	rs986417	1.000	rs1254303	chr14:60886301	A/G	cg27398547	chr14:60952738	C14orf39	-0.65	-7.72	-0.35	8.48e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg18230493	chr5:56204884	C5orf35	0.66	10.45	0.45	6.78e-23	Initial pursuit acceleration;
LUAD	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg03806693	chr22:41940476	POLR3H	-0.78	-11.15	-0.48	1.81e-25	Vitiligo;
LUAD	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg20307385	chr11:47447363	PSMC3	0.45	7.49	0.34	4.08e-13	Neuroticism;
LUAD	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg05340658	chr4:99064831	C4orf37	0.53	9.0	0.4	7.52e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg22482690	chr17:47019901	SNF8	0.47	9.13	0.41	2.89e-18	Type 2 diabetes;
LUAD	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg03433033	chr1:76189801	ACADM	1.02	25.08	0.77	1.04e-85	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg20119798	chr7:94954144	PON1	-0.63	-11.55	-0.49	5.29e-27	Paraoxonase activity;
LUAD	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg06873352	chr17:61820015	STRADA	0.42	7.04	0.32	7.83e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2404602	0.552	rs11072613	chr15:76961526	A/C	cg23625390	chr15:77176239	SCAPER	-0.45	-6.4	-0.3	4.17e-10	Blood metabolite levels;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg14036868	chr2:38604442	ATL2	-0.41	-7.0	-0.32	9.8e-12	Subcortical brain region volumes;
LUAD	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg11859384	chr17:80120422	CCDC57	0.43	7.82	0.36	4.3e-14	Life satisfaction;
LUAD	trans	rs6897795	0.680	rs10074768	chr5:177610700	A/G	cg19598605	chr2:70056955	GMCL1	-0.62	-7.84	-0.36	3.83e-14	Plateletcrit;
LUAD	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg12623918	chr2:306882	NA	0.35	6.9	0.32	1.97e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg24579218	chr15:68104479	NA	-0.55	-8.6	-0.39	1.6e-16	Obesity;
LUAD	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg14416269	chr4:6271139	WFS1	-0.6	-11.92	-0.5	1.97e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs912057	0.695	rs1294419	chr6:6742549	C/G	cg06612196	chr6:6737390	NA	0.55	12.54	0.52	6.73e-31	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	9.21	0.41	1.53e-18	Colorectal cancer;
LUAD	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg06740227	chr12:86229804	RASSF9	-0.43	-7.62	-0.35	1.7e-13	Major depressive disorder;
LUAD	trans	rs6011368	0.749	rs4809418	chr20:62915231	G/A	cg13869341	chr1:15865	WASH5P	-0.46	-8.07	-0.37	7.54e-15	Clozapine-induced cytotoxicity;
LUAD	trans	rs1997103	0.906	rs2177806	chr7:55402609	A/T	cg20935933	chr6:143382018	AIG1	0.53	7.48	0.34	4.32e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6906287	0.647	rs6925641	chr6:118821894	C/T	cg21191810	chr6:118973309	C6orf204	0.5	9.7	0.43	3.16e-20	Electrocardiographic conduction measures;
LUAD	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg23950597	chr19:37808831	NA	-0.6	-7.46	-0.34	4.88e-13	Coronary artery calcification;
LUAD	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03264133	chr6:25882463	NA	-0.57	-9.39	-0.42	3.71e-19	Blood metabolite levels;
LUAD	cis	rs3772130	1.000	rs62268732	chr3:121370455	T/G	cg20356878	chr3:121714668	ILDR1	0.47	7.21	0.33	2.68e-12	Cognitive performance;
LUAD	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg18477163	chr1:228402036	OBSCN	0.4	7.19	0.33	3e-12	Diastolic blood pressure;
LUAD	cis	rs6460942	0.731	rs75994414	chr7:12307992	C/A	cg06484146	chr7:12443880	VWDE	-0.56	-6.9	-0.32	1.94e-11	Coronary artery disease;
LUAD	cis	rs11696501	0.694	rs1487325	chr20:44258989	A/G	cg11783356	chr20:44313418	WFDC10B	0.51	8.08	0.37	7.01e-15	Brain structure;
LUAD	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg04287289	chr16:89883240	FANCA	0.72	13.26	0.54	8.44e-34	Vitiligo;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg25964984	chr22:30783371	RNF215	-0.7	-6.99	-0.32	1.07e-11	Type 2 diabetes;
LUAD	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg03929089	chr4:120376271	NA	-0.88	-16.94	-0.64	1.66e-49	Height;
LUAD	cis	rs7809950	0.953	rs28687365	chr7:107106712	A/C	cg23024343	chr7:107201750	COG5	-0.72	-12.33	-0.51	4.75e-30	Coronary artery disease;
LUAD	trans	rs853679	0.607	rs34396849	chr6:28250955	A/C	cg01620082	chr3:125678407	NA	-1.05	-10.6	-0.46	2e-23	Depression;
LUAD	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg19052272	chr2:3704530	ALLC	-0.61	-10.51	-0.45	4.25e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02987984	chr7:101457447	NA	0.44	6.77	0.31	4.23e-11	Gut microbiome composition (summer);
LUAD	trans	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg01620082	chr3:125678407	NA	-1.02	-8.88	-0.4	1.9e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg25036284	chr2:26402008	FAM59B	0.85	11.1	0.47	2.73e-25	Gut microbiome composition (summer);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10620530	chr9:139922595	C9orf139;ABCA2	-0.42	-6.71	-0.31	6.12e-11	Height;
LUAD	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg10547527	chr2:198650123	BOLL	-0.54	-7.63	-0.35	1.52e-13	Ulcerative colitis;
LUAD	cis	rs868036	1.000	rs1871307	chr15:68100623	C/T	cg08079166	chr15:68083412	MAP2K5	0.3	6.49	0.3	2.39e-10	Restless legs syndrome;
LUAD	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg15704280	chr7:45808275	SEPT13	-0.6	-9.72	-0.43	2.68e-20	HDL cholesterol;
LUAD	cis	rs6430585	0.536	rs60397494	chr2:136470219	C/T	cg07169764	chr2:136633963	MCM6	0.69	7.74	0.35	7.15e-14	Corneal structure;
LUAD	trans	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg27411982	chr8:10470053	RP1L1	0.38	6.79	0.31	3.88e-11	Neuroticism;
LUAD	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg08280861	chr8:58055591	NA	0.56	7.48	0.34	4.25e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs13394619	0.875	rs7576826	chr2:11723021	C/T	cg07314298	chr2:11723111	GREB1	-0.55	-10.14	-0.44	9.05e-22	Endometriosis;
LUAD	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg13390004	chr1:15929781	NA	0.48	8.54	0.38	2.48e-16	Systolic blood pressure;
LUAD	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg09365446	chr1:150670422	GOLPH3L	0.67	12.51	0.52	9.23e-31	Tonsillectomy;
LUAD	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.37	-0.34	8.89e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg18446336	chr7:2847575	GNA12	-0.38	-6.86	-0.32	2.41e-11	Height;
LUAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg21782813	chr7:2030301	MAD1L1	0.44	7.8	0.35	4.92e-14	Bipolar disorder and schizophrenia;
LUAD	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	11.31	0.48	4.33e-26	Resting heart rate;
LUAD	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg01028140	chr2:1542097	TPO	0.59	8.0	0.36	1.24e-14	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg11189052	chr15:85197271	WDR73	0.65	8.33	0.38	1.16e-15	Schizophrenia;
LUAD	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg15445000	chr17:37608096	MED1	-0.45	-8.2	-0.37	2.93e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg08222618	chr4:941054	TMEM175	-0.5	-7.75	-0.35	6.87e-14	Parkinson's disease;
LUAD	trans	rs2735413	0.918	rs11150037	chr16:78075774	A/G	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg09455208	chr3:40491958	NA	0.56	12.03	0.5	7.13e-29	Renal cell carcinoma;
LUAD	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.29	0.51	6.53e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6499255	0.951	rs1437135	chr16:69757828	A/G	cg15192750	chr16:69999425	NA	0.53	8.11	0.37	5.56e-15	IgE levels;
LUAD	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg15181151	chr6:150070149	PCMT1	-0.42	-8.36	-0.38	9.32e-16	Lung cancer;
LUAD	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.41	-6.91	-0.32	1.76e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg07460842	chr6:66804631	NA	-1.06	-16.61	-0.63	4.84e-48	Exhaled nitric oxide output;
LUAD	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-7.04	-0.32	7.76e-12	Personality dimensions;
LUAD	cis	rs899997	0.773	rs62010525	chr15:78968310	C/G	cg04896959	chr15:78267971	NA	-0.6	-9.14	-0.41	2.59e-18	Coronary artery disease or large artery stroke;
LUAD	cis	rs7213347	1.000	rs7213347	chr17:2153257	G/C	cg02569219	chr17:2266849	SGSM2	-0.45	-7.47	-0.34	4.65e-13	Total body bone mineral density;
LUAD	cis	rs896543	1.000	rs896543	chr2:237509207	A/G	cg25295825	chr2:237489920	CXCR7	-0.43	-8.06	-0.36	8.15e-15	Alcohol dependence (age at onset);
LUAD	cis	rs1483890	0.851	rs6762186	chr3:69402923	T/G	cg22125112	chr3:69402811	FRMD4B	0.45	8.05	0.36	8.28e-15	Resting heart rate;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25759457	chr1:172502420	C1orf9	-0.44	-6.95	-0.32	1.37e-11	Height;
LUAD	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg03806693	chr22:41940476	POLR3H	0.72	9.67	0.43	4e-20	Vitiligo;
LUAD	cis	rs68170813	0.523	rs12532447	chr7:106940476	C/T	cg23024343	chr7:107201750	COG5	0.49	7.23	0.33	2.32e-12	Coronary artery disease;
LUAD	cis	rs10254118	0.730	rs6961517	chr7:133130940	G/T	cg10665199	chr7:133106180	EXOC4	0.63	10.72	0.46	7.26e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg10544611	chr16:67998164	SLC12A4	-0.68	-8.12	-0.37	5.15e-15	Schizophrenia;
LUAD	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg16647868	chr5:131706066	SLC22A5	0.51	8.13	0.37	4.78e-15	Breast cancer;
LUAD	cis	rs13315871	0.929	rs34676912	chr3:58320298	C/A	cg20936604	chr3:58311152	NA	-0.78	-8.27	-0.37	1.76e-15	Cholesterol, total;
LUAD	cis	rs364477	0.721	rs279876	chr9:996439	G/T	cg13952963	chr9:998547	NA	-0.53	-7.66	-0.35	1.31e-13	Major depressive disorder;
LUAD	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	8.61	0.39	1.47e-16	Lung cancer in ever smokers;
LUAD	cis	rs7818345	0.967	rs13255677	chr8:19288985	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.98	0.32	1.13e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg27144592	chr16:783916	NARFL	0.36	6.45	0.3	3.07e-10	Height;
LUAD	cis	rs6840360	0.571	rs11931934	chr4:152552082	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.53	-0.3	1.91e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg10729496	chr3:10149963	C3orf24	0.58	9.34	0.41	5.58e-19	Alzheimer's disease;
LUAD	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg05340658	chr4:99064831	C4orf37	0.54	9.19	0.41	1.83e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs939658	0.805	rs12902831	chr15:79433171	G/A	cg17916960	chr15:79447300	NA	-0.53	-11.27	-0.48	5.93e-26	Refractive error;
LUAD	cis	rs9811920	0.732	rs7613864	chr3:99602470	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.37	-6.93	-0.32	1.59e-11	Axial length;
LUAD	cis	rs13082711	0.595	rs7615321	chr3:27368010	A/G	cg02860705	chr3:27208620	NA	0.73	11.57	0.49	4.21e-27	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11811982	0.793	rs79238704	chr1:227441605	A/G	cg24860534	chr1:227506868	CDC42BPA	0.71	7.41	0.34	6.76e-13	Optic disc area;
LUAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg24846343	chr22:24311635	DDTL	-0.72	-14.79	-0.58	3.4e-40	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg27490568	chr2:178487706	NA	-0.69	-9.85	-0.43	9.36e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs3931020	0.566	rs1409782	chr1:75272935	T/A	cg21535942	chr1:75199100	CRYZ;TYW3	0.44	6.98	0.32	1.15e-11	Resistin levels;
LUAD	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg19875535	chr5:140030758	IK	0.45	7.42	0.34	6.44e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10821973	0.505	rs7076551	chr10:64026725	C/T	cg09941381	chr10:64027924	RTKN2	-0.35	-6.85	-0.32	2.64e-11	Hypothyroidism;
LUAD	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.47	-0.3	2.68e-10	Prostate cancer;
LUAD	cis	rs9875589	0.509	rs1488379	chr3:14014719	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	6.49	0.3	2.39e-10	Ovarian reserve;
LUAD	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg12667521	chr19:29218732	NA	0.6	8.17	0.37	3.48e-15	Methadone dose in opioid dependence;
LUAD	cis	rs7192380	0.964	rs11075729	chr16:69620278	G/A	cg26679644	chr16:69762563	NA	0.49	9.53	0.42	1.2e-19	Sjögren's syndrome;
LUAD	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.44	-0.34	5.6e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg17264618	chr3:40429014	ENTPD3	0.43	9.04	0.4	5.59e-18	Renal cell carcinoma;
LUAD	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4268898	1.000	rs1203	chr2:24443330	A/G	cg02683114	chr2:24398427	C2orf84	0.42	7.05	0.32	7.44e-12	Asthma;
LUAD	cis	rs7771547	0.605	rs659726	chr6:36467791	C/G	cg07856975	chr6:36356162	ETV7	0.43	6.62	0.31	1.12e-10	Platelet distribution width;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg10685336	chr3:149688848	PFN2	-0.7	-6.9	-0.32	1.9e-11	Type 2 diabetes;
LUAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg08742575	chr21:47604166	C21orf56	-0.63	-11.26	-0.48	6.67e-26	Testicular germ cell tumor;
LUAD	cis	rs71478720	0.903	rs80011693	chr11:112005483	C/T	cg09122223	chr11:112035175	IL18	0.43	6.59	0.31	1.3e-10	Interleukin-18 levels;
LUAD	cis	rs11048434	0.736	rs12424026	chr12:9110993	T/C	cg04155231	chr12:9217510	LOC144571	0.38	7.26	0.33	1.82e-12	Sjögren's syndrome;
LUAD	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg12373951	chr3:133503437	NA	0.35	7.0	0.32	9.78e-12	Iron status biomarkers;
LUAD	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg24399712	chr22:39784796	NA	-0.79	-14.92	-0.59	9.14e-41	Intelligence (multi-trait analysis);
LUAD	trans	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg14791747	chr16:20752902	THUMPD1	0.48	7.34	0.34	1.13e-12	Dental caries;
LUAD	trans	rs9929218	1.000	rs8045022	chr16:68807087	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.93	-0.56	1.47e-36	Colorectal cancer;
LUAD	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg19761014	chr17:28927070	LRRC37B2	0.83	8.06	0.36	7.92e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg17063962	chr7:91808500	NA	-0.6	-9.79	-0.43	1.59e-20	Breast cancer;
LUAD	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg03733263	chr8:22462867	KIAA1967	0.74	13.11	0.54	3.47e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg03948781	chr1:205179583	DSTYK	0.33	6.47	0.3	2.76e-10	Red blood cell count;
LUAD	cis	rs13082711	0.522	rs551621	chr3:27336325	G/C	cg02860705	chr3:27208620	NA	0.51	8.47	0.38	4.13e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs13315871	1.000	rs71311870	chr3:58399283	T/C	cg12435725	chr3:58293450	RPP14	-0.69	-7.35	-0.34	1.05e-12	Cholesterol, total;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg06594919	chr10:102827590	NA	0.4	6.58	0.3	1.38e-10	Bilirubin levels;
LUAD	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg04181038	chr4:183730758	NA	0.72	10.85	0.47	2.34e-24	Pediatric autoimmune diseases;
LUAD	cis	rs2554380	0.943	rs2585049	chr15:84352873	A/C	cg14598478	chr15:84363061	ADAMTSL3	0.62	9.61	0.42	6.84e-20	Height;
LUAD	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs10189230	0.967	rs11692482	chr2:222352405	C/T	cg14652038	chr2:222343519	EPHA4	0.44	8.83	0.39	2.89e-17	Urate levels in lean individuals;
LUAD	cis	rs7177699	0.581	rs7181432	chr15:79123779	C/T	cg00540400	chr15:79124168	NA	0.44	9.73	0.43	2.48e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg15147215	chr3:52552868	STAB1	-0.4	-7.18	-0.33	3.23e-12	Bipolar disorder;
LUAD	cis	rs7493	0.901	rs13226149	chr7:95025600	G/A	cg19678392	chr7:94953810	PON1	-0.59	-8.45	-0.38	4.59e-16	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.36	-7.74	-0.35	7.36e-14	Hemoglobin concentration;
LUAD	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg17724175	chr1:150552817	MCL1	0.38	8.94	0.4	1.19e-17	Melanoma;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13745513	chr9:131018379	GOLGA2	0.51	6.6	0.31	1.26e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg23945273	chr4:120987944	MAD2L1	-0.66	-6.49	-0.3	2.47e-10	Type 2 diabetes;
LUAD	trans	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg01620082	chr3:125678407	NA	-0.91	-9.46	-0.42	2.17e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.49	-7.13	-0.33	4.31e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11958404	1.000	rs72816528	chr5:157410949	G/A	cg05962755	chr5:157440814	NA	0.44	6.63	0.31	1.01e-10	IgG glycosylation;
LUAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.68	-13.51	-0.55	8e-35	Prudent dietary pattern;
LUAD	cis	rs2412459	1.000	rs2279581	chr15:40300092	A/G	cg10636054	chr15:40330586	SRP14	0.7	7.96	0.36	1.64e-14	Response to haloperidol in psychosis;
LUAD	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg25036284	chr2:26402008	FAM59B	-0.56	-7.91	-0.36	2.27e-14	Gut microbiome composition (summer);
LUAD	cis	rs7851660	0.809	rs7048255	chr9:100665698	A/G	cg13688889	chr9:100608707	NA	-0.54	-9.16	-0.41	2.34e-18	Strep throat;
LUAD	cis	rs9462027	0.628	rs6919654	chr6:34810739	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.84	-0.39	2.61e-17	Systemic lupus erythematosus;
LUAD	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg05564831	chr3:52568323	NT5DC2	0.39	7.63	0.35	1.52e-13	Bipolar disorder;
LUAD	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25427524	chr10:38739819	LOC399744	-0.73	-13.56	-0.55	4.85e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg08645402	chr16:4508243	NA	0.52	8.9	0.4	1.65e-17	Schizophrenia;
LUAD	cis	rs713477	0.967	rs11158039	chr14:55906696	A/T	cg13175173	chr14:55914753	NA	-0.34	-7.2	-0.33	2.8e-12	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.56	-9.52	-0.42	1.38e-19	Glomerular filtration rate;
LUAD	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg16325326	chr1:53192061	ZYG11B	0.59	10.79	0.46	3.97e-24	Monocyte count;
LUAD	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg11266682	chr4:10021025	SLC2A9	0.67	15.52	0.6	2.67e-43	Bone mineral density;
LUAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00149659	chr3:10157352	C3orf10	0.61	8.68	0.39	8.54e-17	Alzheimer's disease;
LUAD	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg17328964	chr8:145687451	CYHR1	0.64	11.39	0.48	2.06e-26	Age at first birth;
LUAD	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg06784218	chr1:46089804	CCDC17	-0.53	-11.84	-0.5	3.99e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs12545109	0.800	rs2610058	chr8:57409120	G/A	cg19413350	chr8:57351067	NA	-0.44	-6.64	-0.31	9.91e-11	Obesity-related traits;
LUAD	cis	rs933688	0.532	rs28637141	chr5:90538743	C/T	cg17503389	chr5:90575422	NA	-0.43	-6.78	-0.31	4.16e-11	Smoking behavior;
LUAD	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg14186256	chr22:23484241	RTDR1	0.46	7.75	0.35	6.85e-14	Bone mineral density;
LUAD	trans	rs3219090	0.924	rs1828445	chr1:226601401	A/G	cg27539482	chr13:111589090	NA	0.43	7.18	0.33	3.24e-12	Melanoma;
LUAD	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg23803603	chr1:2058230	PRKCZ	-0.39	-6.56	-0.3	1.56e-10	Height;
LUAD	cis	rs7731657	0.559	rs2079209	chr5:130354909	A/G	cg08523029	chr5:130500466	HINT1	0.58	7.65	0.35	1.34e-13	Fasting plasma glucose;
LUAD	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.55	0.34	2.65e-13	Morning vs. evening chronotype;
LUAD	cis	rs367943	0.871	rs348938	chr5:112825032	C/A	cg21806985	chr5:112824646	MCC	-0.28	-6.76	-0.31	4.61e-11	Type 2 diabetes;
LUAD	cis	rs9826463	0.582	rs11709758	chr3:142104427	T/C	cg20824294	chr3:142316082	PLS1	0.37	6.59	0.31	1.3e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg23172400	chr8:95962367	TP53INP1	-0.39	-9.45	-0.42	2.42e-19	Type 2 diabetes;
LUAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg05313129	chr8:58192883	C8orf71	-0.54	-6.72	-0.31	6.01e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs8002861	1.000	rs8002861	chr13:44474517	G/A	cg17145862	chr1:211918768	LPGAT1	0.77	17.99	0.66	3.62e-54	Leprosy;
LUAD	cis	rs2637266	1.000	rs7897015	chr10:78366566	G/C	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.1	0.33	5.2e-12	Parkinson's disease;
LUAD	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	7.93	0.36	1.91e-14	Neuroticism;
LUAD	cis	rs654950	0.967	rs621727	chr1:41984612	C/T	cg06885757	chr1:42089581	HIVEP3	-0.39	-8.38	-0.38	7.62e-16	Airway imaging phenotypes;
LUAD	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg18277682	chr1:228362509	C1orf69	-0.4	-6.71	-0.31	6.22e-11	Diastolic blood pressure;
LUAD	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg21471580	chr8:22132874	PIWIL2	0.46	8.3	0.37	1.38e-15	Hypertriglyceridemia;
LUAD	cis	rs7727544	0.582	rs10052046	chr5:131544466	G/T	cg14196790	chr5:131705035	SLC22A5	0.42	7.22	0.33	2.47e-12	Blood metabolite levels;
LUAD	cis	rs250677	0.522	rs17109208	chr5:148378475	G/A	cg12140854	chr5:148520817	ABLIM3	-0.56	-8.76	-0.39	4.66e-17	Breast cancer;
LUAD	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg19875535	chr5:140030758	IK	0.41	6.92	0.32	1.64e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg08436684	chr16:88034427	BANP	0.49	6.52	0.3	1.96e-10	Menopause (age at onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07024458	chr16:56390600	GNAO1	-0.43	-6.73	-0.31	5.51e-11	Height;
LUAD	trans	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg01620082	chr3:125678407	NA	-0.44	-6.67	-0.31	8.04e-11	Depression;
LUAD	cis	rs2066819	1.000	rs744051	chr12:56667298	C/T	cg26714650	chr12:56694279	CS	0.85	7.2	0.33	2.85e-12	Psoriasis vulgaris;
LUAD	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg19413350	chr8:57351067	NA	-0.41	-6.43	-0.3	3.53e-10	Obesity-related traits;
LUAD	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	6.75	0.31	4.74e-11	Lung cancer in ever smokers;
LUAD	cis	rs4380275	0.782	rs4854369	chr2:752530	G/A	cg21665850	chr2:731073	NA	0.36	6.57	0.3	1.51e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUAD	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg27454412	chr7:1067447	C7orf50	-0.35	-6.8	-0.31	3.57e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg00383909	chr3:49044727	WDR6	0.73	8.37	0.38	8.66e-16	Cognitive ability (multi-trait analysis);
LUAD	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.01	-0.5	8.8e-29	Primary sclerosing cholangitis;
LUAD	cis	rs6987853	0.636	rs6988165	chr8:42351176	C/G	cg09913449	chr8:42400586	C8orf40	-0.41	-7.77	-0.35	5.86e-14	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg00933542	chr6:150070202	PCMT1	0.45	9.52	0.42	1.34e-19	Lung cancer;
LUAD	cis	rs7584330	0.554	rs10208231	chr2:238433225	C/T	cg14458575	chr2:238380390	NA	0.6	9.5	0.42	1.5700000000000001e-19	Prostate cancer;
LUAD	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg22532475	chr10:104410764	TRIM8	-0.44	-8.56	-0.38	2.09e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg06784218	chr1:46089804	CCDC17	-0.6	-13.44	-0.55	1.56e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.91	-0.36	2.26e-14	Blood metabolite levels;
LUAD	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg13180566	chr4:1052158	NA	-0.38	-6.55	-0.3	1.71e-10	Recombination rate (females);
LUAD	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg05283184	chr6:79620031	NA	-0.62	-12.39	-0.52	2.64e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.54	-7.05	-0.32	7.4e-12	Body mass index;
LUAD	cis	rs11587400	0.532	rs2268700	chr1:115228879	T/G	cg12756093	chr1:115239321	AMPD1	-0.38	-6.45	-0.3	3.15e-10	Autism;
LUAD	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg13271783	chr10:134563150	INPP5A	-0.4	-6.94	-0.32	1.49e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.06	-0.32	6.73e-12	Type 2 diabetes;
LUAD	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg09117114	chr16:67998030	SLC12A4	-0.58	-7.54	-0.34	2.92e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg10150615	chr22:24372951	LOC391322	0.45	6.47	0.3	2.65e-10	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06544989	chr22:39130855	UNC84B	0.44	8.19	0.37	3.06e-15	Menopause (age at onset);
LUAD	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg03340356	chr1:67600835	NA	0.43	7.47	0.34	4.55e-13	Psoriasis;
LUAD	cis	rs7100689	0.580	rs10736366	chr10:82207921	C/T	cg01528321	chr10:82214614	TSPAN14	0.62	9.79	0.43	1.58e-20	Post bronchodilator FEV1;
LUAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg03188948	chr7:1209495	NA	0.81	9.85	0.43	9.72e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs71636778	0.596	rs2095637	chr1:27232845	A/G	cg12203394	chr1:27248618	NUDC	0.51	6.49	0.3	2.39e-10	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg24578937	chr1:2090814	PRKCZ	0.57	12.33	0.51	4.81e-30	Height;
LUAD	cis	rs1448094	0.617	rs1502800	chr12:86476255	A/G	cg02569458	chr12:86230093	RASSF9	0.35	6.6	0.31	1.27e-10	Major depressive disorder;
LUAD	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.41	-0.34	6.86e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00802000	chr16:706648	WDR90	-0.42	-7.88	-0.36	2.76e-14	Height;
LUAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg15147215	chr3:52552868	STAB1	-0.5	-9.8	-0.43	1.42e-20	Electroencephalogram traits;
LUAD	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21582582	chr3:182698605	DCUN1D1	0.61	10.28	0.45	2.91e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs600231	0.577	rs35826299	chr11:65240964	T/C	cg17120908	chr11:65337727	SSSCA1	-0.63	-8.24	-0.37	2.2e-15	Bone mineral density;
LUAD	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	6.43	0.3	3.36e-10	Tonsillectomy;
LUAD	cis	rs981844	0.714	rs2405204	chr4:154705248	A/G	cg10279832	chr4:154682576	RNF175	0.34	7.11	0.33	4.94e-12	Response to statins (LDL cholesterol change);
LUAD	trans	rs75804782	0.521	rs66477197	chr2:239403832	C/T	cg01134436	chr17:81009848	B3GNTL1	0.79	8.69	0.39	8.27e-17	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.69	10.6	0.46	1.87e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs9399401	0.667	rs12213892	chr6:142702234	A/G	cg04461802	chr6:142623433	GPR126	0.46	8.77	0.39	4.46e-17	Chronic obstructive pulmonary disease;
LUAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.77	-0.31	4.31e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg22117172	chr7:91764530	CYP51A1	0.33	7.47	0.34	4.68e-13	Breast cancer;
LUAD	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.62	-10.8	-0.46	3.55e-24	Lymphocyte counts;
LUAD	cis	rs2030114	0.531	rs1353788	chr16:51606021	A/G	cg03758633	chr16:51611768	NA	0.33	6.91	0.32	1.76e-11	Blood pressure measurement (high sodium and potassium intervention);
LUAD	cis	rs4523957	0.890	rs9900379	chr17:2101134	G/A	cg16513277	chr17:2031491	SMG6	-0.8	-15.44	-0.6	5.63e-43	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4764487	0.687	rs10744702	chr12:6349127	G/A	cg08284733	chr12:6341482	CD9	0.42	7.55	0.34	2.72e-13	Mean platelet volume;
LUAD	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg27661571	chr11:113659931	NA	-0.68	-7.92	-0.36	2.07e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs12681287	0.547	rs7459877	chr8:87505660	G/A	cg27223183	chr8:87520930	FAM82B	-0.72	-10.22	-0.45	4.53e-22	Caudate activity during reward;
LUAD	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg02782426	chr3:40428986	ENTPD3	0.43	9.11	0.4	3.41e-18	Renal cell carcinoma;
LUAD	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg05966235	chr16:28915196	ATP2A1	0.47	7.71	0.35	8.82e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs113835537	0.529	rs78999944	chr11:66251228	C/G	cg26679405	chr11:66247800	DPP3	-0.46	-6.65	-0.31	9.2e-11	Airway imaging phenotypes;
LUAD	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg06453172	chr10:134556979	INPP5A	-0.78	-10.89	-0.47	1.65e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg22166914	chr1:53195759	ZYG11B	-0.47	-8.17	-0.37	3.67e-15	Monocyte count;
LUAD	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg15181151	chr6:150070149	PCMT1	0.39	7.68	0.35	1.1e-13	Lung cancer;
LUAD	cis	rs2901656	0.640	rs4916258	chr1:172413526	T/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.51	9.93	0.43	5.13e-21	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg11707310	chr1:2537719	MMEL1	0.33	7.27	0.33	1.8e-12	Ulcerative colitis;
LUAD	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg02493740	chr2:85810744	VAMP5	-0.45	-8.34	-0.38	1.03e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg20607798	chr8:58055168	NA	0.78	9.18	0.41	1.97e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6489785	0.543	rs4767938	chr12:121261162	C/T	cg02419362	chr12:121203948	SPPL3	0.32	6.36	0.3	5.31e-10	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg05754148	chr16:3507555	NAT15	-0.4	-6.66	-0.31	8.71e-11	Body mass index (adult);
LUAD	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg17063962	chr7:91808500	NA	0.68	11.74	0.5	9.69e-28	Breast cancer;
LUAD	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg04036182	chr15:45458818	NA	-0.42	-7.3	-0.33	1.47e-12	Glomerular filtration rate;
LUAD	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.65	-0.35	1.4e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg17551891	chr7:1960795	MAD1L1	-0.39	-6.76	-0.31	4.6e-11	Neuroticism;
LUAD	cis	rs7520050	0.807	rs12025621	chr1:46228391	G/A	cg06784218	chr1:46089804	CCDC17	-0.35	-7.57	-0.35	2.36e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs752010	0.746	rs10890146	chr1:42089389	G/A	cg06885757	chr1:42089581	HIVEP3	0.48	11.12	0.48	2.29e-25	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg03676636	chr4:99064102	C4orf37	0.31	8.08	0.37	7.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.39	6.41	0.3	3.95e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2294693	0.531	rs12210310	chr6:40950807	T/C	cg14769373	chr6:40998127	UNC5CL	-0.48	-6.53	-0.3	1.89e-10	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs8177876	0.822	rs4306521	chr16:81114893	T/C	cg08591886	chr16:81111003	C16orf46	-0.79	-7.37	-0.34	8.94e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs1595825	0.735	rs1866665	chr2:198925980	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-7.04	-0.32	8.07e-12	Ulcerative colitis;
LUAD	cis	rs7680126	0.580	rs6827401	chr4:10031066	G/A	cg00071950	chr4:10020882	SLC2A9	0.58	7.2	0.33	2.85e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.2	0.33	2.86e-12	Obesity-related traits;
LUAD	cis	rs1832871	0.521	rs62437410	chr6:158822888	G/C	cg07165851	chr6:158734300	TULP4	0.47	7.0	0.32	1.02e-11	Height;
LUAD	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03517284	chr6:25882590	NA	-0.57	-9.28	-0.41	8.66e-19	Blood metabolite levels;
LUAD	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg14458575	chr2:238380390	NA	0.71	13.18	0.54	1.85e-33	Prostate cancer;
LUAD	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg10518543	chr12:38710700	ALG10B	0.5	8.23	0.37	2.37e-15	Morning vs. evening chronotype;
LUAD	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg08470875	chr2:26401718	FAM59B	-0.75	-10.83	-0.47	2.81e-24	Gut microbiome composition (summer);
LUAD	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg11742103	chr11:62369870	EML3;MTA2	-0.56	-9.69	-0.43	3.51e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs6489882	0.703	rs11066452	chr12:113361574	G/T	cg20102336	chr12:113376681	OAS3	-0.58	-8.89	-0.4	1.72e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg17724175	chr1:150552817	MCL1	0.34	7.9	0.36	2.48e-14	Melanoma;
LUAD	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg01200585	chr1:228362443	C1orf69	-0.4	-7.4	-0.34	7.27e-13	Diastolic blood pressure;
LUAD	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg06636001	chr8:8085503	FLJ10661	0.42	6.62	0.31	1.07e-10	Neuroticism;
LUAD	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg14668632	chr7:2872130	GNA12	-0.76	-13.67	-0.55	1.69e-35	Height;
LUAD	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg18827107	chr12:86230957	RASSF9	-0.46	-8.33	-0.38	1.11e-15	Major depressive disorder;
LUAD	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg23649088	chr2:200775458	C2orf69	0.62	8.24	0.37	2.17e-15	Schizophrenia;
LUAD	cis	rs7809615	0.901	rs10808111	chr7:99070884	T/A	cg12290671	chr7:99195819	NA	-0.72	-8.19	-0.37	3.12e-15	Blood metabolite ratios;
LUAD	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.68	13.33	0.54	4.2e-34	Cognitive ability;
LUAD	cis	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg26958806	chr6:27640298	NA	0.67	6.39	0.3	4.34e-10	Depression;
LUAD	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg02753203	chr1:228287806	NA	-0.46	-8.34	-0.38	1.08e-15	Diastolic blood pressure;
LUAD	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg07343612	chr16:622815	PIGQ	-0.82	-16.17	-0.62	4e-46	Height;
LUAD	cis	rs4906332	0.933	rs4906330	chr14:103971202	T/G	cg19000871	chr14:103996768	TRMT61A	-0.41	-6.99	-0.32	1.06e-11	Coronary artery disease;
LUAD	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg01200585	chr1:228362443	C1orf69	-0.39	-7.18	-0.33	3.07e-12	Diastolic blood pressure;
LUAD	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg08999081	chr20:33150536	PIGU	0.49	9.47	0.42	1.93e-19	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg24818145	chr4:99064322	C4orf37	0.45	7.66	0.35	1.3e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg06784218	chr1:46089804	CCDC17	0.51	11.23	0.48	8.7e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9858542	0.537	rs4410472	chr3:49329090	A/T	cg00383909	chr3:49044727	WDR6	0.62	7.99	0.36	1.29e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2050392	0.965	rs2480279	chr10:30700032	C/T	cg18806716	chr10:30721971	MAP3K8	-0.52	-10.55	-0.46	2.91e-23	Inflammatory bowel disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01332181	chr19:47290716	SLC1A5	-0.44	-6.71	-0.31	6.3e-11	Height;
LUAD	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg23262073	chr20:60523788	NA	-0.37	-6.51	-0.3	2.12e-10	Body mass index;
LUAD	cis	rs7759001	0.817	rs1534937	chr6:27354335	A/T	cg18711553	chr6:27366782	ZNF391	0.39	6.43	0.3	3.36e-10	Glomerular filtration rate (creatinine);
LUAD	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg20587970	chr11:113659929	NA	-1.2	-17.81	-0.65	2.43e-53	Hip circumference adjusted for BMI;
LUAD	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg27489772	chr12:121021490	NA	-0.52	-6.51	-0.3	2.16e-10	Type 1 diabetes nephropathy;
LUAD	cis	rs10489202	0.608	rs7556350	chr1:168077797	C/T	cg25738037	chr1:168025549	DCAF6	-0.46	-6.63	-0.31	1.04e-10	Schizophrenia;
LUAD	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg02773041	chr1:40204384	PPIE	0.53	8.81	0.39	3.29e-17	Blood protein levels;
LUAD	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg15997130	chr1:24165203	NA	0.56	9.54	0.42	1.11e-19	Immature fraction of reticulocytes;
LUAD	cis	rs7428	0.527	rs3184780	chr2:85549547	C/T	cg24342717	chr2:85555507	TGOLN2	-0.47	-7.74	-0.35	7.28e-14	Ear protrusion;
LUAD	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg20587970	chr11:113659929	NA	-1.41	-21.41	-0.72	2.07e-69	Hip circumference adjusted for BMI;
LUAD	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18876405	chr7:65276391	NA	0.43	6.75	0.31	4.89e-11	Aortic root size;
LUAD	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	6.59	0.31	1.3e-10	Cognitive test performance;
LUAD	trans	rs12200782	1.000	rs3927423	chr6:26393487	C/T	cg08851530	chr6:28072375	NA	0.74	6.67	0.31	8.1e-11	Small cell lung carcinoma;
LUAD	cis	rs2455799	1.000	rs11921219	chr3:15865369	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.73	-0.31	5.66e-11	Mean platelet volume;
LUAD	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg02951883	chr7:2050386	MAD1L1	-0.74	-12.84	-0.53	4.19e-32	Schizophrenia;
LUAD	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg25251562	chr2:3704773	ALLC	-0.49	-8.11	-0.37	5.7e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs2012796	0.661	rs59969857	chr14:81841579	A/G	cg02996355	chr14:81879375	NA	0.53	8.2	0.37	2.98e-15	Night sleep phenotypes;
LUAD	cis	rs9788721	1.000	rs9788721	chr15:78802869	C/T	cg18825076	chr15:78729989	IREB2	0.58	9.75	0.43	2.11e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.55	7.79	0.35	5.08e-14	Platelet count;
LUAD	cis	rs1595825	0.891	rs10497810	chr2:198895732	C/T	cg00361562	chr2:198649771	BOLL	-0.47	-6.52	-0.3	1.96e-10	Ulcerative colitis;
LUAD	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg15557168	chr22:42548783	NA	-0.52	-9.75	-0.43	2.22e-20	Schizophrenia;
LUAD	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg00852783	chr1:26633632	UBXN11	0.46	7.61	0.35	1.83e-13	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg01620082	chr3:125678407	NA	-1.01	-10.28	-0.45	2.92e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg12935359	chr14:103987150	CKB	-0.5	-8.0	-0.36	1.25e-14	Body mass index;
LUAD	cis	rs9341808	0.727	rs1324120	chr6:80976125	G/C	cg08355045	chr6:80787529	NA	0.57	10.27	0.45	3.13e-22	Sitting height ratio;
LUAD	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg14092988	chr3:52407081	DNAH1	0.37	7.48	0.34	4.47e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg12935359	chr14:103987150	CKB	-0.48	-8.0	-0.36	1.17e-14	Body mass index;
LUAD	cis	rs4638749	1.000	rs1466212	chr2:108856532	G/A	cg25838818	chr2:108905173	SULT1C2	-0.53	-8.46	-0.38	4.29e-16	Blood pressure;
LUAD	cis	rs7017914	0.934	rs62530772	chr8:71601541	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.61	-0.31	1.13e-10	Bone mineral density;
LUAD	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg26384229	chr12:38710491	ALG10B	0.4	6.75	0.31	4.95e-11	Morning vs. evening chronotype;
LUAD	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg02527881	chr3:46936655	PTH1R	-0.51	-10.39	-0.45	1.11e-22	Colorectal cancer;
LUAD	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.53	-0.3	1.88e-10	Alzheimer's disease (late onset);
LUAD	cis	rs7264396	1.000	rs224430	chr20:34153341	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.5	-0.3	2.26e-10	Total cholesterol levels;
LUAD	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg15123519	chr2:136567270	LCT	-0.37	-6.74	-0.31	5.05e-11	Mosquito bite size;
LUAD	cis	rs1152591	0.792	rs1152595	chr14:64674981	T/C	cg21174375	chr14:64681225	SYNE2	0.36	6.84	0.32	2.73e-11	Atrial fibrillation;
LUAD	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22857025	chr5:266934	NA	-0.99	-14.44	-0.57	1.05e-38	Breast cancer;
LUAD	cis	rs6987853	0.787	rs2974335	chr8:42417272	C/T	cg09913449	chr8:42400586	C8orf40	0.51	10.23	0.45	4.27e-22	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2479724	0.776	rs2250428	chr6:41832772	T/A	cg17623882	chr6:41773611	USP49	-0.64	-11.86	-0.5	3.15e-28	Menarche (age at onset);
LUAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg09509183	chr1:209979624	IRF6	0.68	13.88	0.56	2.42e-36	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUAD	trans	rs9951602	0.512	rs1599635	chr18:76643819	G/A	cg02800362	chr5:177631904	HNRNPAB	0.92	14.18	0.57	1.25e-37	Obesity-related traits;
LUAD	cis	rs6867032	0.958	rs4463207	chr5:2017118	G/T	cg26168224	chr5:2018326	NA	0.79	17.8	0.65	2.53e-53	Gut microbiome composition (winter);
LUAD	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg09222892	chr1:25734099	RHCE	-0.49	-8.98	-0.4	9.17e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	6.05e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg06808227	chr14:105710500	BRF1	-0.43	-6.6	-0.31	1.21e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.2	-0.37	2.91e-15	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg23625390	chr15:77176239	SCAPER	-0.46	-7.27	-0.33	1.7e-12	Blood metabolite levels;
LUAD	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg20933634	chr6:27740509	NA	0.52	8.43	0.38	5.43e-16	Parkinson's disease;
LUAD	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg09117114	chr16:67998030	SLC12A4	-0.57	-7.66	-0.35	1.25e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg02423579	chr7:2872169	GNA12	-0.9	-17.03	-0.64	6.5e-50	Height;
LUAD	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg02176678	chr2:219576539	TTLL4	0.68	13.79	0.56	5.33e-36	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs4650994	0.525	rs4650996	chr1:178517365	A/G	cg05059571	chr16:84539110	KIAA1609	-0.74	-13.25	-0.54	9.52e-34	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs1232027	0.656	rs1650662	chr5:79963287	A/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.15	-0.33	3.76e-12	Huntington's disease progression;
LUAD	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg11578532	chr1:161008127	TSTD1	0.42	8.91	0.4	1.5e-17	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg07636037	chr3:49044803	WDR6	0.48	8.09	0.37	6.31e-15	Menarche (age at onset);
LUAD	cis	rs7020830	1.000	rs7020830	chr9:37085184	A/T	cg14294708	chr9:37120828	ZCCHC7	0.8	15.73	0.61	3.24e-44	Schizophrenia;
LUAD	cis	rs4253772	0.575	rs6008684	chr22:46719100	C/G	cg18190219	chr22:46762943	CELSR1	-0.6	-6.83	-0.31	3.06e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7680126	0.596	rs12511337	chr4:10311972	A/G	cg11266682	chr4:10021025	SLC2A9	0.43	6.78	0.31	4.18e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18876405	chr7:65276391	NA	0.56	9.29	0.41	8.07e-19	Aortic root size;
LUAD	cis	rs494562	0.892	rs638745	chr6:86115587	C/G	cg27297263	chr6:86160468	NT5E	0.58	6.42	0.3	3.66e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg18180107	chr4:99064573	C4orf37	0.42	6.56	0.3	1.54e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg24208426	chr11:3819031	PGAP2;NUP98	-0.39	-6.54	-0.3	1.8e-10	Subcortical brain region volumes;
LUAD	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.88	-0.36	2.8e-14	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs9875589	0.509	rs2607757	chr3:14081948	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.37	-6.87	-0.32	2.29e-11	Ovarian reserve;
LUAD	trans	rs877282	0.533	rs10904565	chr10:819991	G/T	cg22713356	chr15:30763199	NA	0.9	11.31	0.48	4.3e-26	Uric acid levels;
LUAD	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg06547715	chr2:218990976	CXCR2	-0.29	-7.01	-0.32	9.74e-12	Colorectal cancer;
LUAD	cis	rs10865541	0.902	rs6739163	chr2:3419011	G/A	cg22182287	chr2:3452347	TTC15	0.46	8.04	0.36	9.09e-15	Obesity-related traits;
LUAD	cis	rs2797160	1.000	rs1739348	chr6:126014573	T/C	cg05901451	chr6:126070800	HEY2	0.45	6.71	0.31	6.22e-11	Endometrial cancer;
LUAD	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg08989290	chr16:615782	NHLRC4	0.31	6.71	0.31	6.22e-11	Height;
LUAD	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg17845761	chr1:175162550	KIAA0040	0.36	9.49	0.42	1.69e-19	Diastolic blood pressure;
LUAD	cis	rs1403694	0.695	rs13317089	chr3:186436217	G/C	cg12454167	chr3:186435060	KNG1	0.51	10.73	0.46	6.26e-24	Blood protein levels;
LUAD	cis	rs847577	0.550	rs12670686	chr7:97708397	A/G	cg24562669	chr7:97807699	LMTK2	0.3	7.05	0.32	7.37e-12	Breast cancer;
LUAD	trans	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg26043149	chr18:55253948	FECH	-0.41	-6.79	-0.31	3.84e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1816752	0.712	rs9507335	chr13:24983904	G/A	cg02811702	chr13:24901961	NA	0.42	7.36	0.34	9.42e-13	Obesity-related traits;
LUAD	cis	rs73206853	0.764	rs73206868	chr12:110816835	G/T	cg12870014	chr12:110450643	ANKRD13A	0.63	7.15	0.33	3.92e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs2637266	0.783	rs846597	chr10:78529114	A/G	cg18941641	chr10:78392320	NA	0.32	6.69	0.31	7.08e-11	Pulmonary function;
LUAD	cis	rs7584330	0.554	rs6739456	chr2:238385092	G/C	cg27051686	chr2:238398490	MLPH	0.4	6.58	0.3	1.41e-10	Prostate cancer;
LUAD	cis	rs3760982	0.585	rs11673534	chr19:44298884	G/A	cg11993925	chr19:44307056	LYPD5	0.54	11.3	0.48	4.71e-26	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs9902453	0.817	rs3115089	chr17:28031881	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.51	0.42	1.45e-19	Coffee consumption (cups per day);
LUAD	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.04	0.32	7.98e-12	Colorectal cancer;
LUAD	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg17385448	chr1:15911702	AGMAT	0.39	6.39	0.3	4.36e-10	Systolic blood pressure;
LUAD	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.81	-13.91	-0.56	1.71e-36	Platelet distribution width;
LUAD	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06022373	chr22:39101656	GTPBP1	0.46	7.15	0.33	3.76e-12	Menopause (age at onset);
LUAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg21782813	chr7:2030301	MAD1L1	0.59	10.13	0.44	9.36e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.41	-6.71	-0.31	6.28e-11	Tonsillectomy;
LUAD	cis	rs4774899	0.966	rs2414492	chr15:57519543	C/T	cg14026238	chr15:57616123	NA	0.35	6.57	0.3	1.49e-10	Urinary tract infection frequency;
LUAD	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg15448220	chr1:150897856	SETDB1	0.52	8.97	0.4	9.47e-18	Melanoma;
LUAD	trans	rs9929218	1.000	rs9937664	chr16:68784603	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-14.66	-0.58	1.23e-39	Colorectal cancer;
LUAD	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.99e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg02569458	chr12:86230093	RASSF9	-0.41	-7.68	-0.35	1.15e-13	Major depressive disorder;
LUAD	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg10978503	chr1:24200527	CNR2	0.52	11.27	0.48	6.07e-26	Immature fraction of reticulocytes;
LUAD	cis	rs7809615	0.901	rs6947974	chr7:99156506	G/A	cg12290671	chr7:99195819	NA	-0.71	-8.2	-0.37	2.85e-15	Blood metabolite ratios;
LUAD	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7944735	0.507	rs10742827	chr11:48102350	C/T	cg15704280	chr7:45808275	SEPT13	0.65	9.32	0.41	6.41e-19	Intraocular pressure;
LUAD	cis	rs13095912	1.000	rs6784842	chr3:185342723	C/T	cg11274856	chr3:185301563	NA	0.38	7.59	0.35	2.07e-13	Systolic blood pressure;
LUAD	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg12310025	chr6:25882481	NA	-0.54	-8.99	-0.4	8.03e-18	Blood metabolite levels;
LUAD	trans	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg26043149	chr18:55253948	FECH	-0.48	-7.86	-0.36	3.11e-14	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9308433	0.643	rs4655330	chr1:214466068	A/G	cg06198575	chr1:214491504	SMYD2	-0.42	-7.08	-0.33	6.01e-12	IgG glycosylation;
LUAD	cis	rs4771122	0.740	rs1006353	chr13:28047269	A/G	cg22138327	chr13:27999177	GTF3A	-0.71	-11.41	-0.49	1.72e-26	Body mass index;
LUAD	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg03467027	chr4:99064603	C4orf37	0.4	6.49	0.3	2.41e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3981351	0.528	rs12768908	chr10:115443894	C/T	cg24846397	chr10:115438155	CASP7	-0.47	-9.31	-0.41	6.77e-19	Obesity-related traits;
LUAD	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg09222892	chr1:25734099	RHCE	0.51	9.43	0.42	2.66e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg27247225	chr6:26970382	C6orf41	-0.42	-6.38	-0.3	4.65e-10	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg21153622	chr11:89784906	NA	-0.34	-6.7	-0.31	6.52e-11	Coronary artery disease;
LUAD	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg06618935	chr21:46677482	NA	-0.37	-6.89	-0.32	2.03e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg03983476	chr2:10830698	NOL10	-0.45	-7.83	-0.36	4.02e-14	Prostate cancer;
LUAD	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24308560	chr3:49941425	MST1R	0.56	9.58	0.42	8.44e-20	Intelligence (multi-trait analysis);
LUAD	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg00769240	chr8:12517080	NA	-0.43	-8.39	-0.38	7.61e-16	Blood pressure (smoking interaction);
LUAD	cis	rs7737355	0.947	rs31584	chr5:130993124	A/G	cg25547332	chr5:131281432	NA	0.44	6.61	0.31	1.15e-10	Life satisfaction;
LUAD	cis	rs943466	0.911	rs111352628	chr6:33742490	A/G	cg07979401	chr6:33739406	LEMD2	-0.37	-6.36	-0.3	5.11e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg13390004	chr1:15929781	NA	0.47	8.36	0.38	9.42e-16	Systolic blood pressure;
LUAD	cis	rs977987	0.806	rs12444589	chr16:75454404	A/T	cg03315344	chr16:75512273	CHST6	-0.62	-13.81	-0.56	4.38e-36	Dupuytren's disease;
LUAD	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg25036284	chr2:26402008	FAM59B	-0.6	-8.34	-0.38	1.02e-15	Gut microbiome composition (summer);
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg16232842	chr15:74286823	PML	0.37	6.37	0.3	4.84e-10	Anger;
LUAD	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.0	0.32	1.04e-11	Motion sickness;
LUAD	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.87	-0.36	3.09e-14	Menopause (age at onset);
LUAD	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg07917127	chr4:99064746	C4orf37	0.42	7.02	0.32	9.15e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7524258	0.835	rs7521425	chr1:7306543	C/T	cg07173049	chr1:7289937	CAMTA1	0.41	7.57	0.35	2.4e-13	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs3813948	0.543	rs11120218	chr1:207278451	C/T	cg22332276	chr1:207277018	C4BPA	-0.63	-8.24	-0.37	2.16e-15	C4b binding protein levels;
LUAD	cis	rs11771526	0.901	rs62457471	chr7:32306737	A/C	cg13207630	chr7:32358064	NA	0.6	7.44	0.34	5.56e-13	Body mass index;
LUAD	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg18446336	chr7:2847575	GNA12	-0.35	-6.62	-0.31	1.1e-10	Height;
LUAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08439880	chr3:133502540	NA	-0.45	-8.96	-0.4	1.01e-17	Iron status biomarkers;
LUAD	cis	rs1215050	0.755	rs9991112	chr4:98651479	A/C	cg17366294	chr4:99064904	C4orf37	-0.46	-7.91	-0.36	2.2e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-7.96	-0.36	1.65e-14	Diabetic kidney disease;
LUAD	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg24768116	chr2:27665128	KRTCAP3	0.26	6.45	0.3	3.11e-10	Oral cavity cancer;
LUAD	trans	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04565464	chr8:145669602	NFKBIL2	0.44	6.85	0.32	2.57e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg27490568	chr2:178487706	NA	0.5	7.75	0.35	7.03e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg17509989	chr5:176798049	RGS14	-0.6	-9.04	-0.4	5.72e-18	Urate levels in lean individuals;
LUAD	cis	rs11958404	0.929	rs79656592	chr5:157430291	G/A	cg05962755	chr5:157440814	NA	0.66	8.83	0.39	2.82e-17	IgG glycosylation;
LUAD	cis	rs7192380	1.000	rs11075726	chr16:69584523	A/G	cg26679644	chr16:69762563	NA	0.45	8.5	0.38	3.19e-16	Sjögren's syndrome;
LUAD	cis	rs7119	0.679	rs34075648	chr15:77847802	G/C	cg27398640	chr15:77910606	LINGO1	-0.37	-6.72	-0.31	5.84e-11	Type 2 diabetes;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg26085966	chr14:64319812	SYNE2	-0.52	-6.68	-0.31	7.49e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.27	0.37	1.74e-15	Breast cancer;
LUAD	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg15226275	chr6:116381976	FRK	-0.24	-7.67	-0.35	1.23e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs1595825	0.891	rs16867018	chr2:198521490	C/T	cg11031976	chr2:198649780	BOLL	-0.46	-6.84	-0.32	2.82e-11	Ulcerative colitis;
LUAD	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.4	8.02	0.36	1.06e-14	Depression;
LUAD	trans	rs2840044	1.000	rs11653310	chr17:33893378	C/G	cg19694781	chr19:47549865	TMEM160	-0.63	-10.3	-0.45	2.37e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	trans	rs6076960	0.652	rs3852946	chr20:6255311	C/T	cg21095983	chr6:86352623	SYNCRIP	0.41	6.71	0.31	6.13e-11	Smooth-surface caries;
LUAD	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-11.23	-0.48	8.89e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4006360	0.546	rs1848812	chr17:39235917	C/T	cg20663846	chr17:39254439	KRTAP4-8	0.35	8.05	0.36	8.62e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg02753203	chr1:228287806	NA	0.57	10.68	0.46	9.98e-24	Diastolic blood pressure;
LUAD	cis	rs7487075	0.619	rs10748450	chr12:46857102	C/T	cg23829395	chr12:46796953	NA	0.3	6.68	0.31	7.44e-11	Itch intensity from mosquito bite;
LUAD	cis	rs6430585	0.702	rs73958637	chr2:136546927	C/T	cg07169764	chr2:136633963	MCM6	0.83	9.76	0.43	1.99e-20	Corneal structure;
LUAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs11597390	0.867	rs11596837	chr10:101850079	C/A	cg19754520	chr10:101825118	CPN1	-0.34	-6.81	-0.31	3.45e-11	Liver enzyme levels;
LUAD	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg25985355	chr7:65971099	NA	-0.53	-6.6	-0.31	1.22e-10	Diabetic kidney disease;
LUAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg12432903	chr7:1882776	MAD1L1	-0.43	-7.01	-0.32	9.33e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg02683114	chr2:24398427	C2orf84	-0.52	-7.77	-0.35	6.05e-14	Asthma;
LUAD	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg17845761	chr1:175162550	KIAA0040	-0.38	-9.76	-0.43	2.03e-20	Alcohol dependence;
LUAD	cis	rs11650175	1.000	rs66792807	chr17:63750763	A/T	cg07283582	chr17:63770753	CCDC46	0.39	7.33	0.34	1.18e-12	Chin dimples;
LUAD	cis	rs7818345	0.935	rs12542575	chr8:19286558	A/T	cg11303988	chr8:19266685	CSGALNACT1	0.3	6.76	0.31	4.47e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg08027265	chr7:2291960	NA	-0.47	-8.17	-0.37	3.67e-15	Schizophrenia;
LUAD	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg01181863	chr3:195395398	SDHAP2	0.66	10.82	0.47	2.97e-24	Bronchopulmonary dysplasia;
LUAD	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg15556689	chr8:8085844	FLJ10661	0.4	6.49	0.3	2.47e-10	Mood instability;
LUAD	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg20556744	chr2:9614537	IAH1	0.66	6.54	0.3	1.81e-10	Opioid sensitivity;
LUAD	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg16479474	chr6:28041457	NA	0.4	7.2	0.33	2.86e-12	Parkinson's disease;
LUAD	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg16325326	chr1:53192061	ZYG11B	-0.7	-12.82	-0.53	4.93e-32	Monocyte count;
LUAD	cis	rs7737355	0.812	rs26003	chr5:130990384	T/C	cg25547332	chr5:131281432	NA	0.42	6.82	0.31	3.12e-11	Life satisfaction;
LUAD	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg03806693	chr22:41940476	POLR3H	0.74	9.95	0.44	4.33e-21	Vitiligo;
LUAD	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg05665937	chr4:1216051	CTBP1	-0.42	-7.29	-0.33	1.52e-12	Obesity-related traits;
LUAD	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg03948781	chr1:205179583	DSTYK	0.33	6.45	0.3	3.09e-10	Red blood cell count;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg20083989	chr14:23039506	DAD1	-0.39	-6.47	-0.3	2.78e-10	Cancer;
LUAD	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg23758822	chr17:41437982	NA	0.99	20.44	0.7	4.46e-65	Menopause (age at onset);
LUAD	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg02423579	chr7:2872169	GNA12	-0.87	-15.32	-0.6	1.87e-42	Height;
LUAD	cis	rs4285028	0.747	rs11916169	chr3:121403211	A/G	cg11130432	chr3:121712080	ILDR1	-0.49	-7.0	-0.32	1.02e-11	Multiple sclerosis;
LUAD	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg15017067	chr4:17643749	FAM184B	0.35	7.0	0.32	1.04e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2795502	0.564	rs72777192	chr10:43436778	G/A	cg20628663	chr10:43360327	NA	0.6	6.94	0.32	1.46e-11	Blood protein levels;
LUAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.56	7.59	0.35	2.1e-13	Renal function-related traits (BUN);
LUAD	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg02807482	chr3:125708958	NA	-0.54	-7.48	-0.34	4.39e-13	Blood pressure (smoking interaction);
LUAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg09436375	chr6:42928200	GNMT	-0.29	-8.31	-0.37	1.32e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.41	0.42	3.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-8.12	-0.37	5.26e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg24813613	chr7:1882135	MAD1L1	-0.45	-7.14	-0.33	4.15e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21041512	chr17:79196677	AZI1	-0.51	-6.44	-0.3	3.34e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg05313129	chr8:58192883	C8orf71	-0.54	-8.04	-0.36	8.85e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.4	-6.97	-0.32	1.25e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg05368731	chr17:41323189	NBR1	0.94	19.4	0.69	2.02e-60	Menopause (age at onset);
LUAD	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg11871910	chr12:69753446	YEATS4	0.5	7.34	0.34	1.09e-12	Response to diuretic therapy;
LUAD	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg07636037	chr3:49044803	WDR6	0.64	12.66	0.52	2.23e-31	Parkinson's disease;
LUAD	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.59	0.42	7.97e-20	Cognitive ability;
LUAD	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.01	0.32	9.71e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-10.64	-0.46	1.41e-23	Gut microbiome composition (summer);
LUAD	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg05535760	chr7:792225	HEATR2	-0.84	-9.86	-0.43	8.63e-21	Cerebrospinal P-tau181p levels;
LUAD	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg01689657	chr7:91764605	CYP51A1	0.38	9.3	0.41	7.48e-19	Breast cancer;
LUAD	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg10518543	chr12:38710700	ALG10B	-0.48	-8.06	-0.36	7.93e-15	Morning vs. evening chronotype;
LUAD	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg01312482	chr5:178451176	ZNF879	0.43	6.73	0.31	5.47e-11	Pubertal anthropometrics;
LUAD	cis	rs868036	1.000	rs9972436	chr15:68098027	G/C	cg08079166	chr15:68083412	MAP2K5	0.3	6.46	0.3	2.91e-10	Restless legs syndrome;
LUAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg24503407	chr1:205819492	PM20D1	0.59	10.93	0.47	1.14e-24	Menarche (age at onset);
LUAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-10.31	-0.45	2.23e-22	Lymphocyte counts;
LUAD	cis	rs1832871	0.683	rs9459852	chr6:158687250	T/G	cg07165851	chr6:158734300	TULP4	0.71	11.07	0.47	3.54e-25	Height;
LUAD	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02475777	chr4:1388615	CRIPAK	0.71	10.23	0.45	4.2e-22	Longevity;
LUAD	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg12035532	chr1:1886765	KIAA1751	0.42	6.89	0.32	2.09e-11	Body mass index;
LUAD	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg00271210	chr6:167070053	RPS6KA2	0.33	6.47	0.3	2.77e-10	Crohn's disease;
LUAD	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg17724175	chr1:150552817	MCL1	0.32	7.35	0.34	1.01e-12	Melanoma;
LUAD	cis	rs11051970	0.679	rs2651366	chr12:32560431	T/C	cg24626660	chr12:32551988	NA	0.35	7.54	0.34	2.84e-13	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg15017067	chr4:17643749	FAM184B	0.37	7.19	0.33	2.88e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs758324	0.812	rs13174462	chr5:131217988	A/G	cg25547332	chr5:131281432	NA	0.41	6.91	0.32	1.84e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg23172400	chr8:95962367	TP53INP1	-0.32	-6.79	-0.31	3.83e-11	Type 2 diabetes;
LUAD	cis	rs7587476	0.906	rs16852750	chr2:215646683	A/G	cg04004882	chr2:215674386	BARD1	0.52	6.38	0.3	4.62e-10	Neuroblastoma;
LUAD	cis	rs57920188	0.535	rs4295856	chr1:4094842	C/T	cg20703997	chr1:4087676	NA	0.48	9.01	0.4	7.04e-18	Interleukin-17 levels;
LUAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg07741184	chr6:167504864	NA	0.31	7.47	0.34	4.74e-13	Crohn's disease;
LUAD	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg04944784	chr2:26401820	FAM59B	-0.88	-12.6	-0.52	4.12e-31	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg24558204	chr6:135376177	HBS1L	0.42	7.36	0.34	9.38e-13	Red blood cell count;
LUAD	cis	rs2795502	0.873	rs1815716	chr10:43410200	G/A	cg20628663	chr10:43360327	NA	0.69	11.11	0.48	2.39e-25	Blood protein levels;
LUAD	cis	rs6545883	0.801	rs778142	chr2:61681428	G/T	cg15711740	chr2:61764176	XPO1	-0.41	-6.53	-0.3	1.84e-10	Tuberculosis;
LUAD	cis	rs2742234	0.590	rs2505506	chr10:43645854	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.51	-9.04	-0.4	5.73e-18	Hirschsprung disease;
LUAD	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg13511324	chr14:104056883	C14orf153	0.27	6.56	0.3	1.59e-10	Reticulocyte count;
LUAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg25703541	chr22:24373054	LOC391322	0.77	13.15	0.54	2.47e-33	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11741688	0.597	rs6880072	chr5:178334480	G/C	cg21944022	chr5:178288650	ZNF354B	0.49	9.08	0.4	4.05e-18	Sleep duration;
LUAD	cis	rs4594175	0.707	rs4901096	chr14:51722826	G/C	cg23942311	chr14:51606299	NA	0.52	8.68	0.39	8.47e-17	Cancer;
LUAD	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg11062466	chr8:58055876	NA	0.71	8.82	0.39	2.96e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg18180107	chr4:99064573	C4orf37	0.42	6.76	0.31	4.56e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg14668821	chr17:77704760	ENPP7	0.33	6.6	0.31	1.24e-10	Menopause (age at onset);
LUAD	cis	rs3820068	0.655	rs72645823	chr1:15887442	C/T	cg13390004	chr1:15929781	NA	0.43	6.86	0.32	2.45e-11	Systolic blood pressure;
LUAD	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg00495681	chr13:53174319	NA	0.53	9.74	0.43	2.27e-20	Lewy body disease;
LUAD	cis	rs7120118	0.517	rs56168519	chr11:47317987	T/C	cg13308137	chr11:47528955	CUGBP1	0.36	6.44	0.3	3.19e-10	HDL cholesterol;
LUAD	cis	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg01251360	chr16:68772225	CDH1	-0.29	-9.15	-0.41	2.46e-18	Colorectal cancer;
LUAD	cis	rs7264396	0.563	rs2425100	chr20:34310115	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.26	-0.37	1.94e-15	Total cholesterol levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg10921922	chr14:53174235	PSMC6	-0.41	-6.7	-0.31	6.56e-11	Cancer;
LUAD	cis	rs7216064	0.531	rs62084683	chr17:66031725	A/G	cg08758996	chr17:66097529	LOC651250	-0.4	-6.71	-0.31	6.38e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs12410462	0.748	rs1495853	chr1:227657336	A/G	cg04117972	chr1:227635322	NA	-0.57	-6.42	-0.3	3.77e-10	Major depressive disorder;
LUAD	cis	rs3752645	1.000	rs113752881	chr7:106775091	A/G	cg02696742	chr7:106810147	HBP1	-0.68	-6.61	-0.31	1.19e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg18225595	chr11:63971243	STIP1	-0.37	-6.51	-0.3	2.14e-10	Platelet count;
LUAD	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11890956	chr21:40555474	PSMG1	-0.55	-9.54	-0.42	1.14e-19	Menarche (age at onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13870041	chr1:227015885	NA	-0.4	-6.38	-0.3	4.77e-10	Height;
LUAD	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.63	-13.01	-0.53	8.4e-33	Hemoglobin concentration;
LUAD	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.59e-12	Breast cancer;
LUAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg27454412	chr7:1067447	C7orf50	0.4	6.65	0.31	9.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg13918804	chr1:2043761	PRKCZ	0.41	6.94	0.32	1.44e-11	Height;
LUAD	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg14092988	chr3:52407081	DNAH1	0.42	8.32	0.37	1.27e-15	Bipolar disorder;
LUAD	cis	rs459571	0.635	rs379471	chr9:136890649	G/A	cg13789015	chr9:136890014	NCRNA00094	0.85	14.53	0.58	4.23e-39	Platelet distribution width;
LUAD	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg05132306	chr1:1846340	CALML6	-0.35	-7.54	-0.34	2.83e-13	Body mass index;
LUAD	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18404041	chr3:52824283	ITIH1	-0.63	-12.7	-0.53	1.52e-31	Bipolar disorder;
LUAD	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg02269571	chr22:50332266	NA	-0.61	-9.22	-0.41	1.46e-18	Schizophrenia;
LUAD	cis	rs7215564	0.908	rs35878324	chr17:78677530	C/T	cg16980736	chr17:78789706	RPTOR	-0.66	-6.74	-0.31	5.17e-11	Myopia (pathological);
LUAD	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.44	-0.42	2.44e-19	Life satisfaction;
LUAD	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg02371401	chr5:676784	TPPP	-0.41	-7.04	-0.32	7.89e-12	Obesity-related traits;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13411962	chr8:28243934	ZNF395	-0.53	-6.45	-0.3	3.14e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg11317459	chr13:21872234	NA	-1.09	-14.71	-0.58	7.3e-40	White matter hyperintensity burden;
LUAD	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg18016565	chr1:150552671	MCL1	-0.35	-6.48	-0.3	2.57e-10	Tonsillectomy;
LUAD	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18404041	chr3:52824283	ITIH1	-0.6	-12.47	-0.52	1.32e-30	Electroencephalogram traits;
LUAD	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg06263672	chr7:65235340	NA	0.49	6.55	0.3	1.64e-10	Aortic root size;
LUAD	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs75920871	0.925	rs11827828	chr11:116755584	A/G	cg04087571	chr11:116723030	SIK3	0.34	7.01	0.32	9.52e-12	Subjective well-being;
LUAD	cis	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg12964065	chr18:77638022	KCNG2	0.55	6.84	0.32	2.85e-11	Opioid sensitivity;
LUAD	cis	rs4460629	0.742	rs6427158	chr1:155074903	G/T	cg23973274	chr1:155060172	NA	-0.37	-6.38	-0.3	4.57e-10	Serum magnesium levels;
LUAD	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg14689365	chr7:158441557	NCAPG2	0.39	6.45	0.3	3.14e-10	Height;
LUAD	cis	rs9811920	0.683	rs1718235	chr3:99583484	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.53	-10.43	-0.45	8.2000000000000006e-23	Axial length;
LUAD	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.5	-0.34	3.89e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.99e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.62	0.31	1.09e-10	Depression;
LUAD	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg12062639	chr20:23401060	NAPB	-0.99	-10.52	-0.46	3.83e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg25358565	chr5:93447407	FAM172A	0.59	7.0	0.32	1e-11	Diabetic retinopathy;
LUAD	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg04414720	chr1:150670196	GOLPH3L	0.73	12.74	0.53	1.06e-31	Melanoma;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg17076397	chr5:10353763	MARCH6	-0.43	-7.17	-0.33	3.34e-12	Schizophrenia;
LUAD	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.38	6.73	0.31	5.61e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.46	9.52	0.42	1.3e-19	Monocyte percentage of white cells;
LUAD	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.62e-18	Life satisfaction;
LUAD	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg04155289	chr7:94953770	PON1	-0.52	-6.89	-0.32	1.99e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg18876405	chr7:65276391	NA	-0.45	-7.21	-0.33	2.66e-12	Aortic root size;
LUAD	cis	rs6500395	1.000	rs3743779	chr16:48574040	T/G	cg04672837	chr16:48644449	N4BP1	0.37	6.5	0.3	2.2e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs11971779	0.680	rs4728465	chr7:139069061	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.54	0.3	1.83e-10	Diisocyanate-induced asthma;
LUAD	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00820581	chr1:174969299	CACYBP	0.43	6.64	0.31	9.65e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs3849570	1.000	rs11711331	chr3:81819040	A/G	cg07356753	chr3:81810745	GBE1	0.71	12.64	0.52	2.7e-31	Waist circumference;Body mass index;
LUAD	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6693567	0.565	rs834242	chr1:150379858	G/A	cg15654264	chr1:150340011	RPRD2	0.36	6.48	0.3	2.52e-10	Migraine;
LUAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.2	0.41	1.59e-18	Alzheimer's disease;
LUAD	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs2108225	0.658	rs1476673	chr7:107435945	C/G	cg18560240	chr7:107437656	SLC26A3	-0.42	-6.9	-0.32	1.91e-11	Ulcerative colitis;
LUAD	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg11833968	chr6:79620685	NA	-0.43	-8.01	-0.36	1.1e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg01171360	chr6:293285	DUSP22	-0.54	-9.31	-0.41	6.85e-19	Menopause (age at onset);
LUAD	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg05623727	chr3:50126028	RBM5	-0.31	-6.75	-0.31	4.91e-11	Body mass index;
LUAD	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs13064411	0.542	rs7650671	chr3:113201216	C/T	cg18753928	chr3:113234510	CCDC52	-0.49	-8.75	-0.39	4.95e-17	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.17	0.37	3.51e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62229266	0.804	rs2835241	chr21:37411380	G/T	cg12218747	chr21:37451666	NA	0.48	8.26	0.37	1.88e-15	Mitral valve prolapse;
LUAD	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg03929089	chr4:120376271	NA	-0.92	-16.85	-0.63	4.22e-49	Height;
LUAD	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg06766960	chr11:133703094	NA	-0.44	-8.27	-0.37	1.74e-15	Childhood ear infection;
LUAD	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	8.59	0.39	1.75e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs7707921	0.881	rs4391141	chr5:81263522	T/A	cg15871215	chr5:81402204	ATG10	-0.66	-9.34	-0.41	5.35e-19	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00630453	chr20:2821369	FAM113A;VPS16	-0.41	-6.53	-0.3	1.9e-10	Height;
LUAD	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg13319975	chr6:146136371	FBXO30	0.6	10.42	0.45	9.07e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.39	0.3	4.41e-10	Breast cancer;
LUAD	cis	rs4074961	0.669	rs4652964	chr1:38078300	A/G	cg12696750	chr1:38022466	DNALI1	0.41	7.01	0.32	9.21e-12	Axial length;
LUAD	cis	rs4072705	0.967	rs10760369	chr9:127397400	A/G	cg14219918	chr9:127249562	NR5A1	0.28	6.35	0.3	5.43e-10	Menarche (age at onset);
LUAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg16606324	chr3:10149918	C3orf24	0.59	9.65	0.42	4.73e-20	Alzheimer's disease;
LUAD	cis	rs9863	0.827	rs4930706	chr12:124417338	T/C	cg17723958	chr12:124429295	CCDC92	-0.4	-6.4	-0.3	4.05e-10	White blood cell count;
LUAD	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg06608945	chr2:219082296	ARPC2	-0.42	-6.95	-0.32	1.36e-11	Colorectal cancer;
LUAD	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg00204512	chr16:28754710	NA	0.33	7.11	0.33	4.84e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs71478720	0.903	rs12797880	chr11:112049191	T/C	cg04929355	chr11:112034997	IL18	0.46	7.18	0.33	3.06e-12	Interleukin-18 levels;
LUAD	trans	rs7404843	0.850	rs6498553	chr16:15539902	T/C	cg02716450	chr16:28638775	NA	-0.7	-7.86	-0.36	3.32e-14	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7107174	1.000	rs2511157	chr11:77972632	G/A	cg02023728	chr11:77925099	USP35	0.54	8.13	0.37	4.94e-15	Testicular germ cell tumor;
LUAD	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg04705435	chr11:17411270	KCNJ11	0.43	7.13	0.33	4.48e-12	Type 2 diabetes;
LUAD	cis	rs9837602	0.748	rs9875878	chr3:99884509	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	7.96	0.36	1.6e-14	Breast cancer;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg16436509	chr12:120875898	COX6A1	-0.4	-7.08	-0.33	6.13e-12	Subcortical brain region volumes;
LUAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg11494091	chr17:61959527	GH2	0.74	18.36	0.67	8.69e-56	Prudent dietary pattern;
LUAD	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg25985355	chr7:65971099	NA	-0.51	-6.51	-0.3	2.16e-10	Diabetic kidney disease;
LUAD	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg12927641	chr6:109611667	NA	-0.51	-8.66	-0.39	9.93e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg15485101	chr11:133734466	NA	0.37	8.37	0.38	8.74e-16	Childhood ear infection;
LUAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg01448562	chr3:133502909	NA	-0.71	-13.52	-0.55	7.15e-35	Iron status biomarkers;
LUAD	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg04414720	chr1:150670196	GOLPH3L	0.66	11.39	0.48	2.08e-26	Melanoma;
LUAD	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg15110403	chr19:17392923	ANKLE1	-0.44	-6.97	-0.32	1.19e-11	Systemic lupus erythematosus;
LUAD	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg12863693	chr15:85201151	NMB	0.43	7.99	0.36	1.28e-14	Schizophrenia;
LUAD	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.14	0.48	1.9e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2637266	1.000	rs1873461	chr10:78338966	A/C	cg18941641	chr10:78392320	NA	-0.31	-6.48	-0.3	2.59e-10	Pulmonary function;
LUAD	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg22681709	chr2:178499509	PDE11A	-0.55	-9.31	-0.41	7.14e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg16384552	chr7:74938386	SPDYE8P	-0.64	-10.76	-0.46	4.83e-24	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs593982	0.920	rs72939198	chr11:65438079	G/A	cg08755490	chr11:65554678	OVOL1	-1.27	-12.91	-0.53	2.25e-32	Atopic dermatitis;
LUAD	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg20290983	chr6:43655470	MRPS18A	1.06	27.12	0.8	1.39e-94	IgG glycosylation;
LUAD	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	7.12	0.33	4.75e-12	Platelet count;
LUAD	cis	rs6987853	0.623	rs10109400	chr8:42455353	T/C	cg09913449	chr8:42400586	C8orf40	0.44	8.36	0.38	9.13e-16	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg08847533	chr14:75593920	NEK9	0.4	6.87	0.32	2.33e-11	Height;
LUAD	cis	rs12210905	0.688	rs72843191	chr6:27383301	G/C	cg08851530	chr6:28072375	NA	1.07	7.8	0.35	4.96e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs7147624	1.000	rs7153497	chr14:65998415	A/G	cg03016385	chr14:66212404	NA	-0.57	-6.51	-0.3	2.14e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg18827107	chr12:86230957	RASSF9	-0.48	-8.49	-0.38	3.58e-16	Major depressive disorder;
LUAD	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg06873352	chr17:61820015	STRADA	-0.66	-12.94	-0.53	1.65e-32	Prudent dietary pattern;
LUAD	cis	rs2652834	1.000	rs2729830	chr15:63395812	G/C	cg25406657	chr15:63342033	TPM1	-0.44	-7.22	-0.33	2.45e-12	HDL cholesterol;
LUAD	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg06784218	chr1:46089804	CCDC17	0.51	11.15	0.48	1.71e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg24829409	chr8:58192753	C8orf71	-0.61	-8.07	-0.37	7.12e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1143633	0.509	rs2068777	chr2:113696126	A/G	cg12858261	chr2:113808755	IL1F8	0.42	7.45	0.34	5.27e-13	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9419702	0.538	rs4074772	chr10:133540006	A/T	cg04492858	chr10:133558786	NA	0.34	6.37	0.3	4.9e-10	Survival in rectal cancer;
LUAD	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg23260525	chr10:116636907	FAM160B1	0.53	12.59	0.52	4.28e-31	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg26587870	chr6:27730563	NA	-0.55	-8.69	-0.39	8.1e-17	Breast cancer;
LUAD	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24308560	chr3:49941425	MST1R	0.55	9.47	0.42	2e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs367943	0.712	rs26969	chr5:112742436	A/G	cg12552261	chr5:112820674	MCC	0.48	9.22	0.41	1.39e-18	Type 2 diabetes;
LUAD	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg12310025	chr6:25882481	NA	-0.4	-6.56	-0.3	1.6e-10	Height;
LUAD	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg27284194	chr4:1044797	NA	0.7	10.14	0.44	9.22e-22	Recombination rate (females);
LUAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg03188948	chr7:1209495	NA	0.79	9.75	0.43	2.14e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs747782	0.582	rs11039571	chr11:48207259	G/A	cg03929089	chr4:120376271	NA	0.59	6.69	0.31	7.31e-11	Intraocular pressure;
LUAD	cis	rs438465	1.000	rs454974	chr6:169812358	C/T	cg11181693	chr6:169825345	NA	-0.64	-8.13	-0.37	4.95e-15	Corneal astigmatism;
LUAD	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg17264618	chr3:40429014	ENTPD3	0.39	8.84	0.39	2.57e-17	Renal cell carcinoma;
LUAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg07677032	chr17:61819896	STRADA	0.57	10.47	0.45	5.92e-23	Prudent dietary pattern;
LUAD	trans	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg25894440	chr7:65020034	NA	-0.63	-6.67	-0.31	8.15e-11	Diabetic kidney disease;
LUAD	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg15485101	chr11:133734466	NA	0.37	7.94	0.36	1.86e-14	Childhood ear infection;
LUAD	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg24069376	chr3:38537580	EXOG	0.32	7.38	0.34	8.49e-13	Electrocardiographic conduction measures;
LUAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg04025307	chr7:1156635	C7orf50	0.66	7.5	0.34	3.81e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7020830	0.825	rs66684257	chr9:37199087	G/T	cg14294708	chr9:37120828	ZCCHC7	0.81	15.99	0.61	2.38e-45	Schizophrenia;
LUAD	cis	rs1965732	0.563	rs13390724	chr2:3721632	G/A	cg25251562	chr2:3704773	ALLC	-0.37	-6.85	-0.32	2.66e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs4409675	0.912	rs11247730	chr1:28270737	A/G	cg23691781	chr1:28212827	C1orf38	-0.25	-6.48	-0.3	2.59e-10	Corneal astigmatism;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg09372755	chr1:43919584	HYI	0.43	6.89	0.32	2.01e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg21724239	chr8:58056113	NA	0.82	9.91	0.43	5.79e-21	Developmental language disorder (linguistic errors);
LUAD	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.07	-0.37	7.46e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs736408	1.000	rs4687552	chr3:52838402	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.16	0.33	3.5e-12	Bipolar disorder;
LUAD	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21582582	chr3:182698605	DCUN1D1	0.6	10.38	0.45	1.19e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg26587870	chr6:27730563	NA	-0.68	-7.22	-0.33	2.36e-12	Depression;
LUAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00166722	chr3:10149974	C3orf24	0.74	12.64	0.52	2.73e-31	Alzheimer's disease;
LUAD	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg00852783	chr1:26633632	UBXN11	0.4	6.97	0.32	1.22e-11	Obesity-related traits;
LUAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg24846343	chr22:24311635	DDTL	0.8	17.91	0.66	8.76e-54	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg15448220	chr1:150897856	SETDB1	0.57	9.84	0.43	1e-20	Melanoma;
LUAD	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.81	-0.31	3.45e-11	Diabetic kidney disease;
LUAD	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.35	-0.38	1.01e-15	Breast cancer;
LUAD	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg19875535	chr5:140030758	IK	0.47	7.71	0.35	8.78e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7095607	0.842	rs2130097	chr10:69919422	A/T	cg18986048	chr10:69913749	MYPN	0.38	6.41	0.3	3.93e-10	Lung function (FVC);
LUAD	cis	rs7432375	0.610	rs7621932	chr3:136517016	C/T	cg15507776	chr3:136538369	TMEM22	0.39	7.01	0.32	9.24e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1403694	0.734	rs266723	chr3:186447047	A/C	cg12454167	chr3:186435060	KNG1	0.35	7.29	0.33	1.58e-12	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg22823121	chr1:150693482	HORMAD1	0.44	8.9	0.4	1.69e-17	Melanoma;
LUAD	cis	rs225245	0.817	rs12150359	chr17:34024584	C/T	cg05299278	chr17:33885742	SLFN14	0.49	11.38	0.48	2.3e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs4891159	1.000	rs4891159	chr18:74101941	A/G	cg24786174	chr18:74118243	ZNF516	0.63	12.23	0.51	1.13e-29	Longevity;
LUAD	cis	rs9323205	0.773	rs11625621	chr14:51713659	G/C	cg23942311	chr14:51606299	NA	-0.6	-8.71	-0.39	6.75e-17	Cancer;
LUAD	cis	rs8027181	0.839	rs10459647	chr15:73035241	T/C	cg25632853	chr15:73088954	NA	0.31	6.74	0.31	5.05e-11	Triglyceride levels;
LUAD	cis	rs12545109	0.613	rs4541914	chr8:57254555	T/G	cg21220214	chr8:57350948	NA	-0.66	-8.56	-0.38	2.04e-16	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg23281280	chr6:28129359	ZNF389	0.46	6.56	0.3	1.55e-10	Depression;
LUAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.4	0.45	1.04e-22	Prudent dietary pattern;
LUAD	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03934478	chr11:495069	RNH1	-0.67	-7.96	-0.36	1.56e-14	Body mass index;
LUAD	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg05966235	chr16:28915196	ATP2A1	0.46	7.48	0.34	4.21e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs747782	0.640	rs11039603	chr11:48256786	G/A	cg15704280	chr7:45808275	SEPT13	0.75	7.76	0.35	6.65e-14	Intraocular pressure;
LUAD	trans	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg03886242	chr7:26192032	NFE2L3	0.45	7.81	0.36	4.63e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	11.1	0.47	2.67e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1268789	0.571	rs949507	chr4:79394086	C/T	cg16854524	chr4:83931902	LIN54	-0.39	-6.42	-0.3	3.67e-10	Hair shape;Hair morphology;
LUAD	cis	rs757110	0.690	rs35271178	chr11:17411020	C/T	cg15432903	chr11:17409602	KCNJ11	0.52	10.1	0.44	1.2e-21	Type 2 diabetes;
LUAD	cis	rs7737355	0.812	rs6891387	chr5:130765917	G/C	cg06307176	chr5:131281290	NA	-0.42	-7.06	-0.32	6.99e-12	Life satisfaction;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg13214185	chr14:107219616	NA	0.42	7.38	0.34	8.24e-13	Menopause (age at onset);
LUAD	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.78	11.56	0.49	4.66e-27	Smoking behavior;
LUAD	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg07917127	chr4:99064746	C4orf37	0.42	7.02	0.32	9.15e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6542838	0.583	rs7565819	chr2:99519265	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.36	-0.34	9.94e-13	Fear of minor pain;
LUAD	cis	rs7172809	0.573	rs74025074	chr15:77439363	T/C	cg11865553	chr15:77376250	NA	-0.39	-6.37	-0.3	4.92e-10	Glucose homeostasis traits;
LUAD	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg04731861	chr2:219085781	ARPC2	0.27	8.38	0.38	7.82e-16	Colorectal cancer;
LUAD	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg14345882	chr6:26364793	BTN3A2	0.7	7.14	0.33	4.13e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg18446336	chr7:2847575	GNA12	-0.38	-7.0	-0.32	9.86e-12	Height;
LUAD	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg08085267	chr17:45401833	C17orf57	0.58	10.61	0.46	1.74e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.57	-0.46	2.43e-23	Schizophrenia;
LUAD	cis	rs250677	0.522	rs919730	chr5:148352401	T/C	cg18129178	chr5:148520854	ABLIM3	0.47	6.79	0.31	3.81e-11	Breast cancer;
LUAD	cis	rs12976411	0.867	rs35113780	chr19:32836430	G/A	cg18253629	chr19:32836317	ZNF507	0.67	6.67	0.31	8.07e-11	Coronary artery disease;
LUAD	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg17420585	chr12:42539391	GXYLT1	-0.37	-6.63	-0.31	1.03e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg15110403	chr19:17392923	ANKLE1	-0.46	-7.39	-0.34	7.91e-13	Systemic lupus erythematosus;
LUAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg10295955	chr4:187884368	NA	-1.1	-25.99	-0.78	1.06e-89	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg04025307	chr7:1156635	C7orf50	0.49	6.44	0.3	3.26e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs80319144	0.521	rs1116969	chr2:159312164	G/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.41	8.0	0.36	1.17e-14	Restless legs syndrome;
LUAD	trans	rs1493916	0.837	rs4992177	chr18:31407020	C/T	cg27147174	chr7:100797783	AP1S1	-0.62	-10.88	-0.47	1.73e-24	Life satisfaction;
LUAD	cis	rs877282	0.853	rs7083589	chr10:754494	G/A	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg14019695	chr9:139328340	INPP5E	0.41	6.65	0.31	9.3e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.71e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2652834	1.000	rs2652832	chr15:63396928	T/C	cg25406657	chr15:63342033	TPM1	-0.43	-6.91	-0.32	1.84e-11	HDL cholesterol;
LUAD	cis	rs863345	0.604	rs10908670	chr1:158502113	T/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg07967210	chr17:47022446	SNF8	0.36	6.54	0.3	1.77e-10	Type 2 diabetes;
LUAD	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.25	6.37	0.3	4.89e-10	Parkinson's disease;
LUAD	cis	rs2386661	0.547	rs11259742	chr10:5647078	C/T	cg17085576	chr10:5658249	NA	-0.4	-6.56	-0.3	1.59e-10	Breast cancer;
LUAD	cis	rs755249	0.508	rs6703800	chr1:39626642	G/A	cg27567593	chr1:39956653	BMP8A	0.35	7.03	0.32	8.14e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7712401	0.601	rs154500	chr5:122211991	T/G	cg19077854	chr5:122220652	SNX24	0.34	6.38	0.3	4.54e-10	Mean platelet volume;
LUAD	cis	rs17683430	0.614	rs2006253	chr22:32530256	A/C	cg00543991	chr22:32367038	NA	0.54	6.46	0.3	2.94e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
LUAD	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg26384229	chr12:38710491	ALG10B	0.49	8.03	0.36	9.43e-15	Heart rate;
LUAD	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg12884169	chr21:40033163	ERG	0.49	10.68	0.46	9.93e-24	Coronary artery disease;
LUAD	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg05665937	chr4:1216051	CTBP1	0.42	7.04	0.32	7.61e-12	Obesity-related traits;
LUAD	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-7.22	-0.33	2.46e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg26043149	chr18:55253948	FECH	-0.48	-7.78	-0.35	5.79e-14	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3739034	0.639	rs17698151	chr2:135543367	T/C	cg12500956	chr2:135428796	TMEM163	0.37	6.63	0.31	1.05e-10	Gut microbiome composition (winter);
LUAD	cis	rs2357013	0.725	rs1858211	chr2:53165520	G/C	cg07782112	chr2:53107842	NA	-0.35	-7.03	-0.32	8.38e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg19077165	chr18:44547161	KATNAL2	-0.41	-7.3	-0.33	1.44e-12	Personality dimensions;
LUAD	trans	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.94	0.44	4.58e-21	Ulcerative colitis;
LUAD	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.61	0.39	1.5e-16	Menarche (age at onset);
LUAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg12016809	chr21:47604291	C21orf56	0.58	10.31	0.45	2.23e-22	Testicular germ cell tumor;
LUAD	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg02158880	chr13:53174818	NA	0.61	10.75	0.46	5.57e-24	Lewy body disease;
LUAD	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg05665937	chr4:1216051	CTBP1	0.44	7.44	0.34	5.59e-13	Obesity-related traits;
LUAD	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg12292205	chr6:26970375	C6orf41	-0.5	-6.9	-0.32	1.9e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg02782426	chr3:40428986	ENTPD3	0.42	9.46	0.42	2.17e-19	Renal cell carcinoma;
LUAD	cis	rs1403694	0.695	rs1851665	chr3:186436398	A/G	cg12454167	chr3:186435060	KNG1	0.51	10.75	0.46	5.56e-24	Blood protein levels;
LUAD	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg16205897	chr5:131564050	P4HA2	0.29	6.4	0.3	4.09e-10	Blood metabolite levels;
LUAD	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	8.75e-12	Aortic root size;
LUAD	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg14092988	chr3:52407081	DNAH1	0.45	8.98	0.4	9.3e-18	Bipolar disorder;
LUAD	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg01324343	chr3:183735012	ABCC5	0.95	25.48	0.78	1.91e-87	Anterior chamber depth;
LUAD	cis	rs7705042	0.828	rs181826	chr5:141526057	C/A	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.69	-0.31	7.2e-11	Asthma;
LUAD	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg05616858	chr17:37843591	ERBB2;PGAP3	0.32	6.67	0.31	7.86e-11	Asthma;
LUAD	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg09455208	chr3:40491958	NA	0.58	12.72	0.53	1.31e-31	Renal cell carcinoma;
LUAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg08132940	chr7:1081526	C7orf50	-0.78	-10.56	-0.46	2.64e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2905347	0.656	rs2051723	chr7:22665843	C/G	cg23521230	chr7:22704884	NA	0.45	6.81	0.31	3.45e-11	Major depression and alcohol dependence;
LUAD	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg16325326	chr1:53192061	ZYG11B	-0.74	-14.45	-0.57	9.57e-39	Monocyte count;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg20488757	chr11:16760048	C11orf58	0.43	6.73	0.31	5.42e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg00277334	chr10:82204260	NA	-0.67	-12.15	-0.51	2.34e-29	Post bronchodilator FEV1;
LUAD	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg16205897	chr5:131564050	P4HA2	-0.42	-9.45	-0.42	2.35e-19	Blood metabolite levels;
LUAD	trans	rs7671266	0.518	rs16895984	chr4:10284727	C/T	cg26043149	chr18:55253948	FECH	0.45	6.9	0.32	1.87e-11	Cardiovascular disease risk factors;
LUAD	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg07195577	chr17:27052828	TLCD1	0.46	6.49	0.3	2.44e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9522267	0.535	rs11069898	chr13:112231512	C/T	cg10483660	chr13:112241077	NA	-0.31	-6.65	-0.31	8.81e-11	Hepatitis;
LUAD	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg22508957	chr16:3507546	NAT15	-0.39	-6.69	-0.31	6.9e-11	Body mass index (adult);
LUAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.75	-9.01	-0.4	7.07e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7107174	0.892	rs11237450	chr11:78023356	C/A	cg02023728	chr11:77925099	USP35	0.52	7.69	0.35	1.04e-13	Testicular germ cell tumor;
LUAD	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg16535667	chr11:65410126	SIPA1	-0.47	-7.5	-0.34	3.74e-13	Blood pressure (age interaction);
LUAD	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg08280861	chr8:58055591	NA	0.74	8.9	0.4	1.69e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4285028	0.747	rs58367397	chr3:121451700	A/G	cg11130432	chr3:121712080	ILDR1	-0.47	-6.76	-0.31	4.71e-11	Multiple sclerosis;
LUAD	cis	rs4889911	0.544	rs2587498	chr17:77830737	G/A	cg00646381	chr17:77835854	NA	0.52	9.05	0.4	5.15e-18	Electroencephalogram traits;
LUAD	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10927875	0.550	rs12121918	chr1:16183556	C/A	cg21385522	chr1:16154831	NA	-0.95	-13.82	-0.56	4.2e-36	Dilated cardiomyopathy;
LUAD	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23158103	chr7:148848205	ZNF398	-0.66	-12.47	-0.52	1.28e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg23260525	chr10:116636907	FAM160B1	0.47	10.7	0.46	8.4e-24	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg20701182	chr2:24300061	SF3B14	0.57	6.89	0.32	2.04e-11	Lymphocyte counts;
LUAD	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11890956	chr21:40555474	PSMG1	-0.55	-9.44	-0.42	2.46e-19	Menarche (age at onset);
LUAD	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.53	-9.42	-0.42	2.98e-19	Prudent dietary pattern;
LUAD	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg06873352	chr17:61820015	STRADA	0.41	6.94	0.32	1.46e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg09399716	chr2:46890238	NA	-0.36	-6.5	-0.3	2.3e-10	Height;
LUAD	trans	rs11671005	0.504	rs3794963	chr19:59071051	C/G	cg22037779	chr5:139682734	PFDN1	0.65	10.34	0.45	1.77e-22	Mean platelet volume;
LUAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg26818010	chr10:134567672	INPP5A	-0.92	-15.29	-0.6	2.49e-42	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2282300	0.702	rs4379811	chr11:30294760	C/T	cg06241208	chr11:30344200	C11orf46	0.57	7.64	0.35	1.43e-13	Morning vs. evening chronotype;
LUAD	trans	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg21582582	chr3:182698605	DCUN1D1	0.61	9.24	0.41	1.21e-18	Resting heart rate;
LUAD	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg11822812	chr5:140052017	DND1	0.38	6.73	0.31	5.42e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7937890	0.559	rs2575837	chr11:14498001	A/G	cg23387056	chr11:14280742	SPON1	-0.34	-6.67	-0.31	8.19e-11	Mitochondrial DNA levels;
LUAD	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg24818145	chr4:99064322	C4orf37	0.45	6.99	0.32	1.09e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg26818010	chr10:134567672	INPP5A	-0.98	-16.21	-0.62	2.5e-46	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg27279351	chr12:120934652	DYNLL1	0.45	6.73	0.31	5.65e-11	High light scatter reticulocyte count;
LUAD	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-9.89	-0.43	6.72e-21	Life satisfaction;
LUAD	cis	rs375066	0.967	rs8104290	chr19:44367338	A/G	cg12072164	chr19:44306565	LYPD5	0.32	6.54	0.3	1.78e-10	Breast cancer;
LUAD	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg20556744	chr2:9614537	IAH1	0.66	6.56	0.3	1.55e-10	Opioid sensitivity;
LUAD	cis	rs4356932	1.000	rs4616778	chr4:76981206	C/T	cg24176760	chr4:76958061	ART3;CXCL11	0.36	6.46	0.3	2.93e-10	Blood protein levels;
LUAD	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg08601574	chr20:25228251	PYGB	-0.47	-8.92	-0.4	1.46e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2251260	0.685	rs1088673	chr14:62005648	A/G	cg13564459	chr14:62004353	PRKCH	-0.44	-6.93	-0.32	1.56e-11	Yeast infection;
LUAD	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	11.51	0.49	7.18e-27	Resting heart rate;
LUAD	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg05665937	chr4:1216051	CTBP1	0.41	6.95	0.32	1.35e-11	Obesity-related traits;
LUAD	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.54	-7.42	-0.34	6.51e-13	Gut microbiome composition (summer);
LUAD	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg02734326	chr4:10020555	SLC2A9	0.63	11.28	0.48	5.67e-26	Bone mineral density;
LUAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg11050988	chr7:1952600	MAD1L1	-0.34	-6.98	-0.32	1.17e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6460942	0.915	rs62448619	chr7:12457743	C/T	cg20607287	chr7:12443886	VWDE	-0.54	-6.78	-0.31	3.96e-11	Coronary artery disease;
LUAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg02869364	chr7:1081709	C7orf50	-0.51	-6.58	-0.3	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.39	6.52	0.3	2.05e-10	Type 2 diabetes;
LUAD	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg00383909	chr3:49044727	WDR6	0.83	9.07	0.4	4.68e-18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg26597838	chr10:835615	NA	-0.52	-8.16	-0.37	3.81e-15	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs11585357	0.895	rs34324150	chr1:17632464	C/G	cg08277548	chr1:17600880	PADI3	-0.97	-14.21	-0.57	9.94e-38	Hair shape;
LUAD	cis	rs28595532	0.702	rs116320061	chr4:119384600	C/T	cg21605333	chr4:119757512	SEC24D	0.67	6.63	0.31	1.06e-10	Cannabis dependence symptom count;
LUAD	cis	rs6545883	0.929	rs2252662	chr2:61670731	T/C	cg15711740	chr2:61764176	XPO1	-0.4	-6.45	-0.3	2.99e-10	Tuberculosis;
LUAD	cis	rs17818399	0.781	rs6746598	chr2:46865773	C/T	cg09399716	chr2:46890238	NA	-0.43	-8.08	-0.37	7.04e-15	Height;
LUAD	trans	rs1493916	0.721	rs4799723	chr18:31367050	T/G	cg27147174	chr7:100797783	AP1S1	-0.71	-12.78	-0.53	7.46e-32	Life satisfaction;
LUAD	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg02493740	chr2:85810744	VAMP5	-0.63	-11.44	-0.49	1.4e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg12437481	chr16:420112	MRPL28	0.39	6.74	0.31	5.05e-11	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg07636037	chr3:49044803	WDR6	0.61	12.0	0.5	9.44e-29	Parkinson's disease;
LUAD	cis	rs11971779	0.590	rs4732374	chr7:139091453	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.57	8.24	0.37	2.19e-15	Gut microbiome composition (summer);
LUAD	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg22875332	chr1:76189707	ACADM	-0.44	-6.46	-0.3	2.94e-10	Daytime sleep phenotypes;
LUAD	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg19825600	chr2:3704501	ALLC	0.39	7.3	0.33	1.48e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs758324	0.617	rs12719447	chr5:131118100	C/A	cg25547332	chr5:131281432	NA	0.45	6.89	0.32	2.06e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg04703951	chr17:43578652	NA	-0.44	-7.15	-0.33	3.83e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs853679	0.607	rs72846780	chr6:28119055	T/C	cg06606381	chr12:133084897	FBRSL1	-1.22	-10.86	-0.47	2.15e-24	Depression;
LUAD	cis	rs673604	1.000	rs10908387	chr1:35677039	C/T	cg12633102	chr1:35676489	NA	-0.68	-8.35	-0.38	9.84e-16	Endometrial cancer;
LUAD	cis	rs62400317	0.701	rs12194924	chr6:44961513	T/C	cg18551225	chr6:44695536	NA	-0.59	-8.89	-0.4	1.8e-17	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08677398	chr8:58056175	NA	0.54	6.94	0.32	1.52e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg07606381	chr6:8435919	SLC35B3	0.4	6.65	0.31	9.07e-11	Motion sickness;
LUAD	cis	rs11209185	0.527	rs11209186	chr1:68434340	A/G	cg22082780	chr1:68452167	NA	-0.51	-10.59	-0.46	2.03e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs6758955	1.000	rs6758955	chr2:10480637	G/T	cg15773312	chr2:10472214	HPCAL1	0.42	6.88	0.32	2.22e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs71478720	0.903	rs80011693	chr11:112005483	C/T	cg26534425	chr11:112034925	IL18	0.49	7.27	0.33	1.71e-12	Interleukin-18 levels;
LUAD	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg19774624	chr17:42201019	HDAC5	-0.38	-6.47	-0.3	2.78e-10	Total body bone mineral density;
LUAD	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg21475434	chr5:93447410	FAM172A	0.75	8.29	0.37	1.48e-15	Diabetic retinopathy;
LUAD	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg13736514	chr6:26305472	NA	-0.71	-13.48	-0.55	1.04e-34	Educational attainment;
LUAD	cis	rs10499694	0.967	rs7786398	chr7:50612906	G/A	cg18232548	chr7:50535776	DDC	-0.5	-8.44	-0.38	5.01e-16	Body mass index;
LUAD	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg21922841	chr17:72744131	SLC9A3R1	-0.25	-6.65	-0.31	9.05e-11	Monocyte count;
LUAD	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg23758822	chr17:41437982	NA	1.01	20.57	0.71	1.2e-65	Menopause (age at onset);
LUAD	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg01416388	chr22:39784598	NA	-0.48	-7.53	-0.34	3.13e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg06671706	chr8:8559999	CLDN23	0.61	10.75	0.46	5.59e-24	Obesity-related traits;
LUAD	cis	rs7833986	0.501	rs2667999	chr8:56950474	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	1.01	18.33	0.67	1.11e-55	Height;
LUAD	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg11517269	chr6:28058789	ZSCAN12L1	0.25	6.39	0.3	4.5e-10	Parkinson's disease;
LUAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg20607798	chr8:58055168	NA	-0.7	-9.02	-0.4	6.41e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs34366173	1	rs34366173	chr15:63998914	CTT/C	cg12036633	chr15:63758958	NA	-0.4	-6.67	-0.31	8.12e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs1595825	0.891	rs1968488	chr2:198721827	C/A	cg00982548	chr2:198649783	BOLL	-0.66	-9.38	-0.41	4.07e-19	Ulcerative colitis;
LUAD	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg14092571	chr14:90743983	NA	0.5	8.74	0.39	5.72e-17	Mortality in heart failure;
LUAD	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.31	6.59	0.31	1.33e-10	Cardiac Troponin-T levels;
LUAD	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg06784218	chr1:46089804	CCDC17	0.52	11.39	0.48	2.19e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs75920871	1.000	rs61907591	chr11:116796855	T/A	cg04087571	chr11:116723030	SIK3	-0.32	-6.46	-0.3	2.86e-10	Subjective well-being;
LUAD	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.22	-0.37	2.6e-15	Prostate cancer;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg03395511	chr6:291903	DUSP22	-0.76	-12.88	-0.53	3.05e-32	Menopause (age at onset);
LUAD	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg18944383	chr4:111397179	ENPEP	0.39	7.81	0.36	4.43e-14	Height;
LUAD	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg03806693	chr22:41940476	POLR3H	-0.63	-8.79	-0.39	3.72e-17	Vitiligo;
LUAD	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg06873352	chr17:61820015	STRADA	0.4	6.7	0.31	6.64e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg09222892	chr1:25734099	RHCE	-0.47	-8.68	-0.39	8.44e-17	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg20307385	chr11:47447363	PSMC3	0.53	7.94	0.36	1.89e-14	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs11811982	0.793	rs78816618	chr1:227512424	T/C	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg17173187	chr15:85201210	NMB	0.51	9.08	0.4	4.2e-18	Schizophrenia;
LUAD	cis	rs6691722	0.503	rs3765431	chr1:24706410	T/C	cg02336364	chr1:24764700	NIPAL3	0.3	6.36	0.3	5.23e-10	Response to interferon beta in multiple sclerosis;
LUAD	cis	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-7.41	-0.34	6.78e-13	Retinal vascular caliber;
LUAD	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg02423579	chr7:2872169	GNA12	-0.56	-9.52	-0.42	1.4e-19	Height;
LUAD	trans	rs7200543	0.961	rs1741	chr16:15130351	G/C	cg24683922	chr1:11983373	KIAA2013	-0.48	-8.04	-0.36	8.91e-15	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg06608945	chr2:219082296	ARPC2	0.46	7.81	0.35	4.64e-14	Colorectal cancer;
LUAD	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg02782426	chr3:40428986	ENTPD3	0.36	7.96	0.36	1.62e-14	Renal cell carcinoma;
LUAD	cis	rs17155006	0.612	rs401145	chr7:107737278	T/C	cg05962710	chr7:107745446	LAMB4	-0.33	-6.6	-0.31	1.2e-10	Pneumococcal bacteremia;
LUAD	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.73	0.31	5.55e-11	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg03467027	chr4:99064603	C4orf37	0.46	7.2	0.33	2.81e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg26354017	chr1:205819088	PM20D1	0.79	16.24	0.62	1.97e-46	Menarche (age at onset);
LUAD	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg01802117	chr1:53393560	SCP2	0.37	7.2	0.33	2.8e-12	Monocyte count;
LUAD	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg06623918	chr6:96969491	KIAA0776	-0.89	-17.65	-0.65	1.21e-52	Headache;
LUAD	cis	rs10465746	0.935	rs11163878	chr1:84442654	G/A	cg10977910	chr1:84465055	TTLL7	0.51	8.35	0.38	9.56e-16	Obesity-related traits;
LUAD	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg12311346	chr5:56204834	C5orf35	0.48	7.65	0.35	1.38e-13	Coronary artery disease;
LUAD	trans	rs2018683	0.834	rs733485	chr7:29026685	C/A	cg19402173	chr7:128379420	CALU	-0.61	-10.39	-0.45	1.15e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg27494647	chr7:150038898	RARRES2	-0.43	-7.15	-0.33	3.86e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg06618935	chr21:46677482	NA	-0.51	-10.32	-0.45	2.03e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1267303	0.682	rs1998545	chr1:46954587	C/T	cg16387850	chr1:46982889	NA	-0.41	-7.42	-0.34	6.49e-13	Monobrow;
LUAD	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg01851573	chr8:8652454	MFHAS1	-0.39	-6.95	-0.32	1.4e-11	Mood instability;
LUAD	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg19622623	chr12:86230825	RASSF9	-0.55	-9.95	-0.44	4.23e-21	Major depressive disorder;
LUAD	cis	rs4700695	0.614	rs152998	chr5:65213066	A/G	cg21114390	chr5:65439923	SFRS12	-0.66	-8.09	-0.37	6.23e-15	Facial morphology (factor 19);
LUAD	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg24920358	chr1:40204285	PPIE	0.7	12.71	0.53	1.45e-31	Blood protein levels;
LUAD	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg26384229	chr12:38710491	ALG10B	-0.4	-6.76	-0.31	4.51e-11	Heart rate;
LUAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg08132940	chr7:1081526	C7orf50	-0.45	-6.9	-0.32	1.92e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg00204512	chr16:28754710	NA	0.31	6.57	0.3	1.52e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs11039798	1.000	rs6485856	chr11:48556298	G/C	cg15704280	chr7:45808275	SEPT13	0.63	7.23	0.33	2.25e-12	Axial length;
LUAD	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.95	0.32	1.39e-11	Mood instability;
LUAD	cis	rs9788721	0.836	rs72738718	chr15:78735438	G/C	cg18825076	chr15:78729989	IREB2	-0.57	-10.01	-0.44	2.55e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.9	0.36	2.43e-14	Breast cancer;
LUAD	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg03579179	chr7:12444095	VWDE	-0.46	-7.23	-0.33	2.34e-12	Coronary artery disease;
LUAD	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25427524	chr10:38739819	LOC399744	-0.74	-13.92	-0.56	1.51e-36	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg21984481	chr17:79567631	NPLOC4	-0.71	-17.14	-0.64	2.2e-50	Eye color traits;
LUAD	trans	rs75804782	0.690	rs56198112	chr2:239348887	A/G	cg01134436	chr17:81009848	B3GNTL1	0.73	8.02	0.36	1.02e-14	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2663905	0.611	rs1509558	chr15:81391244	C/T	cg22872349	chr15:81410745	NA	-0.38	-6.82	-0.31	3.06e-11	QT interval (drug interaction);
LUAD	cis	rs669446	0.561	rs531459	chr1:44090675	T/C	cg12908607	chr1:44402522	ARTN	-0.35	-6.38	-0.3	4.79e-10	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg11494091	chr17:61959527	GH2	0.45	8.46	0.38	4.51e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg00666640	chr1:248458726	OR2T12	0.29	7.04	0.32	7.71e-12	Common traits (Other);
LUAD	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.67	-0.35	1.17e-13	Alzheimer's disease (late onset);
LUAD	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg25358565	chr5:93447407	FAM172A	0.45	6.38	0.3	4.68e-10	Diabetic retinopathy;
LUAD	cis	rs2030114	0.531	rs59891648	chr16:51595251	T/A	cg03758633	chr16:51611768	NA	0.32	6.71	0.31	6.27e-11	Blood pressure measurement (high sodium and potassium intervention);
LUAD	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg08885076	chr2:99613938	TSGA10	0.35	6.47	0.3	2.74e-10	Chronic sinus infection;
LUAD	cis	rs2235649	0.833	rs9939766	chr16:1852808	C/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.41	-6.5	-0.3	2.25e-10	Blood metabolite levels;
LUAD	cis	rs2742234	0.955	rs2435385	chr10:43665750	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.48	-8.49	-0.38	3.63e-16	Hirschsprung disease;
LUAD	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg04546413	chr19:29218101	NA	0.62	8.4	0.38	6.6e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs2708377	0.789	rs3911150	chr12:11202248	A/G	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.68	-7.76	-0.35	6.54e-14	Bitter taste perception;
LUAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06873352	chr17:61820015	STRADA	0.81	18.01	0.66	2.94e-54	Prudent dietary pattern;
LUAD	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg03859395	chr2:55845619	SMEK2	0.73	13.5	0.55	8.96e-35	Metabolic syndrome;
LUAD	trans	rs11039798	0.614	rs8188910	chr11:48825740	C/T	cg03929089	chr4:120376271	NA	0.59	6.8	0.31	3.56e-11	Axial length;
LUAD	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg19761014	chr17:28927070	LRRC37B2	0.86	8.36	0.38	9.21e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.69	0.35	1.05e-13	Breast cancer;
LUAD	cis	rs17095355	0.818	rs56367935	chr10:111783266	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.61	-0.31	1.16e-10	Biliary atresia;
LUAD	cis	rs7524258	0.868	rs4243824	chr1:7289777	G/A	cg07173049	chr1:7289937	CAMTA1	0.56	10.43	0.45	7.77e-23	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	trans	rs10838798	0.504	rs7121133	chr11:48156131	G/A	cg00717180	chr2:96193071	NA	-0.37	-6.75	-0.31	4.76e-11	Height;
LUAD	cis	rs6906287	0.647	rs7772214	chr6:118793703	A/T	cg21191810	chr6:118973309	C6orf204	0.48	9.51	0.42	1.41e-19	Electrocardiographic conduction measures;
LUAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg26554054	chr8:600488	NA	0.8	7.95	0.36	1.67e-14	IgG glycosylation;
LUAD	cis	rs7202877	0.610	rs4536500	chr16:75343197	C/G	cg03315344	chr16:75512273	CHST6	-0.49	-6.96	-0.32	1.33e-11	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg13319975	chr6:146136371	FBXO30	0.59	10.11	0.44	1.11e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg09137382	chr11:130731461	NA	0.39	7.19	0.33	3.02e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2485376	0.967	rs772027	chr10:104074322	T/A	cg20641465	chr10:103991465	PITX3	-0.57	-10.64	-0.46	1.38e-23	QT interval;
LUAD	cis	rs13064411	0.501	rs13092925	chr3:113209375	C/G	cg10517650	chr3:113235015	CCDC52	-0.45	-8.25	-0.37	2.01e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs2797160	1.000	rs1630556	chr6:126013155	A/G	cg05901451	chr6:126070800	HEY2	0.47	7.15	0.33	3.77e-12	Endometrial cancer;
LUAD	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg01528321	chr10:82214614	TSPAN14	0.46	7.29	0.33	1.53e-12	Post bronchodilator FEV1;
LUAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg07157834	chr1:205819609	PM20D1	0.42	6.81	0.31	3.35e-11	Parkinson's disease;
LUAD	cis	rs8060686	0.516	rs8062085	chr16:68289313	C/A	cg05110241	chr16:68378359	PRMT7	-0.58	-7.41	-0.34	6.73e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6752107	0.967	rs12162308	chr2:234172188	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	9.83	0.43	1.14e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.17e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.5	0.45	4.66e-23	Post bronchodilator FEV1;
LUAD	cis	rs4478137	0.931	rs12509756	chr4:164237464	A/T	cg06758707	chr4:164254230	NPY1R	0.48	7.6	0.35	1.92e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg05665937	chr4:1216051	CTBP1	0.41	6.73	0.31	5.61e-11	Obesity-related traits;
LUAD	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg04944784	chr2:26401820	FAM59B	-0.85	-12.91	-0.53	2.21e-32	Gut microbiome composition (summer);
LUAD	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg24818145	chr4:99064322	C4orf37	-0.41	-6.88	-0.32	2.23e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs6499188	0.522	rs8046299	chr16:68672346	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.68	10.51	0.46	3.98e-23	Ulcerative colitis;
LUAD	cis	rs2075165	0.935	rs933489	chr1:156235120	T/C	cg20302342	chr1:156215951	PAQR6	0.38	8.68	0.39	8.38e-17	Tonsillectomy;
LUAD	trans	rs6076960	0.629	rs6054008	chr20:6212370	C/T	cg21095983	chr6:86352623	SYNCRIP	0.46	7.26	0.33	1.84e-12	Smooth-surface caries;
LUAD	cis	rs2797160	1.000	rs2747724	chr6:126004935	G/A	cg05901451	chr6:126070800	HEY2	-0.45	-6.66	-0.31	8.37e-11	Endometrial cancer;
LUAD	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.46	-0.42	2.08e-19	Life satisfaction;
LUAD	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	cis	rs7677751	0.767	rs6554158	chr4:55066077	G/A	cg17187183	chr4:55093834	PDGFRA	0.44	7.21	0.33	2.57e-12	Corneal astigmatism;
LUAD	cis	rs6545883	0.965	rs6718887	chr2:61727215	G/A	cg15711740	chr2:61764176	XPO1	-0.4	-6.42	-0.3	3.61e-10	Tuberculosis;
LUAD	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.67	-0.35	1.23e-13	Personality dimensions;
LUAD	trans	rs9929218	0.954	rs12599393	chr16:68829021	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-12.7	-0.53	1.51e-31	Colorectal cancer;
LUAD	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg00383909	chr3:49044727	WDR6	0.91	10.25	0.45	3.58e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs12893597	0.898	rs12885469	chr14:76809245	C/G	cg20290672	chr14:76816747	NA	-0.41	-6.54	-0.3	1.83e-10	Maximal oxygen uptake response;
LUAD	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.58	-9.88	-0.43	7.54e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs11048434	0.761	rs11494570	chr12:9127147	T/C	cg26114124	chr12:9217669	LOC144571	0.4	7.22	0.33	2.46e-12	Sjögren's syndrome;
LUAD	cis	rs6684514	1.000	rs12117947	chr1:156244058	A/T	cg16558208	chr1:156270281	VHLL	0.53	9.58	0.42	8.12e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	trans	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg01620082	chr3:125678407	NA	-1.03	-10.19	-0.44	5.95e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg11941060	chr3:133502564	NA	-0.42	-6.92	-0.32	1.66e-11	Iron status biomarkers;
LUAD	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg16989719	chr2:238392110	NA	-0.38	-8.11	-0.37	5.66e-15	Prostate cancer;
LUAD	trans	rs9354308	0.868	rs9363465	chr6:66557802	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.38	-0.3	4.52e-10	Metabolite levels;
LUAD	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.66	0.31	8.46e-11	Breast cancer;
LUAD	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08045932	chr20:61659980	NA	0.51	9.67	0.43	4.09e-20	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.59	-9.92	-0.43	5.64e-21	Colorectal cancer;
LUAD	cis	rs35740288	0.770	rs1382534	chr15:86142170	A/T	cg13263323	chr15:86062960	AKAP13	-0.44	-7.1	-0.33	5.46e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg21153622	chr11:89784906	NA	-0.34	-6.79	-0.31	3.75e-11	Height;
LUAD	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg13511324	chr14:104056883	C14orf153	0.27	6.51	0.3	2.15e-10	Reticulocyte count;
LUAD	cis	rs1497828	0.956	rs2815233	chr1:217539236	T/C	cg04411442	chr1:217543379	NA	-0.38	-6.81	-0.31	3.43e-11	Dialysis-related mortality;
LUAD	trans	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg14791747	chr16:20752902	THUMPD1	0.47	6.81	0.31	3.38e-11	Pancreatic cancer;
LUAD	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg04450456	chr4:17643702	FAM184B	0.43	8.54	0.38	2.45e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9888739	0.800	rs11859300	chr16:31355895	G/T	cg15817542	chr16:31343056	ITGAM	-0.45	-7.64	-0.35	1.52e-13	Systemic lupus erythematosus;
LUAD	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg09537434	chr19:41945824	ATP5SL	-0.53	-8.38	-0.38	7.95e-16	Height;
LUAD	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg04154034	chr17:28927549	LRRC37B2	0.55	6.55	0.3	1.7e-10	Body mass index;
LUAD	cis	rs78761021	0.720	rs874307	chr17:9798074	C/G	cg26853458	chr17:9805074	RCVRN	0.4	7.58	0.35	2.21e-13	Type 2 diabetes;
LUAD	cis	rs6672530	0.518	rs1495847	chr1:227734309	G/A	cg12133451	chr1:227746453	NA	0.37	6.68	0.31	7.32e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	7.72	0.35	8.24e-14	Menopause (age at onset);
LUAD	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	24.74	0.77	3.29e-84	Chronic sinus infection;
LUAD	cis	rs13082711	0.516	rs13084067	chr3:27358935	A/T	cg02860705	chr3:27208620	NA	0.64	9.84	0.43	1.06e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs9837602	1.000	rs793496	chr3:99507254	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	7.36	0.34	9.83e-13	Breast cancer;
LUAD	cis	rs7584330	0.504	rs11883500	chr2:238434434	C/T	cg14458575	chr2:238380390	NA	0.59	9.17	0.41	2.03e-18	Prostate cancer;
LUAD	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg08601574	chr20:25228251	PYGB	-0.47	-8.83	-0.39	2.87e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg09359103	chr1:154839909	KCNN3	-0.91	-21.11	-0.72	4.36e-68	Prostate cancer;
LUAD	cis	rs2067615	0.524	rs10778500	chr12:107074410	T/A	cg15890332	chr12:107067104	RFX4	0.42	8.86	0.4	2.18e-17	Heart rate;
LUAD	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg16205897	chr5:131564050	P4HA2	-0.32	-7.38	-0.34	8.55e-13	Blood metabolite levels;
LUAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.27	-0.41	9.64e-19	Alzheimer's disease;
LUAD	cis	rs1595825	0.891	rs75163179	chr2:198895402	G/A	cg00982548	chr2:198649783	BOLL	-0.65	-9.18	-0.41	1.88e-18	Ulcerative colitis;
LUAD	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg02527881	chr3:46936655	PTH1R	-0.46	-8.74	-0.39	5.64e-17	Colorectal cancer;
LUAD	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg05991184	chr2:219186017	PNKD	0.36	6.77	0.31	4.27e-11	Colorectal cancer;
LUAD	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg09222892	chr1:25734099	RHCE	-0.46	-8.54	-0.38	2.5e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg23277830	chr1:3704460	LRRC47	-0.42	-8.49	-0.38	3.6e-16	Red cell distribution width;
LUAD	cis	rs9814567	0.727	rs7430034	chr3:134342127	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.37	-0.52	3.36e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.1	0.37	6.08e-15	Breast cancer;
LUAD	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.84	-0.32	2.86e-11	Heart rate;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11718315	chr15:65579480	PARP16	-0.38	-6.57	-0.3	1.51e-10	Cancer;
LUAD	cis	rs7584330	0.554	rs7571100	chr2:238435305	G/T	cg14458575	chr2:238380390	NA	0.62	9.86	0.43	8.76e-21	Prostate cancer;
LUAD	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg26384229	chr12:38710491	ALG10B	0.42	7.13	0.33	4.28e-12	Heart rate;
LUAD	cis	rs713477	0.967	rs4901568	chr14:55912789	T/A	cg13175173	chr14:55914753	NA	-0.35	-7.24	-0.33	2.07e-12	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg26818010	chr10:134567672	INPP5A	-0.96	-15.85	-0.61	9.8e-45	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs117623576	0.941	rs111379000	chr10:32427247	A/G	cg03047570	chr10:32398778	NA	-0.76	-9.6	-0.42	6.98e-20	Anti-saccade response;
LUAD	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg12179176	chr11:130786555	SNX19	0.54	9.14	0.41	2.68e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6998277	0.830	rs17186961	chr8:103630028	G/A	cg10187029	chr8:103597600	NA	0.8	13.76	0.56	7.44e-36	Migraine;
LUAD	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg21724239	chr8:58056113	NA	0.61	7.87	0.36	2.93e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs78761021	0.867	rs7222481	chr17:9785187	G/C	cg26853458	chr17:9805074	RCVRN	0.37	7.42	0.34	6.6e-13	Type 2 diabetes;
LUAD	trans	rs6678622	0.931	rs4130548	chr1:78463868	C/T	cg20826526	chr3:156266748	SSR3	0.45	6.9	0.32	1.87e-11	Hip circumference;
LUAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg15147215	chr3:52552868	STAB1	-0.49	-9.23	-0.41	1.35e-18	Electroencephalogram traits;
LUAD	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg13012494	chr21:47604986	C21orf56	0.47	7.76	0.35	6.64e-14	Testicular germ cell tumor;
LUAD	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg04398451	chr17:18023971	MYO15A	0.76	13.97	0.56	9.84e-37	Total body bone mineral density;
LUAD	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.67	9.5	0.42	1.5700000000000001e-19	Lymphocyte percentage of white cells;
LUAD	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg27411982	chr8:10470053	RP1L1	-0.36	-6.7	-0.31	6.59e-11	Neuroticism;
LUAD	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-14.88	-0.59	1.43e-40	Headache;
LUAD	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.3	-6.9	-0.32	1.9e-11	Dupuytren's disease;
LUAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg18538332	chr22:24372958	LOC391322	-0.5	-8.32	-0.37	1.26e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg07636037	chr3:49044803	WDR6	0.63	12.12	0.51	3.1e-29	Parkinson's disease;
LUAD	cis	rs67072384	0.818	rs7926287	chr11:72464525	A/G	cg04827223	chr11:72435913	ARAP1	-0.52	-6.5	-0.3	2.3e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg07828340	chr4:882639	GAK	1.08	11.76	0.5	8.2e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs7759001	0.857	rs9468117	chr6:27366862	A/G	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs1595825	0.786	rs77218291	chr2:198565011	A/G	cg11031976	chr2:198649780	BOLL	-0.46	-6.84	-0.32	2.84e-11	Ulcerative colitis;
LUAD	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg06627628	chr2:24431161	ITSN2	-0.65	-10.41	-0.45	9.27e-23	Asthma;
LUAD	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.64	11.93	0.5	1.78e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg06623918	chr6:96969491	KIAA0776	0.87	17.31	0.64	3.8e-51	Headache;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27242549	chr2:113012627	ZC3H8	-0.56	-6.76	-0.31	4.59e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.45	-0.52	1.54e-30	Hip circumference adjusted for BMI;
LUAD	trans	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg14917512	chr19:3094685	GNA11	-0.56	-6.63	-0.31	9.99e-11	Diabetic kidney disease;
LUAD	cis	rs113835537	0.597	rs57288351	chr11:66307489	C/T	cg24851651	chr11:66362959	CCS	0.58	10.13	0.44	9.76e-22	Airway imaging phenotypes;
LUAD	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06544989	chr22:39130855	UNC84B	0.43	8.1	0.37	5.97e-15	Menopause (age at onset);
LUAD	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg01579765	chr21:45077557	HSF2BP	-0.61	-13.75	-0.56	8.21e-36	Mean corpuscular volume;
LUAD	cis	rs4268898	0.965	rs13033241	chr2:24476118	G/C	cg06627628	chr2:24431161	ITSN2	0.44	7.57	0.35	2.3e-13	Asthma;
LUAD	cis	rs12618769	0.601	rs56118505	chr2:99139832	T/G	cg10123293	chr2:99228465	UNC50	0.47	8.15	0.37	4.02e-15	Bipolar disorder;
LUAD	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg06627628	chr2:24431161	ITSN2	-0.56	-9.18	-0.41	1.93e-18	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs6087990	0.769	rs17123658	chr20:31390840	C/A	cg13636640	chr20:31349939	DNMT3B	0.79	13.79	0.56	5.75e-36	Ulcerative colitis;
LUAD	cis	rs9811920	0.603	rs2638948	chr3:99501539	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	6.61	0.31	1.13e-10	Axial length;
LUAD	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg25554036	chr4:6271136	WFS1	0.67	12.99	0.53	1.1e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg10518543	chr12:38710700	ALG10B	-0.43	-7.08	-0.33	5.98e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6684514	1.000	rs67034206	chr1:156270260	C/T	cg16558208	chr1:156270281	VHLL	0.53	9.64	0.42	4.98e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs4481887	0.893	rs7538645	chr1:248478137	C/T	cg00666640	chr1:248458726	OR2T12	0.31	7.6	0.35	1.96e-13	Common traits (Other);
LUAD	cis	rs1032833	0.732	rs3816345	chr2:179974885	A/G	cg23883738	chr2:179974586	SESTD1	0.49	6.42	0.3	3.6e-10	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs11811982	0.793	rs76132272	chr1:227456065	C/T	cg24860534	chr1:227506868	CDC42BPA	0.7	7.34	0.34	1.13e-12	Optic disc area;
LUAD	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg20703242	chr1:230279135	GALNT2	0.68	12.66	0.52	2.36e-31	Coronary artery disease;
LUAD	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg08085267	chr17:45401833	C17orf57	-0.66	-11.94	-0.5	1.54e-28	Glaucoma (primary open-angle);
LUAD	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	trans	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg07817883	chr1:32538562	TMEM39B	1.5	12.56	0.52	5.74e-31	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.54	8.61	0.39	1.48e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs67072384	1.000	rs7125722	chr11:72449716	G/A	cg04827223	chr11:72435913	ARAP1	-0.63	-7.29	-0.33	1.54e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.51	-0.42	1.51e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg24558204	chr6:135376177	HBS1L	-0.41	-6.93	-0.32	1.58e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs6690583	0.524	rs6680422	chr1:85451945	C/T	cg22153463	chr1:85462885	MCOLN2	0.55	6.37	0.3	4.97e-10	Serum sulfate level;
LUAD	cis	rs7814319	0.966	rs2319603	chr8:97270991	G/A	cg20787634	chr8:97240163	UQCRB	-0.39	-7.59	-0.35	2.06e-13	Lung function (FVC);
LUAD	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.38	6.85	0.32	2.62e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4604732	0.631	rs1106721	chr1:247624676	A/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.11	0.33	4.98e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs10465746	0.967	rs12118434	chr1:84328629	C/T	cg10977910	chr1:84465055	TTLL7	0.5	8.22	0.37	2.56e-15	Obesity-related traits;
LUAD	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg09085632	chr11:111637200	PPP2R1B	0.63	9.46	0.42	2.18e-19	Primary sclerosing cholangitis;
LUAD	trans	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	10.13	0.44	9.46e-22	Type 2 diabetes;
LUAD	cis	rs4698790	0.918	rs4629448	chr4:110706247	A/C	cg07850274	chr4:110748770	RRH	-0.39	-6.6	-0.31	1.24e-10	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUAD	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg04414720	chr1:150670196	GOLPH3L	0.67	11.79	0.5	6.3e-28	Melanoma;
LUAD	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg24069376	chr3:38537580	EXOG	0.44	10.66	0.46	1.15e-23	Electrocardiographic conduction measures;
LUAD	cis	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg07460842	chr6:66804631	NA	1.21	30.25	0.83	8.13e-108	Exhaled nitric oxide output;
LUAD	cis	rs2455601	0.786	rs2568068	chr11:8977830	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-6.89	-0.32	1.98e-11	Schizophrenia;
LUAD	cis	rs2932538	1.000	rs2932538	chr1:113216543	A/G	cg22162597	chr1:113214053	CAPZA1	-0.45	-6.8	-0.31	3.6e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.41	-8.13	-0.37	4.66e-15	Glomerular filtration rate;
LUAD	cis	rs9863	0.861	rs3789967	chr12:124447339	T/G	cg17723958	chr12:124429295	CCDC92	-0.39	-6.66	-0.31	8.79e-11	White blood cell count;
LUAD	cis	rs6782228	0.606	rs2001703	chr3:128383097	A/G	cg16766828	chr3:128327626	NA	-0.38	-6.98	-0.32	1.14e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	trans	rs8002861	0.641	rs4942252	chr13:44443039	C/T	cg17145862	chr1:211918768	LPGAT1	0.65	13.15	0.54	2.37e-33	Leprosy;
LUAD	cis	rs7705042	0.865	rs249642	chr5:141524980	G/C	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.93	-0.32	1.57e-11	Asthma;
LUAD	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.56	0.38	2.18e-16	Parkinson's disease;
LUAD	trans	rs564343	0.563	rs570760	chr11:65833631	C/T	cg26701943	chr11:108369231	KDELC2	-0.5	-8.21	-0.37	2.63e-15	Obesity (early onset extreme);
LUAD	cis	rs243505	0.733	rs9987055	chr7:148501758	G/A	cg09806900	chr7:148480153	CUL1	0.43	7.37	0.34	8.8e-13	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg05110241	chr16:68378359	PRMT7	-0.79	-8.58	-0.39	1.76e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2030114	0.531	rs8062350	chr16:51597037	C/T	cg03758633	chr16:51611768	NA	-0.32	-6.64	-0.31	9.64e-11	Blood pressure measurement (high sodium and potassium intervention);
LUAD	cis	rs4378999	0.748	rs4494918	chr3:51683248	C/G	cg12934382	chr3:51741135	GRM2	0.38	6.71	0.31	6.23e-11	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs11676348	0.703	rs6737563	chr2:218945674	T/C	cg06547715	chr2:218990976	CXCR2	0.43	9.99	0.44	3.01e-21	Ulcerative colitis;
LUAD	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.68	0.39	8.43e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7149242	0.849	rs10146962	chr14:101170540	A/G	cg10189261	chr14:101176105	NA	-0.38	-7.2	-0.33	2.7e-12	Platelet count;
LUAD	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg00316803	chr15:76480434	C15orf27	-0.4	-7.53	-0.34	3.13e-13	Blood metabolite levels;
LUAD	cis	rs34734847	0.703	rs7978125	chr12:121167039	A/G	cg13914990	chr12:121174878	ACADS	0.39	7.49	0.34	4.15e-13	Mean corpuscular volume;
LUAD	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg03929089	chr4:120376271	NA	-0.88	-17.04	-0.64	6.24e-50	Height;
LUAD	cis	rs7937890	0.532	rs2256884	chr11:14476402	A/T	cg06199346	chr11:14280333	SPON1	-0.33	-6.6	-0.31	1.25e-10	Mitochondrial DNA levels;
LUAD	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10802521	chr3:52805072	NEK4	-0.61	-11.07	-0.47	3.56e-25	Bipolar disorder;
LUAD	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg21138405	chr5:131827807	IRF1	-0.31	-6.41	-0.3	3.79e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg11301795	chr4:187892539	NA	-0.77	-15.52	-0.6	2.66e-43	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.6	0.52	4.03e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg23985595	chr17:80112537	CCDC57	0.52	9.54	0.42	1.11e-19	Life satisfaction;
LUAD	cis	rs4372836	0.828	rs6728459	chr2:28999336	A/G	cg09522027	chr2:28974177	PPP1CB	-0.55	-8.24	-0.37	2.12e-15	Body mass index;
LUAD	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11890956	chr21:40555474	PSMG1	0.82	14.57	0.58	3.02e-39	Cognitive function;
LUAD	trans	rs4650994	1.000	rs17361251	chr1:178520577	C/A	cg05059571	chr16:84539110	KIAA1609	-0.61	-10.43	-0.45	8.16e-23	HDL cholesterol levels;HDL cholesterol;
LUAD	trans	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg03929089	chr4:120376271	NA	-0.56	-7.3	-0.33	1.46e-12	D-dimer levels;
LUAD	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg20290983	chr6:43655470	MRPS18A	1.08	27.77	0.8	2.21e-97	IgG glycosylation;
LUAD	cis	rs7020830	0.867	rs1339553	chr9:37266123	C/G	cg14294708	chr9:37120828	ZCCHC7	0.88	17.55	0.65	3.31e-52	Schizophrenia;
LUAD	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26314531	chr2:26401878	FAM59B	-0.59	-8.21	-0.37	2.66e-15	Gut microbiome composition (summer);
LUAD	cis	rs2046867	0.818	rs9814945	chr3:72803590	C/T	cg25664220	chr3:72788482	NA	-0.63	-11.27	-0.48	6.28e-26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3760982	0.585	rs8109478	chr19:44298256	C/T	cg12072164	chr19:44306565	LYPD5	0.42	8.57	0.38	1.93e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg22681709	chr2:178499509	PDE11A	-0.45	-7.65	-0.35	1.36e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg24813613	chr7:1882135	MAD1L1	-0.54	-8.9	-0.4	1.67e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg24642844	chr7:1081250	C7orf50	-0.96	-14.27	-0.57	5.21e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg25985355	chr7:65971099	NA	-0.37	-6.86	-0.32	2.47e-11	Aortic root size;
LUAD	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg23625390	chr15:77176239	SCAPER	0.38	6.88	0.32	2.22e-11	Blood metabolite levels;
LUAD	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg16405210	chr4:1374714	KIAA1530	0.48	7.79	0.35	5.09e-14	Obesity-related traits;
LUAD	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg23954153	chr1:44402353	ARTN	-0.36	-6.68	-0.31	7.6e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg06108461	chr20:60628389	TAF4	-0.97	-17.67	-0.65	9.79e-53	Body mass index;
LUAD	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10150615	chr22:24372951	LOC391322	-0.56	-9.25	-0.41	1.08e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg04267008	chr7:1944627	MAD1L1	0.51	7.74	0.35	7.2e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg06713675	chr4:122721982	EXOSC9	0.52	10.05	0.44	1.86e-21	Type 2 diabetes;
LUAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg22907277	chr7:1156413	C7orf50	0.44	7.47	0.34	4.68e-13	Longevity;Endometriosis;
LUAD	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg27284194	chr4:1044797	NA	-0.56	-9.08	-0.4	4.14e-18	Recombination rate (males);
LUAD	cis	rs6906287	0.647	rs11153763	chr6:118938738	G/A	cg05564266	chr6:118973597	C6orf204	0.37	7.69	0.35	1.01e-13	Electrocardiographic conduction measures;
LUAD	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg17366294	chr4:99064904	C4orf37	-0.48	-8.48	-0.38	3.68e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg05044414	chr3:183734942	ABCC5	0.47	9.92	0.43	5.55e-21	Anterior chamber depth;
LUAD	cis	rs11971779	0.680	rs2355783	chr7:139075879	C/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.82	0.31	3.2e-11	Diisocyanate-induced asthma;
LUAD	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg12908607	chr1:44402522	ARTN	-0.51	-9.99	-0.44	3.06e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2281558	0.876	rs6115135	chr20:25279878	C/A	cg08601574	chr20:25228251	PYGB	0.44	6.46	0.3	2.84e-10	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUAD	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg22532475	chr10:104410764	TRIM8	-0.43	-8.05	-0.36	8.35e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs931127	0.719	rs2127507	chr11:65454430	A/G	cg27068330	chr11:65405492	SIPA1	-0.42	-6.83	-0.32	2.89e-11	Systemic lupus erythematosus;
LUAD	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg26384229	chr12:38710491	ALG10B	0.45	7.35	0.34	1.05e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6489882	0.703	rs10774675	chr12:113361237	A/G	cg20102336	chr12:113376681	OAS3	0.56	8.89	0.4	1.73e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg06002616	chr8:101225028	SPAG1	-0.4	-8.09	-0.37	6.58e-15	Atrioventricular conduction;
LUAD	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	10.46	0.45	6.29e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs9341808	0.754	rs3805925	chr6:80883833	T/C	cg08355045	chr6:80787529	NA	0.58	10.45	0.45	7.12e-23	Sitting height ratio;
LUAD	cis	rs2455601	0.574	rs2568094	chr11:8992218	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-8.06	-0.36	7.97e-15	Schizophrenia;
LUAD	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.41	6.38	0.3	4.56e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs931812	0.825	rs34153562	chr8:101893441	T/C	cg20993868	chr7:22813445	NA	0.64	12.54	0.52	6.83e-31	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.77	-0.53	8.13e-32	Dilated cardiomyopathy;
LUAD	cis	rs62400317	0.859	rs6920046	chr6:45159431	A/C	cg20913747	chr6:44695427	NA	-0.43	-6.71	-0.31	6.21e-11	Total body bone mineral density;
LUAD	cis	rs58804349	0.685	rs11239855	chr10:43483879	A/G	cg20628663	chr10:43360327	NA	-0.57	-6.83	-0.32	2.99e-11	Pediatric bone mineral content (radius);
LUAD	cis	rs1524976	1.000	rs62255278	chr3:65475846	A/T	cg16238336	chr3:65465873	MAGI1	-0.66	-7.58	-0.35	2.26e-13	PR interval;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19042540	chr19:17448497	GTPBP3	-0.41	-6.59	-0.31	1.34e-10	Cancer;
LUAD	cis	rs1232027	0.656	rs1650677	chr5:79959253	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.02	-0.32	8.63e-12	Huntington's disease progression;
LUAD	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg23018236	chr17:30244563	NA	-0.69	-8.47	-0.38	3.96e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.74	-13.52	-0.55	7.52e-35	Menarche (age at onset);
LUAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg17724175	chr1:150552817	MCL1	0.37	8.32	0.37	1.26e-15	Melanoma;
LUAD	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.46	7.62	0.35	1.63e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg09359103	chr1:154839909	KCNN3	0.69	14.01	0.56	6.6e-37	Prostate cancer;
LUAD	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg07870213	chr5:140052090	DND1	0.72	11.1	0.47	2.61e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg18225595	chr11:63971243	STIP1	-0.45	-7.67	-0.35	1.19e-13	Platelet count;
LUAD	cis	rs17197710	0.673	rs61896051	chr11:47313569	C/T	cg13308137	chr11:47528955	CUGBP1	0.45	7.14	0.33	3.98e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9462027	0.540	rs2814951	chr6:34695081	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-9.0	-0.4	7.61e-18	Systemic lupus erythematosus;
LUAD	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg04944784	chr2:26401820	FAM59B	-0.71	-9.96	-0.44	3.85e-21	Gut microbiome composition (summer);
LUAD	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg21475434	chr5:93447410	FAM172A	0.75	8.39	0.38	7.16e-16	Diabetic retinopathy;
LUAD	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg00204512	chr16:28754710	NA	0.32	6.81	0.31	3.46e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg20203395	chr5:56204925	C5orf35	0.61	9.41	0.42	3.11e-19	Initial pursuit acceleration;
LUAD	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg14552801	chr7:65878734	NA	0.37	6.37	0.3	5.05e-10	Aortic root size;
LUAD	cis	rs7680126	0.627	rs9291642	chr4:10007275	C/T	cg11266682	chr4:10021025	SLC2A9	0.55	8.19	0.37	3.17e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg11189052	chr15:85197271	WDR73	0.61	7.55	0.34	2.74e-13	Schizophrenia;
LUAD	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg07460842	chr6:66804631	NA	-1.03	-15.43	-0.6	6.08e-43	Exhaled nitric oxide output;
LUAD	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg05340658	chr4:99064831	C4orf37	0.45	7.47	0.34	4.69e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg25753631	chr6:25732923	NA	-0.45	-7.99	-0.36	1.32e-14	Iron status biomarkers;
LUAD	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg26384229	chr12:38710491	ALG10B	0.48	7.71	0.35	9.24e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs77861329	1.000	rs876782	chr3:52107909	C/T	cg08692210	chr3:52188851	WDR51A	-0.85	-8.34	-0.38	1.07e-15	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs933688	0.532	rs12514092	chr5:90540522	T/G	cg00335715	chr5:90575459	NA	-0.41	-6.65	-0.31	9.33e-11	Smoking behavior;
LUAD	cis	rs72928364	1.000	rs35630894	chr3:100661334	T/C	cg10123952	chr3:100791384	NA	0.65	7.51	0.34	3.55e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg09324608	chr17:30823087	MYO1D	0.46	8.62	0.39	1.36e-16	Schizophrenia;
LUAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg13560548	chr3:10150139	C3orf24	0.44	7.3	0.33	1.47e-12	Alzheimer's disease;
LUAD	cis	rs6906287	0.625	rs11968351	chr6:118901509	G/A	cg05564266	chr6:118973597	C6orf204	0.36	7.55	0.34	2.63e-13	Electrocardiographic conduction measures;
LUAD	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg02527881	chr3:46936655	PTH1R	0.45	8.86	0.4	2.19e-17	Colorectal cancer;
LUAD	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg18721089	chr20:30220636	NA	-0.49	-7.06	-0.32	6.99e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg02371401	chr5:676784	TPPP	-0.48	-7.81	-0.36	4.42e-14	Lung disease severity in cystic fibrosis;
LUAD	trans	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.84	-0.32	2.83e-11	Diabetic kidney disease;
LUAD	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11644478	chr21:40555479	PSMG1	0.7	11.71	0.49	1.28e-27	Cognitive function;
LUAD	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg07570687	chr10:102243282	WNT8B	0.46	7.09	0.33	5.58e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg09137382	chr11:130731461	NA	0.44	8.15	0.37	4.03e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg23625390	chr15:77176239	SCAPER	-0.56	-9.12	-0.41	2.98e-18	Blood metabolite levels;
LUAD	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg14779329	chr11:130786720	SNX19	-0.4	-6.8	-0.31	3.55e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs7395662	0.963	rs4882137	chr11:48615671	A/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.5	-0.3	2.33e-10	HDL cholesterol;
LUAD	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.56	-10.21	-0.44	4.9e-22	Breast cancer;
LUAD	cis	rs500891	0.525	rs1535588	chr6:84051050	A/C	cg08257003	chr6:84140564	ME1	0.34	6.65	0.31	9.02e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs739496	0.947	rs2239195	chr12:111881309	G/T	cg10833066	chr12:111807467	FAM109A	0.41	6.56	0.3	1.57e-10	Platelet count;
LUAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6701037	0.967	rs1057302	chr1:175126423	A/G	cg00321850	chr1:175162397	KIAA0040	-0.5	-10.63	-0.46	1.45e-23	Alcohol dependence;
LUAD	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18876405	chr7:65276391	NA	-0.58	-9.91	-0.43	5.83e-21	Aortic root size;
LUAD	trans	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg01620082	chr3:125678407	NA	-0.54	-7.46	-0.34	5.04e-13	Depression;
LUAD	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg26513180	chr16:89883248	FANCA	0.75	6.76	0.31	4.55e-11	Skin colour saturation;
LUAD	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg18305652	chr10:134549665	INPP5A	0.58	11.93	0.5	1.8e-28	Migraine;
LUAD	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg22508957	chr16:3507546	NAT15	0.45	6.97	0.32	1.24e-11	Body mass index (adult);
LUAD	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg26384229	chr12:38710491	ALG10B	0.46	7.39	0.34	7.68e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.06e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg23803603	chr1:2058230	PRKCZ	-0.39	-6.88	-0.32	2.19e-11	Height;
LUAD	trans	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg04775059	chr7:64541387	NA	-0.54	-6.98	-0.32	1.17e-11	Aortic root size;
LUAD	trans	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg18187862	chr3:45730750	SACM1L	0.53	8.13	0.37	4.66e-15	Primary sclerosing cholangitis;
LUAD	cis	rs2224391	0.534	rs2753229	chr6:5246633	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-8.74	-0.39	5.41e-17	Height;
LUAD	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg15744005	chr10:104629667	AS3MT	-0.44	-7.7	-0.35	9.75e-14	Arsenic metabolism;
LUAD	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg04369109	chr6:150039330	LATS1	-0.42	-6.97	-0.32	1.2e-11	Lung cancer;
LUAD	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg14086364	chr5:150678334	SLC36A3	0.58	12.3	0.51	6.21e-30	Skin aging (microtopography measurement);
LUAD	cis	rs1497828	0.956	rs2492872	chr1:217556242	C/A	cg04411442	chr1:217543379	NA	0.38	6.84	0.32	2.79e-11	Dialysis-related mortality;
LUAD	cis	rs6594713	0.851	rs10038521	chr5:112693668	T/A	cg12552261	chr5:112820674	MCC	0.49	7.87	0.36	2.96e-14	Brain cytoarchitecture;
LUAD	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg21724239	chr8:58056113	NA	0.55	7.31	0.33	1.34e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.93	-0.32	1.62e-11	Neuroticism;
LUAD	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.8	-0.5	5.61e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06022373	chr22:39101656	GTPBP1	-0.39	-6.52	-0.3	1.95e-10	Menopause (age at onset);
LUAD	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg04450456	chr4:17643702	FAM184B	0.37	7.02	0.32	8.75e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12478296	1.000	rs6739247	chr2:243039189	C/A	cg06360820	chr2:242988706	NA	-0.84	-9.51	-0.42	1.49e-19	Obesity-related traits;
LUAD	cis	rs1451375	0.712	rs11974297	chr7:50618260	A/G	cg18232548	chr7:50535776	DDC	0.6	10.5	0.45	4.57e-23	Malaria;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08597319	chr8:103876573	AZIN1	-0.61	-7.3	-0.33	1.4e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg10645314	chr2:3704589	ALLC	0.5	7.32	0.34	1.24e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg26384229	chr12:38710491	ALG10B	0.43	7.18	0.33	3.07e-12	Morning vs. evening chronotype;
LUAD	cis	rs4853036	0.672	rs12988897	chr2:70028976	A/G	cg02498382	chr2:70120550	SNRNP27	-0.47	-6.89	-0.32	2.07e-11	Colorectal or endometrial cancer;
LUAD	cis	rs4006360	0.610	rs4986661	chr17:39250448	C/G	cg16090541	chr17:39240343	KRTAP4-7	-0.36	-6.44	-0.3	3.32e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.38	-6.65	-0.31	9.24e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17401966	0.838	rs12120042	chr1:10345325	A/T	cg15208524	chr1:10270712	KIF1B	0.44	6.9	0.32	1.85e-11	Hepatocellular carcinoma;
LUAD	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg05044414	chr3:183734942	ABCC5	0.47	9.89	0.43	6.97e-21	Anterior chamber depth;
LUAD	cis	rs977987	0.806	rs4888418	chr16:75460306	C/G	cg03315344	chr16:75512273	CHST6	0.64	14.05	0.56	4.7e-37	Dupuytren's disease;
LUAD	cis	rs240764	0.817	rs240110	chr6:101059629	T/C	cg09795085	chr6:101329169	ASCC3	0.43	7.43	0.34	6.18e-13	Neuroticism;
LUAD	cis	rs17095355	0.818	rs10509907	chr10:111781715	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.61	-0.31	1.16e-10	Biliary atresia;
LUAD	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-7.08	-0.33	6.16e-12	Lung cancer;
LUAD	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-7.85	-0.36	3.54e-14	Total cholesterol levels;
LUAD	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg21770322	chr7:97807741	LMTK2	0.35	8.24	0.37	2.14e-15	Breast cancer;
LUAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.58	0.35	2.2e-13	Electroencephalogram traits;
LUAD	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg22442454	chr1:209979470	IRF6	0.6	6.74	0.31	5.2e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg22166914	chr1:53195759	ZYG11B	0.41	6.82	0.31	3.09e-11	Monocyte count;
LUAD	trans	rs7181230	0.885	rs28826672	chr15:40360366	G/T	cg22705835	chr10:65332833	REEP3	-0.38	-6.98	-0.32	1.11e-11	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg11707310	chr1:2537719	MMEL1	0.35	7.62	0.35	1.68e-13	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg15448220	chr1:150897856	SETDB1	0.46	7.98	0.36	1.39e-14	Tonsillectomy;
LUAD	cis	rs7903847	0.642	rs11189180	chr10:99143529	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-7.12	-0.33	4.78e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs8017423	0.647	rs1958346	chr14:90824011	G/T	cg14092571	chr14:90743983	NA	0.39	6.54	0.3	1.81e-10	Mortality in heart failure;
LUAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg18621852	chr3:10150065	C3orf24	0.46	8.29	0.37	1.56e-15	Alzheimer's disease;
LUAD	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-12.64	-0.52	2.81e-31	Mean corpuscular volume;
LUAD	trans	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg11693508	chr17:37793320	STARD3	0.76	10.23	0.45	4.22e-22	Bipolar disorder;
LUAD	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg27129171	chr3:47204927	SETD2	0.41	6.49	0.3	2.4e-10	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.41	0.42	3.23e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg19862616	chr7:65841803	NCRNA00174	1.06	27.22	0.8	5.29e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2408955	0.522	rs6580650	chr12:48418556	G/T	cg04545296	chr12:48745243	ZNF641	-0.32	-7.96	-0.36	1.64e-14	Glycated hemoglobin levels;
LUAD	trans	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.14	-28.81	-0.81	8.39e-102	Colorectal cancer;
LUAD	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.62e-18	Life satisfaction;
LUAD	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg11901034	chr3:128598214	ACAD9	-0.43	-6.5	-0.3	2.24e-10	IgG glycosylation;
LUAD	cis	rs1595825	0.891	rs996427	chr2:198685609	G/A	cg00982548	chr2:198649783	BOLL	-0.64	-9.31	-0.41	7e-19	Ulcerative colitis;
LUAD	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.34	-0.38	1.03e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs7786808	0.579	rs12669482	chr7:158188813	G/A	cg02030672	chr11:45687055	CHST1	0.43	7.75	0.35	7.02e-14	Obesity-related traits;
LUAD	cis	rs11958404	0.932	rs72816583	chr5:157432647	T/C	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg09835421	chr16:68378352	PRMT7	-1.04	-11.53	-0.49	5.99e-27	Magnesium levels;
LUAD	trans	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg14917512	chr19:3094685	GNA11	0.37	6.51	0.3	2.09e-10	Aortic root size;
LUAD	cis	rs11098699	0.784	rs4833271	chr4:124242931	A/T	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	cis	rs9393692	0.620	rs6908402	chr6:26293014	A/T	cg13736514	chr6:26305472	NA	-0.51	-8.63	-0.39	1.23e-16	Educational attainment;
LUAD	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.42	7.2	0.33	2.72e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6496044	0.568	rs2880764	chr15:86056408	A/G	cg13263323	chr15:86062960	AKAP13	-0.55	-10.3	-0.45	2.4e-22	Interstitial lung disease;
LUAD	trans	rs2548003	0.518	rs13157411	chr5:28751609	C/T	cg12623145	chr2:97778927	ANKRD36	-0.46	-6.67	-0.31	7.79e-11	Hip geometry;
LUAD	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg22535103	chr8:58192502	C8orf71	-0.69	-9.83	-0.43	1.15e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs4853525	0.522	rs10490538	chr2:191590066	C/T	cg27211696	chr2:191398769	TMEM194B	0.4	6.75	0.31	4.99e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg23262073	chr20:60523788	NA	-0.47	-7.59	-0.35	2.06e-13	Body mass index;
LUAD	cis	rs9826463	0.527	rs56088529	chr3:142146369	A/G	cg20824294	chr3:142316082	PLS1	0.37	6.58	0.3	1.39e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg25036284	chr2:26402008	FAM59B	-0.63	-8.74	-0.39	5.35e-17	Gut microbiome composition (summer);
LUAD	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg22823121	chr1:150693482	HORMAD1	0.44	8.9	0.4	1.69e-17	Tonsillectomy;
LUAD	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg05044414	chr3:183734942	ABCC5	0.47	9.93	0.43	4.82e-21	Anterior chamber depth;
LUAD	trans	rs61332075	0.500	rs55917008	chr2:239380244	C/A	cg01134436	chr17:81009848	B3GNTL1	0.8	8.77	0.39	4.27e-17	Lung function (FEV1/FVC);
LUAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg17372223	chr3:52568218	NT5DC2	-0.51	-10.03	-0.44	2.23e-21	Electroencephalogram traits;
LUAD	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg12016809	chr21:47604291	C21orf56	0.45	7.37	0.34	8.97e-13	Testicular germ cell tumor;
LUAD	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.05	15.57	0.6	1.58e-43	Schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01524091	chr6:44281032	AARS2	-0.6	-7.26	-0.33	1.85e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.67	0.31	7.83e-11	Parkinson's disease;
LUAD	cis	rs9843304	0.585	rs9847009	chr3:149208167	A/G	cg08667024	chr3:149219783	TM4SF4	0.39	7.38	0.34	8.23e-13	Gallstone disease;
LUAD	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg09455208	chr3:40491958	NA	0.6	12.38	0.52	2.97e-30	Renal cell carcinoma;
LUAD	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg06766960	chr11:133703094	NA	-0.43	-8.31	-0.37	1.36e-15	Childhood ear infection;
LUAD	trans	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.46e-11	Depression;
LUAD	cis	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg23950597	chr19:37808831	NA	-0.64	-7.57	-0.35	2.43e-13	Coronary artery calcification;
LUAD	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg14092988	chr3:52407081	DNAH1	0.37	7.47	0.34	4.74e-13	Bipolar disorder;
LUAD	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg16647868	chr5:131706066	SLC22A5	-0.41	-7.01	-0.32	9.27e-12	Blood metabolite levels;
LUAD	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg05044414	chr3:183734942	ABCC5	0.47	9.92	0.43	5.47e-21	Anterior chamber depth;
LUAD	cis	rs2279817	0.955	rs2270978	chr1:18023365	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.55	9.18	0.41	1.98e-18	Neuroticism;
LUAD	cis	rs7917772	0.565	rs1043450	chr10:104434209	A/G	cg22532475	chr10:104410764	TRIM8	-0.6	-10.97	-0.47	8.12e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12210905	1.000	rs9348756	chr6:27228259	G/A	cg08851530	chr6:28072375	NA	0.76	6.46	0.3	2.85e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs977987	0.843	rs28558946	chr16:75489322	G/T	cg03315344	chr16:75512273	CHST6	0.64	14.02	0.56	5.96e-37	Dupuytren's disease;
LUAD	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg02753203	chr1:228287806	NA	0.58	10.69	0.46	8.74e-24	Diastolic blood pressure;
LUAD	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg20203395	chr5:56204925	C5orf35	-0.83	-11.75	-0.5	8.51e-28	Initial pursuit acceleration;
LUAD	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg23533926	chr12:111358616	MYL2	-0.42	-7.31	-0.33	1.39e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs220324	0.688	rs9979344	chr21:43559926	C/T	cg08841829	chr21:43638893	ABCG1	-0.48	-6.62	-0.31	1.07e-10	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs9512730	0.553	rs9512702	chr13:28033485	A/G	cg04070771	chr13:27998621	GTF3A	0.57	8.41	0.38	6.46e-16	Schizophrenia;
LUAD	cis	rs9807989	0.801	rs7558339	chr2:102970243	T/G	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.05e-10	Asthma;
LUAD	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg27113419	chr16:58533979	NDRG4	-0.74	-6.54	-0.3	1.74e-10	Schizophrenia;
LUAD	cis	rs1044826	0.642	rs9833307	chr3:139181370	G/A	cg00490450	chr3:139108681	COPB2	0.41	6.47	0.3	2.74e-10	Obesity-related traits;
LUAD	cis	rs4074961	0.604	rs4411102	chr1:38063424	C/G	cg12696750	chr1:38022466	DNALI1	0.41	7.01	0.32	9.69e-12	Axial length;
LUAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg21226059	chr5:178986404	RUFY1	-0.78	-13.89	-0.56	2.07e-36	Lung cancer;
LUAD	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg27572855	chr1:25598939	RHD	0.55	12.24	0.51	1.04e-29	Erythrocyte sedimentation rate;
LUAD	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg18252515	chr7:66147081	NA	-0.63	-6.86	-0.32	2.39e-11	Diabetic kidney disease;
LUAD	cis	rs300774	0.925	rs300727	chr2:132469	C/A	cg21211680	chr2:198530	NA	-0.47	-7.38	-0.34	8.37e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg16405210	chr4:1374714	KIAA1530	0.58	8.82	0.39	3e-17	Longevity;
LUAD	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg11189052	chr15:85197271	WDR73	0.62	7.99	0.36	1.33e-14	Schizophrenia;
LUAD	cis	rs829880	0.558	rs249817	chr12:98896910	T/A	cg25150519	chr12:98850993	NA	0.42	6.82	0.31	3.19e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg18351406	chr4:77819688	ANKRD56	0.62	10.01	0.44	2.7e-21	Emphysema distribution in smoking;
LUAD	cis	rs4700695	0.841	rs706679	chr5:65317181	A/G	cg21114390	chr5:65439923	SFRS12	-0.6	-7.45	-0.34	5.43e-13	Facial morphology (factor 19);
LUAD	cis	rs6594713	0.533	rs4705464	chr5:112993214	C/G	cg12552261	chr5:112820674	MCC	-0.54	-7.03	-0.32	8.15e-12	Brain cytoarchitecture;
LUAD	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg15017067	chr4:17643749	FAM184B	0.35	6.98	0.32	1.16e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs889398	0.835	rs62050037	chr16:69784670	T/C	cg00738113	chr16:70207722	CLEC18C	0.34	6.79	0.31	3.89e-11	Body mass index;
LUAD	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-7.74	-0.35	7.2e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs12410462	0.901	rs16847844	chr1:227638110	A/G	cg23173402	chr1:227635558	NA	0.63	7.19	0.33	2.9e-12	Major depressive disorder;
LUAD	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.69	-0.39	8.28e-17	Total body bone mineral density;
LUAD	cis	rs1448094	0.617	rs4842569	chr12:86468609	T/G	cg18827107	chr12:86230957	RASSF9	0.48	8.55	0.38	2.29e-16	Major depressive disorder;
LUAD	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15369054	chr17:80825471	TBCD	0.67	11.31	0.48	4.14e-26	Breast cancer;
LUAD	trans	rs9951602	0.512	rs9952372	chr18:76656295	A/G	cg02800362	chr5:177631904	HNRNPAB	0.91	14.4	0.57	1.57e-38	Obesity-related traits;
LUAD	cis	rs6005807	0.563	rs112609566	chr22:29078698	G/T	cg12565055	chr22:29076175	TTC28	0.75	8.52	0.38	2.76e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg06784218	chr1:46089804	CCDC17	-0.36	-7.95	-0.36	1.68e-14	Red blood cell count;Reticulocyte count;
LUAD	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg07432352	chr17:45403706	C17orf57	0.41	7.76	0.35	6.4e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9341808	0.754	rs6918172	chr6:81019242	A/G	cg08355045	chr6:80787529	NA	0.54	9.49	0.42	1.74e-19	Sitting height ratio;
LUAD	cis	rs26868	0.740	rs26869	chr16:2248786	T/C	cg02248941	chr16:2239361	CASKIN1	0.49	9.38	0.42	3.94e-19	Height;
LUAD	cis	rs41311933	0.610	rs72760263	chr9:123950639	C/T	cg13567360	chr9:123745713	C5	-0.74	-8.1	-0.37	5.87e-15	Coronary artery disease;
LUAD	cis	rs2387326	0.717	rs12266400	chr10:129944536	C/G	cg16087940	chr10:129947807	NA	0.62	8.9	0.4	1.64e-17	Select biomarker traits;
LUAD	cis	rs4150161	0.591	rs1056616	chr16:84211718	C/T	cg10106505	chr16:84220380	TAF1C	-0.62	-6.65	-0.31	9.21e-11	Systolic blood pressure response to hydrochlorothiazide in hypertension;
LUAD	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.8	0.39	3.42e-17	Menopause (age at onset);
LUAD	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.01	-0.36	1.09e-14	Diabetic kidney disease;
LUAD	trans	rs2235573	0.527	rs139887	chr22:38371396	G/C	cg19894588	chr14:64061835	NA	0.52	8.22	0.37	2.55e-15	Glioblastoma;Glioma;
LUAD	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg18811423	chr2:55921094	PNPT1	0.55	9.21	0.41	1.56e-18	Metabolic syndrome;
LUAD	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg10755058	chr3:40428713	ENTPD3	0.45	8.43	0.38	5.64e-16	Renal cell carcinoma;
LUAD	cis	rs782590	0.721	rs782641	chr2:55929294	C/T	cg03859395	chr2:55845619	SMEK2	0.68	11.97	0.5	1.18e-28	Metabolic syndrome;
LUAD	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg21918786	chr6:109611834	NA	0.58	11.01	0.47	5.91e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs1816752	0.905	rs7995492	chr13:25013023	A/T	cg02811702	chr13:24901961	NA	0.41	7.09	0.33	5.69e-12	Obesity-related traits;
LUAD	cis	rs7771547	0.692	rs9366909	chr6:36552869	G/A	cg07856975	chr6:36356162	ETV7	0.45	6.39	0.3	4.41e-10	Platelet distribution width;
LUAD	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg08048268	chr3:133502702	NA	-0.45	-8.47	-0.38	4.14e-16	Iron status biomarkers;
LUAD	cis	rs9362426	0.943	rs242291	chr6:88077083	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-6.41	-0.3	3.88e-10	Depressive episodes in bipolar disorder;
LUAD	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg25985355	chr7:65971099	NA	-0.38	-6.89	-0.32	2.02e-11	Aortic root size;
LUAD	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg05579037	chr7:27184853	NA	0.47	6.78	0.31	3.95e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUAD	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg20891558	chr2:74357851	NA	0.85	15.16	0.59	8.94e-42	Gestational age at birth (maternal effect);
LUAD	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg06766960	chr11:133703094	NA	-0.44	-8.26	-0.37	1.85e-15	Childhood ear infection;
LUAD	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg25767906	chr1:53392781	SCP2	-0.39	-7.07	-0.32	6.55e-12	Monocyte count;
LUAD	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg23954153	chr1:44402353	ARTN	-0.33	-6.62	-0.31	1.08e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg15448220	chr1:150897856	SETDB1	0.57	9.73	0.43	2.54e-20	Melanoma;
LUAD	cis	rs62229266	0.804	rs62230822	chr21:37429945	T/C	cg12218747	chr21:37451666	NA	-0.48	-8.16	-0.37	3.84e-15	Mitral valve prolapse;
LUAD	cis	rs13315871	0.929	rs9857333	chr3:58293551	G/C	cg20936604	chr3:58311152	NA	-0.77	-8.41	-0.38	6.3e-16	Cholesterol, total;
LUAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg11416102	chr8:651193	ERICH1	-0.99	-8.14	-0.37	4.34e-15	IgG glycosylation;
LUAD	cis	rs2425143	1.000	rs56116518	chr20:34286251	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.42	-0.34	6.62e-13	Blood protein levels;
LUAD	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.96	13.53	0.55	6.6e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg23649088	chr2:200775458	C2orf69	0.6	7.94	0.36	1.88e-14	Schizophrenia;
LUAD	cis	rs11048434	0.736	rs11048337	chr12:9121330	C/A	cg23795048	chr12:9217529	LOC144571	0.42	7.85	0.36	3.53e-14	Sjögren's syndrome;
LUAD	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg21204522	chr6:27730016	NA	0.48	6.57	0.3	1.46e-10	Depression;
LUAD	cis	rs7493	0.851	rs11770903	chr7:95026327	A/G	cg07404485	chr7:94953653	PON1	-0.51	-7.69	-0.35	1.06e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg04287289	chr16:89883240	FANCA	-0.49	-7.96	-0.36	1.62e-14	Vitiligo;
LUAD	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg10802521	chr3:52805072	NEK4	-0.47	-7.99	-0.36	1.29e-14	Bipolar disorder;
LUAD	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg06636551	chr8:101224915	SPAG1	-0.35	-6.42	-0.3	3.63e-10	Atrioventricular conduction;
LUAD	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg22442454	chr1:209979470	IRF6	0.58	6.49	0.3	2.45e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs12579753	1.000	rs10862373	chr12:82250657	A/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.54	-0.3	1.78e-10	Resting heart rate;
LUAD	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08704250	chr15:31115839	NA	0.47	8.91	0.4	1.51e-17	Huntington's disease progression;
LUAD	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg11822812	chr5:140052017	DND1	0.39	6.93	0.32	1.56e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg07538946	chr5:131705188	SLC22A5	-0.47	-7.6	-0.35	1.95e-13	Breast cancer;Mosquito bite size;
LUAD	cis	rs7737355	0.812	rs2189645	chr5:130804979	A/G	cg06307176	chr5:131281290	NA	-0.42	-6.96	-0.32	1.31e-11	Life satisfaction;
LUAD	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.46	0.52	1.48e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg25894440	chr7:65020034	NA	0.64	6.95	0.32	1.41e-11	Diabetic kidney disease;
LUAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg00934597	chr7:893267	UNC84A	-0.41	-6.54	-0.3	1.73e-10	Subjective well-being;
LUAD	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg07432352	chr17:45403706	C17orf57	-0.42	-8.12	-0.37	5.09e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg05192639	chr6:26864778	GUSBL1	-0.31	-6.61	-0.31	1.15e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7301826	1.000	rs10848205	chr12:131280714	A/G	cg11011512	chr12:131303247	STX2	0.38	6.41	0.3	3.85e-10	Plasma plasminogen activator levels;
LUAD	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg27284194	chr4:1044797	NA	0.7	10.19	0.44	5.85e-22	Recombination rate (females);
LUAD	cis	rs870825	0.655	rs28451943	chr4:185645572	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs977987	0.800	rs11645329	chr16:75336679	C/G	cg03315344	chr16:75512273	CHST6	0.63	13.84	0.56	3.4e-36	Dupuytren's disease;
LUAD	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg21609526	chr1:3105151	PRDM16	-0.35	-7.16	-0.33	3.51e-12	Migraine;
LUAD	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg23954153	chr1:44402353	ARTN	-0.34	-6.73	-0.31	5.62e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4774899	1.000	rs12914410	chr15:57429837	T/C	cg14026238	chr15:57616123	NA	0.37	6.97	0.32	1.2e-11	Urinary tract infection frequency;
LUAD	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg25554036	chr4:6271136	WFS1	0.73	15.0	0.59	4.18e-41	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg17724175	chr1:150552817	MCL1	-0.28	-6.42	-0.3	3.72e-10	Tonsillectomy;
LUAD	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg14092988	chr3:52407081	DNAH1	0.45	8.98	0.4	8.87e-18	Bipolar disorder;
LUAD	cis	rs8018808	0.967	rs12889722	chr14:77850267	T/C	cg20045696	chr14:77926864	AHSA1	-0.37	-6.69	-0.31	7.02e-11	Myeloid white cell count;
LUAD	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-7.71	-0.35	8.89e-14	Tonsillectomy;
LUAD	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.42	0.34	6.46e-13	Bipolar disorder;
LUAD	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg17644776	chr2:200775616	C2orf69	-0.6	-10.38	-0.45	1.22e-22	Osteoporosis;
LUAD	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg07741184	chr6:167504864	NA	-0.31	-7.43	-0.34	6.01e-13	Crohn's disease;
LUAD	cis	rs3106136	0.934	rs34145031	chr4:95167123	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.47	-0.34	4.78e-13	Capecitabine sensitivity;
LUAD	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.63	-10.58	-0.46	2.33e-23	Glomerular filtration rate;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg20247380	chr19:56652071	ZNF444	-0.43	-7.08	-0.33	6.15e-12	Cancer;
LUAD	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg20587970	chr11:113659929	NA	-1.41	-21.01	-0.71	1.21e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs743757	0.878	rs1467913	chr3:50525017	G/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	7.58	0.35	2.27e-13	Diastolic blood pressure;
LUAD	cis	rs6489882	0.966	rs6489881	chr12:113381217	A/T	cg20102336	chr12:113376681	OAS3	-0.56	-8.59	-0.39	1.64e-16	Chronic lymphocytic leukemia;
LUAD	trans	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-10.29	-0.45	2.6e-22	Obesity-related traits;
LUAD	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg11584989	chr19:19387371	SF4	0.59	9.42	0.42	2.96e-19	Bipolar disorder;
LUAD	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.27	0.33	1.77e-12	Blood metabolite levels;
LUAD	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg26513180	chr16:89883248	FANCA	0.8	7.14	0.33	4.09e-12	Skin colour saturation;
LUAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.92	11.06	0.47	3.91e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.41	0.3	3.89e-10	Cognitive test performance;
LUAD	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg06784218	chr1:46089804	CCDC17	0.55	11.77	0.5	7.42e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg00717180	chr2:96193071	NA	-0.42	-7.75	-0.35	6.73e-14	HDL cholesterol;
LUAD	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg08470875	chr2:26401718	FAM59B	-0.57	-7.83	-0.36	3.88e-14	Gut microbiome composition (summer);
LUAD	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg13606994	chr1:44402422	ARTN	-0.37	-7.5	-0.34	3.82e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg01851573	chr8:8652454	MFHAS1	-0.46	-8.25	-0.37	2.06e-15	Mood instability;
LUAD	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg19767477	chr5:127420684	SLC12A2	-0.44	-6.7	-0.31	6.78e-11	Ileal carcinoids;
LUAD	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.8	-0.5	5.62e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs8002861	0.905	rs12874590	chr13:44433363	C/T	cg12856521	chr11:46389249	DGKZ	-0.37	-6.45	-0.3	2.97e-10	Leprosy;
LUAD	cis	rs977987	0.788	rs7184525	chr16:75437186	A/G	cg03315344	chr16:75512273	CHST6	0.64	14.14	0.57	1.96e-37	Dupuytren's disease;
LUAD	cis	rs8067545	0.750	rs28637614	chr17:19985108	G/T	cg04132472	chr17:19861366	AKAP10	0.28	6.6	0.31	1.21e-10	Schizophrenia;
LUAD	cis	rs1595825	0.838	rs73058878	chr2:198895078	T/G	cg00982548	chr2:198649783	BOLL	-0.65	-9.2	-0.41	1.65e-18	Ulcerative colitis;
LUAD	cis	rs6992820	0.967	rs6996402	chr8:56752230	G/C	cg06880721	chr8:56792545	LYN	-0.45	-7.34	-0.34	1.14e-12	Mean platelet volume;
LUAD	cis	rs2249625	0.874	rs1852704	chr6:72880088	C/T	cg18830697	chr6:72922368	RIMS1	-0.36	-6.79	-0.31	3.88e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg12140854	chr5:148520817	ABLIM3	-0.67	-10.92	-0.47	1.29e-24	Breast cancer;
LUAD	cis	rs35883536	0.588	rs12568329	chr1:101104588	A/G	cg06223162	chr1:101003688	GPR88	-0.38	-7.02	-0.32	9.04e-12	Monocyte count;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06496078	chr12:107350075	C12orf23	-0.46	-7.0	-0.32	1.01e-11	Height;
LUAD	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg17747265	chr1:1875780	NA	-0.76	-18.84	-0.68	6.41e-58	Body mass index;
LUAD	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg07169764	chr2:136633963	MCM6	0.82	9.6	0.42	7.17e-20	Corneal structure;
LUAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-6.64	-0.31	9.38e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs3820068	0.871	rs74539603	chr1:15809601	C/T	cg24675056	chr1:15929824	NA	0.44	6.62	0.31	1.12e-10	Systolic blood pressure;
LUAD	cis	rs4077468	1.000	rs4077468	chr1:205914757	A/G	cg14893161	chr1:205819251	PM20D1	-0.37	-6.56	-0.3	1.53e-10	Cystic fibrosis-related diabetes;
LUAD	trans	rs3857536	0.776	rs9294687	chr6:66942919	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.42	-0.3	3.59e-10	Blood trace element (Cu levels);
LUAD	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg22166914	chr1:53195759	ZYG11B	-0.44	-7.62	-0.35	1.73e-13	Monocyte count;
LUAD	cis	rs77972916	0.536	rs59362315	chr2:43594931	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-7.37	-0.34	8.86e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.66	-0.35	1.27e-13	Electroencephalogram traits;
LUAD	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg01851573	chr8:8652454	MFHAS1	0.44	8.13	0.37	4.74e-15	Mood instability;
LUAD	cis	rs2580764	0.566	rs2968795	chr2:55287989	G/A	cg09592903	chr2:55203963	RTN4	0.42	9.37	0.41	4.35e-19	Mean platelet volume;
LUAD	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg27411982	chr8:10470053	RP1L1	0.43	7.89	0.36	2.54e-14	Retinal vascular caliber;
LUAD	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg15147215	chr3:52552868	STAB1	-0.4	-7.46	-0.34	4.91e-13	Bipolar disorder;
LUAD	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	6.83	0.32	2.92e-11	Cognitive test performance;
LUAD	cis	rs6758955	0.850	rs6755410	chr2:10480083	A/C	cg15773312	chr2:10472214	HPCAL1	-0.47	-6.8	-0.31	3.67e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg04455712	chr21:45112962	RRP1B	0.46	8.84	0.39	2.68e-17	Mean corpuscular volume;
LUAD	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg17757837	chr7:157058334	UBE3C	0.46	8.21	0.37	2.63e-15	Body mass index;
LUAD	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg02880119	chr16:3481970	NA	0.49	6.89	0.32	2e-11	Body mass index (adult);
LUAD	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg19717773	chr7:2847554	GNA12	-0.52	-9.87	-0.43	8.05e-21	Height;
LUAD	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg03806693	chr22:41940476	POLR3H	-0.51	-7.43	-0.34	6.13e-13	Vitiligo;
LUAD	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	11.74	0.5	9.5e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg12011299	chr4:100065546	ADH4	0.66	13.76	0.56	7.42e-36	Alcohol dependence;
LUAD	cis	rs62400317	0.762	rs10948176	chr6:44833913	A/G	cg18551225	chr6:44695536	NA	-0.57	-8.73	-0.39	6.02e-17	Total body bone mineral density;
LUAD	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg26587870	chr6:27730563	NA	-0.49	-8.06	-0.37	7.71e-15	Parkinson's disease;
LUAD	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg09455208	chr3:40491958	NA	0.52	10.97	0.47	8.4e-25	Renal cell carcinoma;
LUAD	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg06484146	chr7:12443880	VWDE	-0.6	-7.71	-0.35	9.27e-14	Coronary artery disease;
LUAD	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg25894440	chr7:65020034	NA	-0.62	-6.63	-0.31	1.05e-10	Diabetic kidney disease;
LUAD	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg08125733	chr17:73851984	WBP2	0.55	8.25	0.37	2.05e-15	Psoriasis;
LUAD	trans	rs264943	0.967	rs10185399	chr2:104214676	A/T	cg06589161	chr5:180618230	NA	-0.38	-6.46	-0.3	2.87e-10	HIV-1 viral setpoint;
LUAD	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg15017067	chr4:17643749	FAM184B	-0.37	-7.15	-0.33	3.72e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.44	-0.34	5.52e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg02775129	chr4:119771670	NA	-0.75	-7.28	-0.33	1.66e-12	Cannabis dependence symptom count;
LUAD	cis	rs12946454	0.621	rs11651809	chr17:43255681	C/G	cg10701640	chr17:43249399	NA	0.57	11.42	0.49	1.6e-26	Systolic blood pressure;
LUAD	trans	rs8073060	0.586	rs7208672	chr17:33989759	G/A	cg19694781	chr19:47549865	TMEM160	-1.23	-19.33	-0.68	4.03e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg10909506	chr17:38081995	ORMDL3	0.41	7.12	0.33	4.8e-12	Self-reported allergy;
LUAD	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg16512390	chr1:228756714	NA	0.65	8.68	0.39	8.8e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg27147174	chr7:100797783	AP1S1	-0.68	-12.26	-0.51	9.19e-30	Life satisfaction;
LUAD	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.84	-0.36	3.71e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg17971929	chr21:40555470	PSMG1	0.54	8.06	0.37	7.69e-15	Cognitive function;
LUAD	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg00495681	chr13:53174319	NA	0.52	9.82	0.43	1.23e-20	Lewy body disease;
LUAD	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg11494091	chr17:61959527	GH2	-0.37	-6.52	-0.3	1.95e-10	Height;
LUAD	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg03605463	chr16:89740564	NA	0.46	7.86	0.36	3.17e-14	Vitiligo;
LUAD	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg00784671	chr22:46762841	CELSR1	-0.61	-7.55	-0.34	2.78e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg00784671	chr22:46762841	CELSR1	-0.43	-6.45	-0.3	3.14e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01570182	chr17:44337453	NA	-0.92	-13.58	-0.55	3.98e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7274811	0.744	rs209677	chr20:32140287	C/T	cg13403462	chr20:32256071	NECAB3;C20orf134	0.48	7.46	0.34	5.11e-13	Height;
LUAD	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	8.75e-12	Aortic root size;
LUAD	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.19	15.58	0.6	1.38e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.84	16.68	0.63	2.36e-48	Birth weight;
LUAD	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg25319279	chr11:5960081	NA	-0.42	-7.42	-0.34	6.52e-13	DNA methylation (variation);
LUAD	cis	rs8177876	0.731	rs74878296	chr16:81105545	C/G	cg08591886	chr16:81111003	C16orf46	-0.83	-6.49	-0.3	2.48e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.45e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs713587	0.646	rs2384061	chr2:25135620	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.14	0.41	2.69e-18	Body mass index in non-asthmatics;
LUAD	cis	rs9393692	0.552	rs806789	chr6:26229161	C/A	cg13736514	chr6:26305472	NA	-0.55	-9.79	-0.43	1.59e-20	Educational attainment;
LUAD	cis	rs9392556	0.829	rs629362	chr6:4121831	A/G	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.36	-6.52	-0.3	1.97e-10	Blood metabolite levels;
LUAD	cis	rs887829	0.694	rs7583278	chr2:234617407	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-10.14	-0.44	9.25e-22	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg26384229	chr12:38710491	ALG10B	0.45	7.21	0.33	2.65e-12	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg26043149	chr18:55253948	FECH	0.44	7.32	0.34	1.26e-12	Bone mineral density;
LUAD	cis	rs13082711	0.871	rs13061912	chr3:27495586	A/G	cg02860705	chr3:27208620	NA	0.57	8.83	0.39	2.84e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs3106136	0.967	rs767657	chr4:95227901	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-7.14	-0.33	4.19e-12	Capecitabine sensitivity;
LUAD	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg13390004	chr1:15929781	NA	0.48	8.5	0.38	3.39e-16	Systolic blood pressure;
LUAD	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-7.06	-0.32	6.99e-12	Morning vs. evening chronotype;
LUAD	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg25753631	chr6:25732923	NA	-0.42	-7.44	-0.34	5.66e-13	Iron status biomarkers;
LUAD	cis	rs17401966	1.000	rs12734551	chr1:10391536	A/C	cg15208524	chr1:10270712	KIF1B	0.54	8.19	0.37	3.23e-15	Hepatocellular carcinoma;
LUAD	cis	rs7617773	0.780	rs11720026	chr3:48377921	T/C	cg11946769	chr3:48343235	NME6	0.46	6.87	0.32	2.31e-11	Coronary artery disease;
LUAD	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg23625390	chr15:77176239	SCAPER	0.38	6.79	0.31	3.88e-11	Blood metabolite levels;
LUAD	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg12193833	chr17:30244370	NA	-0.51	-6.74	-0.31	5.11e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs13082711	0.522	rs480646	chr3:27327143	C/T	cg02860705	chr3:27208620	NA	0.52	8.55	0.38	2.23e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	trans	rs2797160	1.000	rs1418642	chr6:125999768	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.57	-0.38	2.02e-16	Endometrial cancer;
LUAD	cis	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg27411982	chr8:10470053	RP1L1	-0.39	-7.07	-0.33	6.41e-12	Neuroticism;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14022530	chr1:100598534	SASS6;CCDC76	-0.53	-6.44	-0.3	3.31e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9788721	0.836	rs11858836	chr15:78783277	G/A	cg18825076	chr15:78729989	IREB2	-0.61	-10.48	-0.45	5.25e-23	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs2742234	0.955	rs2503865	chr10:43659536	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.45	-8.01	-0.36	1.13e-14	Hirschsprung disease;
LUAD	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg00316803	chr15:76480434	C15orf27	-0.39	-7.34	-0.34	1.12e-12	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg08847533	chr14:75593920	NEK9	0.4	6.83	0.32	2.94e-11	Height;
LUAD	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg04398451	chr17:18023971	MYO15A	0.77	14.08	0.56	3.55e-37	Total body bone mineral density;
LUAD	cis	rs9419702	0.806	rs9419701	chr10:133529977	G/A	cg04492858	chr10:133558786	NA	-0.39	-6.52	-0.3	2.03e-10	Survival in rectal cancer;
LUAD	cis	rs11958404	0.860	rs6868839	chr5:157442196	T/G	cg05962755	chr5:157440814	NA	0.71	9.95	0.44	4.36e-21	IgG glycosylation;
LUAD	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg04450456	chr4:17643702	FAM184B	0.42	8.23	0.37	2.38e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	10.68	0.46	9.65e-24	Lung cancer in ever smokers;
LUAD	cis	rs7072216	0.691	rs3829853	chr10:100171174	A/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.68	-0.39	8.56e-17	Metabolite levels;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg07332563	chr6:291687	DUSP22	-0.68	-11.87	-0.5	3.04e-28	Menopause (age at onset);
LUAD	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg11919837	chr8:57350735	NA	-0.43	-6.52	-0.3	1.99e-10	Obesity-related traits;
LUAD	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg25036284	chr2:26402008	FAM59B	-0.61	-8.43	-0.38	5.33e-16	Gut microbiome composition (summer);
LUAD	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg14458575	chr2:238380390	NA	-0.96	-19.83	-0.69	2.27e-62	Prostate cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg18605858	chr6:41862842	USP49	-0.69	-6.97	-0.32	1.23e-11	Type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg08888203	chr3:10149979	C3orf24	0.73	12.78	0.53	7.21e-32	Alzheimer's disease;
LUAD	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs4638749	0.677	rs2378098	chr2:108849381	T/C	cg25838818	chr2:108905173	SULT1C2	-0.43	-7.53	-0.34	3.08e-13	Blood pressure;
LUAD	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg00750074	chr16:89608354	SPG7	0.58	10.31	0.45	2.22e-22	Multiple myeloma (IgH translocation);
LUAD	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.58	-9.97	-0.44	3.49e-21	Electrocardiographic conduction measures;
LUAD	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg08859206	chr1:53392774	SCP2	-0.64	-11.81	-0.5	5.02e-28	Monocyte count;
LUAD	cis	rs745570	0.833	rs1696757	chr17:77800743	C/T	cg25456068	chr17:77800718	NA	-0.34	-6.38	-0.3	4.55e-10	Breast cancer;
LUAD	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg18209359	chr17:80159595	CCDC57	-0.4	-6.8	-0.31	3.61e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg00898013	chr13:113819073	PROZ	-0.84	-15.04	-0.59	2.87e-41	Platelet distribution width;
LUAD	cis	rs494562	0.892	rs7771860	chr6:86130729	C/T	cg13315970	chr6:86159197	NT5E	0.75	8.6	0.39	1.57e-16	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg25173405	chr17:45401733	C17orf57	-0.46	-7.56	-0.34	2.56e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7147624	0.882	rs1956008	chr14:66085429	G/T	cg03016385	chr14:66212404	NA	-0.6	-6.97	-0.32	1.2e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	trans	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg04565464	chr8:145669602	NFKBIL2	-0.45	-6.59	-0.31	1.32e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-25.09	-0.77	8.9e-86	Height;
LUAD	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3862260	0.967	rs3862261	chr1:120160822	G/A	cg16322792	chr1:120165303	ZNF697	0.61	15.06	0.59	2.54e-41	Systemic lupus erythematosus;
LUAD	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg12179176	chr11:130786555	SNX19	0.46	7.72	0.35	8.57e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4006360	0.545	rs365738	chr17:39279082	C/T	cg20663846	chr17:39254439	KRTAP4-8	0.39	8.62	0.39	1.31e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg24579218	chr15:68104479	NA	-0.61	-9.51	-0.42	1.45e-19	Restless legs syndrome;
LUAD	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	24.46	0.77	5.54e-83	Chronic sinus infection;
LUAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg18402987	chr7:1209562	NA	0.63	9.24	0.41	1.19e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg19635926	chr16:89946313	TCF25	0.74	6.53	0.3	1.91e-10	Skin colour saturation;
LUAD	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg03929089	chr4:120376271	NA	0.6	7.83	0.36	3.95e-14	Axial length;
LUAD	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18876405	chr7:65276391	NA	0.43	6.75	0.31	4.89e-11	Aortic root size;
LUAD	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg06873352	chr17:61820015	STRADA	0.4	6.71	0.31	6.21e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6484504	0.600	rs972714	chr11:31358875	T/G	cg26647111	chr11:31128758	NA	0.45	7.84	0.36	3.6e-14	Red blood cell count;
LUAD	cis	rs7187994	0.848	rs7498187	chr16:84770570	G/A	cg07647771	chr16:84786436	USP10	-0.36	-9.03	-0.4	6.08e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs4356932	1.000	rs6850760	chr4:76951684	A/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.35	-6.42	-0.3	3.71e-10	Blood protein levels;
LUAD	cis	rs7552167	0.789	rs6424162	chr1:24512576	T/C	cg01960748	chr1:24522592	NA	-0.79	-10.45	-0.45	7.08e-23	Psoriasis vulgaris;
LUAD	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg00106254	chr7:1943704	MAD1L1	-0.53	-8.16	-0.37	3.85e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg20132735	chr17:80250935	NA	-0.63	-6.37	-0.3	4.87e-10	Type 2 diabetes;
LUAD	cis	rs1953600	0.668	rs3122586	chr10:81950326	C/T	cg00277334	chr10:82204260	NA	0.41	7.0	0.32	9.96e-12	Sarcoidosis;
LUAD	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.61	10.24	0.45	3.78e-22	Cognitive ability;
LUAD	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg24531977	chr5:56204891	C5orf35	-0.4	-6.53	-0.3	1.94e-10	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs7116495	1.000	rs6592453	chr11:71683231	C/G	cg07596299	chr11:71824057	C11orf51	-0.79	-7.18	-0.33	3.15e-12	Severe influenza A (H1N1) infection;
LUAD	cis	rs11098699	0.635	rs2132078	chr4:124240429	G/A	cg09941581	chr4:124220074	SPATA5	0.42	6.75	0.31	4.78e-11	Mosquito bite size;
LUAD	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg21204522	chr6:27730016	NA	-0.44	-6.89	-0.32	2.01e-11	Parkinson's disease;
LUAD	cis	rs41311933	0.656	rs35948313	chr9:123781329	C/T	cg13567360	chr9:123745713	C5	-0.68	-8.12	-0.37	5.12e-15	Coronary artery disease;
LUAD	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg21100191	chr22:23484243	RTDR1	0.68	11.61	0.49	3.01e-27	Bone mineral density;
LUAD	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg21823605	chr1:152486609	CRCT1	0.28	6.47	0.3	2.78e-10	Hair morphology;
LUAD	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg15017067	chr4:17643749	FAM184B	-0.34	-6.72	-0.31	5.97e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.61	0.31	1.15e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg08999081	chr20:33150536	PIGU	0.61	13.69	0.55	1.37e-35	Glomerular filtration rate (creatinine);
LUAD	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06022373	chr22:39101656	GTPBP1	0.39	6.66	0.31	8.65e-11	Menopause (age at onset);
LUAD	cis	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg07929629	chr2:241523174	NA	0.42	6.78	0.31	4.17e-11	Bipolar disorder;
LUAD	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg21672276	chr3:44754072	ZNF502	0.38	6.6	0.31	1.23e-10	Depressive symptoms;
LUAD	cis	rs240110	0.570	rs966741	chr6:101218375	A/G	cg09795085	chr6:101329169	ASCC3	-0.42	-7.37	-0.34	9.31e-13	Neuroticism;
LUAD	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	7.22	0.33	2.49e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg15123519	chr2:136567270	LCT	0.38	7.0	0.32	9.89e-12	Mosquito bite size;
LUAD	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg16479474	chr6:28041457	NA	0.47	8.23	0.37	2.31e-15	Depression;
LUAD	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03352830	chr11:487213	PTDSS2	-0.82	-11.03	-0.47	4.78e-25	Body mass index;
LUAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg13047869	chr3:10149882	C3orf24	-0.66	-10.06	-0.44	1.74e-21	Alzheimer's disease;
LUAD	cis	rs904251	0.523	rs2797799	chr6:37483620	T/G	cg25019722	chr6:37503610	NA	-0.33	-7.6	-0.35	1.95e-13	Cognitive performance;
LUAD	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg02079420	chr8:82753780	SNX16	0.4	8.02	0.36	1.01e-14	Diastolic blood pressure;
LUAD	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg21153622	chr11:89784906	NA	-0.33	-6.38	-0.3	4.54e-10	Coronary artery disease;
LUAD	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg21823605	chr1:152486609	CRCT1	0.28	6.39	0.3	4.49e-10	Hair morphology;
LUAD	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.8	-0.39	3.43e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1448094	0.802	rs11117146	chr12:86382870	C/T	cg18827107	chr12:86230957	RASSF9	0.46	8.38	0.38	7.75e-16	Major depressive disorder;
LUAD	cis	rs733175	0.904	rs3775944	chr4:10019974	G/T	cg11266682	chr4:10021025	SLC2A9	0.42	6.98	0.32	1.16e-11	Psychosis and Alzheimer's disease;
LUAD	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg09998033	chr7:158218633	PTPRN2	-0.48	-8.59	-0.39	1.65e-16	Obesity-related traits;
LUAD	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg00277334	chr10:82204260	NA	-0.49	-7.94	-0.36	1.86e-14	Post bronchodilator FEV1;
LUAD	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg16325326	chr1:53192061	ZYG11B	-0.74	-14.49	-0.58	6.27e-39	Monocyte count;
LUAD	cis	rs9393692	0.557	rs9379846	chr6:26314238	G/C	cg00631329	chr6:26305371	NA	-0.56	-9.44	-0.42	2.62e-19	Educational attainment;
LUAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg21724239	chr8:58056113	NA	0.66	8.13	0.37	4.93e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg09658497	chr7:2847517	GNA12	-0.45	-7.59	-0.35	2.09e-13	Height;
LUAD	cis	rs6738485	0.531	rs72819612	chr2:106846316	T/C	cg15412446	chr2:106886593	NA	-0.83	-11.9	-0.5	2.32e-28	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs8051149	0.793	rs12448415	chr16:87871096	A/G	cg10099957	chr16:87869757	SLC7A5	0.45	7.34	0.34	1.12e-12	Blood metabolite levels;
LUAD	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-10.11	-0.44	1.11e-21	Platelet count;
LUAD	cis	rs6484504	0.576	rs208083	chr11:31196880	C/T	cg14844989	chr11:31128820	NA	-0.44	-8.07	-0.37	7.46e-15	Red blood cell count;
LUAD	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg27129171	chr3:47204927	SETD2	0.41	6.77	0.31	4.28e-11	Colorectal cancer;
LUAD	cis	rs938554	0.657	rs9994216	chr4:9984541	G/T	cg02734326	chr4:10020555	SLC2A9	0.46	7.23	0.33	2.23e-12	Blood metabolite levels;
LUAD	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg25535316	chr11:579198	PHRF1	-0.38	-6.67	-0.31	7.81e-11	Systemic lupus erythematosus;
LUAD	cis	rs7927771	0.524	rs10838771	chr11:47831332	A/G	cg18512352	chr11:47633146	NA	-0.37	-6.61	-0.31	1.19e-10	Subjective well-being;
LUAD	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg12179176	chr11:130786555	SNX19	0.46	7.61	0.35	1.77e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs72928364	0.860	rs13081830	chr3:100791262	G/A	cg10123952	chr3:100791384	NA	0.74	8.23	0.37	2.35e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12478296	1.000	rs55732177	chr2:243040006	C/T	cg06360820	chr2:242988706	NA	-0.84	-9.69	-0.43	3.39e-20	Obesity-related traits;
LUAD	cis	rs89107	0.967	rs4946333	chr6:118565665	A/G	cg18833306	chr6:118973337	C6orf204	-0.48	-8.79	-0.39	3.69e-17	Cardiac structure and function;
LUAD	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15506890	chr2:3487001	NA	-0.44	-7.44	-0.34	5.76e-13	Neurofibrillary tangles;
LUAD	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg17200465	chr3:40428508	ENTPD3	0.27	6.51	0.3	2.08e-10	Renal cell carcinoma;
LUAD	cis	rs12545109	0.765	rs1960727	chr8:57411368	G/A	cg21220214	chr8:57350948	NA	-0.63	-8.76	-0.39	4.92e-17	Obesity-related traits;
LUAD	cis	rs4642101	0.686	rs9822382	chr3:12828828	T/G	cg24848339	chr3:12840334	CAND2	0.41	8.05	0.36	8.2e-15	QRS complex (12-leadsum);
LUAD	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg18131467	chr2:239335373	ASB1	0.72	12.28	0.51	7.58e-30	Multiple system atrophy;
LUAD	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.61	0.31	1.14e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg21475434	chr5:93447410	FAM172A	0.83	8.95	0.4	1.11e-17	Diabetic retinopathy;
LUAD	cis	rs68170813	0.559	rs3801959	chr7:106955666	A/G	cg02696742	chr7:106810147	HBP1	-0.76	-10.41	-0.45	9.42e-23	Coronary artery disease;
LUAD	cis	rs17641971	0.645	rs10504073	chr8:50024944	C/T	cg00325661	chr8:49890786	NA	0.3	6.8	0.31	3.66e-11	Blood metabolite levels;
LUAD	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.38	8.08	0.37	6.9e-15	Parkinson's disease;
LUAD	cis	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg27411982	chr8:10470053	RP1L1	-0.46	-8.36	-0.38	8.97e-16	Neuroticism;
LUAD	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-10.94	-0.47	1.07e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg00280220	chr17:61926910	NA	0.37	7.25	0.33	2.02e-12	Prudent dietary pattern;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg26770187	chr3:14693171	C3orf19	0.4	6.52	0.3	1.95e-10	Schizophrenia;
LUAD	cis	rs1595825	0.838	rs58576043	chr2:198524149	C/T	cg11031976	chr2:198649780	BOLL	-0.46	-6.84	-0.32	2.82e-11	Ulcerative colitis;
LUAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg11062466	chr8:58055876	NA	0.81	9.84	0.43	1.05e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs73198271	0.960	rs73198288	chr8:8613940	G/A	cg01851573	chr8:8652454	MFHAS1	0.51	8.09	0.37	6.18e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg02176678	chr2:219576539	TTLL4	0.74	14.85	0.59	1.91e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg02049041	chr17:27085579	C17orf63	0.66	8.68	0.39	8.92e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs11771526	0.792	rs11770580	chr7:32305009	T/C	cg27532318	chr7:32358331	NA	0.59	7.51	0.34	3.57e-13	Body mass index;
LUAD	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg05304507	chr6:116381966	FRK	0.2	6.81	0.31	3.37e-11	Cholesterol, total;LDL cholesterol;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14242460	chr6:5261506	LYRM4;FARS2	-0.54	-6.55	-0.3	1.64e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg01200585	chr1:228362443	C1orf69	-0.4	-7.23	-0.33	2.35e-12	Diastolic blood pressure;
LUAD	cis	rs1395	0.925	rs2580754	chr2:27398196	A/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.41	7.62	0.35	1.65e-13	Blood metabolite levels;
LUAD	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg04414720	chr1:150670196	GOLPH3L	-0.69	-13.3	-0.54	5.82e-34	Tonsillectomy;
LUAD	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.25	6.61	0.31	1.17e-10	Parkinson's disease;
LUAD	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg06558623	chr16:89946397	TCF25	1.18	10.49	0.45	4.78e-23	Skin colour saturation;
LUAD	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg02696790	chr15:75250997	RPP25	0.38	7.11	0.33	5.14e-12	Breast cancer;
LUAD	cis	rs734999	0.967	rs6671426	chr1:2504234	C/A	cg05697835	chr1:2722811	NA	0.29	6.64	0.31	9.44e-11	Ulcerative colitis;
LUAD	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg26818010	chr10:134567672	INPP5A	-0.97	-15.56	-0.6	1.65e-43	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.39	-7.67	-0.35	1.16e-13	Total body bone mineral density;
LUAD	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg23533926	chr12:111358616	MYL2	-0.4	-6.91	-0.32	1.76e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg14847009	chr1:175162515	KIAA0040	0.3	7.7	0.35	9.91e-14	Diastolic blood pressure;
LUAD	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg18833306	chr6:118973337	C6orf204	-0.49	-7.22	-0.33	2.39e-12	Diastolic blood pressure;
LUAD	cis	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg07169764	chr2:136633963	MCM6	0.62	7.41	0.34	6.89e-13	Corneal structure;
LUAD	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg02782426	chr3:40428986	ENTPD3	0.43	9.07	0.4	4.65e-18	Renal cell carcinoma;
LUAD	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg16797656	chr11:68205561	LRP5	0.45	8.48	0.38	3.83e-16	Total body bone mineral density;
LUAD	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg05590025	chr7:65112418	INTS4L2	0.77	7.92	0.36	2.12e-14	Diabetic kidney disease;
LUAD	cis	rs7793919	0.652	rs10228886	chr7:4783224	C/T	cg09789173	chr7:4769017	FOXK1	-0.66	-13.17	-0.54	1.89e-33	Mosquito bite size;
LUAD	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg11245181	chr6:149772854	ZC3H12D	-0.28	-6.4	-0.3	4.11e-10	Dupuytren's disease;
LUAD	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.62	9.22	0.41	1.39e-18	Ileal carcinoids;
LUAD	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg00666640	chr1:248458726	OR2T12	0.28	6.67	0.31	8.16e-11	Common traits (Other);
LUAD	cis	rs4638749	0.677	rs34449318	chr2:108827222	T/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.27	-0.33	1.76e-12	Blood pressure;
LUAD	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg19418458	chr7:158789849	NA	-0.63	-11.11	-0.48	2.48e-25	Facial morphology (factor 20);
LUAD	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg08508325	chr11:3079039	CARS	-0.58	-12.73	-0.53	1.21e-31	Longevity;
LUAD	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg24069376	chr3:38537580	EXOG	0.37	8.55	0.38	2.22e-16	Electrocardiographic conduction measures;
LUAD	trans	rs7395662	0.889	rs11039754	chr11:48475213	C/G	cg00717180	chr2:96193071	NA	-0.4	-7.41	-0.34	6.81e-13	HDL cholesterol;
LUAD	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg07741184	chr6:167504864	NA	0.36	8.35	0.38	9.89e-16	Crohn's disease;
LUAD	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10802521	chr3:52805072	NEK4	-0.61	-11.16	-0.48	1.56e-25	Bipolar disorder;
LUAD	cis	rs12467847	0.965	rs12467810	chr2:113691060	A/G	cg12858261	chr2:113808755	IL1F8	0.37	6.5	0.3	2.21e-10	Response to amphetamines;
LUAD	cis	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg21775007	chr8:11205619	TDH	-0.39	-6.73	-0.31	5.7e-11	Neuroticism;
LUAD	cis	rs2286503	0.839	rs4722188	chr7:22860211	C/G	cg06496272	chr7:22895283	SNORD93	-0.42	-7.41	-0.34	6.84e-13	Fibrinogen;
LUAD	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs524023	1.000	rs12786214	chr11:64364203	G/A	cg19131476	chr11:64387923	NRXN2	-0.4	-7.66	-0.35	1.26e-13	Urate levels in obese individuals;
LUAD	cis	rs2197308	0.585	rs10878014	chr12:38114496	A/G	cg26384229	chr12:38710491	ALG10B	0.4	6.73	0.31	5.43e-11	Morning vs. evening chronotype;
LUAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg23649088	chr2:200775458	C2orf69	-0.62	-7.77	-0.35	6.15e-14	Schizophrenia;
LUAD	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg25036284	chr2:26402008	FAM59B	-0.6	-8.3	-0.37	1.37e-15	Gut microbiome composition (summer);
LUAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00166722	chr3:10149974	C3orf24	0.74	12.68	0.52	1.89e-31	Alzheimer's disease;
LUAD	cis	rs1044826	0.518	rs295488	chr3:139239323	C/T	cg00490450	chr3:139108681	COPB2	0.46	7.47	0.34	4.68e-13	Obesity-related traits;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06778273	chr1:1137117	NA	-0.6	-6.67	-0.31	8.01e-11	Type 2 diabetes;
LUAD	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg15309053	chr8:964076	NA	0.42	9.29	0.41	8.27e-19	Schizophrenia;
LUAD	cis	rs7267979	0.816	rs6076358	chr20:25519403	G/T	cg08601574	chr20:25228251	PYGB	-0.4	-7.46	-0.34	4.95e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg07606381	chr6:8435919	SLC35B3	0.42	6.86	0.32	2.44e-11	Motion sickness;
LUAD	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg26384229	chr12:38710491	ALG10B	0.45	7.13	0.33	4.42e-12	Heart rate;
LUAD	cis	rs4601821	1.000	rs3897584	chr11:113249725	C/G	cg14159747	chr11:113255604	NA	-0.47	-9.02	-0.4	6.87e-18	Alcoholic chronic pancreatitis;
LUAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg08132940	chr7:1081526	C7orf50	-0.64	-9.43	-0.42	2.79e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg03709012	chr19:19516395	GATAD2A	0.49	6.87	0.32	2.32e-11	Nonalcoholic fatty liver disease;
LUAD	cis	rs7267979	1.000	rs6115191	chr20:25440478	C/T	cg08601574	chr20:25228251	PYGB	0.43	7.95	0.36	1.72e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg08280861	chr8:58055591	NA	0.58	7.71	0.35	9.29e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg10560079	chr2:191398806	TMEM194B	-0.53	-6.97	-0.32	1.2e-11	Diastolic blood pressure;
LUAD	cis	rs220324	0.688	rs9981522	chr21:43568247	A/C	cg08841829	chr21:43638893	ABCG1	-0.47	-6.78	-0.31	3.99e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs68170813	0.559	rs4730231	chr7:106942039	G/C	cg23024343	chr7:107201750	COG5	0.49	7.25	0.33	1.98e-12	Coronary artery disease;
LUAD	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg11189052	chr15:85197271	WDR73	-0.62	-10.32	-0.45	1.99e-22	P wave terminal force;
LUAD	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg25358565	chr5:93447407	FAM172A	-0.59	-7.1	-0.33	5.42e-12	Diabetic retinopathy;
LUAD	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg06740227	chr12:86229804	RASSF9	-0.4	-7.1	-0.33	5.38e-12	Major depressive disorder;
LUAD	cis	rs796825	0.530	rs56103727	chr3:119986843	G/A	cg21790991	chr3:120137480	FSTL1	-0.47	-8.09	-0.37	6.17e-15	HIV-1 susceptibility;
LUAD	cis	rs9837602	1.000	rs9832186	chr3:99728503	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.65	9.43	0.42	2.64e-19	Breast cancer;
LUAD	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg16647868	chr5:131706066	SLC22A5	-0.41	-7.1	-0.33	5.44e-12	Blood metabolite levels;
LUAD	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg21782813	chr7:2030301	MAD1L1	0.4	6.56	0.3	1.55e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg03806693	chr22:41940476	POLR3H	0.73	9.89	0.43	7.14e-21	Vitiligo;
LUAD	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-9.5	-0.42	1.63e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg22508957	chr16:3507546	NAT15	-0.84	-9.25	-0.41	1.16e-18	Tuberculosis;
LUAD	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg03161606	chr19:29218774	NA	0.6	8.65	0.39	1.05e-16	Methadone dose in opioid dependence;
LUAD	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg21433313	chr16:3507492	NAT15	0.74	9.65	0.42	4.92e-20	Tuberculosis;
LUAD	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	trans	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1595825	0.891	rs75163179	chr2:198895402	G/A	cg00361562	chr2:198649771	BOLL	-0.47	-6.52	-0.3	1.96e-10	Ulcerative colitis;
LUAD	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04267008	chr7:1944627	MAD1L1	0.64	10.27	0.45	2.97e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs7851660	0.809	rs10984235	chr9:100660896	C/T	cg13688889	chr9:100608707	NA	-0.54	-9.17	-0.41	2.08e-18	Strep throat;
LUAD	cis	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg08601574	chr20:25228251	PYGB	0.47	8.81	0.39	3.16e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.55	-0.89	7.95e-148	Myeloid white cell count;
LUAD	cis	rs868036	1.000	rs1026733	chr15:68095122	G/A	cg24579218	chr15:68104479	NA	-0.39	-7.29	-0.33	1.53e-12	Restless legs syndrome;
LUAD	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg00071950	chr4:10020882	SLC2A9	-0.78	-15.84	-0.61	1.03e-44	Bone mineral density;
LUAD	cis	rs714515	0.502	rs4916254	chr1:172364012	G/A	cg13446689	chr1:172328377	DNM3	-0.39	-7.82	-0.36	4.36e-14	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs758324	0.947	rs28537859	chr5:131237277	C/G	cg25547332	chr5:131281432	NA	-0.44	-6.72	-0.31	5.85e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.57	10.03	0.44	2.2e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg21220214	chr8:57350948	NA	-0.65	-9.21	-0.41	1.55e-18	Obesity-related traits;
LUAD	cis	rs7927771	0.542	rs3886262	chr11:47817010	T/G	cg18512352	chr11:47633146	NA	0.37	6.44	0.3	3.34e-10	Subjective well-being;
LUAD	cis	rs657075	0.697	rs56996855	chr5:131689638	T/C	cg21138405	chr5:131827807	IRF1	0.52	6.47	0.3	2.69e-10	Rheumatoid arthritis;
LUAD	cis	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.4	-7.65	-0.35	1.38e-13	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs6494488	0.500	rs72744726	chr15:65030995	C/T	cg08069370	chr15:64387884	SNX1	-0.73	-6.47	-0.3	2.78e-10	Coronary artery disease;
LUAD	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.67	10.95	0.47	1.01e-24	Height;
LUAD	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.39	-0.38	7.35e-16	Menopause (age at onset);
LUAD	cis	rs4711350	1.000	rs4711350	chr6:33741716	A/G	cg16010596	chr6:33739607	LEMD2	-0.37	-6.4	-0.3	4.14e-10	Schizophrenia;
LUAD	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg10802521	chr3:52805072	NEK4	-0.63	-11.19	-0.48	1.24e-25	Bipolar disorder;
LUAD	cis	rs3760982	0.565	rs8104300	chr19:44293144	T/C	cg12072164	chr19:44306565	LYPD5	0.42	8.54	0.38	2.36e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.43	8.21	0.37	2.63e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs12681287	0.752	rs9283958	chr8:87253048	T/C	cg27223183	chr8:87520930	FAM82B	-0.62	-8.42	-0.38	5.92e-16	Caudate activity during reward;
LUAD	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg09796270	chr17:17721594	SREBF1	0.39	7.62	0.35	1.65e-13	Total body bone mineral density;
LUAD	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg07741184	chr6:167504864	NA	0.29	7.03	0.32	8.51e-12	Crohn's disease;
LUAD	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg21775007	chr8:11205619	TDH	-0.49	-9.04	-0.4	5.51e-18	Retinal vascular caliber;
LUAD	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg22535103	chr8:58192502	C8orf71	-0.61	-6.66	-0.31	8.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg00376283	chr12:123451042	ABCB9	0.41	6.72	0.31	5.84e-11	Platelet count;
LUAD	cis	rs6541297	0.703	rs598203	chr1:230322122	C/G	cg20703242	chr1:230279135	GALNT2	0.43	6.79	0.31	3.83e-11	Coronary artery disease;
LUAD	cis	rs35146811	0.586	rs12666107	chr7:99778019	G/C	cg22906224	chr7:99728672	NA	0.54	8.65	0.39	1.11e-16	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.85e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.05	-0.32	7.19e-12	Blood metabolite levels;
LUAD	cis	rs6554196	0.508	rs7695300	chr4:55512066	T/C	cg18836493	chr4:55524333	KIT	-0.37	-6.99	-0.32	1.11e-11	Monocyte count;
LUAD	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03517284	chr6:25882590	NA	-0.98	-17.64	-0.65	1.34e-52	Urate levels;
LUAD	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg25769590	chr7:158789503	NA	0.38	7.0	0.32	1.02e-11	Facial morphology (factor 20);
LUAD	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg02574844	chr11:5959923	NA	-0.39	-6.69	-0.31	6.97e-11	DNA methylation (variation);
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09428623	chr2:68480128	PPP3R1	0.44	6.83	0.32	2.9e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	trans	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg07817883	chr1:32538562	TMEM39B	0.66	7.96	0.36	1.65e-14	Monocyte percentage of white cells;
LUAD	cis	rs6087990	0.899	rs1003521	chr20:31366598	T/C	cg13636640	chr20:31349939	DNMT3B	0.81	15.39	0.6	9.23e-43	Ulcerative colitis;
LUAD	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg17689763	chr4:710664	PCGF3	-0.57	-9.73	-0.43	2.54e-20	White blood cell count;
LUAD	cis	rs2730260	0.673	rs56236179	chr7:158843088	G/A	cg02254261	chr7:158964346	NA	-0.54	-6.43	-0.3	3.39e-10	Myopia (pathological);
LUAD	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.5e-19	Life satisfaction;
LUAD	cis	rs11771526	0.792	rs17161105	chr7:32299187	T/C	cg27532318	chr7:32358331	NA	0.56	7.36	0.34	9.64e-13	Body mass index;
LUAD	trans	rs877282	0.741	rs35865720	chr10:753022	G/A	cg22713356	chr15:30763199	NA	1.21	15.06	0.59	2.31e-41	Uric acid levels;
LUAD	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg03395511	chr6:291903	DUSP22	-0.51	-8.3	-0.37	1.42e-15	Menopause (age at onset);
LUAD	cis	rs701145	0.537	rs446144	chr3:153922154	T/C	cg17054900	chr3:154042577	DHX36	0.66	7.35	0.34	1.04e-12	Coronary artery disease;
LUAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg04025307	chr7:1156635	C7orf50	0.6	6.84	0.32	2.78e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.57	-0.3	1.44e-10	Breast cancer;
LUAD	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.44	0.57	1.08e-38	Schizophrenia;
LUAD	trans	rs7395662	1.000	rs10838954	chr11:48579323	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	2.04e-12	HDL cholesterol;
LUAD	cis	rs7727544	0.545	rs10074490	chr5:131340032	C/T	cg22598563	chr5:131563921	P4HA2	-0.27	-6.45	-0.3	3.11e-10	Blood metabolite levels;
LUAD	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg23855989	chr12:50355821	AQP5	0.64	8.58	0.38	1.87e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4389656	0.857	rs5001282	chr5:6757668	T/C	cg10857441	chr5:6722123	POLS	-0.46	-8.01	-0.36	1.15e-14	Coronary artery disease;
LUAD	trans	rs4824093	0.544	rs73443957	chr22:50305515	T/C	cg09872104	chr7:134855509	C7orf49	-0.73	-7.0	-0.32	1.03e-11	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg26384229	chr12:38710491	ALG10B	0.46	7.49	0.34	4.17e-13	Bladder cancer;
LUAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.92	-0.43	5.41e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs346785	0.518	rs3803738	chr17:74303832	G/C	cg09812376	chr17:74270190	QRICH2	-0.39	-7.64	-0.35	1.46e-13	White matter hyperintensities in ischemic stroke;
LUAD	trans	rs3960554	0.867	rs79359354	chr7:75702597	G/A	cg19862616	chr7:65841803	NCRNA00174	0.83	11.88	0.5	2.81e-28	Eotaxin levels;
LUAD	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg13319975	chr6:146136371	FBXO30	0.57	9.64	0.42	5.05e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg18538332	chr22:24372958	LOC391322	0.55	9.1	0.4	3.57e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg12011299	chr4:100065546	ADH4	0.72	13.45	0.55	1.4e-34	Alcohol dependence;
LUAD	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg13319975	chr6:146136371	FBXO30	-0.59	-9.94	-0.44	4.64e-21	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg14343924	chr8:8086146	FLJ10661	0.43	6.58	0.3	1.36e-10	Systolic blood pressure;
LUAD	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg21545522	chr1:205238299	TMCC2	0.38	6.99	0.32	1.09e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg16647868	chr5:131706066	SLC22A5	-0.49	-7.79	-0.35	5.09e-14	Breast cancer;
LUAD	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg23260525	chr10:116636907	FAM160B1	0.47	11.0	0.47	6.26e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1788820	0.917	rs1788819	chr18:21100504	G/A	cg14672496	chr18:21087552	C18orf8	0.35	6.63	0.31	1.04e-10	Body mass index;
LUAD	cis	rs1045714	0.895	rs4719602	chr7:2647800	G/A	cg20813462	chr7:2646259	IQCE	0.63	6.99	0.32	1.04e-11	Urate levels in lean individuals;
LUAD	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11890956	chr21:40555474	PSMG1	-0.77	-13.43	-0.55	1.67e-34	Cognitive function;
LUAD	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.56	-0.35	2.48e-13	Lung cancer;
LUAD	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg03929089	chr4:120376271	NA	0.8	14.34	0.57	2.75e-38	Coronary artery disease;
LUAD	cis	rs877282	0.898	rs11253349	chr10:765897	C/G	cg17470449	chr10:769945	NA	0.61	8.47	0.38	4.14e-16	Uric acid levels;
LUAD	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg26384229	chr12:38710491	ALG10B	0.48	7.78	0.35	5.55e-14	Bladder cancer;
LUAD	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	12.43	0.52	1.82e-30	Monocyte percentage of white cells;
LUAD	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg07402062	chr16:89894098	SPIRE2	0.45	11.38	0.48	2.33e-26	Vitiligo;
LUAD	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg26924012	chr15:45694286	SPATA5L1	0.64	11.06	0.47	3.89e-25	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs16858210	0.913	rs1879255	chr3:183609445	C/A	cg01324343	chr3:183735012	ABCC5	0.42	6.4	0.3	4.18e-10	Menopause (age at onset);
LUAD	cis	rs7589728	0.748	rs35051888	chr2:88482258	G/A	cg09033577	chr2:88485744	THNSL2	-0.56	-6.63	-0.31	1.04e-10	Plasma clusterin levels;
LUAD	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg14634687	chr17:47094252	IGF2BP1	0.28	6.91	0.32	1.81e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.68	0.39	8.68e-17	Menopause (age at onset);
LUAD	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg25019722	chr6:37503610	NA	0.31	6.99	0.32	1.05e-11	Cognitive performance;
LUAD	trans	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg18335740	chr13:41363409	SLC25A15	-0.56	-9.99	-0.44	3.09e-21	Lewy body disease;
LUAD	cis	rs10489202	0.634	rs6427119	chr1:168074145	A/G	cg25738037	chr1:168025549	DCAF6	0.45	6.56	0.3	1.59e-10	Schizophrenia;
LUAD	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg19635926	chr16:89946313	TCF25	0.76	6.78	0.31	4.15e-11	Skin colour saturation;
LUAD	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg12863693	chr15:85201151	NMB	0.41	7.56	0.35	2.46e-13	Schizophrenia;
LUAD	cis	rs432925	0.625	rs1150188	chr16:355870	G/C	cg06233593	chr16:337645	AXIN1	0.31	6.91	0.32	1.75e-11	Morning vs. evening chronotype;
LUAD	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg15664640	chr17:80829946	TBCD	-0.69	-8.43	-0.38	5.49e-16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg15704280	chr7:45808275	SEPT13	0.66	8.86	0.4	2.21e-17	Axial length;
LUAD	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg03526776	chr6:41159608	TREML2	0.33	6.93	0.32	1.58e-11	Alzheimer's disease (late onset);
LUAD	cis	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.43	-8.17	-0.37	3.57e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg26924012	chr15:45694286	SPATA5L1	0.87	14.83	0.58	2.3e-40	Homoarginine levels;
LUAD	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg14844989	chr11:31128820	NA	-0.47	-8.52	-0.38	2.74e-16	Red blood cell count;
LUAD	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg10596483	chr8:143751796	JRK	0.45	7.22	0.33	2.42e-12	Schizophrenia;
LUAD	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg00784671	chr22:46762841	CELSR1	-0.67	-7.99	-0.36	1.32e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg15017067	chr4:17643749	FAM184B	0.36	6.89	0.32	2.08e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg08999081	chr20:33150536	PIGU	0.63	14.36	0.57	2.27e-38	Coronary artery disease;
LUAD	cis	rs1387259	0.929	rs2956703	chr12:48670294	C/T	cg04545296	chr12:48745243	ZNF641	0.4	10.05	0.44	1.83e-21	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs7617773	0.817	rs9818937	chr3:48325281	G/A	cg11946769	chr3:48343235	NME6	0.43	6.7	0.31	6.5500000000000006e-11	Coronary artery disease;
LUAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08219700	chr8:58056026	NA	0.63	8.82	0.39	2.92e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.46	6.86	0.32	2.48e-11	Schizophrenia;
LUAD	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg04398451	chr17:18023971	MYO15A	0.78	14.15	0.57	1.76e-37	Total body bone mineral density;
LUAD	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg22535103	chr8:58192502	C8orf71	-0.65	-9.26	-0.41	1.06e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg12407791	chr17:73824354	UNC13D	-0.35	-7.1	-0.33	5.37e-12	White matter hyperintensity burden;
LUAD	cis	rs7945718	0.839	rs2033908	chr11:12838286	G/T	cg25843174	chr11:12811716	TEAD1	0.23	7.02	0.32	8.65e-12	Educational attainment (years of education);
LUAD	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg21153622	chr11:89784906	NA	-0.35	-6.86	-0.32	2.53e-11	HDL cholesterol;
LUAD	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg11266682	chr4:10021025	SLC2A9	0.59	12.68	0.52	1.86e-31	Bone mineral density;
LUAD	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg03959625	chr15:84868606	LOC388152	0.42	6.74	0.31	5.29e-11	Schizophrenia;
LUAD	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.37	-9.89	-0.43	7.04e-21	Total body bone mineral density;
LUAD	cis	rs3125734	0.633	rs7100297	chr10:63985100	T/C	cg09941381	chr10:64027924	RTKN2	-0.3	-6.92	-0.32	1.72e-11	Rheumatoid arthritis;
LUAD	cis	rs2742417	0.967	rs9877499	chr3:45734404	G/A	cg10512202	chr3:45649293	LIMD1	0.37	6.45	0.3	3.05e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs4523957	0.855	rs12603057	chr17:2112567	T/C	cg16513277	chr17:2031491	SMG6	-0.81	-15.46	-0.6	4.69e-43	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg18833306	chr6:118973337	C6orf204	-0.54	-7.61	-0.35	1.81e-13	Diastolic blood pressure;
LUAD	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg06558623	chr16:89946397	TCF25	1.14	10.37	0.45	1.38e-22	Skin colour saturation;
LUAD	cis	rs6005807	0.719	rs12166475	chr22:28860167	T/G	cg12565055	chr22:29076175	TTC28	0.74	8.56	0.38	2.12e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg18129748	chr3:49941408	MST1R	0.4	6.5	0.3	2.24e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9902453	0.838	rs9646436	chr17:28209059	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.91	0.4	1.57e-17	Coffee consumption (cups per day);
LUAD	cis	rs4700695	0.619	rs37230	chr5:65218264	A/C	cg21114390	chr5:65439923	SFRS12	0.65	7.83	0.36	4.01e-14	Facial morphology (factor 19);
LUAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	7.86	0.36	3.11e-14	Alzheimer's disease;
LUAD	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg16479474	chr6:28041457	NA	0.48	7.9	0.36	2.42e-14	Depression;
LUAD	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.89	-0.32	2.04e-11	Retinal vascular caliber;
LUAD	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg21770322	chr7:97807741	LMTK2	0.34	7.84	0.36	3.67e-14	Breast cancer;
LUAD	cis	rs367615	0.506	rs2963013	chr5:108775811	C/T	cg17395555	chr5:108820864	NA	-0.62	-13.25	-0.54	9.31e-34	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg12588279	chr6:26043732	HIST1H2BB	0.38	6.47	0.3	2.73e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg20701182	chr2:24300061	SF3B14	0.91	13.58	0.55	3.99e-35	Lymphocyte counts;
LUAD	trans	rs62458065	0.513	rs10265319	chr7:32571564	A/C	cg00845942	chr12:64062724	DPY19L2	-0.56	-8.22	-0.37	2.49e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs8177876	0.686	rs2602402	chr16:81086330	A/G	cg08591886	chr16:81111003	C16orf46	-0.59	-6.48	-0.3	2.6e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs2288327	0.557	rs7588593	chr2:179352450	T/C	cg14011486	chr1:26737247	LIN28	0.56	7.57	0.35	2.44e-13	Atrial fibrillation;
LUAD	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg10434728	chr15:90938212	IQGAP1	0.34	6.63	0.31	9.97e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs7809950	0.635	rs62483629	chr7:106866178	T/C	cg23024343	chr7:107201750	COG5	-0.81	-12.89	-0.53	2.71e-32	Coronary artery disease;
LUAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	8.26	0.37	1.85e-15	Alzheimer's disease;
LUAD	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	9.62	0.42	6.04e-20	Lung cancer in ever smokers;
LUAD	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg17264618	chr3:40429014	ENTPD3	0.36	7.7	0.35	9.78e-14	Renal cell carcinoma;
LUAD	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg27572855	chr1:25598939	RHD	-0.55	-12.21	-0.51	1.35e-29	Erythrocyte sedimentation rate;
LUAD	trans	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg04565464	chr8:145669602	NFKBIL2	0.44	6.61	0.31	1.15e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg18131467	chr2:239335373	ASB1	0.6	9.83	0.43	1.09e-20	Multiple system atrophy;
LUAD	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18876405	chr7:65276391	NA	-0.56	-9.44	-0.42	2.49e-19	Aortic root size;
LUAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg07362569	chr17:61921086	SMARCD2	-0.4	-7.05	-0.32	7.55e-12	Prudent dietary pattern;
LUAD	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg24911827	chr22:19170109	CLTCL1	0.35	7.38	0.34	8.28e-13	Metabolite levels;
LUAD	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg19761014	chr17:28927070	LRRC37B2	0.86	8.36	0.38	9.21e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg21918786	chr6:109611834	NA	-0.52	-9.11	-0.41	3.21e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg06623918	chr6:96969491	KIAA0776	0.87	16.92	0.64	2.01e-49	Headache;
LUAD	cis	rs11031096	0.503	rs10835604	chr11:4109709	A/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.33	-0.34	1.19e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.39	-8.15	-0.37	4.25e-15	Lymphocyte counts;
LUAD	cis	rs7809950	0.817	rs4727678	chr7:107083635	C/G	cg23024343	chr7:107201750	COG5	-0.87	-14.53	-0.58	4.27e-39	Coronary artery disease;
LUAD	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg00204512	chr16:28754710	NA	0.31	6.37	0.3	5.01e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg07460842	chr6:66804631	NA	1.03	16.17	0.62	3.95e-46	Exhaled nitric oxide output;
LUAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-6.93	-0.32	1.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg02228675	chr17:40259724	DHX58	-0.44	-7.12	-0.33	4.52e-12	Fibrinogen levels;
LUAD	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg15133208	chr4:90757351	SNCA	-0.5	-7.83	-0.36	3.96e-14	Neuroticism;
LUAD	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg21963583	chr11:68658836	MRPL21	0.66	11.82	0.5	4.92e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg15181151	chr6:150070149	PCMT1	0.36	7.11	0.33	4.91e-12	Lung cancer;
LUAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.39	-0.42	3.7e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg02743256	chr7:2109353	MAD1L1	-0.47	-6.6	-0.31	1.2e-10	Bipolar disorder;
LUAD	cis	rs12431939	0.762	rs61109194	chr14:51698659	T/C	cg23942311	chr14:51606299	NA	-0.54	-7.64	-0.35	1.42e-13	Cancer;
LUAD	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg15028436	chr7:37888078	TXNDC3	0.36	7.42	0.34	6.68e-13	Alzheimer's disease (late onset);
LUAD	cis	rs2017305	0.749	rs115363198	chr10:70791472	C/G	cg01024728	chr10:70782572	NA	0.74	7.03	0.32	8.43e-12	Depression (quantitative trait);
LUAD	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg13699009	chr12:122356056	WDR66	-0.34	-7.43	-0.34	6.17e-13	Mean corpuscular volume;
LUAD	cis	rs113835537	0.529	rs2298806	chr11:66282095	G/A	cg24851651	chr11:66362959	CCS	0.57	10.1	0.44	1.25e-21	Airway imaging phenotypes;
LUAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg00106254	chr7:1943704	MAD1L1	-0.55	-7.95	-0.36	1.69e-14	Bipolar disorder and schizophrenia;
LUAD	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg03929089	chr4:120376271	NA	0.67	9.58	0.42	8.29e-20	Coronary artery disease;
LUAD	cis	rs6500395	0.925	rs6500396	chr16:48625458	A/T	cg04672837	chr16:48644449	N4BP1	0.39	6.67	0.31	8.04e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg02269571	chr22:50332266	NA	-0.67	-9.44	-0.42	2.46e-19	Schizophrenia;
LUAD	cis	rs7843479	1.000	rs10503715	chr8:21850687	G/A	cg03445287	chr8:21823731	XPO7	-0.45	-8.21	-0.37	2.71e-15	Mean corpuscular volume;
LUAD	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.54	7.64	0.35	1.43e-13	Schizophrenia;
LUAD	cis	rs7932354	0.528	rs1872896	chr11:47160623	C/T	cg19486271	chr11:47235900	DDB2	-0.41	-6.62	-0.31	1.06e-10	Bone mineral density (hip);Bone mineral density;
LUAD	trans	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg27411982	chr8:10470053	RP1L1	0.38	7.03	0.32	8.5e-12	Monocyte count;
LUAD	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg15997130	chr1:24165203	NA	-0.57	-10.23	-0.45	4.19e-22	Immature fraction of reticulocytes;
LUAD	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg03929089	chr4:120376271	NA	-0.84	-14.77	-0.58	4.16e-40	Height;
LUAD	cis	rs2066819	1.000	rs78149779	chr12:56694817	A/G	cg26714650	chr12:56694279	CS	-0.86	-7.23	-0.33	2.25e-12	Psoriasis vulgaris;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21295104	chr22:29168639	CCDC117	-0.47	-7.53	-0.34	3.08e-13	Height;
LUAD	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg12310025	chr6:25882481	NA	-0.58	-8.48	-0.38	3.88e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7084921	0.608	rs11596211	chr10:101840119	T/A	cg19754520	chr10:101825118	CPN1	-0.36	-7.17	-0.33	3.29e-12	Bone mineral density;
LUAD	trans	rs2665103	0.589	rs2134046	chr15:82524544	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.4	-6.66	-0.31	8.55e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.1	0.33	5.17e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs758324	0.898	rs11956351	chr5:131137224	G/A	cg06307176	chr5:131281290	NA	0.51	8.0	0.36	1.18e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg20848291	chr7:100343083	ZAN	-0.58	-7.88	-0.36	2.82e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg21775007	chr8:11205619	TDH	-0.49	-8.74	-0.39	5.44e-17	Retinal vascular caliber;
LUAD	cis	rs3087591	1.000	rs12600974	chr17:29589360	A/G	cg24425628	chr17:29625626	OMG;NF1	0.42	6.83	0.32	2.92e-11	Hip circumference;
LUAD	cis	rs853679	0.585	rs201004	chr6:27804934	T/C	cg20933634	chr6:27740509	NA	0.51	7.6	0.35	1.96e-13	Depression;
LUAD	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg15997130	chr1:24165203	NA	0.55	9.5	0.42	1.54e-19	Immature fraction of reticulocytes;
LUAD	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg15448220	chr1:150897856	SETDB1	0.47	8.09	0.37	6.35e-15	Tonsillectomy;
LUAD	cis	rs454510	1.000	rs377033	chr1:120196652	C/G	cg11530693	chr1:120165357	ZNF697	0.58	8.53	0.38	2.56e-16	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg10356904	chr22:49881777	NA	-0.4	-7.6	-0.35	1.88e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2692947	0.537	rs2320170	chr2:96239773	C/T	cg23100626	chr2:96804247	ASTL	-0.32	-7.86	-0.36	3.28e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9399401	0.710	rs6900087	chr6:142717303	A/T	cg03128060	chr6:142623767	GPR126	0.53	10.64	0.46	1.37e-23	Chronic obstructive pulmonary disease;
LUAD	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08704250	chr15:31115839	NA	-0.66	-11.86	-0.5	3.23e-28	Huntington's disease progression;
LUAD	cis	rs738322	0.836	rs4821741	chr22:38514745	A/G	cg25457927	chr22:38595422	NA	-0.46	-10.75	-0.46	5.57e-24	Cutaneous nevi;
LUAD	cis	rs2425143	1.000	rs2425141	chr20:34350123	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.61	-0.35	1.81e-13	Blood protein levels;
LUAD	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10802521	chr3:52805072	NEK4	-0.61	-11.04	-0.47	4.61e-25	Electroencephalogram traits;
LUAD	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.7	13.01	0.53	8.37e-33	Cognitive ability;
LUAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg07677032	chr17:61819896	STRADA	0.57	10.35	0.45	1.61e-22	Prudent dietary pattern;
LUAD	cis	rs12530845	0.945	rs7799891	chr7:135322853	T/C	cg23117316	chr7:135346802	PL-5283	-0.5	-9.26	-0.41	1.08e-18	Red blood cell traits;
LUAD	cis	rs7927771	0.524	rs7116346	chr11:47883880	G/A	cg18512352	chr11:47633146	NA	-0.36	-6.5	-0.3	2.29e-10	Subjective well-being;
LUAD	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21659725	chr3:3221576	CRBN	0.67	11.58	0.49	3.98e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg26924012	chr15:45694286	SPATA5L1	1.02	18.85	0.68	5.65e-58	Homoarginine levels;
LUAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.61	8.21	0.37	2.71e-15	Alzheimer's disease;
LUAD	cis	rs7680126	0.633	rs17389602	chr4:10206926	T/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-7.53	-0.34	3.1400000000000003e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg08859206	chr1:53392774	SCP2	-0.54	-9.77	-0.43	1.85e-20	Monocyte count;
LUAD	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg24069376	chr3:38537580	EXOG	0.35	7.93	0.36	1.93e-14	Electrocardiographic conduction measures;
LUAD	cis	rs28595532	0.920	rs116401323	chr4:119721727	C/T	cg02775129	chr4:119771670	NA	-0.86	-7.74	-0.35	7.56e-14	Cannabis dependence symptom count;
LUAD	cis	rs910873	0.505	rs6058089	chr20:33194257	C/T	cg16810054	chr20:33298113	TP53INP2	0.52	7.85	0.36	3.49e-14	Melanoma;
LUAD	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg03929089	chr4:120376271	NA	-0.96	-20.03	-0.7	3.05e-63	Height;
LUAD	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg05373962	chr22:49881684	NA	-0.51	-10.07	-0.44	1.56e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg09137382	chr11:130731461	NA	0.4	7.42	0.34	6.48e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg03233332	chr7:66118400	NA	-0.46	-6.76	-0.31	4.67e-11	Aortic root size;
LUAD	cis	rs36051895	0.659	rs61284219	chr9:5062816	C/A	cg02405213	chr9:5042618	JAK2	-0.47	-6.91	-0.32	1.84e-11	Pediatric autoimmune diseases;
LUAD	cis	rs2160860	0.930	rs2729484	chr8:39812080	T/C	cg25981315	chr8:39806701	IDO2	0.34	6.41	0.3	4e-10	Blood metabolite levels;
LUAD	cis	rs12410462	0.792	rs994666	chr1:227651454	C/T	cg23173402	chr1:227635558	NA	-0.63	-7.43	-0.34	6.01e-13	Major depressive disorder;
LUAD	cis	rs12210905	1.000	rs12201498	chr6:27030084	C/T	cg11502198	chr6:26597334	ABT1	-0.78	-6.45	-0.3	3.02e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs941764	0.965	rs747159	chr14:91841030	A/C	cg10511902	chr14:91842949	CCDC88C	-0.51	-12.22	-0.51	1.29e-29	Breast cancer;
LUAD	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg25767906	chr1:53392781	SCP2	0.46	8.33	0.38	1.15e-15	Monocyte count;
LUAD	cis	rs9487051	0.735	rs351754	chr6:109537553	A/G	cg01475377	chr6:109611718	NA	0.41	7.65	0.35	1.36e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg26516362	chr5:178986906	RUFY1	0.57	8.81	0.39	3.37e-17	Lung cancer;
LUAD	cis	rs6484504	0.576	rs208090	chr11:31190992	T/C	cg14844989	chr11:31128820	NA	-0.44	-8.08	-0.37	6.68e-15	Red blood cell count;
LUAD	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg02454025	chr1:11042201	C1orf127	1.05	17.9	0.66	9.47e-54	Ewing sarcoma;
LUAD	cis	rs12620999	0.941	rs10803654	chr2:238036570	C/T	cg23555395	chr2:238036564	NA	-0.6	-9.2	-0.41	1.66e-18	Systemic lupus erythematosus;
LUAD	trans	rs7939886	0.764	rs79601668	chr11:55753767	G/C	cg15704280	chr7:45808275	SEPT13	0.68	6.74	0.31	5.23e-11	Myopia (pathological);
LUAD	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg03233332	chr7:66118400	NA	0.44	6.78	0.31	4.15e-11	Aortic root size;
LUAD	cis	rs8099014	0.861	rs4940705	chr18:56120155	G/A	cg12907477	chr18:56117327	MIR122	0.48	7.86	0.36	3.24e-14	Platelet count;
LUAD	cis	rs2688608	0.623	rs2633318	chr10:75690434	T/C	cg23231163	chr10:75533350	FUT11	-0.39	-7.03	-0.32	8.15e-12	Inflammatory bowel disease;
LUAD	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg21782813	chr7:2030301	MAD1L1	0.51	8.36	0.38	8.84e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg08610935	chr16:1836813	NUBP2	0.45	7.01	0.32	9.32e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs243505	1.000	rs1019059	chr7:148424247	A/G	cg09806900	chr7:148480153	CUL1	-0.44	-7.38	-0.34	8.7e-13	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg04511125	chr2:88470314	THNSL2	-0.51	-8.62	-0.39	1.33e-16	Response to metformin (IC50);
LUAD	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg16797656	chr11:68205561	LRP5	0.46	8.96	0.4	1.05e-17	Total body bone mineral density;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg05926606	chr21:40685342	BRWD1	-0.4	-6.47	-0.3	2.69e-10	Schizophrenia;
LUAD	trans	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg24644049	chr4:85504048	CDS1	0.92	7.91	0.36	2.22e-14	Skin colour saturation;
LUAD	cis	rs939658	0.805	rs6495374	chr15:79434031	C/T	cg17916960	chr15:79447300	NA	-0.53	-11.21	-0.48	1.04e-25	Refractive error;
LUAD	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg07917127	chr4:99064746	C4orf37	0.41	6.85	0.32	2.55e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs877282	1.000	rs2004479	chr10:770854	G/A	cg06581033	chr10:766294	NA	-0.55	-7.59	-0.35	2.03e-13	Uric acid levels;
LUAD	cis	rs11756438	0.658	rs6937176	chr6:119007308	A/G	cg21191810	chr6:118973309	C6orf204	0.41	7.36	0.34	9.58e-13	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg13560548	chr3:10150139	C3orf24	0.45	7.34	0.34	1.08e-12	Alzheimer's disease;
LUAD	cis	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg07460842	chr6:66804631	NA	0.7	12.73	0.53	1.23e-31	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg20108693	chr8:143823809	SLURP1	-0.33	-7.99	-0.36	1.31e-14	Urinary tract infection frequency;
LUAD	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg15664640	chr17:80829946	TBCD	0.62	11.58	0.49	4e-27	Breast cancer;
LUAD	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg13902645	chr11:5959945	NA	-0.51	-8.75	-0.39	5e-17	DNA methylation (variation);
LUAD	trans	rs7395662	0.963	rs61930968	chr11:48581649	C/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.56	-0.3	1.54e-10	HDL cholesterol;
LUAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg07677032	chr17:61819896	STRADA	0.57	10.47	0.45	5.92e-23	Prudent dietary pattern;
LUAD	cis	rs2224391	0.656	rs68061889	chr6:5292817	A/G	cg26704043	chr6:5282702	FARS2	0.39	6.38	0.3	4.71e-10	Height;
LUAD	cis	rs2932538	0.961	rs6537747	chr1:113179597	C/T	cg22162597	chr1:113214053	CAPZA1	-0.41	-6.38	-0.3	4.63e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg02158880	chr13:53174818	NA	0.48	8.31	0.37	1.28e-15	Lewy body disease;
LUAD	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg19717773	chr7:2847554	GNA12	-0.55	-9.3	-0.41	7.58e-19	Height;
LUAD	cis	rs68170813	0.559	rs6965001	chr7:106933196	A/G	cg23024343	chr7:107201750	COG5	0.5	7.36	0.34	9.88e-13	Coronary artery disease;
LUAD	cis	rs758324	0.947	rs10478989	chr5:131116055	A/G	cg06307176	chr5:131281290	NA	0.51	8.07	0.37	7.09e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg01579765	chr21:45077557	HSF2BP	-0.61	-13.69	-0.55	1.46e-35	Mean corpuscular volume;
LUAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg05896524	chr21:47604654	C21orf56	0.77	13.45	0.55	1.45e-34	Testicular germ cell tumor;
LUAD	cis	rs7524258	0.900	rs1476047	chr1:7312172	C/T	cg07173049	chr1:7289937	CAMTA1	0.41	7.7	0.35	9.77e-14	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs977987	0.778	rs11858992	chr16:75411445	A/C	cg03315344	chr16:75512273	CHST6	0.65	14.21	0.57	9.42e-38	Dupuytren's disease;
LUAD	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.82	-11.15	-0.48	1.74e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7524258	0.868	rs2412153	chr1:7272412	C/T	cg04342483	chr1:7259290	CAMTA1	-0.28	-6.68	-0.31	7.59e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg22105103	chr4:187893119	NA	0.58	12.81	0.53	5.75e-32	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg05966235	chr16:28915196	ATP2A1	0.48	7.87	0.36	2.91e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24415082	chr16:74700811	RFWD3	0.4	6.5	0.3	2.2e-10	Gut microbiome composition (summer);
LUAD	cis	rs7771547	0.723	rs9368938	chr6:36549752	A/G	cg07856975	chr6:36356162	ETV7	0.45	6.39	0.3	4.41e-10	Platelet distribution width;
LUAD	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg15704280	chr7:45808275	SEPT13	-0.51	-8.1	-0.37	5.96e-15	Coronary artery disease;
LUAD	trans	rs8002861	0.967	rs9525871	chr13:44477712	A/T	cg17145862	chr1:211918768	LPGAT1	0.76	17.92	0.66	7.79e-54	Leprosy;
LUAD	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg26958806	chr6:27640298	NA	0.58	6.78	0.31	4e-11	Breast cancer;
LUAD	cis	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg07460842	chr6:66804631	NA	1.19	29.86	0.82	3.44e-106	Exhaled nitric oxide output;
LUAD	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg13010199	chr12:38710504	ALG10B	0.4	6.51	0.3	2.18e-10	Bladder cancer;
LUAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-7.22	-0.33	2.47e-12	Longevity;Endometriosis;
LUAD	cis	rs7017914	0.967	rs12680988	chr8:71695890	T/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.43	-0.3	3.46e-10	Bone mineral density;
LUAD	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg00631329	chr6:26305371	NA	-0.69	-13.12	-0.54	3.11e-33	Educational attainment;
LUAD	cis	rs7937890	0.559	rs2575831	chr11:14486194	A/T	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.44e-11	Mitochondrial DNA levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12484590	chr1:156475177	NA	-0.47	-7.26	-0.33	1.89e-12	Height;
LUAD	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg04414720	chr1:150670196	GOLPH3L	-0.47	-7.95	-0.36	1.66e-14	Tonsillectomy;
LUAD	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg02807482	chr3:125708958	NA	-0.65	-8.49	-0.38	3.45e-16	Blood pressure (smoking interaction);
LUAD	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg20673091	chr1:2541236	MMEL1	0.33	7.22	0.33	2.49e-12	Ulcerative colitis;
LUAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14893161	chr1:205819251	PM20D1	0.81	17.2	0.64	1.2e-50	Menarche (age at onset);
LUAD	cis	rs113835537	0.935	rs79106199	chr11:66420518	T/C	cg24851651	chr11:66362959	CCS	0.58	8.0	0.36	1.23e-14	Airway imaging phenotypes;
LUAD	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg02423579	chr7:2872169	GNA12	-0.83	-14.44	-0.57	1.02e-38	Height;
LUAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08280861	chr8:58055591	NA	0.63	8.31	0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg27490568	chr2:178487706	NA	-0.5	-8.38	-0.38	7.77e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08677398	chr8:58056175	NA	0.48	6.84	0.32	2.87e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg10544611	chr16:67998164	SLC12A4	-0.68	-8.12	-0.37	5.15e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg03676636	chr4:99064102	C4orf37	0.36	8.3	0.37	1.37e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	7.14	0.33	4.18e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9595066	0.715	rs9567366	chr13:44682973	A/C	cg04068111	chr13:44716778	NA	0.48	8.73	0.39	6.16e-17	Schizophrenia;
LUAD	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg09184832	chr6:79620586	NA	-0.51	-9.74	-0.43	2.34e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg18538332	chr22:24372958	LOC391322	-0.48	-8.19	-0.37	3.2e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2309752	1	rs2309752	chr2:100762169	T/A	cg22139774	chr2:100720529	AFF3	-0.39	-7.57	-0.35	2.41e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.49	8.1	0.37	5.86e-15	Blood metabolite levels;
LUAD	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg02527881	chr3:46936655	PTH1R	-0.56	-11.45	-0.49	1.23e-26	Colorectal cancer;
LUAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg11766577	chr21:47581405	C21orf56	-0.64	-11.78	-0.5	6.91e-28	Testicular germ cell tumor;
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	ch.17.1132347R	chr17:41598698	DHX8	-0.41	-7.26	-0.33	1.83e-12	Migraine with aura;
LUAD	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg20503657	chr10:835505	NA	1.01	15.02	0.59	3.45e-41	Eosinophil percentage of granulocytes;
LUAD	cis	rs6028335	0.610	rs67743908	chr20:37572643	G/A	cg27660920	chr20:37554817	FAM83D	0.54	7.07	0.32	6.61e-12	Alcohol and nicotine co-dependence;
LUAD	cis	rs28374715	0.681	rs77187862	chr15:41619276	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.9	-16.73	-0.63	1.44e-48	Ulcerative colitis;
LUAD	cis	rs7727544	0.570	rs7701237	chr5:131534381	C/T	cg07538946	chr5:131705188	SLC22A5	0.41	6.54	0.3	1.83e-10	Blood metabolite levels;
LUAD	cis	rs868943	0.714	rs1999930	chr6:116387134	C/T	cg15226275	chr6:116381976	FRK	0.23	6.36	0.3	5.22e-10	Total cholesterol levels;
LUAD	cis	rs853679	0.556	rs34706883	chr6:27805255	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.52	6.36	0.3	5.11e-10	Depression;
LUAD	cis	rs7520050	0.778	rs12404197	chr1:46232420	G/A	cg06784218	chr1:46089804	CCDC17	-0.35	-7.56	-0.34	2.61e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg21427119	chr20:30132790	HM13	-0.62	-9.46	-0.42	2.14e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs67311347	0.544	rs60329764	chr3:40334621	C/T	cg02782426	chr3:40428986	ENTPD3	-0.35	-7.55	-0.34	2.77e-13	Renal cell carcinoma;
LUAD	cis	rs6011002	0.590	rs1291212	chr20:62340115	C/G	cg21849932	chr20:62369462	LIME1	-0.78	-6.5	-0.3	2.25e-10	Dental caries;
LUAD	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg06781209	chr11:61594997	FADS2	-0.41	-7.62	-0.35	1.73e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs791888	1.000	rs791882	chr10:89408258	C/T	cg13926569	chr10:89418898	PAPSS2	-0.47	-8.68	-0.39	8.35e-17	Magnesium levels;
LUAD	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.27	-6.54	-0.3	1.82e-10	Coronary artery disease;
LUAD	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-10.76	-0.46	4.9e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6087990	1.000	rs2424901	chr20:31344512	A/G	cg13636640	chr20:31349939	DNMT3B	0.84	15.94	0.61	3.95e-45	Ulcerative colitis;
LUAD	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg24848339	chr3:12840334	CAND2	-0.42	-8.41	-0.38	6.51e-16	QRS complex (12-leadsum);
LUAD	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg06064525	chr11:970664	AP2A2	-0.54	-11.1	-0.48	2.57e-25	Alzheimer's disease (late onset);
LUAD	cis	rs912057	1.000	rs912056	chr6:6736197	A/T	cg06612196	chr6:6737390	NA	0.54	11.91	0.5	2.17e-28	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.52	-0.38	2.94e-16	Height;
LUAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.74	0.43	2.29e-20	Alzheimer's disease;
LUAD	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg17264618	chr3:40429014	ENTPD3	-0.39	-8.39	-0.38	7.16e-16	Renal cell carcinoma;
LUAD	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.22e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.24	-0.33	2.14e-12	Breast cancer;
LUAD	cis	rs6842047	0.563	rs6843711	chr4:187212953	T/C	cg23442198	chr4:187126114	CYP4V2	0.84	8.17	0.37	3.54e-15	Blood protein levels;
LUAD	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg11859384	chr17:80120422	CCDC57	-0.4	-7.28	-0.33	1.62e-12	Life satisfaction;
LUAD	cis	rs17532515	0.652	rs7672664	chr4:141382225	A/G	cg03645522	chr4:141391200	NA	0.4	6.42	0.3	3.57e-10	Select biomarker traits;
LUAD	cis	rs12620999	0.941	rs2875690	chr2:237977737	G/A	cg23555395	chr2:238036564	NA	0.57	8.95	0.4	1.14e-17	Systemic lupus erythematosus;
LUAD	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg17845761	chr1:175162550	KIAA0040	0.37	9.82	0.43	1.23e-20	Alcohol dependence;
LUAD	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg12034118	chr1:209979487	IRF6	0.59	6.59	0.31	1.28e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs9323205	0.765	rs2999388	chr14:51654157	A/G	cg23942311	chr14:51606299	NA	0.54	9.74	0.43	2.39e-20	Cancer;
LUAD	cis	rs12612619	0.732	rs11680096	chr2:27273571	T/C	cg00617064	chr2:27272375	NA	-0.38	-7.12	-0.33	4.6e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg03806693	chr22:41940476	POLR3H	-0.78	-11.01	-0.47	6.01e-25	Vitiligo;
LUAD	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.4	-0.34	7.16e-13	Lung cancer;
LUAD	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg18854424	chr1:2615690	NA	0.43	9.54	0.42	1.14e-19	Ulcerative colitis;
LUAD	cis	rs7520050	0.751	rs592214	chr1:46024505	G/A	cg06784218	chr1:46089804	CCDC17	-0.36	-7.75	-0.35	6.97e-14	Red blood cell count;Reticulocyte count;
LUAD	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg01657329	chr11:68192670	LRP5	-0.41	-6.56	-0.3	1.61e-10	Total body bone mineral density;
LUAD	cis	rs7000551	0.581	rs11136030	chr8:22254235	C/T	cg12081754	chr8:22256438	SLC39A14	0.93	15.87	0.61	8.18e-45	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg00071950	chr4:10020882	SLC2A9	0.64	12.54	0.52	6.83e-31	Bone mineral density;
LUAD	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.62	8.85	0.4	2.49e-17	Gut microbiome composition (summer);
LUAD	cis	rs17152411	0.895	rs11245422	chr10:126588143	T/C	cg07906193	chr10:126599966	NA	0.53	7.55	0.34	2.67e-13	Height;
LUAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg08888203	chr3:10149979	C3orf24	0.64	11.0	0.47	6.54e-25	Alzheimer's disease;
LUAD	cis	rs2625529	0.652	rs2929518	chr15:72332748	A/C	cg16672083	chr15:72433130	SENP8	0.65	12.13	0.51	2.94e-29	Red blood cell count;
LUAD	cis	rs9925964	0.967	rs9936329	chr16:31140799	G/T	cg03418659	chr16:31128414	MYST1	0.4	6.64	0.31	9.86e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	6.58	0.3	1.4e-10	Lung cancer in ever smokers;
LUAD	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg27535305	chr1:53392650	SCP2	-0.32	-6.37	-0.3	5e-10	Monocyte count;
LUAD	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg09826364	chr7:158789723	NA	-0.4	-7.17	-0.33	3.47e-12	Facial morphology (factor 20);
LUAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg03354898	chr7:1950403	MAD1L1	-0.45	-8.75	-0.39	5.05e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs7264396	0.563	rs2066066	chr20:34329359	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.28	-0.37	1.67e-15	Total cholesterol levels;
LUAD	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg11301795	chr4:187892539	NA	-0.74	-14.87	-0.59	1.52e-40	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1847202	0.859	rs4501056	chr3:72948908	A/T	cg25664220	chr3:72788482	NA	-0.44	-7.74	-0.35	7.64e-14	Motion sickness;
LUAD	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.86	-0.5	3.42e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00166722	chr3:10149974	C3orf24	0.73	10.81	0.47	3.15e-24	Alzheimer's disease;
LUAD	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg03684893	chr10:554711	DIP2C	-0.38	-6.71	-0.31	6.37e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.94	-0.4	1.17e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg23950597	chr19:37808831	NA	-0.58	-7.13	-0.33	4.44e-12	Coronary artery calcification;
LUAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.41	-0.38	6.27e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg24818145	chr4:99064322	C4orf37	0.44	7.25	0.33	1.99e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg21385522	chr1:16154831	NA	-0.95	-15.44	-0.6	5.76e-43	Dilated cardiomyopathy;
LUAD	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	trans	rs587242	1.000	rs12757248	chr1:96898294	G/A	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg00631329	chr6:26305371	NA	-0.69	-13.11	-0.54	3.33e-33	Educational attainment;
LUAD	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.29	6.6	0.31	1.23e-10	Parkinson's disease;
LUAD	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22857025	chr5:266934	NA	-0.96	-14.32	-0.57	3.29e-38	Breast cancer;
LUAD	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg11822812	chr5:140052017	DND1	-0.39	-6.9	-0.32	1.95e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg06552810	chr11:31128660	NA	-0.35	-6.87	-0.32	2.31e-11	Red blood cell count;
LUAD	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.13	-0.33	4.47e-12	Total cholesterol levels;
LUAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08677398	chr8:58056175	NA	0.54	6.94	0.32	1.52e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9486719	1.000	rs2499809	chr6:96870110	C/T	cg06623918	chr6:96969491	KIAA0776	0.71	10.01	0.44	2.62e-21	Migraine;Coronary artery disease;
LUAD	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10992471	0.580	rs13284106	chr9:95433845	G/A	cg14631576	chr9:95140430	CENPP	-0.44	-8.24	-0.37	2.25e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs12532214	0.724	rs79042841	chr7:3160660	T/C	cg19214707	chr7:3157722	NA	-0.49	-6.97	-0.32	1.25e-11	Itch intensity from mosquito bite;
LUAD	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg02782426	chr3:40428986	ENTPD3	0.43	9.16	0.41	2.21e-18	Renal cell carcinoma;
LUAD	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg12573674	chr2:1569213	NA	-0.57	-6.8	-0.31	3.56e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs375066	0.762	rs171238	chr19:44379554	A/C	cg12072164	chr19:44306565	LYPD5	0.33	6.79	0.31	3.72e-11	Breast cancer;
LUAD	cis	rs12444979	0.517	rs720176	chr16:19721515	A/G	cg01578585	chr16:19721878	C16orf88	0.51	7.4	0.34	7.17e-13	Body mass index;
LUAD	cis	rs11771526	0.901	rs10282699	chr7:32297967	C/T	cg27532318	chr7:32358331	NA	0.56	7.29	0.33	1.57e-12	Body mass index;
LUAD	cis	rs4478137	0.824	rs4691905	chr4:164221437	T/C	cg06758707	chr4:164254230	NPY1R	0.45	7.1	0.33	5.38e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg10295955	chr4:187884368	NA	-1.12	-26.12	-0.79	2.9e-90	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg21475434	chr5:93447410	FAM172A	-0.51	-6.96	-0.32	1.3e-11	Diabetic retinopathy;
LUAD	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg13180566	chr4:1052158	NA	-0.4	-6.72	-0.31	5.87e-11	Recombination rate (females);
LUAD	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg00277334	chr10:82204260	NA	-0.47	-7.64	-0.35	1.5e-13	Post bronchodilator FEV1;
LUAD	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg10556349	chr10:835070	NA	-0.47	-7.31	-0.33	1.35e-12	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.79	-0.31	3.77e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg06221963	chr1:154839813	KCNN3	-0.88	-19.79	-0.69	3.45e-62	Prostate cancer;
LUAD	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg17264618	chr3:40429014	ENTPD3	0.37	8.13	0.37	4.71e-15	Renal cell carcinoma;
LUAD	cis	rs7903847	0.642	rs7078782	chr10:99168604	C/T	cg20016023	chr10:99160130	RRP12	-0.27	-6.6	-0.31	1.24e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2274273	0.600	rs35112084	chr14:55781100	T/A	cg04306507	chr14:55594613	LGALS3	0.41	7.92	0.36	2.17e-14	Protein biomarker;
LUAD	cis	rs2742234	0.541	rs11238490	chr10:43747598	G/A	cg15436174	chr10:43711423	RASGEF1A	0.51	8.57	0.38	1.9e-16	Hirschsprung disease;
LUAD	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg18132916	chr6:79620363	NA	-0.44	-7.56	-0.34	2.59e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg12436631	chr1:155007014	DCST1;DCST2	0.29	6.66	0.31	8.59e-11	Prostate cancer;
LUAD	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg12016809	chr21:47604291	C21orf56	0.45	7.0	0.32	9.79e-12	Testicular germ cell tumor;
LUAD	cis	rs35883536	0.647	rs2809790	chr1:101040461	C/T	cg06223162	chr1:101003688	GPR88	0.47	9.15	0.41	2.44e-18	Monocyte count;
LUAD	trans	rs877282	0.853	rs10904544	chr10:756966	A/G	cg22713356	chr15:30763199	NA	1.23	15.6	0.6	1.21e-43	Uric acid levels;
LUAD	cis	rs6429082	0.523	rs704718	chr1:235666159	A/T	cg26050004	chr1:235667680	B3GALNT2	0.38	6.43	0.3	3.49e-10	Adiposity;
LUAD	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.54	0.55	5.86e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg27266060	chr8:22091797	NA	0.48	8.82	0.39	3.14e-17	Hypertriglyceridemia;
LUAD	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg07570687	chr10:102243282	WNT8B	0.48	7.4	0.34	7.49e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	7.06	0.32	6.79e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73198271	0.515	rs79282666	chr8:8638225	T/C	cg01851573	chr8:8652454	MFHAS1	0.61	7.99	0.36	1.33e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg14343924	chr8:8086146	FLJ10661	-0.49	-7.87	-0.36	3e-14	Mood instability;
LUAD	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg07810366	chr2:100720526	AFF3	-0.35	-7.2	-0.33	2.7e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg00898013	chr13:113819073	PROZ	0.64	11.84	0.5	3.8e-28	Platelet distribution width;
LUAD	cis	rs250585	1.000	rs6497670	chr16:23536366	A/G	cg00143387	chr16:23521605	GGA2	-0.62	-7.64	-0.35	1.46e-13	Egg allergy;
LUAD	cis	rs2624839	0.704	rs11919418	chr3:50233215	T/G	cg14019146	chr3:50243930	SLC38A3	-0.53	-10.35	-0.45	1.54e-22	Intelligence (multi-trait analysis);
LUAD	trans	rs12517041	1.000	rs16899396	chr5:23304911	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.57	-0.3	1.48e-10	Calcium levels;
LUAD	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg14668632	chr7:2872130	GNA12	-0.76	-14.2	-0.57	1.09e-37	Height;
LUAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg11965913	chr1:205819406	PM20D1	0.52	8.5	0.38	3.25e-16	Parkinson's disease;
LUAD	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg18252515	chr7:66147081	NA	-0.64	-6.93	-0.32	1.6e-11	Diabetic kidney disease;
LUAD	cis	rs9392556	0.829	rs617790	chr6:4115758	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.4	-6.88	-0.32	2.14e-11	Blood metabolite levels;
LUAD	cis	rs7291412	0.929	rs7289457	chr22:46456603	C/T	cg05468064	chr22:46423449	NA	0.44	8.83	0.39	2.8e-17	Dupuytren's disease;Subjective well-being;
LUAD	trans	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.54	-0.34	2.98e-13	Joint mobility (Beighton score);
LUAD	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg13319975	chr6:146136371	FBXO30	-0.61	-10.2	-0.44	5.28e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18404041	chr3:52824283	ITIH1	-0.58	-12.0	-0.5	9.42e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg18230493	chr5:56204884	C5orf35	1.06	15.76	0.61	2.43e-44	Initial pursuit acceleration;
LUAD	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	8.28	0.37	1.62e-15	Menopause (age at onset);
LUAD	cis	rs9863	0.861	rs4765219	chr12:124440110	G/T	cg17723958	chr12:124429295	CCDC92	-0.41	-6.85	-0.32	2.56e-11	White blood cell count;
LUAD	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg21535942	chr1:75199100	CRYZ;TYW3	0.46	7.57	0.35	2.29e-13	Resistin levels;
LUAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg00450029	chr8:599525	NA	0.79	8.01	0.36	1.15e-14	IgG glycosylation;
LUAD	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg06214716	chr4:10118677	WDR1	-0.43	-6.8	-0.31	3.68e-11	Bone mineral density;
LUAD	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg10518543	chr12:38710700	ALG10B	0.42	6.44	0.3	3.26e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.41	-6.95	-0.32	1.38e-11	Colorectal cancer;
LUAD	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg09184832	chr6:79620586	NA	-0.52	-9.75	-0.43	2.23e-20	Intelligence (multi-trait analysis);
LUAD	trans	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg02569823	chr6:5851330	NA	0.41	6.63	0.31	1.04e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs2485376	0.967	rs4919621	chr10:103998671	A/T	cg20641465	chr10:103991465	PITX3	-0.57	-10.59	-0.46	2.04e-23	QT interval;
LUAD	cis	rs4819852	0.958	rs2238787	chr22:19976406	G/A	cg07821417	chr22:19972146	ARVCF	0.4	7.64	0.35	1.45e-13	Pulse pressure;
LUAD	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg17689763	chr4:710664	PCGF3	-0.57	-9.87	-0.43	8.24e-21	White blood cell count;
LUAD	cis	rs354225	0.584	rs11898033	chr2:54821518	G/A	cg01766943	chr2:54829624	SPTBN1	0.38	7.18	0.33	3.16e-12	Schizophrenia;
LUAD	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg20933634	chr6:27740509	NA	0.42	6.8	0.31	3.51e-11	Parkinson's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08448040	chr3:13521693	HDAC11	-0.44	-6.9	-0.32	1.86e-11	Height;
LUAD	cis	rs7512552	0.839	rs1694369	chr1:150351101	A/G	cg15654264	chr1:150340011	RPRD2	0.61	11.63	0.49	2.59e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4842666	0.915	rs11105376	chr12:90088768	G/A	cg00757033	chr12:89920650	WDR51B	0.54	6.92	0.32	1.72e-11	Blood pressure;
LUAD	cis	rs68170813	0.652	rs17481621	chr7:107113852	G/C	cg02696742	chr7:106810147	HBP1	-0.76	-8.99	-0.4	8.04e-18	Coronary artery disease;
LUAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.49	-0.34	4.12e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg06484146	chr7:12443880	VWDE	-0.54	-6.98	-0.32	1.12e-11	Coronary artery disease;
LUAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg11301795	chr4:187892539	NA	-0.77	-15.57	-0.6	1.62e-43	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.81	11.72	0.5	1.13e-27	Smoking behavior;
LUAD	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg05132306	chr1:1846340	CALML6	0.35	7.64	0.35	1.49e-13	Body mass index;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg02584489	chr3:37493436	ITGA9	-0.41	-6.62	-0.31	1.08e-10	Vertical cup-disc ratio;
LUAD	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg02527881	chr3:46936655	PTH1R	0.4	7.79	0.35	5.25e-14	Colorectal cancer;
LUAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-8.12	-0.37	5.13e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6684514	1.000	rs10908496	chr1:156264000	G/A	cg16558208	chr1:156270281	VHLL	0.53	9.64	0.42	4.98e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg11663144	chr21:46675770	NA	-0.48	-9.21	-0.41	1.52e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00149659	chr3:10157352	C3orf10	-0.53	-7.32	-0.34	1.29e-12	Alzheimer's disease;
LUAD	cis	rs3772130	0.962	rs6791046	chr3:121394707	A/G	cg20356878	chr3:121714668	ILDR1	0.48	7.34	0.34	1.09e-12	Cognitive performance;
LUAD	cis	rs79839061	0.536	rs3775128	chr4:885828	T/C	cg07828340	chr4:882639	GAK	0.58	7.06	0.32	6.97e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs34245846	0.769	rs12058931	chr1:154825093	C/A	cg09359103	chr1:154839909	KCNN3	0.51	7.55	0.34	2.66e-13	Atrial fibrillation;
LUAD	cis	rs7759001	0.948	rs11966173	chr6:27391862	T/C	cg18711553	chr6:27366782	ZNF391	0.4	6.49	0.3	2.36e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg04731861	chr2:219085781	ARPC2	0.23	7.02	0.32	8.92e-12	Colorectal cancer;
LUAD	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.71	-12.16	-0.51	2.16e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	trans	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg02030672	chr11:45687055	CHST1	0.45	8.25	0.37	1.96e-15	Obesity-related traits;
LUAD	cis	rs36051895	0.695	rs4527935	chr9:5016455	A/T	cg02405213	chr9:5042618	JAK2	-0.5	-6.87	-0.32	2.28e-11	Pediatric autoimmune diseases;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06610368	chr5:86564371	RASA1	-0.55	-6.56	-0.3	1.55e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.72	-0.35	8.21e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.68	-0.39	8.5e-17	Alzheimer's disease (late onset);
LUAD	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg20701182	chr2:24300061	SF3B14	0.65	7.06	0.32	6.81e-12	Lymphocyte counts;
LUAD	cis	rs8062405	1.000	rs8061590	chr16:28895130	A/G	cg00204512	chr16:28754710	NA	0.32	6.73	0.31	5.65e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs68170813	0.559	rs17427158	chr7:106824259	G/T	cg23024343	chr7:107201750	COG5	0.49	7.09	0.33	5.65e-12	Coronary artery disease;
LUAD	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg13902645	chr11:5959945	NA	-0.57	-10.09	-0.44	1.39e-21	DNA methylation (variation);
LUAD	cis	rs240764	0.817	rs6905221	chr6:101151537	G/A	cg09795085	chr6:101329169	ASCC3	-0.44	-7.57	-0.35	2.39e-13	Neuroticism;
LUAD	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg06784218	chr1:46089804	CCDC17	0.54	11.62	0.49	2.76e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg27284194	chr4:1044797	NA	0.7	10.3	0.45	2.49e-22	Recombination rate (females);
LUAD	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.59e-12	Breast cancer;
LUAD	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg23982607	chr1:1823379	GNB1	0.6	10.7	0.46	8.04e-24	Body mass index;
LUAD	cis	rs713477	0.935	rs12888181	chr14:55906082	A/C	cg13175173	chr14:55914753	NA	-0.33	-6.94	-0.32	1.49e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg19912559	chr1:40204330	PPIE	0.57	9.66	0.43	4.34e-20	Blood protein levels;
LUAD	cis	rs77861329	1.000	rs123681	chr3:52209320	A/G	cg08692210	chr3:52188851	WDR51A	0.86	8.23	0.37	2.42e-15	Macrophage inflammatory protein 1b levels;
LUAD	trans	rs1547374	0.921	rs11700899	chr21:43780426	G/A	cg09521743	chr10:75415752	SYNPO2L	-0.42	-6.92	-0.32	1.68e-11	Pancreatic cancer;
LUAD	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg18306943	chr3:40428807	ENTPD3	0.43	7.22	0.33	2.37e-12	Renal cell carcinoma;
LUAD	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg17652424	chr22:38574118	PLA2G6	-0.33	-9.77	-0.43	1.81e-20	Cutaneous nevi;
LUAD	cis	rs2274273	0.870	rs1109170	chr14:55785788	A/C	cg04306507	chr14:55594613	LGALS3	0.41	8.5	0.38	3.26e-16	Protein biomarker;
LUAD	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg25985355	chr7:65971099	NA	-0.37	-6.81	-0.31	3.28e-11	Aortic root size;
LUAD	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg15017067	chr4:17643749	FAM184B	0.37	7.23	0.33	2.25e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg03690763	chr11:133734501	NA	0.32	7.77	0.35	6.2e-14	Childhood ear infection;
LUAD	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg27572855	chr1:25598939	RHD	0.54	11.68	0.49	1.65e-27	Erythrocyte sedimentation rate;
LUAD	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg07636037	chr3:49044803	WDR6	-0.55	-8.97	-0.4	9.98e-18	Menarche (age at onset);
LUAD	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg08601574	chr20:25228251	PYGB	0.47	8.88	0.4	1.93e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs68092024	0.704	rs792832	chr3:99474862	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.52	-9.7	-0.43	3.22e-20	Cleft lip with or without cleft palate;
LUAD	cis	rs7705042	0.865	rs249641	chr5:141525305	A/G	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.91	-0.32	1.77e-11	Asthma;
LUAD	cis	rs74417235	0.684	rs71590150	chr5:154060512	A/T	cg08754654	chr5:154026448	NA	0.47	8.03	0.36	1.01e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg11021810	chr14:89720620	FOXN3	0.47	7.47	0.34	4.67e-13	Vertical cup-disc ratio;
LUAD	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg05283184	chr6:79620031	NA	-0.59	-11.92	-0.5	1.93e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs926938	0.783	rs10858053	chr1:115297374	A/G	cg12756093	chr1:115239321	AMPD1	-0.4	-7.08	-0.33	5.94e-12	Autism;
LUAD	cis	rs10193935	0.901	rs59890734	chr2:42595662	G/A	cg27598129	chr2:42591480	NA	-0.8	-9.88	-0.43	7.73e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg14416269	chr4:6271139	WFS1	0.61	12.4	0.52	2.51e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs59698941	0.550	rs11748063	chr5:132200943	C/T	cg14825688	chr5:132208181	LEAP2	-0.53	-10.81	-0.47	3.29e-24	Apolipoprotein A-IV levels;
LUAD	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg00383909	chr3:49044727	WDR6	0.77	7.67	0.35	1.19e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg23803603	chr1:2058230	PRKCZ	0.41	6.6	0.31	1.22e-10	Height;
LUAD	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs1595825	0.891	rs7580003	chr2:198517893	C/T	cg10547527	chr2:198650123	BOLL	-0.54	-7.62	-0.35	1.65e-13	Ulcerative colitis;
LUAD	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg02176678	chr2:219576539	TTLL4	0.75	15.22	0.59	4.86e-42	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9715521	0.900	rs4860450	chr4:59827819	G/A	cg11281224	chr4:60001000	NA	-0.57	-9.68	-0.43	3.81e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg19077165	chr18:44547161	KATNAL2	0.41	7.24	0.33	2.17e-12	Personality dimensions;
LUAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg18621852	chr3:10150065	C3orf24	0.48	8.32	0.38	1.2e-15	Alzheimer's disease;
LUAD	cis	rs7072216	0.763	rs7909822	chr10:100172035	A/C	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.76	-0.39	4.88e-17	Metabolite levels;
LUAD	cis	rs8064454	0.764	rs11658063	chr17:36103872	C/G	cg04198914	chr17:36106025	HNF1B	0.42	8.59	0.39	1.74e-16	Prostate cancer;
LUAD	cis	rs4148087	0.860	rs1893589	chr21:43612531	C/T	cg08841829	chr21:43638893	ABCG1	-0.59	-7.7	-0.35	9.9e-14	Eating disorder in bipolar disorder;
LUAD	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg01191920	chr7:158217561	PTPRN2	-0.73	-16.7	-0.63	1.78e-48	Obesity-related traits;
LUAD	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg05754148	chr16:3507555	NAT15	-0.39	-6.64	-0.31	9.53e-11	Body mass index (adult);
LUAD	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg07917127	chr4:99064746	C4orf37	-0.51	-8.23	-0.37	2.35e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4845570	1.000	rs6673002	chr1:151743275	G/T	cg07092448	chr1:151763213	TDRKH	0.73	8.62	0.39	1.34e-16	Coronary artery disease;
LUAD	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg02782426	chr3:40428986	ENTPD3	-0.38	-8.31	-0.37	1.33e-15	Renal cell carcinoma;
LUAD	cis	rs2224391	0.628	rs2753232	chr6:5250765	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.61	-9.29	-0.41	7.97e-19	Height;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg18861140	chr18:3449789	TGIF1	-0.44	-6.82	-0.31	3.25e-11	Vertical cup-disc ratio;
LUAD	cis	rs2692947	0.726	rs13019188	chr2:96774199	A/G	cg23100626	chr2:96804247	ASTL	-0.34	-9.28	-0.41	8.9e-19	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs1448094	0.872	rs4919777	chr12:86358491	C/T	cg00310523	chr12:86230176	RASSF9	0.37	7.84	0.36	3.66e-14	Major depressive disorder;
LUAD	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg13180566	chr4:1052158	NA	-0.38	-6.54	-0.3	1.75e-10	Recombination rate (females);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg11979294	chr10:103880575	LDB1	-0.39	-6.65	-0.31	9.31e-11	Schizophrenia;
LUAD	cis	rs12545109	0.700	rs2670045	chr8:57393695	A/G	cg07776626	chr8:57350775	NA	-0.62	-9.2	-0.41	1.61e-18	Obesity-related traits;
LUAD	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg05457628	chr5:178986728	RUFY1	0.56	9.58	0.42	8.69e-20	Lung cancer;
LUAD	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.35e-11	Breast cancer;
LUAD	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg27170947	chr2:26402098	FAM59B	0.82	11.43	0.49	1.49e-26	Gut microbiome composition (summer);
LUAD	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg08999081	chr20:33150536	PIGU	0.62	13.9	0.56	1.85e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg11494091	chr17:61959527	GH2	0.74	18.64	0.67	5.07e-57	Prudent dietary pattern;
LUAD	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.67	-10.43	-0.45	7.96e-23	Chronic sinus infection;
LUAD	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg14664628	chr15:75095509	CSK	-0.58	-9.19	-0.41	1.78e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs7937890	0.532	rs2575832	chr11:14488810	A/G	cg22961513	chr11:14280813	SPON1	-0.38	-7.3	-0.33	1.46e-12	Mitochondrial DNA levels;
LUAD	trans	rs587242	0.528	rs12086822	chr1:97205775	A/G	cg10631902	chr5:14652156	NA	0.39	6.65	0.31	9.33e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg12311346	chr5:56204834	C5orf35	-0.91	-13.39	-0.55	2.46e-34	Initial pursuit acceleration;
LUAD	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg26384229	chr12:38710491	ALG10B	0.42	7.19	0.33	2.9e-12	Heart rate;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg23097686	chr12:98910128	TMPO;LOC100128191	-0.4	-6.74	-0.31	5.06e-11	Schizophrenia;
LUAD	cis	rs11048434	0.761	rs12827055	chr12:9130861	G/T	cg26114124	chr12:9217669	LOC144571	0.38	6.97	0.32	1.24e-11	Sjögren's syndrome;
LUAD	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg19767477	chr5:127420684	SLC12A2	-0.44	-6.49	-0.3	2.41e-10	Ileal carcinoids;
LUAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg16342193	chr10:102329863	NA	-0.39	-6.95	-0.32	1.39e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7536201	1.000	rs7545113	chr1:25301477	T/A	cg23273869	chr1:25296894	NA	-0.38	-7.83	-0.36	3.94e-14	Psoriasis vulgaris;
LUAD	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18876405	chr7:65276391	NA	-0.42	-6.63	-0.31	1.02e-10	Aortic root size;
LUAD	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg02038168	chr22:39784481	NA	-0.58	-10.2	-0.44	5.49e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs1873147	0.569	rs8029221	chr15:63308583	C/T	cg21584241	chr15:63341463	TPM1	0.42	6.38	0.3	4.53e-10	Orofacial clefts;
LUAD	cis	rs4253772	0.530	rs9615990	chr22:46804154	G/A	cg00784671	chr22:46762841	CELSR1	-0.59	-6.91	-0.32	1.79e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg13334819	chr7:99746414	C7orf59	-0.7	-10.89	-0.47	1.65e-24	Coronary artery disease;
LUAD	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg25036284	chr2:26402008	FAM59B	-0.81	-11.67	-0.49	1.82e-27	Gut microbiome composition (summer);
LUAD	cis	rs4523957	0.788	rs11651451	chr17:2098417	C/T	cg16513277	chr17:2031491	SMG6	-0.73	-13.63	-0.55	2.58e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7216064	0.954	rs8079291	chr17:65887622	A/G	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs3774830	0.811	rs2526306	chr4:5432419	T/G	cg26943120	chr4:5472116	STK32B	-0.35	-6.91	-0.32	1.78e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs8002861	0.626	rs9533634	chr13:44397815	T/C	cg17145862	chr1:211918768	LPGAT1	-0.58	-11.28	-0.48	5.81e-26	Leprosy;
LUAD	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg06547715	chr2:218990976	CXCR2	0.44	10.39	0.45	1.09e-22	Ulcerative colitis;
LUAD	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg22920501	chr2:26401640	FAM59B	-0.81	-11.47	-0.49	1.1e-26	Gut microbiome composition (summer);
LUAD	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.55	0.6	1.85e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2692947	0.537	rs1345917	chr2:96200603	A/C	cg23100626	chr2:96804247	ASTL	0.34	8.45	0.38	4.89e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg08601574	chr20:25228251	PYGB	0.47	8.79	0.39	3.85e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs12042938	0.507	rs1655301	chr1:231731730	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.41	-7.23	-0.33	2.23e-12	Neuranatomic and neurocognitive phenotypes;
LUAD	cis	rs3789045	0.866	rs61817482	chr1:204570347	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.43	-7.38	-0.34	8.66e-13	Educational attainment (college completion);
LUAD	cis	rs3754214	0.823	rs494041	chr1:150270026	T/C	cg15654264	chr1:150340011	RPRD2	-0.35	-6.4	-0.3	4.13e-10	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7147624	1.000	rs8021889	chr14:66214811	A/G	cg03016385	chr14:66212404	NA	-0.58	-6.96	-0.32	1.31e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg00204512	chr16:28754710	NA	0.32	6.78	0.31	4.12e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg15704280	chr7:45808275	SEPT13	0.63	8.08	0.37	6.77e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7116495	1.000	rs12283462	chr11:71835406	T/G	cg07596299	chr11:71824057	C11orf51	0.75	6.51	0.3	2.2e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg10755058	chr3:40428713	ENTPD3	-0.44	-8.59	-0.39	1.66e-16	Renal cell carcinoma;
LUAD	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26314531	chr2:26401878	FAM59B	0.75	10.65	0.46	1.26e-23	Gut microbiome composition (summer);
LUAD	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.95	0.36	1.73e-14	Morning vs. evening chronotype;
LUAD	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg15017067	chr4:17643749	FAM184B	0.34	6.43	0.3	3.37e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg24675056	chr1:15929824	NA	0.48	8.43	0.38	5.39e-16	Systolic blood pressure;
LUAD	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-8.48	-0.38	3.94e-16	Neutrophil percentage of white cells;
LUAD	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg13722127	chr7:150037890	RARRES2	0.42	6.87	0.32	2.29e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg15123519	chr2:136567270	LCT	0.4	7.37	0.34	9.22e-13	Mosquito bite size;
LUAD	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg21427119	chr20:30132790	HM13	-0.62	-9.46	-0.42	2.14e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg14092988	chr3:52407081	DNAH1	0.45	9.01	0.4	7.17e-18	Bipolar disorder;
LUAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	10.57	0.46	2.53e-23	Hip circumference adjusted for BMI;
LUAD	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	9.2	0.41	1.65e-18	Lung cancer in ever smokers;
LUAD	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg07570687	chr10:102243282	WNT8B	0.42	6.43	0.3	3.42e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg08280861	chr8:58055591	NA	0.66	7.36	0.34	9.9e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.88	-0.4	1.86e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg24818145	chr4:99064322	C4orf37	0.39	6.41	0.3	3.96e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg05968270	chr1:65533502	NA	0.46	7.59	0.35	2.03e-13	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg06713675	chr4:122721982	EXOSC9	-0.85	-18.09	-0.66	1.32e-54	Type 2 diabetes;
LUAD	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-10.97	-0.47	8.57e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg11707310	chr1:2537719	MMEL1	-0.4	-8.5	-0.38	3.34e-16	Ulcerative colitis;
LUAD	cis	rs2066819	1.000	rs116849218	chr12:56683975	C/T	cg26714650	chr12:56694279	CS	-0.86	-7.23	-0.33	2.25e-12	Psoriasis vulgaris;
LUAD	cis	rs67981189	0.529	rs2526872	chr14:71384885	C/T	cg15910301	chr14:71632612	NA	-0.42	-6.55	-0.3	1.65e-10	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1894633	0.574	rs17277918	chr1:172322620	A/G	cg13446689	chr1:172328377	DNM3	0.42	6.75	0.31	4.96e-11	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2580764	0.624	rs12713284	chr2:55228861	G/A	cg09592903	chr2:55203963	RTN4	-0.46	-10.52	-0.46	3.69e-23	Mean platelet volume;
LUAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg21724239	chr8:58056113	NA	0.75	9.71	0.43	2.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg08132940	chr7:1081526	C7orf50	-0.79	-10.66	-0.46	1.14e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06873352	chr17:61820015	STRADA	0.81	18.08	0.66	1.46e-54	Prudent dietary pattern;
LUAD	cis	rs738321	0.757	rs3788536	chr22:38534209	C/T	cg17652424	chr22:38574118	PLA2G6	-0.24	-6.41	-0.3	3.88e-10	Breast cancer;
LUAD	cis	rs117623576	0.941	rs16932939	chr10:32407862	T/C	cg03047570	chr10:32398778	NA	-0.89	-11.33	-0.48	3.64e-26	Anti-saccade response;
LUAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg03188948	chr7:1209495	NA	0.81	9.86	0.43	9.06e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg06046430	chr4:77819534	ANKRD56	0.54	8.63	0.39	1.22e-16	Emphysema distribution in smoking;
LUAD	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	6.63	0.31	1.03e-10	Rheumatoid arthritis;
LUAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg04025307	chr7:1156635	C7orf50	0.9	17.71	0.65	6.67e-53	Longevity;Endometriosis;
LUAD	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg25767906	chr1:53392781	SCP2	0.42	7.89	0.36	2.53e-14	Monocyte count;
LUAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.3	0.54	5.87e-34	Prudent dietary pattern;
LUAD	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg20469991	chr17:27169893	C17orf63	-0.51	-6.43	-0.3	3.52e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs68170813	0.641	rs74451547	chr7:107078435	A/C	cg02696742	chr7:106810147	HBP1	-0.79	-10.33	-0.45	1.84e-22	Coronary artery disease;
LUAD	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.98	-0.32	1.14e-11	Height;
LUAD	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg15485101	chr11:133734466	NA	0.39	8.67	0.39	9.39e-17	Childhood ear infection;
LUAD	trans	rs2797160	1.000	rs1777226	chr6:126017691	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.55	8.63	0.39	1.29e-16	Endometrial cancer;
LUAD	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg18404041	chr3:52824283	ITIH1	0.4	7.24	0.33	2.09e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg10729496	chr3:10149963	C3orf24	0.55	8.96	0.4	1.06e-17	Alzheimer's disease;
LUAD	trans	rs1493916	0.748	rs2040203	chr18:31307420	G/T	cg27147174	chr7:100797783	AP1S1	-0.61	-10.5	-0.45	4.42e-23	Life satisfaction;
LUAD	cis	rs7903847	0.642	rs11817875	chr10:99158414	G/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.56	-0.35	2.5e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg05084668	chr3:125655381	ALG1L	-0.89	-11.69	-0.49	1.44e-27	Blood pressure (smoking interaction);
LUAD	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-7.39	-0.34	8.05e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs938554	0.694	rs4697700	chr4:9945792	C/G	cg11266682	chr4:10021025	SLC2A9	0.4	7.17	0.33	3.41e-12	Blood metabolite levels;
LUAD	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg23533926	chr12:111358616	MYL2	-0.4	-6.77	-0.31	4.23e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9479482	0.935	rs9479513	chr6:150367320	G/T	cg08316699	chr6:150357289	NA	0.35	7.06	0.32	6.81e-12	Alopecia areata;
LUAD	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.71	-0.39	6.94e-17	Menopause (age at onset);
LUAD	cis	rs7116495	1.000	rs116781589	chr11:71825006	G/T	cg07596299	chr11:71824057	C11orf51	0.78	6.44	0.3	3.19e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24308560	chr3:49941425	MST1R	-0.59	-9.89	-0.43	7.08e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg27572855	chr1:25598939	RHD	0.59	13.25	0.54	9.03e-34	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-7.89	-0.36	2.62e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs6906287	0.647	rs2077162	chr6:118687469	G/A	cg05564266	chr6:118973597	C6orf204	0.34	7.11	0.33	4.99e-12	Electrocardiographic conduction measures;
LUAD	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.58	-12.44	-0.52	1.75e-30	Monocyte percentage of white cells;
LUAD	cis	rs9512730	0.906	rs4771136	chr13:28070769	C/G	cg22138327	chr13:27999177	GTF3A	0.91	10.39	0.45	1.13e-22	Schizophrenia;
LUAD	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.77	0.31	4.21e-11	Rheumatoid arthritis;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg26649251	chr19:44598564	ZNF224	-0.39	-6.52	-0.3	1.97e-10	Subcortical brain region volumes;
LUAD	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg12863693	chr15:85201151	NMB	0.42	7.53	0.34	3.1e-13	Schizophrenia;
LUAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00166722	chr3:10149974	C3orf24	0.63	10.42	0.45	8.88e-23	Alzheimer's disease;
LUAD	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.54	-0.46	3.14e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg27411982	chr8:10470053	RP1L1	0.37	6.6	0.31	1.24e-10	Retinal vascular caliber;
LUAD	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg14345882	chr6:26364793	BTN3A2	0.7	7.1	0.33	5.18e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6714710	0.603	rs6746768	chr2:98466647	C/T	cg26665480	chr2:98280029	ACTR1B	0.5	8.25	0.37	2.05e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg01475377	chr6:109611718	NA	-0.48	-8.75	-0.39	5.18e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs9560113	0.508	rs2774425	chr13:112235077	A/G	cg10483660	chr13:112241077	NA	-0.47	-9.63	-0.42	5.54e-20	Menarche (age at onset);
LUAD	cis	rs7173743	0.756	rs12903613	chr15:79129076	G/T	cg00540400	chr15:79124168	NA	0.38	7.82	0.36	4.38e-14	Coronary artery disease;
LUAD	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg00701064	chr4:6280414	WFS1	0.67	14.65	0.58	1.33e-39	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs4604732	0.631	rs11490199	chr1:247625737	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg00745463	chr17:30367425	LRRC37B	-0.78	-9.58	-0.42	8.43e-20	Hip circumference adjusted for BMI;
LUAD	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.55	-9.77	-0.43	1.78e-20	Melanoma;
LUAD	cis	rs240764	0.658	rs12212435	chr6:101196080	T/C	cg09795085	chr6:101329169	ASCC3	-0.47	-8.38	-0.38	7.87e-16	Neuroticism;
LUAD	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg18305652	chr10:134549665	INPP5A	0.58	12.06	0.51	5.23e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg16325326	chr1:53192061	ZYG11B	0.56	9.91	0.43	5.68e-21	Monocyte count;
LUAD	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg15181151	chr6:150070149	PCMT1	0.32	6.48	0.3	2.63e-10	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg03233332	chr7:66118400	NA	-0.45	-6.72	-0.31	6.04e-11	Aortic root size;
LUAD	cis	rs68170813	0.559	rs77422419	chr7:106957932	A/G	cg02696742	chr7:106810147	HBP1	-0.76	-10.41	-0.45	9.42e-23	Coronary artery disease;
LUAD	trans	rs7395662	1.000	rs6485882	chr11:48592435	C/G	cg15704280	chr7:45808275	SEPT13	0.42	7.13	0.33	4.32e-12	HDL cholesterol;
LUAD	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg27532560	chr4:187881888	NA	-0.42	-8.41	-0.38	6.5e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg26384229	chr12:38710491	ALG10B	-0.4	-6.76	-0.31	4.7e-11	Heart rate;
LUAD	cis	rs7831492	0.564	rs11787479	chr8:41613496	A/G	cg17182837	chr8:41585554	ANK1	-0.39	-8.31	-0.37	1.34e-15	Colorectal cancer;
LUAD	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg09085632	chr11:111637200	PPP2R1B	0.64	9.9	0.43	6.6e-21	Primary sclerosing cholangitis;
LUAD	cis	rs72901758	0.669	rs17641275	chr17:76247796	A/C	cg25512537	chr17:76250053	NA	-0.32	-6.59	-0.31	1.32e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg11645453	chr3:52864694	ITIH4	0.34	6.61	0.31	1.13e-10	Bipolar disorder;
LUAD	cis	rs870825	0.655	rs6844929	chr4:185653809	C/G	cg04058563	chr4:185651563	MLF1IP	-0.8	-11.64	-0.49	2.41e-27	Blood protein levels;
LUAD	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg04398451	chr17:18023971	MYO15A	-0.92	-18.49	-0.67	2.29e-56	Total body bone mineral density;
LUAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg18402987	chr7:1209562	NA	0.43	6.9	0.32	1.89e-11	Longevity;Endometriosis;
LUAD	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg23815491	chr16:72088622	HP	0.52	9.68	0.43	3.73e-20	Fibrinogen levels;
LUAD	cis	rs8049603	0.812	rs12149882	chr16:23195924	T/G	cg09552652	chr16:23197569	SCNN1G	0.36	6.4	0.3	4.12e-10	Multiple sclerosis;
LUAD	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg09835421	chr16:68378352	PRMT7	-0.74	-8.48	-0.38	3.69e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg00933542	chr6:150070202	PCMT1	0.41	8.55	0.38	2.23e-16	Lung cancer;
LUAD	cis	rs2282300	0.956	rs2685286	chr11:30381588	G/A	cg25418670	chr11:30344373	C11orf46	-0.47	-6.39	-0.3	4.44e-10	Morning vs. evening chronotype;
LUAD	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg00666640	chr1:248458726	OR2T12	0.31	7.55	0.34	2.65e-13	Common traits (Other);
LUAD	cis	rs6076065	0.775	rs6083114	chr20:23379528	G/T	cg11657817	chr20:23433608	CST11	0.57	12.04	0.51	6.46e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs208520	0.690	rs866452	chr6:66849936	A/T	cg07460842	chr6:66804631	NA	-0.99	-15.59	-0.6	1.25e-43	Exhaled nitric oxide output;
LUAD	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg19318889	chr4:1322082	MAEA	0.45	7.31	0.33	1.37e-12	Obesity-related traits;
LUAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00149659	chr3:10157352	C3orf10	0.57	7.35	0.34	1.04e-12	Alzheimer's disease;
LUAD	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg11266682	chr4:10021025	SLC2A9	0.68	15.8	0.61	1.55e-44	Bone mineral density;
LUAD	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg07930552	chr6:133119739	C6orf192	0.68	8.2	0.37	2.81e-15	Type 2 diabetes nephropathy;
LUAD	cis	rs6076065	0.723	rs6137909	chr20:23344728	A/G	cg11657817	chr20:23433608	CST11	0.5	9.14	0.41	2.6e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg03859395	chr2:55845619	SMEK2	0.74	13.91	0.56	1.8e-36	Metabolic syndrome;
LUAD	trans	rs11039798	0.925	rs7482967	chr11:48613527	T/A	cg03929089	chr4:120376271	NA	0.56	6.6	0.31	1.24e-10	Axial length;
LUAD	cis	rs2637266	0.935	rs2579775	chr10:78401677	G/A	cg18941641	chr10:78392320	NA	0.34	7.04	0.32	7.75e-12	Pulmonary function;
LUAD	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg09658497	chr7:2847517	GNA12	-0.44	-8.02	-0.36	1.04e-14	Height;
LUAD	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18876405	chr7:65276391	NA	-0.43	-6.82	-0.31	3.17e-11	Aortic root size;
LUAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13732083	chr21:47605072	C21orf56	0.47	7.76	0.35	6.58e-14	Testicular germ cell tumor;
LUAD	cis	rs4919694	1.000	rs12257935	chr10:104803062	C/A	cg04362960	chr10:104952993	NT5C2	0.73	7.86	0.36	3.28e-14	Arsenic metabolism;
LUAD	cis	rs3739034	0.639	rs4954177	chr2:135543933	A/T	cg12500956	chr2:135428796	TMEM163	0.37	6.63	0.31	1.05e-10	Gut microbiome composition (winter);
LUAD	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg04455712	chr21:45112962	RRP1B	0.47	9.77	0.43	1.9e-20	Mean corpuscular volume;
LUAD	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg13606994	chr1:44402422	ARTN	-0.37	-7.24	-0.33	2.09e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs78707713	0.891	rs17490626	chr10:71218646	G/C	cg12610070	chr10:71211762	TSPAN15	-0.4	-6.96	-0.32	1.33e-11	Venous thromboembolism;
LUAD	cis	rs657075	0.697	rs13184379	chr5:131678145	G/A	cg21138405	chr5:131827807	IRF1	0.54	6.54	0.3	1.81e-10	Rheumatoid arthritis;
LUAD	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg27144592	chr16:783916	NARFL	0.36	6.44	0.3	3.25e-10	Height;
LUAD	cis	rs7633770	0.786	rs1607737	chr3:46681846	G/C	cg11219411	chr3:46661640	NA	0.58	12.9	0.53	2.49e-32	Coronary artery disease;
LUAD	cis	rs6500395	0.963	rs12919278	chr16:48692537	A/G	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.07e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1045714	0.895	rs2293405	chr7:2644607	G/T	cg24848437	chr7:2645542	IQCE	0.69	7.96	0.36	1.59e-14	Urate levels in lean individuals;
LUAD	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg05082376	chr22:42548792	NA	-0.51	-9.21	-0.41	1.58e-18	Schizophrenia;
LUAD	cis	rs11030122	0.547	rs10835324	chr11:3954928	G/C	cg18678763	chr11:4115507	RRM1	-0.37	-6.37	-0.3	4.96e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs11209185	0.602	rs6662448	chr1:68447267	G/A	cg22082780	chr1:68452167	NA	0.38	7.51	0.34	3.44e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg09835421	chr16:68378352	PRMT7	-0.97	-10.91	-0.47	1.44e-24	Schizophrenia;
LUAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24503407	chr1:205819492	PM20D1	0.85	18.99	0.68	1.33e-58	Menarche (age at onset);
LUAD	cis	rs6445967	0.530	rs1126737	chr3:58413405	T/C	cg13750441	chr3:58318267	PXK	-0.31	-6.48	-0.3	2.55e-10	Platelet count;
LUAD	cis	rs5167	0.601	rs892131	chr19:45496996	C/T	cg09555818	chr19:45449301	APOC2	0.36	6.68	0.31	7.53e-11	Blood protein levels;
LUAD	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg25753631	chr6:25732923	NA	-0.37	-6.43	-0.3	3.49e-10	Iron status biomarkers;
LUAD	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg18827107	chr12:86230957	RASSF9	0.53	9.57	0.42	9.33e-20	Major depressive disorder;
LUAD	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.4	6.7	0.31	6.69e-11	Total body bone mineral density;
LUAD	cis	rs62229266	0.563	rs6517325	chr21:37434978	T/C	cg12218747	chr21:37451666	NA	-0.41	-6.96	-0.32	1.28e-11	Mitral valve prolapse;
LUAD	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg14671364	chr1:107599128	PRMT6	0.53	9.06	0.4	4.9e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg22963979	chr7:1858916	MAD1L1	0.49	8.51	0.38	3.02e-16	Bipolar disorder and schizophrenia;
LUAD	trans	rs800082	0.698	rs800077	chr3:144349940	A/G	cg24215973	chr2:240111563	HDAC4	-0.68	-10.9	-0.47	1.53e-24	Smoking behavior;
LUAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00149659	chr3:10157352	C3orf10	0.85	11.71	0.49	1.22e-27	Alzheimer's disease;
LUAD	trans	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg14917512	chr19:3094685	GNA11	0.56	6.76	0.31	4.64e-11	Diabetic kidney disease;
LUAD	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg04842962	chr6:43655489	MRPS18A	0.87	13.74	0.56	8.93e-36	IgG glycosylation;
LUAD	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23158103	chr7:148848205	ZNF398	-0.63	-11.48	-0.49	9.87e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs12912251	1.000	rs71403553	chr15:38989121	C/A	cg01338139	chr15:38987640	C15orf53	-0.59	-9.29	-0.41	7.95e-19	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg02049041	chr17:27085579	C17orf63	0.66	8.64	0.39	1.14e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1595825	0.838	rs73058854	chr2:198885060	G/A	cg10547527	chr2:198650123	BOLL	-0.52	-7.06	-0.32	6.86e-12	Ulcerative colitis;
LUAD	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg23533926	chr12:111358616	MYL2	-0.4	-6.84	-0.32	2.87e-11	Extrinsic epigenetic age acceleration;
LUAD	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	8.3	0.37	1.44e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg14582100	chr15:45693742	SPATA5L1	0.43	8.59	0.39	1.65e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs28602670	1	rs28602670	chr15:78768167	C/G	cg18825076	chr15:78729989	IREB2	0.54	7.62	0.35	1.64e-13	Post bronchodilator FEV1;
LUAD	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg06641503	chr3:48959341	ARIH2	-0.35	-6.53	-0.3	1.92e-10	Menarche (age at onset);
LUAD	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg13010199	chr12:38710504	ALG10B	0.4	6.56	0.3	1.58e-10	Bladder cancer;
LUAD	cis	rs1032833	0.732	rs78758361	chr2:180108616	C/A	cg23883738	chr2:179974586	SESTD1	-0.73	-8.09	-0.37	6.38e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg23978390	chr7:1156363	C7orf50	0.55	7.75	0.35	7e-14	Bronchopulmonary dysplasia;
LUAD	trans	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg13565492	chr6:43139072	SRF	-0.75	-10.46	-0.45	6.44e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.62	0.31	1.09e-10	Depression;
LUAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.31e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg05590025	chr7:65112418	INTS4L2	-0.7	-7.53	-0.34	3.06e-13	Diabetic kidney disease;
LUAD	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg18876405	chr7:65276391	NA	0.4	6.36	0.3	5.4e-10	Aortic root size;
LUAD	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.6	-11.31	-0.48	4.16e-26	Longevity;Endometriosis;
LUAD	cis	rs9796	0.870	rs12910027	chr15:41283817	A/T	cg18705301	chr15:41695430	NDUFAF1	0.39	7.31	0.34	1.32e-12	Menopause (age at onset);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19683962	chr4:108852534	CYP2U1	-0.56	-6.86	-0.32	2.51e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.41	-7.08	-0.33	6.19e-12	Longevity;Endometriosis;
LUAD	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg17063962	chr7:91808500	NA	-0.67	-11.74	-0.5	9.88e-28	Breast cancer;
LUAD	cis	rs3806843	0.551	rs184996	chr5:140323773	T/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.99e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs76878669	0.538	rs4930360	chr11:66143247	T/A	cg18002602	chr11:66138449	SLC29A2	0.48	10.24	0.45	3.88e-22	Educational attainment (years of education);
LUAD	cis	rs669446	0.533	rs3862228	chr1:44196945	C/T	cg12908607	chr1:44402522	ARTN	-0.35	-6.94	-0.32	1.5e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.75	9.31	0.41	6.89e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4948275	0.550	rs7082786	chr10:63176990	C/A	cg03237606	chr10:63212265	TMEM26	-0.37	-7.55	-0.34	2.73e-13	Night sleep phenotypes;
LUAD	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg17366294	chr4:99064904	C4orf37	0.58	9.86	0.43	8.5e-21	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs10802346	0.514	rs5024440	chr1:246372608	G/C	cg13514129	chr1:39547527	MACF1	0.6	10.52	0.46	3.89e-23	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg12373951	chr3:133503437	NA	0.37	7.38	0.34	8.41e-13	Iron status biomarkers;
LUAD	cis	rs1232027	0.700	rs1650696	chr5:79951280	T/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.9	-0.36	2.36e-14	Huntington's disease progression;
LUAD	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg03859395	chr2:55845619	SMEK2	0.7	12.47	0.52	1.29e-30	Metabolic syndrome;
LUAD	cis	rs1941023	0.503	rs2233238	chr11:60145441	G/C	cg08716584	chr11:60157161	MS4A7	-0.49	-9.55	-0.42	1.07e-19	Congenital heart disease (maternal effect);
LUAD	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg23985595	chr17:80112537	CCDC57	0.41	7.49	0.34	4.06e-13	Life satisfaction;
LUAD	cis	rs41271473	0.526	rs2182202	chr1:228733959	G/C	cg10167378	chr1:228756711	NA	0.67	9.08	0.4	4.09e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg15485101	chr11:133734466	NA	-0.41	-9.08	-0.4	4.18e-18	Childhood ear infection;
LUAD	trans	rs1178968	1.000	rs3108462	chr7:72739455	T/C	cg15428835	chr7:75027521	TRIM73;TRIM74	0.5	6.38	0.3	4.77e-10	Triglyceride levels;
LUAD	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg10755058	chr3:40428713	ENTPD3	0.38	6.97	0.32	1.18e-11	Renal cell carcinoma;
LUAD	cis	rs9473147	0.543	rs4711880	chr6:47480676	A/G	cg02130027	chr6:47444894	CD2AP	0.38	7.1	0.33	5.44e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg03859395	chr2:55845619	SMEK2	0.76	14.04	0.56	4.76e-37	Metabolic syndrome;
LUAD	cis	rs55788414	0.872	rs12102958	chr16:81186207	T/A	cg06400318	chr16:81190750	PKD1L2	-0.67	-8.6	-0.39	1.56e-16	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs12760731	0.668	rs73037529	chr1:178410203	A/T	cg00404053	chr1:178313656	RASAL2	0.61	7.84	0.36	3.65e-14	Obesity-related traits;
LUAD	cis	rs10848704	0.956	rs10848703	chr12:2882250	C/T	cg19995117	chr12:2880862	NA	0.65	13.96	0.56	1.08e-36	Quantitative traits;
LUAD	trans	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.22	-0.64	9.57e-51	Exhaled nitric oxide output;
LUAD	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.88	0.32	2.13e-11	Colorectal cancer;
LUAD	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg14186256	chr22:23484241	RTDR1	0.46	7.62	0.35	1.63e-13	Bone mineral density;
LUAD	cis	rs11771526	0.551	rs1123868	chr7:32251972	C/T	cg13207630	chr7:32358064	NA	0.49	6.89	0.32	1.98e-11	Body mass index;
LUAD	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg21171335	chr12:122356390	WDR66	0.78	14.31	0.57	3.63e-38	Mean corpuscular volume;
LUAD	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg09491104	chr22:46646882	C22orf40	-0.57	-7.99	-0.36	1.27e-14	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-7.57	-0.35	2.43e-13	Joint mobility (Beighton score);
LUAD	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg18200150	chr17:30822561	MYO1D	0.67	14.15	0.57	1.72e-37	Schizophrenia;
LUAD	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg03929089	chr4:120376271	NA	-0.93	-17.47	-0.65	7.35e-52	Height;
LUAD	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.67	0.39	9.21e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6906287	0.647	rs12214483	chr6:118780146	G/C	cg05564266	chr6:118973597	C6orf204	0.34	7.18	0.33	3.1e-12	Electrocardiographic conduction measures;
LUAD	cis	rs1595825	0.891	rs1016883	chr2:198881668	A/G	cg00982548	chr2:198649783	BOLL	0.64	9.03	0.4	6.29e-18	Ulcerative colitis;
LUAD	cis	rs9287719	0.649	rs58633964	chr2:10736382	T/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.28	-0.37	1.63e-15	Prostate cancer;
LUAD	trans	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg26043149	chr18:55253948	FECH	0.97	16.07	0.62	1.08e-45	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg09436375	chr6:42928200	GNMT	-0.29	-8.28	-0.37	1.69e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1670533	1.000	rs3816474	chr4:1050653	G/A	cg13180566	chr4:1052158	NA	-0.39	-6.38	-0.3	4.68e-10	Recombination rate (females);
LUAD	cis	rs9341808	0.718	rs9448886	chr6:80825901	C/T	cg08355045	chr6:80787529	NA	0.56	10.1	0.44	1.26e-21	Sitting height ratio;
LUAD	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg02527881	chr3:46936655	PTH1R	0.44	8.42	0.38	5.72e-16	Colorectal cancer;
LUAD	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg00750074	chr16:89608354	SPG7	-0.56	-9.78	-0.43	1.73e-20	Multiple myeloma (IgH translocation);
LUAD	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg26384229	chr12:38710491	ALG10B	0.5	8.19	0.37	3.16e-15	Heart rate;
LUAD	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg18944383	chr4:111397179	ENPEP	0.38	7.62	0.35	1.66e-13	Height;
LUAD	cis	rs41311933	0.562	rs72760251	chr9:123929686	T/G	cg13567360	chr9:123745713	C5	-0.7	-8.33	-0.38	1.16e-15	Coronary artery disease;
LUAD	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg19500851	chr17:37840957	PGAP3	-0.34	-6.67	-0.31	7.93e-11	Asthma;
LUAD	cis	rs931127	0.658	rs4244812	chr11:65480768	A/G	cg27068330	chr11:65405492	SIPA1	-0.41	-6.71	-0.31	6.12e-11	Systemic lupus erythematosus;
LUAD	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35306767	0.668	rs35657988	chr10:1103590	A/G	cg20503657	chr10:835505	NA	0.68	9.63	0.42	5.42e-20	Eosinophil percentage of granulocytes;
LUAD	cis	rs7584330	0.737	rs6758246	chr2:238359891	G/C	cg14458575	chr2:238380390	NA	0.66	12.24	0.51	1.03e-29	Prostate cancer;
LUAD	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg23598886	chr18:12777645	NA	0.64	8.04	0.36	8.85e-15	Inflammatory skin disease;
LUAD	trans	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.16	28.01	0.81	2.08e-98	Colorectal cancer;
LUAD	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	8.74	0.39	5.59e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg08859206	chr1:53392774	SCP2	-0.52	-9.29	-0.41	8.16e-19	Monocyte count;
LUAD	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg02880119	chr16:3481970	NA	0.53	7.95	0.36	1.71e-14	Body mass index (adult);
LUAD	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg10876282	chr6:28092338	ZSCAN16	0.43	6.58	0.3	1.4e-10	Parkinson's disease;
LUAD	cis	rs6743376	0.556	rs768627	chr2:113821653	C/T	cg09040174	chr2:113837401	NA	-0.44	-6.96	-0.32	1.3e-11	Inflammatory biomarkers;
LUAD	cis	rs7147624	0.938	rs10467734	chr14:65913947	C/T	cg03016385	chr14:66212404	NA	-0.6	-7.08	-0.33	6.23e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs13064411	0.696	rs13066742	chr3:113208423	T/C	cg18753928	chr3:113234510	CCDC52	-0.73	-12.37	-0.52	3.33e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg08067268	chr2:26466485	HADHB;HADHA	0.64	8.9	0.4	1.67e-17	Gut microbiome composition (summer);
LUAD	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg21153622	chr11:89784906	NA	-0.32	-6.43	-0.3	3.49e-10	HDL cholesterol;
LUAD	cis	rs4253772	0.530	rs9615362	chr22:46795141	A/C	cg18190219	chr22:46762943	CELSR1	0.52	6.83	0.32	3e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7818345	1.000	rs4392915	chr8:19308938	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.32	7.11	0.33	5.01e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	trans	rs10411161	0.702	rs8113685	chr19:52383890	C/T	cg22319618	chr22:45562946	NUP50	-0.59	-8.24	-0.37	2.13e-15	Breast cancer;
LUAD	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg18131467	chr2:239335373	ASB1	0.69	11.59	0.49	3.52e-27	Multiple system atrophy;
LUAD	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg18105139	chr6:28058856	ZSCAN12L1	0.25	6.37	0.3	5.02e-10	Cardiac Troponin-T levels;
LUAD	cis	rs7072216	0.655	rs3830025	chr10:100176104	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-8.62	-0.39	1.38e-16	Metabolite levels;
LUAD	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg26513180	chr16:89883248	FANCA	0.79	7.14	0.33	4.03e-12	Skin colour saturation;
LUAD	cis	rs1018836	0.923	rs9693182	chr8:91621876	T/C	cg16814680	chr8:91681699	NA	-0.72	-12.2	-0.51	1.58e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4713675	0.565	rs2274458	chr6:33679596	A/C	cg14003231	chr6:33640908	ITPR3	0.49	9.42	0.42	2.96e-19	Plateletcrit;
LUAD	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	cis	rs7267979	0.702	rs449801	chr20:25491847	C/T	cg08601574	chr20:25228251	PYGB	0.39	7.29	0.33	1.54e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26314531	chr2:26401878	FAM59B	-0.74	-10.65	-0.46	1.26e-23	Gut microbiome composition (summer);
LUAD	cis	rs10089	1.000	rs72794396	chr5:127501386	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	9.13	0.41	2.94e-18	Ileal carcinoids;
LUAD	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg19622623	chr12:86230825	RASSF9	-0.55	-9.79	-0.43	1.53e-20	Major depressive disorder;
LUAD	cis	rs4711336	0.527	rs28651968	chr6:33717424	T/C	cg13859433	chr6:33739653	LEMD2	-0.32	-7.64	-0.35	1.43e-13	Height;
LUAD	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.61	8.86	0.4	2.18e-17	Gut microbiome composition (summer);
LUAD	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11644478	chr21:40555479	PSMG1	0.68	10.8	0.47	3.46e-24	Cognitive function;
LUAD	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg13180566	chr4:1052158	NA	-0.38	-6.55	-0.3	1.71e-10	Recombination rate (females);
LUAD	cis	rs8017423	0.967	rs11844225	chr14:90726676	G/A	cg14092571	chr14:90743983	NA	-0.48	-8.35	-0.38	1.01e-15	Mortality in heart failure;
LUAD	cis	rs4974559	0.895	rs10018133	chr4:1338246	C/T	cg07757535	chr4:1339547	NA	0.4	6.47	0.3	2.7e-10	Systolic blood pressure;
LUAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.31	-0.41	6.92e-19	Alzheimer's disease;
LUAD	cis	rs10489202	1.000	rs12727036	chr1:167972147	A/G	cg24449463	chr1:168025552	DCAF6	-0.55	-7.01	-0.32	9.33e-12	Schizophrenia;
LUAD	cis	rs1348850	0.958	rs10930800	chr2:178459669	T/C	cg22681709	chr2:178499509	PDE11A	-0.43	-6.81	-0.31	3.45e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg06740227	chr12:86229804	RASSF9	0.42	7.39	0.34	7.82e-13	Major depressive disorder;
LUAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg00280220	chr17:61926910	NA	0.36	6.96	0.32	1.32e-11	Prudent dietary pattern;
LUAD	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg01299579	chr2:10830716	NOL10	-0.43	-7.55	-0.34	2.68e-13	Prostate cancer;
LUAD	cis	rs7173743	0.756	rs6495337	chr15:79125689	C/G	cg15571903	chr15:79123663	NA	-0.43	-8.75	-0.39	5.21e-17	Coronary artery disease;
LUAD	cis	rs17401966	0.867	rs12403443	chr1:10423988	A/G	cg15208524	chr1:10270712	KIF1B	0.52	7.55	0.34	2.7e-13	Hepatocellular carcinoma;
LUAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg18305652	chr10:134549665	INPP5A	0.61	11.82	0.5	4.88e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg05991184	chr2:219186017	PNKD	0.37	7.13	0.33	4.5e-12	Colorectal cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04329845	chr19:14640100	MIR639;TECR	-0.57	-7.12	-0.33	4.69e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg07507251	chr3:52567010	NT5DC2	0.34	6.59	0.31	1.28e-10	Bipolar disorder;
LUAD	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg20587970	chr11:113659929	NA	-1.2	-18.26	-0.66	2.43e-55	Hip circumference adjusted for BMI;
LUAD	cis	rs68170813	0.559	rs11773514	chr7:106958469	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-10.56	-0.46	2.72e-23	Coronary artery disease;
LUAD	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg17330251	chr7:94953956	PON1	-0.55	-7.61	-0.35	1.83e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg27494647	chr7:150038898	RARRES2	0.54	8.98	0.4	8.85e-18	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7731657	0.537	rs114713366	chr5:130292286	C/T	cg08523029	chr5:130500466	HINT1	-0.58	-7.53	-0.34	3.18e-13	Fasting plasma glucose;
LUAD	cis	rs4691139	1.000	rs10517825	chr4:165893486	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	0.45	8.77	0.39	4.27e-17	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg18721089	chr20:30220636	NA	-0.42	-6.47	-0.3	2.65e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg19622623	chr12:86230825	RASSF9	-0.55	-9.79	-0.43	1.53e-20	Major depressive disorder;
LUAD	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.65	-0.31	9.31e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6489882	0.966	rs6489880	chr12:113380271	C/T	cg20102336	chr12:113376681	OAS3	-0.57	-8.91	-0.4	1.59e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg23625390	chr15:77176239	SCAPER	-0.5	-7.5	-0.34	3.81e-13	Blood metabolite levels;
LUAD	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg18761221	chr20:60518478	NA	0.57	10.13	0.44	9.53e-22	Obesity-related traits;
LUAD	cis	rs3849570	0.643	rs9870954	chr3:81978850	A/G	cg07356753	chr3:81810745	GBE1	-0.5	-8.4	-0.38	6.64e-16	Waist circumference;Body mass index;
LUAD	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg20119798	chr7:94954144	PON1	0.49	6.87	0.32	2.35e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg14917512	chr19:3094685	GNA11	-0.58	-6.84	-0.32	2.83e-11	Diabetic kidney disease;
LUAD	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	9.78	0.43	1.71e-20	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.53	0.3	1.84e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.54e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06594919	chr10:102827590	NA	-0.44	-7.17	-0.33	3.32e-12	Height;
LUAD	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg16205897	chr5:131564050	P4HA2	-0.3	-6.56	-0.3	1.54e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg03579179	chr7:12444095	VWDE	-0.42	-6.45	-0.3	3.04e-10	Coronary artery disease;
LUAD	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg00933542	chr6:150070202	PCMT1	0.49	10.62	0.46	1.61e-23	Lung cancer;
LUAD	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.32e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2235544	0.664	rs55766128	chr1:54477726	T/G	cg25741118	chr1:54482237	LDLRAD1	-0.24	-6.43	-0.3	3.47e-10	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUAD	cis	rs240764	0.658	rs12202621	chr6:101220056	C/A	cg09795085	chr6:101329169	ASCC3	-0.43	-7.6	-0.35	1.96e-13	Neuroticism;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg16467628	chr14:55493573	WDHD1;SOCS4	-0.39	-6.46	-0.3	2.96e-10	Subcortical brain region volumes;
LUAD	cis	rs78773383	0.505	rs10033019	chr4:39391940	A/G	cg16714752	chr4:39368184	RFC1	0.51	8.59	0.39	1.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7776786	0.934	rs17349342	chr7:18815473	A/C	cg13420273	chr7:18810212	HDAC9	0.32	6.77	0.31	4.39e-11	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1941687	0.583	rs8091977	chr18:31359414	T/C	cg15819921	chr19:927150	ARID3A	-0.47	-7.86	-0.36	3.26e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg01448562	chr3:133502909	NA	0.71	13.51	0.55	7.74e-35	Iron status biomarkers;
LUAD	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-7.67	-0.35	1.22e-13	Lung cancer;
LUAD	cis	rs11178918	0.585	rs11178932	chr12:72147872	A/G	cg10168894	chr12:72148281	RAB21	-0.53	-6.46	-0.3	2.88e-10	Economic and political preferences (time);
LUAD	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg26513180	chr16:89883248	FANCA	0.54	9.57	0.42	8.71e-20	Vitiligo;
LUAD	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg06611532	chr13:114900021	NA	0.39	9.13	0.41	2.82e-18	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg20607798	chr8:58055168	NA	0.67	8.77	0.39	4.44e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg26043149	chr18:55253948	FECH	0.48	7.75	0.35	6.84e-14	Bone mineral density;
LUAD	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg18252515	chr7:66147081	NA	0.6	6.68	0.31	7.56e-11	Diabetic kidney disease;
LUAD	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg22823121	chr1:150693482	HORMAD1	0.41	7.78	0.35	5.51e-14	Melanoma;
LUAD	cis	rs1215050	0.791	rs165239	chr4:98682549	C/T	cg05340658	chr4:99064831	C4orf37	0.43	6.98	0.32	1.18e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7799006	0.606	rs34262822	chr7:2304275	C/T	cg08027265	chr7:2291960	NA	-0.73	-14.67	-0.58	1.08e-39	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs8073060	0.544	rs225274	chr17:33971221	C/T	cg19694781	chr19:47549865	TMEM160	1.17	18.48	0.67	2.51e-56	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.79e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1387259	0.929	rs2634666	chr12:48663670	G/T	cg04545296	chr12:48745243	ZNF641	0.4	10.01	0.44	2.65e-21	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs9341808	0.718	rs10943699	chr6:80940541	G/A	cg08355045	chr6:80787529	NA	0.57	10.19	0.44	5.97e-22	Sitting height ratio;
LUAD	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg25985355	chr7:65971099	NA	-0.54	-6.67	-0.31	7.87e-11	Diabetic kidney disease;
LUAD	trans	rs11165623	0.543	rs6656866	chr1:97002238	T/C	cg10631902	chr5:14652156	NA	-0.41	-7.46	-0.34	4.88e-13	Hip circumference;Waist circumference;
LUAD	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg07741184	chr6:167504864	NA	0.4	9.19	0.41	1.73e-18	Crohn's disease;
LUAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.65	-9.4	-0.42	3.4e-19	Alzheimer's disease;
LUAD	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg02527881	chr3:46936655	PTH1R	-0.81	-22.01	-0.73	4.27e-72	Birth weight;
LUAD	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24531977	chr5:56204891	C5orf35	-0.97	-14.74	-0.58	5.75e-40	Initial pursuit acceleration;
LUAD	trans	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg27411982	chr8:10470053	RP1L1	-0.36	-6.54	-0.3	1.79e-10	Mood instability;
LUAD	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg15921436	chr17:44337874	NA	0.74	10.12	0.44	1.06e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	8.67	0.39	9.5e-17	Breast cancer;
LUAD	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.87	0.36	3.11e-14	Breast cancer;
LUAD	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg01181863	chr3:195395398	SDHAP2	0.61	10.15	0.44	8.33e-22	Pancreatic cancer;
LUAD	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.47	-7.5	-0.34	3.78e-13	Body mass index;
LUAD	cis	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg07460842	chr6:66804631	NA	0.77	10.46	0.45	6.05e-23	Exhaled nitric oxide output;
LUAD	cis	rs4638749	1.000	rs12472278	chr2:108873433	A/T	cg06795125	chr2:108905320	SULT1C2	0.41	6.65	0.31	9.2e-11	Blood pressure;
LUAD	cis	rs7274811	0.744	rs2071056	chr20:32265513	A/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.47	-7.23	-0.33	2.25e-12	Height;
LUAD	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg19610905	chr11:61596333	FADS2	-0.67	-11.38	-0.48	2.23e-26	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg01312482	chr5:178451176	ZNF879	-0.45	-6.92	-0.32	1.64e-11	Pubertal anthropometrics;
LUAD	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg09911534	chr15:67153556	NA	-0.42	-8.11	-0.37	5.61e-15	Lung cancer (smoking interaction);
LUAD	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg26597838	chr10:835615	NA	1.01	15.35	0.6	1.35e-42	Eosinophil percentage of granulocytes;
LUAD	cis	rs2979489	0.891	rs4537262	chr8:30306757	T/A	cg26383811	chr8:30366931	RBPMS	0.65	10.17	0.44	6.78e-22	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.61	-10.51	-0.46	4.11e-23	Electrocardiographic conduction measures;
LUAD	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg06641503	chr3:48959341	ARIH2	-0.4	-7.69	-0.35	1.02e-13	Parkinson's disease;
LUAD	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg03929089	chr4:120376271	NA	-0.99	-20.75	-0.71	1.84e-66	Height;
LUAD	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.41	7.12	0.33	4.66e-12	Type 2 diabetes;
LUAD	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg18811423	chr2:55921094	PNPT1	0.5	8.46	0.38	4.39e-16	Metabolic syndrome;
LUAD	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.16	-0.48	1.63e-25	Type 2 diabetes;
LUAD	cis	rs10426930	0.700	rs8106479	chr19:5003940	G/C	cg25246084	chr19:4971487	KDM4B	-0.47	-8.26	-0.37	1.9e-15	Monocyte percentage of white cells;
LUAD	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18876405	chr7:65276391	NA	0.59	10.01	0.44	2.68e-21	Aortic root size;
LUAD	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Depression;
LUAD	cis	rs2455601	0.786	rs11042127	chr11:8947586	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.54	-9.18	-0.41	1.94e-18	Schizophrenia;
LUAD	cis	rs673604	1.000	rs11264119	chr1:35676580	C/G	cg12633102	chr1:35676489	NA	-0.7	-8.93	-0.4	1.34e-17	Endometrial cancer;
LUAD	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-8.08	-0.37	6.81e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg14668632	chr7:2872130	GNA12	-0.46	-8.09	-0.37	6.23e-15	Height;
LUAD	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg21475434	chr5:93447410	FAM172A	-0.57	-7.54	-0.34	2.82e-13	Diabetic retinopathy;
LUAD	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg04365224	chr3:72788183	NA	-0.44	-6.57	-0.3	1.52e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg00080972	chr5:178986291	RUFY1	-0.71	-13.38	-0.55	2.76e-34	Lung cancer;
LUAD	trans	rs12439619	0.883	rs62012045	chr15:82521707	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.55	-8.48	-0.38	3.79e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg26769984	chr7:1090371	C7orf50	0.64	9.86	0.43	8.82e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs9896933	0.615	rs2379354	chr17:80704385	G/A	cg15664640	chr17:80829946	TBCD	-0.6	-7.64	-0.35	1.46e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs7523050	0.730	rs34182354	chr1:109416340	C/T	cg08274380	chr1:109419600	GPSM2	0.74	6.84	0.32	2.83e-11	Fat distribution (HIV);
LUAD	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg03733263	chr8:22462867	KIAA1967	0.73	12.32	0.51	5.21e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg00933542	chr6:150070202	PCMT1	0.43	9.18	0.41	1.88e-18	Lung cancer;
LUAD	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.51	6.99	0.32	1.08e-11	Platelet count;
LUAD	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.81	0.31	3.35e-11	Cognitive test performance;
LUAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg24642844	chr7:1081250	C7orf50	-0.87	-13.58	-0.55	3.97e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg01528321	chr10:82214614	TSPAN14	0.65	10.39	0.45	1.09e-22	Post bronchodilator FEV1;
LUAD	cis	rs9814567	0.762	rs13075332	chr3:134329836	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	12.3	0.51	6.04e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1448094	0.802	rs7487591	chr12:86434112	T/C	cg19622623	chr12:86230825	RASSF9	-0.37	-6.7	-0.31	6.76e-11	Major depressive disorder;
LUAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg10295955	chr4:187884368	NA	1.13	28.28	0.81	1.54e-99	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg00495681	chr13:53174319	NA	0.77	15.82	0.61	1.33e-44	Lewy body disease;
LUAD	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg20476274	chr7:133979776	SLC35B4	0.86	17.56	0.65	3.17e-52	Mean platelet volume;
LUAD	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg09467607	chr2:36825704	FEZ2	-0.57	-11.62	-0.49	2.9e-27	Height;
LUAD	trans	rs8002861	0.781	rs7322781	chr13:44442238	T/C	cg17145862	chr1:211918768	LPGAT1	0.74	17.21	0.64	1.02e-50	Leprosy;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20717612	chr12:21810983	LDHB	-0.45	-6.89	-0.32	2.01e-11	Height;
LUAD	cis	rs2066819	0.892	rs17118431	chr12:56667100	A/G	cg26714650	chr12:56694279	CS	-0.85	-7.2	-0.33	2.85e-12	Psoriasis vulgaris;
LUAD	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg02951883	chr7:2050386	MAD1L1	-0.82	-14.09	-0.57	3.11e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs13315871	0.858	rs13090428	chr3:58314412	A/G	cg12435725	chr3:58293450	RPP14	-0.73	-8.21	-0.37	2.72e-15	Cholesterol, total;
LUAD	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg25324976	chr17:61989376	CSHL1	0.34	6.62	0.31	1.06e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03517284	chr6:25882590	NA	0.46	7.42	0.34	6.33e-13	Blood metabolite levels;
LUAD	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg21724239	chr8:58056113	NA	0.56	7.44	0.34	5.51e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg22875332	chr1:76189707	ACADM	0.87	16.09	0.62	8.93e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg18230493	chr5:56204884	C5orf35	0.68	10.77	0.46	4.47e-24	Initial pursuit acceleration;
LUAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg24101359	chr6:42928495	GNMT	0.45	8.36	0.38	9.13e-16	Plasma homocysteine levels (post-methionine load test);
LUAD	trans	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg18187862	chr3:45730750	SACM1L	0.59	9.22	0.41	1.47e-18	Primary sclerosing cholangitis;
LUAD	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg18854424	chr1:2615690	NA	0.41	9.02	0.4	6.49e-18	Ulcerative colitis;
LUAD	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18876405	chr7:65276391	NA	-0.53	-9.21	-0.41	1.58e-18	Aortic root size;
LUAD	cis	rs9902453	0.765	rs2447935	chr17:28057524	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.31	-0.45	2.27e-22	Coffee consumption (cups per day);
LUAD	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg09537434	chr19:41945824	ATP5SL	-0.45	-7.08	-0.33	6.11e-12	Height;
LUAD	cis	rs1368882	0.814	rs1702020	chr1:55105728	C/T	cg01517571	chr1:55089959	ACOT11;FAM151A	0.47	7.86	0.36	3.29e-14	Non-substance related behavioral disinhibition;
LUAD	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg25985355	chr7:65971099	NA	0.53	6.73	0.31	5.53e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8177876	0.822	rs4889225	chr16:81108496	T/C	cg08591886	chr16:81111003	C16orf46	0.62	6.42	0.3	3.73e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.47	6.68	0.31	7.62e-11	Platelet count;
LUAD	trans	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg26043149	chr18:55253948	FECH	-0.44	-7.23	-0.33	2.21e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg07169764	chr2:136633963	MCM6	0.78	9.09	0.4	3.92e-18	Corneal structure;
LUAD	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg14008862	chr17:28927542	LRRC37B2	0.67	6.74	0.31	5.28e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg12884169	chr21:40033163	ERG	0.49	10.61	0.46	1.77e-23	Coronary artery disease;
LUAD	cis	rs11229555	0.645	rs11229459	chr11:58208025	G/A	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg02574844	chr11:5959923	NA	-0.38	-6.42	-0.3	3.56e-10	DNA methylation (variation);
LUAD	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.18	0.37	3.44e-15	Breast cancer;
LUAD	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg25985355	chr7:65971099	NA	0.35	6.39	0.3	4.49e-10	Aortic root size;
LUAD	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg18404041	chr3:52824283	ITIH1	0.4	7.24	0.33	2.09e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9878978	0.928	rs17786873	chr3:2485728	A/T	cg21928760	chr3:2462534	CNTN4	-0.33	-6.64	-0.31	9.74e-11	Blood pressure (smoking interaction);
LUAD	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg26513180	chr16:89883248	FANCA	0.78	7.09	0.33	5.78e-12	Skin colour saturation;
LUAD	cis	rs11771526	0.681	rs79578813	chr7:32308867	G/T	cg13207630	chr7:32358064	NA	0.61	7.61	0.35	1.83e-13	Body mass index;
LUAD	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg07343612	chr16:622815	PIGQ	-0.79	-15.62	-0.6	9.55e-44	Height;
LUAD	trans	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.33	0.54	4.32e-34	Exhaled nitric oxide output;
LUAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg24503407	chr1:205819492	PM20D1	-0.51	-7.82	-0.36	4.33e-14	Parkinson's disease;
LUAD	cis	rs10916814	0.546	rs1890006	chr1:20898841	G/T	cg24502330	chr1:20914028	CDA	-0.36	-7.18	-0.33	3.14e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6738485	0.895	rs13030981	chr2:106816021	A/C	cg15412446	chr2:106886593	NA	-0.39	-6.49	-0.3	2.4e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs7851660	0.870	rs55960649	chr9:100598695	C/A	cg13688889	chr9:100608707	NA	-0.54	-9.82	-0.43	1.2e-20	Strep throat;
LUAD	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg27284194	chr4:1044797	NA	0.54	8.8	0.39	3.58e-17	Recombination rate (males);
LUAD	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg22681709	chr2:178499509	PDE11A	-0.49	-7.83	-0.36	3.97e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg02951883	chr7:2050386	MAD1L1	-0.91	-16.31	-0.62	9.76e-47	Bipolar disorder and schizophrenia;
LUAD	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg21285383	chr16:89894308	SPIRE2	0.42	10.32	0.45	2.05e-22	Vitiligo;
LUAD	cis	rs7043114	0.525	rs6479416	chr9:95053871	G/T	cg14631576	chr9:95140430	CENPP	-0.42	-8.45	-0.38	4.8e-16	Height;
LUAD	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg18252515	chr7:66147081	NA	-0.63	-6.94	-0.32	1.5e-11	Gout;
LUAD	cis	rs790123	0.692	rs790118	chr3:122380614	C/A	cg15604389	chr3:122379662	NA	0.43	6.84	0.32	2.72e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg13319975	chr6:146136371	FBXO30	-0.64	-11.19	-0.48	1.2e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.96	-0.36	1.56e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg15468180	chr1:107600409	PRMT6	0.43	7.35	0.34	1.04e-12	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.35e-11	Breast cancer;
LUAD	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg18404041	chr3:52824283	ITIH1	-0.56	-9.37	-0.41	4.45e-19	Schizophrenia;
LUAD	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg12863693	chr15:85201151	NMB	0.36	6.58	0.3	1.43e-10	Schizophrenia;
LUAD	cis	rs953387	1.000	rs4954568	chr2:136910690	T/A	cg05194412	chr2:137003533	NA	-0.44	-7.25	-0.33	2.01e-12	Arthritis (juvenile idiopathic);
LUAD	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg06784218	chr1:46089804	CCDC17	-0.59	-13.26	-0.54	8.61e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs471144	0.881	rs12081541	chr1:152441366	T/C	cg23107878	chr1:152161397	NA	0.64	6.37	0.3	5.04e-10	Inflammatory skin disease;
LUAD	cis	rs1032833	0.732	rs76649196	chr2:180127956	T/C	cg23883738	chr2:179974586	SESTD1	-0.72	-8.08	-0.37	6.91e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg15704280	chr7:45808275	SEPT13	0.63	8.42	0.38	5.71e-16	Axial length;
LUAD	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg18404041	chr3:52824283	ITIH1	-0.42	-7.92	-0.36	2.13e-14	Electroencephalogram traits;
LUAD	cis	rs12681288	0.862	rs34510005	chr8:1018943	T/C	cg04851639	chr8:1020857	NA	-0.42	-10.73	-0.46	6.24e-24	Schizophrenia;
LUAD	cis	rs1639906	1.000	rs1639906	chr7:2219966	T/C	cg18044113	chr7:2236405	MAD1L1	-0.39	-7.45	-0.34	5.42e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2070677	0.935	rs11101880	chr10:135412888	T/C	cg20169779	chr10:135381914	SYCE1	-0.52	-8.36	-0.38	9.37e-16	Gout;
LUAD	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.48	-6.99	-0.32	1.06e-11	Alzheimer's disease (late onset);
LUAD	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg23533926	chr12:111358616	MYL2	-0.4	-6.84	-0.32	2.87e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6547741	0.904	rs1528403	chr2:27846645	C/G	cg27432699	chr2:27873401	GPN1	0.54	9.19	0.41	1.73e-18	Oral cavity cancer;
LUAD	cis	rs7614311	0.731	rs73130534	chr3:63859813	A/G	cg22134162	chr3:63841271	THOC7	-0.54	-8.91	-0.4	1.52e-17	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg25404069	chr7:150924520	ABCF2	-0.62	-6.42	-0.3	3.73e-10	Type 2 diabetes;
LUAD	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	7.85	0.36	3.38e-14	Menopause (age at onset);
LUAD	cis	rs9902453	0.933	rs1128156	chr17:28513176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	8.34	0.38	1.02e-15	Coffee consumption (cups per day);
LUAD	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg26022315	chr17:47021804	SNF8	0.41	7.33	0.34	1.17e-12	Type 2 diabetes;
LUAD	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg14598338	chr9:96623480	NA	-0.43	-9.1	-0.4	3.65e-18	DNA methylation (variation);
LUAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg22963979	chr7:1858916	MAD1L1	-0.57	-9.88	-0.43	7.63e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-16.49	-0.63	1.61e-47	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12756686	chr19:29218302	NA	0.68	9.91	0.43	6.06e-21	Methadone dose in opioid dependence;
LUAD	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg14926445	chr8:58193284	C8orf71	-0.47	-6.81	-0.31	3.32e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg23260525	chr10:116636907	FAM160B1	-0.47	-10.98	-0.47	7.3e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg18230493	chr5:56204884	C5orf35	-0.84	-12.35	-0.51	4.05e-30	Initial pursuit acceleration;
LUAD	cis	rs7100689	0.646	rs10887808	chr10:82137367	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.44	0.45	7.42e-23	Post bronchodilator FEV1;
LUAD	cis	rs12422267	0.536	rs11831679	chr12:132609960	C/T	cg09764611	chr12:132620959	NA	-0.63	-10.53	-0.46	3.41e-23	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg18621852	chr3:10150065	C3orf24	0.48	8.38	0.38	8.14e-16	Alzheimer's disease;
LUAD	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	7.85	0.36	3.45e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs758324	0.947	rs11242098	chr5:131206837	T/G	cg06307176	chr5:131281290	NA	0.46	7.68	0.35	1.08e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg21220214	chr8:57350948	NA	-0.6	-8.89	-0.4	1.8e-17	Obesity-related traits;
LUAD	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg06808227	chr14:105710500	BRF1	-0.41	-6.57	-0.3	1.5e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg09491104	chr22:46646882	C22orf40	-0.57	-7.19	-0.33	2.87e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg20744362	chr22:50050164	C22orf34	0.42	9.18	0.41	1.95e-18	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4523957	0.651	rs8082485	chr17:2060407	A/G	cg16513277	chr17:2031491	SMG6	-0.96	-18.89	-0.68	3.82e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg25036284	chr2:26402008	FAM59B	0.5	6.94	0.32	1.52e-11	Gut microbiome composition (summer);
LUAD	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg19875535	chr5:140030758	IK	0.47	7.71	0.35	8.78e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg19773385	chr1:10388646	KIF1B	-0.43	-6.9	-0.32	1.92e-11	Hepatocellular carcinoma;
LUAD	cis	rs1018836	0.847	rs35409073	chr8:91648036	G/T	cg16814680	chr8:91681699	NA	-0.7	-11.99	-0.5	1.02e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg20607798	chr8:58055168	NA	0.67	8.71	0.39	7.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs28830936	1.000	rs11629485	chr15:41904569	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.6	-0.31	1.23e-10	Diastolic blood pressure;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12381575	chr19:36485972	SDHAF1	-0.38	-6.42	-0.3	3.59e-10	Cancer;
LUAD	cis	rs1882538	0.538	rs7783217	chr7:133104117	C/G	cg10665199	chr7:133106180	EXOC4	-0.6	-10.48	-0.45	5.33e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.91e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg14558114	chr2:88469736	THNSL2	0.87	9.31	0.41	6.92e-19	Plasma clusterin levels;
LUAD	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.09e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.92	11.06	0.47	3.91e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg00647820	chr17:40259828	DHX58	-0.44	-7.14	-0.33	4.01e-12	Fibrinogen levels;
LUAD	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg17366294	chr4:99064904	C4orf37	0.64	11.95	0.5	1.48e-28	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1864400	0.690	rs7098237	chr10:43740513	T/A	cg15436174	chr10:43711423	RASGEF1A	0.54	9.26	0.41	1.01e-18	Hirschsprung disease;
LUAD	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22968622	chr17:43663579	NA	0.94	16.27	0.62	1.47e-46	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs977987	0.843	rs62062564	chr16:75442622	G/A	cg03315344	chr16:75512273	CHST6	0.63	13.92	0.56	1.53e-36	Dupuytren's disease;
LUAD	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg13180566	chr4:1052158	NA	-0.38	-6.41	-0.3	3.87e-10	Recombination rate (females);
LUAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg10295955	chr4:187884368	NA	-1.18	-30.7	-0.83	1.05e-109	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg17264618	chr3:40429014	ENTPD3	-0.4	-8.99	-0.4	8.56e-18	Renal cell carcinoma;
LUAD	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.09	-0.33	5.49e-12	Blood metabolite levels;
LUAD	trans	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg07211511	chr3:129823064	LOC729375	-0.91	-12.47	-0.52	1.32e-30	Blood pressure (smoking interaction);
LUAD	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg21724239	chr8:58056113	NA	0.55	7.34	0.34	1.13e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08280861	chr8:58055591	NA	0.55	7.16	0.33	3.53e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11677416	1.000	rs17561	chr2:113537223	C/A	cg27083787	chr2:113543245	IL1A	0.4	6.75	0.31	4.99e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg16680214	chr1:154839983	KCNN3	0.51	10.4	0.45	1.04e-22	Prostate cancer;
LUAD	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06112835	chr11:68658793	MRPL21	0.54	9.59	0.42	7.59e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg19130645	chr7:65235666	NA	0.42	7.2	0.33	2.76e-12	Calcium levels;
LUAD	trans	rs11039798	0.841	rs11039783	chr11:48526828	G/C	cg15704280	chr7:45808275	SEPT13	0.64	7.31	0.33	1.31e-12	Axial length;
LUAD	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	8.73	0.39	5.97e-17	Menarche (age at onset);
LUAD	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg18944383	chr4:111397179	ENPEP	0.51	9.29	0.41	7.9e-19	Coronary artery disease;
LUAD	cis	rs10129255	0.536	rs8004835	chr14:107142378	A/C	cg07958169	chr14:107095056	NA	-0.35	-6.85	-0.32	2.62e-11	Kawasaki disease;
LUAD	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg25233709	chr10:116636983	FAM160B1	0.41	8.26	0.37	1.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg22431228	chr1:16359049	CLCNKA	-0.42	-8.22	-0.37	2.54e-15	Systolic blood pressure;
LUAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.29	0.41	8.04e-19	Alzheimer's disease;
LUAD	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs877282	0.797	rs7079164	chr10:756363	A/G	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.8	0.53	5.97e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg14343924	chr8:8086146	FLJ10661	0.46	7.28	0.33	1.6e-12	Neuroticism;
LUAD	cis	rs1048238	0.506	rs848194	chr1:16285342	G/A	cg21214613	chr1:16344536	HSPB7	-0.41	-7.34	-0.34	1.12e-12	Systolic blood pressure;
LUAD	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg02734326	chr4:10020555	SLC2A9	0.44	7.61	0.35	1.78e-13	Bone mineral density;
LUAD	cis	rs8002180	0.959	rs7996898	chr13:95922453	A/G	cg24476569	chr13:95954382	ABCC4	0.39	6.36	0.3	5.12e-10	Blood metabolite levels;
LUAD	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg25767906	chr1:53392781	SCP2	0.42	7.49	0.34	4.19e-13	Monocyte count;
LUAD	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.15	0.33	3.76e-12	Parkinson's disease;
LUAD	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg11517269	chr6:28058789	ZSCAN12L1	0.27	6.5	0.3	2.3e-10	Parkinson's disease;
LUAD	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.89	9.28	0.41	9.23e-19	Initial pursuit acceleration;
LUAD	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg00316803	chr15:76480434	C15orf27	0.4	6.38	0.3	4.6e-10	Blood metabolite levels;
LUAD	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg22532475	chr10:104410764	TRIM8	-0.45	-8.81	-0.39	3.17e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg12863693	chr15:85201151	NMB	0.39	7.13	0.33	4.35e-12	Schizophrenia;
LUAD	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg01689657	chr7:91764605	CYP51A1	-0.35	-8.42	-0.38	6.04e-16	Breast cancer;
LUAD	cis	rs6691722	0.506	rs1016209	chr1:24745615	A/G	cg02336364	chr1:24764700	NIPAL3	-0.36	-7.78	-0.35	5.74e-14	Response to interferon beta in multiple sclerosis;
LUAD	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg25324976	chr17:61989376	CSHL1	0.38	7.44	0.34	5.84e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg16060761	chr17:80687452	NA	0.47	7.02	0.32	8.92e-12	Breast cancer;
LUAD	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg15704280	chr7:45808275	SEPT13	0.74	10.88	0.47	1.83e-24	Coronary artery disease;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg13236679	chr6:37467396	C6orf129	0.41	6.41	0.3	3.79e-10	Diastolic blood pressure;
LUAD	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg01097406	chr16:89675127	NA	0.3	6.53	0.3	1.84e-10	Hemoglobin concentration;
LUAD	cis	rs8067545	0.641	rs203450	chr17:19823070	C/T	cg04132472	chr17:19861366	AKAP10	0.39	9.21	0.41	1.51e-18	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs7395662	0.654	rs12289625	chr11:48817242	A/G	cg00717180	chr2:96193071	NA	0.36	6.64	0.31	9.81e-11	HDL cholesterol;
LUAD	cis	rs6835098	0.924	rs7672108	chr4:174165126	A/G	cg27433088	chr4:174089019	GALNT7	-0.38	-7.42	-0.34	6.34e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg17724175	chr1:150552817	MCL1	0.4	9.86	0.43	8.9e-21	Tonsillectomy;
LUAD	cis	rs295140	0.526	rs295113	chr2:201197816	C/G	cg23649088	chr2:200775458	C2orf69	0.46	7.99	0.36	1.26e-14	QT interval;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04592976	chr16:89984572	MC1R	-0.47	-7.17	-0.33	3.36e-12	Height;
LUAD	cis	rs7737355	1.000	rs30736	chr5:130724240	A/G	cg06307176	chr5:131281290	NA	-0.47	-7.48	-0.34	4.32e-13	Life satisfaction;
LUAD	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg25019722	chr6:37503610	NA	-0.3	-6.7	-0.31	6.72e-11	Cognitive performance;
LUAD	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg03885332	chr11:832357	CD151	-0.42	-7.96	-0.36	1.64e-14	Mean platelet volume;
LUAD	cis	rs7589342	0.839	rs1465639	chr2:106439181	T/C	cg16077055	chr2:106428750	NCK2	0.35	6.41	0.3	3.9e-10	Addiction;
LUAD	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg06784218	chr1:46089804	CCDC17	0.5	10.92	0.47	1.22e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg00933542	chr6:150070202	PCMT1	0.43	9.26	0.41	1.03e-18	Lung cancer;
LUAD	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg05340658	chr4:99064831	C4orf37	0.46	7.55	0.34	2.75e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19748678	chr4:122722346	EXOSC9	0.43	6.93	0.32	1.62e-11	Type 2 diabetes;
LUAD	cis	rs595982	0.517	rs4801779	chr19:49406651	T/G	cg21252483	chr19:49399788	TULP2	-0.48	-9.24	-0.41	1.18e-18	Red cell distribution width;
LUAD	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg19436804	chr8:8560866	CLDN23	0.42	6.4	0.3	4.01e-10	Obesity-related traits;
LUAD	cis	rs12711979	0.729	rs6714956	chr2:3820454	T/C	cg17052675	chr2:3827356	NA	-0.52	-10.49	-0.45	4.96e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs9560113	0.960	rs9560102	chr13:112173825	G/A	cg14154082	chr13:112174009	NA	0.36	6.66	0.31	8.28e-11	Menarche (age at onset);
LUAD	cis	rs1595825	0.786	rs1902247	chr2:198492826	C/T	cg00982548	chr2:198649783	BOLL	-0.54	-7.88	-0.36	2.73e-14	Ulcerative colitis;
LUAD	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg17644776	chr2:200775616	C2orf69	0.53	7.55	0.34	2.63e-13	Schizophrenia;
LUAD	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06544989	chr22:39130855	UNC84B	0.46	9.24	0.41	1.2e-18	Menopause (age at onset);
LUAD	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg18131467	chr2:239335373	ASB1	0.71	12.09	0.51	3.99e-29	Multiple system atrophy;
LUAD	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg04731861	chr2:219085781	ARPC2	-0.22	-6.58	-0.3	1.36e-10	Colorectal cancer;
LUAD	cis	rs4077515	0.806	rs3812564	chr9:139271190	A/G	cg14019695	chr9:139328340	INPP5E	0.4	7.48	0.34	4.38e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg14895029	chr7:2775587	GNA12	-0.43	-7.13	-0.33	4.48e-12	Height;
LUAD	cis	rs4961252	0.505	rs4961327	chr8:142102053	C/T	cg09914555	chr8:142094789	NA	-0.44	-7.14	-0.33	4.12e-12	Isovolumetric relaxation time;Response to interferon beta therapy;
LUAD	trans	rs236907	0.859	rs1801898	chr1:171765964	A/G	cg13482142	chr2:234261155	NA	0.5	6.49	0.3	2.43e-10	Mean platelet volume;
LUAD	cis	rs250585	0.736	rs250578	chr16:23427110	C/T	cg00143387	chr16:23521605	GGA2	0.54	7.65	0.35	1.41e-13	Egg allergy;
LUAD	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg05110241	chr16:68378359	PRMT7	-0.82	-8.98	-0.4	9.33e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11948739	0.537	rs12518203	chr5:130233745	G/A	cg08523029	chr5:130500466	HINT1	-0.57	-7.38	-0.34	8.48e-13	Pediatric bone mineral content (hip);
LUAD	trans	rs75804782	0.515	rs75251934	chr2:239288387	A/C	cg01134436	chr17:81009848	B3GNTL1	0.76	6.82	0.31	3.2e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs612683	0.664	rs6702766	chr1:100997635	A/G	cg06223162	chr1:101003688	GPR88	-0.53	-10.39	-0.45	1.09e-22	Breast cancer;
LUAD	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg03690763	chr11:133734501	NA	-0.33	-7.85	-0.36	3.52e-14	Childhood ear infection;
LUAD	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21659725	chr3:3221576	CRBN	-0.85	-17.93	-0.66	7.21e-54	Intelligence (multi-trait analysis);
LUAD	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg05665937	chr4:1216051	CTBP1	0.47	7.1	0.33	5.41e-12	Longevity;
LUAD	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.37	0.38	8.62e-16	Breast cancer;
LUAD	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg25535316	chr11:579198	PHRF1	-0.39	-6.46	-0.3	2.95e-10	Systemic lupus erythematosus;
LUAD	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg13918804	chr1:2043761	PRKCZ	-0.39	-6.53	-0.3	1.9e-10	Height;
LUAD	trans	rs4714291	0.775	rs2949019	chr6:40051200	C/T	cg02267698	chr19:7991119	CTXN1	-0.45	-7.07	-0.33	6.5e-12	Strep throat;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19255475	chr2:178417960	TTC30B	-0.49	-7.65	-0.35	1.38e-13	Height;
LUAD	trans	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg06606381	chr12:133084897	FBRSL1	-0.49	-6.39	-0.3	4.26e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.2	29.63	0.82	3.01e-105	Exhaled nitric oxide output;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg23224405	chr12:12715060	DUSP16	-0.35	-6.41	-0.3	3.91e-10	Schizophrenia;
LUAD	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg02683114	chr2:24398427	C2orf84	-0.52	-7.76	-0.35	6.37e-14	Asthma;
LUAD	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg15017067	chr4:17643749	FAM184B	-0.36	-6.96	-0.32	1.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11249608	0.548	rs11960161	chr5:178453837	A/G	cg01312482	chr5:178451176	ZNF879	-0.43	-6.75	-0.31	5.03e-11	Pubertal anthropometrics;
LUAD	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.6	11.48	0.49	9.93e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg23260525	chr10:116636907	FAM160B1	0.47	11.0	0.47	6.26e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs912057	0.797	rs1294430	chr6:6744698	A/G	cg06612196	chr6:6737390	NA	0.55	12.63	0.52	3e-31	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg21153622	chr11:89784906	NA	-0.33	-6.46	-0.3	2.95e-10	Coronary artery disease;
LUAD	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg03433033	chr1:76189801	ACADM	-0.71	-11.46	-0.49	1.12e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.43	-0.34	5.87e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs11676348	1.000	rs11676348	chr2:219010146	C/T	cg06547715	chr2:218990976	CXCR2	0.38	8.78	0.39	4.17e-17	Ulcerative colitis;
LUAD	cis	rs10992471	0.580	rs10992393	chr9:95420983	A/G	cg14631576	chr9:95140430	CENPP	-0.44	-7.9	-0.36	2.42e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs4917300	0.626	rs28375965	chr8:143103882	A/G	cg25363559	chr8:143086065	NA	-0.46	-9.43	-0.42	2.65e-19	Amyotrophic lateral sclerosis;
LUAD	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.7	-0.61	4.39e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs375066	0.762	rs239938	chr19:44390305	T/C	cg12072164	chr19:44306565	LYPD5	0.32	6.56	0.3	1.53e-10	Breast cancer;
LUAD	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	12.49	0.52	1.0500000000000001e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-7.97	-0.36	1.5e-14	Diabetic kidney disease;
LUAD	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg06740227	chr12:86229804	RASSF9	0.44	7.6	0.35	1.98e-13	Major depressive disorder;
LUAD	trans	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-6.87	-0.32	2.38e-11	Body mass index;
LUAD	cis	rs3772130	0.962	rs6789736	chr3:121543084	T/G	cg20356878	chr3:121714668	ILDR1	0.53	8.7	0.39	7.41e-17	Cognitive performance;
LUAD	cis	rs2797160	1.000	rs1739352	chr6:126005310	T/C	cg05901451	chr6:126070800	HEY2	-0.45	-6.66	-0.31	8.37e-11	Endometrial cancer;
LUAD	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg01528321	chr10:82214614	TSPAN14	0.74	11.14	0.48	1.96e-25	Post bronchodilator FEV1;
LUAD	cis	rs12348691	0.503	rs7024345	chr9:100595238	A/G	cg13688889	chr9:100608707	NA	-0.6	-10.0	-0.44	2.75e-21	Alopecia areata;
LUAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08280861	chr8:58055591	NA	0.6	7.71	0.35	9.23e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs713477	1.000	rs10134905	chr14:55911792	G/A	cg13175173	chr14:55914753	NA	-0.34	-7.03	-0.32	8.58e-12	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.4	-7.28	-0.33	1.67e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs79349575	0.721	rs2291725	chr17:47039132	T/C	cg22482690	chr17:47019901	SNF8	0.45	8.55	0.38	2.35e-16	Type 2 diabetes;
LUAD	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg16447950	chr5:562315	NA	-0.38	-7.11	-0.33	4.83e-12	Obesity-related traits;
LUAD	cis	rs17092148	0.887	rs6059937	chr20:33186200	G/C	cg16810054	chr20:33298113	TP53INP2	-0.49	-7.57	-0.35	2.33e-13	Neuroticism;
LUAD	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.3	6.67	0.31	7.88e-11	Depression;
LUAD	cis	rs9503598	0.662	rs2326232	chr6:3451953	A/G	cg00476032	chr6:3446245	SLC22A23	0.33	7.1	0.33	5.36e-12	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg22907277	chr7:1156413	C7orf50	0.72	9.26	0.41	1.06e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg06532163	chr17:45867833	NA	0.46	7.23	0.33	2.24e-12	IgG glycosylation;
LUAD	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08704250	chr15:31115839	NA	0.69	12.33	0.51	4.71e-30	Huntington's disease progression;
LUAD	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg25985355	chr7:65971099	NA	-0.51	-6.36	-0.3	5.25e-10	Diabetic kidney disease;
LUAD	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg24879335	chr3:133465180	TF	0.38	7.89	0.36	2.7e-14	Iron status biomarkers (transferrin levels);
LUAD	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg24733560	chr20:60626293	TAF4	0.46	8.16	0.37	3.91e-15	Body mass index;
LUAD	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg11584989	chr19:19387371	SF4	0.37	6.59	0.31	1.33e-10	Tonsillectomy;
LUAD	cis	rs3823572	0.542	rs2971961	chr7:133639737	G/A	cg03336402	chr7:133662267	EXOC4	0.42	7.65	0.35	1.35e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4911259	0.552	rs13038017	chr20:31467551	T/C	cg13636640	chr20:31349939	DNMT3B	-0.57	-9.37	-0.41	4.5e-19	Inflammatory bowel disease;
LUAD	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg08999081	chr20:33150536	PIGU	-0.62	-13.72	-0.55	1.06e-35	Glomerular filtration rate (creatinine);
LUAD	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg21951975	chr1:209979733	IRF6	0.57	8.22	0.37	2.5e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.32e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.01	-0.44	2.5e-21	Bipolar disorder and schizophrenia;
LUAD	trans	rs11039798	0.764	rs2089208	chr11:48899860	C/T	cg15704280	chr7:45808275	SEPT13	0.68	7.89	0.36	2.69e-14	Axial length;
LUAD	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg01528321	chr10:82214614	TSPAN14	0.54	8.75	0.39	5.11e-17	Post bronchodilator FEV1;
LUAD	trans	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.28	-0.41	9.19e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg11494091	chr17:61959527	GH2	0.43	8.3	0.37	1.4e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg27124370	chr19:33622961	WDR88	0.45	7.25	0.33	1.98e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs727505	0.954	rs1383748	chr7:124638201	A/T	cg23710748	chr7:124431027	NA	-0.42	-8.37	-0.38	8.39e-16	Lewy body disease;
LUAD	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23158103	chr7:148848205	ZNF398	0.5	8.92	0.4	1.44e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg10560079	chr2:191398806	TMEM194B	-0.39	-7.08	-0.33	6.23e-12	Pulse pressure;
LUAD	trans	rs6921919	0.848	rs56131013	chr6:28320677	G/A	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.47	-0.3	2.74e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1079204	1.000	rs59549705	chr2:219166649	C/G	cg05728596	chr2:219128475	GPBAR1	1.02	8.6	0.39	1.55e-16	Smooth-surface caries;
LUAD	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg14092571	chr14:90743983	NA	-0.5	-8.89	-0.4	1.76e-17	Mortality in heart failure;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg10532262	chr3:172428426	NCEH1	-0.42	-7.16	-0.33	3.51e-12	Subcortical brain region volumes;
LUAD	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.82	0.53	5.17e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3750965	0.959	rs4930265	chr11:68855954	A/G	cg06818126	chr11:68850279	TPCN2	-0.47	-7.03	-0.32	8.13e-12	Hair color;
LUAD	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg15962314	chr1:44399869	ARTN	0.32	7.48	0.34	4.43e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg21427119	chr20:30132790	HM13	-0.62	-9.46	-0.42	2.14e-19	Mean corpuscular hemoglobin;
LUAD	trans	rs1941687	0.797	rs2976	chr18:31403254	T/C	cg27147174	chr7:100797783	AP1S1	-0.56	-9.31	-0.41	6.97e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.93	13.25	0.54	8.81e-34	Smoking behavior;
LUAD	cis	rs3813948	0.505	rs17020993	chr1:207288392	A/G	cg11153969	chr1:207277031	C4BPA	-0.57	-7.89	-0.36	2.58e-14	C4b binding protein levels;
LUAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg07362569	chr17:61921086	SMARCD2	0.39	6.75	0.31	4.88e-11	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.85	0.53	3.77e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg12935359	chr14:103987150	CKB	0.65	9.33	0.41	5.88e-19	Bone mineral density;
LUAD	trans	rs7395662	0.929	rs10838956	chr11:48581765	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.12e-12	HDL cholesterol;
LUAD	trans	rs8002861	0.691	rs9525851	chr13:44402132	T/A	cg12856521	chr11:46389249	DGKZ	-0.49	-8.49	-0.38	3.47e-16	Leprosy;
LUAD	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg02505535	chr3:195703920	SDHAP1	-0.36	-7.47	-0.34	4.66e-13	Pancreatic cancer;
LUAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08280861	chr8:58055591	NA	0.59	7.66	0.35	1.32e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs877282	0.891	rs11253393	chr10:788824	G/T	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg08758996	chr17:66097529	LOC651250	0.4	6.75	0.31	4.96e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.66	-8.41	-0.38	6.24e-16	Yeast infection;
LUAD	cis	rs2806561	0.894	rs629107	chr1:23537971	C/T	cg12483005	chr1:23474871	LUZP1	0.39	6.6	0.31	1.27e-10	Height;
LUAD	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg27284194	chr4:1044797	NA	0.69	10.16	0.44	7.44e-22	Recombination rate (females);
LUAD	cis	rs73198271	0.562	rs73519953	chr8:8660278	G/T	cg01851573	chr8:8652454	MFHAS1	0.71	11.21	0.48	9.92e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs61897795	0.657	rs174589	chr11:61615803	C/G	cg19610905	chr11:61596333	FADS2	0.66	9.75	0.43	2.07e-20	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15664640	chr17:80829946	TBCD	-0.85	-17.14	-0.64	2.13e-50	Breast cancer;
LUAD	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg03474202	chr17:45855739	NA	-0.38	-8.98	-0.4	8.96e-18	IgG glycosylation;
LUAD	cis	rs1448094	0.706	rs10863149	chr12:86425498	A/T	cg18827107	chr12:86230957	RASSF9	-0.47	-8.34	-0.38	1.04e-15	Major depressive disorder;
LUAD	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg13319975	chr6:146136371	FBXO30	0.59	9.96	0.44	4.05e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11971779	0.680	rs2355783	chr7:139075879	C/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.4	-0.3	4.05e-10	Diisocyanate-induced asthma;
LUAD	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg18230493	chr5:56204884	C5orf35	-0.48	-8.06	-0.36	7.84e-15	Coronary artery disease;
LUAD	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg06558623	chr16:89946397	TCF25	1.18	10.86	0.47	2.07e-24	Skin colour saturation;
LUAD	trans	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg02002194	chr4:3960332	NA	0.28	6.88	0.32	2.14e-11	Mood instability;
LUAD	cis	rs8014204	0.804	rs2241274	chr14:75251331	G/A	cg06637938	chr14:75390232	RPS6KL1	0.37	6.82	0.31	3.09e-11	Caffeine consumption;
LUAD	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg17644776	chr2:200775616	C2orf69	-0.5	-6.43	-0.3	3.47e-10	Schizophrenia;
LUAD	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	cis	rs3739034	0.938	rs6747870	chr2:135469769	C/T	cg12500956	chr2:135428796	TMEM163	-0.35	-6.67	-0.31	8e-11	Gut microbiome composition (winter);
LUAD	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg17105886	chr17:28927953	LRRC37B2	0.83	8.0	0.36	1.18e-14	Body mass index;
LUAD	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg21782813	chr7:2030301	MAD1L1	0.54	9.08	0.4	4.32e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs9814567	0.752	rs1880378	chr3:134330709	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs12431939	0.779	rs3007081	chr14:51645492	G/A	cg23942311	chr14:51606299	NA	0.42	6.7	0.31	6.84e-11	Cancer;
LUAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7625357	0.651	rs6763160	chr3:169322749	T/G	cg14572252	chr3:169309425	MECOM	-0.47	-7.95	-0.36	1.66e-14	Childhood and early adolescence aggressive behavior;
LUAD	trans	rs2018683	0.803	rs12700920	chr7:28984924	A/G	cg19402173	chr7:128379420	CALU	-0.59	-9.72	-0.43	2.69e-20	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12802200	0.535	rs12282299	chr11:570009	T/C	cg16486109	chr11:613632	IRF7	0.53	8.69	0.39	8.17e-17	Systemic lupus erythematosus;
LUAD	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg09137382	chr11:130731461	NA	0.37	6.5	0.3	2.29e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-14.21	-0.57	1.01e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg08989290	chr16:615782	NHLRC4	0.3	6.61	0.31	1.14e-10	Height;
LUAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg23131131	chr22:24373011	LOC391322	-0.59	-9.95	-0.44	4.17e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg03929089	chr4:120376271	NA	-0.98	-19.66	-0.69	1.39e-61	Height;
LUAD	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg23625390	chr15:77176239	SCAPER	0.4	7.18	0.33	3.11e-12	Blood metabolite levels;
LUAD	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg08470875	chr2:26401718	FAM59B	-0.77	-10.37	-0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-7.16	-0.33	3.61e-12	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.95	-0.44	4.25e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs912057	0.833	rs1024245	chr6:6743319	A/G	cg06612196	chr6:6737390	NA	0.55	12.63	0.52	3e-31	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg14092571	chr14:90743983	NA	-0.49	-8.69	-0.39	7.97e-17	Mortality in heart failure;
LUAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-8.96	-0.4	1.02e-17	Lymphocyte counts;
LUAD	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg17328964	chr8:145687451	CYHR1	0.4	6.85	0.32	2.57e-11	Age at first birth;
LUAD	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.39	-6.39	-0.3	4.29e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg17644776	chr2:200775616	C2orf69	-0.52	-6.53	-0.3	1.9e-10	Schizophrenia;
LUAD	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg13606994	chr1:44402422	ARTN	-0.33	-6.76	-0.31	4.63e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg24308560	chr3:49941425	MST1R	-0.52	-8.65	-0.39	1.07e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg18190219	chr22:46762943	CELSR1	-0.57	-6.5	-0.3	2.28e-10	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg02254774	chr11:50257496	LOC441601	0.53	6.66	0.31	8.71e-11	Axial length;
LUAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg22729335	chr19:2427816	TIMM13	0.86	17.29	0.64	4.76e-51	Cortisol levels (saliva);
LUAD	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.63e-11	Crohn's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16988008	chr11:108463728	EXPH5	-0.53	-6.45	-0.3	3e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg01851573	chr8:8652454	MFHAS1	-0.38	-6.72	-0.31	5.91e-11	Mood instability;
LUAD	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg25894440	chr7:65020034	NA	-0.66	-7.1	-0.33	5.15e-12	Diabetic kidney disease;
LUAD	cis	rs6087990	0.899	rs1333469	chr20:31361249	C/T	cg13636640	chr20:31349939	DNMT3B	0.82	15.47	0.6	4.23e-43	Ulcerative colitis;
LUAD	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg17971929	chr21:40555470	PSMG1	0.56	8.79	0.39	3.81e-17	Cognitive function;
LUAD	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.53	0.3	1.89e-10	Cognitive test performance;
LUAD	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.87	0.36	3.06e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg14558114	chr2:88469736	THNSL2	0.84	9.2	0.41	1.69e-18	Plasma clusterin levels;
LUAD	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24531977	chr5:56204891	C5orf35	-0.98	-14.71	-0.58	7.48e-40	Initial pursuit acceleration;
LUAD	cis	rs6665290	0.904	rs10495273	chr1:227183359	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.36	-0.89	3.86e-147	Myeloid white cell count;
LUAD	cis	rs1215050	0.874	rs2167893	chr4:99048464	A/T	cg05340658	chr4:99064831	C4orf37	0.4	6.4	0.3	4.08e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg00802000	chr16:706648	WDR90	-0.42	-7.82	-0.36	4.34e-14	Height;
LUAD	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg08470875	chr2:26401718	FAM59B	-0.62	-8.52	-0.38	2.89e-16	Gut microbiome composition (summer);
LUAD	cis	rs12900413	0.687	rs62023459	chr15:90308231	A/T	cg24249390	chr15:90295951	MESP1	-0.34	-6.67	-0.31	8.16e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.35	0.38	1.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg23173402	chr1:227635558	NA	0.88	8.45	0.38	4.74e-16	Major depressive disorder;
LUAD	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg21194808	chr1:2205498	SKI	0.4	6.42	0.3	3.76e-10	Height;
LUAD	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg10589385	chr1:150898437	SETDB1	0.39	7.39	0.34	8e-13	Tonsillectomy;
LUAD	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg08847533	chr14:75593920	NEK9	0.39	6.57	0.3	1.46e-10	Height;
LUAD	cis	rs4629710	0.562	rs3798252	chr6:131583758	A/T	cg12606694	chr6:131520996	AKAP7	0.49	7.04	0.32	7.76e-12	Multiple myeloma (IgH translocation);
LUAD	trans	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg26043149	chr18:55253948	FECH	0.49	7.86	0.36	3.15e-14	Bone mineral density;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg02140097	chr12:110719074	ATP2A2	-0.38	-6.45	-0.3	3.1e-10	Schizophrenia;
LUAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg12143784	chr7:64541923	NA	0.53	8.64	0.39	1.21e-16	Calcium levels;
LUAD	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg15704280	chr7:45808275	SEPT13	0.69	9.32	0.41	6.27e-19	Axial length;
LUAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg21951975	chr1:209979733	IRF6	0.55	8.65	0.39	1.05e-16	Cleft lip with or without cleft palate;
LUAD	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.97	20.88	0.71	4.9e-67	Chronic sinus infection;
LUAD	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg26384229	chr12:38710491	ALG10B	0.49	7.85	0.36	3.57e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg15782153	chr7:917662	C7orf20	0.56	10.46	0.45	6.32e-23	Perceived unattractiveness to mosquitoes;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg03468541	chr14:89029199	ZC3H14	-0.39	-6.49	-0.3	2.43e-10	Schizophrenia;
LUAD	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg08847533	chr14:75593920	NEK9	0.42	7.14	0.33	4.05e-12	Height;
LUAD	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg04990556	chr1:26633338	UBXN11	-0.41	-6.54	-0.3	1.8e-10	Obesity-related traits;
LUAD	cis	rs10744422	1.000	rs1532835	chr12:123330665	G/A	cg16953816	chr12:123349952	VPS37B	0.59	6.67	0.31	8.16e-11	Schizophrenia;
LUAD	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg06740227	chr12:86229804	RASSF9	0.46	8.02	0.36	1.08e-14	Major depressive disorder;
LUAD	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg05425664	chr17:57184151	TRIM37	-0.44	-7.84	-0.36	3.71e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7759001	0.857	rs6903254	chr6:27362359	T/C	cg18711553	chr6:27366782	ZNF391	0.39	6.54	0.3	1.81e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg10755058	chr3:40428713	ENTPD3	-0.44	-8.46	-0.38	4.37e-16	Renal cell carcinoma;
LUAD	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg25985355	chr7:65971099	NA	0.54	6.67	0.31	8.07e-11	Diabetic kidney disease;
LUAD	cis	rs1461503	0.966	rs11218910	chr11:122842861	G/A	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs2274273	0.745	rs748017	chr14:55542300	A/G	cg04306507	chr14:55594613	LGALS3	0.32	6.45	0.3	3.13e-10	Protein biomarker;
LUAD	cis	rs6138458	1.000	rs227630	chr20:24913584	A/G	cg06937882	chr20:24974362	C20orf3	-0.32	-6.35	-0.3	5.42e-10	Blood protein levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07350163	chr17:62833479	PLEKHM1P	-0.58	-7.02	-0.32	8.61e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg04586622	chr2:25135609	ADCY3	0.38	8.51	0.38	3e-16	Body mass index;
LUAD	cis	rs17362650	0.694	rs10929582	chr2:9585200	C/G	cg12832956	chr2:9616023	IAH1	0.48	8.71	0.39	6.75e-17	Alcohol dependence (age at onset);
LUAD	cis	rs7598759	0.548	rs1823328	chr2:232355184	G/A	cg19187155	chr2:232395269	NMUR1	0.51	9.62	0.42	5.98e-20	Noise-induced hearing loss;
LUAD	trans	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg04565464	chr8:145669602	NFKBIL2	0.45	6.5	0.3	2.22e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-7.95	-0.36	1.72e-14	Bipolar disorder;
LUAD	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-8.29	-0.37	1.5e-15	Type 2 diabetes;
LUAD	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg07305463	chr2:136567211	LCT	0.38	7.25	0.33	2.04e-12	Mosquito bite size;
LUAD	cis	rs7659604	0.540	rs10020581	chr4:122676559	A/C	cg06713675	chr4:122721982	EXOSC9	0.42	7.68	0.35	1.11e-13	Type 2 diabetes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19767650	chr1:183605181	ARPC5;RGL1	-0.44	-7.53	-0.34	3.05e-13	Cancer;
LUAD	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs4629710	0.592	rs749375	chr6:131553692	C/G	cg12606694	chr6:131520996	AKAP7	0.51	7.36	0.34	9.5e-13	Multiple myeloma (IgH translocation);
LUAD	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21659725	chr3:3221576	CRBN	-0.5	-8.17	-0.37	3.62e-15	Body mass index;
LUAD	trans	rs675828	0.582	rs9557916	chr13:103352613	C/T	cg11864592	chr15:85833204	NA	0.3	6.42	0.3	3.61e-10	Borderline personality disorder;
LUAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.77	-0.31	4.31e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg11833968	chr6:79620685	NA	-0.44	-8.04	-0.36	9.25e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.67	-8.86	-0.4	2.25e-17	Yeast infection;
LUAD	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg15133208	chr4:90757351	SNCA	-0.46	-6.97	-0.32	1.21e-11	Neuroticism;
LUAD	trans	rs412658	0.704	rs8105767	chr19:22215441	A/G	cg17074339	chr11:11642133	GALNTL4	-0.36	-6.63	-0.31	1.01e-10	Telomere length;
LUAD	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg10940203	chr5:177434438	FAM153C	0.47	9.02	0.4	6.58e-18	Methadone dose in opioid dependence;
LUAD	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg23533926	chr12:111358616	MYL2	-0.4	-6.77	-0.31	4.23e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg02725872	chr8:58115012	NA	-0.33	-6.46	-0.3	2.9e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg07432352	chr17:45403706	C17orf57	-0.39	-7.51	-0.34	3.55e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs9354308	0.932	rs1938061	chr6:66545581	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-7.3	-0.33	1.4e-12	Metabolite levels;
LUAD	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	6.72	0.31	6.04e-11	Personality dimensions;
LUAD	cis	rs8062405	0.698	rs10499	chr16:28915527	G/A	cg05966235	chr16:28915196	ATP2A1	-0.54	-8.43	-0.38	5.49e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg13736514	chr6:26305472	NA	0.46	7.62	0.35	1.67e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg26384229	chr12:38710491	ALG10B	0.42	7.02	0.32	8.9e-12	Morning vs. evening chronotype;
LUAD	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg21984481	chr17:79567631	NPLOC4	-0.55	-11.59	-0.49	3.65e-27	Eye color traits;
LUAD	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.64	-0.31	9.8e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7072216	0.770	rs7897357	chr10:100163597	C/T	cg26618903	chr10:100175079	PYROXD2	-0.35	-7.78	-0.35	5.6e-14	Metabolite levels;
LUAD	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg14343924	chr8:8086146	FLJ10661	0.46	7.21	0.33	2.62e-12	Mood instability;
LUAD	trans	rs629535	0.699	rs539956	chr8:70033647	G/A	cg21567404	chr3:27674614	NA	1.01	18.47	0.67	2.91e-56	Dupuytren's disease;
LUAD	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.44	0.45	7.31e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.55	-6.99	-0.32	1.05e-11	Alzheimer's disease;
LUAD	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg15962314	chr1:44399869	ARTN	0.33	7.5	0.34	3.72e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	6.78	0.31	3.95e-11	Platelet count;
LUAD	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg21238619	chr17:78079768	GAA	-0.34	-6.74	-0.31	5.17e-11	Yeast infection;
LUAD	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	14.99	0.59	4.6e-41	Smoking behavior;
LUAD	cis	rs17095355	1.000	rs12569906	chr10:111706856	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.69	-9.22	-0.41	1.46e-18	Biliary atresia;
LUAD	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.66	-11.62	-0.49	2.68e-27	Breast cancer;
LUAD	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg00999904	chr2:3704751	ALLC	-0.38	-7.03	-0.32	8.4e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg02428538	chr16:24856791	SLC5A11	-0.53	-7.3	-0.33	1.47e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.22	-0.41	1.41e-18	Alzheimer's disease;
LUAD	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg11645453	chr3:52864694	ITIH4	0.38	7.86	0.36	3.22e-14	Bipolar disorder;
LUAD	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg22906224	chr7:99728672	NA	0.62	10.04	0.44	2.04e-21	Coronary artery disease;
LUAD	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg21191810	chr6:118973309	C6orf204	-0.52	-8.1	-0.37	5.88e-15	Diastolic blood pressure;
LUAD	cis	rs12900413	0.687	rs12902786	chr15:90304376	G/A	cg24249390	chr15:90295951	MESP1	-0.35	-6.77	-0.31	4.24e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs11811982	0.793	rs116838175	chr1:227442373	C/T	cg24860534	chr1:227506868	CDC42BPA	0.63	6.86	0.32	2.45e-11	Optic disc area;
LUAD	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.65	9.01	0.4	6.98e-18	Gut microbiome composition (summer);
LUAD	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg22532475	chr10:104410764	TRIM8	-0.43	-8.53	-0.38	2.67e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6993813	0.589	rs4397431	chr8:120018413	G/A	cg01975934	chr8:119970761	NA	-0.34	-6.59	-0.3	1.34e-10	Bone mineral density (hip);
LUAD	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.97	0.36	1.5e-14	Depression;
LUAD	cis	rs35995292	0.534	rs28460817	chr7:38921917	T/C	cg19327137	chr7:38886074	VPS41	0.73	15.41	0.6	7.25e-43	Subjective well-being (multi-trait analysis);
LUAD	cis	rs9581857	0.547	rs9319374	chr13:28047587	A/C	cg22138327	chr13:27999177	GTF3A	0.89	9.83	0.43	1.12e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.44	-7.63	-0.35	1.56e-13	Age at first birth;
LUAD	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg19592336	chr6:28129416	ZNF389	-0.42	-6.36	-0.3	5.31e-10	Depression;
LUAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg20607798	chr8:58055168	NA	0.57	7.28	0.33	1.6e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs7395662	0.624	rs11040162	chr11:48959991	C/T	cg15704280	chr7:45808275	SEPT13	0.42	6.55	0.3	1.65e-10	HDL cholesterol;
LUAD	cis	rs72766638	0.806	rs56303154	chr9:136936376	C/T	cg13789015	chr9:136890014	NCRNA00094	0.61	7.87	0.36	3.07e-14	Mosquito bite size;
LUAD	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.27	-6.76	-0.31	4.73e-11	Total body bone mineral density;
LUAD	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg10434728	chr15:90938212	IQGAP1	0.36	7.03	0.32	8.46e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	trans	rs7746199	0.736	rs34038546	chr6:27607660	C/A	cg01620082	chr3:125678407	NA	-1.04	-10.21	-0.44	4.98e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg27129171	chr3:47204927	SETD2	0.43	6.97	0.32	1.2e-11	Colorectal cancer;
LUAD	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.74	0.39	5.73e-17	Menarche (age at onset);
LUAD	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg15448220	chr1:150897856	SETDB1	0.55	9.5	0.42	1.58e-19	Melanoma;
LUAD	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg04703951	chr17:43578652	NA	0.59	8.26	0.37	1.85e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg08798685	chr6:27730294	NA	-0.64	-6.35	-0.3	5.52e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg25554036	chr4:6271136	WFS1	0.67	13.15	0.54	2.32e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg10645314	chr2:3704589	ALLC	-0.44	-7.36	-0.34	9.41e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.46	0.52	1.41e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg22683308	chr4:1340831	KIAA1530	-0.41	-6.65	-0.31	9.15e-11	Longevity;
LUAD	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.84	0.36	3.79e-14	Bladder cancer;
LUAD	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.98	-0.36	1.37e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs12210905	0.688	rs12212348	chr6:27361242	T/C	cg08851530	chr6:28072375	NA	1.09	7.95	0.36	1.69e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg04772025	chr11:68637568	NA	0.56	8.71	0.39	6.96e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg16797656	chr11:68205561	LRP5	-0.46	-10.08	-0.44	1.44e-21	Total body bone mineral density;
LUAD	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg11822812	chr5:140052017	DND1	-0.4	-7.44	-0.34	5.65e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg14829155	chr15:31115871	NA	-0.6	-9.81	-0.43	1.29e-20	Huntington's disease progression;
LUAD	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg19622623	chr12:86230825	RASSF9	-0.44	-7.76	-0.35	6.24e-14	Major depressive disorder;
LUAD	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.33	-0.45	1.83e-22	Monocyte percentage of white cells;
LUAD	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.18	12.59	0.52	4.24e-31	Lung cancer in ever smokers;
LUAD	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg14092988	chr3:52407081	DNAH1	0.42	8.51	0.38	3.02e-16	Bipolar disorder;
LUAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg10729496	chr3:10149963	C3orf24	0.64	9.64	0.42	5.1e-20	Alzheimer's disease;
LUAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06873352	chr17:61820015	STRADA	0.82	18.34	0.67	1.09e-55	Prudent dietary pattern;
LUAD	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23158103	chr7:148848205	ZNF398	-0.64	-11.93	-0.5	1.72e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg02527881	chr3:46936655	PTH1R	-0.56	-11.45	-0.49	1.25e-26	Colorectal cancer;
LUAD	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg03929089	chr4:120376271	NA	-0.97	-21.04	-0.72	9.45e-68	Height;
LUAD	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg09455208	chr3:40491958	NA	0.57	12.56	0.52	5.67e-31	Renal cell carcinoma;
LUAD	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg25319279	chr11:5960081	NA	-0.43	-7.46	-0.34	5.12e-13	DNA methylation (variation);
LUAD	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.37	-7.35	-0.34	1.02e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.01	-0.5	8.8e-29	Primary sclerosing cholangitis;
LUAD	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg25985355	chr7:65971099	NA	0.55	6.9	0.32	1.91e-11	Gout;
LUAD	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg01579765	chr21:45077557	HSF2BP	-0.63	-15.13	-0.59	1.24e-41	Mean corpuscular volume;
LUAD	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg15704280	chr7:45808275	SEPT13	-0.84	-13.73	-0.56	1.01e-35	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11890956	chr21:40555474	PSMG1	0.79	13.79	0.56	5.42e-36	Cognitive function;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06756557	chr10:90639746	STAMBPL1	-0.43	-6.74	-0.31	5.33e-11	Height;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg27063720	chr12:132568987	EP400NL	-0.63	-6.38	-0.3	4.7e-10	Type 2 diabetes;
LUAD	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg21951975	chr1:209979733	IRF6	0.56	8.06	0.36	7.85e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs4699052	0.963	rs11943325	chr4:104178393	T/C	cg16532752	chr4:104119610	CENPE	-0.47	-7.18	-0.33	3.21e-12	Testicular germ cell tumor;
LUAD	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12618769	0.597	rs17502889	chr2:99031745	A/G	cg10123293	chr2:99228465	UNC50	0.45	7.97	0.36	1.48e-14	Bipolar disorder;
LUAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg02869364	chr7:1081709	C7orf50	-0.53	-6.79	-0.31	3.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9863	0.828	rs12833624	chr12:124476873	C/T	cg17723958	chr12:124429295	CCDC92	-0.39	-6.44	-0.3	3.24e-10	White blood cell count;
LUAD	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg03676636	chr4:99064102	C4orf37	0.37	9.22	0.41	1.46e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs208520	0.661	rs207111	chr6:66792513	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.32	-0.64	3.48e-51	Exhaled nitric oxide output;
LUAD	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg02569458	chr12:86230093	RASSF9	0.42	7.56	0.34	2.55e-13	Major depressive disorder;
LUAD	cis	rs13082711	0.516	rs1388786	chr3:27372222	G/A	cg02860705	chr3:27208620	NA	-0.55	-9.23	-0.41	1.33e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs2554380	0.943	rs2033071	chr15:84365434	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.55	-8.36	-0.38	9.35e-16	Height;
LUAD	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.55	7.83	0.36	3.94e-14	Platelet count;
LUAD	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg05340658	chr4:99064831	C4orf37	0.54	9.16	0.41	2.2e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2274273	0.870	rs13379169	chr14:55741287	C/T	cg04306507	chr14:55594613	LGALS3	0.42	8.64	0.39	1.14e-16	Protein biomarker;
LUAD	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg05283184	chr6:79620031	NA	-0.55	-11.03	-0.47	4.8e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs12472274	0.646	rs10929269	chr2:239097423	A/G	cg17459225	chr2:239074497	NA	0.65	7.36	0.34	9.39e-13	Phospholipid levels (plasma);
LUAD	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg02475777	chr4:1388615	CRIPAK	-0.49	-7.21	-0.33	2.63e-12	Obesity-related traits;
LUAD	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg22529645	chr1:3704559	LRRC47	0.52	10.01	0.44	2.54e-21	Red cell distribution width;
LUAD	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.98	0.36	1.42e-14	Parkinson's disease;
LUAD	cis	rs80319144	0.535	rs3771596	chr2:159393539	A/C	cg24986868	chr2:159312599	PKP4;CCDC148	-0.37	-7.43	-0.34	6.11e-13	Restless legs syndrome;
LUAD	cis	rs2235642	0.859	rs9927529	chr16:1619488	C/T	cg09065629	chr16:1709722	CRAMP1L	0.42	7.28	0.33	1.68e-12	Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg21605333	chr4:119757512	SEC24D	0.93	8.76	0.39	4.58e-17	Cannabis dependence symptom count;
LUAD	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg20503657	chr10:835505	NA	0.98	14.74	0.58	5.35e-40	Eosinophil percentage of granulocytes;
LUAD	cis	rs2882667	0.537	rs10057545	chr5:138431008	G/A	cg04439458	chr5:138467593	SIL1	-0.36	-6.67	-0.31	8.27e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg00204512	chr16:28754710	NA	-0.36	-7.78	-0.35	5.69e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg06064525	chr11:970664	AP2A2	-0.55	-11.23	-0.48	8.32e-26	Alzheimer's disease (late onset);
LUAD	cis	rs62400317	0.859	rs10948201	chr6:45093494	A/C	cg18551225	chr6:44695536	NA	0.52	8.08	0.37	6.84e-15	Total body bone mineral density;
LUAD	cis	rs701145	0.640	rs184825	chr3:153931342	C/G	cg17054900	chr3:154042577	DHX36	-0.68	-7.55	-0.34	2.65e-13	Coronary artery disease;
LUAD	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg00666640	chr1:248458726	OR2T12	0.35	8.44	0.38	5.01e-16	Common traits (Other);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg12501923	chr17:73937416	FBF1	0.42	6.86	0.32	2.48e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg16606324	chr3:10149918	C3orf24	0.67	9.78	0.43	1.69e-20	Alzheimer's disease;
LUAD	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg09184832	chr6:79620586	NA	0.5	9.46	0.42	2.25e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs6740322	0.895	rs10172375	chr2:43572047	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.75	-11.0	-0.47	6.2e-25	Coronary artery disease;
LUAD	trans	rs1728785	1.000	rs1615609	chr16:68596401	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.34	0.45	1.73e-22	Ulcerative colitis;
LUAD	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg25894440	chr7:65020034	NA	-0.6	-6.44	-0.3	3.33e-10	Diabetic kidney disease;
LUAD	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.55	-0.34	2.7e-13	Total cholesterol levels;
LUAD	cis	rs7819412	0.560	rs13265553	chr8:10989057	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.5	-0.3	2.28e-10	Triglycerides;
LUAD	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg21918786	chr6:109611834	NA	0.58	10.96	0.47	9.09e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs1018836	0.631	rs2205157	chr8:91472384	C/T	cg16814680	chr8:91681699	NA	-0.56	-9.31	-0.41	6.85e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2835872	0.759	rs2835896	chr21:39066640	A/G	cg06728970	chr21:39037746	KCNJ6	0.38	6.62	0.31	1.1e-10	Electroencephalographic traits in alcoholism;
LUAD	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg04511125	chr2:88470314	THNSL2	-0.52	-8.81	-0.39	3.3e-17	Response to metformin (IC50);
LUAD	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg03433033	chr1:76189801	ACADM	0.84	15.05	0.59	2.6e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg09998033	chr7:158218633	PTPRN2	-0.5	-9.09	-0.4	3.92e-18	Obesity-related traits;
LUAD	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg13012494	chr21:47604986	C21orf56	0.47	7.75	0.35	6.93e-14	Testicular germ cell tumor;
LUAD	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg19442545	chr10:75533431	FUT11	-0.48	-7.88	-0.36	2.75e-14	Inflammatory bowel disease;
LUAD	cis	rs12950390	0.530	rs16947058	chr17:45825186	A/G	cg03474202	chr17:45855739	NA	0.28	6.7	0.31	6.7e-11	IgG glycosylation;
LUAD	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg11833968	chr6:79620685	NA	-0.44	-8.32	-0.38	1.22e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.1	-15.65	-0.61	6.8e-44	Schizophrenia;
LUAD	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg17264618	chr3:40429014	ENTPD3	0.37	8.32	0.37	1.26e-15	Renal cell carcinoma;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04435241	chr20:2442475	SNRPB	0.56	6.95	0.32	1.39e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs501916	0.634	rs603569	chr15:48058929	G/A	cg16110827	chr15:48056943	SEMA6D	-0.35	-6.53	-0.3	1.91e-10	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs4604732	0.536	rs12037221	chr1:247631212	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.12	0.33	4.82e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg10757852	chr3:141319363	RASA2	-0.47	-6.48	-0.3	2.6200000000000003e-10	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4730250	0.707	rs6977868	chr7:106790555	T/G	cg23024343	chr7:107201750	COG5	-0.51	-6.75	-0.31	4.81e-11	Osteoarthritis;
LUAD	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg05887092	chr17:76393375	PGS1	0.41	7.28	0.33	1.65e-12	HDL cholesterol levels;
LUAD	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg18827107	chr12:86230957	RASSF9	-0.68	-12.48	-0.52	1.24e-30	Major depressive disorder;
LUAD	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg11663144	chr21:46675770	NA	-0.49	-8.46	-0.38	4.36e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.58e-13	Tonsillectomy;
LUAD	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	7.74e-16	Body mass index;
LUAD	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg07741184	chr6:167504864	NA	0.32	7.5	0.34	3.8e-13	Crohn's disease;
LUAD	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg00255919	chr5:131827918	IRF1	-0.5	-11.71	-0.49	1.29e-27	Asthma (sex interaction);
LUAD	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg05182265	chr7:156933206	UBE3C	-0.81	-17.37	-0.65	2.13e-51	Body mass index;
LUAD	trans	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-16.49	-0.63	1.49e-47	Colorectal cancer;
LUAD	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg18446336	chr7:2847575	GNA12	-0.37	-6.92	-0.32	1.7e-11	Height;
LUAD	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg14345882	chr6:26364793	BTN3A2	0.7	7.1	0.33	5.18e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16266895	chr12:101674004	UTP20	-0.4	-6.42	-0.3	3.63e-10	Height;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02357741	chr19:55813339	BRSK1	-0.4	-6.49	-0.3	2.4e-10	Cancer;
LUAD	cis	rs9549328	0.589	rs36164841	chr13:113616579	A/G	cg17524180	chr13:113633600	MCF2L	0.3	6.43	0.3	3.51e-10	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg05340658	chr4:99064831	C4orf37	0.53	9.05	0.4	5.17e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.76	-0.35	6.24e-14	Total body bone mineral density;
LUAD	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg22906224	chr7:99728672	NA	-0.57	-9.94	-0.44	4.44e-21	Coronary artery disease;
LUAD	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg25566285	chr7:158114605	PTPRN2	0.53	11.36	0.48	2.88e-26	Calcium levels;
LUAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg16606324	chr3:10149918	C3orf24	0.67	9.78	0.43	1.69e-20	Alzheimer's disease;
LUAD	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02018176	chr4:1364513	KIAA1530	0.7	12.21	0.51	1.39e-29	Longevity;
LUAD	cis	rs478304	0.718	rs1151490	chr11:65390485	A/C	cg27068330	chr11:65405492	SIPA1	0.61	9.55	0.42	1.02e-19	Acne (severe);
LUAD	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg06046430	chr4:77819534	ANKRD56	0.55	8.84	0.4	2.53e-17	Emphysema distribution in smoking;
LUAD	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-7.73	-0.35	8.11e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs35883536	0.647	rs12043865	chr1:101042651	G/A	cg06223162	chr1:101003688	GPR88	-0.47	-9.0	-0.4	7.76e-18	Monocyte count;
LUAD	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg18306943	chr3:40428807	ENTPD3	0.37	6.62	0.31	1.11e-10	Renal cell carcinoma;
LUAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.19	0.54	1.68e-33	Prudent dietary pattern;
LUAD	cis	rs1448094	0.842	rs10779231	chr12:86462237	T/C	cg00310523	chr12:86230176	RASSF9	-0.35	-7.23	-0.33	2.21e-12	Major depressive disorder;
LUAD	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg17366294	chr4:99064904	C4orf37	0.47	8.22	0.37	2.57e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg03806693	chr22:41940476	POLR3H	0.74	9.85	0.43	9.53e-21	Vitiligo;
LUAD	trans	rs9908158	1	rs9908158	chr17:33890083	T/C	cg19694781	chr19:47549865	TMEM160	0.62	10.14	0.44	8.62e-22	Platelet count;Platelet distribution width;
LUAD	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg06781209	chr11:61594997	FADS2	-0.4	-7.53	-0.34	3.15e-13	Trans fatty acid levels;
LUAD	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg12000995	chr2:27665139	KRTCAP3	0.33	8.38	0.38	8.04e-16	Total body bone mineral density;
LUAD	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg08859206	chr1:53392774	SCP2	0.56	10.15	0.44	8.44e-22	Monocyte count;
LUAD	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg27490568	chr2:178487706	NA	0.58	8.6	0.39	1.55e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.29	0.33	1.58e-12	Menopause (age at onset);
LUAD	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg03433033	chr1:76189801	ACADM	-0.51	-7.44	-0.34	5.76e-13	Daytime sleep phenotypes;
LUAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg22963979	chr7:1858916	MAD1L1	-0.54	-9.2	-0.41	1.71e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg08859206	chr1:53392774	SCP2	-0.5	-8.99	-0.4	8.39e-18	Monocyte count;
LUAD	cis	rs7191439	0.789	rs4433802	chr16:88784964	A/G	cg27087555	chr16:88793112	FAM38A	-1.35	-11.75	-0.5	9.08e-28	Plateletcrit;
LUAD	cis	rs36051895	0.632	rs10974983	chr9:5149657	G/T	cg02405213	chr9:5042618	JAK2	-0.51	-6.78	-0.31	4.01e-11	Pediatric autoimmune diseases;
LUAD	cis	rs7215564	0.908	rs34135683	chr17:78652903	G/T	cg09596252	chr17:78655493	RPTOR	0.56	6.91	0.32	1.81e-11	Myopia (pathological);
LUAD	cis	rs7727544	0.582	rs3828675	chr5:131546868	G/A	cg14196790	chr5:131705035	SLC22A5	0.42	7.2	0.33	2.7e-12	Blood metabolite levels;
LUAD	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg02782426	chr3:40428986	ENTPD3	0.42	9.35	0.41	4.95e-19	Renal cell carcinoma;
LUAD	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg08999081	chr20:33150536	PIGU	0.48	9.29	0.41	8.12e-19	Coronary artery disease;
LUAD	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg23262073	chr20:60523788	NA	-0.37	-6.37	-0.3	5.09e-10	Body mass index;
LUAD	cis	rs737008	0.959	rs11865598	chr16:11403432	T/C	cg00044050	chr16:11439710	C16orf75	0.48	6.99	0.32	1.08e-11	Obesity-related traits;
LUAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg08132940	chr7:1081526	C7orf50	-0.44	-6.69	-0.31	7.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg23131131	chr22:24373011	LOC391322	0.47	6.72	0.31	6.02e-11	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08677398	chr8:58056175	NA	0.47	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg18944383	chr4:111397179	ENPEP	0.38	7.76	0.35	6.25e-14	Height;
LUAD	cis	rs72634501	0.517	rs10788925	chr1:39594102	C/T	cg27567593	chr1:39956653	BMP8A	0.35	6.98	0.32	1.11e-11	HDL cholesterol;
LUAD	cis	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg17218026	chr1:154582156	ADAR	-0.42	-8.15	-0.37	4.27e-15	Blood protein levels;
LUAD	cis	rs427394	1.000	rs182135	chr5:6747453	G/A	cg10857441	chr5:6722123	POLS	-0.6	-11.33	-0.48	3.52e-26	Menopause (age at onset);
LUAD	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg08382946	chr5:1082689	SLC12A7	-0.43	-7.26	-0.33	1.93e-12	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg06740227	chr12:86229804	RASSF9	0.46	7.91	0.36	2.26e-14	Major depressive disorder;
LUAD	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.95	-0.36	1.78e-14	Monocyte percentage of white cells;
LUAD	trans	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	11.96	0.5	1.29e-28	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.83	-0.39	2.84e-17	Total body bone mineral density;
LUAD	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg15557168	chr22:42548783	NA	-0.5	-9.19	-0.41	1.79e-18	Schizophrenia;
LUAD	trans	rs2270927	0.510	rs4566771	chr5:75576522	C/T	cg13563193	chr19:33072644	PDCD5	0.98	9.3	0.41	7.48e-19	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg07917127	chr4:99064746	C4orf37	0.39	6.47	0.3	2.64e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg06713675	chr4:122721982	EXOSC9	0.46	8.45	0.38	4.91e-16	Type 2 diabetes;
LUAD	cis	rs7173743	0.756	rs8030937	chr15:79129587	G/T	cg15571903	chr15:79123663	NA	0.42	8.3	0.37	1.41e-15	Coronary artery disease;
LUAD	cis	rs7173743	0.750	rs12903355	chr15:79129145	A/T	cg15571903	chr15:79123663	NA	0.39	7.82	0.36	4.16e-14	Coronary artery disease;
LUAD	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg16102102	chr5:83017553	HAPLN1	-0.62	-12.04	-0.51	6.66e-29	Prostate cancer;
LUAD	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg15900387	chr1:150738905	CTSS	-0.37	-6.72	-0.31	5.98e-11	Melanoma;
LUAD	cis	rs2996428	0.561	rs12134919	chr1:3744641	G/A	cg17848003	chr1:3704513	LRRC47	0.48	9.81	0.43	1.38e-20	Red cell distribution width;
LUAD	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg27490568	chr2:178487706	NA	-0.61	-8.88	-0.4	1.91e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg23625390	chr15:77176239	SCAPER	0.39	6.83	0.32	3.02e-11	Blood metabolite levels;
LUAD	cis	rs6594713	0.837	rs71577447	chr5:112753957	T/C	cg12552261	chr5:112820674	MCC	0.48	6.94	0.32	1.45e-11	Brain cytoarchitecture;
LUAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.55	-9.73	-0.43	2.6e-20	Lymphocyte counts;
LUAD	cis	rs13028485	1.000	rs553165	chr2:174508728	C/T	cg03874601	chr2:174505619	NA	-0.59	-6.41	-0.3	3.84e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs7633770	0.710	rs11710586	chr3:46693457	A/G	cg11219411	chr3:46661640	NA	-0.46	-9.4	-0.42	3.56e-19	Coronary artery disease;
LUAD	trans	rs1547374	0.737	rs178741	chr21:43779408	G/A	cg09521743	chr10:75415752	SYNPO2L	0.51	9.45	0.42	2.43e-19	Pancreatic cancer;
LUAD	cis	rs12208915	0.945	rs12201183	chr6:79570120	A/G	cg05283184	chr6:79620031	NA	0.52	6.45	0.3	3.04e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg21724239	chr8:58056113	NA	0.72	9.56	0.42	1.01e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08219700	chr8:58056026	NA	0.61	8.59	0.39	1.64e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4604732	0.588	rs4925551	chr1:247631724	T/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.12	0.33	4.82e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs72793342	1.000	rs72793342	chr16:30548352	G/A	cg02466173	chr16:30829666	NA	-0.52	-7.15	-0.33	3.77e-12	RANTES levels;
LUAD	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.28	-0.41	8.54e-19	Life satisfaction;
LUAD	cis	rs4774899	0.966	rs1814585	chr15:57509058	A/G	cg14026238	chr15:57616123	NA	0.35	6.62	0.31	1.11e-10	Urinary tract infection frequency;
LUAD	cis	rs4964805	0.770	rs11111779	chr12:104185496	G/A	cg02344784	chr12:104178138	NT5DC3	0.41	7.33	0.34	1.21e-12	Attention deficit hyperactivity disorder;
LUAD	cis	rs603446	0.678	rs664059	chr11:116642137	C/T	cg08672956	chr11:116640933	BUD13	0.33	6.45	0.3	3.09e-10	Triglycerides;
LUAD	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg00484396	chr16:3507460	NAT15	0.71	12.43	0.52	1.91e-30	Tuberculosis;
LUAD	cis	rs909002	0.849	rs10798881	chr1:32101775	G/C	cg13919466	chr1:32135498	COL16A1	-0.36	-8.38	-0.38	7.72e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg24642844	chr7:1081250	C7orf50	-0.96	-14.27	-0.57	5.21e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg24324837	chr19:49891574	CCDC155	0.55	8.6	0.39	1.62e-16	Multiple sclerosis;
LUAD	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg06002616	chr8:101225028	SPAG1	-0.38	-7.73	-0.35	7.91e-14	Atrioventricular conduction;
LUAD	cis	rs813218	0.585	rs9860514	chr3:99917359	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-8.62	-0.39	1.33e-16	Orofacial clefts;
LUAD	cis	rs2880765	0.546	rs36098649	chr15:86056807	C/T	cg13263323	chr15:86062960	AKAP13	-0.52	-8.75	-0.39	5.23e-17	Coronary artery disease;
LUAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg07677032	chr17:61819896	STRADA	-0.54	-9.74	-0.43	2.24e-20	Prudent dietary pattern;
LUAD	cis	rs10781543	0.839	rs7863766	chr9:139381314	T/G	cg14019695	chr9:139328340	INPP5E	0.53	10.34	0.45	1.69e-22	Monocyte percentage of white cells;
LUAD	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg08514558	chr10:81106712	PPIF	0.44	8.32	0.38	1.19e-15	Height;
LUAD	cis	rs524023	0.957	rs561193	chr11:64353029	A/G	cg19131476	chr11:64387923	NRXN2	0.35	6.66	0.31	8.46e-11	Urate levels in obese individuals;
LUAD	cis	rs66823261	0.778	rs2906332	chr8:194943	C/T	cg27532244	chr8:182981	ZNF596;RPL23AP53	-0.67	-8.84	-0.4	2.53e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.81	-0.35	4.63e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-7.03	-0.32	8.33e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs6561151	0.681	rs7995955	chr13:44434836	C/G	cg17145862	chr1:211918768	LPGAT1	0.53	7.32	0.34	1.3e-12	Crohn's disease;
LUAD	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg25767906	chr1:53392781	SCP2	-0.48	-8.62	-0.39	1.33e-16	Monocyte count;
LUAD	cis	rs9323205	0.861	rs55763867	chr14:51608567	G/A	cg23942311	chr14:51606299	NA	-0.62	-10.14	-0.44	9.19e-22	Cancer;
LUAD	trans	rs8002861	0.840	rs1819596	chr13:44429554	A/G	cg17145862	chr1:211918768	LPGAT1	0.73	16.48	0.63	1.74e-47	Leprosy;
LUAD	cis	rs3733418	0.929	rs13149062	chr4:165905360	T/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.49	-6.98	-0.32	1.16e-11	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.51e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg22907277	chr7:1156413	C7orf50	0.71	8.31	0.37	1.29e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg14019146	chr3:50243930	SLC38A3	-0.41	-6.77	-0.31	4.23e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg10468373	chr11:64009913	FKBP2	0.53	6.83	0.32	2.93e-11	Mean platelet volume;
LUAD	cis	rs4774899	0.966	rs12904501	chr15:57507617	C/T	cg14026238	chr15:57616123	NA	0.36	6.76	0.31	4.72e-11	Urinary tract infection frequency;
LUAD	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg03037974	chr15:76606532	NA	0.38	8.03	0.36	9.65e-15	Blood metabolite levels;
LUAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg14789911	chr21:47582049	C21orf56	-0.4	-6.94	-0.32	1.46e-11	Testicular germ cell tumor;
LUAD	cis	rs977987	0.800	rs12935787	chr16:75332335	C/T	cg03315344	chr16:75512273	CHST6	0.64	13.92	0.56	1.55e-36	Dupuytren's disease;
LUAD	cis	rs11800820	0.557	rs10924755	chr1:246666347	T/A	cg16700716	chr1:246684329	NA	0.38	7.04	0.32	7.67e-12	Obesity-related traits;
LUAD	trans	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.9	-0.32	1.97e-11	Diabetic kidney disease;
LUAD	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.08	0.33	6.01e-12	Motion sickness;
LUAD	cis	rs68170813	0.617	rs6964395	chr7:107080667	G/C	cg02696742	chr7:106810147	HBP1	-0.76	-8.87	-0.4	2.1e-17	Coronary artery disease;
LUAD	cis	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg07460842	chr6:66804631	NA	1.04	16.33	0.62	7.55e-47	Exhaled nitric oxide output;
LUAD	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg03806693	chr22:41940476	POLR3H	0.74	9.95	0.44	4.2e-21	Vitiligo;
LUAD	cis	rs1595825	0.891	rs7583917	chr2:198576950	A/G	cg00982548	chr2:198649783	BOLL	-0.62	-9.14	-0.41	2.65e-18	Ulcerative colitis;
LUAD	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg17333051	chr19:2783644	SGTA	0.47	7.24	0.33	2.17e-12	Total cholesterol levels;
LUAD	cis	rs10484885	0.824	rs72921954	chr6:90586656	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.66	-6.59	-0.31	1.3100000000000001e-10	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9399401	0.961	rs9403381	chr6:142661156	A/C	cg03128060	chr6:142623767	GPR126	-0.33	-7.48	-0.34	4.25e-13	Chronic obstructive pulmonary disease;
LUAD	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11890956	chr21:40555474	PSMG1	-0.6	-9.83	-0.43	1.15e-20	Cognitive function;
LUAD	cis	rs3772130	0.564	rs9817555	chr3:121406327	G/A	cg20356878	chr3:121714668	ILDR1	0.59	11.1	0.47	2.69e-25	Cognitive performance;
LUAD	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg24818145	chr4:99064322	C4orf37	0.43	7.17	0.33	3.32e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs72634258	0.945	rs6577459	chr1:8100173	G/T	cg26816564	chr1:7831052	VAMP3	0.57	7.59	0.35	2.02e-13	Inflammatory bowel disease;
LUAD	cis	rs225245	0.782	rs321601	chr17:33892087	A/C	cg05299278	chr17:33885742	SLFN14	-0.51	-11.86	-0.5	3.39e-28	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs2412208	0.664	rs12025462	chr1:7107665	C/T	cg20434152	chr1:7120926	CAMTA1	0.35	7.72	0.35	8.54e-14	Survival in sporadic amyotrophic lateral sclerosis;
LUAD	cis	rs7707921	0.671	rs2406911	chr5:81312256	A/G	cg15871215	chr5:81402204	ATG10	0.52	8.03	0.36	1.01e-14	Breast cancer;
LUAD	trans	rs8002861	0.664	rs9525873	chr13:44482204	T/C	cg17145862	chr1:211918768	LPGAT1	0.63	12.98	0.53	1.19e-32	Leprosy;
LUAD	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.23	0.37	2.26e-15	Menopause (age at onset);
LUAD	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg09222892	chr1:25734099	RHCE	-0.46	-8.54	-0.38	2.5e-16	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs2882667	0.898	rs6862393	chr5:138364698	T/C	cg04439458	chr5:138467593	SIL1	-0.39	-7.11	-0.33	4.96e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs9341808	0.538	rs9443742	chr6:81016929	T/G	cg08355045	chr6:80787529	NA	-0.41	-7.13	-0.33	4.43e-12	Sitting height ratio;
LUAD	cis	rs2932538	0.922	rs11102508	chr1:113141175	T/C	cg22162597	chr1:113214053	CAPZA1	0.41	6.36	0.3	5.17e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs4824093	0.610	rs7410773	chr22:50313727	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	6.35	0.3	5.44e-10	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg00277334	chr10:82204260	NA	-0.64	-8.72	-0.39	6.32e-17	Post bronchodilator FEV1;
LUAD	trans	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	1.04e-10	Diabetic kidney disease;
LUAD	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg09796270	chr17:17721594	SREBF1	-0.37	-6.96	-0.32	1.28e-11	Total body bone mineral density;
LUAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg22907277	chr7:1156413	C7orf50	0.7	8.19	0.37	3.05e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs17490626	0.533	rs5030925	chr10:71211150	A/C	cg12610070	chr10:71211762	TSPAN15	-0.41	-11.01	-0.47	5.84e-25	Thrombosis;
LUAD	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg12179176	chr11:130786555	SNX19	0.55	9.27	0.41	9.37e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg06552810	chr11:31128660	NA	-0.35	-6.85	-0.32	2.56e-11	Red blood cell count;
LUAD	cis	rs6993813	0.872	rs1905784	chr8:120014623	G/A	cg01975934	chr8:119970761	NA	-0.37	-7.18	-0.33	3.11e-12	Bone mineral density (hip);
LUAD	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg18944383	chr4:111397179	ENPEP	0.37	7.42	0.34	6.34e-13	Height;
LUAD	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg09455208	chr3:40491958	NA	0.5	10.61	0.46	1.79e-23	Renal cell carcinoma;
LUAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg01097406	chr16:89675127	NA	-0.3	-6.4	-0.3	4.04e-10	Vitiligo;
LUAD	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg13606994	chr1:44402422	ARTN	-0.33	-6.79	-0.31	3.82e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18876405	chr7:65276391	NA	-0.42	-6.58	-0.3	1.41e-10	Aortic root size;
LUAD	cis	rs4767364	1.000	rs2285810	chr12:112699540	T/C	cg10833066	chr12:111807467	FAM109A	0.34	6.44	0.3	3.19e-10	Oral cavity and pharyngeal cancer;
LUAD	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.42e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg15448220	chr1:150897856	SETDB1	0.47	8.34	0.38	1.08e-15	Tonsillectomy;
LUAD	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg18404041	chr3:52824283	ITIH1	-0.58	-10.77	-0.46	4.76e-24	Bipolar disorder;
LUAD	trans	rs783540	0.967	rs2870966	chr15:83295244	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.8	-0.31	3.64e-11	Schizophrenia;
LUAD	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg13180566	chr4:1052158	NA	-0.4	-6.73	-0.31	5.71e-11	Recombination rate (females);
LUAD	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg02782426	chr3:40428986	ENTPD3	0.35	7.65	0.35	1.33e-13	Renal cell carcinoma;
LUAD	trans	rs11165623	0.792	rs6593599	chr1:96911468	C/T	cg10631902	chr5:14652156	NA	-0.62	-12.11	-0.51	3.59e-29	Hip circumference;Waist circumference;
LUAD	trans	rs7181230	0.885	rs35781999	chr15:40355406	G/C	cg22705835	chr10:65332833	REEP3	-0.36	-6.74	-0.31	5.22e-11	Dehydroepiandrosterone sulphate levels;
LUAD	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg05064044	chr6:292385	DUSP22	-0.57	-9.21	-0.41	1.49e-18	Menopause (age at onset);
LUAD	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.56	6.77	0.31	4.26e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg10755058	chr3:40428713	ENTPD3	0.39	7.5	0.34	3.75e-13	Renal cell carcinoma;
LUAD	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg17761419	chr8:57350749	NA	-0.58	-8.85	-0.4	2.47e-17	Obesity-related traits;
LUAD	cis	rs4730250	0.634	rs11767623	chr7:106792332	C/T	cg23024343	chr7:107201750	COG5	-0.5	-6.87	-0.32	2.3e-11	Osteoarthritis;
LUAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg04025307	chr7:1156635	C7orf50	0.66	7.48	0.34	4.22e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08677398	chr8:58056175	NA	0.51	6.75	0.31	4.89e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10979	1.000	rs9386034	chr6:143890572	T/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.29	-0.45	2.51e-22	Hypospadias;
LUAD	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg20290983	chr6:43655470	MRPS18A	-0.89	-13.88	-0.56	2.34e-36	IgG glycosylation;
LUAD	trans	rs75804782	0.625	rs13382619	chr2:239467636	G/A	cg01134436	chr17:81009848	B3GNTL1	0.71	7.28	0.33	1.64e-12	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2387326	0.717	rs10829338	chr10:129943625	C/T	cg16087940	chr10:129947807	NA	-0.65	-9.09	-0.4	3.81e-18	Select biomarker traits;
LUAD	cis	rs2239547	0.522	rs6771610	chr3:53026104	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-8.82	-0.39	2.94e-17	Schizophrenia;
LUAD	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg01689657	chr7:91764605	CYP51A1	0.32	7.96	0.36	1.63e-14	Breast cancer;
LUAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg22907277	chr7:1156413	C7orf50	0.68	8.04	0.36	9.36e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.01	-0.44	2.61e-21	Monocyte percentage of white cells;
LUAD	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg05234568	chr11:5960015	NA	0.5	8.78	0.39	4.07e-17	DNA methylation (variation);
LUAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg16606324	chr3:10149918	C3orf24	0.68	11.12	0.48	2.23e-25	Alzheimer's disease;
LUAD	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg05182265	chr7:156933206	UBE3C	-0.8	-17.3	-0.64	4.19e-51	Body mass index;
LUAD	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24308560	chr3:49941425	MST1R	0.56	9.55	0.42	1.08e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs17095355	1.000	rs55683820	chr10:111665376	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-7.64	-0.35	1.46e-13	Biliary atresia;
LUAD	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg03714773	chr7:91764589	CYP51A1	0.28	6.51	0.3	2.19e-10	Breast cancer;
LUAD	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	8.17	0.37	3.6e-15	Breast cancer;
LUAD	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.77	0.39	4.55e-17	Menopause (age at onset);
LUAD	cis	rs1983170	0.736	rs11164909	chr1:92002506	T/C	cg02896835	chr1:92012615	NA	0.58	7.84	0.36	3.72e-14	Eosinophil percentage of white cells;
LUAD	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg10523679	chr1:76189770	ACADM	0.87	15.52	0.6	2.65e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.21	-17.75	-0.65	4.2e-53	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.18	-0.41	1.96e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11051970	0.838	rs2651369	chr12:32552769	C/G	cg24626660	chr12:32551988	NA	0.38	7.88	0.36	2.86e-14	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg05457628	chr5:178986728	RUFY1	-0.7	-11.76	-0.5	8.05e-28	Lung cancer;
LUAD	cis	rs9394152	0.845	rs7747216	chr6:33476718	A/G	cg13560919	chr6:33536144	NA	-0.51	-8.73	-0.39	6.17e-17	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21659725	chr3:3221576	CRBN	-0.87	-18.37	-0.67	7.79e-56	Intelligence (multi-trait analysis);
LUAD	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.72	-11.92	-0.5	1.89e-28	Primary sclerosing cholangitis;
LUAD	cis	rs4950928	0.823	rs946262	chr1:203158229	C/T	cg17014757	chr1:203156097	CHI3L1	0.57	8.41	0.38	6.37e-16	YKL-40 levels;
LUAD	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg26408565	chr15:76604113	ETFA	-0.45	-7.32	-0.34	1.28e-12	Blood metabolite levels;
LUAD	cis	rs4148087	1.000	rs2168344	chr21:43621496	C/G	cg08841829	chr21:43638893	ABCG1	-0.58	-7.64	-0.35	1.46e-13	Eating disorder in bipolar disorder;
LUAD	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.41	0.38	6.45e-16	Breast cancer;
LUAD	cis	rs6489882	0.867	rs4766672	chr12:113365148	A/G	cg20102336	chr12:113376681	OAS3	-0.59	-9.12	-0.41	3.1e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14829155	chr15:31115871	NA	0.78	13.23	0.54	1.12e-33	Huntington's disease progression;
LUAD	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg21475434	chr5:93447410	FAM172A	0.73	7.98	0.36	1.42e-14	Diabetic retinopathy;
LUAD	trans	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg19163074	chr7:65112434	INTS4L2	0.49	7.66	0.35	1.25e-13	Aortic root size;
LUAD	trans	rs11039798	1.000	rs8188963	chr11:48685693	C/A	cg03929089	chr4:120376271	NA	0.59	6.8	0.31	3.49e-11	Axial length;
LUAD	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg05896524	chr21:47604654	C21orf56	0.54	9.05	0.4	5.18e-18	Testicular germ cell tumor;
LUAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg07677032	chr17:61819896	STRADA	0.57	10.27	0.45	3.13e-22	Prudent dietary pattern;
LUAD	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.36	0.3	5.35e-10	Cognitive test performance;
LUAD	cis	rs2282300	0.739	rs1222216	chr11:30346052	C/T	cg25418670	chr11:30344373	C11orf46	-0.52	-7.09	-0.33	5.73e-12	Morning vs. evening chronotype;
LUAD	cis	rs89107	0.549	rs4945623	chr6:118980556	G/C	cg21191810	chr6:118973309	C6orf204	0.4	7.41	0.34	6.95e-13	Cardiac structure and function;
LUAD	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg23711669	chr6:146136114	FBXO30	0.4	6.7	0.31	6.53e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-8.56	-0.38	2.15e-16	Menarche (age at onset);
LUAD	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg18230493	chr5:56204884	C5orf35	-0.73	-10.64	-0.46	1.4e-23	Initial pursuit acceleration;
LUAD	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg05044414	chr3:183734942	ABCC5	0.39	7.98	0.36	1.41e-14	Anterior chamber depth;
LUAD	cis	rs11971779	0.648	rs10085708	chr7:139110954	A/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.38e-10	Diisocyanate-induced asthma;
LUAD	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg11494091	chr17:61959527	GH2	0.4	7.03	0.32	8.34e-12	Height;
LUAD	cis	rs758324	0.812	rs11242095	chr5:131152575	A/G	cg25547332	chr5:131281432	NA	0.44	7.16	0.33	3.6e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs738322	0.533	rs2284064	chr22:38547395	A/C	cg17652424	chr22:38574118	PLA2G6	-0.3	-8.42	-0.38	5.95e-16	Cutaneous nevi;
LUAD	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg18944383	chr4:111397179	ENPEP	0.38	7.66	0.35	1.31e-13	Height;
LUAD	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg25566285	chr7:158114605	PTPRN2	-0.54	-11.83	-0.5	4.35e-28	Calcium levels;
LUAD	cis	rs9512730	0.527	rs11619784	chr13:27999643	A/G	cg04070771	chr13:27998621	GTF3A	0.72	11.03	0.47	4.83e-25	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg11062466	chr8:58055876	NA	0.68	9.02	0.4	6.56e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs17401966	1.000	rs12136376	chr1:10296452	C/T	cg15208524	chr1:10270712	KIF1B	0.55	8.28	0.37	1.63e-15	Hepatocellular carcinoma;
LUAD	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.47	-0.3	2.78e-10	Aortic root size;
LUAD	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg07677032	chr17:61819896	STRADA	0.43	6.49	0.3	2.47e-10	Height;
LUAD	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.46	-7.33	-0.34	1.16e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg18252515	chr7:66147081	NA	-0.6	-6.54	-0.3	1.77e-10	Diabetic kidney disease;
LUAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg13560548	chr3:10150139	C3orf24	0.46	7.06	0.32	6.93e-12	Alzheimer's disease;
LUAD	cis	rs11112613	0.609	rs7350593	chr12:106038119	C/T	cg03607813	chr12:105948248	NA	0.49	6.58	0.3	1.42e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	4.04e-11	Depression;
LUAD	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg24675056	chr1:15929824	NA	0.48	8.35	0.38	9.85e-16	Systolic blood pressure;
LUAD	cis	rs6867032	1.000	rs10462750	chr5:2012963	A/G	cg26168224	chr5:2018326	NA	0.78	17.41	0.65	1.46e-51	Gut microbiome composition (winter);
LUAD	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg15790184	chr11:494944	RNH1	0.4	6.59	0.31	1.32e-10	Systemic lupus erythematosus;
LUAD	cis	rs240764	0.645	rs240152	chr6:101067489	G/C	cg09795085	chr6:101329169	ASCC3	0.39	6.74	0.31	5.28e-11	Neuroticism;
LUAD	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg23281280	chr6:28129359	ZNF389	0.46	6.65	0.31	9.18e-11	Depression;
LUAD	cis	rs11098699	0.718	rs13116874	chr4:124212211	T/C	cg09941581	chr4:124220074	SPATA5	0.5	8.15	0.37	4.25e-15	Mosquito bite size;
LUAD	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg23301539	chr8:142222248	SLC45A4	0.49	8.9	0.4	1.6e-17	Immature fraction of reticulocytes;
LUAD	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg21724239	chr8:58056113	NA	0.81	9.79	0.43	1.53e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22075475	chr11:47447566	PSMC3	-0.42	-7.06	-0.32	6.9e-12	Cancer;
LUAD	cis	rs6489785	0.509	rs4767937	chr12:121223244	G/C	cg02419362	chr12:121203948	SPPL3	0.39	7.88	0.36	2.9e-14	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18876405	chr7:65276391	NA	-0.55	-9.41	-0.42	3.3e-19	Aortic root size;
LUAD	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg21775007	chr8:11205619	TDH	-0.53	-9.53	-0.42	1.26e-19	Retinal vascular caliber;
LUAD	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg22676075	chr6:135203613	NA	0.42	7.76	0.35	6.24e-14	Red blood cell count;
LUAD	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg13319975	chr6:146136371	FBXO30	0.67	11.56	0.49	4.63e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg06453172	chr10:134556979	INPP5A	-0.66	-9.77	-0.43	1.84e-20	Migraine;
LUAD	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.92	-0.53	1.96e-32	Breast cancer;
LUAD	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg21100191	chr22:23484243	RTDR1	0.71	12.64	0.52	2.81e-31	Bone mineral density;
LUAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.43	-0.38	5.53e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg08885076	chr2:99613938	TSGA10	-0.4	-6.98	-0.32	1.12e-11	Chronic sinus infection;
LUAD	trans	rs853679	0.546	rs200949	chr6:27835435	A/G	cg01620082	chr3:125678407	NA	-0.79	-8.96	-0.4	1.08e-17	Depression;
LUAD	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg10295955	chr4:187884368	NA	-1.12	-27.72	-0.8	3.86e-97	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg00383909	chr3:49044727	WDR6	0.99	10.63	0.46	1.45e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	trans	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg27411982	chr8:10470053	RP1L1	-0.36	-6.6	-0.31	1.27e-10	Monocyte count;
LUAD	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg23505145	chr19:12996616	KLF1	0.61	9.97	0.44	3.56e-21	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs760794	0.791	rs6907367	chr6:19803831	C/G	cg02404759	chr6:19790362	NA	-0.35	-6.54	-0.3	1.73e-10	Endometriosis;
LUAD	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.7	0.31	6.81e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg13390004	chr1:15929781	NA	0.48	8.51	0.38	3.05e-16	Systolic blood pressure;
LUAD	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg04731861	chr2:219085781	ARPC2	-0.27	-8.16	-0.37	3.89e-15	Colorectal cancer;
LUAD	trans	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.04	-25.33	-0.78	8.12e-87	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4812048	0.649	rs6070706	chr20:57628239	C/T	cg14073986	chr20:57617431	SLMO2	0.83	9.79	0.43	1.55e-20	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.52	0.3	2.02e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg18209359	chr17:80159595	CCDC57	0.39	6.67	0.31	8.09e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg02423579	chr7:2872169	GNA12	-0.53	-8.8	-0.39	3.59e-17	Height;
LUAD	cis	rs4903604	0.581	rs11850485	chr14:78033863	A/G	cg18872420	chr14:78023429	SPTLC2	0.48	8.72	0.39	6.37e-17	Gut microbiome composition (winter);
LUAD	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg24818145	chr4:99064322	C4orf37	0.45	7.67	0.35	1.21e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg08798685	chr6:27730294	NA	-0.66	-7.03	-0.32	8.19e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs208520	1.000	rs208537	chr6:66963544	A/G	cg07460842	chr6:66804631	NA	-0.97	-13.15	-0.54	2.47e-33	Exhaled nitric oxide output;
LUAD	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg20476274	chr7:133979776	SLC35B4	0.84	16.27	0.62	1.4e-46	Mean platelet volume;
LUAD	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg17911788	chr17:44343683	NA	-0.52	-7.28	-0.33	1.6e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg21204522	chr6:27730016	NA	-0.47	-7.54	-0.34	2.83e-13	Parkinson's disease;
LUAD	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26314531	chr2:26401878	FAM59B	0.72	9.7	0.43	3.21e-20	Gut microbiome composition (summer);
LUAD	trans	rs7395662	0.759	rs4347397	chr11:48895946	T/C	cg15704280	chr7:45808275	SEPT13	0.42	6.66	0.31	8.4e-11	HDL cholesterol;
LUAD	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg23758822	chr17:41437982	NA	0.88	13.13	0.54	2.93e-33	Menopause (age at onset);
LUAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg14820908	chr5:178986412	RUFY1	0.62	10.74	0.46	5.99e-24	Lung cancer;
LUAD	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg02990361	chr1:107599529	PRMT6	-0.63	-10.65	-0.46	1.23e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00149659	chr3:10157352	C3orf10	0.6	8.3	0.37	1.46e-15	Alzheimer's disease;
LUAD	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg22823121	chr1:150693482	HORMAD1	0.42	8.19	0.37	3.18e-15	Melanoma;
LUAD	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg16914151	chr15:75249787	RPP25	-0.52	-6.37	-0.3	4.88e-10	Colorectal cancer;
LUAD	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18404041	chr3:52824283	ITIH1	-0.48	-9.71	-0.43	2.91e-20	Bipolar disorder;
LUAD	cis	rs4077515	0.967	rs11145874	chr9:139290011	G/A	cg14169450	chr9:139327907	INPP5E	0.35	6.58	0.3	1.42e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg11814155	chr7:99998594	ZCWPW1	0.43	7.39	0.34	7.73e-13	Platelet count;
LUAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg07677032	chr17:61819896	STRADA	-0.51	-9.16	-0.41	2.2e-18	Prudent dietary pattern;
LUAD	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg23840854	chr1:161414152	NA	-0.9	-11.59	-0.49	3.58e-27	Rheumatoid arthritis;
LUAD	cis	rs2235642	0.533	rs2076436	chr16:1608082	A/G	cg26528668	chr16:1614120	IFT140	0.44	6.76	0.31	4.46e-11	Coronary artery disease;
LUAD	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg05665937	chr4:1216051	CTBP1	-0.44	-7.89	-0.36	2.62e-14	Obesity-related traits;
LUAD	trans	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.91	0.43	6.13e-21	Mean corpuscular volume;
LUAD	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg10591111	chr5:226296	SDHA	-0.55	-7.23	-0.33	2.23e-12	Breast cancer;
LUAD	cis	rs243505	0.559	rs734003	chr7:148505498	T/G	cg09806900	chr7:148480153	CUL1	0.52	8.91	0.4	1.55e-17	Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.84	-0.32	2.81e-11	Systolic blood pressure;
LUAD	trans	rs7395662	1.000	rs10838917	chr11:48503127	G/C	cg00717180	chr2:96193071	NA	-0.4	-7.4	-0.34	7.36e-13	HDL cholesterol;
LUAD	cis	rs938554	0.692	rs4428284	chr4:9996392	A/T	cg11266682	chr4:10021025	SLC2A9	0.54	9.08	0.4	4.08e-18	Blood metabolite levels;
LUAD	cis	rs6906287	0.647	rs12660455	chr6:118717382	C/T	cg05564266	chr6:118973597	C6orf204	0.33	6.99	0.32	1.06e-11	Electrocardiographic conduction measures;
LUAD	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	25.4	0.78	4.02e-87	Chronic sinus infection;
LUAD	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-9.24	-0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs2816062	0.813	rs2816040	chr1:18889536	C/T	cg18795169	chr1:18902165	NA	0.92	22.15	0.73	9.97e-73	Urate levels in lean individuals;
LUAD	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg08422745	chr4:174089978	GALNT7	0.94	16.26	0.62	1.54e-46	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg04034577	chr2:241836375	C2orf54	0.51	11.35	0.48	3.08e-26	Urinary metabolites;
LUAD	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg03690763	chr11:133734501	NA	-0.35	-7.97	-0.36	1.46e-14	Childhood ear infection;
LUAD	cis	rs427394	0.582	rs4701751	chr5:6704137	C/T	cg10857441	chr5:6722123	POLS	-0.57	-10.1	-0.44	1.28e-21	Menopause (age at onset);
LUAD	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.39	-7.14	-0.33	4.16e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4285028	0.948	rs13067270	chr3:121673901	A/C	cg20356878	chr3:121714668	ILDR1	-0.5	-6.79	-0.31	3.8e-11	Multiple sclerosis;
LUAD	cis	rs13631	0.928	rs9411308	chr9:140000115	C/T	cg14289826	chr9:140003911	NA	0.43	8.72	0.39	6.29e-17	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg01528321	chr10:82214614	TSPAN14	0.54	8.67	0.39	9.37e-17	Post bronchodilator FEV1;
LUAD	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg25482853	chr8:67687455	SGK3	1.18	18.2	0.66	4.58e-55	Lung disease severity in cystic fibrosis;
LUAD	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.54	-9.55	-0.42	1.08e-19	Axial length;
LUAD	cis	rs7771547	0.603	rs9357218	chr6:36549858	G/A	cg02952361	chr6:36355661	ETV7	0.48	6.6	0.31	1.2e-10	Platelet distribution width;
LUAD	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg18132916	chr6:79620363	NA	-0.46	-7.75	-0.35	6.88e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7617773	0.780	rs35297486	chr3:48378147	T/A	cg11946769	chr3:48343235	NME6	0.44	6.67	0.31	7.94e-11	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg24829409	chr8:58192753	C8orf71	-0.56	-6.68	-0.31	7.63e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg15485101	chr11:133734466	NA	0.38	8.34	0.38	1.05e-15	Childhood ear infection;
LUAD	trans	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.67	-0.35	1.2e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg04731861	chr2:219085781	ARPC2	-0.21	-6.47	-0.3	2.67e-10	Colorectal cancer;
LUAD	cis	rs11958404	0.615	rs7717235	chr5:157447772	C/G	cg05962755	chr5:157440814	NA	0.42	8.02	0.36	1.02e-14	IgG glycosylation;
LUAD	cis	rs9393692	0.557	rs61534839	chr6:26305623	C/T	cg00631329	chr6:26305371	NA	-0.55	-8.9	-0.4	1.72e-17	Educational attainment;
LUAD	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg11822812	chr5:140052017	DND1	-0.44	-8.2	-0.37	2.88e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg09904177	chr6:26538194	HMGN4	0.43	7.21	0.33	2.51e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs3779273	1.000	rs1829990	chr7:77829312	A/G	cg05596911	chr5:118502651	DMXL1	-0.39	-6.77	-0.31	4.33e-11	Body mass index;
LUAD	cis	rs12618769	0.520	rs11892744	chr2:99237792	C/T	cg10123293	chr2:99228465	UNC50	0.49	8.1	0.37	6.11e-15	Bipolar disorder;
LUAD	cis	rs9644630	0.672	rs4486225	chr8:19313404	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.36	6.69	0.31	7.1e-11	Oropharynx cancer;
LUAD	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg21963583	chr11:68658836	MRPL21	0.63	11.02	0.47	5.45e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs56346965	0.967	rs2159819	chr2:191532737	C/G	cg11845111	chr2:191398756	TMEM194B	-0.47	-8.0	-0.36	1.17e-14	Bone mineral density (Ward's triangle area);
LUAD	trans	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-9.46	-0.42	2.15e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs12681288	0.550	rs59004371	chr8:962393	T/C	cg15309053	chr8:964076	NA	0.5	11.31	0.48	4.22e-26	Schizophrenia;
LUAD	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg00277334	chr10:82204260	NA	0.61	9.87	0.43	8.14e-21	Post bronchodilator FEV1;
LUAD	cis	rs62238980	0.522	rs74748244	chr22:32497724	C/T	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg00204512	chr16:28754710	NA	0.32	6.81	0.31	3.26e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg03983476	chr2:10830698	NOL10	-0.47	-8.19	-0.37	3.04e-15	Prostate cancer;
LUAD	cis	rs11771526	0.901	rs62456038	chr7:32288663	G/A	cg27532318	chr7:32358331	NA	0.63	7.77	0.35	6.04e-14	Body mass index;
LUAD	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.59	8.66	0.39	9.7e-17	IgG glycosylation;
LUAD	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg25809561	chr17:30822961	MYO1D	0.68	12.94	0.53	1.72e-32	Schizophrenia;
LUAD	cis	rs72772090	0.634	rs10515246	chr5:96099265	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.58	-0.35	2.19e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg25358565	chr5:93447407	FAM172A	0.6	7.29	0.33	1.55e-12	Diabetic retinopathy;
LUAD	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg06547715	chr2:218990976	CXCR2	0.44	10.48	0.45	5.37e-23	Ulcerative colitis;
LUAD	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.27	-6.7	-0.31	6.86e-11	Coronary artery disease;
LUAD	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg12454169	chr2:30669597	LCLAT1	0.7	8.9	0.4	1.66e-17	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.91e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs4588572	0.644	rs2115435	chr5:77723700	A/C	cg11547950	chr5:77652471	NA	-0.64	-11.02	-0.47	5.55e-25	Triglycerides;
LUAD	cis	rs12681287	0.640	rs7832493	chr8:87371533	A/C	cg00550725	chr8:87521180	FAM82B	-0.47	-6.72	-0.31	5.83e-11	Caudate activity during reward;
LUAD	cis	rs2070488	0.804	rs7372452	chr3:38444298	C/G	cg24069376	chr3:38537580	EXOG	0.33	7.37	0.34	9.1e-13	Electrocardiographic conduction measures;
LUAD	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.5	8.38	0.38	8.04e-16	Blood metabolite levels;
LUAD	cis	rs244899	0.967	rs244903	chr5:167913510	G/A	cg06604206	chr5:167912465	RARS	-0.41	-7.07	-0.33	6.48e-12	Response to platinum-based chemotherapy (carboplatin);
LUAD	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.4	-0.3	4.03e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6545883	0.929	rs2121660	chr2:61653058	T/C	cg15711740	chr2:61764176	XPO1	0.4	6.46	0.3	2.87e-10	Tuberculosis;
LUAD	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg25358565	chr5:93447407	FAM172A	0.66	7.7	0.35	9.49e-14	Diabetic retinopathy;
LUAD	cis	rs9788721	0.902	rs17486195	chr15:78865197	A/G	cg18825076	chr15:78729989	IREB2	-0.56	-9.13	-0.41	2.93e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg24634471	chr8:143751801	JRK	0.48	7.75	0.35	7.1e-14	Schizophrenia;
LUAD	cis	rs28830936	0.966	rs1107858	chr15:41968226	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.55	-0.3	1.63e-10	Diastolic blood pressure;
LUAD	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg19875535	chr5:140030758	IK	-0.48	-8.07	-0.37	7.26e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12500482	0.509	rs1203784	chr4:2427108	T/C	cg26605046	chr4:2439731	NA	-0.46	-7.79	-0.35	5.15e-14	Cognitive function;
LUAD	cis	rs1691799	0.899	rs903587	chr12:66746061	C/A	cg16791601	chr12:66731901	HELB	-0.36	-6.47	-0.3	2.78e-10	White blood cell count (basophil);
LUAD	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg08601574	chr20:25228251	PYGB	-0.47	-8.9	-0.4	1.66e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg24642844	chr7:1081250	C7orf50	-0.62	-9.47	-0.42	1.94e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg16325326	chr1:53192061	ZYG11B	0.5	8.49	0.38	3.48e-16	Monocyte count;
LUAD	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg25358565	chr5:93447407	FAM172A	0.64	7.58	0.35	2.24e-13	Diabetic retinopathy;
LUAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg00450029	chr8:599525	NA	0.72	6.76	0.31	4.47e-11	IgG glycosylation;
LUAD	trans	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg00953403	chr17:74099816	EXOC7	0.42	6.64	0.31	9.74e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs7937682	0.562	rs519850	chr11:111376888	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.43	-6.94	-0.32	1.48e-11	Primary sclerosing cholangitis;
LUAD	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg02423579	chr7:2872169	GNA12	-0.58	-9.95	-0.44	4.23e-21	Height;
LUAD	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg18721089	chr20:30220636	NA	-0.41	-6.41	-0.3	3.85e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs490234	0.902	rs10739662	chr9:128278687	T/C	cg14078157	chr9:128172775	NA	-0.37	-6.75	-0.31	4.74e-11	Mean arterial pressure;
LUAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg08888203	chr3:10149979	C3orf24	-0.65	-9.62	-0.42	6.27e-20	Alzheimer's disease;
LUAD	cis	rs7520050	0.966	rs785471	chr1:46518677	T/C	cg06784218	chr1:46089804	CCDC17	-0.3	-6.46	-0.3	2.84e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg21984481	chr17:79567631	NPLOC4	-0.71	-16.85	-0.63	4.19e-49	Eye color traits;
LUAD	cis	rs6433857	0.536	rs7557023	chr2:181350474	G/A	cg23363182	chr2:181467187	NA	-0.4	-6.56	-0.3	1.57e-10	Body mass index;
LUAD	cis	rs1232027	0.656	rs1677635	chr5:79962168	T/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03352830	chr11:487213	PTDSS2	0.8	10.09	0.44	1.32e-21	Body mass index;
LUAD	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg01475377	chr6:109611718	NA	-0.5	-9.41	-0.42	3.17e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22857025	chr5:266934	NA	-0.96	-14.39	-0.57	1.75e-38	Breast cancer;
LUAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08219700	chr8:58056026	NA	0.63	8.82	0.39	2.92e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs57502260	0.749	rs67446678	chr11:68227466	C/T	cg16797656	chr11:68205561	LRP5	0.49	7.61	0.35	1.74e-13	Total body bone mineral density (age 45-60);
LUAD	cis	rs2274273	0.686	rs57033289	chr14:55623317	C/A	cg04306507	chr14:55594613	LGALS3	0.42	7.71	0.35	9.18e-14	Protein biomarker;
LUAD	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.55	0.42	1.03e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg18180107	chr4:99064573	C4orf37	0.47	7.25	0.33	2e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg01528321	chr10:82214614	TSPAN14	-0.65	-10.43	-0.45	8.13e-23	Post bronchodilator FEV1;
LUAD	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg27490568	chr2:178487706	NA	0.56	8.33	0.38	1.15e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9549328	0.765	rs1317506	chr13:113631143	C/T	cg17524180	chr13:113633600	MCF2L	-0.36	-7.43	-0.34	5.97e-13	Systolic blood pressure;
LUAD	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg05425664	chr17:57184151	TRIM37	-0.43	-7.57	-0.35	2.39e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg23254163	chr1:152506842	NA	0.27	7.29	0.33	1.52e-12	Hair morphology;
LUAD	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.13	-0.37	4.77e-15	Total body bone mineral density;
LUAD	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.31	-0.48	4.28e-26	Type 2 diabetes;
LUAD	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23583168	chr7:148888333	NA	0.88	18.49	0.67	2.34e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg17644776	chr2:200775616	C2orf69	0.52	6.53	0.3	1.9e-10	Schizophrenia;
LUAD	trans	rs12439619	1.000	rs12439619	chr15:82546946	T/G	cg04831495	chr15:85060580	GOLGA6L5	-0.54	-8.8	-0.39	3.58e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.05e-19	Life satisfaction;
LUAD	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21582582	chr3:182698605	DCUN1D1	0.6	9.8	0.43	1.43e-20	Resting heart rate;
LUAD	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg18404041	chr3:52824283	ITIH1	-0.5	-8.74	-0.39	5.41e-17	Schizophrenia;
LUAD	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg18806716	chr10:30721971	MAP3K8	-0.64	-12.87	-0.53	3.14e-32	Itch intensity from mosquito bite;
LUAD	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg10018233	chr7:150070692	REPIN1	-0.53	-9.49	-0.42	1.64e-19	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21582582	chr3:182698605	DCUN1D1	0.73	14.26	0.57	6.19e-38	Intelligence (multi-trait analysis);
LUAD	cis	rs300774	1.000	rs300782	chr2:110345	C/T	cg21211680	chr2:198530	NA	-0.47	-6.78	-0.31	4.02e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs9837602	0.938	rs793457	chr3:99518987	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-8.67	-0.39	9.28e-17	Breast cancer;
LUAD	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg27211696	chr2:191398769	TMEM194B	-0.72	-9.56	-0.42	9.66e-20	Diastolic blood pressure;
LUAD	trans	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	10.57	0.46	2.59e-23	Type 2 diabetes;
LUAD	cis	rs2274273	0.870	rs10142547	chr14:55763963	T/C	cg04306507	chr14:55594613	LGALS3	0.41	8.44	0.38	4.94e-16	Protein biomarker;
LUAD	trans	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	11.97	0.5	1.19e-28	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg15117754	chr3:10150083	C3orf24	0.42	6.71	0.31	6.34e-11	Alzheimer's disease;
LUAD	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg05340658	chr4:99064831	C4orf37	0.45	7.4	0.34	7.51e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg26597838	chr10:835615	NA	0.98	15.15	0.59	1.01e-41	Eosinophil percentage of granulocytes;
LUAD	trans	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.21	-0.33	2.63e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs6594713	0.921	rs6594714	chr5:112738620	C/G	cg12552261	chr5:112820674	MCC	0.55	8.91	0.4	1.57e-17	Brain cytoarchitecture;
LUAD	trans	rs853679	0.546	rs2232426	chr6:28360659	G/C	cg01620082	chr3:125678407	NA	-1.08	-9.99	-0.44	3.19e-21	Depression;
LUAD	cis	rs6842047	0.809	rs3087505	chr4:187179486	A/G	cg09526685	chr4:187126073	CYP4V2	0.91	9.47	0.42	1.98e-19	Blood protein levels;
LUAD	cis	rs62103177	0.564	rs55867755	chr18:77723434	C/T	cg20368463	chr18:77673604	PQLC1	0.56	7.3	0.33	1.45e-12	Opioid sensitivity;
LUAD	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg27490568	chr2:178487706	NA	0.39	6.5	0.3	2.2e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.32	6.44	0.3	3.19e-10	Obesity-related traits;
LUAD	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg24399712	chr22:39784796	NA	-0.81	-15.8	-0.61	1.63e-44	Intelligence (multi-trait analysis);
LUAD	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.41	7.4	0.34	7.51e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1595825	0.891	rs78198610	chr2:198522769	T/C	cg11031976	chr2:198649780	BOLL	-0.46	-6.84	-0.32	2.82e-11	Ulcerative colitis;
LUAD	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg18867708	chr6:26865862	GUSBL1	0.41	6.55	0.3	1.69e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg12311346	chr5:56204834	C5orf35	1.14	17.4	0.65	1.59e-51	Initial pursuit acceleration;
LUAD	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg03037974	chr15:76606532	NA	0.41	9.18	0.41	1.9e-18	Blood metabolite levels;
LUAD	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg27068330	chr11:65405492	SIPA1	-0.76	-12.62	-0.52	3.3e-31	Acne (severe);
LUAD	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.82	-0.31	3.13e-11	Breast cancer;
LUAD	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg25237894	chr2:233734115	C2orf82	0.63	12.07	0.51	4.82e-29	Coronary artery disease;
LUAD	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg18932078	chr1:2524107	MMEL1	0.37	7.03	0.32	8.24e-12	Ulcerative colitis;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg17772535	chr12:65153236	GNS	-0.51	-6.63	-0.31	1e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs7903847	0.642	rs2297668	chr10:99160046	C/T	cg20016023	chr10:99160130	RRP12	-0.31	-7.5	-0.34	3.76e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9341808	0.718	rs35447745	chr6:80816748	T/C	cg08355045	chr6:80787529	NA	0.56	10.05	0.44	1.88e-21	Sitting height ratio;
LUAD	cis	rs4948275	0.550	rs7904815	chr10:63136612	G/A	cg03237606	chr10:63212265	TMEM26	-0.34	-6.9	-0.32	1.97e-11	Night sleep phenotypes;
LUAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg13047869	chr3:10149882	C3orf24	0.62	10.73	0.46	6.18e-24	Alzheimer's disease;
LUAD	cis	rs9346649	0.606	rs6940383	chr6:168491688	G/A	cg02770688	chr6:168491649	NA	0.54	10.21	0.44	5.25e-22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.58	0.52	4.73e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.891	rs59938443	chr2:198497105	C/T	cg00982548	chr2:198649783	BOLL	-0.62	-8.83	-0.39	2.77e-17	Ulcerative colitis;
LUAD	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg11266682	chr4:10021025	SLC2A9	0.62	14.58	0.58	2.78e-39	Bone mineral density;
LUAD	cis	rs2046867	0.908	rs9880763	chr3:72789805	G/C	cg04365224	chr3:72788183	NA	-0.43	-6.55	-0.3	1.66e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9393777	0.513	rs67540232	chr6:27140866	T/A	cg12292205	chr6:26970375	C6orf41	-0.57	-6.96	-0.32	1.31e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.6	-0.35	1.91e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg04117972	chr1:227635322	NA	0.8	7.13	0.33	4.36e-12	Major depressive disorder;
LUAD	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg06618935	chr21:46677482	NA	-0.42	-8.42	-0.38	6.02e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs933688	0.532	rs11740007	chr5:90545498	C/G	cg00335715	chr5:90575459	NA	-0.43	-6.94	-0.32	1.45e-11	Smoking behavior;
LUAD	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg08859206	chr1:53392774	SCP2	0.51	9.13	0.41	2.74e-18	Monocyte count;
LUAD	cis	rs9796	0.689	rs692195	chr15:41444894	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.42	-7.77	-0.35	6.16e-14	Menopause (age at onset);
LUAD	cis	rs62238980	0.614	rs80272272	chr22:32475924	C/T	cg00543991	chr22:32367038	NA	0.92	8.7	0.39	7.27e-17	Childhood ear infection;
LUAD	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg14092988	chr3:52407081	DNAH1	0.44	8.95	0.4	1.14e-17	Bipolar disorder;
LUAD	cis	rs7903847	0.619	rs10882912	chr10:99138077	C/T	cg20016023	chr10:99160130	RRP12	-0.3	-7.2	-0.33	2.8e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-6.72	-0.31	5.84e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11955175	0.850	rs111959286	chr5:40704141	A/T	cg05478818	chr5:40835740	RPL37	0.77	6.57	0.3	1.44e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs657075	0.697	rs3805668	chr5:131646588	G/A	cg21138405	chr5:131827807	IRF1	0.5	6.42	0.3	3.75e-10	Rheumatoid arthritis;
LUAD	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	ch.11.42038R	chr11:967971	AP2A2	0.42	7.42	0.34	6.46e-13	Alzheimer's disease (late onset);
LUAD	cis	rs2274273	0.615	rs17672058	chr14:55673394	C/T	cg04306507	chr14:55594613	LGALS3	0.43	8.01	0.36	1.14e-14	Protein biomarker;
LUAD	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg10639395	chr11:8710044	RPL27A	0.33	6.5	0.3	2.2e-10	Hemoglobin concentration;
LUAD	trans	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg18335740	chr13:41363409	SLC25A15	0.6	10.94	0.47	1.06e-24	Lewy body disease;
LUAD	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg14343924	chr8:8086146	FLJ10661	-0.47	-7.52	-0.34	3.28e-13	Mood instability;
LUAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg05215272	chr17:6899095	ALOX12	0.46	8.81	0.39	3.24e-17	Tonsillectomy;
LUAD	cis	rs7094131	0.549	rs10764341	chr10:22880313	C/T	cg19500236	chr10:22911537	PIP4K2A	0.44	7.91	0.36	2.27e-14	Obesity-related traits;
LUAD	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg24803719	chr17:45855879	NA	-0.33	-7.22	-0.33	2.43e-12	IgG glycosylation;
LUAD	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg11062466	chr8:58055876	NA	0.54	7.29	0.33	1.55e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg21724239	chr8:58056113	NA	0.78	9.34	0.41	5.35e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs375066	0.551	rs73052639	chr19:44334229	T/C	cg12072164	chr19:44306565	LYPD5	-0.33	-6.53	-0.3	1.86e-10	Breast cancer;
LUAD	cis	rs1018836	0.884	rs7008765	chr8:91632589	C/T	cg16814680	chr8:91681699	NA	-0.7	-11.77	-0.5	7.55e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7582720	1.000	rs72934711	chr2:203709997	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.25	0.41	1.14e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs17095355	1.000	rs4565840	chr10:111717140	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.7	-9.58	-0.42	8.27e-20	Biliary atresia;
LUAD	cis	rs813218	0.527	rs793450	chr3:99532532	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.35	6.51	0.3	2.08e-10	Orofacial clefts;
LUAD	cis	rs6087990	0.568	rs853854	chr20:31420757	T/A	cg13636640	chr20:31349939	DNMT3B	0.65	11.71	0.49	1.31e-27	Ulcerative colitis;
LUAD	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg15448220	chr1:150897856	SETDB1	0.56	9.46	0.42	2.19e-19	Melanoma;
LUAD	trans	rs3960554	0.800	rs80002395	chr7:75814902	C/T	cg19862616	chr7:65841803	NCRNA00174	0.82	11.28	0.48	5.42e-26	Eotaxin levels;
LUAD	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg25828334	chr19:18545568	ISYNA1	-0.39	-7.82	-0.36	4.17e-14	Breast cancer;
LUAD	cis	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg00071950	chr4:10020882	SLC2A9	0.5	7.36	0.34	9.41e-13	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs68170813	0.641	rs74451547	chr7:107078435	A/C	cg23024343	chr7:107201750	COG5	0.51	7.01	0.32	9.44e-12	Coronary artery disease;
LUAD	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg16850897	chr7:100343110	ZAN	0.42	7.44	0.34	5.56e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg21951975	chr1:209979733	IRF6	0.58	6.99	0.32	1.06e-11	Coronary artery disease;
LUAD	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.88	-0.36	2.84e-14	Prostate cancer;
LUAD	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-9.0	-0.4	7.89e-18	Bipolar disorder;
LUAD	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg20258083	chr10:93976192	CPEB3	-0.41	-6.44	-0.3	3.25e-10	Brain structure;
LUAD	cis	rs9807989	0.507	rs10203558	chr2:103027640	T/C	cg03938978	chr2:103052716	IL18RAP	0.45	10.33	0.45	1.82e-22	Asthma;
LUAD	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg27284194	chr4:1044797	NA	0.7	10.1	0.44	1.21e-21	Recombination rate (females);
LUAD	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.61	8.66	0.39	1e-16	Gut microbiome composition (summer);
LUAD	cis	rs7095607	0.813	rs960772	chr10:69931674	A/G	cg18986048	chr10:69913749	MYPN	0.37	6.44	0.3	3.17e-10	Lung function (FVC);
LUAD	cis	rs1003719	0.788	rs2835599	chr21:38466937	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.65	0.39	1.06e-16	Eye color traits;
LUAD	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg02423579	chr7:2872169	GNA12	-0.57	-9.81	-0.43	1.32e-20	Height;
LUAD	trans	rs1493916	0.837	rs9949631	chr18:31410567	G/A	cg27147174	chr7:100797783	AP1S1	-0.62	-10.88	-0.47	1.73e-24	Life satisfaction;
LUAD	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg17366294	chr4:99064904	C4orf37	0.6	10.06	0.44	1.75e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg10792982	chr14:105748885	BRF1	0.46	9.49	0.42	1.72e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg26408565	chr15:76604113	ETFA	-0.43	-6.95	-0.32	1.4e-11	Blood metabolite levels;
LUAD	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg06623918	chr6:96969491	KIAA0776	0.89	17.65	0.65	1.27e-52	Headache;
LUAD	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.27	0.33	1.79e-12	Menopause (age at onset);
LUAD	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22968622	chr17:43663579	NA	1.03	16.55	0.63	8.77e-48	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg16325326	chr1:53192061	ZYG11B	-0.7	-12.82	-0.53	4.93e-32	Monocyte count;
LUAD	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.13	-0.33	4.26e-12	Breast cancer;
LUAD	cis	rs7799006	0.929	rs6951493	chr7:2257612	G/A	cg08027265	chr7:2291960	NA	-0.56	-10.28	-0.45	2.85e-22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg00495681	chr13:53174319	NA	-0.56	-10.73	-0.46	6.42e-24	Lewy body disease;
LUAD	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg12119029	chr16:89752879	CDK10	0.36	7.42	0.34	6.55e-13	Vitiligo;
LUAD	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs9560113	1.000	rs914026	chr13:112182029	G/A	cg14154082	chr13:112174009	NA	0.37	6.75	0.31	4.98e-11	Menarche (age at onset);
LUAD	trans	rs7781370	1.000	rs7781370	chr7:96133531	A/G	cg15846643	chr11:94964345	SESN3	-0.4	-6.76	-0.31	4.55e-11	Bone mineral density (hip);
LUAD	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	11.78	0.5	6.56e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs4481887	0.861	rs7412034	chr1:248434150	G/C	cg00666640	chr1:248458726	OR2T12	0.3	7.56	0.34	2.56e-13	Common traits (Other);
LUAD	cis	rs7465272	1.000	rs7835613	chr8:143682428	C/T	cg10104451	chr8:143696006	ARC	-0.55	-7.53	-0.34	3.1400000000000003e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg17105886	chr17:28927953	LRRC37B2	0.75	6.71	0.31	6.45e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg11993925	chr19:44307056	LYPD5	0.55	11.22	0.48	9.3e-26	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs10193935	0.901	rs2374429	chr2:42677888	A/G	cg27598129	chr2:42591480	NA	-0.71	-9.5	-0.42	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg03690763	chr11:133734501	NA	-0.33	-7.94	-0.36	1.82e-14	Childhood ear infection;
LUAD	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg26384229	chr12:38710491	ALG10B	0.4	6.41	0.3	3.95e-10	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg05340658	chr4:99064831	C4orf37	0.54	9.23	0.41	1.32e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7246865	0.603	rs10423719	chr19:17211568	T/C	cg19418318	chr19:17219073	MYO9B	0.4	6.94	0.32	1.51e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg18196295	chr10:418757	DIP2C	-0.43	-7.38	-0.34	8.49e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg02931644	chr1:25747376	RHCE	0.48	10.3	0.45	2.47e-22	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs7617773	0.778	rs11715776	chr3:48377611	G/C	cg11946769	chr3:48343235	NME6	0.44	6.68	0.31	7.75e-11	Coronary artery disease;
LUAD	cis	rs6782228	0.565	rs67445542	chr3:128330526	T/C	cg16766828	chr3:128327626	NA	-0.38	-6.94	-0.32	1.47e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg06191203	chr2:152266755	RIF1	0.53	8.16	0.37	3.74e-15	Squamous cell lung carcinoma;
LUAD	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg05754148	chr16:3507555	NAT15	0.8	10.48	0.45	5.53e-23	Tuberculosis;
LUAD	cis	rs490234	0.841	rs13285366	chr9:128375047	G/A	cg14078157	chr9:128172775	NA	-0.42	-7.49	-0.34	4.15e-13	Mean arterial pressure;
LUAD	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03264133	chr6:25882463	NA	-0.49	-7.2	-0.33	2.69e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs72772090	0.539	rs55996659	chr5:96114150	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.26	-0.33	1.81e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg01299579	chr2:10830716	NOL10	-0.45	-7.99	-0.36	1.29e-14	Prostate cancer;
LUAD	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg02375832	chr11:62437615	C11orf48	-0.35	-6.89	-0.32	2.01e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs758324	0.947	rs6596041	chr5:131198860	C/T	cg06307176	chr5:131281290	NA	0.49	7.86	0.36	3.2e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg07341007	chr3:195489909	MUC4	0.59	6.96	0.32	1.33e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs17021463	0.902	rs2016483	chr4:95229039	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.61	-0.39	1.48e-16	Testicular germ cell tumor;
LUAD	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg03806693	chr22:41940476	POLR3H	-0.62	-9.26	-0.41	1.04e-18	Vitiligo;
LUAD	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg06453172	chr10:134556979	INPP5A	-0.78	-10.93	-0.47	1.13e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg22676075	chr6:135203613	NA	0.39	7.29	0.33	1.56e-12	Red blood cell count;
LUAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	7.27	0.33	1.73e-12	Alzheimer's disease;
LUAD	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.4	8.14	0.37	4.37e-15	Monocyte percentage of white cells;
LUAD	trans	rs459571	0.959	rs460888	chr9:136913123	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-9.97	-0.44	3.57e-21	Platelet distribution width;
LUAD	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.09	0.33	5.82e-12	Depression;
LUAD	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.58	0.3	1.36e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg14583973	chr4:3374767	RGS12	0.3	7.53	0.34	3.17e-13	Serum sulfate level;
LUAD	trans	rs7395662	0.864	rs7483617	chr11:48551659	A/G	cg15704280	chr7:45808275	SEPT13	-0.41	-6.35	-0.3	5.46e-10	HDL cholesterol;
LUAD	cis	rs6545883	0.868	rs6545887	chr2:61828818	C/G	cg15711740	chr2:61764176	XPO1	-0.41	-6.49	-0.3	2.34e-10	Tuberculosis;
LUAD	trans	rs783540	0.900	rs55924160	chr15:83282196	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.47	-7.77	-0.35	5.9e-14	Schizophrenia;
LUAD	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg11530693	chr1:120165357	ZNF697	0.86	18.56	0.67	1.09e-56	Systemic lupus erythematosus;
LUAD	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg07538946	chr5:131705188	SLC22A5	0.49	8.0	0.36	1.19e-14	Breast cancer;Mosquito bite size;
LUAD	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg02569458	chr12:86230093	RASSF9	0.42	7.94	0.36	1.82e-14	Major depressive disorder;
LUAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg21724239	chr8:58056113	NA	0.66	8.66	0.39	9.86e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg17330251	chr7:94953956	PON1	-0.54	-7.58	-0.35	2.25e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04887335	chr3:196044632	TCTEX1D2	-0.42	-6.46	-0.3	2.94e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs2262909	0.962	rs390730	chr19:22233509	C/A	cg17074339	chr11:11642133	GALNTL4	-0.47	-7.7	-0.35	9.79e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	trans	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.35	0.34	1e-12	Resting heart rate;
LUAD	cis	rs11031096	0.899	rs747883	chr11:4108520	A/C	cg18678763	chr11:4115507	RRM1	0.36	6.35	0.3	5.47e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs1385374	0.858	rs12321643	chr12:129302867	A/T	cg09035930	chr12:129282057	SLC15A4	-0.62	-6.7	-0.31	6.79e-11	Systemic lupus erythematosus;
LUAD	cis	rs35306767	0.501	rs4880763	chr10:1147045	G/A	cg26597838	chr10:835615	NA	0.66	8.03	0.36	9.57e-15	Eosinophil percentage of granulocytes;
LUAD	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-8.71	-0.39	6.8e-17	Gut microbiome composition (summer);
LUAD	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg26022315	chr17:47021804	SNF8	0.4	7.27	0.33	1.77e-12	Type 2 diabetes;
LUAD	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg11266682	chr4:10021025	SLC2A9	0.65	15.38	0.6	1.05e-42	Bone mineral density;
LUAD	cis	rs62238980	0.614	rs77407792	chr22:32461465	C/A	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs6087990	0.899	rs4911110	chr20:31392366	C/T	cg13636640	chr20:31349939	DNMT3B	-0.76	-13.74	-0.56	9.17e-36	Ulcerative colitis;
LUAD	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21659725	chr3:3221576	CRBN	-0.51	-8.21	-0.37	2.69e-15	Body mass index;
LUAD	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg11822812	chr5:140052017	DND1	0.41	7.23	0.33	2.27e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg08470875	chr2:26401718	FAM59B	0.77	10.13	0.44	9.47e-22	Gut microbiome composition (summer);
LUAD	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.59	-0.35	2.1e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8018808	1.000	rs12432247	chr14:77856321	T/C	cg20045696	chr14:77926864	AHSA1	-0.37	-6.59	-0.31	1.28e-10	Myeloid white cell count;
LUAD	cis	rs240764	0.658	rs2132168	chr6:101178491	G/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.64	-0.39	1.2e-16	Neuroticism;
LUAD	trans	rs6561151	0.957	rs1932990	chr13:44460242	C/T	cg12856521	chr11:46389249	DGKZ	0.66	10.39	0.45	1.14e-22	Crohn's disease;
LUAD	cis	rs4786125	0.665	rs1873704	chr16:6907021	C/G	cg03623568	chr16:6915990	A2BP1	-0.49	-10.71	-0.46	7.38e-24	Heart rate variability traits (SDNN);
LUAD	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.32	-0.6	1.92e-42	Chronic sinus infection;
LUAD	cis	rs10899021	1.000	rs61900636	chr11:74359591	G/T	cg25880958	chr11:74394337	NA	-0.63	-8.4	-0.38	6.63e-16	Response to metformin (IC50);
LUAD	cis	rs300774	0.925	rs409572	chr2:153302	A/G	cg21211680	chr2:198530	NA	-0.49	-7.66	-0.35	1.26e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg11766577	chr21:47581405	C21orf56	-0.63	-11.55	-0.49	5.14e-27	Testicular germ cell tumor;
LUAD	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg25237894	chr2:233734115	C2orf82	0.51	9.75	0.43	2.15e-20	Coronary artery disease;
LUAD	trans	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04565464	chr8:145669602	NFKBIL2	0.42	6.46	0.3	2.96e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11890956	chr21:40555474	PSMG1	-0.64	-10.86	-0.47	2.05e-24	Cognitive function;
LUAD	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg06641503	chr3:48959341	ARIH2	-0.36	-6.58	-0.3	1.37e-10	Menarche (age at onset);
LUAD	cis	rs16866061	1.000	rs2047134	chr2:225347713	A/C	cg12698349	chr2:225449008	CUL3	0.74	12.43	0.52	1.8e-30	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg05991184	chr2:219186017	PNKD	0.36	7.01	0.32	9.19e-12	Colorectal cancer;
LUAD	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.45	-7.14	-0.33	4.14e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs6714710	0.603	rs12988571	chr2:98405695	C/T	cg26665480	chr2:98280029	ACTR1B	0.46	7.55	0.34	2.77e-13	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07157834	chr1:205819609	PM20D1	0.72	13.85	0.56	3.06e-36	Menarche (age at onset);
LUAD	cis	rs929596	0.583	rs77070100	chr2:234587847	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-10.26	-0.45	3.22e-22	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs7487075	0.619	rs10880968	chr12:46822960	C/T	cg23829395	chr12:46796953	NA	0.32	7.05	0.32	7.3e-12	Itch intensity from mosquito bite;
LUAD	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg07606381	chr6:8435919	SLC35B3	-0.4	-6.67	-0.31	8.16e-11	Motion sickness;
LUAD	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg03929089	chr4:120376271	NA	-0.6	-9.38	-0.41	3.95e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs62458065	0.713	rs62463968	chr7:32501242	G/A	cg20159608	chr7:32802032	NA	-0.6	-8.24	-0.37	2.16e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs1878931	0.580	rs7194596	chr16:3404408	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.38	6.39	0.3	4.29e-10	Body mass index (adult);
LUAD	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11644478	chr21:40555479	PSMG1	0.68	11.08	0.47	3.08e-25	Cognitive function;
LUAD	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg18016565	chr1:150552671	MCL1	0.41	7.52	0.34	3.34e-13	Tonsillectomy;
LUAD	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.95	-0.36	1.74e-14	Personality dimensions;
LUAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg04025307	chr7:1156635	C7orf50	0.64	7.76	0.35	6.28e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg21385522	chr1:16154831	NA	0.44	6.66	0.31	8.42e-11	Dilated cardiomyopathy;
LUAD	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg18252515	chr7:66147081	NA	0.61	6.67	0.31	7.98e-11	Diabetic kidney disease;
LUAD	cis	rs72772090	0.539	rs3335	chr5:96115070	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.33	-0.34	1.15e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00149659	chr3:10157352	C3orf10	0.87	11.6	0.49	3.49e-27	Alzheimer's disease;
LUAD	trans	rs629535	0.814	rs549643	chr8:70062884	C/T	cg21567404	chr3:27674614	NA	0.97	17.86	0.66	1.38e-53	Dupuytren's disease;
LUAD	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg08859206	chr1:53392774	SCP2	0.59	10.66	0.46	1.19e-23	Monocyte count;
LUAD	cis	rs78487399	0.808	rs6544669	chr2:43736171	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.46	-0.3	2.91e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg19875535	chr5:140030758	IK	-0.48	-8.07	-0.37	7.14e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg24531977	chr5:56204891	C5orf35	-0.48	-8.0	-0.36	1.24e-14	Coronary artery disease;
LUAD	cis	rs738321	0.790	rs4820317	chr22:38543287	T/C	cg25457927	chr22:38595422	NA	-0.49	-10.93	-0.47	1.13e-24	Breast cancer;
LUAD	cis	rs754466	0.651	rs56138814	chr10:79625795	T/C	cg17075019	chr10:79541650	NA	-0.85	-17.56	-0.65	3.08e-52	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7707921	0.767	rs862244	chr5:81586801	G/A	cg15871215	chr5:81402204	ATG10	0.62	9.93	0.43	5.12e-21	Breast cancer;
LUAD	cis	rs2281845	0.929	rs7549337	chr1:201097609	T/G	cg22815214	chr1:201083145	CACNA1S	0.52	8.7	0.39	7.67e-17	Permanent tooth development;
LUAD	cis	rs6740322	0.895	rs10196095	chr2:43571885	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.77	-11.14	-0.48	1.97e-25	Coronary artery disease;
LUAD	cis	rs6543140	0.964	rs7561351	chr2:103077780	A/G	cg04239558	chr2:103089729	SLC9A4	0.36	7.34	0.34	1.11e-12	Blood protein levels;
LUAD	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg17173187	chr15:85201210	NMB	0.51	8.72	0.39	6.27e-17	Schizophrenia;
LUAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg18402987	chr7:1209562	NA	0.77	9.45	0.42	2.3e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-12.91	-0.53	2.16e-32	Extrinsic epigenetic age acceleration;
LUAD	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg00074818	chr8:8560427	CLDN23	0.63	9.77	0.43	1.78e-20	Obesity-related traits;
LUAD	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg08470875	chr2:26401718	FAM59B	-0.62	-8.53	-0.38	2.65e-16	Gut microbiome composition (summer);
LUAD	cis	rs9811920	0.625	rs9847283	chr3:99910320	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.69	-0.39	8.02e-17	Axial length;
LUAD	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg12564285	chr5:131593104	PDLIM4	-0.4	-7.3	-0.33	1.47e-12	Acylcarnitine levels;
LUAD	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg21951975	chr1:209979733	IRF6	0.5	6.65	0.31	9.27e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	10.85	0.47	2.27e-24	Smoking behavior;
LUAD	cis	rs490234	0.783	rs10119855	chr9:128271123	A/T	cg14078157	chr9:128172775	NA	-0.38	-6.81	-0.31	3.34e-11	Mean arterial pressure;
LUAD	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg16479474	chr6:28041457	NA	0.44	7.4	0.34	7.22e-13	Depression;
LUAD	cis	rs7107174	1.000	rs2512537	chr11:77971947	T/C	cg19901956	chr11:77921274	USP35	-0.51	-6.36	-0.3	5.29e-10	Testicular germ cell tumor;
LUAD	cis	rs938554	1.000	rs13137069	chr4:9928017	T/C	cg11266682	chr4:10021025	SLC2A9	0.43	7.61	0.35	1.86e-13	Blood metabolite levels;
LUAD	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg08085267	chr17:45401833	C17orf57	-0.65	-11.67	-0.49	1.85e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.51	-0.38	3.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2131877	0.956	rs10933698	chr3:194868369	T/C	cg19760965	chr3:194868843	C3orf21	0.42	7.02	0.32	8.85e-12	Non-small cell lung cancer;
LUAD	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.23	-0.33	2.22e-12	Coronary artery disease;
LUAD	cis	rs7107174	0.901	rs7941639	chr11:78116959	A/G	cg02023728	chr11:77925099	USP35	-0.42	-6.41	-0.3	3.95e-10	Testicular germ cell tumor;
LUAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg24642844	chr7:1081250	C7orf50	-0.51	-9.37	-0.41	4.34e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg11941060	chr3:133502564	NA	-0.41	-7.02	-0.32	8.99e-12	Iron status biomarkers;
LUAD	cis	rs7264396	0.563	rs2050729	chr20:34294409	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	8.25	0.37	2.07e-15	Total cholesterol levels;
LUAD	cis	rs13064411	0.866	rs35278902	chr3:113239021	A/G	cg10517650	chr3:113235015	CCDC52	-0.51	-6.77	-0.31	4.26e-11	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg13385794	chr1:248469461	NA	0.25	6.81	0.31	3.26e-11	Common traits (Other);
LUAD	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25427524	chr10:38739819	LOC399744	-0.75	-13.39	-0.55	2.38e-34	Extrinsic epigenetic age acceleration;
LUAD	trans	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg24644049	chr4:85504048	CDS1	0.85	7.28	0.33	1.69e-12	Skin colour saturation;
LUAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg16606324	chr3:10149918	C3orf24	0.7	11.51	0.49	7.19e-27	Alzheimer's disease;
LUAD	cis	rs2652834	1.000	rs7181141	chr15:63398552	A/G	cg25406657	chr15:63342033	TPM1	-0.42	-6.81	-0.31	3.36e-11	HDL cholesterol;
LUAD	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg05368731	chr17:41323189	NBR1	0.96	20.46	0.71	3.7e-65	Menopause (age at onset);
LUAD	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-7.94	-0.36	1.85e-14	Total body bone mineral density;
LUAD	cis	rs2235649	0.833	rs55684627	chr16:1848817	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-8.15	-0.37	4.02e-15	Blood metabolite levels;
LUAD	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25427524	chr10:38739819	LOC399744	-0.8	-14.35	-0.57	2.58e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg12599982	chr1:44399894	ARTN	0.35	6.73	0.31	5.4e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03517284	chr6:25882590	NA	-0.59	-9.65	-0.42	4.64e-20	Blood metabolite levels;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg25346576	chr17:28443852	CCDC55;MIR423	0.45	7.29	0.33	1.52e-12	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01473472	chr12:42680699	NA	0.42	6.36	0.3	5.37e-10	Hepatitis;
LUAD	cis	rs11811982	0.793	rs76569448	chr1:227406767	A/G	cg24860534	chr1:227506868	CDC42BPA	0.71	7.66	0.35	1.26e-13	Optic disc area;
LUAD	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.45	-0.3	3.06e-10	Cystic fibrosis severity;
LUAD	cis	rs3849570	0.643	rs11705789	chr3:81969196	G/T	cg07356753	chr3:81810745	GBE1	-0.53	-8.84	-0.39	2.66e-17	Waist circumference;Body mass index;
LUAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-7.86	-0.36	3.21e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	trans	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg01620082	chr3:125678407	NA	-0.44	-6.7	-0.31	6.82e-11	Depression;
LUAD	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg02527881	chr3:46936655	PTH1R	-0.69	-14.89	-0.59	1.29e-40	Birth weight;
LUAD	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg11494091	chr17:61959527	GH2	0.46	8.61	0.39	1.49e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	15.8	0.61	1.58e-44	Exhaled nitric oxide levels;
LUAD	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23248424	chr5:179741104	GFPT2	-0.69	-11.02	-0.47	5.37e-25	Height;
LUAD	cis	rs2882667	0.898	rs13182437	chr5:138387149	T/C	cg04439458	chr5:138467593	SIL1	-0.39	-7.19	-0.33	3.05e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg08997352	chr12:9597637	DDX12	-0.61	-10.45	-0.45	6.58e-23	Breast size;
LUAD	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg01251548	chr11:17372745	DKFZp686O24166	-0.37	-6.72	-0.31	5.73e-11	Type 2 diabetes;
LUAD	cis	rs62400317	0.859	rs10456548	chr6:45219699	T/C	cg18551225	chr6:44695536	NA	-0.55	-8.43	-0.38	5.61e-16	Total body bone mineral density;
LUAD	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-11.69	-0.49	1.54e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg03467027	chr4:99064603	C4orf37	0.4	6.44	0.3	3.29e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg14582100	chr15:45693742	SPATA5L1	0.64	12.6	0.52	3.96e-31	Homoarginine levels;
LUAD	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg12292205	chr6:26970375	C6orf41	-0.41	-7.06	-0.32	7.08e-12	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	8.17	0.37	3.69e-15	Breast cancer;
LUAD	cis	rs7149337	0.869	rs10137445	chr14:51694416	G/A	cg23942311	chr14:51606299	NA	0.83	18.7	0.67	2.75e-57	Cancer;
LUAD	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg19041857	chr6:27730383	NA	-0.43	-7.2	-0.33	2.72e-12	Parkinson's disease;
LUAD	trans	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg25482853	chr8:67687455	SGK3	0.68	10.47	0.45	5.67e-23	Obesity-related traits;
LUAD	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg18132916	chr6:79620363	NA	-0.45	-7.64	-0.35	1.44e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs736408	1.000	rs4687552	chr3:52838402	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-6.67	-0.31	8.21e-11	Bipolar disorder;
LUAD	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-7.63	-0.35	1.5700000000000001e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.69	-0.35	1.05e-13	Bipolar disorder;
LUAD	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg02450064	chr17:40260053	DHX58	-0.44	-7.55	-0.34	2.65e-13	Fibrinogen levels;
LUAD	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-8.47	-0.38	4.18e-16	Menarche (age at onset);
LUAD	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.75	-0.61	2.47e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg10523679	chr1:76189770	ACADM	0.92	18.37	0.67	8.05e-56	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.47	-0.42	1.95e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11690462	0.963	rs34918214	chr2:26628100	C/T	cg13255216	chr2:26625047	C2orf39	0.36	6.36	0.3	5.35e-10	Coronary artery disease;
LUAD	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg15921436	chr17:44337874	NA	-0.63	-9.38	-0.42	3.95e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11890956	chr21:40555474	PSMG1	0.55	9.65	0.42	4.96e-20	Cognitive function;
LUAD	cis	rs3752645	1.000	rs2250121	chr7:106753248	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-6.46	-0.3	2.91e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg27532560	chr4:187881888	NA	-0.35	-6.47	-0.3	2.66e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg06387496	chr7:2775674	GNA12	0.4	6.69	0.31	6.93e-11	Height;
LUAD	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg17178900	chr1:205818956	PM20D1	-0.43	-7.07	-0.33	6.36e-12	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg26567249	chr8:97247842	UQCRB	-0.47	-6.69	-0.31	7.15e-11	Testicular germ cell tumor;
LUAD	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg25324976	chr17:61989376	CSHL1	0.37	7.11	0.33	4.92e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs877282	0.733	rs11253342	chr10:765072	A/G	cg06581033	chr10:766294	NA	-0.58	-7.95	-0.36	1.74e-14	Uric acid levels;
LUAD	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg02423579	chr7:2872169	GNA12	-0.58	-9.75	-0.43	2.07e-20	Height;
LUAD	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg13012494	chr21:47604986	C21orf56	0.47	7.75	0.35	6.93e-14	Testicular germ cell tumor;
LUAD	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg08742575	chr21:47604166	C21orf56	0.42	7.06	0.32	6.84e-12	Testicular germ cell tumor;
LUAD	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg21918786	chr6:109611834	NA	-0.58	-10.64	-0.46	1.33e-23	Reticulocyte fraction of red cells;
LUAD	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg03929089	chr4:120376271	NA	-0.49	-7.96	-0.36	1.63e-14	HDL cholesterol;
LUAD	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg22823121	chr1:150693482	HORMAD1	0.44	8.93	0.4	1.34e-17	Tonsillectomy;
LUAD	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.65	-0.31	9.13e-11	Breast cancer;
LUAD	cis	rs9796	0.870	rs3214068	chr15:41313064	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.37	-7.03	-0.32	8.59e-12	Menopause (age at onset);
LUAD	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.4	6.72	0.31	5.96e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10465746	0.780	rs10874423	chr1:84374071	C/T	cg10977910	chr1:84465055	TTLL7	0.6	9.81	0.43	1.35e-20	Obesity-related traits;
LUAD	cis	rs62400317	0.787	rs10456547	chr6:45219526	T/C	cg18551225	chr6:44695536	NA	-0.56	-8.48	-0.38	3.88e-16	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg23815491	chr16:72088622	HP	0.55	9.92	0.43	5.42e-21	Fibrinogen levels;
LUAD	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs7274811	0.652	rs158672	chr20:32023286	T/C	cg03904042	chr20:32255491	NECAB3;C20orf134	0.51	7.51	0.34	3.6e-13	Height;
LUAD	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg06627628	chr2:24431161	ITSN2	-0.46	-6.49	-0.3	2.42e-10	Lymphocyte counts;
LUAD	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg03188948	chr7:1209495	NA	0.82	9.99	0.44	3.14e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg03929089	chr4:120376271	NA	-0.81	-14.72	-0.58	6.48e-40	Coronary artery disease;
LUAD	cis	rs701145	0.824	rs355767	chr3:154045895	G/A	cg17054900	chr3:154042577	DHX36	0.65	7.15	0.33	3.84e-12	Coronary artery disease;
LUAD	cis	rs7107174	1.000	rs2244508	chr11:77948515	T/A	cg19901956	chr11:77921274	USP35	-0.53	-6.61	-0.31	1.13e-10	Testicular germ cell tumor;
LUAD	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg11814155	chr7:99998594	ZCWPW1	0.43	7.51	0.34	3.61e-13	Platelet count;
LUAD	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg07404485	chr7:94953653	PON1	-0.49	-7.16	-0.33	3.53e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2658782	1.000	rs2608216	chr11:93149172	G/A	cg15737290	chr11:93063684	CCDC67	0.53	7.35	0.34	1.01e-12	Pulmonary function decline;
LUAD	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg24813613	chr7:1882135	MAD1L1	-0.42	-6.44	-0.3	3.22e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg14541582	chr5:601475	NA	-0.38	-8.15	-0.37	4.15e-15	Obesity-related traits;
LUAD	trans	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg03886242	chr7:26192032	NFE2L3	0.36	6.38	0.3	4.54e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg15921436	chr17:44337874	NA	-0.6	-8.94	-0.4	1.19e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg02461776	chr11:598696	PHRF1	0.49	7.06	0.32	7.02e-12	Systemic lupus erythematosus;
LUAD	trans	rs9354308	1.000	rs9360161	chr6:66565457	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.43	6.86	0.32	2.39e-11	Metabolite levels;
LUAD	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.49	7.43	0.34	6.15e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs9951602	0.512	rs4799246	chr18:76653417	A/G	cg02800362	chr5:177631904	HNRNPAB	0.91	14.37	0.57	1.97e-38	Obesity-related traits;
LUAD	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.59	-0.31	1.3100000000000001e-10	Bladder cancer;
LUAD	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg02734326	chr4:10020555	SLC2A9	-0.54	-9.34	-0.41	5.42e-19	Bone mineral density;
LUAD	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.42	-0.38	5.98e-16	Bipolar disorder;
LUAD	cis	rs727505	0.607	rs17387591	chr7:124799471	A/G	cg23710748	chr7:124431027	NA	-0.37	-7.79	-0.35	5.38e-14	Lewy body disease;
LUAD	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg25237894	chr2:233734115	C2orf82	0.6	11.47	0.49	1.03e-26	Coronary artery disease;
LUAD	cis	rs9473147	0.543	rs9381578	chr6:47556634	C/T	cg02130027	chr6:47444894	CD2AP	0.34	6.61	0.31	1.19e-10	Platelet distribution width;Mean platelet volume;
LUAD	trans	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg26043149	chr18:55253948	FECH	1.0	18.34	0.67	1.08e-55	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs11771526	0.681	rs62457535	chr7:32358710	C/G	cg13207630	chr7:32358064	NA	0.71	7.8	0.35	4.75e-14	Body mass index;
LUAD	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.96	0.32	1.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg06131755	chr6:160182447	ACAT2	0.43	6.36	0.3	5.15e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg07305463	chr2:136567211	LCT	0.38	7.14	0.33	4.05e-12	Mosquito bite size;
LUAD	cis	rs4691139	0.658	rs1401398	chr4:165927732	A/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.41	-7.59	-0.35	2.1e-13	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg11189052	chr15:85197271	WDR73	0.56	7.13	0.33	4.24e-12	Schizophrenia;
LUAD	cis	rs220324	0.688	rs9983766	chr21:43570667	C/T	cg08841829	chr21:43638893	ABCG1	-0.49	-6.96	-0.32	1.33e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.98	-0.36	1.41e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18876405	chr7:65276391	NA	0.64	10.62	0.46	1.69e-23	Aortic root size;
LUAD	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg10057126	chr4:77819792	ANKRD56	0.53	9.1	0.4	3.45e-18	Emphysema distribution in smoking;
LUAD	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg06002616	chr8:101225028	SPAG1	-0.4	-8.26	-0.37	1.84e-15	Atrioventricular conduction;
LUAD	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.42	-0.34	6.5e-13	Bone mineral density;
LUAD	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg03467027	chr4:99064603	C4orf37	0.4	6.49	0.3	2.45e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg05084668	chr3:125655381	ALG1L	-0.63	-10.1	-0.44	1.2e-21	Blood pressure (smoking interaction);
LUAD	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg10909506	chr17:38081995	ORMDL3	-0.37	-6.65	-0.31	9.12e-11	Self-reported allergy;
LUAD	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg02733842	chr7:1102375	C7orf50	-0.82	-11.83	-0.5	4.34e-28	Bronchopulmonary dysplasia;
LUAD	cis	rs59104589	0.521	rs886809	chr2:242397460	A/G	cg08645257	chr2:242211290	HDLBP	0.39	6.59	0.31	1.33e-10	Fibrinogen levels;
LUAD	cis	rs3752962	0.569	rs12451788	chr17:1941048	C/T	cg24156229	chr17:1948635	NA	0.46	8.15	0.37	4.16e-15	Itch intensity from mosquito bite;
LUAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.26	0.45	3.23e-22	Prudent dietary pattern;
LUAD	cis	rs9649213	0.533	rs62478235	chr7:98030349	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.79	-11.28	-0.48	5.5e-26	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg06108461	chr20:60628389	TAF4	-0.65	-8.77	-0.39	4.43e-17	Obesity-related traits;
LUAD	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg14582100	chr15:45693742	SPATA5L1	0.64	12.6	0.52	3.96e-31	Homoarginine levels;
LUAD	cis	rs908922	0.676	rs2146120	chr1:152504200	A/T	cg21823605	chr1:152486609	CRCT1	0.3	6.68	0.31	7.68e-11	Hair morphology;
LUAD	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg18180107	chr4:99064573	C4orf37	0.43	7.05	0.32	7.23e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.56	0.55	4.79e-35	Prudent dietary pattern;
LUAD	cis	rs7630877	0.962	rs11708154	chr3:179635808	T/C	cg18765712	chr3:179670323	PEX5L	0.36	6.45	0.3	3.06e-10	Type 2 diabetes;
LUAD	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg01802117	chr1:53393560	SCP2	0.37	7.08	0.33	6.03e-12	Monocyte count;
LUAD	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg25894440	chr7:65020034	NA	-0.59	-6.36	-0.3	5.16e-10	Diabetic kidney disease;
LUAD	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg23649088	chr2:200775458	C2orf69	-0.62	-7.77	-0.35	6.15e-14	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.97	0.32	1.22e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12545109	0.876	rs4738494	chr8:57327438	G/T	cg07776626	chr8:57350775	NA	-0.64	-8.82	-0.39	3.07e-17	Obesity-related traits;
LUAD	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg06627628	chr2:24431161	ITSN2	-0.51	-8.54	-0.38	2.42e-16	Asthma;
LUAD	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg21475434	chr5:93447410	FAM172A	0.77	8.42	0.38	6.08e-16	Diabetic retinopathy;
LUAD	cis	rs13315871	1.000	rs75828026	chr3:58346736	C/T	cg20936604	chr3:58311152	NA	-0.7	-7.31	-0.33	1.34e-12	Cholesterol, total;
LUAD	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1395	0.885	rs7575245	chr2:27527321	G/A	cg23587288	chr2:27483067	SLC30A3	-0.39	-7.44	-0.34	5.64e-13	Blood metabolite levels;
LUAD	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg21475434	chr5:93447410	FAM172A	0.76	8.43	0.38	5.66e-16	Diabetic retinopathy;
LUAD	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg15309053	chr8:964076	NA	0.46	10.28	0.45	2.72e-22	Schizophrenia;
LUAD	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.33	0.38	1.13e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg07153921	chr17:41440717	NA	-0.4	-6.8	-0.31	3.48e-11	Menopause (age at onset);
LUAD	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg06873352	chr17:61820015	STRADA	0.41	6.88	0.32	2.19e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg06784218	chr1:46089804	CCDC17	0.35	7.54	0.34	2.95e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs62238980	0.614	rs56199077	chr22:32436213	T/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs2274273	1.000	rs6573006	chr14:55610432	T/C	cg04306507	chr14:55594613	LGALS3	0.38	7.96	0.36	1.59e-14	Protein biomarker;
LUAD	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.3	-0.37	1.38e-15	Height;
LUAD	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg03433033	chr1:76189801	ACADM	-1.02	-25.26	-0.78	1.67e-86	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg18187862	chr3:45730750	SACM1L	-0.5	-7.9	-0.36	2.38e-14	Primary sclerosing cholangitis;
LUAD	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	8.74	0.39	5.59e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg12373951	chr3:133503437	NA	0.34	6.82	0.31	3.13e-11	Iron status biomarkers;
LUAD	cis	rs8072100	0.869	rs4439799	chr17:45781599	C/T	cg08085267	chr17:45401833	C17orf57	-0.61	-10.77	-0.46	4.43e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10089	0.953	rs4835940	chr5:127406596	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	9.91	0.43	5.82e-21	Ileal carcinoids;
LUAD	cis	rs9786986	0.764	rs2492767	chr1:235695799	A/G	cg08848088	chr1:235714526	GNG4	0.51	6.57	0.3	1.44e-10	Body mass index;
LUAD	cis	rs11118844	0.843	rs58850477	chr1:221927229	G/A	cg04222084	chr1:221915650	DUSP10	-0.81	-8.33	-0.38	1.11e-15	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03814316	chr16:29997655	TAOK2	0.4	6.53	0.3	1.87e-10	Height;
LUAD	cis	rs75229567	0.717	rs74527680	chr12:70235392	A/G	cg10114359	chr12:70132523	RAB3IP	0.96	7.14	0.33	3.97e-12	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.58	8.42	0.38	5.97e-16	Platelet count;
LUAD	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.39	-10.09	-0.44	1.4e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg06713675	chr4:122721982	EXOSC9	0.45	8.34	0.38	1.09e-15	Type 2 diabetes;
LUAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg26554054	chr8:600488	NA	0.81	7.94	0.36	1.81e-14	IgG glycosylation;
LUAD	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18876405	chr7:65276391	NA	-0.54	-9.27	-0.41	9.94e-19	Aortic root size;
LUAD	trans	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg24644049	chr4:85504048	CDS1	0.91	7.72	0.35	8.48e-14	Skin colour saturation;
LUAD	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg22676075	chr6:135203613	NA	-0.49	-8.79	-0.39	3.73e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg22906224	chr7:99728672	NA	-0.61	-10.64	-0.46	1.41e-23	Coronary artery disease;
LUAD	cis	rs3752645	1.000	rs11760966	chr7:106732527	A/T	cg02696742	chr7:106810147	HBP1	-0.65	-6.45	-0.3	3.14e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs2274273	0.686	rs66842809	chr14:55630571	T/C	cg04306507	chr14:55594613	LGALS3	0.39	7.29	0.33	1.49e-12	Protein biomarker;
LUAD	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg18721089	chr20:30220636	NA	-0.46	-6.57	-0.3	1.47e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg18180107	chr4:99064573	C4orf37	0.43	6.87	0.32	2.29e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg02896835	chr1:92012615	NA	-0.58	-11.99	-0.5	1.03e-28	Breast cancer;
LUAD	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg04455712	chr21:45112962	RRP1B	0.43	8.43	0.38	5.56e-16	Mean corpuscular volume;
LUAD	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg06640241	chr16:89574553	SPG7	0.83	15.79	0.61	1.73e-44	Multiple myeloma (IgH translocation);
LUAD	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg20607798	chr8:58055168	NA	0.58	7.97	0.36	1.51e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.46e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4664308	1.000	rs62175517	chr2:160911575	C/T	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.67	-0.31	8.17e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs12368653	0.789	rs17852479	chr12:58126234	C/A	cg12615879	chr12:58013172	SLC26A10	0.49	10.06	0.44	1.71e-21	Multiple sclerosis;
LUAD	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg14835575	chr10:16859367	RSU1	0.78	11.64	0.49	2.33e-27	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs7809799	0.571	rs66478766	chr7:98915401	G/A	cg12290671	chr7:99195819	NA	-0.8	-7.03	-0.32	8.34e-12	Ulcerative colitis;
LUAD	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg07810366	chr2:100720526	AFF3	-0.35	-7.13	-0.33	4.46e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.96	0.32	1.34e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg17644776	chr2:200775616	C2orf69	0.53	7.64	0.35	1.51e-13	Schizophrenia;
LUAD	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg06671706	chr8:8559999	CLDN23	0.68	11.73	0.5	1.09e-27	Obesity-related traits;
LUAD	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg07828340	chr4:882639	GAK	0.98	10.28	0.45	2.89e-22	Parkinson's disease;
LUAD	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.64	-0.35	1.47e-13	Personality dimensions;
LUAD	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07266350	chr3:49460521	AMT;NICN1	-0.36	-6.42	-0.3	3.63e-10	Menarche (age at onset);
LUAD	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg25894440	chr7:65020034	NA	-0.59	-6.36	-0.3	5.16e-10	Diabetic kidney disease;
LUAD	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg21963583	chr11:68658836	MRPL21	0.65	11.46	0.49	1.16e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg14917512	chr19:3094685	GNA11	0.58	6.83	0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs6138458	1.000	rs1977540	chr20:24900290	G/T	cg26195577	chr20:24973756	C20orf3	-0.96	-16.03	-0.61	1.65e-45	Blood protein levels;
LUAD	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-8.93	-0.4	1.33e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs11771526	0.748	rs11765652	chr7:32336444	A/G	cg13207630	chr7:32358064	NA	0.53	6.85	0.32	2.67e-11	Body mass index;
LUAD	cis	rs7833986	1.000	rs13281873	chr8:57101799	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.78	10.28	0.45	2.75e-22	Height;
LUAD	cis	rs75920871	1.000	rs61905705	chr11:116883776	A/T	cg04087571	chr11:116723030	SIK3	-0.32	-6.42	-0.3	3.6e-10	Subjective well-being;
LUAD	cis	rs12347191	0.500	rs1465965	chr9:100620326	C/T	cg13688889	chr9:100608707	NA	-0.63	-10.21	-0.44	4.95e-22	Orofacial clefts;
LUAD	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg01324343	chr3:183735012	ABCC5	0.81	18.7	0.67	2.5e-57	Anterior chamber depth;
LUAD	cis	rs7107174	1.000	rs2511178	chr11:77923220	C/T	cg02023728	chr11:77925099	USP35	0.51	7.89	0.36	2.53e-14	Testicular germ cell tumor;
LUAD	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg07936489	chr17:37558343	FBXL20	0.51	6.71	0.31	6.19e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg15997130	chr1:24165203	NA	0.54	9.28	0.41	8.71e-19	Immature fraction of reticulocytes;
LUAD	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg04287289	chr16:89883240	FANCA	0.75	7.5	0.34	3.85e-13	Skin colour saturation;
LUAD	trans	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.39	-0.34	7.72e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg24813613	chr7:1882135	MAD1L1	-0.56	-9.07	-0.4	4.39e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22442454	chr1:209979470	IRF6	-0.51	-7.44	-0.34	5.78e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	8.13	0.37	4.82e-15	Body mass index;
LUAD	trans	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg25894440	chr7:65020034	NA	-0.63	-6.71	-0.31	6.35e-11	Gout;
LUAD	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.06e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116095464	1.000	rs56700778	chr5:313186	A/T	cg22496380	chr5:211416	CCDC127	-1.05	-8.26	-0.37	1.83e-15	Breast cancer;
LUAD	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.57	-12.21	-0.51	1.44e-29	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg11062466	chr8:58055876	NA	0.45	6.48	0.3	2.56e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg13385794	chr1:248469461	NA	0.25	6.49	0.3	2.34e-10	Common traits (Other);
LUAD	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg05665937	chr4:1216051	CTBP1	0.43	7.52	0.34	3.28e-13	Obesity-related traits;
LUAD	cis	rs7536201	1.000	rs11249213	chr1:25293237	G/A	cg23273869	chr1:25296894	NA	-0.35	-6.93	-0.32	1.6e-11	Psoriasis vulgaris;
LUAD	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg02454025	chr1:11042201	C1orf127	1.04	17.71	0.65	6.82e-53	Ewing sarcoma;
LUAD	trans	rs1445130	1.000	rs13021945	chr2:18849030	G/A	cg04529938	chr17:73084494	SLC16A5	0.54	6.56	0.3	1.55e-10	Bulimia nervosa;
LUAD	cis	rs1941023	0.606	rs7946122	chr11:60172770	G/A	cg08716584	chr11:60157161	MS4A7	-0.45	-8.55	-0.38	2.29e-16	Congenital heart disease (maternal effect);
LUAD	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg26384229	chr12:38710491	ALG10B	0.45	7.33	0.34	1.18e-12	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-8.4	-0.38	6.75e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs8017423	0.536	rs11625794	chr14:90811229	C/T	cg14092571	chr14:90743983	NA	-0.47	-7.65	-0.35	1.42e-13	Mortality in heart failure;
LUAD	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg02660097	chr11:68866761	NA	0.46	6.39	0.3	4.43e-10	Blond vs. brown hair color;
LUAD	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.66	0.31	8.75e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3760982	0.585	rs8109812	chr19:44298494	C/A	cg21496419	chr19:44306685	LYPD5	0.32	7.27	0.33	1.77e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg23422044	chr7:1970798	MAD1L1	0.52	6.47	0.3	2.79e-10	Bipolar disorder;
LUAD	cis	rs2997447	0.846	rs3008417	chr1:26403470	G/A	cg00147160	chr1:26503991	CNKSR1	0.37	6.92	0.32	1.64e-11	QRS complex (12-leadsum);
LUAD	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23158103	chr7:148848205	ZNF398	-0.65	-12.24	-0.51	1.05e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08109568	chr15:31115862	NA	-0.79	-13.64	-0.55	2.35e-35	Huntington's disease progression;
LUAD	cis	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg20368463	chr18:77673604	PQLC1	-0.5	-7.43	-0.34	6.22e-13	Opioid sensitivity;
LUAD	cis	rs11118844	0.843	rs4589119	chr1:221915967	G/A	cg04222084	chr1:221915650	DUSP10	-0.79	-8.72	-0.39	6.5e-17	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg07507251	chr3:52567010	NT5DC2	0.37	7.14	0.33	4.08e-12	Bipolar disorder;
LUAD	cis	rs2730260	0.800	rs73169216	chr7:158834662	G/A	cg02254261	chr7:158964346	NA	-0.53	-6.35	-0.3	5.52e-10	Myopia (pathological);
LUAD	cis	rs7809799	0.571	rs67909852	chr7:98944926	T/C	cg12290671	chr7:99195819	NA	-0.8	-7.03	-0.32	8.34e-12	Ulcerative colitis;
LUAD	cis	rs7818345	0.967	rs7004435	chr8:19282732	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.32	7.15	0.33	3.85e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg02251663	chr11:14281053	SPON1	0.37	7.32	0.34	1.26e-12	Mitochondrial DNA levels;
LUAD	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.25	0.37	1.98e-15	Rheumatoid arthritis;
LUAD	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg19302996	chr17:73780495	UNK	-0.47	-7.81	-0.36	4.55e-14	White matter hyperintensity burden;
LUAD	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs17789174	0.700	rs3794678	chr16:85104486	A/G	cg27466129	chr16:85060822	KIAA0513	0.3	7.44	0.34	5.57e-13	Dysphagia;
LUAD	cis	rs909002	0.800	rs4949454	chr1:32099041	A/G	cg13919466	chr1:32135498	COL16A1	0.36	8.37	0.38	8.35e-16	Intelligence (multi-trait analysis);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04902851	chr8:59572557	NSMAF	-0.39	-6.43	-0.3	3.38e-10	Cancer;
LUAD	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg09796270	chr17:17721594	SREBF1	-0.37	-7.04	-0.32	7.94e-12	Total body bone mineral density;
LUAD	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg25456477	chr12:86230367	RASSF9	0.33	6.51	0.3	2.1e-10	Major depressive disorder;
LUAD	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg01884057	chr2:25150051	NA	-0.32	-6.86	-0.32	2.51e-11	Body mass index;
LUAD	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.22	0.33	2.4e-12	Tonsillectomy;
LUAD	cis	rs889398	0.835	rs12925429	chr16:69801539	G/A	cg00738113	chr16:70207722	CLEC18C	0.34	6.75	0.31	4.88e-11	Body mass index;
LUAD	cis	rs870825	0.721	rs72703528	chr4:185607311	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	11.22	0.48	9.12e-26	Blood protein levels;
LUAD	trans	rs11039798	1.000	rs3902927	chr11:48581457	C/T	cg02254774	chr11:50257496	LOC441601	0.52	6.57	0.3	1.48e-10	Axial length;
LUAD	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-7.65	-0.35	1.37e-13	Major depressive disorder;
LUAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg06074448	chr4:187884817	NA	0.37	7.39	0.34	8.07e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg24503407	chr1:205819492	PM20D1	0.43	6.95	0.32	1.42e-11	Parkinson's disease;
LUAD	trans	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg04565464	chr8:145669602	NFKBIL2	-0.44	-6.88	-0.32	2.11e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg11941060	chr3:133502564	NA	0.63	11.46	0.49	1.15e-26	Iron status biomarkers;
LUAD	cis	rs2011503	0.509	rs884480	chr19:19773923	G/A	cg11584989	chr19:19387371	SF4	0.45	6.36	0.3	5.1e-10	Bipolar disorder;
LUAD	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg17757837	chr7:157058334	UBE3C	0.46	8.07	0.37	7.3e-15	Body mass index;
LUAD	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg27539214	chr16:67997921	SLC12A4	-0.72	-9.19	-0.41	1.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.32	-0.34	1.27e-12	Height;
LUAD	cis	rs921968	0.565	rs13412324	chr2:219620521	T/C	cg02176678	chr2:219576539	TTLL4	-0.59	-12.0	-0.5	9.65e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14159672	chr1:205819179	PM20D1	0.79	16.01	0.61	1.87e-45	Menarche (age at onset);
LUAD	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.68	-0.58	1.03e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg07599136	chr5:415885	AHRR	0.78	8.74	0.39	5.72e-17	Fat distribution (HIV);
LUAD	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg04287289	chr16:89883240	FANCA	0.64	6.75	0.31	4.8e-11	Skin colour saturation;
LUAD	cis	rs748404	0.697	rs1095389	chr15:43566671	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.12	0.37	5.19e-15	Lung cancer;
LUAD	cis	rs7274811	0.681	rs291705	chr20:31969658	A/G	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.45	-7.03	-0.32	8.11e-12	Height;
LUAD	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg27411982	chr8:10470053	RP1L1	0.38	6.73	0.31	5.47e-11	Retinal vascular caliber;
LUAD	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	7.57	0.35	2.3e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg13565492	chr6:43139072	SRF	-0.6	-6.41	-0.3	3.86e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg06558623	chr16:89946397	TCF25	1.21	11.84	0.5	4.09e-28	Skin colour saturation;
LUAD	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg02269571	chr22:50332266	NA	0.59	8.96	0.4	1.05e-17	Schizophrenia;
LUAD	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.66	-0.39	9.95e-17	Total body bone mineral density;
LUAD	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.59	-0.35	2.05e-13	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg17652424	chr22:38574118	PLA2G6	-0.33	-10.19	-0.44	6.1e-22	Cutaneous nevi;
LUAD	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg03714773	chr7:91764589	CYP51A1	0.28	6.75	0.31	5.04e-11	Breast cancer;
LUAD	cis	rs76878669	0.561	rs7948058	chr11:66148111	T/A	cg10616300	chr11:66138557	SLC29A2	-0.36	-7.36	-0.34	9.58e-13	Educational attainment (years of education);
LUAD	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg05234568	chr11:5960015	NA	-0.56	-10.03	-0.44	2.17e-21	DNA methylation (variation);
LUAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg08219700	chr8:58056026	NA	0.42	6.4	0.3	4.22e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10193935	0.901	rs7570083	chr2:42517859	G/A	cg27598129	chr2:42591480	NA	-0.65	-8.54	-0.38	2.39e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62238980	0.614	rs78907591	chr22:32459673	T/C	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs3087591	1.000	rs2905800	chr17:29531980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.4	6.56	0.3	1.61e-10	Hip circumference;
LUAD	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg13390004	chr1:15929781	NA	0.46	8.14	0.37	4.33e-15	Systolic blood pressure;
LUAD	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg02951883	chr7:2050386	MAD1L1	-0.72	-12.68	-0.52	1.88e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg19699088	chr1:15930386	NA	0.33	6.44	0.3	3.27e-10	Systolic blood pressure;
LUAD	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg24578937	chr1:2090814	PRKCZ	0.77	15.41	0.6	7.45e-43	Height;
LUAD	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.49	-7.61	-0.35	1.78e-13	Reticulocyte count;
LUAD	cis	rs7677751	0.806	rs1800813	chr4:55094467	G/A	cg17187183	chr4:55093834	PDGFRA	0.49	8.23	0.37	2.34e-15	Corneal astigmatism;
LUAD	cis	rs7705042	0.828	rs7737631	chr5:141506615	T/G	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.68	-0.31	7.69e-11	Asthma;
LUAD	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg09137382	chr11:130731461	NA	0.4	7.42	0.34	6.48e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg07636037	chr3:49044803	WDR6	-0.48	-8.0	-0.36	1.23e-14	Menarche (age at onset);
LUAD	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg21191810	chr6:118973309	C6orf204	-0.48	-7.66	-0.35	1.28e-13	Diastolic blood pressure;
LUAD	cis	rs12530845	0.673	rs73725437	chr7:135327853	G/A	cg23117316	chr7:135346802	PL-5283	-0.56	-8.81	-0.39	3.3e-17	Red blood cell traits;
LUAD	trans	rs7395662	1.000	rs11039857	chr11:48610853	T/C	cg00717180	chr2:96193071	NA	-0.4	-7.47	-0.34	4.78e-13	HDL cholesterol;
LUAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	12.62	0.52	3.3e-31	Prudent dietary pattern;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23749163	chr14:77563968	KIAA1737	-0.4	-6.36	-0.3	5.32e-10	Height;
LUAD	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg26039829	chr8:22132926	PIWIL2	0.56	10.49	0.45	4.96e-23	Hypertriglyceridemia;
LUAD	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18876405	chr7:65276391	NA	-0.42	-6.46	-0.3	2.86e-10	Aortic root size;
LUAD	cis	rs11214589	0.719	rs10891535	chr11:113201280	C/G	cg14159747	chr11:113255604	NA	0.6	12.3	0.51	6.14e-30	Neuroticism;
LUAD	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg23533926	chr12:111358616	MYL2	-0.42	-7.3	-0.33	1.4e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4253772	0.938	rs41371446	chr22:46637272	T/C	cg09491104	chr22:46646882	C22orf40	-0.5	-6.8	-0.31	3.55e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg10876282	chr6:28092338	ZSCAN16	-0.43	-6.45	-0.3	3.11e-10	Parkinson's disease;
LUAD	cis	rs4072705	0.646	rs915034	chr9:127244955	G/A	cg14219918	chr9:127249562	NR5A1	0.29	6.8	0.31	3.66e-11	Menarche (age at onset);
LUAD	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08109568	chr15:31115862	NA	0.71	13.13	0.54	2.74e-33	Huntington's disease progression;
LUAD	cis	rs2485376	1.000	rs772030	chr10:104023871	C/T	cg20641465	chr10:103991465	PITX3	-0.54	-9.98	-0.44	3.2e-21	QT interval;
LUAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg24503407	chr1:205819492	PM20D1	0.79	16.07	0.62	1.08e-45	Menarche (age at onset);
LUAD	cis	rs35883536	0.647	rs1855630	chr1:101039979	C/G	cg06223162	chr1:101003688	GPR88	-0.45	-8.63	-0.39	1.24e-16	Monocyte count;
LUAD	cis	rs7493	0.950	rs11977702	chr7:95029767	C/T	cg21856205	chr7:94953877	PON1	-0.54	-7.53	-0.34	3.05e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	9.58	0.42	8.07e-20	Colorectal cancer;
LUAD	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg26384229	chr12:38710491	ALG10B	0.5	8.27	0.37	1.71e-15	Heart rate;
LUAD	trans	rs225245	0.782	rs321601	chr17:33892087	A/C	cg19694781	chr19:47549865	TMEM160	0.44	7.3	0.33	1.42e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg23533926	chr12:111358616	MYL2	-0.41	-7.01	-0.32	9.73e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg08027265	chr7:2291960	NA	-0.43	-7.11	-0.33	4.87e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs13082711	0.554	rs73055724	chr3:27380397	T/G	cg02860705	chr3:27208620	NA	0.71	10.92	0.47	1.28e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg13319975	chr6:146136371	FBXO30	0.67	11.67	0.49	1.87e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7617773	0.780	rs4392440	chr3:48343920	C/T	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs4243830	0.737	rs925744	chr1:6615695	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.55	-6.53	-0.3	1.87e-10	Body mass index;
LUAD	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg06064525	chr11:970664	AP2A2	-0.54	-11.1	-0.48	2.57e-25	Alzheimer's disease (late onset);
LUAD	cis	rs6842047	0.809	rs3087505	chr4:187179486	A/G	cg02012338	chr4:187126139	CYP4V2	0.96	9.38	0.42	3.96e-19	Blood protein levels;
LUAD	cis	rs8017423	0.967	rs4900033	chr14:90701963	C/A	cg14092571	chr14:90743983	NA	-0.5	-8.75	-0.39	5.01e-17	Mortality in heart failure;
LUAD	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06112835	chr11:68658793	MRPL21	-0.49	-8.93	-0.4	1.36e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.59	-0.35	2e-13	Blood metabolite levels;
LUAD	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg16797656	chr11:68205561	LRP5	-0.47	-10.08	-0.44	1.52e-21	Total body bone mineral density;
LUAD	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.84	-0.36	3.71e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg23750338	chr8:142222470	SLC45A4	0.33	6.51	0.3	2.16e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg13770153	chr20:60521292	NA	-0.58	-9.07	-0.4	4.6e-18	Body mass index;
LUAD	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg03467027	chr4:99064603	C4orf37	0.45	7.28	0.33	1.64e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg05865280	chr17:75406074	SEPT9	0.61	19.41	0.69	1.72e-60	Airflow obstruction;
LUAD	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg18196295	chr10:418757	DIP2C	0.55	9.45	0.42	2.34e-19	Psychosis in Alzheimer's disease;
LUAD	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg06608945	chr2:219082296	ARPC2	0.47	8.2	0.37	2.81e-15	Colorectal cancer;
LUAD	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg00074818	chr8:8560427	CLDN23	0.66	10.19	0.44	6.13e-22	Obesity-related traits;
LUAD	cis	rs7191700	0.511	rs8043625	chr16:11361895	C/G	cg00044050	chr16:11439710	C16orf75	-0.62	-9.78	-0.43	1.74e-20	Multiple sclerosis;
LUAD	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.01	-0.36	1.09e-14	Diabetic kidney disease;
LUAD	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2882667	0.898	rs10045761	chr5:138397289	G/A	cg04439458	chr5:138467593	SIL1	-0.39	-7.05	-0.32	7.14e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg07538946	chr5:131705188	SLC22A5	0.52	8.27	0.37	1.76e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg06627628	chr2:24431161	ITSN2	-0.55	-6.68	-0.31	7.53e-11	Lymphocyte counts;
LUAD	trans	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.78	-14.93	-0.59	8.42e-41	Brugada syndrome;
LUAD	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-10.82	-0.47	2.98e-24	Hemoglobin concentration;
LUAD	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg09626299	chr10:82213104	TSPAN14	-0.3	-6.6	-0.31	1.26e-10	Post bronchodilator FEV1;
LUAD	trans	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg06606381	chr12:133084897	FBRSL1	-0.94	-8.96	-0.4	1.05e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7737355	0.812	rs10062078	chr5:130764102	A/G	cg06307176	chr5:131281290	NA	-0.41	-6.74	-0.31	5.29e-11	Life satisfaction;
LUAD	cis	rs6543140	0.964	rs6736135	chr2:103064924	A/G	cg03938978	chr2:103052716	IL18RAP	0.36	7.02	0.32	8.85e-12	Blood protein levels;
LUAD	cis	rs62400317	0.859	rs72869127	chr6:45071712	T/C	cg18551225	chr6:44695536	NA	-0.56	-8.6	-0.39	1.57e-16	Total body bone mineral density;
LUAD	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02788857	chr8:22132959	PIWIL2	0.59	11.29	0.48	4.99e-26	Hypertriglyceridemia;
LUAD	cis	rs77861329	1.000	rs893056	chr3:52109564	G/A	cg08692210	chr3:52188851	WDR51A	0.82	7.55	0.34	2.62e-13	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg05564831	chr3:52568323	NT5DC2	0.35	6.36	0.3	5.2e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg12310025	chr6:25882481	NA	-0.85	-11.95	-0.5	1.41e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg06547715	chr2:218990976	CXCR2	-0.27	-6.39	-0.3	4.29e-10	Colorectal cancer;
LUAD	cis	rs7903847	0.642	rs10882926	chr10:99160690	C/T	cg20016023	chr10:99160130	RRP12	0.3	7.32	0.34	1.26e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.52	-0.42	1.3e-19	Life satisfaction;
LUAD	cis	rs4253772	0.515	rs9615968	chr22:46772695	A/G	cg09491104	chr22:46646882	C22orf40	-0.57	-6.51	-0.3	2.11e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs11893307	0.509	rs12611764	chr2:191537143	T/C	cg27211696	chr2:191398769	TMEM194B	-0.43	-6.58	-0.3	1.36e-10	Mean platelet volume;
LUAD	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg10556349	chr10:835070	NA	-0.5	-7.24	-0.33	2.16e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg10591111	chr5:226296	SDHA	-0.55	-7.17	-0.33	3.48e-12	Breast cancer;
LUAD	cis	rs367615	0.537	rs17161729	chr5:108660528	C/G	cg17395555	chr5:108820864	NA	-0.48	-9.15	-0.41	2.49e-18	Colorectal cancer (SNP x SNP interaction);
LUAD	trans	rs2797160	0.967	rs926854	chr6:126021780	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.53	8.47	0.38	4.18e-16	Endometrial cancer;
LUAD	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg04800585	chr6:26043546	HIST1H2BB	0.37	6.66	0.31	8.51e-11	Blood metabolite levels;
LUAD	cis	rs9868809	1.000	rs2310997	chr3:48678011	G/C	cg00383909	chr3:49044727	WDR6	0.66	7.06	0.32	6.9e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg20283391	chr11:68216788	NA	-0.41	-6.7	-0.31	6.77e-11	Total body bone mineral density;
LUAD	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg13319975	chr6:146136371	FBXO30	0.81	13.67	0.55	1.81e-35	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg20607287	chr7:12443886	VWDE	0.51	7.55	0.34	2.62e-13	Coronary artery disease;
LUAD	cis	rs15676	0.786	rs7875300	chr9:131573261	G/A	cg00228799	chr9:131580591	ENDOG	-0.47	-7.1	-0.33	5.44e-12	Blood metabolite levels;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg16370446	chr4:15683284	LOC285550	0.4	6.38	0.3	4.77e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg07537917	chr2:241836409	C2orf54	-0.3	-8.37	-0.38	8.36e-16	Urinary metabolites;
LUAD	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg10518543	chr12:38710700	ALG10B	-0.43	-7.01	-0.32	9.31e-12	Heart rate;
LUAD	cis	rs2309752	1	rs2309752	chr2:100762169	T/A	cg07810366	chr2:100720526	AFF3	-0.37	-7.46	-0.34	4.87e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9715521	0.868	rs6856620	chr4:59820960	A/G	cg11281224	chr4:60001000	NA	-0.56	-9.46	-0.42	2.14e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1595825	1.000	rs59441945	chr2:198879645	T/A	cg00982548	chr2:198649783	BOLL	-0.62	-8.84	-0.39	2.61e-17	Ulcerative colitis;
LUAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg20607798	chr8:58055168	NA	0.58	7.41	0.34	6.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg10560079	chr2:191398806	TMEM194B	-0.54	-7.12	-0.33	4.8e-12	Diastolic blood pressure;
LUAD	cis	rs2004318	1.000	rs79274890	chr19:55078044	G/A	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.93e-13	Blood protein levels;
LUAD	cis	rs10791097	0.702	rs11222346	chr11:130715343	T/C	cg14779329	chr11:130786720	SNX19	-0.36	-6.51	-0.3	2.09e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg24558204	chr6:135376177	HBS1L	0.46	8.58	0.38	1.83e-16	Red blood cell count;
LUAD	cis	rs9462027	0.628	rs9469892	chr6:34769101	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.78	-0.39	4.02e-17	Systemic lupus erythematosus;
LUAD	trans	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	8.27	0.37	1.72e-15	Mean corpuscular volume;
LUAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg26354017	chr1:205819088	PM20D1	-0.7	-14.27	-0.57	5.51e-38	Monocyte percentage of white cells;
LUAD	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.31	6.96	0.32	1.34e-11	Systemic lupus erythematosus;
LUAD	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg06002616	chr8:101225028	SPAG1	-0.39	-8.11	-0.37	5.67e-15	Atrioventricular conduction;
LUAD	cis	rs1395	0.778	rs6749393	chr2:27451000	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.46	8.29	0.37	1.51e-15	Blood metabolite levels;
LUAD	cis	rs859767	0.501	rs1568120	chr2:135406890	A/G	cg12500956	chr2:135428796	TMEM163	-0.28	-7.56	-0.34	2.55e-13	Neuroticism;
LUAD	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg14671364	chr1:107599128	PRMT6	0.53	9.24	0.41	1.25e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg23950597	chr19:37808831	NA	-0.61	-7.19	-0.33	2.92e-12	Coronary artery calcification;
LUAD	cis	rs7017914	0.967	rs13272523	chr8:71641472	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs3931	0.607	rs11676084	chr2:169703974	C/T	cg13605690	chr2:169746671	SPC25	0.52	7.24	0.33	2.1e-12	Monocyte count;
LUAD	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg12927641	chr6:109611667	NA	-0.47	-7.91	-0.36	2.27e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg23018236	chr17:30244563	NA	-0.69	-8.39	-0.38	7.53e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg15181151	chr6:150070149	PCMT1	0.42	8.92	0.4	1.46e-17	Lung cancer;
LUAD	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.21	0.33	2.67e-12	Motion sickness;
LUAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10819733	chr22:24237672	NA	0.37	6.79	0.31	3.76e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg11050988	chr7:1952600	MAD1L1	-0.39	-8.02	-0.36	1.08e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.3	6.57	0.3	1.45e-10	Parkinson's disease;
LUAD	cis	rs7267979	1.000	rs6083862	chr20:25411086	A/T	cg08601574	chr20:25228251	PYGB	-0.44	-8.07	-0.37	7.45e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg03676636	chr4:99064102	C4orf37	0.27	6.86	0.32	2.51e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg23933602	chr10:16859644	RSU1	0.59	8.04	0.36	9.15e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs17095355	0.605	rs58154613	chr10:111633966	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.69	-0.35	1.05e-13	Biliary atresia;
LUAD	cis	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg27411982	chr8:10470053	RP1L1	0.36	6.54	0.3	1.77e-10	Neuroticism;
LUAD	cis	rs9837602	1.000	rs9833980	chr3:99767096	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	9.22	0.41	1.46e-18	Breast cancer;
LUAD	cis	rs870825	0.616	rs7674952	chr4:185622327	A/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.32	0.57	3.35e-38	Blood protein levels;
LUAD	cis	rs6460942	1.000	rs79659770	chr7:12326371	T/C	cg06484146	chr7:12443880	VWDE	-0.54	-6.43	-0.3	3.56e-10	Coronary artery disease;
LUAD	cis	rs77741769	0.529	rs2893876	chr12:121245158	T/C	cg02419362	chr12:121203948	SPPL3	0.41	8.3	0.37	1.38e-15	Mean corpuscular volume;
LUAD	cis	rs116248771	0.739	rs12639329	chr3:158347145	T/C	cg16708174	chr3:158430962	RARRES1	0.47	6.88	0.32	2.22e-11	diarrhoeal disease at age 2;
LUAD	trans	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg14917512	chr19:3094685	GNA11	0.57	6.87	0.32	2.28e-11	Diabetic kidney disease;
LUAD	cis	rs2625529	0.668	rs8192386	chr15:72513148	A/C	cg16672083	chr15:72433130	SENP8	0.77	13.34	0.54	4.12e-34	Red blood cell count;
LUAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.95e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg12599982	chr1:44399894	ARTN	0.31	6.44	0.3	3.17e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7737355	0.947	rs193458	chr5:130816284	G/C	cg06307176	chr5:131281290	NA	0.51	8.17	0.37	3.72e-15	Life satisfaction;
LUAD	cis	rs2579500	0.807	rs10177168	chr2:97280240	A/G	cg23100626	chr2:96804247	ASTL	-0.29	-7.2	-0.33	2.75e-12	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	trans	rs877282	0.842	rs7092986	chr10:756373	G/A	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg23505145	chr19:12996616	KLF1	0.61	9.98	0.44	3.39e-21	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg03806693	chr22:41940476	POLR3H	0.73	9.89	0.43	7.14e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg17105886	chr17:28927953	LRRC37B2	0.82	7.64	0.35	1.46e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg13560548	chr3:10150139	C3orf24	0.45	6.59	0.31	1.3e-10	Alzheimer's disease;
LUAD	cis	rs7177699	0.534	rs7403708	chr15:79123885	T/C	cg15571903	chr15:79123663	NA	-0.4	-8.06	-0.36	8.07e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg26597838	chr10:835615	NA	0.79	10.44	0.45	7.16e-23	Eosinophil percentage of granulocytes;
LUAD	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.51	10.63	0.46	1.47e-23	Monocyte percentage of white cells;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17512782	chr17:71228826	C17orf80;FAM104A	-0.4	-6.65	-0.31	9.19e-11	Cancer;
LUAD	cis	rs708547	0.735	rs1277280	chr4:57866872	T/G	cg00922110	chr4:57842668	C4orf14	-0.42	-7.35	-0.34	1.04e-12	Response to bleomycin (chromatid breaks);
LUAD	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg18512352	chr11:47633146	NA	-0.56	-10.04	-0.44	2.02e-21	Subjective well-being;
LUAD	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg07776626	chr8:57350775	NA	-0.6	-9.01	-0.4	7.35e-18	Obesity-related traits;
LUAD	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg06740227	chr12:86229804	RASSF9	0.41	7.23	0.33	2.32e-12	Major depressive disorder;
LUAD	cis	rs1113500	0.730	rs1781077	chr1:108589589	G/T	cg06207961	chr1:108661230	NA	-0.34	-6.62	-0.31	1.11e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs790123	0.553	rs7612991	chr3:122351791	T/C	cg15604389	chr3:122379662	NA	0.45	7.96	0.36	1.58e-14	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs9905704	0.609	rs72828712	chr17:56897404	A/T	cg19466818	chr17:56409534	MIR142	-0.33	-6.42	-0.3	3.6e-10	Testicular germ cell tumor;
LUAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg22907277	chr7:1156413	C7orf50	0.69	8.09	0.37	6.54e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12545109	0.879	rs2670015	chr8:57376607	T/A	cg09654669	chr8:57350985	NA	-0.7	-9.92	-0.43	5.4e-21	Obesity-related traits;
LUAD	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg22117172	chr7:91764530	CYP51A1	-0.36	-7.75	-0.35	7.08e-14	Breast cancer;
LUAD	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg04545296	chr12:48745243	ZNF641	0.38	9.7	0.43	3.09e-20	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.6	-0.35	1.96e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg22442454	chr1:209979470	IRF6	0.55	7.33	0.34	1.2e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg19717773	chr7:2847554	GNA12	-0.44	-7.22	-0.33	2.48e-12	Height;
LUAD	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg04282206	chr17:62833786	PLEKHM1P	0.61	8.95	0.4	1.12e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg27454412	chr7:1067447	C7orf50	0.48	7.73	0.35	7.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg09365446	chr1:150670422	GOLPH3L	0.66	12.58	0.52	4.9e-31	Tonsillectomy;
LUAD	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg10523679	chr1:76189770	ACADM	0.91	15.68	0.61	4.96e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg14159672	chr1:205819179	PM20D1	-0.5	-8.12	-0.37	5.31e-15	Parkinson's disease;
LUAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00166722	chr3:10149974	C3orf24	0.73	10.81	0.47	3.15e-24	Alzheimer's disease;
LUAD	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	7.85	0.36	3.38e-14	Menopause (age at onset);
LUAD	cis	rs4285028	0.747	rs1574133	chr3:121468794	G/C	cg11130432	chr3:121712080	ILDR1	-0.46	-6.59	-0.31	1.28e-10	Multiple sclerosis;
LUAD	cis	rs6752107	0.967	rs3792109	chr2:234184417	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.57	9.99	0.44	3.11e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs72772090	0.539	rs11750671	chr5:96188482	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-6.77	-0.31	4.28e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg05234568	chr11:5960015	NA	-0.52	-9.11	-0.4	3.44e-18	DNA methylation (variation);
LUAD	cis	rs7727544	0.625	rs4705916	chr5:131407493	C/A	cg07538946	chr5:131705188	SLC22A5	0.42	6.63	0.31	1.05e-10	Blood metabolite levels;
LUAD	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg00339695	chr16:24857497	SLC5A11	0.55	8.79	0.39	3.67e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.91	0.36	2.2e-14	Lung cancer;
LUAD	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg19875535	chr5:140030758	IK	-0.4	-6.83	-0.32	2.99e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9469890	0.604	rs77587944	chr6:34503644	T/G	cg14254433	chr6:34482411	PACSIN1	-0.6	-8.62	-0.39	1.33e-16	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs8060686	0.623	rs2301814	chr16:68105171	C/G	cg26727032	chr16:67993705	SLC12A4	-0.45	-7.42	-0.34	6.2800000000000005e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg25358565	chr5:93447407	FAM172A	0.57	6.73	0.31	5.44e-11	Diabetic retinopathy;
LUAD	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg10518543	chr12:38710700	ALG10B	0.41	6.38	0.3	4.59e-10	Heart rate;
LUAD	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg14196790	chr5:131705035	SLC22A5	0.38	6.72	0.31	5.91e-11	Breast cancer;
LUAD	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.15	0.33	3.88e-12	Motion sickness;
LUAD	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg00647820	chr17:40259828	DHX58	-0.42	-6.84	-0.32	2.74e-11	Fibrinogen levels;
LUAD	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.36	-0.57	2.28e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06028808	chr11:68637592	NA	0.43	7.21	0.33	2.67e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs73206853	0.841	rs7956963	chr12:110947783	G/A	cg12870014	chr12:110450643	ANKRD13A	0.62	7.01	0.32	9.52e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg07549590	chr16:15018862	NA	0.4	7.56	0.34	2.54e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg01528321	chr10:82214614	TSPAN14	0.46	7.3	0.33	1.48e-12	Post bronchodilator FEV1;
LUAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg21226059	chr5:178986404	RUFY1	0.68	12.09	0.51	4.31e-29	Lung cancer;
LUAD	cis	rs859767	0.501	rs4954160	chr2:135431692	A/C	cg12500956	chr2:135428796	TMEM163	-0.27	-7.36	-0.34	9.92e-13	Neuroticism;
LUAD	cis	rs2274471	0.645	rs3780375	chr9:5109431	G/A	cg03390472	chr9:5043263	JAK2	-0.55	-8.01	-0.36	1.11e-14	Crohn's disease;
LUAD	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg17063962	chr7:91808500	NA	-0.7	-12.67	-0.52	2.02e-31	Breast cancer;
LUAD	cis	rs346785	0.692	rs6501881	chr17:74289839	G/A	cg09812376	chr17:74270190	QRICH2	-0.3	-6.39	-0.3	4.46e-10	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg05555928	chr11:63887634	MACROD1	0.49	9.85	0.43	9.62e-21	Platelet count;
LUAD	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg03929089	chr4:120376271	NA	-0.92	-16.95	-0.64	1.5e-49	Height;
LUAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11905131	chr22:24372483	LOC391322	0.42	7.24	0.33	2.19e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.45	-8.89	-0.4	1.82e-17	Urate levels in overweight individuals;
LUAD	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1493916	1.000	rs11081827	chr18:31390228	C/A	cg13755796	chr4:20253514	NA	-0.43	-7.3	-0.33	1.48e-12	Life satisfaction;
LUAD	cis	rs6785206	0.667	rs2253125	chr3:128329793	T/C	cg16766828	chr3:128327626	NA	-0.65	-7.92	-0.36	2.06e-14	Lymphocyte percentage of white cells;
LUAD	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg25817165	chr18:72167213	CNDP2	-0.71	-10.53	-0.46	3.56e-23	Refractive error;
LUAD	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.56	-7.16	-0.33	3.65e-12	Body mass index;
LUAD	cis	rs1546060	0.683	rs11718232	chr3:56448888	C/T	cg24436196	chr3:56448270	ERC2	0.37	6.79	0.31	3.71e-11	Night sleep phenotypes;
LUAD	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg06608945	chr2:219082296	ARPC2	-0.42	-7.04	-0.32	8e-12	Colorectal cancer;
LUAD	cis	rs6062509	0.965	rs6062506	chr20:62352389	T/G	cg21849932	chr20:62369462	LIME1	-0.46	-7.28	-0.33	1.6e-12	Prostate cancer;
LUAD	cis	rs2505998	0.796	rs2505537	chr10:43592158	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.34	-6.49	-0.3	2.46e-10	Hirschsprung disease;
LUAD	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg15181151	chr6:150070149	PCMT1	0.37	7.51	0.34	3.61e-13	Lung cancer;
LUAD	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg03467027	chr4:99064603	C4orf37	0.39	6.37	0.3	5.05e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg10057126	chr4:77819792	ANKRD56	0.54	9.26	0.41	1.01e-18	Emphysema distribution in smoking;
LUAD	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg13180566	chr4:1052158	NA	-0.39	-6.56	-0.3	1.6e-10	Recombination rate (females);
LUAD	cis	rs1904096	0.506	rs17021463	chr4:95224812	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.5	-9.47	-0.42	2.01e-19	Type 2 diabetes;
LUAD	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg10523679	chr1:76189770	ACADM	0.84	15.26	0.6	3.27e-42	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18876405	chr7:65276391	NA	-0.43	-6.7	-0.31	6.5500000000000006e-11	Aortic root size;
LUAD	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg00530320	chr1:46809349	NSUN4	0.5	7.73	0.35	8.03e-14	Menopause (age at onset);
LUAD	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.15	-0.44	8.39e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs7107174	1.000	rs72931639	chr11:78036703	C/T	cg02023728	chr11:77925099	USP35	0.43	6.69	0.31	7.1e-11	Testicular germ cell tumor;
LUAD	cis	rs10899021	0.920	rs61901541	chr11:74317985	T/C	cg25880958	chr11:74394337	NA	-0.62	-8.5	-0.38	3.34e-16	Response to metformin (IC50);
LUAD	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.28	-0.33	1.62e-12	Total body bone mineral density;
LUAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg22907277	chr7:1156413	C7orf50	0.63	10.75	0.46	5.63e-24	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.78	-0.31	3.99e-11	Retinal vascular caliber;
LUAD	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg02696790	chr15:75250997	RPP25	0.41	7.66	0.35	1.26e-13	Breast cancer;
LUAD	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18099408	chr3:52552593	STAB1	-0.46	-8.12	-0.37	5e-15	Bipolar disorder;
LUAD	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	7.98	0.36	1.37e-14	Menopause (age at onset);
LUAD	cis	rs10484885	0.878	rs72921937	chr6:90579863	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.64	-6.41	-0.3	3.98e-10	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg05340658	chr4:99064831	C4orf37	0.53	8.87	0.4	2.08e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg03929089	chr4:120376271	NA	-0.98	-20.96	-0.71	1.99e-67	Height;
LUAD	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg23422044	chr7:1970798	MAD1L1	-0.52	-6.44	-0.3	3.17e-10	Bipolar disorder;
LUAD	cis	rs2806561	1.000	rs2473851	chr1:23489869	A/G	cg12483005	chr1:23474871	LUZP1	0.4	6.97	0.32	1.19e-11	Height;
LUAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27286337	chr10:134555280	INPP5A	0.72	9.58	0.42	8.39e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	trans	rs7939886	0.920	rs2460212	chr11:55886155	C/T	cg15704280	chr7:45808275	SEPT13	-0.65	-6.38	-0.3	4.65e-10	Myopia (pathological);
LUAD	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg02423579	chr7:2872169	GNA12	-0.86	-14.76	-0.58	4.52e-40	Height;
LUAD	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg08888203	chr3:10149979	C3orf24	0.71	12.43	0.52	1.87e-30	Alzheimer's disease;
LUAD	cis	rs13082711	0.554	rs1494423	chr3:27375345	A/G	cg02860705	chr3:27208620	NA	-0.65	-10.13	-0.44	9.81e-22	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs10781543	0.817	rs1128874	chr9:139323424	T/C	cg14169450	chr9:139327907	INPP5E	0.49	9.06	0.4	4.89e-18	Monocyte percentage of white cells;
LUAD	cis	rs67478160	0.608	rs11628787	chr14:104323984	G/A	cg01849466	chr14:104193079	ZFYVE21	0.61	11.15	0.48	1.74e-25	Schizophrenia;
LUAD	cis	rs925255	0.747	rs6547851	chr2:28629367	G/C	cg01273330	chr2:28605224	NA	0.33	6.99	0.32	1.05e-11	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2625529	0.652	rs2899775	chr15:72268354	C/T	cg16672083	chr15:72433130	SENP8	0.64	11.89	0.5	2.41e-28	Red blood cell count;
LUAD	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg25985355	chr7:65971099	NA	-0.55	-6.82	-0.31	3.17e-11	Diabetic kidney disease;
LUAD	cis	rs12530845	1.000	rs77068811	chr7:135334571	A/G	cg23117316	chr7:135346802	PL-5283	-0.49	-9.11	-0.41	3.24e-18	Red blood cell traits;
LUAD	cis	rs12530845	0.673	rs4269479	chr7:135332379	C/T	cg23117316	chr7:135346802	PL-5283	-0.57	-8.73	-0.39	5.78e-17	Red blood cell traits;
LUAD	cis	rs738321	0.757	rs4820314	chr22:38518538	G/A	cg17652424	chr22:38574118	PLA2G6	-0.25	-6.36	-0.3	5.22e-10	Breast cancer;
LUAD	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg04369109	chr6:150039330	LATS1	-0.4	-6.51	-0.3	2.09e-10	Lung cancer;
LUAD	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.32	-0.34	1.28e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg17644776	chr2:200775616	C2orf69	0.54	7.09	0.33	5.71e-12	Schizophrenia;
LUAD	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg11645453	chr3:52864694	ITIH4	-0.38	-7.22	-0.33	2.38e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg23649088	chr2:200775458	C2orf69	0.58	8.38	0.38	7.95e-16	Schizophrenia;
LUAD	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg04414720	chr1:150670196	GOLPH3L	0.73	13.64	0.55	2.2e-35	Tonsillectomy;
LUAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg01448562	chr3:133502909	NA	0.67	12.6	0.52	3.96e-31	Iron status biomarkers;
LUAD	cis	rs1595825	0.891	rs16824376	chr2:198684342	C/T	cg00982548	chr2:198649783	BOLL	-0.65	-9.28	-0.41	9.06e-19	Ulcerative colitis;
LUAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg20607798	chr8:58055168	NA	0.82	9.86	0.43	9.19e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg20673091	chr1:2541236	MMEL1	0.4	8.54	0.38	2.43e-16	Ulcerative colitis;
LUAD	trans	rs4332037	0.805	rs4721142	chr7:1918079	T/C	cg11693508	chr17:37793320	STARD3	0.69	9.36	0.41	4.77e-19	Bipolar disorder;
LUAD	cis	rs7481584	0.886	rs4758621	chr11:3009640	C/T	cg11201177	chr11:2961805	NA	-0.37	-6.39	-0.3	4.28e-10	Calcium levels;
LUAD	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg23985595	chr17:80112537	CCDC57	-0.53	-9.5	-0.42	1.56e-19	Life satisfaction;
LUAD	cis	rs11971779	0.616	rs6944244	chr7:139051186	T/C	cg23387468	chr7:139079360	LUC7L2	0.28	6.49	0.3	2.47e-10	Diisocyanate-induced asthma;
LUAD	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg06263672	chr7:65235340	NA	-0.5	-6.66	-0.31	8.45e-11	Aortic root size;
LUAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.32	-0.41	6.57e-19	Testicular germ cell tumor;
LUAD	cis	rs1215050	0.904	rs9307215	chr4:98813965	A/G	cg17366294	chr4:99064904	C4orf37	0.44	7.46	0.34	5.12e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg09455208	chr3:40491958	NA	-0.54	-12.08	-0.51	4.42e-29	Renal cell carcinoma;
LUAD	cis	rs2425143	1.000	rs2425078	chr20:34298163	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.72	-0.35	8.69e-14	Blood protein levels;
LUAD	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.61	0.35	1.84e-13	Platelet count;
LUAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg11062466	chr8:58055876	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg13073564	chr4:8508604	NA	-0.54	-9.99	-0.44	3.07e-21	Response to antineoplastic agents;
LUAD	cis	rs16854884	0.660	rs990320	chr3:143796305	T/C	cg01302019	chr3:143689584	C3orf58	-0.39	-6.35	-0.3	5.51e-10	Economic and political preferences (feminism/equality);
LUAD	cis	rs714027	1.000	rs4823075	chr22:30519152	T/C	cg11564601	chr22:30592435	NA	-0.39	-8.38	-0.38	8.04e-16	Lymphocyte counts;
LUAD	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.09	-0.33	5.55e-12	Total body bone mineral density;
LUAD	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg20503657	chr10:835505	NA	1.24	17.86	0.66	1.48e-53	Eosinophil percentage of granulocytes;
LUAD	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.78	-0.39	4.09e-17	Initial pursuit acceleration;
LUAD	cis	rs490234	0.812	rs12341150	chr9:128340770	C/T	cg14078157	chr9:128172775	NA	-0.39	-7.1	-0.33	5.29e-12	Mean arterial pressure;
LUAD	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21582582	chr3:182698605	DCUN1D1	0.6	10.24	0.45	4e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg23758822	chr17:41437982	NA	-0.94	-17.58	-0.65	2.46e-52	Menopause (age at onset);
LUAD	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg13319975	chr6:146136371	FBXO30	0.68	11.84	0.5	3.85e-28	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4604732	0.631	rs75600450	chr1:247625492	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05002071	chr11:76510323	NA	-0.42	-6.46	-0.3	2.92e-10	Height;
LUAD	cis	rs79349575	0.691	rs28528789	chr17:46986616	C/T	cg22482690	chr17:47019901	SNF8	-0.37	-7.06	-0.32	6.89e-12	Type 2 diabetes;
LUAD	cis	rs9394159	0.583	rs4713650	chr6:33616828	C/T	cg14003231	chr6:33640908	ITPR3	-0.51	-9.98	-0.44	3.38e-21	Graves' disease;
LUAD	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23158103	chr7:148848205	ZNF398	-0.6	-10.89	-0.47	1.64e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	17.21	0.64	1.11e-50	Exhaled nitric oxide output;
LUAD	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg17074396	chr22:49843754	NA	-0.3	-6.43	-0.3	3.4e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6547631	0.622	rs10210321	chr2:85928128	A/C	cg21473183	chr2:85925749	GNLY	0.37	7.99	0.36	1.31e-14	Blood protein levels;
LUAD	cis	rs62400317	0.859	rs62400267	chr6:45180440	C/T	cg18551225	chr6:44695536	NA	-0.56	-8.32	-0.37	1.24e-15	Total body bone mineral density;
LUAD	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg16988262	chr1:15930761	NA	0.42	6.92	0.32	1.63e-11	Systolic blood pressure;
LUAD	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg09359103	chr1:154839909	KCNN3	0.86	19.92	0.7	9.08e-63	Prostate cancer;
LUAD	cis	rs2658782	0.901	rs11604909	chr11:93218355	C/G	cg15737290	chr11:93063684	CCDC67	0.48	6.59	0.31	1.3100000000000001e-10	Pulmonary function decline;
LUAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg04622731	chr7:157956161	PTPRN2	-0.51	-9.94	-0.44	4.46e-21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2274273	0.624	rs67412516	chr14:55853237	A/T	cg04306507	chr14:55594613	LGALS3	0.42	7.99	0.36	1.25e-14	Protein biomarker;
LUAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg15704280	chr7:45808275	SEPT13	-0.62	-9.29	-0.41	7.99e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4462272	0.503	rs12774352	chr10:101840960	A/G	cg02250046	chr10:101825185	CPN1	-0.32	-6.46	-0.3	2.9e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg04455712	chr21:45112962	RRP1B	0.43	8.31	0.37	1.3e-15	Mean corpuscular volume;
LUAD	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg02038168	chr22:39784481	NA	-0.39	-6.57	-0.3	1.48e-10	IgG glycosylation;
LUAD	cis	rs17433780	0.612	rs7911	chr1:89518120	A/G	cg09516651	chr1:89888402	LOC400759	0.52	10.24	0.45	3.91e-22	Carotid intima media thickness;
LUAD	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.67	-0.35	1.21e-13	Breast cancer;
LUAD	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg12524338	chr4:183729343	NA	0.61	7.34	0.34	1.08e-12	Pediatric autoimmune diseases;
LUAD	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg13319975	chr6:146136371	FBXO30	0.6	10.08	0.44	1.44e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg11965913	chr1:205819406	PM20D1	-0.55	-8.34	-0.38	1.1e-15	Menarche (age at onset);
LUAD	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg26408565	chr15:76604113	ETFA	-0.43	-6.95	-0.32	1.4e-11	Blood metabolite levels;
LUAD	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg08029281	chr1:67600428	NA	-0.35	-6.85	-0.32	2.57e-11	Psoriasis;
LUAD	cis	rs6546550	0.901	rs13015457	chr2:70125763	G/T	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.19	-0.48	1.26e-25	Prevalent atrial fibrillation;
LUAD	cis	rs2996428	0.536	rs12126653	chr1:3773815	C/G	cg17848003	chr1:3704513	LRRC47	0.52	10.23	0.45	4.41e-22	Red cell distribution width;
LUAD	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg04287289	chr16:89883240	FANCA	0.7	6.56	0.3	1.59e-10	Skin colour saturation;
LUAD	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05890377	chr2:74357713	NA	0.82	12.84	0.53	4.39e-32	Gestational age at birth (maternal effect);
LUAD	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg05887092	chr17:76393375	PGS1	0.41	7.28	0.33	1.65e-12	HDL cholesterol levels;
LUAD	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15506890	chr2:3487001	NA	-0.45	-7.95	-0.36	1.75e-14	Neurofibrillary tangles;
LUAD	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg05564831	chr3:52568323	NT5DC2	0.35	6.83	0.31	3.05e-11	Bipolar disorder;
LUAD	cis	rs113835537	0.935	rs117480267	chr11:66398596	C/T	cg24851651	chr11:66362959	CCS	0.58	8.0	0.36	1.24e-14	Airway imaging phenotypes;
LUAD	cis	rs7264396	0.563	rs2425117	chr20:34323776	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.17	-0.37	3.61e-15	Total cholesterol levels;
LUAD	cis	rs4853036	0.586	rs35066995	chr2:70005544	T/C	cg02498382	chr2:70120550	SNRNP27	-0.47	-6.58	-0.3	1.38e-10	Colorectal or endometrial cancer;
LUAD	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg00383909	chr3:49044727	WDR6	0.88	10.24	0.45	4.01e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.43	-8.31	-0.37	1.31e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6906287	0.647	rs13217710	chr6:118843601	A/G	cg05564266	chr6:118973597	C6orf204	0.34	7.15	0.33	3.82e-12	Electrocardiographic conduction measures;
LUAD	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg21545522	chr1:205238299	TMCC2	0.38	7.02	0.32	9.15e-12	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	8.42	0.38	6e-16	Multiple sclerosis;
LUAD	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg05044414	chr3:183734942	ABCC5	0.4	8.05	0.36	8.67e-15	Anterior chamber depth;
LUAD	trans	rs1422110	0.543	rs768240	chr5:85420954	C/T	cg01787110	chr1:109008453	NBPF6	-0.61	-10.42	-0.45	9.12e-23	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs2625529	0.652	rs2957735	chr15:72265173	T/C	cg16672083	chr15:72433130	SENP8	0.64	12.09	0.51	4.3e-29	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg17366294	chr4:99064904	C4orf37	0.64	11.93	0.5	1.72e-28	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg05043794	chr9:111880884	C9orf5	-0.44	-7.48	-0.34	4.23e-13	Menarche (age at onset);
LUAD	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg09658497	chr7:2847517	GNA12	-0.49	-9.27	-0.41	9.24e-19	Height;
LUAD	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg02569458	chr12:86230093	RASSF9	-0.41	-7.76	-0.35	6.57e-14	Major depressive disorder;
LUAD	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg03676636	chr4:99064102	C4orf37	0.35	9.04	0.4	5.73e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3931020	0.566	rs1409782	chr1:75272935	T/A	cg26855724	chr1:75198818	TYW3;CRYZ	0.41	6.49	0.3	2.47e-10	Resistin levels;
LUAD	cis	rs2274273	0.870	rs3825616	chr14:55853288	G/C	cg04306507	chr14:55594613	LGALS3	0.41	8.77	0.39	4.45e-17	Protein biomarker;
LUAD	cis	rs6693567	0.545	rs1694380	chr1:150292341	A/G	cg15654264	chr1:150340011	RPRD2	0.37	6.56	0.3	1.59e-10	Migraine;
LUAD	cis	rs7828089	0.744	rs10108011	chr8:22320806	C/T	cg12081754	chr8:22256438	SLC39A14	0.42	6.8	0.31	3.59e-11	Verbal declarative memory;
LUAD	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg06191203	chr2:152266755	RIF1	0.51	7.88	0.36	2.83e-14	Lung cancer;
LUAD	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.59	-0.35	2.12e-13	Monocyte count;
LUAD	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.53	-9.44	-0.42	2.48e-19	Homoarginine levels;
LUAD	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg17031739	chr1:67600172	NA	0.54	9.54	0.42	1.19e-19	Psoriasis;
LUAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg03188948	chr7:1209495	NA	0.4	6.44	0.3	3.17e-10	Longevity;Endometriosis;
LUAD	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.2	-12.25	-0.51	9.73e-30	Reticulocyte fraction of red cells;Reticulocyte count;
LUAD	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11890956	chr21:40555474	PSMG1	-0.59	-10.29	-0.45	2.5e-22	Menarche (age at onset);
LUAD	cis	rs11971779	0.527	rs4379397	chr7:139043385	G/A	cg23387468	chr7:139079360	LUC7L2	0.28	6.49	0.3	2.47e-10	Diisocyanate-induced asthma;
LUAD	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23158103	chr7:148848205	ZNF398	-0.62	-10.61	-0.46	1.81e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2456568	0.802	rs1108910	chr11:93629677	C/T	cg26875233	chr11:93583750	C11orf90	0.29	6.59	0.31	1.3e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg06064525	chr11:970664	AP2A2	-0.53	-10.86	-0.47	2.05e-24	Alzheimer's disease (late onset);
LUAD	cis	rs17155006	0.664	rs448833	chr7:107739181	A/G	cg05962710	chr7:107745446	LAMB4	-0.35	-7.27	-0.33	1.78e-12	Pneumococcal bacteremia;
LUAD	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg03733263	chr8:22462867	KIAA1967	0.65	10.91	0.47	1.39e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg26924012	chr15:45694286	SPATA5L1	1.02	18.85	0.68	5.65e-58	Homoarginine levels;
LUAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-8.09	-0.37	6.56e-15	Alzheimer's disease;
LUAD	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg06060754	chr5:176797920	RGS14	0.62	10.54	0.46	3.27e-23	Urinary electrolytes (magnesium/calcium ratio);
LUAD	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg15691649	chr6:25882328	NA	-0.45	-7.13	-0.33	4.29e-12	Blood metabolite levels;
LUAD	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg27211696	chr2:191398769	TMEM194B	-0.68	-8.87	-0.4	2.15e-17	Diastolic blood pressure;
LUAD	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-6.99	-0.32	1.05e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg15704280	chr7:45808275	SEPT13	-0.52	-8.21	-0.37	2.8e-15	HDL cholesterol;
LUAD	cis	rs2806561	1.000	rs1571466	chr1:23449183	T/C	cg12483005	chr1:23474871	LUZP1	0.4	6.8	0.31	3.57e-11	Height;
LUAD	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg26384229	chr12:38710491	ALG10B	0.44	7.19	0.33	2.93e-12	Morning vs. evening chronotype;
LUAD	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.46	-0.34	4.95e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg13319975	chr6:146136371	FBXO30	-0.6	-10.04	-0.44	2.08e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg27446573	chr6:127587934	RNF146	0.44	6.62	0.31	1.06e-10	Breast cancer;
LUAD	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.46	-0.3	2.88e-10	Morning vs. evening chronotype;
LUAD	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg21252483	chr19:49399788	TULP2	-0.73	-11.31	-0.48	4.42e-26	Red cell distribution width;
LUAD	cis	rs4711350	1.000	rs10947436	chr6:33739960	A/G	cg16010596	chr6:33739607	LEMD2	-0.38	-6.45	-0.3	3.15e-10	Schizophrenia;
LUAD	cis	rs752010	1.000	rs752010	chr1:42093015	C/T	cg06885757	chr1:42089581	HIVEP3	0.44	9.51	0.42	1.47e-19	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg01528321	chr10:82214614	TSPAN14	0.65	10.5	0.45	4.37e-23	Post bronchodilator FEV1;
LUAD	cis	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-8.24	-0.37	2.21e-15	Neuroticism;
LUAD	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.44	-0.34	5.74e-13	Electroencephalogram traits;
LUAD	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg21475434	chr5:93447410	FAM172A	0.75	8.48	0.38	3.94e-16	Diabetic retinopathy;
LUAD	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg18230493	chr5:56204884	C5orf35	1.06	15.73	0.61	3.04e-44	Initial pursuit acceleration;
LUAD	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg27432699	chr2:27873401	GPN1	0.52	9.02	0.4	6.46e-18	Oral cavity cancer;
LUAD	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg19678392	chr7:94953810	PON1	-0.59	-8.25	-0.37	2.01e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.44	-0.38	5.08e-16	Prostate cancer;
LUAD	cis	rs1448094	0.546	rs17348032	chr12:86318004	A/G	cg00310523	chr12:86230176	RASSF9	0.33	6.49	0.3	2.41e-10	Major depressive disorder;
LUAD	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.38	-0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18404041	chr3:52824283	ITIH1	-0.59	-12.0	-0.5	9.27e-29	Bipolar disorder;
LUAD	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg26384229	chr12:38710491	ALG10B	0.48	7.82	0.36	4.31e-14	Bladder cancer;
LUAD	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg15181151	chr6:150070149	PCMT1	0.39	7.81	0.35	4.69e-14	Lung cancer;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg26614578	chr12:113623930	C12orf52;DDX54	0.38	6.38	0.3	4.63e-10	Bilirubin levels;
LUAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg18402987	chr7:1209562	NA	0.81	9.91	0.43	6.12e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6684514	1.000	rs28372828	chr1:156253031	G/C	cg16558208	chr1:156270281	VHLL	0.53	9.52	0.42	1.36e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs3733418	0.929	rs13134940	chr4:165889612	G/A	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.49	-6.83	-0.32	2.94e-11	Obesity-related traits;
LUAD	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg25251562	chr2:3704773	ALLC	0.39	7.07	0.32	6.54e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs931127	0.719	rs7949980	chr11:65445950	T/C	cg27068330	chr11:65405492	SIPA1	-0.43	-6.97	-0.32	1.24e-11	Systemic lupus erythematosus;
LUAD	cis	rs8062405	0.573	rs7187575	chr16:28990101	C/T	cg05966235	chr16:28915196	ATP2A1	-0.46	-6.93	-0.32	1.54e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7599312	0.534	rs6435711	chr2:213410065	G/A	cg16329650	chr2:213403929	ERBB4	0.6	10.58	0.46	2.26e-23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg05425664	chr17:57184151	TRIM37	-0.43	-7.72	-0.35	8.56e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg09796270	chr17:17721594	SREBF1	-0.39	-7.65	-0.35	1.39e-13	Total body bone mineral density;
LUAD	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg05535760	chr7:792225	HEATR2	0.84	10.5	0.45	4.48e-23	Cerebrospinal P-tau181p levels;
LUAD	cis	rs1832871	0.672	rs6899322	chr6:158753669	G/T	cg07165851	chr6:158734300	TULP4	0.7	10.64	0.46	1.32e-23	Height;
LUAD	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg04450456	chr4:17643702	FAM184B	0.43	8.41	0.38	6.13e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg25722142	chr6:139695762	CITED2	0.45	7.23	0.33	2.25e-12	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg11965913	chr1:205819406	PM20D1	0.81	16.73	0.63	1.35e-48	Menarche (age at onset);
LUAD	cis	rs7043114	0.525	rs7047089	chr9:95117980	C/T	cg14631576	chr9:95140430	CENPP	-0.42	-8.52	-0.38	2.89e-16	Height;
LUAD	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	8.93e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.94	-0.44	4.57e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.76e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18404041	chr3:52824283	ITIH1	-0.58	-11.85	-0.5	3.67e-28	Bipolar disorder;
LUAD	cis	rs7089973	0.610	rs61869271	chr10:116731329	T/C	cg23260525	chr10:116636907	FAM160B1	0.34	6.45	0.3	3.11e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg11814155	chr7:99998594	ZCWPW1	0.43	7.37	0.34	9.23e-13	Platelet count;
LUAD	cis	rs16910800	0.953	rs7110229	chr11:23200546	C/T	cg20040320	chr11:23191996	NA	-0.49	-7.27	-0.33	1.7e-12	Cancer;
LUAD	cis	rs7084921	0.608	rs12775433	chr10:101834092	C/T	cg19754520	chr10:101825118	CPN1	-0.33	-6.66	-0.31	8.7e-11	Bone mineral density;
LUAD	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08704250	chr15:31115839	NA	0.48	8.91	0.4	1.51e-17	Huntington's disease progression;
LUAD	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg00255919	chr5:131827918	IRF1	0.41	8.09	0.37	6.36e-15	Asthma (sex interaction);
LUAD	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg18827107	chr12:86230957	RASSF9	-0.62	-11.05	-0.47	4.05e-25	Major depressive disorder;
LUAD	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg04756594	chr16:24857601	SLC5A11	0.73	12.78	0.53	7.37e-32	Intelligence (multi-trait analysis);
LUAD	trans	rs877282	0.945	rs10904556	chr10:789429	A/G	cg22713356	chr15:30763199	NA	1.34	18.73	0.67	1.85e-57	Uric acid levels;
LUAD	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg25173405	chr17:45401733	C17orf57	-0.53	-8.9	-0.4	1.61e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6543140	0.964	rs2160200	chr2:103033963	G/T	cg03938978	chr2:103052716	IL18RAP	0.35	6.86	0.32	2.5e-11	Blood protein levels;
LUAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg18402987	chr7:1209562	NA	0.79	9.77	0.43	1.84e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7223966	0.729	rs9902761	chr17:62010627	A/G	cg25324976	chr17:61989376	CSHL1	0.41	7.55	0.34	2.62e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg00484396	chr16:3507460	NAT15	0.71	12.89	0.53	2.64e-32	Tuberculosis;
LUAD	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22968622	chr17:43663579	NA	1.39	25.49	0.78	1.64e-87	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.84	-0.36	3.72e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg18180107	chr4:99064573	C4orf37	0.42	6.83	0.32	3.02e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg20200200	chr1:18807388	KLHDC7A	-0.3	-8.0	-0.36	1.18e-14	Breast cancer;
LUAD	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg06064525	chr11:970664	AP2A2	-0.53	-10.86	-0.47	2.05e-24	Alzheimer's disease (late onset);
LUAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg15117754	chr3:10150083	C3orf24	0.4	6.66	0.31	8.79e-11	Alzheimer's disease;
LUAD	cis	rs2455799	0.594	rs11128769	chr3:15926230	C/T	cg16303742	chr3:15540471	COLQ	-0.48	-8.7	-0.39	7.44e-17	Mean platelet volume;
LUAD	cis	rs7927771	0.524	rs10838739	chr11:47672743	A/G	cg18512352	chr11:47633146	NA	-0.37	-6.61	-0.31	1.15e-10	Subjective well-being;
LUAD	cis	rs11771526	0.901	rs13438711	chr7:32297310	G/A	cg27532318	chr7:32358331	NA	0.56	7.1	0.33	5.19e-12	Body mass index;
LUAD	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg12714757	chr17:73874637	TRIM47	-0.45	-6.93	-0.32	1.53e-11	Psoriasis;
LUAD	cis	rs17095355	1.000	rs13377169	chr10:111729414	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.67	-9.14	-0.41	2.59e-18	Biliary atresia;
LUAD	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	8.23	0.37	2.39e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg03929089	chr4:120376271	NA	-0.77	-12.17	-0.51	1.96e-29	Coronary artery disease;
LUAD	cis	rs8018808	1.000	rs2193595	chr14:77845121	A/G	cg20045696	chr14:77926864	AHSA1	-0.38	-6.75	-0.31	4.9e-11	Myeloid white cell count;
LUAD	trans	rs3942852	0.606	rs10734561	chr11:48097480	C/T	cg15704280	chr7:45808275	SEPT13	-0.66	-9.49	-0.42	1.68e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs73198271	1.000	rs11775476	chr8:8607869	T/C	cg01851573	chr8:8652454	MFHAS1	0.51	8.19	0.37	3.07e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs7944735	0.817	rs7942031	chr11:47868474	T/C	cg15704280	chr7:45808275	SEPT13	0.52	7.07	0.33	6.43e-12	Intraocular pressure;
LUAD	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg02493740	chr2:85810744	VAMP5	-0.61	-11.37	-0.48	2.57e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg26384229	chr12:38710491	ALG10B	0.45	7.5	0.34	3.79e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6993813	0.843	rs6999463	chr8:120023302	T/C	cg01975934	chr8:119970761	NA	-0.37	-7.15	-0.33	3.82e-12	Bone mineral density (hip);
LUAD	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg21475434	chr5:93447410	FAM172A	0.73	8.33	0.38	1.15e-15	Diabetic retinopathy;
LUAD	cis	rs4604732	0.536	rs78019731	chr1:247626430	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg02569458	chr12:86230093	RASSF9	-0.41	-7.64	-0.35	1.48e-13	Major depressive disorder;
LUAD	cis	rs62238980	0.614	rs117017176	chr22:32400725	T/G	cg00543991	chr22:32367038	NA	0.95	8.87	0.4	2.05e-17	Childhood ear infection;
LUAD	cis	rs9788682	0.747	rs7174190	chr15:78763617	C/T	cg18825076	chr15:78729989	IREB2	0.56	7.72	0.35	8.28e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg10802521	chr3:52805072	NEK4	-0.47	-8.07	-0.37	7.2e-15	Bipolar disorder;
LUAD	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg00129232	chr17:37814104	STARD3	-0.42	-7.29	-0.33	1.54e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00149659	chr3:10157352	C3orf10	0.53	7.35	0.34	1.06e-12	Alzheimer's disease;
LUAD	cis	rs977987	0.800	rs1011121	chr16:75325933	A/G	cg03315344	chr16:75512273	CHST6	0.63	13.61	0.55	2.96e-35	Dupuytren's disease;
LUAD	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg26513180	chr16:89883248	FANCA	0.74	6.55	0.3	1.64e-10	Skin colour saturation;
LUAD	cis	rs6835098	0.500	rs13112928	chr4:174158132	A/G	cg08422745	chr4:174089978	GALNT7	0.66	11.14	0.48	1.89e-25	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg06697600	chr4:7070879	GRPEL1	-0.51	-8.39	-0.38	7.15e-16	Monocyte percentage of white cells;
LUAD	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-8.56	-0.38	2.05e-16	Total body bone mineral density;
LUAD	cis	rs684232	0.602	rs401592	chr17:551316	T/C	cg15660573	chr17:549704	VPS53	-0.88	-18.37	-0.67	7.72e-56	Prostate cancer;
LUAD	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg09537434	chr19:41945824	ATP5SL	0.49	7.87	0.36	2.94e-14	Height;
LUAD	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg05896524	chr21:47604654	C21orf56	0.54	9.11	0.4	3.34e-18	Testicular germ cell tumor;
LUAD	cis	rs3750082	0.785	rs4720085	chr7:32968136	C/T	cg05721444	chr7:32995514	FKBP9	-0.4	-7.42	-0.34	6.31e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg14345882	chr6:26364793	BTN3A2	0.7	7.17	0.33	3.35e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg18252515	chr7:66147081	NA	-0.6	-6.66	-0.31	8.29e-11	Diabetic kidney disease;
LUAD	cis	rs28735056	0.933	rs72980085	chr18:77631679	A/C	cg20368463	chr18:77673604	PQLC1	-0.44	-6.55	-0.3	1.63e-10	Schizophrenia;
LUAD	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg12927641	chr6:109611667	NA	-0.53	-9.46	-0.42	2.12e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs80319144	0.535	rs3771595	chr2:159393449	T/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	7.42	0.34	6.45e-13	Restless legs syndrome;
LUAD	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg03676636	chr4:99064102	C4orf37	-0.3	-7.87	-0.36	3e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg18180107	chr4:99064573	C4orf37	0.42	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg09035930	chr12:129282057	SLC15A4	0.75	18.06	0.66	1.86e-54	Systemic lupus erythematosus;
LUAD	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg03037974	chr15:76606532	NA	0.38	8.03	0.36	9.65e-15	Blood metabolite levels;
LUAD	cis	rs1962636	1	rs1962636	chr16:22064395	A/C	cg09370801	chr16:22207107	NA	0.48	8.09	0.37	6.44e-15	Schizophrenia;
LUAD	trans	rs3780486	0.846	rs10813960	chr9:33180362	C/T	cg04842962	chr6:43655489	MRPS18A	0.93	17.81	0.65	2.47e-53	IgG glycosylation;
LUAD	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18876405	chr7:65276391	NA	0.43	6.74	0.31	5.36e-11	Aortic root size;
LUAD	cis	rs12024301	0.557	rs16861241	chr1:183589167	C/T	cg19264170	chr1:183622470	APOBEC4;RGL1	0.62	6.64	0.31	9.57e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.73	0.31	5.7e-11	Rheumatoid arthritis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05668205	chr19:16738998	MED26	-0.41	-6.53	-0.3	1.9e-10	Height;
LUAD	cis	rs78761021	0.755	rs62064480	chr17:9794251	G/A	cg26853458	chr17:9805074	RCVRN	0.38	7.02	0.32	9.07e-12	Type 2 diabetes;
LUAD	cis	rs6594713	0.643	rs10077431	chr5:112927686	A/C	cg12552261	chr5:112820674	MCC	-0.6	-9.28	-0.41	9.14e-19	Brain cytoarchitecture;
LUAD	cis	rs897984	0.762	rs897986	chr16:30980902	T/C	cg02466173	chr16:30829666	NA	0.65	12.19	0.51	1.75e-29	Dementia with Lewy bodies;
LUAD	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg23283495	chr1:209979779	IRF6	0.39	7.01	0.32	9.41e-12	Monobrow;
LUAD	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18404041	chr3:52824283	ITIH1	-0.59	-11.92	-0.5	1.99e-28	Bipolar disorder;
LUAD	cis	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg14039649	chr22:38352398	POLR2F	0.37	6.67	0.31	8.06e-11	Glioblastoma;Glioma;
LUAD	trans	rs2262909	1.000	rs436039	chr19:22214873	T/C	cg17074339	chr11:11642133	GALNTL4	-0.43	-6.81	-0.31	3.42e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs524023	0.914	rs11606370	chr11:64378452	C/A	cg19131476	chr11:64387923	NRXN2	-0.42	-8.44	-0.38	4.95e-16	Urate levels in obese individuals;
LUAD	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg15557168	chr22:42548783	NA	-0.51	-9.6	-0.42	6.88e-20	Schizophrenia;
LUAD	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg16797656	chr11:68205561	LRP5	0.43	8.09	0.37	6.5e-15	Total body bone mineral density;
LUAD	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06112835	chr11:68658793	MRPL21	0.51	9.3	0.41	7.34e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg10729496	chr3:10149963	C3orf24	0.49	7.88	0.36	2.73e-14	Alzheimer's disease;
LUAD	cis	rs8177876	0.658	rs2970077	chr16:81074800	C/T	cg08591886	chr16:81111003	C16orf46	-0.61	-6.66	-0.31	8.64e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs3198697	0.663	rs12928099	chr16:15150505	C/A	cg04146151	chr16:2155961	PKD1	-0.5	-7.76	-0.35	6.65e-14	Triglycerides;
LUAD	trans	rs683250	0.931	rs671321	chr11:83292373	G/T	cg11424665	chr3:129158811	IFT122;MBD4	0.43	7.42	0.34	6.63e-13	Subcortical brain region volumes;
LUAD	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg13393036	chr8:95962371	TP53INP1	0.33	7.02	0.32	8.8e-12	Type 2 diabetes;
LUAD	cis	rs61869271	0.871	rs6585310	chr10:116732726	G/A	cg23260525	chr10:116636907	FAM160B1	0.34	6.97	0.32	1.25e-11	Tonsillectomy;
LUAD	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg01528321	chr10:82214614	TSPAN14	-0.66	-10.64	-0.46	1.39e-23	Post bronchodilator FEV1;
LUAD	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.65	-12.0	-0.5	9.71e-29	Diastolic blood pressure;
LUAD	cis	rs9443645	0.588	rs1415310	chr6:79822314	C/T	cg09184832	chr6:79620586	NA	-0.39	-6.75	-0.31	4.79e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg01200585	chr1:228362443	C1orf69	0.42	7.57	0.35	2.34e-13	Diastolic blood pressure;
LUAD	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg16512390	chr1:228756714	NA	0.69	9.16	0.41	2.19e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs2637266	0.935	rs2583054	chr10:78401442	A/G	cg18941641	chr10:78392320	NA	0.34	7.04	0.32	7.75e-12	Pulmonary function;
LUAD	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	9.12	0.41	3.1e-18	Hip circumference adjusted for BMI;
LUAD	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.73	-13.71	-0.55	1.23e-35	Menarche (age at onset);
LUAD	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg25036284	chr2:26402008	FAM59B	-0.81	-11.39	-0.48	2.21e-26	Gut microbiome composition (summer);
LUAD	cis	rs10504073	0.584	rs10504070	chr8:49978554	A/G	cg00325661	chr8:49890786	NA	-0.45	-10.27	-0.45	3.16e-22	Blood metabolite ratios;
LUAD	cis	rs1232027	0.700	rs1643648	chr5:79938615	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg10018233	chr7:150070692	REPIN1	-0.5	-7.81	-0.36	4.5e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs2637266	1.000	rs11001835	chr10:78364770	A/G	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	trans	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-16.95	-0.64	1.52e-49	Exhaled nitric oxide output;
LUAD	cis	rs9972944	0.756	rs6504343	chr17:63755458	C/T	cg07283582	chr17:63770753	CCDC46	-0.52	-11.69	-0.49	1.49e-27	Total body bone mineral density;
LUAD	cis	rs9811920	0.683	rs813218	chr3:99592596	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.51	9.99	0.44	3.16e-21	Axial length;
LUAD	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06028808	chr11:68637592	NA	0.48	8.09	0.37	6.31e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg01765077	chr12:122356316	WDR66	0.52	8.88	0.4	1.88e-17	Mean corpuscular volume;
LUAD	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.13	-0.37	4.77e-15	Total body bone mineral density;
LUAD	cis	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg07460842	chr6:66804631	NA	0.9	12.26	0.51	8.9e-30	Exhaled nitric oxide output;
LUAD	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg10978503	chr1:24200527	CNR2	0.6	12.85	0.53	3.77e-32	Immature fraction of reticulocytes;
LUAD	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg19318889	chr4:1322082	MAEA	0.5	8.11	0.37	5.53e-15	Obesity-related traits;
LUAD	cis	rs17155006	0.691	rs409815	chr7:107745443	A/G	cg05962710	chr7:107745446	LAMB4	0.34	7.21	0.33	2.67e-12	Pneumococcal bacteremia;
LUAD	cis	rs4343996	0.902	rs12540305	chr7:3376072	A/T	cg21248987	chr7:3385318	SDK1	-0.34	-6.41	-0.3	3.88e-10	Motion sickness;
LUAD	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg22875332	chr1:76189707	ACADM	-0.96	-22.72	-0.74	2.95e-75	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg05926928	chr17:57297772	GDPD1	0.63	9.52	0.42	1.32e-19	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUAD	cis	rs10489202	1.000	rs10489202	chr1:167903079	A/C	cg24449463	chr1:168025552	DCAF6	0.58	7.62	0.35	1.7e-13	Schizophrenia;
LUAD	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg08999081	chr20:33150536	PIGU	0.55	12.02	0.5	7.5e-29	Glomerular filtration rate (creatinine);
LUAD	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.54	-9.15	-0.41	2.49e-18	Tonsillectomy;
LUAD	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg14092571	chr14:90743983	NA	-0.51	-8.95	-0.4	1.09e-17	Mortality in heart failure;
LUAD	cis	rs11229555	0.645	rs7930547	chr11:58197616	A/C	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.62	-0.31	1.11e-10	Morning vs. evening chronotype;
LUAD	trans	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg11693508	chr17:37793320	STARD3	0.51	7.3	0.33	1.46e-12	Bipolar disorder;
LUAD	cis	rs240764	0.817	rs239201	chr6:101123993	T/A	cg09795085	chr6:101329169	ASCC3	0.46	7.94	0.36	1.79e-14	Neuroticism;
LUAD	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg21285383	chr16:89894308	SPIRE2	0.42	10.1	0.44	1.26e-21	Vitiligo;
LUAD	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg09455208	chr3:40491958	NA	0.52	11.03	0.47	4.83e-25	Renal cell carcinoma;
LUAD	trans	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.22	-0.41	1.42e-18	Total body bone mineral density;
LUAD	cis	rs6460942	0.732	rs73677575	chr7:12286532	A/G	cg06484146	chr7:12443880	VWDE	-0.5	-6.41	-0.3	3.95e-10	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.96	0.32	1.28e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs587242	1.000	rs509588	chr1:96891552	G/C	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg12863693	chr15:85201151	NMB	0.42	7.61	0.35	1.85e-13	Schizophrenia;
LUAD	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg09796270	chr17:17721594	SREBF1	0.38	7.56	0.34	2.61e-13	Total body bone mineral density;
LUAD	cis	rs7213347	0.799	rs216195	chr17:2203167	T/G	cg16513277	chr17:2031491	SMG6	0.47	7.3	0.33	1.42e-12	Total body bone mineral density;
LUAD	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg07757535	chr4:1339547	NA	0.31	6.36	0.3	5.22e-10	Longevity;
LUAD	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg01849466	chr14:104193079	ZFYVE21	0.46	7.68	0.35	1.15e-13	Body mass index;
LUAD	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08045932	chr20:61659980	NA	0.51	9.67	0.43	4.09e-20	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg15485101	chr11:133734466	NA	0.36	7.85	0.36	3.52e-14	Childhood ear infection;
LUAD	cis	rs1160297	0.609	rs1828336	chr2:53096937	G/T	cg07782112	chr2:53107842	NA	0.41	8.83	0.39	2.71e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg23262073	chr20:60523788	NA	-0.45	-7.79	-0.35	5.35e-14	Body mass index;
LUAD	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg27532560	chr4:187881888	NA	-0.41	-8.12	-0.37	5.23e-15	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg07010633	chr17:73824396	UNC13D	-0.32	-6.57	-0.3	1.48e-10	White matter hyperintensity burden;
LUAD	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg25894440	chr7:65020034	NA	-0.59	-6.36	-0.3	5.16e-10	Diabetic kidney disease;
LUAD	cis	rs4711350	0.765	rs943476	chr6:33750086	A/G	cg07979401	chr6:33739406	LEMD2	-0.52	-9.15	-0.41	2.47e-18	Schizophrenia;
LUAD	cis	rs6960043	0.818	rs1974620	chr7:15065467	A/G	cg19272540	chr7:15055459	NA	0.36	8.13	0.37	4.72e-15	Type 2 diabetes;
LUAD	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	7.04	0.32	7.8e-12	Depression;
LUAD	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg05966235	chr16:28915196	ATP2A1	-0.45	-7.21	-0.33	2.68e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs733175	0.599	rs6856396	chr4:10031163	A/T	cg00071950	chr4:10020882	SLC2A9	0.56	7.37	0.34	9.13e-13	Psychosis and Alzheimer's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05592363	chr5:78908495	PAPD4	-0.62	-7.62	-0.35	1.67e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.74	10.29	0.45	2.57e-22	Smoking behavior;
LUAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg11494091	chr17:61959527	GH2	0.74	18.38	0.67	7.09e-56	Prudent dietary pattern;
LUAD	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.99	-0.32	1.08e-11	Height;
LUAD	cis	rs7598759	0.527	rs7571691	chr2:232369401	C/T	cg19187155	chr2:232395269	NMUR1	0.49	9.53	0.42	1.27e-19	Noise-induced hearing loss;
LUAD	cis	rs9902453	0.967	rs8082175	chr17:28430303	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	9.18	0.41	1.89e-18	Coffee consumption (cups per day);
LUAD	trans	rs2018683	0.707	rs917218	chr7:28975122	A/C	cg19402173	chr7:128379420	CALU	-0.49	-7.95	-0.36	1.77e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg07211511	chr3:129823064	LOC729375	-0.54	-7.11	-0.33	4.83e-12	Blood pressure (smoking interaction);
LUAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg21280719	chr6:42927975	GNMT	-0.39	-11.83	-0.5	4.43e-28	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg18138036	chr10:133769891	PPP2R2D	0.42	6.86	0.32	2.43e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg05590025	chr7:65112418	INTS4L2	-0.72	-7.68	-0.35	1.11e-13	Diabetic kidney disease;
LUAD	cis	rs796364	0.589	rs6743217	chr2:201134914	G/A	cg17644776	chr2:200775616	C2orf69	-0.49	-6.75	-0.31	4.9e-11	Schizophrenia;
LUAD	cis	rs7215564	0.730	rs34579757	chr17:78700077	G/A	cg16980736	chr17:78789706	RPTOR	-0.66	-6.67	-0.31	8.25e-11	Myopia (pathological);
LUAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg24829409	chr8:58192753	C8orf71	-0.66	-8.15	-0.37	4.26e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-8.7	-0.39	7.63e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg25358565	chr5:93447407	FAM172A	0.6	7.1	0.33	5.41e-12	Diabetic retinopathy;
LUAD	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg25358565	chr5:93447407	FAM172A	0.66	7.77	0.35	5.99e-14	Diabetic retinopathy;
LUAD	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg21153622	chr11:89784906	NA	-0.32	-6.36	-0.3	5.12e-10	Coronary artery disease;
LUAD	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg09537434	chr19:41945824	ATP5SL	-0.54	-8.55	-0.38	2.35e-16	Height;
LUAD	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg25324976	chr17:61989376	CSHL1	0.44	8.39	0.38	7.56e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg07636037	chr3:49044803	WDR6	0.39	7.07	0.32	6.63e-12	Parkinson's disease;
LUAD	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg18132916	chr6:79620363	NA	-0.46	-7.76	-0.35	6.61e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs75920871	1.000	rs7125788	chr11:116883396	T/C	cg04087571	chr11:116723030	SIK3	-0.32	-6.42	-0.3	3.6e-10	Subjective well-being;
LUAD	cis	rs123509	0.731	rs73087348	chr3:42811571	C/T	cg12982090	chr3:42733453	KBTBD5	-0.55	-9.22	-0.41	1.44e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg26818010	chr10:134567672	INPP5A	-0.97	-15.97	-0.61	2.85e-45	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4523957	0.928	rs216220	chr17:2148821	G/T	cg16513277	chr17:2031491	SMG6	0.76	14.5	0.58	5.73e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg04944784	chr2:26401820	FAM59B	-0.88	-12.37	-0.52	3.33e-30	Gut microbiome composition (summer);
LUAD	cis	rs6756513	0.520	rs7569566	chr2:70174030	T/C	cg02498382	chr2:70120550	SNRNP27	-0.54	-10.2	-0.44	5.37e-22	Breast cancer;Platelet count;
LUAD	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg18230493	chr5:56204884	C5orf35	-0.45	-7.4	-0.34	7.25e-13	Coronary artery disease;
LUAD	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-7.86	-0.36	3.24e-14	Neutrophil percentage of white cells;
LUAD	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg14668632	chr7:2872130	GNA12	-0.74	-13.45	-0.55	1.45e-34	Height;
LUAD	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg26168224	chr5:2018326	NA	-0.58	-10.1	-0.44	1.27e-21	Gut microbiome composition (winter);
LUAD	cis	rs12474201	0.928	rs1109380	chr2:46924490	G/T	cg09399716	chr2:46890238	NA	-0.35	-6.53	-0.3	1.87e-10	Height;
LUAD	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg18306943	chr3:40428807	ENTPD3	0.41	7.21	0.33	2.57e-12	Renal cell carcinoma;
LUAD	trans	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg02030672	chr11:45687055	CHST1	0.47	8.66	0.39	1.01e-16	Obesity-related traits;
LUAD	cis	rs9427116	0.532	rs9426828	chr1:154591489	G/A	cg17218026	chr1:154582156	ADAR	0.49	9.86	0.43	8.85e-21	Blood protein levels;
LUAD	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg01251548	chr11:17372745	DKFZp686O24166	-0.37	-6.71	-0.31	6.22e-11	Type 2 diabetes;
LUAD	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg07936489	chr17:37558343	FBXL20	-0.46	-7.27	-0.33	1.72e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs35264875	0.808	rs2305498	chr11:68866914	G/A	cg02660097	chr11:68866761	NA	0.5	7.7	0.35	9.64e-14	Blond vs. brown hair color;
LUAD	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg03714773	chr7:91764589	CYP51A1	0.27	6.57	0.3	1.48e-10	Breast cancer;
LUAD	cis	rs78707713	0.841	rs78677622	chr10:71196698	C/T	cg12610070	chr10:71211762	TSPAN15	-0.41	-7.22	-0.33	2.41e-12	Venous thromboembolism;
LUAD	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg11871910	chr12:69753446	YEATS4	0.71	12.15	0.51	2.44e-29	Blood protein levels;
LUAD	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg23625390	chr15:77176239	SCAPER	0.37	6.61	0.31	1.13e-10	Blood metabolite levels;
LUAD	cis	rs4888378	0.576	rs8050367	chr16:75313258	A/G	cg03315344	chr16:75512273	CHST6	-0.41	-6.96	-0.32	1.27e-11	Coronary artery disease;
LUAD	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg17063962	chr7:91808500	NA	0.68	12.15	0.51	2.4e-29	Breast cancer;
LUAD	cis	rs7503807	0.967	rs9915162	chr17:78614326	T/C	cg09596252	chr17:78655493	RPTOR	0.4	7.82	0.36	4.21e-14	Obesity;
LUAD	cis	rs7274811	0.652	rs291672	chr20:31951168	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.54	8.2	0.37	3.01e-15	Height;
LUAD	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.6	8.94	0.4	1.26e-17	Platelet count;
LUAD	cis	rs4144027	0.791	rs11160770	chr14:104362291	A/C	cg12183467	chr14:104352244	NA	0.33	6.53	0.3	1.89e-10	Blood metabolite levels;
LUAD	cis	rs7665090	1.000	rs10027437	chr4:103557251	G/A	cg07973026	chr4:103553119	MANBA	0.47	8.38	0.38	7.83e-16	Primary biliary cholangitis;
LUAD	trans	rs11039798	0.841	rs11039760	chr11:48479009	C/T	cg15704280	chr7:45808275	SEPT13	0.74	7.64	0.35	1.51e-13	Axial length;
LUAD	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg24011408	chr12:48396354	COL2A1	-0.43	-9.6	-0.42	7.13e-20	Plateletcrit;
LUAD	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg01884057	chr2:25150051	NA	0.34	7.22	0.33	2.47e-12	Body mass index;
LUAD	cis	rs921968	0.519	rs72966020	chr2:219642620	C/G	cg02176678	chr2:219576539	TTLL4	-0.74	-15.12	-0.59	1.39e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18876405	chr7:65276391	NA	0.56	9.41	0.42	3.17e-19	Aortic root size;
LUAD	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg19678392	chr7:94953810	PON1	-0.57	-7.8	-0.35	5e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6906287	0.647	rs13192574	chr6:118875258	C/T	cg21191810	chr6:118973309	C6orf204	0.51	9.86	0.43	9.17e-21	Electrocardiographic conduction measures;
LUAD	cis	rs738321	0.757	rs3788535	chr22:38534045	T/C	cg17652424	chr22:38574118	PLA2G6	-0.25	-6.61	-0.31	1.17e-10	Breast cancer;
LUAD	trans	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg06606381	chr12:133084897	FBRSL1	-1.23	-10.79	-0.46	3.73e-24	Depression;
LUAD	cis	rs7927771	0.800	rs11039200	chr11:47379646	A/C	cg18512352	chr11:47633146	NA	-0.52	-8.82	-0.39	3.12e-17	Subjective well-being;
LUAD	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg01475377	chr6:109611718	NA	-0.5	-9.41	-0.42	3.17e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.54	0.3	1.77e-10	Depression;
LUAD	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg16325326	chr1:53192061	ZYG11B	0.56	10.01	0.44	2.64e-21	Monocyte count;
LUAD	cis	rs6500395	0.832	rs8052733	chr16:48691978	C/T	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.07e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg15704280	chr7:45808275	SEPT13	-0.57	-9.29	-0.41	7.99e-19	HDL cholesterol;
LUAD	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	5.84e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9826463	0.582	rs73238173	chr3:142110644	C/G	cg20824294	chr3:142316082	PLS1	0.37	6.69	0.31	7.09e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg00000769	chr12:124086477	DDX55	-0.69	-6.77	-0.31	4.21e-11	Type 2 diabetes;
LUAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg22907277	chr7:1156413	C7orf50	0.7	8.23	0.37	2.35e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8058578	0.943	rs35629860	chr16:30671532	G/A	cg02466173	chr16:30829666	NA	-0.7	-11.83	-0.5	4.17e-28	Multiple myeloma;
LUAD	cis	rs3784262	0.669	rs10851632	chr15:58242475	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.31	-0.34	1.3e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-7.1	-0.33	5.35e-12	Systolic blood pressure;
LUAD	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg03549146	chr16:69966902	MIR140;WWP2	-0.43	-6.42	-0.3	3.58e-10	Menarche (age at onset);
LUAD	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg19717773	chr7:2847554	GNA12	-0.45	-8.22	-0.37	2.52e-15	Height;
LUAD	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg18230493	chr5:56204884	C5orf35	-0.44	-7.43	-0.34	6.08e-13	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs36715	0.953	rs185177	chr5:127547810	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	6.89	0.32	2.03e-11	Breast cancer;
LUAD	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg12292205	chr6:26970375	C6orf41	0.36	6.43	0.3	3.52e-10	Schizophrenia;
LUAD	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg09323728	chr8:95962352	TP53INP1	-0.32	-7.64	-0.35	1.43e-13	Type 2 diabetes;
LUAD	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg16479474	chr6:28041457	NA	0.45	7.73	0.35	7.89e-14	Depression;
LUAD	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.1	0.33	5.17e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg02733842	chr7:1102375	C7orf50	-0.62	-9.88	-0.43	7.63e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg09835421	chr16:68378352	PRMT7	1.05	12.49	0.52	1.13e-30	Schizophrenia;
LUAD	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg15128208	chr22:42549153	NA	0.37	7.59	0.35	2.01e-13	Cognitive function;
LUAD	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.6	-7.12	-0.33	4.77e-12	Body mass index;
LUAD	cis	rs13315871	1.000	rs4585221	chr3:58415567	C/T	cg12435725	chr3:58293450	RPP14	-0.69	-7.36	-0.34	9.51e-13	Cholesterol, total;
LUAD	trans	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg07393940	chr7:158741817	NA	0.69	11.48	0.49	1.01e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10823500	0.640	rs7077538	chr10:71993094	T/G	cg02100629	chr10:71892760	AIFM2	-0.35	-6.97	-0.32	1.21e-11	Blood protein levels;
LUAD	cis	rs907683	0.570	rs3755056	chr2:220281016	T/A	cg15015639	chr2:220282977	DES	0.49	8.9	0.4	1.69e-17	Resting heart rate;
LUAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08677398	chr8:58056175	NA	0.49	6.82	0.31	3.16e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg24558204	chr6:135376177	HBS1L	0.47	8.67	0.39	9.21e-17	Red blood cell count;
LUAD	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg05234568	chr11:5960015	NA	-0.56	-10.14	-0.44	9.02e-22	DNA methylation (variation);
LUAD	cis	rs6489882	0.966	rs7955267	chr12:113379039	C/T	cg20102336	chr12:113376681	OAS3	-0.55	-8.73	-0.39	6.09e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg19041857	chr6:27730383	NA	-0.41	-6.91	-0.32	1.82e-11	Parkinson's disease;
LUAD	trans	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg19163074	chr7:65112434	INTS4L2	0.42	6.4	0.3	4.24e-10	Aortic root size;
LUAD	cis	rs11696501	0.688	rs6032419	chr20:44297963	T/A	cg11783356	chr20:44313418	WFDC10B	-0.39	-7.04	-0.32	7.7e-12	Brain structure;
LUAD	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg16006841	chr5:176797999	RGS14	0.58	10.16	0.44	7.4e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg23933602	chr10:16859644	RSU1	1.02	22.58	0.74	1.21e-74	Platelet distribution width;
LUAD	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.34	7.27	0.33	1.73e-12	Parkinson's disease;
LUAD	cis	rs10761482	0.775	rs1459725	chr10:62138608	C/T	cg18175470	chr10:62150864	ANK3	-0.39	-6.52	-0.3	2.03e-10	Schizophrenia;
LUAD	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg11859384	chr17:80120422	CCDC57	0.43	7.75	0.35	6.84e-14	Life satisfaction;
LUAD	cis	rs7582720	1.000	rs72934706	chr2:203707752	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.26	0.41	1.04e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7705042	0.865	rs11739961	chr5:141508488	A/C	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.78	-0.31	3.96e-11	Asthma;
LUAD	trans	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg26043149	chr18:55253948	FECH	0.51	8.29	0.37	1.47e-15	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg17177755	chr1:15930204	NA	0.43	6.93	0.32	1.57e-11	Systolic blood pressure;
LUAD	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg23301539	chr8:142222248	SLC45A4	-0.48	-8.79	-0.39	3.83e-17	Immature fraction of reticulocytes;
LUAD	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg00300879	chr1:26503847	CNKSR1	0.29	8.38	0.38	8.16e-16	Height;
LUAD	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.5e-19	Life satisfaction;
LUAD	cis	rs8017423	0.605	rs8181930	chr14:90811289	A/G	cg14092571	chr14:90743983	NA	0.52	9.0	0.4	7.65e-18	Mortality in heart failure;
LUAD	cis	rs834811	0.829	rs6980107	chr7:135900757	C/T	cg01726295	chr7:135938950	NA	-0.28	-7.02	-0.32	9.02e-12	Post-traumatic stress disorder;
LUAD	cis	rs12543725	0.601	rs7018178	chr8:142239210	C/T	cg23750338	chr8:142222470	SLC45A4	-0.45	-9.87	-0.43	8.44e-21	Birth weight;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg07719772	chr16:32360419	NA	-0.5	-7.81	-0.36	4.58e-14	Menopause (age at onset);
LUAD	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg08859206	chr1:53392774	SCP2	-0.4	-6.47	-0.3	2.75e-10	Monocyte count;
LUAD	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	8.91e-15	Tonsillectomy;
LUAD	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg21856205	chr7:94953877	PON1	-0.54	-7.52	-0.34	3.39e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg00431813	chr7:1051703	C7orf50	-0.53	-10.55	-0.46	2.9e-23	Longevity;Endometriosis;
LUAD	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg08773314	chr2:239334832	ASB1	0.45	10.27	0.45	3.18e-22	Multiple system atrophy;
LUAD	cis	rs7945705	0.776	rs11042069	chr11:8817315	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.49	8.56	0.38	2.12e-16	Hemoglobin concentration;
LUAD	cis	rs12545109	0.879	rs1581129	chr8:57377476	T/C	cg07776626	chr8:57350775	NA	-0.67	-9.28	-0.41	8.66e-19	Obesity-related traits;
LUAD	cis	rs420259	0.516	rs11074565	chr16:23533008	G/A	cg00143387	chr16:23521605	GGA2	-0.67	-9.24	-0.41	1.17e-18	Bipolar disorder;
LUAD	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23158103	chr7:148848205	ZNF398	-0.6	-10.89	-0.47	1.57e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg21427119	chr20:30132790	HM13	-0.48	-7.77	-0.35	5.94e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg20933634	chr6:27740509	NA	0.46	7.25	0.33	2.02e-12	Parkinson's disease;
LUAD	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg08048268	chr3:133502702	NA	0.42	8.1	0.37	6.1e-15	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg22961513	chr11:14280813	SPON1	0.36	7.0	0.32	1.02e-11	Mitochondrial DNA levels;
LUAD	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.43	6.35	0.3	5.54e-10	Total body bone mineral density;
LUAD	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg08213375	chr14:104286397	PPP1R13B	0.28	7.2	0.33	2.86e-12	Schizophrenia;
LUAD	cis	rs62229266	0.740	rs2835233	chr21:37393582	A/G	cg08632701	chr21:37451849	NA	-0.44	-7.29	-0.33	1.51e-12	Mitral valve prolapse;
LUAD	trans	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21582582	chr3:182698605	DCUN1D1	0.48	7.98	0.36	1.41e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs77741769	0.571	rs11611087	chr12:121267126	C/T	cg02419362	chr12:121203948	SPPL3	0.41	8.28	0.37	1.61e-15	Mean corpuscular volume;
LUAD	cis	rs367615	0.552	rs2963022	chr5:108727185	A/G	cg17395555	chr5:108820864	NA	-0.5	-9.46	-0.42	2.11e-19	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg21385522	chr1:16154831	NA	-0.55	-8.61	-0.39	1.49e-16	Systolic blood pressure;
LUAD	cis	rs2580764	0.598	rs2580772	chr2:55218805	G/T	cg09592903	chr2:55203963	RTN4	0.46	10.61	0.46	1.71e-23	Mean platelet volume;
LUAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg00106254	chr7:1943704	MAD1L1	-0.61	-9.61	-0.42	6.66e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs7216064	1.000	rs4271626	chr17:65930133	G/A	cg08758996	chr17:66097529	LOC651250	0.45	6.99	0.32	1.07e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs4409675	0.576	rs7533918	chr1:28230667	G/A	cg23691781	chr1:28212827	C1orf38	0.39	11.38	0.48	2.32e-26	Corneal astigmatism;
LUAD	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg22482690	chr17:47019901	SNF8	0.45	8.67	0.39	9.59e-17	Type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01772563	chr7:95064399	PON2	-0.56	-6.83	-0.32	2.9e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs8017423	0.967	rs3825662	chr14:90723152	A/G	cg14092571	chr14:90743983	NA	-0.5	-8.87	-0.4	2.07e-17	Mortality in heart failure;
LUAD	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg13319975	chr6:146136371	FBXO30	0.55	8.94	0.4	1.26e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg25828334	chr19:18545568	ISYNA1	-0.36	-7.23	-0.33	2.35e-12	Breast cancer;
LUAD	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg27284194	chr4:1044797	NA	0.71	10.32	0.45	2.02e-22	Recombination rate (females);
LUAD	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg04896959	chr15:78267971	NA	0.56	10.84	0.47	2.44e-24	Coronary artery disease or large artery stroke;
LUAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.49	-0.3	2.38e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg21951975	chr1:209979733	IRF6	0.35	6.39	0.3	4.26e-10	Monobrow;
LUAD	cis	rs123509	0.913	rs121993	chr3:42776601	T/C	cg12982090	chr3:42733453	KBTBD5	0.55	9.85	0.43	9.51e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg18402987	chr7:1209562	NA	0.8	9.84	0.43	1.03e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7200543	1.000	rs14347	chr16:15133889	T/G	cg24683922	chr1:11983373	KIAA2013	-0.49	-8.22	-0.37	2.58e-15	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7586879	0.828	rs1968482	chr2:25086858	T/C	cg04586622	chr2:25135609	ADCY3	0.36	7.2	0.33	2.72e-12	Body mass index;
LUAD	cis	rs56283067	0.577	rs114009236	chr6:44897517	T/C	cg20913747	chr6:44695427	NA	-0.45	-7.03	-0.32	8.4e-12	Total body bone mineral density;
LUAD	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg26384229	chr12:38710491	ALG10B	0.45	7.36	0.34	9.68e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg04772025	chr11:68637568	NA	0.54	8.45	0.38	4.72e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg12311346	chr5:56204834	C5orf35	-0.93	-13.61	-0.55	3.03e-35	Initial pursuit acceleration;
LUAD	cis	rs7737355	0.812	rs12655240	chr5:130752006	G/A	cg06307176	chr5:131281290	NA	-0.42	-6.88	-0.32	2.14e-11	Life satisfaction;
LUAD	trans	rs62458065	0.850	rs10239812	chr7:32460348	A/G	cg00845942	chr12:64062724	DPY19L2	-0.52	-6.71	-0.31	6.24e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs12545109	0.723	rs2610045	chr8:57413439	A/G	cg07776626	chr8:57350775	NA	0.6	9.02	0.4	6.57e-18	Obesity-related traits;
LUAD	cis	rs41278232	1.000	rs7260907	chr20:62663136	A/C	cg03065311	chr20:62601662	ZNF512B	0.5	6.63	0.31	9.99e-11	Tonsillectomy;
LUAD	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.42	-0.38	5.98e-16	Bipolar disorder;
LUAD	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg06671706	chr8:8559999	CLDN23	0.62	10.37	0.45	1.3e-22	Obesity-related traits;
LUAD	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg09658497	chr7:2847517	GNA12	0.51	8.62	0.39	1.35e-16	Height;
LUAD	cis	rs12618769	0.597	rs2278213	chr2:99136059	A/G	cg10123293	chr2:99228465	UNC50	0.46	8.15	0.37	4.17e-15	Bipolar disorder;
LUAD	cis	rs490234	0.812	rs13288963	chr9:128295198	G/A	cg14078157	chr9:128172775	NA	-0.39	-6.89	-0.32	1.98e-11	Mean arterial pressure;
LUAD	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg11266682	chr4:10021025	SLC2A9	0.6	12.93	0.53	1.81e-32	Bone mineral density;
LUAD	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02463440	chr8:22132932	PIWIL2	0.56	10.34	0.45	1.74e-22	Hypertriglyceridemia;
LUAD	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg04705435	chr11:17411270	KCNJ11	0.41	6.87	0.32	2.32e-11	Type 2 diabetes;
LUAD	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg18209359	chr17:80159595	CCDC57	-0.38	-6.4	-0.3	4.08e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	6.84	0.32	2.82e-11	Lung cancer in ever smokers;
LUAD	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.69	-12.68	-0.52	1.89e-31	Cognitive ability;
LUAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.49	-0.3	2.38e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.63e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2658782	0.789	rs3019206	chr11:93111073	A/G	cg15737290	chr11:93063684	CCDC67	0.46	6.71	0.31	6.18e-11	Pulmonary function decline;
LUAD	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg20503657	chr10:835505	NA	0.99	15.53	0.6	2.26e-43	Eosinophil percentage of granulocytes;
LUAD	trans	rs11184708	0.509	rs12045290	chr1:106260316	G/C	cg06936704	chr20:37009829	NA	0.64	6.38	0.3	4.6e-10	Waist-to-hip circumference ratio (ever vs never smoking interaction);
LUAD	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg13606994	chr1:44402422	ARTN	-0.35	-6.88	-0.32	2.12e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4493873	0.869	rs6471265	chr8:92099848	T/G	cg16814680	chr8:91681699	NA	0.42	6.68	0.31	7.59e-11	Migraine - clinic-based;
LUAD	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg13813247	chr22:41461852	NA	-0.46	-7.52	-0.34	3.42e-13	Neuroticism;
LUAD	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-8.78	-0.39	3.98e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg25036284	chr2:26402008	FAM59B	-0.83	-11.78	-0.5	6.58e-28	Gut microbiome composition (summer);
LUAD	trans	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg06437703	chr8:37914619	EIF4EBP1	0.49	7.77	0.35	6.04e-14	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs3106136	0.527	rs10030586	chr4:95150805	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.14	-0.44	8.66e-22	Capecitabine sensitivity;
LUAD	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg18252515	chr7:66147081	NA	-0.62	-6.81	-0.31	3.45e-11	Diabetic kidney disease;
LUAD	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg22907277	chr7:1156413	C7orf50	0.48	7.86	0.36	3.11e-14	Longevity;Endometriosis;
LUAD	cis	rs9796	0.870	rs3986311	chr15:41264339	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.38	-7.12	-0.33	4.63e-12	Menopause (age at onset);
LUAD	cis	rs11771526	0.786	rs6955875	chr7:32443831	C/T	cg27532318	chr7:32358331	NA	0.52	6.44	0.3	3.17e-10	Body mass index;
LUAD	cis	rs11650175	0.964	rs232093	chr17:63725616	A/G	cg07283582	chr17:63770753	CCDC46	-0.36	-7.02	-0.32	9.11e-12	Chin dimples;
LUAD	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg15997130	chr1:24165203	NA	-0.59	-10.46	-0.45	6.1e-23	Immature fraction of reticulocytes;
LUAD	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg04450456	chr4:17643702	FAM184B	0.37	7.05	0.32	7.44e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18045461	chr22:29601862	EMID1	-0.49	-6.56	-0.3	1.55e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.96	0.32	1.32e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9914544	0.545	rs9912568	chr17:18792719	G/A	cg21372672	chr17:16614065	CCDC144A	-0.36	-6.45	-0.3	3.04e-10	Educational attainment (years of education);
LUAD	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.58	0.42	8.17e-20	Cognitive ability;
LUAD	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg11814155	chr7:99998594	ZCWPW1	0.43	7.37	0.34	9.23e-13	Platelet count;
LUAD	cis	rs1403694	0.515	rs822362	chr3:186453065	A/C	cg12454167	chr3:186435060	KNG1	0.41	8.47	0.38	4.03e-16	Blood protein levels;
LUAD	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg13319975	chr6:146136371	FBXO30	-0.59	-10.07	-0.44	1.57e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg02734326	chr4:10020555	SLC2A9	-0.51	-8.83	-0.39	2.86e-17	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2624839	0.704	rs2526384	chr3:50181136	C/T	cg14019146	chr3:50243930	SLC38A3	-0.56	-10.73	-0.46	6.38e-24	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03767357	chr7:130353742	COPG2;TSGA13	-0.56	-6.85	-0.32	2.69e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg03037974	chr15:76606532	NA	-0.37	-7.77	-0.35	6.16e-14	Blood metabolite levels;
LUAD	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg05590025	chr7:65112418	INTS4L2	0.74	8.06	0.36	8.13e-15	Diabetic kidney disease;
LUAD	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg08645402	chr16:4508243	NA	0.54	10.16	0.44	7.78e-22	Schizophrenia;
LUAD	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.89	0.32	2.07e-11	Rheumatoid arthritis;
LUAD	cis	rs35883536	0.647	rs59667512	chr1:101046712	C/T	cg06223162	chr1:101003688	GPR88	-0.48	-9.23	-0.41	1.3e-18	Monocyte count;
LUAD	cis	rs1595825	0.627	rs1435567	chr2:198748726	T/C	cg00361562	chr2:198649771	BOLL	-0.48	-6.79	-0.31	3.73e-11	Ulcerative colitis;
LUAD	cis	rs2580764	0.565	rs2919129	chr2:55216545	G/T	cg09592903	chr2:55203963	RTN4	0.44	10.37	0.45	1.29e-22	Mean platelet volume;
LUAD	cis	rs10821973	0.527	rs10733771	chr10:63982434	A/G	cg09941381	chr10:64027924	RTKN2	-0.34	-6.7	-0.31	6.56e-11	Hypothyroidism;
LUAD	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg06092702	chr1:163392909	NA	-0.41	-9.24	-0.41	1.21e-18	Motion sickness;
LUAD	trans	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21582582	chr3:182698605	DCUN1D1	0.46	7.58	0.35	2.17e-13	Body mass index;
LUAD	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg13010199	chr12:38710504	ALG10B	0.41	6.72	0.31	5.73e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg03806693	chr22:41940476	POLR3H	-0.52	-7.81	-0.35	4.56e-14	Vitiligo;
LUAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg09033563	chr22:24373618	LOC391322	-0.45	-6.82	-0.31	3.2e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg26818010	chr10:134567672	INPP5A	-0.98	-16.24	-0.62	1.94e-46	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg21427119	chr20:30132790	HM13	-0.48	-7.61	-0.35	1.79e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg00999904	chr2:3704751	ALLC	-0.74	-11.67	-0.49	1.74e-27	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs262150	0.625	rs55974535	chr7:158769145	C/G	cg19418458	chr7:158789849	NA	0.68	8.62	0.39	1.32e-16	Facial morphology (factor 20);
LUAD	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.7	9.9	0.43	6.31e-21	IgG glycosylation;
LUAD	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg06484146	chr7:12443880	VWDE	-0.58	-7.36	-0.34	9.91e-13	Coronary artery disease;
LUAD	cis	rs2797160	1.000	rs1777183	chr6:126011995	A/C	cg05901451	chr6:126070800	HEY2	0.46	7.01	0.32	9.2e-12	Endometrial cancer;
LUAD	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg23387056	chr11:14280742	SPON1	-0.4	-8.36	-0.38	9.15e-16	Mitochondrial DNA levels;
LUAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg16486109	chr11:613632	IRF7	0.54	7.83	0.36	3.99e-14	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs1444418	1.000	rs9971328	chr10:64561869	A/G	cg14943953	chr10:64564468	ADO	-0.57	-7.03	-0.32	8.29e-12	Atopic dermatitis;
LUAD	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg13918804	chr1:2043761	PRKCZ	0.4	6.77	0.31	4.35e-11	Height;
LUAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13732083	chr21:47605072	C21orf56	0.51	8.72	0.39	6.49e-17	Testicular germ cell tumor;
LUAD	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.29	6.51	0.3	2.18e-10	Parkinson's disease;
LUAD	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg18110333	chr6:292329	DUSP22	-0.53	-8.67	-0.39	9.19e-17	Menopause (age at onset);
LUAD	trans	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg03886242	chr7:26192032	NFE2L3	-0.43	-7.47	-0.34	4.78e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4975616	0.807	rs28379291	chr5:1313701	A/G	cg06550200	chr5:1325588	CLPTM1L	0.72	13.43	0.55	1.61e-34	Lung cancer;
LUAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	cis	rs870825	0.929	rs72689260	chr4:185590656	G/T	cg04058563	chr4:185651563	MLF1IP	0.74	9.52	0.42	1.37e-19	Blood protein levels;
LUAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg00080972	chr5:178986291	RUFY1	0.51	8.78	0.39	4.2e-17	Lung cancer;
LUAD	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg00495681	chr13:53174319	NA	0.5	9.07	0.4	4.4e-18	Lewy body disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02657244	chr4:99183198	RAP1GDS1	-0.43	-7.28	-0.33	1.6e-12	Cancer;
LUAD	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg18402987	chr7:1209562	NA	0.56	8.51	0.38	3.05e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10193935	0.901	rs222463	chr2:42644080	A/G	cg27598129	chr2:42591480	NA	-0.69	-8.84	-0.39	2.58e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg06214716	chr4:10118677	WDR1	-0.43	-6.76	-0.31	4.53e-11	Bone mineral density;
LUAD	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg02743256	chr7:2109353	MAD1L1	-0.47	-6.64	-0.31	9.37e-11	Bipolar disorder;
LUAD	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg00495681	chr13:53174319	NA	0.55	10.37	0.45	1.33e-22	Lewy body disease;
LUAD	trans	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.07	-27.25	-0.8	3.76e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs3204270	0.639	rs11871678	chr17:79654285	G/A	cg18367735	chr17:79674897	NA	0.59	7.18	0.33	3.08e-12	Dental caries;
LUAD	trans	rs877282	0.842	rs35117541	chr10:764683	C/T	cg22713356	chr15:30763199	NA	1.26	17.41	0.65	1.4e-51	Uric acid levels;
LUAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg07677032	chr17:61819896	STRADA	0.55	9.79	0.43	1.56e-20	Prudent dietary pattern;
LUAD	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg22431228	chr1:16359049	CLCNKA	0.49	8.82	0.39	3.11e-17	Dilated cardiomyopathy;
LUAD	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg02993280	chr1:107599747	PRMT6	0.57	9.34	0.41	5.49e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs3857536	0.813	rs2093253	chr6:66937702	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg22878388	chr2:105853796	NA	-0.4	-7.14	-0.33	4.14e-12	Type 2 diabetes;
LUAD	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.5	-7.81	-0.36	4.58e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg11062466	chr8:58055876	NA	0.67	9.02	0.4	6.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg00495681	chr13:53174319	NA	0.55	10.19	0.44	6.06e-22	Lewy body disease;
LUAD	cis	rs11622475	1.000	rs2236247	chr14:104378087	C/T	cg12183467	chr14:104352244	NA	-0.37	-6.94	-0.32	1.45e-11	Bipolar disorder;
LUAD	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg17480646	chr11:65405466	SIPA1	-0.45	-6.7	-0.31	6.66e-11	Acne (severe);
LUAD	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg18129178	chr5:148520854	ABLIM3	-0.61	-9.42	-0.42	2.97e-19	Breast cancer;
LUAD	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg05283184	chr6:79620031	NA	-0.61	-12.47	-0.52	1.28e-30	Intelligence (multi-trait analysis);
LUAD	trans	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg00953403	chr17:74099816	EXOC7	0.45	7.04	0.32	7.66e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs4006360	0.614	rs6416914	chr17:39262850	A/G	cg20663846	chr17:39254439	KRTAP4-8	0.36	7.46	0.34	5.12e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.16e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg11693508	chr17:37793320	STARD3	0.7	9.13	0.41	2.84e-18	Bipolar disorder;
LUAD	cis	rs62238980	0.614	rs2006867	chr22:32384307	C/T	cg00543991	chr22:32367038	NA	0.92	8.15	0.37	4.03e-15	Childhood ear infection;
LUAD	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg17063962	chr7:91808500	NA	0.64	10.81	0.47	3.37e-24	Breast cancer;
LUAD	cis	rs911555	0.504	rs4906340	chr14:104076645	G/A	cg24130564	chr14:104152367	KLC1	0.51	8.47	0.38	4.12e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg18721089	chr20:30220636	NA	-0.5	-7.09	-0.33	5.77e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg24642844	chr7:1081250	C7orf50	-0.97	-14.71	-0.58	7.38e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11048434	0.636	rs7306165	chr12:9059081	T/C	cg04155231	chr12:9217510	LOC144571	0.37	6.79	0.31	3.73e-11	Sjögren's syndrome;
LUAD	cis	rs9039	1.000	rs9932208	chr16:9218267	T/C	cg08831531	chr16:9218945	NA	-0.43	-7.99	-0.36	1.29e-14	Menopause (age at onset);
LUAD	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg24848339	chr3:12840334	CAND2	0.42	8.17	0.37	3.5e-15	QRS complex (12-leadsum);
LUAD	cis	rs7274811	0.554	rs6120299	chr20:32133491	T/G	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.45	-6.64	-0.31	9.54e-11	Height;
LUAD	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg12311346	chr5:56204834	C5orf35	-0.89	-13.04	-0.54	6.92e-33	Initial pursuit acceleration;
LUAD	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs863345	0.526	rs857676	chr1:158615702	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.51	-0.3	2.13e-10	Pneumococcal bacteremia;
LUAD	cis	rs4713675	0.505	rs2395450	chr6:33654588	C/T	cg14003231	chr6:33640908	ITPR3	0.51	9.76	0.43	1.99e-20	Plateletcrit;
LUAD	cis	rs758324	0.812	rs6893070	chr5:131237599	A/G	cg06307176	chr5:131281290	NA	-0.47	-7.76	-0.35	6.26e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg19894588	chr14:64061835	NA	0.53	8.14	0.37	4.35e-15	Glioblastoma;Glioma;
LUAD	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-8.0	-0.36	1.18e-14	Alzheimer's disease (late onset);
LUAD	cis	rs1215050	0.818	rs6532703	chr4:98777486	A/T	cg05340658	chr4:99064831	C4orf37	0.42	6.81	0.31	3.32e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.83	-0.36	3.92e-14	Diabetic kidney disease;
LUAD	cis	rs6743376	0.556	rs4849146	chr2:113824840	A/T	cg09040174	chr2:113837401	NA	0.48	7.39	0.34	7.66e-13	Inflammatory biomarkers;
LUAD	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg12623918	chr2:306882	NA	-0.35	-7.16	-0.33	3.59e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg21427119	chr20:30132790	HM13	0.5	7.41	0.34	6.83e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs28493229	0.786	rs73546894	chr19:41189203	C/T	cg21869046	chr19:41225005	ITPKC	0.54	8.53	0.38	2.57e-16	Kawasaki disease;
LUAD	trans	rs1681630	0.848	rs1631174	chr11:47974373	A/C	cg03929089	chr4:120376271	NA	-0.44	-6.59	-0.31	1.3100000000000001e-10	Height;
LUAD	cis	rs7119	0.604	rs2271398	chr15:77907784	G/A	cg27398640	chr15:77910606	LINGO1	0.41	8.17	0.37	3.72e-15	Type 2 diabetes;
LUAD	cis	rs3823572	0.586	rs2001282	chr7:133663287	A/G	cg03336402	chr7:133662267	EXOC4	-0.41	-7.61	-0.35	1.85e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg01788221	chr16:89496183	ANKRD11	-0.37	-7.14	-0.33	4.22e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-7.41	-0.34	6.96e-13	Morning vs. evening chronotype;
LUAD	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-6.8	-0.31	3.49e-11	IgG glycosylation;
LUAD	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg03467027	chr4:99064603	C4orf37	0.41	6.51	0.3	2.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2387326	0.672	rs12254264	chr10:129945519	C/T	cg16087940	chr10:129947807	NA	-0.64	-9.06	-0.4	4.97e-18	Select biomarker traits;
LUAD	cis	rs6782228	0.509	rs6780447	chr3:128413808	T/C	cg16766828	chr3:128327626	NA	-0.39	-7.18	-0.33	3.2e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs870825	0.616	rs28672716	chr4:185647345	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs68170813	0.641	rs4730248	chr7:107125939	A/G	cg02696742	chr7:106810147	HBP1	-0.78	-10.51	-0.46	4.15e-23	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg02527881	chr3:46936655	PTH1R	-0.58	-12.04	-0.51	6.71e-29	Colorectal cancer;
LUAD	cis	rs755249	0.501	rs4660669	chr1:39807458	A/C	cg27567593	chr1:39956653	BMP8A	0.34	6.67	0.31	7.94e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs12431939	0.948	rs12436158	chr14:51669891	G/A	cg23942311	chr14:51606299	NA	-0.63	-8.61	-0.39	1.48e-16	Cancer;
LUAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg02136620	chr5:178986620	RUFY1	0.4	6.51	0.3	2.13e-10	Lung cancer;
LUAD	cis	rs3125734	0.608	rs7905731	chr10:64018472	T/C	cg09941381	chr10:64027924	RTKN2	-0.32	-7.35	-0.34	1.06e-12	Rheumatoid arthritis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00232805	chr2:97779565	ANKRD36	-0.41	-6.44	-0.3	3.35e-10	Height;
LUAD	cis	rs2235649	0.561	rs12599786	chr16:1965257	T/G	cg07386859	chr16:1872102	HAGH	0.44	6.38	0.3	4.56e-10	Blood metabolite levels;
LUAD	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg17633681	chr16:88106987	BANP	-0.38	-6.5	-0.3	2.32e-10	Menopause (age at onset);
LUAD	cis	rs6960043	0.818	rs1558318	chr7:15065612	A/T	cg19272540	chr7:15055459	NA	-0.36	-7.8	-0.35	4.85e-14	Type 2 diabetes;
LUAD	cis	rs2625529	0.689	rs12898868	chr15:72112918	A/G	cg16672083	chr15:72433130	SENP8	0.54	9.29	0.41	7.98e-19	Red blood cell count;
LUAD	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg26384229	chr12:38710491	ALG10B	0.52	8.6	0.39	1.6e-16	Heart rate;
LUAD	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg25767906	chr1:53392781	SCP2	0.46	8.54	0.38	2.41e-16	Monocyte count;
LUAD	cis	rs13315871	1.000	rs4367085	chr3:58389235	A/G	cg20936604	chr3:58311152	NA	-0.68	-7.11	-0.33	4.88e-12	Cholesterol, total;
LUAD	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg23758822	chr17:41437982	NA	1.0	20.95	0.71	2.27e-67	Menopause (age at onset);
LUAD	cis	rs11958404	0.932	rs72816549	chr5:157417957	G/A	cg05962755	chr5:157440814	NA	0.53	7.71	0.35	9.02e-14	IgG glycosylation;
LUAD	cis	rs600626	0.891	rs498936	chr11:75454878	T/A	cg24262691	chr11:75473276	NA	0.44	7.14	0.33	4.17e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1113500	0.580	rs1781058	chr1:108564059	C/G	cg06207961	chr1:108661230	NA	0.37	6.66	0.31	8.62e-11	Growth-regulated protein alpha levels;
LUAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg12432903	chr7:1882776	MAD1L1	-0.49	-7.82	-0.36	4.16e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs8018808	0.967	rs176766	chr14:77865367	G/A	cg20045696	chr14:77926864	AHSA1	0.37	6.56	0.3	1.61e-10	Myeloid white cell count;
LUAD	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-6.59	-0.31	1.3100000000000001e-10	Personality dimensions;
LUAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg27454412	chr7:1067447	C7orf50	0.42	6.67	0.31	7.99e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg18944383	chr4:111397179	ENPEP	0.51	9.3	0.41	7.87e-19	Coronary artery disease;
LUAD	cis	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg23950597	chr19:37808831	NA	-0.65	-7.66	-0.35	1.29e-13	Coronary artery calcification;
LUAD	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg00504896	chr12:9437009	LOC642846	-0.58	-9.85	-0.43	9.4499999999999992e-21	Breast size;
LUAD	cis	rs4268898	1.000	rs2303294	chr2:24432620	A/G	cg02683114	chr2:24398427	C2orf84	0.42	7.1	0.33	5.25e-12	Asthma;
LUAD	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg19773385	chr1:10388646	KIF1B	-0.41	-6.69	-0.31	7.19e-11	Hepatocellular carcinoma;
LUAD	cis	rs6489882	0.902	rs3815178	chr12:113376320	C/T	cg20102336	chr12:113376681	OAS3	-0.58	-8.91	-0.4	1.57e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs55665837	1.000	rs10832278	chr11:14496619	G/A	cg19336497	chr11:14380999	RRAS2	-0.5	-10.04	-0.44	1.96e-21	Vitamin D levels;
LUAD	cis	rs12681287	0.605	rs6471296	chr8:87374654	A/G	cg27223183	chr8:87520930	FAM82B	0.61	8.59	0.39	1.65e-16	Caudate activity during reward;
LUAD	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg04455712	chr21:45112962	RRP1B	0.43	8.91	0.4	1.5e-17	Mean corpuscular volume;
LUAD	cis	rs9811920	0.683	rs793439	chr3:99637783	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.37	-7.17	-0.33	3.34e-12	Axial length;
LUAD	cis	rs7805747	1.000	rs7805747	chr7:151407801	G/A	cg17611936	chr7:151411526	PRKAG2	0.47	6.65	0.31	8.85e-11	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg03676636	chr4:99064102	C4orf37	0.3	7.25	0.33	1.96e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.52	-8.84	-0.39	2.58e-17	Alzheimer's disease (late onset);
LUAD	cis	rs731174	0.765	rs510121	chr1:38182960	C/T	cg06917450	chr1:38156652	C1orf109	-0.41	-6.53	-0.3	1.86e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs1595825	0.945	rs73056883	chr2:198824638	A/G	cg00982548	chr2:198649783	BOLL	-0.63	-8.93	-0.4	1.34e-17	Ulcerative colitis;
LUAD	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg10356904	chr22:49881777	NA	-0.33	-6.88	-0.32	2.16e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg16414030	chr3:133502952	NA	-0.67	-12.9	-0.53	2.48e-32	Iron status biomarkers;
LUAD	cis	rs9653442	0.622	rs11685341	chr2:100636757	A/G	cg07810366	chr2:100720526	AFF3	0.36	7.35	0.34	1.04e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	trans	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.36	0.41	4.78e-19	Mean corpuscular volume;
LUAD	cis	rs3823572	0.542	rs10269665	chr7:133630418	A/G	cg03336402	chr7:133662267	EXOC4	0.41	7.52	0.34	3.23e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg11502198	chr6:26597334	ABT1	0.54	9.1	0.4	3.68e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.77	-0.43	1.9e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs17155006	0.655	rs450722	chr7:107726014	G/A	cg05962710	chr7:107745446	LAMB4	-0.3	-6.54	-0.3	1.77e-10	Pneumococcal bacteremia;
LUAD	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg21854759	chr1:92012499	NA	-0.5	-9.13	-0.41	2.75e-18	Breast cancer;
LUAD	trans	rs931812	0.895	rs7831714	chr8:101913987	C/T	cg20993868	chr7:22813445	NA	0.6	11.86	0.5	3.38e-28	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg00255919	chr5:131827918	IRF1	0.5	11.9	0.5	2.21e-28	Asthma (sex interaction);
LUAD	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg10589385	chr1:150898437	SETDB1	0.42	7.71	0.35	9.26e-14	Melanoma;
LUAD	cis	rs1595825	0.891	rs16825188	chr2:198741134	G/C	cg11031976	chr2:198649780	BOLL	-0.5	-7.14	-0.33	3.98e-12	Ulcerative colitis;
LUAD	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14240646	chr10:27532245	ACBD5	0.95	12.38	0.52	3.01e-30	Breast cancer;
LUAD	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg03433033	chr1:76189801	ACADM	-0.48	-7.11	-0.33	4.88e-12	Daytime sleep phenotypes;
LUAD	cis	rs3806843	0.576	rs246007	chr5:140338748	C/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.38	-0.3	4.59e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs9503551	0.584	rs35739945	chr6:3328722	G/T	cg13915676	chr9:139305538	SDCCAG3;PMPCA	0.49	6.41	0.3	3.78e-10	Nicotine dependence;
LUAD	trans	rs4714291	1.000	rs6917453	chr6:39992386	A/G	cg02267698	chr19:7991119	CTXN1	0.46	6.54	0.3	1.79e-10	Strep throat;
LUAD	cis	rs11958404	0.860	rs6885815	chr5:157437253	C/T	cg05962755	chr5:157440814	NA	0.71	9.95	0.44	4.36e-21	IgG glycosylation;
LUAD	cis	rs2806561	0.929	rs641452	chr1:23538386	A/G	cg19743168	chr1:23544995	NA	0.47	8.54	0.38	2.45e-16	Height;
LUAD	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg25767906	chr1:53392781	SCP2	0.4	7.17	0.33	3.36e-12	Monocyte count;
LUAD	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.33	0.48	3.51e-26	Height;
LUAD	cis	rs17490626	0.568	rs2033371	chr10:71212310	G/A	cg12610070	chr10:71211762	TSPAN15	-0.41	-11.09	-0.47	2.82e-25	Thrombosis;
LUAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg07362569	chr17:61921086	SMARCD2	0.39	6.68	0.31	7.71e-11	Prudent dietary pattern;
LUAD	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg25566285	chr7:158114605	PTPRN2	-0.55	-12.02	-0.5	7.53e-29	Calcium levels;
LUAD	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg21724239	chr8:58056113	NA	0.54	7.26	0.33	1.89e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs12681287	0.640	rs13264364	chr8:87466385	G/T	cg27223183	chr8:87520930	FAM82B	-0.68	-9.59	-0.42	7.69e-20	Caudate activity during reward;
LUAD	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg09065629	chr16:1709722	CRAMP1L	0.42	7.32	0.34	1.26e-12	Coronary artery disease;
LUAD	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg09796270	chr17:17721594	SREBF1	0.36	6.81	0.31	3.42e-11	Total body bone mineral density;
LUAD	cis	rs8044868	0.861	rs7192848	chr16:72206955	A/G	cg23815491	chr16:72088622	HP	0.36	6.4	0.3	4.13e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg17757837	chr7:157058334	UBE3C	-0.49	-8.6	-0.39	1.59e-16	Body mass index;
LUAD	trans	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.21	-31.38	-0.84	1.76e-112	Exhaled nitric oxide output;
LUAD	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg08610935	chr16:1836813	NUBP2	0.44	6.91	0.32	1.75e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg21724239	chr8:58056113	NA	0.67	8.63	0.39	1.29e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713675	0.565	rs942640	chr6:33686442	G/T	cg14003231	chr6:33640908	ITPR3	0.49	9.46	0.42	2.2e-19	Plateletcrit;
LUAD	cis	rs2625529	0.590	rs7183196	chr15:72544401	A/G	cg16672083	chr15:72433130	SENP8	-0.66	-11.38	-0.48	2.35e-26	Red blood cell count;
LUAD	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.44	-0.34	5.65e-13	Total body bone mineral density;
LUAD	cis	rs859767	0.741	rs4954155	chr2:135383504	T/C	cg12500956	chr2:135428796	TMEM163	-0.31	-8.17	-0.37	3.49e-15	Neuroticism;
LUAD	cis	rs9473147	0.516	rs2171089	chr6:47515811	A/G	cg20196966	chr6:47445060	CD2AP	0.43	6.75	0.31	4.74e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.42	-0.38	6.04e-16	Prostate cancer;
LUAD	cis	rs1451375	0.617	rs880029	chr7:50569927	G/C	cg18232548	chr7:50535776	DDC	-0.64	-8.91	-0.4	1.52e-17	Malaria;
LUAD	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg24578937	chr1:2090814	PRKCZ	0.79	16.54	0.63	9.74e-48	Height;
LUAD	cis	rs12545109	0.842	rs10958482	chr8:57389331	G/T	cg09654669	chr8:57350985	NA	-0.68	-9.92	-0.43	5.25e-21	Obesity-related traits;
LUAD	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.49	-9.77	-0.43	1.82e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13126279	chr21:47581558	C21orf56	-0.62	-11.15	-0.48	1.67e-25	Testicular germ cell tumor;
LUAD	cis	rs612683	0.560	rs491675	chr1:100902936	A/G	cg06223162	chr1:101003688	GPR88	0.37	6.8	0.31	3.59e-11	Breast cancer;
LUAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg21724239	chr8:58056113	NA	0.74	9.68	0.43	3.79e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg14196790	chr5:131705035	SLC22A5	-0.47	-8.74	-0.39	5.61e-17	Blood metabolite levels;
LUAD	cis	rs6906287	0.647	rs13217710	chr6:118843601	A/G	cg21191810	chr6:118973309	C6orf204	0.49	9.47	0.42	1.96e-19	Electrocardiographic conduction measures;
LUAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg11494091	chr17:61959527	GH2	0.74	18.32	0.67	1.27e-55	Prudent dietary pattern;
LUAD	cis	rs727505	1.000	rs727505	chr7:124462081	C/T	cg23710748	chr7:124431027	NA	-0.45	-9.27	-0.41	9.76e-19	Lewy body disease;
LUAD	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.5	-8.42	-0.38	5.91e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7739264	0.564	rs760794	chr6:19790560	C/T	cg02404759	chr6:19790362	NA	-0.35	-6.8	-0.31	3.47e-11	Endometriosis;
LUAD	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg20703242	chr1:230279135	GALNT2	-0.67	-12.84	-0.53	4.11e-32	Coronary artery disease;
LUAD	cis	rs11229555	0.645	rs11229430	chr11:58181104	G/C	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.92	-0.53	2.07e-32	Dilated cardiomyopathy;
LUAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg03188948	chr7:1209495	NA	0.53	7.74	0.35	7.6e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg03467027	chr4:99064603	C4orf37	0.44	7.2	0.33	2.74e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg06002616	chr8:101225028	SPAG1	-0.4	-8.22	-0.37	2.52e-15	Atrioventricular conduction;
LUAD	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg03929089	chr4:120376271	NA	-0.92	-17.61	-0.65	1.82e-52	Height;
LUAD	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.61	8.66	0.39	1e-16	Gut microbiome composition (summer);
LUAD	cis	rs2235649	0.833	rs9926962	chr16:1851826	A/G	cg08610935	chr16:1836813	NUBP2	-0.45	-6.97	-0.32	1.24e-11	Blood metabolite levels;
LUAD	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg15549821	chr19:49342101	PLEKHA4	-1.1	-15.97	-0.61	3e-45	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2762353	0.574	rs4419666	chr6:25693274	C/T	cg07061783	chr6:25882402	NA	0.57	8.69	0.39	7.91e-17	Blood metabolite levels;
LUAD	cis	rs870825	0.616	rs6552806	chr4:185638231	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	14.04	0.56	4.87e-37	Blood protein levels;
LUAD	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19346786	chr7:2764209	NA	-0.47	-10.09	-0.44	1.36e-21	Height;
LUAD	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.42	7.57	0.35	2.34e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg13390004	chr1:15929781	NA	0.49	8.74	0.39	5.36e-17	Systolic blood pressure;
LUAD	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg00933542	chr6:150070202	PCMT1	0.43	9.24	0.41	1.26e-18	Lung cancer;
LUAD	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg05425664	chr17:57184151	TRIM37	0.4	6.86	0.32	2.39e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs73198271	0.765	rs534103	chr8:8634069	A/G	cg01851573	chr8:8652454	MFHAS1	0.4	7.21	0.33	2.52e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg19761014	chr17:28927070	LRRC37B2	0.93	9.37	0.41	4.48e-19	Body mass index;
LUAD	cis	rs7584330	0.740	rs13418586	chr2:238445593	A/G	cg14458575	chr2:238380390	NA	0.53	9.92	0.43	5.38e-21	Prostate cancer;
LUAD	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg12927641	chr6:109611667	NA	0.54	9.6	0.42	7.2e-20	Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg11062466	chr8:58055876	NA	0.46	6.51	0.3	2.09e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg23815491	chr16:72088622	HP	0.51	9.18	0.41	1.97e-18	Fibrinogen levels;
LUAD	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.63	12.58	0.52	4.66e-31	Hemoglobin concentration;
LUAD	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg19729930	chr2:74357872	NA	1.0	18.54	0.67	1.37e-56	Gestational age at birth (maternal effect);
LUAD	trans	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg26043149	chr18:55253948	FECH	0.52	8.54	0.38	2.52e-16	Bone mineral density;
LUAD	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.53	0.34	3.07e-13	Bipolar disorder;
LUAD	cis	rs7870753	0.628	rs2406004	chr9:99193210	G/A	cg13563390	chr9:99253610	HABP4	-0.38	-6.38	-0.3	4.79e-10	Height;
LUAD	cis	rs10979	0.557	rs9376768	chr6:143909492	C/T	cg25407410	chr6:143891975	LOC285740	-0.53	-7.55	-0.34	2.63e-13	Hypospadias;
LUAD	cis	rs12049351	0.832	rs28798529	chr1:229671614	G/A	cg11742688	chr1:229674241	ABCB10	-0.42	-6.91	-0.32	1.78e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs17095355	0.818	rs2501575	chr10:111849864	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.68	-9.78	-0.43	1.63e-20	Biliary atresia;
LUAD	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg13073564	chr4:8508604	NA	-0.53	-9.74	-0.43	2.33e-20	Response to antineoplastic agents;
LUAD	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.55	-0.38	2.21e-16	Breast cancer;
LUAD	cis	rs4372836	0.681	rs13025377	chr2:28953556	G/A	cg09522027	chr2:28974177	PPP1CB	-0.47	-7.9	-0.36	2.51e-14	Body mass index;
LUAD	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.37	-0.38	8.44e-16	Breast cancer;
LUAD	cis	rs1215050	0.818	rs165238	chr4:98712138	G/T	cg05340658	chr4:99064831	C4orf37	0.43	6.98	0.32	1.18e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10540	0.584	rs6598021	chr11:438939	G/C	cg08200582	chr11:442649	ANO9	0.57	8.04	0.36	9.15e-15	Body mass index;
LUAD	cis	rs12612619	0.677	rs3754733	chr2:27249245	A/G	cg00617064	chr2:27272375	NA	-0.36	-6.65	-0.31	8.84e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg04455712	chr21:45112962	RRP1B	0.46	9.24	0.41	1.23e-18	Mean corpuscular volume;
LUAD	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg11070056	chr1:107600091	PRMT6	-0.65	-11.2	-0.48	1.08e-25	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26629188	chr21:47878281	DIP2A	-0.41	-6.36	-0.3	5.16e-10	Height;
LUAD	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg14664628	chr15:75095509	CSK	-0.52	-8.53	-0.38	2.62e-16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.12	0.33	4.7e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs11048434	0.736	rs1805732	chr12:9090892	A/G	cg04155231	chr12:9217510	LOC144571	-0.41	-7.91	-0.36	2.26e-14	Sjögren's syndrome;
LUAD	cis	rs12545109	0.800	rs1437278	chr8:57357024	T/C	cg21220214	chr8:57350948	NA	-0.67	-9.14	-0.41	2.59e-18	Obesity-related traits;
LUAD	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg04944784	chr2:26401820	FAM59B	-0.7	-9.87	-0.43	8.29e-21	Gut microbiome composition (summer);
LUAD	cis	rs4414128	0.832	rs2386648	chr10:5680914	T/A	cg12223502	chr10:5658492	NA	0.44	6.79	0.31	3.78e-11	Breast cancer;
LUAD	cis	rs7326068	0.543	rs2785740	chr13:21423525	C/G	cg27499820	chr13:21296301	IL17D	0.45	6.84	0.32	2.82e-11	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs7301016	0.707	rs11174587	chr12:63052559	A/T	cg11441379	chr12:63026424	NA	0.61	7.44	0.34	5.49e-13	IgG glycosylation;
LUAD	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg00634984	chr7:65235879	NA	0.48	6.53	0.3	1.91e-10	Aortic root size;
LUAD	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg02176678	chr2:219576539	TTLL4	0.59	11.19	0.48	1.22e-25	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs889398	0.802	rs2937121	chr16:69870409	T/G	cg00738113	chr16:70207722	CLEC18C	0.36	7.21	0.33	2.62e-12	Body mass index;
LUAD	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22857025	chr5:266934	NA	-0.96	-14.39	-0.57	1.75e-38	Breast cancer;
LUAD	trans	rs3942852	0.868	rs6485808	chr11:48109151	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-8.26	-0.37	1.88e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg07570687	chr10:102243282	WNT8B	0.44	6.65	0.31	9.28e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9399401	0.601	rs262113	chr6:142824950	T/G	cg03128060	chr6:142623767	GPR126	0.42	7.71	0.35	9.34e-14	Chronic obstructive pulmonary disease;
LUAD	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.61	0.31	1.15e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.14	0.51	2.73e-29	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg02782426	chr3:40428986	ENTPD3	0.35	7.66	0.35	1.27e-13	Renal cell carcinoma;
LUAD	cis	rs847851	1.000	rs847851	chr6:34904584	A/G	cg07306190	chr6:34760872	UHRF1BP1	0.33	7.44	0.34	5.54e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg05754148	chr16:3507555	NAT15	-0.85	-9.45	-0.42	2.32e-19	Tuberculosis;
LUAD	trans	rs1941687	0.505	rs1389534	chr18:31311161	C/G	cg27147174	chr7:100797783	AP1S1	0.55	8.75	0.39	5.25e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg02493740	chr2:85810744	VAMP5	-0.44	-8.08	-0.37	6.8e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg04944784	chr2:26401820	FAM59B	-0.9	-13.56	-0.55	5.14e-35	Gut microbiome composition (summer);
LUAD	cis	rs2806561	0.780	rs6650086	chr1:23338384	T/C	cg19743168	chr1:23544995	NA	-0.35	-6.38	-0.3	4.7e-10	Height;
LUAD	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg08999081	chr20:33150536	PIGU	0.54	11.47	0.49	1.02e-26	Coronary artery disease;
LUAD	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.16	0.37	3.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg00383909	chr3:49044727	WDR6	0.5	6.58	0.3	1.35e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg19774624	chr17:42201019	HDAC5	-0.4	-6.83	-0.32	2.98e-11	Total body bone mineral density;
LUAD	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-8.14	-0.37	4.38e-15	Type 2 diabetes;
LUAD	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.71	-0.43	2.94e-20	Schizophrenia;
LUAD	cis	rs1232027	0.656	rs56357417	chr5:79958336	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.02	-0.32	8.67e-12	Huntington's disease progression;
LUAD	cis	rs367943	0.712	rs13359330	chr5:112708529	T/C	cg12552261	chr5:112820674	MCC	0.47	9.28	0.41	8.7e-19	Type 2 diabetes;
LUAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg00280220	chr17:61926910	NA	0.37	7.18	0.33	3.23e-12	Prudent dietary pattern;
LUAD	trans	rs1997103	1.000	rs6950311	chr7:55400990	G/A	cg20935933	chr6:143382018	AIG1	0.53	7.48	0.34	4.32e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg05535760	chr7:792225	HEATR2	0.84	11.19	0.48	1.18e-25	Cerebrospinal P-tau181p levels;
LUAD	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg07570687	chr10:102243282	WNT8B	0.44	6.73	0.31	5.55e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1971762	0.583	rs2365345	chr12:54086820	C/T	cg23533419	chr12:54090519	NA	-0.34	-6.38	-0.3	4.65e-10	Height;
LUAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.69	0.31	7.21e-11	Prudent dietary pattern;
LUAD	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg04944784	chr2:26401820	FAM59B	-0.67	-9.65	-0.42	4.7e-20	Gut microbiome composition (summer);
LUAD	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.77	-10.19	-0.44	6.04e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	trans	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg18335740	chr13:41363409	SLC25A15	0.71	13.84	0.56	3.36e-36	Lewy body disease;
LUAD	cis	rs6993813	0.872	rs10505351	chr8:120033998	C/T	cg01975934	chr8:119970761	NA	-0.37	-7.23	-0.33	2.26e-12	Bone mineral density (hip);
LUAD	cis	rs798554	0.629	rs2533875	chr7:2882829	G/A	cg19717773	chr7:2847554	GNA12	-0.47	-8.48	-0.38	3.93e-16	Height;
LUAD	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg04282206	chr17:62833786	PLEKHM1P	0.62	9.12	0.41	3.17e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg22482690	chr17:47019901	SNF8	0.45	8.51	0.38	3.15e-16	Type 2 diabetes;
LUAD	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg23602478	chr1:26503979	CNKSR1	0.28	6.97	0.32	1.26e-11	Height;
LUAD	cis	rs1232027	0.700	rs1677626	chr5:79949445	C/G	cg24059623	chr5:79951536	MSH3;DHFR	0.48	7.89	0.36	2.6e-14	Huntington's disease progression;
LUAD	cis	rs9972944	0.651	rs9906040	chr17:63840825	A/G	cg07283582	chr17:63770753	CCDC46	-0.45	-9.56	-0.42	1.01e-19	Total body bone mineral density;
LUAD	cis	rs6867032	0.527	rs13153217	chr5:2012788	G/T	cg26168224	chr5:2018326	NA	-0.48	-9.56	-0.42	9.82e-20	Gut microbiome composition (winter);
LUAD	cis	rs6541297	0.699	rs966333	chr1:230305477	T/C	cg20703242	chr1:230279135	GALNT2	0.57	7.83	0.36	3.92e-14	Coronary artery disease;
LUAD	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10802521	chr3:52805072	NEK4	-0.62	-11.22	-0.48	9.81e-26	Bipolar disorder;
LUAD	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg09455208	chr3:40491958	NA	0.53	11.8	0.5	5.46e-28	Renal cell carcinoma;
LUAD	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg01689657	chr7:91764605	CYP51A1	-0.37	-8.77	-0.39	4.49e-17	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05318427	chr2:85199320	KCMF1	-0.41	-6.65	-0.31	9.2e-11	Height;
LUAD	trans	rs9354308	0.933	rs55672811	chr6:66571730	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.49	7.44	0.34	5.65e-13	Metabolite levels;
LUAD	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg01802117	chr1:53393560	SCP2	-0.38	-7.48	-0.34	4.27e-13	Monocyte count;
LUAD	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.18	-0.48	1.31e-25	Type 2 diabetes;
LUAD	cis	rs11190604	1.000	rs76683169	chr10:102358397	A/T	cg16342193	chr10:102329863	NA	-0.37	-6.42	-0.3	3.64e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg17063962	chr7:91808500	NA	0.67	11.92	0.5	1.89e-28	Breast cancer;
LUAD	cis	rs10193935	0.892	rs6744964	chr2:42441088	A/G	cg27598129	chr2:42591480	NA	-0.77	-10.19	-0.44	6.14e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12474201	0.963	rs11676737	chr2:46929873	T/C	cg09399716	chr2:46890238	NA	-0.35	-6.4	-0.3	4.06e-10	Height;
LUAD	trans	rs1728785	1.000	rs698717	chr16:68560199	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.55	0.46	2.89e-23	Ulcerative colitis;
LUAD	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg17724175	chr1:150552817	MCL1	-0.38	-8.36	-0.38	8.83e-16	Urate levels;
LUAD	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23221052	chr5:179740743	GFPT2	-0.73	-12.04	-0.51	6.62e-29	Height;
LUAD	cis	rs67981189	0.679	rs221901	chr14:71602226	C/T	cg15816911	chr14:71606274	NA	-0.36	-6.77	-0.31	4.42e-11	Schizophrenia;
LUAD	cis	rs4523957	0.855	rs1231209	chr17:2124972	G/A	cg16513277	chr17:2031491	SMG6	-0.81	-15.06	-0.59	2.45e-41	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs62458065	0.568	rs62463963	chr7:32486691	C/T	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.63	-0.35	1.5700000000000001e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg22467129	chr15:76604101	ETFA	-0.49	-7.95	-0.36	1.71e-14	Blood metabolite levels;
LUAD	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg18252515	chr7:66147081	NA	0.59	6.53	0.3	1.84e-10	Diabetic kidney disease;
LUAD	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg04450456	chr4:17643702	FAM184B	0.37	6.95	0.32	1.37e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs41311933	0.562	rs72760249	chr9:123927547	A/G	cg13567360	chr9:123745713	C5	-0.67	-8.12	-0.37	5.26e-15	Coronary artery disease;
LUAD	cis	rs2019216	0.564	rs1518053	chr17:21924272	G/T	cg22648282	chr17:21454238	C17orf51	-0.43	-7.74	-0.35	7.37e-14	Pelvic organ prolapse;
LUAD	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg17074396	chr22:49843754	NA	-0.32	-6.53	-0.3	1.91e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-9.19	-0.41	1.8e-18	Hemoglobin concentration;
LUAD	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.94	0.32	1.44e-11	Cognitive test performance;
LUAD	trans	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg08071915	chr8:12219732	FAM66A	-0.42	-6.99	-0.32	1.05e-11	Mood instability;
LUAD	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg17366294	chr4:99064904	C4orf37	0.6	10.26	0.45	3.38e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg24578937	chr1:2090814	PRKCZ	0.78	16.14	0.62	5.17e-46	Height;
LUAD	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg08645402	chr16:4508243	NA	0.52	9.7	0.43	3.26e-20	Schizophrenia;
LUAD	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg27411982	chr8:10470053	RP1L1	-0.45	-8.28	-0.37	1.63e-15	Neuroticism;
LUAD	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg24801067	chr17:62843696	NA	0.64	8.72	0.39	6.64e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg22920501	chr2:26401640	FAM59B	0.78	10.21	0.44	5.05e-22	Gut microbiome composition (summer);
LUAD	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg16989719	chr2:238392110	NA	-0.31	-6.75	-0.31	4.87e-11	Prostate cancer;
LUAD	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg02753203	chr1:228287806	NA	0.81	15.01	0.59	4.07e-41	Diastolic blood pressure;
LUAD	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg12927641	chr6:109611667	NA	-0.53	-9.35	-0.41	5.13e-19	Reticulocyte fraction of red cells;
LUAD	trans	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	9.97e-11	Diabetic kidney disease;
LUAD	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg15704280	chr7:45808275	SEPT13	-1.06	-23.72	-0.76	1.02e-79	Height;
LUAD	cis	rs1547553	1	rs1547553	chr18:77926197	C/A	cg14906638	chr18:78001859	PARD6G	-0.62	-7.71	-0.35	9.04e-14	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7095607	0.813	rs2087345	chr10:69922843	T/C	cg18986048	chr10:69913749	MYPN	0.38	6.57	0.3	1.5e-10	Lung function (FVC);
LUAD	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg03467027	chr4:99064603	C4orf37	0.42	6.7	0.31	6.67e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg08472276	chr7:1133186	C7orf50;GPER	-0.47	-8.54	-0.38	2.36e-16	Longevity;Endometriosis;
LUAD	cis	rs7599312	0.534	rs10207878	chr2:213409337	A/G	cg16329650	chr2:213403929	ERBB4	0.62	11.18	0.48	1.39e-25	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg04944784	chr2:26401820	FAM59B	0.88	12.17	0.51	1.98e-29	Mean corpuscular hemoglobin;
LUAD	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.67	-9.48	-0.42	1.81e-19	Lymphocyte percentage of white cells;
LUAD	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg06191203	chr2:152266755	RIF1	-0.53	-8.02	-0.36	1.08e-14	Lung cancer;
LUAD	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	7.08	0.33	6.1e-12	Bipolar disorder;
LUAD	cis	rs68170813	0.559	rs6949961	chr7:106850755	G/T	cg02696742	chr7:106810147	HBP1	0.79	10.76	0.46	4.98e-24	Coronary artery disease;
LUAD	cis	rs732716	0.813	rs760369	chr19:4449287	C/T	cg21934504	chr19:4445085	UBXN6	-0.44	-7.56	-0.34	2.59e-13	Mean corpuscular volume;
LUAD	trans	rs10411161	0.702	rs7250138	chr19:52385232	G/C	cg22319618	chr22:45562946	NUP50	-0.59	-8.34	-0.38	1.05e-15	Breast cancer;
LUAD	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg21770322	chr7:97807741	LMTK2	0.33	7.87	0.36	3.06e-14	Breast cancer;
LUAD	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.5	6.9	0.32	1.85e-11	Platelet count;
LUAD	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg23978390	chr7:1156363	C7orf50	0.45	6.78	0.31	4.04e-11	Longevity;Endometriosis;
LUAD	trans	rs6076960	0.846	rs6053962	chr20:6176915	A/G	cg21095983	chr6:86352623	SYNCRIP	0.5	8.33	0.38	1.18e-15	Smooth-surface caries;
LUAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.07	0.4	4.6e-18	Alzheimer's disease;
LUAD	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg00745463	chr17:30367425	LRRC37B	0.78	8.93	0.4	1.31e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg17724175	chr1:150552817	MCL1	0.39	8.8	0.39	3.55e-17	Melanoma;
LUAD	cis	rs2742417	1.000	rs2673025	chr3:45760483	A/G	cg10512202	chr3:45649293	LIMD1	0.36	6.37	0.3	4.86e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs62400317	0.793	rs6924185	chr6:45017228	C/A	cg20913747	chr6:44695427	NA	-0.4	-6.49	-0.3	2.42e-10	Total body bone mineral density;
LUAD	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.69	-0.61	4.64e-44	Eye color traits;
LUAD	trans	rs5756813	0.833	rs5756819	chr22:38188195	A/C	cg19894588	chr14:64061835	NA	0.6	9.27	0.41	9.62e-19	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg08470875	chr2:26401718	FAM59B	-0.77	-10.37	-0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs62458065	0.850	rs6462362	chr7:32464733	C/T	cg20159608	chr7:32802032	NA	-0.54	-7.38	-0.34	8.2e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	trans	rs1941687	0.509	rs7230319	chr18:31321289	A/T	cg15819921	chr19:927150	ARID3A	-0.46	-7.74	-0.35	7.15e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg03340356	chr1:67600835	NA	0.43	7.5	0.34	3.75e-13	Psoriasis;
LUAD	cis	rs12541635	0.966	rs6469031	chr8:107048095	T/C	cg10147462	chr8:107024639	NA	0.48	8.52	0.38	2.91e-16	Age of smoking initiation;
LUAD	cis	rs6754311	0.593	rs7608045	chr2:136413359	T/C	cg07305463	chr2:136567211	LCT	-0.34	-6.42	-0.3	3.67e-10	Mosquito bite size;
LUAD	cis	rs1472147	0.955	rs3736611	chr7:128509243	C/G	cg00260937	chr7:128520193	KCP	0.42	6.55	0.3	1.66e-10	Calcium levels;
LUAD	trans	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.23	-0.33	2.3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.55	0.3	1.71e-10	Depression;
LUAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.03	0.54	6.97e-33	Prudent dietary pattern;
LUAD	cis	rs11828289	0.660	rs77575887	chr11:23174504	T/A	cg20040320	chr11:23191996	NA	-0.7	-8.04	-0.36	9.16e-15	Cancer;
LUAD	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg24818145	chr4:99064322	C4orf37	0.45	7.59	0.35	2.1e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg12923728	chr3:195709715	SDHAP1	0.44	6.74	0.31	5.32e-11	Mean corpuscular volume;
LUAD	cis	rs250677	0.522	rs10050928	chr5:148353463	C/A	cg18129178	chr5:148520854	ABLIM3	0.52	7.94	0.36	1.81e-14	Breast cancer;
LUAD	cis	rs6087990	0.842	rs4911105	chr20:31330413	G/A	cg13636640	chr20:31349939	DNMT3B	0.77	14.19	0.57	1.2e-37	Ulcerative colitis;
LUAD	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03517284	chr6:25882590	NA	-0.64	-9.36	-0.41	4.71e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg24675658	chr1:53192096	ZYG11B	-0.38	-6.48	-0.3	2.49e-10	Monocyte count;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg02026896	chr6:158589113	GTF2H5;SERAC1	-0.63	-6.46	-0.3	2.92e-10	Type 2 diabetes;
LUAD	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg00383909	chr3:49044727	WDR6	1.01	9.48	0.42	1.85e-19	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs78456975	1.000	rs72776251	chr2:1525097	G/A	cg01028140	chr2:1542097	TPO	-0.6	-7.64	-0.35	1.48e-13	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs3821902	0.597	rs73119079	chr3:64015399	G/A	cg22134162	chr3:63841271	THOC7	-0.42	-6.96	-0.32	1.27e-11	Breast cancer;
LUAD	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg04287289	chr16:89883240	FANCA	0.75	6.37	0.3	5.01e-10	Skin colour saturation;
LUAD	cis	rs2882667	0.858	rs11242448	chr5:138443154	C/A	cg04439458	chr5:138467593	SIL1	-0.54	-9.57	-0.42	8.78e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-25.09	-0.77	8.9e-86	Height;
LUAD	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg24818145	chr4:99064322	C4orf37	-0.41	-6.84	-0.32	2.75e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9902453	0.967	rs4356528	chr17:28489670	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.47	0.38	4.09e-16	Coffee consumption (cups per day);
LUAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2387326	0.767	rs12262323	chr10:129942672	G/A	cg16087940	chr10:129947807	NA	-0.64	-8.81	-0.39	3.16e-17	Select biomarker traits;
LUAD	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-9.03	-0.4	5.99e-18	Life satisfaction;
LUAD	cis	rs4523957	0.928	rs170045	chr17:2196905	A/G	cg16513277	chr17:2031491	SMG6	0.76	14.33	0.57	3.07e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg05373962	chr22:49881684	NA	-0.51	-11.86	-0.5	3.44e-28	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2297797	0.660	rs10858096	chr1:109967104	C/A	cg08367326	chr1:110052010	AMIGO1	0.39	6.67	0.31	7.8e-11	Cognitive function;
LUAD	trans	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.6	9.44	0.42	2.53e-19	Endometrial cancer;
LUAD	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg25237894	chr2:233734115	C2orf82	-0.57	-11.1	-0.47	2.7e-25	Coronary artery disease;
LUAD	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	trans	rs4824093	0.545	rs58876234	chr22:50258868	G/A	cg09872104	chr7:134855509	C7orf49	-0.89	-7.8	-0.35	4.77e-14	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs7512552	0.839	rs1103115	chr1:150332304	G/A	cg15654264	chr1:150340011	RPRD2	0.58	11.1	0.47	2.73e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs75804782	0.625	rs72984594	chr2:239470169	G/A	cg01134436	chr17:81009848	B3GNTL1	0.75	7.6	0.35	1.92e-13	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg06697600	chr4:7070879	GRPEL1	-0.5	-8.35	-0.38	9.85e-16	Monocyte percentage of white cells;
LUAD	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg15664640	chr17:80829946	TBCD	-0.85	-17.35	-0.64	2.58e-51	Breast cancer;
LUAD	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg12311346	chr5:56204834	C5orf35	0.57	9.24	0.41	1.21e-18	Coronary artery disease;
LUAD	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg13732083	chr21:47605072	C21orf56	0.41	6.79	0.31	3.77e-11	Testicular germ cell tumor;
LUAD	cis	rs75920871	0.623	rs625145	chr11:116727936	A/T	cg04087571	chr11:116723030	SIK3	-0.32	-7.5	-0.34	3.89e-13	Subjective well-being;
LUAD	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg19622623	chr12:86230825	RASSF9	0.42	7.49	0.34	3.93e-13	Major depressive disorder;
LUAD	cis	rs35883536	0.647	rs10875312	chr1:101042320	G/C	cg06223162	chr1:101003688	GPR88	-0.45	-8.56	-0.38	2.08e-16	Monocyte count;
LUAD	trans	rs3930017	0.900	rs117026815	chr7:76717606	A/G	cg05913257	chr4:53525745	USP46	-0.41	-6.5	-0.3	2.31e-10	Body mass index;
LUAD	cis	rs9837602	0.872	rs1489816	chr3:99769088	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.63	-9.1	-0.4	3.57e-18	Breast cancer;
LUAD	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg22535103	chr8:58192502	C8orf71	-0.69	-7.53	-0.34	3.17e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs4356932	1.000	rs6846814	chr4:76952288	A/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.41	-0.3	3.88e-10	Blood protein levels;
LUAD	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg14196790	chr5:131705035	SLC22A5	0.48	8.74	0.39	5.51e-17	Blood metabolite levels;
LUAD	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg20607798	chr8:58055168	NA	0.81	9.87	0.43	8.44e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06022373	chr22:39101656	GTPBP1	-0.46	-7.26	-0.33	1.88e-12	Menopause (age at onset);
LUAD	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg15448220	chr1:150897856	SETDB1	0.46	7.98	0.36	1.42e-14	Tonsillectomy;
LUAD	trans	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg14791747	chr16:20752902	THUMPD1	0.71	9.54	0.42	1.12e-19	Cognitive test performance;
LUAD	cis	rs17539620	0.808	rs6904264	chr6:154878380	C/G	cg20019720	chr6:154832845	CNKSR3	-0.47	-9.1	-0.4	3.57e-18	Lipoprotein (a) levels;
LUAD	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg12179176	chr11:130786555	SNX19	0.55	9.33	0.41	6.16e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg18512352	chr11:47633146	NA	0.4	7.13	0.33	4.48e-12	Subjective well-being;
LUAD	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.24	-0.45	3.77e-22	Total body bone mineral density;
LUAD	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg21194808	chr1:2205498	SKI	0.41	6.46	0.3	2.95e-10	Height;
LUAD	cis	rs3772130	0.962	rs6784571	chr3:121539991	C/T	cg20356878	chr3:121714668	ILDR1	0.53	8.57	0.38	2.02e-16	Cognitive performance;
LUAD	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg26513180	chr16:89883248	FANCA	0.65	6.67	0.31	7.99e-11	Skin colour saturation;
LUAD	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg18876405	chr7:65276391	NA	0.6	10.24	0.45	4.02e-22	Aortic root size;
LUAD	cis	rs7593730	0.537	rs1457231	chr2:161101562	C/T	cg22609984	chr2:161126801	NA	0.48	8.74	0.39	5.46e-17	Type 2 diabetes;
LUAD	cis	rs7833986	0.501	rs2719259	chr8:56941630	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.92	15.95	0.61	3.53e-45	Height;
LUAD	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.48	-8.49	-0.38	3.43e-16	Menarche (age at onset);
LUAD	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg18138036	chr10:133769891	PPP2R2D	0.41	6.57	0.3	1.51e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg27094323	chr7:1216898	NA	-0.36	-6.41	-0.3	3.79e-10	Longevity;Endometriosis;
LUAD	cis	rs1044826	0.642	rs1580642	chr3:139132203	A/C	cg00490450	chr3:139108681	COPB2	-0.45	-7.22	-0.33	2.49e-12	Obesity-related traits;
LUAD	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg25324976	chr17:61989376	CSHL1	0.36	7.06	0.32	7.01e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.68	-13.4	-0.55	2.17e-34	Ulcerative colitis;
LUAD	cis	rs4253772	0.550	rs9615347	chr22:46728153	A/G	cg09491104	chr22:46646882	C22orf40	-0.54	-6.56	-0.3	1.55e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg07741184	chr6:167504864	NA	0.32	7.36	0.34	9.42e-13	Primary biliary cholangitis;
LUAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg22907277	chr7:1156413	C7orf50	0.6	10.27	0.45	3.12e-22	Longevity;Endometriosis;
LUAD	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg13535736	chr9:111863775	C9orf5	-0.42	-6.42	-0.3	3.57e-10	Menarche (age at onset);
LUAD	cis	rs10896135	0.526	rs1987169	chr11:66448044	A/G	cg15964523	chr11:66469143	SPTBN2	0.42	6.94	0.32	1.51e-11	Bipolar disorder;
LUAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.49	-7.75	-0.35	7.07e-14	Longevity;Endometriosis;
LUAD	cis	rs4713675	0.584	rs942643	chr6:33668370	A/G	cg13859433	chr6:33739653	LEMD2	-0.31	-7.31	-0.34	1.3e-12	Plateletcrit;
LUAD	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg09365446	chr1:150670422	GOLPH3L	0.61	10.91	0.47	1.43e-24	Melanoma;
LUAD	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg09399716	chr2:46890238	NA	-0.36	-6.9	-0.32	1.92e-11	Height;
LUAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg26554054	chr8:600488	NA	0.81	8.02	0.36	1.04e-14	IgG glycosylation;
LUAD	cis	rs669446	0.562	rs10890273	chr1:44186444	T/A	cg12908607	chr1:44402522	ARTN	-0.35	-7.12	-0.33	4.64e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs2688608	0.672	rs2688621	chr10:75687849	C/T	cg23231163	chr10:75533350	FUT11	-0.36	-6.64	-0.31	9.66e-11	Inflammatory bowel disease;
LUAD	cis	rs6489882	0.703	rs10774673	chr12:113361158	C/T	cg20102336	chr12:113376681	OAS3	-0.55	-8.41	-0.38	6.35e-16	Chronic lymphocytic leukemia;
LUAD	cis	rs4711350	0.954	rs11751943	chr6:33729718	G/C	cg07979401	chr6:33739406	LEMD2	-0.51	-8.16	-0.37	3.86e-15	Schizophrenia;
LUAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg24503407	chr1:205819492	PM20D1	0.73	14.15	0.57	1.65e-37	Monocyte percentage of white cells;
LUAD	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07636037	chr3:49044803	WDR6	0.48	8.35	0.38	1e-15	Menarche (age at onset);
LUAD	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg07570687	chr10:102243282	WNT8B	0.44	6.65	0.31	8.98e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18404041	chr3:52824283	ITIH1	-0.57	-11.96	-0.5	1.32e-28	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9341808	0.529	rs4706840	chr6:81057769	T/A	cg08355045	chr6:80787529	NA	0.47	8.14	0.37	4.49e-15	Sitting height ratio;
LUAD	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.41	0.3	3.84e-10	Depression;
LUAD	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.45	-0.42	2.34e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.79	14.88	0.59	1.46e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7680126	0.596	rs917826	chr4:10295595	C/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-7.46	-0.34	4.89e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg10544611	chr16:67998164	SLC12A4	-0.62	-6.78	-0.31	4.12e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg11062466	chr8:58055876	NA	0.81	10.17	0.44	7.19e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.35	0.38	9.94e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg22532475	chr10:104410764	TRIM8	-0.42	-8.09	-0.37	6.58e-15	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg27661571	chr11:113659931	NA	-0.69	-8.14	-0.37	4.49e-15	Hip circumference adjusted for BMI;
LUAD	trans	rs225245	0.817	rs225290	chr17:33927904	C/G	cg19694781	chr19:47549865	TMEM160	-0.46	-7.54	-0.34	2.95e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.9	-0.4	1.67e-17	Lymphocyte counts;
LUAD	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg10518543	chr12:38710700	ALG10B	0.42	6.42	0.3	3.75e-10	Bladder cancer;
LUAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.83	0.47	2.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg12863693	chr15:85201151	NMB	0.37	6.48	0.3	2.6e-10	Schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06736685	chr16:85589349	NA	-0.43	-6.73	-0.31	5.67e-11	Height;
LUAD	cis	rs7737355	0.947	rs6890784	chr5:130939540	T/C	cg06307176	chr5:131281290	NA	0.51	7.89	0.36	2.65e-14	Life satisfaction;
LUAD	cis	rs731174	0.921	rs6686264	chr1:38192337	A/T	cg06917450	chr1:38156652	C1orf109	-0.4	-6.88	-0.32	2.2e-11	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	3.96e-11	Depression;
LUAD	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg03929089	chr4:120376271	NA	-0.44	-6.76	-0.31	4.55e-11	HDL cholesterol;
LUAD	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg03983476	chr2:10830698	NOL10	-0.47	-8.25	-0.37	2.01e-15	Prostate cancer;
LUAD	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg16049864	chr8:95962084	TP53INP1	-0.6	-13.2	-0.54	1.51e-33	Type 2 diabetes;
LUAD	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg18132916	chr6:79620363	NA	-0.45	-7.75	-0.35	6.96e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg07507251	chr3:52567010	NT5DC2	0.36	7.06	0.32	6.96e-12	Bipolar disorder;
LUAD	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg06108461	chr20:60628389	TAF4	-1.13	-20.76	-0.71	1.55e-66	Body mass index;
LUAD	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg21963583	chr11:68658836	MRPL21	0.64	11.45	0.49	1.21e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	7.4	0.34	7.46e-13	Platelet count;
LUAD	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg07570687	chr10:102243282	WNT8B	-0.43	-6.59	-0.31	1.29e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.83	0.47	2.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg15557168	chr22:42548783	NA	-0.41	-7.23	-0.33	2.29e-12	Cognitive function;
LUAD	cis	rs9972944	0.729	rs1541609	chr17:63773564	G/A	cg07283582	chr17:63770753	CCDC46	0.46	10.03	0.44	2.28e-21	Total body bone mineral density;
LUAD	cis	rs240764	0.717	rs180963	chr6:101127213	T/C	cg09795085	chr6:101329169	ASCC3	0.43	7.36	0.34	9.39e-13	Neuroticism;
LUAD	cis	rs7481584	0.962	rs12805426	chr11:3020580	C/T	cg11201177	chr11:2961805	NA	0.39	6.55	0.3	1.7e-10	Calcium levels;
LUAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg13560548	chr3:10150139	C3orf24	0.42	6.81	0.31	3.45e-11	Alzheimer's disease;
LUAD	cis	rs7737355	0.812	rs30735	chr5:130709422	G/A	cg06307176	chr5:131281290	NA	-0.4	-6.77	-0.31	4.34e-11	Life satisfaction;
LUAD	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg04731861	chr2:219085781	ARPC2	0.23	7.14	0.33	4.17e-12	Colorectal cancer;
LUAD	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg05805236	chr11:65401703	PCNXL3	-0.52	-8.69	-0.39	8.11e-17	Acne (severe);
LUAD	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11890956	chr21:40555474	PSMG1	0.76	13.4	0.55	2.25e-34	Cognitive function;
LUAD	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1403694	0.695	rs11919484	chr3:186432839	G/T	cg12454167	chr3:186435060	KNG1	0.52	10.62	0.46	1.58e-23	Blood protein levels;
LUAD	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg04586622	chr2:25135609	ADCY3	0.36	8.19	0.37	3.14e-15	Body mass index;
LUAD	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.44	-0.34	5.58e-13	Coronary artery disease;
LUAD	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg15921436	chr17:44337874	NA	0.84	11.0	0.47	6.62e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg04731861	chr2:219085781	ARPC2	0.24	7.44	0.34	5.64e-13	Colorectal cancer;
LUAD	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg17757837	chr7:157058334	UBE3C	-0.51	-8.99	-0.4	8.6e-18	Body mass index;
LUAD	cis	rs62229266	0.605	rs11701331	chr21:37458392	T/C	cg08632701	chr21:37451849	NA	-0.67	-12.12	-0.51	3.22e-29	Mitral valve prolapse;
LUAD	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.46	-0.42	2.09e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg14458575	chr2:238380390	NA	0.69	12.65	0.52	2.53e-31	Prostate cancer;
LUAD	trans	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg17145862	chr1:211918768	LPGAT1	-0.66	-13.64	-0.55	2.26e-35	Leprosy;
LUAD	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg09365446	chr1:150670422	GOLPH3L	0.62	10.71	0.46	7.93e-24	Melanoma;
LUAD	trans	rs12210905	0.800	rs12209651	chr6:26660925	A/C	cg08851530	chr6:28072375	NA	0.71	6.46	0.3	2.85e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg25237894	chr2:233734115	C2orf82	-0.59	-10.97	-0.47	8.2e-25	Coronary artery disease;
LUAD	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-7.47	-0.34	4.59e-13	Mood instability;
LUAD	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.36	-0.38	8.83e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs55788414	0.932	rs9940095	chr16:81182108	A/G	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.9	-0.36	2.46e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs992157	0.764	rs4423579	chr2:219185033	G/T	cg05991184	chr2:219186017	PNKD	-0.41	-7.73	-0.35	8.08e-14	Colorectal cancer;
LUAD	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs748404	0.697	rs491804	chr15:43560825	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.14	0.37	4.58e-15	Lung cancer;
LUAD	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg02527881	chr3:46936655	PTH1R	-0.5	-10.29	-0.45	2.61e-22	Colorectal cancer;
LUAD	cis	rs3820068	0.705	rs1800616	chr1:15832229	G/A	cg24675056	chr1:15929824	NA	0.42	6.7	0.31	6.75e-11	Systolic blood pressure;
LUAD	cis	rs7178572	0.568	rs12906708	chr15:77681444	A/G	cg15453836	chr15:77711506	NA	-0.36	-6.42	-0.3	3.59e-10	Type 2 diabetes;
LUAD	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.42	6.36	0.3	5.33e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.74	0.31	5.14e-11	Cognitive test performance;
LUAD	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg21984481	chr17:79567631	NPLOC4	-0.71	-17.13	-0.64	2.43e-50	Eye color traits;
LUAD	cis	rs7116495	1.000	rs7101701	chr11:71762155	A/G	cg07596299	chr11:71824057	C11orf51	-0.78	-6.66	-0.31	8.3e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs7216064	1.000	rs55939964	chr17:65869297	G/A	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs317865	0.529	rs57811439	chr4:16194667	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.6	6.61	0.31	1.19e-10	Kidney disease (early stage) in type 1 diabetes;
LUAD	cis	rs73198271	0.628	rs75693229	chr8:8590926	G/A	cg01851573	chr8:8652454	MFHAS1	0.48	6.98	0.32	1.18e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg26924012	chr15:45694286	SPATA5L1	1.03	19.2	0.68	1.55e-59	Homoarginine levels;
LUAD	trans	rs3857536	0.776	rs4710316	chr6:66935097	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs897984	0.574	rs11647284	chr16:31077335	G/A	cg02466173	chr16:30829666	NA	-0.5	-8.23	-0.37	2.27e-15	Dementia with Lewy bodies;
LUAD	cis	rs4853525	0.522	rs6434412	chr2:191585275	A/G	cg27211696	chr2:191398769	TMEM194B	-0.4	-6.68	-0.31	7.5e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg07234876	chr8:600039	NA	0.84	8.94	0.4	1.19e-17	IgG glycosylation;
LUAD	cis	rs72928364	1.000	rs13099053	chr3:100620904	C/A	cg10123952	chr3:100791384	NA	0.63	7.24	0.33	2.2e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12478665	1	rs12478665	chr2:210123032	C/T	cg09336323	chr2:210074276	NA	0.43	6.89	0.32	2.03e-11	Hippocampal volume;
LUAD	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg16325326	chr1:53192061	ZYG11B	0.63	12.35	0.51	3.74e-30	Monocyte count;
LUAD	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-8.33	-0.38	1.16e-15	Total body bone mineral density;
LUAD	cis	rs9902453	0.817	rs2617880	chr17:28106118	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.1	-0.4	3.47e-18	Coffee consumption (cups per day);
LUAD	cis	rs738322	0.555	rs5756932	chr22:38546118	C/T	cg17652424	chr22:38574118	PLA2G6	-0.27	-7.07	-0.33	6.28e-12	Cutaneous nevi;
LUAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg07402062	chr16:89894098	SPIRE2	0.44	11.15	0.48	1.72e-25	Vitiligo;
LUAD	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg13385794	chr1:248469461	NA	0.26	7.08	0.33	5.93e-12	Common traits (Other);
LUAD	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.55e-11	Crohn's disease;
LUAD	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg06808227	chr14:105710500	BRF1	-0.42	-6.71	-0.31	6.43e-11	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg16405210	chr4:1374714	KIAA1530	-0.38	-6.42	-0.3	3.6e-10	Longevity;
LUAD	cis	rs208520	0.874	rs208485	chr6:66925654	T/C	cg07460842	chr6:66804631	NA	-0.95	-13.6	-0.55	3.4000000000000003e-35	Exhaled nitric oxide output;
LUAD	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.3e-12	Motion sickness;
LUAD	cis	rs6484504	0.576	rs158140	chr11:31212971	T/C	cg14844989	chr11:31128820	NA	-0.44	-8.2	-0.37	2.96e-15	Red blood cell count;
LUAD	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.89e-14	Depression;
LUAD	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg04036182	chr15:45458818	NA	-0.42	-7.28	-0.33	1.67e-12	Glomerular filtration rate;
LUAD	cis	rs7191439	0.722	rs6500491	chr16:88783521	T/C	cg27087555	chr16:88793112	FAM38A	-0.9	-8.18	-0.37	3.35e-15	Plateletcrit;
LUAD	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg11070056	chr1:107600091	PRMT6	0.61	10.53	0.46	3.56e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg18512352	chr11:47633146	NA	-0.57	-10.23	-0.45	4.23e-22	Subjective well-being;
LUAD	cis	rs9814567	0.712	rs4306900	chr3:134334327	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.75	13.17	0.54	1.88e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg10589385	chr1:150898437	SETDB1	0.39	7.39	0.34	8e-13	Tonsillectomy;
LUAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.67	-0.31	8.19e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1215050	0.904	rs890469	chr4:98923293	T/C	cg05340658	chr4:99064831	C4orf37	-0.4	-6.42	-0.3	3.6e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	cis	rs45430	1.000	rs408825	chr21:42743496	A/G	cg22778903	chr21:42741698	MX2	-0.41	-8.84	-0.39	2.66e-17	Melanoma;
LUAD	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.02	0.36	1.05e-14	Lung cancer;
LUAD	cis	rs240764	0.853	rs17303769	chr6:100967531	G/A	cg09795085	chr6:101329169	ASCC3	-0.42	-7.23	-0.33	2.21e-12	Neuroticism;
LUAD	cis	rs12545109	0.613	rs10958480	chr8:57278717	A/T	cg09654669	chr8:57350985	NA	-0.69	-9.61	-0.42	6.5e-20	Obesity-related traits;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg17461271	chr1:172717683	NA	-0.41	-6.68	-0.31	7.52e-11	Schizophrenia;
LUAD	cis	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg07460842	chr6:66804631	NA	0.97	14.16	0.57	1.55e-37	Exhaled nitric oxide output;
LUAD	cis	rs4268898	0.931	rs2111882	chr2:24434424	A/G	cg02683114	chr2:24398427	C2orf84	0.41	6.61	0.31	1.15e-10	Asthma;
LUAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13732083	chr21:47605072	C21orf56	0.56	9.68	0.43	3.64e-20	Testicular germ cell tumor;
LUAD	cis	rs4711350	1.000	rs2395447	chr6:33743174	T/C	cg07979401	chr6:33739406	LEMD2	-0.53	-8.67	-0.39	9.59e-17	Schizophrenia;
LUAD	cis	rs10129255	0.500	rs10143242	chr14:107137831	C/T	cg23076370	chr14:107095027	NA	-0.39	-7.78	-0.35	5.49e-14	Kawasaki disease;
LUAD	cis	rs7020830	0.928	rs11544336	chr9:37089150	A/G	cg14294708	chr9:37120828	ZCCHC7	0.83	16.42	0.62	3.15e-47	Schizophrenia;
LUAD	cis	rs7771547	0.574	rs9366907	chr6:36549554	G/C	cg07856975	chr6:36356162	ETV7	0.45	6.39	0.3	4.41e-10	Platelet distribution width;
LUAD	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg04450456	chr4:17643702	FAM184B	0.42	8.45	0.38	4.59e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs35771425	0.619	rs6689078	chr1:211476423	C/G	cg25617285	chr1:211431773	RCOR3	-0.49	-9.17	-0.41	2.08e-18	Educational attainment (years of education);
LUAD	cis	rs1595825	0.945	rs59553483	chr2:198855201	T/C	cg10547527	chr2:198650123	BOLL	-0.5	-7.25	-0.33	1.95e-12	Ulcerative colitis;
LUAD	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg11189052	chr15:85197271	WDR73	0.66	8.97	0.4	9.47e-18	Schizophrenia;
LUAD	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg02049041	chr17:27085579	C17orf63	0.66	8.72	0.39	6.27e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs8129326	0.718	rs11088282	chr21:35793107	C/T	cg07474852	chr4:123073612	NA	0.45	7.27	0.33	1.73e-12	Cancer;
LUAD	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg04398451	chr17:18023971	MYO15A	-0.78	-14.15	-0.57	1.76e-37	Total body bone mineral density;
LUAD	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg00495681	chr13:53174319	NA	0.72	14.27	0.57	5.65e-38	Lewy body disease;
LUAD	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg18138036	chr10:133769891	PPP2R2D	0.42	6.72	0.31	5.95e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg01065977	chr19:18549689	ISYNA1	-0.39	-7.58	-0.35	2.19e-13	Breast cancer;
LUAD	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg12011299	chr4:100065546	ADH4	0.63	13.04	0.54	6.76e-33	Alcohol dependence;
LUAD	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg23711669	chr6:146136114	FBXO30	-0.39	-6.58	-0.3	1.38e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg02158880	chr13:53174818	NA	0.48	8.31	0.37	1.28e-15	Lewy body disease;
LUAD	cis	rs1595825	0.891	rs2164070	chr2:198881730	G/C	cg11031976	chr2:198649780	BOLL	-0.47	-6.78	-0.31	4.09e-11	Ulcerative colitis;
LUAD	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg10518543	chr12:38710700	ALG10B	0.42	6.41	0.3	3.94e-10	Heart rate;
LUAD	cis	rs859767	0.501	rs10928507	chr2:135396631	C/T	cg12500956	chr2:135428796	TMEM163	0.28	7.31	0.34	1.32e-12	Neuroticism;
LUAD	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg07741184	chr6:167504864	NA	0.35	8.33	0.38	1.12e-15	Primary biliary cholangitis;
LUAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	7.21	0.33	2.66e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg22920501	chr2:26401640	FAM59B	-0.69	-9.58	-0.42	8.6e-20	Gut microbiome composition (summer);
LUAD	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.33	-7.48	-0.34	4.22e-13	Lung cancer;
LUAD	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg21475434	chr5:93447410	FAM172A	0.77	8.5	0.38	3.31e-16	Diabetic retinopathy;
LUAD	trans	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.72	-0.31	6.02e-11	Diabetic kidney disease;
LUAD	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg00339695	chr16:24857497	SLC5A11	0.54	9.77	0.43	1.9e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs12900413	0.687	rs28513927	chr15:90304471	T/G	cg24249390	chr15:90295951	MESP1	-0.35	-6.91	-0.32	1.84e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.55	-0.34	2.68e-13	Menopause (age at onset);
LUAD	cis	rs62400317	0.859	rs10948212	chr6:45156933	A/C	cg20913747	chr6:44695427	NA	-0.43	-6.71	-0.31	6.21e-11	Total body bone mineral density;
LUAD	cis	rs17253792	0.822	rs79921041	chr14:56090779	T/C	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs6738485	0.531	rs72819612	chr2:106846316	T/C	cg23109721	chr2:106886537	NA	-0.57	-7.23	-0.33	2.22e-12	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg02176678	chr2:219576539	TTLL4	0.62	12.5	0.52	9.56e-31	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.07e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9296092	0.538	rs112113649	chr6:33524529	A/G	cg13560919	chr6:33536144	NA	-0.89	-16.52	-0.63	1.19e-47	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg05340658	chr4:99064831	C4orf37	0.54	9.17	0.41	2.01e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg18446336	chr7:2847575	GNA12	-0.38	-7.09	-0.33	5.82e-12	Height;
LUAD	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.42	0.38	5.87e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg05368731	chr17:41323189	NBR1	0.95	19.49	0.69	7.48e-61	Menopause (age at onset);
LUAD	cis	rs7020830	0.898	rs308495	chr9:37277603	G/T	cg14294708	chr9:37120828	ZCCHC7	0.79	15.27	0.6	3.15e-42	Schizophrenia;
LUAD	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg06623918	chr6:96969491	KIAA0776	-0.88	-17.37	-0.65	2e-51	Headache;
LUAD	cis	rs2742417	1.000	rs2673057	chr3:45735730	A/T	cg10512202	chr3:45649293	LIMD1	0.37	6.61	0.31	1.14e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs2282300	0.667	rs10734405	chr11:30273750	T/C	cg06241208	chr11:30344200	C11orf46	0.59	7.76	0.35	6.4e-14	Morning vs. evening chronotype;
LUAD	cis	rs17739794	0.517	rs4439155	chr8:781047	C/T	cg01971667	chr8:817044	NA	-0.37	-8.01	-0.36	1.14e-14	Clozapine-induced cytotoxicity;
LUAD	cis	rs2357013	0.699	rs1510107	chr2:53160137	C/G	cg07782112	chr2:53107842	NA	-0.34	-6.76	-0.31	4.56e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs743757	0.878	rs6786523	chr3:50524221	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.47	-7.28	-0.33	1.69e-12	Diastolic blood pressure;
LUAD	cis	rs7301826	0.651	rs7132657	chr12:131285187	T/C	cg11011512	chr12:131303247	STX2	0.43	7.18	0.33	3.16e-12	Plasma plasminogen activator levels;
LUAD	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg21231944	chr12:82153410	PPFIA2	-0.35	-6.48	-0.3	2.53e-10	Resting heart rate;
LUAD	trans	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.53	8.02	0.36	1.04e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg10207240	chr12:122356781	WDR66	0.45	7.85	0.36	3.42e-14	Mean corpuscular volume;
LUAD	trans	rs2548003	0.565	rs2554899	chr5:28741116	C/T	cg12623145	chr2:97778927	ANKRD36	0.47	6.78	0.31	3.95e-11	Hip geometry;
LUAD	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.98	0.36	1.37e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs11048434	0.736	rs2041624	chr12:9111855	C/G	cg26114124	chr12:9217669	LOC144571	0.36	6.57	0.3	1.45e-10	Sjögren's syndrome;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27435660	chr10:5935953	FBXO18	0.53	6.6	0.31	1.27e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.03	-0.36	1.01e-14	Diabetic kidney disease;
LUAD	cis	rs796825	0.671	rs6774960	chr3:119999058	G/T	cg21790991	chr3:120137480	FSTL1	-0.38	-6.66	-0.31	8.59e-11	HIV-1 susceptibility;
LUAD	cis	rs62238980	0.614	rs79397654	chr22:32468027	C/T	cg00543991	chr22:32367038	NA	0.92	8.7	0.39	7.27e-17	Childhood ear infection;
LUAD	cis	rs12505328	0.966	rs13109367	chr4:174375331	A/G	cg12145043	chr4:174357286	NA	0.6	11.13	0.48	2.03e-25	Chin dimples;
LUAD	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg16205897	chr5:131564050	P4HA2	0.3	6.56	0.3	1.62e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs4888262	0.545	rs8050624	chr16:74686690	A/G	cg01733217	chr16:74700730	RFWD3	-0.51	-8.79	-0.39	3.78e-17	Testicular germ cell tumor;
LUAD	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	0.45	6.92	0.32	1.73e-11	IgG glycosylation;
LUAD	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg26752003	chr8:145688521	CYHR1	0.48	8.46	0.38	4.53e-16	Age at first birth;
LUAD	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22496380	chr5:211416	CCDC127	-0.94	-13.16	-0.54	2.2e-33	Breast cancer;
LUAD	cis	rs2408955	0.504	rs11168441	chr12:48576054	G/A	cg04545296	chr12:48745243	ZNF641	0.32	8.12	0.37	5.03e-15	Glycated hemoglobin levels;
LUAD	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg01689657	chr7:91764605	CYP51A1	0.29	6.75	0.31	4.95e-11	Breast cancer;
LUAD	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg16414030	chr3:133502952	NA	-0.61	-10.64	-0.46	1.35e-23	Iron status biomarkers;
LUAD	cis	rs12049351	0.774	rs1065674	chr1:229623338	C/T	cg11742688	chr1:229674241	ABCB10	0.41	6.9	0.32	1.94e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs2224391	0.628	rs2753224	chr6:5244864	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-8.21	-0.37	2.77e-15	Height;
LUAD	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.56	-9.47	-0.42	2.07e-19	Glomerular filtration rate;
LUAD	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg22681709	chr2:178499509	PDE11A	-0.43	-7.19	-0.33	2.95e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2742234	0.554	rs1270015	chr10:43698240	G/T	cg15436174	chr10:43711423	RASGEF1A	0.53	8.76	0.39	4.67e-17	Hirschsprung disease;
LUAD	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg03806693	chr22:41940476	POLR3H	-0.48	-7.07	-0.33	6.37e-12	Vitiligo;
LUAD	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg26597838	chr10:835615	NA	0.84	12.9	0.53	2.5e-32	Eosinophil percentage of granulocytes;
LUAD	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg17644776	chr2:200775616	C2orf69	0.52	6.51	0.3	2.13e-10	Schizophrenia;
LUAD	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	8.15	0.37	4.29e-15	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUAD	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg23281280	chr6:28129359	ZNF389	0.46	6.68	0.31	7.58e-11	Depression;
LUAD	cis	rs11217036	1	rs11217036	chr11:118675772	C/T	cg19308663	chr11:118741387	NA	0.45	6.46	0.3	2.82e-10	Allergy;
LUAD	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.74	-0.35	7.62e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg12311346	chr5:56204834	C5orf35	-0.44	-7.24	-0.33	2.15e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg20701182	chr2:24300061	SF3B14	0.67	7.42	0.34	6.54e-13	Lymphocyte counts;
LUAD	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.91	-13.23	-0.54	1.13e-33	Schizophrenia;
LUAD	cis	rs2580764	0.678	rs2588521	chr2:55203931	C/G	cg09592903	chr2:55203963	RTN4	0.47	10.91	0.47	1.35e-24	Mean platelet volume;
LUAD	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs2898857	0.504	rs7214496	chr17:47384611	C/G	cg11430096	chr6:110968061	CDK19	0.51	7.52	0.34	3.27e-13	Cancer;
LUAD	cis	rs6489882	0.867	rs4766673	chr12:113365161	C/T	cg20102336	chr12:113376681	OAS3	0.57	9.1	0.4	3.65e-18	Chronic lymphocytic leukemia;
LUAD	trans	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.05	-0.4	5.2e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7017914	1.000	rs7007450	chr8:71640269	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs12135894	0.562	rs6688969	chr1:3743391	C/T	cg13057898	chr1:3703894	LRRC47	0.5	9.05	0.4	5.13e-18	Mean corpuscular volume;
LUAD	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg10909506	chr17:38081995	ORMDL3	0.37	6.52	0.3	1.96e-10	Self-reported allergy;
LUAD	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg24818145	chr4:99064322	C4orf37	0.48	8.06	0.37	7.62e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg22442454	chr1:209979470	IRF6	0.53	6.37	0.3	4.94e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg21433313	chr16:3507492	NAT15	-0.7	-10.25	-0.45	3.71e-22	Tuberculosis;
LUAD	cis	rs2130392	1.000	rs3796689	chr4:185649866	C/A	cg04058563	chr4:185651563	MLF1IP	0.42	7.51	0.34	3.66e-13	Kawasaki disease;
LUAD	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.96	0.32	1.34e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-10.06	-0.44	1.72e-21	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg24558204	chr6:135376177	HBS1L	0.46	7.62	0.35	1.66e-13	Red blood cell count;
LUAD	cis	rs897984	0.721	rs28360557	chr16:30983260	A/C	cg02466173	chr16:30829666	NA	0.65	12.19	0.51	1.75e-29	Dementia with Lewy bodies;
LUAD	cis	rs748404	0.697	rs554001	chr15:43551919	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.35	0.34	1.03e-12	Lung cancer;
LUAD	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg16988262	chr1:15930761	NA	0.43	7.17	0.33	3.29e-12	Systolic blood pressure;
LUAD	cis	rs17102423	0.594	rs1953232	chr14:65570386	A/C	cg11161011	chr14:65562177	MAX	0.42	6.98	0.32	1.15e-11	Obesity-related traits;
LUAD	cis	rs910873	0.505	rs6087607	chr20:33197489	A/G	cg16810054	chr20:33298113	TP53INP2	-0.54	-8.05	-0.36	8.18e-15	Melanoma;
LUAD	trans	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg24644049	chr4:85504048	CDS1	0.89	7.23	0.33	2.21e-12	Skin colour saturation;
LUAD	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg10792982	chr14:105748885	BRF1	0.45	9.86	0.43	8.8e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs11696845	0.626	rs4810439	chr20:43377870	C/G	cg09357268	chr20:43379437	KCNK15	-0.38	-6.8	-0.31	3.66e-11	Obesity-related traits;
LUAD	cis	rs1451375	0.652	rs7779110	chr7:50625651	T/C	cg18232548	chr7:50535776	DDC	0.5	7.07	0.33	6.46e-12	Malaria;
LUAD	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg17173187	chr15:85201210	NMB	0.53	9.36	0.41	4.75e-19	Schizophrenia;
LUAD	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg10544611	chr16:67998164	SLC12A4	-0.56	-7.33	-0.34	1.19e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18876405	chr7:65276391	NA	0.44	6.94	0.32	1.47e-11	Aortic root size;
LUAD	cis	rs9462027	0.628	rs9469894	chr6:34774725	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.81	-0.39	3.16e-17	Systemic lupus erythematosus;
LUAD	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg16988262	chr1:15930761	NA	0.43	7.18	0.33	3.22e-12	Systolic blood pressure;
LUAD	trans	rs56283067	0.887	rs7349931	chr6:44783674	C/T	cg21694044	chr22:41215540	SLC25A17	0.52	6.41	0.3	3.95e-10	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg12432903	chr7:1882776	MAD1L1	-0.4	-6.61	-0.31	1.17e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg15445000	chr17:37608096	MED1	-0.45	-8.35	-0.38	9.73e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg07636037	chr3:49044803	WDR6	-0.48	-8.02	-0.36	1.03e-14	Menarche (age at onset);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg00673674	chr19:19144826	SFRS14;ARMC6	0.4	6.48	0.3	2.53e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1395	0.744	rs3739092	chr2:27462076	C/T	cg23587288	chr2:27483067	SLC30A3	-0.41	-7.71	-0.35	8.94e-14	Blood metabolite levels;
LUAD	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg16479474	chr6:28041457	NA	0.36	6.83	0.32	2.99e-11	Parkinson's disease;
LUAD	trans	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg01620082	chr3:125678407	NA	-1.1	-10.22	-0.45	4.5e-22	Depression;
LUAD	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.82	-0.39	3.03e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg20790798	chr5:1857306	NA	-0.45	-7.72	-0.35	8.44e-14	Cardiovascular disease risk factors;
LUAD	cis	rs62400317	0.859	rs62436760	chr6:45112604	T/C	cg18551225	chr6:44695536	NA	-0.55	-8.66	-0.39	1.01e-16	Total body bone mineral density;
LUAD	cis	rs11756438	0.572	rs1844963	chr6:119002679	C/G	cg21191810	chr6:118973309	C6orf204	0.47	9.16	0.41	2.22e-18	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2034088	0.965	rs11651340	chr17:425099	A/C	cg06217071	chr17:408420	NA	-0.52	-12.31	-0.51	5.78e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs1691799	0.806	rs1168319	chr12:66744857	T/A	cg16791601	chr12:66731901	HELB	-0.35	-6.42	-0.3	3.68e-10	White blood cell count (basophil);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg11752832	chr7:134001865	SLC35B4	-0.63	-6.4	-0.3	4.02e-10	Type 2 diabetes;
LUAD	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg00277334	chr10:82204260	NA	-0.62	-10.35	-0.45	1.62e-22	Post bronchodilator FEV1;
LUAD	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg04851639	chr8:1020857	NA	-0.42	-10.52	-0.46	3.67e-23	Schizophrenia;
LUAD	cis	rs11048434	0.736	rs11048338	chr12:9121362	C/G	cg26114124	chr12:9217669	LOC144571	0.37	6.74	0.31	5.31e-11	Sjögren's syndrome;
LUAD	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg13699009	chr12:122356056	WDR66	0.31	6.83	0.32	2.9e-11	Mean corpuscular volume;
LUAD	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	9.63	0.42	5.43e-20	Lung cancer in ever smokers;
LUAD	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg17063962	chr7:91808500	NA	-0.62	-10.69	-0.46	9.03e-24	Breast cancer;
LUAD	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg04287289	chr16:89883240	FANCA	0.75	6.54	0.3	1.74e-10	Skin colour saturation;
LUAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg24642844	chr7:1081250	C7orf50	-0.7	-10.59	-0.46	2.12e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3818285	0.544	rs9787456	chr10:111711822	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.7	-10.3	-0.45	2.41e-22	Superior crus of antihelix expression;
LUAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg16606324	chr3:10149918	C3orf24	0.7	11.51	0.49	7.19e-27	Alzheimer's disease;
LUAD	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg07211511	chr3:129823064	LOC729375	-0.43	-6.41	-0.3	3.9e-10	Blood pressure (smoking interaction);
LUAD	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06873352	chr17:61820015	STRADA	-0.5	-7.94	-0.36	1.83e-14	Height;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg21951070	chr3:185826924	ETV5	-0.41	-6.75	-0.31	5.02e-11	Schizophrenia;
LUAD	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg06191203	chr2:152266755	RIF1	-0.55	-8.96	-0.4	1.02e-17	Lung cancer;
LUAD	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg23281280	chr6:28129359	ZNF389	0.46	6.56	0.3	1.55e-10	Depression;
LUAD	cis	rs7551222	0.752	rs885012	chr1:204544001	C/A	cg20240347	chr1:204465584	NA	-0.33	-6.44	-0.3	3.25e-10	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg10729496	chr3:10149963	C3orf24	-0.6	-9.84	-0.43	1.05e-20	Alzheimer's disease;
LUAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.53	0.34	3.03e-13	Bipolar disorder;
LUAD	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg15448220	chr1:150897856	SETDB1	-0.41	-7.0	-0.32	9.88e-12	Tonsillectomy;
LUAD	cis	rs477692	0.583	rs2008387	chr10:131448764	C/T	cg05714579	chr10:131428358	MGMT	-0.47	-7.62	-0.35	1.66e-13	Response to temozolomide;
LUAD	cis	rs6906287	0.609	rs10457342	chr6:118948033	A/G	cg05564266	chr6:118973597	C6orf204	0.37	7.64	0.35	1.46e-13	Electrocardiographic conduction measures;
LUAD	cis	rs13095912	1.000	rs36066570	chr3:185314454	C/A	cg11274856	chr3:185301563	NA	0.37	7.48	0.34	4.47e-13	Systolic blood pressure;
LUAD	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg09323728	chr8:95962352	TP53INP1	-0.31	-6.97	-0.32	1.26e-11	Type 2 diabetes;
LUAD	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg14092988	chr3:52407081	DNAH1	0.44	8.97	0.4	9.48e-18	Bipolar disorder;
LUAD	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg13126279	chr21:47581558	C21orf56	-0.49	-8.1	-0.37	5.77e-15	Testicular germ cell tumor;
LUAD	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg11673840	chr17:47092156	IGF2BP1	0.36	7.09	0.33	5.8e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs4523957	0.890	rs9895551	chr17:2115922	C/G	cg16513277	chr17:2031491	SMG6	0.79	14.73	0.58	6.26e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg07169764	chr2:136633963	MCM6	-0.5	-6.66	-0.31	8.33e-11	Mosquito bite size;
LUAD	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.71	-12.16	-0.51	2.16e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.64	-9.55	-0.42	1.06e-19	IgG glycosylation;
LUAD	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg01475377	chr6:109611718	NA	-0.54	-10.34	-0.45	1.76e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs6701037	1.000	rs6677097	chr1:175123897	C/G	cg17845761	chr1:175162550	KIAA0040	-0.33	-8.63	-0.39	1.23e-16	Alcohol dependence;
LUAD	cis	rs4901869	0.902	rs2162491	chr14:59296247	C/T	cg02291164	chr14:59296302	NA	0.65	16.37	0.62	5.3e-47	Panic disorder;
LUAD	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg23262073	chr20:60523788	NA	-0.47	-7.59	-0.35	2.06e-13	Body mass index;
LUAD	cis	rs10078	1.000	rs10078	chr5:438102	G/T	cg08916839	chr5:415575	AHRR	0.57	8.12	0.37	5.23e-15	Fat distribution (HIV);
LUAD	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg02951883	chr7:2050386	MAD1L1	-0.75	-12.99	-0.53	1.09e-32	Bipolar disorder and schizophrenia;
LUAD	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-6.42	-0.3	3.61e-10	Gut microbiome composition (summer);
LUAD	cis	rs9948	0.655	rs78424221	chr2:97410399	A/G	cg20312557	chr2:97357134	FER1L5	-0.73	-8.19	-0.37	3.13e-15	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg00852783	chr1:26633632	UBXN11	0.41	7.3	0.33	1.4e-12	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.32	0.37	1.26e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg22532475	chr10:104410764	TRIM8	-0.48	-9.29	-0.41	8.29e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg03929089	chr4:120376271	NA	0.56	6.99	0.32	1.06e-11	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg03188948	chr7:1209495	NA	0.77	7.04	0.32	7.93e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.51	0.3	2.1e-10	Cardiac Troponin-T levels;
LUAD	cis	rs6025261	0.735	rs6099357	chr20:55508611	A/G	cg04763273	chr20:55502381	NA	0.33	6.62	0.31	1.1e-10	Verbal memory performance (delayed recall level);
LUAD	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg06873352	chr17:61820015	STRADA	-0.41	-6.99	-0.32	1.06e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg22906224	chr7:99728672	NA	-0.53	-9.2	-0.41	1.65e-18	Coronary artery disease;
LUAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg13047869	chr3:10149882	C3orf24	0.64	11.03	0.47	4.89e-25	Alzheimer's disease;
LUAD	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg19717773	chr7:2847554	GNA12	-0.48	-8.73	-0.39	5.91e-17	Height;
LUAD	trans	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg26043149	chr18:55253948	FECH	0.46	7.56	0.35	2.56e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg24579218	chr15:68104479	NA	-0.53	-8.49	-0.38	3.49e-16	Obesity;
LUAD	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg08807101	chr21:30365312	RNF160	-0.43	-7.4	-0.34	7.32e-13	Dental caries;
LUAD	cis	rs7264396	0.563	rs17092980	chr20:34289005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.26	-0.37	1.85e-15	Total cholesterol levels;
LUAD	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.73	-0.46	6.25e-24	Total body bone mineral density;
LUAD	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg02631126	chr6:28058918	ZSCAN12L1	-0.35	-7.33	-0.34	1.17e-12	Depression;
LUAD	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7617773	0.817	rs35414021	chr3:48293524	G/C	cg11946769	chr3:48343235	NME6	0.44	6.75	0.31	4.79e-11	Coronary artery disease;
LUAD	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg00383909	chr3:49044727	WDR6	0.42	6.4	0.3	4.23e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg07936489	chr17:37558343	FBXL20	0.42	6.63	0.31	1.04e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs6545883	0.929	rs10200055	chr2:61628017	T/A	cg15711740	chr2:61764176	XPO1	0.4	6.43	0.3	3.4e-10	Tuberculosis;
LUAD	cis	rs1595825	0.836	rs79748557	chr2:198567912	G/T	cg11031976	chr2:198649780	BOLL	-0.46	-6.87	-0.32	2.28e-11	Ulcerative colitis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00986762	chr1:36107072	PSMB2	-0.43	-6.42	-0.3	3.61e-10	Height;
LUAD	trans	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg00953403	chr17:74099816	EXOC7	-0.49	-7.32	-0.34	1.28e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs11671005	0.616	rs12980907	chr19:58956326	C/T	cg13877915	chr19:58951672	ZNF132	0.57	7.42	0.34	6.63e-13	Mean platelet volume;
LUAD	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg25811766	chr13:21894605	NA	-0.64	-7.45	-0.34	5.46e-13	White matter hyperintensity burden;
LUAD	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg09835421	chr16:68378352	PRMT7	-0.83	-8.65	-0.39	1.11e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg18854424	chr1:2615690	NA	0.43	9.39	0.42	3.64e-19	Ulcerative colitis;
LUAD	cis	rs3761218	0.738	rs4815604	chr20:3772913	C/T	cg02737268	chr20:3780182	CDC25B	0.27	6.41	0.3	3.96e-10	Bipolar disorder;
LUAD	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg06558623	chr16:89946397	TCF25	0.69	7.85	0.36	3.47e-14	Skin colour saturation;
LUAD	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	cis	rs760805	1.000	rs7517302	chr1:25254317	C/T	cg22509179	chr1:25234806	RUNX3	-0.75	-13.5	-0.55	9.05e-35	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg03709012	chr19:19516395	GATAD2A	0.53	7.0	0.32	1.04e-11	Nonalcoholic fatty liver disease;
LUAD	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-6.38	-0.3	4.61e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg04756594	chr16:24857601	SLC5A11	0.76	13.14	0.54	2.66e-33	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	1.000	rs73058832	chr2:198873214	G/T	cg10547527	chr2:198650123	BOLL	-0.5	-6.9	-0.32	1.96e-11	Ulcerative colitis;
LUAD	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg18512352	chr11:47633146	NA	-0.48	-8.42	-0.38	5.96e-16	Subjective well-being;
LUAD	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg02038168	chr22:39784481	NA	-0.57	-9.17	-0.41	2.07e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg14403583	chr14:105418241	AHNAK2	-0.44	-8.3	-0.37	1.42e-15	Rheumatoid arthritis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03811519	chr9:134001305	NUP214	-0.42	-6.65	-0.31	9.16e-11	Height;
LUAD	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18404041	chr3:52824283	ITIH1	-0.6	-12.47	-0.52	1.32e-30	Electroencephalogram traits;
LUAD	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg23933602	chr10:16859644	RSU1	-1.01	-21.79	-0.73	3.78e-71	Platelet distribution width;
LUAD	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg11822812	chr5:140052017	DND1	-0.44	-8.02	-0.36	1.04e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12155623	0.619	rs11775403	chr8:49877323	A/T	cg22283653	chr8:49824208	NA	0.43	7.99	0.36	1.27e-14	Sudden cardiac arrest;
LUAD	trans	rs853679	0.607	rs34218844	chr6:28290647	T/C	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.18	-0.48	1.34e-25	Depression;
LUAD	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.34	6.51	0.3	2.08e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg04450456	chr4:17643702	FAM184B	0.43	8.59	0.39	1.72e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.23	0.33	2.25e-12	Blood metabolite levels;
LUAD	cis	rs131777	0.545	rs131759	chr22:51015481	G/A	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	0.36	6.47	0.3	2.65e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs73206853	0.764	rs55991901	chr12:110962702	C/A	cg12870014	chr12:110450643	ANKRD13A	0.61	6.97	0.32	1.2e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs4763879	0.865	rs4763839	chr12:9882700	T/A	cg27502298	chr12:9555721	NA	0.43	6.66	0.31	8.33e-11	Type 1 diabetes;
LUAD	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg01324343	chr3:183735012	ABCC5	0.94	24.81	0.77	1.65e-84	Anterior chamber depth;
LUAD	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25730573	chr18:60987425	BCL2	-0.44	-6.68	-0.31	7.55e-11	Height;
LUAD	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-9.54	-0.42	1.14e-19	Bipolar disorder;
LUAD	cis	rs4253772	0.626	rs113658408	chr22:46646019	C/G	cg18190219	chr22:46762943	CELSR1	-0.57	-6.53	-0.3	1.86e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg25344623	chr2:136566232	LCT	-0.37	-7.5	-0.34	3.88e-13	Mosquito bite size;
LUAD	cis	rs877282	0.733	rs7092976	chr10:756358	G/A	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11644478	chr21:40555479	PSMG1	0.7	11.78	0.5	6.5e-28	Cognitive function;
LUAD	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	12.8	0.53	6.25e-32	Melanoma;
LUAD	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg04450456	chr4:17643702	FAM184B	0.41	8.17	0.37	3.72e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.67	-0.31	8.19e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10465746	0.967	rs12759527	chr1:84434425	T/C	cg10977910	chr1:84465055	TTLL7	0.51	8.21	0.37	2.71e-15	Obesity-related traits;
LUAD	cis	rs11671005	0.779	rs35631681	chr19:58999840	C/T	cg13877915	chr19:58951672	ZNF132	0.56	6.97	0.32	1.2e-11	Mean platelet volume;
LUAD	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg13390004	chr1:15929781	NA	0.46	8.29	0.37	1.53e-15	Systolic blood pressure;
LUAD	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg27446573	chr6:127587934	RNF146	0.45	6.64	0.31	9.54e-11	Breast cancer;
LUAD	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg12292205	chr6:26970375	C6orf41	0.38	6.73	0.31	5.57e-11	Schizophrenia;
LUAD	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg00530320	chr1:46809349	NSUN4	0.53	8.17	0.37	3.49e-15	Menopause (age at onset);
LUAD	trans	rs9929218	0.954	rs17715762	chr16:68828250	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.76	-0.53	8.79e-32	Colorectal cancer;
LUAD	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg26924012	chr15:45694286	SPATA5L1	1.02	19.06	0.68	6.2e-59	Homoarginine levels;
LUAD	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.86	-0.36	3.12e-14	Type 2 diabetes;
LUAD	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.68	-11.45	-0.49	1.28e-26	Menarche (age at onset);
LUAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg22029157	chr1:209979665	IRF6	0.75	12.08	0.51	4.4e-29	Cleft lip with or without cleft palate;
LUAD	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.05	-0.32	7.29e-12	Breast cancer;
LUAD	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg24130564	chr14:104152367	KLC1	-0.54	-9.61	-0.42	6.54e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2573652	1.000	rs7163481	chr15:100516916	C/G	cg09918751	chr15:100517450	ADAMTS17	0.49	8.68	0.39	8.76e-17	Height;
LUAD	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg16049864	chr8:95962084	TP53INP1	-0.54	-11.59	-0.49	3.72e-27	Type 2 diabetes;
LUAD	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg16479474	chr6:28041457	NA	0.47	7.88	0.36	2.75e-14	Depression;
LUAD	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg22676075	chr6:135203613	NA	0.41	7.59	0.35	2.13e-13	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg05340658	chr4:99064831	C4orf37	0.53	8.93	0.4	1.27e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg09526685	chr4:187126073	CYP4V2	-1.02	-10.65	-0.46	1.22e-23	Blood protein levels;
LUAD	trans	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-9.91	-0.43	5.75e-21	Endometrial cancer;
LUAD	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg03037974	chr15:76606532	NA	0.4	8.75	0.39	4.95e-17	Blood metabolite levels;
LUAD	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg15133208	chr4:90757351	SNCA	-0.46	-7.02	-0.32	8.97e-12	Neuroticism;
LUAD	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg23262073	chr20:60523788	NA	0.45	6.93	0.32	1.56e-11	Body mass index;
LUAD	cis	rs1997103	1.000	rs9642578	chr7:55400320	A/G	cg17469321	chr7:55412551	NA	0.65	11.07	0.47	3.41e-25	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6138458	0.701	rs6138474	chr20:25012427	T/A	cg26195577	chr20:24973756	C20orf3	0.7	11.5	0.49	8.42e-27	Blood protein levels;
LUAD	cis	rs314370	0.570	rs314324	chr7:100433794	C/T	cg10426581	chr7:100472382	SRRT	0.44	6.98	0.32	1.15e-11	Resting heart rate;
LUAD	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.46	0.38	4.49e-16	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8002861	0.905	rs80209017	chr13:44473182	T/C	cg17145862	chr1:211918768	LPGAT1	0.76	17.64	0.65	1.31e-52	Leprosy;
LUAD	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25427524	chr10:38739819	LOC399744	-0.78	-13.69	-0.55	1.47e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.09	-24.51	-0.77	3.35e-83	Ulcerative colitis;
LUAD	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg09537434	chr19:41945824	ATP5SL	0.54	8.5	0.38	3.22e-16	Height;
LUAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg20849893	chr7:64541193	NA	0.44	6.97	0.32	1.25e-11	Calcium levels;
LUAD	cis	rs6594713	0.577	rs6883547	chr5:112916853	A/G	cg12552261	chr5:112820674	MCC	-0.53	-8.57	-0.38	2.01e-16	Brain cytoarchitecture;
LUAD	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg11833968	chr6:79620685	NA	-0.42	-7.94	-0.36	1.82e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg17063962	chr7:91808500	NA	0.67	11.92	0.5	1.89e-28	Breast cancer;
LUAD	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg11766577	chr21:47581405	C21orf56	0.45	6.99	0.32	1.07e-11	Testicular germ cell tumor;
LUAD	cis	rs12949688	0.967	rs9910446	chr17:55821485	G/C	cg12582317	chr17:55822272	NA	0.36	7.32	0.34	1.29e-12	Schizophrenia;
LUAD	trans	rs8002861	0.619	rs1337203	chr13:44423621	T/G	cg17145862	chr1:211918768	LPGAT1	0.65	13.09	0.54	4.09e-33	Leprosy;
LUAD	cis	rs6484504	0.600	rs1323738	chr11:31344898	T/C	cg26647111	chr11:31128758	NA	0.44	7.83	0.36	4.05e-14	Red blood cell count;
LUAD	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg25324976	chr17:61989376	CSHL1	0.36	6.85	0.32	2.56e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg08999081	chr20:33150536	PIGU	-0.6	-13.13	-0.54	2.86e-33	Glomerular filtration rate (creatinine);
LUAD	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg17063962	chr7:91808500	NA	0.7	12.74	0.53	1.13e-31	Breast cancer;
LUAD	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg21724239	chr8:58056113	NA	0.61	7.97	0.36	1.51e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.4	0.34	7.35e-13	Bipolar disorder;
LUAD	cis	rs6594713	0.724	rs6883102	chr5:112757982	A/G	cg12552261	chr5:112820674	MCC	0.48	6.94	0.32	1.45e-11	Brain cytoarchitecture;
LUAD	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg06550200	chr5:1325588	CLPTM1L	0.73	14.23	0.57	7.6e-38	Lung cancer;
LUAD	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg25256661	chr17:7137939	DVL2	0.68	12.77	0.53	8.13e-32	Adiponectin levels;
LUAD	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg00147160	chr1:26503991	CNKSR1	0.38	8.78	0.39	3.95e-17	Height;
LUAD	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg16479474	chr6:28041457	NA	0.42	7.13	0.33	4.27e-12	Parkinson's disease;
LUAD	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg02017074	chr12:117425053	FBXW8	0.66	8.89	0.4	1.82e-17	Subcortical brain region volumes;Hippocampal volume;
LUAD	trans	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	17.21	0.64	1.1e-50	Exhaled nitric oxide output;
LUAD	cis	rs1997103	1.000	rs7779040	chr7:55412947	T/C	cg17469321	chr7:55412551	NA	0.66	11.21	0.48	1.05e-25	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg20368463	chr18:77673604	PQLC1	0.56	9.28	0.41	8.59e-19	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUAD	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg02782426	chr3:40428986	ENTPD3	0.42	8.8	0.39	3.59e-17	Renal cell carcinoma;
LUAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-8.23	-0.37	2.4e-15	Electroencephalogram traits;
LUAD	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg05082376	chr22:42548792	NA	-0.43	-7.63	-0.35	1.55e-13	Schizophrenia;
LUAD	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg07741184	chr6:167504864	NA	-0.29	-7.08	-0.33	6.16e-12	Crohn's disease;
LUAD	cis	rs758324	0.853	rs4705902	chr5:131150267	C/G	cg25547332	chr5:131281432	NA	0.43	6.52	0.3	2.03e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg19077165	chr18:44547161	KATNAL2	0.42	7.4	0.34	7.3e-13	Personality dimensions;
LUAD	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.891	rs60484833	chr2:198812181	C/T	cg11031976	chr2:198649780	BOLL	-0.47	-6.99	-0.32	1.06e-11	Ulcerative colitis;
LUAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg08219700	chr8:58056026	NA	0.42	6.36	0.3	5.17e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs11166629	1.000	rs4909332	chr8:135646340	T/C	cg27224718	chr8:135614730	ZFAT	0.6	10.64	0.46	1.43e-23	Smoking quantity;
LUAD	cis	rs7737355	0.812	rs10515455	chr5:130878789	C/T	cg06307176	chr5:131281290	NA	0.44	7.18	0.33	3.16e-12	Life satisfaction;
LUAD	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.46	-9.6	-0.42	7.13e-20	Total body bone mineral density;
LUAD	cis	rs9914578	0.943	rs7225843	chr17:2001825	A/G	cg16513277	chr17:2031491	SMG6	-0.7	-10.21	-0.44	5.02e-22	Body mass index;
LUAD	cis	rs8051149	0.744	rs4843714	chr16:87874336	G/A	cg10099957	chr16:87869757	SLC7A5	0.43	6.85	0.32	2.54e-11	Blood metabolite levels;
LUAD	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	9.4e-15	Tonsillectomy;
LUAD	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg17971929	chr21:40555470	PSMG1	-0.41	-6.49	-0.3	2.44e-10	Cognitive function;
LUAD	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg11317459	chr13:21872234	NA	1.25	21.34	0.72	4.16e-69	White matter hyperintensity burden;
LUAD	cis	rs7084921	0.608	rs11598979	chr10:101833720	C/T	cg19754520	chr10:101825118	CPN1	-0.33	-6.68	-0.31	7.37e-11	Bone mineral density;
LUAD	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg02569458	chr12:86230093	RASSF9	0.44	8.17	0.37	3.69e-15	Major depressive disorder;
LUAD	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg14689365	chr7:158441557	NCAPG2	0.45	7.75	0.35	6.77e-14	Height;
LUAD	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg12483005	chr1:23474871	LUZP1	0.54	9.12	0.41	3.06e-18	Height;
LUAD	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg23649088	chr2:200775458	C2orf69	0.62	7.77	0.35	6.15e-14	Schizophrenia;
LUAD	cis	rs62229266	0.609	rs12482541	chr21:37419743	A/G	cg08632701	chr21:37451849	NA	-0.38	-6.41	-0.3	3.84e-10	Mitral valve prolapse;
LUAD	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg27494647	chr7:150038898	RARRES2	0.42	6.98	0.32	1.14e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7814319	0.933	rs7827095	chr8:97239126	C/T	cg20787634	chr8:97240163	UQCRB	0.33	6.4	0.3	4.23e-10	Lung function (FVC);
LUAD	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg11317459	chr13:21872234	NA	1.28	20.25	0.7	3.02e-64	White matter hyperintensity burden;
LUAD	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	6.79	0.31	3.9e-11	Multiple sclerosis;
LUAD	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.43	-0.42	2.72e-19	Blood metabolite levels;
LUAD	cis	rs4845570	0.834	rs13376155	chr1:151721270	A/G	cg07092448	chr1:151763213	TDRKH	-0.71	-7.94	-0.36	1.89e-14	Coronary artery disease;
LUAD	cis	rs11585357	1.000	rs11203346	chr1:17600822	A/G	cg08277548	chr1:17600880	PADI3	-0.99	-14.8	-0.58	3.15e-40	Hair shape;
LUAD	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg08758996	chr17:66097529	LOC651250	-0.42	-6.97	-0.32	1.23e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg14008862	chr17:28927542	LRRC37B2	0.78	7.49	0.34	3.98e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg14895029	chr7:2775587	GNA12	-0.45	-7.36	-0.34	9.35e-13	Height;
LUAD	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.89	0.32	2.07e-11	Rheumatoid arthritis;
LUAD	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.67	-0.35	1.21e-13	Bipolar disorder;
LUAD	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03452623	chr4:187889614	NA	0.79	16.57	0.63	7.14e-48	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17818399	0.890	rs34752561	chr2:46850150	G/A	cg21681030	chr2:46777652	RHOQ	0.41	6.95	0.32	1.42e-11	Height;
LUAD	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg10523679	chr1:76189770	ACADM	0.71	9.9	0.43	6.59e-21	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg26811252	chr16:29126840	RRN3P2	0.62	10.45	0.45	6.77e-23	Menopause (age at onset);
LUAD	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.79	15.49	0.6	3.28e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg09365446	chr1:150670422	GOLPH3L	0.61	10.91	0.47	1.39e-24	Melanoma;
LUAD	cis	rs78761021	0.720	rs55735457	chr17:9796710	C/T	cg26853458	chr17:9805074	RCVRN	0.41	7.89	0.36	2.62e-14	Type 2 diabetes;
LUAD	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg05991184	chr2:219186017	PNKD	0.35	6.8	0.31	3.66e-11	Colorectal cancer;
LUAD	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg07541023	chr7:19748670	TWISTNB	0.56	8.02	0.36	1.02e-14	Night sleep phenotypes;
LUAD	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg23795048	chr12:9217529	LOC144571	-0.46	-8.57	-0.38	2.02e-16	Sjögren's syndrome;
LUAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg14582100	chr15:45693742	SPATA5L1	0.62	12.05	0.51	6.16e-29	Homoarginine levels;
LUAD	cis	rs7771547	0.508	rs1570368	chr6:36437136	C/G	cg07856975	chr6:36356162	ETV7	0.43	6.6	0.31	1.25e-10	Platelet distribution width;
LUAD	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg22875332	chr1:76189707	ACADM	0.71	11.88	0.5	2.87e-28	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg02951883	chr7:2050386	MAD1L1	-0.82	-14.05	-0.56	4.56e-37	Bipolar disorder and schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25010622	chr20:32700257	EIF2S2	-0.56	-6.73	-0.31	5.39e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.76	-0.31	4.73e-11	Height;
LUAD	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11890956	chr21:40555474	PSMG1	-0.82	-14.53	-0.58	4.24e-39	Cognitive function;
LUAD	cis	rs12995491	1.000	rs12995491	chr2:88527414	C/T	cg04511125	chr2:88470314	THNSL2	0.47	7.96	0.36	1.63e-14	Response to metformin (IC50);
LUAD	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg04155289	chr7:94953770	PON1	-0.54	-7.36	-0.34	9.91e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs80319144	1.000	rs116466468	chr2:159137557	T/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.64	0.31	9.75e-11	Restless legs syndrome;
LUAD	cis	rs11640533	0.901	rs2908792	chr16:53412419	A/G	cg09744766	chr16:53407421	NA	0.4	6.86	0.32	2.42e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg13271783	chr10:134563150	INPP5A	-0.41	-6.6	-0.31	1.24e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.15	-0.33	3.79e-12	Total cholesterol levels;
LUAD	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg21433313	chr16:3507492	NAT15	-0.75	-8.15	-0.37	4.2e-15	Tuberculosis;
LUAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.54	-0.42	1.18e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg17971929	chr21:40555470	PSMG1	0.54	8.47	0.38	4.18e-16	Cognitive function;
LUAD	cis	rs7107174	1.000	rs2512546	chr11:77957276	T/C	cg19901956	chr11:77921274	USP35	-0.47	-6.58	-0.3	1.44e-10	Testicular germ cell tumor;
LUAD	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.65	-7.21	-0.33	2.54e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg16479474	chr6:28041457	NA	0.46	7.82	0.36	4.18e-14	Depression;
LUAD	cis	rs7582720	0.943	rs72926799	chr2:203828192	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs4853525	1.000	rs4853525	chr2:191737464	T/C	cg27211696	chr2:191398769	TMEM194B	-0.4	-6.93	-0.32	1.62e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	trans	rs1325195	0.881	rs3813643	chr1:179070334	C/G	cg11624085	chr17:8464688	MYH10	0.43	6.86	0.32	2.53e-11	IgE grass sensitization;
LUAD	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23583168	chr7:148888333	NA	-1.0	-21.3	-0.72	5.88e-69	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.55e-11	Crohn's disease;
LUAD	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg18129748	chr3:49941408	MST1R	-0.4	-6.51	-0.3	2.14e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.3	0.33	1.44e-12	Bipolar disorder;
LUAD	trans	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg18187862	chr3:45730750	SACM1L	0.53	8.23	0.37	2.39e-15	Primary sclerosing cholangitis;
LUAD	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg24675056	chr1:15929824	NA	0.47	8.22	0.37	2.46e-15	Systolic blood pressure;
LUAD	cis	rs7799006	0.898	rs34418140	chr7:2278183	C/T	cg02951883	chr7:2050386	MAD1L1	-0.53	-8.02	-0.36	1.04e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.21	0.37	2.75e-15	Breast cancer;
LUAD	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg25319279	chr11:5960081	NA	-0.43	-7.48	-0.34	4.31e-13	DNA methylation (variation);
LUAD	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg17063962	chr7:91808500	NA	0.61	10.1	0.44	1.29e-21	Breast cancer;
LUAD	trans	rs6076960	0.811	rs6053960	chr20:6176778	T/C	cg21095983	chr6:86352623	SYNCRIP	0.53	8.8	0.39	3.55e-17	Smooth-surface caries;
LUAD	cis	rs6558530	0.932	rs7842425	chr8:1706041	G/T	cg19131313	chr8:1704013	NA	-0.45	-7.57	-0.35	2.3e-13	Systolic blood pressure;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg23224405	chr12:12715060	DUSP16	-0.61	-6.54	-0.3	1.78e-10	Type 2 diabetes;
LUAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg22105103	chr4:187893119	NA	0.56	12.32	0.51	5.38e-30	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25740925	chr13:95254690	GPR180	-0.41	-6.57	-0.3	1.45e-10	Height;
LUAD	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg00530320	chr1:46809349	NSUN4	0.52	8.1	0.37	5.93e-15	Menopause (age at onset);
LUAD	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.45	-0.34	5.31e-13	Breast cancer;
LUAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg22907277	chr7:1156413	C7orf50	0.49	8.25	0.37	2.07e-15	Longevity;Endometriosis;
LUAD	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg12034118	chr1:209979487	IRF6	0.58	6.46	0.3	2.92e-10	Coronary artery disease;
LUAD	trans	rs9393777	0.844	rs35909544	chr6:27163456	G/A	cg01620082	chr3:125678407	NA	-0.88	-9.23	-0.41	1.36e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg26338869	chr17:61819248	STRADA	-0.39	-6.58	-0.3	1.37e-10	Prudent dietary pattern;
LUAD	cis	rs6001027	0.540	rs1005529	chr22:38541266	T/C	cg25457927	chr22:38595422	NA	-0.4	-8.93	-0.4	1.27e-17	Melanoma;
LUAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg15117754	chr3:10150083	C3orf24	0.45	7.46	0.34	4.87e-13	Alzheimer's disease;
LUAD	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg02734326	chr4:10020555	SLC2A9	0.64	11.35	0.48	3.01e-26	Bone mineral density;
LUAD	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg15448220	chr1:150897856	SETDB1	0.54	9.16	0.41	2.24e-18	Melanoma;
LUAD	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg10596483	chr8:143751796	JRK	0.45	7.16	0.33	3.59e-12	Schizophrenia;
LUAD	trans	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg14917512	chr19:3094685	GNA11	-0.56	-6.64	-0.31	9.4e-11	Diabetic kidney disease;
LUAD	cis	rs72615157	0.539	rs2261360	chr7:99692993	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.59	8.83	0.39	2.71e-17	Lung function (FEV1/FVC);
LUAD	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg04546413	chr19:29218101	NA	0.7	10.3	0.45	2.36e-22	Methadone dose in opioid dependence;
LUAD	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg03161606	chr19:29218774	NA	0.55	7.31	0.33	1.38e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg06608945	chr2:219082296	ARPC2	0.48	8.36	0.38	8.84e-16	Colorectal cancer;
LUAD	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg21856205	chr7:94953877	PON1	-0.54	-7.42	-0.34	6.56e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg02734326	chr4:10020555	SLC2A9	0.49	7.34	0.34	1.08e-12	Blood metabolite levels;
LUAD	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.39	-7.58	-0.35	2.23e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9811920	0.535	rs792833	chr3:99475268	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.45	8.51	0.38	2.95e-16	Axial length;
LUAD	cis	rs2859741	0.967	rs535876	chr1:37484052	C/G	cg09363841	chr1:37513479	NA	-0.31	-7.71	-0.35	9.38e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs877282	0.853	rs12777155	chr10:754731	G/C	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs6969780	0.915	rs4722657	chr7:27157756	G/A	cg05579037	chr7:27184853	NA	0.46	6.62	0.31	1.06e-10	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUAD	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg09117114	chr16:67998030	SLC12A4	0.5	6.63	0.31	1.04e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2294693	0.898	rs6458195	chr6:40972498	A/T	cg14769373	chr6:40998127	UNC5CL	0.49	7.94	0.36	1.84e-14	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.81	-0.36	4.4e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg05368731	chr17:41323189	NBR1	0.98	20.41	0.7	6.23e-65	Menopause (age at onset);
LUAD	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg10755058	chr3:40428713	ENTPD3	0.44	8.55	0.38	2.21e-16	Renal cell carcinoma;
LUAD	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg09509183	chr1:209979624	IRF6	0.59	7.24	0.33	2.08e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	ch.11.42038R	chr11:967971	AP2A2	0.41	7.27	0.33	1.78e-12	Alzheimer's disease (late onset);
LUAD	cis	rs1451375	0.572	rs3807558	chr7:50571022	A/G	cg18232548	chr7:50535776	DDC	-0.64	-8.84	-0.4	2.52e-17	Malaria;
LUAD	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg15819921	chr19:927150	ARID3A	-0.47	-8.06	-0.36	7.8e-15	Life satisfaction;
LUAD	cis	rs4389656	0.857	rs274703	chr5:6728372	A/C	cg10857441	chr5:6722123	POLS	-0.47	-7.94	-0.36	1.87e-14	Coronary artery disease;
LUAD	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11890956	chr21:40555474	PSMG1	0.71	11.14	0.48	1.87e-25	Cognitive function;
LUAD	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg23254163	chr1:152506842	NA	0.25	7.13	0.33	4.3e-12	Hair morphology;
LUAD	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.45	8.27	0.37	1.76e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg25036284	chr2:26402008	FAM59B	-0.83	-11.78	-0.5	6.58e-28	Gut microbiome composition (summer);
LUAD	cis	rs3823572	0.542	rs28654576	chr7:133624445	A/G	cg03336402	chr7:133662267	EXOC4	0.46	8.15	0.37	4.2e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg06453172	chr10:134556979	INPP5A	0.76	11.24	0.48	8.24e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs5167	0.781	rs11672748	chr19:45490192	A/G	cg13119609	chr19:45449297	APOC2	0.41	7.54	0.34	2.92e-13	Blood protein levels;
LUAD	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg21918786	chr6:109611834	NA	-0.59	-10.9	-0.47	1.45e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg01689657	chr7:91764605	CYP51A1	0.3	7.1	0.33	5.48e-12	Breast cancer;
LUAD	cis	rs7027203	1.000	rs7027203	chr9:96562563	A/C	cg14396892	chr9:96623032	NA	0.4	7.21	0.33	2.51e-12	DNA methylation (variation);
LUAD	cis	rs2835872	0.709	rs1709819	chr21:39036115	A/C	cg06728970	chr21:39037746	KCNJ6	0.4	7.69	0.35	1.02e-13	Electroencephalographic traits in alcoholism;
LUAD	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg07507251	chr3:52567010	NT5DC2	0.36	7.05	0.32	7.26e-12	Bipolar disorder;
LUAD	cis	rs4285028	0.699	rs2689285	chr3:121586486	G/A	cg11130432	chr3:121712080	ILDR1	0.55	7.94	0.36	1.78e-14	Multiple sclerosis;
LUAD	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg04063615	chr12:132293388	NA	-0.39	-6.84	-0.32	2.71e-11	Migraine;
LUAD	trans	rs11039798	0.614	rs8188910	chr11:48825740	C/T	cg02254774	chr11:50257496	LOC441601	0.53	6.68	0.31	7.63e-11	Axial length;
LUAD	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.22	-0.37	2.45e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.13	-0.37	4.97e-15	Personality dimensions;
LUAD	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg01689657	chr7:91764605	CYP51A1	0.37	9.0	0.4	7.83e-18	Breast cancer;
LUAD	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg07570687	chr10:102243282	WNT8B	-0.42	-6.5	-0.3	2.25e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg24733560	chr20:60626293	TAF4	-0.43	-7.25	-0.33	2e-12	Body mass index;
LUAD	cis	rs4924997	0.772	rs2018675	chr17:19441531	A/G	cg19949948	chr17:19361230	NA	0.36	7.23	0.33	2.3e-12	Lymphocyte counts;
LUAD	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg11494091	chr17:61959527	GH2	0.44	8.24	0.37	2.22e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9826463	0.941	rs73238201	chr3:142204728	C/T	cg20824294	chr3:142316082	PLS1	0.36	6.48	0.3	2.54e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6543140	0.855	rs4851591	chr2:103077423	T/C	cg04239558	chr2:103089729	SLC9A4	0.36	7.34	0.34	1.11e-12	Blood protein levels;
LUAD	cis	rs6688613	0.545	rs10800270	chr1:166827602	A/T	cg07049167	chr1:166818506	POGK	0.59	9.33	0.41	6.2e-19	Refractive astigmatism;
LUAD	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg20701182	chr2:24300061	SF3B14	0.53	6.48	0.3	2.6e-10	Lymphocyte counts;
LUAD	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg19163074	chr7:65112434	INTS4L2	0.46	7.07	0.33	6.41e-12	Aortic root size;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg01154537	chr10:95462167	C10orf4	0.42	7.25	0.33	1.99e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg01849466	chr14:104193079	ZFYVE21	0.53	9.91	0.43	5.77e-21	Schizophrenia;
LUAD	cis	rs938554	0.612	rs13113918	chr4:9998493	A/G	cg00071950	chr4:10020882	SLC2A9	0.6	9.35	0.41	5.05e-19	Blood metabolite levels;
LUAD	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg01324343	chr3:183735012	ABCC5	0.95	26.01	0.78	9.2e-90	Anterior chamber depth;
LUAD	cis	rs1595825	0.945	rs73058813	chr2:198858268	A/G	cg00982548	chr2:198649783	BOLL	-0.63	-8.95	-0.4	1.09e-17	Ulcerative colitis;
LUAD	cis	rs72681920	0.881	rs56948765	chr4:100225336	G/A	cg12011299	chr4:100065546	ADH4	-0.6	-6.37	-0.3	4.81e-10	Alcohol dependence;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10317628	chr1:117113342	CD58	-0.43	-6.58	-0.3	1.38e-10	Height;
LUAD	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.94	0.32	1.5e-11	Colorectal cancer;
LUAD	cis	rs2688608	0.647	rs2227575	chr10:75677840	C/A	cg23231163	chr10:75533350	FUT11	-0.38	-6.87	-0.32	2.35e-11	Inflammatory bowel disease;
LUAD	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg19318889	chr4:1322082	MAEA	0.47	7.83	0.36	3.98e-14	Obesity-related traits;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08462117	chr11:62432583	SNORA57;C11orf48;METTL12	-0.38	-6.4	-0.3	4.05e-10	Cancer;
LUAD	cis	rs6723226	0.766	rs398290	chr2:32503526	T/C	cg02381751	chr2:32503542	YIPF4	0.42	6.93	0.32	1.59e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12564526	chr7:66767603	PMS2L4;STAG3L4	-0.53	-6.37	-0.3	4.9e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10504073	0.647	rs12549138	chr8:50007203	C/T	cg00325661	chr8:49890786	NA	0.46	10.31	0.45	2.29e-22	Blood metabolite ratios;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04127825	chr1:167503222	NA	-0.4	-6.5	-0.3	2.33e-10	Height;
LUAD	cis	rs3823572	0.542	rs61286514	chr7:133630693	G/A	cg03336402	chr7:133662267	EXOC4	0.41	7.57	0.35	2.29e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14875093	chr19:38398164	WDR87;SIPA1L3	0.43	7.02	0.32	8.79e-12	Bilirubin levels;
LUAD	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg12483801	chr4:183727862	NA	0.55	6.72	0.31	5.72e-11	Pediatric autoimmune diseases;
LUAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg00280220	chr17:61926910	NA	0.37	7.06	0.32	6.84e-12	Prudent dietary pattern;
LUAD	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg07507251	chr3:52567010	NT5DC2	-0.37	-7.26	-0.33	1.89e-12	Bipolar disorder;
LUAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg19130645	chr7:65235666	NA	0.48	8.17	0.37	3.49e-15	Calcium levels;
LUAD	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg02527881	chr3:46936655	PTH1R	-0.45	-8.67	-0.39	9.46e-17	Colorectal cancer;
LUAD	cis	rs2908197	0.737	rs6465097	chr7:75972914	T/C	cg24580635	chr7:76178542	LOC100133091	-0.42	-6.71	-0.31	6.35e-11	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs6743376	0.556	rs1374285	chr2:113818738	G/A	cg09040174	chr2:113837401	NA	0.52	8.02	0.36	1.02e-14	Inflammatory biomarkers;
LUAD	cis	rs4824093	0.610	rs74371371	chr22:50314074	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.87	-7.71	-0.35	9.29e-14	Amyotrophic lateral sclerosis (sporadic);
LUAD	trans	rs7746199	0.736	rs13212093	chr6:27606716	C/T	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.65	-0.46	1.24e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.88	-0.36	2.79e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs17789174	0.951	rs12596553	chr16:85104752	G/T	cg01715842	chr16:85045600	ZDHHC7	-0.39	-6.56	-0.3	1.58e-10	Dysphagia;
LUAD	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg00277334	chr10:82204260	NA	-0.63	-10.54	-0.46	3.23e-23	Post bronchodilator FEV1;
LUAD	cis	rs73198271	0.545	rs78352360	chr8:8627831	G/A	cg01851573	chr8:8652454	MFHAS1	0.58	7.8	0.35	4.89e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg09796270	chr17:17721594	SREBF1	0.37	7.58	0.35	2.28e-13	Total body bone mineral density;
LUAD	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg05340658	chr4:99064831	C4orf37	-0.46	-7.66	-0.35	1.26e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs28595532	1.000	rs115004746	chr4:119642137	C/T	cg14228332	chr4:119757509	SEC24D	0.78	7.21	0.33	2.54e-12	Cannabis dependence symptom count;
LUAD	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg23262073	chr20:60523788	NA	-0.36	-6.4	-0.3	4.04e-10	Body mass index;
LUAD	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	8.55	0.38	2.33e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10611753	chr15:55489541	RSL24D1	-0.52	-6.39	-0.3	4.49e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7809950	0.911	rs1015411	chr7:107135612	C/T	cg23024343	chr7:107201750	COG5	-0.75	-12.79	-0.53	6.68e-32	Coronary artery disease;
LUAD	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg02461776	chr11:598696	PHRF1	0.46	6.76	0.31	4.51e-11	Systemic lupus erythematosus;
LUAD	trans	rs7246760	0.867	rs61011126	chr19:9814421	A/C	cg02900749	chr2:68251473	NA	-0.6	-6.64	-0.31	9.81e-11	Pursuit maintenance gain;
LUAD	cis	rs17401966	0.898	rs12757288	chr1:10323921	T/C	cg15208524	chr1:10270712	KIF1B	0.44	6.83	0.32	2.9100000000000002e-11	Hepatocellular carcinoma;
LUAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg15147215	chr3:52552868	STAB1	-0.49	-9.23	-0.41	1.35e-18	Electroencephalogram traits;
LUAD	trans	rs10411161	0.702	rs17778790	chr19:52399559	C/T	cg22319618	chr22:45562946	NUP50	-0.66	-9.44	-0.42	2.52e-19	Breast cancer;
LUAD	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg04287289	chr16:89883240	FANCA	0.77	6.73	0.31	5.39e-11	Skin colour saturation;
LUAD	cis	rs4711336	0.638	rs4713664	chr6:33674198	A/G	cg13859433	chr6:33739653	LEMD2	-0.29	-6.87	-0.32	2.29e-11	Height;
LUAD	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.49	-0.3	2.4e-10	Alzheimer's disease (late onset);
LUAD	trans	rs1728785	1.000	rs1364109	chr16:68595505	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.31	0.45	2.19e-22	Ulcerative colitis;
LUAD	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg17063962	chr7:91808500	NA	-0.66	-11.33	-0.48	3.71e-26	Breast cancer;
LUAD	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg14228332	chr4:119757509	SEC24D	0.81	7.56	0.34	2.59e-13	Cannabis dependence symptom count;
LUAD	trans	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8060686	0.623	rs74024145	chr16:68153382	G/C	cg05110241	chr16:68378359	PRMT7	-0.56	-7.2	-0.33	2.72e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1451375	0.785	rs10278338	chr7:50630270	C/T	cg18232548	chr7:50535776	DDC	0.54	8.67	0.39	9.36e-17	Malaria;
LUAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08439880	chr3:133502540	NA	-0.48	-9.28	-0.41	8.81e-19	Iron status biomarkers;
LUAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg26354017	chr1:205819088	PM20D1	0.73	14.81	0.58	2.72e-40	Menarche (age at onset);
LUAD	cis	rs11112613	0.713	rs11112586	chr12:105939816	C/T	cg03607813	chr12:105948248	NA	0.79	11.1	0.48	2.59e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg22963979	chr7:1858916	MAD1L1	-0.62	-10.55	-0.46	2.86e-23	Bipolar disorder and schizophrenia;
LUAD	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg18033235	chr19:16989681	SIN3B	0.56	6.77	0.31	4.42e-11	Colorectal cancer;
LUAD	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.26	-0.33	1.92e-12	Bladder cancer;
LUAD	cis	rs9581857	0.685	rs9319368	chr13:28042275	T/G	cg22138327	chr13:27999177	GTF3A	0.84	9.65	0.42	4.63e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg11871910	chr12:69753446	YEATS4	0.65	10.96	0.47	8.86e-25	Blood protein levels;
LUAD	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	7.89	0.36	2.58e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg14092988	chr3:52407081	DNAH1	0.38	7.59	0.35	2.01e-13	Electroencephalogram traits;
LUAD	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	trans	rs2774920	0.614	rs12091344	chr1:94633910	C/T	cg24762501	chr19:51530751	KLK11	-0.69	-6.77	-0.31	4.32e-11	D-dimer levels;
LUAD	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg01097406	chr16:89675127	NA	-0.3	-6.55	-0.3	1.69e-10	Hemoglobin concentration;
LUAD	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg08798685	chr6:27730294	NA	-0.44	-7.05	-0.32	7.22e-12	Parkinson's disease;
LUAD	cis	rs2777491	0.574	rs72739644	chr15:41719706	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.12	-23.61	-0.75	3.24e-79	Ulcerative colitis;
LUAD	trans	rs7395662	0.658	rs11493304	chr11:48895591	C/T	cg00717180	chr2:96193071	NA	-0.4	-7.55	-0.34	2.72e-13	HDL cholesterol;
LUAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.83	0.47	2.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg17264618	chr3:40429014	ENTPD3	0.38	8.59	0.39	1.74e-16	Renal cell carcinoma;
LUAD	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg13385794	chr1:248469461	NA	0.25	6.95	0.32	1.35e-11	Common traits (Other);
LUAD	cis	rs55788414	0.932	rs729265	chr16:81183600	G/A	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.87	-0.36	3.02e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg21220214	chr8:57350948	NA	-0.59	-8.73	-0.39	6.17e-17	Obesity-related traits;
LUAD	cis	rs684232	0.835	rs12450003	chr17:519015	T/C	cg15660573	chr17:549704	VPS53	-0.48	-7.78	-0.35	5.75e-14	Prostate cancer;
LUAD	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg00933542	chr6:150070202	PCMT1	0.45	9.8	0.43	1.48e-20	Lung cancer;
LUAD	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg24640516	chr1:210004059	C1orf107	0.37	6.74	0.31	5.36e-11	Orofacial clefts;
LUAD	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg04450456	chr4:17643702	FAM184B	0.39	7.63	0.35	1.58e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10197940	0.578	rs2444264	chr2:152310928	G/T	cg06191203	chr2:152266755	RIF1	0.44	6.8	0.31	3.67e-11	Lung cancer;
LUAD	trans	rs9467603	0.547	rs9295661	chr6:25450026	A/C	cg01620082	chr3:125678407	NA	-0.81	-6.9	-0.32	1.89e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg01444801	chr10:135216882	MTG1	-0.54	-7.09	-0.33	5.65e-12	Systemic lupus erythematosus;
LUAD	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg02551604	chr5:131831745	NA	-0.61	-10.02	-0.44	2.39e-21	Asthma (sex interaction);
LUAD	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg22482690	chr17:47019901	SNF8	0.46	8.98	0.4	9.16e-18	Type 2 diabetes;
LUAD	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg14345882	chr6:26364793	BTN3A2	0.65	6.46	0.3	2.88e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg10518543	chr12:38710700	ALG10B	-0.43	-7.05	-0.32	7.31e-12	Morning vs. evening chronotype;
LUAD	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg24531977	chr5:56204891	C5orf35	0.56	9.17	0.41	2.16e-18	Coronary artery disease;
LUAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.53	-7.29	-0.33	1.52e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg17605604	chr5:102612899	C5orf30	-0.39	-6.49	-0.3	2.46e-10	Subcortical brain region volumes;
LUAD	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.04	-0.36	9.26e-15	Breast cancer;
LUAD	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg25588787	chr5:154027256	NA	-0.53	-6.86	-0.32	2.48e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg20607798	chr8:58055168	NA	0.67	8.77	0.39	4.44e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg13385794	chr1:248469461	NA	0.26	6.89	0.32	2.04e-11	Common traits (Other);
LUAD	cis	rs72928364	1.000	rs62275203	chr3:100707947	T/C	cg10123952	chr3:100791384	NA	0.62	7.12	0.33	4.78e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg24558204	chr6:135376177	HBS1L	0.45	7.82	0.36	4.18e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs11771526	0.901	rs11760534	chr7:32262966	C/T	cg13207630	chr7:32358064	NA	0.64	7.75	0.35	6.72e-14	Body mass index;
LUAD	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.57	8.13	0.37	4.79e-15	Platelet count;
LUAD	cis	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg00071950	chr4:10020882	SLC2A9	0.45	6.97	0.32	1.19e-11	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg17200465	chr3:40428508	ENTPD3	0.27	6.73	0.31	5.51e-11	Renal cell carcinoma;
LUAD	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg05110241	chr16:68378359	PRMT7	-0.84	-9.13	-0.41	2.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11249608	0.548	rs6859936	chr5:178451214	T/C	cg01312482	chr5:178451176	ZNF879	-0.44	-6.81	-0.31	3.36e-11	Pubertal anthropometrics;
LUAD	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg00769240	chr8:12517080	NA	-0.39	-6.49	-0.3	2.45e-10	Blood pressure (smoking interaction);
LUAD	cis	rs7586879	0.789	rs13382979	chr2:25131736	G/A	cg04586622	chr2:25135609	ADCY3	0.36	7.26	0.33	1.93e-12	Body mass index;
LUAD	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.35	-7.43	-0.34	5.92e-13	Hemoglobin concentration;
LUAD	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg18827107	chr12:86230957	RASSF9	-0.7	-12.92	-0.53	2.12e-32	Major depressive disorder;
LUAD	cis	rs2554380	1.000	rs2730076	chr15:84315985	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.59	-9.06	-0.4	4.88e-18	Height;
LUAD	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.12	-0.54	3.15e-33	Breast cancer;
LUAD	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg14558114	chr2:88469736	THNSL2	0.68	6.99	0.32	1.07e-11	Plasma clusterin levels;
LUAD	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg02574844	chr11:5959923	NA	-0.36	-6.38	-0.3	4.68e-10	DNA methylation (variation);
LUAD	cis	rs12760731	0.720	rs1397185	chr1:178381698	G/A	cg00404053	chr1:178313656	RASAL2	0.62	7.95	0.36	1.68e-14	Obesity-related traits;
LUAD	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg11050988	chr7:1952600	MAD1L1	-0.37	-7.52	-0.34	3.26e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg11062466	chr8:58055876	NA	0.66	8.67	0.39	9.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.94e-11	Hepatitis;
LUAD	trans	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg11693508	chr17:37793320	STARD3	0.55	7.62	0.35	1.72e-13	Bipolar disorder;
LUAD	cis	rs78707713	0.841	rs77784890	chr10:71199295	G/C	cg12610070	chr10:71211762	TSPAN15	-0.41	-7.34	-0.34	1.08e-12	Venous thromboembolism;
LUAD	cis	rs7937890	0.559	rs2575838	chr11:14498221	C/G	cg06199346	chr11:14280333	SPON1	-0.32	-6.41	-0.3	3.86e-10	Mitochondrial DNA levels;
LUAD	cis	rs113835537	0.529	rs75003264	chr11:66256099	G/A	cg24851651	chr11:66362959	CCS	0.58	9.84	0.43	1.06e-20	Airway imaging phenotypes;
LUAD	trans	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.99	-0.36	1.25e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6062509	0.868	rs3761123	chr20:62342468	G/A	cg21849932	chr20:62369462	LIME1	-0.47	-7.41	-0.34	7.12e-13	Prostate cancer;
LUAD	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.32	6.68	0.31	7.44e-11	Obesity-related traits;
LUAD	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg12698349	chr2:225449008	CUL3	0.86	17.39	0.65	1.8e-51	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg06784218	chr1:46089804	CCDC17	0.51	11.27	0.48	6.21e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg07537917	chr2:241836409	C2orf54	-0.3	-8.46	-0.38	4.56e-16	Urinary metabolites;
LUAD	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg04218760	chr10:45406644	TMEM72	-0.29	-7.27	-0.33	1.73e-12	Mean corpuscular volume;
LUAD	cis	rs6988985	0.703	rs7016594	chr8:143950352	G/A	cg10324643	chr8:143916377	GML	0.31	6.47	0.3	2.64e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg04800585	chr6:26043546	HIST1H2BB	0.5	8.24	0.37	2.17e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18404041	chr3:52824283	ITIH1	-0.53	-10.36	-0.45	1.51e-22	Electroencephalogram traits;
LUAD	cis	rs7100689	0.622	rs10736344	chr10:82133955	T/C	cg00277334	chr10:82204260	NA	-0.63	-10.54	-0.46	3.26e-23	Post bronchodilator FEV1;
LUAD	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.93	0.32	1.54e-11	Hip circumference adjusted for BMI;
LUAD	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg15704280	chr7:45808275	SEPT13	-1.0	-20.27	-0.7	2.58e-64	Height;
LUAD	cis	rs3739034	0.652	rs4953922	chr2:135402521	A/G	cg12500956	chr2:135428796	TMEM163	0.39	7.48	0.34	4.48e-13	Gut microbiome composition (winter);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02728748	chr3:135913490	MSL2	-0.46	-7.03	-0.32	8.46e-12	Height;
LUAD	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg05110241	chr16:68378359	PRMT7	-0.69	-7.84	-0.36	3.72e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg05283184	chr6:79620031	NA	-0.61	-12.38	-0.52	3.04e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg18105134	chr13:113819100	PROZ	-1.05	-19.56	-0.69	3.66e-61	Platelet distribution width;
LUAD	cis	rs62388641	0.539	rs56304710	chr6:1542576	C/T	cg01806741	chr6:1527072	NA	-0.4	-6.7	-0.31	6.74e-11	Daytime sleep phenotypes;
LUAD	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg02569458	chr12:86230093	RASSF9	0.42	7.69	0.35	1.03e-13	Major depressive disorder;
LUAD	cis	rs6484504	0.532	rs7121949	chr11:31288160	G/T	cg26647111	chr11:31128758	NA	-0.45	-8.01	-0.36	1.09e-14	Red blood cell count;
LUAD	cis	rs354033	0.837	rs6945729	chr7:149195972	A/T	cg24335155	chr7:149193227	ZNF746	0.39	6.51	0.3	2.18e-10	Multiple sclerosis;
LUAD	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg26924012	chr15:45694286	SPATA5L1	0.99	18.3	0.66	1.64e-55	Homoarginine levels;
LUAD	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.58e-12	Breast cancer;
LUAD	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg03340356	chr1:67600835	NA	0.41	7.37	0.34	8.88e-13	Psoriasis;
LUAD	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg02423579	chr7:2872169	GNA12	-0.87	-15.44	-0.6	5.77e-43	Height;
LUAD	cis	rs6446731	0.734	rs9996868	chr4:3275484	C/T	cg08886695	chr4:3369023	RGS12	-0.42	-6.71	-0.31	6.22e-11	Mean platelet volume;
LUAD	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg18132916	chr6:79620363	NA	-0.45	-7.81	-0.36	4.51e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg11189052	chr15:85197271	WDR73	0.58	7.21	0.33	2.62e-12	Schizophrenia;
LUAD	cis	rs16882447	0.607	rs28701873	chr5:53489782	G/A	cg06461071	chr5:53490839	ARL15	0.42	7.33	0.34	1.21e-12	Systolic blood pressure (dietary potassium intake interaction);
LUAD	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs2282300	0.739	rs1616223	chr11:30338783	A/C	cg06241208	chr11:30344200	C11orf46	-0.55	-7.14	-0.33	4.22e-12	Morning vs. evening chronotype;
LUAD	cis	rs4481887	0.927	rs4409694	chr1:248485498	C/T	cg00666640	chr1:248458726	OR2T12	0.29	7.0	0.32	1.01e-11	Common traits (Other);
LUAD	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.12	0.48	2.26e-25	Height;
LUAD	cis	rs6761276	1.000	rs6761276	chr2:113832312	C/T	cg02343335	chr2:113785852	IL1F8	0.34	6.85	0.32	2.64e-11	Protein quantitative trait loci;
LUAD	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg20203395	chr5:56204925	C5orf35	-0.81	-11.89	-0.5	2.57e-28	Initial pursuit acceleration;
LUAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg21724239	chr8:58056113	NA	0.73	9.6	0.42	7.28e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2554380	0.891	rs1896816	chr15:84299371	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.52	-7.94	-0.36	1.79e-14	Height;
LUAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2230307	0.656	rs11166389	chr1:100466279	G/A	cg20868668	chr1:100435035	SLC35A3	0.63	7.58	0.35	2.23e-13	Carotid intima media thickness;
LUAD	cis	rs12545109	0.837	rs1437277	chr8:57356734	T/C	cg09654669	chr8:57350985	NA	-0.71	-9.99	-0.44	3e-21	Obesity-related traits;
LUAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg21226059	chr5:178986404	RUFY1	0.76	13.54	0.55	6.01e-35	Lung cancer;
LUAD	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-7.87	-0.36	2.91e-14	Blood metabolite levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25978167	chr4:57301353	PAICS;PPAT	-0.45	-7.15	-0.33	3.72e-12	Height;
LUAD	cis	rs9323205	0.954	rs4258524	chr14:51638739	A/T	cg23942311	chr14:51606299	NA	-0.59	-10.07	-0.44	1.61e-21	Cancer;
LUAD	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.95	0.32	1.39e-11	Cardiac Troponin-T levels;
LUAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg11494091	chr17:61959527	GH2	0.75	18.75	0.67	1.62e-57	Prudent dietary pattern;
LUAD	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg16405210	chr4:1374714	KIAA1530	-0.43	-7.11	-0.33	4.88e-12	Longevity;
LUAD	cis	rs36051895	0.659	rs57204002	chr9:5062610	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-6.97	-0.32	1.24e-11	Pediatric autoimmune diseases;
LUAD	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg22823121	chr1:150693482	HORMAD1	0.44	8.81	0.39	3.22e-17	Melanoma;
LUAD	cis	rs7937682	0.562	rs12275761	chr11:111367083	T/A	cg09085632	chr11:111637200	PPP2R1B	0.43	7.26	0.33	1.93e-12	Primary sclerosing cholangitis;
LUAD	cis	rs10170846	0.572	rs12620873	chr2:223419528	A/C	cg25565276	chr2:223520875	FARSB	0.45	6.68	0.31	7.43e-11	Schizophrenia (inflammation and infection response interaction);
LUAD	cis	rs7474896	0.526	rs1742235	chr10:38052256	T/C	cg25427524	chr10:38739819	LOC399744	-0.61	-8.68	-0.39	8.4e-17	Obesity (extreme);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	ch.7.1264585R	chr7:55212640	EGFR	-0.39	-6.43	-0.3	3.46e-10	Cancer;
LUAD	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg17279839	chr7:150038598	RARRES2	0.43	7.5	0.34	3.83e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs667920	0.573	rs9682783	chr3:136539689	T/C	cg15507776	chr3:136538369	TMEM22	0.65	10.57	0.46	2.44e-23	Coronary artery disease;
LUAD	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg12564285	chr5:131593104	PDLIM4	0.36	6.91	0.32	1.82e-11	Acylcarnitine levels;
LUAD	cis	rs8060686	0.516	rs1975802	chr16:68285847	A/G	cg26727032	chr16:67993705	SLC12A4	-0.51	-8.41	-0.38	6.44e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2455799	0.573	rs2455830	chr3:15749213	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-9.48	-0.42	1.82e-19	Mean platelet volume;
LUAD	trans	rs9393777	0.920	rs35120058	chr6:27358166	A/G	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.74	-0.35	7.43e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6743376	0.642	rs4145014	chr2:113831185	A/G	cg09040174	chr2:113837401	NA	0.57	7.31	0.33	1.36e-12	Inflammatory biomarkers;
LUAD	trans	rs11671005	0.651	rs55716128	chr19:59048754	C/T	cg22037779	chr5:139682734	PFDN1	-0.65	-8.49	-0.38	3.59e-16	Mean platelet volume;
LUAD	cis	rs9786986	0.764	rs291374	chr1:235694600	T/C	cg08848088	chr1:235714526	GNG4	0.51	6.54	0.3	1.81e-10	Body mass index;
LUAD	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg06808227	chr14:105710500	BRF1	-0.43	-6.79	-0.31	3.71e-11	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg23978390	chr7:1156363	C7orf50	0.55	8.63	0.39	1.26e-16	Longevity;Endometriosis;
LUAD	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg07741184	chr6:167504864	NA	0.36	8.31	0.37	1.3e-15	Primary biliary cholangitis;
LUAD	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg15309053	chr8:964076	NA	-0.33	-7.24	-0.33	2.13e-12	Schizophrenia;
LUAD	trans	rs10802346	0.545	rs10802345	chr1:246372834	C/T	cg22732515	chr19:44031385	ETHE1	0.59	9.46	0.42	2.08e-19	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs1034435	0.755	rs5767171	chr22:48891881	A/G	cg05992904	chr22:48892994	FAM19A5	-0.75	-16.75	-0.63	1.09e-48	Late-onset Alzheimer's disease;
LUAD	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg07952391	chr2:88470173	THNSL2	-0.63	-10.01	-0.44	2.51e-21	Response to metformin (IC50);
LUAD	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-8.5	-0.38	3.33e-16	Total body bone mineral density;
LUAD	cis	rs41311933	1.000	rs41311871	chr9:123753253	T/C	cg13567360	chr9:123745713	C5	-0.79	-8.95	-0.4	1.1e-17	Coronary artery disease;
LUAD	trans	rs747782	0.527	rs75915859	chr11:48232931	C/T	cg03929089	chr4:120376271	NA	0.63	6.81	0.31	3.41e-11	Intraocular pressure;
LUAD	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.35	-0.34	1.06e-12	Lung cancer;
LUAD	cis	rs2070488	0.804	rs1870914	chr3:38494220	T/C	cg24069376	chr3:38537580	EXOG	0.33	7.62	0.35	1.72e-13	Electrocardiographic conduction measures;
LUAD	trans	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg15704280	chr7:45808275	SEPT13	0.62	8.17	0.37	3.66e-15	Axial length;
LUAD	cis	rs11048434	0.661	rs34791180	chr12:9110919	T/C	cg23795048	chr12:9217529	LOC144571	0.41	7.59	0.35	2.13e-13	Sjögren's syndrome;
LUAD	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg15147215	chr3:52552868	STAB1	-0.4	-7.22	-0.33	2.42e-12	Bipolar disorder;
LUAD	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg17264618	chr3:40429014	ENTPD3	-0.4	-8.75	-0.39	5.17e-17	Renal cell carcinoma;
LUAD	cis	rs6484504	0.576	rs16922084	chr11:31371109	C/T	cg06552810	chr11:31128660	NA	0.32	6.37	0.3	4.81e-10	Red blood cell count;
LUAD	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg23758822	chr17:41437982	NA	1.0	20.93	0.71	2.87e-67	Menopause (age at onset);
LUAD	cis	rs3936840	0.539	rs11850701	chr14:102983857	G/A	cg18135206	chr14:102964638	TECPR2	0.45	6.59	0.31	1.33e-10	Plateletcrit;
LUAD	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg06808227	chr14:105710500	BRF1	-0.41	-6.4	-0.3	4.21e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg06547715	chr2:218990976	CXCR2	0.43	10.21	0.44	5.11e-22	Ulcerative colitis;
LUAD	cis	rs7818345	0.967	rs7006702	chr8:19272533	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.68	0.31	7.4e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs877282	0.945	rs71489301	chr10:770191	A/G	cg06581033	chr10:766294	NA	-0.54	-7.47	-0.34	4.66e-13	Uric acid levels;
LUAD	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.0	-0.4	7.52e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4285028	0.580	rs2293611	chr3:121643163	G/C	cg20356878	chr3:121714668	ILDR1	-0.58	-8.78	-0.39	4.24e-17	Multiple sclerosis;
LUAD	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg25753631	chr6:25732923	NA	-0.42	-7.44	-0.34	5.79e-13	Iron status biomarkers;
LUAD	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.93	13.34	0.54	4.14e-34	Smoking behavior;
LUAD	cis	rs10489202	0.632	rs12401555	chr1:168069473	G/C	cg25738037	chr1:168025549	DCAF6	-0.45	-6.36	-0.3	5.22e-10	Schizophrenia;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg08364334	chr4:154601692	NA	-0.43	-7.11	-0.33	4.88e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs4711336	0.509	rs764753	chr6:33658109	A/T	cg14003231	chr6:33640908	ITPR3	0.38	6.56	0.3	1.58e-10	Height;
LUAD	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg07507251	chr3:52567010	NT5DC2	0.39	7.93	0.36	1.96e-14	Bipolar disorder;
LUAD	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg16797656	chr11:68205561	LRP5	0.47	9.26	0.41	1.06e-18	Total body bone mineral density;
LUAD	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg09509183	chr1:209979624	IRF6	0.61	7.01	0.32	9.56e-12	Coronary artery disease;
LUAD	cis	rs75229567	0.618	rs11177848	chr12:70180892	A/G	cg10114359	chr12:70132523	RAB3IP	0.86	6.85	0.32	2.63e-11	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg08085267	chr17:45401833	C17orf57	0.71	13.22	0.54	1.2e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24308560	chr3:49941425	MST1R	0.59	10.11	0.44	1.18e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs9796	0.621	rs1659227	chr15:41472398	G/A	cg18705301	chr15:41695430	NDUFAF1	0.47	8.37	0.38	8.42e-16	Menopause (age at onset);
LUAD	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg01119278	chr6:110721349	DDO	-0.46	-8.52	-0.38	2.78e-16	Platelet distribution width;
LUAD	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.42	-0.34	6.68e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg19077165	chr18:44547161	KATNAL2	-0.43	-7.51	-0.34	3.55e-13	Personality dimensions;
LUAD	cis	rs7512552	0.803	rs13294	chr1:150484987	G/A	cg15654264	chr1:150340011	RPRD2	0.56	10.77	0.46	4.71e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg03289416	chr15:75166202	SCAMP2	0.58	10.05	0.44	1.82e-21	Breast cancer;
LUAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.56	7.4	0.34	7.2e-13	Alzheimer's disease;
LUAD	trans	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg07211511	chr3:129823064	LOC729375	-0.93	-10.47	-0.45	5.76e-23	Blood pressure (smoking interaction);
LUAD	trans	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg25835954	chr13:50160062	RCBTB1	0.5	8.16	0.37	3.91e-15	Cortisol levels (saliva);
LUAD	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg01689657	chr7:91764605	CYP51A1	-0.29	-6.96	-0.32	1.34e-11	Breast cancer;
LUAD	trans	rs11165623	0.792	rs6671371	chr1:96977039	A/G	cg10631902	chr5:14652156	NA	-0.55	-10.7	-0.46	7.99e-24	Hip circumference;Waist circumference;
LUAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg02869364	chr7:1081709	C7orf50	-0.35	-6.69	-0.31	7.24e-11	Longevity;Endometriosis;
LUAD	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	6.64	0.31	9.66e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.07e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs8060686	0.516	rs7184821	chr16:68270229	T/C	cg26727032	chr16:67993705	SLC12A4	-0.5	-8.36	-0.38	9.17e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg25665528	chr16:2260870	C16orf79	-0.34	-6.75	-0.31	5.02e-11	Height;
LUAD	trans	rs8002861	0.875	rs12867890	chr13:44423088	A/G	cg12856521	chr11:46389249	DGKZ	-0.38	-6.4	-0.3	4.13e-10	Leprosy;
LUAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg20607798	chr8:58055168	NA	0.79	9.87	0.43	7.9e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg08742575	chr21:47604166	C21orf56	0.5	8.45	0.38	4.61e-16	Testicular germ cell tumor;
LUAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.41	0.55	2.12e-34	Prudent dietary pattern;
LUAD	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg23254163	chr1:152506842	NA	0.25	7.01	0.32	9.3e-12	Hair morphology;
LUAD	cis	rs8077889	0.719	rs57227660	chr17:41858984	T/C	cg26893861	chr17:41843967	DUSP3	1.14	25.67	0.78	2.67e-88	Triglycerides;
LUAD	cis	rs9914544	0.545	rs3826380	chr17:18793225	A/G	cg25390199	chr17:18761479	PRPSAP2	-0.37	-6.43	-0.3	3.39e-10	Educational attainment (years of education);
LUAD	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg12011299	chr4:100065546	ADH4	0.7	12.61	0.52	3.55e-31	Smoking initiation;
LUAD	cis	rs231513	0.954	rs231504	chr17:41970906	C/G	cg26893861	chr17:41843967	DUSP3	-0.54	-6.63	-0.31	1e-10	Cognitive function;
LUAD	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	9.45	0.42	2.42e-19	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	6.91	0.32	1.79e-11	Aortic root size;
LUAD	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.65	-12.41	-0.52	2.16e-30	Diastolic blood pressure;
LUAD	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg01851573	chr8:8652454	MFHAS1	0.42	7.55	0.34	2.79e-13	Mood instability;
LUAD	cis	rs35771425	0.572	rs34552796	chr1:211422229	C/T	cg25617285	chr1:211431773	RCOR3	-0.43	-7.46	-0.34	4.9e-13	Educational attainment (years of education);
LUAD	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg27631724	chr1:11040367	C1orf127	0.53	9.05	0.4	5.25e-18	Ewing sarcoma;
LUAD	cis	rs6005807	0.843	rs9625516	chr22:29024730	C/T	cg12565055	chr22:29076175	TTC28	0.72	7.44	0.34	5.51e-13	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	trans	rs7395662	0.864	rs7483617	chr11:48551659	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.33	-0.34	1.18e-12	HDL cholesterol;
LUAD	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	9.5	0.42	1.52e-19	Ileal carcinoids;
LUAD	cis	rs2742234	0.955	rs2075913	chr10:43622368	T/A	cg02780029	chr10:43622663	RET	-0.41	-6.71	-0.31	6.3e-11	Hirschsprung disease;
LUAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg07677032	chr17:61819896	STRADA	0.56	10.19	0.44	5.84e-22	Prudent dietary pattern;
LUAD	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.82	0.31	3.12e-11	Depression;
LUAD	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg12119029	chr16:89752879	CDK10	0.33	6.95	0.32	1.35e-11	Vitiligo;
LUAD	trans	rs9951602	0.512	rs12607612	chr18:76651799	G/A	cg02800362	chr5:177631904	HNRNPAB	0.91	14.5	0.58	5.82e-39	Obesity-related traits;
LUAD	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg27129171	chr3:47204927	SETD2	0.39	6.42	0.3	3.68e-10	Colorectal cancer;
LUAD	cis	rs4285028	0.948	rs35415993	chr3:121669236	C/A	cg20356878	chr3:121714668	ILDR1	-0.5	-6.73	-0.31	5.44e-11	Multiple sclerosis;
LUAD	cis	rs10979	0.928	rs9496676	chr6:143895610	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.2	-0.44	5.39e-22	Hypospadias;
LUAD	cis	rs62400317	0.762	rs12214794	chr6:44931465	G/A	cg18551225	chr6:44695536	NA	-0.58	-8.78	-0.39	4.01e-17	Total body bone mineral density;
LUAD	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg02733842	chr7:1102375	C7orf50	-0.69	-10.59	-0.46	2.06e-23	Bronchopulmonary dysplasia;
LUAD	cis	rs9473147	0.543	rs9473122	chr6:47474962	C/T	cg12968598	chr6:47444699	CD2AP	0.35	6.35	0.3	5.46e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.33	-0.45	1.89e-22	Platelet count;
LUAD	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg17509989	chr5:176798049	RGS14	0.59	8.62	0.39	1.37e-16	Urate levels in lean individuals;
LUAD	cis	rs657075	0.697	rs13179900	chr5:131647590	A/G	cg21138405	chr5:131827807	IRF1	-0.5	-6.64	-0.31	9.64e-11	Rheumatoid arthritis;
LUAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08219700	chr8:58056026	NA	-0.62	-8.96	-0.4	1.08e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7132746	0.620	rs61928910	chr12:86195948	A/G	cg18827107	chr12:86230957	RASSF9	-0.5	-6.73	-0.31	5.56e-11	Lewy body disease;
LUAD	cis	rs7607369	0.536	rs4646535	chr2:219664663	C/T	cg02176678	chr2:219576539	TTLL4	-0.59	-11.69	-0.49	1.5e-27	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg27539214	chr16:67997921	SLC12A4	-0.58	-8.28	-0.37	1.62e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg27284194	chr4:1044797	NA	0.69	10.44	0.45	7.59e-23	Recombination rate (females);
LUAD	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg22676075	chr6:135203613	NA	0.43	8.01	0.36	1.13e-14	Red blood cell count;
LUAD	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg10523679	chr1:76189770	ACADM	0.9	16.06	0.62	1.23e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1160297	0.609	rs10203699	chr2:53105568	A/G	cg07782112	chr2:53107842	NA	0.43	9.2	0.41	1.62e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg14186256	chr22:23484241	RTDR1	0.46	7.73	0.35	7.86e-14	Bone mineral density;
LUAD	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg00933542	chr6:150070202	PCMT1	0.46	10.0	0.44	2.73e-21	Lung cancer;
LUAD	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg11822812	chr5:140052017	DND1	-0.44	-7.89	-0.36	2.59e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs977987	0.843	rs12927562	chr16:75482860	G/A	cg03315344	chr16:75512273	CHST6	0.65	14.1	0.57	2.7e-37	Dupuytren's disease;
LUAD	cis	rs739496	0.649	rs616513	chr12:112003383	G/T	cg10833066	chr12:111807467	FAM109A	0.47	8.39	0.38	7.49e-16	Platelet count;
LUAD	cis	rs4638749	1.000	rs12472278	chr2:108873433	A/T	cg25838818	chr2:108905173	SULT1C2	0.53	8.63	0.39	1.29e-16	Blood pressure;
LUAD	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.91	0.36	2.31e-14	Lung cancer;
LUAD	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg24450063	chr1:156163899	SLC25A44	0.8	11.7	0.49	1.42e-27	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg17366294	chr4:99064904	C4orf37	0.59	9.94	0.44	4.75e-21	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg18944383	chr4:111397179	ENPEP	0.41	8.26	0.37	1.87e-15	Height;
LUAD	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.36	-6.99	-0.32	1.08e-11	Crohn's disease;
LUAD	cis	rs250585	0.790	rs2285521	chr16:23521780	C/T	cg00143387	chr16:23521605	GGA2	-0.68	-8.0	-0.36	1.17e-14	Egg allergy;
LUAD	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg08280861	chr8:58055591	NA	0.54	7.47	0.34	4.59e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg22467129	chr15:76604101	ETFA	-0.6	-11.17	-0.48	1.44e-25	Blood metabolite levels;
LUAD	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-9.21	-0.41	1.5e-18	Platelet count;
LUAD	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg22117172	chr7:91764530	CYP51A1	0.33	7.34	0.34	1.11e-12	Breast cancer;
LUAD	cis	rs10788264	0.504	rs7090214	chr10:124036494	T/C	cg09507567	chr10:124027408	NA	0.55	12.29	0.51	6.7e-30	Total body bone mineral density;
LUAD	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg00666640	chr1:248458726	OR2T12	0.32	7.88	0.36	2.86e-14	Common traits (Other);
LUAD	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg04450456	chr4:17643702	FAM184B	0.41	8.18	0.37	3.34e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21659725	chr3:3221576	CRBN	-0.49	-7.98	-0.36	1.39e-14	Body mass index;
LUAD	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg02017074	chr12:117425053	FBXW8	0.64	8.31	0.37	1.31e-15	Subcortical brain region volumes;Hippocampal volume;
LUAD	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12923728	chr3:195709715	SDHAP1	-0.8	-13.17	-0.54	1.89e-33	Pancreatic cancer;
LUAD	cis	rs2274273	0.553	rs56166765	chr14:55738018	T/C	cg04306507	chr14:55594613	LGALS3	0.41	7.93	0.36	1.94e-14	Protein biomarker;
LUAD	cis	rs7107174	0.901	rs1055248	chr11:77925573	T/C	cg19901956	chr11:77921274	USP35	-0.49	-6.36	-0.3	5.33e-10	Testicular germ cell tumor;
LUAD	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg02773041	chr1:40204384	PPIE	-0.52	-8.64	-0.39	1.19e-16	Blood protein levels;
LUAD	cis	rs7582720	1.000	rs72936348	chr2:204064839	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.58	0.42	8.55e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs12681288	0.782	rs2600499	chr8:1026619	C/T	cg04851639	chr8:1020857	NA	-0.44	-10.32	-0.45	2.05e-22	Schizophrenia;
LUAD	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg02527881	chr3:46936655	PTH1R	-0.69	-16.1	-0.62	8.21e-46	Birth weight;
LUAD	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21582582	chr3:182698605	DCUN1D1	0.49	8.1	0.37	5.9e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg15664640	chr17:80829946	TBCD	-0.64	-8.39	-0.38	7.19e-16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs1232027	0.700	rs1677680	chr5:79955035	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.76	-0.35	6.44e-14	Huntington's disease progression;
LUAD	cis	rs1816752	0.870	rs2033955	chr13:25010544	T/C	cg02811702	chr13:24901961	NA	0.44	7.53	0.34	3.13e-13	Obesity-related traits;
LUAD	trans	rs17685	1.000	rs17685	chr7:75616105	G/A	cg19862616	chr7:65841803	NCRNA00174	0.86	15.45	0.6	5.15e-43	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg11098525	chr4:1320231	MAEA	-0.39	-6.48	-0.3	2.6200000000000003e-10	Obesity-related traits;
LUAD	cis	rs6456156	0.792	rs7775443	chr6:167513252	A/C	cg07741184	chr6:167504864	NA	-0.33	-8.03	-0.36	9.88e-15	Primary biliary cholangitis;
LUAD	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg13319975	chr6:146136371	FBXO30	0.58	9.73	0.43	2.57e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7264396	0.563	rs6058322	chr20:34367277	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.61	7.97	0.36	1.45e-14	Total cholesterol levels;
LUAD	cis	rs6500395	1.000	rs12597569	chr16:48693342	C/T	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.07e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg07828024	chr6:149772892	ZC3H12D	0.3	6.36	0.3	5.21e-10	Dupuytren's disease;
LUAD	cis	rs7301826	0.557	rs7953184	chr12:131284852	T/G	cg11011512	chr12:131303247	STX2	-0.41	-6.81	-0.31	3.39e-11	Plasma plasminogen activator levels;
LUAD	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg14828511	chr1:107599125	PRMT6	0.5	8.96	0.4	1.04e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg16405210	chr4:1374714	KIAA1530	0.47	7.47	0.34	4.7e-13	Obesity-related traits;
LUAD	cis	rs8067545	0.750	rs62067555	chr17:20001502	T/C	cg04132472	chr17:19861366	AKAP10	0.31	7.32	0.34	1.25e-12	Schizophrenia;
LUAD	cis	rs1448094	0.872	rs12322940	chr12:86406708	G/C	cg00310523	chr12:86230176	RASSF9	0.38	8.08	0.37	6.71e-15	Major depressive disorder;
LUAD	cis	rs7937890	0.559	rs1116739	chr11:14489182	G/C	cg22961513	chr11:14280813	SPON1	-0.38	-7.33	-0.34	1.19e-12	Mitochondrial DNA levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00810945	chr16:21964237	UQCRC2	-0.43	-6.97	-0.32	1.19e-11	Height;
LUAD	cis	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg05084668	chr3:125655381	ALG1L	-0.57	-8.77	-0.39	4.25e-17	Blood pressure (smoking interaction);
LUAD	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg06618935	chr21:46677482	NA	-0.42	-8.32	-0.38	1.21e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11650494	0.706	rs76778410	chr17:47459877	A/T	cg08112188	chr17:47440006	ZNF652	0.84	6.67	0.31	7.98e-11	Prostate cancer;
LUAD	trans	rs1728785	0.901	rs8050289	chr16:68566976	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.78	0.43	1.69e-20	Ulcerative colitis;
LUAD	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg03983476	chr2:10830698	NOL10	0.47	8.37	0.38	8.56e-16	Prostate cancer;
LUAD	cis	rs12612619	0.732	rs11688708	chr2:27199608	T/G	cg00617064	chr2:27272375	NA	-0.36	-7.0	-0.32	9.94e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs9473147	0.516	rs9357546	chr6:47549495	C/T	cg02130027	chr6:47444894	CD2AP	0.34	6.63	0.31	1.01e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg21856205	chr7:94953877	PON1	-0.53	-7.14	-0.33	4.07e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg03676636	chr4:99064102	C4orf37	0.29	7.37	0.34	9.01e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg21252483	chr19:49399788	TULP2	-0.63	-9.0	-0.4	7.84e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg14835575	chr10:16859367	RSU1	0.53	8.06	0.36	8.1e-15	Platelet distribution width;
LUAD	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg20607287	chr7:12443886	VWDE	-0.54	-6.83	-0.32	2.97e-11	Coronary artery disease;
LUAD	cis	rs6577655	0.517	rs6996991	chr8:135589255	G/A	cg17885191	chr8:135476712	NA	0.61	8.13	0.37	4.68e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs4853036	0.586	rs2312551	chr2:70007357	C/T	cg02498382	chr2:70120550	SNRNP27	-0.46	-6.49	-0.3	2.38e-10	Colorectal or endometrial cancer;
LUAD	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg17633681	chr16:88106987	BANP	0.41	6.8	0.31	3.63e-11	Menopause (age at onset);
LUAD	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg27539214	chr16:67997921	SLC12A4	-0.68	-8.82	-0.39	3.11e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1829883	0.804	rs1608435	chr5:98817492	A/G	cg08333243	chr5:99726346	NA	-0.38	-7.34	-0.34	1.09e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg20203395	chr5:56204925	C5orf35	-0.4	-6.59	-0.31	1.3100000000000001e-10	Coronary artery disease;
LUAD	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg21881798	chr11:8931708	C11orf17;ST5	0.58	11.21	0.48	1.05e-25	Hemoglobin concentration;
LUAD	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.7	-13.61	-0.55	3.03e-35	Ulcerative colitis;
LUAD	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18876405	chr7:65276391	NA	-0.41	-6.62	-0.31	1.06e-10	Aortic root size;
LUAD	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg24675056	chr1:15929824	NA	0.49	8.48	0.38	3.92e-16	Systolic blood pressure;
LUAD	trans	rs3219090	0.861	rs2695238	chr1:226604519	C/G	cg27539482	chr13:111589090	NA	-0.44	-7.33	-0.34	1.18e-12	Melanoma;
LUAD	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg15208524	chr1:10270712	KIF1B	0.42	6.38	0.3	4.77e-10	Hepatocellular carcinoma;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02053257	chr3:10353648	SEC13	0.48	6.9	0.32	1.89e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg27535305	chr1:53392650	SCP2	-0.33	-6.67	-0.31	8.07e-11	Monocyte count;
LUAD	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg26384229	chr12:38710491	ALG10B	0.4	6.94	0.32	1.48e-11	Heart rate;
LUAD	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	9.0	0.4	7.8e-18	Tonsillectomy;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg11122148	chr13:45150705	TSC22D1	-0.36	-6.55	-0.3	1.65e-10	Schizophrenia;
LUAD	cis	rs17152411	0.895	rs11245419	chr10:126586392	A/T	cg07906193	chr10:126599966	NA	0.54	7.65	0.35	1.34e-13	Height;
LUAD	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg09658497	chr7:2847517	GNA12	-0.5	-8.48	-0.38	3.94e-16	Height;
LUAD	cis	rs3823572	0.510	rs4731991	chr7:133689090	A/G	cg03336402	chr7:133662267	EXOC4	-0.41	-7.05	-0.32	7.46e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7903847	0.673	rs3818908	chr10:99132701	A/G	cg08345082	chr10:99160200	RRP12	-0.31	-6.36	-0.3	5.13e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg11494091	chr17:61959527	GH2	0.44	8.14	0.37	4.51e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.02e-13	Morning vs. evening chronotype;
LUAD	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.68	-0.58	1.03e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg01097406	chr16:89675127	NA	0.45	9.55	0.42	1.04e-19	Vitiligo;
LUAD	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg04414720	chr1:150670196	GOLPH3L	0.6	10.33	0.45	1.86e-22	Melanoma;
LUAD	cis	rs9522267	0.511	rs1163626	chr13:112225200	A/C	cg10483660	chr13:112241077	NA	-0.33	-7.05	-0.32	7.19e-12	Hepatitis;
LUAD	cis	rs11126435	0.858	rs9636445	chr2:74933257	T/C	cg19285774	chr2:74907978	SEMA4F	0.37	6.41	0.3	3.79e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg06713675	chr4:122721982	EXOSC9	0.44	7.95	0.36	1.7e-14	Type 2 diabetes;
LUAD	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.33	0.34	1.15e-12	Bipolar disorder;
LUAD	trans	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg01620082	chr3:125678407	NA	-0.44	-6.67	-0.31	8.04e-11	Depression;
LUAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg07677032	chr17:61819896	STRADA	0.58	10.55	0.46	2.92e-23	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg11965913	chr1:205819406	PM20D1	-0.53	-8.14	-0.37	4.59e-15	Parkinson's disease;
LUAD	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg27129171	chr3:47204927	SETD2	0.4	6.39	0.3	4.41e-10	Colorectal cancer;
LUAD	cis	rs2346177	0.554	rs13002880	chr2:46708129	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-7.73	-0.35	7.99e-14	HDL cholesterol;
LUAD	cis	rs4785763	0.570	rs4785759	chr16:90050880	G/T	cg09104284	chr16:90050102	AFG3L1	0.27	6.51	0.3	2.19e-10	Melanoma;
LUAD	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg26513180	chr16:89883248	FANCA	0.78	6.75	0.31	4.97e-11	Skin colour saturation;
LUAD	cis	rs7524258	0.900	rs1476047	chr1:7312172	C/T	cg04342483	chr1:7259290	CAMTA1	-0.27	-6.44	-0.3	3.27e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg16205897	chr5:131564050	P4HA2	-0.32	-7.2	-0.33	2.73e-12	Breast cancer;
LUAD	cis	rs877529	0.605	rs139412	chr22:39553003	A/G	cg18708252	chr22:39545030	CBX7	0.3	6.74	0.31	5.23e-11	Multiple myeloma;
LUAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg15117754	chr3:10150083	C3orf24	0.41	6.58	0.3	1.38e-10	Alzheimer's disease;
LUAD	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.85	-0.5	3.7e-28	Bipolar disorder;
LUAD	trans	rs300774	0.764	rs300756	chr2:233416	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.52	-6.37	-0.3	4.88e-10	Suicide attempts in bipolar disorder;
LUAD	cis	rs1816752	0.746	rs9511270	chr13:25018680	C/T	cg02811702	chr13:24901961	NA	0.47	8.06	0.37	7.64e-15	Obesity-related traits;
LUAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	7.0	0.32	9.94e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg07507251	chr3:52567010	NT5DC2	0.35	7.19	0.33	3.02e-12	Bipolar disorder;
LUAD	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.18	-0.33	3.12e-12	Height;
LUAD	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg12863693	chr15:85201151	NMB	0.41	7.5	0.34	3.75e-13	Schizophrenia;
LUAD	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg07636037	chr3:49044803	WDR6	0.52	9.91	0.43	5.83e-21	Menarche (age at onset);
LUAD	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg19418458	chr7:158789849	NA	0.62	8.45	0.38	4.63e-16	Facial morphology (factor 20);
LUAD	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.77	-0.31	4.3e-11	Total body bone mineral density;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04781764	chr12:89893765	WDR51B	0.59	7.22	0.33	2.46e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg08885076	chr2:99613938	TSGA10	-0.4	-6.98	-0.32	1.15e-11	Chronic sinus infection;
LUAD	cis	rs4253772	0.626	rs12169526	chr22:46763846	C/T	cg18190219	chr22:46762943	CELSR1	-0.61	-6.57	-0.3	1.46e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs863345	0.604	rs6669271	chr1:158471999	A/G	cg12129480	chr1:158549410	OR10X1	-0.25	-6.91	-0.32	1.85e-11	Pneumococcal bacteremia;
LUAD	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg24112000	chr20:60950667	NA	-0.88	-13.84	-0.56	3.5e-36	Colorectal cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09551160	chr10:80828924	ZMIZ1	-0.58	-6.9	-0.32	1.93e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6558530	0.965	rs6558529	chr8:1706206	C/T	cg19131313	chr8:1704013	NA	-0.44	-7.16	-0.33	3.6e-12	Systolic blood pressure;
LUAD	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.62	10.98	0.47	7.83e-25	Birth weight;
LUAD	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg12573674	chr2:1569213	NA	-0.62	-6.83	-0.32	2.93e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs28595532	0.920	rs116401323	chr4:119721727	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.41	0.38	6.23e-16	Cannabis dependence symptom count;
LUAD	cis	rs62400317	0.859	rs12212745	chr6:45166258	C/T	cg20913747	chr6:44695427	NA	-0.4	-6.37	-0.3	4.92e-10	Total body bone mineral density;
LUAD	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	11.15	0.48	1.77e-25	Resting heart rate;
LUAD	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	15.82	0.61	1.35e-44	Bone mineral density;
LUAD	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-11.09	-0.47	2.97e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg11645453	chr3:52864694	ITIH4	0.34	6.91	0.32	1.8e-11	Electroencephalogram traits;
LUAD	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-6.56	-0.3	1.58e-10	Bladder cancer;
LUAD	trans	rs2235573	0.657	rs5756890	chr22:38445400	C/A	cg19894588	chr14:64061835	NA	0.46	7.05	0.32	7.13e-12	Glioblastoma;Glioma;
LUAD	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg24733560	chr20:60626293	TAF4	0.39	7.61	0.35	1.76e-13	Body mass index;
LUAD	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg23029597	chr12:123009494	RSRC2	0.51	8.01	0.36	1.15e-14	Body mass index;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg24592846	chr11:129873229	NCRNA00167;PRDM10	-0.47	-8.3	-0.37	1.4e-15	Schizophrenia;
LUAD	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg27170947	chr2:26402098	FAM59B	-0.69	-9.48	-0.42	1.79e-19	Gut microbiome composition (summer);
LUAD	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	9.79	0.43	1.5e-20	Electrocardiographic conduction measures;
LUAD	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.34	6.99	0.32	1.05e-11	Obesity-related traits;
LUAD	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg08439880	chr3:133502540	NA	-0.37	-7.15	-0.33	3.89e-12	Iron status biomarkers;
LUAD	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg06627628	chr2:24431161	ITSN2	-0.68	-10.81	-0.47	3.34e-24	Asthma;
LUAD	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg15448220	chr1:150897856	SETDB1	-0.48	-8.11	-0.37	5.52e-15	Tonsillectomy;
LUAD	cis	rs2992756	0.663	rs2992763	chr1:18804386	G/A	cg24076588	chr1:18808559	KLHDC7A	-0.46	-7.63	-0.35	1.56e-13	Breast cancer;
LUAD	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg22676075	chr6:135203613	NA	0.39	7.25	0.33	1.95e-12	Red blood cell count;
LUAD	cis	rs9811920	0.695	rs793497	chr3:99505610	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	6.6	0.31	1.25e-10	Axial length;
LUAD	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23583168	chr7:148888333	NA	-0.91	-18.0	-0.66	3.51e-54	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg17105886	chr17:28927953	LRRC37B2	0.79	7.88	0.36	2.71e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7274811	0.744	rs209677	chr20:32140287	C/T	cg07470512	chr20:32255052	NECAB3;C20orf134	0.43	6.6	0.31	1.21e-10	Height;
LUAD	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg12310025	chr6:25882481	NA	0.58	9.67	0.43	4.1e-20	Blood metabolite levels;
LUAD	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg20503657	chr10:835505	NA	0.77	11.74	0.5	9.38e-28	Eosinophil percentage of granulocytes;
LUAD	cis	rs2742417	1.000	rs2742420	chr3:45732237	A/G	cg10512202	chr3:45649293	LIMD1	0.37	6.55	0.3	1.66e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg09033563	chr22:24373618	LOC391322	0.63	10.59	0.46	2.19e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6761276	0.899	rs12466799	chr2:113835999	T/C	cg09040174	chr2:113837401	NA	0.81	15.75	0.61	2.68e-44	Protein quantitative trait loci;
LUAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.61	-9.62	-0.42	5.87e-20	Renal function-related traits (BUN);
LUAD	cis	rs4523957	0.583	rs9889861	chr17:2041369	A/G	cg16513277	chr17:2031491	SMG6	-0.98	-20.08	-0.7	1.79e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg16590910	chr6:42928470	GNMT	0.35	6.52	0.3	1.99e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg22482690	chr17:47019901	SNF8	0.45	8.82	0.39	3.02e-17	Type 2 diabetes;
LUAD	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg00701064	chr4:6280414	WFS1	0.63	13.69	0.55	1.48e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs78487399	0.808	rs7570242	chr2:43706002	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-6.92	-0.32	1.71e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg11502198	chr6:26597334	ABT1	0.64	11.21	0.48	9.95e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs2806561	0.894	rs628106	chr1:23537685	C/T	cg12483005	chr1:23474871	LUZP1	0.38	6.42	0.3	3.7e-10	Height;
LUAD	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg26816564	chr1:7831052	VAMP3	-0.61	-8.57	-0.38	1.92e-16	Inflammatory bowel disease;
LUAD	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.24	-0.37	2.1e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs2018683	0.624	rs1006521	chr7:28996220	G/A	cg19402173	chr7:128379420	CALU	-0.5	-8.0	-0.36	1.18e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg06740227	chr12:86229804	RASSF9	0.39	6.89	0.32	2.07e-11	Major depressive disorder;
LUAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14159672	chr1:205819179	PM20D1	0.93	21.56	0.72	4.17e-70	Menarche (age at onset);
LUAD	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg16327482	chr19:10226339	EIF3G	-0.33	-6.97	-0.32	1.21e-11	Narcolepsy;
LUAD	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg17971929	chr21:40555470	PSMG1	0.48	7.26	0.33	1.89e-12	Cognitive function;
LUAD	trans	rs3942852	0.712	rs10742828	chr11:48104555	A/G	cg15704280	chr7:45808275	SEPT13	-0.6	-9.05	-0.4	5.32e-18	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg06873352	chr17:61820015	STRADA	0.42	7.01	0.32	9.4e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.88	9.25	0.41	1.09e-18	Initial pursuit acceleration;
LUAD	cis	rs11696845	0.787	rs6031771	chr20:43363590	C/T	cg25301532	chr20:43378953	KCNK15	0.37	6.4	0.3	4.13e-10	Obesity-related traits;
LUAD	cis	rs1018836	0.923	rs13277387	chr8:91633713	C/G	cg16814680	chr8:91681699	NA	-0.65	-10.59	-0.46	2.08e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.5	6.88	0.32	2.22e-11	Platelet count;
LUAD	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg11189052	chr15:85197271	WDR73	0.59	7.61	0.35	1.84e-13	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.645	rs8181635	chr12:86465136	C/T	cg02569458	chr12:86230093	RASSF9	-0.35	-6.48	-0.3	2.6200000000000003e-10	Major depressive disorder;
LUAD	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg07870213	chr5:140052090	DND1	0.92	12.98	0.53	1.14e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg06060754	chr5:176797920	RGS14	-0.71	-12.97	-0.53	1.26e-32	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-6.97	-0.32	1.21e-11	Personality dimensions;
LUAD	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg12935359	chr14:103987150	CKB	0.51	7.92	0.36	2.11e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19748678	chr4:122722346	EXOSC9	0.43	6.76	0.31	4.64e-11	Type 2 diabetes;
LUAD	cis	rs7216064	0.953	rs11079705	chr17:65835452	A/T	cg08758996	chr17:66097529	LOC651250	0.45	6.92	0.32	1.68e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.33	6.88	0.32	2.15e-11	Parkinson's disease;
LUAD	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg10876282	chr6:28092338	ZSCAN16	0.43	6.54	0.3	1.81e-10	Parkinson's disease;
LUAD	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21171335	chr12:122356390	WDR66	-0.63	-10.87	-0.47	2e-24	Mean corpuscular volume;
LUAD	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg06636551	chr8:101224915	SPAG1	-0.36	-6.85	-0.32	2.64e-11	Atrioventricular conduction;
LUAD	cis	rs6690583	0.623	rs7540706	chr1:85534645	A/G	cg22153463	chr1:85462885	MCOLN2	-0.61	-6.39	-0.3	4.44e-10	Serum sulfate level;
LUAD	cis	rs9906944	0.898	rs9909861	chr17:47079416	C/A	cg14634687	chr17:47094252	IGF2BP1	0.28	7.09	0.33	5.55e-12	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs1209950	0.866	rs1734587	chr21:40180884	A/G	cg01359822	chr21:40176597	ETS2	0.39	6.38	0.3	4.69e-10	Non-small cell lung cancer (survival);
LUAD	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg00784671	chr22:46762841	CELSR1	-0.52	-7.24	-0.33	2.19e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3750082	0.889	rs9639669	chr7:32913395	T/C	cg05721444	chr7:32995514	FKBP9	0.37	6.75	0.31	4.77e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg19980929	chr12:42632907	YAF2	-0.34	-6.55	-0.3	1.64e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs7493	0.901	rs17882539	chr7:95026408	G/A	cg19678392	chr7:94953810	PON1	-0.6	-8.49	-0.38	3.45e-16	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg18402987	chr7:1209562	NA	0.62	8.93	0.4	1.3e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4474465	1.000	rs7928933	chr11:78193921	T/C	cg19901956	chr11:77921274	USP35	-0.46	-6.37	-0.3	4.81e-10	Alzheimer's disease (survival time);
LUAD	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg22467129	chr15:76604101	ETFA	-0.47	-7.93	-0.36	1.98e-14	Blood metabolite levels;
LUAD	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg01788221	chr16:89496183	ANKRD11	-0.34	-6.39	-0.3	4.26e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg03690763	chr11:133734501	NA	-0.36	-8.5	-0.38	3.28e-16	Childhood ear infection;
LUAD	cis	rs2286503	0.780	rs1304431	chr7:22865412	T/C	cg06496272	chr7:22895283	SNORD93	-0.4	-7.03	-0.32	8.49e-12	Fibrinogen;
LUAD	trans	rs7404843	0.925	rs12600043	chr16:15539952	A/G	cg02716450	chr16:28638775	NA	0.69	7.25	0.33	2.06e-12	Testicular germ cell tumor;
LUAD	cis	rs7258465	0.965	rs10408290	chr19:18542701	C/T	cg25828334	chr19:18545568	ISYNA1	-0.38	-7.77	-0.35	5.85e-14	Breast cancer;
LUAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7937890	0.559	rs2575852	chr11:14533368	G/A	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.12e-10	Mitochondrial DNA levels;
LUAD	trans	rs877282	0.838	rs34912955	chr10:772222	T/C	cg22713356	chr15:30763199	NA	1.32	18.6	0.67	7.03e-57	Uric acid levels;
LUAD	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg02176678	chr2:219576539	TTLL4	-0.74	-14.57	-0.58	2.98e-39	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg05368731	chr17:41323189	NBR1	0.83	16.77	0.63	9.36e-49	Menopause (age at onset);
LUAD	trans	rs629535	0.814	rs674429	chr8:70069942	G/A	cg21567404	chr3:27674614	NA	1.0	18.36	0.67	8.53e-56	Dupuytren's disease;
LUAD	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg23803603	chr1:2058230	PRKCZ	0.42	7.9	0.36	2.38e-14	Height;
LUAD	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg12599982	chr1:44399894	ARTN	0.31	6.4	0.3	4.13e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg10755058	chr3:40428713	ENTPD3	-0.37	-6.84	-0.32	2.8e-11	Renal cell carcinoma;
LUAD	cis	rs7394190	0.748	rs2075641	chr10:75562108	G/A	cg02286717	chr10:75415704	SYNPO2L	-0.36	-6.43	-0.3	3.36e-10	Incident atrial fibrillation;
LUAD	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg25535316	chr11:579198	PHRF1	-0.41	-6.51	-0.3	2.19e-10	Systemic lupus erythematosus;
LUAD	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg11859384	chr17:80120422	CCDC57	-0.48	-8.61	-0.39	1.41e-16	Life satisfaction;
LUAD	cis	rs6714710	0.627	rs6748124	chr2:98519014	T/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.18	0.37	3.35e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg27494647	chr7:150038898	RARRES2	0.51	9.06	0.4	5.02e-18	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs17095355	0.605	rs3824623	chr10:111645313	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.65	-8.23	-0.37	2.4e-15	Biliary atresia;
LUAD	cis	rs977987	0.771	rs12929673	chr16:75470295	C/T	cg03315344	chr16:75512273	CHST6	0.65	14.21	0.57	9.86e-38	Dupuytren's disease;
LUAD	cis	rs1497828	0.956	rs2646829	chr1:217542801	T/C	cg04411442	chr1:217543379	NA	0.38	6.81	0.31	3.43e-11	Dialysis-related mortality;
LUAD	cis	rs7617773	0.743	rs71323397	chr3:48374874	A/G	cg11946769	chr3:48343235	NME6	0.44	6.68	0.31	7.75e-11	Coronary artery disease;
LUAD	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.68	-6.4	-0.3	4.04e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg15445000	chr17:37608096	MED1	-0.45	-8.31	-0.37	1.31e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs250585	0.736	rs40817	chr16:23422672	C/G	cg00143387	chr16:23521605	GGA2	0.62	8.99	0.4	8.07e-18	Egg allergy;
LUAD	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg23954153	chr1:44402353	ARTN	-0.34	-6.73	-0.31	5.62e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7301016	0.895	rs11174514	chr12:62895074	G/C	cg11441379	chr12:63026424	NA	0.53	6.52	0.3	1.97e-10	IgG glycosylation;
LUAD	trans	rs9929218	0.954	rs7199991	chr16:68818245	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-13.45	-0.55	1.37e-34	Colorectal cancer;
LUAD	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19717773	chr7:2847554	GNA12	-0.57	-9.68	-0.43	3.65e-20	Height;
LUAD	cis	rs7264396	0.563	rs17093093	chr20:34380925	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-7.62	-0.35	1.63e-13	Total cholesterol levels;
LUAD	cis	rs72949976	0.864	rs13389834	chr2:214025112	G/A	cg08319019	chr2:214017104	IKZF2	-0.55	-8.35	-0.38	9.52e-16	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs3820068	0.705	rs4646096	chr1:15820758	A/G	cg13390004	chr1:15929781	NA	0.4	6.51	0.3	2.15e-10	Systolic blood pressure;
LUAD	cis	rs977987	0.806	rs7188231	chr16:75436561	T/C	cg03315344	chr16:75512273	CHST6	0.63	13.93	0.56	1.5e-36	Dupuytren's disease;
LUAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg22963979	chr7:1858916	MAD1L1	-0.57	-9.76	-0.43	1.98e-20	Bipolar disorder and schizophrenia;
LUAD	trans	rs877282	0.891	rs11253393	chr10:788824	G/T	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg18105134	chr13:113819100	PROZ	0.91	16.42	0.62	3.26e-47	Platelet distribution width;
LUAD	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg18230493	chr5:56204884	C5orf35	-0.85	-12.28	-0.51	7.32e-30	Initial pursuit acceleration;
LUAD	cis	rs4853036	0.951	rs13011127	chr2:70040147	T/C	cg02498382	chr2:70120550	SNRNP27	-0.5	-8.02	-0.36	1.05e-14	Colorectal or endometrial cancer;
LUAD	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg22482690	chr17:47019901	SNF8	0.44	8.37	0.38	8.71e-16	Type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg03714773	chr7:91764589	CYP51A1	0.27	6.53	0.3	1.94e-10	Breast cancer;
LUAD	cis	rs2070433	0.539	rs1008549	chr21:47959698	C/T	cg12379764	chr21:47803548	PCNT	0.47	6.97	0.32	1.23e-11	Lymphocyte counts;
LUAD	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg03806693	chr22:41940476	POLR3H	0.72	10.07	0.44	1.64e-21	Vitiligo;
LUAD	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg01689657	chr7:91764605	CYP51A1	-0.36	-8.86	-0.4	2.22e-17	Breast cancer;
LUAD	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg18306943	chr3:40428807	ENTPD3	0.37	6.41	0.3	3.92e-10	Renal cell carcinoma;
LUAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08677398	chr8:58056175	NA	0.49	6.84	0.32	2.72e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg03395511	chr6:291903	DUSP22	-0.51	-8.41	-0.38	6.45e-16	Menopause (age at onset);
LUAD	cis	rs713587	0.719	rs58048722	chr2:25187825	C/T	cg04586622	chr2:25135609	ADCY3	-0.3	-6.57	-0.3	1.45e-10	Body mass index in non-asthmatics;
LUAD	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg19000871	chr14:103996768	TRMT61A	0.42	7.34	0.34	1.09e-12	Coronary artery disease;
LUAD	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg01528321	chr10:82214614	TSPAN14	0.54	8.63	0.39	1.25e-16	Post bronchodilator FEV1;
LUAD	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	7.5	0.34	3.78e-13	Menopause (age at onset);
LUAD	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg27170947	chr2:26402098	FAM59B	0.83	11.53	0.49	6.12e-27	Mean corpuscular hemoglobin;
LUAD	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg02221750	chr19:17393354	ANKLE1	-0.75	-11.88	-0.5	2.86e-28	Systemic lupus erythematosus;
LUAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg16590910	chr6:42928470	GNMT	0.34	6.45	0.3	3.08e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg08859206	chr1:53392774	SCP2	-0.67	-12.65	-0.52	2.42e-31	Monocyte count;
LUAD	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg07917127	chr4:99064746	C4orf37	0.42	7.01	0.32	9.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg07617317	chr6:118971624	C6orf204	0.54	8.46	0.38	4.34e-16	Diastolic blood pressure;
LUAD	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.14	-0.41	2.57e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg17063962	chr7:91808500	NA	-0.68	-12.25	-0.51	9.82e-30	Breast cancer;
LUAD	cis	rs12760731	0.565	rs11585236	chr1:178108441	G/A	cg00404053	chr1:178313656	RASAL2	0.71	9.16	0.41	2.22e-18	Obesity-related traits;
LUAD	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg08085267	chr17:45401833	C17orf57	-0.49	-8.27	-0.37	1.81e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4144027	0.904	rs35551424	chr14:104341669	A/G	cg12183467	chr14:104352244	NA	-0.36	-6.7	-0.31	6.67e-11	Blood metabolite levels;
LUAD	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg07952391	chr2:88470173	THNSL2	0.79	8.49	0.38	3.46e-16	Plasma clusterin levels;
LUAD	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.12	-0.48	2.16e-25	Type 2 diabetes;
LUAD	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg23711669	chr6:146136114	FBXO30	0.4	6.83	0.32	2.88e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	7.61	0.35	1.74e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20584198	chr12:57637690	STAC3	-0.48	-7.59	-0.35	2.1e-13	Height;
LUAD	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg25324976	chr17:61989376	CSHL1	0.37	7.14	0.33	4.12e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6782228	0.606	rs1697	chr3:128356852	C/T	cg16766828	chr3:128327626	NA	-0.38	-7.2	-0.33	2.7e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	24.35	0.76	1.76e-82	Chronic sinus infection;
LUAD	cis	rs13082711	0.911	rs2371065	chr3:27494589	A/C	cg02860705	chr3:27208620	NA	0.61	9.31	0.41	6.97e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg24801067	chr17:62843696	NA	-0.51	-8.28	-0.37	1.66e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg21028142	chr17:79581711	NPLOC4	0.37	7.36	0.34	9.97e-13	Eye color traits;
LUAD	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-20.33	-0.7	1.42e-64	Height;
LUAD	cis	rs943466	1.000	rs755495	chr6:33734128	A/G	cg16010596	chr6:33739607	LEMD2	0.38	7.19	0.33	2.96e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs7680126	0.596	rs28441463	chr4:10289577	T/C	cg11266682	chr4:10021025	SLC2A9	-0.44	-7.38	-0.34	8.23e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg11859384	chr17:80120422	CCDC57	-0.49	-8.79	-0.39	3.67e-17	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg11502198	chr6:26597334	ABT1	0.55	9.1	0.4	3.71e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7520050	0.902	rs4626927	chr1:46248645	C/T	cg06784218	chr1:46089804	CCDC17	-0.3	-6.53	-0.3	1.87e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs1975974	0.574	rs17052370	chr17:21736353	A/G	cg18423549	chr17:21743878	NA	0.83	15.23	0.6	4.41e-42	Psoriasis;
LUAD	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.98	-0.4	8.9e-18	Total body bone mineral density;
LUAD	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg20701182	chr2:24300061	SF3B14	0.66	7.29	0.33	1.55e-12	Lymphocyte counts;
LUAD	cis	rs6489785	0.577	rs487310	chr12:121278574	G/A	cg02419362	chr12:121203948	SPPL3	-0.34	-6.54	-0.3	1.81e-10	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg14227996	chr4:17616232	MED28	0.7	7.31	0.33	1.38e-12	Opioid sensitivity;
LUAD	cis	rs6460942	1.000	rs75333414	chr7:12303829	T/A	cg06484146	chr7:12443880	VWDE	-0.55	-7.32	-0.34	1.25e-12	Coronary artery disease;
LUAD	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	7.68	0.35	1.14e-13	Schizophrenia;
LUAD	cis	rs9487051	0.735	rs1260594	chr6:109519891	A/C	cg21918786	chr6:109611834	NA	-0.41	-7.53	-0.34	3.02e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs9826463	0.582	rs73238176	chr3:142114256	G/A	cg20824294	chr3:142316082	PLS1	0.39	6.72	0.31	5.85e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9972944	0.756	rs4594282	chr17:63762930	G/A	cg07283582	chr17:63770753	CCDC46	-0.51	-11.57	-0.49	4.41e-27	Total body bone mineral density;
LUAD	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg18446336	chr7:2847575	GNA12	-0.32	-6.67	-0.31	7.94e-11	Height;
LUAD	cis	rs4689388	0.890	rs9993624	chr4:6286528	C/T	cg00701064	chr4:6280414	WFS1	0.68	15.25	0.6	3.71e-42	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs4730250	0.707	rs61014091	chr7:106810107	A/C	cg02696742	chr7:106810147	HBP1	-0.86	-11.71	-0.49	1.28e-27	Osteoarthritis;
LUAD	cis	rs7582720	1.000	rs72926787	chr2:203818299	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs4664304	0.714	rs66496937	chr2:160738509	A/G	cg06573604	chr2:160760825	LY75	-0.39	-6.37	-0.3	4.81e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.38	6.75	0.31	4.8e-11	Systemic lupus erythematosus;
LUAD	cis	rs2742417	1.000	rs2742389	chr3:45756683	G/C	cg10512202	chr3:45649293	LIMD1	0.36	6.4	0.3	4.11e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg15790184	chr11:494944	RNH1	0.56	6.73	0.31	5.62e-11	Body mass index;
LUAD	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg18016565	chr1:150552671	MCL1	0.41	7.5	0.34	3.86e-13	Tonsillectomy;
LUAD	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.58	0.3	1.42e-10	Parkinson's disease;
LUAD	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18876405	chr7:65276391	NA	-0.44	-7.06	-0.32	7.01e-12	Aortic root size;
LUAD	trans	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-32.0	-0.84	4.96e-115	Exhaled nitric oxide output;
LUAD	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg23533926	chr12:111358616	MYL2	-0.41	-7.0	-0.32	1.01e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs6840360	0.615	rs4696290	chr4:152631472	A/G	cg22705602	chr4:152727874	NA	-0.49	-9.32	-0.41	6.74e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06022373	chr22:39101656	GTPBP1	0.46	7.44	0.34	5.56e-13	Menopause (age at onset);
LUAD	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg02221422	chr11:68192511	LRP5	-0.44	-7.11	-0.33	4.89e-12	Total body bone mineral density;
LUAD	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg18132916	chr6:79620363	NA	-0.45	-7.79	-0.35	5.37e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.59	0.52	4.38e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg05234568	chr11:5960015	NA	-0.57	-11.22	-0.48	9.56e-26	DNA methylation (variation);
LUAD	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg24163568	chr5:669837	TPPP	0.38	7.04	0.32	7.96e-12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg27266060	chr8:22091797	NA	0.46	8.48	0.38	3.88e-16	Hypertriglyceridemia;
LUAD	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg06636001	chr8:8085503	FLJ10661	0.44	6.7	0.31	6.53e-11	Mood instability;
LUAD	cis	rs8017423	0.935	rs3737035	chr14:90745422	T/C	cg14092571	chr14:90743983	NA	0.48	8.05	0.36	8.42e-15	Mortality in heart failure;
LUAD	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg19041857	chr6:27730383	NA	-0.43	-7.27	-0.33	1.79e-12	Parkinson's disease;
LUAD	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26314531	chr2:26401878	FAM59B	-0.55	-7.76	-0.35	6.34e-14	Gut microbiome composition (summer);
LUAD	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.65	-0.31	9.31e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg10518543	chr12:38710700	ALG10B	0.42	6.38	0.3	4.71e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2880765	0.835	rs4842884	chr15:86035174	T/C	cg13263323	chr15:86062960	AKAP13	-0.48	-8.92	-0.4	1.44e-17	Coronary artery disease;
LUAD	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg10544611	chr16:67998164	SLC12A4	-0.58	-7.3	-0.33	1.45e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23158103	chr7:148848205	ZNF398	-0.62	-11.59	-0.49	3.61e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs438465	1.000	rs2865089	chr6:169882982	C/A	cg11181693	chr6:169825345	NA	-0.62	-8.03	-0.36	9.54e-15	Corneal astigmatism;
LUAD	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg18833306	chr6:118973337	C6orf204	-0.49	-7.27	-0.33	1.75e-12	Diastolic blood pressure;
LUAD	cis	rs2274471	0.730	rs2031904	chr9:5087087	C/T	cg03390472	chr9:5043263	JAK2	-0.53	-7.45	-0.34	5.17e-13	Crohn's disease;
LUAD	cis	rs7593730	0.636	rs3772071	chr2:161135544	C/T	cg22609984	chr2:161126801	NA	0.53	9.76	0.43	1.92e-20	Type 2 diabetes;
LUAD	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg14008862	chr17:28927542	LRRC37B2	0.66	6.41	0.3	3.86e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs73416724	0.925	rs2651201	chr6:43293366	G/A	cg26312998	chr6:43337775	ZNF318	-0.57	-7.41	-0.34	7.1e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg08280861	chr8:58055591	NA	0.56	7.48	0.34	4.25e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg02038168	chr22:39784481	NA	-0.55	-9.49	-0.42	1.75e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg03885332	chr11:832357	CD151	-0.42	-7.87	-0.36	2.9e-14	Mean platelet volume;
LUAD	trans	rs629535	0.814	rs652483	chr8:70055083	G/A	cg21567404	chr3:27674614	NA	1.02	18.56	0.67	1.07e-56	Dupuytren's disease;
LUAD	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg03467027	chr4:99064603	C4orf37	0.41	6.75	0.31	4.81e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg03037974	chr15:76606532	NA	-0.36	-7.55	-0.34	2.78e-13	Blood metabolite levels;
LUAD	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg18827107	chr12:86230957	RASSF9	0.52	9.3	0.41	7.86e-19	Major depressive disorder;
LUAD	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg17264618	chr3:40429014	ENTPD3	-0.39	-8.5	-0.38	3.19e-16	Renal cell carcinoma;
LUAD	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.21	0.48	1.07e-25	Height;
LUAD	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg03676636	chr4:99064102	C4orf37	0.26	6.61	0.31	1.15e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg00277334	chr10:82204260	NA	0.61	8.43	0.38	5.67e-16	Post bronchodilator FEV1;
LUAD	cis	rs9473147	0.516	rs9357546	chr6:47549495	C/T	cg20196966	chr6:47445060	CD2AP	0.43	6.89	0.32	2.03e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18404041	chr3:52824283	ITIH1	-0.59	-11.86	-0.5	3.19e-28	Bipolar disorder;
LUAD	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg03929089	chr4:120376271	NA	-0.68	-9.73	-0.43	2.57e-20	Coronary artery disease;
LUAD	cis	rs17152411	0.947	rs55674450	chr10:126592153	G/T	cg07906193	chr10:126599966	NA	0.53	7.6	0.35	1.95e-13	Height;
LUAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg11301795	chr4:187892539	NA	-0.78	-15.9	-0.61	5.95e-45	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg06608945	chr2:219082296	ARPC2	-0.42	-6.87	-0.32	2.31e-11	Colorectal cancer;
LUAD	cis	rs1073160	1.000	rs1073160	chr12:9058562	A/G	cg13575925	chr12:9217583	LOC144571	-0.35	-6.51	-0.3	2.16e-10	Small cell lung carcinoma;
LUAD	cis	rs11048434	0.761	rs2377675	chr12:9124765	C/T	cg20380214	chr12:9217688	LOC144571	0.34	6.39	0.3	4.48e-10	Sjögren's syndrome;
LUAD	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.26e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	1.000	rs9897206	chr17:28406108	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-8.93	-0.4	1.31e-17	Coffee consumption (cups per day);
LUAD	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg00750074	chr16:89608354	SPG7	-0.56	-9.71	-0.43	3.05e-20	Multiple myeloma (IgH translocation);
LUAD	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg00666640	chr1:248458726	OR2T12	0.3	7.27	0.33	1.8e-12	Common traits (Other);
LUAD	cis	rs2274273	0.624	rs8005450	chr14:55799165	A/T	cg04306507	chr14:55594613	LGALS3	0.42	8.12	0.37	5.25e-15	Protein biomarker;
LUAD	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg27661571	chr11:113659931	NA	-0.7	-8.14	-0.37	4.58e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs12545109	0.642	rs2055984	chr8:57418332	A/G	cg09654669	chr8:57350985	NA	-0.62	-7.91	-0.36	2.35e-14	Obesity-related traits;
LUAD	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg21427119	chr20:30132790	HM13	-0.36	-6.56	-0.3	1.55e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg07305463	chr2:136567211	LCT	0.38	7.06	0.32	6.78e-12	Mosquito bite size;
LUAD	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg18876405	chr7:65276391	NA	0.61	10.55	0.46	2.83e-23	Calcium levels;
LUAD	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg13877915	chr19:58951672	ZNF132	0.72	13.44	0.55	1.48e-34	Uric acid clearance;
LUAD	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg12311346	chr5:56204834	C5orf35	-0.92	-13.69	-0.55	1.36e-35	Initial pursuit acceleration;
LUAD	cis	rs11031096	0.711	rs4910891	chr11:4153408	A/G	cg18678763	chr11:4115507	RRM1	-0.44	-7.6	-0.35	1.88e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs7107174	0.892	rs7115850	chr11:78045071	C/G	cg19901956	chr11:77921274	USP35	-0.47	-6.81	-0.31	3.44e-11	Testicular germ cell tumor;
LUAD	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg06437144	chr17:45973627	SP2	-0.4	-6.43	-0.3	3.4e-10	Vertical cup-disc ratio;
LUAD	cis	rs6087990	0.735	rs2424915	chr20:31378448	C/T	cg13636640	chr20:31349939	DNMT3B	0.72	12.98	0.53	1.13e-32	Ulcerative colitis;
LUAD	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg23625390	chr15:77176239	SCAPER	0.5	8.32	0.37	1.26e-15	Blood metabolite levels;
LUAD	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg22532475	chr10:104410764	TRIM8	-0.44	-8.69	-0.39	8.03e-17	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg18187862	chr3:45730750	SACM1L	0.5	7.95	0.36	1.68e-14	Primary sclerosing cholangitis;
LUAD	cis	rs7789940	0.904	rs7459185	chr7:75934640	C/G	cg10167463	chr7:75959203	YWHAG	0.67	12.17	0.51	2.1e-29	Multiple sclerosis;
LUAD	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.1	-0.33	5.46e-12	Total body bone mineral density;
LUAD	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg16479474	chr6:28041457	NA	0.36	6.45	0.3	3.07e-10	Parkinson's disease;
LUAD	trans	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg05926928	chr17:57297772	GDPD1	0.63	9.58	0.42	8.42e-20	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUAD	trans	rs4130548	0.626	rs12406019	chr1:78678130	A/G	cg20826526	chr3:156266748	SSR3	-0.49	-7.97	-0.36	1.5e-14	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Waist circumference;
LUAD	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg03188948	chr7:1209495	NA	0.62	6.45	0.3	3.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12155623	0.932	rs34236473	chr8:49828725	A/T	cg22283653	chr8:49824208	NA	0.51	10.02	0.44	2.4e-21	Sudden cardiac arrest;
LUAD	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg19041857	chr6:27730383	NA	-0.44	-7.39	-0.34	7.73e-13	Parkinson's disease;
LUAD	cis	rs420259	0.516	rs2072061	chr16:23541223	G/A	cg00143387	chr16:23521605	GGA2	-0.68	-9.37	-0.41	4.45e-19	Bipolar disorder;
LUAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	12.71	0.53	1.45e-31	Prudent dietary pattern;
LUAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg14789911	chr21:47582049	C21orf56	-0.5	-9.05	-0.4	5.42e-18	Testicular germ cell tumor;
LUAD	cis	rs10242455	0.571	rs73713595	chr7:99326659	G/A	cg18809830	chr7:99032528	PTCD1	-0.87	-7.55	-0.34	2.77e-13	Blood metabolite levels;
LUAD	cis	rs12478296	1.000	rs55758933	chr2:243040289	T/C	cg06360820	chr2:242988706	NA	-0.84	-9.69	-0.43	3.39e-20	Obesity-related traits;
LUAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.81	0.43	1.28e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg20503657	chr10:835505	NA	0.78	10.22	0.45	4.51e-22	Eosinophil percentage of granulocytes;
LUAD	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg21385522	chr1:16154831	NA	0.44	6.66	0.31	8.42e-11	Dilated cardiomyopathy;
LUAD	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg23283495	chr1:209979779	IRF6	-0.73	-9.22	-0.41	1.45e-18	Cleft lip with or without cleft palate;
LUAD	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg06784218	chr1:46089804	CCDC17	0.51	11.15	0.48	1.71e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg08470875	chr2:26401718	FAM59B	-0.74	-10.22	-0.44	4.78e-22	Gut microbiome composition (summer);
LUAD	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.15	-0.37	4.06e-15	Total body bone mineral density;
LUAD	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg22618164	chr12:122356400	WDR66	-0.63	-11.01	-0.47	5.59e-25	Mean corpuscular volume;
LUAD	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg10523679	chr1:76189770	ACADM	0.76	12.16	0.51	2.14e-29	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg16342193	chr10:102329863	NA	-0.35	-6.43	-0.3	3.54e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9905704	0.633	rs2632506	chr17:56467408	G/T	cg19466818	chr17:56409534	MIR142	0.35	6.92	0.32	1.68e-11	Testicular germ cell tumor;
LUAD	cis	rs28374715	0.532	rs28897479	chr15:41690851	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.13	-23.63	-0.75	2.5e-79	Ulcerative colitis;
LUAD	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	6.74	0.31	5.16e-11	Lung cancer in ever smokers;
LUAD	cis	rs7705042	0.793	rs7705547	chr5:141514027	A/G	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.9	-0.32	1.97e-11	Asthma;
LUAD	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg23711669	chr6:146136114	FBXO30	0.4	6.82	0.31	3.13e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg03676636	chr4:99064102	C4orf37	0.32	8.26	0.37	1.92e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-12.48	-0.52	1.23e-30	Migraine;Coronary artery disease;
LUAD	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg05182265	chr7:156933206	UBE3C	0.63	11.9	0.5	2.4e-28	Body mass index;
LUAD	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg17849569	chr6:28058911	ZSCAN12L1	-0.29	-6.38	-0.3	4.74e-10	Depression;
LUAD	cis	rs6684428	1.000	rs12141873	chr1:56374311	G/T	cg11651538	chr1:56320950	NA	-0.4	-6.39	-0.3	4.39e-10	Airflow obstruction;
LUAD	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg11189052	chr15:85197271	WDR73	0.61	7.87	0.36	2.95e-14	Schizophrenia;
LUAD	cis	rs354225	0.544	rs12713269	chr2:54809154	C/G	cg01766943	chr2:54829624	SPTBN1	0.38	7.21	0.33	2.56e-12	Schizophrenia;
LUAD	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.38	-6.79	-0.31	3.84e-11	Caffeine consumption;
LUAD	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg14019146	chr3:50243930	SLC38A3	0.36	6.68	0.31	7.32e-11	Body mass index;
LUAD	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg09491104	chr22:46646882	C22orf40	-0.74	-13.44	-0.55	1.6e-34	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2073300	1.000	rs6132622	chr20:23442240	A/T	cg09953122	chr20:23471693	CST8	-0.65	-6.39	-0.3	4.29e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6429082	0.521	rs704711	chr1:235629802	G/A	cg26050004	chr1:235667680	B3GALNT2	0.38	6.46	0.3	2.87e-10	Adiposity;
LUAD	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg00495681	chr13:53174319	NA	0.6	11.13	0.48	2.1e-25	Lewy body disease;
LUAD	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg07606381	chr6:8435919	SLC35B3	0.42	6.82	0.31	3.13e-11	Motion sickness;
LUAD	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg14343924	chr8:8086146	FLJ10661	-0.49	-7.64	-0.35	1.48e-13	Joint mobility (Beighton score);
LUAD	cis	rs4343996	0.692	rs55848061	chr7:3454639	T/A	cg21248987	chr7:3385318	SDK1	0.35	6.41	0.3	3.97e-10	Motion sickness;
LUAD	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg27572855	chr1:25598939	RHD	-0.53	-11.31	-0.48	4.41e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg17333051	chr19:2783644	SGTA	0.43	6.87	0.32	2.31e-11	Total cholesterol levels;
LUAD	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.79	-13.61	-0.55	3e-35	Platelet distribution width;
LUAD	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg17264618	chr3:40429014	ENTPD3	0.39	8.89	0.4	1.79e-17	Renal cell carcinoma;
LUAD	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg03289416	chr15:75166202	SCAMP2	0.58	9.97	0.44	3.59e-21	Breast cancer;
LUAD	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg09509183	chr1:209979624	IRF6	0.36	6.38	0.3	4.55e-10	Monobrow;
LUAD	cis	rs9283706	0.623	rs1567316	chr5:66312103	T/G	cg11590213	chr5:66331682	MAST4	0.41	6.85	0.32	2.64e-11	Coronary artery disease;
LUAD	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs55665837	0.502	rs12795794	chr11:14846873	A/G	cg19336497	chr11:14380999	RRAS2	-0.39	-7.3	-0.33	1.44e-12	Vitamin D levels;
LUAD	cis	rs2742234	0.590	rs2293020	chr10:43692887	A/G	cg15436174	chr10:43711423	RASGEF1A	0.5	8.28	0.37	1.68e-15	Hirschsprung disease;
LUAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-8.3	-0.37	1.39e-15	Alzheimer's disease;
LUAD	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03264133	chr6:25882463	NA	-0.48	-7.16	-0.33	3.6e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg03161606	chr19:29218774	NA	0.54	7.66	0.35	1.27e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs12618769	0.625	rs3769709	chr2:99187433	A/T	cg10123293	chr2:99228465	UNC50	0.49	8.53	0.38	2.6e-16	Bipolar disorder;
LUAD	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg06784218	chr1:46089804	CCDC17	0.61	13.69	0.55	1.47e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg12310025	chr6:25882481	NA	-0.56	-8.07	-0.37	7.16e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.89	0.32	2e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg11189052	chr15:85197271	WDR73	-0.62	-10.33	-0.45	1.86e-22	P wave terminal force;
LUAD	cis	rs2692947	0.864	rs2579518	chr2:96675259	G/A	cg23100626	chr2:96804247	ASTL	0.32	8.3	0.37	1.4e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.17	15.71	0.61	3.88e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg03433033	chr1:76189801	ACADM	-0.84	-15.54	-0.6	2.11e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs747782	0.527	rs76142260	chr11:48331068	T/C	cg15704280	chr7:45808275	SEPT13	0.75	7.78	0.35	5.75e-14	Intraocular pressure;
LUAD	cis	rs9369695	0.842	rs9395262	chr6:47465267	T/C	cg02130027	chr6:47444894	CD2AP	0.36	6.87	0.32	2.33e-11	Reticulocyte count;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg04533189	chr17:64298763	PRKCA	-0.35	-6.39	-0.3	4.39e-10	Schizophrenia;
LUAD	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg22823121	chr1:150693482	HORMAD1	0.45	8.99	0.4	8.07e-18	Tonsillectomy;
LUAD	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg12935359	chr14:103987150	CKB	0.48	8.01	0.36	1.09e-14	Body mass index;
LUAD	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg27279351	chr12:120934652	DYNLL1	0.44	6.76	0.31	4.72e-11	High light scatter reticulocyte count;
LUAD	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg18512352	chr11:47633146	NA	-0.38	-6.85	-0.32	2.69e-11	Subjective well-being;
LUAD	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.51	-0.34	3.51e-13	Coronary artery disease;
LUAD	trans	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg11693508	chr17:37793320	STARD3	0.74	9.81	0.43	1.28e-20	Bipolar disorder;
LUAD	cis	rs10979	0.965	rs9376758	chr6:143886878	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.15	-0.44	8.6e-22	Hypospadias;
LUAD	cis	rs57502260	0.915	rs7106320	chr11:68210118	C/T	cg16797656	chr11:68205561	LRP5	0.48	7.48	0.34	4.21e-13	Total body bone mineral density (age 45-60);
LUAD	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.77	-0.35	6.16e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06873352	chr17:61820015	STRADA	0.55	8.99	0.4	8.56e-18	Height;
LUAD	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg02931644	chr1:25747376	RHCE	0.46	9.84	0.43	9.98e-21	Erythrocyte sedimentation rate;
LUAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.42	0.42	2.92e-19	Alzheimer's disease;
LUAD	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg00631329	chr6:26305371	NA	-0.68	-13.32	-0.54	4.83e-34	Educational attainment;
LUAD	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7000551	0.681	rs2461488	chr8:22371858	G/A	cg12081754	chr8:22256438	SLC39A14	0.46	7.59	0.35	2.03e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg25173405	chr17:45401733	C17orf57	0.46	7.79	0.35	5.2e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08677398	chr8:58056175	NA	0.47	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs67072384	1.000	rs12292781	chr11:72448385	A/C	cg04827223	chr11:72435913	ARAP1	-0.62	-7.67	-0.35	1.16e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg23283495	chr1:209979779	IRF6	0.73	10.64	0.46	1.37e-23	Cleft lip with or without cleft palate;
LUAD	trans	rs28735056	1.000	rs56376220	chr18:77609462	C/T	cg05926928	chr17:57297772	GDPD1	-0.51	-7.27	-0.33	1.73e-12	Schizophrenia;
LUAD	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg23649088	chr2:200775458	C2orf69	-0.62	-8.25	-0.37	2.03e-15	Schizophrenia;
LUAD	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg03929089	chr4:120376271	NA	-0.69	-9.68	-0.43	3.67e-20	Coronary artery disease;
LUAD	cis	rs12681287	0.640	rs7816275	chr8:87373404	A/G	cg00550725	chr8:87521180	FAM82B	-0.47	-6.72	-0.31	5.83e-11	Caudate activity during reward;
LUAD	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.26	-0.33	1.86e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs11039798	1.000	rs7942284	chr11:48520424	A/G	cg15704280	chr7:45808275	SEPT13	-0.63	-7.11	-0.33	5.03e-12	Axial length;
LUAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg00450029	chr8:599525	NA	0.67	7.21	0.33	2.63e-12	IgG glycosylation;
LUAD	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	6.61	0.31	1.15e-10	Schizophrenia;
LUAD	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22590775	chr19:49891494	CCDC155	0.59	8.55	0.38	2.25e-16	Multiple sclerosis;
LUAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg22907277	chr7:1156413	C7orf50	0.47	7.79	0.35	5.33e-14	Longevity;Endometriosis;
LUAD	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg16405210	chr4:1374714	KIAA1530	-0.39	-6.7	-0.31	6.48e-11	Obesity-related traits;
LUAD	cis	rs1595825	0.735	rs16827465	chr2:198945680	G/T	cg00982548	chr2:198649783	BOLL	-0.61	-8.3	-0.37	1.39e-15	Ulcerative colitis;
LUAD	cis	rs4638749	0.588	rs13401731	chr2:108885340	C/T	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.86	-0.32	2.47e-11	Blood pressure;
LUAD	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg12062639	chr20:23401060	NAPB	1.09	11.16	0.48	1.64e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2294693	0.947	rs6924722	chr6:41002195	C/T	cg14769373	chr6:40998127	UNC5CL	0.53	8.62	0.39	1.34e-16	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg02569458	chr12:86230093	RASSF9	0.37	7.3	0.33	1.42e-12	Major depressive disorder;
LUAD	cis	rs9309473	0.528	rs7573275	chr2:73552542	G/A	cg20560298	chr2:73613845	ALMS1	-0.42	-6.38	-0.3	4.78e-10	Metabolite levels;
LUAD	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg22875332	chr1:76189707	ACADM	0.9	18.28	0.66	1.87e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg08885076	chr2:99613938	TSGA10	0.37	6.67	0.31	8.27e-11	Chronic sinus infection;
LUAD	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.41	-6.83	-0.32	2.98e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg06873352	chr17:61820015	STRADA	0.43	7.11	0.33	4.92e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg25985355	chr7:65971099	NA	0.54	6.8	0.31	3.56e-11	Diabetic kidney disease;
LUAD	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg21475434	chr5:93447410	FAM172A	0.7	8.36	0.38	8.84e-16	Diabetic retinopathy;
LUAD	cis	rs4077515	0.874	rs3812575	chr9:139293259	T/C	cg14019695	chr9:139328340	INPP5E	0.4	7.64	0.35	1.51e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg10518543	chr12:38710700	ALG10B	0.41	6.38	0.3	4.59e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg04414720	chr1:150670196	GOLPH3L	0.7	12.93	0.53	1.91e-32	Tonsillectomy;
LUAD	cis	rs1451375	1.000	rs1451375	chr7:50622712	A/C	cg18232548	chr7:50535776	DDC	-0.59	-9.92	-0.43	5.22e-21	Malaria;
LUAD	cis	rs6546550	0.867	rs4401231	chr2:70063563	G/C	cg02498382	chr2:70120550	SNRNP27	-0.56	-10.65	-0.46	1.27e-23	Prevalent atrial fibrillation;
LUAD	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-15.41	-0.6	7.76e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs112990264	0.772	rs6540755	chr1:212878809	A/T	cg01785514	chr1:212988523	TATDN3	-0.84	-8.07	-0.37	7.21e-15	Itch intensity from mosquito bite;
LUAD	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg09796270	chr17:17721594	SREBF1	-0.37	-6.95	-0.32	1.35e-11	Total body bone mineral density;
LUAD	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg02683114	chr2:24398427	C2orf84	0.43	7.14	0.33	4.05e-12	Asthma;
LUAD	cis	rs17155006	0.746	rs985152	chr7:107750357	G/A	cg05962710	chr7:107745446	LAMB4	-0.34	-7.27	-0.33	1.74e-12	Pneumococcal bacteremia;
LUAD	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg00750074	chr16:89608354	SPG7	0.46	7.75	0.35	6.81e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs4776059	0.876	rs2414163	chr15:52897478	T/C	cg24008177	chr15:52972085	KIAA1370	0.25	6.75	0.31	4.93e-11	Schizophrenia;
LUAD	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg13770153	chr20:60521292	NA	0.47	7.97	0.36	1.52e-14	Body mass index;
LUAD	cis	rs11118844	0.739	rs12070192	chr1:221945870	A/T	cg04222084	chr1:221915650	DUSP10	-0.67	-7.68	-0.35	1.15e-13	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg01849466	chr14:104193079	ZFYVE21	0.46	7.67	0.35	1.17e-13	Body mass index;
LUAD	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.51	-0.42	1.51e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.54	-7.34	-0.34	1.14e-12	Gut microbiome composition (summer);
LUAD	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg08645402	chr16:4508243	NA	0.57	10.02	0.44	2.47e-21	Schizophrenia;
LUAD	cis	rs12519773	0.717	rs6557063	chr5:92493318	T/C	cg18783429	chr5:92414398	NA	0.39	6.76	0.31	4.7e-11	Migraine;
LUAD	cis	rs4713675	0.584	rs560111	chr6:33706277	C/T	cg14003231	chr6:33640908	ITPR3	0.35	6.48	0.3	2.63e-10	Plateletcrit;
LUAD	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg19774624	chr17:42201019	HDAC5	-0.38	-6.49	-0.3	2.47e-10	Total body bone mineral density;
LUAD	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg10556349	chr10:835070	NA	0.59	7.64	0.35	1.48e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs2235649	0.753	rs7200472	chr16:1849669	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-8.1	-0.37	6.05e-15	Blood metabolite levels;
LUAD	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg26587870	chr6:27730563	NA	-0.48	-7.86	-0.36	3.11e-14	Parkinson's disease;
LUAD	cis	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg14019146	chr3:50243930	SLC38A3	-0.54	-10.43	-0.45	7.83e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg06784218	chr1:46089804	CCDC17	-0.54	-11.85	-0.5	3.46e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs11958404	0.932	rs72816550	chr5:157418457	A/T	cg05962755	chr5:157440814	NA	0.42	6.57	0.3	1.46e-10	IgG glycosylation;
LUAD	cis	rs295140	0.506	rs4673854	chr2:201134736	G/A	cg23649088	chr2:200775458	C2orf69	-0.47	-7.94	-0.36	1.78e-14	QT interval;
LUAD	cis	rs7095607	0.813	rs7908489	chr10:69932557	C/T	cg18986048	chr10:69913749	MYPN	0.38	6.46	0.3	2.88e-10	Lung function (FVC);
LUAD	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	6.56	0.3	1.61e-10	Schizophrenia;
LUAD	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.5	6.79	0.31	3.9e-11	Platelet count;
LUAD	cis	rs6961069	0.806	rs10499859	chr7:80258810	A/G	cg04458919	chr7:80252533	CD36	0.36	6.86	0.32	2.53e-11	Platelet count;
LUAD	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg05342682	chr7:94953680	PON1	-0.5	-6.94	-0.32	1.53e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg05082376	chr22:42548792	NA	0.49	8.95	0.4	1.16e-17	Schizophrenia;
LUAD	cis	rs13095912	1.000	rs2034343	chr3:185337854	A/T	cg11274856	chr3:185301563	NA	0.38	7.66	0.35	1.32e-13	Systolic blood pressure;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg13834670	chr9:129677390	RALGPS1	0.37	6.41	0.3	3.95e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg00277334	chr10:82204260	NA	-0.49	-7.98	-0.36	1.36e-14	Post bronchodilator FEV1;
LUAD	cis	rs9393692	0.557	rs62394768	chr6:26326033	C/T	cg00631329	chr6:26305371	NA	-0.55	-9.19	-0.41	1.82e-18	Educational attainment;
LUAD	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg04398451	chr17:18023971	MYO15A	-0.64	-11.7	-0.49	1.41e-27	Total body bone mineral density;
LUAD	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.71	0.35	8.88e-14	Platelet count;
LUAD	cis	rs933688	0.532	rs973332	chr5:90555129	C/T	cg17503389	chr5:90575422	NA	-0.44	-6.61	-0.31	1.2e-10	Smoking behavior;
LUAD	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg00933542	chr6:150070202	PCMT1	0.43	9.37	0.41	4.5e-19	Lung cancer;
LUAD	cis	rs7274811	0.711	rs291689	chr20:32003974	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.48	7.28	0.33	1.67e-12	Height;
LUAD	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg07917127	chr4:99064746	C4orf37	0.44	7.21	0.33	2.6e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2235649	0.592	rs8046208	chr16:1964008	G/A	cg08610935	chr16:1836813	NUBP2	-0.5	-7.31	-0.33	1.36e-12	Blood metabolite levels;
LUAD	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09263875	chr16:632152	PIGQ	0.83	18.46	0.67	3.18e-56	Height;
LUAD	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg22875332	chr1:76189707	ACADM	0.88	16.57	0.63	6.76e-48	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12545109	0.643	rs1119707	chr8:57411548	T/C	cg21220214	chr8:57350948	NA	-0.63	-8.81	-0.39	3.27e-17	Obesity-related traits;
LUAD	cis	rs236352	0.538	rs9470426	chr6:36846988	T/C	cg10099585	chr6:36853529	C6orf89	-0.4	-6.41	-0.3	3.83e-10	Heart rate;
LUAD	cis	rs877282	0.685	rs56234340	chr10:781339	A/G	cg17470449	chr10:769945	NA	0.6	8.98	0.4	9.02e-18	Uric acid levels;
LUAD	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg17264618	chr3:40429014	ENTPD3	0.42	8.84	0.39	2.63e-17	Renal cell carcinoma;
LUAD	cis	rs8177876	0.822	rs56198248	chr16:81108474	G/A	cg08591886	chr16:81111003	C16orf46	-0.84	-6.81	-0.31	3.35e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg06671706	chr8:8559999	CLDN23	-0.55	-9.0	-0.4	7.67e-18	Obesity-related traits;
LUAD	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg00316803	chr15:76480434	C15orf27	-0.43	-8.57	-0.38	1.94e-16	Blood metabolite levels;
LUAD	trans	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg06606381	chr12:133084897	FBRSL1	-1.14	-10.62	-0.46	1.69e-23	Lung cancer in ever smokers;
LUAD	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg21709803	chr11:61594965	FADS2	-0.4	-7.34	-0.34	1.07e-12	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs1018836	0.851	rs7004287	chr8:91620842	G/C	cg16814680	chr8:91681699	NA	-0.69	-11.84	-0.5	3.9e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg14895029	chr7:2775587	GNA12	-0.41	-6.62	-0.31	1.1e-10	Height;
LUAD	cis	rs4589502	1.000	rs12440279	chr15:67133339	G/A	cg09911534	chr15:67153556	NA	-0.5	-6.82	-0.31	3.11e-11	Lung cancer (smoking interaction);
LUAD	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg22920501	chr2:26401640	FAM59B	-0.73	-10.49	-0.45	4.71e-23	Gut microbiome composition (summer);
LUAD	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.59	0.31	1.34e-10	Cardiac Troponin-T levels;
LUAD	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-6.91	-0.32	1.83e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3790645	0.958	rs2278979	chr1:26877708	G/A	cg23229016	chr1:26872525	RPS6KA1	0.21	6.67	0.31	8.24e-11	Glucose homeostasis traits;
LUAD	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.75	0.46	5.2e-24	Smoking behavior;
LUAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg12373951	chr3:133503437	NA	-0.35	-6.96	-0.32	1.28e-11	Iron status biomarkers;
LUAD	cis	rs4908760	0.783	rs301799	chr1:8489302	C/T	cg01447281	chr1:8482689	RERE	-0.39	-8.21	-0.37	2.72e-15	Vitiligo;
LUAD	trans	rs6940638	0.956	rs3922717	chr6:27030924	A/G	cg06606381	chr12:133084897	FBRSL1	-0.48	-6.36	-0.3	5.18e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7044106	0.791	rs4836831	chr9:123496570	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	7.72	0.35	8.47e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs4332037	0.615	rs62435134	chr7:1895463	T/G	cg02421172	chr7:1938701	MAD1L1	0.49	6.83	0.32	2.97e-11	Bipolar disorder;
LUAD	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg11833968	chr6:79620685	NA	-0.43	-8.03	-0.36	9.99e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs932287	0.651	rs1111010	chr11:9049935	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.45	8.11	0.37	5.47e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg15704280	chr7:45808275	SEPT13	-0.51	-8.19	-0.37	3.01e-15	Height;
LUAD	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg01884057	chr2:25150051	NA	0.33	7.15	0.33	3.84e-12	Body mass index;
LUAD	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg03690763	chr11:133734501	NA	-0.32	-7.77	-0.35	6.14e-14	Childhood ear infection;
LUAD	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.45	8.03	0.36	9.64e-15	Lung cancer in ever smokers;
LUAD	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg17279839	chr7:150038598	RARRES2	0.47	7.49	0.34	4.08e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs16866061	0.855	rs11687736	chr2:225405122	A/T	cg12698349	chr2:225449008	CUL3	0.77	13.51	0.55	7.85e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs939658	0.683	rs8024572	chr15:79465600	A/G	cg17916960	chr15:79447300	NA	0.37	6.83	0.32	3e-11	Refractive error;
LUAD	cis	rs3806843	0.576	rs246020	chr5:140334771	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1018836	0.923	rs13255452	chr8:91582988	A/G	cg16814680	chr8:91681699	NA	-0.72	-12.22	-0.51	1.32e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg14227996	chr4:17616232	MED28	0.72	7.58	0.35	2.27e-13	Opioid sensitivity;
LUAD	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg00631329	chr6:26305371	NA	-0.68	-13.21	-0.54	1.41e-33	Educational attainment;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg14026485	chr9:74979581	ZFAND5	-0.38	-6.53	-0.3	1.85e-10	Schizophrenia;
LUAD	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg07936489	chr17:37558343	FBXL20	0.5	6.64	0.31	9.37e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs9362426	0.708	rs7753821	chr6:88100010	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	6.72	0.31	5.95e-11	Depressive episodes in bipolar disorder;
LUAD	cis	rs6840360	0.571	rs7692700	chr4:152552797	C/T	cg22705602	chr4:152727874	NA	-0.4	-6.82	-0.31	3.11e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs929596	0.793	rs2741046	chr2:234580249	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-8.88	-0.4	1.97e-17	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg15691649	chr6:25882328	NA	-0.45	-7.13	-0.33	4.29e-12	Blood metabolite levels;
LUAD	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg00071950	chr4:10020882	SLC2A9	0.85	18.43	0.67	4e-56	Bone mineral density;
LUAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg08513622	chr7:1889785	MAD1L1	-0.41	-6.38	-0.3	4.63e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg11707310	chr1:2537719	MMEL1	-0.35	-7.45	-0.34	5.16e-13	Ulcerative colitis;
LUAD	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg06046430	chr4:77819534	ANKRD56	0.55	8.86	0.4	2.29e-17	Emphysema distribution in smoking;
LUAD	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08109568	chr15:31115862	NA	-0.61	-10.28	-0.45	2.71e-22	Huntington's disease progression;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg01087382	chr6:91297190	MAP3K7	-0.39	-6.59	-0.31	1.29e-10	Subcortical brain region volumes;
LUAD	cis	rs3760982	0.585	rs67704568	chr19:44294019	T/C	cg11993925	chr19:44307056	LYPD5	0.54	11.17	0.48	1.52e-25	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs490234	0.841	rs10114882	chr9:128303425	T/C	cg14078157	chr9:128172775	NA	-0.41	-7.33	-0.34	1.18e-12	Mean arterial pressure;
LUAD	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg26384229	chr12:38710491	ALG10B	0.47	7.61	0.35	1.79e-13	Bladder cancer;
LUAD	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg05187965	chr10:45406764	TMEM72	-0.43	-8.79	-0.39	3.77e-17	Mean corpuscular volume;
LUAD	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg25036284	chr2:26402008	FAM59B	-0.55	-7.8	-0.35	4.84e-14	Gut microbiome composition (summer);
LUAD	cis	rs829880	1.000	rs829880	chr12:98845331	G/T	cg25150519	chr12:98850993	NA	0.64	11.77	0.5	7.27e-28	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-10.2	-0.44	5.31e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg23758822	chr17:41437982	NA	1.01	20.84	0.71	6.8e-67	Menopause (age at onset);
LUAD	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.75	-0.35	6.68e-14	Blood trace element (Zn levels);
LUAD	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg14784868	chr12:69753453	YEATS4	0.45	7.38	0.34	8.24e-13	Blood protein levels;
LUAD	cis	rs2692947	0.644	rs1168974	chr2:96814928	G/A	cg23100626	chr2:96804247	ASTL	0.38	9.82	0.43	1.2e-20	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg24399712	chr22:39784796	NA	-0.81	-16.24	-0.62	1.84e-46	Intelligence (multi-trait analysis);
LUAD	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg13385794	chr1:248469461	NA	0.26	6.94	0.32	1.46e-11	Common traits (Other);
LUAD	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg18944383	chr4:111397179	ENPEP	0.33	6.38	0.3	4.52e-10	Height;
LUAD	trans	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg04995722	chr7:26192034	NFE2L3	-0.41	-7.11	-0.33	4.84e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17818399	0.781	rs12105006	chr2:46862586	C/T	cg09399716	chr2:46890238	NA	0.36	6.87	0.32	2.37e-11	Height;
LUAD	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg12292205	chr6:26970375	C6orf41	-0.4	-7.1	-0.33	5.2e-12	Schizophrenia;
LUAD	cis	rs12545109	0.700	rs2670045	chr8:57393695	A/G	cg09654669	chr8:57350985	NA	-0.65	-9.64	-0.42	5.23e-20	Obesity-related traits;
LUAD	trans	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.51	-0.34	3.43e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs57994353	0.897	rs12551527	chr9:139358425	C/G	cg13856295	chr9:139396418	NOTCH1	-0.42	-6.7	-0.31	6.74e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	7.98	0.36	1.38e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs12431939	1.000	rs12433445	chr14:51666091	G/A	cg23942311	chr14:51606299	NA	-0.63	-8.62	-0.39	1.36e-16	Cancer;
LUAD	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg19773385	chr1:10388646	KIF1B	-0.41	-6.61	-0.31	1.16e-10	Hepatocellular carcinoma;
LUAD	cis	rs9796	0.870	rs7181816	chr15:41358720	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.37	-6.97	-0.32	1.22e-11	Menopause (age at onset);
LUAD	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.81	-0.39	3.39e-17	Alcohol dependence;
LUAD	trans	rs79911532	0.515	rs113056502	chr7:75667901	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	8.66	0.39	9.81e-17	Mononucleosis;
LUAD	cis	rs11677370	0.603	rs11696104	chr2:3849512	C/G	cg17052675	chr2:3827356	NA	-0.62	-10.85	-0.47	2.34e-24	Type 2 diabetes;
LUAD	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg12062639	chr20:23401060	NAPB	1.08	11.36	0.48	2.76e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg21100191	chr22:23484243	RTDR1	0.68	11.77	0.5	7.25e-28	Bone mineral density;
LUAD	cis	rs17253792	0.822	rs75555677	chr14:56096429	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg17644776	chr2:200775616	C2orf69	0.52	6.53	0.3	1.9e-10	Schizophrenia;
LUAD	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.41	-7.12	-0.33	4.79e-12	Platelet count;
LUAD	cis	rs7945718	0.934	rs4553350	chr11:12759834	A/G	cg25843174	chr11:12811716	TEAD1	-0.23	-6.93	-0.32	1.59e-11	Educational attainment (years of education);
LUAD	cis	rs12681287	0.752	rs9297861	chr8:87254730	G/C	cg27223183	chr8:87520930	FAM82B	-0.59	-8.05	-0.36	8.64e-15	Caudate activity during reward;
LUAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08677398	chr8:58056175	NA	0.47	6.55	0.3	1.71e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg02990361	chr1:107599529	PRMT6	0.59	9.82	0.43	1.24e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg17063962	chr7:91808500	NA	0.6	9.85	0.43	9.7e-21	Breast cancer;
LUAD	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg00684032	chr4:1343700	KIAA1530	0.41	6.77	0.31	4.32e-11	Obesity-related traits;
LUAD	trans	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg02030672	chr11:45687055	CHST1	-0.37	-6.43	-0.3	3.48e-10	Obesity-related traits;
LUAD	cis	rs2548003	0.518	rs2548015	chr5:28726109	A/C	cg22863700	chr5:28928346	NA	0.44	6.54	0.3	1.81e-10	Hip geometry;
LUAD	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03517284	chr6:25882590	NA	-0.41	-6.64	-0.31	9.54e-11	Height;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg16245510	chr1:25559209	SYF2	-0.38	-6.35	-0.3	5.62e-10	Subcortical brain region volumes;
LUAD	cis	rs8177876	0.642	rs16954572	chr16:81112904	T/C	cg08591886	chr16:81111003	C16orf46	-0.76	-7.01	-0.32	9.76e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs12050794	0.671	rs7179427	chr15:72516821	G/A	cg16672083	chr15:72433130	SENP8	0.65	11.79	0.5	6.19e-28	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	7.27	0.33	1.73e-12	Alzheimer's disease;
LUAD	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg00647820	chr17:40259828	DHX58	-0.44	-7.14	-0.33	4.01e-12	Fibrinogen levels;
LUAD	cis	rs7707921	1.000	rs6884232	chr5:81550043	G/A	cg15871215	chr5:81402204	ATG10	0.7	10.09	0.44	1.33e-21	Breast cancer;
LUAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg02869364	chr7:1081709	C7orf50	-0.35	-6.64	-0.31	9.84e-11	Longevity;Endometriosis;
LUAD	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg24069376	chr3:38537580	EXOG	0.44	10.69	0.46	8.72e-24	Electrocardiographic conduction measures;
LUAD	cis	rs17152411	1.000	rs11245440	chr10:126634572	C/T	cg07906193	chr10:126599966	NA	0.54	7.17	0.33	3.45e-12	Height;
LUAD	cis	rs6541297	0.703	rs2748115	chr1:230314291	A/G	cg20703242	chr1:230279135	GALNT2	-0.48	-7.07	-0.32	6.64e-12	Coronary artery disease;
LUAD	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg27432699	chr2:27873401	GPN1	-0.39	-6.64	-0.31	9.5e-11	Total body bone mineral density;
LUAD	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.77	9.91	0.43	5.85e-21	Body mass index;
LUAD	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg05368731	chr17:41323189	NBR1	-0.82	-16.31	-0.62	9.82e-47	Menopause (age at onset);
LUAD	trans	rs75804782	0.566	rs77693902	chr2:239260477	T/G	cg01134436	chr17:81009848	B3GNTL1	0.73	6.42	0.3	3.72e-10	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs17152411	1.000	rs11245451	chr10:126661428	C/T	cg07906193	chr10:126599966	NA	0.52	6.94	0.32	1.44e-11	Height;
LUAD	cis	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg07460842	chr6:66804631	NA	0.6	9.32	0.41	6.35e-19	Type 2 diabetes;
LUAD	cis	rs7107174	1.000	rs10899479	chr11:78052539	A/G	cg19901956	chr11:77921274	USP35	-0.49	-6.38	-0.3	4.76e-10	Testicular germ cell tumor;
LUAD	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.23	-0.41	1.31e-18	Type 2 diabetes;
LUAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.54	0.3	1.76e-10	Prudent dietary pattern;
LUAD	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg26566898	chr11:117069891	TAGLN	-0.37	-7.45	-0.34	5.28e-13	Blood protein levels;
LUAD	cis	rs7771547	0.642	rs668499	chr6:36496379	A/G	cg07856975	chr6:36356162	ETV7	0.42	6.54	0.3	1.78e-10	Platelet distribution width;
LUAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg05754148	chr16:3507555	NAT15	-0.45	-6.95	-0.32	1.38e-11	Body mass index (adult);
LUAD	cis	rs2274273	0.840	rs10150760	chr14:55821548	C/T	cg04306507	chr14:55594613	LGALS3	-0.42	-8.67	-0.39	9.08e-17	Protein biomarker;
LUAD	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.68	0.31	7.4e-11	Parkinson's disease;
LUAD	trans	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.46e-11	Depression;
LUAD	cis	rs4888262	0.514	rs8048239	chr16:74578317	A/T	cg01733217	chr16:74700730	RFWD3	0.49	8.32	0.37	1.23e-15	Testicular germ cell tumor;
LUAD	cis	rs11771526	0.901	rs2191000	chr7:32275098	C/A	cg27511599	chr7:32358540	NA	0.53	6.48	0.3	2.49e-10	Body mass index;
LUAD	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.54	7.53	0.34	3.04e-13	Schizophrenia;
LUAD	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-7.13	-0.33	4.45e-12	Retinal vascular caliber;
LUAD	cis	rs2131877	0.956	rs58381781	chr3:194872824	T/C	cg19760965	chr3:194868843	C3orf21	0.39	6.49	0.3	2.39e-10	Non-small cell lung cancer;
LUAD	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg24069376	chr3:38537580	EXOG	0.34	7.8	0.35	4.97e-14	Electrocardiographic conduction measures;
LUAD	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg00852783	chr1:26633632	UBXN11	0.45	7.05	0.32	7.5e-12	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs12200782	0.929	rs10456328	chr6:26347997	C/T	cg08851530	chr6:28072375	NA	0.71	6.36	0.3	5.35e-10	Small cell lung carcinoma;
LUAD	trans	rs17604090	0.529	rs10239226	chr7:29716312	C/G	cg27349345	chr7:35225932	NA	-0.45	-6.46	-0.3	2.97e-10	Facial emotion recognition;Facial emotion recognition (sad faces);
LUAD	cis	rs7705042	0.865	rs2338821	chr5:141509433	A/G	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.78	-0.31	4.1e-11	Asthma;
LUAD	cis	rs41271473	0.607	rs10916361	chr1:228859971	A/T	cg10167378	chr1:228756711	NA	0.4	6.41	0.3	3.91e-10	Chronic lymphocytic leukemia;
LUAD	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.87	0.36	2.95e-14	Morning vs. evening chronotype;
LUAD	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs7828089	0.935	rs2293144	chr8:22262418	A/G	cg12081754	chr8:22256438	SLC39A14	0.57	10.02	0.44	2.4e-21	Verbal declarative memory;
LUAD	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	9.74	0.43	2.24e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg22676075	chr6:135203613	NA	0.5	8.86	0.4	2.21e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg04117972	chr1:227635322	NA	0.87	7.75	0.35	6.71e-14	Major depressive disorder;
LUAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg14820908	chr5:178986412	RUFY1	0.48	8.0	0.36	1.22e-14	Lung cancer;
LUAD	trans	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg26043149	chr18:55253948	FECH	0.42	6.64	0.31	9.62e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg24838063	chr12:130822603	PIWIL1	0.66	10.84	0.47	2.56e-24	Menopause (age at onset);
LUAD	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg11871910	chr12:69753446	YEATS4	0.47	7.55	0.34	2.75e-13	Response to diuretic therapy;
LUAD	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.22	0.37	2.51e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg02887458	chr19:19495540	GATAD2A	-0.44	-7.3	-0.33	1.47e-12	Bipolar disorder;
LUAD	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg23173402	chr1:227635558	NA	0.72	7.87	0.36	2.9e-14	Major depressive disorder;
LUAD	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.12	-0.51	3.03e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg13813247	chr22:41461852	NA	-0.49	-8.1	-0.37	6.08e-15	Neuroticism;
LUAD	cis	rs2041840	0.597	rs10865124	chr2:37576553	A/G	cg25727520	chr2:37576821	QPCT	-0.39	-8.42	-0.38	5.85e-16	Chronic lymphocytic leukemia;
LUAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-7.26	-0.33	1.89e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg20673091	chr1:2541236	MMEL1	0.43	9.08	0.4	4.15e-18	Ulcerative colitis;
LUAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs686320	1.000	rs72643572	chr11:65250967	A/G	cg21890820	chr11:65308645	LTBP3	0.81	8.87	0.4	2.13e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs12618769	0.597	rs72821930	chr2:99127525	C/T	cg10123293	chr2:99228465	UNC50	0.47	8.47	0.38	4.2e-16	Bipolar disorder;
LUAD	cis	rs12210905	0.541	rs56099947	chr6:27490937	G/T	cg08851530	chr6:28072375	NA	0.94	6.85	0.32	2.58e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.03	-0.32	8.42e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7223966	0.729	rs2003549	chr17:62008437	C/T	cg25324976	chr17:61989376	CSHL1	0.4	7.37	0.34	9.07e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg02375832	chr11:62437615	C11orf48	-0.32	-6.71	-0.31	6.14e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg18827107	chr12:86230957	RASSF9	-0.68	-12.35	-0.51	3.82e-30	Major depressive disorder;
LUAD	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg12292205	chr6:26970375	C6orf41	-0.57	-9.97	-0.44	3.56e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg02951883	chr7:2050386	MAD1L1	-0.83	-14.96	-0.59	6.65e-41	Bipolar disorder and schizophrenia;
LUAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg11494091	chr17:61959527	GH2	0.74	18.57	0.67	1.04e-56	Prudent dietary pattern;
LUAD	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg06263672	chr7:65235340	NA	0.49	6.4	0.3	4.07e-10	Aortic root size;
LUAD	cis	rs2455601	0.786	rs3751064	chr11:8958903	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.54	-9.12	-0.41	3.04e-18	Schizophrenia;
LUAD	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg25358565	chr5:93447407	FAM172A	0.64	7.91	0.36	2.31e-14	Diabetic retinopathy;
LUAD	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.67	0.31	8.13e-11	Menarche (age at onset);
LUAD	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.75	-15.52	-0.6	2.61e-43	Lung cancer;
LUAD	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg19346786	chr7:2764209	NA	-0.48	-9.9	-0.43	6.49e-21	Height;
LUAD	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs6484504	0.576	rs208083	chr11:31196880	C/T	cg26647111	chr11:31128758	NA	-0.47	-8.37	-0.38	8.48e-16	Red blood cell count;
LUAD	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg25173405	chr17:45401733	C17orf57	0.45	7.75	0.35	6.82e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg18446336	chr7:2847575	GNA12	-0.39	-7.26	-0.33	1.88e-12	Height;
LUAD	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.41	-0.34	6.98e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg21775007	chr8:11205619	TDH	0.41	6.87	0.32	2.32e-11	Neuroticism;
LUAD	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg17063962	chr7:91808500	NA	-0.67	-11.71	-0.49	1.27e-27	Breast cancer;
LUAD	trans	rs11650494	0.831	rs11650886	chr17:47449193	G/A	cg11430096	chr6:110968061	CDK19	0.89	6.71	0.31	6.14e-11	Prostate cancer;
LUAD	cis	rs1298062	0.717	rs78467973	chr19:50995571	T/C	cg11430371	chr19:50961752	MYBPC2	0.32	6.57	0.3	1.52e-10	Age of smoking initiation;
LUAD	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg03477792	chr4:77819574	ANKRD56	0.48	7.18	0.33	3.2e-12	Emphysema distribution in smoking;
LUAD	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-8.63	-0.39	1.24e-16	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg24558204	chr6:135376177	HBS1L	0.49	9.15	0.41	2.46e-18	Red blood cell count;
LUAD	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg21231944	chr12:82153410	PPFIA2	-0.35	-6.54	-0.3	1.74e-10	Resting heart rate;
LUAD	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-8.12	-0.37	5.18e-15	Height;Educational attainment;Head circumference (infant);
LUAD	cis	rs7202877	0.706	rs8054586	chr16:75410705	G/C	cg03315344	chr16:75512273	CHST6	0.49	6.82	0.31	3.2e-11	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg17264618	chr3:40429014	ENTPD3	0.35	7.46	0.34	4.85e-13	Renal cell carcinoma;
LUAD	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg06387496	chr7:2775674	GNA12	-0.39	-6.55	-0.3	1.72e-10	Height;
LUAD	cis	rs9811920	0.598	rs793470	chr3:99548274	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	11.81	0.5	5.26e-28	Axial length;
LUAD	cis	rs12079745	0.793	rs12071224	chr1:169191945	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-1.1	-8.03	-0.36	9.8e-15	QT interval;
LUAD	cis	rs4588572	0.643	rs9293752	chr5:77798432	A/G	cg11547950	chr5:77652471	NA	0.67	11.2	0.48	1.17e-25	Triglycerides;
LUAD	cis	rs13315871	1.000	rs13060489	chr3:58339287	G/A	cg20936604	chr3:58311152	NA	-0.7	-7.13	-0.33	4.47e-12	Cholesterol, total;
LUAD	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg16486109	chr11:613632	IRF7	0.49	7.41	0.34	6.99e-13	Systemic lupus erythematosus;
LUAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg21724239	chr8:58056113	NA	-0.75	-9.16	-0.41	2.34e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.25	6.49	0.3	2.4e-10	Parkinson's disease;
LUAD	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg18180107	chr4:99064573	C4orf37	0.4	6.4	0.3	4.12e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4700695	0.764	rs36299	chr5:65348120	G/T	cg21114390	chr5:65439923	SFRS12	0.62	7.57	0.35	2.32e-13	Facial morphology (factor 19);
LUAD	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg04369109	chr6:150039330	LATS1	-0.47	-7.59	-0.35	2e-13	Lung cancer;
LUAD	cis	rs12620999	0.941	rs62183344	chr2:237979165	T/C	cg23555395	chr2:238036564	NA	0.57	8.69	0.39	8.29e-17	Systemic lupus erythematosus;
LUAD	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg12179176	chr11:130786555	SNX19	0.55	9.29	0.41	8.21e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg01256987	chr12:42539512	GXYLT1	-0.52	-11.06	-0.47	3.8e-25	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg10755058	chr3:40428713	ENTPD3	0.39	7.5	0.34	3.75e-13	Renal cell carcinoma;
LUAD	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg22676075	chr6:135203613	NA	0.56	9.94	0.44	4.6e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7731657	0.537	rs2214532	chr5:130316001	C/T	cg08523029	chr5:130500466	HINT1	-0.57	-7.33	-0.34	1.2e-12	Fasting plasma glucose;
LUAD	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg13511324	chr14:104056883	C14orf153	0.28	6.77	0.31	4.3e-11	Reticulocyte count;
LUAD	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg25344623	chr2:136566232	LCT	-0.37	-7.18	-0.33	3.26e-12	Mosquito bite size;
LUAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.6	-10.58	-0.46	2.24e-23	Longevity;Endometriosis;
LUAD	cis	rs889398	0.802	rs8051168	chr16:69887274	T/A	cg00738113	chr16:70207722	CLEC18C	-0.34	-6.82	-0.31	3.21e-11	Body mass index;
LUAD	cis	rs7818345	0.640	rs13267801	chr8:19326834	C/G	cg06699216	chr8:19333253	CSGALNACT1	-0.3	-7.03	-0.32	8.48e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs76878669	0.561	rs7107191	chr11:66140397	G/A	cg10616300	chr11:66138557	SLC29A2	0.35	7.3	0.33	1.49e-12	Educational attainment (years of education);
LUAD	cis	rs10193935	0.901	rs2286702	chr2:42555473	C/T	cg27598129	chr2:42591480	NA	-0.8	-10.31	-0.45	2.26e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.23	0.41	1.32e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10203711	1.000	rs6711116	chr2:239596636	T/G	cg14580085	chr2:239553406	NA	0.41	8.77	0.39	4.39e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg14949292	chr17:78079608	GAA	0.35	6.73	0.31	5.69e-11	Yeast infection;
LUAD	cis	rs6740322	0.748	rs13402621	chr2:43458611	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-11.14	-0.48	1.85e-25	Coronary artery disease;
LUAD	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg08280861	chr8:58055591	NA	0.71	8.55	0.38	2.32e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg21659725	chr3:3221576	CRBN	-0.59	-9.58	-0.42	8.49e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.7	0.31	6.76e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg08859206	chr1:53392774	SCP2	-0.68	-12.83	-0.53	4.58e-32	Monocyte count;
LUAD	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15664640	chr17:80829946	TBCD	-0.85	-16.95	-0.64	1.43e-49	Breast cancer;
LUAD	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg24848339	chr3:12840334	CAND2	0.49	10.41	0.45	9.86e-23	QRS complex (12-leadsum);
LUAD	cis	rs2797160	1.000	rs9321050	chr6:126001568	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.66	-0.31	8.69e-11	Endometrial cancer;
LUAD	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg01579765	chr21:45077557	HSF2BP	0.59	12.15	0.51	2.37e-29	Mean corpuscular hemoglobin;
LUAD	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg06618935	chr21:46677482	NA	-0.41	-8.18	-0.37	3.35e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.87e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.812	rs10054168	chr5:130788698	C/T	cg06307176	chr5:131281290	NA	-0.43	-7.12	-0.33	4.76e-12	Life satisfaction;
LUAD	cis	rs2985684	0.948	rs12897941	chr14:50016701	G/C	cg04989706	chr14:50066350	PPIL5	-0.52	-7.82	-0.36	4.3e-14	Carotid intima media thickness;
LUAD	trans	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg06175025	chr14:78082992	SPTLC2	-0.41	-6.68	-0.31	7.37e-11	Bone mineral density;
LUAD	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg25427524	chr10:38739819	LOC399744	-0.64	-9.19	-0.41	1.72e-18	Obesity (extreme);
LUAD	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.36	-0.34	9.73e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg06532163	chr17:45867833	NA	0.48	8.47	0.38	4.02e-16	IgG glycosylation;
LUAD	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg17971929	chr21:40555470	PSMG1	0.55	8.62	0.39	1.39e-16	Cognitive function;
LUAD	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg11822812	chr5:140052017	DND1	0.37	6.48	0.3	2.5e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08219700	chr8:58056026	NA	0.7	9.08	0.4	4.1e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs877282	0.898	rs12356744	chr10:757477	G/C	cg06581033	chr10:766294	NA	-0.56	-7.21	-0.33	2.57e-12	Uric acid levels;
LUAD	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02018176	chr4:1364513	KIAA1530	0.57	10.62	0.46	1.57e-23	Longevity;
LUAD	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg20701182	chr2:24300061	SF3B14	0.56	6.71	0.31	6.14e-11	Lymphocyte counts;
LUAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg24829409	chr8:58192753	C8orf71	-0.62	-9.35	-0.41	5.13e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg05340658	chr4:99064831	C4orf37	0.56	9.47	0.42	2.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.45	7.34	0.34	1.1e-12	Lymphocyte counts;
LUAD	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg20503657	chr10:835505	NA	0.72	8.6	0.39	1.57e-16	Eosinophil percentage of granulocytes;
LUAD	trans	rs11039798	0.764	rs1121450	chr11:48897476	C/T	cg03929089	chr4:120376271	NA	0.58	6.6	0.31	1.21e-10	Axial length;
LUAD	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.64e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.87	0.32	2.33e-11	Retinal vascular caliber;
LUAD	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08109568	chr15:31115862	NA	0.77	13.41	0.55	2.08e-34	Huntington's disease progression;
LUAD	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg00634984	chr7:65235879	NA	0.48	6.42	0.3	3.71e-10	Aortic root size;
LUAD	cis	rs5756813	0.635	rs12160750	chr22:38199054	A/G	cg06521852	chr22:38141419	TRIOBP	0.47	8.5	0.38	3.4e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11890956	chr21:40555474	PSMG1	0.81	14.59	0.58	2.52e-39	Cognitive function;
LUAD	cis	rs8192282	0.739	rs12124333	chr1:154478292	T/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.44	-6.77	-0.31	4.36e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg11494091	chr17:61959527	GH2	-0.45	-8.9	-0.4	1.64e-17	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7833986	1.000	rs34952804	chr8:57097399	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	10.04	0.44	2.03e-21	Height;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg20379012	chr8:126103681	NSMCE2;KIAA0196	-0.37	-6.45	-0.3	3.11e-10	Subcortical brain region volumes;
LUAD	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg21100191	chr22:23484243	RTDR1	0.68	11.97	0.5	1.2e-28	Bone mineral density;
LUAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg11062466	chr8:58055876	NA	0.69	8.96	0.4	1.07e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4662945	0.603	rs1453147	chr2:130271510	A/C	cg05903289	chr2:130345205	NA	-0.33	-7.16	-0.33	3.52e-12	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg04756594	chr16:24857601	SLC5A11	0.77	13.34	0.54	3.93e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs4853525	0.859	rs1882396	chr2:191716012	T/G	cg11845111	chr2:191398756	TMEM194B	-0.38	-6.47	-0.3	2.75e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg05340658	chr4:99064831	C4orf37	0.45	7.47	0.34	4.69e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7020830	0.830	rs12554976	chr9:37244505	G/T	cg14294708	chr9:37120828	ZCCHC7	0.88	17.61	0.65	1.85e-52	Schizophrenia;
LUAD	trans	rs7200543	1.000	rs72774845	chr16:15147954	A/C	cg24683922	chr1:11983373	KIAA2013	-0.47	-7.7	-0.35	9.99e-14	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	trans	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	25.94	0.78	1.75e-89	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs17401966	0.898	rs12117635	chr1:10317445	C/T	cg19773385	chr1:10388646	KIF1B	-0.39	-6.56	-0.3	1.6e-10	Hepatocellular carcinoma;
LUAD	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg00898013	chr13:113819073	PROZ	0.57	10.47	0.45	5.99e-23	Platelet distribution width;
LUAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg06138931	chr13:21896616	NA	0.45	8.04	0.36	8.87e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg00999904	chr2:3704751	ALLC	-0.37	-7.28	-0.33	1.61e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg11915388	chr22:42470451	FAM109B	-0.41	-7.35	-0.34	9.99e-13	Schizophrenia;
LUAD	trans	rs7395662	1.000	rs7945192	chr11:48580737	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.39	-0.34	8.17e-13	HDL cholesterol;
LUAD	cis	rs2274273	0.905	rs2147961	chr14:55585381	T/C	cg04306507	chr14:55594613	LGALS3	0.4	8.24	0.37	2.16e-15	Protein biomarker;
LUAD	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg05991184	chr2:219186017	PNKD	0.37	7.05	0.32	7.17e-12	Colorectal cancer;
LUAD	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg00106254	chr7:1943704	MAD1L1	-0.43	-6.52	-0.3	1.96e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg02176678	chr2:219576539	TTLL4	0.74	14.81	0.58	2.68e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg11062466	chr8:58055876	NA	0.79	9.65	0.42	4.6e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.802	rs7397730	chr12:86416212	T/C	cg02569458	chr12:86230093	RASSF9	0.38	7.27	0.33	1.8e-12	Major depressive disorder;
LUAD	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg00383909	chr3:49044727	WDR6	0.91	10.38	0.45	1.2e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs10821973	0.505	rs2130778	chr10:63995535	A/C	cg09941381	chr10:64027924	RTKN2	-0.34	-6.77	-0.31	4.23e-11	Hypothyroidism;
LUAD	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg17279839	chr7:150038598	RARRES2	0.47	7.78	0.35	5.43e-14	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs1406428	0.573	rs12613632	chr2:51705755	C/G	cg02410754	chr1:32410520	NA	0.43	6.52	0.3	1.96e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7432375	0.609	rs835637	chr3:136673157	A/T	cg15507776	chr3:136538369	TMEM22	0.39	6.89	0.32	2.1e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2302190	0.882	rs8072873	chr17:56669049	G/C	cg25885038	chr17:56607967	SEPT4	-0.51	-8.12	-0.37	5.11e-15	Vitamin D levels;
LUAD	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22968622	chr17:43663579	NA	1.34	25.32	0.78	9.62e-87	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1232027	0.582	rs6151618	chr5:79961673	A/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs7089973	0.872	rs7918253	chr10:116614501	T/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.69	0.43	3.37e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg25753631	chr6:25732923	NA	-0.44	-7.76	-0.35	6.62e-14	Iron status biomarkers;
LUAD	cis	rs236352	0.576	rs2303993	chr6:36842427	C/G	cg10099585	chr6:36853529	C6orf89	-0.39	-6.39	-0.3	4.51e-10	Heart rate;
LUAD	cis	rs17067123	0.614	rs7340789	chr4:180052417	C/T	cg26610307	chr4:180072759	NA	-0.52	-6.78	-0.31	3.96e-11	Response to hepatitis C treatment;
LUAD	trans	rs7591996	0.835	rs7585700	chr2:6504784	A/T	cg16973203	chr2:230876010	FBXO36	-0.4	-6.44	-0.3	3.34e-10	Osteosarcoma;
LUAD	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg27661571	chr11:113659931	NA	-0.69	-8.14	-0.37	4.54e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg06552810	chr11:31128660	NA	-0.35	-6.89	-0.32	1.97e-11	Red blood cell count;
LUAD	cis	rs12681287	0.547	rs4961197	chr8:87512436	T/C	cg27223183	chr8:87520930	FAM82B	-0.71	-10.12	-0.44	1.07e-21	Caudate activity during reward;
LUAD	cis	rs9811920	0.732	rs793446	chr3:99578114	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-11.03	-0.47	4.73e-25	Axial length;
LUAD	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	6.45	0.3	3.14e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg06671706	chr8:8559999	CLDN23	0.65	11.23	0.48	8.35e-26	Obesity-related traits;
LUAD	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.09	-0.33	5.49e-12	Total body bone mineral density;
LUAD	cis	rs6998277	0.830	rs6468838	chr8:103609336	T/C	cg10187029	chr8:103597600	NA	0.85	15.66	0.61	6.09e-44	Migraine;
LUAD	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg09035930	chr12:129282057	SLC15A4	0.75	18.18	0.66	5.6e-55	Systemic lupus erythematosus;
LUAD	cis	rs11971779	0.590	rs9642120	chr7:139083971	C/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.53	-8.5	-0.38	3.25e-16	Renal function-related traits (BUN);
LUAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.8	-0.31	3.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg09526685	chr4:187126073	CYP4V2	0.88	9.77	0.43	1.79e-20	Blood protein levels;
LUAD	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.66	-0.39	9.95e-17	Total body bone mineral density;
LUAD	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg06064525	chr11:970664	AP2A2	-0.54	-11.2	-0.48	1.13e-25	Alzheimer's disease (late onset);
LUAD	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg03983476	chr2:10830698	NOL10	-0.45	-7.78	-0.35	5.5e-14	Prostate cancer;
LUAD	cis	rs3790645	0.958	rs1466286	chr1:26870730	C/G	cg23229016	chr1:26872525	RPS6KA1	0.2	6.68	0.31	7.44e-11	Glucose homeostasis traits;
LUAD	trans	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.29e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg10523679	chr1:76189770	ACADM	0.95	18.66	0.67	4.06e-57	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs13315871	1.000	rs13315871	chr3:58381287	G/A	cg20936604	chr3:58311152	NA	-0.68	-7.06	-0.32	6.92e-12	Cholesterol, total;
LUAD	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg18129178	chr5:148520854	ABLIM3	-0.64	-9.8	-0.43	1.42e-20	Breast cancer;
LUAD	trans	rs9467711	0.591	rs9467622	chr6:25854644	C/A	cg06606381	chr12:133084897	FBRSL1	-0.8	-6.67	-0.31	7.88e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg08645402	chr16:4508243	NA	0.57	9.94	0.44	4.76e-21	Schizophrenia;
LUAD	cis	rs2235649	0.833	rs7190337	chr16:1850469	A/C	cg08610935	chr16:1836813	NUBP2	-0.48	-7.37	-0.34	8.86e-13	Blood metabolite levels;
LUAD	cis	rs62400317	0.723	rs12196188	chr6:44976426	G/C	cg20913747	chr6:44695427	NA	-0.44	-6.95	-0.32	1.42e-11	Total body bone mineral density;
LUAD	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12379764	chr21:47803548	PCNT	-0.43	-6.9	-0.32	1.86e-11	Testicular germ cell tumor;
LUAD	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg24803719	chr17:45855879	NA	-0.33	-7.26	-0.33	1.9e-12	IgG glycosylation;
LUAD	cis	rs17095355	1.000	rs734165	chr10:111697789	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-7.97	-0.36	1.51e-14	Biliary atresia;
LUAD	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg27446573	chr6:127587934	RNF146	0.44	6.7	0.31	6.65e-11	Breast cancer;
LUAD	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg12599982	chr1:44399894	ARTN	0.34	6.86	0.32	2.41e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24531977	chr5:56204891	C5orf35	-0.79	-12.85	-0.53	3.77e-32	Initial pursuit acceleration;
LUAD	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24531977	chr5:56204891	C5orf35	0.77	12.52	0.52	8.39e-31	Initial pursuit acceleration;
LUAD	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg00321850	chr1:175162397	KIAA0040	0.55	11.92	0.5	1.98e-28	Alcohol dependence;
LUAD	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg00310523	chr12:86230176	RASSF9	0.4	7.91	0.36	2.27e-14	Major depressive disorder;
LUAD	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg25358565	chr5:93447407	FAM172A	0.55	6.66	0.31	8.68e-11	Diabetic retinopathy;
LUAD	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-6.85	-0.32	2.56e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs654950	0.875	rs600109	chr1:41998246	A/G	cg06885757	chr1:42089581	HIVEP3	-0.38	-7.7	-0.35	1e-13	Airway imaging phenotypes;
LUAD	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.68	-13.4	-0.55	2.17e-34	Ulcerative colitis;
LUAD	cis	rs2979489	0.891	rs17551512	chr8:30330109	A/G	cg26383811	chr8:30366931	RBPMS	-0.68	-10.48	-0.45	5.36e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23158103	chr7:148848205	ZNF398	-0.66	-12.47	-0.52	1.28e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg14949292	chr17:78079608	GAA	-0.35	-6.59	-0.31	1.29e-10	Yeast infection;
LUAD	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg09658497	chr7:2847517	GNA12	-0.51	-9.73	-0.43	2.48e-20	Height;
LUAD	trans	rs13096760	1	rs13096760	chr3:49476806	T/C	cg21659725	chr3:3221576	CRBN	0.38	6.36	0.3	5.38e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg23625390	chr15:77176239	SCAPER	-0.43	-6.69	-0.31	7.2e-11	Blood metabolite levels;
LUAD	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.29	6.37	0.3	5.09e-10	Depression;
LUAD	cis	rs77861329	1.000	rs9816434	chr3:52197513	C/T	cg08692210	chr3:52188851	WDR51A	0.85	7.91	0.36	2.31e-14	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs877282	0.898	rs71489279	chr10:760510	T/C	cg06581033	chr10:766294	NA	-0.59	-8.06	-0.36	8.04e-15	Uric acid levels;
LUAD	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg20607287	chr7:12443886	VWDE	-0.53	-6.69	-0.31	7.28e-11	Coronary artery disease;
LUAD	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg10434728	chr15:90938212	IQGAP1	0.37	7.23	0.33	2.21e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	trans	rs5756813	0.661	rs5995500	chr22:38204640	A/G	cg19894588	chr14:64061835	NA	-0.54	-7.7	-0.35	9.97e-14	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg21475434	chr5:93447410	FAM172A	-0.5	-6.77	-0.31	4.27e-11	Diabetic retinopathy;
LUAD	cis	rs6669919	1.000	rs6669919	chr1:211674383	T/C	cg10512769	chr1:211675356	NA	-0.32	-6.92	-0.32	1.69e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06544989	chr22:39130855	UNC84B	0.38	7.74	0.35	7.27e-14	Menopause (age at onset);
LUAD	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg08213375	chr14:104286397	PPP1R13B	0.26	6.85	0.32	2.6e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1018836	0.923	rs10808615	chr8:91569704	A/T	cg16814680	chr8:91681699	NA	-0.71	-12.25	-0.51	9.82e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	9.08	0.4	4.18e-18	Menarche (age at onset);
LUAD	cis	rs6499255	0.951	rs10500551	chr16:69666970	C/T	cg15192750	chr16:69999425	NA	0.48	7.63	0.35	1.6e-13	IgE levels;
LUAD	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg27170947	chr2:26402098	FAM59B	0.82	11.43	0.49	1.48e-26	Gut microbiome composition (summer);
LUAD	cis	rs11625487	0.609	rs78371022	chr14:77971029	G/A	cg20045696	chr14:77926864	AHSA1	-0.65	-6.64	-0.31	9.85e-11	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUAD	cis	rs13315871	1.000	rs9850717	chr3:58351875	C/T	cg12435725	chr3:58293450	RPP14	-0.66	-6.79	-0.31	3.85e-11	Cholesterol, total;
LUAD	cis	rs9427116	0.502	rs9426829	chr1:154592201	T/C	cg17218026	chr1:154582156	ADAR	0.5	9.7	0.43	3.08e-20	Blood protein levels;
LUAD	cis	rs11723261	0.582	rs11733927	chr4:166828	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.41	7.34	0.34	1.1e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9486719	0.741	rs2049927	chr6:96848958	C/G	cg06623918	chr6:96969491	KIAA0776	-0.66	-9.25	-0.41	1.12e-18	Migraine;Coronary artery disease;
LUAD	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg01475377	chr6:109611718	NA	-0.49	-8.94	-0.4	1.25e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs11718455	0.960	rs11720974	chr3:43999111	G/C	cg08738300	chr3:44038990	NA	0.42	6.48	0.3	2.55e-10	Coronary artery disease;
LUAD	cis	rs12681287	0.752	rs7822268	chr8:87306440	G/T	cg27223183	chr8:87520930	FAM82B	-0.63	-8.66	-0.39	9.82e-17	Caudate activity during reward;
LUAD	cis	rs1950626	0.827	rs35829821	chr14:101409763	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.38	7.23	0.33	2.32e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg09222892	chr1:25734099	RHCE	-0.5	-9.32	-0.41	6.54e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs2455601	0.638	rs3815991	chr11:9007669	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.49	7.44	0.34	5.64e-13	Schizophrenia;
LUAD	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10802521	chr3:52805072	NEK4	-0.61	-11.03	-0.47	5.07e-25	Bipolar disorder;
LUAD	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg08847533	chr14:75593920	NEK9	0.41	6.91	0.32	1.74e-11	Height;
LUAD	trans	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg17712092	chr4:129076599	LARP1B	0.6	6.97	0.32	1.25e-11	Inflammatory bowel disease;
LUAD	cis	rs4268898	1.000	rs10165445	chr2:24441698	C/T	cg02683114	chr2:24398427	C2orf84	0.42	7.07	0.33	6.25e-12	Asthma;
LUAD	cis	rs57994353	0.897	rs11999532	chr9:139371405	G/C	cg14169450	chr9:139327907	INPP5E	0.4	6.36	0.3	5.19e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg24578937	chr1:2090814	PRKCZ	0.59	12.36	0.52	3.65e-30	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26112564	chr16:2198781	RAB26	-0.46	-7.31	-0.33	1.34e-12	Height;
LUAD	cis	rs117623576	0.941	rs111864818	chr10:32426613	G/A	cg03047570	chr10:32398778	NA	-0.75	-8.81	-0.39	3.34e-17	Anti-saccade response;
LUAD	trans	rs3960554	0.660	rs55671363	chr7:75793405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.95	16.02	0.61	1.82e-45	Eotaxin levels;
LUAD	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.71	-0.61	3.72e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2016266	0.859	rs4759061	chr12:53738214	C/T	cg26875137	chr12:53738046	NA	-0.35	-7.0	-0.32	9.98e-12	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-6.38	-0.3	4.61e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs34734847	0.814	rs17847	chr12:121149475	A/G	cg21892295	chr12:121157589	UNC119B	-0.38	-6.69	-0.31	7.16e-11	Mean corpuscular volume;
LUAD	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.63	12.46	0.52	1.41e-30	Hemoglobin concentration;
LUAD	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg25985355	chr7:65971099	NA	0.5	6.36	0.3	5.38e-10	Diabetic kidney disease;
LUAD	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.45	-7.37	-0.34	9.04e-13	Tonsillectomy;
LUAD	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	trans	rs3942852	0.955	rs4752897	chr11:48136990	C/T	cg15704280	chr7:45808275	SEPT13	-0.58	-8.12	-0.37	5.21e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7923452	1.000	rs7923452	chr10:30751171	T/C	cg18806716	chr10:30721971	MAP3K8	0.58	8.18	0.37	3.24e-15	Itch intensity from mosquito bite;
LUAD	cis	rs11971779	0.680	rs7799598	chr7:139051833	C/T	cg23387468	chr7:139079360	LUC7L2	0.28	6.49	0.3	2.47e-10	Diisocyanate-induced asthma;
LUAD	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs6445967	1.000	rs2292673	chr3:58301901	G/A	cg23715586	chr3:58305044	RPP14	0.42	7.59	0.35	2.03e-13	Platelet count;
LUAD	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg14196790	chr5:131705035	SLC22A5	0.45	8.01	0.36	1.09e-14	Lung function (FEV1/FVC);
LUAD	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.25e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.705	rs16851727	chr1:15857918	C/T	cg13390004	chr1:15929781	NA	0.41	6.68	0.31	7.38e-11	Systolic blood pressure;
LUAD	cis	rs863345	0.604	rs11265016	chr1:158503785	C/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.44	0.3	3.3e-10	Schizophrenia;
LUAD	cis	rs8027181	0.839	rs998021	chr15:72999825	T/C	cg25632853	chr15:73088954	NA	0.31	6.73	0.31	5.71e-11	Triglyceride levels;
LUAD	cis	rs12050794	0.671	rs62022788	chr15:72559326	T/G	cg16672083	chr15:72433130	SENP8	0.65	12.01	0.5	8.23e-29	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg06740227	chr12:86229804	RASSF9	0.46	8.05	0.36	8.19e-15	Major depressive disorder;
LUAD	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.14	-0.33	4.16e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg18621852	chr3:10150065	C3orf24	0.47	8.19	0.37	3.1e-15	Alzheimer's disease;
LUAD	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg06784218	chr1:46089804	CCDC17	0.6	13.29	0.54	6.14e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg11070056	chr1:107600091	PRMT6	0.61	10.55	0.46	2.89e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05922971	chr5:43121458	ZNF131	-0.53	-6.47	-0.3	2.75e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs870825	0.616	rs28620459	chr4:185627132	G/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.46e-37	Blood protein levels;
LUAD	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg02880119	chr16:3481970	NA	-0.53	-8.06	-0.36	7.85e-15	Body mass index (adult);
LUAD	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg12623918	chr2:306882	NA	0.37	7.56	0.34	2.58e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-6.59	-0.31	1.33e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg17178900	chr1:205818956	PM20D1	0.47	7.57	0.35	2.39e-13	Parkinson's disease;
LUAD	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.34	-6.38	-0.3	4.77e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.22	-0.33	2.42e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg25554036	chr4:6271136	WFS1	0.68	13.88	0.56	2.36e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg06636551	chr8:101224915	SPAG1	0.36	6.67	0.31	8.26e-11	Atrioventricular conduction;
LUAD	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg26769984	chr7:1090371	C7orf50	0.57	9.6	0.42	7.15e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs55788414	0.932	rs35066366	chr16:81185280	G/A	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.91	-0.36	2.31e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs11958404	0.929	rs72816533	chr5:157413352	G/T	cg05962755	chr5:157440814	NA	0.52	7.59	0.35	2.05e-13	IgG glycosylation;
LUAD	cis	rs28595532	0.920	rs17323034	chr4:119606518	G/A	cg21605333	chr4:119757512	SEC24D	0.86	7.91	0.36	2.3e-14	Cannabis dependence symptom count;
LUAD	cis	rs7107174	1.000	rs2512533	chr11:77968674	A/C	cg02023728	chr11:77925099	USP35	0.54	8.26	0.37	1.88e-15	Testicular germ cell tumor;
LUAD	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.06	-0.32	6.83e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg21194808	chr1:2205498	SKI	0.4	6.41	0.3	3.86e-10	Height;
LUAD	cis	rs12431939	1.000	rs57212982	chr14:51656464	A/G	cg23942311	chr14:51606299	NA	-0.45	-6.48	-0.3	2.52e-10	Cancer;
LUAD	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.54	0.46	3.31e-23	Post bronchodilator FEV1;
LUAD	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg03806693	chr22:41940476	POLR3H	0.59	8.59	0.39	1.63e-16	Vitiligo;
LUAD	cis	rs8017423	0.904	rs11159963	chr14:90805358	C/T	cg14092571	chr14:90743983	NA	0.47	8.25	0.37	2.02e-15	Mortality in heart failure;
LUAD	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg00933542	chr6:150070202	PCMT1	0.34	7.14	0.33	4.1e-12	Testicular germ cell tumor;
LUAD	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg06873352	chr17:61820015	STRADA	0.4	6.85	0.32	2.63e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19346786	chr7:2764209	NA	-0.58	-12.63	-0.52	3.05e-31	Height;
LUAD	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	8.16	0.37	3.87e-15	Tonsillectomy;
LUAD	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg16850897	chr7:100343110	ZAN	0.41	7.39	0.34	7.88e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs10821973	0.527	rs4979776	chr10:63981857	G/A	cg09941381	chr10:64027924	RTKN2	-0.34	-6.76	-0.31	4.48e-11	Hypothyroidism;
LUAD	trans	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.53	8.07	0.37	7.09e-15	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs427394	0.582	rs274662	chr5:6704860	G/A	cg14682080	chr5:6737778	POLS	0.33	7.33	0.34	1.16e-12	Menopause (age at onset);
LUAD	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.37	0.55	2.89e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg09359103	chr1:154839909	KCNN3	0.69	13.87	0.56	2.61e-36	Prostate cancer;
LUAD	cis	rs2073300	1.000	rs6132621	chr20:23442180	C/T	cg09953122	chr20:23471693	CST8	-0.65	-6.39	-0.3	4.29e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs877282	0.853	rs12763400	chr10:763617	C/T	cg17470449	chr10:769945	NA	0.62	8.83	0.39	2.91e-17	Uric acid levels;
LUAD	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg04450456	chr4:17643702	FAM184B	0.36	6.95	0.32	1.43e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9309473	0.607	rs7604588	chr2:73571417	C/T	cg20560298	chr2:73613845	ALMS1	-0.4	-6.39	-0.3	4.45e-10	Metabolite levels;
LUAD	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg18305652	chr10:134549665	INPP5A	0.61	11.73	0.5	1.09e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg11242978	chr22:46423387	NA	-0.4	-7.18	-0.33	3.18e-12	Dupuytren's disease;
LUAD	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg13073564	chr4:8508604	NA	0.46	7.59	0.35	2.11e-13	Response to antineoplastic agents;
LUAD	cis	rs7937890	0.559	rs6486193	chr11:14437607	C/G	cg22961513	chr11:14280813	SPON1	-0.35	-6.65	-0.31	9.28e-11	Mitochondrial DNA levels;
LUAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg13271783	chr10:134563150	INPP5A	-0.41	-6.55	-0.3	1.63e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs714027	1.000	rs2412970	chr22:30486826	C/T	cg00539347	chr22:30592296	NA	0.3	7.19	0.33	3.03e-12	Lymphocyte counts;
LUAD	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg24733560	chr20:60626293	TAF4	0.47	9.33	0.41	6.03e-19	Body mass index;
LUAD	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg03733263	chr8:22462867	KIAA1967	0.73	12.67	0.52	2.11e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs2404602	0.655	rs10444809	chr15:77124536	G/C	cg22467129	chr15:76604101	ETFA	0.43	7.01	0.32	9.58e-12	Blood metabolite levels;
LUAD	cis	rs11048434	0.698	rs1805784	chr12:9065172	G/T	cg13575925	chr12:9217583	LOC144571	0.36	6.62	0.31	1.09e-10	Sjögren's syndrome;
LUAD	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg06064525	chr11:970664	AP2A2	-0.54	-11.05	-0.47	3.99e-25	Alzheimer's disease (late onset);
LUAD	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg20701182	chr2:24300061	SF3B14	-0.88	-13.13	-0.54	2.78e-33	Lymphocyte counts;
LUAD	trans	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	12.55	0.52	6.2e-31	Exhaled nitric oxide output;
LUAD	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg02527881	chr3:46936655	PTH1R	-0.48	-9.32	-0.41	6.31e-19	Colorectal cancer;
LUAD	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg27170947	chr2:26402098	FAM59B	-0.71	-9.63	-0.42	5.64e-20	Gut microbiome composition (summer);
LUAD	trans	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg19862616	chr7:65841803	NCRNA00174	1.06	27.22	0.8	5.29e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs6542838	0.644	rs7590596	chr2:99467938	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-6.56	-0.3	1.59e-10	Fear of minor pain;
LUAD	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	8.48	0.38	3.75e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg23649088	chr2:200775458	C2orf69	-0.62	-7.79	-0.35	5.38e-14	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.22e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg21827317	chr3:136751795	NA	0.36	6.58	0.3	1.37e-10	Neuroticism;
LUAD	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg01802117	chr1:53393560	SCP2	0.32	6.42	0.3	3.71e-10	Monocyte count;
LUAD	cis	rs36051895	0.695	rs2225125	chr9:4998639	A/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.88	-0.32	2.11e-11	Pediatric autoimmune diseases;
LUAD	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg19346786	chr7:2764209	NA	-0.45	-9.6	-0.42	7.16e-20	Height;
LUAD	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06022373	chr22:39101656	GTPBP1	0.47	7.32	0.34	1.23e-12	Menopause (age at onset);
LUAD	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg26597838	chr10:835615	NA	1.01	16.09	0.62	9.11e-46	Eosinophil percentage of granulocytes;
LUAD	cis	rs9826463	0.582	rs73238136	chr3:142038959	T/C	cg20824294	chr3:142316082	PLS1	0.41	7.05	0.32	7.52e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg24308560	chr3:49941425	MST1R	0.51	8.47	0.38	3.98e-16	Body mass index;
LUAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13732083	chr21:47605072	C21orf56	0.6	10.45	0.45	6.74e-23	Testicular germ cell tumor;
LUAD	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg14686297	chr22:46650375	NA	0.39	6.83	0.31	3.05e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.37	-0.34	9.19e-13	Breast cancer;
LUAD	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-8.65	-0.39	1.08e-16	Type 2 diabetes;
LUAD	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	7.04	0.32	7.9e-12	Cognitive test performance;
LUAD	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg19717773	chr7:2847554	GNA12	-0.54	-9.04	-0.4	5.74e-18	Height;
LUAD	trans	rs8002861	0.846	rs56408817	chr13:44471983	A/G	cg17145862	chr1:211918768	LPGAT1	-0.69	-14.86	-0.59	1.72e-40	Leprosy;
LUAD	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg23954153	chr1:44402353	ARTN	0.34	6.78	0.31	3.96e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7814319	0.674	rs2292835	chr8:97243720	G/A	cg20787634	chr8:97240163	UQCRB	-0.37	-6.89	-0.32	1.99e-11	Lung function (FVC);
LUAD	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.14	14.75	0.58	5.24e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg14324370	chr2:177042789	NA	-0.42	-7.25	-0.33	1.96e-12	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg17757837	chr7:157058334	UBE3C	-0.46	-8.24	-0.37	2.11e-15	Body mass index;
LUAD	cis	rs250677	0.958	rs17109282	chr5:148416677	A/G	cg12140854	chr5:148520817	ABLIM3	0.56	9.46	0.42	2.21e-19	Breast cancer;
LUAD	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	9.17	0.41	2.11e-18	Tonsillectomy;
LUAD	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg06641503	chr3:48959341	ARIH2	-0.4	-7.83	-0.36	3.97e-14	Parkinson's disease;
LUAD	cis	rs877282	1.000	rs12219807	chr10:772870	A/C	cg06581033	chr10:766294	NA	-0.48	-6.77	-0.31	4.2e-11	Uric acid levels;
LUAD	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg12863693	chr15:85201151	NMB	0.38	6.49	0.3	2.36e-10	Schizophrenia;
LUAD	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg12062639	chr20:23401060	NAPB	1.08	10.86	0.47	2.14e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.13	0.33	4.34e-12	Parkinson's disease;
LUAD	cis	rs593982	1.000	rs118030231	chr11:65501905	G/A	cg08755490	chr11:65554678	OVOL1	-1.35	-16.29	-0.62	1.2e-46	Atopic dermatitis;
LUAD	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.98	0.32	1.12e-11	Motion sickness;
LUAD	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg22963979	chr7:1858916	MAD1L1	-0.48	-8.16	-0.37	3.83e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg16647868	chr5:131706066	SLC22A5	0.49	7.8	0.35	4.76e-14	Acylcarnitine levels;
LUAD	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.83	0.31	3.04e-11	Cognitive test performance;
LUAD	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06028808	chr11:68637592	NA	0.45	7.23	0.33	2.22e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg26343298	chr8:95960752	TP53INP1	0.39	8.24	0.37	2.17e-15	Type 2 diabetes;
LUAD	cis	rs7818345	0.967	rs4921638	chr8:19274793	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.64	0.31	9.67e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg07936489	chr17:37558343	FBXL20	0.51	7.03	0.32	8.48e-12	Glomerular filtration rate (creatinine);
LUAD	trans	rs877282	0.947	rs7923867	chr10:768094	G/A	cg22713356	chr15:30763199	NA	1.3	17.85	0.66	1.61e-53	Uric acid levels;
LUAD	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg00933542	chr6:150070202	PCMT1	0.45	10.09	0.44	1.3e-21	Lung cancer;
LUAD	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg16647868	chr5:131706066	SLC22A5	0.42	7.14	0.33	4.18e-12	Blood metabolite levels;
LUAD	cis	rs758324	0.773	rs4540167	chr5:131163022	G/A	cg06307176	chr5:131281290	NA	0.44	7.29	0.33	1.55e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg05457628	chr5:178986728	RUFY1	0.6	9.12	0.41	3.18e-18	Lung cancer;
LUAD	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.09	0.37	6.3e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.5	7.82	0.36	4.19e-14	Total body bone mineral density;
LUAD	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg25173405	chr17:45401733	C17orf57	0.45	7.73	0.35	7.89e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg10556349	chr10:835070	NA	0.5	6.44	0.3	3.31e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs6665290	0.904	rs2297416	chr1:227172935	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.2	-38.77	-0.88	2.44e-141	Myeloid white cell count;
LUAD	cis	rs9902453	0.899	rs8067580	chr17:28471248	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.6	0.39	1.59e-16	Coffee consumption (cups per day);
LUAD	trans	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg26821498	chr1:28415421	EYA3	-0.36	-6.37	-0.3	4.85e-10	Migraine with aura;
LUAD	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg06784218	chr1:46089804	CCDC17	0.6	13.44	0.55	1.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg27411982	chr8:10470053	RP1L1	-0.41	-7.24	-0.33	2.07e-12	Joint mobility (Beighton score);
LUAD	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg11707310	chr1:2537719	MMEL1	0.37	7.86	0.36	3.16e-14	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs35995292	0.927	rs2190666	chr7:38919395	C/T	cg19327137	chr7:38886074	VPS41	0.5	8.0	0.36	1.18e-14	Subjective well-being (multi-trait analysis);
LUAD	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg14196790	chr5:131705035	SLC22A5	-0.38	-6.62	-0.31	1.08e-10	Blood metabolite levels;
LUAD	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg09998033	chr7:158218633	PTPRN2	-0.55	-10.11	-0.44	1.18e-21	Obesity-related traits;
LUAD	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg12599982	chr1:44399894	ARTN	0.31	6.45	0.3	3.06e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs55665837	1.000	rs10047457	chr11:14439459	T/A	cg19336497	chr11:14380999	RRAS2	-0.51	-10.31	-0.45	2.21e-22	Vitamin D levels;
LUAD	cis	rs986417	0.901	rs7159628	chr14:61010688	A/C	cg27398547	chr14:60952738	C14orf39	0.66	7.65	0.35	1.38e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs3935685	0.874	rs28406214	chr15:77996537	G/A	cg25212270	chr15:78015279	NA	0.32	7.13	0.33	4.28e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7927771	0.524	rs7118747	chr11:47889545	C/T	cg18512352	chr11:47633146	NA	-0.36	-6.5	-0.3	2.29e-10	Subjective well-being;
LUAD	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03517284	chr6:25882590	NA	-0.9	-15.0	-0.59	4.51e-41	Blood metabolite levels;
LUAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg04287289	chr16:89883240	FANCA	0.67	12.08	0.51	4.49e-29	Vitiligo;
LUAD	cis	rs7107174	1.000	rs7104222	chr11:78007169	G/A	cg02023728	chr11:77925099	USP35	0.45	7.21	0.33	2.61e-12	Testicular germ cell tumor;
LUAD	cis	rs6901250	0.851	rs7760125	chr6:117123391	A/C	cg12892004	chr6:117198278	RFX6	0.34	7.18	0.33	3.07e-12	C-reactive protein levels;
LUAD	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg13385794	chr1:248469461	NA	0.26	6.92	0.32	1.71e-11	Common traits (Other);
LUAD	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg20933634	chr6:27740509	NA	0.49	7.73	0.35	7.69e-14	Parkinson's disease;
LUAD	cis	rs12122100	0.651	rs12126527	chr1:146551259	C/G	cg03526459	chr1:146549940	NA	-0.4	-7.41	-0.34	7.12e-13	HIV-1 control;
LUAD	cis	rs2073300	1.000	rs6132628	chr20:23446734	G/A	cg09953122	chr20:23471693	CST8	-0.69	-6.58	-0.3	1.36e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg06740227	chr12:86229804	RASSF9	0.42	7.23	0.33	2.31e-12	Major depressive disorder;
LUAD	cis	rs1451375	0.698	rs56233242	chr7:50634053	C/A	cg18232548	chr7:50535776	DDC	0.51	8.37	0.38	8.61e-16	Malaria;
LUAD	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg25828334	chr19:18545568	ISYNA1	-0.39	-7.89	-0.36	2.62e-14	Breast cancer;
LUAD	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg01448562	chr3:133502909	NA	0.55	9.88	0.43	7.58e-21	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs36051895	0.695	rs59384377	chr9:5005034	A/T	cg02405213	chr9:5042618	JAK2	-0.54	-7.53	-0.34	3.12e-13	Pediatric autoimmune diseases;
LUAD	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.08	-0.37	7.09e-15	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg11494091	chr17:61959527	GH2	0.44	8.21	0.37	2.78e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03264133	chr6:25882463	NA	-0.52	-7.63	-0.35	1.59e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg18272543	chr7:27779524	TAX1BP1	0.42	6.7	0.31	6.84e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07674403	chr19:13068176	GADD45GIP1	-0.38	-6.56	-0.3	1.62e-10	Cancer;
LUAD	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg08645402	chr16:4508243	NA	0.55	9.95	0.44	4.34e-21	Schizophrenia;
LUAD	cis	rs12620999	1.000	rs28727919	chr2:238003313	C/T	cg23555395	chr2:238036564	NA	0.6	9.07	0.4	4.59e-18	Systemic lupus erythematosus;
LUAD	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg11189052	chr15:85197271	WDR73	0.58	6.95	0.32	1.39e-11	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg25985355	chr7:65971099	NA	-0.52	-6.43	-0.3	3.43e-10	Diabetic kidney disease;
LUAD	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.36	7.41	0.34	6.89e-13	Depression;
LUAD	trans	rs1493916	0.748	rs1941684	chr18:31304421	C/G	cg15819921	chr19:927150	ARID3A	-0.42	-6.92	-0.32	1.72e-11	Life satisfaction;
LUAD	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg24578937	chr1:2090814	PRKCZ	0.54	11.19	0.48	1.19e-25	Height;
LUAD	cis	rs7107174	1.000	rs2511182	chr11:77982130	G/C	cg02023728	chr11:77925099	USP35	0.47	7.26	0.33	1.88e-12	Testicular germ cell tumor;
LUAD	cis	rs6740322	0.895	rs13384080	chr2:43557363	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.75	-10.84	-0.47	2.56e-24	Coronary artery disease;
LUAD	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-10.69	-0.46	9.29e-24	Hemoglobin concentration;
LUAD	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg00666640	chr1:248458726	OR2T12	0.32	7.71	0.35	9.24e-14	Common traits (Other);
LUAD	cis	rs11585357	0.895	rs72633812	chr1:17623140	T/C	cg08277548	chr1:17600880	PADI3	-0.96	-14.06	-0.56	4.17e-37	Hair shape;
LUAD	cis	rs3784262	1.000	rs10851631	chr15:58242193	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.46	-9.33	-0.41	6.08e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06873352	chr17:61820015	STRADA	0.69	14.35	0.57	2.58e-38	Prudent dietary pattern;
LUAD	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg25753631	chr6:25732923	NA	-0.37	-6.43	-0.3	3.49e-10	Iron status biomarkers;
LUAD	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg06060754	chr5:176797920	RGS14	0.73	12.67	0.52	2.05e-31	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg02527881	chr3:46936655	PTH1R	-0.5	-10.11	-0.44	1.1e-21	Colorectal cancer;
LUAD	trans	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg06606381	chr12:133084897	FBRSL1	-1.19	-10.2	-0.44	5.58e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg16606324	chr3:10149918	C3orf24	-0.73	-12.17	-0.51	2.07e-29	Alzheimer's disease;
LUAD	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-8.0	-0.36	1.17e-14	Monocyte percentage of white cells;
LUAD	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.31	0.37	1.36e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg01579765	chr21:45077557	HSF2BP	-0.57	-12.29	-0.51	6.94e-30	Mean corpuscular volume;
LUAD	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg04450456	chr4:17643702	FAM184B	0.41	8.18	0.37	3.34e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9972944	0.676	rs9303489	chr17:63784817	T/C	cg07283582	chr17:63770753	CCDC46	0.51	10.86	0.47	2.03e-24	Total body bone mineral density;
LUAD	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.44	0.3	3.28e-10	Depression;
LUAD	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg07404485	chr7:94953653	PON1	-0.51	-7.53	-0.34	3.1400000000000003e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg09904177	chr6:26538194	HMGN4	0.41	6.84	0.32	2.73e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg26022315	chr17:47021804	SNF8	0.4	7.27	0.33	1.77e-12	Type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11216682	chr2:131113867	PTPN18	-0.54	-6.5	-0.3	2.32e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg07549590	chr16:15018862	NA	-0.56	-10.66	-0.46	1.16e-23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg12143784	chr7:64541923	NA	-0.44	-7.29	-0.33	1.57e-12	Calcium levels;
LUAD	cis	rs4523957	0.620	rs9906467	chr17:2069003	C/T	cg16513277	chr17:2031491	SMG6	-0.99	-19.75	-0.69	5.57e-62	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1278769	0.786	rs9577175	chr13:113543355	C/T	cg00823993	chr13:113535758	ATP11A	0.5	7.73	0.35	7.82e-14	Interstitial lung disease;
LUAD	cis	rs7588746	0.571	rs4673891	chr2:201156362	C/G	cg23649088	chr2:200775458	C2orf69	-0.5	-7.59	-0.35	2.02e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
LUAD	cis	rs11893307	0.509	rs12612904	chr2:191534847	A/G	cg27211696	chr2:191398769	TMEM194B	-0.43	-6.5	-0.3	2.31e-10	Mean platelet volume;
LUAD	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.29	-6.91	-0.32	1.82e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs807669	0.548	rs5746685	chr22:19192596	C/G	cg02655711	chr22:19163373	SLC25A1	-0.57	-10.9	-0.47	1.51e-24	Metabolite levels;
LUAD	cis	rs11098699	0.784	rs4833895	chr4:124242217	T/C	cg09941581	chr4:124220074	SPATA5	0.42	6.76	0.31	4.53e-11	Mosquito bite size;
LUAD	cis	rs12618769	0.625	rs4850880	chr2:99212417	C/T	cg10123293	chr2:99228465	UNC50	0.5	8.87	0.4	2.09e-17	Bipolar disorder;
LUAD	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg12573674	chr2:1569213	NA	-0.61	-7.16	-0.33	3.62e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.61	10.37	0.45	1.31e-22	Cognitive ability;
LUAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.88	-0.32	2.2e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-8.52	-0.38	2.84e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg20849893	chr7:64541193	NA	-0.45	-7.27	-0.33	1.77e-12	Calcium levels;
LUAD	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg19622623	chr12:86230825	RASSF9	-0.43	-7.42	-0.34	6.52e-13	Major depressive disorder;
LUAD	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg18932078	chr1:2524107	MMEL1	0.36	6.59	0.31	1.32e-10	Ulcerative colitis;
LUAD	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg21427119	chr20:30132790	HM13	-0.35	-6.38	-0.3	4.67e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg06784218	chr1:46089804	CCDC17	-0.55	-11.74	-0.5	9.82e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06002616	chr8:101225028	SPAG1	-0.4	-8.2	-0.37	3e-15	Atrioventricular conduction;
LUAD	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.11	0.33	5.06e-12	Bladder cancer;
LUAD	cis	rs17253792	0.822	rs10483643	chr14:56089931	G/C	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg08888203	chr3:10149979	C3orf24	0.72	12.87	0.53	3.25e-32	Alzheimer's disease;
LUAD	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18099408	chr3:52552593	STAB1	-0.45	-8.17	-0.37	3.5e-15	Bipolar disorder;
LUAD	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg05717871	chr11:638507	DRD4	-0.44	-6.48	-0.3	2.57e-10	Systemic lupus erythematosus;
LUAD	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg15704280	chr7:45808275	SEPT13	0.61	9.23	0.41	1.31e-18	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs796364	0.616	rs2030653	chr2:200677625	C/T	cg23649088	chr2:200775458	C2orf69	0.52	6.43	0.3	3.43e-10	Schizophrenia;
LUAD	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.67	0.35	1.24e-13	Platelet count;
LUAD	cis	rs6840360	0.638	rs2406974	chr4:152601841	G/A	cg22705602	chr4:152727874	NA	-0.48	-8.88	-0.4	1.87e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg03433033	chr1:76189801	ACADM	0.81	14.78	0.58	3.7e-40	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg26647111	chr11:31128758	NA	-0.47	-8.13	-0.37	4.71e-15	Red blood cell count;
LUAD	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg23188684	chr11:67383651	NA	0.4	6.98	0.32	1.15e-11	Mean corpuscular volume;
LUAD	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.8	0.35	4.89e-14	Morning vs. evening chronotype;
LUAD	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg08048268	chr3:133502702	NA	-0.41	-7.78	-0.35	5.73e-14	Iron status biomarkers;
LUAD	trans	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg26811252	chr16:29126840	RRN3P2	0.42	7.3	0.33	1.48e-12	Menopause (age at onset);
LUAD	cis	rs877282	0.945	rs11253396	chr10:789754	C/T	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg18621852	chr3:10150065	C3orf24	0.48	8.43	0.38	5.34e-16	Alzheimer's disease;
LUAD	cis	rs11048434	0.761	rs10842660	chr12:9138897	G/A	cg13575925	chr12:9217583	LOC144571	0.38	7.04	0.32	7.72e-12	Sjögren's syndrome;
LUAD	cis	rs7192380	0.931	rs9302604	chr16:69576894	A/G	cg26679644	chr16:69762563	NA	0.45	8.31	0.37	1.28e-15	Sjögren's syndrome;
LUAD	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	7.07	0.33	6.25e-12	Cognitive test performance;
LUAD	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg24818145	chr4:99064322	C4orf37	0.47	7.36	0.34	9.88e-13	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4650994	0.525	rs2224811	chr1:178544323	C/T	cg05059571	chr16:84539110	KIAA1609	0.73	13.01	0.53	8.56e-33	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs3106136	0.527	rs2632411	chr4:95149434	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.18	-0.44	6.23e-22	Capecitabine sensitivity;
LUAD	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg01324343	chr3:183735012	ABCC5	-0.92	-24.32	-0.76	2.26e-82	Anterior chamber depth;
LUAD	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.67	0.43	4.07e-20	Monocyte percentage of white cells;
LUAD	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.52	-0.34	3.36e-13	Bipolar disorder;
LUAD	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	8.12	0.37	5e-15	Tonsillectomy;
LUAD	cis	rs62400317	0.859	rs11965706	chr6:45141441	T/A	cg20913747	chr6:44695427	NA	-0.4	-6.45	-0.3	3.12e-10	Total body bone mineral density;
LUAD	cis	rs4930103	0.508	rs217205	chr11:1973205	T/C	cg06197492	chr11:2016605	H19	-0.34	-6.57	-0.3	1.5e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg14779329	chr11:130786720	SNX19	0.39	6.84	0.32	2.74e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6740322	0.843	rs6727237	chr2:43562000	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-10.77	-0.46	4.5e-24	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.38e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62400317	0.859	rs10948212	chr6:45156933	A/C	cg18551225	chr6:44695536	NA	-0.56	-8.57	-0.38	1.91e-16	Total body bone mineral density;
LUAD	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.83	-0.36	4.04e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg03467027	chr4:99064603	C4orf37	0.43	6.88	0.32	2.21e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg04565464	chr8:145669602	NFKBIL2	0.43	6.49	0.3	2.36e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg21238619	chr17:78079768	GAA	-0.33	-6.99	-0.32	1.08e-11	Yeast infection;
LUAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.74	-0.35	7.45e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg11494091	chr17:61959527	GH2	0.46	8.46	0.38	4.3e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg07870213	chr5:140052090	DND1	1.05	14.43	0.57	1.18e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08280861	chr8:58055591	NA	0.64	8.41	0.38	6.13e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg08470875	chr2:26401718	FAM59B	-0.56	-7.77	-0.35	6.11e-14	Gut microbiome composition (summer);
LUAD	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg07432352	chr17:45403706	C17orf57	0.45	8.75	0.39	5.1e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg04995722	chr7:26192034	NFE2L3	-0.45	-7.73	-0.35	7.67e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg02038168	chr22:39784481	NA	-0.56	-9.19	-0.41	1.82e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs7119	0.651	rs34607443	chr15:77847892	C/T	cg27398640	chr15:77910606	LINGO1	-0.37	-6.72	-0.31	5.84e-11	Type 2 diabetes;
LUAD	cis	rs10419226	0.511	rs7246437	chr19:18786784	A/G	cg22001208	chr19:18782374	NA	-0.47	-7.92	-0.36	2.1e-14	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs2066819	1.000	rs41392645	chr12:56696742	A/G	cg26714650	chr12:56694279	CS	-0.81	-7.17	-0.33	3.37e-12	Psoriasis vulgaris;
LUAD	cis	rs9914544	0.545	rs7222893	chr17:18811702	A/G	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.59	-0.31	1.3e-10	Educational attainment (years of education);
LUAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00149659	chr3:10157352	C3orf10	-0.85	-11.25	-0.48	7.49e-26	Alzheimer's disease;
LUAD	cis	rs9902453	0.845	rs116840018	chr17:28232049	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.26	0.41	1.02e-18	Coffee consumption (cups per day);
LUAD	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.3	-0.37	1.38e-15	Height;
LUAD	cis	rs1757171	0.542	rs3818986	chr6:37484349	C/A	cg25019722	chr6:37503610	NA	-0.34	-7.68	-0.35	1.13e-13	Cognitive performance;
LUAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.44	-6.89	-0.32	2.1e-11	Longevity;Endometriosis;
LUAD	trans	rs28735056	0.875	rs62103181	chr18:77625652	A/G	cg05926928	chr17:57297772	GDPD1	0.5	7.37	0.34	9.21e-13	Schizophrenia;
LUAD	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg23978390	chr7:1156363	C7orf50	0.57	8.01	0.36	1.15e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.55	-9.16	-0.41	2.19e-18	Glomerular filtration rate;
LUAD	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg15448220	chr1:150897856	SETDB1	0.54	9.11	0.41	3.28e-18	Melanoma;
LUAD	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg00310523	chr12:86230176	RASSF9	0.41	8.03	0.36	9.78e-15	Major depressive disorder;
LUAD	cis	rs752010	0.695	rs12134166	chr1:42105867	C/T	cg06885757	chr1:42089581	HIVEP3	0.38	8.11	0.37	5.64e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs1595825	1.000	rs61605589	chr2:198876532	T/C	cg00982548	chr2:198649783	BOLL	-0.65	-9.25	-0.41	1.14e-18	Ulcerative colitis;
LUAD	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg06191203	chr2:152266755	RIF1	-0.54	-7.96	-0.36	1.57e-14	Squamous cell lung carcinoma;
LUAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg20276088	chr3:133502917	NA	0.37	6.57	0.3	1.46e-10	Iron status biomarkers;
LUAD	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs806215	1.000	rs712704	chr7:127258208	A/G	cg25922125	chr7:127225783	GCC1	-0.49	-6.93	-0.32	1.61e-11	Type 2 diabetes;
LUAD	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg24879335	chr3:133465180	TF	0.39	8.16	0.37	3.85e-15	Iron status biomarkers (transferrin levels);
LUAD	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg22920501	chr2:26401640	FAM59B	-0.86	-13.42	-0.55	1.77e-34	Gut microbiome composition (summer);
LUAD	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg22598563	chr5:131563921	P4HA2	-0.34	-8.63	-0.39	1.23e-16	Blood metabolite levels;
LUAD	cis	rs6432018	0.927	rs6432023	chr2:9736874	C/T	cg12832956	chr2:9616023	IAH1	-0.38	-6.74	-0.31	5.12e-11	Heart rate variability traits;
LUAD	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg01017244	chr2:74357527	NA	0.91	13.5	0.55	8.93e-35	Gestational age at birth (maternal effect);
LUAD	cis	rs870825	0.616	rs7683615	chr4:185618373	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg14458575	chr2:238380390	NA	0.97	18.7	0.67	2.7e-57	Prostate cancer;
LUAD	cis	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg21775007	chr8:11205619	TDH	-0.47	-8.33	-0.38	1.17e-15	Retinal vascular caliber;
LUAD	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	12.06	0.51	5.52e-29	Hip circumference adjusted for BMI;
LUAD	cis	rs12760731	0.720	rs71628282	chr1:178449993	C/G	cg00404053	chr1:178313656	RASAL2	0.71	8.55	0.38	2.25e-16	Obesity-related traits;
LUAD	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-7.92	-0.36	2.09e-14	Blood metabolite levels;
LUAD	trans	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg14917512	chr19:3094685	GNA11	-0.55	-6.51	-0.3	2.14e-10	Diabetic kidney disease;
LUAD	cis	rs2901656	0.677	rs10752957	chr1:172408271	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.53	10.37	0.45	1.37e-22	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg09367891	chr1:107599246	PRMT6	0.58	9.72	0.43	2.63e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.14	0.48	1.9e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg17971929	chr21:40555470	PSMG1	-0.51	-8.1	-0.37	6e-15	Cognitive function;
LUAD	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg10518543	chr12:38710700	ALG10B	0.52	8.54	0.38	2.46e-16	Morning vs. evening chronotype;
LUAD	cis	rs12940923	0.810	rs16942910	chr17:56363513	C/T	cg19466818	chr17:56409534	MIR142	-0.38	-6.61	-0.31	1.13e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs1137	0.855	rs205645	chr2:74938531	A/G	cg19285774	chr2:74907978	SEMA4F	0.36	6.8	0.31	3.56e-11	Myopia (pathological);
LUAD	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg11822812	chr5:140052017	DND1	0.38	6.73	0.31	5.42e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg08027265	chr7:2291960	NA	-0.42	-6.75	-0.31	4.79e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg11901034	chr3:128598214	ACAD9	-0.5	-7.82	-0.36	4.36e-14	IgG glycosylation;
LUAD	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.14	0.37	4.43e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2279817	1.000	rs1339800	chr1:18020201	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.59	-9.76	-0.43	1.93e-20	Neuroticism;
LUAD	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.34	6.82	0.31	3.16e-11	Obesity-related traits;
LUAD	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg12927641	chr6:109611667	NA	-0.52	-9.16	-0.41	2.26e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg17971929	chr21:40555470	PSMG1	-0.42	-6.62	-0.31	1.08e-10	Cognitive function;
LUAD	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.11	-0.33	4.85e-12	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs10795061	0.576	rs10904074	chr10:3710962	G/A	cg22632523	chr10:3711048	NA	0.45	7.6	0.35	1.92e-13	Subjective well-being;
LUAD	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22857025	chr5:266934	NA	-0.99	-14.44	-0.57	1.05e-38	Breast cancer;
LUAD	cis	rs10733682	0.659	rs3861879	chr9:129464856	A/G	cg00232160	chr9:129468157	NA	0.51	9.11	0.41	3.25e-18	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs11039798	0.920	rs9667596	chr11:48691193	T/C	cg15704280	chr7:45808275	SEPT13	0.67	7.84	0.36	3.58e-14	Axial length;
LUAD	cis	rs7089973	0.872	rs7074729	chr10:116632257	C/G	cg25233709	chr10:116636983	FAM160B1	0.39	7.52	0.34	3.3e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08058610	chr19:52674483	ZNF836	-0.42	-6.39	-0.3	4.37e-10	Height;
LUAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08219700	chr8:58056026	NA	0.57	8.08	0.37	6.8e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg11062466	chr8:58055876	NA	0.53	7.33	0.34	1.2e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg21724239	chr8:58056113	NA	0.75	9.34	0.41	5.52e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.4	-0.42	3.45e-19	Life satisfaction;
LUAD	cis	rs10129255	0.518	rs28378320	chr14:107216845	T/C	cg07958169	chr14:107095056	NA	-0.37	-7.24	-0.33	2.07e-12	Kawasaki disease;
LUAD	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg26384229	chr12:38710491	ALG10B	0.48	7.63	0.35	1.5700000000000001e-13	Bladder cancer;
LUAD	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	7.21	0.33	2.58e-12	Hypertriglyceridemia;
LUAD	cis	rs7512552	0.839	rs832622	chr1:150392830	A/G	cg15654264	chr1:150340011	RPRD2	0.58	11.22	0.48	9.82e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg19041857	chr6:27730383	NA	-0.41	-6.94	-0.32	1.48e-11	Parkinson's disease;
LUAD	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg09117114	chr16:67998030	SLC12A4	-0.6	-7.52	-0.34	3.4e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22968622	chr17:43663579	NA	-1.2	-20.04	-0.7	2.55e-63	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg18335740	chr13:41363409	SLC25A15	0.57	9.45	0.42	2.29e-19	Lewy body disease;
LUAD	cis	rs500891	0.525	rs12524172	chr6:84069668	C/T	cg08257003	chr6:84140564	ME1	0.35	6.78	0.31	4.17e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg17761419	chr8:57350749	NA	-0.52	-7.66	-0.35	1.27e-13	Obesity-related traits;
LUAD	cis	rs11048434	0.636	rs7306161	chr12:9059075	T/A	cg13575925	chr12:9217583	LOC144571	0.37	6.89	0.32	2.07e-11	Sjögren's syndrome;
LUAD	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.46	7.64	0.35	1.52e-13	Lung cancer in ever smokers;
LUAD	trans	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg21659725	chr3:3221576	CRBN	-0.58	-9.24	-0.41	1.2e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs12210905	0.688	rs12212389	chr6:27326397	T/C	cg08851530	chr6:28072375	NA	1.09	7.97	0.36	1.45e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs4900538	0.927	rs1190544	chr14:102903398	G/A	cg18135206	chr14:102964638	TECPR2	-1.07	-24.11	-0.76	1.99e-81	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs714027	1.000	rs6006356	chr22:30503171	G/A	cg00539347	chr22:30592296	NA	-0.29	-6.8	-0.31	3.65e-11	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.55e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.8	-0.31	3.65e-11	Type 2 diabetes;
LUAD	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-8.24	-0.37	2.18e-15	Alzheimer's disease (late onset);
LUAD	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg22681709	chr2:178499509	PDE11A	-0.56	-9.63	-0.42	5.74e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg03874509	chr1:107600012	PRMT6	-0.51	-9.11	-0.4	3.38e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg04450456	chr4:17643702	FAM184B	0.38	7.18	0.33	3.17e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs62458065	0.850	rs62458100	chr7:32473142	C/G	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.39	-0.34	8.11e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg14092988	chr3:52407081	DNAH1	0.37	7.53	0.34	3.17e-13	Bipolar disorder;
LUAD	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg04287289	chr16:89883240	FANCA	0.46	7.21	0.33	2.64e-12	Vitiligo;
LUAD	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg00129232	chr17:37814104	STARD3	-0.44	-7.65	-0.35	1.4e-13	Asthma;
LUAD	cis	rs9302635	0.513	rs3902135	chr16:72175820	C/T	cg23815491	chr16:72088622	HP	0.47	7.51	0.34	3.48e-13	Blood protein levels;
LUAD	cis	rs240110	0.539	rs6919745	chr6:101338978	T/C	cg09795085	chr6:101329169	ASCC3	0.49	8.8	0.39	3.52e-17	Neuroticism;
LUAD	cis	rs1448094	0.617	rs1502800	chr12:86476255	A/G	cg00310523	chr12:86230176	RASSF9	0.31	6.4	0.3	4.25e-10	Major depressive disorder;
LUAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00166722	chr3:10149974	C3orf24	0.75	13.15	0.54	2.46e-33	Alzheimer's disease;
LUAD	cis	rs7945718	0.967	rs10765990	chr11:12769444	G/A	cg25843174	chr11:12811716	TEAD1	0.22	6.52	0.3	1.98e-10	Educational attainment (years of education);
LUAD	cis	rs2019216	0.500	rs7210996	chr17:21917331	G/A	cg22648282	chr17:21454238	C17orf51	-0.45	-7.83	-0.36	3.89e-14	Pelvic organ prolapse;
LUAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg22029157	chr1:209979665	IRF6	0.74	12.16	0.51	2.21e-29	Cleft lip with or without cleft palate;
LUAD	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11644478	chr21:40555479	PSMG1	-0.72	-11.98	-0.5	1.13e-28	Cognitive function;
LUAD	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg00495681	chr13:53174319	NA	-0.46	-8.19	-0.37	3.04e-15	Lewy body disease;
LUAD	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	11.8	0.5	5.58e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg26597838	chr10:835615	NA	-0.51	-8.03	-0.36	9.54e-15	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg06641503	chr3:48959341	ARIH2	-0.4	-7.85	-0.36	3.56e-14	Parkinson's disease;
LUAD	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg27144592	chr16:783916	NARFL	0.36	6.55	0.3	1.71e-10	Height;
LUAD	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg04034577	chr2:241836375	C2orf54	-0.46	-10.04	-0.44	1.98e-21	Urinary metabolites;
LUAD	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-1.01	-13.84	-0.56	3.51e-36	Lung cancer in ever smokers;
LUAD	cis	rs12545109	0.800	rs1595940	chr8:57398309	T/C	cg19413350	chr8:57351067	NA	-0.45	-6.88	-0.32	2.18e-11	Obesity-related traits;
LUAD	cis	rs6060717	0.536	rs11167279	chr20:34509107	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.06	-0.32	7.08e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg08601574	chr20:25228251	PYGB	-0.48	-8.99	-0.4	8.29e-18	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg25838465	chr1:92012736	NA	-0.7	-15.0	-0.59	4.3e-41	Breast cancer;
LUAD	cis	rs8067545	0.750	rs4924805	chr17:19997205	C/G	cg04132472	chr17:19861366	AKAP10	0.29	6.83	0.32	2.89e-11	Schizophrenia;
LUAD	trans	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg19163074	chr7:65112434	INTS4L2	0.42	6.4	0.3	4.24e-10	Aortic root size;
LUAD	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg07371521	chr5:154026371	NA	0.48	7.71	0.35	9.13e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9297145	0.585	rs4729521	chr7:98780520	G/T	cg05967295	chr7:98741636	SMURF1	-0.74	-13.45	-0.55	1.41e-34	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.54	-8.95	-0.4	1.13e-17	Electrocardiographic conduction measures;
LUAD	cis	rs1728785	1.000	rs1645976	chr16:68563509	T/C	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.3100000000000001e-10	Ulcerative colitis;
LUAD	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg20487152	chr13:99095054	FARP1	-0.49	-8.24	-0.37	2.23e-15	Longevity;
LUAD	cis	rs4321325	0.536	rs10198483	chr2:127934102	G/A	cg11380483	chr2:127933992	NA	0.6	10.84	0.47	2.55e-24	Protein C levels;
LUAD	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg25358565	chr5:93447407	FAM172A	0.64	7.66	0.35	1.24e-13	Diabetic retinopathy;
LUAD	trans	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg05590025	chr7:65112418	INTS4L2	0.75	7.94	0.36	1.83e-14	Gout;
LUAD	trans	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg17712092	chr4:129076599	LARP1B	-0.68	-11.32	-0.48	4.12e-26	Eosinophil percentage of white cells;
LUAD	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.49	-0.38	3.5e-16	Total body bone mineral density;
LUAD	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg25173405	chr17:45401733	C17orf57	-0.55	-9.39	-0.42	3.83e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs6561151	0.681	rs7989702	chr13:44439150	T/C	cg17145862	chr1:211918768	LPGAT1	0.54	7.4	0.34	7.57e-13	Crohn's disease;
LUAD	cis	rs2278491	0.528	rs4145242	chr8:117728296	C/T	cg23513447	chr8:117778558	UTP23	-0.56	-8.0	-0.36	1.24e-14	Body mass index;
LUAD	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02018176	chr4:1364513	KIAA1530	-0.62	-10.44	-0.45	7.29e-23	Longevity;
LUAD	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03517284	chr6:25882590	NA	-0.87	-12.15	-0.51	2.49e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs904251	0.523	rs10807184	chr6:37483713	C/T	cg25019722	chr6:37503610	NA	-0.34	-7.73	-0.35	7.69e-14	Cognitive performance;
LUAD	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.41	-6.62	-0.31	1.12e-10	Schizophrenia;
LUAD	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg03289416	chr15:75166202	SCAMP2	0.59	10.07	0.44	1.58e-21	Breast cancer;
LUAD	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg12483005	chr1:23474871	LUZP1	0.54	9.11	0.41	3.3e-18	Height;
LUAD	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg27661571	chr11:113659931	NA	-0.7	-8.14	-0.37	4.58e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg15790184	chr11:494944	RNH1	0.54	6.56	0.3	1.58e-10	Body mass index;
LUAD	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg05926928	chr17:57297772	GDPD1	1.39	17.2	0.64	1.21e-50	Opioid sensitivity;
LUAD	cis	rs367943	0.901	rs348951	chr5:112822017	G/C	cg12552261	chr5:112820674	MCC	-0.59	-11.17	-0.48	1.49e-25	Type 2 diabetes;
LUAD	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg07266350	chr3:49460521	AMT;NICN1	-0.38	-6.65	-0.31	9.14e-11	Menarche (age at onset);
LUAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg07414643	chr4:187882934	NA	0.33	6.73	0.31	5.55e-11	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg00717180	chr2:96193071	NA	-0.42	-7.83	-0.36	3.96e-14	HDL cholesterol;
LUAD	cis	rs713587	0.967	rs6752378	chr2:25150116	C/A	cg01884057	chr2:25150051	NA	0.39	8.41	0.38	6.31e-16	Body mass index in non-asthmatics;
LUAD	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg22852734	chr6:133119734	C6orf192	0.79	9.78	0.43	1.67e-20	Type 2 diabetes nephropathy;
LUAD	trans	rs1493916	1.000	rs11081827	chr18:31390228	C/A	cg15819921	chr19:927150	ARID3A	-0.46	-7.49	-0.34	4.06e-13	Life satisfaction;
LUAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg10729496	chr3:10149963	C3orf24	0.48	7.02	0.32	8.81e-12	Alzheimer's disease;
LUAD	trans	rs4650994	0.525	rs2493858	chr1:178541210	A/G	cg05059571	chr16:84539110	KIAA1609	-0.73	-13.01	-0.53	8.56e-33	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00475322	chr7:917719	C7orf20	0.6	10.8	0.47	3.42e-24	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg26408565	chr15:76604113	ETFA	-0.44	-7.12	-0.33	4.77e-12	Blood metabolite levels;
LUAD	cis	rs10206020	0.836	rs10202105	chr2:1553301	C/T	cg12573674	chr2:1569213	NA	-0.59	-8.25	-0.37	2e-15	IgG glycosylation;
LUAD	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg17063962	chr7:91808500	NA	0.68	12.35	0.51	3.89e-30	Breast cancer;
LUAD	cis	rs55788414	0.932	rs4365300	chr16:81184460	C/T	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.91	-0.36	2.31e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.56	-0.3	1.59e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.31	-7.87	-0.36	2.98e-14	Total body bone mineral density;
LUAD	trans	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg18335740	chr13:41363409	SLC25A15	0.59	10.53	0.46	3.55e-23	Lewy body disease;
LUAD	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg20673091	chr1:2541236	MMEL1	0.39	8.16	0.37	3.74e-15	Ulcerative colitis;
LUAD	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg21856205	chr7:94953877	PON1	-0.53	-7.28	-0.33	1.66e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg24579218	chr15:68104479	NA	-0.63	-9.96	-0.44	4.05e-21	Restless legs syndrome;
LUAD	trans	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg14917512	chr19:3094685	GNA11	0.37	6.57	0.3	1.48e-10	Aortic root size;
LUAD	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg00339695	chr16:24857497	SLC5A11	0.68	10.88	0.47	1.85e-24	Intelligence (multi-trait analysis);
LUAD	trans	rs2262909	0.962	rs56369285	chr19:22267185	T/C	cg05197062	chr11:11642011	GALNTL4	0.59	9.17	0.41	2.15e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg05283184	chr6:79620031	NA	-0.55	-10.52	-0.46	3.84e-23	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	0.963	rs12418721	chr11:48618451	C/T	cg00717180	chr2:96193071	NA	-0.4	-7.41	-0.34	7.11e-13	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg04842962	chr6:43655489	MRPS18A	1.05	26.39	0.79	1.96e-91	IgG glycosylation;
LUAD	trans	rs75804782	0.572	rs111233411	chr2:239289041	T/G	cg01134436	chr17:81009848	B3GNTL1	0.76	6.82	0.31	3.2e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs4664304	0.934	rs72957586	chr2:160762687	G/A	cg06573604	chr2:160760825	LY75	-0.39	-6.51	-0.3	2.17e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg27539214	chr16:67997921	SLC12A4	-0.65	-8.19	-0.37	3.02e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs117623576	0.618	rs211413	chr10:32396902	C/A	cg03047570	chr10:32398778	NA	0.71	9.03	0.4	6.25e-18	Anti-saccade response;
LUAD	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.37	0.57	1.99e-38	Schizophrenia;
LUAD	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg02931644	chr1:25747376	RHCE	0.45	9.39	0.42	3.85e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs7520050	0.933	rs6694340	chr1:46289416	C/T	cg06784218	chr1:46089804	CCDC17	-0.3	-6.38	-0.3	4.78e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg06671706	chr8:8559999	CLDN23	0.52	8.66	0.39	1.04e-16	Obesity-related traits;
LUAD	cis	rs11676348	0.772	rs11676275	chr2:218944808	G/A	cg06547715	chr2:218990976	CXCR2	0.31	7.07	0.33	6.52e-12	Ulcerative colitis;
LUAD	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	6.45	0.3	3.09e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg00280220	chr17:61926910	NA	0.36	6.95	0.32	1.37e-11	Prudent dietary pattern;
LUAD	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg19773385	chr1:10388646	KIF1B	-0.42	-6.87	-0.32	2.37e-11	Hepatocellular carcinoma;
LUAD	cis	rs7009516	0.625	rs13262293	chr8:24263618	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.43	-8.64	-0.39	1.19e-16	Hair greying;
LUAD	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs12049351	0.719	rs10799537	chr1:229664544	C/G	cg11742688	chr1:229674241	ABCB10	-0.41	-6.71	-0.31	6.23e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs4523957	0.855	rs9893573	chr17:2126003	A/G	cg16513277	chr17:2031491	SMG6	-0.82	-15.14	-0.59	1.09e-41	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3845702	0.736	rs259811	chr2:180787801	C/T	cg01881094	chr2:180872142	CWC22	-0.79	-8.34	-0.38	1.07e-15	Schizophrenia;
LUAD	trans	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.03	-0.32	8.35e-12	Dental caries;
LUAD	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg23422044	chr7:1970798	MAD1L1	-0.58	-7.22	-0.33	2.37e-12	Bipolar disorder;
LUAD	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg22681709	chr2:178499509	PDE11A	-0.51	-8.28	-0.37	1.58e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7680126	0.632	rs78030862	chr4:10150412	G/A	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.35	-0.34	1.01e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs12545109	0.837	rs1437277	chr8:57356734	T/C	cg11919837	chr8:57350735	NA	-0.47	-6.55	-0.3	1.7e-10	Obesity-related traits;
LUAD	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.81	0.36	4.52e-14	Bladder cancer;
LUAD	cis	rs13223928	0.621	rs4722438	chr7:3155813	A/G	cg19214707	chr7:3157722	NA	0.52	9.47	0.42	2.06e-19	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg07677032	chr17:61819896	STRADA	0.56	10.3	0.45	2.48e-22	Prudent dietary pattern;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11702503	chr19:6215254	MLLT1	0.56	7.23	0.33	2.32e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs1973993	0.967	rs10489741	chr1:96942406	G/A	cg10631902	chr5:14652156	NA	0.59	11.21	0.48	1e-25	Weight;
LUAD	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg03929089	chr4:120376271	NA	-0.97	-20.33	-0.7	1.38e-64	Height;
LUAD	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg11833968	chr6:79620685	NA	-0.43	-8.01	-0.36	1.1e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.38	-6.38	-0.3	4.64e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.74	13.45	0.55	1.43e-34	Axial length;
LUAD	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg04025307	chr7:1156635	C7orf50	0.56	9.39	0.42	3.74e-19	Longevity;Endometriosis;
LUAD	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg05896524	chr21:47604654	C21orf56	0.55	9.1	0.4	3.51e-18	Testicular germ cell tumor;
LUAD	trans	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg26043149	chr18:55253948	FECH	0.49	7.88	0.36	2.85e-14	Bone mineral density;
LUAD	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg24562669	chr7:97807699	LMTK2	0.32	7.45	0.34	5.41e-13	Breast cancer;
LUAD	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg23649088	chr2:200775458	C2orf69	-0.57	-6.71	-0.31	6.25e-11	Schizophrenia;
LUAD	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg08999081	chr20:33150536	PIGU	-0.36	-7.03	-0.32	8.44e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs2235642	0.701	rs2281230	chr16:1601767	T/C	cg26528668	chr16:1614120	IFT140	0.52	8.89	0.4	1.78e-17	Coronary artery disease;
LUAD	cis	rs7189233	1.000	rs62048544	chr16:53537741	C/T	cg04059762	chr16:53544020	NA	-0.41	-6.69	-0.31	7.3e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg24503407	chr1:205819492	PM20D1	0.5	7.69	0.35	1.07e-13	Parkinson's disease;
LUAD	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg00530320	chr1:46809349	NSUN4	0.53	8.17	0.37	3.63e-15	Menopause (age at onset);
LUAD	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.49	-0.3	2.48e-10	Bladder cancer;
LUAD	cis	rs10504073	0.525	rs10081464	chr8:50058707	A/G	cg00325661	chr8:49890786	NA	0.33	6.98	0.32	1.16e-11	Blood metabolite ratios;
LUAD	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg16205897	chr5:131564050	P4HA2	0.3	6.56	0.3	1.62e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.68e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs12618769	0.597	rs55978998	chr2:99049014	A/G	cg10123293	chr2:99228465	UNC50	0.48	8.66	0.39	1.04e-16	Bipolar disorder;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25750404	chr12:6579648	VAMP1	0.41	6.37	0.3	5.04e-10	Bilirubin levels;
LUAD	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.66	10.68	0.46	9.97e-24	Height;
LUAD	cis	rs2004318	1.000	rs76189918	chr19:55082868	C/T	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.85e-13	Blood protein levels;
LUAD	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.34	6.8	0.31	3.69e-11	Obesity-related traits;
LUAD	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg19163074	chr7:65112434	INTS4L2	0.44	6.76	0.31	4.56e-11	Aortic root size;
LUAD	cis	rs62238980	0.522	rs117656576	chr22:32515901	G/A	cg00543991	chr22:32367038	NA	0.88	8.51	0.38	3.06e-16	Childhood ear infection;
LUAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.52	-9.45	-0.42	2.3e-19	Lymphocyte counts;
LUAD	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg22117172	chr7:91764530	CYP51A1	0.31	6.96	0.32	1.29e-11	Breast cancer;
LUAD	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.48	-0.34	4.43e-13	Total body bone mineral density;
LUAD	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-6.68	-0.31	7.42e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8025790	0.508	rs12441823	chr15:67912977	C/T	cg27219399	chr15:67835830	MAP2K5	0.42	7.2	0.33	2.76e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg07607921	chr17:4047574	ZZEF1;CYB5D2	-0.46	-8.18	-0.37	3.25e-15	Type 2 diabetes;
LUAD	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg04154034	chr17:28927549	LRRC37B2	0.58	6.87	0.32	2.3e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs12519773	0.517	rs17360811	chr5:92492349	G/A	cg18783429	chr5:92414398	NA	0.48	8.45	0.38	4.67e-16	Migraine;
LUAD	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg03684893	chr10:554711	DIP2C	0.46	8.48	0.38	3.8e-16	Psychosis in Alzheimer's disease;
LUAD	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg18446336	chr7:2847575	GNA12	-0.35	-6.61	-0.31	1.19e-10	Height;
LUAD	cis	rs17739167	0.550	rs6493013	chr15:42224824	T/C	cg20935245	chr15:42234343	EHD4	0.44	7.72	0.35	8.48e-14	Monocyte count;
LUAD	cis	rs9796	0.621	rs2928142	chr15:41470449	T/C	cg18705301	chr15:41695430	NDUFAF1	0.47	8.56	0.38	2.05e-16	Menopause (age at onset);
LUAD	trans	rs783540	0.867	rs7167880	chr15:83294436	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.44	-7.28	-0.33	1.59e-12	Schizophrenia;
LUAD	cis	rs2637266	1.000	rs35991266	chr10:78378733	A/G	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	trans	rs875971	0.545	rs801199	chr7:66025273	A/G	cg04775059	chr7:64541387	NA	-0.5	-6.72	-0.31	5.89e-11	Aortic root size;
LUAD	cis	rs4072705	1.000	rs722477	chr9:127474594	A/G	cg13476313	chr9:127244764	NR5A1	0.3	7.28	0.33	1.63e-12	Menarche (age at onset);
LUAD	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg06484146	chr7:12443880	VWDE	-0.55	-7.18	-0.33	3.24e-12	Coronary artery disease;
LUAD	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg07952391	chr2:88470173	THNSL2	-0.39	-6.36	-0.3	5.21e-10	Response to metformin (IC50);
LUAD	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.4	-7.5	-0.34	3.67e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg13699009	chr12:122356056	WDR66	0.33	7.34	0.34	1.11e-12	Mean platelet volume;
LUAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg14820908	chr5:178986412	RUFY1	0.62	10.7	0.46	8.06e-24	Lung cancer;
LUAD	cis	rs2535633	0.631	rs2465101	chr3:52991307	A/T	cg11645453	chr3:52864694	ITIH4	-0.39	-7.1	-0.33	5.45e-12	Body mass index;
LUAD	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg13319975	chr6:146136371	FBXO30	0.67	11.7	0.49	1.4e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9394438	0.628	rs4714079	chr6:37544439	C/T	cg00985040	chr6:37553208	NA	-0.44	-9.35	-0.41	5e-19	IgG glycosylation;
LUAD	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg24562669	chr7:97807699	LMTK2	0.34	8.06	0.36	7.73e-15	Breast cancer;
LUAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg17178900	chr1:205818956	PM20D1	0.45	7.39	0.34	7.66e-13	Parkinson's disease;
LUAD	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.35	0.34	1.05e-12	Bipolar disorder;
LUAD	cis	rs68170813	0.641	rs75254991	chr7:106938903	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-11.1	-0.47	2.74e-25	Coronary artery disease;
LUAD	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.37	7.84	0.36	3.79e-14	Parkinson's disease;
LUAD	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg17848003	chr1:3704513	LRRC47	0.47	9.67	0.43	4.2e-20	Red cell distribution width;
LUAD	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg00495681	chr13:53174319	NA	-0.61	-11.52	-0.49	6.82e-27	Lewy body disease;
LUAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00149659	chr3:10157352	C3orf10	0.61	8.88	0.4	1.89e-17	Alzheimer's disease;
LUAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03452623	chr4:187889614	NA	-0.83	-17.3	-0.64	4.07e-51	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg18621852	chr3:10150065	C3orf24	0.42	7.46	0.34	5.08e-13	Alzheimer's disease;
LUAD	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-8.6	-0.39	1.53e-16	Monocyte percentage of white cells;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02689293	chr7:92464971	CDK6	0.39	6.38	0.3	4.76e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg08859206	chr1:53392774	SCP2	0.63	11.73	0.5	1.01e-27	Monocyte count;
LUAD	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg15448220	chr1:150897856	SETDB1	0.47	8.09	0.37	6.35e-15	Tonsillectomy;
LUAD	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg13319975	chr6:146136371	FBXO30	-0.57	-9.6	-0.42	7.09e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-6.8	-0.31	3.61e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg22598563	chr5:131563921	P4HA2	-0.34	-8.71	-0.39	6.7e-17	Blood metabolite levels;
LUAD	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg09165964	chr15:75287851	SCAMP5	-0.47	-7.13	-0.33	4.49e-12	Blood trace element (Zn levels);
LUAD	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-20.31	-0.7	1.58e-64	Height;
LUAD	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg04455712	chr21:45112962	RRP1B	0.47	9.13	0.41	2.79e-18	Mean corpuscular volume;
LUAD	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg15664640	chr17:80829946	TBCD	-0.67	-9.13	-0.41	2.87e-18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.01	0.47	5.95e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs2224391	0.518	rs17736761	chr6:5288319	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.63	-7.5	-0.34	3.78e-13	Height;
LUAD	trans	rs2262909	1.000	rs436039	chr19:22214873	T/C	cg05197062	chr11:11642011	GALNTL4	-0.54	-8.09	-0.37	6.21e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.14	-0.37	4.61e-15	Alzheimer's disease;
LUAD	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg14779329	chr11:130786720	SNX19	0.51	9.13	0.41	2.8e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg21191810	chr6:118973309	C6orf204	0.49	7.64	0.35	1.42e-13	Diastolic blood pressure;
LUAD	cis	rs929596	0.585	rs2018985	chr2:234648860	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-10.51	-0.46	4.09e-23	Total bilirubin levels in HIV-1 infection;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg23123838	chr14:105886072	MTA1	-0.4	-6.81	-0.31	3.45e-11	Schizophrenia;
LUAD	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg24558204	chr6:135376177	HBS1L	0.49	8.98	0.4	9.25e-18	Red blood cell count;
LUAD	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg13813247	chr22:41461852	NA	-0.49	-7.97	-0.36	1.52e-14	Neuroticism;
LUAD	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg26677194	chr12:130822605	PIWIL1	0.56	9.14	0.41	2.68e-18	Menopause (age at onset);
LUAD	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg18755752	chr8:142205143	DENND3	0.48	8.03	0.36	9.42e-15	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg21204522	chr6:27730016	NA	-0.48	-7.57	-0.35	2.38e-13	Parkinson's disease;
LUAD	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg14668632	chr7:2872130	GNA12	-0.46	-8.04	-0.36	9.26e-15	Height;
LUAD	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg18196295	chr10:418757	DIP2C	-0.45	-7.15	-0.33	3.88e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs7737355	0.681	rs11242094	chr5:131072622	A/G	cg25547332	chr5:131281432	NA	0.43	7.01	0.32	9.28e-12	Life satisfaction;
LUAD	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg08999081	chr20:33150536	PIGU	0.48	9.2	0.41	1.6e-18	Coronary artery disease;
LUAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.46	-8.09	-0.37	6.31e-15	Longevity;Endometriosis;
LUAD	cis	rs4842666	0.915	rs117742247	chr12:89991313	C/T	cg00757033	chr12:89920650	WDR51B	0.5	6.58	0.3	1.38e-10	Blood pressure;
LUAD	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.13	0.37	4.91e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg12311346	chr5:56204834	C5orf35	-0.45	-7.35	-0.34	1.03e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg00933542	chr6:150070202	PCMT1	0.45	9.92	0.43	5.41e-21	Lung cancer;
LUAD	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg01819759	chr13:79234251	RNF219	0.59	8.3	0.37	1.39e-15	Large artery stroke;
LUAD	cis	rs73198271	0.681	rs11987924	chr8:8649972	T/C	cg01851573	chr8:8652454	MFHAS1	0.5	8.74	0.39	5.53e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg09835421	chr16:68378352	PRMT7	-0.83	-8.99	-0.4	8.54e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg06558623	chr16:89946397	TCF25	1.18	10.88	0.47	1.76e-24	Skin colour saturation;
LUAD	cis	rs7216064	1.000	rs12451721	chr17:65939075	G/A	cg08758996	chr17:66097529	LOC651250	0.47	7.2	0.33	2.74e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26314531	chr2:26401878	FAM59B	0.74	10.51	0.46	4.06e-23	Gut microbiome composition (summer);
LUAD	trans	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg01620082	chr3:125678407	NA	-0.5	-6.65	-0.31	9.31e-11	Depression;
LUAD	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg05313129	chr8:58192883	C8orf71	-0.53	-6.47	-0.3	2.79e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg23649088	chr2:200775458	C2orf69	-0.52	-6.92	-0.32	1.68e-11	Schizophrenia;
LUAD	cis	rs13082711	0.522	rs594466	chr3:27362069	A/G	cg02860705	chr3:27208620	NA	-0.52	-8.79	-0.39	3.8e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg00933542	chr6:150070202	PCMT1	0.43	9.24	0.41	1.26e-18	Lung cancer;
LUAD	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.47	-0.3	2.77e-10	Mood instability;
LUAD	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg00898013	chr13:113819073	PROZ	-0.69	-12.14	-0.51	2.61e-29	Platelet distribution width;
LUAD	trans	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg26043149	chr18:55253948	FECH	0.42	6.92	0.32	1.64e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg23758822	chr17:41437982	NA	-0.99	-20.58	-0.71	1.06e-65	Menopause (age at onset);
LUAD	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.64	-0.39	1.16e-16	Height;
LUAD	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.24	-0.37	2.22e-15	Prostate cancer;
LUAD	cis	rs4711350	1.000	rs2182659	chr6:33751767	A/G	cg07979401	chr6:33739406	LEMD2	-0.51	-8.49	-0.38	3.6e-16	Schizophrenia;
LUAD	cis	rs4975616	0.773	rs10078017	chr5:1314009	C/T	cg07493874	chr5:1342172	CLPTM1L	0.35	7.47	0.34	4.67e-13	Lung cancer;
LUAD	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg15181151	chr6:150070149	PCMT1	0.32	6.51	0.3	2.17e-10	Testicular germ cell tumor;
LUAD	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg01312482	chr5:178451176	ZNF879	-0.46	-7.03	-0.32	8.09e-12	Pubertal anthropometrics;
LUAD	cis	rs1609391	0.543	rs7651085	chr3:136625339	C/G	cg15507776	chr3:136538369	TMEM22	0.5	8.93	0.4	1.36e-17	Neuroticism;
LUAD	cis	rs12348691	0.503	rs7849834	chr9:100606188	T/C	cg13688889	chr9:100608707	NA	-0.62	-10.19	-0.44	5.75e-22	Alopecia areata;
LUAD	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg21475434	chr5:93447410	FAM172A	0.73	8.51	0.38	2.97e-16	Diabetic retinopathy;
LUAD	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg27068330	chr11:65405492	SIPA1	-0.74	-11.86	-0.5	3.16e-28	Acne (severe);
LUAD	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19346786	chr7:2764209	NA	0.55	12.05	0.51	6e-29	Height;
LUAD	cis	rs1375194	0.582	rs13391166	chr2:33805314	C/T	cg04131969	chr2:33951647	MYADML	0.53	8.16	0.37	3.85e-15	Response to antidepressants in depression;
LUAD	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg08893839	chr5:154027129	NA	-0.49	-6.56	-0.3	1.57e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg09117114	chr16:67998030	SLC12A4	-0.53	-6.98	-0.32	1.12e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg04568274	chr7:158649319	WDR60	-0.44	-6.78	-0.31	4.04e-11	Height;
LUAD	cis	rs12200782	1.000	rs6456742	chr6:26617075	T/C	cg11502198	chr6:26597334	ABT1	-0.79	-6.82	-0.31	3.11e-11	Small cell lung carcinoma;
LUAD	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg09455208	chr3:40491958	NA	0.53	11.34	0.48	3.34e-26	Renal cell carcinoma;
LUAD	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg16325326	chr1:53192061	ZYG11B	-0.63	-11.72	-0.5	1.12e-27	Monocyte count;
LUAD	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg07527032	chr15:84868466	LOC388152	0.44	6.6	0.31	1.27e-10	Schizophrenia;
LUAD	cis	rs1873147	0.569	rs12593531	chr15:63309936	C/G	cg12160578	chr15:63334699	TPM1	0.52	7.89	0.36	2.56e-14	Orofacial clefts;
LUAD	cis	rs6484504	0.576	rs16922084	chr11:31371109	C/T	cg26647111	chr11:31128758	NA	0.45	7.84	0.36	3.6e-14	Red blood cell count;
LUAD	cis	rs10924309	0.737	rs6700721	chr1:245854173	C/T	cg00036263	chr1:245852353	KIF26B	-0.54	-9.25	-0.41	1.16e-18	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs6545883	0.895	rs2256617	chr2:61679924	A/G	cg15711740	chr2:61764176	XPO1	-0.4	-6.45	-0.3	2.99e-10	Tuberculosis;
LUAD	cis	rs78761021	0.867	rs7213983	chr17:9792115	C/T	cg26853458	chr17:9805074	RCVRN	-0.37	-7.2	-0.33	2.79e-12	Type 2 diabetes;
LUAD	cis	rs778371	0.697	rs6717048	chr2:233586427	T/C	cg08000102	chr2:233561755	GIGYF2	0.39	6.45	0.3	3.1e-10	Schizophrenia;
LUAD	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg22961513	chr11:14280813	SPON1	-0.44	-8.82	-0.39	3e-17	Mitochondrial DNA levels;
LUAD	cis	rs17095355	1.000	rs17126902	chr10:111710381	A/G	cg00817464	chr10:111662876	XPNPEP1	0.69	9.23	0.41	1.27e-18	Biliary atresia;
LUAD	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg19163074	chr7:65112434	INTS4L2	0.43	6.82	0.31	3.21e-11	Aortic root size;
LUAD	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg10518543	chr12:38710700	ALG10B	0.42	6.42	0.3	3.68e-10	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18163118	chr11:67250585	AIP	-0.53	-6.37	-0.3	4.8e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2992756	0.617	rs3007719	chr1:18811668	C/T	cg14356550	chr1:18808102	KLHDC7A	0.51	8.46	0.38	4.5e-16	Breast cancer;
LUAD	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06028808	chr11:68637592	NA	0.49	8.03	0.36	9.87e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs13082711	0.522	rs674303	chr3:27332177	T/C	cg02860705	chr3:27208620	NA	0.52	8.57	0.38	1.94e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs41271951	0.512	rs12070256	chr1:151070090	C/T	cg11822372	chr1:151115635	SEMA6C	-0.82	-6.99	-0.32	1.11e-11	Blood protein levels;
LUAD	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs2625529	0.938	rs9120	chr15:72115763	G/A	cg16672083	chr15:72433130	SENP8	-0.73	-11.4	-0.48	1.92e-26	Red blood cell count;
LUAD	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg20701182	chr2:24300061	SF3B14	0.67	7.45	0.34	5.32e-13	Lymphocyte counts;
LUAD	cis	rs4372836	0.658	rs11127189	chr2:28992020	T/G	cg09522027	chr2:28974177	PPP1CB	-0.7	-12.81	-0.53	5.9e-32	Body mass index;
LUAD	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.37	6.55	0.3	1.68e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7771547	0.573	rs544267	chr6:36398302	A/G	cg07856975	chr6:36356162	ETV7	0.49	7.77	0.35	6.21e-14	Platelet distribution width;
LUAD	cis	rs4074961	0.527	rs2294875	chr1:38052445	C/T	cg12696750	chr1:38022466	DNALI1	0.38	6.6	0.31	1.22e-10	Axial length;
LUAD	cis	rs2425143	0.908	rs75331436	chr20:34391052	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.01	-0.32	9.69e-12	Blood protein levels;
LUAD	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg18016565	chr1:150552671	MCL1	0.41	7.52	0.34	3.34e-13	Tonsillectomy;
LUAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg20607798	chr8:58055168	NA	0.57	7.24	0.33	2.1e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg18446336	chr7:2847575	GNA12	-0.37	-6.83	-0.32	2.9e-11	Height;
LUAD	cis	rs76878669	0.561	rs4244813	chr11:66129488	G/C	cg10616300	chr11:66138557	SLC29A2	0.35	7.3	0.33	1.49e-12	Educational attainment (years of education);
LUAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg08888203	chr3:10149979	C3orf24	0.63	10.73	0.46	6.56e-24	Alzheimer's disease;
LUAD	cis	rs11971779	0.680	rs6961812	chr7:139043808	A/C	cg23387468	chr7:139079360	LUC7L2	0.28	6.49	0.3	2.47e-10	Diisocyanate-induced asthma;
LUAD	cis	rs4343996	0.715	rs4722827	chr7:3500379	G/C	cg21248987	chr7:3385318	SDK1	0.35	6.56	0.3	1.56e-10	Motion sickness;
LUAD	cis	rs7187994	0.806	rs12445172	chr16:84747016	C/G	cg07647771	chr16:84786436	USP10	-0.35	-8.91	-0.4	1.54e-17	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22857025	chr5:266934	NA	-0.96	-14.39	-0.57	1.75e-38	Breast cancer;
LUAD	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg07636037	chr3:49044803	WDR6	0.53	10.19	0.44	6.17e-22	Menarche (age at onset);
LUAD	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg13385794	chr1:248469461	NA	0.27	7.18	0.33	3.17e-12	Common traits (Other);
LUAD	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg17177755	chr1:15930204	NA	0.44	7.07	0.32	6.54e-12	Systolic blood pressure;
LUAD	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg26597838	chr10:835615	NA	1.31	21.06	0.72	7.26e-68	Eosinophil percentage of granulocytes;
LUAD	trans	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.21	-0.41	1.52e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg22920501	chr2:26401640	FAM59B	-0.82	-11.51	-0.49	7.66e-27	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg21724239	chr8:58056113	NA	0.63	7.99	0.36	1.33e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.41	6.8	0.31	3.5e-11	Systemic lupus erythematosus;
LUAD	trans	rs11039798	0.764	rs2089208	chr11:48899860	C/T	cg03929089	chr4:120376271	NA	0.6	6.84	0.32	2.84e-11	Axial length;
LUAD	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	7.25	0.33	2e-12	Platelet count;
LUAD	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07343612	chr16:622815	PIGQ	-0.83	-17.1	-0.64	3.14e-50	Height;
LUAD	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg19761014	chr17:28927070	LRRC37B2	0.84	8.27	0.37	1.77e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg14983838	chr19:29218262	NA	0.55	7.44	0.34	5.8e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs9653442	1.000	rs9653442	chr2:100825367	A/G	cg22139774	chr2:100720529	AFF3	0.34	6.54	0.3	1.82e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg25358565	chr5:93447407	FAM172A	-0.58	-7.07	-0.33	6.25e-12	Diabetic retinopathy;
LUAD	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg06641503	chr3:48959341	ARIH2	0.4	7.87	0.36	2.94e-14	Parkinson's disease;
LUAD	trans	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg04775059	chr7:64541387	NA	0.5	6.87	0.32	2.29e-11	Aortic root size;
LUAD	cis	rs2535633	0.631	rs2257216	chr3:52968726	T/C	cg11645453	chr3:52864694	ITIH4	-0.39	-7.22	-0.33	2.37e-12	Body mass index;
LUAD	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg09491104	chr22:46646882	C22orf40	-0.74	-13.44	-0.55	1.6e-34	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2637266	0.875	rs12783253	chr10:78378108	A/G	cg18941641	chr10:78392320	NA	0.33	6.85	0.32	2.66e-11	Pulmonary function;
LUAD	cis	rs2290402	0.536	rs56307842	chr4:854232	T/C	cg23939001	chr4:940644	TMEM175	-0.44	-6.36	-0.3	5.1e-10	Type 2 diabetes;
LUAD	cis	rs4901869	0.966	rs12893803	chr14:59329655	T/C	cg02291164	chr14:59296302	NA	0.63	15.03	0.59	3.11e-41	Panic disorder;
LUAD	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg08807101	chr21:30365312	RNF160	-0.41	-7.04	-0.32	7.98e-12	Dental caries;
LUAD	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18876405	chr7:65276391	NA	-0.59	-10.09	-0.44	1.32e-21	Aortic root size;
LUAD	trans	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-9.66	-0.43	4.43e-20	Ulcerative colitis;
LUAD	cis	rs11811982	0.793	rs11800169	chr1:227452952	C/T	cg24860534	chr1:227506868	CDC42BPA	0.7	7.34	0.34	1.13e-12	Optic disc area;
LUAD	cis	rs220324	0.688	rs4283513	chr21:43566409	G/T	cg08841829	chr21:43638893	ABCG1	-0.5	-7.11	-0.33	5.04e-12	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs10489202	0.633	rs4657734	chr1:168086743	C/T	cg25738037	chr1:168025549	DCAF6	-0.44	-6.36	-0.3	5.15e-10	Schizophrenia;
LUAD	cis	rs225245	0.765	rs226428	chr17:34049950	C/T	cg05299278	chr17:33885742	SLFN14	-0.49	-10.89	-0.47	1.7e-24	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg10792982	chr14:105748885	BRF1	0.45	9.95	0.44	4.18e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg02782426	chr3:40428986	ENTPD3	0.44	9.32	0.41	6.45e-19	Renal cell carcinoma;
LUAD	trans	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.53e-11	Depression;
LUAD	trans	rs12517041	1.000	rs6866732	chr5:23307656	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.61	-0.31	1.13e-10	Calcium levels;
LUAD	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.53	-0.6	2.31e-43	Eye color traits;
LUAD	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg17105886	chr17:28927953	LRRC37B2	0.77	7.66	0.35	1.28e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.5	0.42	1.62e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4523957	0.928	rs4790071	chr17:2173184	A/G	cg16513277	chr17:2031491	SMG6	-0.76	-14.52	-0.58	4.91e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg03233332	chr7:66118400	NA	-0.45	-6.93	-0.32	1.55e-11	Aortic root size;
LUAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg27532560	chr4:187881888	NA	-0.36	-6.91	-0.32	1.8e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4930561	0.714	rs7950451	chr11:67962406	C/A	cg04465784	chr11:67976953	SUV420H1	-0.28	-8.26	-0.37	1.91e-15	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs2235649	0.833	rs9939694	chr16:1852760	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.48	-7.9	-0.36	2.46e-14	Blood metabolite levels;
LUAD	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg15017067	chr4:17643749	FAM184B	0.35	6.9	0.32	1.97e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3818285	0.632	rs536343	chr10:111632879	T/C	cg00817464	chr10:111662876	XPNPEP1	0.82	15.64	0.61	7.77e-44	Superior crus of antihelix expression;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09068198	chr2:65357064	RAB1A	-0.43	-6.56	-0.3	1.62e-10	Height;
LUAD	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg20503657	chr10:835505	NA	1.24	18.4	0.67	5.57e-56	Eosinophil percentage of granulocytes;
LUAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg15117754	chr3:10150083	C3orf24	0.41	6.55	0.3	1.65e-10	Alzheimer's disease;
LUAD	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.27	0.37	1.8e-15	Breast cancer;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg25742201	chr17:35306863	AATF	-0.46	-6.38	-0.3	4.64e-10	Testicular germ cell tumor;
LUAD	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg13390004	chr1:15929781	NA	0.47	8.45	0.38	4.63e-16	Systolic blood pressure;
LUAD	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg26818010	chr10:134567672	INPP5A	-0.75	-13.02	-0.53	7.79e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs225245	0.694	rs321616	chr17:33882720	C/T	cg05299278	chr17:33885742	SLFN14	0.52	11.89	0.5	2.57e-28	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg14769373	chr6:40998127	UNC5CL	0.36	6.37	0.3	4.99e-10	Alzheimer's disease (late onset);
LUAD	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg06108461	chr20:60628389	TAF4	-0.78	-13.37	-0.54	3.03e-34	Body mass index;
LUAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg18538332	chr22:24372958	LOC391322	-0.54	-9.15	-0.41	2.38e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26314531	chr2:26401878	FAM59B	0.73	9.78	0.43	1.66e-20	Gut microbiome composition (summer);
LUAD	cis	rs75920871	0.843	rs17120111	chr11:116744018	C/T	cg04087571	chr11:116723030	SIK3	-0.33	-6.69	-0.31	6.99e-11	Subjective well-being;
LUAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6499255	1.000	rs8045682	chr16:69786092	C/A	cg15192750	chr16:69999425	NA	0.56	8.71	0.39	7e-17	IgE levels;
LUAD	cis	rs240764	0.817	rs239211	chr6:101144965	A/C	cg09795085	chr6:101329169	ASCC3	0.44	7.63	0.35	1.56e-13	Neuroticism;
LUAD	cis	rs4964805	0.586	rs934846	chr12:104185297	C/T	cg02344784	chr12:104178138	NT5DC3	0.49	10.27	0.45	3.14e-22	Attention deficit hyperactivity disorder;
LUAD	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg20933634	chr6:27740509	NA	0.46	7.28	0.33	1.68e-12	Parkinson's disease;
LUAD	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg13319975	chr6:146136371	FBXO30	0.78	13.31	0.54	5.22e-34	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg06627628	chr2:24431161	ITSN2	0.43	7.28	0.33	1.63e-12	Asthma;
LUAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg18621852	chr3:10150065	C3orf24	-0.44	-7.73	-0.35	7.69e-14	Alzheimer's disease;
LUAD	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg11901034	chr3:128598214	ACAD9	-0.54	-8.56	-0.38	2.04e-16	IgG glycosylation;
LUAD	cis	rs4523957	0.928	rs422632	chr17:2162049	G/A	cg16513277	chr17:2031491	SMG6	0.76	14.68	0.58	1.05e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg23301539	chr8:142222248	SLC45A4	0.49	8.75	0.39	4.98e-17	Immature fraction of reticulocytes;
LUAD	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg24531977	chr5:56204891	C5orf35	-0.58	-9.3	-0.41	7.66e-19	Coronary artery disease;
LUAD	cis	rs12618769	0.597	rs17032120	chr2:99082938	A/G	cg10123293	chr2:99228465	UNC50	-0.48	-8.74	-0.39	5.53e-17	Bipolar disorder;
LUAD	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg26924012	chr15:45694286	SPATA5L1	1.02	18.92	0.68	2.86e-58	Homoarginine levels;
LUAD	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg07700843	chr1:2391317	NA	-0.47	-9.12	-0.41	3.09e-18	Non-obstructive azoospermia;
LUAD	cis	rs2742417	0.624	rs2673068	chr3:45768981	G/A	cg10512202	chr3:45649293	LIMD1	0.48	8.89	0.4	1.72e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.09e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1371614	0.611	rs3845685	chr2:27130332	C/T	cg00617064	chr2:27272375	NA	0.34	6.61	0.31	1.16e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg11494091	chr17:61959527	GH2	0.75	18.49	0.67	2.26e-56	Prudent dietary pattern;
LUAD	cis	rs4774899	0.934	rs745652	chr15:57470298	A/G	cg14026238	chr15:57616123	NA	0.35	6.62	0.31	1.09e-10	Urinary tract infection frequency;
LUAD	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.12	-0.37	5.02e-15	Diabetic kidney disease;
LUAD	cis	rs3106136	0.934	rs17376404	chr4:95224046	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.71	-0.35	8.92e-14	Capecitabine sensitivity;
LUAD	cis	rs10203711	1.000	rs13028091	chr2:239569723	C/T	cg14580085	chr2:239553406	NA	0.41	8.85	0.4	2.38e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3106136	0.546	rs2632417	chr4:95137542	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.22	-0.44	4.77e-22	Capecitabine sensitivity;
LUAD	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.05e-19	Life satisfaction;
LUAD	cis	rs4950928	0.700	rs946263	chr1:203165381	A/G	cg17014757	chr1:203156097	CHI3L1	0.56	7.61	0.35	1.81e-13	YKL-40 levels;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg21932255	chr17:46703122	HOXB9	-0.38	-7.07	-0.33	6.37e-12	Subcortical brain region volumes;
LUAD	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg05665937	chr4:1216051	CTBP1	0.49	7.47	0.34	4.54e-13	Longevity;
LUAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg21733973	chr7:65235735	NA	0.52	8.54	0.38	2.47e-16	Calcium levels;
LUAD	cis	rs1595825	0.838	rs58576043	chr2:198524149	C/T	cg00982548	chr2:198649783	BOLL	-0.62	-8.83	-0.39	2.89e-17	Ulcerative colitis;
LUAD	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg26384229	chr12:38710491	ALG10B	-0.41	-6.86	-0.32	2.39e-11	Bladder cancer;
LUAD	cis	rs9303280	0.870	rs6503524	chr17:38069809	C/T	cg10909506	chr17:38081995	ORMDL3	-0.37	-6.65	-0.31	9.05e-11	Self-reported allergy;
LUAD	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg09796270	chr17:17721594	SREBF1	0.36	6.98	0.32	1.11e-11	Total body bone mineral density;
LUAD	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg11915388	chr22:42470451	FAM109B	-0.41	-7.46	-0.34	4.95e-13	Schizophrenia;
LUAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg26304593	chr6:42947056	PEX6	-0.46	-7.5	-0.34	3.7e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg18827107	chr12:86230957	RASSF9	0.54	9.62	0.42	5.98e-20	Major depressive disorder;
LUAD	cis	rs4713675	0.546	rs10947430	chr6:33658534	G/A	cg13859433	chr6:33739653	LEMD2	-0.29	-6.73	-0.31	5.67e-11	Plateletcrit;
LUAD	cis	rs6920965	0.563	rs1544292	chr6:126175093	G/C	cg05901451	chr6:126070800	HEY2	-0.43	-7.01	-0.32	9.19e-12	High light scatter reticulocyte count;
LUAD	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg04455712	chr21:45112962	RRP1B	0.49	9.86	0.43	8.51e-21	Mean corpuscular volume;
LUAD	cis	rs7680126	0.596	rs4698029	chr4:10312798	C/G	cg00071950	chr4:10020882	SLC2A9	0.53	7.25	0.33	1.96e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg09904177	chr6:26538194	HMGN4	0.44	7.23	0.33	2.29e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs731174	0.959	rs11264092	chr1:38190625	T/C	cg06917450	chr1:38156652	C1orf109	-0.44	-7.28	-0.33	1.6e-12	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs6854137	0.904	rs13124822	chr4:169737712	G/A	cg20607169	chr4:169750834	PALLD	0.5	9.5	0.42	1.63e-19	Vein graft stenosis in coronary artery bypass grafting;
LUAD	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg02574844	chr11:5959923	NA	-0.4	-7.05	-0.32	7.43e-12	DNA methylation (variation);
LUAD	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg15445000	chr17:37608096	MED1	0.44	8.0	0.36	1.22e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg07570687	chr10:102243282	WNT8B	0.46	6.86	0.32	2.42e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.37e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03647317	chr4:187891568	NA	-0.35	-6.47	-0.3	2.75e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26370409	chr1:10002828	NMNAT1;LZIC	-0.43	-6.78	-0.31	4.01e-11	Height;
LUAD	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg20503657	chr10:835505	NA	0.86	12.52	0.52	8.16e-31	Eosinophil percentage of granulocytes;
LUAD	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg24818145	chr4:99064322	C4orf37	-0.41	-6.76	-0.31	4.51e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.47	0.3	2.64e-10	Depression;
LUAD	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.45	0.42	2.35e-19	Colorectal cancer;
LUAD	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg27494647	chr7:150038898	RARRES2	0.44	7.24	0.33	2.18e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg18806716	chr10:30721971	MAP3K8	0.77	16.17	0.62	4.01e-46	Inflammatory bowel disease;
LUAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-6.95	-0.32	1.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4006360	0.646	rs11868364	chr17:39236968	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.35	7.96	0.36	1.57e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg06641503	chr3:48959341	ARIH2	-0.41	-8.06	-0.36	7.92e-15	Parkinson's disease;
LUAD	cis	rs11893307	0.509	rs4368360	chr2:191536053	C/G	cg27211696	chr2:191398769	TMEM194B	-0.43	-6.5	-0.3	2.31e-10	Mean platelet volume;
LUAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg10819733	chr22:24237672	NA	-0.46	-8.99	-0.4	8.05e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg00071950	chr4:10020882	SLC2A9	-0.62	-11.85	-0.5	3.56e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs807669	0.772	rs809901	chr22:19228736	C/T	cg24911827	chr22:19170109	CLTCL1	0.32	6.77	0.31	4.24e-11	Metabolite levels;
LUAD	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg23029597	chr12:123009494	RSRC2	-0.47	-7.29	-0.33	1.56e-12	Body mass index;
LUAD	cis	rs17789174	1.000	rs17789174	chr16:85103885	A/G	cg27466129	chr16:85060822	KIAA0513	-0.31	-6.53	-0.3	1.93e-10	Dysphagia;
LUAD	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg00255919	chr5:131827918	IRF1	-0.48	-10.98	-0.47	7.25e-25	Asthma (sex interaction);
LUAD	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg06108461	chr20:60628389	TAF4	-0.96	-17.24	-0.64	8.14e-51	Body mass index;
LUAD	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.73	0.31	5.55e-11	Colorectal cancer;
LUAD	cis	rs354225	0.586	rs966003	chr2:54884870	C/T	cg26097391	chr2:54893211	SPTBN1	0.45	8.08	0.37	7.01e-15	Schizophrenia;
LUAD	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg03289416	chr15:75166202	SCAMP2	0.59	10.16	0.44	7.92e-22	Breast cancer;
LUAD	cis	rs11696501	0.739	rs6073820	chr20:44249272	T/A	cg11783356	chr20:44313418	WFDC10B	-0.49	-7.7	-0.35	9.71e-14	Brain structure;
LUAD	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg27426351	chr10:43362370	NA	-0.53	-8.12	-0.37	5e-15	Blood protein levels;
LUAD	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg25811766	chr13:21894605	NA	0.65	7.55	0.34	2.65e-13	White matter hyperintensity burden;
LUAD	cis	rs6842047	1.000	rs4862665	chr4:187136142	C/T	cg02012338	chr4:187126139	CYP4V2	-0.84	-8.87	-0.4	2.13e-17	Blood protein levels;
LUAD	cis	rs7267979	0.934	rs113469203	chr20:25343258	G/A	cg08601574	chr20:25228251	PYGB	-0.47	-8.62	-0.39	1.34e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg27446573	chr6:127587934	RNF146	0.43	6.47	0.3	2.72e-10	Breast cancer;
LUAD	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg10518543	chr12:38710700	ALG10B	-0.5	-8.32	-0.37	1.26e-15	Morning vs. evening chronotype;
LUAD	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg02158880	chr13:53174818	NA	0.49	8.3	0.37	1.38e-15	Lewy body disease;
LUAD	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.83	14.64	0.58	1.47e-39	Chronic sinus infection;
LUAD	cis	rs7680126	0.596	rs10939723	chr4:10139105	G/T	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.59	-0.31	1.27e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs2268241	0.938	rs17879003	chr21:34778527	C/T	cg14850771	chr21:34775459	IFNGR2	0.58	6.74	0.31	5.32e-11	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg24642844	chr7:1081250	C7orf50	-0.84	-13.26	-0.54	8.48e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6906287	0.647	rs13192574	chr6:118875258	C/T	cg18833306	chr6:118973337	C6orf204	0.48	8.53	0.38	2.65e-16	Electrocardiographic conduction measures;
LUAD	cis	rs4074961	0.565	rs10908362	chr1:38061706	G/C	cg12696750	chr1:38022466	DNALI1	0.37	6.39	0.3	4.35e-10	Axial length;
LUAD	cis	rs13082711	0.554	rs4973729	chr3:27390637	G/A	cg02860705	chr3:27208620	NA	0.73	10.94	0.47	1.03e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg12564285	chr5:131593104	PDLIM4	-0.39	-6.7	-0.31	6.71e-11	Breast cancer;
LUAD	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg03806693	chr22:41940476	POLR3H	-0.56	-8.08	-0.37	6.76e-15	Vitiligo;
LUAD	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	cis	rs6840360	0.571	rs55808836	chr4:152554991	C/T	cg22705602	chr4:152727874	NA	-0.4	-6.94	-0.32	1.52e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7584330	0.504	rs7598417	chr2:238435265	C/G	cg14458575	chr2:238380390	NA	0.46	7.57	0.35	2.37e-13	Prostate cancer;
LUAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg17178900	chr1:205818956	PM20D1	0.74	15.31	0.6	2.09e-42	Menarche (age at onset);
LUAD	trans	rs11088226	0.581	rs2833862	chr21:33884390	A/G	cg09050820	chr6:167586206	TCP10L2	0.47	7.98	0.36	1.4e-14	Gastritis;
LUAD	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18876405	chr7:65276391	NA	0.41	6.47	0.3	2.68e-10	Aortic root size;
LUAD	cis	rs7945705	1.000	rs7937298	chr11:8867509	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.57	10.51	0.45	4.23e-23	Hemoglobin concentration;
LUAD	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg07606381	chr6:8435919	SLC35B3	0.44	7.15	0.33	3.84e-12	Motion sickness;
LUAD	cis	rs80207740	1.000	rs80207740	chr8:21779937	C/G	cg25597362	chr8:21767310	DOK2	-0.68	-8.18	-0.37	3.39e-15	Mean corpuscular hemoglobin;
LUAD	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg06671706	chr8:8559999	CLDN23	0.56	9.39	0.42	3.71e-19	Obesity-related traits;
LUAD	cis	rs6740322	0.895	rs28456986	chr2:43553321	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.78	-11.3	-0.48	4.74e-26	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs4523957	0.928	rs216201	chr17:2198800	C/T	cg16513277	chr17:2031491	SMG6	0.77	14.37	0.57	2.03e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg05434287	chr7:2030229	MAD1L1	0.41	6.64	0.31	9.67e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9462027	0.675	rs7755926	chr6:34722574	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.76	-0.39	4.88e-17	Systemic lupus erythematosus;
LUAD	cis	rs752010	0.806	rs6696511	chr1:42110888	T/C	cg06885757	chr1:42089581	HIVEP3	0.57	12.95	0.53	1.55e-32	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.79e-18	Life satisfaction;
LUAD	cis	rs7582720	1.000	rs72936881	chr2:203794262	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2046867	0.908	rs62251648	chr3:72806083	A/G	cg25664220	chr3:72788482	NA	-0.69	-12.52	-0.52	8.47e-31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2882667	0.628	rs13162420	chr5:138174759	T/C	cg04439458	chr5:138467593	SIL1	-0.44	-7.17	-0.33	3.45e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2979489	0.838	rs2979513	chr8:30397925	G/C	cg26383811	chr8:30366931	RBPMS	-0.69	-10.63	-0.46	1.48e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg09263875	chr16:632152	PIGQ	0.8	17.18	0.64	1.51e-50	Height;
LUAD	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg09359103	chr1:154839909	KCNN3	-0.91	-20.92	-0.71	2.94e-67	Prostate cancer;
LUAD	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg14893161	chr1:205819251	PM20D1	0.48	6.89	0.32	2e-11	Parkinson's disease;
LUAD	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg23254163	chr1:152506842	NA	0.26	7.14	0.33	4.02e-12	Hair morphology;
LUAD	cis	rs2455799	0.573	rs2455834	chr3:15753641	A/G	cg16303742	chr3:15540471	COLQ	-0.52	-9.54	-0.42	1.18e-19	Mean platelet volume;
LUAD	cis	rs6961069	0.742	rs3211849	chr7:80283323	A/G	cg04458919	chr7:80252533	CD36	-0.34	-6.4	-0.3	4.18e-10	Platelet count;
LUAD	trans	rs7944735	0.567	rs77684932	chr11:48024893	A/G	cg15704280	chr7:45808275	SEPT13	0.66	6.5	0.3	2.31e-10	Intraocular pressure;
LUAD	cis	rs28655083	0.828	rs7190227	chr16:77119568	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.45	7.31	0.34	1.32e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6906287	0.625	rs7757892	chr6:118844221	G/A	cg21191810	chr6:118973309	C6orf204	0.49	9.47	0.42	2.06e-19	Electrocardiographic conduction measures;
LUAD	cis	rs2637266	0.935	rs7918777	chr10:78394375	A/G	cg18941641	chr10:78392320	NA	0.34	7.1	0.33	5.39e-12	Pulmonary function;
LUAD	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg18180107	chr4:99064573	C4orf37	0.42	6.72	0.31	5.84e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2294693	0.531	rs10947940	chr6:40948496	C/T	cg14769373	chr6:40998127	UNC5CL	-0.48	-6.53	-0.3	1.89e-10	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg03806693	chr22:41940476	POLR3H	0.77	10.13	0.44	9.98e-22	Vitiligo;
LUAD	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg17724175	chr1:150552817	MCL1	0.29	6.7	0.31	6.5500000000000006e-11	Melanoma;
LUAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	11.0	0.47	6.43e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1018836	0.700	rs7824376	chr8:91521498	T/C	cg16814680	chr8:91681699	NA	-0.71	-11.95	-0.5	1.41e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg27411982	chr8:10470053	RP1L1	-0.39	-7.05	-0.32	7.53e-12	Neuroticism;
LUAD	cis	rs7009516	0.692	rs9650408	chr8:24240670	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.42	-8.58	-0.39	1.75e-16	Hair greying;
LUAD	cis	rs7607369	0.536	rs12623740	chr2:219665715	T/A	cg02176678	chr2:219576539	TTLL4	-0.52	-9.87	-0.43	8.04e-21	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	11.5	0.49	8.26e-27	Resting heart rate;
LUAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg22907277	chr7:1156413	C7orf50	0.59	10.06	0.44	1.73e-21	Longevity;Endometriosis;
LUAD	cis	rs9462027	0.628	rs7752522	chr6:34760583	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.85	-0.4	2.5e-17	Systemic lupus erythematosus;
LUAD	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11890956	chr21:40555474	PSMG1	-0.68	-11.93	-0.5	1.71e-28	Cognitive function;
LUAD	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg14779329	chr11:130786720	SNX19	0.38	6.43	0.3	3.47e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg20607798	chr8:58055168	NA	0.67	8.84	0.39	2.57e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg08645402	chr16:4508243	NA	0.59	10.87	0.47	1.89e-24	Schizophrenia;
LUAD	cis	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.9	-0.32	1.92e-11	Triglycerides;
LUAD	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.42	-6.61	-0.31	1.14e-10	Platelet count;
LUAD	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg11833968	chr6:79620685	NA	-0.42	-7.95	-0.36	1.77e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg02751453	chr18:77725136	HSBP1L1	-0.44	-7.72	-0.35	8.65e-14	Opioid sensitivity;
LUAD	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg07305463	chr2:136567211	LCT	0.37	6.97	0.32	1.19e-11	Mosquito bite size;
LUAD	trans	rs7615952	0.546	rs2922197	chr3:125322032	G/A	cg17147758	chr8:6949321	NA	-0.47	-7.17	-0.33	3.4e-12	Blood pressure (smoking interaction);
LUAD	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg26408565	chr15:76604113	ETFA	-0.47	-7.77	-0.35	6.15e-14	Blood metabolite levels;
LUAD	cis	rs36715	1.000	rs251213	chr5:127545605	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.48	6.66	0.31	8.52e-11	Breast cancer;
LUAD	cis	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg02012338	chr4:187126139	CYP4V2	0.9	9.22	0.41	1.37e-18	Blood protein levels;
LUAD	cis	rs57590327	0.503	rs2372905	chr3:81504592	C/G	cg07356753	chr3:81810745	GBE1	0.48	7.52	0.34	3.32e-13	Extraversion;
LUAD	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.87	-0.36	3.03e-14	Menopause (age at onset);
LUAD	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg25036284	chr2:26402008	FAM59B	0.79	11.66	0.49	1.99e-27	Gut microbiome composition (summer);
LUAD	cis	rs2046867	0.908	rs9880763	chr3:72789805	G/C	cg25664220	chr3:72788482	NA	-0.65	-11.75	-0.5	8.91e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg03690763	chr11:133734501	NA	-0.37	-8.52	-0.38	2.74e-16	Childhood ear infection;
LUAD	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg06627628	chr2:24431161	ITSN2	-0.52	-6.35	-0.3	5.52e-10	Lymphocyte counts;
LUAD	cis	rs12505328	0.966	rs13150564	chr4:174358573	G/A	cg12145043	chr4:174357286	NA	0.55	9.66	0.43	4.44e-20	Chin dimples;
LUAD	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg25894440	chr7:65020034	NA	-0.61	-6.58	-0.3	1.39e-10	Diabetic kidney disease;
LUAD	cis	rs79349575	0.716	rs595767	chr17:46957987	A/G	cg26022315	chr17:47021804	SNF8	0.4	7.16	0.33	3.56e-12	Type 2 diabetes;
LUAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg02524346	chr8:600233	NA	-1.16	-9.91	-0.43	5.72e-21	IgG glycosylation;
LUAD	cis	rs1865721	1.000	rs72977890	chr18:73198776	C/A	cg26385618	chr18:73139727	C18orf62	-0.41	-7.41	-0.34	7e-13	Intelligence;
LUAD	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg13319975	chr6:146136371	FBXO30	-0.72	-12.11	-0.51	3.38e-29	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1941023	0.503	rs894591	chr11:60132647	T/C	cg08716584	chr11:60157161	MS4A7	-0.47	-9.01	-0.4	7.29e-18	Congenital heart disease (maternal effect);
LUAD	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs76878669	0.538	rs1785633	chr11:66107527	C/A	cg10616300	chr11:66138557	SLC29A2	0.34	7.16	0.33	3.53e-12	Educational attainment (years of education);
LUAD	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg24069376	chr3:38537580	EXOG	0.43	10.16	0.44	7.47e-22	Electrocardiographic conduction measures;
LUAD	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg14092988	chr3:52407081	DNAH1	0.44	8.87	0.4	2.04e-17	Bipolar disorder;
LUAD	cis	rs6754311	0.589	rs749873	chr2:136817088	C/T	cg05194412	chr2:137003533	NA	0.45	6.8	0.31	3.52e-11	Mosquito bite size;
LUAD	cis	rs10465746	0.570	rs11163884	chr1:84472760	A/G	cg10977910	chr1:84465055	TTLL7	0.49	7.46	0.34	4.97e-13	Obesity-related traits;
LUAD	cis	rs7607369	0.536	rs13032993	chr2:219666377	T/C	cg02176678	chr2:219576539	TTLL4	-0.55	-10.98	-0.47	7.73e-25	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs7737355	0.947	rs7706785	chr5:130954860	T/C	cg06307176	chr5:131281290	NA	0.51	7.8	0.35	4.73e-14	Life satisfaction;
LUAD	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg00383909	chr3:49044727	WDR6	0.78	8.82	0.39	2.93e-17	Cognitive function;
LUAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg21724239	chr8:58056113	NA	0.7	9.34	0.41	5.67e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg13180566	chr4:1052158	NA	-0.4	-6.92	-0.32	1.73e-11	Recombination rate (females);
LUAD	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg23283495	chr1:209979779	IRF6	-0.69	-9.16	-0.41	2.2e-18	Cleft lip with or without cleft palate;
LUAD	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg03929089	chr4:120376271	NA	0.69	10.67	0.46	1.05e-23	Coronary artery disease;
LUAD	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-6.68	-0.31	7.41e-11	Bipolar disorder;
LUAD	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg00666640	chr1:248458726	OR2T12	0.32	7.65	0.35	1.33e-13	Common traits (Other);
LUAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	9.78	0.43	1.67e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6076065	0.748	rs6048750	chr20:23334192	T/G	cg11657817	chr20:23433608	CST11	0.59	12.29	0.51	7.03e-30	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.98	0.32	1.18e-11	Colorectal cancer;
LUAD	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg03806693	chr22:41940476	POLR3H	-0.61	-8.89	-0.4	1.76e-17	Vitiligo;
LUAD	cis	rs2485376	1.000	rs2281983	chr10:103991381	G/A	cg20641465	chr10:103991465	PITX3	0.57	10.44	0.45	7.23e-23	QT interval;
LUAD	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.6	-0.71	8.12e-66	Height;
LUAD	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg07404485	chr7:94953653	PON1	-0.51	-7.53	-0.34	3.1400000000000003e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg20203395	chr5:56204925	C5orf35	0.97	13.69	0.55	1.45e-35	Initial pursuit acceleration;
LUAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.49	-8.72	-0.39	6.41e-17	Lymphocyte counts;
LUAD	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.31	6.42	0.3	3.75e-10	Depression;
LUAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg10729496	chr3:10149963	C3orf24	0.52	8.21	0.37	2.77e-15	Alzheimer's disease;
LUAD	cis	rs9513627	0.920	rs2390280	chr13:100208802	A/G	cg25919922	chr13:100150906	NA	0.7	6.46	0.3	2.91e-10	Obesity-related traits;
LUAD	trans	rs9929218	1.000	rs2113199	chr16:68814502	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-13.97	-0.56	9.34e-37	Colorectal cancer;
LUAD	cis	rs7903847	0.612	rs9887994	chr10:99159815	T/G	cg20016023	chr10:99160130	RRP12	-0.31	-6.98	-0.32	1.17e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.82	-0.58	2.65e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg24450063	chr1:156163899	SLC25A44	1.22	29.42	0.82	2.26e-104	Testicular germ cell tumor;
LUAD	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	10.26	0.45	3.23e-22	Bone mineral density;
LUAD	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg16680214	chr1:154839983	KCNN3	-0.63	-13.17	-0.54	1.95e-33	Prostate cancer;
LUAD	cis	rs11048434	0.736	rs1805761	chr12:9099533	T/C	cg04155231	chr12:9217510	LOC144571	0.4	7.51	0.34	3.62e-13	Sjögren's syndrome;
LUAD	cis	rs5167	0.781	rs909134	chr19:45493061	T/C	cg13119609	chr19:45449297	APOC2	0.4	7.41	0.34	6.77e-13	Blood protein levels;
LUAD	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg02896835	chr1:92012615	NA	0.52	8.13	0.37	4.67e-15	Eosinophil percentage of white cells;
LUAD	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg00383909	chr3:49044727	WDR6	0.97	10.36	0.45	1.44e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs2294693	0.581	rs11280	chr6:41034858	T/C	cg14769373	chr6:40998127	UNC5CL	-0.46	-7.27	-0.33	1.76e-12	Gastric cancer;Non-cardia gastric cancer;
LUAD	trans	rs7395662	0.791	rs4347396	chr11:48895929	T/C	cg15704280	chr7:45808275	SEPT13	0.42	6.66	0.31	8.4e-11	HDL cholesterol;
LUAD	cis	rs3784262	0.565	rs1899355	chr15:58286989	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.4	-7.62	-0.35	1.69e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg15147215	chr3:52552868	STAB1	-0.49	-9.22	-0.41	1.44e-18	Electroencephalogram traits;
LUAD	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg23533926	chr12:111358616	MYL2	-0.4	-6.77	-0.31	4.23e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2742234	0.504	rs10899780	chr10:43725796	T/C	cg15436174	chr10:43711423	RASGEF1A	0.55	9.05	0.4	5.31e-18	Hirschsprung disease;
LUAD	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg00147160	chr1:26503991	CNKSR1	0.4	9.35	0.41	5.1e-19	Height;
LUAD	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg10518543	chr12:38710700	ALG10B	0.41	6.35	0.3	5.5e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05890377	chr2:74357713	NA	0.81	12.55	0.52	6.33e-31	Gestational age at birth (maternal effect);
LUAD	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg21724239	chr8:58056113	NA	0.63	7.99	0.36	1.26e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg21385522	chr1:16154831	NA	0.44	6.65	0.31	9.07e-11	Dilated cardiomyopathy;
LUAD	cis	rs1044826	0.667	rs2083336	chr3:139201272	T/G	cg00490450	chr3:139108681	COPB2	0.41	6.52	0.3	1.98e-10	Obesity-related traits;
LUAD	cis	rs7944584	0.610	rs2596407	chr11:47361838	A/G	cg20307385	chr11:47447363	PSMC3	-0.42	-6.54	-0.3	1.75e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs9399401	0.626	rs7776356	chr6:142777029	A/G	cg04461802	chr6:142623433	GPR126	0.36	6.5	0.3	2.33e-10	Chronic obstructive pulmonary disease;
LUAD	trans	rs9329221	0.716	rs11989640	chr8:10256054	A/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.58	-0.3	1.41e-10	Neuroticism;
LUAD	cis	rs7737355	0.812	rs2042252	chr5:130980027	A/G	cg25547332	chr5:131281432	NA	-0.42	-6.74	-0.31	5.28e-11	Life satisfaction;
LUAD	cis	rs6546550	0.901	rs7598283	chr2:70128717	A/G	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.0	-0.47	6.47e-25	Prevalent atrial fibrillation;
LUAD	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg07677032	chr17:61819896	STRADA	-0.48	-8.36	-0.38	9.15e-16	Prudent dietary pattern;
LUAD	cis	rs10242455	0.702	rs2293256	chr7:99057701	A/G	cg18809830	chr7:99032528	PTCD1	0.83	6.78	0.31	4.12e-11	Blood metabolite levels;
LUAD	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.45	-6.4	-0.3	4.13e-10	Platelet count;
LUAD	cis	rs1448094	0.967	rs2044617	chr12:86324089	T/C	cg18827107	chr12:86230957	RASSF9	-0.44	-7.93	-0.36	1.94e-14	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg02660097	chr11:68866761	NA	0.46	6.45	0.3	3.01e-10	Blond vs. brown hair color;
LUAD	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	15.35	0.6	1.41e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg13729891	chr17:7108468	DLG4	-0.38	-6.46	-0.3	2.88e-10	Adiponectin levels;
LUAD	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg04772025	chr11:68637568	NA	0.59	9.23	0.41	1.33e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26995992	chr16:87417792	FBXO31	-0.67	-6.58	-0.3	1.42e-10	Type 2 diabetes;
LUAD	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg26587870	chr6:27730563	NA	0.4	7.05	0.32	7.38e-12	Parkinson's disease;
LUAD	trans	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg06606381	chr12:133084897	FBRSL1	-0.64	-7.78	-0.35	5.71e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg04586622	chr2:25135609	ADCY3	0.36	8.17	0.37	3.48e-15	Body mass index;
LUAD	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.33	-0.45	1.93e-22	Monocyte percentage of white cells;
LUAD	cis	rs36051895	0.695	rs10124627	chr9:5025746	T/G	cg02405213	chr9:5042618	JAK2	-0.46	-6.81	-0.31	3.36e-11	Pediatric autoimmune diseases;
LUAD	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-9.17	-0.41	2.04e-18	Bipolar disorder;
LUAD	cis	rs9503598	0.636	rs7766753	chr6:3467708	A/C	cg00476032	chr6:3446245	SLC22A23	0.32	6.65	0.31	9.04e-11	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs8064299	0.655	rs12797	chr17:72766993	G/A	cg21922841	chr17:72744131	SLC9A3R1	0.28	6.9	0.32	1.9e-11	Monocyte count;
LUAD	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg15017067	chr4:17643749	FAM184B	0.35	6.96	0.32	1.32e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg10589385	chr1:150898437	SETDB1	0.41	7.75	0.35	7.13e-14	Tonsillectomy;
LUAD	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg15744005	chr10:104629667	AS3MT	-0.38	-7.39	-0.34	7.72e-13	Arsenic metabolism;
LUAD	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg12179176	chr11:130786555	SNX19	0.45	7.28	0.33	1.62e-12	Schizophrenia;
LUAD	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11644478	chr21:40555479	PSMG1	-0.53	-8.59	-0.39	1.65e-16	Cognitive function;
LUAD	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg15445000	chr17:37608096	MED1	-0.44	-8.1	-0.37	6.1e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs7040024	0.853	rs78690958	chr9:848345	A/G	cg14021170	chr9:826657	NA	-0.41	-6.4	-0.3	4.07e-10	Testicular germ cell tumor;Testicular cancer;
LUAD	cis	rs7542375	0.683	rs1414518	chr1:221091157	T/C	cg16008148	chr1:221062819	NA	0.41	6.54	0.3	1.73e-10	Obesity-related traits;
LUAD	cis	rs11112613	0.653	rs59504344	chr12:105950837	C/T	cg03607813	chr12:105948248	NA	0.74	12.85	0.53	3.82e-32	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg14668632	chr7:2872130	GNA12	-0.75	-13.41	-0.55	1.98e-34	Height;
LUAD	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg08645402	chr16:4508243	NA	0.57	11.14	0.48	1.83e-25	Schizophrenia;
LUAD	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg02990361	chr1:107599529	PRMT6	-0.56	-9.44	-0.42	2.53e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs10793273	1	rs10793273	chr11:77742595	T/C	cg09721595	chr11:77773924	THRSP	-0.93	-20.47	-0.71	3.09e-65	Pelvic organ prolapse;
LUAD	cis	rs6831352	0.691	rs2602887	chr4:100041473	A/G	cg12011299	chr4:100065546	ADH4	0.64	11.41	0.49	1.82e-26	Alcohol dependence;
LUAD	trans	rs2797160	0.967	rs80303782	chr6:126004193	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.44	-0.38	5.25e-16	Endometrial cancer;
LUAD	cis	rs62400317	0.859	rs62400289	chr6:45203783	T/C	cg18551225	chr6:44695536	NA	-0.56	-8.5	-0.38	3.26e-16	Total body bone mineral density;
LUAD	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.43	-0.45	7.96e-23	Monocyte percentage of white cells;
LUAD	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.34	-0.45	1.75e-22	Monocyte percentage of white cells;
LUAD	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg12072164	chr19:44306565	LYPD5	0.41	8.48	0.38	3.7e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.16e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7665090	0.934	rs6533021	chr4:103558853	A/G	cg07973026	chr4:103553119	MANBA	0.47	8.41	0.38	6.57e-16	Primary biliary cholangitis;
LUAD	cis	rs71478720	0.868	rs5744222	chr11:112037014	G/T	cg09122223	chr11:112035175	IL18	0.41	6.48	0.3	2.59e-10	Interleukin-18 levels;
LUAD	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg06740227	chr12:86229804	RASSF9	0.38	6.71	0.31	6.3e-11	Major depressive disorder;
LUAD	trans	rs12210905	0.800	rs12201890	chr6:26662626	A/C	cg08851530	chr6:28072375	NA	0.71	6.46	0.3	2.85e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1160297	0.530	rs4672152	chr2:53224276	C/A	cg07782112	chr2:53107842	NA	-0.33	-6.66	-0.31	8.69e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs490234	0.756	rs1398142	chr9:128226712	C/A	cg14078157	chr9:128172775	NA	-0.44	-8.24	-0.37	2.17e-15	Mean arterial pressure;
LUAD	cis	rs968567	0.705	rs174575	chr11:61602003	C/G	cg06781209	chr11:61594997	FADS2	-0.46	-8.6	-0.39	1.56e-16	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs62229266	0.626	rs7280896	chr21:37460906	G/A	cg08632701	chr21:37451849	NA	-0.65	-11.81	-0.5	5.34e-28	Mitral valve prolapse;
LUAD	cis	rs9902453	0.845	rs2617865	chr17:28049804	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-9.26	-0.41	1.06e-18	Coffee consumption (cups per day);
LUAD	cis	rs977987	0.836	rs8055974	chr16:75470986	C/G	cg03315344	chr16:75512273	CHST6	0.65	14.09	0.57	2.95e-37	Dupuytren's disease;
LUAD	cis	rs7659604	0.502	rs13104233	chr4:122672473	T/C	cg06713675	chr4:122721982	EXOSC9	0.41	7.5	0.34	3.8e-13	Type 2 diabetes;
LUAD	cis	rs1983170	1.000	rs10874785	chr1:92015243	G/A	cg02896835	chr1:92012615	NA	0.51	8.21	0.37	2.61e-15	Eosinophil percentage of white cells;
LUAD	cis	rs2730260	0.537	rs3793222	chr7:158863536	A/C	cg02254261	chr7:158964346	NA	0.47	6.47	0.3	2.78e-10	Myopia (pathological);
LUAD	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg05043794	chr9:111880884	C9orf5	-0.44	-7.54	-0.34	2.96e-13	Menarche (age at onset);
LUAD	cis	rs9341808	0.718	rs3828754	chr6:80900640	C/G	cg08355045	chr6:80787529	NA	0.58	10.52	0.46	3.89e-23	Sitting height ratio;
LUAD	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg18016565	chr1:150552671	MCL1	0.41	7.48	0.34	4.31e-13	Tonsillectomy;
LUAD	cis	rs4253772	0.515	rs8142080	chr22:46647429	G/T	cg09491104	chr22:46646882	C22orf40	-0.64	-8.54	-0.38	2.4e-16	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs11077998	0.933	rs2291395	chr17:80526139	A/G	cg10255544	chr17:80519551	FOXK2	0.34	6.56	0.3	1.53e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg18225595	chr11:63971243	STIP1	0.54	8.97	0.4	9.76e-18	Platelet count;
LUAD	cis	rs10899021	1.000	rs11236193	chr11:74368307	T/C	cg25880958	chr11:74394337	NA	-0.59	-7.65	-0.35	1.34e-13	Response to metformin (IC50);
LUAD	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg00074818	chr8:8560427	CLDN23	0.67	10.22	0.45	4.54e-22	Obesity-related traits;
LUAD	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg26373071	chr5:1325741	CLPTM1L	0.38	7.8	0.35	4.99e-14	Lung cancer;
LUAD	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-7.38	-0.34	8.56e-13	Personality dimensions;
LUAD	cis	rs7737355	1.000	rs798412	chr5:130698474	C/A	cg06307176	chr5:131281290	NA	-0.46	-7.35	-0.34	1e-12	Life satisfaction;
LUAD	cis	rs754466	0.580	rs1344966	chr10:79534527	T/C	cg17075019	chr10:79541650	NA	-0.92	-19.71	-0.69	8.19e-62	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg18180107	chr4:99064573	C4orf37	0.47	6.48	0.3	2.59e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763121	0.657	rs5995603	chr22:39040733	G/A	cg06544989	chr22:39130855	UNC84B	0.42	7.49	0.34	4.1e-13	Menopause (age at onset);
LUAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg27454412	chr7:1067447	C7orf50	0.4	6.69	0.31	6.97e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs698833	0.788	rs1142523	chr2:44545576	T/C	cg04920474	chr2:44395004	PPM1B	0.39	6.96	0.32	1.28e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	trans	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg18335740	chr13:41363409	SLC25A15	0.6	11.04	0.47	4.34e-25	Lewy body disease;
LUAD	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg06766960	chr11:133703094	NA	0.46	8.68	0.39	8.63e-17	Childhood ear infection;
LUAD	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg24450063	chr1:156163899	SLC25A44	0.81	8.12	0.37	5e-15	Paclitaxel disposition in epithelial ovarian cancer;
LUAD	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg06608945	chr2:219082296	ARPC2	-0.42	-6.95	-0.32	1.38e-11	Colorectal cancer;
LUAD	cis	rs9644630	0.804	rs11779939	chr8:19327487	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.37	6.88	0.32	2.2e-11	Oropharynx cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg21397993	chr1:243418055	CEP170;SDCCAG8	-0.7	-6.7	-0.31	6.53e-11	Type 2 diabetes;
LUAD	cis	rs2554380	0.843	rs1019667	chr15:84380849	C/A	cg14598478	chr15:84363061	ADAMTSL3	-0.47	-7.28	-0.33	1.6e-12	Height;
LUAD	cis	rs2992756	0.663	rs12750779	chr1:18805048	G/A	cg14356550	chr1:18808102	KLHDC7A	-0.57	-9.8	-0.43	1.44e-20	Breast cancer;
LUAD	cis	rs7267979	0.727	rs4815431	chr20:25532405	T/C	cg08601574	chr20:25228251	PYGB	-0.38	-7.07	-0.33	6.41e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.98	-0.36	1.35e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.76	-0.31	4.5e-11	Height;
LUAD	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg08470875	chr2:26401718	FAM59B	0.79	11.18	0.48	1.35e-25	Gut microbiome composition (summer);
LUAD	cis	rs1448094	0.967	rs10863118	chr12:86339232	C/G	cg06740227	chr12:86229804	RASSF9	0.36	6.53	0.3	1.91e-10	Major depressive disorder;
LUAD	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg26408565	chr15:76604113	ETFA	-0.45	-7.5	-0.34	3.9e-13	Blood metabolite levels;
LUAD	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg22532475	chr10:104410764	TRIM8	-0.43	-8.53	-0.38	2.67e-16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg13319975	chr6:146136371	FBXO30	0.62	10.32	0.45	1.96e-22	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs6561151	0.645	rs61959960	chr13:44439265	T/G	cg12856521	chr11:46389249	DGKZ	0.93	12.8	0.53	6.47e-32	Crohn's disease;
LUAD	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg15557168	chr22:42548783	NA	-0.56	-10.98	-0.47	7.68e-25	Schizophrenia;
LUAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg15147215	chr3:52552868	STAB1	-0.49	-9.23	-0.41	1.31e-18	Electroencephalogram traits;
LUAD	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21582582	chr3:182698605	DCUN1D1	0.71	14.0	0.56	7.37e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg19196401	chr6:110721138	DDO	-0.48	-9.34	-0.41	5.65e-19	Platelet distribution width;
LUAD	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-11.28	-0.48	5.81e-26	Asthma;
LUAD	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg14829155	chr15:31115871	NA	0.52	8.94	0.4	1.19e-17	Huntington's disease progression;
LUAD	cis	rs2046867	0.908	rs62251601	chr3:72786768	C/G	cg04365224	chr3:72788183	NA	-0.49	-7.48	-0.34	4.3e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs75804782	0.521	rs56120037	chr2:239398464	G/A	cg01134436	chr17:81009848	B3GNTL1	0.79	8.62	0.39	1.33e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg14926445	chr8:58193284	C8orf71	-0.44	-6.55	-0.3	1.68e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs8077889	0.871	rs17675370	chr17:41900030	T/C	cg26893861	chr17:41843967	DUSP3	0.94	14.57	0.58	3.04e-39	Triglycerides;
LUAD	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.21	16.09	0.62	8.57e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs11048434	0.736	rs56130437	chr12:9093001	G/A	cg13575925	chr12:9217583	LOC144571	0.37	6.81	0.31	3.42e-11	Sjögren's syndrome;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09623457	chr3:183735666	ABCC5	-0.57	-6.86	-0.32	2.51e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs754466	0.651	rs11813532	chr10:79637991	T/C	cg17075019	chr10:79541650	NA	-0.85	-17.42	-0.65	1.28e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg00106254	chr7:1943704	MAD1L1	0.52	8.06	0.36	7.72e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg07169764	chr2:136633963	MCM6	0.74	9.16	0.41	2.22e-18	Corneal structure;
LUAD	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg25233709	chr10:116636983	FAM160B1	0.41	8.26	0.37	1.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.7	-9.6	-0.42	7.05e-20	Obesity-related traits;
LUAD	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg06558623	chr16:89946397	TCF25	1.09	11.72	0.5	1.14e-27	Skin colour saturation;
LUAD	cis	rs68170813	0.652	rs79295036	chr7:107193669	C/A	cg23024343	chr7:107201750	COG5	0.55	7.01	0.32	9.55e-12	Coronary artery disease;
LUAD	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.44	-0.34	5.58e-13	Resting heart rate;
LUAD	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-12.89	-0.53	2.75e-32	Breast cancer;
LUAD	cis	rs7759001	0.817	rs4711149	chr6:27365845	C/A	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg21775007	chr8:11205619	TDH	-0.5	-8.83	-0.39	2.77e-17	Retinal vascular caliber;
LUAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.8	14.77	0.58	4.28e-40	Lymphocyte counts;
LUAD	trans	rs9914544	0.545	rs4924945	chr17:18813160	A/G	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.89	-0.32	2.03e-11	Educational attainment (years of education);
LUAD	cis	rs12579753	0.917	rs12311988	chr12:82177209	C/A	cg07988820	chr12:82153109	PPFIA2	-0.45	-7.35	-0.34	1.04e-12	Resting heart rate;
LUAD	cis	rs11098699	0.821	rs11942230	chr4:124199453	A/G	cg09941581	chr4:124220074	SPATA5	0.48	7.86	0.36	3.24e-14	Mosquito bite size;
LUAD	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg20673091	chr1:2541236	MMEL1	-0.43	-9.39	-0.42	3.81e-19	Ulcerative colitis;
LUAD	trans	rs2262909	0.962	rs425781	chr19:22229306	A/G	cg05197062	chr11:11642011	GALNTL4	-0.56	-8.73	-0.39	6.16e-17	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26314531	chr2:26401878	FAM59B	-0.55	-7.8	-0.35	4.77e-14	Gut microbiome composition (summer);
LUAD	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg07936489	chr17:37558343	FBXL20	0.45	7.15	0.33	3.88e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg27279351	chr12:120934652	DYNLL1	0.43	6.57	0.3	1.51e-10	High light scatter reticulocyte count;
LUAD	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.46e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-9.59	-0.42	7.63e-20	Migraine;Coronary artery disease;
LUAD	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.32	0.34	1.3e-12	Obesity-related traits;
LUAD	cis	rs9715521	0.868	rs6848053	chr4:59839309	T/C	cg11281224	chr4:60001000	NA	-0.57	-9.58	-0.42	8.47e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg02527881	chr3:46936655	PTH1R	-0.44	-8.46	-0.38	4.44e-16	Colorectal cancer;
LUAD	cis	rs13082711	0.871	rs35572617	chr3:27499247	A/T	cg02860705	chr3:27208620	NA	0.61	9.35	0.41	5.34e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs2580764	0.566	rs2920878	chr2:55296415	C/T	cg09592903	chr2:55203963	RTN4	0.42	9.4	0.42	3.56e-19	Mean platelet volume;
LUAD	cis	rs12949688	0.967	rs2332966	chr17:55819335	T/C	cg12582317	chr17:55822272	NA	0.38	7.67	0.35	1.17e-13	Schizophrenia;
LUAD	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg27446573	chr6:127587934	RNF146	0.45	6.69	0.31	6.97e-11	Breast cancer;
LUAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00166722	chr3:10149974	C3orf24	0.73	11.21	0.48	1.05e-25	Alzheimer's disease;
LUAD	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg27068330	chr11:65405492	SIPA1	0.54	8.53	0.38	2.67e-16	Acne (severe);
LUAD	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg13319975	chr6:146136371	FBXO30	0.59	9.91	0.43	6.11e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9581857	0.547	rs9581881	chr13:28106637	A/G	cg22138327	chr13:27999177	GTF3A	0.79	8.96	0.4	1.08e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg23260525	chr10:116636907	FAM160B1	0.48	11.41	0.49	1.75e-26	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.39	-7.71	-0.35	9.36e-14	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06544989	chr22:39130855	UNC84B	0.45	8.46	0.38	4.49e-16	Menopause (age at onset);
LUAD	cis	rs6499255	0.951	rs12595869	chr16:69729794	T/G	cg15192750	chr16:69999425	NA	0.55	8.24	0.37	2.19e-15	IgE levels;
LUAD	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg17344516	chr5:154026930	NA	-0.6	-6.61	-0.31	1.18e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.65	0.31	9.11e-11	Depression;
LUAD	cis	rs4711350	0.734	rs9380379	chr6:33766131	A/G	cg07979401	chr6:33739406	LEMD2	-0.54	-9.89	-0.43	6.87e-21	Schizophrenia;
LUAD	cis	rs76878669	0.561	rs12416747	chr11:66135614	A/G	cg10616300	chr11:66138557	SLC29A2	0.34	7.27	0.33	1.77e-12	Educational attainment (years of education);
LUAD	trans	rs11039798	1.000	rs7123704	chr11:48580535	G/A	cg02254774	chr11:50257496	LOC441601	0.51	6.5	0.3	2.28e-10	Axial length;
LUAD	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg22508957	chr16:3507546	NAT15	-0.39	-6.62	-0.31	1.1e-10	Body mass index (adult);
LUAD	cis	rs2795502	0.630	rs2914988	chr10:43509354	A/T	cg08461752	chr10:43522343	NA	-0.83	-9.48	-0.42	1.88e-19	Blood protein levels;
LUAD	cis	rs4664304	0.816	rs67045814	chr2:160821119	A/C	cg23995753	chr2:160760732	LY75	-0.39	-7.01	-0.32	9.37e-12	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9427116	0.702	rs9427108	chr1:154607914	G/A	cg17218026	chr1:154582156	ADAR	0.51	9.92	0.43	5.5e-21	Blood protein levels;
LUAD	cis	rs7536201	0.905	rs7523334	chr1:25294206	G/A	cg23273869	chr1:25296894	NA	-0.35	-6.91	-0.32	1.77e-11	Psoriasis vulgaris;
LUAD	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg13319975	chr6:146136371	FBXO30	-0.58	-9.78	-0.43	1.63e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg23096020	chr7:158799433	NA	0.45	7.94	0.36	1.82e-14	Facial morphology (factor 20);
LUAD	cis	rs6500395	1.000	rs6500397	chr16:48642235	T/C	cg04672837	chr16:48644449	N4BP1	0.39	6.71	0.31	6.41e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.32	0.34	1.22e-12	Blood metabolite levels;
LUAD	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg23254163	chr1:152506842	NA	0.25	7.07	0.33	6.24e-12	Hair morphology;
LUAD	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg14345882	chr6:26364793	BTN3A2	0.66	6.8	0.31	3.58e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs72772090	0.539	rs11738810	chr5:96119055	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-7.18	-0.33	3.2e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9469890	0.604	rs11758420	chr6:34503279	A/C	cg14254433	chr6:34482411	PACSIN1	-0.58	-8.36	-0.38	8.99e-16	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.3	-0.41	7.8e-19	Life satisfaction;
LUAD	cis	rs427394	0.593	rs880993	chr5:6732120	C/G	cg14682080	chr5:6737778	POLS	0.35	7.54	0.34	2.8e-13	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.88	0.32	2.11e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67180937	0.553	rs2936023	chr1:222830331	T/A	cg09820183	chr1:222886073	C1orf58;AIDA	0.52	6.93	0.32	1.59e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LUAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs10802346	0.545	rs12134404	chr1:246372144	A/G	cg13514129	chr1:39547527	MACF1	0.6	10.64	0.46	1.35e-23	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs4631830	0.832	rs67289834	chr10:51501304	C/T	cg20129853	chr10:51489980	NA	0.33	6.45	0.3	2.99e-10	Prostate-specific antigen levels;
LUAD	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg03948781	chr1:205179583	DSTYK	0.34	6.51	0.3	2.08e-10	Red blood cell count;
LUAD	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg09365446	chr1:150670422	GOLPH3L	0.65	12.2	0.51	1.54e-29	Tonsillectomy;
LUAD	cis	rs10193935	1.000	rs58962161	chr2:42400278	T/A	cg27598129	chr2:42591480	NA	-0.71	-9.49	-0.42	1.64e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs490234	0.812	rs4329365	chr9:128445758	A/C	cg14078157	chr9:128172775	NA	-0.45	-8.28	-0.37	1.59e-15	Mean arterial pressure;
LUAD	cis	rs12545109	0.571	rs4314648	chr8:57276937	G/A	cg21220214	chr8:57350948	NA	-0.66	-8.6	-0.39	1.57e-16	Obesity-related traits;
LUAD	cis	rs77741769	0.571	rs35905305	chr12:121328082	T/G	cg02419362	chr12:121203948	SPPL3	0.41	8.29	0.37	1.56e-15	Mean corpuscular volume;
LUAD	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg27129171	chr3:47204927	SETD2	0.4	6.52	0.3	1.97e-10	Colorectal cancer;
LUAD	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg26384229	chr12:38710491	ALG10B	0.44	7.31	0.33	1.32e-12	Morning vs. evening chronotype;
LUAD	cis	rs763121	0.849	rs12004	chr22:38877461	T/G	cg06544989	chr22:39130855	UNC84B	0.4	7.32	0.34	1.3e-12	Menopause (age at onset);
LUAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg08132940	chr7:1081526	C7orf50	-0.79	-10.66	-0.46	1.16e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2996428	0.629	rs12135894	chr1:3728061	C/T	cg17443473	chr1:3703550	LRRC47	0.47	8.04	0.36	9.01e-15	Red cell distribution width;
LUAD	cis	rs6141769	0.866	rs1407256	chr20:31213647	A/G	cg13636640	chr20:31349939	DNMT3B	0.55	6.68	0.31	7.68e-11	Subjective well-being;
LUAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg11965913	chr1:205819406	PM20D1	0.77	15.92	0.61	4.77e-45	Menarche (age at onset);
LUAD	trans	rs62103177	0.608	rs613847	chr18:77845644	A/G	cg05926928	chr17:57297772	GDPD1	-0.82	-10.03	-0.44	2.2e-21	Opioid sensitivity;
LUAD	trans	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg18834416	chr8:37888184	EIF4EBP1	0.5	8.67	0.39	9.53e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs72928364	1.000	rs13077353	chr3:100650307	T/G	cg10123952	chr3:100791384	NA	0.63	7.38	0.34	8.47e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg27490568	chr2:178487706	NA	0.38	6.42	0.3	3.76e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4638749	0.677	rs10174695	chr2:108842164	G/A	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.33	-0.34	1.19e-12	Blood pressure;
LUAD	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg18138036	chr10:133769891	PPP2R2D	0.41	6.65	0.31	9.17e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.53e-11	Depression;
LUAD	trans	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg14917512	chr19:3094685	GNA11	-0.56	-6.7	-0.31	6.82e-11	Diabetic kidney disease;
LUAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg10862848	chr6:42927986	GNMT	-0.33	-9.48	-0.42	1.84e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18867708	chr6:26865862	GUSBL1	-0.41	-6.47	-0.3	2.73e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg19163074	chr7:65112434	INTS4L2	0.44	6.74	0.31	5.07e-11	Aortic root size;
LUAD	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4523957	0.651	rs7214741	chr17:2085598	C/T	cg16513277	chr17:2031491	SMG6	-0.95	-18.61	-0.67	6.67e-57	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs17152411	0.947	rs7079199	chr10:126590820	A/C	cg07906193	chr10:126599966	NA	0.54	7.17	0.33	3.46e-12	Height;
LUAD	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-7.77	-0.35	6.11e-14	Total body bone mineral density;
LUAD	cis	rs367943	0.712	rs26964	chr5:112738532	T/C	cg12552261	chr5:112820674	MCC	0.47	9.07	0.4	4.47e-18	Type 2 diabetes;
LUAD	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg05590025	chr7:65112418	INTS4L2	0.75	7.92	0.36	2.07e-14	Diabetic kidney disease;
LUAD	cis	rs11696501	0.843	rs6073768	chr20:44130146	A/G	cg11783356	chr20:44313418	WFDC10B	-0.49	-7.44	-0.34	5.73e-13	Brain structure;
LUAD	cis	rs7737355	0.812	rs10463886	chr5:130758893	A/T	cg06307176	chr5:131281290	NA	-0.43	-7.07	-0.33	6.25e-12	Life satisfaction;
LUAD	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg09626299	chr10:82213104	TSPAN14	-0.3	-6.53	-0.3	1.93e-10	Post bronchodilator FEV1;
LUAD	cis	rs8060686	0.668	rs8048034	chr16:68210604	A/G	cg09835421	chr16:68378352	PRMT7	-0.5	-6.38	-0.3	4.73e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg08027265	chr7:2291960	NA	-0.43	-7.12	-0.33	4.52e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.55	-7.13	-0.33	4.44e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.55	-0.38	2.22e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg25838465	chr1:92012736	NA	-0.7	-15.1	-0.59	1.55e-41	Breast cancer;
LUAD	cis	rs7017914	0.967	rs35295900	chr8:71642061	G/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg21427119	chr20:30132790	HM13	-0.62	-9.52	-0.42	1.33e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.9	-0.4	1.66e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.65	-0.49	2.07e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-7.49	-0.34	4e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.59	-0.58	2.43e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4462272	0.503	rs11593131	chr10:101843608	G/A	cg02250046	chr10:101825185	CPN1	-0.32	-6.36	-0.3	5.32e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg10589385	chr1:150898437	SETDB1	0.43	8.09	0.37	6.38e-15	Melanoma;
LUAD	cis	rs6076065	1.000	rs2424533	chr20:23375907	C/T	cg11657817	chr20:23433608	CST11	0.44	8.66	0.39	1.03e-16	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.7	-0.35	9.82e-14	Total body bone mineral density;
LUAD	cis	rs75920871	0.920	rs7128071	chr11:116968798	G/A	cg04087571	chr11:116723030	SIK3	-0.32	-6.51	-0.3	2.07e-10	Subjective well-being;
LUAD	cis	rs9323205	0.953	rs11623710	chr14:51694261	C/T	cg23942311	chr14:51606299	NA	-0.61	-9.92	-0.43	5.58e-21	Cancer;
LUAD	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.43	0.34	5.91e-13	Bipolar disorder;
LUAD	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg01528321	chr10:82214614	TSPAN14	0.53	8.51	0.38	3.16e-16	Post bronchodilator FEV1;
LUAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19626725	chr5:178986131	RUFY1	-0.62	-11.62	-0.49	2.89e-27	Lung cancer;
LUAD	trans	rs75804782	0.557	rs10178728	chr2:239360121	T/A	cg01134436	chr17:81009848	B3GNTL1	0.56	7.46	0.34	5.09e-13	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg15147215	chr3:52552868	STAB1	-0.42	-7.57	-0.35	2.34e-13	Bipolar disorder;
LUAD	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.91	-17.96	-0.66	5.2e-54	Ulcerative colitis;
LUAD	cis	rs17532515	0.652	rs7694711	chr4:141378503	C/T	cg03645522	chr4:141391200	NA	0.4	6.41	0.3	3.85e-10	Select biomarker traits;
LUAD	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg05791153	chr7:19748676	TWISTNB	0.71	7.46	0.34	4.94e-13	Thyroid stimulating hormone;
LUAD	cis	rs10129255	0.518	rs10136903	chr14:107187105	T/C	cg07958169	chr14:107095056	NA	-0.37	-7.33	-0.34	1.17e-12	Kawasaki disease;
LUAD	cis	rs12505328	0.514	rs1899390	chr4:174383277	A/G	cg12145043	chr4:174357286	NA	0.42	6.65	0.31	9.17e-11	Chin dimples;
LUAD	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg11189052	chr15:85197271	WDR73	0.6	7.49	0.34	3.93e-13	Schizophrenia;
LUAD	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.69	10.68	0.46	9.98e-24	Lymphocyte percentage of white cells;
LUAD	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg14289826	chr9:140003911	NA	-0.38	-7.64	-0.35	1.42e-13	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7917772	0.565	rs1043450	chr10:104434209	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.57	7.95	0.36	1.76e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7267979	1.000	rs6107046	chr20:25442049	G/A	cg08601574	chr20:25228251	PYGB	0.43	7.95	0.36	1.72e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg13813247	chr22:41461852	NA	-0.5	-8.16	-0.37	3.83e-15	Neuroticism;
LUAD	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg20673091	chr1:2541236	MMEL1	0.36	7.55	0.34	2.72e-13	Multiple sclerosis;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19967433	chr17:7080988	ASGR1	-0.38	-6.45	-0.3	3.01e-10	Cancer;
LUAD	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg05340658	chr4:99064831	C4orf37	0.57	9.69	0.43	3.59e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs78456975	1.000	rs10208449	chr2:1563257	G/A	cg12573674	chr2:1569213	NA	-0.65	-6.51	-0.3	2.18e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg06609049	chr19:2785107	THOP1	1.17	23.81	0.76	4.16e-80	Total cholesterol levels;
LUAD	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg16479474	chr6:28041457	NA	0.35	6.36	0.3	5.21e-10	Cardiac Troponin-T levels;
LUAD	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg25985355	chr7:65971099	NA	-0.51	-6.38	-0.3	4.63e-10	Diabetic kidney disease;
LUAD	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22857025	chr5:266934	NA	-0.96	-14.42	-0.57	1.32e-38	Breast cancer;
LUAD	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg20703242	chr1:230279135	GALNT2	-0.61	-10.58	-0.46	2.2e-23	Coronary artery disease;
LUAD	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg16989719	chr2:238392110	NA	-0.38	-8.11	-0.37	5.66e-15	Prostate cancer;
LUAD	cis	rs2625529	0.617	rs2929509	chr15:72239272	T/C	cg16672083	chr15:72433130	SENP8	0.62	11.42	0.49	1.64e-26	Red blood cell count;
LUAD	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg13732083	chr21:47605072	C21orf56	0.42	6.94	0.32	1.49e-11	Testicular germ cell tumor;
LUAD	cis	rs7264396	0.563	rs2425084	chr20:34301871	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.0	-0.36	1.22e-14	Total cholesterol levels;
LUAD	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg02574844	chr11:5959923	NA	-0.47	-8.75	-0.39	5.28e-17	DNA methylation (variation);
LUAD	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.51	-0.3	2.17e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2224391	0.590	rs72813700	chr6:5275531	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.62	-8.03	-0.36	1.01e-14	Height;
LUAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg08132940	chr7:1081526	C7orf50	-0.78	-10.56	-0.46	2.7e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	7.52	0.34	3.22e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1595825	0.838	rs16826872	chr2:198898055	T/C	cg11031976	chr2:198649780	BOLL	-0.47	-6.81	-0.31	3.4e-11	Ulcerative colitis;
LUAD	cis	rs4700695	0.925	rs12653007	chr5:65396965	G/A	cg21114390	chr5:65439923	SFRS12	-0.59	-8.05	-0.36	8.66e-15	Facial morphology (factor 19);
LUAD	cis	rs7744392	1.000	rs9658080	chr6:35337197	A/G	cg03355690	chr6:35265616	DEF6	0.79	6.48	0.3	2.5e-10	Cataracts in type 2 diabetes;
LUAD	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg15208524	chr1:10270712	KIF1B	0.41	6.38	0.3	4.73e-10	Hepatocellular carcinoma;
LUAD	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg27170947	chr2:26402098	FAM59B	-0.81	-11.48	-0.49	1e-26	Gut microbiome composition (summer);
LUAD	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg22852734	chr6:133119734	C6orf192	-0.8	-9.76	-0.43	2.03e-20	Type 2 diabetes nephropathy;
LUAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg05564831	chr3:52568323	NT5DC2	0.43	8.38	0.38	7.82e-16	Electroencephalogram traits;
LUAD	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.11	0.37	5.37e-15	Rheumatoid arthritis;
LUAD	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg03609598	chr5:56110824	MAP3K1	0.66	8.34	0.38	1.08e-15	Initial pursuit acceleration;
LUAD	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.6	-12.41	-0.52	2.21e-30	Hemoglobin concentration;
LUAD	trans	rs2797160	0.874	rs58305111	chr6:126008386	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.55	8.62	0.39	1.38e-16	Endometrial cancer;
LUAD	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg18131467	chr2:239335373	ASB1	0.7	12.0	0.5	9.42e-29	Multiple system atrophy;
LUAD	cis	rs78761021	0.898	rs17810279	chr17:9774057	T/G	cg26853458	chr17:9805074	RCVRN	0.35	6.68	0.31	7.5e-11	Type 2 diabetes;
LUAD	cis	rs9837602	1.000	rs13064704	chr3:99767541	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	9.22	0.41	1.46e-18	Breast cancer;
LUAD	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.73e-16	Neutrophil percentage of white cells;
LUAD	cis	rs7089973	0.872	rs7075888	chr10:116627117	C/T	cg23260525	chr10:116636907	FAM160B1	0.43	9.68	0.43	3.68e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg19635926	chr16:89946313	TCF25	0.75	6.69	0.31	6.9e-11	Skin colour saturation;
LUAD	cis	rs11031096	0.754	rs3817657	chr11:4142592	T/C	cg18678763	chr11:4115507	RRM1	-0.42	-7.28	-0.33	1.67e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg00071950	chr4:10020882	SLC2A9	0.74	14.86	0.59	1.68e-40	Bone mineral density;
LUAD	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs116095464	1.000	rs3777237	chr5:307641	C/T	cg22857025	chr5:266934	NA	-1.07	-8.39	-0.38	7.16e-16	Breast cancer;
LUAD	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg05368731	chr17:41323189	NBR1	0.93	18.7	0.67	2.52e-57	Menopause (age at onset);
LUAD	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24308560	chr3:49941425	MST1R	-0.56	-9.51	-0.42	1.44e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs35771425	0.509	rs3120782	chr1:211419700	A/T	cg26515805	chr1:211431828	RCOR3	-0.44	-8.63	-0.39	1.3e-16	Educational attainment (years of education);
LUAD	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg05673287	chr15:77411982	SGK269	-0.41	-6.99	-0.32	1.06e-11	Type 2 diabetes;
LUAD	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg19346786	chr7:2764209	NA	-0.59	-12.82	-0.53	5.04e-32	Height;
LUAD	cis	rs4889855	0.614	rs7221663	chr17:78484166	T/C	cg16591659	chr17:78472290	NA	-0.56	-8.74	-0.39	5.49e-17	Fractional excretion of uric acid;
LUAD	cis	rs2908197	0.737	rs6978009	chr7:75992234	A/C	cg24580635	chr7:76178542	LOC100133091	0.41	6.48	0.3	2.51e-10	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg10518543	chr12:38710700	ALG10B	-0.42	-6.8	-0.31	3.6e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.46e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg17724175	chr1:150552817	MCL1	0.39	9.17	0.41	2.12e-18	Tonsillectomy;
LUAD	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-12.84	-0.53	4.15e-32	Breast cancer;
LUAD	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg04865290	chr3:52927548	TMEM110	-0.56	-7.46	-0.34	4.95e-13	Immune reponse to smallpox (secreted IL-2);
LUAD	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03452623	chr4:187889614	NA	-0.86	-18.78	-0.67	1.13e-57	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg12140854	chr5:148520817	ABLIM3	0.63	10.42	0.45	8.72e-23	Breast cancer;
LUAD	trans	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg14791747	chr16:20752902	THUMPD1	0.7	9.41	0.42	3.19e-19	Cognitive test performance;
LUAD	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg02527881	chr3:46936655	PTH1R	0.81	21.91	0.73	1.2e-71	Birth weight;
LUAD	cis	rs12760731	0.565	rs10494511	chr1:178094265	A/G	cg00404053	chr1:178313656	RASAL2	0.62	8.12	0.37	5.26e-15	Obesity-related traits;
LUAD	trans	rs8129326	0.685	rs9980888	chr21:35792223	A/G	cg07474852	chr4:123073612	NA	0.44	7.28	0.33	1.63e-12	Cancer;
LUAD	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg18252515	chr7:66147081	NA	-0.61	-6.67	-0.31	8.18e-11	Diabetic kidney disease;
LUAD	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg04455712	chr21:45112962	RRP1B	0.4	8.3	0.37	1.46e-15	Mean corpuscular volume;
LUAD	cis	rs4711336	0.664	rs4713663	chr6:33674197	G/A	cg13859433	chr6:33739653	LEMD2	-0.28	-6.67	-0.31	7.87e-11	Height;
LUAD	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg21138405	chr5:131827807	IRF1	-0.56	-12.04	-0.51	6.81e-29	Asthma (sex interaction);
LUAD	cis	rs57994353	0.861	rs3812591	chr9:139341612	C/T	cg14364472	chr9:139394549	NOTCH1	0.43	6.72	0.31	5.99e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg03609598	chr5:56110824	MAP3K1	-0.54	-7.81	-0.35	4.69e-14	Initial pursuit acceleration;
LUAD	trans	rs6921919	0.945	rs16901847	chr6:28375851	G/A	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.44	-0.3	3.33e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6712932	1.000	rs28521663	chr2:105846716	T/C	cg22878388	chr2:105853796	NA	-0.41	-7.24	-0.33	2.18e-12	Type 2 diabetes;
LUAD	cis	rs2997447	0.846	rs3008226	chr1:26394997	A/C	cg00147160	chr1:26503991	CNKSR1	0.37	6.87	0.32	2.25e-11	QRS complex (12-leadsum);
LUAD	cis	rs494562	0.892	rs9344518	chr6:86125144	T/A	cg17966619	chr6:86160162	NT5E	0.66	7.83	0.36	4.05e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg17366294	chr4:99064904	C4orf37	0.66	12.76	0.53	9e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg09835421	chr16:68378352	PRMT7	-0.85	-9.11	-0.41	3.31e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3750082	0.855	rs6462430	chr7:32921831	G/A	cg05721444	chr7:32995514	FKBP9	0.37	6.75	0.31	4.76e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.57	6.66	0.31	8.51e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21659725	chr3:3221576	CRBN	0.7	11.71	0.49	1.28e-27	Resting heart rate;
LUAD	cis	rs4604732	0.631	rs12038793	chr1:247624262	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	-0.42	-6.84	-0.32	2.83e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg06627628	chr2:24431161	ITSN2	-0.56	-9.17	-0.41	2.07e-18	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg03467027	chr4:99064603	C4orf37	-0.44	-7.29	-0.33	1.57e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg19442545	chr10:75533431	FUT11	-0.47	-7.8	-0.35	5.01e-14	Inflammatory bowel disease;
LUAD	cis	rs11030122	0.702	rs995498	chr11:3967791	A/G	cg18678763	chr11:4115507	RRM1	-0.44	-7.35	-0.34	1.05e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg06074448	chr4:187884817	NA	-0.42	-8.92	-0.4	1.47e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg17366294	chr4:99064904	C4orf37	0.57	8.64	0.39	1.21e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.41	-0.3	3.82e-10	Breast cancer;
LUAD	cis	rs1395	0.778	rs4665959	chr2:27443256	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.46	8.19	0.37	3.16e-15	Blood metabolite levels;
LUAD	cis	rs12618769	0.520	rs72821904	chr2:99084882	G/A	cg10123293	chr2:99228465	UNC50	0.47	8.35	0.38	9.92e-16	Bipolar disorder;
LUAD	cis	rs2242073	0.660	rs4289171	chr2:209000144	G/A	cg06181187	chr2:209010896	CRYGB	-0.34	-6.66	-0.31	8.42e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.11	13.3	0.54	5.73e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg00080972	chr5:178986291	RUFY1	0.56	9.17	0.41	2.08e-18	Lung cancer;
LUAD	cis	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg22467129	chr15:76604101	ETFA	0.42	6.87	0.32	2.26e-11	Blood metabolite levels;
LUAD	cis	rs834811	0.863	rs834821	chr7:135895713	A/T	cg01726295	chr7:135938950	NA	0.27	6.7	0.31	6.65e-11	Post-traumatic stress disorder;
LUAD	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg26384229	chr12:38710491	ALG10B	0.47	7.78	0.35	5.79e-14	Bladder cancer;
LUAD	cis	rs7223966	0.729	rs7921	chr17:62006259	G/A	cg25324976	chr17:61989376	CSHL1	0.41	7.38	0.34	8.73e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs447921	0.817	rs346811	chr17:74403926	T/C	cg17201438	chr17:74438067	UBE2O	-0.62	-8.23	-0.37	2.34e-15	Mitochondrial DNA levels;
LUAD	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg03467027	chr4:99064603	C4orf37	0.41	6.61	0.31	1.15e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg04944784	chr2:26401820	FAM59B	-0.69	-9.74	-0.43	2.36e-20	Gut microbiome composition (summer);
LUAD	cis	rs73086581	1.000	rs73084575	chr20:3906768	G/T	cg02187196	chr20:3869020	PANK2	0.45	6.43	0.3	3.5e-10	Response to antidepressants in depression;
LUAD	cis	rs7737355	0.773	rs4706023	chr5:130882379	T/C	cg25547332	chr5:131281432	NA	0.43	6.86	0.32	2.41e-11	Life satisfaction;
LUAD	cis	rs5167	0.677	rs2238682	chr19:45458593	C/T	cg13119609	chr19:45449297	APOC2	0.37	6.59	0.31	1.28e-10	Blood protein levels;
LUAD	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg04398451	chr17:18023971	MYO15A	-0.75	-13.77	-0.56	6.79e-36	Total body bone mineral density;
LUAD	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-8.42	-0.38	5.87e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2227564	0.574	rs3849969	chr10:75525999	C/T	cg23231163	chr10:75533350	FUT11	0.41	6.51	0.3	2.18e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg06606381	chr12:133084897	FBRSL1	-0.65	-6.62	-0.31	1.07e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs55665837	0.701	rs11023265	chr11:14616038	C/T	cg19336497	chr11:14380999	RRAS2	-0.4	-7.27	-0.33	1.8e-12	Vitamin D levels;
LUAD	trans	rs2770228	1.000	rs9582143	chr13:98166750	A/G	cg01481609	chr10:134920351	GPR123	-0.48	-6.73	-0.31	5.6e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
LUAD	cis	rs9287719	0.747	rs1534400	chr2:10696833	T/C	cg00105475	chr2:10696890	NA	0.39	6.98	0.32	1.12e-11	Prostate cancer;
LUAD	cis	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg21204522	chr6:27730016	NA	-0.51	-7.41	-0.34	6.71e-13	Parkinson's disease;
LUAD	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg18240062	chr17:79603768	NPLOC4	0.36	6.41	0.3	3.94e-10	Eye color traits;
LUAD	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg25237894	chr2:233734115	C2orf82	0.67	12.41	0.52	2.23e-30	Coronary artery disease;
LUAD	cis	rs7731657	0.537	rs112876284	chr5:130293884	G/C	cg08523029	chr5:130500466	HINT1	-0.57	-7.43	-0.34	5.98e-13	Fasting plasma glucose;
LUAD	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.42	0.55	1.78e-34	Tonsillectomy;
LUAD	cis	rs3784262	0.740	rs2044071	chr15:58270804	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.4	-7.92	-0.36	2.18e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs28830936	0.966	rs17678552	chr15:42066190	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.79	-0.31	3.82e-11	Diastolic blood pressure;
LUAD	cis	rs113835537	0.529	rs75685325	chr11:66235242	A/G	cg24851651	chr11:66362959	CCS	0.61	10.49	0.45	4.76e-23	Airway imaging phenotypes;
LUAD	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg11663144	chr21:46675770	NA	-0.59	-11.07	-0.47	3.34e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg04234412	chr22:24373322	LOC391322	-0.84	-16.37	-0.62	5.44e-47	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg02221422	chr11:68192511	LRP5	-0.4	-6.67	-0.31	7.85e-11	Total body bone mineral density;
LUAD	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg26587870	chr6:27730563	NA	-0.49	-8.18	-0.37	3.36e-15	Parkinson's disease;
LUAD	cis	rs240764	0.658	rs13196803	chr6:101188052	A/T	cg09795085	chr6:101329169	ASCC3	-0.49	-8.67	-0.39	9.25e-17	Neuroticism;
LUAD	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg26408565	chr15:76604113	ETFA	-0.42	-6.51	-0.3	2.12e-10	Blood metabolite levels;
LUAD	cis	rs943466	1.000	rs747692	chr6:33737436	C/T	cg16010596	chr6:33739607	LEMD2	-0.37	-6.96	-0.32	1.34e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs10916814	0.610	rs1890004	chr1:20899066	T/C	cg24502330	chr1:20914028	CDA	-0.36	-7.18	-0.33	3.14e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7524258	0.835	rs75096060	chr1:7270248	G/C	cg07173049	chr1:7289937	CAMTA1	0.49	9.35	0.41	5.31e-19	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg18621852	chr3:10150065	C3orf24	0.45	7.42	0.34	6.44e-13	Alzheimer's disease;
LUAD	cis	rs593982	1.000	rs1941746	chr11:65502413	A/G	cg08755490	chr11:65554678	OVOL1	1.32	20.4	0.7	6.24e-65	Atopic dermatitis;
LUAD	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.39	-6.69	-0.31	6.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg14582100	chr15:45693742	SPATA5L1	0.64	12.5	0.52	9.64e-31	Homoarginine levels;
LUAD	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18404041	chr3:52824283	ITIH1	-0.48	-9.77	-0.43	1.77e-20	Cognitive function;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03732293	chr1:179335087	C1orf125	-0.45	-7.14	-0.33	4.16e-12	Height;
LUAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg12034118	chr1:209979487	IRF6	0.52	7.38	0.34	8.73e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs10911363	0.573	rs2761580	chr1:183516989	A/T	cg09173681	chr1:183549694	NCF2	0.57	10.68	0.46	9.57e-24	Systemic lupus erythematosus;
LUAD	cis	rs2882667	0.537	rs7701116	chr5:138406078	C/T	cg04439458	chr5:138467593	SIL1	-0.36	-6.83	-0.32	3.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs12530845	1.000	rs78186690	chr7:135334991	G/C	cg23117316	chr7:135346802	PL-5283	-0.49	-9.11	-0.41	3.24e-18	Red blood cell traits;
LUAD	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg13511324	chr14:104056883	C14orf153	0.27	6.68	0.31	7.42e-11	Reticulocyte count;
LUAD	cis	rs9796	0.835	rs11856848	chr15:41370961	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.38	-7.21	-0.33	2.54e-12	Menopause (age at onset);
LUAD	cis	rs10823500	0.777	rs10999196	chr10:71982305	T/C	cg02100629	chr10:71892760	AIFM2	-0.38	-7.6	-0.35	1.91e-13	Blood protein levels;
LUAD	cis	rs500891	0.525	rs7753311	chr6:84095038	T/C	cg08257003	chr6:84140564	ME1	0.34	6.52	0.3	1.96e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg17757837	chr7:157058334	UBE3C	0.48	8.48	0.38	3.76e-16	Body mass index;
LUAD	cis	rs2302190	0.769	rs8082396	chr17:56632193	C/T	cg25885038	chr17:56607967	SEPT4	-0.52	-8.31	-0.37	1.36e-15	Vitamin D levels;
LUAD	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.68	13.24	0.54	1.04e-33	Cognitive ability;
LUAD	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg14668632	chr7:2872130	GNA12	-0.71	-12.5	-0.52	1.01e-30	Height;
LUAD	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg19041857	chr6:27730383	NA	-0.43	-7.32	-0.34	1.28e-12	Parkinson's disease;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg02835038	chr21:47743854	PCNT;C21orf58	0.41	6.65	0.31	9.18e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.8	-10.16	-0.44	7.58e-22	Body mass index;
LUAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg05434287	chr7:2030229	MAD1L1	0.41	6.74	0.31	5.04e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg08029281	chr1:67600428	NA	0.36	6.92	0.32	1.7e-11	Psoriasis;
LUAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00166722	chr3:10149974	C3orf24	0.74	12.65	0.52	2.5e-31	Alzheimer's disease;
LUAD	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg02450064	chr17:40260053	DHX58	-0.44	-7.23	-0.33	2.22e-12	Fibrinogen levels;
LUAD	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg17644776	chr2:200775616	C2orf69	0.44	6.96	0.32	1.26e-11	Osteoporosis;
LUAD	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg06781209	chr11:61594997	FADS2	-0.42	-7.56	-0.35	2.51e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg08779649	chr13:50194554	NA	0.42	8.35	0.38	9.78e-16	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg03929089	chr4:120376271	NA	-0.55	-8.21	-0.37	2.62e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7582720	0.943	rs114372659	chr2:203715514	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.0	0.4	7.45e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg24733560	chr20:60626293	TAF4	0.39	7.52	0.34	3.25e-13	Body mass index;
LUAD	cis	rs3784262	1.000	rs7170896	chr15:58252393	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.47	-9.8	-0.43	1.46e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs6840360	0.571	rs6811676	chr4:152562726	T/C	cg22705602	chr4:152727874	NA	-0.38	-6.73	-0.31	5.67e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg22529645	chr1:3704559	LRRC47	0.57	10.63	0.46	1.45e-23	Red cell distribution width;
LUAD	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg00802000	chr16:706648	WDR90	-0.39	-7.33	-0.34	1.22e-12	Height;
LUAD	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg06221963	chr1:154839813	KCNN3	-0.87	-20.9	-0.71	3.95e-67	Prostate cancer;
LUAD	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.72	-0.43	2.64e-20	Schizophrenia;
LUAD	cis	rs6500395	1.000	rs4785247	chr16:48687732	A/C	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.17e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg16479474	chr6:28041457	NA	0.4	6.54	0.3	1.79e-10	Depression;
LUAD	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-6.36	-0.3	5.33e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg04703951	chr17:43578652	NA	0.61	8.38	0.38	8.17e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00149659	chr3:10157352	C3orf10	0.61	8.45	0.38	4.65e-16	Alzheimer's disease;
LUAD	cis	rs16867321	0.694	rs4666853	chr2:181439671	C/T	cg23363182	chr2:181467187	NA	0.42	6.87	0.32	2.33e-11	Obesity;
LUAD	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg25208724	chr1:156163844	SLC25A44	1.01	17.96	0.66	5.19e-54	Testicular germ cell tumor;
LUAD	cis	rs12681288	0.523	rs112307130	chr8:962483	G/A	cg15309053	chr8:964076	NA	0.48	10.61	0.46	1.79e-23	Schizophrenia;
LUAD	cis	rs2425143	1.000	rs6060642	chr20:34449840	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.18	-0.33	3.25e-12	Blood protein levels;
LUAD	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg21385522	chr1:16154831	NA	0.57	8.56	0.38	2.12e-16	Dilated cardiomyopathy;
LUAD	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.79	-0.5	6.27e-28	Bipolar disorder;
LUAD	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg00922110	chr4:57842668	C4orf14	-0.42	-7.35	-0.34	1.03e-12	Response to bleomycin (chromatid breaks);
LUAD	cis	rs9399401	0.710	rs6900087	chr6:142717303	A/T	cg04461802	chr6:142623433	GPR126	0.46	8.61	0.39	1.42e-16	Chronic obstructive pulmonary disease;
LUAD	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg00530320	chr1:46809349	NSUN4	0.53	8.14	0.37	4.46e-15	Menopause (age at onset);
LUAD	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg16325326	chr1:53192061	ZYG11B	0.47	7.7	0.35	9.44e-14	Monocyte count;
LUAD	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg02993280	chr1:107599747	PRMT6	0.51	8.15	0.37	4.29e-15	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs752010	0.714	rs7513753	chr1:42079232	A/G	cg06885757	chr1:42089581	HIVEP3	0.47	10.94	0.47	1.1e-24	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg25319279	chr11:5960081	NA	-0.41	-7.23	-0.33	2.25e-12	DNA methylation (variation);
LUAD	cis	rs9473147	0.516	rs9369695	chr6:47440565	C/A	cg02130027	chr6:47444894	CD2AP	0.38	6.95	0.32	1.39e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2979489	0.740	rs17554408	chr8:30427531	A/G	cg26383811	chr8:30366931	RBPMS	0.66	9.92	0.43	5.29e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs7177699	0.557	rs4433781	chr15:79121835	A/T	cg15571903	chr15:79123663	NA	-0.39	-7.87	-0.36	3e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg08470875	chr2:26401718	FAM59B	-0.67	-8.92	-0.4	1.45e-17	Gut microbiome composition (summer);
LUAD	cis	rs8177876	0.730	rs76656387	chr16:81117467	G/A	cg08591886	chr16:81111003	C16orf46	-0.79	-7.37	-0.34	8.94e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.18	0.33	3.1e-12	Obesity-related traits;
LUAD	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg23982607	chr1:1823379	GNB1	-0.9	-17.86	-0.66	1.49e-53	Body mass index;
LUAD	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg01200585	chr1:228362443	C1orf69	-0.37	-6.77	-0.31	4.38e-11	Diastolic blood pressure;
LUAD	trans	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg21659725	chr3:3221576	CRBN	0.51	8.3	0.37	1.42e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg06453172	chr10:134556979	INPP5A	-0.66	-9.89	-0.43	6.85e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg04539111	chr16:67997858	SLC12A4	-0.51	-6.42	-0.3	3.67e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs73416724	1.000	rs77626494	chr6:43286886	C/T	cg26312998	chr6:43337775	ZNF318	0.55	6.59	0.31	1.32e-10	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg01620082	chr3:125678407	NA	-0.85	-8.67	-0.39	9.18e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs629535	0.783	rs510632	chr8:70034570	A/G	cg21567404	chr3:27674614	NA	1.01	18.57	0.67	9.52e-57	Dupuytren's disease;
LUAD	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg23625390	chr15:77176239	SCAPER	0.37	6.48	0.3	2.58e-10	Blood metabolite levels;
LUAD	cis	rs2274273	0.901	rs7147136	chr14:55826688	G/C	cg04306507	chr14:55594613	LGALS3	0.44	9.09	0.4	3.85e-18	Protein biomarker;
LUAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg20607798	chr8:58055168	NA	0.66	8.82	0.39	3.01e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg13565492	chr6:43139072	SRF	-0.75	-10.15	-0.44	8.27e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg15468180	chr1:107600409	PRMT6	-0.45	-7.75	-0.35	7.13e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6062509	0.965	rs2315007	chr20:62343845	T/C	cg21849932	chr20:62369462	LIME1	-0.46	-7.44	-0.34	5.61e-13	Prostate cancer;
LUAD	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg23649088	chr2:200775458	C2orf69	0.62	8.24	0.37	2.17e-15	Schizophrenia;
LUAD	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg21770322	chr7:97807741	LMTK2	0.34	8.13	0.37	4.65e-15	Breast cancer;
LUAD	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg22029157	chr1:209979665	IRF6	0.47	8.38	0.38	8.03e-16	Monobrow;
LUAD	cis	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.36	-0.34	9.4e-13	Resting heart rate;
LUAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg06074448	chr4:187884817	NA	-0.36	-6.98	-0.32	1.11e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6992820	0.899	rs10435638	chr8:56754115	C/T	cg06880721	chr8:56792545	LYN	-0.43	-6.93	-0.32	1.56e-11	Mean platelet volume;
LUAD	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg13385794	chr1:248469461	NA	0.27	7.31	0.34	1.31e-12	Common traits (Other);
LUAD	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.84	0.5	3.79e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg13789015	chr9:136890014	NCRNA00094	0.84	14.35	0.57	2.61e-38	Platelet distribution width;
LUAD	cis	rs6484504	0.625	rs6484501	chr11:31373100	G/T	cg14844989	chr11:31128820	NA	0.45	8.36	0.38	9.13e-16	Red blood cell count;
LUAD	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg23649088	chr2:200775458	C2orf69	0.49	8.7	0.39	7.43e-17	Asthma (bronchodilator response);
LUAD	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg23982607	chr1:1823379	GNB1	-0.92	-19.32	-0.68	4.29e-60	Body mass index;
LUAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg23958373	chr8:599963	NA	0.94	9.72	0.43	2.7e-20	IgG glycosylation;
LUAD	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg20203395	chr5:56204925	C5orf35	-0.83	-12.04	-0.51	6.27e-29	Initial pursuit acceleration;
LUAD	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg23985595	chr17:80112537	CCDC57	-0.53	-9.6	-0.42	7.27e-20	Life satisfaction;
LUAD	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg21285383	chr16:89894308	SPIRE2	0.41	9.98	0.44	3.25e-21	Vitiligo;
LUAD	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg06640241	chr16:89574553	SPG7	0.51	8.51	0.38	2.97e-16	Multiple myeloma (IgH translocation);
LUAD	cis	rs4285028	0.948	rs12493408	chr3:121692119	C/A	cg11130432	chr3:121712080	ILDR1	-0.59	-8.43	-0.38	5.62e-16	Multiple sclerosis;
LUAD	cis	rs807669	0.505	rs2236759	chr22:19187427	C/G	cg02655711	chr22:19163373	SLC25A1	0.59	11.29	0.48	5.35e-26	Metabolite levels;
LUAD	cis	rs62400317	0.762	rs9367210	chr6:44863395	G/A	cg20913747	chr6:44695427	NA	-0.41	-6.43	-0.3	3.5e-10	Total body bone mineral density;
LUAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg18621852	chr3:10150065	C3orf24	0.49	8.81	0.39	3.21e-17	Alzheimer's disease;
LUAD	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.37	0.34	8.79e-13	Bipolar disorder;
LUAD	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg18867708	chr6:26865862	GUSBL1	-0.41	-6.59	-0.31	1.33e-10	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg26384229	chr12:38710491	ALG10B	0.4	6.35	0.3	5.44e-10	Morning vs. evening chronotype;
LUAD	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.71	0.31	6.33e-11	Depression;
LUAD	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg09654669	chr8:57350985	NA	-0.66	-10.03	-0.44	2.29e-21	Obesity-related traits;
LUAD	cis	rs7177699	0.557	rs55870734	chr15:79117917	A/T	cg15571903	chr15:79123663	NA	-0.39	-7.76	-0.35	6.28e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs6424115	1.000	rs4649115	chr1:24155731	A/G	cg10978503	chr1:24200527	CNR2	-0.57	-12.34	-0.51	4.17e-30	Immature fraction of reticulocytes;
LUAD	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg19767477	chr5:127420684	SLC12A2	-0.42	-6.47	-0.3	2.76e-10	Ileal carcinoids;
LUAD	cis	rs68170813	0.652	rs17482494	chr7:107168487	T/C	cg23024343	chr7:107201750	COG5	0.53	6.68	0.31	7.62e-11	Coronary artery disease;
LUAD	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.55	0.3	1.71e-10	Lung cancer in ever smokers;
LUAD	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.42	6.45	0.3	3.04e-10	Schizophrenia;
LUAD	trans	rs11039798	0.925	rs10769373	chr11:48531980	T/A	cg15704280	chr7:45808275	SEPT13	0.63	7.34	0.34	1.1e-12	Axial length;
LUAD	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg12179176	chr11:130786555	SNX19	0.48	7.92	0.36	2.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4713675	0.565	rs4713670	chr6:33699882	C/T	cg13859433	chr6:33739653	LEMD2	0.3	7.19	0.33	3e-12	Plateletcrit;
LUAD	cis	rs6500395	1.000	rs7196823	chr16:48616278	G/A	cg04672837	chr16:48644449	N4BP1	0.39	6.7	0.31	6.59e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs877282	1.000	rs11253369	chr10:773610	C/G	cg17470449	chr10:769945	NA	0.57	9.31	0.41	7.28e-19	Uric acid levels;
LUAD	cis	rs8062405	0.691	rs11646653	chr16:28922149	C/T	cg05966235	chr16:28915196	ATP2A1	-0.53	-8.56	-0.38	2.06e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9462027	0.628	rs2395604	chr6:34787976	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.77	-0.39	4.4e-17	Systemic lupus erythematosus;
LUAD	cis	rs10203711	1.000	rs4331454	chr2:239594474	G/A	cg14580085	chr2:239553406	NA	0.41	8.75	0.39	5.31e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7010267	0.543	rs6469803	chr8:120040538	G/A	cg01975934	chr8:119970761	NA	-0.34	-6.48	-0.3	2.51e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg27494647	chr7:150038898	RARRES2	0.52	9.45	0.42	2.34e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7116495	0.786	rs1894003	chr11:71750276	A/G	cg07596299	chr11:71824057	C11orf51	-0.78	-6.66	-0.31	8.68e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs4790333	0.967	rs2002863	chr17:2269769	C/T	cg02569219	chr17:2266849	SGSM2	0.7	13.2	0.54	1.42e-33	Proinsulin levels;
LUAD	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg20744362	chr22:50050164	C22orf34	0.41	8.77	0.39	4.46e-17	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08048268	chr3:133502702	NA	-0.52	-10.51	-0.45	4.25e-23	Iron status biomarkers;
LUAD	cis	rs1105228	0.610	rs2874885	chr6:165702037	C/T	cg12582777	chr6:165658423	NA	0.32	6.67	0.31	8.03e-11	Number of pregnancies;Number of children;
LUAD	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg14416269	chr4:6271139	WFS1	0.64	13.16	0.54	2.1e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg21724239	chr8:58056113	NA	0.75	9.71	0.43	2.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg26536354	chr8:144654954	C8orf73	0.6	6.62	0.31	1.08e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg07636037	chr3:49044803	WDR6	0.54	10.05	0.44	1.93e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.7	0.31	6.76e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs6987853	0.686	rs7818789	chr8:42354257	A/G	cg09913449	chr8:42400586	C8orf40	0.43	8.15	0.37	4.23e-15	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg13126279	chr21:47581558	C21orf56	0.45	6.82	0.31	3.2e-11	Testicular germ cell tumor;
LUAD	cis	rs68170813	0.559	rs75007274	chr7:106814543	G/A	cg23024343	chr7:107201750	COG5	0.49	7.09	0.33	5.65e-12	Coronary artery disease;
LUAD	cis	rs1594829	0.553	rs6996531	chr8:26153455	C/A	cg13160058	chr8:26243215	BNIP3L	-0.34	-7.45	-0.34	5.21e-13	Height;
LUAD	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg26677194	chr12:130822605	PIWIL1	0.55	9.04	0.4	5.6e-18	Menopause (age at onset);
LUAD	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg06618935	chr21:46677482	NA	-0.5	-10.22	-0.45	4.54e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg02423579	chr7:2872169	GNA12	-0.83	-14.89	-0.59	1.28e-40	Height;
LUAD	trans	rs853679	1.000	rs735765	chr6:28170297	G/A	cg01620082	chr3:125678407	NA	-0.58	-7.11	-0.33	5.05e-12	Depression;
LUAD	trans	rs9784649	0.760	rs72755820	chr5:25066181	G/A	cg08600765	chr20:34638493	LOC647979	-0.79	-10.45	-0.45	6.6e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1232027	0.632	rs1677706	chr5:79930303	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-10.6	-0.46	1.91e-23	Chronic sinus infection;
LUAD	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-11.29	-0.48	5.3e-26	Bipolar disorder;
LUAD	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg25811766	chr13:21894605	NA	-0.62	-7.53	-0.34	3e-13	White matter hyperintensity burden;
LUAD	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	7.22	0.33	2.49e-12	Cognitive test performance;
LUAD	trans	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	15.84	0.61	1.01e-44	Exhaled nitric oxide levels;
LUAD	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg18105134	chr13:113819100	PROZ	0.89	15.6	0.6	1.17e-43	Platelet distribution width;
LUAD	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.02	0.32	8.9e-12	Hypertriglyceridemia;
LUAD	cis	rs4774899	0.752	rs13313455	chr15:57408980	T/C	cg14026238	chr15:57616123	NA	-0.39	-7.42	-0.34	6.65e-13	Urinary tract infection frequency;
LUAD	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg11062466	chr8:58055876	NA	0.45	6.37	0.3	4.87e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7827290	0.686	rs13253108	chr8:142283565	A/G	cg21312554	chr8:142310691	NA	-0.35	-6.84	-0.32	2.71e-11	Bipolar disorder;
LUAD	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg24818145	chr4:99064322	C4orf37	0.49	8.35	0.38	1.02e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-9.31	-0.41	6.84e-19	Gut microbiome composition (summer);
LUAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg08888203	chr3:10149979	C3orf24	0.73	11.12	0.48	2.2e-25	Alzheimer's disease;
LUAD	trans	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg16011800	chr17:1958478	HIC1	-0.58	-8.19	-0.37	3.24e-15	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg04896959	chr15:78267971	NA	0.57	10.86	0.47	2.03e-24	Coronary artery disease or large artery stroke;
LUAD	cis	rs929596	0.639	rs7571915	chr2:234586574	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.64	-10.75	-0.46	5.25e-24	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs3823572	0.564	rs2953632	chr7:133644261	T/A	cg03336402	chr7:133662267	EXOC4	-0.41	-7.59	-0.35	2.1e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg27087555	chr16:88793112	FAM38A	-1.19	-10.72	-0.46	7.04e-24	Plateletcrit;
LUAD	cis	rs7180079	0.686	rs7165034	chr15:64821498	A/G	cg08069370	chr15:64387884	SNX1	-0.56	-6.77	-0.31	4.25e-11	Monocyte count;
LUAD	cis	rs6835098	0.887	rs12644699	chr4:174142874	A/G	cg08422745	chr4:174089978	GALNT7	0.9	15.1	0.59	1.66e-41	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs73086581	0.947	rs17287577	chr20:3966254	C/T	cg02187196	chr20:3869020	PANK2	0.46	6.51	0.3	2.13e-10	Response to antidepressants in depression;
LUAD	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg21775007	chr8:11205619	TDH	-0.5	-9.01	-0.4	7.16e-18	Retinal vascular caliber;
LUAD	trans	rs9467711	0.651	rs17526722	chr6:25918855	G/A	cg01620082	chr3:125678407	NA	-0.99	-7.66	-0.35	1.27e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.71e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg03188948	chr7:1209495	NA	0.82	9.95	0.44	4.28e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg07936489	chr17:37558343	FBXL20	-0.51	-6.74	-0.31	5.15e-11	Glomerular filtration rate (creatinine);
LUAD	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg03929089	chr4:120376271	NA	-0.99	-20.65	-0.71	4.76e-66	Height;
LUAD	cis	rs367943	0.608	rs2972669	chr5:112983599	C/T	cg12552261	chr5:112820674	MCC	-0.45	-8.38	-0.38	8e-16	Type 2 diabetes;
LUAD	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg00321850	chr1:175162397	KIAA0040	-0.54	-11.83	-0.5	4.34e-28	Diastolic blood pressure;
LUAD	cis	rs11112613	0.818	rs2374507	chr12:106009570	A/C	cg03607813	chr12:105948248	NA	0.62	8.23	0.37	2.34e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.62	8.57	0.38	1.9e-16	Renal function-related traits (BUN);
LUAD	cis	rs4243830	0.522	rs10157142	chr1:6618785	A/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.59	-6.93	-0.32	1.61e-11	Body mass index;
LUAD	cis	rs727505	0.954	rs2054586	chr7:124708414	C/T	cg23710748	chr7:124431027	NA	-0.43	-8.5	-0.38	3.27e-16	Lewy body disease;
LUAD	cis	rs2657888	0.528	rs12304519	chr12:56874522	C/A	cg23002907	chr12:56915593	RBMS2	-0.37	-6.38	-0.3	4.56e-10	Adiponectin levels;
LUAD	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.8	0.35	5.05e-14	Morning vs. evening chronotype;
LUAD	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg06784218	chr1:46089804	CCDC17	0.59	13.22	0.54	1.22e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg24558204	chr6:135376177	HBS1L	0.48	8.88	0.4	1.94e-17	Red blood cell count;
LUAD	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg03388025	chr16:89894329	SPIRE2	0.43	9.89	0.43	6.85e-21	Vitiligo;
LUAD	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg26022315	chr17:47021804	SNF8	0.41	7.38	0.34	8.45e-13	Type 2 diabetes;
LUAD	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg13319975	chr6:146136371	FBXO30	-0.55	-9.42	-0.42	2.9e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg02931644	chr1:25747376	RHCE	0.44	9.33	0.41	6.24e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg23815491	chr16:72088622	HP	0.52	9.6	0.42	6.87e-20	Fibrinogen levels;
LUAD	trans	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.09	-0.33	5.77e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg15309053	chr8:964076	NA	0.37	7.85	0.36	3.37e-14	Schizophrenia;
LUAD	trans	rs12200782	1.000	rs4292511	chr6:26622290	G/T	cg08851530	chr6:28072375	NA	0.72	6.59	0.31	1.3e-10	Small cell lung carcinoma;
LUAD	cis	rs11048434	0.761	rs1805765	chr12:9094548	A/G	cg26114124	chr12:9217669	LOC144571	0.35	6.45	0.3	3.08e-10	Sjögren's syndrome;
LUAD	cis	rs7940866	0.804	rs6590540	chr11:130805444	T/C	cg12179176	chr11:130786555	SNX19	0.44	7.0	0.32	1.03e-11	Schizophrenia;
LUAD	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg03477792	chr4:77819574	ANKRD56	0.48	7.27	0.33	1.74e-12	Emphysema distribution in smoking;
LUAD	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.98	-0.32	1.14e-11	Height;
LUAD	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg25554036	chr4:6271136	WFS1	0.68	13.31	0.54	5.12e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00879206	chr16:30661867	PRR14	-0.38	-6.42	-0.3	3.69e-10	Cancer;
LUAD	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg10591111	chr5:226296	SDHA	-0.56	-7.07	-0.33	6.33e-12	Breast cancer;
LUAD	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg08989290	chr16:615782	NHLRC4	0.33	7.07	0.33	6.49e-12	Height;
LUAD	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.37	7.82	0.36	4.34e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9393692	0.620	rs4412193	chr6:26338056	A/G	cg00631329	chr6:26305371	NA	-0.52	-9.11	-0.4	3.37e-18	Educational attainment;
LUAD	cis	rs11640533	0.901	rs11862250	chr16:53415038	C/A	cg10144400	chr16:53407678	NA	0.42	7.16	0.33	3.61e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg08742575	chr21:47604166	C21orf56	0.62	10.82	0.47	2.94e-24	Testicular germ cell tumor;
LUAD	trans	rs6561151	0.681	rs61959998	chr13:44462501	A/T	cg17145862	chr1:211918768	LPGAT1	0.53	7.49	0.34	4.01e-13	Crohn's disease;
LUAD	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg05187965	chr10:45406764	TMEM72	0.47	9.51	0.42	1.48e-19	Mean corpuscular volume;
LUAD	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg00933542	chr6:150070202	PCMT1	0.45	10.1	0.44	1.22e-21	Lung cancer;
LUAD	cis	rs1595825	0.838	rs73056856	chr2:198801209	C/G	cg11031976	chr2:198649780	BOLL	-0.47	-6.99	-0.32	1.06e-11	Ulcerative colitis;
LUAD	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg11502198	chr6:26597334	ABT1	0.56	9.32	0.41	6.72e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg04546413	chr19:29218101	NA	0.7	10.39	0.45	1.14e-22	Methadone dose in opioid dependence;
LUAD	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	7.54	0.34	2.95e-13	Tonsillectomy;
LUAD	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg05368731	chr17:41323189	NBR1	0.95	19.36	0.69	3.05e-60	Menopause (age at onset);
LUAD	cis	rs2996428	0.504	rs3765780	chr1:3767696	C/T	cg23277830	chr1:3704460	LRRC47	-0.37	-8.39	-0.38	7.12e-16	Red cell distribution width;
LUAD	cis	rs4072705	0.614	rs7020027	chr9:127241414	G/A	cg13476313	chr9:127244764	NR5A1	-0.36	-8.92	-0.4	1.43e-17	Menarche (age at onset);
LUAD	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg23254163	chr1:152506842	NA	0.25	6.68	0.31	7.46e-11	Hair morphology;
LUAD	cis	rs6740322	0.748	rs6732337	chr2:43462822	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.81	12.24	0.51	1.02e-29	Coronary artery disease;
LUAD	cis	rs11971779	0.553	rs11973507	chr7:139099461	A/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg01689657	chr7:91764605	CYP51A1	0.29	7.11	0.33	4.85e-12	Breast cancer;
LUAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg27588902	chr6:42928151	GNMT	-0.35	-9.11	-0.41	3.28e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg25703541	chr22:24373054	LOC391322	0.83	15.6	0.6	1.16e-43	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26314531	chr2:26401878	FAM59B	-0.57	-7.93	-0.36	1.94e-14	Gut microbiome composition (summer);
LUAD	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg18827107	chr12:86230957	RASSF9	-0.7	-12.92	-0.53	2.12e-32	Major depressive disorder;
LUAD	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11890956	chr21:40555474	PSMG1	-0.57	-9.94	-0.44	4.66e-21	Menarche (age at onset);
LUAD	cis	rs1113500	0.509	rs17020915	chr1:108647006	G/T	cg06207961	chr1:108661230	NA	0.42	6.61	0.31	1.18e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs6684514	1.000	rs12027103	chr1:156244856	G/A	cg16558208	chr1:156270281	VHLL	0.53	9.52	0.42	1.36e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg18306943	chr3:40428807	ENTPD3	0.4	6.9	0.32	1.89e-11	Renal cell carcinoma;
LUAD	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg27572855	chr1:25598939	RHD	-0.57	-13.12	-0.54	3.01e-33	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	8.12	0.37	5.22e-15	Rheumatoid arthritis;
LUAD	cis	rs12474201	0.928	rs17822019	chr2:46934505	T/C	cg09399716	chr2:46890238	NA	-0.34	-6.36	-0.3	5.12e-10	Height;
LUAD	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg21775007	chr8:11205619	TDH	0.46	8.27	0.37	1.81e-15	Retinal vascular caliber;
LUAD	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg08085267	chr17:45401833	C17orf57	0.59	10.71	0.46	7.43e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6558530	0.932	rs7846610	chr8:1706675	C/T	cg19131313	chr8:1704013	NA	-0.46	-7.69	-0.35	1.06e-13	Systolic blood pressure;
LUAD	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.45	7.79	0.35	5.12e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg00277334	chr10:82204260	NA	-0.63	-9.95	-0.44	4.34e-21	Post bronchodilator FEV1;
LUAD	cis	rs9902453	0.967	rs12602258	chr17:28317657	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	8.82	0.39	3e-17	Coffee consumption (cups per day);
LUAD	trans	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-15.36	-0.6	1.23e-42	Exhaled nitric oxide levels;
LUAD	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg00316803	chr15:76480434	C15orf27	-0.39	-7.18	-0.33	3.08e-12	Blood metabolite levels;
LUAD	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08280861	chr8:58055591	NA	0.69	8.54	0.38	2.36e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg05865280	chr17:75406074	SEPT9	0.61	19.16	0.68	2.4e-59	Airflow obstruction;
LUAD	trans	rs75804782	0.521	rs56227677	chr2:239449867	C/T	cg01134436	chr17:81009848	B3GNTL1	0.78	8.53	0.38	2.58e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs6594713	0.642	rs6871934	chr5:112787828	T/C	cg12552261	chr5:112820674	MCC	0.58	7.79	0.35	5.29e-14	Brain cytoarchitecture;
LUAD	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg04842962	chr6:43655489	MRPS18A	1.06	27.09	0.8	1.9e-94	IgG glycosylation;
LUAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.57	-9.97	-0.44	3.5e-21	Longevity;Endometriosis;
LUAD	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.19	-0.48	1.26e-25	Depression;
LUAD	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.49	-6.76	-0.31	4.63e-11	Iron status biomarkers;
LUAD	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.2	0.44	5.63e-22	Ileal carcinoids;
LUAD	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg05564831	chr3:52568323	NT5DC2	0.36	6.93	0.32	1.63e-11	Bipolar disorder;
LUAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06873352	chr17:61820015	STRADA	0.82	18.3	0.66	1.55e-55	Prudent dietary pattern;
LUAD	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.42	6.6	0.31	1.2e-10	Platelet count;
LUAD	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg21823605	chr1:152486609	CRCT1	0.29	6.7	0.31	6.61e-11	Hair morphology;
LUAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.63	8.64	0.39	1.18e-16	Renal function-related traits (BUN);
LUAD	cis	rs3820068	0.705	rs58424111	chr1:15868470	A/C	cg24675056	chr1:15929824	NA	0.42	6.65	0.31	9.23e-11	Systolic blood pressure;
LUAD	cis	rs11811982	0.793	rs75972256	chr1:227605097	C/T	cg24860534	chr1:227506868	CDC42BPA	0.67	7.0	0.32	1.02e-11	Optic disc area;
LUAD	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg18854424	chr1:2615690	NA	0.42	9.31	0.41	7.19e-19	Ulcerative colitis;
LUAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg09436375	chr6:42928200	GNMT	-0.3	-8.66	-0.39	1.02e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs62238980	0.614	rs10483163	chr22:32459451	A/G	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg09085632	chr11:111637200	PPP2R1B	0.66	10.29	0.45	2.51e-22	Primary sclerosing cholangitis;
LUAD	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg20701182	chr2:24300061	SF3B14	0.53	6.48	0.3	2.6e-10	Lymphocyte counts;
LUAD	cis	rs71403859	0.502	rs12919417	chr16:71579711	A/G	cg08717414	chr16:71523259	ZNF19	0.6	7.15	0.33	3.92e-12	Post bronchodilator FEV1;
LUAD	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg27661571	chr11:113659931	NA	-0.7	-8.14	-0.37	4.58e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs6922632	1.000	rs6922632	chr6:24107093	C/A	cg26194775	chr6:24126114	NRSN1	-0.51	-8.82	-0.39	3.11e-17	Information processing speed;
LUAD	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg05084668	chr3:125655381	ALG1L	-0.46	-6.94	-0.32	1.44e-11	Blood pressure (smoking interaction);
LUAD	cis	rs6669919	0.553	rs7546343	chr1:211671801	C/T	cg10512769	chr1:211675356	NA	-0.41	-8.15	-0.37	4.1e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs17818399	0.815	rs17768132	chr2:46863249	G/T	cg09399716	chr2:46890238	NA	0.41	7.65	0.35	1.36e-13	Height;
LUAD	trans	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.04	-0.47	4.33e-25	Depression;
LUAD	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg08085267	chr17:45401833	C17orf57	0.57	10.27	0.45	3.01e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2282300	0.739	rs1222208	chr11:30361377	A/C	cg06241208	chr11:30344200	C11orf46	-0.55	-7.1	-0.33	5.4e-12	Morning vs. evening chronotype;
LUAD	cis	rs6684514	1.000	rs66965793	chr1:156285814	G/A	cg16558208	chr1:156270281	VHLL	0.53	9.78	0.43	1.66e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg20203395	chr5:56204925	C5orf35	-0.94	-13.72	-0.56	1.03e-35	Initial pursuit acceleration;
LUAD	cis	rs7937890	0.559	rs2597196	chr11:14491601	C/T	cg06199346	chr11:14280333	SPON1	0.32	6.36	0.3	5.16e-10	Mitochondrial DNA levels;
LUAD	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25427524	chr10:38739819	LOC399744	-0.74	-13.14	-0.54	2.5e-33	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7584330	0.518	rs79618460	chr2:238419959	T/C	cg14458575	chr2:238380390	NA	0.85	12.31	0.51	5.52e-30	Prostate cancer;
LUAD	trans	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.86	0.47	2.2e-24	Mean corpuscular volume;
LUAD	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg00701064	chr4:6280414	WFS1	0.68	14.54	0.58	3.78e-39	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg08601574	chr20:25228251	PYGB	0.49	9.0	0.4	7.84e-18	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg22467129	chr15:76604101	ETFA	-0.49	-8.41	-0.38	6.52e-16	Blood metabolite levels;
LUAD	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21659725	chr3:3221576	CRBN	0.65	10.87	0.47	1.93e-24	Resting heart rate;
LUAD	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg02569458	chr12:86230093	RASSF9	0.42	7.6	0.35	1.87e-13	Major depressive disorder;
LUAD	cis	rs12519773	0.555	rs1845840	chr5:92388210	G/A	cg18783429	chr5:92414398	NA	-0.5	-8.6	-0.39	1.57e-16	Migraine;
LUAD	trans	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17712092	chr4:129076599	LARP1B	0.89	16.76	0.63	1.07e-48	Eosinophil percentage of white cells;
LUAD	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg14668632	chr7:2872130	GNA12	0.39	6.69	0.31	7.1e-11	Plateletcrit;
LUAD	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg18232548	chr7:50535776	DDC	-0.69	-12.63	-0.52	3.03e-31	Systemic sclerosis;
LUAD	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.02	0.32	8.9e-12	Hypertriglyceridemia;
LUAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27297192	chr10:134578999	INPP5A	0.38	6.7	0.31	6.64e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.53	0.52	7.6e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs240764	0.555	rs4840150	chr6:101183774	T/C	cg09795085	chr6:101329169	ASCC3	0.44	7.9	0.36	2.46e-14	Neuroticism;
LUAD	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg14598338	chr9:96623480	NA	-0.42	-8.97	-0.4	9.73e-18	DNA methylation (variation);
LUAD	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg04476341	chr5:669733	TPPP	0.41	8.01	0.36	1.16e-14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg16325326	chr1:53192061	ZYG11B	-0.72	-13.99	-0.56	8.25e-37	Monocyte count;
LUAD	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22857025	chr5:266934	NA	-1.04	-13.48	-0.55	1.09e-34	Breast cancer;
LUAD	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg13126279	chr21:47581558	C21orf56	-0.44	-7.56	-0.35	2.46e-13	Testicular germ cell tumor;
LUAD	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg15147215	chr3:52552868	STAB1	-0.39	-7.19	-0.33	2.99e-12	Bipolar disorder;
LUAD	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg27102117	chr16:15229624	NA	0.7	12.79	0.53	6.81e-32	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg14834391	chr1:2537342	MMEL1	0.31	6.55	0.3	1.66e-10	Ulcerative colitis;
LUAD	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg20587970	chr11:113659929	NA	-1.38	-20.91	-0.71	3.54e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs10979	1.000	rs9386032	chr6:143887492	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.18	-0.44	6.7e-22	Hypospadias;
LUAD	cis	rs714027	1.000	rs4823075	chr22:30519152	T/C	cg00539347	chr22:30592296	NA	-0.28	-6.6	-0.31	1.26e-10	Lymphocyte counts;
LUAD	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg11292332	chr7:45801988	SEPT13	-0.29	-6.4	-0.3	4.19e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg06064525	chr11:970664	AP2A2	-0.55	-11.1	-0.48	2.62e-25	Alzheimer's disease (late onset);
LUAD	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.26	-0.45	3.38e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg15997130	chr1:24165203	NA	0.56	9.54	0.42	1.11e-19	Immature fraction of reticulocytes;
LUAD	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg15147215	chr3:52552868	STAB1	-0.4	-7.24	-0.33	2.2e-12	Bipolar disorder;
LUAD	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg14403583	chr14:105418241	AHNAK2	-0.44	-8.11	-0.37	5.36e-15	Rheumatoid arthritis;
LUAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	trans	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg26043149	chr18:55253948	FECH	0.5	8.14	0.37	4.32e-15	Bone mineral density;
LUAD	cis	rs7707921	0.587	rs1501654	chr5:81679914	A/T	cg15871215	chr5:81402204	ATG10	-0.51	-6.95	-0.32	1.39e-11	Breast cancer;
LUAD	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg22906224	chr7:99728672	NA	-0.62	-10.83	-0.47	2.74e-24	Coronary artery disease;
LUAD	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg18854424	chr1:2615690	NA	-0.32	-7.58	-0.35	2.23e-13	Ulcerative colitis;
LUAD	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg09085632	chr11:111637200	PPP2R1B	0.63	9.41	0.42	3.31e-19	Primary sclerosing cholangitis;
LUAD	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg18944383	chr4:111397179	ENPEP	0.42	8.25	0.37	1.97e-15	Height;
LUAD	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	ch.11.42038R	chr11:967971	AP2A2	0.4	6.97	0.32	1.21e-11	Alzheimer's disease (late onset);
LUAD	trans	rs7395662	1.000	rs4882120	chr11:48573529	C/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.55	-0.3	1.71e-10	HDL cholesterol;
LUAD	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg06263672	chr7:65235340	NA	0.47	6.41	0.3	3.8e-10	Aortic root size;
LUAD	cis	rs31251	0.967	rs2240525	chr5:131315884	C/T	cg06307176	chr5:131281290	NA	0.37	6.75	0.31	4.88e-11	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs921968	0.528	rs13022583	chr2:219589175	T/C	cg02176678	chr2:219576539	TTLL4	-0.59	-11.99	-0.5	1.06e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg15445000	chr17:37608096	MED1	-0.45	-8.35	-0.38	1e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg04731861	chr2:219085781	ARPC2	-0.21	-6.47	-0.3	2.67e-10	Colorectal cancer;
LUAD	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg11663144	chr21:46675770	NA	-0.61	-12.12	-0.51	3.24e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.43	-0.3	3.46e-10	Breast cancer;
LUAD	cis	rs10089	1.000	rs10057122	chr5:127512063	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	8.71	0.39	7.13e-17	Ileal carcinoids;
LUAD	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg10518543	chr12:38710700	ALG10B	0.5	8.19	0.37	3.08e-15	Morning vs. evening chronotype;
LUAD	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg03929089	chr4:120376271	NA	-0.69	-10.26	-0.45	3.42e-22	Height;
LUAD	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg01689657	chr7:91764605	CYP51A1	-0.29	-6.88	-0.32	2.23e-11	Breast cancer;
LUAD	cis	rs6546550	0.935	rs3771541	chr2:70031797	C/G	cg02498382	chr2:70120550	SNRNP27	-0.54	-9.79	-0.43	1.57e-20	Prevalent atrial fibrillation;
LUAD	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg04990556	chr1:26633338	UBXN11	-0.42	-6.86	-0.32	2.47e-11	Obesity-related traits;
LUAD	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg05368731	chr17:41323189	NBR1	0.98	20.4	0.7	6.3e-65	Menopause (age at onset);
LUAD	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18876405	chr7:65276391	NA	0.6	9.86	0.43	8.62e-21	Aortic root size;
LUAD	cis	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg05084668	chr3:125655381	ALG1L	-0.61	-8.95	-0.4	1.14e-17	Blood pressure (smoking interaction);
LUAD	cis	rs7177699	0.557	rs4389112	chr15:79122099	G/A	cg15571903	chr15:79123663	NA	-0.37	-7.21	-0.33	2.58e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26314531	chr2:26401878	FAM59B	-0.58	-7.98	-0.36	1.41e-14	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg07606381	chr6:8435919	SLC35B3	0.42	6.88	0.32	2.12e-11	Motion sickness;
LUAD	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.38	6.47	0.3	2.7e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs9372498	0.505	rs62422248	chr6:118987610	T/C	cg18833306	chr6:118973337	C6orf204	-0.54	-7.81	-0.35	4.58e-14	Diastolic blood pressure;
LUAD	trans	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg05926928	chr17:57297772	GDPD1	-0.6	-7.64	-0.35	1.45e-13	Opioid sensitivity;
LUAD	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg20607798	chr8:58055168	NA	0.77	9.36	0.41	4.82e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg09455208	chr3:40491958	NA	0.64	14.11	0.57	2.48e-37	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg16989719	chr2:238392110	NA	-0.38	-7.97	-0.36	1.45e-14	Prostate cancer;
LUAD	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg04450456	chr4:17643702	FAM184B	0.41	8.05	0.36	8.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs7200543	1.000	rs4985154	chr16:15131642	G/C	cg24683922	chr1:11983373	KIAA2013	-0.48	-8.09	-0.37	6.22e-15	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs4664304	0.900	rs62176692	chr2:160743463	C/T	cg23995753	chr2:160760732	LY75	-0.45	-7.93	-0.36	2.03e-14	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg18135555	chr8:22132992	PIWIL2	0.42	7.6	0.35	1.98e-13	Hypertriglyceridemia;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg01716223	chr13:53023979	VPS36	0.41	6.84	0.32	2.78e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.37	6.58	0.3	1.37e-10	Blood metabolite levels;
LUAD	cis	rs4730250	0.707	rs257381	chr7:106803963	T/C	cg23024343	chr7:107201750	COG5	0.5	6.83	0.32	3e-11	Osteoarthritis;
LUAD	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.43	6.97	0.32	1.19e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs3087591	0.960	rs2952979	chr17:29474298	T/A	cg24425628	chr17:29625626	OMG;NF1	0.42	6.84	0.32	2.85e-11	Hip circumference;
LUAD	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg20701182	chr2:24300061	SF3B14	0.54	6.47	0.3	2.65e-10	Lymphocyte counts;
LUAD	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg14983838	chr19:29218262	NA	0.66	9.69	0.43	3.46e-20	Methadone dose in opioid dependence;
LUAD	cis	rs1595825	0.891	rs73054867	chr2:198700417	C/G	cg00361562	chr2:198649771	BOLL	-0.49	-7.08	-0.33	6.03e-12	Ulcerative colitis;
LUAD	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg18490616	chr2:88469792	THNSL2	-0.41	-6.43	-0.3	3.53e-10	Response to metformin (IC50);
LUAD	cis	rs7107174	0.892	rs2510038	chr11:77966034	C/T	cg02023728	chr11:77925099	USP35	0.48	7.43	0.34	5.98e-13	Testicular germ cell tumor;
LUAD	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18876405	chr7:65276391	NA	-0.4	-6.41	-0.3	3.82e-10	Aortic root size;
LUAD	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg23649088	chr2:200775458	C2orf69	0.58	8.37	0.38	8.78e-16	Schizophrenia;
LUAD	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	15.35	0.6	1.41e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg14728415	chr7:32535168	LSM5;AVL9	0.68	12.38	0.52	2.95e-30	Cognitive ability;
LUAD	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg11822812	chr5:140052017	DND1	0.37	6.86	0.32	2.53e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.7	-13.01	-0.53	9.05e-33	Menarche (age at onset);
LUAD	cis	rs1182180	0.538	rs4722006	chr7:2765723	A/G	cg03366574	chr7:2764599	NA	0.4	6.86	0.32	2.44e-11	Platelet count;
LUAD	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg03037974	chr15:76606532	NA	0.37	7.74	0.35	7.19e-14	Blood metabolite levels;
LUAD	cis	rs7640424	0.649	rs13094403	chr3:107930210	G/T	cg09227934	chr3:107805635	CD47	-0.47	-8.55	-0.38	2.22e-16	Body mass index;
LUAD	cis	rs12618769	0.571	rs72821939	chr2:99138872	T/C	cg10123293	chr2:99228465	UNC50	0.46	8.21	0.37	2.77e-15	Bipolar disorder;
LUAD	cis	rs3739034	0.646	rs114658932	chr2:135491302	T/G	cg12500956	chr2:135428796	TMEM163	0.38	6.8	0.31	3.63e-11	Gut microbiome composition (winter);
LUAD	cis	rs752010	0.875	rs11210502	chr1:42093712	A/C	cg06885757	chr1:42089581	HIVEP3	0.48	10.98	0.47	7.76e-25	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg08027265	chr7:2291960	NA	-0.41	-7.1	-0.33	5.25e-12	Schizophrenia;
LUAD	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg07936489	chr17:37558343	FBXL20	-0.55	-7.44	-0.34	5.7e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs2282300	0.739	rs67670125	chr11:30214914	C/T	cg06241208	chr11:30344200	C11orf46	-0.56	-7.34	-0.34	1.11e-12	Morning vs. evening chronotype;
LUAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg17178900	chr1:205818956	PM20D1	0.53	9.55	0.42	1.08e-19	Prostate cancer;
LUAD	trans	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg26043149	chr18:55253948	FECH	-0.42	-7.04	-0.32	7.9e-12	Bone mineral density;
LUAD	trans	rs9914544	0.932	rs11870265	chr17:18820985	A/T	cg21372672	chr17:16614065	CCDC144A	-0.4	-6.73	-0.31	5.42e-11	Educational attainment (years of education);
LUAD	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9914988	1.000	rs9895443	chr17:27182944	A/G	cg20469991	chr17:27169893	C17orf63	-0.49	-6.39	-0.3	4.49e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg21385522	chr1:16154831	NA	0.58	9.25	0.41	1.14e-18	Systolic blood pressure;
LUAD	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.15e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	10.93	0.47	1.21e-24	Eosinophil percentage of white cells;
LUAD	trans	rs783540	0.934	rs783530	chr15:83266549	G/C	cg18393722	chr15:85113863	UBE2QP1	-0.45	-7.32	-0.34	1.23e-12	Schizophrenia;
LUAD	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg07810366	chr2:100720526	AFF3	-0.35	-7.18	-0.33	3.11e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs4072705	0.616	rs915033	chr9:127245558	C/G	cg13476313	chr9:127244764	NR5A1	0.36	8.94	0.4	1.24e-17	Menarche (age at onset);
LUAD	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg06532163	chr17:45867833	NA	0.48	8.47	0.38	4.02e-16	IgG glycosylation;
LUAD	cis	rs698833	0.819	rs12053381	chr2:44570804	C/A	cg04920474	chr2:44395004	PPM1B	0.39	7.02	0.32	8.99e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22496380	chr5:211416	CCDC127	-0.95	-13.36	-0.54	3.27e-34	Breast cancer;
LUAD	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg12011299	chr4:100065546	ADH4	0.71	12.93	0.53	1.8e-32	Smoking initiation;
LUAD	cis	rs652260	1.000	rs604938	chr19:7903484	A/G	cg26014689	chr19:7917955	EVI5L	0.42	7.85	0.36	3.46e-14	Menarche (age at onset);
LUAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg20607798	chr8:58055168	NA	0.58	7.54	0.34	2.94e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg14779329	chr11:130786720	SNX19	0.39	6.83	0.32	2.93e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg16989719	chr2:238392110	NA	-0.33	-7.2	-0.33	2.7e-12	Prostate cancer;
LUAD	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg26587870	chr6:27730563	NA	-0.68	-7.21	-0.33	2.63e-12	Depression;
LUAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg23131131	chr22:24373011	LOC391322	-0.56	-9.22	-0.41	1.41e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg00530320	chr1:46809349	NSUN4	0.51	7.57	0.35	2.34e-13	Menopause (age at onset);
LUAD	cis	rs2455799	1.000	rs1584324	chr3:15833653	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-6.58	-0.3	1.36e-10	Mean platelet volume;
LUAD	cis	rs3806843	0.576	rs155363	chr5:140301543	A/G	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.39	-0.3	4.35e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11264213	0.591	rs4653158	chr1:36556187	G/A	cg27506609	chr1:36549197	TEKT2	-0.68	-7.82	-0.36	4.12e-14	Schizophrenia;
LUAD	cis	rs1692580	0.840	rs696094	chr1:2169215	G/A	cg21194808	chr1:2205498	SKI	0.39	6.49	0.3	2.38e-10	Coronary artery disease;
LUAD	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg04450456	chr4:17643702	FAM184B	0.42	8.3	0.37	1.42e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10465746	0.570	rs2147950	chr1:84465545	C/T	cg10977910	chr1:84465055	TTLL7	0.48	7.39	0.34	7.72e-13	Obesity-related traits;
LUAD	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-12.27	-0.51	8.42e-30	Mean corpuscular volume;
LUAD	cis	rs2836633	0.895	rs991816	chr21:40042150	C/A	cg12884169	chr21:40033163	ERG	0.47	9.91	0.43	5.75e-21	Coronary artery disease;
LUAD	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg00204512	chr16:28754710	NA	0.33	7.15	0.33	3.85e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.8	-0.61	1.58e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg03806693	chr22:41940476	POLR3H	0.58	8.5	0.38	3.33e-16	Vitiligo;
LUAD	cis	rs9863	0.861	rs12301673	chr12:124455818	C/T	cg17723958	chr12:124429295	CCDC92	-0.42	-6.86	-0.32	2.51e-11	White blood cell count;
LUAD	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg02775129	chr4:119771670	NA	-0.86	-8.15	-0.37	4.09e-15	Cannabis dependence symptom count;
LUAD	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg18527919	chr2:24398170	C2orf84	-0.39	-6.5	-0.3	2.32e-10	Asthma;
LUAD	cis	rs12134245	0.755	rs11164928	chr1:92012678	G/A	cg25838465	chr1:92012736	NA	-0.77	-16.99	-0.64	9.6e-50	Breast cancer;
LUAD	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg15448220	chr1:150897856	SETDB1	0.57	9.88	0.43	7.45e-21	Melanoma;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01353569	chr7:106810328	HBP1	-0.47	-7.28	-0.33	1.59e-12	Height;
LUAD	cis	rs953387	0.910	rs4954573	chr2:136927094	T/G	cg05194412	chr2:137003533	NA	-0.42	-6.71	-0.31	6.44e-11	Arthritis (juvenile idiopathic);
LUAD	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-6.75	-0.31	5.02e-11	Blood metabolite levels;
LUAD	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg21214613	chr1:16344536	HSPB7	0.43	7.76	0.35	6.55e-14	Systolic blood pressure;
LUAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg08888203	chr3:10149979	C3orf24	0.63	10.75	0.46	5.31e-24	Alzheimer's disease;
LUAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg24846343	chr22:24311635	DDTL	0.77	17.34	0.64	2.72e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1032833	0.732	rs78129581	chr2:180040691	T/C	cg23883738	chr2:179974586	SESTD1	-0.71	-7.98	-0.36	1.39e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	trans	rs62458065	0.640	rs4141788	chr7:32519264	T/C	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.35	-0.34	1.02e-12	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg00310523	chr12:86230176	RASSF9	0.39	8.45	0.38	4.67e-16	Major depressive disorder;
LUAD	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg07617317	chr6:118971624	C6orf204	0.55	8.26	0.37	1.92e-15	Diastolic blood pressure;
LUAD	cis	rs3784262	0.679	rs4238326	chr15:58336000	C/T	cg12031962	chr15:58353849	ALDH1A2	0.49	9.47	0.42	2.04e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs8017423	0.967	rs12889636	chr14:90689953	A/C	cg14092571	chr14:90743983	NA	0.46	7.86	0.36	3.28e-14	Mortality in heart failure;
LUAD	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg24558204	chr6:135376177	HBS1L	0.45	8.37	0.38	8.58e-16	Red blood cell count;
LUAD	cis	rs4971059	0.654	rs4276913	chr1:155131673	A/G	cg23973274	chr1:155060172	NA	-0.38	-6.53	-0.3	1.94e-10	Breast cancer;
LUAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg24642844	chr7:1081250	C7orf50	-0.81	-11.92	-0.5	1.85e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7937890	0.531	rs2575828	chr11:14484192	T/C	cg06199346	chr11:14280333	SPON1	-0.33	-6.49	-0.3	2.4e-10	Mitochondrial DNA levels;
LUAD	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg00310523	chr12:86230176	RASSF9	0.41	8.55	0.38	2.3e-16	Major depressive disorder;
LUAD	cis	rs6987853	0.761	rs2974356	chr8:42434633	C/T	cg09913449	chr8:42400586	C8orf40	0.51	10.24	0.45	4.04e-22	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg10523679	chr1:76189770	ACADM	0.92	18.39	0.67	6.1e-56	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs28595532	1.000	rs28600971	chr4:119712728	G/T	cg14228332	chr4:119757509	SEC24D	0.76	7.2	0.33	2.74e-12	Cannabis dependence symptom count;
LUAD	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.86	0.36	3.32e-14	Depression;
LUAD	cis	rs16910800	0.689	rs56101126	chr11:23188861	T/A	cg20040320	chr11:23191996	NA	-0.75	-10.02	-0.44	2.32e-21	Cancer;
LUAD	cis	rs11771526	0.901	rs17161124	chr7:32307324	A/T	cg27532318	chr7:32358331	NA	-0.57	-7.51	-0.34	3.65e-13	Body mass index;
LUAD	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg17971929	chr21:40555470	PSMG1	0.55	8.35	0.38	9.85e-16	Cognitive function;
LUAD	cis	rs34638657	0.702	rs12599946	chr16:82199831	T/C	cg09439754	chr16:82129088	HSD17B2	-0.37	-7.07	-0.33	6.52e-12	Lung adenocarcinoma;
LUAD	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.07	-14.3	-0.57	3.95e-38	Schizophrenia;
LUAD	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg03477792	chr4:77819574	ANKRD56	0.47	7.19	0.33	3.04e-12	Emphysema distribution in smoking;
LUAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg09165964	chr15:75287851	SCAMP5	-0.47	-7.12	-0.33	4.67e-12	Blood trace element (Zn levels);
LUAD	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	6.82	0.31	3.14e-11	Mood instability;
LUAD	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26314531	chr2:26401878	FAM59B	0.71	9.49	0.42	1.7e-19	Gut microbiome composition (summer);
LUAD	cis	rs10865541	0.902	rs13399186	chr2:3423201	G/T	cg22182287	chr2:3452347	TTC15	0.46	8.03	0.36	1e-14	Obesity-related traits;
LUAD	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg22823121	chr1:150693482	HORMAD1	0.38	7.5	0.34	3.86e-13	Melanoma;
LUAD	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg10755058	chr3:40428713	ENTPD3	-0.44	-8.08	-0.37	6.65e-15	Renal cell carcinoma;
LUAD	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg16606324	chr3:10149918	C3orf24	0.66	11.16	0.48	1.54e-25	Alzheimer's disease;
LUAD	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg04450456	chr4:17643702	FAM184B	0.4	7.85	0.36	3.41e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg07460842	chr6:66804631	NA	-1.06	-16.52	-0.63	1.2e-47	Exhaled nitric oxide output;
LUAD	cis	rs1816752	0.749	rs77832754	chr13:24990154	G/A	cg02811702	chr13:24901961	NA	0.43	7.41	0.34	6.86e-13	Obesity-related traits;
LUAD	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.69	-12.75	-0.53	1e-31	Ulcerative colitis;
LUAD	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg08885076	chr2:99613938	TSGA10	-0.4	-7.18	-0.33	3.2e-12	Chronic sinus infection;
LUAD	cis	rs17102423	0.755	rs7161394	chr14:65563309	G/T	cg11161011	chr14:65562177	MAX	-0.52	-8.35	-0.38	1.01e-15	Obesity-related traits;
LUAD	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-11.5	-0.49	8.41e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg18180107	chr4:99064573	C4orf37	0.42	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg24565620	chr2:194026	NA	0.45	7.21	0.33	2.66e-12	Blood protein levels;
LUAD	cis	rs8078723	0.668	rs3907022	chr17:38134889	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.36	-6.86	-0.32	2.45e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs9837602	1.000	rs2291495	chr3:99782227	T/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.91	-0.32	1.79e-11	Breast cancer;
LUAD	cis	rs4604732	0.631	rs10802509	chr1:247627158	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.4e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.67	-0.31	7.99e-11	Crohn's disease;
LUAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg05313129	chr8:58192883	C8orf71	-0.55	-7.15	-0.33	3.91e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs629535	0.814	rs558511	chr8:70069908	C/A	cg21567404	chr3:27674614	NA	1.0	18.36	0.67	8.53e-56	Dupuytren's disease;
LUAD	cis	rs8112211	0.731	rs8101488	chr19:38825094	A/G	cg01275006	chr19:38876250	GGN	-0.5	-6.48	-0.3	2.58e-10	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg07917127	chr4:99064746	C4orf37	0.42	7.03	0.32	8.37e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg15448220	chr1:150897856	SETDB1	0.5	8.61	0.39	1.48e-16	Tonsillectomy;
LUAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25550878	chr5:131132870	FNIP1	-0.41	-6.44	-0.3	3.3e-10	Height;
LUAD	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.57	0.3	1.46e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg26924012	chr15:45694286	SPATA5L1	0.64	10.87	0.47	1.94e-24	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg18129748	chr3:49941408	MST1R	-0.43	-7.13	-0.33	4.3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs986417	0.901	rs12886086	chr14:61042091	A/G	cg27398547	chr14:60952738	C14orf39	0.68	7.96	0.36	1.62e-14	Gut microbiota (bacterial taxa);
LUAD	trans	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg05926928	chr17:57297772	GDPD1	-0.77	-9.43	-0.42	2.8e-19	Opioid sensitivity;
LUAD	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.7e-32	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
LUAD	cis	rs1451375	0.698	rs1813214	chr7:50637525	A/G	cg18232548	chr7:50535776	DDC	0.5	8.23	0.37	2.27e-15	Malaria;
LUAD	cis	rs2535633	0.631	rs2581827	chr3:52966558	C/T	cg11645453	chr3:52864694	ITIH4	-0.38	-7.01	-0.32	9.6e-12	Body mass index;
LUAD	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg22029157	chr1:209979665	IRF6	0.79	11.69	0.49	1.53e-27	Cleft lip with or without cleft palate;
LUAD	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg04155289	chr7:94953770	PON1	-0.53	-7.07	-0.33	6.28e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9525916	1.000	rs9525916	chr13:44702869	A/T	cg04068111	chr13:44716778	NA	-0.32	-7.09	-0.33	5.58e-12	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUAD	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg03714773	chr7:91764589	CYP51A1	0.29	6.96	0.32	1.31e-11	Breast cancer;
LUAD	cis	rs9469913	0.799	rs2814996	chr6:34621314	T/C	cg14254433	chr6:34482411	PACSIN1	-0.42	-6.57	-0.3	1.45e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	trans	rs75804782	0.641	rs59499060	chr2:239341411	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	8.24	0.37	2.25e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7799006	0.527	rs3779009	chr7:2203692	G/C	cg08027265	chr7:2291960	NA	-0.52	-8.94	-0.4	1.2e-17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18404041	chr3:52824283	ITIH1	-0.6	-12.51	-0.52	9.39e-31	Bipolar disorder;
LUAD	cis	rs2836633	0.929	rs2836610	chr21:40044502	C/T	cg12884169	chr21:40033163	ERG	0.47	9.89	0.43	7.17e-21	Coronary artery disease;
LUAD	trans	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg04565464	chr8:145669602	NFKBIL2	0.46	7.1	0.33	5.26e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.75	-0.65	4.6e-53	Height;
LUAD	cis	rs4722404	0.592	rs13221367	chr7:3119823	C/T	cg19214707	chr7:3157722	NA	-0.42	-6.73	-0.31	5.4e-11	Atopic dermatitis;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg05757007	chr6:101053555	ASCC3	0.39	6.41	0.3	3.89e-10	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg26354017	chr1:205819088	PM20D1	-0.52	-8.75	-0.39	4.96e-17	Parkinson's disease;
LUAD	cis	rs1832871	0.683	rs11752399	chr6:158711188	G/A	cg07165851	chr6:158734300	TULP4	0.71	11.16	0.48	1.62e-25	Height;
LUAD	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg09222892	chr1:25734099	RHCE	-0.49	-9.32	-0.41	6.27e-19	Erythrocyte sedimentation rate;
LUAD	trans	rs62458065	0.713	rs62463967	chr7:32498329	G/A	cg00845942	chr12:64062724	DPY19L2	-0.55	-7.56	-0.35	2.59e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg16205897	chr5:131564050	P4HA2	-0.45	-10.65	-0.46	1.29e-23	Blood metabolite levels;
LUAD	cis	rs7927592	0.513	rs630225	chr11:68194611	A/C	cg16797656	chr11:68205561	LRP5	0.52	11.19	0.48	1.17e-25	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.808	rs78154346	chr17:28169493	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	9.05	0.4	5.41e-18	Coffee consumption (cups per day);
LUAD	cis	rs736801	0.964	rs17622656	chr5:131820997	A/G	cg07538946	chr5:131705188	SLC22A5	-0.49	-7.99	-0.36	1.26e-14	Breast cancer;Mosquito bite size;
LUAD	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-8.3	-0.37	1.43e-15	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg25767906	chr1:53392781	SCP2	-0.54	-10.13	-0.44	9.42e-22	Monocyte count;
LUAD	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg03929089	chr4:120376271	NA	-0.92	-17.46	-0.65	8.02e-52	Coronary artery disease;
LUAD	cis	rs2387326	0.717	rs12254442	chr10:129945793	C/T	cg16087940	chr10:129947807	NA	-0.63	-9.01	-0.4	6.94e-18	Select biomarker traits;
LUAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg00106254	chr7:1943704	MAD1L1	-0.55	-7.91	-0.36	2.27e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs6138458	0.847	rs56312312	chr20:24959386	C/A	cg26195577	chr20:24973756	C20orf3	0.97	15.03	0.59	3.22e-41	Blood protein levels;
LUAD	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.5	-8.31	-0.37	1.29e-15	Lymphocyte percentage of white cells;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg14668821	chr17:77704760	ENPP7	0.32	6.4	0.3	4.11e-10	Menopause (age at onset);
LUAD	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg22961513	chr11:14280813	SPON1	-0.42	-8.57	-0.38	2.03e-16	Mitochondrial DNA levels;
LUAD	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.88	0.32	2.21e-11	Motion sickness;
LUAD	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg01884057	chr2:25150051	NA	0.34	7.22	0.33	2.47e-12	Body mass index;
LUAD	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg26597838	chr10:835615	NA	0.99	15.31	0.6	1.95e-42	Eosinophil percentage of granulocytes;
LUAD	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg12311346	chr5:56204834	C5orf35	0.74	11.75	0.5	8.75e-28	Initial pursuit acceleration;
LUAD	cis	rs910187	0.571	rs3746490	chr20:45801712	G/A	cg27589058	chr20:45804311	EYA2	-0.37	-8.46	-0.38	4.53e-16	Migraine;
LUAD	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg17366294	chr4:99064904	C4orf37	0.66	12.59	0.52	4.51e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4006360	0.574	rs6503592	chr17:39253010	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.29	0.37	1.48e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg14664628	chr15:75095509	CSK	-0.42	-6.41	-0.3	3.97e-10	Breast cancer;
LUAD	cis	rs10489202	0.683	rs7515429	chr1:168066659	A/G	cg24449463	chr1:168025552	DCAF6	-0.61	-9.24	-0.41	1.24e-18	Schizophrenia;
LUAD	cis	rs6028335	0.610	rs1130247	chr20:37581437	A/G	cg27660920	chr20:37554817	FAM83D	0.55	7.35	0.34	1.03e-12	Alcohol and nicotine co-dependence;
LUAD	trans	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.73	12.39	0.52	2.61e-30	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs5167	0.743	rs8111069	chr19:45483438	A/C	cg09555818	chr19:45449301	APOC2	0.39	7.35	0.34	1.05e-12	Blood protein levels;
LUAD	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.15	0.44	8.6e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg22166914	chr1:53195759	ZYG11B	0.46	7.52	0.34	3.3e-13	Monocyte count;
LUAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg25173405	chr17:45401733	C17orf57	-0.41	-6.63	-0.31	1.06e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.11	-0.33	4.91e-12	Total body bone mineral density;
LUAD	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02018176	chr4:1364513	KIAA1530	-0.67	-11.89	-0.5	2.54e-28	Longevity;
LUAD	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg06547715	chr2:218990976	CXCR2	-0.29	-6.95	-0.32	1.39e-11	Colorectal cancer;
LUAD	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg09835421	chr16:68378352	PRMT7	-0.73	-8.28	-0.37	1.66e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12530845	1.000	rs4291212	chr7:135335465	C/T	cg23117316	chr7:135346802	PL-5283	-0.49	-9.12	-0.41	3.16e-18	Red blood cell traits;
LUAD	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg08132940	chr7:1081526	C7orf50	-0.69	-6.96	-0.32	1.33e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3772130	1.000	rs17691170	chr3:121357626	G/C	cg20356878	chr3:121714668	ILDR1	0.48	7.4	0.34	7.27e-13	Cognitive performance;
LUAD	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.44	-0.38	5.11e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg21775007	chr8:11205619	TDH	0.56	9.93	0.43	4.89e-21	Retinal vascular caliber;
LUAD	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.48	-0.45	5.41e-23	Total body bone mineral density;
LUAD	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg26384229	chr12:38710491	ALG10B	0.49	8.06	0.37	7.69e-15	Heart rate;
LUAD	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	8.37	0.38	8.44e-16	Schizophrenia;
LUAD	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg24558204	chr6:135376177	HBS1L	0.49	9.14	0.41	2.61e-18	Red blood cell count;
LUAD	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.7	-0.39	7.21e-17	Alcohol dependence;
LUAD	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.37	-0.3	4.94e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs2262909	0.719	rs12461632	chr19:22245089	G/A	cg11619707	chr19:22235551	ZNF257	0.49	7.52	0.34	3.34e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2302190	0.882	rs8068135	chr17:56654210	A/C	cg25885038	chr17:56607967	SEPT4	-0.52	-8.21	-0.37	2.69e-15	Vitamin D levels;
LUAD	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06112835	chr11:68658793	MRPL21	0.51	9.14	0.41	2.6e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg27284194	chr4:1044797	NA	0.69	10.09	0.44	1.32e-21	Recombination rate (females);
LUAD	cis	rs62400317	0.859	rs10948221	chr6:45236707	T/G	cg20913747	chr6:44695427	NA	-0.41	-6.57	-0.3	1.44e-10	Total body bone mineral density;
LUAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08048268	chr3:133502702	NA	-0.54	-10.94	-0.47	1.09e-24	Iron status biomarkers;
LUAD	cis	rs67072384	0.892	rs72964172	chr11:72436436	G/A	cg04827223	chr11:72435913	ARAP1	-0.65	-7.19	-0.33	2.97e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg13560548	chr3:10150139	C3orf24	-0.44	-7.33	-0.34	1.18e-12	Alzheimer's disease;
LUAD	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg21475434	chr5:93447410	FAM172A	0.73	8.4	0.38	6.84e-16	Diabetic retinopathy;
LUAD	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg19622623	chr12:86230825	RASSF9	-0.53	-9.32	-0.41	6.25e-19	Major depressive disorder;
LUAD	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.95	-0.4	1.09e-17	Gut microbiome composition (summer);
LUAD	cis	rs870825	0.929	rs72689266	chr4:185591053	T/C	cg04058563	chr4:185651563	MLF1IP	0.74	9.52	0.42	1.37e-19	Blood protein levels;
LUAD	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.24	-0.37	2.12e-15	Breast cancer;
LUAD	cis	rs9902453	0.900	rs12451122	chr17:28486376	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.51	0.38	3.04e-16	Coffee consumption (cups per day);
LUAD	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg19678392	chr7:94953810	PON1	-0.56	-7.39	-0.34	7.76e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24531977	chr5:56204891	C5orf35	-0.98	-14.71	-0.58	7.48e-40	Initial pursuit acceleration;
LUAD	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg03714773	chr7:91764589	CYP51A1	0.27	6.41	0.3	3.9e-10	Breast cancer;
LUAD	cis	rs7301826	0.651	rs2277336	chr12:131286119	A/G	cg11011512	chr12:131303247	STX2	-0.39	-6.36	-0.3	5.37e-10	Plasma plasminogen activator levels;
LUAD	cis	rs2286885	0.965	rs4837091	chr9:129244928	A/G	cg15282417	chr9:129245246	FAM125B	0.42	8.63	0.39	1.3e-16	Intraocular pressure;
LUAD	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03264133	chr6:25882463	NA	-0.58	-9.47	-0.42	1.95e-19	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs3820068	0.705	rs11583306	chr1:15860803	A/G	cg13390004	chr1:15929781	NA	-0.42	-6.78	-0.31	4.17e-11	Systolic blood pressure;
LUAD	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.16	-0.33	3.62e-12	Breast cancer;
LUAD	trans	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg26811252	chr16:29126840	RRN3P2	0.6	10.29	0.45	2.59e-22	Menopause (age at onset);
LUAD	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03517284	chr6:25882590	NA	-0.58	-9.53	-0.42	1.22e-19	Blood metabolite levels;
LUAD	cis	rs9300255	0.679	rs10846507	chr12:123786492	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.54	-0.3	1.78e-10	Neutrophil percentage of white cells;
LUAD	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg18944383	chr4:111397179	ENPEP	0.39	7.81	0.36	4.43e-14	Height;
LUAD	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg05082376	chr22:42548792	NA	0.44	7.66	0.35	1.27e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.62	-0.31	1.11e-10	Mood instability;
LUAD	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg05590025	chr7:65112418	INTS4L2	0.74	8.05	0.36	8.39e-15	Diabetic kidney disease;
LUAD	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.77	-0.46	4.38e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg13902645	chr11:5959945	NA	-0.52	-9.03	-0.4	6.32e-18	DNA methylation (variation);
LUAD	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg22906224	chr7:99728672	NA	0.52	8.52	0.38	2.77e-16	Coronary artery disease;
LUAD	cis	rs938554	0.571	rs4144	chr4:10016322	T/C	cg02734326	chr4:10020555	SLC2A9	0.49	7.55	0.34	2.62e-13	Blood metabolite levels;
LUAD	cis	rs10193935	0.818	rs10221927	chr2:42546680	A/C	cg27598129	chr2:42591480	NA	-0.74	-9.5	-0.42	1.6e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.74	0.35	7.17e-14	Bladder cancer;
LUAD	cis	rs6445967	0.569	rs12493748	chr3:58311282	A/G	cg13750441	chr3:58318267	PXK	-0.32	-6.55	-0.3	1.63e-10	Platelet count;
LUAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03452623	chr4:187889614	NA	-0.81	-16.56	-0.63	7.77e-48	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11971779	0.680	rs11980313	chr7:139034643	C/G	cg23387468	chr7:139079360	LUC7L2	0.28	6.42	0.3	3.57e-10	Diisocyanate-induced asthma;
LUAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27286337	chr10:134555280	INPP5A	0.72	9.42	0.42	3e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs208520	0.874	rs208470	chr6:66916402	G/A	cg07460842	chr6:66804631	NA	-0.97	-13.96	-0.56	1.07e-36	Exhaled nitric oxide output;
LUAD	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.65	0.31	8.98e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs752010	0.619	rs10789406	chr1:42105182	G/T	cg06885757	chr1:42089581	HIVEP3	-0.42	-9.32	-0.41	6.71e-19	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs4604732	0.631	rs1106719	chr1:247624713	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.46	-7.65	-0.35	1.34e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs73198271	0.960	rs73198290	chr8:8616009	A/T	cg01851573	chr8:8652454	MFHAS1	0.52	8.31	0.37	1.34e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs62238980	0.614	rs79592323	chr22:32442742	A/G	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg18477163	chr1:228402036	OBSCN	0.44	7.86	0.36	3.23e-14	Diastolic blood pressure;
LUAD	cis	rs7659604	0.521	rs13114801	chr4:122670855	C/A	cg06713675	chr4:122721982	EXOSC9	0.41	7.49	0.34	4.07e-13	Type 2 diabetes;
LUAD	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.84	0.39	2.63e-17	Menopause (age at onset);
LUAD	cis	rs1448094	0.785	rs6539941	chr12:86452813	G/T	cg06740227	chr12:86229804	RASSF9	-0.36	-6.66	-0.31	8.68e-11	Major depressive disorder;
LUAD	cis	rs11958404	0.860	rs72816577	chr5:157431806	A/G	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15369054	chr17:80825471	TBCD	0.39	6.53	0.3	1.86e-10	Breast cancer;
LUAD	trans	rs9951602	0.512	rs9946120	chr18:76654548	A/T	cg02800362	chr5:177631904	HNRNPAB	0.92	14.62	0.58	1.88e-39	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg12436631	chr1:155007014	DCST1;DCST2	0.31	7.18	0.33	3.24e-12	Prostate cancer;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg24904084	chr5:14653382	NA	0.38	6.54	0.3	1.83e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg17063962	chr7:91808500	NA	0.67	11.9	0.5	2.3e-28	Breast cancer;
LUAD	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	24.97	0.77	3.03e-85	Chronic sinus infection;
LUAD	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg08761264	chr16:28874980	SH2B1	-0.42	-6.37	-0.3	4.99e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg06558623	chr16:89946397	TCF25	1.16	10.19	0.44	6.15e-22	Skin colour saturation;
LUAD	cis	rs2029213	0.523	rs2035450	chr3:53269317	C/T	cg16894138	chr3:53270350	TKT	0.34	7.98	0.36	1.41e-14	Heart rate;
LUAD	trans	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg06606381	chr12:133084897	FBRSL1	-1.09	-8.17	-0.37	3.52e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.3	0.37	1.46e-15	Breast cancer;
LUAD	cis	rs1550582	1.000	rs62523710	chr8:135538773	T/C	cg17885191	chr8:135476712	NA	0.7	9.72	0.43	2.76e-20	Educational attainment;
LUAD	cis	rs1550582	1.000	rs7822348	chr8:135542483	C/G	cg17885191	chr8:135476712	NA	0.63	8.98	0.4	8.88e-18	Educational attainment;
LUAD	cis	rs62400317	0.859	rs17209678	chr6:45163601	C/T	cg20913747	chr6:44695427	NA	-0.43	-6.7	-0.31	6.57e-11	Total body bone mineral density;
LUAD	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg24801067	chr17:62843696	NA	-0.51	-8.31	-0.37	1.36e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg04632378	chr13:21900426	NA	0.42	7.34	0.34	1.08e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.43	0.34	5.94e-13	Morning vs. evening chronotype;
LUAD	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg04731861	chr2:219085781	ARPC2	-0.2	-6.4	-0.3	4.2e-10	Colorectal cancer;
LUAD	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg13535736	chr9:111863775	C9orf5	-0.43	-6.55	-0.3	1.64e-10	Menarche (age at onset);
LUAD	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg02569458	chr12:86230093	RASSF9	0.44	8.01	0.36	1.11e-14	Major depressive disorder;
LUAD	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg03806693	chr22:41940476	POLR3H	0.56	8.23	0.37	2.34e-15	Vitiligo;
LUAD	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03352830	chr11:487213	PTDSS2	0.82	10.54	0.46	3.14e-23	Body mass index;
LUAD	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg26924012	chr15:45694286	SPATA5L1	1.02	19.01	0.68	1.11e-58	Homoarginine levels;
LUAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg14926445	chr8:58193284	C8orf71	-0.48	-6.96	-0.32	1.32e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg06925179	chr17:43578568	NA	0.45	6.42	0.3	3.59e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg18944383	chr4:111397179	ENPEP	0.37	7.42	0.34	6.2800000000000005e-13	Height;
LUAD	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	6.97	0.32	1.22e-11	Motion sickness;
LUAD	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg01657329	chr11:68192670	LRP5	0.47	8.33	0.38	1.17e-15	Total body bone mineral density;
LUAD	cis	rs494562	0.892	rs522915	chr6:86116321	A/G	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs7614311	1.000	rs2087704	chr3:63820493	A/C	cg22134162	chr3:63841271	THOC7	0.35	6.8	0.31	3.55e-11	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs657075	0.697	rs2304081	chr5:131667548	A/G	cg21138405	chr5:131827807	IRF1	-0.48	-6.5	-0.3	2.26e-10	Rheumatoid arthritis;
LUAD	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg15448220	chr1:150897856	SETDB1	0.48	8.27	0.37	1.81e-15	Tonsillectomy;
LUAD	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg20891283	chr12:69753455	YEATS4	-0.42	-6.96	-0.32	1.31e-11	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs6754311	0.773	rs2322818	chr2:136775898	T/C	cg25344623	chr2:136566232	LCT	-0.32	-6.44	-0.3	3.25e-10	Mosquito bite size;
LUAD	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg11845111	chr2:191398756	TMEM194B	-0.73	-9.77	-0.43	1.84e-20	Diastolic blood pressure;
LUAD	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg14343924	chr8:8086146	FLJ10661	-0.48	-7.76	-0.35	6.39e-14	Mood instability;
LUAD	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg21204522	chr6:27730016	NA	-0.51	-7.66	-0.35	1.26e-13	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
LUAD	trans	rs4650994	0.625	rs6681354	chr1:178526279	A/G	cg05059571	chr16:84539110	KIAA1609	-0.59	-10.1	-0.44	1.27e-21	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs2249625	0.545	rs2496488	chr6:72875985	A/T	cg18830697	chr6:72922368	RIMS1	-0.46	-8.41	-0.38	6.42e-16	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg00933542	chr6:150070202	PCMT1	0.42	8.56	0.38	2.14e-16	Lung cancer;
LUAD	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg00310523	chr12:86230176	RASSF9	0.4	8.06	0.36	8.13e-15	Major depressive disorder;
LUAD	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg02461776	chr11:598696	PHRF1	0.47	6.68	0.31	7.73e-11	Systemic lupus erythematosus;
LUAD	cis	rs10979	0.679	rs35914889	chr6:143886392	A/T	cg25407410	chr6:143891975	LOC285740	-0.55	-8.01	-0.36	1.16e-14	Hypospadias;
LUAD	cis	rs910873	0.505	rs2378249	chr20:33218090	G/A	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.05	-0.36	8.57e-15	Melanoma;
LUAD	trans	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg01620082	chr3:125678407	NA	-0.71	-7.22	-0.33	2.44e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg07169764	chr2:136633963	MCM6	0.66	8.45	0.38	4.64e-16	Corneal structure;
LUAD	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11644478	chr21:40555479	PSMG1	0.66	10.8	0.47	3.41e-24	Cognitive function;
LUAD	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg22963979	chr7:1858916	MAD1L1	-0.48	-8.22	-0.37	2.44e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg13319975	chr6:146136371	FBXO30	0.64	10.95	0.47	9.42e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs34734847	0.787	rs1814851	chr12:121128633	C/G	cg13914990	chr12:121174878	ACADS	0.4	7.88	0.36	2.81e-14	Mean corpuscular volume;
LUAD	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.11	-0.37	5.52e-15	Diabetic kidney disease;
LUAD	cis	rs870825	0.616	rs7682677	chr4:185640717	C/G	cg04058563	chr4:185651563	MLF1IP	0.88	14.17	0.57	1.49e-37	Blood protein levels;
LUAD	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.54	0.34	2.94e-13	Menopause (age at onset);
LUAD	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg10295955	chr4:187884368	NA	1.1	27.27	0.8	3.25e-95	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18404041	chr3:52824283	ITIH1	-0.6	-12.57	-0.52	5.16e-31	Electroencephalogram traits;
LUAD	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	8.37	0.38	8.64e-16	Tonsillectomy;
LUAD	trans	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg07211511	chr3:129823064	LOC729375	-0.9	-10.16	-0.44	7.6e-22	Blood pressure (smoking interaction);
LUAD	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg06640241	chr16:89574553	SPG7	0.68	11.85	0.5	3.6e-28	Multiple myeloma (IgH translocation);
LUAD	cis	rs6494488	0.500	rs72742993	chr15:65006023	G/C	cg08069370	chr15:64387884	SNX1	-0.76	-6.77	-0.31	4.23e-11	Coronary artery disease;
LUAD	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22968622	chr17:43663579	NA	0.94	16.68	0.63	2.3e-48	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9837602	0.938	rs9828079	chr3:99806645	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	9.32	0.41	6.39e-19	Breast cancer;
LUAD	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg18527919	chr2:24398170	C2orf84	0.4	6.63	0.31	1.05e-10	Asthma;
LUAD	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg11344533	chr11:111475393	SIK2	-0.36	-6.58	-0.3	1.42e-10	Primary sclerosing cholangitis;
LUAD	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg13334819	chr7:99746414	C7orf59	-0.64	-9.96	-0.44	4.07e-21	Coronary artery disease;
LUAD	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg26408565	chr15:76604113	ETFA	-0.44	-7.2	-0.33	2.69e-12	Blood metabolite levels;
LUAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg00280220	chr17:61926910	NA	0.37	7.03	0.32	8.08e-12	Prudent dietary pattern;
LUAD	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg07404485	chr7:94953653	PON1	-0.48	-6.72	-0.31	5.92e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.53	-0.3	1.94e-10	Prostate cancer;
LUAD	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg03526776	chr6:41159608	TREML2	0.33	6.94	0.32	1.49e-11	Alzheimer's disease (late onset);
LUAD	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg13770153	chr20:60521292	NA	-0.48	-8.08	-0.37	6.86e-15	Body mass index;
LUAD	cis	rs758324	0.773	rs10069521	chr5:131174215	A/G	cg06307176	chr5:131281290	NA	0.44	7.4	0.34	7.55e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg14345882	chr6:26364793	BTN3A2	0.7	7.1	0.33	5.18e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-20.22	-0.7	4.42e-64	Height;
LUAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-9.24	-0.41	1.2e-18	Alzheimer's disease;
LUAD	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg23029597	chr12:123009494	RSRC2	-0.52	-7.91	-0.36	2.2e-14	Body mass index;
LUAD	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs11651000	0.654	rs12451801	chr17:45820975	T/C	cg06532163	chr17:45867833	NA	0.46	7.35	0.34	1.04e-12	IgG glycosylation;
LUAD	trans	rs7395662	1.000	rs10838966	chr11:48589723	C/G	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.12e-12	HDL cholesterol;
LUAD	cis	rs7818345	0.967	rs11786847	chr8:19277200	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.32	7.09	0.33	5.69e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg21724239	chr8:58056113	NA	0.78	9.27	0.41	9.26e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs4474465	0.688	rs7940507	chr11:78284453	T/C	cg19901956	chr11:77921274	USP35	0.46	6.37	0.3	5.07e-10	Alzheimer's disease (survival time);
LUAD	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg25767906	chr1:53392781	SCP2	-0.42	-7.87	-0.36	2.96e-14	Monocyte count;
LUAD	cis	rs9560113	1.000	rs4771757	chr13:112176379	G/T	cg14154082	chr13:112174009	NA	0.37	6.85	0.32	2.54e-11	Menarche (age at onset);
LUAD	cis	rs524023	0.914	rs80841	chr11:64437490	T/C	cg19131476	chr11:64387923	NRXN2	-0.43	-8.46	-0.38	4.38e-16	Urate levels in obese individuals;
LUAD	cis	rs25645	0.771	rs11078936	chr17:38197914	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.68	13.65	0.55	1.99e-35	Myeloid white cell count;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00205436	chr2:132766767	NA	0.43	7.07	0.33	6.5e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6842047	1.000	rs9995366	chr4:187131384	T/C	cg23442198	chr4:187126114	CYP4V2	0.92	9.86	0.43	9.07e-21	Blood protein levels;
LUAD	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg06671706	chr8:8559999	CLDN23	0.65	11.27	0.48	5.94e-26	Obesity-related traits;
LUAD	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg05368731	chr17:41323189	NBR1	0.96	20.46	0.71	3.7e-65	Menopause (age at onset);
LUAD	cis	rs6987853	0.731	rs10958717	chr8:42351585	G/C	cg09913449	chr8:42400586	C8orf40	-0.38	-6.81	-0.31	3.31e-11	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs225245	1.000	rs225245	chr17:33946107	A/G	cg05299278	chr17:33885742	SLFN14	0.46	10.35	0.45	1.52e-22	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg20503657	chr10:835505	NA	0.93	14.08	0.56	3.38e-37	Eosinophil percentage of granulocytes;
LUAD	cis	rs68170813	0.559	rs76208112	chr7:106964222	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.21	-0.44	4.95e-22	Coronary artery disease;
LUAD	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.83	0.39	2.71e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs295140	0.605	rs1436164	chr2:201158411	C/T	cg23649088	chr2:200775458	C2orf69	-0.46	-7.88	-0.36	2.81e-14	QT interval;
LUAD	cis	rs870825	0.929	rs72689273	chr4:185592750	C/T	cg04058563	chr4:185651563	MLF1IP	0.75	10.06	0.44	1.73e-21	Blood protein levels;
LUAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg24813613	chr7:1882135	MAD1L1	-0.43	-6.91	-0.32	1.85e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.44	0.38	5.18e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs17253792	0.822	rs112739186	chr14:56065167	A/T	cg01858014	chr14:56050164	KTN1	-0.64	-6.38	-0.3	4.79e-10	Putamen volume;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg18222961	chr2:48009935	MSH6	-0.65	-6.57	-0.3	1.52e-10	Type 2 diabetes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03672602	chr19:19754555	GMIP	-0.41	-6.69	-0.31	7.26e-11	Height;
LUAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.18	0.54	1.83e-33	Prudent dietary pattern;
LUAD	trans	rs9914544	0.545	rs8078993	chr17:18797126	A/G	cg21372672	chr17:16614065	CCDC144A	-0.36	-6.46	-0.3	2.9e-10	Educational attainment (years of education);
LUAD	cis	rs9283706	0.594	rs7717020	chr5:66353322	A/C	cg11590213	chr5:66331682	MAST4	0.41	6.54	0.3	1.83e-10	Coronary artery disease;
LUAD	cis	rs7809950	0.678	rs2237661	chr7:106863123	T/C	cg23024343	chr7:107201750	COG5	-0.81	-12.96	-0.53	1.34e-32	Coronary artery disease;
LUAD	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg24558204	chr6:135376177	HBS1L	0.46	8.41	0.38	6.48e-16	Red blood cell count;
LUAD	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg10518543	chr12:38710700	ALG10B	0.41	6.37	0.3	5.02e-10	Bladder cancer;
LUAD	cis	rs12049351	0.774	rs754025	chr1:229637297	C/T	cg11742688	chr1:229674241	ABCB10	-0.42	-6.42	-0.3	3.7e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg23018236	chr17:30244563	NA	-0.68	-8.21	-0.37	2.64e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg07828340	chr4:882639	GAK	0.99	10.19	0.44	5.97e-22	Parkinson's disease;
LUAD	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg00376283	chr12:123451042	ABCB9	0.41	6.72	0.31	5.84e-11	Platelet count;
LUAD	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg08761264	chr16:28874980	SH2B1	-0.46	-6.81	-0.31	3.31e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9972944	0.756	rs12600343	chr17:63764721	G/A	cg07283582	chr17:63770753	CCDC46	-0.5	-11.2	-0.48	1.11e-25	Total body bone mineral density;
LUAD	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg09365446	chr1:150670422	GOLPH3L	0.66	12.34	0.51	4.22e-30	Tonsillectomy;
LUAD	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg15704280	chr7:45808275	SEPT13	0.64	8.17	0.37	3.52e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg06671706	chr8:8559999	CLDN23	0.67	11.76	0.5	8.43e-28	Obesity-related traits;
LUAD	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg27170947	chr2:26402098	FAM59B	0.83	11.56	0.49	4.58e-27	Gut microbiome composition (summer);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04297258	chr16:88772664	RNF166;CTU2	-0.46	-7.19	-0.33	3.05e-12	Height;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg07190450	chr5:154320539	MRPL22	-0.4	-6.67	-0.31	7.8e-11	Subcortical brain region volumes;
LUAD	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.97	-0.5	1.18e-28	Mean corpuscular volume;
LUAD	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg14396892	chr9:96623032	NA	-0.43	-8.33	-0.38	1.1e-15	DNA methylation (variation);
LUAD	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg21471580	chr8:22132874	PIWIL2	0.47	8.72	0.39	6.62e-17	Hypertriglyceridemia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08695724	chr9:95527179	BICD2	-0.39	-6.35	-0.3	5.57e-10	Cancer;
LUAD	trans	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg18402987	chr7:1209562	NA	0.78	9.48	0.42	1.89e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2066819	1.000	rs77853814	chr12:56687572	G/T	cg26714650	chr12:56694279	CS	-0.86	-7.23	-0.33	2.25e-12	Psoriasis vulgaris;
LUAD	cis	rs7680126	0.536	rs4525975	chr4:10037390	T/C	cg11266682	chr4:10021025	SLC2A9	0.54	7.5	0.34	3.72e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg01475377	chr6:109611718	NA	-0.49	-9.08	-0.4	4.26e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.67	-10.96	-0.47	9.06e-25	Primary sclerosing cholangitis;
LUAD	cis	rs6662572	0.806	rs12047498	chr1:45954632	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	6.36	0.3	5.09e-10	Blood protein levels;
LUAD	cis	rs11800820	0.615	rs7513288	chr1:246661679	A/G	cg16700716	chr1:246684329	NA	-0.39	-7.13	-0.33	4.24e-12	Obesity-related traits;
LUAD	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg18232548	chr7:50535776	DDC	-0.63	-11.38	-0.48	2.35e-26	Systemic sclerosis;
LUAD	cis	rs113835537	0.935	rs79496339	chr11:66467769	T/A	cg24851651	chr11:66362959	CCS	0.59	7.88	0.36	2.81e-14	Airway imaging phenotypes;
LUAD	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	6.8	0.31	3.53e-11	Cognitive test performance;
LUAD	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg11822812	chr5:140052017	DND1	0.38	6.73	0.31	5.42e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg00745463	chr17:30367425	LRRC37B	-0.87	-11.18	-0.48	1.35e-25	Hip circumference adjusted for BMI;
LUAD	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	8.74	0.39	5.55e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1950626	0.833	rs34463495	chr14:101411186	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.38	7.23	0.33	2.32e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs4478037	0.822	rs77355992	chr3:33107518	T/C	cg19404215	chr3:33155277	CRTAP	0.63	6.83	0.32	2.95e-11	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4072705	0.646	rs915032	chr9:127245682	G/C	cg14219918	chr9:127249562	NR5A1	0.28	6.4	0.3	4.17e-10	Menarche (age at onset);
LUAD	cis	rs10242455	0.571	rs45527841	chr7:99310965	C/T	cg18809830	chr7:99032528	PTCD1	-0.87	-7.56	-0.34	2.61e-13	Blood metabolite levels;
LUAD	cis	rs6087990	0.806	rs1474738	chr20:31380309	G/A	cg13636640	chr20:31349939	DNMT3B	0.78	13.78	0.56	5.87e-36	Ulcerative colitis;
LUAD	cis	rs4523957	0.614	rs7219693	chr17:2061101	C/A	cg16513277	chr17:2031491	SMG6	-0.96	-18.77	-0.67	1.3e-57	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3087591	0.960	rs9807077	chr17:29634457	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.57	-0.3	1.51e-10	Hip circumference;
LUAD	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg12573674	chr2:1569213	NA	-0.58	-6.53	-0.3	1.85e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg21051086	chr3:73046214	PPP4R2	-0.46	-7.56	-0.35	2.46e-13	Pancreatic cancer;
LUAD	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg10518543	chr12:38710700	ALG10B	0.41	6.38	0.3	4.54e-10	Bladder cancer;
LUAD	cis	rs1043515	0.748	rs11657530	chr17:36942814	T/C	cg20826740	chr17:37024042	NA	0.4	6.85	0.32	2.63e-11	Height;
LUAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg22907277	chr7:1156413	C7orf50	0.83	12.58	0.52	4.87e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs727505	1.000	rs68007199	chr7:124491307	T/C	cg23710748	chr7:124431027	NA	-0.49	-9.79	-0.43	1.5e-20	Lewy body disease;
LUAD	cis	rs6960043	0.738	rs2358159	chr7:15054908	T/C	cg19272540	chr7:15055459	NA	0.36	8.1	0.37	6.11e-15	Type 2 diabetes;
LUAD	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg25358565	chr5:93447407	FAM172A	0.54	6.82	0.31	3.12e-11	Diabetic retinopathy;
LUAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.78	14.68	0.58	9.91e-40	Lymphocyte counts;
LUAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06873352	chr17:61820015	STRADA	0.82	18.18	0.66	5.66e-55	Prudent dietary pattern;
LUAD	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg23954153	chr1:44402353	ARTN	-0.36	-6.72	-0.31	5.79e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6489882	0.836	rs10850099	chr12:113364504	A/G	cg20102336	chr12:113376681	OAS3	-0.6	-9.28	-0.41	8.88e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg06028808	chr11:68637592	NA	0.49	8.11	0.37	5.48e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.77	-0.35	6.02e-14	Monocyte count;
LUAD	cis	rs9341808	0.718	rs9448899	chr6:80845864	G/A	cg08355045	chr6:80787529	NA	0.55	9.94	0.44	4.45e-21	Sitting height ratio;
LUAD	cis	rs7107174	1.000	rs10899474	chr11:78043636	T/C	cg02023728	chr11:77925099	USP35	0.43	6.79	0.31	3.73e-11	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg08280861	chr8:58055591	NA	0.55	7.5	0.34	3.87e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7216064	0.601	rs35453056	chr17:66039668	A/G	cg08758996	chr17:66097529	LOC651250	-0.42	-7.09	-0.33	5.49e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg14416269	chr4:6271139	WFS1	0.65	13.3	0.54	5.61e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg07169764	chr2:136633963	MCM6	0.66	7.87	0.36	2.94e-14	Corneal structure;
LUAD	cis	rs77956314	0.818	rs12296869	chr12:117431203	G/A	cg02017074	chr12:117425053	FBXW8	-0.61	-6.88	-0.32	2.12e-11	Subcortical brain region volumes;Hippocampal volume;
LUAD	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg15181151	chr6:150070149	PCMT1	0.33	6.52	0.3	2e-10	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg05340658	chr4:99064831	C4orf37	0.53	9.07	0.4	4.46e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg14196790	chr5:131705035	SLC22A5	-0.46	-8.36	-0.38	9.09e-16	Breast cancer;Mosquito bite size;
LUAD	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg09491104	chr22:46646882	C22orf40	-0.74	-13.49	-0.55	9.93e-35	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.46	0.55	1.24e-34	Prudent dietary pattern;
LUAD	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.04	-0.32	7.86e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4243830	0.850	rs12760251	chr1:6601336	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.55	-7.01	-0.32	9.41e-12	Body mass index;
LUAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg13560548	chr3:10150139	C3orf24	0.42	6.82	0.31	3.14e-11	Alzheimer's disease;
LUAD	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.8	9.03	0.4	6.32e-18	Initial pursuit acceleration;
LUAD	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-13.92	-0.56	1.52e-36	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg08885076	chr2:99613938	TSGA10	0.4	7.55	0.34	2.79e-13	Chronic sinus infection;
LUAD	cis	rs12900413	0.687	rs28465116	chr15:90310152	T/C	cg24249390	chr15:90295951	MESP1	-0.34	-6.62	-0.31	1.08e-10	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs67397200	0.590	rs12327712	chr19:17424947	T/G	cg02221750	chr19:17393354	ANKLE1	-0.4	-6.9	-0.32	1.9e-11	Breast cancer;Breast Cancer in BRCA1 mutation carriers;Breast cancer (estrogen-receptor negative);
LUAD	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg06623918	chr6:96969491	KIAA0776	-0.83	-14.75	-0.58	4.92e-40	Headache;
LUAD	trans	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg21051086	chr3:73046214	PPP4R2	-0.45	-7.31	-0.33	1.34e-12	Pancreatic cancer;
LUAD	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg26818010	chr10:134567672	INPP5A	-0.52	-9.08	-0.4	4.3e-18	Migraine;
LUAD	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg12573674	chr2:1569213	NA	-0.55	-6.59	-0.31	1.27e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.48	-7.8	-0.35	4.92e-14	Alzheimer's disease (late onset);
LUAD	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg14668632	chr7:2872130	GNA12	-0.37	-6.5	-0.3	2.28e-10	Plateletcrit;
LUAD	trans	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg19862616	chr7:65841803	NCRNA00174	1.05	26.51	0.79	5.76e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs10489202	0.633	rs4657734	chr1:168086743	C/T	cg24449463	chr1:168025552	DCAF6	-0.61	-9.52	-0.42	1.37e-19	Schizophrenia;
LUAD	cis	rs7945718	0.967	rs12291695	chr11:12795662	A/G	cg25843174	chr11:12811716	TEAD1	-0.26	-7.77	-0.35	5.97e-14	Educational attainment (years of education);
LUAD	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.62	-0.31	1.12e-10	Joint mobility (Beighton score);
LUAD	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg22963979	chr7:1858916	MAD1L1	0.46	7.85	0.36	3.39e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.91	9.78	0.43	1.75e-20	Initial pursuit acceleration;
LUAD	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg00757033	chr12:89920650	WDR51B	0.7	12.2	0.51	1.47e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg24818145	chr4:99064322	C4orf37	0.39	6.53	0.3	1.89e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2286503	0.809	rs4719716	chr7:22861369	G/A	cg06496272	chr7:22895283	SNORD93	-0.41	-7.25	-0.33	1.99e-12	Fibrinogen;
LUAD	trans	rs701145	0.585	rs357473	chr3:153895147	C/T	cg14299572	chr10:34021103	NA	-0.39	-6.35	-0.3	5.49e-10	Coronary artery disease;
LUAD	cis	rs6076065	0.723	rs7988	chr20:23352685	C/A	cg11657817	chr20:23433608	CST11	0.47	8.98	0.4	8.7e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg04155793	chr16:89752847	CDK10	0.31	6.68	0.31	7.5e-11	Hemoglobin concentration;
LUAD	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.63	-0.35	1.54e-13	Blood metabolite levels;
LUAD	trans	rs3942852	0.712	rs2174129	chr11:48108557	A/C	cg15704280	chr7:45808275	SEPT13	-0.61	-9.24	-0.41	1.17e-18	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg08885076	chr2:99613938	TSGA10	0.39	7.3	0.33	1.48e-12	Chronic sinus infection;
LUAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.61	-0.42	6.39e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg13012494	chr21:47604986	C21orf56	-0.43	-7.15	-0.33	3.8e-12	Testicular germ cell tumor;
LUAD	trans	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg09872104	chr7:134855509	C7orf49	-0.87	-7.54	-0.34	2.84e-13	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs2406342	0.511	rs472676	chr18:74607924	C/T	cg16472389	chr18:74514291	NA	0.51	8.75	0.39	5.19e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LUAD	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg02782426	chr3:40428986	ENTPD3	0.41	8.85	0.4	2.4e-17	Renal cell carcinoma;
LUAD	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23158103	chr7:148848205	ZNF398	-0.61	-11.08	-0.47	3.23e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs750460	0.966	rs4243042	chr15:74241624	A/T	cg01349856	chr15:74220517	LOXL1	0.4	6.77	0.31	4.45e-11	Height;
LUAD	cis	rs2004318	1.000	rs77568158	chr19:55078544	A/G	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.93e-13	Blood protein levels;
LUAD	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg03874509	chr1:107600012	PRMT6	0.5	8.74	0.39	5.37e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg15704280	chr7:45808275	SEPT13	0.69	9.7	0.43	3.24e-20	Coronary artery disease;
LUAD	trans	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-16.69	-0.63	2.01e-48	Colorectal cancer;
LUAD	cis	rs11771526	0.901	rs62457467	chr7:32301101	T/A	cg27532318	chr7:32358331	NA	0.56	7.21	0.33	2.54e-12	Body mass index;
LUAD	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7258465	1.000	rs3810429	chr19:18543270	G/T	cg01065977	chr19:18549689	ISYNA1	-0.39	-7.55	-0.34	2.74e-13	Breast cancer;
LUAD	cis	rs3125734	0.607	rs7923556	chr10:64024648	A/G	cg19640130	chr10:64028056	RTKN2	-0.36	-7.72	-0.35	8.63e-14	Rheumatoid arthritis;
LUAD	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg02733842	chr7:1102375	C7orf50	-0.57	-8.81	-0.39	3.34e-17	Bronchopulmonary dysplasia;
LUAD	cis	rs8060686	0.516	rs7187202	chr16:68273895	T/C	cg26727032	chr16:67993705	SLC12A4	-0.48	-7.9	-0.36	2.37e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3087591	1.000	rs6505234	chr17:29688299	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.42	-6.77	-0.31	4.43e-11	Hip circumference;
LUAD	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg15790184	chr11:494944	RNH1	0.4	6.56	0.3	1.6e-10	Systemic lupus erythematosus;
LUAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.38	6.57	0.3	1.47e-10	Renal function-related traits (BUN);
LUAD	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg08508325	chr11:3079039	CARS	0.51	10.76	0.46	5.16e-24	Longevity;
LUAD	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.55	0.3	1.71e-10	Lung cancer in ever smokers;
LUAD	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg02782426	chr3:40428986	ENTPD3	0.43	9.06	0.4	4.82e-18	Renal cell carcinoma;
LUAD	cis	rs7975161	0.638	rs4592489	chr12:104619699	C/T	cg25273343	chr12:104657179	TXNRD1	-0.55	-8.23	-0.37	2.31e-15	Toenail selenium levels;
LUAD	cis	rs7731657	0.537	rs4705976	chr5:130286160	T/C	cg08523029	chr5:130500466	HINT1	0.57	7.38	0.34	8.5e-13	Fasting plasma glucose;
LUAD	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg18351406	chr4:77819688	ANKRD56	0.61	9.86	0.43	9.14e-21	Emphysema distribution in smoking;
LUAD	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.59	-10.94	-0.47	1.11e-24	Hip circumference adjusted for BMI;
LUAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.82	-18.19	-0.66	4.82e-55	Longevity;Endometriosis;
LUAD	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11644478	chr21:40555479	PSMG1	-0.56	-9.27	-0.41	9.49e-19	Cognitive function;
LUAD	cis	rs977987	0.806	rs1030262	chr16:75491327	C/A	cg03315344	chr16:75512273	CHST6	0.65	14.46	0.58	8.94e-39	Dupuytren's disease;
LUAD	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg08677398	chr8:58056175	NA	0.48	6.59	0.31	1.32e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs11098699	0.821	rs1562063	chr4:124204110	G/A	cg09941581	chr4:124220074	SPATA5	0.49	8.02	0.36	1.05e-14	Mosquito bite size;
LUAD	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg00666640	chr1:248458726	OR2T12	0.3	7.24	0.33	2.14e-12	Common traits (Other);
LUAD	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg21153622	chr11:89784906	NA	-0.34	-6.64	-0.31	9.5e-11	Coronary artery disease;
LUAD	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.96	0.76	9e-81	Chronic sinus infection;
LUAD	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg11317459	chr13:21872234	NA	-0.98	-13.39	-0.55	2.43e-34	White matter hyperintensity burden;
LUAD	cis	rs250677	1.000	rs36079	chr5:148430504	G/A	cg18129178	chr5:148520854	ABLIM3	-0.57	-9.09	-0.4	3.75e-18	Breast cancer;
LUAD	cis	rs295140	0.605	rs295149	chr2:201175244	A/G	cg23649088	chr2:200775458	C2orf69	-0.48	-8.34	-0.38	1.09e-15	QT interval;
LUAD	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg05535760	chr7:792225	HEATR2	1.01	12.33	0.51	4.65e-30	Cerebrospinal P-tau181p levels;
LUAD	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg14634687	chr17:47094252	IGF2BP1	0.27	6.76	0.31	4.65e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs2235649	0.789	rs4567715	chr16:1849363	G/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-6.72	-0.31	6.01e-11	Blood metabolite levels;
LUAD	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg13390004	chr1:15929781	NA	0.44	7.92	0.36	2.14e-14	Systolic blood pressure;
LUAD	cis	rs11771526	0.901	rs11760534	chr7:32262966	C/T	cg27511599	chr7:32358540	NA	0.53	6.61	0.31	1.18e-10	Body mass index;
LUAD	cis	rs1232027	0.700	rs1650717	chr5:79930579	A/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.83	-0.36	3.9e-14	Huntington's disease progression;
LUAD	cis	rs2835872	0.758	rs1787396	chr21:39036487	A/C	cg06728970	chr21:39037746	KCNJ6	0.4	7.69	0.35	1.05e-13	Electroencephalographic traits in alcoholism;
LUAD	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14240646	chr10:27532245	ACBD5	0.77	11.69	0.49	1.5e-27	Breast cancer;
LUAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg08132940	chr7:1081526	C7orf50	-0.79	-10.66	-0.46	1.14e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs11039798	0.588	rs589834	chr11:48419382	C/G	cg15704280	chr7:45808275	SEPT13	-0.58	-7.79	-0.35	5.12e-14	Axial length;
LUAD	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg20790798	chr5:1857306	NA	-0.44	-7.4	-0.34	7.61e-13	Cardiovascular disease risk factors;
LUAD	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg08514558	chr10:81106712	PPIF	0.47	9.39	0.42	3.86e-19	Height;
LUAD	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg04287289	chr16:89883240	FANCA	0.78	6.98	0.32	1.15e-11	Skin colour saturation;
LUAD	cis	rs7116495	1.000	rs482013	chr11:71803962	G/A	cg07596299	chr11:71824057	C11orf51	-0.77	-6.69	-0.31	7.28e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg20991723	chr1:152506922	NA	0.33	6.43	0.3	3.36e-10	Hair morphology;
LUAD	cis	rs7677751	0.806	rs7682912	chr4:55085620	T/G	cg17187183	chr4:55093834	PDGFRA	0.5	8.23	0.37	2.35e-15	Corneal astigmatism;
LUAD	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22496380	chr5:211416	CCDC127	-0.95	-13.3	-0.54	5.54e-34	Breast cancer;
LUAD	cis	rs757110	0.690	rs35271178	chr11:17411020	C/T	cg04705435	chr11:17411270	KCNJ11	0.53	9.59	0.42	7.88e-20	Type 2 diabetes;
LUAD	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg00074818	chr8:8560427	CLDN23	0.63	9.77	0.43	1.83e-20	Obesity-related traits;
LUAD	cis	rs868036	1.000	rs4776974	chr15:68095927	G/A	cg08079166	chr15:68083412	MAP2K5	0.3	6.43	0.3	3.36e-10	Restless legs syndrome;
LUAD	trans	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg03929089	chr4:120376271	NA	-0.49	-6.38	-0.3	4.53e-10	Axial length;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg18080670	chr7:5569112	ACTB	-0.66	-6.73	-0.31	5.46e-11	Type 2 diabetes;
LUAD	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.38	6.85	0.32	2.59e-11	Systemic lupus erythematosus;
LUAD	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.39	-0.38	7.48e-16	Menopause (age at onset);
LUAD	trans	rs4650994	0.507	rs56229230	chr1:178526563	G/A	cg05059571	chr16:84539110	KIAA1609	-0.73	-13.03	-0.54	7.01e-33	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs36051895	0.695	rs62541532	chr9:5017384	C/A	cg02405213	chr9:5042618	JAK2	-0.48	-6.38	-0.3	4.56e-10	Pediatric autoimmune diseases;
LUAD	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg15017067	chr4:17643749	FAM184B	0.34	6.38	0.3	4.61e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg02508848	chr16:68573721	ZFP90	-0.42	-6.5	-0.3	2.22e-10	Ulcerative colitis;
LUAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg24846343	chr22:24311635	DDTL	0.83	19.67	0.69	1.24e-61	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg00277334	chr10:82204260	NA	-0.49	-8.03	-0.36	9.49e-15	Post bronchodilator FEV1;
LUAD	cis	rs11229555	0.874	rs12800710	chr11:58314540	C/T	cg15696309	chr11:58395628	NA	-0.73	-10.45	-0.45	6.76e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs240764	0.853	rs11155498	chr6:101019551	G/C	cg09795085	chr6:101329169	ASCC3	-0.42	-7.11	-0.33	5.12e-12	Neuroticism;
LUAD	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg06618935	chr21:46677482	NA	-0.51	-10.29	-0.45	2.62e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg13334819	chr7:99746414	C7orf59	0.64	9.83	0.43	1.14e-20	Coronary artery disease;
LUAD	cis	rs9581857	0.579	rs2780341	chr13:27996401	C/T	cg22138327	chr13:27999177	GTF3A	-0.97	-11.83	-0.5	4.18e-28	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs13315871	1.000	rs11719957	chr3:58415031	A/G	cg20936604	chr3:58311152	NA	-0.69	-6.92	-0.32	1.68e-11	Cholesterol, total;
LUAD	trans	rs7395662	0.890	rs11039806	chr11:48547716	T/A	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.1e-12	HDL cholesterol;
LUAD	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg11494091	chr17:61959527	GH2	0.45	8.58	0.39	1.76e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.49	0.38	3.47e-16	Menopause (age at onset);
LUAD	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.71	-0.35	9.39e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg02569458	chr12:86230093	RASSF9	0.41	7.6	0.35	1.94e-13	Major depressive disorder;
LUAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.25	-0.37	2.05e-15	Alzheimer's disease;
LUAD	trans	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg14917512	chr19:3094685	GNA11	-0.38	-6.61	-0.31	1.18e-10	Aortic root size;
LUAD	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg12311346	chr5:56204834	C5orf35	-0.59	-9.07	-0.4	4.47e-18	Type 2 diabetes;
LUAD	cis	rs11122272	0.615	rs1465740	chr1:231495255	T/A	cg06096015	chr1:231504339	EGLN1	0.34	6.41	0.3	3.83e-10	Hemoglobin concentration;
LUAD	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg04369109	chr6:150039330	LATS1	-0.4	-6.51	-0.3	2.17e-10	Lung cancer;
LUAD	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg13126279	chr21:47581558	C21orf56	-0.42	-7.34	-0.34	1.1e-12	Testicular germ cell tumor;
LUAD	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg00310523	chr12:86230176	RASSF9	0.39	8.11	0.37	5.69e-15	Major depressive disorder;
LUAD	cis	rs12618769	0.652	rs6736755	chr2:99204428	A/G	cg10123293	chr2:99228465	UNC50	-0.47	-8.51	-0.38	2.98e-16	Bipolar disorder;
LUAD	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.36	-7.66	-0.35	1.29e-13	Hemoglobin concentration;
LUAD	trans	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.21	-31.3	-0.84	3.6e-112	Exhaled nitric oxide output;
LUAD	trans	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-9.59	-0.42	7.81e-20	Brugada syndrome;
LUAD	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg07432352	chr17:45403706	C17orf57	-0.41	-7.92	-0.36	2.09e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10899021	0.920	rs11236181	chr11:74345823	A/C	cg25880958	chr11:74394337	NA	-0.55	-7.39	-0.34	7.89e-13	Response to metformin (IC50);
LUAD	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg22676075	chr6:135203613	NA	0.4	7.29	0.33	1.57e-12	Red blood cell count;
LUAD	cis	rs11651000	0.761	rs11657388	chr17:45820707	C/G	cg06532163	chr17:45867833	NA	0.45	7.32	0.34	1.25e-12	IgG glycosylation;
LUAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg22907277	chr7:1156413	C7orf50	0.56	7.13	0.33	4.37e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg05590025	chr7:65112418	INTS4L2	0.59	6.75	0.31	4.87e-11	Diabetic kidney disease;
LUAD	trans	rs1493916	1.000	rs1493916	chr18:31392577	T/G	cg15819921	chr19:927150	ARID3A	-0.44	-7.21	-0.33	2.59e-12	Life satisfaction;
LUAD	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg17480646	chr11:65405466	SIPA1	-0.45	-6.66	-0.31	8.45e-11	Acne (severe);
LUAD	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg10356904	chr22:49881777	NA	-0.4	-8.58	-0.39	1.79e-16	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg02527881	chr3:46936655	PTH1R	-0.57	-11.8	-0.5	5.54e-28	Colorectal cancer;
LUAD	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.46	6.77	0.31	4.3e-11	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg22117172	chr7:91764530	CYP51A1	0.34	7.66	0.35	1.25e-13	Breast cancer;
LUAD	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg26597838	chr10:835615	NA	1.31	20.55	0.71	1.41e-65	Eosinophil percentage of granulocytes;
LUAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg02951883	chr7:2050386	MAD1L1	-0.97	-18.67	-0.67	3.53e-57	Bipolar disorder and schizophrenia;
LUAD	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.89e-14	Depression;
LUAD	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg22920501	chr2:26401640	FAM59B	0.95	13.69	0.55	1.42e-35	Gut microbiome composition (summer);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg16841327	chr22:46466183	NA	-0.41	-6.79	-0.31	3.84e-11	Schizophrenia;
LUAD	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg10556349	chr10:835070	NA	0.59	7.28	0.33	1.61e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs864745	0.653	rs1635853	chr7:28189549	A/C	cg22892036	chr7:28189139	JAZF1	0.43	7.36	0.34	9.71e-13	Crohn's disease;Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg03929089	chr4:120376271	NA	-0.56	-8.37	-0.38	8.35e-16	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg02683114	chr2:24398427	C2orf84	-0.4	-6.38	-0.3	4.52e-10	Asthma;
LUAD	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.06e-11	Depression;
LUAD	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg24818145	chr4:99064322	C4orf37	0.42	7.02	0.32	8.66e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg09060608	chr5:178986726	RUFY1	0.66	9.9	0.43	6.42e-21	Lung cancer;
LUAD	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg08798685	chr6:27730294	NA	-0.65	-7.02	-0.32	8.89e-12	Breast cancer;
LUAD	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg26528668	chr16:1614120	IFT140	0.57	10.36	0.45	1.48e-22	Coronary artery disease;
LUAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07157834	chr1:205819609	PM20D1	0.72	14.03	0.56	5.47e-37	Menarche (age at onset);
LUAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg02869364	chr7:1081709	C7orf50	-0.51	-6.58	-0.3	1.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg13319975	chr6:146136371	FBXO30	-0.65	-11.09	-0.47	2.85e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17152411	1.000	rs7083298	chr10:126590691	T/C	cg07906193	chr10:126599966	NA	0.53	7.6	0.35	1.95e-13	Height;
LUAD	cis	rs977987	0.843	rs10431974	chr16:75435461	A/G	cg03315344	chr16:75512273	CHST6	0.64	13.97	0.56	1.01e-36	Dupuytren's disease;
LUAD	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22857025	chr5:266934	NA	-0.97	-14.67	-0.58	1.11e-39	Breast cancer;
LUAD	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	9.41	0.42	3.31e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg06221963	chr1:154839813	KCNN3	-0.86	-19.45	-0.69	1.12e-60	Prostate cancer;
LUAD	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg20701182	chr2:24300061	SF3B14	0.53	6.49	0.3	2.44e-10	Lymphocyte counts;
LUAD	cis	rs4790333	0.653	rs2447103	chr17:2262997	A/C	cg02569219	chr17:2266849	SGSM2	0.63	12.09	0.51	4.23e-29	Proinsulin levels;
LUAD	cis	rs59698941	0.882	rs12514947	chr5:132311567	G/T	cg14825688	chr5:132208181	LEAP2	-0.48	-6.51	-0.3	2.09e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.91	-0.32	1.84e-11	Diabetic kidney disease;
LUAD	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.33e-13	Tonsillectomy;
LUAD	cis	rs11126435	0.858	rs9636446	chr2:74933320	G/A	cg19285774	chr2:74907978	SEMA4F	0.37	6.41	0.3	3.79e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs13082711	0.911	rs6789539	chr3:27444076	T/A	cg02860705	chr3:27208620	NA	0.56	8.79	0.39	3.66e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg10729496	chr3:10149963	C3orf24	0.57	9.45	0.42	2.37e-19	Alzheimer's disease;
LUAD	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg26408565	chr15:76604113	ETFA	-0.47	-7.9	-0.36	2.37e-14	Blood metabolite levels;
LUAD	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg04450456	chr4:17643702	FAM184B	0.39	7.41	0.34	6.99e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg24644049	chr4:85504048	CDS1	0.85	7.17	0.33	3.38e-12	Skin colour saturation;
LUAD	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg13770153	chr20:60521292	NA	-0.46	-7.78	-0.35	5.77e-14	Body mass index;
LUAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00149659	chr3:10157352	C3orf10	0.57	7.98	0.36	1.34e-14	Alzheimer's disease;
LUAD	trans	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg05926928	chr17:57297772	GDPD1	-0.63	-8.47	-0.38	4.09e-16	Opioid sensitivity;
LUAD	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg18129178	chr5:148520854	ABLIM3	-0.7	-10.04	-0.44	2.09e-21	Breast cancer;
LUAD	cis	rs8044868	0.548	rs3852784	chr16:72185001	G/A	cg23815491	chr16:72088622	HP	0.47	8.7	0.39	7.5e-17	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg09033563	chr22:24373618	LOC391322	-0.68	-11.3	-0.48	4.77e-26	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg16989719	chr2:238392110	NA	-0.31	-6.75	-0.31	4.87e-11	Prostate cancer;
LUAD	cis	rs2637266	0.745	rs2579732	chr10:78442778	T/C	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.76e-11	Pulmonary function;
LUAD	cis	rs10392	0.543	rs56660421	chr20:37559329	G/T	cg27552599	chr20:37590471	DHX35	0.42	7.05	0.32	7.5e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg11901034	chr3:128598214	ACAD9	-0.5	-7.61	-0.35	1.85e-13	IgG glycosylation;
LUAD	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.77	-0.35	5.97e-14	Prostate cancer;
LUAD	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg13732083	chr21:47605072	C21orf56	0.45	7.44	0.34	5.8e-13	Testicular germ cell tumor;
LUAD	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg07169764	chr2:136633963	MCM6	0.84	10.1	0.44	1.25e-21	Corneal structure;
LUAD	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg22676075	chr6:135203613	NA	-0.36	-6.68	-0.31	7.36e-11	Red blood cell count;
LUAD	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg11494091	chr17:61959527	GH2	0.45	8.58	0.39	1.76e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg18932078	chr1:2524107	MMEL1	0.36	6.59	0.31	1.32e-10	Ulcerative colitis;
LUAD	cis	rs7737355	1.000	rs12521320	chr5:130755920	A/G	cg25547332	chr5:131281432	NA	-0.43	-6.46	-0.3	2.88e-10	Life satisfaction;
LUAD	cis	rs35150201	0.529	rs7806221	chr7:135318779	T/C	cg23117316	chr7:135346802	PL-5283	-0.39	-7.99	-0.36	1.34e-14	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
LUAD	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg10518543	chr12:38710700	ALG10B	-0.43	-7.06	-0.32	6.84e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg18198730	chr1:247681584	NA	0.44	7.62	0.35	1.71e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg18827107	chr12:86230957	RASSF9	0.54	9.74	0.43	2.24e-20	Major depressive disorder;
LUAD	cis	rs7932354	0.528	rs1965952	chr11:47181040	G/A	cg19486271	chr11:47235900	DDB2	0.44	6.99	0.32	1.06e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08280861	chr8:58055591	NA	0.67	8.78	0.39	4.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg00933542	chr6:150070202	PCMT1	0.46	9.36	0.41	4.83e-19	Lung cancer;
LUAD	cis	rs7127129	0.503	rs1131715	chr11:70053487	C/T	cg06159181	chr11:70072977	NA	-0.45	-9.03	-0.4	6.14e-18	Aortic root size;
LUAD	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg24531977	chr5:56204891	C5orf35	-0.6	-9.32	-0.41	6.74e-19	Type 2 diabetes;
LUAD	cis	rs9443645	0.527	rs949846	chr6:79817596	C/T	cg09184832	chr6:79620586	NA	-0.4	-6.66	-0.31	8.28e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7771547	0.547	rs1076931	chr6:36562021	G/C	cg04289385	chr6:36355825	ETV7	0.48	6.43	0.3	3.55e-10	Platelet distribution width;
LUAD	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg19717773	chr7:2847554	GNA12	-0.49	-8.25	-0.37	2e-15	Height;
LUAD	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg03474202	chr17:45855739	NA	-0.38	-9.01	-0.4	7e-18	IgG glycosylation;
LUAD	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg08726005	chr2:223726022	ACSL3	-0.36	-6.53	-0.3	1.87e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06873352	chr17:61820015	STRADA	0.52	8.63	0.39	1.24e-16	Height;
LUAD	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg04287289	chr16:89883240	FANCA	0.71	6.66	0.31	8.69e-11	Skin colour saturation;
LUAD	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg04731861	chr2:219085781	ARPC2	-0.23	-6.89	-0.32	2.01e-11	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13012494	chr21:47604986	C21orf56	0.66	11.71	0.49	1.25e-27	Testicular germ cell tumor;
LUAD	cis	rs1215050	0.765	rs588851	chr4:98678247	C/T	cg24818145	chr4:99064322	C4orf37	0.41	6.77	0.31	4.2e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg03806693	chr22:41940476	POLR3H	-0.56	-8.38	-0.38	8e-16	Vitiligo;
LUAD	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg19193384	chr17:30244184	NA	-0.51	-6.44	-0.3	3.32e-10	Hip circumference adjusted for BMI;
LUAD	trans	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg27411982	chr8:10470053	RP1L1	0.43	7.74	0.35	7.59e-14	Mood instability;
LUAD	cis	rs748404	0.578	rs510108	chr15:43605439	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.23	0.33	2.33e-12	Lung cancer;
LUAD	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg20129853	chr10:51489980	NA	0.34	6.86	0.32	2.4e-11	Prostate-specific antigen levels;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg15966315	chr17:77751636	CBX2	-0.44	-7.06	-0.32	6.77e-12	Vertical cup-disc ratio;
LUAD	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg23625390	chr15:77176239	SCAPER	-0.51	-7.84	-0.36	3.79e-14	Blood metabolite levels;
LUAD	cis	rs6076065	0.723	rs743022	chr20:23401129	G/C	cg11657817	chr20:23433608	CST11	0.47	8.76	0.39	4.72e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs447921	0.861	rs12951513	chr17:74455069	C/T	cg17201438	chr17:74438067	UBE2O	0.68	8.59	0.39	1.66e-16	Mitochondrial DNA levels;
LUAD	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.904	rs4528633	chr17:28356136	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.6	-0.46	1.89e-23	Coffee consumption (cups per day);
LUAD	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg18477163	chr1:228402036	OBSCN	0.41	8.22	0.37	2.53e-15	Diastolic blood pressure;
LUAD	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg20607287	chr7:12443886	VWDE	-0.54	-6.83	-0.32	2.97e-11	Coronary artery disease;
LUAD	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	trans	rs783540	0.900	rs783525	chr15:83284629	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.44	-7.25	-0.33	2e-12	Schizophrenia;
LUAD	cis	rs7771547	0.574	rs9394361	chr6:36551370	A/C	cg12173498	chr6:36355764	ETV7	0.47	6.38	0.3	4.78e-10	Platelet distribution width;
LUAD	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg02782426	chr3:40428986	ENTPD3	0.35	7.43	0.34	6.15e-13	Renal cell carcinoma;
LUAD	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg23649088	chr2:200775458	C2orf69	0.6	8.72	0.39	6.2e-17	Schizophrenia;
LUAD	trans	rs3960554	0.932	rs76873475	chr7:75829199	C/A	cg19862616	chr7:65841803	NCRNA00174	0.83	11.19	0.48	1.26e-25	Eotaxin levels;
LUAD	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg21017887	chr14:105400489	NA	0.75	14.36	0.57	2.19e-38	Rheumatoid arthritis;
LUAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg18402987	chr7:1209562	NA	0.78	9.55	0.42	1.04e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03647317	chr4:187891568	NA	-0.39	-7.33	-0.34	1.17e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs62229266	0.609	rs12482541	chr21:37419743	A/G	cg12218747	chr21:37451666	NA	-0.43	-7.39	-0.34	7.79e-13	Mitral valve prolapse;
LUAD	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.12	0.33	4.7e-12	Motion sickness;
LUAD	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg23260525	chr10:116636907	FAM160B1	0.47	11.0	0.47	6.26e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg07234876	chr8:600039	NA	1.06	10.29	0.45	2.65e-22	IgG glycosylation;
LUAD	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg11707310	chr1:2537719	MMEL1	0.4	8.42	0.38	6e-16	Ulcerative colitis;
LUAD	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg27068330	chr11:65405492	SIPA1	-0.79	-12.89	-0.53	2.64e-32	Acne (severe);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26912688	chr1:176176562	RFWD2	-0.45	-6.97	-0.32	1.21e-11	Height;
LUAD	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg08847533	chr14:75593920	NEK9	0.39	6.68	0.31	7.41e-11	Height;
LUAD	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.41	6.96	0.32	1.3e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.93	0.76	1.24e-80	Chronic sinus infection;
LUAD	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg26924012	chr15:45694286	SPATA5L1	0.86	14.7	0.58	8.06e-40	Homoarginine levels;
LUAD	cis	rs734999	0.967	rs6671426	chr1:2504234	C/A	cg18854424	chr1:2615690	NA	0.34	8.01	0.36	1.12e-14	Ulcerative colitis;
LUAD	cis	rs8099014	0.559	rs9319928	chr18:56099996	T/G	cg12907477	chr18:56117327	MIR122	0.49	7.04	0.32	7.81e-12	Platelet count;
LUAD	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23583168	chr7:148888333	NA	-0.93	-19.18	-0.68	1.85e-59	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs938554	1.000	rs938552	chr4:9925524	T/C	cg11266682	chr4:10021025	SLC2A9	0.43	7.52	0.34	3.25e-13	Blood metabolite levels;
LUAD	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg18230493	chr5:56204884	C5orf35	-0.85	-12.54	-0.52	6.65e-31	Initial pursuit acceleration;
LUAD	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg05890377	chr2:74357713	NA	0.8	11.32	0.48	3.83e-26	Gestational age at birth (maternal effect);
LUAD	cis	rs7805747	0.961	rs10224002	chr7:151415041	C/T	cg17611936	chr7:151411526	PRKAG2	-0.49	-7.17	-0.33	3.34e-12	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LUAD	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	cg06064525	chr11:970664	AP2A2	-0.45	-8.75	-0.39	5.01e-17	Alzheimer's disease (late onset);
LUAD	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg15900387	chr1:150738905	CTSS	-0.37	-6.8	-0.31	3.48e-11	Melanoma;
LUAD	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg06618935	chr21:46677482	NA	-0.5	-10.04	-0.44	2.07e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.82	0.31	3.12e-11	Depression;
LUAD	cis	rs11048434	0.723	rs2080116	chr12:9138183	A/G	cg04155231	chr12:9217510	LOC144571	0.41	7.69	0.35	1.01e-13	Sjögren's syndrome;
LUAD	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg22875332	chr1:76189707	ACADM	0.81	14.83	0.58	2.38e-40	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg27366882	chr3:133540807	NA	-0.43	-7.79	-0.35	5.17e-14	Alcohol consumption (transferrin glycosylation);
LUAD	trans	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.7	-9.62	-0.42	5.94e-20	Obesity-related traits;
LUAD	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg19761014	chr17:28927070	LRRC37B2	0.69	6.75	0.31	4.76e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.74	0.31	5.29e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg17410650	chr12:54324560	NA	-0.55	-11.04	-0.47	4.59e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.8	-0.39	3.47e-17	Alzheimer's disease (late onset);
LUAD	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg22508957	chr16:3507546	NAT15	0.76	13.32	0.54	4.68e-34	Tuberculosis;
LUAD	cis	rs9394841	0.667	rs9394831	chr6:41753084	C/T	cg25600774	chr6:41776562	USP49	-0.44	-6.7	-0.31	6.63e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg25208724	chr1:156163844	SLC25A44	1.11	24.67	0.77	6.52e-84	Testicular germ cell tumor;
LUAD	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	6.47	0.3	2.73e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.26	-0.54	8.48e-34	Chronic sinus infection;
LUAD	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs1160297	0.539	rs7559124	chr2:53134517	C/G	cg07782112	chr2:53107842	NA	-0.36	-7.56	-0.35	2.46e-13	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.98	0.32	1.12e-11	Colorectal cancer;
LUAD	cis	rs11948739	0.576	rs11242051	chr5:130261276	G/A	cg08523029	chr5:130500466	HINT1	0.58	7.44	0.34	5.79e-13	Pediatric bone mineral content (hip);
LUAD	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg12756686	chr19:29218302	NA	0.71	9.1	0.4	3.64e-18	Methadone dose in opioid dependence;
LUAD	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10802521	chr3:52805072	NEK4	-0.54	-9.15	-0.41	2.5e-18	Bipolar disorder;
LUAD	cis	rs1595825	0.891	rs111340803	chr2:198612877	A/G	cg11031976	chr2:198649780	BOLL	-0.48	-7.17	-0.33	3.34e-12	Ulcerative colitis;
LUAD	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg04369109	chr6:150039330	LATS1	-0.44	-7.44	-0.34	5.68e-13	Lung cancer;
LUAD	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7607369	0.536	rs12990447	chr2:219667413	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-10.19	-0.44	5.96e-22	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14169450	chr9:139327907	INPP5E	-0.46	-8.69	-0.39	7.99e-17	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg02896835	chr1:92012615	NA	-0.58	-12.05	-0.51	6.16e-29	Breast cancer;
LUAD	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg15691649	chr6:25882328	NA	-0.46	-7.17	-0.33	3.28e-12	Blood metabolite levels;
LUAD	trans	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg06606381	chr12:133084897	FBRSL1	-0.68	-7.24	-0.33	2.17e-12	Breast cancer;
LUAD	cis	rs1950626	0.833	rs35436326	chr14:101396148	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.38	7.21	0.33	2.55e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg18230493	chr5:56204884	C5orf35	-0.69	-10.93	-0.47	1.14e-24	Initial pursuit acceleration;
LUAD	cis	rs12478296	0.748	rs10185596	chr2:243001029	C/A	cg06360820	chr2:242988706	NA	-0.68	-9.0	-0.4	7.61e-18	Obesity-related traits;
LUAD	cis	rs10207060	0.500	rs4380264	chr2:240699378	G/T	cg07506560	chr2:240697449	NA	0.41	6.81	0.31	3.37e-11	Obesity-related traits;
LUAD	cis	rs877282	1.000	rs112522746	chr10:772288	T/C	cg06581033	chr10:766294	NA	-0.48	-6.77	-0.31	4.2e-11	Uric acid levels;
LUAD	cis	rs9473147	0.543	rs1004173	chr6:47445017	C/T	cg02130027	chr6:47444894	CD2AP	0.38	7.06	0.32	6.86e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg13511324	chr14:104056883	C14orf153	0.27	6.59	0.31	1.32e-10	Reticulocyte count;
LUAD	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs7267979	0.816	rs390123	chr20:25480105	C/G	cg08601574	chr20:25228251	PYGB	0.41	7.72	0.35	8.52e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4604732	0.631	rs12039642	chr1:247624898	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.11	0.33	4.98e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg26384229	chr12:38710491	ALG10B	0.41	7.04	0.32	7.96e-12	Morning vs. evening chronotype;
LUAD	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01154537	chr10:95462167	C10orf4	-0.39	-6.77	-0.31	4.25e-11	Cancer;
LUAD	cis	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg27411982	chr8:10470053	RP1L1	0.46	8.28	0.37	1.63e-15	Neuroticism;
LUAD	cis	rs11048434	0.698	rs1805745	chr12:9065226	A/T	cg13575925	chr12:9217583	LOC144571	0.36	6.64	0.31	9.47e-11	Sjögren's syndrome;
LUAD	cis	rs1387259	0.931	rs1107654	chr12:48681097	T/G	cg04545296	chr12:48745243	ZNF641	0.4	10.06	0.44	1.78e-21	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs897984	0.542	rs7197717	chr16:31083075	A/C	cg02466173	chr16:30829666	NA	-0.55	-9.51	-0.42	1.51e-19	Dementia with Lewy bodies;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20707008	chr6:160210612	MRPL18;TCP1	-0.47	-7.27	-0.33	1.78e-12	Height;
LUAD	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.61	9.5	0.42	1.54e-19	Colorectal cancer;
LUAD	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg00933542	chr6:150070202	PCMT1	0.4	8.25	0.37	2.07e-15	Lung cancer;
LUAD	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg18827107	chr12:86230957	RASSF9	-0.7	-12.95	-0.53	1.49e-32	Major depressive disorder;
LUAD	cis	rs17253792	0.822	rs113350960	chr14:56087713	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs9522267	0.535	rs6492373	chr13:112238627	T/C	cg10483660	chr13:112241077	NA	0.34	7.33	0.34	1.22e-12	Hepatitis;
LUAD	cis	rs741677	0.893	rs1978963	chr17:483832	T/C	cg13332499	chr17:408570	NA	0.35	7.08	0.33	5.93e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg08027265	chr7:2291960	NA	-0.51	-8.93	-0.4	1.28e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs887829	0.569	rs6431628	chr2:234647478	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-8.56	-0.38	2.14e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg07169764	chr2:136633963	MCM6	0.65	8.1	0.37	5.75e-15	Corneal structure;
LUAD	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	7.16	0.33	3.56e-12	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	8.38	0.38	7.72e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.5	0.3	2.33e-10	Aortic root size;
LUAD	cis	rs4253772	0.515	rs77797820	chr22:46771270	C/T	cg09491104	chr22:46646882	C22orf40	-0.57	-6.51	-0.3	2.11e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7640424	0.680	rs68147515	chr3:107903216	T/A	cg09227934	chr3:107805635	CD47	-0.47	-8.45	-0.38	4.75e-16	Body mass index;
LUAD	cis	rs151234	0.741	rs11644791	chr16:28601186	G/C	cg04609801	chr16:28609176	SULT1A2	0.62	8.82	0.39	2.95e-17	Platelet distribution width;
LUAD	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.61	-11.53	-0.49	6.27e-27	Schizophrenia;
LUAD	cis	rs2677744	0.626	rs11207	chr15:91497239	C/T	cg23684204	chr15:91497937	RCCD1	0.41	6.65	0.31	9.07e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.45e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4891159	0.790	rs35516239	chr18:74129942	C/T	cg24786174	chr18:74118243	ZNF516	-0.8	-15.43	-0.6	6.55e-43	Longevity;
LUAD	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03352830	chr11:487213	PTDSS2	0.78	9.71	0.43	2.98e-20	Body mass index;
LUAD	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg25036284	chr2:26402008	FAM59B	0.83	11.71	0.49	1.27e-27	Gut microbiome composition (summer);
LUAD	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg09324608	chr17:30823087	MYO1D	0.46	8.58	0.39	1.78e-16	Schizophrenia;
LUAD	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg21427119	chr20:30132790	HM13	-0.56	-8.42	-0.38	5.92e-16	Mean corpuscular hemoglobin;
LUAD	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg14196790	chr5:131705035	SLC22A5	0.38	6.7	0.31	6.5500000000000006e-11	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs73198271	0.531	rs17154756	chr8:8652394	C/T	cg01851573	chr8:8652454	MFHAS1	0.71	11.31	0.48	4.43e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2485376	1.000	rs2485376	chr10:104050006	G/A	cg20641465	chr10:103991465	PITX3	-0.57	-10.34	-0.45	1.65e-22	QT interval;
LUAD	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg27068330	chr11:65405492	SIPA1	-0.76	-11.61	-0.49	3.07e-27	Acne (severe);
LUAD	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg11494091	chr17:61959527	GH2	0.4	6.98	0.32	1.12e-11	Height;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg14964403	chr8:145149739	CYC1	-0.41	-6.82	-0.31	3.18e-11	Vertical cup-disc ratio;
LUAD	trans	rs4650994	0.544	rs6675811	chr1:178499068	T/A	cg05059571	chr16:84539110	KIAA1609	-0.72	-13.31	-0.54	5.34e-34	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs3813948	0.505	rs17020993	chr1:207288392	A/G	cg22332276	chr1:207277018	C4BPA	-0.55	-7.83	-0.36	3.87e-14	C4b binding protein levels;
LUAD	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg10876282	chr6:28092338	ZSCAN16	0.43	6.65	0.31	9.32e-11	Cardiac Troponin-T levels;
LUAD	cis	rs12200560	0.505	rs2015196	chr6:97075331	G/C	cg06623918	chr6:96969491	KIAA0776	0.47	7.28	0.33	1.64e-12	Coronary heart disease;
LUAD	cis	rs76419734	0.510	rs2216516	chr4:106749857	G/C	cg05309399	chr4:106552544	FLJ20184	0.51	7.21	0.33	2.57e-12	Post bronchodilator FEV1;
LUAD	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg08027265	chr7:2291960	NA	-0.52	-9.14	-0.41	2.64e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg01579765	chr21:45077557	HSF2BP	-0.59	-13.62	-0.55	2.7900000000000003e-35	Mean corpuscular volume;
LUAD	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg15448220	chr1:150897856	SETDB1	0.57	9.88	0.43	7.45e-21	Melanoma;
LUAD	trans	rs9379945	1	rs9379945	chr6:26907831	T/C	cg01620082	chr3:125678407	NA	-0.67	-7.24	-0.33	2.08e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4692589	1.000	rs7666219	chr4:170932739	T/C	cg19918862	chr4:170955249	NA	0.28	6.6	0.31	1.24e-10	Anxiety disorder;
LUAD	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg11062466	chr8:58055876	NA	0.45	6.46	0.3	2.84e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs12701220	0.595	rs12532837	chr7:1122851	T/A	cg26769984	chr7:1090371	C7orf50	0.59	8.74	0.39	5.47e-17	Bronchopulmonary dysplasia;
LUAD	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.38	6.97	0.32	1.2e-11	Systemic lupus erythematosus;
LUAD	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg11070056	chr1:107600091	PRMT6	-0.64	-11.19	-0.48	1.21e-25	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs8067545	0.750	rs28666381	chr17:19984809	C/G	cg04132472	chr17:19861366	AKAP10	0.28	6.6	0.31	1.21e-10	Schizophrenia;
LUAD	cis	rs420259	0.510	rs12921516	chr16:23521403	T/G	cg00143387	chr16:23521605	GGA2	-0.69	-9.54	-0.42	1.13e-19	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.35	0.38	9.67e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg00631329	chr6:26305371	NA	-0.68	-13.32	-0.54	4.81e-34	Educational attainment;
LUAD	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.51e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.43	8.17	0.37	3.67e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg13736514	chr6:26305472	NA	-0.68	-12.93	-0.53	1.88e-32	Educational attainment;
LUAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg13012494	chr21:47604986	C21orf56	0.55	9.17	0.41	2.06e-18	Testicular germ cell tumor;
LUAD	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg18306943	chr3:40428807	ENTPD3	0.43	7.22	0.33	2.36e-12	Renal cell carcinoma;
LUAD	cis	rs6906287	0.647	rs11753128	chr6:118853514	C/T	cg05564266	chr6:118973597	C6orf204	0.34	7.15	0.33	3.82e-12	Electrocardiographic conduction measures;
LUAD	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg17757837	chr7:157058334	UBE3C	-0.47	-8.31	-0.37	1.36e-15	Body mass index;
LUAD	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.46	6.92	0.32	1.68e-11	Schizophrenia;
LUAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg27454412	chr7:1067447	C7orf50	0.48	7.73	0.35	7.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9287719	0.601	rs10178751	chr2:10734203	T/C	cg03983476	chr2:10830698	NOL10	-0.38	-6.41	-0.3	3.88e-10	Prostate cancer;
LUAD	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg22529645	chr1:3704559	LRRC47	0.58	10.86	0.47	2.1e-24	Red cell distribution width;
LUAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg08236123	chr12:132219811	SFRS8	-0.35	-6.43	-0.3	3.52e-10	Migraine;
LUAD	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg25767906	chr1:53392781	SCP2	-0.42	-7.87	-0.36	2.96e-14	Monocyte count;
LUAD	cis	rs7009516	0.692	rs9650409	chr8:24240704	A/G	cg01759110	chr8:24241694	ADAMDEC1	0.4	8.18	0.37	3.44e-15	Hair greying;
LUAD	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg12927641	chr6:109611667	NA	-0.53	-9.24	-0.41	1.18e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg22532475	chr10:104410764	TRIM8	-0.44	-8.66	-0.39	1.04e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg13813247	chr22:41461852	NA	-0.5	-8.06	-0.36	7.73e-15	Neuroticism;
LUAD	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.62e-13	Menopause (age at onset);
LUAD	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg02782426	chr3:40428986	ENTPD3	0.4	8.55	0.38	2.24e-16	Renal cell carcinoma;
LUAD	trans	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg16011800	chr17:1958478	HIC1	-0.55	-7.84	-0.36	3.77e-14	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg15083037	chr5:83017644	HAPLN1	-0.53	-7.96	-0.36	1.6e-14	Prostate cancer;
LUAD	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-9.0	-0.4	7.7e-18	Life satisfaction;
LUAD	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	6.51	0.3	2.14e-10	Obesity-related traits;
LUAD	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg21709803	chr11:61594965	FADS2	-0.39	-7.11	-0.33	5.1e-12	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs9972944	0.756	rs8072765	chr17:63763508	T/C	cg07283582	chr17:63770753	CCDC46	-0.5	-11.39	-0.48	2.2e-26	Total body bone mineral density;
LUAD	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg24531977	chr5:56204891	C5orf35	-0.54	-8.75	-0.39	5.04e-17	Coronary artery disease;
LUAD	cis	rs6489882	0.671	rs4767028	chr12:113359188	A/G	cg20102336	chr12:113376681	OAS3	-0.54	-8.32	-0.38	1.19e-15	Chronic lymphocytic leukemia;
LUAD	trans	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	1.04e-10	Diabetic kidney disease;
LUAD	cis	rs78487399	0.808	rs13396401	chr2:43701213	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-6.36	-0.3	5.36e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg19875535	chr5:140030758	IK	-0.39	-6.61	-0.31	1.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10089324	chr1:51984752	EPS15	-0.45	-7.15	-0.33	3.9e-12	Height;
LUAD	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg00074818	chr8:8560427	CLDN23	0.62	9.51	0.42	1.5e-19	Obesity-related traits;
LUAD	trans	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg04565464	chr8:145669602	NFKBIL2	0.47	7.06	0.32	6.83e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg17724175	chr1:150552817	MCL1	0.38	9.15	0.41	2.38e-18	Tonsillectomy;
LUAD	cis	rs2041840	1.000	rs10177970	chr2:37512968	A/G	cg25727520	chr2:37576821	QPCT	0.36	7.27	0.33	1.75e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs11756438	0.572	rs2638552	chr6:118999412	C/T	cg21191810	chr6:118973309	C6orf204	0.5	9.59	0.42	7.66e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg10755058	chr3:40428713	ENTPD3	-0.42	-7.96	-0.36	1.57e-14	Renal cell carcinoma;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg15413566	chr7:8301971	ICA1	-0.41	-7.18	-0.33	3.25e-12	Schizophrenia;
LUAD	cis	rs6489882	0.867	rs4766663	chr12:113362974	C/T	cg20102336	chr12:113376681	OAS3	0.56	9.04	0.4	5.64e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs6489882	0.807	rs1859333	chr12:113370966	T/C	cg20102336	chr12:113376681	OAS3	-0.61	-9.52	-0.42	1.3e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.48	9.2	0.41	1.71e-18	Hemoglobin concentration;
LUAD	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.62	12.07	0.51	5.19e-29	Hemoglobin concentration;
LUAD	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.61	8.89	0.4	1.79e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg18190219	chr22:46762943	CELSR1	-0.55	-6.4	-0.3	4.13e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg22166914	chr1:53195759	ZYG11B	-0.51	-8.82	-0.39	2.92e-17	Monocyte count;
LUAD	cis	rs62238980	0.614	rs75143283	chr22:32413768	G/A	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg25036284	chr2:26402008	FAM59B	-0.83	-11.79	-0.5	6.2e-28	Gut microbiome composition (summer);
LUAD	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg12292205	chr6:26970375	C6orf41	0.49	8.51	0.38	3.08e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.55	0.3	1.66e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs11195062	0.521	rs4918485	chr10:111949323	A/T	cg00817464	chr10:111662876	XPNPEP1	0.48	8.05	0.36	8.37e-15	Multiple myeloma;
LUAD	cis	rs7089973	0.872	rs7072364	chr10:116620840	G/A	cg25233709	chr10:116636983	FAM160B1	0.39	7.58	0.35	2.18e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg06028605	chr16:24865363	SLC5A11	0.45	6.78	0.31	4.1e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7020830	0.522	rs10814509	chr9:37111057	A/G	cg14294708	chr9:37120828	ZCCHC7	0.59	10.44	0.45	7.15e-23	Schizophrenia;
LUAD	cis	rs2030114	0.531	rs2647988	chr16:51594261	C/G	cg03758633	chr16:51611768	NA	0.31	6.37	0.3	4.87e-10	Blood pressure measurement (high sodium and potassium intervention);
LUAD	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg21733973	chr7:65235735	NA	0.48	6.4	0.3	4.07e-10	Aortic root size;
LUAD	cis	rs3820068	0.705	rs11583306	chr1:15860803	A/G	cg24675056	chr1:15929824	NA	-0.42	-6.8	-0.31	3.68e-11	Systolic blood pressure;
LUAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-9.48	-0.42	1.89e-19	Longevity;Endometriosis;
LUAD	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.59	0.3	1.34e-10	Depression;
LUAD	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg08999081	chr20:33150536	PIGU	-0.62	-13.72	-0.55	1.06e-35	Glomerular filtration rate (creatinine);
LUAD	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg13685833	chr1:53393034	SCP2	-0.45	-7.33	-0.34	1.18e-12	Monocyte count;
LUAD	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.12	15.28	0.6	2.75e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.41	-0.34	6.91e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9287719	0.601	rs1861300	chr2:10763961	A/G	cg03983476	chr2:10830698	NOL10	-0.39	-6.45	-0.3	2.99e-10	Prostate cancer;
LUAD	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg06641503	chr3:48959341	ARIH2	0.36	7.26	0.33	1.91e-12	Menarche (age at onset);
LUAD	cis	rs17597773	0.527	rs2484699	chr1:221083752	C/T	cg16008148	chr1:221062819	NA	0.41	8.16	0.37	3.85e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg07570687	chr10:102243282	WNT8B	0.41	6.37	0.3	4.92e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg10523679	chr1:76189770	ACADM	0.91	16.11	0.62	7e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.45	0.3	3.08e-10	Cognitive test performance;
LUAD	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg24818145	chr4:99064322	C4orf37	0.44	7.3	0.33	1.42e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	8.72	0.39	6.24e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.37	0.34	8.85e-13	Menopause (age at onset);
LUAD	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg20290983	chr6:43655470	MRPS18A	1.07	26.68	0.79	1.13e-92	IgG glycosylation;
LUAD	cis	rs738321	0.757	rs2235345	chr22:38518177	C/T	cg25457927	chr22:38595422	NA	-0.51	-11.24	-0.48	8.23e-26	Breast cancer;
LUAD	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg05342682	chr7:94953680	PON1	-0.52	-7.43	-0.34	6.16e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7727544	0.582	rs2278398	chr5:131530441	C/T	cg14196790	chr5:131705035	SLC22A5	-0.42	-7.17	-0.33	3.26e-12	Blood metabolite levels;
LUAD	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.31	0.45	2.28e-22	Ileal carcinoids;
LUAD	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg04450456	chr4:17643702	FAM184B	0.37	6.77	0.31	4.33e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-10.54	-0.46	3.08e-23	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6840360	0.571	rs4696279	chr4:152560449	G/A	cg22705602	chr4:152727874	NA	-0.38	-6.73	-0.31	5.55e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.32	-6.46	-0.3	2.94e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10465746	0.570	rs11163887	chr1:84474718	C/T	cg10977910	chr1:84465055	TTLL7	0.42	6.48	0.3	2.53e-10	Obesity-related traits;
LUAD	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg05776053	chr2:74358815	NA	0.46	6.8	0.31	3.55e-11	Gestational age at birth (maternal effect);
LUAD	cis	rs11229555	0.645	rs10896778	chr11:58193925	T/G	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-15.03	-0.59	3.16e-41	Intelligence (multi-trait analysis);
LUAD	trans	rs7939886	0.920	rs11231901	chr11:55811529	A/G	cg15704280	chr7:45808275	SEPT13	0.66	6.38	0.3	4.7e-10	Myopia (pathological);
LUAD	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.63	9.05	0.4	5.35e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.24	0.41	1.21e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2267137	0.903	rs715494	chr22:29782433	G/T	cg07256473	chr22:29710276	RASL10A	-0.42	-7.93	-0.36	1.93e-14	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13315871	0.929	rs71311854	chr3:58319159	G/A	cg20936604	chr3:58311152	NA	-0.74	-7.39	-0.34	8.14e-13	Cholesterol, total;
LUAD	cis	rs2067615	0.579	rs10746066	chr12:107129108	G/A	cg15890332	chr12:107067104	RFX4	0.37	8.04	0.36	9.1e-15	Heart rate;
LUAD	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg20607287	chr7:12443886	VWDE	-0.48	-6.96	-0.32	1.28e-11	Coronary artery disease;
LUAD	cis	rs859767	0.709	rs4954154	chr2:135370656	G/A	cg12500956	chr2:135428796	TMEM163	-0.31	-8.28	-0.37	1.63e-15	Neuroticism;
LUAD	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg17757837	chr7:157058334	UBE3C	0.48	8.47	0.38	4.2e-16	Body mass index;
LUAD	cis	rs1232027	0.700	rs2405880	chr5:79953793	A/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.88	-0.36	2.8e-14	Huntington's disease progression;
LUAD	cis	rs236352	0.576	rs2116447	chr6:36837364	T/C	cg10099585	chr6:36853529	C6orf89	-0.4	-6.39	-0.3	4.32e-10	Heart rate;
LUAD	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg09654669	chr8:57350985	NA	-0.65	-9.79	-0.43	1.53e-20	Obesity-related traits;
LUAD	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg04155289	chr7:94953770	PON1	-0.55	-7.62	-0.35	1.66e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg17173187	chr15:85201210	NMB	0.55	9.51	0.42	1.48e-19	Schizophrenia;
LUAD	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg19743168	chr1:23544995	NA	0.39	6.86	0.32	2.52e-11	Height;
LUAD	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg27490568	chr2:178487706	NA	0.52	8.25	0.37	2.06e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg21475434	chr5:93447410	FAM172A	0.74	8.59	0.39	1.72e-16	Diabetic retinopathy;
LUAD	trans	rs7395662	0.681	rs2865641	chr11:48941099	A/C	cg00717180	chr2:96193071	NA	-0.44	-8.55	-0.38	2.25e-16	HDL cholesterol;
LUAD	cis	rs6459804	0.566	rs76186270	chr7:157512420	C/T	cg05731713	chr7:157510257	PTPRN2	0.39	8.15	0.37	4.26e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg20891283	chr12:69753455	YEATS4	0.45	7.28	0.33	1.69e-12	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs939658	0.728	rs12904323	chr15:79412583	A/C	cg17916960	chr15:79447300	NA	-0.48	-9.57	-0.42	8.74e-20	Refractive error;
LUAD	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	11.65	0.49	2.2e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg27068330	chr11:65405492	SIPA1	0.8	13.03	0.54	6.99e-33	Acne (severe);
LUAD	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-7.39	-0.34	8.17e-13	IgG glycosylation;
LUAD	trans	rs13086611	1	rs13086611	chr3:49385417	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-8.59	-0.39	1.65e-16	Educational attainment;
LUAD	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg24829409	chr8:58192753	C8orf71	-0.6	-7.1	-0.33	5.25e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg21984481	chr17:79567631	NPLOC4	-0.54	-11.54	-0.49	5.62e-27	Eye color traits;
LUAD	cis	rs877282	0.786	rs10904558	chr10:797509	C/T	cg17470449	chr10:769945	NA	0.65	9.93	0.43	4.96e-21	Uric acid levels;
LUAD	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg12458913	chr13:53173898	NA	0.39	7.05	0.32	7.47e-12	Lewy body disease;
LUAD	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg26408565	chr15:76604113	ETFA	-0.43	-6.96	-0.32	1.29e-11	Blood metabolite levels;
LUAD	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg26384229	chr12:38710491	ALG10B	0.42	7.01	0.32	9.63e-12	Morning vs. evening chronotype;
LUAD	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-7.15	-0.33	3.96e-12	Glaucoma (primary open-angle);
LUAD	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.06	-0.7	2.23e-63	Height;
LUAD	trans	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg02002194	chr4:3960332	NA	-0.3	-7.19	-0.33	2.91e-12	Mood instability;
LUAD	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg22920501	chr2:26401640	FAM59B	-0.52	-7.61	-0.35	1.76e-13	Gut microbiome composition (summer);
LUAD	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg14582100	chr15:45693742	SPATA5L1	0.35	7.06	0.32	6.84e-12	Glomerular filtration rate;
LUAD	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg23262073	chr20:60523788	NA	-0.38	-6.87	-0.32	2.37e-11	Body mass index;
LUAD	cis	rs4660214	0.789	rs1984142	chr1:39745608	G/C	cg27567593	chr1:39956653	BMP8A	0.34	6.79	0.31	3.72e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs61905145	1	rs61905145	chr11:116718415	G/A	cg04087571	chr11:116723030	SIK3	-0.34	-6.62	-0.31	1.11e-10	Subjective well-being;
LUAD	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg22532475	chr10:104410764	TRIM8	-0.42	-8.06	-0.37	7.68e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00166722	chr3:10149974	C3orf24	0.63	10.43	0.45	8.13e-23	Alzheimer's disease;
LUAD	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.53e-11	Crohn's disease;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18455490	chr2:181845411	UBE2E3	-0.4	-6.54	-0.3	1.77e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg23711669	chr6:146136114	FBXO30	0.41	7.03	0.32	8.11e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg03885332	chr11:832357	CD151	-0.42	-7.96	-0.36	1.63e-14	Mean platelet volume;
LUAD	cis	rs3736594	0.959	rs10201247	chr2:27974971	A/G	cg27432699	chr2:27873401	GPN1	-0.47	-7.4	-0.34	7.23e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs6005807	0.719	rs16986308	chr22:28717032	G/A	cg12565055	chr22:29076175	TTC28	0.65	6.75	0.31	4.81e-11	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs9393692	0.557	rs9379845	chr6:26291601	C/T	cg00631329	chr6:26305371	NA	-0.54	-8.7	-0.39	7.33e-17	Educational attainment;
LUAD	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg05082376	chr22:42548792	NA	0.44	7.68	0.35	1.11e-13	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg03929089	chr4:120376271	NA	-0.5	-8.04	-0.36	8.8e-15	Coronary artery disease;
LUAD	cis	rs684232	0.583	rs2543776	chr17:557149	G/A	cg15660573	chr17:549704	VPS53	-0.85	-17.3	-0.64	4.34e-51	Prostate cancer;
LUAD	cis	rs7617773	0.817	rs13094727	chr3:48323489	G/A	cg11946769	chr3:48343235	NME6	0.43	6.66	0.31	8.44e-11	Coronary artery disease;
LUAD	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg16850897	chr7:100343110	ZAN	-0.61	-10.13	-0.44	9.79e-22	Other erythrocyte phenotypes;
LUAD	cis	rs2836633	0.895	rs2836597	chr21:40024424	A/G	cg12884169	chr21:40033163	ERG	0.42	9.14	0.41	2.56e-18	Coronary artery disease;
LUAD	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.33	0.34	1.15e-12	Menopause (age at onset);
LUAD	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg26022315	chr17:47021804	SNF8	0.41	7.3	0.33	1.47e-12	Type 2 diabetes;
LUAD	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.46	-0.38	4.46e-16	Breast cancer;
LUAD	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg00310523	chr12:86230176	RASSF9	0.41	8.46	0.38	4.27e-16	Major depressive disorder;
LUAD	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg19761014	chr17:28927070	LRRC37B2	0.74	8.73	0.39	6.15e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg24733560	chr20:60626293	TAF4	0.49	9.66	0.43	4.24e-20	Body mass index;
LUAD	cis	rs6445967	0.530	rs62258105	chr3:58381262	C/T	cg23715586	chr3:58305044	RPP14	0.41	6.6	0.31	1.26e-10	Platelet count;
LUAD	cis	rs758324	0.812	rs2088718	chr5:131179189	C/T	cg06307176	chr5:131281290	NA	0.45	7.44	0.34	5.55e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7017914	0.934	rs10504479	chr8:71577515	T/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.52	-0.3	1.98e-10	Bone mineral density;
LUAD	cis	rs9341808	0.718	rs10080237	chr6:80854470	T/C	cg08355045	chr6:80787529	NA	0.54	9.74	0.43	2.35e-20	Sitting height ratio;
LUAD	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg18252515	chr7:66147081	NA	-0.6	-6.6	-0.31	1.24e-10	Diabetic kidney disease;
LUAD	cis	rs8192282	0.739	rs4845636	chr1:154486370	A/G	cg16683920	chr1:154474344	TDRD10;SHE	-0.44	-6.82	-0.31	3.09e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg17105886	chr17:28927953	LRRC37B2	0.83	8.02	0.36	1.05e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08219700	chr8:58056026	NA	0.59	8.37	0.38	8.78e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs2262909	0.962	rs17459246	chr19:22278121	T/C	cg17074339	chr11:11642133	GALNTL4	0.48	7.73	0.35	7.68e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg11871910	chr12:69753446	YEATS4	0.5	7.42	0.34	6.61e-13	Response to diuretic therapy;
LUAD	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg06618935	chr21:46677482	NA	-0.45	-8.44	-0.38	5.05e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg14416269	chr4:6271139	WFS1	0.6	11.14	0.48	1.9e-25	Cisplatin-induced ototoxicity;
LUAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg02931644	chr1:25747376	RHCE	0.48	10.39	0.45	1.17e-22	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs12618769	0.597	rs4069739	chr2:99049528	G/C	cg10123293	chr2:99228465	UNC50	0.45	8.15	0.37	4.06e-15	Bipolar disorder;
LUAD	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg07870213	chr5:140052090	DND1	-0.8	-11.04	-0.47	4.34e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg16205897	chr5:131564050	P4HA2	-0.44	-10.47	-0.45	5.77e-23	Blood metabolite levels;
LUAD	cis	rs12210905	1.000	rs12209800	chr6:27189517	C/T	cg11502198	chr6:26597334	ABT1	0.76	6.47	0.3	2.65e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1975974	0.935	rs11870387	chr17:21730236	G/C	cg18423549	chr17:21743878	NA	-0.8	-13.92	-0.56	1.55e-36	Psoriasis;
LUAD	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg14343924	chr8:8086146	FLJ10661	0.45	7.29	0.33	1.5e-12	Mood instability;
LUAD	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg27247225	chr6:26970382	C6orf41	-0.42	-6.41	-0.3	3.85e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7809950	1.000	rs2253146	chr7:107200319	A/G	cg23024343	chr7:107201750	COG5	-0.71	-11.99	-0.5	1.05e-28	Coronary artery disease;
LUAD	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg06360820	chr2:242988706	NA	-0.71	-8.49	-0.38	3.42e-16	Obesity-related traits;
LUAD	cis	rs7827545	0.644	rs4909452	chr8:135521053	C/G	cg17885191	chr8:135476712	NA	-0.6	-9.54	-0.42	1.18e-19	Hypertension (SNP x SNP interaction);
LUAD	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg20503657	chr10:835505	NA	1.04	15.98	0.61	2.53e-45	Eosinophil percentage of granulocytes;
LUAD	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.43	-0.3	3.46e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg19717773	chr7:2847554	GNA12	-0.55	-10.07	-0.44	1.66e-21	Height;
LUAD	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg23985595	chr17:80112537	CCDC57	0.52	9.56	0.42	1e-19	Life satisfaction;
LUAD	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06112835	chr11:68658793	MRPL21	-0.43	-7.77	-0.35	6.12e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2455601	0.882	rs11042118	chr11:8928791	T/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.53	-8.6	-0.39	1.6e-16	Schizophrenia;
LUAD	cis	rs727505	1.000	rs12111865	chr7:124498035	G/A	cg23710748	chr7:124431027	NA	-0.44	-9.36	-0.41	4.69e-19	Lewy body disease;
LUAD	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg17644776	chr2:200775616	C2orf69	0.54	7.22	0.33	2.36e-12	Schizophrenia;
LUAD	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg11887960	chr12:57824829	NA	0.59	7.34	0.34	1.1e-12	Lung disease severity in cystic fibrosis;
LUAD	trans	rs9951602	0.512	rs61021837	chr18:76648210	A/C	cg02800362	chr5:177631904	HNRNPAB	0.92	14.21	0.57	9.84e-38	Obesity-related traits;
LUAD	cis	rs12618769	0.625	rs72819982	chr2:99043337	A/G	cg10123293	chr2:99228465	UNC50	0.45	8.22	0.37	2.51e-15	Bipolar disorder;
LUAD	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.71	0.35	9.38e-14	Depression;
LUAD	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.37	-6.6	-0.31	1.24e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg07870213	chr5:140052090	DND1	1.04	14.77	0.58	4.23e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg02527881	chr3:46936655	PTH1R	0.43	8.37	0.38	8.39e-16	Colorectal cancer;
LUAD	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg07636037	chr3:49044803	WDR6	0.48	8.02	0.36	1.02e-14	Menarche (age at onset);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00626599	chr2:64068905	UGP2	-0.42	-7.1	-0.33	5.16e-12	Cancer;
LUAD	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg21475434	chr5:93447410	FAM172A	0.72	8.67	0.39	8.98e-17	Diabetic retinopathy;
LUAD	cis	rs300774	1.000	rs300802	chr2:104762	G/A	cg21211680	chr2:198530	NA	-0.45	-6.49	-0.3	2.37e-10	Suicide attempts in bipolar disorder;
LUAD	cis	rs1823874	0.581	rs12910401	chr15:100339897	T/C	cg16400843	chr15:100339927	C15orf51	0.35	7.33	0.34	1.16e-12	IgG glycosylation;
LUAD	cis	rs17102423	0.594	rs942628	chr14:65539463	C/G	cg16583315	chr14:65563665	MAX	-0.34	-6.54	-0.3	1.73e-10	Obesity-related traits;
LUAD	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21659725	chr3:3221576	CRBN	0.85	18.12	0.66	9.94e-55	Intelligence (multi-trait analysis);
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg02985366	chr16:32360428	NA	-0.39	-6.87	-0.32	2.34e-11	Menopause (age at onset);
LUAD	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.21	0.44	4.89e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg06641503	chr3:48959341	ARIH2	-0.42	-7.07	-0.33	6.4e-12	Menarche (age at onset);
LUAD	cis	rs6906287	0.647	rs7746778	chr6:118725871	C/A	cg18833306	chr6:118973337	C6orf204	0.48	8.54	0.38	2.49e-16	Electrocardiographic conduction measures;
LUAD	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg26384229	chr12:38710491	ALG10B	0.49	7.91	0.36	2.28e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg02524346	chr8:600233	NA	1.08	10.68	0.46	1.01e-23	IgG glycosylation;
LUAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg23743428	chr13:21893420	NA	-0.47	-8.86	-0.4	2.18e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg21220214	chr8:57350948	NA	-0.59	-8.73	-0.39	6.17e-17	Obesity-related traits;
LUAD	cis	rs208520	0.633	rs79679034	chr6:66701724	A/C	cg07460842	chr6:66804631	NA	1.03	17.66	0.65	1.11e-52	Exhaled nitric oxide output;
LUAD	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg04492858	chr10:133558786	NA	-0.4	-7.82	-0.36	4.31e-14	Survival in rectal cancer;
LUAD	cis	rs8099014	0.861	rs8097365	chr18:56131080	G/A	cg12907477	chr18:56117327	MIR122	0.48	7.93	0.36	1.96e-14	Platelet count;
LUAD	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg26528668	chr16:1614120	IFT140	0.57	10.46	0.45	6.16e-23	Coronary artery disease;
LUAD	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg04287289	chr16:89883240	FANCA	0.76	6.72	0.31	5.74e-11	Skin colour saturation;
LUAD	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg19318889	chr4:1322082	MAEA	-0.45	-7.75	-0.35	7.02e-14	Obesity-related traits;
LUAD	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-9.67	-0.43	4.07e-20	Gut microbiome composition (summer);
LUAD	cis	rs9392556	0.829	rs659025	chr6:4119051	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.41	-7.16	-0.33	3.57e-12	Blood metabolite levels;
LUAD	cis	rs11229555	0.645	rs12801475	chr11:58189034	C/T	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg01416388	chr22:39784598	NA	-0.47	-7.75	-0.35	6.79e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs629535	0.814	rs654452	chr8:70074344	C/G	cg21567404	chr3:27674614	NA	1.0	18.25	0.66	2.56e-55	Dupuytren's disease;
LUAD	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg18230493	chr5:56204884	C5orf35	-0.44	-7.37	-0.34	8.87e-13	Breast cancer;Breast cancer (early onset);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18538297	chr19:58892579	ZNF837	-0.55	-6.75	-0.31	4.79e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4604732	0.588	rs7552443	chr1:247628583	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	9.17	0.41	2.14e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06873352	chr17:61820015	STRADA	0.8	17.72	0.65	6e-53	Prudent dietary pattern;
LUAD	cis	rs735539	0.521	rs2818995	chr13:21420964	T/G	cg27499820	chr13:21296301	IL17D	0.45	6.81	0.31	3.28e-11	Dental caries;
LUAD	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg20542592	chr8:11973495	FAM66D	-0.4	-6.46	-0.3	2.83e-10	Joint mobility (Beighton score);
LUAD	cis	rs790123	1.000	rs790123	chr3:122388993	T/C	cg24850323	chr3:122379709	NA	0.4	7.25	0.33	2.06e-12	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg09509183	chr1:209979624	IRF6	0.38	6.4	0.3	4.15e-10	Monobrow;
LUAD	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg21918786	chr6:109611834	NA	-0.58	-10.6	-0.46	1.97e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg07636037	chr3:49044803	WDR6	0.61	9.93	0.43	5.1e-21	Menarche (age at onset);
LUAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08439880	chr3:133502540	NA	-0.49	-9.97	-0.44	3.66e-21	Iron status biomarkers;
LUAD	trans	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg11887960	chr12:57824829	NA	0.5	6.57	0.3	1.49e-10	Obesity-related traits;
LUAD	cis	rs2019216	0.835	rs402052	chr17:21908388	G/C	cg05591447	chr17:21909280	FLJ36000	-0.3	-7.87	-0.36	2.9e-14	Pelvic organ prolapse;
LUAD	cis	rs6489882	0.807	rs1859334	chr12:113367332	C/T	cg20102336	chr12:113376681	OAS3	-0.59	-9.08	-0.4	4.13e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg14196790	chr5:131705035	SLC22A5	0.47	8.34	0.38	1.03e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg04025307	chr7:1156635	C7orf50	0.86	16.34	0.62	7.05e-47	Longevity;Endometriosis;
LUAD	trans	rs4650994	0.816	rs2811304	chr1:178596794	A/T	cg05059571	chr16:84539110	KIAA1609	0.47	8.07	0.37	7.59e-15	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg27572855	chr1:25598939	RHD	0.53	11.29	0.48	5e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg21775007	chr8:11205619	TDH	0.37	6.37	0.3	5e-10	Neuroticism;
LUAD	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg09367891	chr1:107599246	PRMT6	-0.48	-8.06	-0.36	7.89e-15	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.94	-0.32	1.44e-11	Retinal vascular caliber;
LUAD	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg01765077	chr12:122356316	WDR66	0.56	9.85	0.43	9.25e-21	Mean corpuscular volume;
LUAD	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg24397884	chr7:158709396	WDR60	0.58	10.47	0.45	5.56e-23	Height;
LUAD	cis	rs9487051	0.803	rs410449	chr6:109539853	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.44	-0.3	3.23e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg03188948	chr7:1209495	NA	0.82	10.16	0.44	7.79e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg04450456	chr4:17643702	FAM184B	-0.41	-8.0	-0.36	1.19e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2835872	0.760	rs2835893	chr21:39060893	G/A	cg06728970	chr21:39037746	KCNJ6	-0.38	-6.54	-0.3	1.75e-10	Electroencephalographic traits in alcoholism;
LUAD	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg16099169	chr2:106886729	NA	-0.8	-15.16	-0.59	8.87e-42	Facial morphology (factor 23);
LUAD	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg26536354	chr8:144654954	C8orf73	0.59	6.52	0.3	2.03e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs9393692	0.552	rs806789	chr6:26229161	C/A	cg00631329	chr6:26305371	NA	-0.53	-9.56	-0.42	1.01e-19	Educational attainment;
LUAD	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg16850897	chr7:100343110	ZAN	-0.62	-10.14	-0.44	9.07e-22	Other erythrocyte phenotypes;
LUAD	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg05966235	chr16:28915196	ATP2A1	0.42	6.84	0.32	2.78e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs886126	1.000	rs7969686	chr12:111665388	G/A	cg10833066	chr12:111807467	FAM109A	0.58	10.81	0.47	3.34e-24	Coronary heart disease;
LUAD	cis	rs7072216	0.763	rs12763044	chr10:100167451	C/G	cg26618903	chr10:100175079	PYROXD2	-0.36	-7.94	-0.36	1.8e-14	Metabolite levels;
LUAD	cis	rs1448094	0.617	rs1502799	chr12:86474921	T/C	cg18827107	chr12:86230957	RASSF9	0.5	8.92	0.4	1.43e-17	Major depressive disorder;
LUAD	cis	rs4891159	0.790	rs8085133	chr18:74144083	A/C	cg24786174	chr18:74118243	ZNF516	-0.83	-18.52	-0.67	1.7e-56	Longevity;
LUAD	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg26022315	chr17:47021804	SNF8	0.4	7.29	0.33	1.54e-12	Type 2 diabetes;
LUAD	cis	rs335206	0.641	rs335210	chr5:122501864	A/G	cg16368670	chr5:122501738	PRDM6	-0.32	-6.6	-0.31	1.26e-10	QRS duration;
LUAD	cis	rs9394841	0.667	rs3747750	chr6:41760372	C/G	cg25600774	chr6:41776562	USP49	-0.44	-6.7	-0.31	6.63e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.91	0.32	1.76e-11	Parkinson's disease;
LUAD	trans	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg14917512	chr19:3094685	GNA11	0.57	6.77	0.31	4.22e-11	Diabetic kidney disease;
LUAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg23958373	chr8:599963	NA	0.81	8.26	0.37	1.85e-15	IgG glycosylation;
LUAD	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	14.29	0.57	4.32e-38	Schizophrenia;
LUAD	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg07432352	chr17:45403706	C17orf57	-0.39	-7.29	-0.33	1.58e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg01444801	chr10:135216882	MTG1	-0.54	-7.07	-0.33	6.48e-12	Systemic lupus erythematosus;
LUAD	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg03433033	chr1:76189801	ACADM	-0.45	-6.44	-0.3	3.33e-10	Daytime sleep phenotypes;
LUAD	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg14092988	chr3:52407081	DNAH1	0.45	9.04	0.4	5.62e-18	Bipolar disorder;
LUAD	cis	rs4343996	0.934	rs4495320	chr7:3369936	G/A	cg21248987	chr7:3385318	SDK1	-0.34	-6.36	-0.3	5.22e-10	Motion sickness;
LUAD	cis	rs2046867	0.628	rs61159664	chr3:72916958	C/G	cg25664220	chr3:72788482	NA	-0.55	-10.04	-0.44	2.07e-21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.43	-7.61	-0.35	1.75e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs62400317	0.859	rs12198376	chr6:45153681	G/C	cg18551225	chr6:44695536	NA	-0.52	-8.21	-0.37	2.67e-15	Total body bone mineral density;
LUAD	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg10523679	chr1:76189770	ACADM	0.81	12.54	0.52	7.03e-31	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08439880	chr3:133502540	NA	0.44	8.94	0.4	1.25e-17	Iron status biomarkers;
LUAD	cis	rs11112613	0.818	rs117644588	chr12:106022040	G/C	cg03607813	chr12:105948248	NA	0.58	7.26	0.33	1.91e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs4786125	0.636	rs7187960	chr16:6919183	G/T	cg03623568	chr16:6915990	A2BP1	-0.48	-10.24	-0.45	3.77e-22	Heart rate variability traits (SDNN);
LUAD	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg23254163	chr1:152506842	NA	0.26	7.18	0.33	3.2e-12	Hair morphology;
LUAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.61	-0.31	1.16e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg19980929	chr12:42632907	YAF2	-0.34	-6.47	-0.3	2.77e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg15790184	chr11:494944	RNH1	0.53	6.54	0.3	1.76e-10	Body mass index;
LUAD	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.31	-6.82	-0.31	3.18e-11	Dupuytren's disease;
LUAD	cis	rs9837602	1.000	rs7627991	chr3:99808338	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-6.88	-0.32	2.14e-11	Breast cancer;
LUAD	trans	rs225245	0.782	rs178649	chr17:33908197	C/G	cg19694781	chr19:47549865	TMEM160	-0.46	-7.64	-0.35	1.47e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg00802000	chr16:706648	WDR90	-0.39	-7.05	-0.32	7.22e-12	Height;
LUAD	cis	rs10089	0.552	rs56718459	chr5:127546214	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.46	6.51	0.3	2.07e-10	Ileal carcinoids;
LUAD	cis	rs59104589	0.583	rs73018185	chr2:242241706	C/T	cg08645257	chr2:242211290	HDLBP	0.5	7.81	0.35	4.59e-14	Fibrinogen levels;
LUAD	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.74	15.71	0.61	3.93e-44	White blood cell count;
LUAD	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg09253696	chr17:73873529	TRIM47	-0.43	-7.52	-0.34	3.32e-13	Psoriasis;
LUAD	cis	rs2932538	0.961	rs2932529	chr1:113193364	G/A	cg22162597	chr1:113214053	CAPZA1	-0.45	-6.57	-0.3	1.49e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.77	-10.19	-0.44	6.04e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7799006	1.000	rs7810970	chr7:2276385	A/G	cg12745145	chr7:2261452	MAD1L1	-0.36	-6.96	-0.32	1.33e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg22875332	chr1:76189707	ACADM	0.78	14.61	0.58	2e-39	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2016266	0.859	rs11170507	chr12:53740682	C/A	cg26875137	chr12:53738046	NA	-0.37	-7.17	-0.33	3.36e-12	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs79839061	0.732	rs73207773	chr4:827249	G/A	cg07828340	chr4:882639	GAK	1.0	8.69	0.39	8.01e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21659725	chr3:3221576	CRBN	0.85	17.5	0.65	5.75e-52	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg17063962	chr7:91808500	NA	-0.71	-12.99	-0.53	1.04e-32	Breast cancer;
LUAD	trans	rs2735413	0.881	rs12927515	chr16:78080141	T/G	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.82e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7508679	1.000	rs10401485	chr19:7222234	T/C	cg09779027	chr19:7224513	INSR	0.76	16.55	0.63	8.68e-48	Hypothyroidism;
LUAD	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.62	12.01	0.5	8.64e-29	Homoarginine levels;
LUAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.06	-0.32	6.83e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs10227331	1.000	rs10227331	chr7:157294938	A/T	cg04156418	chr7:157293606	NA	0.42	9.09	0.4	3.85e-18	Inattentive symptoms;
LUAD	cis	rs3862030	0.720	rs3740414	chr10:104232809	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.95	-0.36	1.76e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs7590720	0.840	rs705648	chr2:216933792	C/T	cg12620499	chr2:216877984	MREG	0.5	7.76	0.35	6.55e-14	Alcohol dependence;
LUAD	cis	rs71403859	0.502	rs12927456	chr16:71505706	A/G	cg08717414	chr16:71523259	ZNF19	-0.65	-7.91	-0.36	2.21e-14	Post bronchodilator FEV1;
LUAD	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg00981070	chr1:2046702	PRKCZ	-0.32	-6.55	-0.3	1.67e-10	Height;
LUAD	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg02158880	chr13:53174818	NA	0.52	9.05	0.4	5.09e-18	Lewy body disease;
LUAD	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg09491104	chr22:46646882	C22orf40	-0.65	-8.88	-0.4	1.85e-17	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9322817	0.691	rs2486143	chr6:105308593	A/G	cg02098413	chr6:105308735	HACE1	0.41	8.74	0.39	5.55e-17	Thyroid stimulating hormone;
LUAD	cis	rs2835872	0.758	rs1709818	chr21:39036211	T/C	cg06728970	chr21:39037746	KCNJ6	0.4	7.7	0.35	9.65e-14	Electroencephalographic traits in alcoholism;
LUAD	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg11822812	chr5:140052017	DND1	-0.39	-7.32	-0.34	1.3e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg11494091	chr17:61959527	GH2	0.73	18.13	0.66	8.86e-55	Prudent dietary pattern;
LUAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg22907277	chr7:1156413	C7orf50	0.79	11.72	0.5	1.11e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg00495681	chr13:53174319	NA	0.41	6.94	0.32	1.52e-11	Lewy body disease;
LUAD	cis	rs7107174	1.000	rs2511156	chr11:77971167	G/C	cg02023728	chr11:77925099	USP35	0.52	7.95	0.36	1.71e-14	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg11062466	chr8:58055876	NA	0.66	8.23	0.37	2.39e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1043515	0.642	rs8592	chr17:36958065	A/G	cg20826740	chr17:37024042	NA	0.38	6.48	0.3	2.61e-10	Height;
LUAD	trans	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg00530320	chr1:46809349	NSUN4	0.52	8.07	0.37	7.42e-15	Menopause (age at onset);
LUAD	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg03433033	chr1:76189801	ACADM	0.77	12.57	0.52	5.06e-31	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs240764	0.853	rs11155496	chr6:100988939	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-7.14	-0.33	4.04e-12	Neuroticism;
LUAD	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg06873352	chr17:61820015	STRADA	0.42	7.01	0.32	9.38e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs9784649	1.000	rs9784649	chr5:25011524	G/A	cg11038491	chr20:34638489	LOC647979	-0.67	-8.28	-0.37	1.64e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg00431813	chr7:1051703	C7orf50	-0.41	-7.94	-0.36	1.86e-14	Longevity;Endometriosis;
LUAD	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg04827223	chr11:72435913	ARAP1	-0.46	-6.78	-0.31	4.02e-11	Type 2 diabetes;
LUAD	cis	rs7677751	0.848	rs7673625	chr4:55088586	C/T	cg17187183	chr4:55093834	PDGFRA	0.51	8.63	0.39	1.23e-16	Corneal astigmatism;
LUAD	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg27411982	chr8:10470053	RP1L1	0.45	7.98	0.36	1.41e-14	Mood instability;
LUAD	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-1.04	-14.01	-0.56	6.34e-37	Lung cancer in ever smokers;
LUAD	cis	rs17102423	0.594	rs1271582	chr14:65564703	T/G	cg11161011	chr14:65562177	MAX	-0.42	-7.13	-0.33	4.27e-12	Obesity-related traits;
LUAD	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg19622623	chr12:86230825	RASSF9	-0.55	-9.81	-0.43	1.37e-20	Major depressive disorder;
LUAD	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg04896959	chr15:78267971	NA	0.64	12.18	0.51	1.88e-29	Coronary artery disease or large artery stroke;
LUAD	cis	rs3733418	0.929	rs2280325	chr4:165928254	C/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.5	-6.64	-0.31	9.49e-11	Obesity-related traits;
LUAD	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg19792802	chr11:65647270	CTSW	-0.42	-6.58	-0.3	1.36e-10	Crohn's disease;
LUAD	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.83	-11.18	-0.48	1.33e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs986417	1.000	rs1254318	chr14:60902549	T/C	cg27398547	chr14:60952738	C14orf39	-0.66	-7.82	-0.36	4.21e-14	Gut microbiota (bacterial taxa);
LUAD	trans	rs2735413	0.881	rs12918547	chr16:78082746	G/A	cg01028844	chr5:122736986	CEP120	0.41	6.5	0.3	2.24e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg10518543	chr12:38710700	ALG10B	-0.41	-6.79	-0.31	3.8e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg14671364	chr1:107599128	PRMT6	-0.62	-10.63	-0.46	1.5e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg12756686	chr19:29218302	NA	0.52	6.62	0.31	1.07e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg09065629	chr16:1709722	CRAMP1L	0.43	7.44	0.34	5.85e-13	Coronary artery disease;
LUAD	cis	rs9902453	0.967	rs8072664	chr17:28333385	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-8.99	-0.4	8.33e-18	Coffee consumption (cups per day);
LUAD	cis	rs58804349	0.685	rs9422448	chr10:43288816	A/G	cg08461752	chr10:43522343	NA	-0.83	-8.18	-0.37	3.4e-15	Pediatric bone mineral content (radius);
LUAD	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg08761264	chr16:28874980	SH2B1	-0.45	-6.9	-0.32	1.88e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03342113	chr11:61197477	CPSF7;SDHAF2	-0.56	-7.01	-0.32	9.76e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg13319975	chr6:146136371	FBXO30	0.59	9.91	0.43	6.11e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs71478720	0.903	rs12797880	chr11:112049191	T/C	cg09122223	chr11:112035175	IL18	0.41	6.45	0.3	3e-10	Interleukin-18 levels;
LUAD	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg19418458	chr7:158789849	NA	-0.63	-11.12	-0.48	2.17e-25	Facial morphology (factor 20);
LUAD	cis	rs68170813	0.562	rs7810216	chr7:107000353	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-10.05	-0.44	1.95e-21	Coronary artery disease;
LUAD	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg07988820	chr12:82153109	PPFIA2	-0.49	-7.88	-0.36	2.86e-14	Resting heart rate;
LUAD	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg01528321	chr10:82214614	TSPAN14	0.65	9.97	0.44	3.59e-21	Post bronchodilator FEV1;
LUAD	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.11	-24.32	-0.76	2.23e-82	Ulcerative colitis;
LUAD	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg18105134	chr13:113819100	PROZ	-1.0	-18.52	-0.67	1.66e-56	Platelet distribution width;
LUAD	cis	rs12474201	0.963	rs3829835	chr2:46925789	C/T	cg09399716	chr2:46890238	NA	-0.36	-6.59	-0.31	1.27e-10	Height;
LUAD	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05901451	chr6:126070800	HEY2	-0.83	-16.17	-0.62	4e-46	Brugada syndrome;
LUAD	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg03474202	chr17:45855739	NA	0.38	9.34	0.41	5.48e-19	IgG glycosylation;
LUAD	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg05697835	chr1:2722811	NA	0.31	6.41	0.3	3.99e-10	Ulcerative colitis;
LUAD	cis	rs58799304	0.531	rs12035615	chr1:156055344	C/T	cg24450063	chr1:156163899	SLC25A44	0.51	6.73	0.31	5.55e-11	Ischemic stroke;
LUAD	cis	rs17135859	1.000	rs10059373	chr5:113002991	G/A	cg12552261	chr5:112820674	MCC	0.57	7.47	0.34	4.63e-13	F-cell distribution;
LUAD	cis	rs80319144	1.000	rs74970153	chr2:159251210	C/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.96	0.32	1.28e-11	Restless legs syndrome;
LUAD	cis	rs74181299	0.819	rs2723087	chr2:65298282	T/A	cg05010058	chr2:65284262	CEP68	0.31	6.69	0.31	7.08e-11	Pulse pressure;
LUAD	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg23985595	chr17:80112537	CCDC57	0.52	9.54	0.42	1.11e-19	Life satisfaction;
LUAD	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg05110241	chr16:68378359	PRMT7	-0.92	-10.33	-0.45	1.88e-22	Schizophrenia;
LUAD	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg16680214	chr1:154839983	KCNN3	0.61	12.91	0.53	2.16e-32	Prostate cancer;
LUAD	cis	rs7017914	0.902	rs11991273	chr8:71645860	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg06640241	chr16:89574553	SPG7	0.46	7.37	0.34	8.89e-13	Multiple myeloma (IgH translocation);
LUAD	cis	rs9393692	0.557	rs12665035	chr6:26275649	T/C	cg00631329	chr6:26305371	NA	-0.52	-8.31	-0.37	1.35e-15	Educational attainment;
LUAD	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg03467027	chr4:99064603	C4orf37	0.46	7.37	0.34	9.17e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg05872129	chr22:39784769	NA	-0.8	-14.08	-0.56	3.36e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs16866061	0.926	rs17479770	chr2:225335814	A/G	cg12698349	chr2:225449008	CUL3	0.73	12.57	0.52	5.2500000000000004e-31	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs2657888	0.931	rs7301093	chr12:56933244	G/T	cg23002907	chr12:56915593	RBMS2	0.36	6.59	0.31	1.3100000000000001e-10	Adiponectin levels;
LUAD	cis	rs12903285	1	rs12903285	chr15:78778953	A/G	cg18825076	chr15:78729989	IREB2	-0.41	-6.98	-0.32	1.16e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.68	-8.12	-0.37	5.01e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7809950	0.678	rs7777950	chr7:107004672	T/C	cg23024343	chr7:107201750	COG5	-0.81	-13.82	-0.56	4.13e-36	Coronary artery disease;
LUAD	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg16205897	chr5:131564050	P4HA2	-0.34	-7.98	-0.36	1.38e-14	Blood metabolite levels;
LUAD	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg08989290	chr16:615782	NHLRC4	0.31	6.74	0.31	5.12e-11	Height;
LUAD	cis	rs1595825	0.735	rs57603546	chr2:198918524	C/A	cg00361562	chr2:198649771	BOLL	-0.47	-6.48	-0.3	2.49e-10	Ulcerative colitis;
LUAD	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.31	-0.45	2.13e-22	Platelet count;
LUAD	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10802521	chr3:52805072	NEK4	-0.54	-9.1	-0.4	3.69e-18	Bipolar disorder;
LUAD	cis	rs4072705	0.967	rs10818984	chr9:127413551	T/C	cg14219918	chr9:127249562	NR5A1	0.28	6.37	0.3	4.97e-10	Menarche (age at onset);
LUAD	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	7.02	0.32	9.09e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11811982	0.793	rs11802399	chr1:227353753	C/T	cg24860534	chr1:227506868	CDC42BPA	-0.67	-7.61	-0.35	1.84e-13	Optic disc area;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06828538	chr7:5463627	TNRC18	-0.38	-6.36	-0.3	5.31e-10	Cancer;
LUAD	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg06608945	chr2:219082296	ARPC2	0.52	8.86	0.4	2.2e-17	Colorectal cancer;
LUAD	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg22117172	chr7:91764530	CYP51A1	0.38	8.22	0.37	2.5e-15	Breast cancer;
LUAD	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg03929089	chr4:120376271	NA	0.57	7.15	0.33	3.86e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs3738814	0.529	rs761422	chr1:17301780	A/G	cg14973240	chr1:17287501	CROCC	-0.39	-7.07	-0.33	6.5e-12	Waist circumference adjusted for BMI in active individuals;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg22189786	chr22:42395067	WBP2NL	0.46	6.6	0.31	1.25e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	5.75e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg06175025	chr14:78082992	SPTLC2	-0.4	-6.54	-0.3	1.78e-10	Bone mineral density;
LUAD	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-8.39	-0.38	7.43e-16	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17095355	1.000	rs57440982	chr10:111735772	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.69	-9.24	-0.41	1.18e-18	Biliary atresia;
LUAD	cis	rs870825	0.929	rs871254	chr4:185589226	G/C	cg04058563	chr4:185651563	MLF1IP	0.73	9.19	0.41	1.84e-18	Blood protein levels;
LUAD	cis	rs9902453	0.904	rs7218379	chr17:28402737	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-9.88	-0.43	7.68e-21	Coffee consumption (cups per day);
LUAD	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.02	0.36	1.04e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7395662	0.963	rs11039937	chr11:48712582	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	2.03e-12	HDL cholesterol;
LUAD	cis	rs977987	0.806	rs11640473	chr16:75403289	C/A	cg03315344	chr16:75512273	CHST6	0.65	14.14	0.57	1.91e-37	Dupuytren's disease;
LUAD	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg12310025	chr6:25882481	NA	-0.47	-6.74	-0.31	5.17e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg15242686	chr22:24348715	GSTTP1	0.47	8.21	0.37	2.78e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09844983	chr1:28240714	RPA2	-0.44	-6.87	-0.32	2.28e-11	Height;
LUAD	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg19622623	chr12:86230825	RASSF9	0.45	7.73	0.35	7.66e-14	Major depressive disorder;
LUAD	cis	rs897984	0.542	rs11865038	chr16:31095171	C/T	cg02466173	chr16:30829666	NA	-0.56	-9.64	-0.42	5.39e-20	Dementia with Lewy bodies;
LUAD	cis	rs751728	0.865	rs751726	chr6:33764386	G/A	cg13859433	chr6:33739653	LEMD2	-0.38	-8.83	-0.39	2.73e-17	Crohn's disease;
LUAD	trans	rs11039798	0.764	rs7294013	chr11:48762416	G/A	cg02254774	chr11:50257496	LOC441601	0.53	6.61	0.31	1.19e-10	Axial length;
LUAD	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg06558623	chr16:89946397	TCF25	1.11	12.32	0.51	5.11e-30	Skin colour saturation;
LUAD	trans	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.77	-14.68	-0.58	1.02e-39	Brugada syndrome;
LUAD	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.38	6.79	0.31	3.81e-11	Blood metabolite levels;
LUAD	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg27490568	chr2:178487706	NA	0.43	7.28	0.33	1.66e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2479724	0.636	rs2265139	chr6:41819407	C/G	cg17623882	chr6:41773611	USP49	-0.51	-7.63	-0.35	1.58e-13	Menarche (age at onset);
LUAD	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg16647868	chr5:131706066	SLC22A5	-0.39	-6.64	-0.31	9.75e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs886126	0.761	rs4766556	chr12:111659074	A/G	cg10833066	chr12:111807467	FAM109A	0.51	9.4	0.42	3.5e-19	Coronary heart disease;
LUAD	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.66	-0.39	1e-16	Total body bone mineral density;
LUAD	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg17264618	chr3:40429014	ENTPD3	0.37	8.02	0.36	1.02e-14	Renal cell carcinoma;
LUAD	cis	rs62238980	0.522	rs75380258	chr22:32413280	C/T	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	trans	rs1973993	0.745	rs986427	chr1:96932736	A/G	cg10631902	chr5:14652156	NA	-0.5	-8.64	-0.39	1.13e-16	Weight;
LUAD	trans	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg26043149	chr18:55253948	FECH	-0.48	-8.09	-0.37	6.57e-15	Bone mineral density;
LUAD	cis	rs2580764	0.598	rs6755468	chr2:55240026	A/C	cg09592903	chr2:55203963	RTN4	-0.46	-10.5	-0.45	4.49e-23	Mean platelet volume;
LUAD	cis	rs2455826	0.520	rs2470521	chr3:15765388	G/A	cg16303742	chr3:15540471	COLQ	-0.39	-6.78	-0.31	3.95e-11	Inflammatory skin disease;
LUAD	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs375066	0.762	rs239939	chr19:44387967	A/T	cg12072164	chr19:44306565	LYPD5	0.32	6.56	0.3	1.53e-10	Breast cancer;
LUAD	trans	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg03886242	chr7:26192032	NFE2L3	-0.44	-7.73	-0.35	7.86e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs344364	0.576	rs238677	chr16:1883279	T/C	cg08610935	chr16:1836813	NUBP2	-0.48	-7.55	-0.34	2.77e-13	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg04414720	chr1:150670196	GOLPH3L	0.72	13.03	0.54	7.18e-33	Melanoma;
LUAD	cis	rs490234	0.871	rs4837019	chr9:128276081	C/G	cg14078157	chr9:128172775	NA	-0.38	-6.77	-0.31	4.29e-11	Mean arterial pressure;
LUAD	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg07917127	chr4:99064746	C4orf37	0.41	6.72	0.31	5.72e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg02527881	chr3:46936655	PTH1R	0.41	7.78	0.35	5.77e-14	Colorectal cancer;
LUAD	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg15962314	chr1:44399869	ARTN	0.32	6.82	0.31	3.22e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4481887	0.512	rs1538702	chr1:248519665	A/G	cg07483650	chr1:248525007	OR2T4	0.5	8.25	0.37	1.96e-15	Common traits (Other);
LUAD	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg08027265	chr7:2291960	NA	-0.48	-8.25	-0.37	2.05e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs17608059	1.000	rs17608059	chr17:13910549	C/T	cg11395062	chr17:14139857	CDRT15	0.55	8.99	0.4	8.54e-18	Temperament;
LUAD	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	9.23	0.41	1.34e-18	Electrocardiographic conduction measures;
LUAD	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg01849466	chr14:104193079	ZFYVE21	0.45	7.5	0.34	3.75e-13	Body mass index;
LUAD	cis	rs4843185	0.769	rs709805	chr16:85706564	A/G	cg26571870	chr16:85723150	GINS2	0.35	6.62	0.31	1.07e-10	Platelet distribution width;
LUAD	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg00277334	chr10:82204260	NA	-0.65	-11.68	-0.49	1.7e-27	Post bronchodilator FEV1;
LUAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.85	16.23	0.62	2.23e-46	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg18180107	chr4:99064573	C4orf37	0.42	6.79	0.31	3.87e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7582720	1.000	rs115396314	chr2:203721314	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.71	8.78	0.39	3.94e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg03354898	chr7:1950403	MAD1L1	-0.39	-7.52	-0.34	3.32e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg00814883	chr7:100076585	TSC22D4	-0.85	-12.45	-0.52	1.55e-30	Platelet count;
LUAD	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.98	0.32	1.18e-11	Colorectal cancer;
LUAD	trans	rs9408928	0.778	rs9409230	chr9:123967760	A/T	cg26534993	chr2:3291401	TSSC1	-0.68	-6.41	-0.3	3.9e-10	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs7731657	0.537	rs2189504	chr5:130298900	C/A	cg08523029	chr5:130500466	HINT1	-0.58	-7.45	-0.34	5.28e-13	Fasting plasma glucose;
LUAD	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.59	11.42	0.49	1.65e-26	Birth weight;
LUAD	cis	rs4285028	0.948	rs1920290	chr3:121672305	A/G	cg20356878	chr3:121714668	ILDR1	-0.5	-6.77	-0.31	4.2e-11	Multiple sclerosis;
LUAD	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.25	0.37	2.07e-15	Menopause (age at onset);
LUAD	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	9.2	0.41	1.65e-18	Electrocardiographic conduction measures;
LUAD	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg02423579	chr7:2872169	GNA12	-0.85	-14.85	-0.59	1.83e-40	Height;
LUAD	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg21252483	chr19:49399788	TULP2	-0.74	-12.04	-0.51	6.34e-29	Red cell distribution width;
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg12952179	chr4:111866981	NA	0.45	6.8	0.31	3.6e-11	Hepatitis;
LUAD	cis	rs870825	0.587	rs7682995	chr4:185640684	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	14.17	0.57	1.49e-37	Blood protein levels;
LUAD	trans	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-9.59	-0.42	7.81e-20	Brugada syndrome;
LUAD	cis	rs7582720	1.000	rs72926771	chr2:203801226	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg22681709	chr2:178499509	PDE11A	-0.5	-8.48	-0.38	3.85e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg06484146	chr7:12443880	VWDE	-0.52	-6.69	-0.31	7.23e-11	Coronary artery disease;
LUAD	cis	rs7945718	0.905	rs10831908	chr11:12812419	G/A	cg25843174	chr11:12811716	TEAD1	0.27	8.11	0.37	5.43e-15	Educational attainment (years of education);
LUAD	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg18512352	chr11:47633146	NA	-0.41	-7.11	-0.33	4.89e-12	Subjective well-being;
LUAD	cis	rs743757	1.000	rs2236955	chr3:50429876	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.44	6.75	0.31	4.9e-11	Diastolic blood pressure;
LUAD	cis	rs7119	0.637	rs2667775	chr15:77864802	T/G	cg27398640	chr15:77910606	LINGO1	0.38	6.96	0.32	1.29e-11	Type 2 diabetes;
LUAD	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs1387259	0.839	rs7486941	chr12:48578631	C/G	cg04545296	chr12:48745243	ZNF641	-0.31	-8.52	-0.38	2.88e-16	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs829883	0.646	rs249836	chr12:98878342	T/C	cg25150519	chr12:98850993	NA	0.42	6.93	0.32	1.59e-11	Colorectal adenoma (advanced);
LUAD	trans	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	10.6	0.46	1.98e-23	Type 2 diabetes;
LUAD	cis	rs55788414	0.725	rs34929001	chr16:81188792	C/A	cg06400318	chr16:81190750	PKD1L2	-0.76	-10.06	-0.44	1.67e-21	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg12432903	chr7:1882776	MAD1L1	-0.43	-7.13	-0.33	4.26e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg21427119	chr20:30132790	HM13	-0.48	-7.63	-0.35	1.56e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.89	0.32	2.07e-11	Rheumatoid arthritis;
LUAD	cis	rs2806561	1.000	rs1757044	chr1:23515631	T/C	cg12483005	chr1:23474871	LUZP1	0.38	6.64	0.31	9.66e-11	Height;
LUAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg27454412	chr7:1067447	C7orf50	0.43	7.32	0.34	1.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg04455712	chr21:45112962	RRP1B	0.42	8.57	0.38	2.01e-16	Mean corpuscular volume;
LUAD	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg17971929	chr21:40555470	PSMG1	0.57	9.05	0.4	5.46e-18	Cognitive function;
LUAD	cis	rs4378999	0.748	rs12632046	chr3:51368858	G/A	cg12934382	chr3:51741135	GRM2	0.4	7.0	0.32	1.01e-11	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs897984	0.568	rs8050107	chr16:30893451	C/T	cg02466173	chr16:30829666	NA	0.66	10.34	0.45	1.67e-22	Dementia with Lewy bodies;
LUAD	cis	rs9372498	0.536	rs62422221	chr6:118925581	T/C	cg21191810	chr6:118973309	C6orf204	-0.54	-8.12	-0.37	5.32e-15	Diastolic blood pressure;
LUAD	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg16647868	chr5:131706066	SLC22A5	-0.41	-7.11	-0.33	5.07e-12	Blood metabolite levels;
LUAD	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg19318889	chr4:1322082	MAEA	0.91	15.58	0.6	1.46e-43	Longevity;
LUAD	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg05182265	chr7:156933206	UBE3C	0.64	12.03	0.5	7.36e-29	Body mass index;
LUAD	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg20891558	chr2:74357851	NA	1.01	16.16	0.62	4.12e-46	Gestational age at birth (maternal effect);
LUAD	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg23029597	chr12:123009494	RSRC2	-0.48	-7.45	-0.34	5.44e-13	Body mass index;
LUAD	cis	rs113835537	0.877	rs57127845	chr11:66318325	C/T	cg24851651	chr11:66362959	CCS	0.59	8.11	0.37	5.44e-15	Airway imaging phenotypes;
LUAD	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg08999081	chr20:33150536	PIGU	0.48	9.25	0.41	1.12e-18	Coronary artery disease;
LUAD	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg04851639	chr8:1020857	NA	-0.39	-9.47	-0.42	1.92e-19	Schizophrenia;
LUAD	cis	rs6543140	0.964	rs4851589	chr2:103077145	A/G	cg03938978	chr2:103052716	IL18RAP	0.33	6.56	0.3	1.57e-10	Blood protein levels;
LUAD	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg10523679	chr1:76189770	ACADM	0.94	19.18	0.68	1.91e-59	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg24801067	chr17:62843696	NA	0.65	8.98	0.4	9.06e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.27	-7.07	-0.33	6.47e-12	Schizophrenia;
LUAD	cis	rs7707921	0.767	rs6894520	chr5:81594748	C/T	cg15871215	chr5:81402204	ATG10	-0.57	-9.06	-0.4	4.97e-18	Breast cancer;
LUAD	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.43	7.07	0.33	6.52e-12	Hemoglobin concentration;
LUAD	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg04851639	chr8:1020857	NA	-0.4	-9.28	-0.41	8.64e-19	Schizophrenia;
LUAD	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg13722127	chr7:150037890	RARRES2	0.45	7.69	0.35	1.01e-13	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs62458065	0.513	rs787220	chr7:32581139	C/G	cg00845942	chr12:64062724	DPY19L2	-0.58	-8.42	-0.38	5.9e-16	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs6445967	0.569	rs7622771	chr3:58282930	A/G	cg13750441	chr3:58318267	PXK	-0.31	-6.67	-0.31	7.89e-11	Platelet count;
LUAD	trans	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg02030672	chr11:45687055	CHST1	-0.41	-7.45	-0.34	5.33e-13	Obesity-related traits;
LUAD	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg21427119	chr20:30132790	HM13	-0.56	-8.12	-0.37	5.22e-15	Mean corpuscular hemoglobin;
LUAD	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.42	-0.38	5.83e-16	Total cholesterol levels;
LUAD	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs41311933	0.706	rs78103352	chr9:123774605	C/T	cg13567360	chr9:123745713	C5	-0.67	-8.06	-0.37	7.7e-15	Coronary artery disease;
LUAD	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Hypertriglyceridemia;
LUAD	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.63	0.31	1.05e-10	Parkinson's disease;
LUAD	cis	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg14348967	chr4:10160060	NA	-0.41	-6.81	-0.31	3.26e-11	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg04851639	chr8:1020857	NA	-0.33	-7.5	-0.34	3.67e-13	Schizophrenia;
LUAD	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg05717871	chr11:638507	DRD4	-0.41	-6.38	-0.3	4.6e-10	Systemic lupus erythematosus;
LUAD	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg21171335	chr12:122356390	WDR66	0.76	14.27	0.57	5.16e-38	Mean corpuscular volume;
LUAD	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.33	6.45	0.3	2.99e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg22920501	chr2:26401640	FAM59B	-0.77	-11.14	-0.48	1.92e-25	Gut microbiome composition (summer);
LUAD	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.44	-6.71	-0.31	6.17e-11	Breast cancer;
LUAD	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.47	0.38	4.11e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg08601574	chr20:25228251	PYGB	0.39	6.63	0.31	1.02e-10	Colorectal or endometrial cancer;
LUAD	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg19318889	chr4:1322082	MAEA	0.52	8.97	0.4	9.84e-18	Longevity;
LUAD	cis	rs11677416	1.000	rs6542094	chr2:113528625	A/G	cg27083787	chr2:113543245	IL1A	0.38	6.64	0.31	9.65e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg18351406	chr4:77819688	ANKRD56	0.63	10.16	0.44	7.36e-22	Emphysema distribution in smoking;
LUAD	cis	rs36715	1.000	rs251212	chr5:127545910	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	6.83	0.32	2.88e-11	Breast cancer;
LUAD	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg12310025	chr6:25882481	NA	0.48	7.84	0.36	3.71e-14	Blood metabolite levels;
LUAD	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg24813613	chr7:1882135	MAD1L1	-0.4	-6.35	-0.3	5.44e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg19610905	chr11:61596333	FADS2	0.68	11.08	0.47	3.16e-25	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	trans	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg00953403	chr17:74099816	EXOC7	0.49	7.63	0.35	1.52e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg10434728	chr15:90938212	IQGAP1	0.37	7.16	0.33	3.52e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg07741184	chr6:167504864	NA	0.39	8.77	0.39	4.52e-17	Rheumatoid arthritis;
LUAD	cis	rs713477	1.000	rs28478984	chr14:55911326	C/A	cg13175173	chr14:55914753	NA	-0.33	-6.95	-0.32	1.41e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03517284	chr6:25882590	NA	-0.58	-9.56	-0.42	1.02e-19	Blood metabolite levels;
LUAD	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg05313129	chr8:58192883	C8orf71	0.56	7.21	0.33	2.57e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg09491104	chr22:46646882	C22orf40	-0.59	-8.23	-0.37	2.39e-15	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6545883	0.929	rs55806663	chr2:61740487	G/T	cg15711740	chr2:61764176	XPO1	-0.4	-6.48	-0.3	2.56e-10	Tuberculosis;
LUAD	cis	rs748404	0.697	rs498227	chr15:43573052	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.5	8.24	0.37	2.13e-15	Lung cancer;
LUAD	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg06064525	chr11:970664	AP2A2	-0.56	-11.58	-0.49	3.88e-27	Alzheimer's disease (late onset);
LUAD	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg14686297	chr22:46650375	NA	-0.38	-6.57	-0.3	1.44e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg17757837	chr7:157058334	UBE3C	-0.46	-8.07	-0.37	7.34e-15	Body mass index;
LUAD	cis	rs2797685	1.000	rs707472	chr1:7906008	A/C	cg04725166	chr1:7887271	PER3	0.47	7.01	0.32	9.36e-12	Crohn's disease;
LUAD	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.84	-0.36	3.66e-14	Total body bone mineral density;
LUAD	cis	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-6.98	-0.32	1.13e-11	Systolic blood pressure;
LUAD	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg25828334	chr19:18545568	ISYNA1	-0.36	-7.2	-0.33	2.86e-12	Breast cancer;
LUAD	cis	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg21204522	chr6:27730016	NA	-0.49	-7.13	-0.33	4.4e-12	Breast cancer;
LUAD	cis	rs12612619	0.732	rs1465881	chr2:27237614	A/G	cg00617064	chr2:27272375	NA	-0.37	-7.08	-0.33	6.04e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.76	-0.5	7.89e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg21775007	chr8:11205619	TDH	0.56	10.38	0.45	1.26e-22	Retinal vascular caliber;
LUAD	cis	rs7737355	0.645	rs184950	chr5:130852847	G/A	cg06307176	chr5:131281290	NA	0.49	7.77	0.35	5.99e-14	Life satisfaction;
LUAD	cis	rs62400317	0.826	rs11963924	chr6:45306562	C/T	cg18551225	chr6:44695536	NA	-0.55	-8.55	-0.38	2.2e-16	Total body bone mineral density;
LUAD	cis	rs3087591	0.960	rs2905794	chr17:29470002	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	6.91	0.32	1.76e-11	Hip circumference;
LUAD	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10802521	chr3:52805072	NEK4	-0.61	-11.16	-0.48	1.56e-25	Bipolar disorder;
LUAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg08888203	chr3:10149979	C3orf24	0.65	11.08	0.47	3.31e-25	Alzheimer's disease;
LUAD	trans	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg02574844	chr11:5959923	NA	-0.37	-6.89	-0.32	2.01e-11	DNA methylation (variation);
LUAD	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg16680214	chr1:154839983	KCNN3	-0.63	-13.23	-0.54	1.11e-33	Prostate cancer;
LUAD	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg06713675	chr4:122721982	EXOSC9	0.47	8.47	0.38	4.23e-16	Type 2 diabetes;
LUAD	cis	rs859767	0.774	rs6758396	chr2:135416857	T/C	cg12500956	chr2:135428796	TMEM163	-0.31	-8.13	-0.37	4.91e-15	Neuroticism;
LUAD	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.59	-0.58	2.43e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	7.49	0.34	4.07e-13	Rheumatoid arthritis;
LUAD	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg06784218	chr1:46089804	CCDC17	-0.59	-13.27	-0.54	7.54e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.32	6.69	0.31	7.31e-11	Obesity-related traits;
LUAD	trans	rs629535	0.773	rs655299	chr8:70074534	C/T	cg21567404	chr3:27674614	NA	1.0	18.27	0.66	2.26e-55	Dupuytren's disease;
LUAD	cis	rs7625357	0.599	rs35829594	chr3:169321197	G/A	cg14572252	chr3:169309425	MECOM	-0.47	-7.88	-0.36	2.89e-14	Childhood and early adolescence aggressive behavior;
LUAD	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19346786	chr7:2764209	NA	-0.56	-12.22	-0.51	1.28e-29	Height;
LUAD	cis	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg07460842	chr6:66804631	NA	0.61	9.71	0.43	3.06e-20	Type 2 diabetes;
LUAD	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg23992470	chr4:843637	GAK	0.76	8.02	0.36	1.04e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3815700	1.000	rs10407204	chr19:33097353	C/T	cg02997394	chr19:33096574	ANKRD27	0.65	8.73	0.39	5.94e-17	Eosinophilic esophagitis;
LUAD	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg20628663	chr10:43360327	NA	-0.73	-11.33	-0.48	3.61e-26	Blood protein levels;
LUAD	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg24558204	chr6:135376177	HBS1L	0.48	8.16	0.37	3.84e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg22431228	chr1:16359049	CLCNKA	-0.53	-9.55	-0.42	1.08e-19	Dilated cardiomyopathy;
LUAD	cis	rs10751667	0.560	rs10902265	chr11:1003642	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-6.72	-0.31	5.71e-11	Alzheimer's disease (late onset);
LUAD	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg22815214	chr1:201083145	CACNA1S	0.5	8.61	0.39	1.46e-16	Permanent tooth development;
LUAD	cis	rs1865721	0.682	rs35282535	chr18:73141206	G/A	cg26385618	chr18:73139727	C18orf62	-0.49	-10.12	-0.44	1.07e-21	Intelligence;
LUAD	cis	rs35995292	0.963	rs2240555	chr7:38949424	T/C	cg19327137	chr7:38886074	VPS41	0.51	8.37	0.38	8.47e-16	Subjective well-being (multi-trait analysis);
LUAD	trans	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg26043149	chr18:55253948	FECH	-0.5	-8.58	-0.39	1.8e-16	Bone mineral density;
LUAD	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23248424	chr5:179741104	GFPT2	-0.66	-10.64	-0.46	1.33e-23	Height;
LUAD	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03517284	chr6:25882590	NA	-0.59	-8.53	-0.38	2.65e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs910187	0.572	rs6018325	chr20:45810335	A/G	cg27589058	chr20:45804311	EYA2	-0.34	-7.63	-0.35	1.61e-13	Migraine;
LUAD	cis	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg20368463	chr18:77673604	PQLC1	-0.59	-10.17	-0.44	6.85e-22	Schizophrenia;
LUAD	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg19622623	chr12:86230825	RASSF9	0.44	7.93	0.36	1.97e-14	Major depressive disorder;
LUAD	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg25554036	chr4:6271136	WFS1	0.67	13.56	0.55	4.73e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg14458575	chr2:238380390	NA	-0.72	-13.33	-0.54	4.37e-34	Prostate cancer;
LUAD	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg05709478	chr1:6581295	PLEKHG5	0.54	6.61	0.31	1.14e-10	Body mass index;
LUAD	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.7	-0.31	6.64e-11	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs12200782	0.929	rs72843734	chr6:26448344	C/G	cg08851530	chr6:28072375	NA	0.75	6.72	0.31	5.86e-11	Small cell lung carcinoma;
LUAD	cis	rs4631830	0.720	rs12763717	chr10:51500874	C/G	cg20129853	chr10:51489980	NA	0.33	6.43	0.3	3.48e-10	Prostate-specific antigen levels;
LUAD	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg06002616	chr8:101225028	SPAG1	-0.39	-7.92	-0.36	2.06e-14	Atrioventricular conduction;
LUAD	cis	rs12760731	0.720	rs722321	chr1:178420220	C/T	cg00404053	chr1:178313656	RASAL2	0.73	9.21	0.41	1.53e-18	Obesity-related traits;
LUAD	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg11301795	chr4:187892539	NA	-0.79	-16.59	-0.63	5.6e-48	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg14092988	chr3:52407081	DNAH1	0.39	7.91	0.36	2.33e-14	Electroencephalogram traits;
LUAD	trans	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg18335740	chr13:41363409	SLC25A15	0.72	13.62	0.55	2.81e-35	Lewy body disease;
LUAD	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg19318889	chr4:1322082	MAEA	-0.72	-12.45	-0.52	1.55e-30	Obesity-related traits;
LUAD	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg15744005	chr10:104629667	AS3MT	-0.4	-7.09	-0.33	5.56e-12	Arsenic metabolism;
LUAD	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-9.09	-0.4	4.02e-18	Gut microbiome composition (summer);
LUAD	cis	rs12681288	0.782	rs2600500	chr8:1029031	G/C	cg04851639	chr8:1020857	NA	-0.42	-9.86	-0.43	8.73e-21	Schizophrenia;
LUAD	cis	rs36051895	0.659	rs10974944	chr9:5070831	C/G	cg02405213	chr9:5042618	JAK2	-0.5	-6.86	-0.32	2.44e-11	Pediatric autoimmune diseases;
LUAD	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg01416388	chr22:39784598	NA	0.42	6.62	0.31	1.12e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs2637266	0.846	rs2637260	chr10:78320346	C/T	cg18941641	chr10:78392320	NA	-0.32	-6.59	-0.31	1.3100000000000001e-10	Pulmonary function;
LUAD	cis	rs2414856	0.510	rs72757002	chr15:64615024	C/A	cg08069370	chr15:64387884	SNX1	-0.84	-7.27	-0.33	1.73e-12	Pulse pressure;Systolic blood pressure;
LUAD	cis	rs367943	0.666	rs6594703	chr5:112691999	A/G	cg21806985	chr5:112824646	MCC	0.25	6.47	0.3	2.69e-10	Type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg22117172	chr7:91764530	CYP51A1	-0.34	-7.41	-0.34	6.91e-13	Breast cancer;
LUAD	cis	rs7202877	0.656	rs4888370	chr16:75308230	T/C	cg03315344	chr16:75512273	CHST6	0.48	6.68	0.31	7.41e-11	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.52	8.37	0.38	8.43e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00431236	chr2:264988	ACP1;SH3YL1	-0.41	-6.48	-0.3	2.59e-10	Height;
LUAD	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.73	0.43	2.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7552167	0.925	rs3932666	chr1:24511566	G/A	cg01960748	chr1:24522592	NA	-0.79	-10.4	-0.45	1.04e-22	Psoriasis vulgaris;
LUAD	cis	rs7107174	1.000	rs2511155	chr11:77969223	G/A	cg02023728	chr11:77925099	USP35	0.53	8.28	0.37	1.69e-15	Testicular germ cell tumor;
LUAD	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg08859206	chr1:53392774	SCP2	-0.58	-10.5	-0.45	4.4e-23	Monocyte count;
LUAD	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg12935359	chr14:103987150	CKB	-0.49	-7.93	-0.36	2.01e-14	Body mass index;
LUAD	cis	rs428668	0.681	rs192193	chr5:150692590	A/G	cg11125805	chr5:150678162	SLC36A3	0.48	8.97	0.4	9.83e-18	Skin aging (microtopography measurement);
LUAD	cis	rs738322	0.577	rs4820320	chr22:38572977	G/A	cg17652424	chr22:38574118	PLA2G6	-0.35	-10.4	-0.45	9.99e-23	Cutaneous nevi;
LUAD	cis	rs2041840	0.521	rs2251879	chr2:37485215	A/T	cg25727520	chr2:37576821	QPCT	-0.3	-6.41	-0.3	3.97e-10	Chronic lymphocytic leukemia;
LUAD	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg01097406	chr16:89675127	NA	0.45	9.86	0.43	9.05e-21	Vitiligo;
LUAD	trans	rs13096760	1	rs13096760	chr3:49476806	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.64	0.35	1.52e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg07217954	chr7:1067459	C7orf50	0.43	6.66	0.31	8.41e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg18252515	chr7:66147081	NA	-0.61	-6.76	-0.31	4.72e-11	Diabetic kidney disease;
LUAD	cis	rs9517302	0.847	rs9517297	chr13:99094961	A/C	cg22223119	chr13:99095684	FARP1	-0.66	-11.74	-0.5	9.97e-28	Obesity-related traits;
LUAD	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg02275930	chr1:2372054	NA	-0.43	-10.92	-0.47	1.31e-24	Schizophrenia;
LUAD	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.26	0.33	1.82e-12	Tonsillectomy;
LUAD	cis	rs10504073	0.626	rs9298106	chr8:50007508	T/G	cg00325661	chr8:49890786	NA	0.45	10.14	0.44	8.83e-22	Blood metabolite ratios;
LUAD	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg14343924	chr8:8086146	FLJ10661	0.43	7.11	0.33	4.83e-12	Mood instability;
LUAD	cis	rs68170813	0.559	rs6947675	chr7:106817184	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-11.2	-0.48	1.09e-25	Coronary artery disease;
LUAD	cis	rs240764	0.746	rs240141	chr6:101084946	G/A	cg09795085	chr6:101329169	ASCC3	0.42	7.2	0.33	2.79e-12	Neuroticism;
LUAD	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg20307385	chr11:47447363	PSMC3	0.59	9.49	0.42	1.73e-19	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.34e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs739496	0.895	rs2283357	chr12:111897379	G/C	cg10833066	chr12:111807467	FAM109A	0.42	6.8	0.31	3.66e-11	Platelet count;
LUAD	cis	rs3784262	0.669	rs4646645	chr15:58245151	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.4	-7.68	-0.35	1.14e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg02421172	chr7:1938701	MAD1L1	0.45	6.51	0.3	2.19e-10	Neuroticism;
LUAD	cis	rs262150	0.536	rs4909109	chr7:158787168	C/G	cg09640425	chr7:158790006	NA	0.46	6.55	0.3	1.71e-10	Facial morphology (factor 20);
LUAD	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.61	7.48	0.34	4.31e-13	Body mass index;
LUAD	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg15017067	chr4:17643749	FAM184B	0.37	7.19	0.33	3.03e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg16325326	chr1:53192061	ZYG11B	-0.63	-11.55	-0.49	5.02e-27	Monocyte count;
LUAD	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg14668632	chr7:2872130	GNA12	-0.46	-8.11	-0.37	5.71e-15	Height;
LUAD	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg08999081	chr20:33150536	PIGU	-0.58	-12.5	-0.52	9.8e-31	Glomerular filtration rate (creatinine);
LUAD	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg05313129	chr8:58192883	C8orf71	-0.54	-8.22	-0.37	2.43e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs939658	0.683	rs11634726	chr15:79465894	A/G	cg17916960	chr15:79447300	NA	-0.36	-6.88	-0.32	2.17e-11	Refractive error;
LUAD	cis	rs6489882	0.934	rs1859331	chr12:113376331	C/A	cg20102336	chr12:113376681	OAS3	-0.48	-7.52	-0.34	3.24e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg00071950	chr4:10020882	SLC2A9	0.85	18.61	0.67	6.84e-57	Bone mineral density;
LUAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg08677398	chr8:58056175	NA	0.43	6.67	0.31	7.8e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs13064411	0.866	rs35278902	chr3:113239021	A/G	cg18753928	chr3:113234510	CCDC52	-0.67	-8.65	-0.39	1.12e-16	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg03929089	chr4:120376271	NA	0.58	6.59	0.31	1.33e-10	Axial length;
LUAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg10360139	chr7:1886902	MAD1L1	-0.41	-6.44	-0.3	3.16e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg24579218	chr15:68104479	NA	-0.57	-9.78	-0.43	1.69e-20	Restless legs syndrome;
LUAD	cis	rs2554380	0.943	rs2585061	chr15:84347751	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.58	-8.98	-0.4	8.67e-18	Height;
LUAD	cis	rs727505	1.000	rs6943653	chr7:124512249	G/A	cg23710748	chr7:124431027	NA	-0.47	-9.56	-0.42	9.77e-20	Lewy body disease;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg15906409	chr17:17685582	RAI1	0.41	6.4	0.3	4.14e-10	Bilirubin levels;
LUAD	cis	rs68170813	0.652	rs76742243	chr7:107144202	G/A	cg02696742	chr7:106810147	HBP1	-0.76	-9.12	-0.41	3.08e-18	Coronary artery disease;
LUAD	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.63	0.31	1.02e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19270308	chr1:218458869	RRP15	-0.38	-6.37	-0.3	4.84e-10	Cancer;
LUAD	cis	rs2485376	0.842	rs11593146	chr10:104184981	A/G	cg20641465	chr10:103991465	PITX3	-0.53	-9.21	-0.41	1.51e-18	QT interval;
LUAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg05564831	chr3:52568323	NT5DC2	0.39	7.33	0.34	1.15e-12	Electroencephalogram traits;
LUAD	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg02807482	chr3:125708958	NA	-0.66	-8.77	-0.39	4.47e-17	Blood pressure (smoking interaction);
LUAD	cis	rs3774749	0.565	rs6800021	chr3:50190346	G/A	cg14019146	chr3:50243930	SLC38A3	-0.4	-7.69	-0.35	1.03e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.32	-7.17	-0.33	3.31e-12	Lung cancer;
LUAD	cis	rs4631830	0.832	rs1585378	chr10:51523213	A/T	cg20129853	chr10:51489980	NA	-0.34	-6.61	-0.31	1.16e-10	Prostate-specific antigen levels;
LUAD	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg00316803	chr15:76480434	C15orf27	-0.39	-6.78	-0.31	4.05e-11	Blood metabolite levels;
LUAD	cis	rs4077515	0.806	rs3812564	chr9:139271190	A/G	cg14169450	chr9:139327907	INPP5E	0.4	7.27	0.33	1.81e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs12410462	1.000	rs76233861	chr1:227673909	G/A	cg23173402	chr1:227635558	NA	0.68	7.11	0.33	4.89e-12	Major depressive disorder;
LUAD	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg23752985	chr2:85803571	VAMP8	0.34	6.72	0.31	5.96e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	trans	rs12406019	0.548	rs7524877	chr1:78615645	A/G	cg20826526	chr3:156266748	SSR3	-0.49	-8.28	-0.37	1.66e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg05182265	chr7:156933206	UBE3C	-0.8	-17.24	-0.64	8.1e-51	Body mass index;
LUAD	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg03467027	chr4:99064603	C4orf37	0.39	6.37	0.3	5.05e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	cis	rs17102423	0.594	rs1998688	chr14:65562306	C/G	cg16583315	chr14:65563665	MAX	0.35	6.5	0.3	2.2e-10	Obesity-related traits;
LUAD	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.36	-9.29	-0.41	8.15e-19	Total body bone mineral density;
LUAD	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg11645453	chr3:52864694	ITIH4	-0.53	-10.0	-0.44	2.92e-21	Schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08165151	chr6:88411075	NCRNA00120;AKIRIN2	-0.5	-7.85	-0.36	3.36e-14	Height;
LUAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg00280220	chr17:61926910	NA	0.37	6.98	0.32	1.14e-11	Prudent dietary pattern;
LUAD	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg03929089	chr4:120376271	NA	0.71	10.87	0.47	2e-24	Height;
LUAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg27454412	chr7:1067447	C7orf50	0.44	7.02	0.32	8.71e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg27124370	chr19:33622961	WDR88	0.46	7.17	0.33	3.32e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg03929089	chr4:120376271	NA	0.57	7.41	0.34	6.91e-13	Axial length;
LUAD	cis	rs250585	0.850	rs250550	chr16:23473175	T/C	cg00143387	chr16:23521605	GGA2	0.64	7.9	0.36	2.52e-14	Egg allergy;
LUAD	cis	rs7131987	0.834	rs12228468	chr12:29453610	A/C	cg09582351	chr12:29534625	ERGIC2	0.35	6.86	0.32	2.48e-11	QT interval;
LUAD	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg24069376	chr3:38537580	EXOG	0.37	8.6	0.39	1.52e-16	Electrocardiographic conduction measures;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg21548813	chr6:291882	DUSP22	-0.78	-13.24	-0.54	1.02e-33	Menopause (age at onset);
LUAD	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg06002616	chr8:101225028	SPAG1	-0.39	-8.27	-0.37	1.79e-15	Atrioventricular conduction;
LUAD	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg22906224	chr7:99728672	NA	0.55	9.5	0.42	1.5700000000000001e-19	Coronary artery disease;
LUAD	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16744531	chr19:17905626	B3GNT3	0.48	8.59	0.39	1.72e-16	Tumor biomarkers;
LUAD	cis	rs72928364	1.000	rs67991823	chr3:100631677	C/T	cg10123952	chr3:100791384	NA	0.65	7.47	0.34	4.65e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg12140854	chr5:148520817	ABLIM3	0.61	10.2	0.44	5.4e-22	Breast cancer;
LUAD	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.85	0.32	2.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.47	-8.15	-0.37	4.1e-15	Alzheimer's disease (late onset);
LUAD	trans	rs9929218	1.000	rs4783681	chr16:68806508	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.93	-0.56	1.47e-36	Colorectal cancer;
LUAD	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg20487152	chr13:99095054	FARP1	-0.49	-8.4	-0.38	7.03e-16	Neuroticism;
LUAD	trans	rs87938	0.966	rs430727	chr3:41128564	T/C	cg11224624	chr8:145049280	PLEC1	0.4	6.67	0.31	7.83e-11	Bone mineral density (hip);
LUAD	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg10518543	chr12:38710700	ALG10B	0.5	8.41	0.38	6.29e-16	Morning vs. evening chronotype;
LUAD	cis	rs174601	0.861	rs174584	chr11:61610750	G/A	cg06781209	chr11:61594997	FADS2	-0.35	-6.73	-0.31	5.57e-11	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs367943	1.000	rs348946	chr5:112822814	C/T	cg12552261	chr5:112820674	MCC	-0.59	-11.17	-0.48	1.49e-25	Type 2 diabetes;
LUAD	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg01448562	chr3:133502909	NA	-0.7	-12.8	-0.53	5.93e-32	Iron status biomarkers;
LUAD	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg03732007	chr1:2071316	PRKCZ	0.33	6.72	0.31	6.03e-11	Height;
LUAD	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg25767906	chr1:53392781	SCP2	-0.36	-6.6	-0.31	1.22e-10	Monocyte count;
LUAD	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg16325326	chr1:53192061	ZYG11B	0.62	10.99	0.47	6.84e-25	Monocyte count;
LUAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7395662	1.000	rs11039862	chr11:48618306	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.57	-0.3	1.5e-10	HDL cholesterol;
LUAD	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg06641503	chr3:48959341	ARIH2	-0.39	-7.56	-0.35	2.46e-13	Parkinson's disease;
LUAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg21724239	chr8:58056113	NA	0.74	9.62	0.42	5.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs929596	0.606	rs7604115	chr2:234658116	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.64	-11.1	-0.48	2.63e-25	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg15549821	chr19:49342101	PLEKHA4	-1.18	-18.35	-0.67	9.13e-56	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg00745463	chr17:30367425	LRRC37B	0.98	11.44	0.49	1.33e-26	Hip circumference adjusted for BMI;
LUAD	cis	rs10193935	0.901	rs13384323	chr2:42631346	C/T	cg27598129	chr2:42591480	NA	-0.64	-8.08	-0.37	6.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg22532475	chr10:104410764	TRIM8	-0.42	-8.06	-0.37	7.68e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.23	-0.37	2.38e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg11859384	chr17:80120422	CCDC57	0.5	9.05	0.4	5.37e-18	Life satisfaction;
LUAD	cis	rs3736594	1.000	rs12477908	chr2:27987046	A/C	cg27432699	chr2:27873401	GPN1	-0.44	-6.98	-0.32	1.17e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg06263672	chr7:65235340	NA	-0.47	-6.41	-0.3	3.97e-10	Aortic root size;
LUAD	cis	rs4713675	0.584	rs6916949	chr6:33678290	C/G	cg14003231	chr6:33640908	ITPR3	0.49	9.41	0.42	3.32e-19	Plateletcrit;
LUAD	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg08999081	chr20:33150536	PIGU	0.49	9.46	0.42	2.12e-19	Coronary artery disease;
LUAD	cis	rs2041840	0.924	rs759461	chr2:37473655	A/C	cg25727520	chr2:37576821	QPCT	-0.36	-7.38	-0.34	8.69e-13	Chronic lymphocytic leukemia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg17957827	chr17:79895524	PYCR1	-0.68	-7.02	-0.32	9.01e-12	Type 2 diabetes;
LUAD	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg19318889	chr4:1322082	MAEA	0.49	8.56	0.38	2.12e-16	Obesity-related traits;
LUAD	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.8	-0.31	3.56e-11	Breast cancer;
LUAD	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.53	-9.33	-0.41	6.16e-19	Axial length;
LUAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg20607798	chr8:58055168	NA	0.83	10.02	0.44	2.39e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg26408565	chr15:76604113	ETFA	-0.43	-6.95	-0.32	1.37e-11	Blood metabolite levels;
LUAD	trans	rs7395662	0.927	rs2135690	chr11:48733601	A/G	cg00717180	chr2:96193071	NA	0.35	6.46	0.3	2.81e-10	HDL cholesterol;
LUAD	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg03433033	chr1:76189801	ACADM	0.74	11.15	0.48	1.81e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg12927641	chr6:109611667	NA	-0.53	-9.3	-0.41	7.7e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.48	7.73	0.35	7.88e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg26043149	chr18:55253948	FECH	-0.4	-6.41	-0.3	3.86e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg27284194	chr4:1044797	NA	-0.71	-10.25	-0.45	3.53e-22	Recombination rate (females);
LUAD	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg09184832	chr6:79620586	NA	-0.51	-9.57	-0.42	9.14e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg04025307	chr7:1156635	C7orf50	0.58	8.58	0.39	1.82e-16	Bronchopulmonary dysplasia;
LUAD	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg06360820	chr2:242988706	NA	-0.86	-9.44	-0.42	2.58e-19	Obesity-related traits;
LUAD	cis	rs7737355	0.947	rs31240	chr5:130811146	T/A	cg25547332	chr5:131281432	NA	0.43	6.62	0.31	1.07e-10	Life satisfaction;
LUAD	trans	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg11693508	chr17:37793320	STARD3	0.74	9.79	0.43	1.5e-20	Bipolar disorder;
LUAD	cis	rs11800820	0.557	rs12045741	chr1:246664634	A/T	cg16700716	chr1:246684329	NA	-0.34	-6.38	-0.3	4.54e-10	Obesity-related traits;
LUAD	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg01335087	chr22:19950166	COMT	-0.25	-6.91	-0.32	1.8e-11	Blood metabolite levels;
LUAD	cis	rs7107174	1.000	rs11601161	chr11:78073280	A/G	cg02023728	chr11:77925099	USP35	0.46	7.33	0.34	1.2e-12	Testicular germ cell tumor;
LUAD	cis	rs4790333	0.531	rs2447107	chr17:2257864	A/G	cg02569219	chr17:2266849	SGSM2	0.52	9.76	0.43	1.95e-20	Proinsulin levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12226046	chr10:91403655	PANK1	-0.36	-6.37	-0.3	4.85e-10	Cancer;
LUAD	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg06221963	chr1:154839813	KCNN3	-0.84	-19.89	-0.7	1.25e-62	Prostate cancer;
LUAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10819733	chr22:24237672	NA	0.37	6.98	0.32	1.11e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg12373951	chr3:133503437	NA	0.39	7.46	0.34	4.87e-13	Iron status biomarkers;
LUAD	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg14893161	chr1:205819251	PM20D1	-0.53	-8.02	-0.36	1.03e-14	Menarche (age at onset);
LUAD	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg18721089	chr20:30220636	NA	-0.49	-7.01	-0.32	9.69e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg03806693	chr22:41940476	POLR3H	-0.75	-9.98	-0.44	3.39e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08280861	chr8:58055591	NA	0.63	8.31	0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6961069	0.745	rs1527479	chr7:80272568	C/T	cg04458919	chr7:80252533	CD36	-0.38	-7.39	-0.34	7.66e-13	Platelet count;
LUAD	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.38	0.41	4.09e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1018836	0.892	rs4140680	chr8:91584157	G/A	cg16814680	chr8:91681699	NA	-0.63	-10.33	-0.45	1.85e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg03030879	chr14:75389066	RPS6KL1	0.36	6.62	0.31	1.09e-10	Caffeine consumption;
LUAD	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg10518543	chr12:38710700	ALG10B	0.43	6.42	0.3	3.59e-10	Bladder cancer;
LUAD	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg26668828	chr6:292823	DUSP22	-0.59	-10.01	-0.44	2.54e-21	Menopause (age at onset);
LUAD	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.89	-0.32	2.07e-11	Retinal vascular caliber;
LUAD	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.69	0.31	6.95e-11	Depression;
LUAD	cis	rs7737355	0.812	rs6596008	chr5:130603119	C/T	cg06307176	chr5:131281290	NA	-0.37	-6.4	-0.3	4.17e-10	Life satisfaction;
LUAD	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg04111992	chr7:158790115	NA	-0.51	-8.74	-0.39	5.48e-17	Facial morphology (factor 20);
LUAD	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.78	-0.43	1.63e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22857025	chr5:266934	NA	-1.05	-12.8	-0.53	5.93e-32	Breast cancer;
LUAD	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg08676812	chr11:65308423	LTBP3	0.96	7.28	0.33	1.59e-12	Height;
LUAD	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg14416269	chr4:6271139	WFS1	-0.61	-12.97	-0.53	1.29e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7923837	0.687	rs1111875	chr10:94462882	C/T	cg25093409	chr10:94429542	NA	0.37	6.75	0.31	4.95e-11	Body mass index;Multiple sclerosis;
LUAD	cis	rs1003719	0.591	rs9636914	chr21:38589732	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.42	6.98	0.32	1.12e-11	Eye color traits;
LUAD	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg06697600	chr4:7070879	GRPEL1	-0.6	-9.5	-0.42	1.54e-19	Monocyte percentage of white cells;
LUAD	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg27490568	chr2:178487706	NA	-0.56	-7.86	-0.36	3.25e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg26384229	chr12:38710491	ALG10B	0.41	6.89	0.32	1.98e-11	Morning vs. evening chronotype;
LUAD	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.47	-0.34	4.58e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24823832	chr8:67974235	COPS5	-0.38	-6.44	-0.3	3.28e-10	Cancer;
LUAD	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg15485101	chr11:133734466	NA	0.36	8.08	0.37	6.95e-15	Childhood ear infection;
LUAD	cis	rs17152411	1.000	rs7089014	chr10:126590342	G/A	cg07906193	chr10:126599966	NA	0.53	7.6	0.35	1.95e-13	Height;
LUAD	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg14725641	chr11:61582763	MIR1908;FADS1	-0.56	-6.99	-0.32	1.09e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	7.59	0.35	2.01e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.37	-7.04	-0.32	7.92e-12	Longevity;Endometriosis;
LUAD	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg14664628	chr15:75095509	CSK	-0.42	-6.58	-0.3	1.42e-10	Breast cancer;
LUAD	cis	rs11741688	0.557	rs2004503	chr5:178337122	C/T	cg21944022	chr5:178288650	ZNF354B	0.49	9.15	0.41	2.37e-18	Sleep duration;
LUAD	cis	rs986417	0.901	rs2351171	chr14:61000322	T/C	cg27398547	chr14:60952738	C14orf39	0.66	7.72	0.35	8.64e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.21	0.37	2.79e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg09184832	chr6:79620586	NA	-0.39	-6.66	-0.31	8.68e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg15744005	chr10:104629667	AS3MT	-0.35	-6.88	-0.32	2.1e-11	Arsenic metabolism;
LUAD	trans	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg26811252	chr16:29126840	RRN3P2	0.65	10.97	0.47	7.94e-25	Menopause (age at onset);
LUAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00166722	chr3:10149974	C3orf24	-0.65	-11.01	-0.47	6.04e-25	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg10909506	chr17:38081995	ORMDL3	0.38	6.56	0.3	1.57e-10	Self-reported allergy;
LUAD	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.44	-0.34	5.79e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1692580	0.807	rs4648818	chr1:2178999	C/T	cg21194808	chr1:2205498	SKI	0.4	6.69	0.31	6.93e-11	Coronary artery disease;
LUAD	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.86	-0.32	2.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.17	0.33	3.32e-12	Motion sickness;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23753457	chr11:69455870	CCND1	-0.41	-6.36	-0.3	5.35e-10	Height;
LUAD	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg12458913	chr13:53173898	NA	0.39	7.21	0.33	2.64e-12	Lewy body disease;
LUAD	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg03959625	chr15:84868606	LOC388152	0.4	6.52	0.3	2.03e-10	Schizophrenia;
LUAD	cis	rs1215050	0.791	rs1585088	chr4:98675071	C/A	cg05340658	chr4:99064831	C4orf37	-0.43	-7.01	-0.32	9.21e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-6.59	-0.31	1.29e-10	Retinal vascular caliber;
LUAD	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg25173405	chr17:45401733	C17orf57	-0.46	-7.62	-0.35	1.66e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11890956	chr21:40555474	PSMG1	-0.55	-9.54	-0.42	1.19e-19	Menarche (age at onset);
LUAD	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg00857998	chr1:205179979	DSTYK	0.41	6.82	0.31	3.22e-11	Red blood cell count;
LUAD	cis	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.37	-0.34	9.1e-13	Triglycerides;
LUAD	cis	rs1018836	0.892	rs13267237	chr8:91550820	T/C	cg16814680	chr8:91681699	NA	-0.61	-10.4	-0.45	1.02e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg24579218	chr15:68104479	NA	-0.54	-9.25	-0.41	1.1e-18	Restless legs syndrome;
LUAD	cis	rs2932538	0.922	rs36029940	chr1:113106444	T/G	cg22162597	chr1:113214053	CAPZA1	0.45	6.7	0.31	6.77e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg00071950	chr4:10020882	SLC2A9	0.59	10.67	0.46	1.08e-23	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg02002194	chr4:3960332	NA	-0.26	-6.49	-0.3	2.35e-10	Retinal vascular caliber;
LUAD	cis	rs1609391	0.543	rs9881139	chr3:136634040	A/G	cg15507776	chr3:136538369	TMEM22	0.5	8.95	0.4	1.16e-17	Neuroticism;
LUAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg01448562	chr3:133502909	NA	-0.78	-15.74	-0.61	2.82e-44	Iron status biomarkers;
LUAD	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06022373	chr22:39101656	GTPBP1	0.48	7.89	0.36	2.68e-14	Menopause (age at onset);
LUAD	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg01884057	chr2:25150051	NA	0.31	6.5	0.3	2.33e-10	Body mass index;
LUAD	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-12.69	-0.52	1.8e-31	Breast cancer;
LUAD	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg18512352	chr11:47633146	NA	-0.47	-8.26	-0.37	1.91e-15	Subjective well-being;
LUAD	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg21827317	chr3:136751795	NA	0.36	6.53	0.3	1.86e-10	Neuroticism;
LUAD	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg09826364	chr7:158789723	NA	-0.39	-6.97	-0.32	1.19e-11	Facial morphology (factor 20);
LUAD	cis	rs10865541	0.778	rs10779975	chr2:3420032	A/G	cg13173536	chr2:3403300	TTC15	-0.34	-6.61	-0.31	1.17e-10	Obesity-related traits;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg19459675	chr4:166249239	SC4MOL	0.38	6.36	0.3	5.31e-10	Schizophrenia;
LUAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	8.1	0.37	5.99e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg27284194	chr4:1044797	NA	-0.68	-9.7	-0.43	3.29e-20	Recombination rate (females);
LUAD	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.52	0.34	3.2e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg00376283	chr12:123451042	ABCB9	0.41	6.67	0.31	8.23e-11	Platelet count;
LUAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg26354017	chr1:205819088	PM20D1	0.81	17.34	0.64	2.96e-51	Menarche (age at onset);
LUAD	cis	rs12997796	0.556	rs34353387	chr2:86974834	A/C	cg23743911	chr2:86949715	RMND5A	0.43	6.37	0.3	4.82e-10	Schizophrenia;
LUAD	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg18944383	chr4:111397179	ENPEP	0.38	7.66	0.35	1.24e-13	Height;
LUAD	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg25554036	chr4:6271136	WFS1	0.67	13.35	0.54	3.63e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06022373	chr22:39101656	GTPBP1	0.44	6.96	0.32	1.33e-11	Menopause (age at onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11502736	chr1:179923845	CEP350	-0.43	-6.6	-0.31	1.22e-10	Height;
LUAD	cis	rs4372836	0.543	rs3768665	chr2:29005602	G/A	cg09522027	chr2:28974177	PPP1CB	-0.62	-10.65	-0.46	1.23e-23	Body mass index;
LUAD	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg07917127	chr4:99064746	C4orf37	0.42	7.01	0.32	9.2e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg18621852	chr3:10150065	C3orf24	0.42	7.34	0.34	1.09e-12	Alzheimer's disease;
LUAD	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg08859206	chr1:53392774	SCP2	-0.48	-8.9	-0.4	1.69e-17	Monocyte count;
LUAD	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg13319975	chr6:146136371	FBXO30	0.58	9.75	0.43	2.07e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4006360	0.546	rs2874201	chr17:39238382	A/G	cg20663846	chr17:39254439	KRTAP4-8	-0.36	-8.02	-0.36	1.08e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg16479474	chr6:28041457	NA	0.39	6.86	0.32	2.49e-11	Parkinson's disease;
LUAD	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.13e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	ch.11.42038R	chr11:967971	AP2A2	0.4	7.01	0.32	9.49e-12	Alzheimer's disease (late onset);
LUAD	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg17200465	chr3:40428508	ENTPD3	0.28	6.71	0.31	6.42e-11	Renal cell carcinoma;
LUAD	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07636037	chr3:49044803	WDR6	-0.48	-8.3	-0.37	1.36e-15	Menarche (age at onset);
LUAD	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg05887092	chr17:76393375	PGS1	0.41	7.28	0.33	1.65e-12	HDL cholesterol levels;
LUAD	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg21427119	chr20:30132790	HM13	-0.48	-7.66	-0.35	1.3e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg18713687	chr3:195489789	MUC4	-0.59	-6.76	-0.31	4.7e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs12541635	0.801	rs12155858	chr8:107105205	G/A	cg10147462	chr8:107024639	NA	-0.42	-7.34	-0.34	1.11e-12	Age of smoking initiation;
LUAD	cis	rs6743376	0.556	rs1530548	chr2:113817402	G/A	cg09040174	chr2:113837401	NA	0.52	8.06	0.37	7.7e-15	Inflammatory biomarkers;
LUAD	cis	rs34734847	1.000	rs56273049	chr12:121156041	A/T	cg21892295	chr12:121157589	UNC119B	-0.45	-8.14	-0.37	4.43e-15	Mean corpuscular volume;
LUAD	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg08280861	chr8:58055591	NA	0.56	7.74	0.35	7.37e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg15083037	chr5:83017644	HAPLN1	0.48	7.8	0.35	4.98e-14	Prostate cancer;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg00338122	chr6:151711850	ZBTB2	-0.38	-6.59	-0.31	1.3100000000000001e-10	Schizophrenia;
LUAD	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg02753203	chr1:228287806	NA	0.56	10.18	0.44	6.46e-22	Diastolic blood pressure;
LUAD	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg25985355	chr7:65971099	NA	-0.51	-6.46	-0.3	2.83e-10	Diabetic kidney disease;
LUAD	cis	rs427394	0.659	rs274717	chr5:6721067	C/T	cg14682080	chr5:6737778	POLS	-0.34	-7.52	-0.34	3.21e-13	Menopause (age at onset);
LUAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.76	-0.35	6.43e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg04155289	chr7:94953770	PON1	-0.49	-6.42	-0.3	3.58e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.08	0.33	5.94e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7586879	0.828	rs10184813	chr2:25090236	T/C	cg04586622	chr2:25135609	ADCY3	0.35	7.19	0.33	2.99e-12	Body mass index;
LUAD	cis	rs1816752	0.712	rs6490932	chr13:25017451	A/G	cg02811702	chr13:24901961	NA	0.46	7.89	0.36	2.6e-14	Obesity-related traits;
LUAD	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.06	-0.4	4.71e-18	Total body bone mineral density;
LUAD	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg20476274	chr7:133979776	SLC35B4	0.75	13.09	0.54	4e-33	Mean platelet volume;
LUAD	cis	rs7010267	0.583	rs1485303	chr8:119976256	G/A	cg01975934	chr8:119970761	NA	-0.36	-6.92	-0.32	1.64e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs6076065	0.676	rs6083085	chr20:23336119	C/T	cg11657817	chr20:23433608	CST11	-0.49	-9.37	-0.41	4.45e-19	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg01324343	chr3:183735012	ABCC5	0.95	25.44	0.78	2.85e-87	Anterior chamber depth;
LUAD	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg00898013	chr13:113819073	PROZ	-0.65	-11.84	-0.5	4.1e-28	Platelet distribution width;
LUAD	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg18944383	chr4:111397179	ENPEP	0.4	8.15	0.37	4.06e-15	Height;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg22254299	chr17:77772001	CBX8	-0.7	-6.95	-0.32	1.38e-11	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg11062466	chr8:58055876	NA	0.44	6.56	0.3	1.62e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg19729930	chr2:74357872	NA	1.0	18.75	0.67	1.51e-57	Gestational age at birth (maternal effect);
LUAD	trans	rs7615952	0.546	rs2979333	chr3:125360343	T/A	cg00769240	chr8:12517080	NA	-0.38	-6.57	-0.3	1.45e-10	Blood pressure (smoking interaction);
LUAD	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.41	-0.3	3.97e-10	Neuroticism;
LUAD	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg18252515	chr7:66147081	NA	-0.63	-6.85	-0.32	2.58e-11	Diabetic kidney disease;
LUAD	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg12011299	chr4:100065546	ADH4	0.78	15.99	0.61	2.44e-45	Alcohol dependence;
LUAD	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg05865280	chr17:75406074	SEPT9	0.61	19.25	0.68	9.39e-60	Airflow obstruction;
LUAD	cis	rs7116495	1.000	rs12293885	chr11:71816092	T/A	cg07596299	chr11:71824057	C11orf51	0.76	6.42	0.3	3.61e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs2816062	0.965	rs2816061	chr1:18903819	A/G	cg18795169	chr1:18902165	NA	0.81	17.63	0.65	1.53e-52	Urate levels in lean individuals;
LUAD	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg14917512	chr19:3094685	GNA11	-0.56	-6.75	-0.31	4.81e-11	Diabetic kidney disease;
LUAD	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg09491104	chr22:46646882	C22orf40	-0.57	-7.33	-0.34	1.16e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6750795	0.569	rs1797387	chr2:232414692	A/G	cg19187155	chr2:232395269	NMUR1	0.5	9.16	0.41	2.23e-18	Height;
LUAD	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg26818010	chr10:134567672	INPP5A	-0.98	-16.09	-0.62	8.51e-46	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg06484146	chr7:12443880	VWDE	-0.51	-6.53	-0.3	1.93e-10	Coronary artery disease;
LUAD	cis	rs6545883	0.965	rs3771261	chr2:61762161	A/G	cg15711740	chr2:61764176	XPO1	-0.42	-6.8	-0.31	3.64e-11	Tuberculosis;
LUAD	cis	rs3750082	0.582	rs3750079	chr7:32969419	G/A	cg05721444	chr7:32995514	FKBP9	0.44	7.4	0.34	7.26e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs4243830	0.826	rs12565181	chr1:6620545	G/A	cg05709478	chr1:6581295	PLEKHG5	0.55	6.96	0.32	1.32e-11	Body mass index;
LUAD	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.48	-8.86	-0.4	2.24e-17	Menarche (age at onset);
LUAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00149659	chr3:10157352	C3orf10	0.57	8.06	0.36	7.87e-15	Alzheimer's disease;
LUAD	cis	rs6005807	0.563	rs12169262	chr22:29079353	C/T	cg12565055	chr22:29076175	TTC28	0.75	8.3	0.37	1.38e-15	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg07917127	chr4:99064746	C4orf37	0.42	6.37	0.3	4.94e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg25753631	chr6:25732923	NA	-0.39	-6.51	-0.3	2.17e-10	Height;
LUAD	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg06608945	chr2:219082296	ARPC2	-0.45	-7.47	-0.34	4.68e-13	Colorectal cancer;
LUAD	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg07870213	chr5:140052090	DND1	-0.62	-9.49	-0.42	1.75e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg02569458	chr12:86230093	RASSF9	0.44	8.3	0.37	1.41e-15	Major depressive disorder;
LUAD	cis	rs7759001	0.857	rs6923539	chr6:27362483	C/A	cg18711553	chr6:27366782	ZNF391	0.39	6.54	0.3	1.81e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs7937890	0.559	rs2575836	chr11:14497864	T/G	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.12e-10	Mitochondrial DNA levels;
LUAD	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg09455208	chr3:40491958	NA	0.52	10.83	0.47	2.77e-24	Renal cell carcinoma;
LUAD	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.34	-6.55	-0.3	1.67e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs8073060	0.821	rs11080355	chr17:33872694	T/A	cg05299278	chr17:33885742	SLFN14	-0.36	-6.55	-0.3	1.65e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg04450456	chr4:17643702	FAM184B	0.38	7.46	0.34	5.08e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg19761014	chr17:28927070	LRRC37B2	0.76	8.91	0.4	1.52e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9308433	0.529	rs4655243	chr1:214497291	A/G	cg06198575	chr1:214491504	SMYD2	0.46	7.86	0.36	3.21e-14	IgG glycosylation;
LUAD	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg02734326	chr4:10020555	SLC2A9	0.56	9.91	0.43	5.81e-21	Bone mineral density;
LUAD	cis	rs7582720	1.000	rs72934745	chr2:203744454	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.46	0.42	2.11e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg26769984	chr7:1090371	C7orf50	0.44	7.4	0.34	7.57e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.52	-0.38	2.9e-16	Neutrophil percentage of white cells;
LUAD	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs909002	1.000	rs909002	chr1:32139635	C/T	cg13919466	chr1:32135498	COL16A1	-0.44	-10.74	-0.46	5.66e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs6835098	1.000	rs1054497	chr4:174089048	A/T	cg08422745	chr4:174089978	GALNT7	0.93	17.73	0.65	5.58e-53	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg10518543	chr12:38710700	ALG10B	-0.47	-7.78	-0.35	5.71e-14	Morning vs. evening chronotype;
LUAD	cis	rs7937682	0.562	rs630002	chr11:111377758	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.43	-7.0	-0.32	1.03e-11	Primary sclerosing cholangitis;
LUAD	cis	rs28655083	1.000	rs1843456	chr16:77072393	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-6.99	-0.32	1.07e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23158103	chr7:148848205	ZNF398	-0.6	-11.27	-0.48	5.96e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23158103	chr7:148848205	ZNF398	-0.57	-9.52	-0.42	1.39e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6975373	0.730	rs1009528	chr7:4456304	G/T	cg04153130	chr7:4456396	NA	-0.5	-6.52	-0.3	2.06e-10	Borderline personality disorder;
LUAD	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg10523679	chr1:76189770	ACADM	-0.75	-11.72	-0.5	1.14e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs17401966	1.000	rs11121552	chr1:10435324	C/A	cg15208524	chr1:10270712	KIF1B	0.52	7.61	0.35	1.78e-13	Hepatocellular carcinoma;
LUAD	cis	rs6840360	0.571	rs6833814	chr4:152539679	A/G	cg22705602	chr4:152727874	NA	-0.44	-7.55	-0.34	2.68e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs494562	1.000	rs495472	chr6:86117021	C/T	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg04772025	chr11:68637568	NA	0.55	8.57	0.38	2.02e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7827290	0.723	rs13267590	chr8:142280083	T/C	cg21312554	chr8:142310691	NA	-0.33	-6.43	-0.3	3.5e-10	Bipolar disorder;
LUAD	cis	rs1595825	0.735	rs2228135	chr2:198950029	A/G	cg10547527	chr2:198650123	BOLL	-0.5	-6.72	-0.31	5.8e-11	Ulcerative colitis;
LUAD	cis	rs1873147	0.861	rs2899687	chr15:63325548	C/T	cg12160578	chr15:63334699	TPM1	-0.36	-6.37	-0.3	4.88e-10	Orofacial clefts;
LUAD	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg25985355	chr7:65971099	NA	-0.53	-6.62	-0.31	1.09e-10	Diabetic kidney disease;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03022937	chr11:44117063	EXT2	0.39	6.36	0.3	5.3e-10	Gut microbiome composition (summer);
LUAD	trans	rs853679	0.607	rs66868086	chr6:27865902	A/T	cg06606381	chr12:133084897	FBRSL1	-1.25	-10.88	-0.47	1.83e-24	Depression;
LUAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.59	-10.18	-0.44	6.35e-22	Longevity;Endometriosis;
LUAD	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg07061783	chr6:25882402	NA	0.53	8.28	0.37	1.58e-15	Blood metabolite levels;
LUAD	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg05187965	chr10:45406764	TMEM72	-0.47	-9.18	-0.41	1.91e-18	Mean corpuscular volume;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26419957	chr12:122252518	SETD1B	0.55	6.6	0.31	1.22e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg21775007	chr8:11205619	TDH	-0.38	-6.57	-0.3	1.49e-10	Neuroticism;
LUAD	cis	rs68170813	0.652	rs74374590	chr7:107172470	G/A	cg23024343	chr7:107201750	COG5	0.53	6.68	0.31	7.62e-11	Coronary artery disease;
LUAD	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg05182265	chr7:156933206	UBE3C	-0.8	-17.34	-0.64	2.9e-51	Body mass index;
LUAD	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06544989	chr22:39130855	UNC84B	0.35	7.19	0.33	2.99e-12	Menopause (age at onset);
LUAD	cis	rs977987	0.806	rs72787160	chr16:75445162	G/C	cg03315344	chr16:75512273	CHST6	0.64	14.07	0.56	3.87e-37	Dupuytren's disease;
LUAD	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg21017887	chr14:105400489	NA	0.76	14.66	0.58	1.22e-39	Rheumatoid arthritis;
LUAD	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg12062639	chr20:23401060	NAPB	1.06	11.11	0.48	2.37e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7851660	0.933	rs13302470	chr9:100615553	A/G	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg07606381	chr6:8435919	SLC35B3	0.4	6.59	0.31	1.3100000000000001e-10	Motion sickness;
LUAD	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.46e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.13	0.48	2.11e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-7.72	-0.35	8.24e-14	Tonsillectomy;
LUAD	cis	rs1030877	0.960	rs3792050	chr2:105902255	T/C	cg02079111	chr2:105885981	TGFBRAP1	-0.57	-10.97	-0.47	8.56e-25	Obesity-related traits;
LUAD	trans	rs1728785	0.901	rs1631910	chr16:68603335	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.39	0.45	1.14e-22	Ulcerative colitis;
LUAD	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.47	-0.49	1.08e-26	Primary sclerosing cholangitis;
LUAD	trans	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg27411982	chr8:10470053	RP1L1	0.41	7.23	0.33	2.32e-12	Mood instability;
LUAD	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-9.24	-0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.5	8.62	0.39	1.37e-16	Alzheimer's disease (late onset);
LUAD	cis	rs3845702	0.733	rs12693217	chr2:180841914	T/G	cg01881094	chr2:180872142	CWC22	-0.79	-8.26	-0.37	1.9e-15	Schizophrenia;
LUAD	cis	rs12579753	0.872	rs11519752	chr12:82207300	A/G	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.22	-0.33	2.49e-12	Resting heart rate;
LUAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00166722	chr3:10149974	C3orf24	0.69	12.16	0.51	2.3e-29	Alzheimer's disease;
LUAD	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg10265740	chr3:44622865	ZNF167	0.37	6.59	0.31	1.28e-10	Depressive symptoms;
LUAD	cis	rs3845702	0.668	rs12693215	chr2:180826007	A/C	cg01881094	chr2:180872142	CWC22	-0.74	-8.07	-0.37	7.55e-15	Schizophrenia;
LUAD	cis	rs9487051	0.768	rs9480910	chr6:109521707	T/C	cg01475377	chr6:109611718	NA	-0.37	-6.79	-0.31	3.92e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.42	7.0	0.32	1.02e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg02527881	chr3:46936655	PTH1R	-0.5	-9.75	-0.43	2.09e-20	Colorectal cancer;
LUAD	trans	rs853679	1.000	rs1778511	chr6:28229411	G/A	cg06606381	chr12:133084897	FBRSL1	0.57	7.24	0.33	2.12e-12	Depression;
LUAD	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg06627628	chr2:24431161	ITSN2	-0.5	-8.26	-0.37	1.94e-15	Asthma;
LUAD	cis	rs2235649	0.746	rs35104579	chr16:1848657	A/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-6.72	-0.31	6.01e-11	Blood metabolite levels;
LUAD	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg08601574	chr20:25228251	PYGB	-0.48	-8.91	-0.4	1.48e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg06627557	chr7:32535165	LSM5;AVL9	0.69	13.42	0.55	1.78e-34	Cognitive ability;
LUAD	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-16.13	-0.62	5.71e-46	Schizophrenia;
LUAD	cis	rs6594713	0.756	rs6872490	chr5:112784592	T/C	cg12552261	chr5:112820674	MCC	0.64	9.71	0.43	2.94e-20	Brain cytoarchitecture;
LUAD	cis	rs1692580	0.807	rs12040414	chr1:2192948	T/C	cg24578937	chr1:2090814	PRKCZ	0.56	10.84	0.47	2.54e-24	Coronary artery disease;
LUAD	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg04586622	chr2:25135609	ADCY3	0.37	8.23	0.37	2.39e-15	Body mass index;
LUAD	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg12292205	chr6:26970375	C6orf41	0.39	6.86	0.32	2.42e-11	Schizophrenia;
LUAD	cis	rs55788414	0.932	rs59201365	chr16:81185681	C/G	cg06400318	chr16:81190750	PKD1L2	-0.59	-7.87	-0.36	2.9e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg25767906	chr1:53392781	SCP2	-0.41	-7.81	-0.35	4.6e-14	Monocyte count;
LUAD	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg01884057	chr2:25150051	NA	0.33	6.96	0.32	1.3e-11	Body mass index in non-asthmatics;
LUAD	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.68	13.05	0.54	6e-33	Cognitive ability;
LUAD	trans	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg21659725	chr3:3221576	CRBN	-0.6	-9.61	-0.42	6.76e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg11909912	chr17:43974919	MAPT;LOC100130148	0.39	6.62	0.31	1.09e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg26408565	chr15:76604113	ETFA	-0.43	-6.95	-0.32	1.37e-11	Blood metabolite levels;
LUAD	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg09509183	chr1:209979624	IRF6	0.4	7.11	0.33	4.83e-12	Monobrow;
LUAD	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg22079354	chr11:130786696	SNX19	-0.46	-8.16	-0.37	3.81e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs738322	0.600	rs4821751	chr22:38564457	T/C	cg17652424	chr22:38574118	PLA2G6	-0.31	-8.65	-0.39	1.06e-16	Cutaneous nevi;
LUAD	cis	rs3818285	0.679	rs2475275	chr10:111633979	C/T	cg00817464	chr10:111662876	XPNPEP1	0.82	16.06	0.62	1.17e-45	Superior crus of antihelix expression;
LUAD	cis	rs2479724	0.868	rs2249703	chr6:41814760	A/G	cg17623882	chr6:41773611	USP49	-0.68	-12.69	-0.53	1.74e-31	Menarche (age at onset);
LUAD	trans	rs1422110	0.718	rs10079231	chr5:85439369	A/G	cg01787110	chr1:109008453	NBPF6	0.64	10.62	0.46	1.65e-23	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs10193935	0.901	rs10170082	chr2:42623452	T/C	cg27598129	chr2:42591480	NA	-0.7	-9.08	-0.4	4.12e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.73	-0.53	1.14e-31	Bone mineral density;
LUAD	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg16479474	chr6:28041457	NA	0.35	6.39	0.3	4.34e-10	Parkinson's disease;
LUAD	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg22117172	chr7:91764530	CYP51A1	-0.34	-7.55	-0.34	2.74e-13	Breast cancer;
LUAD	trans	rs11039798	0.844	rs7126949	chr11:48972166	A/G	cg15704280	chr7:45808275	SEPT13	0.67	7.8	0.35	4.95e-14	Axial length;
LUAD	cis	rs240764	0.725	rs239212	chr6:101145178	G/A	cg09795085	chr6:101329169	ASCC3	0.4	6.68	0.31	7.77e-11	Neuroticism;
LUAD	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-9.51	-0.42	1.46e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11771526	0.710	rs7804577	chr7:32373104	A/G	cg27532318	chr7:32358331	NA	0.54	6.81	0.31	3.45e-11	Body mass index;
LUAD	cis	rs6489882	0.867	rs7315441	chr12:113365687	G/T	cg20102336	chr12:113376681	OAS3	-0.57	-9.28	-0.41	8.61e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.1	0.37	5.93e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg24399712	chr22:39784796	NA	-0.79	-15.23	-0.6	4.68e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg20291162	chr17:40259547	DHX58	0.7	11.18	0.48	1.29e-25	Fibrinogen levels;
LUAD	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg03732007	chr1:2071316	PRKCZ	0.34	6.75	0.31	4.76e-11	Height;
LUAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13012494	chr21:47604986	C21orf56	-0.66	-11.55	-0.49	5.33e-27	Testicular germ cell tumor;
LUAD	cis	rs6604026	0.740	rs2893225	chr1:93368496	G/C	cg17283838	chr1:93427260	FAM69A	-0.44	-6.88	-0.32	2.17e-11	Multiple sclerosis;
LUAD	cis	rs7937890	0.559	rs2597188	chr11:14516906	G/A	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.25e-11	Mitochondrial DNA levels;
LUAD	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg21709803	chr11:61594965	FADS2	-0.37	-6.8	-0.31	3.52e-11	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
LUAD	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg04117972	chr1:227635322	NA	0.66	6.7	0.31	6.85e-11	Major depressive disorder;
LUAD	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg26587870	chr6:27730563	NA	-0.67	-7.2	-0.33	2.81e-12	Depression;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04579211	chr15:41221939	DLL4	-0.39	-6.36	-0.3	5.23e-10	Height;
LUAD	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg25036284	chr2:26402008	FAM59B	0.83	11.58	0.49	4.07e-27	Gut microbiome composition (summer);
LUAD	trans	rs853679	0.607	rs13217619	chr6:28306671	T/C	cg01620082	chr3:125678407	NA	-1.11	-10.41	-0.45	9.45e-23	Depression;
LUAD	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg23352942	chr3:46931381	PTH1R	-0.37	-7.58	-0.35	2.24e-13	Birth weight;
LUAD	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg27411982	chr8:10470053	RP1L1	-0.39	-6.99	-0.32	1.1e-11	Neuroticism;
LUAD	cis	rs11771526	0.901	rs10223907	chr7:32297813	G/C	cg27532318	chr7:32358331	NA	0.56	7.1	0.33	5.19e-12	Body mass index;
LUAD	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg17105886	chr17:28927953	LRRC37B2	0.79	7.74	0.35	7.5e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg22618164	chr12:122356400	WDR66	0.73	13.46	0.55	1.28e-34	Mean corpuscular volume;
LUAD	cis	rs57590327	0.555	rs6795133	chr3:81756267	A/G	cg07356753	chr3:81810745	GBE1	-0.62	-10.01	-0.44	2.53e-21	Extraversion;
LUAD	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10979	0.631	rs12530338	chr6:143872563	C/T	cg25407410	chr6:143891975	LOC285740	-0.43	-6.49	-0.3	2.42e-10	Hypospadias;
LUAD	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg15208524	chr1:10270712	KIF1B	0.42	6.38	0.3	4.54e-10	Hepatocellular carcinoma;
LUAD	trans	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	11.87	0.5	2.98e-28	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.47	-7.74	-0.35	7.27e-14	Hematocrit;
LUAD	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg18129748	chr3:49941408	MST1R	-0.41	-6.59	-0.3	1.35e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg12432903	chr7:1882776	MAD1L1	-0.51	-8.45	-0.38	4.64e-16	Bipolar disorder and schizophrenia;
LUAD	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg03929089	chr4:120376271	NA	0.57	7.13	0.33	4.42e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg00310523	chr12:86230176	RASSF9	0.41	8.15	0.37	4.29e-15	Major depressive disorder;
LUAD	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.53	0.38	2.62e-16	Parkinson's disease;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg08833169	chr11:810149	RPLP2	-0.38	-6.59	-0.31	1.35e-10	Schizophrenia;
LUAD	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.49	7.72	0.35	8.24e-14	Total body bone mineral density;
LUAD	cis	rs4961252	0.505	rs12680168	chr8:142102522	A/T	cg09914555	chr8:142094789	NA	-0.45	-7.2	-0.33	2.81e-12	Isovolumetric relaxation time;Response to interferon beta therapy;
LUAD	cis	rs184539343	1	rs184539343	chr2:159293749	C/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.86	0.32	2.4e-11	Cerebrospinal fluid AB1-42 levels;
LUAD	cis	rs2735413	0.875	rs12925138	chr16:78083923	C/T	cg04733911	chr16:78082701	NA	-0.34	-8.17	-0.37	3.53e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7737355	0.947	rs31254	chr5:130829404	C/T	cg25547332	chr5:131281432	NA	0.43	6.64	0.31	9.58e-11	Life satisfaction;
LUAD	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg20203395	chr5:56204925	C5orf35	0.97	13.69	0.55	1.45e-35	Initial pursuit acceleration;
LUAD	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg05872129	chr22:39784769	NA	-0.71	-11.43	-0.49	1.53e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg10057126	chr4:77819792	ANKRD56	0.51	8.63	0.39	1.24e-16	Emphysema distribution in smoking;
LUAD	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06112835	chr11:68658793	MRPL21	0.51	9.24	0.41	1.23e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs743757	0.878	rs1467914	chr3:50523668	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.45	6.41	0.3	3.92e-10	Diastolic blood pressure;
LUAD	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg06713675	chr4:122721982	EXOSC9	-0.83	-18.34	-0.67	1.03e-55	Type 2 diabetes;
LUAD	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg13397359	chr6:42928475	GNMT	0.51	7.93	0.36	2.02e-14	Blood protein levels;
LUAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00166722	chr3:10149974	C3orf24	0.71	12.36	0.52	3.47e-30	Alzheimer's disease;
LUAD	cis	rs12900413	0.562	rs28450767	chr15:90298228	A/G	cg24249390	chr15:90295951	MESP1	-0.35	-6.8	-0.31	3.56e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11890956	chr21:40555474	PSMG1	0.68	11.94	0.5	1.6e-28	Cognitive function;
LUAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg27454412	chr7:1067447	C7orf50	0.45	7.16	0.33	3.5e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.12	13.82	0.56	4.02e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs55788414	0.932	rs34444956	chr16:81185412	C/T	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.91	-0.36	2.31e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg24558204	chr6:135376177	HBS1L	0.47	7.91	0.36	2.3e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg07917127	chr4:99064746	C4orf37	0.42	6.96	0.32	1.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg22907277	chr7:1156413	C7orf50	0.68	7.97	0.36	1.49e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9487051	0.768	rs437779	chr6:109527691	T/G	cg01475377	chr6:109611718	NA	-0.38	-6.94	-0.32	1.45e-11	Reticulocyte fraction of red cells;
LUAD	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.31	-0.33	1.38e-12	Joint mobility (Beighton score);
LUAD	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.53	8.39	0.38	7.13e-16	Cognitive ability;
LUAD	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg07570687	chr10:102243282	WNT8B	0.43	6.4	0.3	4.22e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.68	10.25	0.45	3.76e-22	Ulcerative colitis;
LUAD	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg21385522	chr1:16154831	NA	0.45	7.02	0.32	9.17e-12	Dilated cardiomyopathy;
LUAD	trans	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.73	0.31	5.65e-11	Joint mobility (Beighton score);
LUAD	cis	rs8060686	0.858	rs20549	chr16:67969930	A/G	cg26727032	chr16:67993705	SLC12A4	-0.51	-8.45	-0.38	4.86e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg04756594	chr16:24857601	SLC5A11	0.53	10.22	0.45	4.52e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg09835421	chr16:68378352	PRMT7	-0.81	-8.82	-0.39	2.93e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08219700	chr8:58056026	NA	0.59	8.37	0.38	8.78e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg17074396	chr22:49843754	NA	-0.32	-6.53	-0.3	1.83e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs1403694	1.000	rs1403694	chr3:186439998	T/C	cg12454167	chr3:186435060	KNG1	0.42	8.82	0.39	3.14e-17	Blood protein levels;
LUAD	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg01851573	chr8:8652454	MFHAS1	0.44	7.95	0.36	1.72e-14	Neuroticism;
LUAD	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg17264618	chr3:40429014	ENTPD3	-0.38	-8.47	-0.38	4.02e-16	Renal cell carcinoma;
LUAD	cis	rs8060686	0.516	rs4640173	chr16:68163602	C/A	cg26727032	chr16:67993705	SLC12A4	-0.46	-7.45	-0.34	5.24e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg18335740	chr13:41363409	SLC25A15	-0.51	-9.09	-0.4	3.96e-18	Lewy body disease;
LUAD	cis	rs9341808	0.690	rs2505932	chr6:80839252	G/T	cg08355045	chr6:80787529	NA	0.46	8.04	0.36	9.22e-15	Sitting height ratio;
LUAD	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg17644776	chr2:200775616	C2orf69	0.51	7.94	0.36	1.85e-14	Schizophrenia;
LUAD	cis	rs4954585	0.683	rs11678502	chr2:136994454	C/T	cg05194412	chr2:137003533	NA	0.61	10.94	0.47	1.02e-24	Colorectal cancer;
LUAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg02734326	chr4:10020555	SLC2A9	-0.42	-7.22	-0.33	2.45e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg26384229	chr12:38710491	ALG10B	0.47	7.59	0.35	2.05e-13	Bladder cancer;
LUAD	cis	rs4285028	0.851	rs1986368	chr3:121710969	A/T	cg20356878	chr3:121714668	ILDR1	-0.5	-6.75	-0.31	4.85e-11	Multiple sclerosis;
LUAD	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg01802117	chr1:53393560	SCP2	-0.4	-8.01	-0.36	1.09e-14	Monocyte count;
LUAD	trans	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg01620082	chr3:125678407	NA	-0.56	-7.38	-0.34	8.4e-13	Lung cancer in ever smokers;
LUAD	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg06064525	chr11:970664	AP2A2	-0.44	-8.67	-0.39	9.56e-17	Alzheimer's disease (late onset);
LUAD	cis	rs7589728	0.925	rs78829281	chr2:88502293	T/A	cg04511125	chr2:88470314	THNSL2	0.79	8.37	0.38	8.39e-16	Plasma clusterin levels;
LUAD	cis	rs10992471	0.528	rs10514815	chr9:95256695	C/A	cg14631576	chr9:95140430	CENPP	-0.49	-10.16	-0.44	7.85e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg05590025	chr7:65112418	INTS4L2	-0.78	-8.26	-0.37	1.9e-15	Diabetic kidney disease;
LUAD	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg15921436	chr17:44337874	NA	0.86	11.38	0.48	2.35e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg10518543	chr12:38710700	ALG10B	0.43	7.08	0.33	6.12e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	8.77	0.39	4.54e-17	Breast cancer;
LUAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.66	-0.31	8.59e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19346786	chr7:2764209	NA	-0.54	-11.63	-0.49	2.47e-27	Height;
LUAD	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg15691649	chr6:25882328	NA	-0.45	-6.37	-0.3	5.06e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs3733418	0.929	rs17623445	chr4:165894658	C/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.53	-7.11	-0.33	5.03e-12	Obesity-related traits;
LUAD	cis	rs10504073	0.584	rs11776843	chr8:49928449	C/T	cg00325661	chr8:49890786	NA	0.45	10.23	0.45	4.2e-22	Blood metabolite ratios;
LUAD	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.58	0.3	1.37e-10	Breast cancer;
LUAD	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg18171855	chr10:2543474	NA	0.36	7.11	0.33	5.14e-12	Age-related hearing impairment;
LUAD	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg26924012	chr15:45694286	SPATA5L1	0.65	11.22	0.48	9.34e-26	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg08798685	chr6:27730294	NA	-0.44	-7.07	-0.32	6.57e-12	Parkinson's disease;
LUAD	cis	rs4243830	1.000	rs12027598	chr1:6600804	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.83	8.63	0.39	1.26e-16	Body mass index;
LUAD	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg15704280	chr7:45808275	SEPT13	-0.89	-14.7	-0.58	8.19e-40	Height;
LUAD	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg18512352	chr11:47633146	NA	-0.56	-10.04	-0.44	2.02e-21	Subjective well-being;
LUAD	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg00310523	chr12:86230176	RASSF9	0.37	7.48	0.34	4.42e-13	Major depressive disorder;
LUAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg08132940	chr7:1081526	C7orf50	-0.75	-10.71	-0.46	7.32e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4481887	0.676	rs6691314	chr1:248548020	G/A	cg13385794	chr1:248469461	NA	0.24	6.45	0.3	3.05e-10	Common traits (Other);
LUAD	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg03289416	chr15:75166202	SCAMP2	0.51	8.66	0.39	9.94e-17	Breast cancer;
LUAD	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-24.55	-0.77	2.15e-83	Height;
LUAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg11905131	chr22:24372483	LOC391322	-0.59	-9.99	-0.44	3.13e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg25237894	chr2:233734115	C2orf82	0.61	11.48	0.49	9.35e-27	Coronary artery disease;
LUAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg05434287	chr7:2030229	MAD1L1	0.38	6.48	0.3	2.63e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg04731861	chr2:219085781	ARPC2	-0.21	-6.45	-0.3	3.03e-10	Colorectal cancer;
LUAD	cis	rs13315871	1.000	rs13320620	chr3:58408845	A/G	cg12435725	chr3:58293450	RPP14	-0.69	-7.64	-0.35	1.47e-13	Cholesterol, total;
LUAD	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg05042697	chr2:10830656	NOL10	-0.37	-6.41	-0.3	3.92e-10	Prostate cancer;
LUAD	cis	rs9341808	0.754	rs6907729	chr6:81004922	A/T	cg08355045	chr6:80787529	NA	-0.54	-9.6	-0.42	7.09e-20	Sitting height ratio;
LUAD	trans	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg18834416	chr8:37888184	EIF4EBP1	0.45	7.35	0.34	1e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg01416388	chr22:39784598	NA	-0.53	-8.77	-0.39	4.25e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg07460842	chr6:66804631	NA	-1.23	-31.84	-0.84	2.22e-114	Exhaled nitric oxide output;
LUAD	cis	rs10129255	0.556	rs8010005	chr14:107186226	A/G	cg23076370	chr14:107095027	NA	-0.44	-8.68	-0.39	8.54e-17	Kawasaki disease;
LUAD	cis	rs4888262	0.564	rs8050850	chr16:74582597	C/A	cg01733217	chr16:74700730	RFWD3	0.48	8.17	0.37	3.67e-15	Testicular germ cell tumor;
LUAD	cis	rs11681884	0.818	rs11886754	chr2:113844342	C/G	cg12858261	chr2:113808755	IL1F8	0.5	6.41	0.3	3.89e-10	Stroke;
LUAD	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg25838465	chr1:92012736	NA	-0.47	-7.72	-0.35	8.38e-14	Eosinophil percentage of white cells;
LUAD	trans	rs11039798	0.541	rs11040166	chr11:48965449	T/C	cg15704280	chr7:45808275	SEPT13	0.76	7.7	0.35	9.92e-14	Axial length;
LUAD	cis	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg09998033	chr7:158218633	PTPRN2	-0.44	-7.72	-0.35	8.45e-14	Obesity-related traits;
LUAD	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg11189052	chr15:85197271	WDR73	0.59	7.61	0.35	1.84e-13	Schizophrenia;
LUAD	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg22467129	chr15:76604101	ETFA	-0.47	-7.76	-0.35	6.64e-14	Blood metabolite levels;
LUAD	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg06221963	chr1:154839813	KCNN3	-0.85	-20.1	-0.7	1.48e-63	Prostate cancer;
LUAD	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg11266682	chr4:10021025	SLC2A9	0.53	11.42	0.49	1.57e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg22117172	chr7:91764530	CYP51A1	-0.32	-6.99	-0.32	1.07e-11	Breast cancer;
LUAD	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.32e-15	Prostate cancer;
LUAD	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs9902453	0.740	rs2617884	chr17:28120430	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.56	-0.46	2.66e-23	Coffee consumption (cups per day);
LUAD	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg17747265	chr1:1875780	NA	-0.75	-17.97	-0.66	4.82e-54	Body mass index;
LUAD	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg17177755	chr1:15930204	NA	0.45	7.19	0.33	3.02e-12	Systolic blood pressure;
LUAD	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg04369109	chr6:150039330	LATS1	-0.44	-7.4	-0.34	7.33e-13	Lung cancer;
LUAD	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg08798685	chr6:27730294	NA	-0.42	-6.74	-0.31	5.25e-11	Parkinson's disease;
LUAD	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg18512352	chr11:47633146	NA	-0.38	-6.56	-0.3	1.54e-10	Subjective well-being;
LUAD	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg17279839	chr7:150038598	RARRES2	0.46	7.74	0.35	7.5e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs13315871	1.000	rs71311855	chr3:58320507	A/G	cg12435725	chr3:58293450	RPP14	-0.73	-7.68	-0.35	1.1e-13	Cholesterol, total;
LUAD	trans	rs877282	0.898	rs12356709	chr10:763365	A/G	cg22713356	chr15:30763199	NA	1.26	17.41	0.65	1.4e-51	Uric acid levels;
LUAD	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg15997130	chr1:24165203	NA	0.56	9.92	0.43	5.23e-21	Immature fraction of reticulocytes;
LUAD	cis	rs7737355	0.741	rs6875363	chr5:130581195	A/G	cg06307176	chr5:131281290	NA	-0.44	-6.85	-0.32	2.67e-11	Life satisfaction;
LUAD	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg22875332	chr1:76189707	ACADM	0.84	16.93	0.64	1.76e-49	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg02275930	chr1:2372054	NA	-0.32	-6.7	-0.31	6.65e-11	Non-obstructive azoospermia;
LUAD	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg15017067	chr4:17643749	FAM184B	-0.35	-6.63	-0.31	1.05e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs806795	0.525	rs12661552	chr6:26265200	G/A	cg13736514	chr6:26305472	NA	-0.52	-8.4	-0.38	6.67e-16	Mosquito bite size;
LUAD	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg03714773	chr7:91764589	CYP51A1	-0.27	-6.5	-0.3	2.3e-10	Breast cancer;
LUAD	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg14779329	chr11:130786720	SNX19	0.39	6.89	0.32	2e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7953508	0.711	rs11611927	chr12:93977591	A/G	cg18151635	chr12:93972918	NA	-0.69	-11.02	-0.47	5.58e-25	Pubertal anthropometrics;
LUAD	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg08085267	chr17:45401833	C17orf57	-0.64	-11.31	-0.48	4.4e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg05132306	chr1:1846340	CALML6	-0.35	-7.64	-0.35	1.44e-13	Body mass index;
LUAD	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.06	-0.4	4.77e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg05966235	chr16:28915196	ATP2A1	0.43	6.84	0.32	2.8e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7677751	0.806	rs7689569	chr4:55096398	G/A	cg17187183	chr4:55093834	PDGFRA	0.51	8.53	0.38	2.6e-16	Corneal astigmatism;
LUAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg07217954	chr7:1067459	C7orf50	0.43	6.61	0.31	1.14e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4380275	1.000	rs73143802	chr2:773826	T/C	cg21665850	chr2:731073	NA	0.5	8.94	0.4	1.24e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUAD	cis	rs12600304	0.684	rs2405129	chr16:58015841	G/A	cg03859792	chr16:58121049	NA	-0.37	-7.7	-0.35	9.8e-14	Aggressiveness in attention deficit hyperactivity disorder;
LUAD	trans	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.2	-30.52	-0.83	5.98e-109	Exhaled nitric oxide output;
LUAD	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg07217954	chr7:1067459	C7orf50	-0.39	-6.98	-0.32	1.13e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs9715521	0.935	rs62301184	chr4:59836168	A/G	cg11281224	chr4:60001000	NA	-0.56	-9.43	-0.42	2.72e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs17608059	0.634	rs10852819	chr17:13921426	C/A	cg11395062	chr17:14139857	CDRT15	0.42	6.75	0.31	4.94e-11	Temperament;
LUAD	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.73	-0.5	1.03e-27	Mean corpuscular volume;
LUAD	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg22532475	chr10:104410764	TRIM8	-0.43	-7.94	-0.36	1.8e-14	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6089584	0.586	rs2296087	chr20:60584328	T/A	cg24733560	chr20:60626293	TAF4	0.41	7.98	0.36	1.41e-14	Body mass index;
LUAD	cis	rs6499255	0.951	rs3743673	chr16:69711311	A/T	cg15192750	chr16:69999425	NA	0.53	8.1	0.37	6e-15	IgE levels;
LUAD	trans	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg04565464	chr8:145669602	NFKBIL2	0.41	6.36	0.3	5.18e-10	Schizophrenia;
LUAD	cis	rs4588572	0.601	rs10942855	chr5:77737529	G/A	cg11547950	chr5:77652471	NA	-0.77	-12.6	-0.52	3.88e-31	Triglycerides;
LUAD	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg02574844	chr11:5959923	NA	-0.38	-6.4	-0.3	4.03e-10	DNA methylation (variation);
LUAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14159672	chr1:205819179	PM20D1	0.8	16.22	0.62	2.3e-46	Menarche (age at onset);
LUAD	cis	rs6005807	0.719	rs12165893	chr22:29033545	T/C	cg12565055	chr22:29076175	TTC28	0.74	8.71	0.39	6.98e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.44	0.34	5.59e-13	Bladder cancer;
LUAD	cis	rs41311933	0.656	rs72760233	chr9:123902079	T/A	cg13567360	chr9:123745713	C5	-0.73	-8.46	-0.38	4.36e-16	Coronary artery disease;
LUAD	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18876405	chr7:65276391	NA	-0.44	-6.98	-0.32	1.16e-11	Aortic root size;
LUAD	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg14186256	chr22:23484241	RTDR1	0.47	8.1	0.37	6.08e-15	Bone mineral density;
LUAD	cis	rs2445762	0.642	rs8025191	chr15:51623785	A/G	cg00184732	chr15:51633821	GLDN	0.42	7.01	0.32	9.25e-12	Hormone measurements;
LUAD	trans	rs1337391	0.649	rs113571602	chr9:16573511	T/C	cg08976687	chr2:85515537	TCF7L1	0.44	6.66	0.31	8.63e-11	Heschl's gyrus morphology;
LUAD	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10203711	0.933	rs10187441	chr2:239577654	C/G	cg14580085	chr2:239553406	NA	0.42	9.19	0.41	1.74e-18	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs7246760	0.867	rs73011937	chr19:9832530	T/C	cg02900749	chr2:68251473	NA	-0.58	-6.64	-0.31	9.4e-11	Pursuit maintenance gain;
LUAD	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg07936489	chr17:37558343	FBXL20	-0.47	-7.54	-0.34	2.9e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.86	-0.36	3.15e-14	Diabetic kidney disease;
LUAD	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg23750338	chr8:142222470	SLC45A4	0.62	14.1	0.57	2.71e-37	Immature fraction of reticulocytes;
LUAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.66	0.31	8.54e-11	Prudent dietary pattern;
LUAD	cis	rs7737355	0.812	rs11746227	chr5:130961236	C/T	cg06307176	chr5:131281290	NA	0.41	6.62	0.31	1.07e-10	Life satisfaction;
LUAD	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg24163568	chr5:669837	TPPP	0.36	6.76	0.31	4.52e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg12623302	chr6:28058802	ZSCAN12L1	0.29	6.46	0.3	2.81e-10	Parkinson's disease;
LUAD	cis	rs7074356	0.523	rs7087728	chr10:82033470	G/A	cg27171509	chr10:82033454	MAT1A	-0.46	-6.86	-0.32	2.42e-11	Borderline personality disorder;
LUAD	cis	rs11971779	0.648	rs6974099	chr7:139098566	A/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg20203395	chr5:56204925	C5orf35	-0.63	-9.63	-0.42	5.54e-20	Initial pursuit acceleration;
LUAD	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg27490568	chr2:178487706	NA	0.44	7.55	0.34	2.67e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-9.98	-0.44	3.45e-21	Lymphocyte counts;
LUAD	cis	rs7189233	0.911	rs72801854	chr16:53517242	G/A	cg04059762	chr16:53544020	NA	-0.41	-6.55	-0.3	1.72e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg13126279	chr21:47581558	C21orf56	-0.43	-7.36	-0.34	9.43e-13	Testicular germ cell tumor;
LUAD	cis	rs6758955	0.850	rs6758633	chr2:10480201	T/C	cg15773312	chr2:10472214	HPCAL1	-0.47	-6.8	-0.31	3.67e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg16414030	chr3:133502952	NA	-0.5	-9.02	-0.4	6.42e-18	Iron status biomarkers;
LUAD	cis	rs714027	1.000	rs2412971	chr22:30494371	G/A	cg11564601	chr22:30592435	NA	-0.4	-8.76	-0.39	4.85e-17	Lymphocyte counts;
LUAD	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg10356904	chr22:49881777	NA	-0.39	-8.15	-0.37	4.2e-15	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs657075	0.697	rs34362950	chr5:131766503	G/A	cg21138405	chr5:131827807	IRF1	0.53	6.47	0.3	2.73e-10	Rheumatoid arthritis;
LUAD	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06544989	chr22:39130855	UNC84B	0.42	7.88	0.36	2.89e-14	Menopause (age at onset);
LUAD	cis	rs59104589	0.617	rs60614486	chr2:242274998	C/G	cg08645257	chr2:242211290	HDLBP	0.5	7.8	0.35	4.75e-14	Fibrinogen levels;
LUAD	trans	rs459571	0.959	rs465724	chr9:136910097	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.59	-8.7	-0.39	7.41e-17	Platelet distribution width;
LUAD	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg19442545	chr10:75533431	FUT11	0.49	8.65	0.39	1.12e-16	Inflammatory bowel disease;
LUAD	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.54	0.3	1.77e-10	Depression;
LUAD	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.56	0.35	2.45e-13	Breast cancer;
LUAD	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg13902645	chr11:5959945	NA	-0.59	-11.31	-0.48	4.3e-26	DNA methylation (variation);
LUAD	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg12311346	chr5:56204834	C5orf35	-0.92	-13.64	-0.55	2.32e-35	Initial pursuit acceleration;
LUAD	cis	rs600231	0.542	rs12360896	chr11:65238306	G/T	cg17120908	chr11:65337727	SSSCA1	-0.63	-8.24	-0.37	2.2e-15	Bone mineral density;
LUAD	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg19875535	chr5:140030758	IK	0.44	7.41	0.34	6.93e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.41	-0.45	9.77e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.7	-0.31	6.78e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg19610905	chr11:61596333	FADS2	-0.66	-11.3	-0.48	4.74e-26	Trans fatty acid levels;
LUAD	cis	rs2274273	0.624	rs12050123	chr14:55840386	G/A	cg04306507	chr14:55594613	LGALS3	0.41	7.91	0.36	2.24e-14	Protein biomarker;
LUAD	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg12403142	chr1:92012408	NA	-0.36	-6.65	-0.31	9.18e-11	Breast cancer;
LUAD	trans	rs2270927	0.510	rs10942765	chr5:75591324	G/A	cg13563193	chr19:33072644	PDCD5	0.97	8.95	0.4	1.16e-17	Mean corpuscular volume;
LUAD	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg08761264	chr16:28874980	SH2B1	-0.44	-6.62	-0.31	1.1e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg23750338	chr8:142222470	SLC45A4	0.61	14.13	0.57	2.12e-37	Immature fraction of reticulocytes;
LUAD	cis	rs2996428	0.504	rs3765780	chr1:3767696	C/T	cg22529645	chr1:3704559	LRRC47	-0.51	-10.31	-0.45	2.25e-22	Red cell distribution width;
LUAD	cis	rs12711979	0.692	rs6751947	chr2:3820739	G/A	cg17052675	chr2:3827356	NA	-0.51	-10.53	-0.46	3.55e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	trans	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.94	0.44	4.58e-21	Ulcerative colitis;
LUAD	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg18230493	chr5:56204884	C5orf35	-0.86	-12.47	-0.52	1.26e-30	Initial pursuit acceleration;
LUAD	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg13334819	chr7:99746414	C7orf59	0.65	10.3	0.45	2.41e-22	Coronary artery disease;
LUAD	cis	rs7819412	0.522	rs13266785	chr8:10989521	G/A	cg27411982	chr8:10470053	RP1L1	-0.37	-6.55	-0.3	1.72e-10	Triglycerides;
LUAD	trans	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg26043149	chr18:55253948	FECH	-0.42	-6.89	-0.32	2.04e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg25036284	chr2:26402008	FAM59B	-0.61	-8.43	-0.38	5.33e-16	Gut microbiome composition (summer);
LUAD	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg17264618	chr3:40429014	ENTPD3	0.35	7.45	0.34	5.18e-13	Renal cell carcinoma;
LUAD	cis	rs752010	0.806	rs4641303	chr1:42091310	A/G	cg06885757	chr1:42089581	HIVEP3	0.48	10.86	0.47	2.11e-24	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg05044414	chr3:183734942	ABCC5	0.48	10.07	0.44	1.64e-21	Anterior chamber depth;
LUAD	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.42	-0.34	6.4e-13	Total body bone mineral density;
LUAD	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg02734326	chr4:10020555	SLC2A9	0.57	9.81	0.43	1.27e-20	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs934734	0.752	rs2661795	chr2:65626806	C/T	cg11674355	chr2:65610261	SPRED2	0.36	6.47	0.3	2.68e-10	Rheumatoid arthritis;
LUAD	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg00129232	chr17:37814104	STARD3	-0.47	-7.69	-0.35	1.03e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.66	-10.28	-0.45	2.76e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg11494091	chr17:61959527	GH2	0.4	6.96	0.32	1.34e-11	Height;
LUAD	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.41	-0.34	7.13e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	8.26	0.37	1.9e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs62238980	0.614	rs78781151	chr22:32375462	C/T	cg00543991	chr22:32367038	NA	0.91	8.21	0.37	2.8e-15	Childhood ear infection;
LUAD	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.43	-6.94	-0.32	1.44e-11	Multiple sclerosis;
LUAD	trans	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.06	-0.4	4.77e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4638749	0.953	rs4676033	chr2:108869368	G/A	cg06795125	chr2:108905320	SULT1C2	-0.43	-6.64	-0.31	9.47e-11	Blood pressure;
LUAD	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.75	-0.31	4.87e-11	Triglycerides;
LUAD	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg27124370	chr19:33622961	WDR88	0.45	6.94	0.32	1.46e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg11070056	chr1:107600091	PRMT6	-0.57	-9.43	-0.42	2.77e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg23029597	chr12:123009494	RSRC2	-0.5	-7.67	-0.35	1.21e-13	Body mass index;
LUAD	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg00898013	chr13:113819073	PROZ	-0.69	-12.17	-0.51	2.05e-29	Platelet distribution width;
LUAD	cis	rs68170813	0.641	rs6979368	chr7:107089009	C/G	cg23024343	chr7:107201750	COG5	0.51	7.05	0.32	7.13e-12	Coronary artery disease;
LUAD	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg17848003	chr1:3704513	LRRC47	-0.53	-10.82	-0.47	3e-24	Red cell distribution width;
LUAD	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg01528321	chr10:82214614	TSPAN14	0.58	9.42	0.42	2.87e-19	Post bronchodilator FEV1;
LUAD	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1079204	1.000	rs11888211	chr2:219146988	G/A	cg05728596	chr2:219128475	GPBAR1	1.11	10.85	0.47	2.34e-24	Smooth-surface caries;
LUAD	trans	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg08071915	chr8:12219732	FAM66A	0.43	7.19	0.33	3.02e-12	Joint mobility (Beighton score);
LUAD	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg22482690	chr17:47019901	SNF8	0.45	8.67	0.39	9.59e-17	Type 2 diabetes;
LUAD	cis	rs210138	0.832	rs375555	chr6:33557741	T/C	cg17865955	chr6:33601177	ITPR3	0.41	6.38	0.3	4.72e-10	Testicular germ cell tumor;
LUAD	cis	rs16910800	0.689	rs7101825	chr11:23164951	C/G	cg20040320	chr11:23191996	NA	0.6	8.22	0.37	2.57e-15	Cancer;
LUAD	cis	rs6740322	0.857	rs11690012	chr2:43542480	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-10.58	-0.46	2.25e-23	Coronary artery disease;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg22986084	chr14:39901328	FBXO33	-0.44	-7.23	-0.33	2.25e-12	Schizophrenia;
LUAD	cis	rs2637266	0.967	rs12246430	chr10:78352879	C/T	cg18941641	chr10:78392320	NA	0.34	7.2	0.33	2.77e-12	Pulmonary function;
LUAD	cis	rs7100689	0.580	rs7083519	chr10:82207524	C/G	cg01528321	chr10:82214614	TSPAN14	0.62	9.83	0.43	1.16e-20	Post bronchodilator FEV1;
LUAD	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg05368731	chr17:41323189	NBR1	0.95	19.82	0.69	2.54e-62	Menopause (age at onset);
LUAD	cis	rs4711350	1.000	rs943472	chr6:33738442	T/C	cg18005901	chr6:33739558	LEMD2	-0.52	-7.61	-0.35	1.84e-13	Schizophrenia;
LUAD	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg23533926	chr12:111358616	MYL2	-0.42	-7.25	-0.33	2.01e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg17063962	chr7:91808500	NA	-0.63	-10.7	-0.46	8.31e-24	Breast cancer;
LUAD	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg26354017	chr1:205819088	PM20D1	-0.53	-8.19	-0.37	3.09e-15	Menarche (age at onset);
LUAD	cis	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg07460842	chr6:66804631	NA	0.96	12.93	0.53	1.93e-32	Exhaled nitric oxide output;
LUAD	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg26924012	chr15:45694286	SPATA5L1	0.86	14.76	0.58	4.61e-40	Homoarginine levels;
LUAD	cis	rs11077815	0.733	rs4516263	chr17:74432562	A/G	cg06840243	chr17:74442338	UBE2O	0.38	7.0	0.32	1.02e-11	Lymphocyte counts;
LUAD	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.32	-0.34	1.27e-12	Total body bone mineral density;
LUAD	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg02569458	chr12:86230093	RASSF9	0.38	7.28	0.33	1.62e-12	Major depressive disorder;
LUAD	cis	rs897984	0.609	rs72800847	chr16:31022639	G/A	cg02466173	chr16:30829666	NA	-0.56	-9.42	-0.42	3.06e-19	Dementia with Lewy bodies;
LUAD	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg02176678	chr2:219576539	TTLL4	-0.82	-17.07	-0.64	4.29e-50	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg22875332	chr1:76189707	ACADM	-0.85	-16.25	-0.62	1.69e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg04565464	chr8:145669602	NFKBIL2	0.45	6.67	0.31	7.85e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg02569458	chr12:86230093	RASSF9	0.39	7.25	0.33	2.05e-12	Major depressive disorder;
LUAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg03188948	chr7:1209495	NA	0.66	9.6	0.42	7.32e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2637266	1.000	rs1907305	chr10:78339512	C/G	cg18941641	chr10:78392320	NA	0.32	6.61	0.31	1.14e-10	Pulmonary function;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg13577407	chr3:57994372	FLNB	0.4	6.41	0.3	3.99e-10	Optic cup area;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg16025584	chr9:139887217	C9orf142	0.45	7.17	0.33	3.47e-12	Diastolic blood pressure;
LUAD	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg16405210	chr4:1374714	KIAA1530	-0.37	-6.4	-0.3	4.19e-10	Obesity-related traits;
LUAD	cis	rs7119	0.651	rs35657172	chr15:77847813	T/C	cg27398640	chr15:77910606	LINGO1	-0.37	-6.72	-0.31	5.84e-11	Type 2 diabetes;
LUAD	cis	rs60154123	0.686	rs227222	chr1:210191272	T/C	cg23283495	chr1:209979779	IRF6	-0.62	-6.51	-0.3	2.1e-10	Coronary artery disease;
LUAD	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg13877915	chr19:58951672	ZNF132	0.72	13.62	0.55	2.86e-35	Uric acid clearance;
LUAD	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg18180107	chr4:99064573	C4orf37	0.48	7.49	0.34	4.05e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg15128208	chr22:42549153	NA	0.4	6.39	0.3	4.28e-10	Birth weight;
LUAD	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg03433033	chr1:76189801	ACADM	0.86	17.24	0.64	7.58e-51	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12976411	0.867	rs34877796	chr19:32829045	C/T	cg18253629	chr19:32836317	ZNF507	0.65	7.09	0.33	5.62e-12	Coronary artery disease;
LUAD	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	10.43	0.45	8.13e-23	Smoking behavior;
LUAD	trans	rs12517041	1.000	rs6888168	chr5:23304401	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.57	-0.3	1.47e-10	Calcium levels;
LUAD	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg24596788	chr1:163392923	NA	-0.32	-7.0	-0.32	9.98e-12	Motion sickness;
LUAD	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg15448220	chr1:150897856	SETDB1	0.53	9.32	0.41	6.74e-19	Melanoma;
LUAD	cis	rs4730250	0.707	rs257377	chr7:106801088	G/T	cg23024343	chr7:107201750	COG5	0.51	6.84	0.32	2.82e-11	Osteoarthritis;
LUAD	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg02527881	chr3:46936655	PTH1R	0.42	8.04	0.36	9.08e-15	Colorectal cancer;
LUAD	trans	rs911186	0.812	rs35454259	chr6:27254475	G/A	cg06606381	chr12:133084897	FBRSL1	-0.5	-6.76	-0.31	4.62e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11644478	chr21:40555479	PSMG1	0.67	11.16	0.48	1.62e-25	Cognitive function;
LUAD	cis	rs2839627	0.598	rs9975526	chr21:44266573	T/A	cg03543861	chr21:44258195	NA	0.64	9.39	0.42	3.75e-19	Information processing speed;
LUAD	cis	rs12612619	0.732	rs3754734	chr2:27299598	G/T	cg00617064	chr2:27272375	NA	-0.38	-7.32	-0.34	1.29e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs9341808	0.690	rs2322634	chr6:80874014	A/C	cg08355045	chr6:80787529	NA	0.55	9.87	0.43	8.12e-21	Sitting height ratio;
LUAD	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg05368731	chr17:41323189	NBR1	0.98	20.31	0.7	1.68e-64	Menopause (age at onset);
LUAD	cis	rs3820068	0.871	rs2861484	chr1:15812665	G/T	cg24675056	chr1:15929824	NA	0.47	6.6	0.31	1.27e-10	Systolic blood pressure;
LUAD	cis	rs68149176	0.772	rs997761	chr16:87879522	A/C	cg03553613	chr16:87879502	SLC7A5	0.62	9.01	0.4	7.27e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg16850897	chr7:100343110	ZAN	-0.59	-8.14	-0.37	4.31e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs1422110	0.543	rs888804	chr5:85411181	G/A	cg01787110	chr1:109008453	NBPF6	0.58	9.48	0.42	1.87e-19	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs2979489	1.000	rs2979469	chr8:30285091	C/G	cg26383811	chr8:30366931	RBPMS	0.61	9.88	0.43	7.24e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	trans	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg07817883	chr1:32538562	TMEM39B	1.25	11.92	0.5	1.9e-28	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9584850	1.000	rs9584850	chr13:99101426	G/C	cg20750642	chr13:99100586	FARP1	-0.32	-6.66	-0.31	8.47e-11	Neuroticism;
LUAD	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.16	0.37	3.85e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1941687	0.797	rs12967889	chr18:31399371	G/A	cg27147174	chr7:100797783	AP1S1	-0.56	-9.34	-0.41	5.4e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg05340658	chr4:99064831	C4orf37	-0.46	-7.62	-0.35	1.63e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs13315871	1.000	rs13317400	chr3:58408792	T/G	cg12435725	chr3:58293450	RPP14	-0.69	-7.64	-0.35	1.47e-13	Cholesterol, total;
LUAD	cis	rs35740288	0.770	rs62023931	chr15:86132752	T/C	cg13263323	chr15:86062960	AKAP13	-0.44	-7.1	-0.33	5.46e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg11645453	chr3:52864694	ITIH4	0.39	7.62	0.35	1.7e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg27490568	chr2:178487706	NA	0.4	6.68	0.31	7.6e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg11833968	chr6:79620685	NA	-0.42	-7.87	-0.36	2.92e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7103648	0.838	rs11039244	chr11:47466442	G/A	cg20307385	chr11:47447363	PSMC3	0.64	10.03	0.44	2.24e-21	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg06671706	chr8:8559999	CLDN23	0.65	11.15	0.48	1.76e-25	Obesity-related traits;
LUAD	cis	rs1113500	0.932	rs1343205	chr1:108597873	C/G	cg06207961	chr1:108661230	NA	0.44	8.25	0.37	1.97e-15	Growth-regulated protein alpha levels;
LUAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg16606324	chr3:10149918	C3orf24	0.65	10.96	0.47	9.27e-25	Alzheimer's disease;
LUAD	cis	rs6543140	0.964	rs7561351	chr2:103077780	A/G	cg03938978	chr2:103052716	IL18RAP	0.35	6.8	0.31	3.6e-11	Blood protein levels;
LUAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg18538332	chr22:24372958	LOC391322	-0.54	-8.89	-0.4	1.82e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11625487	0.609	rs74063377	chr14:77951431	C/G	cg20045696	chr14:77926864	AHSA1	-0.65	-7.17	-0.33	3.4e-12	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUAD	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg12311346	chr5:56204834	C5orf35	-0.75	-11.84	-0.5	3.8e-28	Initial pursuit acceleration;
LUAD	cis	rs7851660	0.809	rs9299258	chr9:100666543	T/G	cg13688889	chr9:100608707	NA	-0.54	-9.16	-0.41	2.34e-18	Strep throat;
LUAD	cis	rs3772130	0.962	rs13433692	chr3:121484714	G/T	cg20356878	chr3:121714668	ILDR1	0.52	8.17	0.37	3.58e-15	Cognitive performance;
LUAD	cis	rs6062509	0.868	rs3761123	chr20:62342468	G/A	cg01176363	chr20:62369445	LIME1	-0.49	-7.81	-0.36	4.47e-14	Prostate cancer;
LUAD	cis	rs4285028	0.847	rs1986712	chr3:121710986	A/G	cg20356878	chr3:121714668	ILDR1	-0.5	-6.65	-0.31	9.35e-11	Multiple sclerosis;
LUAD	cis	rs78761021	0.898	rs9674498	chr17:9777841	T/G	cg26853458	chr17:9805074	RCVRN	0.35	6.75	0.31	4.87e-11	Type 2 diabetes;
LUAD	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg06637938	chr14:75390232	RPS6KL1	0.38	6.85	0.32	2.66e-11	Caffeine consumption;
LUAD	cis	rs868036	0.756	rs2241421	chr15:68082825	G/A	cg24579218	chr15:68104479	NA	-0.38	-7.12	-0.33	4.57e-12	Restless legs syndrome;
LUAD	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg22823121	chr1:150693482	HORMAD1	-0.39	-7.64	-0.35	1.46e-13	Melanoma;
LUAD	cis	rs79057730	0.684	rs6955004	chr7:790792	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.8	8.77	0.39	4.5e-17	Initial pursuit acceleration;
LUAD	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06028808	chr11:68637592	NA	0.45	7.32	0.34	1.28e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg23982607	chr1:1823379	GNB1	-0.92	-19.32	-0.68	4.29e-60	Body mass index;
LUAD	trans	rs853679	0.607	rs67040724	chr6:27905509	T/C	cg06606381	chr12:133084897	FBRSL1	-1.24	-10.94	-0.47	1.11e-24	Depression;
LUAD	cis	rs939584	0.799	rs2683992	chr2:600575	G/T	cg03444855	chr2:621920	NA	-0.41	-6.39	-0.3	4.44e-10	Body mass index;
LUAD	cis	rs6714710	0.603	rs953320	chr2:98606770	T/C	cg26665480	chr2:98280029	ACTR1B	0.55	9.04	0.4	5.86e-18	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg20607798	chr8:58055168	NA	0.82	9.86	0.43	9.19e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg19413350	chr8:57351067	NA	-0.41	-6.54	-0.3	1.75e-10	Obesity-related traits;
LUAD	trans	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.98	-0.36	1.4e-14	Gout;
LUAD	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg21138405	chr5:131827807	IRF1	0.59	13.41	0.55	2.07e-34	Asthma (sex interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06759117	chr16:53088791	CHD9	-0.43	-6.54	-0.3	1.8e-10	Height;
LUAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg05665937	chr4:1216051	CTBP1	-0.42	-7.24	-0.33	2.19e-12	Obesity-related traits;
LUAD	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.53	-9.69	-0.43	3.38e-20	Schizophrenia;
LUAD	cis	rs2046867	0.866	rs2244246	chr3:72789191	G/A	cg04365224	chr3:72788183	NA	0.42	6.41	0.3	3.82e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg24818145	chr4:99064322	C4orf37	0.46	7.22	0.33	2.44e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6723108	0.713	rs6728095	chr2:135376072	T/A	cg12500956	chr2:135428796	TMEM163	-0.28	-7.37	-0.34	8.85e-13	Type 2 diabetes;
LUAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	11.94	0.5	1.57e-28	Prudent dietary pattern;
LUAD	cis	rs36051895	0.626	rs7870694	chr9:5100628	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-6.73	-0.31	5.61e-11	Pediatric autoimmune diseases;
LUAD	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg07169764	chr2:136633963	MCM6	0.76	8.92	0.4	1.41e-17	Corneal structure;
LUAD	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg09222892	chr1:25734099	RHCE	-0.49	-9.04	-0.4	5.71e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg16049864	chr8:95962084	TP53INP1	-0.54	-11.6	-0.49	3.33e-27	Type 2 diabetes;
LUAD	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg12863693	chr15:85201151	NMB	0.4	7.54	0.34	2.82e-13	Schizophrenia;
LUAD	cis	rs3791556	0.853	rs56122162	chr2:240131281	T/C	cg03281426	chr2:240109471	HDAC4	0.38	6.78	0.31	4.13e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg22823121	chr1:150693482	HORMAD1	-0.44	-8.35	-0.38	1.01e-15	Blood protein levels;
LUAD	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg12016809	chr21:47604291	C21orf56	0.45	7.25	0.33	1.95e-12	Testicular germ cell tumor;
LUAD	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg23750338	chr8:142222470	SLC45A4	0.34	6.52	0.3	1.99e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2625529	0.556	rs55679065	chr15:72433395	C/T	cg16672083	chr15:72433130	SENP8	0.63	12.06	0.51	5.36e-29	Red blood cell count;
LUAD	cis	rs72781680	0.566	rs72796106	chr2:23901362	A/C	cg20701182	chr2:24300061	SF3B14	0.66	8.16	0.37	3.8e-15	Lymphocyte counts;
LUAD	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg21100191	chr22:23484243	RTDR1	0.69	12.12	0.51	3.23e-29	Bone mineral density;
LUAD	cis	rs10927875	0.691	rs2017583	chr1:16350028	A/G	cg22431228	chr1:16359049	CLCNKA	-0.54	-9.68	-0.43	3.65e-20	Dilated cardiomyopathy;
LUAD	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs1073160	1.000	rs1073160	chr12:9058562	A/G	cg23795048	chr12:9217529	LOC144571	-0.38	-6.98	-0.32	1.12e-11	Small cell lung carcinoma;
LUAD	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg12011299	chr4:100065546	ADH4	0.66	12.17	0.51	2.06e-29	Alcohol dependence;
LUAD	cis	rs698833	0.501	rs10194161	chr2:44507213	A/G	cg04920474	chr2:44395004	PPM1B	-0.52	-10.24	-0.45	4.04e-22	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs2070677	0.935	rs4582924	chr10:135409033	T/G	cg20169779	chr10:135381914	SYCE1	-0.52	-8.39	-0.38	7.56e-16	Gout;
LUAD	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg06558623	chr16:89946397	TCF25	1.14	9.96	0.44	4.02e-21	Skin colour saturation;
LUAD	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg02951883	chr7:2050386	MAD1L1	-0.79	-14.04	-0.56	4.78e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg01689657	chr7:91764605	CYP51A1	0.29	7.12	0.33	4.66e-12	Breast cancer;
LUAD	cis	rs7215564	0.908	rs2315922	chr17:78695127	C/T	cg16980736	chr17:78789706	RPTOR	-0.66	-6.81	-0.31	3.4e-11	Myopia (pathological);
LUAD	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg10518543	chr12:38710700	ALG10B	0.42	6.42	0.3	3.68e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs17095355	1.000	rs12570423	chr10:111690942	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.71	-9.36	-0.41	4.66e-19	Biliary atresia;
LUAD	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22857025	chr5:266934	NA	-0.97	-14.42	-0.57	1.24e-38	Breast cancer;
LUAD	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18099408	chr3:52552593	STAB1	-0.46	-7.97	-0.36	1.46e-14	Bipolar disorder;
LUAD	cis	rs7503807	0.967	rs7215486	chr17:78612034	C/T	cg09596252	chr17:78655493	RPTOR	0.4	7.76	0.35	6.59e-14	Obesity;
LUAD	cis	rs4698036	0.626	rs11737042	chr4:10412350	A/G	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.37	-0.3	4.82e-10	Cardiovascular disease risk factors;
LUAD	cis	rs2235649	0.592	rs8046208	chr16:1964008	G/A	cg07386859	chr16:1872102	HAGH	0.44	6.36	0.3	5.23e-10	Blood metabolite levels;
LUAD	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg22598563	chr5:131563921	P4HA2	-0.28	-6.84	-0.32	2.83e-11	Blood metabolite levels;
LUAD	cis	rs2944755	0.959	rs2977491	chr8:141574277	A/G	cg26074100	chr8:141568712	EIF2C2	0.4	7.2	0.33	2.73e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21582582	chr3:182698605	DCUN1D1	0.59	9.55	0.42	1.06e-19	Resting heart rate;
LUAD	cis	rs1448094	0.842	rs12318815	chr12:86452281	T/C	cg00310523	chr12:86230176	RASSF9	-0.35	-7.29	-0.33	1.54e-12	Major depressive disorder;
LUAD	cis	rs12681287	0.640	rs7007855	chr8:87429491	T/G	cg00550725	chr8:87521180	FAM82B	-0.45	-6.63	-0.31	1.02e-10	Caudate activity during reward;
LUAD	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg08805041	chr16:621841	PIGQ	-0.32	-6.52	-0.3	1.99e-10	Height;
LUAD	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg07926092	chr13:79233506	RNF219	0.82	11.43	0.49	1.49e-26	Large artery stroke;
LUAD	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg27631724	chr1:11040367	C1orf127	0.55	9.67	0.43	4.01e-20	Ewing sarcoma;
LUAD	cis	rs713587	0.719	rs4665736	chr2:25187599	C/T	cg04586622	chr2:25135609	ADCY3	-0.31	-6.72	-0.31	6.01e-11	Body mass index in non-asthmatics;
LUAD	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-7.97	-0.36	1.53e-14	Myeloid white cell count;
LUAD	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	9.32	0.41	6.37e-19	Total body bone mineral density;
LUAD	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.12	0.37	5.16e-15	Menopause (age at onset);
LUAD	cis	rs9462027	0.628	rs9469859	chr6:34722902	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.76	-0.39	4.88e-17	Systemic lupus erythematosus;
LUAD	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23583168	chr7:148888333	NA	-0.91	-18.84	-0.68	6.36e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs4653767	1.000	rs10495249	chr1:226919119	A/G	cg05049329	chr1:226924846	ITPKB	0.46	8.13	0.37	4.77e-15	Parkinson's disease;
LUAD	cis	rs7107174	0.892	rs1017907	chr11:77959124	A/T	cg19901956	chr11:77921274	USP35	-0.52	-6.71	-0.31	6.25e-11	Testicular germ cell tumor;
LUAD	cis	rs490234	0.783	rs10986848	chr9:128461889	T/C	cg14078157	chr9:128172775	NA	-0.46	-8.54	-0.38	2.53e-16	Mean arterial pressure;
LUAD	cis	rs77861329	1.000	rs171294	chr3:52203599	C/G	cg08692210	chr3:52188851	WDR51A	0.86	8.27	0.37	1.79e-15	Macrophage inflammatory protein 1b levels;
LUAD	trans	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06028605	chr16:24865363	SLC5A11	-0.55	-8.46	-0.38	4.33e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg07741184	chr6:167504864	NA	0.36	8.17	0.37	3.66e-15	Primary biliary cholangitis;
LUAD	cis	rs1997103	1.000	rs2331063	chr7:55408914	A/G	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg17724175	chr1:150552817	MCL1	0.4	9.72	0.43	2.81e-20	Tonsillectomy;
LUAD	cis	rs713477	0.967	rs7146170	chr14:55914054	G/C	cg13175173	chr14:55914753	NA	-0.35	-7.4	-0.34	7.41e-13	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg25753631	chr6:25732923	NA	-0.45	-7.9	-0.36	2.45e-14	Iron status biomarkers;
LUAD	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg10057126	chr4:77819792	ANKRD56	0.55	9.62	0.42	6.09e-20	Emphysema distribution in smoking;
LUAD	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg06547715	chr2:218990976	CXCR2	0.29	6.92	0.32	1.73e-11	Colorectal cancer;
LUAD	cis	rs9393777	0.502	rs3823427	chr6:27256346	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-6.53	-0.3	1.84e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg16479474	chr6:28041457	NA	0.38	7.03	0.32	8.23e-12	Parkinson's disease;
LUAD	trans	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg25482853	chr8:67687455	SGK3	1.06	16.65	0.63	2.99e-48	Obesity-related traits;
LUAD	cis	rs11249608	0.548	rs6875473	chr5:178451387	C/A	cg01312482	chr5:178451176	ZNF879	-0.44	-6.81	-0.31	3.46e-11	Pubertal anthropometrics;
LUAD	cis	rs559928	0.576	rs750830	chr11:64163446	G/A	cg05555928	chr11:63887634	MACROD1	-0.47	-7.65	-0.35	1.38e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUAD	trans	rs9961915	1.000	rs7227665	chr18:24659179	A/G	cg05451974	chr20:43991922	SYS1;SYS1-DBNDD2	0.41	6.38	0.3	4.75e-10	Dental caries;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg25820224	chr2:95787551	MRPS5	-0.38	-6.38	-0.3	4.54e-10	Vertical cup-disc ratio;
LUAD	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg04450456	chr4:17643702	FAM184B	0.39	7.53	0.34	3.09e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg08213375	chr14:104286397	PPP1R13B	0.27	6.94	0.32	1.47e-11	Schizophrenia;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg25970120	chr1:39325951	RRAGC	-0.4	-6.67	-0.31	7.93e-11	Subcortical brain region volumes;
LUAD	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg15147215	chr3:52552868	STAB1	-0.42	-7.51	-0.34	3.46e-13	Bipolar disorder;
LUAD	trans	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-8.83	-0.39	2.85e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg13319975	chr6:146136371	FBXO30	0.65	11.46	0.49	1.17e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12618769	0.597	rs10199199	chr2:99061834	T/C	cg10123293	chr2:99228465	UNC50	0.47	8.42	0.38	5.79e-16	Bipolar disorder;
LUAD	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg25427524	chr10:38739819	LOC399744	-0.64	-8.95	-0.4	1.13e-17	Obesity (extreme);
LUAD	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg22491629	chr6:157744540	C6orf35	0.79	9.23	0.41	1.33e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs17095355	1.000	rs9630101	chr10:111738451	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.67	-9.1	-0.4	3.56e-18	Biliary atresia;
LUAD	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11890956	chr21:40555474	PSMG1	0.82	14.7	0.58	8.2e-40	Cognitive function;
LUAD	cis	rs6545883	0.965	rs9989775	chr2:61761774	A/G	cg15711740	chr2:61764176	XPO1	-0.42	-6.7	-0.31	6.54e-11	Tuberculosis;
LUAD	cis	rs72949976	0.584	rs12467619	chr2:214022933	T/C	cg08319019	chr2:214017104	IKZF2	0.57	8.8	0.39	3.58e-17	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg02428538	chr16:24856791	SLC5A11	-0.51	-7.38	-0.34	8.36e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs877282	0.797	rs7079164	chr10:756363	A/G	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.48	-0.3	2.48e-10	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.72	-9.9	-0.43	6.41e-21	Obesity-related traits;
LUAD	cis	rs909002	0.849	rs7546297	chr1:32106494	A/G	cg13919466	chr1:32135498	COL16A1	-0.35	-8.14	-0.37	4.57e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-8.38	-0.38	8.19e-16	Menarche (age at onset);
LUAD	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg04842962	chr6:43655489	MRPS18A	-0.82	-12.36	-0.52	3.7e-30	IgG glycosylation;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08806622	chr17:27279525	PHF12	-0.69	-6.49	-0.3	2.39e-10	Type 2 diabetes;
LUAD	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg10544611	chr16:67998164	SLC12A4	-0.68	-8.13	-0.37	4.79e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg01579765	chr21:45077557	HSF2BP	-0.66	-15.06	-0.59	2.34e-41	Mean corpuscular volume;
LUAD	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg06558623	chr16:89946397	TCF25	1.17	10.78	0.46	4.32e-24	Skin colour saturation;
LUAD	cis	rs9875589	0.509	rs1873005	chr3:14060223	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	6.55	0.3	1.66e-10	Ovarian reserve;
LUAD	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.47	-8.28	-0.37	1.61e-15	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.7	0.31	6.5500000000000006e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12681287	0.640	rs13251006	chr8:87469105	C/T	cg27223183	chr8:87520930	FAM82B	-0.67	-9.54	-0.42	1.12e-19	Caudate activity during reward;
LUAD	cis	rs12579753	0.917	rs12822036	chr12:82183009	C/T	cg07988820	chr12:82153109	PPFIA2	-0.44	-7.19	-0.33	2.88e-12	Resting heart rate;
LUAD	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg04944784	chr2:26401820	FAM59B	-0.71	-10.02	-0.44	2.37e-21	Gut microbiome composition (summer);
LUAD	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg27124370	chr19:33622961	WDR88	0.46	7.15	0.33	3.92e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg02753203	chr1:228287806	NA	0.75	14.17	0.57	1.43e-37	Diastolic blood pressure;
LUAD	trans	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg02030672	chr11:45687055	CHST1	0.43	7.73	0.35	8.09e-14	Obesity-related traits;
LUAD	cis	rs75920871	0.800	rs17120251	chr11:116923488	A/G	cg04087571	chr11:116723030	SIK3	-0.3	-6.45	-0.3	3.08e-10	Subjective well-being;
LUAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08677398	chr8:58056175	NA	0.51	6.91	0.32	1.81e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs13064411	0.696	rs6438156	chr3:113206929	C/A	cg18753928	chr3:113234510	CCDC52	-0.74	-12.4	-0.52	2.46e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg08422745	chr4:174089978	GALNT7	-0.94	-16.54	-0.63	9.34e-48	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs11229555	0.645	rs7116007	chr11:58218701	C/T	cg15696309	chr11:58395628	NA	-0.8	-10.75	-0.46	5.45e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6546550	0.935	rs7563062	chr2:70050725	G/A	cg02498382	chr2:70120550	SNRNP27	-0.55	-10.36	-0.45	1.43e-22	Prevalent atrial fibrillation;
LUAD	cis	rs7593730	0.537	rs4597468	chr2:161200265	T/C	cg22609984	chr2:161126801	NA	0.5	9.09	0.4	4.01e-18	Type 2 diabetes;
LUAD	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	cg06064525	chr11:970664	AP2A2	-0.34	-6.65	-0.31	9.06e-11	Alzheimer's disease (late onset);
LUAD	cis	rs11153730	0.503	rs445099	chr6:118618252	T/C	cg18833306	chr6:118973337	C6orf204	0.55	10.24	0.45	3.95e-22	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg17264618	chr3:40429014	ENTPD3	-0.41	-8.93	-0.4	1.35e-17	Renal cell carcinoma;
LUAD	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg19052272	chr2:3704530	ALLC	-0.42	-7.8	-0.35	4.78e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg06641503	chr3:48959341	ARIH2	-0.36	-7.1	-0.33	5.17e-12	Menarche (age at onset);
LUAD	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05890377	chr2:74357713	NA	0.82	12.68	0.52	1.84e-31	Gestational age at birth (maternal effect);
LUAD	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg21798802	chr22:38057573	PDXP	0.49	9.83	0.43	1.13e-20	Fat distribution (HIV);
LUAD	cis	rs6987853	0.787	rs2923405	chr8:42448126	T/G	cg09913449	chr8:42400586	C8orf40	0.47	9.21	0.41	1.56e-18	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs11126435	0.858	rs363671	chr2:74930042	C/T	cg19285774	chr2:74907978	SEMA4F	0.37	6.49	0.3	2.45e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs240764	0.697	rs239199	chr6:101134108	C/T	cg09795085	chr6:101329169	ASCC3	0.4	6.74	0.31	5.14e-11	Neuroticism;
LUAD	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg04414720	chr1:150670196	GOLPH3L	0.72	12.45	0.52	1.53e-30	Melanoma;
LUAD	cis	rs16854884	0.586	rs11914731	chr3:143725594	A/G	cg01302019	chr3:143689584	C3orf58	-0.37	-6.63	-0.31	1.02e-10	Economic and political preferences (feminism/equality);
LUAD	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	7.9	0.36	2.38e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13732083	chr21:47605072	C21orf56	0.47	7.8	0.35	4.88e-14	Testicular germ cell tumor;
LUAD	cis	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg12884169	chr21:40033163	ERG	0.38	7.9	0.36	2.47e-14	Coronary artery disease;
LUAD	cis	rs7095607	0.785	rs10762190	chr10:69919905	C/A	cg18986048	chr10:69913749	MYPN	0.38	6.41	0.3	3.92e-10	Lung function (FVC);
LUAD	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19748678	chr4:122722346	EXOSC9	0.42	6.78	0.31	4.16e-11	Type 2 diabetes;
LUAD	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg11189052	chr15:85197271	WDR73	0.65	8.17	0.37	3.53e-15	Schizophrenia;
LUAD	cis	rs3125734	0.534	rs10821973	chr10:64052337	G/A	cg09941381	chr10:64027924	RTKN2	-0.31	-7.18	-0.33	3.19e-12	Rheumatoid arthritis;
LUAD	cis	rs76878669	0.561	rs7940980	chr11:66172910	C/T	cg18002602	chr11:66138449	SLC29A2	-0.49	-10.23	-0.45	4.27e-22	Educational attainment (years of education);
LUAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg00431813	chr7:1051703	C7orf50	-0.46	-9.15	-0.41	2.35e-18	Longevity;Endometriosis;
LUAD	cis	rs2235649	0.798	rs9932983	chr16:1848184	A/G	cg08610935	chr16:1836813	NUBP2	-0.5	-7.72	-0.35	8.49e-14	Blood metabolite levels;
LUAD	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg05368731	chr17:41323189	NBR1	0.84	16.48	0.63	1.75e-47	Menopause (age at onset);
LUAD	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg14895029	chr7:2775587	GNA12	-0.44	-7.1	-0.33	5.16e-12	Height;
LUAD	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.65e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg01017244	chr2:74357527	NA	0.82	13.57	0.55	4.68e-35	Gestational age at birth (maternal effect);
LUAD	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg22823121	chr1:150693482	HORMAD1	0.37	7.25	0.33	1.96e-12	Melanoma;
LUAD	cis	rs2580764	0.678	rs2255112	chr2:55200800	T/G	cg09592903	chr2:55203963	RTN4	0.47	10.98	0.47	7.63e-25	Mean platelet volume;
LUAD	cis	rs11741688	0.557	rs10043579	chr5:178330174	C/T	cg20935368	chr5:178288625	ZNF354B	0.36	6.39	0.3	4.51e-10	Sleep duration;
LUAD	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	cg06064525	chr11:970664	AP2A2	-0.46	-9.16	-0.41	2.2e-18	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg18180107	chr4:99064573	C4orf37	0.42	6.66	0.31	8.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg18876405	chr7:65276391	NA	-0.45	-7.19	-0.33	2.89e-12	Aortic root size;
LUAD	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg18944383	chr4:111397179	ENPEP	0.43	8.57	0.38	2e-16	Height;
LUAD	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg18252515	chr7:66147081	NA	-0.62	-6.92	-0.32	1.73e-11	Diabetic kidney disease;
LUAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg13397359	chr6:42928475	GNMT	0.6	11.26	0.48	6.86e-26	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg24397884	chr7:158709396	WDR60	0.48	8.22	0.37	2.61e-15	Height;
LUAD	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg02734326	chr4:10020555	SLC2A9	0.42	7.26	0.33	1.87e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg22532475	chr10:104410764	TRIM8	-0.46	-9.01	-0.4	6.93e-18	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-12.27	-0.51	8.12e-30	Bone mineral density;
LUAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg24813613	chr7:1882135	MAD1L1	-0.58	-9.37	-0.41	4.52e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs3849570	0.695	rs6792696	chr3:81874009	G/A	cg07356753	chr3:81810745	GBE1	-0.59	-9.55	-0.42	1.08e-19	Waist circumference;Body mass index;
LUAD	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg15468180	chr1:107600409	PRMT6	-0.39	-6.46	-0.3	2.84e-10	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs3806843	0.583	rs408652	chr5:140330013	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.66	-0.31	8.65e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg24818145	chr4:99064322	C4orf37	0.4	6.62	0.31	1.08e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg02371401	chr5:676784	TPPP	-0.48	-7.83	-0.36	3.9e-14	Lung disease severity in cystic fibrosis;
LUAD	cis	rs11677416	0.813	rs4848299	chr2:113523454	C/A	cg27083787	chr2:113543245	IL1A	0.38	6.64	0.31	9.56e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg08514558	chr10:81106712	PPIF	-0.5	-9.8	-0.43	1.45e-20	Height;
LUAD	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg09537434	chr19:41945824	ATP5SL	-0.45	-6.93	-0.32	1.59e-11	Height;
LUAD	cis	rs75920871	1.000	rs4938325	chr11:116898479	G/A	cg04087571	chr11:116723030	SIK3	-0.32	-6.48	-0.3	2.63e-10	Subjective well-being;
LUAD	cis	rs775227	0.574	rs13064411	chr3:113046640	A/G	cg18753928	chr3:113234510	CCDC52	-0.66	-8.26	-0.37	1.84e-15	Dental caries;
LUAD	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg10426581	chr7:100472382	SRRT	0.73	9.47	0.42	2.05e-19	Resting heart rate;
LUAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg04025307	chr7:1156635	C7orf50	0.9	17.71	0.65	6.77e-53	Longevity;Endometriosis;
LUAD	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg25767906	chr1:53392781	SCP2	0.42	7.85	0.36	3.45e-14	Monocyte count;
LUAD	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg26513180	chr16:89883248	FANCA	0.45	7.52	0.34	3.39e-13	Vitiligo;
LUAD	cis	rs11696501	0.739	rs6104252	chr20:44254323	G/A	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.2	-0.37	2.94e-15	Brain structure;
LUAD	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg13334819	chr7:99746414	C7orf59	0.65	10.47	0.45	5.83e-23	Coronary artery disease;
LUAD	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.87	0.36	2.95e-14	Morning vs. evening chronotype;
LUAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06873352	chr17:61820015	STRADA	0.78	16.66	0.63	2.88e-48	Prudent dietary pattern;
LUAD	trans	rs11650494	0.908	rs111834333	chr17:47411814	C/T	cg11430096	chr6:110968061	CDK19	0.86	6.79	0.31	3.77e-11	Prostate cancer;
LUAD	cis	rs367943	0.626	rs7718480	chr5:112704486	G/T	cg12552261	chr5:112820674	MCC	0.44	8.88	0.4	1.95e-17	Type 2 diabetes;
LUAD	cis	rs78366141	0.649	rs112818517	chr4:89653103	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.91	6.37	0.3	4.9e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg04539111	chr16:67997858	SLC12A4	-0.48	-6.4	-0.3	4.18e-10	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg02030672	chr11:45687055	CHST1	0.44	8.11	0.37	5.57e-15	Obesity-related traits;
LUAD	cis	rs6740322	0.696	rs10188539	chr2:43484675	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-10.79	-0.46	3.77e-24	Coronary artery disease;
LUAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.12	0.41	3.18e-18	Alzheimer's disease;
LUAD	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg22532475	chr10:104410764	TRIM8	-0.42	-8.09	-0.37	6.58e-15	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2019216	0.500	rs2169916	chr17:21884670	G/C	cg22648282	chr17:21454238	C17orf51	-0.48	-7.96	-0.36	1.58e-14	Pelvic organ prolapse;
LUAD	cis	rs6062509	0.965	rs1056441	chr20:62370349	T/C	cg02966332	chr20:62369605	LIME1	-0.48	-7.56	-0.35	2.53e-13	Prostate cancer;
LUAD	cis	rs7132746	0.620	rs61930068	chr12:86210857	T/C	cg18827107	chr12:86230957	RASSF9	-0.49	-6.56	-0.3	1.55e-10	Lewy body disease;
LUAD	cis	rs10992471	0.630	rs10992322	chr9:95159196	A/G	cg14631576	chr9:95140430	CENPP	-0.41	-8.38	-0.38	7.76e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg09365446	chr1:150670422	GOLPH3L	0.55	9.57	0.42	8.72e-20	Melanoma;
LUAD	cis	rs62458065	0.850	rs7785999	chr7:32461262	G/T	cg20159608	chr7:32802032	NA	-0.53	-7.15	-0.33	3.91e-12	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg13319975	chr6:146136371	FBXO30	0.58	9.68	0.43	3.91e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg07606381	chr6:8435919	SLC35B3	0.42	6.95	0.32	1.38e-11	Motion sickness;
LUAD	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg00071950	chr4:10020882	SLC2A9	-0.75	-14.81	-0.58	2.73e-40	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg24558204	chr6:135376177	HBS1L	0.48	8.81	0.39	3.28e-17	Red blood cell count;
LUAD	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.57	6.5	0.3	2.25e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg01200585	chr1:228362443	C1orf69	0.42	7.7	0.35	9.68e-14	Diastolic blood pressure;
LUAD	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg06740227	chr12:86229804	RASSF9	0.39	6.91	0.32	1.77e-11	Major depressive disorder;
LUAD	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg19622623	chr12:86230825	RASSF9	-0.56	-9.94	-0.44	4.76e-21	Major depressive disorder;
LUAD	cis	rs1595825	0.891	rs7573687	chr2:198893376	A/G	cg00982548	chr2:198649783	BOLL	-0.65	-9.2	-0.41	1.65e-18	Ulcerative colitis;
LUAD	cis	rs9326248	0.581	rs10892048	chr11:116814596	A/G	cg20608306	chr11:116969690	SIK3	0.33	7.4	0.34	7.58e-13	Blood protein levels;
LUAD	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg25769590	chr7:158789503	NA	-0.38	-7.03	-0.32	8.17e-12	Facial morphology (factor 20);
LUAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg04025307	chr7:1156635	C7orf50	0.65	7.38	0.34	8.47e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10823500	0.748	rs2394668	chr10:71943951	G/A	cg02100629	chr10:71892760	AIFM2	-0.38	-7.57	-0.35	2.4e-13	Blood protein levels;
LUAD	cis	rs67072384	0.892	rs7104664	chr11:72444450	C/T	cg04827223	chr11:72435913	ARAP1	-0.63	-7.58	-0.35	2.19e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg21724239	chr8:58056113	NA	0.89	16.66	0.63	2.67e-48	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg24813613	chr7:1882135	MAD1L1	-0.44	-7.25	-0.33	2.01e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg19622623	chr12:86230825	RASSF9	-0.55	-9.8	-0.43	1.46e-20	Major depressive disorder;
LUAD	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg02569458	chr12:86230093	RASSF9	0.44	8.08	0.37	6.84e-15	Major depressive disorder;
LUAD	cis	rs13315871	1.000	rs28417694	chr3:58373939	A/G	cg20936604	chr3:58311152	NA	-0.68	-7.09	-0.33	5.62e-12	Cholesterol, total;
LUAD	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg07395648	chr5:131743802	NA	-0.38	-6.43	-0.3	3.35e-10	Acylcarnitine levels;
LUAD	cis	rs11811982	0.793	rs74840653	chr1:227281814	A/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.44	0.34	5.54e-13	Optic disc area;
LUAD	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg15181151	chr6:150070149	PCMT1	0.36	7.05	0.32	7.5e-12	Lung cancer;
LUAD	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg05966235	chr16:28915196	ATP2A1	0.47	7.61	0.35	1.83e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21659725	chr3:3221576	CRBN	0.85	17.34	0.64	2.8e-51	Intelligence (multi-trait analysis);
LUAD	cis	rs6601327	0.641	rs4840437	chr8:9606264	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-6.67	-0.31	8.2e-11	Multiple myeloma (hyperdiploidy);
LUAD	cis	rs8014204	0.743	rs35809608	chr14:75254762	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.34	-6.45	-0.3	3.03e-10	Caffeine consumption;
LUAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg26516362	chr5:178986906	RUFY1	0.67	11.87	0.5	3.1e-28	Lung cancer;
LUAD	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg21153622	chr11:89784906	NA	0.32	6.4	0.3	4.02e-10	Coronary artery disease;
LUAD	trans	rs11039798	0.841	rs7950737	chr11:48590678	T/G	cg15704280	chr7:45808275	SEPT13	0.64	7.59	0.35	2.13e-13	Axial length;
LUAD	cis	rs1904096	0.506	rs2865350	chr4:95212813	A/T	cg11021082	chr4:95130006	SMARCAD1	0.51	8.84	0.39	2.64e-17	Type 2 diabetes;
LUAD	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.63	10.88	0.47	1.81e-24	Cognitive ability;
LUAD	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg09021430	chr5:549028	NA	0.47	11.99	0.5	1.01e-28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg14634687	chr17:47094252	IGF2BP1	0.27	6.76	0.31	4.52e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs11650494	0.710	rs16948071	chr17:47468706	T/G	cg08112188	chr17:47440006	ZNF652	0.78	6.43	0.3	3.41e-10	Prostate cancer;
LUAD	cis	rs12976411	0.575	rs59290294	chr19:32827336	T/C	cg02282382	chr19:32836354	ZNF507	0.71	6.39	0.3	4.33e-10	Coronary artery disease;
LUAD	cis	rs250677	0.958	rs36078	chr5:148430567	G/A	cg18129178	chr5:148520854	ABLIM3	-0.55	-7.97	-0.36	1.45e-14	Breast cancer;
LUAD	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg15017067	chr4:17643749	FAM184B	0.34	6.58	0.3	1.39e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg12483005	chr1:23474871	LUZP1	0.52	8.97	0.4	9.62e-18	Height;
LUAD	cis	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg17063962	chr7:91808500	NA	0.39	6.9	0.32	1.94e-11	Breast cancer;
LUAD	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg06623918	chr6:96969491	KIAA0776	0.7	9.78	0.43	1.72e-20	Migraine;Coronary artery disease;
LUAD	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg04455712	chr21:45112962	RRP1B	0.47	9.38	0.41	4.18e-19	Mean corpuscular volume;
LUAD	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg24838063	chr12:130822603	PIWIL1	0.64	10.68	0.46	9.9899999999999993e-24	Menopause (age at onset);
LUAD	trans	rs853679	0.546	rs35883476	chr6:28368508	G/C	cg01620082	chr3:125678407	NA	-1.1	-10.07	-0.44	1.57e-21	Depression;
LUAD	cis	rs1950626	0.750	rs35820579	chr14:101435515	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.6	0.35	1.97e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.43	0.3	3.48e-10	Cognitive test performance;
LUAD	trans	rs2840044	1.000	rs225259	chr17:33958168	A/G	cg19694781	chr19:47549865	TMEM160	-0.63	-10.19	-0.44	6.17e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg11494091	chr17:61959527	GH2	0.45	8.49	0.38	3.43e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19717773	chr7:2847554	GNA12	-0.57	-9.77	-0.43	1.88e-20	Height;
LUAD	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06112835	chr11:68658793	MRPL21	0.5	9.12	0.41	3.02e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg06606381	chr12:133084897	FBRSL1	-0.75	-7.04	-0.32	7.79e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg00530320	chr1:46809349	NSUN4	0.52	8.16	0.37	3.96e-15	Menopause (age at onset);
LUAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00149659	chr3:10157352	C3orf10	0.53	7.33	0.34	1.14e-12	Alzheimer's disease;
LUAD	cis	rs7072216	0.881	rs2147897	chr10:100147813	A/C	cg26618903	chr10:100175079	PYROXD2	0.29	6.35	0.3	5.51e-10	Metabolite levels;
LUAD	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg08261032	chr1:23886002	ID3	-0.39	-6.47	-0.3	2.72e-10	Gallstone disease;
LUAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg20849893	chr7:64541193	NA	-0.55	-8.92	-0.4	1.43e-17	Calcium levels;
LUAD	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.53	0.58	4.35e-39	Schizophrenia;
LUAD	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg16447950	chr5:562315	NA	-0.41	-6.41	-0.3	3.89e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs17155006	0.746	rs420753	chr7:107746253	A/G	cg05962710	chr7:107745446	LAMB4	-0.34	-7.31	-0.33	1.37e-12	Pneumococcal bacteremia;
LUAD	cis	rs10924309	0.546	rs2000100	chr1:245867921	C/T	cg00036263	chr1:245852353	KIF26B	0.38	6.41	0.3	3.9e-10	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs7809950	0.953	rs2520267	chr7:107187497	T/C	cg23024343	chr7:107201750	COG5	-0.71	-11.96	-0.5	1.39e-28	Coronary artery disease;
LUAD	cis	rs4409675	0.576	rs7356	chr1:28218100	T/C	cg23691781	chr1:28212827	C1orf38	0.39	11.33	0.48	3.76e-26	Corneal astigmatism;
LUAD	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg04398451	chr17:18023971	MYO15A	0.42	6.99	0.32	1.08e-11	Body mass index;
LUAD	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg01689657	chr7:91764605	CYP51A1	0.32	8.04	0.36	9.14e-15	Breast cancer;
LUAD	cis	rs2387326	0.671	rs11016103	chr10:129946285	A/G	cg16087940	chr10:129947807	NA	-0.6	-8.45	-0.38	4.64e-16	Select biomarker traits;
LUAD	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22968622	chr17:43663579	NA	1.38	25.14	0.77	5.6e-86	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2274273	0.905	rs28429419	chr14:55574793	T/C	cg04306507	chr14:55594613	LGALS3	0.39	8.09	0.37	6.39e-15	Protein biomarker;
LUAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg26338869	chr17:61819248	STRADA	-0.39	-6.47	-0.3	2.71e-10	Prudent dietary pattern;
LUAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg22663859	chr13:21900854	NA	0.49	7.69	0.35	1.03e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs4650994	0.507	rs12141152	chr1:178514165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.74	-13.35	-0.54	3.76e-34	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg15485101	chr11:133734466	NA	0.38	8.31	0.37	1.35e-15	Childhood ear infection;
LUAD	cis	rs7264396	0.563	rs2425122	chr20:34328848	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.97	-0.36	1.47e-14	Total cholesterol levels;
LUAD	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg08999081	chr20:33150536	PIGU	0.44	7.72	0.35	8.45e-14	Coronary artery disease;
LUAD	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg24818145	chr4:99064322	C4orf37	0.43	7.18	0.33	3.22e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg22907277	chr7:1156413	C7orf50	0.63	10.93	0.47	1.14e-24	Longevity;Endometriosis;
LUAD	cis	rs6750795	0.569	rs1667313	chr2:232408018	A/C	cg19187155	chr2:232395269	NMUR1	0.48	8.83	0.39	2.81e-17	Height;
LUAD	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.7	0.39	7.63e-17	Menarche (age at onset);
LUAD	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg10523679	chr1:76189770	ACADM	0.75	11.03	0.47	5.05e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg11707310	chr1:2537719	MMEL1	0.39	8.18	0.37	3.33e-15	Ulcerative colitis;
LUAD	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg09658497	chr7:2847517	GNA12	-0.55	-9.19	-0.41	1.77e-18	Height;
LUAD	cis	rs7120118	0.517	rs17726390	chr11:47319706	C/T	cg13308137	chr11:47528955	CUGBP1	0.36	6.48	0.3	2.49e-10	HDL cholesterol;
LUAD	cis	rs701145	0.537	rs357479	chr3:153891489	A/G	cg17054900	chr3:154042577	DHX36	0.58	6.39	0.3	4.41e-10	Coronary artery disease;
LUAD	cis	rs4604732	0.631	rs12080860	chr1:247623053	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.43	7.07	0.33	6.35e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2109514	1.000	rs2270189	chr7:116140616	A/G	cg12739419	chr7:116140593	CAV2	-0.36	-7.71	-0.35	8.88e-14	Prevalent atrial fibrillation;
LUAD	trans	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg11693508	chr17:37793320	STARD3	0.51	7.55	0.34	2.65e-13	Bipolar disorder;
LUAD	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg14582100	chr15:45693742	SPATA5L1	0.64	12.58	0.52	4.95e-31	Homoarginine levels;
LUAD	cis	rs669446	0.562	rs304303	chr1:44178070	T/G	cg12908607	chr1:44402522	ARTN	-0.36	-6.78	-0.31	4.17e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg18230493	chr5:56204884	C5orf35	-0.58	-9.49	-0.42	1.67e-19	Coronary artery disease;
LUAD	cis	rs438034	0.967	rs417082	chr1:214829791	T/C	cg16144317	chr1:214725524	PTPN14	-0.36	-6.78	-0.31	4.05e-11	Response to antineoplastic agents;
LUAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	8.49	0.38	3.57e-16	Alzheimer's disease;
LUAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg01874867	chr7:94954059	PON1	-0.55	-10.08	-0.44	1.46e-21	Paraoxonase activity;
LUAD	cis	rs4604732	0.631	rs10802509	chr1:247627158	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs11088226	1.000	rs2833888	chr21:33927560	A/G	cg09050820	chr6:167586206	TCP10L2	0.58	7.86	0.36	3.23e-14	Gastritis;
LUAD	cis	rs7116495	1.000	rs17161966	chr11:71815308	T/C	cg07596299	chr11:71824057	C11orf51	0.76	6.42	0.3	3.61e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs11771526	0.681	rs62457535	chr7:32358710	C/G	cg27532318	chr7:32358331	NA	0.72	8.25	0.37	2.01e-15	Body mass index;
LUAD	cis	rs490234	0.683	rs9409281	chr9:128159171	C/G	cg13590414	chr9:128173245	NA	-0.33	-6.38	-0.3	4.56e-10	Mean arterial pressure;
LUAD	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg24955955	chr5:415729	AHRR	0.8	8.96	0.4	1.05e-17	Fat distribution (HIV);
LUAD	trans	rs7395662	0.929	rs11493665	chr11:48721035	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.24	-0.33	2.12e-12	HDL cholesterol;
LUAD	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg21475434	chr5:93447410	FAM172A	0.75	8.58	0.39	1.81e-16	Diabetic retinopathy;
LUAD	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg03929089	chr4:120376271	NA	-0.91	-17.21	-0.64	1.05e-50	Coronary artery disease;
LUAD	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg19773385	chr1:10388646	KIF1B	-0.4	-6.62	-0.31	1.11e-10	Hepatocellular carcinoma;
LUAD	cis	rs7909074	0.651	rs10900127	chr10:45390103	C/A	cg05187965	chr10:45406764	TMEM72	-0.41	-8.38	-0.38	7.65e-16	Mean corpuscular volume;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09784081	chr7:130792059	FLJ43663	-0.44	-7.4	-0.34	7.18e-13	Cancer;
LUAD	cis	rs559928	0.502	rs10897504	chr11:64190137	C/G	cg05555928	chr11:63887634	MACROD1	-0.46	-7.23	-0.33	2.26e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUAD	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg23281280	chr6:28129359	ZNF389	0.46	6.65	0.31	9.18e-11	Parkinson's disease;
LUAD	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg17328964	chr8:145687451	CYHR1	0.67	12.3	0.51	6.37e-30	Age at first birth;
LUAD	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-7.08	-0.33	6e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg14458575	chr2:238380390	NA	0.87	16.79	0.63	7.73e-49	Prostate cancer;
LUAD	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg17366294	chr4:99064904	C4orf37	0.48	8.54	0.38	2.42e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg22532475	chr10:104410764	TRIM8	-0.43	-8.41	-0.38	6.17e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg04756594	chr16:24857601	SLC5A11	-0.58	-9.85	-0.43	9.79e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg03563238	chr19:33554763	RHPN2	-0.34	-8.12	-0.37	5.14e-15	Bone properties (heel);
LUAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-7.24	-0.33	2.07e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg21051086	chr3:73046214	PPP4R2	-0.44	-7.24	-0.33	2.14e-12	Pancreatic cancer;
LUAD	cis	rs9650315	0.706	rs36112366	chr8:57138676	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	7.54	0.34	2.98e-13	Height;
LUAD	cis	rs9302065	0.565	rs2992905	chr13:95958190	C/T	cg26751094	chr13:95954534	ABCC4	-0.54	-11.37	-0.48	2.6e-26	Blood metabolite levels;
LUAD	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg17644776	chr2:200775616	C2orf69	-0.38	-6.35	-0.3	5.46e-10	QT interval;
LUAD	cis	rs9296092	0.517	rs6911036	chr6:33471652	C/G	cg13560919	chr6:33536144	NA	-0.78	-12.25	-0.51	9.84e-30	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs4356932	1.000	rs4580676	chr4:76953295	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.5	-0.3	2.22e-10	Blood protein levels;
LUAD	cis	rs6494488	0.500	rs72742916	chr15:64850675	T/A	cg08069370	chr15:64387884	SNX1	-0.76	-6.77	-0.31	4.45e-11	Coronary artery disease;
LUAD	cis	rs751837	0.591	rs10136828	chr14:103427555	T/C	cg10087771	chr14:103399429	CDC42BPB	0.69	6.9	0.32	1.88e-11	Large B-cell lymphoma;
LUAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg09074113	chr2:20870087	GDF7	-0.49	-9.96	-0.44	3.93e-21	Abdominal aortic aneurysm;
LUAD	cis	rs16854884	0.609	rs9872126	chr3:143683851	G/A	cg01302019	chr3:143689584	C3orf58	-0.46	-7.98	-0.36	1.43e-14	Economic and political preferences (feminism/equality);
LUAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.45e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs8073060	0.614	rs72829932	chr17:34055935	A/G	cg19694781	chr19:47549865	TMEM160	1.21	18.7	0.67	2.55e-57	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg14196790	chr5:131705035	SLC22A5	0.51	9.27	0.41	9.92e-19	Blood metabolite levels;
LUAD	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.37	-6.67	-0.31	8.02e-11	Caffeine consumption;
LUAD	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg01884057	chr2:25150051	NA	0.31	6.71	0.31	6.25e-11	Body mass index;
LUAD	cis	rs1564271	1.000	rs1197422	chr10:27012078	A/G	cg13837822	chr10:26931731	LOC731789	0.39	7.57	0.35	2.43e-13	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUAD	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg13298116	chr11:62369859	EML3;MTA2	-0.55	-9.95	-0.44	4.33e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9535307	0.745	rs1407440	chr13:50286218	T/C	cg04663916	chr13:50265991	EBPL	0.58	6.82	0.31	3.1e-11	Obesity-related traits;
LUAD	cis	rs4588572	0.644	rs6870646	chr5:77741082	G/A	cg11547950	chr5:77652471	NA	-0.62	-10.46	-0.45	6.04e-23	Triglycerides;
LUAD	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg23533926	chr12:111358616	MYL2	-0.42	-7.14	-0.33	4.22e-12	Extrinsic epigenetic age acceleration;
LUAD	trans	rs3858145	0.588	rs78041174	chr10:70038771	G/A	cg04882175	chr6:131122610	NA	-0.6	-7.28	-0.33	1.63e-12	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUAD	trans	rs2797160	1.000	rs61299898	chr6:126007651	G/C	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.81	0.39	3.36e-17	Endometrial cancer;
LUAD	cis	rs9837602	1.000	rs793499	chr3:99565576	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.49	7.25	0.33	1.95e-12	Breast cancer;
LUAD	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg00750074	chr16:89608354	SPG7	-0.55	-9.53	-0.42	1.23e-19	Multiple myeloma (IgH translocation);
LUAD	cis	rs2398668	0.570	rs4721548	chr7:2330496	A/G	cg08027265	chr7:2291960	NA	-0.49	-9.23	-0.41	1.36e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg24450063	chr1:156163899	SLC25A44	1.06	21.96	0.73	7.03e-72	Testicular germ cell tumor;
LUAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.61	-0.31	1.19e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg09509183	chr1:209979624	IRF6	0.59	8.13	0.37	4.86e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs17532515	0.628	rs3113196	chr4:141477273	T/C	cg09181644	chr4:141490428	UCP1	0.33	7.26	0.33	1.92e-12	Select biomarker traits;
LUAD	trans	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-8.24	-0.37	2.23e-15	Endometrial cancer;
LUAD	cis	rs4372836	1.000	rs72782294	chr2:28953390	C/G	cg09522027	chr2:28974177	PPP1CB	0.62	10.04	0.44	2.05e-21	Body mass index;
LUAD	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.35	7.28	0.33	1.66e-12	Hemoglobin concentration;
LUAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.69	-13.28	-0.54	6.97e-34	Prudent dietary pattern;
LUAD	cis	rs9581857	0.685	rs9319370	chr13:28042493	G/T	cg22138327	chr13:27999177	GTF3A	0.84	9.65	0.42	4.63e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs3087591	0.821	rs1034705	chr17:29536133	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.38	-6.43	-0.3	3.38e-10	Hip circumference;
LUAD	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg04876069	chr12:132293656	NA	-0.41	-7.11	-0.33	4.87e-12	Migraine;
LUAD	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg06740227	chr12:86229804	RASSF9	0.39	6.88	0.32	2.2e-11	Major depressive disorder;
LUAD	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg25767906	chr1:53392781	SCP2	0.41	7.43	0.34	5.93e-13	Monocyte count;
LUAD	cis	rs1949733	0.543	rs62287446	chr4:8535988	G/A	cg13073564	chr4:8508604	NA	0.39	6.78	0.31	4.09e-11	Response to antineoplastic agents;
LUAD	cis	rs12540874	0.507	rs4947644	chr7:50618876	C/T	cg18232548	chr7:50535776	DDC	0.44	7.57	0.35	2.31e-13	Systemic sclerosis;
LUAD	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg07402062	chr16:89894098	SPIRE2	-0.44	-11.24	-0.48	7.86e-26	Vitiligo;
LUAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg24642844	chr7:1081250	C7orf50	-0.98	-14.73	-0.58	6.34e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg00901687	chr17:48585270	MYCBPAP	0.56	7.31	0.33	1.37e-12	Visceral fat;
LUAD	cis	rs731174	0.797	rs539585	chr1:38148123	T/G	cg06917450	chr1:38156652	C1orf109	-0.41	-6.42	-0.3	3.71e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03934478	chr11:495069	RNH1	0.66	7.62	0.35	1.65e-13	Body mass index;
LUAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg24846343	chr22:24311635	DDTL	0.71	15.66	0.61	6.06e-44	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs9929218	0.954	rs9646284	chr16:68791306	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.67	-0.55	1.73e-35	Colorectal cancer;
LUAD	trans	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg01620082	chr3:125678407	NA	-0.88	-8.23	-0.37	2.41e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.37	-0.41	4.57e-19	Life satisfaction;
LUAD	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg00339695	chr16:24857497	SLC5A11	0.46	8.49	0.38	3.52e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs9394169	0.818	rs1547671	chr6:33777260	C/T	cg16010596	chr6:33739607	LEMD2	-0.33	-6.89	-0.32	2.02e-11	Essential tremor;
LUAD	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg19875535	chr5:140030758	IK	-0.45	-7.62	-0.35	1.69e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.27	0.37	1.73e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3857536	0.813	rs9294688	chr6:66945904	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg20673091	chr1:2541236	MMEL1	-0.4	-8.57	-0.38	1.97e-16	Ulcerative colitis;
LUAD	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.67	-0.31	7.89e-11	Bladder cancer;
LUAD	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg21433313	chr16:3507492	NAT15	0.73	9.59	0.42	7.59e-20	Tuberculosis;
LUAD	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg03929089	chr4:120376271	NA	-0.9	-17.23	-0.64	8.92e-51	Height;
LUAD	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg04772025	chr11:68637568	NA	-0.5	-7.78	-0.35	5.51e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs300703	0.872	rs428697	chr2:213302	G/A	cg21211680	chr2:198530	NA	0.6	6.38	0.3	4.63e-10	Blood protein levels;
LUAD	trans	rs830383	0.653	rs31737	chr5:165451047	C/G	cg08684991	chr12:11662075	NA	-0.3	-6.36	-0.3	5.36e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg00716675	chr1:38478417	UTP11L	-0.7	-6.71	-0.31	6.12e-11	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.06e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg07636037	chr3:49044803	WDR6	-0.48	-8.03	-0.36	9.96e-15	Menarche (age at onset);
LUAD	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg18755752	chr8:142205143	DENND3	-0.7	-14.08	-0.56	3.3e-37	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg18944383	chr4:111397179	ENPEP	0.41	8.26	0.37	1.87e-15	Height;
LUAD	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	10.74	0.46	5.83e-24	Lung cancer in ever smokers;
LUAD	cis	rs2625529	0.586	rs11639282	chr15:72435260	G/A	cg16672083	chr15:72433130	SENP8	0.61	11.34	0.48	3.35e-26	Red blood cell count;
LUAD	cis	rs9837602	0.745	rs9816538	chr3:99907924	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	7.85	0.36	3.4e-14	Breast cancer;
LUAD	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg16735072	chr8:11994639	FAM66D	0.44	6.56	0.3	1.59e-10	Joint mobility (Beighton score);
LUAD	cis	rs870825	0.616	rs28444118	chr4:185621692	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs13315871	1.000	rs9860970	chr3:58353781	C/T	cg20936604	chr3:58311152	NA	-0.69	-7.12	-0.33	4.52e-12	Cholesterol, total;
LUAD	cis	rs13064411	0.696	rs7619913	chr3:113017503	A/G	cg18753928	chr3:113234510	CCDC52	-0.59	-9.33	-0.41	5.93e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg26587870	chr6:27730563	NA	-0.44	-7.15	-0.33	3.76e-12	Parkinson's disease;
LUAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg11062466	chr8:58055876	NA	0.79	10.15	0.44	8.55e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg27432699	chr2:27873401	GPN1	-0.38	-6.46	-0.3	2.9e-10	Total body bone mineral density;
LUAD	cis	rs2070677	1.000	rs2515641	chr10:135351362	T/C	cg20169779	chr10:135381914	SYCE1	0.49	7.56	0.35	2.46e-13	Gout;
LUAD	cis	rs5750339	0.666	rs2413435	chr22:37312264	A/C	cg16356956	chr22:37317934	CSF2RB	-0.3	-6.39	-0.3	4.33e-10	Itch intensity from mosquito bite adjusted by bite size;Mosquito bite size;Perceived unattractiveness to mosquitoes;Itch intensity from mosquito bite;
LUAD	cis	rs938554	0.571	rs12509955	chr4:10024303	C/T	cg02734326	chr4:10020555	SLC2A9	-0.46	-7.07	-0.33	6.45e-12	Blood metabolite levels;
LUAD	cis	rs7809950	0.954	rs2520241	chr7:107135443	A/G	cg23024343	chr7:107201750	COG5	-0.74	-12.61	-0.52	3.54e-31	Coronary artery disease;
LUAD	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg00814883	chr7:100076585	TSC22D4	-0.86	-12.96	-0.53	1.45e-32	Platelet count;
LUAD	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg07741184	chr6:167504864	NA	-0.3	-7.14	-0.33	4.16e-12	Crohn's disease;
LUAD	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg00784671	chr22:46762841	CELSR1	-0.49	-7.25	-0.33	2.02e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.43	7.04	0.32	7.68e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg10295955	chr4:187884368	NA	1.09	25.76	0.78	1.1e-88	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg25767906	chr1:53392781	SCP2	0.38	6.97	0.32	1.21e-11	Monocyte count;
LUAD	cis	rs7737355	0.947	rs4706028	chr5:130946227	T/C	cg06307176	chr5:131281290	NA	0.5	7.8	0.35	4.98e-14	Life satisfaction;
LUAD	cis	rs62400317	0.859	rs62400267	chr6:45180440	C/T	cg20913747	chr6:44695427	NA	-0.43	-6.58	-0.3	1.37e-10	Total body bone mineral density;
LUAD	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg05373962	chr22:49881684	NA	-0.54	-12.91	-0.53	2.22e-32	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg11887960	chr12:57824829	NA	0.59	7.3	0.33	1.46e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs10129255	0.500	rs6576225	chr14:107186359	G/C	cg07958169	chr14:107095056	NA	-0.37	-7.35	-0.34	1.03e-12	Kawasaki disease;
LUAD	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg11833968	chr6:79620685	NA	-0.44	-8.11	-0.37	5.56e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg07167872	chr1:205819463	PM20D1	0.52	8.7	0.39	7.21e-17	Parkinson's disease;
LUAD	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs34734847	1.000	rs3752531	chr12:121157851	A/G	cg21892295	chr12:121157589	UNC119B	-0.45	-8.2	-0.37	2.88e-15	Mean corpuscular volume;
LUAD	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg04398451	chr17:18023971	MYO15A	-0.63	-11.4	-0.48	2.01e-26	Total body bone mineral density;
LUAD	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg25208724	chr1:156163844	SLC25A44	0.99	18.07	0.66	1.61e-54	Testicular germ cell tumor;
LUAD	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.5	-8.46	-0.38	4.26e-16	Electrocardiographic conduction measures;
LUAD	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.38	-6.45	-0.3	3.11e-10	Colorectal cancer;
LUAD	cis	rs739496	0.793	rs1557685	chr12:111901204	C/A	cg10833066	chr12:111807467	FAM109A	0.46	8.36	0.38	9.22e-16	Platelet count;
LUAD	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg06784218	chr1:46089804	CCDC17	0.52	11.41	0.49	1.74e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11890956	chr21:40555474	PSMG1	0.81	13.88	0.56	2.42e-36	Cognitive function;
LUAD	trans	rs360929	0.935	rs191711	chr4:152903538	A/T	cg22822647	chr19:16771056	TMEM38A;C19orf42	-0.52	-6.52	-0.3	2.02e-10	Volumetric brain MRI;
LUAD	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg12311346	chr5:56204834	C5orf35	0.53	8.48	0.38	3.84e-16	Coronary artery disease;
LUAD	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg13685833	chr1:53393034	SCP2	-0.4	-6.63	-0.31	9.97e-11	Monocyte count;
LUAD	cis	rs6684514	0.961	rs11264463	chr1:156242806	A/G	cg16558208	chr1:156270281	VHLL	0.48	8.72	0.39	6.19e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg09417038	chr21:47716443	C21orf57	0.46	7.91	0.36	2.29e-14	Testicular germ cell tumor;
LUAD	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg11189052	chr15:85197271	WDR73	0.62	7.65	0.35	1.39e-13	Schizophrenia;
LUAD	trans	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17712092	chr4:129076599	LARP1B	0.83	15.51	0.6	2.72e-43	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg09359103	chr1:154839909	KCNN3	-0.74	-14.5	-0.58	5.97e-39	Prostate cancer;
LUAD	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg10544611	chr16:67998164	SLC12A4	-0.54	-6.87	-0.32	2.38e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3820068	0.705	rs59502343	chr1:15872617	T/C	cg24675056	chr1:15929824	NA	0.42	6.65	0.31	9.23e-11	Systolic blood pressure;
LUAD	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg23803603	chr1:2058230	PRKCZ	0.41	7.75	0.35	6.76e-14	Height;
LUAD	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg24069376	chr3:38537580	EXOG	0.46	11.18	0.48	1.29e-25	Electrocardiographic conduction measures;
LUAD	trans	rs225245	0.782	rs161183	chr17:33919475	G/C	cg19694781	chr19:47549865	TMEM160	-0.46	-7.58	-0.35	2.14e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg23719950	chr11:63933701	MACROD1	-0.62	-7.26	-0.33	1.87e-12	Mean platelet volume;
LUAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg03188948	chr7:1209495	NA	0.83	10.13	0.44	9.98e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6688613	0.685	rs10918600	chr1:166919342	C/T	cg07049167	chr1:166818506	POGK	-0.48	-7.51	-0.34	3.43e-13	Refractive astigmatism;
LUAD	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg27535305	chr1:53392650	SCP2	0.44	9.0	0.4	7.76e-18	Monocyte count;
LUAD	cis	rs9535307	0.929	rs6561552	chr13:50260905	A/G	cg04663916	chr13:50265991	EBPL	0.56	6.8	0.31	3.48e-11	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg23281280	chr6:28129359	ZNF389	0.46	6.56	0.3	1.55e-10	Depression;
LUAD	cis	rs7587476	0.736	rs62202002	chr2:215690600	T/C	cg04004882	chr2:215674386	BARD1	0.52	6.56	0.3	1.53e-10	Neuroblastoma;
LUAD	cis	rs68170813	0.559	rs75313693	chr7:106863170	T/C	cg23024343	chr7:107201750	COG5	0.49	7.03	0.32	8.41e-12	Coronary artery disease;
LUAD	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg25894440	chr7:65020034	NA	-0.64	-7.0	-0.32	1.02e-11	Diabetic kidney disease;
LUAD	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg13354988	chr2:263656	ACP1;SH3YL1	0.3	6.46	0.3	2.96e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg14582100	chr15:45693742	SPATA5L1	0.64	12.48	0.52	1.23e-30	Homoarginine levels;
LUAD	cis	rs4372836	0.504	rs7475	chr2:29023749	A/G	cg09522027	chr2:28974177	PPP1CB	-0.61	-10.76	-0.46	4.94e-24	Body mass index;
LUAD	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.6	8.54	0.38	2.47e-16	Platelet count;
LUAD	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg13770153	chr20:60521292	NA	-0.58	-9.69	-0.43	3.61e-20	Body mass index;
LUAD	cis	rs1018836	0.884	rs9643307	chr8:91625257	A/C	cg16814680	chr8:91681699	NA	-0.69	-11.67	-0.49	1.77e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg06766960	chr11:133703094	NA	-0.45	-8.47	-0.38	3.95e-16	Childhood ear infection;
LUAD	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg27210415	chr4:713949	PCGF3	0.64	9.76	0.43	2.05e-20	White blood cell count;
LUAD	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06022373	chr22:39101656	GTPBP1	0.48	7.96	0.36	1.57e-14	Menopause (age at onset);
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg08180934	chr12:16035177	STRAP	0.42	6.47	0.3	2.66e-10	QT interval;
LUAD	trans	rs7395662	0.963	rs11039772	chr11:48513892	T/A	cg00717180	chr2:96193071	NA	-0.39	-7.29	-0.33	1.5e-12	HDL cholesterol;
LUAD	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg20991723	chr1:152506922	NA	0.34	6.64	0.31	9.55e-11	Hair morphology;
LUAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08219700	chr8:58056026	NA	0.57	8.08	0.37	6.8e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.47	0.34	4.48e-13	Breast cancer;
LUAD	cis	rs16910800	0.731	rs59845980	chr11:23191511	T/G	cg20040320	chr11:23191996	NA	-0.74	-9.84	-0.43	1.03e-20	Cancer;
LUAD	cis	rs3791556	0.853	rs35245395	chr2:240107661	C/T	cg03281426	chr2:240109471	HDAC4	0.51	9.65	0.42	4.66e-20	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg20891283	chr12:69753455	YEATS4	0.43	7.12	0.33	4.7e-12	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs11811982	0.793	rs78707022	chr1:227574765	A/G	cg24860534	chr1:227506868	CDC42BPA	0.66	7.2	0.33	2.8e-12	Optic disc area;
LUAD	trans	rs78049276	0.688	rs1878406	chr4:148393664	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.64	-7.28	-0.33	1.69e-12	Pulse pressure;
LUAD	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg27432699	chr2:27873401	GPN1	-0.58	-10.14	-0.44	8.91e-22	Oral cavity cancer;
LUAD	cis	rs7210086	0.768	rs72849445	chr17:70637985	T/G	cg04206342	chr17:70636940	NA	-0.35	-6.49	-0.3	2.47e-10	Ulcerative colitis;
LUAD	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg25173405	chr17:45401733	C17orf57	-0.53	-9.06	-0.4	4.75e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs75804782	0.625	rs72984524	chr2:239468692	G/T	cg01134436	chr17:81009848	B3GNTL1	0.76	7.68	0.35	1.12e-13	Morning vs. evening chronotype;Chronotype;
LUAD	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22968622	chr17:43663579	NA	1.36	23.96	0.76	8.67e-81	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg23281280	chr6:28129359	ZNF389	0.48	6.7	0.31	6.8e-11	Depression;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26529371	chr19:12911983	PRDX2	-0.5	-6.48	-0.3	2.57e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs870825	0.858	rs2014964	chr4:185588836	G/A	cg04058563	chr4:185651563	MLF1IP	0.78	9.24	0.41	1.2e-18	Blood protein levels;
LUAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg08888203	chr3:10149979	C3orf24	0.73	12.78	0.53	7.21e-32	Alzheimer's disease;
LUAD	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg19761014	chr17:28927070	LRRC37B2	0.65	7.43	0.34	6.21e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6960043	0.818	rs12699673	chr7:15049604	T/C	cg19272540	chr7:15055459	NA	0.37	8.41	0.38	6.46e-16	Type 2 diabetes;
LUAD	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg02221422	chr11:68192511	LRP5	0.4	6.65	0.31	9.24e-11	Total body bone mineral density;
LUAD	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg05340658	chr4:99064831	C4orf37	0.53	9.05	0.4	5.17e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs12900413	0.603	rs12907030	chr15:90301439	C/T	cg24249390	chr15:90295951	MESP1	-0.35	-6.85	-0.32	2.66e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg09509183	chr1:209979624	IRF6	-0.46	-8.61	-0.39	1.44e-16	Orofacial clefts;
LUAD	cis	rs2652834	0.950	rs2729789	chr15:63400345	G/A	cg25406657	chr15:63342033	TPM1	-0.43	-6.85	-0.32	2.59e-11	HDL cholesterol;
LUAD	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg05043794	chr9:111880884	C9orf5	-0.45	-7.77	-0.35	5.87e-14	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg25427524	chr10:38739819	LOC399744	-0.46	-7.72	-0.35	8.74e-14	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04565464	chr8:145669602	NFKBIL2	0.44	6.7	0.31	6.8e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11644478	chr21:40555479	PSMG1	-0.51	-8.16	-0.37	3.91e-15	Cognitive function;
LUAD	cis	rs6028335	0.674	rs67379757	chr20:37671051	C/G	cg27660920	chr20:37554817	FAM83D	0.53	6.67	0.31	7.98e-11	Alcohol and nicotine co-dependence;
LUAD	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg19041857	chr6:27730383	NA	-0.41	-6.94	-0.32	1.46e-11	Parkinson's disease;
LUAD	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14240646	chr10:27532245	ACBD5	-0.9	-12.19	-0.51	1.7e-29	Breast cancer;
LUAD	trans	rs1728785	0.892	rs4783562	chr16:68562963	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.68	10.25	0.45	3.76e-22	Ulcerative colitis;
LUAD	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg18404041	chr3:52824283	ITIH1	-0.62	-12.6	-0.52	3.88e-31	Bipolar disorder;
LUAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg12034118	chr1:209979487	IRF6	0.82	18.02	0.66	2.9e-54	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUAD	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg02734326	chr4:10020555	SLC2A9	0.54	9.68	0.43	3.71e-20	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-9.31	-0.41	7.17e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg23815491	chr16:72088622	HP	0.54	9.85	0.43	9.55e-21	Fibrinogen levels;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21194723	chr11:60681294	TMEM109	0.44	6.78	0.31	3.99e-11	Gut microbiome composition (summer);
LUAD	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg22906224	chr7:99728672	NA	-0.62	-10.83	-0.47	2.74e-24	Coronary artery disease;
LUAD	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg23301539	chr8:142222248	SLC45A4	0.48	8.75	0.39	5.18e-17	Immature fraction of reticulocytes;
LUAD	cis	rs7224314	1.000	rs11079691	chr17:65362552	T/A	cg01507342	chr17:65387096	PITPNC1	-0.52	-8.19	-0.37	3.05e-15	Diisocyanate-induced asthma;
LUAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-7.25	-0.33	2.05e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21582582	chr3:182698605	DCUN1D1	0.6	10.28	0.45	2.83e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.576	rs246045	chr5:140329884	C/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.41	-0.3	3.86e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg06550200	chr5:1325588	CLPTM1L	0.72	14.1	0.57	2.69e-37	Lung cancer;
LUAD	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg14008862	chr17:28927542	LRRC37B2	0.64	6.36	0.3	5.2400000000000005e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg16680214	chr1:154839983	KCNN3	-0.61	-12.56	-0.52	5.52e-31	Prostate cancer;
LUAD	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg07636037	chr3:49044803	WDR6	0.58	9.38	0.42	4.02e-19	Menarche (age at onset);
LUAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg13560548	chr3:10150139	C3orf24	0.46	7.54	0.34	2.86e-13	Alzheimer's disease;
LUAD	trans	rs911555	0.755	rs2756122	chr14:103983033	C/G	cg15876417	chr12:40014132	ABCD2	-0.4	-6.54	-0.3	1.75e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg11766577	chr21:47581405	C21orf56	-0.46	-7.83	-0.36	3.89e-14	Testicular germ cell tumor;
LUAD	cis	rs1448094	0.617	rs4842569	chr12:86468609	T/G	cg02569458	chr12:86230093	RASSF9	-0.34	-6.37	-0.3	5.07e-10	Major depressive disorder;
LUAD	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg20503657	chr10:835505	NA	0.76	10.31	0.45	2.22e-22	Eosinophil percentage of granulocytes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23819836	chr6:15663134	DTNBP1	-0.56	-6.77	-0.31	4.39e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs870825	0.616	rs7683799	chr4:185632164	T/C	cg04058563	chr4:185651563	MLF1IP	0.89	14.06	0.56	4e-37	Blood protein levels;
LUAD	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg02753203	chr1:228287806	NA	-0.46	-8.29	-0.37	1.48e-15	Diastolic blood pressure;
LUAD	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg01028140	chr2:1542097	TPO	-0.52	-6.87	-0.32	2.25e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs8062405	0.573	rs11645306	chr16:28983936	G/C	cg05966235	chr16:28915196	ATP2A1	-0.46	-7.03	-0.32	8.5e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg00316803	chr15:76480434	C15orf27	-0.42	-6.84	-0.32	2.72e-11	Blood metabolite levels;
LUAD	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg09658497	chr7:2847517	GNA12	-0.45	-8.31	-0.37	1.33e-15	Height;
LUAD	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-24.5	-0.77	3.57e-83	Height;
LUAD	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg23750338	chr8:142222470	SLC45A4	-0.35	-6.88	-0.32	2.18e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg03714773	chr7:91764589	CYP51A1	-0.31	-7.22	-0.33	2.47e-12	Breast cancer;
LUAD	cis	rs7215564	0.908	rs35542453	chr17:78687242	T/G	cg09596252	chr17:78655493	RPTOR	0.56	6.89	0.32	2.08e-11	Myopia (pathological);
LUAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.71e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg13214185	chr14:107219616	NA	0.42	7.28	0.33	1.67e-12	Menopause (age at onset);
LUAD	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg19413350	chr8:57351067	NA	-0.41	-6.52	-0.3	1.95e-10	Obesity-related traits;
LUAD	cis	rs4774899	0.902	rs11633061	chr15:57488193	A/C	cg14026238	chr15:57616123	NA	0.35	6.47	0.3	2.64e-10	Urinary tract infection frequency;
LUAD	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg14092988	chr3:52407081	DNAH1	0.33	6.52	0.3	1.95e-10	Bipolar disorder;
LUAD	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg21849932	chr20:62369462	LIME1	-0.48	-7.6	-0.35	1.92e-13	Prostate cancer;
LUAD	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg23442198	chr4:187126114	CYP4V2	1.08	11.09	0.47	2.95e-25	Blood protein levels;
LUAD	cis	rs1595825	0.627	rs78002594	chr2:198467113	A/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.73	-0.31	5.69e-11	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.44	0.38	5.18e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg18016565	chr1:150552671	MCL1	-0.37	-6.43	-0.3	3.39e-10	Tonsillectomy;
LUAD	cis	rs7512552	0.803	rs11205385	chr1:150476516	G/A	cg15654264	chr1:150340011	RPRD2	0.59	11.28	0.48	5.44e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg15147215	chr3:52552868	STAB1	-0.41	-7.47	-0.34	4.72e-13	Bipolar disorder;
LUAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg10802521	chr3:52805072	NEK4	-0.47	-7.07	-0.33	6.26e-12	Bipolar disorder;
LUAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg21951975	chr1:209979733	IRF6	0.58	9.32	0.41	6.27e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs910187	0.605	rs6066223	chr20:45803998	A/G	cg27589058	chr20:45804311	EYA2	0.38	8.8	0.39	3.53e-17	Migraine;
LUAD	cis	rs1448094	0.645	rs8181635	chr12:86465136	C/T	cg19622623	chr12:86230825	RASSF9	0.4	7.11	0.33	4.89e-12	Major depressive disorder;
LUAD	trans	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	15.43	0.6	6.41e-43	Exhaled nitric oxide levels;
LUAD	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg14895029	chr7:2775587	GNA12	-0.44	-7.05	-0.32	7.18e-12	Height;
LUAD	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg00316803	chr15:76480434	C15orf27	-0.41	-7.59	-0.35	2.03e-13	Blood metabolite levels;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg26085966	chr14:64319812	SYNE2	0.42	6.48	0.3	2.58e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs13315871	1.000	rs9821570	chr3:58335919	C/G	cg12435725	chr3:58293450	RPP14	-0.71	-7.74	-0.35	7.29e-14	Cholesterol, total;
LUAD	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.75	-0.31	4.91e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.18	0.37	3.33e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72928364	1.000	rs41386544	chr3:100759067	A/G	cg10123952	chr3:100791384	NA	-0.67	-8.13	-0.37	4.79e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.6	0.31	1.26e-10	Prudent dietary pattern;
LUAD	cis	rs12530845	0.945	rs59664351	chr7:135314717	C/A	cg23117316	chr7:135346802	PL-5283	-0.52	-9.5	-0.42	1.52e-19	Red blood cell traits;
LUAD	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg11814155	chr7:99998594	ZCWPW1	0.46	7.78	0.35	5.71e-14	Platelet count;
LUAD	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg27279351	chr12:120934652	DYNLL1	0.43	6.56	0.3	1.56e-10	Reticulocyte fraction of red cells;
LUAD	trans	rs4942242	0.663	rs7332737	chr13:44215043	C/T	cg19169023	chr15:41853346	TYRO3	-0.68	-11.65	-0.49	2.14e-27	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg19875535	chr5:140030758	IK	0.44	7.25	0.33	1.99e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg24558204	chr6:135376177	HBS1L	0.45	8.28	0.37	1.61e-15	Red blood cell count;
LUAD	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg19875535	chr5:140030758	IK	-0.39	-6.57	-0.3	1.49e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2688608	1.000	rs2675680	chr10:75658864	T/C	cg19442545	chr10:75533431	FUT11	-0.4	-6.79	-0.31	3.72e-11	Inflammatory bowel disease;
LUAD	cis	rs4776059	1.000	rs11070907	chr15:52924231	G/T	cg24008177	chr15:52972085	KIAA1370	0.23	6.45	0.3	3.07e-10	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.81	-0.31	3.45e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.22	0.37	2.59e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12667521	chr19:29218732	NA	0.61	8.57	0.38	1.89e-16	Methadone dose in opioid dependence;
LUAD	cis	rs13315871	0.790	rs115288459	chr3:58324283	A/G	cg20936604	chr3:58311152	NA	-0.78	-8.27	-0.37	1.76e-15	Cholesterol, total;
LUAD	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg22442454	chr1:209979470	IRF6	0.55	6.57	0.3	1.46e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg09184832	chr6:79620586	NA	-0.5	-9.35	-0.41	5.07e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs7512552	0.839	rs11577600	chr1:150407443	G/A	cg15654264	chr1:150340011	RPRD2	0.58	11.3	0.48	4.68e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg13385794	chr1:248469461	NA	0.27	7.29	0.33	1.5e-12	Common traits (Other);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07623702	chr17:15902660	ZSWIM7;TTC19	-0.4	-7.1	-0.33	5.15e-12	Cancer;
LUAD	trans	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg06606381	chr12:133084897	FBRSL1	-1.16	-10.34	-0.45	1.67e-22	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg02018176	chr4:1364513	KIAA1530	0.49	8.83	0.39	2.87e-17	Longevity;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16815825	chr1:70670919	LRRC40;SFRS11	-0.38	-6.42	-0.3	3.67e-10	Cancer;
LUAD	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg27433088	chr4:174089019	GALNT7	-0.41	-7.5	-0.34	3.75e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs13315871	0.858	rs13090428	chr3:58314412	A/G	cg20936604	chr3:58311152	NA	-0.78	-8.37	-0.38	8.66e-16	Cholesterol, total;
LUAD	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg11235426	chr6:292522	DUSP22	-0.58	-9.61	-0.42	6.64e-20	Menopause (age at onset);
LUAD	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg10295955	chr4:187884368	NA	-1.18	-31.5	-0.84	5.35e-113	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs73206853	0.841	rs7967246	chr12:110756569	G/A	cg12870014	chr12:110450643	ANKRD13A	0.62	6.77	0.31	4.22e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs9462027	0.628	rs10738078	chr6:34693917	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.35	9.0	0.4	7.61e-18	Systemic lupus erythematosus;
LUAD	cis	rs6076065	0.707	rs1419007	chr20:23336895	T/C	cg11657817	chr20:23433608	CST11	0.6	12.45	0.52	1.58e-30	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs8062405	0.757	rs2411453	chr16:28632021	A/C	cg00204512	chr16:28754710	NA	-0.3	-6.41	-0.3	3.85e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg15017067	chr4:17643749	FAM184B	0.34	6.43	0.3	3.4e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9902453	1.000	rs11080114	chr17:28407287	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-8.91	-0.4	1.57e-17	Coffee consumption (cups per day);
LUAD	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	7.46	0.34	5.09e-13	Platelet count;
LUAD	cis	rs4853525	0.859	rs6434425	chr2:191722316	A/G	cg11845111	chr2:191398756	TMEM194B	0.38	6.41	0.3	3.79e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22442454	chr1:209979470	IRF6	0.52	7.43	0.34	5.99e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg25817165	chr18:72167213	CNDP2	-0.81	-14.11	-0.57	2.55e-37	Refractive error;
LUAD	cis	rs2730245	0.569	rs842692	chr7:158657228	T/C	cg14689365	chr7:158441557	NCAPG2	0.5	8.43	0.38	5.64e-16	Height;
LUAD	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.43	-7.34	-0.34	1.13e-12	Tonsillectomy;
LUAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg11062466	chr8:58055876	NA	0.68	9.02	0.4	6.56e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg00981070	chr1:2046702	PRKCZ	0.36	6.84	0.32	2.72e-11	Height;
LUAD	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg03806693	chr22:41940476	POLR3H	0.76	10.74	0.46	6.1e-24	Vitiligo;
LUAD	cis	rs7187994	0.672	rs11863406	chr16:84802666	T/G	cg07647771	chr16:84786436	USP10	-0.31	-7.87	-0.36	2.92e-14	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.22	0.33	2.48e-12	Lung cancer in ever smokers;
LUAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.44	-7.45	-0.34	5.43e-13	Longevity;Endometriosis;
LUAD	cis	rs7737355	0.947	rs40989	chr5:130992284	T/G	cg25547332	chr5:131281432	NA	0.44	6.61	0.31	1.15e-10	Life satisfaction;
LUAD	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg05535760	chr7:792225	HEATR2	-0.89	-11.62	-0.49	2.78e-27	Cerebrospinal P-tau181p levels;
LUAD	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg15485101	chr11:133734466	NA	0.38	8.28	0.37	1.68e-15	Childhood ear infection;
LUAD	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg00277334	chr10:82204260	NA	0.43	7.21	0.33	2.61e-12	Post bronchodilator FEV1;
LUAD	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs4664304	0.764	rs2063440	chr2:160800102	A/C	cg23995753	chr2:160760732	LY75	-0.41	-7.27	-0.33	1.8e-12	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26314531	chr2:26401878	FAM59B	0.7	9.03	0.4	6.07e-18	Gut microbiome composition (summer);
LUAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg10729496	chr3:10149963	C3orf24	-0.61	-9.94	-0.44	4.53e-21	Alzheimer's disease;
LUAD	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg11247378	chr22:39784982	NA	-0.71	-13.05	-0.54	6.14e-33	Intelligence (multi-trait analysis);
LUAD	cis	rs7192380	1.000	rs8049728	chr16:69654790	G/T	cg26679644	chr16:69762563	NA	0.49	9.51	0.42	1.5e-19	Sjögren's syndrome;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23551753	chr12:67462881	NA	-0.4	-6.42	-0.3	3.6e-10	Height;
LUAD	cis	rs12545109	0.723	rs2610045	chr8:57413439	A/G	cg21220214	chr8:57350948	NA	0.6	8.93	0.4	1.33e-17	Obesity-related traits;
LUAD	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg03477792	chr4:77819574	ANKRD56	0.48	7.27	0.33	1.74e-12	Emphysema distribution in smoking;
LUAD	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.52	-0.3	2.01e-10	Alzheimer's disease (late onset);
LUAD	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.41	-0.6	7.61e-43	Chronic sinus infection;
LUAD	cis	rs3931020	0.548	rs12145183	chr1:75272480	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.42	6.62	0.31	1.11e-10	Resistin levels;
LUAD	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg00684032	chr4:1343700	KIAA1530	0.41	6.77	0.31	4.32e-11	Obesity-related traits;
LUAD	cis	rs1232027	0.656	rs1677638	chr5:79962545	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg01475377	chr6:109611718	NA	-0.48	-8.81	-0.39	3.25e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg07157834	chr1:205819609	PM20D1	0.47	7.43	0.34	5.94e-13	Parkinson's disease;
LUAD	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg23229984	chr5:148520753	ABLIM3	0.49	7.63	0.35	1.62e-13	Breast cancer;
LUAD	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg20744362	chr22:50050164	C22orf34	0.4	8.66	0.39	9.72e-17	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs12545109	0.876	rs1992120	chr8:57337112	G/A	cg21220214	chr8:57350948	NA	-0.68	-9.08	-0.4	4.1e-18	Obesity-related traits;
LUAD	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg02251663	chr11:14281053	SPON1	0.38	7.49	0.34	4.05e-13	Mitochondrial DNA levels;
LUAD	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg18404041	chr3:52824283	ITIH1	0.4	7.34	0.34	1.1e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3806843	0.547	rs246065	chr5:140323638	A/G	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.44	-0.3	3.32e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.74	-12.43	-0.52	1.91e-30	Primary sclerosing cholangitis;
LUAD	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg10518543	chr12:38710700	ALG10B	-0.42	-6.88	-0.32	2.16e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.3	-7.64	-0.35	1.44e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg21724239	chr8:58056113	NA	0.64	8.16	0.37	3.84e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs863345	0.604	rs12059669	chr1:158501480	T/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg06713675	chr4:122721982	EXOSC9	0.45	8.17	0.37	3.64e-15	Type 2 diabetes;
LUAD	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.57	9.15	0.41	2.36e-18	Platelet count;
LUAD	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg00106254	chr7:1943704	MAD1L1	-0.53	-7.89	-0.36	2.53e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg18138036	chr10:133769891	PPP2R2D	0.41	6.79	0.31	3.86e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.65e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg00717180	chr2:96193071	NA	-0.4	-7.31	-0.33	1.34e-12	Height;
LUAD	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg26597838	chr10:835615	NA	0.84	11.61	0.49	3.06e-27	Eosinophil percentage of granulocytes;
LUAD	cis	rs62458065	0.640	rs28587905	chr7:32533054	C/T	cg20159608	chr7:32802032	NA	-0.61	-8.14	-0.37	4.33e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs12681287	0.547	rs13261956	chr8:87478765	G/A	cg27223183	chr8:87520930	FAM82B	-0.67	-9.61	-0.42	6.38e-20	Caudate activity during reward;
LUAD	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-9.74	-0.43	2.36e-20	Gut microbiome composition (summer);
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20651758	chr15:93425245	NA	0.51	7.07	0.33	6.28e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg18806716	chr10:30721971	MAP3K8	-0.64	-12.76	-0.53	9.03e-32	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUAD	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22857025	chr5:266934	NA	-0.96	-14.42	-0.57	1.32e-38	Breast cancer;
LUAD	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg06263672	chr7:65235340	NA	-0.48	-6.62	-0.31	1.08e-10	Aortic root size;
LUAD	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg06002616	chr8:101225028	SPAG1	-0.4	-8.26	-0.37	1.84e-15	Atrioventricular conduction;
LUAD	cis	rs12545109	0.879	rs1581129	chr8:57377476	T/C	cg21220214	chr8:57350948	NA	-0.66	-9.13	-0.41	2.89e-18	Obesity-related traits;
LUAD	cis	rs7707921	0.690	rs6870335	chr5:81590070	A/T	cg15871215	chr5:81402204	ATG10	-0.61	-9.76	-0.43	1.94e-20	Breast cancer;
LUAD	cis	rs1232027	0.700	rs865647	chr5:79942276	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-7.95	-0.36	1.74e-14	Huntington's disease progression;
LUAD	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg06781209	chr11:61594997	FADS2	-0.37	-6.88	-0.32	2.23e-11	Trans fatty acid levels;
LUAD	cis	rs62064224	0.589	rs4132610	chr17:30801441	C/T	cg18200150	chr17:30822561	MYO1D	0.43	7.94	0.36	1.78e-14	Schizophrenia;
LUAD	cis	rs6752107	1.000	rs12994997	chr2:234173503	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	9.89	0.43	7.05e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg25568561	chr14:102276087	PPP2R5C	-0.43	-7.33	-0.34	1.2e-12	Cancer;
LUAD	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg26384229	chr12:38710491	ALG10B	0.44	7.3	0.33	1.48e-12	Morning vs. evening chronotype;
LUAD	cis	rs8051149	0.688	rs55776570	chr16:87869516	C/G	cg01412419	chr16:87856264	NA	0.46	8.23	0.37	2.4e-15	Blood metabolite levels;
LUAD	cis	rs7714584	1.000	rs12652003	chr5:150231945	T/C	cg22134413	chr5:150180641	NA	0.58	6.37	0.3	4.91e-10	Crohn's disease;
LUAD	trans	rs5756813	0.715	rs5756825	chr22:38199950	T/C	cg19894588	chr14:64061835	NA	0.82	14.27	0.57	5.65e-38	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs909002	0.849	rs1464306	chr1:32076261	T/C	cg13919466	chr1:32135498	COL16A1	-0.35	-7.95	-0.36	1.73e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.61	-0.31	1.18e-10	Breast cancer;
LUAD	cis	rs17253792	0.822	rs11546	chr14:56146357	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-6.41	-0.3	3.99e-10	Putamen volume;
LUAD	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg07952391	chr2:88470173	THNSL2	-0.42	-6.85	-0.32	2.59e-11	Response to metformin (IC50);
LUAD	trans	rs11039798	0.764	rs1121450	chr11:48897476	C/T	cg15704280	chr7:45808275	SEPT13	0.66	7.64	0.35	1.48e-13	Axial length;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg00993799	chr7:104653126	LOC100216545	-0.38	-6.35	-0.3	5.49e-10	Subcortical brain region volumes;
LUAD	cis	rs6714710	0.535	rs13033383	chr2:98339513	C/T	cg26665480	chr2:98280029	ACTR1B	0.57	9.13	0.41	2.77e-18	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg02176678	chr2:219576539	TTLL4	0.61	11.85	0.5	3.54e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs36051895	0.695	rs60221565	chr9:5029077	T/G	cg02405213	chr9:5042618	JAK2	-0.48	-6.51	-0.3	2.11e-10	Pediatric autoimmune diseases;
LUAD	trans	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg06606381	chr12:133084897	FBRSL1	-0.56	-7.23	-0.33	2.26e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7640424	0.620	rs17231503	chr3:107817299	C/T	cg09227934	chr3:107805635	CD47	-0.63	-10.22	-0.44	4.83e-22	Body mass index;
LUAD	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg07343612	chr16:622815	PIGQ	-0.8	-15.66	-0.61	6.17e-44	Height;
LUAD	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06544989	chr22:39130855	UNC84B	-0.34	-6.95	-0.32	1.37e-11	Menopause (age at onset);
LUAD	cis	rs6665290	0.935	rs12403236	chr1:227196502	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-42.09	-0.9	2.48e-153	Myeloid white cell count;
LUAD	cis	rs10504073	0.584	rs56068225	chr8:49923988	A/G	cg00325661	chr8:49890786	NA	0.48	10.54	0.46	3.16e-23	Blood metabolite ratios;
LUAD	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg18252515	chr7:66147081	NA	0.59	6.49	0.3	2.42e-10	Diabetic kidney disease;
LUAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg21724239	chr8:58056113	NA	0.74	9.62	0.42	5.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs68170813	0.599	rs12532514	chr7:107000952	C/T	cg23024343	chr7:107201750	COG5	0.52	7.33	0.34	1.18e-12	Coronary artery disease;
LUAD	cis	rs6594713	0.837	rs13187823	chr5:112722164	C/G	cg12552261	chr5:112820674	MCC	0.47	6.86	0.32	2.43e-11	Brain cytoarchitecture;
LUAD	cis	rs698833	0.886	rs17580226	chr2:44570776	C/T	cg04920474	chr2:44395004	PPM1B	0.39	6.92	0.32	1.73e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg20362242	chr5:692897	TPPP	0.55	6.82	0.31	3.22e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7937890	0.598	rs10734225	chr11:14442994	C/G	cg23387056	chr11:14280742	SPON1	-0.35	-6.48	-0.3	2.52e-10	Mitochondrial DNA levels;
LUAD	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.45	0.3	2.98e-10	Aortic root size;
LUAD	cis	rs55665837	0.539	rs10832310	chr11:14878442	C/G	cg19336497	chr11:14380999	RRAS2	-0.39	-7.37	-0.34	8.8e-13	Vitamin D levels;
LUAD	cis	rs1018836	0.828	rs9297870	chr8:91570691	C/G	cg16814680	chr8:91681699	NA	-0.62	-10.36	-0.45	1.43e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg11344533	chr11:111475393	SIK2	-0.35	-6.64	-0.31	9.9e-11	Primary sclerosing cholangitis;
LUAD	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg14552801	chr7:65878734	NA	-0.38	-6.37	-0.3	4.96e-10	Aortic root size;
LUAD	cis	rs11809207	0.810	rs17356937	chr1:26504036	G/A	cg00300879	chr1:26503847	CNKSR1	0.3	7.1	0.33	5.3e-12	Height;
LUAD	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg17971929	chr21:40555470	PSMG1	0.53	8.25	0.37	2e-15	Cognitive function;
LUAD	cis	rs1371614	0.611	rs4665922	chr2:27133934	G/T	cg00617064	chr2:27272375	NA	0.35	6.67	0.31	8.21e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs6494488	0.500	rs72741328	chr15:64734339	C/T	cg08069370	chr15:64387884	SNX1	-0.75	-6.73	-0.31	5.58e-11	Coronary artery disease;
LUAD	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg19767477	chr5:127420684	SLC12A2	-0.41	-6.45	-0.3	3.04e-10	Ileal carcinoids;
LUAD	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg17105886	chr17:28927953	LRRC37B2	0.86	8.3	0.37	1.42e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg21699342	chr2:239360505	ASB1	0.43	7.74	0.35	7.22e-14	Multiple system atrophy;
LUAD	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19717773	chr7:2847554	GNA12	-0.51	-8.8	-0.39	3.44e-17	Height;
LUAD	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7512552	1.000	rs7512552	chr1:150265704	T/C	cg15654264	chr1:150340011	RPRD2	-0.45	-8.41	-0.38	6.38e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg13732083	chr21:47605072	C21orf56	0.42	7.04	0.32	7.58e-12	Testicular germ cell tumor;
LUAD	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.49	-9.25	-0.41	1.16e-18	Longevity;Endometriosis;
LUAD	cis	rs62229266	0.804	rs11088331	chr21:37421872	T/C	cg08632701	chr21:37451849	NA	-0.44	-7.23	-0.33	2.3e-12	Mitral valve prolapse;
LUAD	cis	rs2880765	0.710	rs11630457	chr15:86004801	T/C	cg13263323	chr15:86062960	AKAP13	-0.47	-8.6	-0.39	1.54e-16	Coronary artery disease;
LUAD	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg24955955	chr5:415729	AHRR	0.78	8.87	0.4	2.14e-17	Fat distribution (HIV);
LUAD	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg00631329	chr6:26305371	NA	-0.73	-13.99	-0.56	8.19e-37	Educational attainment;
LUAD	trans	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.85	-0.32	2.54e-11	Diabetic kidney disease;
LUAD	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg22823121	chr1:150693482	HORMAD1	-0.4	-8.33	-0.38	1.17e-15	Tonsillectomy;
LUAD	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg10518543	chr12:38710700	ALG10B	0.49	8.15	0.37	4.17e-15	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1395	0.922	rs11693052	chr2:27484620	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.4	7.55	0.34	2.62e-13	Blood metabolite levels;
LUAD	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg06873352	chr17:61820015	STRADA	0.4	6.85	0.32	2.63e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18876405	chr7:65276391	NA	0.56	9.41	0.42	3.17e-19	Aortic root size;
LUAD	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg25753631	chr6:25732923	NA	-0.45	-7.94	-0.36	1.9e-14	Iron status biomarkers;
LUAD	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg21770322	chr7:97807741	LMTK2	0.34	7.81	0.36	4.42e-14	Breast cancer;
LUAD	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg01689657	chr7:91764605	CYP51A1	0.35	8.77	0.39	4.54e-17	Breast cancer;
LUAD	cis	rs7640424	0.691	rs17231712	chr3:107829562	C/G	cg09227934	chr3:107805635	CD47	0.35	6.45	0.3	3.11e-10	Body mass index;
LUAD	cis	rs2535633	0.661	rs4515041	chr3:52996032	T/A	cg11645453	chr3:52864694	ITIH4	-0.37	-6.87	-0.32	2.28e-11	Body mass index;
LUAD	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.4	-7.28	-0.33	1.62e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg08027265	chr7:2291960	NA	-0.48	-8.48	-0.38	3.86e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs4660214	0.666	rs11205739	chr1:39656401	G/A	cg27567593	chr1:39956653	BMP8A	0.35	6.73	0.31	5.37e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.4	0.3	4.23e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.65	0.35	1.36e-13	Platelet count;
LUAD	cis	rs2857078	0.772	rs4793086	chr17:42320751	C/T	cg13607699	chr17:42295918	UBTF	-0.5	-7.86	-0.36	3.14e-14	Red cell distribution width;Reticulocyte count;
LUAD	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg02421172	chr7:1938701	MAD1L1	0.47	6.77	0.31	4.41e-11	Bipolar disorder;
LUAD	cis	rs12545109	0.571	rs4314648	chr8:57276937	G/A	cg09654669	chr8:57350985	NA	-0.7	-9.37	-0.41	4.36e-19	Obesity-related traits;
LUAD	cis	rs76878669	0.561	rs6591217	chr11:66174653	G/A	cg18002602	chr11:66138449	SLC29A2	-0.47	-10.02	-0.44	2.48e-21	Educational attainment (years of education);
LUAD	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg15123519	chr2:136567270	LCT	0.39	7.33	0.34	1.15e-12	Mosquito bite size;
LUAD	cis	rs12541635	0.677	rs55639043	chr8:107055993	C/T	cg10147462	chr8:107024639	NA	0.52	9.38	0.42	3.92e-19	Age of smoking initiation;
LUAD	cis	rs11585357	0.842	rs72633804	chr1:17617024	T/C	cg08277548	chr1:17600880	PADI3	-0.95	-13.88	-0.56	2.3e-36	Hair shape;
LUAD	cis	rs7177699	0.557	rs4389112	chr15:79122099	G/A	cg00540400	chr15:79124168	NA	-0.45	-9.32	-0.41	6.39e-19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs9902453	0.791	rs3115100	chr17:28045744	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.33	0.45	1.93e-22	Coffee consumption (cups per day);
LUAD	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.82	0.31	3.14e-11	Blood metabolite levels;
LUAD	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.93	-0.5	1.81e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs56077333	1	rs56077333	chr15:78899003	C/A	cg18825076	chr15:78729989	IREB2	-0.59	-9.59	-0.42	7.47e-20	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03330867	chr16:1543988	TELO2	-0.39	-6.36	-0.3	5.27e-10	Height;
LUAD	cis	rs3806843	0.612	rs246075	chr5:140300557	T/C	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.45	-0.3	3.01e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg00450029	chr8:599525	NA	-0.84	-7.17	-0.33	3.43e-12	IgG glycosylation;
LUAD	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg26924012	chr15:45694286	SPATA5L1	1.02	19.06	0.68	6.2e-59	Homoarginine levels;
LUAD	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg11707310	chr1:2537719	MMEL1	0.38	7.95	0.36	1.73e-14	Ulcerative colitis;
LUAD	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg20607798	chr8:58055168	NA	0.58	7.8	0.35	4.72e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs3736594	0.879	rs77154381	chr2:27982119	A/G	cg27432699	chr2:27873401	GPN1	0.45	6.97	0.32	1.21e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs758324	0.947	rs56081930	chr5:131235274	T/G	cg06307176	chr5:131281290	NA	-0.54	-8.59	-0.39	1.67e-16	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg27411982	chr8:10470053	RP1L1	0.39	6.65	0.31	8.81e-11	Neuroticism;
LUAD	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg07967210	chr17:47022446	SNF8	0.36	6.45	0.3	3.03e-10	Type 2 diabetes;
LUAD	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-8.1	-0.37	5.9e-15	Monocyte percentage of white cells;
LUAD	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg25173405	chr17:45401733	C17orf57	-0.46	-7.61	-0.35	1.8e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg03452623	chr4:187889614	NA	-0.79	-16.19	-0.62	3.15e-46	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67072384	0.688	rs66948758	chr11:72440074	A/G	cg04827223	chr11:72435913	ARAP1	-0.68	-8.33	-0.38	1.17e-15	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	8.79	0.39	3.68e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7665090	0.936	rs2866411	chr4:103554340	C/T	cg07973026	chr4:103553119	MANBA	0.49	8.73	0.39	6e-17	Primary biliary cholangitis;
LUAD	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg06740227	chr12:86229804	RASSF9	0.43	7.74	0.35	7.61e-14	Major depressive disorder;
LUAD	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg06713675	chr4:122721982	EXOSC9	-0.59	-11.58	-0.49	3.85e-27	Type 2 diabetes;
LUAD	cis	rs7180079	1.000	rs1117087	chr15:64598823	T/G	cg08069370	chr15:64387884	SNX1	0.51	6.45	0.3	3.1e-10	Monocyte count;
LUAD	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.87	0.4	2.11e-17	Menopause (age at onset);
LUAD	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg01028140	chr2:1542097	TPO	-0.46	-6.64	-0.31	9.91e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7301826	1.000	rs4759523	chr12:131315412	T/C	cg11011512	chr12:131303247	STX2	0.38	6.56	0.3	1.58e-10	Plasma plasminogen activator levels;
LUAD	cis	rs8060686	0.516	rs8059575	chr16:68272635	C/G	cg05110241	chr16:68378359	PRMT7	-0.59	-7.48	-0.34	4.28e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg09640425	chr7:158790006	NA	-0.55	-9.33	-0.41	5.84e-19	Facial morphology (factor 20);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25228510	chr10:62538235	CDK1;CDC2	-0.55	-6.8	-0.31	3.51e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4588572	0.644	rs2241566	chr5:77784738	C/T	cg11547950	chr5:77652471	NA	0.58	9.61	0.42	6.62e-20	Triglycerides;
LUAD	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg17264618	chr3:40429014	ENTPD3	0.41	8.77	0.39	4.51e-17	Renal cell carcinoma;
LUAD	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26314531	chr2:26401878	FAM59B	-0.57	-7.93	-0.36	1.94e-14	Gut microbiome composition (summer);
LUAD	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg00321850	chr1:175162397	KIAA0040	0.52	11.09	0.47	3.01e-25	Alcohol dependence;
LUAD	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg14779329	chr11:130786720	SNX19	0.39	6.84	0.32	2.74e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs912057	0.601	rs1294411	chr6:6739034	T/C	cg06612196	chr6:6737390	NA	0.65	16.24	0.62	1.84e-46	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg14186256	chr22:23484241	RTDR1	0.46	7.98	0.36	1.44e-14	Bone mineral density;
LUAD	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg22117172	chr7:91764530	CYP51A1	0.38	8.23	0.37	2.28e-15	Breast cancer;
LUAD	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg22875332	chr1:76189707	ACADM	-0.7	-11.23	-0.48	8.8e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-7.33	-0.34	1.17e-12	Coronary artery disease;
LUAD	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg22508957	chr16:3507546	NAT15	0.46	7.74	0.35	7.15e-14	Body mass index (adult);
LUAD	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg07917127	chr4:99064746	C4orf37	0.45	7.26	0.33	1.93e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs877282	0.853	rs11253332	chr10:755262	G/C	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs13082711	0.522	rs864241	chr3:27332674	T/C	cg02860705	chr3:27208620	NA	0.52	8.52	0.38	2.82e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7274811	0.711	rs291677	chr20:32027915	A/G	cg14921437	chr20:32255988	NECAB3;C20orf134	0.46	7.06	0.32	6.85e-12	Height;
LUAD	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg15997130	chr1:24165203	NA	-0.46	-7.15	-0.33	3.84e-12	Immature fraction of reticulocytes;
LUAD	cis	rs7020830	0.825	rs10973248	chr9:37197768	C/T	cg14294708	chr9:37120828	ZCCHC7	0.89	18.64	0.67	4.68e-57	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg08888203	chr3:10149979	C3orf24	0.72	12.87	0.53	3.25e-32	Alzheimer's disease;
LUAD	cis	rs9467160	0.871	rs9461014	chr6:24449008	T/G	cg20631270	chr6:24437470	GPLD1	0.43	6.68	0.31	7.72e-11	Liver enzyme levels;
LUAD	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg15133208	chr4:90757351	SNCA	-0.46	-6.85	-0.32	2.63e-11	Neuroticism;
LUAD	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg20744362	chr22:50050164	C22orf34	0.32	6.75	0.31	4.88e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00684032	chr4:1343700	KIAA1530	0.49	8.1	0.37	5.77e-15	Obesity-related traits;
LUAD	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg21191810	chr6:118973309	C6orf204	-0.51	-8.13	-0.37	4.92e-15	Diastolic blood pressure;
LUAD	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.84	-12.48	-0.52	1.23e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.57e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg22875332	chr1:76189707	ACADM	0.86	15.69	0.61	4.9e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2294693	0.891	rs9367093	chr6:41012117	A/C	cg14769373	chr6:40998127	UNC5CL	-0.46	-7.07	-0.32	6.58e-12	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs11948739	0.501	rs9327584	chr5:130336059	C/T	cg08523029	chr5:130500466	HINT1	0.56	7.41	0.34	6.9e-13	Pediatric bone mineral content (hip);
LUAD	cis	rs4604732	0.678	rs74154674	chr1:247625685	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg27411982	chr8:10470053	RP1L1	0.38	6.74	0.31	5.14e-11	Retinal vascular caliber;
LUAD	cis	rs654950	1.000	rs679449	chr1:41988634	G/T	cg06885757	chr1:42089581	HIVEP3	-0.45	-10.01	-0.44	2.62e-21	Airway imaging phenotypes;
LUAD	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-7.45	-0.34	5.41e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6582630	0.538	rs12305104	chr12:38336353	C/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.25	-0.33	1.94e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg11663144	chr21:46675770	NA	-0.62	-12.41	-0.52	2.17e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.06	0.32	6.7e-12	Platelet count;
LUAD	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg06002616	chr8:101225028	SPAG1	-0.41	-8.34	-0.38	1.06e-15	Atrioventricular conduction;
LUAD	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg21775007	chr8:11205619	TDH	-0.48	-8.78	-0.39	4e-17	Retinal vascular caliber;
LUAD	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg13319975	chr6:146136371	FBXO30	-0.63	-11.03	-0.47	5.06e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.19	0.37	3.05e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs72928364	1.000	rs62275204	chr3:100714606	G/A	cg10123952	chr3:100791384	NA	0.63	7.29	0.33	1.51e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08005411	chr12:69753742	YEATS4	-0.43	-6.68	-0.31	7.36e-11	Height;
LUAD	cis	rs1595825	0.891	rs16825188	chr2:198741134	G/C	cg10547527	chr2:198650123	BOLL	-0.54	-7.37	-0.34	9.09e-13	Ulcerative colitis;
LUAD	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.82	0.31	3.25e-11	Cardiac Troponin-T levels;
LUAD	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg27211696	chr2:191398769	TMEM194B	-0.59	-8.03	-0.36	9.56e-15	Diastolic blood pressure;
LUAD	trans	rs10411161	0.702	rs1433081	chr19:52390710	A/C	cg22319618	chr22:45562946	NUP50	-0.66	-9.5	-0.42	1.61e-19	Breast cancer;
LUAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-7.25	-0.33	1.98e-12	Morning vs. evening chronotype;
LUAD	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg11266682	chr4:10021025	SLC2A9	0.53	11.52	0.49	7.01e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg20607798	chr8:58055168	NA	0.66	8.74	0.39	5.66e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg09365446	chr1:150670422	GOLPH3L	0.64	12.12	0.51	3.23e-29	Tonsillectomy;
LUAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13732083	chr21:47605072	C21orf56	-0.61	-10.56	-0.46	2.69e-23	Testicular germ cell tumor;
LUAD	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	6.88	0.32	2.19e-11	Platelet count;
LUAD	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg18932078	chr1:2524107	MMEL1	0.35	6.41	0.3	3.79e-10	Ulcerative colitis;
LUAD	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg02176678	chr2:219576539	TTLL4	0.74	14.87	0.59	1.63e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7727544	0.582	rs116749111	chr5:131462918	G/T	cg14196790	chr5:131705035	SLC22A5	0.41	7.01	0.32	9.24e-12	Blood metabolite levels;
LUAD	cis	rs2019216	0.651	rs6565378	chr17:21831307	A/G	cg05591447	chr17:21909280	FLJ36000	-0.28	-6.98	-0.32	1.15e-11	Pelvic organ prolapse;
LUAD	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg09165964	chr15:75287851	SCAMP5	-0.49	-7.24	-0.33	2.12e-12	Blood trace element (Zn levels);
LUAD	cis	rs6554196	0.508	rs10488849	chr4:55510862	C/T	cg18836493	chr4:55524333	KIT	-0.37	-7.01	-0.32	9.38e-12	Monocyte count;
LUAD	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg15181151	chr6:150070149	PCMT1	0.41	8.49	0.38	3.58e-16	Lung cancer;
LUAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00149659	chr3:10157352	C3orf10	0.49	6.81	0.31	3.35e-11	Alzheimer's disease;
LUAD	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24838063	chr12:130822603	PIWIL1	0.64	10.7	0.46	8.19e-24	Menopause (age at onset);
LUAD	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg13507964	chr21:42792703	MX1	-0.36	-6.36	-0.3	5.26e-10	IgG glycosylation;
LUAD	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg26384229	chr12:38710491	ALG10B	0.45	7.23	0.33	2.22e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg07936489	chr17:37558343	FBXL20	-0.48	-7.56	-0.35	2.48e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs3752645	1.000	rs74382914	chr7:106775164	T/G	cg02696742	chr7:106810147	HBP1	-0.68	-6.61	-0.31	1.19e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs68170813	0.559	rs6971675	chr7:106833797	G/A	cg23024343	chr7:107201750	COG5	0.49	7.12	0.33	4.73e-12	Coronary artery disease;
LUAD	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg19318889	chr4:1322082	MAEA	0.47	7.91	0.36	2.32e-14	Obesity-related traits;
LUAD	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg03948781	chr1:205179583	DSTYK	-0.34	-6.58	-0.3	1.41e-10	Red blood cell count;
LUAD	cis	rs62064224	0.578	rs2109158	chr17:30695964	T/C	cg25809561	chr17:30822961	MYO1D	0.45	8.08	0.37	7.08e-15	Schizophrenia;
LUAD	cis	rs7680126	0.626	rs929575	chr4:10196886	C/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-7.65	-0.35	1.39e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9914544	0.545	rs12451200	chr17:18778493	A/G	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.49	-0.3	2.45e-10	Educational attainment (years of education);
LUAD	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg15704280	chr7:45808275	SEPT13	0.68	9.22	0.41	1.44e-18	Axial length;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25970082	chr1:119683285	WARS2	-0.4	-6.46	-0.3	2.89e-10	Height;
LUAD	trans	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg01620082	chr3:125678407	NA	-0.65	-7.76	-0.35	6.64e-14	Depression;
LUAD	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.6	-0.39	1.56e-16	Alzheimer's disease (late onset);
LUAD	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.25	-0.51	9.34e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg26769984	chr7:1090371	C7orf50	0.62	10.13	0.44	9.7e-22	Bronchopulmonary dysplasia;
LUAD	cis	rs4588572	0.643	rs1560195	chr5:77701913	A/G	cg11547950	chr5:77652471	NA	0.78	12.79	0.53	7e-32	Triglycerides;
LUAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.3	0.41	7.44e-19	Alzheimer's disease;
LUAD	cis	rs3820068	0.705	rs4646031	chr1:15834648	A/G	cg24675056	chr1:15929824	NA	0.42	6.78	0.31	3.98e-11	Systolic blood pressure;
LUAD	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg06713675	chr4:122721982	EXOSC9	0.45	8.33	0.38	1.12e-15	Type 2 diabetes;
LUAD	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.11	-0.33	4.87e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs17152411	1.000	rs41303609	chr10:126670613	G/T	cg07906193	chr10:126599966	NA	0.54	7.54	0.34	2.94e-13	Height;
LUAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg20607798	chr8:58055168	NA	0.56	6.88	0.32	2.17e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs68170813	0.652	rs6976759	chr7:107158506	A/G	cg02696742	chr7:106810147	HBP1	-0.76	-8.98	-0.4	8.67e-18	Coronary artery disease;
LUAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10150615	chr22:24372951	LOC391322	0.49	8.04	0.36	9.24e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-9.15	-0.41	2.5e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg02569458	chr12:86230093	RASSF9	0.44	8.12	0.37	5.09e-15	Major depressive disorder;
LUAD	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg15128208	chr22:42549153	NA	0.36	7.44	0.34	5.81e-13	Cognitive function;
LUAD	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.47e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9287719	0.745	rs4997809	chr2:10755542	G/A	cg00105475	chr2:10696890	NA	0.37	6.66	0.31	8.64e-11	Prostate cancer;
LUAD	cis	rs6546550	0.869	rs6720498	chr2:70124805	T/C	cg02498382	chr2:70120550	SNRNP27	-0.59	-11.42	-0.49	1.6e-26	Prevalent atrial fibrillation;
LUAD	cis	rs9341808	0.718	rs9343978	chr6:80971978	A/G	cg08355045	chr6:80787529	NA	0.57	10.49	0.45	4.88e-23	Sitting height ratio;
LUAD	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg02527881	chr3:46936655	PTH1R	-0.49	-9.65	-0.42	4.62e-20	Colorectal cancer;
LUAD	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg24069376	chr3:38537580	EXOG	0.33	7.52	0.34	3.34e-13	Electrocardiographic conduction measures;
LUAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14159672	chr1:205819179	PM20D1	0.86	18.79	0.67	9.89e-58	Menarche (age at onset);
LUAD	trans	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg21659725	chr3:3221576	CRBN	0.51	8.29	0.37	1.51e-15	Body mass index;
LUAD	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.42	0.55	1.78e-34	Tonsillectomy;
LUAD	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg17105886	chr17:28927953	LRRC37B2	0.69	7.37	0.34	9.29e-13	Body mass index;
LUAD	cis	rs3820068	0.705	rs11584398	chr1:15880275	G/A	cg24675056	chr1:15929824	NA	0.43	6.79	0.31	3.76e-11	Systolic blood pressure;
LUAD	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg14092571	chr14:90743983	NA	-0.49	-8.7	-0.39	7.47e-17	Mortality in heart failure;
LUAD	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg15900387	chr1:150738905	CTSS	-0.37	-6.71	-0.31	6.41e-11	Melanoma;
LUAD	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg01788221	chr16:89496183	ANKRD11	-0.35	-6.8	-0.31	3.5e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs758324	0.947	rs6886188	chr5:131178252	C/T	cg06307176	chr5:131281290	NA	0.5	7.87	0.36	2.93e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25671651	chr2:203776787	ALS2CR8;WDR12	-0.44	-6.89	-0.32	2e-11	Height;
LUAD	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg20476274	chr7:133979776	SLC35B4	0.74	14.07	0.56	3.89e-37	Mean platelet volume;
LUAD	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg18200150	chr17:30822561	MYO1D	-0.44	-8.04	-0.36	8.82e-15	Schizophrenia;
LUAD	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-6.56	-0.3	1.57e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	11.59	0.49	3.79e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-13.98	-0.56	8.87e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg06558623	chr16:89946397	TCF25	1.2	10.96	0.47	9.15e-25	Skin colour saturation;
LUAD	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg01528321	chr10:82214614	TSPAN14	0.76	10.09	0.44	1.38e-21	Post bronchodilator FEV1;
LUAD	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg06685644	chr7:32801497	NA	-0.33	-6.62	-0.31	1.1e-10	Brain structure;
LUAD	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg12908607	chr1:44402522	ARTN	-0.52	-9.86	-0.43	9.15e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08280861	chr8:58055591	NA	0.68	8.88	0.4	1.93e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1904096	0.506	rs4558832	chr4:95148042	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.24	-0.45	3.92e-22	Type 2 diabetes;
LUAD	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg17182837	chr8:41585554	ANK1	-0.34	-6.87	-0.32	2.37e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUAD	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg15962314	chr1:44399869	ARTN	-0.34	-7.73	-0.35	7.83e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7584330	0.554	rs9646713	chr2:238443542	T/C	cg14458575	chr2:238380390	NA	0.6	9.65	0.42	4.63e-20	Prostate cancer;
LUAD	cis	rs12135894	0.562	rs6688969	chr1:3743391	C/T	cg10555106	chr1:3691387	LOC388588	0.42	7.35	0.34	1.03e-12	Mean corpuscular volume;
LUAD	cis	rs7192380	0.651	rs11643240	chr16:69635916	A/G	cg15192750	chr16:69999425	NA	0.4	6.38	0.3	4.65e-10	Sjögren's syndrome;
LUAD	cis	rs758324	0.812	rs7709934	chr5:131145210	C/T	cg25547332	chr5:131281432	NA	0.42	6.72	0.31	6.03e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg18833306	chr6:118973337	C6orf204	-0.49	-7.27	-0.33	1.75e-12	Diastolic blood pressure;
LUAD	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg26384229	chr12:38710491	ALG10B	0.4	6.95	0.32	1.41e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4481887	0.927	rs11204631	chr1:248479530	A/G	cg00666640	chr1:248458726	OR2T12	0.31	7.43	0.34	5.99e-13	Common traits (Other);
LUAD	trans	rs2018683	0.711	rs1874977	chr7:28968083	A/G	cg19402173	chr7:128379420	CALU	-0.58	-9.39	-0.42	3.62e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9788721	0.902	rs114205691	chr15:78901113	C/T	cg18825076	chr15:78729989	IREB2	-0.58	-9.43	-0.42	2.8e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg04756594	chr16:24857601	SLC5A11	0.73	12.0	0.5	9.07e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg25237894	chr2:233734115	C2orf82	0.61	11.46	0.49	1.16e-26	Coronary artery disease;
LUAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-7.12	-0.33	4.53e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.51	6.94	0.32	1.47e-11	Platelet count;
LUAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03188948	chr7:1209495	NA	0.46	7.78	0.35	5.51e-14	Longevity;Endometriosis;
LUAD	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg10253484	chr15:75165896	SCAMP2	-0.41	-6.39	-0.3	4.42e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.51	-8.59	-0.39	1.72e-16	Longevity;Endometriosis;
LUAD	trans	rs11039798	0.920	rs11500574	chr11:48713986	A/T	cg15704280	chr7:45808275	SEPT13	0.67	7.89	0.36	2.62e-14	Axial length;
LUAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03647317	chr4:187891568	NA	-0.36	-6.61	-0.31	1.16e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs490234	0.932	rs474489	chr9:128317881	C/G	cg14078157	chr9:128172775	NA	0.39	7.31	0.33	1.37e-12	Mean arterial pressure;
LUAD	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg02775129	chr4:119771670	NA	-0.87	-8.15	-0.37	4.24e-15	Cannabis dependence symptom count;
LUAD	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg03340356	chr1:67600835	NA	0.38	6.73	0.31	5.54e-11	Psoriasis;
LUAD	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg10755058	chr3:40428713	ENTPD3	0.38	7.29	0.33	1.58e-12	Renal cell carcinoma;
LUAD	cis	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg02240030	chr7:2089880	MAD1L1	0.36	6.91	0.32	1.76e-11	Neuroticism;
LUAD	cis	rs10992471	0.702	rs10820967	chr9:95101729	C/G	cg14631576	chr9:95140430	CENPP	-0.49	-9.91	-0.43	5.79e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg26168224	chr5:2018326	NA	-0.68	-13.15	-0.54	2.27e-33	Gut microbiome composition (winter);
LUAD	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg24829409	chr8:58192753	C8orf71	-0.62	-9.37	-0.41	4.41e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg05901451	chr6:126070800	HEY2	-0.57	-9.25	-0.41	1.12e-18	Brugada syndrome;
LUAD	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg14458575	chr2:238380390	NA	0.67	12.92	0.53	2.12e-32	Prostate cancer;
LUAD	trans	rs4653425	1.000	rs56260304	chr1:225884662	A/G	cg09308580	chr2:43405947	NA	0.38	6.56	0.3	1.61e-10	Neuroticism;
LUAD	cis	rs7301016	0.948	rs11174537	chr12:62929827	G/C	cg11441379	chr12:63026424	NA	0.59	7.31	0.34	1.32e-12	IgG glycosylation;
LUAD	trans	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	7.58	0.35	2.27e-13	Resting heart rate;
LUAD	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23158103	chr7:148848205	ZNF398	-0.49	-8.74	-0.39	5.39e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs738322	0.555	rs6001027	chr22:38545619	A/G	cg17652424	chr22:38574118	PLA2G6	-0.28	-7.43	-0.34	5.99e-13	Cutaneous nevi;
LUAD	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg10518543	chr12:38710700	ALG10B	0.51	8.41	0.38	6.48e-16	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.5	0.42	1.62e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9323205	0.954	rs7150336	chr14:51584596	A/T	cg23942311	chr14:51606299	NA	-0.57	-8.7	-0.39	7.36e-17	Cancer;
LUAD	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg03605463	chr16:89740564	NA	0.64	10.98	0.47	7.24e-25	Vitiligo;
LUAD	cis	rs4389656	0.784	rs274723	chr5:6718563	A/G	cg10857441	chr5:6722123	POLS	-0.47	-8.11	-0.37	5.35e-15	Coronary artery disease;
LUAD	trans	rs2834485	1.000	rs5010906	chr21:35818590	G/C	cg07474852	chr4:123073612	NA	0.54	8.27	0.37	1.79e-15	Cancer;
LUAD	cis	rs6908034	0.556	rs77486465	chr6:19803862	T/G	cg02682789	chr6:19804855	NA	0.97	9.5	0.42	1.6e-19	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.73	13.08	0.54	4.7e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg27490568	chr2:178487706	NA	0.57	8.62	0.39	1.34e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg25767906	chr1:53392781	SCP2	0.41	7.53	0.34	3e-13	Monocyte count;
LUAD	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg10792982	chr14:105748885	BRF1	0.45	9.93	0.43	4.91e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs68170813	0.559	rs10953532	chr7:106881808	C/T	cg23024343	chr7:107201750	COG5	0.51	7.35	0.34	1e-12	Coronary artery disease;
LUAD	cis	rs1692580	0.777	rs7547453	chr1:2195117	C/T	cg21194808	chr1:2205498	SKI	0.39	6.45	0.3	2.99e-10	Coronary artery disease;
LUAD	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg04455712	chr21:45112962	RRP1B	0.4	8.3	0.37	1.46e-15	Mean corpuscular volume;
LUAD	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg21252483	chr19:49399788	TULP2	-0.88	-14.3	-0.57	3.88e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg14345882	chr6:26364793	BTN3A2	0.7	7.15	0.33	3.76e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-9.58	-0.42	8.25e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-7.91	-0.36	2.24e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7177699	0.557	rs12898712	chr15:79112622	G/T	cg15571903	chr15:79123663	NA	0.37	7.26	0.33	1.84e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs225245	0.817	rs1476553	chr17:33994566	C/T	cg05299278	chr17:33885742	SLFN14	0.5	11.22	0.48	9.53e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg15485101	chr11:133734466	NA	-0.38	-8.23	-0.37	2.42e-15	Childhood ear infection;
LUAD	cis	rs7520050	0.897	rs4440807	chr1:46470878	T/C	cg06784218	chr1:46089804	CCDC17	-0.3	-6.48	-0.3	2.54e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs68170813	0.559	rs7981	chr7:106843133	G/C	cg23024343	chr7:107201750	COG5	0.49	7.05	0.32	7.33e-12	Coronary artery disease;
LUAD	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg21775007	chr8:11205619	TDH	-0.49	-8.97	-0.4	9.41e-18	Retinal vascular caliber;
LUAD	cis	rs1190552	0.739	rs1998421	chr14:102979644	C/T	cg18135206	chr14:102964638	TECPR2	0.46	6.5	0.3	2.32e-10	Blood protein levels;
LUAD	trans	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg01620082	chr3:125678407	NA	-0.83	-8.59	-0.39	1.75e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.88	0.36	2.75e-14	Depression;
LUAD	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg15557168	chr22:42548783	NA	0.5	9.3	0.41	7.69e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg16049864	chr8:95962084	TP53INP1	-0.54	-11.51	-0.49	7.69e-27	Type 2 diabetes;
LUAD	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg27632911	chr20:34205182	SPAG4	0.37	6.4	0.3	4.18e-10	Total cholesterol levels;
LUAD	cis	rs4660214	0.666	rs61783383	chr1:39807018	T/C	cg27567593	chr1:39956653	BMP8A	0.36	7.36	0.34	9.45e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1975974	1.000	rs67946006	chr17:21723940	T/C	cg18423549	chr17:21743878	NA	-0.77	-13.89	-0.56	2.16e-36	Psoriasis;
LUAD	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.21	-0.37	2.79e-15	Total body bone mineral density;
LUAD	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg17644776	chr2:200775616	C2orf69	-0.52	-6.53	-0.3	1.9e-10	Schizophrenia;
LUAD	cis	rs2227564	0.620	rs11000785	chr10:75575963	T/C	cg23231163	chr10:75533350	FUT11	-0.42	-6.67	-0.31	7.78e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg18252515	chr7:66147081	NA	-0.63	-6.84	-0.32	2.86e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg07917127	chr4:99064746	C4orf37	0.5	8.02	0.36	1.03e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8008758	0.500	rs1763212	chr14:101693911	G/A	cg26224664	chr14:101693935	NA	-0.48	-12.28	-0.51	7.68e-30	Body mass index (alcohol intake interaction);
LUAD	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-8.27	-0.37	1.73e-15	Height;Educational attainment;Head circumference (infant);
LUAD	cis	rs62064224	0.614	rs728718	chr17:30708960	T/G	cg25809561	chr17:30822961	MYO1D	0.48	8.64	0.39	1.17e-16	Schizophrenia;
LUAD	cis	rs1697139	0.604	rs874550	chr5:66530945	C/T	cg11553311	chr5:66541588	NA	-0.42	-7.83	-0.36	4.03e-14	Breast cancer;
LUAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg22907277	chr7:1156413	C7orf50	0.74	11.05	0.47	4.15e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg09455208	chr3:40491958	NA	0.54	11.11	0.48	2.5e-25	Renal cell carcinoma;
LUAD	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg23978390	chr7:1156363	C7orf50	0.55	6.78	0.31	4.08e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg04545296	chr12:48745243	ZNF641	-0.39	-9.79	-0.43	1.55e-20	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg09455208	chr3:40491958	NA	0.52	11.0	0.47	6.55e-25	Renal cell carcinoma;
LUAD	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.66	-0.35	1.26e-13	Breast cancer;
LUAD	cis	rs7827545	1.000	rs9644456	chr8:135568656	G/T	cg17885191	chr8:135476712	NA	0.49	7.56	0.34	2.6e-13	Hypertension (SNP x SNP interaction);
LUAD	cis	rs2019216	0.500	rs1877497	chr17:21940171	C/T	cg22648282	chr17:21454238	C17orf51	-0.42	-6.62	-0.31	1.12e-10	Pelvic organ prolapse;
LUAD	cis	rs1232027	0.700	rs1643661	chr5:79933576	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg23649088	chr2:200775458	C2orf69	0.8	14.85	0.59	1.92e-40	Osteoporosis;
LUAD	cis	rs6499255	0.951	rs3169315	chr16:69720964	G/A	cg15192750	chr16:69999425	NA	0.45	6.78	0.31	3.94e-11	IgE levels;
LUAD	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	8.79	0.39	3.86e-17	Blood metabolite levels;
LUAD	cis	rs870825	0.616	rs7692367	chr4:185651056	T/C	cg04058563	chr4:185651563	MLF1IP	0.9	14.58	0.58	2.63e-39	Blood protein levels;
LUAD	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg27432699	chr2:27873401	GPN1	0.54	9.54	0.42	1.11e-19	Oral cavity cancer;
LUAD	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg12863693	chr15:85201151	NMB	-0.38	-6.73	-0.31	5.65e-11	Schizophrenia;
LUAD	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg15448220	chr1:150897856	SETDB1	0.57	9.76	0.43	1.91e-20	Melanoma;
LUAD	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg17105886	chr17:28927953	LRRC37B2	0.83	8.04	0.36	8.84e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7119038	0.818	rs57494551	chr11:118661398	C/T	cg19308663	chr11:118741387	NA	0.47	6.63	0.31	1.01e-10	Sjögren's syndrome;
LUAD	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg15704280	chr7:45808275	SEPT13	-0.75	-11.65	-0.49	2.17e-27	Coronary artery disease;
LUAD	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg18171855	chr10:2543474	NA	0.35	6.64	0.31	9.56e-11	Age-related hearing impairment;
LUAD	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg26373071	chr5:1325741	CLPTM1L	0.36	7.52	0.34	3.38e-13	Lung cancer;
LUAD	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.2	-0.33	2.71e-12	Total body bone mineral density;
LUAD	cis	rs7843479	0.601	rs4872207	chr8:21842751	C/G	cg03445287	chr8:21823731	XPO7	0.48	9.01	0.4	6.93e-18	Mean corpuscular volume;
LUAD	cis	rs17641971	0.684	rs1876717	chr8:49994968	T/G	cg00325661	chr8:49890786	NA	0.3	6.75	0.31	5.02e-11	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2130392	0.926	rs4610379	chr4:185624388	A/G	cg04058563	chr4:185651563	MLF1IP	0.36	6.38	0.3	4.71e-10	Kawasaki disease;
LUAD	cis	rs4774899	0.752	rs28414972	chr15:57399694	T/C	cg14026238	chr15:57616123	NA	-0.43	-8.14	-0.37	4.48e-15	Urinary tract infection frequency;
LUAD	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg00071950	chr4:10020882	SLC2A9	0.83	17.77	0.65	3.44e-53	Bone mineral density;
LUAD	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg06784218	chr1:46089804	CCDC17	-0.53	-11.59	-0.49	3.67e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1595825	1.000	rs73058829	chr2:198871145	G/A	cg00982548	chr2:198649783	BOLL	-0.6	-8.64	-0.39	1.14e-16	Ulcerative colitis;
LUAD	cis	rs28595532	0.764	rs115916994	chr4:119688758	A/G	cg14228332	chr4:119757509	SEC24D	0.8	7.57	0.35	2.28e-13	Cannabis dependence symptom count;
LUAD	cis	rs12618769	0.625	rs113342082	chr2:99034198	G/A	cg10123293	chr2:99228465	UNC50	0.45	8.02	0.36	1.06e-14	Bipolar disorder;
LUAD	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg00750074	chr16:89608354	SPG7	-0.54	-9.39	-0.42	3.88e-19	Multiple myeloma (IgH translocation);
LUAD	cis	rs17102423	0.755	rs942627	chr14:65550025	A/G	cg11161011	chr14:65562177	MAX	-0.48	-7.77	-0.35	5.94e-14	Obesity-related traits;
LUAD	cis	rs4285028	0.731	rs2332035	chr3:121715432	C/T	cg20356878	chr3:121714668	ILDR1	-0.52	-7.59	-0.35	2.12e-13	Multiple sclerosis;
LUAD	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg05340658	chr4:99064831	C4orf37	0.55	9.39	0.42	3.79e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg06740227	chr12:86229804	RASSF9	0.39	7.04	0.32	7.91e-12	Major depressive disorder;
LUAD	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg05991184	chr2:219186017	PNKD	-0.37	-7.21	-0.33	2.64e-12	Colorectal cancer;
LUAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs78049276	0.688	rs61075980	chr4:148374767	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.65	-7.58	-0.35	2.26e-13	Pulse pressure;
LUAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg04160749	chr8:58172571	NA	-0.37	-7.02	-0.32	9.13e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4947962	0.618	rs59119563	chr7:55090048	T/C	cg23757825	chr7:55092271	EGFR	-0.57	-7.7	-0.35	9.89e-14	Subjective response to lithium treatment;
LUAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg04775059	chr7:64541387	NA	0.52	8.47	0.38	4.17e-16	Calcium levels;
LUAD	cis	rs711245	0.637	rs11894187	chr2:36781708	T/A	cg09467607	chr2:36825704	FEZ2	0.58	11.01	0.47	5.93e-25	Height;
LUAD	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg06387496	chr7:2775674	GNA12	-0.4	-6.75	-0.31	4.76e-11	Height;
LUAD	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg17173187	chr15:85201210	NMB	0.49	8.4	0.38	7.07e-16	Schizophrenia;
LUAD	cis	rs9302065	1.000	rs7490267	chr13:95970258	T/C	cg24476569	chr13:95954382	ABCC4	-0.49	-8.99	-0.4	8.06e-18	Blood metabolite levels;
LUAD	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg21285383	chr16:89894308	SPIRE2	0.41	9.92	0.43	5.24e-21	Vitiligo;
LUAD	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg13699009	chr12:122356056	WDR66	0.31	6.78	0.31	3.98e-11	Mean corpuscular volume;
LUAD	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	8.67	0.39	9.24e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.56	-0.42	9.63e-20	Alzheimer's disease;
LUAD	cis	rs2629540	0.847	rs34032724	chr10:126408869	T/G	cg08799069	chr10:126477246	METTL10	0.47	6.9	0.32	1.87e-11	Cocaine dependence;
LUAD	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.1	-0.44	1.28e-21	Migraine;Coronary artery disease;
LUAD	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg20933634	chr6:27740509	NA	0.41	6.35	0.3	5.52e-10	Parkinson's disease;
LUAD	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg05340658	chr4:99064831	C4orf37	0.44	6.75	0.31	4.95e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2625529	0.730	rs2957725	chr15:72248205	C/A	cg16672083	chr15:72433130	SENP8	0.63	11.66	0.49	2e-27	Red blood cell count;
LUAD	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg09365446	chr1:150670422	GOLPH3L	0.66	12.28	0.51	7.28e-30	Tonsillectomy;
LUAD	cis	rs8048589	0.948	rs71385189	chr16:12182179	G/T	cg03816625	chr16:12192430	SNX29	0.53	7.84	0.36	3.66e-14	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg09137382	chr11:130731461	NA	0.42	7.59	0.35	2.1e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg18230493	chr5:56204884	C5orf35	-0.79	-9.77	-0.43	1.84e-20	Type 2 diabetes;
LUAD	cis	rs7216064	1.000	rs11079706	chr17:65835470	G/T	cg08758996	chr17:66097529	LOC651250	0.45	6.92	0.32	1.68e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg23281280	chr6:28129359	ZNF389	0.46	6.58	0.3	1.39e-10	Depression;
LUAD	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg09658497	chr7:2847517	GNA12	-0.53	-8.74	-0.39	5.55e-17	Height;
LUAD	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19717773	chr7:2847554	GNA12	-0.55	-9.4	-0.42	3.47e-19	Height;
LUAD	trans	rs78049276	0.736	rs17612742	chr4:148414651	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	0.59	6.74	0.31	5.32e-11	Pulse pressure;
LUAD	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg02527881	chr3:46936655	PTH1R	-0.55	-11.24	-0.48	7.96e-26	Colorectal cancer;
LUAD	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg03474202	chr17:45855739	NA	-0.37	-8.7	-0.39	7.57e-17	IgG glycosylation;
LUAD	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg05717871	chr11:638507	DRD4	-0.47	-6.75	-0.31	4.83e-11	Systemic lupus erythematosus;
LUAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00149659	chr3:10157352	C3orf10	0.61	8.41	0.38	6.45e-16	Alzheimer's disease;
LUAD	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.06	-0.32	6.66e-12	Joint mobility (Beighton score);
LUAD	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03352830	chr11:487213	PTDSS2	0.82	10.87	0.47	1.91e-24	Body mass index;
LUAD	cis	rs877282	0.898	rs71489279	chr10:760510	T/C	cg17470449	chr10:769945	NA	0.6	8.56	0.38	2.14e-16	Uric acid levels;
LUAD	cis	rs113835537	0.529	rs11227515	chr11:66287383	C/T	cg26679405	chr11:66247800	DPP3	-0.44	-6.49	-0.3	2.37e-10	Airway imaging phenotypes;
LUAD	cis	rs7274811	0.681	rs291705	chr20:31969658	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.51	-7.74	-0.35	7.41e-14	Height;
LUAD	cis	rs7680126	0.597	rs78917351	chr4:10208063	A/C	cg02734326	chr4:10020555	SLC2A9	-0.53	-6.88	-0.32	2.11e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg05340658	chr4:99064831	C4orf37	0.45	7.47	0.34	4.6e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7945718	0.781	rs10741604	chr11:12840940	C/A	cg25843174	chr11:12811716	TEAD1	0.22	6.46	0.3	2.88e-10	Educational attainment (years of education);
LUAD	trans	rs6598955	0.671	rs11579630	chr1:26612297	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.72	-9.91	-0.43	5.93e-21	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg02221422	chr11:68192511	LRP5	-0.41	-6.79	-0.31	3.82e-11	Total body bone mineral density;
LUAD	cis	rs897984	0.609	rs35468353	chr16:31056433	A/G	cg02466173	chr16:30829666	NA	-0.56	-9.82	-0.43	1.25e-20	Dementia with Lewy bodies;
LUAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg05313129	chr8:58192883	C8orf71	-0.54	-6.73	-0.31	5.66e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12530845	0.767	rs7784162	chr7:135305886	G/T	cg23117316	chr7:135346802	PL-5283	-0.48	-9.07	-0.4	4.45e-18	Red blood cell traits;
LUAD	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg19622623	chr12:86230825	RASSF9	-0.55	-9.7	-0.43	3.13e-20	Major depressive disorder;
LUAD	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg24733560	chr20:60626293	TAF4	0.4	7.77	0.35	5.91e-14	Body mass index;
LUAD	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.44	-0.38	4.99e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.26	-0.51	8.67e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg08761264	chr16:28874980	SH2B1	-0.45	-6.93	-0.32	1.58e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg06197492	chr11:2016605	H19	0.41	8.31	0.37	1.28e-15	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg20301340	chr19:41815941	CCDC97	0.42	6.44	0.3	3.27e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs2882667	0.931	rs7720150	chr5:138334069	C/A	cg04439458	chr5:138467593	SIL1	-0.4	-7.47	-0.34	4.75e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg07607921	chr17:4047574	ZZEF1;CYB5D2	-0.44	-7.93	-0.36	2.01e-14	Type 2 diabetes;
LUAD	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg00634984	chr7:65235879	NA	0.52	7.08	0.33	5.86e-12	Aortic root size;
LUAD	cis	rs654950	0.807	rs61773660	chr1:41993298	C/T	cg06885757	chr1:42089581	HIVEP3	-0.39	-8.0	-0.36	1.18e-14	Airway imaging phenotypes;
LUAD	cis	rs870825	0.550	rs35981185	chr4:185639720	A/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.12	0.57	2.26e-37	Blood protein levels;
LUAD	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.45	7.57	0.35	2.35e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg25767906	chr1:53392781	SCP2	-0.46	-8.36	-0.38	9.09e-16	Monocyte count;
LUAD	cis	rs240764	0.578	rs9498252	chr6:101194481	A/G	cg09795085	chr6:101329169	ASCC3	0.44	7.74	0.35	7.36e-14	Neuroticism;
LUAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg22963979	chr7:1858916	MAD1L1	-0.61	-10.44	-0.45	7.15e-23	Bipolar disorder and schizophrenia;
LUAD	trans	rs9354308	0.933	rs12194424	chr6:66574007	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.48	7.3	0.33	1.47e-12	Metabolite levels;
LUAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg13271783	chr10:134563150	INPP5A	-0.41	-6.6	-0.31	1.24e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg05665937	chr4:1216051	CTBP1	0.39	6.39	0.3	4.38e-10	Obesity-related traits;
LUAD	cis	rs4711350	0.953	rs1951930	chr6:33782655	C/A	cg07979401	chr6:33739406	LEMD2	-0.46	-7.18	-0.33	3.11e-12	Schizophrenia;
LUAD	trans	rs11039798	0.610	rs11530356	chr11:48836290	C/A	cg15704280	chr7:45808275	SEPT13	0.68	7.85	0.36	3.41e-14	Axial length;
LUAD	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg05966235	chr16:28915196	ATP2A1	0.42	6.77	0.31	4.21e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7017914	0.935	rs56289931	chr8:71837754	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.41	-0.3	3.97e-10	Bone mineral density;
LUAD	cis	rs11031096	0.782	rs4910888	chr11:4152915	G/A	cg18678763	chr11:4115507	RRM1	-0.42	-7.41	-0.34	6.79e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs12617721	0.574	rs6542754	chr2:99025400	C/T	cg10123293	chr2:99228465	UNC50	0.46	8.26	0.37	1.88e-15	Bipolar disorder with mood-incongruent psychosis;
LUAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2224391	0.628	rs2773318	chr6:5258843	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.67	-10.21	-0.44	5.07e-22	Height;
LUAD	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg11859384	chr17:80120422	CCDC57	0.5	9.04	0.4	5.52e-18	Life satisfaction;
LUAD	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06544989	chr22:39130855	UNC84B	0.45	8.36	0.38	9.27e-16	Menopause (age at onset);
LUAD	cis	rs7945718	0.839	rs763373	chr11:12840342	C/G	cg25843174	chr11:12811716	TEAD1	-0.22	-6.58	-0.3	1.37e-10	Educational attainment (years of education);
LUAD	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.64	-0.31	9.9e-11	Joint mobility (Beighton score);
LUAD	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3960554	0.741	rs28446604	chr7:75662518	C/T	cg19862616	chr7:65841803	NCRNA00174	0.82	11.09	0.47	2.97e-25	Eotaxin levels;
LUAD	cis	rs986417	1.000	rs2351176	chr14:61073731	A/T	cg27398547	chr14:60952738	C14orf39	0.65	7.25	0.33	1.98e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs4919694	1.000	rs17727044	chr10:104821256	A/T	cg04362960	chr10:104952993	NT5C2	0.8	8.41	0.38	6.36e-16	Arsenic metabolism;
LUAD	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg01579765	chr21:45077557	HSF2BP	0.54	12.0	0.5	9.5e-29	Mean corpuscular volume;
LUAD	cis	rs4006360	0.505	rs9916287	chr17:39286884	T/G	cg20663846	chr17:39254439	KRTAP4-8	0.35	7.33	0.34	1.22e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2692947	0.509	rs4907303	chr2:96217234	C/G	cg23100626	chr2:96804247	ASTL	0.32	7.68	0.35	1.11e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg02569458	chr12:86230093	RASSF9	0.41	7.79	0.35	5.38e-14	Major depressive disorder;
LUAD	cis	rs4691139	0.903	rs6812176	chr4:165919972	T/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.45	-8.71	-0.39	7.07e-17	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.54	-8.86	-0.4	2.17e-17	Primary sclerosing cholangitis;
LUAD	cis	rs4443100	0.535	rs13055979	chr22:23474085	C/T	cg21100191	chr22:23484243	RTDR1	0.46	6.62	0.31	1.06e-10	Serum parathyroid hormone levels;
LUAD	cis	rs4356932	1.000	rs4859598	chr4:76959828	C/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.52	-0.3	2.05e-10	Blood protein levels;
LUAD	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.43	-0.38	5.56e-16	Height;
LUAD	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	7.0	0.32	9.95e-12	Cognitive test performance;
LUAD	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg00383909	chr3:49044727	WDR6	0.98	9.79	0.43	1.61e-20	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs10489202	0.634	rs11582396	chr1:168077636	C/T	cg25738037	chr1:168025549	DCAF6	-0.45	-6.55	-0.3	1.69e-10	Schizophrenia;
LUAD	trans	rs10838798	0.523	rs11039593	chr11:48240112	A/G	cg21153622	chr11:89784906	NA	-0.33	-6.4	-0.3	4.23e-10	Height;
LUAD	cis	rs10865541	0.806	rs4971503	chr2:3417221	G/A	cg13173536	chr2:3403300	TTC15	-0.34	-6.61	-0.31	1.16e-10	Obesity-related traits;
LUAD	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg20503657	chr10:835505	NA	0.79	10.59	0.46	2.15e-23	Eosinophil percentage of granulocytes;
LUAD	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg08888203	chr3:10149979	C3orf24	0.66	8.89	0.4	1.77e-17	Alzheimer's disease;
LUAD	cis	rs4077515	0.839	rs3812563	chr9:139271106	A/G	cg14019695	chr9:139328340	INPP5E	0.4	7.41	0.34	6.99e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg05623727	chr3:50126028	RBM5	-0.29	-6.38	-0.3	4.69e-10	Body mass index;
LUAD	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.44	7.13	0.33	4.45e-12	Bipolar disorder;
LUAD	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg27411982	chr8:10470053	RP1L1	0.4	7.07	0.32	6.61e-12	Retinal vascular caliber;
LUAD	cis	rs758324	0.947	rs253943	chr5:131320730	C/T	cg06307176	chr5:131281290	NA	0.5	7.9	0.36	2.45e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-8.33	-0.38	1.12e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg09033563	chr22:24373618	LOC391322	-0.56	-9.31	-0.41	6.76e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg00310523	chr12:86230176	RASSF9	0.38	7.73	0.35	7.94e-14	Major depressive disorder;
LUAD	cis	rs9549328	0.837	rs9549618	chr13:113628648	G/A	cg17524180	chr13:113633600	MCF2L	-0.39	-7.79	-0.35	5.07e-14	Systolic blood pressure;
LUAD	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-10.53	-0.46	3.35e-23	Hemoglobin concentration;
LUAD	cis	rs2637266	1.000	rs2395388	chr10:78357203	C/T	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg17264618	chr3:40429014	ENTPD3	-0.41	-9.03	-0.4	6.01e-18	Renal cell carcinoma;
LUAD	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.38	0.34	8.69e-13	Menopause (age at onset);
LUAD	cis	rs929596	0.755	rs3771341	chr2:234673239	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.75	-13.19	-0.54	1.64e-33	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg12648201	chr2:27665141	KRTCAP3	0.3	7.64	0.35	1.44e-13	Total body bone mineral density;
LUAD	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg00666640	chr1:248458726	OR2T12	0.29	6.86	0.32	2.41e-11	Common traits (Other);
LUAD	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg02371401	chr5:676784	TPPP	-0.47	-7.68	-0.35	1.12e-13	Lung disease severity in cystic fibrosis;
LUAD	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg17147758	chr8:6949321	NA	-0.5	-8.94	-0.4	1.25e-17	Blood pressure (smoking interaction);
LUAD	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg23281280	chr6:28129359	ZNF389	0.46	6.58	0.3	1.39e-10	Depression;
LUAD	cis	rs6761276	0.899	rs12711750	chr2:113835380	C/A	cg06383401	chr2:113825234	IL1F10	-0.3	-6.41	-0.3	3.97e-10	Protein quantitative trait loci;
LUAD	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7937890	0.559	rs6486193	chr11:14437607	C/G	cg23387056	chr11:14280742	SPON1	-0.34	-6.55	-0.3	1.67e-10	Mitochondrial DNA levels;
LUAD	cis	rs1298062	0.535	rs2463240	chr19:50941905	A/G	cg11430371	chr19:50961752	MYBPC2	0.37	7.68	0.35	1.13e-13	Age of smoking initiation;
LUAD	cis	rs887829	0.569	rs4663967	chr2:234653184	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-8.38	-0.38	8.07e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs7843479	0.601	rs4872204	chr8:21841396	T/C	cg03445287	chr8:21823731	XPO7	-0.48	-9.01	-0.4	7.32e-18	Mean corpuscular volume;
LUAD	cis	rs7903847	0.642	rs11189167	chr10:99125722	A/G	cg20016023	chr10:99160130	RRP12	-0.32	-6.99	-0.32	1.1e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.68	12.44	0.52	1.74e-30	Cognitive ability;
LUAD	trans	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.44	0.52	1.7e-30	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs116248771	0.739	rs73156425	chr3:158345677	G/A	cg16708174	chr3:158430962	RARRES1	0.46	6.8	0.31	3.62e-11	diarrhoeal disease at age 2;
LUAD	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg18132916	chr6:79620363	NA	-0.44	-7.64	-0.35	1.47e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs870825	0.616	rs57316663	chr4:185630011	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg00271210	chr6:167070053	RPS6KA2	0.34	6.59	0.31	1.33e-10	Crohn's disease;
LUAD	cis	rs11811982	0.793	rs77703354	chr1:227370713	C/T	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic disc area;
LUAD	cis	rs12760731	0.641	rs12038910	chr1:178444907	C/T	cg00404053	chr1:178313656	RASAL2	0.54	7.24	0.33	2.1e-12	Obesity-related traits;
LUAD	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg07617317	chr6:118971624	C6orf204	0.55	8.33	0.38	1.14e-15	Diastolic blood pressure;
LUAD	cis	rs300774	1.000	rs400978	chr2:119437	A/G	cg21211680	chr2:198530	NA	-0.49	-7.05	-0.32	7.44e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs732716	0.740	rs78869060	chr19:4444742	A/G	cg21934504	chr19:4445085	UBXN6	0.46	7.76	0.35	6.36e-14	Mean corpuscular volume;
LUAD	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg15467112	chr14:75489610	MLH3	-0.35	-6.44	-0.3	3.24e-10	Height;
LUAD	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg12935359	chr14:103987150	CKB	-0.48	-7.57	-0.35	2.32e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg22906224	chr7:99728672	NA	0.63	10.81	0.47	3.22e-24	Coronary artery disease;
LUAD	cis	rs7216064	0.700	rs4791295	chr17:65997317	G/A	cg08758996	chr17:66097529	LOC651250	0.5	7.77	0.35	5.97e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg08470875	chr2:26401718	FAM59B	0.66	9.4	0.42	3.52e-19	Gut microbiome composition (summer);
LUAD	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg05283184	chr6:79620031	NA	-0.6	-12.21	-0.51	1.37e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg22676075	chr6:135203613	NA	0.42	7.81	0.35	4.58e-14	Red blood cell count;
LUAD	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs73206853	0.841	rs2339511	chr12:110789372	C/T	cg12870014	chr12:110450643	ANKRD13A	0.58	6.48	0.3	2.52e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs16854884	0.710	rs9829796	chr3:143801416	C/T	cg01302019	chr3:143689584	C3orf58	-0.39	-6.35	-0.3	5.51e-10	Economic and political preferences (feminism/equality);
LUAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg08132940	chr7:1081526	C7orf50	-0.45	-6.73	-0.31	5.47e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg21709803	chr11:61594965	FADS2	-0.38	-6.98	-0.32	1.12e-11	Trans fatty acid levels;
LUAD	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.34	6.74	0.31	5.15e-11	Parkinson's disease;
LUAD	cis	rs1788820	0.917	rs1788760	chr18:21137442	A/G	cg14672496	chr18:21087552	C18orf8	0.35	6.37	0.3	5.03e-10	Body mass index;
LUAD	cis	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg11143507	chr3:125485238	NA	-0.44	-7.44	-0.34	5.53e-13	Blood pressure (smoking interaction);
LUAD	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg27124370	chr19:33622961	WDR88	0.46	7.12	0.33	4.57e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.79	-0.35	5.18e-14	Type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs7395662	0.654	rs12289625	chr11:48817242	A/G	cg15704280	chr7:45808275	SEPT13	0.41	6.39	0.3	4.33e-10	HDL cholesterol;
LUAD	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02018176	chr4:1364513	KIAA1530	-0.68	-11.98	-0.5	1.13e-28	Longevity;
LUAD	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.64	-0.35	1.5e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg11901034	chr3:128598214	ACAD9	-0.55	-8.75	-0.39	5.24e-17	IgG glycosylation;
LUAD	cis	rs41271951	0.512	rs11204774	chr1:151062957	C/T	cg11822372	chr1:151115635	SEMA6C	-0.77	-7.02	-0.32	8.79e-12	Blood protein levels;
LUAD	cis	rs4604732	0.536	rs7528219	chr1:247628307	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.17	0.33	3.35e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg06191203	chr2:152266755	RIF1	-0.54	-8.19	-0.37	3.2e-15	Squamous cell lung carcinoma;
LUAD	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	7.68	0.35	1.1e-13	Personality dimensions;
LUAD	cis	rs454510	0.816	rs838987	chr1:120176127	A/G	cg11530693	chr1:120165357	ZNF697	0.62	9.31	0.41	6.91e-19	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	trans	rs1997103	1.000	rs4947501	chr7:55407342	C/T	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg06636551	chr8:101224915	SPAG1	-0.37	-7.05	-0.32	7.54e-12	Atrioventricular conduction;
LUAD	cis	rs7570971	1.000	rs6730157	chr2:135907088	C/T	cg07305463	chr2:136567211	LCT	0.35	6.69	0.31	7.25e-11	Blood metabolite levels;Body mass index;Cholesterol, total;
LUAD	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg07741184	chr6:167504864	NA	-0.3	-7.11	-0.33	5.05e-12	Crohn's disease;
LUAD	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.47	-0.34	4.54e-13	Electroencephalogram traits;
LUAD	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	11.63	0.49	2.67e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg14416269	chr4:6271139	WFS1	0.6	12.4	0.52	2.57e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7512552	0.809	rs9436108	chr1:150360930	A/G	cg15654264	chr1:150340011	RPRD2	0.58	11.08	0.47	3.24e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg09835421	chr16:68378352	PRMT7	-0.74	-8.32	-0.38	1.2e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3784262	0.528	rs11071364	chr15:58334113	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-7.15	-0.33	3.88e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs870825	0.616	rs7654208	chr4:185648877	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.15e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg09835421	chr16:68378352	PRMT7	-0.64	-7.38	-0.34	8.72e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06873352	chr17:61820015	STRADA	-0.71	-14.55	-0.58	3.64e-39	Prudent dietary pattern;
LUAD	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg23985595	chr17:80112537	CCDC57	0.54	9.96	0.44	3.76e-21	Life satisfaction;
LUAD	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg21963583	chr11:68658836	MRPL21	0.62	10.83	0.47	2.72e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.85	0.43	9.44e-21	Ulcerative colitis;
LUAD	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg18016565	chr1:150552671	MCL1	0.41	7.5	0.34	3.86e-13	Tonsillectomy;
LUAD	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg02493740	chr2:85810744	VAMP5	-0.62	-11.24	-0.48	7.9e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs1497828	0.956	rs2646861	chr1:217521978	G/A	cg04411442	chr1:217543379	NA	-0.39	-6.91	-0.32	1.73e-11	Dialysis-related mortality;
LUAD	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg13647721	chr17:30228624	UTP6	0.48	6.67	0.31	8.22e-11	Height;
LUAD	cis	rs921968	0.643	rs485765	chr2:219480804	C/G	cg02176678	chr2:219576539	TTLL4	0.57	10.79	0.46	3.84e-24	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg12935359	chr14:103987150	CKB	0.45	7.66	0.35	1.32e-13	Body mass index;
LUAD	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg24069376	chr3:38537580	EXOG	0.45	11.0	0.47	6.54e-25	Electrocardiographic conduction measures;
LUAD	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.55	-0.34	2.74e-13	Breast cancer;
LUAD	trans	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.45	-0.3	3.04e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg20848291	chr7:100343083	ZAN	-0.65	-9.82	-0.43	1.27e-20	Other erythrocyte phenotypes;
LUAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg03354898	chr7:1950403	MAD1L1	-0.43	-8.23	-0.37	2.42e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg27454412	chr7:1067447	C7orf50	0.48	7.7	0.35	9.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg11062466	chr8:58055876	NA	0.81	10.39	0.45	1.14e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13315871	1.000	rs11709976	chr3:58325347	A/G	cg12435725	chr3:58293450	RPP14	-0.76	-8.4	-0.38	6.7e-16	Cholesterol, total;
LUAD	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg03948781	chr1:205179583	DSTYK	0.33	6.45	0.3	3.09e-10	Red blood cell count;
LUAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg22963979	chr7:1858916	MAD1L1	-0.62	-10.69	-0.46	8.81e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs9584850	0.834	rs17574378	chr13:99116384	T/C	cg20750642	chr13:99100586	FARP1	-0.35	-7.27	-0.33	1.72e-12	Neuroticism;
LUAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05535760	chr7:792225	HEATR2	1.0	12.52	0.52	8.33e-31	Cerebrospinal P-tau181p levels;
LUAD	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg17264618	chr3:40429014	ENTPD3	0.38	8.4	0.38	6.62e-16	Renal cell carcinoma;
LUAD	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg12573674	chr2:1569213	NA	-0.6	-7.51	-0.34	3.59e-13	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25427524	chr10:38739819	LOC399744	-0.75	-13.39	-0.55	2.38e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg21214613	chr1:16344536	HSPB7	0.6	11.6	0.49	3.35e-27	Dilated cardiomyopathy;
LUAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08219700	chr8:58056026	NA	0.61	8.66	0.39	9.78e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21659725	chr3:3221576	CRBN	0.51	8.32	0.38	1.18e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs11048434	0.736	rs1805733	chr12:9089272	A/C	cg04155231	chr12:9217510	LOC144571	0.38	7.16	0.33	3.58e-12	Sjögren's syndrome;
LUAD	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg14008862	chr17:28927542	LRRC37B2	0.54	6.45	0.3	3.14e-10	Body mass index;
LUAD	cis	rs7100689	0.784	rs6585986	chr10:82171559	T/C	cg01528321	chr10:82214614	TSPAN14	0.71	10.85	0.47	2.32e-24	Post bronchodilator FEV1;
LUAD	cis	rs7640424	0.691	rs35168062	chr3:107829507	A/G	cg09227934	chr3:107805635	CD47	-0.36	-6.62	-0.31	1.09e-10	Body mass index;
LUAD	cis	rs738322	0.533	rs2284064	chr22:38547395	A/C	cg25457927	chr22:38595422	NA	-0.53	-12.37	-0.52	3.19e-30	Cutaneous nevi;
LUAD	cis	rs6594713	0.837	rs17327964	chr5:112729116	C/G	cg12552261	chr5:112820674	MCC	-0.47	-7.1	-0.33	5.35e-12	Brain cytoarchitecture;
LUAD	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.6	-0.35	1.96e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs790123	1.000	rs790125	chr3:122388464	A/G	cg17380795	chr3:122379686	NA	0.49	8.47	0.38	4.2e-16	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7943203	0.568	rs597788	chr11:108256859	C/T	cg04873221	chr11:107992290	ACAT1	-0.49	-7.43	-0.34	6.25e-13	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs4588572	0.779	rs3088102	chr5:77654679	G/A	cg11547950	chr5:77652471	NA	0.79	12.16	0.51	2.25e-29	Triglycerides;
LUAD	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.54	0.38	2.46e-16	Platelet count;
LUAD	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg11901034	chr3:128598214	ACAD9	-0.49	-7.61	-0.35	1.8e-13	IgG glycosylation;
LUAD	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg16049864	chr8:95962084	TP53INP1	-0.6	-13.11	-0.54	3.4e-33	Type 2 diabetes;
LUAD	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg09796270	chr17:17721594	SREBF1	-0.4	-7.96	-0.36	1.63e-14	Total body bone mineral density;
LUAD	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg06191203	chr2:152266755	RIF1	-0.61	-9.46	-0.42	2.18e-19	Lung cancer;
LUAD	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.6	-0.52	3.83e-31	Monocyte count;
LUAD	cis	rs2806561	1.000	rs2806563	chr1:23506625	C/T	cg19743168	chr1:23544995	NA	-0.39	-7.03	-0.32	8.23e-12	Height;
LUAD	cis	rs1448094	0.967	rs10863109	chr12:86328415	A/G	cg18827107	chr12:86230957	RASSF9	-0.44	-7.93	-0.36	1.94e-14	Major depressive disorder;
LUAD	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg15448220	chr1:150897856	SETDB1	-0.45	-7.57	-0.35	2.41e-13	Tonsillectomy;
LUAD	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg09184832	chr6:79620586	NA	-0.52	-9.71	-0.43	3e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg27411982	chr8:10470053	RP1L1	-0.39	-6.93	-0.32	1.6e-11	Retinal vascular caliber;
LUAD	cis	rs9314323	0.767	rs1865305	chr8:26233325	G/A	cg13160058	chr8:26243215	BNIP3L	-0.47	-9.64	-0.42	5.02e-20	Red cell distribution width;
LUAD	trans	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg19862616	chr7:65841803	NCRNA00174	-1.06	-27.09	-0.8	1.96e-94	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs13315871	1.000	rs13078787	chr3:58430487	C/T	cg20936604	chr3:58311152	NA	-0.67	-7.07	-0.33	6.51e-12	Cholesterol, total;
LUAD	cis	rs68170813	0.559	rs10487271	chr7:106898458	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-10.64	-0.46	1.37e-23	Coronary artery disease;
LUAD	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg20891283	chr12:69753455	YEATS4	0.44	7.14	0.33	4.18e-12	Blood protein levels;
LUAD	cis	rs68170813	0.563	rs6979198	chr7:107197694	T/G	cg02696742	chr7:106810147	HBP1	-0.8	-10.41	-0.45	9.43e-23	Coronary artery disease;
LUAD	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg03209412	chr4:183728196	NA	0.79	10.98	0.47	7.28e-25	Pediatric autoimmune diseases;
LUAD	trans	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.03	-0.32	8.35e-12	Dental caries;
LUAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg23958373	chr8:599963	NA	-0.95	-10.34	-0.45	1.71e-22	IgG glycosylation;
LUAD	cis	rs1595825	0.732	rs77357334	chr2:198455607	G/A	cg00982548	chr2:198649783	BOLL	-0.52	-6.75	-0.31	5.04e-11	Ulcerative colitis;
LUAD	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.06e-19	Life satisfaction;
LUAD	cis	rs4523957	0.757	rs1002135	chr17:2097583	T/G	cg16513277	chr17:2031491	SMG6	-0.75	-14.15	-0.57	1.79e-37	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18876405	chr7:65276391	NA	-0.44	-6.91	-0.32	1.83e-11	Aortic root size;
LUAD	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg00684032	chr4:1343700	KIAA1530	0.42	6.95	0.32	1.42e-11	Obesity-related traits;
LUAD	cis	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg26587870	chr6:27730563	NA	-0.59	-6.51	-0.3	2.1e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9843304	0.585	rs9842139	chr3:149207517	T/C	cg08667024	chr3:149219783	TM4SF4	0.38	7.05	0.32	7.56e-12	Gallstone disease;
LUAD	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg13012494	chr21:47604986	C21orf56	0.46	7.58	0.35	2.26e-13	Testicular germ cell tumor;
LUAD	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg25985355	chr7:65971099	NA	0.53	6.57	0.3	1.49e-10	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9633740	1.000	rs1870138	chr10:82269611	A/G	cg01528321	chr10:82214614	TSPAN14	0.71	9.37	0.41	4.38e-19	Post bronchodilator FEV1;
LUAD	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg05082376	chr22:42548792	NA	0.45	7.86	0.36	3.18e-14	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg13385794	chr1:248469461	NA	0.26	7.12	0.33	4.76e-12	Common traits (Other);
LUAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.85	-0.32	2.68e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg07460842	chr6:66804631	NA	0.58	9.25	0.41	1.12e-18	Type 2 diabetes;
LUAD	cis	rs758324	0.947	rs10054618	chr5:131195002	C/T	cg25547332	chr5:131281432	NA	0.44	6.7	0.31	6.85e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg09085632	chr11:111637200	PPP2R1B	0.66	9.78	0.43	1.72e-20	Primary sclerosing cholangitis;
LUAD	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg13319975	chr6:146136371	FBXO30	-0.62	-10.65	-0.46	1.24e-23	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs8073060	0.660	rs58266733	chr17:34003812	A/T	cg19694781	chr19:47549865	TMEM160	-1.22	-19.55	-0.69	4.14e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-7.12	-0.33	4.8e-12	Triglycerides;
LUAD	cis	rs4660306	0.961	rs4660864	chr1:45966582	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.53	-8.29	-0.37	1.54e-15	Homocysteine levels;
LUAD	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg27284194	chr4:1044797	NA	0.58	9.54	0.42	1.16e-19	Recombination rate (males);
LUAD	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg15704280	chr7:45808275	SEPT13	-1.07	-25.01	-0.77	2.01e-85	Height;
LUAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.83	0.47	2.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2742234	0.541	rs10793426	chr10:43745280	G/A	cg15436174	chr10:43711423	RASGEF1A	0.52	8.62	0.39	1.33e-16	Hirschsprung disease;
LUAD	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg02018176	chr4:1364513	KIAA1530	0.36	6.37	0.3	5.04e-10	Obesity-related traits;
LUAD	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11644478	chr21:40555479	PSMG1	-0.58	-9.75	-0.43	2.08e-20	Cognitive function;
LUAD	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg06618935	chr21:46677482	NA	-0.46	-9.33	-0.41	5.87e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg08885076	chr2:99613938	TSGA10	0.38	6.8	0.31	3.68e-11	Chronic sinus infection;
LUAD	cis	rs3845702	1.000	rs3768837	chr2:180835792	T/A	cg01881094	chr2:180872142	CWC22	-0.59	-7.6	-0.35	1.97e-13	Schizophrenia;
LUAD	cis	rs7177699	0.557	rs72749206	chr15:79122948	G/A	cg15571903	chr15:79123663	NA	-0.37	-7.27	-0.33	1.8e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg02475777	chr4:1388615	CRIPAK	-0.52	-7.64	-0.35	1.51e-13	Obesity-related traits;
LUAD	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg10589385	chr1:150898437	SETDB1	0.41	7.66	0.35	1.24e-13	Melanoma;
LUAD	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg05342682	chr7:94953680	PON1	-0.53	-7.19	-0.33	2.94e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg14552801	chr7:65878734	NA	0.39	6.79	0.31	3.92e-11	Aortic root size;
LUAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg26354017	chr1:205819088	PM20D1	0.5	8.22	0.37	2.59e-15	Parkinson's disease;
LUAD	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg17264618	chr3:40429014	ENTPD3	-0.35	-7.42	-0.34	6.48e-13	Renal cell carcinoma;
LUAD	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg26898376	chr11:64110657	CCDC88B	0.36	6.46	0.3	2.93e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg26924012	chr15:45694286	SPATA5L1	1.02	18.92	0.68	2.86e-58	Homoarginine levels;
LUAD	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg12292205	chr6:26970375	C6orf41	0.45	7.75	0.35	6.92e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg26022315	chr17:47021804	SNF8	0.4	7.04	0.32	7.59e-12	Type 2 diabetes;
LUAD	cis	rs9811920	0.535	rs1610509	chr3:99474327	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.48	9.24	0.41	1.24e-18	Axial length;
LUAD	cis	rs7202877	0.572	rs4888371	chr16:75308781	G/A	cg03315344	chr16:75512273	CHST6	0.47	6.67	0.31	8.26e-11	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs7267979	1.000	rs6132835	chr20:25434667	A/G	cg08601574	chr20:25228251	PYGB	0.47	8.7	0.39	7.3e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg12908607	chr1:44402522	ARTN	-0.51	-9.79	-0.43	1.59e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6076065	0.775	rs761723	chr20:23330720	A/G	cg11657817	chr20:23433608	CST11	0.59	12.29	0.51	6.95e-30	Facial morphology (factor 15, philtrum width);
LUAD	trans	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg15704280	chr7:45808275	SEPT13	0.65	7.64	0.35	1.48e-13	Axial length;
LUAD	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg03433033	chr1:76189801	ACADM	-0.72	-10.86	-0.47	2.03e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs55665837	1.000	rs7945167	chr11:14451820	T/G	cg19336497	chr11:14380999	RRAS2	-0.5	-10.21	-0.44	5.12e-22	Vitamin D levels;
LUAD	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg24955955	chr5:415729	AHRR	0.69	8.0	0.36	1.21e-14	Fat distribution (HIV);
LUAD	trans	rs208520	1.000	rs208537	chr6:66963544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-13.49	-0.55	9.96e-35	Exhaled nitric oxide output;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg09200668	chr13:31773954	B3GALTL	-0.52	-6.58	-0.3	1.38e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7274811	0.652	rs291694	chr20:32000351	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.49	7.21	0.33	2.66e-12	Height;
LUAD	trans	rs994533	0.928	rs7594625	chr2:218293564	A/C	cg14576616	chr7:91763911	CYP51A1	0.42	6.6	0.31	1.27e-10	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01423368	chr11:76155379	C11orf30	-0.41	-6.57	-0.3	1.52e-10	Height;
LUAD	trans	rs75804782	0.630	rs57033609	chr2:239228512	C/T	cg01134436	chr17:81009848	B3GNTL1	0.7	6.35	0.3	5.71e-10	Morning vs. evening chronotype;Chronotype;
LUAD	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg05064044	chr6:292385	DUSP22	-0.56	-9.16	-0.41	2.28e-18	Menopause (age at onset);
LUAD	trans	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg26043149	chr18:55253948	FECH	0.5	8.3	0.37	1.4e-15	Bone mineral density;
LUAD	cis	rs6500395	0.962	rs1564980	chr16:48651377	A/T	cg04672837	chr16:48644449	N4BP1	0.38	6.59	0.31	1.32e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1784581	0.588	rs1784583	chr6:162410132	C/T	cg17173639	chr6:162384350	PARK2	-0.46	-8.27	-0.37	1.74e-15	Itch intensity from mosquito bite;
LUAD	cis	rs1997103	0.911	rs6945663	chr7:55407011	C/G	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6494488	0.500	rs72741344	chr15:64767531	C/T	cg08069370	chr15:64387884	SNX1	-0.75	-6.73	-0.31	5.58e-11	Coronary artery disease;
LUAD	cis	rs10465746	0.780	rs6703493	chr1:84435812	G/A	cg10977910	chr1:84465055	TTLL7	0.6	9.92	0.43	5.64e-21	Obesity-related traits;
LUAD	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg03474202	chr17:45855739	NA	-0.38	-9.06	-0.4	4.88e-18	IgG glycosylation;
LUAD	cis	rs7799006	0.929	rs6461233	chr7:2261468	G/A	cg08027265	chr7:2291960	NA	-0.56	-10.22	-0.45	4.61e-22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg14917512	chr19:3094685	GNA11	-0.56	-6.45	-0.3	3.13e-10	Diabetic kidney disease;
LUAD	cis	rs12681288	0.550	rs12675410	chr8:957845	T/C	cg04851639	chr8:1020857	NA	-0.34	-8.0	-0.36	1.23e-14	Schizophrenia;
LUAD	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	7.29	0.33	1.54e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg27170947	chr2:26402098	FAM59B	0.83	12.4	0.52	2.58e-30	Gut microbiome composition (summer);
LUAD	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.62	-0.35	1.67e-13	Lung cancer;
LUAD	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg27411982	chr8:10470053	RP1L1	-0.43	-7.66	-0.35	1.32e-13	Neuroticism;
LUAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg16606324	chr3:10149918	C3orf24	0.67	9.78	0.43	1.69e-20	Alzheimer's disease;
LUAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg00769240	chr8:12517080	NA	-0.39	-6.53	-0.3	1.87e-10	Blood pressure (smoking interaction);
LUAD	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg25482853	chr8:67687455	SGK3	-1.09	-16.86	-0.63	3.9e-49	Obesity-related traits;
LUAD	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg21709803	chr11:61594965	FADS2	-0.39	-7.04	-0.32	8.01e-12	Trans fatty acid levels;
LUAD	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg14092988	chr3:52407081	DNAH1	0.32	6.61	0.31	1.17e-10	Bipolar disorder;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03414631	chr1:26146153	FAM54B	-0.4	-6.54	-0.3	1.82e-10	Cancer;
LUAD	cis	rs807669	0.777	rs9605972	chr22:19253274	C/T	cg24911827	chr22:19170109	CLTCL1	0.33	7.3	0.33	1.48e-12	Metabolite levels;
LUAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg12379764	chr21:47803548	PCNT	-0.45	-7.41	-0.34	6.97e-13	Testicular germ cell tumor;
LUAD	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg06191203	chr2:152266755	RIF1	-0.59	-8.76	-0.39	4.66e-17	Lung cancer;
LUAD	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg08085267	chr17:45401833	C17orf57	-0.49	-8.06	-0.37	7.64e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg21918786	chr6:109611834	NA	-0.57	-10.66	-0.46	1.12e-23	Reticulocyte fraction of red cells;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg05052031	chr3:33138450	TMPPE;GLB1	0.4	7.11	0.33	5.02e-12	Optic cup area;
LUAD	cis	rs9902453	0.619	rs2244585	chr17:28072176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.36	-0.41	4.92e-19	Coffee consumption (cups per day);
LUAD	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg15900387	chr1:150738905	CTSS	-0.36	-6.5	-0.3	2.21e-10	Melanoma;
LUAD	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg21475434	chr5:93447410	FAM172A	0.75	8.4	0.38	6.97e-16	Diabetic retinopathy;
LUAD	cis	rs2996428	0.561	rs72640913	chr1:3747023	C/G	cg17443473	chr1:3703550	LRRC47	0.44	7.55	0.34	2.76e-13	Red cell distribution width;
LUAD	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	8.54	0.38	2.49e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs6740322	0.748	rs6544634	chr2:43471528	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.77	-11.63	-0.49	2.59e-27	Coronary artery disease;
LUAD	cis	rs12681288	0.782	rs2600500	chr8:1029031	G/C	cg15309053	chr8:964076	NA	0.4	8.38	0.38	7.99e-16	Schizophrenia;
LUAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg11062466	chr8:58055876	NA	0.45	6.45	0.3	3.04e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg18761221	chr20:60518478	NA	0.39	6.8	0.31	3.64e-11	Body mass index;
LUAD	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05901451	chr6:126070800	HEY2	-0.78	-14.08	-0.56	3.38e-37	Brugada syndrome;
LUAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.12	0.41	3.07e-18	Alzheimer's disease;
LUAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg08888203	chr3:10149979	C3orf24	0.72	12.89	0.53	2.61e-32	Alzheimer's disease;
LUAD	cis	rs7172809	0.573	rs28437977	chr15:77681453	C/T	cg11865553	chr15:77376250	NA	-0.39	-6.5	-0.3	2.24e-10	Glucose homeostasis traits;
LUAD	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg21427119	chr20:30132790	HM13	-0.49	-7.72	-0.35	8.73e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs7017914	0.934	rs13255152	chr8:71859619	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.31	-6.4	-0.3	4.02e-10	Bone mineral density;
LUAD	cis	rs9467160	0.765	rs793717	chr6:24444534	A/C	cg16211469	chr6:24423932	MRS2	-0.4	-6.44	-0.3	3.31e-10	Liver enzyme levels;
LUAD	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.66	10.59	0.46	2.14e-23	Height;
LUAD	trans	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg04775059	chr7:64541387	NA	0.51	6.92	0.32	1.68e-11	Aortic root size;
LUAD	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg23840854	chr1:161414152	NA	-0.87	-11.19	-0.48	1.24e-25	Rheumatoid arthritis;
LUAD	cis	rs13315871	1.000	rs13315871	chr3:58381287	G/A	cg12435725	chr3:58293450	RPP14	-0.67	-7.34	-0.34	1.12e-12	Cholesterol, total;
LUAD	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg18180107	chr4:99064573	C4orf37	0.42	6.76	0.31	4.64e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2281845	0.859	rs4915216	chr1:201077469	T/G	cg17810781	chr1:201082982	CACNA1S	0.37	6.63	0.31	1.01e-10	Permanent tooth development;
LUAD	trans	rs7395662	0.784	rs2170661	chr11:48378186	C/T	cg00717180	chr2:96193071	NA	-0.38	-7.02	-0.32	9.04e-12	HDL cholesterol;
LUAD	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	7.94	0.36	1.83e-14	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs55788414	0.725	rs13339033	chr16:81189034	G/A	cg06400318	chr16:81190750	PKD1L2	-0.79	-10.72	-0.46	7.13e-24	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg07741184	chr6:167504864	NA	0.4	9.19	0.41	1.73e-18	Crohn's disease;
LUAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg23283495	chr1:209979779	IRF6	-0.7	-11.38	-0.48	2.25e-26	Cleft lip with or without cleft palate;
LUAD	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg03733263	chr8:22462867	KIAA1967	0.75	13.08	0.54	4.75e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	trans	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg14917512	chr19:3094685	GNA11	0.56	6.69	0.31	7.21e-11	Diabetic kidney disease;
LUAD	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.58e-11	Depression;
LUAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg22907277	chr7:1156413	C7orf50	0.71	8.32	0.37	1.24e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg18446336	chr7:2847575	GNA12	-0.37	-6.99	-0.32	1.07e-11	Height;
LUAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg04025307	chr7:1156635	C7orf50	0.66	7.69	0.35	1.02e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	7.57	0.35	2.39e-13	Menopause (age at onset);
LUAD	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.42	-7.08	-0.33	6.05e-12	Hypertriglyceridemia;
LUAD	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg27129171	chr3:47204927	SETD2	0.46	7.48	0.34	4.26e-13	Colorectal cancer;
LUAD	trans	rs213599	0.576	rs9539886	chr13:31458636	A/G	cg19706446	chr10:3440313	NA	-0.35	-6.42	-0.3	3.69e-10	Cognitive function;
LUAD	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg06873352	chr17:61820015	STRADA	0.4	6.88	0.32	2.16e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	17.16	0.64	1.75e-50	Exhaled nitric oxide output;
LUAD	trans	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.78	0.46	4.04e-24	Mean corpuscular volume;
LUAD	trans	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.23	0.45	4.32e-22	Mean corpuscular volume;
LUAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03452623	chr4:187889614	NA	-0.81	-16.81	-0.63	6.37e-49	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-9.07	-0.4	4.47e-18	Bone mineral density;
LUAD	cis	rs11958404	0.860	rs7723564	chr5:157449396	C/T	cg05962755	chr5:157440814	NA	0.72	10.09	0.44	1.31e-21	IgG glycosylation;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03705947	chr1:68152081	GADD45A	-0.41	-6.7	-0.31	6.69e-11	Height;
LUAD	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.95	0.36	1.71e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg25237894	chr2:233734115	C2orf82	0.6	11.36	0.48	2.8e-26	Coronary artery disease;
LUAD	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg16205897	chr5:131564050	P4HA2	-0.32	-6.96	-0.32	1.27e-11	Blood metabolite levels;
LUAD	cis	rs7000551	0.715	rs2443502	chr8:22340499	G/A	cg12081754	chr8:22256438	SLC39A14	0.47	7.7	0.35	9.87e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.62	11.97	0.5	1.18e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg22117172	chr7:91764530	CYP51A1	0.34	7.66	0.35	1.24e-13	Breast cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09019002	chr7:102715232	ARMC10;FBXL13	-0.61	-7.43	-0.34	6.01e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg11814155	chr7:99998594	ZCWPW1	0.43	7.48	0.34	4.27e-13	Platelet count;
LUAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08280861	chr8:58055591	NA	-0.64	-8.4	-0.38	6.69e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg26408565	chr15:76604113	ETFA	-0.45	-7.22	-0.33	2.39e-12	Blood metabolite levels;
LUAD	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg14092988	chr3:52407081	DNAH1	0.44	8.87	0.4	2.04e-17	Bipolar disorder;
LUAD	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg23758822	chr17:41437982	NA	1.02	20.97	0.71	1.88e-67	Menopause (age at onset);
LUAD	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg01689657	chr7:91764605	CYP51A1	-0.29	-7.28	-0.33	1.62e-12	Breast cancer;
LUAD	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.26	-0.45	3.42e-22	Total body bone mineral density;
LUAD	cis	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg00071950	chr4:10020882	SLC2A9	0.51	7.38	0.34	8.32e-13	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.63	0.52	2.94e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18876405	chr7:65276391	NA	-0.63	-10.91	-0.47	1.33e-24	Aortic root size;
LUAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg04025307	chr7:1156635	C7orf50	0.6	6.78	0.31	4.07e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs11671005	0.610	rs4756	chr19:59074653	T/C	cg22037779	chr5:139682734	PFDN1	-0.66	-10.48	-0.45	5.39e-23	Mean platelet volume;
LUAD	cis	rs9314323	0.557	rs3779916	chr8:26250906	C/A	cg13160058	chr8:26243215	BNIP3L	-0.35	-7.66	-0.35	1.29e-13	Red cell distribution width;
LUAD	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg03929089	chr4:120376271	NA	-0.91	-17.19	-0.64	1.35e-50	Coronary artery disease;
LUAD	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg06453172	chr10:134556979	INPP5A	0.42	6.95	0.32	1.35e-11	Migraine;
LUAD	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg17971929	chr21:40555470	PSMG1	0.53	8.19	0.37	3.22e-15	Cognitive function;
LUAD	cis	rs11696845	0.787	rs6017408	chr20:43363529	A/G	cg25301532	chr20:43378953	KCNK15	0.37	6.61	0.31	1.17e-10	Obesity-related traits;
LUAD	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg05234568	chr11:5960015	NA	0.51	8.93	0.4	1.27e-17	DNA methylation (variation);
LUAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg24846343	chr22:24311635	DDTL	0.58	11.45	0.49	1.23e-26	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg04546413	chr19:29218101	NA	0.68	9.67	0.43	4.15e-20	Methadone dose in opioid dependence;
LUAD	cis	rs8067545	0.750	rs34290687	chr17:19991211	G/A	cg04132472	chr17:19861366	AKAP10	0.3	7.18	0.33	3.2e-12	Schizophrenia;
LUAD	cis	rs6430585	0.527	rs59413285	chr2:136444185	G/T	cg07169764	chr2:136633963	MCM6	0.59	6.92	0.32	1.66e-11	Corneal structure;
LUAD	cis	rs2795502	0.564	rs72777187	chr10:43432224	C/T	cg08461752	chr10:43522343	NA	-0.76	-8.42	-0.38	5.83e-16	Blood protein levels;
LUAD	cis	rs7617773	0.817	rs11928691	chr3:48286765	C/T	cg11946769	chr3:48343235	NME6	0.42	6.8	0.31	3.63e-11	Coronary artery disease;
LUAD	cis	rs2762353	0.574	rs4409177	chr6:25694491	T/G	cg12310025	chr6:25882481	NA	0.83	13.71	0.55	1.19e-35	Blood metabolite levels;
LUAD	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg24829409	chr8:58192753	C8orf71	-0.54	-8.28	-0.37	1.69e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg18436788	chr1:3704244	LRRC47	0.31	6.38	0.3	4.7e-10	Red cell distribution width;
LUAD	trans	rs629535	0.911	rs688612	chr8:70011887	C/T	cg21567404	chr3:27674614	NA	-1.0	-18.7	-0.67	2.49e-57	Dupuytren's disease;
LUAD	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg02734326	chr4:10020555	SLC2A9	0.6	10.32	0.45	2.09e-22	Bone mineral density;
LUAD	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg04414720	chr1:150670196	GOLPH3L	0.72	13.35	0.54	3.72e-34	Melanoma;
LUAD	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2637266	0.935	rs2252661	chr10:78404793	A/G	cg18941641	chr10:78392320	NA	0.34	7.04	0.32	7.75e-12	Pulmonary function;
LUAD	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg18138036	chr10:133769891	PPP2R2D	0.41	6.65	0.31	8.98e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs2688608	0.592	rs7080579	chr10:75504029	T/A	cg23231163	chr10:75533350	FUT11	-0.52	-9.48	-0.42	1.85e-19	Inflammatory bowel disease;
LUAD	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg25036284	chr2:26402008	FAM59B	0.59	8.18	0.37	3.36e-15	Gut microbiome composition (summer);
LUAD	cis	rs6782228	0.606	rs2811500	chr3:128366256	C/T	cg16766828	chr3:128327626	NA	-0.38	-7.19	-0.33	2.9e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg26597838	chr10:835615	NA	1.29	20.18	0.7	6.04e-64	Eosinophil percentage of granulocytes;
LUAD	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg26818010	chr10:134567672	INPP5A	-0.84	-14.61	-0.58	2e-39	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg21399703	chr1:247681439	NA	0.43	7.82	0.36	4.36e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs10504073	0.605	rs62507176	chr8:49930321	G/A	cg00325661	chr8:49890786	NA	0.48	10.54	0.46	3.16e-23	Blood metabolite ratios;
LUAD	cis	rs6920965	0.507	rs4285341	chr6:126205589	T/G	cg05901451	chr6:126070800	HEY2	-0.5	-7.57	-0.35	2.37e-13	High light scatter reticulocyte count;
LUAD	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg05043794	chr9:111880884	C9orf5	-0.38	-6.42	-0.3	3.69e-10	Menarche (age at onset);
LUAD	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg20891558	chr2:74357851	NA	0.97	15.72	0.61	3.47e-44	Gestational age at birth (maternal effect);
LUAD	cis	rs1003719	0.591	rs1053966	chr21:38568009	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.42	-6.88	-0.32	2.18e-11	Eye color traits;
LUAD	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg00383909	chr3:49044727	WDR6	0.44	6.58	0.3	1.36e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-9.97	-0.44	3.62e-21	Platelet distribution width;
LUAD	cis	rs11741688	0.557	rs10043579	chr5:178330174	C/T	cg09339527	chr5:178322752	ZFP2	-0.35	-7.37	-0.34	8.84e-13	Sleep duration;
LUAD	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg26022315	chr17:47021804	SNF8	0.4	7.29	0.33	1.54e-12	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg18944383	chr4:111397179	ENPEP	0.38	7.74	0.35	7.27e-14	Height;
LUAD	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg18252515	chr7:66147081	NA	-0.61	-6.74	-0.31	5.28e-11	Gout;
LUAD	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg14668632	chr7:2872130	GNA12	-0.73	-13.31	-0.54	5.39e-34	Height;
LUAD	cis	rs240764	0.853	rs10457808	chr6:100979506	A/T	cg09795085	chr6:101329169	ASCC3	-0.42	-7.32	-0.34	1.3e-12	Neuroticism;
LUAD	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg23262073	chr20:60523788	NA	-0.44	-7.61	-0.35	1.78e-13	Body mass index;
LUAD	cis	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.23	-0.33	2.24e-12	Resting heart rate;
LUAD	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg09650180	chr20:62225654	GMEB2	-0.46	-6.69	-0.31	7.03e-11	Glioblastoma;
LUAD	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg10518543	chr12:38710700	ALG10B	0.41	6.37	0.3	4.9e-10	Bladder cancer;
LUAD	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.46	0.38	4.26e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62229266	0.652	rs7280551	chr21:37409609	T/A	cg12218747	chr21:37451666	NA	-0.43	-7.53	-0.34	3.16e-13	Mitral valve prolapse;
LUAD	cis	rs9394841	0.667	rs10807268	chr6:41777591	A/T	cg17623882	chr6:41773611	USP49	-0.51	-7.23	-0.33	2.35e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg20701182	chr2:24300061	SF3B14	-0.94	-13.87	-0.56	2.44e-36	Lymphocyte counts;
LUAD	cis	rs6665290	0.669	rs3768421	chr1:227177193	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.11	-28.8	-0.81	9.18e-102	Myeloid white cell count;
LUAD	cis	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.14	-0.37	4.43e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg12935359	chr14:103987150	CKB	-0.46	-7.4	-0.34	7.19e-13	Body mass index;
LUAD	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg16486109	chr11:613632	IRF7	0.49	8.12	0.37	5.2e-15	Systemic lupus erythematosus;
LUAD	cis	rs8017423	0.647	rs12895269	chr14:90822430	T/C	cg14092571	chr14:90743983	NA	0.39	6.54	0.3	1.81e-10	Mortality in heart failure;
LUAD	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03264133	chr6:25882463	NA	0.55	8.84	0.39	2.59e-17	Blood metabolite levels;
LUAD	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg20291162	chr17:40259547	DHX58	-0.68	-10.5	-0.45	4.51e-23	Fibrinogen levels;
LUAD	trans	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg26043149	chr18:55253948	FECH	-0.44	-7.12	-0.33	4.7e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6460942	1.000	rs6948314	chr7:12418363	T/A	cg20607287	chr7:12443886	VWDE	-0.5	-6.44	-0.3	3.26e-10	Coronary artery disease;
LUAD	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27297192	chr10:134578999	INPP5A	0.38	6.72	0.31	5.97e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg25324976	chr17:61989376	CSHL1	0.38	7.39	0.34	7.68e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2455601	0.744	rs2163626	chr11:8983547	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.49	-8.38	-0.38	7.68e-16	Schizophrenia;
LUAD	cis	rs12900413	0.603	rs12911871	chr15:90301429	T/C	cg24249390	chr15:90295951	MESP1	-0.35	-6.97	-0.32	1.23e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg15790184	chr11:494944	RNH1	0.56	6.73	0.31	5.39e-11	Body mass index;
LUAD	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg18827107	chr12:86230957	RASSF9	-0.53	-9.33	-0.41	5.79e-19	Major depressive disorder;
LUAD	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg21862992	chr11:68658383	NA	0.52	9.7	0.43	3.22e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.77	0.31	4.44e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7301016	0.846	rs73124315	chr12:62970437	C/T	cg11441379	chr12:63026424	NA	0.61	7.8	0.35	4.99e-14	IgG glycosylation;
LUAD	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg02931644	chr1:25747376	RHCE	0.43	8.85	0.4	2.5e-17	Erythrocyte sedimentation rate;
LUAD	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg02221422	chr11:68192511	LRP5	-0.4	-6.51	-0.3	2.11e-10	Total body bone mineral density;
LUAD	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg25828334	chr19:18545568	ISYNA1	-0.36	-7.18	-0.33	3.13e-12	Breast cancer;
LUAD	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.7	-11.86	-0.5	3.16e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg05082376	chr22:42548792	NA	0.45	7.86	0.36	3.2e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6842047	0.520	rs4253425	chr4:187205929	T/C	cg09526685	chr4:187126073	CYP4V2	0.68	6.96	0.32	1.34e-11	Blood protein levels;
LUAD	cis	rs6714710	0.603	rs78006955	chr2:98455510	G/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.19	0.37	3.17e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	trans	rs10838798	0.563	rs4752902	chr11:48148779	G/A	cg00717180	chr2:96193071	NA	-0.37	-6.94	-0.32	1.44e-11	Height;
LUAD	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.27	-0.33	1.81e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg25344623	chr2:136566232	LCT	0.34	6.67	0.31	7.91e-11	Mosquito bite size;
LUAD	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18404041	chr3:52824283	ITIH1	-0.6	-11.87	-0.5	3e-28	Bipolar disorder;
LUAD	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg09365446	chr1:150670422	GOLPH3L	-0.49	-8.5	-0.38	3.31e-16	Tonsillectomy;
LUAD	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg03563238	chr19:33554763	RHPN2	-0.34	-8.26	-0.37	1.84e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg25753631	chr6:25732923	NA	-0.45	-7.92	-0.36	2.06e-14	Iron status biomarkers;
LUAD	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.39	0.34	7.87e-13	Hypertriglyceridemia;
LUAD	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg10518543	chr12:38710700	ALG10B	0.41	6.38	0.3	4.74e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.54	0.3	1.74e-10	Cardiac Troponin-T levels;
LUAD	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg10356904	chr22:49881777	NA	-0.4	-7.48	-0.34	4.39e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg27494647	chr7:150038898	RARRES2	0.5	8.6	0.39	1.59e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg00431813	chr7:1051703	C7orf50	-0.45	-8.65	-0.39	1.08e-16	Longevity;Endometriosis;
LUAD	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg19318889	chr4:1322082	MAEA	0.58	9.91	0.43	5.83e-21	Longevity;
LUAD	cis	rs11229555	0.645	rs6591475	chr11:58193551	G/T	cg15696309	chr11:58395628	NA	0.7	9.97	0.44	3.61e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	12.26	0.51	9.16e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg26384229	chr12:38710491	ALG10B	0.41	7.1	0.33	5.38e-12	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14159672	chr1:205819179	PM20D1	0.79	16.01	0.61	1.87e-45	Menarche (age at onset);
LUAD	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg22823121	chr1:150693482	HORMAD1	0.4	8.11	0.37	5.49e-15	Melanoma;
LUAD	cis	rs12612619	0.732	rs7560595	chr2:27229372	C/G	cg00617064	chr2:27272375	NA	-0.39	-7.65	-0.35	1.39e-13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs62229266	0.659	rs2835245	chr21:37416708	C/T	cg12218747	chr21:37451666	NA	-0.43	-7.37	-0.34	9.21e-13	Mitral valve prolapse;
LUAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.86	-0.4	2.31e-17	Lymphocyte counts;
LUAD	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg03433033	chr1:76189801	ACADM	0.86	15.72	0.61	3.62e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7180079	1.000	rs8037297	chr15:64560833	C/T	cg08069370	chr15:64387884	SNX1	-0.51	-6.56	-0.3	1.6e-10	Monocyte count;
LUAD	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg04369109	chr6:150039330	LATS1	0.47	7.83	0.36	4.01e-14	Lung cancer;
LUAD	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg15448220	chr1:150897856	SETDB1	0.57	9.88	0.43	7.45e-21	Melanoma;
LUAD	cis	rs2629540	0.889	rs10901808	chr10:126399159	A/C	cg08799069	chr10:126477246	METTL10	0.46	6.86	0.32	2.39e-11	Cocaine dependence;
LUAD	cis	rs9469913	0.740	rs2814943	chr6:34552736	C/T	cg14254433	chr6:34482411	PACSIN1	-0.41	-6.49	-0.3	2.46e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22584172	chr6:56954677	ZNF451	-0.43	-7.23	-0.33	2.22e-12	Cancer;
LUAD	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg13870426	chr17:30244630	NA	-0.55	-6.49	-0.3	2.41e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs3750965	0.806	rs7107680	chr11:68859894	C/T	cg06818126	chr11:68850279	TPCN2	-0.48	-7.08	-0.33	6.14e-12	Hair color;
LUAD	cis	rs6688613	1.000	rs7554962	chr1:166956297	C/T	cg07049167	chr1:166818506	POGK	0.41	6.9	0.32	1.92e-11	Refractive astigmatism;
LUAD	trans	rs6921919	1.000	rs6921919	chr6:28325201	C/G	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.63	-0.31	1.06e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	7.38	0.34	8.71e-13	Alzheimer's disease;
LUAD	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg22823121	chr1:150693482	HORMAD1	-0.38	-7.34	-0.34	1.12e-12	Melanoma;
LUAD	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg11247378	chr22:39784982	NA	-0.67	-10.91	-0.47	1.4e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg02569458	chr12:86230093	RASSF9	0.42	7.99	0.36	1.29e-14	Major depressive disorder;
LUAD	cis	rs2281845	1.000	rs2281845	chr1:201081943	C/T	cg22815214	chr1:201083145	CACNA1S	0.57	9.65	0.42	4.64e-20	Permanent tooth development;
LUAD	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg26373071	chr5:1325741	CLPTM1L	0.33	6.84	0.32	2.77e-11	Lung cancer;
LUAD	trans	rs7200543	1.000	rs1135999	chr16:15131962	A/G	cg24683922	chr1:11983373	KIAA2013	-0.48	-8.09	-0.37	6.22e-15	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg04365224	chr3:72788183	NA	-0.44	-6.56	-0.3	1.55e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg01620082	chr3:125678407	NA	-0.83	-9.42	-0.42	3.02e-19	Depression;
LUAD	cis	rs8177876	0.749	rs10459872	chr16:81094951	C/T	cg08591886	chr16:81111003	C16orf46	0.67	6.59	0.31	1.28e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7945705	0.846	rs4929911	chr11:8816495	T/C	cg12365402	chr11:9010492	NRIP3	0.37	6.46	0.3	2.85e-10	Hemoglobin concentration;
LUAD	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg07936489	chr17:37558343	FBXL20	0.51	6.98	0.32	1.14e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg21385522	chr1:16154831	NA	0.47	7.17	0.33	3.44e-12	Dilated cardiomyopathy;
LUAD	trans	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.73	11.87	0.5	3.02e-28	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs17401966	0.838	rs12737239	chr1:10323973	C/G	cg19773385	chr1:10388646	KIF1B	-0.39	-6.46	-0.3	2.89e-10	Hepatocellular carcinoma;
LUAD	cis	rs4372836	0.504	rs13011935	chr2:29014746	C/T	cg09522027	chr2:28974177	PPP1CB	-0.61	-10.9	-0.47	1.49e-24	Body mass index;
LUAD	cis	rs4268898	1.000	rs6746005	chr2:24434345	G/A	cg06627628	chr2:24431161	ITSN2	0.45	7.84	0.36	3.82e-14	Asthma;
LUAD	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg04000281	chr11:63949212	NA	-0.28	-6.57	-0.3	1.48e-10	Platelet count;
LUAD	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg22117172	chr7:91764530	CYP51A1	0.35	7.8	0.35	4.93e-14	Breast cancer;
LUAD	cis	rs3789045	0.779	rs12043569	chr1:204560004	C/G	cg17419461	chr1:204415978	PIK3C2B	-0.37	-6.45	-0.3	3.06e-10	Educational attainment (college completion);
LUAD	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg13319975	chr6:146136371	FBXO30	-0.57	-9.75	-0.43	2.14e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3540	0.960	rs10083661	chr15:91022339	G/A	cg10434728	chr15:90938212	IQGAP1	0.37	6.76	0.31	4.55e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg07917127	chr4:99064746	C4orf37	0.5	8.14	0.37	4.54e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836633	0.895	rs2212606	chr21:40044940	A/C	cg12884169	chr21:40033163	ERG	0.39	8.17	0.37	3.48e-15	Coronary artery disease;
LUAD	cis	rs6854137	0.758	rs7349731	chr4:169739407	A/C	cg20607169	chr4:169750834	PALLD	0.41	7.14	0.33	4.04e-12	Vein graft stenosis in coronary artery bypass grafting;
LUAD	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg16049864	chr8:95962084	TP53INP1	-0.48	-8.56	-0.38	2.14e-16	Type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.21	0.37	2.75e-15	Breast cancer;
LUAD	cis	rs4523957	0.651	rs4790316	chr17:2074977	T/C	cg16513277	chr17:2031491	SMG6	-0.97	-19.27	-0.68	7.79e-60	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg04731861	chr2:219085781	ARPC2	0.23	7.16	0.33	3.68e-12	Colorectal cancer;
LUAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg22105103	chr4:187893119	NA	0.57	12.43	0.52	1.82e-30	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1865721	0.917	rs62089506	chr18:73178913	A/G	cg26385618	chr18:73139727	C18orf62	-0.43	-7.87	-0.36	3.07e-14	Intelligence;
LUAD	cis	rs2455601	0.744	rs11042133	chr11:8966511	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-7.76	-0.35	6.65e-14	Schizophrenia;
LUAD	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg06064525	chr11:970664	AP2A2	-0.53	-10.86	-0.47	2.05e-24	Alzheimer's disease (late onset);
LUAD	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg15704280	chr7:45808275	SEPT13	0.65	8.24	0.37	2.24e-15	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs1973993	0.691	rs553785	chr1:96895325	G/A	cg10631902	chr5:14652156	NA	0.73	15.36	0.6	1.3e-42	Weight;
LUAD	cis	rs11771526	0.551	rs6462344	chr7:32254889	T/C	cg13207630	chr7:32358064	NA	-0.51	-7.19	-0.33	2.98e-12	Body mass index;
LUAD	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg03676636	chr4:99064102	C4orf37	0.32	8.35	0.38	1e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg11941060	chr3:133502564	NA	-0.65	-11.7	-0.49	1.35e-27	Iron status biomarkers;
LUAD	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg26769984	chr7:1090371	C7orf50	0.7	11.31	0.48	4.26e-26	Bronchopulmonary dysplasia;
LUAD	cis	rs7903847	0.642	rs1048442	chr10:99160152	A/G	cg20016023	chr10:99160130	RRP12	-0.31	-7.41	-0.34	6.72e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg23649088	chr2:200775458	C2orf69	0.57	10.14	0.44	8.95e-22	Systolic blood pressure;
LUAD	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18404041	chr3:52824283	ITIH1	-0.61	-12.3	-0.51	6.09e-30	Bipolar disorder;
LUAD	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg14847009	chr1:175162515	KIAA0040	0.3	7.65	0.35	1.42e-13	Alcohol dependence;
LUAD	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	trans	rs1997103	1.000	rs1997103	chr7:55395390	C/G	cg20935933	chr6:143382018	AIG1	0.53	7.35	0.34	1.05e-12	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg18252515	chr7:66147081	NA	0.62	6.75	0.31	4.94e-11	Diabetic kidney disease;
LUAD	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.08	-22.94	-0.74	2.85e-76	Ulcerative colitis;
LUAD	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg17724175	chr1:150552817	MCL1	0.34	7.87	0.36	3.01e-14	Melanoma;
LUAD	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg21782813	chr7:2030301	MAD1L1	0.44	7.45	0.34	5.21e-13	Schizophrenia;
LUAD	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg08859206	chr1:53392774	SCP2	0.6	11.04	0.47	4.63e-25	Monocyte count;
LUAD	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg18306943	chr3:40428807	ENTPD3	0.4	6.99	0.32	1.05e-11	Renal cell carcinoma;
LUAD	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg05182265	chr7:156933206	UBE3C	-0.8	-17.36	-0.64	2.36e-51	Body mass index;
LUAD	trans	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg26043149	chr18:55253948	FECH	0.5	8.3	0.37	1.4e-15	Bone mineral density;
LUAD	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg05425664	chr17:57184151	TRIM37	-0.43	-7.61	-0.35	1.84e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1395	0.677	rs113353646	chr2:27492674	C/T	cg23587288	chr2:27483067	SLC30A3	-0.41	-7.74	-0.35	7.64e-14	Blood metabolite levels;
LUAD	trans	rs2797160	0.935	rs60515555	chr6:126000638	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.79	-0.39	3.9e-17	Endometrial cancer;
LUAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg07217954	chr7:1067459	C7orf50	0.43	6.63	0.31	1.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6484504	0.817	rs67707190	chr11:31210500	A/G	cg26647111	chr11:31128758	NA	-0.42	-6.5	-0.3	2.29e-10	Red blood cell count;
LUAD	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg17971929	chr21:40555470	PSMG1	0.53	8.57	0.38	1.93e-16	Cognitive function;
LUAD	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg19318889	chr4:1322082	MAEA	0.52	8.57	0.38	2.01e-16	Longevity;
LUAD	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	trans	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg25894440	chr7:65020034	NA	-0.63	-6.73	-0.31	5.63e-11	Gout;
LUAD	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.62	0.35	1.7e-13	Platelet count;
LUAD	cis	rs12612619	0.761	rs7606840	chr2:27243364	A/G	cg00617064	chr2:27272375	NA	-0.38	-7.25	-0.33	1.96e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs9467160	1.000	rs9467161	chr6:24441963	C/T	cg16211469	chr6:24423932	MRS2	0.44	7.06	0.32	6.93e-12	Liver enzyme levels;
LUAD	cis	rs12545109	0.842	rs10958482	chr8:57389331	G/T	cg17761419	chr8:57350749	NA	-0.56	-8.21	-0.37	2.69e-15	Obesity-related traits;
LUAD	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg06191203	chr2:152266755	RIF1	-0.57	-8.35	-0.38	1.01e-15	Lung cancer;
LUAD	cis	rs6484504	0.600	rs2761593	chr11:31326752	G/T	cg26647111	chr11:31128758	NA	0.43	7.55	0.34	2.63e-13	Red blood cell count;
LUAD	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg04414720	chr1:150670196	GOLPH3L	0.59	10.08	0.44	1.42e-21	Melanoma;
LUAD	trans	rs10411161	0.810	rs77458785	chr19:52384295	T/G	cg22319618	chr22:45562946	NUP50	-0.65	-7.51	-0.34	3.55e-13	Breast cancer;
LUAD	cis	rs2485376	1.000	rs4244350	chr10:104008751	C/T	cg20641465	chr10:103991465	PITX3	0.56	10.09	0.44	1.37e-21	QT interval;
LUAD	cis	rs4880487	1.000	rs4880487	chr10:1246883	C/T	cg03183215	chr10:1252341	ADARB2	-0.29	-6.41	-0.3	3.89e-10	Migraine;
LUAD	trans	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg03929089	chr4:120376271	NA	0.57	6.45	0.3	3.15e-10	Intraocular pressure;
LUAD	cis	rs1232027	0.632	rs1677701	chr5:79931332	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs524023	1.000	rs524023	chr11:64358265	C/T	cg19131476	chr11:64387923	NRXN2	0.36	6.77	0.31	4.42e-11	Urate levels in obese individuals;
LUAD	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg09835421	chr16:68378352	PRMT7	-1.08	-12.61	-0.52	3.43e-31	Magnesium levels;
LUAD	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg01802117	chr1:53393560	SCP2	-0.35	-7.0	-0.32	1.01e-11	Monocyte count;
LUAD	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg07617317	chr6:118971624	C6orf204	0.55	8.56	0.38	2.11e-16	Diastolic blood pressure;
LUAD	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg26597838	chr10:835615	NA	0.76	10.15	0.44	8.1e-22	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	7.99	0.36	1.33e-14	Rheumatoid arthritis;
LUAD	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg11502198	chr6:26597334	ABT1	0.55	9.09	0.4	3.73e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs76419734	0.558	rs11730080	chr4:106521859	C/G	cg05309399	chr4:106552544	FLJ20184	-0.56	-6.9	-0.32	1.88e-11	Post bronchodilator FEV1;
LUAD	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03264133	chr6:25882463	NA	-0.53	-8.78	-0.39	4.08e-17	Blood metabolite levels;
LUAD	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg18252515	chr7:66147081	NA	-0.61	-6.78	-0.31	4.07e-11	Diabetic kidney disease;
LUAD	cis	rs4700695	0.614	rs446618	chr5:65210062	G/A	cg21114390	chr5:65439923	SFRS12	0.64	7.98	0.36	1.4e-14	Facial morphology (factor 19);
LUAD	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg20135002	chr11:47629003	NA	0.4	7.04	0.32	7.73e-12	Subjective well-being;
LUAD	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg06558623	chr16:89946397	TCF25	-0.65	-7.64	-0.35	1.48e-13	Skin colour saturation;
LUAD	cis	rs7779181	0.951	rs6952609	chr7:32343335	A/G	cg13207630	chr7:32358064	NA	0.45	6.97	0.32	1.21e-11	Body mass index;
LUAD	cis	rs1232027	0.700	rs1382539	chr5:79952154	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.9	-0.36	2.36e-14	Huntington's disease progression;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg20703752	chr17:42977117	CCDC103;EFTUD2	-0.4	-6.88	-0.32	2.14e-11	Cancer;
LUAD	cis	rs9837602	0.938	rs17393059	chr3:99761908	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-7.68	-0.35	1.13e-13	Breast cancer;
LUAD	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	8.96e-15	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs208520	0.690	rs851459	chr6:66813989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-17.88	-0.66	1.17e-53	Exhaled nitric oxide output;
LUAD	trans	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg13565492	chr6:43139072	SRF	-0.6	-6.42	-0.3	3.67e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7582720	0.945	rs114604411	chr2:203811912	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00149659	chr3:10157352	C3orf10	0.61	8.68	0.39	8.54e-17	Alzheimer's disease;
LUAD	cis	rs9487051	0.698	rs59502176	chr6:109644719	T/C	cg21918786	chr6:109611834	NA	-0.46	-7.39	-0.34	7.76e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.82	0.5	4.58e-28	Colorectal cancer;
LUAD	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg10556349	chr10:835070	NA	-0.45	-6.85	-0.32	2.7e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.57	-10.91	-0.47	1.43e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.47e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg11645453	chr3:52864694	ITIH4	0.37	7.04	0.32	7.67e-12	Bipolar disorder;
LUAD	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-8.5	-0.38	3.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg08029281	chr1:67600428	NA	0.36	6.96	0.32	1.31e-11	Psoriasis;
LUAD	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23248424	chr5:179741104	GFPT2	-0.66	-10.68	-0.46	9.52e-24	Height;
LUAD	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	6.72	0.31	5.83e-11	Bipolar disorder;
LUAD	cis	rs7095607	0.813	rs10823143	chr10:69924903	T/A	cg18986048	chr10:69913749	MYPN	0.38	6.52	0.3	2.04e-10	Lung function (FVC);
LUAD	cis	rs9902453	0.834	rs9901694	chr17:28271645	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	10.17	0.44	7.01e-22	Coffee consumption (cups per day);
LUAD	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg26168224	chr5:2018326	NA	0.54	9.62	0.42	6.01e-20	Gut microbiome composition (winter);
LUAD	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg23602478	chr1:26503979	CNKSR1	0.27	6.42	0.3	3.64e-10	Height;
LUAD	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg03877420	chr5:1004367	NA	0.35	7.13	0.33	4.24e-12	QT interval;
LUAD	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg15900387	chr1:150738905	CTSS	-0.36	-6.53	-0.3	1.9e-10	Melanoma;
LUAD	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg00802000	chr16:706648	WDR90	-0.37	-6.94	-0.32	1.45e-11	Height;
LUAD	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg01448562	chr3:133502909	NA	-0.48	-8.47	-0.38	4e-16	Iron status biomarkers;
LUAD	trans	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg26043149	chr18:55253948	FECH	-0.51	-8.19	-0.37	3.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs55823223	0.618	rs72860390	chr17:73869914	A/G	cg04225089	chr17:73874465	TRIM47	-0.47	-8.1	-0.37	5.97e-15	Psoriasis;
LUAD	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg26384229	chr12:38710491	ALG10B	0.47	7.66	0.35	1.25e-13	Morning vs. evening chronotype;
LUAD	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.65	9.01	0.4	7.11e-18	Gut microbiome composition (summer);
LUAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13126279	chr21:47581558	C21orf56	-0.61	-11.21	-0.48	1.04e-25	Testicular germ cell tumor;
LUAD	trans	rs75804782	0.572	rs56400267	chr2:239247213	G/A	cg01134436	chr17:81009848	B3GNTL1	0.77	6.89	0.32	1.97e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs870825	0.860	rs72703518	chr4:185602109	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	11.22	0.48	9.12e-26	Blood protein levels;
LUAD	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg20933634	chr6:27740509	NA	0.53	7.86	0.36	3.28e-14	Parkinson's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02923393	chr16:1543003	TELO2	-0.43	-6.94	-0.32	1.53e-11	Height;
LUAD	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.66	8.59	0.39	1.67e-16	Gut microbiome composition (summer);
LUAD	cis	rs899997	0.773	rs7178423	chr15:78964961	T/G	cg04896959	chr15:78267971	NA	0.58	8.99	0.4	8.33e-18	Coronary artery disease or large artery stroke;
LUAD	cis	rs10821973	0.527	rs4147233	chr10:63982668	A/G	cg09941381	chr10:64027924	RTKN2	-0.34	-6.77	-0.31	4.23e-11	Hypothyroidism;
LUAD	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg11494091	chr17:61959527	GH2	0.38	6.75	0.31	4.88e-11	Height;
LUAD	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg08885076	chr2:99613938	TSGA10	0.36	6.53	0.3	1.86e-10	Chronic sinus infection;
LUAD	cis	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg08601574	chr20:25228251	PYGB	0.47	8.56	0.38	2.17e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg16479474	chr6:28041457	NA	0.48	8.18	0.37	3.31e-15	Depression;
LUAD	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg06637938	chr14:75390232	RPS6KL1	0.48	8.29	0.37	1.56e-15	Caffeine consumption;
LUAD	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.32	-0.37	1.26e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.29	-0.33	1.52e-12	Resting heart rate;
LUAD	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg00677455	chr12:58241039	CTDSP2	0.43	7.21	0.33	2.66e-12	Multiple sclerosis;
LUAD	cis	rs597539	0.690	rs7104351	chr11:68617886	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	12.76	0.53	8.75e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.77	-0.35	6.02e-14	Monocyte count;
LUAD	cis	rs16854884	0.586	rs7642551	chr3:143732167	C/T	cg01302019	chr3:143689584	C3orf58	-0.36	-6.5	-0.3	2.32e-10	Economic and political preferences (feminism/equality);
LUAD	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg17971929	chr21:40555470	PSMG1	0.56	8.89	0.4	1.84e-17	Cognitive function;
LUAD	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg09455208	chr3:40491958	NA	0.63	13.73	0.56	1.02e-35	Renal cell carcinoma;
LUAD	cis	rs68170813	0.641	rs4730228	chr7:106904077	T/C	cg23024343	chr7:107201750	COG5	0.48	6.99	0.32	1.11e-11	Coronary artery disease;
LUAD	trans	rs78049276	0.736	rs6841581	chr4:148401190	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.55	-6.56	-0.3	1.55e-10	Pulse pressure;
LUAD	cis	rs727505	1.000	rs10281582	chr7:124423688	A/G	cg23710748	chr7:124431027	NA	-0.44	-9.41	-0.42	3.09e-19	Lewy body disease;
LUAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	6.53	0.3	1.93e-10	Electroencephalogram traits;
LUAD	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg00129232	chr17:37814104	STARD3	-0.49	-8.82	-0.39	3.03e-17	Asthma;
LUAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg02869364	chr7:1081709	C7orf50	-0.5	-6.42	-0.3	3.62e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg00631329	chr6:26305371	NA	-0.5	-9.39	-0.42	3.64e-19	Educational attainment;
LUAD	cis	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg21775007	chr8:11205619	TDH	0.52	9.46	0.42	2.18e-19	Retinal vascular caliber;
LUAD	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19346786	chr7:2764209	NA	-0.54	-11.61	-0.49	3.17e-27	Height;
LUAD	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg09904177	chr6:26538194	HMGN4	0.44	7.4	0.34	7.22e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-11.23	-0.48	8.7e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg18621852	chr3:10150065	C3orf24	0.48	8.33	0.38	1.1e-15	Alzheimer's disease;
LUAD	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg05425664	chr17:57184151	TRIM37	-0.45	-7.96	-0.36	1.58e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs62400317	0.859	rs12205523	chr6:45296618	T/C	cg20913747	chr6:44695427	NA	-0.41	-6.66	-0.31	8.48e-11	Total body bone mineral density;
LUAD	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg17845761	chr1:175162550	KIAA0040	-0.34	-8.96	-0.4	1.07e-17	Alcohol dependence;
LUAD	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg08085267	chr17:45401833	C17orf57	-0.51	-8.42	-0.38	6e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs3942852	0.868	rs10769315	chr11:48110367	A/G	cg15704280	chr7:45808275	SEPT13	-0.58	-7.9	-0.36	2.35e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.55	0.34	2.62e-13	Tonsillectomy;
LUAD	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg15704280	chr7:45808275	SEPT13	-0.99	-20.32	-0.7	1.56e-64	Coronary artery disease;
LUAD	cis	rs438465	1.000	rs452888	chr6:169816416	C/T	cg11181693	chr6:169825345	NA	-0.63	-7.91	-0.36	2.31e-14	Corneal astigmatism;
LUAD	cis	rs1395	0.677	rs113353646	chr2:27492674	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.3	-6.37	-0.3	4.91e-10	Blood metabolite levels;
LUAD	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg21775007	chr8:11205619	TDH	-0.52	-9.46	-0.42	2.09e-19	Retinal vascular caliber;
LUAD	cis	rs6460942	0.915	rs62448619	chr7:12457743	C/T	cg06484146	chr7:12443880	VWDE	-0.58	-7.32	-0.34	1.28e-12	Coronary artery disease;
LUAD	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.52	-0.38	2.74e-16	Total body bone mineral density;
LUAD	cis	rs11809207	1.000	rs41284333	chr1:26517267	A/G	cg00300879	chr1:26503847	CNKSR1	0.27	6.67	0.31	7.89e-11	Height;
LUAD	cis	rs2302190	0.882	rs11656888	chr17:56546725	T/A	cg25885038	chr17:56607967	SEPT4	-0.52	-8.2	-0.37	2.97e-15	Vitamin D levels;
LUAD	cis	rs3823572	0.586	rs2953625	chr7:133657789	A/G	cg03336402	chr7:133662267	EXOC4	-0.41	-7.59	-0.35	2.08e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg11494091	chr17:61959527	GH2	0.74	18.32	0.67	1.27e-55	Prudent dietary pattern;
LUAD	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg00484396	chr16:3507460	NAT15	0.72	12.21	0.51	1.46e-29	Tuberculosis;
LUAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg26554054	chr8:600488	NA	0.74	7.74	0.35	7.4e-14	IgG glycosylation;
LUAD	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg07636037	chr3:49044803	WDR6	0.62	10.5	0.45	4.4e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18404041	chr3:52824283	ITIH1	-0.59	-11.93	-0.5	1.76e-28	Bipolar disorder;
LUAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg02725872	chr8:58115012	NA	-0.33	-6.46	-0.3	2.9e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs12760731	0.641	rs12691479	chr1:178328754	G/A	cg00404053	chr1:178313656	RASAL2	0.65	8.46	0.38	4.56e-16	Obesity-related traits;
LUAD	cis	rs4253772	0.591	rs739165	chr22:46684528	C/T	cg00784671	chr22:46762841	CELSR1	-0.63	-7.6	-0.35	1.89e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.44	-7.41	-0.34	7.16e-13	Renal function-related traits (BUN);
LUAD	trans	rs12406019	0.510	rs2025614	chr1:78618151	G/A	cg20826526	chr3:156266748	SSR3	-0.54	-9.18	-0.41	1.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg11822812	chr5:140052017	DND1	0.38	6.66	0.31	8.67e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg23254163	chr1:152506842	NA	0.26	7.17	0.33	3.28e-12	Hair morphology;
LUAD	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg00310523	chr12:86230176	RASSF9	0.37	7.46	0.34	4.93e-13	Major depressive disorder;
LUAD	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg21823605	chr1:152486609	CRCT1	0.29	6.53	0.3	1.84e-10	Hair morphology;
LUAD	trans	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg19862616	chr7:65841803	NCRNA00174	1.06	27.31	0.8	2.21e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg07617317	chr6:118971624	C6orf204	0.55	8.24	0.37	2.12e-15	Diastolic blood pressure;
LUAD	cis	rs2425143	1.000	rs6060557	chr20:34270266	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.28	-0.33	1.6e-12	Blood protein levels;
LUAD	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.01	0.32	9.46e-12	Motion sickness;
LUAD	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg07570687	chr10:102243282	WNT8B	0.45	6.58	0.3	1.42e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg11494091	chr17:61959527	GH2	0.45	8.56	0.38	2.04e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs72634258	0.945	rs67717282	chr1:8041290	C/T	cg26816564	chr1:7831052	VAMP3	0.5	6.44	0.3	3.31e-10	Inflammatory bowel disease;
LUAD	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.79	-0.46	3.69e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg00717180	chr2:96193071	NA	-0.36	-6.57	-0.3	1.47e-10	Coronary artery disease;
LUAD	trans	rs7395662	0.929	rs10839173	chr11:48930758	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.43	-0.34	5.88e-13	HDL cholesterol;
LUAD	cis	rs8067545	0.750	rs7208635	chr17:19990990	T/C	cg04132472	chr17:19861366	AKAP10	0.29	7.02	0.32	8.77e-12	Schizophrenia;
LUAD	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg18129748	chr3:49941408	MST1R	-0.4	-6.56	-0.3	1.56e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6011002	0.683	rs6089966	chr20:62361250	A/G	cg21849932	chr20:62369462	LIME1	-0.78	-6.45	-0.3	3.09e-10	Dental caries;
LUAD	cis	rs2017305	0.749	rs114004206	chr10:70790544	G/A	cg01024728	chr10:70782572	NA	0.74	7.03	0.32	8.43e-12	Depression (quantitative trait);
LUAD	cis	rs68170813	0.523	rs12535093	chr7:107020182	C/T	cg23024343	chr7:107201750	COG5	0.46	6.7	0.31	6.56e-11	Coronary artery disease;
LUAD	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg15556689	chr8:8085844	FLJ10661	0.42	6.7	0.31	6.68e-11	Mood instability;
LUAD	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg16797656	chr11:68205561	LRP5	0.47	9.23	0.41	1.31e-18	Total body bone mineral density;
LUAD	cis	rs877282	0.898	rs11253344	chr10:765162	C/T	cg06581033	chr10:766294	NA	-0.58	-7.95	-0.36	1.74e-14	Uric acid levels;
LUAD	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.32	6.49	0.3	2.42e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg23018236	chr17:30244563	NA	-0.71	-8.7	-0.39	7.23e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs454510	0.826	rs347903	chr1:120192431	C/T	cg11530693	chr1:120165357	ZNF697	0.62	9.69	0.43	3.43e-20	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs6066825	0.532	rs6012506	chr20:47285637	A/G	cg18078177	chr20:47281410	PREX1	0.42	6.89	0.32	2.01e-11	Colorectal cancer;
LUAD	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg06064525	chr11:970664	AP2A2	-0.54	-11.06	-0.47	3.79e-25	Alzheimer's disease (late onset);
LUAD	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg04414720	chr1:150670196	GOLPH3L	0.71	12.59	0.52	4.52e-31	Melanoma;
LUAD	cis	rs1609391	0.543	rs2117009	chr3:136633571	A/T	cg15507776	chr3:136538369	TMEM22	-0.47	-8.36	-0.38	8.88e-16	Neuroticism;
LUAD	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg01620082	chr3:125678407	NA	-1.11	-10.63	-0.46	1.51e-23	Depression;
LUAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27297192	chr10:134578999	INPP5A	0.38	6.7	0.31	6.64e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg22139774	chr2:100720529	AFF3	0.39	7.75	0.35	6.79e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg25535316	chr11:579198	PHRF1	-0.43	-7.14	-0.33	3.99e-12	Systemic lupus erythematosus;
LUAD	cis	rs4523957	0.583	rs2760735	chr17:2036835	A/G	cg16513277	chr17:2031491	SMG6	-0.98	-19.94	-0.7	7.73e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg07157834	chr1:205819609	PM20D1	-0.5	-7.61	-0.35	1.81e-13	Parkinson's disease;
LUAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg10862848	chr6:42927986	GNMT	-0.32	-9.31	-0.41	6.77e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg14598338	chr9:96623480	NA	-0.44	-9.5	-0.42	1.63e-19	DNA methylation (variation);
LUAD	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11890956	chr21:40555474	PSMG1	0.82	14.73	0.58	6.31e-40	Cognitive function;
LUAD	cis	rs17169635	0.879	rs7801596	chr7:134544054	T/A	cg07876788	chr7:134849633	TMEM140	-0.4	-6.55	-0.3	1.71e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs490234	0.756	rs925473	chr9:128228026	A/G	cg14078157	chr9:128172775	NA	-0.41	-7.17	-0.33	3.33e-12	Mean arterial pressure;
LUAD	cis	rs7943953	0.714	rs9787746	chr11:59211874	T/C	cg00706994	chr11:59190310	OR5A2	0.34	6.37	0.3	4.95e-10	Odorant perception (&beta-ionone);
LUAD	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.29	0.41	8.04e-19	Alzheimer's disease;
LUAD	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.47e-11	Crohn's disease;
LUAD	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.59	-11.16	-0.48	1.6e-25	Bone mineral density;
LUAD	cis	rs2458413	0.543	rs2514658	chr8:105337871	G/A	cg04554929	chr8:105342491	NA	-0.46	-8.92	-0.4	1.38e-17	Paget's disease;
LUAD	cis	rs9581857	0.615	rs9581848	chr13:28003997	C/T	cg22138327	chr13:27999177	GTF3A	0.91	10.43	0.45	8.38e-23	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs877282	0.629	rs78997110	chr10:764388	A/G	cg17470449	chr10:769945	NA	0.62	8.61	0.39	1.41e-16	Uric acid levels;
LUAD	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg07936489	chr17:37558343	FBXL20	-0.5	-6.7	-0.31	6.79e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg06618935	chr21:46677482	NA	0.5	10.25	0.45	3.69e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg12935359	chr14:103987150	CKB	0.5	7.78	0.35	5.71e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg10636054	chr15:40330586	SRP14	0.5	6.8	0.31	3.6e-11	Response to haloperidol in psychosis;
LUAD	cis	rs897984	0.520	rs4889536	chr16:30871755	G/T	cg02466173	chr16:30829666	NA	0.7	11.27	0.48	6.23e-26	Dementia with Lewy bodies;
LUAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg20607798	chr8:58055168	NA	0.67	8.77	0.39	4.44e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg02951883	chr7:2050386	MAD1L1	-0.81	-14.2	-0.57	1.11e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs7759001	0.817	rs4339442	chr6:27372127	A/T	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	trans	rs6601327	0.670	rs6990418	chr8:9422006	C/G	cg27411982	chr8:10470053	RP1L1	0.4	7.36	0.34	9.42e-13	Multiple myeloma (hyperdiploidy);
LUAD	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21582582	chr3:182698605	DCUN1D1	0.72	14.1	0.57	2.78e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs9976767	0.608	rs2277797	chr21:43823910	A/G	cg23042151	chr21:43824109	UBASH3A	-0.32	-7.04	-0.32	7.83e-12	Type 1 diabetes;
LUAD	cis	rs9811920	0.770	rs4928237	chr3:99731330	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.6	-11.31	-0.48	4.19e-26	Axial length;
LUAD	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-7.89	-0.36	2.53e-14	Bladder cancer;
LUAD	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.83	-0.32	2.9e-11	Neuroticism;
LUAD	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg17971929	chr21:40555470	PSMG1	0.55	8.61	0.39	1.51e-16	Cognitive function;
LUAD	cis	rs8099014	1.000	rs11152073	chr18:56108266	A/T	cg12907477	chr18:56117327	MIR122	0.38	6.64	0.31	9.68e-11	Platelet count;
LUAD	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.5	-8.0	-0.36	1.24e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg02569458	chr12:86230093	RASSF9	0.4	7.41	0.34	6.9e-13	Major depressive disorder;
LUAD	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg09137382	chr11:130731461	NA	0.4	7.42	0.34	6.48e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22496380	chr5:211416	CCDC127	-1.22	-15.59	-0.6	1.29e-43	Breast cancer;
LUAD	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg19875535	chr5:140030758	IK	0.42	7.23	0.33	2.27e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg14458575	chr2:238380390	NA	0.64	12.43	0.52	1.86e-30	Prostate cancer;
LUAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-7.25	-0.33	2.05e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg13699009	chr12:122356056	WDR66	0.39	8.8	0.39	3.62e-17	Mean corpuscular volume;
LUAD	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg06263672	chr7:65235340	NA	0.5	6.88	0.32	2.1e-11	Aortic root size;
LUAD	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg22681709	chr2:178499509	PDE11A	-0.47	-7.9	-0.36	2.39e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs71478720	0.953	rs7121554	chr11:112048051	C/T	cg09122223	chr11:112035175	IL18	0.41	6.48	0.3	2.59e-10	Interleukin-18 levels;
LUAD	cis	rs7688540	0.800	rs73793597	chr4:255905	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.32	6.41	0.3	3.92e-10	Facial morphology (factor 6, height of vermillion lower lip);
LUAD	cis	rs11792861	0.525	rs2417975	chr9:111860185	A/C	cg05043794	chr9:111880884	C9orf5	-0.37	-6.83	-0.32	3e-11	Menarche (age at onset);
LUAD	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg16099169	chr2:106886729	NA	-0.67	-9.75	-0.43	2.12e-20	Facial morphology (factor 23);
LUAD	trans	rs970548	0.688	rs1059696	chr10:45934437	G/A	cg14222797	chr10:16859974	RSU1	-0.56	-6.81	-0.31	3.39e-11	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg22598563	chr5:131563921	P4HA2	-0.28	-6.89	-0.32	1.99e-11	Blood metabolite levels;
LUAD	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg14196790	chr5:131705035	SLC22A5	-0.36	-6.36	-0.3	5.11e-10	Blood metabolite levels;
LUAD	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg02782426	chr3:40428986	ENTPD3	0.43	9.13	0.41	2.84e-18	Renal cell carcinoma;
LUAD	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg04546413	chr19:29218101	NA	0.7	10.39	0.45	1.14e-22	Methadone dose in opioid dependence;
LUAD	cis	rs6961069	0.777	rs4731643	chr7:80248029	A/G	cg04458919	chr7:80252533	CD36	-0.38	-7.19	-0.33	2.87e-12	Platelet count;
LUAD	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg11584989	chr19:19387371	SF4	0.37	6.78	0.31	4.18e-11	Tonsillectomy;
LUAD	cis	rs12949688	0.967	rs12949028	chr17:55825470	A/C	cg12582317	chr17:55822272	NA	0.34	6.91	0.32	1.83e-11	Schizophrenia;
LUAD	cis	rs317865	0.737	rs73234667	chr4:16240097	T/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.69	6.46	0.3	2.96e-10	Kidney disease (early stage) in type 1 diabetes;
LUAD	cis	rs367943	0.871	rs348940	chr5:112824530	C/A	cg21806985	chr5:112824646	MCC	-0.28	-6.76	-0.31	4.63e-11	Type 2 diabetes;
LUAD	cis	rs494562	0.892	rs544408	chr6:86119110	A/T	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1595825	0.891	rs114426561	chr2:198698891	A/G	cg00982548	chr2:198649783	BOLL	-0.65	-9.3	-0.41	7.77e-19	Ulcerative colitis;
LUAD	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg15921436	chr17:44337874	NA	0.87	11.55	0.49	5.36e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg26408565	chr15:76604113	ETFA	-0.41	-6.59	-0.31	1.32e-10	Blood metabolite levels;
LUAD	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.54	-9.1	-0.4	3.65e-18	Glomerular filtration rate;
LUAD	trans	rs7095944	0.614	rs12570348	chr10:126438963	A/C	cg17144760	chr11:27384507	CCDC34	0.44	6.45	0.3	2.98e-10	Asthma;
LUAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg21724239	chr8:58056113	NA	0.71	9.36	0.41	4.75e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg14092988	chr3:52407081	DNAH1	0.45	8.78	0.39	3.95e-17	Bipolar disorder;
LUAD	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg13722127	chr7:150037890	RARRES2	0.5	8.31	0.37	1.3e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs447921	0.861	rs4789297	chr17:74447351	G/T	cg17201438	chr17:74438067	UBE2O	0.6	8.23	0.37	2.28e-15	Mitochondrial DNA levels;
LUAD	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18876405	chr7:65276391	NA	0.57	9.45	0.42	2.36e-19	Aortic root size;
LUAD	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg09796270	chr17:17721594	SREBF1	0.37	7.16	0.33	3.52e-12	Total body bone mineral density;
LUAD	cis	rs727505	0.954	rs1009450	chr7:124628723	C/G	cg23710748	chr7:124431027	NA	-0.4	-8.05	-0.36	8.69e-15	Lewy body disease;
LUAD	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg02269571	chr22:50332266	NA	-0.58	-8.1	-0.37	5.9e-15	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg17366294	chr4:99064904	C4orf37	0.66	12.61	0.52	3.64e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg20607798	chr8:58055168	NA	0.7	8.72	0.39	6.46e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs11167764	0.895	rs7734160	chr5:141473144	G/T	cg08523384	chr5:141488047	NDFIP1	-0.47	-7.17	-0.33	3.41e-12	Crohn's disease;
LUAD	cis	rs1395	0.778	rs1978881	chr2:27400850	C/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	8.39	0.38	7.3e-16	Blood metabolite levels;
LUAD	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg00784671	chr22:46762841	CELSR1	-0.43	-6.42	-0.3	3.7e-10	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg26043149	chr18:55253948	FECH	1.1	20.19	0.7	5.86e-64	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg19077165	chr18:44547161	KATNAL2	-0.39	-6.73	-0.31	5.41e-11	Personality dimensions;
LUAD	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg12292205	chr6:26970375	C6orf41	0.5	8.55	0.38	2.2e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7923837	0.650	rs10882098	chr10:94444793	C/T	cg25093409	chr10:94429542	NA	0.4	7.1	0.33	5.21e-12	Body mass index;Multiple sclerosis;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg03350042	chr15:40733177	BAHD1	-0.46	-7.57	-0.35	2.29e-13	Vertical cup-disc ratio;
LUAD	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg14530993	chr4:882597	GAK	0.73	6.9	0.32	1.89e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg10295955	chr4:187884368	NA	-1.09	-24.83	-0.77	1.3e-84	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg08999081	chr20:33150536	PIGU	-0.37	-7.24	-0.33	2.15e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs597583	0.664	rs10892133	chr11:117383694	C/T	cg27161313	chr11:117392002	DSCAML1	-0.54	-8.18	-0.37	3.38e-15	Putamen volume;
LUAD	cis	rs9487051	0.735	rs351756	chr6:109538773	A/G	cg01475377	chr6:109611718	NA	0.41	7.64	0.35	1.47e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.44	0.3	3.17e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4343996	0.747	rs13237637	chr7:3503207	G/C	cg21248987	chr7:3385318	SDK1	0.36	6.59	0.31	1.3100000000000001e-10	Motion sickness;
LUAD	trans	rs564343	0.933	rs526852	chr11:65891432	G/A	cg26701943	chr11:108369231	KDELC2	-0.46	-7.7	-0.35	9.48e-14	Obesity (early onset extreme);
LUAD	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg15704280	chr7:45808275	SEPT13	0.74	10.8	0.46	3.66e-24	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg05340658	chr4:99064831	C4orf37	0.54	9.23	0.41	1.32e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06022373	chr22:39101656	GTPBP1	-0.45	-6.96	-0.32	1.33e-11	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.3	-6.9	-0.32	1.93e-11	Dupuytren's disease;
LUAD	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg25358565	chr5:93447407	FAM172A	0.55	6.53	0.3	1.86e-10	Diabetic retinopathy;
LUAD	cis	rs11077998	0.967	rs4789782	chr17:80489323	G/T	cg10255544	chr17:80519551	FOXK2	-0.36	-7.14	-0.33	4.23e-12	Reticulocyte fraction of red cells;
LUAD	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.49	-0.3	2.46e-10	Neuroticism;
LUAD	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs1079204	1.000	rs7600989	chr2:219119134	G/T	cg05728596	chr2:219128475	GPBAR1	1.07	10.23	0.45	4.23e-22	Smooth-surface caries;
LUAD	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg13073564	chr4:8508604	NA	0.46	7.9	0.36	2.46e-14	Response to antineoplastic agents;
LUAD	cis	rs3784262	0.542	rs2899611	chr15:58327347	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.41	-8.23	-0.37	2.39e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs34638657	0.702	rs62044259	chr16:82199523	A/T	cg09439754	chr16:82129088	HSD17B2	-0.37	-7.07	-0.33	6.52e-12	Lung adenocarcinoma;
LUAD	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	8.79	0.39	3.82e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg05805236	chr11:65401703	PCNXL3	0.39	6.59	0.31	1.28e-10	Acne (severe);
LUAD	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg27446573	chr6:127587934	RNF146	0.42	6.45	0.3	3.11e-10	Breast cancer;
LUAD	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg22532475	chr10:104410764	TRIM8	-0.57	-10.35	-0.45	1.62e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9302635	0.816	rs7202323	chr16:72217113	T/G	cg23815491	chr16:72088622	HP	0.42	6.5	0.3	2.28e-10	Blood protein levels;
LUAD	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg05991184	chr2:219186017	PNKD	-0.36	-7.0	-0.32	1.01e-11	Colorectal cancer;
LUAD	cis	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.98	-0.36	1.35e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg00784671	chr22:46762841	CELSR1	-0.63	-7.59	-0.35	2.07e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4285028	0.948	rs12488851	chr3:121687192	C/T	cg20356878	chr3:121714668	ILDR1	-0.5	-6.76	-0.31	4.51e-11	Multiple sclerosis;
LUAD	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg03264133	chr6:25882463	NA	0.47	7.59	0.35	2.12e-13	Blood metabolite levels;
LUAD	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg11494091	chr17:61959527	GH2	0.4	6.91	0.32	1.74e-11	Height;
LUAD	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg17757837	chr7:157058334	UBE3C	-0.48	-8.6	-0.39	1.61e-16	Body mass index;
LUAD	cis	rs300703	0.515	rs440617	chr2:189818	A/G	cg21211680	chr2:198530	NA	-0.54	-8.02	-0.36	1.05e-14	Blood protein levels;
LUAD	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs8099014	0.553	rs8096955	chr18:56130816	G/C	cg12907477	chr18:56117327	MIR122	0.51	6.92	0.32	1.73e-11	Platelet count;
LUAD	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.7	-12.79	-0.53	6.57e-32	Cognitive ability;
LUAD	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.54	-0.34	2.92e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08844988	chr16:24741147	TNRC6A	-0.55	-6.72	-0.31	5.86e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg26354017	chr1:205819088	PM20D1	-0.52	-8.66	-0.39	1e-16	Parkinson's disease;
LUAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg12432903	chr7:1882776	MAD1L1	0.53	8.64	0.39	1.13e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.48e-15	Prostate cancer;
LUAD	cis	rs13223928	0.565	rs10951053	chr7:3155579	C/T	cg19214707	chr7:3157722	NA	-0.51	-9.23	-0.41	1.29e-18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg27490568	chr2:178487706	NA	0.41	6.78	0.31	4.12e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg13397359	chr6:42928475	GNMT	-0.58	-11.03	-0.47	4.77e-25	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg01620082	chr3:125678407	NA	-0.89	-6.99	-0.32	1.08e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs397969	0.646	rs6813	chr17:19808445	C/T	cg04132472	chr17:19861366	AKAP10	-0.32	-6.6	-0.31	1.2e-10	Platelet count;
LUAD	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.37	7.43	0.34	5.96e-13	Obesity-related traits;
LUAD	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg06221963	chr1:154839813	KCNN3	-0.82	-18.72	-0.67	2.12e-57	Prostate cancer;
LUAD	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	trans	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.98	-0.32	1.12e-11	Systolic blood pressure;
LUAD	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg18944383	chr4:111397179	ENPEP	0.4	7.92	0.36	2.19e-14	Height;
LUAD	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg02569458	chr12:86230093	RASSF9	-0.35	-6.59	-0.31	1.32e-10	Major depressive disorder;
LUAD	cis	rs11771526	0.892	rs1376282	chr7:32370492	A/G	cg13207630	chr7:32358064	NA	0.68	7.72	0.35	8.52e-14	Body mass index;
LUAD	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg06064525	chr11:970664	AP2A2	-0.54	-11.0	-0.47	6.57e-25	Alzheimer's disease (late onset);
LUAD	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-6.96	-0.32	1.34e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.38	-0.3	4.58e-10	Aortic root size;
LUAD	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg23173402	chr1:227635558	NA	0.74	7.93	0.36	1.98e-14	Major depressive disorder;
LUAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg26354017	chr1:205819088	PM20D1	0.92	22.33	0.74	1.56e-73	Menarche (age at onset);
LUAD	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.73	-0.31	5.46e-11	Crohn's disease;
LUAD	cis	rs12612619	0.732	rs6547401	chr2:27284845	A/G	cg00617064	chr2:27272375	NA	-0.37	-7.1	-0.33	5.18e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs6840360	1.000	rs10023298	chr4:152666768	A/C	cg22705602	chr4:152727874	NA	-0.32	-6.48	-0.3	2.57e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg11070056	chr1:107600091	PRMT6	-0.54	-9.37	-0.41	4.3e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg13397359	chr6:42928475	GNMT	0.58	10.98	0.47	7.61e-25	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs12122100	0.837	rs12742539	chr1:146507845	G/A	cg03526459	chr1:146549940	NA	-0.38	-7.11	-0.33	5.05e-12	HIV-1 control;
LUAD	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.38	-0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs10089	0.953	rs17164427	chr5:127361736	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.62	-9.79	-0.43	1.56e-20	Ileal carcinoids;
LUAD	cis	rs713477	0.967	rs6573029	chr14:55913550	A/C	cg13175173	chr14:55914753	NA	-0.35	-7.33	-0.34	1.17e-12	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs7582720	1.000	rs72936882	chr2:203794439	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg02869364	chr7:1081709	C7orf50	-0.5	-6.46	-0.3	2.91e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs79349575	0.721	rs4794004	chr17:47038471	C/T	cg22482690	chr17:47019901	SNF8	0.4	7.6	0.35	1.93e-13	Type 2 diabetes;
LUAD	cis	rs55665837	0.540	rs4757261	chr11:14669802	C/A	cg19336497	chr11:14380999	RRAS2	-0.41	-7.92	-0.36	2.06e-14	Vitamin D levels;
LUAD	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.48	-0.38	3.74e-16	Height;
LUAD	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg02896835	chr1:92012615	NA	-0.57	-12.04	-0.51	6.56e-29	Breast cancer;
LUAD	cis	rs7737355	0.947	rs31258	chr5:130824536	G/A	cg06307176	chr5:131281290	NA	0.49	7.81	0.36	4.44e-14	Life satisfaction;
LUAD	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg03609598	chr5:56110824	MAP3K1	-0.45	-6.59	-0.31	1.32e-10	Initial pursuit acceleration;
LUAD	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg02049041	chr17:27085579	C17orf63	0.65	8.66	0.39	1.04e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.13	0.48	2.09e-25	Eosinophil percentage of white cells;
LUAD	cis	rs752010	0.695	rs12123834	chr1:42105727	T/C	cg06885757	chr1:42089581	HIVEP3	0.38	8.11	0.37	5.64e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg24640516	chr1:210004059	C1orf107	0.35	6.42	0.3	3.75e-10	Orofacial clefts;
LUAD	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg14121845	chr20:25566513	NINL	0.4	7.2	0.33	2.82e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1816752	0.819	rs7400583	chr13:24990054	C/T	cg02811702	chr13:24901961	NA	0.42	7.32	0.34	1.27e-12	Obesity-related traits;
LUAD	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18876405	chr7:65276391	NA	-0.44	-6.98	-0.32	1.16e-11	Aortic root size;
LUAD	cis	rs17095355	0.786	rs61624875	chr10:111722489	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.68	-9.16	-0.41	2.21e-18	Biliary atresia;
LUAD	cis	rs7520050	0.966	rs12049588	chr1:46472422	G/A	cg06784218	chr1:46089804	CCDC17	-0.3	-6.49	-0.3	2.44e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg10729496	chr3:10149963	C3orf24	0.58	9.43	0.42	2.66e-19	Alzheimer's disease;
LUAD	cis	rs9796	0.558	rs7166205	chr15:41514733	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.44	-7.94	-0.36	1.81e-14	Menopause (age at onset);
LUAD	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg14834391	chr1:2537342	MMEL1	-0.31	-6.53	-0.3	1.83e-10	Ulcerative colitis;
LUAD	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg05187965	chr10:45406764	TMEM72	-0.47	-9.15	-0.41	2.48e-18	Mean corpuscular volume;
LUAD	cis	rs2046867	0.908	rs62251649	chr3:72809610	A/C	cg25664220	chr3:72788482	NA	-0.69	-12.52	-0.52	8.47e-31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg03714773	chr7:91764589	CYP51A1	0.27	6.46	0.3	2.89e-10	Breast cancer;
LUAD	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18876405	chr7:65276391	NA	-0.46	-7.39	-0.34	8.06e-13	Aortic root size;
LUAD	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg12599982	chr1:44399894	ARTN	-0.35	-7.07	-0.33	6.46e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.47	8.18	0.37	3.26e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.42	8.11	0.37	5.36e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg18490616	chr2:88469792	THNSL2	0.68	6.91	0.32	1.74e-11	Plasma clusterin levels;
LUAD	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg02160872	chr5:212506	CCDC127	-0.52	-6.58	-0.3	1.4e-10	Breast cancer;
LUAD	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg22532475	chr10:104410764	TRIM8	-0.45	-8.58	-0.38	1.86e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs3087591	0.960	rs2952976	chr17:29486152	G/A	cg24425628	chr17:29625626	OMG;NF1	0.41	6.58	0.3	1.36e-10	Hip circumference;
LUAD	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg00852783	chr1:26633632	UBXN11	0.44	7.68	0.35	1.13e-13	Obesity-related traits;
LUAD	cis	rs6665290	0.904	rs11587443	chr1:227187896	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.91	-0.89	1.63e-145	Myeloid white cell count;
LUAD	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg15128208	chr22:42549153	NA	0.4	8.05	0.36	8.19e-15	Cognitive function;
LUAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg20607798	chr8:58055168	NA	0.72	9.44	0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.93	-0.36	1.98e-14	Personality dimensions;
LUAD	trans	rs12439619	0.846	rs62013464	chr15:82580591	A/C	cg04831495	chr15:85060580	GOLGA6L5	-0.48	-6.61	-0.31	1.15e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg02887458	chr19:19495540	GATAD2A	0.44	6.57	0.3	1.48e-10	Bipolar disorder;
LUAD	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs2046867	0.661	rs7637050	chr3:72910790	A/C	cg04365224	chr3:72788183	NA	-0.4	-6.38	-0.3	4.56e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4523957	0.583	rs2760738	chr17:2024600	A/G	cg16513277	chr17:2031491	SMG6	-0.96	-19.09	-0.68	4.76e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg12756686	chr19:29218302	NA	0.68	8.75	0.39	5.27e-17	Methadone dose in opioid dependence;
LUAD	trans	rs8073060	0.586	rs117573546	chr17:33909588	G/A	cg19694781	chr19:47549865	TMEM160	1.25	19.64	0.69	1.71e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.55	0.34	2.76e-13	Breast cancer;
LUAD	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg13511324	chr14:104056883	C14orf153	0.25	6.38	0.3	4.53e-10	Coronary artery disease;
LUAD	cis	rs13064411	0.542	rs9874747	chr3:113221258	G/A	cg18753928	chr3:113234510	CCDC52	-0.55	-9.68	-0.43	3.7e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg18252515	chr7:66147081	NA	-0.63	-6.89	-0.32	2.01e-11	Diabetic kidney disease;
LUAD	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg17372223	chr3:52568218	NT5DC2	0.4	7.48	0.34	4.25e-13	Electroencephalogram traits;
LUAD	cis	rs4700695	0.764	rs251593	chr5:65313889	G/A	cg21114390	chr5:65439923	SFRS12	0.65	7.78	0.35	5.48e-14	Facial morphology (factor 19);
LUAD	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg24558204	chr6:135376177	HBS1L	0.46	8.6	0.39	1.54e-16	Red blood cell count;
LUAD	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg13870426	chr17:30244630	NA	-0.56	-6.62	-0.31	1.12e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs7680126	0.626	rs929575	chr4:10196886	C/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-7.36	-0.34	9.82e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg18944383	chr4:111397179	ENPEP	0.38	7.69	0.35	1.07e-13	Height;
LUAD	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	9.85	0.43	9.39e-21	Electrocardiographic conduction measures;
LUAD	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg11062466	chr8:58055876	NA	0.76	9.34	0.41	5.65e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg17031739	chr1:67600172	NA	0.43	7.8	0.35	4.96e-14	Psoriasis;
LUAD	cis	rs1062746	0.834	rs9308347	chr16:87371752	C/T	cg02258303	chr16:87377426	FBXO31	-0.46	-8.01	-0.36	1.16e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs10106298	1.000	rs17773903	chr8:103685172	A/G	cg10187029	chr8:103597600	NA	0.44	7.21	0.33	2.65e-12	Schizophrenia;
LUAD	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg22963979	chr7:1858916	MAD1L1	-0.49	-8.18	-0.37	3.26e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg08885076	chr2:99613938	TSGA10	-0.37	-6.44	-0.3	3.16e-10	Chronic sinus infection;
LUAD	cis	rs6960043	0.818	rs2191349	chr7:15064309	G/T	cg19272540	chr7:15055459	NA	-0.36	-7.72	-0.35	8.22e-14	Type 2 diabetes;
LUAD	trans	rs1728785	0.901	rs11865339	chr16:68565296	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.78	0.43	1.69e-20	Ulcerative colitis;
LUAD	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg04731861	chr2:219085781	ARPC2	-0.22	-6.58	-0.3	1.41e-10	Colorectal cancer;
LUAD	cis	rs1451375	0.698	rs12669770	chr7:50656334	G/A	cg18232548	chr7:50535776	DDC	0.49	7.88	0.36	2.81e-14	Malaria;
LUAD	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.7	-0.31	6.71e-11	Electroencephalogram traits;
LUAD	trans	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg19676328	chr12:49525230	TUBA1B	-0.71	-11.68	-0.49	1.61e-27	Total cholesterol levels;
LUAD	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.09	11.0	0.47	6.38e-25	Schizophrenia;
LUAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg07167872	chr1:205819463	PM20D1	0.48	7.86	0.36	3.19e-14	Parkinson's disease;
LUAD	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.53	0.34	3.03e-13	Bipolar disorder;
LUAD	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg14345882	chr6:26364793	BTN3A2	0.64	6.44	0.3	3.32e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23583168	chr7:148888333	NA	-0.93	-19.34	-0.69	3.52e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs1045714	0.895	rs73035504	chr7:2642878	G/A	cg20813462	chr7:2646259	IQCE	0.67	7.5	0.34	3.78e-13	Urate levels in lean individuals;
LUAD	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.25	0.41	1.12e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11229555	0.598	rs11229426	chr11:58180063	T/C	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1215050	0.818	rs165238	chr4:98712138	G/T	cg24818145	chr4:99064322	C4orf37	0.41	6.85	0.32	2.61e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs13095912	0.889	rs35917986	chr3:185310041	G/A	cg11274856	chr3:185301563	NA	0.37	7.48	0.34	4.47e-13	Systolic blood pressure;
LUAD	cis	rs877529	0.625	rs139416	chr22:39554749	A/G	cg18708252	chr22:39545030	CBX7	-0.29	-6.47	-0.3	2.65e-10	Multiple myeloma;
LUAD	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	9.44	0.42	2.52e-19	Colorectal cancer;
LUAD	trans	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg18335740	chr13:41363409	SLC25A15	0.54	9.82	0.43	1.17e-20	Lewy body disease;
LUAD	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg07404485	chr7:94953653	PON1	-0.5	-7.21	-0.33	2.6e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg03340356	chr1:67600835	NA	0.41	7.03	0.32	8.32e-12	Psoriasis;
LUAD	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg26318627	chr11:63887540	MACROD1	0.36	7.22	0.33	2.49e-12	Platelet count;
LUAD	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg04414720	chr1:150670196	GOLPH3L	0.61	10.58	0.46	2.2e-23	Melanoma;
LUAD	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg14458575	chr2:238380390	NA	-0.8	-14.8	-0.58	3.04e-40	Prostate cancer;
LUAD	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg03959625	chr15:84868606	LOC388152	0.41	6.55	0.3	1.63e-10	Schizophrenia;
LUAD	cis	rs2242073	0.660	rs4338947	chr2:209001440	C/T	cg06181187	chr2:209010896	CRYGB	0.33	6.67	0.31	8.26e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs12216545	0.737	rs7788962	chr7:150227227	G/A	cg08960815	chr7:150264767	GIMAP4	-0.31	-6.68	-0.31	7.55e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs737008	0.922	rs2550475	chr16:11371986	C/T	cg00044050	chr16:11439710	C16orf75	0.48	6.96	0.32	1.3e-11	Obesity-related traits;
LUAD	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg27454412	chr7:1067447	C7orf50	-0.43	-7.99	-0.36	1.31e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs10465746	0.967	rs5028806	chr1:84329295	G/A	cg10977910	chr1:84465055	TTLL7	0.51	8.22	0.37	2.54e-15	Obesity-related traits;
LUAD	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg05234568	chr11:5960015	NA	-0.47	-8.54	-0.38	2.43e-16	DNA methylation (variation);
LUAD	cis	rs7809615	0.901	rs12535424	chr7:99053816	G/A	cg12290671	chr7:99195819	NA	-0.68	-7.22	-0.33	2.48e-12	Blood metabolite ratios;
LUAD	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg23254163	chr1:152506842	NA	0.25	6.96	0.32	1.31e-11	Hair morphology;
LUAD	cis	rs3087591	0.887	rs2905875	chr17:29541339	A/T	cg24425628	chr17:29625626	OMG;NF1	0.43	6.96	0.32	1.34e-11	Hip circumference;
LUAD	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg06028605	chr16:24865363	SLC5A11	0.37	6.74	0.31	5.23e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs476633	0.691	rs28568756	chr15:41539371	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.62	-0.39	1.37e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.68	-0.31	7.63e-11	Total cholesterol levels;
LUAD	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg14552801	chr7:65878734	NA	0.37	6.37	0.3	5.05e-10	Aortic root size;
LUAD	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg06064525	chr11:970664	AP2A2	-0.56	-11.58	-0.49	3.85e-27	Alzheimer's disease (late onset);
LUAD	cis	rs6076065	0.925	rs2281430	chr20:23399314	T/C	cg11657817	chr20:23433608	CST11	0.45	8.8	0.39	3.41e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg03874509	chr1:107600012	PRMT6	0.47	7.68	0.35	1.15e-13	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs59104589	0.617	rs3771550	chr2:242302811	A/G	cg08645257	chr2:242211290	HDLBP	0.43	7.04	0.32	7.74e-12	Fibrinogen levels;
LUAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg05313129	chr8:58192883	C8orf71	-0.57	-8.42	-0.38	5.89e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7524258	0.868	rs8179413	chr1:7267729	T/G	cg07173049	chr1:7289937	CAMTA1	0.51	9.4	0.42	3.55e-19	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg01849466	chr14:104193079	ZFYVE21	0.52	8.53	0.38	2.67e-16	Body mass index;
LUAD	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg13047869	chr3:10149882	C3orf24	0.52	7.08	0.33	5.96e-12	Alzheimer's disease;
LUAD	trans	rs7395662	0.963	rs9666932	chr11:48726240	G/A	cg15704280	chr7:45808275	SEPT13	0.43	6.75	0.31	5.04e-11	HDL cholesterol;
LUAD	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg25554036	chr4:6271136	WFS1	-0.64	-12.77	-0.53	8.45e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04083965	chr8:101962788	YWHAZ	-0.39	-6.51	-0.3	2.16e-10	Cancer;
LUAD	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg09117114	chr16:67998030	SLC12A4	-0.48	-6.82	-0.31	3.06e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs970821	0.667	rs10956146	chr8:124749704	T/G	cg00283535	chr8:124749564	ANXA13	-0.35	-6.42	-0.3	3.57e-10	Breast cancer;
LUAD	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg06608945	chr2:219082296	ARPC2	0.47	8.21	0.37	2.79e-15	Colorectal cancer;
LUAD	cis	rs6761276	0.752	rs12477866	chr2:113835908	C/T	cg09040174	chr2:113837401	NA	0.81	15.75	0.61	2.68e-44	Protein quantitative trait loci;
LUAD	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg03037974	chr15:76606532	NA	0.41	9.13	0.41	2.91e-18	Blood metabolite levels;
LUAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg26338869	chr17:61819248	STRADA	-0.39	-6.57	-0.3	1.53e-10	Prudent dietary pattern;
LUAD	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg07917127	chr4:99064746	C4orf37	0.41	6.85	0.32	2.67e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6500395	1.000	rs6500398	chr16:48650332	C/T	cg04672837	chr16:48644449	N4BP1	0.39	6.7	0.31	6.62e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4280164	0.945	rs3181384	chr14:24786976	C/T	cg22990158	chr14:24802150	ADCY4	0.44	6.41	0.3	3.78e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg07636037	chr3:49044803	WDR6	0.35	6.41	0.3	4e-10	Resting heart rate;
LUAD	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg11707310	chr1:2537719	MMEL1	-0.39	-8.4	-0.38	7.09e-16	Ulcerative colitis;
LUAD	cis	rs1032833	0.732	rs17454192	chr2:180000816	C/G	cg23883738	chr2:179974586	SESTD1	-0.7	-7.65	-0.35	1.39e-13	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg20607798	chr8:58055168	NA	-0.58	-7.92	-0.36	2.15e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg12863693	chr15:85201151	NMB	0.37	6.46	0.3	2.87e-10	Schizophrenia;
LUAD	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg22467129	chr15:76604101	ETFA	-0.47	-7.85	-0.36	3.42e-14	Blood metabolite levels;
LUAD	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg24803719	chr17:45855879	NA	-0.32	-7.31	-0.33	1.38e-12	IgG glycosylation;
LUAD	cis	rs7582720	1.000	rs72934765	chr2:203758551	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.7	9.25	0.41	1.14e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg11494091	chr17:61959527	GH2	0.43	8.22	0.37	2.45e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg23281280	chr6:28129359	ZNF389	0.46	6.53	0.3	1.9e-10	Depression;
LUAD	cis	rs9341808	0.628	rs9294172	chr6:80918561	G/A	cg08355045	chr6:80787529	NA	0.53	9.5	0.42	1.5700000000000001e-19	Sitting height ratio;
LUAD	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg23625390	chr15:77176239	SCAPER	0.4	6.99	0.32	1.11e-11	Blood metabolite levels;
LUAD	cis	rs367943	0.712	rs27567	chr5:112741798	C/T	cg12552261	chr5:112820674	MCC	0.47	9.08	0.4	4.13e-18	Type 2 diabetes;
LUAD	trans	rs2797160	0.547	rs10872298	chr6:125956348	A/C	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-7.37	-0.34	9.21e-13	Endometrial cancer;
LUAD	cis	rs868036	1.000	rs1026736	chr15:68101813	T/C	cg08079166	chr15:68083412	MAP2K5	0.3	6.49	0.3	2.39e-10	Restless legs syndrome;
LUAD	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg20991723	chr1:152506922	NA	0.35	7.09	0.33	5.68e-12	Hair morphology;
LUAD	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg11517269	chr6:28058789	ZSCAN12L1	0.27	6.48	0.3	2.61e-10	Cardiac Troponin-T levels;
LUAD	cis	rs7903847	0.632	rs11189157	chr10:99113729	G/A	cg20016023	chr10:99160130	RRP12	-0.31	-6.95	-0.32	1.37e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-9.58	-0.42	8.21e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg18190219	chr22:46762943	CELSR1	-0.58	-6.44	-0.3	3.33e-10	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs2544390	1.000	rs2673172	chr2:170204800	A/C	cg26260369	chr14:68141723	VTI1B	0.41	6.94	0.32	1.48e-11	Urate levels;
LUAD	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg00784671	chr22:46762841	CELSR1	-0.43	-6.42	-0.3	3.7e-10	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21659725	chr3:3221576	CRBN	0.67	11.7	0.49	1.33e-27	Intelligence (multi-trait analysis);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg13303229	chr5:154136254	LARP1	-0.38	-6.75	-0.31	4.78e-11	Subcortical brain region volumes;
LUAD	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-11.73	-0.5	1.03e-27	Hemoglobin concentration;
LUAD	cis	rs9929218	0.508	rs1559366	chr16:68799611	A/G	cg01251360	chr16:68772225	CDH1	-0.25	-7.83	-0.36	3.9e-14	Colorectal cancer;
LUAD	trans	rs1997103	1.000	rs2177805	chr7:55404381	T/A	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02334915	chr10:7860872	TAF3	0.42	6.41	0.3	3.86e-10	Gut microbiome composition (summer);
LUAD	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg19442545	chr10:75533431	FUT11	-0.48	-7.94	-0.36	1.78e-14	Inflammatory bowel disease;
LUAD	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg24531977	chr5:56204891	C5orf35	-0.42	-6.85	-0.32	2.67e-11	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs459571	0.920	rs417142	chr9:136891370	G/T	cg13789015	chr9:136890014	NCRNA00094	0.85	14.6	0.58	2.3e-39	Platelet distribution width;
LUAD	cis	rs3135063	0.504	rs78139882	chr4:3287361	C/T	cg08817983	chr4:3391423	RGS12	-0.51	-7.44	-0.34	5.62e-13	Blood protein levels;
LUAD	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg19318889	chr4:1322082	MAEA	0.47	7.78	0.35	5.45e-14	Obesity-related traits;
LUAD	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg08213375	chr14:104286397	PPP1R13B	0.28	7.24	0.33	2.12e-12	Schizophrenia;
LUAD	cis	rs7746082	0.627	rs7770156	chr6:106471509	T/A	cg02270332	chr6:106475062	NA	-0.38	-6.38	-0.3	4.77e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg15147215	chr3:52552868	STAB1	-0.39	-7.03	-0.32	8.47e-12	Bipolar disorder;
LUAD	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg26597838	chr10:835615	NA	0.99	15.55	0.6	1.86e-43	Eosinophil percentage of granulocytes;
LUAD	cis	rs6087990	0.735	rs1040554	chr20:31380073	C/T	cg13636640	chr20:31349939	DNMT3B	0.72	13.14	0.54	2.67e-33	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8002861	0.905	rs12874590	chr13:44433363	C/T	cg17145862	chr1:211918768	LPGAT1	-0.65	-14.36	-0.57	2.22e-38	Leprosy;
LUAD	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg27490568	chr2:178487706	NA	0.45	7.59	0.35	2.07e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7224314	1.000	rs62084081	chr17:65387148	G/C	cg01507342	chr17:65387096	PITPNC1	-0.55	-9.24	-0.41	1.2e-18	Diisocyanate-induced asthma;
LUAD	cis	rs35883536	0.631	rs2783704	chr1:101040652	T/A	cg06223162	chr1:101003688	GPR88	0.47	9.15	0.41	2.44e-18	Monocyte count;
LUAD	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.37	6.68	0.31	7.71e-11	Blood metabolite levels;
LUAD	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg03388025	chr16:89894329	SPIRE2	0.32	7.01	0.32	9.33e-12	Vitiligo;
LUAD	trans	rs2735413	0.846	rs72800943	chr16:78079555	G/A	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs669446	0.561	rs628342	chr1:44090736	C/T	cg12908607	chr1:44402522	ARTN	-0.35	-6.38	-0.3	4.79e-10	Amyotrophic lateral sclerosis (age of onset);
LUAD	trans	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg14917512	chr19:3094685	GNA11	0.55	6.57	0.3	1.44e-10	Diabetic kidney disease;
LUAD	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg08632164	chr7:65971372	NA	-0.37	-6.42	-0.3	3.69e-10	Aortic root size;
LUAD	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg10057126	chr4:77819792	ANKRD56	0.54	9.15	0.41	2.51e-18	Emphysema distribution in smoking;
LUAD	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg08027265	chr7:2291960	NA	0.48	8.18	0.37	3.41e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7572644	0.680	rs12465012	chr2:28028191	C/T	cg27432699	chr2:27873401	GPN1	0.42	6.37	0.3	4.89e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.61	0.31	1.19e-10	Prudent dietary pattern;
LUAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg14983838	chr19:29218262	NA	0.65	9.56	0.42	9.44e-20	Methadone dose in opioid dependence;
LUAD	cis	rs68170813	0.559	rs75723759	chr7:106962407	A/G	cg23024343	chr7:107201750	COG5	0.5	7.15	0.33	3.78e-12	Coronary artery disease;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg19767650	chr1:183605181	ARPC5;RGL1	-0.38	-6.51	-0.3	2.12e-10	Subcortical brain region volumes;
LUAD	cis	rs7274811	0.744	rs2071056	chr20:32265513	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.5	-7.46	-0.34	5.04e-13	Height;
LUAD	trans	rs190945449	1	rs190945449	chr6:26828359	C/T	cg01620082	chr3:125678407	NA	-0.89	-9.08	-0.4	4.15e-18	Urinary tract infection frequency;
LUAD	cis	rs80319144	1.000	rs113658628	chr2:159215951	G/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.36	6.72	0.31	5.85e-11	Restless legs syndrome;
LUAD	cis	rs807669	0.548	rs9605957	chr22:19187375	G/A	cg24911827	chr22:19170109	CLTCL1	0.34	7.14	0.33	4.11e-12	Metabolite levels;
LUAD	trans	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg02002194	chr4:3960332	NA	0.29	7.2	0.33	2.76e-12	Mood instability;
LUAD	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg01528321	chr10:82214614	TSPAN14	0.66	10.55	0.46	3.07e-23	Post bronchodilator FEV1;
LUAD	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg00701064	chr4:6280414	WFS1	0.65	14.27	0.57	5.55e-38	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg10556349	chr10:835070	NA	0.53	7.2	0.33	2.74e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs1448094	0.802	rs12369634	chr12:86406792	C/G	cg06740227	chr12:86229804	RASSF9	0.39	7.13	0.33	4.3e-12	Major depressive disorder;
LUAD	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.65e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg11266682	chr4:10021025	SLC2A9	0.49	8.88	0.4	1.97e-17	Blood metabolite levels;
LUAD	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg21427119	chr20:30132790	HM13	-0.59	-8.74	-0.39	5.5e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs2742417	0.624	rs2742394	chr3:45757591	C/T	cg10512202	chr3:45649293	LIMD1	0.49	9.25	0.41	1.11e-18	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs28719689	0.655	rs58892423	chr8:1276014	A/C	cg22761795	chr8:1265118	NA	0.53	6.85	0.32	2.56e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg03859395	chr2:55845619	SMEK2	-0.44	-6.74	-0.31	5.24e-11	Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	6.2e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg05340658	chr4:99064831	C4orf37	0.51	8.52	0.38	2.9e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg23029597	chr12:123009494	RSRC2	0.52	7.96	0.36	1.64e-14	Body mass index;
LUAD	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg15369054	chr17:80825471	TBCD	-0.42	-7.12	-0.33	4.66e-12	Breast cancer;
LUAD	cis	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg27642588	chr6:29709602	LOC285830	0.45	7.07	0.33	6.35e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg16070123	chr10:51489643	NA	0.39	7.16	0.33	3.65e-12	Prostate-specific antigen levels;
LUAD	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-7.05	-0.32	7.12e-12	Menarche (age at onset);
LUAD	cis	rs4819852	0.958	rs1034564	chr22:19984013	A/G	cg07821417	chr22:19972146	ARVCF	-0.39	-7.71	-0.35	9.09e-14	Pulse pressure;
LUAD	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28735056	0.967	rs11660941	chr18:77630600	G/C	cg20368463	chr18:77673604	PQLC1	-0.42	-6.36	-0.3	5.16e-10	Schizophrenia;
LUAD	cis	rs12900413	0.687	rs35060998	chr15:90310294	A/G	cg24249390	chr15:90295951	MESP1	-0.34	-6.62	-0.31	1.08e-10	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg16325326	chr1:53192061	ZYG11B	0.61	10.95	0.47	9.58e-25	Monocyte count;
LUAD	cis	rs2281845	0.859	rs4915216	chr1:201077469	T/G	cg22815214	chr1:201083145	CACNA1S	0.55	9.28	0.41	9.1e-19	Permanent tooth development;
LUAD	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg18135555	chr8:22132992	PIWIL2	0.43	7.81	0.35	4.61e-14	Hypertriglyceridemia;
LUAD	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg25767906	chr1:53392781	SCP2	-0.41	-7.44	-0.34	5.81e-13	Monocyte count;
LUAD	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	9.0	0.4	7.72e-18	Hip circumference adjusted for BMI;
LUAD	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-8.24	-0.37	2.22e-15	Height;
LUAD	trans	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	17.49	0.65	6.44e-52	Exhaled nitric oxide output;
LUAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg16571642	chr7:158045996	PTPRN2	0.34	6.74	0.31	5.15e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.51	-0.3	2.14e-10	Prostate cancer;
LUAD	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg21475434	chr5:93447410	FAM172A	0.76	8.49	0.38	3.63e-16	Diabetic retinopathy;
LUAD	cis	rs61897795	0.657	rs174589	chr11:61615803	C/G	cg06781209	chr11:61594997	FADS2	0.44	7.35	0.34	1.04e-12	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg21984481	chr17:79567631	NPLOC4	0.71	16.71	0.63	1.71e-48	Eye color traits;
LUAD	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg19077165	chr18:44547161	KATNAL2	0.42	7.4	0.34	7.42e-13	Personality dimensions;
LUAD	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21028142	chr17:79581711	NPLOC4	0.45	9.79	0.43	1.54e-20	Eye color traits;
LUAD	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg14664628	chr15:75095509	CSK	-0.57	-9.12	-0.41	2.98e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg16060761	chr17:80687452	NA	0.53	7.88	0.36	2.8e-14	Breast cancer;
LUAD	cis	rs17683430	0.681	rs12159823	chr22:32563229	A/G	cg00543991	chr22:32367038	NA	0.69	7.14	0.33	3.97e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LUAD	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-9.48	-0.42	1.83e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3772130	0.962	rs9883467	chr3:121517833	G/A	cg20356878	chr3:121714668	ILDR1	0.53	8.55	0.38	2.27e-16	Cognitive performance;
LUAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18402987	chr7:1209562	NA	0.38	6.43	0.3	3.41e-10	Longevity;Endometriosis;
LUAD	cis	rs41311933	0.610	rs76874058	chr9:123952604	C/T	cg13567360	chr9:123745713	C5	-0.75	-8.33	-0.38	1.12e-15	Coronary artery disease;
LUAD	cis	rs10992471	0.528	rs10115290	chr9:95195858	G/A	cg14631576	chr9:95140430	CENPP	-0.49	-10.01	-0.44	2.61e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22857025	chr5:266934	NA	-0.97	-14.67	-0.58	1.11e-39	Breast cancer;
LUAD	cis	rs17092148	0.887	rs2068474	chr20:33231079	A/G	cg16810054	chr20:33298113	TP53INP2	-0.51	-7.66	-0.35	1.32e-13	Neuroticism;
LUAD	trans	rs1864729	1.000	rs2583504	chr8:98283404	G/C	cg08679828	chr8:102218111	ZNF706	-0.78	-8.22	-0.37	2.48e-15	Estradiol plasma levels (breast cancer);
LUAD	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.84e-26	Alzheimer's disease (late onset);
LUAD	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23158103	chr7:148848205	ZNF398	-0.6	-10.93	-0.47	1.2e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg02734326	chr4:10020555	SLC2A9	-0.53	-9.14	-0.41	2.63e-18	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg22823121	chr1:150693482	HORMAD1	0.41	7.96	0.36	1.57e-14	Melanoma;
LUAD	cis	rs2625529	0.617	rs7175792	chr15:72431883	C/G	cg16672083	chr15:72433130	SENP8	-0.65	-12.35	-0.51	3.89e-30	Red blood cell count;
LUAD	cis	rs501916	1.000	rs599111	chr15:48053334	G/T	cg16110827	chr15:48056943	SEMA6D	-0.36	-7.2	-0.33	2.84e-12	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	cis	rs9473147	0.543	rs9369716	chr6:47552180	A/T	cg02130027	chr6:47444894	CD2AP	0.36	6.87	0.32	2.31e-11	Platelet distribution width;Mean platelet volume;
LUAD	trans	rs12517041	1.000	rs12519798	chr5:23290006	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.49	-0.3	2.38e-10	Calcium levels;
LUAD	cis	rs7178375	0.607	rs34178381	chr15:31222585	G/C	cg03767031	chr15:31195708	MTMR15	0.82	8.24	0.37	2.19e-15	Hypertriglyceridemia;
LUAD	cis	rs10465746	0.687	rs6576954	chr1:84323701	C/T	cg10977910	chr1:84465055	TTLL7	-0.45	-7.06	-0.32	6.84e-12	Obesity-related traits;
LUAD	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg08027265	chr7:2291960	NA	-0.47	-8.43	-0.38	5.45e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg04842962	chr6:43655489	MRPS18A	-1.02	-24.84	-0.77	1.15e-84	IgG glycosylation;
LUAD	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg26343298	chr8:95960752	TP53INP1	0.35	7.38	0.34	8.41e-13	Type 2 diabetes;
LUAD	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg16479474	chr6:28041457	NA	0.38	6.84	0.32	2.83e-11	Cardiac Troponin-T levels;
LUAD	cis	rs2274273	0.624	rs7151581	chr14:55788445	A/G	cg04306507	chr14:55594613	LGALS3	-0.42	-7.95	-0.36	1.77e-14	Protein biomarker;
LUAD	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg11062466	chr8:58055876	NA	0.45	6.44	0.3	3.34e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg05754148	chr16:3507555	NAT15	0.46	6.95	0.32	1.39e-11	Body mass index (adult);
LUAD	trans	rs4942242	1.000	rs9533572	chr13:44234265	A/C	cg19169023	chr15:41853346	TYRO3	-0.48	-8.31	-0.37	1.32e-15	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9354308	0.899	rs1938059	chr6:66539291	G/A	cg07460842	chr6:66804631	NA	0.49	7.44	0.34	5.55e-13	Metabolite levels;
LUAD	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg16414030	chr3:133502952	NA	0.4	7.14	0.33	4.15e-12	Iron status biomarkers;
LUAD	cis	rs1594829	0.535	rs1434022	chr8:26153222	G/A	cg13160058	chr8:26243215	BNIP3L	-0.34	-7.45	-0.34	5.21e-13	Height;
LUAD	trans	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg21659725	chr3:3221576	CRBN	-0.59	-9.5	-0.42	1.61e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg11965913	chr1:205819406	PM20D1	0.64	11.83	0.5	4.16e-28	Menarche (age at onset);
LUAD	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.15	-0.37	4.24e-15	Cannabis dependence symptom count;
LUAD	cis	rs62400317	0.859	rs55779653	chr6:45265960	C/T	cg18551225	chr6:44695536	NA	-0.53	-8.36	-0.38	9.31e-16	Total body bone mineral density;
LUAD	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg26343298	chr8:95960752	TP53INP1	0.33	6.8	0.31	3.53e-11	Type 2 diabetes;
LUAD	cis	rs7590720	1.000	rs6435930	chr2:216885852	A/G	cg12620499	chr2:216877984	MREG	0.52	8.25	0.37	1.97e-15	Alcohol dependence;
LUAD	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg22244940	chr12:132335942	MMP17	0.43	7.03	0.32	8.28e-12	Migraine;
LUAD	cis	rs1374313	0.586	rs13019918	chr2:120090165	C/T	cg23562675	chr2:120107745	C2orf76	-0.38	-6.62	-0.31	1.08e-10	Obesity-related traits;
LUAD	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg24578937	chr1:2090814	PRKCZ	-0.57	-10.94	-0.47	1.09e-24	Height;
LUAD	cis	rs137699	1.000	rs760742	chr22:39755190	G/T	cg11247378	chr22:39784982	NA	-0.51	-8.6	-0.39	1.52e-16	IgG glycosylation;
LUAD	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg07538946	chr5:131705188	SLC22A5	0.53	8.75	0.39	5.02e-17	Breast cancer;Mosquito bite size;
LUAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.19	0.54	1.6e-33	Prudent dietary pattern;
LUAD	cis	rs6545883	0.929	rs3732170	chr2:61749716	C/T	cg15711740	chr2:61764176	XPO1	-0.4	-6.38	-0.3	4.71e-10	Tuberculosis;
LUAD	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg10591111	chr5:226296	SDHA	-0.55	-7.23	-0.33	2.23e-12	Breast cancer;
LUAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03517284	chr6:25882590	NA	0.5	7.54	0.34	2.93e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg00074818	chr8:8560427	CLDN23	0.64	9.87	0.43	8.16e-21	Obesity-related traits;
LUAD	cis	rs11771526	0.901	rs62457494	chr7:32312299	T/G	cg27532318	chr7:32358331	NA	0.6	7.78	0.35	5.59e-14	Body mass index;
LUAD	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg12310025	chr6:25882481	NA	-0.5	-7.3	-0.33	1.47e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg02176678	chr2:219576539	TTLL4	0.61	11.75	0.5	8.57e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg05304507	chr6:116381966	FRK	0.2	6.79	0.31	3.89e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg25358565	chr5:93447407	FAM172A	0.58	6.88	0.32	2.19e-11	Diabetic retinopathy;
LUAD	cis	rs2692947	0.526	rs4907225	chr2:96576670	C/T	cg23100626	chr2:96804247	ASTL	0.32	7.76	0.35	6.24e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.66	-8.23	-0.37	2.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1595825	0.838	rs73058854	chr2:198885060	G/A	cg00361562	chr2:198649771	BOLL	-0.49	-6.83	-0.32	2.94e-11	Ulcerative colitis;
LUAD	cis	rs17433780	0.857	rs12144445	chr1:89465238	C/T	cg09516651	chr1:89888402	LOC400759	0.49	8.73	0.39	5.88e-17	Carotid intima media thickness;
LUAD	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.81	0.35	4.6e-14	Parkinson's disease;
LUAD	cis	rs7474896	0.537	rs1208587	chr10:38207759	A/G	cg25427524	chr10:38739819	LOC399744	0.6	8.68	0.39	8.52e-17	Obesity (extreme);
LUAD	trans	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg07393940	chr7:158741817	NA	-0.37	-6.37	-0.3	4.8e-10	Life satisfaction;
LUAD	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg19418458	chr7:158789849	NA	0.56	10.09	0.44	1.35e-21	Facial morphology (factor 20);
LUAD	cis	rs73086581	0.838	rs41398349	chr20:4024439	C/T	cg02187196	chr20:3869020	PANK2	-0.44	-6.35	-0.3	5.45e-10	Response to antidepressants in depression;
LUAD	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.92	-0.36	2.16e-14	Total body bone mineral density;
LUAD	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg15704280	chr7:45808275	SEPT13	-0.61	-9.26	-0.41	1.06e-18	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg06641503	chr3:48959341	ARIH2	-0.41	-8.09	-0.37	6.19e-15	Parkinson's disease;
LUAD	cis	rs3087591	0.960	rs12942479	chr17:29461912	T/A	cg24425628	chr17:29625626	OMG;NF1	0.42	6.73	0.31	5.54e-11	Hip circumference;
LUAD	cis	rs9522267	0.535	rs7339347	chr13:112237920	C/T	cg10483660	chr13:112241077	NA	-0.33	-7.03	-0.32	8.26e-12	Hepatitis;
LUAD	trans	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.2	-0.33	2.83e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg04282206	chr17:62833786	PLEKHM1P	-0.55	-8.14	-0.37	4.43e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg09117114	chr16:67998030	SLC12A4	-0.54	-7.12	-0.33	4.7e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg07936489	chr17:37558343	FBXL20	-0.54	-7.17	-0.33	3.28e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.78	14.33	0.57	2.99e-38	Lymphocyte counts;
LUAD	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11165623	0.792	rs13375510	chr1:96920723	A/G	cg10631902	chr5:14652156	NA	-0.61	-11.87	-0.5	2.99e-28	Hip circumference;Waist circumference;
LUAD	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg27147174	chr7:100797783	AP1S1	0.68	12.05	0.51	5.96e-29	Life satisfaction;
LUAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg22442454	chr1:209979470	IRF6	0.5	7.26	0.33	1.89e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.56	6.67	0.31	7.8e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10489202	0.683	rs4657730	chr1:168072738	A/T	cg25738037	chr1:168025549	DCAF6	-0.46	-6.62	-0.31	1.06e-10	Schizophrenia;
LUAD	cis	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg07460842	chr6:66804631	NA	-1.02	-16.08	-0.62	9.29e-46	Exhaled nitric oxide output;
LUAD	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg24733560	chr20:60626293	TAF4	0.41	8.16	0.37	3.96e-15	Body mass index;
LUAD	cis	rs2425143	1.000	rs6058325	chr20:34388806	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.01	-0.32	9.69e-12	Blood protein levels;
LUAD	cis	rs12137527	1	rs12137527	chr1:10315297	G/A	cg17425144	chr1:10567563	PEX14	-0.52	-7.02	-0.32	8.99e-12	Tonsillectomy;
LUAD	cis	rs17067123	0.614	rs11723608	chr4:180077492	A/C	cg26610307	chr4:180072759	NA	-0.5	-6.51	-0.3	2.17e-10	Response to hepatitis C treatment;
LUAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg14159672	chr1:205819179	PM20D1	0.46	7.37	0.34	9.22e-13	Parkinson's disease;
LUAD	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg03714773	chr7:91764589	CYP51A1	0.28	6.57	0.3	1.48e-10	Breast cancer;
LUAD	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-15.58	-0.6	1.45e-43	Schizophrenia;
LUAD	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg10518543	chr12:38710700	ALG10B	0.42	6.45	0.3	2.97e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.86e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2057149	0.633	rs7748253	chr6:110701451	C/T	cg01119278	chr6:110721349	DDO	0.37	6.47	0.3	2.76e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg16049864	chr8:95962084	TP53INP1	-0.39	-7.03	-0.32	8.26e-12	Type 2 diabetes;
LUAD	cis	rs3540	0.960	rs12440447	chr15:91022694	C/G	cg10434728	chr15:90938212	IQGAP1	0.37	6.76	0.31	4.55e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg26384229	chr12:38710491	ALG10B	0.48	7.68	0.35	1.08e-13	Morning vs. evening chronotype;
LUAD	cis	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-7.41	-0.34	7.03e-13	Neuroticism;
LUAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-10.75	-0.46	5.49e-24	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs877282	0.945	rs35342920	chr10:790484	T/C	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg04414720	chr1:150670196	GOLPH3L	0.72	13.36	0.54	3.28e-34	Tonsillectomy;
LUAD	trans	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg01620082	chr3:125678407	NA	-0.71	-7.22	-0.33	2.44e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs13315871	0.929	rs7635697	chr3:58313706	G/A	cg12435725	chr3:58293450	RPP14	-0.71	-7.59	-0.35	2.05e-13	Cholesterol, total;
LUAD	trans	rs75804782	0.641	rs11885523	chr2:239344263	G/A	cg01134436	chr17:81009848	B3GNTL1	0.74	8.18	0.37	3.29e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg14784868	chr12:69753453	YEATS4	0.45	7.35	0.34	1.06e-12	Blood protein levels;
LUAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg22963979	chr7:1858916	MAD1L1	-0.59	-10.14	-0.44	9.03e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.06	23.73	0.76	9.46e-80	Chronic sinus infection;
LUAD	cis	rs727505	0.520	rs1454125	chr7:124862733	C/T	cg23710748	chr7:124431027	NA	-0.37	-7.4	-0.34	7.64e-13	Lewy body disease;
LUAD	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg10518543	chr12:38710700	ALG10B	-0.43	-7.01	-0.32	9.31e-12	Heart rate;
LUAD	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg00717180	chr2:96193071	NA	-0.4	-7.53	-0.34	2.99e-13	Height;
LUAD	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg14019146	chr3:50243930	SLC38A3	-0.42	-6.78	-0.31	4.09e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs870825	0.616	rs4623060	chr4:185642943	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.7	0.55	1.26e-35	Blood protein levels;
LUAD	cis	rs7771547	0.519	rs12202691	chr6:36377820	G/A	cg04289385	chr6:36355825	ETV7	0.49	7.31	0.34	1.32e-12	Platelet distribution width;
LUAD	cis	rs7843479	0.965	rs17616085	chr8:21857267	C/T	cg03445287	chr8:21823731	XPO7	-0.43	-7.89	-0.36	2.52e-14	Mean corpuscular volume;
LUAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg06263672	chr7:65235340	NA	-0.48	-7.73	-0.35	7.67e-14	Calcium levels;
LUAD	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.81	0.39	3.21e-17	Menopause (age at onset);
LUAD	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg16479474	chr6:28041457	NA	0.43	7.38	0.34	8.39e-13	Depression;
LUAD	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg17724175	chr1:150552817	MCL1	0.37	8.51	0.38	2.95e-16	Melanoma;
LUAD	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.34	0.38	1.06e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-12.07	-0.51	5.07e-29	Bipolar disorder;
LUAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14159672	chr1:205819179	PM20D1	0.8	16.1	0.62	8.16e-46	Menarche (age at onset);
LUAD	cis	rs4077515	0.901	rs11791262	chr9:139271919	C/T	cg14019695	chr9:139328340	INPP5E	0.42	7.9	0.36	2.47e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-7.52	-0.34	3.36e-13	Tonsillectomy;
LUAD	cis	rs7107174	1.000	rs2511168	chr11:77965081	T/G	cg02023728	chr11:77925099	USP35	0.5	7.56	0.35	2.46e-13	Testicular germ cell tumor;
LUAD	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06544989	chr22:39130855	UNC84B	-0.41	-8.27	-0.37	1.73e-15	Menopause (age at onset);
LUAD	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg16850897	chr7:100343110	ZAN	0.42	7.45	0.34	5.22e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs2282300	0.739	rs2225909	chr11:30329744	T/C	cg25418670	chr11:30344373	C11orf46	0.53	7.21	0.33	2.62e-12	Morning vs. evening chronotype;
LUAD	cis	rs6005807	0.719	rs9625438	chr22:28637606	G/T	cg12565055	chr22:29076175	TTC28	0.66	6.58	0.3	1.41e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs13064411	0.696	rs6798938	chr3:113218206	C/T	cg18753928	chr3:113234510	CCDC52	-0.72	-12.38	-0.52	3.04e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg03609598	chr5:56110824	MAP3K1	0.48	7.08	0.33	6.11e-12	Initial pursuit acceleration;
LUAD	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg11317459	chr13:21872234	NA	1.16	15.76	0.61	2.37e-44	White matter hyperintensity burden;
LUAD	cis	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg07460842	chr6:66804631	NA	0.62	9.77	0.43	1.8899999999999998e-20	Type 2 diabetes;
LUAD	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg21709803	chr11:61594965	FADS2	-0.4	-7.13	-0.33	4.33e-12	Trans fatty acid levels;
LUAD	trans	rs783540	0.867	rs11855735	chr15:83296545	A/T	cg18393722	chr15:85113863	UBE2QP1	0.41	6.71	0.31	6.16e-11	Schizophrenia;
LUAD	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg18806716	chr10:30721971	MAP3K8	-0.79	-16.97	-0.64	1.27e-49	Inflammatory bowel disease;
LUAD	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	7.45	0.34	5.45e-13	Parkinson's disease;
LUAD	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg23625390	chr15:77176239	SCAPER	0.37	6.4	0.3	4.25e-10	Blood metabolite levels;
LUAD	cis	rs11811982	1.000	rs11811982	chr1:227581520	C/A	cg24860534	chr1:227506868	CDC42BPA	0.72	7.58	0.35	2.18e-13	Optic disc area;
LUAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg09365446	chr1:150670422	GOLPH3L	0.62	11.16	0.48	1.57e-25	Melanoma;
LUAD	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg08470875	chr2:26401718	FAM59B	-0.57	-7.84	-0.36	3.81e-14	Gut microbiome composition (summer);
LUAD	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.02	0.32	8.93e-12	Motion sickness;
LUAD	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg19442545	chr10:75533431	FUT11	-0.48	-7.89	-0.36	2.63e-14	Inflammatory bowel disease;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg20295040	chr1:192778396	RGS2	-0.39	-6.54	-0.3	1.8e-10	Subcortical brain region volumes;
LUAD	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg24768116	chr2:27665128	KRTCAP3	0.38	10.3	0.45	2.4e-22	Total body bone mineral density;
LUAD	cis	rs1865721	0.958	rs57073257	chr18:73172316	A/G	cg26385618	chr18:73139727	C18orf62	-0.42	-7.56	-0.35	2.52e-13	Intelligence;
LUAD	cis	rs10992471	0.603	rs1980848	chr9:95248571	A/G	cg14631576	chr9:95140430	CENPP	0.55	11.43	0.49	1.54e-26	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg14668632	chr7:2872130	GNA12	-0.75	-13.53	-0.55	6.27e-35	Height;
LUAD	cis	rs921968	0.613	rs1344642	chr2:219555262	G/A	cg02176678	chr2:219576539	TTLL4	-0.6	-12.2	-0.51	1.55e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs11118844	0.793	rs17010720	chr1:221946403	A/G	cg04222084	chr1:221915650	DUSP10	-0.65	-7.48	-0.34	4.35e-13	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	cis	rs6906287	0.609	rs13191610	chr6:118945317	G/A	cg21191810	chr6:118973309	C6orf204	0.5	9.55	0.42	1.08e-19	Electrocardiographic conduction measures;
LUAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.91	-0.4	1.58e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs11958404	0.789	rs72800604	chr5:157502940	C/T	cg05962755	chr5:157440814	NA	0.61	8.43	0.38	5.42e-16	IgG glycosylation;
LUAD	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg12310025	chr6:25882481	NA	-0.58	-9.55	-0.42	1.1e-19	Blood metabolite levels;
LUAD	cis	rs1215050	1.000	rs1215050	chr4:98849826	A/G	cg17366294	chr4:99064904	C4orf37	-0.44	-7.43	-0.34	6.2e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs977987	0.806	rs11860284	chr16:75412907	A/G	cg03315344	chr16:75512273	CHST6	0.65	14.35	0.57	2.38e-38	Dupuytren's disease;
LUAD	cis	rs2880765	0.743	rs16940052	chr15:86006674	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.46	-0.3	2.8e-10	Coronary artery disease;
LUAD	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg10802521	chr3:52805072	NEK4	-0.47	-7.97	-0.36	1.47e-14	Bipolar disorder;
LUAD	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg08601574	chr20:25228251	PYGB	0.47	8.77	0.39	4.54e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg17849569	chr6:28058911	ZSCAN12L1	0.42	7.52	0.34	3.22e-13	Lung cancer in ever smokers;
LUAD	trans	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg06606381	chr12:133084897	FBRSL1	-0.68	-7.1	-0.33	5.24e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg26384229	chr12:38710491	ALG10B	0.49	7.9	0.36	2.47e-14	Morning vs. evening chronotype;
LUAD	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.78	-0.31	4.09e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs3087591	1.000	rs7406983	chr17:29703374	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.4	-6.58	-0.3	1.41e-10	Hip circumference;
LUAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg00080972	chr5:178986291	RUFY1	-0.61	-11.25	-0.48	7.47e-26	Lung cancer;
LUAD	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg18230493	chr5:56204884	C5orf35	-0.84	-12.35	-0.51	4.02e-30	Initial pursuit acceleration;
LUAD	cis	rs11771526	0.892	rs62457534	chr7:32357652	G/A	cg27532318	chr7:32358331	NA	0.72	8.28	0.37	1.66e-15	Body mass index;
LUAD	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg13319975	chr6:146136371	FBXO30	-0.57	-9.47	-0.42	2.01e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg02734326	chr4:10020555	SLC2A9	-0.42	-7.33	-0.34	1.17e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg19875535	chr5:140030758	IK	0.43	7.41	0.34	6.79e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg18252515	chr7:66147081	NA	-0.6	-6.54	-0.3	1.77e-10	Diabetic kidney disease;
LUAD	cis	rs6543140	0.890	rs61122764	chr2:102999520	A/G	cg03938978	chr2:103052716	IL18RAP	0.35	6.83	0.32	2.99e-11	Blood protein levels;
LUAD	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.08e-11	Depression;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04100724	chr12:92539208	BTG1	-0.42	-6.66	-0.31	8.63e-11	Height;
LUAD	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg06618935	chr21:46677482	NA	-0.51	-10.01	-0.44	2.7e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg06618935	chr21:46677482	NA	0.5	10.06	0.44	1.68e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2625529	0.586	rs7175197	chr15:72461648	G/A	cg16672083	chr15:72433130	SENP8	0.64	12.08	0.51	4.49e-29	Red blood cell count;
LUAD	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg18512352	chr11:47633146	NA	-0.57	-10.26	-0.45	3.42e-22	Subjective well-being;
LUAD	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.56	-0.38	2.16e-16	Total body bone mineral density;
LUAD	cis	rs7786877	0.583	rs41303510	chr7:100226129	C/T	cg20848291	chr7:100343083	ZAN	-0.6	-7.85	-0.36	3.52e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs16866061	1.000	rs72974222	chr2:225424143	C/T	cg12698349	chr2:225449008	CUL3	0.77	13.5	0.55	8.79e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs62238980	0.614	rs79022443	chr22:32456717	T/C	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs6063312	1.000	rs11699576	chr20:47349878	A/C	cg18078177	chr20:47281410	PREX1	0.62	8.0	0.36	1.22e-14	Tonometry;
LUAD	cis	rs6489882	0.607	rs4767033	chr12:113364382	T/A	cg20102336	chr12:113376681	OAS3	-0.6	-9.28	-0.41	8.88e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.14	-0.41	2.55e-18	Life satisfaction;
LUAD	trans	rs1941687	0.505	rs12605642	chr18:31313965	G/T	cg27147174	chr7:100797783	AP1S1	-0.58	-10.01	-0.44	2.54e-21	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.78	-0.31	3.96e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4073416	0.508	rs10152007	chr14:66047434	A/T	cg10998611	chr14:65879393	FUT8;LOC645431	-0.43	-6.46	-0.3	2.93e-10	N-glycan levels;
LUAD	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	trans	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04565464	chr8:145669602	NFKBIL2	0.48	7.19	0.33	3.03e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg13319975	chr6:146136371	FBXO30	-0.55	-9.22	-0.41	1.37e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg06618935	chr21:46677482	NA	-0.51	-10.02	-0.44	2.32e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg05621596	chr22:47072043	GRAMD4	-0.66	-10.91	-0.47	1.38e-24	Urate levels in obese individuals;
LUAD	cis	rs3916	1.000	rs2014355	chr12:121175524	A/G	cg27246729	chr12:121163418	ACADS	0.48	7.7	0.35	9.7e-14	Urinary metabolites (H-NMR features);
LUAD	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg01689657	chr7:91764605	CYP51A1	-0.36	-8.9	-0.4	1.59e-17	Breast cancer;
LUAD	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.9	-0.36	2.47e-14	Diabetic kidney disease;
LUAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.43	-0.34	5.87e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg02891314	chr5:179741120	GFPT2	-0.75	-12.62	-0.52	3.31e-31	Height;
LUAD	cis	rs418053	0.648	rs204232	chr6:13659079	T/G	cg02206980	chr6:13574034	SIRT5	-0.35	-7.53	-0.34	3.17e-13	Breast cancer;
LUAD	cis	rs77741769	0.571	rs4454799	chr12:121317075	A/C	cg02419362	chr12:121203948	SPPL3	-0.4	-8.31	-0.37	1.31e-15	Mean corpuscular volume;
LUAD	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	7.34	0.34	1.12e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg17105886	chr17:28927953	LRRC37B2	0.75	7.11	0.33	4.94e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg19318889	chr4:1322082	MAEA	0.43	7.6	0.35	1.92e-13	Obesity-related traits;
LUAD	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg04398451	chr17:18023971	MYO15A	-0.77	-14.03	-0.56	5.58e-37	Total body bone mineral density;
LUAD	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg10556349	chr10:835070	NA	0.6	7.63	0.35	1.55e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.29	0.41	8.04e-19	Alzheimer's disease;
LUAD	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.06	24.46	0.77	5.62e-83	Chronic sinus infection;
LUAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg13047869	chr3:10149882	C3orf24	0.52	7.85	0.36	3.47e-14	Alzheimer's disease;
LUAD	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg11833968	chr6:79620685	NA	-0.42	-8.07	-0.37	7.23e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg03467027	chr4:99064603	C4orf37	0.39	6.35	0.3	5.5e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6138458	0.816	rs2151463	chr20:24911819	A/C	cg26195577	chr20:24973756	C20orf3	0.96	16.32	0.62	8.79e-47	Blood protein levels;
LUAD	trans	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.78	-0.46	4.08e-24	Obesity-related traits;
LUAD	cis	rs59698941	0.943	rs67860107	chr5:132276825	G/C	cg14825688	chr5:132208181	LEAP2	-0.5	-6.94	-0.32	1.45e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg13390004	chr1:15929781	NA	0.47	8.33	0.38	1.16e-15	Systolic blood pressure;
LUAD	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06022373	chr22:39101656	GTPBP1	0.46	7.13	0.33	4.42e-12	Menopause (age at onset);
LUAD	cis	rs999737	0.853	rs71423318	chr14:69005887	G/A	cg04147497	chr14:69052728	RAD51L1	-0.46	-7.11	-0.33	4.99e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg14092988	chr3:52407081	DNAH1	0.32	6.61	0.31	1.17e-10	Cognitive function;
LUAD	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg23018236	chr17:30244563	NA	-0.69	-8.3	-0.37	1.46e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-8.7	-0.39	7.21e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg27411982	chr8:10470053	RP1L1	-0.4	-7.52	-0.34	3.25e-13	Neuroticism;
LUAD	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.42	-7.15	-0.33	3.95e-12	Multiple sclerosis;
LUAD	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg15133208	chr4:90757351	SNCA	0.48	7.0	0.32	1.04e-11	Neuroticism;
LUAD	trans	rs4650994	0.816	rs2811303	chr1:178595646	G/T	cg05059571	chr16:84539110	KIAA1609	0.5	8.22	0.37	2.46e-15	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg14019146	chr3:50243930	SLC38A3	-0.41	-6.72	-0.31	5.8e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg14917512	chr19:3094685	GNA11	-0.55	-6.42	-0.3	3.74e-10	Diabetic kidney disease;
LUAD	cis	rs1873147	0.569	rs59418037	chr15:63310871	A/G	cg12160578	chr15:63334699	TPM1	0.52	7.91	0.36	2.24e-14	Orofacial clefts;
LUAD	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg14092988	chr3:52407081	DNAH1	0.37	7.47	0.34	4.74e-13	Bipolar disorder;
LUAD	cis	rs7937890	0.559	rs1548074	chr11:14534825	A/G	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.12e-10	Mitochondrial DNA levels;
LUAD	cis	rs2806561	0.754	rs750354	chr1:23297406	T/C	cg19743168	chr1:23544995	NA	-0.35	-6.4	-0.3	4.04e-10	Height;
LUAD	cis	rs4006360	0.628	rs34859541	chr17:39226322	C/T	cg20663846	chr17:39254439	KRTAP4-8	0.38	8.64	0.39	1.12e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg23245007	chr3:195682326	NA	-0.39	-6.36	-0.3	5.36e-10	Pancreatic cancer;
LUAD	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg05926928	chr17:57297772	GDPD1	1.39	17.2	0.64	1.21e-50	Opioid sensitivity;
LUAD	cis	rs11958404	0.789	rs78112793	chr5:157428226	A/G	cg05962755	chr5:157440814	NA	0.61	8.66	0.39	1.02e-16	IgG glycosylation;
LUAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg18621852	chr3:10150065	C3orf24	0.42	7.46	0.34	5.08e-13	Alzheimer's disease;
LUAD	cis	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg05084668	chr3:125655381	ALG1L	-0.58	-9.38	-0.41	4.05e-19	Blood pressure (smoking interaction);
LUAD	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg17757837	chr7:157058334	UBE3C	0.48	8.47	0.38	4.2e-16	Body mass index;
LUAD	cis	rs58804349	0.605	rs117540287	chr10:43512040	G/T	cg08461752	chr10:43522343	NA	-0.82	-9.42	-0.42	2.88e-19	Pediatric bone mineral content (radius);
LUAD	cis	rs9560113	1.000	rs4773386	chr13:112180896	C/G	cg14154082	chr13:112174009	NA	0.36	6.64	0.31	9.5e-11	Menarche (age at onset);
LUAD	cis	rs367943	0.608	rs4705563	chr5:112979539	T/C	cg12552261	chr5:112820674	MCC	0.43	7.95	0.36	1.66e-14	Type 2 diabetes;
LUAD	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.55	-0.3	1.72e-10	Aortic root size;
LUAD	cis	rs7100689	0.646	rs7077712	chr10:82134894	A/G	cg00277334	chr10:82204260	NA	-0.63	-10.54	-0.46	3.26e-23	Post bronchodilator FEV1;
LUAD	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-10.86	-0.47	2.07e-24	Chronic sinus infection;
LUAD	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	10.43	0.45	8.24e-23	Ileal carcinoids;
LUAD	cis	rs911186	0.812	rs35454259	chr6:27254475	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-6.53	-0.3	1.88e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg26343298	chr8:95960752	TP53INP1	0.37	7.82	0.36	4.12e-14	Type 2 diabetes;
LUAD	cis	rs887829	0.694	rs6749496	chr2:234624286	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-10.99	-0.47	6.71e-25	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs7177699	0.567	rs67745769	chr15:79124832	G/A	cg00540400	chr15:79124168	NA	-0.47	-10.02	-0.44	2.39e-21	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs367943	0.712	rs10053654	chr5:112724314	G/C	cg12552261	chr5:112820674	MCC	0.48	9.32	0.41	6.2800000000000005e-19	Type 2 diabetes;
LUAD	cis	rs1232027	0.656	rs836804	chr5:79976446	C/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.42	-6.52	-0.3	1.97e-10	Huntington's disease progression;
LUAD	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg20503657	chr10:835505	NA	0.91	13.25	0.54	9.27e-34	Eosinophil percentage of granulocytes;
LUAD	cis	rs59698941	0.943	rs17691542	chr5:132279227	T/C	cg14825688	chr5:132208181	LEAP2	-0.48	-6.48	-0.3	2.55e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg02423579	chr7:2872169	GNA12	-0.55	-9.29	-0.41	8.04e-19	Height;
LUAD	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23158103	chr7:148848205	ZNF398	-0.63	-11.47	-0.49	1.06e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg08755490	chr11:65554678	OVOL1	0.4	6.43	0.3	3.42e-10	Acne (severe);
LUAD	cis	rs4900538	0.963	rs2273905	chr14:102974999	T/C	cg18135206	chr14:102964638	TECPR2	1.05	23.31	0.75	6.54e-78	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg04352962	chr1:209979756	IRF6	0.6	11.16	0.48	1.53e-25	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUAD	trans	rs11039798	0.920	rs12292685	chr11:48571032	G/T	cg03929089	chr4:120376271	NA	0.55	6.36	0.3	5.18e-10	Axial length;
LUAD	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg17971929	chr21:40555470	PSMG1	0.48	6.96	0.32	1.29e-11	Cognitive function;
LUAD	cis	rs9650657	0.711	rs7007318	chr8:10592278	C/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.45	-0.3	2.98e-10	Neuroticism;
LUAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg03188948	chr7:1209495	NA	0.39	6.45	0.3	3.09e-10	Longevity;Endometriosis;
LUAD	cis	rs11828289	0.599	rs75341566	chr11:23186941	C/A	cg20040320	chr11:23191996	NA	-0.7	-8.11	-0.37	5.7e-15	Cancer;
LUAD	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg19418458	chr7:158789849	NA	-0.58	-10.2	-0.44	5.42e-22	Facial morphology (factor 20);
LUAD	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg22029157	chr1:209979665	IRF6	-0.73	-9.03	-0.4	6.02e-18	Coronary artery disease;
LUAD	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg21798802	chr22:38057573	PDXP	0.49	9.92	0.43	5.62e-21	Fat distribution (HIV);
LUAD	cis	rs6541297	0.703	rs621328	chr1:230310414	G/A	cg20703242	chr1:230279135	GALNT2	-0.48	-6.92	-0.32	1.7e-11	Coronary artery disease;
LUAD	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg05717871	chr11:638507	DRD4	-0.46	-6.62	-0.31	1.09e-10	Systemic lupus erythematosus;
LUAD	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg12863693	chr15:85201151	NMB	-0.38	-6.73	-0.31	5.45e-11	Schizophrenia;
LUAD	cis	rs943466	0.955	rs1887340	chr6:33730095	C/T	cg16010596	chr6:33739607	LEMD2	-0.36	-6.67	-0.31	7.87e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg17031739	chr1:67600172	NA	0.43	7.71	0.35	9.36e-14	Psoriasis;
LUAD	cis	rs9658691	0.607	rs3740281	chr10:90772150	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-7.34	-0.34	1.08e-12	Mosquito bite size;
LUAD	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.21	0.33	2.66e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4664304	1.000	rs57771571	chr2:160767804	G/C	cg23995753	chr2:160760732	LY75	-0.49	-8.77	-0.39	4.53e-17	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg04287289	chr16:89883240	FANCA	0.71	13.11	0.54	3.37e-33	Vitiligo;
LUAD	cis	rs1957429	0.901	rs1957435	chr14:65349697	G/A	cg23373153	chr14:65346875	NA	0.55	6.45	0.3	2.99e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06112835	chr11:68658793	MRPL21	0.53	9.6	0.42	7.18e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.46	-0.34	4.9e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6494488	0.500	rs80142506	chr15:64995147	G/C	cg08069370	chr15:64387884	SNX1	-0.76	-6.84	-0.32	2.71e-11	Coronary artery disease;
LUAD	cis	rs12900413	0.687	rs10152954	chr15:90307442	T/C	cg24249390	chr15:90295951	MESP1	-0.34	-6.66	-0.31	8.62e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg17971929	chr21:40555470	PSMG1	0.49	7.36	0.34	9.77e-13	Cognitive function;
LUAD	cis	rs7000551	0.689	rs12545909	chr8:22310052	A/G	cg12081754	chr8:22256438	SLC39A14	-0.43	-7.1	-0.33	5.24e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg07169764	chr2:136633963	MCM6	0.68	7.92	0.36	2.17e-14	Corneal structure;
LUAD	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11890956	chr21:40555474	PSMG1	0.79	13.92	0.56	1.56e-36	Cognitive function;
LUAD	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.56	0.3	1.55e-10	Depression;
LUAD	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.13	-0.41	2.84e-18	Life satisfaction;
LUAD	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg11887960	chr12:57824829	NA	0.59	7.3	0.33	1.46e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg20542592	chr8:11973495	FAM66D	0.47	7.95	0.36	1.66e-14	Neuroticism;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02590972	chr2:217363392	RPL37A	0.46	6.88	0.32	2.2e-11	Gut microbiome composition (summer);
LUAD	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.39	-0.42	3.69e-19	Dilated cardiomyopathy;
LUAD	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.21	0.37	2.72e-15	Menopause (age at onset);
LUAD	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg19622623	chr12:86230825	RASSF9	-0.54	-9.56	-0.42	9.71e-20	Major depressive disorder;
LUAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg07167872	chr1:205819463	PM20D1	0.49	7.97	0.36	1.45e-14	Parkinson's disease;
LUAD	cis	rs3820068	0.705	rs72645803	chr1:15868232	G/A	cg24675056	chr1:15929824	NA	0.42	6.55	0.3	1.71e-10	Systolic blood pressure;
LUAD	cis	rs9902453	0.845	rs7221516	chr17:28232506	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.14	0.44	9.08e-22	Coffee consumption (cups per day);
LUAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg10729496	chr3:10149963	C3orf24	0.49	7.88	0.36	2.73e-14	Alzheimer's disease;
LUAD	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs2033908	0.620	rs7113256	chr11:12845849	T/C	cg25843174	chr11:12811716	TEAD1	-0.21	-6.36	-0.3	5.22e-10	Sitting height ratio;
LUAD	cis	rs2067615	0.579	rs3910854	chr12:107165669	T/C	cg15890332	chr12:107067104	RFX4	0.39	8.38	0.38	8.03e-16	Heart rate;
LUAD	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	9.86	0.43	8.97e-21	Axial length;
LUAD	cis	rs9902453	0.791	rs2628166	chr17:28113123	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.34	-0.41	5.38e-19	Coffee consumption (cups per day);
LUAD	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg24848339	chr3:12840334	CAND2	0.44	8.68	0.39	8.61e-17	QRS complex (12-leadsum);
LUAD	cis	rs4711336	0.664	rs4713663	chr6:33674197	G/A	cg14003231	chr6:33640908	ITPR3	0.49	9.55	0.42	1.04e-19	Height;
LUAD	cis	rs727505	0.954	rs7789055	chr7:124677543	G/T	cg23710748	chr7:124431027	NA	-0.44	-8.77	-0.39	4.39e-17	Lewy body disease;
LUAD	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg05313129	chr8:58192883	C8orf71	-0.54	-7.07	-0.33	6.42e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg24813613	chr7:1882135	MAD1L1	-0.45	-7.14	-0.33	4.1e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg27170947	chr2:26402098	FAM59B	-0.82	-11.49	-0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	trans	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.71	-9.59	-0.42	7.52e-20	Obesity-related traits;
LUAD	cis	rs1983170	0.736	rs11589162	chr1:91974743	C/G	cg25838465	chr1:92012736	NA	0.53	6.76	0.31	4.56e-11	Eosinophil percentage of white cells;
LUAD	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg15445000	chr17:37608096	MED1	-0.44	-8.31	-0.37	1.36e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1003719	0.762	rs9975361	chr21:38450025	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.54	0.38	2.51e-16	Eye color traits;
LUAD	trans	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.09	-0.47	3.02e-25	Depression;
LUAD	cis	rs2274273	0.744	rs8011808	chr14:55823344	A/T	cg04306507	chr14:55594613	LGALS3	0.41	8.55	0.38	2.25e-16	Protein biomarker;
LUAD	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.38	-0.3	4.78e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg13319975	chr6:146136371	FBXO30	-0.62	-10.69	-0.46	9.36e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.35	0.54	3.74e-34	Prudent dietary pattern;
LUAD	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19524238	chr7:2802976	GNA12	-0.31	-6.39	-0.3	4.37e-10	Height;
LUAD	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.47	-7.39	-0.34	7.86e-13	Tonsillectomy;
LUAD	cis	rs9584850	0.794	rs9630321	chr13:99106979	C/G	cg17380943	chr13:99100506	FARP1	-0.34	-6.53	-0.3	1.94e-10	Neuroticism;
LUAD	cis	rs1403694	0.695	rs1523435	chr3:186436306	G/A	cg12454167	chr3:186435060	KNG1	0.51	10.68	0.46	9.88e-24	Blood protein levels;
LUAD	cis	rs7945718	0.967	rs7931147	chr11:12748884	C/A	cg25843174	chr11:12811716	TEAD1	0.22	6.7	0.31	6.67e-11	Educational attainment (years of education);
LUAD	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg24768116	chr2:27665128	KRTCAP3	0.26	6.46	0.3	2.93e-10	Oral cavity cancer;
LUAD	trans	rs783540	0.967	rs1145172	chr15:83223616	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.69	-0.31	7.13e-11	Schizophrenia;
LUAD	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg12311346	chr5:56204834	C5orf35	-0.43	-7.12	-0.33	4.66e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg08798685	chr6:27730294	NA	-0.42	-6.67	-0.31	8.03e-11	Parkinson's disease;
LUAD	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg03859395	chr2:55845619	SMEK2	0.73	13.55	0.55	5.63e-35	Metabolic syndrome;
LUAD	cis	rs2012796	0.743	rs12435764	chr14:81836866	A/C	cg02996355	chr14:81879375	NA	0.52	7.94	0.36	1.83e-14	Night sleep phenotypes;
LUAD	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.7e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13064411	0.696	rs869342	chr3:113226330	C/T	cg10517650	chr3:113235015	CCDC52	-0.56	-9.68	-0.43	3.73e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg06606381	chr12:133084897	FBRSL1	-0.68	-7.1	-0.33	5.24e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	6.51	0.3	2.11e-10	Electroencephalogram traits;
LUAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg04082016	chr2:20871401	NA	-0.47	-8.8	-0.39	3.52e-17	Abdominal aortic aneurysm;
LUAD	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.35	-6.89	-0.32	2.02e-11	IgG glycosylation;
LUAD	trans	rs931812	0.895	rs4734013	chr8:101908687	A/C	cg20993868	chr7:22813445	NA	0.65	13.69	0.55	1.49e-35	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	trans	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg21659725	chr3:3221576	CRBN	-0.59	-9.59	-0.42	7.51e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs494562	0.892	rs547963	chr6:86118743	T/C	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.53	-6.63	-0.31	1.05e-10	Body mass index;
LUAD	cis	rs13315871	1.000	rs28626602	chr3:58409786	G/C	cg12435725	chr3:58293450	RPP14	-0.69	-7.66	-0.35	1.31e-13	Cholesterol, total;
LUAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg08888203	chr3:10149979	C3orf24	0.62	9.55	0.42	1.03e-19	Alzheimer's disease;
LUAD	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg19875535	chr5:140030758	IK	-0.46	-7.71	-0.35	9.03e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg12927641	chr6:109611667	NA	-0.51	-8.81	-0.39	3.15e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg02931644	chr1:25747376	RHCE	-0.41	-8.44	-0.38	5.1e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg24503407	chr1:205819492	PM20D1	-0.42	-6.54	-0.3	1.82e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	trans	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg01620082	chr3:125678407	NA	-0.69	-7.95	-0.36	1.73e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg04756594	chr16:24857601	SLC5A11	-0.77	-13.43	-0.55	1.64e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg20607798	chr8:58055168	NA	0.48	6.55	0.3	1.68e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg12483005	chr1:23474871	LUZP1	0.54	9.11	0.41	3.3e-18	Height;
LUAD	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg21699342	chr2:239360505	ASB1	-0.55	-10.76	-0.46	4.94e-24	Multiple system atrophy;
LUAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg18402987	chr7:1209562	NA	0.78	9.54	0.42	1.15e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg05623727	chr3:50126028	RBM5	0.3	6.58	0.3	1.41e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg18252515	chr7:66147081	NA	-0.63	-6.96	-0.32	1.34e-11	Diabetic kidney disease;
LUAD	cis	rs2658782	0.724	rs1869914	chr11:93112492	C/G	cg15737290	chr11:93063684	CCDC67	0.47	6.81	0.31	3.27e-11	Pulmonary function decline;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	ch.7.2226368R	chr7:103835598	ORC5L	-0.4	-6.79	-0.31	3.87e-11	Anger;
LUAD	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg08132940	chr7:1081526	C7orf50	-0.57	-6.47	-0.3	2.74e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6546550	0.935	rs6546551	chr2:70073703	C/T	cg02498382	chr2:70120550	SNRNP27	-0.56	-10.66	-0.46	1.14e-23	Prevalent atrial fibrillation;
LUAD	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26314531	chr2:26401878	FAM59B	-0.72	-9.81	-0.43	1.37e-20	Gut microbiome composition (summer);
LUAD	cis	rs7336332	0.517	rs9581842	chr13:27978953	G/C	cg22138327	chr13:27999177	GTF3A	0.86	11.25	0.48	6.97e-26	Weight;
LUAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg12432903	chr7:1882776	MAD1L1	-0.45	-7.42	-0.34	6.48e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg06387496	chr7:2775674	GNA12	-0.41	-6.95	-0.32	1.38e-11	Height;
LUAD	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg25554036	chr4:6271136	WFS1	0.67	13.03	0.54	7.61e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs11051970	0.636	rs2733703	chr12:32561794	C/T	cg24626660	chr12:32551988	NA	0.35	7.47	0.34	4.5e-13	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg27170947	chr2:26402098	FAM59B	0.84	12.42	0.52	1.97e-30	Gut microbiome composition (summer);
LUAD	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg04450456	chr4:17643702	FAM184B	0.43	8.5	0.38	3.4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	8.89	0.4	1.74e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg04756594	chr16:24857601	SLC5A11	0.5	9.9	0.43	6.23e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs6906287	0.647	rs12194555	chr6:118819212	C/A	cg21191810	chr6:118973309	C6orf204	0.47	9.09	0.4	3.91e-18	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.07	0.37	7.6e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs782590	0.902	rs4672052	chr2:55732018	A/C	cg18811423	chr2:55921094	PNPT1	0.48	7.9	0.36	2.47e-14	Metabolic syndrome;
LUAD	cis	rs6693567	0.565	rs4926395	chr1:150405298	T/C	cg15654264	chr1:150340011	RPRD2	0.36	6.49	0.3	2.41e-10	Migraine;
LUAD	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg21427119	chr20:30132790	HM13	-0.44	-7.0	-0.32	1e-11	Monocyte count;
LUAD	cis	rs427394	0.582	rs4701751	chr5:6704137	C/T	cg12316010	chr5:6737918	POLS	0.36	6.85	0.32	2.58e-11	Menopause (age at onset);
LUAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg02136620	chr5:178986620	RUFY1	0.44	6.37	0.3	4.86e-10	Lung cancer;
LUAD	cis	rs11676348	0.774	rs13397673	chr2:219047782	A/G	cg06547715	chr2:218990976	CXCR2	0.28	6.37	0.3	4.85e-10	Ulcerative colitis;
LUAD	cis	rs863345	0.625	rs6663286	chr1:158473725	C/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.45	-0.3	2.98e-10	Pneumococcal bacteremia;
LUAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08219700	chr8:58056026	NA	0.63	8.81	0.39	3.3e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9644630	0.897	rs6984644	chr8:19363425	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.3	-6.94	-0.32	1.49e-11	Oropharynx cancer;
LUAD	cis	rs1595825	1.000	rs73058821	chr2:198864597	A/G	cg00982548	chr2:198649783	BOLL	-0.63	-8.87	-0.4	2.01e-17	Ulcerative colitis;
LUAD	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg22681709	chr2:178499509	PDE11A	-0.45	-7.62	-0.35	1.69e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg04000281	chr11:63949212	NA	-0.29	-6.62	-0.31	1.08e-10	Platelet count;
LUAD	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg04414720	chr1:150670196	GOLPH3L	0.68	12.76	0.53	8.88e-32	Tonsillectomy;
LUAD	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg02574844	chr11:5959923	NA	-0.42	-6.91	-0.32	1.79e-11	DNA methylation (variation);
LUAD	cis	rs4588572	0.643	rs1560196	chr5:77701982	G/C	cg11547950	chr5:77652471	NA	0.78	12.79	0.53	7e-32	Triglycerides;
LUAD	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg09796270	chr17:17721594	SREBF1	-0.41	-8.28	-0.37	1.63e-15	Total body bone mineral density;
LUAD	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-9.05	-0.4	5.08e-18	Total body bone mineral density;
LUAD	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg00074818	chr8:8560427	CLDN23	0.68	10.52	0.46	3.85e-23	Obesity-related traits;
LUAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.63	-10.64	-0.46	1.43e-23	Longevity;Endometriosis;
LUAD	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg10792982	chr14:105748885	BRF1	0.46	9.95	0.44	4.1e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg21475434	chr5:93447410	FAM172A	0.57	7.22	0.33	2.41e-12	Diabetic retinopathy;
LUAD	cis	rs73206853	0.841	rs73206870	chr12:110819953	T/C	cg12870014	chr12:110450643	ANKRD13A	0.61	6.6	0.31	1.27e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs1595825	0.891	rs4491721	chr2:198521407	C/G	cg00982548	chr2:198649783	BOLL	-0.62	-8.83	-0.39	2.89e-17	Ulcerative colitis;
LUAD	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg20701182	chr2:24300061	SF3B14	0.89	13.39	0.55	2.48e-34	Lymphocyte counts;
LUAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg11062466	chr8:58055876	NA	0.8	10.1	0.44	1.27e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg05425664	chr17:57184151	TRIM37	-0.43	-7.72	-0.35	8.67e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs12042107	0.570	rs4146669	chr1:91200191	C/T	cg13456504	chr1:91191583	NA	0.32	6.54	0.3	1.77e-10	Educational attainment;
LUAD	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg27535305	chr1:53392650	SCP2	-0.32	-6.52	-0.3	2.01e-10	Monocyte count;
LUAD	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.65	-9.6	-0.42	6.89e-20	Lymphocyte percentage of white cells;
LUAD	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg20587970	chr11:113659929	NA	-1.41	-20.86	-0.71	5.65e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg18621852	chr3:10150065	C3orf24	0.42	7.38	0.34	8.73e-13	Alzheimer's disease;
LUAD	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.79e-18	Life satisfaction;
LUAD	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg24768116	chr2:27665128	KRTCAP3	0.26	6.39	0.3	4.34e-10	Oral cavity cancer;
LUAD	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg07741184	chr6:167504864	NA	0.39	8.95	0.4	1.15e-17	Primary biliary cholangitis;
LUAD	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg21918786	chr6:109611834	NA	-0.57	-10.67	-0.46	1.05e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg04025307	chr7:1156635	C7orf50	0.78	14.26	0.57	5.7800000000000005e-38	Longevity;Endometriosis;
LUAD	cis	rs9807989	0.811	rs67088699	chr2:102968751	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.05e-10	Asthma;
LUAD	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg15208524	chr1:10270712	KIF1B	0.43	6.49	0.3	2.44e-10	Hepatocellular carcinoma;
LUAD	cis	rs7843479	1.000	rs7843479	chr8:21820813	G/T	cg03445287	chr8:21823731	XPO7	-0.46	-8.43	-0.38	5.33e-16	Mean corpuscular volume;
LUAD	cis	rs62238980	0.614	rs117358438	chr22:32374532	A/G	cg00543991	chr22:32367038	NA	0.91	8.21	0.37	2.8e-15	Childhood ear infection;
LUAD	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg18761221	chr20:60518478	NA	0.38	6.77	0.31	4.25e-11	Body mass index;
LUAD	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg02269571	chr22:50332266	NA	-0.57	-8.93	-0.4	1.32e-17	Schizophrenia;
LUAD	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07343612	chr16:622815	PIGQ	-0.83	-16.89	-0.63	2.8e-49	Height;
LUAD	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg02733842	chr7:1102375	C7orf50	-0.6	-9.24	-0.41	1.26e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs7528419	0.895	rs583104	chr1:109821307	G/T	cg00908766	chr1:109817496	CELSR2	0.64	12.68	0.52	1.89e-31	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUAD	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg27279351	chr12:120934652	DYNLL1	0.43	6.51	0.3	2.13e-10	High light scatter reticulocyte count;
LUAD	trans	rs2944755	0.959	rs2977491	chr8:141574277	A/G	cg08444427	chr17:41987800	NA	0.41	6.4	0.3	4.15e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.61	10.35	0.45	1.55e-22	Cognitive ability;
LUAD	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg17328964	chr8:145687451	CYHR1	-0.55	-9.87	-0.43	8.12e-21	Age at first birth;
LUAD	cis	rs6906287	0.647	rs12215793	chr6:118956857	A/T	cg05564266	chr6:118973597	C6orf204	0.37	7.67	0.35	1.2e-13	Electrocardiographic conduction measures;
LUAD	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg20848291	chr7:100343083	ZAN	-0.6	-7.88	-0.36	2.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1395	0.778	rs11693660	chr2:27468856	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.51	9.07	0.4	4.37e-18	Blood metabolite levels;
LUAD	cis	rs897984	0.542	rs73530203	chr16:31099859	G/A	cg02466173	chr16:30829666	NA	-0.48	-7.85	-0.36	3.5e-14	Dementia with Lewy bodies;
LUAD	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg11494091	chr17:61959527	GH2	-0.69	-16.02	-0.61	1.69e-45	Prudent dietary pattern;
LUAD	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg22117172	chr7:91764530	CYP51A1	-0.34	-7.52	-0.34	3.39e-13	Breast cancer;
LUAD	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg18765753	chr7:1198926	ZFAND2A	0.4	6.94	0.32	1.45e-11	Longevity;Endometriosis;
LUAD	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg23954153	chr1:44402353	ARTN	0.38	6.59	0.31	1.29e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7707921	0.522	rs10070637	chr5:81490608	A/G	cg15871215	chr5:81402204	ATG10	0.65	11.4	0.48	1.94e-26	Breast cancer;
LUAD	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg00701064	chr4:6280414	WFS1	0.66	14.42	0.57	1.27e-38	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg23018236	chr17:30244563	NA	-0.69	-8.47	-0.38	3.96e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs7677751	0.806	rs67432867	chr4:55104454	A/T	cg17187183	chr4:55093834	PDGFRA	0.5	8.52	0.38	2.92e-16	Corneal astigmatism;
LUAD	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg14092571	chr14:90743983	NA	-0.94	-18.36	-0.67	8.44e-56	Gut microbiota (bacterial taxa);
LUAD	cis	rs4888262	0.526	rs4887772	chr16:74537591	C/T	cg01733217	chr16:74700730	RFWD3	0.49	8.19	0.37	3.14e-15	Testicular germ cell tumor;
LUAD	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-12.67	-0.52	2.04e-31	Mean corpuscular volume;
LUAD	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg08999081	chr20:33150536	PIGU	-0.63	-14.12	-0.57	2.25e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg09085632	chr11:111637200	PPP2R1B	0.68	10.3	0.45	2.32e-22	Primary sclerosing cholangitis;
LUAD	cis	rs3789045	1.000	rs3747631	chr1:204587569	G/C	cg17419461	chr1:204415978	PIK3C2B	-0.39	-6.6	-0.31	1.23e-10	Educational attainment (college completion);
LUAD	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9296092	0.560	rs9469505	chr6:33527348	A/G	cg13560919	chr6:33536144	NA	-0.9	-16.72	-0.63	1.49e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg04025307	chr7:1156635	C7orf50	0.6	6.74	0.31	5.18e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg20290983	chr6:43655470	MRPS18A	1.07	26.7	0.79	8.83e-93	IgG glycosylation;
LUAD	trans	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg18335740	chr13:41363409	SLC25A15	0.52	9.08	0.4	4.11e-18	Lewy body disease;
LUAD	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg19318889	chr4:1322082	MAEA	0.44	7.08	0.33	6.2e-12	Obesity-related traits;
LUAD	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.03	-0.32	8.42e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2479724	0.935	rs1887718	chr6:41857691	C/T	cg17623882	chr6:41773611	USP49	-0.65	-12.07	-0.51	5.13e-29	Menarche (age at onset);
LUAD	trans	rs264537	0.565	rs1816957	chr3:76703866	G/T	cg18086592	chr12:13153464	HTR7P;HEBP1	-0.42	-6.48	-0.3	2.48e-10	Periodontitis (PAL4Q3);
LUAD	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg08601574	chr20:25228251	PYGB	-0.44	-8.12	-0.37	5.33e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.52	0.3	1.99e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.39	6.68	0.31	7.42e-11	Multiple sclerosis;
LUAD	cis	rs13315871	1.000	rs71311855	chr3:58320507	A/G	cg20936604	chr3:58311152	NA	-0.72	-7.22	-0.33	2.51e-12	Cholesterol, total;
LUAD	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg05368731	chr17:41323189	NBR1	0.97	20.25	0.7	3.08e-64	Menopause (age at onset);
LUAD	cis	rs76878669	0.561	rs7110944	chr11:66118217	C/T	cg10616300	chr11:66138557	SLC29A2	-0.36	-7.46	-0.34	5.11e-13	Educational attainment (years of education);
LUAD	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg03709012	chr19:19516395	GATAD2A	0.52	6.89	0.32	1.99e-11	Nonalcoholic fatty liver disease;
LUAD	trans	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg02002194	chr4:3960332	NA	-0.28	-6.86	-0.32	2.4e-11	Mood instability;
LUAD	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.8	0.39	3.48e-17	Menopause (age at onset);
LUAD	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg07570687	chr10:102243282	WNT8B	0.46	6.96	0.32	1.28e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg14458575	chr2:238380390	NA	0.73	14.67	0.58	1.11e-39	Prostate cancer;
LUAD	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11890956	chr21:40555474	PSMG1	0.54	9.39	0.42	3.86e-19	Menarche (age at onset);
LUAD	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg18198730	chr1:247681584	NA	0.47	8.0	0.36	1.18e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg22590775	chr19:49891494	CCDC155	0.67	7.48	0.34	4.22e-13	Multiple sclerosis;
LUAD	cis	rs7707921	0.767	rs226196	chr5:81576965	C/A	cg15871215	chr5:81402204	ATG10	0.63	10.13	0.44	9.55e-22	Breast cancer;
LUAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg07234876	chr8:600039	NA	1.06	10.13	0.44	9.73e-22	IgG glycosylation;
LUAD	cis	rs12545109	0.800	rs2576602	chr8:57394495	C/T	cg17761419	chr8:57350749	NA	-0.58	-8.52	-0.38	2.82e-16	Obesity-related traits;
LUAD	cis	rs3820068	0.734	rs6674806	chr1:15902656	A/G	cg13390004	chr1:15929781	NA	0.42	6.75	0.31	4.77e-11	Systolic blood pressure;
LUAD	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg19318889	chr4:1322082	MAEA	0.44	7.0	0.32	1.01e-11	Obesity-related traits;
LUAD	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.54	9.16	0.41	2.27e-18	Electrocardiographic conduction measures;
LUAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg07362569	chr17:61921086	SMARCD2	0.4	6.91	0.32	1.8e-11	Prudent dietary pattern;
LUAD	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg18200150	chr17:30822561	MYO1D	0.42	7.87	0.36	3.04e-14	Schizophrenia;
LUAD	cis	rs6430585	0.646	rs12476116	chr2:136497199	A/G	cg07169764	chr2:136633963	MCM6	0.85	9.89	0.43	6.9299999999999992e-21	Corneal structure;
LUAD	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg15017067	chr4:17643749	FAM184B	0.36	7.03	0.32	8.13e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg12143784	chr7:64541923	NA	0.47	7.76	0.35	6.57e-14	Calcium levels;
LUAD	cis	rs806795	0.513	rs10946808	chr6:26233387	A/G	cg00631329	chr6:26305371	NA	-0.51	-7.97	-0.36	1.5e-14	Mosquito bite size;
LUAD	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11644478	chr21:40555479	PSMG1	0.7	11.66	0.49	1.93e-27	Cognitive function;
LUAD	cis	rs11249608	0.600	rs6859767	chr5:178451107	T/C	cg01312482	chr5:178451176	ZNF879	-0.44	-6.88	-0.32	2.14e-11	Pubertal anthropometrics;
LUAD	cis	rs600550	0.528	rs12805696	chr11:59832571	G/C	cg02771260	chr11:59836817	MS4A3	0.31	6.47	0.3	2.71e-10	Lipoprotein-associated phospholipase A2 activity and mass;
LUAD	cis	rs7795096	1.000	rs7795096	chr7:151546589	A/G	cg07804434	chr7:151527349	PRKAG2	0.36	6.44	0.3	3.3e-10	Bipolar disorder (age of onset and psychotic symptoms);
LUAD	cis	rs2692947	0.537	rs1834135	chr2:96244225	C/A	cg23100626	chr2:96804247	ASTL	0.32	7.9	0.36	2.36e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg15962314	chr1:44399869	ARTN	0.32	7.34	0.34	1.08e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg07507251	chr3:52567010	NT5DC2	0.39	7.65	0.35	1.35e-13	Electroencephalogram traits;
LUAD	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg07828340	chr4:882639	GAK	-0.95	-9.87	-0.43	8.11e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs2992756	0.663	rs1360916	chr1:18801697	G/A	cg14356550	chr1:18808102	KLHDC7A	-0.57	-9.75	-0.43	2.15e-20	Breast cancer;
LUAD	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg03732007	chr1:2071316	PRKCZ	0.35	7.1	0.33	5.19e-12	Height;
LUAD	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg15123519	chr2:136567270	LCT	-0.38	-7.11	-0.33	4.92e-12	Mosquito bite size;
LUAD	cis	rs7617773	0.817	rs34225441	chr3:48308891	T/A	cg11946769	chr3:48343235	NME6	0.43	6.62	0.31	1.09e-10	Coronary artery disease;
LUAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg11494091	chr17:61959527	GH2	0.74	18.42	0.67	4.77e-56	Prudent dietary pattern;
LUAD	cis	rs1215050	0.782	rs6853916	chr4:98653387	C/T	cg05340658	chr4:99064831	C4orf37	-0.43	-7.01	-0.32	9.19e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg18252515	chr7:66147081	NA	0.6	6.68	0.31	7.56e-11	Diabetic kidney disease;
LUAD	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-14.95	-0.59	7.26e-41	Chronic sinus infection;
LUAD	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg09455208	chr3:40491958	NA	0.61	13.57	0.55	4.66e-35	Renal cell carcinoma;
LUAD	cis	rs11098699	0.769	rs13136692	chr4:124229169	G/A	cg09941581	chr4:124220074	SPATA5	0.46	7.31	0.33	1.33e-12	Mosquito bite size;
LUAD	cis	rs7727544	0.647	rs6898270	chr5:131421190	C/T	cg16205897	chr5:131564050	P4HA2	-0.35	-7.63	-0.35	1.6e-13	Blood metabolite levels;
LUAD	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg10755058	chr3:40428713	ENTPD3	0.43	7.82	0.36	4.27e-14	Renal cell carcinoma;
LUAD	cis	rs346785	0.965	rs443970	chr17:74303370	G/A	cg09812376	chr17:74270190	QRICH2	-0.31	-7.14	-0.33	4.08e-12	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.75	-0.31	4.94e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs758324	0.947	rs9327622	chr5:131125080	T/A	cg06307176	chr5:131281290	NA	0.52	8.14	0.37	4.53e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg01689657	chr7:91764605	CYP51A1	-0.29	-6.81	-0.31	3.37e-11	Breast cancer;
LUAD	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg07404485	chr7:94953653	PON1	-0.51	-7.53	-0.34	3.15e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11644478	chr21:40555479	PSMG1	0.61	9.49	0.42	1.74e-19	Cognitive function;
LUAD	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg18209359	chr17:80159595	CCDC57	0.4	6.91	0.32	1.79e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg05342682	chr7:94953680	PON1	-0.58	-10.53	-0.46	3.36e-23	Paraoxonase activity;
LUAD	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg08085267	chr17:45401833	C17orf57	-0.49	-8.08	-0.37	6.63e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-7.4	-0.34	7.4e-13	Daytime sleep phenotypes;
LUAD	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg00495681	chr13:53174319	NA	-0.44	-7.48	-0.34	4.44e-13	Lewy body disease;
LUAD	trans	rs4799710	0.500	rs4799715	chr18:31277004	C/T	cg27147174	chr7:100797783	AP1S1	0.41	6.64	0.31	9.85e-11	Pulmonary function;
LUAD	cis	rs11893307	0.537	rs6731208	chr2:191503225	A/G	cg11845111	chr2:191398756	TMEM194B	-0.45	-6.52	-0.3	1.99e-10	Mean platelet volume;
LUAD	trans	rs75804782	0.630	rs11900807	chr2:239309989	G/A	cg01134436	chr17:81009848	B3GNTL1	0.71	6.58	0.3	1.43e-10	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg27490568	chr2:178487706	NA	0.44	6.97	0.32	1.22e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03228054	chr9:19049082	RRAGA	-0.42	-6.5	-0.3	2.26e-10	Height;
LUAD	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg15369054	chr17:80825471	TBCD	-0.42	-7.12	-0.33	4.66e-12	Breast cancer;
LUAD	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-8.01	-0.36	1.16e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg24768116	chr2:27665128	KRTCAP3	0.3	6.7	0.31	6.6e-11	Blood metabolite levels;
LUAD	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg05234568	chr11:5960015	NA	0.55	10.44	0.45	7.34e-23	DNA methylation (variation);
LUAD	cis	rs17270561	0.609	rs9366627	chr6:25686405	C/T	cg25753631	chr6:25732923	NA	-0.39	-6.94	-0.32	1.48e-11	Iron status biomarkers;
LUAD	cis	rs4372836	0.729	rs10865508	chr2:29053704	G/C	cg09522027	chr2:28974177	PPP1CB	0.67	12.05	0.51	5.93e-29	Body mass index;
LUAD	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26314531	chr2:26401878	FAM59B	-0.72	-9.81	-0.43	1.33e-20	Gut microbiome composition (summer);
LUAD	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.44e-10	Prostate cancer;
LUAD	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg20701182	chr2:24300061	SF3B14	0.64	7.24	0.33	2.19e-12	Lymphocyte percentage of white cells;
LUAD	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg26441486	chr22:50317300	CRELD2	0.44	6.61	0.31	1.15e-10	Schizophrenia;
LUAD	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg17849569	chr6:28058911	ZSCAN12L1	0.3	6.64	0.31	9.55e-11	Parkinson's disease;
LUAD	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.0	22.46	0.74	4.25e-74	Chronic sinus infection;
LUAD	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg18827107	chr12:86230957	RASSF9	-0.53	-9.34	-0.41	5.41e-19	Major depressive disorder;
LUAD	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg26384229	chr12:38710491	ALG10B	0.47	7.79	0.35	5.4e-14	Bladder cancer;
LUAD	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg01528321	chr10:82214614	TSPAN14	0.65	9.92	0.43	5.22e-21	Post bronchodilator FEV1;
LUAD	cis	rs7772486	0.777	rs1546966	chr6:146386018	G/T	cg13319975	chr6:146136371	FBXO30	-0.62	-9.64	-0.42	5.27e-20	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.34	18.32	0.67	1.23e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08677398	chr8:58056175	NA	0.48	6.72	0.31	5.97e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs57590327	0.508	rs13093082	chr3:81949958	C/T	cg07356753	chr3:81810745	GBE1	-0.56	-9.46	-0.42	2.25e-19	Extraversion;
LUAD	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg09263875	chr16:632152	PIGQ	0.81	17.39	0.65	1.66e-51	Height;
LUAD	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg01181863	chr3:195395398	SDHAP2	-0.62	-9.31	-0.41	7.06e-19	Pancreatic cancer;
LUAD	cis	rs11811982	0.793	rs115655458	chr1:227465458	G/A	cg24860534	chr1:227506868	CDC42BPA	0.7	7.57	0.35	2.36e-13	Optic disc area;
LUAD	trans	rs6076960	0.684	rs6054049	chr20:6254909	A/G	cg21095983	chr6:86352623	SYNCRIP	-0.44	-7.09	-0.33	5.8e-12	Smooth-surface caries;
LUAD	cis	rs9394841	0.667	rs9367112	chr6:41769920	T/C	cg17623882	chr6:41773611	USP49	-0.52	-7.34	-0.34	1.1e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg13180566	chr4:1052158	NA	-0.38	-6.52	-0.3	2.07e-10	Recombination rate (females);
LUAD	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg21214613	chr1:16344536	HSPB7	-0.41	-6.88	-0.32	2.21e-11	Dilated cardiomyopathy;
LUAD	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg26022315	chr17:47021804	SNF8	0.41	7.37	0.34	9.33e-13	Type 2 diabetes;
LUAD	trans	rs9914544	0.564	rs8072860	chr17:18807884	T/C	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.69	-0.31	6.95e-11	Educational attainment (years of education);
LUAD	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.6	-0.39	1.54e-16	Alzheimer's disease (late onset);
LUAD	trans	rs1941687	0.765	rs11874521	chr18:31391966	G/A	cg27147174	chr7:100797783	AP1S1	-0.5	-8.26	-0.37	1.93e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	trans	rs10411161	0.702	rs7251929	chr19:52389258	C/T	cg22319618	chr22:45562946	NUP50	-0.64	-9.14	-0.41	2.58e-18	Breast cancer;
LUAD	trans	rs3960554	0.709	rs73138006	chr7:75769990	T/C	cg19862616	chr7:65841803	NCRNA00174	0.86	11.78	0.5	6.49e-28	Eotaxin levels;
LUAD	cis	rs68170813	0.562	rs11770061	chr7:107071310	A/G	cg23024343	chr7:107201750	COG5	0.52	7.2	0.33	2.84e-12	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg26647111	chr11:31128758	NA	-0.46	-7.98	-0.36	1.36e-14	Red blood cell count;
LUAD	cis	rs427394	0.659	rs274695	chr5:6732252	G/C	cg12316010	chr5:6737918	POLS	0.39	7.42	0.34	6.42e-13	Menopause (age at onset);
LUAD	cis	rs11811982	0.793	rs114038031	chr1:227459144	A/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.34	0.34	1.13e-12	Optic disc area;
LUAD	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg13511324	chr14:104056883	C14orf153	0.27	6.56	0.3	1.59e-10	Reticulocyte count;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg00414561	chr15:23034473	NIPA2	0.4	6.54	0.3	1.82e-10	Optic cup area;
LUAD	cis	rs6906287	0.647	rs7766375	chr6:118918269	G/A	cg05564266	chr6:118973597	C6orf204	0.36	7.59	0.35	2.08e-13	Electrocardiographic conduction measures;
LUAD	cis	rs12545109	0.800	rs2576591	chr8:57423606	A/G	cg17761419	chr8:57350749	NA	-0.49	-7.0	-0.32	1.02e-11	Obesity-related traits;
LUAD	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.62	0.35	1.67e-13	Breast cancer;
LUAD	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg10207240	chr12:122356781	WDR66	0.45	7.85	0.36	3.42e-14	Mean corpuscular volume;
LUAD	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg08085267	chr17:45401833	C17orf57	-0.49	-8.13	-0.37	4.88e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7737355	0.947	rs739952	chr5:130796568	A/T	cg06307176	chr5:131281290	NA	-0.49	-7.69	-0.35	1.03e-13	Life satisfaction;
LUAD	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg12573674	chr2:1569213	NA	-0.62	-6.83	-0.32	2.93e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.66	-0.35	1.26e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg14820908	chr5:178986412	RUFY1	-0.61	-10.09	-0.44	1.4e-21	Lung cancer;
LUAD	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4889855	0.556	rs11651818	chr17:78530300	A/G	cg16591659	chr17:78472290	NA	0.43	7.82	0.36	4.39e-14	Fractional excretion of uric acid;
LUAD	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg27539214	chr16:67997921	SLC12A4	-0.69	-8.99	-0.4	8.57e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7107174	1.000	rs2512547	chr11:77960888	T/C	cg19901956	chr11:77921274	USP35	-0.54	-6.96	-0.32	1.34e-11	Testicular germ cell tumor;
LUAD	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.49	0.34	4.18e-13	Cannabis dependence symptom count;
LUAD	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg04082016	chr2:20871401	NA	-0.45	-8.57	-0.38	1.96e-16	Abdominal aortic aneurysm;
LUAD	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.81	0.35	4.68e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.4	-0.45	1.06e-22	Total body bone mineral density;
LUAD	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.68	0.31	7.58e-11	Depression;
LUAD	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg26384229	chr12:38710491	ALG10B	-0.45	-7.59	-0.35	2.04e-13	Bladder cancer;
LUAD	cis	rs4906332	0.966	rs12885786	chr14:103972503	C/T	cg13511324	chr14:104056883	C14orf153	0.26	6.46	0.3	2.85e-10	Coronary artery disease;
LUAD	cis	rs2797160	1.000	rs1739373	chr6:126011509	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.62	0.31	1.08e-10	Endometrial cancer;
LUAD	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.63	-0.42	5.68e-20	Schizophrenia;
LUAD	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg21204522	chr6:27730016	NA	-0.44	-6.96	-0.32	1.34e-11	Parkinson's disease;
LUAD	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg25208724	chr1:156163844	SLC25A44	1.1	20.55	0.71	1.39e-65	Testicular germ cell tumor;
LUAD	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg03806693	chr22:41940476	POLR3H	0.76	10.23	0.45	4.38e-22	Vitiligo;
LUAD	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg18827107	chr12:86230957	RASSF9	-0.7	-13.06	-0.54	5.27e-33	Major depressive disorder;
LUAD	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg01145583	chr6:160211477	TCP1;MRPL18	0.45	6.7	0.31	6.6e-11	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs9296095	1.000	rs5745582	chr6:33546498	C/T	cg07679836	chr6:33548423	BAK1	0.39	6.42	0.3	3.56e-10	Platelet count;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg02562109	chr6:11538014	TMEM170B	-0.66	-6.94	-0.32	1.46e-11	Type 2 diabetes;
LUAD	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg11663144	chr21:46675770	NA	-0.61	-11.61	-0.49	2.94e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg21033440	chr11:65409861	SIPA1	-0.48	-7.4	-0.34	7.33e-13	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg03354898	chr7:1950403	MAD1L1	-0.37	-7.15	-0.33	3.85e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs877282	0.733	rs7092976	chr10:756358	G/A	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg03609598	chr5:56110824	MAP3K1	-0.49	-7.82	-0.36	4.14e-14	Coronary artery disease;
LUAD	cis	rs2279817	0.863	rs28481933	chr1:18026277	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.54	9.01	0.4	6.98e-18	Neuroticism;
LUAD	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg05623727	chr3:50126028	RBM5	-0.31	-6.87	-0.32	2.26e-11	Body mass index;
LUAD	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg17848003	chr1:3704513	LRRC47	0.53	10.68	0.46	1.01e-23	Red cell distribution width;
LUAD	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg25985355	chr7:65971099	NA	0.38	7.0	0.32	9.98e-12	Aortic root size;
LUAD	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg25767906	chr1:53392781	SCP2	-0.36	-6.92	-0.32	1.72e-11	Monocyte count;
LUAD	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg20673091	chr1:2541236	MMEL1	0.4	8.51	0.38	3.1e-16	Ulcerative colitis;
LUAD	cis	rs7809799	0.826	rs61740607	chr7:98884089	G/T	cg12290671	chr7:99195819	NA	-0.79	-6.53	-0.3	1.87e-10	Ulcerative colitis;
LUAD	cis	rs9354308	0.901	rs12197136	chr6:66590953	T/C	cg07460842	chr6:66804631	NA	0.5	7.34	0.34	1.07e-12	Metabolite levels;
LUAD	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg21775007	chr8:11205619	TDH	0.49	8.67	0.39	9.67e-17	Retinal vascular caliber;
LUAD	cis	rs938554	0.657	rs7660895	chr4:9985445	A/G	cg00071950	chr4:10020882	SLC2A9	0.58	9.88	0.43	7.54e-21	Blood metabolite levels;
LUAD	cis	rs8040855	0.644	rs7495437	chr15:85726290	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.43	6.92	0.32	1.73e-11	Bulimia nervosa;
LUAD	cis	rs7187994	0.848	rs35019923	chr16:84782214	A/C	cg07647771	chr16:84786436	USP10	-0.38	-9.66	-0.43	4.36e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg09455208	chr3:40491958	NA	0.66	14.41	0.57	1.42e-38	Renal cell carcinoma;
LUAD	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg01579765	chr21:45077557	HSF2BP	0.57	12.82	0.53	5.29e-32	Mean corpuscular volume;
LUAD	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg26587870	chr6:27730563	NA	-0.38	-6.81	-0.31	3.38e-11	Parkinson's disease;
LUAD	cis	rs17095355	1.000	rs921351	chr10:111704715	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.71	-9.87	-0.43	8.29e-21	Biliary atresia;
LUAD	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg04450456	chr4:17643702	FAM184B	0.42	8.28	0.37	1.58e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19955521	chr10:1102667	WDR37	-0.51	-6.49	-0.3	2.35e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg22907277	chr7:1156413	C7orf50	0.76	11.32	0.48	3.83e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg07402062	chr16:89894098	SPIRE2	0.46	11.68	0.49	1.72e-27	Vitiligo;
LUAD	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg21775007	chr8:11205619	TDH	-0.5	-9.17	-0.41	2.07e-18	Retinal vascular caliber;
LUAD	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg11822812	chr5:140052017	DND1	-0.42	-7.68	-0.35	1.13e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg23625390	chr15:77176239	SCAPER	-0.51	-7.84	-0.36	3.58e-14	Blood metabolite levels;
LUAD	cis	rs2677744	0.626	rs867468	chr15:91498127	G/A	cg23684204	chr15:91497937	RCCD1	0.43	7.16	0.33	3.49e-12	Attention deficit hyperactivity disorder;
LUAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg11416102	chr8:651193	ERICH1	0.94	8.99	0.4	8.51e-18	IgG glycosylation;
LUAD	cis	rs3772130	1.000	rs13083794	chr3:121464928	T/G	cg20356878	chr3:121714668	ILDR1	0.5	7.82	0.36	4.36e-14	Cognitive performance;
LUAD	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg00071950	chr4:10020882	SLC2A9	-0.66	-12.63	-0.52	3.02e-31	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg16950941	chr11:66035639	RAB1B	0.45	7.51	0.34	3.43e-13	Gout;
LUAD	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg21724239	chr8:58056113	NA	0.73	8.87	0.4	2.03e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg17120908	chr11:65337727	SSSCA1	0.59	9.09	0.4	3.89e-18	Bone mineral density;
LUAD	cis	rs727505	1.000	rs28392553	chr7:124442944	C/T	cg23710748	chr7:124431027	NA	-0.44	-9.42	-0.42	2.88e-19	Lewy body disease;
LUAD	cis	rs1816752	1.000	rs9511265	chr13:25012359	T/C	cg02811702	chr13:24901961	NA	0.46	7.71	0.35	9.2e-14	Obesity-related traits;
LUAD	trans	rs2797160	0.967	rs6910786	chr6:126017141	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.94	0.4	1.19e-17	Endometrial cancer;
LUAD	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg21849932	chr20:62369462	LIME1	-0.47	-7.53	-0.34	3.16e-13	Prostate cancer;
LUAD	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg04455712	chr21:45112962	RRP1B	0.48	9.42	0.42	2.95e-19	Mean corpuscular volume;
LUAD	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22496380	chr5:211416	CCDC127	-0.93	-13.12	-0.54	3.15e-33	Breast cancer;
LUAD	cis	rs897984	0.542	rs11864806	chr16:31095204	G/C	cg02466173	chr16:30829666	NA	-0.56	-9.64	-0.42	5.39e-20	Dementia with Lewy bodies;
LUAD	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg18180107	chr4:99064573	C4orf37	0.42	6.79	0.31	3.87e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg03396347	chr1:1875803	NA	-0.61	-15.76	-0.61	2.43e-44	Body mass index;
LUAD	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg13126279	chr21:47581558	C21orf56	-0.49	-8.05	-0.36	8.31e-15	Testicular germ cell tumor;
LUAD	cis	rs9394841	0.667	rs3827633	chr6:41759846	A/C	cg17623882	chr6:41773611	USP49	-0.52	-7.34	-0.34	1.1e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg10755058	chr3:40428713	ENTPD3	0.39	7.03	0.32	8.11e-12	Renal cell carcinoma;
LUAD	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg09904177	chr6:26538194	HMGN4	0.43	7.21	0.33	2.56e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6541297	0.645	rs2103827	chr1:230298285	T/A	cg20703242	chr1:230279135	GALNT2	0.56	8.12	0.37	5.29e-15	Coronary artery disease;
LUAD	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.67	-8.51	-0.38	3.14e-16	Yeast infection;
LUAD	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.43	-0.45	8.17e-23	Monocyte percentage of white cells;
LUAD	cis	rs6906287	0.647	rs11755121	chr6:118828124	G/C	cg18833306	chr6:118973337	C6orf204	0.45	7.99	0.36	1.26e-14	Electrocardiographic conduction measures;
LUAD	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.61	-0.31	1.17e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg04398451	chr17:18023971	MYO15A	-0.63	-11.4	-0.48	2.01e-26	Total body bone mineral density;
LUAD	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg04369109	chr6:150039330	LATS1	0.43	7.31	0.33	1.35e-12	Lung cancer;
LUAD	cis	rs6906287	0.625	rs9320648	chr6:118690014	A/C	cg21191810	chr6:118973309	C6orf204	0.54	10.98	0.47	7.57e-25	Electrocardiographic conduction measures;
LUAD	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10865541	0.902	rs10173635	chr2:3421213	G/A	cg22182287	chr2:3452347	TTC15	0.47	8.17	0.37	3.52e-15	Obesity-related traits;
LUAD	cis	rs10992471	0.605	rs7872375	chr9:95064843	C/G	cg14631576	chr9:95140430	CENPP	-0.41	-8.39	-0.38	7.2e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23583168	chr7:148888333	NA	-0.94	-19.29	-0.68	5.95e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg13856295	chr9:139396418	NOTCH1	0.36	6.44	0.3	3.32e-10	Monocyte percentage of white cells;
LUAD	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg25358565	chr5:93447407	FAM172A	0.61	7.42	0.34	6.56e-13	Diabetic retinopathy;
LUAD	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg02158880	chr13:53174818	NA	0.44	7.6	0.35	1.89e-13	Lewy body disease;
LUAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.54	-8.91	-0.4	1.53e-17	Renal function-related traits (BUN);
LUAD	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg18180107	chr4:99064573	C4orf37	0.42	6.57	0.3	1.48e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.38	-0.42	3.95e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg22963979	chr7:1858916	MAD1L1	-0.6	-9.98	-0.44	3.24e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12756686	chr19:29218302	NA	0.64	8.16	0.37	3.91e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg00495681	chr13:53174319	NA	0.64	12.01	0.5	8.34e-29	Lewy body disease;
LUAD	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg14159672	chr1:205819179	PM20D1	-0.45	-7.13	-0.33	4.27e-12	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs2996428	0.561	rs72640913	chr1:3747023	C/G	cg22529645	chr1:3704559	LRRC47	0.52	9.85	0.43	9.8e-21	Red cell distribution width;
LUAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs8002861	0.619	rs9562516	chr13:44431738	T/C	cg12856521	chr11:46389249	DGKZ	0.48	7.8	0.35	4.94e-14	Leprosy;
LUAD	cis	rs2302190	0.882	rs9901693	chr17:56606915	C/T	cg25885038	chr17:56607967	SEPT4	-0.51	-8.28	-0.37	1.61e-15	Vitamin D levels;
LUAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg10729496	chr3:10149963	C3orf24	0.58	9.34	0.41	5.58e-19	Alzheimer's disease;
LUAD	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg18016565	chr1:150552671	MCL1	0.4	7.46	0.34	5.05e-13	Tonsillectomy;
LUAD	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.19	-0.37	3.14e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg20673091	chr1:2541236	MMEL1	-0.38	-8.09	-0.37	6.18e-15	Ulcerative colitis;
LUAD	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-7.38	-0.34	8.3e-13	Alzheimer's disease (late onset);
LUAD	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg20476274	chr7:133979776	SLC35B4	0.69	12.35	0.51	3.9e-30	Mean platelet volume;
LUAD	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-8.05	-0.36	8.73e-15	Blood metabolite levels;
LUAD	cis	rs73198271	0.562	rs76960788	chr8:8674049	C/T	cg01851573	chr8:8652454	MFHAS1	0.67	9.92	0.43	5.25e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7474896	0.583	rs1735621	chr10:38167723	G/T	cg25427524	chr10:38739819	LOC399744	0.6	8.52	0.38	2.9e-16	Obesity (extreme);
LUAD	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg20848291	chr7:100343083	ZAN	-0.64	-9.77	-0.43	1.82e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg02869364	chr7:1081709	C7orf50	-0.49	-6.36	-0.3	5.1e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs748404	0.697	rs546170	chr15:43564849	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.37	0.34	9.05e-13	Lung cancer;
LUAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg00280220	chr17:61926910	NA	0.36	7.0	0.32	1.03e-11	Prudent dietary pattern;
LUAD	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.61	0.31	1.16e-10	Parkinson's disease;
LUAD	trans	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg19862616	chr7:65841803	NCRNA00174	1.05	26.22	0.79	1.07e-90	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs13190036	0.892	rs71601339	chr5:176544496	A/G	cg06733329	chr5:176740039	MXD3	0.53	6.63	0.31	1.06e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	cis	rs1595825	1.000	rs1440087	chr2:198871476	G/C	cg00982548	chr2:198649783	BOLL	-0.66	-9.31	-0.41	7.16e-19	Ulcerative colitis;
LUAD	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg14092988	chr3:52407081	DNAH1	0.55	10.86	0.47	2.18e-24	Bipolar disorder;
LUAD	cis	rs9788721	1.000	rs931794	chr15:78826180	G/A	cg18825076	chr15:78729989	IREB2	0.58	9.7	0.43	3.24e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs2224391	0.822	rs36055504	chr6:5262230	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-9.82	-0.43	1.22e-20	Height;
LUAD	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg22705602	chr4:152727874	NA	-0.43	-7.56	-0.34	2.6e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg18180107	chr4:99064573	C4orf37	0.44	6.91	0.32	1.84e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg14844989	chr11:31128820	NA	-0.46	-8.43	-0.38	5.37e-16	Red blood cell count;
LUAD	cis	rs35883536	1.000	rs12724990	chr1:101137030	G/A	cg06223162	chr1:101003688	GPR88	0.35	6.5	0.3	2.2e-10	Monocyte count;
LUAD	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg09835421	chr16:68378352	PRMT7	-0.85	-9.1	-0.4	3.55e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg08645402	chr16:4508243	NA	0.57	10.76	0.46	4.8e-24	Schizophrenia;
LUAD	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs3812762	0.879	rs4929910	chr11:8784869	C/T	cg03980550	chr11:8754370	ST5	0.36	6.36	0.3	5.15e-10	Hypospadias;
LUAD	cis	rs2274273	0.773	rs8012380	chr14:55735010	T/G	cg04306507	chr14:55594613	LGALS3	0.4	8.38	0.38	7.85e-16	Protein biomarker;
LUAD	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg03676636	chr4:99064102	C4orf37	0.3	7.91	0.36	2.23e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	8.61	0.39	1.47e-16	Lung cancer in ever smokers;
LUAD	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg16479474	chr6:28041457	NA	0.47	7.88	0.36	2.75e-14	Depression;
LUAD	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg25811766	chr13:21894605	NA	-0.62	-7.54	-0.34	2.91e-13	White matter hyperintensity burden;
LUAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.81	0.43	1.32e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.48	-0.3	2.55e-10	Depression;
LUAD	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg25894440	chr7:65020034	NA	-0.6	-6.68	-0.31	7.56e-11	Diabetic kidney disease;
LUAD	trans	rs225245	0.531	rs321609	chr17:33880676	G/T	cg19694781	chr19:47549865	TMEM160	-0.64	-10.35	-0.45	1.52e-22	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7809950	0.598	rs2283038	chr7:106835410	C/T	cg23024343	chr7:107201750	COG5	-0.84	-13.45	-0.55	1.44e-34	Coronary artery disease;
LUAD	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.07	0.33	6.49e-12	Rheumatoid arthritis;
LUAD	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg21153622	chr11:89784906	NA	-0.34	-6.71	-0.31	6.11e-11	HDL cholesterol;
LUAD	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg06558623	chr16:89946397	TCF25	-1.06	-11.67	-0.49	1.84e-27	Skin colour saturation;
LUAD	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.4	0.55	2.3e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs12545109	0.643	rs1119707	chr8:57411548	T/C	cg17761419	chr8:57350749	NA	-0.54	-7.66	-0.35	1.24e-13	Obesity-related traits;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg26731897	chr17:79633822	C17orf90;CCDC137	-0.55	-6.56	-0.3	1.6e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs807669	0.868	rs2800973	chr22:19168616	A/G	cg02655711	chr22:19163373	SLC25A1	0.85	17.87	0.66	1.28e-53	Metabolite levels;
LUAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-6.43	-0.3	3.38e-10	Longevity;Endometriosis;
LUAD	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.61	9.58	0.42	8.48e-20	Platelet count;
LUAD	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg12927641	chr6:109611667	NA	-0.51	-8.85	-0.4	2.34e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg05457628	chr5:178986728	RUFY1	-0.74	-13.54	-0.55	5.8e-35	Lung cancer;
LUAD	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-8.14	-0.37	4.53e-15	Asthma;
LUAD	cis	rs7773004	0.875	rs9393700	chr6:26309380	G/A	cg13736514	chr6:26305472	NA	-0.51	-8.55	-0.38	2.3e-16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg16346588	chr10:242978	ZMYND11	-0.4	-6.38	-0.3	4.68e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs240764	0.853	rs1875400	chr6:101020968	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-7.11	-0.33	5.11e-12	Neuroticism;
LUAD	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-7.28	-0.33	1.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg25358565	chr5:93447407	FAM172A	0.62	7.22	0.33	2.46e-12	Diabetic retinopathy;
LUAD	cis	rs922692	0.744	rs12903203	chr15:79084933	T/C	cg04896959	chr15:78267971	NA	0.35	6.76	0.31	4.56e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs8099014	0.911	rs4383234	chr18:56126247	C/G	cg12907477	chr18:56117327	MIR122	0.37	6.38	0.3	4.52e-10	Platelet count;
LUAD	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg02683114	chr2:24398427	C2orf84	-0.52	-7.63	-0.35	1.6e-13	Asthma;
LUAD	cis	rs4285028	0.731	rs2877561	chr3:121712051	A/C	cg20356878	chr3:121714668	ILDR1	0.53	7.68	0.35	1.1e-13	Multiple sclerosis;
LUAD	cis	rs887829	0.588	rs6715325	chr2:234635241	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-9.21	-0.41	1.5e-18	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.55	-10.24	-0.45	3.98e-22	Axial length;
LUAD	cis	rs13223928	0.605	rs10951052	chr7:3155301	A/G	cg19214707	chr7:3157722	NA	-0.47	-8.16	-0.37	3.94e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.33e-13	Menopause (age at onset);
LUAD	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg11859384	chr17:80120422	CCDC57	-0.52	-9.23	-0.41	1.35e-18	Life satisfaction;
LUAD	trans	rs7404843	0.925	rs7404803	chr16:15530454	T/C	cg02716450	chr16:28638775	NA	-0.69	-7.54	-0.34	2.97e-13	Testicular germ cell tumor;
LUAD	trans	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg03886242	chr7:26192032	NFE2L3	0.45	8.0	0.36	1.24e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs62238980	0.522	rs2413065	chr22:32458608	C/A	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.11	0.33	5.06e-12	Menopause (age at onset);
LUAD	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg22166914	chr1:53195759	ZYG11B	0.42	7.38	0.34	8.74e-13	Monocyte count;
LUAD	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.7	-0.35	9.91e-14	Blood trace element (Zn levels);
LUAD	cis	rs654950	0.875	rs2810550	chr1:41995339	T/C	cg06885757	chr1:42089581	HIVEP3	-0.32	-6.75	-0.31	4.74e-11	Airway imaging phenotypes;
LUAD	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg18105134	chr13:113819100	PROZ	0.75	13.03	0.54	7.43e-33	Platelet distribution width;
LUAD	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.64	-0.31	9.73e-11	Neuroticism;
LUAD	cis	rs2677744	0.626	rs3743452	chr15:91497515	C/T	cg23684204	chr15:91497937	RCCD1	-0.43	-7.31	-0.33	1.39e-12	Attention deficit hyperactivity disorder;
LUAD	cis	rs490234	0.756	rs2416963	chr9:128241414	C/T	cg14078157	chr9:128172775	NA	-0.42	-7.8	-0.35	4.9e-14	Mean arterial pressure;
LUAD	trans	rs6601327	0.670	rs7004937	chr8:9420961	T/A	cg27411982	chr8:10470053	RP1L1	0.39	7.32	0.34	1.27e-12	Multiple myeloma (hyperdiploidy);
LUAD	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg09323728	chr8:95962352	TP53INP1	0.29	6.39	0.3	4.48e-10	Type 2 diabetes;
LUAD	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg27490568	chr2:178487706	NA	0.56	9.45	0.42	2.27e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg00083206	chr6:110721305	DDO	-0.42	-7.76	-0.35	6.57e-14	Platelet distribution width;
LUAD	cis	rs12545109	0.800	rs2670028	chr8:57423673	G/A	cg07776626	chr8:57350775	NA	-0.59	-8.64	-0.39	1.13e-16	Obesity-related traits;
LUAD	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.38	6.37	0.3	5.01e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.21	-17.75	-0.65	4.2e-53	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15541040	chr2:3486749	NA	-0.41	-6.93	-0.32	1.58e-11	Neurofibrillary tangles;
LUAD	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.8	0.31	3.52e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg15445000	chr17:37608096	MED1	0.45	8.31	0.37	1.29e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg08742575	chr21:47604166	C21orf56	0.43	7.26	0.33	1.93e-12	Testicular germ cell tumor;
LUAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg08027265	chr7:2291960	NA	-0.43	-7.04	-0.32	7.94e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs9902453	0.780	rs62068621	chr17:28170382	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.7	0.43	3.17e-20	Coffee consumption (cups per day);
LUAD	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg15445000	chr17:37608096	MED1	-0.45	-8.39	-0.38	7.09e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg22467129	chr15:76604101	ETFA	-0.59	-10.96	-0.47	8.69e-25	Blood metabolite levels;
LUAD	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg10434728	chr15:90938212	IQGAP1	-0.37	-7.32	-0.34	1.29e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg18811423	chr2:55921094	PNPT1	0.47	7.59	0.35	2.11e-13	Metabolic syndrome;
LUAD	cis	rs68170813	0.523	rs7777976	chr7:106888594	C/T	cg23024343	chr7:107201750	COG5	0.5	7.28	0.33	1.62e-12	Coronary artery disease;
LUAD	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg19767477	chr5:127420684	SLC12A2	-0.42	-6.51	-0.3	2.13e-10	Ileal carcinoids;
LUAD	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg14396892	chr9:96623032	NA	-0.43	-8.31	-0.37	1.34e-15	DNA methylation (variation);
LUAD	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg08213375	chr14:104286397	PPP1R13B	0.26	6.55	0.3	1.72e-10	Schizophrenia;
LUAD	cis	rs2046867	0.862	rs58538718	chr3:72800563	C/A	cg25664220	chr3:72788482	NA	-0.68	-11.9	-0.5	2.37e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10901296	0.660	rs2855197	chr9:133764406	A/G	cg03924115	chr9:133768966	QRFP	0.51	6.55	0.3	1.63e-10	Bilirubin levels;
LUAD	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-8.26	-0.37	1.94e-15	Monocyte percentage of white cells;
LUAD	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg10434728	chr15:90938212	IQGAP1	0.37	7.35	0.34	1.02e-12	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs7937890	0.559	rs1548074	chr11:14534825	A/G	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.25e-11	Mitochondrial DNA levels;
LUAD	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg12615879	chr12:58013172	SLC26A10	0.52	10.89	0.47	1.59e-24	Multiple sclerosis;
LUAD	cis	rs12760731	0.565	rs12403070	chr1:178094429	A/G	cg00404053	chr1:178313656	RASAL2	0.71	9.2	0.41	1.66e-18	Obesity-related traits;
LUAD	cis	rs12210905	1.000	rs12192446	chr6:26995638	C/A	cg11502198	chr6:26597334	ABT1	-0.79	-6.76	-0.31	4.66e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg00701064	chr4:6280414	WFS1	-0.65	-14.19	-0.57	1.13e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-7.99	-0.36	1.33e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg06623918	chr6:96969491	KIAA0776	-0.84	-15.48	-0.6	3.71e-43	Headache;
LUAD	cis	rs7707921	0.767	rs862241	chr5:81588011	G/A	cg15871215	chr5:81402204	ATG10	0.61	9.85	0.43	9.54e-21	Breast cancer;
LUAD	cis	rs9296092	0.517	rs11751684	chr6:33528739	G/T	cg13560919	chr6:33536144	NA	-0.9	-16.07	-0.62	1.02e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs10080237	0.564	rs2490230	chr6:80812464	G/A	cg08355045	chr6:80787529	NA	0.62	11.4	0.48	1.91e-26	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUAD	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg15704280	chr7:45808275	SEPT13	-1.06	-24.55	-0.77	2.15e-83	Height;
LUAD	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg22920501	chr2:26401640	FAM59B	-0.69	-9.89	-0.43	6.9299999999999992e-21	Gut microbiome composition (summer);
LUAD	cis	rs17095355	1.000	rs12571872	chr10:111676114	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-7.58	-0.35	2.15e-13	Biliary atresia;
LUAD	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg10518543	chr12:38710700	ALG10B	-0.43	-7.15	-0.33	3.92e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg16010596	chr6:33739607	LEMD2	-0.42	-7.74	-0.35	7.27e-14	Schizophrenia;
LUAD	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.56	-0.3	1.58e-10	Aortic root size;
LUAD	cis	rs6541297	1.000	rs6665367	chr1:230279169	G/A	cg20703242	chr1:230279135	GALNT2	0.66	12.26	0.51	8.85e-30	Coronary artery disease;
LUAD	cis	rs734999	0.967	rs10910089	chr1:2498618	G/T	cg18854424	chr1:2615690	NA	0.34	7.99	0.36	1.34e-14	Ulcerative colitis;
LUAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg05564831	chr3:52568323	NT5DC2	0.42	8.11	0.37	5.71e-15	Electroencephalogram traits;
LUAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.22	0.54	1.26e-33	Prudent dietary pattern;
LUAD	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg25344623	chr2:136566232	LCT	-0.37	-7.36	-0.34	9.95e-13	Mosquito bite size;
LUAD	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg00852783	chr1:26633632	UBXN11	0.41	7.35	0.34	1.03e-12	Obesity-related traits;
LUAD	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg23442198	chr4:187126114	CYP4V2	1.11	11.31	0.48	4.48e-26	Blood protein levels;
LUAD	cis	rs13095912	0.785	rs6783023	chr3:185330189	A/G	cg11274856	chr3:185301563	NA	0.52	9.86	0.43	8.96e-21	Systolic blood pressure;
LUAD	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.92	0.4	1.44e-17	Gut microbiome composition (summer);
LUAD	cis	rs6684514	0.778	rs11264477	chr1:156321154	C/T	cg16558208	chr1:156270281	VHLL	0.41	7.8	0.35	4.94e-14	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg00784671	chr22:46762841	CELSR1	-0.65	-8.55	-0.38	2.24e-16	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg14022721	chr22:25507536	KIAA1671	0.43	6.79	0.31	3.89e-11	Monocyte percentage of white cells;
LUAD	cis	rs2652822	0.504	rs2134263	chr15:63365394	C/T	cg25406657	chr15:63342033	TPM1	-0.35	-7.57	-0.35	2.42e-13	Metabolic traits;
LUAD	cis	rs4683142	0.518	rs4682801	chr3:46021218	G/T	cg11211486	chr3:46033800	FYCO1	-0.41	-6.75	-0.31	5.02e-11	Methadone dose in opioid dependence;
LUAD	cis	rs6028335	0.502	rs6028235	chr20:37608550	A/G	cg27552599	chr20:37590471	DHX35	0.38	6.49	0.3	2.37e-10	Alcohol and nicotine co-dependence;
LUAD	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07343612	chr16:622815	PIGQ	-0.78	-15.43	-0.6	5.95e-43	Height;
LUAD	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.74	10.28	0.45	2.79e-22	Smoking behavior;
LUAD	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.31	-0.45	2.13e-22	Platelet count;
LUAD	cis	rs7119038	0.774	rs11217038	chr11:118677355	G/A	cg19308663	chr11:118741387	NA	0.45	6.46	0.3	2.82e-10	Sjögren's syndrome;
LUAD	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg26384229	chr12:38710491	ALG10B	0.47	7.55	0.34	2.72e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg09365446	chr1:150670422	GOLPH3L	-0.66	-12.47	-0.52	1.33e-30	Tonsillectomy;
LUAD	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg08470875	chr2:26401718	FAM59B	-0.71	-10.36	-0.45	1.45e-22	Gut microbiome composition (summer);
LUAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg15242686	chr22:24348715	GSTTP1	0.4	6.91	0.32	1.76e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	9.74	0.43	2.31e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs77861329	0.748	rs9851576	chr3:52091254	C/T	cg08692210	chr3:52188851	WDR51A	-0.54	-7.07	-0.33	6.32e-12	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg12432903	chr7:1882776	MAD1L1	-0.44	-7.17	-0.33	3.4e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.65	0.35	1.38e-13	Electroencephalogram traits;
LUAD	cis	rs7267979	0.816	rs6037158	chr20:25595466	C/A	cg08601574	chr20:25228251	PYGB	0.41	7.69	0.35	1.03e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2455799	1.000	rs4685263	chr3:15853682	G/A	cg16303742	chr3:15540471	COLQ	-0.37	-6.52	-0.3	2.04e-10	Mean platelet volume;
LUAD	cis	rs9393692	0.557	rs2893842	chr6:26338434	T/G	cg00631329	chr6:26305371	NA	-0.52	-8.33	-0.38	1.12e-15	Educational attainment;
LUAD	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	8.58	0.39	1.81e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs738322	0.600	rs6001030	chr22:38555904	T/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-7.66	-0.35	1.32e-13	Cutaneous nevi;
LUAD	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg00255919	chr5:131827918	IRF1	-0.3	-6.56	-0.3	1.56e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06873352	chr17:61820015	STRADA	0.82	18.3	0.66	1.55e-55	Prudent dietary pattern;
LUAD	cis	rs7107174	1.000	rs2512532	chr11:77968641	T/C	cg02023728	chr11:77925099	USP35	0.53	8.32	0.37	1.23e-15	Testicular germ cell tumor;
LUAD	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg18306943	chr3:40428807	ENTPD3	0.42	6.85	0.32	2.66e-11	Renal cell carcinoma;
LUAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg18621852	chr3:10150065	C3orf24	0.47	7.5	0.34	3.81e-13	Alzheimer's disease;
LUAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.43	-0.38	5.34e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs909002	0.800	rs10914459	chr1:32096918	T/C	cg13919466	chr1:32135498	COL16A1	-0.35	-8.09	-0.37	6.53e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2017305	0.749	rs7476854	chr10:70788552	A/G	cg01024728	chr10:70782572	NA	0.65	6.61	0.31	1.17e-10	Depression (quantitative trait);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02731540	chr11:31391568	DCDC1;DNAJC24	-0.44	-6.92	-0.32	1.71e-11	Height;
LUAD	cis	rs2882667	0.824	rs13189485	chr5:138475401	C/T	cg04439458	chr5:138467593	SIL1	-0.56	-10.11	-0.44	1.17e-21	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs1493916	0.655	rs4534926	chr18:31349072	G/C	cg15819921	chr19:927150	ARID3A	-0.49	-8.16	-0.37	3.84e-15	Life satisfaction;
LUAD	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg10523679	chr1:76189770	ACADM	0.97	19.52	0.69	5.77e-61	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2880765	0.743	rs11630410	chr15:86004741	T/A	cg13263323	chr15:86062960	AKAP13	-0.47	-8.6	-0.39	1.54e-16	Coronary artery disease;
LUAD	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg26769984	chr7:1090371	C7orf50	0.58	9.47	0.42	2.01e-19	Bronchopulmonary dysplasia;
LUAD	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg03433033	chr1:76189801	ACADM	-0.47	-6.76	-0.31	4.58e-11	Daytime sleep phenotypes;
LUAD	cis	rs2857891	1.000	rs1388527	chr11:6948441	C/T	cg04053776	chr11:6947353	ZNF215	0.47	6.67	0.31	8.25e-11	Response to cytadine analogues (cytosine arabinoside);
LUAD	cis	rs4372836	0.675	rs72782280	chr2:28911349	C/T	cg09522027	chr2:28974177	PPP1CB	0.55	7.35	0.34	1.03e-12	Body mass index;
LUAD	cis	rs240764	0.817	rs239219	chr6:101116146	C/T	cg09795085	chr6:101329169	ASCC3	0.44	7.51	0.34	3.56e-13	Neuroticism;
LUAD	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27297192	chr10:134578999	INPP5A	0.34	6.37	0.3	5.01e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg22963979	chr7:1858916	MAD1L1	-0.48	-8.17	-0.37	3.65e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg18827107	chr12:86230957	RASSF9	-0.62	-10.99	-0.47	6.84e-25	Major depressive disorder;
LUAD	trans	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.79	-14.71	-0.58	7.2e-40	Brugada syndrome;
LUAD	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg10876282	chr6:28092338	ZSCAN16	0.47	7.34	0.34	1.11e-12	Cardiac Troponin-T levels;
LUAD	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg12940439	chr1:67600707	NA	-0.45	-8.69	-0.39	7.95e-17	Psoriasis;
LUAD	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg03563238	chr19:33554763	RHPN2	0.36	8.51	0.38	3.03e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.45e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg19894588	chr14:64061835	NA	0.52	7.97	0.36	1.49e-14	Glioblastoma;Glioma;
LUAD	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg14092988	chr3:52407081	DNAH1	-0.42	-8.47	-0.38	3.95e-16	Bipolar disorder;
LUAD	cis	rs4642101	0.662	rs4034942	chr3:12836792	C/T	cg24848339	chr3:12840334	CAND2	0.5	10.45	0.45	6.81e-23	QRS complex (12-leadsum);
LUAD	cis	rs932287	0.545	rs1960181	chr11:9046767	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.48	7.02	0.32	8.98e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs600231	0.665	rs1621277	chr11:65221954	A/G	cg21890820	chr11:65308645	LTBP3	-0.48	-7.73	-0.35	8.06e-14	Bone mineral density;
LUAD	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg04450456	chr4:17643702	FAM184B	0.42	8.31	0.37	1.28e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.72	-0.35	8.21e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg23029597	chr12:123009494	RSRC2	-0.53	-8.18	-0.37	3.25e-15	Body mass index;
LUAD	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg14092988	chr3:52407081	DNAH1	0.37	7.51	0.34	3.43e-13	Bipolar disorder;
LUAD	cis	rs7000551	0.646	rs2979302	chr8:22359156	G/A	cg12081754	chr8:22256438	SLC39A14	0.43	7.12	0.33	4.65e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg21782813	chr7:2030301	MAD1L1	0.44	6.98	0.32	1.14e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg03563238	chr19:33554763	RHPN2	-0.33	-8.01	-0.36	1.13e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs931812	0.757	rs4734015	chr8:101909258	C/G	cg20993868	chr7:22813445	NA	0.54	11.63	0.49	2.49e-27	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg13731338	chr3:128145454	NA	-0.51	-6.78	-0.31	4.08e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs67981189	0.784	rs58984901	chr14:71551988	C/T	cg15816911	chr14:71606274	NA	0.36	6.38	0.3	4.53e-10	Schizophrenia;
LUAD	cis	rs758324	0.812	rs12653237	chr5:131241778	C/T	cg06307176	chr5:131281290	NA	0.48	8.07	0.37	7.32e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg26587870	chr6:27730563	NA	-0.69	-7.52	-0.34	3.38e-13	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg00106254	chr7:1943704	MAD1L1	-0.5	-7.44	-0.34	5.51e-13	Schizophrenia;
LUAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07157834	chr1:205819609	PM20D1	0.55	9.76	0.43	1.94e-20	Menarche (age at onset);
LUAD	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg06671706	chr8:8559999	CLDN23	0.64	10.92	0.47	1.31e-24	Obesity-related traits;
LUAD	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg00277334	chr10:82204260	NA	-0.61	-10.35	-0.45	1.57e-22	Post bronchodilator FEV1;
LUAD	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg20283391	chr11:68216788	NA	-0.41	-6.6	-0.31	1.21e-10	Total body bone mineral density;
LUAD	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06028605	chr16:24865363	SLC5A11	0.56	8.42	0.38	6.03e-16	Intelligence (multi-trait analysis);
LUAD	trans	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg19862616	chr7:65841803	NCRNA00174	-1.06	-26.88	-0.79	1.5e-93	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs77741769	0.529	rs525425	chr12:121195625	A/G	cg02419362	chr12:121203948	SPPL3	0.41	8.3	0.37	1.44e-15	Mean corpuscular volume;
LUAD	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg27284194	chr4:1044797	NA	-0.71	-9.96	-0.44	4.04e-21	Recombination rate (females);
LUAD	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg15448220	chr1:150897856	SETDB1	0.53	8.96	0.4	1.08e-17	Melanoma;
LUAD	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg20503657	chr10:835505	NA	1.25	18.96	0.68	1.73e-58	Eosinophil percentage of granulocytes;
LUAD	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg12863693	chr15:85201151	NMB	0.4	7.4	0.34	7.2e-13	Schizophrenia;
LUAD	cis	rs4285028	0.948	rs7615571	chr3:121665950	A/C	cg20356878	chr3:121714668	ILDR1	-0.5	-6.73	-0.31	5.44e-11	Multiple sclerosis;
LUAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.8	-0.31	3.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg12311346	chr5:56204834	C5orf35	-0.74	-11.81	-0.5	5.05e-28	Initial pursuit acceleration;
LUAD	cis	rs12142240	0.770	rs112869704	chr1:46780285	C/T	cg00530320	chr1:46809349	NSUN4	0.44	6.87	0.32	2.29e-11	Menopause (age at onset);
LUAD	cis	rs2235649	0.843	rs9932890	chr16:1847868	G/T	cg08610935	chr16:1836813	NUBP2	0.5	7.77	0.35	6.06e-14	Blood metabolite levels;
LUAD	cis	rs6138458	1.000	rs6114988	chr20:24977586	C/T	cg26195577	chr20:24973756	C20orf3	0.98	17.5	0.65	5.46e-52	Blood protein levels;
LUAD	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg05368731	chr17:41323189	NBR1	0.96	20.46	0.71	3.7e-65	Menopause (age at onset);
LUAD	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-10.92	-0.47	1.3e-24	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs2797160	1.000	rs1418639	chr6:125999940	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.79	-0.39	3.9e-17	Endometrial cancer;
LUAD	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.94e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7010267	0.596	rs67819415	chr8:120016916	A/G	cg01975934	chr8:119970761	NA	-0.35	-6.57	-0.3	1.51e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg05253716	chr12:129299332	SLC15A4;MGC16384	-0.38	-6.44	-0.3	3.31e-10	Systemic lupus erythematosus;
LUAD	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg17346650	chr17:80929145	B3GNTL1	0.4	6.8	0.31	3.53e-11	Glycated hemoglobin levels;
LUAD	cis	rs1983170	0.935	rs578155	chr1:91976541	G/A	cg21854759	chr1:92012499	NA	-0.48	-6.83	-0.32	2.92e-11	Eosinophil percentage of white cells;
LUAD	cis	rs9810890	1.000	rs73198881	chr3:128542760	T/G	cg15033153	chr3:128514015	RAB7A	0.7	6.39	0.3	4.29e-10	Dental caries;
LUAD	cis	rs9517320	1.000	rs7994160	chr13:99132749	C/A	cg20487152	chr13:99095054	FARP1	0.37	6.64	0.31	9.56e-11	Longevity;
LUAD	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg21475434	chr5:93447410	FAM172A	-0.57	-7.25	-0.33	1.98e-12	Diabetic retinopathy;
LUAD	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg03929089	chr4:120376271	NA	-0.98	-20.58	-0.71	1.01e-65	Height;
LUAD	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.47	-8.36	-0.38	9.48e-16	Homoarginine levels;
LUAD	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg17366294	chr4:99064904	C4orf37	0.65	12.47	0.52	1.32e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19717773	chr7:2847554	GNA12	-0.58	-9.81	-0.43	1.28e-20	Height;
LUAD	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg16049864	chr8:95962084	TP53INP1	-0.55	-11.83	-0.5	4.46e-28	Type 2 diabetes;
LUAD	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg15181151	chr6:150070149	PCMT1	0.38	7.68	0.35	1.12e-13	Lung cancer;
LUAD	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg21220214	chr8:57350948	NA	-0.6	-8.69	-0.39	8.27e-17	Obesity-related traits;
LUAD	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg15181151	chr6:150070149	PCMT1	0.37	7.35	0.34	1.06e-12	Lung cancer;
LUAD	cis	rs11048434	0.673	rs1124402	chr12:9062606	C/T	cg23795048	chr12:9217529	LOC144571	0.41	7.42	0.34	6.29e-13	Sjögren's syndrome;
LUAD	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26314531	chr2:26401878	FAM59B	0.61	8.76	0.39	4.74e-17	Gut microbiome composition (summer);
LUAD	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg18876405	chr7:65276391	NA	0.46	7.55	0.34	2.73e-13	Aortic root size;
LUAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg10074409	chr1:209979377	IRF6	0.37	8.59	0.39	1.65e-16	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUAD	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg01251548	chr11:17372745	DKFZp686O24166	-0.36	-6.65	-0.31	9.1e-11	Type 2 diabetes;
LUAD	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg14828511	chr1:107599125	PRMT6	-0.51	-9.09	-0.4	3.87e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg22110770	chr11:66360551	CCDC87;CCS	-0.66	-6.39	-0.3	4.35e-10	Type 2 diabetes;
LUAD	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg17372223	chr3:52568218	NT5DC2	-0.38	-7.0	-0.32	1.02e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs938554	0.956	rs6838021	chr4:9927620	T/C	cg11266682	chr4:10021025	SLC2A9	0.43	7.66	0.35	1.27e-13	Blood metabolite levels;
LUAD	cis	rs7705042	0.897	rs12515668	chr5:141496090	G/T	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.61	-0.31	1.13e-10	Asthma;
LUAD	cis	rs12541635	0.677	rs6999580	chr8:107018254	C/T	cg10147462	chr8:107024639	NA	0.54	9.91	0.43	6.03e-21	Age of smoking initiation;
LUAD	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.83	-0.5	4.41e-28	Mean corpuscular volume;
LUAD	cis	rs2235642	0.582	rs8051374	chr16:1566284	T/C	cg26528668	chr16:1614120	IFT140	0.4	6.42	0.3	3.67e-10	Coronary artery disease;
LUAD	cis	rs7851660	0.874	rs925487	chr9:100636398	C/T	cg13688889	chr9:100608707	NA	-0.49	-8.41	-0.38	6.51e-16	Strep throat;
LUAD	cis	rs62400317	0.762	rs9367210	chr6:44863395	G/A	cg18551225	chr6:44695536	NA	-0.56	-8.47	-0.38	4.04e-16	Total body bone mineral density;
LUAD	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg15181151	chr6:150070149	PCMT1	0.37	7.26	0.33	1.89e-12	Lung cancer;
LUAD	cis	rs7177699	0.526	rs7165733	chr15:79123505	G/A	cg15571903	chr15:79123663	NA	0.42	8.82	0.39	3e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg09915433	chr19:53449742	NA	-0.67	-12.71	-0.53	1.41e-31	Psoriasis;
LUAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00166722	chr3:10149974	C3orf24	0.62	10.36	0.45	1.48e-22	Alzheimer's disease;
LUAD	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	10.15	0.44	8.49e-22	Electrocardiographic conduction measures;
LUAD	cis	rs240764	0.817	rs239221	chr6:101113085	G/A	cg09795085	chr6:101329169	ASCC3	0.44	7.51	0.34	3.56e-13	Neuroticism;
LUAD	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.692	rs4729021	chr7:91758422	C/A	cg01689657	chr7:91764605	CYP51A1	0.29	6.88	0.32	2.17e-11	Breast cancer;
LUAD	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	6.63	0.31	1.05e-10	Rheumatoid arthritis;
LUAD	cis	rs16866061	0.962	rs72972361	chr2:225341550	G/A	cg12698349	chr2:225449008	CUL3	0.74	12.83	0.53	4.69e-32	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg05865280	chr17:75406074	SEPT9	0.61	19.15	0.68	2.7e-59	Airflow obstruction;
LUAD	cis	rs7903847	0.642	rs12258560	chr10:99137048	T/C	cg20016023	chr10:99160130	RRP12	-0.3	-7.31	-0.33	1.39e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00149659	chr3:10157352	C3orf10	0.6	8.19	0.37	3.2e-15	Alzheimer's disease;
LUAD	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg17551891	chr7:1960795	MAD1L1	-0.38	-6.53	-0.3	1.84e-10	Neuroticism;
LUAD	cis	rs10916814	0.655	rs4291476	chr1:20897019	A/G	cg24502330	chr1:20914028	CDA	-0.36	-7.12	-0.33	4.66e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg23750338	chr8:142222470	SLC45A4	-0.57	-13.01	-0.53	8.75e-33	Immature fraction of reticulocytes;
LUAD	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg14668632	chr7:2872130	GNA12	-0.48	-8.81	-0.39	3.2e-17	Height;
LUAD	cis	rs4285028	0.699	rs7637495	chr3:121573850	C/T	cg11130432	chr3:121712080	ILDR1	-0.57	-8.33	-0.38	1.1e-15	Multiple sclerosis;
LUAD	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	9.81	0.43	1.34e-20	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg22875332	chr1:76189707	ACADM	0.88	16.8	0.63	6.98e-49	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg25208724	chr1:156163844	SLC25A44	0.98	15.05	0.59	2.71e-41	Testicular germ cell tumor;
LUAD	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg07776626	chr8:57350775	NA	-0.61	-9.04	-0.4	5.77e-18	Obesity-related traits;
LUAD	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg04731861	chr2:219085781	ARPC2	-0.24	-7.31	-0.33	1.34e-12	Colorectal cancer;
LUAD	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg05872129	chr22:39784769	NA	-0.79	-14.5	-0.58	6.04e-39	Intelligence (multi-trait analysis);
LUAD	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg21856205	chr7:94953877	PON1	-0.52	-7.02	-0.32	8.78e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7927771	0.524	rs11039419	chr11:47851354	C/T	cg18512352	chr11:47633146	NA	0.36	6.41	0.3	3.97e-10	Subjective well-being;
LUAD	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.05e-19	Life satisfaction;
LUAD	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.79	-0.39	3.71e-17	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.64	0.31	9.62e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg00310523	chr12:86230176	RASSF9	0.37	7.46	0.34	4.93e-13	Major depressive disorder;
LUAD	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg00757033	chr12:89920650	WDR51B	0.7	11.86	0.5	3.2e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	6.95	0.32	1.39e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12545109	0.800	rs1371936	chr8:57422715	A/G	cg21220214	chr8:57350948	NA	-0.63	-8.73	-0.39	6.04e-17	Obesity-related traits;
LUAD	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03517284	chr6:25882590	NA	-0.57	-9.3	-0.41	7.78e-19	Blood metabolite levels;
LUAD	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg21951975	chr1:209979733	IRF6	0.36	6.62	0.31	1.08e-10	Monobrow;
LUAD	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs11112613	0.713	rs11112591	chr12:105951620	C/T	cg03607813	chr12:105948248	NA	0.75	12.76	0.53	8.9e-32	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg16205897	chr5:131564050	P4HA2	-0.37	-8.02	-0.36	1.03e-14	Acylcarnitine levels;
LUAD	cis	rs11958404	0.932	rs72816571	chr5:157429759	C/T	cg05962755	chr5:157440814	NA	0.69	9.52	0.42	1.31e-19	IgG glycosylation;
LUAD	trans	rs55986470	0.817	rs6710301	chr2:239441308	A/C	cg01134436	chr17:81009848	B3GNTL1	-0.62	-7.46	-0.34	5.03e-13	Chronotype;
LUAD	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	12.15	0.51	2.52e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs986417	0.818	rs10139251	chr14:60959958	A/C	cg27398547	chr14:60952738	C14orf39	0.52	6.75	0.31	4.86e-11	Gut microbiota (bacterial taxa);
LUAD	cis	rs35264875	1.000	rs6591370	chr11:68843003	G/A	cg02660097	chr11:68866761	NA	0.46	6.41	0.3	3.99e-10	Blond vs. brown hair color;
LUAD	cis	rs938554	0.692	rs6449213	chr4:9994215	A/G	cg00071950	chr4:10020882	SLC2A9	-0.61	-9.37	-0.41	4.37e-19	Blood metabolite levels;
LUAD	cis	rs28830936	1.000	rs12441300	chr15:42102845	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.35	-6.87	-0.32	2.24e-11	Diastolic blood pressure;
LUAD	trans	rs1997103	0.906	rs6593231	chr7:55402914	T/A	cg20935933	chr6:143382018	AIG1	0.53	7.48	0.34	4.32e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs806794	0.804	rs9379833	chr6:26207175	C/A	cg13736514	chr6:26305472	NA	-0.48	-7.19	-0.33	3e-12	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUAD	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg06641503	chr3:48959341	ARIH2	-0.41	-7.86	-0.36	3.12e-14	Parkinson's disease;
LUAD	cis	rs7095607	0.538	rs2255136	chr10:69921733	T/A	cg18986048	chr10:69913749	MYPN	0.47	8.1	0.37	5.84e-15	Lung function (FVC);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg10698098	chr6:160148397	WTAP	-0.65	-6.43	-0.3	3.4e-10	Type 2 diabetes;
LUAD	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	9.82	0.43	1.19e-20	Total body bone mineral density;
LUAD	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg14668632	chr7:2872130	GNA12	-0.71	-12.59	-0.52	4.32e-31	Height;
LUAD	cis	rs7665090	0.967	rs13106325	chr4:103554992	A/G	cg07973026	chr4:103553119	MANBA	0.47	8.43	0.38	5.37e-16	Primary biliary cholangitis;
LUAD	cis	rs7043114	0.507	rs7856204	chr9:95173814	G/C	cg14631576	chr9:95140430	CENPP	-0.42	-8.51	-0.38	3.02e-16	Height;
LUAD	cis	rs2455799	1.000	rs2700009	chr3:15781005	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-6.52	-0.3	2.01e-10	Mean platelet volume;
LUAD	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg13319975	chr6:146136371	FBXO30	0.66	11.09	0.47	2.84e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12464483	0.524	rs4952173	chr2:30888346	G/T	cg12454169	chr2:30669597	LCLAT1	0.55	7.61	0.35	1.81e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs2073300	1.000	rs6137962	chr20:23443966	T/C	cg12062639	chr20:23401060	NAPB	0.98	8.35	0.38	9.91e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6494488	0.500	rs72742926	chr15:64864461	G/A	cg08069370	chr15:64387884	SNX1	-0.76	-6.77	-0.31	4.45e-11	Coronary artery disease;
LUAD	cis	rs12618769	0.520	rs4851135	chr2:99050705	T/A	cg10123293	chr2:99228465	UNC50	0.47	8.46	0.38	4.43e-16	Bipolar disorder;
LUAD	cis	rs2806561	0.704	rs6426779	chr1:23310485	T/C	cg19743168	chr1:23544995	NA	-0.35	-6.4	-0.3	4.08e-10	Height;
LUAD	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg26384229	chr12:38710491	ALG10B	0.47	7.64	0.35	1.48e-13	Morning vs. evening chronotype;
LUAD	cis	rs7771547	0.723	rs35707365	chr6:36556634	C/A	cg07856975	chr6:36356162	ETV7	0.45	6.39	0.3	4.32e-10	Platelet distribution width;
LUAD	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg21204522	chr6:27730016	NA	-0.47	-7.4	-0.34	7.54e-13	Parkinson's disease;
LUAD	cis	rs701145	0.585	rs357468	chr3:153898560	A/G	cg17054900	chr3:154042577	DHX36	0.57	6.43	0.3	3.36e-10	Coronary artery disease;
LUAD	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-7.78	-0.35	5.7e-14	Blood metabolite levels;
LUAD	cis	rs9875589	0.509	rs2731332	chr3:14110083	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.35	6.36	0.3	5.32e-10	Ovarian reserve;
LUAD	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.56	-0.35	2.48e-13	Lung cancer;
LUAD	trans	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17712092	chr4:129076599	LARP1B	0.87	15.87	0.61	7.91e-45	Eosinophil percentage of white cells;
LUAD	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.64	0.31	9.92e-11	Schizophrenia;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg22256960	chr15:77711686	NA	-0.48	-6.81	-0.31	3.34e-11	Testicular germ cell tumor;
LUAD	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg04034577	chr2:241836375	C2orf54	-0.51	-11.41	-0.49	1.73e-26	Urinary metabolites;
LUAD	trans	rs7395662	1.000	rs11039871	chr11:48626620	C/T	cg15704280	chr7:45808275	SEPT13	0.41	6.37	0.3	5.08e-10	HDL cholesterol;
LUAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg04025307	chr7:1156635	C7orf50	0.59	6.76	0.31	4.68e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11811982	0.793	rs77762169	chr1:227509201	C/T	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg01874867	chr7:94954059	PON1	-0.48	-6.48	-0.3	2.49e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7527798	0.545	rs6696228	chr1:207846830	G/A	cg09232269	chr1:207846808	CR1L	-0.38	-6.95	-0.32	1.39e-11	Erythrocyte sedimentation rate;
LUAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg05564831	chr3:52568323	NT5DC2	0.43	8.35	0.38	9.52e-16	Electroencephalogram traits;
LUAD	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg09467607	chr2:36825704	FEZ2	-0.67	-14.7	-0.58	8.58e-40	Height;
LUAD	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.29	-0.37	1.51e-15	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg02569458	chr12:86230093	RASSF9	0.45	8.24	0.37	2.12e-15	Major depressive disorder;
LUAD	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg24690094	chr11:67383802	NA	0.39	7.03	0.32	8.3e-12	Mean corpuscular volume;
LUAD	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg08601574	chr20:25228251	PYGB	0.45	8.23	0.37	2.42e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg10518543	chr12:38710700	ALG10B	-0.42	-6.93	-0.32	1.53e-11	Bladder cancer;
LUAD	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg00666640	chr1:248458726	OR2T12	0.29	6.84	0.32	2.78e-11	Common traits (Other);
LUAD	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg04546413	chr19:29218101	NA	0.7	10.36	0.45	1.45e-22	Methadone dose in opioid dependence;
LUAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg15117754	chr3:10150083	C3orf24	0.42	6.83	0.32	2.98e-11	Alzheimer's disease;
LUAD	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg15468180	chr1:107600409	PRMT6	0.41	6.99	0.32	1.07e-11	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6460942	1.000	rs112794590	chr7:12319426	G/A	cg06484146	chr7:12443880	VWDE	-0.54	-6.44	-0.3	3.32e-10	Coronary artery disease;
LUAD	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg22532475	chr10:104410764	TRIM8	-0.43	-8.39	-0.38	7.58e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg27426351	chr10:43362370	NA	0.52	8.12	0.37	5.31e-15	Blood protein levels;
LUAD	trans	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.2	-30.96	-0.83	8.65e-111	Exhaled nitric oxide output;
LUAD	cis	rs1595825	0.891	rs73058864	chr2:198889587	C/T	cg00361562	chr2:198649771	BOLL	-0.46	-6.47	-0.3	2.72e-10	Ulcerative colitis;
LUAD	cis	rs727505	0.789	rs66756015	chr7:124740641	C/A	cg23710748	chr7:124431027	NA	-0.42	-8.58	-0.38	1.88e-16	Lewy body disease;
LUAD	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg06263672	chr7:65235340	NA	0.48	6.43	0.3	3.42e-10	Aortic root size;
LUAD	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06544989	chr22:39130855	UNC84B	0.43	8.61	0.39	1.41e-16	Menopause (age at onset);
LUAD	trans	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg04775059	chr7:64541387	NA	0.5	6.72	0.31	5.94e-11	Aortic root size;
LUAD	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg24531977	chr5:56204891	C5orf35	-0.69	-11.01	-0.47	6.08e-25	Coronary artery disease;
LUAD	cis	rs262150	0.592	rs56062559	chr7:158769109	T/C	cg19418458	chr7:158789849	NA	0.68	8.62	0.39	1.32e-16	Facial morphology (factor 20);
LUAD	cis	rs796825	0.512	rs35964791	chr3:120007467	A/T	cg21790991	chr3:120137480	FSTL1	-0.46	-7.69	-0.35	1.03e-13	HIV-1 susceptibility;
LUAD	trans	rs7395662	0.746	rs8186207	chr11:48765365	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.22	-0.33	2.48e-12	HDL cholesterol;
LUAD	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg26668828	chr6:292823	DUSP22	-0.59	-10.28	-0.45	2.78e-22	Menopause (age at onset);
LUAD	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg03233332	chr7:66118400	NA	-0.42	-6.51	-0.3	2.16e-10	Aortic root size;
LUAD	cis	rs7737355	0.947	rs42264	chr5:130810028	T/G	cg25547332	chr5:131281432	NA	0.42	6.37	0.3	5.04e-10	Life satisfaction;
LUAD	cis	rs7336332	0.598	rs45622135	chr13:28011594	T/C	cg22138327	chr13:27999177	GTF3A	0.77	10.1	0.44	1.22e-21	Weight;
LUAD	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg06623918	chr6:96969491	KIAA0776	0.88	17.24	0.64	7.83e-51	Headache;
LUAD	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg02733842	chr7:1102375	C7orf50	-0.6	-9.36	-0.41	4.7e-19	Bronchopulmonary dysplasia;
LUAD	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg05665937	chr4:1216051	CTBP1	-0.43	-7.83	-0.36	3.87e-14	Obesity-related traits;
LUAD	cis	rs4906332	0.966	rs12885786	chr14:103972503	C/T	cg19000871	chr14:103996768	TRMT61A	-0.41	-6.99	-0.32	1.06e-11	Coronary artery disease;
LUAD	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.64	-0.49	2.39e-27	Bipolar disorder;
LUAD	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg04034577	chr2:241836375	C2orf54	-0.47	-10.25	-0.45	3.64e-22	Urinary metabolites;
LUAD	cis	rs11828289	0.660	rs17306384	chr11:23189320	T/C	cg20040320	chr11:23191996	NA	-0.7	-8.11	-0.37	5.7e-15	Cancer;
LUAD	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.89	0.32	2.05e-11	Schizophrenia;
LUAD	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.87	-13.47	-0.55	1.15e-34	IgG glycosylation;
LUAD	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-6.82	-0.31	3.09e-11	Cystic fibrosis severity;
LUAD	cis	rs9462027	0.651	rs6940395	chr6:34736553	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.88	-0.4	1.97e-17	Systemic lupus erythematosus;
LUAD	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg13319975	chr6:146136371	FBXO30	-0.64	-10.96	-0.47	9.06e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7267979	0.714	rs6115107	chr20:25237390	A/G	cg08601574	chr20:25228251	PYGB	0.45	8.35	0.38	1e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg04398451	chr17:18023971	MYO15A	-0.65	-11.71	-0.49	1.3e-27	Total body bone mineral density;
LUAD	cis	rs17401966	0.838	rs17034643	chr1:10332102	A/G	cg15208524	chr1:10270712	KIF1B	-0.43	-6.77	-0.31	4.41e-11	Hepatocellular carcinoma;
LUAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.6	0.31	1.26e-10	Prudent dietary pattern;
LUAD	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg05697835	chr1:2722811	NA	0.32	6.66	0.31	8.67e-11	Ulcerative colitis;
LUAD	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg12623302	chr6:28058802	ZSCAN12L1	-0.31	-6.52	-0.3	2.06e-10	Parkinson's disease;
LUAD	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg06092702	chr1:163392909	NA	-0.36	-8.5	-0.38	3.32e-16	Motion sickness;
LUAD	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg17105886	chr17:28927953	LRRC37B2	0.84	7.75	0.35	6.72e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg26384229	chr12:38710491	ALG10B	0.41	6.55	0.3	1.66e-10	Morning vs. evening chronotype;
LUAD	cis	rs62458065	0.713	rs921406	chr7:32486205	G/C	cg20159608	chr7:32802032	NA	-0.6	-8.13	-0.37	4.71e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg24813613	chr7:1882135	MAD1L1	-0.45	-7.24	-0.33	2.11e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg06873352	chr17:61820015	STRADA	0.65	12.59	0.52	4.36e-31	Prudent dietary pattern;
LUAD	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg01689657	chr7:91764605	CYP51A1	0.35	8.77	0.39	4.54e-17	Breast cancer;
LUAD	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.55	-0.34	2.76e-13	Monocyte count;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg21871735	chr16:2015157	SNHG9;RPS2;SNORA78	0.41	6.35	0.3	5.54e-10	Monocyte percentage of white cells;
LUAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg25703541	chr22:24373054	LOC391322	-0.83	-15.29	-0.6	2.51e-42	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg03609598	chr5:56110824	MAP3K1	-0.68	-9.23	-0.41	1.26e-18	Initial pursuit acceleration;
LUAD	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg17279839	chr7:150038598	RARRES2	0.41	7.24	0.33	2.15e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg25173405	chr17:45401733	C17orf57	0.45	7.7	0.35	9.67e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg18230493	chr5:56204884	C5orf35	-0.85	-12.74	-0.53	1.12e-31	Initial pursuit acceleration;
LUAD	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg00922110	chr4:57842668	C4orf14	-0.42	-7.41	-0.34	6.93e-13	Response to bleomycin (chromatid breaks);
LUAD	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg15704280	chr7:45808275	SEPT13	-0.61	-9.23	-0.41	1.33e-18	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg01620082	chr3:125678407	NA	-0.83	-8.98	-0.4	9.2e-18	Depression;
LUAD	cis	rs6430585	0.583	rs11886852	chr2:136589379	G/A	cg07169764	chr2:136633963	MCM6	0.68	8.4	0.38	6.92e-16	Corneal structure;
LUAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg22907277	chr7:1156413	C7orf50	0.44	7.49	0.34	4.03e-13	Longevity;Endometriosis;
LUAD	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-16.49	-0.63	1.61e-47	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.76	-0.5	7.89e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg24308560	chr3:49941425	MST1R	0.5	8.11	0.37	5.38e-15	Body mass index;
LUAD	cis	rs1572438	1.000	rs873560	chr6:875559	A/G	cg13447295	chr6:887704	NA	-0.33	-6.41	-0.3	3.78e-10	Aging;
LUAD	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg00933542	chr6:150070202	PCMT1	0.45	9.76	0.43	1.94e-20	Lung cancer;
LUAD	cis	rs1595825	0.945	rs1518369	chr2:198859183	C/T	cg00982548	chr2:198649783	BOLL	-0.61	-8.75	-0.39	5.13e-17	Ulcerative colitis;
LUAD	cis	rs1595825	0.786	rs79490184	chr2:198894219	T/A	cg10547527	chr2:198650123	BOLL	-0.51	-7.0	-0.32	1.02e-11	Ulcerative colitis;
LUAD	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg21427119	chr20:30132790	HM13	-0.51	-7.56	-0.34	2.56e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs6906287	0.573	rs7757943	chr6:118697981	C/G	cg05564266	chr6:118973597	C6orf204	0.33	7.09	0.33	5.5e-12	Electrocardiographic conduction measures;
LUAD	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22496380	chr5:211416	CCDC127	-0.94	-13.18	-0.54	1.73e-33	Breast cancer;
LUAD	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.6e-12	Crohn's disease;
LUAD	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.86	-0.36	3.11e-14	Menopause (age at onset);
LUAD	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg25173405	chr17:45401733	C17orf57	-0.47	-7.77	-0.35	5.97e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7771547	0.519	rs67313027	chr6:36363487	G/C	cg04289385	chr6:36355825	ETV7	0.52	7.71	0.35	8.79e-14	Platelet distribution width;
LUAD	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg15704280	chr7:45808275	SEPT13	-0.71	-12.01	-0.5	8.86e-29	Coronary artery disease;
LUAD	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg01616529	chr11:638424	DRD4	-0.43	-6.37	-0.3	4.85e-10	Systemic lupus erythematosus;
LUAD	cis	rs12079745	0.793	rs12063863	chr1:169269557	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.11	-8.07	-0.37	7.41e-15	QT interval;
LUAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg08888203	chr3:10149979	C3orf24	0.7	11.91	0.5	2.17e-28	Alzheimer's disease;
LUAD	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	10.15	0.44	8.49e-22	Electrocardiographic conduction measures;
LUAD	cis	rs4766566	0.651	rs933306	chr12:111737985	A/T	cg10833066	chr12:111807467	FAM109A	0.67	13.78	0.56	5.91e-36	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUAD	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg13319975	chr6:146136371	FBXO30	-0.65	-11.08	-0.47	3.17e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.36	0.34	9.52e-13	Bladder cancer;
LUAD	cis	rs11048434	0.736	rs12812913	chr12:9110836	C/G	cg26114124	chr12:9217669	LOC144571	0.36	6.74	0.31	5.04e-11	Sjögren's syndrome;
LUAD	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg23283495	chr1:209979779	IRF6	0.75	9.11	0.4	3.4e-18	Cleft lip with or without cleft palate;
LUAD	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg01689657	chr7:91764605	CYP51A1	-0.37	-9.12	-0.41	3.01e-18	Breast cancer;
LUAD	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg22508957	chr16:3507546	NAT15	0.76	12.97	0.53	1.27e-32	Tuberculosis;
LUAD	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg23978390	chr7:1156363	C7orf50	0.57	8.01	0.36	1.15e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg17105886	chr17:28927953	LRRC37B2	0.76	7.18	0.33	3.25e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs208520	0.909	rs9345809	chr6:67017543	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	10.94	0.47	1.05e-24	Exhaled nitric oxide output;
LUAD	cis	rs7193541	0.640	rs4072222	chr16:74706736	A/C	cg01733217	chr16:74700730	RFWD3	0.68	13.01	0.53	8.55e-33	Multiple myeloma;
LUAD	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.58	-7.42	-0.34	6.68e-13	Body mass index;
LUAD	trans	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg01620082	chr3:125678407	NA	-0.8	-8.06	-0.36	8.14e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs41311933	0.710	rs34119250	chr9:123688217	G/A	cg13567360	chr9:123745713	C5	-0.83	-7.22	-0.33	2.36e-12	Coronary artery disease;
LUAD	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg00277334	chr10:82204260	NA	-0.5	-8.36	-0.38	9.21e-16	Post bronchodilator FEV1;
LUAD	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg07169764	chr2:136633963	MCM6	0.7	8.27	0.37	1.71e-15	Corneal structure;
LUAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08677398	chr8:58056175	NA	0.48	6.81	0.31	3.36e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11112613	0.713	rs4015312	chr12:105948757	A/G	cg03607813	chr12:105948248	NA	0.87	13.71	0.55	1.2e-35	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg11871910	chr12:69753446	YEATS4	0.5	7.46	0.34	5.02e-13	Response to diuretic therapy;
LUAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg16606324	chr3:10149918	C3orf24	0.63	9.84	0.43	1.01e-20	Alzheimer's disease;
LUAD	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg00933542	chr6:150070202	PCMT1	0.43	9.28	0.41	8.58e-19	Lung cancer;
LUAD	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.35	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg17724175	chr1:150552817	MCL1	0.37	8.37	0.38	8.58e-16	Melanoma;
LUAD	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg03690763	chr11:133734501	NA	-0.3	-7.06	-0.32	6.88e-12	Childhood ear infection;
LUAD	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg09835421	chr16:68378352	PRMT7	-1.02	-11.51	-0.49	7.59e-27	Magnesium levels;
LUAD	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg01200585	chr1:228362443	C1orf69	0.42	6.82	0.31	3.17e-11	Diastolic blood pressure;
LUAD	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-8.1	-0.37	5.92e-15	Monocyte percentage of white cells;
LUAD	trans	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg07817883	chr1:32538562	TMEM39B	-0.51	-7.12	-0.33	4.81e-12	Monocyte percentage of white cells;
LUAD	trans	rs7246760	1.000	rs67844335	chr19:9898039	G/A	cg02900749	chr2:68251473	NA	-0.63	-6.87	-0.32	2.25e-11	Pursuit maintenance gain;
LUAD	cis	rs1497828	0.871	rs2815248	chr1:217572871	C/T	cg04411442	chr1:217543379	NA	0.36	6.48	0.3	2.51e-10	Dialysis-related mortality;
LUAD	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	7.52	0.34	3.27e-13	Menarche (age at onset);
LUAD	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg27284194	chr4:1044797	NA	0.7	10.14	0.44	8.97e-22	Recombination rate (females);
LUAD	cis	rs9826463	0.702	rs73228758	chr3:142320559	A/G	cg20824294	chr3:142316082	PLS1	0.48	8.32	0.37	1.25e-15	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg18833306	chr6:118973337	C6orf204	-0.53	-7.58	-0.35	2.24e-13	Diastolic blood pressure;
LUAD	cis	rs2066819	1.000	rs17118409	chr12:56630764	G/A	cg26714650	chr12:56694279	CS	-0.83	-6.99	-0.32	1.05e-11	Psoriasis vulgaris;
LUAD	cis	rs11771526	0.892	rs62457539	chr7:32364604	G/A	cg27532318	chr7:32358331	NA	0.68	7.9	0.36	2.44e-14	Body mass index;
LUAD	cis	rs62458065	0.850	rs62458100	chr7:32473142	C/G	cg20159608	chr7:32802032	NA	-0.57	-7.42	-0.34	6.43e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs10992471	0.528	rs10117627	chr9:95203953	G/A	cg14631576	chr9:95140430	CENPP	-0.49	-9.93	-0.43	5.05e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs1385374	0.858	rs959989	chr12:129292708	A/T	cg09035930	chr12:129282057	SLC15A4	-0.65	-6.91	-0.32	1.79e-11	Systemic lupus erythematosus;
LUAD	cis	rs4664304	0.629	rs1606117	chr2:160850716	C/T	cg23995753	chr2:160760732	LY75	-0.4	-6.87	-0.32	2.31e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs738321	0.671	rs3761446	chr22:38595483	G/A	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.8	-0.31	3.55e-11	Breast cancer;
LUAD	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg03886242	chr7:26192032	NFE2L3	-0.47	-8.37	-0.38	8.51e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs490234	0.934	rs10119068	chr9:128424508	A/G	cg14078157	chr9:128172775	NA	-0.38	-6.82	-0.31	3.09e-11	Mean arterial pressure;
LUAD	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg08999081	chr20:33150536	PIGU	-0.62	-13.97	-0.56	1e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg07404485	chr7:94953653	PON1	-0.49	-7.11	-0.33	5.11e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6732160	0.834	rs57456443	chr2:73366441	C/A	cg01422370	chr2:73384389	NA	0.36	6.83	0.32	2.89e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.51	-8.03	-0.36	9.92e-15	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.81	-0.36	4.47e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4638749	0.603	rs34153365	chr2:108846583	C/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.3	-0.33	1.39e-12	Blood pressure;
LUAD	cis	rs738322	0.533	rs5756934	chr22:38547279	G/A	cg25457927	chr22:38595422	NA	-0.56	-13.12	-0.54	3.18e-33	Cutaneous nevi;
LUAD	trans	rs587242	1.000	rs12744063	chr1:96898431	T/C	cg10631902	chr5:14652156	NA	0.44	7.28	0.33	1.63e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.59	8.53	0.38	2.61e-16	Platelet count;
LUAD	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.76	0.31	4.49e-11	Platelet count;
LUAD	cis	rs9039	1.000	rs17652208	chr16:9196463	C/T	cg08831531	chr16:9218945	NA	-0.39	-6.45	-0.3	3e-10	Menopause (age at onset);
LUAD	trans	rs8002861	0.875	rs12428432	chr13:44464043	A/G	cg17145862	chr1:211918768	LPGAT1	-0.69	-14.97	-0.59	5.73e-41	Leprosy;
LUAD	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg03563238	chr19:33554763	RHPN2	-0.33	-7.95	-0.36	1.77e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg20730634	chr19:37709434	NA	0.4	6.35	0.3	5.56e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1215050	0.743	rs6532692	chr4:98648005	C/A	cg17366294	chr4:99064904	C4orf37	-0.46	-7.91	-0.36	2.2e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6594713	0.570	rs35933960	chr5:112841469	T/C	cg12552261	chr5:112820674	MCC	0.54	7.49	0.34	4.05e-13	Brain cytoarchitecture;
LUAD	cis	rs34421088	0.564	rs6983129	chr8:11591136	A/C	cg13293535	chr8:11597251	GATA4	-0.29	-6.77	-0.31	4.44e-11	Neuroticism;
LUAD	cis	rs6005807	0.719	rs16986398	chr22:28815629	A/C	cg12565055	chr22:29076175	TTC28	0.71	8.79	0.39	3.7e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg18305652	chr10:134549665	INPP5A	-0.39	-8.85	-0.4	2.35e-17	Migraine;
LUAD	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21582582	chr3:182698605	DCUN1D1	0.59	9.55	0.42	1.06e-19	Resting heart rate;
LUAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg18402987	chr7:1209562	NA	0.48	7.76	0.35	6.41e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10540	0.584	rs6598021	chr11:438939	G/C	cg19913688	chr11:428466	ANO9	0.57	7.64	0.35	1.49e-13	Body mass index;
LUAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.29	0.45	2.52e-22	Prudent dietary pattern;
LUAD	cis	rs6499255	1.000	rs73579458	chr16:69804764	G/C	cg15192750	chr16:69999425	NA	0.55	8.61	0.39	1.5e-16	IgE levels;
LUAD	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg14582100	chr15:45693742	SPATA5L1	0.63	12.48	0.52	1.21e-30	Homoarginine levels;
LUAD	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg26408565	chr15:76604113	ETFA	-0.56	-9.85	-0.43	9.83e-21	Blood metabolite levels;
LUAD	cis	rs9303280	0.901	rs921650	chr17:38069076	G/A	cg10909506	chr17:38081995	ORMDL3	-0.37	-6.61	-0.31	1.17e-10	Self-reported allergy;
LUAD	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg02371401	chr5:676784	TPPP	-0.4	-6.85	-0.32	2.65e-11	Obesity-related traits;
LUAD	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg20744362	chr22:50050164	C22orf34	0.38	7.81	0.35	4.64e-14	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9796	0.621	rs2918462	chr15:41481254	A/G	cg18705301	chr15:41695430	NDUFAF1	0.46	8.33	0.38	1.16e-15	Menopause (age at onset);
LUAD	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	10.36	0.45	1.47e-22	Colorectal cancer;
LUAD	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	11.71	0.49	1.25e-27	Mean platelet volume;
LUAD	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg26597838	chr10:835615	NA	0.82	12.69	0.53	1.65e-31	Eosinophil percentage of granulocytes;
LUAD	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.44	-0.42	2.5e-19	Gut microbiome composition (summer);
LUAD	cis	rs6920965	0.527	rs584032	chr6:126165003	G/A	cg05901451	chr6:126070800	HEY2	0.43	7.0	0.32	1.02e-11	High light scatter reticulocyte count;
LUAD	trans	rs7181230	0.885	rs749748	chr15:40349909	C/G	cg22705835	chr10:65332833	REEP3	-0.34	-6.38	-0.3	4.63e-10	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg26587870	chr6:27730563	NA	-0.54	-8.5	-0.38	3.38e-16	Breast cancer;
LUAD	cis	rs2233152	0.656	rs2287691	chr19:41286163	C/G	cg21869046	chr19:41225005	ITPKC	0.45	8.26	0.37	1.94e-15	Kawasaki disease;
LUAD	cis	rs938554	1.000	rs13137069	chr4:9928017	T/C	cg00071950	chr4:10020882	SLC2A9	0.54	8.6	0.39	1.62e-16	Blood metabolite levels;
LUAD	cis	rs62238980	0.614	rs74924328	chr22:32416228	G/A	cg00543991	chr22:32367038	NA	0.97	9.02	0.4	6.57e-18	Childhood ear infection;
LUAD	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg01884057	chr2:25150051	NA	0.34	7.24	0.33	2.13e-12	Body mass index;
LUAD	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg16647868	chr5:131706066	SLC22A5	0.46	7.1	0.33	5.19e-12	Breast cancer;
LUAD	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg22705602	chr4:152727874	NA	-0.4	-7.07	-0.33	6.28e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs244731	1.000	rs244729	chr5:176539018	C/G	cg16006841	chr5:176797999	RGS14	0.55	8.76	0.39	4.71e-17	Urate levels in lean individuals;
LUAD	cis	rs494562	0.892	rs7771860	chr6:86130729	C/T	cg17966619	chr6:86160162	NT5E	0.68	8.34	0.38	1.09e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg14668632	chr7:2872130	GNA12	-0.45	-7.88	-0.36	2.79e-14	Height;
LUAD	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg16989719	chr2:238392110	NA	-0.37	-7.14	-0.33	4.1e-12	Prostate cancer;
LUAD	cis	rs593982	0.920	rs521678	chr11:65485727	T/G	cg08755490	chr11:65554678	OVOL1	1.26	14.92	0.59	9.97e-41	Atopic dermatitis;
LUAD	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg00666640	chr1:248458726	OR2T12	0.3	7.24	0.33	2.14e-12	Common traits (Other);
LUAD	cis	rs7945718	0.967	rs11022496	chr11:12789561	G/A	cg25843174	chr11:12811716	TEAD1	0.26	7.86	0.36	3.21e-14	Educational attainment (years of education);
LUAD	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg20456258	chr4:962124	DGKQ	0.41	6.94	0.32	1.49e-11	Sjögren's syndrome;
LUAD	cis	rs7177699	0.534	rs4387568	chr15:79109514	C/G	cg00540400	chr15:79124168	NA	-0.43	-9.05	-0.4	5.34e-18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs12505328	0.593	rs7659018	chr4:174376198	C/T	cg12145043	chr4:174357286	NA	-0.54	-8.09	-0.37	6.26e-15	Chin dimples;
LUAD	cis	rs7119	0.717	rs12916973	chr15:77808099	C/T	cg27398640	chr15:77910606	LINGO1	0.33	6.36	0.3	5.36e-10	Type 2 diabetes;
LUAD	cis	rs2742417	0.603	rs2742371	chr3:45782763	G/A	cg10512202	chr3:45649293	LIMD1	0.48	8.95	0.4	1.16e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs6066835	1.000	rs6066833	chr20:47354494	G/C	cg18078177	chr20:47281410	PREX1	0.69	6.41	0.3	3.84e-10	Multiple myeloma;
LUAD	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg20290983	chr6:43655470	MRPS18A	1.07	27.07	0.8	2.34e-94	IgG glycosylation;
LUAD	cis	rs1003719	0.788	rs2835579	chr21:38457965	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.34e-16	Eye color traits;
LUAD	cis	rs986417	0.901	rs1024224	chr14:60926942	C/G	cg27398547	chr14:60952738	C14orf39	0.63	7.72	0.35	8.34e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs859767	0.741	rs11898084	chr2:135428054	T/C	cg12500956	chr2:135428796	TMEM163	-0.33	-8.56	-0.38	2.19e-16	Neuroticism;
LUAD	cis	rs9811920	0.893	rs9814549	chr3:99892190	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.57	-10.41	-0.45	9.77e-23	Axial length;
LUAD	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg05590025	chr7:65112418	INTS4L2	-0.71	-7.61	-0.35	1.84e-13	Diabetic kidney disease;
LUAD	cis	rs4631830	0.657	rs2611502	chr10:51500301	A/G	cg20129853	chr10:51489980	NA	-0.36	-7.14	-0.33	4.04e-12	Prostate-specific antigen levels;
LUAD	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg08989290	chr16:615782	NHLRC4	0.32	6.81	0.31	3.4e-11	Height;
LUAD	trans	rs587242	0.528	rs7513314	chr1:97202856	T/C	cg10631902	chr5:14652156	NA	0.39	6.65	0.31	9.33e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg18131467	chr2:239335373	ASB1	0.67	11.6	0.49	3.31e-27	Multiple system atrophy;
LUAD	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg23533926	chr12:111358616	MYL2	-0.39	-6.72	-0.31	5.98e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs317865	0.737	rs28483204	chr4:16205098	A/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.82	8.14	0.37	4.37e-15	Kidney disease (early stage) in type 1 diabetes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14532069	chr18:59993399	TNFRSF11A	-0.4	-6.55	-0.3	1.69e-10	Cancer;
LUAD	trans	rs9929218	1.000	rs12599517	chr16:68814590	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.93	-0.56	1.47e-36	Colorectal cancer;
LUAD	cis	rs1448094	0.842	rs7301280	chr12:86455752	G/T	cg18827107	chr12:86230957	RASSF9	0.45	8.01	0.36	1.14e-14	Major depressive disorder;
LUAD	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.34	7.11	0.33	4.88e-12	Obesity-related traits;
LUAD	cis	rs193541	0.632	rs7729834	chr5:122122159	A/G	cg19077854	chr5:122220652	SNX24	0.38	6.72	0.31	5.78e-11	Glucose homeostasis traits;
LUAD	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.8	-0.5	5.62e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg20398880	chr6:41068722	NFYA;LOC221442	0.37	6.43	0.3	3.42e-10	Alzheimer's disease (late onset);
LUAD	trans	rs2797160	1.000	rs926853	chr6:126021435	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.53	8.51	0.38	3.14e-16	Endometrial cancer;
LUAD	cis	rs59104589	0.583	rs3771573	chr2:242387346	G/A	cg08645257	chr2:242211290	HDLBP	0.46	7.45	0.34	5.23e-13	Fibrinogen levels;
LUAD	cis	rs2046867	0.908	rs11927166	chr3:72795149	C/G	cg25664220	chr3:72788482	NA	-0.68	-12.43	-0.52	1.96e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.71	-12.11	-0.51	3.52e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs243505	0.898	rs243524	chr7:148418181	A/C	cg09806900	chr7:148480153	CUL1	-0.39	-6.61	-0.31	1.18e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.6	-0.42	7.19e-20	Life satisfaction;
LUAD	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg25809561	chr17:30822961	MYO1D	-0.54	-10.23	-0.45	4.3e-22	Schizophrenia;
LUAD	cis	rs6691722	0.506	rs12030365	chr1:24739220	T/A	cg18323236	chr1:24743029	NIPAL3	0.46	7.97	0.36	1.54e-14	Response to interferon beta in multiple sclerosis;
LUAD	cis	rs2274273	0.840	rs6573014	chr14:55735892	C/T	cg04306507	chr14:55594613	LGALS3	-0.41	-8.53	-0.38	2.67e-16	Protein biomarker;
LUAD	cis	rs10489202	0.683	rs202260	chr1:167956167	G/T	cg24449463	chr1:168025552	DCAF6	-0.72	-12.01	-0.5	8.55e-29	Schizophrenia;
LUAD	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.9	-0.47	1.56e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs2235573	0.551	rs139897	chr22:38399098	A/G	cg14039649	chr22:38352398	POLR2F	0.35	6.36	0.3	5.38e-10	Glioblastoma;Glioma;
LUAD	trans	rs3858145	0.588	rs61854831	chr10:70035837	C/T	cg04882175	chr6:131122610	NA	-0.59	-7.04	-0.32	8.06e-12	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUAD	cis	rs986417	0.688	rs965454	chr14:60960251	T/C	cg27398547	chr14:60952738	C14orf39	0.52	6.75	0.31	4.86e-11	Gut microbiota (bacterial taxa);
LUAD	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg23649088	chr2:200775458	C2orf69	-0.62	-7.77	-0.35	6.15e-14	Schizophrenia;
LUAD	cis	rs12681287	0.752	rs4389908	chr8:87274852	A/G	cg27223183	chr8:87520930	FAM82B	-0.6	-8.28	-0.37	1.59e-15	Caudate activity during reward;
LUAD	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg22029157	chr1:209979665	IRF6	0.77	10.09	0.44	1.34e-21	Cleft lip with or without cleft palate;
LUAD	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg27661571	chr11:113659931	NA	-0.53	-6.55	-0.3	1.64e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg27539214	chr16:67997921	SLC12A4	-0.71	-8.79	-0.39	3.68e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg16205897	chr5:131564050	P4HA2	0.31	6.83	0.32	2.94e-11	Blood metabolite levels;
LUAD	trans	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.3e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg08888203	chr3:10149979	C3orf24	-0.71	-10.98	-0.47	7.72e-25	Alzheimer's disease;
LUAD	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg04727924	chr7:799746	HEATR2	-0.57	-7.67	-0.35	1.17e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs116248771	0.739	rs7617983	chr3:158323716	T/A	cg16708174	chr3:158430962	RARRES1	0.48	6.84	0.32	2.8e-11	diarrhoeal disease at age 2;
LUAD	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg18876405	chr7:65276391	NA	0.47	7.6	0.35	1.99e-13	Aortic root size;
LUAD	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Colorectal cancer;
LUAD	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg27411982	chr8:10470053	RP1L1	0.4	6.94	0.32	1.46e-11	Joint mobility (Beighton score);
LUAD	cis	rs11229555	0.645	rs7929028	chr11:58188258	C/T	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21659725	chr3:3221576	CRBN	0.86	18.51	0.67	1.87e-56	Intelligence (multi-trait analysis);
LUAD	cis	rs240764	0.658	rs10872628	chr6:101176349	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-8.36	-0.38	9.04e-16	Neuroticism;
LUAD	cis	rs9796	0.870	rs8042088	chr15:41337487	C/T	cg18705301	chr15:41695430	NDUFAF1	0.36	6.71	0.31	6.1e-11	Menopause (age at onset);
LUAD	cis	rs9807989	0.507	rs10208196	chr2:102996345	G/A	cg03938978	chr2:103052716	IL18RAP	0.45	10.24	0.45	3.99e-22	Asthma;
LUAD	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg04772025	chr11:68637568	NA	0.58	9.15	0.41	2.49e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg13010199	chr12:38710504	ALG10B	0.4	6.59	0.31	1.29e-10	Bladder cancer;
LUAD	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg13870426	chr17:30244630	NA	-0.56	-6.62	-0.31	1.12e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg12062639	chr20:23401060	NAPB	1.09	11.27	0.48	6.28e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7084921	0.552	rs11598495	chr10:101889417	T/C	cg19754520	chr10:101825118	CPN1	-0.33	-6.85	-0.32	2.59e-11	Bone mineral density;
LUAD	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.53	-0.34	3.09e-13	Schizophrenia;
LUAD	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.28	-6.85	-0.32	2.63e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg18180107	chr4:99064573	C4orf37	0.42	6.81	0.31	3.47e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1493916	1.000	rs1493916	chr18:31392577	T/G	cg27147174	chr7:100797783	AP1S1	-0.67	-11.83	-0.5	4.29e-28	Life satisfaction;
LUAD	cis	rs17095355	1.000	rs11194917	chr10:111692552	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.67	-8.88	-0.4	1.93e-17	Biliary atresia;
LUAD	cis	rs1829883	1.000	rs2461991	chr5:98793332	C/G	cg08333243	chr5:99726346	NA	-0.36	-6.91	-0.32	1.76e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg00280220	chr17:61926910	NA	0.36	6.9	0.32	1.9e-11	Prudent dietary pattern;
LUAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg21724239	chr8:58056113	NA	0.89	10.73	0.46	6.28e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs6489882	0.902	rs10774679	chr12:113374748	A/G	cg20102336	chr12:113376681	OAS3	0.47	7.56	0.35	2.51e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg22963979	chr7:1858916	MAD1L1	-0.6	-10.63	-0.46	1.48e-23	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg20265528	chr2:105853269	NA	-0.38	-6.68	-0.31	7.35e-11	Type 2 diabetes;
LUAD	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg06131755	chr6:160182447	ACAT2	0.46	6.85	0.32	2.54e-11	Age-related macular degeneration (geographic atrophy);
LUAD	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg20587970	chr11:113659929	NA	1.11	13.31	0.54	5.17e-34	Hip circumference adjusted for BMI;
LUAD	cis	rs73198271	0.653	rs10087742	chr8:8660474	A/G	cg01851573	chr8:8652454	MFHAS1	0.46	8.19	0.37	3.2e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg21252483	chr19:49399788	TULP2	-0.61	-10.08	-0.44	1.52e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg13722127	chr7:150037890	RARRES2	0.45	7.66	0.35	1.25e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg18721089	chr20:30220636	NA	-0.47	-6.56	-0.3	1.59e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg07217954	chr7:1067459	C7orf50	-0.35	-6.44	-0.3	3.27e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs72949976	0.646	rs11681232	chr2:214033002	G/A	cg08319019	chr2:214017104	IKZF2	0.55	8.3	0.37	1.37e-15	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.58	0.3	1.42e-10	Parkinson's disease;
LUAD	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg12011299	chr4:100065546	ADH4	0.63	11.4	0.48	2.04e-26	Alcohol dependence;
LUAD	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.09	-0.37	6.56e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.75	10.05	0.44	1.82e-21	Body mass index;
LUAD	cis	rs9875589	0.509	rs1386932	chr3:14061369	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	7.2	0.33	2.7e-12	Ovarian reserve;
LUAD	trans	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.14	28.08	0.81	1.1e-98	Colorectal cancer;
LUAD	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg15448220	chr1:150897856	SETDB1	0.49	8.2	0.37	2.92e-15	Melanoma;
LUAD	trans	rs4698036	0.586	rs7672759	chr4:10285015	G/A	cg26043149	chr18:55253948	FECH	0.43	6.63	0.31	1.02e-10	Cardiovascular disease risk factors;
LUAD	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18404041	chr3:52824283	ITIH1	-0.61	-12.28	-0.51	7.69e-30	Bipolar disorder;
LUAD	cis	rs4730250	0.708	rs4730242	chr7:107057373	G/C	cg23024343	chr7:107201750	COG5	0.52	7.19	0.33	2.96e-12	Osteoarthritis;
LUAD	cis	rs7043114	0.525	rs10820969	chr9:95106678	G/C	cg14631576	chr9:95140430	CENPP	-0.43	-8.63	-0.39	1.28e-16	Height;
LUAD	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02018176	chr4:1364513	KIAA1530	0.71	12.43	0.52	1.8e-30	Longevity;
LUAD	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg06766960	chr11:133703094	NA	-0.46	-8.69	-0.39	7.78e-17	Childhood ear infection;
LUAD	cis	rs739496	0.615	rs3809276	chr12:112073916	A/G	cg10833066	chr12:111807467	FAM109A	0.42	6.83	0.32	2.92e-11	Platelet count;
LUAD	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg04989706	chr14:50066350	PPIL5	-0.54	-7.77	-0.35	5.95e-14	Carotid intima media thickness;
LUAD	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg03609598	chr5:56110824	MAP3K1	-0.65	-9.18	-0.41	1.97e-18	Initial pursuit acceleration;
LUAD	trans	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg18187862	chr3:45730750	SACM1L	0.5	7.81	0.36	4.45e-14	Primary sclerosing cholangitis;
LUAD	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg12927641	chr6:109611667	NA	-0.51	-8.72	-0.39	6.51e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg26384229	chr12:38710491	ALG10B	0.43	7.31	0.34	1.31e-12	Heart rate;
LUAD	cis	rs938554	0.779	rs9998811	chr4:9966477	G/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.31	-0.33	1.34e-12	Blood metabolite levels;
LUAD	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg09117114	chr16:67998030	SLC12A4	-0.6	-8.1	-0.37	5.75e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	7.48	0.34	4.27e-13	Menopause (age at onset);
LUAD	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg00316803	chr15:76480434	C15orf27	-0.41	-7.88	-0.36	2.88e-14	Blood metabolite levels;
LUAD	cis	rs2262909	0.962	rs436662	chr19:22232107	C/T	cg11619707	chr19:22235551	ZNF257	-0.48	-7.48	-0.34	4.22e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs981844	0.767	rs6857738	chr4:154689140	A/C	cg10279832	chr4:154682576	RNF175	0.34	7.09	0.33	5.53e-12	Response to statins (LDL cholesterol change);
LUAD	cis	rs877282	0.853	rs11595510	chr10:756757	C/G	cg17470449	chr10:769945	NA	0.57	8.19	0.37	3.22e-15	Uric acid levels;
LUAD	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg26924012	chr15:45694286	SPATA5L1	0.99	18.46	0.67	3.17e-56	Homoarginine levels;
LUAD	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.8	-13.74	-0.56	9.16e-36	Chronic sinus infection;
LUAD	cis	rs10193935	0.901	rs6713242	chr2:42470794	C/T	cg27598129	chr2:42591480	NA	-0.78	-8.82	-0.39	3.02e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.22	-0.41	1.38e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg08873628	chr1:175162347	KIAA0040	0.39	6.64	0.31	9.39e-11	Alcohol dependence;
LUAD	cis	rs4077468	0.963	rs1342064	chr1:205913073	T/C	cg07167872	chr1:205819463	PM20D1	-0.37	-6.64	-0.31	9.48e-11	Cystic fibrosis-related diabetes;
LUAD	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg15181151	chr6:150070149	PCMT1	0.39	7.6	0.35	1.91e-13	Lung cancer;
LUAD	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-8.75	-0.39	5.01e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.25	-0.41	1.16e-18	Total body bone mineral density;
LUAD	cis	rs4243830	0.677	rs6693922	chr1:6584804	A/T	cg05709478	chr1:6581295	PLEKHG5	0.61	8.45	0.38	4.77e-16	Body mass index;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15459742	chr9:111775564	CTNNAL1	-0.44	-6.99	-0.32	1.07e-11	Height;
LUAD	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.8	0.43	1.38e-20	Colorectal cancer;
LUAD	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg15181151	chr6:150070149	PCMT1	0.42	8.63	0.39	1.27e-16	Lung cancer;
LUAD	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-15.16	-0.59	9.2e-42	Chronic sinus infection;
LUAD	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.99	-0.5	1.05e-28	Mean corpuscular volume;
LUAD	cis	rs4763879	0.752	rs10772083	chr12:9874898	T/C	cg27502298	chr12:9555721	NA	-0.42	-6.44	-0.3	3.19e-10	Type 1 diabetes;
LUAD	cis	rs6761276	0.899	rs6759676	chr2:113836348	A/G	cg02343335	chr2:113785852	IL1F8	0.36	7.27	0.33	1.78e-12	Protein quantitative trait loci;
LUAD	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	cis	rs7428	0.527	rs4459734	chr2:85547429	G/T	cg24342717	chr2:85555507	TGOLN2	-0.49	-7.9	-0.36	2.37e-14	Ear protrusion;
LUAD	cis	rs68170813	0.559	rs12537342	chr7:106943563	T/C	cg23024343	chr7:107201750	COG5	0.5	7.25	0.33	2.06e-12	Coronary artery disease;
LUAD	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg16797656	chr11:68205561	LRP5	0.45	8.48	0.38	3.83e-16	Total body bone mineral density;
LUAD	cis	rs912330	0.529	rs4772100	chr13:99196573	G/T	cg07423050	chr13:99094983	FARP1	-0.37	-6.67	-0.31	8.02e-11	Alzheimer's disease;
LUAD	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg20476274	chr7:133979776	SLC35B4	0.86	17.46	0.65	8.8e-52	Mean platelet volume;
LUAD	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.07	0.37	7.33e-15	Menopause (age at onset);
LUAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27297192	chr10:134578999	INPP5A	-0.37	-6.73	-0.31	5.46e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg20203395	chr5:56204925	C5orf35	-0.7	-10.06	-0.44	1.74e-21	Initial pursuit acceleration;
LUAD	cis	rs11650494	0.908	rs77488129	chr17:47448970	G/A	cg08112188	chr17:47440006	ZNF652	0.98	8.22	0.37	2.52e-15	Prostate cancer;
LUAD	trans	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	12.55	0.52	6.2e-31	Exhaled nitric oxide output;
LUAD	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg06608945	chr2:219082296	ARPC2	-0.4	-6.84	-0.32	2.75e-11	Colorectal cancer;
LUAD	cis	rs2281636	0.792	rs10883385	chr10:101381713	G/A	cg17885402	chr10:101492224	COX15;CUTC	-0.37	-6.39	-0.3	4.33e-10	Obesity-related traits;
LUAD	cis	rs7640424	0.589	rs78673584	chr3:107813133	A/G	cg09227934	chr3:107805635	CD47	-0.66	-10.42	-0.45	8.42e-23	Body mass index;
LUAD	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg24675056	chr1:15929824	NA	0.49	8.48	0.38	3.92e-16	Systolic blood pressure;
LUAD	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg24558204	chr6:135376177	HBS1L	-0.5	-8.57	-0.38	1.94e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.1	-0.51	3.68e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2797160	1.000	rs6910933	chr6:126017155	C/G	cg05901451	chr6:126070800	HEY2	0.45	6.58	0.3	1.39e-10	Endometrial cancer;
LUAD	cis	rs4711350	0.723	rs608971	chr6:33702079	C/T	cg18005901	chr6:33739558	LEMD2	0.54	6.45	0.3	2.99e-10	Schizophrenia;
LUAD	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	8.74	0.39	5.55e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg00933542	chr6:150070202	PCMT1	0.41	8.69	0.39	8.09e-17	Lung cancer;
LUAD	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg06641503	chr3:48959341	ARIH2	-0.35	-6.53	-0.3	1.92e-10	Menarche (age at onset);
LUAD	cis	rs10927875	0.501	rs9660676	chr1:16279041	C/T	cg21385522	chr1:16154831	NA	-0.93	-13.48	-0.55	1.05e-34	Dilated cardiomyopathy;
LUAD	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg23422044	chr7:1970798	MAD1L1	-0.6	-7.38	-0.34	8.42e-13	Bipolar disorder;
LUAD	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.64	0.55	2.2e-35	Tonsillectomy;
LUAD	trans	rs931812	0.825	rs35515344	chr8:101896769	C/G	cg20993868	chr7:22813445	NA	0.63	12.52	0.52	7.92e-31	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg06641503	chr3:48959341	ARIH2	-0.35	-6.53	-0.3	1.92e-10	Menarche (age at onset);
LUAD	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg03929089	chr4:120376271	NA	-0.5	-8.05	-0.36	8.63e-15	HDL cholesterol;
LUAD	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg17105886	chr17:28927953	LRRC37B2	0.77	7.66	0.35	1.24e-13	Body mass index;
LUAD	cis	rs2004318	1.000	rs113056067	chr19:55087702	C/T	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.85e-13	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg02038168	chr22:39784481	NA	-0.57	-10.1	-0.44	1.26e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg17845761	chr1:175162550	KIAA0040	0.34	9.11	0.4	3.32e-18	Alcohol dependence;
LUAD	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg21775007	chr8:11205619	TDH	-0.49	-9.04	-0.4	5.51e-18	Retinal vascular caliber;
LUAD	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08677398	chr8:58056175	NA	0.53	6.93	0.32	1.57e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg11833968	chr6:79620685	NA	-0.44	-8.32	-0.38	1.22e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs5756391	0.546	rs9607392	chr22:37315592	C/T	cg16356956	chr22:37317934	CSF2RB	0.32	7.1	0.33	5.24e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	trans	rs8073060	0.586	rs4796098	chr17:33913436	T/C	cg19694781	chr19:47549865	TMEM160	1.25	19.78	0.69	3.82e-62	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.19	0.33	3.01e-12	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg05926928	chr17:57297772	GDPD1	1.48	20.3	0.7	1.89e-64	Opioid sensitivity;
LUAD	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg08847533	chr14:75593920	NEK9	0.4	6.81	0.31	3.42e-11	Height;
LUAD	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg03714773	chr7:91764589	CYP51A1	0.27	6.55	0.3	1.64e-10	Breast cancer;
LUAD	trans	rs1941687	0.563	rs1565784	chr18:31358491	G/T	cg27147174	chr7:100797783	AP1S1	0.66	12.16	0.51	2.25e-29	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04275040	chr17:78936628	RPTOR	0.51	7.08	0.33	6.15e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.31e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg16479474	chr6:28041457	NA	0.48	8.18	0.37	3.31e-15	Depression;
LUAD	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.77	0.39	4.32e-17	Lung cancer in ever smokers;
LUAD	trans	rs9929218	0.953	rs3114411	chr16:68734591	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.89	14.81	0.58	2.91e-40	Colorectal cancer;
LUAD	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.43	-6.94	-0.32	1.52e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg00981070	chr1:2046702	PRKCZ	0.34	7.44	0.34	5.79e-13	Height;
LUAD	cis	rs2227564	0.794	rs2688607	chr10:75663736	C/T	cg23231163	chr10:75533350	FUT11	0.42	6.71	0.31	6.4e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg21918786	chr6:109611834	NA	-0.53	-9.84	-0.43	1.05e-20	Reticulocyte fraction of red cells;
LUAD	cis	rs17401966	0.838	rs17034643	chr1:10332102	A/G	cg19773385	chr1:10388646	KIF1B	0.39	6.54	0.3	1.83e-10	Hepatocellular carcinoma;
LUAD	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.49	-0.3	2.4e-10	Alzheimer's disease (late onset);
LUAD	cis	rs4594175	0.962	rs72688734	chr14:51634618	T/C	cg23942311	chr14:51606299	NA	0.66	11.38	0.48	2.41e-26	Cancer;
LUAD	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg22535103	chr8:58192502	C8orf71	-0.75	-10.61	-0.46	1.8e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs9658691	0.607	rs9658791	chr10:90777338	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-7.0	-0.32	9.81e-12	Mosquito bite size;
LUAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg02951883	chr7:2050386	MAD1L1	-0.95	-18.98	-0.68	1.49e-58	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	10.95	0.47	9.73e-25	Hip circumference adjusted for BMI;
LUAD	trans	rs7944735	0.628	rs4752879	chr11:47897772	C/T	cg03929089	chr4:120376271	NA	0.52	6.97	0.32	1.24e-11	Intraocular pressure;
LUAD	cis	rs1595825	0.891	rs60129872	chr2:198653192	A/G	cg11031976	chr2:198649780	BOLL	-0.44	-6.6	-0.31	1.21e-10	Ulcerative colitis;
LUAD	cis	rs600626	0.636	rs11236517	chr11:75452721	T/C	cg24262691	chr11:75473276	NA	0.55	7.17	0.33	3.28e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg25554036	chr4:6271136	WFS1	0.66	12.71	0.53	1.39e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg04568274	chr7:158649319	WDR60	-0.44	-6.81	-0.31	3.45e-11	Height;
LUAD	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.94	0.36	1.85e-14	Bladder cancer;
LUAD	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg07570687	chr10:102243282	WNT8B	0.44	6.91	0.32	1.83e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs11030122	0.673	rs10835474	chr11:4020819	G/T	cg18678763	chr11:4115507	RRM1	-0.46	-7.48	-0.34	4.37e-13	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg19862616	chr7:65841803	NCRNA00174	1.05	24.97	0.77	3.04e-85	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg26587870	chr6:27730563	NA	-0.57	-6.79	-0.31	3.76e-11	Breast cancer;
LUAD	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg08859206	chr1:53392774	SCP2	0.57	10.12	0.44	1.1e-21	Monocyte count;
LUAD	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.81	-0.31	3.44e-11	Personality dimensions;
LUAD	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-6.71	-0.31	6.31e-11	Fear of minor pain;
LUAD	cis	rs7904368	0.754	rs66491181	chr10:16849430	T/C	cg14835575	chr10:16859367	RSU1	0.92	13.26	0.54	8.33e-34	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs1953600	0.870	rs2573356	chr10:81949363	C/T	cg00277334	chr10:82204260	NA	0.42	7.11	0.33	4.91e-12	Sarcoidosis;
LUAD	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg25767906	chr1:53392781	SCP2	-0.42	-7.44	-0.34	5.79e-13	Monocyte count;
LUAD	cis	rs7630877	0.924	rs11709733	chr3:179628320	A/C	cg18765712	chr3:179670323	PEX5L	0.37	6.46	0.3	2.85e-10	Type 2 diabetes;
LUAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg07677032	chr17:61819896	STRADA	0.56	10.09	0.44	1.34e-21	Prudent dietary pattern;
LUAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.91e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg04727924	chr7:799746	HEATR2	-0.53	-7.14	-0.33	4.04e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs3924048	0.559	rs6541039	chr1:12626261	T/C	cg00291366	chr1:12616550	NA	0.33	6.53	0.3	1.86e-10	Optic cup area;
LUAD	cis	rs68170813	0.559	rs11769527	chr7:106912948	C/T	cg23024343	chr7:107201750	COG5	0.5	7.33	0.34	1.2e-12	Coronary artery disease;
LUAD	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11890956	chr21:40555474	PSMG1	-0.57	-9.16	-0.41	2.32e-18	Cognitive function;
LUAD	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.75	0.31	5.03e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs57994353	0.793	rs33982662	chr9:139324737	C/A	cg14019695	chr9:139328340	INPP5E	0.4	6.69	0.31	7e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg16797656	chr11:68205561	LRP5	0.46	8.73	0.39	6.16e-17	Total body bone mineral density;
LUAD	cis	rs73198271	0.628	rs11780486	chr8:8589494	C/T	cg01851573	chr8:8652454	MFHAS1	-0.46	-6.64	-0.31	9.57e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.09	-0.33	5.79e-12	Lung cancer;
LUAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg05434287	chr7:2030229	MAD1L1	0.4	6.63	0.31	1.03e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6998277	1.000	rs34217554	chr8:103646352	T/C	cg10187029	chr8:103597600	NA	0.75	11.43	0.49	1.55e-26	Migraine;
LUAD	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg05665937	chr4:1216051	CTBP1	0.39	6.48	0.3	2.53e-10	Obesity-related traits;
LUAD	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03934478	chr11:495069	RNH1	0.77	9.06	0.4	4.85e-18	Body mass index;
LUAD	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg09137382	chr11:130731461	NA	0.42	7.54	0.34	2.95e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg15309053	chr8:964076	NA	0.47	10.37	0.45	1.38e-22	Schizophrenia;
LUAD	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg18230493	chr5:56204884	C5orf35	-0.78	-11.72	-0.5	1.18e-27	Initial pursuit acceleration;
LUAD	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg17551891	chr7:1960795	MAD1L1	-0.4	-6.94	-0.32	1.51e-11	Neuroticism;
LUAD	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-9.79	-0.43	1.52e-20	Platelet count;
LUAD	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg04851639	chr8:1020857	NA	-0.39	-9.18	-0.41	1.89e-18	Schizophrenia;
LUAD	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg02018176	chr4:1364513	KIAA1530	0.37	7.0	0.32	9.97e-12	Obesity-related traits;
LUAD	cis	rs2033908	0.620	rs1371753	chr11:12853703	G/A	cg25843174	chr11:12811716	TEAD1	-0.21	-6.43	-0.3	3.38e-10	Sitting height ratio;
LUAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg24813613	chr7:1882135	MAD1L1	-0.53	-8.44	-0.38	5.23e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs56283067	0.887	rs9463042	chr6:44770527	T/C	cg18551225	chr6:44695536	NA	-0.48	-7.5	-0.34	3.82e-13	Total body bone mineral density;
LUAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg25703541	chr22:24373054	LOC391322	-0.92	-18.98	-0.68	1.48e-58	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21659725	chr3:3221576	CRBN	-0.5	-8.3	-0.37	1.38e-15	Body mass index;
LUAD	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg11915388	chr22:42470451	FAM109B	0.4	7.2	0.33	2.84e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs684232	0.666	rs366151	chr17:598311	A/C	cg12384639	chr17:618140	VPS53	0.5	8.61	0.39	1.44e-16	Prostate cancer;
LUAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07157834	chr1:205819609	PM20D1	0.83	17.56	0.65	3.04e-52	Menarche (age at onset);
LUAD	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	0.61	10.53	0.46	3.61e-23	Menarche (age at onset);
LUAD	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg25894440	chr7:65020034	NA	-0.68	-7.36	-0.34	9.49e-13	Diabetic kidney disease;
LUAD	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg27432699	chr2:27873401	GPN1	-0.38	-6.44	-0.3	3.21e-10	Total body bone mineral density;
LUAD	cis	rs7799006	0.527	rs3779009	chr7:2203692	G/C	cg04267008	chr7:1944627	MAD1L1	-0.44	-6.46	-0.3	2.86e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg04944784	chr2:26401820	FAM59B	-0.76	-10.54	-0.46	3.16e-23	Gut microbiome composition (summer);
LUAD	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg05368731	chr17:41323189	NBR1	0.97	20.87	0.71	5.27e-67	Menopause (age at onset);
LUAD	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg22117172	chr7:91764530	CYP51A1	0.36	7.69	0.35	1.05e-13	Breast cancer;
LUAD	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg04155289	chr7:94953770	PON1	-0.54	-7.36	-0.34	9.91e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	7.08	0.33	5.95e-12	Cognitive test performance;
LUAD	cis	rs2637266	0.935	rs6480822	chr10:78354092	A/C	cg18941641	chr10:78392320	NA	0.35	7.34	0.34	1.07e-12	Pulmonary function;
LUAD	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg26513180	chr16:89883248	FANCA	0.79	7.27	0.33	1.76e-12	Skin colour saturation;
LUAD	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg22823121	chr1:150693482	HORMAD1	0.45	9.18	0.41	1.93e-18	Tonsillectomy;
LUAD	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg08085267	chr17:45401833	C17orf57	0.64	11.27	0.48	6.37e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg02012338	chr4:187126139	CYP4V2	1.06	10.37	0.45	1.31e-22	Blood protein levels;
LUAD	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg10518543	chr12:38710700	ALG10B	0.42	6.42	0.3	3.68e-10	Bladder cancer;
LUAD	cis	rs73206853	0.563	rs7301623	chr12:111170903	T/C	cg12870014	chr12:110450643	ANKRD13A	0.6	7.0	0.32	1.02e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs7395662	0.500	rs7947055	chr11:48977086	C/T	cg00717180	chr2:96193071	NA	0.37	6.86	0.32	2.4e-11	HDL cholesterol;
LUAD	trans	rs11039798	1.000	rs7125913	chr11:48984318	G/A	cg03929089	chr4:120376271	NA	0.58	6.57	0.3	1.44e-10	Axial length;
LUAD	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg26384229	chr12:38710491	ALG10B	0.47	7.58	0.35	2.15e-13	Morning vs. evening chronotype;
LUAD	cis	rs11971779	0.680	rs6467846	chr7:139079385	G/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.82	0.31	3.2e-11	Diisocyanate-induced asthma;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02970425	chr20:48552805	RNF114	-0.43	-6.72	-0.31	5.89e-11	Height;
LUAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9905704	0.681	rs4277402	chr17:56581651	C/G	cg19466818	chr17:56409534	MIR142	0.34	6.66	0.31	8.36e-11	Testicular germ cell tumor;
LUAD	cis	rs9473147	0.543	rs9381578	chr6:47556634	C/T	cg20196966	chr6:47445060	CD2AP	0.43	6.86	0.32	2.39e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs877282	0.853	rs4579862	chr10:753298	A/C	cg17470449	chr10:769945	NA	0.59	8.12	0.37	5.12e-15	Uric acid levels;
LUAD	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg27170947	chr2:26402098	FAM59B	-0.82	-11.49	-0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs11229555	0.645	rs12805062	chr11:58214584	A/G	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg13732083	chr21:47605072	C21orf56	0.42	6.95	0.32	1.39e-11	Testicular germ cell tumor;
LUAD	cis	rs68170813	0.617	rs10464499	chr7:107137571	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-8.9	-0.4	1.66e-17	Coronary artery disease;
LUAD	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg07570687	chr10:102243282	WNT8B	0.48	7.35	0.34	1.04e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg27572855	chr1:25598939	RHD	0.61	13.66	0.55	1.88e-35	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg15181151	chr6:150070149	PCMT1	0.33	6.5	0.3	2.33e-10	Lung cancer;
LUAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04155289	chr7:94953770	PON1	-0.62	-11.39	-0.48	2.19e-26	Paraoxonase activity;
LUAD	cis	rs1403694	0.515	rs1624569	chr3:186450069	A/G	cg12454167	chr3:186435060	KNG1	0.38	7.86	0.36	3.2e-14	Blood protein levels;
LUAD	cis	rs2066819	1.000	rs2371454	chr12:56647243	A/G	cg26714650	chr12:56694279	CS	0.86	7.3	0.33	1.46e-12	Psoriasis vulgaris;
LUAD	cis	rs1595825	1.000	rs73058832	chr2:198873214	G/T	cg00361562	chr2:198649771	BOLL	-0.48	-6.63	-0.31	1e-10	Ulcerative colitis;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14265380	chr11:63741847	COX8A	-0.39	-6.4	-0.3	4.02e-10	Cancer;
LUAD	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08564027	chr20:61660810	NA	0.87	18.66	0.67	4.14e-57	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg06131755	chr6:160182447	ACAT2	0.74	10.62	0.46	1.68e-23	Iron status biomarkers;
LUAD	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg14092988	chr3:52407081	DNAH1	0.45	8.98	0.4	8.87e-18	Bipolar disorder;
LUAD	cis	rs870825	0.616	rs28375770	chr4:185647395	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs9925964	0.933	rs2303222	chr16:31085470	A/G	cg03418659	chr16:31128414	MYST1	0.42	7.53	0.34	3.15e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs240764	0.817	rs239204	chr6:101135580	T/C	cg09795085	chr6:101329169	ASCC3	0.45	7.8	0.35	5.02e-14	Neuroticism;
LUAD	cis	rs9581857	0.685	rs9581856	chr13:28025615	G/C	cg22138327	chr13:27999177	GTF3A	0.9	10.54	0.46	3.27e-23	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs9308433	0.529	rs10465696	chr1:214499883	G/A	cg06198575	chr1:214491504	SMYD2	0.45	7.62	0.35	1.65e-13	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.3	0.37	1.42e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06505273	chr16:24850292	NA	-0.46	-6.61	-0.31	1.18e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg00431236	chr2:264988	ACP1;SH3YL1	0.41	6.58	0.3	1.38e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2235649	0.828	rs9938694	chr16:1849872	T/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.4	-6.42	-0.3	3.7e-10	Blood metabolite levels;
LUAD	cis	rs54211	0.572	rs79290	chr22:39685832	G/A	cg24399712	chr22:39784796	NA	-0.52	-6.65	-0.31	8.98e-11	Sudden cardiac arrest;
LUAD	cis	rs1045714	0.848	rs73033686	chr7:2635085	C/G	cg20813462	chr7:2646259	IQCE	0.69	7.66	0.35	1.27e-13	Urate levels in lean individuals;
LUAD	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg12365402	chr11:9010492	NRIP3	-0.44	-8.26	-0.37	1.95e-15	Hemoglobin concentration;
LUAD	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg03806693	chr22:41940476	POLR3H	0.77	10.28	0.45	2.78e-22	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg02158880	chr13:53174818	NA	0.59	10.27	0.45	3.09e-22	Lewy body disease;
LUAD	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg00271210	chr6:167070053	RPS6KA2	0.36	7.17	0.33	3.47e-12	Crohn's disease;
LUAD	trans	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.06	-27.31	-0.8	2.2199999999999998e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs13315871	1.000	rs12330157	chr3:58364562	C/T	cg12435725	chr3:58293450	RPP14	-0.67	-7.3	-0.33	1.42e-12	Cholesterol, total;
LUAD	cis	rs55788414	0.932	rs2317123	chr16:81182636	A/T	cg06400318	chr16:81190750	PKD1L2	-0.61	-8.02	-0.36	1.04e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg26384229	chr12:38710491	ALG10B	0.49	7.91	0.36	2.27e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9910055	0.552	rs4793084	chr17:42317371	G/T	cg13607699	chr17:42295918	UBTF	-0.57	-9.14	-0.41	2.6e-18	Total body bone mineral density;
LUAD	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56283067	0.847	rs10456118	chr6:44692825	G/T	cg18551225	chr6:44695536	NA	-0.61	-10.15	-0.44	8.03e-22	Total body bone mineral density;
LUAD	cis	rs6543140	0.964	rs6543142	chr2:103082006	T/C	cg03938978	chr2:103052716	IL18RAP	0.35	6.82	0.31	3.26e-11	Blood protein levels;
LUAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.76	-0.31	4.58e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs13315871	1.000	rs9821570	chr3:58335919	C/G	cg20936604	chr3:58311152	NA	-0.69	-7.19	-0.33	2.89e-12	Cholesterol, total;
LUAD	cis	rs2274273	0.648	rs58553156	chr14:55582694	T/A	cg04306507	chr14:55594613	LGALS3	0.38	7.24	0.33	2.16e-12	Protein biomarker;
LUAD	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.13	0.33	4.51e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg18538332	chr22:24372958	LOC391322	-0.53	-9.04	-0.4	5.74e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs250585	1.000	rs488131	chr16:23475140	C/T	cg00143387	chr16:23521605	GGA2	-0.62	-7.4	-0.34	7.65e-13	Egg allergy;
LUAD	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.33	-0.45	1.89e-22	Total body bone mineral density;
LUAD	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg24308560	chr3:49941425	MST1R	-0.51	-8.15	-0.37	4.13e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs45509595	0.841	rs17751184	chr6:27775028	C/T	cg01620082	chr3:125678407	NA	-1.01	-10.18	-0.44	6.4e-22	Breast cancer;
LUAD	cis	rs758324	0.853	rs10051653	chr5:131248894	G/A	cg06307176	chr5:131281290	NA	-0.46	-7.69	-0.35	1.01e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg17848003	chr1:3704513	LRRC47	0.5	10.69	0.46	8.76e-24	Red cell distribution width;
LUAD	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg21385522	chr1:16154831	NA	-1.08	-23.07	-0.75	8.12e-77	Dilated cardiomyopathy;
LUAD	cis	rs7100689	0.646	rs10736345	chr10:82134140	C/T	cg00277334	chr10:82204260	NA	-0.63	-10.54	-0.46	3.26e-23	Post bronchodilator FEV1;
LUAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-9.5	-0.42	1.52e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg13736514	chr6:26305472	NA	-0.71	-13.36	-0.54	3.28e-34	Educational attainment;
LUAD	cis	rs78366141	0.536	rs78517451	chr4:89650437	C/A	cg01026744	chr4:89619053	NAP1L5;HERC3	1.02	6.99	0.32	1.07e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg06608945	chr2:219082296	ARPC2	0.43	7.22	0.33	2.41e-12	Colorectal cancer;
LUAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg22907277	chr7:1156413	C7orf50	0.7	8.2	0.37	2.97e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18876405	chr7:65276391	NA	0.63	10.85	0.47	2.24e-24	Aortic root size;
LUAD	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs10788264	0.513	rs10749455	chr10:124035030	A/G	cg09507567	chr10:124027408	NA	0.51	11.26	0.48	6.87e-26	Total body bone mineral density;
LUAD	cis	rs10744422	0.858	rs12426809	chr12:123327143	C/T	cg16953816	chr12:123349952	VPS37B	0.62	7.17	0.33	3.34e-12	Schizophrenia;
LUAD	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs4803468	0.967	rs16975238	chr19:41944985	T/A	cg09537434	chr19:41945824	ATP5SL	0.51	7.91	0.36	2.23e-14	Height;
LUAD	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg05665937	chr4:1216051	CTBP1	-0.45	-8.16	-0.37	3.84e-15	Obesity-related traits;
LUAD	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg25036284	chr2:26402008	FAM59B	-0.83	-11.68	-0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg11663144	chr21:46675770	NA	0.6	11.42	0.49	1.62e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg23260525	chr10:116636907	FAM160B1	0.47	10.84	0.47	2.48e-24	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg01097406	chr16:89675127	NA	-0.34	-6.68	-0.31	7.53e-11	Vitiligo;
LUAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12016809	chr21:47604291	C21orf56	-0.65	-11.03	-0.47	5.06e-25	Testicular germ cell tumor;
LUAD	cis	rs4243830	0.737	rs925745	chr1:6615690	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.51	-6.72	-0.31	5.99e-11	Body mass index;
LUAD	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg00933542	chr6:150070202	PCMT1	0.44	9.6	0.42	6.92e-20	Lung cancer;
LUAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg22963979	chr7:1858916	MAD1L1	-0.63	-10.84	-0.47	2.61e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.58	0.39	1.8e-16	Rheumatoid arthritis;
LUAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg18402987	chr7:1209562	NA	0.59	7.92	0.36	2.16e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg03035419	chr20:60962318	RPS21	-0.68	-6.79	-0.31	3.84e-11	Type 2 diabetes;
LUAD	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.56	-9.59	-0.42	7.5e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs4824093	0.610	rs28473584	chr22:50315413	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-7.2	-0.33	2.74e-12	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg17264618	chr3:40429014	ENTPD3	0.43	9.17	0.41	2.14e-18	Renal cell carcinoma;
LUAD	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg10556349	chr10:835070	NA	0.59	7.58	0.35	2.15e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg04450003	chr12:50355995	AQP5	0.58	9.14	0.41	2.61e-18	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13744070	chr11:61197882	SDHAF2;CPSF7	-0.38	-6.38	-0.3	4.67e-10	Cancer;
LUAD	cis	rs35740288	0.770	rs35447727	chr15:86174399	C/T	cg13263323	chr15:86062960	AKAP13	-0.45	-7.28	-0.33	1.61e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.52	-6.42	-0.3	3.68e-10	Body mass index;
LUAD	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg07870213	chr5:140052090	DND1	-0.83	-11.39	-0.48	2.15e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs12612619	0.732	rs722911	chr2:27211212	A/G	cg00617064	chr2:27272375	NA	-0.35	-6.68	-0.31	7.77e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg07460842	chr6:66804631	NA	1.09	16.97	0.64	1.26e-49	Exhaled nitric oxide output;
LUAD	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg23533926	chr12:111358616	MYL2	-0.42	-7.18	-0.33	3.2e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg04450456	chr4:17643702	FAM184B	0.38	7.41	0.34	6.95e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg01448562	chr3:133502909	NA	-0.52	-9.08	-0.4	4.02e-18	Iron status biomarkers;
LUAD	cis	rs7301826	0.967	rs4759792	chr12:131296631	G/A	cg11011512	chr12:131303247	STX2	0.39	6.71	0.31	6.2e-11	Plasma plasminogen activator levels;
LUAD	cis	rs7590720	1.000	rs7559031	chr2:216902583	A/G	cg12620499	chr2:216877984	MREG	0.56	8.95	0.4	1.15e-17	Alcohol dependence;
LUAD	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.46e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg17595323	chr11:93583763	C11orf90	-0.43	-9.07	-0.4	4.57e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs2012796	0.785	rs61986599	chr14:81860917	G/A	cg02996355	chr14:81879375	NA	0.54	8.29	0.37	1.54e-15	Night sleep phenotypes;
LUAD	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg07402062	chr16:89894098	SPIRE2	0.46	11.98	0.5	1.14e-28	Vitiligo;
LUAD	cis	rs9393692	0.557	rs725575	chr6:26301919	A/T	cg13736514	chr6:26305472	NA	-0.54	-8.87	-0.4	2.05e-17	Educational attainment;
LUAD	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg16479474	chr6:28041457	NA	0.48	8.25	0.37	1.98e-15	Depression;
LUAD	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg18198730	chr1:247681584	NA	0.41	7.65	0.35	1.39e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs11671005	0.735	rs12981649	chr19:58930043	G/C	cg13877915	chr19:58951672	ZNF132	0.56	7.42	0.34	6.67e-13	Mean platelet volume;
LUAD	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg08280861	chr8:58055591	NA	0.56	7.07	0.33	6.27e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9513627	1.000	rs2390279	chr13:100208705	A/G	cg25919922	chr13:100150906	NA	-0.64	-6.42	-0.3	3.58e-10	Obesity-related traits;
LUAD	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg18404041	chr3:52824283	ITIH1	-0.41	-7.66	-0.35	1.24e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg08085267	chr17:45401833	C17orf57	-0.65	-11.49	-0.49	8.62e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg22532475	chr10:104410764	TRIM8	-0.44	-8.72	-0.39	6.46e-17	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg06606381	chr12:133084897	FBRSL1	-1.11	-8.35	-0.38	9.78e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg09222892	chr1:25734099	RHCE	-0.52	-9.66	-0.43	4.31e-20	Erythrocyte sedimentation rate;
LUAD	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg02196655	chr2:10830764	NOL10	-0.43	-7.75	-0.35	6.8e-14	Prostate cancer;
LUAD	cis	rs3096299	0.933	rs2930219	chr16:89492049	G/A	cg06640241	chr16:89574553	SPG7	0.47	7.63	0.35	1.55e-13	Multiple myeloma (IgH translocation);
LUAD	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06544989	chr22:39130855	UNC84B	0.38	7.07	0.33	6.4e-12	Menopause (age at onset);
LUAD	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg05340658	chr4:99064831	C4orf37	-0.46	-7.64	-0.35	1.48e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11657217	0.638	rs4313839	chr17:77698619	C/T	cg06901238	chr17:77706717	ENPP7	-0.73	-14.3	-0.57	4.24e-38	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
LUAD	trans	rs7127307	0.740	rs4144896	chr11:128182026	C/T	cg20719122	chr6:35523700	NA	0.53	6.97	0.32	1.22e-11	Atopic dermatitis;
LUAD	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg05590025	chr7:65112418	INTS4L2	0.69	7.56	0.34	2.54e-13	Diabetic kidney disease;
LUAD	trans	rs3857536	0.674	rs9345798	chr6:66951331	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.66	-0.31	8.67e-11	Blood trace element (Cu levels);
LUAD	trans	rs9914544	0.545	rs8071783	chr17:18807939	C/G	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.69	-0.31	6.95e-11	Educational attainment (years of education);
LUAD	trans	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg16554228	chr10:79794011	RPS24	-0.45	-6.44	-0.3	3.27e-10	Fibrinogen levels;
LUAD	trans	rs984440	0.560	rs7816346	chr8:139084529	A/G	cg03334052	chr1:168888044	NA	-0.44	-7.31	-0.33	1.36e-12	Obesity-related traits;
LUAD	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.75	-15.44	-0.6	5.75e-43	Lung cancer;
LUAD	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg17724175	chr1:150552817	MCL1	0.39	9.43	0.42	2.64e-19	Tonsillectomy;
LUAD	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg09945482	chr18:12777974	NA	0.54	6.8	0.31	3.53e-11	Inflammatory skin disease;
LUAD	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg03806693	chr22:41940476	POLR3H	-0.75	-10.1	-0.44	1.26e-21	Vitiligo;
LUAD	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg06873352	chr17:61820015	STRADA	0.41	6.84	0.32	2.72e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg27411982	chr8:10470053	RP1L1	-0.45	-8.42	-0.38	6.03e-16	Triglycerides;
LUAD	cis	rs2535633	0.594	rs2581789	chr3:53096230	C/T	cg11645453	chr3:52864694	ITIH4	-0.34	-6.38	-0.3	4.7e-10	Body mass index;
LUAD	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg09184832	chr6:79620586	NA	-0.52	-9.76	-0.43	1.92e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs1160297	0.585	rs12713227	chr2:53090018	A/G	cg07782112	chr2:53107842	NA	0.36	7.56	0.35	2.46e-13	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	9.57	0.42	9.24e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs12545109	0.879	rs2609994	chr8:57365844	A/G	cg11919837	chr8:57350735	NA	-0.49	-6.8	-0.31	3.58e-11	Obesity-related traits;
LUAD	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg27411982	chr8:10470053	RP1L1	-0.39	-7.25	-0.33	2.04e-12	Triglycerides;
LUAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg12373951	chr3:133503437	NA	0.37	7.33	0.34	1.21e-12	Iron status biomarkers;
LUAD	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg17173187	chr15:85201210	NMB	0.48	8.38	0.38	7.98e-16	Schizophrenia;
LUAD	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg02990361	chr1:107599529	PRMT6	-0.64	-10.83	-0.47	2.68e-24	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg13685833	chr1:53393034	SCP2	-0.41	-6.51	-0.3	2.15e-10	Monocyte count;
LUAD	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg26384229	chr12:38710491	ALG10B	-0.44	-7.41	-0.34	6.93e-13	Morning vs. evening chronotype;
LUAD	trans	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg06606381	chr12:133084897	FBRSL1	-0.81	-8.03	-0.36	9.89e-15	Depression;
LUAD	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg06558623	chr16:89946397	TCF25	1.15	10.16	0.44	7.69e-22	Skin colour saturation;
LUAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg00280220	chr17:61926910	NA	0.37	7.06	0.32	7.05e-12	Prudent dietary pattern;
LUAD	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg03388025	chr16:89894329	SPIRE2	0.31	7.05	0.32	7.32e-12	Vitiligo;
LUAD	cis	rs4925114	0.568	rs11656775	chr17:17654319	A/G	cg09796270	chr17:17721594	SREBF1	-0.36	-7.07	-0.32	6.65e-12	Body mass index;
LUAD	cis	rs7127900	0.614	rs72853920	chr11:2206429	T/C	cg25635251	chr11:2234043	NA	-0.78	-10.55	-0.46	2.96e-23	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
LUAD	cis	rs6854137	0.758	rs4692949	chr4:169733334	C/T	cg20607169	chr4:169750834	PALLD	0.37	6.51	0.3	2.15e-10	Vein graft stenosis in coronary artery bypass grafting;
LUAD	trans	rs783540	0.967	rs1259183	chr15:83279433	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.44	-7.02	-0.32	9.13e-12	Schizophrenia;
LUAD	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg02951883	chr7:2050386	MAD1L1	-0.81	-14.01	-0.56	6.44e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs597539	0.690	rs1249359	chr11:68618279	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	12.76	0.53	8.75e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.45	6.81	0.31	3.29e-11	Schizophrenia;
LUAD	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg05304507	chr6:116381966	FRK	0.2	6.79	0.31	3.7e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg22189786	chr22:42395067	WBP2NL	0.45	6.52	0.3	2.02e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg00280220	chr17:61926910	NA	0.36	6.88	0.32	2.23e-11	Prudent dietary pattern;
LUAD	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg10434728	chr15:90938212	IQGAP1	0.36	7.15	0.33	3.83e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg24112000	chr20:60950667	NA	-0.72	-10.41	-0.45	9.58e-23	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs4713118	1.000	rs4713118	chr6:27676794	A/G	cg26587870	chr6:27730563	NA	-0.4	-6.45	-0.3	2.98e-10	Parkinson's disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg24158452	chr17:40428550	STAT5B	-0.73	-7.23	-0.33	2.26e-12	Type 2 diabetes;
LUAD	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg05110241	chr16:68378359	PRMT7	-0.8	-8.88	-0.4	1.91e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7617773	0.784	rs9850672	chr3:48301172	C/A	cg11946769	chr3:48343235	NME6	0.43	6.85	0.32	2.54e-11	Coronary artery disease;
LUAD	cis	rs354225	0.544	rs10182538	chr2:54808251	T/A	cg01766943	chr2:54829624	SPTBN1	0.39	7.34	0.34	1.1e-12	Schizophrenia;
LUAD	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg26384229	chr12:38710491	ALG10B	0.47	7.56	0.35	2.48e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg11494091	chr17:61959527	GH2	0.74	18.58	0.67	9.11e-57	Prudent dietary pattern;
LUAD	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg03806693	chr22:41940476	POLR3H	-0.78	-11.0	-0.47	6.52e-25	Vitiligo;
LUAD	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg22676075	chr6:135203613	NA	0.39	7.29	0.33	1.56e-12	Red blood cell count;
LUAD	cis	rs500891	0.525	rs1170483	chr6:84038253	G/C	cg08257003	chr6:84140564	ME1	0.34	6.35	0.3	5.43e-10	Platelet-derived growth factor BB levels;
LUAD	trans	rs507506	0.771	rs929229	chr17:7105399	C/T	cg15655154	chr3:113604241	GRAMD1C	0.7	13.05	0.54	6.19e-33	Adiponectin levels;
LUAD	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg25804541	chr17:80189381	SLC16A3	-0.33	-7.33	-0.34	1.16e-12	Life satisfaction;
LUAD	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg05966235	chr16:28915196	ATP2A1	0.53	8.42	0.38	6.1e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.83	-0.32	2.89e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs208520	0.690	rs207096	chr6:66797287	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-17.73	-0.65	5.21e-53	Exhaled nitric oxide output;
LUAD	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg06484146	chr7:12443880	VWDE	-0.58	-7.36	-0.34	9.91e-13	Coronary artery disease;
LUAD	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-14.54	-0.58	3.93e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7705042	0.826	rs13184323	chr5:141494719	T/G	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.53	-0.3	1.85e-10	Asthma;
LUAD	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.61	-9.54	-0.42	1.16e-19	Primary sclerosing cholangitis;
LUAD	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg19610905	chr11:61596333	FADS2	-0.67	-10.94	-0.47	1.03e-24	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs1595825	0.891	rs75163179	chr2:198895402	G/A	cg11031976	chr2:198649780	BOLL	-0.45	-6.53	-0.3	1.84e-10	Ulcerative colitis;
LUAD	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg12564285	chr5:131593104	PDLIM4	0.34	6.54	0.3	1.82e-10	Blood metabolite levels;
LUAD	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	8.58	0.38	1.87e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7127900	0.614	rs11564708	chr11:2206326	C/G	cg25635251	chr11:2234043	NA	0.77	10.56	0.46	2.69e-23	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
LUAD	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg17105886	chr17:28927953	LRRC37B2	0.72	6.57	0.3	1.53e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs68170813	0.641	rs1978085	chr7:107095216	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-10.59	-0.46	2.15e-23	Coronary artery disease;
LUAD	cis	rs34734847	0.787	rs1814851	chr12:121128633	C/G	cg21892295	chr12:121157589	UNC119B	-0.37	-6.6	-0.31	1.24e-10	Mean corpuscular volume;
LUAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg17372223	chr3:52568218	NT5DC2	0.45	8.71	0.39	6.7e-17	Electroencephalogram traits;
LUAD	cis	rs4711350	1.000	rs943472	chr6:33738442	T/C	cg13859433	chr6:33739653	LEMD2	-0.36	-6.89	-0.32	2.02e-11	Schizophrenia;
LUAD	trans	rs1941687	0.563	rs9947894	chr18:31328720	G/T	cg27147174	chr7:100797783	AP1S1	0.68	12.45	0.52	1.55e-30	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.4	0.38	6.82e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7524258	0.868	rs6693725	chr1:7307810	G/T	cg07173049	chr1:7289937	CAMTA1	0.43	8.2	0.37	2.85e-15	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg18402987	chr7:1209562	NA	0.8	9.84	0.43	1.03e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg00802000	chr16:706648	WDR90	-0.39	-7.05	-0.32	7.22e-12	Height;
LUAD	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg13679303	chr9:96623674	NA	-0.36	-7.26	-0.33	1.85e-12	DNA methylation (variation);
LUAD	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg13813247	chr22:41461852	NA	-0.49	-7.97	-0.36	1.52e-14	Neuroticism;
LUAD	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg18404041	chr3:52824283	ITIH1	-0.4	-7.36	-0.34	9.87e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2651899	0.865	rs2817126	chr1:3083246	T/G	cg24679453	chr1:3079069	PRDM16	-0.29	-6.52	-0.3	1.98e-10	Migraine;
LUAD	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg24675658	chr1:53192096	ZYG11B	-0.4	-6.56	-0.3	1.56e-10	Monocyte count;
LUAD	cis	rs7177699	0.557	rs72749206	chr15:79122948	G/A	cg00540400	chr15:79124168	NA	-0.45	-9.25	-0.41	1.15e-18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs870825	0.616	rs7668009	chr4:185641998	A/C	cg04058563	chr4:185651563	MLF1IP	0.89	14.71	0.58	7.55e-40	Blood protein levels;
LUAD	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg20503657	chr10:835505	NA	0.8	10.63	0.46	1.49e-23	Eosinophil percentage of granulocytes;
LUAD	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.39	-6.37	-0.3	4.94e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg12365402	chr11:9010492	NRIP3	0.48	9.17	0.41	2.1e-18	Hemoglobin concentration;
LUAD	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg16479474	chr6:28041457	NA	0.36	6.59	0.31	1.29e-10	Parkinson's disease;
LUAD	cis	rs2692947	0.795	rs2252697	chr2:96778190	G/C	cg23100626	chr2:96804247	ASTL	-0.35	-9.43	-0.42	2.67e-19	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs4713118	1.000	rs9468195	chr6:27676309	A/G	cg26587870	chr6:27730563	NA	-0.39	-6.39	-0.3	4.47e-10	Parkinson's disease;
LUAD	cis	rs12681287	0.608	rs2953511	chr8:87340870	G/A	cg27223183	chr8:87520930	FAM82B	-0.69	-9.71	-0.43	3.03e-20	Caudate activity during reward;
LUAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg22907277	chr7:1156413	C7orf50	0.71	8.26	0.37	1.84e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg23173402	chr1:227635558	NA	-0.65	-6.48	-0.3	2.52e-10	Major depressive disorder;
LUAD	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg06453172	chr10:134556979	INPP5A	-0.79	-11.15	-0.48	1.69e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg09117114	chr16:67998030	SLC12A4	-0.53	-6.98	-0.32	1.12e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg08125733	chr17:73851984	WBP2	0.57	8.41	0.38	6.47e-16	Psoriasis;
LUAD	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg04398451	chr17:18023971	MYO15A	0.78	14.28	0.57	4.71e-38	Total body bone mineral density;
LUAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg09033563	chr22:24373618	LOC391322	-0.57	-9.36	-0.41	4.72e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9287719	0.566	rs34595606	chr2:10722518	G/A	cg02196655	chr2:10830764	NOL10	-0.38	-6.5	-0.3	2.24e-10	Prostate cancer;
LUAD	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg15017067	chr4:17643749	FAM184B	0.35	6.74	0.31	5.21e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.49	-8.28	-0.37	1.65e-15	Longevity;Endometriosis;
LUAD	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21659725	chr3:3221576	CRBN	0.85	18.39	0.67	6.46e-56	Intelligence (multi-trait analysis);
LUAD	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg10523679	chr1:76189770	ACADM	-0.88	-15.45	-0.6	4.89e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg03526776	chr6:41159608	TREML2	0.32	6.57	0.3	1.48e-10	Alzheimer's disease (late onset);
LUAD	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg14196790	chr5:131705035	SLC22A5	0.38	6.89	0.32	2.04e-11	Blood metabolite levels;
LUAD	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21659725	chr3:3221576	CRBN	-0.64	-10.18	-0.44	6.25e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs3760982	0.585	rs67704568	chr19:44294019	T/C	cg21496419	chr19:44306685	LYPD5	0.33	7.4	0.34	7.17e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs7575217	0.697	rs796067	chr2:101707009	C/T	cg23907051	chr2:101730305	TBC1D8	-0.27	-6.44	-0.3	3.29e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg11814155	chr7:99998594	ZCWPW1	0.43	7.48	0.34	4.27e-13	Platelet count;
LUAD	cis	rs7289126	1.000	rs7290309	chr22:38630287	C/T	cg17652424	chr22:38574118	PLA2G6	-0.22	-6.37	-0.3	4.8e-10	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg00933542	chr6:150070202	PCMT1	0.41	8.56	0.38	2.18e-16	Lung cancer;
LUAD	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-6.63	-0.31	1.04e-10	Tonsillectomy;
LUAD	cis	rs7116495	1.000	rs10751193	chr11:71785356	A/C	cg07596299	chr11:71824057	C11orf51	-0.77	-6.53	-0.3	1.86e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06873352	chr17:61820015	STRADA	0.81	18.01	0.66	2.94e-54	Prudent dietary pattern;
LUAD	cis	rs12976411	0.575	rs6510240	chr19:32820082	A/G	cg02282382	chr19:32836354	ZNF507	0.71	6.42	0.3	3.6e-10	Coronary artery disease;
LUAD	trans	rs7944735	0.607	rs34895872	chr11:48021778	A/G	cg03929089	chr4:120376271	NA	0.57	7.89	0.36	2.58e-14	Intraocular pressure;
LUAD	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg00933542	chr6:150070202	PCMT1	0.34	6.96	0.32	1.29e-11	Lung cancer;
LUAD	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg00933542	chr6:150070202	PCMT1	0.44	9.52	0.42	1.34e-19	Lung cancer;
LUAD	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg00666640	chr1:248458726	OR2T12	-0.28	-7.12	-0.33	4.63e-12	Common traits (Other);
LUAD	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg17178900	chr1:205818956	PM20D1	-0.46	-7.14	-0.33	4.03e-12	Menarche (age at onset);
LUAD	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg11822812	chr5:140052017	DND1	-0.41	-7.52	-0.34	3.3e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs912057	0.833	rs1294424	chr6:6744135	G/A	cg06612196	chr6:6737390	NA	0.55	12.57	0.52	5.11e-31	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs3008870	0.727	rs2862729	chr1:67500828	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.47	7.56	0.35	2.45e-13	Lymphocyte percentage of white cells;
LUAD	cis	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg27411982	chr8:10470053	RP1L1	-0.4	-7.28	-0.33	1.62e-12	Retinal vascular caliber;
LUAD	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.5e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg00784671	chr22:46762841	CELSR1	-0.54	-7.05	-0.32	7.32e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03647317	chr4:187891568	NA	-0.38	-7.17	-0.33	3.42e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12681287	0.640	rs13253296	chr8:87448245	C/T	cg27223183	chr8:87520930	FAM82B	-0.67	-9.58	-0.42	8.35e-20	Caudate activity during reward;
LUAD	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg07952391	chr2:88470173	THNSL2	0.78	8.42	0.38	5.88e-16	Plasma clusterin levels;
LUAD	cis	rs56283067	0.847	rs1283948	chr6:44691702	C/T	cg20913747	chr6:44695427	NA	-0.45	-7.73	-0.35	8.19e-14	Total body bone mineral density;
LUAD	cis	rs12760731	0.668	rs72482621	chr1:178410442	C/T	cg00404053	chr1:178313656	RASAL2	0.63	8.12	0.37	5.31e-15	Obesity-related traits;
LUAD	cis	rs9811920	0.809	rs6806323	chr3:99722564	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	7.67	0.35	1.17e-13	Axial length;
LUAD	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg18512352	chr11:47633146	NA	0.47	8.59	0.39	1.69e-16	Neuroticism;Neuroticism (multi-trait analysis);
LUAD	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg22532475	chr10:104410764	TRIM8	0.45	8.56	0.38	2.11e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7903847	0.620	rs10882904	chr10:99115683	A/G	cg20016023	chr10:99160130	RRP12	-0.29	-7.04	-0.32	7.98e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.46	0.34	4.79e-13	Depression;
LUAD	cis	rs1595825	0.891	rs73054825	chr2:198636355	G/C	cg11031976	chr2:198649780	BOLL	-0.45	-6.67	-0.31	7.79e-11	Ulcerative colitis;
LUAD	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg05673287	chr15:77411982	SGK269	-0.41	-7.18	-0.33	3.06e-12	Type 2 diabetes;
LUAD	cis	rs2242073	0.597	rs3820906	chr2:208993830	A/G	cg06181187	chr2:209010896	CRYGB	0.33	6.45	0.3	3.06e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg27411982	chr8:10470053	RP1L1	0.4	7.06	0.32	6.87e-12	Neuroticism;
LUAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg00280220	chr17:61926910	NA	0.37	7.21	0.33	2.55e-12	Prudent dietary pattern;
LUAD	trans	rs783540	1.000	rs698500	chr15:83237769	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.46	-0.3	2.87e-10	Schizophrenia;
LUAD	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg00255919	chr5:131827918	IRF1	0.5	11.8	0.5	5.69e-28	Asthma (sex interaction);
LUAD	cis	rs243505	0.762	rs10241408	chr7:148481488	G/A	cg09806900	chr7:148480153	CUL1	0.47	8.21	0.37	2.68e-15	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs36051895	0.659	rs7036476	chr9:5063664	T/C	cg02405213	chr9:5042618	JAK2	-0.48	-6.98	-0.32	1.15e-11	Pediatric autoimmune diseases;
LUAD	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg07917127	chr4:99064746	C4orf37	0.4	6.61	0.31	1.16e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg16988262	chr1:15930761	NA	0.42	6.95	0.32	1.37e-11	Systolic blood pressure;
LUAD	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg00666640	chr1:248458726	OR2T12	0.3	7.24	0.33	2.14e-12	Common traits (Other);
LUAD	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.51	-0.34	3.54e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg21433313	chr16:3507492	NAT15	-0.77	-12.65	-0.52	2.56e-31	Tuberculosis;
LUAD	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg18721089	chr20:30220636	NA	-0.46	-6.73	-0.31	5.39e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg14668632	chr7:2872130	GNA12	-0.69	-11.76	-0.5	8.29e-28	Height;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg24655899	chr17:79519568	C17orf70	0.42	6.35	0.3	5.69e-10	QT interval;
LUAD	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg07501729	chr16:846077	CHTF18	0.38	7.15	0.33	3.87e-12	Mean corpuscular volume;
LUAD	trans	rs1268789	0.571	rs949507	chr4:79394086	C/T	cg22174410	chr3:42641766	NKTR	-0.4	-6.43	-0.3	3.4e-10	Hair shape;Hair morphology;
LUAD	cis	rs250585	1.000	rs4968013	chr16:23512592	A/C	cg00143387	chr16:23521605	GGA2	0.67	7.79	0.35	5.4e-14	Egg allergy;
LUAD	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.24	0.37	2.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504073	0.631	rs341813	chr8:50039916	T/C	cg00325661	chr8:49890786	NA	0.39	8.94	0.4	1.22e-17	Blood metabolite ratios;
LUAD	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg22963979	chr7:1858916	MAD1L1	-0.59	-10.17	-0.44	6.84e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg13770153	chr20:60521292	NA	-0.44	-7.23	-0.33	2.24e-12	Body mass index;
LUAD	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg03690763	chr11:133734501	NA	-0.34	-8.06	-0.37	7.7e-15	Childhood ear infection;
LUAD	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg11645453	chr3:52864694	ITIH4	-0.37	-7.34	-0.34	1.12e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg13126279	chr21:47581558	C21orf56	0.5	8.46	0.38	4.25e-16	Testicular germ cell tumor;
LUAD	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01570182	chr17:44337453	NA	1.15	18.06	0.66	1.83e-54	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	9.1	0.4	3.52e-18	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21659725	chr3:3221576	CRBN	0.64	11.08	0.47	3.09e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg22907277	chr7:1156413	C7orf50	0.7	8.89	0.4	1.84e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg05110241	chr16:68378359	PRMT7	-0.79	-8.26	-0.37	1.85e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4638749	0.953	rs4676033	chr2:108869368	G/A	cg25838818	chr2:108905173	SULT1C2	-0.56	-8.84	-0.39	2.66e-17	Blood pressure;
LUAD	cis	rs7809950	0.678	rs2395869	chr7:106940098	C/A	cg23024343	chr7:107201750	COG5	-0.77	-13.08	-0.54	4.46e-33	Coronary artery disease;
LUAD	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg09365446	chr1:150670422	GOLPH3L	0.66	12.58	0.52	4.9e-31	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.46e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6460942	0.915	rs2216050	chr7:12304073	T/C	cg20607287	chr7:12443886	VWDE	-0.45	-6.83	-0.32	2.99e-11	Coronary artery disease;
LUAD	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.7	0.31	6.57e-11	Parkinson's disease;
LUAD	cis	rs4964805	0.657	rs11111783	chr12:104188523	A/G	cg02344784	chr12:104178138	NT5DC3	0.45	9.3	0.41	7.77e-19	Attention deficit hyperactivity disorder;
LUAD	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg18305652	chr10:134549665	INPP5A	0.63	11.57	0.49	4.29e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6714710	0.603	rs11691494	chr2:98419726	T/A	cg26665480	chr2:98280029	ACTR1B	0.5	8.18	0.37	3.37e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs1904096	0.506	rs28522293	chr4:95167087	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-9.49	-0.42	1.7e-19	Type 2 diabetes;
LUAD	cis	rs2067615	0.524	rs10778505	chr12:107143126	G/C	cg15890332	chr12:107067104	RFX4	0.39	8.43	0.38	5.42e-16	Heart rate;
LUAD	cis	rs13082711	0.911	rs3755652	chr3:27472936	A/G	cg02860705	chr3:27208620	NA	-0.54	-7.91	-0.36	2.32e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg00106254	chr7:1943704	MAD1L1	-0.45	-6.83	-0.32	2.94e-11	Schizophrenia;
LUAD	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg26384229	chr12:38710491	ALG10B	0.42	7.19	0.33	3.01e-12	Heart rate;
LUAD	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg02990361	chr1:107599529	PRMT6	-0.63	-10.66	-0.46	1.18e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs559928	0.524	rs4963222	chr11:64184735	T/C	cg05555928	chr11:63887634	MACROD1	-0.48	-7.55	-0.34	2.66e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUAD	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg12179176	chr11:130786555	SNX19	0.55	9.3	0.41	7.43e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7709909	0.532	rs26780	chr5:80053255	T/C	cg24059623	chr5:79951536	MSH3;DHFR	0.48	7.23	0.33	2.26e-12	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.17	-0.33	3.48e-12	Neuroticism;
LUAD	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg05805236	chr11:65401703	PCNXL3	0.41	6.99	0.32	1.08e-11	Acne (severe);
LUAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg27588902	chr6:42928151	GNMT	-0.36	-9.6	-0.42	6.96e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg20607798	chr8:58055168	NA	0.58	7.54	0.34	2.94e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2806561	0.734	rs2143156	chr1:23374629	T/G	cg12483005	chr1:23474871	LUZP1	0.43	6.91	0.32	1.81e-11	Height;
LUAD	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg03806693	chr22:41940476	POLR3H	0.64	9.54	0.42	1.14e-19	Vitiligo;
LUAD	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg07538946	chr5:131705188	SLC22A5	0.48	8.03	0.36	9.72e-15	Blood metabolite levels;
LUAD	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9039	1.000	rs17567434	chr16:9221447	C/G	cg08831531	chr16:9218945	NA	-0.42	-7.12	-0.33	4.59e-12	Menopause (age at onset);
LUAD	trans	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.32	0.54	4.65e-34	Exhaled nitric oxide output;
LUAD	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-9.4	-0.42	3.37e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14159672	chr1:205819179	PM20D1	0.74	14.49	0.58	6.66e-39	Menarche (age at onset);
LUAD	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg04990556	chr1:26633338	UBXN11	-0.41	-6.74	-0.31	5.15e-11	Obesity-related traits;
LUAD	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg09555818	chr19:45449301	APOC2	0.59	13.23	0.54	1.06e-33	Blood protein levels;
LUAD	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg19622623	chr12:86230825	RASSF9	-0.47	-8.09	-0.37	6.58e-15	Major depressive disorder;
LUAD	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg11707310	chr1:2537719	MMEL1	-0.4	-8.61	-0.39	1.45e-16	Ulcerative colitis;
LUAD	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg05590025	chr7:65112418	INTS4L2	0.75	7.92	0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg23283495	chr1:209979779	IRF6	-0.68	-8.43	-0.38	5.68e-16	Coronary artery disease;
LUAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg18621852	chr3:10150065	C3orf24	0.49	8.94	0.4	1.25e-17	Alzheimer's disease;
LUAD	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg00310523	chr12:86230176	RASSF9	0.38	7.64	0.35	1.5e-13	Major depressive disorder;
LUAD	cis	rs12612619	0.732	rs13021112	chr2:27259794	G/A	cg00617064	chr2:27272375	NA	-0.39	-7.48	-0.34	4.34e-13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs113835537	0.529	rs11227503	chr11:66275242	G/C	cg24851651	chr11:66362959	CCS	0.56	9.94	0.44	4.56e-21	Airway imaging phenotypes;
LUAD	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg22705602	chr4:152727874	NA	-0.4	-6.95	-0.32	1.38e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg09455208	chr3:40491958	NA	0.56	12.44	0.52	1.73e-30	Renal cell carcinoma;
LUAD	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg14668632	chr7:2872130	GNA12	-0.47	-8.37	-0.38	8.55e-16	Height;
LUAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-6.95	-0.32	1.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4680	1.000	rs165722	chr22:19949013	C/T	cg01335087	chr22:19950166	COMT	0.23	6.53	0.3	1.88e-10	Blood metabolite levels;
LUAD	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg10518543	chr12:38710700	ALG10B	-0.43	-7.06	-0.32	6.84e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg02782426	chr3:40428986	ENTPD3	0.36	7.69	0.35	1.03e-13	Renal cell carcinoma;
LUAD	cis	rs738321	0.694	rs4821749	chr22:38542074	A/G	cg25457927	chr22:38595422	NA	-0.54	-12.02	-0.5	7.93e-29	Breast cancer;
LUAD	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.18	0.33	3.16e-12	Motion sickness;
LUAD	cis	rs11048434	0.723	rs1805737	chr12:9084670	A/T	cg13575925	chr12:9217583	LOC144571	0.38	7.07	0.32	6.56e-12	Sjögren's syndrome;
LUAD	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg19700328	chr14:106028568	NA	-0.47	-7.99	-0.36	1.26e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs62229266	0.659	rs2835242	chr21:37413532	A/C	cg12218747	chr21:37451666	NA	-0.42	-7.36	-0.34	9.62e-13	Mitral valve prolapse;
LUAD	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg18105134	chr13:113819100	PROZ	-1.0	-18.55	-0.67	1.2e-56	Platelet distribution width;
LUAD	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.86	-0.4	2.16e-17	Alzheimer's disease (late onset);
LUAD	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg00825309	chr19:58991885	ZNF446	0.36	6.39	0.3	4.35e-10	Uric acid clearance;
LUAD	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg02733842	chr7:1102375	C7orf50	-0.67	-10.12	-0.44	1.04e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg09085632	chr11:111637200	PPP2R1B	0.78	12.08	0.51	4.7e-29	Primary sclerosing cholangitis;
LUAD	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg14711859	chr11:8959438	ASCL3	0.36	6.89	0.32	2.01e-11	Hematocrit;
LUAD	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.79	-0.35	5.27e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13598790	chr5:55007947	SLC38A9	-0.52	-6.35	-0.3	5.47e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2294693	0.945	rs13216361	chr6:41007046	C/T	cg14769373	chr6:40998127	UNC5CL	-0.53	-7.88	-0.36	2.74e-14	Gastric cancer;Non-cardia gastric cancer;
LUAD	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg24801067	chr17:62843696	NA	0.62	8.35	0.38	1.01e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	6.55	0.3	1.67e-10	Renal function-related traits (BUN);
LUAD	cis	rs7584330	0.740	rs11891348	chr2:238440449	T/G	cg14458575	chr2:238380390	NA	0.68	12.85	0.53	4.01e-32	Prostate cancer;
LUAD	cis	rs7107174	1.000	rs2510046	chr11:77988817	T/C	cg02023728	chr11:77925099	USP35	0.52	7.84	0.36	3.69e-14	Testicular germ cell tumor;
LUAD	cis	rs315934	0.664	rs1688077	chr2:113855478	A/G	cg09040174	chr2:113837401	NA	-0.61	-7.4	-0.34	7.6e-13	Dysmenorrheic pain;
LUAD	cis	rs1113500	0.787	rs11185266	chr1:108642664	G/A	cg06207961	chr1:108661230	NA	0.35	6.62	0.31	1.12e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.77	-10.19	-0.44	6.04e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.94	0.53	1.73e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg01849466	chr14:104193079	ZFYVE21	0.46	7.73	0.35	8.12e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg23950597	chr19:37808831	NA	-0.61	-7.74	-0.35	7.28e-14	Coronary artery calcification;
LUAD	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg01416388	chr22:39784598	NA	-0.52	-8.73	-0.39	6.03e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg18230493	chr5:56204884	C5orf35	0.71	11.35	0.48	3.16e-26	Initial pursuit acceleration;
LUAD	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg17971929	chr21:40555470	PSMG1	0.54	8.5	0.38	3.3e-16	Cognitive function;
LUAD	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg10523679	chr1:76189770	ACADM	0.9	15.76	0.61	2.35e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10465746	0.967	rs28567085	chr1:84428859	G/A	cg10977910	chr1:84465055	TTLL7	0.5	8.07	0.37	7.53e-15	Obesity-related traits;
LUAD	cis	rs62238980	0.614	rs78000724	chr22:32479736	G/T	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs12618769	0.597	rs72821920	chr2:99111591	A/G	cg10123293	chr2:99228465	UNC50	0.46	8.12	0.37	5.1e-15	Bipolar disorder;
LUAD	cis	rs9807989	0.507	rs6755905	chr2:103048207	C/A	cg03938978	chr2:103052716	IL18RAP	0.46	10.49	0.45	4.89e-23	Asthma;
LUAD	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg21890820	chr11:65308645	LTBP3	0.48	7.67	0.35	1.2e-13	Bone mineral density;
LUAD	cis	rs2109514	0.870	rs6976316	chr7:116122943	G/A	cg12739419	chr7:116140593	CAV2	-0.33	-6.89	-0.32	2.08e-11	Prevalent atrial fibrillation;
LUAD	trans	rs225245	0.782	rs321617	chr17:33915246	A/G	cg19694781	chr19:47549865	TMEM160	-0.47	-7.68	-0.35	1.13e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.37	6.67	0.31	8.15e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs13064411	0.696	rs6438156	chr3:113206929	C/A	cg10517650	chr3:113235015	CCDC52	-0.56	-9.5	-0.42	1.62e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.57	6.62	0.31	1.1e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6430585	0.527	rs76622824	chr2:136411879	A/G	cg07169764	chr2:136633963	MCM6	0.57	6.77	0.31	4.19e-11	Corneal structure;
LUAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg11766577	chr21:47581405	C21orf56	0.56	9.5	0.42	1.56e-19	Testicular germ cell tumor;
LUAD	cis	rs9837602	0.592	rs694429	chr3:99459669	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-7.04	-0.32	7.9e-12	Breast cancer;
LUAD	cis	rs16958440	0.867	rs114475395	chr18:44691010	A/G	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg19875535	chr5:140030758	IK	0.46	7.7	0.35	9.66e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10129255	0.500	rs11628999	chr14:107208446	C/T	cg07958169	chr14:107095056	NA	-0.37	-7.4	-0.34	7.23e-13	Kawasaki disease;
LUAD	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg23711669	chr6:146136114	FBXO30	0.38	6.46	0.3	2.82e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg13319975	chr6:146136371	FBXO30	0.65	11.37	0.48	2.59e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06112835	chr11:68658793	MRPL21	0.5	9.05	0.4	5.44e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1843834	1.000	rs1843834	chr2:225558042	A/G	cg22455342	chr2:225449267	CUL3	0.46	6.38	0.3	4.53e-10	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg03037974	chr15:76606532	NA	0.37	8.33	0.38	1.11e-15	Blood metabolite levels;
LUAD	cis	rs9902453	0.967	rs4473252	chr17:28454423	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.62	0.39	1.35e-16	Coffee consumption (cups per day);
LUAD	cis	rs4409675	0.576	rs6660899	chr1:28214281	G/C	cg23691781	chr1:28212827	C1orf38	0.38	11.08	0.47	3.13e-25	Corneal astigmatism;
LUAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg22105103	chr4:187893119	NA	-0.53	-11.46	-0.49	1.14e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	7.26	0.33	1.87e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg25233709	chr10:116636983	FAM160B1	0.41	8.22	0.37	2.55e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg13402656	chr8:1511478	DLGAP2	0.67	13.26	0.54	8.71e-34	Lung cancer;
LUAD	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg00383909	chr3:49044727	WDR6	0.9	10.06	0.44	1.75e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs9394841	0.692	rs34073739	chr6:41829970	A/G	cg17623882	chr6:41773611	USP49	-0.52	-7.28	-0.33	1.65e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg19077165	chr18:44547161	KATNAL2	-0.44	-7.54	-0.34	2.87e-13	Personality dimensions;
LUAD	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg23992470	chr4:843637	GAK	0.7	7.28	0.33	1.65e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01777103	chr8:145550585	DGAT1	-0.73	-7.05	-0.32	7.48e-12	Type 2 diabetes;
LUAD	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11890956	chr21:40555474	PSMG1	0.83	14.85	0.59	1.86e-40	Cognitive function;
LUAD	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg18277682	chr1:228362509	C1orf69	-0.39	-6.67	-0.31	8.23e-11	Diastolic blood pressure;
LUAD	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg23950597	chr19:37808831	NA	-0.64	-7.57	-0.35	2.43e-13	Coronary artery calcification;
LUAD	cis	rs68170813	0.641	rs12534124	chr7:107119047	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-10.06	-0.44	1.75e-21	Coronary artery disease;
LUAD	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg22875332	chr1:76189707	ACADM	0.78	13.06	0.54	5.64e-33	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1595825	0.891	rs41468149	chr2:198910107	C/G	cg00361562	chr2:198649771	BOLL	0.48	6.72	0.31	5.85e-11	Ulcerative colitis;
LUAD	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg12615879	chr12:58013172	SLC26A10	0.4	8.23	0.37	2.42e-15	Multiple sclerosis;
LUAD	cis	rs11641365	0.678	rs877579	chr16:88770621	A/G	cg00034003	chr16:88779146	CTU2	-0.47	-6.86	-0.32	2.39e-11	Autism spectrum disorder-related traits;
LUAD	cis	rs3916	0.794	rs10431384	chr12:121127347	C/T	cg27246729	chr12:121163418	ACADS	-0.42	-7.78	-0.35	5.73e-14	Urinary metabolites (H-NMR features);
LUAD	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg12379764	chr21:47803548	PCNT	-0.38	-6.45	-0.3	2.99e-10	Testicular germ cell tumor;
LUAD	cis	rs35771425	0.642	rs3767380	chr1:211452845	A/G	cg25617285	chr1:211431773	RCOR3	-0.46	-8.25	-0.37	2.03e-15	Educational attainment (years of education);
LUAD	trans	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.59	0.46	2.06e-23	Mean corpuscular volume;
LUAD	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg15181151	chr6:150070149	PCMT1	0.39	7.78	0.35	5.72e-14	Lung cancer;
LUAD	cis	rs3815700	1.000	rs10404211	chr19:33093565	C/T	cg02997394	chr19:33096574	ANKRD27	0.6	7.07	0.33	6.49e-12	Eosinophilic esophagitis;
LUAD	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg23985595	chr17:80112537	CCDC57	-0.51	-9.31	-0.41	7.17e-19	Life satisfaction;
LUAD	trans	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg19894588	chr14:64061835	NA	0.52	8.24	0.37	2.16e-15	Glioblastoma;Glioma;
LUAD	cis	rs68170813	0.559	rs61406169	chr7:106903421	A/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.71	-0.46	7.32e-24	Coronary artery disease;
LUAD	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg22920501	chr2:26401640	FAM59B	-0.76	-11.01	-0.47	5.77e-25	Gut microbiome composition (summer);
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg07332563	chr6:291687	DUSP22	0.67	11.75	0.5	9.08e-28	Menopause (age at onset);
LUAD	cis	rs9394169	0.613	rs4713685	chr6:33774525	C/T	cg18005901	chr6:33739558	LEMD2	0.4	6.7	0.31	6.62e-11	Essential tremor;
LUAD	cis	rs877282	0.853	rs11596346	chr10:756673	A/T	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg11062466	chr8:58055876	NA	0.67	8.96	0.4	1.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.51	0.55	7.95e-35	Prudent dietary pattern;
LUAD	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg19610905	chr11:61596333	FADS2	-0.74	-12.05	-0.51	6.09e-29	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.66	-0.31	8.53e-11	Menopause (age at onset);
LUAD	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg00310523	chr12:86230176	RASSF9	0.38	7.69	0.35	1.05e-13	Major depressive disorder;
LUAD	trans	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.05	-0.4	5.43e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs427941	0.655	rs2529095	chr7:101749663	C/T	cg06246474	chr7:101738831	CUX1	0.37	6.44	0.3	3.28e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25427524	chr10:38739819	LOC399744	-0.76	-13.63	-0.55	2.58e-35	Extrinsic epigenetic age acceleration;
LUAD	trans	rs7246760	0.867	rs8107594	chr19:9835957	G/C	cg02900749	chr2:68251473	NA	-0.6	-6.55	-0.3	1.72e-10	Pursuit maintenance gain;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg05082095	chr1:155099843	EFNA1	0.38	6.36	0.3	5.13e-10	Anger;
LUAD	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg15448220	chr1:150897856	SETDB1	0.58	9.7	0.43	3.26e-20	Melanoma;
LUAD	cis	rs6782228	0.606	rs2253144	chr3:128329920	C/T	cg16766828	chr3:128327626	NA	0.38	6.97	0.32	1.23e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg11344533	chr11:111475393	SIK2	-0.35	-6.64	-0.31	9.9e-11	Primary sclerosing cholangitis;
LUAD	trans	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.65	-9.5	-0.42	1.5700000000000001e-19	Blood trace element (Cu levels);
LUAD	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg03874509	chr1:107600012	PRMT6	0.53	9.18	0.41	1.95e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.82e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10819733	chr22:24237672	NA	-0.41	-7.65	-0.35	1.39e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22496380	chr5:211416	CCDC127	-0.92	-12.71	-0.53	1.49e-31	Breast cancer;
LUAD	cis	rs7180079	1.000	rs62021592	chr15:64522368	T/G	cg08069370	chr15:64387884	SNX1	-0.51	-6.54	-0.3	1.81e-10	Monocyte count;
LUAD	cis	rs10849893	0.538	rs4980994	chr12:121919295	G/A	cg01154721	chr12:121881891	KDM2B	0.48	8.07	0.37	7.37e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg04727924	chr7:799746	HEATR2	-0.53	-7.2	-0.33	2.72e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg16680214	chr1:154839983	KCNN3	-0.62	-13.15	-0.54	2.36e-33	Prostate cancer;
LUAD	trans	rs4650994	0.550	rs11581618	chr1:178572720	G/A	cg05059571	chr16:84539110	KIAA1609	0.45	6.66	0.31	8.41e-11	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs10489202	1.000	rs34192847	chr1:168064317	A/T	cg24449463	chr1:168025552	DCAF6	-0.56	-6.95	-0.32	1.35e-11	Schizophrenia;
LUAD	cis	rs6586163	0.546	rs12359362	chr10:90753145	G/C	cg03111039	chr10:90751583	FAS;ACTA2	0.69	11.67	0.49	1.83e-27	Chronic lymphocytic leukemia;
LUAD	trans	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1018836	0.608	rs6986165	chr8:91477062	C/G	cg16814680	chr8:91681699	NA	-0.52	-8.73	-0.39	6.11e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs758324	0.947	rs4705838	chr5:131150593	G/T	cg06307176	chr5:131281290	NA	0.49	7.79	0.35	5.32e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg25036284	chr2:26402008	FAM59B	0.82	10.87	0.47	1.93e-24	Gut microbiome composition (summer);
LUAD	trans	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg26043149	chr18:55253948	FECH	0.49	7.86	0.36	3.15e-14	Bone mineral density;
LUAD	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22590775	chr19:49891494	CCDC155	0.68	10.26	0.45	3.29e-22	Multiple sclerosis;
LUAD	cis	rs2882667	0.824	rs1560656	chr5:138470789	A/G	cg04439458	chr5:138467593	SIL1	0.51	9.78	0.43	1.65e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg14917512	chr19:3094685	GNA11	0.57	6.73	0.31	5.43e-11	Diabetic kidney disease;
LUAD	cis	rs524023	1.000	rs9734313	chr11:64358311	C/T	cg19131476	chr11:64387923	NRXN2	-0.35	-6.72	-0.31	5.81e-11	Urate levels in obese individuals;
LUAD	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11890956	chr21:40555474	PSMG1	-0.56	-9.87	-0.43	8.24e-21	Menarche (age at onset);
LUAD	cis	rs7216064	1.000	rs62084248	chr17:65874541	C/T	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs5769707	0.656	rs135875	chr22:50012419	T/G	cg10356904	chr22:49881777	NA	-0.41	-8.0	-0.36	1.23e-14	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs3752645	0.649	rs10241140	chr7:106744512	T/G	cg02696742	chr7:106810147	HBP1	-0.66	-6.55	-0.3	1.7e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg13319975	chr6:146136371	FBXO30	-0.57	-9.39	-0.42	3.72e-19	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg15704280	chr7:45808275	SEPT13	0.64	8.17	0.37	3.52e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs471144	0.881	rs12081541	chr1:152441366	T/C	cg13498757	chr1:152161927	NA	0.74	7.68	0.35	1.08e-13	Inflammatory skin disease;
LUAD	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg17264618	chr3:40429014	ENTPD3	0.42	9.11	0.4	3.39e-18	Renal cell carcinoma;
LUAD	trans	rs4714291	0.963	rs12194361	chr6:40116264	T/G	cg02267698	chr19:7991119	CTXN1	-0.44	-6.74	-0.31	5.16e-11	Strep throat;
LUAD	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.05	-0.36	8.53e-15	Cystic fibrosis severity;
LUAD	cis	rs9863	0.828	rs12303671	chr12:124492610	T/G	cg17723958	chr12:124429295	CCDC92	-0.4	-6.76	-0.31	4.52e-11	White blood cell count;
LUAD	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg12407791	chr17:73824354	UNC13D	-0.35	-7.08	-0.33	6.09e-12	White matter hyperintensity burden;
LUAD	cis	rs7671266	0.528	rs11728025	chr4:10408221	C/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.25	-0.33	1.94e-12	Cardiovascular disease risk factors;
LUAD	cis	rs597539	0.690	rs1249359	chr11:68618279	C/T	cg04772025	chr11:68637568	NA	0.59	9.35	0.41	4.95e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.91	0.76	1.47e-80	Chronic sinus infection;
LUAD	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg25036284	chr2:26402008	FAM59B	-0.57	-8.11	-0.37	5.42e-15	Gut microbiome composition (summer);
LUAD	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg04287289	chr16:89883240	FANCA	-0.69	-12.48	-0.52	1.22e-30	Vitiligo;
LUAD	cis	rs9948	1.000	rs62152793	chr2:97484948	C/T	cg20312557	chr2:97357134	FER1L5	-0.6	-7.1	-0.33	5.28e-12	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs2996428	0.709	rs6667255	chr1:3711689	T/C	cg23277830	chr1:3704460	LRRC47	0.48	10.0	0.44	2.88e-21	Red cell distribution width;
LUAD	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg00852783	chr1:26633632	UBXN11	-0.37	-6.38	-0.3	4.71e-10	Obesity-related traits;
LUAD	cis	rs853679	0.607	rs35030260	chr6:28305508	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.55	6.45	0.3	3.1e-10	Depression;
LUAD	cis	rs11948739	0.610	rs4705853	chr5:130232339	T/C	cg08523029	chr5:130500466	HINT1	-0.58	-7.51	-0.34	3.43e-13	Pediatric bone mineral content (hip);
LUAD	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg11166453	chr1:247681781	NA	0.38	7.02	0.32	8.74e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg23803603	chr1:2058230	PRKCZ	0.37	6.73	0.31	5.66e-11	Height;
LUAD	cis	rs806215	1.000	rs712701	chr7:127251188	T/G	cg25922125	chr7:127225783	GCC1	0.51	7.38	0.34	8.29e-13	Type 2 diabetes;
LUAD	cis	rs9473147	0.543	rs13211285	chr6:47479618	C/T	cg12968598	chr6:47444699	CD2AP	0.35	6.35	0.3	5.46e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg11663144	chr21:46675770	NA	0.55	10.12	0.44	1.07e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg05966235	chr16:28915196	ATP2A1	0.42	6.75	0.31	4.81e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg13047869	chr3:10149882	C3orf24	0.54	7.06	0.32	7.05e-12	Alzheimer's disease;
LUAD	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg10468373	chr11:64009913	FKBP2	0.55	6.89	0.32	2e-11	Mean platelet volume;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21989094	chr19:39421295	MRPS12;SARS2	-0.43	-6.78	-0.31	3.98e-11	Height;
LUAD	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg13606994	chr1:44402422	ARTN	-0.34	-6.88	-0.32	2.22e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs428668	0.681	rs430961	chr5:150700559	C/G	cg11125805	chr5:150678162	SLC36A3	0.48	9.08	0.4	4.07e-18	Skin aging (microtopography measurement);
LUAD	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.58	-0.3	1.41e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.4e-13	Menopause (age at onset);
LUAD	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg17689763	chr4:710664	PCGF3	-0.59	-9.98	-0.44	3.24e-21	White blood cell count;
LUAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-9.03	-0.4	6.22e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg25985355	chr7:65971099	NA	-0.55	-6.82	-0.31	3.13e-11	Gout;
LUAD	trans	rs3942852	0.703	rs11039513	chr11:48107204	C/T	cg03929089	chr4:120376271	NA	0.63	9.07	0.4	4.48e-18	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19717773	chr7:2847554	GNA12	-0.55	-9.75	-0.43	2.16e-20	Height;
LUAD	trans	rs683250	0.931	rs671321	chr11:83292373	G/T	cg26973714	chr12:104609524	TXNRD1	0.4	6.75	0.31	5.03e-11	Subcortical brain region volumes;
LUAD	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg07917127	chr4:99064746	C4orf37	0.4	6.53	0.3	1.84e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg22676075	chr6:135203613	NA	0.39	7.12	0.33	4.82e-12	Red blood cell count;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22524267	chr4:4543474	STX18	0.42	6.44	0.3	3.29e-10	Gut microbiome composition (summer);
LUAD	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg22683308	chr4:1340831	KIAA1530	-0.45	-7.31	-0.33	1.35e-12	Longevity;
LUAD	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg18404041	chr3:52824283	ITIH1	0.41	7.54	0.34	2.81e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs75229567	0.618	rs11177853	chr12:70184924	A/G	cg10114359	chr12:70132523	RAB3IP	0.86	6.85	0.32	2.63e-11	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs6430585	0.583	rs59243420	chr2:136584538	A/T	cg07169764	chr2:136633963	MCM6	0.86	10.19	0.44	5.74e-22	Corneal structure;
LUAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg04352962	chr1:209979756	IRF6	0.51	7.24	0.33	2.11e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6445967	0.545	rs62259789	chr3:58435822	C/T	cg13750441	chr3:58318267	PXK	-0.32	-6.54	-0.3	1.73e-10	Platelet count;
LUAD	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg23283495	chr1:209979779	IRF6	0.75	9.34	0.41	5.38e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg10356904	chr22:49881777	NA	-0.37	-6.64	-0.31	9.7e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs59104589	0.617	rs3771561	chr2:242353704	A/G	cg08645257	chr2:242211290	HDLBP	-0.41	-6.83	-0.32	2.9100000000000002e-11	Fibrinogen levels;
LUAD	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg10755058	chr3:40428713	ENTPD3	0.46	8.7	0.39	7.56e-17	Renal cell carcinoma;
LUAD	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg21963583	chr11:68658836	MRPL21	0.66	11.88	0.5	2.71e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg19774624	chr17:42201019	HDAC5	-0.38	-6.51	-0.3	2.13e-10	Total body bone mineral density;
LUAD	trans	rs9354308	0.868	rs1938063	chr6:66559098	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.45	-0.3	2.99e-10	Metabolite levels;
LUAD	cis	rs3813948	0.543	rs2808466	chr1:207273751	T/C	cg26044340	chr1:207277291	C4BPA	-0.51	-7.69	-0.35	1.02e-13	C4b binding protein levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg24847481	chr1:100435557	SLC35A3	-0.37	-6.45	-0.3	3.02e-10	Schizophrenia;
LUAD	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg25985355	chr7:65971099	NA	0.53	6.73	0.31	5.53e-11	Diabetic kidney disease;
LUAD	cis	rs11048434	0.736	rs12833375	chr12:9112018	A/T	cg04155231	chr12:9217510	LOC144571	0.39	7.45	0.34	5.23e-13	Sjögren's syndrome;
LUAD	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg13047869	chr3:10149882	C3orf24	0.59	9.94	0.44	4.62e-21	Alzheimer's disease;
LUAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.65	0.31	8.95e-11	Prudent dietary pattern;
LUAD	cis	rs4728302	0.559	rs7779409	chr7:133158475	A/G	cg10665199	chr7:133106180	EXOC4	0.67	11.75	0.5	8.81e-28	Intelligence;Intelligence (multi-trait analysis);
LUAD	cis	rs9811920	0.809	rs1384062	chr3:99597928	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.37	-6.93	-0.32	1.59e-11	Axial length;
LUAD	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg08798685	chr6:27730294	NA	-0.69	-7.35	-0.34	1.05e-12	Depression;
LUAD	cis	rs2108225	1.000	rs2108226	chr7:107453279	A/C	cg18560240	chr7:107437656	SLC26A3	-0.41	-6.72	-0.31	5.81e-11	Ulcerative colitis;
LUAD	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg09365446	chr1:150670422	GOLPH3L	0.67	12.69	0.53	1.67e-31	Tonsillectomy;
LUAD	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg20290983	chr6:43655470	MRPS18A	1.08	27.43	0.8	6.44e-96	IgG glycosylation;
LUAD	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg06873352	chr17:61820015	STRADA	0.41	6.78	0.31	4.09e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg11965913	chr1:205819406	PM20D1	-0.45	-7.14	-0.33	4.2e-12	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg04756594	chr16:24857601	SLC5A11	0.54	10.35	0.45	1.63e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg02696790	chr15:75250997	RPP25	0.35	6.46	0.3	2.89e-10	Breast cancer;
LUAD	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg00701064	chr4:6280414	WFS1	0.55	9.33	0.41	5.9e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg23758822	chr17:41437982	NA	1.01	20.86	0.71	5.96e-67	Menopause (age at onset);
LUAD	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg11148817	chr5:312970	AHRR;PDCD6	-0.47	-6.44	-0.3	3.23e-10	Breast cancer;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05066851	chr19:55580852	RDH13	0.37	6.4	0.3	4.02e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg06784218	chr1:46089804	CCDC17	0.58	12.86	0.53	3.47e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs73198271	0.813	rs17697237	chr8:8615874	A/C	cg01851573	chr8:8652454	MFHAS1	-0.42	-7.39	-0.34	8.01e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.67	-12.89	-0.53	2.62e-32	Longevity;Endometriosis;
LUAD	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg21475434	chr5:93447410	FAM172A	0.72	8.1	0.37	5.99e-15	Diabetic retinopathy;
LUAD	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg02896835	chr1:92012615	NA	-0.47	-9.11	-0.4	3.4e-18	Breast cancer;
LUAD	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg24324837	chr19:49891574	CCDC155	0.53	7.94	0.36	1.83e-14	Multiple sclerosis;
LUAD	cis	rs4638749	0.677	rs10190865	chr2:108843624	T/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.33	-0.34	1.19e-12	Blood pressure;
LUAD	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg02569458	chr12:86230093	RASSF9	0.44	8.02	0.36	1.06e-14	Major depressive disorder;
LUAD	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg26647111	chr11:31128758	NA	-0.45	-7.92	-0.36	2.14e-14	Red blood cell count;
LUAD	cis	rs2302190	0.882	rs2270098	chr17:56572081	C/T	cg25885038	chr17:56607967	SEPT4	-0.52	-8.28	-0.37	1.62e-15	Vitamin D levels;
LUAD	cis	rs72766638	0.895	rs72766630	chr9:136926791	G/T	cg13789015	chr9:136890014	NCRNA00094	0.59	7.48	0.34	4.37e-13	Mosquito bite size;
LUAD	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.39	8.04	0.36	9.13e-15	Monocyte percentage of white cells;
LUAD	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg04455712	chr21:45112962	RRP1B	0.42	8.6	0.39	1.59e-16	Mean corpuscular volume;
LUAD	cis	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg07460842	chr6:66804631	NA	0.62	9.74	0.43	2.42e-20	Type 2 diabetes;
LUAD	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg10755058	chr3:40428713	ENTPD3	-0.37	-7.2	-0.33	2.79e-12	Renal cell carcinoma;
LUAD	cis	rs2880765	0.835	rs7163958	chr15:86045215	G/A	cg13263323	chr15:86062960	AKAP13	-0.5	-9.24	-0.41	1.21e-18	Coronary artery disease;
LUAD	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12756686	chr19:29218302	NA	0.68	9.07	0.4	4.6e-18	Methadone dose in opioid dependence;
LUAD	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg27490568	chr2:178487706	NA	0.57	9.22	0.41	1.45e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.51	-6.87	-0.32	2.3e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg19163074	chr7:65112434	INTS4L2	-0.44	-6.57	-0.3	1.49e-10	Aortic root size;
LUAD	cis	rs7132746	0.553	rs61928907	chr12:86194084	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-6.45	-0.3	3.02e-10	Lewy body disease;
LUAD	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg17063962	chr7:91808500	NA	0.7	12.67	0.52	2.06e-31	Breast cancer;
LUAD	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.46	7.63	0.35	1.55e-13	Lung cancer in ever smokers;
LUAD	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg17147758	chr8:6949321	NA	-0.5	-8.77	-0.39	4.25e-17	Blood pressure (smoking interaction);
LUAD	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-10.25	-0.45	3.54e-22	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.66	0.31	8.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg21280719	chr6:42927975	GNMT	-0.4	-12.19	-0.51	1.63e-29	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs12545109	0.571	rs7002482	chr8:57295200	C/T	cg17761419	chr8:57350749	NA	-0.53	-7.49	-0.34	4.05e-13	Obesity-related traits;
LUAD	cis	rs2387326	0.672	rs10829344	chr10:129944569	A/C	cg16087940	chr10:129947807	NA	-0.63	-8.99	-0.4	8.02e-18	Select biomarker traits;
LUAD	cis	rs55665837	1.000	rs12283797	chr11:14442262	C/G	cg19336497	chr11:14380999	RRAS2	-0.51	-10.33	-0.45	1.85e-22	Vitamin D levels;
LUAD	trans	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg18834416	chr8:37888184	EIF4EBP1	0.4	6.42	0.3	3.58e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg17105886	chr17:28927953	LRRC37B2	0.81	7.84	0.36	3.63e-14	Body mass index;
LUAD	cis	rs4594175	1.000	rs4594175	chr14:51606541	C/A	cg23942311	chr14:51606299	NA	0.64	10.96	0.47	9.36e-25	Cancer;
LUAD	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.69	-15.07	-0.59	2.09e-41	Urate levels in overweight individuals;
LUAD	cis	rs2073300	1.000	rs6137959	chr20:23442640	T/C	cg09953122	chr20:23471693	CST8	-0.65	-6.39	-0.3	4.29e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs11048434	0.736	rs12423746	chr12:9113002	G/T	cg13575925	chr12:9217583	LOC144571	0.36	6.77	0.31	4.27e-11	Sjögren's syndrome;
LUAD	cis	rs10751667	0.601	rs10902272	chr11:1040821	A/C	cg06064525	chr11:970664	AP2A2	-0.47	-7.32	-0.34	1.28e-12	Alzheimer's disease (late onset);
LUAD	trans	rs10411161	0.702	rs16983196	chr19:52384779	C/A	cg22319618	chr22:45562946	NUP50	-0.59	-8.35	-0.38	9.98e-16	Breast cancer;
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg16319310	chr10:52390957	NA	0.43	6.42	0.3	3.77e-10	Hepatitis;
LUAD	cis	rs1215050	0.755	rs7696354	chr4:98820330	T/C	cg05340658	chr4:99064831	C4orf37	0.46	7.54	0.34	2.93e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.16	0.48	1.57e-25	Height;
LUAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-9.53	-0.42	1.27e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11890956	chr21:40555474	PSMG1	-0.59	-9.63	-0.42	5.48e-20	Cognitive function;
LUAD	cis	rs6840360	0.615	rs4696096	chr4:152475387	A/G	cg22705602	chr4:152727874	NA	-0.37	-6.71	-0.31	6.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.16	-0.33	3.54e-12	Joint mobility (Beighton score);
LUAD	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg14671364	chr1:107599128	PRMT6	0.55	9.11	0.4	3.4e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg25535316	chr11:579198	PHRF1	-0.4	-6.54	-0.3	1.77e-10	Systemic lupus erythematosus;
LUAD	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	6.98	0.32	1.11e-11	Motion sickness;
LUAD	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg07757535	chr4:1339547	NA	0.31	6.92	0.32	1.69e-11	Longevity;
LUAD	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg02734326	chr4:10020555	SLC2A9	0.53	9.51	0.42	1.44e-19	Bone mineral density;
LUAD	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg27541892	chr1:1571801	CDK11B	-0.62	-10.65	-0.46	1.32e-23	Body mass index;
LUAD	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg18306943	chr3:40428807	ENTPD3	0.42	7.05	0.32	7.27e-12	Renal cell carcinoma;
LUAD	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg23649088	chr2:200775458	C2orf69	-0.56	-6.36	-0.3	5.26e-10	Schizophrenia;
LUAD	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg12011299	chr4:100065546	ADH4	0.69	12.49	0.52	1.07e-30	Smoking initiation;
LUAD	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18876405	chr7:65276391	NA	0.43	6.81	0.31	3.44e-11	Aortic root size;
LUAD	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg06623918	chr6:96969491	KIAA0776	0.72	10.07	0.44	1.58e-21	Migraine;Coronary artery disease;
LUAD	cis	rs35771425	0.518	rs1055565	chr1:211605697	G/A	cg25617285	chr1:211431773	RCOR3	-0.53	-10.34	-0.45	1.78e-22	Educational attainment (years of education);
LUAD	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.42	0.3	3.6e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg24818145	chr4:99064322	C4orf37	0.49	8.09	0.37	6.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg15448220	chr1:150897856	SETDB1	0.48	8.12	0.37	5.25e-15	Blood protein levels;
LUAD	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	8.13	0.37	4.66e-15	Parkinson's disease;
LUAD	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg11189052	chr15:85197271	WDR73	0.85	14.96	0.59	6.66e-41	P wave terminal force;
LUAD	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg10518543	chr12:38710700	ALG10B	-0.44	-7.2	-0.33	2.69e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg25767906	chr1:53392781	SCP2	-0.44	-8.17	-0.37	3.55e-15	Monocyte count;
LUAD	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg20933634	chr6:27740509	NA	0.44	6.94	0.32	1.5e-11	Parkinson's disease;
LUAD	cis	rs654950	0.841	rs676383	chr1:41993753	C/T	cg06885757	chr1:42089581	HIVEP3	-0.38	-7.87	-0.36	3e-14	Airway imaging phenotypes;
LUAD	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg06784218	chr1:46089804	CCDC17	-0.6	-13.41	-0.55	2.12e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.41	0.49	1.81e-26	Breast cancer;
LUAD	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg20701182	chr2:24300061	SF3B14	0.61	6.77	0.31	4.19e-11	Lymphocyte counts;
LUAD	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	7.02	0.32	9.06e-12	Renal cell carcinoma;
LUAD	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg23096020	chr7:158799433	NA	-0.35	-6.47	-0.3	2.64e-10	Facial morphology (factor 20);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg27072323	chr1:40506858	CAP1	-0.4	-6.75	-0.31	4.87e-11	Subcortical brain region volumes;
LUAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06873352	chr17:61820015	STRADA	0.8	18.08	0.66	1.49e-54	Prudent dietary pattern;
LUAD	cis	rs57590327	0.555	rs13084107	chr3:81833577	T/C	cg07356753	chr3:81810745	GBE1	-0.64	-10.38	-0.45	1.21e-22	Extraversion;
LUAD	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.68	-0.35	1.15e-13	Alzheimer's disease (late onset);
LUAD	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg08999081	chr20:33150536	PIGU	0.62	13.72	0.55	1.08e-35	Glomerular filtration rate (creatinine);
LUAD	cis	rs10899021	0.790	rs10899022	chr11:74339386	C/T	cg25880958	chr11:74394337	NA	-0.59	-8.04	-0.36	8.92e-15	Response to metformin (IC50);
LUAD	cis	rs7799006	0.929	rs6951493	chr7:2257612	G/A	cg02951883	chr7:2050386	MAD1L1	-0.49	-7.76	-0.35	6.32e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs113835537	0.529	rs80100524	chr11:66245936	C/T	cg24851651	chr11:66362959	CCS	0.57	10.1	0.44	1.29e-21	Airway imaging phenotypes;
LUAD	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-6.83	-0.32	3.01e-11	IgG glycosylation;
LUAD	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	7.68	0.35	1.1e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs739496	0.947	rs7134740	chr12:111927739	G/A	cg10833066	chr12:111807467	FAM109A	0.41	6.65	0.31	8.88e-11	Platelet count;
LUAD	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg06766960	chr11:133703094	NA	-0.45	-8.47	-0.38	3.95e-16	Childhood ear infection;
LUAD	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg27411982	chr8:10470053	RP1L1	0.4	6.92	0.32	1.66e-11	Retinal vascular caliber;
LUAD	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg20607287	chr7:12443886	VWDE	-0.55	-8.15	-0.37	4.3e-15	Coronary artery disease;
LUAD	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg19196401	chr6:110721138	DDO	-0.47	-9.04	-0.4	5.8e-18	Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg00634984	chr7:65235879	NA	-0.48	-6.39	-0.3	4.38e-10	Aortic root size;
LUAD	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg25287198	chr4:183728479	NA	0.53	6.52	0.3	2.04e-10	Pediatric autoimmune diseases;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12713142	chr12:57081325	PTGES3	-0.41	-6.64	-0.31	9.41e-11	Height;
LUAD	cis	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg00071950	chr4:10020882	SLC2A9	0.5	7.19	0.33	3e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	trans	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.53	-0.38	2.59e-16	Endometrial cancer;
LUAD	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg03467027	chr4:99064603	C4orf37	0.44	7.31	0.33	1.38e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg13699009	chr12:122356056	WDR66	0.31	6.55	0.3	1.7e-10	Mean corpuscular volume;
LUAD	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg22455342	chr2:225449267	CUL3	0.44	6.45	0.3	3.06e-10	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs7250872	0.647	rs12976128	chr19:1817113	A/C	cg10370574	chr19:1840461	REXO1	-0.64	-10.81	-0.47	3.2e-24	Bipolar disorder;
LUAD	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg16647868	chr5:131706066	SLC22A5	-0.48	-7.68	-0.35	1.09e-13	Breast cancer;
LUAD	trans	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg14343924	chr8:8086146	FLJ10661	0.46	7.07	0.33	6.52e-12	Neuroticism;
LUAD	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg26587870	chr6:27730563	NA	-0.65	-7.07	-0.33	6.28e-12	Breast cancer;
LUAD	cis	rs60154123	0.730	rs11119455	chr1:210457762	C/T	cg22029157	chr1:209979665	IRF6	0.55	6.56	0.3	1.59e-10	Coronary artery disease;
LUAD	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg07371521	chr5:154026371	NA	0.46	7.47	0.34	4.49e-13	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg11502198	chr6:26597334	ABT1	0.48	7.57	0.35	2.28e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs11958404	0.932	rs7706111	chr5:157416053	C/T	cg05962755	chr5:157440814	NA	0.45	7.33	0.34	1.19e-12	IgG glycosylation;
LUAD	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg08645402	chr16:4508243	NA	0.58	10.07	0.44	1.65e-21	Schizophrenia;
LUAD	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg11344533	chr11:111475393	SIK2	-0.35	-6.44	-0.3	3.2e-10	Primary sclerosing cholangitis;
LUAD	cis	rs877282	1.000	rs2004479	chr10:770854	G/A	cg17470449	chr10:769945	NA	0.65	9.53	0.42	1.22e-19	Uric acid levels;
LUAD	cis	rs6665290	0.904	rs6664955	chr1:227183434	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.43	-0.89	9.16e-144	Myeloid white cell count;
LUAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.41	-0.3	3.89e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg17372223	chr3:52568218	NT5DC2	0.45	8.7	0.39	7.24e-17	Electroencephalogram traits;
LUAD	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg25985355	chr7:65971099	NA	-0.53	-6.58	-0.3	1.41e-10	Diabetic kidney disease;
LUAD	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg23873523	chr11:2398502	CD81	0.4	7.14	0.33	4.19e-12	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.46	7.62	0.35	1.63e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12541635	0.966	rs1496182	chr8:107024505	C/T	cg10147462	chr8:107024639	NA	0.5	9.11	0.4	3.39e-18	Age of smoking initiation;
LUAD	cis	rs7009516	0.819	rs11997686	chr8:24221608	A/G	cg01759110	chr8:24241694	ADAMDEC1	-0.39	-7.87	-0.36	3.01e-14	Hair greying;
LUAD	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg06387496	chr7:2775674	GNA12	-0.38	-6.38	-0.3	4.72e-10	Height;
LUAD	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg13319975	chr6:146136371	FBXO30	0.68	11.67	0.49	1.74e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12545109	0.765	rs1960727	chr8:57411368	G/A	cg07776626	chr8:57350775	NA	-0.61	-8.67	-0.39	9.63e-17	Obesity-related traits;
LUAD	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg11822812	chr5:140052017	DND1	0.4	7.18	0.33	3.12e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg18827107	chr12:86230957	RASSF9	0.54	9.65	0.42	4.74e-20	Major depressive disorder;
LUAD	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg25817165	chr18:72167213	CNDP2	-0.79	-13.97	-0.56	9.57e-37	Refractive error;
LUAD	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg16950941	chr11:66035639	RAB1B	-0.39	-6.57	-0.3	1.5e-10	Gout;
LUAD	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg00933542	chr6:150070202	PCMT1	-0.41	-8.87	-0.4	2.1e-17	Lung cancer;
LUAD	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.88	-16.92	-0.64	2.01e-49	Menarche (age at onset);
LUAD	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg06002616	chr8:101225028	SPAG1	-0.39	-8.11	-0.37	5.42e-15	Atrioventricular conduction;
LUAD	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.33	6.42	0.3	3.57e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs6005807	0.719	rs12169880	chr22:29054875	G/C	cg12565055	chr22:29076175	TTC28	0.74	8.71	0.39	6.98e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12052896	chr2:172379846	CYBRD1	-0.38	-6.37	-0.3	4.95e-10	Cancer;
LUAD	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg11645453	chr3:52864694	ITIH4	0.54	9.89	0.43	6.83e-21	Schizophrenia;
LUAD	cis	rs2734839	0.964	rs2734831	chr11:113293596	G/T	cg14159747	chr11:113255604	NA	-0.48	-9.29	-0.41	8.08e-19	Information processing speed;
LUAD	cis	rs6987853	0.787	rs2974354	chr8:42413943	A/G	cg09913449	chr8:42400586	C8orf40	0.48	9.31	0.41	7.26e-19	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs240764	0.658	rs9498390	chr6:101241438	T/A	cg09795085	chr6:101329169	ASCC3	-0.43	-7.64	-0.35	1.5e-13	Neuroticism;
LUAD	trans	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg26811252	chr16:29126840	RRN3P2	0.67	11.22	0.48	9.73e-26	Menopause (age at onset);
LUAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg02136620	chr5:178986620	RUFY1	-0.47	-7.45	-0.34	5.25e-13	Lung cancer;
LUAD	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg25985355	chr7:65971099	NA	0.38	7.15	0.33	3.73e-12	Aortic root size;
LUAD	cis	rs12431939	1.000	rs11845886	chr14:51635873	G/A	cg23942311	chr14:51606299	NA	-0.59	-8.2	-0.37	2.86e-15	Cancer;
LUAD	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	trans	rs7944735	0.567	rs79837139	chr11:48000780	T/C	cg15704280	chr7:45808275	SEPT13	0.66	6.44	0.3	3.31e-10	Intraocular pressure;
LUAD	cis	rs4664304	0.900	rs3828327	chr2:160742095	G/A	cg23995753	chr2:160760732	LY75	-0.45	-7.98	-0.36	1.39e-14	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs11048434	0.736	rs12821842	chr12:9108984	G/A	cg26114124	chr12:9217669	LOC144571	0.36	6.74	0.31	5.04e-11	Sjögren's syndrome;
LUAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg10729496	chr3:10149963	C3orf24	-0.55	-8.94	-0.4	1.22e-17	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.79	-10.36	-0.45	1.41e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	trans	rs853679	0.599	rs149949	chr6:28011516	T/C	cg06606381	chr12:133084897	FBRSL1	-0.67	-7.55	-0.34	2.67e-13	Depression;
LUAD	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.5	10.25	0.45	3.55e-22	Monocyte percentage of white cells;
LUAD	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg12403142	chr1:92012408	NA	-0.37	-6.82	-0.31	3.13e-11	Breast cancer;
LUAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-9.2	-0.41	1.69e-18	Alzheimer's disease;
LUAD	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg20019720	chr6:154832845	CNKSR3	0.65	12.84	0.53	4.41e-32	Lipoprotein (a) levels;
LUAD	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg21248554	chr2:27665150	KRTCAP3	0.32	8.25	0.37	2.04e-15	Total body bone mineral density;
LUAD	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg16342193	chr10:102329863	NA	-0.36	-6.52	-0.3	2.01e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg11707310	chr1:2537719	MMEL1	0.4	8.37	0.38	8.29e-16	Ulcerative colitis;
LUAD	cis	rs864537	0.584	rs7523907	chr1:167427247	A/G	cg22356347	chr1:167427500	CD247	-0.37	-7.32	-0.34	1.23e-12	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg03388025	chr16:89894329	SPIRE2	-0.49	-12.83	-0.53	4.75e-32	Vitiligo;
LUAD	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.24	0.37	2.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg23950597	chr19:37808831	NA	-0.64	-7.57	-0.35	2.43e-13	Coronary artery calcification;
LUAD	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg07741184	chr6:167504864	NA	0.39	8.77	0.39	4.39e-17	Crohn's disease;
LUAD	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg12483005	chr1:23474871	LUZP1	-0.51	-8.86	-0.4	2.24e-17	Height;
LUAD	trans	rs9354308	0.901	rs2814121	chr6:66566915	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.51	7.6	0.35	1.91e-13	Metabolite levels;
LUAD	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg13385794	chr1:248469461	NA	0.24	6.43	0.3	3.48e-10	Common traits (Other);
LUAD	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg17796960	chr10:135278976	LOC619207	-0.46	-6.42	-0.3	3.66e-10	Systemic lupus erythematosus;
LUAD	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg03467027	chr4:99064603	C4orf37	0.47	7.38	0.34	8.26e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12530845	1.000	rs12530845	chr7:135329978	T/C	cg23117316	chr7:135346802	PL-5283	-0.5	-9.3	-0.41	7.55e-19	Red blood cell traits;
LUAD	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg03433033	chr1:76189801	ACADM	-0.45	-6.59	-0.31	1.32e-10	Daytime sleep phenotypes;
LUAD	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg16479474	chr6:28041457	NA	0.35	6.57	0.3	1.44e-10	Parkinson's disease;
LUAD	cis	rs10242455	0.571	rs73713594	chr7:99326498	A/G	cg18809830	chr7:99032528	PTCD1	-0.85	-7.44	-0.34	5.58e-13	Blood metabolite levels;
LUAD	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg18132916	chr6:79620363	NA	-0.45	-7.68	-0.35	1.11e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23091741	chr1:226111643	PYCR2	-0.41	-6.98	-0.32	1.14e-11	Cancer;
LUAD	cis	rs11098699	0.821	rs931705	chr4:124205194	C/T	cg09941581	chr4:124220074	SPATA5	0.49	8.02	0.36	1.05e-14	Mosquito bite size;
LUAD	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg15790184	chr11:494944	RNH1	0.4	6.67	0.31	8.25e-11	Systemic lupus erythematosus;
LUAD	cis	rs758324	0.947	rs7725924	chr5:131118165	C/G	cg06307176	chr5:131281290	NA	0.51	8.07	0.37	7.09e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7177699	0.557	rs7403714	chr15:79118650	C/T	cg00540400	chr15:79124168	NA	-0.47	-9.85	-0.43	9.58e-21	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg05805236	chr11:65401703	PCNXL3	-0.52	-8.68	-0.39	8.81e-17	Acne (severe);
LUAD	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.42	6.6	0.31	1.2e-10	Platelet count;
LUAD	cis	rs3818285	0.504	rs7100154	chr10:111650150	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.66	-10.07	-0.44	1.65e-21	Superior crus of antihelix expression;
LUAD	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	7.15	0.33	3.86e-12	Schizophrenia;
LUAD	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg14196790	chr5:131705035	SLC22A5	-0.42	-7.6	-0.35	1.87e-13	Breast cancer;
LUAD	cis	rs9616064	0.740	rs6520049	chr22:46996309	C/T	cg05621596	chr22:47072043	GRAMD4	-0.52	-8.71	-0.39	7.08e-17	Urate levels in obese individuals;
LUAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg11062466	chr8:58055876	NA	0.67	9.02	0.4	6.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs12545109	0.842	rs2670050	chr8:57402914	T/G	cg21220214	chr8:57350948	NA	-0.59	-8.54	-0.38	2.47e-16	Obesity-related traits;
LUAD	cis	rs12545109	0.876	rs4738494	chr8:57327438	G/T	cg21220214	chr8:57350948	NA	-0.63	-8.56	-0.38	2.08e-16	Obesity-related traits;
LUAD	trans	rs4824093	0.610	rs73443974	chr22:50314316	G/A	cg09872104	chr7:134855509	C7orf49	-0.82	-7.26	-0.33	1.9e-12	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg27541892	chr1:1571801	CDK11B	-0.46	-7.65	-0.35	1.34e-13	Body mass index;
LUAD	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg00495681	chr13:53174319	NA	0.72	14.27	0.57	5.23e-38	Lewy body disease;
LUAD	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg15704280	chr7:45808275	SEPT13	-0.6	-8.06	-0.36	8.12e-15	Axial length;
LUAD	cis	rs78761021	0.867	rs62067563	chr17:9786520	C/T	cg26853458	chr17:9805074	RCVRN	0.36	7.33	0.34	1.18e-12	Type 2 diabetes;
LUAD	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg00383909	chr3:49044727	WDR6	0.72	8.38	0.38	7.84e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7107174	1.000	rs2373009	chr11:77945815	T/A	cg02023728	chr11:77925099	USP35	0.49	7.29	0.33	1.49e-12	Testicular germ cell tumor;
LUAD	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg26513180	chr16:89883248	FANCA	0.8	7.16	0.33	3.56e-12	Skin colour saturation;
LUAD	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg02176678	chr2:219576539	TTLL4	0.74	14.83	0.58	2.23e-40	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs11247915	0.501	rs34209692	chr1:26608782	C/T	cg01568347	chr1:26488053	GRRP1	0.34	6.49	0.3	2.38e-10	Obesity-related traits;
LUAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg17178900	chr1:205818956	PM20D1	0.72	14.73	0.58	6.2e-40	Menarche (age at onset);
LUAD	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-11.38	-0.48	2.28e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs600626	0.588	rs11236526	chr11:75467605	G/A	cg24262691	chr11:75473276	NA	0.61	8.7	0.39	7.26e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg15691649	chr6:25882328	NA	-0.45	-6.45	-0.3	3.14e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9902453	0.904	rs4077465	chr17:28300144	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	10.12	0.44	1.1e-21	Coffee consumption (cups per day);
LUAD	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg14092988	chr3:52407081	DNAH1	-0.43	-8.67	-0.39	9.35e-17	Bipolar disorder;
LUAD	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06544989	chr22:39130855	UNC84B	0.48	9.56	0.42	9.49e-20	Menopause (age at onset);
LUAD	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg06873352	chr17:61820015	STRADA	0.41	6.5	0.3	2.29e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg04727924	chr7:799746	HEATR2	-0.57	-7.24	-0.33	2.1e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06544989	chr22:39130855	UNC84B	0.39	7.19	0.33	3.01e-12	Menopause (age at onset);
LUAD	cis	rs7937890	0.559	rs2597188	chr11:14516906	G/A	cg06199346	chr11:14280333	SPON1	-0.32	-6.42	-0.3	3.58e-10	Mitochondrial DNA levels;
LUAD	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg20203395	chr5:56204925	C5orf35	-0.49	-7.71	-0.35	9.22e-14	Coronary artery disease;
LUAD	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg05717871	chr11:638507	DRD4	-0.41	-6.42	-0.3	3.73e-10	Systemic lupus erythematosus;
LUAD	cis	rs1595825	0.891	rs7587716	chr2:198630667	G/T	cg11031976	chr2:198649780	BOLL	-0.48	-7.01	-0.32	9.37e-12	Ulcerative colitis;
LUAD	cis	rs1595825	0.735	rs16827267	chr2:198924967	G/A	cg00361562	chr2:198649771	BOLL	-0.47	-6.49	-0.3	2.38e-10	Ulcerative colitis;
LUAD	cis	rs454510	0.726	rs376910	chr1:120181277	A/C	cg11530693	chr1:120165357	ZNF697	-0.46	-7.26	-0.33	1.89e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.48	0.52	1.15e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.81e-11	Crohn's disease;
LUAD	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg01416388	chr22:39784598	NA	-0.52	-8.67	-0.39	9.62e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs922182	0.595	rs7176387	chr15:64219108	A/G	cg02919090	chr15:64263738	DAPK2	-0.38	-7.16	-0.33	3.65e-12	Blood protein levels;
LUAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-8.07	-0.37	7.12e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.04	0.36	8.78e-15	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.82	0.53	5.17e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8177876	0.749	rs75923695	chr16:81093894	T/C	cg08591886	chr16:81111003	C16orf46	-0.76	-6.89	-0.32	2.08e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs775227	0.574	rs35765657	chr3:113078384	C/T	cg18753928	chr3:113234510	CCDC52	-0.65	-8.57	-0.38	1.93e-16	Dental caries;
LUAD	cis	rs9535307	0.929	rs942032	chr13:50251145	T/G	cg04663916	chr13:50265991	EBPL	0.63	7.19	0.33	2.94e-12	Obesity-related traits;
LUAD	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg04731861	chr2:219085781	ARPC2	-0.24	-7.31	-0.33	1.34e-12	Colorectal cancer;
LUAD	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg15247329	chr7:2764246	NA	-0.36	-6.52	-0.3	2.05e-10	Height;
LUAD	cis	rs4629710	0.592	rs13206776	chr6:131576679	T/G	cg12606694	chr6:131520996	AKAP7	0.5	7.33	0.34	1.16e-12	Multiple myeloma (IgH translocation);
LUAD	trans	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg14791747	chr16:20752902	THUMPD1	0.46	6.47	0.3	2.76e-10	Pancreatic cancer;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg06190759	chr16:71757240	NA	-0.39	-6.52	-0.3	1.95e-10	Schizophrenia;
LUAD	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg23442198	chr4:187126114	CYP4V2	1.13	11.26	0.48	6.78e-26	Blood protein levels;
LUAD	cis	rs1595825	0.735	rs6752454	chr2:198938959	T/G	cg00982548	chr2:198649783	BOLL	-0.65	-9.03	-0.4	6.24e-18	Ulcerative colitis;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg05959577	chr3:48129425	MAP4	-0.4	-6.76	-0.31	4.51e-11	Subcortical brain region volumes;
LUAD	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg11098525	chr4:1320231	MAEA	-0.37	-6.45	-0.3	3.06e-10	Obesity-related traits;
LUAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg02136620	chr5:178986620	RUFY1	0.5	8.37	0.38	8.8e-16	Lung cancer;
LUAD	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	7.89	0.36	2.55e-14	Hip circumference adjusted for BMI;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg25959527	chr3:195163920	ACAP2	-0.72	-6.78	-0.31	4.05e-11	Type 2 diabetes;
LUAD	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg19875535	chr5:140030758	IK	-0.4	-6.65	-0.31	8.99e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg18854424	chr1:2615690	NA	-0.42	-9.16	-0.41	2.27e-18	Multiple sclerosis;
LUAD	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg10755058	chr3:40428713	ENTPD3	-0.44	-8.42	-0.38	5.95e-16	Renal cell carcinoma;
LUAD	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg04369109	chr6:150039330	LATS1	-0.42	-7.02	-0.32	8.97e-12	Lung cancer;
LUAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18404041	chr3:52824283	ITIH1	-0.52	-10.22	-0.45	4.6e-22	Electroencephalogram traits;
LUAD	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg00383909	chr3:49044727	WDR6	0.72	8.3	0.37	1.43e-15	Cognitive function;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg20495206	chr7:151215566	RHEB	0.42	6.68	0.31	7.75e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs6785206	1.000	rs6785206	chr3:128412024	A/G	cg16766828	chr3:128327626	NA	-0.87	-9.28	-0.41	8.56e-19	Lymphocyte percentage of white cells;
LUAD	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg11189052	chr15:85197271	WDR73	0.67	8.99	0.4	8.24e-18	Schizophrenia;
LUAD	cis	rs2657888	0.965	rs2657905	chr12:56935402	T/A	cg23002907	chr12:56915593	RBMS2	0.35	6.56	0.3	1.59e-10	Adiponectin levels;
LUAD	cis	rs62400317	0.859	rs72869118	chr6:45064626	T/C	cg18551225	chr6:44695536	NA	-0.57	-8.77	-0.39	4.48e-17	Total body bone mineral density;
LUAD	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg01851573	chr8:8652454	MFHAS1	0.45	8.1	0.37	6.12e-15	Mood instability;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17371436	chr19:3185547	NCLN	-0.42	-6.56	-0.3	1.56e-10	Height;
LUAD	trans	rs1493916	0.905	rs7239283	chr18:31395397	G/A	cg15819921	chr19:927150	ARID3A	-0.47	-7.79	-0.35	5.14e-14	Life satisfaction;
LUAD	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	9.18	0.41	2e-18	Breast cancer;
LUAD	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg03806693	chr22:41940476	POLR3H	0.73	9.81	0.43	1.33e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2130392	0.962	rs7660116	chr4:185626542	G/A	cg04058563	chr4:185651563	MLF1IP	0.37	6.62	0.31	1.12e-10	Kawasaki disease;
LUAD	cis	rs2230307	0.536	rs554742	chr1:100512568	G/A	cg20868668	chr1:100435035	SLC35A3	0.51	7.16	0.33	3.63e-12	Carotid intima media thickness;
LUAD	cis	rs422249	0.819	rs174608	chr11:61627484	A/G	cg19610905	chr11:61596333	FADS2	-0.51	-7.7	-0.35	9.79e-14	Trans fatty acid levels;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg08877624	chr8:141521446	CHRAC1	0.39	6.52	0.3	2.01e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs68170813	0.605	rs10464620	chr7:107135653	A/G	cg02696742	chr7:106810147	HBP1	0.75	9.94	0.44	4.74e-21	Coronary artery disease;
LUAD	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg05082376	chr22:42548792	NA	0.45	7.85	0.36	3.38e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg11266682	chr4:10021025	SLC2A9	0.39	6.63	0.31	1.01e-10	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg26384229	chr12:38710491	ALG10B	0.46	7.52	0.34	3.2e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg19743168	chr1:23544995	NA	0.39	6.86	0.32	2.44e-11	Height;
LUAD	cis	rs76878669	0.561	rs4630308	chr11:66162587	G/A	cg18002602	chr11:66138449	SLC29A2	0.48	10.35	0.45	1.6400000000000001e-22	Educational attainment (years of education);
LUAD	trans	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.32	0.45	2.07e-22	Mean corpuscular volume;
LUAD	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg16006841	chr5:176797999	RGS14	-0.59	-8.94	-0.4	1.22e-17	Urate levels in lean individuals;
LUAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.77	-0.31	4.39e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg05373962	chr22:49881684	NA	-0.48	-10.2	-0.44	5.35e-22	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.33	-0.41	6.06e-19	Type 2 diabetes;
LUAD	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg15704280	chr7:45808275	SEPT13	-0.89	-16.22	-0.62	2.24e-46	Height;
LUAD	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.69	13.03	0.54	7.52e-33	Cognitive ability;
LUAD	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg26818010	chr10:134567672	INPP5A	-0.85	-14.66	-0.58	1.17e-39	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg26408565	chr15:76604113	ETFA	-0.45	-7.31	-0.34	1.32e-12	Blood metabolite levels;
LUAD	cis	rs7089973	0.836	rs12765350	chr10:116635305	G/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.57	0.42	9.13e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg02466173	chr16:30829666	NA	-0.86	-17.47	-0.65	7.45e-52	Dementia with Lewy bodies;
LUAD	trans	rs853679	0.546	rs200953	chr6:27837267	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.07	-0.37	7.33e-15	Depression;
LUAD	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg00339695	chr16:24857497	SLC5A11	-0.47	-8.84	-0.39	2.6e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7507204	0.530	rs4807470	chr19:3443470	A/T	cg08380311	chr19:3435252	NFIC	0.43	6.87	0.32	2.25e-11	Height;
LUAD	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg23758822	chr17:41437982	NA	0.99	20.48	0.71	2.94e-65	Menopause (age at onset);
LUAD	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg22532475	chr10:104410764	TRIM8	-0.45	-8.81	-0.39	3.17e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	trans	rs1493916	0.805	rs1452648	chr18:31411003	G/T	cg15819921	chr19:927150	ARID3A	-0.42	-6.86	-0.32	2.44e-11	Life satisfaction;
LUAD	cis	rs2932538	0.922	rs3790611	chr1:113067792	A/G	cg22162597	chr1:113214053	CAPZA1	0.46	6.8	0.31	3.56e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg05043794	chr9:111880884	C9orf5	-0.44	-7.53	-0.34	3.1e-13	Menarche (age at onset);
LUAD	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.4	6.7	0.31	6.69e-11	Total body bone mineral density;
LUAD	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg11292332	chr7:45801988	SEPT13	-0.31	-6.84	-0.32	2.81e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03517284	chr6:25882590	NA	0.51	8.62	0.39	1.35e-16	Blood metabolite levels;
LUAD	cis	rs6987853	0.901	rs2923429	chr8:42389743	A/G	cg09913449	chr8:42400586	C8orf40	0.43	7.92	0.36	2.14e-14	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7264396	1.000	rs224437	chr20:34154371	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.5	-0.3	2.26e-10	Total cholesterol levels;
LUAD	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg25324976	chr17:61989376	CSHL1	0.34	6.76	0.31	4.73e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg05805236	chr11:65401703	PCNXL3	-0.55	-8.76	-0.39	4.7e-17	Acne (severe);
LUAD	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.09	-24.15	-0.76	1.27e-81	Ulcerative colitis;
LUAD	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg07549590	chr16:15018862	NA	-0.4	-7.53	-0.34	3.18e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg01579765	chr21:45077557	HSF2BP	-0.61	-13.67	-0.55	1.77e-35	Mean corpuscular volume;
LUAD	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg02782426	chr3:40428986	ENTPD3	0.35	7.71	0.35	9.11e-14	Renal cell carcinoma;
LUAD	cis	rs2637266	0.739	rs2395404	chr10:78380513	G/T	cg18941641	chr10:78392320	NA	0.33	6.84	0.32	2.79e-11	Pulmonary function;
LUAD	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg02423579	chr7:2872169	GNA12	0.48	7.89	0.36	2.67e-14	Plateletcrit;
LUAD	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg09796270	chr17:17721594	SREBF1	0.37	7.57	0.35	2.44e-13	Total body bone mineral density;
LUAD	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg24829409	chr8:58192753	C8orf71	-0.58	-8.74	-0.39	5.48e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg12310025	chr6:25882481	NA	-0.58	-9.55	-0.42	1.1e-19	Blood metabolite levels;
LUAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg03188948	chr7:1209495	NA	0.65	9.31	0.41	6.88e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg24531977	chr5:56204891	C5orf35	-0.4	-6.56	-0.3	1.55e-10	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs986417	0.688	rs8018111	chr14:60964347	A/G	cg27398547	chr14:60952738	C14orf39	0.52	6.75	0.31	4.86e-11	Gut microbiota (bacterial taxa);
LUAD	cis	rs8177876	0.554	rs56286107	chr16:81117832	C/A	cg08591886	chr16:81111003	C16orf46	-0.86	-6.7	-0.31	6.5500000000000006e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg20587970	chr11:113659929	NA	-1.17	-17.5	-0.65	5.58e-52	Hip circumference adjusted for BMI;
LUAD	cis	rs41311933	0.656	rs72760236	chr9:123910416	C/G	cg13567360	chr9:123745713	C5	-0.71	-8.27	-0.37	1.73e-15	Coronary artery disease;
LUAD	cis	rs758324	0.947	rs4705900	chr5:131140241	G/A	cg25547332	chr5:131281432	NA	0.44	6.71	0.31	6.38e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg07266350	chr3:49460521	AMT;NICN1	0.36	6.39	0.3	4.5e-10	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs117623576	0.941	rs11008775	chr10:32410307	T/C	cg03047570	chr10:32398778	NA	-0.86	-11.48	-0.49	9.52e-27	Anti-saccade response;
LUAD	cis	rs7119	0.689	rs11630557	chr15:77820712	A/G	cg27398640	chr15:77910606	LINGO1	-0.35	-6.52	-0.3	2.02e-10	Type 2 diabetes;
LUAD	cis	rs7020830	0.867	rs7852593	chr9:37332380	A/T	cg14294708	chr9:37120828	ZCCHC7	0.88	17.67	0.65	9.8e-53	Schizophrenia;
LUAD	cis	rs354225	0.544	rs1137645	chr2:54807592	C/G	cg01766943	chr2:54829624	SPTBN1	0.39	7.34	0.34	1.1e-12	Schizophrenia;
LUAD	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg05991184	chr2:219186017	PNKD	-0.35	-6.8	-0.31	3.65e-11	Colorectal cancer;
LUAD	cis	rs9948	0.655	rs62152771	chr2:97447121	C/G	cg20312557	chr2:97357134	FER1L5	-0.75	-8.45	-0.38	4.9e-16	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs7593730	0.636	rs6757491	chr2:161147743	G/C	cg22609984	chr2:161126801	NA	0.52	9.51	0.42	1.43e-19	Type 2 diabetes;
LUAD	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.1	0.37	6.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs240764	0.658	rs4840148	chr6:101182500	G/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.55	-0.38	2.24e-16	Neuroticism;
LUAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg10295955	chr4:187884368	NA	-1.17	-30.82	-0.83	3.54e-110	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg01689657	chr7:91764605	CYP51A1	0.35	8.77	0.39	4.54e-17	Breast cancer;
LUAD	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg11166453	chr1:247681781	NA	0.38	7.29	0.33	1.49e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg08779649	chr13:50194554	NA	0.42	8.37	0.38	8.21e-16	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg00484396	chr16:3507460	NAT15	-0.73	-8.2	-0.37	2.92e-15	Tuberculosis;
LUAD	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.02	0.32	8.87e-12	Hypertriglyceridemia;
LUAD	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg14779329	chr11:130786720	SNX19	0.39	6.84	0.32	2.78e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7828089	0.522	rs4872484	chr8:22255859	C/T	cg12081754	chr8:22256438	SLC39A14	0.86	15.33	0.6	1.7e-42	Verbal declarative memory;
LUAD	cis	rs1160297	0.552	rs6545316	chr2:53223038	A/G	cg07782112	chr2:53107842	NA	-0.33	-6.69	-0.31	7e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs12681287	0.640	rs13269259	chr8:87470453	G/A	cg00550725	chr8:87521180	FAM82B	0.45	6.52	0.3	1.98e-10	Caudate activity during reward;
LUAD	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg09367891	chr1:107599246	PRMT6	0.54	8.86	0.4	2.2e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs9929218	1.000	rs13330350	chr16:68800849	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.69	-0.55	1.48e-35	Colorectal cancer;
LUAD	cis	rs7017914	0.934	rs1993862	chr8:71579362	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.47	-0.3	2.79e-10	Bone mineral density;
LUAD	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg21220214	chr8:57350948	NA	-0.59	-8.93	-0.4	1.33e-17	Obesity-related traits;
LUAD	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg06028605	chr16:24865363	SLC5A11	0.39	6.79	0.31	3.85e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs965604	1.000	rs12916801	chr15:78769130	A/G	cg18825076	chr15:78729989	IREB2	-0.42	-7.19	-0.33	2.95e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg11845111	chr2:191398756	TMEM194B	-0.68	-8.75	-0.39	5.06e-17	Diastolic blood pressure;
LUAD	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg23750338	chr8:142222470	SLC45A4	-0.6	-12.8	-0.53	6.44e-32	Immature fraction of reticulocytes;
LUAD	cis	rs9581857	0.579	rs7332104	chr13:27957831	C/G	cg22138327	chr13:27999177	GTF3A	-0.9	-10.49	-0.45	4.83e-23	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg18105134	chr13:113819100	PROZ	-0.81	-14.44	-0.57	1.02e-38	Platelet distribution width;
LUAD	cis	rs2073300	1.000	rs12626013	chr20:23442215	G/A	cg12062639	chr20:23401060	NAPB	1.0	9.21	0.41	1.47e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg14416269	chr4:6271139	WFS1	0.62	12.77	0.53	8.06e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg07393940	chr7:158741817	NA	0.67	11.58	0.49	3.85e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10979	0.965	rs9496679	chr6:143896741	G/T	cg25407410	chr6:143891975	LOC285740	-0.64	-10.26	-0.45	3.46e-22	Hypospadias;
LUAD	cis	rs35771425	0.536	rs6656860	chr1:211620805	A/G	cg26515805	chr1:211431828	RCOR3	-0.43	-8.85	-0.4	2.37e-17	Educational attainment (years of education);
LUAD	trans	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg06606381	chr12:133084897	FBRSL1	-1.07	-10.05	-0.44	1.88e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg24399712	chr22:39784796	NA	-0.82	-16.27	-0.62	1.4e-46	Intelligence (multi-trait analysis);
LUAD	trans	rs17689437	0.671	rs1177648	chr16:68598007	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.41	6.55	0.3	1.72e-10	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LUAD	trans	rs3930017	1.000	rs7783809	chr7:76719551	G/A	cg05913257	chr4:53525745	USP46	-0.41	-6.57	-0.3	1.44e-10	Body mass index;
LUAD	cis	rs4006360	0.685	rs2320221	chr17:39251266	A/C	cg20663846	chr17:39254439	KRTAP4-8	-0.4	-8.88	-0.4	1.99e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg02880119	chr16:3481970	NA	0.58	8.42	0.38	5.94e-16	Body mass index (adult);
LUAD	trans	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg21284400	chr1:149981654	OTUD7B	-0.38	-6.63	-0.31	1.02e-10	Longevity;Endometriosis;
LUAD	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg19336497	chr11:14380999	RRAS2	-0.61	-13.06	-0.54	5.62e-33	Vitamin D levels;
LUAD	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg00339695	chr16:24857497	SLC5A11	-0.56	-8.96	-0.4	1.04e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg03690763	chr11:133734501	NA	-0.34	-8.0	-0.36	1.22e-14	Childhood ear infection;
LUAD	cis	rs6993813	0.843	rs10098408	chr8:120039721	T/C	cg01975934	chr8:119970761	NA	-0.37	-7.2	-0.33	2.83e-12	Bone mineral density (hip);
LUAD	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg19610905	chr11:61596333	FADS2	-0.66	-11.34	-0.48	3.41e-26	Trans fatty acid levels;
LUAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg07806771	chr7:64541737	NA	0.53	8.59	0.39	1.69e-16	Calcium levels;
LUAD	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg09137382	chr11:130731461	NA	0.41	7.51	0.34	3.62e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9807989	0.801	rs10176664	chr2:102976172	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	6.38	0.3	4.76e-10	Asthma;
LUAD	cis	rs9535307	0.719	rs9562927	chr13:50363677	A/G	cg04663916	chr13:50265991	EBPL	0.55	6.8	0.31	3.47e-11	Obesity-related traits;
LUAD	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	ch.11.42038R	chr11:967971	AP2A2	0.39	6.91	0.32	1.82e-11	Alzheimer's disease (late onset);
LUAD	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs12928939	0.517	rs12445641	chr16:71967783	C/T	cg03805757	chr16:71968109	PKD1L3	-0.54	-8.53	-0.38	2.69e-16	Post bronchodilator FEV1;
LUAD	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg12935359	chr14:103987150	CKB	0.46	7.06	0.32	6.67e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6121246	0.559	rs10439607	chr20:30258541	G/A	cg21427119	chr20:30132790	HM13	-0.36	-6.48	-0.3	2.54e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs10733682	0.659	rs867560	chr9:129465233	C/G	cg00232160	chr9:129468157	NA	-0.49	-8.92	-0.4	1.37e-17	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-11.15	-0.48	1.69e-25	Longevity;Endometriosis;
LUAD	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg24531977	chr5:56204891	C5orf35	-0.59	-9.47	-0.42	1.95e-19	Coronary artery disease;
LUAD	cis	rs11153730	0.503	rs12212582	chr6:118626480	A/G	cg21191810	chr6:118973309	C6orf204	0.45	9.02	0.4	6.87e-18	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.62	9.19	0.41	1.79e-18	Platelet count;
LUAD	cis	rs3806843	0.548	rs246038	chr5:140331699	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.66	-0.31	8.76e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg19367466	chr12:123717773	C12orf65	-0.4	-6.69	-0.31	7.3e-11	Schizophrenia;
LUAD	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg27087555	chr16:88793112	FAM38A	-0.85	-8.12	-0.37	5.13e-15	Plateletcrit;
LUAD	cis	rs9296092	0.500	rs9461885	chr6:33521069	G/T	cg13560919	chr6:33536144	NA	-0.89	-16.71	-0.63	1.64e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg18105134	chr13:113819100	PROZ	-0.81	-14.59	-0.58	2.51e-39	Platelet distribution width;
LUAD	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg00383909	chr3:49044727	WDR6	0.87	10.1	0.44	1.23e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg15691649	chr6:25882328	NA	0.63	9.73	0.43	2.61e-20	Blood metabolite levels;
LUAD	cis	rs684232	0.602	rs10521107	chr17:511156	G/A	cg15660573	chr17:549704	VPS53	-0.88	-17.97	-0.66	4.77e-54	Prostate cancer;
LUAD	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg08470875	chr2:26401718	FAM59B	-0.46	-6.67	-0.31	7.91e-11	Gut microbiome composition (summer);
LUAD	cis	rs12210905	1.000	rs72842200	chr6:27068036	C/A	cg11502198	chr6:26597334	ABT1	-0.78	-6.36	-0.3	5.28e-10	Hip circumference adjusted for BMI;
LUAD	trans	rs7395662	0.926	rs10742848	chr11:48468788	T/G	cg00717180	chr2:96193071	NA	-0.4	-7.41	-0.34	6.81e-13	HDL cholesterol;
LUAD	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg23422044	chr7:1970798	MAD1L1	-0.55	-6.66	-0.31	8.51e-11	Bipolar disorder;
LUAD	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.33	7.08	0.33	6.12e-12	Cardiac Troponin-T levels;
LUAD	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg10792982	chr14:105748885	BRF1	0.44	9.63	0.42	5.49e-20	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg24558204	chr6:135376177	HBS1L	0.43	7.31	0.33	1.36e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg10876282	chr6:28092338	ZSCAN16	0.46	7.52	0.34	3.25e-13	Parkinson's disease;
LUAD	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg27219399	chr15:67835830	MAP2K5	0.39	6.45	0.3	3.04e-10	Obesity;
LUAD	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg21890820	chr11:65308645	LTBP3	0.46	7.34	0.34	1.11e-12	Bone mineral density;
LUAD	cis	rs8027181	0.797	rs8033580	chr15:72994968	C/A	cg25632853	chr15:73088954	NA	0.32	6.8	0.31	3.49e-11	Triglyceride levels;
LUAD	cis	rs500891	0.504	rs976065	chr6:84092514	C/T	cg08257003	chr6:84140564	ME1	0.34	6.68	0.31	7.52e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg17971929	chr21:40555470	PSMG1	0.53	8.41	0.38	6.43e-16	Cognitive function;
LUAD	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg20476274	chr7:133979776	SLC35B4	-0.56	-9.81	-0.43	1.34e-20	Mean platelet volume;
LUAD	trans	rs412658	0.535	rs1651558	chr19:22089575	A/G	cg17074339	chr11:11642133	GALNTL4	0.4	7.3	0.33	1.4e-12	Telomere length;
LUAD	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg14847009	chr1:175162515	KIAA0040	-0.33	-8.71	-0.39	7.09e-17	Alcohol dependence;
LUAD	cis	rs4664308	1.000	rs17831161	chr2:160909360	A/G	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.75	-0.31	4.93e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.75	0.53	9.8e-32	Cognitive ability;
LUAD	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg16479474	chr6:28041457	NA	0.42	7.33	0.34	1.2e-12	Depression;
LUAD	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg26727032	chr16:67993705	SLC12A4	-0.49	-6.98	-0.32	1.16e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11905131	chr22:24372483	LOC391322	-0.54	-9.43	-0.42	2.65e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs231513	0.638	rs79139991	chr17:42010359	C/T	cg26893861	chr17:41843967	DUSP3	0.65	6.65	0.31	8.81e-11	Cognitive function;
LUAD	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg10053473	chr17:62856997	LRRC37A3	0.77	11.33	0.48	3.67e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7727544	0.506	rs10040809	chr5:131343017	A/C	cg14196790	chr5:131705035	SLC22A5	0.4	6.94	0.32	1.47e-11	Blood metabolite levels;
LUAD	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg27170947	chr2:26402098	FAM59B	-0.83	-12.27	-0.51	8.38e-30	Gut microbiome composition (summer);
LUAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg03188948	chr7:1209495	NA	0.91	12.37	0.52	3.4e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg21582582	chr3:182698605	DCUN1D1	0.49	8.02	0.36	1.03e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	8.79	0.39	3.89e-17	Schizophrenia;
LUAD	cis	rs6546550	0.694	rs12467361	chr2:70019127	G/A	cg02498382	chr2:70120550	SNRNP27	-0.5	-8.77	-0.39	4.55e-17	Prevalent atrial fibrillation;
LUAD	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg01475377	chr6:109611718	NA	-0.54	-10.34	-0.45	1.75e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg17724175	chr1:150552817	MCL1	0.37	8.37	0.38	8.58e-16	Melanoma;
LUAD	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg25036284	chr2:26402008	FAM59B	-0.6	-8.34	-0.38	1.02e-15	Gut microbiome composition (summer);
LUAD	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg15790184	chr11:494944	RNH1	0.42	6.77	0.31	4.33e-11	Systemic lupus erythematosus;
LUAD	cis	rs886126	1.000	rs876027	chr12:111678458	A/T	cg10833066	chr12:111807467	FAM109A	0.58	10.72	0.46	6.91e-24	Coronary heart disease;
LUAD	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg14779329	chr11:130786720	SNX19	0.43	7.39	0.34	7.86e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg07460842	chr6:66804631	NA	-0.98	-14.72	-0.58	7.02e-40	Exhaled nitric oxide output;
LUAD	cis	rs2580764	0.598	rs6726158	chr2:55239202	G/T	cg09592903	chr2:55203963	RTN4	-0.45	-10.32	-0.45	2.07e-22	Mean platelet volume;
LUAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	cis	rs12200782	0.932	rs12212145	chr6:26646418	T/A	cg11502198	chr6:26597334	ABT1	-0.76	-6.54	-0.3	1.77e-10	Small cell lung carcinoma;
LUAD	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg06623918	chr6:96969491	KIAA0776	-0.88	-17.28	-0.64	5.26e-51	Headache;
LUAD	cis	rs1595825	0.891	rs16824264	chr2:198675917	T/C	cg00982548	chr2:198649783	BOLL	-0.66	-9.29	-0.41	7.97e-19	Ulcerative colitis;
LUAD	cis	rs6987853	0.933	rs2356610	chr8:42446238	T/G	cg09913449	chr8:42400586	C8orf40	0.42	7.65	0.35	1.36e-13	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg22823121	chr1:150693482	HORMAD1	0.38	7.41	0.34	7.09e-13	Melanoma;
LUAD	cis	rs9513627	0.749	rs73556143	chr13:100116907	G/A	cg25919922	chr13:100150906	NA	-0.66	-6.43	-0.3	3.45e-10	Obesity-related traits;
LUAD	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.08	0.33	6.15e-12	Motion sickness;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg03395511	chr6:291903	DUSP22	-0.74	-12.68	-0.52	1.91e-31	Menopause (age at onset);
LUAD	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	24.17	0.76	1.04e-81	Chronic sinus infection;
LUAD	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg04414720	chr1:150670196	GOLPH3L	0.72	12.56	0.52	5.87e-31	Melanoma;
LUAD	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg09085632	chr11:111637200	PPP2R1B	0.61	9.18	0.41	1.88e-18	Primary sclerosing cholangitis;
LUAD	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg12373951	chr3:133503437	NA	0.38	7.31	0.33	1.34e-12	Iron status biomarkers;
LUAD	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg17644776	chr2:200775616	C2orf69	0.52	6.53	0.3	1.9e-10	Schizophrenia;
LUAD	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg15664640	chr17:80829946	TBCD	-0.59	-11.33	-0.48	3.57e-26	Breast cancer;
LUAD	cis	rs1448094	0.785	rs7955173	chr12:86447214	G/A	cg02569458	chr12:86230093	RASSF9	-0.37	-7.17	-0.33	3.26e-12	Major depressive disorder;
LUAD	cis	rs4906332	0.782	rs7161305	chr14:104002234	G/A	cg19000871	chr14:103996768	TRMT61A	-0.54	-9.17	-0.41	2.08e-18	Coronary artery disease;
LUAD	cis	rs7799006	0.929	rs7781856	chr7:2257199	C/T	cg12745145	chr7:2261452	MAD1L1	-0.33	-6.42	-0.3	3.74e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.58	8.25	0.37	1.97e-15	Gut microbiome composition (summer);
LUAD	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.61	-7.23	-0.33	2.29e-12	Body mass index;
LUAD	cis	rs4253772	0.938	rs14842	chr22:46639457	A/T	cg09491104	chr22:46646882	C22orf40	-0.51	-6.99	-0.32	1.11e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs497273	0.512	rs1177585	chr12:121325321	C/T	cg02419362	chr12:121203948	SPPL3	-0.37	-7.43	-0.34	6.13e-13	Systemic lupus erythematosus;
LUAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg11941060	chr3:133502564	NA	-0.7	-13.19	-0.54	1.6e-33	Iron status biomarkers;
LUAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.79	-0.43	1.59e-20	Alzheimer's disease;
LUAD	cis	rs17655565	0.533	rs12301094	chr12:52707610	A/G	cg08257133	chr12:52711352	KRT83	0.41	10.04	0.44	2.12e-21	Plasma amyloid beta peptide concentrations (ABx-42);
LUAD	cis	rs2731664	0.792	rs2544809	chr5:176885499	T/C	cg23176889	chr5:176863531	GRK6	-0.7	-13.11	-0.54	3.5e-33	Intelligence (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12473036	chr20:62611207	SAMD10;PRPF6	-0.49	-7.7	-0.35	9.88e-14	Height;
LUAD	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg02176678	chr2:219576539	TTLL4	-0.82	-17.2	-0.64	1.15e-50	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs74400468	0.529	rs11239742	chr10:43205653	G/A	cg18403995	chr10:43134038	ZNF33B	-0.79	-8.17	-0.37	3.57e-15	Cannabis dependence symptom count;
LUAD	trans	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg18335740	chr13:41363409	SLC25A15	0.54	9.76	0.43	1.91e-20	Lewy body disease;
LUAD	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg17724175	chr1:150552817	MCL1	0.3	6.77	0.31	4.23e-11	Tonsillectomy;
LUAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02353165	chr6:42928485	GNMT	0.45	8.51	0.38	3e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6484504	0.576	rs208091	chr11:31190099	G/C	cg26647111	chr11:31128758	NA	-0.47	-8.3	-0.37	1.45e-15	Red blood cell count;
LUAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg08888203	chr3:10149979	C3orf24	0.63	9.84	0.43	1.07e-20	Alzheimer's disease;
LUAD	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs13064411	0.735	rs13098166	chr3:113210038	A/G	cg18753928	chr3:113234510	CCDC52	-0.73	-12.43	-0.52	1.82e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg01620082	chr3:125678407	NA	-0.46	-7.02	-0.32	8.71e-12	Parkinson's disease;
LUAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-10.3	-0.45	2.39e-22	Lymphocyte counts;
LUAD	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23583168	chr7:148888333	NA	-0.81	-14.14	-0.57	1.84e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg08859206	chr1:53392774	SCP2	0.59	10.6	0.46	1.98e-23	Monocyte count;
LUAD	trans	rs2262909	0.925	rs73019900	chr19:22286680	G/A	cg17074339	chr11:11642133	GALNTL4	0.48	7.78	0.35	5.56e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00475322	chr7:917719	C7orf20	0.57	10.35	0.45	1.63e-22	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs7593730	1.000	rs10168504	chr2:161202588	G/A	cg22609984	chr2:161126801	NA	0.43	6.87	0.32	2.25e-11	Type 2 diabetes;
LUAD	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg15017067	chr4:17643749	FAM184B	0.35	7.0	0.32	1.04e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg00280220	chr17:61926910	NA	0.36	6.97	0.32	1.22e-11	Prudent dietary pattern;
LUAD	cis	rs1461503	0.932	rs10790542	chr11:122838243	C/T	cg27398637	chr11:122830231	C11orf63	-0.37	-7.25	-0.33	2.06e-12	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6426558	0.537	rs7512409	chr1:227484038	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.53	-8.64	-0.39	1.14e-16	Neutrophil percentage of white cells;
LUAD	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg13685833	chr1:53393034	SCP2	-0.42	-6.78	-0.31	4.15e-11	Monocyte count;
LUAD	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg06263672	chr7:65235340	NA	0.49	6.43	0.3	3.5e-10	Aortic root size;
LUAD	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg21385522	chr1:16154831	NA	-0.63	-11.3	-0.48	4.67e-26	Dilated cardiomyopathy;
LUAD	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.8	-0.31	3.54e-11	Retinal vascular caliber;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22461615	chr4:83821917	THAP9	-0.55	-6.85	-0.32	2.66e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.61	-0.52	3.68e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg18404041	chr3:52824283	ITIH1	-0.53	-9.0	-0.4	7.75e-18	Schizophrenia;
LUAD	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg04539111	chr16:67997858	SLC12A4	-0.48	-6.4	-0.3	4.1e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4853036	1.000	rs28362672	chr2:70056866	A/G	cg02498382	chr2:70120550	SNRNP27	-0.5	-8.03	-0.36	9.67e-15	Colorectal or endometrial cancer;
LUAD	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg22029157	chr1:209979665	IRF6	-0.4	-7.26	-0.33	1.85e-12	Monobrow;
LUAD	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg25767906	chr1:53392781	SCP2	0.46	8.38	0.38	7.79e-16	Monocyte count;
LUAD	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg17264618	chr3:40429014	ENTPD3	0.39	8.86	0.4	2.25e-17	Renal cell carcinoma;
LUAD	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg21545522	chr1:205238299	TMCC2	0.37	6.81	0.31	3.46e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs2073300	1.000	rs112057098	chr20:23448901	C/T	cg12062639	chr20:23401060	NAPB	0.75	6.96	0.32	1.3e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.32	0.48	4.06e-26	Mean corpuscular volume;
LUAD	cis	rs62238980	0.521	rs80342684	chr22:32380494	G/A	cg00543991	chr22:32367038	NA	0.94	8.78	0.39	4.09e-17	Childhood ear infection;
LUAD	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.43	-7.78	-0.35	5.42e-14	Longevity;Endometriosis;
LUAD	cis	rs220324	0.688	rs9974977	chr21:43563496	G/A	cg08841829	chr21:43638893	ABCG1	-0.5	-6.91	-0.32	1.85e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7193541	0.585	rs3851729	chr16:74485529	A/G	cg01733217	chr16:74700730	RFWD3	-0.48	-8.72	-0.39	6.33e-17	Multiple myeloma;
LUAD	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg02450064	chr17:40260053	DHX58	-0.45	-7.6	-0.35	1.87e-13	Fibrinogen levels;
LUAD	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg09835421	chr16:68378352	PRMT7	-0.73	-8.37	-0.38	8.28e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7975161	0.786	rs10861181	chr12:104651110	T/C	cg25273343	chr12:104657179	TXNRD1	-0.66	-8.47	-0.38	4.13e-16	Toenail selenium levels;
LUAD	trans	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg26043149	chr18:55253948	FECH	-0.44	-7.03	-0.32	8.36e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg15147215	chr3:52552868	STAB1	-0.41	-7.37	-0.34	9.12e-13	Bipolar disorder;
LUAD	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg16205897	chr5:131564050	P4HA2	-0.34	-7.63	-0.35	1.55e-13	Blood metabolite levels;
LUAD	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg05340658	chr4:99064831	C4orf37	0.54	9.21	0.41	1.56e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg25767906	chr1:53392781	SCP2	-0.6	-11.58	-0.49	4.08e-27	Monocyte count;
LUAD	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg11189052	chr15:85197271	WDR73	0.65	8.73	0.39	5.92e-17	Schizophrenia;
LUAD	cis	rs10916814	0.610	rs4655222	chr1:20901418	C/T	cg24502330	chr1:20914028	CDA	-0.36	-7.15	-0.33	3.76e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg15147215	chr3:52552868	STAB1	-0.41	-7.49	-0.34	4.08e-13	Bipolar disorder;
LUAD	cis	rs4372836	0.504	rs12185717	chr2:29069551	C/A	cg09522027	chr2:28974177	PPP1CB	-0.6	-10.55	-0.46	2.97e-23	Body mass index;
LUAD	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg26408565	chr15:76604113	ETFA	-0.44	-7.17	-0.33	3.35e-12	Blood metabolite levels;
LUAD	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.39	8.02	0.36	1.08e-14	Hemoglobin concentration;
LUAD	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg06608945	chr2:219082296	ARPC2	0.51	8.85	0.4	2.36e-17	Colorectal cancer;
LUAD	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.19	-0.33	2.94e-12	Breast cancer;
LUAD	cis	rs68170813	0.521	rs75035695	chr7:106818731	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-11.09	-0.47	3.01e-25	Coronary artery disease;
LUAD	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg13319975	chr6:146136371	FBXO30	-0.58	-9.51	-0.42	1.43e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg14779329	chr11:130786720	SNX19	0.37	6.55	0.3	1.64e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg03340356	chr1:67600835	NA	-0.43	-7.33	-0.34	1.2e-12	Psoriasis;
LUAD	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg20701182	chr2:24300061	SF3B14	0.64	7.42	0.34	6.6e-13	Lymphocyte counts;
LUAD	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg16205897	chr5:131564050	P4HA2	-0.29	-6.47	-0.3	2.67e-10	Blood metabolite levels;
LUAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg11062466	chr8:58055876	NA	0.67	8.47	0.38	4.18e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4523957	0.928	rs375245	chr17:2199754	G/A	cg16513277	chr17:2031491	SMG6	0.76	14.29	0.57	4.41e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg00431813	chr7:1051703	C7orf50	-0.37	-6.53	-0.3	1.94e-10	Longevity;Endometriosis;
LUAD	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg19622623	chr12:86230825	RASSF9	-0.54	-9.69	-0.43	3.47e-20	Major depressive disorder;
LUAD	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg02176678	chr2:219576539	TTLL4	0.68	13.54	0.55	6.08e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg22166914	chr1:53195759	ZYG11B	-0.53	-9.29	-0.41	8.54e-19	Monocyte count;
LUAD	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg00316803	chr15:76480434	C15orf27	0.4	6.41	0.3	3.85e-10	Blood metabolite levels;
LUAD	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg08859206	chr1:53392774	SCP2	-0.49	-9.09	-0.4	3.74e-18	Monocyte count;
LUAD	cis	rs12791968	1.000	rs1005935	chr11:45002498	A/C	cg11846598	chr11:44996168	LOC221122	-0.78	-13.95	-0.56	1.15e-36	Inhibitory control;
LUAD	cis	rs6489882	0.867	rs7306205	chr12:113366899	A/G	cg20102336	chr12:113376681	OAS3	-0.6	-9.4	-0.42	3.51e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs7267979	0.933	rs6138571	chr20:25435388	A/G	cg08601574	chr20:25228251	PYGB	0.47	8.7	0.39	7.19e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs28595532	1.000	rs116030177	chr4:119650768	T/C	cg02775129	chr4:119771670	NA	-0.82	-7.62	-0.35	1.7e-13	Cannabis dependence symptom count;
LUAD	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg17264618	chr3:40429014	ENTPD3	0.39	8.83	0.39	2.71e-17	Renal cell carcinoma;
LUAD	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.05e-19	Life satisfaction;
LUAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.45	-8.63	-0.39	1.25e-16	Longevity;Endometriosis;
LUAD	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg00933542	chr6:150070202	PCMT1	0.36	7.22	0.33	2.45e-12	Testicular germ cell tumor;
LUAD	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.48	-0.3	2.49e-10	Heart rate;
LUAD	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg11494091	chr17:61959527	GH2	0.46	8.65	0.39	1.04e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg12310025	chr6:25882481	NA	-0.57	-9.18	-0.41	1.98e-18	Blood metabolite levels;
LUAD	cis	rs11971779	0.680	rs2355785	chr7:139070983	C/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.46	-0.3	2.86e-10	Diisocyanate-induced asthma;
LUAD	cis	rs12989701	0.877	rs35860453	chr2:127866047	C/T	cg08168897	chr2:127865431	BIN1	0.44	6.8	0.31	3.62e-11	Alzheimer's disease (late onset);
LUAD	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-10.06	-0.44	1.72e-21	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg04775059	chr7:64541387	NA	0.5	6.79	0.31	3.82e-11	Aortic root size;
LUAD	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg04476341	chr5:669733	TPPP	0.42	8.27	0.37	1.78e-15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.63	8.72	0.39	6.59e-17	Renal function-related traits (BUN);
LUAD	cis	rs12579753	0.871	rs4255611	chr12:82215969	C/A	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.88	-0.32	2.13e-11	Resting heart rate;
LUAD	cis	rs6484504	0.625	rs796341	chr11:31414151	G/A	cg14844989	chr11:31128820	NA	0.45	8.15	0.37	4.1e-15	Red blood cell count;
LUAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08677398	chr8:58056175	NA	0.46	6.47	0.3	2.68e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07636037	chr3:49044803	WDR6	0.48	8.39	0.38	7.24e-16	Menarche (age at onset);
LUAD	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7202877	0.610	rs8053632	chr16:75364940	C/T	cg03315344	chr16:75512273	CHST6	0.48	6.82	0.31	3.23e-11	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.42	-8.25	-0.37	2.02e-15	Glomerular filtration rate;
LUAD	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg20503657	chr10:835505	NA	1.03	15.43	0.6	5.95e-43	Eosinophil percentage of granulocytes;
LUAD	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg08213375	chr14:104286397	PPP1R13B	0.27	6.92	0.32	1.67e-11	Schizophrenia;
LUAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg26818010	chr10:134567672	INPP5A	-0.96	-15.8	-0.61	1.63e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10992471	0.528	rs7037194	chr9:95216745	G/A	cg14631576	chr9:95140430	CENPP	-0.5	-10.17	-0.44	7.21e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg07305463	chr2:136567211	LCT	0.37	6.93	0.32	1.58e-11	Mosquito bite size;
LUAD	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.44	7.99	0.36	1.33e-14	Depression;
LUAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.16	-0.33	3.52e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs8062405	1.000	rs8061590	chr16:28895130	A/G	cg05966235	chr16:28915196	ATP2A1	0.47	7.64	0.35	1.44e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg16988262	chr1:15930761	NA	-0.4	-6.82	-0.31	3.12e-11	Systolic blood pressure;
LUAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.74	-8.83	-0.39	2.86e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.39	-0.34	8.1e-13	Lung cancer;
LUAD	cis	rs9297145	0.565	rs4729516	chr7:98745679	G/A	cg05967295	chr7:98741636	SMURF1	-0.76	-13.78	-0.56	6.24e-36	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg02527881	chr3:46936655	PTH1R	-0.76	-18.5	-0.67	2.04e-56	Birth weight;
LUAD	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg23281280	chr6:28129359	ZNF389	-0.42	-6.43	-0.3	3.35e-10	Depression;
LUAD	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg25237894	chr2:233734115	C2orf82	0.6	11.52	0.49	6.84e-27	Coronary artery disease;
LUAD	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg01528321	chr10:82214614	TSPAN14	0.68	11.25	0.48	7.03e-26	Post bronchodilator FEV1;
LUAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg07217954	chr7:1067459	C7orf50	0.45	7.1	0.33	5.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.15	-0.33	3.91e-12	Blood metabolite levels;
LUAD	cis	rs11971779	0.650	rs10085842	chr7:139064582	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.76	0.31	4.63e-11	Diisocyanate-induced asthma;
LUAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.57	-10.01	-0.44	2.67e-21	Longevity;Endometriosis;
LUAD	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg12623302	chr6:28058802	ZSCAN12L1	-0.32	-6.7	-0.31	6.53e-11	Depression;
LUAD	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg03929089	chr4:120376271	NA	0.54	7.15	0.33	3.88e-12	Axial length;
LUAD	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs8112211	0.834	rs3178327	chr19:38798086	T/C	cg14299480	chr19:38876666	GGN	-0.45	-7.65	-0.35	1.33e-13	Blood protein levels;
LUAD	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg04287289	chr16:89883240	FANCA	0.79	6.87	0.32	2.25e-11	Skin colour saturation;
LUAD	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg00631329	chr6:26305371	NA	-0.73	-14.12	-0.57	2.28e-37	Educational attainment;
LUAD	cis	rs62400317	0.826	rs10807321	chr6:45330974	T/C	cg20913747	chr6:44695427	NA	-0.4	-6.42	-0.3	3.59e-10	Total body bone mineral density;
LUAD	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg26384229	chr12:38710491	ALG10B	0.44	7.27	0.33	1.74e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7617773	0.780	rs13082158	chr3:48372470	T/C	cg11946769	chr3:48343235	NME6	0.44	6.66	0.31	8.32e-11	Coronary artery disease;
LUAD	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg10164272	chr16:89456328	ANKRD11	-0.39	-6.35	-0.3	5.49e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs7089973	0.872	rs12773943	chr10:116631184	G/A	cg25233709	chr10:116636983	FAM160B1	0.39	7.52	0.34	3.3e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg20607798	chr8:58055168	NA	0.83	10.02	0.44	2.39e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg12927641	chr6:109611667	NA	-0.51	-8.71	-0.39	6.67e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg08997352	chr12:9597637	DDX12	-0.68	-12.15	-0.51	2.38e-29	Breast size;
LUAD	cis	rs752010	0.934	rs11210503	chr1:42101134	A/G	cg06885757	chr1:42089581	HIVEP3	0.44	9.34	0.41	5.61e-19	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs10465746	0.545	rs12145516	chr1:84480376	A/G	cg10977910	chr1:84465055	TTLL7	0.48	7.14	0.33	4.07e-12	Obesity-related traits;
LUAD	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg21782813	chr7:2030301	MAD1L1	0.43	7.48	0.34	4.47e-13	Schizophrenia;
LUAD	cis	rs7267979	0.789	rs2260197	chr20:25284343	T/C	cg08601574	chr20:25228251	PYGB	0.38	7.12	0.33	4.54e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg18230493	chr5:56204884	C5orf35	0.81	12.07	0.51	5.14e-29	Initial pursuit acceleration;
LUAD	trans	rs11644601	1	rs11644601	chr16:15172118	T/C	cg04492929	chr16:2155436	PKD1	-0.43	-6.73	-0.31	5.65e-11	Metabolite levels (lipid measures);
LUAD	cis	rs4919694	1.000	rs12246689	chr10:104817031	C/T	cg04362960	chr10:104952993	NT5C2	0.73	7.86	0.36	3.28e-14	Arsenic metabolism;
LUAD	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg01579765	chr21:45077557	HSF2BP	0.55	11.8	0.5	5.74e-28	Mean corpuscular volume;
LUAD	cis	rs7100689	0.646	rs10736356	chr10:82148325	A/G	cg00277334	chr10:82204260	NA	-0.6	-10.02	-0.44	2.41e-21	Post bronchodilator FEV1;
LUAD	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs7809950	0.871	rs11771278	chr7:107285925	C/T	cg23024343	chr7:107201750	COG5	0.56	9.47	0.42	2.07e-19	Coronary artery disease;
LUAD	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26314531	chr2:26401878	FAM59B	-0.72	-9.81	-0.43	1.33e-20	Gut microbiome composition (summer);
LUAD	cis	rs757647	1.000	rs7734755	chr5:137770557	A/G	cg10676309	chr5:137685565	NA	0.36	6.89	0.32	2.08e-11	Menarche (age at onset);
LUAD	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg02371401	chr5:676784	TPPP	-0.41	-7.13	-0.33	4.44e-12	Obesity-related traits;
LUAD	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.1	-0.4	3.69e-18	Bipolar disorder;
LUAD	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg13010199	chr12:38710504	ALG10B	0.41	6.75	0.31	4.86e-11	Bladder cancer;
LUAD	cis	rs8060686	0.858	rs7187289	chr16:67967878	A/C	cg04539111	chr16:67997858	SLC12A4	-0.44	-6.64	-0.31	9.56e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1595825	0.891	rs75373125	chr2:198657044	G/A	cg10547527	chr2:198650123	BOLL	-0.54	-6.98	-0.32	1.12e-11	Ulcerative colitis;
LUAD	cis	rs2046867	0.661	rs7637050	chr3:72910790	A/C	cg25664220	chr3:72788482	NA	-0.57	-10.56	-0.46	2.79e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6906287	0.647	rs6938226	chr6:118852561	C/A	cg05564266	chr6:118973597	C6orf204	0.34	7.15	0.33	3.82e-12	Electrocardiographic conduction measures;
LUAD	cis	rs4372836	0.677	rs4632298	chr2:29076282	T/C	cg09522027	chr2:28974177	PPP1CB	0.67	11.93	0.5	1.84e-28	Body mass index;
LUAD	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg02176678	chr2:219576539	TTLL4	0.74	15.04	0.59	3.03e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.31	-8.27	-0.37	1.7e-15	Total body bone mineral density;
LUAD	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.05	-0.32	7.52e-12	Height;
LUAD	cis	rs4664304	1.000	rs4664304	chr2:160794008	A/G	cg06573604	chr2:160760825	LY75	-0.4	-6.59	-0.31	1.29e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs73206853	0.764	rs58535454	chr12:111003457	C/T	cg12870014	chr12:110450643	ANKRD13A	0.63	7.07	0.33	6.46e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs11771526	0.901	rs41519845	chr7:32315443	A/T	cg27511599	chr7:32358540	NA	0.51	6.46	0.3	2.93e-10	Body mass index;
LUAD	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg07169764	chr2:136633963	MCM6	-0.58	-6.95	-0.32	1.35e-11	Corneal structure;
LUAD	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg02423579	chr7:2872169	GNA12	-0.39	-6.42	-0.3	3.6e-10	Height;
LUAD	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg00074818	chr8:8560427	CLDN23	-0.71	-10.91	-0.47	1.39e-24	Obesity-related traits;
LUAD	cis	rs7818345	0.967	rs4391454	chr8:19275653	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.32	6.98	0.32	1.17e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg20064569	chr19:3572546	HMG20B	-0.39	-6.48	-0.3	2.61e-10	Cancer;
LUAD	cis	rs478304	0.593	rs75162774	chr11:65492483	G/A	cg27068330	chr11:65405492	SIPA1	-0.76	-11.85	-0.5	3.48e-28	Acne (severe);
LUAD	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg03433033	chr1:76189801	ACADM	0.75	11.65	0.49	2.11e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6500395	0.928	rs2080509	chr16:48690915	T/C	cg04672837	chr16:48644449	N4BP1	-0.38	-6.69	-0.31	7.31e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg06168050	chr17:30677336	ZNF207	0.49	8.31	0.37	1.36e-15	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs11153730	0.503	rs283057	chr6:118625734	T/C	cg21191810	chr6:118973309	C6orf204	0.5	9.95	0.44	4.11e-21	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs9914544	0.564	rs8072860	chr17:18807884	T/C	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.5	-0.3	2.26e-10	Educational attainment (years of education);
LUAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-9.53	-0.42	1.29e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg00074818	chr8:8560427	CLDN23	0.62	9.35	0.41	4.94e-19	Obesity-related traits;
LUAD	trans	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg19676328	chr12:49525230	TUBA1B	-0.66	-10.9	-0.47	1.45e-24	Total cholesterol levels;
LUAD	cis	rs1232027	0.622	rs836800	chr5:79985329	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.41	-6.5	-0.3	2.3e-10	Huntington's disease progression;
LUAD	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.22	15.5	0.6	3.07e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2046867	0.819	rs34132129	chr3:72829100	A/G	cg04365224	chr3:72788183	NA	-0.47	-6.99	-0.32	1.1e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg12573674	chr2:1569213	NA	-0.56	-8.13	-0.37	4.76e-15	IgG glycosylation;
LUAD	cis	rs12431939	0.744	rs12888250	chr14:51669195	C/G	cg23942311	chr14:51606299	NA	0.43	6.69	0.31	7.15e-11	Cancer;
LUAD	cis	rs9346649	0.654	rs35453512	chr6:168491906	C/G	cg02770688	chr6:168491649	NA	0.53	10.05	0.44	1.84e-21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg18105134	chr13:113819100	PROZ	-1.01	-18.25	-0.66	2.69e-55	Platelet distribution width;
LUAD	cis	rs72634258	0.740	rs35223180	chr1:8185902	G/T	cg26816564	chr1:7831052	VAMP3	0.5	6.46	0.3	2.81e-10	Inflammatory bowel disease;
LUAD	cis	rs7512552	0.966	rs2274127	chr1:150252984	T/G	cg15654264	chr1:150340011	RPRD2	-0.43	-7.9	-0.36	2.38e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg07211511	chr3:129823064	LOC729375	-0.48	-6.43	-0.3	3.52e-10	Blood pressure (smoking interaction);
LUAD	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg26587870	chr6:27730563	NA	-0.59	-6.82	-0.31	3.23e-11	Depression;
LUAD	cis	rs912057	0.841	rs1294423	chr6:6743795	C/T	cg06612196	chr6:6737390	NA	0.55	12.63	0.52	3e-31	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.82	-0.39	2.99e-17	Total body bone mineral density;
LUAD	cis	rs7727544	0.548	rs35696821	chr5:131508017	C/T	cg14196790	chr5:131705035	SLC22A5	0.42	7.26	0.33	1.89e-12	Blood metabolite levels;
LUAD	cis	rs4588572	0.686	rs4703756	chr5:77683490	T/C	cg11547950	chr5:77652471	NA	0.74	11.67	0.49	1.79e-27	Triglycerides;
LUAD	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg02269571	chr22:50332266	NA	0.59	8.96	0.4	1.05e-17	Schizophrenia;
LUAD	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg00769240	chr8:12517080	NA	-0.4	-6.64	-0.31	9.48e-11	Blood pressure (smoking interaction);
LUAD	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.47	7.99	0.36	1.25e-14	Squamous cell carcinoma;
LUAD	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg15445000	chr17:37608096	MED1	-0.44	-8.26	-0.37	1.87e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.61	-0.42	6.75e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.33e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs80319144	0.521	rs77502408	chr2:159316964	A/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.41	8.06	0.36	7.79e-15	Restless legs syndrome;
LUAD	cis	rs73198271	0.562	rs75525911	chr8:8659359	C/A	cg01851573	chr8:8652454	MFHAS1	0.73	11.1	0.48	2.63e-25	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07157834	chr1:205819609	PM20D1	-0.68	-13.43	-0.55	1.69e-34	Menarche (age at onset);
LUAD	cis	rs2979489	0.699	rs17554116	chr8:30419334	C/T	cg26383811	chr8:30366931	RBPMS	-0.62	-9.46	-0.42	2.25e-19	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	trans	rs7395662	0.889	rs11039972	chr11:48759252	A/G	cg00717180	chr2:96193071	NA	0.39	7.2	0.33	2.85e-12	HDL cholesterol;
LUAD	trans	rs2834485	0.816	rs1547356	chr21:35822572	C/T	cg07474852	chr4:123073612	NA	0.5	7.54	0.34	2.84e-13	Cancer;
LUAD	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg22117172	chr7:91764530	CYP51A1	-0.34	-7.2	-0.33	2.76e-12	Breast cancer;
LUAD	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg11833968	chr6:79620685	NA	-0.45	-8.27	-0.37	1.79e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg04036182	chr15:45458818	NA	-0.41	-7.2	-0.33	2.78e-12	Glomerular filtration rate;
LUAD	cis	rs7665090	0.967	rs7699231	chr4:103550075	A/G	cg07973026	chr4:103553119	MANBA	0.47	8.4	0.38	6.94e-16	Primary biliary cholangitis;
LUAD	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.39	0.34	7.87e-13	Hypertriglyceridemia;
LUAD	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.66	-0.61	6.36e-44	Eye color traits;
LUAD	cis	rs3790645	1.000	rs3127013	chr1:26891360	T/G	cg23229016	chr1:26872525	RPS6KA1	0.2	6.79	0.31	3.83e-11	Glucose homeostasis traits;
LUAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg11062466	chr8:58055876	NA	0.67	9.01	0.4	7.2e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7487075	0.619	rs4768717	chr12:46831561	C/T	cg23829395	chr12:46796953	NA	0.32	7.11	0.33	5e-12	Itch intensity from mosquito bite;
LUAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg18402987	chr7:1209562	NA	0.71	9.27	0.41	9.8e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.43	-7.24	-0.33	2.14e-12	Tonsillectomy;
LUAD	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg08761264	chr16:28874980	SH2B1	-0.44	-6.82	-0.31	3.2e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg00757033	chr12:89920650	WDR51B	-0.64	-11.66	-0.49	1.97e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7772486	0.840	rs2814864	chr6:146345046	A/C	cg13319975	chr6:146136371	FBXO30	-0.58	-9.01	-0.4	7.38e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-11.75	-0.5	8.58e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.32	0.45	2.05e-22	Ileal carcinoids;
LUAD	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg09640425	chr7:158790006	NA	0.46	7.79	0.35	5.26e-14	Facial morphology (factor 20);
LUAD	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg07741184	chr6:167504864	NA	0.44	9.83	0.43	1.15e-20	Primary biliary cholangitis;
LUAD	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg10755058	chr3:40428713	ENTPD3	0.47	8.66	0.39	1.03e-16	Renal cell carcinoma;
LUAD	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg10556349	chr10:835070	NA	0.6	7.64	0.35	1.48e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg19622623	chr12:86230825	RASSF9	-0.4	-7.11	-0.33	5.02e-12	Major depressive disorder;
LUAD	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg23172400	chr8:95962367	TP53INP1	0.31	6.63	0.31	1.02e-10	Type 2 diabetes;
LUAD	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg22683308	chr4:1340831	KIAA1530	-0.41	-6.75	-0.31	5.01e-11	Longevity;
LUAD	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg05887092	chr17:76393375	PGS1	0.41	7.28	0.33	1.65e-12	HDL cholesterol levels;
LUAD	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg13319975	chr6:146136371	FBXO30	0.62	10.56	0.46	2.67e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg03467027	chr4:99064603	C4orf37	0.4	6.49	0.3	2.41e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13394619	0.562	rs34532804	chr2:11746003	G/A	cg07314298	chr2:11723111	GREB1	0.43	7.83	0.36	3.92e-14	Endometriosis;
LUAD	cis	rs11585357	0.947	rs72646789	chr1:17610030	C/T	cg08277548	chr1:17600880	PADI3	-0.96	-14.11	-0.57	2.51e-37	Hair shape;
LUAD	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.64	-10.64	-0.46	1.41e-23	Colorectal cancer;
LUAD	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg23283495	chr1:209979779	IRF6	0.74	8.98	0.4	9.29e-18	Coronary artery disease;
LUAD	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.49	7.52	0.34	3.26e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23583168	chr7:148888333	NA	-0.8	-13.97	-0.56	9.91e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg10589385	chr1:150898437	SETDB1	0.39	7.3	0.33	1.48e-12	Tonsillectomy;
LUAD	cis	rs10489202	0.608	rs7553238	chr1:168076768	G/A	cg24449463	chr1:168025552	DCAF6	-0.61	-9.41	-0.42	3.25e-19	Schizophrenia;
LUAD	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-7.62	-0.35	1.69e-13	Lung cancer;
LUAD	cis	rs743757	0.938	rs2282753	chr3:50436716	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	7.26	0.33	1.92e-12	Diastolic blood pressure;
LUAD	cis	rs2286503	0.901	rs2286505	chr7:22854840	G/A	cg06496272	chr7:22895283	SNORD93	-0.41	-7.3	-0.33	1.47e-12	Fibrinogen;
LUAD	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg04731861	chr2:219085781	ARPC2	0.27	8.2	0.37	2.86e-15	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs1997103	0.705	rs56301138	chr7:55396555	G/T	cg17469321	chr7:55412551	NA	0.66	11.32	0.48	3.86e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg16486109	chr11:613632	IRF7	0.52	7.79	0.35	5.13e-14	Systemic lupus erythematosus;
LUAD	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg15448220	chr1:150897856	SETDB1	-0.52	-8.91	-0.4	1.52e-17	Melanoma;
LUAD	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg23933602	chr10:16859644	RSU1	0.54	7.18	0.33	3.12e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg24818145	chr4:99064322	C4orf37	0.47	7.81	0.36	4.44e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.61	-0.35	1.85e-13	Blood metabolite levels;
LUAD	trans	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04565464	chr8:145669602	NFKBIL2	0.51	7.78	0.35	5.47e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg18016565	chr1:150552671	MCL1	0.41	7.5	0.34	3.86e-13	Tonsillectomy;
LUAD	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	7.48	0.34	4.2e-13	Schizophrenia;
LUAD	cis	rs7020830	0.898	rs997318	chr9:37364094	C/T	cg14294708	chr9:37120828	ZCCHC7	0.88	17.95	0.66	5.62e-54	Schizophrenia;
LUAD	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg26818010	chr10:134567672	INPP5A	-0.96	-15.75	-0.61	2.59e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7665090	1.000	rs2866408	chr4:103554113	T/A	cg07973026	chr4:103553119	MANBA	0.49	8.67	0.39	8.99e-17	Primary biliary cholangitis;
LUAD	cis	rs10129255	0.530	rs11624912	chr14:107129907	A/G	cg07958169	chr14:107095056	NA	-0.37	-7.28	-0.33	1.66e-12	Kawasaki disease;
LUAD	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg23262073	chr20:60523788	NA	0.44	6.86	0.32	2.39e-11	Body mass index;
LUAD	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg21605333	chr4:119757512	SEC24D	0.93	8.76	0.39	4.9e-17	Cannabis dependence symptom count;
LUAD	trans	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg24112916	chr14:91294708	NA	-0.36	-6.4	-0.3	4.18e-10	Height;
LUAD	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg08754654	chr5:154026448	NA	-0.47	-7.95	-0.36	1.77e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.78	-0.31	4.03e-11	Type 2 diabetes;
LUAD	cis	rs7107174	1.000	rs2450123	chr11:77952771	T/C	cg02023728	chr11:77925099	USP35	0.5	7.64	0.35	1.51e-13	Testicular germ cell tumor;
LUAD	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg00745463	chr17:30367425	LRRC37B	-0.83	-10.21	-0.44	5.21e-22	Hip circumference adjusted for BMI;
LUAD	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg02569458	chr12:86230093	RASSF9	0.44	7.96	0.36	1.61e-14	Major depressive disorder;
LUAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg18402987	chr7:1209562	NA	0.38	6.57	0.3	1.51e-10	Longevity;Endometriosis;
LUAD	trans	rs8073060	0.586	rs7221203	chr17:34015532	T/C	cg19694781	chr19:47549865	TMEM160	-1.23	-19.62	-0.69	2.03e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg26384229	chr12:38710491	ALG10B	0.44	7.31	0.33	1.37e-12	Bladder cancer;
LUAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg02951883	chr7:2050386	MAD1L1	-0.71	-12.04	-0.51	6.28e-29	Schizophrenia;
LUAD	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg20119798	chr7:94954144	PON1	-0.49	-6.96	-0.32	1.31e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.61	0.42	6.48e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs295140	0.546	rs295119	chr2:201117944	C/T	cg23649088	chr2:200775458	C2orf69	0.5	8.57	0.38	1.9e-16	QT interval;
LUAD	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg07212818	chr11:638076	DRD4	-0.45	-6.73	-0.31	5.64e-11	Systemic lupus erythematosus;
LUAD	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg27129171	chr3:47204927	SETD2	0.39	6.42	0.3	3.68e-10	Colorectal cancer;
LUAD	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg09915433	chr19:53449742	NA	-0.56	-9.92	-0.43	5.59e-21	Psoriasis;
LUAD	cis	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.74	-0.35	7.34e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.47	-0.34	4.58e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-11.06	-0.47	3.81e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg03676636	chr4:99064102	C4orf37	0.31	8.13	0.37	4.82e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18876405	chr7:65276391	NA	0.62	10.92	0.47	1.22e-24	Aortic root size;
LUAD	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg01299579	chr2:10830716	NOL10	-0.43	-7.65	-0.35	1.38e-13	Prostate cancer;
LUAD	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg02683114	chr2:24398427	C2orf84	-0.51	-7.55	-0.34	2.78e-13	Asthma;
LUAD	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg23533926	chr12:111358616	MYL2	-0.42	-7.03	-0.32	8.12e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.51e-10	Prudent dietary pattern;
LUAD	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg12062639	chr20:23401060	NAPB	1.1	11.43	0.49	1.54e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg27661571	chr11:113659931	NA	-0.56	-6.85	-0.32	2.58e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg12403142	chr1:92012408	NA	-0.37	-6.77	-0.31	4.37e-11	Breast cancer;
LUAD	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-8.35	-0.38	1.02e-15	Total cholesterol levels;
LUAD	cis	rs6546550	0.630	rs9309429	chr2:69995580	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.5	-0.34	3.86e-13	Prevalent atrial fibrillation;
LUAD	cis	rs1478897	0.510	rs11786148	chr8:11423781	C/G	cg21175976	chr8:11421337	BLK	-0.35	-6.67	-0.31	7.93e-11	Systemic lupus erythematosus;
LUAD	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg03929089	chr4:120376271	NA	-0.98	-21.12	-0.72	4.05e-68	Height;
LUAD	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg08493051	chr2:3487164	NA	-0.44	-7.69	-0.35	1.05e-13	Neurofibrillary tangles;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg14968603	chr10:102046143	BLOC1S2	0.38	6.63	0.31	1.02e-10	Anger;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15358743	chr18:56807035	SEC11C	-0.42	-6.8	-0.31	3.56e-11	Height;
LUAD	trans	rs75565482	0.793	rs77581879	chr1:168483788	G/A	cg05043794	chr9:111880884	C9orf5	0.75	6.51	0.3	2.19e-10	Emphysema imaging phenotypes;
LUAD	cis	rs1559088	1.000	rs12985438	chr19:33559368	G/A	cg03563238	chr19:33554763	RHPN2	-0.38	-8.91	-0.4	1.56e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg24578937	chr1:2090814	PRKCZ	0.76	14.64	0.58	1.5e-39	Height;
LUAD	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg22681709	chr2:178499509	PDE11A	0.48	7.95	0.36	1.67e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg11871910	chr12:69753446	YEATS4	0.71	12.0	0.5	9.02e-29	Blood protein levels;
LUAD	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg16325326	chr1:53192061	ZYG11B	0.63	11.58	0.49	4.04e-27	Monocyte count;
LUAD	cis	rs9616064	0.506	rs737135	chr22:47061791	C/T	cg05621596	chr22:47072043	GRAMD4	-0.54	-9.47	-0.42	1.99e-19	Urate levels in obese individuals;
LUAD	cis	rs736801	0.704	rs56399423	chr5:131672657	T/C	cg00255919	chr5:131827918	IRF1	-0.3	-6.56	-0.3	1.6e-10	Breast cancer;Mosquito bite size;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20340149	chr2:122407145	CLASP1	-0.58	-7.13	-0.33	4.37e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg21918786	chr6:109611834	NA	-0.62	-11.54	-0.49	5.83e-27	Reticulocyte fraction of red cells;
LUAD	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg21827317	chr3:136751795	NA	0.37	6.67	0.31	7.78e-11	Neuroticism;
LUAD	cis	rs868036	0.718	rs28675295	chr15:68116400	C/A	cg24579218	chr15:68104479	NA	-0.54	-9.33	-0.41	6.09e-19	Restless legs syndrome;
LUAD	cis	rs6733011	0.519	rs12712034	chr2:99458933	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.82	-0.31	3.24e-11	Bipolar disorder;
LUAD	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.44	8.0	0.36	1.19e-14	Systemic lupus erythematosus;
LUAD	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg18132916	chr6:79620363	NA	-0.45	-7.64	-0.35	1.44e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg08027265	chr7:2291960	NA	-0.51	-9.13	-0.41	2.81e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03517284	chr6:25882590	NA	-0.56	-8.24	-0.37	2.21e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs11756438	0.683	rs4027595	chr6:119017504	C/T	cg18833306	chr6:118973337	C6orf204	-0.39	-6.43	-0.3	3.4e-10	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg13319975	chr6:146136371	FBXO30	-0.59	-10.16	-0.44	7.44e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.92	0.32	1.67e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.623	rs7205935	chr16:68152157	A/G	cg09835421	chr16:68378352	PRMT7	-0.53	-6.75	-0.31	4.84e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.62	-7.96	-0.36	1.58e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02366844	chr16:31044544	STX4	-0.53	-6.4	-0.3	4.05e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg09117114	chr16:67998030	SLC12A4	-0.63	-8.34	-0.38	1.09e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg24642844	chr7:1081250	C7orf50	-0.96	-10.45	-0.45	6.88e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg10792982	chr14:105748885	BRF1	0.44	9.42	0.42	3.03e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.33	6.68	0.31	7.64e-11	Obesity-related traits;
LUAD	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg01689657	chr7:91764605	CYP51A1	0.27	6.43	0.3	3.41e-10	Breast cancer;
LUAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-9.11	-0.4	3.43e-18	Alzheimer's disease;
LUAD	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18876405	chr7:65276391	NA	0.57	9.49	0.42	1.75e-19	Aortic root size;
LUAD	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg12011299	chr4:100065546	ADH4	0.73	13.72	0.55	1.1e-35	Alcohol dependence;
LUAD	cis	rs7737355	0.773	rs1019122	chr5:131099227	C/T	cg25547332	chr5:131281432	NA	0.43	6.92	0.32	1.72e-11	Life satisfaction;
LUAD	cis	rs9652601	0.959	rs7198621	chr16:11167458	C/G	cg04616529	chr16:11181986	CLEC16A	0.38	6.91	0.32	1.75e-11	Systemic lupus erythematosus;
LUAD	cis	rs7188873	1	rs7188873	chr16:24727064	A/G	cg00339695	chr16:24857497	SLC5A11	-0.41	-7.55	-0.34	2.76e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.65e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg19163074	chr7:65112434	INTS4L2	0.42	6.43	0.3	3.38e-10	Aortic root size;
LUAD	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg01299579	chr2:10830716	NOL10	-0.43	-7.49	-0.34	4e-13	Prostate cancer;
LUAD	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg08807101	chr21:30365312	RNF160	-0.46	-7.95	-0.36	1.77e-14	Dental caries;
LUAD	cis	rs977987	0.778	rs12930452	chr16:75462055	A/G	cg03315344	chr16:75512273	CHST6	0.65	14.01	0.56	6.59e-37	Dupuytren's disease;
LUAD	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.43	-8.5	-0.38	3.27e-16	Glomerular filtration rate;
LUAD	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.43	-7.55	-0.34	2.63e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg15181151	chr6:150070149	PCMT1	0.39	7.84	0.36	3.79e-14	Lung cancer;
LUAD	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	12.4	0.52	2.41e-30	Migraine;Coronary artery disease;
LUAD	cis	rs6906287	0.609	rs6938041	chr6:118852468	C/A	cg18833306	chr6:118973337	C6orf204	0.46	8.12	0.37	5.19e-15	Electrocardiographic conduction measures;
LUAD	cis	rs10992471	0.528	rs10429459	chr9:95258119	C/T	cg14631576	chr9:95140430	CENPP	0.49	10.11	0.44	1.15e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7927592	0.789	rs2291467	chr11:68216756	C/T	cg16797656	chr11:68205561	LRP5	0.46	8.46	0.38	4.36e-16	Total body bone mineral density;
LUAD	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg01145583	chr6:160211477	TCP1;MRPL18	0.45	6.54	0.3	1.81e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.9	-0.32	1.88e-11	Morning vs. evening chronotype;
LUAD	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg21918786	chr6:109611834	NA	-0.59	-10.87	-0.47	1.96e-24	Reticulocyte fraction of red cells;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04902049	chr1:36622448	MAP7D1	0.41	6.45	0.3	3.1e-10	Gut microbiome composition (summer);
LUAD	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg03526776	chr6:41159608	TREML2	0.35	7.31	0.34	1.31e-12	Alzheimer's disease (late onset);
LUAD	cis	rs7680126	0.632	rs11731464	chr4:10148376	G/A	cg11266682	chr4:10021025	SLC2A9	-0.43	-6.65	-0.31	8.8e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg12373951	chr3:133503437	NA	0.37	7.19	0.33	2.98e-12	Iron status biomarkers;
LUAD	cis	rs67981189	0.529	rs2526868	chr14:71390389	C/T	cg15910301	chr14:71632612	NA	-0.41	-6.4	-0.3	4.17e-10	Schizophrenia;
LUAD	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg04450456	chr4:17643702	FAM184B	0.38	7.53	0.34	3e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2625529	0.504	rs11072349	chr15:72464471	T/C	cg16672083	chr15:72433130	SENP8	0.63	11.39	0.48	2.1e-26	Red blood cell count;
LUAD	trans	rs7395662	1.000	rs10838966	chr11:48589723	C/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.76e-10	HDL cholesterol;
LUAD	cis	rs2230307	0.656	rs7531066	chr1:100463804	A/G	cg20868668	chr1:100435035	SLC35A3	0.63	7.58	0.35	2.21e-13	Carotid intima media thickness;
LUAD	cis	rs7818345	0.967	rs7015440	chr8:19276991	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.3	6.61	0.31	1.15e-10	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs12286929	0.679	rs11601041	chr11:115083348	A/G	cg04055981	chr11:115044050	NA	0.42	7.58	0.35	2.19e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	8.08	0.37	6.75e-15	Breast cancer;
LUAD	cis	rs11976180	0.569	rs12703565	chr7:143754401	C/T	cg16347377	chr7:143956670	OR2A7	-0.46	-7.31	-0.33	1.35e-12	Obesity-related traits;
LUAD	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg03929089	chr4:120376271	NA	-0.56	-8.29	-0.37	1.55e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg25036284	chr2:26402008	FAM59B	-0.83	-11.68	-0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.48e-10	Prostate cancer;
LUAD	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.51	8.2	0.37	2.92e-15	Total body bone mineral density;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03399598	chr4:174091002	GALNT7	-0.41	-6.75	-0.31	4.77e-11	Height;
LUAD	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22857025	chr5:266934	NA	-0.97	-14.53	-0.58	4.25e-39	Breast cancer;
LUAD	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01570182	chr17:44337453	NA	1.12	16.91	0.64	2.23e-49	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7809950	1.000	rs2712214	chr7:107188031	G/A	cg23024343	chr7:107201750	COG5	-0.73	-12.24	-0.51	1.11e-29	Coronary artery disease;
LUAD	cis	rs738322	0.600	rs6001030	chr22:38555904	T/G	cg25457927	chr22:38595422	NA	-0.53	-11.83	-0.5	4.29e-28	Cutaneous nevi;
LUAD	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg12564285	chr5:131593104	PDLIM4	-0.38	-6.6	-0.31	1.23e-10	Blood metabolite levels;
LUAD	cis	rs2485376	1.000	rs3781295	chr10:104140602	G/A	cg20641465	chr10:103991465	PITX3	-0.59	-10.54	-0.46	3.19e-23	QT interval;
LUAD	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg02527881	chr3:46936655	PTH1R	0.44	8.32	0.38	1.19e-15	Colorectal cancer;
LUAD	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.33	7.67	0.35	1.2e-13	Prostate cancer;
LUAD	trans	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg18187862	chr3:45730750	SACM1L	-0.58	-9.23	-0.41	1.35e-18	Primary sclerosing cholangitis;
LUAD	cis	rs12210905	0.688	rs72839479	chr6:27332910	G/A	cg08851530	chr6:28072375	NA	1.1	7.92	0.36	2.15e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg04352962	chr1:209979756	IRF6	0.46	6.7	0.31	6.79e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg03806693	chr22:41940476	POLR3H	0.54	7.9	0.36	2.36e-14	Vitiligo;
LUAD	cis	rs11696845	0.666	rs6103849	chr20:43365687	C/T	cg09357268	chr20:43379437	KCNK15	-0.37	-6.37	-0.3	4.88e-10	Obesity-related traits;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01571169	chr16:87367721	FBXO31	0.55	6.66	0.31	8.35e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.57e-13	Tonsillectomy;
LUAD	cis	rs754466	0.580	rs10824575	chr10:79549047	A/G	cg17075019	chr10:79541650	NA	-0.92	-20.06	-0.7	2.21e-63	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4713675	0.584	rs6457739	chr6:33673831	A/G	cg13859433	chr6:33739653	LEMD2	-0.3	-7.06	-0.32	7e-12	Plateletcrit;
LUAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg19500098	chr13:21900506	NA	0.38	6.54	0.3	1.73e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg01475377	chr6:109611718	NA	-0.54	-10.28	-0.45	2.71e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs12545109	0.879	rs7845180	chr8:57324431	C/T	cg21220214	chr8:57350948	NA	0.61	8.61	0.39	1.46e-16	Obesity-related traits;
LUAD	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg26597838	chr10:835615	NA	0.82	11.18	0.48	1.39e-25	Eosinophil percentage of granulocytes;
LUAD	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.49	-0.3	2.47e-10	Aortic root size;
LUAD	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg15226275	chr6:116381976	FRK	0.23	7.64	0.35	1.49e-13	Cholesterol, total;LDL cholesterol;
LUAD	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg23533926	chr12:111358616	MYL2	-0.39	-6.57	-0.3	1.51e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg21211680	chr2:198530	NA	-0.57	-7.68	-0.35	1.14e-13	Blood protein levels;
LUAD	cis	rs12765878	1.000	rs11191846	chr10:105649813	A/G	cg11005552	chr10:105648138	OBFC1	0.44	8.34	0.38	1.05e-15	Coronary artery disease;
LUAD	cis	rs11048434	0.761	rs11494570	chr12:9127147	T/C	cg13575925	chr12:9217583	LOC144571	0.39	7.25	0.33	2.03e-12	Sjögren's syndrome;
LUAD	cis	rs2658782	0.756	rs3019222	chr11:93079718	C/T	cg15737290	chr11:93063684	CCDC67	0.55	7.77	0.35	6.05e-14	Pulmonary function decline;
LUAD	cis	rs73086581	1.000	rs113812453	chr20:3963193	T/C	cg02187196	chr20:3869020	PANK2	0.46	6.51	0.3	2.13e-10	Response to antidepressants in depression;
LUAD	cis	rs2455799	1.000	rs11923804	chr3:15827664	C/A	cg16303742	chr3:15540471	COLQ	-0.39	-6.75	-0.31	4.78e-11	Mean platelet volume;
LUAD	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg10755058	chr3:40428713	ENTPD3	0.38	7.03	0.32	8.33e-12	Renal cell carcinoma;
LUAD	trans	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg19676328	chr12:49525230	TUBA1B	-0.56	-8.12	-0.37	4.98e-15	Total cholesterol levels;
LUAD	trans	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg01620082	chr3:125678407	NA	0.7	7.13	0.33	4.49e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg02240030	chr7:2089880	MAD1L1	0.38	6.4	0.3	4.24e-10	Neuroticism;
LUAD	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg13511324	chr14:104056883	C14orf153	0.25	6.41	0.3	3.84e-10	Coronary artery disease;
LUAD	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg07599136	chr5:415885	AHRR	0.74	8.23	0.37	2.42e-15	Fat distribution (HIV);
LUAD	cis	rs71478720	0.953	rs7131094	chr11:112044917	C/T	cg04929355	chr11:112034997	IL18	0.45	7.15	0.33	3.81e-12	Interleukin-18 levels;
LUAD	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg27068330	chr11:65405492	SIPA1	-0.56	-8.91	-0.4	1.53e-17	Acne (severe);
LUAD	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.83	0.43	1.09e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg07636037	chr3:49044803	WDR6	0.55	8.17	0.37	3.62e-15	Menarche (age at onset);
LUAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.86	16.53	0.63	1.06e-47	Lymphocyte counts;
LUAD	cis	rs7493	0.901	rs11767787	chr7:95026753	T/C	cg21856205	chr7:94953877	PON1	-0.57	-8.12	-0.37	5.22e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs922182	0.569	rs6494457	chr15:64263532	C/A	cg02919090	chr15:64263738	DAPK2	0.41	8.17	0.37	3.59e-15	Blood protein levels;
LUAD	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.39	-7.07	-0.33	6.37e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs7582720	1.000	rs72932774	chr2:203685728	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.32	0.41	6.71e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs208520	0.690	rs176289	chr6:66766522	C/T	cg07460842	chr6:66804631	NA	-1.05	-16.39	-0.62	4.09e-47	Exhaled nitric oxide output;
LUAD	cis	rs12493885	0.818	rs7641039	chr3:153768638	A/C	cg17054900	chr3:154042577	DHX36	0.5	6.51	0.3	2.12e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg13902645	chr11:5959945	NA	-0.54	-9.06	-0.4	4.89e-18	DNA methylation (variation);
LUAD	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.51	-0.38	3.11e-16	Height;
LUAD	trans	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	12.93	0.53	1.9e-32	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs7799006	0.527	rs3779009	chr7:2203692	G/C	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.49	-0.3	2.4e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs4691139	0.903	rs10434177	chr4:165915531	A/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.5	-7.17	-0.33	3.32e-12	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.72	-0.35	8.21e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9535307	0.929	rs9526593	chr13:50288777	T/C	cg04663916	chr13:50265991	EBPL	0.58	6.82	0.31	3.1e-11	Obesity-related traits;
LUAD	cis	rs6690583	0.623	rs12042910	chr1:85452580	G/A	cg22153463	chr1:85462885	MCOLN2	0.55	6.37	0.3	4.97e-10	Serum sulfate level;
LUAD	cis	rs7633770	0.805	rs12330414	chr3:46662428	T/C	cg11219411	chr3:46661640	NA	0.61	14.41	0.57	1.46e-38	Coronary artery disease;
LUAD	cis	rs11690462	0.528	rs1344734	chr2:26637068	C/T	cg22920501	chr2:26401640	FAM59B	0.44	6.38	0.3	4.67e-10	Coronary artery disease;
LUAD	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg09640425	chr7:158790006	NA	0.49	6.5	0.3	2.22e-10	Facial morphology (factor 20);
LUAD	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.66	-0.31	8.4e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg08742575	chr21:47604166	C21orf56	0.43	7.26	0.33	1.93e-12	Testicular germ cell tumor;
LUAD	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg03714773	chr7:91764589	CYP51A1	0.27	6.46	0.3	2.89e-10	Breast cancer;
LUAD	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg21951975	chr1:209979733	IRF6	0.5	6.65	0.31	9.27e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.67	-12.59	-0.52	4.3e-31	Cognitive ability;
LUAD	cis	rs2289328	0.825	rs35777573	chr15:40644246	T/A	cg08996748	chr15:40651036	DISP2	-0.45	-6.54	-0.3	1.76e-10	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LUAD	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg04944784	chr2:26401820	FAM59B	-0.48	-6.91	-0.32	1.74e-11	Gut microbiome composition (summer);
LUAD	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg27129171	chr3:47204927	SETD2	0.39	6.35	0.3	5.41e-10	Colorectal cancer;
LUAD	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg02782426	chr3:40428986	ENTPD3	0.35	7.5	0.34	3.89e-13	Renal cell carcinoma;
LUAD	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg07936489	chr17:37558343	FBXL20	-0.5	-6.66	-0.31	8.77e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs2535633	0.631	rs2710326	chr3:52995444	T/C	cg11645453	chr3:52864694	ITIH4	-0.37	-6.87	-0.32	2.28e-11	Body mass index;
LUAD	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg15921436	chr17:44337874	NA	-0.72	-9.58	-0.42	8.12e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9487051	0.735	rs1146246	chr6:109519741	C/T	cg01475377	chr6:109611718	NA	-0.39	-7.33	-0.34	1.18e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg04369109	chr6:150039330	LATS1	-0.48	-7.72	-0.35	8.54e-14	Lung cancer;
LUAD	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg07169764	chr2:136633963	MCM6	0.82	9.73	0.43	2.52e-20	Corneal structure;
LUAD	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.85	-14.19	-0.57	1.16e-37	Homoarginine levels;
LUAD	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.89	0.53	2.7e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs494562	0.892	rs619299	chr6:86121482	A/T	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	cis	rs8112211	1.000	rs12609247	chr19:38821697	C/T	cg14299480	chr19:38876666	GGN	-0.42	-7.53	-0.34	3.06e-13	Blood protein levels;
LUAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg09904177	chr6:26538194	HMGN4	-0.43	-7.35	-0.34	1e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg06221963	chr1:154839813	KCNN3	-0.83	-19.19	-0.68	1.69e-59	Prostate cancer;
LUAD	trans	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg14917512	chr19:3094685	GNA11	-0.55	-6.46	-0.3	2.92e-10	Diabetic kidney disease;
LUAD	cis	rs28493229	0.708	rs78084428	chr19:41160097	G/A	cg21869046	chr19:41225005	ITPKC	0.52	9.11	0.41	3.19e-18	Kawasaki disease;
LUAD	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.47	7.13	0.33	4.27e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	7.11	0.33	4.84e-12	Parkinson's disease;
LUAD	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	8.77	0.39	4.54e-17	Breast cancer;
LUAD	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg10645314	chr2:3704589	ALLC	0.43	7.26	0.33	1.83e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg04234412	chr22:24373322	LOC391322	-0.72	-12.48	-0.52	1.17e-30	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg11859384	chr17:80120422	CCDC57	-0.48	-8.61	-0.39	1.41e-16	Life satisfaction;
LUAD	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.85	-0.36	3.35e-14	Neutrophil percentage of white cells;
LUAD	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg04369109	chr6:150039330	LATS1	-0.47	-7.64	-0.35	1.43e-13	Lung cancer;
LUAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.39	-0.38	7.58e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs427394	0.659	rs274678	chr5:6752385	A/G	cg12316010	chr5:6737918	POLS	-0.38	-7.23	-0.33	2.21e-12	Menopause (age at onset);
LUAD	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg01236616	chr12:121019343	POP5	1.24	19.45	0.69	1.21e-60	Type 1 diabetes nephropathy;
LUAD	cis	rs4273100	1.000	rs4924986	chr17:19242467	C/T	cg03711562	chr17:18936298	GRAP	0.4	7.98	0.36	1.39e-14	Schizophrenia;
LUAD	cis	rs806795	0.513	rs80292109	chr6:26237068	A/G	cg13736514	chr6:26305472	NA	-0.49	-7.35	-0.34	1.06e-12	Mosquito bite size;
LUAD	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.93	-0.61	4.48e-45	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6076065	0.963	rs6048777	chr20:23373302	C/T	cg11657817	chr20:23433608	CST11	0.47	9.53	0.42	1.22e-19	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg22508957	chr16:3507546	NAT15	0.43	6.58	0.3	1.36e-10	Body mass index (adult);
LUAD	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.14	-0.33	4.11e-12	Total body bone mineral density;
LUAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg07217954	chr7:1067459	C7orf50	0.43	6.69	0.31	7.14e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg21984481	chr17:79567631	NPLOC4	-0.54	-11.48	-0.49	9.4e-27	Eye color traits;
LUAD	cis	rs4786125	0.706	rs8062094	chr16:6902585	A/G	cg03623568	chr16:6915990	A2BP1	-0.45	-9.81	-0.43	1.33e-20	Heart rate variability traits (SDNN);
LUAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg23958373	chr8:599963	NA	1.06	10.46	0.45	6.27e-23	IgG glycosylation;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg26306882	chr20:34824605	C20orf4	0.36	6.44	0.3	3.28e-10	Bipolar disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15929201	chr5:31531945	RNASEN;C5orf22	-0.44	-6.96	-0.32	1.29e-11	Height;
LUAD	cis	rs9837602	0.938	rs9814359	chr3:99797013	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.58	8.91	0.4	1.51e-17	Breast cancer;
LUAD	cis	rs1865721	0.804	rs72977818	chr18:73146852	T/C	cg26385618	chr18:73139727	C18orf62	-0.51	-10.15	-0.44	8.32e-22	Intelligence;
LUAD	cis	rs7779181	0.855	rs215610	chr7:32339594	G/A	cg27532318	chr7:32358331	NA	-0.44	-7.27	-0.33	1.75e-12	Body mass index;
LUAD	cis	rs6961069	0.837	rs1761662	chr7:80238463	C/T	cg04458919	chr7:80252533	CD36	-0.36	-6.81	-0.31	3.29e-11	Platelet count;
LUAD	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg00383909	chr3:49044727	WDR6	0.66	8.38	0.38	7.87e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1784581	0.928	rs1789995	chr6:162396518	C/T	cg17173639	chr6:162384350	PARK2	-0.59	-10.93	-0.47	1.21e-24	Itch intensity from mosquito bite;
LUAD	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg17366294	chr4:99064904	C4orf37	0.6	11.35	0.48	3.07e-26	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2282300	0.739	rs10742237	chr11:30310659	C/T	cg06241208	chr11:30344200	C11orf46	0.58	7.5	0.34	3.86e-13	Morning vs. evening chronotype;
LUAD	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05776053	chr2:74358815	NA	0.45	7.06	0.32	6.96e-12	Gestational age at birth (maternal effect);
LUAD	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg15704280	chr7:45808275	SEPT13	-1.06	-23.93	-0.76	1.21e-80	Height;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg04020066	chr7:28220514	JAZF1	0.43	6.57	0.3	1.5e-10	QT interval;
LUAD	cis	rs13082711	0.689	rs34946790	chr3:27345170	G/A	cg02860705	chr3:27208620	NA	0.82	12.48	0.52	1.16e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.8	0.39	3.47e-17	Menarche (age at onset);
LUAD	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06544989	chr22:39130855	UNC84B	-0.37	-7.46	-0.34	4.96e-13	Menopause (age at onset);
LUAD	cis	rs1595825	0.735	rs1866665	chr2:198925980	A/G	cg00982548	chr2:198649783	BOLL	-0.66	-9.01	-0.4	7.01e-18	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7773004	0.905	rs994379	chr6:26305407	C/G	cg13736514	chr6:26305472	NA	0.5	8.52	0.38	2.9e-16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg26528668	chr16:1614120	IFT140	0.51	8.94	0.4	1.21e-17	Coronary artery disease;
LUAD	cis	rs11229555	0.609	rs11229451	chr11:58201687	T/C	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1784581	0.588	rs9295179	chr6:162420546	G/A	cg17173639	chr6:162384350	PARK2	0.44	7.87	0.36	2.93e-14	Itch intensity from mosquito bite;
LUAD	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14829155	chr15:31115871	NA	-0.79	-13.45	-0.55	1.38e-34	Huntington's disease progression;
LUAD	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.74	-12.91	-0.53	2.2e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg21153622	chr11:89784906	NA	-0.35	-6.86	-0.32	2.44e-11	HDL cholesterol;
LUAD	cis	rs9581857	0.579	rs3759434	chr13:27997700	A/C	cg22138327	chr13:27999177	GTF3A	0.91	12.8	0.53	6.42e-32	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs2294693	0.786	rs12055704	chr6:40988504	C/T	cg14769373	chr6:40998127	UNC5CL	-0.53	-7.56	-0.35	2.45e-13	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg20607287	chr7:12443886	VWDE	-0.53	-6.79	-0.31	3.74e-11	Coronary artery disease;
LUAD	cis	rs36051895	0.664	rs10121077	chr9:5098411	G/A	cg02405213	chr9:5042618	JAK2	-0.43	-6.36	-0.3	5.33e-10	Pediatric autoimmune diseases;
LUAD	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg00666640	chr1:248458726	OR2T12	0.33	7.7	0.35	9.74e-14	Common traits (Other);
LUAD	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg26587870	chr6:27730563	NA	0.45	6.94	0.32	1.48e-11	Parkinson's disease;
LUAD	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg23018236	chr17:30244563	NA	-0.7	-8.72	-0.39	6.28e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.74	15.87	0.61	7.63e-45	White blood cell count (basophil);White blood cell count;
LUAD	trans	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.29	0.54	6.43e-34	Exhaled nitric oxide output;
LUAD	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg20673091	chr1:2541236	MMEL1	0.41	8.51	0.38	3.05e-16	Ulcerative colitis;
LUAD	cis	rs4853525	0.859	rs1882396	chr2:191716012	T/G	cg27211696	chr2:191398769	TMEM194B	-0.37	-6.62	-0.31	1.08e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs17193922	0.798	rs7203644	chr16:53547209	C/T	cg04059762	chr16:53544020	NA	-0.41	-6.43	-0.3	3.38e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg02505535	chr3:195703920	SDHAP1	-0.34	-7.04	-0.32	7.89e-12	Pancreatic cancer;
LUAD	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.68	0.31	7.75e-11	Breast cancer;
LUAD	cis	rs12540874	0.500	rs12719030	chr7:50485073	T/C	cg18232548	chr7:50535776	DDC	-0.62	-11.11	-0.48	2.49e-25	Systemic sclerosis;
LUAD	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.48	-0.45	5.41e-23	Total body bone mineral density;
LUAD	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg17366294	chr4:99064904	C4orf37	-0.48	-8.53	-0.38	2.56e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg15181151	chr6:150070149	PCMT1	0.39	7.8	0.35	5e-14	Lung cancer;
LUAD	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg07936489	chr17:37558343	FBXL20	0.44	6.94	0.32	1.45e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs6867032	0.958	rs4505990	chr5:2015811	A/G	cg26168224	chr5:2018326	NA	0.8	18.21	0.66	4e-55	Gut microbiome composition (winter);
LUAD	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.8	0.35	5.02e-14	Breast cancer;
LUAD	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg05182265	chr7:156933206	UBE3C	-0.79	-17.1	-0.64	3.17e-50	Body mass index;
LUAD	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg24130564	chr14:104152367	KLC1	0.5	8.77	0.39	4.41e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg21385606	chr21:47601150	C21orf56	-0.36	-6.46	-0.3	2.81e-10	Testicular germ cell tumor;
LUAD	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg12257156	chr7:158823799	VIPR2	0.38	6.61	0.31	1.19e-10	Facial morphology (factor 20);
LUAD	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg27490568	chr2:178487706	NA	0.39	6.55	0.3	1.69e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6669919	0.553	rs12733443	chr1:211667751	C/T	cg10512769	chr1:211675356	NA	-0.42	-8.26	-0.37	1.92e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs977987	0.843	rs17696749	chr16:75403062	C/G	cg03315344	chr16:75512273	CHST6	0.64	13.7	0.55	1.24e-35	Dupuytren's disease;
LUAD	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg22482690	chr17:47019901	SNF8	0.45	8.45	0.38	4.8e-16	Coronary heart disease;
LUAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	7.86	0.36	3.19e-14	Alzheimer's disease;
LUAD	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg16797656	chr11:68205561	LRP5	0.44	8.43	0.38	5.4e-16	Total body bone mineral density;
LUAD	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg04450456	chr4:17643702	FAM184B	0.37	7.11	0.33	5.03e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg02951883	chr7:2050386	MAD1L1	-0.78	-13.75	-0.56	7.75e-36	Bipolar disorder and schizophrenia;
LUAD	cis	rs2294693	0.679	rs10947942	chr6:40958205	G/A	cg14769373	chr6:40998127	UNC5CL	-0.49	-7.08	-0.33	6.14e-12	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg07810366	chr2:100720526	AFF3	-0.35	-7.2	-0.33	2.74e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg17105886	chr17:28927953	LRRC37B2	0.81	7.79	0.35	5.13e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4604732	0.536	rs76191272	chr1:247628055	A/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.18	0.33	3.06e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg05368731	chr17:41323189	NBR1	0.97	20.37	0.7	9.04e-65	Menopause (age at onset);
LUAD	trans	rs2262909	0.962	rs12609368	chr19:22263996	T/C	cg17074339	chr11:11642133	GALNTL4	0.48	7.75	0.35	7.12e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.87	-0.32	2.27e-11	Mood instability;
LUAD	cis	rs11078597	0.671	rs34599286	chr17:1645747	C/A	cg18436246	chr17:1640651	WDR81	0.8	12.66	0.52	2.21e-31	Serum albumin level;
LUAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg11050988	chr7:1952600	MAD1L1	-0.32	-6.68	-0.31	7.73e-11	Schizophrenia;
LUAD	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg27211696	chr2:191398769	TMEM194B	-0.71	-14.85	-0.59	1.99e-40	Pulse pressure;
LUAD	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg01145583	chr6:160211477	TCP1;MRPL18	-0.44	-6.36	-0.3	5.17e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg00701064	chr4:6280414	WFS1	-0.59	-11.99	-0.5	9.91e-29	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg05064044	chr6:292385	DUSP22	-0.57	-9.24	-0.41	1.23e-18	Menopause (age at onset);
LUAD	trans	rs2262909	1.000	rs2175366	chr19:22128279	C/T	cg05197062	chr11:11642011	GALNTL4	-0.54	-8.34	-0.38	1.05e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-7.19	-0.33	2.87e-12	Lung cancer;
LUAD	trans	rs7395662	0.963	rs2135680	chr11:48728425	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	2.03e-12	HDL cholesterol;
LUAD	cis	rs4774899	0.800	rs2733341	chr15:57466232	T/A	cg14026238	chr15:57616123	NA	0.39	7.34	0.34	1.11e-12	Urinary tract infection frequency;
LUAD	cis	rs6669919	0.967	rs7513031	chr1:211671900	C/T	cg10512769	chr1:211675356	NA	0.32	6.86	0.32	2.5e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00014085	chr2:85581505	ELMOD3;RETSAT	-0.4	-6.66	-0.31	8.36e-11	Cancer;
LUAD	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg23625390	chr15:77176239	SCAPER	0.38	6.57	0.3	1.45e-10	Blood metabolite levels;
LUAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg18621852	chr3:10150065	C3orf24	0.41	7.05	0.32	7.56e-12	Alzheimer's disease;
LUAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg16606324	chr3:10149918	C3orf24	0.54	8.02	0.36	1.06e-14	Alzheimer's disease;
LUAD	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg07936489	chr17:37558343	FBXL20	0.45	7.17	0.33	3.45e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg06138931	chr13:21896616	NA	0.44	6.46	0.3	2.94e-10	White matter hyperintensity burden;
LUAD	cis	rs67385638	0.962	rs2187608	chr11:5269931	G/C	cg12559170	chr11:5275217	HBG2	0.35	7.26	0.33	1.88e-12	Hemoglobin levels;
LUAD	cis	rs870825	0.860	rs72689297	chr4:185600957	A/T	cg04058563	chr4:185651563	MLF1IP	0.86	11.51	0.49	7.31e-27	Blood protein levels;
LUAD	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.35	7.02	0.32	8.68e-12	Obesity-related traits;
LUAD	cis	rs4730250	0.707	rs6946931	chr7:106788621	G/T	cg02696742	chr7:106810147	HBP1	-0.84	-11.35	-0.48	2.9e-26	Osteoarthritis;
LUAD	trans	rs747782	0.527	rs2279822	chr11:48146114	C/T	cg15704280	chr7:45808275	SEPT13	0.67	7.22	0.33	2.46e-12	Intraocular pressure;
LUAD	cis	rs12210905	0.688	rs114843651	chr6:27449611	A/G	cg08851530	chr6:28072375	NA	1.03	7.92	0.36	2.19e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg11814155	chr7:99998594	ZCWPW1	0.42	7.24	0.33	2.18e-12	Platelet count;
LUAD	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	7.57	0.35	2.38e-13	Menopause (age at onset);
LUAD	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.84e-26	Alzheimer's disease (late onset);
LUAD	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg17724175	chr1:150552817	MCL1	-0.38	-9.05	-0.4	5.46e-18	Tonsillectomy;
LUAD	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg17063962	chr7:91808500	NA	0.7	12.69	0.52	1.78e-31	Breast cancer;
LUAD	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg15557168	chr22:42548783	NA	-0.45	-8.22	-0.37	2.43e-15	Cognitive function;
LUAD	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs11048434	0.736	rs35870866	chr12:9129091	C/A	cg26114124	chr12:9217669	LOC144571	0.39	7.11	0.33	5.11e-12	Sjögren's syndrome;
LUAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg24642844	chr7:1081250	C7orf50	-0.96	-14.36	-0.57	2.34e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg18761221	chr20:60518478	NA	0.36	6.37	0.3	4.97e-10	Body mass index;
LUAD	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15123824	chr2:85581917	ELMOD3;RETSAT	0.4	6.43	0.3	3.38e-10	Survival in pancreatic cancer;
LUAD	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg21285383	chr16:89894308	SPIRE2	-0.41	-9.96	-0.44	3.8e-21	Vitiligo;
LUAD	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg21775007	chr8:11205619	TDH	-0.5	-9.05	-0.4	5.27e-18	Retinal vascular caliber;
LUAD	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg11618577	chr2:27665543	KRTCAP3	0.24	6.39	0.3	4.36e-10	Total body bone mineral density;
LUAD	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg14092988	chr3:52407081	DNAH1	0.38	7.45	0.34	5.33e-13	Bipolar disorder;
LUAD	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg19318889	chr4:1322082	MAEA	0.45	7.3	0.33	1.4e-12	Obesity-related traits;
LUAD	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg18402987	chr7:1209562	NA	0.68	6.87	0.32	2.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1003719	0.680	rs2835621	chr21:38510616	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-8.99	-0.4	8.25e-18	Eye color traits;
LUAD	cis	rs6906287	0.647	rs34479834	chr6:118826244	T/A	cg05564266	chr6:118973597	C6orf204	0.35	7.4	0.34	7.5e-13	Electrocardiographic conduction measures;
LUAD	trans	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg01620082	chr3:125678407	NA	0.44	6.71	0.31	6.27e-11	Depression;
LUAD	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg17757837	chr7:157058334	UBE3C	0.45	8.02	0.36	1.06e-14	Body mass index;
LUAD	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg02569458	chr12:86230093	RASSF9	0.42	7.59	0.35	2.07e-13	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg24818145	chr4:99064322	C4orf37	0.45	7.7	0.35	9.53e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg15123519	chr2:136567270	LCT	0.38	7.0	0.32	1.02e-11	Mosquito bite size;
LUAD	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.08	-0.33	6.09e-12	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs36051895	0.659	rs1576271	chr9:5039652	A/C	cg02405213	chr9:5042618	JAK2	-0.53	-7.46	-0.34	5.11e-13	Pediatric autoimmune diseases;
LUAD	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg10518543	chr12:38710700	ALG10B	-0.49	-8.05	-0.36	8.23e-15	Morning vs. evening chronotype;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26389465	chr11:112097071	PTS	-0.52	-6.48	-0.3	2.55e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs59698941	0.765	rs67045943	chr5:132219956	C/T	cg14825688	chr5:132208181	LEAP2	-0.47	-6.65	-0.31	8.85e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.13	0.33	4.46e-12	Hypertriglyceridemia;
LUAD	cis	rs494562	0.892	rs9344518	chr6:86125144	T/A	cg13315970	chr6:86159197	NT5E	0.71	7.86	0.36	3.15e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg21252483	chr19:49399788	TULP2	-0.88	-14.48	-0.58	6.9e-39	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs10089	1.000	rs10064357	chr5:127417272	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	10.7	0.46	8.35e-24	Ileal carcinoids;
LUAD	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg06627628	chr2:24431161	ITSN2	-0.56	-9.49	-0.42	1.76e-19	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg22823121	chr1:150693482	HORMAD1	0.43	8.45	0.38	4.9e-16	Melanoma;
LUAD	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg14829155	chr15:31115871	NA	-0.62	-9.55	-0.42	1.1e-19	Huntington's disease progression;
LUAD	cis	rs870825	0.616	rs7678849	chr4:185648868	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg07404485	chr7:94953653	PON1	-0.48	-6.75	-0.31	5.02e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs758324	0.947	rs4705900	chr5:131140241	G/A	cg06307176	chr5:131281290	NA	0.51	8.0	0.36	1.18e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.7	0.39	7.31e-17	Parkinson's disease;
LUAD	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg24399712	chr22:39784796	NA	-0.83	-16.24	-0.62	1.97e-46	Intelligence (multi-trait analysis);
LUAD	cis	rs1232027	0.700	rs1650694	chr5:79952426	G/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.94	-0.36	1.9e-14	Huntington's disease progression;
LUAD	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.01	0.36	1.11e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs41311933	0.656	rs41309850	chr9:123778688	A/C	cg13567360	chr9:123745713	C5	-0.68	-8.08	-0.37	6.82e-15	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	2.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg12062639	chr20:23401060	NAPB	1.1	11.43	0.49	1.54e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg05926928	chr17:57297772	GDPD1	1.14	13.94	0.56	1.29e-36	Opioid sensitivity;
LUAD	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11644478	chr21:40555479	PSMG1	0.71	12.01	0.5	8.29e-29	Cognitive function;
LUAD	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg00684032	chr4:1343700	KIAA1530	0.42	7.1	0.33	5.29e-12	Obesity-related traits;
LUAD	cis	rs6489882	0.867	rs916972	chr12:113366049	G/T	cg20102336	chr12:113376681	OAS3	-0.61	-9.4	-0.42	3.36e-19	Chronic lymphocytic leukemia;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg09706180	chr15:50647709	GABPB1;FLJ10038;LOC100129387	-0.37	-6.55	-0.3	1.69e-10	Schizophrenia;
LUAD	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg05754148	chr16:3507555	NAT15	-0.61	-9.08	-0.4	4.19e-18	Tuberculosis;
LUAD	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg04842962	chr6:43655489	MRPS18A	1.05	26.45	0.79	1.09e-91	IgG glycosylation;
LUAD	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg18404041	chr3:52824283	ITIH1	-0.61	-12.28	-0.51	7.32e-30	Bipolar disorder;
LUAD	cis	rs4689388	0.581	rs4688985	chr4:6285715	A/G	cg00701064	chr4:6280414	WFS1	0.55	9.45	0.42	2.35e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg09491104	chr22:46646882	C22orf40	-0.71	-12.94	-0.53	1.69e-32	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.22	0.37	2.6e-15	Rheumatoid arthritis;
LUAD	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg00339695	chr16:24857497	SLC5A11	-0.53	-9.61	-0.42	6.78e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.48	0.42	1.89e-19	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg12458913	chr13:53173898	NA	0.44	7.89	0.36	2.69e-14	Lewy body disease;
LUAD	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg13906792	chr15:75199810	C15orf17	-0.34	-6.38	-0.3	4.67e-10	Caffeine consumption;
LUAD	trans	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg18335740	chr13:41363409	SLC25A15	0.86	16.82	0.63	5.53e-49	Lewy body disease;
LUAD	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg05110241	chr16:68378359	PRMT7	-0.84	-9.13	-0.41	2.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg16606324	chr3:10149918	C3orf24	0.67	10.97	0.47	8.41e-25	Alzheimer's disease;
LUAD	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg06064525	chr11:970664	AP2A2	-0.54	-11.1	-0.48	2.57e-25	Alzheimer's disease (late onset);
LUAD	cis	rs72949976	0.934	rs13406406	chr2:214034826	C/T	cg08319019	chr2:214017104	IKZF2	-0.49	-7.52	-0.34	3.26e-13	Lung cancer;Squamous cell lung carcinoma;
LUAD	trans	rs7395662	1.000	rs7479498	chr11:48660499	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.31	-0.33	1.37e-12	HDL cholesterol;
LUAD	cis	rs66731853	0.557	rs477190	chr1:20898514	C/A	cg04087271	chr1:20915334	CDA	-0.45	-7.98	-0.36	1.38e-14	Mean corpuscular volume;
LUAD	cis	rs853679	0.585	rs201000	chr6:27809159	C/T	cg19041857	chr6:27730383	NA	-0.44	-7.06	-0.32	7.07e-12	Depression;
LUAD	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg18200150	chr17:30822561	MYO1D	0.68	14.39	0.57	1.72e-38	Schizophrenia;
LUAD	cis	rs2412208	0.681	rs11800442	chr1:7069252	C/T	cg20434152	chr1:7120926	CAMTA1	-0.29	-6.35	-0.3	5.47e-10	Survival in sporadic amyotrophic lateral sclerosis;
LUAD	cis	rs6489882	0.867	rs4766675	chr12:113365453	A/T	cg20102336	chr12:113376681	OAS3	-0.53	-8.38	-0.38	7.78e-16	Chronic lymphocytic leukemia;
LUAD	cis	rs7709909	0.967	rs6151661	chr5:79973195	T/C	cg24059623	chr5:79951536	MSH3;DHFR	0.39	6.74	0.31	5.07e-11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10927875	0.691	rs2017583	chr1:16350028	A/G	cg21385522	chr1:16154831	NA	0.58	8.58	0.38	1.89e-16	Dilated cardiomyopathy;
LUAD	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg14583973	chr4:3374767	RGS12	0.29	7.42	0.34	6.42e-13	Serum sulfate level;
LUAD	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg15017067	chr4:17643749	FAM184B	0.36	6.94	0.32	1.46e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6484504	0.600	rs2616815	chr11:31327316	C/T	cg14844989	chr11:31128820	NA	0.45	8.3	0.37	1.42e-15	Red blood cell count;
LUAD	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg16647868	chr5:131706066	SLC22A5	0.4	6.95	0.32	1.36e-11	Blood metabolite levels;
LUAD	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg15557168	chr22:42548783	NA	0.49	8.67	0.39	9.62e-17	Schizophrenia;
LUAD	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg17652424	chr22:38574118	PLA2G6	0.3	8.61	0.39	1.41e-16	Cutaneous nevi;
LUAD	cis	rs79349575	0.715	rs11657238	chr17:46985634	A/G	cg22482690	chr17:47019901	SNF8	0.35	6.74	0.31	5.18e-11	Type 2 diabetes;
LUAD	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg15128208	chr22:42549153	NA	0.42	6.6	0.31	1.2e-10	Birth weight;
LUAD	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg10876282	chr6:28092338	ZSCAN16	0.47	7.33	0.34	1.18e-12	Cardiac Troponin-T levels;
LUAD	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.84	0.53	4.41e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7731657	0.537	rs13355837	chr5:130360537	C/T	cg08523029	chr5:130500466	HINT1	-0.58	-7.41	-0.34	6.8e-13	Fasting plasma glucose;
LUAD	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg12573674	chr2:1569213	NA	-0.5	-6.41	-0.3	4e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs6496044	0.526	rs4291869	chr15:86054523	G/A	cg13263323	chr15:86062960	AKAP13	-0.54	-10.04	-0.44	1.99e-21	Interstitial lung disease;
LUAD	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg23262073	chr20:60523788	NA	-0.38	-6.76	-0.31	4.71e-11	Body mass index;
LUAD	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg18876405	chr7:65276391	NA	0.6	10.36	0.45	1.43e-22	Aortic root size;
LUAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg20991723	chr1:152506922	NA	0.32	6.43	0.3	3.42e-10	Hair morphology;
LUAD	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg13390004	chr1:15929781	NA	0.48	8.54	0.38	2.51e-16	Systolic blood pressure;
LUAD	cis	rs62064224	0.530	rs8073708	chr17:30680493	T/C	cg18200150	chr17:30822561	MYO1D	0.42	7.91	0.36	2.34e-14	Schizophrenia;
LUAD	trans	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg18187862	chr3:45730750	SACM1L	0.5	7.88	0.36	2.75e-14	Primary sclerosing cholangitis;
LUAD	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg15448220	chr1:150897856	SETDB1	0.53	8.88	0.4	1.88e-17	Melanoma;
LUAD	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg17264618	chr3:40429014	ENTPD3	0.38	8.22	0.37	2.61e-15	Renal cell carcinoma;
LUAD	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.47	8.41	0.38	6.15e-16	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg10876282	chr6:28092338	ZSCAN16	0.47	7.28	0.33	1.69e-12	Cardiac Troponin-T levels;
LUAD	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg09796270	chr17:17721594	SREBF1	-0.39	-7.84	-0.36	3.58e-14	Total body bone mineral density;
LUAD	trans	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.25	-0.64	6.93e-51	Exhaled nitric oxide output;
LUAD	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg00129232	chr17:37814104	STARD3	-0.45	-7.75	-0.35	6.99e-14	Asthma;
LUAD	cis	rs4604732	0.631	rs11490198	chr1:247625703	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6542838	0.641	rs4553869	chr2:99505940	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.26	-0.33	1.84e-12	Fear of minor pain;
LUAD	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg01884057	chr2:25150051	NA	0.35	7.45	0.34	5.32e-13	Body mass index;
LUAD	cis	rs7771547	0.642	rs12214285	chr6:36434679	C/T	cg07856975	chr6:36356162	ETV7	-0.43	-6.67	-0.31	7.81e-11	Platelet distribution width;
LUAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.29	0.37	1.55e-15	Alzheimer's disease;
LUAD	trans	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg07393940	chr7:158741817	NA	-0.68	-11.63	-0.49	2.6e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9399401	0.667	rs6903424	chr6:142699948	A/C	cg03128060	chr6:142623767	GPR126	0.48	9.83	0.43	1.13e-20	Chronic obstructive pulmonary disease;
LUAD	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.7	13.4	0.55	2.22e-34	Cognitive ability;
LUAD	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg02018176	chr4:1364513	KIAA1530	0.55	10.35	0.45	1.53e-22	Longevity;
LUAD	cis	rs2274273	0.624	rs68138420	chr14:55777967	G/T	cg04306507	chr14:55594613	LGALS3	0.4	7.85	0.36	3.43e-14	Protein biomarker;
LUAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg05340658	chr4:99064831	C4orf37	-0.45	-7.28	-0.33	1.62e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg05590025	chr7:65112418	INTS4L2	0.74	8.05	0.36	8.39e-15	Diabetic kidney disease;
LUAD	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	7.53	0.34	3.18e-13	Menarche (age at onset);
LUAD	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg07599136	chr5:415885	AHRR	0.63	7.19	0.33	2.94e-12	Fat distribution (HIV);
LUAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.57	0.35	2.33e-13	Electroencephalogram traits;
LUAD	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-6.81	-0.31	3.4e-11	IgG glycosylation;
LUAD	cis	rs9473147	0.543	rs13211285	chr6:47479618	C/T	cg20196966	chr6:47445060	CD2AP	0.45	7.08	0.33	6.11e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg04267008	chr7:1944627	MAD1L1	-0.73	-11.12	-0.48	2.19e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg04539111	chr16:67997858	SLC12A4	-0.59	-6.92	-0.32	1.67e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2270927	0.510	rs2913265	chr5:75603886	C/A	cg13563193	chr19:33072644	PDCD5	0.97	9.02	0.4	6.43e-18	Mean corpuscular volume;
LUAD	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg05313129	chr8:58192883	C8orf71	-0.57	-8.41	-0.38	6.38e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg02508848	chr16:68573721	ZFP90	-0.42	-6.6	-0.31	1.22e-10	Ulcerative colitis;
LUAD	cis	rs73058052	1.000	rs2288920	chr19:50091798	G/T	cg21913888	chr19:50084626	PRRG2;NOSIP	0.34	7.65	0.35	1.4e-13	Fibrinogen levels;
LUAD	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg16049864	chr8:95962084	TP53INP1	0.47	8.72	0.39	6.36e-17	Type 2 diabetes;
LUAD	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-9.84	-0.43	1.05e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs999737	0.821	rs11621276	chr14:68996466	A/G	cg04147497	chr14:69052728	RAD51L1	-0.49	-7.46	-0.34	5.03e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg26597838	chr10:835615	NA	0.84	11.61	0.49	3.06e-27	Eosinophil percentage of granulocytes;
LUAD	cis	rs7210086	0.768	rs4485409	chr17:70640381	C/T	cg04206342	chr17:70636940	NA	-0.36	-6.94	-0.32	1.47e-11	Ulcerative colitis;
LUAD	cis	rs4389656	0.857	rs453536	chr5:6736458	T/G	cg10857441	chr5:6722123	POLS	-0.46	-7.84	-0.36	3.58e-14	Coronary artery disease;
LUAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.65	11.98	0.5	1.09e-28	Lymphocyte counts;
LUAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.42	-0.3	3.75e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg00922110	chr4:57842668	C4orf14	-0.41	-6.9	-0.32	1.86e-11	Response to bleomycin (chromatid breaks);
LUAD	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg22105103	chr4:187893119	NA	0.54	11.33	0.48	3.63e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs71478720	0.953	rs1834481	chr11:112023827	C/G	cg04929355	chr11:112034997	IL18	-0.45	-7.2	-0.33	2.83e-12	Interleukin-18 levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06437144	chr17:45973627	SP2	-0.55	-6.79	-0.31	3.79e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg02527881	chr3:46936655	PTH1R	-0.49	-9.74	-0.43	2.41e-20	Colorectal cancer;
LUAD	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg06713675	chr4:122721982	EXOSC9	0.43	7.95	0.36	1.74e-14	Type 2 diabetes;
LUAD	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg04539111	chr16:67997858	SLC12A4	-0.61	-7.6	-0.35	1.92e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs938554	0.577	rs7683856	chr4:10000947	A/G	cg11266682	chr4:10021025	SLC2A9	0.53	9.24	0.41	1.21e-18	Blood metabolite levels;
LUAD	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg09365446	chr1:150670422	GOLPH3L	0.64	11.19	0.48	1.27e-25	Melanoma;
LUAD	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg25797454	chr6:150327115	RAET1K	0.37	7.93	0.36	2.02e-14	Alopecia areata;
LUAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.29	0.37	1.55e-15	Alzheimer's disease;
LUAD	cis	rs7258465	0.896	rs8103660	chr19:18566395	T/C	cg01065977	chr19:18549689	ISYNA1	-0.41	-7.86	-0.36	3.21e-14	Breast cancer;
LUAD	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg09137382	chr11:130731461	NA	0.4	7.43	0.34	6.19e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg11707310	chr1:2537719	MMEL1	-0.39	-8.24	-0.37	2.24e-15	Ulcerative colitis;
LUAD	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg18230493	chr5:56204884	C5orf35	-0.44	-7.28	-0.33	1.64e-12	Coronary artery disease;
LUAD	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg09915433	chr19:53449742	NA	-0.67	-12.69	-0.53	1.73e-31	Psoriasis;
LUAD	cis	rs250677	0.522	rs10040798	chr5:148367324	A/G	cg12140854	chr5:148520817	ABLIM3	0.56	8.94	0.4	1.19e-17	Breast cancer;
LUAD	cis	rs59698941	0.943	rs4705873	chr5:132267167	G/A	cg14825688	chr5:132208181	LEAP2	-0.47	-6.46	-0.3	2.82e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-7.97	-0.36	1.5e-14	Diabetic kidney disease;
LUAD	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg09184832	chr6:79620586	NA	-0.52	-9.64	-0.42	5.24e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7731657	0.537	rs6595976	chr5:130328123	T/A	cg08523029	chr5:130500466	HINT1	0.56	7.35	0.34	1.01e-12	Fasting plasma glucose;
LUAD	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg07677032	chr17:61819896	STRADA	-0.5	-8.41	-0.38	6.36e-16	Prudent dietary pattern;
LUAD	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg27068330	chr11:65405492	SIPA1	0.54	8.6	0.39	1.6e-16	Acne (severe);
LUAD	cis	rs736408	0.812	rs9881468	chr3:52828628	C/T	cg18404041	chr3:52824283	ITIH1	-0.72	-14.92	-0.59	9.52e-41	Bipolar disorder;
LUAD	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg27284194	chr4:1044797	NA	0.58	9.47	0.42	1.98e-19	Recombination rate (males);
LUAD	cis	rs870825	0.616	rs10022818	chr4:185619282	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	13.59	0.55	3.78e-35	Blood protein levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg13977323	chr12:1704065	FBXL14	-0.69	-6.86	-0.32	2.52e-11	Type 2 diabetes;
LUAD	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg04414720	chr1:150670196	GOLPH3L	0.67	11.79	0.5	6.3e-28	Melanoma;
LUAD	trans	rs2262909	0.893	rs4244912	chr19:22203237	T/A	cg05197062	chr11:11642011	GALNTL4	-0.54	-8.09	-0.37	6.54e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg11211951	chr8:145729740	GPT	0.37	7.29	0.33	1.49e-12	Age at first birth;
LUAD	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.66	-0.31	8.37e-11	Personality dimensions;
LUAD	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg24634471	chr8:143751801	JRK	0.48	7.62	0.35	1.72e-13	Schizophrenia;
LUAD	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg03037974	chr15:76606532	NA	0.38	8.0	0.36	1.22e-14	Blood metabolite levels;
LUAD	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg03433033	chr1:76189801	ACADM	-0.84	-15.0	-0.59	4.3e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2109514	0.840	rs2402080	chr7:116135016	G/C	cg12739419	chr7:116140593	CAV2	-0.33	-6.89	-0.32	1.97e-11	Prevalent atrial fibrillation;
LUAD	cis	rs1395	0.778	rs1978881	chr2:27400850	C/A	cg23587288	chr2:27483067	SLC30A3	-0.41	-7.62	-0.35	1.7e-13	Blood metabolite levels;
LUAD	cis	rs7107174	1.000	rs10899451	chr11:77991222	A/C	cg02023728	chr11:77925099	USP35	0.51	7.8	0.35	4.93e-14	Testicular germ cell tumor;
LUAD	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg24803719	chr17:45855879	NA	-0.33	-7.44	-0.34	5.66e-13	IgG glycosylation;
LUAD	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg05110241	chr16:68378359	PRMT7	-0.84	-9.24	-0.41	1.24e-18	Schizophrenia;
LUAD	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18876405	chr7:65276391	NA	0.45	7.19	0.33	2.9e-12	Aortic root size;
LUAD	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg27539214	chr16:67997921	SLC12A4	-0.68	-8.25	-0.37	1.97e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg06873352	chr17:61820015	STRADA	0.43	7.14	0.33	4.04e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs908922	0.651	rs4845442	chr1:152485545	G/A	cg20991723	chr1:152506922	NA	0.34	6.71	0.31	6.19e-11	Hair morphology;
LUAD	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg26384229	chr12:38710491	ALG10B	0.48	7.74	0.35	7.17e-14	Morning vs. evening chronotype;
LUAD	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg13271783	chr10:134563150	INPP5A	-0.42	-7.18	-0.33	3.24e-12	Migraine;
LUAD	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg04450456	chr4:17643702	FAM184B	0.41	7.87	0.36	3.01e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs5756813	0.661	rs2071910	chr22:38204259	C/T	cg19894588	chr14:64061835	NA	-0.54	-7.51	-0.34	3.57e-13	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg13390004	chr1:15929781	NA	-0.48	-8.64	-0.39	1.16e-16	Systolic blood pressure;
LUAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg18538332	chr22:24372958	LOC391322	-0.54	-8.89	-0.4	1.75e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.84	-0.32	2.75e-11	Height;
LUAD	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-6.87	-0.32	2.32e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg04842962	chr6:43655489	MRPS18A	0.78	15.3	0.6	2.32e-42	IgG glycosylation;
LUAD	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg00300879	chr1:26503847	CNKSR1	0.27	7.51	0.34	3.47e-13	Height;
LUAD	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg09835421	chr16:68378352	PRMT7	-0.91	-9.74	-0.43	2.41e-20	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1595825	0.838	rs60079260	chr2:198673636	G/A	cg00361562	chr2:198649771	BOLL	-0.5	-6.73	-0.31	5.4e-11	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.63	0.31	1.04e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13064411	0.542	rs13082603	chr3:113223362	T/C	cg18753928	chr3:113234510	CCDC52	-0.55	-9.71	-0.43	3e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	6.77	0.31	4.37e-11	Menarche (age at onset);
LUAD	trans	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.43	-0.3	3.5e-10	Aortic root size;
LUAD	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.36	7.55	0.34	2.73e-13	Parkinson's disease;
LUAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg11062466	chr8:58055876	NA	0.67	8.95	0.4	1.15e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg06558623	chr16:89946397	TCF25	1.09	11.72	0.5	1.14e-27	Skin colour saturation;
LUAD	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg15181151	chr6:150070149	PCMT1	0.39	7.82	0.36	4.39e-14	Lung cancer;
LUAD	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06028808	chr11:68637592	NA	0.46	7.68	0.35	1.15e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs72634258	0.554	rs12723500	chr1:7857374	G/C	cg26816564	chr1:7831052	VAMP3	0.79	10.16	0.44	7.43e-22	Inflammatory bowel disease;
LUAD	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg17063962	chr7:91808500	NA	0.67	11.91	0.5	2.11e-28	Breast cancer;
LUAD	cis	rs7771547	0.723	rs12153820	chr6:36554030	A/G	cg07856975	chr6:36356162	ETV7	0.45	6.46	0.3	2.97e-10	Platelet distribution width;
LUAD	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg14582100	chr15:45693742	SPATA5L1	0.64	12.48	0.52	1.23e-30	Homoarginine levels;
LUAD	cis	rs17092148	0.945	rs6060009	chr20:33303974	T/G	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.26	-0.37	1.85e-15	Neuroticism;
LUAD	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	9.38	0.41	4.07e-19	Melanoma;
LUAD	trans	rs11671005	0.568	rs55987239	chr19:59085045	G/A	cg22037779	chr5:139682734	PFDN1	-0.68	-8.94	-0.4	1.22e-17	Mean platelet volume;
LUAD	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg18721089	chr20:30220636	NA	-0.49	-7.04	-0.32	7.57e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs2677744	0.626	rs11857545	chr15:91489705	G/A	cg23684204	chr15:91497937	RCCD1	0.43	6.99	0.32	1.09e-11	Attention deficit hyperactivity disorder;
LUAD	trans	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg04565464	chr8:145669602	NFKBIL2	0.43	6.53	0.3	1.93e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs12545109	0.800	rs1837617	chr8:57417592	C/T	cg21220214	chr8:57350948	NA	-0.62	-8.84	-0.39	2.55e-17	Obesity-related traits;
LUAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg21733973	chr7:65235735	NA	-0.46	-7.4	-0.34	7.51e-13	Calcium levels;
LUAD	cis	rs7107174	1.000	rs2512533	chr11:77968674	A/C	cg19901956	chr11:77921274	USP35	-0.51	-6.36	-0.3	5.25e-10	Testicular germ cell tumor;
LUAD	cis	rs12545109	0.842	rs2670050	chr8:57402914	T/G	cg17761419	chr8:57350749	NA	-0.53	-7.93	-0.36	1.99e-14	Obesity-related traits;
LUAD	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg21496419	chr19:44306685	LYPD5	0.39	8.91	0.4	1.53e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs2625529	0.652	rs12148078	chr15:72300471	G/C	cg16672083	chr15:72433130	SENP8	0.67	12.32	0.51	5.08e-30	Red blood cell count;
LUAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08048268	chr3:133502702	NA	-0.53	-10.61	-0.46	1.82e-23	Iron status biomarkers;
LUAD	cis	rs6908034	0.660	rs7750716	chr6:19804839	C/T	cg02682789	chr6:19804855	NA	0.9	10.24	0.45	3.96e-22	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg18252515	chr7:66147081	NA	-0.6	-6.54	-0.3	1.77e-10	Diabetic kidney disease;
LUAD	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg04727924	chr7:799746	HEATR2	0.56	6.85	0.32	2.62e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.29	0.33	1.51e-12	Menopause (age at onset);
LUAD	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg03289416	chr15:75166202	SCAMP2	0.58	10.33	0.45	1.8e-22	Breast cancer;
LUAD	cis	rs2286503	0.966	rs2286507	chr7:22854760	T/C	cg06496272	chr7:22895283	SNORD93	-0.4	-7.26	-0.33	1.89e-12	Fibrinogen;
LUAD	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg09323728	chr8:95962352	TP53INP1	0.29	6.41	0.3	3.95e-10	Type 2 diabetes;
LUAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg08027265	chr7:2291960	NA	-0.43	-7.21	-0.33	2.54e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2109514	0.840	rs6953982	chr7:116129290	C/T	cg12739419	chr7:116140593	CAV2	-0.33	-6.8	-0.31	3.58e-11	Prevalent atrial fibrillation;
LUAD	cis	rs713587	0.713	rs1982200	chr2:25205427	C/T	cg04586622	chr2:25135609	ADCY3	-0.32	-6.84	-0.32	2.76e-11	Body mass index in non-asthmatics;
LUAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03647317	chr4:187891568	NA	-0.35	-6.47	-0.3	2.79e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7771547	0.573	rs9470278	chr6:36399239	G/A	cg07856975	chr6:36356162	ETV7	-0.48	-7.5	-0.34	3.9e-13	Platelet distribution width;
LUAD	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg16479474	chr6:28041457	NA	0.43	7.38	0.34	8.39e-13	Depression;
LUAD	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg26384229	chr12:38710491	ALG10B	0.4	6.49	0.3	2.46e-10	Morning vs. evening chronotype;
LUAD	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg15691649	chr6:25882328	NA	-0.45	-6.45	-0.3	3.1e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg21191810	chr6:118973309	C6orf204	-0.53	-8.2	-0.37	2.9e-15	Diastolic blood pressure;
LUAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-10.86	-0.47	2.04e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg02018176	chr4:1364513	KIAA1530	0.36	6.36	0.3	5.19e-10	Obesity-related traits;
LUAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg26354017	chr1:205819088	PM20D1	0.74	14.77	0.58	4.16e-40	Monocyte percentage of white cells;
LUAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg16606324	chr3:10149918	C3orf24	0.59	9.65	0.42	4.73e-20	Alzheimer's disease;
LUAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-9.24	-0.41	1.2e-18	Alzheimer's disease;
LUAD	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05901451	chr6:126070800	HEY2	-0.85	-16.25	-0.62	1.69e-46	Brugada syndrome;
LUAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg26516362	chr5:178986906	RUFY1	0.51	8.95	0.4	1.12e-17	Lung cancer;
LUAD	cis	rs7095607	0.704	rs6480309	chr10:69953066	G/A	cg18986048	chr10:69913749	MYPN	0.42	7.42	0.34	6.49e-13	Lung function (FVC);
LUAD	cis	rs4072705	1.000	rs4838206	chr9:127511924	T/G	cg13476313	chr9:127244764	NR5A1	0.28	6.95	0.32	1.4e-11	Menarche (age at onset);
LUAD	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg07636037	chr3:49044803	WDR6	0.63	12.27	0.51	7.96e-30	Parkinson's disease;
LUAD	cis	rs6881634	0.501	rs10060186	chr5:77722362	A/C	cg11547950	chr5:77652471	NA	-0.36	-6.58	-0.3	1.41e-10	Hippocampal atrophy;
LUAD	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.68e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs864537	0.646	rs1773542	chr1:167432949	T/C	cg22356347	chr1:167427500	CD247	-0.46	-9.18	-0.41	1.87e-18	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	trans	rs2288327	0.673	rs35504893	chr2:179421294	C/T	cg14011486	chr1:26737247	LIN28	0.41	6.64	0.31	9.41e-11	Atrial fibrillation;
LUAD	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg07570687	chr10:102243282	WNT8B	0.49	7.4	0.34	7.21e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs806794	0.810	rs62396185	chr6:26180634	G/C	cg00631329	chr6:26305371	NA	-0.48	-7.4	-0.34	7.38e-13	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUAD	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg03714773	chr7:91764589	CYP51A1	0.31	7.31	0.33	1.37e-12	Breast cancer;
LUAD	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg11266682	chr4:10021025	SLC2A9	0.6	13.46	0.55	1.22e-34	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.55	-9.99	-0.44	3.06e-21	Longevity;Endometriosis;
LUAD	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg14186256	chr22:23484241	RTDR1	0.46	7.8	0.35	5.02e-14	Bone mineral density;
LUAD	cis	rs59724122	0.542	rs28633173	chr8:27446980	A/G	cg01579299	chr8:27450062	NA	0.53	7.5	0.34	3.76e-13	Bipolar disorder lithium response (categorical) or schizophrenia;
LUAD	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg03233332	chr7:66118400	NA	-0.43	-6.5	-0.3	2.21e-10	Aortic root size;
LUAD	trans	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg07817883	chr1:32538562	TMEM39B	1.18	12.44	0.52	1.65e-30	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2235642	0.701	rs2281230	chr16:1601767	T/C	cg03034668	chr16:1723424	CRAMP1L	-0.44	-7.34	-0.34	1.12e-12	Coronary artery disease;
LUAD	cis	rs7771547	0.519	rs12663882	chr6:36362441	G/T	cg04289385	chr6:36355825	ETV7	-0.47	-7.11	-0.33	4.84e-12	Platelet distribution width;
LUAD	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.42	-0.3	3.76e-10	Breast cancer;
LUAD	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg12310025	chr6:25882481	NA	0.59	9.82	0.43	1.24e-20	Blood metabolite levels;
LUAD	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg04944784	chr2:26401820	FAM59B	-0.72	-10.19	-0.44	6.17e-22	Gut microbiome composition (summer);
LUAD	cis	rs9522267	0.535	rs9515453	chr13:112234612	T/C	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.93e-11	Hepatitis;
LUAD	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg23758822	chr17:41437982	NA	0.99	20.82	0.71	8.69e-67	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.82	0.53	5.17e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322817	0.691	rs2168394	chr6:105259152	C/T	cg02098413	chr6:105308735	HACE1	-0.42	-8.91	-0.4	1.51e-17	Thyroid stimulating hormone;
LUAD	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg21427119	chr20:30132790	HM13	-0.62	-9.41	-0.42	3.2e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg00310523	chr12:86230176	RASSF9	0.38	7.84	0.36	3.61e-14	Major depressive disorder;
LUAD	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg00717180	chr2:96193071	NA	-0.45	-8.61	-0.39	1.48e-16	HDL cholesterol;
LUAD	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg25767906	chr1:53392781	SCP2	-0.4	-7.42	-0.34	6.56e-13	Monocyte count;
LUAD	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.71	-0.39	7.02e-17	Total body bone mineral density;
LUAD	cis	rs62238980	0.614	rs116859544	chr22:32433155	A/T	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21582582	chr3:182698605	DCUN1D1	0.72	14.11	0.57	2.63e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07157834	chr1:205819609	PM20D1	0.83	17.33	0.64	3.26e-51	Menarche (age at onset);
LUAD	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	8.75e-12	Aortic root size;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg15420318	chr15:73925796	NPTN	0.37	7.02	0.32	8.81e-12	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg09491104	chr22:46646882	C22orf40	-0.65	-10.91	-0.47	1.37e-24	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs892961	0.932	rs12452788	chr17:75406866	T/C	cg05865280	chr17:75406074	SEPT9	0.63	19.86	0.69	1.78e-62	Airflow obstruction;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16944820	chr13:45492071	NA	-0.54	-6.51	-0.3	2.14e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7587476	0.601	rs13021937	chr2:215673937	C/T	cg04004882	chr2:215674386	BARD1	-0.54	-7.29	-0.33	1.53e-12	Neuroblastoma;
LUAD	cis	rs6430585	0.702	rs2015532	chr2:136555525	G/T	cg07169764	chr2:136633963	MCM6	-0.84	-10.27	-0.45	3.05e-22	Corneal structure;
LUAD	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg05110241	chr16:68378359	PRMT7	0.6	7.08	0.33	6.16e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1950626	0.833	rs2400963	chr14:101395706	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.38	7.45	0.34	5.18e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs2224391	0.628	rs2773304	chr6:5242602	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-8.74	-0.39	5.46e-17	Height;
LUAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg04025307	chr7:1156635	C7orf50	0.65	7.95	0.36	1.76e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs68170813	0.559	rs2107318	chr7:106845969	A/G	cg23024343	chr7:107201750	COG5	0.49	7.02	0.32	8.68e-12	Coronary artery disease;
LUAD	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg26513180	chr16:89883248	FANCA	0.7	13.43	0.55	1.64e-34	Vitiligo;
LUAD	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6782228	0.585	rs3122175	chr3:128361276	C/T	cg16766828	chr3:128327626	NA	-0.38	-7.2	-0.33	2.7e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg18200150	chr17:30822561	MYO1D	-0.52	-10.34	-0.45	1.77e-22	Schizophrenia;
LUAD	cis	rs7621025	0.500	rs4678275	chr3:136653683	C/T	cg15507776	chr3:136538369	TMEM22	0.59	9.38	0.42	4.02e-19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUAD	cis	rs240764	0.687	rs239209	chr6:101140977	T/C	cg09795085	chr6:101329169	ASCC3	0.41	7.2	0.33	2.75e-12	Neuroticism;
LUAD	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14829155	chr15:31115871	NA	0.73	12.76	0.53	9.09e-32	Huntington's disease progression;
LUAD	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg00631329	chr6:26305371	NA	0.48	7.9	0.36	2.49e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg07741184	chr6:167504864	NA	0.29	7.03	0.32	8.43e-12	Crohn's disease;
LUAD	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg17800788	chr1:21766015	NBPF3	0.36	6.87	0.32	2.31e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.39	-0.3	4.41e-10	Mood instability;
LUAD	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg18944383	chr4:111397179	ENPEP	0.37	7.47	0.34	4.61e-13	Height;
LUAD	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg01528321	chr10:82214614	TSPAN14	0.46	7.37	0.34	9.11e-13	Post bronchodilator FEV1;
LUAD	trans	rs3857536	0.776	rs2040593	chr6:66944076	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.49	-0.3	2.45e-10	Blood trace element (Cu levels);
LUAD	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg23018236	chr17:30244563	NA	-0.62	-8.19	-0.37	3.03e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg26384229	chr12:38710491	ALG10B	0.4	6.94	0.32	1.48e-11	Heart rate;
LUAD	cis	rs1448094	0.617	rs1502800	chr12:86476255	A/G	cg19622623	chr12:86230825	RASSF9	-0.41	-7.42	-0.34	6.44e-13	Major depressive disorder;
LUAD	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg16647868	chr5:131706066	SLC22A5	-0.4	-7.02	-0.32	8.7e-12	Blood metabolite levels;
LUAD	cis	rs12900413	0.603	rs2882677	chr15:90299514	C/T	cg24249390	chr15:90295951	MESP1	-0.35	-6.97	-0.32	1.25e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs642803	0.569	rs44205	chr11:65564786	G/A	cg08755490	chr11:65554678	OVOL1	-0.43	-6.71	-0.31	6.34e-11	Urate levels;
LUAD	cis	rs11051970	0.879	rs2728682	chr12:32580193	G/A	cg24626660	chr12:32551988	NA	0.32	6.5	0.3	2.23e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg15445000	chr17:37608096	MED1	-0.44	-8.19	-0.37	3.12e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg21775007	chr8:11205619	TDH	0.55	10.1	0.44	1.28e-21	Retinal vascular caliber;
LUAD	cis	rs1044826	0.553	rs295469	chr3:139212900	G/A	cg00490450	chr3:139108681	COPB2	0.45	7.05	0.32	7.44e-12	Obesity-related traits;
LUAD	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.62	0.31	1.12e-10	Colorectal cancer;
LUAD	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.47	-0.6	4.22e-43	Eye color traits;
LUAD	cis	rs727505	0.754	rs55723877	chr7:124780899	T/A	cg23710748	chr7:124431027	NA	-0.39	-7.97	-0.36	1.51e-14	Lewy body disease;
LUAD	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.15	0.33	3.87e-12	Menopause (age at onset);
LUAD	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.11	-0.33	4.93e-12	Reticulocyte count;
LUAD	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg00255919	chr5:131827918	IRF1	0.5	11.9	0.5	2.21e-28	Asthma (sex interaction);
LUAD	cis	rs7586879	0.663	rs6760328	chr2:25077991	T/C	cg04586622	chr2:25135609	ADCY3	0.37	7.37	0.34	8.88e-13	Body mass index;
LUAD	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg07460842	chr6:66804631	NA	0.59	9.44	0.42	2.45e-19	Type 2 diabetes;
LUAD	cis	rs6906287	0.609	rs11153759	chr6:118920860	T/A	cg21191810	chr6:118973309	C6orf204	0.5	9.67	0.43	4.11e-20	Electrocardiographic conduction measures;
LUAD	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	10.32	0.45	1.96e-22	Axial length;
LUAD	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg21709803	chr11:61594965	FADS2	-0.46	-7.15	-0.33	3.73e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22442454	chr1:209979470	IRF6	0.52	7.46	0.34	4.92e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.74	-14.81	-0.58	2.81e-40	Lung cancer;
LUAD	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg14530993	chr4:882597	GAK	0.74	7.03	0.32	8.58e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7809615	0.901	rs10230784	chr7:99113672	G/A	cg03133378	chr7:99195931	NA	-0.56	-6.62	-0.31	1.08e-10	Blood metabolite ratios;
LUAD	cis	rs6987853	0.865	rs2923445	chr8:42400743	C/A	cg09913449	chr8:42400586	C8orf40	0.43	8.13	0.37	4.63e-15	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs11048434	0.736	rs11048337	chr12:9121330	C/A	cg13575925	chr12:9217583	LOC144571	0.38	7.17	0.33	3.36e-12	Sjögren's syndrome;
LUAD	cis	rs708547	0.647	rs1713982	chr4:57881715	G/A	cg00922110	chr4:57842668	C4orf14	-0.44	-8.13	-0.37	4.7e-15	Response to bleomycin (chromatid breaks);
LUAD	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg22079354	chr11:130786696	SNX19	0.39	6.64	0.31	9.72e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg23950597	chr19:37808831	NA	-0.61	-7.56	-0.35	2.5e-13	Coronary artery calcification;
LUAD	cis	rs1595825	0.891	rs73058876	chr2:198895022	A/G	cg00361562	chr2:198649771	BOLL	-0.47	-6.53	-0.3	1.84e-10	Ulcerative colitis;
LUAD	cis	rs7267979	0.932	rs6115200	chr20:25487377	G/T	cg08601574	chr20:25228251	PYGB	0.42	7.61	0.35	1.8e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07396495	chr16:53468716	RBL2	-0.59	-7.11	-0.33	5.09e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7119	0.604	rs907383	chr15:77870646	A/G	cg27398640	chr15:77910606	LINGO1	0.39	7.06	0.32	6.7e-12	Type 2 diabetes;
LUAD	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.47	2.75e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.34	6.91	0.32	1.84e-11	Menopause (age at onset);
LUAD	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg02782426	chr3:40428986	ENTPD3	0.36	7.86	0.36	3.21e-14	Renal cell carcinoma;
LUAD	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg05754148	chr16:3507555	NAT15	-0.41	-6.66	-0.31	8.38e-11	Body mass index (adult);
LUAD	cis	rs2040771	0.740	rs9617783	chr22:19260575	C/A	cg02655711	chr22:19163373	SLC25A1	0.56	10.42	0.45	8.43e-23	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.68e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06221963	chr1:154839813	KCNN3	-0.87	-21.0	-0.71	1.32e-67	Prostate cancer;
LUAD	cis	rs657075	0.697	rs3805669	chr5:131646762	A/G	cg21138405	chr5:131827807	IRF1	0.5	6.42	0.3	3.75e-10	Rheumatoid arthritis;
LUAD	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg17346650	chr17:80929145	B3GNTL1	-0.4	-7.59	-0.35	2.13e-13	Glycated hemoglobin levels;
LUAD	trans	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-11.19	-0.48	1.26e-25	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg24154853	chr7:158122151	PTPRN2	-0.56	-11.42	-0.49	1.6e-26	Calcium levels;
LUAD	cis	rs4604732	0.631	rs12039596	chr1:247624766	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.11	0.33	4.98e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-9.3	-0.41	7.38e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11077998	0.933	rs6502121	chr17:80531314	A/G	cg10255544	chr17:80519551	FOXK2	0.34	6.66	0.31	8.42e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs250585	0.704	rs11861636	chr16:23439997	T/C	cg00143387	chr16:23521605	GGA2	0.61	8.9	0.4	1.69e-17	Egg allergy;
LUAD	cis	rs2262909	0.962	rs1526884	chr19:22303651	A/G	cg11619707	chr19:22235551	ZNF257	0.49	7.55	0.34	2.71e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4604732	0.527	rs12031949	chr1:247624463	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	9.13	0.41	2.93e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2692947	0.567	rs4907276	chr2:96391109	G/T	cg23100626	chr2:96804247	ASTL	-0.34	-8.43	-0.38	5.48e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs1448094	0.842	rs12809288	chr12:86455427	C/T	cg18827107	chr12:86230957	RASSF9	0.44	7.88	0.36	2.72e-14	Major depressive disorder;
LUAD	cis	rs1451375	0.698	rs7797131	chr7:50647934	A/G	cg18232548	chr7:50535776	DDC	0.5	8.23	0.37	2.27e-15	Malaria;
LUAD	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg19318889	chr4:1322082	MAEA	0.48	8.47	0.38	4.14e-16	Obesity-related traits;
LUAD	cis	rs13190036	0.901	rs10056655	chr5:176676351	T/C	cg06733329	chr5:176740039	MXD3	-0.51	-7.04	-0.32	7.82e-12	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	cis	rs12545109	0.917	rs10098993	chr8:57323116	T/C	cg21220214	chr8:57350948	NA	-0.63	-8.57	-0.38	1.99e-16	Obesity-related traits;
LUAD	cis	rs8077889	1.000	rs17742905	chr17:41891143	C/A	cg26893861	chr17:41843967	DUSP3	0.94	14.5	0.58	5.99e-39	Triglycerides;
LUAD	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18404041	chr3:52824283	ITIH1	-0.67	-14.52	-0.58	4.76e-39	Bipolar disorder;
LUAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg04025307	chr7:1156635	C7orf50	0.6	6.77	0.31	4.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21582582	chr3:182698605	DCUN1D1	0.62	10.47	0.45	5.6e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg26855724	chr1:75198818	TYW3;CRYZ	0.4	6.56	0.3	1.62e-10	Resistin levels;
LUAD	cis	rs4523957	0.855	rs143499	chr17:2132324	T/C	cg16513277	chr17:2031491	SMG6	0.8	14.87	0.59	1.61e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21659725	chr3:3221576	CRBN	-0.87	-18.37	-0.67	7.79e-56	Intelligence (multi-trait analysis);
LUAD	cis	rs12079745	0.590	rs3766088	chr1:169268692	A/T	cg09363564	chr1:169337483	NME7;BLZF1	1.08	8.35	0.38	9.61e-16	QT interval;
LUAD	cis	rs1816752	0.905	rs6490927	chr13:25013940	C/G	cg02811702	chr13:24901961	NA	0.45	7.88	0.36	2.72e-14	Obesity-related traits;
LUAD	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg02450064	chr17:40260053	DHX58	-0.45	-7.55	-0.34	2.62e-13	Fibrinogen levels;
LUAD	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg27490568	chr2:178487706	NA	0.41	6.78	0.31	4.12e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg14917512	chr19:3094685	GNA11	0.55	6.45	0.3	3.11e-10	Diabetic kidney disease;
LUAD	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg02993280	chr1:107599747	PRMT6	-0.56	-9.13	-0.41	2.94e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.48	7.48	0.34	4.47e-13	Schizophrenia;
LUAD	cis	rs3087591	0.960	rs2285812	chr17:29533871	A/G	cg24425628	chr17:29625626	OMG;NF1	0.41	6.62	0.31	1.08e-10	Hip circumference;
LUAD	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg00784671	chr22:46762841	CELSR1	-0.45	-6.68	-0.31	7.67e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs13082711	0.911	rs13081368	chr3:27521998	G/T	cg02860705	chr3:27208620	NA	0.61	8.98	0.4	8.79e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg01579765	chr21:45077557	HSF2BP	-0.61	-13.74	-0.56	9.23e-36	Mean corpuscular volume;
LUAD	cis	rs2458413	1.000	rs2458414	chr8:105355840	A/G	cg04554929	chr8:105342491	NA	0.36	6.93	0.32	1.62e-11	Paget's disease;
LUAD	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg16325326	chr1:53192061	ZYG11B	0.65	11.63	0.49	2.65e-27	Monocyte count;
LUAD	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg04455712	chr21:45112962	RRP1B	-0.38	-7.6	-0.35	1.87e-13	Mean corpuscular volume;
LUAD	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.57	-0.42	9.37e-20	Life satisfaction;
LUAD	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06544989	chr22:39130855	UNC84B	0.42	7.73	0.35	8.09e-14	Menopause (age at onset);
LUAD	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg19635926	chr16:89946313	TCF25	0.72	6.43	0.3	3.55e-10	Skin colour saturation;
LUAD	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg25767906	chr1:53392781	SCP2	0.41	7.53	0.34	3e-13	Monocyte count;
LUAD	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.76	-9.99	-0.44	3.06e-21	Body mass index;
LUAD	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg23750338	chr8:142222470	SLC45A4	0.61	13.91	0.56	1.82e-36	Immature fraction of reticulocytes;
LUAD	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg05110241	chr16:68378359	PRMT7	-0.8	-8.72	-0.39	6.41e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg05368731	chr17:41323189	NBR1	-0.84	-16.61	-0.63	4.57e-48	Menopause (age at onset);
LUAD	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg26769984	chr7:1090371	C7orf50	0.61	9.63	0.42	5.62e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg10483660	chr13:112241077	NA	-0.32	-6.97	-0.32	1.23e-11	Hepatitis;
LUAD	cis	rs7932354	0.554	rs6485721	chr11:47040854	A/G	cg19486271	chr11:47235900	DDB2	-0.42	-6.67	-0.31	8.12e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs727505	1.000	rs66922607	chr7:124512555	T/A	cg23710748	chr7:124431027	NA	-0.49	-9.82	-0.43	1.18e-20	Lewy body disease;
LUAD	cis	rs12681288	0.676	rs34282191	chr8:991290	G/A	cg15309053	chr8:964076	NA	0.42	8.76	0.39	4.6e-17	Schizophrenia;
LUAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg11062466	chr8:58055876	NA	0.64	8.47	0.38	4.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg18811423	chr2:55921094	PNPT1	0.51	8.45	0.38	4.65e-16	Metabolic syndrome;
LUAD	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.6	11.34	0.48	3.18e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3750965	0.734	rs11604251	chr11:68820429	A/G	cg06818126	chr11:68850279	TPCN2	0.47	6.75	0.31	4.98e-11	Hair color;
LUAD	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.93	13.06	0.54	5.41e-33	Smoking behavior;
LUAD	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs12541635	0.902	rs62525696	chr8:106968703	C/T	cg10147462	chr8:107024639	NA	0.47	8.12	0.37	5.33e-15	Age of smoking initiation;
LUAD	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg17509989	chr5:176798049	RGS14	0.58	10.39	0.45	1.09e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg11050988	chr7:1952600	MAD1L1	-0.38	-7.76	-0.35	6.52e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs4774899	0.934	rs11636201	chr15:57470533	A/G	cg14026238	chr15:57616123	NA	0.37	6.93	0.32	1.6e-11	Urinary tract infection frequency;
LUAD	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21659725	chr3:3221576	CRBN	0.61	9.23	0.41	1.34e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs7017212	0.551	rs1385256	chr8:10018850	A/G	cg23173586	chr14:20945319	PNP	-0.38	-6.41	-0.3	3.9e-10	Schizophrenia;
LUAD	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg08601574	chr20:25228251	PYGB	-0.47	-8.89	-0.4	1.72e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs11811982	0.793	rs79098346	chr1:227220437	G/A	cg24860534	chr1:227506868	CDC42BPA	0.64	6.89	0.32	2.07e-11	Optic disc area;
LUAD	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.71	-11.24	-0.48	7.7e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.51	0.34	3.46e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg13057898	chr1:3703894	LRRC47	0.62	10.6	0.46	1.89e-23	Red cell distribution width;
LUAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg22535103	chr8:58192502	C8orf71	-0.75	-9.17	-0.41	2.16e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs5758659	0.512	rs4822072	chr22:42360833	G/C	cg15128208	chr22:42549153	NA	-0.37	-7.17	-0.33	3.27e-12	Cognitive function;
LUAD	cis	rs7737355	0.947	rs6596027	chr5:130879547	A/G	cg06307176	chr5:131281290	NA	0.52	8.13	0.37	4.69e-15	Life satisfaction;
LUAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg08888203	chr3:10149979	C3orf24	0.73	12.78	0.53	7.21e-32	Alzheimer's disease;
LUAD	cis	rs4713118	0.581	rs200504	chr6:27785820	T/C	cg19041857	chr6:27730383	NA	-0.43	-6.89	-0.32	2.06e-11	Parkinson's disease;
LUAD	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg25237894	chr2:233734115	C2orf82	0.6	11.21	0.48	9.99e-26	Coronary artery disease;
LUAD	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.59	-6.59	-0.31	1.32e-10	Lung cancer in ever smokers;
LUAD	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg00634984	chr7:65235879	NA	0.47	6.37	0.3	4.91e-10	Aortic root size;
LUAD	cis	rs708547	0.647	rs4864609	chr4:57878141	T/A	cg00922110	chr4:57842668	C4orf14	-0.44	-8.13	-0.37	4.7e-15	Response to bleomycin (chromatid breaks);
LUAD	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24531977	chr5:56204891	C5orf35	-0.79	-12.85	-0.53	3.77e-32	Initial pursuit acceleration;
LUAD	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg07538946	chr5:131705188	SLC22A5	0.46	7.36	0.34	9.39e-13	Blood metabolite levels;
LUAD	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg14019146	chr3:50243930	SLC38A3	-0.56	-11.01	-0.47	6.08e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.5	0.3	2.33e-10	Aortic root size;
LUAD	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg20135002	chr11:47629003	NA	-0.41	-7.33	-0.34	1.2e-12	Subjective well-being;
LUAD	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.82	-0.36	4.14e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2070677	1.000	rs4301745	chr10:135421636	T/G	cg20169779	chr10:135381914	SYCE1	-0.5	-7.89	-0.36	2.6e-14	Gout;
LUAD	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg14582100	chr15:45693742	SPATA5L1	-0.35	-6.92	-0.32	1.69e-11	Glomerular filtration rate;
LUAD	cis	rs8099014	0.954	rs9961522	chr18:56107279	T/C	cg12907477	chr18:56117327	MIR122	0.39	6.66	0.31	8.51e-11	Platelet count;
LUAD	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg09085632	chr11:111637200	PPP2R1B	0.67	10.22	0.45	4.48e-22	Primary sclerosing cholangitis;
LUAD	cis	rs9972944	0.756	rs6504357	chr17:63770621	C/T	cg07283582	chr17:63770753	CCDC46	-0.5	-11.31	-0.48	4.15e-26	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6940638	1.000	rs6940638	chr6:27046250	A/G	cg01620082	chr3:125678407	NA	-0.5	-7.03	-0.32	8.25e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-9.2	-0.41	1.69e-18	Alzheimer's disease;
LUAD	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg15335139	chr3:50242325	SLC38A3	-0.39	-6.83	-0.32	2.88e-11	Menarche (age at onset);
LUAD	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg14186256	chr22:23484241	RTDR1	-0.43	-7.43	-0.34	6.24e-13	Bone mineral density;
LUAD	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg06108461	chr20:60628389	TAF4	-0.96	-17.03	-0.64	6.33e-50	Body mass index;
LUAD	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg27170947	chr2:26402098	FAM59B	0.83	12.19	0.51	1.69e-29	Gut microbiome composition (summer);
LUAD	cis	rs10929159	0.894	rs1349729	chr2:236928217	A/G	cg14895183	chr2:236924282	AGAP1	0.38	6.53	0.3	1.94e-10	Parkinson's disease;
LUAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg05564831	chr3:52568323	NT5DC2	0.35	6.49	0.3	2.39e-10	Electroencephalogram traits;
LUAD	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg22676075	chr6:135203613	NA	0.41	7.33	0.34	1.2e-12	Red blood cell count;
LUAD	cis	rs12760731	0.777	rs6701080	chr1:178382261	A/C	cg00404053	chr1:178313656	RASAL2	0.72	9.04	0.4	5.85e-18	Obesity-related traits;
LUAD	cis	rs5771069	0.897	rs137858	chr22:50445601	T/C	cg27467552	chr22:50353597	PIM3	-0.46	-8.49	-0.38	3.59e-16	Ulcerative colitis;
LUAD	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg13010199	chr12:38710504	ALG10B	0.41	6.76	0.31	4.66e-11	Bladder cancer;
LUAD	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg11502198	chr6:26597334	ABT1	0.44	7.1	0.33	5.31e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03193865	chr8:145510099	BOP1	0.54	6.65	0.31	9.24e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4006360	0.606	rs11657468	chr17:39233876	G/A	cg16090541	chr17:39240343	KRTAP4-7	-0.37	-6.49	-0.3	2.47e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg18621852	chr3:10150065	C3orf24	0.47	8.12	0.37	5.17e-15	Alzheimer's disease;
LUAD	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg01689657	chr7:91764605	CYP51A1	0.31	7.57	0.35	2.3e-13	Breast cancer;
LUAD	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg16049864	chr8:95962084	TP53INP1	-0.54	-11.51	-0.49	7.69e-27	Type 2 diabetes;
LUAD	cis	rs3774830	0.714	rs12509727	chr4:5470800	T/G	cg26943120	chr4:5472116	STK32B	0.37	7.54	0.34	2.97e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg22823121	chr1:150693482	HORMAD1	0.45	9.17	0.41	2.15e-18	Tonsillectomy;
LUAD	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11644478	chr21:40555479	PSMG1	0.57	8.85	0.4	2.33e-17	Cognitive function;
LUAD	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg00999904	chr2:3704751	ALLC	0.44	6.98	0.32	1.16e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg26022315	chr17:47021804	SNF8	0.4	7.18	0.33	3.11e-12	Type 2 diabetes;
LUAD	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-8.9	-0.4	1.6e-17	Gut microbiome composition (summer);
LUAD	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg25452165	chr22:42524984	CYP2D6	-0.38	-6.36	-0.3	5.25e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7771547	0.723	rs61211228	chr6:36553416	T/C	cg07856975	chr6:36356162	ETV7	0.45	6.39	0.3	4.41e-10	Platelet distribution width;
LUAD	cis	rs7665090	0.603	rs17033015	chr4:103546304	A/C	cg07973026	chr4:103553119	MANBA	0.41	6.48	0.3	2.51e-10	Primary biliary cholangitis;
LUAD	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg27494647	chr7:150038898	RARRES2	0.48	8.42	0.38	5.86e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg15445000	chr17:37608096	MED1	0.45	8.21	0.37	2.77e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.84	-0.53	4.15e-32	Breast cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03063347	chr6:36515153	STK38	-0.37	-6.39	-0.3	4.39e-10	Cancer;
LUAD	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.75	-0.35	6.69e-14	Breast cancer;
LUAD	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg12863693	chr15:85201151	NMB	0.39	6.91	0.32	1.78e-11	Schizophrenia;
LUAD	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg02269571	chr22:50332266	NA	0.59	9.04	0.4	5.64e-18	Schizophrenia;
LUAD	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg25036284	chr2:26402008	FAM59B	-0.83	-11.68	-0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg22117172	chr7:91764530	CYP51A1	0.35	7.9	0.36	2.43e-14	Breast cancer;
LUAD	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.91	0.32	1.78e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg08027265	chr7:2291960	NA	-0.42	-6.81	-0.31	3.35e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg20607798	chr8:58055168	NA	0.6	9.85	0.43	9.26e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg07936489	chr17:37558343	FBXL20	0.44	6.94	0.32	1.45e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs2992756	0.663	rs3007734	chr1:18803022	T/C	cg24076588	chr1:18808559	KLHDC7A	-0.44	-7.3	-0.33	1.42e-12	Breast cancer;
LUAD	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg00074818	chr8:8560427	CLDN23	0.66	10.16	0.44	7.55e-22	Obesity-related traits;
LUAD	cis	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg21775007	chr8:11205619	TDH	0.37	6.39	0.3	4.27e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs68170813	0.652	rs116894096	chr7:107178477	G/A	cg02696742	chr7:106810147	HBP1	-0.76	-9.1	-0.4	3.71e-18	Coronary artery disease;
LUAD	cis	rs36405	0.500	rs2109273	chr14:72360964	C/T	cg23396177	chr14:72358413	NA	-0.38	-6.48	-0.3	2.54e-10	Yang-deficiency constitution;
LUAD	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.88	0.36	2.89e-14	Depression;
LUAD	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.9	-0.36	2.45e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg26587870	chr6:27730563	NA	0.6	6.74	0.31	5.16e-11	Depression;
LUAD	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg11502198	chr6:26597334	ABT1	0.63	10.36	0.45	1.47e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg22117172	chr7:91764530	CYP51A1	0.33	7.31	0.33	1.37e-12	Breast cancer;
LUAD	cis	rs12681287	0.547	rs9942792	chr8:87509046	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-10.12	-0.44	1.07e-21	Caudate activity during reward;
LUAD	trans	rs9951602	0.512	rs6506874	chr18:76653467	G/T	cg02800362	chr5:177631904	HNRNPAB	0.91	14.55	0.58	3.71e-39	Obesity-related traits;
LUAD	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg15083037	chr5:83017644	HAPLN1	-0.51	-7.6	-0.35	1.97e-13	Prostate cancer;
LUAD	trans	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg04565464	chr8:145669602	NFKBIL2	-0.41	-6.49	-0.3	2.37e-10	Schizophrenia;
LUAD	cis	rs7771547	0.519	rs6923337	chr6:36369260	C/T	cg07856975	chr6:36356162	ETV7	0.53	7.98	0.36	1.4e-14	Platelet distribution width;
LUAD	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg27446573	chr6:127587934	RNF146	0.4	6.37	0.3	4.86e-10	Breast cancer;
LUAD	cis	rs6500395	1.000	rs9933187	chr16:48556573	A/C	cg04672837	chr16:48644449	N4BP1	-0.4	-6.97	-0.32	1.21e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.39	6.36	0.3	5.23e-10	Personality dimensions;
LUAD	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg20503657	chr10:835505	NA	0.8	10.63	0.46	1.49e-23	Eosinophil percentage of granulocytes;
LUAD	cis	rs739496	0.615	rs4767939	chr12:112206895	A/G	cg10833066	chr12:111807467	FAM109A	0.42	6.69	0.31	7.13e-11	Platelet count;
LUAD	cis	rs7177699	0.557	rs7403728	chr15:79112016	T/G	cg15571903	chr15:79123663	NA	-0.38	-7.6	-0.35	1.91e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg06671706	chr8:8559999	CLDN23	0.65	11.23	0.48	8.35e-26	Obesity-related traits;
LUAD	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg10755058	chr3:40428713	ENTPD3	0.46	8.47	0.38	4.13e-16	Renal cell carcinoma;
LUAD	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg06873352	chr17:61820015	STRADA	0.42	7.04	0.32	7.92e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg05373962	chr22:49881684	NA	-0.49	-10.36	-0.45	1.45e-22	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9788682	0.747	rs2568488	chr15:78736593	T/A	cg18825076	chr15:78729989	IREB2	-0.55	-7.77	-0.35	6.01e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.78	0.35	5.45e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg02782426	chr3:40428986	ENTPD3	0.45	9.36	0.41	4.77e-19	Renal cell carcinoma;
LUAD	cis	rs4700695	0.719	rs27082	chr5:65436152	A/C	cg21114390	chr5:65439923	SFRS12	-0.92	-13.95	-0.56	1.19e-36	Facial morphology (factor 19);
LUAD	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg09455208	chr3:40491958	NA	0.65	14.18	0.57	1.28e-37	Renal cell carcinoma;
LUAD	cis	rs8027181	0.839	rs998020	chr15:72999635	C/T	cg25632853	chr15:73088954	NA	0.31	6.68	0.31	7.42e-11	Triglyceride levels;
LUAD	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg16989719	chr2:238392110	NA	-0.37	-6.84	-0.32	2.75e-11	Prostate cancer;
LUAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg02951883	chr7:2050386	MAD1L1	-0.89	-16.62	-0.63	4.02e-48	Bipolar disorder and schizophrenia;
LUAD	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg10591111	chr5:226296	SDHA	0.54	7.15	0.33	3.83e-12	Breast cancer;
LUAD	cis	rs7044106	0.655	rs1359329	chr9:123370985	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.54	0.3	1.8e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg07570687	chr10:102243282	WNT8B	0.48	7.28	0.33	1.63e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7116495	1.000	rs656640	chr11:71781710	T/C	cg07596299	chr11:71824057	C11orf51	-0.77	-6.53	-0.3	1.86e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs6489882	0.867	rs1859336	chr12:113367309	A/G	cg20102336	chr12:113376681	OAS3	0.45	6.67	0.31	7.87e-11	Chronic lymphocytic leukemia;
LUAD	cis	rs12210905	0.688	rs57075114	chr6:27491169	T/G	cg08851530	chr6:28072375	NA	0.94	6.85	0.32	2.58e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg20701182	chr2:24300061	SF3B14	0.63	6.98	0.32	1.18e-11	Lymphocyte counts;
LUAD	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18876405	chr7:65276391	NA	-0.44	-7.22	-0.33	2.38e-12	Aortic root size;
LUAD	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	12.12	0.51	3.08e-29	Monocyte percentage of white cells;
LUAD	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs2485376	0.967	rs11191267	chr10:104112737	T/C	cg20641465	chr10:103991465	PITX3	-0.57	-10.64	-0.46	1.38e-23	QT interval;
LUAD	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg22535103	chr8:58192502	C8orf71	-0.65	-9.26	-0.41	1.06e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9972944	0.651	rs1819910	chr17:63814576	C/A	cg07283582	chr17:63770753	CCDC46	-0.45	-9.6	-0.42	6.96e-20	Total body bone mineral density;
LUAD	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg08805041	chr16:621841	PIGQ	-0.31	-6.4	-0.3	4.06e-10	Height;
LUAD	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.3	6.97	0.32	1.19e-11	Prostate cancer;
LUAD	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg11057378	chr10:81107060	PPIF	0.38	7.19	0.33	2.95e-12	Height;
LUAD	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg03877420	chr5:1004367	NA	-0.34	-6.85	-0.32	2.64e-11	QT interval;
LUAD	cis	rs2625529	0.775	rs4777484	chr15:72376543	T/C	cg16672083	chr15:72433130	SENP8	-0.75	-12.5	-0.52	9.61e-31	Red blood cell count;
LUAD	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg27489772	chr12:121021490	NA	-0.56	-6.86	-0.32	2.53e-11	Type 1 diabetes nephropathy;
LUAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg11494091	chr17:61959527	GH2	0.74	18.3	0.66	1.52e-55	Prudent dietary pattern;
LUAD	cis	rs938554	0.876	rs6449139	chr4:9934111	A/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.54	-0.34	2.94e-13	Blood metabolite levels;
LUAD	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg00666640	chr1:248458726	OR2T12	0.3	7.22	0.33	2.47e-12	Common traits (Other);
LUAD	cis	rs375066	0.592	rs349050	chr19:44301425	G/A	cg11993925	chr19:44307056	LYPD5	-0.38	-7.52	-0.34	3.33e-13	Breast cancer;
LUAD	cis	rs10821973	0.527	rs10733770	chr10:63982386	C/G	cg09941381	chr10:64027924	RTKN2	-0.34	-6.76	-0.31	4.48e-11	Hypothyroidism;
LUAD	cis	rs2816062	0.786	rs735946	chr1:18901323	T/C	cg18795169	chr1:18902165	NA	-0.93	-21.92	-0.73	1.01e-71	Urate levels in lean individuals;
LUAD	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg04539111	chr16:67997858	SLC12A4	-0.52	-6.51	-0.3	2.08e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs62229266	0.693	rs2835264	chr21:37435965	C/T	cg12218747	chr21:37451666	NA	-0.41	-6.95	-0.32	1.4e-11	Mitral valve prolapse;
LUAD	cis	rs500891	0.574	rs13193879	chr6:84123006	T/C	cg08257003	chr6:84140564	ME1	0.33	6.43	0.3	3.38e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg20487152	chr13:99095054	FARP1	-0.48	-8.32	-0.37	1.27e-15	Neuroticism;
LUAD	cis	rs7119	0.717	rs12910951	chr15:77806797	A/G	cg27398640	chr15:77910606	LINGO1	-0.34	-6.38	-0.3	4.74e-10	Type 2 diabetes;
LUAD	cis	rs2735413	0.914	rs2262658	chr16:78060267	A/G	cg04733911	chr16:78082701	NA	-0.28	-6.38	-0.3	4.6e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg26408565	chr15:76604113	ETFA	-0.43	-7.02	-0.32	9.11e-12	Blood metabolite levels;
LUAD	cis	rs3931020	0.688	rs452242	chr1:75225625	G/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.49	-6.55	-0.3	1.63e-10	Resistin levels;
LUAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.84	0.43	1.07e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08109568	chr15:31115862	NA	-0.77	-12.87	-0.53	3.11e-32	Huntington's disease progression;
LUAD	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg01849466	chr14:104193079	ZFYVE21	0.43	7.18	0.33	3.23e-12	Body mass index;
LUAD	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	6.97	0.32	1.22e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2282300	0.739	rs7925340	chr11:30280408	A/C	cg06241208	chr11:30344200	C11orf46	0.59	7.76	0.35	6.34e-14	Morning vs. evening chronotype;
LUAD	cis	rs12760731	0.516	rs12403484	chr1:178129059	C/A	cg00404053	chr1:178313656	RASAL2	0.65	8.39	0.38	7.22e-16	Obesity-related traits;
LUAD	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.19	-0.37	3.2e-15	Height;
LUAD	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg24642844	chr7:1081250	C7orf50	-0.67	-7.89	-0.36	2.54e-14	Longevity;Endometriosis;
LUAD	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs2637266	0.756	rs2583063	chr10:78558048	T/C	cg18941641	chr10:78392320	NA	0.31	6.41	0.3	3.94e-10	Pulmonary function;
LUAD	cis	rs7737355	0.898	rs2161414	chr5:131063073	C/T	cg25547332	chr5:131281432	NA	0.45	6.78	0.31	4.16e-11	Life satisfaction;
LUAD	cis	rs7771547	0.519	rs6457912	chr6:36373794	C/A	cg07856975	chr6:36356162	ETV7	0.52	7.83	0.36	3.98e-14	Platelet distribution width;
LUAD	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg08798685	chr6:27730294	NA	-0.69	-7.3	-0.33	1.47e-12	Depression;
LUAD	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-9.94	-0.43	4.79e-21	Monocyte percentage of white cells;
LUAD	cis	rs1232027	0.700	rs1643660	chr5:79934027	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg09436375	chr6:42928200	GNMT	-0.28	-8.11	-0.37	5.39e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06544989	chr22:39130855	UNC84B	-0.37	-6.87	-0.32	2.32e-11	Menopause (age at onset);
LUAD	cis	rs2637266	1.000	rs12252604	chr10:78352591	T/C	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.29e-11	Pulmonary function;
LUAD	trans	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg06606381	chr12:133084897	FBRSL1	-0.95	-9.18	-0.41	1.96e-18	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.62	-11.93	-0.5	1.7e-28	Prudent dietary pattern;
LUAD	cis	rs9443645	0.507	rs1475046	chr6:79461801	G/A	cg18132916	chr6:79620363	NA	-0.42	-7.17	-0.33	3.44e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg24503407	chr1:205819492	PM20D1	0.45	7.42	0.34	6.4e-13	Parkinson's disease;
LUAD	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg00083206	chr6:110721305	DDO	-0.39	-6.89	-0.32	2.06e-11	Platelet distribution width;
LUAD	trans	rs877282	0.838	rs11253374	chr10:774961	C/T	cg22713356	chr15:30763199	NA	1.26	17.45	0.65	9.53e-52	Uric acid levels;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg07719772	chr16:32360419	NA	-0.48	-7.6	-0.35	1.91e-13	Menopause (age at onset);
LUAD	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg20991723	chr1:152506922	NA	0.33	6.53	0.3	1.87e-10	Hair morphology;
LUAD	cis	rs595982	0.546	rs9941490	chr19:49396737	G/A	cg21252483	chr19:49399788	TULP2	-0.53	-10.16	-0.44	7.87e-22	Red cell distribution width;
LUAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg08742575	chr21:47604166	C21orf56	0.43	7.18	0.33	3.13e-12	Testicular germ cell tumor;
LUAD	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg11915388	chr22:42470451	FAM109B	-0.38	-6.99	-0.32	1.08e-11	Schizophrenia;
LUAD	cis	rs11771526	0.901	rs62457469	chr7:32303052	T/C	cg13207630	chr7:32358064	NA	0.6	7.32	0.34	1.27e-12	Body mass index;
LUAD	cis	rs7779181	1.000	rs12531858	chr7:32340099	G/T	cg27532318	chr7:32358331	NA	0.44	7.28	0.33	1.64e-12	Body mass index;
LUAD	cis	rs250677	0.522	rs12520924	chr5:148349149	C/T	cg18129178	chr5:148520854	ABLIM3	0.48	6.86	0.32	2.51e-11	Breast cancer;
LUAD	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg11189052	chr15:85197271	WDR73	-0.78	-13.58	-0.55	4.25e-35	P wave terminal force;
LUAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.57	-0.42	8.95e-20	Alzheimer's disease;
LUAD	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg06641503	chr3:48959341	ARIH2	-0.36	-7.09	-0.33	5.49e-12	Parkinson's disease;
LUAD	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg08109568	chr15:31115862	NA	-0.66	-10.41	-0.45	9.32e-23	Huntington's disease progression;
LUAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06873352	chr17:61820015	STRADA	0.81	18.02	0.66	2.74e-54	Prudent dietary pattern;
LUAD	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg05110241	chr16:68378359	PRMT7	-0.56	-6.4	-0.3	4.02e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg04990556	chr1:26633338	UBXN11	-0.39	-6.48	-0.3	2.55e-10	Obesity-related traits;
LUAD	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg09658497	chr7:2847517	GNA12	-0.49	-8.96	-0.4	1.03e-17	Height;
LUAD	cis	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg07460842	chr6:66804631	NA	-0.65	-11.5	-0.49	7.79e-27	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg07402062	chr16:89894098	SPIRE2	0.45	11.36	0.48	2.71e-26	Vitiligo;
LUAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg11062466	chr8:58055876	NA	0.65	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg11833968	chr6:79620685	NA	-0.45	-8.34	-0.38	1.05e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg24690094	chr11:67383802	NA	0.39	7.03	0.32	8.3e-12	Mean corpuscular volume;
LUAD	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03517284	chr6:25882590	NA	-0.58	-9.56	-0.42	1.02e-19	Blood metabolite levels;
LUAD	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4285028	0.948	rs7640872	chr3:121697168	C/A	cg20356878	chr3:121714668	ILDR1	-0.5	-6.7	-0.31	6.73e-11	Multiple sclerosis;
LUAD	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg17177755	chr1:15930204	NA	0.45	7.32	0.34	1.28e-12	Systolic blood pressure;
LUAD	cis	rs4638749	1.000	rs1466213	chr2:108856607	G/A	cg06795125	chr2:108905320	SULT1C2	-0.42	-6.56	-0.3	1.54e-10	Blood pressure;
LUAD	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg05535760	chr7:792225	HEATR2	-0.82	-9.66	-0.43	4.49e-20	Cerebrospinal P-tau181p levels;
LUAD	cis	rs28595532	1.000	rs114778020	chr4:119662584	C/A	cg14228332	chr4:119757509	SEC24D	0.83	7.52	0.34	3.26e-13	Cannabis dependence symptom count;
LUAD	cis	rs11734570	0.581	rs73808504	chr4:38600593	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.45	6.41	0.3	3.96e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.8	0.43	1.47e-20	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9837602	1.000	rs1688771	chr3:99503359	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-8.73	-0.39	6.04e-17	Breast cancer;
LUAD	cis	rs7707921	1.000	rs2407064	chr5:81457358	C/A	cg15871215	chr5:81402204	ATG10	0.68	9.79	0.43	1.57e-20	Breast cancer;
LUAD	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg22875332	chr1:76189707	ACADM	-0.79	-13.16	-0.54	2.12e-33	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg08601574	chr20:25228251	PYGB	0.45	7.91	0.36	2.23e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg06618935	chr21:46677482	NA	-0.44	-8.4	-0.38	6.91e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2455799	0.613	rs2470548	chr3:15737689	G/A	cg16303742	chr3:15540471	COLQ	-0.49	-9.04	-0.4	5.78e-18	Mean platelet volume;
LUAD	trans	rs11165623	0.564	rs9887887	chr1:96996930	A/G	cg10631902	chr5:14652156	NA	-0.4	-7.25	-0.33	1.98e-12	Hip circumference;Waist circumference;
LUAD	trans	rs7395662	0.658	rs8189235	chr11:48740064	G/A	cg15704280	chr7:45808275	SEPT13	0.41	6.4	0.3	4.17e-10	HDL cholesterol;
LUAD	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg08601574	chr20:25228251	PYGB	-0.47	-8.88	-0.4	1.86e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.49	-8.72	-0.39	6.41e-17	Lymphocyte counts;
LUAD	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg16989719	chr2:238392110	NA	-0.38	-8.07	-0.37	7.25e-15	Prostate cancer;
LUAD	cis	rs3806843	0.576	rs246011	chr5:140336405	G/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.4	6.74	0.31	5.31e-11	Total body bone mineral density;
LUAD	trans	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg01620082	chr3:125678407	NA	-0.88	-8.81	-0.39	3.38e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.39	-7.07	-0.33	6.37e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3818285	1.000	rs3740138	chr10:111630931	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.59	-8.12	-0.37	5.25e-15	Superior crus of antihelix expression;
LUAD	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg18944383	chr4:111397179	ENPEP	0.38	7.61	0.35	1.74e-13	Height;
LUAD	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg25233709	chr10:116636983	FAM160B1	0.42	8.24	0.37	2.12e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg20119798	chr7:94954144	PON1	-0.47	-6.37	-0.3	4.94e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg11871910	chr12:69753446	YEATS4	-0.49	-7.85	-0.36	3.55e-14	Blood protein levels;
LUAD	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg24558204	chr6:135376177	HBS1L	0.48	8.25	0.37	2.06e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs2073300	1.000	rs12625999	chr20:23442085	A/G	cg12062639	chr20:23401060	NAPB	-0.94	-8.53	-0.38	2.67e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg08807101	chr21:30365312	RNF160	-0.51	-8.78	-0.39	4.09e-17	Dental caries;
LUAD	cis	rs7681423	1.000	rs2066864	chr4:155525695	G/A	cg20735720	chr4:155535218	FGG	-0.52	-7.54	-0.34	2.89e-13	Fibrinogen;
LUAD	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg08213375	chr14:104286397	PPP1R13B	0.27	7.11	0.33	5.04e-12	Schizophrenia;
LUAD	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg12311346	chr5:56204834	C5orf35	-0.95	-13.99	-0.56	8.27e-37	Initial pursuit acceleration;
LUAD	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.22	16.48	0.63	1.65e-47	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg15704280	chr7:45808275	SEPT13	0.63	8.31	0.37	1.29e-15	Axial length;
LUAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg02951883	chr7:2050386	MAD1L1	-0.81	-14.07	-0.56	3.87e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs62400317	0.859	rs72858517	chr6:45223467	A/C	cg18551225	chr6:44695536	NA	-0.54	-8.53	-0.38	2.59e-16	Total body bone mineral density;
LUAD	trans	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.65	-12.03	-0.5	7.46e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg22963979	chr7:1858916	MAD1L1	-0.57	-9.63	-0.42	5.69e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs2735413	0.881	rs12919672	chr16:78082760	C/G	cg04733911	chr16:78082701	NA	-0.35	-8.21	-0.37	2.74e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg05425664	chr17:57184151	TRIM37	-0.41	-7.35	-0.34	1.04e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg10645314	chr2:3704589	ALLC	-0.43	-7.1	-0.33	5.22e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.82e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs367943	0.966	rs455435	chr5:112799412	T/C	cg12552261	chr5:112820674	MCC	-0.59	-11.1	-0.47	2.72e-25	Type 2 diabetes;
LUAD	cis	rs12532878	0.652	rs11768465	chr7:100198386	C/T	cg20848291	chr7:100343083	ZAN	-0.43	-6.57	-0.3	1.45e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg22467129	chr15:76604101	ETFA	-0.48	-7.95	-0.36	1.67e-14	Blood metabolite levels;
LUAD	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg11344533	chr11:111475393	SIK2	-0.35	-6.63	-0.31	1.04e-10	Primary sclerosing cholangitis;
LUAD	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg23283495	chr1:209979779	IRF6	0.72	8.81	0.39	3.38e-17	Coronary artery disease;
LUAD	cis	rs11696501	0.688	rs4810461	chr20:44278445	G/A	cg11783356	chr20:44313418	WFDC10B	-0.43	-7.49	-0.34	4.03e-13	Brain structure;
LUAD	cis	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg01191920	chr7:158217561	PTPRN2	-0.68	-14.58	-0.58	2.61e-39	Obesity-related traits;
LUAD	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg18132916	chr6:79620363	NA	-0.45	-7.66	-0.35	1.24e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg11494091	chr17:61959527	GH2	-0.36	-6.43	-0.3	3.38e-10	Height;
LUAD	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg05887092	chr17:76393375	PGS1	0.4	7.18	0.33	3.1e-12	HDL cholesterol levels;
LUAD	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg09323728	chr8:95962352	TP53INP1	-0.34	-7.2	-0.33	2.7e-12	Type 2 diabetes;
LUAD	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.82	-0.47	3.09e-24	Total body bone mineral density;
LUAD	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg15181151	chr6:150070149	PCMT1	0.42	8.75	0.39	5.05e-17	Lung cancer;
LUAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg23622369	chr17:40706682	HSD17B1	-0.46	-8.48	-0.38	3.84e-16	Colorectal or endometrial cancer;
LUAD	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg03467027	chr4:99064603	C4orf37	-0.42	-6.88	-0.32	2.1e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg00280220	chr17:61926910	NA	0.36	6.98	0.32	1.17e-11	Prudent dietary pattern;
LUAD	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg17264618	chr3:40429014	ENTPD3	0.42	8.93	0.4	1.32e-17	Renal cell carcinoma;
LUAD	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg18016565	chr1:150552671	MCL1	0.41	7.52	0.34	3.22e-13	Tonsillectomy;
LUAD	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.84e-26	Alzheimer's disease (late onset);
LUAD	cis	rs6906287	0.647	rs3951042	chr6:118722495	C/T	cg18833306	chr6:118973337	C6orf204	0.48	8.51	0.38	3.06e-16	Electrocardiographic conduction measures;
LUAD	cis	rs73198271	0.710	rs7837843	chr8:8656485	A/G	cg01851573	chr8:8652454	MFHAS1	0.48	8.52	0.38	2.76e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg19346786	chr7:2764209	NA	-0.47	-10.06	-0.44	1.72e-21	Height;
LUAD	cis	rs13095912	0.889	rs34765114	chr3:185335156	T/A	cg11274856	chr3:185301563	NA	0.38	7.56	0.35	2.47e-13	Systolic blood pressure;
LUAD	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg21862992	chr11:68658383	NA	0.54	9.7	0.43	3.08e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6456156	1.000	rs9457274	chr6:167520865	G/T	cg07741184	chr6:167504864	NA	0.3	6.98	0.32	1.13e-11	Primary biliary cholangitis;
LUAD	cis	rs11586313	1.000	rs11586313	chr1:152890470	C/T	cg07796016	chr1:152779584	LCE1C	-0.4	-7.46	-0.34	5.09e-13	Vitamin D levels;
LUAD	cis	rs791888	0.858	rs1555434	chr10:89419143	G/C	cg13926569	chr10:89418898	PAPSS2	-0.53	-9.92	-0.43	5.41e-21	Magnesium levels;
LUAD	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg26924012	chr15:45694286	SPATA5L1	1.02	18.85	0.68	5.65e-58	Homoarginine levels;
LUAD	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	6.97	0.32	1.19e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs300703	0.654	rs393277	chr2:121539	G/T	cg21211680	chr2:198530	NA	-0.62	-7.98	-0.36	1.36e-14	Blood protein levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg11808854	chr20:60697627	LSM14B	-0.37	-6.57	-0.3	1.46e-10	Schizophrenia;
LUAD	cis	rs9811920	0.809	rs1387647	chr3:99826942	T/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-6.64	-0.31	9.89e-11	Axial length;
LUAD	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg09359103	chr1:154839909	KCNN3	-0.89	-20.01	-0.7	3.61e-63	Prostate cancer;
LUAD	cis	rs7737355	0.812	rs2158294	chr5:130878215	A/G	cg25547332	chr5:131281432	NA	0.43	6.86	0.32	2.41e-11	Life satisfaction;
LUAD	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg24642844	chr7:1081250	C7orf50	-0.95	-10.25	-0.45	3.63e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs981844	0.740	rs6815202	chr4:154682440	A/G	cg10279832	chr4:154682576	RNF175	0.34	7.16	0.33	3.69e-12	Response to statins (LDL cholesterol change);
LUAD	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg13319975	chr6:146136371	FBXO30	-0.57	-9.49	-0.42	1.67e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg11344533	chr11:111475393	SIK2	-0.35	-6.64	-0.31	9.9e-11	Primary sclerosing cholangitis;
LUAD	cis	rs4711350	0.834	rs9461905	chr6:33721933	T/C	cg07979401	chr6:33739406	LEMD2	-0.41	-6.85	-0.32	2.56e-11	Schizophrenia;
LUAD	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.65	0.39	1.07e-16	Parkinson's disease;
LUAD	cis	rs9837602	0.630	rs73138610	chr3:99683653	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	7.51	0.34	3.48e-13	Breast cancer;
LUAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg00280220	chr17:61926910	NA	0.37	7.06	0.32	6.84e-12	Prudent dietary pattern;
LUAD	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg21770322	chr7:97807741	LMTK2	0.3	7.17	0.33	3.44e-12	Breast cancer;
LUAD	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg06627628	chr2:24431161	ITSN2	-0.69	-10.97	-0.47	8.34e-25	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs4006360	0.604	rs3914090	chr17:39230058	A/T	cg20663846	chr17:39254439	KRTAP4-8	0.38	8.52	0.38	2.89e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg05340658	chr4:99064831	C4orf37	0.53	9.07	0.4	4.46e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg08132940	chr7:1081526	C7orf50	-0.68	-9.73	-0.43	2.55e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg04287289	chr16:89883240	FANCA	0.76	6.72	0.31	5.74e-11	Skin colour saturation;
LUAD	cis	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.95	-0.36	1.74e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg18132916	chr6:79620363	NA	-0.45	-7.72	-0.35	8.52e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs11771526	0.686	rs62457463	chr7:32289856	C/T	cg13207630	chr7:32358064	NA	0.66	7.88	0.36	2.81e-14	Body mass index;
LUAD	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg24503407	chr1:205819492	PM20D1	-0.55	-9.84	-0.43	1.02e-20	Menarche (age at onset);
LUAD	cis	rs10899021	1.000	rs11236201	chr11:74375633	A/G	cg25880958	chr11:74394337	NA	-0.71	-8.43	-0.38	5.44e-16	Response to metformin (IC50);
LUAD	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.71	-12.25	-0.51	9.95e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs490234	0.586	rs12553548	chr9:128155261	T/G	cg13590414	chr9:128173245	NA	-0.33	-6.58	-0.3	1.37e-10	Mean arterial pressure;
LUAD	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.23	0.48	8.73e-26	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg23018236	chr17:30244563	NA	0.63	7.93	0.36	2.04e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	8.51	0.38	3.02e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg19717773	chr7:2847554	GNA12	-0.52	-9.81	-0.43	1.33e-20	Height;
LUAD	cis	rs2073300	1.000	rs6137961	chr20:23443102	G/T	cg12062639	chr20:23401060	NAPB	0.98	8.35	0.38	9.91e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg06627628	chr2:24431161	ITSN2	-0.52	-6.37	-0.3	4.86e-10	Lymphocyte counts;
LUAD	cis	rs17253792	0.822	rs58589065	chr14:56152478	T/C	cg01858014	chr14:56050164	KTN1	-0.59	-6.49	-0.3	2.42e-10	Putamen volume;
LUAD	cis	rs7264396	0.563	rs6060567	chr20:34288250	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.24	-0.37	2.2e-15	Total cholesterol levels;
LUAD	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg01802117	chr1:53393560	SCP2	-0.4	-7.8	-0.35	4.92e-14	Monocyte count;
LUAD	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg17372223	chr3:52568218	NT5DC2	0.35	6.78	0.31	4.02e-11	Bipolar disorder;
LUAD	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.46	7.92	0.36	2.16e-14	Age at first birth;
LUAD	cis	rs9287719	0.745	rs4997810	chr2:10755540	T/A	cg00105475	chr2:10696890	NA	0.37	6.66	0.31	8.64e-11	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg24818145	chr4:99064322	C4orf37	0.45	7.67	0.35	1.21e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9811920	0.809	rs766778	chr3:99751480	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.62	-11.48	-0.49	9.96e-27	Axial length;
LUAD	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg23985595	chr17:80112537	CCDC57	-0.55	-9.81	-0.43	1.3e-20	Life satisfaction;
LUAD	trans	rs877282	0.853	rs7083589	chr10:754494	G/A	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18876405	chr7:65276391	NA	0.44	6.98	0.32	1.15e-11	Aortic root size;
LUAD	cis	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg07460842	chr6:66804631	NA	1.05	16.47	0.63	1.87e-47	Exhaled nitric oxide output;
LUAD	cis	rs11971779	0.680	rs6467848	chr7:139080205	T/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs7737355	0.773	rs1422870	chr5:130942624	G/T	cg06307176	chr5:131281290	NA	0.41	6.66	0.31	8.7e-11	Life satisfaction;
LUAD	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg00024416	chr22:24240387	NA	-0.51	-8.99	-0.4	8.29e-18	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg12884169	chr21:40033163	ERG	0.48	10.2	0.44	5.48e-22	Coronary artery disease;
LUAD	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg12179176	chr11:130786555	SNX19	0.46	7.67	0.35	1.17e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7215564	0.908	rs2340770	chr17:78754770	T/C	cg09596252	chr17:78655493	RPTOR	-0.51	-6.47	-0.3	2.78e-10	Myopia (pathological);
LUAD	cis	rs6499255	0.951	rs78772829	chr16:69607098	G/A	cg15192750	chr16:69999425	NA	0.49	7.75	0.35	6.9e-14	IgE levels;
LUAD	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg10591111	chr5:226296	SDHA	-0.56	-7.3	-0.33	1.42e-12	Breast cancer;
LUAD	cis	rs1395	0.778	rs2078616	chr2:27441904	A/G	cg23587288	chr2:27483067	SLC30A3	-0.4	-7.75	-0.35	6.94e-14	Blood metabolite levels;
LUAD	cis	rs13088645	0.532	rs7623580	chr3:134164345	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.5	8.57	0.38	2.02e-16	Coronary artery disease;
LUAD	cis	rs758324	0.755	rs2221674	chr5:131242218	T/A	cg06307176	chr5:131281290	NA	-0.47	-7.86	-0.36	3.26e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg01028140	chr2:1542097	TPO	-0.51	-6.89	-0.32	2.04e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg08470875	chr2:26401718	FAM59B	-0.6	-8.2	-0.37	2.96e-15	Gut microbiome composition (summer);
LUAD	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg25894440	chr7:65020034	NA	-0.67	-7.11	-0.33	5.1e-12	Diabetic kidney disease;
LUAD	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg05283184	chr6:79620031	NA	-0.61	-12.25	-0.51	9.99e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg17105886	chr17:28927953	LRRC37B2	0.66	7.65	0.35	1.33e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs367615	1.000	rs367615	chr5:108948937	C/T	cg17395555	chr5:108820864	NA	-0.47	-8.23	-0.37	2.32e-15	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg13385794	chr1:248469461	NA	0.26	6.97	0.32	1.23e-11	Common traits (Other);
LUAD	cis	rs3733418	1.000	rs3733418	chr4:165878335	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.49	-6.72	-0.31	5.8e-11	Obesity-related traits;
LUAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg18538332	chr22:24372958	LOC391322	-0.54	-8.89	-0.4	1.82e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg08798685	chr6:27730294	NA	-0.7	-7.42	-0.34	6.42e-13	Depression;
LUAD	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg25730555	chr22:47059586	GRAMD4	0.38	6.36	0.3	5.28e-10	Urate levels in obese individuals;
LUAD	cis	rs853679	0.607	rs13201308	chr6:28130089	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.56	6.53	0.3	1.91e-10	Depression;
LUAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg10729496	chr3:10149963	C3orf24	0.54	8.6	0.39	1.58e-16	Alzheimer's disease;
LUAD	cis	rs9394841	0.620	rs9462746	chr6:41816279	T/A	cg17623882	chr6:41773611	USP49	-0.5	-7.02	-0.32	8.74e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	12.72	0.53	1.28e-31	Monocyte percentage of white cells;
LUAD	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg14530993	chr4:882597	GAK	-0.66	-6.37	-0.3	4.81e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg22532475	chr10:104410764	TRIM8	-0.48	-9.21	-0.41	1.53e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-8.09	-0.37	6.6e-15	Bipolar disorder;
LUAD	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg09904177	chr6:26538194	HMGN4	0.43	7.31	0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.07	-22.78	-0.74	1.49e-75	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs870825	0.616	rs28463742	chr4:185611005	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	13.26	0.54	8.22e-34	Blood protein levels;
LUAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg22907277	chr7:1156413	C7orf50	0.68	8.01	0.36	1.12e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg18827107	chr12:86230957	RASSF9	-0.62	-11.01	-0.47	5.74e-25	Major depressive disorder;
LUAD	cis	rs7737355	0.812	rs7729787	chr5:131066577	A/C	cg06307176	chr5:131281290	NA	0.47	7.88	0.36	2.86e-14	Life satisfaction;
LUAD	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg04398451	chr17:18023971	MYO15A	-0.88	-16.9	-0.63	2.43e-49	Total body bone mineral density;
LUAD	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10802521	chr3:52805072	NEK4	0.56	9.93	0.43	5.21e-21	Electroencephalogram traits;
LUAD	cis	rs5756813	0.727	rs13055462	chr22:38184685	A/G	cg06521852	chr22:38141419	TRIOBP	0.48	9.12	0.41	3.13e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	9.19	0.41	1.81e-18	Hip circumference adjusted for BMI;
LUAD	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg05110241	chr16:68378359	PRMT7	-0.82	-8.89	-0.4	1.79e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6459804	0.588	rs2109303	chr7:157506846	G/A	cg05731713	chr7:157510257	PTPRN2	0.39	8.09	0.37	6.34e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg00530320	chr1:46809349	NSUN4	0.53	8.23	0.37	2.31e-15	Menopause (age at onset);
LUAD	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	9.36	0.41	4.66e-19	Hip circumference adjusted for BMI;
LUAD	cis	rs2579500	0.807	rs7584930	chr2:97298290	C/T	cg23100626	chr2:96804247	ASTL	-0.29	-7.18	-0.33	3.11e-12	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.35	-0.3	5.51e-10	Neuroticism;
LUAD	cis	rs1448094	1.000	rs4919776	chr12:86353763	T/C	cg19622623	chr12:86230825	RASSF9	-0.37	-6.88	-0.32	2.19e-11	Major depressive disorder;
LUAD	cis	rs738322	0.577	rs4820320	chr22:38572977	G/A	cg25457927	chr22:38595422	NA	-0.4	-9.28	-0.41	9.06e-19	Cutaneous nevi;
LUAD	cis	rs240764	0.782	rs151637	chr6:101104191	C/T	cg09795085	chr6:101329169	ASCC3	0.44	7.51	0.34	3.56e-13	Neuroticism;
LUAD	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg21709803	chr11:61594965	FADS2	-0.51	-9.04	-0.4	5.75e-18	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.21	0.37	2.79e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9354308	0.868	rs9345692	chr6:66544714	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.87	-0.32	2.3e-11	Metabolite levels;
LUAD	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg26446133	chr18:72167187	CNDP2	-0.9	-16.12	-0.62	6.61e-46	Refractive error;
LUAD	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.78	0.35	5.45e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-7.69	-0.35	1.04e-13	Bladder cancer;
LUAD	cis	rs7588746	0.571	rs10931896	chr2:201148076	C/T	cg23649088	chr2:200775458	C2orf69	-0.47	-7.26	-0.33	1.9e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
LUAD	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	10.91	0.47	1.43e-24	Hip circumference adjusted for BMI;
LUAD	cis	rs11048434	0.698	rs1805745	chr12:9065226	A/T	cg04155231	chr12:9217510	LOC144571	0.37	6.89	0.32	2.05e-11	Sjögren's syndrome;
LUAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.47	-8.89	-0.4	1.81e-17	Lymphocyte counts;
LUAD	cis	rs6499129	0.558	rs60626639	chr16:67625797	A/G	cg26727032	chr16:67993705	SLC12A4	-0.43	-7.15	-0.33	3.81e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs5756813	0.688	rs8140207	chr22:38130459	G/T	cg06521852	chr22:38141419	TRIOBP	0.5	8.72	0.39	6.32e-17	Optic cup area;Vertical cup-disc ratio;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21270074	chr20:49412129	BCAS4	-0.42	-7.35	-0.34	1e-12	Cancer;
LUAD	cis	rs986417	1.000	rs2351175	chr14:61066730	C/T	cg27398547	chr14:60952738	C14orf39	0.64	7.12	0.33	4.64e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03517284	chr6:25882590	NA	-0.59	-9.67	-0.43	4.21e-20	Blood metabolite levels;
LUAD	trans	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	14.9	0.59	1.17e-40	Exhaled nitric oxide output;
LUAD	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg17724175	chr1:150552817	MCL1	0.33	7.64	0.35	1.47e-13	Melanoma;
LUAD	cis	rs727505	1.000	rs10244817	chr7:124467470	T/C	cg23710748	chr7:124431027	NA	-0.45	-9.27	-0.41	9.55e-19	Lewy body disease;
LUAD	cis	rs490234	0.841	rs1250736	chr9:128438005	A/G	cg14078157	chr9:128172775	NA	0.35	6.39	0.3	4.35e-10	Mean arterial pressure;
LUAD	cis	rs2637266	0.765	rs2438993	chr10:78414604	A/C	cg18941641	chr10:78392320	NA	0.31	6.38	0.3	4.77e-10	Pulmonary function;
LUAD	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg16447950	chr5:562315	NA	-0.38	-7.01	-0.32	9.77e-12	Obesity-related traits;
LUAD	cis	rs2425143	1.000	rs4602287	chr20:34368028	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	7.44	0.34	5.54e-13	Blood protein levels;
LUAD	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24531977	chr5:56204891	C5orf35	-0.79	-12.85	-0.53	3.77e-32	Initial pursuit acceleration;
LUAD	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.58	0.39	1.8e-16	Rheumatoid arthritis;
LUAD	cis	rs2455601	0.573	rs2653573	chr11:8989874	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-7.62	-0.35	1.72e-13	Schizophrenia;
LUAD	trans	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg19469189	chr11:128781035	KCNJ5	-0.43	-6.71	-0.31	6.4e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	trans	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg13698153	chr12:118541722	VSIG10	-0.43	-6.61	-0.31	1.14e-10	Vitiligo;
LUAD	cis	rs806215	1.000	rs806219	chr7:127240094	A/C	cg25922125	chr7:127225783	GCC1	0.48	7.15	0.33	3.93e-12	Type 2 diabetes;
LUAD	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg26022315	chr17:47021804	SNF8	0.41	7.3	0.33	1.47e-12	Type 2 diabetes;
LUAD	cis	rs4925114	0.568	rs9900803	chr17:17650978	C/T	cg04398451	chr17:18023971	MYO15A	0.4	6.53	0.3	1.95e-10	Body mass index;
LUAD	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg14092988	chr3:52407081	DNAH1	0.38	7.4	0.34	7.28e-13	Bipolar disorder;
LUAD	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg01119278	chr6:110721349	DDO	-0.42	-7.77	-0.35	6.08e-14	Platelet distribution width;
LUAD	cis	rs490234	0.902	rs7038668	chr9:128239920	T/C	cg14078157	chr9:128172775	NA	-0.37	-6.68	-0.31	7.64e-11	Mean arterial pressure;
LUAD	cis	rs7677751	0.767	rs6832597	chr4:55076237	C/A	cg17187183	chr4:55093834	PDGFRA	0.44	7.25	0.33	2.01e-12	Corneal astigmatism;
LUAD	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg04025307	chr7:1156635	C7orf50	0.56	9.29	0.41	8.29e-19	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg20607798	chr8:58055168	NA	0.58	7.95	0.36	1.75e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs35205176	0.646	rs71542307	chr7:51557659	T/C	cg20478239	chr7:51544475	NA	-0.35	-6.55	-0.3	1.66e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg03469805	chr14:105330648	KIAA0284	-0.29	-7.07	-0.32	6.63e-12	IgG glycosylation;
LUAD	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.48	-0.3	2.48e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4285028	0.747	rs9852845	chr3:121390618	A/C	cg11130432	chr3:121712080	ILDR1	-0.47	-6.81	-0.31	3.27e-11	Multiple sclerosis;
LUAD	cis	rs2040771	0.745	rs362148	chr22:19262852	T/C	cg02655711	chr22:19163373	SLC25A1	0.55	10.12	0.44	1.08e-21	Metabolite levels (small molecules and protein measures);
LUAD	trans	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg18187862	chr3:45730750	SACM1L	0.49	7.74	0.35	7.53e-14	Primary sclerosing cholangitis;
LUAD	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg21798802	chr22:38057573	PDXP	0.49	9.92	0.43	5.62e-21	Fat distribution (HIV);
LUAD	cis	rs6906287	0.647	rs12214483	chr6:118780146	G/C	cg18833306	chr6:118973337	C6orf204	0.46	8.16	0.37	3.89e-15	Electrocardiographic conduction measures;
LUAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg08132940	chr7:1081526	C7orf50	-0.77	-10.31	-0.45	2.21e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg17366294	chr4:99064904	C4orf37	0.65	12.55	0.52	6.47e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg27284194	chr4:1044797	NA	0.69	9.87	0.43	8.07e-21	Recombination rate (females);
LUAD	cis	rs490234	0.783	rs7852065	chr9:128462023	T/C	cg14078157	chr9:128172775	NA	-0.44	-8.24	-0.37	2.22e-15	Mean arterial pressure;
LUAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg13752114	chr3:195489708	MUC4	0.6	7.16	0.33	3.64e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg08219700	chr8:58056026	NA	0.67	8.36	0.38	9.23e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg10518543	chr12:38710700	ALG10B	-0.41	-6.74	-0.31	5.17e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs240764	0.817	rs239246	chr6:101089134	G/A	cg09795085	chr6:101329169	ASCC3	0.43	7.48	0.34	4.29e-13	Neuroticism;
LUAD	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg23435118	chr5:141488016	NDFIP1	-0.48	-7.32	-0.34	1.28e-12	Crohn's disease;
LUAD	trans	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.47	7.99	0.36	1.31e-14	Resting heart rate;
LUAD	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	9.77	0.43	1.8e-20	Lung cancer in ever smokers;
LUAD	cis	rs3862030	0.668	rs12781718	chr10:104227433	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-8.01	-0.36	1.14e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	trans	rs12310956	0.510	rs4931758	chr12:33871870	C/T	cg10518543	chr12:38710700	ALG10B	0.39	6.47	0.3	2.75e-10	Morning vs. evening chronotype;
LUAD	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.04e-13	Morning vs. evening chronotype;
LUAD	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.46	-7.6	-0.35	1.95e-13	Body mass index;
LUAD	cis	rs6547631	0.622	rs12845	chr2:85925848	C/G	cg21473183	chr2:85925749	GNLY	0.35	7.47	0.34	4.68e-13	Blood protein levels;
LUAD	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg27572855	chr1:25598939	RHD	0.53	11.91	0.5	2.02e-28	Erythrocyte sedimentation rate;
LUAD	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg24578937	chr1:2090814	PRKCZ	0.78	16.18	0.62	3.45e-46	Height;
LUAD	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.6	-0.35	1.87e-13	Blood metabolite levels;
LUAD	cis	rs9302690	0.557	rs223875	chr16:57506915	C/T	cg27017172	chr16:57497170	POLR2C	0.69	6.85	0.32	2.59e-11	Blood protein levels;
LUAD	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg20108693	chr8:143823809	SLURP1	0.33	7.84	0.36	3.69e-14	Urinary tract infection frequency;
LUAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18713687	chr3:195489789	MUC4	0.58	6.69	0.31	6.99e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs1595825	1.000	rs7582715	chr2:198874310	T/G	cg10547527	chr2:198650123	BOLL	-0.47	-6.63	-0.31	1.03e-10	Ulcerative colitis;
LUAD	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg00074818	chr8:8560427	CLDN23	0.63	9.81	0.43	1.36e-20	Obesity-related traits;
LUAD	cis	rs36051895	0.658	rs12346093	chr9:5021140	T/A	cg02405213	chr9:5042618	JAK2	-0.48	-6.65	-0.31	9.07e-11	Pediatric autoimmune diseases;
LUAD	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg24818145	chr4:99064322	C4orf37	0.43	7.18	0.33	3.22e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg02782426	chr3:40428986	ENTPD3	0.42	9.33	0.41	5.86e-19	Renal cell carcinoma;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01618114	chr15:68870979	CORO2B	-0.55	-6.48	-0.3	2.54e-10	Type 2 diabetes;
LUAD	cis	rs11098699	0.821	rs2099955	chr4:124214160	C/T	cg09941581	chr4:124220074	SPATA5	0.5	8.09	0.37	6.23e-15	Mosquito bite size;
LUAD	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	7.92	0.36	2.05e-14	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00149659	chr3:10157352	C3orf10	0.86	11.57	0.49	4.56e-27	Alzheimer's disease;
LUAD	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg03161606	chr19:29218774	NA	0.54	7.66	0.35	1.27e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.17	15.71	0.61	3.88e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg00634984	chr7:65235879	NA	-0.5	-6.58	-0.3	1.4e-10	Aortic root size;
LUAD	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg18190219	chr22:46762943	CELSR1	-0.56	-6.74	-0.31	5.13e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg05340658	chr4:99064831	C4orf37	0.45	6.87	0.32	2.29e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.7	-0.31	6.69e-11	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg06606381	chr12:133084897	FBRSL1	-0.67	-6.55	-0.3	1.67e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg11909912	chr17:43974919	MAPT;LOC100130148	0.39	6.59	0.3	1.34e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg01028140	chr2:1542097	TPO	-0.43	-7.19	-0.33	3e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs4662750	0.619	rs2244042	chr2:128404998	A/G	cg03462943	chr2:128407068	GPR17;LIMS2	-0.46	-7.76	-0.35	6.23e-14	Renal cell carcinoma;
LUAD	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg17849569	chr6:28058911	ZSCAN12L1	-0.33	-7.09	-0.33	5.69e-12	Parkinson's disease;
LUAD	cis	rs734999	0.967	rs6672381	chr1:2502834	A/G	cg18854424	chr1:2615690	NA	0.34	7.89	0.36	2.63e-14	Ulcerative colitis;
LUAD	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	8.75e-12	Aortic root size;
LUAD	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg00383909	chr3:49044727	WDR6	0.89	8.12	0.37	5.28e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg05043794	chr9:111880884	C9orf5	-0.44	-7.48	-0.34	4.23e-13	Menarche (age at onset);
LUAD	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg01119278	chr6:110721349	DDO	-0.44	-8.01	-0.36	1.12e-14	Platelet distribution width;
LUAD	trans	rs4650994	0.593	rs10798618	chr1:178519124	A/C	cg05059571	chr16:84539110	KIAA1609	0.47	7.31	0.33	1.31e-12	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs240764	0.658	rs12174806	chr6:101219581	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-7.61	-0.35	1.76e-13	Neuroticism;
LUAD	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg07636037	chr3:49044803	WDR6	0.48	9.25	0.41	1.09e-18	Menarche (age at onset);
LUAD	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg04568274	chr7:158649319	WDR60	0.42	6.83	0.32	3.02e-11	Height;
LUAD	trans	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg01620082	chr3:125678407	NA	-1.01	-9.07	-0.4	4.55e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs6424115	0.679	rs2267961	chr1:24071048	A/G	cg10978503	chr1:24200527	CNR2	-0.43	-7.86	-0.36	3.29e-14	Immature fraction of reticulocytes;
LUAD	trans	rs3960554	0.673	rs57358338	chr7:75732923	T/C	cg19862616	chr7:65841803	NCRNA00174	0.83	11.88	0.5	2.81e-28	Eotaxin levels;
LUAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.66	-0.31	8.3e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.95	-0.36	1.78e-14	Monocyte percentage of white cells;
LUAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.76e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg06197492	chr11:2016605	H19	0.42	8.46	0.38	4.45e-16	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg21285383	chr16:89894308	SPIRE2	0.42	10.24	0.45	3.87e-22	Vitiligo;
LUAD	cis	rs6543140	0.964	rs6734203	chr2:103080066	G/C	cg03938978	chr2:103052716	IL18RAP	0.35	6.82	0.31	3.26e-11	Blood protein levels;
LUAD	cis	rs4849845	0.612	rs3806491	chr2:121008675	G/A	cg24070213	chr2:121070622	NA	0.41	7.74	0.35	7.52e-14	Mean platelet volume;
LUAD	cis	rs1894633	0.547	rs61806090	chr1:172343604	A/G	cg13446689	chr1:172328377	DNM3	0.4	6.64	0.31	9.87e-11	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3820068	0.705	rs4646022	chr1:15839112	G/A	cg13390004	chr1:15929781	NA	0.42	6.78	0.31	4.06e-11	Systolic blood pressure;
LUAD	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.37	0.3	4.95e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg22105103	chr4:187893119	NA	0.53	11.38	0.48	2.29e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg10518543	chr12:38710700	ALG10B	-0.45	-7.09	-0.33	5.66e-12	Morning vs. evening chronotype;
LUAD	cis	rs2282300	0.739	rs7942129	chr11:30224692	G/A	cg25418670	chr11:30344373	C11orf46	-0.52	-7.12	-0.33	4.57e-12	Morning vs. evening chronotype;
LUAD	cis	rs231513	0.911	rs231476	chr17:41985845	A/G	cg26893861	chr17:41843967	DUSP3	-0.63	-7.01	-0.32	9.34e-12	Cognitive function;
LUAD	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg15691649	chr6:25882328	NA	0.63	9.73	0.43	2.61e-20	Blood metabolite levels;
LUAD	cis	rs6484504	0.532	rs2761589	chr11:31311429	C/G	cg14844989	chr11:31128820	NA	0.46	8.44	0.38	5.22e-16	Red blood cell count;
LUAD	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg08859206	chr1:53392774	SCP2	-0.58	-10.69	-0.46	9.16e-24	Monocyte count;
LUAD	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.79	-0.39	3.71e-17	Alzheimer's disease (late onset);
LUAD	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.79e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs11048434	0.636	rs11047953	chr12:9064923	A/C	cg23795048	chr12:9217529	LOC144571	0.41	7.22	0.33	2.36e-12	Sjögren's syndrome;
LUAD	cis	rs7640424	0.649	rs11917909	chr3:107864673	G/A	cg09227934	chr3:107805635	CD47	-0.48	-8.67	-0.39	9.54e-17	Body mass index;
LUAD	cis	rs17155006	0.655	rs378641	chr7:107722149	C/T	cg05962710	chr7:107745446	LAMB4	0.3	6.58	0.3	1.4e-10	Pneumococcal bacteremia;
LUAD	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.08	-0.37	6.72e-15	Bipolar disorder;
LUAD	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg05776053	chr2:74358815	NA	0.46	6.71	0.31	6.26e-11	Gestational age at birth (maternal effect);
LUAD	cis	rs853679	0.607	rs34878803	chr6:28250179	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.51	6.4	0.3	4.03e-10	Depression;
LUAD	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18876405	chr7:65276391	NA	-0.56	-9.45	-0.42	2.41e-19	Aortic root size;
LUAD	cis	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg02508848	chr16:68573721	ZFP90	-0.42	-6.57	-0.3	1.44e-10	Ulcerative colitis;
LUAD	cis	rs494562	0.892	rs618448	chr6:86121324	G/A	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs17401966	1.000	rs35837142	chr1:10322358	C/G	cg15208524	chr1:10270712	KIF1B	0.56	8.21	0.37	2.64e-15	Hepatocellular carcinoma;
LUAD	cis	rs7737355	0.812	rs994453	chr5:130872520	G/T	cg25547332	chr5:131281432	NA	-0.44	-7.15	-0.33	3.76e-12	Life satisfaction;
LUAD	cis	rs1160297	0.585	rs12614959	chr2:53090302	T/C	cg07782112	chr2:53107842	NA	0.41	8.77	0.39	4.53e-17	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg18992706	chr13:44453352	CCDC122;C13orf31	-0.39	-6.96	-0.32	1.29e-11	Schizophrenia;
LUAD	cis	rs9399401	0.667	rs6912639	chr6:142770548	T/C	cg03128060	chr6:142623767	GPR126	0.44	8.62	0.39	1.38e-16	Chronic obstructive pulmonary disease;
LUAD	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-15.24	-0.6	4.28e-42	Schizophrenia;
LUAD	cis	rs4713675	0.565	rs4713659	chr6:33667839	A/G	cg14003231	chr6:33640908	ITPR3	0.49	9.61	0.42	6.64e-20	Plateletcrit;
LUAD	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg17372223	chr3:52568218	NT5DC2	-0.39	-7.05	-0.32	7.24e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9914544	0.545	rs3803835	chr17:18793061	C/T	cg25390199	chr17:18761479	PRPSAP2	-0.37	-6.43	-0.3	3.39e-10	Educational attainment (years of education);
LUAD	cis	rs6558530	0.626	rs6558524	chr8:1702512	T/G	cg19131313	chr8:1704013	NA	-0.42	-6.48	-0.3	2.63e-10	Systolic blood pressure;
LUAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.43	0.55	1.73e-34	Prudent dietary pattern;
LUAD	cis	rs8018808	0.935	rs176772	chr14:77881808	A/G	cg20045696	chr14:77926864	AHSA1	0.37	6.52	0.3	2.01e-10	Myeloid white cell count;
LUAD	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg15704280	chr7:45808275	SEPT13	-0.99	-20.31	-0.7	1.58e-64	Height;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg01353464	chr3:38180116	ACAA1;MYD88	-0.43	-6.87	-0.32	2.36e-11	Vertical cup-disc ratio;
LUAD	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.47e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.31	0.51	5.67e-30	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg27284194	chr4:1044797	NA	0.69	9.97	0.44	3.76e-21	Recombination rate (females);
LUAD	cis	rs11958404	0.789	rs72818145	chr5:157476552	G/C	cg05962755	chr5:157440814	NA	0.65	8.73	0.39	5.78e-17	IgG glycosylation;
LUAD	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg11494091	chr17:61959527	GH2	0.44	8.31	0.37	1.28e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg13010199	chr12:38710504	ALG10B	0.41	6.71	0.31	6.4e-11	Bladder cancer;
LUAD	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg09658497	chr7:2847517	GNA12	-0.43	-7.86	-0.36	3.2e-14	Height;
LUAD	cis	rs513349	1.000	rs210146	chr6:33549098	A/G	cg07679836	chr6:33548423	BAK1	0.45	8.58	0.39	1.82e-16	Platelet count;
LUAD	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg05535760	chr7:792225	HEATR2	0.85	11.39	0.48	2.11e-26	Cerebrospinal P-tau181p levels;
LUAD	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.26	-0.37	1.89e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg09065629	chr16:1709722	CRAMP1L	0.41	7.27	0.33	1.7e-12	Coronary artery disease;
LUAD	cis	rs12949688	0.967	rs12950062	chr17:55825534	G/A	cg12582317	chr17:55822272	NA	0.35	7.03	0.32	8.55e-12	Schizophrenia;
LUAD	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg06713675	chr4:122721982	EXOSC9	-0.84	-17.76	-0.65	4.01e-53	Type 2 diabetes;
LUAD	cis	rs454510	0.857	rs838990	chr1:120193252	A/G	cg16322792	chr1:120165303	ZNF697	0.47	9.24	0.41	1.23e-18	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs9868809	0.881	rs13063312	chr3:48661985	G/A	cg00383909	chr3:49044727	WDR6	0.68	7.47	0.34	4.67e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg10468373	chr11:64009913	FKBP2	0.51	6.36	0.3	5.17e-10	Mean platelet volume;
LUAD	cis	rs4474465	1.000	rs7925034	chr11:78193242	A/G	cg19901956	chr11:77921274	USP35	-0.47	-6.36	-0.3	5.23e-10	Alzheimer's disease (survival time);
LUAD	cis	rs7953508	0.741	rs1498707	chr12:93997128	G/A	cg18151635	chr12:93972918	NA	-0.5	-8.08	-0.37	7.01e-15	Pubertal anthropometrics;
LUAD	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg15962314	chr1:44399869	ARTN	0.36	7.79	0.35	5.31e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg26043149	chr18:55253948	FECH	-0.5	-8.15	-0.37	4.07e-15	Bone mineral density;
LUAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.04	0.36	9.04e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg03806693	chr22:41940476	POLR3H	0.74	9.95	0.44	4.33e-21	Vitiligo;
LUAD	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg19318889	chr4:1322082	MAEA	-0.91	-15.44	-0.6	5.68e-43	Longevity;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24786176	chr4:113153431	AP1AR	0.44	6.78	0.31	3.95e-11	Monocyte percentage of white cells;
LUAD	cis	rs6138458	1.000	rs227621	chr20:24910528	A/C	cg06937882	chr20:24974362	C20orf3	-0.33	-6.43	-0.3	3.52e-10	Blood protein levels;
LUAD	cis	rs6601327	0.585	rs1394	chr8:9511654	G/A	cg27411982	chr8:10470053	RP1L1	-0.37	-6.84	-0.32	2.75e-11	Multiple myeloma (hyperdiploidy);
LUAD	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.01	-0.44	2.63e-21	Monocyte percentage of white cells;
LUAD	cis	rs9807989	0.507	rs1833174	chr2:103034843	T/A	cg03938978	chr2:103052716	IL18RAP	0.44	10.14	0.44	8.64e-22	Asthma;
LUAD	trans	rs7181230	1.000	rs11638521	chr15:40360314	T/C	cg22705835	chr10:65332833	REEP3	0.38	7.82	0.36	4.21e-14	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg12035532	chr1:1886765	KIAA1751	0.42	6.92	0.32	1.67e-11	Body mass index;
LUAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13012494	chr21:47604986	C21orf56	0.69	11.86	0.5	3.17e-28	Testicular germ cell tumor;
LUAD	cis	rs1691799	0.867	rs1027399	chr12:66760942	G/A	cg16791601	chr12:66731901	HELB	-0.36	-6.53	-0.3	1.95e-10	White blood cell count (basophil);
LUAD	cis	rs7809950	0.911	rs7778250	chr7:107224565	C/A	cg23024343	chr7:107201750	COG5	0.76	12.39	0.52	2.7e-30	Coronary artery disease;
LUAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg13047869	chr3:10149882	C3orf24	0.64	10.84	0.47	2.5300000000000002e-24	Alzheimer's disease;
LUAD	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-7.64	-0.35	1.48e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs2455799	0.613	rs13071730	chr3:15891035	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-9.63	-0.42	5.61e-20	Mean platelet volume;
LUAD	cis	rs250677	0.522	rs891920	chr5:148369418	G/T	cg12140854	chr5:148520817	ABLIM3	-0.56	-8.68	-0.39	8.81e-17	Breast cancer;
LUAD	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg27661571	chr11:113659931	NA	-0.68	-7.92	-0.36	2.06e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg10523679	chr1:76189770	ACADM	0.8	12.48	0.52	1.2e-30	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg04731861	chr2:219085781	ARPC2	0.27	8.31	0.37	1.36e-15	Colorectal cancer;
LUAD	cis	rs72772090	0.539	rs55773007	chr5:96124918	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-7.02	-0.32	8.82e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.69	-11.97	-0.5	1.24e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg13560548	chr3:10150139	C3orf24	0.45	7.33	0.34	1.22e-12	Alzheimer's disease;
LUAD	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-6.86	-0.32	2.46e-11	Total body bone mineral density;
LUAD	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg22532475	chr10:104410764	TRIM8	0.45	8.56	0.38	2.11e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2408955	0.521	rs10875749	chr12:48531917	T/A	cg04545296	chr12:48745243	ZNF641	-0.31	-8.05	-0.36	8.26e-15	Glycated hemoglobin levels;
LUAD	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.38	-0.45	1.21e-22	Total body bone mineral density;
LUAD	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg04287289	chr16:89883240	FANCA	0.73	13.61	0.55	3.11e-35	Vitiligo;
LUAD	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg00677455	chr12:58241039	CTDSP2	0.44	7.27	0.33	1.72e-12	Multiple sclerosis;
LUAD	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg01475377	chr6:109611718	NA	-0.48	-8.89	-0.4	1.81e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.51	-8.62	-0.39	1.39e-16	Longevity;Endometriosis;
LUAD	cis	rs12760731	0.720	rs35781686	chr1:178261262	G/A	cg00404053	chr1:178313656	RASAL2	0.75	9.46	0.42	2.15e-19	Obesity-related traits;
LUAD	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg27661571	chr11:113659931	NA	-0.67	-7.81	-0.36	4.42e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg19875535	chr5:140030758	IK	-0.46	-7.61	-0.35	1.84e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg13126279	chr21:47581558	C21orf56	-0.4	-6.39	-0.3	4.34e-10	Testicular germ cell tumor;
LUAD	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.06	23.73	0.76	9.46e-80	Chronic sinus infection;
LUAD	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs57590327	0.503	rs898763	chr3:81513408	T/C	cg07356753	chr3:81810745	GBE1	0.49	7.65	0.35	1.33e-13	Extraversion;
LUAD	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg04455712	chr21:45112962	RRP1B	0.43	8.83	0.39	2.87e-17	Mean corpuscular volume;
LUAD	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg19041857	chr6:27730383	NA	0.47	8.17	0.37	3.65e-15	Parkinson's disease;
LUAD	cis	rs8077889	0.871	rs72836549	chr17:41904360	G/T	cg26893861	chr17:41843967	DUSP3	0.94	14.66	0.58	1.18e-39	Triglycerides;
LUAD	cis	rs8049603	0.697	rs5732	chr16:23197562	A/G	cg09552652	chr16:23197569	SCNN1G	0.36	6.44	0.3	3.17e-10	Multiple sclerosis;
LUAD	trans	rs7395662	1.000	rs6485882	chr11:48592435	C/G	cg20091107	chr2:38604853	ATL2	0.35	6.53	0.3	1.92e-10	HDL cholesterol;
LUAD	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg27411982	chr8:10470053	RP1L1	0.4	7.02	0.32	9.09e-12	Mood instability;
LUAD	cis	rs13095912	0.785	rs6791954	chr3:185335709	C/T	cg11274856	chr3:185301563	NA	-0.48	-9.37	-0.41	4.56e-19	Systolic blood pressure;
LUAD	cis	rs494562	0.892	rs7750970	chr6:86128570	A/T	cg13315970	chr6:86159197	NT5E	0.72	7.94	0.36	1.83e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg10518543	chr12:38710700	ALG10B	-0.48	-8.06	-0.36	8.13e-15	Morning vs. evening chronotype;
LUAD	cis	rs6446731	1.000	rs6446731	chr4:3284751	G/A	cg08886695	chr4:3369023	RGS12	-0.46	-7.08	-0.33	6.19e-12	Mean platelet volume;
LUAD	cis	rs2742417	1.000	rs2742452	chr3:45765708	C/T	cg10512202	chr3:45649293	LIMD1	0.36	6.4	0.3	4.03e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.06	13.2	0.54	1.46e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs12517041	1.000	rs10520889	chr5:23280920	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.47	-0.3	2.73e-10	Calcium levels;
LUAD	trans	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg16724585	chr3:197361211	NA	-0.51	-7.69	-0.35	1.03e-13	Pancreatic cancer;
LUAD	cis	rs6714710	0.535	rs13006932	chr2:98370698	T/A	cg26665480	chr2:98280029	ACTR1B	0.55	8.94	0.4	1.23e-17	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg09365446	chr1:150670422	GOLPH3L	-0.41	-7.06	-0.32	6.99e-12	Tonsillectomy;
LUAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg24829409	chr8:58192753	C8orf71	-0.48	-6.76	-0.31	4.45e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg15664640	chr17:80829946	TBCD	0.5	9.6	0.42	6.89e-20	Breast cancer;
LUAD	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg19980929	chr12:42632907	YAF2	-0.35	-6.7	-0.31	6.58e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg18129748	chr3:49941408	MST1R	0.42	7.06	0.32	7.06e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg03929089	chr4:120376271	NA	-0.92	-17.61	-0.65	1.82e-52	Height;
LUAD	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.95	-0.4	1.16e-17	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg24818145	chr4:99064322	C4orf37	0.47	7.91	0.36	2.22e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg22676075	chr6:135203613	NA	0.44	8.15	0.37	4.23e-15	Red blood cell count;
LUAD	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg04000281	chr11:63949212	NA	0.27	6.39	0.3	4.5e-10	Platelet count;
LUAD	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg22117172	chr7:91764530	CYP51A1	0.37	8.07	0.37	7.49e-15	Breast cancer;
LUAD	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg01579765	chr21:45077557	HSF2BP	0.6	12.82	0.53	4.96e-32	Mean corpuscular volume;
LUAD	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg06671706	chr8:8559999	CLDN23	0.66	11.4	0.48	1.87e-26	Obesity-related traits;
LUAD	cis	rs2882667	0.898	rs2882792	chr5:138380480	G/T	cg04439458	chr5:138467593	SIL1	-0.41	-7.38	-0.34	8.69e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.01	-0.4	6.99e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7072216	0.763	rs6584198	chr10:100169906	G/C	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.68	-0.39	8.56e-17	Metabolite levels;
LUAD	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg14598338	chr9:96623480	NA	-0.44	-9.43	-0.42	2.82e-19	DNA methylation (variation);
LUAD	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg24450063	chr1:156163899	SLC25A44	1.05	16.88	0.63	3.18e-49	Testicular germ cell tumor;
LUAD	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg05182265	chr7:156933206	UBE3C	0.81	17.37	0.65	2.13e-51	Body mass index;
LUAD	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg03806693	chr22:41940476	POLR3H	-0.54	-8.01	-0.36	1.13e-14	Vitiligo;
LUAD	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg05754148	chr16:3507555	NAT15	-0.47	-7.24	-0.33	2.06e-12	Body mass index (adult);
LUAD	cis	rs12200560	0.505	rs1334321	chr6:97079571	C/T	cg06623918	chr6:96969491	KIAA0776	-0.45	-6.98	-0.32	1.13e-11	Coronary heart disease;
LUAD	cis	rs4285028	0.580	rs2293611	chr3:121643163	G/C	cg11130432	chr3:121712080	ILDR1	-0.44	-6.61	-0.31	1.19e-10	Multiple sclerosis;
LUAD	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg20135002	chr11:47629003	NA	-0.42	-7.32	-0.34	1.22e-12	Subjective well-being;
LUAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg04234412	chr22:24373322	LOC391322	0.73	12.26	0.51	8.95e-30	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg21427119	chr20:30132790	HM13	-0.37	-6.49	-0.3	2.43e-10	Subcortical brain region volumes;Putamen volume;
LUAD	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg06784218	chr1:46089804	CCDC17	0.56	12.24	0.51	1.11e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg15606819	chr19:49661083	TRPM4	-0.38	-6.52	-0.3	1.95e-10	Schizophrenia;
LUAD	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg20283391	chr11:68216788	NA	-0.41	-6.6	-0.31	1.21e-10	Total body bone mineral density;
LUAD	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg14983838	chr19:29218262	NA	0.66	9.69	0.43	3.46e-20	Methadone dose in opioid dependence;
LUAD	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg17971929	chr21:40555470	PSMG1	0.56	8.87	0.4	2.04e-17	Cognitive function;
LUAD	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18876405	chr7:65276391	NA	0.56	9.33	0.41	6.17e-19	Aortic root size;
LUAD	trans	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg18187862	chr3:45730750	SACM1L	0.51	7.83	0.36	4.08e-14	Primary sclerosing cholangitis;
LUAD	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	cis	rs2066819	0.786	rs116934693	chr12:56696545	T/G	cg26714650	chr12:56694279	CS	-0.86	-7.23	-0.33	2.23e-12	Psoriasis vulgaris;
LUAD	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg17063962	chr7:91808500	NA	0.6	9.77	0.43	1.84e-20	Breast cancer;
LUAD	cis	rs775227	0.574	rs35274817	chr3:113266391	A/G	cg10517650	chr3:113235015	CCDC52	-0.5	-7.17	-0.33	3.36e-12	Dental caries;
LUAD	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg01236616	chr12:121019343	POP5	1.12	17.27	0.64	5.6e-51	Type 1 diabetes nephropathy;
LUAD	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg27426351	chr10:43362370	NA	-0.51	-7.81	-0.36	4.5e-14	Blood protein levels;
LUAD	cis	rs10493773	0.577	rs17398175	chr1:86074710	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.47	-7.28	-0.33	1.61e-12	Urate levels in overweight individuals;
LUAD	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg22681709	chr2:178499509	PDE11A	-0.51	-8.17	-0.37	3.66e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs977987	0.806	rs8054769	chr16:75401113	T/C	cg03315344	chr16:75512273	CHST6	0.65	14.03	0.56	5.38e-37	Dupuytren's disease;
LUAD	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg12615879	chr12:58013172	SLC26A10	-0.36	-6.82	-0.31	3.11e-11	Celiac disease or Rheumatoid arthritis;
LUAD	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08859206	chr1:53392774	SCP2	-0.72	-13.71	-0.55	1.16e-35	Monocyte count;
LUAD	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg17366294	chr4:99064904	C4orf37	-0.55	-9.45	-0.42	2.31e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg01579765	chr21:45077557	HSF2BP	-0.65	-15.16	-0.59	8.89e-42	Mean corpuscular volume;
LUAD	cis	rs7127129	0.872	rs11607654	chr11:70055721	C/T	cg06159181	chr11:70072977	NA	-0.35	-6.63	-0.31	1.05e-10	Aortic root size;
LUAD	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.56	0.3	1.6e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg05754148	chr16:3507555	NAT15	0.81	10.7	0.46	8.55e-24	Tuberculosis;
LUAD	cis	rs7731657	0.537	rs4705883	chr5:130358471	A/G	cg08523029	chr5:130500466	HINT1	0.52	6.93	0.32	1.54e-11	Fasting plasma glucose;
LUAD	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg18099408	chr3:52552593	STAB1	-0.41	-6.96	-0.32	1.31e-11	Electroencephalogram traits;
LUAD	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg22852734	chr6:133119734	C6orf192	0.79	9.96	0.44	3.96e-21	Type 2 diabetes nephropathy;
LUAD	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg27170947	chr2:26402098	FAM59B	0.82	11.43	0.49	1.48e-26	Gut microbiome composition (summer);
LUAD	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg22508957	chr16:3507546	NAT15	-0.4	-6.48	-0.3	2.63e-10	Body mass index (adult);
LUAD	cis	rs17092148	1.000	rs3787223	chr20:33331385	C/T	cg16810054	chr20:33298113	TP53INP2	0.53	8.32	0.37	1.24e-15	Neuroticism;
LUAD	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg08472276	chr7:1133186	C7orf50;GPER	-0.43	-7.86	-0.36	3.17e-14	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg05340658	chr4:99064831	C4orf37	0.54	9.03	0.4	6.03e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg18944383	chr4:111397179	ENPEP	0.39	7.85	0.36	3.56e-14	Height;
LUAD	cis	rs526821	0.595	rs499446	chr11:55355722	A/G	cg04317927	chr11:55418816	OR4S2	0.4	7.58	0.35	2.24e-13	Pediatric bone mineral density (spine);
LUAD	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.93	0.36	1.99e-14	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg00666640	chr1:248458726	OR2T12	0.33	8.1	0.37	5.83e-15	Common traits (Other);
LUAD	cis	rs7274811	0.681	rs291670	chr20:31945861	G/A	cg13403462	chr20:32256071	NECAB3;C20orf134	0.49	7.5	0.34	3.85e-13	Height;
LUAD	cis	rs62400317	0.762	rs12193264	chr6:44930793	T/C	cg18551225	chr6:44695536	NA	-0.58	-8.78	-0.39	4.01e-17	Total body bone mineral density;
LUAD	cis	rs35883536	0.647	rs945329	chr1:101084273	C/T	cg06223162	chr1:101003688	GPR88	-0.44	-8.22	-0.37	2.6e-15	Monocyte count;
LUAD	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.41	-0.45	9.92e-23	Monocyte percentage of white cells;
LUAD	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg04414720	chr1:150670196	GOLPH3L	0.75	13.29	0.54	6.55e-34	Melanoma;
LUAD	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg01689657	chr7:91764605	CYP51A1	0.35	8.79	0.39	3.69e-17	Breast cancer;
LUAD	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	5.93e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10916814	0.610	rs1890005	chr1:20899016	T/C	cg24502330	chr1:20914028	CDA	-0.36	-7.18	-0.33	3.14e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg18180107	chr4:99064573	C4orf37	0.42	6.76	0.31	4.61e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs904251	0.600	rs4714068	chr6:37455642	A/C	cg25019722	chr6:37503610	NA	-0.3	-6.9	-0.32	1.85e-11	Cognitive performance;
LUAD	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg03433033	chr1:76189801	ACADM	0.86	15.53	0.6	2.27e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg04225089	chr17:73874465	TRIM47	-0.41	-7.13	-0.33	4.26e-12	Psoriasis;
LUAD	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg05234568	chr11:5960015	NA	-0.55	-9.93	-0.43	5.15e-21	DNA methylation (variation);
LUAD	cis	rs68170813	0.559	rs1548523	chr7:106944408	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-10.68	-0.46	9.67e-24	Coronary artery disease;
LUAD	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg11247378	chr22:39784982	NA	-0.75	-13.92	-0.56	1.53e-36	Intelligence (multi-trait analysis);
LUAD	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg06781209	chr11:61594997	FADS2	-0.65	-9.65	-0.42	4.8e-20	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg04155289	chr7:94953770	PON1	-0.52	-7.0	-0.32	1.02e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg19626725	chr5:178986131	RUFY1	-0.48	-8.82	-0.39	3e-17	Lung cancer;
LUAD	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg06028605	chr16:24865363	SLC5A11	0.57	8.32	0.38	1.2e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg18827107	chr12:86230957	RASSF9	-0.7	-13.07	-0.54	5.13e-33	Major depressive disorder;
LUAD	cis	rs7851660	0.809	rs1561957	chr9:100670272	T/C	cg13688889	chr9:100608707	NA	-0.56	-9.34	-0.41	5.6e-19	Strep throat;
LUAD	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg19912559	chr1:40204330	PPIE	0.57	9.94	0.44	4.64e-21	Blood protein levels;
LUAD	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg27284194	chr4:1044797	NA	0.71	10.29	0.45	2.68e-22	Recombination rate (females);
LUAD	cis	rs13064411	0.696	rs6787026	chr3:113162117	A/G	cg18753928	chr3:113234510	CCDC52	-0.7	-11.26	-0.48	6.61e-26	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs113835537	0.529	rs11550299	chr11:66254085	G/T	cg26679405	chr11:66247800	DPP3	-0.46	-6.7	-0.31	6.49e-11	Airway imaging phenotypes;
LUAD	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.53	-10.0	-0.44	2.76e-21	Homoarginine levels;
LUAD	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg06641503	chr3:48959341	ARIH2	-0.4	-7.91	-0.36	2.24e-14	Parkinson's disease;
LUAD	cis	rs10504073	0.584	rs4873092	chr8:49974053	T/C	cg00325661	chr8:49890786	NA	0.45	10.28	0.45	2.88e-22	Blood metabolite ratios;
LUAD	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg03929089	chr4:120376271	NA	-0.97	-19.83	-0.69	2.29e-62	Height;
LUAD	cis	rs13095912	0.752	rs13092283	chr3:185338005	T/C	cg11274856	chr3:185301563	NA	0.5	9.58	0.42	8.07e-20	Systolic blood pressure;
LUAD	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg23992470	chr4:843637	GAK	0.67	7.09	0.33	5.62e-12	Parkinson's disease;
LUAD	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg06713521	chr6:7313605	SSR1	-0.51	-6.38	-0.3	4.76e-10	Colorectal cancer;
LUAD	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg14844989	chr11:31128820	NA	-0.44	-8.1	-0.37	5.76e-15	Red blood cell count;
LUAD	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg17724175	chr1:150552817	MCL1	0.39	9.43	0.42	2.64e-19	Tonsillectomy;
LUAD	cis	rs12618769	0.597	rs72821943	chr2:99141640	T/C	cg10123293	chr2:99228465	UNC50	0.47	8.52	0.38	2.88e-16	Bipolar disorder;
LUAD	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg02228675	chr17:40259724	DHX58	-0.46	-7.49	-0.34	3.93e-13	Fibrinogen levels;
LUAD	cis	rs6933660	0.744	rs35143743	chr6:151768532	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.5	-7.29	-0.33	1.52e-12	Menarche (age at onset);
LUAD	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg23166289	chr1:210001082	C1orf107	0.5	6.98	0.32	1.12e-11	Orofacial clefts;
LUAD	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg12432903	chr7:1882776	MAD1L1	-0.47	-7.84	-0.36	3.7e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	9.62	0.42	6.25e-20	Lung cancer in ever smokers;
LUAD	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg22823121	chr1:150693482	HORMAD1	0.42	8.43	0.38	5.69e-16	Tonsillectomy;
LUAD	cis	rs1395	0.710	rs58965570	chr2:27481460	C/T	cg23587288	chr2:27483067	SLC30A3	-0.41	-7.56	-0.34	2.59e-13	Blood metabolite levels;
LUAD	trans	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.08	25.99	0.78	1.12e-89	Colorectal cancer;
LUAD	cis	rs13315871	0.929	rs35376204	chr3:58325563	T/C	cg12435725	chr3:58293450	RPP14	-0.73	-7.68	-0.35	1.1e-13	Cholesterol, total;
LUAD	trans	rs7939886	0.920	rs12223014	chr11:55878290	G/A	cg15704280	chr7:45808275	SEPT13	0.65	6.44	0.3	3.22e-10	Myopia (pathological);
LUAD	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.44	0.3	3.28e-10	Depression;
LUAD	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg06713675	chr4:122721982	EXOSC9	-0.83	-17.87	-0.66	1.23e-53	Type 2 diabetes;
LUAD	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg16512390	chr1:228756714	NA	0.69	9.16	0.41	2.19e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg06784218	chr1:46089804	CCDC17	-0.59	-13.22	-0.54	1.27e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg03714773	chr7:91764589	CYP51A1	0.27	6.37	0.3	4.82e-10	Breast cancer;
LUAD	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg11292332	chr7:45801988	SEPT13	-0.28	-6.36	-0.3	5.26e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg00310523	chr12:86230176	RASSF9	0.41	8.71	0.39	6.76e-17	Major depressive disorder;
LUAD	cis	rs9322817	0.625	rs2499655	chr6:105307435	G/A	cg02098413	chr6:105308735	HACE1	0.4	8.73	0.39	5.89e-17	Thyroid stimulating hormone;
LUAD	cis	rs28595532	0.545	rs13144171	chr4:119257458	G/A	cg02775129	chr4:119771670	NA	-0.58	-6.44	-0.3	3.23e-10	Cannabis dependence symptom count;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg27272293	chr12:76531007	NA	0.41	6.64	0.31	9.81e-11	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs2688608	0.901	rs2664282	chr10:75620757	T/C	cg19442545	chr10:75533431	FUT11	-0.42	-7.12	-0.33	4.74e-12	Inflammatory bowel disease;
LUAD	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg26587870	chr6:27730563	NA	-0.4	-7.15	-0.33	3.72e-12	Parkinson's disease;
LUAD	trans	rs617791	0.530	rs735942	chr11:65749337	A/G	cg17712092	chr4:129076599	LARP1B	-0.76	-11.89	-0.5	2.48e-28	Breast cancer;
LUAD	cis	rs7166081	0.688	rs4776361	chr15:67762056	G/A	cg24579218	chr15:68104479	NA	-0.49	-8.2	-0.37	2.98e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	6.93	0.32	1.57e-11	Platelet count;
LUAD	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg17644776	chr2:200775616	C2orf69	-0.57	-7.41	-0.34	6.71e-13	Schizophrenia;
LUAD	cis	rs3791556	0.898	rs3828222	chr2:240109568	A/G	cg03281426	chr2:240109471	HDAC4	-0.51	-9.92	-0.43	5.58e-21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7731657	0.537	rs12516770	chr5:130222575	T/C	cg08523029	chr5:130500466	HINT1	-0.57	-7.31	-0.33	1.37e-12	Fasting plasma glucose;
LUAD	cis	rs1395	0.710	rs11682913	chr2:27473649	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.47	7.97	0.36	1.48e-14	Blood metabolite levels;
LUAD	cis	rs3806843	0.576	rs246009	chr5:140338069	A/G	cg18668511	chr5:140557227	PCDHB8	0.37	6.69	0.31	7.23e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg03714773	chr7:91764589	CYP51A1	0.3	6.85	0.32	2.66e-11	Breast cancer;
LUAD	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg24562669	chr7:97807699	LMTK2	0.33	7.87	0.36	3.1e-14	Breast cancer;
LUAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	7.27	0.33	1.73e-12	Alzheimer's disease;
LUAD	cis	rs6785206	0.892	rs2712429	chr3:128336221	A/C	cg16766828	chr3:128327626	NA	-0.84	-9.5	-0.42	1.55e-19	Lymphocyte percentage of white cells;
LUAD	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg04398451	chr17:18023971	MYO15A	-0.92	-18.76	-0.67	1.48e-57	Total body bone mineral density;
LUAD	cis	rs2485376	0.935	rs7916262	chr10:104015818	G/T	cg20641465	chr10:103991465	PITX3	0.56	10.37	0.45	1.32e-22	QT interval;
LUAD	trans	rs970548	0.643	rs7080474	chr10:45931899	C/T	cg14222797	chr10:16859974	RSU1	-0.5	-6.36	-0.3	5.15e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg14689365	chr7:158441557	NCAPG2	-0.4	-6.37	-0.3	5.07e-10	Height;
LUAD	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.46	7.04	0.32	7.6e-12	Total body bone mineral density;
LUAD	cis	rs79839061	0.636	rs76839318	chr4:837810	T/A	cg14530993	chr4:882597	GAK	0.77	6.42	0.3	3.64e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg03388025	chr16:89894329	SPIRE2	0.5	13.17	0.54	1.94e-33	Vitiligo;
LUAD	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg12365402	chr11:9010492	NRIP3	0.45	8.2	0.37	2.91e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg05665937	chr4:1216051	CTBP1	0.39	6.71	0.31	6.16e-11	Obesity-related traits;
LUAD	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg23533926	chr12:111358616	MYL2	-0.42	-7.16	-0.33	3.69e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg08125733	chr17:73851984	WBP2	0.63	6.53	0.3	1.93e-10	Psoriasis;
LUAD	cis	rs713477	0.967	rs1572613	chr14:55909897	C/T	cg13175173	chr14:55914753	NA	-0.33	-6.95	-0.32	1.41e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs12579753	0.597	rs2244802	chr12:82153749	C/G	cg07988820	chr12:82153109	PPFIA2	0.37	6.6	0.31	1.27e-10	Resting heart rate;
LUAD	cis	rs7799006	0.929	rs35629140	chr7:2257171	G/C	cg02951883	chr7:2050386	MAD1L1	-0.5	-7.7	-0.35	9.46e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg06740227	chr12:86229804	RASSF9	0.4	6.89	0.32	2.02e-11	Major depressive disorder;
LUAD	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg27211696	chr2:191398769	TMEM194B	0.77	16.12	0.62	6.19e-46	Pulse pressure;
LUAD	cis	rs367615	0.506	rs2914680	chr5:108787146	A/G	cg17395555	chr5:108820864	NA	-0.61	-12.82	-0.53	5.03e-32	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs600626	0.636	rs11236518	chr11:75453066	C/T	cg24262691	chr11:75473276	NA	0.54	7.1	0.33	5.22e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg14779329	chr11:130786720	SNX19	0.44	7.43	0.34	6.25e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7289126	0.966	rs5995554	chr22:38630272	T/C	cg17652424	chr22:38574118	PLA2G6	-0.25	-7.32	-0.34	1.26e-12	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg22681709	chr2:178499509	PDE11A	-0.38	-6.92	-0.32	1.67e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.27	0.45	3.02e-22	Lung cancer in ever smokers;
LUAD	cis	rs758324	0.947	rs11242098	chr5:131206837	T/G	cg25547332	chr5:131281432	NA	0.42	6.84	0.32	2.7e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg18105139	chr6:28058856	ZSCAN12L1	0.27	6.53	0.3	1.89e-10	Depression;
LUAD	trans	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	6.07e-11	Depression;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg04370807	chr17:29248951	ADAP2	0.41	6.36	0.3	5.16e-10	QT interval;
LUAD	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg03433033	chr1:76189801	ACADM	0.77	12.42	0.52	2.05e-30	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7072216	0.763	rs7911036	chr10:100167015	A/T	cg26618903	chr10:100175079	PYROXD2	-0.36	-7.94	-0.36	1.8e-14	Metabolite levels;
LUAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg22907277	chr7:1156413	C7orf50	0.56	9.43	0.42	2.82e-19	Longevity;Endometriosis;
LUAD	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg26769984	chr7:1090371	C7orf50	0.45	7.95	0.36	1.77e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg04154034	chr17:28927549	LRRC37B2	0.68	6.78	0.31	4e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6024905	0.722	rs2275954	chr20:36962667	C/T	cg07053727	chr20:36965646	BPI	-0.38	-7.57	-0.35	2.4e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs1003719	0.788	rs2835576	chr21:38457393	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.34e-16	Eye color traits;
LUAD	trans	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg03929089	chr4:120376271	NA	0.59	6.81	0.31	3.43e-11	Axial length;
LUAD	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg07217954	chr7:1067459	C7orf50	-0.43	-7.34	-0.34	1.1e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs17092148	1.000	rs6060017	chr20:33313042	G/T	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.31	-0.37	1.3e-15	Neuroticism;
LUAD	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg02423579	chr7:2872169	GNA12	-0.56	-9.51	-0.42	1.42e-19	Height;
LUAD	cis	rs12348691	0.503	rs7023267	chr9:100603935	G/A	cg13688889	chr9:100608707	NA	-0.62	-10.22	-0.45	4.45e-22	Alopecia areata;
LUAD	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg13319975	chr6:146136371	FBXO30	0.6	9.82	0.43	1.26e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs16928809	0.520	rs74050440	chr11:2962443	G/T	cg01104590	chr11:3073136	CARS	0.43	6.41	0.3	3.83e-10	Bilirubin levels;
LUAD	cis	rs7688540	0.610	rs6830496	chr4:215774	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.34	6.4	0.3	4.13e-10	Facial morphology (factor 6, height of vermillion lower lip);
LUAD	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg21191810	chr6:118973309	C6orf204	-0.51	-8.09	-0.37	6.35e-15	Diastolic blood pressure;
LUAD	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg09021430	chr5:549028	NA	-0.67	-14.31	-0.57	3.8e-38	Obesity-related traits;
LUAD	trans	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg18335740	chr13:41363409	SLC25A15	0.51	9.03	0.4	5.91e-18	Lewy body disease;
LUAD	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.64	0.55	2.2e-35	Tonsillectomy;
LUAD	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg06637938	chr14:75390232	RPS6KL1	0.49	8.32	0.38	1.22e-15	Caffeine consumption;
LUAD	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg19622623	chr12:86230825	RASSF9	-0.39	-6.93	-0.32	1.58e-11	Major depressive disorder;
LUAD	cis	rs13064411	0.696	rs6798938	chr3:113218206	C/T	cg10517650	chr3:113235015	CCDC52	-0.55	-9.52	-0.42	1.31e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs8073060	0.586	rs8064895	chr17:34001121	T/C	cg19694781	chr19:47549865	TMEM160	-1.22	-19.51	-0.69	6.52e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg20673091	chr1:2541236	MMEL1	0.44	9.69	0.43	3.49e-20	Ulcerative colitis;
LUAD	cis	rs686320	1.000	rs616599	chr11:65254025	T/G	cg21890820	chr11:65308645	LTBP3	0.74	8.13	0.37	4.66e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs11811982	0.793	rs78903489	chr1:227485912	A/G	cg24860534	chr1:227506868	CDC42BPA	0.71	7.5	0.34	3.79e-13	Optic disc area;
LUAD	cis	rs62400317	0.859	rs10456546	chr6:45217424	C/T	cg18551225	chr6:44695536	NA	-0.55	-8.39	-0.38	7.19e-16	Total body bone mineral density;
LUAD	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg19046167	chr17:80928561	B3GNTL1	0.44	6.4	0.3	4.06e-10	Glycated hemoglobin levels;
LUAD	cis	rs7493	0.901	rs11767787	chr7:95026753	T/C	cg05342682	chr7:94953680	PON1	-0.53	-7.62	-0.35	1.64e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs500891	0.525	rs1361784	chr6:84090690	A/T	cg08257003	chr6:84140564	ME1	0.34	6.59	0.31	1.27e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs780096	1.000	rs780096	chr2:27741072	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.28	-7.29	-0.33	1.51e-12	Total body bone mineral density;
LUAD	cis	rs600626	0.529	rs2008476	chr11:75470813	C/T	cg24262691	chr11:75473276	NA	0.59	8.05	0.36	8.44e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	cis	rs863345	0.604	rs10908674	chr1:158503920	A/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg18806716	chr10:30721971	MAP3K8	0.66	13.45	0.55	1.39e-34	Inflammatory bowel disease;
LUAD	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg23985595	chr17:80112537	CCDC57	0.53	9.74	0.43	2.39e-20	Life satisfaction;
LUAD	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg15448220	chr1:150897856	SETDB1	0.57	9.54	0.42	1.17e-19	Melanoma;
LUAD	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg25024717	chr12:54324583	NA	-0.33	-6.67	-0.31	7.88e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg08859206	chr1:53392774	SCP2	-0.59	-10.75	-0.46	5.26e-24	Monocyte count;
LUAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg15117754	chr3:10150083	C3orf24	0.44	7.09	0.33	5.76e-12	Alzheimer's disease;
LUAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg21782813	chr7:2030301	MAD1L1	0.62	10.58	0.46	2.26e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-7.59	-0.35	2.05e-13	Tonsillectomy;
LUAD	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg02221422	chr11:68192511	LRP5	-0.4	-6.66	-0.31	8.52e-11	Total body bone mineral density;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg12703194	chr16:3086867	CCDC64B	0.39	6.69	0.31	7.23e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.36	-6.57	-0.3	1.52e-10	Caffeine consumption;
LUAD	cis	rs17102423	0.594	rs1256417	chr14:65563678	C/T	cg11161011	chr14:65562177	MAX	-0.44	-7.42	-0.34	6.49e-13	Obesity-related traits;
LUAD	cis	rs7072216	0.763	rs45523432	chr10:100167436	T/C	cg26618903	chr10:100175079	PYROXD2	-0.36	-7.93	-0.36	2.01e-14	Metabolite levels;
LUAD	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg15123519	chr2:136567270	LCT	-0.38	-7.12	-0.33	4.66e-12	Mosquito bite size;
LUAD	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg23815491	chr16:72088622	HP	-0.48	-8.52	-0.38	2.81e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg14039649	chr22:38352398	POLR2F	0.37	6.63	0.31	1.06e-10	Glioblastoma;Glioma;
LUAD	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.57	-0.3	1.45e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1467026	0.563	rs58674721	chr3:12811233	G/A	cg24848339	chr3:12840334	CAND2	0.32	6.41	0.3	3.79e-10	P wave duration;
LUAD	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg10523679	chr1:76189770	ACADM	0.9	16.25	0.62	1.77e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg15181151	chr6:150070149	PCMT1	0.42	8.72	0.39	6.26e-17	Lung cancer;
LUAD	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg07570687	chr10:102243282	WNT8B	0.47	7.2	0.33	2.76e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.53	-8.86	-0.4	2.27e-17	Cognitive ability;
LUAD	cis	rs7789940	0.904	rs73140040	chr7:75936240	C/T	cg10167463	chr7:75959203	YWHAG	-0.67	-11.7	-0.49	1.35e-27	Multiple sclerosis;
LUAD	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg25036284	chr2:26402008	FAM59B	0.84	12.53	0.52	7.64e-31	Gut microbiome composition (summer);
LUAD	cis	rs10193935	0.901	rs222479	chr2:42656857	T/G	cg27598129	chr2:42591480	NA	-0.67	-8.82	-0.39	3.14e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg07402062	chr16:89894098	SPIRE2	0.45	11.42	0.49	1.59e-26	Vitiligo;
LUAD	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06221963	chr1:154839813	KCNN3	-0.87	-21.0	-0.71	1.32e-67	Prostate cancer;
LUAD	cis	rs250585	0.920	rs250553	chr16:23441465	G/C	cg00143387	chr16:23521605	GGA2	0.6	7.44	0.34	5.62e-13	Egg allergy;
LUAD	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg07936489	chr17:37558343	FBXL20	0.45	7.09	0.33	5.8e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg22431228	chr1:16359049	CLCNKA	-0.41	-8.07	-0.37	7.51e-15	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs10802346	0.545	rs2362252	chr1:246371574	A/C	cg22732515	chr19:44031385	ETHE1	0.59	9.55	0.42	1.05e-19	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs6500395	0.926	rs7192297	chr16:48670421	G/A	cg04672837	chr16:48644449	N4BP1	0.38	6.69	0.31	7.06e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg25894440	chr7:65020034	NA	-0.62	-6.69	-0.31	6.99e-11	Diabetic kidney disease;
LUAD	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg14835575	chr10:16859367	RSU1	0.94	13.59	0.55	3.75e-35	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg07917127	chr4:99064746	C4orf37	0.44	7.3	0.33	1.43e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg06060754	chr5:176797920	RGS14	-0.55	-9.04	-0.4	5.88e-18	Urate levels in lean individuals;
LUAD	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg14343924	chr8:8086146	FLJ10661	-0.4	-6.44	-0.3	3.33e-10	Neuroticism;
LUAD	cis	rs72949976	0.934	rs1441172	chr2:214037703	C/T	cg08319019	chr2:214017104	IKZF2	-0.49	-7.43	-0.34	5.92e-13	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08704250	chr15:31115839	NA	-0.6	-10.13	-0.44	9.74e-22	Huntington's disease progression;
LUAD	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.61	8.86	0.4	2.18e-17	Gut microbiome composition (summer);
LUAD	trans	rs3960554	0.808	rs868555	chr7:75697418	G/A	cg19862616	chr7:65841803	NCRNA00174	0.82	11.17	0.48	1.45e-25	Eotaxin levels;
LUAD	cis	rs4363385	0.867	rs310103	chr1:153042554	C/A	cg07796016	chr1:152779584	LCE1C	-0.36	-6.36	-0.3	5.2400000000000005e-10	Inflammatory skin disease;
LUAD	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg20701182	chr2:24300061	SF3B14	0.68	7.64	0.35	1.51e-13	Immature fraction of reticulocytes;
LUAD	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg19346786	chr7:2764209	NA	0.5	11.02	0.47	5.37e-25	Height;
LUAD	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg09137382	chr11:130731461	NA	0.42	7.61	0.35	1.74e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10203711	0.933	rs11693286	chr2:239585278	A/T	cg14580085	chr2:239553406	NA	0.4	8.62	0.39	1.39e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1160297	0.609	rs78310136	chr2:53093171	G/A	cg07782112	chr2:53107842	NA	0.39	8.32	0.38	1.18e-15	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg15147215	chr3:52552868	STAB1	-0.39	-7.17	-0.33	3.31e-12	Bipolar disorder;
LUAD	cis	rs775227	0.574	rs13083453	chr3:113096943	G/A	cg18753928	chr3:113234510	CCDC52	-0.7	-9.25	-0.41	1.13e-18	Dental caries;
LUAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13732083	chr21:47605072	C21orf56	-0.59	-10.36	-0.45	1.41e-22	Testicular germ cell tumor;
LUAD	cis	rs1113500	0.548	rs17020971	chr1:108655288	C/A	cg06207961	chr1:108661230	NA	0.42	6.79	0.31	3.91e-11	Growth-regulated protein alpha levels;
LUAD	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg26850624	chr5:429559	AHRR	-0.42	-6.65	-0.31	9.24e-11	Cystic fibrosis severity;
LUAD	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg13699009	chr12:122356056	WDR66	0.39	8.7	0.39	7.73e-17	Mean corpuscular volume;
LUAD	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-6.98	-0.32	1.14e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs877282	0.583	rs11253441	chr10:828288	C/T	cg22713356	chr15:30763199	NA	-0.85	-11.16	-0.48	1.53e-25	Uric acid levels;
LUAD	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.51	-10.65	-0.46	1.26e-23	Monocyte percentage of white cells;
LUAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg04352962	chr1:209979756	IRF6	0.49	7.02	0.32	8.88e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs56283067	0.847	rs10456536	chr6:44692995	G/C	cg18551225	chr6:44695536	NA	-0.61	-10.16	-0.44	7.59e-22	Total body bone mineral density;
LUAD	cis	rs6743376	0.556	rs2515392	chr2:113817181	C/T	cg09040174	chr2:113837401	NA	0.52	8.06	0.37	7.7e-15	Inflammatory biomarkers;
LUAD	cis	rs16958440	0.867	rs78547658	chr18:44669852	C/T	cg17192377	chr18:44677553	HDHD2	0.84	7.85	0.36	3.48e-14	Sitting height ratio;
LUAD	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg18446336	chr7:2847575	GNA12	-0.32	-6.71	-0.31	6.26e-11	Height;
LUAD	cis	rs7000551	0.751	rs2469755	chr8:22360212	G/A	cg12081754	chr8:22256438	SLC39A14	0.47	7.83	0.36	4.06e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs1215050	0.782	rs6532693	chr4:98655815	T/C	cg05340658	chr4:99064831	C4orf37	-0.43	-7.01	-0.32	9.19e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg13877915	chr19:58951672	ZNF132	0.74	14.01	0.56	6.44e-37	Uric acid clearance;
LUAD	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg22431228	chr1:16359049	CLCNKA	-0.65	-13.26	-0.54	8.28e-34	Systolic blood pressure;
LUAD	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg01324343	chr3:183735012	ABCC5	0.93	24.38	0.76	1.25e-82	Anterior chamber depth;
LUAD	cis	rs2070488	0.662	rs6599202	chr3:38480651	T/C	cg24069376	chr3:38537580	EXOG	0.31	6.66	0.31	8.3e-11	Electrocardiographic conduction measures;
LUAD	cis	rs6446731	0.593	rs2858083	chr4:3272331	T/A	cg08886695	chr4:3369023	RGS12	-0.49	-8.22	-0.37	2.48e-15	Mean platelet volume;
LUAD	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.44	8.0	0.36	1.19e-14	Systemic lupus erythematosus;
LUAD	trans	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg14917512	chr19:3094685	GNA11	-0.57	-6.8	-0.31	3.69e-11	Diabetic kidney disease;
LUAD	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg17425144	chr1:10567563	PEX14	0.62	12.97	0.53	1.33e-32	Breast size;
LUAD	trans	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.98	-0.36	1.4e-14	Gout;
LUAD	cis	rs7252981	0.632	rs739461	chr19:19715794	T/C	cg11584989	chr19:19387371	SF4	-0.46	-7.44	-0.34	5.85e-13	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.1	-0.33	5.34e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg18827107	chr12:86230957	RASSF9	-0.71	-13.07	-0.54	4.86e-33	Major depressive disorder;
LUAD	trans	rs11039798	0.687	rs11499938	chr11:48957297	G/A	cg15704280	chr7:45808275	SEPT13	0.67	7.8	0.35	4.95e-14	Axial length;
LUAD	cis	rs2387326	0.717	rs11016102	chr10:129945154	A/G	cg16087940	chr10:129947807	NA	-0.64	-9.1	-0.4	3.62e-18	Select biomarker traits;
LUAD	cis	rs10992471	0.528	rs7022562	chr9:95216340	A/G	cg14631576	chr9:95140430	CENPP	-0.5	-10.17	-0.44	7.21e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.5	-0.45	4.5e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg00450029	chr8:599525	NA	0.73	6.8	0.31	3.6e-11	IgG glycosylation;
LUAD	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg06028605	chr16:24865363	SLC5A11	0.38	6.85	0.32	2.62e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7932354	0.528	rs7947878	chr11:47028531	C/T	cg19486271	chr11:47235900	DDB2	-0.43	-6.96	-0.32	1.32e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs2235649	0.663	rs6600168	chr16:1848927	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-8.18	-0.37	3.42e-15	Blood metabolite levels;
LUAD	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg18944383	chr4:111397179	ENPEP	0.57	10.89	0.47	1.6e-24	Height;
LUAD	cis	rs57502260	0.704	rs72936570	chr11:68307139	A/G	cg16797656	chr11:68205561	LRP5	0.45	6.57	0.3	1.52e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs1595825	0.786	rs79490184	chr2:198894219	T/A	cg00361562	chr2:198649771	BOLL	-0.47	-6.52	-0.3	1.96e-10	Ulcerative colitis;
LUAD	cis	rs9487051	0.735	rs1260594	chr6:109519891	A/C	cg01475377	chr6:109611718	NA	-0.39	-7.44	-0.34	5.78e-13	Reticulocyte fraction of red cells;
LUAD	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg15704280	chr7:45808275	SEPT13	-0.52	-8.21	-0.37	2.73e-15	HDL cholesterol;
LUAD	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg03929089	chr4:120376271	NA	-0.88	-16.94	-0.64	1.66e-49	Height;
LUAD	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg00277334	chr10:82204260	NA	-0.49	-8.03	-0.36	9.69e-15	Post bronchodilator FEV1;
LUAD	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	12.28	0.51	7.24e-30	Homoarginine levels;
LUAD	cis	rs11048434	0.698	rs1805784	chr12:9065172	G/T	cg04155231	chr12:9217510	LOC144571	0.37	6.87	0.32	2.28e-11	Sjögren's syndrome;
LUAD	cis	rs1691799	0.867	rs1168341	chr12:66759080	G/C	cg16791601	chr12:66731901	HELB	-0.37	-6.78	-0.31	3.98e-11	White blood cell count (basophil);
LUAD	trans	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg14917512	chr19:3094685	GNA11	-0.54	-6.52	-0.3	2.03e-10	Diabetic kidney disease;
LUAD	cis	rs4523957	0.614	rs7220685	chr17:2059385	A/G	cg16513277	chr17:2031491	SMG6	-0.96	-19.02	-0.68	9.6e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs11112613	0.818	rs73184093	chr12:106010066	G/C	cg03607813	chr12:105948248	NA	0.61	7.48	0.34	4.43e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs758324	0.898	rs6877358	chr5:131111360	G/A	cg06307176	chr5:131281290	NA	0.51	8.07	0.37	7.09e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg03354898	chr7:1950403	MAD1L1	-0.41	-7.37	-0.34	9.05e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs4730250	0.554	rs17428504	chr7:106914944	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-8.81	-0.39	3.25e-17	Osteoarthritis;
LUAD	cis	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg21775007	chr8:11205619	TDH	0.38	6.65	0.31	9.03e-11	Neuroticism;
LUAD	cis	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg21775007	chr8:11205619	TDH	0.36	6.36	0.3	5.28e-10	Myopia (pathological);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07567630	chr7:127776125	NA	-0.4	-6.44	-0.3	3.31e-10	Cancer;
LUAD	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.09	-0.33	5.61e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg26597838	chr10:835615	NA	1.09	17.12	0.64	2.66e-50	Eosinophil percentage of granulocytes;
LUAD	cis	rs7512552	0.809	rs1694377	chr1:150293153	A/G	cg15654264	chr1:150340011	RPRD2	0.61	11.46	0.49	1.14e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg00898013	chr13:113819073	PROZ	-0.64	-11.58	-0.49	3.98e-27	Platelet distribution width;
LUAD	cis	rs2629540	0.824	rs10901809	chr10:126410804	C/T	cg08799069	chr10:126477246	METTL10	0.45	7.16	0.33	3.59e-12	Cocaine dependence;
LUAD	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.57	-9.86	-0.43	8.65e-21	Melanoma;
LUAD	cis	rs6500395	1.000	rs6500395	chr16:48621402	T/C	cg04672837	chr16:48644449	N4BP1	0.39	6.67	0.31	8.04e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg00310523	chr12:86230176	RASSF9	0.42	8.83	0.39	2.75e-17	Major depressive disorder;
LUAD	cis	rs7191700	0.644	rs918738	chr16:11439679	C/G	cg00044050	chr16:11439710	C16orf75	-0.72	-12.29	-0.51	6.71e-30	Multiple sclerosis;
LUAD	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg18825076	chr15:78729989	IREB2	0.46	6.43	0.3	3.54e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	cis	rs7903847	0.642	rs9888026	chr10:99159869	G/T	cg20016023	chr10:99160130	RRP12	0.31	7.66	0.35	1.24e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg23029597	chr12:123009494	RSRC2	-0.53	-8.09	-0.37	6.49e-15	Body mass index;
LUAD	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.5	-7.8	-0.35	4.74e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs67073037	0.592	rs4558548	chr2:28985674	C/G	cg09522027	chr2:28974177	PPP1CB	-0.55	-8.55	-0.38	2.34e-16	Breast cancer;Breast cancer (estrogen-receptor negative);
LUAD	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg07936489	chr17:37558343	FBXL20	-0.47	-7.5	-0.34	3.76e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs9814567	0.686	rs1404289	chr3:134358109	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.73	13.31	0.54	5.16e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2404602	0.622	rs11632365	chr15:77139080	G/A	cg23625390	chr15:77176239	SCAPER	-0.47	-6.49	-0.3	2.37e-10	Blood metabolite levels;
LUAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	9.03	0.4	5.91e-18	Alzheimer's disease;
LUAD	cis	rs9768139	0.658	rs28425474	chr7:158116360	C/T	cg25566285	chr7:158114605	PTPRN2	0.53	11.24	0.48	7.86e-26	Calcium levels;
LUAD	cis	rs10979	1.000	rs34960207	chr6:143886398	C/T	cg25407410	chr6:143891975	LOC285740	-0.63	-9.97	-0.44	3.68e-21	Hypospadias;
LUAD	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	6.05e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-10.55	-0.46	3.02e-23	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg05082376	chr22:42548792	NA	0.45	7.8	0.35	4.73e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs981844	0.740	rs7653960	chr4:154697430	T/G	cg10279832	chr4:154682576	RNF175	0.36	7.43	0.34	5.89e-13	Response to statins (LDL cholesterol change);
LUAD	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg01579765	chr21:45077557	HSF2BP	-0.63	-15.12	-0.59	1.29e-41	Mean corpuscular volume;
LUAD	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	6.2e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7172809	0.573	rs13380152	chr15:77436386	A/T	cg11865553	chr15:77376250	NA	-0.38	-6.37	-0.3	4.83e-10	Glucose homeostasis traits;
LUAD	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.6	10.89	0.47	1.7e-24	Eosinophil percentage of white cells;
LUAD	trans	rs11054731	1.000	rs10845501	chr12:12415697	A/G	cg13275176	chr2:97534450	SEMA4C	0.43	6.69	0.31	7.19e-11	Coronary artery calcification;
LUAD	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg01475377	chr6:109611718	NA	-0.53	-10.06	-0.44	1.76e-21	Reticulocyte fraction of red cells;
LUAD	trans	rs17685	0.884	rs8565	chr7:75630274	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.93	-18.75	-0.67	1.61e-57	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9296092	0.517	rs3912041	chr6:33521271	T/C	cg13560919	chr6:33536144	NA	-0.89	-16.71	-0.63	1.64e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9914544	0.545	rs8071458	chr17:18790840	C/A	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.49	-0.3	2.45e-10	Educational attainment (years of education);
LUAD	cis	rs4843185	0.763	rs1974868	chr16:85710983	C/T	cg26571870	chr16:85723150	GINS2	-0.35	-6.81	-0.31	3.34e-11	Platelet distribution width;
LUAD	cis	rs7095607	0.785	rs4746731	chr10:69920924	C/A	cg18986048	chr10:69913749	MYPN	0.38	6.41	0.3	3.92e-10	Lung function (FVC);
LUAD	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.39	0.34	7.87e-13	Hypertriglyceridemia;
LUAD	cis	rs7100689	0.646	rs11202721	chr10:82135762	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.26	0.45	3.26e-22	Post bronchodilator FEV1;
LUAD	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.38	-6.74	-0.31	5.19e-11	Blood metabolite levels;
LUAD	trans	rs7944735	0.517	rs7952205	chr11:48199227	A/G	cg03929089	chr4:120376271	NA	0.59	6.65	0.31	9.1e-11	Intraocular pressure;
LUAD	cis	rs4594175	0.926	rs66625118	chr14:51631062	T/C	cg23942311	chr14:51606299	NA	0.65	11.44	0.49	1.42e-26	Cancer;
LUAD	cis	rs35771425	0.619	rs7538812	chr1:211442186	A/G	cg25617285	chr1:211431773	RCOR3	-0.51	-9.89	-0.43	6.96e-21	Educational attainment (years of education);
LUAD	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg14983838	chr19:29218262	NA	0.56	7.48	0.34	4.34e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00802000	chr16:706648	WDR90	-0.4	-7.61	-0.35	1.83e-13	Height;
LUAD	trans	rs7395662	1.000	rs10838975	chr11:48617615	C/T	cg00717180	chr2:96193071	NA	-0.4	-7.41	-0.34	7.11e-13	HDL cholesterol;
LUAD	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg06636551	chr8:101224915	SPAG1	-0.37	-6.76	-0.31	4.62e-11	Atrioventricular conduction;
LUAD	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.86	-12.08	-0.51	4.63e-29	Red cell distribution width;
LUAD	cis	rs986417	1.000	rs1254265	chr14:60840478	T/C	cg27398547	chr14:60952738	C14orf39	-0.61	-7.37	-0.34	8.96e-13	Gut microbiota (bacterial taxa);
LUAD	trans	rs225245	0.755	rs226441	chr17:34033072	C/T	cg19694781	chr19:47549865	TMEM160	-0.46	-7.66	-0.35	1.31e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs67981189	0.647	rs36555	chr14:71364561	C/T	cg15910301	chr14:71632612	NA	-0.41	-6.52	-0.3	2.04e-10	Schizophrenia;
LUAD	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg03806693	chr22:41940476	POLR3H	0.69	9.84	0.43	1.08e-20	Vitiligo;
LUAD	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.19	-0.33	2.98e-12	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg05564831	chr3:52568323	NT5DC2	0.39	7.47	0.34	4.62e-13	Bipolar disorder;
LUAD	cis	rs12765878	0.675	rs3752946	chr10:105670849	A/T	cg11005552	chr10:105648138	OBFC1	0.39	7.36	0.34	9.56e-13	Coronary artery disease;
LUAD	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg17644776	chr2:200775616	C2orf69	0.52	6.53	0.3	1.9e-10	Schizophrenia;
LUAD	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg11663144	chr21:46675770	NA	-0.6	-11.83	-0.5	4.19e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg11766577	chr21:47581405	C21orf56	-0.45	-7.79	-0.35	5.35e-14	Testicular germ cell tumor;
LUAD	trans	rs853679	0.607	rs13197574	chr6:28060239	T/C	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.09	-0.47	3.02e-25	Depression;
LUAD	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg10589385	chr1:150898437	SETDB1	0.45	8.28	0.37	1.68e-15	Melanoma;
LUAD	cis	rs9837602	1.000	rs7610486	chr3:99732564	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-7.06	-0.32	7.06e-12	Breast cancer;
LUAD	cis	rs2985684	0.789	rs1957979	chr14:50063332	A/G	cg04989706	chr14:50066350	PPIL5	-0.51	-7.55	-0.34	2.7e-13	Carotid intima media thickness;
LUAD	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg15704280	chr7:45808275	SEPT13	-0.92	-16.82	-0.63	5.47e-49	Height;
LUAD	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg06108461	chr20:60628389	TAF4	-0.94	-16.8	-0.63	6.65e-49	Body mass index;
LUAD	cis	rs4332037	0.722	rs28705934	chr7:1916116	T/A	cg25834613	chr7:1915315	MAD1L1	-0.41	-6.53	-0.3	1.87e-10	Bipolar disorder;
LUAD	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg03433033	chr1:76189801	ACADM	0.64	10.22	0.45	4.53e-22	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg11057378	chr10:81107060	PPIF	0.39	7.22	0.33	2.5e-12	Height;
LUAD	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25427524	chr10:38739819	LOC399744	-0.72	-13.44	-0.55	1.56e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg20607798	chr8:58055168	NA	0.72	9.44	0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg14917512	chr19:3094685	GNA11	0.55	6.49	0.3	2.47e-10	Diabetic kidney disease;
LUAD	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11644478	chr21:40555479	PSMG1	-0.4	-6.65	-0.31	8.89e-11	Menarche (age at onset);
LUAD	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg24829409	chr8:58192753	C8orf71	-0.55	-6.48	-0.3	2.6200000000000003e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.43e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs78663649	0.908	rs79083128	chr19:16556222	G/C	cg05286348	chr19:16641544	CHERP	-0.85	-8.55	-0.38	2.3e-16	White blood cell count;
LUAD	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.65	-9.86	-0.43	8.84e-21	Ileal carcinoids;
LUAD	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.67e-15	Bipolar disorder;
LUAD	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg04369109	chr6:150039330	LATS1	-0.44	-7.44	-0.34	5.61e-13	Lung cancer;
LUAD	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg20503657	chr10:835505	NA	-0.48	-7.52	-0.34	3.29e-13	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs4372836	0.681	rs9309664	chr2:28939626	A/G	cg09522027	chr2:28974177	PPP1CB	0.44	7.23	0.33	2.31e-12	Body mass index;
LUAD	cis	rs7705042	0.793	rs1036207	chr5:141499041	A/G	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.78	-0.31	3.98e-11	Asthma;
LUAD	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg15181151	chr6:150070149	PCMT1	0.39	7.91	0.36	2.31e-14	Lung cancer;
LUAD	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg20848291	chr7:100343083	ZAN	-0.58	-7.9	-0.36	2.41e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2286503	1.000	rs2286503	chr7:22856606	C/T	cg06496272	chr7:22895283	SNORD93	-0.4	-7.18	-0.33	3.15e-12	Fibrinogen;
LUAD	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg06873352	chr17:61820015	STRADA	0.41	6.98	0.32	1.12e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs12540874	0.542	rs3807562	chr7:50566671	G/A	cg18232548	chr7:50535776	DDC	-0.67	-12.48	-0.52	1.2e-30	Systemic sclerosis;
LUAD	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg14345882	chr6:26364793	BTN3A2	0.7	7.08	0.33	5.98e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.36	-0.45	1.48e-22	Glomerular filtration rate;
LUAD	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03352830	chr11:487213	PTDSS2	0.82	10.61	0.46	1.78e-23	Body mass index;
LUAD	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs73198271	0.740	rs10094270	chr8:8646633	G/A	cg01851573	chr8:8652454	MFHAS1	0.48	8.54	0.38	2.53e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2066819	1.000	rs17118439	chr12:56667604	C/T	cg26714650	chr12:56694279	CS	0.71	6.48	0.3	2.51e-10	Psoriasis vulgaris;
LUAD	cis	rs7737355	0.947	rs10463887	chr5:130776854	C/G	cg25547332	chr5:131281432	NA	-0.41	-6.35	-0.3	5.48e-10	Life satisfaction;
LUAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11905131	chr22:24372483	LOC391322	-0.56	-9.64	-0.42	5.16e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg11822812	chr5:140052017	DND1	-0.35	-6.37	-0.3	4.92e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg23815491	chr16:72088622	HP	0.52	9.56	0.42	9.44e-20	Fibrinogen levels;
LUAD	cis	rs13064411	0.518	rs6769604	chr3:113185064	A/G	cg10517650	chr3:113235015	CCDC52	-0.37	-7.2	-0.33	2.74e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs117623576	0.941	rs72778753	chr10:32426579	A/T	cg03047570	chr10:32398778	NA	-0.76	-9.53	-0.42	1.25e-19	Anti-saccade response;
LUAD	cis	rs12200560	0.505	rs211172	chr6:97070691	C/A	cg06623918	chr6:96969491	KIAA0776	0.46	7.05	0.32	7.27e-12	Coronary heart disease;
LUAD	trans	rs2797160	1.000	rs6910933	chr6:126017155	C/G	cg05039488	chr6:79577232	IRAK1BP1	0.55	8.68	0.39	8.39e-17	Endometrial cancer;
LUAD	cis	rs2286503	0.839	rs1054471	chr7:22852643	T/A	cg06496272	chr7:22895283	SNORD93	-0.39	-6.95	-0.32	1.4e-11	Fibrinogen;
LUAD	cis	rs13095912	1.000	rs13095912	chr3:185302098	G/A	cg11274856	chr3:185301563	NA	0.38	7.53	0.34	3.02e-13	Systolic blood pressure;
LUAD	cis	rs2692947	0.826	rs7423942	chr2:96645257	G/A	cg23100626	chr2:96804247	ASTL	0.29	7.64	0.35	1.47e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg06671706	chr8:8559999	CLDN23	0.65	11.28	0.48	5.66e-26	Obesity-related traits;
LUAD	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg05234568	chr11:5960015	NA	-0.51	-9.06	-0.4	4.91e-18	DNA methylation (variation);
LUAD	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.8	-0.31	3.48e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg18230493	chr5:56204884	C5orf35	0.7	11.31	0.48	4.27e-26	Initial pursuit acceleration;
LUAD	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg16686185	chr17:78078845	GAA	-0.39	-6.39	-0.3	4.45e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.92	0.36	2.07e-14	Depression;
LUAD	cis	rs1160297	0.575	rs10865272	chr2:53093447	C/T	cg07782112	chr2:53107842	NA	0.36	7.54	0.34	2.84e-13	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg02493740	chr2:85810744	VAMP5	-0.46	-8.37	-0.38	8.21e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg00757033	chr12:89920650	WDR51B	0.68	11.48	0.49	9.47e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg21475434	chr5:93447410	FAM172A	0.73	8.23	0.37	2.31e-15	Diabetic retinopathy;
LUAD	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg09904177	chr6:26538194	HMGN4	0.44	7.29	0.33	1.52e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4638749	0.734	rs6722745	chr2:108875244	C/T	cg25838818	chr2:108905173	SULT1C2	0.39	6.85	0.32	2.64e-11	Blood pressure;
LUAD	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg05616858	chr17:37843591	ERBB2;PGAP3	0.34	6.76	0.31	4.52e-11	Asthma;
LUAD	cis	rs7927771	0.542	rs10769300	chr11:47865560	C/T	cg18512352	chr11:47633146	NA	0.36	6.39	0.3	4.37e-10	Subjective well-being;
LUAD	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs7582720	1.000	rs72926779	chr2:203805929	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg04414720	chr1:150670196	GOLPH3L	0.73	12.8	0.53	6.25e-32	Melanoma;
LUAD	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18876405	chr7:65276391	NA	-0.44	-6.91	-0.32	1.83e-11	Aortic root size;
LUAD	cis	rs1816752	0.774	rs2862895	chr13:24984466	T/A	cg02811702	chr13:24901961	NA	0.42	7.28	0.33	1.61e-12	Obesity-related traits;
LUAD	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg01689657	chr7:91764605	CYP51A1	-0.31	-7.53	-0.34	3.17e-13	Breast cancer;
LUAD	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.53	-0.3	1.92e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg23758822	chr17:41437982	NA	0.99	20.42	0.7	5.13e-65	Menopause (age at onset);
LUAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.63	-10.86	-0.47	2.04e-24	Lymphocyte counts;
LUAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg24846343	chr22:24311635	DDTL	0.84	20.88	0.71	4.48e-67	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs17026425	1.000	rs953553	chr4:150668027	C/T	cg12328660	chr3:119896128	GPR156	-0.45	-6.35	-0.3	5.57e-10	Survival in rectal cancer;
LUAD	cis	rs7493	0.901	rs11767787	chr7:95026753	T/C	cg01874867	chr7:94954059	PON1	-0.53	-7.46	-0.34	4.95e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg24733560	chr20:60626293	TAF4	0.46	8.88	0.4	2e-17	Body mass index;
LUAD	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg11822812	chr5:140052017	DND1	0.38	6.84	0.32	2.76e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7274811	0.744	rs3746460	chr20:32248163	C/T	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.47	-6.73	-0.31	5.43e-11	Height;
LUAD	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg19318889	chr4:1322082	MAEA	0.88	14.75	0.58	5.09e-40	Longevity;
LUAD	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg04842962	chr6:43655489	MRPS18A	0.93	17.48	0.65	7.07e-52	IgG glycosylation;
LUAD	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs657075	0.595	rs4877	chr5:131607588	G/T	cg21138405	chr5:131827807	IRF1	0.47	6.4	0.3	4.25e-10	Rheumatoid arthritis;
LUAD	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	-0.35	-6.75	-0.31	4.95e-11	Menopause (age at onset);
LUAD	cis	rs6743376	0.556	rs1530553	chr2:113818171	G/A	cg09040174	chr2:113837401	NA	0.52	8.0	0.36	1.17e-14	Inflammatory biomarkers;
LUAD	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.76	0.53	9e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.68	12.96	0.53	1.39e-32	Cognitive ability;
LUAD	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg26022315	chr17:47021804	SNF8	0.4	7.3	0.33	1.46e-12	Type 2 diabetes;
LUAD	cis	rs2806561	0.929	rs2903545	chr1:23541108	C/T	cg19743168	chr1:23544995	NA	-0.45	-8.39	-0.38	7.55e-16	Height;
LUAD	trans	rs629535	0.814	rs62513373	chr8:70080753	C/T	cg21567404	chr3:27674614	NA	-0.98	-18.0	-0.66	3.4e-54	Dupuytren's disease;
LUAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg11301795	chr4:187892539	NA	0.76	15.34	0.6	1.5e-42	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg00776166	chr8:613548	NA	0.56	6.46	0.3	2.93e-10	IgG glycosylation;
LUAD	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.2	-0.44	5.31e-22	Migraine;Coronary artery disease;
LUAD	trans	rs8073060	0.614	rs225275	chr17:33972567	G/C	cg19694781	chr19:47549865	TMEM160	-1.24	-19.49	-0.69	7.52e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs4389656	0.857	rs274699	chr5:6730332	A/C	cg10857441	chr5:6722123	POLS	-0.47	-8.0	-0.36	1.18e-14	Coronary artery disease;
LUAD	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg08632164	chr7:65971372	NA	-0.55	-6.37	-0.3	4.93e-10	Diabetic kidney disease;
LUAD	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-7.51	-0.34	3.56e-13	Lung cancer;
LUAD	cis	rs28374715	0.662	rs72737793	chr15:41516823	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.9	-16.82	-0.63	5.57e-49	Ulcerative colitis;
LUAD	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs4077468	0.927	rs1342063	chr1:205912859	C/T	cg14893161	chr1:205819251	PM20D1	-0.37	-6.57	-0.3	1.45e-10	Cystic fibrosis-related diabetes;
LUAD	cis	rs62238980	0.614	rs79526483	chr22:32539822	T/G	cg00543991	chr22:32367038	NA	0.93	8.06	0.36	7.97e-15	Childhood ear infection;
LUAD	cis	rs684232	0.666	rs838373	chr17:567171	T/C	cg15660573	chr17:549704	VPS53	-0.79	-15.27	-0.6	3e-42	Prostate cancer;
LUAD	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23583168	chr7:148888333	NA	-1.0	-23.8	-0.76	4.52e-80	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg02421172	chr7:1938701	MAD1L1	0.44	6.42	0.3	3.67e-10	Bipolar disorder;
LUAD	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg13334819	chr7:99746414	C7orf59	0.69	10.77	0.46	4.45e-24	Coronary artery disease;
LUAD	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg05110241	chr16:68378359	PRMT7	-0.87	-9.29	-0.41	7.97e-19	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg16988262	chr1:15930761	NA	0.41	6.85	0.32	2.61e-11	Systolic blood pressure;
LUAD	cis	rs427941	0.703	rs201447	chr7:101738384	C/A	cg06246474	chr7:101738831	CUX1	0.41	7.26	0.33	1.87e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg26384229	chr12:38710491	ALG10B	-0.42	-7.24	-0.33	2.17e-12	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.02	0.32	9.13e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9302690	1.000	rs16957051	chr16:57468408	C/T	cg27017172	chr16:57497170	POLR2C	-1.1	-10.18	-0.44	6.57e-22	Blood protein levels;
LUAD	cis	rs12049351	0.774	rs754023	chr1:229637503	A/T	cg11742688	chr1:229674241	ABCB10	-0.43	-7.03	-0.32	8.11e-12	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs11771526	0.901	rs11773754	chr7:32304801	A/G	cg27532318	chr7:32358331	NA	0.59	7.51	0.34	3.57e-13	Body mass index;
LUAD	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg21252483	chr19:49399788	TULP2	-0.7	-11.76	-0.5	7.96e-28	Red cell distribution width;
LUAD	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg22676075	chr6:135203613	NA	-0.39	-7.21	-0.33	2.66e-12	Red blood cell count;
LUAD	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg12292205	chr6:26970375	C6orf41	-0.39	-6.79	-0.31	3.82e-11	Schizophrenia;
LUAD	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.08e-11	Depression;
LUAD	cis	rs2637266	1.000	rs7900616	chr10:78367075	C/T	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.72e-11	Pulmonary function;
LUAD	cis	rs56161922	1.000	rs74401244	chr1:207844799	T/C	cg11752769	chr1:207818423	CR1L	-0.67	-7.0	-0.32	9.84e-12	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg05283184	chr6:79620031	NA	-0.61	-12.41	-0.52	2.33e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs7301016	1.000	rs11614022	chr12:62891329	A/G	cg11441379	chr12:63026424	NA	0.53	6.52	0.3	1.97e-10	IgG glycosylation;
LUAD	cis	rs599083	0.590	rs661988	chr11:68189251	T/G	cg01657329	chr11:68192670	LRP5	-0.42	-6.4	-0.3	4.07e-10	Bone mineral density (spine);
LUAD	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg20701182	chr2:24300061	SF3B14	0.64	7.24	0.33	2.19e-12	Lymphocyte counts;
LUAD	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg15017067	chr4:17643749	FAM184B	-0.36	-7.15	-0.33	3.84e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg18230493	chr5:56204884	C5orf35	-0.44	-7.48	-0.34	4.43e-13	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.39	-7.74	-0.35	7.52e-14	Menarche (age at onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19343871	chr19:48103651	NA	-0.41	-6.56	-0.3	1.6e-10	Height;
LUAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.56	-10.57	-0.46	2.45e-23	Longevity;Endometriosis;
LUAD	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg06627628	chr2:24431161	ITSN2	-0.69	-10.99	-0.47	6.81e-25	Asthma;
LUAD	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg19442545	chr10:75533431	FUT11	-0.47	-7.7	-0.35	1e-13	Inflammatory bowel disease;
LUAD	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg09323728	chr8:95962352	TP53INP1	-0.33	-7.97	-0.36	1.45e-14	Type 2 diabetes;
LUAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08219700	chr8:58056026	NA	0.58	7.99	0.36	1.33e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs751837	0.591	rs12100549	chr14:103417030	C/T	cg10087771	chr14:103399429	CDC42BPB	0.65	7.28	0.33	1.65e-12	Large B-cell lymphoma;
LUAD	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg17346650	chr17:80929145	B3GNTL1	0.39	6.83	0.32	2.89e-11	Glycated hemoglobin levels;
LUAD	cis	rs7246657	0.943	rs13343471	chr19:37932130	A/G	cg23950597	chr19:37808831	NA	-0.65	-7.4	-0.34	7.17e-13	Coronary artery calcification;
LUAD	cis	rs17155006	0.664	rs440938	chr7:107741092	C/G	cg05962710	chr7:107745446	LAMB4	-0.35	-7.32	-0.34	1.29e-12	Pneumococcal bacteremia;
LUAD	cis	rs427394	0.659	rs274675	chr5:6755319	C/T	cg10857441	chr5:6722123	POLS	-0.61	-11.17	-0.48	1.47e-25	Menopause (age at onset);
LUAD	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg15181151	chr6:150070149	PCMT1	0.39	7.84	0.36	3.79e-14	Lung cancer;
LUAD	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.21	0.33	2.6e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg00784671	chr22:46762841	CELSR1	-0.43	-6.65	-0.31	9.02e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7809950	1.000	rs2520265	chr7:107181231	A/G	cg23024343	chr7:107201750	COG5	-0.72	-11.97	-0.5	1.23e-28	Coronary artery disease;
LUAD	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg23985595	chr17:80112537	CCDC57	-0.53	-9.52	-0.42	1.3e-19	Life satisfaction;
LUAD	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg16329650	chr2:213403929	ERBB4	-0.42	-7.09	-0.33	5.61e-12	Symmetrical dimethylarginine levels;
LUAD	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg01236616	chr12:121019343	POP5	-1.22	-18.76	-0.67	1.37e-57	Type 1 diabetes nephropathy;
LUAD	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-23.63	-0.75	2.46e-79	Height;
LUAD	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg11494091	chr17:61959527	GH2	0.43	8.35	0.38	9.99e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg17971929	chr21:40555470	PSMG1	0.54	8.42	0.38	6.09e-16	Cognitive function;
LUAD	cis	rs798554	0.629	rs2533875	chr7:2882829	G/A	cg09658497	chr7:2847517	GNA12	-0.41	-7.17	-0.33	3.42e-12	Height;
LUAD	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg05132306	chr1:1846340	CALML6	-0.34	-7.3	-0.33	1.42e-12	Body mass index;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01630567	chr9:26892919	C9orf82	-0.44	-6.84	-0.32	2.78e-11	Height;
LUAD	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg00933542	chr6:150070202	PCMT1	0.43	9.19	0.41	1.84e-18	Lung cancer;
LUAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	cis	rs2806561	0.734	rs10799788	chr1:23356864	G/A	cg12483005	chr1:23474871	LUZP1	0.43	6.91	0.32	1.78e-11	Height;
LUAD	cis	rs2625529	0.652	rs2278987	chr15:72409769	T/C	cg16672083	chr15:72433130	SENP8	0.64	12.04	0.51	6.46e-29	Red blood cell count;
LUAD	cis	rs9902453	0.872	rs34698290	chr17:28500465	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.48	0.38	3.67e-16	Coffee consumption (cups per day);
LUAD	cis	rs4253772	0.872	rs41362646	chr22:46633505	G/A	cg09491104	chr22:46646882	C22orf40	-0.5	-6.84	-0.32	2.71e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7843479	0.601	rs878873	chr8:21834581	T/C	cg03445287	chr8:21823731	XPO7	-0.48	-8.91	-0.4	1.51e-17	Mean corpuscular volume;
LUAD	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg11845111	chr2:191398756	TMEM194B	0.88	11.44	0.49	1.34e-26	Diastolic blood pressure;
LUAD	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg01851573	chr8:8652454	MFHAS1	0.43	7.74	0.35	7.56e-14	Mood instability;
LUAD	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.79	-0.39	3.85e-17	Total body bone mineral density;
LUAD	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg07936489	chr17:37558343	FBXL20	-0.42	-6.6	-0.31	1.2e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs7267979	1.000	rs422424	chr20:25445446	G/C	cg08601574	chr20:25228251	PYGB	0.47	8.7	0.39	7.19e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.4	-6.39	-0.3	4.3e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs17092148	0.943	rs4911160	chr20:33349940	G/A	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.19	-0.37	3.09e-15	Neuroticism;
LUAD	cis	rs3820068	0.705	rs4645992	chr1:15849742	G/T	cg24675056	chr1:15929824	NA	0.44	6.87	0.32	2.33e-11	Systolic blood pressure;
LUAD	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg00204512	chr16:28754710	NA	0.35	7.77	0.35	6.09e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg04546413	chr19:29218101	NA	0.71	10.08	0.44	1.41e-21	Methadone dose in opioid dependence;
LUAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg21724239	chr8:58056113	NA	-0.62	-7.95	-0.36	1.7e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9796	0.689	rs692153	chr15:41452681	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.43	-7.72	-0.35	8.42e-14	Menopause (age at onset);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg05370988	chr3:186500739	EIF4A2	-0.4	-6.94	-0.32	1.52e-11	Subcortical brain region volumes;
LUAD	cis	rs7617773	0.817	rs9819094	chr3:48319558	C/T	cg11946769	chr3:48343235	NME6	0.42	6.8	0.31	3.61e-11	Coronary artery disease;
LUAD	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg05283184	chr6:79620031	NA	-0.61	-12.41	-0.52	2.26e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs739496	0.793	rs76604970	chr12:111967155	A/T	cg10833066	chr12:111807467	FAM109A	0.41	6.55	0.3	1.68e-10	Platelet count;
LUAD	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg13385794	chr1:248469461	NA	0.26	7.04	0.32	7.92e-12	Common traits (Other);
LUAD	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.58	0.35	2.25e-13	Morning vs. evening chronotype;
LUAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.65	-8.22	-0.37	2.45e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7692976	0.552	rs62325266	chr4:110941216	G/A	cg06981781	chr4:110842888	EGF	-0.41	-7.1	-0.33	5.43e-12	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs7918232	0.662	rs10741125	chr10:27288925	G/A	cg14240646	chr10:27532245	ACBD5	-0.66	-9.66	-0.43	4.3e-20	Breast cancer;
LUAD	cis	rs4774899	0.932	rs12902170	chr15:57522836	G/A	cg14026238	chr15:57616123	NA	0.35	6.65	0.31	9.24e-11	Urinary tract infection frequency;
LUAD	cis	rs7089973	0.934	rs12771956	chr10:116576228	C/G	cg25233709	chr10:116636983	FAM160B1	0.37	6.54	0.3	1.78e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg00666640	chr1:248458726	OR2T12	0.32	7.71	0.35	9.24e-14	Common traits (Other);
LUAD	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg27170947	chr2:26402098	FAM59B	-0.63	-8.92	-0.4	1.46e-17	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg03676636	chr4:99064102	C4orf37	0.32	8.24	0.37	2.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1997103	0.954	rs6593235	chr7:55410986	A/G	cg17469321	chr7:55412551	NA	0.68	11.48	0.49	9.66e-27	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1215050	0.791	rs165241	chr4:98681112	C/T	cg05340658	chr4:99064831	C4orf37	0.43	7.01	0.32	9.19e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg17644776	chr2:200775616	C2orf69	0.49	6.83	0.31	3.06e-11	Schizophrenia;
LUAD	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.9	-0.32	1.93e-11	Mood instability;
LUAD	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg14634687	chr17:47094252	IGF2BP1	0.27	6.83	0.32	2.89e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg08027265	chr7:2291960	NA	-0.4	-6.7	-0.31	6.74e-11	Testicular germ cell tumor;
LUAD	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.21e-16	Prostate cancer;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg21605986	chr5:175788725	KIAA1191	-0.37	-6.7	-0.31	6.51e-11	Subcortical brain region volumes;
LUAD	cis	rs2730260	0.537	rs73169238	chr7:158883818	G/A	cg13710308	chr7:158854763	VIPR2	-0.51	-6.43	-0.3	3.49e-10	Myopia (pathological);
LUAD	cis	rs2235649	0.753	rs4316755	chr16:1849916	T/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.4	-6.42	-0.3	3.7e-10	Blood metabolite levels;
LUAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.34	0.45	1.77e-22	Prudent dietary pattern;
LUAD	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg22823121	chr1:150693482	HORMAD1	-0.38	-7.48	-0.34	4.4e-13	Tonsillectomy;
LUAD	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg20607798	chr8:58055168	NA	0.68	8.88	0.4	1.91e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9644630	0.841	rs4292704	chr8:19329303	G/C	cg06699216	chr8:19333253	CSGALNACT1	-0.33	-8.14	-0.37	4.34e-15	Oropharynx cancer;
LUAD	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg18827107	chr12:86230957	RASSF9	-0.53	-9.21	-0.41	1.56e-18	Major depressive disorder;
LUAD	trans	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg07211511	chr3:129823064	LOC729375	0.65	9.27	0.41	9.39e-19	Blood pressure (smoking interaction);
LUAD	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg21427119	chr20:30132790	HM13	-0.5	-8.02	-0.36	1.04e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs68170813	0.559	rs17428126	chr7:106897037	C/T	cg23024343	chr7:107201750	COG5	0.49	7.19	0.33	2.99e-12	Coronary artery disease;
LUAD	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg07905836	chr2:113190072	RGPD8;RGPD5	0.81	9.36	0.41	4.92e-19	Yeast infection;
LUAD	cis	rs68170813	0.559	rs6963917	chr7:106953427	T/G	cg23024343	chr7:107201750	COG5	0.5	7.2	0.33	2.82e-12	Coronary artery disease;
LUAD	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg19729930	chr2:74357872	NA	0.89	16.58	0.63	6.37e-48	Gestational age at birth (maternal effect);
LUAD	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg07828340	chr4:882639	GAK	1.05	10.84	0.47	2.47e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.19	-0.41	1.77e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs367943	0.712	rs26959	chr5:112736615	A/G	cg12552261	chr5:112820674	MCC	0.46	8.79	0.39	3.86e-17	Type 2 diabetes;
LUAD	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg02931644	chr1:25747376	RHCE	0.5	10.85	0.47	2.21e-24	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs3106136	0.934	rs34396188	chr4:95191292	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-7.07	-0.32	6.61e-12	Capecitabine sensitivity;
LUAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-9.45	-0.42	2.36e-19	Alzheimer's disease;
LUAD	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs11948739	0.573	rs736046	chr5:130278613	A/G	cg08523029	chr5:130500466	HINT1	0.58	7.45	0.34	5.42e-13	Pediatric bone mineral content (hip);
LUAD	cis	rs7617773	0.815	rs6793150	chr3:48351560	G/A	cg11946769	chr3:48343235	NME6	0.44	6.79	0.31	3.79e-11	Coronary artery disease;
LUAD	cis	rs2901656	0.583	rs6702667	chr1:172400484	A/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.42	8.09	0.37	6.45e-15	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs9323205	0.798	rs11157805	chr14:51658390	C/G	cg23942311	chr14:51606299	NA	0.55	9.81	0.43	1.28e-20	Cancer;
LUAD	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg06611532	chr13:114900021	NA	0.35	8.23	0.37	2.41e-15	Schizophrenia;
LUAD	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg18721089	chr20:30220636	NA	-0.42	-6.64	-0.31	9.37e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg23719950	chr11:63933701	MACROD1	-0.55	-6.67	-0.31	7.99e-11	Mean platelet volume;
LUAD	cis	rs55665837	0.665	rs11023273	chr11:14630819	G/A	cg19336497	chr11:14380999	RRAS2	-0.4	-7.14	-0.33	3.99e-12	Vitamin D levels;
LUAD	cis	rs3764563	0.935	rs667386	chr19:15695617	T/C	cg20725493	chr19:15740067	CYP4F8	0.61	6.53	0.3	1.92e-10	Inflammatory biomarkers;
LUAD	cis	rs7043114	0.507	rs6479420	chr9:95116406	T/C	cg14631576	chr9:95140430	CENPP	-0.42	-8.52	-0.38	2.89e-16	Height;
LUAD	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg25817165	chr18:72167213	CNDP2	-0.69	-10.4	-0.45	1.04e-22	Refractive error;
LUAD	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	8.61	0.39	1.47e-16	Lung cancer in ever smokers;
LUAD	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg10518543	chr12:38710700	ALG10B	-0.45	-7.41	-0.34	6.77e-13	Morning vs. evening chronotype;
LUAD	cis	rs736801	0.521	rs41525648	chr5:131827775	A/G	cg02551604	chr5:131831745	NA	0.51	8.31	0.37	1.35e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg17173187	chr15:85201210	NMB	0.55	9.78	0.43	1.73e-20	Schizophrenia;
LUAD	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg05926928	chr17:57297772	GDPD1	1.39	17.2	0.64	1.21e-50	Opioid sensitivity;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg06443542	chr10:100206752	HPS1	-0.36	-6.37	-0.3	4.88e-10	Schizophrenia;
LUAD	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.73	-0.5	1.03e-27	Mean corpuscular volume;
LUAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg15117754	chr3:10150083	C3orf24	0.45	7.38	0.34	8.61e-13	Alzheimer's disease;
LUAD	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg00204512	chr16:28754710	NA	0.35	7.49	0.34	4.06e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg14829155	chr15:31115871	NA	-0.59	-9.8	-0.43	1.45e-20	Huntington's disease progression;
LUAD	cis	rs758324	0.773	rs2404777	chr5:131172803	C/A	cg25547332	chr5:131281432	NA	0.42	6.88	0.32	2.11e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg02176678	chr2:219576539	TTLL4	0.74	14.81	0.58	2.93e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-11.02	-0.47	5.27e-25	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg18252515	chr7:66147081	NA	0.59	6.66	0.31	8.52e-11	Diabetic kidney disease;
LUAD	cis	rs1595825	0.838	rs80172713	chr2:198508044	T/C	cg00982548	chr2:198649783	BOLL	-0.61	-8.63	-0.39	1.29e-16	Ulcerative colitis;
LUAD	cis	rs56283067	0.887	rs12202698	chr6:44784724	G/T	cg18551225	chr6:44695536	NA	-0.49	-7.57	-0.35	2.43e-13	Total body bone mineral density;
LUAD	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg20476274	chr7:133979776	SLC35B4	-0.66	-11.46	-0.49	1.11e-26	Mean platelet volume;
LUAD	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg00717180	chr2:96193071	NA	-0.45	-8.65	-0.39	1.12e-16	HDL cholesterol;
LUAD	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21659725	chr3:3221576	CRBN	0.69	11.11	0.48	2.52e-25	Resting heart rate;
LUAD	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg05731713	chr7:157510257	PTPRN2	0.43	10.02	0.44	2.34e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7851660	0.527	rs7870540	chr9:100573925	T/C	cg13688889	chr9:100608707	NA	-0.62	-10.69	-0.46	8.74e-24	Strep throat;
LUAD	cis	rs1950626	0.699	rs12880424	chr14:101459660	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.42	7.3	0.33	1.46e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs7474896	0.583	rs34185758	chr10:37990854	T/C	cg25427524	chr10:38739819	LOC399744	-0.62	-8.62	-0.39	1.35e-16	Obesity (extreme);
LUAD	trans	rs264537	0.565	rs1816957	chr3:76703866	G/T	cg17605604	chr5:102612899	C5orf30	0.42	6.43	0.3	3.53e-10	Periodontitis (PAL4Q3);
LUAD	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg16414030	chr3:133502952	NA	-0.52	-9.1	-0.4	3.47e-18	Iron status biomarkers;
LUAD	cis	rs367615	0.537	rs431669	chr5:108663115	G/A	cg17395555	chr5:108820864	NA	0.52	9.8	0.43	1.48e-20	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.28	-0.48	5.38e-26	Bone mineral density;
LUAD	cis	rs11264213	0.591	rs274755	chr1:36544237	T/C	cg27506609	chr1:36549197	TEKT2	-0.71	-6.57	-0.3	1.47e-10	Schizophrenia;
LUAD	cis	rs11195062	0.766	rs7922679	chr10:112014428	T/G	cg19214408	chr10:111981687	MXI1	-0.39	-6.48	-0.3	2.53e-10	Multiple myeloma;
LUAD	cis	rs751728	1.000	rs6925273	chr6:33732448	A/G	cg13859433	chr6:33739653	LEMD2	-0.4	-9.43	-0.42	2.66e-19	Crohn's disease;
LUAD	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg14092571	chr14:90743983	NA	-0.51	-8.92	-0.4	1.37e-17	Mortality in heart failure;
LUAD	trans	rs11039798	0.764	rs11039771	chr11:48513273	C/T	cg03929089	chr4:120376271	NA	0.57	6.58	0.3	1.39e-10	Axial length;
LUAD	cis	rs4767364	0.961	rs10850024	chr12:112718510	C/A	cg10833066	chr12:111807467	FAM109A	0.35	6.51	0.3	2.09e-10	Oral cavity and pharyngeal cancer;
LUAD	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg04539111	chr16:67997858	SLC12A4	-0.56	-6.96	-0.32	1.28e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs412658	0.504	rs17769372	chr19:22114704	T/C	cg17074339	chr11:11642133	GALNTL4	-0.39	-7.14	-0.33	4.06e-12	Telomere length;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01297674	chr2:122406765	CLASP1	-0.42	-6.44	-0.3	3.26e-10	Height;
LUAD	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22857025	chr5:266934	NA	-1.01	-12.74	-0.53	1.08e-31	Breast cancer;
LUAD	cis	rs7216064	1.000	rs12602655	chr17:65909442	A/G	cg08758996	chr17:66097529	LOC651250	0.48	7.24	0.33	2.08e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg17346650	chr17:80929145	B3GNTL1	0.41	7.16	0.33	3.53e-12	Glycated hemoglobin levels;
LUAD	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg15017067	chr4:17643749	FAM184B	0.35	6.9	0.32	1.89e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs870825	0.616	rs6844588	chr4:185644517	T/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg11707310	chr1:2537719	MMEL1	-0.39	-8.24	-0.37	2.24e-15	Ulcerative colitis;
LUAD	cis	rs938554	0.657	rs7660895	chr4:9985445	A/G	cg02734326	chr4:10020555	SLC2A9	0.46	7.18	0.33	3.14e-12	Blood metabolite levels;
LUAD	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg11833968	chr6:79620685	NA	-0.44	-8.13	-0.37	4.8e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg23803603	chr1:2058230	PRKCZ	0.4	7.17	0.33	3.42e-12	Height;
LUAD	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg00071950	chr4:10020882	SLC2A9	0.79	15.96	0.61	3.17e-45	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg10556349	chr10:835070	NA	-0.41	-6.53	-0.3	1.89e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24838063	chr12:130822603	PIWIL1	0.64	10.7	0.46	8.19e-24	Menopause (age at onset);
LUAD	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg14092988	chr3:52407081	DNAH1	0.34	6.81	0.31	3.38e-11	Bipolar disorder;
LUAD	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg18225595	chr11:63971243	STIP1	0.39	6.82	0.31	3.12e-11	Platelet count;
LUAD	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg06484146	chr7:12443880	VWDE	-0.61	-7.65	-0.35	1.41e-13	Coronary artery disease;
LUAD	cis	rs8027181	0.682	rs11637168	chr15:73100694	C/A	cg25632853	chr15:73088954	NA	0.31	6.75	0.31	4.85e-11	Triglyceride levels;
LUAD	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg22598563	chr5:131563921	P4HA2	-0.34	-8.62	-0.39	1.35e-16	Blood metabolite levels;
LUAD	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.59	-0.35	2.08e-13	Personality dimensions;
LUAD	cis	rs2235544	0.664	rs41366847	chr1:54476967	C/G	cg25741118	chr1:54482237	LDLRAD1	-0.24	-6.65	-0.31	9.13e-11	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUAD	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg05805236	chr11:65401703	PCNXL3	-0.52	-8.61	-0.39	1.49e-16	Acne (severe);
LUAD	cis	rs6489882	0.703	rs10850097	chr12:113361117	C/T	cg20102336	chr12:113376681	OAS3	-0.5	-7.63	-0.35	1.61e-13	Chronic lymphocytic leukemia;
LUAD	trans	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.26	-0.37	1.93e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg07930552	chr6:133119739	C6orf192	0.65	7.91	0.36	2.28e-14	Type 2 diabetes nephropathy;
LUAD	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg17724175	chr1:150552817	MCL1	0.31	7.16	0.33	3.56e-12	Melanoma;
LUAD	cis	rs2131877	0.956	rs60023213	chr3:194870505	A/T	cg19760965	chr3:194868843	C3orf21	0.41	6.83	0.31	3.05e-11	Non-small cell lung cancer;
LUAD	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg00857998	chr1:205179979	DSTYK	0.41	6.75	0.31	4.75e-11	Red blood cell count;
LUAD	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg18404041	chr3:52824283	ITIH1	0.42	7.64	0.35	1.45e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg06547715	chr2:218990976	CXCR2	0.28	6.72	0.31	6.03e-11	Colorectal cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07421368	chr2:67624930	ETAA1	-0.47	-7.41	-0.34	6.7e-13	Height;
LUAD	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg02696790	chr15:75250997	RPP25	0.38	7.07	0.33	6.36e-12	Breast cancer;
LUAD	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg18180107	chr4:99064573	C4orf37	0.42	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs57994353	0.861	rs3812591	chr9:139341612	C/T	cg14019695	chr9:139328340	INPP5E	-0.38	-6.5	-0.3	2.29e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg26384229	chr12:38710491	ALG10B	0.47	7.64	0.35	1.48e-13	Morning vs. evening chronotype;
LUAD	cis	rs6087990	0.899	rs998382	chr20:31384136	C/T	cg13636640	chr20:31349939	DNMT3B	-0.78	-14.63	-0.58	1.65e-39	Ulcerative colitis;
LUAD	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg03609598	chr5:56110824	MAP3K1	0.67	8.58	0.38	1.88e-16	Initial pursuit acceleration;
LUAD	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.41	6.39	0.3	4.28e-10	Schizophrenia;
LUAD	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg26924012	chr15:45694286	SPATA5L1	1.02	18.99	0.68	1.33e-58	Homoarginine levels;
LUAD	cis	rs9296092	0.538	rs62407564	chr6:33534010	C/T	cg13560919	chr6:33536144	NA	-0.9	-16.07	-0.62	1.02e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.25	0.33	2e-12	Blood metabolite levels;
LUAD	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	6.91	0.32	1.83e-11	Tonsillectomy;
LUAD	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg05535760	chr7:792225	HEATR2	0.81	10.16	0.44	7.51e-22	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.38	-0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg17644776	chr2:200775616	C2orf69	-0.53	-7.23	-0.33	2.32e-12	Schizophrenia;
LUAD	cis	rs6484504	0.576	rs169623	chr11:31184157	T/C	cg26647111	chr11:31128758	NA	-0.47	-8.31	-0.37	1.33e-15	Red blood cell count;
LUAD	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.77	-0.31	4.31e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg18230493	chr5:56204884	C5orf35	-0.47	-7.81	-0.35	4.66e-14	Coronary artery disease;
LUAD	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg13319975	chr6:146136371	FBXO30	0.58	9.38	0.42	4e-19	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg06606381	chr12:133084897	FBRSL1	-0.67	-7.04	-0.32	7.83e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg06636001	chr8:8085503	FLJ10661	0.44	7.03	0.32	8.09e-12	Mood instability;
LUAD	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg08470875	chr2:26401718	FAM59B	0.78	10.78	0.46	4.1e-24	Gut microbiome composition (summer);
LUAD	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg14092988	chr3:52407081	DNAH1	0.44	8.87	0.4	2.04e-17	Bipolar disorder;
LUAD	cis	rs420259	0.516	rs9931842	chr16:23524558	T/A	cg00143387	chr16:23521605	GGA2	-0.69	-9.82	-0.43	1.22e-20	Bipolar disorder;
LUAD	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg12403142	chr1:92012408	NA	-0.38	-6.83	-0.32	2.96e-11	Breast cancer;
LUAD	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg10544611	chr16:67998164	SLC12A4	-0.62	-7.25	-0.33	2.05e-12	Schizophrenia;
LUAD	cis	rs6665290	0.558	rs1319103	chr1:227219314	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.72	-12.44	-0.52	1.72e-30	Myeloid white cell count;
LUAD	cis	rs9522267	0.535	rs4773392	chr13:112227358	A/G	cg10483660	chr13:112241077	NA	0.32	6.95	0.32	1.41e-11	Hepatitis;
LUAD	cis	rs10857712	0.950	rs7906765	chr10:135225460	G/T	cg01444801	chr10:135216882	MTG1	-0.51	-6.78	-0.31	4.03e-11	Systemic lupus erythematosus;
LUAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg11050988	chr7:1952600	MAD1L1	-0.37	-7.67	-0.35	1.16e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs117623576	0.941	rs7912584	chr10:32416623	C/T	cg03047570	chr10:32398778	NA	-0.84	-10.9	-0.47	1.52e-24	Anti-saccade response;
LUAD	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg11859384	chr17:80120422	CCDC57	0.5	9.04	0.4	5.52e-18	Life satisfaction;
LUAD	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg23985595	chr17:80112537	CCDC57	-0.53	-9.69	-0.43	3.39e-20	Life satisfaction;
LUAD	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-7.63	-0.35	1.5700000000000001e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg02569458	chr12:86230093	RASSF9	0.41	7.6	0.35	1.96e-13	Major depressive disorder;
LUAD	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	trans	rs11989744	1.000	rs17782111	chr8:23565784	A/G	cg03492747	chr16:86543808	FOXF1	0.41	6.67	0.31	8.17e-11	Waist-hip ratio;
LUAD	cis	rs225245	0.531	rs321609	chr17:33880676	G/T	cg05299278	chr17:33885742	SLFN14	0.4	7.86	0.36	3.19e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg14458575	chr2:238380390	NA	0.68	12.74	0.53	1.07e-31	Prostate cancer;
LUAD	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.95	0.4	1.14e-17	Menopause (age at onset);
LUAD	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg26384229	chr12:38710491	ALG10B	0.46	7.38	0.34	8.49e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.73	-0.31	5.7e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6931421	0.800	rs12662365	chr6:80905389	T/A	cg08355045	chr6:80787529	NA	0.55	8.78	0.39	4.11e-17	Sitting height ratio;
LUAD	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg09367891	chr1:107599246	PRMT6	0.55	9.23	0.41	1.33e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.52	-8.47	-0.38	3.95e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs2730245	0.615	rs2527207	chr7:158743078	A/G	cg24397884	chr7:158709396	WDR60	-0.73	-10.16	-0.44	7.45e-22	Height;
LUAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.51	-9.05	-0.4	5.34e-18	Lymphocyte counts;
LUAD	cis	rs2580764	0.565	rs6760429	chr2:55228499	C/T	cg09592903	chr2:55203963	RTN4	-0.46	-10.65	-0.46	1.24e-23	Mean platelet volume;
LUAD	cis	rs2816062	0.813	rs6698315	chr1:18895806	A/G	cg18795169	chr1:18902165	NA	-0.92	-21.83	-0.73	2.69e-71	Urate levels in lean individuals;
LUAD	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg12645284	chr15:79092878	ADAMTS7	0.45	7.18	0.33	3.1e-12	Coronary artery disease or large artery stroke;
LUAD	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg04756594	chr16:24857601	SLC5A11	-0.54	-10.39	-0.45	1.08e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs10189230	0.967	rs1367241	chr2:222353413	G/A	cg14652038	chr2:222343519	EPHA4	0.43	8.56	0.38	2.14e-16	Urate levels in lean individuals;
LUAD	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg00074818	chr8:8560427	CLDN23	0.66	10.12	0.44	1.06e-21	Obesity-related traits;
LUAD	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs9796	0.689	rs692511	chr15:41446252	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.42	-7.73	-0.35	7.98e-14	Menopause (age at onset);
LUAD	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg26818010	chr10:134567672	INPP5A	0.54	9.63	0.42	5.43e-20	Migraine;
LUAD	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg00898013	chr13:113819073	PROZ	-0.65	-11.96	-0.5	1.32e-28	Platelet distribution width;
LUAD	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg26384229	chr12:38710491	ALG10B	-0.4	-6.79	-0.31	3.71e-11	Heart rate;
LUAD	cis	rs10129255	0.500	rs6576229	chr14:107186773	G/A	cg23076370	chr14:107095027	NA	-0.44	-8.74	-0.39	5.5e-17	Kawasaki disease;
LUAD	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg19761014	chr17:28927070	LRRC37B2	-0.78	-8.58	-0.38	1.86e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg18876405	chr7:65276391	NA	0.4	6.36	0.3	5.4e-10	Aortic root size;
LUAD	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg13319975	chr6:146136371	FBXO30	0.63	10.89	0.47	1.65e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6066825	0.644	rs926629	chr20:47335736	A/G	cg18078177	chr20:47281410	PREX1	0.38	6.39	0.3	4.32e-10	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.85e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.77	-0.31	4.39e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4243830	0.850	rs12760251	chr1:6601336	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.63	-7.51	-0.34	3.47e-13	Body mass index;
LUAD	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.41	-6.81	-0.31	3.37e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4481887	0.790	rs6587440	chr1:248415662	A/G	cg00666640	chr1:248458726	OR2T12	0.29	7.2	0.33	2.72e-12	Common traits (Other);
LUAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.74	-0.31	5.36e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9527	0.518	rs11191530	chr10:104800044	C/T	cg15744005	chr10:104629667	AS3MT	0.46	6.38	0.3	4.53e-10	Arsenic metabolism;
LUAD	cis	rs4523957	0.583	rs8077597	chr17:2043818	C/T	cg16513277	chr17:2031491	SMG6	-0.98	-20.08	-0.7	1.79e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg17372223	chr3:52568218	NT5DC2	0.44	8.4	0.38	7.04e-16	Electroencephalogram traits;
LUAD	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg25324976	chr17:61989376	CSHL1	0.34	6.6	0.31	1.26e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg12927641	chr6:109611667	NA	-0.53	-9.46	-0.42	2.12e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg13699009	chr12:122356056	WDR66	0.31	6.83	0.32	2.9e-11	Mean corpuscular volume;
LUAD	trans	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg19955956	chr7:72299837	SBDSP;TYW1B	0.59	10.69	0.46	8.78e-24	Blood metabolite levels;
LUAD	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg25811766	chr13:21894605	NA	-0.62	-7.54	-0.34	2.91e-13	White matter hyperintensity burden;
LUAD	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg19678392	chr7:94953810	PON1	-0.59	-8.26	-0.37	1.93e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg20476274	chr7:133979776	SLC35B4	0.82	16.29	0.62	1.15e-46	Mean platelet volume;
LUAD	cis	rs7727544	0.582	rs4361509	chr5:131536753	A/G	cg14196790	chr5:131705035	SLC22A5	-0.4	-7.05	-0.32	7.44e-12	Blood metabolite levels;
LUAD	cis	rs10788264	0.544	rs9630110	chr10:124017308	C/T	cg09507567	chr10:124027408	NA	-0.54	-12.25	-0.51	9.72e-30	Total body bone mineral density;
LUAD	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg19318889	chr4:1322082	MAEA	0.51	8.78	0.39	3.96e-17	Longevity;
LUAD	cis	rs11828289	0.660	rs76458473	chr11:23237355	T/G	cg20040320	chr11:23191996	NA	-0.69	-7.87	-0.36	3.05e-14	Cancer;
LUAD	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg17105886	chr17:28927953	LRRC37B2	0.77	7.72	0.35	8.51e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg27600084	chr12:12264075	NA	0.37	6.8	0.31	3.67e-11	Breast size;
LUAD	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg11901034	chr3:128598214	ACAD9	-0.48	-7.46	-0.34	4.89e-13	IgG glycosylation;
LUAD	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18404041	chr3:52824283	ITIH1	0.66	13.72	0.55	1.06e-35	Bipolar disorder;
LUAD	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg06713675	chr4:122721982	EXOSC9	-0.84	-18.16	-0.66	6.49e-55	Type 2 diabetes;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg06529459	chr11:67397595	NUDT8	-0.41	-6.87	-0.32	2.36e-11	Schizophrenia;
LUAD	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg14773178	chr5:1868261	NA	0.34	6.47	0.3	2.78e-10	Cardiovascular disease risk factors;
LUAD	cis	rs4691139	0.595	rs10000199	chr4:165922965	G/A	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.42	-7.76	-0.35	6.57e-14	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg00277334	chr10:82204260	NA	-0.66	-11.77	-0.5	7.55e-28	Post bronchodilator FEV1;
LUAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg18402987	chr7:1209562	NA	0.77	9.3	0.41	7.73e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9308433	0.553	rs11120299	chr1:214509407	C/A	cg06198575	chr1:214491504	SMYD2	0.43	7.23	0.33	2.27e-12	IgG glycosylation;
LUAD	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.38	-0.38	8.12e-16	Breast cancer;
LUAD	cis	rs7107174	0.892	rs1893449	chr11:77968977	G/C	cg02023728	chr11:77925099	USP35	0.52	7.96	0.36	1.61e-14	Testicular germ cell tumor;
LUAD	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	7.03	0.32	8.27e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.39	-0.42	3.66e-19	Schizophrenia;
LUAD	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.61	0.35	1.8e-13	Cannabis dependence symptom count;
LUAD	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.56	8.83	0.39	2.8e-17	Birth weight;
LUAD	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-12.3	-0.51	6.15e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg20607798	chr8:58055168	NA	0.66	8.55	0.38	2.21e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1497828	0.956	rs2646839	chr1:217553421	G/A	cg04411442	chr1:217543379	NA	0.39	7.0	0.32	9.95e-12	Dialysis-related mortality;
LUAD	cis	rs56161922	1.000	rs56235509	chr1:207839769	C/G	cg11752769	chr1:207818423	CR1L	-0.66	-7.0	-0.32	1.04e-11	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg22920501	chr2:26401640	FAM59B	-0.76	-10.95	-0.47	9.86e-25	Gut microbiome composition (summer);
LUAD	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.56	0.55	4.71e-35	Tonsillectomy;
LUAD	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg04944784	chr2:26401820	FAM59B	0.91	13.67	0.55	1.67e-35	Gut microbiome composition (summer);
LUAD	cis	rs13064411	0.518	rs9842559	chr3:113252705	A/C	cg10517650	chr3:113235015	CCDC52	-0.37	-6.93	-0.32	1.59e-11	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg18252515	chr7:66147081	NA	-0.63	-6.89	-0.32	2.01e-11	Diabetic kidney disease;
LUAD	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg14834391	chr1:2537342	MMEL1	0.31	6.42	0.3	3.6e-10	Ulcerative colitis;
LUAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg07217954	chr7:1067459	C7orf50	0.45	7.07	0.33	6.38e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg10523679	chr1:76189770	ACADM	-0.75	-11.42	-0.49	1.7e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg17366294	chr4:99064904	C4orf37	0.65	12.47	0.52	1.27e-30	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg15704280	chr7:45808275	SEPT13	-0.69	-11.05	-0.47	4.22e-25	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18909525	chr9:132403873	ASB6	-0.42	-6.45	-0.3	3.08e-10	Height;
LUAD	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	0.8	10.0	0.44	2.79e-21	Body mass index;
LUAD	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg23018236	chr17:30244563	NA	-0.55	-7.45	-0.34	5.35e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs17401966	0.931	rs12408430	chr1:10323339	T/A	cg19773385	chr1:10388646	KIF1B	-0.42	-6.74	-0.31	5.21e-11	Hepatocellular carcinoma;
LUAD	cis	rs7582720	1.000	rs72934738	chr2:203740861	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.45	0.42	2.39e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg16606324	chr3:10149918	C3orf24	0.7	11.69	0.49	1.53e-27	Alzheimer's disease;
LUAD	cis	rs55665837	1.000	rs10832271	chr11:14466919	C/G	cg19336497	chr11:14380999	RRAS2	-0.51	-10.3	-0.45	2.32e-22	Vitamin D levels;
LUAD	cis	rs62238980	0.614	rs743764	chr22:32459217	C/T	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg10645314	chr2:3704589	ALLC	0.62	10.02	0.44	2.49e-21	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03517284	chr6:25882590	NA	-0.5	-7.54	-0.34	2.87e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4853525	0.522	rs6744420	chr2:191589082	A/G	cg11845111	chr2:191398756	TMEM194B	0.44	7.05	0.32	7.11e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs220324	0.688	rs8133222	chr21:43568683	A/G	cg09727148	chr21:43560719	UMODL1	0.48	7.56	0.35	2.51e-13	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg21171335	chr12:122356390	WDR66	-0.74	-13.75	-0.56	8.38e-36	Mean corpuscular volume;
LUAD	trans	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.65	-11.72	-0.5	1.11e-27	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg11057378	chr10:81107060	PPIF	0.38	7.04	0.32	7.72e-12	Height;
LUAD	cis	rs9487051	0.735	rs396000	chr6:109519611	A/G	cg21918786	chr6:109611834	NA	0.41	7.47	0.34	4.74e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs760805	1.000	rs4648884	chr1:25261386	C/T	cg22509179	chr1:25234806	RUNX3	0.75	13.56	0.55	4.99e-35	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7487075	0.619	rs2408498	chr12:46796900	G/A	cg23829395	chr12:46796953	NA	0.32	7.15	0.33	3.79e-12	Itch intensity from mosquito bite;
LUAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg24101359	chr6:42928495	GNMT	0.52	10.09	0.44	1.33e-21	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2282300	0.739	rs6484478	chr11:30306440	A/G	cg06241208	chr11:30344200	C11orf46	0.58	7.5	0.34	3.86e-13	Morning vs. evening chronotype;
LUAD	cis	rs4268898	0.722	rs7563958	chr2:24422381	C/A	cg06627628	chr2:24431161	ITSN2	0.44	7.67	0.35	1.24e-13	Asthma;
LUAD	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg12444411	chr7:2802554	GNA12	-0.36	-6.54	-0.3	1.78e-10	Height;
LUAD	trans	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg14791747	chr16:20752902	THUMPD1	0.47	7.1	0.33	5.16e-12	Dental caries;
LUAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg18402987	chr7:1209562	NA	0.79	9.62	0.42	6.17e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg23625390	chr15:77176239	SCAPER	0.47	7.56	0.35	2.5e-13	Blood metabolite levels;
LUAD	cis	rs7289126	0.966	rs2267378	chr22:38630956	G/A	cg25457927	chr22:38595422	NA	-0.4	-9.28	-0.41	8.75e-19	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-8.92	-0.4	1.46e-17	Gut microbiome composition (summer);
LUAD	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.41	-0.45	9.44e-23	Glomerular filtration rate;
LUAD	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg15017067	chr4:17643749	FAM184B	0.37	6.99	0.32	1.07e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg01448562	chr3:133502909	NA	-0.52	-9.09	-0.4	4.01e-18	Iron status biomarkers;
LUAD	cis	rs7833986	0.501	rs2719245	chr8:56894359	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.92	14.71	0.58	7.66e-40	Height;
LUAD	trans	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg14917512	chr19:3094685	GNA11	-0.56	-6.75	-0.31	4.81e-11	Diabetic kidney disease;
LUAD	trans	rs877282	0.891	rs11253355	chr10:768367	C/G	cg22713356	chr15:30763199	NA	1.3	17.91	0.66	8.45e-54	Uric acid levels;
LUAD	cis	rs3733418	0.929	rs13149062	chr4:165905360	T/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-6.73	-0.31	5.59e-11	Obesity-related traits;
LUAD	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg20203395	chr5:56204925	C5orf35	-0.94	-12.95	-0.53	1.54e-32	Initial pursuit acceleration;
LUAD	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.1	-0.57	2.78e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs1032833	0.732	rs75929971	chr2:179959838	T/C	cg23883738	chr2:179974586	SESTD1	-0.72	-8.26	-0.37	1.86e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26314531	chr2:26401878	FAM59B	0.72	9.71	0.43	3.04e-20	Gut microbiome composition (summer);
LUAD	cis	rs17102423	0.594	rs1256417	chr14:65563678	C/T	cg16583315	chr14:65563665	MAX	-0.36	-6.81	-0.31	3.26e-11	Obesity-related traits;
LUAD	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg19912559	chr1:40204330	PPIE	-0.56	-9.65	-0.42	4.78e-20	Blood protein levels;
LUAD	trans	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg06606381	chr12:133084897	FBRSL1	-0.5	-6.65	-0.31	9.04e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs11811982	0.793	rs75767425	chr1:227577520	C/T	cg24860534	chr1:227506868	CDC42BPA	0.72	7.58	0.35	2.15e-13	Optic disc area;
LUAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg03188948	chr7:1209495	NA	0.81	9.93	0.43	5.2e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.25	6.43	0.3	3.35e-10	Parkinson's disease;
LUAD	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg21285383	chr16:89894308	SPIRE2	0.42	10.22	0.44	4.82e-22	Vitiligo;
LUAD	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg10544611	chr16:67998164	SLC12A4	-0.62	-7.25	-0.33	2.05e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg04450456	chr4:17643702	FAM184B	0.43	8.5	0.38	3.4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs939658	0.805	rs11634679	chr15:79432475	T/C	cg17916960	chr15:79447300	NA	-0.51	-10.69	-0.46	9.24e-24	Refractive error;
LUAD	cis	rs4774899	0.752	rs2951904	chr15:57364814	G/A	cg14026238	chr15:57616123	NA	0.42	8.07	0.37	7.61e-15	Urinary tract infection frequency;
LUAD	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg11057378	chr10:81107060	PPIF	0.42	7.73	0.35	8.12e-14	Height;
LUAD	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg01689657	chr7:91764605	CYP51A1	0.37	9.06	0.4	5e-18	Breast cancer;
LUAD	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg18252515	chr7:66147081	NA	-0.63	-6.89	-0.32	2.01e-11	Diabetic kidney disease;
LUAD	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg11859384	chr17:80120422	CCDC57	-0.49	-8.95	-0.4	1.14e-17	Life satisfaction;
LUAD	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg22823121	chr1:150693482	HORMAD1	0.44	8.91	0.4	1.55e-17	Tonsillectomy;
LUAD	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg19761014	chr17:28927070	LRRC37B2	0.71	6.36	0.3	5.3e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10979	0.931	rs12191837	chr6:143898200	T/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.09	-0.44	1.31e-21	Hypospadias;
LUAD	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19346786	chr7:2764209	NA	-0.54	-11.77	-0.5	7.09e-28	Height;
LUAD	cis	rs916888	0.779	rs199526	chr17:44847707	C/G	cg01570182	chr17:44337453	NA	-0.8	-12.67	-0.52	2.09e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1497828	0.871	rs2047401	chr1:217544107	T/A	cg04411442	chr1:217543379	NA	0.39	6.97	0.32	1.2e-11	Dialysis-related mortality;
LUAD	cis	rs7224737	0.789	rs8071235	chr17:40300126	C/A	cg02228675	chr17:40259724	DHX58	-0.44	-6.94	-0.32	1.46e-11	Fibrinogen levels;
LUAD	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg18854424	chr1:2615690	NA	0.42	9.1	0.4	3.71e-18	Ulcerative colitis;
LUAD	trans	rs208520	0.874	rs208515	chr6:66945749	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-14.84	-0.59	2.01e-40	Exhaled nitric oxide output;
LUAD	cis	rs12122100	0.651	rs12737860	chr1:146546343	G/T	cg03526459	chr1:146549940	NA	-0.39	-7.14	-0.33	4.22e-12	HIV-1 control;
LUAD	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	7.9	0.36	2.39e-14	Menopause (age at onset);
LUAD	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg02421172	chr7:1938701	MAD1L1	0.45	6.5	0.3	2.24e-10	Neuroticism;
LUAD	cis	rs57590327	0.555	rs3821556	chr3:81630790	G/A	cg07356753	chr3:81810745	GBE1	-0.44	-6.75	-0.31	4.75e-11	Extraversion;
LUAD	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg26408565	chr15:76604113	ETFA	-0.56	-9.8	-0.43	1.41e-20	Blood metabolite levels;
LUAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08677398	chr8:58056175	NA	0.48	6.65	0.31	8.98e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.51	0.3	2.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg06360820	chr2:242988706	NA	-1.05	-12.63	-0.52	2.92e-31	Obesity-related traits;
LUAD	cis	rs4523957	0.651	rs7212342	chr17:2084305	A/G	cg16513277	chr17:2031491	SMG6	-0.95	-18.95	-0.68	2.08e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg03929089	chr4:120376271	NA	-0.74	-11.76	-0.5	8.01e-28	Coronary artery disease;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg24838391	chr1:36106988	PSMB2	-0.5	-6.68	-0.31	7.71e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03934478	chr11:495069	RNH1	0.74	8.92	0.4	1.4e-17	Body mass index;
LUAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg02524346	chr8:600233	NA	1.08	10.71	0.46	7.41e-24	IgG glycosylation;
LUAD	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg12698349	chr2:225449008	CUL3	0.68	10.11	0.44	1.15e-21	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs7827545	1.000	rs6578237	chr8:135569358	C/G	cg17885191	chr8:135476712	NA	-0.45	-7.46	-0.34	4.83e-13	Hypertension (SNP x SNP interaction);
LUAD	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg24450063	chr1:156163899	SLC25A44	0.79	8.12	0.37	5.21e-15	Paclitaxel disposition in epithelial ovarian cancer;
LUAD	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-13.72	-0.55	1.09e-35	Schizophrenia;
LUAD	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg21951975	chr1:209979733	IRF6	0.55	7.13	0.33	4.48e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg16479474	chr6:28041457	NA	0.48	8.18	0.37	3.31e-15	Parkinson's disease;
LUAD	trans	rs877282	0.898	rs11253356	chr10:768604	G/A	cg22713356	chr15:30763199	NA	1.21	16.19	0.62	3.33e-46	Uric acid levels;
LUAD	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg06108461	chr20:60628389	TAF4	-0.96	-17.48	-0.65	6.76e-52	Body mass index;
LUAD	cis	rs1697139	0.583	rs11739603	chr5:66540687	C/T	cg11553311	chr5:66541588	NA	0.44	8.13	0.37	4.68e-15	Breast cancer;
LUAD	cis	rs9399401	0.667	rs11759653	chr6:142720354	G/A	cg03128060	chr6:142623767	GPR126	0.54	10.61	0.46	1.79e-23	Chronic obstructive pulmonary disease;
LUAD	cis	rs758324	0.812	rs601441	chr5:131284433	C/T	cg25547332	chr5:131281432	NA	-0.39	-6.4	-0.3	4.13e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.59	0.42	7.72e-20	Monocyte percentage of white cells;
LUAD	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg11833968	chr6:79620685	NA	-0.41	-7.84	-0.36	3.81e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.36e-12	Lung cancer;
LUAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.64	-0.42	4.99e-20	Alzheimer's disease;
LUAD	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg07636037	chr3:49044803	WDR6	0.62	10.38	0.45	1.19e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg18512352	chr11:47633146	NA	-0.4	-6.99	-0.32	1.1e-11	Subjective well-being;
LUAD	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.65	-0.31	9.13e-11	Breast cancer;
LUAD	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg24596788	chr1:163392923	NA	-0.36	-7.93	-0.36	1.92e-14	Motion sickness;
LUAD	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.1	-24.16	-0.76	1.18e-81	Ulcerative colitis;
LUAD	cis	rs7107174	1.000	rs10899469	chr11:78018313	T/C	cg02023728	chr11:77925099	USP35	0.52	7.85	0.36	3.49e-14	Testicular germ cell tumor;
LUAD	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg04539111	chr16:67997858	SLC12A4	-0.62	-7.76	-0.35	6.57e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6076065	0.723	rs6083088	chr20:23343793	G/T	cg11657817	chr20:23433608	CST11	0.48	8.9	0.4	1.67e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg27411982	chr8:10470053	RP1L1	0.38	6.52	0.3	2.06e-10	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs12681288	0.748	rs2123054	chr8:1028227	C/G	cg15309053	chr8:964076	NA	0.39	7.96	0.36	1.55e-14	Schizophrenia;
LUAD	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.78	0.35	5.55e-14	Bladder cancer;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg00197636	chr8:57906363	IMPAD1	-0.52	-6.35	-0.3	5.54e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg04990556	chr1:26633338	UBXN11	-0.4	-6.57	-0.3	1.49e-10	Obesity-related traits;
LUAD	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg20362242	chr5:692897	TPPP	0.56	6.89	0.32	2.02e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg18854424	chr1:2615690	NA	-0.42	-9.17	-0.41	2.15e-18	Ulcerative colitis;
LUAD	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg09365446	chr1:150670422	GOLPH3L	0.63	10.99	0.47	6.79e-25	Melanoma;
LUAD	cis	rs36051895	0.659	rs7859390	chr9:5062473	A/T	cg02405213	chr9:5042618	JAK2	-0.47	-6.84	-0.32	2.78e-11	Pediatric autoimmune diseases;
LUAD	cis	rs12618769	0.652	rs11537554	chr2:99216531	A/G	cg10123293	chr2:99228465	UNC50	0.5	8.54	0.38	2.53e-16	Bipolar disorder;
LUAD	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg12034118	chr1:209979487	IRF6	0.54	7.09	0.33	5.68e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg11494091	chr17:61959527	GH2	0.44	8.17	0.37	3.49e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10540	0.584	rs6598021	chr11:438939	G/C	cg03934478	chr11:495069	RNH1	-0.5	-6.83	-0.32	3.04e-11	Body mass index;
LUAD	cis	rs4919694	1.000	rs12253284	chr10:104665145	G/C	cg04362960	chr10:104952993	NT5C2	0.72	7.75	0.35	6.87e-14	Arsenic metabolism;
LUAD	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18404041	chr3:52824283	ITIH1	-0.59	-11.81	-0.5	4.94e-28	Bipolar disorder;
LUAD	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg08632164	chr7:65971372	NA	-0.38	-6.62	-0.31	1.09e-10	Aortic root size;
LUAD	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg05373962	chr22:49881684	NA	-0.55	-13.0	-0.53	9.66e-33	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg02734326	chr4:10020555	SLC2A9	0.58	10.04	0.44	2.06e-21	Bone mineral density;
LUAD	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg02176678	chr2:219576539	TTLL4	0.74	14.87	0.59	1.63e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2637266	1.000	rs12258924	chr10:78364758	G/A	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.72e-11	Pulmonary function;
LUAD	cis	rs6714710	0.603	rs11678591	chr2:98541001	T/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.18	0.37	3.28e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg23992470	chr4:843637	GAK	0.67	7.08	0.33	5.85e-12	Parkinson's disease;
LUAD	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg27211696	chr2:191398769	TMEM194B	-0.67	-9.05	-0.4	5.3e-18	Diastolic blood pressure;
LUAD	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg23262073	chr20:60523788	NA	0.39	7.03	0.32	8.32e-12	Body mass index;
LUAD	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg22681709	chr2:178499509	PDE11A	-0.5	-8.35	-0.38	1.01e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs877282	0.945	rs11253390	chr10:788678	A/G	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.8	0.46	3.55e-24	Smoking behavior;
LUAD	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-9.45	-0.42	2.28e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.32	7.14	0.33	4.23e-12	Prostate cancer;
LUAD	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg04511125	chr2:88470314	THNSL2	-0.52	-8.77	-0.39	4.4e-17	Response to metformin (IC50);
LUAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.74	-0.35	7.33e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg23649088	chr2:200775458	C2orf69	0.62	8.21	0.37	2.77e-15	Schizophrenia;
LUAD	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg09904177	chr6:26538194	HMGN4	0.39	6.46	0.3	2.82e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs887829	0.588	rs4663969	chr2:234655313	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-9.18	-0.41	1.89e-18	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs921968	0.643	rs4674319	chr2:219510320	C/T	cg02176678	chr2:219576539	TTLL4	0.59	11.32	0.48	3.98e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9308433	0.529	rs11120298	chr1:214500620	A/G	cg06198575	chr1:214491504	SMYD2	0.44	7.55	0.34	2.71e-13	IgG glycosylation;
LUAD	cis	rs10540	0.584	rs10751659	chr11:437559	C/T	cg03352830	chr11:487213	PTDSS2	-0.49	-6.98	-0.32	1.16e-11	Body mass index;
LUAD	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg17724175	chr1:150552817	MCL1	0.32	7.42	0.34	6.42e-13	Melanoma;
LUAD	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg02493740	chr2:85810744	VAMP5	-0.43	-7.9	-0.36	2.51e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs2625529	0.824	rs12595464	chr15:72294398	C/T	cg16672083	chr15:72433130	SENP8	-0.76	-12.69	-0.53	1.76e-31	Red blood cell count;
LUAD	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg05754148	chr16:3507555	NAT15	-0.63	-10.04	-0.44	1.96e-21	Tuberculosis;
LUAD	cis	rs7809950	0.815	rs62482495	chr7:106965009	A/G	cg23024343	chr7:107201750	COG5	-0.82	-13.97	-0.56	9.44e-37	Coronary artery disease;
LUAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg27094323	chr7:1216898	NA	-0.37	-7.13	-0.33	4.32e-12	Longevity;Endometriosis;
LUAD	trans	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg01620082	chr3:125678407	NA	-0.54	-7.08	-0.33	6.23e-12	Depression;
LUAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg00280220	chr17:61926910	NA	0.35	6.83	0.31	3.06e-11	Prudent dietary pattern;
LUAD	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.46e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg03929089	chr4:120376271	NA	0.61	9.59	0.42	7.43e-20	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg13319975	chr6:146136371	FBXO30	-0.54	-9.28	-0.41	8.84e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg15691649	chr6:25882328	NA	-0.45	-7.13	-0.33	4.29e-12	Blood metabolite levels;
LUAD	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg03233332	chr7:66118400	NA	0.43	6.62	0.31	1.12e-10	Aortic root size;
LUAD	trans	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg19862616	chr7:65841803	NCRNA00174	1.02	24.43	0.76	7.39e-83	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg06074448	chr4:187884817	NA	-0.4	-8.01	-0.36	1.15e-14	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg09796270	chr17:17721594	SREBF1	0.38	7.56	0.34	2.61e-13	Total body bone mineral density;
LUAD	cis	rs13064411	0.627	rs28710051	chr3:113143531	G/A	cg10517650	chr3:113235015	CCDC52	-0.53	-8.76	-0.39	4.6e-17	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg06636551	chr8:101224915	SPAG1	-0.37	-6.84	-0.32	2.83e-11	Atrioventricular conduction;
LUAD	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg25036284	chr2:26402008	FAM59B	-0.57	-7.79	-0.35	5.05e-14	Gut microbiome composition (summer);
LUAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg03188948	chr7:1209495	NA	0.83	10.11	0.44	1.13e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg25457927	chr22:38595422	NA	-0.53	-13.87	-0.56	2.48e-36	Cutaneous nevi;
LUAD	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg07741184	chr6:167504864	NA	0.31	7.11	0.33	5.13e-12	Crohn's disease;
LUAD	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg18404041	chr3:52824283	ITIH1	0.41	7.56	0.34	2.54e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg02753203	chr1:228287806	NA	-0.49	-8.74	-0.39	5.5e-17	Diastolic blood pressure;
LUAD	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg06558623	chr16:89946397	TCF25	1.12	9.97	0.44	3.57e-21	Skin colour saturation;
LUAD	cis	rs17362650	1.000	rs12474969	chr2:9697067	C/T	cg12832956	chr2:9616023	IAH1	-0.45	-7.28	-0.33	1.59e-12	Alcohol dependence (age at onset);
LUAD	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg03676636	chr4:99064102	C4orf37	0.32	8.47	0.38	4.21e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg04944784	chr2:26401820	FAM59B	0.88	12.15	0.51	2.37e-29	Gut microbiome composition (summer);
LUAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.48	-8.8	-0.39	3.49e-17	Longevity;Endometriosis;
LUAD	trans	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg19862616	chr7:65841803	NCRNA00174	1.04	24.4	0.76	9.89e-83	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.21	-0.54	1.34e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg23254163	chr1:152506842	NA	0.25	7.08	0.33	6.14e-12	Hair morphology;
LUAD	cis	rs57994353	0.793	rs12552167	chr9:139322927	C/T	cg14169450	chr9:139327907	INPP5E	0.41	6.67	0.31	8.24e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg23625390	chr15:77176239	SCAPER	0.38	6.8	0.31	3.62e-11	Blood metabolite levels;
LUAD	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg19875535	chr5:140030758	IK	-0.44	-7.38	-0.34	8.23e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg17401720	chr7:158221031	PTPRN2	0.32	6.6	0.31	1.24e-10	Obesity-related traits;
LUAD	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg25344623	chr2:136566232	LCT	0.34	6.54	0.3	1.8e-10	Mosquito bite size;
LUAD	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg27170947	chr2:26402098	FAM59B	0.62	8.67	0.39	9.24e-17	Gut microbiome composition (summer);
LUAD	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg23649088	chr2:200775458	C2orf69	0.62	8.25	0.37	2.06e-15	Schizophrenia;
LUAD	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Parkinson's disease;
LUAD	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.12e-14	Prostate cancer;
LUAD	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg13334819	chr7:99746414	C7orf59	-0.62	-9.17	-0.41	2.12e-18	Coronary artery disease;
LUAD	trans	rs853679	0.607	rs67998226	chr6:28238059	T/C	cg06606381	chr12:133084897	FBRSL1	-1.19	-11.22	-0.48	9.05e-26	Depression;
LUAD	cis	rs13064411	0.542	rs9877649	chr3:113226874	C/T	cg18753928	chr3:113234510	CCDC52	-0.55	-9.71	-0.43	3e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7267979	0.844	rs2424703	chr20:25270124	G/A	cg08601574	chr20:25228251	PYGB	0.41	7.63	0.35	1.54e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg04225089	chr17:73874465	TRIM47	-0.38	-6.81	-0.31	3.4e-11	Psoriasis;
LUAD	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg03806693	chr22:41940476	POLR3H	0.69	9.83	0.43	1.09e-20	Vitiligo;
LUAD	cis	rs4954585	0.593	rs12691881	chr2:137029668	A/G	cg05194412	chr2:137003533	NA	0.62	11.23	0.48	8.39e-26	Colorectal cancer;
LUAD	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg03676636	chr4:99064102	C4orf37	0.37	9.57	0.42	8.85e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18876405	chr7:65276391	NA	-0.44	-7.02	-0.32	8.72e-12	Aortic root size;
LUAD	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg25894440	chr7:65020034	NA	-0.62	-6.7	-0.31	6.74e-11	Diabetic kidney disease;
LUAD	cis	rs997295	0.684	rs4776970	chr15:68080886	A/T	cg24579218	chr15:68104479	NA	-0.37	-6.84	-0.32	2.85e-11	Motion sickness;
LUAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.68	0.31	7.6e-11	Prudent dietary pattern;
LUAD	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg20607287	chr7:12443886	VWDE	-0.53	-6.67	-0.31	7.88e-11	Coronary artery disease;
LUAD	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg09904177	chr6:26538194	HMGN4	0.43	7.31	0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg03342759	chr3:160939853	NMD3	-0.46	-6.45	-0.3	3.08e-10	Parkinson's disease;
LUAD	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.56	-0.38	2.16e-16	Total body bone mineral density;
LUAD	cis	rs921968	1.000	rs921968	chr2:219272294	G/T	cg02176678	chr2:219576539	TTLL4	0.5	9.51	0.42	1.49e-19	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg02527881	chr3:46936655	PTH1R	0.42	8.12	0.37	5.02e-15	Colorectal cancer;
LUAD	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs11229555	0.645	rs34054511	chr11:58204943	A/C	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg08085267	chr17:45401833	C17orf57	-0.69	-12.24	-0.51	1.09e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg12373951	chr3:133503437	NA	0.37	7.33	0.34	1.2e-12	Iron status biomarkers;
LUAD	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg09658497	chr7:2847517	GNA12	-0.53	-8.71	-0.39	7.1e-17	Height;
LUAD	cis	rs17095355	0.605	rs3740140	chr10:111632937	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.54	-0.34	2.89e-13	Biliary atresia;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg00417742	chr7:112580528	C7orf60	-0.47	-6.69	-0.31	7.16e-11	Testicular germ cell tumor;
LUAD	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg05665937	chr4:1216051	CTBP1	0.43	7.61	0.35	1.78e-13	Obesity-related traits;
LUAD	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg25566285	chr7:158114605	PTPRN2	0.52	11.21	0.48	1.02e-25	Calcium levels;
LUAD	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg02807482	chr3:125708958	NA	-0.66	-8.91	-0.4	1.5e-17	Blood pressure (smoking interaction);
LUAD	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg21100191	chr22:23484243	RTDR1	0.67	11.7	0.49	1.4e-27	Bone mineral density;
LUAD	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.8	0.35	4.93e-14	Breast cancer;
LUAD	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg21153622	chr11:89784906	NA	0.33	6.46	0.3	2.92e-10	Coronary artery disease;
LUAD	cis	rs6500395	0.925	rs9933148	chr16:48672099	C/T	cg04672837	chr16:48644449	N4BP1	0.38	6.55	0.3	1.64e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7809950	1.000	rs2237673	chr7:107131580	T/C	cg23024343	chr7:107201750	COG5	-0.71	-11.96	-0.5	1.33e-28	Coronary artery disease;
LUAD	cis	rs6684428	0.614	rs11206680	chr1:56364414	A/G	cg11651538	chr1:56320950	NA	-0.4	-6.39	-0.3	4.39e-10	Airflow obstruction;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13226139	chr14:45605129	FKBP3;FANCM	-0.38	-6.47	-0.3	2.64e-10	Cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06045225	chr5:65892993	MAST4	-0.45	-7.16	-0.33	3.7e-12	Height;
LUAD	cis	rs7621025	0.664	rs6439657	chr3:136494639	C/T	cg15507776	chr3:136538369	TMEM22	-0.42	-6.42	-0.3	3.68e-10	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUAD	cis	rs12369635	1.000	rs12369635	chr12:129561356	C/T	cg01909103	chr12:129572610	TMEM132D	-0.64	-7.06	-0.32	6.74e-12	Schizophrenia (inflammation and infection response interaction);
LUAD	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg13870426	chr17:30244630	NA	-0.58	-6.88	-0.32	2.15e-11	Hip circumference adjusted for BMI;
LUAD	trans	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs7671266	0.747	rs6827946	chr4:10151335	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-6.64	-0.31	9.6e-11	Cardiovascular disease risk factors;
LUAD	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg09796270	chr17:17721594	SREBF1	-0.38	-7.79	-0.35	5.2e-14	Total body bone mineral density;
LUAD	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg02023728	chr11:77925099	USP35	0.4	6.48	0.3	2.59e-10	Testicular germ cell tumor;
LUAD	trans	rs9354308	0.933	rs10455586	chr6:66571498	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.51	7.6	0.35	1.91e-13	Metabolite levels;
LUAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	8.47	0.38	4.11e-16	Alzheimer's disease;
LUAD	trans	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg22153745	chr1:153894579	GATAD2B	-0.54	-8.07	-0.37	7.5e-15	Total cholesterol levels;
LUAD	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg05340658	chr4:99064831	C4orf37	0.54	9.03	0.4	6.03e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg06002616	chr8:101225028	SPAG1	-0.4	-8.26	-0.37	1.84e-15	Atrioventricular conduction;
LUAD	cis	rs6484504	0.532	rs10835757	chr11:31281902	C/T	cg14844989	chr11:31128820	NA	-0.43	-8.05	-0.36	8.63e-15	Red blood cell count;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18058077	chr11:319009	NA	-0.41	-6.51	-0.3	2.14e-10	Height;
LUAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06873352	chr17:61820015	STRADA	0.82	18.41	0.67	5.27e-56	Prudent dietary pattern;
LUAD	cis	rs5756391	0.568	rs11705450	chr22:37317529	A/G	cg16356956	chr22:37317934	CSF2RB	0.31	6.51	0.3	2.19e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg05966235	chr16:28915196	ATP2A1	0.47	7.63	0.35	1.52e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg26043149	chr18:55253948	FECH	0.5	7.99	0.36	1.31e-14	Bone mineral density;
LUAD	cis	rs68170813	0.523	rs11762152	chr7:106811374	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-11.05	-0.47	4.29e-25	Coronary artery disease;
LUAD	cis	rs9658691	0.920	rs72809352	chr10:90742624	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.88	-10.1	-0.44	1.21e-21	Mosquito bite size;
LUAD	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg25358565	chr5:93447407	FAM172A	0.66	7.75	0.35	6.74e-14	Diabetic retinopathy;
LUAD	cis	rs679087	0.932	rs7312697	chr12:29933069	T/C	cg14258853	chr12:29935411	TMTC1	0.61	11.51	0.49	7.62e-27	Schizophrenia;
LUAD	cis	rs6494488	0.500	rs112190405	chr15:64766025	G/T	cg08069370	chr15:64387884	SNX1	-0.75	-6.73	-0.31	5.58e-11	Coronary artery disease;
LUAD	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg05872129	chr22:39784769	NA	-0.81	-14.94	-0.59	7.67e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs992157	0.764	rs2891079	chr2:219184691	A/G	cg05991184	chr2:219186017	PNKD	-0.41	-7.73	-0.35	8.06e-14	Colorectal cancer;
LUAD	trans	rs372883	0.638	rs117213	chr21:30720536	G/A	cg14791747	chr16:20752902	THUMPD1	0.48	7.09	0.33	5.57e-12	Pancreatic cancer;
LUAD	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg17863274	chr19:49399704	TULP2	-0.55	-8.36	-0.38	9.17e-16	Red cell distribution width;
LUAD	cis	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg11143507	chr3:125485238	NA	-0.47	-7.85	-0.36	3.54e-14	Blood pressure (smoking interaction);
LUAD	cis	rs6554196	0.508	rs6554200	chr4:55529409	G/C	cg18836493	chr4:55524333	KIT	-0.38	-7.26	-0.33	1.84e-12	Monocyte count;
LUAD	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg22105103	chr4:187893119	NA	0.57	12.34	0.51	4.48e-30	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg05665937	chr4:1216051	CTBP1	0.38	6.41	0.3	3.8e-10	Obesity-related traits;
LUAD	cis	rs9486719	0.948	rs2472881	chr6:96862562	C/T	cg06623918	chr6:96969491	KIAA0776	0.71	9.96	0.44	3.8e-21	Migraine;Coronary artery disease;
LUAD	trans	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg27411982	chr8:10470053	RP1L1	0.38	6.58	0.3	1.43e-10	Neuroticism;
LUAD	trans	rs1493916	0.721	rs4471760	chr18:31374233	G/A	cg13755796	chr4:20253514	NA	-0.41	-7.0	-0.32	1.03e-11	Life satisfaction;
LUAD	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg23795048	chr12:9217529	LOC144571	0.46	8.31	0.37	1.35e-15	Sjögren's syndrome;
LUAD	cis	rs2625529	0.652	rs2899776	chr15:72268365	A/T	cg16672083	chr15:72433130	SENP8	0.65	12.11	0.51	3.61e-29	Red blood cell count;
LUAD	cis	rs367943	0.799	rs13154055	chr5:112971516	A/T	cg12552261	chr5:112820674	MCC	0.53	9.13	0.41	2.86e-18	Type 2 diabetes;
LUAD	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg00814883	chr7:100076585	TSC22D4	-0.85	-12.48	-0.52	1.24e-30	Platelet count;
LUAD	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg03395511	chr6:291903	DUSP22	-0.52	-8.47	-0.38	4.21e-16	Menopause (age at onset);
LUAD	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg17420585	chr12:42539391	GXYLT1	-0.49	-9.06	-0.4	4.96e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	trans	rs4799710	0.523	rs7232064	chr18:31279512	T/G	cg27147174	chr7:100797783	AP1S1	-0.42	-6.82	-0.31	3.18e-11	Pulmonary function;
LUAD	cis	rs12210905	0.688	rs12194842	chr6:27367978	A/C	cg08851530	chr6:28072375	NA	1.09	7.94	0.36	1.88e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg20673091	chr1:2541236	MMEL1	0.39	8.2	0.37	2.84e-15	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6005807	0.843	rs9306457	chr22:28898127	G/A	cg12565055	chr22:29076175	TTC28	0.67	6.52	0.3	1.99e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs1497828	0.956	rs2646828	chr1:217542361	C/T	cg04411442	chr1:217543379	NA	0.37	6.73	0.31	5.65e-11	Dialysis-related mortality;
LUAD	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.5	-0.3	2.3e-10	Mood instability;
LUAD	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.76	-9.68	-0.43	3.83e-20	Body mass index;
LUAD	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.48e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.62	11.97	0.5	1.22e-28	Hemoglobin concentration;
LUAD	cis	rs66823261	0.741	rs7841786	chr8:191746	A/C	cg27532244	chr8:182981	ZNF596;RPL23AP53	-0.62	-8.24	-0.37	2.24e-15	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs2882667	0.898	rs6863347	chr5:138361135	C/T	cg04439458	chr5:138467593	SIL1	-0.36	-6.67	-0.31	8.19e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg10518543	chr12:38710700	ALG10B	0.42	6.44	0.3	3.27e-10	Bladder cancer;
LUAD	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg14324370	chr2:177042789	NA	-0.42	-7.26	-0.33	1.92e-12	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs55788414	0.932	rs9936302	chr16:81190790	C/T	cg06400318	chr16:81190750	PKD1L2	-0.83	-10.86	-0.47	2.15e-24	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs735539	0.598	rs2149769	chr13:21266227	C/T	cg27499820	chr13:21296301	IL17D	-0.46	-8.29	-0.37	1.55e-15	Dental caries;
LUAD	cis	rs9308433	0.529	rs1391553	chr1:214474119	T/C	cg06198575	chr1:214491504	SMYD2	0.48	8.12	0.37	5.25e-15	IgG glycosylation;
LUAD	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg03874509	chr1:107600012	PRMT6	-0.57	-9.99	-0.44	3.06e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.65	-11.53	-0.49	6.34e-27	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs8044868	0.530	rs2550870	chr16:72070129	C/T	cg23815491	chr16:72088622	HP	0.49	8.73	0.39	5.86e-17	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg03037974	chr15:76606532	NA	0.4	8.69	0.39	8.18e-17	Blood metabolite levels;
LUAD	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08704250	chr15:31115839	NA	-0.73	-13.42	-0.55	1.81e-34	Huntington's disease progression;
LUAD	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs7017914	0.967	rs7814648	chr8:71603984	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg07460842	chr6:66804631	NA	0.96	12.93	0.53	1.93e-32	Exhaled nitric oxide output;
LUAD	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-6.89	-0.32	2.08e-11	Total cholesterol levels;
LUAD	cis	rs8060686	0.858	rs2271294	chr16:67902326	A/T	cg26727032	chr16:67993705	SLC12A4	-0.52	-8.74	-0.39	5.67e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.48	7.73	0.35	7.88e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg05425664	chr17:57184151	TRIM37	0.42	7.48	0.34	4.34e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4523957	0.614	rs7217108	chr17:2059408	G/C	cg16513277	chr17:2031491	SMG6	-0.97	-19.38	-0.69	2.4e-60	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg24503407	chr1:205819492	PM20D1	-0.51	-7.77	-0.35	6.02e-14	Menarche (age at onset);
LUAD	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg15017067	chr4:17643749	FAM184B	0.35	6.82	0.31	3.22e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg25324976	chr17:61989376	CSHL1	0.34	6.61	0.31	1.19e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg21862992	chr11:68658383	NA	0.55	10.05	0.44	1.95e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg22532475	chr10:104410764	TRIM8	0.32	6.59	0.3	1.34e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg09904177	chr6:26538194	HMGN4	0.42	6.92	0.32	1.68e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg19875535	chr5:140030758	IK	0.46	7.58	0.35	2.23e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	10.08	0.44	1.41e-21	Electrocardiographic conduction measures;
LUAD	cis	rs17095355	1.000	rs12263484	chr10:111697255	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.78	-11.09	-0.47	3e-25	Biliary atresia;
LUAD	trans	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg01620082	chr3:125678407	NA	-0.89	-8.95	-0.4	1.16e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4478137	0.931	rs3967762	chr4:164244976	T/C	cg06758707	chr4:164254230	NPY1R	0.42	6.73	0.31	5.7e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg15112475	chr7:1198522	ZFAND2A	-0.33	-6.47	-0.3	2.79e-10	Longevity;Endometriosis;
LUAD	trans	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.67	11.48	0.49	1e-26	Mean corpuscular volume;
LUAD	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg17847044	chr15:42102381	MAPKBP1	0.53	12.55	0.52	6.24e-31	Diastolic blood pressure;
LUAD	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg19500851	chr17:37840957	PGAP3	-0.33	-6.53	-0.3	1.84e-10	Asthma;
LUAD	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg03806693	chr22:41940476	POLR3H	0.74	9.98	0.44	3.25e-21	Vitiligo;
LUAD	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg16989719	chr2:238392110	NA	-0.35	-6.61	-0.31	1.18e-10	Prostate cancer;
LUAD	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg00898013	chr13:113819073	PROZ	0.61	11.02	0.47	5.32e-25	Platelet distribution width;
LUAD	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs2018683	0.677	rs12540529	chr7:28969384	A/G	cg19402173	chr7:128379420	CALU	-0.52	-8.44	-0.38	5.13e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.61	-9.73	-0.43	2.48e-20	Longevity;Endometriosis;
LUAD	cis	rs8060686	0.516	rs8048365	chr16:68253326	T/A	cg05110241	chr16:68378359	PRMT7	-0.58	-7.49	-0.34	4e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg00277334	chr10:82204260	NA	-0.68	-10.72	-0.46	7e-24	Post bronchodilator FEV1;
LUAD	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg14671364	chr1:107599128	PRMT6	0.53	9.14	0.41	2.6e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.33	7.08	0.33	6.21e-12	Cardiac Troponin-T levels;
LUAD	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22857025	chr5:266934	NA	-0.96	-14.33	-0.57	2.98e-38	Breast cancer;
LUAD	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg06766960	chr11:133703094	NA	-0.43	-8.19	-0.37	3.24e-15	Childhood ear infection;
LUAD	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg21775007	chr8:11205619	TDH	0.47	8.1	0.37	5.98e-15	Retinal vascular caliber;
LUAD	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg15145296	chr3:125709740	NA	-0.55	-6.63	-0.31	1.06e-10	Blood pressure (smoking interaction);
LUAD	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg12615879	chr12:58013172	SLC26A10	0.52	10.98	0.47	7.52e-25	Multiple sclerosis;
LUAD	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg17366294	chr4:99064904	C4orf37	0.65	10.38	0.45	1.26e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.17	0.37	3.53e-15	Rheumatoid arthritis;
LUAD	cis	rs790123	0.933	rs1092556	chr3:122387354	T/G	cg24850323	chr3:122379709	NA	0.47	8.76	0.39	4.71e-17	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg00852783	chr1:26633632	UBXN11	0.45	7.05	0.32	7.5e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7589342	1.000	rs7589342	chr2:106433478	C/T	cg16077055	chr2:106428750	NCK2	0.36	6.39	0.3	4.26e-10	Addiction;
LUAD	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg05966235	chr16:28915196	ATP2A1	0.47	7.71	0.35	8.82e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2412208	1.000	rs35447019	chr1:7093158	T/A	cg20434152	chr1:7120926	CAMTA1	-0.31	-6.59	-0.31	1.3100000000000001e-10	Survival in sporadic amyotrophic lateral sclerosis;
LUAD	trans	rs3010562	1.000	rs3010562	chr6:167765251	A/G	cg13679164	chr6:161258479	NA	-0.41	-7.39	-0.34	7.95e-13	Gut microbiome composition (summer and winter);
LUAD	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg01689657	chr7:91764605	CYP51A1	0.34	8.68	0.39	8.95e-17	Breast cancer;
LUAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08048268	chr3:133502702	NA	0.54	11.38	0.48	2.36e-26	Iron status biomarkers;
LUAD	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.48	0.3	2.57e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg13397359	chr6:42928475	GNMT	0.58	10.96	0.47	8.87e-25	Plasma homocysteine levels (post-methionine load test);
LUAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00166722	chr3:10149974	C3orf24	0.73	10.94	0.47	1.1e-24	Alzheimer's disease;
LUAD	cis	rs2731664	0.792	rs1130857	chr5:176863519	G/C	cg23176889	chr5:176863531	GRK6	-0.73	-14.05	-0.56	4.37e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs6087990	0.806	rs910085	chr20:31383353	T/G	cg13636640	chr20:31349939	DNMT3B	0.78	13.87	0.56	2.5e-36	Ulcerative colitis;
LUAD	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg23719950	chr11:63933701	MACROD1	-0.62	-7.32	-0.34	1.29e-12	Mean platelet volume;
LUAD	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg14345882	chr6:26364793	BTN3A2	0.64	6.44	0.3	3.32e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7474896	0.583	rs11011341	chr10:37998500	G/A	cg25427524	chr10:38739819	LOC399744	-0.64	-9.31	-0.41	7.11e-19	Obesity (extreme);
LUAD	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg05044414	chr3:183734942	ABCC5	0.46	9.92	0.43	5.27e-21	Anterior chamber depth;
LUAD	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg16680214	chr1:154839983	KCNN3	-0.62	-13.04	-0.54	6.92e-33	Prostate cancer;
LUAD	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg20503657	chr10:835505	NA	0.82	11.12	0.48	2.19e-25	Eosinophil percentage of granulocytes;
LUAD	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg05304507	chr6:116381966	FRK	-0.2	-6.73	-0.31	5.47e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg04025307	chr7:1156635	C7orf50	0.6	6.75	0.31	4.88e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg02158880	chr13:53174818	NA	0.52	9.06	0.4	4.9e-18	Lewy body disease;
LUAD	cis	rs13082711	0.911	rs4973769	chr3:27425746	T/C	cg02860705	chr3:27208620	NA	0.55	8.55	0.38	2.34e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs9807989	0.507	rs6743516	chr2:103036335	A/G	cg03938978	chr2:103052716	IL18RAP	0.45	10.33	0.45	1.82e-22	Asthma;
LUAD	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg06484146	chr7:12443880	VWDE	-0.5	-7.11	-0.33	4.93e-12	Coronary artery disease;
LUAD	cis	rs113835537	0.529	rs57724777	chr11:66236431	G/A	cg24851651	chr11:66362959	CCS	0.61	10.49	0.45	4.76e-23	Airway imaging phenotypes;
LUAD	cis	rs7177699	0.557	rs10083696	chr15:79124016	G/A	cg00540400	chr15:79124168	NA	-0.47	-9.92	-0.43	5.54e-21	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg08125733	chr17:73851984	WBP2	0.55	8.23	0.37	2.32e-15	Psoriasis;
LUAD	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg13385794	chr1:248469461	NA	-0.23	-6.36	-0.3	5.13e-10	Common traits (Other);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05902997	chr5:65440515	SFRS12	-0.68	-6.45	-0.3	3.05e-10	Type 2 diabetes;
LUAD	cis	rs2239547	0.522	rs6771610	chr3:53026104	T/C	cg11645453	chr3:52864694	ITIH4	0.55	10.71	0.46	7.54e-24	Schizophrenia;
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg07719772	chr16:32360419	NA	0.48	7.72	0.35	8.54e-14	Menopause (age at onset);
LUAD	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg04267008	chr7:1944627	MAD1L1	-0.51	-7.54	-0.34	2.88e-13	Schizophrenia;
LUAD	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	6.36	0.3	5.33e-10	Lung cancer in ever smokers;
LUAD	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.9	12.92	0.53	2.11e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg18446336	chr7:2847575	GNA12	-0.32	-6.56	-0.3	1.62e-10	Height;
LUAD	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06544989	chr22:39130855	UNC84B	0.45	9.0	0.4	7.87e-18	Menopause (age at onset);
LUAD	cis	rs3007168	1.000	rs2999365	chr14:51600192	A/G	cg23942311	chr14:51606299	NA	0.52	7.11	0.33	4.91e-12	Cancer;
LUAD	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg04450456	chr4:17643702	FAM184B	0.43	8.45	0.38	4.86e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2688608	0.933	rs2633307	chr10:75653881	G/A	cg19442545	chr10:75533431	FUT11	-0.4	-6.79	-0.31	3.81e-11	Inflammatory bowel disease;
LUAD	cis	rs3809912	0.509	rs4499304	chr18:13001512	G/C	cg12848697	chr18:13133368	NA	0.34	6.46	0.3	2.87e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.79	11.3	0.48	4.89e-26	Smoking behavior;
LUAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg13560548	chr3:10150139	C3orf24	0.42	6.93	0.32	1.54e-11	Alzheimer's disease;
LUAD	trans	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg26043149	chr18:55253948	FECH	-0.44	-7.23	-0.33	2.21e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg10556349	chr10:835070	NA	0.52	6.79	0.31	3.81e-11	Eosinophil percentage of granulocytes;
LUAD	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg00277334	chr10:82204260	NA	-0.95	-21.66	-0.73	1.52e-70	Post bronchodilator FEV1;
LUAD	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.71	-0.39	7.08e-17	Alzheimer's disease (late onset);
LUAD	cis	rs4786125	0.581	rs1967404	chr16:6921483	G/A	cg03623568	chr16:6915990	A2BP1	-0.48	-10.12	-0.44	1.07e-21	Heart rate variability traits (SDNN);
LUAD	cis	rs863345	0.584	rs10797024	chr1:158497163	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.39	-0.3	4.26e-10	Pneumococcal bacteremia;
LUAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12379764	chr21:47803548	PCNT	0.41	6.73	0.31	5.65e-11	Testicular germ cell tumor;
LUAD	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.3	-8.23	-0.37	2.29e-15	Total body bone mineral density;
LUAD	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg02734326	chr4:10020555	SLC2A9	0.64	11.42	0.49	1.62e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg07211511	chr3:129823064	LOC729375	-0.53	-7.02	-0.32	8.63e-12	Blood pressure (smoking interaction);
LUAD	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg11645453	chr3:52864694	ITIH4	-0.55	-10.1	-0.44	1.25e-21	Schizophrenia;
LUAD	cis	rs7043114	0.525	rs7023004	chr9:95098712	A/G	cg14631576	chr9:95140430	CENPP	-0.42	-8.65	-0.39	1.11e-16	Height;
LUAD	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg03433033	chr1:76189801	ACADM	-0.84	-15.0	-0.59	4.21e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03762994	chr17:6899332	ALOX12	-0.39	-7.26	-0.33	1.88e-12	Tonsillectomy;
LUAD	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.51	-10.54	-0.46	3.16e-23	Monocyte percentage of white cells;
LUAD	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg00631329	chr6:26305371	NA	0.69	13.15	0.54	2.42e-33	Educational attainment;
LUAD	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg14092571	chr14:90743983	NA	-0.93	-17.77	-0.65	3.43e-53	Gut microbiota (bacterial taxa);
LUAD	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-7.26	-0.33	1.83e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00149659	chr3:10157352	C3orf10	0.63	8.76	0.39	4.71e-17	Alzheimer's disease;
LUAD	cis	rs1904096	0.506	rs10028613	chr4:95223698	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.5	-8.73	-0.39	6.11e-17	Type 2 diabetes;
LUAD	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg18827107	chr12:86230957	RASSF9	-0.54	-9.54	-0.42	1.12e-19	Major depressive disorder;
LUAD	cis	rs62238980	0.614	rs4820066	chr22:32409269	T/C	cg00543991	chr22:32367038	NA	0.96	9.05	0.4	5.32e-18	Childhood ear infection;
LUAD	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg19875535	chr5:140030758	IK	-0.44	-7.3	-0.33	1.44e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg00684032	chr4:1343700	KIAA1530	0.41	6.81	0.31	3.41e-11	Obesity-related traits;
LUAD	trans	rs6076960	0.846	rs6053962	chr20:6176915	A/G	cg17788362	chr6:86352627	SYNCRIP	0.47	7.69	0.35	1.05e-13	Smooth-surface caries;
LUAD	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.96	0.32	1.34e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg18209359	chr17:80159595	CCDC57	0.38	6.39	0.3	4.26e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg08999081	chr20:33150536	PIGU	0.63	14.53	0.58	4.13e-39	Coronary artery disease;
LUAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg18402987	chr7:1209562	NA	0.8	9.85	0.43	9.51e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1959947	0.585	rs8008487	chr14:41534471	A/C	cg12533308	chr21:47878746	DIP2A	0.37	6.46	0.3	2.81e-10	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs17092148	1.000	rs910872	chr20:33334540	T/C	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.34	-0.38	1.05e-15	Neuroticism;
LUAD	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg03929089	chr4:120376271	NA	-0.73	-10.9	-0.47	1.46e-24	Coronary artery disease;
LUAD	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg07636037	chr3:49044803	WDR6	0.63	12.19	0.51	1.64e-29	Parkinson's disease;
LUAD	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg13393036	chr8:95962371	TP53INP1	-0.43	-10.37	-0.45	1.32e-22	Type 2 diabetes;
LUAD	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg22681709	chr2:178499509	PDE11A	0.46	7.63	0.35	1.56e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs76878669	0.561	rs10791876	chr11:66169646	C/T	cg18002602	chr11:66138449	SLC29A2	-0.5	-10.51	-0.46	4.04e-23	Educational attainment (years of education);
LUAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg13047869	chr3:10149882	C3orf24	0.67	11.48	0.49	9.3e-27	Alzheimer's disease;
LUAD	cis	rs17102423	0.531	rs2763888	chr14:65571493	T/C	cg16583315	chr14:65563665	MAX	-0.37	-6.92	-0.32	1.66e-11	Obesity-related traits;
LUAD	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg04248312	chr19:17393744	ANKLE1	-0.98	-17.54	-0.65	3.92e-52	Systemic lupus erythematosus;
LUAD	cis	rs9302065	0.565	rs2993586	chr13:95962578	T/C	cg24476569	chr13:95954382	ABCC4	-0.58	-10.69	-0.46	8.99e-24	Blood metabolite levels;
LUAD	cis	rs1045714	0.895	rs17833498	chr7:2647007	A/G	cg24848437	chr7:2645542	IQCE	-0.71	-8.44	-0.38	4.97e-16	Urate levels in lean individuals;
LUAD	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg15704280	chr7:45808275	SEPT13	-0.51	-8.05	-0.36	8.34e-15	Height;
LUAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00166722	chr3:10149974	C3orf24	0.74	11.02	0.47	5.41e-25	Alzheimer's disease;
LUAD	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg10468373	chr11:64009913	FKBP2	0.56	6.9	0.32	1.93e-11	Mean platelet volume;
LUAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg21280719	chr6:42927975	GNMT	-0.39	-11.95	-0.5	1.53e-28	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg14416269	chr4:6271139	WFS1	0.63	13.38	0.55	2.75e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg01689657	chr7:91764605	CYP51A1	-0.28	-6.93	-0.32	1.53e-11	Breast cancer;
LUAD	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg21427119	chr20:30132790	HM13	-0.5	-7.96	-0.36	1.59e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg04772025	chr11:68637568	NA	0.57	9.11	0.41	3.24e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs67072384	1.000	rs7120605	chr11:72444615	A/G	cg04827223	chr11:72435913	ARAP1	-0.62	-7.6	-0.35	1.96e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg00316803	chr15:76480434	C15orf27	-0.42	-8.2	-0.37	2.83e-15	Blood metabolite levels;
LUAD	trans	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.7e-10	Aortic root size;
LUAD	cis	rs6594713	0.643	rs59195845	chr5:112738011	C/T	cg12552261	chr5:112820674	MCC	0.56	8.97	0.4	9.46e-18	Brain cytoarchitecture;
LUAD	cis	rs3849570	0.673	rs9877408	chr3:81974558	A/G	cg07356753	chr3:81810745	GBE1	-0.49	-8.35	-0.38	9.78e-16	Waist circumference;Body mass index;
LUAD	trans	rs8002861	0.765	rs12868462	chr13:44453480	C/T	cg12856521	chr11:46389249	DGKZ	-0.38	-6.45	-0.3	3.06e-10	Leprosy;
LUAD	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg16989719	chr2:238392110	NA	-0.35	-7.53	-0.34	3.07e-13	Prostate cancer;
LUAD	cis	rs17362650	0.694	rs34003003	chr2:9572928	C/T	cg12832956	chr2:9616023	IAH1	-0.5	-8.64	-0.39	1.13e-16	Alcohol dependence (age at onset);
LUAD	cis	rs10484885	0.887	rs114928443	chr6:90602455	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.69	-8.58	-0.38	1.87e-16	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs7939886	0.920	rs10501343	chr11:55759573	G/T	cg15704280	chr7:45808275	SEPT13	0.68	6.74	0.31	5.23e-11	Myopia (pathological);
LUAD	cis	rs7799006	1.000	rs7810970	chr7:2276385	A/G	cg08027265	chr7:2291960	NA	-0.59	-11.12	-0.48	2.28e-25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg25985355	chr7:65971099	NA	-0.53	-6.62	-0.31	1.09e-10	Diabetic kidney disease;
LUAD	cis	rs7680126	0.596	rs10939723	chr4:10139105	G/T	cg00071950	chr4:10020882	SLC2A9	-0.49	-7.85	-0.36	3.52e-14	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs2046867	0.774	rs9820293	chr3:72876237	T/A	cg25664220	chr3:72788482	NA	-0.62	-11.09	-0.47	2.82e-25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs68170813	0.523	rs12154285	chr7:106993573	G/A	cg23024343	chr7:107201750	COG5	0.52	7.42	0.34	6.42e-13	Coronary artery disease;
LUAD	trans	rs11039798	0.614	rs2174703	chr11:48788242	G/A	cg15704280	chr7:45808275	SEPT13	0.67	7.77	0.35	6.19e-14	Axial length;
LUAD	trans	rs11039798	1.000	rs7942284	chr11:48520424	A/G	cg02254774	chr11:50257496	LOC441601	-0.56	-6.95	-0.32	1.35e-11	Axial length;
LUAD	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.38	-6.8	-0.31	3.61e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg06552810	chr11:31128660	NA	-0.33	-6.59	-0.31	1.33e-10	Bone mineral density (spine);
LUAD	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg16680214	chr1:154839983	KCNN3	-0.63	-13.12	-0.54	3.08e-33	Prostate cancer;
LUAD	cis	rs73416724	1.000	rs4714675	chr6:43287893	T/C	cg26312998	chr6:43337775	ZNF318	-0.57	-7.41	-0.34	7.1e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg09455208	chr3:40491958	NA	0.66	14.54	0.58	4.1e-39	Renal cell carcinoma;
LUAD	cis	rs6433857	0.657	rs2368177	chr2:181501242	T/C	cg23363182	chr2:181467187	NA	-0.44	-7.43	-0.34	6.06e-13	Body mass index;
LUAD	cis	rs6752107	0.837	rs3792108	chr2:234184952	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.57	9.95	0.44	4.36e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg03037974	chr15:76606532	NA	0.33	7.04	0.32	8.01e-12	Blood metabolite levels;
LUAD	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg12940439	chr1:67600707	NA	0.48	8.96	0.4	1.01e-17	Psoriasis;
LUAD	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-9.4	-0.42	3.54e-19	Gut microbiome composition (summer);
LUAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg05896524	chr21:47604654	C21orf56	-0.55	-7.97	-0.36	1.51e-14	Testicular germ cell tumor;
LUAD	cis	rs68170813	0.559	rs6964966	chr7:106933099	C/G	cg02696742	chr7:106810147	HBP1	-0.76	-10.53	-0.46	3.44e-23	Coronary artery disease;
LUAD	trans	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg26043149	chr18:55253948	FECH	0.41	6.76	0.31	4.69e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.36	-6.94	-0.32	1.49e-11	Crohn's disease;
LUAD	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg07538946	chr5:131705188	SLC22A5	0.49	8.09	0.37	6.35e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg27494647	chr7:150038898	RARRES2	0.54	8.94	0.4	1.24e-17	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg27170947	chr2:26402098	FAM59B	0.83	11.52	0.49	6.5e-27	Gut microbiome composition (summer);
LUAD	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg05665937	chr4:1216051	CTBP1	0.38	6.41	0.3	3.8e-10	Obesity-related traits;
LUAD	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.7e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg25427524	chr10:38739819	LOC399744	0.6	8.53	0.38	2.72e-16	Obesity (extreme);
LUAD	cis	rs4889855	0.530	rs12451459	chr17:78589668	G/A	cg16591659	chr17:78472290	NA	0.45	7.81	0.36	4.44e-14	Fractional excretion of uric acid;
LUAD	cis	rs10927875	0.619	rs28537253	chr1:16148600	A/C	cg21385522	chr1:16154831	NA	-0.65	-11.73	-0.5	1.1e-27	Dilated cardiomyopathy;
LUAD	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg05731713	chr7:157510257	PTPRN2	0.43	10.05	0.44	1.85e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg26597838	chr10:835615	NA	-0.47	-7.38	-0.34	8.36e-13	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg15181151	chr6:150070149	PCMT1	0.39	7.52	0.34	3.33e-13	Lung cancer;
LUAD	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg06532163	chr17:45867833	NA	0.45	8.16	0.37	3.83e-15	IgG glycosylation;
LUAD	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg15997130	chr1:24165203	NA	-0.55	-9.65	-0.42	4.95e-20	Immature fraction of reticulocytes;
LUAD	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg17366294	chr4:99064904	C4orf37	0.48	8.51	0.38	2.95e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3784262	0.631	rs4646584	chr15:58305402	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.66	-0.35	1.24e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2067615	0.579	rs10861663	chr12:107183589	G/A	cg15890332	chr12:107067104	RFX4	0.4	8.63	0.39	1.3e-16	Heart rate;
LUAD	cis	rs12908161	0.959	rs61074241	chr15:85333396	C/T	cg17173187	chr15:85201210	NMB	0.51	8.53	0.38	2.68e-16	Schizophrenia;
LUAD	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg24154853	chr7:158122151	PTPRN2	-0.56	-11.35	-0.48	2.93e-26	Calcium levels;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg24425560	chr11:95522946	CEP57;FAM76B	-0.39	-6.84	-0.32	2.79e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1385374	0.698	rs2170988	chr12:129290876	A/C	cg09035930	chr12:129282057	SLC15A4	-0.65	-6.91	-0.32	1.79e-11	Systemic lupus erythematosus;
LUAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg09033563	chr22:24373618	LOC391322	-0.51	-8.06	-0.37	7.68e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504073	0.647	rs10504072	chr8:49993083	G/A	cg00325661	chr8:49890786	NA	0.45	10.07	0.44	1.64e-21	Blood metabolite ratios;
LUAD	cis	rs4378999	0.748	rs4974104	chr3:51383354	G/A	cg12934382	chr3:51741135	GRM2	0.39	7.03	0.32	8.36e-12	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.79	-0.31	3.82e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs877426	0.591	rs56188498	chr13:114827804	A/G	cg21461300	chr13:114830702	RASA3	-0.42	-6.42	-0.3	3.57e-10	Facial morphology (factor 14, intercanthal width);
LUAD	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg10434728	chr15:90938212	IQGAP1	0.35	6.69	0.31	7.07e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg23985595	chr17:80112537	CCDC57	-0.53	-9.51	-0.42	1.43e-19	Life satisfaction;
LUAD	cis	rs938554	0.735	rs12498742	chr4:9944052	A/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.25	-0.37	2.02e-15	Blood metabolite levels;
LUAD	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg22852734	chr6:133119734	C6orf192	0.62	6.9	0.32	1.95e-11	Type 2 diabetes nephropathy;
LUAD	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg20476274	chr7:133979776	SLC35B4	0.55	9.76	0.43	2.04e-20	Mean platelet volume;
LUAD	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs11585357	1.000	rs72646785	chr1:17603472	G/T	cg08277548	chr1:17600880	PADI3	-0.97	-13.89	-0.56	2.03e-36	Hair shape;
LUAD	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11890956	chr21:40555474	PSMG1	-0.56	-9.85	-0.43	9.73e-21	Menarche (age at onset);
LUAD	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg13902645	chr11:5959945	NA	0.38	6.8	0.31	3.62e-11	DNA methylation (variation);
LUAD	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg26384229	chr12:38710491	ALG10B	0.47	7.61	0.35	1.75e-13	Morning vs. evening chronotype;
LUAD	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg19318889	chr4:1322082	MAEA	0.46	7.45	0.34	5.27e-13	Obesity-related traits;
LUAD	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	13.06	0.54	5.6e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7089973	0.872	rs34683721	chr10:116619849	G/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.69	0.43	3.5e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg08219700	chr8:58056026	NA	0.59	7.67	0.35	1.18e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs959260	1.000	rs4789189	chr17:73397985	C/G	cg07104495	chr17:73266070	MIF4GD	-0.31	-6.57	-0.3	1.52e-10	Systemic lupus erythematosus;
LUAD	cis	rs7192380	0.756	rs12596945	chr16:69780819	C/A	cg00738113	chr16:70207722	CLEC18C	0.4	8.1	0.37	6.14e-15	Sjögren's syndrome;
LUAD	cis	rs1448094	0.872	rs7300073	chr12:86393513	A/C	cg06740227	chr12:86229804	RASSF9	0.36	6.54	0.3	1.74e-10	Major depressive disorder;
LUAD	cis	rs367943	0.712	rs9326886	chr5:112728458	A/C	cg12552261	chr5:112820674	MCC	0.48	9.33	0.41	5.87e-19	Type 2 diabetes;
LUAD	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg07404485	chr7:94953653	PON1	-0.52	-7.3	-0.33	1.43e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9902453	0.769	rs7210288	chr17:28243473	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.26	0.41	1.02e-18	Coffee consumption (cups per day);
LUAD	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg04455712	chr21:45112962	RRP1B	-0.38	-7.53	-0.34	3e-13	Mean corpuscular volume;
LUAD	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.47	7.68	0.35	1.13e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs3750965	0.959	rs2253658	chr11:68856804	C/G	cg06818126	chr11:68850279	TPCN2	-0.49	-7.26	-0.33	1.82e-12	Hair color;
LUAD	cis	rs9863	0.828	rs7307277	chr12:124475156	A/G	cg17723958	chr12:124429295	CCDC92	-0.4	-6.66	-0.31	8.62e-11	White blood cell count;
LUAD	cis	rs7149337	0.836	rs12588488	chr14:51660217	C/A	cg23942311	chr14:51606299	NA	0.84	19.14	0.68	2.9e-59	Cancer;
LUAD	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg15628303	chr1:26608928	UBXN11	-0.37	-6.57	-0.3	1.51e-10	Height;
LUAD	cis	rs4919694	1.000	rs4917988	chr10:104752830	T/G	cg04362960	chr10:104952993	NT5C2	0.71	7.55	0.34	2.63e-13	Arsenic metabolism;
LUAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg20607798	chr8:58055168	NA	0.67	8.77	0.39	4.44e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg16647868	chr5:131706066	SLC22A5	0.4	6.9	0.32	1.89e-11	Blood metabolite levels;
LUAD	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg19622623	chr12:86230825	RASSF9	-0.37	-6.75	-0.31	4.9e-11	Major depressive disorder;
LUAD	trans	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-10.19	-0.44	6.11e-22	Brugada syndrome;
LUAD	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08109568	chr15:31115862	NA	-0.6	-10.03	-0.44	2.26e-21	Huntington's disease progression;
LUAD	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.24	-0.41	1.18e-18	Life satisfaction;
LUAD	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg20503657	chr10:835505	NA	0.95	14.57	0.58	2.92e-39	Eosinophil percentage of granulocytes;
LUAD	cis	rs346785	1.000	rs164106	chr17:74290566	C/A	cg09812376	chr17:74270190	QRICH2	-0.3	-6.99	-0.32	1.05e-11	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg00383909	chr3:49044727	WDR6	0.72	8.38	0.38	8.01e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs11677416	1.000	rs6542092	chr2:113528322	C/G	cg27083787	chr2:113543245	IL1A	0.38	6.64	0.31	9.65e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg17509989	chr5:176798049	RGS14	-0.52	-9.19	-0.41	1.8e-18	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15506890	chr2:3487001	NA	-0.45	-7.91	-0.36	2.28e-14	Neurofibrillary tangles;
LUAD	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg22920501	chr2:26401640	FAM59B	0.96	13.85	0.56	2.96e-36	Gut microbiome composition (summer);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03144560	chr20:55043299	C20orf43	-0.53	-6.58	-0.3	1.38e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs887829	0.694	rs6725478	chr2:234615400	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-10.15	-0.44	7.98e-22	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.7	-13.7	-0.55	1.31e-35	Ulcerative colitis;
LUAD	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg15110403	chr19:17392923	ANKLE1	0.47	7.75	0.35	6.86e-14	Systemic lupus erythematosus;
LUAD	cis	rs939658	0.776	rs869672	chr15:79430860	G/A	cg17916960	chr15:79447300	NA	-0.51	-10.58	-0.46	2.3e-23	Refractive error;
LUAD	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.66	10.76	0.46	4.98e-24	Height;
LUAD	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.91	0.32	1.78e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs113835537	0.529	rs17496250	chr11:66270774	C/G	cg24851651	chr11:66362959	CCS	0.56	9.72	0.43	2.64e-20	Airway imaging phenotypes;
LUAD	trans	rs9302065	1.000	rs2389236	chr13:95971477	G/A	cg19955956	chr7:72299837	SBDSP;TYW1B	0.37	6.44	0.3	3.28e-10	Blood metabolite levels;
LUAD	cis	rs9467773	1.000	rs1570061	chr6:26575986	T/C	cg09904177	chr6:26538194	HMGN4	0.44	7.03	0.32	8.25e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg07741184	chr6:167504864	NA	0.35	8.14	0.37	4.46e-15	Primary biliary cholangitis;
LUAD	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg01851573	chr8:8652454	MFHAS1	-0.45	-8.29	-0.37	1.52e-15	Mood instability;
LUAD	cis	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg21775007	chr8:11205619	TDH	-0.4	-6.83	-0.31	3.05e-11	Neuroticism;
LUAD	cis	rs11948739	0.501	rs971699	chr5:130361558	A/G	cg08523029	chr5:130500466	HINT1	-0.59	-7.57	-0.35	2.34e-13	Pediatric bone mineral content (hip);
LUAD	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg16006841	chr5:176797999	RGS14	0.59	9.08	0.4	4.1e-18	Urate levels in lean individuals;
LUAD	cis	rs4689388	0.647	rs9997824	chr4:6283253	T/C	cg14416269	chr4:6271139	WFS1	0.6	11.11	0.48	2.4e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg17633681	chr16:88106987	BANP	0.39	6.89	0.32	2.05e-11	Menopause (age at onset);
LUAD	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg18944383	chr4:111397179	ENPEP	0.41	8.26	0.37	1.87e-15	Height;
LUAD	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg05896524	chr21:47604654	C21orf56	0.54	8.33	0.38	1.14e-15	Testicular germ cell tumor;
LUAD	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg12034118	chr1:209979487	IRF6	0.54	6.59	0.31	1.33e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg25319279	chr11:5960081	NA	-0.4	-7.21	-0.33	2.55e-12	DNA methylation (variation);
LUAD	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg07677032	chr17:61819896	STRADA	0.56	10.28	0.45	2.7e-22	Prudent dietary pattern;
LUAD	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg22705602	chr4:152727874	NA	-0.41	-7.12	-0.33	4.82e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs887829	0.641	rs10167119	chr2:234589312	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-9.76	-0.43	1.97e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	trans	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg04565464	chr8:145669602	NFKBIL2	0.44	6.54	0.3	1.81e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs89107	0.576	rs117344633	chr6:118837268	T/C	cg21191810	chr6:118973309	C6orf204	0.4	7.43	0.34	5.98e-13	Cardiac structure and function;
LUAD	cis	rs13315871	0.929	rs11720747	chr3:58267833	G/A	cg20936604	chr3:58311152	NA	-0.76	-7.66	-0.35	1.28e-13	Cholesterol, total;
LUAD	cis	rs17092148	0.887	rs2889849	chr20:33164277	A/G	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.17	-0.37	3.53e-15	Neuroticism;
LUAD	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg22431228	chr1:16359049	CLCNKA	-0.53	-9.55	-0.42	1.07e-19	Dilated cardiomyopathy;
LUAD	trans	rs1728785	0.688	rs698729	chr16:68624205	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	10.57	0.46	2.42e-23	Ulcerative colitis;
LUAD	trans	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.29e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg07606381	chr6:8435919	SLC35B3	0.4	6.59	0.31	1.3100000000000001e-10	Motion sickness;
LUAD	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg03395511	chr6:291903	DUSP22	-0.51	-8.4	-0.38	6.6e-16	Menopause (age at onset);
LUAD	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.57	-0.3	1.45e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg15445000	chr17:37608096	MED1	0.44	8.23	0.37	2.26e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg24531977	chr5:56204891	C5orf35	-0.39	-6.49	-0.3	2.47e-10	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg02592271	chr2:27665507	KRTCAP3	0.29	7.81	0.36	4.53e-14	Total body bone mineral density;
LUAD	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg16049864	chr8:95962084	TP53INP1	0.45	8.77	0.39	4.35e-17	Type 2 diabetes;
LUAD	cis	rs752010	0.631	rs7515066	chr1:42076915	A/G	cg06885757	chr1:42089581	HIVEP3	-0.61	-14.07	-0.56	3.7e-37	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs4006360	0.514	rs1588393	chr17:39247900	T/C	cg16090541	chr17:39240343	KRTAP4-7	-0.36	-6.35	-0.3	5.41e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs806215	1.000	rs806196	chr7:127248414	A/G	cg25922125	chr7:127225783	GCC1	0.49	7.1	0.33	5.47e-12	Type 2 diabetes;
LUAD	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.38	-6.82	-0.31	3.22e-11	Insulin-like growth factors;
LUAD	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg05623727	chr3:50126028	RBM5	0.32	7.05	0.32	7.1e-12	Body mass index;
LUAD	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg05425664	chr17:57184151	TRIM37	0.4	7.11	0.33	4.83e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg03560586	chr2:239334908	ASB1	-0.3	-6.35	-0.3	5.45e-10	Multiple system atrophy;
LUAD	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg07570687	chr10:102243282	WNT8B	0.46	7.09	0.33	5.53e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.43	-0.38	5.34e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs141518190	1	rs141518190	chr15:78900647	A/G	cg18825076	chr15:78729989	IREB2	-0.58	-9.46	-0.42	2.23e-19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg13319975	chr6:146136371	FBXO30	0.65	11.37	0.48	2.59e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.14	0.33	4.19e-12	Motion sickness;
LUAD	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg21699342	chr2:239360505	ASB1	0.59	11.86	0.5	3.27e-28	Multiple system atrophy;
LUAD	cis	rs4144027	0.935	rs881056	chr14:104354225	G/A	cg12183467	chr14:104352244	NA	-0.36	-6.91	-0.32	1.81e-11	Blood metabolite levels;
LUAD	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg11189052	chr15:85197271	WDR73	0.66	8.86	0.4	2.32e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg12016809	chr21:47604291	C21orf56	0.46	7.61	0.35	1.75e-13	Testicular germ cell tumor;
LUAD	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-7.79	-0.35	5.4e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.49	-8.61	-0.39	1.44e-16	Tonsillectomy;
LUAD	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg21475434	chr5:93447410	FAM172A	0.77	8.6	0.39	1.57e-16	Diabetic retinopathy;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06015203	chr14:51297334	NIN	-0.39	-6.39	-0.3	4.34e-10	Cancer;
LUAD	trans	rs10411161	0.657	rs67462252	chr19:52382851	T/C	cg22319618	chr22:45562946	NUP50	-0.6	-8.4	-0.38	7.02e-16	Breast cancer;
LUAD	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.38	-0.45	1.18e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg06138931	chr13:21896616	NA	0.44	7.69	0.35	1.07e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs4285028	0.699	rs73855465	chr3:121574219	C/T	cg11130432	chr3:121712080	ILDR1	-0.57	-8.19	-0.37	3.12e-15	Multiple sclerosis;
LUAD	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg15997130	chr1:24165203	NA	0.54	9.26	0.41	1.03e-18	Immature fraction of reticulocytes;
LUAD	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg22482690	chr17:47019901	SNF8	0.44	8.32	0.37	1.25e-15	Type 2 diabetes;
LUAD	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg14598338	chr9:96623480	NA	-0.42	-9.01	-0.4	6.96e-18	DNA methylation (variation);
LUAD	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg24558204	chr6:135376177	HBS1L	0.43	7.29	0.33	1.59e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg08601574	chr20:25228251	PYGB	0.47	8.88	0.4	1.93e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1448094	0.872	rs7305869	chr12:86440114	A/G	cg06740227	chr12:86229804	RASSF9	0.35	6.39	0.3	4.44e-10	Major depressive disorder;
LUAD	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg23758822	chr17:41437982	NA	1.0	20.4	0.7	6.27e-65	Menopause (age at onset);
LUAD	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg00933542	chr6:150070202	PCMT1	0.41	8.14	0.37	4.55e-15	Lung cancer;
LUAD	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.87	-0.32	2.25e-11	Height;
LUAD	cis	rs8017423	0.967	rs1005788	chr14:90692747	C/T	cg14092571	chr14:90743983	NA	-0.48	-8.42	-0.38	5.71e-16	Mortality in heart failure;
LUAD	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg23950597	chr19:37808831	NA	-0.63	-7.38	-0.34	8.71e-13	Coronary artery calcification;
LUAD	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg24011408	chr12:48396354	COL2A1	-0.43	-9.64	-0.42	5.39e-20	Plateletcrit;
LUAD	cis	rs7771547	0.574	rs11756557	chr6:36597695	A/G	cg12173498	chr6:36355764	ETV7	0.5	6.66	0.31	8.54e-11	Platelet distribution width;
LUAD	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.99	-0.36	1.33e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg00255919	chr5:131827918	IRF1	0.28	6.43	0.3	3.47e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs62238980	0.522	rs117304447	chr22:32422267	C/T	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg14820908	chr5:178986412	RUFY1	0.55	8.03	0.36	9.81e-15	Lung cancer;
LUAD	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg02038168	chr22:39784481	NA	-0.58	-10.3	-0.45	2.42e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg07423050	chr13:99094983	FARP1	-0.54	-9.1	-0.4	3.6e-18	Longevity;
LUAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08677398	chr8:58056175	NA	0.47	6.59	0.31	1.34e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg17264618	chr3:40429014	ENTPD3	-0.4	-8.66	-0.39	9.89e-17	Renal cell carcinoma;
LUAD	cis	rs7593730	0.945	rs4277476	chr2:161219181	A/T	cg22609984	chr2:161126801	NA	0.41	6.61	0.31	1.15e-10	Type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18845578	chr2:240003174	HDAC4	0.55	6.91	0.32	1.79e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4853036	1.000	rs1454499	chr2:70062939	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.24	-0.33	2.15e-12	Colorectal or endometrial cancer;
LUAD	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg02569458	chr12:86230093	RASSF9	-0.42	-7.87	-0.36	2.92e-14	Major depressive disorder;
LUAD	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg02782426	chr3:40428986	ENTPD3	0.37	8.1	0.37	5.86e-15	Renal cell carcinoma;
LUAD	cis	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg26958806	chr6:27640298	NA	0.65	6.48	0.3	2.49e-10	Urinary tract infection frequency;
LUAD	trans	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg21659725	chr3:3221576	CRBN	-0.43	-7.14	-0.33	4.04e-12	Menarche (age at onset);
LUAD	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg08885076	chr2:99613938	TSGA10	0.36	6.47	0.3	2.74e-10	Chronic sinus infection;
LUAD	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg18367735	chr17:79674897	NA	0.54	6.85	0.32	2.65e-11	Dental caries;
LUAD	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.75	-0.35	7.14e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4588572	0.643	rs10068686	chr5:77795220	C/T	cg11547950	chr5:77652471	NA	-0.76	-12.23	-0.51	1.12e-29	Triglycerides;
LUAD	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg18944383	chr4:111397179	ENPEP	-0.52	-9.54	-0.42	1.12e-19	Coronary artery disease;
LUAD	cis	rs11048434	0.736	rs7301381	chr12:9123932	T/C	cg26114124	chr12:9217669	LOC144571	0.36	6.63	0.31	1.04e-10	Sjögren's syndrome;
LUAD	trans	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg15704280	chr7:45808275	SEPT13	-0.66	-8.87	-0.4	2.12e-17	D-dimer levels;
LUAD	cis	rs727505	1.000	rs7777947	chr7:124436063	T/G	cg23710748	chr7:124431027	NA	-0.43	-9.08	-0.4	4.26e-18	Lewy body disease;
LUAD	trans	rs3942852	0.868	rs58407618	chr11:48104167	T/G	cg15704280	chr7:45808275	SEPT13	-0.58	-7.85	-0.36	3.51e-14	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg24644049	chr4:85504048	CDS1	0.88	7.59	0.35	2.1e-13	Skin colour saturation;
LUAD	cis	rs4523957	0.583	rs903159	chr17:2055109	C/T	cg16513277	chr17:2031491	SMG6	-0.98	-19.34	-0.69	3.69e-60	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4776059	1.000	rs4776066	chr15:52930499	T/C	cg24008177	chr15:52972085	KIAA1370	0.24	6.63	0.31	1e-10	Schizophrenia;
LUAD	cis	rs9549328	0.800	rs9549619	chr13:113632620	C/G	cg17524180	chr13:113633600	MCF2L	-0.38	-7.61	-0.35	1.78e-13	Systolic blood pressure;
LUAD	cis	rs1564271	0.506	rs1148163	chr10:26929671	G/C	cg13837822	chr10:26931731	LOC731789	0.55	11.42	0.49	1.59e-26	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUAD	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-10.73	-0.46	6.34e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14337900	chr22:36783947	MYH9	-0.44	-7.06	-0.32	7.03e-12	Height;
LUAD	cis	rs4268898	1.000	rs10195436	chr2:24436112	C/T	cg02683114	chr2:24398427	C2orf84	0.42	6.92	0.32	1.7e-11	Asthma;
LUAD	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg04455712	chr21:45112962	RRP1B	0.46	9.2	0.41	1.66e-18	Mean corpuscular volume;
LUAD	cis	rs12681287	0.640	rs10086340	chr8:87446789	G/T	cg27223183	chr8:87520930	FAM82B	-0.6	-8.95	-0.4	1.12e-17	Caudate activity during reward;
LUAD	cis	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg11143507	chr3:125485238	NA	-0.45	-7.37	-0.34	9.24e-13	Blood pressure (smoking interaction);
LUAD	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23158103	chr7:148848205	ZNF398	-0.66	-12.47	-0.52	1.28e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg02753203	chr1:228287806	NA	0.81	14.8	0.58	3.22e-40	Diastolic blood pressure;
LUAD	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg15017067	chr4:17643749	FAM184B	0.38	7.29	0.33	1.57e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg06784218	chr1:46089804	CCDC17	0.6	13.41	0.55	2.08e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1595825	0.891	rs58111212	chr2:198889896	T/C	cg11031976	chr2:198649780	BOLL	-0.45	-6.56	-0.3	1.62e-10	Ulcerative colitis;
LUAD	cis	rs73206853	0.841	rs73194013	chr12:111100677	T/C	cg12870014	chr12:110450643	ANKRD13A	0.58	6.36	0.3	5.32e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg13319975	chr6:146136371	FBXO30	-0.65	-11.28	-0.48	5.54e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg27532560	chr4:187881888	NA	-0.37	-7.18	-0.33	3.2e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7707921	0.881	rs6875409	chr5:81297077	A/G	cg15871215	chr5:81402204	ATG10	-0.7	-9.86	-0.43	8.87e-21	Breast cancer;
LUAD	cis	rs7617773	0.817	rs11710861	chr3:48297560	C/T	cg11946769	chr3:48343235	NME6	0.44	7.02	0.32	8.95e-12	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg07917127	chr4:99064746	C4orf37	-0.43	-7.06	-0.32	6.98e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg05425664	chr17:57184151	TRIM37	-0.42	-7.62	-0.35	1.65e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15356674	chr10:79471309	NA	-0.39	-6.48	-0.3	2.59e-10	Height;
LUAD	cis	rs8044995	0.501	rs73613952	chr16:68352808	G/C	cg05110241	chr16:68378359	PRMT7	-0.94	-10.49	-0.45	4.82e-23	Schizophrenia;
LUAD	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.6	8.45	0.38	4.59e-16	Gut microbiome composition (summer);
LUAD	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg12458913	chr13:53173898	NA	0.5	8.76	0.39	4.69e-17	Lewy body disease;
LUAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.51	-9.05	-0.4	5.33e-18	Lymphocyte counts;
LUAD	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.1	-0.33	5.45e-12	Joint mobility (Beighton score);
LUAD	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg23758822	chr17:41437982	NA	1.01	20.62	0.71	6.95e-66	Menopause (age at onset);
LUAD	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.73	-8.62	-0.39	1.39e-16	Body mass index;
LUAD	cis	rs9900062	0.586	rs12600679	chr17:62687327	T/G	cg02097616	chr17:62675921	NA	0.71	11.91	0.5	2.08e-28	QT interval;
LUAD	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg05234568	chr11:5960015	NA	-0.51	-9.07	-0.4	4.62e-18	DNA methylation (variation);
LUAD	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.9	-13.41	-0.55	2.03e-34	Red cell distribution width;
LUAD	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg10518543	chr12:38710700	ALG10B	0.41	6.38	0.3	4.74e-10	Bladder cancer;
LUAD	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg20203395	chr5:56204925	C5orf35	-0.7	-10.19	-0.44	5.83e-22	Initial pursuit acceleration;
LUAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg24642844	chr7:1081250	C7orf50	-0.98	-14.9	-0.59	1.22e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg05717871	chr11:638507	DRD4	-0.41	-6.45	-0.3	3.12e-10	Systemic lupus erythematosus;
LUAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg15117754	chr3:10150083	C3orf24	0.41	6.61	0.31	1.19e-10	Alzheimer's disease;
LUAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.76e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg10515982	chr10:120966350	GRK5	-0.39	-6.5	-0.3	2.33e-10	Cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24035104	chr1:44445524	B4GALT2	-0.53	-6.54	-0.3	1.81e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2230307	0.536	rs526128	chr1:100473427	T/A	cg20868668	chr1:100435035	SLC35A3	0.54	7.78	0.35	5.7e-14	Carotid intima media thickness;
LUAD	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.5	-8.59	-0.39	1.68e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg10518543	chr12:38710700	ALG10B	-0.43	-7.1	-0.33	5.42e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg00933542	chr6:150070202	PCMT1	0.44	9.24	0.41	1.21e-18	Lung cancer;
LUAD	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg09796270	chr17:17721594	SREBF1	-0.4	-8.07	-0.37	7.34e-15	Total body bone mineral density;
LUAD	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg27454412	chr7:1067447	C7orf50	-0.34	-6.58	-0.3	1.37e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs1843834	0.716	rs6716600	chr2:225481991	A/T	cg22455342	chr2:225449267	CUL3	0.45	6.87	0.32	2.29e-11	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23583168	chr7:148888333	NA	-0.9	-18.52	-0.67	1.58e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7072216	0.763	rs3814140	chr10:100170762	C/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.68	-0.39	8.56e-17	Metabolite levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg18821316	chr1:153931119	CRTC2	-0.44	-7.27	-0.33	1.81e-12	Cancer;
LUAD	trans	rs7395662	0.864	rs11039872	chr11:48629533	C/T	cg00717180	chr2:96193071	NA	-0.38	-7.14	-0.33	4.17e-12	HDL cholesterol;
LUAD	cis	rs9515201	0.859	rs9515199	chr13:111033704	C/T	cg05272587	chr13:111038400	COL4A2	0.36	6.73	0.31	5.47e-11	White matter hyperintensity burden;
LUAD	cis	rs8060686	0.668	rs9932414	chr16:68219969	A/G	cg26727032	chr16:67993705	SLC12A4	-0.44	-7.35	-0.34	1.01e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg07460842	chr6:66804631	NA	0.61	9.6	0.42	7.41e-20	Type 2 diabetes;
LUAD	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg13902645	chr11:5959945	NA	-0.56	-10.44	-0.45	7.46e-23	DNA methylation (variation);
LUAD	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg20476274	chr7:133979776	SLC35B4	-0.57	-9.06	-0.4	4.95e-18	Mean platelet volume;
LUAD	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg27661571	chr11:113659931	NA	-0.7	-8.17	-0.37	3.56e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs8044868	0.561	rs3909542	chr16:72183505	C/T	cg23815491	chr16:72088622	HP	0.53	10.01	0.44	2.53e-21	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.86	-0.36	3.29e-14	Total body bone mineral density;
LUAD	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg06092702	chr1:163392909	NA	0.4	9.08	0.4	4.03e-18	Motion sickness;
LUAD	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg12564285	chr5:131593104	PDLIM4	0.34	6.42	0.3	3.76e-10	Breast cancer;
LUAD	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.73	-14.12	-0.57	2.39e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg18180107	chr4:99064573	C4orf37	0.42	6.74	0.31	5.2e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg11494091	chr17:61959527	GH2	0.44	8.65	0.39	1.09e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs3806843	0.547	rs246048	chr5:140327900	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg01528321	chr10:82214614	TSPAN14	0.57	9.25	0.41	1.11e-18	Post bronchodilator FEV1;
LUAD	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg05373962	chr22:49881684	NA	-0.49	-9.48	-0.42	1.79e-19	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg27572855	chr1:25598939	RHD	0.59	13.3	0.54	5.56e-34	Erythrocyte sedimentation rate;
LUAD	cis	rs9826463	0.757	rs73238202	chr3:142205344	C/T	cg20824294	chr3:142316082	PLS1	0.42	7.49	0.34	3.98e-13	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg09658497	chr7:2847517	GNA12	-0.55	-9.38	-0.42	3.97e-19	Height;
LUAD	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg02734326	chr4:10020555	SLC2A9	0.47	8.29	0.37	1.51e-15	Bone mineral density;
LUAD	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg18129178	chr5:148520854	ABLIM3	-0.63	-9.64	-0.42	5.18e-20	Breast cancer;
LUAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.14	-0.37	4.61e-15	Alzheimer's disease;
LUAD	trans	rs853679	0.607	rs13211507	chr6:28257377	T/C	cg06606381	chr12:133084897	FBRSL1	-1.19	-11.36	-0.48	2.75e-26	Depression;
LUAD	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg18230493	chr5:56204884	C5orf35	-0.43	-7.27	-0.33	1.76e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg00310523	chr12:86230176	RASSF9	0.42	8.83	0.39	2.75e-17	Major depressive disorder;
LUAD	cis	rs2455601	0.882	rs11042116	chr11:8928472	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-7.33	-0.34	1.17e-12	Schizophrenia;
LUAD	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg00106254	chr7:1943704	MAD1L1	-0.5	-7.54	-0.34	2.91e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg00981070	chr1:2046702	PRKCZ	0.37	6.99	0.32	1.05e-11	Height;
LUAD	cis	rs7264396	0.563	rs11906854	chr20:34383634	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.65	-0.35	1.36e-13	Total cholesterol levels;
LUAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.65	-11.48	-0.49	9.53e-27	Longevity;Endometriosis;
LUAD	cis	rs7267979	1.000	rs398036	chr20:25439850	C/T	cg08601574	chr20:25228251	PYGB	0.46	8.52	0.38	2.83e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9894429	0.527	rs7405469	chr17:79566596	G/C	cg21028142	chr17:79581711	NPLOC4	-0.36	-6.57	-0.3	1.45e-10	Eye color traits;
LUAD	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg03467027	chr4:99064603	C4orf37	0.43	6.93	0.32	1.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7301016	0.802	rs11613011	chr12:63023078	T/C	cg11441379	chr12:63026424	NA	0.64	7.86	0.36	3.13e-14	IgG glycosylation;
LUAD	cis	rs68170813	0.559	rs78610616	chr7:106951369	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-10.58	-0.46	2.37e-23	Coronary artery disease;
LUAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	6.94	0.32	1.44e-11	Renal function-related traits (BUN);
LUAD	trans	rs372883	0.638	rs371432	chr21:30710876	G/A	cg14791747	chr16:20752902	THUMPD1	0.49	7.14	0.33	4.09e-12	Pancreatic cancer;
LUAD	cis	rs9653442	0.712	rs6749757	chr2:100730111	A/C	cg22139774	chr2:100720529	AFF3	0.34	6.63	0.31	1.02e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs72634258	1.000	rs72634258	chr1:8150638	T/C	cg26816564	chr1:7831052	VAMP3	0.57	7.25	0.33	1.96e-12	Inflammatory bowel disease;
LUAD	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg19318889	chr4:1322082	MAEA	-0.44	-7.57	-0.35	2.32e-13	Obesity-related traits;
LUAD	cis	rs55665837	1.000	rs11023223	chr11:14457112	A/G	cg19336497	chr11:14380999	RRAS2	-0.5	-10.21	-0.44	5.12e-22	Vitamin D levels;
LUAD	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.55	-9.16	-0.41	2.19e-18	Glomerular filtration rate;
LUAD	cis	rs6076065	0.823	rs743021	chr20:23401707	C/T	cg11657817	chr20:23433608	CST11	-0.47	-9.49	-0.42	1.7e-19	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	trans	rs4650994	0.550	rs12047530	chr1:178543407	A/G	cg05059571	chr16:84539110	KIAA1609	0.44	6.75	0.31	4.85e-11	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg22681709	chr2:178499509	PDE11A	-0.5	-8.31	-0.37	1.36e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25509428	chr10:75118432	TTC18	-0.41	-6.47	-0.3	2.78e-10	Height;
LUAD	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.61	11.36	0.48	2.79e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3785574	0.650	rs2320125	chr17:62008318	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-8.31	-0.37	1.35e-15	Height;
LUAD	cis	rs3823572	0.548	rs2971981	chr7:133651555	T/C	cg03336402	chr7:133662267	EXOC4	-0.42	-7.7	-0.35	9.59e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg22338127	chr1:209979572	IRF6	0.49	6.81	0.31	3.29e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg06671706	chr8:8559999	CLDN23	-0.69	-11.79	-0.5	6.21e-28	Obesity-related traits;
LUAD	cis	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg21775007	chr8:11205619	TDH	0.37	6.44	0.3	3.16e-10	Neuroticism;
LUAD	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg20933634	chr6:27740509	NA	0.48	7.8	0.35	5e-14	Parkinson's disease;
LUAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.66	-12.52	-0.52	8.38e-31	Longevity;Endometriosis;
LUAD	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.41	-0.52	2.34e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs4862307	0.836	rs4862304	chr4:184996607	C/T	cg06737308	chr4:185021514	ENPP6	0.57	9.54	0.42	1.17e-19	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	6.91	0.32	1.8e-11	Lung cancer in ever smokers;
LUAD	cis	rs9469578	1.000	rs9469580	chr6:33715837	A/G	cg18708504	chr6:33715942	IP6K3	-0.7	-8.53	-0.38	2.7e-16	Phosphorus levels;
LUAD	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg19318889	chr4:1322082	MAEA	-0.74	-12.66	-0.52	2.33e-31	Obesity-related traits;
LUAD	cis	rs7771547	0.519	rs12663882	chr6:36362441	G/T	cg07856975	chr6:36356162	ETV7	-0.49	-7.56	-0.35	2.44e-13	Platelet distribution width;
LUAD	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg10589385	chr1:150898437	SETDB1	0.43	8.23	0.37	2.32e-15	Melanoma;
LUAD	cis	rs12928939	0.517	rs8050058	chr16:71981374	T/G	cg03805757	chr16:71968109	PKD1L3	-0.52	-8.3	-0.37	1.41e-15	Post bronchodilator FEV1;
LUAD	cis	rs4604732	0.588	rs6677477	chr1:247629411	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.45	7.3	0.33	1.4e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs11025523	0.950	rs12576548	chr11:20381654	T/G	cg02900213	chr11:20385756	HTATIP2	0.48	7.44	0.34	5.86e-13	Obesity-related traits;
LUAD	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg15147215	chr3:52552868	STAB1	-0.46	-8.64	-0.39	1.16e-16	Electroencephalogram traits;
LUAD	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg07636037	chr3:49044803	WDR6	0.64	12.26	0.51	8.7e-30	Parkinson's disease;
LUAD	cis	rs2455799	0.835	rs11923217	chr3:15872730	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-6.67	-0.31	8.25e-11	Mean platelet volume;
LUAD	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg19678392	chr7:94953810	PON1	-0.58	-7.96	-0.36	1.56e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3849570	0.925	rs13091492	chr3:81891476	A/G	cg07356753	chr3:81810745	GBE1	-0.6	-10.52	-0.46	3.7e-23	Waist circumference;Body mass index;
LUAD	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg01689657	chr7:91764605	CYP51A1	0.32	7.96	0.36	1.65e-14	Breast cancer;
LUAD	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg03733263	chr8:22462867	KIAA1967	0.72	12.64	0.52	2.65e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg25811766	chr13:21894605	NA	-0.62	-7.54	-0.34	2.91e-13	White matter hyperintensity burden;
LUAD	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg11919837	chr8:57350735	NA	-0.43	-6.41	-0.3	3.98e-10	Obesity-related traits;
LUAD	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg05665937	chr4:1216051	CTBP1	-0.43	-7.7	-0.35	1.01e-13	Obesity-related traits;
LUAD	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg24642844	chr7:1081250	C7orf50	-0.58	-7.01	-0.32	9.56e-12	Longevity;Endometriosis;
LUAD	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.74	13.62	0.55	2.76e-35	Axial length;
LUAD	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg00204512	chr16:28754710	NA	0.33	7.11	0.33	4.84e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1403694	1.000	rs1648716	chr3:186439529	C/T	cg12454167	chr3:186435060	KNG1	0.42	8.85	0.4	2.46e-17	Blood protein levels;
LUAD	cis	rs9473147	0.543	rs9296559	chr6:47452270	T/C	cg20196966	chr6:47445060	CD2AP	0.43	6.58	0.3	1.37e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.18	0.54	1.79e-33	Prudent dietary pattern;
LUAD	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg10792982	chr14:105748885	BRF1	0.41	9.18	0.41	1.99e-18	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg12908607	chr1:44402522	ARTN	-0.45	-8.77	-0.39	4.25e-17	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.26	0.33	1.9e-12	Melanoma;
LUAD	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg08859206	chr1:53392774	SCP2	0.59	10.6	0.46	1.98e-23	Monocyte count;
LUAD	trans	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg07211511	chr3:129823064	LOC729375	-0.52	-7.32	-0.34	1.22e-12	Blood pressure (smoking interaction);
LUAD	cis	rs2019216	0.500	rs6565385	chr17:21897646	C/A	cg05591447	chr17:21909280	FLJ36000	-0.27	-6.5	-0.3	2.24e-10	Pelvic organ prolapse;
LUAD	cis	rs6669119	1.000	rs6669544	chr1:19109036	C/G	cg19637330	chr1:19110922	NA	-0.62	-6.39	-0.3	4.44e-10	Percentage gas trapping;
LUAD	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.42	-0.38	5.77e-16	Gut microbiome composition (summer);
LUAD	cis	rs9796	0.689	rs28497404	chr15:41449510	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.44	-8.01	-0.36	1.11e-14	Menopause (age at onset);
LUAD	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.57	-0.35	2.42e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg07636037	chr3:49044803	WDR6	0.63	12.1	0.51	3.65e-29	Parkinson's disease;
LUAD	cis	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg00071950	chr4:10020882	SLC2A9	0.48	7.3	0.33	1.4e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs1371614	0.655	rs509047	chr2:27128529	T/C	cg00617064	chr2:27272375	NA	0.35	6.75	0.31	5.02e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs2224391	0.590	rs72815603	chr6:5278701	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.62	-7.94	-0.36	1.89e-14	Height;
LUAD	cis	rs17608059	0.634	rs10852819	chr17:13921426	C/A	cg27005118	chr17:13972210	COX10	-0.33	-6.8	-0.31	3.62e-11	Temperament;
LUAD	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg26898376	chr11:64110657	CCDC88B	0.37	6.86	0.32	2.52e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg15181151	chr6:150070149	PCMT1	0.42	8.65	0.39	1.1e-16	Lung cancer;
LUAD	cis	rs9329289	0.851	rs9732077	chr10:2539925	A/T	cg15501526	chr10:2543763	NA	0.68	15.35	0.6	1.44e-42	Age-related hearing impairment;
LUAD	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg22532475	chr10:104410764	TRIM8	-0.35	-7.02	-0.32	8.86e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg10468373	chr11:64009913	FKBP2	0.5	6.42	0.3	3.77e-10	Mean platelet volume;
LUAD	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg19761014	chr17:28927070	LRRC37B2	0.87	10.19	0.44	6.15e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs989128	0.600	rs739924	chr17:48631607	T/C	cg24438145	chr17:48624694	SPATA20	0.37	6.53	0.3	1.92e-10	Type 2 diabetes;
LUAD	trans	rs7944735	0.507	rs7114598	chr11:48101766	C/T	cg15704280	chr7:45808275	SEPT13	0.66	9.46	0.42	2.19e-19	Intraocular pressure;
LUAD	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	8.68	0.39	8.96e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg12140854	chr5:148520817	ABLIM3	-0.68	-10.93	-0.47	1.2e-24	Breast cancer;
LUAD	cis	rs9462027	0.585	rs2814974	chr6:34572028	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.78	-0.39	3.98e-17	Systemic lupus erythematosus;
LUAD	cis	rs28595532	0.623	rs34082100	chr4:119220563	C/T	cg02775129	chr4:119771670	NA	-0.63	-6.81	-0.31	3.36e-11	Cannabis dependence symptom count;
LUAD	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg03188948	chr7:1209495	NA	0.72	6.8	0.31	3.58e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12681287	0.711	rs28506490	chr8:87246118	T/C	cg27223183	chr8:87520930	FAM82B	-0.58	-8.34	-0.38	1.07e-15	Caudate activity during reward;
LUAD	cis	rs9644630	0.841	rs3185	chr8:19328959	A/C	cg06699216	chr8:19333253	CSGALNACT1	0.31	7.18	0.33	3.23e-12	Oropharynx cancer;
LUAD	trans	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	15.43	0.6	6.41e-43	Exhaled nitric oxide levels;
LUAD	cis	rs934734	0.752	rs268139	chr2:65606991	A/C	cg11674355	chr2:65610261	SPRED2	0.36	6.41	0.3	4e-10	Rheumatoid arthritis;
LUAD	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg21385522	chr1:16154831	NA	-0.56	-9.18	-0.41	1.9e-18	Systolic blood pressure;
LUAD	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.9	0.32	1.89e-11	Blood metabolite levels;
LUAD	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs7659604	0.540	rs7676867	chr4:122671315	T/C	cg06713675	chr4:122721982	EXOSC9	0.41	7.44	0.34	5.75e-13	Type 2 diabetes;
LUAD	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg21194808	chr1:2205498	SKI	0.4	6.38	0.3	4.79e-10	Height;
LUAD	cis	rs12618769	0.597	rs10514774	chr2:99028695	A/G	cg10123293	chr2:99228465	UNC50	0.45	8.02	0.36	1.06e-14	Bipolar disorder;
LUAD	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.56	0.34	2.59e-13	Cannabis dependence symptom count;
LUAD	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.6	0.35	1.93e-13	Cannabis dependence symptom count;
LUAD	cis	rs743757	1.000	rs2236964	chr3:50449062	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.47	-7.35	-0.34	1.01e-12	Diastolic blood pressure;
LUAD	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg17443473	chr1:3703550	LRRC47	0.46	7.9	0.36	2.41e-14	Red cell distribution width;
LUAD	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg08645402	chr16:4508243	NA	0.59	11.01	0.47	5.75e-25	Schizophrenia;
LUAD	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg12927641	chr6:109611667	NA	-0.51	-8.76	-0.39	4.78e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs75229567	0.717	rs17107156	chr12:70234066	A/G	cg10114359	chr12:70132523	RAB3IP	-0.82	-7.13	-0.33	4.49e-12	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs2274273	0.967	rs1009978	chr14:55603061	C/G	cg04306507	chr14:55594613	LGALS3	0.4	8.45	0.38	4.76e-16	Protein biomarker;
LUAD	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg20469991	chr17:27169893	C17orf63	-0.52	-6.6	-0.31	1.22e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg05714579	chr10:131428358	MGMT	-0.49	-8.14	-0.37	4.41e-15	Response to temozolomide;
LUAD	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg10053473	chr17:62856997	LRRC37A3	0.64	10.41	0.45	9.16e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02683314	chr19:4182606	SIRT6;ANKRD24	-0.57	-6.91	-0.32	1.74e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg23978390	chr7:1156363	C7orf50	0.46	7.14	0.33	3.97e-12	Longevity;Endometriosis;
LUAD	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg04944784	chr2:26401820	FAM59B	-0.87	-12.59	-0.52	4.47e-31	Gut microbiome composition (summer);
LUAD	cis	rs6489882	0.867	rs7134391	chr12:113366691	A/G	cg20102336	chr12:113376681	OAS3	0.51	8.2	0.37	3.01e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs11677416	1.000	rs6542090	chr2:113524795	T/C	cg27083787	chr2:113543245	IL1A	0.38	6.64	0.31	9.56e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg23954153	chr1:44402353	ARTN	-0.36	-6.68	-0.31	7.6e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs698833	0.859	rs786612	chr2:44600819	G/C	cg04920474	chr2:44395004	PPM1B	0.39	7.12	0.33	4.65e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs6424115	0.931	rs2473377	chr1:24148260	T/C	cg10978503	chr1:24200527	CNR2	0.55	11.88	0.5	2.73e-28	Immature fraction of reticulocytes;
LUAD	cis	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg07460842	chr6:66804631	NA	0.97	12.95	0.53	1.48e-32	Exhaled nitric oxide output;
LUAD	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-7.3	-0.33	1.42e-12	Monocyte percentage of white cells;
LUAD	cis	rs3931020	0.548	rs12145183	chr1:75272480	G/A	cg21535942	chr1:75199100	CRYZ;TYW3	0.44	6.98	0.32	1.15e-11	Resistin levels;
LUAD	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.77	-0.53	7.87e-32	Monocyte count;
LUAD	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg04287289	chr16:89883240	FANCA	-0.41	-6.47	-0.3	2.68e-10	Vitiligo;
LUAD	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg15448220	chr1:150897856	SETDB1	0.53	8.97	0.4	9.86e-18	Melanoma;
LUAD	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg20135002	chr11:47629003	NA	-0.41	-7.16	-0.33	3.54e-12	Subjective well-being;
LUAD	cis	rs3812762	0.833	rs3850933	chr11:8801135	C/A	cg03980550	chr11:8754370	ST5	0.38	6.61	0.31	1.15e-10	Hypospadias;
LUAD	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg00802000	chr16:706648	WDR90	-0.37	-6.86	-0.32	2.45e-11	Height;
LUAD	trans	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg10208301	chr11:6592745	DNHD1	0.5	6.42	0.3	3.67e-10	Coronary artery calcification;
LUAD	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg12034118	chr1:209979487	IRF6	0.58	6.46	0.3	2.92e-10	Coronary artery disease;
LUAD	cis	rs9392556	0.600	rs664299	chr6:4112241	T/G	cg10424681	chr6:4079350	C6orf201;C6orf146	0.28	6.83	0.32	3.03e-11	Blood metabolite levels;
LUAD	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.35	0.38	9.99e-16	Body mass index;
LUAD	cis	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg07460842	chr6:66804631	NA	-1.06	-16.63	-0.63	3.86e-48	Exhaled nitric oxide output;
LUAD	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg24069376	chr3:38537580	EXOG	0.44	10.67	0.46	1.09e-23	Electrocardiographic conduction measures;
LUAD	cis	rs12549902	0.966	rs17659386	chr8:41513531	T/C	cg17182837	chr8:41585554	ANK1	-0.36	-7.49	-0.34	4.16e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUAD	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg01448562	chr3:133502909	NA	-0.67	-12.19	-0.51	1.65e-29	Iron status biomarkers;
LUAD	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.95	-13.98	-0.56	8.48e-37	Schizophrenia;
LUAD	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg05966235	chr16:28915196	ATP2A1	0.48	7.79	0.35	5.17e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7216064	1.000	rs62085992	chr17:65923083	T/A	cg08758996	chr17:66097529	LOC651250	0.48	7.26	0.33	1.91e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08280861	chr8:58055591	NA	0.55	7.36	0.34	9.78e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg13870426	chr17:30244630	NA	-0.55	-6.49	-0.3	2.35e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg13319975	chr6:146136371	FBXO30	0.81	14.16	0.57	1.5e-37	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1232027	0.656	rs1677655	chr5:79968496	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.42	-6.68	-0.31	7.74e-11	Huntington's disease progression;
LUAD	cis	rs6516091	0.850	rs75701968	chr20:6049985	C/T	cg25325723	chr20:6104886	FERMT1	-0.59	-6.68	-0.31	7.54e-11	Abdominal aortic aneurysm;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg13214185	chr14:107219616	NA	0.41	7.08	0.33	6.05e-12	Menopause (age at onset);
LUAD	trans	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg14917512	chr19:3094685	GNA11	-0.54	-6.41	-0.3	3.79e-10	Diabetic kidney disease;
LUAD	trans	rs984440	0.524	rs6577869	chr8:139083777	C/A	cg03334052	chr1:168888044	NA	0.44	7.44	0.34	5.61e-13	Obesity-related traits;
LUAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg24101359	chr6:42928495	GNMT	-0.5	-9.52	-0.42	1.39e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg16680214	chr1:154839983	KCNN3	-0.63	-13.26	-0.54	8.05e-34	Prostate cancer;
LUAD	cis	rs9788682	0.747	rs2915695	chr15:78739471	T/C	cg18825076	chr15:78729989	IREB2	-0.55	-7.77	-0.35	6.01e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs10078	0.615	rs2720997	chr5:433654	A/G	cg24955955	chr5:415729	AHRR	0.73	8.12	0.37	5.05e-15	Fat distribution (HIV);
LUAD	trans	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.76	13.8	0.56	5.03e-36	Mean corpuscular volume;
LUAD	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg16681516	chr19:46297285	DMWD	0.45	8.98	0.4	9.12e-18	Coronary artery disease;
LUAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.57	-7.5	-0.34	3.92e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg05234568	chr11:5960015	NA	-0.54	-10.61	-0.46	1.85e-23	DNA methylation (variation);
LUAD	cis	rs9341808	0.667	rs583426	chr6:80946687	G/A	cg08355045	chr6:80787529	NA	-0.47	-8.35	-0.38	1e-15	Sitting height ratio;
LUAD	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg15605315	chr1:45957053	TESK2	0.49	7.68	0.35	1.09e-13	High light scatter reticulocyte count;
LUAD	cis	rs1451375	1.000	rs2329341	chr7:50620275	A/C	cg18232548	chr7:50535776	DDC	0.61	9.97	0.44	3.62e-21	Malaria;
LUAD	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg17330251	chr7:94953956	PON1	-0.57	-7.63	-0.35	1.59e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs8177876	0.822	rs1412	chr16:81115842	A/G	cg08591886	chr16:81111003	C16orf46	-0.79	-7.37	-0.34	8.94e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs922182	0.557	rs2004231	chr15:64195769	C/T	cg02919090	chr15:64263738	DAPK2	0.35	6.56	0.3	1.54e-10	Blood protein levels;
LUAD	trans	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	17.39	0.65	1.79e-51	Exhaled nitric oxide output;
LUAD	cis	rs4849845	0.664	rs12053228	chr2:120994419	G/A	cg24070213	chr2:121070622	NA	0.41	7.59	0.35	2.06e-13	Mean platelet volume;
LUAD	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg03161606	chr19:29218774	NA	0.61	8.75	0.39	5.32e-17	Methadone dose in opioid dependence;
LUAD	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10802521	chr3:52805072	NEK4	-0.54	-9.1	-0.4	3.69e-18	Bipolar disorder;
LUAD	cis	rs12545109	0.800	rs1595940	chr8:57398309	T/C	cg11919837	chr8:57350735	NA	-0.46	-6.54	-0.3	1.73e-10	Obesity-related traits;
LUAD	cis	rs6987853	0.931	rs3099936	chr8:42384331	C/T	cg09913449	chr8:42400586	C8orf40	-0.43	-7.93	-0.36	1.97e-14	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.64	9.57	0.42	9.35e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg04842962	chr6:43655489	MRPS18A	1.02	25.73	0.78	1.45e-88	IgG glycosylation;
LUAD	trans	rs7395662	0.700	rs11493668	chr11:48727582	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	2.03e-12	HDL cholesterol;
LUAD	cis	rs17095355	0.818	rs11194997	chr10:111889779	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.64	-8.72	-0.39	6.44e-17	Biliary atresia;
LUAD	cis	rs806215	0.950	rs3757793	chr7:127225780	G/A	cg25922125	chr7:127225783	GCC1	-0.51	-6.92	-0.32	1.63e-11	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg17366294	chr4:99064904	C4orf37	0.65	12.6	0.52	3.99e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg01765077	chr12:122356316	WDR66	-0.55	-9.58	-0.42	8.11e-20	Mean corpuscular volume;
LUAD	trans	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg26043149	chr18:55253948	FECH	0.49	7.88	0.36	2.85e-14	Bone mineral density;
LUAD	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg02228675	chr17:40259724	DHX58	-0.45	-7.15	-0.33	3.72e-12	Fibrinogen levels;
LUAD	cis	rs9302065	1.000	rs9302065	chr13:95971016	C/T	cg24476569	chr13:95954382	ABCC4	0.47	8.66	0.39	9.77e-17	Blood metabolite levels;
LUAD	cis	rs13064411	0.542	rs2399477	chr3:113222998	A/G	cg18753928	chr3:113234510	CCDC52	-0.55	-9.72	-0.43	2.66e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs11048434	0.761	rs2110190	chr12:9128289	A/C	cg26114124	chr12:9217669	LOC144571	0.38	6.88	0.32	2.12e-11	Sjögren's syndrome;
LUAD	cis	rs367943	0.712	rs1607159	chr5:112681044	C/A	cg12552261	chr5:112820674	MCC	0.46	8.86	0.4	2.27e-17	Type 2 diabetes;
LUAD	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02475777	chr4:1388615	CRIPAK	0.59	8.47	0.38	4.17e-16	Longevity;
LUAD	trans	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg01620082	chr3:125678407	NA	-0.71	-7.15	-0.33	3.79e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg05625103	chr10:2543513	NA	0.39	6.78	0.31	4.13e-11	Age-related hearing impairment;
LUAD	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.64	11.2	0.48	1.12e-25	Birth weight;
LUAD	cis	rs1032833	0.660	rs10497534	chr2:180036775	A/G	cg23883738	chr2:179974586	SESTD1	0.6	6.87	0.32	2.25e-11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs977987	0.527	rs62059844	chr16:75429737	T/C	cg03315344	chr16:75512273	CHST6	0.64	14.02	0.56	6.11e-37	Dupuytren's disease;
LUAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg18402987	chr7:1209562	NA	0.85	11.35	0.48	3.01e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs68170813	0.559	rs17427123	chr7:106823661	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-11.2	-0.48	1.09e-25	Coronary artery disease;
LUAD	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg27411982	chr8:10470053	RP1L1	0.4	6.95	0.32	1.41e-11	Retinal vascular caliber;
LUAD	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg04218760	chr10:45406644	TMEM72	-0.3	-7.8	-0.35	5.04e-14	Mean corpuscular volume;
LUAD	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg03934478	chr11:495069	RNH1	0.74	8.4	0.38	6.93e-16	Body mass index;
LUAD	cis	rs16958440	0.867	rs76558586	chr18:44737613	C/T	cg17192377	chr18:44677553	HDHD2	0.84	8.06	0.36	7.77e-15	Sitting height ratio;
LUAD	cis	rs739496	0.527	rs11066090	chr12:112365523	T/C	cg10833066	chr12:111807467	FAM109A	0.43	6.96	0.32	1.32e-11	Platelet count;
LUAD	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg08847533	chr14:75593920	NEK9	0.4	6.98	0.32	1.13e-11	Height;
LUAD	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06022373	chr22:39101656	GTPBP1	0.44	7.31	0.34	1.32e-12	Menopause (age at onset);
LUAD	cis	rs7759001	0.857	rs4711148	chr6:27360690	T/C	cg18711553	chr6:27366782	ZNF391	0.39	6.53	0.3	1.94e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg22029157	chr1:209979665	IRF6	0.73	11.02	0.47	5.23e-25	Cleft lip with or without cleft palate;
LUAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg00106254	chr7:1943704	MAD1L1	-0.57	-8.86	-0.4	2.31e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg21843114	chr4:26334859	RBPJ	-0.46	-7.33	-0.34	1.14e-12	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg06606381	chr12:133084897	FBRSL1	-1.13	-10.53	-0.46	3.64e-23	Depression;
LUAD	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg00852783	chr1:26633632	UBXN11	0.41	7.31	0.33	1.34e-12	Obesity-related traits;
LUAD	cis	rs2242073	0.660	rs6710715	chr2:209002681	A/G	cg06181187	chr2:209010896	CRYGB	-0.33	-6.57	-0.3	1.46e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs11249608	0.548	rs34054398	chr5:178458371	A/G	cg01312482	chr5:178451176	ZNF879	-0.45	-6.96	-0.32	1.29e-11	Pubertal anthropometrics;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg22705016	chr2:27272692	NA	-0.62	-6.48	-0.3	2.58e-10	Type 2 diabetes;
LUAD	cis	rs7027203	1.000	rs7854820	chr9:96526027	A/G	cg14396892	chr9:96623032	NA	0.38	6.9	0.32	1.9e-11	DNA methylation (variation);
LUAD	cis	rs1497828	1.000	rs2646810	chr1:217523112	A/G	cg04411442	chr1:217543379	NA	-0.35	-6.46	-0.3	2.9e-10	Dialysis-related mortality;
LUAD	trans	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg21659725	chr3:3221576	CRBN	0.38	6.4	0.3	4.15e-10	Resting heart rate;
LUAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg16606324	chr3:10149918	C3orf24	0.69	10.16	0.44	7.59e-22	Alzheimer's disease;
LUAD	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	7.94e-19	Tonsillectomy;
LUAD	cis	rs7680126	0.596	rs11722185	chr4:10317482	C/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-7.06	-0.32	6.66e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs2274273	0.840	rs7159144	chr14:55821324	G/A	cg04306507	chr14:55594613	LGALS3	0.41	8.56	0.38	2.06e-16	Protein biomarker;
LUAD	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg25036284	chr2:26402008	FAM59B	-0.81	-11.66	-0.49	2e-27	Gut microbiome composition (summer);
LUAD	trans	rs7395662	1.000	rs4882120	chr11:48573529	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.36	-0.34	9.81e-13	HDL cholesterol;
LUAD	cis	rs6500395	1.000	rs1106386	chr16:48593065	C/A	cg04672837	chr16:48644449	N4BP1	0.38	6.49	0.3	2.41e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13922124	chr7:105221991	EFCAB10	-0.38	-6.43	-0.3	3.47e-10	Height;
LUAD	cis	rs2249625	0.545	rs60835713	chr6:72880349	T/C	cg18830697	chr6:72922368	RIMS1	0.46	8.22	0.37	2.56e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	trans	rs1816213	0.744	rs3731872	chr2:219520895	T/C	cg06194010	chr12:2493567	CACNA1C	0.54	6.49	0.3	2.34e-10	Diastolic blood pressure;
LUAD	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg18477163	chr1:228402036	OBSCN	-0.36	-7.18	-0.33	3.13e-12	Diastolic blood pressure;
LUAD	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg08000102	chr2:233561755	GIGYF2	-0.42	-6.45	-0.3	3.05e-10	Schizophrenia;
LUAD	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg20203395	chr5:56204925	C5orf35	-0.79	-11.15	-0.48	1.75e-25	Initial pursuit acceleration;
LUAD	cis	rs1387259	0.640	rs10783243	chr12:48653003	G/A	cg04545296	chr12:48745243	ZNF641	-0.26	-6.46	-0.3	2.97e-10	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg13334819	chr7:99746414	C7orf59	0.6	9.48	0.42	1.79e-19	Coronary artery disease;
LUAD	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg16049864	chr8:95962084	TP53INP1	-0.39	-7.03	-0.32	8.26e-12	Type 2 diabetes;
LUAD	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24531977	chr5:56204891	C5orf35	-0.99	-15.17	-0.59	8.56e-42	Initial pursuit acceleration;
LUAD	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.61	11.74	0.5	9.48e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg10729496	chr3:10149963	C3orf24	0.57	9.51	0.42	1.49e-19	Alzheimer's disease;
LUAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-11.04	-0.47	4.62e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg12927641	chr6:109611667	NA	-0.47	-7.87	-0.36	2.99e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg26513180	chr16:89883248	FANCA	0.65	12.01	0.5	8.18e-29	Vitiligo;
LUAD	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg16680214	chr1:154839983	KCNN3	-0.67	-14.15	-0.57	1.78e-37	Prostate cancer;
LUAD	trans	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg00784671	chr22:46762841	CELSR1	-0.71	-8.19	-0.37	3.14e-15	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs727505	0.564	rs67745021	chr7:124868018	T/C	cg23710748	chr7:124431027	NA	-0.37	-7.4	-0.34	7.26e-13	Lewy body disease;
LUAD	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg19318889	chr4:1322082	MAEA	0.44	7.07	0.33	6.32e-12	Obesity-related traits;
LUAD	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-13.67	-0.55	1.69e-35	Headache;
LUAD	cis	rs490234	0.841	rs7044663	chr9:128268263	C/T	cg14078157	chr9:128172775	NA	-0.42	-7.79	-0.35	5.36e-14	Mean arterial pressure;
LUAD	cis	rs4481887	0.800	rs4514268	chr1:248444600	T/G	cg00666640	chr1:248458726	OR2T12	0.32	7.97	0.36	1.49e-14	Common traits (Other);
LUAD	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.61	-0.31	1.13e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs68170813	0.559	rs3801958	chr7:106961139	C/T	cg23024343	chr7:107201750	COG5	0.49	7.13	0.33	4.35e-12	Coronary artery disease;
LUAD	cis	rs2073300	1.000	rs6137977	chr20:23464191	G/T	cg12062639	chr20:23401060	NAPB	0.95	8.87	0.4	2e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg04455712	chr21:45112962	RRP1B	0.47	9.58	0.42	8.05e-20	Mean corpuscular volume;
LUAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.39	-0.38	7.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs912057	1.000	rs1294407	chr6:6738103	C/G	cg06612196	chr6:6737390	NA	0.55	12.14	0.51	2.7e-29	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06873352	chr17:61820015	STRADA	0.57	9.22	0.41	1.37e-18	Height;
LUAD	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg26924012	chr15:45694286	SPATA5L1	1.03	19.34	0.69	3.7e-60	Homoarginine levels;
LUAD	cis	rs2806561	1.000	rs1757048	chr1:23510601	A/C	cg19743168	chr1:23544995	NA	0.4	7.48	0.34	4.46e-13	Height;
LUAD	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg23649088	chr2:200775458	C2orf69	0.66	9.73	0.43	2.52e-20	Schizophrenia;
LUAD	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19717773	chr7:2847554	GNA12	-0.51	-9.0	-0.4	7.78e-18	Height;
LUAD	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.86	-12.08	-0.51	4.63e-29	Red cell distribution width;
LUAD	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.6	0.31	1.23e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg17063962	chr7:91808500	NA	0.64	10.94	0.47	1.08e-24	Breast cancer;
LUAD	cis	rs12618769	0.597	rs7593615	chr2:99030598	C/A	cg10123293	chr2:99228465	UNC50	0.45	8.03	0.36	9.87e-15	Bipolar disorder;
LUAD	cis	rs2445762	0.642	rs8025191	chr15:51623785	A/G	cg20344442	chr15:51633704	GLDN	0.53	9.03	0.4	6.37e-18	Hormone measurements;
LUAD	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg23262073	chr20:60523788	NA	-0.46	-7.93	-0.36	1.96e-14	Body mass index;
LUAD	cis	rs62229266	0.557	rs4817760	chr21:37395301	T/C	cg08632701	chr21:37451849	NA	-0.43	-6.76	-0.31	4.71e-11	Mitral valve prolapse;
LUAD	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg09137382	chr11:130731461	NA	0.4	7.3	0.33	1.43e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg03806693	chr22:41940476	POLR3H	-0.81	-11.43	-0.49	1.51e-26	Vitiligo;
LUAD	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg22117172	chr7:91764530	CYP51A1	0.36	7.61	0.35	1.85e-13	Breast cancer;
LUAD	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg12863693	chr15:85201151	NMB	-0.31	-6.59	-0.31	1.32e-10	P wave terminal force;
LUAD	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg19767477	chr5:127420684	SLC12A2	-0.41	-6.43	-0.3	3.52e-10	Ileal carcinoids;
LUAD	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg00631329	chr6:26305371	NA	-0.69	-13.11	-0.54	3.33e-33	Educational attainment;
LUAD	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01570182	chr17:44337453	NA	-0.95	-14.02	-0.56	5.84e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs738321	0.701	rs2413506	chr22:38593128	T/C	cg25457927	chr22:38595422	NA	-0.57	-12.72	-0.53	1.29e-31	Breast cancer;
LUAD	cis	rs72772090	0.539	rs72773947	chr5:96125533	T/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-7.02	-0.32	8.82e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.39	-8.14	-0.37	4.43e-15	Lymphocyte counts;
LUAD	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg00316803	chr15:76480434	C15orf27	0.41	8.18	0.37	3.4e-15	Blood metabolite levels;
LUAD	cis	rs7264396	0.563	rs2425103	chr20:34312329	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2.04e-15	Total cholesterol levels;
LUAD	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.59	-0.58	2.52e-39	Schizophrenia;
LUAD	cis	rs13082711	0.522	rs569960	chr3:27329540	C/T	cg02860705	chr3:27208620	NA	0.52	8.57	0.38	1.98e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.53	-0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs35883536	0.626	rs11799819	chr1:101049382	G/A	cg06223162	chr1:101003688	GPR88	-0.47	-8.96	-0.4	1.04e-17	Monocyte count;
LUAD	cis	rs2882667	0.518	rs10041986	chr5:138424437	A/G	cg04439458	chr5:138467593	SIL1	-0.33	-6.35	-0.3	5.48e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-7.99	-0.36	1.26e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.68	-10.43	-0.45	8.02e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs6484504	0.600	rs366758	chr11:31222499	A/C	cg14844989	chr11:31128820	NA	-0.44	-8.2	-0.37	2.96e-15	Red blood cell count;
LUAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg13560548	chr3:10150139	C3orf24	0.45	7.66	0.35	1.27e-13	Alzheimer's disease;
LUAD	cis	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg08601574	chr20:25228251	PYGB	-0.46	-8.74	-0.39	5.71e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs89107	0.688	rs283086	chr6:118596941	C/T	cg18833306	chr6:118973337	C6orf204	0.52	9.46	0.42	2.1e-19	Cardiac structure and function;
LUAD	cis	rs6761276	0.899	rs13389457	chr2:113834885	T/C	cg09040174	chr2:113837401	NA	0.8	15.65	0.61	7.33e-44	Protein quantitative trait loci;
LUAD	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg20503657	chr10:835505	NA	0.83	12.57	0.52	5.44e-31	Eosinophil percentage of granulocytes;
LUAD	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.57	0.3	1.45e-10	Lung cancer in ever smokers;
LUAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg11062466	chr8:58055876	NA	0.82	10.04	0.44	2.11e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs727505	0.954	rs55768077	chr7:124663216	A/G	cg23710748	chr7:124431027	NA	-0.42	-8.35	-0.38	1.01e-15	Lewy body disease;
LUAD	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg24011408	chr12:48396354	COL2A1	-0.43	-9.58	-0.42	8.36e-20	Plateletcrit;
LUAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg18305652	chr10:134549665	INPP5A	0.61	11.82	0.5	4.88e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg17063962	chr7:91808500	NA	-0.66	-11.53	-0.49	6.24e-27	Breast cancer;
LUAD	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg11098525	chr4:1320231	MAEA	-0.39	-6.67	-0.31	8.07e-11	Obesity-related traits;
LUAD	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg02775129	chr4:119771670	NA	-0.86	-8.0	-0.36	1.21e-14	Cannabis dependence symptom count;
LUAD	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg04398451	chr17:18023971	MYO15A	-0.63	-11.45	-0.49	1.21e-26	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg11062466	chr8:58055876	NA	0.68	9.02	0.4	6.56e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs713477	1.000	rs12888234	chr14:55911352	T/A	cg13175173	chr14:55914753	NA	-0.33	-6.95	-0.32	1.41e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs877282	0.898	rs34490091	chr10:765800	A/C	cg17470449	chr10:769945	NA	0.6	8.39	0.38	7.62e-16	Uric acid levels;
LUAD	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg04851639	chr8:1020857	NA	-0.4	-9.33	-0.41	6.21e-19	Schizophrenia;
LUAD	cis	rs12681287	0.752	rs6985427	chr8:87302745	C/T	cg27223183	chr8:87520930	FAM82B	-0.62	-8.53	-0.38	2.65e-16	Caudate activity during reward;
LUAD	cis	rs7095607	0.813	rs10997973	chr10:69930054	T/C	cg18986048	chr10:69913749	MYPN	0.37	6.39	0.3	4.41e-10	Lung function (FVC);
LUAD	trans	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.42	-7.04	-0.32	8.02e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2932538	0.922	rs12402469	chr1:113076625	G/A	cg22162597	chr1:113214053	CAPZA1	0.45	6.68	0.31	7.56e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg08601574	chr20:25228251	PYGB	-0.44	-8.16	-0.37	3.83e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs739496	0.895	rs7977752	chr12:111850230	G/A	cg10833066	chr12:111807467	FAM109A	0.42	6.63	0.31	1.02e-10	Platelet count;
LUAD	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.13e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.56	0.3	1.57e-10	Cognitive test performance;
LUAD	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/A	cg00631329	chr6:26305371	NA	-0.55	-9.19	-0.41	1.82e-18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg23625390	chr15:77176239	SCAPER	-0.52	-8.08	-0.37	6.71e-15	Blood metabolite levels;
LUAD	cis	rs240764	0.817	rs12199888	chr6:101154419	T/A	cg09795085	chr6:101329169	ASCC3	-0.43	-7.26	-0.33	1.89e-12	Neuroticism;
LUAD	cis	rs1018836	0.608	rs6992512	chr8:91477936	C/A	cg16814680	chr8:91681699	NA	-0.54	-8.77	-0.39	4.42e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg14552801	chr7:65878734	NA	-0.38	-6.37	-0.3	4.96e-10	Aortic root size;
LUAD	trans	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.83	-0.36	3.97e-14	Breast cancer;
LUAD	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg06627628	chr2:24431161	ITSN2	-0.49	-8.39	-0.38	7.16e-16	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs6076065	0.723	rs2253925	chr20:23388021	C/G	cg11657817	chr20:23433608	CST11	0.47	8.86	0.4	2.21e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00149659	chr3:10157352	C3orf10	0.55	7.63	0.35	1.5700000000000001e-13	Alzheimer's disease;
LUAD	cis	rs7707921	0.587	rs55834537	chr5:81657329	T/G	cg15871215	chr5:81402204	ATG10	-0.51	-6.92	-0.32	1.69e-11	Breast cancer;
LUAD	trans	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg04995722	chr7:26192034	NFE2L3	-0.44	-7.53	-0.34	3.2e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.04	0.36	9.24e-15	Menopause (age at onset);
LUAD	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-8.79	-0.39	3.74e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1784581	0.588	rs6455789	chr6:162417948	C/T	cg17173639	chr6:162384350	PARK2	0.43	7.73	0.35	7.74e-14	Itch intensity from mosquito bite;
LUAD	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg10295955	chr4:187884368	NA	-1.11	-27.59	-0.8	1.29e-96	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02249930	chr10:70166207	RUFY2	0.53	6.89	0.32	1.98e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs77861329	1.000	rs55664415	chr3:52124885	G/A	cg08692210	chr3:52188851	WDR51A	0.78	6.41	0.3	3.86e-10	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg24846343	chr22:24311635	DDTL	0.8	17.88	0.66	1.19e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7903847	0.642	rs10786339	chr10:99153076	A/G	cg20016023	chr10:99160130	RRP12	-0.31	-7.42	-0.34	6.64e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg20607798	chr8:58055168	NA	0.67	8.71	0.39	7.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg07677032	chr17:61819896	STRADA	0.51	9.11	0.4	3.41e-18	Prudent dietary pattern;
LUAD	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg15556689	chr8:8085844	FLJ10661	0.42	6.81	0.31	3.35e-11	Mood instability;
LUAD	cis	rs2652834	0.718	rs2729832	chr15:63396401	A/G	cg25406657	chr15:63342033	TPM1	-0.4	-6.92	-0.32	1.67e-11	HDL cholesterol;
LUAD	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg02574844	chr11:5959923	NA	-0.39	-6.77	-0.31	4.26e-11	DNA methylation (variation);
LUAD	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg15181151	chr6:150070149	PCMT1	0.42	8.52	0.38	2.84e-16	Lung cancer;
LUAD	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.64	0.31	9.55e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7072216	0.763	rs6584204	chr10:100173580	C/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.7	-0.39	7.57e-17	Metabolite levels;
LUAD	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg19761014	chr17:28927070	LRRC37B2	0.9	8.82	0.39	3.11e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg11663144	chr21:46675770	NA	-0.51	-9.08	-0.4	4.25e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg03611598	chr17:48586076	MYCBPAP	-0.71	-9.92	-0.43	5.55e-21	Visceral fat;
LUAD	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.14	-0.57	1.91e-37	Blood protein levels;
LUAD	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg20203395	chr5:56204925	C5orf35	0.57	8.88	0.4	1.92e-17	Coronary artery disease;
LUAD	cis	rs11771526	0.901	rs10239582	chr7:32298116	T/A	cg27532318	chr7:32358331	NA	0.56	7.35	0.34	1.04e-12	Body mass index;
LUAD	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.56	8.11	0.37	5.72e-15	Platelet count;
LUAD	cis	rs5756391	0.568	rs4821568	chr22:37316476	T/C	cg16356956	chr22:37317934	CSF2RB	0.31	6.53	0.3	1.84e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs367615	0.552	rs3828603	chr5:108712068	G/C	cg17395555	chr5:108820864	NA	-0.5	-9.47	-0.42	2.01e-19	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.18	0.41	1.91e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg20848291	chr7:100343083	ZAN	0.4	6.88	0.32	2.1e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs6445967	0.932	rs13093235	chr3:58296706	A/T	cg23715586	chr3:58305044	RPP14	0.46	8.15	0.37	4.1e-15	Platelet count;
LUAD	trans	rs12210905	1.000	rs76889265	chr6:27008835	T/C	cg08851530	chr6:28072375	NA	0.73	6.4	0.3	4.1e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg00280220	chr17:61926910	NA	0.37	7.05	0.32	7.37e-12	Prudent dietary pattern;
LUAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg04267008	chr7:1944627	MAD1L1	-0.75	-12.06	-0.51	5.55e-29	Bipolar disorder and schizophrenia;
LUAD	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.5	-7.77	-0.35	6.05e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.73	0.31	5.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6426558	0.524	rs2813948	chr1:227459621	A/T	cg10327440	chr1:227177885	CDC42BPA	0.55	8.94	0.4	1.24e-17	Neutrophil percentage of white cells;
LUAD	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg03690763	chr11:133734501	NA	-0.32	-7.69	-0.35	1.06e-13	Childhood ear infection;
LUAD	trans	rs1728785	1.000	rs1645936	chr16:68563743	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	9.68	0.43	3.74e-20	Ulcerative colitis;
LUAD	cis	rs62238980	0.614	rs79045014	chr22:32509595	C/T	cg00543991	chr22:32367038	NA	0.88	8.51	0.38	3.06e-16	Childhood ear infection;
LUAD	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg18305652	chr10:134549665	INPP5A	0.59	12.11	0.51	3.39e-29	Migraine;
LUAD	trans	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg06606381	chr12:133084897	FBRSL1	-0.67	-7.01	-0.32	9.31e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg07395648	chr5:131743802	NA	0.38	6.48	0.3	2.6e-10	Breast cancer;
LUAD	cis	rs7274811	0.656	rs293736	chr20:31925189	A/C	cg03904042	chr20:32255491	NECAB3;C20orf134	0.46	6.53	0.3	1.94e-10	Height;
LUAD	trans	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg14917512	chr19:3094685	GNA11	0.56	6.73	0.31	5.48e-11	Diabetic kidney disease;
LUAD	trans	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg21659725	chr3:3221576	CRBN	-0.6	-9.61	-0.42	6.76e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs73198271	0.740	rs3827807	chr8:8679385	G/A	cg01851573	chr8:8652454	MFHAS1	0.49	8.62	0.39	1.4e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.55	8.11	0.37	5.34e-15	Gut microbiome composition (summer);
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg04531794	chr10:99609860	GOLGA7B	-0.53	-7.19	-0.33	2.95e-12	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg27494647	chr7:150038898	RARRES2	0.48	8.48	0.38	3.87e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg04944784	chr2:26401820	FAM59B	-0.76	-11.4	-0.48	1.94e-26	Gut microbiome composition (summer);
LUAD	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg15992532	chr8:142229932	SLC45A4	-0.44	-7.79	-0.35	5.23e-14	Immature fraction of reticulocytes;
LUAD	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg27124370	chr19:33622961	WDR88	0.44	6.71	0.31	6.31e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10193935	0.901	rs10171643	chr2:42532912	C/T	cg27598129	chr2:42591480	NA	-0.74	-9.51	-0.42	1.45e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg08029281	chr1:67600428	NA	-0.36	-6.96	-0.32	1.32e-11	Psoriasis;
LUAD	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg07570687	chr10:102243282	WNT8B	-0.43	-6.55	-0.3	1.71e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg02990361	chr1:107599529	PRMT6	-0.62	-10.46	-0.45	6.12e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9549328	0.700	rs4907568	chr13:113617574	A/T	cg17524180	chr13:113633600	MCF2L	-0.3	-6.58	-0.3	1.35e-10	Systolic blood pressure;
LUAD	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg00898013	chr13:113819073	PROZ	-0.65	-11.96	-0.5	1.32e-28	Platelet distribution width;
LUAD	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg14983838	chr19:29218262	NA	0.64	9.11	0.41	3.25e-18	Methadone dose in opioid dependence;
LUAD	cis	rs68170813	0.652	rs56949084	chr7:107157387	G/A	cg23024343	chr7:107201750	COG5	0.53	6.68	0.31	7.35e-11	Coronary artery disease;
LUAD	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs3784262	0.669	rs2414527	chr15:58256672	A/G	cg12031962	chr15:58353849	ALDH1A2	0.41	8.18	0.37	3.3e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs877282	0.898	rs11253346	chr10:765313	A/G	cg06581033	chr10:766294	NA	-0.58	-7.95	-0.36	1.74e-14	Uric acid levels;
LUAD	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg07507251	chr3:52567010	NT5DC2	0.34	6.7	0.31	6.65e-11	Bipolar disorder;
LUAD	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.62	-0.35	1.68e-13	Lung cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12230010	chr10:72163718	EIF4EBP2	-0.43	-6.53	-0.3	1.88e-10	Height;
LUAD	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg17063962	chr7:91808500	NA	0.64	10.84	0.47	2.54e-24	Breast cancer;
LUAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg11494091	chr17:61959527	GH2	-0.73	-18.11	-0.66	1.13e-54	Prudent dietary pattern;
LUAD	cis	rs7746082	0.627	rs6938089	chr6:106470070	A/G	cg02270332	chr6:106475062	NA	0.37	6.61	0.31	1.18e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs629535	0.821	rs680993	chr8:70050247	G/A	cg21567404	chr3:27674614	NA	1.02	18.56	0.67	1.07e-56	Dupuytren's disease;
LUAD	cis	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg21775007	chr8:11205619	TDH	0.54	9.87	0.43	7.95e-21	Retinal vascular caliber;
LUAD	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg06623918	chr6:96969491	KIAA0776	0.74	12.04	0.51	6.3e-29	Migraine;Coronary artery disease;
LUAD	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg08439880	chr3:133502540	NA	-0.38	-7.2	-0.33	2.8e-12	Iron status biomarkers;
LUAD	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg05925327	chr15:68127851	NA	-0.44	-6.56	-0.3	1.54e-10	Restless legs syndrome;
LUAD	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24531977	chr5:56204891	C5orf35	0.8	13.05	0.54	6.06e-33	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8002861	0.869	rs7989857	chr13:44464090	C/T	cg17145862	chr1:211918768	LPGAT1	0.76	18.02	0.66	2.72e-54	Leprosy;
LUAD	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg16479474	chr6:28041457	NA	0.34	6.4	0.3	4.06e-10	Parkinson's disease;
LUAD	cis	rs367615	0.918	rs13173339	chr5:108871318	T/A	cg17395555	chr5:108820864	NA	0.44	7.19	0.33	3.04e-12	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg05234568	chr11:5960015	NA	-0.56	-10.07	-0.44	1.61e-21	DNA methylation (variation);
LUAD	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg07936489	chr17:37558343	FBXL20	0.51	7.56	0.35	2.48e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.2	-0.33	2.73e-12	Coronary artery disease;
LUAD	cis	rs2050392	0.799	rs2907	chr10:30728250	A/G	cg18806716	chr10:30721971	MAP3K8	-0.56	-11.05	-0.47	4.19e-25	Inflammatory bowel disease;
LUAD	trans	rs2262909	0.962	rs436662	chr19:22232107	C/T	cg17074339	chr11:11642133	GALNTL4	-0.47	-7.73	-0.35	8.11e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07157834	chr1:205819609	PM20D1	0.79	16.36	0.62	5.81e-47	Menarche (age at onset);
LUAD	cis	rs7617773	0.817	rs6794644	chr3:48330037	T/C	cg11946769	chr3:48343235	NME6	0.43	6.65	0.31	8.89e-11	Coronary artery disease;
LUAD	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg01689657	chr7:91764605	CYP51A1	-0.3	-7.3	-0.33	1.41e-12	Breast cancer;
LUAD	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg14092988	chr3:52407081	DNAH1	0.45	9.0	0.4	7.89e-18	Bipolar disorder;
LUAD	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21659725	chr3:3221576	CRBN	0.7	11.65	0.49	2.23e-27	Resting heart rate;
LUAD	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1941023	0.503	rs7952244	chr11:60132164	G/A	cg08716584	chr11:60157161	MS4A7	-0.47	-9.02	-0.4	6.73e-18	Congenital heart disease (maternal effect);
LUAD	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg11494091	chr17:61959527	GH2	0.46	8.86	0.4	2.23e-17	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg05368731	chr17:41323189	NBR1	0.98	20.62	0.71	6.67e-66	Menopause (age at onset);
LUAD	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.22	-0.37	2.55e-15	Total body bone mineral density;
LUAD	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg04450456	chr4:17643702	FAM184B	0.37	7.16	0.33	3.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11644478	chr21:40555479	PSMG1	0.58	7.26	0.33	1.88e-12	Cognitive function;
LUAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg23958373	chr8:599963	NA	0.86	9.14	0.41	2.57e-18	IgG glycosylation;
LUAD	cis	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg01251360	chr16:68772225	CDH1	0.29	8.97	0.4	9.74e-18	Colorectal cancer;
LUAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.25	-0.37	2.05e-15	Alzheimer's disease;
LUAD	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg09491104	chr22:46646882	C22orf40	-0.58	-7.21	-0.33	2.61e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7671266	0.518	rs16895984	chr4:10284727	C/T	cg02734326	chr4:10020555	SLC2A9	0.41	6.47	0.3	2.68e-10	Cardiovascular disease risk factors;
LUAD	cis	rs7731657	0.509	rs6595975	chr5:130328051	C/A	cg08523029	chr5:130500466	HINT1	0.56	7.36	0.34	9.74e-13	Fasting plasma glucose;
LUAD	cis	rs13190036	0.551	rs7710269	chr5:176614529	G/A	cg06733329	chr5:176740039	MXD3	0.45	6.54	0.3	1.78e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	trans	rs2072153	0.715	rs12948327	chr17:47333478	C/T	cg11430096	chr6:110968061	CDK19	0.51	7.65	0.35	1.34e-13	Height;
LUAD	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.75	0.31	4.74e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs6424115	0.931	rs2473377	chr1:24148260	T/C	cg15997130	chr1:24165203	NA	0.56	9.89	0.43	6.69e-21	Immature fraction of reticulocytes;
LUAD	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg06623918	chr6:96969491	KIAA0776	0.73	11.65	0.49	2.08e-27	Migraine;Coronary artery disease;
LUAD	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.69	10.55	0.46	3.06e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg27535305	chr1:53392650	SCP2	0.38	7.97	0.36	1.52e-14	Monocyte count;
LUAD	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg13319975	chr6:146136371	FBXO30	-0.63	-10.93	-0.47	1.13e-24	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02056921	chr1:901892	PLEKHN1	0.41	6.49	0.3	2.34e-10	Gut microbiome composition (summer);
LUAD	cis	rs6138458	1.000	rs227627	chr20:24912107	T/C	cg26195577	chr20:24973756	C20orf3	0.96	16.32	0.62	8.79e-47	Blood protein levels;
LUAD	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg14196790	chr5:131705035	SLC22A5	0.5	9.08	0.4	4.12e-18	Blood metabolite levels;
LUAD	cis	rs7945705	0.875	rs10769957	chr11:8809016	A/C	cg12365402	chr11:9010492	NRIP3	-0.36	-6.38	-0.3	4.57e-10	Hemoglobin concentration;
LUAD	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg00634984	chr7:65235879	NA	0.47	6.37	0.3	4.91e-10	Aortic root size;
LUAD	cis	rs12545109	0.876	rs1992120	chr8:57337112	G/A	cg07776626	chr8:57350775	NA	-0.68	-9.22	-0.41	1.46e-18	Obesity-related traits;
LUAD	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg03161606	chr19:29218774	NA	0.6	8.67	0.39	9.67e-17	Methadone dose in opioid dependence;
LUAD	cis	rs9487051	0.703	rs351755	chr6:109538073	G/A	cg21918786	chr6:109611834	NA	0.45	8.08	0.37	7e-15	Reticulocyte fraction of red cells;
LUAD	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg03806693	chr22:41940476	POLR3H	0.66	9.87	0.43	8e-21	Vitiligo;
LUAD	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg00020340	chr7:910388	UNC84A	0.63	6.69	0.31	7.11e-11	Initial pursuit acceleration;
LUAD	cis	rs12541635	0.934	rs62527400	chr8:107054229	G/A	cg10147462	chr8:107024639	NA	0.48	8.52	0.38	2.91e-16	Age of smoking initiation;
LUAD	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg00310523	chr12:86230176	RASSF9	-0.4	-7.96	-0.36	1.64e-14	Major depressive disorder;
LUAD	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg02807482	chr3:125708958	NA	-0.56	-7.9	-0.36	2.5e-14	Blood pressure (smoking interaction);
LUAD	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg15782153	chr7:917662	C7orf20	0.55	10.43	0.45	8.0700000000000006e-23	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.38	-6.67	-0.31	8.14e-11	Alzheimer's disease (late onset);
LUAD	cis	rs2377058	0.882	rs11646741	chr16:89730084	G/C	cg04155793	chr16:89752847	CDK10	-0.33	-6.64	-0.31	9.93e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs6906287	0.631	rs9320665	chr6:118986309	G/A	cg18833306	chr6:118973337	C6orf204	0.48	8.43	0.38	5.56e-16	Electrocardiographic conduction measures;
LUAD	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg20587970	chr11:113659929	NA	-1.15	-17.2	-0.64	1.17e-50	Hip circumference adjusted for BMI;
LUAD	cis	rs76878669	0.561	rs4930177	chr11:66120784	T/C	cg10616300	chr11:66138557	SLC29A2	0.34	7.28	0.33	1.61e-12	Educational attainment (years of education);
LUAD	cis	rs738322	0.600	rs5995542	chr22:38558141	C/T	cg17652424	chr22:38574118	PLA2G6	-0.3	-8.22	-0.37	2.58e-15	Cutaneous nevi;
LUAD	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg21475434	chr5:93447410	FAM172A	0.76	8.84	0.39	2.67e-17	Diabetic retinopathy;
LUAD	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg04727924	chr7:799746	HEATR2	-0.55	-7.31	-0.33	1.35e-12	Cerebrospinal P-tau181p levels;
LUAD	trans	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.35	0.54	3.51e-34	Exhaled nitric oxide output;
LUAD	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg01657329	chr11:68192670	LRP5	-0.41	-6.64	-0.31	9.69e-11	Total body bone mineral density;
LUAD	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs897984	0.806	rs10782002	chr16:30946506	A/G	cg02466173	chr16:30829666	NA	0.64	11.55	0.49	5.39e-27	Dementia with Lewy bodies;
LUAD	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.6	11.48	0.49	9.93e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2455799	0.613	rs7617039	chr3:15800740	A/G	cg16303742	chr3:15540471	COLQ	0.45	8.24	0.37	2.25e-15	Mean platelet volume;
LUAD	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg22907277	chr7:1156413	C7orf50	0.7	8.23	0.37	2.4e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg01620082	chr3:125678407	NA	0.41	6.46	0.3	2.81e-10	Parkinson's disease;
LUAD	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.54	-0.46	3.33e-23	Monocyte percentage of white cells;
LUAD	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg11247378	chr22:39784982	NA	-0.73	-13.23	-0.54	1.06e-33	Intelligence (multi-trait analysis);
LUAD	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg05304507	chr6:116381966	FRK	0.2	6.79	0.31	3.85e-11	Cholesterol, total;LDL cholesterol;
LUAD	trans	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	7.9	0.36	2.39e-14	Menopause (age at onset);
LUAD	cis	rs2455601	0.574	rs2568094	chr11:8992218	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.48	-8.63	-0.39	1.26e-16	Schizophrenia;
LUAD	cis	rs4730250	0.554	rs112665932	chr7:106916121	A/G	cg02696742	chr7:106810147	HBP1	-0.71	-8.95	-0.4	1.14e-17	Osteoarthritis;
LUAD	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11890956	chr21:40555474	PSMG1	0.78	13.83	0.56	3.69e-36	Cognitive function;
LUAD	cis	rs62238980	0.614	rs118010731	chr22:32376308	G/T	cg00543991	chr22:32367038	NA	0.91	8.21	0.37	2.8e-15	Childhood ear infection;
LUAD	cis	rs2806561	1.000	rs2806558	chr1:23503456	T/C	cg12483005	chr1:23474871	LUZP1	0.4	6.9	0.32	1.94e-11	Height;
LUAD	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg14008862	chr17:28927542	LRRC37B2	0.56	6.72	0.31	5.72e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	7.25	0.33	1.95e-12	Schizophrenia;
LUAD	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-8.43	-0.38	5.33e-16	Gut microbiome composition (summer);
LUAD	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg07870213	chr5:140052090	DND1	-0.81	-11.04	-0.47	4.69e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg20362242	chr5:692897	TPPP	0.57	7.07	0.32	6.65e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.87	-13.21	-0.54	1.32e-33	IgG glycosylation;
LUAD	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg01028140	chr2:1542097	TPO	-0.43	-7.16	-0.33	3.56e-12	IgG glycosylation;
LUAD	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg26384229	chr12:38710491	ALG10B	0.52	8.61	0.39	1.47e-16	Heart rate;
LUAD	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg03433033	chr1:76189801	ACADM	0.83	14.84	0.59	2.08e-40	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg04705435	chr11:17411270	KCNJ11	0.41	6.83	0.31	3.04e-11	Type 2 diabetes;
LUAD	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg06131755	chr6:160182447	ACAT2	0.43	6.43	0.3	3.36e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-7.36	-0.34	9.87e-13	Personality dimensions;
LUAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg03188948	chr7:1209495	NA	0.41	6.61	0.31	1.18e-10	Longevity;Endometriosis;
LUAD	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.06	-0.32	6.83e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs10911363	0.592	rs4047798	chr1:183421406	C/T	cg09173681	chr1:183549694	NCF2	-0.57	-10.26	-0.45	3.21e-22	Systemic lupus erythematosus;
LUAD	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg14458575	chr2:238380390	NA	0.66	12.49	0.52	1.0500000000000001e-30	Prostate cancer;
LUAD	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.52	-10.73	-0.46	6.17e-24	Monocyte percentage of white cells;
LUAD	cis	rs1572438	0.896	rs9405366	chr6:858296	A/C	cg13447295	chr6:887704	NA	-0.35	-6.51	-0.3	2.18e-10	Aging;
LUAD	cis	rs6087771	0.851	rs6087775	chr20:30325765	G/A	cg21427119	chr20:30132790	HM13	-0.35	-6.44	-0.3	3.34e-10	Subcortical brain region volumes;Putamen volume;
LUAD	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg03433033	chr1:76189801	ACADM	0.8	14.89	0.59	1.25e-40	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7072216	0.763	rs10732782	chr10:100166506	C/A	cg26618903	chr10:100175079	PYROXD2	-0.37	-8.09	-0.37	6.25e-15	Metabolite levels;
LUAD	cis	rs7773004	1.000	rs7773004	chr6:26267755	A/G	cg00631329	chr6:26305371	NA	-0.55	-9.31	-0.41	7.09e-19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg27170947	chr2:26402098	FAM59B	-0.81	-11.48	-0.49	1e-26	Gut microbiome composition (summer);
LUAD	cis	rs921968	0.613	rs2710251	chr2:219543433	T/C	cg02176678	chr2:219576539	TTLL4	-0.58	-11.52	-0.49	6.73e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4523957	0.553	rs2476355	chr17:2029559	A/G	cg16513277	chr17:2031491	SMG6	-0.98	-20.08	-0.7	1.79e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05513509	chr18:20513742	RBBP8	-0.54	-6.57	-0.3	1.44e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6594713	0.717	rs2972690	chr5:112945945	T/C	cg12552261	chr5:112820674	MCC	-0.55	-7.95	-0.36	1.67e-14	Brain cytoarchitecture;
LUAD	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg16479474	chr6:28041457	NA	0.44	7.44	0.34	5.66e-13	Depression;
LUAD	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg27490568	chr2:178487706	NA	0.53	8.83	0.39	2.91e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26185531	chr11:75479825	DGAT2	-0.43	-6.58	-0.3	1.37e-10	Height;
LUAD	trans	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg14917512	chr19:3094685	GNA11	0.37	6.51	0.3	2.09e-10	Aortic root size;
LUAD	cis	rs45430	1.000	rs416981	chr21:42745414	G/A	cg22778903	chr21:42741698	MX2	0.39	8.11	0.37	5.54e-15	Melanoma;
LUAD	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg10792982	chr14:105748885	BRF1	0.46	10.12	0.44	1.02e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg11189052	chr15:85197271	WDR73	0.65	8.73	0.39	5.92e-17	Schizophrenia;
LUAD	cis	rs6460942	0.915	rs6460907	chr7:12304449	G/A	cg06484146	chr7:12443880	VWDE	-0.47	-7.09	-0.33	5.77e-12	Coronary artery disease;
LUAD	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg16989719	chr2:238392110	NA	-0.31	-6.55	-0.3	1.68e-10	Prostate cancer;
LUAD	trans	rs800082	1.000	rs11718059	chr3:144305997	G/A	cg24215973	chr2:240111563	HDAC4	-0.42	-6.6	-0.31	1.26e-10	Smoking behavior;
LUAD	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.57	-0.42	8.77e-20	Schizophrenia;
LUAD	trans	rs12517041	1.000	rs16892325	chr5:23283742	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.48	-0.3	2.55e-10	Calcium levels;
LUAD	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11890956	chr21:40555474	PSMG1	-0.65	-11.27	-0.48	5.97e-26	Cognitive function;
LUAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg18854424	chr1:2615690	NA	0.43	9.43	0.42	2.76e-19	Ulcerative colitis;
LUAD	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg23649088	chr2:200775458	C2orf69	-0.54	-7.09	-0.33	5.61e-12	Schizophrenia;
LUAD	cis	rs790123	0.666	rs790124	chr3:122388605	A/G	cg15604389	chr3:122379662	NA	0.47	7.84	0.36	3.61e-14	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs12200782	1.000	rs72844495	chr6:26610640	T/C	cg11502198	chr6:26597334	ABT1	-0.78	-6.76	-0.31	4.6e-11	Small cell lung carcinoma;
LUAD	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg03929089	chr4:120376271	NA	-0.97	-19.76	-0.69	5e-62	Height;
LUAD	cis	rs4243830	0.737	rs11122083	chr1:6593532	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.74	-8.4	-0.38	7.07e-16	Body mass index;
LUAD	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg00666640	chr1:248458726	OR2T12	0.32	7.71	0.35	9.24e-14	Common traits (Other);
LUAD	cis	rs12760731	0.565	rs12030488	chr1:178094751	A/C	cg00404053	chr1:178313656	RASAL2	-0.66	-8.63	-0.39	1.22e-16	Obesity-related traits;
LUAD	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.4	-0.45	1.06e-22	Total body bone mineral density;
LUAD	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.4e-12	Lung cancer;
LUAD	trans	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg11693508	chr17:37793320	STARD3	0.72	9.19	0.41	1.82e-18	Bipolar disorder;
LUAD	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg18132916	chr6:79620363	NA	-0.44	-7.67	-0.35	1.16e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg25985355	chr7:65971099	NA	-0.53	-6.62	-0.31	1.09e-10	Diabetic kidney disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07352798	chr5:141488591	NDFIP1	-0.63	-7.66	-0.35	1.28e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg04944784	chr2:26401820	FAM59B	-0.88	-12.6	-0.52	4.12e-31	Gut microbiome composition (summer);
LUAD	trans	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg21284400	chr1:149981654	OTUD7B	-0.38	-6.48	-0.3	2.55e-10	Longevity;Endometriosis;
LUAD	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg03433033	chr1:76189801	ACADM	0.93	19.16	0.68	2.25e-59	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg26043149	chr18:55253948	FECH	-0.44	-7.26	-0.33	1.82e-12	Bone mineral density;
LUAD	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg21285383	chr16:89894308	SPIRE2	0.43	10.27	0.45	3.18e-22	Vitiligo;
LUAD	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.6	8.64	0.39	1.19e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg10518543	chr12:38710700	ALG10B	0.42	6.36	0.3	5.13e-10	Bladder cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09848198	chr12:93323497	EEA1	-0.43	-6.62	-0.31	1.07e-10	Height;
LUAD	cis	rs416603	0.901	rs149597	chr16:11343942	C/G	cg00044050	chr16:11439710	C16orf75	-0.59	-9.36	-0.41	4.68e-19	Type 1 diabetes;
LUAD	cis	rs2046867	0.862	rs7648954	chr3:72838756	C/A	cg04365224	chr3:72788183	NA	-0.43	-6.55	-0.3	1.64e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs9929218	0.954	rs4420522	chr16:68822971	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.72	-0.53	1.32e-31	Colorectal cancer;
LUAD	trans	rs853679	0.546	rs200981	chr6:27833174	A/G	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.15	-0.37	4.13e-15	Depression;
LUAD	trans	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg06774039	chr2:74056087	STAMBP	0.42	6.71	0.31	6.08e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg12927641	chr6:109611667	NA	-0.53	-9.46	-0.42	2.15e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg23950597	chr19:37808831	NA	-0.6	-7.52	-0.34	3.32e-13	Coronary artery calcification;
LUAD	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg00106254	chr7:1943704	MAD1L1	-0.52	-8.05	-0.36	8.74e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg07741184	chr6:167504864	NA	0.33	7.77	0.35	6.15e-14	Crohn's disease;
LUAD	cis	rs6738485	0.861	rs13014335	chr2:106802805	A/G	cg16099169	chr2:106886729	NA	-0.4	-6.8	-0.31	3.58e-11	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg05665937	chr4:1216051	CTBP1	0.42	7.62	0.35	1.74e-13	Obesity-related traits;
LUAD	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-20.88	-0.71	4.79e-67	Coronary artery disease;
LUAD	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg20469991	chr17:27169893	C17orf63	-0.51	-6.43	-0.3	3.52e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg18721089	chr20:30220636	NA	-0.42	-6.61	-0.31	1.14e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg06640241	chr16:89574553	SPG7	0.48	7.79	0.35	5.31e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg20701182	chr2:24300061	SF3B14	0.66	7.29	0.33	1.55e-12	Lymphocyte counts;
LUAD	cis	rs1003719	0.715	rs9981715	chr21:38499610	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.53	-8.93	-0.4	1.28e-17	Eye color traits;
LUAD	cis	rs240764	0.559	rs9404049	chr6:101237129	C/A	cg09795085	chr6:101329169	ASCC3	-0.43	-7.64	-0.35	1.49e-13	Neuroticism;
LUAD	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg00339695	chr16:24857497	SLC5A11	0.47	8.52	0.38	2.73e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs2548003	0.565	rs2554894	chr5:28762951	A/G	cg22863700	chr5:28928346	NA	0.42	6.54	0.3	1.72e-10	Hip geometry;
LUAD	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg07570687	chr10:102243282	WNT8B	0.48	7.28	0.33	1.6e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg05373962	chr22:49881684	NA	-0.48	-9.87	-0.43	7.85e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg16950941	chr11:66035639	RAB1B	0.45	7.52	0.34	3.42e-13	Gout;
LUAD	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg17757837	chr7:157058334	UBE3C	0.47	8.39	0.38	7.42e-16	Body mass index;
LUAD	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg04414720	chr1:150670196	GOLPH3L	0.66	11.49	0.49	9.16e-27	Melanoma;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg15264303	chr12:7013902	LRRC23	-0.48	-8.27	-0.37	1.79e-15	Cancer;
LUAD	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg02773041	chr1:40204384	PPIE	0.51	8.34	0.38	1.04e-15	Blood protein levels;
LUAD	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg06641503	chr3:48959341	ARIH2	-0.41	-7.18	-0.33	3.23e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg21475434	chr5:93447410	FAM172A	0.73	8.4	0.38	7.08e-16	Diabetic retinopathy;
LUAD	trans	rs459571	0.834	rs379417	chr9:136890704	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.66	-9.67	-0.43	4.12e-20	Platelet distribution width;
LUAD	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.77	-0.31	4.4e-11	Bipolar disorder;
LUAD	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.05e-19	Life satisfaction;
LUAD	cis	rs117623576	0.941	rs17488859	chr10:32386072	A/G	cg03047570	chr10:32398778	NA	0.77	9.36	0.41	4.86e-19	Anti-saccade response;
LUAD	cis	rs10979	0.603	rs9321920	chr6:143883588	C/G	cg25407410	chr6:143891975	LOC285740	-0.55	-7.93	-0.36	2.01e-14	Hypospadias;
LUAD	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg27454412	chr7:1067447	C7orf50	-0.4	-7.67	-0.35	1.21e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg21782813	chr7:2030301	MAD1L1	0.48	8.35	0.38	1.02e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg07757535	chr4:1339547	NA	0.3	6.52	0.3	2.06e-10	Longevity;
LUAD	trans	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.39	-0.3	4.33e-10	Aortic root size;
LUAD	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg10876282	chr6:28092338	ZSCAN16	0.45	7.31	0.33	1.34e-12	Parkinson's disease;
LUAD	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg17724175	chr1:150552817	MCL1	0.35	7.92	0.36	2.04e-14	Melanoma;
LUAD	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs57994353	0.861	rs3812591	chr9:139341612	C/T	cg14169450	chr9:139327907	INPP5E	-0.41	-6.82	-0.31	3.08e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs1881797	0.527	rs78398999	chr1:247686970	G/A	cg14830002	chr1:247616686	OR2B11	0.47	6.38	0.3	4.57e-10	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.56	-0.35	2.57e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg12062639	chr20:23401060	NAPB	1.1	11.43	0.49	1.54e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg13390004	chr1:15929781	NA	0.46	8.14	0.37	4.33e-15	Systolic blood pressure;
LUAD	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg16797656	chr11:68205561	LRP5	0.45	8.62	0.39	1.34e-16	Total body bone mineral density;
LUAD	cis	rs7394190	0.748	rs3088070	chr10:75530013	C/T	cg02286717	chr10:75415704	SYNPO2L	-0.37	-6.46	-0.3	2.93e-10	Incident atrial fibrillation;
LUAD	cis	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg05901451	chr6:126070800	HEY2	0.43	6.63	0.31	1.01e-10	Endometrial cancer;
LUAD	cis	rs9535307	0.929	rs6561550	chr13:50249423	C/T	cg04663916	chr13:50265991	EBPL	0.63	7.19	0.33	2.94e-12	Obesity-related traits;
LUAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg25324976	chr17:61989376	CSHL1	0.34	6.69	0.31	6.89e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs1997103	0.871	rs1997101	chr7:55399652	A/T	cg20935933	chr6:143382018	AIG1	0.53	7.46	0.34	4.94e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg24596788	chr1:163392923	NA	-0.34	-7.69	-0.35	1.07e-13	Motion sickness;
LUAD	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg06618935	chr21:46677482	NA	-0.52	-10.23	-0.45	4.13e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg03227570	chr1:17766306	RCC2	-0.42	-6.66	-0.31	8.73e-11	Vertical cup-disc ratio;
LUAD	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.85	0.36	3.56e-14	Bladder cancer;
LUAD	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg19635926	chr16:89946313	TCF25	0.74	6.93	0.32	1.62e-11	Skin colour saturation;
LUAD	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg25809561	chr17:30822961	MYO1D	0.47	8.5	0.38	3.21e-16	Schizophrenia;
LUAD	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg19767477	chr5:127420684	SLC12A2	-0.42	-6.52	-0.3	1.99e-10	Ileal carcinoids;
LUAD	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.56	-8.96	-0.4	1.08e-17	Colorectal cancer;
LUAD	trans	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg11693508	chr17:37793320	STARD3	0.52	7.54	0.34	2.9e-13	Neuroticism;
LUAD	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg06558623	chr16:89946397	TCF25	1.18	10.85	0.47	2.29e-24	Skin colour saturation;
LUAD	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg02527881	chr3:46936655	PTH1R	-0.5	-9.89	-0.43	6.65e-21	Colorectal cancer;
LUAD	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.93	13.11	0.54	3.37e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9649213	0.614	rs9640655	chr7:98017099	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.74	-10.74	-0.46	6.09e-24	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs735539	0.521	rs2818990	chr13:21388724	A/G	cg27499820	chr13:21296301	IL17D	-0.51	-8.44	-0.38	4.96e-16	Dental caries;
LUAD	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.55	-0.3	1.66e-10	Total body bone mineral density;
LUAD	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg17178900	chr1:205818956	PM20D1	-0.44	-7.4	-0.34	7.59e-13	Parkinson's disease;
LUAD	cis	rs2540226	0.844	rs1035139	chr2:39999315	G/A	cg22354234	chr2:40006543	THUMPD2	0.36	6.38	0.3	4.68e-10	Personality dimensions;
LUAD	cis	rs6750795	0.746	rs1667301	chr2:232423717	C/T	cg19187155	chr2:232395269	NMUR1	0.64	12.15	0.51	2.45e-29	Height;
LUAD	cis	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg06360820	chr2:242988706	NA	-0.89	-9.6	-0.42	7.28e-20	Obesity-related traits;
LUAD	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-7.64	-0.35	1.5e-13	Longevity;Endometriosis;
LUAD	cis	rs7731657	0.537	rs2189510	chr5:130316231	C/T	cg08523029	chr5:130500466	HINT1	-0.57	-7.22	-0.33	2.43e-12	Fasting plasma glucose;
LUAD	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg06608945	chr2:219082296	ARPC2	-0.5	-8.45	-0.38	4.68e-16	Colorectal cancer;
LUAD	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg08085267	chr17:45401833	C17orf57	0.64	11.29	0.48	5.32e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs73086581	0.945	rs6052222	chr20:3972793	G/A	cg02187196	chr20:3869020	PANK2	0.44	6.36	0.3	5.15e-10	Response to antidepressants in depression;
LUAD	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg17724175	chr1:150552817	MCL1	0.35	8.02	0.36	1.04e-14	Melanoma;
LUAD	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg22467129	chr15:76604101	ETFA	-0.5	-8.81	-0.39	3.19e-17	Blood metabolite levels;
LUAD	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg09137382	chr11:130731461	NA	0.41	7.51	0.34	3.48e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg11189052	chr15:85197271	WDR73	-0.61	-10.09	-0.44	1.36e-21	P wave terminal force;
LUAD	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg10755058	chr3:40428713	ENTPD3	0.47	8.68	0.39	8.54e-17	Renal cell carcinoma;
LUAD	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg25804541	chr17:80189381	SLC16A3	0.32	6.95	0.32	1.42e-11	Life satisfaction;
LUAD	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg23301539	chr8:142222248	SLC45A4	0.39	7.01	0.32	9.6e-12	Immature fraction of reticulocytes;
LUAD	cis	rs758324	0.947	rs683749	chr5:131283376	C/T	cg06307176	chr5:131281290	NA	-0.52	-8.31	-0.37	1.36e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg11494091	chr17:61959527	GH2	0.73	17.8	0.65	2.76e-53	Prudent dietary pattern;
LUAD	trans	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	17.92	0.66	7.53e-54	Exhaled nitric oxide output;
LUAD	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs999737	0.735	rs36028293	chr14:68976059	G/A	cg04147497	chr14:69052728	RAD51L1	-0.44	-6.69	-0.31	7.25e-11	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg01475377	chr6:109611718	NA	-0.51	-9.53	-0.42	1.27e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg26168224	chr5:2018326	NA	-0.66	-12.85	-0.53	4.08e-32	Gut microbiome composition (winter);
LUAD	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg13535736	chr9:111863775	C9orf5	-0.42	-6.5	-0.3	2.27e-10	Menarche (age at onset);
LUAD	trans	rs9951602	0.512	rs4799244	chr18:76649763	T/C	cg02800362	chr5:177631904	HNRNPAB	0.92	14.03	0.56	5.64e-37	Obesity-related traits;
LUAD	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg11344533	chr11:111475393	SIK2	-0.35	-6.68	-0.31	7.77e-11	Primary sclerosing cholangitis;
LUAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg05434287	chr7:2030229	MAD1L1	0.4	6.43	0.3	3.47e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg11070056	chr1:107600091	PRMT6	0.56	8.99	0.4	8.29e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs12532878	0.652	rs11768465	chr7:100198386	C/T	cg16850897	chr7:100343110	ZAN	-0.43	-6.77	-0.31	4.44e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs9341808	0.667	rs3805913	chr6:80927322	A/G	cg08355045	chr6:80787529	NA	0.52	9.31	0.41	7.18e-19	Sitting height ratio;
LUAD	cis	rs11958404	0.932	rs72816595	chr5:157435957	A/G	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg18129748	chr3:49941408	MST1R	-0.44	-7.24	-0.33	2.12e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.24	-0.41	1.22e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-7.33	-0.34	1.19e-12	Platelet count;
LUAD	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg00310523	chr12:86230176	RASSF9	0.39	7.83	0.36	3.93e-14	Major depressive disorder;
LUAD	cis	rs12545109	0.959	rs12547974	chr8:57314785	G/T	cg07776626	chr8:57350775	NA	-0.63	-8.95	-0.4	1.1e-17	Obesity-related traits;
LUAD	cis	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.49	-0.3	2.4e-10	Neuroticism;
LUAD	cis	rs10821973	0.527	rs5006763	chr10:63977673	C/A	cg09941381	chr10:64027924	RTKN2	-0.34	-6.72	-0.31	5.72e-11	Hypothyroidism;
LUAD	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-18.32	-0.67	1.35e-55	Coronary artery disease;
LUAD	cis	rs9811920	0.809	rs793476	chr3:99541747	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.55	-10.48	-0.45	5.35e-23	Axial length;
LUAD	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.36	0.34	9.89e-13	Menopause (age at onset);
LUAD	cis	rs35995292	0.517	rs6948026	chr7:38920854	A/G	cg19327137	chr7:38886074	VPS41	0.72	14.58	0.58	2.61e-39	Subjective well-being (multi-trait analysis);
LUAD	cis	rs6690583	0.623	rs55721024	chr1:85454447	A/C	cg22153463	chr1:85462885	MCOLN2	0.55	6.37	0.3	4.97e-10	Serum sulfate level;
LUAD	cis	rs4919694	1.000	rs7099987	chr10:104807926	C/T	cg04362960	chr10:104952993	NT5C2	0.73	7.86	0.36	3.28e-14	Arsenic metabolism;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03550917	chr16:5121879	ALG1	0.42	6.5	0.3	2.23e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs9473147	0.543	rs1872505	chr6:47480975	C/G	cg02130027	chr6:47444894	CD2AP	0.36	6.96	0.32	1.3e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs9560113	0.959	rs4773385	chr13:112178452	C/T	cg14154082	chr13:112174009	NA	0.37	6.87	0.32	2.32e-11	Menarche (age at onset);
LUAD	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03264133	chr6:25882463	NA	-0.47	-7.05	-0.32	7.11e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9394841	0.536	rs6899876	chr6:41796970	A/G	cg25600774	chr6:41776562	USP49	-0.41	-6.64	-0.31	9.43e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg09021430	chr5:549028	NA	-0.68	-14.46	-0.58	8.35e-39	Obesity-related traits;
LUAD	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg05283184	chr6:79620031	NA	-0.61	-12.41	-0.52	2.26e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs62229266	1.000	rs62229266	chr21:37460271	A/T	cg08632701	chr21:37451849	NA	-0.48	-7.84	-0.36	3.75e-14	Mitral valve prolapse;
LUAD	cis	rs6005807	0.719	rs9625520	chr22:29037864	C/A	cg12565055	chr22:29076175	TTC28	0.73	8.53	0.38	2.6e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs2992756	0.663	rs2992755	chr1:18807897	C/G	cg24076588	chr1:18808559	KLHDC7A	-0.46	-7.65	-0.35	1.34e-13	Breast cancer;
LUAD	trans	rs4650994	0.509	rs7519794	chr1:178542390	G/T	cg05059571	chr16:84539110	KIAA1609	0.44	6.75	0.31	4.85e-11	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg08798685	chr6:27730294	NA	-0.43	-6.97	-0.32	1.23e-11	Parkinson's disease;
LUAD	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg03453431	chr7:157225567	NA	-0.41	-6.9	-0.32	1.92e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs13315871	0.929	rs13082278	chr3:58318224	A/G	cg12435725	chr3:58293450	RPP14	-0.75	-8.3	-0.37	1.41e-15	Cholesterol, total;
LUAD	trans	rs7395662	0.963	rs9667588	chr11:48730337	C/T	cg00717180	chr2:96193071	NA	0.39	7.23	0.33	2.27e-12	HDL cholesterol;
LUAD	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg19163074	chr7:65112434	INTS4L2	0.44	6.76	0.31	4.56e-11	Aortic root size;
LUAD	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.64	-0.35	1.5e-13	Monocyte percentage of white cells;
LUAD	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.75	-0.31	4.91e-11	Type 2 diabetes;
LUAD	cis	rs73198271	0.710	rs3827808	chr8:8679357	A/T	cg01851573	chr8:8652454	MFHAS1	0.49	8.9	0.4	1.68e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg19622623	chr12:86230825	RASSF9	-0.56	-9.91	-0.43	5.92e-21	Major depressive disorder;
LUAD	cis	rs11048434	0.736	rs4309200	chr12:9121856	A/C	cg13575925	chr12:9217583	LOC144571	0.36	6.74	0.31	5.15e-11	Sjögren's syndrome;
LUAD	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg19622623	chr12:86230825	RASSF9	0.43	7.59	0.35	2e-13	Major depressive disorder;
LUAD	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg16325326	chr1:53192061	ZYG11B	0.56	9.85	0.43	9.92e-21	Monocyte count;
LUAD	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs612683	0.518	rs660945	chr1:100831830	A/T	cg06223162	chr1:101003688	GPR88	-0.37	-7.02	-0.32	9.06e-12	Breast cancer;
LUAD	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg20587970	chr11:113659929	NA	-1.4	-20.93	-0.71	2.68e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg02549819	chr16:58548995	SETD6	0.83	6.93	0.32	1.61e-11	Schizophrenia;
LUAD	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg15691649	chr6:25882328	NA	-0.44	-6.94	-0.32	1.45e-11	Blood metabolite levels;
LUAD	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg16479474	chr6:28041457	NA	0.44	7.4	0.34	7.22e-13	Depression;
LUAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07167872	chr1:205819463	PM20D1	0.71	13.9	0.56	1.99e-36	Menarche (age at onset);
LUAD	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.63	-12.67	-0.52	2.06e-31	Homoarginine levels;
LUAD	trans	rs7395662	0.687	rs11602892	chr11:48959152	G/A	cg00717180	chr2:96193071	NA	-0.4	-7.52	-0.34	3.34e-13	HDL cholesterol;
LUAD	cis	rs6005807	0.843	rs73439811	chr22:28780451	T/C	cg12565055	chr22:29076175	TTC28	0.69	6.85	0.32	2.6e-11	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg03563238	chr19:33554763	RHPN2	-0.33	-7.74	-0.35	7.27e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg10755058	chr3:40428713	ENTPD3	0.37	7.17	0.33	3.46e-12	Renal cell carcinoma;
LUAD	cis	rs10189230	0.935	rs1864461	chr2:222347615	A/G	cg14652038	chr2:222343519	EPHA4	0.44	8.7	0.39	7.64e-17	Urate levels in lean individuals;
LUAD	cis	rs6906287	0.647	rs10457338	chr6:118784018	T/C	cg05564266	chr6:118973597	C6orf204	0.33	7.14	0.33	4.13e-12	Electrocardiographic conduction measures;
LUAD	cis	rs10489202	0.657	rs3767479	chr1:168069840	C/A	cg25738037	chr1:168025549	DCAF6	-0.45	-6.38	-0.3	4.78e-10	Schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01459673	chr8:95907442	CCNE2	-0.68	-6.73	-0.31	5.52e-11	Type 2 diabetes;
LUAD	trans	rs6540	1.000	rs568373	chr11:255014	A/G	cg01022370	chr8:8749074	MFHAS1	0.69	7.21	0.33	2.53e-12	Endometriosis;
LUAD	trans	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-9.35	-0.41	4.95e-19	Endometrial cancer;
LUAD	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg11645453	chr3:52864694	ITIH4	0.32	6.43	0.3	3.46e-10	Electroencephalogram traits;
LUAD	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg13770153	chr20:60521292	NA	-0.6	-9.45	-0.42	2.27e-19	Body mass index;
LUAD	cis	rs11077998	0.935	rs11653926	chr17:80484953	G/A	cg10255544	chr17:80519551	FOXK2	0.35	7.04	0.32	7.77e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs13082711	0.863	rs36055621	chr3:27436797	T/C	cg02860705	chr3:27208620	NA	0.56	8.76	0.39	4.91e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	ch.21.228978R	chr21:27297434	APP	-0.42	-7.12	-0.33	4.8e-12	Cancer;
LUAD	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg04369109	chr6:150039330	LATS1	-0.44	-7.53	-0.34	3.13e-13	Lung cancer;
LUAD	cis	rs1003719	0.788	rs11911508	chr21:38470504	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.64	0.39	1.13e-16	Eye color traits;
LUAD	cis	rs9914988	0.943	rs7217547	chr17:27106872	C/G	cg02049041	chr17:27085579	C17orf63	0.62	8.31	0.37	1.34e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9486719	0.947	rs72932805	chr6:96902933	T/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.15	-0.44	8.17e-22	Migraine;Coronary artery disease;
LUAD	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg09359103	chr1:154839909	KCNN3	-0.93	-22.07	-0.73	2.2e-72	Prostate cancer;
LUAD	trans	rs7395662	0.611	rs11040073	chr11:48855624	G/A	cg15704280	chr7:45808275	SEPT13	0.41	6.45	0.3	3.03e-10	HDL cholesterol;
LUAD	cis	rs1816752	0.905	rs7317850	chr13:24994037	C/G	cg02811702	chr13:24901961	NA	0.42	7.1	0.33	5.43e-12	Obesity-related traits;
LUAD	cis	rs9549367	0.804	rs9549704	chr13:113885187	T/C	cg18105134	chr13:113819100	PROZ	-0.79	-12.77	-0.53	8.04e-32	Platelet distribution width;
LUAD	cis	rs6906287	0.647	rs6569015	chr6:118686344	C/T	cg21191810	chr6:118973309	C6orf204	0.49	9.25	0.41	1.1e-18	Electrocardiographic conduction measures;
LUAD	cis	rs3752962	0.569	rs3803806	chr17:1940713	T/C	cg24156229	chr17:1948635	NA	-0.46	-8.06	-0.36	7.72e-15	Itch intensity from mosquito bite;
LUAD	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg21724239	chr8:58056113	NA	0.78	9.33	0.41	6.04e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	11.87	0.5	3.15e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg04111992	chr7:158790115	NA	0.51	8.68	0.39	8.96e-17	Facial morphology (factor 20);
LUAD	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg02454025	chr1:11042201	C1orf127	1.02	17.76	0.65	3.78e-53	Ewing sarcoma;
LUAD	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.61	11.74	0.5	9.48e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7789940	0.809	rs12533836	chr7:75935622	G/T	cg10167463	chr7:75959203	YWHAG	-0.66	-11.52	-0.49	6.87e-27	Multiple sclerosis;
LUAD	cis	rs6496044	0.568	rs6496065	chr15:86075372	C/T	cg13263323	chr15:86062960	AKAP13	-0.57	-10.6	-0.46	1.88e-23	Interstitial lung disease;
LUAD	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg07936489	chr17:37558343	FBXL20	-0.47	-7.5	-0.34	3.76e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg02240030	chr7:2089880	MAD1L1	0.34	6.78	0.31	3.96e-11	Neuroticism;
LUAD	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg26597838	chr10:835615	NA	0.79	10.94	0.47	1.03e-24	Eosinophil percentage of granulocytes;
LUAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-9.65	-0.42	4.84e-20	Renal function-related traits (BUN);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14339216	chr19:47853009	DHX34	-0.38	-6.36	-0.3	5.11e-10	Cancer;
LUAD	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg04000281	chr11:63949212	NA	-0.29	-6.62	-0.31	1.07e-10	Platelet count;
LUAD	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg09367891	chr1:107599246	PRMT6	0.47	7.98	0.36	1.37e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6714710	0.603	rs11679828	chr2:98517626	G/A	cg26665480	chr2:98280029	ACTR1B	0.5	8.14	0.37	4.35e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg04772025	chr11:68637568	NA	-0.59	-9.47	-0.42	2.07e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg19163074	chr7:65112434	INTS4L2	0.45	6.83	0.32	3e-11	Aortic root size;
LUAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-9.23	-0.41	1.32e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg09359103	chr1:154839909	KCNN3	-0.91	-18.25	-0.66	2.54e-55	Prostate cancer;
LUAD	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	7.12	0.33	4.72e-12	Tonsillectomy;
LUAD	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.58	0.35	2.14e-13	Tonsillectomy;
LUAD	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg01475377	chr6:109611718	NA	-0.51	-9.44	-0.42	2.47e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.46	0.42	2.18e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg00933542	chr6:150070202	PCMT1	0.41	8.58	0.38	1.85e-16	Lung cancer;
LUAD	trans	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	8.75	0.39	5.04e-17	Exhaled nitric oxide output;
LUAD	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg17372223	chr3:52568218	NT5DC2	-0.39	-7.07	-0.32	6.57e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1595825	0.891	rs73058864	chr2:198889587	C/T	cg11031976	chr2:198649780	BOLL	-0.45	-6.51	-0.3	2.19e-10	Ulcerative colitis;
LUAD	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg08085267	chr17:45401833	C17orf57	0.64	11.6	0.49	3.28e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg18252515	chr7:66147081	NA	-0.63	-6.95	-0.32	1.38e-11	Diabetic kidney disease;
LUAD	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.51	-0.38	3.12e-16	Gut microbiome composition (summer);
LUAD	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg01416388	chr22:39784598	NA	0.48	8.27	0.37	1.77e-15	IgG glycosylation;
LUAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg07395648	chr5:131743802	NA	0.38	6.43	0.3	3.48e-10	Breast cancer;
LUAD	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg21385522	chr1:16154831	NA	0.71	10.95	0.47	9.52e-25	Dilated cardiomyopathy;
LUAD	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg15128208	chr22:42549153	NA	0.4	8.06	0.36	8.11e-15	Cognitive function;
LUAD	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-9.83	-0.43	1.15e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.09	0.37	6.3e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.42e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg18811423	chr2:55921094	PNPT1	0.5	8.41	0.38	6.58e-16	Metabolic syndrome;
LUAD	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg15557168	chr22:42548783	NA	0.5	9.09	0.4	3.94e-18	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg11262906	chr1:85462892	MCOLN2	-0.48	-6.52	-0.3	1.99e-10	Serum sulfate level;
LUAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg26338869	chr17:61819248	STRADA	-0.39	-6.55	-0.3	1.7e-10	Prudent dietary pattern;
LUAD	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-20.86	-0.71	5.91e-67	Height;
LUAD	cis	rs6138458	0.620	rs914314	chr20:24897355	C/T	cg26195577	chr20:24973756	C20orf3	-0.9	-9.9	-0.43	6.22e-21	Blood protein levels;
LUAD	trans	rs994533	0.928	rs7594625	chr2:218293564	A/C	cg09687332	chr3:49977370	RBM6	0.41	6.6	0.31	1.24e-10	Height;
LUAD	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.89	0.32	1.99e-11	Colorectal cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09147710	chr20:57607335	ATP5E	-0.69	-6.53	-0.3	1.93e-10	Type 2 diabetes;
LUAD	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.6	11.07	0.47	3.55e-25	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs7771547	0.507	rs6457918	chr6:36414308	A/T	cg07856975	chr6:36356162	ETV7	-0.45	-6.9	-0.32	1.94e-11	Platelet distribution width;
LUAD	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg24397884	chr7:158709396	WDR60	0.57	10.37	0.45	1.36e-22	Height;
LUAD	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg04155289	chr7:94953770	PON1	-0.52	-6.89	-0.32	2.09e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg14196790	chr5:131705035	SLC22A5	0.52	9.49	0.42	1.69e-19	Blood metabolite levels;
LUAD	cis	rs73416724	1.000	rs112472472	chr6:43279276	G/A	cg26312998	chr6:43337775	ZNF318	0.55	6.58	0.3	1.36e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs713477	0.967	rs2152975	chr14:55907919	C/T	cg13175173	chr14:55914753	NA	-0.33	-6.94	-0.32	1.52e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg04455712	chr21:45112962	RRP1B	-0.49	-9.76	-0.43	2.02e-20	Mean corpuscular volume;
LUAD	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg03929089	chr4:120376271	NA	-0.97	-20.33	-0.7	1.38e-64	Height;
LUAD	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg21681030	chr2:46777652	RHOQ	0.37	6.78	0.31	4.14e-11	Height;
LUAD	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg21204522	chr6:27730016	NA	-0.48	-7.57	-0.35	2.4e-13	Parkinson's disease;
LUAD	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg04842962	chr6:43655489	MRPS18A	-0.87	-13.64	-0.55	2.24e-35	IgG glycosylation;
LUAD	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg01884057	chr2:25150051	NA	0.32	6.79	0.31	3.86e-11	Body mass index;
LUAD	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg11915388	chr22:42470451	FAM109B	0.41	7.37	0.34	8.84e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21984481	chr17:79567631	NPLOC4	0.65	15.63	0.6	8.92e-44	Eye color traits;
LUAD	cis	rs240764	0.595	rs1039033	chr6:101191397	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-7.35	-0.34	1e-12	Neuroticism;
LUAD	cis	rs28830936	1.000	rs28754734	chr15:42093152	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.34	-6.87	-0.32	2.27e-11	Diastolic blood pressure;
LUAD	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg15485101	chr11:133734466	NA	0.37	8.16	0.37	3.87e-15	Childhood ear infection;
LUAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00166722	chr3:10149974	C3orf24	0.71	11.72	0.5	1.11e-27	Alzheimer's disease;
LUAD	cis	rs7301826	0.651	rs4759517	chr12:131283698	G/A	cg11011512	chr12:131303247	STX2	0.4	6.68	0.31	7.65e-11	Plasma plasminogen activator levels;
LUAD	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.56	-7.16	-0.33	3.52e-12	Body mass index;
LUAD	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.3	6.56	0.3	1.6e-10	Systemic lupus erythematosus;
LUAD	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	trans	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg19862616	chr7:65841803	NCRNA00174	1.05	26.66	0.79	1.38e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg01788221	chr16:89496183	ANKRD11	-0.35	-6.53	-0.3	1.93e-10	Multiple myeloma (IgH translocation);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06889350	chr14:75530936	ACYP1	-0.38	-6.36	-0.3	5.2400000000000005e-10	Cancer;
LUAD	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-11.96	-0.5	1.36e-28	Electroencephalogram traits;
LUAD	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06873352	chr17:61820015	STRADA	0.55	9.01	0.4	7.04e-18	Height;
LUAD	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg16322792	chr1:120165303	ZNF697	0.72	19.4	0.69	1.86e-60	Systemic lupus erythematosus;
LUAD	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg10589385	chr1:150898437	SETDB1	0.45	8.29	0.37	1.57e-15	Melanoma;
LUAD	cis	rs7705042	0.865	rs4385236	chr5:141513396	G/A	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.6	-0.31	1.2e-10	Asthma;
LUAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2625529	0.824	rs12906711	chr15:72215065	A/G	cg16672083	chr15:72433130	SENP8	-0.75	-12.39	-0.52	2.79e-30	Red blood cell count;
LUAD	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.75	0.53	9.8e-32	Cognitive ability;
LUAD	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg15691649	chr6:25882328	NA	-0.61	-9.44	-0.42	2.47e-19	Blood metabolite levels;
LUAD	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg14345882	chr6:26364793	BTN3A2	0.59	6.66	0.31	8.59e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg03732007	chr1:2071316	PRKCZ	-0.35	-6.53	-0.3	1.91e-10	Height;
LUAD	cis	rs1997103	1.000	rs6973450	chr7:55396537	A/G	cg17469321	chr7:55412551	NA	0.67	11.41	0.49	1.73e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.55	-0.3	1.66e-10	Total body bone mineral density;
LUAD	cis	rs4888262	0.545	rs7193959	chr16:74664969	T/A	cg01733217	chr16:74700730	RFWD3	0.52	8.75	0.39	5.18e-17	Testicular germ cell tumor;
LUAD	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg06641503	chr3:48959341	ARIH2	-0.41	-8.03	-0.36	9.78e-15	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9878978	0.964	rs34966409	chr3:2488889	C/G	cg21928760	chr3:2462534	CNTN4	-0.33	-6.51	-0.3	2.17e-10	Blood pressure (smoking interaction);
LUAD	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg15962314	chr1:44399869	ARTN	0.3	6.83	0.32	2.9100000000000002e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs13315871	0.929	rs7643185	chr3:58311158	A/C	cg12435725	chr3:58293450	RPP14	0.67	7.63	0.35	1.59e-13	Cholesterol, total;
LUAD	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg06138931	chr13:21896616	NA	0.44	6.46	0.3	2.96e-10	White matter hyperintensity burden;
LUAD	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg27494647	chr7:150038898	RARRES2	0.43	7.11	0.33	5.11e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg00321850	chr1:175162397	KIAA0040	-0.51	-10.61	-0.46	1.81e-23	Alcohol dependence;
LUAD	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg21724239	chr8:58056113	NA	0.57	7.56	0.35	2.45e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2735413	0.813	rs11644471	chr16:78077237	A/T	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7943203	0.568	rs61913891	chr11:108335075	A/G	cg04873221	chr11:107992290	ACAT1	-0.48	-7.28	-0.33	1.69e-12	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs4604732	0.631	rs11490199	chr1:247625737	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07631383	chr7:131012765	MKLN1	0.42	6.66	0.31	8.39e-11	Gut microbiome composition (summer);
LUAD	cis	rs7100689	0.646	rs11202724	chr10:82136190	T/C	cg01528321	chr10:82214614	TSPAN14	0.65	10.26	0.45	3.26e-22	Post bronchodilator FEV1;
LUAD	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg11070056	chr1:107600091	PRMT6	0.59	10.22	0.44	4.72e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.08	-0.33	6.17e-12	Total cholesterol levels;
LUAD	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg13319975	chr6:146136371	FBXO30	-0.58	-9.69	-0.43	3.56e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17362650	1.000	rs66835002	chr2:9655260	T/C	cg12832956	chr2:9616023	IAH1	-0.48	-7.64	-0.35	1.44e-13	Alcohol dependence (age at onset);
LUAD	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg22117172	chr7:91764530	CYP51A1	-0.35	-7.94	-0.36	1.9e-14	Breast cancer;
LUAD	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg19678392	chr7:94953810	PON1	-0.55	-7.32	-0.34	1.23e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2050392	0.965	rs1543725	chr10:30698873	A/G	cg18806716	chr10:30721971	MAP3K8	-0.52	-10.34	-0.45	1.76e-22	Inflammatory bowel disease;
LUAD	trans	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg19862616	chr7:65841803	NCRNA00174	1.06	27.46	0.8	4.59e-96	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	-0.43	-6.86	-0.32	2.5e-11	Resistin levels;
LUAD	cis	rs6761276	0.868	rs13386602	chr2:113834820	A/C	cg02343335	chr2:113785852	IL1F8	-0.35	-7.01	-0.32	9.57e-12	Protein quantitative trait loci;
LUAD	cis	rs3815148	0.569	rs12705406	chr7:106792554	A/G	cg02696742	chr7:106810147	HBP1	0.75	7.79	0.35	5.39e-14	Osteoarthritis;
LUAD	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg01579765	chr21:45077557	HSF2BP	-0.6	-14.35	-0.57	2.61e-38	Mean corpuscular volume;
LUAD	trans	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.69	-0.31	7.09e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6545883	0.931	rs7557230	chr2:61736652	A/T	cg15711740	chr2:61764176	XPO1	-0.4	-6.41	-0.3	3.88e-10	Tuberculosis;
LUAD	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg21433313	chr16:3507492	NAT15	-0.7	-8.1	-0.37	6.09e-15	Tuberculosis;
LUAD	cis	rs11958404	0.929	rs80162289	chr5:157354639	T/C	cg05962755	chr5:157440814	NA	0.61	8.12	0.37	5.02e-15	IgG glycosylation;
LUAD	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg18811423	chr2:55921094	PNPT1	0.45	7.32	0.34	1.24e-12	Metabolic syndrome;
LUAD	cis	rs7678296	0.649	rs77896458	chr4:37237843	A/G	cg06805348	chr4:37245195	KIAA1239	0.55	6.38	0.3	4.73e-10	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg18240062	chr17:79603768	NPLOC4	0.46	8.23	0.37	2.37e-15	Eye color traits;
LUAD	trans	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-16.07	-0.62	1.09e-45	Exhaled nitric oxide output;
LUAD	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.52	-0.42	1.3e-19	Life satisfaction;
LUAD	cis	rs2820315	0.540	rs10920259	chr1:201797696	C/T	cg06775570	chr1:201857621	SHISA4	-0.26	-6.47	-0.3	2.71e-10	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUAD	cis	rs6783573	0.535	rs6442006	chr3:46629382	C/G	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.4	-7.28	-0.33	1.69e-12	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg01620082	chr3:125678407	NA	-0.77	-8.29	-0.37	1.54e-15	Breast cancer;
LUAD	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg25985355	chr7:65971099	NA	0.54	6.67	0.31	8.07e-11	Diabetic kidney disease;
LUAD	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg05623727	chr3:50126028	RBM5	0.33	7.27	0.33	1.76e-12	Body mass index;
LUAD	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg06640241	chr16:89574553	SPG7	0.71	12.47	0.52	1.33e-30	Multiple myeloma (IgH translocation);
LUAD	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg22906224	chr7:99728672	NA	0.55	9.5	0.42	1.5700000000000001e-19	Coronary artery disease;
LUAD	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg10057126	chr4:77819792	ANKRD56	0.52	8.83	0.39	2.76e-17	Emphysema distribution in smoking;
LUAD	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.43	-0.34	6.08e-13	Bipolar disorder;
LUAD	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg25452165	chr22:42524984	CYP2D6	-0.38	-6.39	-0.3	4.43e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg04025307	chr7:1156635	C7orf50	0.69	12.36	0.52	3.49e-30	Longevity;Endometriosis;
LUAD	trans	rs6598955	0.671	rs12354062	chr1:26608761	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.71	-9.48	-0.42	1.78e-19	Obesity-related traits;
LUAD	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg23281280	chr6:28129359	ZNF389	0.46	6.68	0.31	7.58e-11	Parkinson's disease;
LUAD	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.57	-8.89	-0.4	1.81e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg15704280	chr7:45808275	SEPT13	-1.02	-20.65	-0.71	4.85e-66	Height;
LUAD	cis	rs7224314	1.000	rs62084080	chr17:65387014	C/T	cg01507342	chr17:65387096	PITPNC1	-0.55	-9.2	-0.41	1.66e-18	Diisocyanate-induced asthma;
LUAD	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.21	-0.33	2.52e-12	Bipolar disorder;
LUAD	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg14582100	chr15:45693742	SPATA5L1	0.64	12.08	0.51	4.7e-29	Homoarginine levels;
LUAD	cis	rs2073300	1.000	rs6106656	chr20:23444301	A/G	cg12062639	chr20:23401060	NAPB	0.88	7.78	0.35	5.57e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg27284194	chr4:1044797	NA	0.59	9.64	0.42	5.25e-20	Recombination rate (males);
LUAD	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03934478	chr11:495069	RNH1	0.77	9.25	0.41	1.13e-18	Body mass index;
LUAD	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	7.61	0.35	1.76e-13	Parkinson's disease;
LUAD	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg11845111	chr2:191398756	TMEM194B	-0.83	-10.66	-0.46	1.18e-23	Diastolic blood pressure;
LUAD	cis	rs4343996	0.902	rs4722693	chr7:3374312	C/T	cg21248987	chr7:3385318	SDK1	-0.35	-6.54	-0.3	1.81e-10	Motion sickness;
LUAD	cis	rs6906287	0.573	rs12205899	chr6:118699928	C/G	cg18833306	chr6:118973337	C6orf204	0.46	8.31	0.37	1.28e-15	Electrocardiographic conduction measures;
LUAD	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-6.65	-0.31	9.24e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10203711	0.933	rs1810139	chr2:239568154	A/C	cg14580085	chr2:239553406	NA	0.39	8.29	0.37	1.53e-15	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.64	0.39	1.21e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	6.45	0.3	2.97e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg04287289	chr16:89883240	FANCA	0.75	6.37	0.3	5.01e-10	Skin colour saturation;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05033052	chr10:21815715	C10orf140	-0.4	-6.89	-0.32	1.99e-11	Cancer;
LUAD	cis	rs12711979	0.509	rs10192699	chr2:3824297	A/G	cg17052675	chr2:3827356	NA	-0.84	-19.39	-0.69	2.24e-60	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09658438	chr12:56693554	CS	-0.43	-6.66	-0.31	8.56e-11	Height;
LUAD	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg07917127	chr4:99064746	C4orf37	0.39	6.5	0.3	2.33e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg27284194	chr4:1044797	NA	-0.69	-10.11	-0.44	1.15e-21	Recombination rate (females);
LUAD	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg15485101	chr11:133734466	NA	0.38	8.64	0.39	1.13e-16	Childhood ear infection;
LUAD	cis	rs4713675	0.565	rs6928010	chr6:33676590	T/C	cg14003231	chr6:33640908	ITPR3	0.49	9.54	0.42	1.17e-19	Plateletcrit;
LUAD	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg06808227	chr14:105710500	BRF1	-0.44	-6.87	-0.32	2.37e-11	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7617773	0.780	rs34946886	chr3:48338487	A/G	cg11946769	chr3:48343235	NME6	0.44	6.8	0.31	3.52e-11	Coronary artery disease;
LUAD	cis	rs9369695	0.883	rs9381581	chr6:47580695	G/A	cg20196966	chr6:47445060	CD2AP	0.45	7.01	0.32	9.35e-12	Reticulocyte count;
LUAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg00450029	chr8:599525	NA	-0.67	-7.2	-0.33	2.79e-12	IgG glycosylation;
LUAD	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg18196295	chr10:418757	DIP2C	0.5	8.37	0.38	8.38e-16	Psychosis in Alzheimer's disease;
LUAD	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg11062466	chr8:58055876	NA	0.46	6.49	0.3	2.42e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg19678392	chr7:94953810	PON1	-0.54	-7.24	-0.33	2.14e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg15628303	chr1:26608928	UBXN11	-0.37	-6.53	-0.3	1.87e-10	Height;
LUAD	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg25036284	chr2:26402008	FAM59B	-0.82	-12.37	-0.52	3.27e-30	Gut microbiome composition (summer);
LUAD	trans	rs9408928	0.778	rs9409230	chr9:123967760	A/T	cg05489143	chr3:40498640	RPL14	0.68	6.66	0.31	8.6e-11	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	8.68	0.39	8.74e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	0.963	rs4882109	chr11:48557685	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.1e-12	HDL cholesterol;
LUAD	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg26850624	chr5:429559	AHRR	-0.42	-6.65	-0.31	9.24e-11	Cystic fibrosis severity;
LUAD	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg00631329	chr6:26305371	NA	0.57	10.22	0.45	4.5e-22	Mosquito bite size;
LUAD	trans	rs1997103	1.000	rs4948012	chr7:55412578	A/C	cg20935933	chr6:143382018	AIG1	0.55	7.81	0.36	4.5e-14	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg25036284	chr2:26402008	FAM59B	-0.83	-12.35	-0.51	4.08e-30	Gut microbiome composition (summer);
LUAD	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg16479474	chr6:28041457	NA	0.41	6.98	0.32	1.16e-11	Parkinson's disease;
LUAD	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg01181863	chr3:195395398	SDHAP2	-0.74	-10.75	-0.46	5.59e-24	Pancreatic cancer;
LUAD	cis	rs2806561	0.734	rs11578046	chr1:23425139	G/A	cg12483005	chr1:23474871	LUZP1	0.44	7.1	0.33	5.18e-12	Height;
LUAD	cis	rs3935685	1.000	rs62007781	chr15:78026601	G/A	cg25212270	chr15:78015279	NA	0.34	6.42	0.3	3.63e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs77727587	chr7:106815754	C/G	cg02696742	chr7:106810147	HBP1	-0.81	-11.44	-0.49	1.34e-26	Coronary artery disease;
LUAD	cis	rs7017914	0.967	rs34558600	chr8:71586152	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.58	-0.3	1.44e-10	Bone mineral density;
LUAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg26554054	chr8:600488	NA	0.8	7.95	0.36	1.7e-14	IgG glycosylation;
LUAD	cis	rs11083475	0.557	rs2368519	chr19:39259241	C/T	cg07905965	chr19:39260460	NA	0.55	9.98	0.44	3.24e-21	Heart rate;
LUAD	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.55	9.67	0.43	3.98e-20	Axial length;
LUAD	cis	rs939658	0.935	rs4778651	chr15:79447810	G/A	cg17916960	chr15:79447300	NA	-0.49	-10.15	-0.44	8.43e-22	Refractive error;
LUAD	cis	rs7771547	0.519	rs28371845	chr6:36377709	C/T	cg07856975	chr6:36356162	ETV7	0.54	8.09	0.37	6.38e-15	Platelet distribution width;
LUAD	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg22029157	chr1:209979665	IRF6	0.74	10.72	0.46	7.15e-24	Cleft lip with or without cleft palate;
LUAD	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg20283391	chr11:68216788	NA	-0.41	-6.55	-0.3	1.71e-10	Total body bone mineral density;
LUAD	cis	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg07460842	chr6:66804631	NA	0.94	15.07	0.59	2.16e-41	Exhaled nitric oxide levels;
LUAD	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg18105134	chr13:113819100	PROZ	-1.0	-18.58	-0.67	8.93e-57	Platelet distribution width;
LUAD	cis	rs1030268	0.667	rs12707111	chr7:133330144	C/T	cg10665199	chr7:133106180	EXOC4	0.45	6.43	0.3	3.39e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.66	0.31	8.45e-11	Cardiac Troponin-T levels;
LUAD	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg06608945	chr2:219082296	ARPC2	0.46	7.47	0.34	4.6e-13	Colorectal cancer;
LUAD	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg11993925	chr19:44307056	LYPD5	0.6	12.65	0.52	2.56e-31	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg17863274	chr19:49399704	TULP2	-0.65	-9.9	-0.43	6.22e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	trans	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg27411982	chr8:10470053	RP1L1	0.44	7.86	0.36	3.17e-14	Mood instability;
LUAD	cis	rs1595825	0.891	rs1030796	chr2:198674673	A/G	cg10547527	chr2:198650123	BOLL	-0.53	-7.35	-0.34	1.04e-12	Ulcerative colitis;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg08522087	chr5:14871910	ANKH	-0.41	-6.93	-0.32	1.62e-11	Subcortical brain region volumes;
LUAD	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg18833306	chr6:118973337	C6orf204	-0.5	-7.36	-0.34	9.86e-13	Diastolic blood pressure;
LUAD	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg03929089	chr4:120376271	NA	-0.96	-19.52	-0.69	5.46e-61	Height;
LUAD	trans	rs9567307	1	rs9567307	chr13:44471877	A/G	cg12856521	chr11:46389249	DGKZ	0.66	10.38	0.45	1.24e-22	Leprosy;
LUAD	cis	rs68170813	0.523	rs11762152	chr7:106811374	G/A	cg23024343	chr7:107201750	COG5	0.45	6.63	0.31	1.05e-10	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-11.56	-0.49	4.72e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg03609598	chr5:56110824	MAP3K1	-0.57	-7.81	-0.35	4.67e-14	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg07917127	chr4:99064746	C4orf37	0.44	7.27	0.33	1.77e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg27411982	chr8:10470053	RP1L1	0.35	6.36	0.3	5.32e-10	Neuroticism;
LUAD	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.88	-0.32	2.23e-11	Height;
LUAD	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg17366294	chr4:99064904	C4orf37	0.48	8.42	0.38	5.73e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.39	-6.5	-0.3	2.24e-10	Longevity;Endometriosis;
LUAD	cis	rs7116495	1.000	rs7116495	chr11:71762085	C/T	cg07596299	chr11:71824057	C11orf51	-0.78	-6.66	-0.31	8.3e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs7786877	0.583	rs41303510	chr7:100226129	C/T	cg16850897	chr7:100343110	ZAN	-0.6	-8.15	-0.37	4.23e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs790123	0.842	rs796889	chr3:122398461	T/C	cg00926285	chr3:122398533	PARP14	-0.38	-6.68	-0.31	7.46e-11	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14358282	chr2:219866628	MIR375	-0.55	-6.46	-0.3	2.9e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg01579765	chr21:45077557	HSF2BP	-0.57	-13.34	-0.54	3.97e-34	Mean corpuscular volume;
LUAD	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg13319975	chr6:146136371	FBXO30	0.64	11.05	0.47	4.31e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9653442	0.866	rs11123811	chr2:100760172	T/C	cg07810366	chr2:100720526	AFF3	-0.37	-7.52	-0.34	3.42e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg04267008	chr7:1944627	MAD1L1	-0.55	-8.12	-0.37	5.13e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg11742103	chr11:62369870	EML3;MTA2	-0.5	-9.33	-0.41	5.8e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg17063962	chr7:91808500	NA	0.68	12.37	0.52	3.35e-30	Breast cancer;
LUAD	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg05182265	chr7:156933206	UBE3C	0.81	17.35	0.64	2.66e-51	Body mass index;
LUAD	cis	rs733175	0.953	rs4485819	chr4:10037393	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	7.81	0.35	4.69e-14	Psychosis and Alzheimer's disease;
LUAD	cis	rs6782228	0.606	rs2811488	chr3:128336517	C/T	cg16766828	chr3:128327626	NA	-0.38	-7.21	-0.33	2.58e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs73416724	1.000	rs73416724	chr6:43337802	A/G	cg26312998	chr6:43337775	ZNF318	0.58	7.48	0.34	4.22e-13	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10947003	chr16:67218230	KIAA0895L	-0.45	-7.06	-0.32	7.07e-12	Height;
LUAD	trans	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg24644049	chr4:85504048	CDS1	0.88	7.39	0.34	8.02e-13	Skin colour saturation;
LUAD	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg02569458	chr12:86230093	RASSF9	0.46	8.35	0.38	9.79e-16	Major depressive disorder;
LUAD	cis	rs9302690	0.557	rs223869	chr16:57494992	C/A	cg27017172	chr16:57497170	POLR2C	0.77	7.3	0.33	1.46e-12	Blood protein levels;
LUAD	cis	rs78707713	0.841	rs13377102	chr10:71213386	T/A	cg12610070	chr10:71211762	TSPAN15	-0.4	-7.39	-0.34	7.85e-13	Venous thromboembolism;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15586420	chr15:90294517	MESP1	-0.43	-6.48	-0.3	2.6200000000000003e-10	Height;
LUAD	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-38.42	-0.88	5.23e-140	Myeloid white cell count;
LUAD	trans	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg00953403	chr17:74099816	EXOC7	0.49	7.79	0.35	5.08e-14	Psychosis in Alzheimer's disease;
LUAD	cis	rs67072384	0.901	rs11235586	chr11:72476025	C/G	cg04827223	chr11:72435913	ARAP1	-0.59	-6.44	-0.3	3.26e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg24690094	chr11:67383802	NA	0.4	7.12	0.33	4.63e-12	Mean corpuscular volume;
LUAD	trans	rs4942242	0.663	rs9525817	chr13:44225189	C/T	cg19169023	chr15:41853346	TYRO3	0.69	11.89	0.5	2.61e-28	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg18230493	chr5:56204884	C5orf35	-0.64	-10.28	-0.45	2.79e-22	Coronary artery disease;
LUAD	cis	rs17253792	0.822	rs79262019	chr14:56092704	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg03037974	chr15:76606532	NA	0.38	8.12	0.37	5.25e-15	Blood metabolite levels;
LUAD	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg14159672	chr1:205819179	PM20D1	0.53	8.05	0.36	8.59e-15	Menarche (age at onset);
LUAD	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg23260525	chr10:116636907	FAM160B1	0.47	10.81	0.47	3.14e-24	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	12.83	0.53	4.62e-32	Chronic sinus infection;
LUAD	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-6.52	-0.3	2.06e-10	Tonsillectomy;
LUAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg00080972	chr5:178986291	RUFY1	0.64	11.58	0.49	3.96e-27	Lung cancer;
LUAD	trans	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg09872104	chr7:134855509	C7orf49	-0.83	-7.16	-0.33	3.69e-12	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs4824093	0.610	rs74371371	chr22:50314074	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	6.35	0.3	5.44e-10	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg18827107	chr12:86230957	RASSF9	-0.69	-12.54	-0.52	6.66e-31	Major depressive disorder;
LUAD	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg27490568	chr2:178487706	NA	0.53	8.83	0.39	2.91e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg10518543	chr12:38710700	ALG10B	0.5	8.39	0.38	7.28e-16	Morning vs. evening chronotype;
LUAD	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg15556689	chr8:8085844	FLJ10661	0.46	7.33	0.34	1.19e-12	Systolic blood pressure;
LUAD	cis	rs753778	0.962	rs2043422	chr8:142236337	C/T	cg18755752	chr8:142205143	DENND3	-0.46	-7.69	-0.35	1.07e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs1018836	0.886	rs12545351	chr8:91636668	C/T	cg16814680	chr8:91681699	NA	-0.67	-11.65	-0.49	2.07e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs478304	0.593	rs12576766	chr11:65488556	C/T	cg05805236	chr11:65401703	PCNXL3	-0.56	-9.22	-0.41	1.46e-18	Acne (severe);
LUAD	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg02807482	chr3:125708958	NA	-0.66	-8.81	-0.39	3.32e-17	Blood pressure (smoking interaction);
LUAD	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg05043794	chr9:111880884	C9orf5	-0.38	-6.37	-0.3	5.07e-10	Menarche (age at onset);
LUAD	cis	rs3845702	1.000	rs259808	chr2:180791419	T/G	cg01881094	chr2:180872142	CWC22	-0.59	-7.19	-0.33	3.02e-12	Schizophrenia;
LUAD	cis	rs790123	0.579	rs9875934	chr3:122396599	A/C	cg15604389	chr3:122379662	NA	0.44	6.69	0.31	7e-11	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs11088226	0.581	rs2833856	chr21:33877691	A/G	cg09050820	chr6:167586206	TCP10L2	-0.48	-8.16	-0.37	3.95e-15	Gastritis;
LUAD	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg16262614	chr3:133464971	TF	0.41	8.19	0.37	3.13e-15	Iron status biomarkers (transferrin levels);
LUAD	trans	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg13698153	chr12:118541722	VSIG10	-0.43	-6.62	-0.31	1.09e-10	Vitiligo;
LUAD	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg06606381	chr12:133084897	FBRSL1	-0.96	-9.31	-0.41	6.82e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg02753203	chr1:228287806	NA	-0.46	-8.46	-0.38	4.44e-16	Diastolic blood pressure;
LUAD	cis	rs9486719	1.000	rs28623445	chr6:96899116	G/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.17	-0.44	6.77e-22	Migraine;Coronary artery disease;
LUAD	cis	rs12618769	0.681	rs72823792	chr2:99215142	G/A	cg10123293	chr2:99228465	UNC50	0.5	8.87	0.4	2.09e-17	Bipolar disorder;
LUAD	cis	rs1595825	0.628	rs6760078	chr2:198563742	A/T	cg10547527	chr2:198650123	BOLL	-0.54	-7.83	-0.36	4e-14	Ulcerative colitis;
LUAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg17372223	chr3:52568218	NT5DC2	0.38	7.04	0.32	7.89e-12	Electroencephalogram traits;
LUAD	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.46	0.52	1.4e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg07817883	chr1:32538562	TMEM39B	0.98	9.95	0.44	4.38e-21	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7943203	1.000	rs4753842	chr11:108311606	G/C	cg04873221	chr11:107992290	ACAT1	-0.43	-6.99	-0.32	1.07e-11	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.36	-6.46	-0.3	2.85e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg23978390	chr7:1156363	C7orf50	0.58	9.05	0.4	5.12e-18	Longevity;Endometriosis;
LUAD	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg06636551	chr8:101224915	SPAG1	-0.37	-6.76	-0.31	4.62e-11	Atrioventricular conduction;
LUAD	cis	rs1534166	1.000	rs1534166	chr3:133537067	C/T	cg08048268	chr3:133502702	NA	-0.35	-6.52	-0.3	2.01e-10	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.63	0.31	9.95e-11	Parkinson's disease;
LUAD	cis	rs1971762	0.583	rs11170648	chr12:54089660	C/T	cg23533419	chr12:54090519	NA	-0.34	-6.4	-0.3	4.17e-10	Height;
LUAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg09737314	chr17:6899359	ALOX12	0.39	7.4	0.34	7.43e-13	Tonsillectomy;
LUAD	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.29	0.33	1.58e-12	Tonsillectomy;
LUAD	cis	rs1403694	0.695	rs13095338	chr3:186435583	T/C	cg12454167	chr3:186435060	KNG1	0.51	10.73	0.46	6.63e-24	Blood protein levels;
LUAD	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg19729930	chr2:74357872	NA	0.99	16.26	0.62	1.51e-46	Gestational age at birth (maternal effect);
LUAD	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg18833306	chr6:118973337	C6orf204	-0.54	-7.72	-0.35	8.23e-14	Diastolic blood pressure;
LUAD	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.52	-0.42	1.3e-19	Life satisfaction;
LUAD	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg01874867	chr7:94954059	PON1	-0.51	-7.0	-0.32	1.02e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs1941687	0.797	rs12963804	chr18:31391208	T/C	cg27147174	chr7:100797783	AP1S1	-0.5	-8.26	-0.37	1.93e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.42	-8.47	-0.38	4.23e-16	Glomerular filtration rate;
LUAD	cis	rs1003719	0.713	rs7277150	chr21:38490006	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.47	0.38	4.01e-16	Eye color traits;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14868726	chr18:2571660	METTL4;NDC80	-0.43	-6.47	-0.3	2.68e-10	Height;
LUAD	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg05368731	chr17:41323189	NBR1	0.94	19.34	0.69	3.46e-60	Menopause (age at onset);
LUAD	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg06221963	chr1:154839813	KCNN3	-0.85	-20.05	-0.7	2.38e-63	Prostate cancer;
LUAD	cis	rs73416724	0.858	rs4466248	chr6:43279652	T/C	cg26312998	chr6:43337775	ZNF318	-0.56	-7.07	-0.33	6.36e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg26384229	chr12:38710491	ALG10B	0.4	6.39	0.3	4.3e-10	Morning vs. evening chronotype;
LUAD	cis	rs10189230	0.967	rs13026378	chr2:222352712	G/A	cg14652038	chr2:222343519	EPHA4	0.43	8.59	0.39	1.73e-16	Urate levels in lean individuals;
LUAD	cis	rs752010	0.841	rs11210498	chr1:42077958	T/G	cg06885757	chr1:42089581	HIVEP3	0.38	8.04	0.36	9.31e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg11494091	chr17:61959527	GH2	0.74	18.35	0.67	9.02e-56	Prudent dietary pattern;
LUAD	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg12714757	chr17:73874637	TRIM47	-0.4	-6.38	-0.3	4.77e-10	Psoriasis;
LUAD	cis	rs73206853	0.841	rs55754138	chr12:110869335	G/T	cg12870014	chr12:110450643	ANKRD13A	0.62	6.82	0.31	3.14e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg04398451	chr17:18023971	MYO15A	-0.78	-13.96	-0.56	1.1e-36	Total body bone mineral density;
LUAD	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg23602478	chr1:26503979	CNKSR1	0.28	7.01	0.32	9.26e-12	Height;
LUAD	cis	rs12049351	0.774	rs1065675	chr1:229622162	A/G	cg11742688	chr1:229674241	ABCB10	-0.41	-6.76	-0.31	4.59e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg03609598	chr5:56110824	MAP3K1	0.46	6.86	0.32	2.42e-11	Initial pursuit acceleration;
LUAD	cis	rs524023	0.874	rs495130	chr11:64449307	C/T	cg19131476	chr11:64387923	NRXN2	-0.42	-8.33	-0.38	1.13e-15	Urate levels in obese individuals;
LUAD	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg20487152	chr13:99095054	FARP1	-0.59	-12.1	-0.51	3.85e-29	Neuroticism;
LUAD	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg00316803	chr15:76480434	C15orf27	0.4	6.63	0.31	1.06e-10	Blood metabolite levels;
LUAD	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg18944383	chr4:111397179	ENPEP	0.38	7.66	0.35	1.31e-13	Height;
LUAD	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.63	0.31	1.03e-10	Schizophrenia;
LUAD	cis	rs11948739	0.539	rs1119863	chr5:130282399	T/G	cg08523029	chr5:130500466	HINT1	0.58	7.4	0.34	7.27e-13	Pediatric bone mineral content (hip);
LUAD	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg26647111	chr11:31128758	NA	-0.47	-8.11	-0.37	5.4e-15	Red blood cell count;
LUAD	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg08045932	chr20:61659980	NA	0.55	10.58	0.46	2.21e-23	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs1395	0.677	rs113353646	chr2:27492674	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.52	9.28	0.41	8.84e-19	Blood metabolite levels;
LUAD	cis	rs72772090	0.539	rs10515247	chr5:96111726	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-7.36	-0.34	9.6e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs68170813	0.559	rs6964798	chr7:106933013	C/G	cg02696742	chr7:106810147	HBP1	-0.76	-10.48	-0.45	5.48e-23	Coronary artery disease;
LUAD	cis	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg07460842	chr6:66804631	NA	0.91	14.45	0.57	9.31e-39	Exhaled nitric oxide levels;
LUAD	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.59	-0.49	3.54e-27	Primary sclerosing cholangitis;
LUAD	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.48	-0.3	2.55e-10	Parkinson's disease;
LUAD	cis	rs12900413	0.687	rs28475471	chr15:90311749	C/T	cg24249390	chr15:90295951	MESP1	-0.33	-6.62	-0.31	1.08e-10	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg05991184	chr2:219186017	PNKD	0.37	7.1	0.33	5.47e-12	Colorectal cancer;
LUAD	trans	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg01620082	chr3:125678407	NA	-0.81	-8.36	-0.38	9.46e-16	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs2380220	0.574	rs7766765	chr6:95997362	G/A	cg21865736	chr4:2628771	FAM193A	-0.42	-6.54	-0.3	1.77e-10	Behavioural disinhibition (generation interaction);
LUAD	cis	rs2249625	0.523	rs2496554	chr6:72855840	A/T	cg18830697	chr6:72922368	RIMS1	-0.39	-7.5	-0.34	3.9e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs701145	0.640	rs896016	chr3:153929902	C/T	cg17054900	chr3:154042577	DHX36	0.66	7.56	0.35	2.49e-13	Coronary artery disease;
LUAD	cis	rs7584330	0.518	rs74003106	chr2:238447004	A/G	cg14458575	chr2:238380390	NA	0.76	11.07	0.47	3.54e-25	Prostate cancer;
LUAD	cis	rs7731657	0.537	rs4705995	chr5:130350688	G/A	cg08523029	chr5:130500466	HINT1	-0.6	-7.75	-0.35	6.72e-14	Fasting plasma glucose;
LUAD	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg05896524	chr21:47604654	C21orf56	0.57	9.49	0.42	1.68e-19	Testicular germ cell tumor;
LUAD	cis	rs11112613	0.713	rs17041546	chr12:105950801	G/T	cg03607813	chr12:105948248	NA	-0.7	-12.4	-0.52	2.41e-30	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg00071950	chr4:10020882	SLC2A9	0.79	15.97	0.61	2.94e-45	Bone mineral density;
LUAD	cis	rs3760982	0.585	rs61013802	chr19:44292142	A/T	cg12072164	chr19:44306565	LYPD5	0.42	8.46	0.38	4.4e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg21033440	chr11:65409861	SIPA1	-0.5	-7.93	-0.36	2.01e-14	Blood pressure (age interaction);
LUAD	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg21798802	chr22:38057573	PDXP	0.49	9.92	0.43	5.44e-21	Fat distribution (HIV);
LUAD	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg02269571	chr22:50332266	NA	-0.69	-9.93	-0.43	4.88e-21	Schizophrenia;
LUAD	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg01802117	chr1:53393560	SCP2	-0.36	-7.07	-0.33	6.33e-12	Monocyte count;
LUAD	cis	rs11622475	1.000	rs11625697	chr14:104464800	C/T	cg12183467	chr14:104352244	NA	-0.41	-7.38	-0.34	8.43e-13	Bipolar disorder;
LUAD	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg22431228	chr1:16359049	CLCNKA	-0.65	-13.32	-0.54	4.86e-34	Systolic blood pressure;
LUAD	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg01689657	chr7:91764605	CYP51A1	0.36	8.61	0.39	1.43e-16	Breast cancer;
LUAD	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg10518543	chr12:38710700	ALG10B	-0.42	-6.97	-0.32	1.24e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4711336	1.000	rs4711337	chr6:33659987	T/C	cg13859433	chr6:33739653	LEMD2	-0.3	-7.02	-0.32	8.72e-12	Height;
LUAD	cis	rs669446	0.561	rs643445	chr1:44089632	C/T	cg12908607	chr1:44402522	ARTN	0.37	6.88	0.32	2.1e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg20607798	chr8:58055168	NA	0.63	8.21	0.37	2.78e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg00071950	chr4:10020882	SLC2A9	-0.6	-11.13	-0.48	2.15e-25	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.39	0.42	3.82e-19	Tonsillectomy;
LUAD	cis	rs10864907	0.614	rs10199311	chr2:113697961	C/T	cg12858261	chr2:113808755	IL1F8	0.39	7.1	0.33	5.19e-12	Pulmonary function;
LUAD	cis	rs8068544	0.606	rs77681389	chr17:40154419	T/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.2	-12.25	-0.51	9.73e-30	Reticulocyte fraction of red cells;Reticulocyte count;
LUAD	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg00757033	chr12:89920650	WDR51B	0.71	12.27	0.51	8.07e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2357013	0.725	rs13426096	chr2:53206582	A/G	cg07782112	chr2:53107842	NA	0.34	6.76	0.31	4.6e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs758324	0.773	rs13183449	chr5:131116082	C/A	cg06307176	chr5:131281290	NA	0.45	7.42	0.34	6.38e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14240646	chr10:27532245	ACBD5	-0.68	-10.88	-0.47	1.82e-24	Breast cancer;
LUAD	cis	rs4074961	0.692	rs11264075	chr1:38083941	C/G	cg12696750	chr1:38022466	DNALI1	0.41	7.11	0.33	5.07e-12	Axial length;
LUAD	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg26818010	chr10:134567672	INPP5A	0.56	9.92	0.43	5.6e-21	Migraine;
LUAD	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg10560079	chr2:191398806	TMEM194B	-0.48	-6.47	-0.3	2.72e-10	Diastolic blood pressure;
LUAD	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg05623727	chr3:50126028	RBM5	0.3	6.66	0.31	8.59e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg12292205	chr6:26970375	C6orf41	-0.39	-6.69	-0.31	7.3e-11	Schizophrenia;
LUAD	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg22117172	chr7:91764530	CYP51A1	-0.31	-6.79	-0.31	3.84e-11	Breast cancer;
LUAD	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg25324976	chr17:61989376	CSHL1	0.34	6.6	0.31	1.23e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg00071950	chr4:10020882	SLC2A9	0.72	14.83	0.58	2.4e-40	Bone mineral density;
LUAD	cis	rs3204270	0.684	rs57405099	chr17:79637065	T/C	cg18367735	chr17:79674897	NA	0.59	7.25	0.33	2.04e-12	Dental caries;
LUAD	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.03	-0.36	9.69e-15	Diabetic kidney disease;
LUAD	cis	rs751728	1.000	rs6904991	chr6:33732262	T/G	cg13859433	chr6:33739653	LEMD2	-0.41	-9.56	-0.42	9.64e-20	Crohn's disease;
LUAD	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23158103	chr7:148848205	ZNF398	-0.64	-12.19	-0.51	1.73e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7487075	0.619	rs12314541	chr12:46794766	T/C	cg23829395	chr12:46796953	NA	0.32	7.15	0.33	3.84e-12	Itch intensity from mosquito bite;
LUAD	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7617773	0.851	rs6775179	chr3:48313418	T/C	cg11946769	chr3:48343235	NME6	0.43	6.76	0.31	4.52e-11	Coronary artery disease;
LUAD	cis	rs6942407	0.592	rs2057984	chr7:86826540	C/T	cg02420886	chr7:86849541	C7orf23	0.63	7.3	0.33	1.46e-12	Food allergy;
LUAD	cis	rs7937890	0.559	rs6486197	chr11:14529874	C/G	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.25e-11	Mitochondrial DNA levels;
LUAD	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg16325326	chr1:53192061	ZYG11B	0.66	12.61	0.52	3.67e-31	Monocyte count;
LUAD	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg27144592	chr16:783916	NARFL	0.36	6.5	0.3	2.32e-10	Height;
LUAD	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.47	7.71	0.35	8.94e-14	Lymphocyte counts;
LUAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg10802521	chr3:52805072	NEK4	-0.46	-7.72	-0.35	8.42e-14	Electroencephalogram traits;
LUAD	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.54	7.57	0.35	2.4e-13	Schizophrenia;
LUAD	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.04	0.32	8.03e-12	Menopause (age at onset);
LUAD	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg01849466	chr14:104193079	ZFYVE21	0.5	8.15	0.37	4.29e-15	Body mass index;
LUAD	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.14	-0.33	3.98e-12	Breast cancer;
LUAD	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg03233332	chr7:66118400	NA	0.44	6.6	0.31	1.22e-10	Aortic root size;
LUAD	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg21475434	chr5:93447410	FAM172A	-0.64	-7.0	-0.32	9.83e-12	Diabetic retinopathy;
LUAD	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg16680214	chr1:154839983	KCNN3	-0.53	-10.44	-0.45	7.22e-23	Prostate cancer;
LUAD	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.77	-0.31	4.28e-11	Personality dimensions;
LUAD	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg04450456	chr4:17643702	FAM184B	0.39	7.82	0.36	4.2e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg21775007	chr8:11205619	TDH	0.39	6.49	0.3	2.47e-10	Mood instability;
LUAD	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	8.67	0.39	9.01e-17	Schizophrenia;
LUAD	cis	rs11756438	0.546	rs9489497	chr6:118999636	T/C	cg18833306	chr6:118973337	C6orf204	0.54	9.67	0.43	4.03e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25789511	chr20:60757919	GTPBP5	-0.58	-7.1	-0.33	5.47e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg19761014	chr17:28927070	LRRC37B2	0.83	8.21	0.37	2.8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs875971	0.571	rs160641	chr7:65577346	G/A	cg04775059	chr7:64541387	NA	-0.51	-6.77	-0.31	4.23e-11	Aortic root size;
LUAD	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg24733560	chr20:60626293	TAF4	0.38	7.5	0.34	3.9e-13	Body mass index;
LUAD	cis	rs1065852	0.510	rs5751247	chr22:42633054	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.42	7.34	0.34	1.11e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg09650180	chr20:62225654	GMEB2	-0.47	-6.7	-0.31	6.84e-11	Glioblastoma;
LUAD	cis	rs6840360	1.000	rs4696291	chr4:152631637	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.36	-0.3	5.28e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1032833	0.732	rs2008215	chr2:180040127	C/G	cg23883738	chr2:179974586	SESTD1	-0.71	-7.98	-0.36	1.39e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg03433033	chr1:76189801	ACADM	0.85	15.12	0.59	1.3e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs146817970	1	rs146817970	chr5:81512947	TA/T	cg15871215	chr5:81402204	ATG10	-0.71	-10.18	-0.44	6.5600000000000005e-22	Breast cancer;
LUAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-9.82	-0.43	1.21e-20	Alzheimer's disease;
LUAD	trans	rs7246760	1.000	rs17849496	chr19:9922223	G/A	cg02900749	chr2:68251473	NA	-0.63	-6.83	-0.32	3.05e-11	Pursuit maintenance gain;
LUAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg12373951	chr3:133503437	NA	-0.38	-7.68	-0.35	1.08e-13	Iron status biomarkers;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg21548813	chr6:291882	DUSP22	-0.77	-13.17	-0.54	1.92e-33	Menopause (age at onset);
LUAD	cis	rs9394152	0.845	rs7743060	chr6:33470519	C/T	cg13560919	chr6:33536144	NA	0.53	9.15	0.41	2.51e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg08219700	chr8:58056026	NA	0.43	6.46	0.3	2.88e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg11050988	chr7:1952600	MAD1L1	0.31	6.5	0.3	2.25e-10	Schizophrenia;
LUAD	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg00106254	chr7:1943704	MAD1L1	-0.63	-9.71	-0.43	2.86e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg21399703	chr1:247681439	NA	0.43	7.77	0.35	5.82e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7799006	0.527	rs3779009	chr7:2203692	G/C	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.65	-0.46	1.24e-23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.71	-0.31	6.35e-11	Longevity;
LUAD	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg08601574	chr20:25228251	PYGB	0.46	8.64	0.39	1.17e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg06532163	chr17:45867833	NA	0.48	8.37	0.38	8.63e-16	IgG glycosylation;
LUAD	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg23625390	chr15:77176239	SCAPER	-0.53	-8.09	-0.37	6.58e-15	Blood metabolite levels;
LUAD	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg18446336	chr7:2847575	GNA12	-0.39	-7.34	-0.34	1.09e-12	Height;
LUAD	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05731713	chr7:157510257	PTPRN2	0.44	10.23	0.45	4.38e-22	Bipolar disorder and schizophrenia;
LUAD	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg23533926	chr12:111358616	MYL2	-0.4	-6.8	-0.31	3.49e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs3007168	0.951	rs8022611	chr14:51658932	G/C	cg23942311	chr14:51606299	NA	0.56	7.54	0.34	2.8e-13	Cancer;
LUAD	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.77	-0.31	4.44e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs959260	1.000	rs2053158	chr17:73393459	A/T	cg07104495	chr17:73266070	MIF4GD	0.33	7.28	0.33	1.6e-12	Systemic lupus erythematosus;
LUAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg18402987	chr7:1209562	NA	0.79	9.7	0.43	3.27e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg18305652	chr10:134549665	INPP5A	0.63	12.05	0.51	5.78e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg09796270	chr17:17721594	SREBF1	-0.4	-8.06	-0.36	7.77e-15	Total body bone mineral density;
LUAD	cis	rs953387	0.869	rs1519525	chr2:136965117	C/T	cg05194412	chr2:137003533	NA	-0.42	-6.64	-0.31	9.7e-11	Arthritis (juvenile idiopathic);
LUAD	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg03929089	chr4:120376271	NA	-0.98	-20.45	-0.71	4.02e-65	Height;
LUAD	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg11814155	chr7:99998594	ZCWPW1	0.45	7.7	0.35	9.5e-14	Platelet count;
LUAD	cis	rs754466	0.580	rs11002289	chr10:79532580	G/A	cg17075019	chr10:79541650	NA	-0.91	-19.03	-0.68	8.52e-59	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg25036284	chr2:26402008	FAM59B	-0.83	-11.79	-0.5	6.2e-28	Gut microbiome composition (summer);
LUAD	cis	rs6752107	0.936	rs1045100	chr2:234203597	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	9.46	0.42	2.24e-19	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg15921436	chr17:44337874	NA	0.88	11.65	0.49	2.06e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9039	1.000	rs12924275	chr16:9191790	C/T	cg08831531	chr16:9218945	NA	-0.42	-7.17	-0.33	3.44e-12	Menopause (age at onset);
LUAD	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg03714773	chr7:91764589	CYP51A1	0.32	7.49	0.34	4.12e-13	Breast cancer;
LUAD	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.16	0.33	3.67e-12	Menopause (age at onset);
LUAD	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg08859206	chr1:53392774	SCP2	-0.66	-11.64	-0.49	2.4200000000000002e-27	Monocyte count;
LUAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.77	-15.45	-0.6	4.94e-43	Longevity;Endometriosis;
LUAD	cis	rs864537	1.000	rs840015	chr1:167409114	G/A	cg22356347	chr1:167427500	CD247	-0.34	-6.43	-0.3	3.5e-10	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs2658782	0.666	rs2925361	chr11:93098823	G/A	cg15737290	chr11:93063684	CCDC67	0.48	6.91	0.32	1.83e-11	Pulmonary function decline;
LUAD	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg24558204	chr6:135376177	HBS1L	-0.39	-6.73	-0.31	5.42e-11	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7584330	0.628	rs7591065	chr2:238390739	G/T	cg14458575	chr2:238380390	NA	0.58	9.01	0.4	7.13e-18	Prostate cancer;
LUAD	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg18305652	chr10:134549665	INPP5A	0.61	12.71	0.53	1.37e-31	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg07636037	chr3:49044803	WDR6	0.61	12.03	0.5	7.36e-29	Parkinson's disease;
LUAD	cis	rs7779181	1.000	rs7779180	chr7:32347202	A/G	cg27532318	chr7:32358331	NA	0.44	6.88	0.32	2.19e-11	Body mass index;
LUAD	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg20503657	chr10:835505	NA	-0.45	-6.87	-0.32	2.27e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7737355	0.853	rs593767	chr5:131043660	T/G	cg25547332	chr5:131281432	NA	0.46	6.89	0.32	1.99e-11	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg07917127	chr4:99064746	C4orf37	0.42	7.02	0.32	9.15e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg04117972	chr1:227635322	NA	0.66	6.69	0.31	7e-11	Major depressive disorder;
LUAD	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg17105886	chr17:28927953	LRRC37B2	0.75	7.51	0.34	3.54e-13	Body mass index;
LUAD	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg15997130	chr1:24165203	NA	0.55	9.5	0.42	1.54e-19	Immature fraction of reticulocytes;
LUAD	cis	rs7512552	0.839	rs12046446	chr1:150460855	T/G	cg15654264	chr1:150340011	RPRD2	0.59	11.32	0.48	3.97e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg09324608	chr17:30823087	MYO1D	0.46	8.42	0.38	5.82e-16	Schizophrenia;
LUAD	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg05665937	chr4:1216051	CTBP1	0.41	6.73	0.31	5.63e-11	Obesity-related traits;
LUAD	cis	rs752010	0.841	rs58737163	chr1:42079821	G/T	cg06885757	chr1:42089581	HIVEP3	0.38	8.13	0.37	4.82e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.86	-12.11	-0.51	3.38e-29	Red cell distribution width;
LUAD	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg09796270	chr17:17721594	SREBF1	-0.41	-8.1	-0.37	5.75e-15	Total body bone mineral density;
LUAD	cis	rs4889855	0.556	rs9911795	chr17:78626115	T/C	cg16591659	chr17:78472290	NA	-0.44	-7.62	-0.35	1.65e-13	Fractional excretion of uric acid;
LUAD	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg12062639	chr20:23401060	NAPB	1.09	11.27	0.48	6.24e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg26384229	chr12:38710491	ALG10B	-0.43	-7.36	-0.34	9.67e-13	Morning vs. evening chronotype;
LUAD	cis	rs7937890	0.532	rs2575827	chr11:14475515	A/G	cg22961513	chr11:14280813	SPON1	-0.36	-6.9	-0.32	1.87e-11	Mitochondrial DNA levels;
LUAD	cis	rs7851660	0.967	rs3021526	chr9:100617021	C/T	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	cis	rs6076065	0.748	rs2180139	chr20:23405281	G/A	cg11657817	chr20:23433608	CST11	0.58	12.1	0.51	3.82e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg10518543	chr12:38710700	ALG10B	0.41	6.35	0.3	5.51e-10	Bladder cancer;
LUAD	cis	rs7737355	0.947	rs2215190	chr5:130921666	C/T	cg06307176	chr5:131281290	NA	0.49	7.6	0.35	1.91e-13	Life satisfaction;
LUAD	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg02158880	chr13:53174818	NA	-0.42	-7.12	-0.33	4.73e-12	Lewy body disease;
LUAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.51	-9.6	-0.42	7.22e-20	Longevity;Endometriosis;
LUAD	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg27113419	chr16:58533979	NDRG4	-0.68	-6.37	-0.3	4.87e-10	Schizophrenia;
LUAD	cis	rs13064411	0.735	rs722392	chr3:113228294	A/G	cg18753928	chr3:113234510	CCDC52	-0.73	-12.36	-0.52	3.57e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs12618769	0.597	rs1847550	chr2:99052299	C/T	cg10123293	chr2:99228465	UNC50	0.46	8.43	0.38	5.42e-16	Bipolar disorder;
LUAD	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg22166914	chr1:53195759	ZYG11B	-0.43	-7.5	-0.34	3.88e-13	Monocyte count;
LUAD	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg06636001	chr8:8085503	FLJ10661	0.41	6.46	0.3	2.84e-10	Joint mobility (Beighton score);
LUAD	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg09594475	chr20:60884601	LAMA5	0.45	6.37	0.3	4.83e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7814319	0.674	rs7836698	chr8:97242849	C/T	cg20787634	chr8:97240163	UQCRB	-0.37	-6.89	-0.32	1.99e-11	Lung function (FVC);
LUAD	cis	rs11696501	0.688	rs6073855	chr20:44309670	C/T	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.2	-0.37	2.92e-15	Brain structure;
LUAD	cis	rs2016266	0.859	rs10783575	chr12:53742885	C/T	cg26875137	chr12:53738046	NA	-0.35	-7.47	-0.34	4.66e-13	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg08873628	chr1:175162347	KIAA0040	0.4	6.7	0.31	6.73e-11	Alcohol dependence;
LUAD	trans	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg19862616	chr7:65841803	NCRNA00174	1.05	26.66	0.79	1.38e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg21285383	chr16:89894308	SPIRE2	0.41	9.97	0.44	3.53e-21	Vitiligo;
LUAD	cis	rs7799006	0.606	rs878534	chr7:2314652	G/A	cg08027265	chr7:2291960	NA	-0.74	-15.03	-0.59	3.13e-41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.92	-0.36	2.08e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg17264618	chr3:40429014	ENTPD3	0.39	8.26	0.37	1.89e-15	Renal cell carcinoma;
LUAD	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg18131467	chr2:239335373	ASB1	-0.7	-12.22	-0.51	1.3e-29	Multiple system atrophy;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21767207	chr19:36236454	PSENEN;U2AF1L4	-0.54	-6.52	-0.3	1.97e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9324022	0.580	rs10151519	chr14:101175798	G/A	cg18089426	chr14:101175970	NA	0.55	8.08	0.37	6.69e-15	Plateletcrit;
LUAD	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg21194808	chr1:2205498	SKI	0.42	6.68	0.31	7.41e-11	Height;
LUAD	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg02176678	chr2:219576539	TTLL4	0.61	11.75	0.5	8.57e-28	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg18944383	chr4:111397179	ENPEP	0.41	8.26	0.37	1.87e-15	Height;
LUAD	cis	rs2387326	0.717	rs11016101	chr10:129945003	C/T	cg16087940	chr10:129947807	NA	-0.62	-8.87	-0.4	2.11e-17	Select biomarker traits;
LUAD	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg13180566	chr4:1052158	NA	-0.41	-6.59	-0.31	1.29e-10	Recombination rate (females);
LUAD	cis	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg07460842	chr6:66804631	NA	0.92	14.39	0.57	1.7e-38	Exhaled nitric oxide levels;
LUAD	cis	rs74181299	0.819	rs2252867	chr2:65296280	T/C	cg05010058	chr2:65284262	CEP68	0.29	6.41	0.3	3.8e-10	Pulse pressure;
LUAD	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg09117114	chr16:67998030	SLC12A4	-0.53	-7.0	-0.32	1.01e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg24037166	chr10:75255724	PPP3CB	-0.67	-6.5	-0.3	2.28e-10	Type 2 diabetes;
LUAD	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg06671706	chr8:8559999	CLDN23	0.66	11.46	0.49	1.17e-26	Obesity-related traits;
LUAD	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg16262614	chr3:133464971	TF	0.43	8.76	0.39	4.82e-17	Iron status biomarkers (transferrin levels);
LUAD	cis	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg07460842	chr6:66804631	NA	0.83	9.8	0.43	1.43e-20	Exhaled nitric oxide output;
LUAD	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg22117172	chr7:91764530	CYP51A1	0.35	7.88	0.36	2.87e-14	Breast cancer;
LUAD	cis	rs11048434	0.736	rs1805724	chr12:9104609	T/C	cg26114124	chr12:9217669	LOC144571	0.37	6.88	0.32	2.18e-11	Sjögren's syndrome;
LUAD	cis	rs11126435	0.858	rs35588759	chr2:74928545	C/T	cg19285774	chr2:74907978	SEMA4F	0.36	6.41	0.3	3.99e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.43	-0.42	2.64e-19	Life satisfaction;
LUAD	cis	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg06532163	chr17:45867833	NA	0.44	7.0	0.32	9.9e-12	IgG glycosylation;
LUAD	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-13.59	-0.55	3.56e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1031925	0.935	rs3821829	chr3:51736644	T/C	cg12934382	chr3:51741135	GRM2	0.41	6.41	0.3	3.91e-10	Melanoma;
LUAD	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.88	0.36	2.75e-14	Depression;
LUAD	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg26446133	chr18:72167187	CNDP2	-0.79	-11.99	-0.5	1.01e-28	Refractive error;
LUAD	cis	rs12760731	0.565	rs7550699	chr1:178209584	T/G	cg00404053	chr1:178313656	RASAL2	0.73	9.13	0.41	2.81e-18	Obesity-related traits;
LUAD	cis	rs877282	0.947	rs957642	chr10:773966	C/T	cg17470449	chr10:769945	NA	0.69	11.19	0.48	1.2e-25	Uric acid levels;
LUAD	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg21214613	chr1:16344536	HSPB7	0.43	7.66	0.35	1.3e-13	Dilated cardiomyopathy;
LUAD	cis	rs2835872	0.758	rs1787398	chr21:39037504	A/C	cg06728970	chr21:39037746	KCNJ6	0.4	7.69	0.35	1.05e-13	Electroencephalographic traits in alcoholism;
LUAD	cis	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.72	-0.35	8.21e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg27631724	chr1:11040367	C1orf127	0.53	8.98	0.4	8.82e-18	Ewing sarcoma;
LUAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.61	-11.36	-0.48	2.82e-26	Prudent dietary pattern;
LUAD	cis	rs7593730	1.000	rs7593730	chr2:161171454	C/T	cg22609984	chr2:161126801	NA	-0.44	-7.19	-0.33	2.9e-12	Type 2 diabetes;
LUAD	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	trans	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg25894440	chr7:65020034	NA	-0.63	-6.71	-0.31	6.35e-11	Gout;
LUAD	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9309473	0.607	rs12478346	chr2:73584360	C/T	cg20560298	chr2:73613845	ALMS1	-0.42	-6.49	-0.3	2.43e-10	Metabolite levels;
LUAD	cis	rs1868673	1.000	rs1868673	chr3:150187314	A/C	cg04908077	chr3:150187338	NA	-0.33	-6.72	-0.31	5.89e-11	Waist circumference;
LUAD	trans	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg26043149	chr18:55253948	FECH	0.49	8.08	0.37	6.7e-15	Bone mineral density;
LUAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg04025307	chr7:1156635	C7orf50	0.66	7.55	0.34	2.66e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4930561	1.000	rs10896298	chr11:67931459	C/T	cg04465784	chr11:67976953	SUV420H1	-0.32	-9.88	-0.43	7.74e-21	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg02951883	chr7:2050386	MAD1L1	-0.8	-14.07	-0.56	3.71e-37	Schizophrenia;
LUAD	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg04450456	chr4:17643702	FAM184B	0.37	7.17	0.33	3.35e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg08071915	chr8:12219732	FAM66A	-0.4	-6.61	-0.31	1.16e-10	Mood instability;
LUAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg21724239	chr8:58056113	NA	0.66	8.66	0.39	9.86e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7737355	0.812	rs3776013	chr5:130867404	C/T	cg06307176	chr5:131281290	NA	0.44	7.19	0.33	3.02e-12	Life satisfaction;
LUAD	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg18132916	chr6:79620363	NA	-0.46	-8.06	-0.36	8.12e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs6967745	chr7:106850548	G/T	cg02696742	chr7:106810147	HBP1	-0.78	-10.74	-0.46	5.65e-24	Coronary artery disease;
LUAD	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg10167378	chr1:228756711	NA	0.64	8.68	0.39	8.65e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg04025307	chr7:1156635	C7orf50	0.55	6.71	0.31	6.09e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg16325326	chr1:53192061	ZYG11B	0.53	8.95	0.4	1.13e-17	Monocyte count;
LUAD	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg09365446	chr1:150670422	GOLPH3L	0.67	12.64	0.52	2.82e-31	Tonsillectomy;
LUAD	cis	rs10992471	0.631	rs2296667	chr9:95274338	A/G	cg14631576	chr9:95140430	CENPP	-0.41	-8.23	-0.37	2.42e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg26924012	chr15:45694286	SPATA5L1	0.87	14.17	0.57	1.48e-37	Homoarginine levels;
LUAD	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26314531	chr2:26401878	FAM59B	-0.67	-8.64	-0.39	1.17e-16	Gut microbiome composition (summer);
LUAD	cis	rs8017423	0.967	rs2277517	chr14:90722778	G/A	cg14092571	chr14:90743983	NA	-0.5	-8.87	-0.4	2.08e-17	Mortality in heart failure;
LUAD	cis	rs11971779	0.680	rs11760420	chr7:139114768	C/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.87	0.32	2.25e-11	Diisocyanate-induced asthma;
LUAD	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06112835	chr11:68658793	MRPL21	0.51	9.08	0.4	4.23e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6460942	0.915	rs7803056	chr7:12306913	A/C	cg06484146	chr7:12443880	VWDE	-0.46	-6.72	-0.31	6.04e-11	Coronary artery disease;
LUAD	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg13870426	chr17:30244630	NA	-0.57	-6.5	-0.3	2.27e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs7395662	0.804	rs8186428	chr11:48734677	C/T	cg00717180	chr2:96193071	NA	-0.44	-8.42	-0.38	5.97e-16	HDL cholesterol;
LUAD	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg05283184	chr6:79620031	NA	-0.6	-12.2	-0.51	1.5e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg15117754	chr3:10150083	C3orf24	0.45	7.46	0.34	4.87e-13	Alzheimer's disease;
LUAD	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg07167872	chr1:205819463	PM20D1	0.54	8.27	0.37	1.78e-15	Menarche (age at onset);
LUAD	cis	rs12801636	0.512	rs7119750	chr11:65422591	C/T	cg24147428	chr11:65409760	SIPA1	-0.53	-7.69	-0.35	1.05e-13	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg14008862	chr17:28927542	LRRC37B2	-0.65	-7.15	-0.33	3.78e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg25237894	chr2:233734115	C2orf82	-0.6	-11.99	-0.5	1.05e-28	Coronary artery disease;
LUAD	cis	rs11249608	0.636	rs13359549	chr5:178449178	T/A	cg01312482	chr5:178451176	ZNF879	-0.45	-6.98	-0.32	1.14e-11	Pubertal anthropometrics;
LUAD	cis	rs4523957	0.893	rs9909895	chr17:2161633	G/A	cg16513277	chr17:2031491	SMG6	-0.76	-14.68	-0.58	1.05e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg19442545	chr10:75533431	FUT11	-0.47	-7.7	-0.35	1e-13	Inflammatory bowel disease;
LUAD	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-6.99	-0.32	1.05e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg11707310	chr1:2537719	MMEL1	0.37	7.84	0.36	3.8e-14	Ulcerative colitis;
LUAD	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg17509989	chr5:176798049	RGS14	-0.6	-9.14	-0.41	2.56e-18	Urate levels in lean individuals;
LUAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg04025307	chr7:1156635	C7orf50	0.7	12.31	0.51	5.51e-30	Longevity;Endometriosis;
LUAD	cis	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg05084668	chr3:125655381	ALG1L	0.46	7.24	0.33	2.09e-12	Blood pressure (smoking interaction);
LUAD	cis	rs7274811	0.779	rs13039908	chr20:32052070	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.51	-7.72	-0.35	8.43e-14	Height;
LUAD	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg17173187	chr15:85201210	NMB	0.53	9.27	0.41	9.64e-19	Schizophrenia;
LUAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.87	16.76	0.63	1.03e-48	Lymphocyte counts;
LUAD	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg25894440	chr7:65020034	NA	-0.61	-6.54	-0.3	1.81e-10	Diabetic kidney disease;
LUAD	cis	rs7107174	0.892	rs1567891	chr11:78101985	A/G	cg02023728	chr11:77925099	USP35	0.47	7.25	0.33	1.95e-12	Testicular germ cell tumor;
LUAD	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.55	9.22	0.41	1.38e-18	Breast cancer;
LUAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.56	7.01	0.32	9.69e-12	Alzheimer's disease;
LUAD	trans	rs10838798	0.563	rs4752894	chr11:48120936	G/A	cg21153622	chr11:89784906	NA	-0.35	-6.92	-0.32	1.67e-11	Height;
LUAD	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg18230493	chr5:56204884	C5orf35	-0.85	-12.45	-0.52	1.53e-30	Initial pursuit acceleration;
LUAD	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26314531	chr2:26401878	FAM59B	-0.55	-7.78	-0.35	5.46e-14	Gut microbiome composition (summer);
LUAD	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg05425664	chr17:57184151	TRIM37	-0.37	-6.55	-0.3	1.71e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs10189230	1.000	rs10189230	chr2:222357961	T/A	cg14652038	chr2:222343519	EPHA4	0.43	8.66	0.39	9.72e-17	Urate levels in lean individuals;
LUAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg21280719	chr6:42927975	GNMT	-0.38	-11.77	-0.5	7.68e-28	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7917772	0.582	rs7922780	chr10:104401203	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.69	-0.31	7.18e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs877282	0.891	rs11595385	chr10:800539	A/G	cg17470449	chr10:769945	NA	0.64	9.4	0.42	3.34e-19	Uric acid levels;
LUAD	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg00316803	chr15:76480434	C15orf27	-0.41	-7.59	-0.35	2.02e-13	Blood metabolite levels;
LUAD	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg12011299	chr4:100065546	ADH4	0.71	13.84	0.56	3.4e-36	Alcohol dependence;
LUAD	trans	rs148734725	1	rs148734725	chr3:49406708	G/A	cg21659725	chr3:3221576	CRBN	-0.6	-9.61	-0.42	6.76e-20	Educational attainment (college completion);
LUAD	cis	rs490234	0.934	rs7865246	chr9:128269511	T/C	cg14078157	chr9:128172775	NA	-0.37	-6.88	-0.32	2.17e-11	Mean arterial pressure;
LUAD	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-6.96	-0.32	1.3e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13223928	0.541	rs17132968	chr7:3136074	T/G	cg19214707	chr7:3157722	NA	-0.46	-7.77	-0.35	5.91e-14	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs7945718	0.935	rs4757059	chr11:12812356	G/A	cg25843174	chr11:12811716	TEAD1	-0.24	-7.23	-0.33	2.24e-12	Educational attainment (years of education);
LUAD	cis	rs7680126	0.633	rs4697745	chr4:10305081	G/A	cg00071950	chr4:10020882	SLC2A9	-0.59	-8.26	-0.37	1.93e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs6684428	1.000	rs61774843	chr1:56367384	C/T	cg11651538	chr1:56320950	NA	-0.4	-6.39	-0.3	4.39e-10	Airflow obstruction;
LUAD	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg22482690	chr17:47019901	SNF8	0.45	8.45	0.38	4.67e-16	Type 2 diabetes;
LUAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-11.02	-0.47	5.5e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg26022315	chr17:47021804	SNF8	0.4	7.27	0.33	1.77e-12	Type 2 diabetes;
LUAD	cis	rs8017423	0.630	rs4900038	chr14:90821677	A/G	cg14092571	chr14:90743983	NA	0.39	6.54	0.3	1.77e-10	Mortality in heart failure;
LUAD	cis	rs4888262	0.526	rs4888253	chr16:74583146	C/T	cg01733217	chr16:74700730	RFWD3	0.48	8.17	0.37	3.67e-15	Testicular germ cell tumor;
LUAD	cis	rs698833	0.886	rs698775	chr2:44588941	G/A	cg04920474	chr2:44395004	PPM1B	0.38	6.78	0.31	4.13e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs6782228	0.606	rs1127030	chr3:128338953	T/C	cg16766828	chr3:128327626	NA	-0.38	-7.14	-0.33	4.05e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg22676075	chr6:135203613	NA	-0.54	-10.24	-0.45	4.08e-22	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.06	0.32	7.06e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00149659	chr3:10157352	C3orf10	0.86	11.57	0.49	4.56e-27	Alzheimer's disease;
LUAD	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg27124370	chr19:33622961	WDR88	0.42	6.83	0.32	2.92e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg15485101	chr11:133734466	NA	0.39	8.19	0.37	3.22e-15	Childhood ear infection;
LUAD	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg00204512	chr16:28754710	NA	0.33	7.12	0.33	4.52e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-6.54	-0.3	1.78e-10	Tonsillectomy;
LUAD	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	8.83	0.39	2.85e-17	Rheumatoid arthritis;
LUAD	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg24069376	chr3:38537580	EXOG	0.31	7.31	0.33	1.37e-12	Electrocardiographic conduction measures;
LUAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg04025307	chr7:1156635	C7orf50	0.54	6.49	0.3	2.39e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28374715	1.000	rs28374715	chr15:41563950	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.91	-17.25	-0.64	6.94e-51	Ulcerative colitis;
LUAD	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg21963583	chr11:68658836	MRPL21	0.65	11.62	0.49	2.87e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4481887	0.679	rs4466692	chr1:248423174	C/G	cg00666640	chr1:248458726	OR2T12	0.29	6.94	0.32	1.45e-11	Common traits (Other);
LUAD	cis	rs853679	0.607	rs56075693	chr6:28290328	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.54	6.37	0.3	4.99e-10	Depression;
LUAD	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg09654669	chr8:57350985	NA	-0.65	-9.41	-0.42	3.21e-19	Obesity-related traits;
LUAD	cis	rs9427116	0.502	rs903323	chr1:154572228	A/G	cg17218026	chr1:154582156	ADAR	-0.5	-9.73	-0.43	2.58e-20	Blood protein levels;
LUAD	cis	rs77741769	0.571	rs11065284	chr12:121266621	G/A	cg02419362	chr12:121203948	SPPL3	0.4	8.26	0.37	1.86e-15	Mean corpuscular volume;
LUAD	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg27572855	chr1:25598939	RHD	0.54	11.69	0.49	1.52e-27	Erythrocyte sedimentation rate;
LUAD	cis	rs427394	0.659	rs419128	chr5:6739791	G/A	cg10857441	chr5:6722123	POLS	-0.6	-10.58	-0.46	2.23e-23	Menopause (age at onset);
LUAD	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg21191810	chr6:118973309	C6orf204	-0.51	-8.09	-0.37	6.35e-15	Diastolic blood pressure;
LUAD	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg02018176	chr4:1364513	KIAA1530	0.37	6.45	0.3	3.02e-10	Obesity-related traits;
LUAD	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg15557168	chr22:42548783	NA	-0.57	-11.16	-0.48	1.59e-25	Schizophrenia;
LUAD	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.6	11.34	0.48	3.24e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg23719950	chr11:63933701	MACROD1	-0.58	-6.96	-0.32	1.3e-11	Mean platelet volume;
LUAD	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg23029597	chr12:123009494	RSRC2	-0.57	-8.81	-0.39	3.27e-17	Body mass index;
LUAD	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg18811423	chr2:55921094	PNPT1	0.48	7.99	0.36	1.29e-14	Metabolic syndrome;
LUAD	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg18016565	chr1:150552671	MCL1	0.42	7.73	0.35	7.9e-14	Tonsillectomy;
LUAD	cis	rs7264396	0.623	rs761827	chr20:34207897	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-7.3	-0.33	1.43e-12	Total cholesterol levels;
LUAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08677398	chr8:58056175	NA	0.48	6.38	0.3	4.69e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12942165	chr11:9286299	DENND5A	-0.38	-6.4	-0.3	4.24e-10	Cancer;
LUAD	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg07570687	chr10:102243282	WNT8B	0.41	6.86	0.32	2.53e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs870825	0.616	rs28490461	chr4:185651638	C/T	cg04058563	chr4:185651563	MLF1IP	0.9	14.58	0.58	2.63e-39	Blood protein levels;
LUAD	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg20556744	chr2:9614537	IAH1	0.66	6.56	0.3	1.55e-10	Opioid sensitivity;
LUAD	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg02574844	chr11:5959923	NA	-0.46	-8.29	-0.37	1.53e-15	DNA methylation (variation);
LUAD	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3784262	0.654	rs4646568	chr15:58344290	A/G	cg12031962	chr15:58353849	ALDH1A2	0.47	9.28	0.41	8.82e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7300001	0.667	rs7302441	chr12:110506468	T/C	cg12870014	chr12:110450643	ANKRD13A	0.89	8.49	0.38	3.61e-16	Headache;
LUAD	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.3	-0.37	1.38e-15	Prostate cancer;
LUAD	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg00310523	chr12:86230176	RASSF9	0.39	7.82	0.36	4.23e-14	Major depressive disorder;
LUAD	cis	rs4812048	0.649	rs3761255	chr20:57618802	T/C	cg14073986	chr20:57617431	SLMO2	0.82	9.81	0.43	1.32e-20	Mean platelet volume;
LUAD	trans	rs1493916	0.777	rs1941685	chr18:31304318	G/T	cg27147174	chr7:100797783	AP1S1	-0.61	-10.56	-0.46	2.72e-23	Life satisfaction;
LUAD	cis	rs6484504	0.625	rs7112412	chr11:31370271	T/C	cg14844989	chr11:31128820	NA	0.44	8.04	0.36	9.12e-15	Red blood cell count;
LUAD	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg04944784	chr2:26401820	FAM59B	-0.9	-13.56	-0.55	5.14e-35	Gut microbiome composition (summer);
LUAD	cis	rs1018836	0.632	rs7017295	chr8:91482356	C/T	cg16814680	chr8:91681699	NA	0.66	11.07	0.47	3.51e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg08999081	chr20:33150536	PIGU	0.64	14.13	0.57	2.12e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg03714773	chr7:91764589	CYP51A1	0.28	6.66	0.31	8.34e-11	Breast cancer;
LUAD	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg18180107	chr4:99064573	C4orf37	0.43	6.71	0.31	6.32e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg08213375	chr14:104286397	PPP1R13B	0.28	7.33	0.34	1.2e-12	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	6.45	0.3	2.98e-10	Aortic root size;
LUAD	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg22117172	chr7:91764530	CYP51A1	0.33	7.23	0.33	2.34e-12	Breast cancer;
LUAD	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-7.16	-0.33	3.69e-12	IgG glycosylation;
LUAD	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg19980929	chr12:42632907	YAF2	0.33	6.45	0.3	3.08e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg24634471	chr8:143751801	JRK	0.47	7.62	0.35	1.71e-13	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg25894440	chr7:65020034	NA	-0.68	-7.18	-0.33	3.16e-12	Diabetic kidney disease;
LUAD	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg26513180	chr16:89883248	FANCA	0.65	6.62	0.31	1.09e-10	Skin colour saturation;
LUAD	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg16479474	chr6:28041457	NA	0.36	6.45	0.3	3.12e-10	Parkinson's disease;
LUAD	cis	rs17818399	0.890	rs34752561	chr2:46850150	G/A	cg09399716	chr2:46890238	NA	-0.44	-8.19	-0.37	3.19e-15	Height;
LUAD	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg12483005	chr1:23474871	LUZP1	0.52	9.1	0.4	3.63e-18	Height;
LUAD	cis	rs7493	0.901	rs13226149	chr7:95025600	G/A	cg04155289	chr7:94953770	PON1	-0.55	-7.56	-0.35	2.47e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2070433	0.539	rs2839314	chr21:47961067	A/G	cg12379764	chr21:47803548	PCNT	0.46	6.83	0.32	3.02e-11	Lymphocyte counts;
LUAD	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg02993280	chr1:107599747	PRMT6	0.56	9.07	0.4	4.59e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05473447	chr8:96281195	C8orf37	-0.38	-6.5	-0.3	2.28e-10	Cancer;
LUAD	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg01874867	chr7:94954059	PON1	-0.51	-6.97	-0.32	1.25e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13126279	chr21:47581558	C21orf56	-0.61	-10.99	-0.47	6.88e-25	Testicular germ cell tumor;
LUAD	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg03433033	chr1:76189801	ACADM	-0.48	-7.05	-0.32	7.31e-12	Daytime sleep phenotypes;
LUAD	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.75	16.06	0.62	1.15e-45	White blood cell count;
LUAD	cis	rs897984	0.520	rs4889534	chr16:30865440	T/C	cg02466173	chr16:30829666	NA	0.7	11.22	0.48	9.16e-26	Dementia with Lewy bodies;
LUAD	cis	rs8017423	0.967	rs7147952	chr14:90720831	G/A	cg14092571	chr14:90743983	NA	-0.5	-8.92	-0.4	1.45e-17	Mortality in heart failure;
LUAD	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg18932078	chr1:2524107	MMEL1	-0.37	-6.93	-0.32	1.55e-11	Multiple sclerosis;
LUAD	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg17509989	chr5:176798049	RGS14	0.83	15.69	0.61	4.75e-44	Urinary electrolytes (magnesium/calcium ratio);
LUAD	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg15790184	chr11:494944	RNH1	0.56	6.76	0.31	4.68e-11	Body mass index;
LUAD	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg05368731	chr17:41323189	NBR1	0.97	20.41	0.7	6.15e-65	Menopause (age at onset);
LUAD	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg06784218	chr1:46089804	CCDC17	-0.53	-11.59	-0.49	3.71e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.82	-0.31	3.18e-11	Systolic blood pressure;
LUAD	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.32	-0.34	1.27e-12	Total body bone mineral density;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg02796970	chr10:39023768	NA	-0.49	-7.76	-0.35	6.55e-14	Menopause (age at onset);
LUAD	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg25566285	chr7:158114605	PTPRN2	0.48	9.93	0.43	5.09e-21	Calcium levels;
LUAD	trans	rs2544390	1.000	rs2673172	chr2:170204800	A/C	cg17328068	chr11:96122542	CCDC82;JRKL	-0.4	-7.21	-0.33	2.65e-12	Urate levels;
LUAD	trans	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	8.73	0.39	6.06e-17	Mean corpuscular volume;
LUAD	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg06618935	chr21:46677482	NA	-0.51	-10.21	-0.44	4.95e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	10.26	0.45	3.43e-22	Lung cancer in ever smokers;
LUAD	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg07776626	chr8:57350775	NA	-0.6	-9.01	-0.4	7.35e-18	Obesity-related traits;
LUAD	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg15128208	chr22:42549153	NA	-0.35	-6.95	-0.32	1.38e-11	Cognitive function;
LUAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.51	-9.04	-0.4	5.51e-18	Lymphocyte counts;
LUAD	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg15962314	chr1:44399869	ARTN	0.3	6.87	0.32	2.36e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs72928364	1.000	rs13060137	chr3:100647927	A/G	cg10123952	chr3:100791384	NA	0.64	7.29	0.33	1.51e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg04287289	chr16:89883240	FANCA	0.75	6.36	0.3	5.13e-10	Skin colour saturation;
LUAD	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg25894440	chr7:65020034	NA	-0.62	-6.66	-0.31	8.79e-11	Diabetic kidney disease;
LUAD	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg12623918	chr2:306882	NA	-0.35	-7.56	-0.35	2.52e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg24069376	chr3:38537580	EXOG	-0.43	-10.28	-0.45	2.73e-22	Electrocardiographic conduction measures;
LUAD	cis	rs1011018	0.628	rs56079671	chr7:139466379	G/A	cg26515926	chr7:139453581	HIPK2	-0.52	-6.65	-0.31	9.19e-11	Systolic blood pressure;
LUAD	cis	rs4711350	0.954	rs11751943	chr6:33729718	G/C	cg18005901	chr6:33739558	LEMD2	-0.53	-7.51	-0.34	3.45e-13	Schizophrenia;
LUAD	trans	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg14917512	chr19:3094685	GNA11	0.58	6.84	0.32	2.72e-11	Diabetic kidney disease;
LUAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg10295955	chr4:187884368	NA	-1.1	-25.77	-0.78	9.53e-89	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12135894	0.648	rs4648423	chr1:3765678	C/T	cg17443473	chr1:3703550	LRRC47	-0.36	-6.53	-0.3	1.86e-10	Mean corpuscular volume;
LUAD	cis	rs17155006	0.664	rs387981	chr7:107741337	T/A	cg05962710	chr7:107745446	LAMB4	-0.35	-7.32	-0.34	1.29e-12	Pneumococcal bacteremia;
LUAD	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg06618935	chr21:46677482	NA	-0.44	-8.85	-0.4	2.35e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg08085267	chr17:45401833	C17orf57	-0.59	-10.31	-0.45	2.23e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.8	-13.21	-0.54	1.38e-33	Primary sclerosing cholangitis;
LUAD	cis	rs9411298	0.630	rs9411299	chr9:139938793	C/G	cg14024893	chr9:139943146	ENTPD2	-0.73	-13.93	-0.56	1.48e-36	Monocyte percentage of white cells;
LUAD	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg25566285	chr7:158114605	PTPRN2	0.49	9.97	0.44	3.7e-21	Calcium levels;
LUAD	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg02269571	chr22:50332266	NA	-0.67	-9.44	-0.42	2.53e-19	Schizophrenia;
LUAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08677398	chr8:58056175	NA	0.45	6.45	0.3	3.07e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg06627628	chr2:24431161	ITSN2	-0.46	-6.36	-0.3	5.38e-10	Lymphocyte counts;
LUAD	cis	rs7584330	0.554	rs74001384	chr2:238424530	T/C	cg14458575	chr2:238380390	NA	0.6	9.75	0.43	2.21e-20	Prostate cancer;
LUAD	cis	rs2046867	0.862	rs11920131	chr3:72858630	C/G	cg25664220	chr3:72788482	NA	-0.6	-10.94	-0.47	1.11e-24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2040771	0.745	rs361956	chr22:19265799	C/T	cg02655711	chr22:19163373	SLC25A1	0.54	10.07	0.44	1.6e-21	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs859767	0.741	rs6729090	chr2:135401878	G/A	cg12500956	chr2:135428796	TMEM163	-0.3	-7.9	-0.36	2.4e-14	Neuroticism;
LUAD	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg14582100	chr15:45693742	SPATA5L1	0.62	12.35	0.51	3.83e-30	Homoarginine levels;
LUAD	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg23985595	chr17:80112537	CCDC57	0.52	9.51	0.42	1.48e-19	Life satisfaction;
LUAD	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	8.77	0.39	4.57e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.66	-0.39	1e-16	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg07917127	chr4:99064746	C4orf37	0.41	6.72	0.31	6.05e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12711979	0.740	rs6711963	chr2:3820915	A/T	cg17052675	chr2:3827356	NA	-0.51	-10.53	-0.46	3.55e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg22963979	chr7:1858916	MAD1L1	-0.72	-12.43	-0.52	1.83e-30	Bipolar disorder and schizophrenia;
LUAD	cis	rs12900413	0.687	rs13343254	chr15:90311283	G/A	cg24249390	chr15:90295951	MESP1	-0.34	-6.64	-0.31	9.46e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs2057149	0.776	rs1980531	chr6:110724518	C/T	cg01119278	chr6:110721349	DDO	0.41	7.33	0.34	1.21e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	10.21	0.44	5.18e-22	Lung cancer in ever smokers;
LUAD	cis	rs11166629	1.000	rs894349	chr8:135638055	T/C	cg27224718	chr8:135614730	ZFAT	0.62	11.05	0.47	3.96e-25	Smoking quantity;
LUAD	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg00631329	chr6:26305371	NA	-0.73	-13.99	-0.56	7.83e-37	Educational attainment;
LUAD	cis	rs6025261	0.761	rs3848695	chr20:55513254	C/T	cg04763273	chr20:55502381	NA	0.33	6.57	0.3	1.51e-10	Verbal memory performance (delayed recall level);
LUAD	cis	rs7010267	0.602	rs1485307	chr8:120007395	T/C	cg01975934	chr8:119970761	NA	-0.36	-6.96	-0.32	1.29e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg08219700	chr8:58056026	NA	0.51	7.4	0.34	7.3e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs12545109	0.800	rs2118260	chr8:57393481	T/C	cg07776626	chr8:57350775	NA	-0.65	-9.28	-0.41	8.61e-19	Obesity-related traits;
LUAD	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg06740227	chr12:86229804	RASSF9	0.39	7.03	0.32	8.51e-12	Major depressive disorder;
LUAD	cis	rs57920188	0.535	rs10915659	chr1:4092949	G/A	cg10510935	chr1:4059661	NA	0.45	6.87	0.32	2.31e-11	Interleukin-17 levels;
LUAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg08132940	chr7:1081526	C7orf50	-0.76	-10.27	-0.45	3.19e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.51	0.38	2.96e-16	Breast cancer;
LUAD	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.12	0.33	4.65e-12	Motion sickness;
LUAD	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.71	0.39	7.03e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4700695	1.000	rs153319	chr5:65419423	C/T	cg21114390	chr5:65439923	SFRS12	-0.6	-7.8	-0.35	4.96e-14	Facial morphology (factor 19);
LUAD	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg21823605	chr1:152486609	CRCT1	0.28	6.4	0.3	4.11e-10	Hair morphology;
LUAD	cis	rs9972944	0.729	rs1421033	chr17:63766714	A/C	cg07283582	chr17:63770753	CCDC46	-0.5	-11.18	-0.48	1.28e-25	Total body bone mineral density;
LUAD	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg05340658	chr4:99064831	C4orf37	0.44	7.28	0.33	1.68e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg08132940	chr7:1081526	C7orf50	-0.46	-7.07	-0.33	6.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg18230493	chr5:56204884	C5orf35	-0.86	-12.47	-0.52	1.31e-30	Initial pursuit acceleration;
LUAD	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg03859395	chr2:55845619	SMEK2	0.75	14.1	0.57	2.78e-37	Metabolic syndrome;
LUAD	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.21	0.37	2.8e-15	Breast cancer;
LUAD	trans	rs629535	0.814	rs506931	chr8:70068129	T/G	cg21567404	chr3:27674614	NA	1.0	18.36	0.67	8.53e-56	Dupuytren's disease;
LUAD	cis	rs1975974	0.748	rs67473406	chr17:21726745	G/A	cg18423549	chr17:21743878	NA	-0.8	-13.98	-0.56	8.69e-37	Psoriasis;
LUAD	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg07153921	chr17:41440717	NA	-0.43	-7.23	-0.33	2.28e-12	Menopause (age at onset);
LUAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg07217954	chr7:1067459	C7orf50	0.43	6.61	0.31	1.19e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg23283495	chr1:209979779	IRF6	0.41	7.32	0.34	1.24e-12	Monobrow;
LUAD	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg04034577	chr2:241836375	C2orf54	-0.51	-11.41	-0.49	1.73e-26	Urinary metabolites;
LUAD	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	6.8	0.31	3.64e-11	Platelet count;
LUAD	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg23649088	chr2:200775458	C2orf69	-0.81	-15.06	-0.59	2.36e-41	Osteoporosis;
LUAD	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg24634471	chr8:143751801	JRK	0.47	7.56	0.35	2.52e-13	Schizophrenia;
LUAD	cis	rs9951698	0.557	rs544011	chr18:13077315	A/G	cg12848697	chr18:13133368	NA	0.36	6.85	0.32	2.56e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.81	0.31	3.41e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7584330	0.740	rs2292885	chr2:238443407	G/C	cg14458575	chr2:238380390	NA	0.52	9.75	0.43	2.15e-20	Prostate cancer;
LUAD	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg17147758	chr8:6949321	NA	-0.48	-8.18	-0.37	3.36e-15	Blood pressure (smoking interaction);
LUAD	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg06784218	chr1:46089804	CCDC17	0.51	11.31	0.48	4.27e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27286337	chr10:134555280	INPP5A	0.7	9.13	0.41	2.92e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs11771526	0.901	rs28631129	chr7:32305044	G/C	cg13207630	chr7:32358064	NA	0.61	7.56	0.35	2.47e-13	Body mass index;
LUAD	cis	rs420259	0.516	rs10153059	chr16:23512383	C/T	cg00143387	chr16:23521605	GGA2	-0.69	-9.48	-0.42	1.83e-19	Bipolar disorder;
LUAD	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs28595532	0.925	rs116785973	chr4:119611350	G/A	cg02775129	chr4:119771670	NA	-0.84	-7.77	-0.35	6.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs4689388	0.609	rs4234729	chr4:6286087	T/C	cg14416269	chr4:6271139	WFS1	0.59	10.05	0.44	1.82e-21	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1018836	0.828	rs4734250	chr8:91591239	C/G	cg16814680	chr8:91681699	NA	0.59	9.92	0.43	5.43e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs77741769	0.571	rs7969140	chr12:121303626	T/C	cg02419362	chr12:121203948	SPPL3	0.41	8.28	0.37	1.67e-15	Mean corpuscular volume;
LUAD	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg10556349	chr10:835070	NA	0.47	6.46	0.3	2.96e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg21724239	chr8:58056113	NA	0.78	9.07	0.4	4.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg02196655	chr2:10830764	NOL10	-0.43	-7.75	-0.35	6.78e-14	Prostate cancer;
LUAD	cis	rs262150	0.625	rs117651953	chr7:158780563	G/A	cg09640425	chr7:158790006	NA	0.53	6.56	0.3	1.62e-10	Facial morphology (factor 20);
LUAD	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg00647820	chr17:40259828	DHX58	0.45	7.28	0.33	1.61e-12	Fibrinogen levels;
LUAD	cis	rs10746514	0.833	rs2026302	chr1:232264047	A/G	cg09506761	chr1:232265262	NA	-0.39	-7.3	-0.33	1.4e-12	Response to statin therapy;
LUAD	trans	rs62458065	0.850	rs28677012	chr7:32469811	C/A	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.41	-0.34	7.16e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg04034577	chr2:241836375	C2orf54	-0.5	-11.1	-0.47	2.67e-25	Urinary metabolites;
LUAD	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg15445000	chr17:37608096	MED1	0.44	8.07	0.37	7.56e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03352830	chr11:487213	PTDSS2	0.8	10.31	0.45	2.24e-22	Body mass index;
LUAD	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg04756594	chr16:24857601	SLC5A11	0.51	10.01	0.44	2.59e-21	Intelligence (multi-trait analysis);
LUAD	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg13081381	chr13:82264192	NA	-0.46	-6.62	-0.31	1.11e-10	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8192282	0.691	rs6696177	chr1:154477263	G/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.31	-0.33	1.33e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs11112613	0.713	rs73184083	chr12:105952593	T/A	cg03607813	chr12:105948248	NA	0.74	12.78	0.53	7.56e-32	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg16405210	chr4:1374714	KIAA1530	-0.63	-9.57	-0.42	8.73e-20	Longevity;
LUAD	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg02993280	chr1:107599747	PRMT6	-0.51	-8.34	-0.38	1.05e-15	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg15242686	chr22:24348715	GSTTP1	0.47	8.18	0.37	3.42e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.4	-7.31	-0.33	1.37e-12	Urate levels in overweight individuals;
LUAD	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg15181151	chr6:150070149	PCMT1	0.41	8.39	0.38	7.38e-16	Lung cancer;
LUAD	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg15017067	chr4:17643749	FAM184B	0.36	7.17	0.33	3.37e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg21028142	chr17:79581711	NPLOC4	0.42	8.79	0.39	3.71e-17	Eye color traits;
LUAD	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg15309053	chr8:964076	NA	0.34	7.41	0.34	7.03e-13	Schizophrenia;
LUAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.63	-11.02	-0.47	5.4e-25	Lymphocyte counts;
LUAD	cis	rs1816752	0.721	rs7399656	chr13:24989846	A/G	cg02811702	chr13:24901961	NA	0.43	7.51	0.34	3.62e-13	Obesity-related traits;
LUAD	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-10.02	-0.44	2.37e-21	Gut microbiome composition (summer);
LUAD	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg22681709	chr2:178499509	PDE11A	-0.53	-9.08	-0.4	4.11e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9296092	0.560	rs9469511	chr6:33530930	T/G	cg13560919	chr6:33536144	NA	-0.87	-15.59	-0.6	1.29e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24308560	chr3:49941425	MST1R	-0.56	-9.31	-0.41	6.76e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs1595825	0.891	rs16824264	chr2:198675917	T/C	cg00361562	chr2:198649771	BOLL	-0.48	-6.75	-0.31	4.89e-11	Ulcerative colitis;
LUAD	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg01528321	chr10:82214614	TSPAN14	0.59	9.25	0.41	1.15e-18	Post bronchodilator FEV1;
LUAD	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg13319975	chr6:146136371	FBXO30	-0.61	-10.24	-0.45	3.84e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg08027265	chr7:2291960	NA	-0.42	-7.1	-0.33	5.46e-12	Schizophrenia;
LUAD	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg13012494	chr21:47604986	C21orf56	0.47	7.75	0.35	6.93e-14	Testicular germ cell tumor;
LUAD	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg26384229	chr12:38710491	ALG10B	0.4	6.41	0.3	3.95e-10	Morning vs. evening chronotype;
LUAD	cis	rs877282	0.755	rs1769242	chr10:787896	T/C	cg17470449	chr10:769945	NA	0.48	7.13	0.33	4.5e-12	Uric acid levels;
LUAD	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg07402062	chr16:89894098	SPIRE2	0.45	11.47	0.49	1.09e-26	Vitiligo;
LUAD	trans	rs8002861	0.664	rs1466005	chr13:44424210	T/C	cg17145862	chr1:211918768	LPGAT1	0.65	13.03	0.54	7.48e-33	Leprosy;
LUAD	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg02683114	chr2:24398427	C2orf84	-0.56	-8.16	-0.37	4.01e-15	Asthma;
LUAD	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg18446336	chr7:2847575	GNA12	-0.36	-6.67	-0.31	8.16e-11	Height;
LUAD	trans	rs75804782	0.641	rs60841092	chr2:239349640	G/A	cg01134436	chr17:81009848	B3GNTL1	0.81	8.56	0.38	2.16e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs1865721	0.804	rs72977816	chr18:73146779	A/T	cg26385618	chr18:73139727	C18orf62	-0.51	-10.15	-0.44	8.32e-22	Intelligence;
LUAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg21226059	chr5:178986404	RUFY1	-0.76	-14.17	-0.57	1.49e-37	Lung cancer;
LUAD	cis	rs1595825	0.945	rs73056890	chr2:198831260	A/G	cg11031976	chr2:198649780	BOLL	-0.47	-6.94	-0.32	1.5e-11	Ulcerative colitis;
LUAD	cis	rs17095355	0.901	rs9783184	chr10:111760499	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.26	-0.37	1.95e-15	Biliary atresia;
LUAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.49	0.45	4.97e-23	Prudent dietary pattern;
LUAD	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg21385522	chr1:16154831	NA	-0.56	-9.33	-0.41	6.2e-19	Systolic blood pressure;
LUAD	cis	rs6430585	0.759	rs4954623	chr2:136535876	G/A	cg07169764	chr2:136633963	MCM6	-0.68	-7.92	-0.36	2.09e-14	Corneal structure;
LUAD	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg06618935	chr21:46677482	NA	-0.49	-9.88	-0.43	7.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.31	7.71	0.35	9e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs669446	0.591	rs586339	chr1:44137257	C/A	cg12908607	chr1:44402522	ARTN	-0.37	-6.92	-0.32	1.64e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00166722	chr3:10149974	C3orf24	0.73	12.34	0.51	4.33e-30	Alzheimer's disease;
LUAD	cis	rs12618769	0.652	rs3754878	chr2:99179384	G/A	cg10123293	chr2:99228465	UNC50	0.49	8.56	0.38	2.09e-16	Bipolar disorder;
LUAD	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.01	0.32	9.52e-12	Motion sickness;
LUAD	trans	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	15.43	0.6	6.41e-43	Exhaled nitric oxide levels;
LUAD	cis	rs8044868	0.548	rs12930702	chr16:72077000	C/G	cg23815491	chr16:72088622	HP	0.47	8.44	0.38	4.96e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs62229266	0.804	rs62230821	chr21:37425116	C/T	cg12218747	chr21:37451666	NA	-0.47	-8.15	-0.37	4.16e-15	Mitral valve prolapse;
LUAD	cis	rs72928364	1.000	rs17399603	chr3:100736139	A/G	cg10123952	chr3:100791384	NA	0.62	7.29	0.33	1.52e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg21775007	chr8:11205619	TDH	-0.37	-6.38	-0.3	4.55e-10	Systolic blood pressure;
LUAD	trans	rs1728785	0.901	rs1645974	chr16:68564774	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.78	0.43	1.69e-20	Ulcerative colitis;
LUAD	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg16099599	chr11:93583650	C11orf90	-0.32	-6.39	-0.3	4.43e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg06808227	chr14:105710500	BRF1	-0.42	-6.51	-0.3	2.09e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg24848339	chr3:12840334	CAND2	0.44	9.06	0.4	4.74e-18	QRS complex (12-leadsum);
LUAD	cis	rs4853036	0.953	rs35667002	chr2:70032867	A/G	cg02498382	chr2:70120550	SNRNP27	-0.51	-7.79	-0.35	5.09e-14	Colorectal or endometrial cancer;
LUAD	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg13755796	chr4:20253514	NA	0.43	7.19	0.33	2.92e-12	Life satisfaction;
LUAD	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg15790184	chr11:494944	RNH1	0.47	7.56	0.34	2.54e-13	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg01689657	chr7:91764605	CYP51A1	-0.29	-6.85	-0.32	2.66e-11	Breast cancer;
LUAD	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg05373962	chr22:49881684	NA	-0.57	-13.84	-0.56	3.35e-36	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9393692	0.620	rs6908402	chr6:26293014	A/T	cg00631329	chr6:26305371	NA	-0.52	-9.05	-0.4	5.37e-18	Educational attainment;
LUAD	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg16049864	chr8:95962084	TP53INP1	0.39	7.26	0.33	1.84e-12	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg20607798	chr8:58055168	NA	0.67	8.73	0.39	5.82e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg05434287	chr7:2030229	MAD1L1	0.45	7.46	0.34	5.01e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg06623918	chr6:96969491	KIAA0776	-0.66	-10.46	-0.45	6.49e-23	Migraine;Coronary artery disease;
LUAD	cis	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05901451	chr6:126070800	HEY2	0.45	6.71	0.31	6.28e-11	Endometrial cancer;
LUAD	cis	rs6867032	0.958	rs4975798	chr5:2015580	G/A	cg26168224	chr5:2018326	NA	0.79	18.15	0.66	7.17e-55	Gut microbiome composition (winter);
LUAD	cis	rs8044995	0.925	rs9928653	chr16:68252079	T/C	cg05110241	chr16:68378359	PRMT7	-0.59	-7.6	-0.35	1.91e-13	Schizophrenia;
LUAD	trans	rs3960554	0.599	rs56090527	chr7:75762125	A/C	cg19862616	chr7:65841803	NCRNA00174	0.85	11.77	0.5	7.49e-28	Eotaxin levels;
LUAD	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg00321850	chr1:175162397	KIAA0040	-0.55	-11.63	-0.49	2.62e-27	Alcohol dependence;
LUAD	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg01579765	chr21:45077557	HSF2BP	-0.58	-13.67	-0.55	1.79e-35	Mean corpuscular volume;
LUAD	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg20283391	chr11:68216788	NA	-0.41	-6.45	-0.3	2.99e-10	Total body bone mineral density;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg20776722	chr5:130970743	RAPGEF6	-0.41	-6.81	-0.31	3.33e-11	Cancer;
LUAD	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg02454025	chr1:11042201	C1orf127	0.97	17.14	0.64	2.09e-50	Ewing sarcoma;
LUAD	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.69	13.09	0.54	4.2e-33	Cognitive ability;
LUAD	cis	rs3733418	0.929	rs12512234	chr4:165908865	C/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-6.99	-0.32	1.08e-11	Obesity-related traits;
LUAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg07217954	chr7:1067459	C7orf50	0.43	6.63	0.31	1.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg09323728	chr8:95962352	TP53INP1	-0.35	-8.46	-0.38	4.46e-16	Type 2 diabetes;
LUAD	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.5	0.3	2.23e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg16797656	chr11:68205561	LRP5	-0.45	-9.47	-0.42	1.98e-19	Total body bone mineral density;
LUAD	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg03433033	chr1:76189801	ACADM	0.86	15.7	0.61	4.22e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg12436631	chr1:155007014	DCST1;DCST2	-0.31	-7.18	-0.33	3.18e-12	Prostate cancer;
LUAD	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.65e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs72949976	0.734	rs62189579	chr2:214016984	T/A	cg08319019	chr2:214017104	IKZF2	-0.53	-7.83	-0.36	3.88e-14	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs2404602	0.735	rs2461871	chr15:76822418	C/G	cg23625390	chr15:77176239	SCAPER	-0.41	-6.61	-0.31	1.17e-10	Blood metabolite levels;
LUAD	cis	rs10227331	0.521	rs17667159	chr7:157296065	A/C	cg04156418	chr7:157293606	NA	0.35	6.89	0.32	1.99e-11	Inattentive symptoms;
LUAD	cis	rs12541635	0.677	rs7003520	chr8:107061724	G/A	cg10147462	chr8:107024639	NA	0.53	9.38	0.42	3.98e-19	Age of smoking initiation;
LUAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7671266	0.528	rs11728025	chr4:10408221	C/G	cg00071950	chr4:10020882	SLC2A9	-0.49	-7.63	-0.35	1.58e-13	Cardiovascular disease risk factors;
LUAD	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg02450064	chr17:40260053	DHX58	-0.44	-7.55	-0.34	2.65e-13	Fibrinogen levels;
LUAD	cis	rs6942407	0.546	rs3789252	chr7:86793362	G/C	cg02420886	chr7:86849541	C7orf23	0.63	7.29	0.33	1.55e-12	Food allergy;
LUAD	cis	rs2487048	0.725	rs2246293	chr9:107690838	C/G	cg14470647	chr9:107690075	ABCA1	0.4	6.79	0.31	3.74e-11	Intraocular pressure;
LUAD	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.78e-19	Life satisfaction;
LUAD	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg09467607	chr2:36825704	FEZ2	0.6	11.82	0.5	4.59e-28	Height;
LUAD	trans	rs11165623	0.740	rs11165638	chr1:96921357	C/A	cg10631902	chr5:14652156	NA	-0.61	-11.81	-0.5	5.12e-28	Hip circumference;Waist circumference;
LUAD	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg09184832	chr6:79620586	NA	-0.52	-9.84	-0.43	1.03e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2235649	0.798	rs9932983	chr16:1848184	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.5	-8.49	-0.38	3.47e-16	Blood metabolite levels;
LUAD	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg18305652	chr10:134549665	INPP5A	0.59	12.44	0.52	1.71e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4604732	0.631	rs4411161	chr1:247632374	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	9.34	0.41	5.66e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9914988	0.832	rs11650788	chr17:27174523	T/A	cg02049041	chr17:27085579	C17orf63	0.63	8.39	0.38	7.19e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04785461	chr10:14996236	DCLRE1C	-0.42	-6.42	-0.3	3.72e-10	Height;
LUAD	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs947211	0.752	rs1572931	chr1:205744218	C/T	cg14893161	chr1:205819251	PM20D1	-0.52	-6.42	-0.3	3.67e-10	Parkinson's disease;
LUAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg18402987	chr7:1209562	NA	0.78	9.52	0.42	1.37e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06022373	chr22:39101656	GTPBP1	0.48	7.8	0.35	4.83e-14	Menopause (age at onset);
LUAD	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg13319975	chr6:146136371	FBXO30	0.61	10.19	0.44	5.87e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08280861	chr8:58055591	NA	0.54	6.73	0.31	5.69e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs68170813	0.559	rs74774133	chr7:106941449	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.61	-0.46	1.75e-23	Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs59698941	0.943	rs55767930	chr5:132203952	G/A	cg14825688	chr5:132208181	LEAP2	-0.47	-6.64	-0.31	9.5e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg21984481	chr17:79567631	NPLOC4	-0.57	-11.84	-0.5	4.04e-28	Eye color traits;
LUAD	cis	rs7746082	0.627	rs12201431	chr6:106496905	G/A	cg02270332	chr6:106475062	NA	-0.39	-6.49	-0.3	2.48e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24308560	chr3:49941425	MST1R	-0.57	-9.74	-0.43	2.24e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06505273	chr16:24850292	NA	0.51	7.54	0.34	2.99e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.585	rs201001	chr6:27808899	T/C	cg19041857	chr6:27730383	NA	-0.44	-7.06	-0.32	7.07e-12	Depression;
LUAD	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg06873352	chr17:61820015	STRADA	0.42	7.01	0.32	9.4e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2455826	0.917	rs2471809	chr3:15680525	G/A	cg16303742	chr3:15540471	COLQ	0.41	6.48	0.3	2.51e-10	Inflammatory skin disease;
LUAD	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg11266682	chr4:10021025	SLC2A9	0.57	12.06	0.51	5.32e-29	Bone mineral density;
LUAD	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.43	-0.52	1.89e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.19	-0.51	1.63e-29	Platelet count;
LUAD	cis	rs868036	0.957	rs9920662	chr15:68104297	G/A	cg24579218	chr15:68104479	NA	-0.4	-7.44	-0.34	5.78e-13	Restless legs syndrome;
LUAD	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg23985595	chr17:80112537	CCDC57	0.52	9.55	0.42	1.08e-19	Life satisfaction;
LUAD	cis	rs6445967	0.569	rs1135089	chr3:58304112	C/T	cg13750441	chr3:58318267	PXK	-0.31	-6.42	-0.3	3.64e-10	Platelet count;
LUAD	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg15128208	chr22:42549153	NA	0.43	6.75	0.31	4.92e-11	Birth weight;
LUAD	trans	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.78	-14.93	-0.59	8.42e-41	Brugada syndrome;
LUAD	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg06453172	chr10:134556979	INPP5A	-0.67	-10.08	-0.44	1.45e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.28	-0.57	5.01e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg12908607	chr1:44402522	ARTN	0.51	10.14	0.44	8.63e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7727544	0.582	rs3805681	chr5:131537860	T/G	cg14196790	chr5:131705035	SLC22A5	0.42	7.36	0.34	9.94e-13	Blood metabolite levels;
LUAD	cis	rs13315871	0.790	rs13066409	chr3:58428444	A/G	cg20936604	chr3:58311152	NA	-0.67	-7.07	-0.33	6.51e-12	Cholesterol, total;
LUAD	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg23758822	chr17:41437982	NA	1.01	21.22	0.72	1.4e-68	Menopause (age at onset);
LUAD	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-7.31	-0.33	1.37e-12	Alzheimer's disease (late onset);
LUAD	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg26597838	chr10:835615	NA	0.69	9.86	0.43	8.71e-21	Eosinophil percentage of granulocytes;
LUAD	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg00933542	chr6:150070202	PCMT1	0.45	9.52	0.42	1.34e-19	Lung cancer;
LUAD	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg18827107	chr12:86230957	RASSF9	-0.54	-9.54	-0.42	1.12e-19	Major depressive disorder;
LUAD	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.84e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg18129748	chr3:49941408	MST1R	0.42	6.93	0.32	1.57e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg08027265	chr7:2291960	NA	-0.51	-9.04	-0.4	5.65e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg27432699	chr2:27873401	GPN1	-0.41	-6.96	-0.32	1.34e-11	Total body bone mineral density;
LUAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg00078996	chr12:132293329	NA	-0.42	-7.64	-0.35	1.47e-13	Migraine;
LUAD	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg03806693	chr22:41940476	POLR3H	-0.72	-9.67	-0.43	3.96e-20	Vitiligo;
LUAD	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg11247378	chr22:39784982	NA	-0.66	-10.88	-0.47	1.72e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg00339695	chr16:24857497	SLC5A11	0.69	11.42	0.49	1.68e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12049351	0.774	rs6671385	chr1:229642652	C/T	cg11742688	chr1:229674241	ABCB10	-0.41	-6.38	-0.3	4.56e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg06753367	chr22:24256600	NA	-0.38	-6.85	-0.32	2.63e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs6921919	0.848	rs6903652	chr6:28322120	C/G	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.52	-0.3	1.96e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg02993280	chr1:107599747	PRMT6	0.54	8.71	0.39	6.82e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.72	-0.35	8.21e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs17826219	0.562	rs719600	chr17:28731262	G/A	cg17105886	chr17:28927953	LRRC37B2	-0.69	-6.83	-0.32	2.94e-11	Body mass index;
LUAD	trans	rs4650994	0.544	rs2476561	chr1:178619900	C/T	cg05059571	chr16:84539110	KIAA1609	-0.65	-11.61	-0.49	3.08e-27	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg23262073	chr20:60523788	NA	-0.48	-7.77	-0.35	5.86e-14	Body mass index;
LUAD	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg04944784	chr2:26401820	FAM59B	-0.89	-12.57	-0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.53	-9.78	-0.43	1.65e-20	Schizophrenia;
LUAD	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg06784218	chr1:46089804	CCDC17	-0.54	-11.63	-0.49	2.61e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs13064411	0.542	rs2399477	chr3:113222998	A/G	cg10517650	chr3:113235015	CCDC52	-0.45	-8.19	-0.37	3.14e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg26343298	chr8:95960752	TP53INP1	0.37	7.85	0.36	3.5e-14	Type 2 diabetes;
LUAD	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg09455208	chr3:40491958	NA	0.5	10.49	0.45	4.68e-23	Renal cell carcinoma;
LUAD	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg25894440	chr7:65020034	NA	-0.7	-7.45	-0.34	5.26e-13	Diabetic kidney disease;
LUAD	cis	rs2880765	0.546	rs8042776	chr15:86055629	T/C	cg13263323	chr15:86062960	AKAP13	-0.48	-8.11	-0.37	5.4e-15	Coronary artery disease;
LUAD	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.94	13.46	0.55	1.26e-34	Smoking behavior;
LUAD	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-11.05	-0.47	4.13e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg22920501	chr2:26401640	FAM59B	-0.76	-10.97	-0.47	8.37e-25	Gut microbiome composition (summer);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01436486	chr19:58963005	ZNF324B	-0.42	-6.48	-0.3	2.57e-10	Height;
LUAD	cis	rs2651899	0.934	rs10909887	chr1:3087373	A/T	cg22396632	chr1:3079212	PRDM16	0.38	8.64	0.39	1.2e-16	Migraine;
LUAD	cis	rs11724804	0.532	rs62295557	chr4:855708	G/A	cg08222618	chr4:941054	TMEM175	0.57	8.59	0.39	1.68e-16	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg06453172	chr10:134556979	INPP5A	-0.79	-11.26	-0.48	6.57e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg27494647	chr7:150038898	RARRES2	0.55	9.38	0.41	4.17e-19	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs1997103	0.863	rs2140916	chr7:55403154	A/C	cg20935933	chr6:143382018	AIG1	0.53	7.48	0.34	4.32e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6754311	0.509	rs13412397	chr2:136470714	G/A	cg07305463	chr2:136567211	LCT	0.34	6.45	0.3	3.11e-10	Mosquito bite size;
LUAD	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg14092988	chr3:52407081	DNAH1	-0.33	-6.65	-0.31	8.95e-11	Bipolar disorder;
LUAD	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg21385522	chr1:16154831	NA	-0.64	-11.48	-0.49	1e-26	Dilated cardiomyopathy;
LUAD	cis	rs7589728	0.748	rs35051888	chr2:88482258	G/A	cg07952391	chr2:88470173	THNSL2	0.67	6.89	0.32	2.09e-11	Plasma clusterin levels;
LUAD	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg15704280	chr7:45808275	SEPT13	-0.88	-16.21	-0.62	2.69e-46	Height;
LUAD	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg23583168	chr7:148888333	NA	-0.91	-18.57	-0.67	9.68e-57	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg08888203	chr3:10149979	C3orf24	0.69	12.36	0.51	3.73e-30	Alzheimer's disease;
LUAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg17372223	chr3:52568218	NT5DC2	0.51	10.36	0.45	1.5e-22	Hemoglobin concentration;
LUAD	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg17330251	chr7:94953956	PON1	-0.58	-8.35	-0.38	1.02e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7737355	0.945	rs245801	chr5:130666955	T/C	cg06307176	chr5:131281290	NA	-0.46	-7.35	-0.34	1.01e-12	Life satisfaction;
LUAD	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.35	-0.38	1.01e-15	Breast cancer;
LUAD	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.52	-8.6	-0.39	1.51e-16	Reticulocyte count;
LUAD	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg11098525	chr4:1320231	MAEA	-0.37	-6.55	-0.3	1.72e-10	Obesity-related traits;
LUAD	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg02527881	chr3:46936655	PTH1R	-0.45	-8.67	-0.39	9.46e-17	Colorectal cancer;
LUAD	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg14844989	chr11:31128820	NA	-0.46	-8.27	-0.37	1.76e-15	Red blood cell count;
LUAD	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg00898013	chr13:113819073	PROZ	0.73	13.15	0.54	2.33e-33	Platelet distribution width;
LUAD	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg05082376	chr22:42548792	NA	-0.51	-9.39	-0.42	3.77e-19	Schizophrenia;
LUAD	cis	rs10089	0.953	rs4836358	chr5:127376869	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	10.05	0.44	1.91e-21	Ileal carcinoids;
LUAD	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.3	6.6	0.31	1.27e-10	Systemic lupus erythematosus;
LUAD	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg14752069	chr8:11977206	FAM66D	-0.29	-6.37	-0.3	4.98e-10	Triglycerides;
LUAD	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg21984481	chr17:79567631	NPLOC4	-0.55	-11.74	-0.5	9.76e-28	Eye color traits;
LUAD	cis	rs2658782	0.789	rs56091149	chr11:93073640	A/C	cg15737290	chr11:93063684	CCDC67	-0.57	-8.16	-0.37	3.91e-15	Pulmonary function decline;
LUAD	cis	rs262150	0.625	rs117651953	chr7:158780563	G/A	cg19418458	chr7:158789849	NA	0.67	8.44	0.38	5.12e-16	Facial morphology (factor 20);
LUAD	cis	rs741677	0.963	rs9907102	chr17:464832	C/T	cg13332499	chr17:408570	NA	0.32	6.35	0.3	5.51e-10	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.72	13.43	0.55	1.71e-34	Lymphocyte counts;
LUAD	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.59	8.09	0.37	6.39e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs13082711	0.911	rs13100751	chr3:27454964	A/G	cg02860705	chr3:27208620	NA	0.64	9.46	0.42	2.12e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg16701003	chr16:89028210	CBFA2T3	0.49	9.86	0.43	8.51e-21	Social autistic-like traits;
LUAD	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg03929089	chr4:120376271	NA	0.54	7.02	0.32	8.88e-12	Axial length;
LUAD	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg06784218	chr1:46089804	CCDC17	-0.54	-11.63	-0.49	2.61e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg20891283	chr12:69753455	YEATS4	0.44	7.13	0.33	4.3e-12	Blood protein levels;
LUAD	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg09796270	chr17:17721594	SREBF1	0.36	6.87	0.32	2.27e-11	Total body bone mineral density;
LUAD	cis	rs457287	0.772	rs79075814	chr9:4808971	C/T	cg14182974	chr9:4791918	RCL1	-0.49	-6.37	-0.3	4.92e-10	Platelet count;
LUAD	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.38	6.64	0.31	9.73e-11	Body mass index (adult);
LUAD	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.52	6.99	0.32	1.06e-11	Platelet count;
LUAD	cis	rs4285028	0.948	rs1920291	chr3:121672440	C/T	cg11130432	chr3:121712080	ILDR1	-0.59	-8.35	-0.38	9.95e-16	Multiple sclerosis;
LUAD	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg06547715	chr2:218990976	CXCR2	-0.27	-6.69	-0.31	7.17e-11	Colorectal cancer;
LUAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg21280719	chr6:42927975	GNMT	-0.39	-11.79	-0.5	6.12e-28	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg08213375	chr14:104286397	PPP1R13B	0.25	6.66	0.31	8.66e-11	Schizophrenia;
LUAD	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg14686297	chr22:46650375	NA	-0.38	-6.57	-0.3	1.44e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg05234568	chr11:5960015	NA	-0.5	-8.78	-0.39	4.16e-17	DNA methylation (variation);
LUAD	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg04705435	chr11:17411270	KCNJ11	0.41	6.92	0.32	1.73e-11	Type 2 diabetes;
LUAD	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg24558204	chr6:135376177	HBS1L	0.48	8.89	0.4	1.77e-17	Red blood cell count;
LUAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.52	-0.3	1.99e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg15839431	chr19:19639596	YJEFN3	-0.53	-8.65	-0.39	1.11e-16	Bipolar disorder;
LUAD	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.8	-0.35	4.93e-14	Neutrophil percentage of white cells;
LUAD	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg24818145	chr4:99064322	C4orf37	0.47	7.94	0.36	1.87e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg14668632	chr7:2872130	GNA12	-0.68	-12.18	-0.51	1.76e-29	Height;
LUAD	cis	rs2971970	0.519	rs2346270	chr7:133647033	G/A	cg03336402	chr7:133662267	EXOC4	-0.41	-7.6	-0.35	1.9e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4150161	0.656	rs1056612	chr16:84211788	G/C	cg10106505	chr16:84220380	TAF1C	-0.67	-6.64	-0.31	9.48e-11	Systolic blood pressure response to hydrochlorothiazide in hypertension;
LUAD	cis	rs2455601	1.000	rs12418190	chr11:8899818	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.47	-6.79	-0.31	3.77e-11	Schizophrenia;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12828867	chr5:61708427	IPO11	0.45	6.98	0.32	1.16e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	trans	rs6076960	0.652	rs3905171	chr20:6211177	T/C	cg21095983	chr6:86352623	SYNCRIP	0.4	6.58	0.3	1.42e-10	Smooth-surface caries;
LUAD	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg05373962	chr22:49881684	NA	-0.51	-10.61	-0.46	1.71e-23	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9902453	0.845	rs10853135	chr17:28188675	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	9.28	0.41	9.08e-19	Coffee consumption (cups per day);
LUAD	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg15910486	chr5:142783621	NR3C1	-0.34	-6.48	-0.3	2.58e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
LUAD	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.66	0.31	8.7e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.21e-32	Immature fraction of reticulocytes;
LUAD	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-7.26	-0.33	1.87e-12	Monocyte percentage of white cells;
LUAD	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06028605	chr16:24865363	SLC5A11	0.58	8.97	0.4	9.58e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7707921	0.881	rs73134709	chr5:81268499	G/A	cg15871215	chr5:81402204	ATG10	-0.7	-9.99	-0.44	2.99e-21	Breast cancer;
LUAD	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.5	-0.34	3.78e-13	Coronary artery disease;
LUAD	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg08742575	chr21:47604166	C21orf56	0.43	7.26	0.33	1.93e-12	Testicular germ cell tumor;
LUAD	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg18252515	chr7:66147081	NA	-0.63	-6.94	-0.32	1.5e-11	Gout;
LUAD	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.3	6.38	0.3	4.59e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-8.27	-0.37	1.8e-15	Alzheimer's disease;
LUAD	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg00495681	chr13:53174319	NA	-0.73	-14.51	-0.58	5.09e-39	Lewy body disease;
LUAD	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	6.43	0.3	3.41e-10	Aortic root size;
LUAD	cis	rs7617773	0.743	rs7621785	chr3:48343708	T/C	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg12927641	chr6:109611667	NA	-0.49	-8.64	-0.39	1.13e-16	Reticulocyte fraction of red cells;
LUAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg18305652	chr10:134549665	INPP5A	0.62	11.92	0.5	1.93e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg21724239	chr8:58056113	NA	0.65	8.35	0.38	9.78e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg10591111	chr5:226296	SDHA	-0.54	-6.93	-0.32	1.53e-11	Breast cancer;
LUAD	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.56	6.77	0.31	4.26e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg24397884	chr7:158709396	WDR60	-0.71	-9.87	-0.43	8.12e-21	Height;
LUAD	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg00376283	chr12:123451042	ABCB9	0.41	6.68	0.31	7.77e-11	Platelet count;
LUAD	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-23.72	-0.76	1.02e-79	Height;
LUAD	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.59	-10.11	-0.44	1.1e-21	Electrocardiographic conduction measures;
LUAD	cis	rs1997103	1.000	rs6977292	chr7:55396335	T/C	cg17469321	chr7:55412551	NA	0.67	11.41	0.49	1.73e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.59	0.35	2.07e-13	Depression;
LUAD	cis	rs7727544	0.584	rs7714191	chr5:131341541	C/G	cg22598563	chr5:131563921	P4HA2	-0.28	-6.76	-0.31	4.48e-11	Blood metabolite levels;
LUAD	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg13606994	chr1:44402422	ARTN	-0.33	-6.76	-0.31	4.6e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs76145119	chr7:107052368	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-10.37	-0.45	1.35e-22	Coronary artery disease;
LUAD	cis	rs11671005	0.735	rs11084543	chr19:58932701	T/C	cg13877915	chr19:58951672	ZNF132	0.56	7.35	0.34	1.04e-12	Mean platelet volume;
LUAD	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg03030879	chr14:75389066	RPS6KL1	0.36	6.62	0.31	1.09e-10	Caffeine consumption;
LUAD	cis	rs35883536	0.626	rs10783140	chr1:101042083	A/G	cg06223162	chr1:101003688	GPR88	-0.47	-9.0	-0.4	7.76e-18	Monocyte count;
LUAD	trans	rs9747201	0.609	rs9303022	chr17:80170651	C/G	cg07393940	chr7:158741817	NA	0.66	10.93	0.47	1.16e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs11153730	0.503	rs188181	chr6:118620094	C/T	cg05564266	chr6:118973597	C6orf204	0.3	6.38	0.3	4.78e-10	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg21823605	chr1:152486609	CRCT1	0.29	6.42	0.3	3.64e-10	Hair morphology;
LUAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg26338869	chr17:61819248	STRADA	-0.39	-6.57	-0.3	1.53e-10	Prudent dietary pattern;
LUAD	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg23985595	chr17:80112537	CCDC57	-0.51	-9.35	-0.41	5.17e-19	Life satisfaction;
LUAD	cis	rs9633740	0.685	rs10749608	chr10:82243986	A/G	cg01528321	chr10:82214614	TSPAN14	0.74	6.41	0.3	3.92e-10	Post bronchodilator FEV1;
LUAD	cis	rs13315871	0.929	rs71311853	chr3:58319152	C/T	cg20936604	chr3:58311152	NA	-0.74	-7.39	-0.34	8.14e-13	Cholesterol, total;
LUAD	cis	rs11214589	0.747	rs1893695	chr11:113206085	A/C	cg14159747	chr11:113255604	NA	0.62	12.69	0.53	1.75e-31	Neuroticism;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg16203607	chr17:62500946	DDX5	-0.37	-6.37	-0.3	4.84e-10	Subcortical brain region volumes;
LUAD	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg00933542	chr6:150070202	PCMT1	0.45	9.72	0.43	2.65e-20	Lung cancer;
LUAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg25703541	chr22:24373054	LOC391322	0.8	12.39	0.52	2.66e-30	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs11809207	1.000	rs34587428	chr1:26522392	C/T	cg00147160	chr1:26503991	CNKSR1	0.44	8.81	0.39	3.33e-17	Height;
LUAD	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg02527881	chr3:46936655	PTH1R	-0.51	-10.39	-0.45	1.11e-22	Colorectal cancer;
LUAD	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg24154853	chr7:158122151	PTPRN2	-0.58	-11.79	-0.5	6.09e-28	Calcium levels;
LUAD	cis	rs9346649	0.583	rs4708642	chr6:168491500	G/A	cg02770688	chr6:168491649	NA	0.53	10.13	0.44	9.52e-22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg08027265	chr7:2291960	NA	-0.43	-7.18	-0.33	3.25e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg11814155	chr7:99998594	ZCWPW1	0.43	7.24	0.33	2.13e-12	Platelet count;
LUAD	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg06636551	chr8:101224915	SPAG1	-0.36	-6.64	-0.31	9.46e-11	Atrioventricular conduction;
LUAD	cis	rs6499255	0.951	rs689455	chr16:69761661	T/G	cg15192750	chr16:69999425	NA	0.54	8.18	0.37	3.43e-15	IgE levels;
LUAD	cis	rs62458065	1.000	rs10246687	chr7:32465183	T/A	cg20159608	chr7:32802032	NA	-0.47	-6.74	-0.31	5.13e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg26384229	chr12:38710491	ALG10B	0.46	7.58	0.35	2.24e-13	Bladder cancer;
LUAD	cis	rs7072216	0.763	rs10748729	chr10:100171371	G/C	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.68	-0.39	8.56e-17	Metabolite levels;
LUAD	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.02	-0.36	1.02e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg01620082	chr3:125678407	NA	-1.1	-10.56	-0.46	2.69e-23	Depression;
LUAD	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg06064525	chr11:970664	AP2A2	-0.54	-10.98	-0.47	7.29e-25	Alzheimer's disease (late onset);
LUAD	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.47	8.22	0.37	2.59e-15	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs8002861	0.619	rs9567289	chr13:44437104	C/T	cg17145862	chr1:211918768	LPGAT1	0.65	13.02	0.53	8e-33	Leprosy;
LUAD	cis	rs12122100	0.913	rs61838896	chr1:146513139	A/G	cg03526459	chr1:146549940	NA	-0.39	-7.11	-0.33	5.07e-12	HIV-1 control;
LUAD	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.78	-0.35	5.45e-14	Blood trace element (Zn levels);
LUAD	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg23625390	chr15:77176239	SCAPER	0.39	6.86	0.32	2.42e-11	Blood metabolite levels;
LUAD	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24308560	chr3:49941425	MST1R	0.6	10.32	0.45	1.96e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.69	10.63	0.46	1.48e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.88	-0.4	1.93e-17	Total body bone mineral density;
LUAD	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.86	-0.36	3.12e-14	Diabetic kidney disease;
LUAD	cis	rs2880765	0.743	rs8039631	chr15:86007931	A/G	cg13263323	chr15:86062960	AKAP13	-0.48	-8.66	-0.39	9.83e-17	Coronary artery disease;
LUAD	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg10523679	chr1:76189770	ACADM	0.9	16.24	0.62	1.99e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg00701064	chr4:6280414	WFS1	0.74	17.26	0.64	6.28e-51	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs9473147	0.543	rs9349417	chr6:47580657	A/G	cg02130027	chr6:47444894	CD2AP	0.36	6.78	0.31	4.02e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.75	-0.35	6.92e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg16606324	chr3:10149918	C3orf24	0.68	11.39	0.48	2.07e-26	Alzheimer's disease;
LUAD	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg15147215	chr3:52552868	STAB1	-0.42	-7.59	-0.35	2.12e-13	Bipolar disorder;
LUAD	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25427524	chr10:38739819	LOC399744	-0.76	-13.63	-0.55	2.62e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg23803603	chr1:2058230	PRKCZ	0.41	6.6	0.31	1.22e-10	Height;
LUAD	cis	rs10992471	0.639	rs10821008	chr9:95487497	C/T	cg14631576	chr9:95140430	CENPP	-0.45	-9.24	-0.41	1.18e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg03929089	chr4:120376271	NA	-0.89	-17.04	-0.64	5.78e-50	Height;
LUAD	cis	rs9863	0.861	rs4930725	chr12:124428162	T/A	cg17723958	chr12:124429295	CCDC92	-0.42	-7.01	-0.32	9.72e-12	White blood cell count;
LUAD	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.57	-7.75	-0.35	6.78e-14	Body mass index;
LUAD	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.44	-0.52	1.73e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs61869271	0.871	rs6585308	chr10:116727532	G/A	cg23260525	chr10:116636907	FAM160B1	0.32	6.47	0.3	2.72e-10	Tonsillectomy;
LUAD	cis	rs28595532	1.000	rs11931194	chr4:119631160	C/T	cg02775129	chr4:119771670	NA	-0.82	-7.69	-0.35	1.04e-13	Cannabis dependence symptom count;
LUAD	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	8.8	0.39	3.59e-17	Schizophrenia;
LUAD	cis	rs780096	1.000	rs780095	chr2:27741105	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.27	-7.1	-0.33	5.36e-12	Total body bone mineral density;
LUAD	cis	rs4891159	0.790	rs660029	chr18:74149668	A/G	cg24786174	chr18:74118243	ZNF516	0.85	19.29	0.68	6.19e-60	Longevity;
LUAD	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg22532475	chr10:104410764	TRIM8	-0.43	-8.07	-0.37	7.16e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4919694	1.000	rs77505796	chr10:104647774	A/T	cg04362960	chr10:104952993	NT5C2	0.85	8.87	0.4	2.01e-17	Arsenic metabolism;
LUAD	cis	rs2404602	0.552	rs11630185	chr15:76959783	A/T	cg23625390	chr15:77176239	SCAPER	-0.46	-6.4	-0.3	4.14e-10	Blood metabolite levels;
LUAD	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg08601574	chr20:25228251	PYGB	-0.47	-8.83	-0.39	2.87e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06028605	chr16:24865363	SLC5A11	-0.56	-8.58	-0.38	1.85e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3772130	0.962	rs7629369	chr3:121566282	T/C	cg20356878	chr3:121714668	ILDR1	0.52	8.36	0.38	8.93e-16	Cognitive performance;
LUAD	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.48	-0.38	3.82e-16	Height;
LUAD	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg04036182	chr15:45458818	NA	-0.41	-7.19	-0.33	3e-12	Glomerular filtration rate;
LUAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg10862848	chr6:42927986	GNMT	-0.32	-9.16	-0.41	2.28e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg14092988	chr3:52407081	DNAH1	0.4	8.04	0.36	9.25e-15	Electroencephalogram traits;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09008917	chr22:36462410	NA	-0.4	-6.76	-0.31	4.62e-11	Cancer;
LUAD	trans	rs783540	0.656	rs783524	chr15:83284144	A/C	cg16105309	chr15:79090380	ADAMTS7	0.42	7.64	0.35	1.44e-13	Schizophrenia;
LUAD	cis	rs6741892	1.000	rs13012704	chr2:38918793	T/C	cg23643435	chr2:38893251	GALM	-0.58	-6.39	-0.3	4.34e-10	5-HTT brain serotonin transporter levels;
LUAD	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg04673462	chr1:38461896	NA	-0.42	-8.54	-0.38	2.51e-16	Coronary artery disease;
LUAD	cis	rs7017914	0.902	rs7831792	chr8:71565356	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.52	-0.3	1.99e-10	Bone mineral density;
LUAD	cis	rs4900538	0.855	rs12590993	chr14:102844064	A/G	cg18135206	chr14:102964638	TECPR2	-1.01	-21.03	-0.71	1.05e-67	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg01689657	chr7:91764605	CYP51A1	0.29	6.93	0.32	1.6e-11	Breast cancer;
LUAD	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg06873352	chr17:61820015	STRADA	0.42	6.99	0.32	1.11e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg06108461	chr20:60628389	TAF4	-0.96	-17.42	-0.65	1.21e-51	Body mass index;
LUAD	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg13685833	chr1:53393034	SCP2	-0.48	-7.94	-0.36	1.81e-14	Monocyte count;
LUAD	cis	rs713477	1.000	rs12886860	chr14:55911150	G/C	cg13175173	chr14:55914753	NA	-0.33	-6.95	-0.32	1.4e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs656900	0.874	rs584055	chr15:80126521	A/T	cg02196730	chr15:80188777	MTHFS	-0.43	-6.87	-0.32	2.24e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.53	0.3	1.85e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs11112613	0.775	rs12305225	chr12:105963266	G/C	cg03607813	chr12:105948248	NA	0.7	11.31	0.48	4.35e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs2880765	0.805	rs34598679	chr15:86042205	G/A	cg13263323	chr15:86062960	AKAP13	-0.5	-9.24	-0.41	1.21e-18	Coronary artery disease;
LUAD	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg04586622	chr2:25135609	ADCY3	0.31	6.93	0.32	1.53e-11	Body mass index in non-asthmatics;
LUAD	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.69	-0.31	7.31e-11	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22028544	chr8:86132837	C8orf59	-0.42	-6.54	-0.3	1.77e-10	Height;
LUAD	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg17279839	chr7:150038598	RARRES2	0.39	6.77	0.31	4.25e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg19875535	chr5:140030758	IK	-0.48	-8.07	-0.37	7.46e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24531977	chr5:56204891	C5orf35	0.95	14.6	0.58	2.09e-39	Initial pursuit acceleration;
LUAD	cis	rs7640424	0.652	rs12152307	chr3:107861766	T/C	cg09227934	chr3:107805635	CD47	-0.56	-9.66	-0.42	4.58e-20	Body mass index;
LUAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg04025307	chr7:1156635	C7orf50	0.66	9.34	0.41	5.5e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg11663144	chr21:46675770	NA	-0.59	-11.7	-0.49	1.34e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.47	0.3	2.75e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg09517075	chr8:22133004	PIWIL2	0.48	9.0	0.4	7.71e-18	Hypertriglyceridemia;
LUAD	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25427524	chr10:38739819	LOC399744	-0.79	-14.4	-0.57	1.6e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg01017244	chr2:74357527	NA	0.92	13.91	0.56	1.8e-36	Gestational age at birth (maternal effect);
LUAD	cis	rs2070677	0.866	rs2492664	chr10:135387240	G/T	cg20169779	chr10:135381914	SYCE1	-0.52	-8.57	-0.38	1.95e-16	Gout;
LUAD	cis	rs3820068	0.705	rs4646085	chr1:15825411	A/T	cg17385448	chr1:15911702	AGMAT	0.39	6.38	0.3	4.75e-10	Systolic blood pressure;
LUAD	trans	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.59	9.72	0.43	2.74e-20	Birth weight;
LUAD	trans	rs4714291	0.963	rs1304602	chr6:40013471	T/G	cg02267698	chr19:7991119	CTXN1	0.44	6.73	0.31	5.68e-11	Strep throat;
LUAD	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg16797656	chr11:68205561	LRP5	0.52	10.92	0.47	1.24e-24	Total body bone mineral density;
LUAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg10729496	chr3:10149963	C3orf24	0.58	9.45	0.42	2.26e-19	Alzheimer's disease;
LUAD	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg09650180	chr20:62225654	GMEB2	-0.48	-6.84	-0.32	2.87e-11	Glioblastoma;
LUAD	cis	rs2637266	0.714	rs6480835	chr10:78446863	T/C	cg18941641	chr10:78392320	NA	0.32	6.63	0.31	1.05e-10	Pulmonary function;
LUAD	trans	rs1325195	0.920	rs4651012	chr1:179071865	G/A	cg11624085	chr17:8464688	MYH10	-0.42	-6.39	-0.3	4.47e-10	IgE grass sensitization;
LUAD	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg08869376	chr19:10226304	EIF3G	0.37	7.56	0.34	2.59e-13	Narcolepsy;
LUAD	cis	rs9341808	0.538	rs9343980	chr6:81023432	A/G	cg08355045	chr6:80787529	NA	-0.41	-7.09	-0.33	5.77e-12	Sitting height ratio;
LUAD	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26314531	chr2:26401878	FAM59B	-0.58	-7.99	-0.36	1.33e-14	Gut microbiome composition (summer);
LUAD	cis	rs11031096	0.782	rs2165728	chr11:4147004	T/C	cg18678763	chr11:4115507	RRM1	-0.42	-7.33	-0.34	1.16e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg06640241	chr16:89574553	SPG7	0.7	12.48	0.52	1.18e-30	Multiple myeloma (IgH translocation);
LUAD	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	8.9	0.4	1.62e-17	Multiple sclerosis;
LUAD	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg17366294	chr4:99064904	C4orf37	0.59	9.94	0.44	4.75e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05776053	chr2:74358815	NA	0.44	6.96	0.32	1.27e-11	Gestational age at birth (maternal effect);
LUAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg21782813	chr7:2030301	MAD1L1	0.57	10.11	0.44	1.13e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs863345	0.604	rs12133791	chr1:158506682	C/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.6	-0.31	1.21e-10	Pneumococcal bacteremia;
LUAD	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg18827107	chr12:86230957	RASSF9	-0.5	-9.09	-0.4	3.9e-18	Major depressive disorder;
LUAD	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg14343924	chr8:8086146	FLJ10661	0.51	8.07	0.37	7.6e-15	Mood instability;
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg24232869	chr12:48478849	SENP1	0.46	7.12	0.33	4.71e-12	Hepatitis;
LUAD	cis	rs295140	0.773	rs13007517	chr2:201129729	C/T	cg23649088	chr2:200775458	C2orf69	-0.39	-6.42	-0.3	3.63e-10	QT interval;
LUAD	cis	rs6906287	0.647	rs11153734	chr6:118726220	A/G	cg18833306	chr6:118973337	C6orf204	0.48	8.41	0.38	6.43e-16	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.13e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9392556	0.829	rs620484	chr6:4114211	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.42	-7.25	-0.33	1.95e-12	Blood metabolite levels;
LUAD	trans	rs9784649	0.882	rs72753879	chr5:24947395	C/T	cg08600765	chr20:34638493	LOC647979	-0.6	-7.61	-0.35	1.82e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-7.76	-0.35	6.49e-14	Morning vs. evening chronotype;
LUAD	cis	rs9535307	0.745	rs2181185	chr13:50311925	C/T	cg04663916	chr13:50265991	EBPL	0.58	6.89	0.32	2.03e-11	Obesity-related traits;
LUAD	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg07936489	chr17:37558343	FBXL20	-0.45	-7.06	-0.32	6.82e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs9341808	0.667	rs3828753	chr6:80912746	C/T	cg08355045	chr6:80787529	NA	0.49	8.83	0.39	2.73e-17	Sitting height ratio;
LUAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg07507251	chr3:52567010	NT5DC2	0.39	7.65	0.35	1.35e-13	Electroencephalogram traits;
LUAD	cis	rs7027203	0.759	rs10761282	chr9:96586175	G/A	cg13679303	chr9:96623674	NA	-0.34	-6.9	-0.32	1.92e-11	DNA methylation (variation);
LUAD	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg01416388	chr22:39784598	NA	-0.43	-6.67	-0.31	8.09e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.42	-0.38	6.09e-16	Neutrophil percentage of white cells;
LUAD	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg13010199	chr12:38710504	ALG10B	0.4	6.39	0.3	4.41e-10	Bladder cancer;
LUAD	cis	rs1776421	0.760	rs61768412	chr1:53901450	C/G	cg10892335	chr1:53966318	NA	0.48	7.19	0.33	2.97e-12	PR interval in Tripanosoma cruzi seropositivity;
LUAD	trans	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.87	-0.32	2.37e-11	Aortic root size;
LUAD	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg25251562	chr2:3704773	ALLC	-0.51	-8.36	-0.38	9.18e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg19862616	chr7:65841803	NCRNA00174	1.05	26.51	0.79	5.76e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg11822812	chr5:140052017	DND1	-0.41	-7.47	-0.34	4.61e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	9.08	0.4	4.18e-18	Menarche (age at onset);
LUAD	cis	rs367615	0.512	rs414724	chr5:108670421	A/G	cg17395555	chr5:108820864	NA	0.52	9.78	0.43	1.74e-20	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10802521	chr3:52805072	NEK4	-0.5	-8.81	-0.39	3.33e-17	Bipolar disorder;
LUAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	3.98e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7680126	0.626	rs11721501	chr4:10189135	G/A	cg02734326	chr4:10020555	SLC2A9	-0.51	-6.58	-0.3	1.36e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs1595825	0.838	rs57437055	chr2:198782617	A/C	cg00361562	chr2:198649771	BOLL	-0.47	-6.73	-0.31	5.53e-11	Ulcerative colitis;
LUAD	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg05872129	chr22:39784769	NA	-0.79	-14.39	-0.57	1.77e-38	Intelligence (multi-trait analysis);
LUAD	cis	rs4763879	0.865	rs4763840	chr12:9884410	A/G	cg27502298	chr12:9555721	NA	0.42	6.65	0.31	9.33e-11	Type 1 diabetes;
LUAD	trans	rs8073060	0.586	rs7217533	chr17:34015876	A/G	cg19694781	chr19:47549865	TMEM160	-1.22	-19.42	-0.69	1.67e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs10746514	0.804	rs11122429	chr1:232261532	G/A	cg09506761	chr1:232265262	NA	-0.39	-7.3	-0.33	1.41e-12	Response to statin therapy;
LUAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg18621852	chr3:10150065	C3orf24	-0.48	-8.54	-0.38	2.36e-16	Alzheimer's disease;
LUAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-8.07	-0.37	7.12e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	6.6	0.31	1.22e-10	Lung cancer in ever smokers;
LUAD	cis	rs1018836	0.663	rs3950221	chr8:91478108	G/A	cg16814680	chr8:91681699	NA	-0.66	-10.95	-0.47	9.48e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg25753631	chr6:25732923	NA	-0.44	-7.76	-0.35	6.26e-14	Iron status biomarkers;
LUAD	cis	rs9486719	1.000	rs9400016	chr6:96940883	G/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-9.78	-0.43	1.67e-20	Migraine;Coronary artery disease;
LUAD	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg11822812	chr5:140052017	DND1	-0.43	-7.58	-0.35	2.22e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6445967	0.530	rs4553990	chr3:58381180	T/A	cg13750441	chr3:58318267	PXK	-0.33	-6.74	-0.31	5.23e-11	Platelet count;
LUAD	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg17063962	chr7:91808500	NA	0.68	12.05	0.51	5.76e-29	Breast cancer;
LUAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg02524346	chr8:600233	NA	1.09	10.7	0.46	8.48e-24	IgG glycosylation;
LUAD	cis	rs494562	0.892	rs9344518	chr6:86125144	T/A	cg21730993	chr6:86159210	NT5E	0.71	7.75	0.35	6.84e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg09184832	chr6:79620586	NA	-0.4	-6.63	-0.31	1.04e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg12501888	chr15:85177176	SCAND2	-0.46	-7.07	-0.33	6.31e-12	P wave terminal force;
LUAD	cis	rs300774	0.925	rs365967	chr2:123233	G/A	cg21211680	chr2:198530	NA	-0.46	-6.69	-0.31	7e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03264133	chr6:25882463	NA	-0.71	-10.29	-0.45	2.55e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs6540559	0.551	rs17389436	chr1:209972297	A/T	cg23283495	chr1:209979779	IRF6	0.72	7.72	0.35	8.59e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs877282	0.842	rs35872126	chr10:764545	G/A	cg06581033	chr10:766294	NA	-0.59	-7.98	-0.36	1.39e-14	Uric acid levels;
LUAD	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg27219399	chr15:67835830	MAP2K5	0.41	6.62	0.31	1.1e-10	Restless legs syndrome;
LUAD	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg21204522	chr6:27730016	NA	-0.46	-7.31	-0.33	1.36e-12	Parkinson's disease;
LUAD	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-8.28	-0.37	1.69e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs863345	0.504	rs2482966	chr1:158563321	T/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.5	-0.3	2.25e-10	Pneumococcal bacteremia;
LUAD	cis	rs4594175	0.892	rs10135768	chr14:51671017	G/T	cg23942311	chr14:51606299	NA	0.61	10.46	0.45	6.18e-23	Cancer;
LUAD	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg04455712	chr21:45112962	RRP1B	-0.34	-6.58	-0.3	1.43e-10	Mean corpuscular volume;
LUAD	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg18252515	chr7:66147081	NA	-0.63	-6.82	-0.31	3.15e-11	Diabetic kidney disease;
LUAD	cis	rs73206853	0.764	rs7299230	chr12:110618512	A/T	cg12870014	chr12:110450643	ANKRD13A	0.64	7.91	0.36	2.24e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg15226275	chr6:116381976	FRK	0.23	7.64	0.35	1.49e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs7536201	0.740	rs2370234	chr1:25304464	C/T	cg23273869	chr1:25296894	NA	-0.36	-7.34	-0.34	1.11e-12	Psoriasis vulgaris;
LUAD	cis	rs7809950	1.000	rs2237677	chr7:107202502	A/C	cg23024343	chr7:107201750	COG5	-0.66	-11.21	-0.48	1.07e-25	Coronary artery disease;
LUAD	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg25173405	chr17:45401733	C17orf57	-0.46	-7.51	-0.34	3.53e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg25767906	chr1:53392781	SCP2	-0.4	-7.37	-0.34	8.8e-13	Monocyte count;
LUAD	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg06108461	chr20:60628389	TAF4	-0.97	-17.6	-0.65	2.06e-52	Body mass index;
LUAD	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg14196790	chr5:131705035	SLC22A5	0.39	6.81	0.31	3.32e-11	Breast cancer;
LUAD	cis	rs73206853	0.841	rs111612251	chr12:111017607	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.79	0.35	5.38e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg10728214	chr13:29298228	NA	-0.38	-6.5	-0.3	2.33e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.77	-10.14	-0.44	8.81e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg07870213	chr5:140052090	DND1	-0.81	-11.05	-0.47	4.17e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9902453	0.967	rs4294864	chr17:28440138	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	9.23	0.41	1.34e-18	Coffee consumption (cups per day);
LUAD	cis	rs78366141	0.649	rs78959409	chr4:89659712	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.91	6.39	0.3	4.33e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7737355	1.000	rs6872972	chr5:130621533	C/T	cg06307176	chr5:131281290	NA	0.46	7.33	0.34	1.21e-12	Life satisfaction;
LUAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg24813613	chr7:1882135	MAD1L1	-0.4	-6.5	-0.3	2.27e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg06671706	chr8:8559999	CLDN23	0.64	10.61	0.46	1.76e-23	Obesity-related traits;
LUAD	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg21171335	chr12:122356390	WDR66	0.66	11.88	0.5	2.74e-28	Mean corpuscular volume;
LUAD	cis	rs10465746	0.714	rs12730621	chr1:84433745	C/G	cg10977910	chr1:84465055	TTLL7	0.6	9.86	0.43	8.77e-21	Obesity-related traits;
LUAD	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24308560	chr3:49941425	MST1R	0.6	10.18	0.44	6.67e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg08316699	chr6:150357289	NA	0.37	7.79	0.35	5.3e-14	Alopecia areata;
LUAD	trans	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg14917512	chr19:3094685	GNA11	-0.55	-6.63	-0.31	1.01e-10	Diabetic kidney disease;
LUAD	trans	rs853679	0.546	rs200977	chr6:27854301	T/C	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.22	-0.37	2.51e-15	Depression;
LUAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-7.24	-0.33	2.11e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs13315871	0.929	rs13094898	chr3:58290143	G/A	cg20936604	chr3:58311152	NA	-0.75	-7.61	-0.35	1.82e-13	Cholesterol, total;
LUAD	cis	rs739496	0.843	rs10774631	chr12:112023001	A/G	cg10833066	chr12:111807467	FAM109A	-0.41	-6.49	-0.3	2.38e-10	Platelet count;
LUAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg26354017	chr1:205819088	PM20D1	0.51	8.3	0.37	1.4e-15	Parkinson's disease;
LUAD	cis	rs7945718	0.811	rs7104832	chr11:12786489	A/G	cg25843174	chr11:12811716	TEAD1	0.25	7.21	0.33	2.61e-12	Educational attainment (years of education);
LUAD	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg18129748	chr3:49941408	MST1R	-0.4	-6.51	-0.3	2.14e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs868036	1.000	rs4325504	chr15:68055570	A/G	cg24579218	chr15:68104479	NA	0.36	6.73	0.31	5.47e-11	Restless legs syndrome;
LUAD	cis	rs7107174	0.681	rs4340079	chr11:78007920	C/T	cg02023728	chr11:77925099	USP35	0.39	6.38	0.3	4.63e-10	Testicular germ cell tumor;
LUAD	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	ch.11.42038R	chr11:967971	AP2A2	0.41	7.32	0.34	1.25e-12	Alzheimer's disease (late onset);
LUAD	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg00071950	chr4:10020882	SLC2A9	0.72	14.84	0.59	2.08e-40	Bone mineral density;
LUAD	cis	rs1003719	0.788	rs9977314	chr21:38471963	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.65	0.39	1.06e-16	Eye color traits;
LUAD	cis	rs2408955	0.500	rs12816820	chr12:48558325	A/G	cg04545296	chr12:48745243	ZNF641	0.31	7.95	0.36	1.68e-14	Glycated hemoglobin levels;
LUAD	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg03929089	chr4:120376271	NA	-0.96	-19.52	-0.69	5.46e-61	Height;
LUAD	trans	rs7944735	0.517	rs11039520	chr11:48130794	A/G	cg03929089	chr4:120376271	NA	0.6	6.4	0.3	4.19e-10	Intraocular pressure;
LUAD	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg25828334	chr19:18545568	ISYNA1	-0.39	-7.95	-0.36	1.71e-14	Breast cancer;
LUAD	trans	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg21659725	chr3:3221576	CRBN	0.4	6.8	0.31	3.65e-11	Resting heart rate;
LUAD	cis	rs4680	1.000	rs165722	chr22:19949013	C/T	cg22546130	chr22:19950026	COMT	0.36	7.87	0.36	3.08e-14	Blood metabolite levels;
LUAD	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg24308560	chr3:49941425	MST1R	0.5	8.22	0.37	2.44e-15	Body mass index;
LUAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg08888203	chr3:10149979	C3orf24	0.72	12.87	0.53	3.25e-32	Alzheimer's disease;
LUAD	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg01097406	chr16:89675127	NA	-0.33	-6.53	-0.3	1.94e-10	Vitiligo;
LUAD	cis	rs4481887	0.927	rs10749646	chr1:248429719	A/G	cg00666640	chr1:248458726	OR2T12	-0.32	-8.0	-0.36	1.24e-14	Common traits (Other);
LUAD	cis	rs2742234	0.518	rs2505514	chr10:43633248	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.51	-8.74	-0.39	5.49e-17	Hirschsprung disease;
LUAD	cis	rs2408955	0.522	rs3997	chr12:48481587	T/C	cg04545296	chr12:48745243	ZNF641	-0.34	-8.69	-0.39	7.92e-17	Glycated hemoglobin levels;
LUAD	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg16325326	chr1:53192061	ZYG11B	0.67	12.94	0.53	1.63e-32	Monocyte count;
LUAD	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg24634471	chr8:143751801	JRK	0.49	7.86	0.36	3.28e-14	Schizophrenia;
LUAD	cis	rs12541635	0.677	rs6469032	chr8:107057509	A/T	cg10147462	chr8:107024639	NA	0.52	9.36	0.41	4.66e-19	Age of smoking initiation;
LUAD	cis	rs4711350	0.954	rs1536501	chr6:33727885	C/T	cg07979401	chr6:33739406	LEMD2	0.5	8.19	0.37	3.14e-15	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg13047869	chr3:10149882	C3orf24	-0.63	-10.73	-0.46	6.56e-24	Alzheimer's disease;
LUAD	trans	rs8002861	0.935	rs9525865	chr13:44459647	A/T	cg17145862	chr1:211918768	LPGAT1	0.77	18.33	0.67	1.19e-55	Leprosy;
LUAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.67	-12.89	-0.53	2.62e-32	Longevity;Endometriosis;
LUAD	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs9463078	0.547	rs4449629	chr6:44717808	T/C	cg25276700	chr6:44698697	NA	0.35	6.64	0.31	9.84e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUAD	cis	rs6696239	0.513	rs3010193	chr1:227798322	T/C	cg12133451	chr1:227746453	NA	-0.36	-6.39	-0.3	4.32e-10	Height;
LUAD	cis	rs17362650	0.960	rs13034367	chr2:9673372	T/A	cg12832956	chr2:9616023	IAH1	-0.47	-7.4	-0.34	7.6e-13	Alcohol dependence (age at onset);
LUAD	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg04287289	chr16:89883240	FANCA	0.71	6.66	0.31	8.69e-11	Skin colour saturation;
LUAD	cis	rs354225	0.819	rs241661	chr2:54924467	G/T	cg26097391	chr2:54893211	SPTBN1	0.45	7.11	0.33	5.07e-12	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg16989719	chr2:238392110	NA	-0.36	-7.74	-0.35	7.64e-14	Prostate cancer;
LUAD	cis	rs57561814	0.510	rs2066992	chr7:22768249	G/T	cg01770232	chr7:22766155	IL6	0.74	7.37	0.34	9.13e-13	Tonsillectomy;
LUAD	cis	rs2637266	1.000	rs2130798	chr10:78329563	C/T	cg18941641	chr10:78392320	NA	0.34	6.94	0.32	1.51e-11	Pulmonary function;
LUAD	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg23719950	chr11:63933701	MACROD1	-0.62	-7.4	-0.34	7.25e-13	Mean platelet volume;
LUAD	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.53	-0.34	3.1400000000000003e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg01200585	chr1:228362443	C1orf69	0.46	7.51	0.34	3.56e-13	Diastolic blood pressure;
LUAD	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg00814883	chr7:100076585	TSC22D4	-0.83	-11.8	-0.5	5.63e-28	Platelet count;
LUAD	cis	rs300703	0.654	rs300771	chr2:117241	A/G	cg24565620	chr2:194026	NA	0.47	7.22	0.33	2.38e-12	Blood protein levels;
LUAD	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg11344533	chr11:111475393	SIK2	-0.35	-6.64	-0.31	9.9e-11	Primary sclerosing cholangitis;
LUAD	cis	rs13394619	0.935	rs12468019	chr2:11725049	T/C	cg07314298	chr2:11723111	GREB1	-0.51	-9.46	-0.42	2.2e-19	Endometriosis;
LUAD	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg07685180	chr8:600429	NA	0.64	6.71	0.31	6.42e-11	IgG glycosylation;
LUAD	cis	rs8044995	0.925	rs9928653	chr16:68252079	T/C	cg09835421	chr16:68378352	PRMT7	-0.53	-6.67	-0.31	7.84e-11	Schizophrenia;
LUAD	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg19761014	chr17:28927070	LRRC37B2	0.65	7.59	0.35	2.03e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3784262	0.616	rs2704197	chr15:58323236	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.36	-6.87	-0.32	2.31e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs6594713	0.851	rs7717630	chr5:112704266	A/G	cg12552261	chr5:112820674	MCC	0.49	8.07	0.37	7.1e-15	Brain cytoarchitecture;
LUAD	cis	rs9296092	0.538	rs75652975	chr6:33516251	C/T	cg13560919	chr6:33536144	NA	-0.87	-15.45	-0.6	4.9e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	trans	rs2735413	0.918	rs4888728	chr16:78077199	C/G	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs6543140	0.964	rs11903551	chr2:103084181	C/G	cg03938978	chr2:103052716	IL18RAP	0.35	6.72	0.31	5.97e-11	Blood protein levels;
LUAD	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg07432352	chr17:45403706	C17orf57	0.41	7.77	0.35	6.03e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg01788221	chr16:89496183	ANKRD11	-0.34	-6.41	-0.3	4.01e-10	Multiple myeloma (IgH translocation);
LUAD	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.44	-0.3	3.22e-10	Coronary artery disease;
LUAD	cis	rs2880765	0.835	rs7162502	chr15:86044473	G/T	cg04831495	chr15:85060580	GOLGA6L5	-0.37	-6.35	-0.3	5.56e-10	Coronary artery disease;
LUAD	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg17264618	chr3:40429014	ENTPD3	0.39	8.84	0.4	2.51e-17	Renal cell carcinoma;
LUAD	cis	rs7937890	0.559	rs2597188	chr11:14516906	G/A	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.15e-12	Mitochondrial DNA levels;
LUAD	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg01299579	chr2:10830716	NOL10	-0.42	-7.42	-0.34	6.53e-13	Prostate cancer;
LUAD	cis	rs11971779	0.680	rs2355788	chr7:139101897	T/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.38e-10	Diisocyanate-induced asthma;
LUAD	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg18944383	chr4:111397179	ENPEP	-0.39	-7.05	-0.32	7.46e-12	Coronary artery disease;
LUAD	cis	rs494562	0.892	rs520090	chr6:86116635	G/A	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg04450456	chr4:17643702	FAM184B	-0.42	-8.11	-0.37	5.38e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03352830	chr11:487213	PTDSS2	0.8	10.56	0.46	2.62e-23	Body mass index;
LUAD	cis	rs7680126	0.626	rs11723388	chr4:10195802	G/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-7.38	-0.34	8.64e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9811920	0.809	rs4928150	chr3:99685991	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-7.13	-0.33	4.48e-12	Axial length;
LUAD	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg06453172	chr10:134556979	INPP5A	-0.67	-9.91	-0.43	5.69e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg11530693	chr1:120165357	ZNF697	0.85	18.31	0.66	1.44e-55	Systemic lupus erythematosus;
LUAD	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg06640241	chr16:89574553	SPG7	0.53	7.85	0.36	3.41e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.62	-11.09	-0.47	3.05e-25	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.62	0.31	1.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg19635926	chr16:89946313	TCF25	0.76	6.78	0.31	4.15e-11	Skin colour saturation;
LUAD	cis	rs9868809	0.772	rs28452701	chr3:48708575	C/T	cg00383909	chr3:49044727	WDR6	0.7	7.57	0.35	2.39e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7274811	0.744	rs6120309	chr20:32169600	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.51	-7.74	-0.35	7.49e-14	Height;
LUAD	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.33	7.14	0.33	4.22e-12	Cardiac Troponin-T levels;
LUAD	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg26384229	chr12:38710491	ALG10B	0.47	7.65	0.35	1.37e-13	Morning vs. evening chronotype;
LUAD	cis	rs755249	0.508	rs586057	chr1:39858794	G/C	cg27567593	chr1:39956653	BMP8A	-0.36	-7.23	-0.33	2.26e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg27426351	chr10:43362370	NA	0.54	8.25	0.37	1.99e-15	Blood protein levels;
LUAD	cis	rs220324	0.738	rs9325631	chr21:43590845	A/C	cg08841829	chr21:43638893	ABCG1	-0.5	-6.82	-0.31	3.23e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg13535736	chr9:111863775	C9orf5	-0.41	-6.38	-0.3	4.69e-10	Menarche (age at onset);
LUAD	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.64	-0.42	5.01e-20	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg26384229	chr12:38710491	ALG10B	0.47	7.58	0.35	2.23e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs12144309	1.000	rs12144309	chr1:114315493	C/T	cg03325407	chr1:114423726	BCL2L15	0.43	6.61	0.31	1.13e-10	Coronary artery disease;
LUAD	trans	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04565464	chr8:145669602	NFKBIL2	0.43	6.6	0.31	1.21e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.73	0.31	5.45e-11	Aortic root size;
LUAD	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg12011299	chr4:100065546	ADH4	0.69	12.23	0.51	1.17e-29	Alcohol dependence;
LUAD	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.42	-7.12	-0.33	4.56e-12	Longevity;Endometriosis;
LUAD	cis	rs1045714	0.943	rs1045711	chr7:2653571	C/T	cg24848437	chr7:2645542	IQCE	0.75	8.53	0.38	2.67e-16	Urate levels in lean individuals;
LUAD	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg18110333	chr6:292329	DUSP22	-0.55	-8.86	-0.4	2.27e-17	Menopause (age at onset);
LUAD	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg06108461	chr20:60628389	TAF4	-0.74	-12.72	-0.53	1.3e-31	Body mass index;
LUAD	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg11766577	chr21:47581405	C21orf56	0.42	7.4	0.34	7.42e-13	Testicular germ cell tumor;
LUAD	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg07636037	chr3:49044803	WDR6	-0.48	-8.03	-0.36	9.96e-15	Menarche (age at onset);
LUAD	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-8.73	-0.39	5.9e-17	Monocyte percentage of white cells;
LUAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00149659	chr3:10157352	C3orf10	0.57	7.7	0.35	9.84e-14	Alzheimer's disease;
LUAD	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.8e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10766172	chr7:27498479	NA	-0.53	-7.3	-0.33	1.45e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	10.66	0.46	1.12e-23	Type 2 diabetes;
LUAD	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg11859384	chr17:80120422	CCDC57	0.52	9.38	0.41	4.05e-19	Life satisfaction;
LUAD	cis	rs735539	0.914	rs7997065	chr13:21273796	A/G	cg27499820	chr13:21296301	IL17D	-0.36	-6.63	-0.31	1.02e-10	Dental caries;
LUAD	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg12310025	chr6:25882481	NA	-0.84	-11.73	-0.5	1.07e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs7177699	0.526	rs7182529	chr15:79123631	T/C	cg00540400	chr15:79124168	NA	0.44	9.73	0.43	2.48e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	trans	rs7746199	0.736	rs34543938	chr6:27624640	A/G	cg01620082	chr3:125678407	NA	-1.04	-10.21	-0.44	4.98e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg11247378	chr22:39784982	NA	-0.68	-11.41	-0.49	1.84e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20809690	chr4:2757764	TNIP2	-0.54	-6.71	-0.31	6.17e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3733418	0.929	rs17623445	chr4:165894658	C/T	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.49	-6.61	-0.31	1.19e-10	Obesity-related traits;
LUAD	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.86	-0.4	2.28e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg20290983	chr6:43655470	MRPS18A	1.09	27.67	0.8	6.03e-97	IgG glycosylation;
LUAD	cis	rs748404	0.697	rs475227	chr15:43546446	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.45	0.34	5.29e-13	Lung cancer;
LUAD	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg13606994	chr1:44402422	ARTN	-0.37	-7.24	-0.33	2.09e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg00745463	chr17:30367425	LRRC37B	-0.78	-9.58	-0.42	8.43e-20	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg16606324	chr3:10149918	C3orf24	0.68	11.37	0.48	2.59e-26	Alzheimer's disease;
LUAD	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg21862992	chr11:68658383	NA	0.52	9.54	0.42	1.11e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4343996	0.869	rs6651070	chr7:3465411	G/C	cg21248987	chr7:3385318	SDK1	0.34	6.37	0.3	5.05e-10	Motion sickness;
LUAD	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg02734326	chr4:10020555	SLC2A9	0.42	7.39	0.34	7.99e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6489882	0.966	rs7980275	chr12:113380529	T/A	cg20102336	chr12:113376681	OAS3	-0.55	-8.79	-0.39	3.77e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg07169764	chr2:136633963	MCM6	-0.78	-9.02	-0.4	6.68e-18	Corneal structure;
LUAD	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg11645453	chr3:52864694	ITIH4	0.58	11.0	0.47	6.28e-25	Schizophrenia;
LUAD	cis	rs986417	0.748	rs4400969	chr14:61013298	A/C	cg27398547	chr14:60952738	C14orf39	0.66	7.65	0.35	1.38e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs62458065	0.713	rs28421905	chr7:32489501	G/A	cg00845942	chr12:64062724	DPY19L2	-0.55	-7.55	-0.34	2.67e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2735413	0.918	rs11643649	chr16:78081199	T/C	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg08213375	chr14:104286397	PPP1R13B	0.28	7.24	0.33	2.19e-12	Schizophrenia;
LUAD	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg23283495	chr1:209979779	IRF6	0.72	9.24	0.41	1.18e-18	Cleft lip with or without cleft palate;
LUAD	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg26513180	chr16:89883248	FANCA	0.8	7.14	0.33	4.09e-12	Skin colour saturation;
LUAD	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg26169700	chr22:42538906	CYP2D7P1	-0.54	-7.0	-0.32	1.02e-11	Birth weight;
LUAD	cis	rs17102423	0.594	rs1957948	chr14:65542629	A/G	cg11161011	chr14:65562177	MAX	0.43	7.09	0.33	5.82e-12	Obesity-related traits;
LUAD	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.53	-0.42	1.2e-19	Life satisfaction;
LUAD	cis	rs1003719	0.788	rs4817844	chr21:38447064	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-8.2	-0.37	2.87e-15	Eye color traits;
LUAD	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg00933542	chr6:150070202	PCMT1	0.44	9.08	0.4	4.27e-18	Lung cancer;
LUAD	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	9.93	0.43	4.89e-21	Electrocardiographic conduction measures;
LUAD	cis	rs6490294	0.500	rs4767284	chr12:112440731	G/A	cg10833066	chr12:111807467	FAM109A	0.35	6.67	0.31	7.78e-11	Mean platelet volume;
LUAD	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.73	0.31	5.57e-11	Menarche (age at onset);
LUAD	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg14092988	chr3:52407081	DNAH1	0.44	8.87	0.4	2.04e-17	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg17366294	chr4:99064904	C4orf37	0.65	12.61	0.52	3.67e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.559	rs77641084	chr7:106970522	G/A	cg23024343	chr7:107201750	COG5	0.48	6.76	0.31	4.52e-11	Coronary artery disease;
LUAD	cis	rs16854884	0.683	rs920968	chr3:143770698	C/G	cg01302019	chr3:143689584	C3orf58	-0.4	-6.74	-0.31	5.1e-11	Economic and political preferences (feminism/equality);
LUAD	cis	rs7677751	0.767	rs6846502	chr4:55062090	T/C	cg17187183	chr4:55093834	PDGFRA	0.43	7.01	0.32	9.36e-12	Corneal astigmatism;
LUAD	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.515	rs9615969	chr22:46773592	C/G	cg18190219	chr22:46762943	CELSR1	-0.62	-6.39	-0.3	4.49e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg16680214	chr1:154839983	KCNN3	-0.62	-13.04	-0.54	6.92e-33	Prostate cancer;
LUAD	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg03806693	chr22:41940476	POLR3H	0.5	7.35	0.34	1.06e-12	Vitiligo;
LUAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.17	0.37	3.64e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7174348	1	rs7174348	chr15:78792439	G/A	cg18825076	chr15:78729989	IREB2	0.54	7.52	0.34	3.32e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg06609049	chr19:2785107	THOP1	0.69	11.5	0.49	8.38e-27	Total cholesterol levels;
LUAD	cis	rs12545109	0.959	rs12546307	chr8:57314790	T/A	cg17761419	chr8:57350749	NA	-0.58	-8.53	-0.38	2.67e-16	Obesity-related traits;
LUAD	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg06064525	chr11:970664	AP2A2	0.34	6.64	0.31	9.38e-11	Alzheimer's disease (late onset);
LUAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg07157834	chr1:205819609	PM20D1	0.41	6.51	0.3	2.11e-10	Parkinson's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18208742	chr17:42992872	GFAP	0.44	6.45	0.3	3.12e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg21890820	chr11:65308645	LTBP3	0.48	7.54	0.34	2.8e-13	Bone mineral density;
LUAD	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg18446336	chr7:2847575	GNA12	-0.37	-6.79	-0.31	3.86e-11	Height;
LUAD	cis	rs68170813	0.559	rs12532967	chr7:106937418	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-10.55	-0.46	2.94e-23	Coronary artery disease;
LUAD	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg04455712	chr21:45112962	RRP1B	0.46	9.06	0.4	5.05e-18	Mean corpuscular volume;
LUAD	cis	rs4642101	0.883	rs6810325	chr3:12840934	T/C	cg24848339	chr3:12840334	CAND2	0.36	6.86	0.32	2.42e-11	QRS complex (12-leadsum);
LUAD	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg17633681	chr16:88106987	BANP	0.39	6.91	0.32	1.82e-11	Menopause (age at onset);
LUAD	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg26769984	chr7:1090371	C7orf50	0.61	10.03	0.44	2.19e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg18446336	chr7:2847575	GNA12	0.37	6.93	0.32	1.57e-11	Height;
LUAD	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg27572855	chr1:25598939	RHD	0.55	11.92	0.5	2.01e-28	Erythrocyte sedimentation rate;
LUAD	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg03806693	chr22:41940476	POLR3H	-0.58	-8.22	-0.37	2.48e-15	Vitiligo;
LUAD	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg09137382	chr11:130731461	NA	0.42	7.6	0.35	1.93e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg02466173	chr16:30829666	NA	0.82	16.79	0.63	7.5e-49	Dementia with Lewy bodies;
LUAD	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg17366294	chr4:99064904	C4orf37	-0.57	-9.68	-0.43	3.81e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg03563238	chr19:33554763	RHPN2	-0.38	-8.95	-0.4	1.09e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg23262073	chr20:60523788	NA	-0.45	-7.21	-0.33	2.53e-12	Body mass index;
LUAD	cis	rs7010267	0.712	rs4567065	chr8:120008274	C/A	cg01975934	chr8:119970761	NA	-0.36	-6.79	-0.31	3.92e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs12681287	0.673	rs4464946	chr8:87326259	G/A	cg27223183	chr8:87520930	FAM82B	-0.67	-9.23	-0.41	1.32e-18	Caudate activity during reward;
LUAD	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg15448220	chr1:150897856	SETDB1	0.53	9.25	0.41	1.08e-18	Melanoma;
LUAD	cis	rs1448094	1.000	rs10083080	chr12:86348579	G/C	cg19622623	chr12:86230825	RASSF9	-0.36	-6.6	-0.31	1.25e-10	Major depressive disorder;
LUAD	trans	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg04775059	chr7:64541387	NA	0.51	6.82	0.31	3.08e-11	Aortic root size;
LUAD	cis	rs7193541	0.965	rs7199068	chr16:74698263	C/G	cg01733217	chr16:74700730	RFWD3	0.58	9.94	0.44	4.57e-21	Multiple myeloma;
LUAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg23978390	chr7:1156363	C7orf50	0.46	7.59	0.35	2.07e-13	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg14416269	chr4:6271139	WFS1	0.62	13.13	0.54	2.96e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	7.63	0.35	1.55e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs72928364	1.000	rs62273935	chr3:100669576	G/C	cg10123952	chr3:100791384	NA	0.65	7.51	0.34	3.55e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.23	-0.33	2.21e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs75920871	0.925	rs17120241	chr11:116915020	T/C	cg04087571	chr11:116723030	SIK3	-0.33	-6.76	-0.31	4.53e-11	Subjective well-being;
LUAD	cis	rs7759001	0.857	rs2206252	chr6:27358462	A/C	cg18711553	chr6:27366782	ZNF391	0.38	6.36	0.3	5.39e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs500891	0.574	rs34783351	chr6:84139030	G/T	cg08257003	chr6:84140564	ME1	0.34	6.42	0.3	3.64e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs6564851	0.905	rs9708919	chr16:81260786	C/T	cg00908271	chr16:81254010	PKD1L2	0.3	6.66	0.31	8.74e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs11051970	0.636	rs1045751	chr12:32569496	T/C	cg02745156	chr12:32552066	NA	0.3	6.39	0.3	4.33e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21659725	chr3:3221576	CRBN	-0.5	-8.26	-0.37	1.88e-15	Body mass index;
LUAD	cis	rs1385374	1.000	rs1385374	chr12:129300694	C/T	cg09035930	chr12:129282057	SLC15A4	-0.62	-7.2	-0.33	2.79e-12	Systemic lupus erythematosus;
LUAD	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg10018233	chr7:150070692	REPIN1	0.5	7.88	0.36	2.8e-14	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs2840044	0.554	rs225267	chr17:33964228	T/C	cg19694781	chr19:47549865	TMEM160	-1.24	-19.59	-0.69	2.7e-61	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs80319144	0.565	rs3771652	chr2:159483802	T/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.36	6.99	0.32	1.05e-11	Restless legs syndrome;
LUAD	cis	rs11811982	0.793	rs114003530	chr1:227602109	G/A	cg24860534	chr1:227506868	CDC42BPA	0.66	6.99	0.32	1.05e-11	Optic disc area;
LUAD	cis	rs1448094	0.845	rs10863123	chr12:86346254	G/A	cg18827107	chr12:86230957	RASSF9	-0.47	-8.48	-0.38	3.67e-16	Major depressive disorder;
LUAD	cis	rs642803	0.551	rs1308020	chr11:65497558	G/A	cg27068330	chr11:65405492	SIPA1	0.43	6.65	0.31	9.13e-11	Urate levels;
LUAD	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg27661571	chr11:113659931	NA	-0.68	-7.92	-0.36	2.05e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs74181299	0.855	rs2723066	chr2:65279321	T/G	cg05010058	chr2:65284262	CEP68	0.3	6.51	0.3	2.12e-10	Pulse pressure;
LUAD	cis	rs1595825	0.891	rs7595819	chr2:198543156	A/C	cg00982548	chr2:198649783	BOLL	0.57	8.09	0.37	6.41e-15	Ulcerative colitis;
LUAD	cis	rs4268898	0.552	rs6754391	chr2:24369019	C/T	cg06627628	chr2:24431161	ITSN2	-0.44	-7.53	-0.34	3e-13	Asthma;
LUAD	cis	rs977987	0.843	rs4887820	chr16:75397287	C/T	cg03315344	chr16:75512273	CHST6	0.64	13.98	0.56	9.05e-37	Dupuytren's disease;
LUAD	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg18944383	chr4:111397179	ENPEP	0.42	8.25	0.37	1.97e-15	Height;
LUAD	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	8.75	0.39	5e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.8	-14.41	-0.57	1.41e-38	Bipolar disorder and schizophrenia;
LUAD	cis	rs10129255	0.500	rs9324092	chr14:107139823	A/G	cg23076370	chr14:107095027	NA	0.43	8.57	0.38	2.03e-16	Kawasaki disease;
LUAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.56	-8.93	-0.4	1.36e-17	Longevity;Endometriosis;
LUAD	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.48	-0.3	2.52e-10	Aortic root size;
LUAD	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg08798685	chr6:27730294	NA	-0.45	-7.31	-0.33	1.37e-12	Parkinson's disease;
LUAD	trans	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.31	0.45	2.19e-22	Mean corpuscular volume;
LUAD	trans	rs75804782	0.630	rs11895642	chr2:239308280	C/T	cg01134436	chr17:81009848	B3GNTL1	0.7	6.52	0.3	2.05e-10	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs514406	0.734	rs581118	chr1:53311324	T/C	cg08859206	chr1:53392774	SCP2	-0.59	-10.31	-0.45	2.12e-22	Monocyte count;
LUAD	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg17749961	chr2:30669863	LCLAT1	0.57	6.8	0.31	3.52e-11	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs11030122	0.673	rs4910869	chr11:4006438	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.22	-0.33	2.39e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg03605463	chr16:89740564	NA	0.67	11.88	0.5	2.75e-28	Vitiligo;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25762580	chr7:108210082	THAP5;DNAJB9	-0.42	-6.39	-0.3	4.32e-10	Height;
LUAD	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg22875332	chr1:76189707	ACADM	0.84	16.8	0.63	6.48e-49	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg26354017	chr1:205819088	PM20D1	0.53	9.87	0.43	8.07e-21	Menarche (age at onset);
LUAD	cis	rs853679	0.546	rs34546986	chr6:28362309	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.6	6.85	0.32	2.57e-11	Depression;
LUAD	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.31	-0.34	1.31e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs17641971	0.662	rs2385229	chr8:50003869	T/C	cg00325661	chr8:49890786	NA	0.31	6.76	0.31	4.61e-11	Blood metabolite levels;
LUAD	cis	rs9948	0.655	rs2280356	chr2:97366324	C/T	cg20312557	chr2:97357134	FER1L5	0.57	7.22	0.33	2.4e-12	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg05731713	chr7:157510257	PTPRN2	0.44	10.29	0.45	2.68e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs6479527	0.840	rs2094927	chr9:96765386	C/A	cg14459158	chr9:96720562	NA	0.36	6.36	0.3	5.11e-10	Esophageal adenocarcinoma;
LUAD	trans	rs7395662	0.963	rs10838967	chr11:48595007	C/T	cg00717180	chr2:96193071	NA	-0.38	-7.23	-0.33	2.3e-12	HDL cholesterol;
LUAD	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.68	-0.35	1.1e-13	Personality dimensions;
LUAD	trans	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg26043149	chr18:55253948	FECH	0.43	7.15	0.33	3.91e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs62238980	0.614	rs118130048	chr22:32413324	C/A	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg08439880	chr3:133502540	NA	-0.34	-6.61	-0.31	1.19e-10	Iron status biomarkers;
LUAD	cis	rs1232027	0.700	rs1677693	chr5:79936318	G/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.81	-0.36	4.4e-14	Huntington's disease progression;
LUAD	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg24154853	chr7:158122151	PTPRN2	0.6	11.81	0.5	5.2e-28	Calcium levels;
LUAD	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg00784671	chr22:46762841	CELSR1	-0.43	-6.42	-0.3	3.7e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg08645402	chr16:4508243	NA	0.53	9.2	0.41	1.69e-18	Schizophrenia;
LUAD	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	13.04	0.54	6.55e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg24531977	chr5:56204891	C5orf35	0.53	8.34	0.38	1.05e-15	Coronary artery disease;
LUAD	trans	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg18187862	chr3:45730750	SACM1L	0.46	6.95	0.32	1.39e-11	Primary sclerosing cholangitis;
LUAD	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06873352	chr17:61820015	STRADA	0.52	8.64	0.39	1.18e-16	Height;
LUAD	cis	rs1483890	0.723	rs34184121	chr3:69411426	A/T	cg22125112	chr3:69402811	FRMD4B	0.45	7.66	0.35	1.31e-13	Resting heart rate;
LUAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg00106254	chr7:1943704	MAD1L1	-0.59	-8.99	-0.4	8.18e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.72	-0.35	8.21e-14	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs12517041	1.000	rs34069672	chr5:23281789	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.47	-0.3	2.73e-10	Calcium levels;
LUAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg24813613	chr7:1882135	MAD1L1	-0.58	-9.37	-0.41	4.52e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs977987	0.843	rs35737321	chr16:75439185	A/T	cg03315344	chr16:75512273	CHST6	0.63	13.56	0.55	4.72e-35	Dupuytren's disease;
LUAD	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg21475434	chr5:93447410	FAM172A	0.8	8.57	0.38	2.02e-16	Diabetic retinopathy;
LUAD	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg15181151	chr6:150070149	PCMT1	0.35	6.84	0.32	2.76e-11	Lung cancer;
LUAD	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg10755058	chr3:40428713	ENTPD3	-0.43	-8.49	-0.38	3.55e-16	Renal cell carcinoma;
LUAD	cis	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg07460842	chr6:66804631	NA	-0.92	-14.72	-0.58	6.69e-40	Exhaled nitric oxide levels;
LUAD	cis	rs2806561	1.000	rs1208932	chr1:23429122	T/G	cg19743168	chr1:23544995	NA	-0.38	-6.87	-0.32	2.27e-11	Height;
LUAD	cis	rs7671266	0.532	rs4608811	chr4:10049675	A/C	cg00071950	chr4:10020882	SLC2A9	0.53	7.52	0.34	3.28e-13	Cardiovascular disease risk factors;
LUAD	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23583168	chr7:148888333	NA	-0.93	-19.34	-0.69	3.52e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg13397359	chr6:42928475	GNMT	0.59	11.28	0.48	5.54e-26	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg00071950	chr4:10020882	SLC2A9	-0.62	-12.08	-0.51	4.67e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.5	-8.31	-0.37	1.28e-15	Tonsillectomy;
LUAD	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg19302996	chr17:73780495	UNK	-0.42	-6.48	-0.3	2.57e-10	Psoriasis;
LUAD	cis	rs6740322	0.895	rs11684601	chr2:43574242	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-10.75	-0.46	5.22e-24	Coronary artery disease;
LUAD	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	9.55	0.42	1.03e-19	Electrocardiographic conduction measures;
LUAD	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg09365446	chr1:150670422	GOLPH3L	-0.4	-6.56	-0.3	1.55e-10	Tonsillectomy;
LUAD	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg15485101	chr11:133734466	NA	0.34	7.69	0.35	1.05e-13	Childhood ear infection;
LUAD	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg20848291	chr7:100343083	ZAN	-0.66	-10.51	-0.46	4.11e-23	Other erythrocyte phenotypes;
LUAD	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg23978390	chr7:1156363	C7orf50	-0.54	-7.61	-0.35	1.8e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg00106254	chr7:1943704	MAD1L1	-0.54	-7.74	-0.35	7.47e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg02371401	chr5:676784	TPPP	-0.36	-6.56	-0.3	1.61e-10	Ulcerative colitis;
LUAD	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg26384229	chr12:38710491	ALG10B	0.51	8.09	0.37	6.46e-15	Bladder cancer;
LUAD	cis	rs7208859	0.614	rs7216394	chr17:28825756	T/C	cg19761014	chr17:28927070	LRRC37B2	-0.68	-7.14	-0.33	4.04e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs11051970	1.000	rs11051970	chr12:32537488	G/T	cg02745156	chr12:32552066	NA	0.32	6.64	0.31	9.76e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.54	0.34	2.9e-13	Breast cancer;
LUAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg09509183	chr1:209979624	IRF6	0.54	8.29	0.37	1.52e-15	Cleft lip with or without cleft palate;
LUAD	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg23533926	chr12:111358616	MYL2	-0.42	-7.31	-0.33	1.39e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06022373	chr22:39101656	GTPBP1	0.46	7.15	0.33	3.87e-12	Menopause (age at onset);
LUAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg05434287	chr7:2030229	MAD1L1	0.39	6.44	0.3	3.18e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7177699	0.581	rs7181432	chr15:79123779	C/T	cg15571903	chr15:79123663	NA	0.42	8.82	0.39	3e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs12753569	1.000	rs12753569	chr1:76484014	G/T	cg00791851	chr1:76518896	NA	-0.29	-6.56	-0.3	1.56e-10	Personality dimensions;
LUAD	cis	rs7000551	0.751	rs2449341	chr8:22390937	C/A	cg12081754	chr8:22256438	SLC39A14	0.42	6.89	0.32	2.05e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg27411982	chr8:10470053	RP1L1	-0.41	-7.48	-0.34	4.43e-13	Morning vs. evening chronotype;
LUAD	cis	rs7189233	0.955	rs60420081	chr16:53520804	A/G	cg04059762	chr16:53544020	NA	-0.43	-6.92	-0.32	1.72e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7771547	0.573	rs7744363	chr6:36424665	A/C	cg07856975	chr6:36356162	ETV7	-0.43	-6.67	-0.31	8.25e-11	Platelet distribution width;
LUAD	cis	rs9715521	0.900	rs72634620	chr4:59822396	C/T	cg11281224	chr4:60001000	NA	-0.55	-9.25	-0.41	1.15e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1595825	0.891	rs2045244	chr2:198506466	C/T	cg11031976	chr2:198649780	BOLL	-0.47	-6.94	-0.32	1.49e-11	Ulcerative colitis;
LUAD	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg12599982	chr1:44399894	ARTN	0.35	6.73	0.31	5.4e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg08742575	chr21:47604166	C21orf56	0.44	7.38	0.34	8.68e-13	Testicular germ cell tumor;
LUAD	cis	rs2282300	0.739	rs12577729	chr11:30257377	C/T	cg25418670	chr11:30344373	C11orf46	-0.54	-7.46	-0.34	5.03e-13	Morning vs. evening chronotype;
LUAD	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.03	-0.32	8.42e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4601821	1.000	rs877138	chr11:113256508	A/G	cg14159747	chr11:113255604	NA	-0.48	-8.96	-0.4	1.06e-17	Alcoholic chronic pancreatitis;
LUAD	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.66	0.31	8.66e-11	Menarche (age at onset);
LUAD	cis	rs3106136	0.967	rs13135934	chr4:95207688	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.62	-0.35	1.71e-13	Capecitabine sensitivity;
LUAD	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg14728415	chr7:32535168	LSM5;AVL9	-0.59	-9.45	-0.42	2.42e-19	Cognitive ability;
LUAD	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg25208724	chr1:156163844	SLC25A44	1.16	26.23	0.79	9.59e-91	Testicular germ cell tumor;
LUAD	cis	rs9796	0.870	rs2412574	chr15:41259707	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.4	-7.55	-0.34	2.75e-13	Menopause (age at onset);
LUAD	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg15921436	chr17:44337874	NA	-0.6	-8.94	-0.4	1.19e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg11845111	chr2:191398756	TMEM194B	0.88	11.48	0.49	9.79e-27	Diastolic blood pressure;
LUAD	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg03806693	chr22:41940476	POLR3H	0.69	9.84	0.43	1.08e-20	Vitiligo;
LUAD	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg27411982	chr8:10470053	RP1L1	-0.39	-6.92	-0.32	1.63e-11	Retinal vascular caliber;
LUAD	cis	rs8060686	0.668	rs8046355	chr16:68205214	T/A	cg09835421	chr16:68378352	PRMT7	-0.51	-6.4	-0.3	4.09e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11971779	0.564	rs6467841	chr7:139066092	T/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.46	-0.3	2.86e-10	Diisocyanate-induced asthma;
LUAD	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg05110241	chr16:68378359	PRMT7	-0.94	-10.23	-0.45	4.13e-22	Magnesium levels;
LUAD	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg03609598	chr5:56110824	MAP3K1	-0.46	-6.73	-0.31	5.68e-11	Initial pursuit acceleration;
LUAD	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg21951975	chr1:209979733	IRF6	0.58	7.01	0.32	9.46e-12	Coronary artery disease;
LUAD	trans	rs8002861	0.664	rs9533662	chr13:44435988	T/A	cg12856521	chr11:46389249	DGKZ	0.48	8.04	0.36	9.06e-15	Leprosy;
LUAD	cis	rs7737355	0.853	rs26005	chr5:130988029	A/G	cg06307176	chr5:131281290	NA	0.54	8.51	0.38	2.97e-16	Life satisfaction;
LUAD	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg14983838	chr19:29218262	NA	0.55	7.7	0.35	1e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.45	-7.61	-0.35	1.81e-13	Longevity;Endometriosis;
LUAD	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg16797656	chr11:68205561	LRP5	0.48	9.33	0.41	6.19e-19	Total body bone mineral density;
LUAD	trans	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg04775059	chr7:64541387	NA	0.54	7.15	0.33	3.86e-12	Aortic root size;
LUAD	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.66	-10.46	-0.45	6.04e-23	Primary sclerosing cholangitis;
LUAD	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg26875233	chr11:93583750	C11orf90	-0.4	-8.89	-0.4	1.79e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs72799341	1.000	rs7200879	chr16:30947572	A/G	cg02466173	chr16:30829666	NA	-0.61	-9.12	-0.41	3.01e-18	Diastolic blood pressure;
LUAD	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg21605333	chr4:119757512	SEC24D	0.93	8.74	0.39	5.54e-17	Cannabis dependence symptom count;
LUAD	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg01299579	chr2:10830716	NOL10	-0.41	-7.17	-0.33	3.38e-12	Prostate cancer;
LUAD	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg11859384	chr17:80120422	CCDC57	0.47	8.23	0.37	2.34e-15	Life satisfaction;
LUAD	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg08754654	chr5:154026448	NA	0.47	7.92	0.36	2.05e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs977987	0.806	rs11149833	chr16:75464002	G/C	cg03315344	chr16:75512273	CHST6	0.64	13.99	0.56	7.87e-37	Dupuytren's disease;
LUAD	cis	rs11955175	0.717	rs41271053	chr5:40835393	A/C	cg04002187	chr5:40835754	RPL37	0.76	6.59	0.31	1.32e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs870825	0.929	rs1405941	chr4:185591518	A/C	cg04058563	chr4:185651563	MLF1IP	-0.71	-9.68	-0.43	3.72e-20	Blood protein levels;
LUAD	cis	rs1113500	0.933	rs10494089	chr1:108626695	T/G	cg06207961	chr1:108661230	NA	0.45	8.52	0.38	2.83e-16	Growth-regulated protein alpha levels;
LUAD	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-25.01	-0.77	2.01e-85	Height;
LUAD	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg01528321	chr10:82214614	TSPAN14	0.46	7.38	0.34	8.42e-13	Post bronchodilator FEV1;
LUAD	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg21775007	chr8:11205619	TDH	-0.52	-9.27	-0.41	9.92e-19	Retinal vascular caliber;
LUAD	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.1	-22.25	-0.73	3.58e-73	Ulcerative colitis;
LUAD	cis	rs600626	0.636	rs11236516	chr11:75451668	C/T	cg24262691	chr11:75473276	NA	-0.53	-6.99	-0.32	1.08e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7665090	1.000	rs735404	chr4:103553665	C/T	cg07973026	chr4:103553119	MANBA	0.47	8.48	0.38	3.78e-16	Primary biliary cholangitis;
LUAD	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg11292332	chr7:45801988	SEPT13	-0.31	-6.95	-0.32	1.39e-11	Breast cancer;
LUAD	cis	rs2109514	0.542	rs7796627	chr7:116086716	T/C	cg04696780	chr7:116139425	CAV2	-0.32	-7.27	-0.33	1.81e-12	Prevalent atrial fibrillation;
LUAD	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg23985595	chr17:80112537	CCDC57	-0.53	-9.51	-0.42	1.43e-19	Life satisfaction;
LUAD	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06028808	chr11:68637592	NA	0.49	8.11	0.37	5.4e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg01802117	chr1:53393560	SCP2	0.37	7.23	0.33	2.25e-12	Monocyte count;
LUAD	cis	rs10129255	0.500	rs6576229	chr14:107186773	G/A	cg07958169	chr14:107095056	NA	-0.37	-7.34	-0.34	1.08e-12	Kawasaki disease;
LUAD	trans	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg27411982	chr8:10470053	RP1L1	-0.37	-6.47	-0.3	2.68e-10	Mood instability;
LUAD	cis	rs1448094	0.842	rs10863159	chr12:86459140	T/C	cg18827107	chr12:86230957	RASSF9	0.42	7.5	0.34	3.8e-13	Major depressive disorder;
LUAD	cis	rs62064224	0.614	rs8065246	chr17:30682274	T/C	cg18200150	chr17:30822561	MYO1D	0.42	7.87	0.36	3.04e-14	Schizophrenia;
LUAD	cis	rs11677416	1.000	rs3783559	chr2:113529837	A/G	cg27083787	chr2:113543245	IL1A	0.39	6.7	0.31	6.82e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs4664304	0.772	rs17830558	chr2:160878364	A/C	cg23995753	chr2:160760732	LY75	-0.43	-7.5	-0.34	3.75e-13	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.48	0.34	4.46e-13	Tonsillectomy;
LUAD	cis	rs28830936	1.000	rs17677199	chr15:41954613	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.63	-0.31	1.03e-10	Diastolic blood pressure;
LUAD	cis	rs11696501	0.688	rs6073862	chr20:44331705	T/C	cg11783356	chr20:44313418	WFDC10B	-0.47	-7.34	-0.34	1.09e-12	Brain structure;
LUAD	cis	rs2742234	0.590	rs2115817	chr10:43686552	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.52	-8.89	-0.4	1.82e-17	Hirschsprung disease;
LUAD	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg26597838	chr10:835615	NA	0.69	9.77	0.43	1.77e-20	Eosinophil percentage of granulocytes;
LUAD	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.44	-0.49	1.35e-26	Type 2 diabetes;
LUAD	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg04546413	chr19:29218101	NA	0.73	9.4	0.42	3.38e-19	Methadone dose in opioid dependence;
LUAD	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg02951883	chr7:2050386	MAD1L1	-0.81	-13.5	-0.55	8.4e-35	Bipolar disorder and schizophrenia;
LUAD	cis	rs684232	0.602	rs416662	chr17:535699	A/G	cg15660573	chr17:549704	VPS53	-0.88	-18.18	-0.66	5.65e-55	Prostate cancer;
LUAD	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg10523679	chr1:76189770	ACADM	0.79	11.88	0.5	2.79e-28	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg26924012	chr15:45694286	SPATA5L1	1.01	19.37	0.69	2.65e-60	Homoarginine levels;
LUAD	cis	rs10540	0.584	rs6598021	chr11:438939	G/C	cg03352830	chr11:487213	PTDSS2	-0.51	-7.32	-0.34	1.26e-12	Body mass index;
LUAD	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg20991723	chr1:152506922	NA	0.35	6.87	0.32	2.33e-11	Hair morphology;
LUAD	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg10518543	chr12:38710700	ALG10B	-0.43	-6.99	-0.32	1.06e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg13334819	chr7:99746414	C7orf59	-0.58	-8.65	-0.39	1.1e-16	Coronary artery disease;
LUAD	cis	rs7107174	1.000	rs2511170	chr11:77980582	A/G	cg19901956	chr11:77921274	USP35	-0.5	-6.45	-0.3	3.05e-10	Testicular germ cell tumor;
LUAD	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19717773	chr7:2847554	GNA12	-0.54	-9.5	-0.42	1.5700000000000001e-19	Height;
LUAD	cis	rs1524976	1.000	rs11707527	chr3:65450416	G/A	cg16238336	chr3:65465873	MAGI1	-0.67	-7.58	-0.35	2.15e-13	PR interval;
LUAD	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg03929089	chr4:120376271	NA	-0.86	-16.29	-0.62	1.11e-46	Height;
LUAD	cis	rs698833	0.828	rs2165421	chr2:44526010	G/A	cg04920474	chr2:44395004	PPM1B	0.41	7.58	0.35	2.2e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs80319144	0.953	rs2883853	chr2:159202835	G/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.72	0.31	5.73e-11	Restless legs syndrome;
LUAD	cis	rs6499255	0.951	rs57565297	chr16:69723122	G/T	cg15192750	chr16:69999425	NA	0.54	8.15	0.37	4.04e-15	IgE levels;
LUAD	cis	rs4919694	1.000	rs10509760	chr10:104634107	A/G	cg04362960	chr10:104952993	NT5C2	0.67	7.53	0.34	3.16e-13	Arsenic metabolism;
LUAD	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.87	0.36	2.96e-14	Morning vs. evening chronotype;
LUAD	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg06263672	chr7:65235340	NA	0.51	6.89	0.32	2.05e-11	Aortic root size;
LUAD	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg01528321	chr10:82214614	TSPAN14	0.54	8.72	0.39	6.3e-17	Post bronchodilator FEV1;
LUAD	trans	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg18834416	chr8:37888184	EIF4EBP1	0.39	6.48	0.3	2.58e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg16606324	chr3:10149918	C3orf24	0.54	7.77	0.35	6.09e-14	Alzheimer's disease;
LUAD	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg12745145	chr7:2261452	MAD1L1	-0.34	-6.39	-0.3	4.37e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs4072705	0.967	rs6478677	chr9:127422179	C/G	cg13476313	chr9:127244764	NR5A1	0.34	8.11	0.37	5.44e-15	Menarche (age at onset);
LUAD	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg21214613	chr1:16344536	HSPB7	0.42	7.6	0.35	1.89e-13	Systolic blood pressure;
LUAD	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg05425664	chr17:57184151	TRIM37	-0.43	-7.66	-0.35	1.29e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.07	-0.33	6.36e-12	Total cholesterol levels;
LUAD	trans	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg24644049	chr4:85504048	CDS1	0.92	7.94	0.36	1.78e-14	Skin colour saturation;
LUAD	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg03929089	chr4:120376271	NA	-0.8	-14.27	-0.57	5.66e-38	Coronary artery disease;
LUAD	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg14752069	chr8:11977206	FAM66D	-0.29	-6.57	-0.3	1.5e-10	Neuroticism;
LUAD	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg19761014	chr17:28927070	LRRC37B2	0.7	6.41	0.3	3.83e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg00071950	chr4:10020882	SLC2A9	-0.62	-12.05	-0.51	5.75e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg11941060	chr3:133502564	NA	-0.46	-7.71	-0.35	8.93e-14	Iron status biomarkers;
LUAD	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.89	-0.53	2.75e-32	Breast cancer;
LUAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg05434287	chr7:2030229	MAD1L1	0.43	6.93	0.32	1.61e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg18129748	chr3:49941408	MST1R	0.42	7.01	0.32	9.3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs11677416	1.000	rs2071375	chr2:113535438	C/T	cg27083787	chr2:113543245	IL1A	0.4	6.75	0.31	4.99e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-7.01	-0.32	9.41e-12	IgG glycosylation;
LUAD	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg11822812	chr5:140052017	DND1	-0.36	-6.42	-0.3	3.56e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg15147215	chr3:52552868	STAB1	-0.41	-7.49	-0.34	4.08e-13	Bipolar disorder;
LUAD	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg16989719	chr2:238392110	NA	-0.34	-7.44	-0.34	5.54e-13	Prostate cancer;
LUAD	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg06064525	chr11:970664	AP2A2	-0.56	-11.49	-0.49	8.88e-27	Alzheimer's disease (late onset);
LUAD	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg16681516	chr19:46297285	DMWD	0.46	9.21	0.41	1.54e-18	Coronary artery disease;
LUAD	cis	rs6714710	0.603	rs11123974	chr2:98605982	A/G	cg26665480	chr2:98280029	ACTR1B	0.5	8.13	0.37	4.76e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg15704280	chr7:45808275	SEPT13	-0.82	-13.94	-0.56	1.3e-36	Coronary artery disease;
LUAD	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg02683114	chr2:24398427	C2orf84	0.42	6.97	0.32	1.2e-11	Asthma;
LUAD	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg15181151	chr6:150070149	PCMT1	0.41	8.55	0.38	2.19e-16	Lung cancer;
LUAD	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg01689657	chr7:91764605	CYP51A1	0.34	8.5	0.38	3.2e-16	Breast cancer;
LUAD	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg27494647	chr7:150038898	RARRES2	0.51	9.33	0.41	5.88e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg10729496	chr3:10149963	C3orf24	0.6	10.05	0.44	1.82e-21	Alzheimer's disease;
LUAD	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg12940439	chr1:67600707	NA	-0.43	-8.45	-0.38	4.82e-16	Psoriasis;
LUAD	trans	rs62458065	1.000	rs6462363	chr7:32464759	T/G	cg00845942	chr12:64062724	DPY19L2	-0.45	-6.55	-0.3	1.7e-10	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg06611532	chr13:114900021	NA	0.38	9.2	0.41	1.62e-18	Schizophrenia;
LUAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.56	8.15	0.37	4.02e-15	Platelet count;
LUAD	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg21016266	chr12:122356598	WDR66	0.69	12.79	0.53	6.76e-32	Mean corpuscular volume;
LUAD	cis	rs7487075	0.578	rs4072304	chr12:46826187	A/G	cg23829395	chr12:46796953	NA	0.3	6.39	0.3	4.4e-10	Itch intensity from mosquito bite;
LUAD	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26314531	chr2:26401878	FAM59B	0.72	9.77	0.43	1.78e-20	Gut microbiome composition (summer);
LUAD	cis	rs7020830	0.867	rs563132	chr9:37245476	A/T	cg14294708	chr9:37120828	ZCCHC7	0.83	16.34	0.62	7.17e-47	Schizophrenia;
LUAD	cis	rs7107174	1.000	rs10793297	chr11:78009660	T/C	cg02023728	chr11:77925099	USP35	0.49	7.35	0.34	1.02e-12	Testicular germ cell tumor;
LUAD	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.84e-26	Alzheimer's disease (late onset);
LUAD	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg09491104	chr22:46646882	C22orf40	-0.52	-7.39	-0.34	7.73e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg26769984	chr7:1090371	C7orf50	0.7	11.4	0.48	1.95e-26	Bronchopulmonary dysplasia;
LUAD	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg12373951	chr3:133503437	NA	0.32	6.7	0.31	6.56e-11	Ankle injury;
LUAD	cis	rs62400317	0.762	rs12209944	chr6:44788156	G/C	cg18551225	chr6:44695536	NA	-0.49	-7.54	-0.34	2.87e-13	Total body bone mineral density;
LUAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg11050988	chr7:1952600	MAD1L1	-0.39	-8.02	-0.36	1.05e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs7737355	0.947	rs32110	chr5:131045835	T/C	cg06307176	chr5:131281290	NA	0.55	8.48	0.38	3.79e-16	Life satisfaction;
LUAD	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg05340658	chr4:99064831	C4orf37	0.45	7.36	0.34	9.65e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg23985595	chr17:80112537	CCDC57	-0.53	-9.47	-0.42	2.07e-19	Life satisfaction;
LUAD	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.34	-0.34	1.11e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg24531977	chr5:56204891	C5orf35	-0.51	-8.17	-0.37	3.6e-15	Coronary artery disease;
LUAD	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg01299579	chr2:10830716	NOL10	-0.43	-7.64	-0.35	1.45e-13	Prostate cancer;
LUAD	cis	rs7178572	0.568	rs28524916	chr15:77599002	T/A	cg15453836	chr15:77711506	NA	0.37	6.4	0.3	4.24e-10	Type 2 diabetes;
LUAD	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg26850624	chr5:429559	AHRR	-0.42	-6.65	-0.31	9.24e-11	Cystic fibrosis severity;
LUAD	cis	rs7394190	0.748	rs60212594	chr10:75414344	G/C	cg02286717	chr10:75415704	SYNPO2L	-0.38	-6.86	-0.32	2.44e-11	Incident atrial fibrillation;
LUAD	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-7.71	-0.35	9.29e-14	Lung cancer;
LUAD	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg01017244	chr2:74357527	NA	0.89	13.49	0.55	9.66e-35	Gestational age at birth (maternal effect);
LUAD	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs73206853	0.841	rs3759382	chr12:110889483	G/A	cg12870014	chr12:110450643	ANKRD13A	0.61	6.67	0.31	7.93e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs4975616	0.773	rs10078017	chr5:1314009	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.37	-7.32	-0.34	1.26e-12	Lung cancer;
LUAD	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg27432699	chr2:27873401	GPN1	0.55	9.75	0.43	2.21e-20	Oral cavity cancer;
LUAD	cis	rs2485376	0.904	rs1541047	chr10:103997645	C/T	cg20641465	chr10:103991465	PITX3	0.57	10.44	0.45	7.3e-23	QT interval;
LUAD	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg26513180	chr16:89883248	FANCA	0.73	6.48	0.3	2.5e-10	Skin colour saturation;
LUAD	trans	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg27411982	chr8:10470053	RP1L1	-0.36	-6.4	-0.3	4.25e-10	Mood instability;
LUAD	cis	rs10392	0.543	rs6028200	chr20:37540615	C/T	cg27552599	chr20:37590471	DHX35	0.39	6.57	0.3	1.45e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs41278232	0.925	rs73916684	chr20:62661274	T/C	cg03065311	chr20:62601662	ZNF512B	0.53	6.95	0.32	1.38e-11	Tonsillectomy;
LUAD	cis	rs1045714	0.848	rs73033686	chr7:2635085	C/G	cg24848437	chr7:2645542	IQCE	0.7	8.03	0.36	9.62e-15	Urate levels in lean individuals;
LUAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg24846343	chr22:24311635	DDTL	0.77	17.34	0.64	2.72e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-10.21	-0.44	5.12e-22	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22496380	chr5:211416	CCDC127	-0.95	-13.32	-0.54	4.88e-34	Breast cancer;
LUAD	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg00933542	chr6:150070202	PCMT1	0.45	10.09	0.44	1.37e-21	Lung cancer;
LUAD	cis	rs989128	0.600	rs9913430	chr17:48628470	A/T	cg24438145	chr17:48624694	SPATA20	0.36	6.4	0.3	4.04e-10	Type 2 diabetes;
LUAD	cis	rs208520	0.754	rs851592	chr6:66875175	G/T	cg07460842	chr6:66804631	NA	-1.02	-15.41	-0.6	7.61e-43	Exhaled nitric oxide output;
LUAD	trans	rs10838798	0.584	rs1566732	chr11:48151494	A/C	cg21153622	chr11:89784906	NA	0.33	6.57	0.3	1.44e-10	Height;
LUAD	cis	rs45430	0.665	rs431563	chr21:42740949	C/T	cg22778903	chr21:42741698	MX2	0.34	7.06	0.32	6.99e-12	Melanoma;
LUAD	trans	rs7246760	0.867	rs12461215	chr19:9782461	G/A	cg02900749	chr2:68251473	NA	-0.59	-6.56	-0.3	1.59e-10	Pursuit maintenance gain;
LUAD	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.67	-10.87	-0.47	1.93e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg16205897	chr5:131564050	P4HA2	-0.34	-7.63	-0.35	1.54e-13	Breast cancer;
LUAD	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.31	0.41	6.89e-19	Colorectal cancer;
LUAD	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg09184832	chr6:79620586	NA	-0.52	-9.9	-0.43	6.15e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg00981070	chr1:2046702	PRKCZ	-0.37	-7.78	-0.35	5.67e-14	Height;
LUAD	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.18	0.54	1.73e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg21252483	chr19:49399788	TULP2	-0.84	-13.61	-0.55	3.17e-35	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-11.38	-0.48	2.31e-26	Gut microbiome composition (summer);
LUAD	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg01802117	chr1:53393560	SCP2	0.37	7.2	0.33	2.8e-12	Monocyte count;
LUAD	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg22467129	chr15:76604101	ETFA	-0.47	-7.91	-0.36	2.26e-14	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg07402062	chr16:89894098	SPIRE2	0.4	9.13	0.41	2.86e-18	Vitiligo;
LUAD	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg16205897	chr5:131564050	P4HA2	-0.34	-7.98	-0.36	1.42e-14	Blood metabolite levels;
LUAD	cis	rs877282	0.853	rs7092652	chr10:756109	G/A	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg16606324	chr3:10149918	C3orf24	0.68	11.41	0.49	1.78e-26	Alzheimer's disease;
LUAD	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg13319975	chr6:146136371	FBXO30	-0.61	-10.41	-0.45	9.87e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4767364	1.000	rs7979545	chr12:112790648	T/C	cg10833066	chr12:111807467	FAM109A	0.35	6.67	0.31	8.24e-11	Oral cavity and pharyngeal cancer;
LUAD	cis	rs755249	0.565	rs7555699	chr1:39957301	G/A	cg27567593	chr1:39956653	BMP8A	0.36	7.32	0.34	1.29e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs17092148	0.887	rs6059928	chr20:33167349	A/G	cg16810054	chr20:33298113	TP53INP2	-0.48	-7.2	-0.33	2.69e-12	Neuroticism;
LUAD	trans	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	15.95	0.61	3.53e-45	Exhaled nitric oxide levels;
LUAD	cis	rs427394	0.582	rs274667	chr5:6710771	A/G	cg14682080	chr5:6737778	POLS	-0.34	-7.38	-0.34	8.65e-13	Menopause (age at onset);
LUAD	cis	rs9581857	0.547	rs75085794	chr13:28095944	A/C	cg22138327	chr13:27999177	GTF3A	0.87	9.24	0.41	1.23e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg05373962	chr22:49881684	NA	-0.44	-9.09	-0.4	3.92e-18	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg04546413	chr19:29218101	NA	0.67	10.56	0.46	2.65e-23	Methadone dose in opioid dependence;
LUAD	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg05340658	chr4:99064831	C4orf37	0.45	6.79	0.31	3.7e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11072805	1	rs11072805	chr15:79078518	T/C	cg12645284	chr15:79092878	ADAMTS7	0.43	7.31	0.33	1.36e-12	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.69	-12.75	-0.53	1e-31	Ulcerative colitis;
LUAD	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg07414643	chr4:187882934	NA	0.34	6.97	0.32	1.23e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.52	0.34	3.2e-13	Breast cancer;
LUAD	cis	rs6066825	0.644	rs6019386	chr20:47326440	T/G	cg18078177	chr20:47281410	PREX1	0.38	6.37	0.3	4.93e-10	Colorectal cancer;
LUAD	cis	rs796825	0.893	rs1085611	chr3:119987936	C/T	cg21790991	chr3:120137480	FSTL1	-0.38	-6.4	-0.3	4.02e-10	HIV-1 susceptibility;
LUAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.33	0.41	6.24e-19	Alzheimer's disease;
LUAD	cis	rs758324	0.738	rs399714	chr5:131318788	C/T	cg06307176	chr5:131281290	NA	-0.42	-7.03	-0.32	8.32e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg05340658	chr4:99064831	C4orf37	0.48	6.89	0.32	2.04e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg04414720	chr1:150670196	GOLPH3L	0.73	13.63	0.55	2.63e-35	Tonsillectomy;
LUAD	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg18827107	chr12:86230957	RASSF9	-0.7	-12.93	-0.53	1.93e-32	Major depressive disorder;
LUAD	cis	rs758324	0.812	rs11750031	chr5:131171251	G/A	cg25547332	chr5:131281432	NA	0.42	6.8	0.31	3.54e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9788721	0.836	rs72738736	chr15:78765122	G/T	cg18825076	chr15:78729989	IREB2	-0.55	-9.41	-0.42	3.24e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	trans	rs10802346	0.514	rs4443861	chr1:246372574	G/T	cg13514129	chr1:39547527	MACF1	0.6	10.52	0.46	3.89e-23	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.57	0.3	1.5e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs738321	0.757	rs9622732	chr22:38524149	G/C	cg17652424	chr22:38574118	PLA2G6	-0.25	-6.55	-0.3	1.64e-10	Breast cancer;
LUAD	cis	rs6489882	0.872	rs7132797	chr12:113375036	A/C	cg20102336	chr12:113376681	OAS3	-0.57	-8.99	-0.4	8.28e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-6.76	-0.31	4.48e-11	Bipolar disorder;
LUAD	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg16060761	chr17:80687452	NA	0.47	7.61	0.35	1.85e-13	Breast cancer;
LUAD	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg23803603	chr1:2058230	PRKCZ	0.4	7.18	0.33	3.25e-12	Height;
LUAD	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24531977	chr5:56204891	C5orf35	-0.88	-13.24	-0.54	1.01e-33	Initial pursuit acceleration;
LUAD	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.26	-0.54	8.48e-34	Chronic sinus infection;
LUAD	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg25894440	chr7:65020034	NA	-0.66	-7.16	-0.33	3.5e-12	Diabetic kidney disease;
LUAD	cis	rs4072705	1.000	rs4524900	chr9:127343209	G/A	cg13476313	chr9:127244764	NR5A1	0.3	7.18	0.33	3.11e-12	Menarche (age at onset);
LUAD	cis	rs7274811	0.901	rs17404047	chr20:32305781	A/T	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.47	-6.59	-0.31	1.33e-10	Height;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg21588998	chr6:14117903	CD83	-0.62	-6.41	-0.3	3.87e-10	Type 2 diabetes;
LUAD	cis	rs3772130	1.000	rs33988592	chr3:121415610	G/A	cg20356878	chr3:121714668	ILDR1	0.5	7.79	0.35	5.34e-14	Cognitive performance;
LUAD	cis	rs3125734	0.633	rs7088891	chr10:64034019	G/T	cg19640130	chr10:64028056	RTKN2	-0.38	-8.18	-0.37	3.33e-15	Rheumatoid arthritis;
LUAD	cis	rs1829883	0.931	rs7720138	chr5:98879849	G/C	cg08333243	chr5:99726346	NA	0.36	6.9	0.32	1.89e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs36051895	0.664	rs12344629	chr9:5109208	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-6.36	-0.3	5.29e-10	Pediatric autoimmune diseases;
LUAD	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg07080864	chr8:57359956	PENK	-0.37	-6.61	-0.31	1.14e-10	Obesity-related traits;
LUAD	cis	rs367615	0.704	rs7705399	chr5:108850351	G/C	cg17395555	chr5:108820864	NA	0.67	14.32	0.57	3.41e-38	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs12210905	1.000	rs72843643	chr6:27211247	G/C	cg11502198	chr6:26597334	ABT1	-0.8	-6.54	-0.3	1.81e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs9399401	0.667	rs6900233	chr6:142717283	C/G	cg03128060	chr6:142623767	GPR126	0.55	10.87	0.47	1.99e-24	Chronic obstructive pulmonary disease;
LUAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11302575	chr7:43769014	C7orf44	-0.44	-6.91	-0.32	1.82e-11	Height;
LUAD	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg03859395	chr2:55845619	SMEK2	0.74	13.82	0.56	4.28e-36	Metabolic syndrome;
LUAD	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg06740227	chr12:86229804	RASSF9	0.46	7.95	0.36	1.69e-14	Major depressive disorder;
LUAD	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg19346786	chr7:2764209	NA	-0.31	-6.54	-0.3	1.75e-10	Height;
LUAD	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2033711	0.503	rs7254299	chr19:58884965	A/G	cg13691442	chr19:58878570	NA	-0.34	-6.95	-0.32	1.38e-11	Uric acid clearance;
LUAD	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg18016565	chr1:150552671	MCL1	0.37	6.54	0.3	1.75e-10	Melanoma;
LUAD	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg14784868	chr12:69753453	YEATS4	0.45	7.35	0.34	1.06e-12	Blood protein levels;
LUAD	cis	rs760794	0.755	rs6921766	chr6:19800972	G/A	cg02404759	chr6:19790362	NA	-0.35	-6.48	-0.3	2.55e-10	Endometriosis;
LUAD	trans	rs7395662	0.927	rs117030714	chr11:48760511	C/T	cg00717180	chr2:96193071	NA	0.39	7.2	0.33	2.85e-12	HDL cholesterol;
LUAD	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg07402062	chr16:89894098	SPIRE2	0.45	11.39	0.48	2.15e-26	Vitiligo;
LUAD	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg18230493	chr5:56204884	C5orf35	-0.85	-12.54	-0.52	6.65e-31	Initial pursuit acceleration;
LUAD	cis	rs939658	0.776	rs35904425	chr15:79444567	G/A	cg17916960	chr15:79447300	NA	-0.54	-11.28	-0.48	5.61e-26	Refractive error;
LUAD	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg07917127	chr4:99064746	C4orf37	0.39	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg26752003	chr8:145688521	CYHR1	-0.42	-7.6	-0.35	1.9e-13	Age at first birth;
LUAD	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg15900387	chr1:150738905	CTSS	-0.36	-6.56	-0.3	1.56e-10	Melanoma;
LUAD	cis	rs7017914	0.967	rs35207116	chr8:71708971	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.43	-0.3	3.46e-10	Bone mineral density;
LUAD	trans	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg18335740	chr13:41363409	SLC25A15	0.53	9.23	0.41	1.27e-18	Lewy body disease;
LUAD	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg22139774	chr2:100720529	AFF3	-0.34	-6.74	-0.31	5.2e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg16606324	chr3:10149918	C3orf24	0.56	8.25	0.37	2.1e-15	Alzheimer's disease;
LUAD	trans	rs3219090	0.962	rs2793655	chr1:226602814	T/A	cg27539482	chr13:111589090	NA	0.43	7.22	0.33	2.5e-12	Melanoma;
LUAD	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-12.19	-0.51	1.71e-29	Mean corpuscular volume;
LUAD	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg08999081	chr20:33150536	PIGU	-0.44	-7.96	-0.36	1.64e-14	Coronary artery disease;
LUAD	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg12179176	chr11:130786555	SNX19	0.55	9.29	0.41	8.21e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.81	11.31	0.48	4.2e-26	Smoking behavior;
LUAD	cis	rs6484504	0.512	rs2774402	chr11:31312897	G/C	cg26647111	chr11:31128758	NA	0.44	7.75	0.35	6.68e-14	Red blood cell count;
LUAD	cis	rs6426558	0.537	rs4500279	chr1:227484482	G/A	cg10327440	chr1:227177885	CDC42BPA	0.53	8.61	0.39	1.41e-16	Neutrophil percentage of white cells;
LUAD	cis	rs501916	0.634	rs10851459	chr15:48061510	C/A	cg16110827	chr15:48056943	SEMA6D	-0.35	-6.43	-0.3	3.41e-10	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.51e-10	Prudent dietary pattern;
LUAD	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg20673091	chr1:2541236	MMEL1	0.35	7.72	0.35	8.67e-14	Ulcerative colitis;
LUAD	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg00290607	chr11:67383545	NA	0.41	6.74	0.31	5.12e-11	Mean corpuscular volume;
LUAD	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg02931644	chr1:25747376	RHCE	0.43	8.96	0.4	1.04e-17	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg00784671	chr22:46762841	CELSR1	-0.66	-7.67	-0.35	1.21e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18876405	chr7:65276391	NA	0.45	7.1	0.33	5.29e-12	Aortic root size;
LUAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.72	13.43	0.55	1.71e-34	Lymphocyte counts;
LUAD	trans	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	11.73	0.5	1.06e-27	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7833986	0.501	rs2953910	chr8:56968761	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	1.01	18.37	0.67	7.54e-56	Height;
LUAD	cis	rs78707713	0.560	rs17569412	chr10:71237536	C/A	cg12610070	chr10:71211762	TSPAN15	-0.38	-9.42	-0.42	2.95e-19	Venous thromboembolism;
LUAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg20276088	chr3:133502917	NA	-0.38	-6.66	-0.31	8.66e-11	Iron status biomarkers;
LUAD	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-8.63	-0.39	1.27e-16	Gut microbiome composition (summer);
LUAD	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg10755058	chr3:40428713	ENTPD3	-0.44	-8.47	-0.38	3.96e-16	Renal cell carcinoma;
LUAD	cis	rs713477	0.967	rs6573028	chr14:55913397	C/T	cg13175173	chr14:55914753	NA	-0.35	-7.37	-0.34	8.89e-13	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg00383909	chr3:49044727	WDR6	0.91	10.38	0.45	1.2e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs2016266	0.819	rs6580942	chr12:53662624	C/A	cg26875137	chr12:53738046	NA	0.32	6.49	0.3	2.36e-10	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs5756813	0.700	rs1894525	chr22:38186400	G/A	cg06521852	chr22:38141419	TRIOBP	0.48	8.99	0.4	8.34e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg13385794	chr1:248469461	NA	-0.25	-6.66	-0.31	8.48e-11	Common traits (Other);
LUAD	cis	rs7107174	1.000	rs2512547	chr11:77960888	T/C	cg02023728	chr11:77925099	USP35	0.45	7.01	0.32	9.43e-12	Testicular germ cell tumor;
LUAD	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg22117172	chr7:91764530	CYP51A1	-0.34	-7.5	-0.34	3.69e-13	Breast cancer;
LUAD	cis	rs17539620	0.534	rs6557363	chr6:154827813	A/G	cg20019720	chr6:154832845	CNKSR3	0.55	11.45	0.49	1.29e-26	Lipoprotein (a) levels;
LUAD	cis	rs6714710	0.627	rs11680883	chr2:98472610	T/C	cg26665480	chr2:98280029	ACTR1B	0.55	8.81	0.39	3.36e-17	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg00383909	chr3:49044727	WDR6	0.96	9.59	0.42	7.53e-20	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg21963583	chr11:68658836	MRPL21	-0.62	-11.28	-0.48	5.81e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg11584989	chr19:19387371	SF4	0.35	6.4	0.3	4.02e-10	Tonsillectomy;
LUAD	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg03709012	chr19:19516395	GATAD2A	0.5	6.77	0.31	4.44e-11	Nonalcoholic fatty liver disease;
LUAD	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs564343	0.560	rs2845570	chr11:65790527	G/T	cg26701943	chr11:108369231	KDELC2	-0.49	-8.04	-0.36	8.98e-15	Obesity (early onset extreme);
LUAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.14	-0.37	4.61e-15	Alzheimer's disease;
LUAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.67e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg09021430	chr5:549028	NA	-0.67	-13.14	-0.54	2.54e-33	Obesity-related traits;
LUAD	trans	rs6921919	0.562	rs13198809	chr6:28323702	G/A	cg06606381	chr12:133084897	FBRSL1	-1.26	-11.31	-0.48	4.31e-26	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17712092	chr4:129076599	LARP1B	0.88	16.63	0.63	3.86e-48	Eosinophil percentage of white cells;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09732510	chr15:72978892	HIGD2B;BBS4	0.42	6.44	0.3	3.2e-10	Gut microbiome composition (summer);
LUAD	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg18105134	chr13:113819100	PROZ	-0.81	-14.33	-0.57	2.8900000000000003e-38	Platelet distribution width;
LUAD	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg23254163	chr1:152506842	NA	0.26	7.05	0.32	7.19e-12	Hair morphology;
LUAD	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg10596483	chr8:143751796	JRK	0.45	7.19	0.33	2.99e-12	Schizophrenia;
LUAD	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-7.34	-0.34	1.12e-12	Personality dimensions;
LUAD	cis	rs2070677	0.877	rs8192777	chr10:135350871	G/T	cg20169779	chr10:135381914	SYCE1	0.49	7.59	0.35	2.04e-13	Gout;
LUAD	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg23758822	chr17:41437982	NA	1.01	20.42	0.7	5.25e-65	Menopause (age at onset);
LUAD	cis	rs701145	0.585	rs242577	chr3:153941208	G/A	cg17054900	chr3:154042577	DHX36	0.65	6.72	0.31	5.99e-11	Coronary artery disease;
LUAD	cis	rs6906287	0.647	rs7773274	chr6:118934740	C/G	cg21191810	chr6:118973309	C6orf204	0.5	9.64	0.42	4.98e-20	Electrocardiographic conduction measures;
LUAD	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg07169764	chr2:136633963	MCM6	0.77	9.0	0.4	7.74e-18	Corneal structure;
LUAD	cis	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg02508848	chr16:68573721	ZFP90	-0.42	-6.6	-0.31	1.22e-10	Ulcerative colitis;
LUAD	cis	rs2764208	0.576	rs6457791	chr6:34759954	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.0	-0.4	7.78e-18	Systemic lupus erythematosus;
LUAD	cis	rs7523050	0.730	rs72984612	chr1:109434826	T/C	cg08274380	chr1:109419600	GPSM2	0.71	6.57	0.3	1.49e-10	Fat distribution (HIV);
LUAD	trans	rs62458065	0.713	rs62463968	chr7:32501242	G/A	cg00845942	chr12:64062724	DPY19L2	-0.55	-7.55	-0.34	2.77e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs1707322	0.638	rs1416706	chr1:46602844	G/A	cg06784218	chr1:46089804	CCDC17	-0.45	-9.68	-0.43	3.82e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4891159	0.526	rs2848961	chr18:74129886	C/G	cg24786174	chr18:74118243	ZNF516	-0.88	-22.42	-0.74	6.09e-74	Longevity;
LUAD	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.36	7.1	0.33	5.42e-12	Obesity-related traits;
LUAD	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg08470875	chr2:26401718	FAM59B	0.77	10.13	0.44	9.47e-22	Gut microbiome composition (summer);
LUAD	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg25233709	chr10:116636983	FAM160B1	0.44	8.74	0.39	5.33e-17	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg27411982	chr8:10470053	RP1L1	-0.44	-7.87	-0.36	3.01e-14	Neuroticism;
LUAD	cis	rs2637266	0.967	rs4979898	chr10:78355672	G/A	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg18230493	chr5:56204884	C5orf35	-0.45	-7.55	-0.34	2.75e-13	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg15181151	chr6:150070149	PCMT1	0.33	6.56	0.3	1.62e-10	Testicular germ cell tumor;
LUAD	trans	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg21153622	chr11:89784906	NA	-0.34	-6.68	-0.31	7.49e-11	HDL cholesterol;
LUAD	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg01849466	chr14:104193079	ZFYVE21	0.51	9.48	0.42	1.8e-19	Schizophrenia;
LUAD	cis	rs6496044	0.507	rs7175731	chr15:86154346	C/T	cg13263323	chr15:86062960	AKAP13	0.39	6.75	0.31	4.75e-11	Interstitial lung disease;
LUAD	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg27170947	chr2:26402098	FAM59B	-0.62	-8.7	-0.39	7.22e-17	Gut microbiome composition (summer);
LUAD	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9372498	0.536	rs9481825	chr6:118876092	C/T	cg21191810	chr6:118973309	C6orf204	-0.5	-7.86	-0.36	3.15e-14	Diastolic blood pressure;
LUAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg20849893	chr7:64541193	NA	0.57	9.18	0.41	1.87e-18	Calcium levels;
LUAD	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg08859206	chr1:53392774	SCP2	0.56	10.12	0.44	1.03e-21	Monocyte count;
LUAD	cis	rs7177699	0.557	rs7403714	chr15:79118650	C/T	cg15571903	chr15:79123663	NA	-0.39	-7.71	-0.35	9.01e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22029157	chr1:209979665	IRF6	0.78	12.5	0.52	1.01e-30	Cleft lip with or without cleft palate;
LUAD	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.49	0.3	2.42e-10	Cardiac Troponin-T levels;
LUAD	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg20701182	chr2:24300061	SF3B14	0.6	6.76	0.31	4.68e-11	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.02	0.36	1.02e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11098699	0.687	rs4833906	chr4:124246251	A/T	cg09941581	chr4:124220074	SPATA5	0.42	6.72	0.31	6.07e-11	Mosquito bite size;
LUAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg00634984	chr7:65235879	NA	-0.49	-6.85	-0.32	2.62e-11	Aortic root size;
LUAD	cis	rs208520	0.955	rs12216176	chr6:67005130	G/T	cg07460842	chr6:66804631	NA	0.73	9.61	0.42	6.64e-20	Exhaled nitric oxide output;
LUAD	cis	rs17155006	1.000	rs17155006	chr7:107757843	A/G	cg05962710	chr7:107745446	LAMB4	-0.31	-6.65	-0.31	8.82e-11	Pneumococcal bacteremia;
LUAD	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg01528321	chr10:82214614	TSPAN14	0.76	10.43	0.45	8.06e-23	Post bronchodilator FEV1;
LUAD	cis	rs7630877	0.924	rs73060760	chr3:179658851	C/T	cg18765712	chr3:179670323	PEX5L	0.36	6.56	0.3	1.58e-10	Type 2 diabetes;
LUAD	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg17200465	chr3:40428508	ENTPD3	0.29	6.85	0.32	2.66e-11	Renal cell carcinoma;
LUAD	trans	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.65	-10.7	-0.46	8.4e-24	Type 2 diabetes;
LUAD	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22496380	chr5:211416	CCDC127	-1.24	-16.81	-0.63	6.05e-49	Breast cancer;
LUAD	cis	rs501916	0.634	rs1561483	chr15:48069488	A/C	cg16110827	chr15:48056943	SEMA6D	-0.37	-6.88	-0.32	2.15e-11	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg21775007	chr8:11205619	TDH	-0.4	-6.73	-0.31	5.49e-11	Retinal vascular caliber;
LUAD	cis	rs4073416	0.508	rs2898818	chr14:65972584	G/C	cg10998611	chr14:65879393	FUT8;LOC645431	-0.43	-6.45	-0.3	3.02e-10	N-glycan levels;
LUAD	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg04731861	chr2:219085781	ARPC2	0.23	7.13	0.33	4.31e-12	Colorectal cancer;
LUAD	cis	rs9341808	0.628	rs2490245	chr6:80892427	A/G	cg08355045	chr6:80787529	NA	0.53	9.53	0.42	1.27e-19	Sitting height ratio;
LUAD	trans	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg11663144	chr21:46675770	NA	-0.6	-11.83	-0.5	4.19e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg17063962	chr7:91808500	NA	0.65	11.09	0.47	2.93e-25	Breast cancer;
LUAD	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg19773385	chr1:10388646	KIF1B	0.41	6.76	0.31	4.69e-11	Hepatocellular carcinoma;
LUAD	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg09035930	chr12:129282057	SLC15A4	0.7	15.92	0.61	4.57e-45	Systemic lupus erythematosus;
LUAD	cis	rs6961069	0.777	rs2366855	chr7:80253455	A/T	cg04458919	chr7:80252533	CD36	-0.37	-6.93	-0.32	1.56e-11	Platelet count;
LUAD	cis	rs758324	0.853	rs6882899	chr5:131172467	G/C	cg06307176	chr5:131281290	NA	0.5	7.86	0.36	3.17e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg13334819	chr7:99746414	C7orf59	-0.64	-10.26	-0.45	3.2e-22	Coronary artery disease;
LUAD	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg21951975	chr1:209979733	IRF6	0.35	6.39	0.3	4.26e-10	Monobrow;
LUAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.77	-0.31	4.31e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg00495681	chr13:53174319	NA	0.48	7.72	0.35	8.57e-14	Lewy body disease;
LUAD	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg13770153	chr20:60521292	NA	-0.46	-7.61	-0.35	1.85e-13	Body mass index;
LUAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13126279	chr21:47581558	C21orf56	-0.51	-8.85	-0.4	2.37e-17	Testicular germ cell tumor;
LUAD	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.55	-0.34	2.78e-13	Total body bone mineral density;
LUAD	cis	rs240764	0.621	rs6570930	chr6:101181258	C/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.55	-0.38	2.24e-16	Neuroticism;
LUAD	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-7.62	-0.35	1.63e-13	Lung cancer;
LUAD	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs7771547	0.603	rs7743396	chr6:36579252	C/T	cg07856975	chr6:36356162	ETV7	0.53	7.08	0.33	6.09e-12	Platelet distribution width;
LUAD	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg02931644	chr1:25747376	RHCE	0.43	8.97	0.4	9.74e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs6894268	0.762	rs4701139	chr5:179033094	G/A	cg26135573	chr5:179059668	NA	0.65	8.97	0.4	9.72e-18	Eating disorders;
LUAD	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg01579765	chr21:45077557	HSF2BP	-0.62	-13.74	-0.56	8.88e-36	Mean corpuscular volume;
LUAD	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.92	-0.36	2.07e-14	Monocyte percentage of white cells;
LUAD	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg18129748	chr3:49941408	MST1R	-0.45	-7.46	-0.34	5.08e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg00316803	chr15:76480434	C15orf27	-0.4	-7.88	-0.36	2.89e-14	Blood metabolite levels;
LUAD	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg03526776	chr6:41159608	TREML2	0.36	7.66	0.35	1.28e-13	Alzheimer's disease (late onset);
LUAD	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg07636037	chr3:49044803	WDR6	0.6	11.34	0.48	3.29e-26	Parkinson's disease;
LUAD	cis	rs6011002	0.745	rs1758206	chr20:62336334	T/C	cg21849932	chr20:62369462	LIME1	-0.73	-6.4	-0.3	4.19e-10	Dental caries;
LUAD	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg27494647	chr7:150038898	RARRES2	0.51	9.07	0.4	4.61e-18	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs10419226	0.511	rs2214524	chr19:18787661	C/A	cg22001208	chr19:18782374	NA	-0.47	-7.92	-0.36	2.1e-14	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.24	-0.37	2.22e-15	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9914988	0.943	rs4795467	chr17:27180784	C/T	cg02049041	chr17:27085579	C17orf63	0.65	8.09	0.37	6.3e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14467955	chr12:109490248	USP30	-0.43	-6.74	-0.31	5.22e-11	Height;
LUAD	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg15557168	chr22:42548783	NA	0.36	6.67	0.31	7.96e-11	Cognitive function;
LUAD	cis	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg12964065	chr18:77638022	KCNG2	0.55	6.84	0.32	2.85e-11	Opioid sensitivity;
LUAD	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg14983838	chr19:29218262	NA	0.67	9.36	0.41	4.87e-19	Methadone dose in opioid dependence;
LUAD	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg10544611	chr16:67998164	SLC12A4	-0.54	-6.87	-0.32	2.38e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg03806693	chr22:41940476	POLR3H	0.52	7.71	0.35	9.07e-14	Cannabis dependence symptom count;
LUAD	cis	rs7267979	0.816	rs443009	chr20:25499817	A/G	cg08601574	chr20:25228251	PYGB	-0.41	-7.57	-0.35	2.32e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg11845111	chr2:191398756	TMEM194B	-0.65	-11.94	-0.5	1.63e-28	Pulse pressure;
LUAD	cis	rs4713675	0.546	rs3818521	chr6:33657246	C/T	cg13859433	chr6:33739653	LEMD2	-0.29	-6.73	-0.31	5.56e-11	Plateletcrit;
LUAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.61	8.18	0.37	3.26e-15	Renal function-related traits (BUN);
LUAD	trans	rs587242	0.528	rs12091543	chr1:97206112	G/C	cg10631902	chr5:14652156	NA	0.39	6.65	0.31	9.33e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg16235748	chr6:149772707	ZC3H12D	0.29	6.39	0.3	4.27e-10	Dupuytren's disease;
LUAD	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg24069376	chr3:38537580	EXOG	0.43	10.07	0.44	1.62e-21	Electrocardiographic conduction measures;
LUAD	cis	rs11030122	0.673	rs4910597	chr11:4094923	G/A	cg18678763	chr11:4115507	RRM1	-0.44	-7.06	-0.32	7.08e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg14345882	chr6:26364793	BTN3A2	0.7	7.14	0.33	4.13e-12	Urinary tract infection frequency;
LUAD	cis	rs2548003	0.518	rs2554901	chr5:28733310	T/C	cg22863700	chr5:28928346	NA	0.43	6.49	0.3	2.44e-10	Hip geometry;
LUAD	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg02463440	chr8:22132932	PIWIL2	0.56	10.28	0.45	2.8e-22	Hypertriglyceridemia;
LUAD	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg15445000	chr17:37608096	MED1	0.44	8.12	0.37	5.14e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs813218	0.565	rs4244712	chr3:99679461	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.38	-0.38	7.84e-16	Orofacial clefts;
LUAD	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.65	-10.86	-0.47	2.18e-24	Glomerular filtration rate;
LUAD	trans	rs6921919	0.789	rs1119211	chr6:28309136	C/G	cg06606381	chr12:133084897	FBRSL1	0.47	6.63	0.31	1.04e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg26516362	chr5:178986906	RUFY1	-0.55	-10.02	-0.44	2.39e-21	Lung cancer;
LUAD	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg26384229	chr12:38710491	ALG10B	0.49	7.72	0.35	8.38e-14	Bladder cancer;
LUAD	cis	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg26958806	chr6:27640298	NA	0.53	6.61	0.31	1.15e-10	Breast cancer;
LUAD	cis	rs7737355	0.812	rs251015	chr5:131029683	A/G	cg06307176	chr5:131281290	NA	0.44	7.38	0.34	8.56e-13	Life satisfaction;
LUAD	cis	rs9326248	0.559	rs10892052	chr11:116834313	G/A	cg20608306	chr11:116969690	SIK3	0.3	6.79	0.31	3.87e-11	Blood protein levels;
LUAD	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg21385522	chr1:16154831	NA	-1.07	-23.49	-0.75	1.1e-78	Dilated cardiomyopathy;
LUAD	cis	rs11112613	0.713	rs2374502	chr12:105938939	T/C	cg03607813	chr12:105948248	NA	0.83	13.11	0.54	3.42e-33	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg20487152	chr13:99095054	FARP1	-0.47	-8.07	-0.37	7.29e-15	Neuroticism;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg04155600	chr16:2932470	FLYWCH2	-0.66	-6.49	-0.3	2.43e-10	Type 2 diabetes;
LUAD	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg08885076	chr2:99613938	TSGA10	-0.4	-7.18	-0.33	3.2e-12	Chronic sinus infection;
LUAD	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg03037974	chr15:76606532	NA	-0.38	-8.19	-0.37	3.11e-15	Blood metabolite levels;
LUAD	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg17105886	chr17:28927953	LRRC37B2	0.8	7.82	0.36	4.29e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10149470	0.549	rs9652403	chr14:104036024	G/C	cg24130564	chr14:104152367	KLC1	-0.53	-9.24	-0.41	1.26e-18	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14685339	chr14:77787351	POMT2;GSTZ1	-0.44	-6.87	-0.32	2.31e-11	Height;
LUAD	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg15485101	chr11:133734466	NA	0.37	7.94	0.36	1.87e-14	Childhood ear infection;
LUAD	cis	rs9560113	0.580	rs9560116	chr13:112193731	G/A	cg10483660	chr13:112241077	NA	0.43	8.4	0.38	7e-16	Menarche (age at onset);
LUAD	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	8.51	0.38	3.02e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs17095355	1.000	rs12267704	chr10:111722008	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.69	-9.35	-0.41	5.32e-19	Biliary atresia;
LUAD	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg17074396	chr22:49843754	NA	-0.33	-6.87	-0.32	2.3e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03352830	chr11:487213	PTDSS2	0.79	10.0	0.44	2.79e-21	Body mass index;
LUAD	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg15448220	chr1:150897856	SETDB1	0.49	8.22	0.37	2.44e-15	Melanoma;
LUAD	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.64	-0.39	1.15e-16	Alzheimer's disease (late onset);
LUAD	cis	rs6840360	0.550	rs12651635	chr4:152557786	C/T	cg22705602	chr4:152727874	NA	-0.42	-7.17	-0.33	3.38e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4604732	0.588	rs9943231	chr1:247629829	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.1	0.33	5.32e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12618769	0.597	rs3769734	chr2:99096149	A/T	cg10123293	chr2:99228465	UNC50	0.46	8.04	0.36	9.19e-15	Bipolar disorder;
LUAD	cis	rs7119038	0.774	rs10892290	chr11:118653503	G/T	cg19308663	chr11:118741387	NA	0.48	6.7	0.31	6.59e-11	Sjögren's syndrome;
LUAD	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg07169764	chr2:136633963	MCM6	0.79	9.22	0.41	1.43e-18	Corneal structure;
LUAD	cis	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.87	-0.36	3.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4523957	0.553	rs9909515	chr17:2039733	T/C	cg16513277	chr17:2031491	SMG6	-0.98	-19.94	-0.7	7.73e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg01851573	chr8:8652454	MFHAS1	0.41	7.35	0.34	1.06e-12	Mood instability;
LUAD	trans	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg25482853	chr8:67687455	SGK3	0.96	15.77	0.61	2.15e-44	Ulcerative colitis;
LUAD	trans	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg18187862	chr3:45730750	SACM1L	0.54	8.3	0.37	1.43e-15	Primary sclerosing cholangitis;
LUAD	cis	rs28830936	1.000	rs17677991	chr15:42032383	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.36	-7.57	-0.35	2.29e-13	Diastolic blood pressure;
LUAD	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg16083429	chr3:49237500	CCDC36	-0.34	-6.38	-0.3	4.61e-10	Menarche (age at onset);
LUAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg03188948	chr7:1209495	NA	0.65	9.31	0.41	6.88e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	8.98	0.4	9.27e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg13397359	chr6:42928475	GNMT	-0.61	-11.85	-0.5	3.65e-28	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs41311933	0.803	rs17612	chr9:123725926	T/G	cg13567360	chr9:123745713	C5	-0.82	-7.15	-0.33	3.91e-12	Coronary artery disease;
LUAD	cis	rs2262909	0.962	rs17459246	chr19:22278121	T/C	cg11619707	chr19:22235551	ZNF257	0.49	7.52	0.34	3.26e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-8.48	-0.38	3.91e-16	Monocyte percentage of white cells;
LUAD	cis	rs10761482	0.813	rs7087726	chr10:62162582	G/C	cg18175470	chr10:62150864	ANK3	-0.39	-6.5	-0.3	2.25e-10	Schizophrenia;
LUAD	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg26647111	chr11:31128758	NA	-0.45	-7.93	-0.36	1.93e-14	Red blood cell count;
LUAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06873352	chr17:61820015	STRADA	0.76	16.18	0.62	3.35e-46	Prudent dietary pattern;
LUAD	cis	rs4253772	0.938	rs41378347	chr22:46636976	G/A	cg09491104	chr22:46646882	C22orf40	-0.53	-7.52	-0.34	3.21e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7187994	0.848	rs35210690	chr16:84782857	C/G	cg07647771	chr16:84786436	USP10	-0.35	-9.02	-0.4	6.39e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg05768032	chr16:30646687	NA	0.45	8.07	0.37	7.29e-15	Multiple myeloma;
LUAD	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg18200150	chr17:30822561	MYO1D	0.7	14.7	0.58	8.38e-40	Schizophrenia;
LUAD	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg09945482	chr18:12777974	NA	0.53	6.64	0.31	9.65e-11	Inflammatory skin disease;
LUAD	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.4	8.43	0.38	5.64e-16	Hemoglobin concentration;
LUAD	cis	rs7945705	0.875	rs10769947	chr11:8758114	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.48	8.97	0.4	9.44e-18	Hemoglobin concentration;
LUAD	cis	rs7107174	1.000	rs2292573	chr11:78053139	A/G	cg19901956	chr11:77921274	USP35	-0.51	-7.14	-0.33	3.98e-12	Testicular germ cell tumor;
LUAD	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg03388025	chr16:89894329	SPIRE2	0.33	7.68	0.35	1.12e-13	Vitiligo;
LUAD	cis	rs2041840	1.000	rs2160395	chr2:37479862	C/T	cg25727520	chr2:37576821	QPCT	-0.36	-7.36	-0.34	9.88e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg25985355	chr7:65971099	NA	-0.52	-6.56	-0.3	1.56e-10	Diabetic kidney disease;
LUAD	cis	rs11048434	0.626	rs1805736	chr12:9084931	A/G	cg26114124	chr12:9217669	LOC144571	-0.36	-6.51	-0.3	2.09e-10	Sjögren's syndrome;
LUAD	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg07169764	chr2:136633963	MCM6	-0.49	-6.54	-0.3	1.76e-10	Mosquito bite size;
LUAD	cis	rs72634258	0.519	rs36040967	chr1:7931804	A/G	cg26816564	chr1:7831052	VAMP3	0.58	7.96	0.36	1.57e-14	Inflammatory bowel disease;
LUAD	cis	rs6960043	0.875	rs6976381	chr7:15048814	T/C	cg19272540	chr7:15055459	NA	-0.31	-6.43	-0.3	3.36e-10	Type 2 diabetes;
LUAD	cis	rs9652601	0.959	rs2058531	chr16:11172109	T/C	cg04616529	chr16:11181986	CLEC16A	0.37	6.55	0.3	1.64e-10	Systemic lupus erythematosus;
LUAD	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg15485101	chr11:133734466	NA	0.38	8.05	0.36	8.58e-15	Childhood ear infection;
LUAD	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg18105134	chr13:113819100	PROZ	-0.85	-14.78	-0.58	3.94e-40	Platelet distribution width;
LUAD	cis	rs7481584	1.000	rs12798150	chr11:3019260	C/T	cg11201177	chr11:2961805	NA	0.39	6.54	0.3	1.76e-10	Calcium levels;
LUAD	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg27490568	chr2:178487706	NA	0.38	6.36	0.3	5.2400000000000005e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7394190	0.748	rs4746147	chr10:75527708	A/G	cg02286717	chr10:75415704	SYNPO2L	-0.37	-6.42	-0.3	3.7e-10	Incident atrial fibrillation;
LUAD	cis	rs2067615	0.579	rs7297592	chr12:107223969	G/T	cg15890332	chr12:107067104	RFX4	0.42	9.0	0.4	7.61e-18	Heart rate;
LUAD	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg21231944	chr12:82153410	PPFIA2	-0.36	-6.65	-0.31	8.98e-11	Resting heart rate;
LUAD	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg17595323	chr11:93583763	C11orf90	-0.43	-9.06	-0.4	4.83e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs897984	0.568	rs4889651	chr16:30895545	C/T	cg02466173	chr16:30829666	NA	-0.64	-10.21	-0.44	5.13e-22	Dementia with Lewy bodies;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11759246	chr18:9615209	PPP4R1	-0.41	-6.35	-0.3	5.51e-10	Height;
LUAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-9.2	-0.41	1.69e-18	Alzheimer's disease;
LUAD	trans	rs587242	0.955	rs12739556	chr1:96977901	C/T	cg10631902	chr5:14652156	NA	0.4	6.41	0.3	3.85e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs2692947	0.673	rs2229169	chr2:96780716	T/G	cg23100626	chr2:96804247	ASTL	-0.37	-9.85	-0.43	9.42e-21	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg23260525	chr10:116636907	FAM160B1	0.47	10.96	0.47	8.6e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21659725	chr3:3221576	CRBN	0.85	17.19	0.64	1.25e-50	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg23625390	chr15:77176239	SCAPER	-0.52	-8.22	-0.37	2.51e-15	Blood metabolite levels;
LUAD	cis	rs877426	0.634	rs867438	chr13:114757361	C/T	cg21461300	chr13:114830702	RASA3	-0.44	-6.69	-0.31	7.25e-11	Facial morphology (factor 14, intercanthal width);
LUAD	cis	rs12545109	0.879	rs2609994	chr8:57365844	A/G	cg07776626	chr8:57350775	NA	-0.66	-9.29	-0.41	8.28e-19	Obesity-related traits;
LUAD	cis	rs11657217	0.677	rs8071194	chr17:77698458	A/C	cg06901238	chr17:77706717	ENPP7	0.73	14.2	0.57	1.05e-37	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
LUAD	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg14092988	chr3:52407081	DNAH1	0.33	6.51	0.3	2.14e-10	Bipolar disorder;
LUAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg13752114	chr3:195489708	MUC4	0.68	7.75	0.35	6.97e-14	Lung disease severity in cystic fibrosis;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg20339296	chr12:50135280	TMBIM6	-0.69	-6.71	-0.31	6.14e-11	Type 2 diabetes;
LUAD	cis	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg26958806	chr6:27640298	NA	0.67	6.64	0.31	9.51e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg01065977	chr19:18549689	ISYNA1	-0.39	-7.53	-0.34	3.01e-13	Breast cancer;
LUAD	cis	rs870825	0.616	rs61539306	chr4:185650276	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	14.31	0.57	3.59e-38	Blood protein levels;
LUAD	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg01657329	chr11:68192670	LRP5	-0.54	-9.48	-0.42	1.84e-19	Total body bone mineral density;
LUAD	cis	rs909002	0.849	rs6425777	chr1:32105447	G/C	cg13919466	chr1:32135498	COL16A1	-0.36	-8.34	-0.38	1.04e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs17102423	0.594	rs4902360	chr14:65546722	A/C	cg11161011	chr14:65562177	MAX	-0.42	-7.04	-0.32	7.65e-12	Obesity-related traits;
LUAD	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg05665937	chr4:1216051	CTBP1	0.41	6.73	0.31	5.53e-11	Obesity-related traits;
LUAD	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg09455208	chr3:40491958	NA	0.64	13.61	0.55	3.16e-35	Renal cell carcinoma;
LUAD	cis	rs240764	0.658	rs6909880	chr6:101179354	A/C	cg09795085	chr6:101329169	ASCC3	-0.46	-8.17	-0.37	3.52e-15	Neuroticism;
LUAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.65	0.31	8.85e-11	Prudent dietary pattern;
LUAD	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg27494647	chr7:150038898	RARRES2	0.54	9.59	0.42	7.98e-20	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg04731861	chr2:219085781	ARPC2	0.23	6.93	0.32	1.61e-11	Colorectal cancer;
LUAD	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg01884057	chr2:25150051	NA	0.32	6.69	0.31	7e-11	Body mass index;
LUAD	trans	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg17712092	chr4:129076599	LARP1B	-0.77	-11.9	-0.5	2.34e-28	Breast cancer;
LUAD	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18867708	chr6:26865862	GUSBL1	-0.41	-6.47	-0.3	2.73e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	21.53	0.72	5.55e-70	Chronic sinus infection;
LUAD	cis	rs1032833	0.732	rs16866673	chr2:180048294	G/C	cg23883738	chr2:179974586	SESTD1	-0.72	-8.01	-0.36	1.12e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26314531	chr2:26401878	FAM59B	-0.56	-7.72	-0.35	8.58e-14	Gut microbiome composition (summer);
LUAD	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.62	-0.31	1.11e-10	Mood instability;
LUAD	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg00495681	chr13:53174319	NA	0.54	9.93	0.43	5.17e-21	Lewy body disease;
LUAD	cis	rs2544523	0.511	rs2544536	chr2:15906854	T/C	cg26669897	chr2:15909070	NA	0.47	8.12	0.37	5.06e-15	Asthma or chronic obstructive pulmonary disease;
LUAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08677398	chr8:58056175	NA	0.45	6.45	0.3	3.07e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg26924012	chr15:45694286	SPATA5L1	1.02	19.16	0.68	2.32e-59	Homoarginine levels;
LUAD	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9649213	0.614	rs3801258	chr7:97988428	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.74	-11.11	-0.48	2.42e-25	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs9322817	0.691	rs4504502	chr6:105325332	A/G	cg02098413	chr6:105308735	HACE1	0.41	8.8	0.39	3.53e-17	Thyroid stimulating hormone;
LUAD	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg05896524	chr21:47604654	C21orf56	0.55	9.07	0.4	4.53e-18	Testicular germ cell tumor;
LUAD	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg25804541	chr17:80189381	SLC16A3	0.33	7.3	0.33	1.42e-12	Life satisfaction;
LUAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs11229555	0.874	rs11601687	chr11:58338628	T/C	cg15696309	chr11:58395628	NA	-0.72	-10.3	-0.45	2.35e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs926938	0.584	rs2798663	chr1:115363582	G/A	cg12756093	chr1:115239321	AMPD1	0.36	6.54	0.3	1.8e-10	Autism;
LUAD	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg05187965	chr10:45406764	TMEM72	-0.49	-9.75	-0.43	2.22e-20	Mean corpuscular volume;
LUAD	cis	rs9296092	0.517	rs76662639	chr6:33508476	G/A	cg13560919	chr6:33536144	NA	-0.85	-13.17	-0.54	2.04e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg24768116	chr2:27665128	KRTCAP3	0.27	6.56	0.3	1.6e-10	Oral cavity cancer;
LUAD	cis	rs6690583	0.623	rs2028304	chr1:85488030	G/A	cg22153463	chr1:85462885	MCOLN2	-0.6	-7.14	-0.33	4.17e-12	Serum sulfate level;
LUAD	trans	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg19862616	chr7:65841803	NCRNA00174	1.03	25.27	0.78	1.46e-86	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg25985355	chr7:65971099	NA	-0.55	-6.82	-0.31	3.17e-11	Diabetic kidney disease;
LUAD	cis	rs4356932	1.000	rs6532114	chr4:76957974	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.35	-6.4	-0.3	4.14e-10	Blood protein levels;
LUAD	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg00495681	chr13:53174319	NA	0.75	14.57	0.58	2.92e-39	Lewy body disease;
LUAD	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg08859206	chr1:53392774	SCP2	-0.5	-8.9	-0.4	1.6e-17	Monocyte count;
LUAD	cis	rs62400317	0.859	rs10948223	chr6:45273921	A/C	cg20913747	chr6:44695427	NA	-0.4	-6.46	-0.3	2.94e-10	Total body bone mineral density;
LUAD	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg14668632	chr7:2872130	GNA12	-0.75	-13.65	-0.55	2.03e-35	Height;
LUAD	cis	rs2425143	0.818	rs6060726	chr20:34555878	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.63	-0.31	1.01e-10	Blood protein levels;
LUAD	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg00310523	chr12:86230176	RASSF9	0.41	8.08	0.37	6.88e-15	Major depressive disorder;
LUAD	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.45	0.3	2.98e-10	Depression;
LUAD	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg11919837	chr8:57350735	NA	-0.43	-6.52	-0.3	1.99e-10	Obesity-related traits;
LUAD	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg05187965	chr10:45406764	TMEM72	-0.43	-8.7	-0.39	7.25e-17	Mean corpuscular volume;
LUAD	cis	rs4280164	0.887	rs11158634	chr14:24776457	C/G	cg22990158	chr14:24802150	ADCY4	0.45	6.48	0.3	2.48e-10	Parent of origin effect on language impairment (paternal);
LUAD	trans	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg27411982	chr8:10470053	RP1L1	-0.36	-6.5	-0.3	2.27e-10	Mood instability;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg04776735	chr22:29137963	CHEK2;HSCB	-0.66	-6.43	-0.3	3.46e-10	Type 2 diabetes;
LUAD	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg10523679	chr1:76189770	ACADM	0.7	9.81	0.43	1.35e-20	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg03676636	chr4:99064102	C4orf37	0.3	7.32	0.34	1.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.37	7.32	0.34	1.25e-12	Neutrophil percentage of white cells;
LUAD	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg12193833	chr17:30244370	NA	-0.55	-7.13	-0.33	4.33e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg14664628	chr15:75095509	CSK	-0.61	-9.74	-0.43	2.33e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg10523679	chr1:76189770	ACADM	0.94	18.88	0.68	4.23e-58	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg03929089	chr4:120376271	NA	0.79	14.31	0.57	3.76e-38	Coronary artery disease;
LUAD	cis	rs7524258	0.900	rs4908611	chr1:7313861	G/A	cg07173049	chr1:7289937	CAMTA1	0.37	6.56	0.3	1.54e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs4986172	0.655	rs1044977	chr17:43227214	T/C	cg10701640	chr17:43249399	NA	0.58	10.25	0.45	3.66e-22	Height;
LUAD	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg04990556	chr1:26633338	UBXN11	-0.41	-6.82	-0.31	3.07e-11	Obesity-related traits;
LUAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08219700	chr8:58056026	NA	0.69	8.89	0.4	1.82e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.76	0.31	4.45e-11	Parkinson's disease;
LUAD	cis	rs17401966	0.838	rs1013953	chr1:10319459	T/A	cg19773385	chr1:10388646	KIF1B	-0.4	-6.56	-0.3	1.61e-10	Hepatocellular carcinoma;
LUAD	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg18180107	chr4:99064573	C4orf37	0.43	6.76	0.31	4.68e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7677751	0.806	rs1800812	chr4:55094629	G/T	cg17187183	chr4:55093834	PDGFRA	0.51	8.63	0.39	1.23e-16	Corneal astigmatism;
LUAD	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg19442545	chr10:75533431	FUT11	-0.47	-7.76	-0.35	6.35e-14	Inflammatory bowel disease;
LUAD	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.82	-0.39	3.1e-17	Initial pursuit acceleration;
LUAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg12432903	chr7:1882776	MAD1L1	-0.41	-6.69	-0.31	7.09e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg18404041	chr3:52824283	ITIH1	0.41	7.51	0.34	3.52e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs8002861	0.935	rs9567299	chr13:44456969	G/A	cg17145862	chr1:211918768	LPGAT1	0.77	18.33	0.67	1.18e-55	Leprosy;
LUAD	trans	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg06437703	chr8:37914619	EIF4EBP1	0.59	10.67	0.46	1.06e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4523957	0.757	rs216208	chr17:2195146	T/A	cg16513277	chr17:2031491	SMG6	0.78	14.37	0.57	1.96e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4889855	0.530	rs12603265	chr17:78618637	A/G	cg16591659	chr17:78472290	NA	-0.44	-7.66	-0.35	1.3e-13	Fractional excretion of uric acid;
LUAD	cis	rs7680126	0.633	rs17389602	chr4:10206926	T/A	cg00071950	chr4:10020882	SLC2A9	-0.6	-8.1	-0.37	5.93e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs4356932	1.000	rs10003240	chr4:76955330	C/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.54	-0.3	1.78e-10	Blood protein levels;
LUAD	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1953600	0.870	rs1049550	chr10:81926702	G/A	cg00277334	chr10:82204260	NA	-0.4	-6.82	-0.31	3.14e-11	Sarcoidosis;
LUAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg19626725	chr5:178986131	RUFY1	0.48	8.78	0.39	4.03e-17	Lung cancer;
LUAD	cis	rs12200782	1.000	rs4515370	chr6:26625319	T/C	cg11502198	chr6:26597334	ABT1	-0.77	-6.69	-0.31	7.16e-11	Small cell lung carcinoma;
LUAD	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg00310523	chr12:86230176	RASSF9	0.39	7.76	0.35	6.41e-14	Major depressive disorder;
LUAD	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg08422745	chr4:174089978	GALNT7	-0.92	-16.46	-0.62	2.18e-47	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg02176678	chr2:219576539	TTLL4	-0.6	-11.73	-0.5	1.1e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg00339695	chr16:24857497	SLC5A11	0.73	11.77	0.5	7.38e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs7851660	0.772	rs6478471	chr9:100664382	A/G	cg13688889	chr9:100608707	NA	-0.54	-9.17	-0.41	2.14e-18	Strep throat;
LUAD	cis	rs698833	0.819	rs2340809	chr2:44536249	A/G	cg04920474	chr2:44395004	PPM1B	0.4	7.4	0.34	7.2e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg09904177	chr6:26538194	HMGN4	0.44	7.45	0.34	5.15e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg02038168	chr22:39784481	NA	-0.58	-10.3	-0.45	2.44e-22	Intelligence (multi-trait analysis);
LUAD	trans	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg07817883	chr1:32538562	TMEM39B	0.63	7.73	0.35	7.87e-14	Monocyte percentage of white cells;
LUAD	cis	rs2235649	0.588	rs11863172	chr16:1909083	C/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-7.4	-0.34	7.25e-13	Blood metabolite levels;
LUAD	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg15557168	chr22:42548783	NA	0.51	9.48	0.42	1.92e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg12365402	chr11:9010492	NRIP3	0.48	8.87	0.4	2.04e-17	Hemoglobin concentration;
LUAD	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.5	0.34	3.91e-13	Breast cancer;
LUAD	cis	rs12122100	0.696	rs12733095	chr1:146545741	C/T	cg03526459	chr1:146549940	NA	-0.39	-7.31	-0.34	1.31e-12	HIV-1 control;
LUAD	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg04944784	chr2:26401820	FAM59B	0.74	10.93	0.47	1.16e-24	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg20607798	chr8:58055168	NA	0.58	7.82	0.36	4.25e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26991812	chr17:27621123	NUFIP2	-0.42	-6.69	-0.31	7.06e-11	Height;
LUAD	cis	rs28655083	1.000	rs11864710	chr16:77075284	A/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.38	-6.57	-0.3	1.5e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6490294	0.583	rs4767364	chr12:112521448	G/A	cg10833066	chr12:111807467	FAM109A	0.36	6.79	0.31	3.9e-11	Mean platelet volume;
LUAD	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.58	-0.3	1.38e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.85	0.47	2.23e-24	Mean corpuscular volume;
LUAD	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg06740227	chr12:86229804	RASSF9	0.47	8.24	0.37	2.16e-15	Major depressive disorder;
LUAD	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.43	0.3	3.53e-10	Parkinson's disease;
LUAD	trans	rs4650994	0.507	rs2811312	chr1:178617603	A/G	cg05059571	chr16:84539110	KIAA1609	0.65	11.4	0.48	2e-26	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg18350739	chr11:68623251	NA	-0.37	-6.37	-0.3	4.95e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3087591	0.922	rs11867284	chr17:29597464	G/A	cg24425628	chr17:29625626	OMG;NF1	0.4	6.51	0.3	2.14e-10	Hip circumference;
LUAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.85	0.56	3.1e-36	Prudent dietary pattern;
LUAD	cis	rs758324	0.947	rs1948704	chr5:131171653	A/G	cg25547332	chr5:131281432	NA	0.43	6.62	0.31	1.07e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg13736514	chr6:26305472	NA	-0.69	-12.87	-0.53	3.36e-32	Educational attainment;
LUAD	cis	rs11971779	0.680	rs7792752	chr7:139066196	G/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.46	-0.3	2.86e-10	Diisocyanate-induced asthma;
LUAD	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg17328964	chr8:145687451	CYHR1	0.68	12.27	0.51	7.75e-30	Age at first birth;
LUAD	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg02493740	chr2:85810744	VAMP5	-0.63	-11.44	-0.49	1.4e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.15	0.33	3.76e-12	Parkinson's disease;
LUAD	cis	rs4072705	0.586	rs7023736	chr9:127247946	G/A	cg13476313	chr9:127244764	NR5A1	0.35	8.53	0.38	2.73e-16	Menarche (age at onset);
LUAD	cis	rs3106136	0.967	rs8026	chr4:95212185	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.71	-0.35	8.92e-14	Capecitabine sensitivity;
LUAD	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg02569458	chr12:86230093	RASSF9	0.44	8.05	0.36	8.3e-15	Major depressive disorder;
LUAD	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg19761014	chr17:28927070	LRRC37B2	0.83	8.13	0.37	4.82e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs977987	0.806	rs4887823	chr16:75433074	T/A	cg03315344	chr16:75512273	CHST6	0.64	14.02	0.56	5.99e-37	Dupuytren's disease;
LUAD	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg02551604	chr5:131831745	NA	0.65	10.45	0.45	7.04e-23	Asthma (sex interaction);
LUAD	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg10755058	chr3:40428713	ENTPD3	0.47	8.68	0.39	8.54e-17	Renal cell carcinoma;
LUAD	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs4481887	0.927	rs11204631	chr1:248479530	A/G	cg13385794	chr1:248469461	NA	0.25	6.77	0.31	4.39e-11	Common traits (Other);
LUAD	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg18876405	chr7:65276391	NA	0.64	11.02	0.47	5.56e-25	Aortic root size;
LUAD	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26314531	chr2:26401878	FAM59B	-0.58	-7.99	-0.36	1.3e-14	Gut microbiome composition (summer);
LUAD	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg18200150	chr17:30822561	MYO1D	0.72	15.47	0.6	4.4e-43	Schizophrenia;
LUAD	cis	rs990171	0.513	rs7573566	chr2:103115205	T/C	cg03938978	chr2:103052716	IL18RAP	0.33	6.53	0.3	1.88e-10	Lymphocyte counts;
LUAD	cis	rs938554	0.876	rs10017945	chr4:9937852	A/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.9	-0.36	2.42e-14	Blood metabolite levels;
LUAD	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	7.5	0.34	3.7e-13	Menarche (age at onset);
LUAD	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg16405210	chr4:1374714	KIAA1530	-0.43	-7.29	-0.33	1.54e-12	Longevity;
LUAD	cis	rs2742234	0.541	rs7098236	chr10:43740508	T/C	cg15436174	chr10:43711423	RASGEF1A	0.54	9.26	0.41	1.01e-18	Hirschsprung disease;
LUAD	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg21475434	chr5:93447410	FAM172A	0.76	8.29	0.37	1.51e-15	Diabetic retinopathy;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg12583927	chr10:61469753	SLC16A9	-0.53	-6.42	-0.3	3.77e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg24768116	chr2:27665128	KRTCAP3	-0.41	-11.03	-0.47	4.92e-25	Total body bone mineral density;
LUAD	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.61	-0.31	1.19e-10	Neuroticism;
LUAD	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs599083	0.793	rs314750	chr11:68182028	G/A	cg01657329	chr11:68192670	LRP5	0.48	7.87	0.36	2.95e-14	Bone mineral density (spine);
LUAD	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg24558204	chr6:135376177	HBS1L	0.47	8.71	0.39	6.82e-17	Red blood cell count;
LUAD	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg10876282	chr6:28092338	ZSCAN16	0.45	7.29	0.33	1.53e-12	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg07305463	chr2:136567211	LCT	0.36	6.79	0.31	3.79e-11	Corneal structure;
LUAD	cis	rs12548874	0.607	rs12543492	chr8:95891843	C/A	cg13393036	chr8:95962371	TP53INP1	-0.3	-6.38	-0.3	4.61e-10	Hemoglobin concentration;
LUAD	cis	rs7512552	0.646	rs1694367	chr1:150329469	T/A	cg15654264	chr1:150340011	RPRD2	0.58	11.1	0.47	2.73e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6541297	0.645	rs4846919	chr1:230301451	A/G	cg20703242	chr1:230279135	GALNT2	0.54	7.82	0.36	4.37e-14	Coronary artery disease;
LUAD	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg06641503	chr3:48959341	ARIH2	-0.41	-8.08	-0.37	6.95e-15	Parkinson's disease;
LUAD	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg26924012	chr15:45694286	SPATA5L1	1.03	19.2	0.68	1.47e-59	Homoarginine levels;
LUAD	trans	rs4650994	1.000	rs17276513	chr1:178520604	A/T	cg05059571	chr16:84539110	KIAA1609	0.61	10.77	0.46	4.7e-24	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg11494091	chr17:61959527	GH2	0.75	18.53	0.67	1.57e-56	Prudent dietary pattern;
LUAD	cis	rs977987	0.806	rs4638613	chr16:75425553	C/T	cg03315344	chr16:75512273	CHST6	0.63	13.68	0.55	1.61e-35	Dupuytren's disease;
LUAD	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg06641503	chr3:48959341	ARIH2	-0.36	-6.46	-0.3	2.8e-10	Menarche (age at onset);
LUAD	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg22823121	chr1:150693482	HORMAD1	0.4	7.74	0.35	7.52e-14	Melanoma;
LUAD	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg16850897	chr7:100343110	ZAN	-0.63	-10.38	-0.45	1.23e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg18721089	chr20:30220636	NA	-0.49	-7.04	-0.32	7.57e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19748678	chr4:122722346	EXOSC9	0.44	7.0	0.32	1.04e-11	Type 2 diabetes;
LUAD	trans	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.27	-0.37	1.72e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12667521	chr19:29218732	NA	0.62	7.96	0.36	1.61e-14	Methadone dose in opioid dependence;
LUAD	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7731657	0.537	rs6595982	chr5:130335557	G/A	cg08523029	chr5:130500466	HINT1	0.56	7.39	0.34	7.72e-13	Fasting plasma glucose;
LUAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg24101359	chr6:42928495	GNMT	0.51	9.62	0.42	6.17e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg02918483	chr4:84406202	FAM175A	-0.66	-6.46	-0.3	2.92e-10	Type 2 diabetes;
LUAD	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg21475434	chr5:93447410	FAM172A	-0.76	-8.55	-0.38	2.27e-16	Diabetic retinopathy;
LUAD	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg25767906	chr1:53392781	SCP2	0.41	7.43	0.34	5.93e-13	Monocyte count;
LUAD	cis	rs67311347	1.000	rs67311347	chr3:40533243	G/A	cg02782426	chr3:40428986	ENTPD3	0.37	7.65	0.35	1.4e-13	Renal cell carcinoma;
LUAD	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.6	0.35	1.93e-13	Cannabis dependence symptom count;
LUAD	trans	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg04565464	chr8:145669602	NFKBIL2	0.45	6.6	0.31	1.24e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs4006360	0.657	rs7225713	chr17:39252092	T/C	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.27	0.37	1.79e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs2235573	0.653	rs3026670	chr22:38426774	T/C	cg19894588	chr14:64061835	NA	0.42	6.54	0.3	1.83e-10	Glioblastoma;Glioma;
LUAD	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-8.21	-0.37	2.79e-15	HDL cholesterol;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06371306	chr7:5595256	NA	-0.42	-6.94	-0.32	1.45e-11	Cancer;
LUAD	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg16325326	chr1:53192061	ZYG11B	0.5	8.49	0.38	3.59e-16	Monocyte count;
LUAD	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg26769984	chr7:1090371	C7orf50	0.64	9.65	0.42	4.91e-20	Bronchopulmonary dysplasia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03205208	chr10:7830848	KIN;ATP5C1	-0.41	-6.9	-0.32	1.92e-11	Cancer;
LUAD	cis	rs34286592	0.929	rs1045968	chr16:29826365	G/T	cg08218971	chr16:29826754	C16orf53;PRRT2	0.4	6.43	0.3	3.36e-10	Multiple sclerosis;
LUAD	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg01579765	chr21:45077557	HSF2BP	-0.59	-13.49	-0.55	1e-34	Mean corpuscular volume;
LUAD	cis	rs7113874	0.802	rs7941510	chr11:8677063	C/A	cg10639395	chr11:8710044	RPL27A	0.36	6.4	0.3	4.14e-10	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.15e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.6	11.51	0.49	7.49e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs240764	0.631	rs6932158	chr6:101246010	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-7.68	-0.35	1.12e-13	Neuroticism;
LUAD	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg00814883	chr7:100076585	TSC22D4	-0.8	-11.59	-0.49	3.55e-27	Platelet count;
LUAD	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25427524	chr10:38739819	LOC399744	-0.76	-14.54	-0.58	3.85e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg12034118	chr1:209979487	IRF6	0.55	6.47	0.3	2.72e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg11317459	chr13:21872234	NA	1.13	17.96	0.66	5.26e-54	White matter hyperintensity burden;
LUAD	trans	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg18187862	chr3:45730750	SACM1L	0.53	8.18	0.37	3.25e-15	Primary sclerosing cholangitis;
LUAD	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg08754478	chr10:133766260	PPP2R2D	0.64	11.54	0.49	5.51e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	trans	rs8002861	0.664	rs9567292	chr13:44444816	A/G	cg12856521	chr11:46389249	DGKZ	0.48	8.1	0.37	6.14e-15	Leprosy;
LUAD	trans	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg01620082	chr3:125678407	NA	-0.44	-6.67	-0.31	7.84e-11	Depression;
LUAD	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg00717180	chr2:96193071	NA	-0.41	-7.6	-0.35	1.95e-13	HDL cholesterol;
LUAD	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	7.45	0.34	5.24e-13	Tonsillectomy;
LUAD	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg19318889	chr4:1322082	MAEA	0.91	15.79	0.61	1.66e-44	Longevity;
LUAD	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg11909912	chr17:43974919	MAPT;LOC100130148	0.4	6.62	0.31	1.1e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs12540874	0.522	rs4947641	chr7:50489038	C/T	cg18232548	chr7:50535776	DDC	-0.63	-11.69	-0.49	1.52e-27	Systemic sclerosis;
LUAD	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg12615879	chr12:58013172	SLC26A10	0.51	10.94	0.47	1.1e-24	Multiple sclerosis;
LUAD	trans	rs564343	0.560	rs2576	chr11:65808467	C/T	cg26701943	chr11:108369231	KDELC2	-0.49	-8.06	-0.36	7.77e-15	Obesity (early onset extreme);
LUAD	cis	rs1728785	1.000	rs698712	chr16:68561879	G/A	cg02508848	chr16:68573721	ZFP90	-0.41	-6.55	-0.3	1.66e-10	Ulcerative colitis;
LUAD	cis	rs892961	0.932	rs11657725	chr17:75405501	G/C	cg05865280	chr17:75406074	SEPT9	0.62	18.76	0.67	1.43e-57	Airflow obstruction;
LUAD	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg09365446	chr1:150670422	GOLPH3L	0.63	11.03	0.47	4.85e-25	Melanoma;
LUAD	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4917300	0.626	rs902821	chr8:143100074	G/A	cg25363559	chr8:143086065	NA	-0.47	-9.54	-0.42	1.11e-19	Amyotrophic lateral sclerosis;
LUAD	cis	rs2880765	0.714	rs6497187	chr15:86011350	A/G	cg13263323	chr15:86062960	AKAP13	-0.48	-8.64	-0.39	1.14e-16	Coronary artery disease;
LUAD	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg23719950	chr11:63933701	MACROD1	-0.58	-6.92	-0.32	1.63e-11	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.17	0.41	2.06e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg08999081	chr20:33150536	PIGU	-0.59	-12.95	-0.53	1.53e-32	Glomerular filtration rate (creatinine);
LUAD	cis	rs8192282	0.691	rs4845640	chr1:154497802	C/T	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.36	-0.34	9.84e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg11707310	chr1:2537719	MMEL1	-0.38	-8.0	-0.36	1.19e-14	Ulcerative colitis;
LUAD	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg06627628	chr2:24431161	ITSN2	0.4	6.86	0.32	2.46e-11	Asthma;
LUAD	cis	rs57590327	0.528	rs4856346	chr3:81502655	T/G	cg07356753	chr3:81810745	GBE1	0.48	7.56	0.35	2.45e-13	Extraversion;
LUAD	trans	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	10.47	0.45	5.74e-23	Type 2 diabetes;
LUAD	trans	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg16011800	chr17:1958478	HIC1	-0.55	-7.8	-0.35	4.98e-14	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	8.49	0.38	3.54e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1003719	0.641	rs13046844	chr21:38517603	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.49	-0.38	3.54e-16	Eye color traits;
LUAD	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18876405	chr7:65276391	NA	-0.43	-6.85	-0.32	2.55e-11	Aortic root size;
LUAD	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg11292332	chr7:45801988	SEPT13	-0.31	-6.8	-0.31	3.65e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg22166914	chr1:53195759	ZYG11B	-0.39	-6.4	-0.3	4.08e-10	Monocyte count;
LUAD	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg18833306	chr6:118973337	C6orf204	-0.52	-7.57	-0.35	2.32e-13	Renal cell carcinoma;
LUAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg04568274	chr7:158649319	WDR60	0.45	7.15	0.33	3.76e-12	Height;
LUAD	trans	rs7746199	0.736	rs13212093	chr6:27606716	C/T	cg01620082	chr3:125678407	NA	-1.04	-10.21	-0.44	4.98e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.12	-0.37	5.24e-15	Prostate cancer;
LUAD	trans	rs16857031	0.630	rs10082199	chr1:162090051	A/G	cg11316386	chr1:247275808	C1orf229	0.36	6.35	0.3	5.58e-10	QT interval;
LUAD	trans	rs9747201	0.963	rs9747989	chr17:80176092	A/G	cg07393940	chr7:158741817	NA	0.59	10.15	0.44	8.11e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.64	-0.42	4.99e-20	Alzheimer's disease;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg15813570	chr14:64854563	MTHFD1	0.42	6.74	0.31	5.33e-11	Bilirubin levels;
LUAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.77	-9.43	-0.42	2.82e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2041840	0.961	rs3902740	chr2:37506166	T/C	cg25727520	chr2:37576821	QPCT	-0.33	-6.8	-0.31	3.67e-11	Chronic lymphocytic leukemia;
LUAD	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg14895029	chr7:2775587	GNA12	-0.45	-7.15	-0.33	3.87e-12	Height;
LUAD	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg08355456	chr11:67383691	NA	0.46	7.87	0.36	2.98e-14	Mean corpuscular volume;
LUAD	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg17366294	chr4:99064904	C4orf37	0.68	13.08	0.54	4.59e-33	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2625529	0.938	rs2723343	chr15:72108269	C/T	cg16672083	chr15:72433130	SENP8	-0.7	-10.55	-0.46	3.06e-23	Red blood cell count;
LUAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	8.24	0.37	2.17e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.71	-13.19	-0.54	1.65e-33	Ulcerative colitis;
LUAD	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg11494091	chr17:61959527	GH2	0.4	7.04	0.32	7.6e-12	Height;
LUAD	trans	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg26043149	chr18:55253948	FECH	-0.51	-8.74	-0.39	5.37e-17	Bone mineral density;
LUAD	cis	rs6087990	0.735	rs1003522	chr20:31368560	T/C	cg13636640	chr20:31349939	DNMT3B	0.73	13.08	0.54	4.49e-33	Ulcerative colitis;
LUAD	cis	rs870825	0.860	rs2696044	chr4:185595988	C/G	cg04058563	chr4:185651563	MLF1IP	0.79	10.68	0.46	9.98e-24	Blood protein levels;
LUAD	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-14.78	-0.58	3.82e-40	Schizophrenia;
LUAD	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg27532560	chr4:187881888	NA	-0.39	-7.5	-0.34	3.87e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.33	6.77	0.31	4.32e-11	Obesity-related traits;
LUAD	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg26769984	chr7:1090371	C7orf50	0.59	9.67	0.43	4.17e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg05805236	chr11:65401703	PCNXL3	-0.52	-8.62	-0.39	1.31e-16	Acne (severe);
LUAD	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.12	0.41	2.96e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg14582100	chr15:45693742	SPATA5L1	0.62	12.11	0.51	3.4e-29	Homoarginine levels;
LUAD	cis	rs2019216	0.542	rs12450889	chr17:21889379	A/G	cg22648282	chr17:21454238	C17orf51	-0.48	-8.36	-0.38	8.88e-16	Pelvic organ prolapse;
LUAD	cis	rs13082711	0.595	rs4973761	chr3:27358620	T/C	cg02860705	chr3:27208620	NA	0.77	11.9	0.5	2.4e-28	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs10193935	0.901	rs6544549	chr2:42693056	C/T	cg27598129	chr2:42591480	NA	0.78	9.37	0.41	4.23e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.607	rs67998226	chr6:28238059	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.52	6.47	0.3	2.69e-10	Depression;
LUAD	cis	rs7614311	0.636	rs73117066	chr3:63926236	A/G	cg22134162	chr3:63841271	THOC7	-0.52	-8.63	-0.39	1.28e-16	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11644478	chr21:40555479	PSMG1	-0.4	-6.66	-0.31	8.45e-11	Menarche (age at onset);
LUAD	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.35	-7.2	-0.33	2.71e-12	Platelet count;
LUAD	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg10909506	chr17:38081995	ORMDL3	0.37	6.45	0.3	3.08e-10	Self-reported allergy;
LUAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg03188948	chr7:1209495	NA	0.81	9.88	0.43	7.48e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg19622623	chr12:86230825	RASSF9	-0.39	-6.91	-0.32	1.78e-11	Major depressive disorder;
LUAD	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg21724239	chr8:58056113	NA	0.55	7.34	0.34	1.13e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2479724	0.591	rs2479726	chr6:41898096	A/G	cg17623882	chr6:41773611	USP49	-0.47	-6.98	-0.32	1.12e-11	Menarche (age at onset);
LUAD	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	15.1	0.59	1.66e-41	Intelligence (multi-trait analysis);
LUAD	trans	rs2797160	1.000	rs2797154	chr6:126005197	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-8.89	-0.4	1.78e-17	Endometrial cancer;
LUAD	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg09658497	chr7:2847517	GNA12	-0.45	-8.26	-0.37	1.84e-15	Height;
LUAD	cis	rs494562	0.892	rs544408	chr6:86119110	A/T	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg20203395	chr5:56204925	C5orf35	0.81	11.6	0.49	3.36e-27	Initial pursuit acceleration;
LUAD	cis	rs41311933	1.000	rs41259344	chr9:123751648	C/T	cg13567360	chr9:123745713	C5	-0.79	-8.62	-0.39	1.31e-16	Coronary artery disease;
LUAD	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.82	-0.47	3.1e-24	Menopause (age at onset);
LUAD	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg01579765	chr21:45077557	HSF2BP	-0.63	-15.15	-0.59	9.95e-42	Mean corpuscular volume;
LUAD	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg08219700	chr8:58056026	NA	0.42	6.53	0.3	1.84e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg16049864	chr8:95962084	TP53INP1	-0.4	-7.21	-0.33	2.66e-12	Type 2 diabetes;
LUAD	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg26384229	chr12:38710491	ALG10B	0.51	8.32	0.38	1.19e-15	Heart rate;
LUAD	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg00204512	chr16:28754710	NA	0.32	6.62	0.31	1.06e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg18621852	chr3:10150065	C3orf24	0.5	9.06	0.4	5.05e-18	Alzheimer's disease;
LUAD	cis	rs2692947	0.537	rs11682182	chr2:96378210	A/G	cg23100626	chr2:96804247	ASTL	0.3	7.57	0.35	2.33e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.08	-0.33	6.05e-12	Blood metabolite levels;
LUAD	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg27068330	chr11:65405492	SIPA1	-0.76	-11.64	-0.49	2.4200000000000002e-27	Acne (severe);
LUAD	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg00814883	chr7:100076585	TSC22D4	-0.85	-13.13	-0.54	2.94e-33	Platelet count;
LUAD	cis	rs7301016	0.846	rs11174576	chr12:63026436	C/T	cg11441379	chr12:63026424	NA	0.62	7.39	0.34	7.79e-13	IgG glycosylation;
LUAD	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg18446336	chr7:2847575	GNA12	-0.39	-7.12	-0.33	4.56e-12	Height;
LUAD	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs1497828	0.956	rs2815224	chr1:217529327	T/C	cg04411442	chr1:217543379	NA	-0.38	-6.89	-0.32	2.07e-11	Dialysis-related mortality;
LUAD	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg20991723	chr1:152506922	NA	0.35	6.82	0.31	3.25e-11	Hair morphology;
LUAD	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg26441486	chr22:50317300	CRELD2	0.43	6.38	0.3	4.6e-10	Schizophrenia;
LUAD	cis	rs12618769	0.597	rs11901568	chr2:99128621	C/T	cg10123293	chr2:99228465	UNC50	-0.46	-8.21	-0.37	2.77e-15	Bipolar disorder;
LUAD	cis	rs4285028	0.747	rs7648340	chr3:121426188	G/C	cg11130432	chr3:121712080	ILDR1	-0.47	-6.82	-0.31	3.11e-11	Multiple sclerosis;
LUAD	cis	rs1232027	0.700	rs2618372	chr5:79925610	C/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs4594175	0.886	rs11157801	chr14:51622918	C/T	cg23942311	chr14:51606299	NA	0.65	11.41	0.48	1.86e-26	Cancer;
LUAD	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg00814883	chr7:100076585	TSC22D4	-0.87	-13.15	-0.54	2.28e-33	Platelet count;
LUAD	trans	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17712092	chr4:129076599	LARP1B	-0.84	-15.38	-0.6	1.05e-42	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg01256987	chr12:42539512	GXYLT1	-0.34	-6.7	-0.31	6.87e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg04944784	chr2:26401820	FAM59B	0.6	8.44	0.38	5.09e-16	Gut microbiome composition (summer);
LUAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg10729496	chr3:10149963	C3orf24	0.55	8.96	0.4	1.06e-17	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.46e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06544989	chr22:39130855	UNC84B	0.43	8.03	0.36	9.95e-15	Menopause (age at onset);
LUAD	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg14008862	chr17:28927542	LRRC37B2	0.65	6.35	0.3	5.44e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs5756391	0.546	rs4239882	chr22:37314008	A/G	cg16356956	chr22:37317934	CSF2RB	0.34	7.38	0.34	8.7e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs1003719	0.628	rs2835635	chr21:38528866	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.46	-7.68	-0.35	1.11e-13	Eye color traits;
LUAD	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08280861	chr8:58055591	NA	0.67	8.72	0.39	6.27e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs657075	0.697	rs78003854	chr5:131760389	T/C	cg21138405	chr5:131827807	IRF1	0.55	6.58	0.3	1.35e-10	Rheumatoid arthritis;
LUAD	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	9.98	0.44	3.23e-21	Ileal carcinoids;
LUAD	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg20283391	chr11:68216788	NA	-0.41	-6.67	-0.31	7.88e-11	Total body bone mineral density;
LUAD	cis	rs3781426	0.824	rs3781427	chr10:126703215	A/G	cg04494136	chr10:126703576	CTBP2	-0.36	-7.11	-0.33	4.97e-12	Height;
LUAD	cis	rs7680126	0.596	rs28441463	chr4:10289577	T/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.06	-0.37	7.65e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00149659	chr3:10157352	C3orf10	0.55	7.57	0.35	2.41e-13	Alzheimer's disease;
LUAD	cis	rs17539620	0.519	rs4077066	chr6:154838448	C/G	cg20019720	chr6:154832845	CNKSR3	0.65	13.71	0.55	1.16e-35	Lipoprotein (a) levels;
LUAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg09436375	chr6:42928200	GNMT	0.26	7.47	0.34	4.74e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9487051	0.768	rs437779	chr6:109527691	T/G	cg21918786	chr6:109611834	NA	-0.42	-7.27	-0.33	1.75e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg01802117	chr1:53393560	SCP2	0.43	8.07	0.37	7.39e-15	Monocyte count;
LUAD	cis	rs807669	0.802	rs762528	chr22:19166680	A/G	cg02655711	chr22:19163373	SLC25A1	0.88	19.35	0.69	3.24e-60	Metabolite levels;
LUAD	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs2625529	0.617	rs2306576	chr15:72170686	C/T	cg16672083	chr15:72433130	SENP8	0.63	11.89	0.5	2.48e-28	Red blood cell count;
LUAD	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg02421172	chr7:1938701	MAD1L1	0.48	7.0	0.32	1.03e-11	Bipolar disorder;
LUAD	cis	rs7809950	0.731	rs4730238	chr7:107054787	G/A	cg23024343	chr7:107201750	COG5	-0.87	-14.59	-0.58	2.49e-39	Coronary artery disease;
LUAD	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg12310025	chr6:25882481	NA	-0.5	-7.51	-0.34	3.44e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6754311	0.593	rs313524	chr2:136444123	C/T	cg07305463	chr2:136567211	LCT	-0.34	-6.4	-0.3	4.13e-10	Mosquito bite size;
LUAD	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.54	-0.34	2.94e-13	Fear of minor pain;
LUAD	cis	rs7818345	0.967	rs4481612	chr8:19285336	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.35	7.48	0.34	4.43e-13	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs758324	0.812	rs477086	chr5:131284610	C/T	cg06307176	chr5:131281290	NA	-0.43	-7.18	-0.33	3.11e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg06002616	chr8:101225028	SPAG1	-0.39	-7.82	-0.36	4.39e-14	Atrioventricular conduction;
LUAD	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg17749961	chr2:30669863	LCLAT1	0.57	6.99	0.32	1.08e-11	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs7177699	0.557	rs12442476	chr15:79117856	G/A	cg00540400	chr15:79124168	NA	0.44	9.62	0.42	6.23e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg05340658	chr4:99064831	C4orf37	0.54	9.18	0.41	1.91e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.62	0.55	2.67e-35	Tonsillectomy;
LUAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.68	-0.31	7.58e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03264133	chr6:25882463	NA	-0.79	-13.25	-0.54	8.9e-34	Blood metabolite levels;
LUAD	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg08213375	chr14:104286397	PPP1R13B	0.26	6.85	0.32	2.6e-11	Schizophrenia;
LUAD	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg01299579	chr2:10830716	NOL10	0.44	7.73	0.35	7.92e-14	Prostate cancer;
LUAD	cis	rs4604732	0.631	rs11490201	chr1:247626262	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05994294	chr4:1374658	KIAA1530	0.54	6.68	0.31	7.4e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg21918786	chr6:109611834	NA	-0.58	-10.87	-0.47	1.97e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg22875332	chr1:76189707	ACADM	0.73	11.32	0.48	3.82e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18876405	chr7:65276391	NA	-0.6	-10.1	-0.44	1.24e-21	Aortic root size;
LUAD	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg11062466	chr8:58055876	NA	0.76	9.34	0.41	5.65e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg17761419	chr8:57350749	NA	-0.52	-7.89	-0.36	2.64e-14	Obesity-related traits;
LUAD	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg22823121	chr1:150693482	HORMAD1	-0.36	-6.94	-0.32	1.49e-11	Melanoma;
LUAD	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg17264618	chr3:40429014	ENTPD3	-0.36	-7.79	-0.35	5.3e-14	Renal cell carcinoma;
LUAD	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg18105134	chr13:113819100	PROZ	0.91	16.49	0.63	1.5e-47	Platelet distribution width;
LUAD	cis	rs62238980	0.614	rs4289286	chr22:32458612	G/A	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05996236	chr5:178286857	ZNF354B	-0.69	-6.77	-0.31	4.42e-11	Type 2 diabetes;
LUAD	trans	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg16724585	chr3:197361211	NA	-0.51	-7.68	-0.35	1.11e-13	Pancreatic cancer;
LUAD	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg00701064	chr4:6280414	WFS1	0.66	14.67	0.58	1.14e-39	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg20476274	chr7:133979776	SLC35B4	0.82	15.98	0.61	2.5e-45	Mean platelet volume;
LUAD	cis	rs10489202	0.608	rs6659593	chr1:168072152	A/T	cg24449463	chr1:168025552	DCAF6	-0.63	-10.01	-0.44	2.65e-21	Schizophrenia;
LUAD	cis	rs34638657	0.702	rs11866709	chr16:82201017	A/G	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.95	-0.32	1.43e-11	Lung adenocarcinoma;
LUAD	cis	rs9976767	0.637	rs2156309	chr21:43824529	G/A	cg23042151	chr21:43824109	UBASH3A	-0.31	-6.8	-0.31	3.49e-11	Type 1 diabetes;
LUAD	cis	rs11958404	0.615	rs7717217	chr5:157447749	C/T	cg05962755	chr5:157440814	NA	0.44	8.43	0.38	5.43e-16	IgG glycosylation;
LUAD	cis	rs7582720	1.000	rs6722332	chr2:203745327	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.42	0.34	6.47e-13	Bipolar disorder;
LUAD	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg22117172	chr7:91764530	CYP51A1	0.37	8.08	0.37	6.75e-15	Breast cancer;
LUAD	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Body mass index;
LUAD	cis	rs7119	0.651	rs12902072	chr15:77848732	T/C	cg27398640	chr15:77910606	LINGO1	-0.36	-6.62	-0.31	1.08e-10	Type 2 diabetes;
LUAD	cis	rs6546550	0.868	rs12713682	chr2:70154134	G/A	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.0	-0.47	6.47e-25	Prevalent atrial fibrillation;
LUAD	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg02782426	chr3:40428986	ENTPD3	0.35	7.51	0.34	3.61e-13	Renal cell carcinoma;
LUAD	trans	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg26043149	chr18:55253948	FECH	0.5	8.02	0.36	1.01e-14	Bone mineral density;
LUAD	cis	rs9811920	0.535	rs793481	chr3:99488742	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-8.54	-0.38	2.53e-16	Axial length;
LUAD	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg18196295	chr10:418757	DIP2C	-0.45	-7.12	-0.33	4.74e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg23231163	chr10:75533350	FUT11	-0.52	-9.64	-0.42	5.23e-20	Inflammatory bowel disease;
LUAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg08027265	chr7:2291960	NA	-0.41	-7.09	-0.33	5.72e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg13319975	chr6:146136371	FBXO30	-0.8	-13.68	-0.55	1.55e-35	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs748404	0.697	rs493177	chr15:43543258	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	7.19	0.33	3.03e-12	Lung cancer;
LUAD	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg11125805	chr5:150678162	SLC36A3	0.75	16.28	0.62	1.28e-46	Skin aging (microtopography measurement);
LUAD	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg08213375	chr14:104286397	PPP1R13B	0.28	6.96	0.32	1.31e-11	Schizophrenia;
LUAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07234876	chr8:600039	NA	0.96	9.92	0.43	5.31e-21	IgG glycosylation;
LUAD	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06873352	chr17:61820015	STRADA	0.55	9.0	0.4	7.69e-18	Height;
LUAD	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg18252515	chr7:66147081	NA	-0.61	-6.79	-0.31	3.86e-11	Diabetic kidney disease;
LUAD	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg02782426	chr3:40428986	ENTPD3	-0.36	-7.96	-0.36	1.64e-14	Renal cell carcinoma;
LUAD	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg11266682	chr4:10021025	SLC2A9	0.67	15.52	0.6	2.67e-43	Bone mineral density;
LUAD	cis	rs12519773	0.526	rs6897863	chr5:92512481	A/C	cg18783429	chr5:92414398	NA	0.44	7.71	0.35	9.04e-14	Migraine;
LUAD	cis	rs77741769	0.571	rs3809313	chr12:121329967	T/C	cg02419362	chr12:121203948	SPPL3	0.41	8.27	0.37	1.71e-15	Mean corpuscular volume;
LUAD	cis	rs847851	1.000	rs2473615	chr6:34893910	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.3	-6.65	-0.31	9.09e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4372836	0.729	rs4611608	chr2:29064536	A/G	cg09522027	chr2:28974177	PPP1CB	0.7	12.62	0.52	3.38e-31	Body mass index;
LUAD	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg11189052	chr15:85197271	WDR73	-0.71	-11.82	-0.5	4.89e-28	P wave terminal force;
LUAD	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22590775	chr19:49891494	CCDC155	0.61	8.81	0.39	3.3e-17	Multiple sclerosis;
LUAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.07e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs3820068	0.608	rs11544523	chr1:15904318	C/T	cg13390004	chr1:15929781	NA	0.42	6.69	0.31	7.26e-11	Systolic blood pressure;
LUAD	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg25358565	chr5:93447407	FAM172A	-0.66	-7.82	-0.36	4.33e-14	Diabetic retinopathy;
LUAD	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg25173405	chr17:45401733	C17orf57	0.56	9.17	0.41	2.17e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2625529	0.668	rs34189331	chr15:72404573	A/T	cg16672083	chr15:72433130	SENP8	-0.72	-12.52	-0.52	7.94e-31	Red blood cell count;
LUAD	cis	rs4072705	1.000	rs4838201	chr9:127460617	C/T	cg13476313	chr9:127244764	NR5A1	0.32	7.6	0.35	1.88e-13	Menarche (age at onset);
LUAD	cis	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg26587870	chr6:27730563	NA	-0.59	-6.5	-0.3	2.23e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg06641503	chr3:48959341	ARIH2	-0.4	-7.69	-0.35	1.06e-13	Parkinson's disease;
LUAD	cis	rs7197653	0.667	rs12599876	chr16:68393405	C/T	cg09835421	chr16:68378352	PRMT7	-1.02	-11.1	-0.47	2.75e-25	Magnesium levels;
LUAD	cis	rs8040855	0.559	rs6496801	chr15:85728399	G/A	cg04831495	chr15:85060580	GOLGA6L5	0.46	7.24	0.33	2.12e-12	Bulimia nervosa;
LUAD	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg07967210	chr17:47022446	SNF8	0.35	6.38	0.3	4.54e-10	Type 2 diabetes;
LUAD	cis	rs12579753	0.827	rs7311917	chr12:82187551	G/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.35	-0.34	1.02e-12	Resting heart rate;
LUAD	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.36	0.38	9.48e-16	Breast cancer;
LUAD	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg12483005	chr1:23474871	LUZP1	-0.53	-8.99	-0.4	8.25e-18	Height;
LUAD	cis	rs4795519	0.922	rs8076631	chr17:22172118	C/T	cg22648282	chr17:21454238	C17orf51	-0.38	-6.58	-0.3	1.38e-10	Chronic myeloid leukemia;
LUAD	trans	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg06606381	chr12:133084897	FBRSL1	-1.12	-10.31	-0.45	2.2e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4790333	1.000	rs4790333	chr17:2262703	A/G	cg27406664	chr17:2294951	MNT	-0.4	-8.0	-0.36	1.23e-14	Proinsulin levels;
LUAD	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg17644776	chr2:200775616	C2orf69	-0.53	-7.45	-0.34	5.35e-13	Schizophrenia;
LUAD	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg27489772	chr12:121021490	NA	0.55	6.94	0.32	1.48e-11	Type 1 diabetes nephropathy;
LUAD	cis	rs7809950	0.648	rs114452520	chr7:107176780	C/T	cg23024343	chr7:107201750	COG5	-0.74	-12.49	-0.52	1.06e-30	Coronary artery disease;
LUAD	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg10295955	chr4:187884368	NA	-1.11	-24.07	-0.76	2.87e-81	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.49	-0.34	4.05e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs1832871	0.711	rs9459904	chr6:158700982	C/T	cg07165851	chr6:158734300	TULP4	0.7	10.89	0.47	1.58e-24	Height;
LUAD	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18876405	chr7:65276391	NA	-0.53	-9.21	-0.41	1.49e-18	Aortic root size;
LUAD	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg15790184	chr11:494944	RNH1	0.56	6.88	0.32	2.11e-11	Body mass index;
LUAD	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg00310523	chr12:86230176	RASSF9	0.39	7.77	0.35	5.93e-14	Major depressive disorder;
LUAD	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg11663144	chr21:46675770	NA	-0.6	-11.83	-0.5	4.19e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg23625390	chr15:77176239	SCAPER	0.4	6.99	0.32	1.11e-11	Blood metabolite levels;
LUAD	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.7	0.31	6.5500000000000006e-11	Menarche (age at onset);
LUAD	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg03609598	chr5:56110824	MAP3K1	-0.67	-9.03	-0.4	6.19e-18	Initial pursuit acceleration;
LUAD	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg12288994	chr5:1860383	NA	0.27	6.45	0.3	3.04e-10	Cardiovascular disease risk factors;
LUAD	cis	rs1594829	0.553	rs2046224	chr8:26151604	G/T	cg13160058	chr8:26243215	BNIP3L	-0.34	-7.39	-0.34	7.77e-13	Height;
LUAD	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg10553204	chr2:20871195	GDF7	-0.39	-6.69	-0.31	7.18e-11	Abdominal aortic aneurysm;
LUAD	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg06360820	chr2:242988706	NA	-0.97	-13.16	-0.54	2.07e-33	Obesity-related traits;
LUAD	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg08422745	chr4:174089978	GALNT7	-0.95	-18.43	-0.67	4.23e-56	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs12519773	0.502	rs4613686	chr5:92498497	A/G	cg18783429	chr5:92414398	NA	0.38	6.81	0.31	3.27e-11	Migraine;
LUAD	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg12365402	chr11:9010492	NRIP3	-0.52	-10.51	-0.46	4.15e-23	Hemoglobin concentration;
LUAD	cis	rs7524258	0.900	rs7514988	chr1:7271651	C/T	cg07173049	chr1:7289937	CAMTA1	0.4	7.47	0.34	4.64e-13	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs71478720	0.953	rs4988359	chr11:112025915	T/C	cg26534425	chr11:112034925	IL18	0.47	7.12	0.33	4.76e-12	Interleukin-18 levels;
LUAD	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.34	7.07	0.32	6.58e-12	Menopause (age at onset);
LUAD	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg21475434	chr5:93447410	FAM172A	0.8	8.9	0.4	1.62e-17	Diabetic retinopathy;
LUAD	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg21427119	chr20:30132790	HM13	-0.64	-9.53	-0.42	1.28e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.2	-0.41	1.65e-18	Total body bone mineral density;
LUAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg17178900	chr1:205818956	PM20D1	0.74	15.33	0.6	1.65e-42	Menarche (age at onset);
LUAD	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg10356904	chr22:49881777	NA	-0.41	-8.08	-0.37	6.61e-15	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg15704280	chr7:45808275	SEPT13	-1.05	-23.63	-0.75	2.46e-79	Height;
LUAD	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg08470875	chr2:26401718	FAM59B	0.77	10.3	0.45	2.39e-22	Gut microbiome composition (summer);
LUAD	trans	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.26	-0.37	1.93e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17641971	0.645	rs4873099	chr8:50025683	G/T	cg00325661	chr8:49890786	NA	0.3	6.75	0.31	5.04e-11	Blood metabolite levels;
LUAD	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg08742575	chr21:47604166	C21orf56	0.49	7.98	0.36	1.35e-14	Testicular germ cell tumor;
LUAD	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg19302996	chr17:73780495	UNK	0.39	6.45	0.3	3.15e-10	White matter hyperintensity burden;
LUAD	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg17971929	chr21:40555470	PSMG1	0.54	8.13	0.37	4.67e-15	Cognitive function;
LUAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg00080972	chr5:178986291	RUFY1	0.65	11.88	0.5	2.83e-28	Lung cancer;
LUAD	cis	rs912057	0.965	rs1294415	chr6:6740633	G/A	cg06612196	chr6:6737390	NA	0.56	12.62	0.52	3.2e-31	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs9296092	0.538	rs34222093	chr6:33519584	G/C	cg13560919	chr6:33536144	NA	-0.89	-16.71	-0.63	1.64e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg25753631	chr6:25732923	NA	-0.37	-6.43	-0.3	3.49e-10	Iron status biomarkers;
LUAD	cis	rs877282	0.945	rs17293517	chr10:778770	C/T	cg06581033	chr10:766294	NA	-0.58	-7.89	-0.36	2.69e-14	Uric acid levels;
LUAD	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg00933542	chr6:150070202	PCMT1	0.44	9.21	0.41	1.58e-18	Lung cancer;
LUAD	cis	rs10795433	0.630	rs3858184	chr10:16968785	A/G	cg00939682	chr10:16933505	CUBN	0.5	7.11	0.33	4.84e-12	Urinary albumin-to-creatinine ratio;Microalbuminuria;
LUAD	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.75	-0.35	7.13e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg09137382	chr11:130731461	NA	0.4	7.43	0.34	6.19e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg11941060	chr3:133502564	NA	-0.69	-12.91	-0.53	2.22e-32	Iron status biomarkers;
LUAD	trans	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg11693508	chr17:37793320	STARD3	0.52	7.58	0.35	2.18e-13	Neuroticism;
LUAD	trans	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg13722127	chr7:150037890	RARRES2	0.47	8.47	0.38	4.13e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.05e-19	Life satisfaction;
LUAD	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg00316803	chr15:76480434	C15orf27	-0.4	-7.52	-0.34	3.29e-13	Blood metabolite levels;
LUAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.85	0.56	3.1e-36	Prudent dietary pattern;
LUAD	cis	rs6594713	0.885	rs6594716	chr5:112745118	G/A	cg12552261	chr5:112820674	MCC	0.55	8.56	0.38	2.09e-16	Brain cytoarchitecture;
LUAD	cis	rs9902453	0.845	rs3102556	chr17:28042542	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.37	0.41	4.35e-19	Coffee consumption (cups per day);
LUAD	cis	rs11809207	0.723	rs57653638	chr1:26524401	A/G	cg00147160	chr1:26503991	CNKSR1	0.44	8.82	0.39	3.03e-17	Height;
LUAD	cis	rs12530845	0.832	rs56306315	chr7:135329107	C/T	cg23117316	chr7:135346802	PL-5283	-0.5	-9.3	-0.41	7.55e-19	Red blood cell traits;
LUAD	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg26384229	chr12:38710491	ALG10B	-0.38	-6.51	-0.3	2.19e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg26408565	chr15:76604113	ETFA	-0.43	-7.02	-0.32	9.11e-12	Blood metabolite levels;
LUAD	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg06558623	chr16:89946397	TCF25	1.17	10.78	0.46	4.32e-24	Skin colour saturation;
LUAD	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg05283184	chr6:79620031	NA	-0.45	-7.81	-0.35	4.68e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.45	-7.46	-0.34	4.81e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg24558204	chr6:135376177	HBS1L	0.48	8.13	0.37	4.76e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg26384229	chr12:38710491	ALG10B	-0.47	-7.5	-0.34	3.76e-13	Heart rate;
LUAD	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg27446573	chr6:127587934	RNF146	0.44	6.55	0.3	1.72e-10	Breast cancer;
LUAD	cis	rs4006360	0.646	rs7501601	chr17:39293957	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.36	7.85	0.36	3.54e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs7705042	0.865	rs6863411	chr5:141513204	A/T	cg23435118	chr5:141488016	NDFIP1	-0.4	-7.1	-0.33	5.35e-12	Asthma;
LUAD	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.26	0.33	1.82e-12	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.89	0.53	2.7e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg20991723	chr1:152506922	NA	0.32	6.43	0.3	3.42e-10	Hair morphology;
LUAD	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.76	-0.35	6.56e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12367572	1.000	rs10880704	chr12:45318430	C/T	cg04608330	chr12:45269318	NELL2	-0.39	-7.22	-0.33	2.42e-12	Gut microbiome composition (summer);
LUAD	cis	rs9487051	0.768	rs442405	chr6:109526980	T/G	cg21918786	chr6:109611834	NA	-0.41	-7.11	-0.33	5.07e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg05368731	chr17:41323189	NBR1	0.96	19.54	0.69	4.53e-61	Menopause (age at onset);
LUAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg24642844	chr7:1081250	C7orf50	-0.96	-14.39	-0.57	1.62e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg14784868	chr12:69753453	YEATS4	0.46	7.58	0.35	2.25e-13	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.28	-0.57	5.01e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4523957	0.583	rs2760739	chr17:2024217	C/T	cg16513277	chr17:2031491	SMG6	-0.95	-19.14	-0.68	2.98e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg23068057	chr6:136611228	BCLAF1	0.36	6.41	0.3	3.97e-10	Bipolar disorder;
LUAD	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg19622623	chr12:86230825	RASSF9	-0.55	-9.88	-0.43	7.47e-21	Major depressive disorder;
LUAD	cis	rs354225	0.584	rs10188545	chr2:54831875	A/G	cg01766943	chr2:54829624	SPTBN1	0.39	7.16	0.33	3.5e-12	Schizophrenia;
LUAD	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24308560	chr3:49941425	MST1R	0.56	9.54	0.42	1.19e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	12.26	0.51	9.09e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg19622623	chr12:86230825	RASSF9	0.43	7.59	0.35	2e-13	Major depressive disorder;
LUAD	trans	rs11650494	0.908	rs74830554	chr17:47431950	G/A	cg11430096	chr6:110968061	CDK19	0.86	6.55	0.3	1.63e-10	Prostate cancer;
LUAD	cis	rs6993813	0.786	rs6469797	chr8:120018159	C/T	cg01975934	chr8:119970761	NA	-0.37	-7.21	-0.33	2.52e-12	Bone mineral density (hip);
LUAD	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg06108461	chr20:60628389	TAF4	-0.96	-17.35	-0.64	2.55e-51	Body mass index;
LUAD	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg13012494	chr21:47604986	C21orf56	-0.43	-6.71	-0.31	6.28e-11	Testicular germ cell tumor;
LUAD	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg22920501	chr2:26401640	FAM59B	-0.73	-10.49	-0.45	4.71e-23	Gut microbiome composition (summer);
LUAD	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg13390004	chr1:15929781	NA	0.49	8.6	0.39	1.6e-16	Systolic blood pressure;
LUAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12379764	chr21:47803548	PCNT	-0.44	-7.24	-0.33	2.1e-12	Testicular germ cell tumor;
LUAD	cis	rs2637266	0.783	rs58247832	chr10:78471383	C/A	cg18941641	chr10:78392320	NA	0.32	6.79	0.31	3.77e-11	Pulmonary function;
LUAD	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg26513180	chr16:89883248	FANCA	0.84	7.36	0.34	9.58e-13	Skin colour saturation;
LUAD	cis	rs698833	0.828	rs6705951	chr2:44534012	A/C	cg04920474	chr2:44395004	PPM1B	0.41	7.51	0.34	3.58e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs7264396	0.616	rs6060744	chr20:34581555	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-6.69	-0.31	7.14e-11	Total cholesterol levels;
LUAD	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	7.29	0.33	1.51e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs6840360	0.571	rs4696272	chr4:152528229	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.68	-0.31	7.66e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg02574844	chr11:5959923	NA	0.38	6.38	0.3	4.6e-10	DNA methylation (variation);
LUAD	trans	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg06606381	chr12:133084897	FBRSL1	-0.85	-8.36	-0.38	9.1e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs2839627	0.638	rs7276320	chr21:44269588	A/G	cg03543861	chr21:44258195	NA	-0.6	-8.17	-0.37	3.64e-15	Information processing speed;
LUAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.5	-9.64	-0.42	5.18e-20	Longevity;Endometriosis;
LUAD	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg19761014	chr17:28927070	LRRC37B2	0.73	6.64	0.31	9.82e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg03609598	chr5:56110824	MAP3K1	-0.68	-9.22	-0.41	1.44e-18	Initial pursuit acceleration;
LUAD	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg22823121	chr1:150693482	HORMAD1	0.39	7.61	0.35	1.81e-13	Melanoma;
LUAD	cis	rs9814567	0.964	rs6805388	chr3:134173534	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-13.91	-0.56	1.74e-36	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs897984	0.542	rs7294	chr16:31102321	A/G	cg02466173	chr16:30829666	NA	0.53	9.02	0.4	6.79e-18	Dementia with Lewy bodies;
LUAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg11062466	chr8:58055876	NA	0.45	6.45	0.3	3.04e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs225245	0.817	rs2301730	chr17:33998683	A/G	cg05299278	chr17:33885742	SLFN14	0.5	11.35	0.48	3.09e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs9581857	0.547	rs75800999	chr13:28055293	A/G	cg22138327	chr13:27999177	GTF3A	0.84	9.18	0.41	1.93e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg12564285	chr5:131593104	PDLIM4	0.39	6.72	0.31	5.94e-11	Breast cancer;
LUAD	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg06784218	chr1:46089804	CCDC17	-0.51	-11.31	-0.48	4.16e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9747201	0.963	rs9747989	chr17:80176092	A/G	cg18209359	chr17:80159595	CCDC57	-0.38	-6.62	-0.31	1.06e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg27631724	chr1:11040367	C1orf127	0.53	8.98	0.4	8.82e-18	Ewing sarcoma;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg15804432	chr15:64454965	PPIB	-0.69	-6.47	-0.3	2.72e-10	Type 2 diabetes;
LUAD	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg06784218	chr1:46089804	CCDC17	0.51	11.23	0.48	8.7e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg07636037	chr3:49044803	WDR6	0.52	9.32	0.41	6.52e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs939584	1.000	rs6739303	chr2:628749	C/T	cg03444855	chr2:621920	NA	-0.42	-6.69	-0.31	7.27e-11	Body mass index;
LUAD	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg21471580	chr8:22132874	PIWIL2	-0.45	-7.96	-0.36	1.64e-14	Hypertriglyceridemia;
LUAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13126279	chr21:47581558	C21orf56	0.62	11.29	0.48	4.94e-26	Testicular germ cell tumor;
LUAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-9.75	-0.43	2.17e-20	Longevity;Endometriosis;
LUAD	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg22875332	chr1:76189707	ACADM	0.8	13.39	0.55	2.55e-34	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.53	0.38	2.64e-16	Breast cancer;
LUAD	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg17200465	chr3:40428508	ENTPD3	-0.29	-6.95	-0.32	1.43e-11	Renal cell carcinoma;
LUAD	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg08085267	chr17:45401833	C17orf57	-0.58	-10.53	-0.46	3.5e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg15242686	chr22:24348715	GSTTP1	-0.42	-7.71	-0.35	9.06e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs28374715	0.662	rs72737786	chr15:41500361	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.89	-16.54	-0.63	9.43e-48	Ulcerative colitis;
LUAD	trans	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg14917512	chr19:3094685	GNA11	0.58	6.9	0.32	1.86e-11	Gout;
LUAD	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.14	-0.64	2.18e-50	Height;
LUAD	cis	rs10493773	1.000	rs10493773	chr1:86125753	C/T	cg17807903	chr1:86174739	ZNHIT6	0.55	9.22	0.41	1.41e-18	Urate levels in overweight individuals;
LUAD	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg09796270	chr17:17721594	SREBF1	-0.39	-7.65	-0.35	1.36e-13	Total body bone mineral density;
LUAD	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05776053	chr2:74358815	NA	0.44	6.92	0.32	1.67e-11	Gestational age at birth (maternal effect);
LUAD	cis	rs2224391	1.000	rs2773320	chr6:5261681	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-9.77	-0.43	1.82e-20	Height;
LUAD	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.66	0.31	8.43e-11	Colorectal cancer;
LUAD	cis	rs9900062	1.000	rs2521879	chr17:62742678	A/G	cg02097616	chr17:62675921	NA	0.6	8.44	0.38	5.14e-16	QT interval;
LUAD	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.36	-0.57	2.28e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs3125734	0.633	rs10740068	chr10:63982254	A/C	cg19640130	chr10:64028056	RTKN2	-0.34	-7.2	-0.33	2.74e-12	Rheumatoid arthritis;
LUAD	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg15181151	chr6:150070149	PCMT1	0.38	7.65	0.35	1.33e-13	Lung cancer;
LUAD	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg20933634	chr6:27740509	NA	0.45	7.12	0.33	4.68e-12	Parkinson's disease;
LUAD	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg19163074	chr7:65112434	INTS4L2	0.44	6.95	0.32	1.38e-11	Aortic root size;
LUAD	cis	rs7614311	0.681	rs73117042	chr3:63896543	T/C	cg22134162	chr3:63841271	THOC7	-0.52	-8.65	-0.39	1.08e-16	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg13047869	chr3:10149882	C3orf24	0.66	11.09	0.47	2.88e-25	Alzheimer's disease;
LUAD	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg02773041	chr1:40204384	PPIE	0.52	8.54	0.38	2.52e-16	Blood protein levels;
LUAD	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11644478	chr21:40555479	PSMG1	-0.64	-10.56	-0.46	2.69e-23	Cognitive function;
LUAD	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	15.35	0.6	1.41e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs62400317	0.859	rs12214749	chr6:45307906	A/G	cg20913747	chr6:44695427	NA	-0.41	-6.69	-0.31	7.21e-11	Total body bone mineral density;
LUAD	cis	rs9399401	0.710	rs10484733	chr6:142710988	C/G	cg04461802	chr6:142623433	GPR126	0.46	8.62	0.39	1.34e-16	Chronic obstructive pulmonary disease;
LUAD	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.31	0.34	1.32e-12	Electroencephalogram traits;
LUAD	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.21e-16	Prostate cancer;
LUAD	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg15467112	chr14:75489610	MLH3	-0.35	-6.51	-0.3	2.1e-10	Height;
LUAD	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg08470875	chr2:26401718	FAM59B	0.76	9.99	0.44	2.96e-21	Gut microbiome composition (summer);
LUAD	cis	rs4889911	0.544	rs2650254	chr17:77833655	A/G	cg02876276	chr17:77834299	NA	0.51	7.56	0.34	2.61e-13	Electroencephalogram traits;
LUAD	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg03983476	chr2:10830698	NOL10	-0.46	-8.08	-0.37	6.83e-15	Prostate cancer;
LUAD	trans	rs208520	0.633	rs79679034	chr6:66701724	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.06	18.88	0.68	4.09e-58	Exhaled nitric oxide output;
LUAD	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg26513180	chr16:89883248	FANCA	0.44	6.94	0.32	1.48e-11	Vitiligo;
LUAD	cis	rs7582720	0.943	rs72936839	chr2:203773237	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg02782426	chr3:40428986	ENTPD3	0.43	9.51	0.42	1.42e-19	Renal cell carcinoma;
LUAD	cis	rs9522267	0.737	rs12429582	chr13:112226657	A/G	cg10483660	chr13:112241077	NA	-0.31	-6.53	-0.3	1.88e-10	Hepatitis;
LUAD	trans	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg04995722	chr7:26192034	NFE2L3	-0.44	-7.53	-0.34	3.2e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs829883	0.646	rs1641638	chr12:98891031	A/G	cg25150519	chr12:98850993	NA	0.43	7.02	0.32	9.05e-12	Colorectal adenoma (advanced);
LUAD	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.82	0.31	3.12e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.42	-7.61	-0.35	1.84e-13	Tonsillectomy;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg22114827	chr17:4852349	PFN1	-0.38	-6.43	-0.3	3.42e-10	Schizophrenia;
LUAD	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg10356904	chr22:49881777	NA	-0.38	-7.65	-0.35	1.38e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg14324370	chr2:177042789	NA	0.41	7.77	0.35	5.96e-14	IgG glycosylation;
LUAD	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg21016266	chr12:122356598	WDR66	-0.66	-12.35	-0.51	4.08e-30	Mean corpuscular volume;
LUAD	cis	rs10992471	0.835	rs12686606	chr9:95563128	A/G	cg14631576	chr9:95140430	CENPP	0.38	7.66	0.35	1.27e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg06740227	chr12:86229804	RASSF9	0.46	7.94	0.36	1.78e-14	Major depressive disorder;
LUAD	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg23887609	chr12:130822674	PIWIL1	0.41	6.81	0.31	3.43e-11	Menopause (age at onset);
LUAD	cis	rs295140	0.605	rs296818	chr2:201176944	C/T	cg23649088	chr2:200775458	C2orf69	0.47	8.24	0.37	2.18e-15	QT interval;
LUAD	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	trans	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg13565492	chr6:43139072	SRF	-0.6	-6.37	-0.3	4.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.39	6.36	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs12537011	chr7:107027833	G/A	cg02696742	chr7:106810147	HBP1	-0.8	-10.68	-0.46	9.46e-24	Coronary artery disease;
LUAD	cis	rs7737355	1.000	rs257389	chr5:130744263	A/C	cg06307176	chr5:131281290	NA	-0.41	-6.91	-0.32	1.78e-11	Life satisfaction;
LUAD	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg09658497	chr7:2847517	GNA12	-0.46	-7.78	-0.35	5.7e-14	Height;
LUAD	trans	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg19862616	chr7:65841803	NCRNA00174	1.02	25.14	0.77	5.37e-86	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg00277334	chr10:82204260	NA	-0.64	-10.33	-0.45	1.83e-22	Post bronchodilator FEV1;
LUAD	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg00310523	chr12:86230176	RASSF9	0.4	7.85	0.36	3.35e-14	Major depressive disorder;
LUAD	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg00316803	chr15:76480434	C15orf27	0.44	8.44	0.38	5.06e-16	Blood metabolite levels;
LUAD	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg18721089	chr20:30220636	NA	-0.43	-6.48	-0.3	2.51e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.61	-0.31	1.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg08132940	chr7:1081526	C7orf50	-0.78	-10.55	-0.46	2.93e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg22683308	chr4:1340831	KIAA1530	-0.44	-7.41	-0.34	6.72e-13	Longevity;
LUAD	cis	rs750460	1.000	rs12441130	chr15:74234902	T/C	cg23484268	chr15:74220776	LOXL1	-0.34	-6.57	-0.3	1.49e-10	Height;
LUAD	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg02903104	chr8:1507517	DLGAP2	-0.31	-6.71	-0.31	6.14e-11	Lung cancer;
LUAD	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg11901034	chr3:128598214	ACAD9	-0.44	-6.53	-0.3	1.91e-10	IgG glycosylation;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg23104823	chr14:45553408	PRPF39	0.4	6.64	0.31	9.42e-11	Bilirubin levels;
LUAD	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg22029157	chr1:209979665	IRF6	0.79	11.52	0.49	6.57e-27	Cleft lip with or without cleft palate;
LUAD	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg01849466	chr14:104193079	ZFYVE21	0.44	7.4	0.34	7.5e-13	Body mass index;
LUAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg02524346	chr8:600233	NA	1.02	9.89	0.43	7.04e-21	IgG glycosylation;
LUAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg07362569	chr17:61921086	SMARCD2	-0.38	-6.49	-0.3	2.41e-10	Prudent dietary pattern;
LUAD	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg07636037	chr3:49044803	WDR6	0.58	10.75	0.46	5.61e-24	Parkinson's disease;
LUAD	cis	rs3849570	0.695	rs6809528	chr3:81872048	A/C	cg07356753	chr3:81810745	GBE1	-0.51	-8.23	-0.37	2.39e-15	Waist circumference;Body mass index;
LUAD	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg12311346	chr5:56204834	C5orf35	-0.43	-7.14	-0.33	4.21e-12	Coronary artery disease;
LUAD	cis	rs2274273	0.870	rs11625423	chr14:55795913	G/A	cg04306507	chr14:55594613	LGALS3	0.43	9.04	0.4	5.71e-18	Protein biomarker;
LUAD	cis	rs2281845	0.859	rs4915217	chr1:201077470	T/A	cg22815214	chr1:201083145	CACNA1S	0.55	9.28	0.41	9.1e-19	Permanent tooth development;
LUAD	trans	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg07923666	chr12:49932857	KCNH3	-0.53	-7.01	-0.32	9.36e-12	Resting heart rate;
LUAD	cis	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg07460842	chr6:66804631	NA	0.59	9.25	0.41	1.09e-18	Type 2 diabetes;
LUAD	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg15147215	chr3:52552868	STAB1	-0.4	-7.48	-0.34	4.38e-13	Electroencephalogram traits;
LUAD	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg11822812	chr5:140052017	DND1	0.38	6.96	0.32	1.28e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg01017244	chr2:74357527	NA	0.93	13.37	0.54	3.01e-34	Gestational age at birth (maternal effect);
LUAD	cis	rs123509	0.863	rs339662	chr3:42752093	T/C	cg10144569	chr3:42726640	KBTBD5	0.48	7.28	0.33	1.63e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs8099014	1.000	rs2002088	chr18:56132725	G/A	cg12907477	chr18:56117327	MIR122	0.38	6.46	0.3	2.84e-10	Platelet count;
LUAD	trans	rs8002861	0.664	rs9533686	chr13:44468494	A/G	cg17145862	chr1:211918768	LPGAT1	0.64	13.22	0.54	1.17e-33	Leprosy;
LUAD	cis	rs4523957	0.928	rs216204	chr17:2196659	G/A	cg16513277	chr17:2031491	SMG6	0.76	14.33	0.57	3.07e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	14.58	0.58	2.69e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg17105886	chr17:28927953	LRRC37B2	0.73	6.7	0.31	6.69e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs868036	1.000	rs6494694	chr15:68057142	A/C	cg24579218	chr15:68104479	NA	0.37	6.9	0.32	1.85e-11	Restless legs syndrome;
LUAD	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg13393036	chr8:95962371	TP53INP1	-0.4	-9.47	-0.42	1.97e-19	Type 2 diabetes;
LUAD	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg12573674	chr2:1569213	NA	-0.6	-8.67	-0.39	9e-17	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg10518543	chr12:38710700	ALG10B	-0.51	-8.28	-0.37	1.69e-15	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1018836	0.665	rs7000724	chr8:91516335	A/T	cg16814680	chr8:91681699	NA	-0.65	-10.9	-0.47	1.49e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg18306943	chr3:40428807	ENTPD3	0.37	6.54	0.3	1.75e-10	Renal cell carcinoma;
LUAD	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	8.49	0.38	3.5e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg08885076	chr2:99613938	TSGA10	0.37	6.77	0.31	4.38e-11	Chronic sinus infection;
LUAD	cis	rs2657888	1.000	rs2657888	chr12:56938383	A/C	cg23002907	chr12:56915593	RBMS2	0.35	6.59	0.31	1.28e-10	Adiponectin levels;
LUAD	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg15704280	chr7:45808275	SEPT13	0.66	8.86	0.4	2.21e-17	Axial length;
LUAD	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg26875233	chr11:93583750	C11orf90	-0.39	-8.86	-0.4	2.23e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg02049041	chr17:27085579	C17orf63	0.65	8.54	0.38	2.37e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg13385794	chr1:248469461	NA	0.25	6.46	0.3	2.84e-10	Common traits (Other);
LUAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13012494	chr21:47604986	C21orf56	0.69	11.86	0.5	3.31e-28	Testicular germ cell tumor;
LUAD	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg05872129	chr22:39784769	NA	-0.79	-15.12	-0.59	1.37e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs9914988	0.559	rs1109024	chr17:27189971	C/T	cg20469991	chr17:27169893	C17orf63	0.51	6.65	0.31	8.82e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs490234	0.586	rs12553548	chr9:128155261	T/G	cg14078157	chr9:128172775	NA	-0.46	-8.79	-0.39	3.84e-17	Mean arterial pressure;
LUAD	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg06784218	chr1:46089804	CCDC17	-0.6	-13.55	-0.55	5.61e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg18132916	chr6:79620363	NA	-0.47	-8.09	-0.37	6.23e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs216205	0.547	rs2641431	chr17:2030507	C/G	cg16513277	chr17:2031491	SMG6	-0.84	-12.4	-0.52	2.57e-30	Mitral valve prolapse;
LUAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	3.98e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg18932078	chr1:2524107	MMEL1	-0.37	-6.95	-0.32	1.37e-11	Ulcerative colitis;
LUAD	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg07917127	chr4:99064746	C4orf37	0.43	6.6	0.31	1.23e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg23719950	chr11:63933701	MACROD1	-0.58	-7.05	-0.32	7.4e-12	Mean platelet volume;
LUAD	cis	rs9807989	0.507	rs4851004	chr2:103009537	A/G	cg03938978	chr2:103052716	IL18RAP	-0.43	-9.96	-0.44	3.88e-21	Asthma;
LUAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg00280220	chr17:61926910	NA	0.36	6.95	0.32	1.37e-11	Prudent dietary pattern;
LUAD	cis	rs36051895	0.695	rs7043489	chr9:5023604	A/C	cg02405213	chr9:5042618	JAK2	-0.44	-6.57	-0.3	1.52e-10	Pediatric autoimmune diseases;
LUAD	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg19761014	chr17:28927070	LRRC37B2	0.82	8.28	0.37	1.6e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs12765878	1.000	rs10883942	chr10:105651386	A/G	cg11005552	chr10:105648138	OBFC1	0.44	8.38	0.38	7.89e-16	Coronary artery disease;
LUAD	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg14092988	chr3:52407081	DNAH1	0.41	8.26	0.37	1.88e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-8.01	-0.36	1.15e-14	Insulin-like growth factors;
LUAD	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg13319975	chr6:146136371	FBXO30	-0.61	-10.3	-0.45	2.48e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.54	7.81	0.35	4.66e-14	Gut microbiome composition (summer);
LUAD	cis	rs3733418	0.858	rs11100583	chr4:165877645	C/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.55	-7.42	-0.34	6.37e-13	Obesity-related traits;
LUAD	cis	rs4285028	0.580	rs1523519	chr3:121631841	C/T	cg11130432	chr3:121712080	ILDR1	-0.43	-6.71	-0.31	6.35e-11	Multiple sclerosis;
LUAD	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg26384229	chr12:38710491	ALG10B	-0.38	-6.54	-0.3	1.78e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg24558204	chr6:135376177	HBS1L	0.46	8.56	0.38	2.1e-16	Red blood cell count;
LUAD	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.84	-0.39	2.55e-17	Total body bone mineral density;
LUAD	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg20503657	chr10:835505	NA	0.84	12.93	0.53	1.88e-32	Eosinophil percentage of granulocytes;
LUAD	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.38	6.76	0.31	4.72e-11	Blood metabolite levels;
LUAD	cis	rs990171	0.538	rs4851012	chr2:103115915	A/G	cg03938978	chr2:103052716	IL18RAP	-0.33	-6.44	-0.3	3.31e-10	Lymphocyte counts;
LUAD	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg06074448	chr4:187884817	NA	-0.42	-8.73	-0.39	5.73e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg00750074	chr16:89608354	SPG7	-0.6	-10.37	-0.45	1.31e-22	Multiple myeloma (IgH translocation);
LUAD	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs999737	0.778	rs11624097	chr14:68986036	A/T	cg04147497	chr14:69052728	RAD51L1	-0.46	-6.98	-0.32	1.16e-11	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.4	-11.06	-0.47	3.77e-25	Total body bone mineral density;
LUAD	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg05714579	chr10:131428358	MGMT	-0.39	-6.49	-0.3	2.47e-10	Response to temozolomide;
LUAD	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.81	-0.5	5.17e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg12667521	chr19:29218732	NA	0.51	7.18	0.33	3.26e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.9	9.55	0.42	1.06e-19	Initial pursuit acceleration;
LUAD	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg09835421	chr16:68378352	PRMT7	-0.77	-8.23	-0.37	2.36e-15	HDL cholesterol;
LUAD	trans	rs10838798	0.563	rs2870080	chr11:48144224	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.48	-0.34	4.23e-13	Height;
LUAD	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg01324343	chr3:183735012	ABCC5	0.96	25.62	0.78	4.41e-88	Anterior chamber depth;
LUAD	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-20.08	-0.7	1.74e-63	Coronary artery disease;
LUAD	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg05991184	chr2:219186017	PNKD	0.37	7.02	0.32	8.88e-12	Colorectal cancer;
LUAD	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg05872129	chr22:39784769	NA	0.52	9.07	0.4	4.66e-18	IgG glycosylation;
LUAD	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg12310025	chr6:25882481	NA	-0.48	-7.18	-0.33	3.08e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9462027	0.628	rs2764207	chr6:34712998	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.04	-0.4	5.87e-18	Systemic lupus erythematosus;
LUAD	cis	rs12760731	0.565	rs12036491	chr1:178163651	C/A	cg00404053	chr1:178313656	RASAL2	0.73	9.11	0.41	3.27e-18	Obesity-related traits;
LUAD	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg06191203	chr2:152266755	RIF1	0.52	8.02	0.36	1.05e-14	Lung cancer;
LUAD	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg09359103	chr1:154839909	KCNN3	0.92	21.07	0.72	6.26e-68	Prostate cancer;
LUAD	cis	rs3204270	0.714	rs79243595	chr17:79681220	T/C	cg18367735	chr17:79674897	NA	0.54	6.79	0.31	3.89e-11	Dental caries;
LUAD	cis	rs2742234	0.915	rs2742233	chr10:43610558	C/T	cg02780029	chr10:43622663	RET	-0.42	-6.8	-0.31	3.66e-11	Hirschsprung disease;
LUAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg04025307	chr7:1156635	C7orf50	0.75	13.26	0.54	8.61e-34	Longevity;Endometriosis;
LUAD	cis	rs11771526	1.000	rs62457533	chr7:32355334	G/A	cg27532318	chr7:32358331	NA	0.72	8.27	0.37	1.73e-15	Body mass index;
LUAD	cis	rs7107174	1.000	rs2510047	chr11:77988668	C/T	cg02023728	chr11:77925099	USP35	-0.4	-6.7	-0.31	6.5500000000000006e-11	Testicular germ cell tumor;
LUAD	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21659725	chr3:3221576	CRBN	0.8	15.83	0.61	1.17e-44	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg23978390	chr7:1156363	C7orf50	0.43	6.72	0.31	5.8200000000000003e-11	Longevity;Endometriosis;
LUAD	cis	rs10254118	0.757	rs6467491	chr7:133138761	A/G	cg10665199	chr7:133106180	EXOC4	0.6	10.15	0.44	8.42e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs4853036	0.904	rs13015957	chr2:70032316	C/T	cg02498382	chr2:70120550	SNRNP27	-0.51	-7.79	-0.35	5.09e-14	Colorectal or endometrial cancer;
LUAD	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg02423579	chr7:2872169	GNA12	-0.57	-9.66	-0.43	4.41e-20	Height;
LUAD	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.53	0.3	1.9e-10	Parkinson's disease;
LUAD	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.39e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.56	-0.46	2.69e-23	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg18446336	chr7:2847575	GNA12	0.32	6.54	0.3	1.74e-10	Plateletcrit;
LUAD	cis	rs17401966	0.800	rs12725210	chr1:10416993	G/A	cg19773385	chr1:10388646	KIF1B	-0.4	-6.47	-0.3	2.64e-10	Hepatocellular carcinoma;
LUAD	trans	rs877282	0.700	rs816311	chr10:796490	C/A	cg22713356	chr15:30763199	NA	1.1	15.59	0.6	1.22e-43	Uric acid levels;
LUAD	cis	rs6496044	0.568	rs6496039	chr15:86061963	A/T	cg13263323	chr15:86062960	AKAP13	-0.58	-10.82	-0.47	3e-24	Interstitial lung disease;
LUAD	cis	rs6901250	0.851	rs168128	chr6:117166865	A/G	cg12892004	chr6:117198278	RFX6	-0.34	-7.08	-0.33	6.12e-12	C-reactive protein levels;
LUAD	cis	rs11031096	0.587	rs2920145	chr11:4070552	G/T	cg18678763	chr11:4115507	RRM1	0.38	6.93	0.32	1.61e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg13685833	chr1:53393034	SCP2	-0.46	-7.66	-0.35	1.3e-13	Monocyte count;
LUAD	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg13722127	chr7:150037890	RARRES2	0.4	6.47	0.3	2.64e-10	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26314531	chr2:26401878	FAM59B	-0.55	-7.71	-0.35	9.38e-14	Gut microbiome composition (summer);
LUAD	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg13334819	chr7:99746414	C7orf59	-0.64	-10.24	-0.45	4e-22	Coronary artery disease;
LUAD	cis	rs7917772	0.690	rs11191369	chr10:104457456	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-6.83	-0.31	3.06e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg10150615	chr22:24372951	LOC391322	-0.44	-7.24	-0.33	2.17e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23158103	chr7:148848205	ZNF398	0.64	11.83	0.5	4.49e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg20933634	chr6:27740509	NA	0.49	7.33	0.34	1.17e-12	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
LUAD	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg27535305	chr1:53392650	SCP2	-0.42	-8.63	-0.39	1.28e-16	Monocyte count;
LUAD	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg26384229	chr12:38710491	ALG10B	0.48	7.67	0.35	1.21e-13	Bladder cancer;
LUAD	cis	rs6867032	0.527	rs4975792	chr5:2010496	T/G	cg26168224	chr5:2018326	NA	0.47	9.19	0.41	1.73e-18	Gut microbiome composition (winter);
LUAD	cis	rs853679	0.760	rs9357067	chr6:28210293	C/G	cg16479474	chr6:28041457	NA	0.41	6.65	0.31	9.3e-11	Depression;
LUAD	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg22508957	chr16:3507546	NAT15	0.82	10.83	0.47	2.82e-24	Tuberculosis;
LUAD	cis	rs4253772	0.591	rs9615348	chr22:46729338	C/G	cg00784671	chr22:46762841	CELSR1	-0.63	-7.58	-0.35	2.16e-13	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg03929089	chr4:120376271	NA	-0.88	-16.94	-0.64	1.66e-49	Height;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg04139749	chr14:77786727	GSTZ1;POMT2	-0.74	-7.3	-0.33	1.41e-12	Type 2 diabetes;
LUAD	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg08125733	chr17:73851984	WBP2	0.61	8.96	0.4	1.07e-17	Psoriasis;
LUAD	cis	rs1816752	0.633	rs8002387	chr13:24990444	A/G	cg02811702	chr13:24901961	NA	0.44	7.51	0.34	3.59e-13	Obesity-related traits;
LUAD	cis	rs13333054	1.000	rs13333054	chr16:86011033	C/T	cg04454285	chr16:86016317	NA	0.42	6.76	0.31	4.65e-11	Multiple sclerosis;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg15209934	chr19:52800385	ZNF480	-0.4	-6.53	-0.3	1.91e-10	Schizophrenia;
LUAD	cis	rs4660214	0.666	rs11205828	chr1:39719346	C/T	cg27567593	chr1:39956653	BMP8A	0.34	6.76	0.31	4.6e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs476633	0.573	rs2099652	chr15:41528745	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.59	-10.77	-0.46	4.53e-24	Glomerular filtration rate (creatinine);
LUAD	cis	rs490234	0.683	rs9409281	chr9:128159171	C/G	cg14078157	chr9:128172775	NA	-0.45	-8.55	-0.38	2.26e-16	Mean arterial pressure;
LUAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg00684032	chr4:1343700	KIAA1530	0.39	6.62	0.31	1.11e-10	Obesity-related traits;
LUAD	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg01851573	chr8:8652454	MFHAS1	-0.38	-6.44	-0.3	3.17e-10	Mood instability;
LUAD	trans	rs747782	0.527	rs7129364	chr11:48150576	G/A	cg15704280	chr7:45808275	SEPT13	0.67	7.22	0.33	2.46e-12	Intraocular pressure;
LUAD	cis	rs10899021	0.704	rs11236177	chr11:74339067	T/C	cg25880958	chr11:74394337	NA	-0.59	-8.04	-0.36	8.92e-15	Response to metformin (IC50);
LUAD	cis	rs1032833	0.732	rs80238877	chr2:179959713	T/C	cg23883738	chr2:179974586	SESTD1	-0.72	-8.26	-0.37	1.9e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs9972944	0.756	rs4791132	chr17:63769124	T/C	cg07283582	chr17:63770753	CCDC46	-0.51	-11.6	-0.49	3.32e-27	Total body bone mineral density;
LUAD	trans	rs9354308	0.838	rs7769057	chr6:66540229	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.85	-0.32	2.62e-11	Metabolite levels;
LUAD	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg17063962	chr7:91808500	NA	-0.66	-11.23	-0.48	9e-26	Breast cancer;
LUAD	cis	rs600626	0.578	rs11821808	chr11:75451187	C/T	cg24262691	chr11:75473276	NA	0.57	7.97	0.36	1.53e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg23172400	chr8:95962367	TP53INP1	-0.35	-8.47	-0.38	4.07e-16	Type 2 diabetes;
LUAD	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.79	-0.35	5.27e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.65	-0.42	4.72e-20	Alzheimer's disease;
LUAD	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23583168	chr7:148888333	NA	-0.9	-18.36	-0.67	8.61e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs889398	0.770	rs8052225	chr16:69883653	G/A	cg00738113	chr16:70207722	CLEC18C	-0.35	-6.91	-0.32	1.75e-11	Body mass index;
LUAD	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.83	0.53	4.51e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg10544611	chr16:67998164	SLC12A4	-0.58	-7.23	-0.33	2.21e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg10862848	chr6:42927986	GNMT	-0.33	-9.4	-0.42	3.61e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs8177876	0.822	rs8177940	chr16:81117394	G/A	cg08591886	chr16:81111003	C16orf46	-0.79	-7.37	-0.34	8.94e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs1497828	0.956	rs2646814	chr1:217523440	A/G	cg04411442	chr1:217543379	NA	-0.36	-6.51	-0.3	2.16e-10	Dialysis-related mortality;
LUAD	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg16325326	chr1:53192061	ZYG11B	0.59	10.65	0.46	1.31e-23	Monocyte count;
LUAD	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg02896835	chr1:92012615	NA	-0.53	-10.41	-0.45	9.65e-23	Breast cancer;
LUAD	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24308560	chr3:49941425	MST1R	-0.57	-9.74	-0.43	2.4e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg00634984	chr7:65235879	NA	0.49	6.58	0.3	1.42e-10	Aortic root size;
LUAD	cis	rs9826463	0.582	rs7642634	chr3:142110818	T/C	cg20824294	chr3:142316082	PLS1	0.37	6.42	0.3	3.69e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg18538332	chr22:24372958	LOC391322	-0.54	-9.12	-0.41	3e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg12193833	chr17:30244370	NA	-0.6	-7.2	-0.33	2.78e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7089973	0.836	rs1966384	chr10:116627910	G/T	cg23260525	chr10:116636907	FAM160B1	0.43	9.63	0.42	5.44e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg12179176	chr11:130786555	SNX19	0.56	9.45	0.42	2.35e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg05887092	chr17:76393375	PGS1	0.41	7.37	0.34	9.19e-13	HDL cholesterol levels;
LUAD	trans	rs3857536	0.813	rs4710580	chr6:66935200	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg16205897	chr5:131564050	P4HA2	-0.35	-7.55	-0.34	2.71e-13	Acylcarnitine levels;
LUAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg02493798	chr17:6899577	ALOX12	0.37	6.89	0.32	1.99e-11	Tonsillectomy;
LUAD	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg13736514	chr6:26305472	NA	-0.69	-12.64	-0.52	2.69e-31	Educational attainment;
LUAD	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg11494091	chr17:61959527	GH2	0.4	7.06	0.32	6.68e-12	Height;
LUAD	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg21252483	chr19:49399788	TULP2	0.72	12.23	0.51	1.21e-29	Red cell distribution width;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20167264	chr10:75385394	NA	-0.4	-6.4	-0.3	4.09e-10	Height;
LUAD	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg14558114	chr2:88469736	THNSL2	0.86	9.28	0.41	9.13e-19	Plasma clusterin levels;
LUAD	trans	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg11693508	chr17:37793320	STARD3	0.55	7.66	0.35	1.32e-13	Bipolar disorder;
LUAD	cis	rs6489882	0.867	rs1859335	chr12:113367325	C/T	cg20102336	chr12:113376681	OAS3	-0.59	-9.08	-0.4	4.13e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs3813567	0.759	rs12594550	chr15:78959037	C/G	cg05914723	chr15:78953907	NA	-0.51	-7.13	-0.33	4.51e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg15105011	chr4:940614	TMEM175	0.56	8.82	0.39	3.11e-17	Sjögren's syndrome;
LUAD	cis	rs72949976	0.606	rs1922797	chr2:214027642	G/A	cg08319019	chr2:214017104	IKZF2	0.51	7.7	0.35	9.94e-14	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg14829155	chr15:31115871	NA	-0.58	-9.32	-0.41	6.33e-19	Huntington's disease progression;
LUAD	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg05340658	chr4:99064831	C4orf37	0.55	9.34	0.41	5.72e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg07432352	chr17:45403706	C17orf57	0.38	7.25	0.33	1.97e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25427524	chr10:38739819	LOC399744	0.71	12.54	0.52	6.54e-31	Extrinsic epigenetic age acceleration;
LUAD	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	9.05e-12	Aortic root size;
LUAD	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.44	0.3	3.28e-10	Depression;
LUAD	cis	rs6546550	0.935	rs1377995	chr2:70064155	C/G	cg02498382	chr2:70120550	SNRNP27	-0.56	-10.65	-0.46	1.26e-23	Prevalent atrial fibrillation;
LUAD	cis	rs7043114	0.544	rs7852510	chr9:95316359	T/G	cg14631576	chr9:95140430	CENPP	-0.39	-7.95	-0.36	1.71e-14	Height;
LUAD	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11644478	chr21:40555479	PSMG1	-0.42	-6.94	-0.32	1.45e-11	Menarche (age at onset);
LUAD	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.66	-0.43	4.48e-20	Schizophrenia;
LUAD	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02018176	chr4:1364513	KIAA1530	-0.64	-10.69	-0.46	8.99e-24	Longevity;
LUAD	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg19318889	chr4:1322082	MAEA	0.41	6.81	0.31	3.44e-11	Obesity-related traits;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg08809260	chr2:177054140	HOXD1	-0.49	-7.09	-0.33	5.56e-12	Testicular germ cell tumor;
LUAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg08132940	chr7:1081526	C7orf50	-0.78	-10.58	-0.46	2.22e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7072216	0.881	rs2182168	chr10:100148353	C/G	cg26618903	chr10:100175079	PYROXD2	-0.3	-6.51	-0.3	2.13e-10	Metabolite levels;
LUAD	cis	rs7945718	0.967	rs2241857	chr11:12815831	C/T	cg25843174	chr11:12811716	TEAD1	-0.23	-6.86	-0.32	2.48e-11	Educational attainment (years of education);
LUAD	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg05044414	chr3:183734942	ABCC5	0.47	9.92	0.43	5.5e-21	Anterior chamber depth;
LUAD	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg24818145	chr4:99064322	C4orf37	-0.42	-6.85	-0.32	2.57e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg07538946	chr5:131705188	SLC22A5	0.49	7.84	0.36	3.65e-14	Breast cancer;Mosquito bite size;
LUAD	cis	rs11893307	0.537	rs1558473	chr2:191504064	A/C	cg27211696	chr2:191398769	TMEM194B	-0.41	-6.42	-0.3	3.71e-10	Mean platelet volume;
LUAD	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg02527881	chr3:46936655	PTH1R	-0.55	-11.33	-0.48	3.59e-26	Colorectal cancer;
LUAD	cis	rs938554	0.784	rs1071988	chr4:9974638	A/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-7.7	-0.35	9.54e-14	Blood metabolite levels;
LUAD	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg13798912	chr7:905769	UNC84A	-0.63	-7.21	-0.33	2.55e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs354225	0.544	rs10184128	chr2:54803816	A/G	cg01766943	chr2:54829624	SPTBN1	0.38	6.95	0.32	1.41e-11	Schizophrenia;
LUAD	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg05665937	chr4:1216051	CTBP1	0.39	6.58	0.3	1.4e-10	Obesity-related traits;
LUAD	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg22676075	chr6:135203613	NA	0.54	9.63	0.42	5.42e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7043114	0.507	rs2007837	chr9:95189767	A/T	cg14631576	chr9:95140430	CENPP	-0.42	-8.49	-0.38	3.48e-16	Height;
LUAD	cis	rs7493	0.950	rs11977702	chr7:95029767	C/T	cg07404485	chr7:94953653	PON1	-0.48	-6.9	-0.32	1.87e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6545883	0.929	rs778155	chr2:61647901	A/G	cg15711740	chr2:61764176	XPO1	0.4	6.43	0.3	3.43e-10	Tuberculosis;
LUAD	cis	rs12545109	0.842	rs10958482	chr8:57389331	G/T	cg11919837	chr8:57350735	NA	-0.45	-6.55	-0.3	1.69e-10	Obesity-related traits;
LUAD	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.57	9.71	0.43	3.07e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs7851660	0.967	rs13288000	chr9:100608980	A/G	cg13688889	chr9:100608707	NA	-0.52	-9.59	-0.42	7.44e-20	Strep throat;
LUAD	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26314531	chr2:26401878	FAM59B	0.72	9.72	0.43	2.76e-20	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg20607798	chr8:58055168	NA	0.57	7.28	0.33	1.6e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10883723	0.962	rs11191294	chr10:104225837	T/G	cg22532475	chr10:104410764	TRIM8	-0.43	-8.01	-0.36	1.12e-14	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg12908607	chr1:44402522	ARTN	-0.45	-9.38	-0.41	4.09e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.37	-0.48	2.63e-26	Type 2 diabetes;
LUAD	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg27266060	chr8:22091797	NA	0.46	8.33	0.38	1.15e-15	Hypertriglyceridemia;
LUAD	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg15017067	chr4:17643749	FAM184B	0.37	7.17	0.33	3.4e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2797160	0.905	rs1418640	chr6:125999866	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.79	-0.39	3.9e-17	Endometrial cancer;
LUAD	cis	rs7119	0.651	rs12904200	chr15:77845902	C/G	cg27398640	chr15:77910606	LINGO1	-0.36	-6.61	-0.31	1.13e-10	Type 2 diabetes;
LUAD	cis	rs11650494	0.831	rs11650886	chr17:47449193	G/A	cg08112188	chr17:47440006	ZNF652	0.98	8.19	0.37	3.23e-15	Prostate cancer;
LUAD	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg10591111	chr5:226296	SDHA	-0.53	-6.74	-0.31	5.31e-11	Breast cancer;
LUAD	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg13854012	chr2:162103682	NA	-0.46	-9.09	-0.4	3.94e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	trans	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-9.27	-0.41	9.98e-19	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11947960	chr2:112655492	MERTK	-0.46	-7.21	-0.33	2.68e-12	Height;
LUAD	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg07256732	chr16:621771	PIGQ	-0.32	-6.58	-0.3	1.42e-10	Height;
LUAD	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg06873352	chr17:61820015	STRADA	0.44	7.29	0.33	1.56e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10504073	0.584	rs7820270	chr8:49971395	G/T	cg00325661	chr8:49890786	NA	0.45	10.19	0.44	6.09e-22	Blood metabolite ratios;
LUAD	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg13318129	chr22:45737514	FAM118A	0.56	6.37	0.3	5.05e-10	Tonsillectomy;
LUAD	cis	rs2688608	0.839	rs2633310	chr10:75594050	G/T	cg23231163	chr10:75533350	FUT11	0.47	8.77	0.39	4.33e-17	Inflammatory bowel disease;
LUAD	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.76	-0.31	4.72e-11	Height;
LUAD	trans	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.73	13.09	0.54	4.31e-33	Mean corpuscular volume;
LUAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg07677032	chr17:61819896	STRADA	0.55	10.09	0.44	1.41e-21	Prudent dietary pattern;
LUAD	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00802000	chr16:706648	WDR90	-0.42	-7.89	-0.36	2.62e-14	Height;
LUAD	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22455342	chr2:225449267	CUL3	-0.64	-10.03	-0.44	2.14e-21	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs56283067	0.886	rs2023311	chr6:44678306	A/T	cg20913747	chr6:44695427	NA	-0.42	-7.21	-0.33	2.65e-12	Total body bone mineral density;
LUAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg11965913	chr1:205819406	PM20D1	0.62	11.54	0.49	5.61e-27	Menarche (age at onset);
LUAD	trans	rs629535	0.783	rs538832	chr8:70033817	A/G	cg21567404	chr3:27674614	NA	1.01	18.57	0.67	9.52e-57	Dupuytren's disease;
LUAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg13397359	chr6:42928475	GNMT	0.61	11.55	0.49	5.27e-27	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg09137382	chr11:130731461	NA	0.41	7.44	0.34	5.49e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg24308560	chr3:49941425	MST1R	-0.49	-7.81	-0.35	4.62e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg00717180	chr2:96193071	NA	-0.41	-7.55	-0.34	2.65e-13	HDL cholesterol;
LUAD	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg17761419	chr8:57350749	NA	-0.54	-7.84	-0.36	3.6e-14	Obesity-related traits;
LUAD	cis	rs2985684	0.901	rs2354448	chr14:50098296	G/A	cg04989706	chr14:50066350	PPIL5	-0.46	-6.72	-0.31	5.79e-11	Carotid intima media thickness;
LUAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg16606324	chr3:10149918	C3orf24	0.55	7.99	0.36	1.33e-14	Alzheimer's disease;
LUAD	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Depression;
LUAD	cis	rs6867032	0.917	rs4975719	chr5:2010162	C/T	cg26168224	chr5:2018326	NA	0.74	15.24	0.6	4.02e-42	Gut microbiome composition (winter);
LUAD	cis	rs6785206	0.667	rs6439139	chr3:128410285	T/C	cg16766828	chr3:128327626	NA	-0.87	-9.28	-0.41	8.56e-19	Lymphocyte percentage of white cells;
LUAD	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg03388025	chr16:89894329	SPIRE2	-0.33	-7.49	-0.34	3.93e-13	Vitiligo;
LUAD	cis	rs4380275	1.000	rs7562792	chr2:774469	T/C	cg21665850	chr2:731073	NA	0.5	8.94	0.4	1.24e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUAD	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg27124370	chr19:33622961	WDR88	0.46	7.15	0.33	3.92e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg11915388	chr22:42470451	FAM109B	-0.42	-7.25	-0.33	2.02e-12	Schizophrenia;
LUAD	cis	rs6005807	0.668	rs60065194	chr22:28993756	A/G	cg12565055	chr22:29076175	TTC28	0.75	8.76	0.39	4.71e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.49	-7.36	-0.34	9.42e-13	Gut microbiome composition (summer);
LUAD	cis	rs938554	0.876	rs7670751	chr4:9938773	A/C	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.81	-0.35	4.58e-14	Blood metabolite levels;
LUAD	cis	rs7107174	1.000	rs901104	chr11:77930499	C/T	cg02023728	chr11:77925099	USP35	0.53	8.07	0.37	7.26e-15	Testicular germ cell tumor;
LUAD	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg19318889	chr4:1322082	MAEA	0.81	13.6	0.55	3.51e-35	Longevity;
LUAD	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg14092988	chr3:52407081	DNAH1	0.38	7.51	0.34	3.45e-13	Electroencephalogram traits;
LUAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03647317	chr4:187891568	NA	-0.36	-6.73	-0.31	5.42e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17095355	1.000	rs11194926	chr10:111700922	A/G	cg00817464	chr10:111662876	XPNPEP1	0.68	8.88	0.4	1.99e-17	Biliary atresia;
LUAD	trans	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.26	-0.37	1.93e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4594175	0.926	rs72688713	chr14:51598375	C/T	cg23942311	chr14:51606299	NA	0.64	10.96	0.47	8.86e-25	Cancer;
LUAD	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg00271210	chr6:167070053	RPS6KA2	0.34	6.6	0.31	1.27e-10	Crohn's disease;
LUAD	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg18180107	chr4:99064573	C4orf37	-0.41	-6.67	-0.31	8.28e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg15992532	chr8:142229932	SLC45A4	0.48	8.6	0.39	1.63e-16	Immature fraction of reticulocytes;
LUAD	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	6.96	0.32	1.27e-11	Schizophrenia;
LUAD	cis	rs2688608	0.901	rs2675671	chr10:75632760	C/T	cg23231163	chr10:75533350	FUT11	-0.44	-8.1	-0.37	5.8e-15	Inflammatory bowel disease;
LUAD	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.13	-0.33	4.31e-12	Heart rate;
LUAD	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.6	9.52	0.42	1.33e-19	Cognitive ability;
LUAD	cis	rs6087990	0.965	rs2424903	chr20:31349315	C/T	cg13636640	chr20:31349939	DNMT3B	0.84	16.03	0.61	1.65e-45	Ulcerative colitis;
LUAD	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg01689657	chr7:91764605	CYP51A1	-0.37	-8.88	-0.4	1.95e-17	Breast cancer;
LUAD	cis	rs9796	0.621	rs690733	chr15:41476465	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.46	-8.34	-0.38	1.05e-15	Menopause (age at onset);
LUAD	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg06046430	chr4:77819534	ANKRD56	0.55	8.92	0.4	1.46e-17	Emphysema distribution in smoking;
LUAD	trans	rs3857536	0.813	rs7757118	chr6:66946661	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg26677194	chr12:130822605	PIWIL1	0.55	9.07	0.4	4.52e-18	Menopause (age at onset);
LUAD	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg05564831	chr3:52568323	NT5DC2	0.36	6.91	0.32	1.82e-11	Cognitive function;
LUAD	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg14895029	chr7:2775587	GNA12	-0.45	-7.32	-0.34	1.23e-12	Height;
LUAD	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg12403142	chr1:92012408	NA	-0.41	-7.4	-0.34	7.51e-13	Breast cancer;
LUAD	trans	rs1997103	0.863	rs4480062	chr7:55401299	T/C	cg20935933	chr6:143382018	AIG1	0.53	7.48	0.34	4.32e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg18538332	chr22:24372958	LOC391322	-0.51	-8.76	-0.39	4.89e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg13047869	chr3:10149882	C3orf24	0.57	9.73	0.43	2.5e-20	Alzheimer's disease;
LUAD	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg11031976	chr2:198649780	BOLL	0.48	7.12	0.33	4.6e-12	Ulcerative colitis;
LUAD	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg18367735	chr17:79674897	NA	0.53	6.85	0.32	2.64e-11	Dental caries;
LUAD	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg13685833	chr1:53393034	SCP2	-0.49	-8.12	-0.37	5.12e-15	Monocyte count;
LUAD	cis	rs7020830	0.894	rs12337316	chr9:37148105	G/A	cg14294708	chr9:37120828	ZCCHC7	0.79	15.11	0.59	1.5e-41	Schizophrenia;
LUAD	cis	rs7731657	0.537	rs4377699	chr5:130354830	T/G	cg08523029	chr5:130500466	HINT1	0.58	7.65	0.35	1.34e-13	Fasting plasma glucose;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg21795699	chr17:15903687	ZSWIM7;TTC19	0.4	6.39	0.3	4.31e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.73	13.09	0.54	4.17e-33	Mean corpuscular volume;
LUAD	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg14598338	chr9:96623480	NA	-0.43	-9.06	-0.4	4.85e-18	DNA methylation (variation);
LUAD	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23158103	chr7:148848205	ZNF398	-0.65	-12.18	-0.51	1.79e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg13685833	chr1:53393034	SCP2	-0.4	-6.71	-0.31	6.39e-11	Monocyte count;
LUAD	cis	rs1816752	0.633	rs9578729	chr13:24999244	T/A	cg02811702	chr13:24901961	NA	0.41	7.24	0.33	2.08e-12	Obesity-related traits;
LUAD	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-8.21	-0.37	2.71e-15	Lung cancer;
LUAD	cis	rs7177699	0.557	rs3971829	chr15:79109052	A/G	cg00540400	chr15:79124168	NA	0.45	9.25	0.41	1.12e-18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg25237894	chr2:233734115	C2orf82	0.62	11.78	0.5	6.79e-28	Coronary artery disease;
LUAD	cis	rs72928364	1.000	rs2713782	chr3:100629304	G/A	cg10123952	chr3:100791384	NA	-0.55	-6.98	-0.32	1.15e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs55788414	0.932	rs12102293	chr16:81181607	T/C	cg06400318	chr16:81190750	PKD1L2	-0.65	-8.17	-0.37	3.61e-15	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg22963979	chr7:1858916	MAD1L1	-0.59	-10.06	-0.44	1.71e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs7607369	0.618	rs62193298	chr2:219655211	T/G	cg02176678	chr2:219576539	TTLL4	-0.7	-14.08	-0.56	3.54e-37	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg18129178	chr5:148520854	ABLIM3	-0.58	-8.71	-0.39	6.9e-17	Breast cancer;
LUAD	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg20476274	chr7:133979776	SLC35B4	0.83	16.73	0.63	1.44e-48	Mean platelet volume;
LUAD	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg13877915	chr19:58951672	ZNF132	0.73	13.82	0.56	4.13e-36	Uric acid clearance;
LUAD	cis	rs790123	1.000	rs790116	chr3:122380923	G/C	cg17380795	chr3:122379686	NA	0.46	7.84	0.36	3.76e-14	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg00316803	chr15:76480434	C15orf27	0.4	6.71	0.31	6.2e-11	Blood metabolite levels;
LUAD	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg09365446	chr1:150670422	GOLPH3L	0.66	12.54	0.52	7.1e-31	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg10862848	chr6:42927986	GNMT	0.32	9.35	0.41	5.3e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs73086581	1.000	rs73086549	chr20:3954662	C/A	cg02187196	chr20:3869020	PANK2	0.46	6.49	0.3	2.34e-10	Response to antidepressants in depression;
LUAD	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-8.21	-0.37	2.68e-15	Menarche (age at onset);
LUAD	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg23803603	chr1:2058230	PRKCZ	0.4	7.18	0.33	3.25e-12	Height;
LUAD	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg11189052	chr15:85197271	WDR73	-0.76	-13.5	-0.55	8.4e-35	P wave terminal force;
LUAD	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg18446336	chr7:2847575	GNA12	-0.33	-6.42	-0.3	3.7e-10	Height;
LUAD	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg26384229	chr12:38710491	ALG10B	0.49	7.91	0.36	2.27e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg03563238	chr19:33554763	RHPN2	-0.37	-8.62	-0.39	1.33e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs739496	0.947	rs739497	chr12:111858086	C/T	cg10833066	chr12:111807467	FAM109A	0.42	6.76	0.31	4.51e-11	Platelet count;
LUAD	cis	rs6942407	0.592	rs10085726	chr7:86851397	T/A	cg02420886	chr7:86849541	C7orf23	0.65	7.51	0.34	3.64e-13	Food allergy;
LUAD	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg00071950	chr4:10020882	SLC2A9	0.83	16.97	0.64	1.22e-49	Bone mineral density;
LUAD	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg06766960	chr11:133703094	NA	-0.37	-7.13	-0.33	4.26e-12	Childhood ear infection;
LUAD	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg05754148	chr16:3507555	NAT15	0.72	11.76	0.5	7.85e-28	Tuberculosis;
LUAD	cis	rs10106298	0.846	rs2099408	chr8:103680416	A/C	cg10187029	chr8:103597600	NA	0.41	6.75	0.31	5.04e-11	Schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04970839	chr7:1942763	MAD1L1	0.53	6.55	0.3	1.67e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg17200465	chr3:40428508	ENTPD3	0.27	6.48	0.3	2.61e-10	Renal cell carcinoma;
LUAD	cis	rs1003719	0.788	rs2835588	chr21:38462716	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.33e-16	Eye color traits;
LUAD	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg06781209	chr11:61594997	FADS2	-0.41	-7.64	-0.35	1.48e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg00769240	chr8:12517080	NA	0.39	6.67	0.31	8.24e-11	Blood pressure (smoking interaction);
LUAD	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg11502198	chr6:26597334	ABT1	0.66	11.13	0.48	2.03e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg26022315	chr17:47021804	SNF8	0.4	7.27	0.33	1.77e-12	Type 2 diabetes;
LUAD	cis	rs11195062	0.732	rs3737315	chr10:112035508	G/T	cg19214408	chr10:111981687	MXI1	-0.38	-6.35	-0.3	5.43e-10	Multiple myeloma;
LUAD	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg22764044	chr5:178986830	RUFY1	0.58	8.63	0.39	1.22e-16	Lung cancer;
LUAD	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg20203395	chr5:56204925	C5orf35	-0.82	-11.8	-0.5	5.55e-28	Initial pursuit acceleration;
LUAD	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg06387496	chr7:2775674	GNA12	-0.39	-6.62	-0.31	1.07e-10	Height;
LUAD	cis	rs2274273	0.588	rs11158037	chr14:55832152	C/A	cg04306507	chr14:55594613	LGALS3	0.42	8.06	0.36	7.82e-15	Protein biomarker;
LUAD	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11890956	chr21:40555474	PSMG1	0.79	13.71	0.55	1.19e-35	Cognitive function;
LUAD	cis	rs1018836	0.892	rs2187981	chr8:91549629	T/C	cg16814680	chr8:91681699	NA	-0.61	-10.58	-0.46	2.23e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs116095464	1.000	rs62331560	chr5:346785	G/C	cg22857025	chr5:266934	NA	-1.09	-8.83	-0.39	2.73e-17	Breast cancer;
LUAD	cis	rs10865541	0.902	rs33997548	chr2:3419366	A/G	cg13173536	chr2:3403300	TTC15	-0.34	-6.61	-0.31	1.16e-10	Obesity-related traits;
LUAD	cis	rs847577	0.569	rs35101190	chr7:97695888	G/A	cg24562669	chr7:97807699	LMTK2	0.3	7.03	0.32	8.48e-12	Breast cancer;
LUAD	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg04944784	chr2:26401820	FAM59B	-0.69	-9.74	-0.43	2.36e-20	Gut microbiome composition (summer);
LUAD	cis	rs11771526	0.901	rs17161123	chr7:32305426	G/A	cg13207630	chr7:32358064	NA	0.61	7.56	0.35	2.47e-13	Body mass index;
LUAD	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg25358565	chr5:93447407	FAM172A	0.62	7.22	0.33	2.46e-12	Diabetic retinopathy;
LUAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-8.13	-0.37	4.77e-15	Alzheimer's disease;
LUAD	cis	rs11051970	1.000	rs6488051	chr12:32532733	G/C	cg02745156	chr12:32552066	NA	0.32	6.64	0.31	9.81e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18876405	chr7:65276391	NA	0.44	6.91	0.32	1.84e-11	Aortic root size;
LUAD	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg02683114	chr2:24398427	C2orf84	-0.43	-6.64	-0.31	9.56e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg13390004	chr1:15929781	NA	0.49	8.6	0.39	1.6e-16	Systolic blood pressure;
LUAD	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg01528321	chr10:82214614	TSPAN14	0.65	10.51	0.46	3.9699999999999997e-23	Post bronchodilator FEV1;
LUAD	cis	rs11031096	0.899	rs7110060	chr11:4106577	C/G	cg18678763	chr11:4115507	RRM1	0.37	6.59	0.31	1.3e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05535760	chr7:792225	HEATR2	1.01	12.97	0.53	1.33e-32	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7107174	1.000	rs10899467	chr11:78014057	G/T	cg19901956	chr11:77921274	USP35	-0.54	-6.64	-0.31	9.65e-11	Testicular germ cell tumor;
LUAD	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg17063962	chr7:91808500	NA	0.68	12.15	0.51	2.4e-29	Breast cancer;
LUAD	cis	rs2920503	0.659	rs17029006	chr3:12329452	C/T	cg23514324	chr3:12329213	PPARG	0.47	6.94	0.32	1.47e-11	LDL cholesterol;
LUAD	cis	rs7737355	0.947	rs3776028	chr5:130789750	G/A	cg06307176	chr5:131281290	NA	-0.49	-7.69	-0.35	1.03e-13	Life satisfaction;
LUAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg18404041	chr3:52824283	ITIH1	0.42	7.95	0.36	1.68e-14	Electroencephalogram traits;
LUAD	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg21214613	chr1:16344536	HSPB7	0.53	10.05	0.44	1.92e-21	Dilated cardiomyopathy;
LUAD	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg00757033	chr12:89920650	WDR51B	-0.6	-10.62	-0.46	1.69e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg03929089	chr4:120376271	NA	0.57	7.13	0.33	4.42e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg13180566	chr4:1052158	NA	-0.39	-6.69	-0.31	6.92e-11	Recombination rate (females);
LUAD	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg07936489	chr17:37558343	FBXL20	-0.45	-7.06	-0.32	6.82e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs12819124	0.502	rs10875718	chr12:48411102	G/T	cg15465823	chr12:48382534	COL2A1	0.32	6.37	0.3	5.07e-10	Glycated hemoglobin levels;
LUAD	cis	rs790123	0.692	rs790126	chr3:122387655	G/A	cg15604389	chr3:122379662	NA	0.47	7.84	0.36	3.61e-14	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg13319975	chr6:146136371	FBXO30	-0.57	-9.52	-0.42	1.33e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg00784671	chr22:46762841	CELSR1	-0.59	-7.45	-0.34	5.48e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg03388025	chr16:89894329	SPIRE2	0.49	12.83	0.53	4.48e-32	Vitiligo;
LUAD	cis	rs11958404	0.932	rs72816585	chr5:157433901	A/C	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg15691649	chr6:25882328	NA	-0.66	-8.87	-0.4	2.09e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.1	-0.51	3.69e-29	Primary sclerosing cholangitis;
LUAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg14820908	chr5:178986412	RUFY1	-0.7	-12.03	-0.5	7.19e-29	Lung cancer;
LUAD	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg20628663	chr10:43360327	NA	-0.74	-11.34	-0.48	3.42e-26	Blood protein levels;
LUAD	cis	rs4321325	0.733	rs79995601	chr2:127947452	T/C	cg11380483	chr2:127933992	NA	0.48	6.72	0.31	5.98e-11	Protein C levels;
LUAD	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg27535305	chr1:53392650	SCP2	-0.42	-8.54	-0.38	2.52e-16	Monocyte count;
LUAD	cis	rs7512552	0.839	rs2873669	chr1:150426224	C/T	cg15654264	chr1:150340011	RPRD2	-0.59	-11.3	-0.48	4.84e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10802521	chr3:52805072	NEK4	-0.53	-9.1	-0.4	3.69e-18	Bipolar disorder;
LUAD	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg26384229	chr12:38710491	ALG10B	0.4	6.44	0.3	3.27e-10	Morning vs. evening chronotype;
LUAD	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.78	-0.35	5.42e-14	Blood metabolite levels;
LUAD	trans	rs3903072	0.528	rs12800497	chr11:65579762	C/T	cg17712092	chr4:129076599	LARP1B	0.6	9.26	0.41	1.06e-18	Breast cancer;
LUAD	cis	rs863345	0.604	rs11265008	chr1:158498671	C/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs7072216	0.727	rs942809	chr10:100168001	G/A	cg26618903	chr10:100175079	PYROXD2	-0.37	-7.99	-0.36	1.29e-14	Metabolite levels;
LUAD	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15506890	chr2:3487001	NA	-0.45	-7.95	-0.36	1.75e-14	Neurofibrillary tangles;
LUAD	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	8.29	0.37	1.55e-15	Rheumatoid arthritis;
LUAD	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.42	-8.25	-0.37	1.98e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg10518543	chr12:38710700	ALG10B	0.42	6.44	0.3	3.27e-10	Bladder cancer;
LUAD	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg05368731	chr17:41323189	NBR1	-0.85	-16.94	-0.64	1.59e-49	Menopause (age at onset);
LUAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27297192	chr10:134578999	INPP5A	0.36	6.37	0.3	5.08e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9486719	1.000	rs11756315	chr6:97008678	A/G	cg06623918	chr6:96969491	KIAA0776	0.61	8.56	0.38	2.12e-16	Migraine;Coronary artery disease;
LUAD	cis	rs7149337	0.805	rs3007069	chr14:51597392	G/A	cg23942311	chr14:51606299	NA	0.86	19.61	0.69	2.25e-61	Cancer;
LUAD	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-12.26	-0.51	8.91e-30	Schizophrenia;
LUAD	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg15900387	chr1:150738905	CTSS	-0.37	-6.69	-0.31	7.19e-11	Melanoma;
LUAD	cis	rs6594499	0.542	rs7722241	chr5:110460747	T/A	cg17157872	chr5:110408788	TSLP	0.33	6.78	0.31	3.95e-11	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg25894440	chr7:65020034	NA	-0.69	-7.31	-0.33	1.34e-12	Diabetic kidney disease;
LUAD	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg06131755	chr6:160182447	ACAT2	-0.46	-6.94	-0.32	1.45e-11	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs55823223	0.752	rs34974290	chr17:73888354	G/A	cg08125733	chr17:73851984	WBP2	0.64	9.22	0.41	1.37e-18	Psoriasis;
LUAD	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg09455208	chr3:40491958	NA	0.67	14.45	0.57	9.34e-39	Renal cell carcinoma;
LUAD	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg25894440	chr7:65020034	NA	-0.64	-6.83	-0.32	2.96e-11	Diabetic kidney disease;
LUAD	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg19163074	chr7:65112434	INTS4L2	-0.45	-6.75	-0.31	4.82e-11	Aortic root size;
LUAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg09033563	chr22:24373618	LOC391322	-0.57	-9.02	-0.4	6.71e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6005807	0.719	rs60693420	chr22:29045930	T/C	cg12565055	chr22:29076175	TTC28	0.74	8.71	0.39	6.98e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg08793459	chr17:57784647	PTRH2;TMEM49	0.4	6.59	0.31	1.29e-10	Anger;
LUAD	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg04369109	chr6:150039330	LATS1	-0.44	-7.29	-0.33	1.59e-12	Lung cancer;
LUAD	cis	rs1018836	0.608	rs12679836	chr8:91465287	A/G	cg16814680	chr8:91681699	NA	-0.55	-8.99	-0.4	8.21e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7737355	0.947	rs10073137	chr5:131091089	A/G	cg25547332	chr5:131281432	NA	0.45	6.79	0.31	3.75e-11	Life satisfaction;
LUAD	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg19875535	chr5:140030758	IK	0.46	7.71	0.35	9.21e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg11871910	chr12:69753446	YEATS4	0.71	12.14	0.51	2.74e-29	Blood protein levels;
LUAD	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg00933542	chr6:150070202	PCMT1	0.34	6.95	0.32	1.42e-11	Testicular germ cell tumor;
LUAD	cis	rs57994353	0.897	rs67220311	chr9:139376668	T/C	cg14169450	chr9:139327907	INPP5E	0.41	6.51	0.3	2.19e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs1215050	0.791	rs165244	chr4:98687889	C/T	cg17366294	chr4:99064904	C4orf37	0.47	8.41	0.38	6.44e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2239547	0.522	rs2581823	chr3:53022076	C/G	cg18404041	chr3:52824283	ITIH1	0.53	9.25	0.41	1.09e-18	Schizophrenia;
LUAD	cis	rs7771547	0.603	rs9296193	chr6:36601456	C/G	cg02952361	chr6:36355661	ETV7	-0.47	-6.53	-0.3	1.89e-10	Platelet distribution width;
LUAD	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg22491629	chr6:157744540	C6orf35	-0.8	-8.82	-0.39	3.01e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg14092988	chr3:52407081	DNAH1	0.45	8.84	0.39	2.62e-17	Bipolar disorder;
LUAD	cis	rs17152411	0.895	rs61872121	chr10:126586795	T/C	cg07906193	chr10:126599966	NA	0.54	7.67	0.35	1.16e-13	Height;
LUAD	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg10356904	chr22:49881777	NA	-0.41	-8.7	-0.39	7.31e-17	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25411849	chr6:89855994	PM20D2	-0.54	-6.43	-0.3	3.49e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs8002861	0.902	rs1445557	chr13:44464827	C/T	cg17145862	chr1:211918768	LPGAT1	0.76	18.02	0.66	2.72e-54	Leprosy;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14777817	chr13:80055594	NDFIP2	-0.58	-6.94	-0.32	1.48e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9931543	0.565	rs56313388	chr16:56207769	T/C	cg02433656	chr16:56322654	GNAO1	0.42	6.58	0.3	1.37e-10	Subjective well-being;
LUAD	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21214613	chr1:16344536	HSPB7	-0.49	-8.8	-0.39	3.51e-17	Dilated cardiomyopathy;
LUAD	cis	rs3784262	0.740	rs1372369	chr15:58294381	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.43	-8.45	-0.38	4.85e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7216064	0.953	rs80135947	chr17:65836001	A/C	cg08758996	chr17:66097529	LOC651250	0.45	6.99	0.32	1.09e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs1160297	0.576	rs12475542	chr2:53111504	A/G	cg07782112	chr2:53107842	NA	-0.37	-8.13	-0.37	4.72e-15	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg11424665	chr3:129158811	IFT122;MBD4	-0.42	-6.59	-0.31	1.34e-10	Vertical cup-disc ratio;
LUAD	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg04025307	chr7:1156635	C7orf50	0.56	8.84	0.39	2.64e-17	Bronchopulmonary dysplasia;
LUAD	cis	rs2430307	0.556	rs3905501	chr7:76542080	C/T	cg05843312	chr7:76586131	NA	-0.46	-6.76	-0.31	4.73e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg10523679	chr1:76189770	ACADM	-0.45	-6.43	-0.3	3.39e-10	Daytime sleep phenotypes;
LUAD	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg07936489	chr17:37558343	FBXL20	-0.46	-7.27	-0.33	1.71e-12	Glomerular filtration rate (creatinine);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg08215925	chr3:71633214	FOXP1	-0.41	-6.77	-0.31	4.44e-11	Subcortical brain region volumes;
LUAD	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg26597838	chr10:835615	NA	1.08	16.97	0.64	1.23e-49	Eosinophil percentage of granulocytes;
LUAD	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg08470875	chr2:26401718	FAM59B	-0.78	-10.53	-0.46	3.44e-23	Gut microbiome composition (summer);
LUAD	cis	rs9549328	0.614	rs35299896	chr13:113617229	G/T	cg17524180	chr13:113633600	MCF2L	0.3	6.46	0.3	2.81e-10	Systolic blood pressure;
LUAD	cis	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg27411982	chr8:10470053	RP1L1	0.43	7.33	0.34	1.2e-12	Neuroticism;
LUAD	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg17724175	chr1:150552817	MCL1	0.39	9.4	0.42	3.51e-19	Tonsillectomy;
LUAD	cis	rs6691722	0.506	rs12030365	chr1:24739220	T/A	cg02336364	chr1:24764700	NIPAL3	0.36	7.7	0.35	9.91e-14	Response to interferon beta in multiple sclerosis;
LUAD	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg26314531	chr2:26401878	FAM59B	-0.7	-10.23	-0.45	4.44e-22	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg08219700	chr8:58056026	NA	0.51	7.3	0.33	1.42e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs11031096	0.838	rs12364664	chr11:4099715	A/G	cg18678763	chr11:4115507	RRM1	0.38	6.65	0.31	8.98e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg04287289	chr16:89883240	FANCA	0.78	7.01	0.32	9.31e-12	Skin colour saturation;
LUAD	cis	rs17095355	0.818	rs928213	chr10:111856224	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.64	-9.0	-0.4	7.67e-18	Biliary atresia;
LUAD	cis	rs500891	0.525	rs1145895	chr6:84042326	C/A	cg08257003	chr6:84140564	ME1	0.34	6.68	0.31	7.45e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.4	-7.34	-0.34	1.11e-12	Longevity;Endometriosis;
LUAD	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg06641503	chr3:48959341	ARIH2	-0.4	-7.82	-0.36	4.37e-14	Menarche (age at onset);
LUAD	cis	rs4372836	0.729	rs11127190	chr2:29043212	G/C	cg09522027	chr2:28974177	PPP1CB	0.67	12.05	0.51	6.03e-29	Body mass index;
LUAD	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg24112000	chr20:60950667	NA	0.72	12.09	0.51	3.99e-29	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs9487051	0.768	rs12176068	chr6:109521629	C/T	cg01475377	chr6:109611718	NA	-0.36	-6.73	-0.31	5.43e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs9649213	0.614	rs59120980	chr7:98017730	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.74	-10.74	-0.46	6.09e-24	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7582720	1.000	rs72926782	chr2:203811628	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2066819	1.000	rs79824801	chr12:56728137	T/C	cg26714650	chr12:56694279	CS	-0.86	-7.09	-0.33	5.59e-12	Psoriasis vulgaris;
LUAD	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.04	0.36	9.29e-15	Menopause (age at onset);
LUAD	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg16049864	chr8:95962084	TP53INP1	-0.39	-7.12	-0.33	4.69e-12	Type 2 diabetes;
LUAD	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.51	-7.65	-0.35	1.41e-13	IgG glycosylation;
LUAD	trans	rs10838798	0.523	rs11039543	chr11:48168103	G/A	cg15704280	chr7:45808275	SEPT13	-0.54	-8.43	-0.38	5.65e-16	Height;
LUAD	cis	rs240764	0.817	rs12193960	chr6:101150326	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-7.8	-0.35	5.01e-14	Neuroticism;
LUAD	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg07061783	chr6:25882402	NA	-0.49	-6.53	-0.3	1.93e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg21918786	chr6:109611834	NA	-0.58	-10.65	-0.46	1.24e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg11189052	chr15:85197271	WDR73	0.68	9.09	0.4	3.73e-18	Schizophrenia;
LUAD	cis	rs7630877	0.886	rs940523	chr3:179621954	A/T	cg18765712	chr3:179670323	PEX5L	-0.37	-6.6	-0.31	1.26e-10	Type 2 diabetes;
LUAD	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg07636037	chr3:49044803	WDR6	0.64	12.53	0.52	7.64e-31	Parkinson's disease;
LUAD	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg21609526	chr1:3105151	PRDM16	0.34	6.91	0.32	1.77e-11	Migraine;
LUAD	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.03	-0.44	2.15e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg08807101	chr21:30365312	RNF160	-0.5	-8.42	-0.38	5.88e-16	Dental caries;
LUAD	cis	rs758324	0.812	rs3756287	chr5:131135478	A/G	cg06307176	chr5:131281290	NA	0.46	7.54	0.34	2.93e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg20991723	chr1:152506922	NA	0.33	6.6	0.31	1.21e-10	Hair morphology;
LUAD	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.78	0.31	3.96e-11	Mood instability;
LUAD	cis	rs1113500	0.799	rs1777459	chr1:108584999	G/C	cg06207961	chr1:108661230	NA	-0.42	-7.56	-0.35	2.53e-13	Growth-regulated protein alpha levels;
LUAD	cis	rs9503598	0.778	rs10155771	chr6:3465930	G/A	cg00476032	chr6:3446245	SLC22A23	0.37	7.87	0.36	3e-14	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs113835537	0.529	rs12099041	chr11:66232773	C/T	cg26679405	chr11:66247800	DPP3	-0.44	-6.51	-0.3	2.1e-10	Airway imaging phenotypes;
LUAD	cis	rs16948098	1	rs16948098	chr15:44219607	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	6.52	0.3	1.96e-10	Serum albumin level;
LUAD	cis	rs4006360	0.646	rs8080447	chr17:39301276	T/A	cg20663846	chr17:39254439	KRTAP4-8	0.39	9.1	0.4	3.57e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg02038168	chr22:39784481	NA	-0.58	-10.2	-0.44	5.33e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.75	0.53	9.54e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.38	0.52	2.9e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg02017074	chr12:117425053	FBXW8	0.65	8.67	0.39	9.44e-17	Subcortical brain region volumes;Hippocampal volume;
LUAD	cis	rs7903847	0.642	rs11814021	chr10:99158386	A/G	cg20016023	chr10:99160130	RRP12	-0.32	-7.53	-0.34	3.15e-13	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg01091258	chr2:46844529	PIGF;CRIPT	-0.37	-6.4	-0.3	4.18e-10	Subcortical brain region volumes;
LUAD	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.35	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21659725	chr3:3221576	CRBN	0.64	11.21	0.48	9.97e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg00204512	chr16:28754710	NA	0.31	6.76	0.31	4.56e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg19622623	chr12:86230825	RASSF9	-0.55	-9.9	-0.43	6.53e-21	Major depressive disorder;
LUAD	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg17644776	chr2:200775616	C2orf69	-0.5	-6.43	-0.3	3.47e-10	Schizophrenia;
LUAD	cis	rs3812111	0.510	rs6930059	chr6:116577623	T/C	cg18828861	chr6:116576566	TSPYL4	0.37	7.09	0.33	5.84e-12	Age-related macular degeneration;
LUAD	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	9.91	0.43	5.8e-21	Breast cancer;
LUAD	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg14664628	chr15:75095509	CSK	-0.58	-9.24	-0.41	1.2e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	trans	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg04565464	chr8:145669602	NFKBIL2	0.44	7.03	0.32	8.36e-12	Schizophrenia;
LUAD	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg06108461	chr20:60628389	TAF4	-0.66	-8.84	-0.39	2.62e-17	Obesity-related traits;
LUAD	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg03929089	chr4:120376271	NA	-0.92	-17.21	-0.64	1.06e-50	Height;
LUAD	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06022373	chr22:39101656	GTPBP1	0.46	7.21	0.33	2.6e-12	Menopause (age at onset);
LUAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06873352	chr17:61820015	STRADA	0.83	18.59	0.67	8.47e-57	Prudent dietary pattern;
LUAD	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg20503657	chr10:835505	NA	1.25	18.38	0.67	7.13e-56	Eosinophil percentage of granulocytes;
LUAD	trans	rs225245	0.782	rs225293	chr17:33925906	A/G	cg19694781	chr19:47549865	TMEM160	-0.47	-7.68	-0.35	1.13e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg24955955	chr5:415729	AHRR	0.81	9.02	0.4	6.57e-18	Fat distribution (HIV);
LUAD	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg26384229	chr12:38710491	ALG10B	0.5	8.03	0.36	9.5e-15	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6738485	0.930	rs13015630	chr2:106790253	T/C	cg16099169	chr2:106886729	NA	-0.38	-6.36	-0.3	5.36e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs66731853	0.769	rs476582	chr1:20894450	A/G	cg04087271	chr1:20915334	CDA	-0.59	-11.2	-0.48	1.17e-25	Mean corpuscular volume;
LUAD	cis	rs1997103	0.906	rs4618644	chr7:55402037	T/G	cg17469321	chr7:55412551	NA	0.67	11.39	0.48	2.05e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs3823572	0.503	rs4731990	chr7:133689074	C/T	cg03336402	chr7:133662267	EXOC4	-0.43	-7.42	-0.34	6.31e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg14530993	chr4:882597	GAK	-0.75	-7.16	-0.33	3.6e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.24	-0.33	2.13e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg18129748	chr3:49941408	MST1R	-0.4	-6.66	-0.31	8.28e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2996428	0.709	rs7527973	chr1:3704041	C/T	cg22529645	chr1:3704559	LRRC47	0.58	10.81	0.47	3.32e-24	Red cell distribution width;
LUAD	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg18135555	chr8:22132992	PIWIL2	0.39	7.06	0.32	6.8e-12	Hypertriglyceridemia;
LUAD	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.09	-0.44	1.4e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4631830	0.932	rs4581397	chr10:51532367	A/G	cg20129853	chr10:51489980	NA	-0.32	-6.38	-0.3	4.75e-10	Prostate-specific antigen levels;
LUAD	cis	rs9296095	0.607	rs9469485	chr6:33514093	C/T	cg14003231	chr6:33640908	ITPR3	0.47	8.6	0.39	1.57e-16	Platelet count;
LUAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00149659	chr3:10157352	C3orf10	0.58	8.38	0.38	7.64e-16	Alzheimer's disease;
LUAD	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs17608059	0.611	rs62052300	chr17:13916799	G/A	cg27005118	chr17:13972210	COX10	-0.33	-6.87	-0.32	2.31e-11	Temperament;
LUAD	trans	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-7.16	-0.33	3.51e-12	Personality dimensions;
LUAD	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-11.07	-0.47	3.42e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10193935	0.901	rs2374405	chr2:42479874	A/C	cg27598129	chr2:42591480	NA	-0.79	-9.71	-0.43	2.97e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2224391	0.656	rs66646775	chr6:5284395	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-8.11	-0.37	5.71e-15	Height;
LUAD	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg09904177	chr6:26538194	HMGN4	-0.41	-6.98	-0.32	1.16e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg16606324	chr3:10149918	C3orf24	0.67	10.95	0.47	9.53e-25	Alzheimer's disease;
LUAD	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg00745463	chr17:30367425	LRRC37B	-0.79	-10.16	-0.44	7.6e-22	Hip circumference adjusted for BMI;
LUAD	cis	rs73110464	0.505	rs2682296	chr12:53308265	G/A	cg05393297	chr12:53359155	NA	-0.43	-7.08	-0.33	6e-12	Cancer (pleiotropy);
LUAD	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.4	6.78	0.31	4.08e-11	HDL cholesterol;
LUAD	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg27432699	chr2:27873401	GPN1	0.58	10.19	0.44	5.81e-22	Oral cavity cancer;
LUAD	cis	rs6490294	0.687	rs648300	chr12:112175819	C/G	cg10833066	chr12:111807467	FAM109A	0.36	6.75	0.31	5.02e-11	Mean platelet volume;
LUAD	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-7.02	-0.32	8.97e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs11048434	0.723	rs2080116	chr12:9138183	A/G	cg23795048	chr12:9217529	LOC144571	0.43	7.92	0.36	2.14e-14	Sjögren's syndrome;
LUAD	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg07599136	chr5:415885	AHRR	0.75	8.43	0.38	5.38e-16	Fat distribution (HIV);
LUAD	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg23649088	chr2:200775458	C2orf69	-0.58	-7.41	-0.34	6.94e-13	Schizophrenia;
LUAD	cis	rs7107174	0.901	rs2512522	chr11:77925855	G/C	cg02023728	chr11:77925099	USP35	0.51	7.88	0.36	2.7e-14	Testicular germ cell tumor;
LUAD	cis	rs1595825	1.000	rs7579905	chr2:198868109	T/A	cg11031976	chr2:198649780	BOLL	-0.42	-6.37	-0.3	4.99e-10	Ulcerative colitis;
LUAD	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg21545522	chr1:205238299	TMCC2	0.38	7.01	0.32	9.75e-12	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg04705435	chr11:17411270	KCNJ11	0.4	6.79	0.31	3.85e-11	Type 2 diabetes;
LUAD	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg01416388	chr22:39784598	NA	-0.47	-7.02	-0.32	8.72e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	trans	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg24644049	chr4:85504048	CDS1	0.92	7.91	0.36	2.22e-14	Skin colour saturation;
LUAD	cis	rs9394169	1.000	rs9394169	chr6:33778964	A/G	cg13859433	chr6:33739653	LEMD2	-0.27	-6.46	-0.3	2.88e-10	Essential tremor;
LUAD	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg07402062	chr16:89894098	SPIRE2	0.44	11.07	0.47	3.49e-25	Vitiligo;
LUAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg09033563	chr22:24373618	LOC391322	0.45	6.4	0.3	4.22e-10	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	trans	rs587242	0.911	rs80336582	chr1:96901001	G/A	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg03676636	chr4:99064102	C4orf37	0.33	8.52	0.38	2.91e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3772130	1.000	rs13087578	chr3:121369207	A/C	cg20356878	chr3:121714668	ILDR1	0.49	7.73	0.35	7.7e-14	Cognitive performance;
LUAD	cis	rs55788414	1.000	rs67345347	chr16:81185125	G/C	cg06400318	chr16:81190750	PKD1L2	-0.66	-8.36	-0.38	9.41e-16	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs7508679	1.000	rs4804411	chr19:7222377	G/C	cg09779027	chr19:7224513	INSR	0.76	16.53	0.63	1.04e-47	Hypothyroidism;
LUAD	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg02733842	chr7:1102375	C7orf50	-0.55	-8.68	-0.39	8.68e-17	Bronchopulmonary dysplasia;
LUAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.28	0.41	8.83e-19	Alzheimer's disease;
LUAD	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg11189052	chr15:85197271	WDR73	0.58	6.89	0.32	2.08e-11	Schizophrenia;
LUAD	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg08601574	chr20:25228251	PYGB	0.46	8.69	0.39	7.91e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg22676075	chr6:135203613	NA	0.42	7.79	0.35	5.41e-14	Red blood cell count;
LUAD	cis	rs986417	1.000	rs1955699	chr14:61045989	A/G	cg27398547	chr14:60952738	C14orf39	0.6	7.41	0.34	6.95e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg00129232	chr17:37814104	STARD3	0.45	7.73	0.35	7.68e-14	Asthma;
LUAD	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.12	0.33	4.7e-12	Motion sickness;
LUAD	trans	rs11039798	0.614	rs11039954	chr11:48741818	A/G	cg02254774	chr11:50257496	LOC441601	0.52	6.58	0.3	1.4e-10	Axial length;
LUAD	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26314531	chr2:26401878	FAM59B	-0.55	-7.65	-0.35	1.39e-13	Gut microbiome composition (summer);
LUAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg21951975	chr1:209979733	IRF6	-0.58	-9.41	-0.42	3.11e-19	Cleft lip with or without cleft palate;
LUAD	trans	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-10.79	-0.46	4.01e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg12863693	chr15:85201151	NMB	0.38	6.49	0.3	2.36e-10	Schizophrenia;
LUAD	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg13012494	chr21:47604986	C21orf56	0.46	7.64	0.35	1.48e-13	Testicular germ cell tumor;
LUAD	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg05110241	chr16:68378359	PRMT7	-0.82	-8.71	-0.39	6.81e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg00129232	chr17:37814104	STARD3	-0.46	-8.02	-0.36	1.08e-14	Asthma;
LUAD	cis	rs12286929	0.644	rs9645660	chr11:115081563	C/T	cg04055981	chr11:115044050	NA	0.47	8.74	0.39	5.53e-17	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg11062466	chr8:58055876	NA	0.67	8.87	0.4	2.01e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg00631329	chr6:26305371	NA	-0.72	-13.63	-0.55	2.61e-35	Educational attainment;
LUAD	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-13.33	-0.54	4.25e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7640424	0.716	rs35703078	chr3:107859558	A/G	cg09227934	chr3:107805635	CD47	-0.56	-9.75	-0.43	2.18e-20	Body mass index;
LUAD	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.44	-0.34	5.84e-13	Resting heart rate;
LUAD	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg18404041	chr3:52824283	ITIH1	0.43	7.88	0.36	2.81e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg15369054	chr17:80825471	TBCD	0.67	10.67	0.46	1.04e-23	Breast cancer;
LUAD	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg14092571	chr14:90743983	NA	-0.44	-7.84	-0.36	3.62e-14	Mortality in heart failure;
LUAD	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg00339695	chr16:24857497	SLC5A11	0.47	8.66	0.39	1.04e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg08601574	chr20:25228251	PYGB	0.48	9.0	0.4	7.68e-18	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.56	-0.42	9.49e-20	Platelet count;
LUAD	trans	rs66573146	1.000	rs59683609	chr4:6964910	C/G	cg07817883	chr1:32538562	TMEM39B	1.56	13.45	0.55	1.46e-34	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg08213375	chr14:104286397	PPP1R13B	0.26	6.88	0.32	2.15e-11	Schizophrenia;
LUAD	cis	rs2731664	0.792	rs2545795	chr5:176887106	A/C	cg23176889	chr5:176863531	GRK6	-0.7	-13.05	-0.54	6.02e-33	Intelligence (multi-trait analysis);
LUAD	cis	rs7582720	1.000	rs72932793	chr2:203701004	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.39	0.42	3.83e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2882667	0.893	rs7717375	chr5:138291405	A/G	cg04439458	chr5:138467593	SIL1	-0.38	-6.88	-0.32	2.19e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-10.48	-0.45	5.43e-23	Chronic sinus infection;
LUAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.51	0.55	7.95e-35	Prudent dietary pattern;
LUAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13732083	chr21:47605072	C21orf56	-0.62	-10.64	-0.46	1.44e-23	Testicular germ cell tumor;
LUAD	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23583168	chr7:148888333	NA	-0.91	-18.81	-0.67	8.7e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs3812762	0.917	rs2873297	chr11:8791227	C/T	cg03980550	chr11:8754370	ST5	0.37	6.47	0.3	2.8e-10	Hypospadias;
LUAD	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-7.0	-0.32	1.04e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11622475	0.677	rs12889842	chr14:104344947	G/T	cg12183467	chr14:104352244	NA	-0.61	-12.2	-0.51	1.51e-29	Bipolar disorder;
LUAD	cis	rs7707921	0.667	rs111549985	chr5:81268070	C/G	cg15871215	chr5:81402204	ATG10	-0.69	-9.72	-0.43	2.76e-20	Breast cancer;
LUAD	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg24531977	chr5:56204891	C5orf35	0.74	11.81	0.5	5.13e-28	Initial pursuit acceleration;
LUAD	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.31	0.41	6.89e-19	Colorectal cancer;
LUAD	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg19041857	chr6:27730383	NA	-0.43	-7.39	-0.34	8.11e-13	Parkinson's disease;
LUAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.49	-0.3	2.38e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg05966235	chr16:28915196	ATP2A1	0.47	7.63	0.35	1.52e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7527798	0.592	rs6702222	chr1:207825627	C/T	cg09232269	chr1:207846808	CR1L	-0.36	-6.98	-0.32	1.12e-11	Erythrocyte sedimentation rate;
LUAD	cis	rs7408868	1.000	rs2074622	chr19:15277620	G/C	cg14696996	chr19:15285081	NOTCH3	0.82	10.59	0.46	2.07e-23	Pulse pressure;
LUAD	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.47	-0.3	2.78e-10	Aortic root size;
LUAD	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg10518543	chr12:38710700	ALG10B	-0.44	-7.12	-0.33	4.61e-12	Morning vs. evening chronotype;
LUAD	trans	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.36	-0.3	5.18e-10	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs1997103	1.000	rs9642580	chr7:55400359	G/A	cg20935933	chr6:143382018	AIG1	0.54	7.54	0.34	2.85e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01926595	chr17:4851808	PFN1	-0.68	-7.16	-0.33	3.7e-12	Type 2 diabetes;
LUAD	cis	rs7192380	0.651	rs9788803	chr16:69691995	A/T	cg26679644	chr16:69762563	NA	0.44	7.18	0.33	3.11e-12	Sjögren's syndrome;
LUAD	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg17848003	chr1:3704513	LRRC47	0.52	10.36	0.45	1.5e-22	Red cell distribution width;
LUAD	cis	rs17095355	0.901	rs61579832	chr10:111766275	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.39	-0.38	7.09e-16	Biliary atresia;
LUAD	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg00277334	chr10:82204260	NA	-0.51	-7.94	-0.36	1.89e-14	Post bronchodilator FEV1;
LUAD	cis	rs35123781	0.696	rs356433	chr5:139071193	C/T	cg10513866	chr5:139070639	NA	0.57	9.28	0.41	9.17e-19	Schizophrenia;
LUAD	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08109568	chr15:31115862	NA	0.78	13.48	0.55	1.08e-34	Huntington's disease progression;
LUAD	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	8.51	0.38	3.07e-16	Breast cancer;
LUAD	cis	rs9487051	0.698	rs35757653	chr6:109644599	A/C	cg01475377	chr6:109611718	NA	-0.41	-6.51	-0.3	2.09e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs3815700	1.000	rs8104729	chr19:33093979	C/T	cg02997394	chr19:33096574	ANKRD27	0.66	8.7	0.39	7.31e-17	Eosinophilic esophagitis;
LUAD	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg23587288	chr2:27483067	SLC30A3	-0.38	-6.67	-0.31	7.94e-11	Blood metabolite levels;
LUAD	cis	rs9443645	0.527	rs1415859	chr6:79794858	A/G	cg09184832	chr6:79620586	NA	-0.4	-6.58	-0.3	1.41e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg06453172	chr10:134556979	INPP5A	-0.78	-10.84	-0.47	2.48e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.5	0.55	8.82e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg07741184	chr6:167504864	NA	0.31	7.37	0.34	9.03e-13	Crohn's disease;
LUAD	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg08645402	chr16:4508243	NA	0.56	10.28	0.45	2.89e-22	Schizophrenia;
LUAD	cis	rs8112211	0.731	rs11673012	chr19:38823971	C/A	cg14299480	chr19:38876666	GGN	-0.44	-6.39	-0.3	4.38e-10	Blood protein levels;
LUAD	trans	rs208520	0.874	rs208512	chr6:66943869	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-14.64	-0.58	1.47e-39	Exhaled nitric oxide output;
LUAD	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg12179176	chr11:130786555	SNX19	0.55	9.12	0.41	2.97e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.42	-0.34	6.53e-13	Resting heart rate;
LUAD	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg08085267	chr17:45401833	C17orf57	-0.5	-8.34	-0.38	1.08e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg18252515	chr7:66147081	NA	-0.62	-6.93	-0.32	1.55e-11	Diabetic kidney disease;
LUAD	trans	rs9784649	1.000	rs56156666	chr5:24999440	A/T	cg11038491	chr20:34638489	LOC647979	-0.65	-8.16	-0.37	3.91e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.66	0.31	8.31e-11	Depression;
LUAD	cis	rs11958404	0.860	rs72818116	chr5:157440616	G/T	cg05962755	chr5:157440814	NA	0.55	8.28	0.37	1.65e-15	IgG glycosylation;
LUAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03452623	chr4:187889614	NA	-0.83	-17.3	-0.64	4.07e-51	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg18825076	chr15:78729989	IREB2	0.46	6.41	0.3	3.91e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs11696501	0.688	rs6065861	chr20:44311056	A/G	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.39	-0.38	7.49e-16	Brain structure;
LUAD	cis	rs7254827	0.522	rs1077795	chr19:17222584	A/G	cg19418318	chr19:17219073	MYO9B	-0.49	-6.81	-0.31	3.31e-11	Mean platelet volume;
LUAD	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg12432903	chr7:1882776	MAD1L1	-0.41	-6.55	-0.3	1.63e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	7.77	0.35	6.16e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7274811	0.901	rs1074683	chr20:32304653	C/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.5	-6.89	-0.32	2.05e-11	Height;
LUAD	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg06558623	chr16:89946397	TCF25	1.19	10.94	0.47	1.03e-24	Skin colour saturation;
LUAD	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg04586622	chr2:25135609	ADCY3	0.38	8.63	0.39	1.25e-16	Body mass index;
LUAD	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.56e-11	Depression;
LUAD	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.44	-0.34	5.5e-13	Bipolar disorder;
LUAD	cis	rs4774899	0.752	rs2464430	chr15:57348225	C/T	cg14026238	chr15:57616123	NA	0.43	8.37	0.38	8.28e-16	Urinary tract infection frequency;
LUAD	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg02734326	chr4:10020555	SLC2A9	0.49	8.59	0.39	1.7e-16	Bone mineral density;
LUAD	trans	rs7395662	0.892	rs11040010	chr11:48776929	G/T	cg00717180	chr2:96193071	NA	0.39	7.24	0.33	2.14e-12	HDL cholesterol;
LUAD	cis	rs4790333	0.967	rs2002863	chr17:2269769	C/T	cg27406664	chr17:2294951	MNT	0.43	7.93	0.36	1.91e-14	Proinsulin levels;
LUAD	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg24397884	chr7:158709396	WDR60	0.74	13.51	0.55	7.81e-35	Height;
LUAD	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg23260525	chr10:116636907	FAM160B1	0.54	12.94	0.53	1.69e-32	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg21153622	chr11:89784906	NA	-0.32	-6.37	-0.3	4.83e-10	Coronary artery disease;
LUAD	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg18306943	chr3:40428807	ENTPD3	0.38	6.47	0.3	2.69e-10	Renal cell carcinoma;
LUAD	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg23281280	chr6:28129359	ZNF389	0.46	6.53	0.3	1.92e-10	Depression;
LUAD	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	15.11	0.59	1.44e-41	Smoking behavior;
LUAD	cis	rs3806843	0.520	rs265312	chr5:140296272	T/G	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.46	-0.3	2.81e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4853036	0.503	rs34198970	chr2:70012933	C/A	cg02498382	chr2:70120550	SNRNP27	-0.47	-6.6	-0.31	1.25e-10	Colorectal or endometrial cancer;
LUAD	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg22907277	chr7:1156413	C7orf50	0.4	6.74	0.31	5.24e-11	Longevity;Endometriosis;
LUAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg26338869	chr17:61819248	STRADA	-0.39	-6.46	-0.3	2.86e-10	Prudent dietary pattern;
LUAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg13047869	chr3:10149882	C3orf24	0.59	9.99	0.44	2.95e-21	Alzheimer's disease;
LUAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg21724239	chr8:58056113	NA	-0.63	-8.38	-0.38	8.18e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg02951883	chr7:2050386	MAD1L1	-0.8	-13.65	-0.55	2.1e-35	Bipolar disorder and schizophrenia;
LUAD	trans	rs11039798	0.764	rs12418936	chr11:48986418	T/C	cg03929089	chr4:120376271	NA	0.66	6.52	0.3	2.05e-10	Axial length;
LUAD	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg00280220	chr17:61926910	NA	0.35	6.7	0.31	6.87e-11	Prudent dietary pattern;
LUAD	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg16647868	chr5:131706066	SLC22A5	-0.48	-7.73	-0.35	8.01e-14	Breast cancer;
LUAD	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg11502198	chr6:26597334	ABT1	0.68	11.85	0.5	3.69e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg26513180	chr16:89883248	FANCA	0.79	7.18	0.33	3.25e-12	Skin colour saturation;
LUAD	trans	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg14917512	chr19:3094685	GNA11	0.56	6.37	0.3	4.8e-10	Diabetic kidney disease;
LUAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg20607798	chr8:58055168	NA	0.58	7.41	0.34	6.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.08	-0.33	5.91e-12	Total body bone mineral density;
LUAD	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-10.53	-0.46	3.64e-23	Gut microbiome composition (summer);
LUAD	cis	rs747650	0.892	rs1976143	chr11:47225534	G/A	cg19486271	chr11:47235900	DDB2	-0.44	-7.22	-0.33	2.47e-12	Acne (severe);
LUAD	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg15017067	chr4:17643749	FAM184B	0.36	7.06	0.32	6.98e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg14345882	chr6:26364793	BTN3A2	0.7	7.14	0.33	4.13e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg03929089	chr4:120376271	NA	-0.51	-6.74	-0.31	5.16e-11	Axial length;
LUAD	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg00071950	chr4:10020882	SLC2A9	0.74	15.16	0.59	8.71e-42	Bone mineral density;
LUAD	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01570182	chr17:44337453	NA	-0.64	-10.19	-0.44	6.12e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg21782813	chr7:2030301	MAD1L1	0.46	7.87	0.36	2.91e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg23985595	chr17:80112537	CCDC57	-0.53	-9.61	-0.42	6.55e-20	Life satisfaction;
LUAD	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22455342	chr2:225449267	CUL3	0.66	10.24	0.45	3.99e-22	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg08885076	chr2:99613938	TSGA10	0.36	6.55	0.3	1.67e-10	Chronic sinus infection;
LUAD	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg11645453	chr3:52864694	ITIH4	0.59	11.04	0.47	4.48e-25	Schizophrenia;
LUAD	cis	rs7258465	0.965	rs2385088	chr19:18545540	A/G	cg25828334	chr19:18545568	ISYNA1	-0.39	-7.94	-0.36	1.9e-14	Breast cancer;
LUAD	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg07169764	chr2:136633963	MCM6	0.82	9.6	0.42	7.35e-20	Corneal structure;
LUAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.52	-0.52	8.1e-31	Platelet count;
LUAD	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg17264618	chr3:40429014	ENTPD3	0.4	8.72	0.39	6.55e-17	Renal cell carcinoma;
LUAD	cis	rs1776421	0.760	rs61768414	chr1:53906995	C/T	cg10892335	chr1:53966318	NA	0.51	7.28	0.33	1.64e-12	PR interval in Tripanosoma cruzi seropositivity;
LUAD	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg09826364	chr7:158789723	NA	-0.38	-6.76	-0.31	4.57e-11	Facial morphology (factor 20);
LUAD	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg15123519	chr2:136567270	LCT	0.39	7.22	0.33	2.48e-12	Mosquito bite size;
LUAD	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.64	0.31	9.87e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg21100191	chr22:23484243	RTDR1	0.63	11.08	0.47	3.29e-25	Bone mineral density;
LUAD	cis	rs7241530	0.595	rs35856696	chr18:75898218	G/A	cg14642773	chr18:75888474	NA	0.35	6.35	0.3	5.46e-10	Educational attainment (years of education);
LUAD	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.5e-19	Life satisfaction;
LUAD	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg10589385	chr1:150898437	SETDB1	0.45	8.26	0.37	1.91e-15	Melanoma;
LUAD	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg20891558	chr2:74357851	NA	0.98	17.38	0.65	1.94e-51	Gestational age at birth (maternal effect);
LUAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg16606324	chr3:10149918	C3orf24	0.65	10.87	0.47	1.95e-24	Alzheimer's disease;
LUAD	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg14668632	chr7:2872130	GNA12	-0.74	-13.18	-0.54	1.79e-33	Height;
LUAD	cis	rs9399401	0.667	rs6912639	chr6:142770548	T/C	cg04461802	chr6:142623433	GPR126	0.38	7.1	0.33	5.26e-12	Chronic obstructive pulmonary disease;
LUAD	cis	rs938554	0.577	rs7683856	chr4:10000947	A/G	cg02734326	chr4:10020555	SLC2A9	0.47	6.7	0.31	6.79e-11	Blood metabolite levels;
LUAD	cis	rs11031096	0.899	rs11604649	chr11:4106251	C/T	cg18678763	chr11:4115507	RRM1	0.38	6.68	0.31	7.62e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs4743820	0.651	rs10820838	chr9:93930913	G/A	cg14446406	chr9:93919335	NA	-0.51	-8.72	-0.39	6.47e-17	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12756686	chr19:29218302	NA	0.66	10.1	0.44	1.22e-21	Methadone dose in opioid dependence;
LUAD	cis	rs35740288	0.770	rs11630112	chr15:86120246	T/C	cg13263323	chr15:86062960	AKAP13	-0.43	-6.87	-0.32	2.26e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs870825	0.616	rs28524599	chr4:185647414	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg05434287	chr7:2030229	MAD1L1	0.4	6.58	0.3	1.38e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs1422110	1.000	rs1422110	chr5:85466140	C/T	cg01787110	chr1:109008453	NBPF6	-0.53	-8.64	-0.39	1.19e-16	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.44	-0.49	1.38e-26	Primary sclerosing cholangitis;
LUAD	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg20203395	chr5:56204925	C5orf35	0.64	9.9	0.43	6.63e-21	Initial pursuit acceleration;
LUAD	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg26875233	chr11:93583750	C11orf90	-0.39	-8.8	-0.39	3.6e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs17362650	0.921	rs35848871	chr2:9657827	A/G	cg12832956	chr2:9616023	IAH1	-0.47	-7.38	-0.34	8.39e-13	Alcohol dependence (age at onset);
LUAD	cis	rs56283067	0.847	rs11962872	chr6:44690740	T/G	cg20913747	chr6:44695427	NA	-0.44	-7.46	-0.34	5.03e-13	Total body bone mineral density;
LUAD	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg22467129	chr15:76604101	ETFA	-0.47	-7.83	-0.36	3.87e-14	Blood metabolite levels;
LUAD	cis	rs6138458	1.000	rs1977540	chr20:24900290	G/T	cg06937882	chr20:24974362	C20orf3	0.34	6.51	0.3	2.16e-10	Blood protein levels;
LUAD	cis	rs62238980	0.614	rs117744580	chr22:32566631	G/T	cg00543991	chr22:32367038	NA	0.83	7.49	0.34	4.07e-13	Childhood ear infection;
LUAD	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg15017067	chr4:17643749	FAM184B	0.37	7.3	0.33	1.45e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.51	-8.19	-0.37	3.07e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2067615	0.524	rs10861646	chr12:107071182	C/T	cg15890332	chr12:107067104	RFX4	0.42	8.86	0.4	2.18e-17	Heart rate;
LUAD	trans	rs4942242	0.659	rs1105586	chr13:44232633	C/T	cg19169023	chr15:41853346	TYRO3	0.6	10.24	0.45	3.86e-22	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg17173187	chr15:85201210	NMB	0.49	8.69	0.39	8.25e-17	Schizophrenia;
LUAD	cis	rs7707921	0.767	rs226199	chr5:81572464	G/C	cg15871215	chr5:81402204	ATG10	0.65	10.26	0.45	3.2e-22	Breast cancer;
LUAD	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03934478	chr11:495069	RNH1	0.66	7.62	0.35	1.65e-13	Body mass index;
LUAD	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg15691649	chr6:25882328	NA	-0.45	-7.13	-0.33	4.29e-12	Blood metabolite levels;
LUAD	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg14583973	chr4:3374767	RGS12	0.29	7.23	0.33	2.21e-12	Serum sulfate level;
LUAD	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg08601574	chr20:25228251	PYGB	0.47	8.89	0.4	1.77e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6060717	0.536	rs17431878	chr20:34502107	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.06	-0.32	7.08e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs524023	0.914	rs2277311	chr11:64387932	G/A	cg19131476	chr11:64387923	NRXN2	-0.42	-8.32	-0.38	1.18e-15	Urate levels in obese individuals;
LUAD	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg22532475	chr10:104410764	TRIM8	-0.43	-8.42	-0.38	6.02e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.95	0.53	1.55e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg02683114	chr2:24398427	C2orf84	-0.52	-7.67	-0.35	1.18e-13	Asthma;
LUAD	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg07570687	chr10:102243282	WNT8B	0.48	7.52	0.34	3.24e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs11229555	1.000	rs11229545	chr11:58386650	A/G	cg15696309	chr11:58395628	NA	-0.73	-10.98	-0.47	7.29e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg08888203	chr3:10149979	C3orf24	0.72	11.26	0.48	6.58e-26	Alzheimer's disease;
LUAD	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg16797656	chr11:68205561	LRP5	0.45	8.62	0.39	1.34e-16	Total body bone mineral density;
LUAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.47e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03352830	chr11:487213	PTDSS2	0.77	9.56	0.42	9.84e-20	Body mass index;
LUAD	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg21984481	chr17:79567631	NPLOC4	-0.6	-12.89	-0.53	2.65e-32	Eye color traits;
LUAD	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg25173405	chr17:45401733	C17orf57	0.5	8.37	0.38	8.8e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14132868	chr11:18343680	HPS5;GTF2H1	-0.56	-6.67	-0.31	8.09e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.44	-8.16	-0.37	3.84e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7737355	0.947	rs6596009	chr5:130608093	C/A	cg06307176	chr5:131281290	NA	0.46	6.82	0.31	3.24e-11	Life satisfaction;
LUAD	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs68170813	0.559	rs60255281	chr7:106963913	C/T	cg23024343	chr7:107201750	COG5	0.45	6.5	0.3	2.23e-10	Coronary artery disease;
LUAD	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg20607287	chr7:12443886	VWDE	-0.54	-6.99	-0.32	1.07e-11	Coronary artery disease;
LUAD	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.63	0.39	1.26e-16	Menarche (age at onset);
LUAD	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg05590025	chr7:65112418	INTS4L2	-0.68	-7.34	-0.34	1.14e-12	Diabetic kidney disease;
LUAD	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	9.82	0.43	1.26e-20	Ileal carcinoids;
LUAD	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg15445000	chr17:37608096	MED1	0.44	8.23	0.37	2.37e-15	Glomerular filtration rate (creatinine);
LUAD	trans	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg04775059	chr7:64541387	NA	0.5	6.9	0.32	1.87e-11	Aortic root size;
LUAD	cis	rs7927771	0.524	rs6485773	chr11:47763509	A/G	cg18512352	chr11:47633146	NA	0.37	6.44	0.3	3.24e-10	Subjective well-being;
LUAD	cis	rs2038227	1	rs2038227	chr16:539140	C/A	cg06259664	chr16:537672	RAB11FIP3	0.66	11.89	0.5	2.57e-28	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.43	6.76	0.31	4.59e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg08601574	chr20:25228251	PYGB	0.46	8.54	0.38	2.5e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs921968	0.565	rs2272188	chr2:219612282	C/T	cg02176678	chr2:219576539	TTLL4	0.6	12.3	0.51	6.31e-30	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg08470875	chr2:26401718	FAM59B	-0.77	-10.24	-0.45	3.84e-22	Gut microbiome composition (summer);
LUAD	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.62	0.35	1.65e-13	Bladder cancer;
LUAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08677398	chr8:58056175	NA	0.48	6.85	0.32	2.64e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg02782426	chr3:40428986	ENTPD3	0.36	7.98	0.36	1.39e-14	Renal cell carcinoma;
LUAD	cis	rs3125734	0.719	rs3852410	chr10:64037563	A/G	cg09941381	chr10:64027924	RTKN2	0.32	7.39	0.34	8e-13	Rheumatoid arthritis;
LUAD	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg20703242	chr1:230279135	GALNT2	0.66	11.14	0.48	1.97e-25	Coronary artery disease;
LUAD	cis	rs34526934	0.566	rs9141	chr2:177037970	T/C	cg14324370	chr2:177042789	NA	-0.43	-7.25	-0.33	1.97e-12	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs12208915	0.945	rs12190108	chr6:79562655	T/C	cg05283184	chr6:79620031	NA	0.52	6.49	0.3	2.41e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg11859384	chr17:80120422	CCDC57	-0.48	-8.67	-0.39	9.17e-17	Life satisfaction;
LUAD	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg19717773	chr7:2847554	GNA12	-0.54	-10.31	-0.45	2.16e-22	Height;
LUAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08280861	chr8:58055591	NA	0.63	8.24	0.37	2.25e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4308124	0.708	rs6727313	chr2:111971540	G/A	cg04571233	chr2:111982156	NA	-0.46	-6.53	-0.3	1.84e-10	Vitiligo;
LUAD	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.75	16.39	0.62	4.17e-47	White blood cell count;
LUAD	cis	rs6543140	0.964	rs10169192	chr2:103072211	A/G	cg03938978	chr2:103052716	IL18RAP	0.35	6.8	0.31	3.6e-11	Blood protein levels;
LUAD	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.25	0.33	2.01e-12	Cannabis dependence symptom count;
LUAD	cis	rs7771547	0.574	rs11756557	chr6:36597695	A/G	cg04289385	chr6:36355825	ETV7	0.52	6.9	0.32	1.88e-11	Platelet distribution width;
LUAD	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg25985355	chr7:65971099	NA	-0.55	-6.75	-0.31	4.77e-11	Diabetic kidney disease;
LUAD	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg25985355	chr7:65971099	NA	0.38	7.02	0.32	8.89e-12	Aortic root size;
LUAD	cis	rs15676	0.783	rs2977996	chr9:131582625	C/T	cg00228799	chr9:131580591	ENDOG	0.48	7.9	0.36	2.4e-14	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03934478	chr11:495069	RNH1	0.75	9.12	0.41	3.11e-18	Body mass index;
LUAD	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg02782426	chr3:40428986	ENTPD3	-0.37	-8.12	-0.37	5.03e-15	Renal cell carcinoma;
LUAD	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg17372223	chr3:52568218	NT5DC2	-0.39	-7.07	-0.33	6.44e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg21605333	chr4:119757512	SEC24D	0.93	8.76	0.39	4.9e-17	Cannabis dependence symptom count;
LUAD	cis	rs62400317	0.762	rs10456120	chr6:44900107	C/T	cg20913747	chr6:44695427	NA	-0.45	-6.98	-0.32	1.15e-11	Total body bone mineral density;
LUAD	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg15962314	chr1:44399869	ARTN	0.31	6.75	0.31	4.9e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg02251663	chr11:14281053	SPON1	-0.36	-7.01	-0.32	9.44e-12	Mitochondrial DNA levels;
LUAD	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg02079420	chr8:82753780	SNX16	0.42	8.51	0.38	3.11e-16	Diastolic blood pressure;
LUAD	cis	rs10794720	0.541	rs59686718	chr10:1166600	G/A	cg22747480	chr10:1166867	WDR37	-0.55	-6.91	-0.32	1.76e-11	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
LUAD	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg05368731	chr17:41323189	NBR1	0.96	19.81	0.69	2.82e-62	Menopause (age at onset);
LUAD	cis	rs9948	0.786	rs62152765	chr2:97440420	G/A	cg20312557	chr2:97357134	FER1L5	-0.63	-7.36	-0.34	9.71e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs72772090	0.539	rs10515248	chr5:96112005	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-7.36	-0.34	9.41e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg24578937	chr1:2090814	PRKCZ	0.78	16.13	0.62	5.82e-46	Height;
LUAD	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.72	-13.3	-0.54	5.89e-34	Tonsillectomy;
LUAD	cis	rs8177876	0.642	rs76909932	chr16:81119054	A/C	cg08591886	chr16:81111003	C16orf46	-0.8	-7.39	-0.34	7.72e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg01851573	chr8:8652454	MFHAS1	-0.46	-8.24	-0.37	2.16e-15	Mood instability;
LUAD	cis	rs13315871	0.929	rs7628038	chr3:58313813	T/C	cg12435725	chr3:58293450	RPP14	-0.74	-8.38	-0.38	8.05e-16	Cholesterol, total;
LUAD	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-7.38	-0.34	8.4e-13	Platelet count;
LUAD	cis	rs72634258	0.945	rs7539255	chr1:8133352	T/C	cg26816564	chr1:7831052	VAMP3	0.55	7.15	0.33	3.89e-12	Inflammatory bowel disease;
LUAD	cis	rs11229555	0.645	rs35735990	chr11:58187371	G/A	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2073300	1.000	rs114718317	chr20:23442620	T/C	cg12062639	chr20:23401060	NAPB	1.0	9.21	0.41	1.47e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6489882	0.703	rs2057778	chr12:113350796	A/C	cg20102336	chr12:113376681	OAS3	0.54	8.42	0.38	5.88e-16	Chronic lymphocytic leukemia;
LUAD	cis	rs4891159	0.790	rs689885	chr18:74110563	T/G	cg24786174	chr18:74118243	ZNF516	0.78	14.72	0.58	6.73e-40	Longevity;
LUAD	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg07636037	chr3:49044803	WDR6	0.64	12.56	0.52	5.59e-31	Parkinson's disease;
LUAD	cis	rs9814567	0.752	rs4318591	chr3:134328333	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg17200465	chr3:40428508	ENTPD3	0.26	6.65	0.31	9e-11	Renal cell carcinoma;
LUAD	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.54	-6.91	-0.32	1.78e-11	Body mass index;
LUAD	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg21823605	chr1:152486609	CRCT1	0.28	6.4	0.3	4.25e-10	Hair morphology;
LUAD	trans	rs7939886	0.920	rs11227273	chr11:55893034	T/G	cg15704280	chr7:45808275	SEPT13	0.66	6.5	0.3	2.21e-10	Myopia (pathological);
LUAD	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg20135002	chr11:47629003	NA	-0.41	-7.2	-0.33	2.71e-12	Subjective well-being;
LUAD	cis	rs2242073	0.627	rs13007922	chr2:209004186	G/A	cg06181187	chr2:209010896	CRYGB	-0.33	-6.61	-0.31	1.14e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg09640425	chr7:158790006	NA	0.4	7.13	0.33	4.28e-12	Facial morphology (factor 20);
LUAD	cis	rs73206853	0.841	rs74503171	chr12:111061652	A/G	cg12870014	chr12:110450643	ANKRD13A	0.6	6.7	0.31	6.84e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg13047869	chr3:10149882	C3orf24	0.6	10.03	0.44	2.24e-21	Alzheimer's disease;
LUAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18402987	chr7:1209562	NA	0.44	7.47	0.34	4.59e-13	Longevity;Endometriosis;
LUAD	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg05887092	chr17:76393375	PGS1	0.42	7.44	0.34	5.83e-13	HDL cholesterol levels;
LUAD	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg20283391	chr11:68216788	NA	-0.42	-6.56	-0.3	1.56e-10	Total body bone mineral density;
LUAD	cis	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg21775007	chr8:11205619	TDH	-0.37	-6.35	-0.3	5.42e-10	Neuroticism;
LUAD	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg00677455	chr12:58241039	CTDSP2	0.43	7.22	0.33	2.42e-12	Multiple sclerosis;
LUAD	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg26384229	chr12:38710491	ALG10B	0.45	7.41	0.34	7.01e-13	Bladder cancer;
LUAD	cis	rs11030122	0.702	rs7128762	chr11:3943277	C/G	cg18678763	chr11:4115507	RRM1	-0.45	-7.45	-0.34	5.26e-13	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg17366294	chr4:99064904	C4orf37	0.49	8.55	0.38	2.29e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1395	0.778	rs11693660	chr2:27468856	T/C	cg23587288	chr2:27483067	SLC30A3	-0.41	-7.68	-0.35	1.1e-13	Blood metabolite levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18313702	chr3:183853126	EIF2B5	-0.47	-7.34	-0.34	1.08e-12	Height;
LUAD	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg09117114	chr16:67998030	SLC12A4	-0.47	-6.71	-0.31	6.18e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs57994353	0.897	rs67220311	chr9:139376668	T/C	cg14364472	chr9:139394549	NOTCH1	-0.45	-6.87	-0.32	2.24e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg24558204	chr6:135376177	HBS1L	0.47	8.71	0.39	7e-17	Red blood cell count;
LUAD	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg06609049	chr19:2785107	THOP1	1.16	22.86	0.74	6.88e-76	Total cholesterol levels;
LUAD	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg04218760	chr10:45406644	TMEM72	-0.32	-8.22	-0.37	2.49e-15	Mean corpuscular volume;
LUAD	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg15900387	chr1:150738905	CTSS	-0.37	-6.78	-0.31	3.98e-11	Melanoma;
LUAD	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg16479474	chr6:28041457	NA	0.39	6.95	0.32	1.37e-11	Depression;
LUAD	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg20703242	chr1:230279135	GALNT2	0.68	12.51	0.52	9.26e-31	Coronary artery disease;
LUAD	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg25237894	chr2:233734115	C2orf82	-0.6	-11.7	-0.49	1.33e-27	Coronary artery disease;
LUAD	cis	rs6005807	0.843	rs9625525	chr22:29053009	C/A	cg12565055	chr22:29076175	TTC28	0.66	6.53	0.3	1.93e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	7.25	0.33	2e-12	Platelet count;
LUAD	cis	rs12976411	0.867	rs12985626	chr19:32828993	A/G	cg18253629	chr19:32836317	ZNF507	-0.64	-7.21	-0.33	2.59e-12	Coronary artery disease;
LUAD	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.57	-0.3	1.44e-10	Morning vs. evening chronotype;
LUAD	cis	rs13315871	1.000	rs3196769	chr3:58409361	A/T	cg12435725	chr3:58293450	RPP14	-0.69	-7.64	-0.35	1.47e-13	Cholesterol, total;
LUAD	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg18527919	chr2:24398170	C2orf84	0.38	6.39	0.3	4.35e-10	Asthma;
LUAD	cis	rs7659604	0.540	rs4833769	chr4:122672970	A/C	cg06713675	chr4:122721982	EXOSC9	-0.43	-7.86	-0.36	3.15e-14	Type 2 diabetes;
LUAD	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.61	11.54	0.49	5.87e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs2806561	1.000	rs2776822	chr1:23492782	A/G	cg01839850	chr22:38240395	ANKRD54;MIR658	0.37	6.39	0.3	4.27e-10	Height;
LUAD	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg02221750	chr19:17393354	ANKLE1	-0.73	-12.1	-0.51	3.73e-29	Systemic lupus erythematosus;
LUAD	trans	rs11039798	1.000	rs11039978	chr11:48760237	A/G	cg15704280	chr7:45808275	SEPT13	0.67	7.84	0.36	3.58e-14	Axial length;
LUAD	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg13073564	chr4:8508604	NA	-0.58	-10.26	-0.45	3.45e-22	Response to antineoplastic agents;
LUAD	cis	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg08601574	chr20:25228251	PYGB	0.46	8.72	0.39	6.46e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg03806693	chr22:41940476	POLR3H	0.54	8.06	0.36	7.93e-15	Vitiligo;
LUAD	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg27446573	chr6:127587934	RNF146	-0.43	-6.45	-0.3	3.15e-10	Breast cancer;
LUAD	cis	rs62238980	0.614	rs78680556	chr22:32395329	T/C	cg00543991	chr22:32367038	NA	0.92	8.16	0.37	3.95e-15	Childhood ear infection;
LUAD	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg12573674	chr2:1569213	NA	-0.6	-6.81	-0.31	3.33e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg07617317	chr6:118971624	C6orf204	0.55	8.08	0.37	6.98e-15	Diastolic blood pressure;
LUAD	cis	rs9837602	1.000	rs4279135	chr3:99733096	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.98	-0.32	1.12e-11	Breast cancer;
LUAD	trans	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg06606381	chr12:133084897	FBRSL1	-0.58	-7.39	-0.34	8.09e-13	Depression;
LUAD	cis	rs10193935	0.792	rs2053349	chr2:42516205	G/A	cg27598129	chr2:42591480	NA	-0.67	-8.74	-0.39	5.42e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.34	0.38	1.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1697139	0.583	rs11960733	chr5:66538715	C/T	cg11553311	chr5:66541588	NA	0.44	8.17	0.37	3.72e-15	Breast cancer;
LUAD	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.96	0.36	1.62e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1691799	0.867	rs1168311	chr12:66725912	A/C	cg16791601	chr12:66731901	HELB	0.35	6.37	0.3	4.96e-10	White blood cell count (basophil);
LUAD	cis	rs9434723	0.920	rs11801562	chr1:9293156	G/A	cg04199779	chr1:9294473	H6PD	0.65	7.34	0.34	1.13e-12	Height;
LUAD	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.47	0.38	4.01e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg05425664	chr17:57184151	TRIM37	0.4	6.99	0.32	1.06e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs714515	0.900	rs991790	chr1:172340917	C/G	cg14508705	chr1:172360182	DNM3	-0.37	-6.48	-0.3	2.6200000000000003e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg12179176	chr11:130786555	SNX19	0.55	9.27	0.41	9.37e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg00999904	chr2:3704751	ALLC	-0.38	-7.28	-0.33	1.69e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg04282206	chr17:62833786	PLEKHM1P	-0.54	-8.26	-0.37	1.89e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg25985355	chr7:65971099	NA	0.53	6.6	0.31	1.25e-10	Diabetic kidney disease;
LUAD	cis	rs4711350	1.000	rs751727	chr6:33764158	A/G	cg16010596	chr6:33739607	LEMD2	-0.38	-6.55	-0.3	1.67e-10	Schizophrenia;
LUAD	cis	rs2905347	0.520	rs2905309	chr7:22648542	C/T	cg23521230	chr7:22704884	NA	0.46	7.16	0.33	3.69e-12	Major depression and alcohol dependence;
LUAD	trans	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg06606381	chr12:133084897	FBRSL1	-0.5	-6.58	-0.3	1.38e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22496380	chr5:211416	CCDC127	-0.95	-13.32	-0.54	4.88e-34	Breast cancer;
LUAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg19130645	chr7:65235666	NA	0.42	7.1	0.33	5.24e-12	Calcium levels;
LUAD	cis	rs420259	0.516	rs717998	chr16:23560771	C/A	cg00143387	chr16:23521605	GGA2	-0.7	-9.81	-0.43	1.32e-20	Bipolar disorder;
LUAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg11062466	chr8:58055876	NA	0.69	9.14	0.41	2.59e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs11677416	1.000	rs61381693	chr2:113525912	C/A	cg27083787	chr2:113543245	IL1A	0.41	6.91	0.32	1.79e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs2554380	0.843	rs2562783	chr15:84387926	G/C	cg14598478	chr15:84363061	ADAMTSL3	-0.49	-7.59	-0.35	2.09e-13	Height;
LUAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.22	-0.41	1.45e-18	Alzheimer's disease;
LUAD	cis	rs2985684	0.894	rs2883436	chr14:50013822	T/C	cg04989706	chr14:50066350	PPIL5	-0.5	-7.25	-0.33	1.98e-12	Carotid intima media thickness;
LUAD	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg05872129	chr22:39784769	NA	0.7	11.99	0.5	1.03e-28	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.95	-0.36	1.76e-14	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs61101201	0.962	rs10835790	chr11:31610022	C/T	cg25173401	chr4:53548	ZNF595;ZNF718	0.38	6.44	0.3	3.22e-10	Optic disc area;
LUAD	cis	rs490234	0.783	rs2416967	chr9:128440014	T/C	cg14078157	chr9:128172775	NA	-0.45	-8.3	-0.37	1.44e-15	Mean arterial pressure;
LUAD	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg06558623	chr16:89946397	TCF25	1.16	10.95	0.47	9.98e-25	Skin colour saturation;
LUAD	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg23625390	chr15:77176239	SCAPER	-0.45	-7.24	-0.33	2.17e-12	Blood metabolite levels;
LUAD	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg07936489	chr17:37558343	FBXL20	-0.43	-6.64	-0.31	9.82e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg21214613	chr1:16344536	HSPB7	-0.42	-7.67	-0.35	1.23e-13	Systolic blood pressure;
LUAD	cis	rs73206853	0.841	rs73191839	chr12:110967652	G/T	cg12870014	chr12:110450643	ANKRD13A	0.6	6.78	0.31	4.14e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg18105134	chr13:113819100	PROZ	-0.81	-14.41	-0.57	1.46e-38	Platelet distribution width;
LUAD	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg05425664	chr17:57184151	TRIM37	-0.38	-6.77	-0.31	4.28e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg11062466	chr8:58055876	NA	0.45	6.43	0.3	3.43e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9473147	0.516	rs9367284	chr6:47516369	A/G	cg20196966	chr6:47445060	CD2AP	0.46	7.3	0.33	1.45e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2637266	0.935	rs1978927	chr10:78399786	A/T	cg18941641	chr10:78392320	NA	0.34	7.22	0.33	2.46e-12	Pulmonary function;
LUAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg16606324	chr3:10149918	C3orf24	0.7	11.48	0.49	9.38e-27	Alzheimer's disease;
LUAD	cis	rs73416724	1.000	rs112336903	chr6:43338115	T/C	cg26312998	chr6:43337775	ZNF318	0.55	6.69	0.31	7.22e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2294693	0.581	rs2057000	chr6:41016952	A/C	cg14769373	chr6:40998127	UNC5CL	-0.45	-7.27	-0.33	1.8e-12	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg25237894	chr2:233734115	C2orf82	0.61	11.4	0.48	1.88e-26	Coronary artery disease;
LUAD	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.61	-0.31	1.16e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs137699	0.695	rs137653	chr22:39732171	A/G	cg05872129	chr22:39784769	NA	0.38	6.6	0.31	1.21e-10	IgG glycosylation;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg00659421	chr7:86781760	DMTF1	-0.73	-7.2	-0.33	2.69e-12	Type 2 diabetes;
LUAD	trans	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.03	-0.36	9.69e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg21918786	chr6:109611834	NA	-0.55	-10.15	-0.44	8.18e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs1816752	1.000	rs9507341	chr13:25006578	G/T	cg02811702	chr13:24901961	NA	-0.44	-7.18	-0.33	3.09e-12	Obesity-related traits;
LUAD	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg09359103	chr1:154839909	KCNN3	-0.93	-22.07	-0.73	2.2e-72	Prostate cancer;
LUAD	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg05535760	chr7:792225	HEATR2	0.9	11.81	0.5	5.28e-28	Cerebrospinal P-tau181p levels;
LUAD	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg06766960	chr11:133703094	NA	-0.39	-7.48	-0.34	4.39e-13	Childhood ear infection;
LUAD	cis	rs790123	1.000	rs790117	chr3:122380888	C/T	cg17380795	chr3:122379686	NA	0.47	7.87	0.36	3.04e-14	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg21095983	chr6:86352623	SYNCRIP	0.44	7.0	0.32	1.01e-11	Smooth-surface caries;
LUAD	cis	rs6543140	0.964	rs10193485	chr2:103089573	T/C	cg03938978	chr2:103052716	IL18RAP	0.35	6.72	0.31	6.04e-11	Blood protein levels;
LUAD	cis	rs9287719	0.601	rs10084172	chr2:10771228	A/C	cg03983476	chr2:10830698	NOL10	-0.39	-6.45	-0.3	2.99e-10	Prostate cancer;
LUAD	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg02158880	chr13:53174818	NA	0.52	9.04	0.4	5.67e-18	Lewy body disease;
LUAD	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg03676636	chr4:99064102	C4orf37	0.32	8.38	0.38	7.67e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg00101154	chr16:420108	MRPL28	-0.48	-7.03	-0.32	8.53e-12	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg23954153	chr1:44402353	ARTN	-0.37	-7.05	-0.32	7.23e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs28595532	0.925	rs28627331	chr4:119665345	T/C	cg02775129	chr4:119771670	NA	-0.86	-7.93	-0.36	1.99e-14	Cannabis dependence symptom count;
LUAD	cis	rs6490294	0.904	rs7295722	chr12:112394260	C/T	cg10833066	chr12:111807467	FAM109A	0.43	6.95	0.32	1.42e-11	Mean platelet volume;
LUAD	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.11	-0.51	3.37e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.44	-6.77	-0.31	4.34e-11	Breast cancer;
LUAD	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg07917127	chr4:99064746	C4orf37	0.42	7.03	0.32	8.27e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg25173405	chr17:45401733	C17orf57	-0.4	-6.52	-0.3	1.96e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	7.34	0.34	1.09e-12	Rheumatoid arthritis;
LUAD	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.74	0.43	2.28e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg15744005	chr10:104629667	AS3MT	-0.35	-6.83	-0.32	3.01e-11	Arsenic metabolism;
LUAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00166722	chr3:10149974	C3orf24	0.73	10.87	0.47	2.02e-24	Alzheimer's disease;
LUAD	cis	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	8.1	0.37	6.15e-15	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg02931644	chr1:25747376	RHCE	0.42	8.78	0.39	4.13e-17	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs9560113	0.597	rs947170	chr13:112241062	G/A	cg10483660	chr13:112241077	NA	-0.49	-10.24	-0.45	3.77e-22	Menarche (age at onset);
LUAD	trans	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg06606381	chr12:133084897	FBRSL1	-1.23	-10.79	-0.46	3.73e-24	Depression;
LUAD	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.96	0.32	1.31e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13064411	0.696	rs869343	chr3:113226705	C/T	cg10517650	chr3:113235015	CCDC52	-0.56	-9.68	-0.43	3.73e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg10426581	chr7:100472382	SRRT	0.77	10.26	0.45	3.32e-22	Resting heart rate;
LUAD	cis	rs4523957	0.928	rs216176	chr17:2168509	G/C	cg16513277	chr17:2031491	SMG6	0.77	14.88	0.59	1.48e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg14598338	chr9:96623480	NA	-0.43	-9.27	-0.41	9.86e-19	DNA methylation (variation);
LUAD	cis	rs7010267	0.570	rs28893333	chr8:120046473	A/G	cg01975934	chr8:119970761	NA	-0.35	-6.6	-0.31	1.22e-10	Total body bone mineral density (age 45-60);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg24294857	chr1:20812821	CAMK2N1	-0.66	-6.45	-0.3	3.03e-10	Type 2 diabetes;
LUAD	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg01191920	chr7:158217561	PTPRN2	-0.72	-15.67	-0.61	6.01e-44	Obesity-related traits;
LUAD	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.5	0.34	3.82e-13	Breast cancer;
LUAD	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg19302996	chr17:73780495	UNK	-0.38	-6.4	-0.3	4.12e-10	White matter hyperintensity burden;
LUAD	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg22508957	chr16:3507546	NAT15	0.84	10.62	0.46	1.62e-23	Tuberculosis;
LUAD	trans	rs8002861	0.747	rs12866387	chr13:44391936	A/G	cg17145862	chr1:211918768	LPGAT1	0.56	11.42	0.49	1.64e-26	Leprosy;
LUAD	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.18e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1847202	0.859	rs4550778	chr3:72949198	G/A	cg25664220	chr3:72788482	NA	-0.43	-7.56	-0.34	2.54e-13	Motion sickness;
LUAD	cis	rs9768139	0.708	rs6459858	chr7:158115055	A/G	cg24154853	chr7:158122151	PTPRN2	0.57	11.26	0.48	6.52e-26	Calcium levels;
LUAD	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg22676075	chr6:135203613	NA	0.43	7.99	0.36	1.33e-14	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.9	0.36	2.45e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4372836	0.504	rs13009357	chr2:29041877	T/C	cg09522027	chr2:28974177	PPP1CB	-0.61	-11.0	-0.47	6.34e-25	Body mass index;
LUAD	cis	rs2882667	0.858	rs11242447	chr5:138426173	T/C	cg04439458	chr5:138467593	SIL1	-0.54	-9.61	-0.42	6.78e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg12292205	chr6:26970375	C6orf41	0.49	8.51	0.38	3.08e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg27454412	chr7:1067447	C7orf50	-0.34	-6.6	-0.31	1.21e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg24675056	chr1:15929824	NA	0.46	7.92	0.36	2.09e-14	Systolic blood pressure;
LUAD	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg06623918	chr6:96969491	KIAA0776	-0.88	-17.37	-0.65	2.11e-51	Headache;
LUAD	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg10792982	chr14:105748885	BRF1	0.45	9.42	0.42	2.87e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg00431813	chr7:1051703	C7orf50	-0.34	-6.39	-0.3	4.41e-10	Longevity;Endometriosis;
LUAD	cis	rs11030122	0.702	rs10835311	chr11:3949027	G/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.22	-0.33	2.43e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-6.51	-0.3	2.17e-10	Lung cancer;
LUAD	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	6.93	0.32	1.55e-11	Cognitive test performance;
LUAD	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21984481	chr17:79567631	NPLOC4	0.65	15.66	0.61	6.36e-44	Eye color traits;
LUAD	cis	rs500891	0.525	rs13215578	chr6:84107234	C/T	cg08257003	chr6:84140564	ME1	0.34	6.49	0.3	2.47e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg09658497	chr7:2847517	GNA12	-0.54	-9.08	-0.4	4.21e-18	Height;
LUAD	cis	rs4845570	0.850	rs4618976	chr1:151766588	A/G	cg07092448	chr1:151763213	TDRKH	0.75	8.9	0.4	1.6e-17	Coronary artery disease;
LUAD	cis	rs2979489	0.773	rs10954993	chr8:30303388	C/T	cg26383811	chr8:30366931	RBPMS	0.64	9.84	0.43	1.06e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs12681288	0.523	rs73176528	chr8:961962	G/A	cg04851639	chr8:1020857	NA	-0.31	-7.24	-0.33	2.19e-12	Schizophrenia;
LUAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg23978390	chr7:1156363	C7orf50	0.57	8.83	0.39	2.74e-17	Longevity;Endometriosis;
LUAD	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg22166914	chr1:53195759	ZYG11B	-0.4	-6.56	-0.3	1.55e-10	Monocyte count;
LUAD	cis	rs9837602	1.000	rs7616988	chr3:99701134	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-8.82	-0.39	3.09e-17	Breast cancer;
LUAD	trans	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg26043149	chr18:55253948	FECH	0.51	8.31	0.37	1.34e-15	Bone mineral density;
LUAD	trans	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg01620082	chr3:125678407	NA	-0.7	-8.0	-0.36	1.23e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.42	-0.42	3e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.96	-0.36	1.62e-14	Personality dimensions;
LUAD	cis	rs12541635	0.677	rs1006480	chr8:106975524	T/C	cg10147462	chr8:107024639	NA	0.53	9.59	0.42	8.01e-20	Age of smoking initiation;
LUAD	cis	rs829883	0.867	rs1641640	chr12:98896017	A/G	cg25150519	chr12:98850993	NA	0.67	11.08	0.47	3.26e-25	Colorectal adenoma (advanced);
LUAD	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.35	-18.12	-0.66	9.73e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs10979	0.597	rs9390118	chr6:143907610	A/G	cg25407410	chr6:143891975	LOC285740	-0.54	-7.66	-0.35	1.26e-13	Hypospadias;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03428813	chr2:62115351	CCT4	-0.41	-6.36	-0.3	5.15e-10	Height;
LUAD	cis	rs9462027	0.628	rs6905393	chr6:34776626	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.76	-0.39	4.66e-17	Systemic lupus erythematosus;
LUAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg21782813	chr7:2030301	MAD1L1	0.41	6.57	0.3	1.53e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs8002861	0.619	rs9567289	chr13:44437104	C/T	cg12856521	chr11:46389249	DGKZ	0.48	8.04	0.36	9.06e-15	Leprosy;
LUAD	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg24838063	chr12:130822603	PIWIL1	0.64	10.81	0.47	3.28e-24	Menopause (age at onset);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg15021531	chr12:57913928	DDIT3	-0.39	-6.47	-0.3	2.67e-10	Cancer;
LUAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	8.94	0.4	1.19e-17	Alzheimer's disease;
LUAD	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg09033577	chr2:88485744	THNSL2	-0.54	-6.5	-0.3	2.22e-10	Plasma clusterin levels;
LUAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg12419862	chr22:24373484	LOC391322	-0.78	-14.2	-0.57	1.09e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg19318889	chr4:1322082	MAEA	0.43	7.03	0.32	8.43e-12	Obesity-related traits;
LUAD	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg27286337	chr10:134555280	INPP5A	0.7	9.99	0.44	3.13e-21	Migraine;
LUAD	cis	rs7799006	0.789	rs4719468	chr7:2285019	G/C	cg02951883	chr7:2050386	MAD1L1	-0.47	-7.07	-0.33	6.27e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2109514	1.000	rs3919515	chr7:116151784	C/G	cg12739419	chr7:116140593	CAV2	0.37	8.02	0.36	1.04e-14	Prevalent atrial fibrillation;
LUAD	trans	rs564343	0.560	rs11227384	chr11:65799332	G/T	cg26701943	chr11:108369231	KDELC2	-0.49	-8.0	-0.36	1.16e-14	Obesity (early onset extreme);
LUAD	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	6.82	0.31	3.13e-11	Motion sickness;
LUAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.61	-0.31	1.17e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg02158880	chr13:53174818	NA	-0.55	-9.67	-0.43	4.18e-20	Lewy body disease;
LUAD	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg22563815	chr15:78856949	CHRNA5	-0.32	-6.4	-0.3	4.2e-10	Sudden cardiac arrest;
LUAD	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg06074448	chr4:187884817	NA	-0.36	-7.08	-0.33	6.04e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12618769	0.625	rs78518453	chr2:99213899	T/C	cg10123293	chr2:99228465	UNC50	0.5	8.54	0.38	2.53e-16	Bipolar disorder;
LUAD	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg20744362	chr22:50050164	C22orf34	0.4	8.89	0.4	1.81e-17	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg24147428	chr11:65409760	SIPA1	-0.62	-9.71	-0.43	2.93e-20	Blood pressure (age interaction);
LUAD	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg08601574	chr20:25228251	PYGB	0.46	8.82	0.39	2.94e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg10755058	chr3:40428713	ENTPD3	0.45	8.5	0.38	3.23e-16	Renal cell carcinoma;
LUAD	cis	rs62229266	0.804	rs2255858	chr21:37412752	T/C	cg08632701	chr21:37451849	NA	-0.44	-7.25	-0.33	1.98e-12	Mitral valve prolapse;
LUAD	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg07917127	chr4:99064746	C4orf37	0.44	7.21	0.33	2.6e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg24642844	chr7:1081250	C7orf50	-0.96	-14.36	-0.57	2.34e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg12863693	chr15:85201151	NMB	0.42	7.61	0.35	1.85e-13	Schizophrenia;
LUAD	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg00750074	chr16:89608354	SPG7	-0.55	-9.5	-0.42	1.52e-19	Multiple myeloma (IgH translocation);
LUAD	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg00147160	chr1:26503991	CNKSR1	0.38	8.75	0.39	5.19e-17	Height;
LUAD	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg05082376	chr22:42548792	NA	-0.43	-7.37	-0.34	9.02e-13	Schizophrenia;
LUAD	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.49	-0.6	3.46e-43	Chronic sinus infection;
LUAD	cis	rs6494488	0.500	rs72742931	chr15:64871996	C/T	cg08069370	chr15:64387884	SNX1	-0.75	-6.59	-0.3	1.34e-10	Coronary artery disease;
LUAD	cis	rs2067615	0.524	rs1922433	chr12:107077172	A/G	cg15890332	chr12:107067104	RFX4	0.42	8.76	0.39	4.64e-17	Heart rate;
LUAD	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg04414720	chr1:150670196	GOLPH3L	0.73	13.64	0.55	2.2e-35	Tonsillectomy;
LUAD	cis	rs2425143	1.000	rs12481228	chr20:34218673	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.6	-0.31	1.26e-10	Blood protein levels;
LUAD	cis	rs9715521	0.867	rs4860465	chr4:59832537	G/T	cg11281224	chr4:60001000	NA	-0.56	-9.51	-0.42	1.5e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.71	-14.09	-0.57	3.06e-37	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg08280861	chr8:58055591	NA	0.64	8.29	0.37	1.49e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg07362569	chr17:61921086	SMARCD2	-0.38	-6.67	-0.31	8.25e-11	Prudent dietary pattern;
LUAD	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg21214613	chr1:16344536	HSPB7	0.6	11.52	0.49	7.02e-27	Dilated cardiomyopathy;
LUAD	cis	rs10203711	0.966	rs10929288	chr2:239583146	A/G	cg14580085	chr2:239553406	NA	0.42	9.01	0.4	7.39e-18	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg14917512	chr19:3094685	GNA11	-0.57	-6.65	-0.31	8.96e-11	Diabetic kidney disease;
LUAD	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg18129748	chr3:49941408	MST1R	-0.43	-7.13	-0.33	4.3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06544989	chr22:39130855	UNC84B	0.42	7.76	0.35	6.43e-14	Menopause (age at onset);
LUAD	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.45	6.82	0.31	3.19e-11	Schizophrenia;
LUAD	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg10057126	chr4:77819792	ANKRD56	0.53	9.11	0.4	3.35e-18	Emphysema distribution in smoking;
LUAD	cis	rs1003719	0.788	rs9977602	chr21:38450650	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.52	0.38	2.87e-16	Eye color traits;
LUAD	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg02782426	chr3:40428986	ENTPD3	-0.38	-8.18	-0.37	3.41e-15	Renal cell carcinoma;
LUAD	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg02160872	chr5:212506	CCDC127	-0.51	-6.62	-0.31	1.1e-10	Breast cancer;
LUAD	cis	rs2554380	0.943	rs2562776	chr15:84368163	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.59	-8.65	-0.39	1.08e-16	Height;
LUAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg11062466	chr8:58055876	NA	-0.64	-8.84	-0.39	2.63e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg20673091	chr1:2541236	MMEL1	0.45	9.87	0.43	8.08e-21	Ulcerative colitis;
LUAD	cis	rs8060686	0.668	rs2418739	chr16:68092850	G/C	cg09835421	chr16:68378352	PRMT7	-0.51	-6.59	-0.31	1.3e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg26566898	chr11:117069891	TAGLN	-0.36	-7.07	-0.33	6.51e-12	Blood protein levels;
LUAD	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg03929089	chr4:120376271	NA	0.57	7.13	0.33	4.42e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg04155289	chr7:94953770	PON1	-0.54	-7.36	-0.34	9.74e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg21798802	chr22:38057573	PDXP	0.34	6.98	0.32	1.16e-11	Fat distribution (HIV);
LUAD	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg05340658	chr4:99064831	C4orf37	-0.54	-9.06	-0.4	4.83e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.45	-0.34	5.23e-13	Menarche (age at onset);
LUAD	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg07432352	chr17:45403706	C17orf57	0.45	8.66	0.39	9.85e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4372836	0.658	rs10178852	chr2:28997835	C/T	cg09522027	chr2:28974177	PPP1CB	-0.45	-7.46	-0.34	5.08e-13	Body mass index;
LUAD	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg22815214	chr1:201083145	CACNA1S	-0.56	-9.71	-0.43	2.84e-20	Permanent tooth development;
LUAD	cis	rs732716	0.785	rs62130978	chr19:4429007	C/T	cg21934504	chr19:4445085	UBXN6	0.44	7.3	0.33	1.44e-12	Mean corpuscular volume;
LUAD	trans	rs9914544	0.524	rs7209853	chr17:18798600	G/A	cg21372672	chr17:16614065	CCDC144A	-0.36	-6.46	-0.3	2.9e-10	Educational attainment (years of education);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg26100149	chr5:173315151	CPEB4	-0.4	-6.73	-0.31	5.47e-11	Subcortical brain region volumes;
LUAD	cis	rs62229266	0.659	rs2835245	chr21:37416708	C/T	cg08632701	chr21:37451849	NA	-0.39	-6.45	-0.3	3.01e-10	Mitral valve prolapse;
LUAD	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-11.52	-0.49	7.08e-27	Hemoglobin concentration;
LUAD	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg24154853	chr7:158122151	PTPRN2	0.49	8.09	0.37	6.54e-15	Response to amphetamines;
LUAD	cis	rs1298062	0.717	rs74176110	chr19:50995568	G/C	cg11430371	chr19:50961752	MYBPC2	0.32	6.49	0.3	2.39e-10	Age of smoking initiation;
LUAD	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.33	0.34	1.18e-12	Tonsillectomy;
LUAD	trans	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg26043149	chr18:55253948	FECH	-0.42	-6.89	-0.32	1.98e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg12310025	chr6:25882481	NA	-0.88	-14.47	-0.58	7.58e-39	Blood metabolite levels;
LUAD	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg19346786	chr7:2764209	NA	-0.49	-10.29	-0.45	2.61e-22	Height;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg15383120	chr6:291909	DUSP22	-0.7	-11.76	-0.5	8.3e-28	Menopause (age at onset);
LUAD	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.77	0.31	4.19e-11	Breast cancer;
LUAD	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.05	0.36	8.46e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg07817883	chr1:32538562	TMEM39B	-0.54	-7.06	-0.32	6.82e-12	Monocyte percentage of white cells;
LUAD	cis	rs11190604	0.747	rs11190516	chr10:102173525	G/A	cg07570687	chr10:102243282	WNT8B	0.44	6.35	0.3	5.43e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg00204512	chr16:28754710	NA	0.33	7.11	0.33	4.84e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg17845761	chr1:175162550	KIAA0040	-0.34	-8.96	-0.4	1.07e-17	Alcohol dependence;
LUAD	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg02527881	chr3:46936655	PTH1R	-0.49	-9.65	-0.42	4.62e-20	Colorectal cancer;
LUAD	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.35	6.52	0.3	2.05e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg24818145	chr4:99064322	C4orf37	0.46	7.9	0.36	2.44e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.51	-8.0	-0.36	1.23e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-7.95	-0.36	1.74e-14	Monocyte percentage of white cells;
LUAD	cis	rs4481887	0.893	rs1934543	chr1:248505602	C/G	cg00666640	chr1:248458726	OR2T12	0.28	7.06	0.32	6.67e-12	Common traits (Other);
LUAD	cis	rs9807989	0.729	rs10170583	chr2:102974764	G/A	cg03938978	chr2:103052716	IL18RAP	0.32	6.51	0.3	2.12e-10	Asthma;
LUAD	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.22	0.33	2.4e-12	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg03467027	chr4:99064603	C4orf37	0.41	6.73	0.31	5.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg02993280	chr1:107599747	PRMT6	-0.44	-7.25	-0.33	2.04e-12	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg18867708	chr6:26865862	GUSBL1	0.41	6.54	0.3	1.81e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg08885076	chr2:99613938	TSGA10	0.36	6.55	0.3	1.67e-10	Chronic sinus infection;
LUAD	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg11814155	chr7:99998594	ZCWPW1	0.44	7.49	0.34	4.15e-13	Platelet count;
LUAD	cis	rs494562	1.000	rs494562	chr6:86117129	A/G	cg21730993	chr6:86159210	NT5E	0.73	8.29	0.37	1.49e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg04111992	chr7:158790115	NA	-0.5	-8.48	-0.38	3.82e-16	Facial morphology (factor 20);
LUAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	cis	rs2066819	1.000	rs871130	chr12:56648777	A/G	cg26714650	chr12:56694279	CS	0.74	6.45	0.3	3.08e-10	Psoriasis vulgaris;
LUAD	cis	rs7100689	0.646	rs10736347	chr10:82134465	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.26	0.45	3.26e-22	Post bronchodilator FEV1;
LUAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg16606324	chr3:10149918	C3orf24	0.69	9.97	0.44	3.76e-21	Alzheimer's disease;
LUAD	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg25358565	chr5:93447407	FAM172A	0.58	6.94	0.32	1.44e-11	Diabetic retinopathy;
LUAD	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18876405	chr7:65276391	NA	-0.42	-6.72	-0.31	6.02e-11	Aortic root size;
LUAD	cis	rs2979489	0.891	rs4733495	chr8:30366883	A/G	cg26383811	chr8:30366931	RBPMS	0.7	11.44	0.49	1.42e-26	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08704250	chr15:31115839	NA	-0.73	-13.42	-0.55	1.81e-34	Huntington's disease progression;
LUAD	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg04455712	chr21:45112962	RRP1B	0.47	9.46	0.42	2.17e-19	Mean corpuscular volume;
LUAD	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg20203395	chr5:56204925	C5orf35	-0.5	-7.82	-0.36	4.34e-14	Coronary artery disease;
LUAD	cis	rs4820318	1	rs4820318	chr22:38570313	G/A	cg25457927	chr22:38595422	NA	-0.53	-12.4	-0.52	2.49e-30	Breast cancer;
LUAD	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21582582	chr3:182698605	DCUN1D1	0.72	13.57	0.55	4.42e-35	Intelligence (multi-trait analysis);
LUAD	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg20673091	chr1:2541236	MMEL1	-0.38	-8.09	-0.37	6.18e-15	Ulcerative colitis;
LUAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08280861	chr8:58055591	NA	0.76	9.49	0.42	1.68e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg27494647	chr7:150038898	RARRES2	0.51	9.21	0.41	1.56e-18	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg22920501	chr2:26401640	FAM59B	-0.8	-11.11	-0.48	2.54e-25	Gut microbiome composition (summer);
LUAD	cis	rs2074585	0.802	rs2589940	chr15:90931363	C/T	cg10434728	chr15:90938212	IQGAP1	0.39	7.83	0.36	4.1e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUAD	trans	rs1493916	0.837	rs1027332	chr18:31410097	A/C	cg15819921	chr19:927150	ARID3A	-0.42	-6.86	-0.32	2.44e-11	Life satisfaction;
LUAD	cis	rs2282300	0.702	rs2211018	chr11:30330079	C/T	cg25418670	chr11:30344373	C11orf46	0.53	7.21	0.33	2.62e-12	Morning vs. evening chronotype;
LUAD	cis	rs6840360	0.533	rs13145446	chr4:152729035	G/A	cg22705602	chr4:152727874	NA	0.44	8.61	0.39	1.42e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg21862992	chr11:68658383	NA	0.51	9.42	0.42	2.86e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.83	0.32	2.97e-11	Obesity-related traits;
LUAD	cis	rs939658	0.805	rs4778924	chr15:79443363	T/C	cg17916960	chr15:79447300	NA	-0.54	-11.45	-0.49	1.22e-26	Refractive error;
LUAD	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg09796270	chr17:17721594	SREBF1	-0.39	-7.82	-0.36	4.32e-14	Total body bone mineral density;
LUAD	cis	rs6564851	0.506	rs11645428	chr16:81258896	C/T	cg00908271	chr16:81254010	PKD1L2	0.32	6.64	0.31	9.78e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg03806693	chr22:41940476	POLR3H	0.72	9.2	0.41	1.6e-18	Vitiligo;
LUAD	cis	rs7707921	0.881	rs57621982	chr5:81406770	C/T	cg15871215	chr5:81402204	ATG10	-0.68	-9.6	-0.42	7.12e-20	Breast cancer;
LUAD	cis	rs4766566	0.609	rs1344438	chr12:111735954	C/G	cg10833066	chr12:111807467	FAM109A	0.67	13.7	0.55	1.32e-35	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUAD	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg15790184	chr11:494944	RNH1	0.56	6.73	0.31	5.62e-11	Body mass index;
LUAD	cis	rs13315871	1.000	rs71311869	chr3:58398922	C/T	cg20936604	chr3:58311152	NA	-0.69	-6.9	-0.32	1.86e-11	Cholesterol, total;
LUAD	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg21862992	chr11:68658383	NA	0.5	9.02	0.4	6.63e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1957429	0.808	rs1570296	chr14:65332294	T/A	cg23373153	chr14:65346875	NA	0.6	6.6	0.31	1.2e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg20476274	chr7:133979776	SLC35B4	0.79	14.66	0.58	1.17e-39	Mean platelet volume;
LUAD	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-8.09	-0.37	6.17e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg03929089	chr4:120376271	NA	-0.97	-19.79	-0.69	3.55e-62	Height;
LUAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.25	0.41	1.09e-18	Alzheimer's disease;
LUAD	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg11189052	chr15:85197271	WDR73	0.65	8.87	0.4	2.05e-17	Schizophrenia;
LUAD	cis	rs11893307	0.537	rs6731208	chr2:191503225	A/G	cg27211696	chr2:191398769	TMEM194B	-0.42	-6.38	-0.3	4.75e-10	Mean platelet volume;
LUAD	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05776053	chr2:74358815	NA	0.48	7.21	0.33	2.61e-12	Gestational age at birth (maternal effect);
LUAD	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg11189052	chr15:85197271	WDR73	0.65	8.87	0.4	2.1e-17	Schizophrenia;
LUAD	cis	rs6494488	0.500	rs72742999	chr15:65010510	G/A	cg08069370	chr15:64387884	SNX1	-0.76	-6.77	-0.31	4.43e-11	Coronary artery disease;
LUAD	trans	rs7395662	0.794	rs11511967	chr11:48820453	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.36	-0.34	9.44e-13	HDL cholesterol;
LUAD	cis	rs4523957	0.590	rs9899427	chr17:2063550	A/T	cg16513277	chr17:2031491	SMG6	-0.97	-19.25	-0.68	9.35e-60	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg25036284	chr2:26402008	FAM59B	-0.82	-12.52	-0.52	8.35e-31	Gut microbiome composition (summer);
LUAD	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg19622623	chr12:86230825	RASSF9	-0.38	-6.81	-0.31	3.32e-11	Major depressive disorder;
LUAD	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg19729930	chr2:74357872	NA	0.95	15.53	0.6	2.35e-43	Gestational age at birth (maternal effect);
LUAD	cis	rs7017914	0.967	rs7001162	chr8:71587470	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.58	-0.3	1.44e-10	Bone mineral density;
LUAD	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg10518543	chr12:38710700	ALG10B	-0.49	-8.19	-0.37	3.21e-15	Morning vs. evening chronotype;
LUAD	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg01802117	chr1:53393560	SCP2	-0.33	-6.43	-0.3	3.43e-10	Monocyte count;
LUAD	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg18827107	chr12:86230957	RASSF9	-0.7	-12.93	-0.53	1.93e-32	Major depressive disorder;
LUAD	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg04546413	chr19:29218101	NA	0.71	10.52	0.46	3.77e-23	Methadone dose in opioid dependence;
LUAD	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg00074818	chr8:8560427	CLDN23	0.66	10.26	0.45	3.29e-22	Obesity-related traits;
LUAD	cis	rs12505328	0.569	rs6832610	chr4:174359345	C/T	cg12145043	chr4:174357286	NA	-0.53	-7.88	-0.36	2.73e-14	Chin dimples;
LUAD	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg17863274	chr19:49399704	TULP2	-0.55	-8.36	-0.38	9.17e-16	Red cell distribution width;
LUAD	cis	rs7216064	0.628	rs62084702	chr17:66043157	C/T	cg08758996	chr17:66097529	LOC651250	-0.42	-7.09	-0.33	5.49e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs9796	0.866	rs1678750	chr15:41410705	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.38	-7.07	-0.33	6.28e-12	Menopause (age at onset);
LUAD	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg00814883	chr7:100076585	TSC22D4	-0.86	-12.46	-0.52	1.45e-30	Platelet count;
LUAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg22907277	chr7:1156413	C7orf50	0.62	7.66	0.35	1.28e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11048434	0.736	rs11048338	chr12:9121362	C/G	cg13575925	chr12:9217583	LOC144571	0.38	7.18	0.33	3.22e-12	Sjögren's syndrome;
LUAD	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg07776626	chr8:57350775	NA	-0.61	-8.94	-0.4	1.19e-17	Obesity-related traits;
LUAD	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg03676636	chr4:99064102	C4orf37	0.32	8.1	0.37	6.14e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg12292205	chr6:26970375	C6orf41	0.49	8.54	0.38	2.47e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg24558204	chr6:135376177	HBS1L	0.47	8.58	0.38	1.83e-16	Red blood cell count;
LUAD	cis	rs11771526	0.901	rs34376799	chr7:32316932	T/C	cg27532318	chr7:32358331	NA	0.59	7.64	0.35	1.51e-13	Body mass index;
LUAD	cis	rs2692947	0.760	rs2438924	chr2:96645069	A/G	cg23100626	chr2:96804247	ASTL	0.29	7.64	0.35	1.47e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg11693508	chr17:37793320	STARD3	-0.74	-9.65	-0.42	4.64e-20	Bipolar disorder;
LUAD	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg11871910	chr12:69753446	YEATS4	0.55	8.65	0.39	1.07e-16	Blood protein levels;
LUAD	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg16701003	chr16:89028210	CBFA2T3	0.52	10.44	0.45	7.51e-23	Social autistic-like traits;
LUAD	cis	rs2046867	0.908	rs1106310	chr3:72818902	A/T	cg25664220	chr3:72788482	NA	0.59	11.15	0.48	1.79e-25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg22532475	chr10:104410764	TRIM8	0.33	6.85	0.32	2.64e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg07936489	chr17:37558343	FBXL20	0.44	6.87	0.32	2.37e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg24818145	chr4:99064322	C4orf37	0.47	7.98	0.36	1.41e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62400317	0.762	rs1329711	chr6:44963401	A/G	cg20913747	chr6:44695427	NA	-0.45	-7.01	-0.32	9.47e-12	Total body bone mineral density;
LUAD	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.35	-0.41	4.99e-19	Life satisfaction;
LUAD	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg06618935	chr21:46677482	NA	-0.43	-8.25	-0.37	2.1e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.83	-0.36	3.94e-14	Blood metabolite levels;
LUAD	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg14828511	chr1:107599125	PRMT6	0.55	9.39	0.42	3.8e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs10802346	0.545	rs2362253	chr1:246371676	G/A	cg22732515	chr19:44031385	ETHE1	0.59	9.53	0.42	1.2e-19	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs11676348	0.755	rs62183956	chr2:219046122	C/T	cg06547715	chr2:218990976	CXCR2	-0.41	-9.78	-0.43	1.68e-20	Ulcerative colitis;
LUAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg03188948	chr7:1209495	NA	0.76	9.85	0.43	9.47e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg08601574	chr20:25228251	PYGB	-0.45	-8.21	-0.37	2.73e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs3806843	0.576	rs246036	chr5:140331886	T/G	cg18668511	chr5:140557227	PCDHB8	-0.37	-6.52	-0.3	2e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg06558623	chr16:89946397	TCF25	1.12	9.85	0.43	9.8e-21	Skin colour saturation;
LUAD	trans	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.4	-0.3	4.19e-10	Neuroticism;
LUAD	cis	rs12210905	0.688	rs115030474	chr6:27512220	C/T	cg08851530	chr6:28072375	NA	0.89	6.45	0.3	2.99e-10	Hip circumference adjusted for BMI;
LUAD	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg27661571	chr11:113659931	NA	-0.68	-7.92	-0.36	2.05e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.79	-0.43	1.59e-20	Alzheimer's disease;
LUAD	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg02951883	chr7:2050386	MAD1L1	-0.64	-10.21	-0.44	5.14e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg02423579	chr7:2872169	GNA12	-0.89	-16.17	-0.62	3.87e-46	Height;
LUAD	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg11494091	chr17:61959527	GH2	0.4	7.08	0.33	6.14e-12	Height;
LUAD	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg22532475	chr10:104410764	TRIM8	0.34	6.96	0.32	1.34e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg26022315	chr17:47021804	SNF8	0.41	7.43	0.34	6.13e-13	Type 2 diabetes;
LUAD	cis	rs3750082	0.889	rs7781915	chr7:32923159	T/C	cg05721444	chr7:32995514	FKBP9	0.37	6.75	0.31	4.76e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg14779329	chr11:130786720	SNX19	0.37	6.52	0.3	2e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg02030672	chr11:45687055	CHST1	0.46	8.33	0.38	1.12e-15	Obesity-related traits;
LUAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg03188948	chr7:1209495	NA	0.82	9.95	0.44	4.28e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs68170813	0.596	rs76888321	chr7:106945926	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.52	-0.46	3.82e-23	Coronary artery disease;
LUAD	cis	rs1712517	0.771	rs10883858	chr10:105127708	G/A	cg05636881	chr10:105038444	INA	0.32	6.36	0.3	5.16e-10	Migraine;
LUAD	cis	rs12612619	0.695	rs4665935	chr2:27229892	C/A	cg00617064	chr2:27272375	NA	0.35	6.62	0.31	1.07e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.55	-0.3	1.66e-10	Total body bone mineral density;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09639837	chr10:30722502	MAP3K8	-0.68	-6.57	-0.3	1.45e-10	Type 2 diabetes;
LUAD	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg10518543	chr12:38710700	ALG10B	-0.42	-7.12	-0.33	4.61e-12	Morning vs. evening chronotype;
LUAD	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.11	-0.37	5.54e-15	Prostate cancer;
LUAD	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg25894440	chr7:65020034	NA	-0.62	-6.63	-0.31	1.05e-10	Diabetic kidney disease;
LUAD	cis	rs7192380	0.893	rs12921782	chr16:69780022	C/T	cg26679644	chr16:69762563	NA	-0.5	-9.4	-0.42	3.39e-19	Sjögren's syndrome;
LUAD	cis	rs2677744	0.626	rs11854429	chr15:91489685	C/T	cg23684204	chr15:91497937	RCCD1	-0.43	-7.04	-0.32	7.65e-12	Attention deficit hyperactivity disorder;
LUAD	trans	rs17685	0.753	rs10476	chr7:75696420	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.05	-27.29	-0.8	2.51e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1232027	0.622	rs1650648	chr5:79968258	A/T	cg24059623	chr5:79951536	MSH3;DHFR	0.41	6.66	0.31	8.76e-11	Huntington's disease progression;
LUAD	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg25237894	chr2:233734115	C2orf82	0.63	11.93	0.5	1.77e-28	Coronary artery disease;
LUAD	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg05044414	chr3:183734942	ABCC5	0.47	9.95	0.44	4.28e-21	Anterior chamber depth;
LUAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg27454412	chr7:1067447	C7orf50	0.44	7.01	0.32	9.47e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01416487	chr12:96252677	SNRPF	-0.45	-7.66	-0.35	1.28e-13	Cancer;
LUAD	cis	rs427941	0.632	rs201509	chr7:101765002	C/T	cg06246474	chr7:101738831	CUX1	0.37	6.45	0.3	2.99e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs10411161	1.000	rs72626249	chr19:52364875	C/T	cg22319618	chr22:45562946	NUP50	-0.52	-6.42	-0.3	3.76e-10	Breast cancer;
LUAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg20849893	chr7:64541193	NA	0.45	7.2	0.33	2.81e-12	Calcium levels;
LUAD	cis	rs2235649	0.833	rs9939694	chr16:1852760	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.41	-6.5	-0.3	2.25e-10	Blood metabolite levels;
LUAD	cis	rs4372836	1.000	rs7579277	chr2:28996295	G/A	cg09522027	chr2:28974177	PPP1CB	-0.6	-9.51	-0.42	1.5e-19	Body mass index;
LUAD	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg04154034	chr17:28927549	LRRC37B2	0.69	6.96	0.32	1.32e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg21138405	chr5:131827807	IRF1	0.6	13.88	0.56	2.35e-36	Asthma (sex interaction);
LUAD	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg06064525	chr11:970664	AP2A2	-0.55	-11.1	-0.48	2.62e-25	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg03676636	chr4:99064102	C4orf37	0.31	8.15	0.37	4.23e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.52	0.34	3.27e-13	Breast cancer;
LUAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.66	-0.35	1.25e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs2046867	0.862	rs62251645	chr3:72805733	T/C	cg04365224	chr3:72788183	NA	-0.46	-7.03	-0.32	8.18e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09352908	chr3:37017749	NA	0.53	6.41	0.3	3.87e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs208520	1.000	rs208536	chr6:66963440	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-13.49	-0.55	9.96e-35	Exhaled nitric oxide output;
LUAD	cis	rs12200560	0.505	rs211179	chr6:97074103	A/G	cg06623918	chr6:96969491	KIAA0776	0.47	7.21	0.33	2.64e-12	Coronary heart disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05265258	chr11:5705995	TRIM5	-0.37	-6.38	-0.3	4.68e-10	Cancer;
LUAD	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg05425664	chr17:57184151	TRIM37	-0.44	-7.84	-0.36	3.71e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg05340658	chr4:99064831	C4orf37	0.56	9.46	0.42	2.13e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg23815491	chr16:72088622	HP	0.48	7.85	0.36	3.5e-14	Blood protein levels;
LUAD	cis	rs4889855	0.556	rs4297763	chr17:78533626	G/C	cg16591659	chr17:78472290	NA	0.37	6.68	0.31	7.58e-11	Fractional excretion of uric acid;
LUAD	cis	rs2742417	1.000	rs9821974	chr3:45784963	T/C	cg10512202	chr3:45649293	LIMD1	0.38	6.72	0.31	5.79e-11	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg21681030	chr2:46777652	RHOQ	0.37	6.52	0.3	1.96e-10	Height;
LUAD	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg11062466	chr8:58055876	NA	0.77	9.37	0.41	4.39e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02735721	chr1:144932625	PDE4DIP	0.43	6.63	0.31	9.99e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs4588572	0.643	rs10063742	chr5:77759362	A/G	cg11547950	chr5:77652471	NA	-0.77	-12.55	-0.52	6.24e-31	Triglycerides;
LUAD	cis	rs4911253	0.527	rs853859	chr20:31402269	A/G	cg13636640	chr20:31349939	DNMT3B	0.61	10.25	0.45	3.67e-22	Lymphocyte counts;
LUAD	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg00339695	chr16:24857497	SLC5A11	0.47	8.67	0.39	9.13e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg00431813	chr7:1051703	C7orf50	-0.4	-7.77	-0.35	6e-14	Longevity;Endometriosis;
LUAD	cis	rs986417	0.901	rs1007152	chr14:60999493	C/T	cg27398547	chr14:60952738	C14orf39	0.66	8.07	0.37	7.54e-15	Gut microbiota (bacterial taxa);
LUAD	cis	rs6960043	0.905	rs10231021	chr7:15060429	T/A	cg19272540	chr7:15055459	NA	-0.32	-6.97	-0.32	1.22e-11	Type 2 diabetes;
LUAD	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11890956	chr21:40555474	PSMG1	0.82	14.52	0.58	4.63e-39	Cognitive function;
LUAD	cis	rs12545109	0.800	rs2670028	chr8:57423673	G/A	cg21220214	chr8:57350948	NA	-0.58	-8.38	-0.38	7.69e-16	Obesity-related traits;
LUAD	cis	rs4711350	0.765	rs2182658	chr6:33748831	G/T	cg18005901	chr6:33739558	LEMD2	0.57	9.28	0.41	8.93e-19	Schizophrenia;
LUAD	trans	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg27411982	chr8:10470053	RP1L1	0.43	7.94	0.36	1.82e-14	Mood instability;
LUAD	cis	rs6669072	0.647	rs814543	chr1:91241709	C/T	cg08895590	chr1:91227319	NA	0.31	6.54	0.3	1.74e-10	Cognitive function;
LUAD	cis	rs673604	1.000	rs925718	chr1:35675764	C/G	cg12633102	chr1:35676489	NA	-0.64	-8.36	-0.38	8.82e-16	Endometrial cancer;
LUAD	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg11645453	chr3:52864694	ITIH4	-0.36	-7.02	-0.32	9.03e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg18811423	chr2:55921094	PNPT1	0.47	7.59	0.35	2.11e-13	Metabolic syndrome;
LUAD	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg03714773	chr7:91764589	CYP51A1	0.3	7.02	0.32	9.05e-12	Breast cancer;
LUAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg03321319	chr22:22222323	MAPK1	-0.42	-6.65	-0.31	9.01e-11	Vertical cup-disc ratio;
LUAD	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg00933542	chr6:150070202	PCMT1	0.45	10.01	0.44	2.58e-21	Lung cancer;
LUAD	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg17173187	chr15:85201210	NMB	0.51	8.68	0.39	8.86e-17	Schizophrenia;
LUAD	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	9.61	0.42	6.56e-20	Total body bone mineral density;
LUAD	cis	rs7607369	0.559	rs4674342	chr2:219660064	T/C	cg02176678	chr2:219576539	TTLL4	-0.54	-10.46	-0.45	6.41e-23	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg02990361	chr1:107599529	PRMT6	0.63	10.54	0.46	3.2e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg11062466	chr8:58055876	NA	0.54	7.26	0.33	1.85e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs15676	0.783	rs2280843	chr9:131585069	A/G	cg00228799	chr9:131580591	ENDOG	0.47	7.35	0.34	1.02e-12	Blood metabolite levels;
LUAD	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg10057126	chr4:77819792	ANKRD56	0.53	9.01	0.4	7.02e-18	Emphysema distribution in smoking;
LUAD	trans	rs7246760	0.737	rs60584926	chr19:9797014	C/T	cg02900749	chr2:68251473	NA	-0.59	-6.56	-0.3	1.59e-10	Pursuit maintenance gain;
LUAD	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg23887609	chr12:130822674	PIWIL1	-0.44	-7.16	-0.33	3.54e-12	Menopause (age at onset);
LUAD	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.46	-0.6	4.69e-43	Chronic sinus infection;
LUAD	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg07741184	chr6:167504864	NA	0.36	8.17	0.37	3.66e-15	Primary biliary cholangitis;
LUAD	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.83	12.1	0.51	3.87e-29	Smoking behavior;
LUAD	trans	rs9929218	1.000	rs13333528	chr16:68790502	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-14.36	-0.57	2.26e-38	Colorectal cancer;
LUAD	cis	rs8014204	1.000	rs10483863	chr14:75322327	A/G	cg03030879	chr14:75389066	RPS6KL1	0.34	6.39	0.3	4.29e-10	Caffeine consumption;
LUAD	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg12311346	chr5:56204834	C5orf35	0.66	10.48	0.45	5.16e-23	Coronary artery disease;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg25261059	chr19:44031185	ETHE1	-0.46	-7.67	-0.35	1.18e-13	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg17105886	chr17:28927953	LRRC37B2	0.62	7.04	0.32	7.92e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg17724175	chr1:150552817	MCL1	0.41	9.84	0.43	1.04e-20	Tonsillectomy;
LUAD	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg00255919	chr5:131827918	IRF1	-0.49	-11.46	-0.49	1.11e-26	Asthma (sex interaction);
LUAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg16606324	chr3:10149918	C3orf24	0.62	9.79	0.43	1.5e-20	Alzheimer's disease;
LUAD	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg04036182	chr15:45458818	NA	-0.36	-6.48	-0.3	2.6200000000000003e-10	Glomerular filtration rate;
LUAD	cis	rs2688608	0.725	rs2675666	chr10:75682651	G/T	cg23231163	chr10:75533350	FUT11	-0.37	-6.91	-0.32	1.84e-11	Inflammatory bowel disease;
LUAD	cis	rs1461503	0.966	rs10790545	chr11:122838350	G/C	cg27398637	chr11:122830231	C11orf63	-0.36	-7.01	-0.32	9.34e-12	Menarche (age at onset);
LUAD	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg22681709	chr2:178499509	PDE11A	0.43	7.31	0.33	1.38e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs7665090	1.000	rs4586937	chr4:103556462	C/G	cg07973026	chr4:103553119	MANBA	-0.43	-7.66	-0.35	1.3e-13	Primary biliary cholangitis;
LUAD	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-9.22	-0.41	1.39e-18	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs727479	0.543	rs8023263	chr15:51517597	G/T	cg19946085	chr15:51559439	CYP19A1	-0.36	-6.63	-0.31	1.04e-10	Estradiol levels;
LUAD	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.51	-0.42	1.42e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg25985355	chr7:65971099	NA	0.38	7.04	0.32	8.03e-12	Aortic root size;
LUAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg26516362	chr5:178986906	RUFY1	0.48	8.21	0.37	2.64e-15	Lung cancer;
LUAD	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg27433088	chr4:174089019	GALNT7	0.41	7.69	0.35	1.06e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg25985355	chr7:65971099	NA	-0.51	-6.36	-0.3	5.22e-10	Diabetic kidney disease;
LUAD	cis	rs36715	1.000	rs36693	chr5:127548700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.48	6.73	0.31	5.46e-11	Breast cancer;
LUAD	cis	rs7215564	0.908	rs77750710	chr17:78717117	C/T	cg09596252	chr17:78655493	RPTOR	0.58	6.53	0.3	1.84e-10	Myopia (pathological);
LUAD	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg23933602	chr10:16859644	RSU1	0.61	8.32	0.38	1.19e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs7503807	0.967	rs8064502	chr17:78562434	C/A	cg09596252	chr17:78655493	RPTOR	0.37	7.01	0.32	9.48e-12	Obesity;
LUAD	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg04842962	chr6:43655489	MRPS18A	1.06	26.87	0.79	1.71e-93	IgG glycosylation;
LUAD	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg08645402	chr16:4508243	NA	0.56	10.43	0.45	7.92e-23	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08219700	chr8:58056026	NA	-0.64	-8.37	-0.38	8.42e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs2637266	0.935	rs2583048	chr10:78404507	C/G	cg18941641	chr10:78392320	NA	0.34	7.08	0.33	6.08e-12	Pulmonary function;
LUAD	cis	rs2806561	0.704	rs7532266	chr1:23551623	A/C	cg19743168	chr1:23544995	NA	-0.39	-6.67	-0.31	8.14e-11	Height;
LUAD	trans	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg14791747	chr16:20752902	THUMPD1	-0.62	-9.42	-0.42	3.02e-19	Cognitive test performance;
LUAD	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg06108461	chr20:60628389	TAF4	-0.96	-17.48	-0.65	6.76e-52	Body mass index;
LUAD	cis	rs2795502	0.564	rs11239840	chr10:43439353	C/T	cg20628663	chr10:43360327	NA	0.6	6.87	0.32	2.25e-11	Blood protein levels;
LUAD	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg18196295	chr10:418757	DIP2C	0.44	7.35	0.34	1.02e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs4664308	1.000	rs10929965	chr2:160906931	C/T	cg03641300	chr2:160917029	PLA2R1	0.4	6.94	0.32	1.49e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg00898013	chr13:113819073	PROZ	-0.65	-11.66	-0.49	1.97e-27	Platelet distribution width;
LUAD	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.14	-0.33	4.1e-12	Mood instability;
LUAD	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22496380	chr5:211416	CCDC127	-1.2	-15.52	-0.6	2.54e-43	Breast cancer;
LUAD	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg00383909	chr3:49044727	WDR6	0.83	7.69	0.35	1.06e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg23229984	chr5:148520753	ABLIM3	0.5	7.75	0.35	6.91e-14	Breast cancer;
LUAD	cis	rs739496	0.744	rs10849951	chr12:111910912	G/A	cg10833066	chr12:111807467	FAM109A	0.46	8.35	0.38	1.01e-15	Platelet count;
LUAD	cis	rs7107174	1.000	rs2248407	chr11:77937800	G/A	cg19901956	chr11:77921274	USP35	-0.51	-6.69	-0.31	7.15e-11	Testicular germ cell tumor;
LUAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg10295955	chr4:187884368	NA	-1.17	-30.82	-0.83	3.54e-110	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg18180107	chr4:99064573	C4orf37	0.44	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12505328	0.966	rs11132984	chr4:174358851	A/G	cg12145043	chr4:174357286	NA	-0.59	-10.38	-0.45	1.27e-22	Chin dimples;
LUAD	cis	rs1595825	0.945	rs16826320	chr2:198845623	T/C	cg11031976	chr2:198649780	BOLL	-0.47	-7.02	-0.32	9.13e-12	Ulcerative colitis;
LUAD	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg05182265	chr7:156933206	UBE3C	0.8	17.11	0.64	2.98e-50	Body mass index;
LUAD	cis	rs877282	0.898	rs11253350	chr10:765968	G/A	cg06581033	chr10:766294	NA	-0.62	-8.35	-0.38	1.02e-15	Uric acid levels;
LUAD	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg16006841	chr5:176797999	RGS14	-0.6	-9.36	-0.41	4.68e-19	Urate levels in lean individuals;
LUAD	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24308560	chr3:49941425	MST1R	-0.56	-9.43	-0.42	2.65e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-8.13	-0.37	4.83e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4906332	0.966	rs34372508	chr14:103977515	G/A	cg13511324	chr14:104056883	C14orf153	0.26	6.37	0.3	5.07e-10	Coronary artery disease;
LUAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.86	16.44	0.62	2.69e-47	Lymphocyte counts;
LUAD	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.49	0.6	3.38e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg05044414	chr3:183734942	ABCC5	0.39	8.03	0.36	9.7e-15	Anterior chamber depth;
LUAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06873352	chr17:61820015	STRADA	0.83	18.65	0.67	4.54e-57	Prudent dietary pattern;
LUAD	cis	rs55788414	0.932	rs9921748	chr16:81181783	T/C	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.9	-0.36	2.46e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg23887609	chr12:130822674	PIWIL1	0.4	6.66	0.31	8.62e-11	Menopause (age at onset);
LUAD	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.82	-0.5	4.73e-28	Mean corpuscular volume;
LUAD	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg25767906	chr1:53392781	SCP2	0.42	7.9	0.36	2.48e-14	Monocyte count;
LUAD	cis	rs7107174	1.000	rs7113042	chr11:78035832	C/T	cg19901956	chr11:77921274	USP35	0.45	6.55	0.3	1.63e-10	Testicular germ cell tumor;
LUAD	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.92	-0.32	1.66e-11	Total cholesterol levels;
LUAD	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg00204512	chr16:28754710	NA	0.32	6.6	0.31	1.21e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01320780	chr8:22298453	PPP3CC	-0.53	-6.67	-0.31	8.15e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.74	-0.5	9.47e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg19773385	chr1:10388646	KIF1B	-0.42	-6.82	-0.31	3.24e-11	Hepatocellular carcinoma;
LUAD	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.77	-0.35	6e-14	Monocyte percentage of white cells;
LUAD	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg05283184	chr6:79620031	NA	-0.61	-12.28	-0.51	7.72e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg20607798	chr8:58055168	NA	0.79	9.69	0.43	3.43e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs12681287	0.640	rs13269259	chr8:87470453	G/A	cg27223183	chr8:87520930	FAM82B	-0.67	-9.54	-0.42	1.12e-19	Caudate activity during reward;
LUAD	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg26597838	chr10:835615	NA	1.04	15.53	0.6	2.36e-43	Eosinophil percentage of granulocytes;
LUAD	cis	rs977987	0.778	rs7206541	chr16:75436713	A/T	cg03315344	chr16:75512273	CHST6	0.64	14.14	0.57	1.96e-37	Dupuytren's disease;
LUAD	cis	rs9462027	0.628	rs2764197	chr6:34705055	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.02	-0.4	6.62e-18	Systemic lupus erythematosus;
LUAD	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg16329197	chr12:53359506	NA	-0.85	-15.31	-0.6	1.98e-42	Cancer (pleiotropy);
LUAD	cis	rs11677416	1.000	rs1800794	chr2:113543273	G/A	cg27083787	chr2:113543245	IL1A	0.41	6.75	0.31	4.77e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.33	-7.48	-0.34	4.22e-13	Lung cancer;
LUAD	cis	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg27411982	chr8:10470053	RP1L1	0.39	7.6	0.35	1.92e-13	Neuroticism;
LUAD	cis	rs8067545	0.685	rs4479309	chr17:19971583	C/T	cg04132472	chr17:19861366	AKAP10	0.29	6.83	0.32	3e-11	Schizophrenia;
LUAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg08219700	chr8:58056026	NA	0.42	6.39	0.3	4.39e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs17152411	0.947	rs61873270	chr10:126595923	C/A	cg07906193	chr10:126599966	NA	0.53	7.6	0.35	1.95e-13	Height;
LUAD	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg19622623	chr12:86230825	RASSF9	-0.39	-7.02	-0.32	9.09e-12	Major depressive disorder;
LUAD	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg07917127	chr4:99064746	C4orf37	0.41	6.85	0.32	2.55e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg12623302	chr6:28058802	ZSCAN12L1	-0.34	-6.79	-0.31	3.92e-11	Depression;
LUAD	trans	rs7395662	0.963	rs1857786	chr11:48967424	G/A	cg00717180	chr2:96193071	NA	-0.4	-7.51	-0.34	3.45e-13	HDL cholesterol;
LUAD	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg13010199	chr12:38710504	ALG10B	0.39	6.37	0.3	5.05e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg00750074	chr16:89608354	SPG7	-0.52	-8.6	-0.39	1.56e-16	Multiple myeloma (IgH translocation);
LUAD	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg04517722	chr19:17905589	B3GNT3	0.44	8.0	0.36	1.2e-14	Tumor biomarkers;
LUAD	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg17366294	chr4:99064904	C4orf37	0.67	12.99	0.53	1.07e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7665090	1.000	rs7699678	chr4:103550096	G/A	cg07973026	chr4:103553119	MANBA	0.47	8.4	0.38	6.94e-16	Primary biliary cholangitis;
LUAD	cis	rs300774	0.800	rs393008	chr2:125639	A/G	cg21211680	chr2:198530	NA	-0.46	-6.66	-0.31	8.34e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs1595825	1.000	rs1440088	chr2:198871417	A/C	cg10547527	chr2:198650123	BOLL	-0.47	-6.62	-0.31	1.08e-10	Ulcerative colitis;
LUAD	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg15445000	chr17:37608096	MED1	-0.45	-8.35	-0.38	1.01e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	10.32	0.45	2.1e-22	Lung cancer in ever smokers;
LUAD	cis	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg02966332	chr20:62369605	LIME1	0.46	7.61	0.35	1.85e-13	Prostate cancer;
LUAD	cis	rs1595825	0.786	rs77773624	chr2:198514845	G/A	cg00982548	chr2:198649783	BOLL	-0.62	-8.88	-0.4	1.95e-17	Ulcerative colitis;
LUAD	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg04756594	chr16:24857601	SLC5A11	0.49	9.62	0.42	6.2e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2742417	1.000	rs1969624	chr3:45734818	C/T	cg10512202	chr3:45649293	LIMD1	-0.36	-6.43	-0.3	3.53e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg10518543	chr12:38710700	ALG10B	0.42	6.43	0.3	3.49e-10	Bladder cancer;
LUAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.15	-0.37	4.02e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs11098699	0.821	rs13114886	chr4:124217302	T/A	cg09941581	chr4:124220074	SPATA5	0.48	7.83	0.36	3.93e-14	Mosquito bite size;
LUAD	cis	rs7020830	0.858	rs67036212	chr9:37133538	A/G	cg14294708	chr9:37120828	ZCCHC7	0.86	16.41	0.62	3.39e-47	Schizophrenia;
LUAD	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg13870426	chr17:30244630	NA	-0.55	-6.6	-0.31	1.23e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1997103	0.954	rs1917769	chr7:55392325	T/A	cg17469321	chr7:55412551	NA	0.68	11.6	0.49	3.38e-27	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg16329650	chr2:213403929	ERBB4	0.6	10.58	0.46	2.34e-23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs2544390	1.000	rs2673172	chr2:170204800	A/C	cg26297968	chr2:211035960	C2orf67	-0.37	-6.38	-0.3	4.79e-10	Urate levels;
LUAD	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg17366294	chr4:99064904	C4orf37	0.59	9.94	0.44	4.52e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713675	0.565	rs942640	chr6:33686442	G/T	cg13859433	chr6:33739653	LEMD2	-0.3	-7.15	-0.33	3.87e-12	Plateletcrit;
LUAD	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg15737290	chr11:93063684	CCDC67	0.52	7.26	0.33	1.88e-12	Pulmonary function decline;
LUAD	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg07169764	chr2:136633963	MCM6	0.77	9.02	0.4	6.39e-18	Corneal structure;
LUAD	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	6.85	0.32	2.57e-11	Menarche (age at onset);
LUAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03647317	chr4:187891568	NA	-0.37	-6.91	-0.32	1.83e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg03477792	chr4:77819574	ANKRD56	0.48	7.3	0.33	1.4e-12	Emphysema distribution in smoking;
LUAD	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-0.5	-6.92	-0.32	1.73e-11	Platelet count;
LUAD	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg17366294	chr4:99064904	C4orf37	0.6	10.26	0.45	3.38e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg07169764	chr2:136633963	MCM6	0.8	9.39	0.42	3.72e-19	Corneal structure;
LUAD	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg05110241	chr16:68378359	PRMT7	-0.83	-9.16	-0.41	2.3e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg08601574	chr20:25228251	PYGB	-0.47	-8.89	-0.4	1.83e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6066835	1.000	rs6066837	chr20:47357337	A/C	cg18078177	chr20:47281410	PREX1	0.72	6.55	0.3	1.64e-10	Multiple myeloma;
LUAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.29	0.41	8.04e-19	Alzheimer's disease;
LUAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg18918831	chr3:195489782	MUC4	-0.66	-7.55	-0.34	2.66e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg18180107	chr4:99064573	C4orf37	0.42	6.78	0.31	4.11e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg21709803	chr11:61594965	FADS2	-0.63	-9.03	-0.4	6.22e-18	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs8072100	0.537	rs9912450	chr17:45402208	C/T	cg08085267	chr17:45401833	C17orf57	-0.81	-14.32	-0.57	3.38e-38	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg01851573	chr8:8652454	MFHAS1	0.43	7.74	0.35	7.58e-14	Mood instability;
LUAD	cis	rs3760982	0.585	rs1386502	chr19:44293356	T/C	cg21496419	chr19:44306685	LYPD5	0.33	7.3	0.33	1.41e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.78	-10.29	-0.45	2.66e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7582720	1.000	rs72926791	chr2:203822891	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2425143	0.514	rs8114246	chr20:34581979	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-6.92	-0.32	1.65e-11	Blood protein levels;
LUAD	cis	rs929596	0.639	rs2070959	chr2:234602191	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.65	-10.95	-0.47	9.56e-25	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg05368731	chr17:41323189	NBR1	0.96	20.39	0.7	7.37e-65	Menopause (age at onset);
LUAD	cis	rs9309473	0.607	rs7574291	chr2:73594941	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-6.86	-0.32	2.4e-11	Metabolite levels;
LUAD	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg09184832	chr6:79620586	NA	-0.52	-9.78	-0.43	1.74e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg18811423	chr2:55921094	PNPT1	0.58	9.85	0.43	9.77e-21	Metabolic syndrome;
LUAD	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg22189786	chr22:42395067	WBP2NL	0.46	6.61	0.31	1.17e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs6840360	0.571	rs11726892	chr4:152555106	A/G	cg22705602	chr4:152727874	NA	-0.4	-6.94	-0.32	1.52e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg11062466	chr8:58055876	NA	0.45	6.68	0.31	7.46e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs113835537	0.529	rs11227502	chr11:66274148	T/G	cg24851651	chr11:66362959	CCS	0.56	9.95	0.44	4.23e-21	Airway imaging phenotypes;
LUAD	trans	rs9393777	0.764	rs35565446	chr6:27145341	C/T	cg01620082	chr3:125678407	NA	-0.99	-9.06	-0.4	4.69e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs9487051	0.698	rs13202939	chr6:109649655	A/G	cg21918786	chr6:109611834	NA	-0.42	-6.54	-0.3	1.73e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs1403694	0.695	rs10439971	chr3:186434188	C/T	cg12454167	chr3:186435060	KNG1	0.51	10.6	0.46	1.96e-23	Blood protein levels;
LUAD	cis	rs7187994	0.848	rs7185949	chr16:84779248	T/G	cg07647771	chr16:84786436	USP10	-0.37	-9.57	-0.42	9.21e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.42	-0.38	5.73e-16	Breast cancer;
LUAD	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg05283184	chr6:79620031	NA	-0.53	-10.2	-0.44	5.37e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg20607798	chr8:58055168	NA	0.61	7.82	0.36	4.14e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713675	0.584	rs3227	chr6:33662295	G/C	cg13859433	chr6:33739653	LEMD2	-0.3	-7.06	-0.32	7.05e-12	Plateletcrit;
LUAD	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26314531	chr2:26401878	FAM59B	-0.57	-7.91	-0.36	2.32e-14	Gut microbiome composition (summer);
LUAD	cis	rs208520	0.690	rs207107	chr6:66794385	T/C	cg07460842	chr6:66804631	NA	-1.06	-16.63	-0.63	3.97e-48	Exhaled nitric oxide output;
LUAD	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg18827107	chr12:86230957	RASSF9	-0.49	-8.72	-0.39	6.27e-17	Major depressive disorder;
LUAD	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg08027265	chr7:2291960	NA	-0.53	-9.2	-0.41	1.6e-18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg06740227	chr12:86229804	RASSF9	0.39	6.8	0.31	3.66e-11	Major depressive disorder;
LUAD	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg16405210	chr4:1374714	KIAA1530	0.59	9.18	0.41	1.88e-18	Longevity;
LUAD	cis	rs58141407	1	rs58141407	chr8:21791772	C/T	cg25597362	chr8:21767310	DOK2	-0.67	-8.07	-0.37	7.32e-15	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.27	-0.48	6.11e-26	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg07917127	chr4:99064746	C4orf37	0.42	7.01	0.32	9.44e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg26408565	chr15:76604113	ETFA	-0.55	-9.53	-0.42	1.21e-19	Blood metabolite levels;
LUAD	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg27454412	chr7:1067447	C7orf50	0.44	7.01	0.32	9.47e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg07395648	chr5:131743802	NA	-0.37	-6.42	-0.3	3.6e-10	Breast cancer;
LUAD	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg22618164	chr12:122356400	WDR66	-0.53	-8.6	-0.39	1.53e-16	Mean corpuscular volume;
LUAD	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg02018176	chr4:1364513	KIAA1530	0.47	8.38	0.38	8.05e-16	Longevity;
LUAD	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg14668632	chr7:2872130	GNA12	-0.48	-8.4	-0.38	6.82e-16	Height;
LUAD	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg17200465	chr3:40428508	ENTPD3	0.27	6.63	0.31	1.01e-10	Renal cell carcinoma;
LUAD	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg03929089	chr4:120376271	NA	-0.97	-20.08	-0.7	1.84e-63	Height;
LUAD	cis	rs977987	0.762	rs1364079	chr16:75393131	C/A	cg03315344	chr16:75512273	CHST6	0.64	13.81	0.56	4.4e-36	Dupuytren's disease;
LUAD	cis	rs6542838	0.641	rs7565510	chr2:99494833	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-7.16	-0.33	3.54e-12	Fear of minor pain;
LUAD	cis	rs11696845	0.626	rs1111032	chr20:43378770	A/G	cg25301532	chr20:43378953	KCNK15	0.46	7.94	0.36	1.87e-14	Obesity-related traits;
LUAD	cis	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg21775007	chr8:11205619	TDH	0.57	10.05	0.44	1.82e-21	Retinal vascular caliber;
LUAD	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	5.93e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937890	0.668	rs12361851	chr11:14267668	C/T	cg23387056	chr11:14280742	SPON1	0.34	7.07	0.33	6.52e-12	Mitochondrial DNA levels;
LUAD	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg23625390	chr15:77176239	SCAPER	-0.46	-8.14	-0.37	4.59e-15	Blood metabolite levels;
LUAD	cis	rs2066819	1.000	rs17118403	chr12:56630067	C/T	cg26714650	chr12:56694279	CS	-0.83	-6.99	-0.32	1.05e-11	Psoriasis vulgaris;
LUAD	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg00631329	chr6:26305371	NA	-0.52	-9.43	-0.42	2.78e-19	Educational attainment;
LUAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg27454412	chr7:1067447	C7orf50	0.48	7.73	0.35	7.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg15147215	chr3:52552868	STAB1	-0.41	-7.43	-0.34	6.14e-13	Bipolar disorder;
LUAD	cis	rs17155006	0.664	rs6974722	chr7:107738836	T/C	cg05962710	chr7:107745446	LAMB4	-0.35	-7.27	-0.33	1.78e-12	Pneumococcal bacteremia;
LUAD	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg05110241	chr16:68378359	PRMT7	-0.84	-9.13	-0.41	2.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs71636778	0.543	rs34409791	chr1:27245363	A/G	cg12203394	chr1:27248618	NUDC	0.52	6.59	0.31	1.33e-10	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10849893	0.554	rs10849888	chr12:121892786	A/G	cg01154721	chr12:121881891	KDM2B	-0.41	-6.68	-0.31	7.54e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg12623918	chr2:306882	NA	0.34	6.97	0.32	1.25e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.48	0.3	2.5e-10	Aortic root size;
LUAD	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg13319975	chr6:146136371	FBXO30	0.57	9.07	0.4	4.38e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.48	7.73	0.35	7.88e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.26	-0.37	1.88e-15	Prostate cancer;
LUAD	trans	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.98	-0.36	1.4e-14	Gout;
LUAD	cis	rs9039	1.000	rs9921107	chr16:9219845	G/T	cg08831531	chr16:9218945	NA	-0.42	-7.75	-0.35	6.87e-14	Menopause (age at onset);
LUAD	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg16988262	chr1:15930761	NA	0.41	6.86	0.32	2.53e-11	Systolic blood pressure;
LUAD	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg15445000	chr17:37608096	MED1	-0.44	-8.1	-0.37	5.8e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg17264618	chr3:40429014	ENTPD3	0.38	8.42	0.38	6.03e-16	Renal cell carcinoma;
LUAD	cis	rs669446	0.533	rs3791041	chr1:44202991	A/G	cg12908607	chr1:44402522	ARTN	-0.36	-6.83	-0.32	2.97e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg14552801	chr7:65878734	NA	0.37	6.37	0.3	5.05e-10	Aortic root size;
LUAD	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg23172400	chr8:95962367	TP53INP1	-0.37	-8.89	-0.4	1.77e-17	Type 2 diabetes;
LUAD	cis	rs2070677	0.935	rs12242613	chr10:135419831	C/T	cg20169779	chr10:135381914	SYCE1	-0.52	-8.14	-0.37	4.47e-15	Gout;
LUAD	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.81	0.36	4.41e-14	Platelet count;
LUAD	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg17911788	chr17:44343683	NA	-0.5	-6.98	-0.32	1.18e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7737355	0.947	rs6875058	chr5:130882702	C/G	cg06307176	chr5:131281290	NA	0.51	8.07	0.37	7.24e-15	Life satisfaction;
LUAD	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18876405	chr7:65276391	NA	0.42	6.59	0.31	1.29e-10	Aortic root size;
LUAD	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg12193833	chr17:30244370	NA	0.52	6.52	0.3	2.01e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg05340658	chr4:99064831	C4orf37	-0.45	-7.39	-0.34	8.01e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	7.59	0.35	2.12e-13	Personality dimensions;
LUAD	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg10556349	chr10:835070	NA	0.58	7.57	0.35	2.38e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg11859384	chr17:80120422	CCDC57	0.51	9.23	0.41	1.27e-18	Life satisfaction;
LUAD	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg24579218	chr15:68104479	NA	-0.54	-9.4	-0.42	3.44e-19	Restless legs syndrome;
LUAD	cis	rs11153730	0.503	rs4946336	chr6:118632335	A/C	cg21191810	chr6:118973309	C6orf204	0.49	9.58	0.42	8.67e-20	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.77	-0.46	4.38e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg25251562	chr2:3704773	ALLC	-0.39	-7.23	-0.33	2.32e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.77	-0.31	4.3e-11	Diabetic kidney disease;
LUAD	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg17264618	chr3:40429014	ENTPD3	0.4	8.81	0.39	3.21e-17	Renal cell carcinoma;
LUAD	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg15691649	chr6:25882328	NA	-0.42	-6.74	-0.31	5.11e-11	Blood metabolite levels;
LUAD	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg24838063	chr12:130822603	PIWIL1	0.66	10.72	0.46	6.71e-24	Menopause (age at onset);
LUAD	cis	rs1950626	0.751	rs12883799	chr14:101396850	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.37	7.13	0.33	4.4e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs7267979	0.873	rs6037062	chr20:25202892	G/A	cg08601574	chr20:25228251	PYGB	0.43	7.79	0.35	5.21e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg14582100	chr15:45693742	SPATA5L1	0.52	9.84	0.43	1.04e-20	Homoarginine levels;
LUAD	cis	rs459571	0.834	rs379417	chr9:136890704	G/A	cg13789015	chr9:136890014	NCRNA00094	0.85	14.43	0.57	1.2e-38	Platelet distribution width;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg16072664	chr21:35014885	ITSN1;CRYZL1	-0.4	-6.39	-0.3	4.27e-10	Vertical cup-disc ratio;
LUAD	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg04248312	chr19:17393744	ANKLE1	-1.0	-18.41	-0.67	5.17e-56	Systemic lupus erythematosus;
LUAD	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-12.35	-0.51	4.02e-30	Hemoglobin concentration;
LUAD	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg13918804	chr1:2043761	PRKCZ	0.41	6.96	0.32	1.33e-11	Height;
LUAD	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.57	-9.86	-0.43	8.74e-21	Cognitive ability;
LUAD	cis	rs2455799	0.634	rs11128764	chr3:15902836	G/C	cg16303742	chr3:15540471	COLQ	-0.5	-9.01	-0.4	7.11e-18	Mean platelet volume;
LUAD	cis	rs67478160	0.634	rs2144079	chr14:104258884	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.62	-11.45	-0.49	1.29e-26	Schizophrenia;
LUAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg24829409	chr8:58192753	C8orf71	-0.62	-9.33	-0.41	6.24e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs75804782	0.641	rs6715311	chr2:239363321	A/G	cg01134436	chr17:81009848	B3GNTL1	0.67	7.79	0.35	5.29e-14	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg10589385	chr1:150898437	SETDB1	0.44	8.23	0.37	2.37e-15	Melanoma;
LUAD	cis	rs67981189	0.758	rs221921	chr14:71586128	T/C	cg15816911	chr14:71606274	NA	-0.36	-6.45	-0.3	3.01e-10	Schizophrenia;
LUAD	cis	rs909002	0.849	rs3753611	chr1:32082486	C/T	cg13919466	chr1:32135498	COL16A1	-0.34	-7.82	-0.36	4.39e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg21138405	chr5:131827807	IRF1	0.57	12.42	0.52	1.99e-30	Asthma (sex interaction);
LUAD	cis	rs9341808	0.700	rs12215236	chr6:80975058	A/T	cg08355045	chr6:80787529	NA	0.57	10.44	0.45	7.34e-23	Sitting height ratio;
LUAD	trans	rs1728785	1.000	rs1170426	chr16:68603798	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.34	0.45	1.73e-22	Ulcerative colitis;
LUAD	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg03340356	chr1:67600835	NA	0.45	7.8	0.35	4.82e-14	Psoriasis;
LUAD	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg21433313	chr16:3507492	NAT15	0.74	9.7	0.43	3.09e-20	Tuberculosis;
LUAD	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg03526776	chr6:41159608	TREML2	0.33	6.89	0.32	1.99e-11	Alzheimer's disease (late onset);
LUAD	cis	rs11958404	0.932	rs72816543	chr5:157416464	A/G	cg05962755	chr5:157440814	NA	0.6	8.31	0.37	1.27e-15	IgG glycosylation;
LUAD	cis	rs10193935	0.901	rs13384885	chr2:42536646	G/C	cg27598129	chr2:42591480	NA	-0.77	-9.67	-0.43	4e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg13560548	chr3:10150139	C3orf24	0.44	7.16	0.33	3.66e-12	Alzheimer's disease;
LUAD	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg22681709	chr2:178499509	PDE11A	-0.45	-7.52	-0.34	3.29e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs3219090	0.962	rs2793380	chr1:226588977	C/G	cg27539482	chr13:111589090	NA	0.42	7.12	0.33	4.72e-12	Melanoma;
LUAD	cis	rs12410462	0.502	rs114121935	chr1:227959336	A/G	cg23173402	chr1:227635558	NA	0.68	7.09	0.33	5.52e-12	Major depressive disorder;
LUAD	cis	rs4594175	0.926	rs12323654	chr14:51630894	G/T	cg23942311	chr14:51606299	NA	0.65	11.29	0.48	5.22e-26	Cancer;
LUAD	cis	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg10518543	chr12:38710700	ALG10B	-0.42	-6.85	-0.32	2.7e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7944584	0.655	rs11039183	chr11:47346940	G/A	cg20307385	chr11:47447363	PSMC3	0.46	7.02	0.32	9.01e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg22029157	chr1:209979665	IRF6	0.47	8.39	0.38	7.36e-16	Monobrow;
LUAD	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg12935359	chr14:103987150	CKB	-0.47	-7.88	-0.36	2.78e-14	Body mass index;
LUAD	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg04944784	chr2:26401820	FAM59B	-0.89	-12.57	-0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.77	0.35	5.82e-14	Breast cancer;
LUAD	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg22508957	chr16:3507546	NAT15	0.79	13.39	0.55	2.5e-34	Tuberculosis;
LUAD	cis	rs35995292	1.000	rs10266891	chr7:38914805	A/G	cg19327137	chr7:38886074	VPS41	0.5	8.23	0.37	2.41e-15	Subjective well-being (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg12623302	chr6:28058802	ZSCAN12L1	-0.34	-6.6	-0.31	1.2e-10	Depression;
LUAD	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg12623918	chr2:306882	NA	0.34	6.96	0.32	1.28e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs2046867	0.908	rs6779684	chr3:72787586	G/A	cg04365224	chr3:72788183	NA	-0.51	-7.63	-0.35	1.56e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9902453	0.935	rs9905950	chr17:28431198	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	10.01	0.44	2.65e-21	Coffee consumption (cups per day);
LUAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.39	-0.38	7.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7709909	0.967	rs245335	chr5:80029408	T/C	cg24059623	chr5:79951536	MSH3;DHFR	0.39	6.51	0.3	2.19e-10	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg09324608	chr17:30823087	MYO1D	0.44	8.21	0.37	2.7e-15	Schizophrenia;
LUAD	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg11247378	chr22:39784982	NA	-0.73	-13.23	-0.54	1.06e-33	Intelligence (multi-trait analysis);
LUAD	cis	rs13190036	0.901	rs6556309	chr5:176693835	C/T	cg06733329	chr5:176740039	MXD3	-0.5	-6.9	-0.32	1.95e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg04398451	chr17:18023971	MYO15A	-0.63	-11.4	-0.48	2.01e-26	Total body bone mineral density;
LUAD	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg09835421	chr16:68378352	PRMT7	-1.02	-11.59	-0.49	3.55e-27	Schizophrenia;
LUAD	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.31	8.0	0.36	1.18e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg14820908	chr5:178986412	RUFY1	0.54	8.45	0.38	4.8e-16	Lung cancer;
LUAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.47	6.67	0.31	7.82e-11	Renal function-related traits (BUN);
LUAD	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg06387496	chr7:2775674	GNA12	-0.39	-6.67	-0.31	7.86e-11	Height;
LUAD	cis	rs11696501	0.843	rs6065830	chr20:44141024	T/G	cg11783356	chr20:44313418	WFDC10B	-0.39	-6.37	-0.3	5.02e-10	Brain structure;
LUAD	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg17063962	chr7:91808500	NA	-0.68	-11.81	-0.5	5.37e-28	Breast cancer;
LUAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg18402987	chr7:1209562	NA	0.43	6.91	0.32	1.75e-11	Longevity;Endometriosis;
LUAD	cis	rs2920503	0.959	rs2920502	chr3:12329195	G/C	cg23514324	chr3:12329213	PPARG	0.52	8.21	0.37	2.74e-15	LDL cholesterol;
LUAD	cis	rs6076065	0.723	rs2424552	chr20:23402833	G/A	cg11657817	chr20:23433608	CST11	0.49	8.84	0.4	2.52e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-7.47	-0.34	4.67e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.46	-7.46	-0.34	5.13e-13	Tonsillectomy;
LUAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs34311866	0.808	rs17783233	chr4:976598	T/C	cg23992470	chr4:843637	GAK	0.62	6.6	0.31	1.25e-10	Parkinson's disease;
LUAD	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-9.74	-0.43	2.26e-20	Gut microbiome composition (summer);
LUAD	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg10518543	chr12:38710700	ALG10B	-0.51	-8.34	-0.38	1.09e-15	Morning vs. evening chronotype;
LUAD	cis	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg17551891	chr7:1960795	MAD1L1	-0.4	-6.65	-0.31	8.99e-11	Neuroticism;
LUAD	cis	rs2224391	1.000	rs13191012	chr6:5261292	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-9.86	-0.43	8.54e-21	Height;
LUAD	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg13770153	chr20:60521292	NA	-0.58	-9.66	-0.42	4.59e-20	Body mass index;
LUAD	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg18252515	chr7:66147081	NA	-0.61	-6.62	-0.31	1.11e-10	Diabetic kidney disease;
LUAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg00450029	chr8:599525	NA	0.81	8.04	0.36	8.87e-15	IgG glycosylation;
LUAD	cis	rs1595825	0.891	rs1851779	chr2:198647108	C/T	cg00361562	chr2:198649771	BOLL	-0.48	-6.76	-0.31	4.54e-11	Ulcerative colitis;
LUAD	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg21918786	chr6:109611834	NA	-0.54	-9.5	-0.42	1.6e-19	Reticulocyte fraction of red cells;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07017284	chr1:173684020	KLHL20	-0.42	-6.62	-0.31	1.09e-10	Height;
LUAD	cis	rs62229266	0.605	rs11701331	chr21:37458392	T/C	cg12218747	chr21:37451666	NA	-0.67	-12.44	-0.52	1.66e-30	Mitral valve prolapse;
LUAD	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg05805236	chr11:65401703	PCNXL3	-0.59	-9.43	-0.42	2.64e-19	Acne (severe);
LUAD	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg06360820	chr2:242988706	NA	-0.83	-9.48	-0.42	1.81e-19	Obesity-related traits;
LUAD	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg21191810	chr6:118973309	C6orf204	-0.53	-8.22	-0.37	2.57e-15	Diastolic blood pressure;
LUAD	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.53e-11	Depression;
LUAD	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg19163074	chr7:65112434	INTS4L2	0.43	6.48	0.3	2.5e-10	Aortic root size;
LUAD	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14893161	chr1:205819251	PM20D1	-0.59	-10.59	-0.46	2.09e-23	Menarche (age at onset);
LUAD	trans	rs7395662	0.895	rs4882238	chr11:48755540	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.22	-0.33	2.48e-12	HDL cholesterol;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09410434	chr3:48885326	PRKAR2A	-0.64	-6.65	-0.31	9e-11	Type 2 diabetes;
LUAD	cis	rs13631	0.728	rs10118245	chr9:139979592	C/T	cg14289826	chr9:140003911	NA	0.38	7.13	0.33	4.29e-12	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg26384229	chr12:38710491	ALG10B	0.49	7.9	0.36	2.44e-14	Bladder cancer;
LUAD	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg09658497	chr7:2847517	GNA12	0.44	7.53	0.34	3.2e-13	Height;
LUAD	trans	rs1997103	0.871	rs1997100	chr7:55399656	C/G	cg20935933	chr6:143382018	AIG1	0.53	7.46	0.34	4.94e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2708377	0.789	rs3911150	chr12:11202248	A/G	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	0.57	6.4	0.3	4.14e-10	Bitter taste perception;
LUAD	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg12645284	chr15:79092878	ADAMTS7	0.5	7.93	0.36	1.93e-14	Coronary artery disease or large artery stroke;
LUAD	cis	rs6906287	0.647	rs12197337	chr6:118884092	C/T	cg21191810	chr6:118973309	C6orf204	0.51	9.97	0.44	3.5e-21	Electrocardiographic conduction measures;
LUAD	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg02880119	chr16:3481970	NA	0.53	8.17	0.37	3.52e-15	Body mass index (adult);
LUAD	cis	rs7584330	0.554	rs10183995	chr2:238433307	G/A	cg14458575	chr2:238380390	NA	0.6	9.5	0.42	1.5700000000000001e-19	Prostate cancer;
LUAD	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg00666640	chr1:248458726	OR2T12	0.33	8.08	0.37	6.8e-15	Common traits (Other);
LUAD	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg06064525	chr11:970664	AP2A2	-0.43	-8.38	-0.38	8.2e-16	Alzheimer's disease (late onset);
LUAD	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg19163074	chr7:65112434	INTS4L2	0.43	6.48	0.3	2.5e-10	Aortic root size;
LUAD	cis	rs1030877	1.000	rs2241797	chr2:105885961	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.6	11.65	0.49	2.12e-27	Obesity-related traits;
LUAD	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg05340658	chr4:99064831	C4orf37	-0.46	-7.66	-0.35	1.25e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg24308560	chr3:49941425	MST1R	0.53	8.78	0.39	4.1e-17	Body mass index;
LUAD	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg23277830	chr1:3704460	LRRC47	0.44	9.08	0.4	4.33e-18	Red cell distribution width;
LUAD	cis	rs2686555	0.502	rs693074	chr12:121077728	A/C	cg18477009	chr12:121087777	CABP1	0.45	7.83	0.36	4.02e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs11676348	0.772	rs7422358	chr2:218952778	C/T	cg06547715	chr2:218990976	CXCR2	0.33	7.54	0.34	2.84e-13	Ulcerative colitis;
LUAD	cis	rs13095912	0.512	rs115865582	chr3:185308598	A/C	cg11274856	chr3:185301563	NA	0.49	9.2	0.41	1.62e-18	Systolic blood pressure;
LUAD	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg13722127	chr7:150037890	RARRES2	0.47	8.34	0.38	1.03e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg25985355	chr7:65971099	NA	0.37	7.01	0.32	9.71e-12	Aortic root size;
LUAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg00280220	chr17:61926910	NA	0.36	7.03	0.32	8.36e-12	Prudent dietary pattern;
LUAD	cis	rs713587	0.713	rs4665276	chr2:25213333	C/T	cg01884057	chr2:25150051	NA	-0.32	-6.63	-0.31	1.02e-10	Body mass index in non-asthmatics;
LUAD	cis	rs752010	0.574	rs2148636	chr1:42119844	C/T	cg06885757	chr1:42089581	HIVEP3	-0.41	-8.77	-0.39	4.3e-17	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03264133	chr6:25882463	NA	0.82	13.61	0.55	2.92e-35	Blood metabolite levels;
LUAD	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.04	0.36	9.29e-15	Menopause (age at onset);
LUAD	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg25753631	chr6:25732923	NA	-0.45	-7.9	-0.36	2.45e-14	Iron status biomarkers;
LUAD	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.92	-14.76	-0.58	4.79e-40	Homoarginine levels;
LUAD	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg02275930	chr1:2372054	NA	-0.44	-10.97	-0.47	8.07e-25	Schizophrenia;
LUAD	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg18240062	chr17:79603768	NPLOC4	0.44	7.57	0.35	2.37e-13	Eye color traits;
LUAD	cis	rs7173743	1.000	rs4567668	chr15:79140692	T/C	cg00540400	chr15:79124168	NA	-0.33	-6.35	-0.3	5.47e-10	Coronary artery disease;
LUAD	cis	rs5167	0.743	rs57204168	chr19:45496776	A/G	cg09555818	chr19:45449301	APOC2	0.37	7.0	0.32	1.01e-11	Blood protein levels;
LUAD	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.57	-0.35	2.39e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg14668632	chr7:2872130	GNA12	-0.37	-6.43	-0.3	3.41e-10	Height;
LUAD	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg09455208	chr3:40491958	NA	0.65	14.1	0.57	2.84e-37	Renal cell carcinoma;
LUAD	cis	rs1232027	0.700	rs1382540	chr5:79952165	C/G	cg24059623	chr5:79951536	MSH3;DHFR	0.5	8.05	0.36	8.68e-15	Huntington's disease progression;
LUAD	cis	rs28735056	0.933	rs499260	chr18:77589689	G/A	cg20368463	chr18:77673604	PQLC1	-0.41	-6.43	-0.3	3.43e-10	Schizophrenia;
LUAD	trans	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg26811252	chr16:29126840	RRN3P2	0.61	10.47	0.45	5.9e-23	Menopause (age at onset);
LUAD	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg17863274	chr19:49399704	TULP2	-0.65	-9.96	-0.44	3.83e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11644478	chr21:40555479	PSMG1	0.67	11.16	0.48	1.62e-25	Cognitive function;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg14711201	chr5:36152436	SKP2;LMBRD2	-0.41	-6.88	-0.32	2.21e-11	Subcortical brain region volumes;
LUAD	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg09835421	chr16:68378352	PRMT7	-0.56	-6.5	-0.3	2.23e-10	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg04703951	chr17:43578652	NA	0.42	6.69	0.31	7.26e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs11958404	0.932	rs111802867	chr5:157424971	G/A	cg05962755	chr5:157440814	NA	0.69	9.52	0.42	1.31e-19	IgG glycosylation;
LUAD	cis	rs6564851	0.935	rs12926540	chr16:81258987	T/C	cg00908271	chr16:81254010	PKD1L2	-0.33	-7.19	-0.33	2.92e-12	Carotenoid and tocopherol levels;
LUAD	cis	rs1018836	0.828	rs7014967	chr8:91557843	G/T	cg16814680	chr8:91681699	NA	-0.61	-10.21	-0.44	4.87e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7072216	0.881	rs1079179	chr10:100149346	T/C	cg26618903	chr10:100175079	PYROXD2	-0.3	-6.46	-0.3	2.94e-10	Metabolite levels;
LUAD	cis	rs2455826	0.521	rs6442546	chr3:15789996	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.41	-0.3	3.81e-10	Inflammatory skin disease;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg13184886	chr1:27153565	ZDHHC18	-0.38	-6.9	-0.32	1.87e-11	Schizophrenia;
LUAD	cis	rs7189233	1.000	rs16952251	chr16:53483138	A/G	cg04059762	chr16:53544020	NA	-0.41	-6.64	-0.31	9.4e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg23719950	chr11:63933701	MACROD1	-0.56	-6.91	-0.32	1.75e-11	Mean platelet volume;
LUAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-10.32	-0.45	2.04e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg02569458	chr12:86230093	RASSF9	-0.41	-7.6	-0.35	1.95e-13	Major depressive disorder;
LUAD	cis	rs10540	0.541	rs7480899	chr11:438459	T/C	cg03352830	chr11:487213	PTDSS2	-0.51	-7.29	-0.33	1.54e-12	Body mass index;
LUAD	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-7.79	-0.35	5.3e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs375066	0.762	rs12610287	chr19:44400663	T/C	cg12072164	chr19:44306565	LYPD5	-0.32	-6.44	-0.3	3.27e-10	Breast cancer;
LUAD	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg03433033	chr1:76189801	ACADM	-0.45	-6.63	-0.31	1.05e-10	Daytime sleep phenotypes;
LUAD	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg23281280	chr6:28129359	ZNF389	0.43	6.4	0.3	4.25e-10	Depression;
LUAD	cis	rs12541635	0.934	rs2029882	chr8:107022894	G/A	cg10147462	chr8:107024639	NA	0.49	8.68	0.39	8.85e-17	Age of smoking initiation;
LUAD	cis	rs887829	0.569	rs4663963	chr2:234650193	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.26	-0.37	1.83e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	trans	rs994533	0.928	rs7594625	chr2:218293564	A/C	cg11963883	chr10:70715832	DDX21	0.46	7.24	0.33	2.2e-12	Height;
LUAD	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg17279839	chr7:150038598	RARRES2	0.45	7.47	0.34	4.55e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg06784218	chr1:46089804	CCDC17	-0.55	-11.74	-0.5	9.69e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg18105139	chr6:28058856	ZSCAN12L1	-0.28	-6.51	-0.3	2.13e-10	Depression;
LUAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg12419862	chr22:24373484	LOC391322	-0.75	-13.1	-0.54	3.95e-33	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg19825600	chr2:3704501	ALLC	0.4	7.53	0.34	3.15e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs10465746	0.747	rs1952066	chr1:84436456	T/C	cg10977910	chr1:84465055	TTLL7	0.59	9.74	0.43	2.24e-20	Obesity-related traits;
LUAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.99	-0.4	8.42e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6684514	1.000	rs12027741	chr1:156248148	T/G	cg16558208	chr1:156270281	VHLL	0.53	9.52	0.42	1.36e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9929218	0.954	rs7198799	chr16:68818390	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.75	-0.56	8.18e-36	Colorectal cancer;
LUAD	cis	rs12286929	0.609	rs12417740	chr11:115098436	A/G	cg04055981	chr11:115044050	NA	-0.43	-7.53	-0.34	3.13e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg13535736	chr9:111863775	C9orf5	-0.44	-6.87	-0.32	2.26e-11	Menarche (age at onset);
LUAD	cis	rs7166081	0.672	rs3865018	chr15:67892766	A/G	cg24579218	chr15:68104479	NA	0.49	8.16	0.37	3.8e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg27211696	chr2:191398769	TMEM194B	-0.67	-8.99	-0.4	8.11e-18	Diastolic blood pressure;
LUAD	cis	rs6424115	1.000	rs12116511	chr1:24162662	A/G	cg15997130	chr1:24165203	NA	-0.55	-9.76	-0.43	2e-20	Immature fraction of reticulocytes;
LUAD	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	8.61	0.39	1.47e-16	Lung cancer in ever smokers;
LUAD	trans	rs11039798	0.920	rs11039940	chr11:48716316	C/T	cg15704280	chr7:45808275	SEPT13	0.67	7.89	0.36	2.62e-14	Axial length;
LUAD	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	9.16	0.41	2.21e-18	Tonsillectomy;
LUAD	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg17761419	chr8:57350749	NA	-0.52	-7.89	-0.36	2.64e-14	Obesity-related traits;
LUAD	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg11166453	chr1:247681781	NA	-0.41	-8.19	-0.37	3.06e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg27068330	chr11:65405492	SIPA1	-0.76	-11.77	-0.5	7.7e-28	Acne (severe);
LUAD	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24531977	chr5:56204891	C5orf35	1.18	18.43	0.67	4.08e-56	Initial pursuit acceleration;
LUAD	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg16405210	chr4:1374714	KIAA1530	-0.39	-6.47	-0.3	2.64e-10	Obesity-related traits;
LUAD	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg07570687	chr10:102243282	WNT8B	0.44	6.71	0.31	6.31e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg08085267	chr17:45401833	C17orf57	-0.51	-8.64	-0.39	1.16e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs225245	0.791	rs4796103	chr17:34025182	A/G	cg05299278	chr17:33885742	SLFN14	0.5	11.24	0.48	7.66e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.34	-0.34	1.1e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10129255	0.509	rs756583	chr14:107136019	C/T	cg23076370	chr14:107095027	NA	-0.4	-7.99	-0.36	1.28e-14	Kawasaki disease;
LUAD	cis	rs17067123	0.614	rs6857122	chr4:180062550	G/C	cg26610307	chr4:180072759	NA	-0.55	-6.5	-0.3	2.24e-10	Response to hepatitis C treatment;
LUAD	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg06740227	chr12:86229804	RASSF9	0.41	7.2	0.33	2.86e-12	Major depressive disorder;
LUAD	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.43	-0.45	8.18e-23	Monocyte percentage of white cells;
LUAD	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg13385794	chr1:248469461	NA	0.26	6.97	0.32	1.23e-11	Common traits (Other);
LUAD	cis	rs4700695	0.841	rs153367	chr5:65419170	G/A	cg21114390	chr5:65439923	SFRS12	-0.56	-6.96	-0.32	1.32e-11	Facial morphology (factor 19);
LUAD	cis	rs62400317	0.826	rs12194628	chr6:45329376	G/C	cg18551225	chr6:44695536	NA	-0.53	-8.19	-0.37	3.03e-15	Total body bone mineral density;
LUAD	cis	rs11649653	0.502	rs62057232	chr16:30820866	T/C	cg02466173	chr16:30829666	NA	0.56	10.05	0.44	1.9e-21	Triglycerides;
LUAD	cis	rs9486719	1.000	rs67996804	chr6:96884387	C/T	cg06623918	chr6:96969491	KIAA0776	-0.71	-10.02	-0.44	2.32e-21	Migraine;Coronary artery disease;
LUAD	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	7.11	0.33	4.87e-12	Platelet count;
LUAD	cis	rs9899728	0.539	rs11077772	chr17:73035698	C/T	cg27626185	chr17:73056755	KCTD2	-0.99	-11.35	-0.48	2.94e-26	Alzheimer's disease or small vessel stroke;
LUAD	cis	rs1003719	0.667	rs2835606	chr21:38490851	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.46	7.6	0.35	1.96e-13	Eye color traits;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10335659	chr2:99757356	C2orf15;TSGA10	-0.42	-6.35	-0.3	5.68e-10	Height;
LUAD	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg16797656	chr11:68205561	LRP5	0.46	8.78	0.39	4.18e-17	Total body bone mineral density;
LUAD	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg05182265	chr7:156933206	UBE3C	-0.81	-17.36	-0.65	2.21e-51	Body mass index;
LUAD	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg24818145	chr4:99064322	C4orf37	-0.39	-6.37	-0.3	4.81e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9807989	0.839	rs1420099	chr2:102980543	C/G	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	4.82e-10	Asthma;
LUAD	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22968622	chr17:43663579	NA	1.39	25.96	0.78	1.48e-89	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1784581	0.851	rs1784591	chr6:162388893	C/G	cg17173639	chr6:162384350	PARK2	-0.6	-10.85	-0.47	2.4e-24	Itch intensity from mosquito bite;
LUAD	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg23978390	chr7:1156363	C7orf50	-0.5	-6.45	-0.3	3.07e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs2046867	0.908	rs9841994	chr3:72820503	A/C	cg25664220	chr3:72788482	NA	-0.64	-11.84	-0.5	4e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11771526	0.786	rs28670858	chr7:32293126	G/A	cg13207630	chr7:32358064	NA	0.58	7.35	0.34	1.02e-12	Body mass index;
LUAD	cis	rs1003719	0.645	rs8131944	chr21:38547215	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.43	-0.38	5.42e-16	Eye color traits;
LUAD	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg00666640	chr1:248458726	OR2T12	0.33	7.83	0.36	3.92e-14	Common traits (Other);
LUAD	cis	rs775227	0.574	rs60279293	chr3:113096087	T/G	cg18753928	chr3:113234510	CCDC52	-0.65	-8.57	-0.38	1.93e-16	Dental caries;
LUAD	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg11859384	chr17:80120422	CCDC57	-0.52	-9.16	-0.41	2.3e-18	Life satisfaction;
LUAD	trans	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.45	0.52	1.57e-30	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs9951602	0.512	rs12458828	chr18:76648522	C/T	cg02800362	chr5:177631904	HNRNPAB	-0.91	-14.3	-0.57	4.01e-38	Obesity-related traits;
LUAD	trans	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg06606381	chr12:133084897	FBRSL1	-0.63	-6.81	-0.31	3.44e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03517284	chr6:25882590	NA	-0.58	-9.56	-0.42	1.02e-19	Blood metabolite levels;
LUAD	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg18225595	chr11:63971243	STIP1	0.52	8.65	0.39	1.09e-16	Platelet count;
LUAD	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg26384229	chr12:38710491	ALG10B	0.49	7.87	0.36	2.95e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26314531	chr2:26401878	FAM59B	-0.55	-7.72	-0.35	8.46e-14	Gut microbiome composition (summer);
LUAD	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg09998033	chr7:158218633	PTPRN2	-0.46	-8.13	-0.37	4.92e-15	Obesity-related traits;
LUAD	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg18180107	chr4:99064573	C4orf37	0.42	6.68	0.31	7.57e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg10057126	chr4:77819792	ANKRD56	0.53	9.02	0.4	6.47e-18	Emphysema distribution in smoking;
LUAD	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	6.83	0.32	2.96e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7017914	0.967	rs3954897	chr8:71635955	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24308560	chr3:49941425	MST1R	-0.56	-9.29	-0.41	8.24e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg04772025	chr11:68637568	NA	0.57	9.07	0.4	4.47e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs62388641	0.539	rs56016631	chr6:1542575	T/G	cg01806741	chr6:1527072	NA	-0.39	-6.52	-0.3	2.01e-10	Daytime sleep phenotypes;
LUAD	cis	rs752010	0.967	rs4083593	chr1:42099583	A/G	cg06885757	chr1:42089581	HIVEP3	0.44	9.24	0.41	1.22e-18	Lupus nephritis in systemic lupus erythematosus;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08052428	chr9:135996421	RALGDS	0.39	6.41	0.3	3.97e-10	Gut microbiome composition (summer);
LUAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg05313129	chr8:58192883	C8orf71	-0.57	-8.42	-0.38	5.89e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg13798912	chr7:905769	UNC84A	-0.62	-7.11	-0.33	5.02e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs3125734	0.653	rs1007976	chr10:63970144	C/T	cg19640130	chr10:64028056	RTKN2	0.31	6.5	0.3	2.33e-10	Rheumatoid arthritis;
LUAD	cis	rs13082711	0.911	rs34878935	chr3:27466123	A/C	cg02860705	chr3:27208620	NA	0.61	9.51	0.42	1.41e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg22676075	chr6:135203613	NA	0.45	8.07	0.37	7.15e-15	Red blood cell count;
LUAD	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26314531	chr2:26401878	FAM59B	-0.57	-7.93	-0.36	1.94e-14	Gut microbiome composition (summer);
LUAD	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg24397884	chr7:158709396	WDR60	0.47	8.09	0.37	6.57e-15	Height;
LUAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg03188948	chr7:1209495	NA	0.76	9.31	0.41	6.91e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23158103	chr7:148848205	ZNF398	-0.53	-9.48	-0.42	1.84e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg26384229	chr12:38710491	ALG10B	0.5	8.08	0.37	6.81e-15	Heart rate;
LUAD	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03517284	chr6:25882590	NA	0.59	9.8	0.43	1.46e-20	Blood metabolite levels;
LUAD	cis	rs220324	0.688	rs56326363	chr21:43560295	G/A	cg08841829	chr21:43638893	ABCG1	-0.47	-6.47	-0.3	2.73e-10	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.3	-7.91	-0.36	2.27e-14	Total body bone mineral density;
LUAD	trans	rs587242	0.910	rs6593608	chr1:96987688	C/T	cg10631902	chr5:14652156	NA	0.4	6.37	0.3	5e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg22508957	chr16:3507546	NAT15	0.74	13.1	0.54	3.65e-33	Tuberculosis;
LUAD	cis	rs731174	1.000	rs731174	chr1:38196841	C/T	cg06917450	chr1:38156652	C1orf109	0.44	7.32	0.34	1.29e-12	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.668	rs8048034	chr16:68210604	A/G	cg05110241	chr16:68378359	PRMT7	-0.55	-7.11	-0.33	4.94e-12	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs7395662	0.963	rs11040172	chr11:48968497	A/T	cg00717180	chr2:96193071	NA	-0.4	-7.52	-0.34	3.35e-13	HDL cholesterol;
LUAD	cis	rs9914988	0.619	rs34580233	chr17:27317935	A/T	cg02049041	chr17:27085579	C17orf63	0.5	6.39	0.3	4.29e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.56	-0.38	2.04e-16	Neutrophil percentage of white cells;
LUAD	cis	rs4889855	0.556	rs4506961	chr17:78543182	G/A	cg16591659	chr17:78472290	NA	0.45	7.89	0.36	2.57e-14	Fractional excretion of uric acid;
LUAD	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg01802117	chr1:53393560	SCP2	0.33	6.62	0.31	1.12e-10	Monocyte count;
LUAD	trans	rs12517041	1.000	rs2081951	chr5:23287576	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.45	-0.3	3.1e-10	Calcium levels;
LUAD	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg24803719	chr17:45855879	NA	-0.33	-7.53	-0.34	3.13e-13	IgG glycosylation;
LUAD	cis	rs1595825	0.891	rs74965164	chr2:198499162	C/T	cg10547527	chr2:198650123	BOLL	-0.54	-7.74	-0.35	7.64e-14	Ulcerative colitis;
LUAD	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg17063962	chr7:91808500	NA	0.65	11.0	0.47	6.59e-25	Breast cancer;
LUAD	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg11941060	chr3:133502564	NA	0.39	6.57	0.3	1.47e-10	Alcohol consumption (transferrin glycosylation);
LUAD	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22968622	chr17:43663579	NA	1.38	23.97	0.76	8.34e-81	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg13319975	chr6:146136371	FBXO30	0.57	9.61	0.42	6.48e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-10.97	-0.47	8.41e-25	Developmental language disorder (linguistic errors);
LUAD	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg25237894	chr2:233734115	C2orf82	-0.57	-10.73	-0.46	6.17e-24	Coronary artery disease;
LUAD	cis	rs897984	0.684	rs6950	chr16:30995669	T/C	cg02466173	chr16:30829666	NA	0.66	12.07	0.51	5.01e-29	Dementia with Lewy bodies;
LUAD	cis	rs2281636	0.931	rs2804419	chr10:101509113	A/G	cg17885402	chr10:101492224	COX15;CUTC	0.39	6.68	0.31	7.46e-11	Obesity-related traits;
LUAD	cis	rs6761276	0.899	rs11693750	chr2:113835602	C/T	cg09040174	chr2:113837401	NA	0.81	15.75	0.61	2.68e-44	Protein quantitative trait loci;
LUAD	cis	rs10504073	0.584	rs1511368	chr8:49949523	A/T	cg00325661	chr8:49890786	NA	0.44	10.25	0.45	3.76e-22	Blood metabolite ratios;
LUAD	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.48	-6.75	-0.31	4.87e-11	Iron status biomarkers;
LUAD	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22496380	chr5:211416	CCDC127	-1.22	-15.59	-0.6	1.29e-43	Breast cancer;
LUAD	cis	rs7727544	0.625	rs4705916	chr5:131407493	C/A	cg22598563	chr5:131563921	P4HA2	-0.27	-6.5	-0.3	2.27e-10	Blood metabolite levels;
LUAD	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg05132306	chr1:1846340	CALML6	-0.36	-7.78	-0.35	5.57e-14	Body mass index;
LUAD	cis	rs2554380	0.943	rs2585038	chr15:84337258	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.58	-8.85	-0.4	2.41e-17	Height;
LUAD	cis	rs6696239	0.513	rs4653849	chr1:227729000	C/T	cg12133451	chr1:227746453	NA	-0.35	-6.42	-0.3	3.57e-10	Height;
LUAD	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg00898013	chr13:113819073	PROZ	-0.69	-12.17	-0.51	2.05e-29	Platelet distribution width;
LUAD	trans	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.89	-0.32	2.09e-11	Neuroticism;
LUAD	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg21211367	chr2:162094118	NA	0.45	7.92	0.36	2.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg27572855	chr1:25598939	RHD	0.62	14.35	0.57	2.43e-38	Erythrocyte sedimentation rate;
LUAD	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg24112000	chr20:60950667	NA	-0.86	-15.13	-0.59	1.26e-41	Colorectal cancer;
LUAD	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11890956	chr21:40555474	PSMG1	-0.62	-10.61	-0.46	1.81e-23	Cognitive function;
LUAD	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg01802117	chr1:53393560	SCP2	-0.35	-6.9	-0.32	1.86e-11	Monocyte count;
LUAD	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg08219700	chr8:58056026	NA	0.51	7.44	0.34	5.83e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs9487051	0.799	rs830553	chr6:109550017	T/G	cg01475377	chr6:109611718	NA	-0.4	-7.3	-0.33	1.45e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg04800585	chr6:26043546	HIST1H2BB	0.41	7.02	0.32	8.88e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	9.0	0.4	7.48e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg07677032	chr17:61819896	STRADA	0.57	10.58	0.46	2.22e-23	Prudent dietary pattern;
LUAD	cis	rs220324	0.688	rs9983760	chr21:43570639	C/T	cg09727148	chr21:43560719	UMODL1	0.48	7.41	0.34	6.99e-13	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10896135	0.526	rs484262	chr11:66399681	C/T	cg24851651	chr11:66362959	CCS	-0.55	-8.83	-0.39	2.77e-17	Bipolar disorder;
LUAD	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg00750074	chr16:89608354	SPG7	-0.55	-9.33	-0.41	5.94e-19	Multiple myeloma (IgH translocation);
LUAD	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg00316803	chr15:76480434	C15orf27	-0.41	-7.63	-0.35	1.5700000000000001e-13	Blood metabolite levels;
LUAD	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.87	9.89	0.43	7.16e-21	Initial pursuit acceleration;
LUAD	trans	rs8073060	0.559	rs10438814	chr17:34007065	A/G	cg19694781	chr19:47549865	TMEM160	-1.22	-19.55	-0.69	4.14e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7759001	0.857	rs2223463	chr6:27356193	G/C	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.83e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg21427119	chr20:30132790	HM13	-0.63	-9.64	-0.42	5.36e-20	Mean corpuscular hemoglobin;
LUAD	cis	rs6499255	0.951	rs60472033	chr16:69677709	A/G	cg15192750	chr16:69999425	NA	0.52	8.18	0.37	3.42e-15	IgE levels;
LUAD	cis	rs6564851	0.506	rs62054666	chr16:81259721	C/G	cg00908271	chr16:81254010	PKD1L2	0.32	6.65	0.31	9.35e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs6494488	0.500	rs72741320	chr15:64721745	C/A	cg08069370	chr15:64387884	SNX1	-0.75	-6.64	-0.31	9.44e-11	Coronary artery disease;
LUAD	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg04586622	chr2:25135609	ADCY3	0.36	8.22	0.37	2.55e-15	Body mass index;
LUAD	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15664640	chr17:80829946	TBCD	-0.85	-17.35	-0.64	2.68e-51	Breast cancer;
LUAD	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg07741184	chr6:167504864	NA	-0.33	-7.68	-0.35	1.1e-13	Crohn's disease;
LUAD	cis	rs4638749	0.677	rs10454132	chr2:108828111	T/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.26	-0.33	1.88e-12	Blood pressure;
LUAD	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.32	-0.34	1.26e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg03188948	chr7:1209495	NA	0.43	6.91	0.32	1.74e-11	Longevity;Endometriosis;
LUAD	cis	rs17401966	0.838	rs912963	chr1:10348042	C/T	cg19773385	chr1:10388646	KIF1B	-0.38	-6.39	-0.3	4.43e-10	Hepatocellular carcinoma;
LUAD	cis	rs7192380	0.571	rs10852456	chr16:69605613	G/T	cg26679644	chr16:69762563	NA	0.48	9.41	0.42	3.32e-19	Sjögren's syndrome;
LUAD	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg02269571	chr22:50332266	NA	0.63	9.29	0.41	8.41e-19	Schizophrenia;
LUAD	cis	rs7192380	0.895	rs2917671	chr16:69758741	A/T	cg00738113	chr16:70207722	CLEC18C	0.35	7.04	0.32	7.88e-12	Sjögren's syndrome;
LUAD	cis	rs6495122	0.662	rs12898997	chr15:75090349	C/T	cg14664628	chr15:75095509	CSK	-0.49	-8.06	-0.36	8.06e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg02931644	chr1:25747376	RHCE	0.41	8.46	0.38	4.36e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg20628663	chr10:43360327	NA	-0.73	-11.33	-0.48	3.61e-26	Blood protein levels;
LUAD	cis	rs10821973	0.527	rs4590753	chr10:63976449	C/T	cg09941381	chr10:64027924	RTKN2	-0.34	-6.74	-0.31	5.22e-11	Hypothyroidism;
LUAD	cis	rs1555895	0.544	rs1555897	chr10:853674	A/C	cg20503657	chr10:835505	NA	0.41	6.61	0.31	1.15e-10	Survival in rectal cancer;
LUAD	trans	rs1493916	1.000	rs12457802	chr18:31389865	A/G	cg27147174	chr7:100797783	AP1S1	0.68	11.98	0.5	1.09e-28	Life satisfaction;
LUAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg13047869	chr3:10149882	C3orf24	0.64	11.02	0.47	5.16e-25	Alzheimer's disease;
LUAD	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg17863274	chr19:49399704	TULP2	-0.66	-10.02	-0.44	2.43e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	trans	rs875971	1.000	rs875971	chr7:65617595	A/G	cg14917512	chr19:3094685	GNA11	0.37	6.43	0.3	3.37e-10	Aortic root size;
LUAD	cis	rs986417	1.000	rs4243618	chr14:61067022	T/C	cg27398547	chr14:60952738	C14orf39	0.65	7.19	0.33	2.92e-12	Gut microbiota (bacterial taxa);
LUAD	trans	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg19676328	chr12:49525230	TUBA1B	-0.55	-8.0	-0.36	1.22e-14	Total cholesterol levels;
LUAD	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7119038	0.818	rs4936444	chr11:118743338	A/G	cg19308663	chr11:118741387	NA	-0.58	-8.73	-0.39	6.01e-17	Sjögren's syndrome;
LUAD	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg14092571	chr14:90743983	NA	-0.49	-8.44	-0.38	5.05e-16	Mortality in heart failure;
LUAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg00431813	chr7:1051703	C7orf50	-0.45	-8.65	-0.39	1.11e-16	Longevity;Endometriosis;
LUAD	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	8.46e-19	Tonsillectomy;
LUAD	cis	rs4698790	0.635	rs13129180	chr4:110686413	A/T	cg07850274	chr4:110748770	RRH	-0.39	-6.49	-0.3	2.45e-10	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUAD	cis	rs12431939	0.948	rs12433249	chr14:51669661	T/C	cg23942311	chr14:51606299	NA	-0.49	-7.23	-0.33	2.29e-12	Cancer;
LUAD	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg09065629	chr16:1709722	CRAMP1L	0.46	7.94	0.36	1.86e-14	Coronary artery disease;
LUAD	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00290607	chr11:67383545	NA	0.54	9.07	0.4	4.4e-18	Mean corpuscular volume;
LUAD	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg13699009	chr12:122356056	WDR66	0.34	7.65	0.35	1.36e-13	Mean corpuscular volume;
LUAD	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg25208724	chr1:156163844	SLC25A44	1.15	26.17	0.79	1.78e-90	Testicular germ cell tumor;
LUAD	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.35	-7.43	-0.34	5.91e-13	Hemoglobin concentration;
LUAD	cis	rs1595825	0.678	rs57265854	chr2:198917263	C/A	cg00361562	chr2:198649771	BOLL	-0.47	-6.47	-0.3	2.66e-10	Ulcerative colitis;
LUAD	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg11859384	chr17:80120422	CCDC57	0.49	8.79	0.39	3.83e-17	Life satisfaction;
LUAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14893161	chr1:205819251	PM20D1	0.95	23.31	0.75	6.76e-78	Menarche (age at onset);
LUAD	cis	rs713477	0.967	rs8020152	chr14:55907025	T/A	cg13175173	chr14:55914753	NA	-0.33	-6.88	-0.32	2.21e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs1215050	0.791	rs10856931	chr4:98819306	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.82	0.36	4.17e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3815700	1.000	rs8109990	chr19:33095636	A/G	cg02997394	chr19:33096574	ANKRD27	0.65	8.54	0.38	2.36e-16	Eosinophilic esophagitis;
LUAD	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg04450456	chr4:17643702	FAM184B	0.38	7.48	0.34	4.33e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg11663144	chr21:46675770	NA	-0.61	-12.07	-0.51	4.8e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg06221963	chr1:154839813	KCNN3	-0.88	-21.25	-0.72	1.04e-68	Prostate cancer;
LUAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg08888203	chr3:10149979	C3orf24	-0.66	-11.39	-0.48	2.11e-26	Alzheimer's disease;
LUAD	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg20587970	chr11:113659929	NA	-1.38	-20.5	-0.71	2.42e-65	Hip circumference adjusted for BMI;
LUAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.51	7.09	0.33	5.69e-12	Renal function-related traits (BUN);
LUAD	cis	rs11214589	0.747	rs10502172	chr11:113199146	C/T	cg14159747	chr11:113255604	NA	0.62	12.62	0.52	3.28e-31	Neuroticism;
LUAD	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg22875332	chr1:76189707	ACADM	-0.68	-10.71	-0.46	7.64e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg09365446	chr1:150670422	GOLPH3L	-0.57	-9.35	-0.41	5.3e-19	Blood protein levels;
LUAD	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg06618935	chr21:46677482	NA	-0.43	-7.87	-0.36	3e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs7746199	0.673	rs72847313	chr6:27730082	C/T	cg01620082	chr3:125678407	NA	-1.0	-10.23	-0.45	4.43e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg06064525	chr11:970664	AP2A2	-0.42	-8.18	-0.37	3.26e-15	Alzheimer's disease (late onset);
LUAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg08027265	chr7:2291960	NA	-0.44	-7.34	-0.34	1.07e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.22	-0.44	4.74e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg17105886	chr17:28927953	LRRC37B2	0.83	8.0	0.36	1.18e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10129255	0.500	rs12101190	chr14:107192386	C/T	cg07958169	chr14:107095056	NA	-0.37	-7.36	-0.34	9.91e-13	Kawasaki disease;
LUAD	cis	rs7009516	0.819	rs5012230	chr8:24208934	A/C	cg01759110	chr8:24241694	ADAMDEC1	0.42	8.48	0.38	3.71e-16	Hair greying;
LUAD	cis	rs6908034	0.607	rs79406203	chr6:19816221	T/G	cg02682789	chr6:19804855	NA	0.93	9.06	0.4	4.98e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	trans	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-7.47	-0.34	4.53e-13	Joint mobility (Beighton score);
LUAD	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg14582100	chr15:45693742	SPATA5L1	0.51	9.7	0.43	3.27e-20	Homoarginine levels;
LUAD	cis	rs7607369	0.648	rs7559629	chr2:219657013	A/T	cg02176678	chr2:219576539	TTLL4	-0.69	-13.74	-0.56	9.1e-36	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs758324	0.947	rs924434	chr5:131143369	A/C	cg25547332	chr5:131281432	NA	0.43	6.48	0.3	2.6e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs6940638	0.956	rs12190473	chr6:27024687	C/T	cg06606381	chr12:133084897	FBRSL1	-0.49	-6.59	-0.31	1.32e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1113500	0.897	rs11185263	chr1:108639804	C/G	cg06207961	chr1:108661230	NA	0.43	8.27	0.37	1.81e-15	Growth-regulated protein alpha levels;
LUAD	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg15147215	chr3:52552868	STAB1	-0.38	-7.36	-0.34	9.73e-13	Bipolar disorder;
LUAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg00280220	chr17:61926910	NA	0.37	7.08	0.33	6.2e-12	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.58	0.3	1.35e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg25358565	chr5:93447407	FAM172A	0.63	7.78	0.35	5.58e-14	Diabetic retinopathy;
LUAD	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg10978503	chr1:24200527	CNR2	0.59	12.8	0.53	6.02e-32	Immature fraction of reticulocytes;
LUAD	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg02569458	chr12:86230093	RASSF9	0.44	8.17	0.37	3.69e-15	Major depressive disorder;
LUAD	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg26384229	chr12:38710491	ALG10B	0.43	7.23	0.33	2.29e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg21798802	chr22:38057573	PDXP	0.36	7.52	0.34	3.35e-13	Fat distribution (HIV);
LUAD	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg23533926	chr12:111358616	MYL2	-0.41	-7.1	-0.33	5.22e-12	Extrinsic epigenetic age acceleration;
LUAD	trans	rs9467711	0.651	rs13210041	chr6:26037601	G/A	cg06606381	chr12:133084897	FBRSL1	-1.16	-8.64	-0.39	1.13e-16	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs853679	0.546	rs35656932	chr6:28191288	G/T	cg01620082	chr3:125678407	NA	-1.1	-10.34	-0.45	1.67e-22	Depression;
LUAD	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg07169764	chr2:136633963	MCM6	0.77	9.15	0.41	2.47e-18	Corneal structure;
LUAD	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	10.39	0.45	1.12e-22	Colorectal cancer;
LUAD	trans	rs11088226	0.846	rs2833884	chr21:33923075	A/G	cg09050820	chr6:167586206	TCP10L2	0.64	9.68	0.43	3.65e-20	Gastritis;
LUAD	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	14.05	0.56	4.42e-37	Smoking behavior;
LUAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08219700	chr8:58056026	NA	0.63	8.82	0.39	2.92e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg21984481	chr17:79567631	NPLOC4	-0.55	-11.74	-0.5	9.76e-28	Eye color traits;
LUAD	cis	rs12681288	0.550	rs12675410	chr8:957845	T/C	cg15309053	chr8:964076	NA	0.44	9.78	0.43	1.68e-20	Schizophrenia;
LUAD	cis	rs11811982	0.655	rs115344261	chr1:227420111	C/T	cg24860534	chr1:227506868	CDC42BPA	0.7	7.58	0.35	2.27e-13	Optic disc area;
LUAD	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26314531	chr2:26401878	FAM59B	-0.72	-9.81	-0.43	1.33e-20	Gut microbiome composition (summer);
LUAD	cis	rs3818285	0.556	rs944966	chr10:111658334	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.69	-10.67	-0.46	1.05e-23	Superior crus of antihelix expression;
LUAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08677398	chr8:58056175	NA	0.47	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs8067545	0.750	rs9896411	chr17:19987610	A/T	cg04132472	chr17:19861366	AKAP10	0.28	6.62	0.31	1.1e-10	Schizophrenia;
LUAD	trans	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.16	-0.64	1.71e-50	Exhaled nitric oxide output;
LUAD	cis	rs12545109	0.800	rs2118261	chr8:57393286	A/G	cg17761419	chr8:57350749	NA	0.52	7.82	0.36	4.21e-14	Obesity-related traits;
LUAD	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.77e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg06623918	chr6:96969491	KIAA0776	-0.74	-10.17	-0.44	7.01e-22	Migraine;Coronary artery disease;
LUAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg02951883	chr7:2050386	MAD1L1	-0.93	-18.25	-0.66	2.74e-55	Bipolar disorder and schizophrenia;
LUAD	cis	rs220324	0.688	rs9983760	chr21:43570639	C/T	cg08841829	chr21:43638893	ABCG1	-0.49	-6.96	-0.32	1.33e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs11971779	0.680	rs2355788	chr7:139101897	T/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	7.16e-11	Diisocyanate-induced asthma;
LUAD	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.13	-0.41	2.8e-18	Life satisfaction;
LUAD	cis	rs3087591	1.000	rs7226006	chr17:29650656	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.43	-6.97	-0.32	1.25e-11	Hip circumference;
LUAD	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.38	-0.34	8.28e-13	Lung cancer;
LUAD	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg19052272	chr2:3704530	ALLC	-0.42	-7.85	-0.36	3.45e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs698833	0.892	rs1067403	chr2:44675851	G/A	cg04920474	chr2:44395004	PPM1B	0.38	6.44	0.3	3.24e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg25358565	chr5:93447407	FAM172A	0.62	7.07	0.33	6.51e-12	Diabetic retinopathy;
LUAD	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg23283495	chr1:209979779	IRF6	0.74	10.81	0.47	3.18e-24	Cleft lip with or without cleft palate;
LUAD	cis	rs2485376	0.967	rs772016	chr10:104031289	T/C	cg20641465	chr10:103991465	PITX3	-0.58	-10.72	-0.46	6.9e-24	QT interval;
LUAD	cis	rs17095355	0.792	rs3780953	chr10:111650634	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.64	-7.47	-0.34	4.58e-13	Biliary atresia;
LUAD	cis	rs933688	0.532	rs997737	chr5:90567031	C/G	cg17503389	chr5:90575422	NA	-0.45	-7.22	-0.33	2.42e-12	Smoking behavior;
LUAD	cis	rs243505	1.000	rs243510	chr7:148432534	A/G	cg09806900	chr7:148480153	CUL1	-0.44	-7.42	-0.34	6.57e-13	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg02454025	chr1:11042201	C1orf127	1.01	17.78	0.65	3.2e-53	Ewing sarcoma;
LUAD	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg04492858	chr10:133558786	NA	0.4	7.91	0.36	2.27e-14	Survival in rectal cancer;
LUAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg12432903	chr7:1882776	MAD1L1	-0.52	-8.62	-0.39	1.34e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs6669072	0.647	rs814544	chr1:91241693	G/A	cg08895590	chr1:91227319	NA	-0.32	-6.57	-0.3	1.44e-10	Cognitive function;
LUAD	cis	rs714027	0.967	rs193477	chr22:30451486	C/T	cg11564601	chr22:30592435	NA	-0.39	-8.34	-0.38	1.05e-15	Lymphocyte counts;
LUAD	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg17652424	chr22:38574118	PLA2G6	-0.32	-9.72	-0.43	2.71e-20	Cutaneous nevi;
LUAD	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.18	-0.33	3.26e-12	Breast cancer;
LUAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg24503407	chr1:205819492	PM20D1	0.49	7.77	0.35	5.93e-14	Parkinson's disease;
LUAD	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.47	0.38	4.01e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs733175	0.855	rs10018666	chr4:10004805	C/T	cg00071950	chr4:10020882	SLC2A9	0.59	9.42	0.42	2.98e-19	Psychosis and Alzheimer's disease;
LUAD	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg09467607	chr2:36825704	FEZ2	0.6	11.97	0.5	1.24e-28	Height;
LUAD	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg02782426	chr3:40428986	ENTPD3	0.35	7.42	0.34	6.68e-13	Renal cell carcinoma;
LUAD	cis	rs4074961	0.586	rs10908360	chr1:38058693	T/C	cg12696750	chr1:38022466	DNALI1	0.43	7.38	0.34	8.65e-13	Axial length;
LUAD	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg07507251	chr3:52567010	NT5DC2	0.37	7.32	0.34	1.26e-12	Bipolar disorder;
LUAD	cis	rs56161922	1.000	rs57587123	chr1:207825415	A/G	cg11752769	chr1:207818423	CR1L	-0.64	-6.68	-0.31	7.42e-11	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs11958404	0.932	rs76228149	chr5:157434486	G/A	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg14458575	chr2:238380390	NA	0.67	12.9	0.53	2.44e-32	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg21204522	chr6:27730016	NA	-0.46	-7.28	-0.33	1.6e-12	Parkinson's disease;
LUAD	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg24838063	chr12:130822603	PIWIL1	-0.7	-11.49	-0.49	9.22e-27	Menopause (age at onset);
LUAD	cis	rs8064299	0.597	rs6501736	chr17:72775358	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.41	6.71	0.31	6.23e-11	Monocyte count;
LUAD	cis	rs6138458	0.961	rs11700073	chr20:24975215	C/G	cg06937882	chr20:24974362	C20orf3	-0.34	-6.9	-0.32	1.96e-11	Blood protein levels;
LUAD	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg04827223	chr11:72435913	ARAP1	-0.49	-7.39	-0.34	7.7e-13	Type 2 diabetes;
LUAD	cis	rs762407	0.648	rs11701801	chr21:45169733	C/T	cg19815989	chr21:45161359	PDXK	0.37	6.65	0.31	9.36e-11	Systolic blood pressure change trajectories;
LUAD	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg14092988	chr3:52407081	DNAH1	0.37	7.53	0.34	3.09e-13	Bipolar disorder;
LUAD	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18876405	chr7:65276391	NA	0.4	6.43	0.3	3.44e-10	Aortic root size;
LUAD	cis	rs55823223	0.648	rs72860389	chr17:73866071	C/T	cg09253696	chr17:73873529	TRIM47	-0.49	-8.26	-0.37	1.9e-15	Psoriasis;
LUAD	trans	rs17685	0.890	rs76021834	chr7:75607155	A/G	cg19862616	chr7:65841803	NCRNA00174	0.82	15.0	0.59	4.47e-41	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg14668632	chr7:2872130	GNA12	-0.76	-13.65	-0.55	2.05e-35	Height;
LUAD	cis	rs4631830	0.863	rs7081532	chr10:51526093	A/G	cg20129853	chr10:51489980	NA	-0.32	-6.4	-0.3	4.06e-10	Prostate-specific antigen levels;
LUAD	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg00898013	chr13:113819073	PROZ	-0.81	-14.92	-0.59	9.16e-41	Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7975161	0.572	rs10861163	chr12:104568613	C/A	cg25273343	chr12:104657179	TXNRD1	-0.64	-6.85	-0.32	2.58e-11	Toenail selenium levels;
LUAD	trans	rs11088226	0.846	rs13047501	chr21:33924660	G/A	cg09050820	chr6:167586206	TCP10L2	0.64	9.74	0.43	2.41e-20	Gastritis;
LUAD	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.27	-0.33	1.77e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9902453	0.904	rs9894893	chr17:28270350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.5	0.45	4.43e-23	Coffee consumption (cups per day);
LUAD	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27286337	chr10:134555280	INPP5A	0.72	9.36	0.41	4.83e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.55	7.51	0.34	3.65e-13	Gut microbiome composition (summer);
LUAD	cis	rs6543140	0.964	rs10169192	chr2:103072211	A/G	cg04239558	chr2:103089729	SLC9A4	0.36	7.34	0.34	1.11e-12	Blood protein levels;
LUAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg22535103	chr8:58192502	C8orf71	-0.74	-9.2	-0.41	1.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	9.1	0.4	3.64e-18	Hip circumference adjusted for BMI;
LUAD	cis	rs12545109	0.800	rs2576602	chr8:57394495	C/T	cg07776626	chr8:57350775	NA	-0.64	-9.23	-0.41	1.35e-18	Obesity-related traits;
LUAD	cis	rs6674176	0.542	rs3011225	chr1:44319373	G/A	cg13606994	chr1:44402422	ARTN	-0.33	-6.6	-0.31	1.25e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs12545109	0.765	rs2576589	chr8:57425647	C/T	cg17761419	chr8:57350749	NA	-0.5	-7.2	-0.33	2.74e-12	Obesity-related traits;
LUAD	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg20556744	chr2:9614537	IAH1	0.66	6.56	0.3	1.55e-10	Opioid sensitivity;
LUAD	cis	rs8010715	0.804	rs1134334	chr14:24594114	A/G	cg23112188	chr14:24563095	PCK2	-0.32	-6.51	-0.3	2.12e-10	IgG glycosylation;
LUAD	cis	rs13082711	0.911	rs997680	chr3:27443638	G/A	cg02860705	chr3:27208620	NA	0.57	8.83	0.39	2.89e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg17757837	chr7:157058334	UBE3C	0.5	8.9	0.4	1.68e-17	Body mass index;
LUAD	cis	rs17608059	0.566	rs5005684	chr17:13910633	T/C	cg11395062	chr17:14139857	CDRT15	0.46	7.38	0.34	8.61e-13	Temperament;
LUAD	trans	rs225245	0.791	rs7216391	chr17:34024706	G/A	cg19694781	chr19:47549865	TMEM160	-0.48	-7.93	-0.36	1.99e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg07460842	chr6:66804631	NA	-1.06	-16.52	-0.63	1.2e-47	Exhaled nitric oxide output;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24243429	chr4:148653539	ARHGAP10	-0.47	-7.5	-0.34	3.78e-13	Height;
LUAD	cis	rs9652601	0.959	rs12708715	chr16:11177824	C/T	cg04616529	chr16:11181986	CLEC16A	0.37	6.53	0.3	1.89e-10	Systemic lupus erythematosus;
LUAD	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg18512352	chr11:47633146	NA	0.46	8.09	0.37	6.33e-15	Subjective well-being;
LUAD	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08695707	chr1:197871847	C1orf53	0.43	6.7	0.31	6.52e-11	Monocyte percentage of white cells;
LUAD	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg06558623	chr16:89946397	TCF25	0.95	10.5	0.45	4.43e-23	Skin colour saturation;
LUAD	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.63	11.92	0.5	1.95e-28	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs11811982	0.793	rs115516662	chr1:227418455	T/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.57	0.35	2.33e-13	Optic disc area;
LUAD	trans	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg07461501	chr17:79650226	HGS;ARL16	0.7	10.06	0.44	1.67e-21	Obesity-related traits;
LUAD	trans	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17712092	chr4:129076599	LARP1B	0.89	16.73	0.63	1.33e-48	Eosinophil percentage of white cells;
LUAD	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg07606381	chr6:8435919	SLC35B3	0.42	6.88	0.32	2.15e-11	Motion sickness;
LUAD	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03264133	chr6:25882463	NA	-0.53	-7.73	-0.35	8.02e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.14	-0.33	4.05e-12	Breast cancer;
LUAD	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.32e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-7.21	-0.33	2.55e-12	IgG glycosylation;
LUAD	cis	rs34734847	0.787	rs695949	chr12:121149736	A/G	cg21892295	chr12:121157589	UNC119B	-0.41	-7.37	-0.34	9.27e-13	Mean corpuscular volume;
LUAD	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg02569458	chr12:86230093	RASSF9	0.45	8.2	0.37	2.97e-15	Major depressive disorder;
LUAD	cis	rs6138458	0.887	rs227622	chr20:24910597	T/C	cg26195577	chr20:24973756	C20orf3	0.96	16.32	0.62	8.79e-47	Blood protein levels;
LUAD	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg15997130	chr1:24165203	NA	-0.47	-7.43	-0.34	6.21e-13	Immature fraction of reticulocytes;
LUAD	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg00383909	chr3:49044727	WDR6	0.86	9.97	0.44	3.66e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg13770153	chr20:60521292	NA	1.03	16.94	0.64	1.59e-49	Obesity-related traits;
LUAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg16606324	chr3:10149918	C3orf24	0.7	11.5	0.49	8.21e-27	Alzheimer's disease;
LUAD	trans	rs11227306	0.934	rs11227315	chr11:65590389	C/A	cg17712092	chr4:129076599	LARP1B	0.68	10.68	0.46	1.01e-23	DNA methylation (variation);
LUAD	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg26384229	chr12:38710491	ALG10B	0.47	7.61	0.35	1.8e-13	Morning vs. evening chronotype;
LUAD	cis	rs2387326	0.767	rs12257487	chr10:129943286	A/G	cg16087940	chr10:129947807	NA	-0.65	-9.11	-0.4	3.39e-18	Select biomarker traits;
LUAD	cis	rs8099014	0.861	rs4940709	chr18:56134792	G/A	cg12907477	chr18:56117327	MIR122	0.51	7.95	0.36	1.74e-14	Platelet count;
LUAD	cis	rs10733682	0.524	rs10987418	chr9:129462563	A/G	cg00232160	chr9:129468157	NA	0.48	8.43	0.38	5.62e-16	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg18530282	chr10:115439379	CASP7	0.39	6.45	0.3	3.14e-10	Optic cup area;
LUAD	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg06074448	chr4:187884817	NA	-0.35	-6.93	-0.32	1.58e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg18621852	chr3:10150065	C3orf24	0.48	8.45	0.38	4.89e-16	Alzheimer's disease;
LUAD	trans	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg01620082	chr3:125678407	NA	-0.49	-6.62	-0.31	1.06e-10	Depression;
LUAD	trans	rs877282	0.898	rs11253343	chr10:765117	C/T	cg22713356	chr15:30763199	NA	1.27	17.4	0.65	1.56e-51	Uric acid levels;
LUAD	cis	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg26958806	chr6:27640298	NA	0.64	6.53	0.3	1.91e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11905131	chr22:24372483	LOC391322	-0.5	-8.59	-0.39	1.69e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.47	7.2	0.33	2.83e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg19610905	chr11:61596333	FADS2	-0.81	-10.33	-0.45	1.9e-22	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs877282	0.947	rs7904978	chr10:768078	C/T	cg17470449	chr10:769945	NA	0.62	8.71	0.39	7.04e-17	Uric acid levels;
LUAD	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg11057378	chr10:81107060	PPIF	0.38	7.04	0.32	7.58e-12	Height;
LUAD	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg09455208	chr3:40491958	NA	-0.62	-13.29	-0.54	6.05e-34	Renal cell carcinoma;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg01947862	chr2:86116624	ST3GAL5	0.4	6.48	0.3	2.61e-10	Bilirubin levels;
LUAD	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg00634984	chr7:65235879	NA	0.44	7.07	0.33	6.42e-12	Aortic root size;
LUAD	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03517284	chr6:25882590	NA	-0.6	-8.68	-0.39	8.94e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs3845702	0.736	rs16867131	chr2:180848651	A/G	cg01881094	chr2:180872142	CWC22	-0.77	-8.22	-0.37	2.58e-15	Schizophrenia;
LUAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg22535103	chr8:58192502	C8orf71	0.75	9.22	0.41	1.43e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg18016565	chr1:150552671	MCL1	0.41	7.65	0.35	1.38e-13	Tonsillectomy;
LUAD	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg17366294	chr4:99064904	C4orf37	0.58	9.88	0.43	7.8e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg03676636	chr4:99064102	C4orf37	0.31	8.16	0.37	3.89e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9972944	0.902	rs9972881	chr17:63771334	A/G	cg07283582	chr17:63770753	CCDC46	0.53	12.2	0.51	1.49e-29	Total body bone mineral density;
LUAD	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11890956	chr21:40555474	PSMG1	-0.64	-11.13	-0.48	2.1e-25	Cognitive function;
LUAD	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg26384229	chr12:38710491	ALG10B	0.45	7.33	0.34	1.18e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4771122	0.697	rs1475220	chr13:28037448	G/C	cg22138327	chr13:27999177	GTF3A	-0.59	-8.64	-0.39	1.16e-16	Body mass index;
LUAD	cis	rs9372498	0.764	rs9320652	chr6:118720448	A/G	cg07617317	chr6:118971624	C6orf204	0.54	6.72	0.31	5.73e-11	Diastolic blood pressure;
LUAD	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg01181863	chr3:195395398	SDHAP2	-0.63	-9.43	-0.42	2.7e-19	Pancreatic cancer;
LUAD	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	12.1	0.51	3.64e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs637571	0.607	rs589253	chr11:65693080	G/A	cg17712092	chr4:129076599	LARP1B	1.0	20.18	0.7	6.11e-64	Eosinophil percentage of white cells;
LUAD	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg00383909	chr3:49044727	WDR6	0.68	8.54	0.38	2.49e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2535633	0.631	rs2710313	chr3:52969529	T/A	cg18404041	chr3:52824283	ITIH1	0.38	6.46	0.3	2.92e-10	Body mass index;
LUAD	cis	rs9322817	0.715	rs6918700	chr6:105244526	A/T	cg02098413	chr6:105308735	HACE1	-0.41	-8.82	-0.39	2.93e-17	Thyroid stimulating hormone;
LUAD	cis	rs56309584	0.560	rs56346215	chr17:8076917	A/C	cg08322244	chr17:8066669	VAMP2	-0.48	-6.56	-0.3	1.53e-10	Initial pursuit acceleration;
LUAD	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg01097406	chr16:89675127	NA	0.45	9.67	0.43	4.19e-20	Vitiligo;
LUAD	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.24	-0.33	2.09e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg26769984	chr7:1090371	C7orf50	0.58	9.54	0.42	1.11e-19	Bronchopulmonary dysplasia;
LUAD	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7119	0.717	rs8032071	chr15:77745762	C/T	cg05673287	chr15:77411982	SGK269	0.43	6.78	0.31	4.15e-11	Type 2 diabetes;
LUAD	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.54	0.34	2.94e-13	Menopause (age at onset);
LUAD	trans	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.16	-0.64	1.71e-50	Exhaled nitric oxide output;
LUAD	cis	rs9399401	0.710	rs12190271	chr6:142681409	A/G	cg03128060	chr6:142623767	GPR126	-0.49	-9.88	-0.43	7.61e-21	Chronic obstructive pulmonary disease;
LUAD	cis	rs727505	0.954	rs67146030	chr7:124561790	T/G	cg23710748	chr7:124431027	NA	-0.49	-9.82	-0.43	1.24e-20	Lewy body disease;
LUAD	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg23625390	chr15:77176239	SCAPER	0.39	7.03	0.32	8.39e-12	Blood metabolite levels;
LUAD	cis	rs829883	0.573	rs73136486	chr12:98913727	T/A	cg25150519	chr12:98850993	NA	-0.52	-8.21	-0.37	2.74e-15	Colorectal adenoma (advanced);
LUAD	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18876405	chr7:65276391	NA	0.44	7.08	0.33	6.08e-12	Aortic root size;
LUAD	cis	rs3806843	0.576	rs246017	chr5:140335060	C/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12472274	0.529	rs11677996	chr2:239118007	A/G	cg17459225	chr2:239074497	NA	0.67	7.5	0.34	3.83e-13	Phospholipid levels (plasma);
LUAD	cis	rs11811982	0.793	rs11807425	chr1:227511793	A/C	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs78761021	0.898	rs7216359	chr17:9775419	G/C	cg26853458	chr17:9805074	RCVRN	0.35	6.68	0.31	7.5e-11	Type 2 diabetes;
LUAD	cis	rs501916	0.833	rs3809486	chr15:48051549	G/T	cg16110827	chr15:48056943	SEMA6D	-0.41	-7.3	-0.33	1.45e-12	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07636037	chr3:49044803	WDR6	-0.47	-7.91	-0.36	2.24e-14	Menarche (age at onset);
LUAD	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg15691649	chr6:25882328	NA	0.63	9.73	0.43	2.61e-20	Blood metabolite levels;
LUAD	trans	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04565464	chr8:145669602	NFKBIL2	0.47	7.13	0.33	4.49e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg09365446	chr1:150670422	GOLPH3L	0.66	12.58	0.52	4.9e-31	Tonsillectomy;
LUAD	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg26647111	chr11:31128758	NA	-0.47	-8.14	-0.37	4.42e-15	Red blood cell count;
LUAD	cis	rs9462027	0.628	rs6906759	chr6:34742990	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.94	-0.4	1.27e-17	Systemic lupus erythematosus;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09894040	chr3:126422945	CHCHD6	-0.42	-6.93	-0.32	1.55e-11	Cancer;
LUAD	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg22676075	chr6:135203613	NA	0.41	7.69	0.35	1.08e-13	Red blood cell count;
LUAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg27454412	chr7:1067447	C7orf50	0.48	7.74	0.35	7.46e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg00310523	chr12:86230176	RASSF9	0.39	7.8	0.35	4.99e-14	Major depressive disorder;
LUAD	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg14834391	chr1:2537342	MMEL1	-0.31	-6.53	-0.3	1.83e-10	Ulcerative colitis;
LUAD	trans	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg01620082	chr3:125678407	NA	-0.72	-8.13	-0.37	4.96e-15	Depression;
LUAD	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.72	0.31	6.01e-11	Depression;
LUAD	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg13390004	chr1:15929781	NA	0.49	8.61	0.39	1.49e-16	Systolic blood pressure;
LUAD	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg05368731	chr17:41323189	NBR1	0.81	16.28	0.62	1.33e-46	Menopause (age at onset);
LUAD	cis	rs733175	0.855	rs9291641	chr4:10007259	C/T	cg11266682	chr4:10021025	SLC2A9	0.43	7.42	0.34	6.63e-13	Psychosis and Alzheimer's disease;
LUAD	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-10.79	-0.46	3.99e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg13606994	chr1:44402422	ARTN	-0.37	-7.24	-0.33	2.09e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02978827	chr13:48877687	RB1	-0.41	-6.91	-0.32	1.77e-11	Cancer;
LUAD	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg03806693	chr22:41940476	POLR3H	-0.82	-11.65	-0.49	2.09e-27	Vitiligo;
LUAD	trans	rs587242	0.955	rs35251373	chr1:96970538	C/T	cg10631902	chr5:14652156	NA	0.41	6.46	0.3	2.94e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg14668632	chr7:2872130	GNA12	-0.75	-13.55	-0.55	5.43e-35	Height;
LUAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg06074448	chr4:187884817	NA	-0.36	-7.24	-0.33	2.08e-12	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg13276752	chr17:57970287	TUBD1;RPS6KB1	0.41	6.56	0.3	1.55e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	cis	rs829883	0.738	rs249846	chr12:98868739	T/C	cg25150519	chr12:98850993	NA	0.78	14.54	0.58	3.91e-39	Colorectal adenoma (advanced);
LUAD	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg00074818	chr8:8560427	CLDN23	0.66	10.08	0.44	1.46e-21	Obesity-related traits;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24996263	chr1:31297444	NA	-0.42	-6.81	-0.31	3.46e-11	Cancer;
LUAD	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg14092988	chr3:52407081	DNAH1	0.45	8.98	0.4	8.87e-18	Bipolar disorder;
LUAD	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg20276088	chr3:133502917	NA	-0.43	-7.58	-0.35	2.27e-13	Iron status biomarkers;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg21235838	chr10:97321106	SORBS1	-0.53	-6.42	-0.3	3.61e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg02683114	chr2:24398427	C2orf84	-0.52	-7.75	-0.35	7.03e-14	Asthma;
LUAD	cis	rs9473147	0.543	rs9349407	chr6:47453378	C/G	cg12968598	chr6:47444699	CD2AP	0.37	7.03	0.32	8.19e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.78	-0.43	1.63e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg18621852	chr3:10150065	C3orf24	0.49	8.83	0.39	2.72e-17	Alzheimer's disease;
LUAD	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.55	-0.3	1.64e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg10755058	chr3:40428713	ENTPD3	-0.42	-8.26	-0.37	1.93e-15	Renal cell carcinoma;
LUAD	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg27624424	chr6:160112604	SOD2	-0.45	-6.45	-0.3	3.06e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg07917127	chr4:99064746	C4orf37	0.45	7.55	0.34	2.65e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg11915388	chr22:42470451	FAM109B	0.41	7.38	0.34	8.67e-13	Schizophrenia;
LUAD	cis	rs6684514	1.000	rs6684514	chr1:156255456	G/A	cg16558208	chr1:156270281	VHLL	0.53	9.55	0.42	1.05e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg10755058	chr3:40428713	ENTPD3	-0.43	-8.13	-0.37	4.96e-15	Renal cell carcinoma;
LUAD	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg13393036	chr8:95962371	TP53INP1	-0.44	-10.49	-0.45	4.95e-23	Type 2 diabetes;
LUAD	cis	rs738322	0.772	rs9619724	chr22:38517880	T/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-8.41	-0.38	6.46e-16	Cutaneous nevi;
LUAD	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg25324976	chr17:61989376	CSHL1	0.37	7.34	0.34	1.13e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10465746	0.967	rs11163874	chr1:84424437	G/C	cg10977910	chr1:84465055	TTLL7	0.5	8.1	0.37	5.91e-15	Obesity-related traits;
LUAD	cis	rs10899021	0.512	rs10219168	chr11:74374453	A/T	cg25880958	chr11:74394337	NA	0.46	8.0	0.36	1.2e-14	Response to metformin (IC50);
LUAD	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg09085632	chr11:111637200	PPP2R1B	0.67	11.18	0.48	1.36e-25	Primary sclerosing cholangitis;
LUAD	trans	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg14917512	chr19:3094685	GNA11	-0.58	-6.85	-0.32	2.54e-11	Diabetic kidney disease;
LUAD	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg02734326	chr4:10020555	SLC2A9	-0.49	-8.78	-0.39	4.06e-17	Bone mineral density;
LUAD	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg00634984	chr7:65235879	NA	-0.49	-6.86	-0.32	2.49e-11	Aortic root size;
LUAD	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg08773314	chr2:239334832	ASB1	0.46	10.5	0.45	4.59e-23	Multiple system atrophy;
LUAD	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg06627628	chr2:24431161	ITSN2	-0.45	-6.37	-0.3	4.9e-10	Lymphocyte counts;
LUAD	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg21252483	chr19:49399788	TULP2	-0.7	-11.09	-0.47	2.96e-25	Red cell distribution width;
LUAD	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	8.05	0.36	8.63e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs12545109	0.800	rs1996105	chr8:57413123	A/G	cg07776626	chr8:57350775	NA	-0.62	-8.7	-0.39	7.41e-17	Obesity-related traits;
LUAD	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg25767906	chr1:53392781	SCP2	0.42	7.59	0.35	2e-13	Monocyte count;
LUAD	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg21724239	chr8:58056113	NA	0.52	7.03	0.32	8.44e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg09796270	chr17:17721594	SREBF1	0.38	7.51	0.34	3.64e-13	Total body bone mineral density;
LUAD	trans	rs800082	0.690	rs2118001	chr3:144336609	T/C	cg24215973	chr2:240111563	HDAC4	-0.61	-9.89	-0.43	7.2e-21	Smoking behavior;
LUAD	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg07741184	chr6:167504864	NA	0.31	7.15	0.33	3.94e-12	Crohn's disease;
LUAD	cis	rs57920188	0.584	rs12128330	chr1:4092926	G/A	cg10510935	chr1:4059661	NA	0.45	6.84	0.32	2.79e-11	Interleukin-17 levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08831701	chr17:65241304	HELZ	-0.39	-6.43	-0.3	3.51e-10	Height;
LUAD	cis	rs4372836	0.729	rs12714241	chr2:28969413	T/C	cg09522027	chr2:28974177	PPP1CB	-0.69	-12.78	-0.53	7.58e-32	Body mass index;
LUAD	cis	rs72772090	0.539	rs72773922	chr5:96116660	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.3	-0.33	1.4e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.53	-0.3	1.91e-10	Triglycerides;
LUAD	trans	rs8073060	0.927	rs7502331	chr17:33868858	A/G	cg19694781	chr19:47549865	TMEM160	0.8	12.87	0.53	3.29e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg26384229	chr12:38710491	ALG10B	0.45	7.35	0.34	1.05e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2274273	0.638	rs58269011	chr14:55684388	A/G	cg04306507	chr14:55594613	LGALS3	0.43	8.06	0.36	7.9e-15	Protein biomarker;
LUAD	cis	rs9616064	0.506	rs6008944	chr22:47060976	C/T	cg05621596	chr22:47072043	GRAMD4	-0.54	-9.61	-0.42	6.33e-20	Urate levels in obese individuals;
LUAD	cis	rs250585	0.736	rs30010	chr16:23422658	G/C	cg00143387	chr16:23521605	GGA2	0.62	8.99	0.4	8.07e-18	Egg allergy;
LUAD	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg05966235	chr16:28915196	ATP2A1	0.47	7.61	0.35	1.75e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg07460842	chr6:66804631	NA	0.91	14.45	0.57	9.31e-39	Exhaled nitric oxide levels;
LUAD	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg19767477	chr5:127420684	SLC12A2	-0.43	-6.48	-0.3	2.56e-10	Ileal carcinoids;
LUAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-9.51	-0.42	1.46e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg00933542	chr6:150070202	PCMT1	0.42	9.1	0.4	3.7e-18	Lung cancer;
LUAD	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg09417038	chr21:47716443	C21orf57	-0.49	-8.28	-0.37	1.67e-15	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg02454025	chr1:11042201	C1orf127	1.04	17.76	0.65	3.83e-53	Ewing sarcoma;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14312959	chr17:79008933	FLJ90757;BAIAP2	-0.58	-7.19	-0.33	3.03e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg26408565	chr15:76604113	ETFA	-0.44	-7.13	-0.33	4.3e-12	Blood metabolite levels;
LUAD	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg19622623	chr12:86230825	RASSF9	-0.42	-7.36	-0.34	9.55e-13	Major depressive disorder;
LUAD	cis	rs11167764	0.945	rs6878397	chr5:141474012	A/G	cg08523384	chr5:141488047	NDFIP1	-0.47	-7.08	-0.33	6.04e-12	Crohn's disease;
LUAD	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	8.64	0.39	1.2e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.14	-0.33	4.16e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg15181151	chr6:150070149	PCMT1	0.41	8.36	0.38	8.92e-16	Lung cancer;
LUAD	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg18180107	chr4:99064573	C4orf37	0.42	6.74	0.31	5.2e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg21475434	chr5:93447410	FAM172A	0.57	7.39	0.34	7.91e-13	Diabetic retinopathy;
LUAD	cis	rs1728785	1.000	rs698719	chr16:68560125	C/T	cg02508848	chr16:68573721	ZFP90	-0.41	-6.55	-0.3	1.66e-10	Ulcerative colitis;
LUAD	cis	rs9393692	0.620	rs6930616	chr6:26331969	A/G	cg00631329	chr6:26305371	NA	-0.52	-9.11	-0.4	3.37e-18	Educational attainment;
LUAD	cis	rs9512730	0.553	rs1007701	chr13:28049143	C/G	cg04070771	chr13:27998621	GTF3A	-0.53	-7.7	-0.35	9.59e-14	Schizophrenia;
LUAD	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg01616529	chr11:638424	DRD4	-0.44	-6.43	-0.3	3.42e-10	Systemic lupus erythematosus;
LUAD	cis	rs907683	0.584	rs1058284	chr2:220286142	G/A	cg15015639	chr2:220282977	DES	-0.49	-9.11	-0.41	3.3e-18	Resting heart rate;
LUAD	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg05340658	chr4:99064831	C4orf37	0.51	8.5	0.38	3.3e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg16797656	chr11:68205561	LRP5	0.47	9.88	0.43	7.76e-21	Total body bone mineral density;
LUAD	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg00504896	chr12:9437009	LOC642846	-0.51	-8.45	-0.38	4.75e-16	Breast size;
LUAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.66	-0.46	1.16e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg11494091	chr17:61959527	GH2	0.45	8.48	0.38	3.73e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4888262	0.545	rs7342732	chr16:74698716	A/C	cg01733217	chr16:74700730	RFWD3	0.52	8.51	0.38	2.95e-16	Testicular germ cell tumor;
LUAD	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg00277334	chr10:82204260	NA	-0.65	-12.27	-0.51	8.05e-30	Post bronchodilator FEV1;
LUAD	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.0	-0.5	9.34e-29	Primary sclerosing cholangitis;
LUAD	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg05110241	chr16:68378359	PRMT7	-0.8	-8.78	-0.39	4.06e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11696501	0.688	rs8123346	chr20:44309987	A/T	cg11783356	chr20:44313418	WFDC10B	-0.49	-7.98	-0.36	1.43e-14	Brain structure;
LUAD	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg10518543	chr12:38710700	ALG10B	-0.51	-8.33	-0.38	1.11e-15	Morning vs. evening chronotype;
LUAD	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg14227996	chr4:17616232	MED28	0.71	7.38	0.34	8.62e-13	Opioid sensitivity;
LUAD	trans	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.2	-0.33	2.83e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg10636054	chr15:40330586	SRP14	-0.94	-11.83	-0.5	4.14e-28	Corneal curvature;
LUAD	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg15017067	chr4:17643749	FAM184B	0.38	7.42	0.34	6.2800000000000005e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg01448562	chr3:133502909	NA	-0.78	-14.6	-0.58	2.14e-39	Iron status biomarkers;
LUAD	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg14582100	chr15:45693742	SPATA5L1	0.64	12.48	0.52	1.16e-30	Homoarginine levels;
LUAD	cis	rs2131877	0.830	rs62290330	chr3:194843755	A/G	cg19760965	chr3:194868843	C3orf21	0.47	6.57	0.3	1.48e-10	Non-small cell lung cancer;
LUAD	trans	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg04565464	chr8:145669602	NFKBIL2	0.44	6.65	0.31	8.92e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs10489202	0.608	rs35059151	chr1:168079393	C/A	cg24449463	chr1:168025552	DCAF6	-0.62	-9.86	-0.43	8.54e-21	Schizophrenia;
LUAD	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg04851639	chr8:1020857	NA	-0.38	-9.3	-0.41	7.61e-19	Schizophrenia;
LUAD	cis	rs6005807	0.719	rs73430179	chr22:28998821	T/C	cg12565055	chr22:29076175	TTC28	0.75	8.76	0.39	4.71e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg08645402	chr16:4508243	NA	0.59	10.98	0.47	7.48e-25	Schizophrenia;
LUAD	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg21951975	chr1:209979733	IRF6	0.56	8.21	0.37	2.76e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg17366294	chr4:99064904	C4orf37	0.65	12.41	0.52	2.27e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6761276	0.649	rs12711751	chr2:113837765	T/G	cg10479672	chr2:113810641	IL1F8	-0.36	-7.15	-0.33	3.94e-12	Protein quantitative trait loci;
LUAD	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg02493740	chr2:85810744	VAMP5	-0.47	-8.58	-0.39	1.82e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs1461503	0.900	rs10892935	chr11:122838590	C/T	cg27398637	chr11:122830231	C11orf63	-0.36	-7.01	-0.32	9.34e-12	Menarche (age at onset);
LUAD	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg02160872	chr5:212506	CCDC127	-0.5	-6.42	-0.3	3.72e-10	Breast cancer;
LUAD	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg05616858	chr17:37843591	ERBB2;PGAP3	0.31	6.49	0.3	2.39e-10	Asthma;
LUAD	cis	rs3796352	0.527	rs11715498	chr3:52943551	G/C	cg04865290	chr3:52927548	TMEM110	-0.54	-7.29	-0.33	1.49e-12	Immune reponse to smallpox (secreted IL-2);
LUAD	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg27572855	chr1:25598939	RHD	0.53	11.36	0.48	2.74e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg07917127	chr4:99064746	C4orf37	0.4	6.6	0.31	1.26e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35995292	0.534	rs7793692	chr7:38940580	G/C	cg19327137	chr7:38886074	VPS41	0.74	15.74	0.61	3.01e-44	Subjective well-being (multi-trait analysis);
LUAD	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg24818145	chr4:99064322	C4orf37	0.43	7.24	0.33	2.14e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08219700	chr8:58056026	NA	0.63	8.82	0.39	2.92e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg00603274	chr11:61596626	FADS2	-0.41	-6.98	-0.32	1.16e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg13393036	chr8:95962371	TP53INP1	-0.44	-10.83	-0.47	2.79e-24	Type 2 diabetes;
LUAD	cis	rs1595825	0.786	rs1902246	chr2:198492827	C/T	cg10547527	chr2:198650123	BOLL	-0.46	-6.64	-0.31	9.49e-11	Ulcerative colitis;
LUAD	trans	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg18187862	chr3:45730750	SACM1L	-0.45	-6.4	-0.3	4.06e-10	Primary sclerosing cholangitis;
LUAD	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg06060754	chr5:176797920	RGS14	-0.55	-8.7	-0.39	7.53e-17	Urate levels in lean individuals;
LUAD	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg17724175	chr1:150552817	MCL1	0.39	9.28	0.41	9.17e-19	Tonsillectomy;
LUAD	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg08798685	chr6:27730294	NA	-0.71	-7.61	-0.35	1.82e-13	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.42	-7.17	-0.33	3.46e-12	Tonsillectomy;
LUAD	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg03929089	chr4:120376271	NA	-0.45	-6.95	-0.32	1.35e-11	HDL cholesterol;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg22769031	chr20:35580195	SAMHD1	0.4	6.39	0.3	4.38e-10	Bilirubin levels;
LUAD	cis	rs17067123	0.539	rs11735192	chr4:180065076	A/C	cg26610307	chr4:180072759	NA	-0.52	-6.75	-0.31	4.86e-11	Response to hepatitis C treatment;
LUAD	cis	rs9393692	0.620	rs9393691	chr6:26272829	T/C	cg00631329	chr6:26305371	NA	-0.54	-9.54	-0.42	1.12e-19	Educational attainment;
LUAD	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24308560	chr3:49941425	MST1R	0.54	9.09	0.4	4.02e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg19318889	chr4:1322082	MAEA	0.47	7.8	0.35	4.92e-14	Obesity-related traits;
LUAD	cis	rs3772130	0.962	rs4280673	chr3:121526107	C/T	cg20356878	chr3:121714668	ILDR1	0.53	8.55	0.38	2.27e-16	Cognitive performance;
LUAD	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg18230493	chr5:56204884	C5orf35	-0.51	-8.38	-0.38	7.82e-16	Coronary artery disease;
LUAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	12.5	0.52	1.01e-30	Lymphocyte counts;
LUAD	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.41	0.42	3.22e-19	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg03467027	chr4:99064603	C4orf37	0.4	6.48	0.3	2.59e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg04278597	chr1:63154320	DOCK7	-0.47	-6.41	-0.3	4e-10	Testicular germ cell tumor;
LUAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg18621852	chr3:10150065	C3orf24	0.42	7.34	0.34	1.09e-12	Alzheimer's disease;
LUAD	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg02569458	chr12:86230093	RASSF9	0.45	8.19	0.37	3.08e-15	Major depressive disorder;
LUAD	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg18944383	chr4:111397179	ENPEP	0.41	8.26	0.37	1.87e-15	Height;
LUAD	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg18944383	chr4:111397179	ENPEP	0.38	7.62	0.35	1.66e-13	Height;
LUAD	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg02734326	chr4:10020555	SLC2A9	0.53	9.25	0.41	1.09e-18	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg08601574	chr20:25228251	PYGB	-0.46	-8.58	-0.39	1.79e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	10.91	0.47	1.36e-24	Height;
LUAD	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg15147215	chr3:52552868	STAB1	-0.41	-7.41	-0.34	7.02e-13	Bipolar disorder;
LUAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg04352962	chr1:209979756	IRF6	0.51	7.08	0.33	5.87e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs910187	0.605	rs8124995	chr20:45811788	G/T	cg27589058	chr20:45804311	EYA2	-0.34	-7.53	-0.34	3.05e-13	Migraine;
LUAD	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.88	0.53	2.98e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg17173187	chr15:85201210	NMB	0.46	8.04	0.36	8.83e-15	Schizophrenia;
LUAD	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg01851573	chr8:8652454	MFHAS1	-0.45	-8.16	-0.37	3.78e-15	Mood instability;
LUAD	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg19041857	chr6:27730383	NA	0.44	7.53	0.34	3.06e-13	Parkinson's disease;
LUAD	cis	rs6987853	0.787	rs2974309	chr8:42426961	G/A	cg09913449	chr8:42400586	C8orf40	0.51	10.16	0.44	7.47e-22	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg15448220	chr1:150897856	SETDB1	-0.46	-7.12	-0.33	4.59e-12	Urate levels;
LUAD	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.36	-6.91	-0.32	1.75e-11	Crohn's disease;
LUAD	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg06623918	chr6:96969491	KIAA0776	-0.7	-9.59	-0.42	7.63e-20	Migraine;Coronary artery disease;
LUAD	cis	rs12618769	0.597	rs10496327	chr2:99066827	A/G	cg10123293	chr2:99228465	UNC50	0.47	8.31	0.37	1.36e-15	Bipolar disorder;
LUAD	cis	rs7582720	1.000	rs72936869	chr2:203788950	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg12863693	chr15:85201151	NMB	0.44	8.24	0.37	2.2e-15	Schizophrenia;
LUAD	cis	rs9916302	0.821	rs11078916	chr17:37746307	T/C	cg15445000	chr17:37608096	MED1	0.43	7.62	0.35	1.64e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs77741769	0.571	rs1542859	chr12:121336766	A/G	cg02419362	chr12:121203948	SPPL3	0.42	8.6	0.39	1.59e-16	Mean corpuscular volume;
LUAD	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg07741184	chr6:167504864	NA	0.33	7.96	0.36	1.59e-14	Primary biliary cholangitis;
LUAD	cis	rs17608059	0.611	rs2108591	chr17:13922625	C/A	cg11395062	chr17:14139857	CDRT15	0.43	6.75	0.31	4.77e-11	Temperament;
LUAD	cis	rs11030122	0.632	rs11030599	chr11:4031677	A/G	cg18678763	chr11:4115507	RRM1	-0.44	-7.32	-0.34	1.3e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.06	24.31	0.76	2.55e-82	Chronic sinus infection;
LUAD	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg04586622	chr2:25135609	ADCY3	0.37	8.54	0.38	2.45e-16	Body mass index;
LUAD	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg14558114	chr2:88469736	THNSL2	0.7	7.22	0.33	2.4e-12	Plasma clusterin levels;
LUAD	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg07700843	chr1:2391317	NA	-0.48	-9.39	-0.42	3.63e-19	Non-obstructive azoospermia;
LUAD	cis	rs300774	0.925	rs435919	chr2:128890	T/G	cg21211680	chr2:198530	NA	-0.48	-7.45	-0.34	5.4e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg21475434	chr5:93447410	FAM172A	0.75	8.4	0.38	6.97e-16	Diabetic retinopathy;
LUAD	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg12407791	chr17:73824354	UNC13D	-0.32	-6.62	-0.31	1.11e-10	White matter hyperintensity burden;
LUAD	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg15997130	chr1:24165203	NA	0.54	9.29	0.41	8.45e-19	Immature fraction of reticulocytes;
LUAD	cis	rs151234	0.612	rs11641853	chr16:28589719	A/G	cg04643524	chr16:28609220	SULT1A2	0.65	9.23	0.41	1.27e-18	Platelet distribution width;
LUAD	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg06784218	chr1:46089804	CCDC17	0.6	13.37	0.55	2.99e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg27446573	chr6:127587934	RNF146	0.43	6.47	0.3	2.7e-10	Breast cancer;
LUAD	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg03874509	chr1:107600012	PRMT6	-0.48	-8.62	-0.39	1.35e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg07988820	chr12:82153109	PPFIA2	0.5	7.73	0.35	8.05e-14	Resting heart rate;
LUAD	cis	rs8067545	0.935	rs7209734	chr17:19988543	C/A	cg04132472	chr17:19861366	AKAP10	0.29	6.87	0.32	2.28e-11	Schizophrenia;
LUAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg26516362	chr5:178986906	RUFY1	0.45	7.83	0.36	3.85e-14	Lung cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22371845	chr8:140718096	NA	-0.45	-7.26	-0.33	1.84e-12	Height;
LUAD	cis	rs11098699	0.821	rs6835952	chr4:124230974	A/C	cg09941581	chr4:124220074	SPATA5	0.46	7.3	0.33	1.46e-12	Mosquito bite size;
LUAD	cis	rs727505	1.000	rs67585224	chr7:124537476	A/C	cg23710748	chr7:124431027	NA	-0.49	-9.93	-0.43	4.96e-21	Lewy body disease;
LUAD	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg06740227	chr12:86229804	RASSF9	-0.41	-7.36	-0.34	9.88e-13	Major depressive disorder;
LUAD	cis	rs7010267	0.935	rs7463176	chr8:119957625	A/G	cg01975934	chr8:119970761	NA	-0.4	-7.58	-0.35	2.16e-13	Total body bone mineral density (age 45-60);
LUAD	cis	rs1478897	0.898	rs2248696	chr8:11393803	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-6.52	-0.3	1.98e-10	Systemic lupus erythematosus;
LUAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg15117754	chr3:10150083	C3orf24	-0.42	-6.92	-0.32	1.71e-11	Alzheimer's disease;
LUAD	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg22467129	chr15:76604101	ETFA	0.6	11.0	0.47	6.63e-25	Blood metabolite levels;
LUAD	cis	rs36051895	0.659	rs62541556	chr9:5049092	G/T	cg02405213	chr9:5042618	JAK2	-0.49	-6.79	-0.31	3.84e-11	Pediatric autoimmune diseases;
LUAD	cis	rs4588572	0.686	rs4352584	chr5:77682948	C/G	cg11547950	chr5:77652471	NA	0.75	11.81	0.5	5.1e-28	Triglycerides;
LUAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg00035636	chr13:21900591	NA	0.38	6.46	0.3	2.92e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs1045714	0.895	rs4721866	chr7:2643341	G/A	cg24848437	chr7:2645542	IQCE	0.71	8.29	0.37	1.54e-15	Urate levels in lean individuals;
LUAD	cis	rs12049351	0.774	rs4925457	chr1:229633571	C/T	cg11742688	chr1:229674241	ABCB10	-0.42	-6.44	-0.3	3.18e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03934478	chr11:495069	RNH1	0.78	9.36	0.41	4.83e-19	Body mass index;
LUAD	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg21709803	chr11:61594965	FADS2	-0.4	-7.43	-0.34	6.25e-13	Trans fatty acid levels;
LUAD	cis	rs113835537	0.529	rs17147644	chr11:66256660	C/T	cg26679405	chr11:66247800	DPP3	-0.45	-6.57	-0.3	1.47e-10	Airway imaging phenotypes;
LUAD	cis	rs4664304	0.781	rs6432570	chr2:160808314	A/G	cg23995753	chr2:160760732	LY75	-0.41	-7.45	-0.34	5.29e-13	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg21724239	chr8:58056113	NA	0.72	9.5	0.42	1.6e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs12517041	1.000	rs10805749	chr5:23300740	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.49	-0.3	2.4e-10	Calcium levels;
LUAD	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg22532475	chr10:104410764	TRIM8	0.35	7.29	0.33	1.49e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg05340658	chr4:99064831	C4orf37	0.54	8.74	0.39	5.49e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg11062466	chr8:58055876	NA	0.67	9.01	0.4	7.2e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs11958404	0.932	rs72816600	chr5:157436349	T/C	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg08132940	chr7:1081526	C7orf50	-0.7	-7.26	-0.33	1.87e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg18016565	chr1:150552671	MCL1	0.37	6.48	0.3	2.52e-10	Melanoma;
LUAD	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg02733842	chr7:1102375	C7orf50	-0.5	-7.72	-0.35	8.32e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg04756594	chr16:24857601	SLC5A11	-0.66	-11.04	-0.47	4.42e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4006360	0.579	rs6416910	chr17:39235562	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.36	7.83	0.36	3.95e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg16797656	chr11:68205561	LRP5	-0.38	-7.09	-0.33	5.75e-12	Bone mineral density (spine);
LUAD	cis	rs7607369	0.536	rs12694443	chr2:219664977	G/T	cg02176678	chr2:219576539	TTLL4	-0.53	-10.42	-0.45	8.54e-23	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg06623918	chr6:96969491	KIAA0776	-0.76	-11.22	-0.48	9.32e-26	Migraine;Coronary artery disease;
LUAD	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg12310025	chr6:25882481	NA	-0.53	-7.73	-0.35	7.68e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7107174	1.000	rs2512549	chr11:77940163	A/G	cg02023728	chr11:77925099	USP35	-0.39	-6.66	-0.31	8.66e-11	Testicular germ cell tumor;
LUAD	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg26168224	chr5:2018326	NA	0.68	13.25	0.54	8.81e-34	Gut microbiome composition (winter);
LUAD	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg17849569	chr6:28058911	ZSCAN12L1	0.42	7.49	0.34	3.98e-13	Lung cancer in ever smokers;
LUAD	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg14664628	chr15:75095509	CSK	-0.39	-6.35	-0.3	5.53e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	trans	rs7395662	1.000	rs6485882	chr11:48592435	C/G	cg00717180	chr2:96193071	NA	0.38	7.83	0.36	4.06e-14	HDL cholesterol;
LUAD	cis	rs68170813	0.563	rs6979198	chr7:107197694	T/G	cg23024343	chr7:107201750	COG5	0.5	6.79	0.31	3.75e-11	Coronary artery disease;
LUAD	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg04267008	chr7:1944627	MAD1L1	-0.68	-10.36	-0.45	1.4e-22	Bipolar disorder and schizophrenia;
LUAD	trans	rs7395662	1.000	rs7928083	chr11:48613148	C/G	cg00717180	chr2:96193071	NA	-0.4	-7.41	-0.34	7.11e-13	HDL cholesterol;
LUAD	cis	rs4308124	0.708	rs28766030	chr2:111962429	T/C	cg04571233	chr2:111982156	NA	-0.45	-6.41	-0.3	3.78e-10	Vitiligo;
LUAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9888739	0.800	rs1143678	chr16:31343005	C/T	cg15817542	chr16:31343056	ITGAM	-0.47	-7.77	-0.35	6.21e-14	Systemic lupus erythematosus;
LUAD	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg18132916	chr6:79620363	NA	-0.44	-7.48	-0.34	4.3e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	8.16	0.37	3.82e-15	Breast cancer;
LUAD	cis	rs2742234	0.910	rs2503866	chr10:43646261	T/A	cg02780029	chr10:43622663	RET	-0.42	-6.91	-0.32	1.76e-11	Hirschsprung disease;
LUAD	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg25233709	chr10:116636983	FAM160B1	0.39	7.73	0.35	7.74e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10992471	0.580	rs4744143	chr9:95438627	A/C	cg14631576	chr9:95140430	CENPP	-0.45	-8.71	-0.39	6.89e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.05	-0.51	5.96e-29	Primary sclerosing cholangitis;
LUAD	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.8	0.35	5e-14	Lung cancer;
LUAD	cis	rs2692947	0.666	rs7566050	chr2:96626030	T/C	cg23100626	chr2:96804247	ASTL	0.31	7.75	0.35	6.69e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs6005807	0.563	rs9620811	chr22:29058409	T/C	cg12565055	chr22:29076175	TTC28	0.75	8.78	0.39	4e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs4664308	1.000	rs6719686	chr2:160908292	T/G	cg03641300	chr2:160917029	PLA2R1	-0.4	-6.94	-0.32	1.5e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs1497828	0.956	rs2454117	chr1:217552823	T/C	cg04411442	chr1:217543379	NA	0.38	6.84	0.32	2.79e-11	Dialysis-related mortality;
LUAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg21724239	chr8:58056113	NA	0.67	8.63	0.39	1.29e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg00666640	chr1:248458726	OR2T12	-0.29	-7.02	-0.32	8.61e-12	Common traits (Other);
LUAD	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-6.95	-0.32	1.39e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.46	0.3	2.93e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.5	0.3	2.24e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg13214185	chr14:107219616	NA	0.42	7.31	0.33	1.39e-12	Menopause (age at onset);
LUAD	cis	rs16854884	0.632	rs1466941	chr3:143670131	A/G	cg01302019	chr3:143689584	C3orf58	-0.39	-6.77	-0.31	4.36e-11	Economic and political preferences (feminism/equality);
LUAD	cis	rs2046867	0.866	rs2244246	chr3:72789191	G/A	cg25664220	chr3:72788482	NA	0.65	11.9	0.5	2.38e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg08847533	chr14:75593920	NEK9	0.43	7.43	0.34	6.05e-13	Height;
LUAD	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6684514	1.000	rs12142808	chr1:156230546	G/A	cg16558208	chr1:156270281	VHLL	0.52	9.27	0.41	9.74e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs7264396	0.563	rs2425120	chr20:34324456	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2e-15	Total cholesterol levels;
LUAD	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg00898013	chr13:113819073	PROZ	-0.81	-14.99	-0.59	4.93e-41	Platelet distribution width;
LUAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg20607798	chr8:58055168	NA	0.58	7.54	0.34	2.94e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.4	0.45	1.06e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg26384229	chr12:38710491	ALG10B	-0.45	-7.42	-0.34	6.56e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg10523679	chr1:76189770	ACADM	0.93	18.67	0.67	3.43e-57	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg27141850	chr2:20869434	GDF7	-0.45	-11.08	-0.47	3.3e-25	Abdominal aortic aneurysm;
LUAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg18621852	chr3:10150065	C3orf24	0.49	8.83	0.39	2.72e-17	Alzheimer's disease;
LUAD	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg14227996	chr4:17616232	MED28	0.71	7.38	0.34	8.62e-13	Opioid sensitivity;
LUAD	trans	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.92	0.43	5.53e-21	Ulcerative colitis;
LUAD	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11890956	chr21:40555474	PSMG1	-0.54	-9.2	-0.41	1.68e-18	Menarche (age at onset);
LUAD	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-8.37	-0.38	8.64e-16	Blood metabolite levels;
LUAD	cis	rs13095912	1.000	rs13100229	chr3:185343200	C/T	cg11274856	chr3:185301563	NA	0.37	7.51	0.34	3.53e-13	Systolic blood pressure;
LUAD	cis	rs2274273	0.624	rs8015211	chr14:55841447	A/G	cg04306507	chr14:55594613	LGALS3	0.41	7.91	0.36	2.27e-14	Protein biomarker;
LUAD	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg21475434	chr5:93447410	FAM172A	-0.71	-8.58	-0.39	1.78e-16	Diabetic retinopathy;
LUAD	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg18806716	chr10:30721971	MAP3K8	-0.79	-17.1	-0.64	3.19e-50	Inflammatory bowel disease;
LUAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00166722	chr3:10149974	C3orf24	0.63	10.42	0.45	8.88e-23	Alzheimer's disease;
LUAD	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs7777754	0.512	rs11238131	chr7:50538589	T/C	cg18232548	chr7:50535776	DDC	-0.7	-12.25	-0.51	9.63e-30	Response to zileuton treatment in asthma (FEV1 change interaction);
LUAD	cis	rs12079745	0.623	rs2901092	chr1:169456393	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.95	-7.46	-0.34	5.11e-13	QT interval;
LUAD	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.41	6.87	0.32	2.34e-11	Total body bone mineral density;
LUAD	trans	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg01620082	chr3:125678407	NA	-0.44	-6.48	-0.3	2.55e-10	Parkinson's disease;
LUAD	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg16988262	chr1:15930761	NA	0.41	6.87	0.32	2.34e-11	Systolic blood pressure;
LUAD	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg00933542	chr6:150070202	PCMT1	0.46	9.89	0.43	6.68e-21	Lung cancer;
LUAD	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg06611532	chr13:114900021	NA	0.38	9.02	0.4	6.52e-18	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.35e-11	Breast cancer;
LUAD	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21659725	chr3:3221576	CRBN	-0.5	-8.22	-0.37	2.47e-15	Body mass index;
LUAD	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg24308560	chr3:49941425	MST1R	0.51	8.35	0.38	9.51e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg27411982	chr8:10470053	RP1L1	0.41	7.23	0.33	2.28e-12	Retinal vascular caliber;
LUAD	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg24829409	chr8:58192753	C8orf71	-0.62	-9.39	-0.42	3.84e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg07636037	chr3:49044803	WDR6	0.48	8.04	0.36	8.87e-15	Menarche (age at onset);
LUAD	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.46	0.3	2.95e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg10755058	chr3:40428713	ENTPD3	0.37	7.29	0.33	1.52e-12	Renal cell carcinoma;
LUAD	cis	rs2857891	1.000	rs72845397	chr11:6950903	C/T	cg04053776	chr11:6947353	ZNF215	0.48	6.78	0.31	4.05e-11	Response to cytadine analogues (cytosine arabinoside);
LUAD	cis	rs13082711	0.863	rs35797268	chr3:27418862	T/C	cg02860705	chr3:27208620	NA	0.62	9.34	0.41	5.73e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg23719950	chr11:63933701	MACROD1	-0.61	-7.32	-0.34	1.26e-12	Mean platelet volume;
LUAD	cis	rs1957429	0.901	rs1951490	chr14:65346957	G/T	cg23373153	chr14:65346875	NA	0.56	6.42	0.3	3.57e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs3087591	0.960	rs2905880	chr17:29546175	A/G	cg24425628	chr17:29625626	OMG;NF1	0.42	6.81	0.31	3.3e-11	Hip circumference;
LUAD	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg15147215	chr3:52552868	STAB1	-0.37	-6.9	-0.32	1.91e-11	Bipolar disorder;
LUAD	trans	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg20587970	chr11:113659929	NA	0.91	13.01	0.53	8.66e-33	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg15181151	chr6:150070149	PCMT1	0.41	8.53	0.38	2.66e-16	Lung cancer;
LUAD	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg15448220	chr1:150897856	SETDB1	0.46	7.93	0.36	1.97e-14	Tonsillectomy;
LUAD	cis	rs59698941	0.943	rs12516416	chr5:132248630	C/T	cg14825688	chr5:132208181	LEAP2	-0.47	-6.41	-0.3	3.91e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg03563238	chr19:33554763	RHPN2	-0.39	-9.06	-0.4	4.91e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg13319975	chr6:146136371	FBXO30	0.64	11.01	0.47	5.66e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4988958	0.565	rs6760621	chr2:102999952	T/C	cg03938978	chr2:103052716	IL18RAP	0.45	10.24	0.45	3.99e-22	Asthma (childhood onset);
LUAD	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg00277334	chr10:82204260	NA	-0.66	-11.81	-0.5	5.2e-28	Post bronchodilator FEV1;
LUAD	cis	rs3752645	1.000	rs17153861	chr7:106769639	G/A	cg02696742	chr7:106810147	HBP1	-0.67	-6.46	-0.3	2.85e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg13560548	chr3:10150139	C3orf24	0.45	7.33	0.34	1.22e-12	Alzheimer's disease;
LUAD	cis	rs11098699	0.821	rs2083935	chr4:124214338	A/C	cg09941581	chr4:124220074	SPATA5	0.49	8.01	0.36	1.1e-14	Mosquito bite size;
LUAD	cis	rs10193935	0.901	rs1044562	chr2:42516884	C/G	cg27598129	chr2:42591480	NA	-0.78	-9.99	-0.44	3.12e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg18230493	chr5:56204884	C5orf35	-0.72	-10.55	-0.46	2.93e-23	Initial pursuit acceleration;
LUAD	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg00802000	chr16:706648	WDR90	-0.42	-6.55	-0.3	1.69e-10	Height;
LUAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg13047869	chr3:10149882	C3orf24	-0.61	-10.37	-0.45	1.33e-22	Alzheimer's disease;
LUAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.22	0.37	2.57e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg13334819	chr7:99746414	C7orf59	-0.67	-10.32	-0.45	2.1e-22	Coronary artery disease;
LUAD	cis	rs7945718	0.905	rs4454698	chr11:12720560	A/G	cg25843174	chr11:12811716	TEAD1	-0.22	-6.54	-0.3	1.8e-10	Educational attainment (years of education);
LUAD	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.64	0.39	1.17e-16	Menopause (age at onset);
LUAD	cis	rs7809950	1.000	rs4727681	chr7:107096144	T/C	cg23024343	chr7:107201750	COG5	-0.73	-12.27	-0.51	8.36e-30	Coronary artery disease;
LUAD	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg19610905	chr11:61596333	FADS2	-0.8	-10.19	-0.44	5.9e-22	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26294578	chr17:79319535	NA	-0.44	-6.94	-0.32	1.46e-11	Height;
LUAD	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs9863	0.861	rs7312404	chr12:124446728	A/G	cg17723958	chr12:124429295	CCDC92	-0.42	-6.91	-0.32	1.84e-11	White blood cell count;
LUAD	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg15704280	chr7:45808275	SEPT13	-0.74	-10.96	-0.47	9.34e-25	Height;
LUAD	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg05717871	chr11:638507	DRD4	-0.44	-6.48	-0.3	2.57e-10	Systemic lupus erythematosus;
LUAD	cis	rs4604732	0.631	rs1106720	chr1:247624681	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.11	0.33	4.98e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg19318889	chr4:1322082	MAEA	0.45	7.64	0.35	1.49e-13	Obesity-related traits;
LUAD	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21659725	chr3:3221576	CRBN	0.65	11.28	0.48	5.46e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg22166914	chr1:53195759	ZYG11B	0.46	7.46	0.34	4.83e-13	Monocyte count;
LUAD	cis	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg05084668	chr3:125655381	ALG1L	-0.53	-8.54	-0.38	2.4e-16	Blood pressure (smoking interaction);
LUAD	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg02493740	chr2:85810744	VAMP5	0.61	11.07	0.47	3.5e-25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg01689657	chr7:91764605	CYP51A1	-0.32	-7.82	-0.36	4.39e-14	Breast cancer;
LUAD	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg11859384	chr17:80120422	CCDC57	0.51	9.12	0.41	3.02e-18	Life satisfaction;
LUAD	cis	rs1950500	0.509	rs12895424	chr14:24823186	G/T	cg22990158	chr14:24802150	ADCY4	-0.39	-7.05	-0.32	7.3e-12	Height;
LUAD	trans	rs148734725	1	rs148734725	chr3:49406708	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.29e-13	Educational attainment (college completion);
LUAD	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.35	-6.57	-0.3	1.47e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg07936489	chr17:37558343	FBXL20	-0.46	-7.27	-0.33	1.78e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg00049323	chr5:472564	LOC25845	0.46	7.57	0.35	2.39e-13	Cystic fibrosis severity;
LUAD	cis	rs6942407	0.546	rs2190424	chr7:86841971	T/C	cg02420886	chr7:86849541	C7orf23	0.65	7.61	0.35	1.77e-13	Food allergy;
LUAD	cis	rs1691799	0.836	rs1184552	chr12:66756215	A/G	cg16791601	chr12:66731901	HELB	-0.37	-6.7	-0.31	6.85e-11	White blood cell count (basophil);
LUAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg21285383	chr16:89894308	SPIRE2	0.39	9.35	0.41	4.96e-19	Vitiligo;
LUAD	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-8.57	-0.38	1.89e-16	Gut microbiome composition (summer);
LUAD	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg11292332	chr7:45801988	SEPT13	-0.28	-6.35	-0.3	5.63e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg17063962	chr7:91808500	NA	-0.67	-11.71	-0.49	1.27e-27	Breast cancer;
LUAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06873352	chr17:61820015	STRADA	-0.81	-18.04	-0.66	2.19e-54	Prudent dietary pattern;
LUAD	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg00484396	chr16:3507460	NAT15	0.71	11.92	0.5	1.99e-28	Tuberculosis;
LUAD	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg06784218	chr1:46089804	CCDC17	0.61	13.69	0.55	1.47e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2637266	0.783	rs1660908	chr10:78494856	T/C	cg18941641	chr10:78392320	NA	0.32	6.77	0.31	4.33e-11	Pulmonary function;
LUAD	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg25804541	chr17:80189381	SLC16A3	0.3	6.4	0.3	4.11e-10	Life satisfaction;
LUAD	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg06697600	chr4:7070879	GRPEL1	-0.54	-9.03	-0.4	6.22e-18	Monocyte percentage of white cells;
LUAD	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg17173187	chr15:85201210	NMB	0.41	6.65	0.31	9.33e-11	Schizophrenia;
LUAD	cis	rs10426930	0.700	rs7246791	chr19:5013776	T/C	cg25246084	chr19:4971487	KDM4B	-0.45	-7.91	-0.36	2.28e-14	Monocyte percentage of white cells;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg21086156	chr19:54694904	MBOAT7;TSEN34	-0.66	-6.54	-0.3	1.75e-10	Type 2 diabetes;
LUAD	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg26924012	chr15:45694286	SPATA5L1	1.03	19.23	0.68	1.13e-59	Homoarginine levels;
LUAD	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg06740227	chr12:86229804	RASSF9	0.38	6.44	0.3	3.19e-10	Major depressive disorder;
LUAD	cis	rs2734839	0.896	rs11608109	chr11:113303448	G/C	cg14159747	chr11:113255604	NA	0.54	9.87	0.43	8.11e-21	Information processing speed;
LUAD	cis	rs7017914	0.934	rs13255886	chr8:71565954	G/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.63	-0.31	1.02e-10	Bone mineral density;
LUAD	cis	rs4481887	0.800	rs4639798	chr1:248515703	A/G	cg13385794	chr1:248469461	NA	0.23	6.41	0.3	3.92e-10	Common traits (Other);
LUAD	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.29	-0.33	1.57e-12	Lung cancer;
LUAD	trans	rs8002861	0.967	rs9533689	chr13:44480413	A/C	cg17145862	chr1:211918768	LPGAT1	0.75	17.76	0.65	3.8e-53	Leprosy;
LUAD	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg05887092	chr17:76393375	PGS1	0.42	7.4	0.34	7.47e-13	HDL cholesterol levels;
LUAD	cis	rs3739034	0.877	rs4954164	chr2:135458065	T/A	cg12500956	chr2:135428796	TMEM163	0.36	6.64	0.31	9.79e-11	Gut microbiome composition (winter);
LUAD	cis	rs6782228	0.606	rs2712404	chr3:128332679	C/T	cg16766828	chr3:128327626	NA	0.38	7.12	0.33	4.64e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg13902645	chr11:5959945	NA	-0.56	-10.31	-0.45	2.28e-22	DNA methylation (variation);
LUAD	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg11919837	chr8:57350735	NA	-0.43	-6.52	-0.3	1.99e-10	Obesity-related traits;
LUAD	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg06046430	chr4:77819534	ANKRD56	0.49	8.06	0.36	7.82e-15	Emphysema distribution in smoking;
LUAD	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg21963583	chr11:68658836	MRPL21	0.65	11.85	0.5	3.76e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7291412	0.579	rs11090867	chr22:46454792	T/C	cg05468064	chr22:46423449	NA	0.35	7.61	0.35	1.8e-13	Dupuytren's disease;Subjective well-being;
LUAD	cis	rs7072216	0.727	rs7901577	chr10:100164442	A/G	cg26618903	chr10:100175079	PYROXD2	-0.36	-7.64	-0.35	1.49e-13	Metabolite levels;
LUAD	cis	rs77106637	0.789	rs76550717	chr11:72428172	A/G	cg03878208	chr11:72483293	STARD10	0.56	7.59	0.35	2.07e-13	Type 2 diabetes;
LUAD	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg00204512	chr16:28754710	NA	0.34	7.28	0.33	1.66e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10792830	0.832	rs583162	chr11:85813817	A/G	cg07180834	chr11:85838833	NA	-0.31	-6.43	-0.3	3.42e-10	Psychosis and Alzheimer's disease;
LUAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg13047869	chr3:10149882	C3orf24	0.63	9.43	0.42	2.8e-19	Alzheimer's disease;
LUAD	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg12927641	chr6:109611667	NA	-0.52	-9.06	-0.4	4.89e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.49	-8.54	-0.38	2.47e-16	Alzheimer's disease (late onset);
LUAD	cis	rs714027	0.837	rs713875	chr22:30592487	C/G	cg11564601	chr22:30592435	NA	-0.42	-9.07	-0.4	4.38e-18	Lymphocyte counts;
LUAD	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.25	0.41	1.1e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-8.22	-0.37	2.44e-15	Monocyte percentage of white cells;
LUAD	cis	rs977987	0.806	rs11640674	chr16:75394944	A/G	cg03315344	chr16:75512273	CHST6	0.65	14.19	0.57	1.22e-37	Dupuytren's disease;
LUAD	cis	rs9296095	1.000	rs9296095	chr6:33542523	A/G	cg14003231	chr6:33640908	ITPR3	0.48	8.94	0.4	1.22e-17	Platelet count;
LUAD	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg19875535	chr5:140030758	IK	-0.4	-6.82	-0.31	3.26e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg04565464	chr8:145669602	NFKBIL2	0.47	7.05	0.32	7.52e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4711336	1.000	rs11759396	chr6:33656654	C/G	cg13859433	chr6:33739653	LEMD2	-0.29	-6.78	-0.31	3.93e-11	Height;
LUAD	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.62e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9814567	0.712	rs4245905	chr3:134328864	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7119	0.634	rs2667782	chr15:77862296	A/C	cg27398640	chr15:77910606	LINGO1	0.36	6.75	0.31	4.76e-11	Type 2 diabetes;
LUAD	cis	rs41271951	0.512	rs12068365	chr1:151015868	G/A	cg11822372	chr1:151115635	SEMA6C	-0.8	-6.49	-0.3	2.35e-10	Blood protein levels;
LUAD	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg24848339	chr3:12840334	CAND2	0.48	10.1	0.44	1.27e-21	QRS complex (12-leadsum);
LUAD	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg02734326	chr4:10020555	SLC2A9	-0.5	-8.84	-0.39	2.7e-17	Bone mineral density;
LUAD	cis	rs897984	0.760	rs11076	chr16:30995528	A/G	cg02466173	chr16:30829666	NA	0.66	12.16	0.51	2.11e-29	Dementia with Lewy bodies;
LUAD	cis	rs910187	0.605	rs2281367	chr20:45808960	T/C	cg27589058	chr20:45804311	EYA2	-0.35	-8.08	-0.37	6.73e-15	Migraine;
LUAD	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6669919	0.967	rs894983	chr1:211675279	T/C	cg10512769	chr1:211675356	NA	-0.32	-6.86	-0.32	2.39e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-15.25	-0.6	3.75e-42	Headache;
LUAD	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg04586622	chr2:25135609	ADCY3	0.37	8.54	0.38	2.43e-16	Body mass index;
LUAD	cis	rs239198	0.568	rs9404059	chr6:101331497	T/C	cg09795085	chr6:101329169	ASCC3	0.39	6.9	0.32	1.93e-11	Menarche (age at onset);
LUAD	cis	rs7827545	1.000	rs6995244	chr8:135568959	A/G	cg17885191	chr8:135476712	NA	0.51	7.94	0.36	1.9e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg11915388	chr22:42470451	FAM109B	0.41	7.37	0.34	8.84e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.87	-16.74	-0.63	1.21e-48	Menarche (age at onset);
LUAD	cis	rs7617773	0.817	rs6800492	chr3:48323890	G/A	cg11946769	chr3:48343235	NME6	0.43	6.64	0.31	9.75e-11	Coronary artery disease;
LUAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg21782813	chr7:2030301	MAD1L1	-0.39	-6.72	-0.31	6.04e-11	Schizophrenia;
LUAD	cis	rs12049351	0.774	rs3738187	chr1:229683264	G/A	cg11742688	chr1:229674241	ABCB10	-0.42	-6.91	-0.32	1.78e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg05182265	chr7:156933206	UBE3C	-0.81	-17.36	-0.65	2.21e-51	Body mass index;
LUAD	cis	rs6445967	0.530	rs62258132	chr3:58398070	T/C	cg23715586	chr3:58305044	RPP14	0.41	6.73	0.31	5.6e-11	Platelet count;
LUAD	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.42	0.34	6.51e-13	Tonsillectomy;
LUAD	cis	rs2625529	0.824	rs11072339	chr15:72247190	C/T	cg16672083	chr15:72433130	SENP8	-0.76	-12.44	-0.52	1.64e-30	Red blood cell count;
LUAD	cis	rs6688613	1.000	rs6699159	chr1:166946072	T/C	cg07049167	chr1:166818506	POGK	0.38	6.37	0.3	4.82e-10	Refractive astigmatism;
LUAD	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-7.76	-0.35	6.65e-14	Tonsillectomy;
LUAD	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg03732007	chr1:2071316	PRKCZ	0.34	6.76	0.31	4.62e-11	Height;
LUAD	cis	rs367615	0.918	rs72797472	chr5:108881343	C/T	cg17395555	chr5:108820864	NA	0.53	8.66	0.39	1.03e-16	Colorectal cancer (SNP x SNP interaction);
LUAD	trans	rs9929218	1.000	rs17772363	chr16:68788909	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-15.0	-0.59	4.56e-41	Colorectal cancer;
LUAD	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg07930552	chr6:133119739	C6orf192	0.58	6.66	0.31	8.49e-11	Type 2 diabetes nephropathy;
LUAD	cis	rs11030122	0.661	rs10835561	chr11:4087594	C/T	cg18678763	chr11:4115507	RRM1	-0.43	-7.05	-0.32	7.19e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs3106136	0.967	rs3113862	chr4:95143122	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.78	-0.35	5.57e-14	Capecitabine sensitivity;
LUAD	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg13870426	chr17:30244630	NA	-0.57	-6.66	-0.31	8.78e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg06532163	chr17:45867833	NA	0.48	8.65	0.39	1.07e-16	IgG glycosylation;
LUAD	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg18490616	chr2:88469792	THNSL2	0.68	6.94	0.32	1.51e-11	Plasma clusterin levels;
LUAD	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg26924012	chr15:45694286	SPATA5L1	0.97	16.95	0.64	1.5e-49	Homoarginine levels;
LUAD	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg17063962	chr7:91808500	NA	0.66	11.56	0.49	4.59e-27	Breast cancer;
LUAD	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg25344623	chr2:136566232	LCT	-0.33	-6.42	-0.3	3.59e-10	Mosquito bite size;
LUAD	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.88e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73198271	0.531	rs17154758	chr8:8653343	G/A	cg01851573	chr8:8652454	MFHAS1	0.7	11.3	0.48	4.9e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg06641503	chr3:48959341	ARIH2	0.37	6.92	0.32	1.71e-11	Menarche (age at onset);
LUAD	cis	rs921968	0.565	rs4674329	chr2:219595507	A/G	cg02176678	chr2:219576539	TTLL4	-0.59	-11.89	-0.5	2.42e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7107174	1.000	rs10793308	chr11:78086005	C/T	cg19901956	chr11:77921274	USP35	-0.49	-7.07	-0.33	6.39e-12	Testicular germ cell tumor;
LUAD	cis	rs870825	0.616	rs28660669	chr4:185623312	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-20.08	-0.7	1.77e-63	Coronary artery disease;
LUAD	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg03037974	chr15:76606532	NA	0.38	7.97	0.36	1.46e-14	Blood metabolite levels;
LUAD	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg25233709	chr10:116636983	FAM160B1	0.42	8.27	0.37	1.82e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg15200796	chr22:21821976	NA	-0.42	-6.93	-0.32	1.54e-11	Cancer;
LUAD	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg15383120	chr6:291909	DUSP22	-0.72	-12.18	-0.51	1.85e-29	Menopause (age at onset);
LUAD	cis	rs55665837	1.000	rs11023227	chr11:14459087	T/C	cg19336497	chr11:14380999	RRAS2	-0.5	-10.12	-0.44	1.05e-21	Vitamin D levels;
LUAD	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.57	-7.34	-0.34	1.11e-12	Body mass index;
LUAD	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg22868518	chr11:507468	RNH1	-0.68	-6.83	-0.32	3.02e-11	Body mass index;
LUAD	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg21153622	chr11:89784906	NA	-0.33	-6.45	-0.3	3.12e-10	Coronary artery disease;
LUAD	trans	rs9302065	0.565	rs2993585	chr13:95961966	G/A	cg19955956	chr7:72299837	SBDSP;TYW1B	0.54	9.26	0.41	1.05e-18	Blood metabolite levels;
LUAD	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.89	-0.32	1.99e-11	Lung cancer;
LUAD	cis	rs6906287	0.647	rs2356492	chr6:118809437	C/G	cg18833306	chr6:118973337	C6orf204	0.47	8.43	0.38	5.44e-16	Electrocardiographic conduction measures;
LUAD	cis	rs6840360	0.571	rs4696102	chr4:152529658	C/T	cg22705602	chr4:152727874	NA	-0.44	-7.51	-0.34	3.57e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs73206853	0.640	rs35026231	chr12:110832125	A/G	cg12870014	chr12:110450643	ANKRD13A	0.64	7.17	0.33	3.47e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg15790184	chr11:494944	RNH1	0.55	6.87	0.32	2.32e-11	Body mass index;
LUAD	trans	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.42	0.55	1.77e-34	Exhaled nitric oxide output;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26120584	chr12:50795366	LARP4	-0.47	-7.27	-0.33	1.81e-12	Height;
LUAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg11941060	chr3:133502564	NA	-0.64	-11.51	-0.49	7.59e-27	Iron status biomarkers;
LUAD	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg18755752	chr8:142205143	DENND3	0.48	8.06	0.36	7.91e-15	Immature fraction of reticulocytes;
LUAD	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg06671706	chr8:8559999	CLDN23	-0.36	-6.35	-0.3	5.48e-10	Mood instability;
LUAD	trans	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg14791747	chr16:20752902	THUMPD1	-0.45	-6.98	-0.32	1.17e-11	Dental caries;
LUAD	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	7.07	0.32	6.6e-12	Multiple sclerosis;
LUAD	cis	rs4700695	0.841	rs402100	chr5:65266125	A/G	cg21114390	chr5:65439923	SFRS12	0.61	7.01	0.32	9.68e-12	Facial morphology (factor 19);
LUAD	trans	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg13698153	chr12:118541722	VSIG10	-0.44	-6.83	-0.32	2.93e-11	Vitiligo;
LUAD	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg21475434	chr5:93447410	FAM172A	-0.77	-8.73	-0.39	5.81e-17	Diabetic retinopathy;
LUAD	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg10596483	chr8:143751796	JRK	0.44	7.07	0.33	6.41e-12	Schizophrenia;
LUAD	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg05535760	chr7:792225	HEATR2	-0.82	-9.53	-0.42	1.24e-19	Cerebrospinal P-tau181p levels;
LUAD	trans	rs7939886	0.920	rs11227321	chr11:55904828	A/G	cg15704280	chr7:45808275	SEPT13	0.66	6.38	0.3	4.79e-10	Myopia (pathological);
LUAD	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.27	0.37	1.72e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4523957	0.579	rs903162	chr17:2092200	C/T	cg16513277	chr17:2031491	SMG6	-0.86	-16.47	-0.63	1.86e-47	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2274273	1.000	rs7160110	chr14:55594635	A/G	cg04306507	chr14:55594613	LGALS3	0.39	8.11	0.37	5.43e-15	Protein biomarker;
LUAD	trans	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs7737355	0.947	rs2191001	chr5:131096677	C/G	cg25547332	chr5:131281432	NA	0.45	6.76	0.31	4.47e-11	Life satisfaction;
LUAD	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg19622623	chr12:86230825	RASSF9	-0.55	-9.8	-0.43	1.46e-20	Major depressive disorder;
LUAD	trans	rs4650994	0.525	rs4650991	chr1:178511165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.76	-13.77	-0.56	6.56e-36	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg16681516	chr19:46297285	DMWD	0.44	8.58	0.38	1.83e-16	Coronary artery disease;
LUAD	cis	rs6906287	0.647	rs12211576	chr6:118872080	G/A	cg05564266	chr6:118973597	C6orf204	0.35	7.44	0.34	5.61e-13	Electrocardiographic conduction measures;
LUAD	cis	rs807669	0.548	rs5748028	chr22:19172281	G/A	cg24911827	chr22:19170109	CLTCL1	0.37	7.73	0.35	8.15e-14	Metabolite levels;
LUAD	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.63	7.28	0.33	1.63e-12	Body mass index;
LUAD	trans	rs7246760	1.000	rs12462027	chr19:9926860	G/A	cg02900749	chr2:68251473	NA	-0.62	-6.75	-0.31	4.78e-11	Pursuit maintenance gain;
LUAD	trans	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.1	-0.33	5.32e-12	Dental caries;
LUAD	cis	rs250677	0.522	rs17109208	chr5:148378475	G/A	cg18129178	chr5:148520854	ABLIM3	-0.51	-7.61	-0.35	1.85e-13	Breast cancer;
LUAD	cis	rs9837602	0.688	rs793492	chr3:99499736	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.59	-8.29	-0.37	1.57e-15	Breast cancer;
LUAD	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg23018236	chr17:30244563	NA	0.62	7.79	0.35	5.19e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs2485376	0.967	rs2273555	chr10:104127171	A/G	cg20641465	chr10:103991465	PITX3	-0.52	-9.7	-0.43	3.11e-20	QT interval;
LUAD	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.02	0.36	1.02e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs11696845	0.666	rs6073533	chr20:43361082	G/T	cg09357268	chr20:43379437	KCNK15	-0.36	-6.4	-0.3	4.15e-10	Obesity-related traits;
LUAD	cis	rs6665290	0.870	rs1045289	chr1:227178713	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.9	-0.89	4.52e-149	Myeloid white cell count;
LUAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg11845111	chr2:191398756	TMEM194B	-0.84	-11.27	-0.48	6.1e-26	Diastolic blood pressure;
LUAD	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg13354988	chr2:263656	ACP1;SH3YL1	0.3	6.48	0.3	2.54e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.51e-10	Prudent dietary pattern;
LUAD	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg27433088	chr4:174089019	GALNT7	-0.41	-7.59	-0.35	2.12e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg04369109	chr6:150039330	LATS1	-0.44	-7.43	-0.34	5.91e-13	Lung cancer;
LUAD	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6554196	0.525	rs2237036	chr4:55526175	G/C	cg18836493	chr4:55524333	KIT	-0.37	-7.01	-0.32	9.64e-12	Monocyte count;
LUAD	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg20607287	chr7:12443886	VWDE	-0.54	-6.82	-0.31	3.25e-11	Coronary artery disease;
LUAD	cis	rs3219474	0.505	rs487174	chr1:46009536	C/T	cg06784218	chr1:46089804	CCDC17	0.62	8.48	0.38	3.73e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02438591	chr16:2205559	TRAF7;SNORD60	-0.53	-6.43	-0.3	3.38e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.41	0.55	2.09e-34	Prudent dietary pattern;
LUAD	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg04772025	chr11:68637568	NA	0.59	9.41	0.42	3.25e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7536201	1.000	rs10903122	chr1:25303576	A/G	cg23273869	chr1:25296894	NA	-0.4	-8.05	-0.36	8.43e-15	Psoriasis vulgaris;
LUAD	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg18404041	chr3:52824283	ITIH1	0.56	9.34	0.41	5.73e-19	Schizophrenia;
LUAD	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg04398451	chr17:18023971	MYO15A	-0.64	-11.55	-0.49	5.19e-27	Total body bone mineral density;
LUAD	cis	rs6740322	0.793	rs13414908	chr2:43546658	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-10.91	-0.47	1.37e-24	Coronary artery disease;
LUAD	cis	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg01579765	chr21:45077557	HSF2BP	0.55	11.82	0.5	4.65e-28	Mean corpuscular hemoglobin;
LUAD	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg04282206	chr17:62833786	PLEKHM1P	-0.54	-8.12	-0.37	5.31e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-7.28	-0.33	1.61e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg02660097	chr11:68866761	NA	0.51	7.12	0.33	4.63e-12	Blond vs. brown hair color;
LUAD	cis	rs62400317	0.762	rs72865923	chr6:44878942	T/G	cg18551225	chr6:44695536	NA	-0.59	-8.88	-0.4	1.98e-17	Total body bone mineral density;
LUAD	cis	rs1375194	0.582	rs4670735	chr2:33801456	C/T	cg04131969	chr2:33951647	MYADML	-0.56	-8.68	-0.39	8.49e-17	Response to antidepressants in depression;
LUAD	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06022373	chr22:39101656	GTPBP1	0.42	6.55	0.3	1.68e-10	Menopause (age at onset);
LUAD	cis	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg05084668	chr3:125655381	ALG1L	-0.57	-9.1	-0.4	3.65e-18	Blood pressure (smoking interaction);
LUAD	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg10591111	chr5:226296	SDHA	-0.56	-7.28	-0.33	1.64e-12	Breast cancer;
LUAD	cis	rs6906287	0.647	rs3734381	chr6:118887303	A/G	cg21191810	chr6:118973309	C6orf204	0.46	8.75	0.39	4.98e-17	Electrocardiographic conduction measures;
LUAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg03188948	chr7:1209495	NA	-0.4	-6.46	-0.3	2.9e-10	Longevity;Endometriosis;
LUAD	cis	rs8067545	0.641	rs203458	chr17:19816898	A/C	cg04132472	chr17:19861366	AKAP10	0.39	9.14	0.41	2.61e-18	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.52	0.3	2.05e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg00684032	chr4:1343700	KIAA1530	0.41	7.06	0.32	7.08e-12	Obesity-related traits;
LUAD	cis	rs7493	0.950	rs11977702	chr7:95029767	C/T	cg19678392	chr7:94953810	PON1	-0.57	-7.73	-0.35	7.96e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs11166629	1.000	rs1867059	chr8:135647019	A/G	cg27224718	chr8:135614730	ZFAT	0.57	10.23	0.45	4.21e-22	Smoking quantity;
LUAD	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg08885076	chr2:99613938	TSGA10	-0.41	-7.67	-0.35	1.18e-13	Chronic sinus infection;
LUAD	cis	rs4006360	0.540	rs9915780	chr17:39301074	T/C	cg12981595	chr17:39254427	KRTAP4-8	0.32	6.57	0.3	1.45e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg11494091	chr17:61959527	GH2	0.42	7.76	0.35	6.48e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7523050	0.643	rs35907086	chr1:109406625	A/G	cg08274380	chr1:109419600	GPSM2	0.78	6.7	0.31	6.59e-11	Fat distribution (HIV);
LUAD	cis	rs6993813	0.967	rs6469805	chr8:120048149	C/T	cg01975934	chr8:119970761	NA	-0.37	-7.17	-0.33	3.34e-12	Bone mineral density (hip);
LUAD	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.74	-12.26	-0.51	9.03e-30	Primary sclerosing cholangitis;
LUAD	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg14416269	chr4:6271139	WFS1	0.63	13.38	0.55	2.75e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.71	-0.31	6.41e-11	Total body bone mineral density;
LUAD	cis	rs7851660	0.967	rs7860598	chr9:100600702	G/A	cg13688889	chr9:100608707	NA	-0.52	-9.61	-0.42	6.33e-20	Strep throat;
LUAD	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg00898013	chr13:113819073	PROZ	-0.66	-11.64	-0.49	2.32e-27	Platelet distribution width;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22798821	chr11:11864085	USP47	-0.46	-7.16	-0.33	3.62e-12	Height;
LUAD	cis	rs6121246	0.609	rs2376998	chr20:30340663	T/C	cg21427119	chr20:30132790	HM13	-0.35	-6.41	-0.3	3.95e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg03161606	chr19:29218774	NA	0.62	7.74	0.35	7.27e-14	Methadone dose in opioid dependence;
LUAD	cis	rs12618769	0.597	rs12619665	chr2:99126551	A/T	cg10123293	chr2:99228465	UNC50	0.42	7.75	0.35	6.93e-14	Bipolar disorder;
LUAD	cis	rs7809950	0.723	rs62483633	chr7:106876644	T/G	cg23024343	chr7:107201750	COG5	-0.82	-13.86	-0.56	2.72e-36	Coronary artery disease;
LUAD	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg00277334	chr10:82204260	NA	-0.6	-10.02	-0.44	2.48e-21	Post bronchodilator FEV1;
LUAD	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg15704280	chr7:45808275	SEPT13	-1.07	-24.35	-0.76	1.6e-82	Height;
LUAD	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg09092052	chr15:45571596	NA	0.41	6.41	0.3	3.78e-10	Glomerular filtration rate;
LUAD	trans	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	10.76	0.46	4.92e-24	Exhaled nitric oxide output;
LUAD	trans	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.84	0.36	3.68e-14	Resting heart rate;
LUAD	cis	rs1497828	0.956	rs2815222	chr1:217522229	T/A	cg04411442	chr1:217543379	NA	-0.36	-6.51	-0.3	2.19e-10	Dialysis-related mortality;
LUAD	cis	rs12474201	0.889	rs2346878	chr2:46922870	C/T	cg09399716	chr2:46890238	NA	-0.36	-6.8	-0.31	3.68e-11	Height;
LUAD	cis	rs877282	0.628	rs11253435	chr10:824169	T/C	cg13775593	chr10:823151	NA	0.36	6.44	0.3	3.32e-10	Uric acid levels;
LUAD	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg08085267	chr17:45401833	C17orf57	0.59	10.55	0.46	3.03e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11098699	0.821	rs13120866	chr4:124199293	A/G	cg09941581	chr4:124220074	SPATA5	0.48	7.86	0.36	3.24e-14	Mosquito bite size;
LUAD	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg06064525	chr11:970664	AP2A2	-0.56	-11.49	-0.49	8.88e-27	Alzheimer's disease (late onset);
LUAD	cis	rs12681287	0.547	rs60982560	chr8:87515046	C/T	cg27223183	chr8:87520930	FAM82B	-0.73	-10.28	-0.45	2.86e-22	Caudate activity during reward;
LUAD	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Body mass index;
LUAD	cis	rs2235649	0.746	rs35104579	chr16:1848657	A/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-8.15	-0.37	4.02e-15	Blood metabolite levels;
LUAD	cis	rs9473147	0.516	rs2151974	chr6:47515630	G/A	cg20196966	chr6:47445060	CD2AP	0.46	7.37	0.34	9.11e-13	Platelet distribution width;Mean platelet volume;
LUAD	trans	rs877282	0.898	rs12359731	chr10:759497	A/G	cg22713356	chr15:30763199	NA	1.22	17.64	0.65	1.33e-52	Uric acid levels;
LUAD	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg13319975	chr6:146136371	FBXO30	0.81	13.66	0.55	1.92e-35	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3849570	0.695	rs6804587	chr3:81873423	T/C	cg07356753	chr3:81810745	GBE1	-0.59	-9.55	-0.42	1.08e-19	Waist circumference;Body mass index;
LUAD	cis	rs12431939	1.000	rs67113863	chr14:51653103	G/C	cg23942311	chr14:51606299	NA	-0.6	-7.91	-0.36	2.22e-14	Cancer;
LUAD	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg12645284	chr15:79092878	ADAMTS7	0.45	7.16	0.33	3.52e-12	Coronary artery disease or large artery stroke;
LUAD	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg11814155	chr7:99998594	ZCWPW1	0.4	6.53	0.3	1.88e-10	Platelet count;
LUAD	trans	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.92	-16.34	-0.62	7.3e-47	Colorectal cancer;
LUAD	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12516959	chr21:47718080	NA	-0.38	-6.77	-0.31	4.35e-11	Testicular germ cell tumor;
LUAD	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg19163074	chr7:65112434	INTS4L2	-0.45	-6.73	-0.31	5.4e-11	Aortic root size;
LUAD	cis	rs9826463	0.582	rs11714244	chr3:142138294	C/T	cg20824294	chr3:142316082	PLS1	0.38	6.43	0.3	3.52e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg13535736	chr9:111863775	C9orf5	-0.43	-6.67	-0.31	7.96e-11	Menarche (age at onset);
LUAD	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg21823605	chr1:152486609	CRCT1	0.28	6.59	0.31	1.3e-10	Hair morphology;
LUAD	cis	rs10925040	0.666	rs10737808	chr1:247622940	C/T	cg14830002	chr1:247616686	OR2B11	-0.34	-7.79	-0.35	5.16e-14	Tumor necrosis factor beta levels;
LUAD	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.34e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28830936	1.000	rs11632424	chr15:42095351	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.34	-6.87	-0.32	2.27e-11	Diastolic blood pressure;
LUAD	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.82	-0.36	4.23e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.42	-0.6	6.83e-43	Chronic sinus infection;
LUAD	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg27490568	chr2:178487706	NA	0.42	7.09	0.33	5.56e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2224391	0.656	rs17140118	chr6:5291334	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-8.77	-0.39	4.54e-17	Height;
LUAD	cis	rs11622475	1.000	rs7143936	chr14:104459452	A/C	cg12183467	chr14:104352244	NA	-0.42	-7.47	-0.34	4.66e-13	Bipolar disorder;
LUAD	trans	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg02002194	chr4:3960332	NA	-0.26	-6.66	-0.31	8.68e-11	Mood instability;
LUAD	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg14552801	chr7:65878734	NA	0.38	6.38	0.3	4.71e-10	Aortic root size;
LUAD	cis	rs738321	0.757	rs3788536	chr22:38534209	C/T	cg25457927	chr22:38595422	NA	-0.49	-10.94	-0.47	1.08e-24	Breast cancer;
LUAD	cis	rs68170813	0.559	rs3779498	chr7:106923158	C/G	cg23024343	chr7:107201750	COG5	0.5	7.36	0.34	9.88e-13	Coronary artery disease;
LUAD	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.83	0.36	4.09e-14	Morning vs. evening chronotype;
LUAD	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg20744362	chr22:50050164	C22orf34	0.37	6.67	0.31	7.97e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7727544	0.514	rs3846728	chr5:131436217	G/A	cg14196790	chr5:131705035	SLC22A5	0.42	7.37	0.34	9.22e-13	Blood metabolite levels;
LUAD	cis	rs7937890	0.532	rs2575832	chr11:14488810	A/G	cg23387056	chr11:14280742	SPON1	-0.35	-6.87	-0.32	2.3e-11	Mitochondrial DNA levels;
LUAD	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg05966235	chr16:28915196	ATP2A1	0.45	7.38	0.34	8.73e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4889855	0.585	rs17848706	chr17:78704618	G/T	cg16591659	chr17:78472290	NA	0.49	8.0	0.36	1.18e-14	Fractional excretion of uric acid;
LUAD	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg01299579	chr2:10830716	NOL10	0.41	7.11	0.33	4.82e-12	Prostate cancer;
LUAD	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg10950924	chr17:47092072	IGF2BP1	-0.34	-6.73	-0.31	5.46e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs9512730	0.527	rs11619722	chr13:27998600	T/C	cg04070771	chr13:27998621	GTF3A	0.74	11.62	0.49	2.75e-27	Schizophrenia;
LUAD	cis	rs7851660	0.874	rs7868534	chr9:100632606	G/A	cg13688889	chr9:100608707	NA	-0.48	-8.27	-0.37	1.72e-15	Strep throat;
LUAD	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06028605	chr16:24865363	SLC5A11	-0.55	-8.5	-0.38	3.3e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-10.93	-0.47	1.17e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7503807	0.967	rs4889867	chr17:78593058	C/T	cg09596252	chr17:78655493	RPTOR	0.39	7.64	0.35	1.51e-13	Obesity;
LUAD	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg16414030	chr3:133502952	NA	-0.68	-12.75	-0.53	1.01e-31	Iron status biomarkers;
LUAD	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg14552801	chr7:65878734	NA	-0.38	-6.37	-0.3	4.96e-10	Aortic root size;
LUAD	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs1003719	0.715	rs9974494	chr21:38566566	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.26	-0.37	1.89e-15	Eye color traits;
LUAD	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.3	0.6	2.16e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg11901034	chr3:128598214	ACAD9	-0.54	-8.45	-0.38	4.65e-16	IgG glycosylation;
LUAD	cis	rs28830936	0.510	rs11858843	chr15:42092915	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.57	-13.7	-0.55	1.31e-35	Diastolic blood pressure;
LUAD	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg00745463	chr17:30367425	LRRC37B	-1.07	-12.32	-0.51	5.31e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg06740227	chr12:86229804	RASSF9	0.46	8.06	0.37	7.67e-15	Major depressive disorder;
LUAD	cis	rs17826219	0.585	rs8064302	chr17:28724938	G/A	cg14008862	chr17:28927542	LRRC37B2	-0.62	-6.35	-0.3	5.54e-10	Body mass index;
LUAD	cis	rs7116495	0.609	rs7113436	chr11:71689599	A/T	cg18441811	chr11:71824068	C11orf51	0.94	6.99	0.32	1.07e-11	Severe influenza A (H1N1) infection;
LUAD	trans	rs9354308	0.903	rs1938064	chr6:66559172	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.45	-0.3	2.99e-10	Metabolite levels;
LUAD	cis	rs1801251	0.574	rs2250660	chr2:233752551	G/C	cg25237894	chr2:233734115	C2orf82	-0.5	-9.47	-0.42	1.94e-19	Coronary artery disease;
LUAD	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg24450063	chr1:156163899	SLC25A44	1.23	30.09	0.83	3.59e-107	Testicular germ cell tumor;
LUAD	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06022373	chr22:39101656	GTPBP1	0.46	7.07	0.33	6.52e-12	Menopause (age at onset);
LUAD	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg09359103	chr1:154839909	KCNN3	-0.92	-19.97	-0.7	5.72e-63	Prostate cancer;
LUAD	cis	rs2387326	0.717	rs10829343	chr10:129944496	T/C	cg16087940	chr10:129947807	NA	-0.64	-9.02	-0.4	6.53e-18	Select biomarker traits;
LUAD	cis	rs1595825	0.945	rs76877032	chr2:198840000	G/A	cg11031976	chr2:198649780	BOLL	-0.47	-6.95	-0.32	1.41e-11	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.42e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs68170813	0.559	rs77829121	chr7:106968470	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-10.53	-0.46	3.54e-23	Coronary artery disease;
LUAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg18305652	chr10:134549665	INPP5A	-0.61	-11.79	-0.5	6.19e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-7.08	-0.33	5.93e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg12740337	chr6:28058973	ZSCAN12L1	0.25	6.44	0.3	3.35e-10	Parkinson's disease;
LUAD	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg21775007	chr8:11205619	TDH	0.51	9.04	0.4	5.78e-18	Retinal vascular caliber;
LUAD	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.06	0.32	6.86e-12	Parkinson's disease;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg19553056	chr4:142142166	ZNF330	0.43	6.91	0.32	1.83e-11	Bilirubin levels;
LUAD	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg02782426	chr3:40428986	ENTPD3	0.33	7.15	0.33	3.72e-12	Renal cell carcinoma;
LUAD	cis	rs1595825	0.838	rs16826872	chr2:198898055	T/C	cg00982548	chr2:198649783	BOLL	-0.68	-9.53	-0.42	1.22e-19	Ulcerative colitis;
LUAD	cis	rs4691139	1.000	rs9991678	chr4:165885039	G/A	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.46	-8.88	-0.4	1.86e-17	Ovarian cancer in BRCA1 mutation carriers;
LUAD	trans	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg07211511	chr3:129823064	LOC729375	-0.84	-12.18	-0.51	1.79e-29	Blood pressure (smoking interaction);
LUAD	cis	rs9323205	1.000	rs12589519	chr14:51596684	C/G	cg23942311	chr14:51606299	NA	-0.62	-9.95	-0.44	4.16e-21	Cancer;
LUAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg08132940	chr7:1081526	C7orf50	-0.59	-8.35	-0.38	9.91e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg15485101	chr11:133734466	NA	0.37	7.97	0.36	1.52e-14	Childhood ear infection;
LUAD	cis	rs61774743	0.557	rs4359027	chr1:41848296	G/A	cg08462924	chr1:41848221	NA	0.49	8.95	0.4	1.1e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs4481887	0.893	rs6587450	chr1:248480496	T/A	cg13385794	chr1:248469461	NA	0.26	6.97	0.32	1.21e-11	Common traits (Other);
LUAD	cis	rs758324	0.947	rs1500114	chr5:131138120	C/A	cg25547332	chr5:131281432	NA	0.44	6.71	0.31	6.38e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg03676636	chr4:99064102	C4orf37	0.36	8.28	0.37	1.64e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg22868518	chr11:507468	RNH1	-0.65	-6.55	-0.3	1.62e-10	Body mass index;
LUAD	trans	rs459571	0.916	rs109536	chr9:136889987	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.65	-9.54	-0.42	1.18e-19	Platelet distribution width;
LUAD	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg02527881	chr3:46936655	PTH1R	-0.57	-11.81	-0.5	5.02e-28	Colorectal cancer;
LUAD	cis	rs3784262	0.607	rs4646576	chr15:58338998	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.53	-10.28	-0.45	2.85e-22	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs2274273	0.840	rs6573020	chr14:55871452	C/T	cg04306507	chr14:55594613	LGALS3	0.41	8.42	0.38	5.92e-16	Protein biomarker;
LUAD	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.6	7.56	0.34	2.6e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs11971779	0.680	rs11764236	chr7:139118514	C/T	cg23387468	chr7:139079360	LUC7L2	0.3	6.96	0.32	1.29e-11	Diisocyanate-induced asthma;
LUAD	cis	rs28374715	0.532	rs3204853	chr15:41689166	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.11	-23.94	-0.76	1.13e-80	Ulcerative colitis;
LUAD	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-14.86	-0.59	1.7e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs113835537	0.597	rs3825065	chr11:66311011	A/G	cg24851651	chr11:66362959	CCS	0.6	10.61	0.46	1.72e-23	Airway imaging phenotypes;
LUAD	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19346786	chr7:2764209	NA	-0.59	-12.85	-0.53	3.72e-32	Height;
LUAD	cis	rs9393692	0.557	rs9379846	chr6:26314238	G/C	cg13736514	chr6:26305472	NA	-0.53	-8.63	-0.39	1.23e-16	Educational attainment;
LUAD	cis	rs3820068	0.705	rs927206	chr1:15893338	C/T	cg13390004	chr1:15929781	NA	0.43	6.8	0.31	3.67e-11	Systolic blood pressure;
LUAD	cis	rs6594713	0.757	rs13154300	chr5:112719356	T/C	cg12552261	chr5:112820674	MCC	0.47	6.93	0.32	1.61e-11	Brain cytoarchitecture;
LUAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-9.55	-0.42	1.04e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs17685	0.712	rs869805	chr7:75688596	C/T	cg19862616	chr7:65841803	NCRNA00174	1.06	27.46	0.8	4.59e-96	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.73	-8.62	-0.39	1.39e-16	Body mass index;
LUAD	trans	rs9467711	0.591	rs6913795	chr6:25848025	T/C	cg06606381	chr12:133084897	FBRSL1	-0.8	-6.67	-0.31	7.88e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg27572855	chr1:25598939	RHD	0.54	11.72	0.5	1.17e-27	Erythrocyte sedimentation rate;
LUAD	cis	rs2067615	0.524	rs10778503	chr12:107090616	C/T	cg15890332	chr12:107067104	RFX4	0.4	8.51	0.38	2.98e-16	Heart rate;
LUAD	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg06002616	chr8:101225028	SPAG1	0.37	7.7	0.35	9.92e-14	Atrioventricular conduction;
LUAD	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg14784868	chr12:69753453	YEATS4	0.45	7.35	0.34	1.06e-12	Blood protein levels;
LUAD	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg02574844	chr11:5959923	NA	-0.44	-7.5	-0.34	3.72e-13	DNA methylation (variation);
LUAD	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg00277334	chr10:82204260	NA	-0.96	-22.08	-0.73	2.06e-72	Post bronchodilator FEV1;
LUAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg07234876	chr8:600039	NA	1.04	10.21	0.44	5.07e-22	IgG glycosylation;
LUAD	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg22705602	chr4:152727874	NA	-0.37	-6.67	-0.31	7.87e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs11112613	0.609	rs17037380	chr12:106036708	C/T	cg03607813	chr12:105948248	NA	0.49	6.58	0.3	1.42e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	trans	rs1493916	0.655	rs4534926	chr18:31349072	G/C	cg27147174	chr7:100797783	AP1S1	-0.71	-12.76	-0.53	8.71e-32	Life satisfaction;
LUAD	cis	rs4380275	0.931	rs4538239	chr2:774238	C/T	cg21665850	chr2:731073	NA	0.5	8.97	0.4	9.74e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUAD	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg05340658	chr4:99064831	C4orf37	0.56	9.55	0.42	1.04e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	6.09e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.38	0.38	7.67e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg13319975	chr6:146136371	FBXO30	0.58	9.75	0.43	2.15e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg23954153	chr1:44402353	ARTN	-0.37	-6.91	-0.32	1.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg20203395	chr5:56204925	C5orf35	0.64	9.83	0.43	1.14e-20	Initial pursuit acceleration;
LUAD	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg05234568	chr11:5960015	NA	-0.47	-8.48	-0.38	3.82e-16	DNA methylation (variation);
LUAD	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg05082376	chr22:42548792	NA	-0.43	-7.57	-0.35	2.29e-13	Schizophrenia;
LUAD	cis	rs17818399	0.926	rs35682608	chr2:46836542	A/T	cg09399716	chr2:46890238	NA	-0.41	-7.8	-0.35	4.97e-14	Height;
LUAD	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg02696790	chr15:75250997	RPP25	0.37	7.31	0.34	1.32e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg21475434	chr5:93447410	FAM172A	0.8	8.96	0.4	1.08e-17	Diabetic retinopathy;
LUAD	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg20628663	chr10:43360327	NA	0.74	11.34	0.48	3.44e-26	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9473147	0.543	rs9296559	chr6:47452270	T/C	cg12968598	chr6:47444699	CD2AP	0.37	6.48	0.3	2.6200000000000003e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg27539214	chr16:67997921	SLC12A4	-0.66	-8.3	-0.37	1.42e-15	Schizophrenia;
LUAD	cis	rs55788414	0.932	rs12102728	chr16:81181436	C/T	cg06400318	chr16:81190750	PKD1L2	-0.64	-8.34	-0.38	1.02e-15	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs62400317	0.762	rs12190313	chr6:44903902	T/G	cg20913747	chr6:44695427	NA	-0.44	-6.94	-0.32	1.5e-11	Total body bone mineral density;
LUAD	cis	rs2731664	0.765	rs2630766	chr5:176874941	A/C	cg23176889	chr5:176863531	GRK6	-0.68	-13.02	-0.53	8.06e-33	Intelligence (multi-trait analysis);
LUAD	cis	rs113835537	0.529	rs116867234	chr11:66209024	C/T	cg24851651	chr11:66362959	CCS	0.61	10.58	0.46	2.33e-23	Airway imaging phenotypes;
LUAD	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg02896835	chr1:92012615	NA	-0.61	-12.73	-0.53	1.21e-31	Breast cancer;
LUAD	cis	rs7116495	1.000	rs607446	chr11:71789252	G/A	cg07596299	chr11:71824057	C11orf51	-0.77	-6.53	-0.3	1.86e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs6678622	0.931	rs4130548	chr1:78463868	C/T	cg21968580	chr1:78470640	DNAJB4	-0.41	-6.79	-0.31	3.93e-11	Hip circumference;
LUAD	cis	rs6433857	0.657	rs2368178	chr2:181501938	T/C	cg23363182	chr2:181467187	NA	-0.43	-7.22	-0.33	2.47e-12	Body mass index;
LUAD	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg12311346	chr5:56204834	C5orf35	-0.59	-9.4	-0.42	3.45e-19	Coronary artery disease;
LUAD	cis	rs12760731	0.720	rs7548163	chr1:178306695	G/A	cg00404053	chr1:178313656	RASAL2	0.65	8.47	0.38	4.11e-16	Obesity-related traits;
LUAD	cis	rs1448094	0.872	rs10863147	chr12:86408441	G/C	cg02569458	chr12:86230093	RASSF9	0.37	7.13	0.33	4.27e-12	Major depressive disorder;
LUAD	cis	rs11622475	1.000	rs34964872	chr14:104448435	T/A	cg12183467	chr14:104352244	NA	-0.41	-7.31	-0.33	1.33e-12	Bipolar disorder;
LUAD	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg18200150	chr17:30822561	MYO1D	0.42	7.78	0.35	5.59e-14	Schizophrenia;
LUAD	cis	rs1497828	0.913	rs2646836	chr1:217550020	A/T	cg04411442	chr1:217543379	NA	0.39	7.0	0.32	9.95e-12	Dialysis-related mortality;
LUAD	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg12193833	chr17:30244370	NA	-0.58	-6.95	-0.32	1.35e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs9302690	1.000	rs62037110	chr16:57444771	A/G	cg27017172	chr16:57497170	POLR2C	1.23	9.64	0.42	5.37e-20	Blood protein levels;
LUAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg13560548	chr3:10150139	C3orf24	0.44	6.87	0.32	2.25e-11	Alzheimer's disease;
LUAD	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-8.0	-0.36	1.25e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7520050	0.966	rs1707336	chr1:46493460	T/G	cg06784218	chr1:46089804	CCDC17	-0.3	-6.46	-0.3	2.91e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs7524258	0.903	rs763197	chr1:7289959	A/G	cg07173049	chr1:7289937	CAMTA1	0.56	10.51	0.45	4.21e-23	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg25985355	chr7:65971099	NA	-0.53	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg00071950	chr4:10020882	SLC2A9	0.86	18.37	0.67	7.89e-56	Bone mineral density;
LUAD	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg17063962	chr7:91808500	NA	-0.61	-10.29	-0.45	2.68e-22	Breast cancer;
LUAD	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg26384229	chr12:38710491	ALG10B	0.47	7.65	0.35	1.37e-13	Morning vs. evening chronotype;
LUAD	cis	rs9302065	0.681	rs59108692	chr13:95962424	C/A	cg26751094	chr13:95954534	ABCC4	-0.51	-10.8	-0.46	3.48e-24	Blood metabolite levels;
LUAD	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06544989	chr22:39130855	UNC84B	-0.36	-6.66	-0.31	8.35e-11	Menopause (age at onset);
LUAD	trans	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg01620082	chr3:125678407	NA	-0.7	-7.04	-0.32	7.89e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7771547	0.573	rs10440841	chr6:36399086	G/A	cg07856975	chr6:36356162	ETV7	-0.48	-7.5	-0.34	3.9e-13	Platelet distribution width;
LUAD	cis	rs4523957	0.928	rs394752	chr17:2199749	C/A	cg16513277	chr17:2031491	SMG6	0.76	14.29	0.57	4.41e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.07e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6087990	0.735	rs4911261	chr20:31391360	A/G	cg13636640	chr20:31349939	DNMT3B	0.74	13.17	0.54	1.9e-33	Ulcerative colitis;
LUAD	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg25233709	chr10:116636983	FAM160B1	-0.4	-7.93	-0.36	2e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.98	0.32	1.17e-11	Schizophrenia;
LUAD	cis	rs12681287	0.640	rs4961193	chr8:87486168	C/T	cg27223183	chr8:87520930	FAM82B	0.62	9.05	0.4	5.41e-18	Caudate activity during reward;
LUAD	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.49	-0.3	2.38e-10	Prostate cancer;
LUAD	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg16205897	chr5:131564050	P4HA2	0.32	7.06	0.32	6.68e-12	Blood metabolite levels;
LUAD	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg04455712	chr21:45112962	RRP1B	-0.51	-10.69	-0.46	9.16e-24	Mean corpuscular volume;
LUAD	cis	rs977987	0.843	rs6564260	chr16:75447426	A/G	cg03315344	chr16:75512273	CHST6	0.64	14.06	0.56	4.3e-37	Dupuytren's disease;
LUAD	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg07570687	chr10:102243282	WNT8B	0.44	6.44	0.3	3.19e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs250677	0.522	rs2217638	chr5:148364355	A/G	cg18129178	chr5:148520854	ABLIM3	0.51	7.63	0.35	1.54e-13	Breast cancer;
LUAD	cis	rs6733011	0.538	rs11900524	chr2:99466731	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.38	-0.3	4.71e-10	Bipolar disorder;
LUAD	cis	rs10746514	0.768	rs11122427	chr1:232261085	C/T	cg09506761	chr1:232265262	NA	-0.38	-7.23	-0.33	2.26e-12	Response to statin therapy;
LUAD	cis	rs6840360	0.967	rs1511170	chr4:152701110	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.37	-0.3	5.06e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg13334819	chr7:99746414	C7orf59	-0.64	-9.42	-0.42	2.9e-19	Coronary artery disease;
LUAD	cis	rs806215	0.950	rs989099	chr7:127220827	A/G	cg25922125	chr7:127225783	GCC1	-0.48	-6.64	-0.31	9.75e-11	Type 2 diabetes;
LUAD	cis	rs250677	0.522	rs4562031	chr5:148368451	A/G	cg18129178	chr5:148520854	ABLIM3	0.51	7.58	0.35	2.27e-13	Breast cancer;
LUAD	trans	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg07817883	chr1:32538562	TMEM39B	1.5	12.56	0.52	5.74e-31	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg07460842	chr6:66804631	NA	-1.22	-30.88	-0.83	1.96e-110	Exhaled nitric oxide output;
LUAD	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg27462398	chr1:86174642	ZNHIT6	-0.39	-7.78	-0.35	5.48e-14	Urate levels in overweight individuals;
LUAD	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg18932078	chr1:2524107	MMEL1	0.38	7.05	0.32	7.33e-12	Ulcerative colitis;
LUAD	trans	rs2262909	0.962	rs17459246	chr19:22278121	T/C	cg05197062	chr11:11642011	GALNTL4	0.58	8.99	0.4	8.5e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg24163568	chr5:669837	TPPP	0.37	6.86	0.32	2.48e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.39	0.34	7.8e-13	Hypertriglyceridemia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04672650	chr10:96943563	NA	-0.53	-6.56	-0.3	1.59e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7584330	0.780	rs9973650	chr2:238380266	G/A	cg14458575	chr2:238380390	NA	0.71	13.01	0.53	8.69e-33	Prostate cancer;
LUAD	cis	rs3764563	1.000	rs2283603	chr19:15731128	T/C	cg20725493	chr19:15740067	CYP4F8	-0.68	-7.5	-0.34	3.68e-13	Inflammatory biomarkers;
LUAD	cis	rs4409675	0.576	rs2078328	chr1:28224976	A/G	cg23691781	chr1:28212827	C1orf38	0.38	11.17	0.48	1.42e-25	Corneal astigmatism;
LUAD	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.04	-0.36	9.24e-15	Cystic fibrosis severity;
LUAD	cis	rs4660306	1.000	rs11211132	chr1:45990516	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.5	-7.98	-0.36	1.36e-14	Homocysteine levels;
LUAD	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg12667521	chr19:29218732	NA	0.58	7.94	0.36	1.78e-14	Methadone dose in opioid dependence;
LUAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg05434287	chr7:2030229	MAD1L1	0.42	6.59	0.3	1.35e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs12986413	0.651	rs2238612	chr19:2149694	C/T	cg09261902	chr19:2140048	AP3D1	-0.4	-7.82	-0.36	4.17e-14	Height;
LUAD	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg00634984	chr7:65235879	NA	-0.49	-6.53	-0.3	1.9e-10	Aortic root size;
LUAD	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg02018176	chr4:1364513	KIAA1530	0.37	6.45	0.3	3.07e-10	Obesity-related traits;
LUAD	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.32	-0.45	1.96e-22	Monocyte percentage of white cells;
LUAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-8.24	-0.37	2.14e-15	Alzheimer's disease;
LUAD	cis	rs41311933	0.614	rs62578403	chr9:123705650	C/T	cg13567360	chr9:123745713	C5	-0.83	-7.22	-0.33	2.36e-12	Coronary artery disease;
LUAD	cis	rs62400317	0.762	rs12215263	chr6:44831364	C/A	cg18551225	chr6:44695536	NA	-0.59	-8.88	-0.4	1.93e-17	Total body bone mineral density;
LUAD	cis	rs12541635	0.966	rs4734894	chr8:106995313	G/A	cg10147462	chr8:107024639	NA	0.48	8.37	0.38	8.81e-16	Age of smoking initiation;
LUAD	cis	rs12210905	0.688	rs72845008	chr6:27492961	C/G	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg06618935	chr21:46677482	NA	-0.51	-10.36	-0.45	1.49e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11229555	1.000	rs10896795	chr11:58366561	A/G	cg15696309	chr11:58395628	NA	-0.73	-10.98	-0.47	7.29e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg23954153	chr1:44402353	ARTN	0.37	7.1	0.33	5.4e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs701145	0.938	rs355773	chr3:154036657	A/G	cg17054900	chr3:154042577	DHX36	-0.65	-7.25	-0.33	1.94e-12	Coronary artery disease;
LUAD	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg13319975	chr6:146136371	FBXO30	0.65	11.1	0.47	2.66e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg05434287	chr7:2030229	MAD1L1	0.4	6.74	0.31	5.25e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs17608059	0.679	rs9898056	chr17:13951966	C/G	cg27005118	chr17:13972210	COX10	-0.41	-8.9	-0.4	1.68e-17	Temperament;
LUAD	cis	rs34638657	0.673	rs67661146	chr16:82199669	G/A	cg09439754	chr16:82129088	HSD17B2	-0.37	-7.07	-0.33	6.52e-12	Lung adenocarcinoma;
LUAD	cis	rs4253772	0.515	rs9615969	chr22:46773592	C/G	cg00784671	chr22:46762841	CELSR1	-0.67	-7.37	-0.34	8.86e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.43	0.34	5.95e-13	Bipolar disorder;
LUAD	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.17e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg17971929	chr21:40555470	PSMG1	0.51	7.69	0.35	1.06e-13	Cognitive function;
LUAD	cis	rs1003719	0.788	rs2835589	chr21:38463342	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.33e-16	Eye color traits;
LUAD	cis	rs6494488	0.500	rs72742997	chr15:65009527	G/A	cg08069370	chr15:64387884	SNX1	-0.76	-6.77	-0.31	4.23e-11	Coronary artery disease;
LUAD	cis	rs6499255	0.904	rs10852458	chr16:69672410	G/A	cg00738113	chr16:70207722	CLEC18C	-0.41	-6.91	-0.32	1.81e-11	IgE levels;
LUAD	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg03806693	chr22:41940476	POLR3H	-0.65	-9.38	-0.41	4.04e-19	Vitiligo;
LUAD	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg10518543	chr12:38710700	ALG10B	-0.45	-7.32	-0.34	1.23e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg11098525	chr4:1320231	MAEA	-0.38	-6.71	-0.31	6.45e-11	Obesity-related traits;
LUAD	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.63	11.79	0.5	6.12e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs9354308	0.834	rs12212376	chr6:66598879	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.51	7.67	0.35	1.16e-13	Metabolite levels;
LUAD	trans	rs853679	0.599	rs202906	chr6:28011652	C/T	cg01620082	chr3:125678407	NA	0.51	6.51	0.3	2.17e-10	Depression;
LUAD	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg16060761	chr17:80687452	NA	-0.57	-8.04	-0.36	9.25e-15	Glycated hemoglobin levels;
LUAD	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg13319975	chr6:146136371	FBXO30	0.66	11.41	0.48	1.87e-26	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg01620082	chr3:125678407	NA	-0.88	-8.77	-0.39	4.51e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg04450456	chr4:17643702	FAM184B	0.41	8.18	0.37	3.34e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1006703	0.544	rs8068362	chr17:3838757	T/C	cg09591406	chr17:3833873	ATP2A3	-0.55	-6.61	-0.31	1.16e-10	Glucose homeostasis traits;
LUAD	cis	rs9399401	0.634	rs984932	chr6:142803037	C/T	cg03128060	chr6:142623767	GPR126	0.37	7.13	0.33	4.32e-12	Chronic obstructive pulmonary disease;
LUAD	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-6.38	-0.3	4.64e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7680126	0.672	rs10939819	chr4:10290661	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-6.61	-0.31	1.14e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg19622623	chr12:86230825	RASSF9	-0.41	-7.17	-0.33	3.34e-12	Major depressive disorder;
LUAD	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg26384229	chr12:38710491	ALG10B	0.53	8.57	0.38	2e-16	Heart rate;
LUAD	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg18252515	chr7:66147081	NA	-0.63	-6.84	-0.32	2.71e-11	Diabetic kidney disease;
LUAD	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	cg01733217	chr16:74700730	RFWD3	-0.53	-8.9	-0.4	1.61e-17	Testicular germ cell tumor;
LUAD	cis	rs4642101	0.765	rs9870269	chr3:12853450	T/G	cg24848339	chr3:12840334	CAND2	0.38	7.53	0.34	3.13e-13	QRS complex (12-leadsum);
LUAD	cis	rs6906287	0.647	rs10457338	chr6:118784018	T/C	cg21191810	chr6:118973309	C6orf204	0.49	9.6	0.42	7.38e-20	Electrocardiographic conduction measures;
LUAD	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg22029157	chr1:209979665	IRF6	-0.57	-11.07	-0.47	3.41e-25	Orofacial clefts;
LUAD	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	15.35	0.6	1.41e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.6	9.53	0.42	1.21e-19	Lymphocyte percentage of white cells;
LUAD	cis	rs3106136	0.967	rs2306803	chr4:95161996	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.38	-6.83	-0.32	2.97e-11	Capecitabine sensitivity;
LUAD	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg00129232	chr17:37814104	STARD3	-0.46	-7.97	-0.36	1.49e-14	Asthma;
LUAD	cis	rs7937890	0.631	rs7118886	chr11:14427517	T/C	cg02886208	chr11:14281011	SPON1	-0.34	-6.63	-0.31	1.02e-10	Mitochondrial DNA levels;
LUAD	cis	rs733175	0.855	rs10016075	chr4:10006663	G/T	cg11266682	chr4:10021025	SLC2A9	0.42	7.17	0.33	3.4e-12	Psychosis and Alzheimer's disease;
LUAD	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.37	-7.44	-0.34	5.75e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg13722127	chr7:150037890	RARRES2	0.45	8.01	0.36	1.1e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-6.67	-0.31	7.84e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7020830	0.898	rs495863	chr9:37346955	T/C	cg14294708	chr9:37120828	ZCCHC7	0.84	16.99	0.64	9.71e-50	Schizophrenia;
LUAD	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg25036284	chr2:26402008	FAM59B	-0.6	-8.34	-0.38	1.02e-15	Gut microbiome composition (summer);
LUAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg04025307	chr7:1156635	C7orf50	0.62	7.04	0.32	7.91e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg06740227	chr12:86229804	RASSF9	0.44	7.57	0.35	2.34e-13	Major depressive disorder;
LUAD	cis	rs17102423	0.755	rs11158572	chr14:65577411	C/T	cg11161011	chr14:65562177	MAX	-0.52	-8.13	-0.37	4.65e-15	Obesity-related traits;
LUAD	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg02931644	chr1:25747376	RHCE	0.44	9.39	0.42	3.63e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs9633740	0.578	rs11185951	chr10:82301536	G/C	cg01528321	chr10:82214614	TSPAN14	-0.63	-7.1	-0.33	5.31e-12	Post bronchodilator FEV1;
LUAD	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg00666640	chr1:248458726	OR2T12	0.33	7.85	0.36	3.5e-14	Common traits (Other);
LUAD	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-23.49	-0.75	1.03e-78	Height;
LUAD	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.38	0.38	7.77e-16	Platelet count;
LUAD	cis	rs2730260	0.736	rs7784586	chr7:158836379	T/C	cg02254261	chr7:158964346	NA	-0.53	-6.65	-0.31	9.1e-11	Myopia (pathological);
LUAD	trans	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg01620082	chr3:125678407	NA	-1.11	-10.83	-0.47	2.63e-24	Depression;
LUAD	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.09	0.37	6.38e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14733031	chr19:17904427	B3GNT3	-0.42	-6.59	-0.31	1.28e-10	Height;
LUAD	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg14196790	chr5:131705035	SLC22A5	0.38	7.04	0.32	7.95e-12	Blood metabolite levels;
LUAD	cis	rs8044868	0.887	rs12449073	chr16:72171004	A/T	cg23815491	chr16:72088622	HP	0.37	6.47	0.3	2.68e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg23982607	chr1:1823379	GNB1	-0.92	-19.39	-0.69	2.27e-60	Body mass index;
LUAD	cis	rs62400317	0.826	rs12203466	chr6:45330263	T/A	cg20913747	chr6:44695427	NA	-0.4	-6.42	-0.3	3.59e-10	Total body bone mineral density;
LUAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg08027265	chr7:2291960	NA	-0.42	-7.16	-0.33	3.51e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.36e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1461503	0.966	rs11218905	chr11:122840303	A/G	cg27398637	chr11:122830231	C11orf63	0.35	6.86	0.32	2.47e-11	Menarche (age at onset);
LUAD	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.65	0.31	8.94e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg16405210	chr4:1374714	KIAA1530	-0.36	-6.35	-0.3	5.49e-10	Obesity-related traits;
LUAD	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg12311346	chr5:56204834	C5orf35	-0.56	-8.99	-0.4	8.58e-18	Coronary artery disease;
LUAD	cis	rs7927771	0.839	rs59360790	chr11:47669175	T/C	cg18512352	chr11:47633146	NA	-0.39	-7.18	-0.33	3.18e-12	Subjective well-being;
LUAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg24829409	chr8:58192753	C8orf71	-0.53	-6.73	-0.31	5.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11650494	0.803	rs117801358	chr17:47447950	C/A	cg08112188	chr17:47440006	ZNF652	0.98	8.25	0.37	1.99e-15	Prostate cancer;
LUAD	cis	rs494562	0.892	rs498289	chr6:86116721	A/G	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-6.84	-0.32	2.75e-11	Lung cancer;
LUAD	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg05926928	chr17:57297772	GDPD1	1.4	17.96	0.66	5.07e-54	Opioid sensitivity;
LUAD	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg00757033	chr12:89920650	WDR51B	0.67	11.55	0.49	5.43e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg20302342	chr1:156215951	PAQR6	0.38	8.64	0.39	1.2e-16	Tonsillectomy;
LUAD	cis	rs9633740	0.842	rs1870140	chr10:82246749	A/G	cg00277334	chr10:82204260	NA	-0.64	-7.51	-0.34	3.46e-13	Post bronchodilator FEV1;
LUAD	trans	rs11650494	0.908	rs8076023	chr17:47399633	C/G	cg11430096	chr6:110968061	CDK19	0.87	6.76	0.31	4.51e-11	Prostate cancer;
LUAD	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg16447950	chr5:562315	NA	-0.44	-6.94	-0.32	1.45e-11	Obesity-related traits;
LUAD	cis	rs12893668	0.637	rs4525427	chr14:104072793	C/A	cg13511324	chr14:104056883	C14orf153	0.26	6.5	0.3	2.29e-10	Reticulocyte count;
LUAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg23978390	chr7:1156363	C7orf50	0.46	7.31	0.33	1.37e-12	Longevity;Endometriosis;
LUAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg00106254	chr7:1943704	MAD1L1	-0.59	-8.99	-0.4	8.18e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00166722	chr3:10149974	C3orf24	0.72	12.63	0.52	2.89e-31	Alzheimer's disease;
LUAD	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg26384229	chr12:38710491	ALG10B	0.5	8.07	0.37	7.61e-15	Morning vs. evening chronotype;
LUAD	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg07305463	chr2:136567211	LCT	0.4	7.56	0.35	2.52e-13	Mosquito bite size;
LUAD	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg13722127	chr7:150037890	RARRES2	0.52	9.11	0.4	3.39e-18	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1018836	0.663	rs12674903	chr8:91475774	T/C	cg16814680	chr8:91681699	NA	-0.68	-11.21	-0.48	1.01e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg01528321	chr10:82214614	TSPAN14	0.47	7.5	0.34	3.84e-13	Post bronchodilator FEV1;
LUAD	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	7.85	0.36	3.38e-14	Menopause (age at onset);
LUAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg04025307	chr7:1156635	C7orf50	0.66	9.34	0.41	5.5e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4372836	0.543	rs10204329	chr2:28998077	C/G	cg09522027	chr2:28974177	PPP1CB	-0.59	-10.34	-0.45	1.7e-22	Body mass index;
LUAD	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg06064525	chr11:970664	AP2A2	-0.54	-11.06	-0.47	3.79e-25	Alzheimer's disease (late onset);
LUAD	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08439880	chr3:133502540	NA	0.42	8.51	0.38	2.97e-16	Iron status biomarkers;
LUAD	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg11707310	chr1:2537719	MMEL1	-0.4	-8.61	-0.39	1.45e-16	Ulcerative colitis;
LUAD	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg18721089	chr20:30220636	NA	-0.44	-6.49	-0.3	2.41e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg08027265	chr7:2291960	NA	-0.42	-7.04	-0.32	7.76e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg26513180	chr16:89883248	FANCA	0.86	7.74	0.35	7.57e-14	Skin colour saturation;
LUAD	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06544989	chr22:39130855	UNC84B	0.43	7.92	0.36	2.09e-14	Menopause (age at onset);
LUAD	cis	rs3106136	1.000	rs3106134	chr4:95128091	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.79	-0.35	5.33e-14	Capecitabine sensitivity;
LUAD	cis	rs7707921	0.550	rs116241532	chr5:81675055	C/T	cg15871215	chr5:81402204	ATG10	-0.51	-6.96	-0.32	1.29e-11	Breast cancer;
LUAD	cis	rs1864400	0.696	rs2742239	chr10:43621712	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.51	-8.57	-0.38	1.97e-16	Hirschsprung disease;
LUAD	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg04455712	chr21:45112962	RRP1B	0.45	8.92	0.4	1.37e-17	Mean corpuscular volume;
LUAD	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg09835421	chr16:68378352	PRMT7	-0.62	-7.13	-0.33	4.44e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg04154034	chr17:28927549	LRRC37B2	0.69	6.96	0.32	1.32e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs62229266	0.659	rs2835243	chr21:37413946	C/T	cg12218747	chr21:37451666	NA	-0.42	-7.36	-0.34	9.62e-13	Mitral valve prolapse;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13411897	chr3:12526166	TSEN2	-0.54	-6.52	-0.3	1.97e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08280861	chr8:58055591	NA	0.77	9.56	0.42	9.62e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs73198271	0.740	rs11781430	chr8:8651733	G/C	cg01851573	chr8:8652454	MFHAS1	0.52	9.29	0.41	8.16e-19	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs454510	0.857	rs838990	chr1:120193252	A/G	cg11530693	chr1:120165357	ZNF697	0.6	9.72	0.43	2.83e-20	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg22920501	chr2:26401640	FAM59B	-0.96	-14.21	-0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg08798685	chr6:27730294	NA	-0.44	-7.05	-0.32	7.22e-12	Parkinson's disease;
LUAD	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.42	-8.01	-0.36	1.1e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg20283391	chr11:68216788	NA	-0.42	-6.6	-0.31	1.23e-10	Total body bone mineral density;
LUAD	cis	rs10193935	0.892	rs12622152	chr2:42482929	C/A	cg27598129	chr2:42591480	NA	-0.79	-9.71	-0.43	2.97e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs77972916	0.561	rs17406174	chr2:43557484	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-7.07	-0.32	6.54e-12	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs11088226	0.541	rs75873023	chr21:33910658	G/A	cg09050820	chr6:167586206	TCP10L2	0.43	6.38	0.3	4.71e-10	Gastritis;
LUAD	cis	rs10426930	0.700	rs10413045	chr19:5024099	G/T	cg25246084	chr19:4971487	KDM4B	-0.44	-7.82	-0.36	4.36e-14	Monocyte percentage of white cells;
LUAD	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg01528321	chr10:82214614	TSPAN14	-0.71	-11.16	-0.48	1.56e-25	Post bronchodilator FEV1;
LUAD	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.39	-6.37	-0.3	4.93e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg03433033	chr1:76189801	ACADM	0.57	8.59	0.39	1.71e-16	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg18854424	chr1:2615690	NA	0.43	9.39	0.42	3.64e-19	Ulcerative colitis;
LUAD	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg16049864	chr8:95962084	TP53INP1	-0.55	-11.71	-0.49	1.27e-27	Type 2 diabetes;
LUAD	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs733175	0.857	rs3796838	chr4:10011030	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	9.02	0.4	6.83e-18	Psychosis and Alzheimer's disease;
LUAD	cis	rs804280	0.638	rs36038176	chr8:11609995	C/T	cg23972785	chr8:11611189	GATA4	-0.46	-7.32	-0.34	1.26e-12	Myopia (pathological);
LUAD	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg19761014	chr17:28927070	LRRC37B2	0.7	6.43	0.3	3.37e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4786125	0.665	rs6500858	chr16:6906111	T/C	cg03623568	chr16:6915990	A2BP1	-0.49	-10.72	-0.46	7.28e-24	Heart rate variability traits (SDNN);
LUAD	cis	rs13064411	0.542	rs7650671	chr3:113201216	C/T	cg10517650	chr3:113235015	CCDC52	-0.38	-7.26	-0.33	1.89e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg15133208	chr4:90757351	SNCA	-0.46	-7.04	-0.32	7.57e-12	Neuroticism;
LUAD	cis	rs13064411	0.696	rs6438161	chr3:113227637	G/A	cg18753928	chr3:113234510	CCDC52	-0.73	-12.41	-0.52	2.31e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs684232	0.602	rs379998	chr17:556884	A/G	cg15660573	chr17:549704	VPS53	-0.88	-18.38	-0.67	7.1e-56	Prostate cancer;
LUAD	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg08999081	chr20:33150536	PIGU	0.63	14.0	0.56	7.58e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg21918786	chr6:109611834	NA	-0.56	-10.51	-0.46	4.04e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg26597838	chr10:835615	NA	0.84	13.03	0.54	7.36e-33	Eosinophil percentage of granulocytes;
LUAD	cis	rs2932538	0.922	rs9429694	chr1:113158289	G/A	cg22162597	chr1:113214053	CAPZA1	0.47	7.1	0.33	5.34e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg05665937	chr4:1216051	CTBP1	0.42	7.76	0.35	6.52e-14	Obesity-related traits;
LUAD	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.56	-0.3	1.56e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg20203395	chr5:56204925	C5orf35	-0.82	-11.58	-0.49	4.04e-27	Initial pursuit acceleration;
LUAD	cis	rs72949976	0.606	rs2178756	chr2:214031423	A/G	cg08319019	chr2:214017104	IKZF2	0.53	8.0	0.36	1.24e-14	Lung cancer;Squamous cell lung carcinoma;
LUAD	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg20587970	chr11:113659929	NA	-1.21	-18.1	-0.66	1.21e-54	Hip circumference adjusted for BMI;
LUAD	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-21.34	-0.72	3.88e-69	Height;
LUAD	trans	rs1941687	0.797	rs6507071	chr18:31393333	C/T	cg27147174	chr7:100797783	AP1S1	-0.5	-8.32	-0.38	1.26e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg13319975	chr6:146136371	FBXO30	-0.6	-10.09	-0.44	1.38e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13095912	1.000	rs6784948	chr3:185342787	C/T	cg11274856	chr3:185301563	NA	0.38	7.59	0.35	2.03e-13	Systolic blood pressure;
LUAD	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	8.09	0.37	6.21e-15	Platelet count;
LUAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.58e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg04995722	chr7:26192034	NFE2L3	-0.41	-7.2	-0.33	2.84e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg16314058	chr1:43312353	ZNF691	-0.66	-6.88	-0.32	2.18e-11	Type 2 diabetes;
LUAD	cis	rs7520050	0.898	rs34175029	chr1:46483871	C/T	cg06784218	chr1:46089804	CCDC17	-0.3	-6.4	-0.3	4.02e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg10792982	chr14:105748885	BRF1	0.43	9.38	0.42	3.95e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg26597838	chr10:835615	NA	1.02	15.92	0.61	4.62e-45	Eosinophil percentage of granulocytes;
LUAD	cis	rs7625357	0.964	rs10513679	chr3:169353184	C/T	cg14572252	chr3:169309425	MECOM	-0.39	-6.44	-0.3	3.19e-10	Childhood and early adolescence aggressive behavior;
LUAD	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-8.78	-0.39	3.98e-17	Gut microbiome composition (summer);
LUAD	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg02891314	chr5:179741120	GFPT2	-0.69	-11.23	-0.48	8.93e-26	Height;
LUAD	cis	rs3106136	0.527	rs4693376	chr4:95157240	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.04	-0.4	5.65e-18	Capecitabine sensitivity;
LUAD	cis	rs240764	0.631	rs9322174	chr6:101204193	G/C	cg09795085	chr6:101329169	ASCC3	-0.42	-7.4	-0.34	7.59e-13	Neuroticism;
LUAD	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg20503657	chr10:835505	NA	0.64	9.04	0.4	5.83e-18	Eosinophil percentage of granulocytes;
LUAD	cis	rs11756438	0.572	rs1771756	chr6:119018502	C/T	cg21191810	chr6:118973309	C6orf204	0.49	9.58	0.42	8.07e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10504073	0.647	rs62507252	chr8:50028795	C/G	cg00325661	chr8:49890786	NA	0.44	9.52	0.42	1.32e-19	Blood metabolite ratios;
LUAD	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-8.23	-0.37	2.3e-15	Alzheimer's disease (late onset);
LUAD	cis	rs752092	0.855	rs7171515	chr15:101769618	C/T	cg19997662	chr15:101784653	CHSY1	-0.48	-8.85	-0.4	2.39e-17	Corneal structure;
LUAD	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.3	-7.26	-0.33	1.87e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg05182265	chr7:156933206	UBE3C	-0.81	-17.53	-0.65	4.11e-52	Body mass index;
LUAD	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg05182265	chr7:156933206	UBE3C	-0.78	-15.96	-0.61	3.32e-45	Body mass index;
LUAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg22963979	chr7:1858916	MAD1L1	0.42	7.25	0.33	1.95e-12	Schizophrenia;
LUAD	cis	rs7737355	0.812	rs798413	chr5:130696586	C/T	cg06307176	chr5:131281290	NA	0.37	6.37	0.3	5.08e-10	Life satisfaction;
LUAD	cis	rs3106136	0.967	rs2306802	chr4:95186055	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.1	-0.33	5.31e-12	Capecitabine sensitivity;
LUAD	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg13319975	chr6:146136371	FBXO30	0.64	10.94	0.47	1.06e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.61	10.46	0.45	6.03e-23	Cognitive ability;
LUAD	cis	rs1595825	0.891	rs4422151	chr2:198544183	A/T	cg00982548	chr2:198649783	BOLL	-0.63	-9.12	-0.41	3.06e-18	Ulcerative colitis;
LUAD	cis	rs11958404	0.932	rs72816563	chr5:157427447	C/T	cg05962755	chr5:157440814	NA	0.62	8.99	0.4	8.18e-18	IgG glycosylation;
LUAD	cis	rs427941	0.703	rs201458	chr7:101741439	T/C	cg06246474	chr7:101738831	CUX1	0.41	7.29	0.33	1.57e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg27170947	chr2:26402098	FAM59B	-0.78	-11.73	-0.5	1.05e-27	Gut microbiome composition (summer);
LUAD	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg07741184	chr6:167504864	NA	0.29	7.02	0.32	8.74e-12	Crohn's disease;
LUAD	cis	rs11098699	0.784	rs1048476	chr4:124239803	A/G	cg09941581	chr4:124220074	SPATA5	0.44	7.13	0.33	4.36e-12	Mosquito bite size;
LUAD	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg01324343	chr3:183735012	ABCC5	-0.63	-11.86	-0.5	3.38e-28	Anterior chamber depth;
LUAD	cis	rs41271473	0.526	rs2182202	chr1:228733959	G/C	cg16512390	chr1:228756714	NA	0.69	9.15	0.41	2.47e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	7.95	0.36	1.68e-14	Rheumatoid arthritis;
LUAD	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27297192	chr10:134578999	INPP5A	0.34	6.37	0.3	4.8e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-6.72	-0.31	6.01e-11	Tonsillectomy;
LUAD	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg21963583	chr11:68658836	MRPL21	-0.42	-7.27	-0.33	1.74e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.45	-7.97	-0.36	1.53e-14	Alzheimer's disease (late onset);
LUAD	cis	rs7520050	0.807	rs4353138	chr1:46219803	C/T	cg06784218	chr1:46089804	CCDC17	-0.34	-7.38	-0.34	8.45e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg20503657	chr10:835505	NA	0.82	11.12	0.48	2.19e-25	Eosinophil percentage of granulocytes;
LUAD	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.7	0.31	6.87e-11	Joint mobility (Beighton score);
LUAD	cis	rs1003719	0.715	rs2835642	chr21:38539066	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.43	-0.38	5.44e-16	Eye color traits;
LUAD	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg04287289	chr16:89883240	FANCA	0.46	7.42	0.34	6.59e-13	Vitiligo;
LUAD	cis	rs2455601	0.638	rs2568092	chr11:8987438	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.42	7.73	0.35	8.02e-14	Schizophrenia;
LUAD	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2274273	0.623	rs1187881	chr14:55489197	G/A	cg04306507	chr14:55594613	LGALS3	-0.34	-6.97	-0.32	1.2e-11	Protein biomarker;
LUAD	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg01689657	chr7:91764605	CYP51A1	0.33	8.35	0.38	9.91e-16	Breast cancer;
LUAD	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg04772025	chr11:68637568	NA	0.57	8.96	0.4	1.05e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg18827107	chr12:86230957	RASSF9	-0.7	-12.79	-0.53	6.99e-32	Major depressive disorder;
LUAD	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg01416388	chr22:39784598	NA	-0.51	-8.9	-0.4	1.66e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	trans	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg03886242	chr7:26192032	NFE2L3	0.36	6.44	0.3	3.23e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg22852734	chr6:133119734	C6orf192	0.96	7.23	0.33	2.32e-12	Type 2 diabetes nephropathy;
LUAD	cis	rs6087990	0.735	rs6058891	chr20:31386347	T/C	cg13636640	chr20:31349939	DNMT3B	0.73	13.1	0.54	3.61e-33	Ulcerative colitis;
LUAD	cis	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg27411982	chr8:10470053	RP1L1	0.38	7.06	0.32	7.08e-12	Morning vs. evening chronotype;
LUAD	cis	rs10129255	0.518	rs12590732	chr14:107187851	C/T	cg23076370	chr14:107095027	NA	0.43	8.53	0.38	2.7e-16	Kawasaki disease;
LUAD	cis	rs4680	1.000	rs165656	chr22:19948863	C/G	cg22546130	chr22:19950026	COMT	-0.31	-6.43	-0.3	3.39e-10	Blood metabolite levels;
LUAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00149659	chr3:10157352	C3orf10	0.61	8.41	0.38	6.45e-16	Alzheimer's disease;
LUAD	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg17063962	chr7:91808500	NA	-0.66	-11.36	-0.48	2.72e-26	Breast cancer;
LUAD	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.41	8.03	0.36	9.64e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs760794	0.577	rs7752808	chr6:19792896	C/T	cg02682789	chr6:19804855	NA	0.42	6.61	0.31	1.14e-10	Endometriosis;
LUAD	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg11901034	chr3:128598214	ACAD9	-0.5	-7.6	-0.35	1.98e-13	IgG glycosylation;
LUAD	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg03929089	chr4:120376271	NA	0.54	6.94	0.32	1.47e-11	Axial length;
LUAD	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg09455208	chr3:40491958	NA	0.51	10.8	0.47	3.44e-24	Renal cell carcinoma;
LUAD	cis	rs76878669	0.561	rs56321771	chr11:66161072	C/T	cg18002602	chr11:66138449	SLC29A2	0.48	10.35	0.45	1.6400000000000001e-22	Educational attainment (years of education);
LUAD	cis	rs2992756	0.663	rs1360915	chr1:18801804	T/C	cg24076588	chr1:18808559	KLHDC7A	-0.46	-7.41	-0.34	6.85e-13	Breast cancer;
LUAD	cis	rs7107174	1.000	rs72931639	chr11:78036703	C/T	cg19901956	chr11:77921274	USP35	-0.5	-6.42	-0.3	3.64e-10	Testicular germ cell tumor;
LUAD	cis	rs2131877	0.956	rs955825	chr3:194870922	T/C	cg19760965	chr3:194868843	C3orf21	0.4	6.59	0.3	1.34e-10	Non-small cell lung cancer;
LUAD	trans	rs11039798	0.698	rs6485805	chr11:48101723	C/T	cg03929089	chr4:120376271	NA	0.62	6.58	0.3	1.43e-10	Axial length;
LUAD	trans	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg20587970	chr11:113659929	NA	-0.71	-10.9	-0.47	1.51e-24	Height;
LUAD	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.52	0.3	2.05e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg20744362	chr22:50050164	C22orf34	0.34	6.38	0.3	4.76e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.11	-0.33	4.91e-12	Total body bone mineral density;
LUAD	cis	rs9296092	0.538	rs62407567	chr6:33537213	A/G	cg13560919	chr6:33536144	NA	-0.87	-14.31	-0.57	3.65e-38	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg27068330	chr11:65405492	SIPA1	-0.75	-11.33	-0.48	3.66e-26	Acne (severe);
LUAD	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg03037974	chr15:76606532	NA	0.38	8.06	0.36	7.95e-15	Blood metabolite levels;
LUAD	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg24558204	chr6:135376177	HBS1L	0.43	7.68	0.35	1.15e-13	Red blood cell count;
LUAD	cis	rs60871478	1.000	rs62432223	chr7:787959	A/G	cg05535760	chr7:792225	HEATR2	0.87	11.24	0.48	7.85e-26	Cerebrospinal P-tau181p levels;
LUAD	cis	rs2227564	0.678	rs2242257	chr10:75597605	A/G	cg00564723	chr10:75632066	CAMK2G	0.32	6.62	0.31	1.09e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg10518543	chr12:38710700	ALG10B	0.42	6.42	0.3	3.68e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.67	10.89	0.47	1.7e-24	Height;
LUAD	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg05340658	chr4:99064831	C4orf37	0.54	9.14	0.41	2.7e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.58	-10.03	-0.44	2.29e-21	Intelligence (multi-trait analysis);
LUAD	trans	rs12200782	1.000	rs12205909	chr6:26630999	G/A	cg08851530	chr6:28072375	NA	0.72	6.56	0.3	1.53e-10	Small cell lung carcinoma;
LUAD	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg01849466	chr14:104193079	ZFYVE21	0.45	7.55	0.34	2.62e-13	Body mass index;
LUAD	cis	rs62238980	0.614	rs79173736	chr22:32379966	T/C	cg02631450	chr22:32366979	NA	0.79	6.46	0.3	2.9e-10	Childhood ear infection;
LUAD	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg18016565	chr1:150552671	MCL1	0.43	7.9	0.36	2.45e-14	Tonsillectomy;
LUAD	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg13402656	chr8:1511478	DLGAP2	-0.59	-11.3	-0.48	4.5e-26	Lung cancer;
LUAD	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg22004693	chr7:99632812	ZKSCAN1	0.48	7.39	0.34	7.99e-13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg05805236	chr11:65401703	PCNXL3	-0.59	-9.41	-0.42	3.1e-19	Acne (severe);
LUAD	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-7.9	-0.36	2.52e-14	Total cholesterol levels;
LUAD	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.41	6.9	0.32	1.86e-11	Total body bone mineral density;
LUAD	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg02079420	chr8:82753780	SNX16	-0.41	-8.33	-0.38	1.17e-15	Diastolic blood pressure;
LUAD	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg24112000	chr20:60950667	NA	0.63	9.41	0.42	3.26e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg05368731	chr17:41323189	NBR1	0.83	16.4	0.62	3.96e-47	Menopause (age at onset);
LUAD	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg23887609	chr12:130822674	PIWIL1	0.41	6.92	0.32	1.68e-11	Menopause (age at onset);
LUAD	trans	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg24644049	chr4:85504048	CDS1	0.88	7.16	0.33	3.55e-12	Skin colour saturation;
LUAD	cis	rs9739070	1	rs9739070	chr12:123771032	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.4	-0.3	4.16e-10	Allergy;
LUAD	cis	rs2839186	0.584	rs2032111	chr21:47904569	G/A	cg13012494	chr21:47604986	C21orf56	0.43	6.47	0.3	2.67e-10	Testicular germ cell tumor;
LUAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14159672	chr1:205819179	PM20D1	0.92	20.97	0.71	1.87e-67	Menarche (age at onset);
LUAD	cis	rs6761276	0.868	rs12468224	chr2:113834434	G/C	cg10479672	chr2:113810641	IL1F8	-0.38	-7.72	-0.35	8.74e-14	Protein quantitative trait loci;
LUAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	cis	rs62400317	0.859	rs12153922	chr6:45256159	T/C	cg18551225	chr6:44695536	NA	-0.53	-8.38	-0.38	7.7e-16	Total body bone mineral density;
LUAD	cis	rs9399401	0.710	rs12197866	chr6:142706063	C/T	cg03128060	chr6:142623767	GPR126	0.52	10.33	0.45	1.82e-22	Chronic obstructive pulmonary disease;
LUAD	cis	rs6445967	0.554	rs4364180	chr3:58452639	C/T	cg13750441	chr3:58318267	PXK	-0.32	-6.48	-0.3	2.5e-10	Platelet count;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg00116463	chr17:19266443	B9D1	-0.41	-6.56	-0.3	1.58e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg12935359	chr14:103987150	CKB	-0.48	-7.44	-0.34	5.82e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg03929089	chr4:120376271	NA	0.7	11.02	0.47	5.2e-25	Coronary artery disease;
LUAD	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg14343924	chr8:8086146	FLJ10661	0.43	6.74	0.31	5.3e-11	Neuroticism;
LUAD	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18099408	chr3:52552593	STAB1	-0.46	-8.18	-0.37	3.46e-15	Bipolar disorder;
LUAD	cis	rs1044826	0.642	rs295473	chr3:139215585	T/C	cg00490450	chr3:139108681	COPB2	0.4	6.42	0.3	3.59e-10	Obesity-related traits;
LUAD	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg19717773	chr7:2847554	GNA12	-0.46	-8.21	-0.37	2.75e-15	Height;
LUAD	cis	rs72928364	0.858	rs16843198	chr3:100783075	A/C	cg10123952	chr3:100791384	NA	-0.63	-7.35	-0.34	1.03e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg21862992	chr11:68658383	NA	0.56	10.14	0.44	9.33e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg27170947	chr2:26402098	FAM59B	-0.62	-8.93	-0.4	1.32e-17	Gut microbiome composition (summer);
LUAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg03188948	chr7:1209495	NA	0.38	6.38	0.3	4.74e-10	Longevity;Endometriosis;
LUAD	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg14583973	chr4:3374767	RGS12	0.29	7.33	0.34	1.14e-12	Serum sulfate level;
LUAD	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19346786	chr7:2764209	NA	-0.55	-11.88	-0.5	2.8e-28	Height;
LUAD	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg04772025	chr11:68637568	NA	0.54	8.42	0.38	6e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg03233332	chr7:66118400	NA	0.47	6.79	0.31	3.72e-11	Aortic root size;
LUAD	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg24578937	chr1:2090814	PRKCZ	0.55	10.6	0.46	1.91e-23	Coronary artery disease;
LUAD	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg21984481	chr17:79567631	NPLOC4	-0.66	-15.59	-0.6	1.31e-43	Eye color traits;
LUAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg13047869	chr3:10149882	C3orf24	0.64	11.02	0.47	5.16e-25	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg24642844	chr7:1081250	C7orf50	-0.84	-12.97	-0.53	1.22e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs300703	0.872	rs300752	chr2:209292	A/G	cg24565620	chr2:194026	NA	-0.52	-6.9	-0.32	1.93e-11	Blood protein levels;
LUAD	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7771547	0.603	rs7743396	chr6:36579252	C/T	cg02952361	chr6:36355661	ETV7	0.47	6.42	0.3	3.63e-10	Platelet distribution width;
LUAD	cis	rs250677	0.522	rs10040798	chr5:148367324	A/G	cg18129178	chr5:148520854	ABLIM3	0.53	8.02	0.36	1.06e-14	Breast cancer;
LUAD	trans	rs11088226	0.846	rs2154500	chr21:33926391	T/C	cg09050820	chr6:167586206	TCP10L2	0.65	9.79	0.43	1.52e-20	Gastritis;
LUAD	cis	rs7180079	1.000	rs1388216	chr15:64500148	A/G	cg08069370	chr15:64387884	SNX1	-0.51	-6.58	-0.3	1.37e-10	Monocyte count;
LUAD	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg25985355	chr7:65971099	NA	-0.39	-7.11	-0.33	4.92e-12	Aortic root size;
LUAD	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg19622623	chr12:86230825	RASSF9	-0.43	-7.65	-0.35	1.37e-13	Major depressive disorder;
LUAD	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.27	-0.45	2.97e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg26384229	chr12:38710491	ALG10B	-0.38	-6.52	-0.3	2.03e-10	Heart rate;
LUAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06873352	chr17:61820015	STRADA	0.83	18.57	0.67	9.95e-57	Prudent dietary pattern;
LUAD	cis	rs758324	0.773	rs11951407	chr5:131142661	T/C	cg06307176	chr5:131281290	NA	0.44	7.31	0.33	1.36e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1595825	0.891	rs73061068	chr2:198908439	A/G	cg00982548	chr2:198649783	BOLL	-0.66	-9.15	-0.41	2.36e-18	Ulcerative colitis;
LUAD	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10802521	chr3:52805072	NEK4	-0.56	-9.54	-0.42	1.13e-19	Bipolar disorder;
LUAD	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg21475434	chr5:93447410	FAM172A	0.73	8.74	0.39	5.34e-17	Diabetic retinopathy;
LUAD	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg03714773	chr7:91764589	CYP51A1	0.29	6.72	0.31	5.89e-11	Breast cancer;
LUAD	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg00898013	chr13:113819073	PROZ	0.73	13.17	0.54	2e-33	Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6906287	0.669	rs2184402	chr6:118935341	T/C	cg18833306	chr6:118973337	C6orf204	0.49	8.49	0.38	3.42e-16	Electrocardiographic conduction measures;
LUAD	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg26898376	chr11:64110657	CCDC88B	0.39	7.13	0.33	4.39e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	trans	rs7395662	0.963	rs11039870	chr11:48626478	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	1.99e-12	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4969178	0.965	rs8071884	chr17:76398058	C/G	cg05887092	chr17:76393375	PGS1	0.4	6.91	0.32	1.77e-11	HDL cholesterol levels;
LUAD	cis	rs4268898	0.529	rs4426488	chr2:24372815	A/G	cg06627628	chr2:24431161	ITSN2	0.44	7.51	0.34	3.47e-13	Asthma;
LUAD	trans	rs877282	1.000	rs11253366	chr10:773386	C/T	cg22713356	chr15:30763199	NA	1.17	16.72	0.63	1.61e-48	Uric acid levels;
LUAD	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27297192	chr10:134578999	INPP5A	0.38	6.74	0.31	5.07e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1043515	0.607	rs4795318	chr17:36949053	C/T	cg09592244	chr17:37024020	NA	0.39	6.66	0.31	8.39e-11	Height;
LUAD	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg19318889	chr4:1322082	MAEA	0.44	7.08	0.33	6.19e-12	Obesity-related traits;
LUAD	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg15128208	chr22:42549153	NA	-0.42	-8.74	-0.39	5.67e-17	Cognitive function;
LUAD	cis	rs7827545	1.000	rs4909910	chr8:135565201	T/C	cg17885191	chr8:135476712	NA	0.5	7.97	0.36	1.53e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg18132916	chr6:79620363	NA	-0.46	-7.95	-0.36	1.68e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg07708487	chr16:89387014	ANKRD11	-0.33	-6.74	-0.31	5.15e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg13271783	chr10:134563150	INPP5A	-0.4	-7.19	-0.33	3.01e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs736801	0.704	rs56399423	chr5:131672657	T/C	cg07538946	chr5:131705188	SLC22A5	0.52	8.17	0.37	3.71e-15	Breast cancer;Mosquito bite size;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11767392	chr11:71814388	LRTOMT;C11orf59	-0.57	-6.82	-0.31	3.19e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg20933634	chr6:27740509	NA	0.51	7.75	0.35	6.88e-14	Parkinson's disease;
LUAD	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg13870426	chr17:30244630	NA	-0.55	-6.49	-0.3	2.35e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs897984	0.770	rs12930657	chr16:30931968	C/T	cg02466173	chr16:30829666	NA	0.67	12.53	0.52	7.66e-31	Dementia with Lewy bodies;
LUAD	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg11584989	chr19:19387371	SF4	0.58	9.04	0.4	5.64e-18	Bipolar disorder;
LUAD	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg25237894	chr2:233734115	C2orf82	-0.57	-11.18	-0.48	1.38e-25	Coronary artery disease;
LUAD	cis	rs7493	0.851	rs11770903	chr7:95026327	A/G	cg21856205	chr7:94953877	PON1	-0.55	-7.87	-0.36	2.95e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22857025	chr5:266934	NA	-0.99	-14.49	-0.58	6.69e-39	Breast cancer;
LUAD	cis	rs1160297	0.609	rs10168840	chr2:53084498	A/G	cg07782112	chr2:53107842	NA	0.35	7.37	0.34	9.24e-13	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg05896524	chr21:47604654	C21orf56	0.55	9.21	0.41	1.5e-18	Testicular germ cell tumor;
LUAD	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg26022315	chr17:47021804	SNF8	0.41	7.3	0.33	1.47e-12	Type 2 diabetes;
LUAD	cis	rs28595532	1.000	rs11931194	chr4:119631160	C/T	cg21605333	chr4:119757512	SEC24D	0.81	7.53	0.34	3.16e-13	Cannabis dependence symptom count;
LUAD	cis	rs2224391	0.554	rs928170	chr6:5255154	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-8.79	-0.39	3.83e-17	Height;
LUAD	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg13856295	chr9:139396418	NOTCH1	-0.43	-6.8	-0.31	3.66e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg11833968	chr6:79620685	NA	-0.44	-8.18	-0.37	3.41e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs75229567	0.717	rs77874289	chr12:70234203	A/G	cg10114359	chr12:70132523	RAB3IP	0.88	7.26	0.33	1.93e-12	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	trans	rs7395662	1.000	rs12421879	chr11:48689978	A/T	cg15704280	chr7:45808275	SEPT13	-0.41	-6.35	-0.3	5.43e-10	HDL cholesterol;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg08811588	chr7:100473311	SRRT	-0.48	-6.71	-0.31	6.34e-11	Testicular germ cell tumor;
LUAD	trans	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	12.65	0.52	2.59e-31	Exhaled nitric oxide output;
LUAD	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg23719950	chr11:63933701	MACROD1	-0.55	-6.66	-0.31	8.76e-11	Mean platelet volume;
LUAD	cis	rs2249625	0.844	rs2463749	chr6:72918148	C/G	cg18830697	chr6:72922368	RIMS1	0.37	6.89	0.32	2.06e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg18016565	chr1:150552671	MCL1	0.37	6.55	0.3	1.71e-10	Melanoma;
LUAD	cis	rs3772130	1.000	rs3772128	chr3:121345094	G/T	cg20356878	chr3:121714668	ILDR1	0.47	7.32	0.34	1.24e-12	Cognitive performance;
LUAD	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg25427524	chr10:38739819	LOC399744	0.56	9.79	0.43	1.53e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08280861	chr8:58055591	NA	0.77	9.56	0.42	9.62e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg12483005	chr1:23474871	LUZP1	0.52	9.14	0.41	2.62e-18	Height;
LUAD	cis	rs17401966	1.000	rs12757820	chr1:10266671	A/T	cg15208524	chr1:10270712	KIF1B	0.54	7.89	0.36	2.67e-14	Hepatocellular carcinoma;
LUAD	cis	rs7809615	0.901	rs10261661	chr7:99189722	A/T	cg12290671	chr7:99195819	NA	-0.66	-7.44	-0.34	5.78e-13	Blood metabolite ratios;
LUAD	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg13319975	chr6:146136371	FBXO30	-0.6	-10.03	-0.44	2.28e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7975161	0.608	rs10861169	chr12:104610640	C/T	cg04063896	chr12:104565784	NA	-0.36	-6.5	-0.3	2.21e-10	Toenail selenium levels;
LUAD	cis	rs4691139	1.000	rs6821283	chr4:165901645	T/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.46	-9.01	-0.4	7.32e-18	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg22482690	chr17:47019901	SNF8	0.45	8.58	0.38	1.86e-16	Type 2 diabetes;
LUAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg22907277	chr7:1156413	C7orf50	0.79	12.09	0.51	4.14e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg13902645	chr11:5959945	NA	-0.59	-10.14	-0.44	8.79e-22	DNA methylation (variation);
LUAD	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg05283184	chr6:79620031	NA	-0.61	-12.47	-0.52	1.28e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs2658782	1.000	rs2605585	chr11:93171862	C/T	cg15737290	chr11:93063684	CCDC67	0.51	6.9	0.32	1.97e-11	Pulmonary function decline;
LUAD	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg05966235	chr16:28915196	ATP2A1	-0.5	-7.96	-0.36	1.58e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg17724175	chr1:150552817	MCL1	0.41	9.81	0.43	1.32e-20	Tonsillectomy;
LUAD	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.5	-7.92	-0.36	2.18e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg22535103	chr8:58192502	C8orf71	0.7	8.99	0.4	8.28e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg05535760	chr7:792225	HEATR2	0.87	11.58	0.49	4.12e-27	Cerebrospinal P-tau181p levels;
LUAD	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg07217954	chr7:1067459	C7orf50	-0.38	-6.8	-0.31	3.57e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs9394152	0.845	rs769051	chr6:33473894	T/G	cg13560919	chr6:33536144	NA	0.51	8.63	0.39	1.23e-16	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg04025307	chr7:1156635	C7orf50	0.51	7.14	0.33	4.14e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs7665090	1.000	rs2866407	chr4:103554108	C/G	cg07973026	chr4:103553119	MANBA	0.49	8.67	0.39	8.99e-17	Primary biliary cholangitis;
LUAD	cis	rs61008539	1.000	rs61008539	chr7:858506	C/G	cg07138768	chr7:917805	C7orf20	0.38	7.49	0.34	4.12e-13	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg11738485	chr19:12877000	HOOK2	0.44	7.15	0.33	3.83e-12	Bipolar disorder;
LUAD	cis	rs11696501	0.539	rs6073849	chr20:44299385	A/T	cg11783356	chr20:44313418	WFDC10B	-0.48	-8.07	-0.37	7.47e-15	Brain structure;
LUAD	cis	rs77106637	0.860	rs7129793	chr11:72455885	C/T	cg03713592	chr11:72463424	ARAP1	0.91	11.11	0.48	2.36e-25	Type 2 diabetes;
LUAD	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg05590025	chr7:65112418	INTS4L2	-0.56	-6.52	-0.3	2.06e-10	Diabetic kidney disease;
LUAD	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg09263875	chr16:632152	PIGQ	0.78	15.82	0.61	1.31e-44	Height;
LUAD	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg17031739	chr1:67600172	NA	0.46	8.47	0.38	3.97e-16	Psoriasis;
LUAD	cis	rs1505368	0.532	rs2888093	chr2:213328348	G/A	cg16329650	chr2:213403929	ERBB4	0.46	7.56	0.34	2.57e-13	Symmetrical dimethylarginine levels;
LUAD	cis	rs1595825	0.891	rs73056823	chr2:198769788	T/C	cg11031976	chr2:198649780	BOLL	-0.48	-7.19	-0.33	2.89e-12	Ulcerative colitis;
LUAD	cis	rs921968	0.613	rs1427445	chr2:219555573	C/A	cg02176678	chr2:219576539	TTLL4	-0.58	-11.56	-0.49	4.87e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	24.64	0.77	8.45e-84	Chronic sinus infection;
LUAD	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.44	0.57	1.08e-38	Schizophrenia;
LUAD	cis	rs12545109	0.679	rs1973628	chr8:57429360	T/C	cg21220214	chr8:57350948	NA	-0.65	-7.55	-0.34	2.64e-13	Obesity-related traits;
LUAD	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg16205897	chr5:131564050	P4HA2	-0.3	-6.55	-0.3	1.66e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs1215050	0.682	rs6839343	chr4:98839732	G/A	cg05340658	chr4:99064831	C4orf37	0.45	6.86	0.32	2.5e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg17178900	chr1:205818956	PM20D1	0.49	9.16	0.41	2.27e-18	Menarche (age at onset);
LUAD	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg26343298	chr8:95960752	TP53INP1	0.38	8.02	0.36	1.08e-14	Type 2 diabetes;
LUAD	trans	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg13301069	chr11:6624877	ILK;RRP8	-0.38	-6.78	-0.31	3.95e-11	Schizophrenia;
LUAD	cis	rs6076065	0.541	rs8118688	chr20:23320850	G/A	cg11657817	chr20:23433608	CST11	0.49	8.91	0.4	1.59e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg17177755	chr1:15930204	NA	0.46	7.43	0.34	5.89e-13	Systolic blood pressure;
LUAD	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg13385794	chr1:248469461	NA	0.27	7.29	0.33	1.5e-12	Common traits (Other);
LUAD	cis	rs9560113	1.000	rs9555811	chr13:112181532	A/C	cg14154082	chr13:112174009	NA	0.35	6.56	0.3	1.6e-10	Menarche (age at onset);
LUAD	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg15208524	chr1:10270712	KIF1B	-0.46	-7.07	-0.33	6.51e-12	Hepatocellular carcinoma;
LUAD	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg22875332	chr1:76189707	ACADM	0.88	16.59	0.63	5.78e-48	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg05110241	chr16:68378359	PRMT7	-0.66	-7.47	-0.34	4.68e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg16988262	chr1:15930761	NA	0.43	7.15	0.33	3.81e-12	Systolic blood pressure;
LUAD	cis	rs2274273	0.840	rs17674463	chr14:55824863	A/T	cg04306507	chr14:55594613	LGALS3	0.44	9.11	0.4	3.39e-18	Protein biomarker;
LUAD	trans	rs7181230	0.885	rs2412478	chr15:40361172	C/T	cg22705835	chr10:65332833	REEP3	-0.37	-7.0	-0.32	1.03e-11	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs4481887	0.893	rs28787378	chr1:248504447	C/T	cg00666640	chr1:248458726	OR2T12	0.28	7.06	0.32	6.67e-12	Common traits (Other);
LUAD	cis	rs7192380	0.651	rs11643240	chr16:69635916	A/G	cg26679644	chr16:69762563	NA	0.41	6.62	0.31	1.08e-10	Sjögren's syndrome;
LUAD	cis	rs73110464	0.505	rs2638503	chr12:53307369	C/G	cg14581129	chr12:53358946	NA	-0.41	-6.74	-0.31	5.22e-11	Cancer (pleiotropy);
LUAD	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg06618935	chr21:46677482	NA	-0.49	-9.88	-0.43	7.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg22166914	chr1:53195759	ZYG11B	-0.51	-8.73	-0.39	6.1e-17	Monocyte count;
LUAD	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg06387496	chr7:2775674	GNA12	-0.4	-6.77	-0.31	4.23e-11	Height;
LUAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03452623	chr4:187889614	NA	-0.82	-16.56	-0.63	7.92e-48	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg27446573	chr6:127587934	RNF146	0.44	6.57	0.3	1.5e-10	Breast cancer;
LUAD	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21659725	chr3:3221576	CRBN	-0.85	-17.93	-0.66	7.21e-54	Intelligence (multi-trait analysis);
LUAD	cis	rs686320	1.000	rs2957267	chr11:65235792	C/T	cg21890820	chr11:65308645	LTBP3	0.81	8.49	0.38	3.53e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs2985684	1.000	rs1952012	chr14:50098896	T/A	cg04989706	chr14:50066350	PPIL5	-0.47	-6.9	-0.32	1.93e-11	Carotid intima media thickness;
LUAD	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg24829409	chr8:58192753	C8orf71	-0.6	-8.99	-0.4	8.57e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg07636037	chr3:49044803	WDR6	0.46	7.65	0.35	1.38e-13	Menarche (age at onset);
LUAD	cis	rs877282	0.945	rs12776447	chr10:790625	A/G	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	cis	rs1395	0.626	rs72817537	chr2:27497549	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.52	8.62	0.39	1.34e-16	Blood metabolite levels;
LUAD	cis	rs72928364	1.000	rs36165056	chr3:100615815	C/T	cg10123952	chr3:100791384	NA	0.6	7.03	0.32	8.33e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6961069	0.745	rs3211839	chr7:80280462	G/A	cg04458919	chr7:80252533	CD36	-0.36	-6.89	-0.32	2.03e-11	Platelet count;
LUAD	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg03929089	chr4:120376271	NA	0.57	7.13	0.33	4.42e-12	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg10053473	chr17:62856997	LRRC37A3	-0.67	-9.42	-0.42	2.95e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.98	23.17	0.75	2.76e-77	Birth weight;
LUAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg10729496	chr3:10149963	C3orf24	0.65	9.55	0.42	1.1e-19	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.33e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3087591	0.887	rs12150521	chr17:29595108	C/T	cg24425628	chr17:29625626	OMG;NF1	0.4	6.55	0.3	1.67e-10	Hip circumference;
LUAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg15117754	chr3:10150083	C3orf24	0.42	6.99	0.32	1.07e-11	Alzheimer's disease;
LUAD	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg24558204	chr6:135376177	HBS1L	0.49	8.98	0.4	9.03e-18	Red blood cell count;
LUAD	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg24112000	chr20:60950667	NA	-0.64	-10.59	-0.46	2.18e-23	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg01551176	chr1:28844397	SNHG3-RCC1;RCC1	0.39	6.73	0.31	5.51e-11	Bipolar disorder;
LUAD	cis	rs11696501	0.688	rs6104295	chr20:44326917	C/T	cg11783356	chr20:44313418	WFDC10B	-0.51	-8.38	-0.38	8.12e-16	Brain structure;
LUAD	trans	rs2262909	0.925	rs56073035	chr19:22276298	C/G	cg05197062	chr11:11642011	GALNTL4	0.59	9.06	0.4	5.02e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg06547715	chr2:218990976	CXCR2	0.29	6.91	0.32	1.8e-11	Colorectal cancer;
LUAD	trans	rs2018683	0.624	rs6462119	chr7:29003725	G/C	cg19402173	chr7:128379420	CALU	-0.55	-8.97	-0.4	9.61e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs141670911	1	rs141670911	chr6:26581258	A/T	cg08851530	chr6:28072375	NA	0.74	6.75	0.31	4.87e-11	Small cell lung carcinoma;
LUAD	cis	rs9462027	0.675	rs13206387	chr6:34696792	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.94	-0.4	1.18e-17	Systemic lupus erythematosus;
LUAD	cis	rs2274471	0.582	rs57839907	chr9:5082671	T/A	cg03390472	chr9:5043263	JAK2	-0.56	-8.15	-0.37	4.02e-15	Crohn's disease;
LUAD	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	12.47	0.52	1.34e-30	Monocyte percentage of white cells;
LUAD	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10802521	chr3:52805072	NEK4	-0.62	-11.08	-0.47	3.05e-25	Bipolar disorder;
LUAD	cis	rs807669	0.903	rs2854643	chr22:19189706	T/C	cg24911827	chr22:19170109	CLTCL1	0.45	9.32	0.41	6.65e-19	Metabolite levels;
LUAD	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg15704280	chr7:45808275	SEPT13	-0.9	-17.28	-0.64	5.03e-51	Coronary artery disease;
LUAD	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	15.8	0.61	1.55e-44	Bone mineral density;
LUAD	cis	rs7107174	1.000	rs4945270	chr11:78068216	A/G	cg02023728	chr11:77925099	USP35	0.46	7.08	0.33	6.11e-12	Testicular germ cell tumor;
LUAD	trans	rs28735056	0.967	rs61090726	chr18:77631219	A/G	cg05926928	chr17:57297772	GDPD1	-0.47	-6.49	-0.3	2.45e-10	Schizophrenia;
LUAD	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg11502198	chr6:26597334	ABT1	0.67	11.73	0.5	1.08e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg11584989	chr19:19387371	SF4	0.58	9.3	0.41	7.53e-19	Bipolar disorder;
LUAD	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg07741184	chr6:167504864	NA	0.36	8.24	0.37	2.11e-15	Primary biliary cholangitis;
LUAD	cis	rs514406	0.734	rs581118	chr1:53311324	T/C	cg22166914	chr1:53195759	ZYG11B	0.44	7.15	0.33	3.81e-12	Monocyte count;
LUAD	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg09455208	chr3:40491958	NA	0.55	12.18	0.51	1.83e-29	Renal cell carcinoma;
LUAD	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg11098525	chr4:1320231	MAEA	-0.41	-6.94	-0.32	1.52e-11	Obesity-related traits;
LUAD	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg06028605	chr16:24865363	SLC5A11	0.41	7.18	0.33	3.2e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg06988368	chr1:147142773	ACP6	0.4	6.54	0.3	1.83e-10	Optic cup area;
LUAD	cis	rs3784262	0.631	rs12903724	chr15:58310387	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.33	-0.34	1.18e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs3754214	0.769	rs509345	chr1:150276022	A/G	cg15654264	chr1:150340011	RPRD2	-0.41	-7.83	-0.36	4.02e-14	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg24147428	chr11:65409760	SIPA1	-0.6	-9.09	-0.4	3.94e-18	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg04225089	chr17:73874465	TRIM47	-0.37	-6.63	-0.31	1e-10	Psoriasis;
LUAD	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-7.28	-0.33	1.61e-12	Schizophrenia;
LUAD	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg11822812	chr5:140052017	DND1	-0.37	-6.63	-0.31	1.02e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.97	0.32	1.24e-11	Schizophrenia;
LUAD	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg11707310	chr1:2537719	MMEL1	0.38	8.13	0.37	4.8e-15	Ulcerative colitis;
LUAD	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg17652424	chr22:38574118	PLA2G6	0.28	8.22	0.37	2.48e-15	Cutaneous nevi;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg18691242	chr12:107487714	CRY1	-0.44	-6.44	-0.3	3.31e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg21709803	chr11:61594965	FADS2	-0.39	-7.17	-0.33	3.28e-12	Trans fatty acid levels;
LUAD	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg13319975	chr6:146136371	FBXO30	0.6	10.43	0.45	7.84e-23	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05704196	chr1:21059189	SH2D5	-0.38	-6.42	-0.3	3.68e-10	Cancer;
LUAD	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10899021	0.920	rs10899014	chr11:74325109	A/G	cg25880958	chr11:74394337	NA	-0.62	-8.45	-0.38	4.87e-16	Response to metformin (IC50);
LUAD	cis	rs2742234	0.590	rs2435339	chr10:43642173	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.5	-8.69	-0.39	7.96e-17	Hirschsprung disease;
LUAD	cis	rs7705042	0.865	rs6580229	chr5:141510754	A/G	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.87	-0.32	2.32e-11	Asthma;
LUAD	cis	rs231513	0.954	rs170766	chr17:41963407	C/G	cg26893861	chr17:41843967	DUSP3	-0.54	-6.63	-0.31	1.04e-10	Cognitive function;
LUAD	cis	rs2637266	1.000	rs12251434	chr10:78345468	C/A	cg18941641	chr10:78392320	NA	0.33	6.82	0.31	3.24e-11	Pulmonary function;
LUAD	cis	rs9393692	0.557	rs2393649	chr6:26338538	T/G	cg00631329	chr6:26305371	NA	-0.52	-8.21	-0.37	2.67e-15	Educational attainment;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22314900	chr2:109150331	NA	-0.41	-6.56	-0.3	1.58e-10	Height;
LUAD	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg11871910	chr12:69753446	YEATS4	0.68	11.3	0.48	4.7e-26	Blood protein levels;
LUAD	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg15017067	chr4:17643749	FAM184B	0.34	6.64	0.31	9.46e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs686320	1.000	rs1787666	chr11:65249089	A/C	cg21890820	chr11:65308645	LTBP3	0.72	8.26	0.37	1.85e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs1403694	0.695	rs11927941	chr3:186433046	A/G	cg12454167	chr3:186435060	KNG1	0.52	10.73	0.46	6.44e-24	Blood protein levels;
LUAD	cis	rs6906287	0.625	rs7764272	chr6:118692498	A/C	cg18833306	chr6:118973337	C6orf204	0.52	9.4	0.42	3.57e-19	Electrocardiographic conduction measures;
LUAD	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg12927641	chr6:109611667	NA	-0.52	-9.23	-0.41	1.28e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22307029	chr19:49891270	CCDC155	-0.7	-9.99	-0.44	3.01e-21	Multiple sclerosis;
LUAD	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg05425664	chr17:57184151	TRIM37	-0.42	-7.4	-0.34	7.34e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs6674176	0.569	rs11210935	chr1:44369444	G/A	cg12908607	chr1:44402522	ARTN	-0.46	-8.43	-0.38	5.42e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.48	0.34	4.31e-13	Tonsillectomy;
LUAD	trans	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg18187862	chr3:45730750	SACM1L	0.56	8.78	0.39	4.02e-17	Primary sclerosing cholangitis;
LUAD	cis	rs4356932	1.000	rs6844097	chr4:76950757	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.5	-0.3	2.29e-10	Blood protein levels;
LUAD	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg00603274	chr11:61596626	FADS2	-0.37	-6.52	-0.3	2.06e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.71	-0.46	7.52e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg18105134	chr13:113819100	PROZ	-0.87	-15.14	-0.59	1.1e-41	Platelet distribution width;
LUAD	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg09658497	chr7:2847517	GNA12	-0.44	-7.97	-0.36	1.5e-14	Height;
LUAD	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg18446336	chr7:2847575	GNA12	-0.39	-7.23	-0.33	2.29e-12	Height;
LUAD	cis	rs2455601	0.766	rs1109304	chr11:8955455	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.54	-9.17	-0.41	2.12e-18	Schizophrenia;
LUAD	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg04248312	chr19:17393744	ANKLE1	-1.03	-18.68	-0.67	3.32e-57	Systemic lupus erythematosus;
LUAD	cis	rs6489882	0.867	rs1859332	chr12:113371114	T/C	cg20102336	chr12:113376681	OAS3	-0.61	-9.52	-0.42	1.3e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg06784218	chr1:46089804	CCDC17	0.6	13.33	0.54	4.38e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4372836	0.715	rs66904522	chr2:29080892	A/C	cg09522027	chr2:28974177	PPP1CB	0.67	11.88	0.5	2.82e-28	Body mass index;
LUAD	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg04287289	chr16:89883240	FANCA	0.86	7.47	0.34	4.78e-13	Skin colour saturation;
LUAD	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg05234568	chr11:5960015	NA	-0.56	-10.13	-0.44	9.4e-22	DNA methylation (variation);
LUAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.42	-7.62	-0.35	1.68e-13	Longevity;Endometriosis;
LUAD	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11890956	chr21:40555474	PSMG1	-0.58	-9.48	-0.42	1.83e-19	Cognitive function;
LUAD	cis	rs9581857	0.547	rs7989917	chr13:28071271	G/A	cg22138327	chr13:27999177	GTF3A	0.88	9.64	0.42	5.28e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs5167	0.539	rs4803783	chr19:45470458	G/C	cg09555818	chr19:45449301	APOC2	-0.34	-6.37	-0.3	4.95e-10	Blood protein levels;
LUAD	cis	rs4460629	0.742	rs7548955	chr1:155082298	T/C	cg23973274	chr1:155060172	NA	-0.37	-6.46	-0.3	2.88e-10	Serum magnesium levels;
LUAD	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg04414720	chr1:150670196	GOLPH3L	0.73	13.65	0.55	2.13e-35	Tonsillectomy;
LUAD	cis	rs2050392	0.792	rs684395	chr10:30719112	C/G	cg18806716	chr10:30721971	MAP3K8	-0.55	-10.98	-0.47	7.58e-25	Inflammatory bowel disease;
LUAD	cis	rs2901656	0.677	rs2301455	chr1:172418268	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.53	10.27	0.45	3.18e-22	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg25358565	chr5:93447407	FAM172A	0.62	7.38	0.34	8.29e-13	Diabetic retinopathy;
LUAD	cis	rs2346177	0.519	rs4563285	chr2:46669944	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-8.01	-0.36	1.11e-14	HDL cholesterol;
LUAD	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg15790184	chr11:494944	RNH1	0.57	6.97	0.32	1.19e-11	Body mass index;
LUAD	cis	rs9902453	0.845	rs3102559	chr17:28029723	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.33	0.41	6.1e-19	Coffee consumption (cups per day);
LUAD	cis	rs7512552	0.839	rs7523428	chr1:150430472	G/A	cg15654264	chr1:150340011	RPRD2	0.59	11.47	0.49	1.06e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg11502198	chr6:26597334	ABT1	0.55	9.09	0.4	3.73e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7216064	1.000	rs7224923	chr17:65842265	T/G	cg08758996	chr17:66097529	LOC651250	0.46	6.98	0.32	1.15e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs7107174	1.000	rs7939352	chr11:78003151	G/A	cg19901956	chr11:77921274	USP35	-0.48	-6.66	-0.31	8.44e-11	Testicular germ cell tumor;
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg14668821	chr17:77704760	ENPP7	-0.33	-6.7	-0.31	6.49e-11	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.86	0.53	3.55e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.37	6.51	0.3	2.16e-10	Type 2 diabetes;
LUAD	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg00852783	chr1:26633632	UBXN11	0.4	6.76	0.31	4.48e-11	Obesity-related traits;
LUAD	cis	rs7072216	0.806	rs9804285	chr10:100169472	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-8.42	-0.38	5.88e-16	Metabolite levels;
LUAD	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg11247378	chr22:39784982	NA	-0.72	-12.94	-0.53	1.66e-32	Intelligence (multi-trait analysis);
LUAD	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg12863693	chr15:85201151	NMB	0.43	7.95	0.36	1.75e-14	Schizophrenia;
LUAD	trans	rs6045676	0.958	rs6045666	chr20:1940504	C/T	cg02470959	chr12:132196036	SFRS8	-0.43	-6.71	-0.31	6.25e-11	Aortic root size;
LUAD	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg21153622	chr11:89784906	NA	-0.33	-6.45	-0.3	3.05e-10	Coronary artery disease;
LUAD	cis	rs17539620	0.565	rs61383594	chr6:154841632	A/T	cg20019720	chr6:154832845	CNKSR3	0.63	11.46	0.49	1.17e-26	Lipoprotein (a) levels;
LUAD	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.51	-0.42	1.51e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4280164	0.887	rs12886362	chr14:24791571	A/C	cg07162820	chr14:24837146	NFATC4	-0.34	-6.59	-0.31	1.28e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs4356932	0.935	rs4345214	chr4:76954169	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.52	-0.3	2e-10	Blood protein levels;
LUAD	cis	rs7737355	0.947	rs7720339	chr5:130837134	T/C	cg06307176	chr5:131281290	NA	0.51	8.04	0.36	8.98e-15	Life satisfaction;
LUAD	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.54	-9.04	-0.4	5.77e-18	Electrocardiographic conduction measures;
LUAD	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs6499255	1.000	rs6499255	chr16:69830328	A/G	cg00738113	chr16:70207722	CLEC18C	-0.4	-6.91	-0.32	1.83e-11	IgE levels;
LUAD	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg02375832	chr11:62437615	C11orf48	0.34	7.31	0.33	1.34e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg06064525	chr11:970664	AP2A2	-0.54	-11.18	-0.48	1.32e-25	Alzheimer's disease (late onset);
LUAD	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg20203395	chr5:56204925	C5orf35	-0.83	-11.83	-0.5	4.5e-28	Initial pursuit acceleration;
LUAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.65	-12.07	-0.51	5.21e-29	Longevity;Endometriosis;
LUAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.22	-0.37	2.56e-15	Alzheimer's disease;
LUAD	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg04287289	chr16:89883240	FANCA	0.72	13.25	0.54	9.34e-34	Vitiligo;
LUAD	cis	rs9652601	0.779	rs7186106	chr16:11210831	G/A	cg04616529	chr16:11181986	CLEC16A	0.4	6.93	0.32	1.54e-11	Systemic lupus erythematosus;
LUAD	cis	rs12049351	0.774	rs2295624	chr1:229644157	G/T	cg11742688	chr1:229674241	ABCB10	-0.41	-6.49	-0.3	2.42e-10	Circulating myeloperoxidase levels (plasma);
LUAD	trans	rs11247915	0.600	rs61775118	chr1:26659692	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.38	-6.36	-0.3	5.39e-10	Obesity-related traits;
LUAD	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg09163369	chr1:210001066	C1orf107	0.5	7.19	0.33	3e-12	Orofacial clefts;
LUAD	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg04450456	chr4:17643702	FAM184B	-0.41	-8.06	-0.36	7.76e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg02524346	chr8:600233	NA	0.82	7.64	0.35	1.47e-13	IgG glycosylation;
LUAD	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg27433088	chr4:174089019	GALNT7	0.41	7.69	0.35	1.06e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg07636037	chr3:49044803	WDR6	-0.5	-8.04	-0.36	9.02e-15	Menarche (age at onset);
LUAD	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg08027265	chr7:2291960	NA	-0.4	-6.47	-0.3	2.78e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9595066	0.627	rs4394973	chr13:44753309	G/A	cg04068111	chr13:44716778	NA	0.41	7.33	0.34	1.2e-12	Schizophrenia;
LUAD	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg18944383	chr4:111397179	ENPEP	0.38	7.78	0.35	5.65e-14	Height;
LUAD	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.3	-0.37	1.45e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg24119722	chr22:42347272	LOC339674	-0.28	-6.39	-0.3	4.4e-10	Cognitive function;
LUAD	cis	rs68170813	0.641	rs4730248	chr7:107125939	A/G	cg23024343	chr7:107201750	COG5	0.49	6.89	0.32	1.98e-11	Coronary artery disease;
LUAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.93	-0.43	4.9e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs2625529	0.641	rs2035379	chr15:72293202	C/T	cg16672083	chr15:72433130	SENP8	-0.76	-12.69	-0.53	1.76e-31	Red blood cell count;
LUAD	cis	rs73198271	0.700	rs10090152	chr8:8652104	C/A	cg01851573	chr8:8652454	MFHAS1	0.52	9.31	0.41	6.82e-19	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg14092988	chr3:52407081	DNAH1	0.37	7.47	0.34	4.74e-13	Electroencephalogram traits;
LUAD	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg09367891	chr1:107599246	PRMT6	-0.59	-10.05	-0.44	1.84e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1403694	1.000	rs2651640	chr3:186438393	G/A	cg12454167	chr3:186435060	KNG1	0.43	8.78	0.39	3.99e-17	Blood protein levels;
LUAD	cis	rs17253792	0.822	rs28549152	chr14:56091239	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg01528321	chr10:82214614	TSPAN14	0.46	7.3	0.33	1.48e-12	Post bronchodilator FEV1;
LUAD	cis	rs9372498	0.536	rs9489460	chr6:118925754	C/T	cg18833306	chr6:118973337	C6orf204	-0.53	-7.59	-0.35	2e-13	Diastolic blood pressure;
LUAD	cis	rs4321325	0.733	rs79208542	chr2:127935686	G/C	cg11380483	chr2:127933992	NA	0.5	6.62	0.31	1.11e-10	Protein C levels;
LUAD	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg13012494	chr21:47604986	C21orf56	0.46	7.64	0.35	1.48e-13	Testicular germ cell tumor;
LUAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg18621852	chr3:10150065	C3orf24	0.46	7.13	0.33	4.38e-12	Alzheimer's disease;
LUAD	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.13	0.37	4.76e-15	Menopause (age at onset);
LUAD	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg07570687	chr10:102243282	WNT8B	0.41	6.4	0.3	4.12e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs55788414	0.932	rs12103403	chr16:81185904	C/A	cg06400318	chr16:81190750	PKD1L2	-0.6	-8.15	-0.37	4.25e-15	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22442454	chr1:209979470	IRF6	0.53	7.78	0.35	5.71e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg20628663	chr10:43360327	NA	0.7	10.96	0.47	8.66e-25	Blood protein levels;
LUAD	cis	rs12900413	0.645	rs28507224	chr15:90305393	T/C	cg24249390	chr15:90295951	MESP1	-0.34	-6.59	-0.3	1.35e-10	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs12681288	0.676	rs6983981	chr8:1016011	A/C	cg04851639	chr8:1020857	NA	-0.42	-9.94	-0.44	4.57e-21	Schizophrenia;
LUAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg12334488	chr2:20871173	GDF7	-0.41	-7.26	-0.33	1.83e-12	Abdominal aortic aneurysm;
LUAD	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg18404041	chr3:52824283	ITIH1	-0.41	-7.36	-0.34	9.44e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-9.99	-0.44	3.1e-21	Migraine;Coronary artery disease;
LUAD	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg23649088	chr2:200775458	C2orf69	0.57	8.23	0.37	2.3e-15	Schizophrenia;
LUAD	cis	rs4953318	0.619	rs13406773	chr2:46362868	T/C	cg12428440	chr2:46370979	PRKCE	0.42	6.84	0.32	2.78e-11	Red blood cell count;Hematocrit;Red blood cell traits;
LUAD	trans	rs853679	0.607	rs13211507	chr6:28257377	T/C	cg01620082	chr3:125678407	NA	-1.05	-10.62	-0.46	1.58e-23	Depression;
LUAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg01448562	chr3:133502909	NA	0.76	14.52	0.58	4.59e-39	Iron status biomarkers;
LUAD	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.59	0.31	1.3e-10	Depression;
LUAD	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.51	-8.93	-0.4	1.29e-17	Eosinophil percentage of white cells;
LUAD	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg05457628	chr5:178986728	RUFY1	0.45	7.71	0.35	9.36e-14	Lung cancer;
LUAD	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-8.99	-0.4	8.53e-18	Monocyte percentage of white cells;
LUAD	cis	rs7177699	0.557	rs9920493	chr15:79113846	A/C	cg00540400	chr15:79124168	NA	0.44	9.48	0.42	1.84e-19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.23	-0.33	2.24e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg10755058	chr3:40428713	ENTPD3	-0.41	-8.04	-0.36	9.11e-15	Renal cell carcinoma;
LUAD	cis	rs6484504	0.576	rs16922084	chr11:31371109	C/T	cg14844989	chr11:31128820	NA	0.45	8.36	0.38	9.13e-16	Red blood cell count;
LUAD	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg18827107	chr12:86230957	RASSF9	-0.7	-12.92	-0.53	2.12e-32	Major depressive disorder;
LUAD	cis	rs11723261	0.564	rs60994255	chr4:77446	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.47	7.58	0.35	2.2e-13	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg18230493	chr5:56204884	C5orf35	-0.44	-7.48	-0.34	4.23e-13	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.75	-9.06	-0.4	4.69e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg27411982	chr8:10470053	RP1L1	0.38	6.77	0.31	4.39e-11	Retinal vascular caliber;
LUAD	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14240646	chr10:27532245	ACBD5	-0.65	-9.74	-0.43	2.25e-20	Breast cancer;
LUAD	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg03714773	chr7:91764589	CYP51A1	-0.27	-6.53	-0.3	1.92e-10	Breast cancer;
LUAD	cis	rs796825	0.530	rs34014378	chr3:119946506	T/A	cg21790991	chr3:120137480	FSTL1	-0.42	-7.24	-0.33	2.14e-12	HIV-1 susceptibility;
LUAD	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg18131467	chr2:239335373	ASB1	0.73	12.68	0.52	1.84e-31	Multiple system atrophy;
LUAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg14780466	chr2:20870812	GDF7	-0.44	-8.17	-0.37	3.57e-15	Abdominal aortic aneurysm;
LUAD	cis	rs652260	0.646	rs693941	chr19:7903851	C/T	cg26014689	chr19:7917955	EVI5L	-0.56	-10.84	-0.47	2.54e-24	Menarche (age at onset);
LUAD	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg01601518	chr4:2404284	ZFYVE28	0.68	7.73	0.35	7.95e-14	Influenza A (H1N1) severity;
LUAD	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.71	0.35	9.28e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00166722	chr3:10149974	C3orf24	0.74	12.6	0.52	3.78e-31	Alzheimer's disease;
LUAD	cis	rs57502260	0.680	rs55654976	chr11:68393541	C/T	cg16797656	chr11:68205561	LRP5	0.45	6.84	0.32	2.86e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg16850897	chr7:100343110	ZAN	-0.58	-8.18	-0.37	3.24e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs773506	0.655	rs10991796	chr9:93930243	G/T	cg14446406	chr9:93919335	NA	-0.38	-6.87	-0.32	2.31e-11	Type 2 diabetes nephropathy;
LUAD	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg10518543	chr12:38710700	ALG10B	0.41	6.38	0.3	4.66e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg05665937	chr4:1216051	CTBP1	0.42	7.54	0.34	2.83e-13	Obesity-related traits;
LUAD	trans	rs8002861	0.935	rs7320988	chr13:44413523	C/T	cg17145862	chr1:211918768	LPGAT1	0.75	17.53	0.65	4.31e-52	Leprosy;
LUAD	cis	rs4444359	0.770	rs9929563	chr16:11558346	C/G	cg08104224	chr16:11588532	NA	0.37	6.35	0.3	5.51e-10	Facial morphology (factor 17, height of vermillion upper lip);
LUAD	cis	rs2625529	0.761	rs3743224	chr15:72466799	C/T	cg16672083	chr15:72433130	SENP8	-0.78	-13.1	-0.54	3.82e-33	Red blood cell count;
LUAD	cis	rs6496044	0.547	rs1564719	chr15:86054266	C/T	cg13263323	chr15:86062960	AKAP13	-0.54	-9.98	-0.44	3.41e-21	Interstitial lung disease;
LUAD	cis	rs62400317	0.859	rs2093900	chr6:45176683	C/T	cg18551225	chr6:44695536	NA	-0.56	-8.27	-0.37	1.7e-15	Total body bone mineral density;
LUAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.7	-13.69	-0.55	1.4e-35	Longevity;Endometriosis;
LUAD	cis	rs7301826	0.651	rs10744485	chr12:131298550	A/G	cg11011512	chr12:131303247	STX2	0.44	7.42	0.34	6.59e-13	Plasma plasminogen activator levels;
LUAD	cis	rs4676380	0.927	rs1583259	chr2:241644934	G/T	cg06356454	chr2:241631498	AQP12A	0.38	6.6	0.31	1.22e-10	Response to metformin (IC50);
LUAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg23958373	chr8:599963	NA	1.06	10.78	0.46	4.19e-24	IgG glycosylation;
LUAD	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg18944383	chr4:111397179	ENPEP	0.38	7.62	0.35	1.66e-13	Height;
LUAD	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg21770322	chr7:97807741	LMTK2	0.35	8.24	0.37	2.15e-15	Breast cancer;
LUAD	cis	rs3774830	1.000	rs6827240	chr4:5440224	G/T	cg26943120	chr4:5472116	STK32B	0.33	6.74	0.31	5.24e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg22906224	chr7:99728672	NA	-0.56	-9.68	-0.43	3.82e-20	Coronary artery disease;
LUAD	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg03859395	chr2:55845619	SMEK2	0.68	12.36	0.51	3.72e-30	Metabolic syndrome;
LUAD	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg10978503	chr1:24200527	CNR2	0.54	11.48	0.49	9.45e-27	Immature fraction of reticulocytes;
LUAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.85	0.56	3.1e-36	Prudent dietary pattern;
LUAD	trans	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg25894440	chr7:65020034	NA	-0.63	-6.67	-0.31	8.12e-11	Diabetic kidney disease;
LUAD	cis	rs367943	0.547	rs11241218	chr5:112958258	T/C	cg12552261	chr5:112820674	MCC	0.38	6.53	0.3	1.85e-10	Type 2 diabetes;
LUAD	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.82	0.53	5.17e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.16	0.37	3.86e-15	Rheumatoid arthritis;
LUAD	cis	rs9811920	0.625	rs9868170	chr3:99914139	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.45	8.58	0.39	1.77e-16	Axial length;
LUAD	cis	rs11958404	0.932	rs60504573	chr5:157436786	T/A	cg05962755	chr5:157440814	NA	0.54	8.12	0.37	5.05e-15	IgG glycosylation;
LUAD	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg01851573	chr8:8652454	MFHAS1	0.38	6.84	0.32	2.85e-11	Mood instability;
LUAD	cis	rs9462027	0.606	rs412392	chr6:34549699	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.73	-0.39	5.82e-17	Systemic lupus erythematosus;
LUAD	cis	rs7264396	0.563	rs6060570	chr20:34291166	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2.04e-15	Total cholesterol levels;
LUAD	cis	rs7493	0.950	rs11981299	chr7:95029701	T/A	cg17330251	chr7:94953956	PON1	-0.55	-7.41	-0.34	6.92e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.46e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62238980	0.614	rs75526838	chr22:32451830	A/G	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	8.14	0.37	4.45e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs753778	0.559	rs2288997	chr8:142200731	A/G	cg18755752	chr8:142205143	DENND3	0.48	6.78	0.31	4.18e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg01689657	chr7:91764605	CYP51A1	0.32	8.04	0.36	9.14e-15	Breast cancer;
LUAD	cis	rs7737355	0.947	rs2108871	chr5:131089044	A/C	cg25547332	chr5:131281432	NA	0.45	6.76	0.31	4.59e-11	Life satisfaction;
LUAD	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg16325326	chr1:53192061	ZYG11B	0.69	13.25	0.54	9.26e-34	Monocyte count;
LUAD	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.88	-9.44	-0.42	2.48e-19	Lung cancer in ever smokers;
LUAD	trans	rs3219090	0.962	rs2695236	chr1:226603003	T/C	cg27539482	chr13:111589090	NA	0.43	7.22	0.33	2.5e-12	Melanoma;
LUAD	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg20587970	chr11:113659929	NA	-1.43	-20.63	-0.71	5.95e-66	Hip circumference adjusted for BMI;
LUAD	cis	rs4700695	0.841	rs706680	chr5:65317338	T/C	cg21114390	chr5:65439923	SFRS12	0.63	7.54	0.34	2.86e-13	Facial morphology (factor 19);
LUAD	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg20578329	chr17:80767326	TBCD	-0.56	-7.04	-0.32	8.06e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.21	-0.33	2.55e-12	Lung cancer;
LUAD	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg26513180	chr16:89883248	FANCA	0.78	6.73	0.31	5.65e-11	Skin colour saturation;
LUAD	cis	rs9399401	0.667	rs12213892	chr6:142702234	A/G	cg03128060	chr6:142623767	GPR126	0.51	10.3	0.45	2.37e-22	Chronic obstructive pulmonary disease;
LUAD	cis	rs62238980	0.614	rs10483162	chr22:32394890	G/C	cg00543991	chr22:32367038	NA	0.92	8.16	0.37	3.95e-15	Childhood ear infection;
LUAD	trans	rs208520	0.909	rs9354410	chr6:67018584	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.81	0.47	3.12e-24	Exhaled nitric oxide output;
LUAD	cis	rs62400317	0.859	rs58769170	chr6:45298531	C/T	cg20913747	chr6:44695427	NA	-0.41	-6.66	-0.31	8.48e-11	Total body bone mineral density;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg07630564	chr3:128445061	RAB7A	-0.44	-6.88	-0.32	2.11e-11	Vertical cup-disc ratio;
LUAD	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg06873352	chr17:61820015	STRADA	0.41	6.78	0.31	4.09e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1509123	0.609	rs8070405	chr17:6720396	C/T	cg12642237	chr17:6703447	TEKT1	-0.46	-6.7	-0.31	6.82e-11	Blood metabolite levels;
LUAD	cis	rs7771547	0.519	rs6928287	chr6:36375438	G/A	cg04289385	chr6:36355825	ETV7	0.48	7.09	0.33	5.81e-12	Platelet distribution width;
LUAD	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg22117172	chr7:91764530	CYP51A1	0.36	7.93	0.36	1.99e-14	Breast cancer;
LUAD	cis	rs4006360	0.604	rs3914090	chr17:39230058	A/T	cg16090541	chr17:39240343	KRTAP4-7	-0.38	-6.72	-0.31	5.75e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6537837	0.701	rs6680537	chr1:110155022	T/C	cg05049280	chr1:110155535	GNAT2	0.57	6.95	0.32	1.43e-11	Major depressive disorder;
LUAD	cis	rs1975974	1.000	rs1985717	chr17:21731807	T/A	cg18423549	chr17:21743878	NA	-0.78	-13.65	-0.55	2.17e-35	Psoriasis;
LUAD	trans	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg07817883	chr1:32538562	TMEM39B	1.02	11.48	0.49	1e-26	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	cis	rs28655083	1.000	rs8059347	chr16:77068259	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.41	-6.93	-0.32	1.56e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24531977	chr5:56204891	C5orf35	-0.79	-12.9	-0.53	2.35e-32	Initial pursuit acceleration;
LUAD	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg03983476	chr2:10830698	NOL10	0.4	6.78	0.31	3.99e-11	Prostate cancer;
LUAD	cis	rs1595825	1.000	rs7579905	chr2:198868109	T/A	cg10547527	chr2:198650123	BOLL	-0.47	-6.64	-0.31	9.64e-11	Ulcerative colitis;
LUAD	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg23815491	chr16:72088622	HP	0.44	7.98	0.36	1.43e-14	Prostate cancer;
LUAD	cis	rs8017423	0.967	rs7155315	chr14:90700787	G/A	cg14092571	chr14:90743983	NA	-0.5	-8.8	-0.39	3.61e-17	Mortality in heart failure;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg12820191	chr3:186524311	RFC4	-0.62	-6.37	-0.3	4.81e-10	Type 2 diabetes;
LUAD	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg07506560	chr2:240697449	NA	0.48	9.53	0.42	1.24e-19	Obesity-related traits;
LUAD	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg17366294	chr4:99064904	C4orf37	0.54	9.91	0.43	5.91e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72928364	1.000	rs34999788	chr3:100617668	G/T	cg10123952	chr3:100791384	NA	0.6	6.89	0.32	2.07e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg05535760	chr7:792225	HEATR2	0.94	11.88	0.5	2.7e-28	Cerebrospinal P-tau181p levels;
LUAD	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.44	-7.65	-0.35	1.42e-13	Age at first birth;
LUAD	cis	rs7274811	0.554	rs35556109	chr20:32133489	G/A	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.45	-6.64	-0.31	9.54e-11	Height;
LUAD	cis	rs4664308	1.000	rs4664308	chr2:160917497	A/G	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.79	-0.31	3.88e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10802521	chr3:52805072	NEK4	-0.54	-9.1	-0.4	3.59e-18	Bipolar disorder;
LUAD	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg15448220	chr1:150897856	SETDB1	0.46	7.97	0.36	1.47e-14	Tonsillectomy;
LUAD	cis	rs4653767	1.000	rs10916030	chr1:226919908	C/T	cg05049329	chr1:226924846	ITPKB	0.45	8.02	0.36	1.04e-14	Parkinson's disease;
LUAD	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-9.8	-0.43	1.44e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg24846343	chr22:24311635	DDTL	0.83	20.27	0.7	2.51e-64	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.62	0.35	1.7e-13	Platelet count;
LUAD	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg03538708	chr1:25844672	NA	-0.37	-6.38	-0.3	4.57e-10	Erythrocyte sedimentation rate;
LUAD	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11890956	chr21:40555474	PSMG1	-0.51	-8.61	-0.39	1.5e-16	Menarche (age at onset);
LUAD	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg06740227	chr12:86229804	RASSF9	-0.41	-7.23	-0.33	2.27e-12	Major depressive disorder;
LUAD	cis	rs13082711	0.595	rs1445114	chr3:27345489	C/A	cg02860705	chr3:27208620	NA	0.78	12.03	0.5	7.24e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs367943	1.000	rs348928	chr5:112815295	C/T	cg12552261	chr5:112820674	MCC	-0.58	-11.04	-0.47	4.66e-25	Type 2 diabetes;
LUAD	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg12310025	chr6:25882481	NA	-0.53	-7.71	-0.35	8.82e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg10819733	chr22:24237672	NA	-0.46	-8.9	-0.4	1.62e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.82	0.31	3.11e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg08885076	chr2:99613938	TSGA10	-0.4	-7.18	-0.33	3.2e-12	Chronic sinus infection;
LUAD	cis	rs9287719	0.639	rs2357649	chr2:10696788	C/T	cg03983476	chr2:10830698	NOL10	0.39	6.46	0.3	2.94e-10	Prostate cancer;
LUAD	cis	rs12431939	1.000	rs11848143	chr14:51651560	T/A	cg23942311	chr14:51606299	NA	-0.54	-7.45	-0.34	5.4e-13	Cancer;
LUAD	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg07343612	chr16:622815	PIGQ	-0.47	-6.44	-0.3	3.22e-10	Height;
LUAD	cis	rs6066825	0.644	rs6095248	chr20:47320932	A/G	cg18078177	chr20:47281410	PREX1	0.39	6.47	0.3	2.76e-10	Colorectal cancer;
LUAD	cis	rs116248771	0.690	rs16847125	chr3:158417699	C/T	cg16708174	chr3:158430962	RARRES1	0.48	6.94	0.32	1.46e-11	diarrhoeal disease at age 2;
LUAD	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.38	6.47	0.3	2.74e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg24642844	chr7:1081250	C7orf50	-0.97	-14.71	-0.58	7.38e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg05044414	chr3:183734942	ABCC5	0.47	9.97	0.44	3.67e-21	Anterior chamber depth;
LUAD	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg17971929	chr21:40555470	PSMG1	0.56	8.9	0.4	1.62e-17	Cognitive function;
LUAD	cis	rs9297145	0.585	rs62473049	chr7:98777685	T/C	cg05967295	chr7:98741636	SMURF1	-0.74	-13.39	-0.55	2.38e-34	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18404041	chr3:52824283	ITIH1	-0.59	-11.79	-0.5	5.98e-28	Bipolar disorder;
LUAD	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.48	-0.38	3.78e-16	Total body bone mineral density;
LUAD	cis	rs4604732	0.578	rs12036417	chr1:247624805	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.11	0.33	4.98e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs28595532	1.000	rs55634130	chr4:119655093	C/T	cg02775129	chr4:119771670	NA	-0.82	-7.62	-0.35	1.7e-13	Cannabis dependence symptom count;
LUAD	cis	rs9039	0.959	rs12148920	chr16:9183900	C/G	cg08831531	chr16:9218945	NA	0.42	7.39	0.34	7.81e-13	Menopause (age at onset);
LUAD	trans	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg14791747	chr16:20752902	THUMPD1	0.48	7.3	0.33	1.48e-12	Dental caries;
LUAD	trans	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg07817883	chr1:32538562	TMEM39B	1.5	12.56	0.52	5.74e-31	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-11.85	-0.5	3.7e-28	Bipolar disorder;
LUAD	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg08798685	chr6:27730294	NA	-0.7	-7.42	-0.34	6.42e-13	Depression;
LUAD	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	11.5	0.49	8.24e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7000551	0.715	rs1600877	chr8:22378118	C/T	cg12081754	chr8:22256438	SLC39A14	0.47	7.76	0.35	6.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs1996152	0.543	rs4789658	chr17:72389526	A/T	cg23221732	chr17:72383708	NA	0.45	6.62	0.31	1.09e-10	Interleukin-12p70 levels;
LUAD	cis	rs7903847	0.619	rs10786336	chr10:99134953	A/C	cg20016023	chr10:99160130	RRP12	-0.3	-7.24	-0.33	2.12e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg16205897	chr5:131564050	P4HA2	0.4	9.04	0.4	5.69e-18	Blood metabolite levels;
LUAD	cis	rs2070433	0.800	rs11702190	chr21:47877367	C/T	cg12379764	chr21:47803548	PCNT	0.49	6.54	0.3	1.77e-10	Lymphocyte counts;
LUAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg07677032	chr17:61819896	STRADA	-0.5	-8.93	-0.4	1.28e-17	Prudent dietary pattern;
LUAD	cis	rs11597390	0.865	rs12781812	chr10:101891222	G/T	cg19754520	chr10:101825118	CPN1	-0.33	-6.85	-0.32	2.68e-11	Liver enzyme levels;
LUAD	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg08798685	chr6:27730294	NA	-0.44	-7.08	-0.33	6.2e-12	Parkinson's disease;
LUAD	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg18827107	chr12:86230957	RASSF9	-0.71	-13.17	-0.54	2.04e-33	Major depressive disorder;
LUAD	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00475322	chr7:917719	C7orf20	0.65	11.82	0.5	4.64e-28	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-8.0	-0.36	1.2e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs62238980	0.614	rs75584049	chr22:32468790	C/A	cg00543991	chr22:32367038	NA	0.92	8.7	0.39	7.27e-17	Childhood ear infection;
LUAD	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg02782426	chr3:40428986	ENTPD3	0.43	9.0	0.4	7.49e-18	Renal cell carcinoma;
LUAD	cis	rs9341808	0.622	rs684283	chr6:80967317	T/G	cg08355045	chr6:80787529	NA	-0.47	-8.33	-0.38	1.14e-15	Sitting height ratio;
LUAD	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg21427119	chr20:30132790	HM13	-0.59	-8.82	-0.39	3.09e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-10.74	-0.46	5.89e-24	Lymphocyte counts;
LUAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg07677032	chr17:61819896	STRADA	0.57	10.34	0.45	1.78e-22	Prudent dietary pattern;
LUAD	cis	rs6840360	0.615	rs10001603	chr4:152647577	T/A	cg22705602	chr4:152727874	NA	-0.47	-9.11	-0.41	3.27e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1997103	0.871	rs9649855	chr7:55410222	T/C	cg17469321	chr7:55412551	NA	0.65	11.08	0.47	3.29e-25	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg16074309	chr8:11760061	NA	0.46	7.56	0.35	2.47e-13	Diastolic blood pressure;
LUAD	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg26513180	chr16:89883248	FANCA	0.64	6.37	0.3	4.96e-10	Skin colour saturation;
LUAD	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-8.49	-0.38	3.64e-16	Cutaneous nevi;
LUAD	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg18512352	chr11:47633146	NA	-0.54	-9.68	-0.43	3.73e-20	Subjective well-being;
LUAD	cis	rs798554	0.591	rs1636248	chr7:2882030	T/C	cg09658497	chr7:2847517	GNA12	-0.41	-7.25	-0.33	1.95e-12	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05013942	chr17:36003336	DDX52	-0.56	-6.74	-0.31	5.31e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg15744005	chr10:104629667	AS3MT	-0.35	-6.96	-0.32	1.34e-11	Arsenic metabolism;
LUAD	trans	rs8002861	0.935	rs1822969	chr13:44418164	G/A	cg17145862	chr1:211918768	LPGAT1	0.75	17.79	0.65	2.91e-53	Leprosy;
LUAD	trans	rs3219090	0.962	rs2666427	chr1:226601874	G/A	cg27539482	chr13:111589090	NA	0.43	7.12	0.33	4.81e-12	Melanoma;
LUAD	cis	rs8058578	0.832	rs35969813	chr16:30714417	T/C	cg05768032	chr16:30646687	NA	0.46	7.81	0.36	4.53e-14	Multiple myeloma;
LUAD	trans	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	9.95	0.44	4.33e-21	Mean corpuscular volume;
LUAD	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg11494091	chr17:61959527	GH2	0.4	7.1	0.33	5.48e-12	Height;
LUAD	cis	rs7633770	0.786	rs1520489	chr3:46677519	A/G	cg11219411	chr3:46661640	NA	-0.58	-13.32	-0.54	4.88e-34	Coronary artery disease;
LUAD	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg19717773	chr7:2847554	GNA12	-0.52	-8.65	-0.39	1.06e-16	Height;
LUAD	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.34	-0.34	1.13e-12	Blood metabolite levels;
LUAD	cis	rs6500395	1.000	rs3848321	chr16:48620780	A/T	cg04672837	chr16:48644449	N4BP1	0.39	6.67	0.31	8.04e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg00431813	chr7:1051703	C7orf50	-0.46	-8.67	-0.39	9.67e-17	Longevity;Endometriosis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05563107	chr19:50528575	VRK3;ZNF473	-0.5	-7.78	-0.35	5.68e-14	Height;
LUAD	cis	rs2070433	0.556	rs8129460	chr21:47822544	C/T	cg12379764	chr21:47803548	PCNT	0.5	6.59	0.31	1.27e-10	Lymphocyte counts;
LUAD	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg27446573	chr6:127587934	RNF146	0.43	6.47	0.3	2.72e-10	Breast cancer;
LUAD	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.57	-8.24	-0.37	2.13e-15	Gut microbiome composition (summer);
LUAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg08888203	chr3:10149979	C3orf24	-0.69	-12.26	-0.51	8.85e-30	Alzheimer's disease;
LUAD	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg09491104	chr22:46646882	C22orf40	-0.57	-7.99	-0.36	1.27e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7814319	0.966	rs10955069	chr8:97253788	C/T	cg20787634	chr8:97240163	UQCRB	-0.39	-7.66	-0.35	1.26e-13	Lung function (FVC);
LUAD	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg07776626	chr8:57350775	NA	-0.61	-9.04	-0.4	5.77e-18	Obesity-related traits;
LUAD	cis	rs861020	0.883	rs680331	chr1:209959872	G/A	cg09163369	chr1:210001066	C1orf107	0.48	6.5	0.3	2.2e-10	Orofacial clefts;
LUAD	trans	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg18335740	chr13:41363409	SLC25A15	0.72	13.87	0.56	2.55e-36	Lewy body disease;
LUAD	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.57	-0.35	2.44e-13	Blood metabolite levels;
LUAD	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.39	7.35	0.34	1.01e-12	Lung cancer in ever smokers;
LUAD	trans	rs10802346	0.545	rs2362252	chr1:246371574	A/C	cg13514129	chr1:39547527	MACF1	0.62	11.16	0.48	1.62e-25	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs10089	0.953	rs4836359	chr5:127385518	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	10.09	0.44	1.35e-21	Ileal carcinoids;
LUAD	trans	rs1728785	1.000	rs11642045	chr16:68583892	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	9.95	0.44	4.32e-21	Ulcerative colitis;
LUAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg15117754	chr3:10150083	C3orf24	0.4	6.66	0.31	8.79e-11	Alzheimer's disease;
LUAD	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg06558623	chr16:89946397	TCF25	1.15	9.93	0.43	4.92e-21	Skin colour saturation;
LUAD	trans	rs6940638	0.956	rs72838268	chr6:27021173	A/G	cg01620082	chr3:125678407	NA	-0.49	-6.42	-0.3	3.59e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg27532560	chr4:187881888	NA	-0.39	-7.59	-0.35	2.11e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1003719	0.788	rs7276917	chr21:38451334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.55	0.38	2.25e-16	Eye color traits;
LUAD	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg11645453	chr3:52864694	ITIH4	0.52	9.94	0.44	4.58e-21	Schizophrenia;
LUAD	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.27	-0.33	1.7e-12	Myopia (pathological);
LUAD	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg13180566	chr4:1052158	NA	-0.4	-6.72	-0.31	5.87e-11	Recombination rate (females);
LUAD	cis	rs4481887	0.830	rs6686474	chr1:248477116	A/C	cg13385794	chr1:248469461	NA	0.26	7.0	0.32	1.01e-11	Common traits (Other);
LUAD	cis	rs76878669	0.561	rs1892940	chr11:66111251	A/G	cg10616300	chr11:66138557	SLC29A2	-0.32	-6.87	-0.32	2.34e-11	Educational attainment (years of education);
LUAD	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.44	0.57	1.08e-38	Schizophrenia;
LUAD	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg08999081	chr20:33150536	PIGU	-0.38	-7.51	-0.34	3.58e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.7	0.31	6.81e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-7.5	-0.34	3.76e-13	Tonsillectomy;
LUAD	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg27411982	chr8:10470053	RP1L1	-0.46	-8.59	-0.39	1.71e-16	Neuroticism;
LUAD	cis	rs3007168	1.000	rs2999363	chr14:51605141	A/G	cg23942311	chr14:51606299	NA	0.53	7.31	0.33	1.35e-12	Cancer;
LUAD	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg12940439	chr1:67600707	NA	0.48	9.1	0.4	3.46e-18	Psoriasis;
LUAD	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg15181151	chr6:150070149	PCMT1	0.33	6.56	0.3	1.62e-10	Testicular germ cell tumor;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11698762	chr2:74648964	WDR54	0.4	6.38	0.3	4.74e-10	Gut microbiome composition (summer);
LUAD	cis	rs7084921	0.608	rs11592689	chr10:101865516	A/T	cg19754520	chr10:101825118	CPN1	-0.34	-6.69	-0.31	7.15e-11	Bone mineral density;
LUAD	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg22618164	chr12:122356400	WDR66	0.75	13.92	0.56	1.56e-36	Mean corpuscular volume;
LUAD	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22968622	chr17:43663579	NA	1.35	24.14	0.76	1.43e-81	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9473147	0.503	rs9473123	chr6:47475339	G/A	cg12968598	chr6:47444699	CD2AP	0.35	6.38	0.3	4.78e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg26587870	chr6:27730563	NA	-0.4	-6.79	-0.31	3.93e-11	Parkinson's disease;
LUAD	cis	rs4774899	0.934	rs11636348	chr15:57470630	G/T	cg14026238	chr15:57616123	NA	0.37	6.93	0.32	1.6e-11	Urinary tract infection frequency;
LUAD	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg04234412	chr22:24373322	LOC391322	-0.57	-8.05	-0.36	8.43e-15	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs2322633	0.515	rs1892474	chr6:80862349	G/A	cg08355045	chr6:80787529	NA	0.43	6.81	0.31	3.43e-11	Height;
LUAD	cis	rs10504073	0.669	rs818560	chr8:50035417	C/T	cg00325661	chr8:49890786	NA	0.4	9.02	0.4	6.66e-18	Blood metabolite ratios;
LUAD	cis	rs1030877	0.515	rs2679893	chr2:105909554	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.41	6.63	0.31	1.05e-10	Obesity-related traits;
LUAD	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg26566898	chr11:117069891	TAGLN	0.34	6.55	0.3	1.63e-10	Blood protein levels;
LUAD	cis	rs1497828	0.956	rs5002693	chr1:217530191	T/A	cg04411442	chr1:217543379	NA	-0.38	-6.89	-0.32	2.07e-11	Dialysis-related mortality;
LUAD	trans	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg18335740	chr13:41363409	SLC25A15	0.6	11.05	0.47	4.06e-25	Lewy body disease;
LUAD	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg05340658	chr4:99064831	C4orf37	0.46	7.55	0.34	2.75e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs886126	0.650	rs4766566	chr12:111706877	C/T	cg10833066	chr12:111807467	FAM109A	0.6	11.83	0.5	4.31e-28	Coronary heart disease;
LUAD	cis	rs6489882	0.703	rs10850092	chr12:113359703	C/G	cg20102336	chr12:113376681	OAS3	-0.55	-8.31	-0.37	1.3e-15	Chronic lymphocytic leukemia;
LUAD	trans	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg01620082	chr3:125678407	NA	-0.72	-7.28	-0.33	1.62e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	9.92	0.43	5.53e-21	Electrocardiographic conduction measures;
LUAD	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg15147215	chr3:52552868	STAB1	-0.4	-7.24	-0.33	2.2e-12	Bipolar disorder;
LUAD	trans	rs4714291	0.832	rs6936016	chr6:40097013	A/G	cg02267698	chr19:7991119	CTXN1	-0.44	-7.02	-0.32	8.69e-12	Strep throat;
LUAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg10729496	chr3:10149963	C3orf24	0.58	9.34	0.41	5.58e-19	Alzheimer's disease;
LUAD	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg02158880	chr13:53174818	NA	-0.53	-9.2	-0.41	1.65e-18	Lewy body disease;
LUAD	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg27532560	chr4:187881888	NA	0.4	7.83	0.36	3.92e-14	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	10.21	0.44	5.12e-22	Type 2 diabetes;
LUAD	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.12	0.33	4.56e-12	Motion sickness;
LUAD	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg09137382	chr11:130731461	NA	0.41	7.51	0.34	3.57e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7707921	0.881	rs7733122	chr5:81351443	C/T	cg15871215	chr5:81402204	ATG10	-0.7	-9.99	-0.44	3.1e-21	Breast cancer;
LUAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg23978390	chr7:1156363	C7orf50	0.57	8.97	0.4	9.62e-18	Longevity;Endometriosis;
LUAD	cis	rs656900	0.692	rs7171819	chr15:80108019	A/G	cg02196730	chr15:80188777	MTHFS	0.42	6.95	0.32	1.38e-11	Cerebrospinal P-tau181p levels;
LUAD	trans	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.31	0.45	2.17e-22	Mean corpuscular volume;
LUAD	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg01191920	chr7:158217561	PTPRN2	-0.67	-14.49	-0.58	6.12e-39	Obesity-related traits;
LUAD	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg01475377	chr6:109611718	NA	-0.52	-10.05	-0.44	1.91e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs9287719	0.578	rs10168852	chr2:10746323	C/A	cg03983476	chr2:10830698	NOL10	-0.39	-6.54	-0.3	1.75e-10	Prostate cancer;
LUAD	cis	rs6446731	0.614	rs7661630	chr4:3280106	G/A	cg08886695	chr4:3369023	RGS12	-0.5	-8.3	-0.37	1.45e-15	Mean platelet volume;
LUAD	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg11189052	chr15:85197271	WDR73	0.58	7.33	0.34	1.17e-12	Schizophrenia;
LUAD	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg15017067	chr4:17643749	FAM184B	0.38	7.42	0.34	6.2800000000000005e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg24803719	chr17:45855879	NA	0.35	8.13	0.37	4.76e-15	IgG glycosylation;
LUAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	cis	rs73086581	1.000	rs73086540	chr20:3950850	T/C	cg02187196	chr20:3869020	PANK2	0.46	6.49	0.3	2.34e-10	Response to antidepressants in depression;
LUAD	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg07936489	chr17:37558343	FBXL20	-0.51	-6.97	-0.32	1.21e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg12863693	chr15:85201151	NMB	-0.31	-6.65	-0.31	9.16e-11	P wave terminal force;
LUAD	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.69	0.31	6.95e-11	Depression;
LUAD	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg06287003	chr12:125626642	AACS	-0.43	-7.27	-0.33	1.76e-12	Post bronchodilator FEV1/FVC ratio;
LUAD	trans	rs459571	1.000	rs467387	chr9:136907005	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-9.97	-0.44	3.51e-21	Platelet distribution width;
LUAD	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg00933542	chr6:150070202	PCMT1	0.35	7.09	0.33	5.72e-12	Testicular germ cell tumor;
LUAD	cis	rs11048434	0.649	rs11613650	chr12:9060396	T/C	cg04155231	chr12:9217510	LOC144571	0.37	6.88	0.32	2.16e-11	Sjögren's syndrome;
LUAD	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.44	0.45	7.31e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg08773314	chr2:239334832	ASB1	0.45	10.39	0.45	1.12e-22	Multiple system atrophy;
LUAD	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg18305652	chr10:134549665	INPP5A	0.54	11.58	0.49	3.98e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg05313129	chr8:58192883	C8orf71	-0.53	-6.43	-0.3	3.48e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.41	-7.34	-0.34	1.12e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg10729496	chr3:10149963	C3orf24	0.58	9.5	0.42	1.63e-19	Alzheimer's disease;
LUAD	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.58	-0.6	1.38e-43	Chronic sinus infection;
LUAD	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg10434728	chr15:90938212	IQGAP1	0.36	6.95	0.32	1.41e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg06532163	chr17:45867833	NA	0.45	7.76	0.35	6.32e-14	IgG glycosylation;
LUAD	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06873352	chr17:61820015	STRADA	0.56	9.08	0.4	4.15e-18	Height;
LUAD	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg10755058	chr3:40428713	ENTPD3	0.37	7.26	0.33	1.85e-12	Renal cell carcinoma;
LUAD	trans	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg20587970	chr11:113659929	NA	-1.12	-15.45	-0.6	5.27e-43	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg07917127	chr4:99064746	C4orf37	0.44	7.18	0.33	3.17e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg18621852	chr3:10150065	C3orf24	0.44	7.78	0.35	5.58e-14	Alzheimer's disease;
LUAD	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg24801067	chr17:62843696	NA	-0.54	-7.57	-0.35	2.34e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-14.22	-0.57	8.84e-38	Headache;
LUAD	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg03859395	chr2:55845619	SMEK2	0.77	14.36	0.57	2.22e-38	Metabolic syndrome;
LUAD	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg12311346	chr5:56204834	C5orf35	-0.43	-7.03	-0.32	8.41e-12	Breast cancer;Breast cancer (early onset);
LUAD	trans	rs1941687	0.563	rs7232237	chr18:31324934	C/T	cg15819921	chr19:927150	ARID3A	0.49	8.36	0.38	8.98e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg11189052	chr15:85197271	WDR73	-0.61	-7.68	-0.35	1.08e-13	Schizophrenia;
LUAD	cis	rs1232027	0.700	rs861373	chr5:79948062	T/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-8.07	-0.37	7.25e-15	Huntington's disease progression;
LUAD	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.43	-7.09	-0.33	5.75e-12	Tonsillectomy;
LUAD	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg23625390	chr15:77176239	SCAPER	0.38	6.76	0.31	4.61e-11	Blood metabolite levels;
LUAD	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg20848291	chr7:100343083	ZAN	0.64	10.25	0.45	3.55e-22	Other erythrocyte phenotypes;
LUAD	cis	rs28374715	0.662	rs28382348	chr15:41487934	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.9	-16.68	-0.63	2.18e-48	Ulcerative colitis;
LUAD	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg10792982	chr14:105748885	BRF1	0.44	9.42	0.42	3.03e-19	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg15704280	chr7:45808275	SEPT13	0.75	11.06	0.47	3.89e-25	Coronary artery disease;
LUAD	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg07917127	chr4:99064746	C4orf37	0.51	7.24	0.33	2.09e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7089973	0.872	rs34064819	chr10:116621154	C/A	cg25233709	chr10:116636983	FAM160B1	0.39	7.58	0.35	2.18e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg10556349	chr10:835070	NA	0.58	7.31	0.34	1.3e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg04546413	chr19:29218101	NA	0.59	7.66	0.35	1.27e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.17e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg10518543	chr12:38710700	ALG10B	-0.45	-7.51	-0.34	3.62e-13	Heart rate;
LUAD	cis	rs76419734	0.558	rs10516520	chr4:106534110	A/G	cg05309399	chr4:106552544	FLJ20184	-0.58	-7.02	-0.32	8.75e-12	Post bronchodilator FEV1;
LUAD	cis	rs3784262	0.528	rs8027964	chr15:58335272	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-7.03	-0.32	8.15e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg26354017	chr1:205819088	PM20D1	0.81	17.18	0.64	1.51e-50	Menarche (age at onset);
LUAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg26354017	chr1:205819088	PM20D1	0.48	7.88	0.36	2.71e-14	Parkinson's disease;
LUAD	cis	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.99	-0.36	1.34e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg18621852	chr3:10150065	C3orf24	0.5	9.01	0.4	7.16e-18	Alzheimer's disease;
LUAD	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg20701182	chr2:24300061	SF3B14	0.92	13.72	0.56	1.02e-35	Lymphocyte counts;
LUAD	cis	rs912330	0.825	rs7317938	chr13:99234361	C/T	cg20487152	chr13:99095054	FARP1	-0.39	-6.94	-0.32	1.44e-11	Alzheimer's disease;
LUAD	cis	rs6543140	0.964	rs6761350	chr2:103030776	A/G	cg03938978	chr2:103052716	IL18RAP	0.35	6.86	0.32	2.5e-11	Blood protein levels;
LUAD	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg17366294	chr4:99064904	C4orf37	0.65	12.46	0.52	1.4e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.3	-0.51	6.25e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg09491104	chr22:46646882	C22orf40	-0.57	-8.04	-0.36	8.8e-15	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg09359103	chr1:154839909	KCNN3	-0.89	-20.01	-0.7	3.61e-63	Prostate cancer;
LUAD	cis	rs7100689	0.524	rs7902460	chr10:82199263	T/A	cg00277334	chr10:82204260	NA	-0.72	-13.32	-0.54	4.82e-34	Post bronchodilator FEV1;
LUAD	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.29	0.33	1.57e-12	Menopause (age at onset);
LUAD	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg03037974	chr15:76606532	NA	0.36	7.5	0.34	3.87e-13	Blood metabolite levels;
LUAD	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg11057378	chr10:81107060	PPIF	0.36	6.77	0.31	4.29e-11	Height;
LUAD	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg05776053	chr2:74358815	NA	0.43	6.68	0.31	7.33e-11	Gestational age at birth (maternal effect);
LUAD	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg02569458	chr12:86230093	RASSF9	-0.41	-7.64	-0.35	1.48e-13	Major depressive disorder;
LUAD	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg07636037	chr3:49044803	WDR6	0.46	7.67	0.35	1.17e-13	Menarche (age at onset);
LUAD	cis	rs6500395	1.000	rs9924078	chr16:48557918	A/C	cg04672837	chr16:48644449	N4BP1	-0.37	-6.41	-0.3	3.89e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1298062	0.535	rs2463240	chr19:50941905	A/G	cg17071417	chr19:50962282	MYBPC2	0.39	6.49	0.3	2.4e-10	Age of smoking initiation;
LUAD	cis	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg21775007	chr8:11205619	TDH	0.55	9.97	0.44	3.58e-21	Retinal vascular caliber;
LUAD	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg08632164	chr7:65971372	NA	0.36	6.38	0.3	4.65e-10	Aortic root size;
LUAD	trans	rs6561151	0.681	rs7989702	chr13:44439150	T/C	cg12856521	chr11:46389249	DGKZ	0.84	11.46	0.49	1.16e-26	Crohn's disease;
LUAD	cis	rs600626	0.588	rs10160802	chr11:75457950	A/C	cg24262691	chr11:75473276	NA	0.58	7.82	0.36	4.28e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg13918804	chr1:2043761	PRKCZ	0.39	6.36	0.3	5.33e-10	Height;
LUAD	trans	rs12517041	1.000	rs995216	chr5:23285541	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.4	-0.3	4.24e-10	Calcium levels;
LUAD	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg00981070	chr1:2046702	PRKCZ	0.36	6.84	0.32	2.76e-11	Height;
LUAD	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg00339695	chr16:24857497	SLC5A11	-0.53	-9.45	-0.42	2.3e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs642743	0.517	rs157077	chr10:106037894	C/T	cg23659134	chr10:106035168	GSTO2	-0.34	-6.44	-0.3	3.26e-10	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg06766960	chr11:133703094	NA	-0.38	-7.2	-0.33	2.76e-12	Childhood ear infection;
LUAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg03188948	chr7:1209495	NA	0.83	10.1	0.44	1.29e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg18621852	chr3:10150065	C3orf24	0.46	7.22	0.33	2.44e-12	Alzheimer's disease;
LUAD	cis	rs1870323	0.527	rs4944586	chr11:86207608	A/G	cg01663953	chr11:86133777	CCDC81	-0.39	-6.98	-0.32	1.18e-11	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule);
LUAD	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg00634984	chr7:65235879	NA	0.52	7.08	0.33	5.86e-12	Aortic root size;
LUAD	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg19622623	chr12:86230825	RASSF9	-0.38	-6.77	-0.31	4.28e-11	Major depressive disorder;
LUAD	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg27266060	chr8:22091797	NA	0.45	8.24	0.37	2.17e-15	Hypertriglyceridemia;
LUAD	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg22166914	chr1:53195759	ZYG11B	0.4	6.66	0.31	8.55e-11	Monocyte count;
LUAD	cis	rs7833986	0.501	rs72651502	chr8:56875533	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.92	14.39	0.57	1.62e-38	Height;
LUAD	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg01299579	chr2:10830716	NOL10	-0.42	-7.42	-0.34	6.53e-13	Prostate cancer;
LUAD	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg04025307	chr7:1156635	C7orf50	-0.51	-6.94	-0.32	1.47e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg10687131	chr2:20871002	GDF7	-0.47	-8.73	-0.39	6.1e-17	Abdominal aortic aneurysm;
LUAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-7.39	-0.34	8.02e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2835872	0.726	rs12482570	chr21:39077777	A/G	cg06728970	chr21:39037746	KCNJ6	-0.39	-6.88	-0.32	2.11e-11	Electroencephalographic traits in alcoholism;
LUAD	trans	rs9393777	0.844	rs35909544	chr6:27163456	G/A	cg06606381	chr12:133084897	FBRSL1	-1.03	-10.22	-0.45	4.48e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs72928364	1.000	rs62273927	chr3:100648440	C/T	cg10123952	chr3:100791384	NA	0.65	7.4	0.34	7.53e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs75920871	0.858	rs7950501	chr11:116963965	C/T	cg04087571	chr11:116723030	SIK3	-0.33	-6.69	-0.31	7.14e-11	Subjective well-being;
LUAD	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg00769240	chr8:12517080	NA	-0.38	-6.47	-0.3	2.71e-10	Blood pressure (smoking interaction);
LUAD	cis	rs2455601	0.671	rs2568091	chr11:8986048	C/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.47	-8.26	-0.37	1.87e-15	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.54	0.34	2.9e-13	Breast cancer;
LUAD	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Colorectal cancer;
LUAD	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg25828334	chr19:18545568	ISYNA1	-0.39	-8.0	-0.36	1.22e-14	Breast cancer;
LUAD	cis	rs7737355	0.898	rs32109	chr5:131041590	C/T	cg25547332	chr5:131281432	NA	0.45	6.74	0.31	5.08e-11	Life satisfaction;
LUAD	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg21194808	chr1:2205498	SKI	0.47	8.36	0.38	9.05e-16	Coronary artery disease;
LUAD	trans	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	6.07e-11	Depression;
LUAD	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg05283184	chr6:79620031	NA	-0.42	-7.53	-0.34	3.19e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4774899	0.752	rs2264904	chr15:57373739	G/A	cg14026238	chr15:57616123	NA	0.42	8.06	0.37	7.67e-15	Urinary tract infection frequency;
LUAD	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.86	-0.4	2.23e-17	Total body bone mineral density;
LUAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg11494091	chr17:61959527	GH2	0.74	18.32	0.67	1.27e-55	Prudent dietary pattern;
LUAD	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg02450064	chr17:40260053	DHX58	-0.44	-7.44	-0.34	5.55e-13	Fibrinogen levels;
LUAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg13271783	chr10:134563150	INPP5A	-0.41	-6.6	-0.31	1.24e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9948	0.655	rs62156216	chr2:97405127	C/T	cg20312557	chr2:97357134	FER1L5	-0.72	-8.08	-0.37	6.78e-15	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg05110241	chr16:68378359	PRMT7	-0.7	-7.99	-0.36	1.26e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12760731	0.720	rs12022731	chr1:178416358	A/G	cg00404053	chr1:178313656	RASAL2	0.61	7.85	0.36	3.5e-14	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7927771	0.524	rs754434	chr11:47814280	A/G	cg18512352	chr11:47633146	NA	0.36	6.38	0.3	4.66e-10	Subjective well-being;
LUAD	cis	rs7705042	0.865	rs249643	chr5:141524746	C/G	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.69	-0.31	7.2e-11	Asthma;
LUAD	cis	rs2050392	0.858	rs306583	chr10:30710057	C/T	cg18806716	chr10:30721971	MAP3K8	0.52	10.43	0.45	8.31e-23	Inflammatory bowel disease;
LUAD	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg27284194	chr4:1044797	NA	0.69	10.11	0.44	1.17e-21	Recombination rate (females);
LUAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg06074448	chr4:187884817	NA	-0.39	-7.89	-0.36	2.57e-14	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3219474	0.614	rs114562368	chr1:45899178	G/A	cg06784218	chr1:46089804	CCDC17	0.58	7.4	0.34	7.23e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg25554036	chr4:6271136	WFS1	0.69	13.83	0.56	3.65e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg00339695	chr16:24857497	SLC5A11	0.47	8.76	0.39	4.75e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg21984481	chr17:79567631	NPLOC4	-0.54	-11.29	-0.48	5.26e-26	Eye color traits;
LUAD	cis	rs2262909	0.962	rs55735642	chr19:22241176	C/T	cg11619707	chr19:22235551	ZNF257	0.49	7.61	0.35	1.84e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-6.85	-0.32	2.57e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg08888203	chr3:10149979	C3orf24	0.74	12.87	0.53	3.31e-32	Alzheimer's disease;
LUAD	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg14092988	chr3:52407081	DNAH1	0.37	7.48	0.34	4.47e-13	Bipolar disorder;
LUAD	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg08508325	chr11:3079039	CARS	0.54	11.66	0.49	1.97e-27	Longevity;
LUAD	cis	rs73198271	0.515	rs75155748	chr8:8628957	G/C	cg01851573	chr8:8652454	MFHAS1	0.59	7.84	0.36	3.77e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg13770153	chr20:60521292	NA	-0.55	-9.13	-0.41	2.86e-18	Body mass index;
LUAD	cis	rs11048434	0.736	rs2377673	chr12:9112551	A/G	cg26114124	chr12:9217669	LOC144571	0.36	6.74	0.31	5.04e-11	Sjögren's syndrome;
LUAD	cis	rs3812111	0.510	rs9372456	chr6:116592956	A/G	cg18828861	chr6:116576566	TSPYL4	0.37	7.15	0.33	3.81e-12	Age-related macular degeneration;
LUAD	cis	rs10465746	0.682	rs882897	chr1:84426049	A/T	cg10977910	chr1:84465055	TTLL7	0.59	9.59	0.42	7.71e-20	Obesity-related traits;
LUAD	trans	rs2018683	0.707	rs4722877	chr7:28972906	A/G	cg19402173	chr7:128379420	CALU	-0.52	-8.38	-0.38	7.7e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11677416	1.000	rs6542093	chr2:113528536	G/A	cg27083787	chr2:113543245	IL1A	0.38	6.64	0.31	9.65e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	trans	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	trans	rs2262909	1.000	rs765527	chr19:22129555	A/G	cg05197062	chr11:11642011	GALNTL4	0.53	8.44	0.38	5.24e-16	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg16262614	chr3:133464971	TF	0.43	8.73	0.39	6.02e-17	Iron status biomarkers;
LUAD	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg03690763	chr11:133734501	NA	-0.33	-7.87	-0.36	2.95e-14	Childhood ear infection;
LUAD	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg04287289	chr16:89883240	FANCA	0.73	13.48	0.55	1.03e-34	Vitiligo;
LUAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.56	0.3	1.61e-10	Prudent dietary pattern;
LUAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg07677032	chr17:61819896	STRADA	0.57	10.26	0.45	3.23e-22	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg03467027	chr4:99064603	C4orf37	0.41	6.66	0.31	8.61e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg16988262	chr1:15930761	NA	0.44	7.4	0.34	7.63e-13	Systolic blood pressure;
LUAD	cis	rs11048434	0.736	rs35870866	chr12:9129091	C/A	cg23795048	chr12:9217529	LOC144571	0.45	8.26	0.37	1.89e-15	Sjögren's syndrome;
LUAD	cis	rs11048434	0.636	rs7306165	chr12:9059081	T/C	cg26114124	chr12:9217669	LOC144571	0.36	6.59	0.3	1.34e-10	Sjögren's syndrome;
LUAD	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg17158414	chr2:27665306	KRTCAP3	0.29	7.91	0.36	2.32e-14	Total body bone mineral density;
LUAD	cis	rs2663905	0.611	rs1509558	chr15:81391244	C/T	cg09888468	chr15:81410853	NA	-0.56	-9.78	-0.43	1.7e-20	QT interval (drug interaction);
LUAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg11494091	chr17:61959527	GH2	0.74	18.36	0.67	8.69e-56	Prudent dietary pattern;
LUAD	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg05966235	chr16:28915196	ATP2A1	0.51	8.15	0.37	4.12e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs3213961	0.529	rs6708	chr2:33789534	A/G	cg04131969	chr2:33951647	MYADML	0.48	7.07	0.32	6.57e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg10518543	chr12:38710700	ALG10B	0.42	6.47	0.3	2.73e-10	Bladder cancer;
LUAD	cis	rs2455799	0.964	rs2654651	chr3:15781620	G/C	cg16303742	chr3:15540471	COLQ	-0.38	-6.54	-0.3	1.82e-10	Mean platelet volume;
LUAD	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg00745463	chr17:30367425	LRRC37B	-0.66	-8.55	-0.38	2.35e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg22535103	chr8:58192502	C8orf71	-0.72	-8.94	-0.4	1.24e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg17366294	chr4:99064904	C4orf37	0.65	12.48	0.52	1.15e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs315934	0.664	rs1618889	chr2:113855863	C/A	cg09040174	chr2:113837401	NA	-0.61	-7.4	-0.34	7.6e-13	Dysmenorrheic pain;
LUAD	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg01200585	chr1:228362443	C1orf69	-0.37	-6.88	-0.32	2.2e-11	Diastolic blood pressure;
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg08365438	chr10:21683093	NA	-0.43	-6.69	-0.31	7.19e-11	Height;
LUAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg20607798	chr8:58055168	NA	0.58	7.54	0.34	2.94e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.735	rs2048856	chr15:76800083	C/T	cg23625390	chr15:77176239	SCAPER	-0.43	-6.95	-0.32	1.37e-11	Blood metabolite levels;
LUAD	cis	rs2016266	0.614	rs7303922	chr12:53654219	A/G	cg26875137	chr12:53738046	NA	0.37	6.94	0.32	1.48e-11	Bone mineral density (spine);Bone mineral density;
LUAD	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg04842962	chr6:43655489	MRPS18A	1.05	26.6	0.79	2.56e-92	IgG glycosylation;
LUAD	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg15147215	chr3:52552868	STAB1	-0.42	-7.63	-0.35	1.6e-13	Bipolar disorder;
LUAD	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.44	-0.34	5.6e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.76	0.31	4.72e-11	Obesity-related traits;
LUAD	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg22532475	chr10:104410764	TRIM8	-0.45	-8.59	-0.39	1.66e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00679716	chr14:23067188	ABHD4	-0.43	-6.8	-0.31	3.63e-11	Height;
LUAD	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.09	0.33	5.5e-12	Prostate cancer;
LUAD	cis	rs10916814	0.513	rs1253805	chr1:20885618	G/A	cg04087271	chr1:20915334	CDA	-0.37	-6.72	-0.31	5.87e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg03806693	chr22:41940476	POLR3H	0.73	9.72	0.43	2.81e-20	Cannabis dependence symptom count;
LUAD	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-8.48	-0.38	3.89e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.62	-7.38	-0.34	8.26e-13	Body mass index;
LUAD	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg25797454	chr6:150327115	RAET1K	0.34	7.34	0.34	1.11e-12	Alopecia areata;
LUAD	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg13918804	chr1:2043761	PRKCZ	0.4	6.74	0.31	5.22e-11	Height;
LUAD	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg00129232	chr17:37814104	STARD3	-0.45	-7.75	-0.35	6.99e-14	Asthma;
LUAD	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg00290607	chr11:67383545	NA	0.39	6.52	0.3	1.98e-10	Mean corpuscular volume;
LUAD	trans	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.39	-0.3	4.45e-10	Aortic root size;
LUAD	cis	rs735539	0.521	rs1570672	chr13:21408818	C/T	cg27499820	chr13:21296301	IL17D	0.44	7.36	0.34	9.94e-13	Dental caries;
LUAD	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg10518543	chr12:38710700	ALG10B	-0.42	-6.89	-0.32	2e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg13319975	chr6:146136371	FBXO30	-0.55	-9.18	-0.41	1.95e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg04414720	chr1:150670196	GOLPH3L	-0.47	-7.4	-0.34	7.48e-13	Tonsillectomy;
LUAD	cis	rs713587	0.713	rs1982200	chr2:25205427	C/T	cg01884057	chr2:25150051	NA	-0.33	-6.86	-0.32	2.48e-11	Body mass index in non-asthmatics;
LUAD	cis	rs4594175	0.926	rs10138345	chr14:51624651	A/G	cg23942311	chr14:51606299	NA	0.66	11.21	0.48	9.89e-26	Cancer;
LUAD	cis	rs4481887	0.790	rs4382760	chr1:248422343	A/C	cg00666640	chr1:248458726	OR2T12	-0.31	-7.38	-0.34	8.49e-13	Common traits (Other);
LUAD	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg12863693	chr15:85201151	NMB	0.43	8.09	0.37	6.6e-15	Schizophrenia;
LUAD	cis	rs2996428	0.593	rs7513053	chr1:3709487	A/G	cg17443473	chr1:3703550	LRRC47	0.43	7.27	0.33	1.72e-12	Red cell distribution width;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11183136	chr7:150595671	NA	-0.38	-6.41	-0.3	3.83e-10	Cancer;
LUAD	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10802521	chr3:52805072	NEK4	-0.55	-9.18	-0.41	1.91e-18	Bipolar disorder;
LUAD	cis	rs8067545	0.750	rs11868084	chr17:19992717	A/G	cg04132472	chr17:19861366	AKAP10	0.29	6.99	0.32	1.05e-11	Schizophrenia;
LUAD	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6594713	0.842	rs1602862	chr5:112686942	T/C	cg12552261	chr5:112820674	MCC	0.52	7.95	0.36	1.71e-14	Brain cytoarchitecture;
LUAD	cis	rs116095464	1.000	rs3777237	chr5:307641	C/T	cg22496380	chr5:211416	CCDC127	-1.05	-7.9	-0.36	2.37e-14	Breast cancer;
LUAD	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04074766	chr7:100861094	ZNHIT1;PLOD3	0.42	6.36	0.3	5.22e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs796364	0.589	rs6743217	chr2:201134914	G/A	cg23649088	chr2:200775458	C2orf69	-0.57	-7.87	-0.36	2.91e-14	Schizophrenia;
LUAD	cis	rs7000551	0.581	rs2293145	chr8:22262654	A/T	cg12081754	chr8:22256438	SLC39A14	0.91	14.59	0.58	2.31e-39	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg06157335	chr1:53164003	C1orf163	0.42	6.59	0.31	1.35e-10	Diastolic blood pressure;
LUAD	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg12573674	chr2:1569213	NA	-0.56	-8.41	-0.38	6.55e-16	IgG glycosylation;
LUAD	cis	rs1595825	0.891	rs1992313	chr2:198896766	T/C	cg00982548	chr2:198649783	BOLL	-0.65	-9.18	-0.41	1.88e-18	Ulcerative colitis;
LUAD	trans	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg06437703	chr8:37914619	EIF4EBP1	0.54	8.27	0.37	1.71e-15	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs1451375	0.657	rs12665904	chr7:50635399	A/G	cg18232548	chr7:50535776	DDC	0.51	8.42	0.38	6.03e-16	Malaria;
LUAD	cis	rs6430585	0.528	rs586964	chr2:136652491	G/A	cg07169764	chr2:136633963	MCM6	0.69	8.2	0.37	2.94e-15	Corneal structure;
LUAD	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.38	-0.34	8.59e-13	Breast cancer;
LUAD	cis	rs6543140	0.693	rs7579737	chr2:102987361	A/G	cg03938978	chr2:103052716	IL18RAP	0.34	6.76	0.31	4.66e-11	Blood protein levels;
LUAD	cis	rs3540	0.960	rs8030722	chr15:90974920	G/A	cg10434728	chr15:90938212	IQGAP1	0.36	6.57	0.3	1.48e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg06287003	chr12:125626642	AACS	-0.44	-6.64	-0.31	9.75e-11	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs62238980	0.522	rs79257145	chr22:32545097	T/C	cg00543991	chr22:32367038	NA	0.93	8.06	0.36	8.03e-15	Childhood ear infection;
LUAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg14926445	chr8:58193284	C8orf71	-0.46	-6.68	-0.31	7.49e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6445967	0.569	rs73081531	chr3:58289946	T/G	cg13750441	chr3:58318267	PXK	-0.31	-6.45	-0.3	3e-10	Platelet count;
LUAD	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg00666640	chr1:248458726	OR2T12	0.33	8.13	0.37	4.68e-15	Common traits (Other);
LUAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.74	-8.83	-0.39	2.86e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs78487399	0.808	rs13405158	chr2:43705286	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.59	6.95	0.32	1.37e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs10129255	0.500	rs988134	chr14:107184937	A/G	cg07958169	chr14:107095056	NA	-0.37	-7.34	-0.34	1.08e-12	Kawasaki disease;
LUAD	cis	rs17789174	0.810	rs8051308	chr16:85081953	A/G	cg27466129	chr16:85060822	KIAA0513	0.36	7.99	0.36	1.33e-14	Dysphagia;
LUAD	cis	rs231513	0.911	rs231525	chr17:41951283	C/T	cg26893861	chr17:41843967	DUSP3	-0.54	-6.52	-0.3	1.99e-10	Cognitive function;
LUAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.33	0.38	1.1e-15	Alzheimer's disease;
LUAD	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg05535760	chr7:792225	HEATR2	-0.81	-9.53	-0.42	1.24e-19	Cerebrospinal P-tau181p levels;
LUAD	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg03713592	chr11:72463424	ARAP1	0.92	11.72	0.5	1.14e-27	Type 2 diabetes;
LUAD	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg18512352	chr11:47633146	NA	-0.51	-8.94	-0.4	1.21e-17	Subjective well-being;
LUAD	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg06108461	chr20:60628389	TAF4	0.75	9.66	0.43	4.36e-20	Obesity-related traits;
LUAD	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg20607798	chr8:58055168	NA	0.74	9.1	0.4	3.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg11494091	chr17:61959527	GH2	0.45	8.49	0.38	3.43e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9341808	0.538	rs688867	chr6:80939228	A/G	cg08355045	chr6:80787529	NA	0.48	8.49	0.38	3.43e-16	Sitting height ratio;
LUAD	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg02454025	chr1:11042201	C1orf127	1.02	18.09	0.66	1.3e-54	Ewing sarcoma;
LUAD	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10802521	chr3:52805072	NEK4	-0.64	-11.55	-0.49	5.4e-27	Bipolar disorder;
LUAD	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15664640	chr17:80829946	TBCD	-0.59	-11.46	-0.49	1.13e-26	Breast cancer;
LUAD	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.72	-14.86	-0.59	1.78e-40	Urate levels in overweight individuals;
LUAD	cis	rs807669	1.000	rs807670	chr22:19154608	A/C	cg02655711	chr22:19163373	SLC25A1	0.74	15.04	0.59	3.06e-41	Metabolite levels;
LUAD	cis	rs4523957	0.855	rs216212	chr17:2134214	T/C	cg16513277	chr17:2031491	SMG6	0.79	14.37	0.57	2.06e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg07741184	chr6:167504864	NA	0.35	8.06	0.36	8.11e-15	Primary biliary cholangitis;
LUAD	cis	rs7584330	0.554	rs74001399	chr2:238445440	G/A	cg14458575	chr2:238380390	NA	0.61	9.81	0.43	1.37e-20	Prostate cancer;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg18000306	chr6:288505	NA	0.43	7.98	0.36	1.42e-14	Menopause (age at onset);
LUAD	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg22823121	chr1:150693482	HORMAD1	0.38	7.41	0.34	7.09e-13	Melanoma;
LUAD	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7677751	0.806	rs4864861	chr4:55097685	C/T	cg17187183	chr4:55093834	PDGFRA	0.51	8.53	0.38	2.6e-16	Corneal astigmatism;
LUAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08048268	chr3:133502702	NA	-0.54	-10.69	-0.46	8.89e-24	Iron status biomarkers;
LUAD	cis	rs1444418	1.000	rs7922917	chr10:64559027	C/G	cg14943953	chr10:64564468	ADO	-0.58	-7.04	-0.32	7.74e-12	Atopic dermatitis;
LUAD	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg01868782	chr6:126071099	HEY2	0.32	6.72	0.31	5.87e-11	Brugada syndrome;
LUAD	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.99e-19	Life satisfaction;
LUAD	trans	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg07393940	chr7:158741817	NA	-0.69	-11.85	-0.5	3.75e-28	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg18621852	chr3:10150065	C3orf24	0.47	8.09	0.37	6.19e-15	Alzheimer's disease;
LUAD	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg25233709	chr10:116636983	FAM160B1	0.44	8.82	0.39	3.12e-17	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg09904177	chr6:26538194	HMGN4	-0.44	-7.33	-0.34	1.19e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg22676075	chr6:135203613	NA	0.4	7.46	0.34	4.95e-13	Red blood cell count;
LUAD	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg26875233	chr11:93583750	C11orf90	-0.39	-8.87	-0.4	2.06e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg12935359	chr14:103987150	CKB	-0.7	-10.01	-0.44	2.55e-21	Body mass index;
LUAD	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg25894440	chr7:65020034	NA	0.6	6.46	0.3	2.8e-10	Diabetic kidney disease;
LUAD	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg18806716	chr10:30721971	MAP3K8	0.79	16.59	0.63	5.89e-48	Inflammatory bowel disease;
LUAD	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg15017067	chr4:17643749	FAM184B	0.36	7.16	0.33	3.57e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg16006841	chr5:176797999	RGS14	0.53	9.41	0.42	3.3e-19	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg05434287	chr7:2030229	MAD1L1	0.39	6.44	0.3	3.29e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg11070056	chr1:107600091	PRMT6	-0.52	-9.32	-0.41	6.27e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg17425144	chr1:10567563	PEX14	0.59	12.73	0.53	1.14e-31	Breast size;
LUAD	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg12863693	chr15:85201151	NMB	0.37	6.45	0.3	3.11e-10	Schizophrenia;
LUAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00166722	chr3:10149974	C3orf24	-0.73	-10.87	-0.47	1.94e-24	Alzheimer's disease;
LUAD	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg16322792	chr1:120165303	ZNF697	0.71	19.05	0.68	6.95e-59	Systemic lupus erythematosus;
LUAD	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg21984481	chr17:79567631	NPLOC4	-0.55	-11.69	-0.49	1.53e-27	Eye color traits;
LUAD	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg12016809	chr21:47604291	C21orf56	0.45	7.49	0.34	4.18e-13	Testicular germ cell tumor;
LUAD	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07266350	chr3:49460521	AMT;NICN1	-0.37	-6.57	-0.3	1.45e-10	Menarche (age at onset);
LUAD	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg23281280	chr6:28129359	ZNF389	0.46	6.58	0.3	1.39e-10	Parkinson's disease;
LUAD	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11644478	chr21:40555479	PSMG1	0.7	11.71	0.49	1.28e-27	Cognitive function;
LUAD	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.75	0.39	5.22e-17	Menopause (age at onset);
LUAD	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg08601574	chr20:25228251	PYGB	0.47	8.56	0.38	2.17e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.19	15.37	0.6	1.14e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg24675056	chr1:15929824	NA	0.49	8.12	0.37	5.1e-15	Systolic blood pressure;
LUAD	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg08859206	chr1:53392774	SCP2	0.58	10.49	0.45	4.86e-23	Monocyte count;
LUAD	cis	rs10129255	0.500	rs10142931	chr14:107190525	A/C	cg23076370	chr14:107095027	NA	-0.44	-8.74	-0.39	5.59e-17	Kawasaki disease;
LUAD	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg06740227	chr12:86229804	RASSF9	0.41	7.15	0.33	3.79e-12	Major depressive disorder;
LUAD	trans	rs7395662	1.000	rs12420372	chr11:48497603	A/C	cg00717180	chr2:96193071	NA	0.38	7.23	0.33	2.24e-12	HDL cholesterol;
LUAD	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg05373962	chr22:49881684	NA	-0.53	-11.35	-0.48	3.09e-26	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs8192282	0.739	rs10908846	chr1:154501364	C/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.45	-6.91	-0.32	1.8e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg03161606	chr19:29218774	NA	0.54	8.21	0.37	2.67e-15	Methadone dose in opioid dependence;
LUAD	cis	rs1595825	0.945	rs76510735	chr2:198823095	G/A	cg00982548	chr2:198649783	BOLL	-0.63	-8.93	-0.4	1.34e-17	Ulcerative colitis;
LUAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg08888203	chr3:10149979	C3orf24	0.72	12.87	0.53	3.25e-32	Alzheimer's disease;
LUAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.62	-10.8	-0.46	3.55e-24	Lymphocyte counts;
LUAD	cis	rs4594175	0.926	rs11157803	chr14:51627700	C/T	cg23942311	chr14:51606299	NA	0.65	11.6	0.49	3.45e-27	Cancer;
LUAD	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg02886208	chr11:14281011	SPON1	0.4	8.22	0.37	2.43e-15	Mitochondrial DNA levels;
LUAD	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg04398451	chr17:18023971	MYO15A	-0.63	-11.52	-0.49	6.7399999999999993e-27	Total body bone mineral density;
LUAD	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg26384229	chr12:38710491	ALG10B	0.48	7.76	0.35	6.23e-14	Bladder cancer;
LUAD	cis	rs34734847	0.787	rs658521	chr12:121162414	G/T	cg27246729	chr12:121163418	ACADS	0.38	6.99	0.32	1.07e-11	Mean corpuscular volume;
LUAD	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg03929089	chr4:120376271	NA	-0.5	-7.86	-0.36	3.28e-14	HDL cholesterol;
LUAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg11965913	chr1:205819406	PM20D1	0.95	22.38	0.74	9.6e-74	Menarche (age at onset);
LUAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg22868518	chr11:507468	RNH1	-0.68	-6.79	-0.31	3.76e-11	Body mass index;
LUAD	cis	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg02508848	chr16:68573721	ZFP90	-0.43	-6.62	-0.31	1.1e-10	Ulcerative colitis;
LUAD	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg26384229	chr12:38710491	ALG10B	0.48	7.79	0.35	5.28e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25427524	chr10:38739819	LOC399744	-0.76	-13.67	-0.55	1.66e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9394169	0.613	rs2395399	chr6:33777432	T/C	cg07979401	chr6:33739406	LEMD2	-0.41	-7.47	-0.34	4.68e-13	Essential tremor;
LUAD	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg00666640	chr1:248458726	OR2T12	0.32	7.81	0.36	4.46e-14	Common traits (Other);
LUAD	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.56	9.69	0.43	3.55e-20	Menarche (age at onset);
LUAD	cis	rs863345	0.604	rs11265015	chr1:158503252	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.46	-0.3	2.84e-10	Pneumococcal bacteremia;
LUAD	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11644478	chr21:40555479	PSMG1	0.61	10.27	0.45	2.99e-22	Cognitive function;
LUAD	trans	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg19862616	chr7:65841803	NCRNA00174	1.04	25.89	0.78	3.02e-89	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg05966235	chr16:28915196	ATP2A1	0.43	7.04	0.32	7.77e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg18833306	chr6:118973337	C6orf204	-0.53	-7.58	-0.35	2.24e-13	Diastolic blood pressure;
LUAD	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-7.2	-0.33	2.8e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg06640241	chr16:89574553	SPG7	0.49	7.95	0.36	1.67e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs9837602	1.000	rs7610486	chr3:99732564	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.65	9.44	0.42	2.5e-19	Breast cancer;
LUAD	cis	rs10493773	0.894	rs12067749	chr1:86197922	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.56	-9.49	-0.42	1.75e-19	Urate levels in overweight individuals;
LUAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	6.66	0.31	8.7e-11	Hemoglobin concentration;
LUAD	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg23029597	chr12:123009494	RSRC2	-0.5	-7.84	-0.36	3.66e-14	Body mass index;
LUAD	cis	rs9427116	0.840	rs9427114	chr1:154626705	T/C	cg17218026	chr1:154582156	ADAR	0.43	8.19	0.37	3.2e-15	Blood protein levels;
LUAD	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg02269571	chr22:50332266	NA	-0.67	-9.44	-0.42	2.44e-19	Schizophrenia;
LUAD	cis	rs758324	0.741	rs10075660	chr5:131240843	C/A	cg06307176	chr5:131281290	NA	-0.5	-8.12	-0.37	5.02e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg16482183	chr6:26056742	HIST1H1C	0.46	6.69	0.31	7.07e-11	Iron status biomarkers;
LUAD	cis	rs977987	0.806	rs4888383	chr16:75386349	C/T	cg03315344	chr16:75512273	CHST6	0.65	14.13	0.57	2.09e-37	Dupuytren's disease;
LUAD	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg18305652	chr10:134549665	INPP5A	-0.39	-8.69	-0.39	8.17e-17	Migraine;
LUAD	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg03474202	chr17:45855739	NA	-0.38	-9.08	-0.4	4.11e-18	IgG glycosylation;
LUAD	cis	rs10193935	0.901	rs9309082	chr2:42581412	A/G	cg27598129	chr2:42591480	NA	-0.75	-9.78	-0.43	1.7e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg07870213	chr5:140052090	DND1	-0.67	-9.7	-0.43	3.18e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg24558204	chr6:135376177	HBS1L	-0.47	-8.08	-0.37	6.63e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg02176678	chr2:219576539	TTLL4	0.59	11.55	0.49	5.38e-27	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg20587970	chr11:113659929	NA	-1.37	-20.06	-0.7	2.24e-63	Hip circumference adjusted for BMI;
LUAD	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg07570687	chr10:102243282	WNT8B	0.45	6.96	0.32	1.3e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs7615952	0.546	rs2979333	chr3:125360343	T/A	cg17147758	chr8:6949321	NA	-0.51	-8.12	-0.37	5.29e-15	Blood pressure (smoking interaction);
LUAD	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg13770153	chr20:60521292	NA	-0.59	-10.02	-0.44	2.48e-21	Body mass index;
LUAD	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg03676636	chr4:99064102	C4orf37	-0.32	-8.38	-0.38	7.67e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg02423579	chr7:2872169	GNA12	-0.82	-13.79	-0.56	5.37e-36	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09529537	chr5:78531947	JMY	-0.46	-7.41	-0.34	7.06e-13	Height;
LUAD	cis	rs1215050	0.791	rs165242	chr4:98686482	A/C	cg05340658	chr4:99064831	C4orf37	-0.4	-6.43	-0.3	3.41e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.5	-0.38	3.35e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg07305463	chr2:136567211	LCT	0.37	6.67	0.31	8.23e-11	Mosquito bite size;
LUAD	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg12193833	chr17:30244370	NA	-0.55	-7.1	-0.33	5.3e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg02038168	chr22:39784481	NA	-0.53	-8.73	-0.39	6.1e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs12135894	0.562	rs6688969	chr1:3743391	C/T	cg17443473	chr1:3703550	LRRC47	0.4	7.41	0.34	6.85e-13	Mean corpuscular volume;
LUAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14893161	chr1:205819251	PM20D1	0.63	11.72	0.5	1.11e-27	Menarche (age at onset);
LUAD	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg23985595	chr17:80112537	CCDC57	0.53	9.74	0.43	2.25e-20	Life satisfaction;
LUAD	trans	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.89	-0.36	2.67e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9902453	0.933	rs7224199	chr17:28523726	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	8.57	0.38	1.98e-16	Coffee consumption (cups per day);
LUAD	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg00933542	chr6:150070202	PCMT1	0.41	8.69	0.39	8.09e-17	Lung cancer;
LUAD	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg03433033	chr1:76189801	ACADM	0.84	15.04	0.59	2.85e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7100689	0.646	rs9804236	chr10:82135100	T/C	cg00277334	chr10:82204260	NA	-0.63	-10.54	-0.46	3.26e-23	Post bronchodilator FEV1;
LUAD	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg01579765	chr21:45077557	HSF2BP	-0.66	-15.04	-0.59	3.07e-41	Mean corpuscular volume;
LUAD	cis	rs7119	0.634	rs11635634	chr15:77863412	T/C	cg27398640	chr15:77910606	LINGO1	0.34	6.47	0.3	2.69e-10	Type 2 diabetes;
LUAD	trans	rs10411161	0.810	rs8102738	chr19:52388229	T/C	cg22319618	chr22:45562946	NUP50	-0.69	-7.97	-0.36	1.53e-14	Breast cancer;
LUAD	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.37	7.49	0.34	4.18e-13	Depression;
LUAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.56	0.3	1.61e-10	Prudent dietary pattern;
LUAD	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg25894440	chr7:65020034	NA	-0.65	-6.94	-0.32	1.44e-11	Diabetic kidney disease;
LUAD	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg00898013	chr13:113819073	PROZ	-0.81	-14.9	-0.59	1.2e-40	Platelet distribution width;
LUAD	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	7.29	0.33	1.51e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg08859206	chr1:53392774	SCP2	0.59	10.66	0.46	1.19e-23	Monocyte count;
LUAD	cis	rs926938	0.563	rs360576	chr1:115459174	A/C	cg12756093	chr1:115239321	AMPD1	-0.38	-6.52	-0.3	1.95e-10	Autism;
LUAD	cis	rs7493	0.901	rs17882539	chr7:95026408	G/A	cg04155289	chr7:94953770	PON1	-0.55	-7.67	-0.35	1.22e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg05768032	chr16:30646687	NA	0.42	7.19	0.33	2.96e-12	Multiple myeloma;
LUAD	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03934478	chr11:495069	RNH1	0.77	8.91	0.4	1.58e-17	Body mass index;
LUAD	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg14664628	chr15:75095509	CSK	0.49	8.26	0.37	1.82e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg04511125	chr2:88470314	THNSL2	0.83	9.52	0.42	1.35e-19	Plasma clusterin levels;
LUAD	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.6	12.37	0.52	3.23e-30	Hemoglobin concentration;
LUAD	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg03929089	chr4:120376271	NA	-0.92	-17.03	-0.64	6.58e-50	Height;
LUAD	cis	rs7027203	1.000	rs7856374	chr9:96529791	G/A	cg14598338	chr9:96623480	NA	0.37	7.37	0.34	9.16e-13	DNA methylation (variation);
LUAD	cis	rs12216545	0.765	rs2140141	chr7:150249079	A/G	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.39	-0.3	4.27e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg03929089	chr4:120376271	NA	0.54	7.13	0.33	4.32e-12	Axial length;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg21781916	chr12:122018375	KDM2B	-0.54	-6.74	-0.31	5.27e-11	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg27051686	chr2:238398490	MLPH	-0.38	-6.5	-0.3	2.26e-10	Prostate cancer;
LUAD	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg06784218	chr1:46089804	CCDC17	0.59	13.05	0.54	5.92e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1198430	0.929	rs1210852	chr1:23753533	T/C	cg12023170	chr1:23751761	TCEA3	-0.46	-6.37	-0.3	5.06e-10	Total cholesterol levels;
LUAD	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg16325326	chr1:53192061	ZYG11B	0.68	12.35	0.51	3.78e-30	Monocyte count;
LUAD	cis	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-6.62	-0.31	1.1e-10	Ulcerative colitis;
LUAD	cis	rs16910800	1.000	rs11027021	chr11:23183529	C/T	cg20040320	chr11:23191996	NA	0.49	7.26	0.33	1.88e-12	Cancer;
LUAD	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg05926928	chr17:57297772	GDPD1	1.39	17.2	0.64	1.21e-50	Opioid sensitivity;
LUAD	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.09	0.33	5.5e-12	Parkinson's disease;
LUAD	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.55	-9.1	-0.4	3.59e-18	Electrocardiographic conduction measures;
LUAD	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg08885076	chr2:99613938	TSGA10	0.37	6.6	0.31	1.22e-10	Chronic sinus infection;
LUAD	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg17724175	chr1:150552817	MCL1	0.34	7.87	0.36	3.01e-14	Melanoma;
LUAD	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.88	0.36	2.75e-14	Depression;
LUAD	cis	rs17641971	0.684	rs4873100	chr8:50025772	G/A	cg00325661	chr8:49890786	NA	0.3	6.74	0.31	5.15e-11	Blood metabolite levels;
LUAD	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.66	-0.31	8.37e-11	Personality dimensions;
LUAD	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-11.09	-0.47	2.93e-25	Electroencephalogram traits;
LUAD	trans	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg04565464	chr8:145669602	NFKBIL2	0.44	6.48	0.3	2.5e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg00277334	chr10:82204260	NA	-0.63	-10.45	-0.45	6.87e-23	Post bronchodilator FEV1;
LUAD	cis	rs11585357	0.895	rs72633823	chr1:17630779	G/A	cg08277548	chr1:17600880	PADI3	-0.97	-14.11	-0.57	2.46e-37	Hair shape;
LUAD	cis	rs7707921	0.767	rs178931	chr5:81575601	T/A	cg15871215	chr5:81402204	ATG10	0.64	10.05	0.44	1.9e-21	Breast cancer;
LUAD	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.79	-0.31	3.79e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg07917127	chr4:99064746	C4orf37	0.42	6.87	0.32	2.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg03806693	chr22:41940476	POLR3H	0.77	10.28	0.45	2.78e-22	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7072216	0.881	rs6584192	chr10:100152373	T/G	cg26618903	chr10:100175079	PYROXD2	-0.3	-6.48	-0.3	2.53e-10	Metabolite levels;
LUAD	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.05	-0.36	8.53e-15	Cystic fibrosis severity;
LUAD	cis	rs17197710	0.673	rs3816724	chr11:47312045	C/G	cg13308137	chr11:47528955	CUGBP1	-0.43	-6.87	-0.32	2.31e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg18132916	chr6:79620363	NA	-0.45	-7.76	-0.35	6.63e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg13877915	chr19:58951672	ZNF132	0.74	14.07	0.56	3.61e-37	Uric acid clearance;
LUAD	cis	rs7809950	1.000	rs12667527	chr7:107086969	T/C	cg23024343	chr7:107201750	COG5	-0.75	-12.84	-0.53	4.21e-32	Coronary artery disease;
LUAD	cis	rs1595825	0.891	rs73056877	chr2:198816724	A/C	cg00982548	chr2:198649783	BOLL	-0.63	-8.93	-0.4	1.34e-17	Ulcerative colitis;
LUAD	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.49	6.6	0.31	1.25e-10	Platelet count;
LUAD	cis	rs9928842	0.712	rs10871304	chr16:75223491	G/T	cg03088958	chr16:75232330	NA	-0.36	-6.47	-0.3	2.64e-10	Alcoholic chronic pancreatitis;
LUAD	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg13334819	chr7:99746414	C7orf59	-0.65	-9.91	-0.43	5.66e-21	Coronary artery disease;
LUAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.74	-0.35	7.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg13057898	chr1:3703894	LRRC47	0.59	10.62	0.46	1.63e-23	Red cell distribution width;
LUAD	trans	rs3812049	1.000	rs3812049	chr5:127418850	C/G	cg16011800	chr17:1958478	HIC1	-0.57	-8.09	-0.37	6.43e-15	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg02038168	chr22:39784481	NA	-0.6	-10.73	-0.46	6.63e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9650657	0.737	rs4504595	chr8:10655505	A/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.48	-0.3	2.54e-10	Neuroticism;
LUAD	cis	rs12618769	0.652	rs7595120	chr2:99231805	C/G	cg10123293	chr2:99228465	UNC50	0.5	8.87	0.4	2.12e-17	Bipolar disorder;
LUAD	trans	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg18187862	chr3:45730750	SACM1L	0.5	7.79	0.35	5.22e-14	Primary sclerosing cholangitis;
LUAD	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11890956	chr21:40555474	PSMG1	0.79	13.35	0.54	3.54e-34	Cognitive function;
LUAD	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg00701064	chr4:6280414	WFS1	0.65	13.68	0.55	1.51e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.56	8.0	0.36	1.23e-14	Platelet count;
LUAD	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.42	0.34	6.47e-13	Bipolar disorder;
LUAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.07e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6591341	0.515	rs599301	chr11:68189945	G/C	cg16797656	chr11:68205561	LRP5	0.52	10.74	0.46	6.1e-24	Lean body mass;
LUAD	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg06784218	chr1:46089804	CCDC17	0.61	13.73	0.56	9.66e-36	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.17	-0.33	3.34e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.7	-0.31	6.52e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs4799710	0.500	rs4799713	chr18:31276884	A/T	cg27147174	chr7:100797783	AP1S1	-0.4	-6.71	-0.31	6.43e-11	Pulmonary function;
LUAD	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg04586622	chr2:25135609	ADCY3	0.38	8.6	0.39	1.55e-16	Body mass index;
LUAD	cis	rs17213078	0.602	rs4851113	chr2:106747009	G/C	cg15412446	chr2:106886593	NA	0.38	6.42	0.3	3.58e-10	Facial morphology (factor 23);
LUAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg04352962	chr1:209979756	IRF6	0.51	7.3	0.33	1.46e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg17173187	chr15:85201210	NMB	0.41	6.61	0.31	1.14e-10	Schizophrenia;
LUAD	cis	rs6758955	0.850	rs60661460	chr2:10478239	A/G	cg15773312	chr2:10472214	HPCAL1	-0.48	-7.22	-0.33	2.4e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.48	-9.13	-0.41	2.77e-18	Longevity;Endometriosis;
LUAD	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.5	9.04	0.4	5.65e-18	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg13770153	chr20:60521292	NA	-0.48	-8.13	-0.37	4.72e-15	Body mass index;
LUAD	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg15448220	chr1:150897856	SETDB1	0.46	7.97	0.36	1.47e-14	Tonsillectomy;
LUAD	cis	rs447921	0.724	rs346797	chr17:74378901	A/C	cg17201438	chr17:74438067	UBE2O	-0.62	-8.17	-0.37	3.73e-15	Mitochondrial DNA levels;
LUAD	cis	rs2692947	0.667	rs4144055	chr2:96647856	G/T	cg23100626	chr2:96804247	ASTL	0.3	7.68	0.35	1.14e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs1595825	1.000	rs79508374	chr2:198864568	G/A	cg10547527	chr2:198650123	BOLL	-0.46	-6.64	-0.31	9.67e-11	Ulcerative colitis;
LUAD	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-8.49	-0.38	3.67e-16	Hemoglobin concentration;
LUAD	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg11822812	chr5:140052017	DND1	0.38	6.84	0.32	2.78e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.37	-0.34	8.87e-13	Bipolar disorder;
LUAD	trans	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg01620082	chr3:125678407	NA	-0.97	-8.86	-0.4	2.21e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg10596483	chr8:143751796	JRK	0.45	7.25	0.33	2.03e-12	Schizophrenia;
LUAD	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg21016266	chr12:122356598	WDR66	0.7	12.84	0.53	4.22e-32	Mean platelet volume;
LUAD	trans	rs7395662	1.000	rs1809986	chr11:48987539	C/A	cg00717180	chr2:96193071	NA	-0.4	-7.6	-0.35	1.96e-13	HDL cholesterol;
LUAD	cis	rs990171	0.538	rs6728288	chr2:103117268	A/T	cg03938978	chr2:103052716	IL18RAP	0.33	6.54	0.3	1.76e-10	Lymphocyte counts;
LUAD	cis	rs7943953	0.714	rs1453550	chr11:59193527	C/T	cg00706994	chr11:59190310	OR5A2	0.34	6.37	0.3	4.95e-10	Odorant perception (&beta-ionone);
LUAD	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.44	0.38	5.18e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.48	-7.78	-0.35	5.62e-14	Alzheimer's disease (late onset);
LUAD	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.67	-0.39	9.42e-17	Alzheimer's disease (late onset);
LUAD	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg02269571	chr22:50332266	NA	-0.61	-9.26	-0.41	1e-18	Schizophrenia;
LUAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg15147215	chr3:52552868	STAB1	-0.48	-8.87	-0.4	2e-17	Electroencephalogram traits;
LUAD	cis	rs10193935	0.901	rs222486	chr2:42649664	C/T	cg27598129	chr2:42591480	NA	-0.68	-8.77	-0.39	4.45e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12976411	0.575	rs34398998	chr19:32820820	C/A	cg18253629	chr19:32836317	ZNF507	0.65	6.84	0.32	2.87e-11	Coronary artery disease;
LUAD	cis	rs1595825	0.891	rs79745588	chr2:198516835	G/A	cg11031976	chr2:198649780	BOLL	-0.47	-6.91	-0.32	1.81e-11	Ulcerative colitis;
LUAD	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg20203395	chr5:56204925	C5orf35	-0.5	-7.95	-0.36	1.7e-14	Coronary artery disease;
LUAD	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22496380	chr5:211416	CCDC127	-1.2	-15.52	-0.6	2.54e-43	Breast cancer;
LUAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg26470479	chr17:40805923	NA	0.36	7.07	0.33	6.36e-12	Colorectal or endometrial cancer;
LUAD	cis	rs55665837	1.000	rs10832269	chr11:14465069	C/A	cg19336497	chr11:14380999	RRAS2	-0.51	-10.3	-0.45	2.32e-22	Vitamin D levels;
LUAD	cis	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg16735072	chr8:11994639	FAM66D	-0.42	-6.58	-0.3	1.4e-10	Neuroticism;
LUAD	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg02527881	chr3:46936655	PTH1R	-0.56	-11.65	-0.49	2.23e-27	Colorectal cancer;
LUAD	cis	rs4713675	0.584	rs6917140	chr6:33678394	C/G	cg14003231	chr6:33640908	ITPR3	0.49	9.41	0.42	3.32e-19	Plateletcrit;
LUAD	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02475777	chr4:1388615	CRIPAK	-0.5	-7.25	-0.33	1.96e-12	Obesity-related traits;
LUAD	cis	rs9811920	0.809	rs796976	chr3:99621002	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.38	-7.03	-0.32	8.27e-12	Axial length;
LUAD	cis	rs9905704	0.681	rs2680710	chr17:56552902	A/G	cg19466818	chr17:56409534	MIR142	0.33	6.6	0.31	1.22e-10	Testicular germ cell tumor;
LUAD	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg18306943	chr3:40428807	ENTPD3	0.41	7.19	0.33	2.87e-12	Renal cell carcinoma;
LUAD	cis	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg14039649	chr22:38352398	POLR2F	0.37	6.63	0.31	1.03e-10	Glioblastoma;Glioma;
LUAD	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg24818145	chr4:99064322	C4orf37	0.46	7.84	0.36	3.59e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg18230493	chr5:56204884	C5orf35	-0.44	-7.26	-0.33	1.9e-12	Coronary artery disease;
LUAD	cis	rs9649213	0.586	rs11768599	chr7:97974555	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.74	-11.05	-0.47	4.18e-25	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.71	-0.43	2.93e-20	Alzheimer's disease;
LUAD	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg21775007	chr8:11205619	TDH	0.4	7.21	0.33	2.61e-12	Retinal vascular caliber;
LUAD	cis	rs9287719	0.578	rs13425171	chr2:10731966	C/G	cg02196655	chr2:10830764	NOL10	-0.39	-6.73	-0.31	5.5e-11	Prostate cancer;
LUAD	cis	rs739496	0.615	rs7962138	chr12:112180177	A/G	cg10833066	chr12:111807467	FAM109A	0.42	6.82	0.31	3.19e-11	Platelet count;
LUAD	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg01448562	chr3:133502909	NA	-0.54	-9.94	-0.44	4.72e-21	Alcohol consumption (transferrin glycosylation);
LUAD	trans	rs412658	0.704	rs8105767	chr19:22215441	A/G	cg05197062	chr11:11642011	GALNTL4	-0.41	-7.06	-0.32	6.79e-12	Telomere length;
LUAD	cis	rs9341808	0.655	rs9350846	chr6:80865481	T/A	cg08355045	chr6:80787529	NA	0.55	9.81	0.43	1.3e-20	Sitting height ratio;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27079446	chr18:3449844	TGIF1	-0.59	-7.09	-0.33	5.59e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.51	0.42	1.46e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7089973	0.872	rs12773943	chr10:116631184	G/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.53	0.42	1.25e-19	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.82	0.31	3.12e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9283706	0.689	rs11956654	chr5:66318196	A/G	cg11590213	chr5:66331682	MAST4	0.41	6.76	0.31	4.49e-11	Coronary artery disease;
LUAD	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg11663144	chr21:46675770	NA	-0.48	-9.24	-0.41	1.24e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1448094	0.845	rs10863123	chr12:86346254	G/A	cg00310523	chr12:86230176	RASSF9	0.36	7.48	0.34	4.3e-13	Major depressive disorder;
LUAD	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.42	6.53	0.3	1.86e-10	Platelet count;
LUAD	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg14668632	chr7:2872130	GNA12	-0.46	-7.99	-0.36	1.28e-14	Height;
LUAD	cis	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg26958806	chr6:27640298	NA	0.65	6.38	0.3	4.73e-10	Depression;
LUAD	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg16384552	chr7:74938386	SPDYE8P	0.6	9.61	0.42	6.75e-20	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs524023	0.914	rs7932437	chr11:64373504	T/C	cg19131476	chr11:64387923	NRXN2	-0.42	-8.09	-0.37	6.23e-15	Urate levels in obese individuals;
LUAD	trans	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg18834416	chr8:37888184	EIF4EBP1	0.4	6.67	0.31	7.8e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg01689657	chr7:91764605	CYP51A1	0.37	9.02	0.4	6.58e-18	Breast cancer;
LUAD	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg20920097	chr3:127057149	NA	-0.54	-7.6	-0.35	1.89e-13	Interleukin-10 levels;Interleukin-13 levels;
LUAD	cis	rs11153730	0.503	rs283066	chr6:118620064	A/G	cg21191810	chr6:118973309	C6orf204	0.52	10.52	0.46	3.87e-23	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.13	-0.41	2.85e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs300774	0.925	rs375613	chr2:130618	C/G	cg21211680	chr2:198530	NA	0.49	7.59	0.35	2.1e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs6445967	0.506	rs7433237	chr3:58466864	A/G	cg13750441	chr3:58318267	PXK	-0.34	-6.61	-0.31	1.19e-10	Platelet count;
LUAD	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg13319975	chr6:146136371	FBXO30	0.57	9.54	0.42	1.19e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9658691	0.736	rs9658727	chr10:90761865	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.8	-9.0	-0.4	7.43e-18	Mosquito bite size;
LUAD	cis	rs4713675	0.565	rs4711343	chr6:33714548	G/A	cg13859433	chr6:33739653	LEMD2	-0.3	-7.19	-0.33	2.96e-12	Plateletcrit;
LUAD	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg03929089	chr4:120376271	NA	-0.53	-7.78	-0.35	5.72e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg08807101	chr21:30365312	RNF160	0.52	8.93	0.4	1.34e-17	Dental caries;
LUAD	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg14582100	chr15:45693742	SPATA5L1	0.43	8.59	0.39	1.65e-16	Response to fenofibrate (adiponectin levels);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg25004270	chr1:1550864	MIB2	-0.69	-6.73	-0.31	5.64e-11	Type 2 diabetes;
LUAD	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.4	-7.23	-0.33	2.23e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg22166914	chr1:53195759	ZYG11B	-0.4	-6.56	-0.3	1.55e-10	Monocyte count;
LUAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.37e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg26597838	chr10:835615	NA	0.97	15.17	0.59	8.07e-42	Eosinophil percentage of granulocytes;
LUAD	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg15147215	chr3:52552868	STAB1	0.37	7.13	0.33	4.44e-12	Bipolar disorder;
LUAD	cis	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg08601574	chr20:25228251	PYGB	-0.45	-8.22	-0.37	2.49e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs8192282	0.739	rs11265627	chr1:154496286	A/C	cg07911225	chr1:154474108	TDRD10;SHE	0.39	7.32	0.34	1.26e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg13393036	chr8:95962371	TP53INP1	-0.44	-10.49	-0.45	4.75e-23	Type 2 diabetes;
LUAD	cis	rs9976767	0.608	rs9784208	chr21:43824986	A/G	cg23042151	chr21:43824109	UBASH3A	-0.3	-6.52	-0.3	1.97e-10	Type 1 diabetes;
LUAD	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg17724175	chr1:150552817	MCL1	0.39	9.37	0.41	4.54e-19	Tonsillectomy;
LUAD	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg26446133	chr18:72167187	CNDP2	-0.82	-12.25	-0.51	9.91e-30	Refractive error;
LUAD	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-8.33	-0.38	1.15e-15	Hemoglobin concentration;
LUAD	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg01324343	chr3:183735012	ABCC5	0.94	25.24	0.78	2.14e-86	Anterior chamber depth;
LUAD	trans	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg19955956	chr7:72299837	SBDSP;TYW1B	0.54	9.31	0.41	6.85e-19	Blood metabolite levels;
LUAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg14092988	chr3:52407081	DNAH1	0.39	7.83	0.36	3.95e-14	Electroencephalogram traits;
LUAD	cis	rs2070433	1.000	rs2839302	chr21:47952364	G/A	cg12379764	chr21:47803548	PCNT	0.49	6.6	0.31	1.2e-10	Lymphocyte counts;
LUAD	cis	rs704	0.585	rs2227735	chr17:26693258	C/T	cg10342447	chr17:26645325	TMEM97	-0.4	-7.98	-0.36	1.41e-14	Osteoprotegerin levels;
LUAD	cis	rs669446	0.528	rs4660743	chr1:44195404	C/T	cg12908607	chr1:44402522	ARTN	-0.35	-7.01	-0.32	9.74e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs870825	0.616	rs28459754	chr4:185636280	C/A	cg04058563	chr4:185651563	MLF1IP	0.88	14.04	0.56	4.87e-37	Blood protein levels;
LUAD	cis	rs1461503	0.868	rs11602682	chr11:122842315	A/T	cg27398637	chr11:122830231	C11orf63	-0.35	-6.67	-0.31	7.87e-11	Menarche (age at onset);
LUAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg04025307	chr7:1156635	C7orf50	0.6	6.74	0.31	5.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2985684	0.841	rs2281836	chr14:50065717	G/C	cg04989706	chr14:50066350	PPIL5	-0.53	-7.69	-0.35	1.01e-13	Carotid intima media thickness;
LUAD	cis	rs7586879	0.616	rs916485	chr2:25082273	T/C	cg04586622	chr2:25135609	ADCY3	0.37	8.59	0.39	1.72e-16	Body mass index;
LUAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-6.93	-0.32	1.56e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.83	-0.36	3.97e-14	Diabetic kidney disease;
LUAD	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg05425664	chr17:57184151	TRIM37	0.43	7.72	0.35	8.77e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2859741	1.000	rs2859741	chr1:37509352	C/T	cg09363841	chr1:37513479	NA	-0.33	-8.12	-0.37	5.1e-15	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg00933542	chr6:150070202	PCMT1	0.43	9.32	0.41	6.44e-19	Lung cancer;
LUAD	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg18105134	chr13:113819100	PROZ	0.73	12.91	0.53	2.2e-32	Platelet distribution width;
LUAD	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg19318889	chr4:1322082	MAEA	0.57	9.66	0.43	4.27e-20	Longevity;
LUAD	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg22920501	chr2:26401640	FAM59B	-0.82	-11.54	-0.49	5.88e-27	Gut microbiome composition (summer);
LUAD	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg03806693	chr22:41940476	POLR3H	0.52	7.66	0.35	1.31e-13	Vitiligo;
LUAD	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg05182265	chr7:156933206	UBE3C	-0.8	-17.26	-0.64	6.54e-51	Body mass index;
LUAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9902453	0.765	rs8079209	chr17:28186773	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	10.42	0.45	8.5e-23	Coffee consumption (cups per day);
LUAD	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg06641503	chr3:48959341	ARIH2	-0.41	-8.12	-0.37	5.07e-15	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.45	0.52	1.58e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg19318889	chr4:1322082	MAEA	0.46	7.45	0.34	5.27e-13	Obesity-related traits;
LUAD	cis	rs12545109	0.800	rs1530218	chr8:57407864	C/G	cg21220214	chr8:57350948	NA	-0.62	-8.61	-0.39	1.49e-16	Obesity-related traits;
LUAD	cis	rs55823223	0.752	rs34974290	chr17:73888354	G/A	cg14955151	chr17:73874635	TRIM47	-0.41	-6.39	-0.3	4.33e-10	Psoriasis;
LUAD	cis	rs6740322	0.895	rs9309098	chr2:43554972	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.77	11.25	0.48	7.15e-26	Coronary artery disease;
LUAD	trans	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg14917512	chr19:3094685	GNA11	0.57	6.81	0.31	3.47e-11	Diabetic kidney disease;
LUAD	cis	rs11249608	0.548	rs12152869	chr5:178462520	A/G	cg01312482	chr5:178451176	ZNF879	-0.45	-7.07	-0.33	6.26e-12	Pubertal anthropometrics;
LUAD	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12667521	chr19:29218732	NA	0.59	8.38	0.38	7.92e-16	Methadone dose in opioid dependence;
LUAD	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.26	-0.54	8.48e-34	Chronic sinus infection;
LUAD	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg22906224	chr7:99728672	NA	0.59	9.76	0.43	1.99e-20	Coronary artery disease;
LUAD	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg24818145	chr4:99064322	C4orf37	0.45	7.1	0.33	5.38e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12413816	0.857	rs1571009	chr10:13760975	G/A	cg16485048	chr10:13749193	FRMD4A	0.38	6.72	0.31	5.96e-11	Red cell distribution width;
LUAD	cis	rs600626	0.529	rs11236527	chr11:75469310	A/G	cg24262691	chr11:75473276	NA	-0.54	-7.9	-0.36	2.44e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg24558204	chr6:135376177	HBS1L	0.45	8.2	0.37	2.89e-15	Red blood cell count;
LUAD	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.08	-0.33	6.17e-12	Total cholesterol levels;
LUAD	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-14.61	-0.58	2.06e-39	Chronic sinus infection;
LUAD	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg00784671	chr22:46762841	CELSR1	-0.62	-7.6	-0.35	1.95e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7107174	1.000	rs10899495	chr11:78123293	C/T	cg02023728	chr11:77925099	USP35	0.43	6.63	0.31	1.02e-10	Testicular germ cell tumor;
LUAD	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg25036284	chr2:26402008	FAM59B	-0.83	-11.68	-0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg00277334	chr10:82204260	NA	-0.66	-11.85	-0.5	3.56e-28	Post bronchodilator FEV1;
LUAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08677398	chr8:58056175	NA	0.46	6.54	0.3	1.76e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg11062466	chr8:58055876	NA	0.68	9.02	0.4	6.56e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg03467027	chr4:99064603	C4orf37	0.41	6.46	0.3	2.95e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.55	0.3	1.71e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg00310523	chr12:86230176	RASSF9	0.36	7.27	0.33	1.73e-12	Major depressive disorder;
LUAD	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.4	-0.42	3.45e-19	Life satisfaction;
LUAD	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.28	-0.51	7.17e-30	Primary sclerosing cholangitis;
LUAD	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg18827107	chr12:86230957	RASSF9	-0.46	-8.37	-0.38	8.38e-16	Major depressive disorder;
LUAD	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg21823605	chr1:152486609	CRCT1	0.29	6.67	0.31	8.06e-11	Hair morphology;
LUAD	cis	rs870825	1.000	rs72689245	chr4:185579788	G/A	cg04058563	chr4:185651563	MLF1IP	0.76	9.47	0.42	2.03e-19	Blood protein levels;
LUAD	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg27124370	chr19:33622961	WDR88	0.42	6.66	0.31	8.75e-11	Bone properties (heel);
LUAD	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg05110241	chr16:68378359	PRMT7	-0.9	-10.43	-0.45	8.37e-23	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6087990	0.731	rs2424897	chr20:31338098	A/T	cg13636640	chr20:31349939	DNMT3B	0.77	14.35	0.57	2.54e-38	Ulcerative colitis;
LUAD	trans	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.88	0.5	2.83e-28	Mean corpuscular volume;
LUAD	cis	rs829883	0.616	rs249832	chr12:98832387	C/T	cg25150519	chr12:98850993	NA	0.71	13.23	0.54	1.1e-33	Colorectal adenoma (advanced);
LUAD	cis	rs6430585	0.702	rs2304601	chr2:136528034	C/A	cg07169764	chr2:136633963	MCM6	0.79	8.99	0.4	8.57e-18	Corneal structure;
LUAD	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03264133	chr6:25882463	NA	-0.41	-6.78	-0.31	4.14e-11	Height;
LUAD	cis	rs4789939	0.528	rs2377003	chr17:76878902	T/C	cg26927190	chr17:76875678	TIMP2	-0.62	-6.72	-0.31	5.89e-11	Dupuytren's disease;
LUAD	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	10.37	0.45	1.33e-22	Colorectal cancer;
LUAD	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.64	11.19	0.48	1.23e-25	Birth weight;
LUAD	cis	rs9811920	0.665	rs1872609	chr3:99906579	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.8	-0.39	3.41e-17	Axial length;
LUAD	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg20933634	chr6:27740509	NA	0.47	7.44	0.34	5.62e-13	Parkinson's disease;
LUAD	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg15358701	chr1:161410459	NA	-0.69	-7.17	-0.33	3.3e-12	Rheumatoid arthritis;
LUAD	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg23173402	chr1:227635558	NA	0.84	7.35	0.34	1.03e-12	Major depressive disorder;
LUAD	cis	rs7512552	0.803	rs3738487	chr1:150477061	C/T	cg15654264	chr1:150340011	RPRD2	0.59	11.28	0.48	5.44e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs11195062	0.805	rs10884942	chr10:112016926	A/G	cg19214408	chr10:111981687	MXI1	-0.44	-7.29	-0.33	1.53e-12	Multiple myeloma;
LUAD	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg19318889	chr4:1322082	MAEA	0.91	15.63	0.6	8.86e-44	Longevity;
LUAD	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg09035930	chr12:129282057	SLC15A4	0.75	17.71	0.65	6.34e-53	Systemic lupus erythematosus;
LUAD	cis	rs4911259	0.552	rs13037833	chr20:31459562	C/T	cg13636640	chr20:31349939	DNMT3B	-0.59	-9.73	-0.43	2.57e-20	Inflammatory bowel disease;
LUAD	cis	rs7147624	0.938	rs7147231	chr14:66212371	A/G	cg03016385	chr14:66212404	NA	-0.6	-6.88	-0.32	2.2e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs6500395	0.963	rs4785528	chr16:48687908	A/C	cg04672837	chr16:48644449	N4BP1	-0.4	-6.93	-0.32	1.58e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg10978503	chr1:24200527	CNR2	-0.57	-12.59	-0.52	4.13e-31	Immature fraction of reticulocytes;
LUAD	cis	rs1448094	0.872	rs7305869	chr12:86440114	A/G	cg19622623	chr12:86230825	RASSF9	-0.36	-6.56	-0.3	1.53e-10	Major depressive disorder;
LUAD	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg17279839	chr7:150038598	RARRES2	0.39	6.89	0.32	2.09e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-7.82	-0.36	4.34e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg20503657	chr10:835505	NA	0.94	14.34	0.57	2.66e-38	Eosinophil percentage of granulocytes;
LUAD	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.55	7.86	0.36	3.19e-14	Platelet count;
LUAD	cis	rs868036	1.000	rs1471460	chr15:68089299	G/A	cg24579218	chr15:68104479	NA	-0.38	-7.12	-0.33	4.57e-12	Restless legs syndrome;
LUAD	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18876405	chr7:65276391	NA	0.41	6.35	0.3	5.53e-10	Aortic root size;
LUAD	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-7.81	-0.36	4.46e-14	Breast cancer;
LUAD	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg11266682	chr4:10021025	SLC2A9	0.65	14.09	0.57	3.04e-37	Bone mineral density;
LUAD	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.53	0.38	2.62e-16	Parkinson's disease;
LUAD	cis	rs2692947	0.550	rs12623771	chr2:96633504	A/G	cg23100626	chr2:96804247	ASTL	0.3	7.73	0.35	8.18e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.63	-8.05	-0.36	8.43e-15	Iron status biomarkers;
LUAD	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg05340658	chr4:99064831	C4orf37	0.51	8.47	0.38	4.14e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg18016565	chr1:150552671	MCL1	0.41	7.58	0.35	2.14e-13	Tonsillectomy;
LUAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg22907277	chr7:1156413	C7orf50	0.68	8.0	0.36	1.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg22907277	chr7:1156413	C7orf50	0.68	7.97	0.36	1.52e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg21827317	chr3:136751795	NA	0.36	6.62	0.31	1.09e-10	Neuroticism;
LUAD	cis	rs3087591	0.960	rs11080146	chr17:29578724	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.77	-0.31	4.24e-11	Hip circumference;
LUAD	trans	rs7939886	0.920	rs74699881	chr11:55913852	A/T	cg15704280	chr7:45808275	SEPT13	0.66	6.38	0.3	4.79e-10	Myopia (pathological);
LUAD	cis	rs12545109	0.879	rs2576580	chr8:57365828	G/C	cg11919837	chr8:57350735	NA	-0.49	-6.8	-0.31	3.58e-11	Obesity-related traits;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21657490	chr7:150815391	AGAP3	0.5	6.58	0.3	1.42e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12049351	0.774	rs12033236	chr1:229640471	A/G	cg11742688	chr1:229674241	ABCB10	-0.41	-6.41	-0.3	3.78e-10	Circulating myeloperoxidase levels (plasma);
LUAD	trans	rs1422110	0.819	rs1422114	chr5:85483880	A/G	cg01787110	chr1:109008453	NBPF6	0.59	9.58	0.42	8.68e-20	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	7.15	0.33	3.92e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1865721	1.000	rs11659761	chr18:73186974	A/G	cg26385618	chr18:73139727	C18orf62	-0.42	-7.67	-0.35	1.23e-13	Intelligence;
LUAD	cis	rs4906332	0.933	rs4906330	chr14:103971202	T/G	cg13511324	chr14:104056883	C14orf153	0.26	6.46	0.3	2.85e-10	Coronary artery disease;
LUAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg26338869	chr17:61819248	STRADA	-0.38	-6.38	-0.3	4.65e-10	Prudent dietary pattern;
LUAD	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg04944784	chr2:26401820	FAM59B	-0.87	-12.58	-0.52	4.71e-31	Gut microbiome composition (summer);
LUAD	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.11	13.49	0.55	9.33e-35	Lung cancer in ever smokers;
LUAD	cis	rs3784262	1.000	rs4646629	chr15:58255215	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.46	-9.6	-0.42	7.3e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	trans	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg17712092	chr4:129076599	LARP1B	0.93	17.48	0.65	6.91e-52	Eosinophil percentage of white cells;
LUAD	cis	rs7216064	1.000	rs62084240	chr17:65859233	C/A	cg08758996	chr17:66097529	LOC651250	0.47	7.2	0.33	2.79e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	trans	rs5756813	0.661	rs2246503	chr22:38204540	C/A	cg19894588	chr14:64061835	NA	-0.54	-7.7	-0.35	9.97e-14	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg03806693	chr22:41940476	POLR3H	0.61	8.99	0.4	8.61e-18	Vitiligo;
LUAD	cis	rs7089973	0.966	rs17721283	chr10:116644141	A/G	cg25233709	chr10:116636983	FAM160B1	0.35	6.54	0.3	1.77e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg01475377	chr6:109611718	NA	0.52	9.95	0.44	4.11e-21	Reticulocyte fraction of red cells;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg03929741	chr13:107187681	EFNB2	-0.72	-7.18	-0.33	3.21e-12	Type 2 diabetes;
LUAD	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.29	6.78	0.31	4.01e-11	Prostate cancer;
LUAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg21782813	chr7:2030301	MAD1L1	0.58	10.33	0.45	1.93e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg18180107	chr4:99064573	C4orf37	0.43	6.96	0.32	1.27e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg03859395	chr2:55845619	SMEK2	0.77	14.68	0.58	9.64e-40	Metabolic syndrome;
LUAD	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22496380	chr5:211416	CCDC127	-0.93	-13.12	-0.54	3.15e-33	Breast cancer;
LUAD	trans	rs6782299	0.784	rs7640601	chr3:180524764	G/C	cg01783070	chr20:21686293	PAX1	-0.33	-6.37	-0.3	5.05e-10	Schizophrenia;
LUAD	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg00316803	chr15:76480434	C15orf27	-0.4	-7.76	-0.35	6.51e-14	Blood metabolite levels;
LUAD	trans	rs11989744	0.500	rs7826966	chr8:23569106	G/T	cg03492747	chr16:86543808	FOXF1	-0.53	-11.45	-0.49	1.28e-26	Waist-hip ratio;
LUAD	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg00814883	chr7:100076585	TSC22D4	-0.87	-13.12	-0.54	3.02e-33	Platelet count;
LUAD	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	18.34	0.67	1.04e-55	Bone mineral density;
LUAD	cis	rs3733418	0.929	rs1401401	chr4:165927956	G/A	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.48	-6.69	-0.31	7.06e-11	Obesity-related traits;
LUAD	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg09365446	chr1:150670422	GOLPH3L	0.66	12.24	0.51	1.1e-29	Tonsillectomy;
LUAD	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	15.82	0.61	1.35e-44	Bone mineral density;
LUAD	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.61	-0.31	1.19e-10	Neutrophil percentage of white cells;
LUAD	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg05991184	chr2:219186017	PNKD	-0.35	-6.7	-0.31	6.56e-11	Colorectal cancer;
LUAD	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg24558204	chr6:135376177	HBS1L	-0.41	-6.98	-0.32	1.18e-11	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg07167872	chr1:205819463	PM20D1	0.49	7.93	0.36	1.96e-14	Parkinson's disease;
LUAD	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg27411982	chr8:10470053	RP1L1	0.44	7.94	0.36	1.8e-14	Retinal vascular caliber;
LUAD	cis	rs877282	1.000	rs12763443	chr10:771941	G/A	cg06581033	chr10:766294	NA	-0.56	-7.5	-0.34	3.76e-13	Uric acid levels;
LUAD	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg13319975	chr6:146136371	FBXO30	-0.59	-9.59	-0.42	7.58e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9462027	0.628	rs6925623	chr6:34800896	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.59	-0.39	1.63e-16	Systemic lupus erythematosus;
LUAD	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg00757033	chr12:89920650	WDR51B	0.7	11.68	0.49	1.62e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg04703951	chr17:43578652	NA	0.45	7.17	0.33	3.34e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg15704280	chr7:45808275	SEPT13	0.63	7.25	0.33	2.01e-12	Axial length;
LUAD	cis	rs3815700	0.920	rs10424732	chr19:33096487	C/T	cg02997394	chr19:33096574	ANKRD27	0.65	8.36	0.38	9.13e-16	Eosinophilic esophagitis;
LUAD	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.71	-0.31	6.42e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg03289416	chr15:75166202	SCAMP2	0.59	10.16	0.44	7.52e-22	Breast cancer;
LUAD	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.42	-0.6	6.74e-43	Chronic sinus infection;
LUAD	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg22598563	chr5:131563921	P4HA2	0.26	6.39	0.3	4.38e-10	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09770068	chr12:52294251	NA	0.51	6.47	0.3	2.63e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg23985595	chr17:80112537	CCDC57	-0.53	-9.51	-0.42	1.43e-19	Life satisfaction;
LUAD	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg03806693	chr22:41940476	POLR3H	0.56	8.11	0.37	5.37e-15	Vitiligo;
LUAD	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	ch.11.42038R	chr11:967971	AP2A2	0.41	7.29	0.33	1.55e-12	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg07917127	chr4:99064746	C4orf37	0.4	6.62	0.31	1.07e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8018808	0.846	rs11624990	chr14:77943616	C/T	cg20045696	chr14:77926864	AHSA1	0.38	6.61	0.31	1.18e-10	Myeloid white cell count;
LUAD	cis	rs938554	0.744	rs938558	chr4:9939205	G/A	cg11266682	chr4:10021025	SLC2A9	0.34	6.36	0.3	5.28e-10	Blood metabolite levels;
LUAD	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg08798685	chr6:27730294	NA	-0.41	-6.62	-0.31	1.08e-10	Parkinson's disease;
LUAD	cis	rs9905704	0.589	rs2680696	chr17:56473013	C/T	cg19466818	chr17:56409534	MIR142	0.34	6.74	0.31	5.31e-11	Testicular germ cell tumor;
LUAD	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg14784868	chr12:69753453	YEATS4	0.46	7.63	0.35	1.5700000000000001e-13	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg04369109	chr6:150039330	LATS1	-0.47	-7.58	-0.35	2.19e-13	Lung cancer;
LUAD	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg24558204	chr6:135376177	HBS1L	0.46	8.27	0.37	1.72e-15	Red blood cell count;
LUAD	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg08508325	chr11:3079039	CARS	0.44	9.16	0.41	2.2e-18	Calcium levels;
LUAD	cis	rs56116382	0.605	rs12715435	chr3:49338992	G/A	cg00383909	chr3:49044727	WDR6	0.63	8.12	0.37	5.05e-15	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
LUAD	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.83	-0.5	4.14e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1723838	0.510	rs45523540	chr11:73692990	G/A	cg10064339	chr11:73693792	UCP2	1.36	10.93	0.47	1.19e-24	Obesity-related traits;
LUAD	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg04225089	chr17:73874465	TRIM47	-0.51	-6.6	-0.31	1.2e-10	Psoriasis;
LUAD	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg17366294	chr4:99064904	C4orf37	0.51	9.15	0.41	2.43e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg00129232	chr17:37814104	STARD3	-0.46	-8.01	-0.36	1.13e-14	Asthma;
LUAD	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg17279839	chr7:150038598	RARRES2	0.4	6.92	0.32	1.7e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.41	-0.34	6.93e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7705042	0.865	rs7733850	chr5:141515564	C/T	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.9	-0.32	1.97e-11	Asthma;
LUAD	cis	rs11048434	0.736	rs7301381	chr12:9123932	T/C	cg23795048	chr12:9217529	LOC144571	0.43	7.87	0.36	2.95e-14	Sjögren's syndrome;
LUAD	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg08027265	chr7:2291960	NA	-0.47	-8.39	-0.38	7.3e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg04025307	chr7:1156635	C7orf50	0.55	9.2	0.41	1.63e-18	Longevity;Endometriosis;
LUAD	trans	rs877282	0.755	rs2486578	chr10:785227	C/T	cg22713356	chr15:30763199	NA	-0.98	-14.62	-0.58	1.76e-39	Uric acid levels;
LUAD	cis	rs78707713	0.841	rs12242391	chr10:71201504	C/T	cg12610070	chr10:71211762	TSPAN15	-0.41	-7.44	-0.34	5.79e-13	Venous thromboembolism;
LUAD	cis	rs7851660	0.844	rs10119853	chr9:100624981	G/A	cg13688889	chr9:100608707	NA	-0.5	-8.38	-0.38	7.66e-16	Strep throat;
LUAD	cis	rs6546550	0.900	rs2054047	chr2:70117421	A/C	cg02498382	chr2:70120550	SNRNP27	-0.6	-11.47	-0.49	1.07e-26	Prevalent atrial fibrillation;
LUAD	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg05044414	chr3:183734942	ABCC5	0.49	10.09	0.44	1.36e-21	Anterior chamber depth;
LUAD	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg13263323	chr15:86062960	AKAP13	-0.48	-8.92	-0.4	1.44e-17	Coronary artery disease;
LUAD	cis	rs10821973	0.527	rs2116581	chr10:64014095	A/G	cg09941381	chr10:64027924	RTKN2	0.36	7.34	0.34	1.12e-12	Hypothyroidism;
LUAD	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.1	-0.57	2.78e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs10129255	0.518	rs8009612	chr14:107185749	G/T	cg23076370	chr14:107095027	NA	-0.44	-8.91	-0.4	1.56e-17	Kawasaki disease;
LUAD	cis	rs113835537	0.529	rs11227525	chr11:66308065	T/G	cg24851651	chr11:66362959	CCS	0.58	10.11	0.44	1.14e-21	Airway imaging phenotypes;
LUAD	cis	rs2274273	0.870	rs17741831	chr14:55816715	T/A	cg04306507	chr14:55594613	LGALS3	0.43	9.04	0.4	5.72e-18	Protein biomarker;
LUAD	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06022373	chr22:39101656	GTPBP1	0.43	6.75	0.31	4.94e-11	Menopause (age at onset);
LUAD	cis	rs68170813	0.559	rs6965001	chr7:106933196	A/G	cg02696742	chr7:106810147	HBP1	-0.76	-10.53	-0.46	3.44e-23	Coronary artery disease;
LUAD	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg20744362	chr22:50050164	C22orf34	0.37	6.55	0.3	1.65e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs28595532	1.000	rs56000725	chr4:119637675	G/A	cg02775129	chr4:119771670	NA	-0.84	-7.8	-0.35	4.94e-14	Cannabis dependence symptom count;
LUAD	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg00290607	chr11:67383545	NA	0.4	6.58	0.3	1.38e-10	Mean corpuscular volume;
LUAD	cis	rs2692947	0.628	rs1997257	chr2:96429625	A/G	cg23100626	chr2:96804247	ASTL	0.29	7.4	0.34	7.58e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg08859206	chr1:53392774	SCP2	-0.58	-10.58	-0.46	2.24e-23	Monocyte count;
LUAD	cis	rs9487051	0.799	rs351725	chr6:109547939	G/A	cg01475377	chr6:109611718	NA	-0.38	-7.1	-0.33	5.27e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg09455208	chr3:40491958	NA	0.57	12.51	0.52	9.42e-31	Renal cell carcinoma;
LUAD	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.51	8.07	0.37	7.6e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg07305463	chr2:136567211	LCT	0.39	7.39	0.34	7.81e-13	Mosquito bite size;
LUAD	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg21427119	chr20:30132790	HM13	-0.47	-7.62	-0.35	1.63e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-8.96	-0.4	1.02e-17	Lymphocyte counts;
LUAD	cis	rs3106136	0.872	rs2059605	chr4:95255212	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.37	-6.84	-0.32	2.79e-11	Capecitabine sensitivity;
LUAD	cis	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg27411982	chr8:10470053	RP1L1	-0.41	-7.37	-0.34	8.81e-13	Triglycerides;
LUAD	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.69	-0.35	1.05e-13	Bipolar disorder;
LUAD	cis	rs6594713	0.717	rs10065790	chr5:112911165	C/T	cg12552261	chr5:112820674	MCC	0.58	8.89	0.4	1.77e-17	Brain cytoarchitecture;
LUAD	trans	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg21659725	chr3:3221576	CRBN	-0.59	-8.87	-0.4	2.07e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs11039798	0.844	rs11040177	chr11:48976211	G/C	cg15704280	chr7:45808275	SEPT13	0.67	7.8	0.35	4.95e-14	Axial length;
LUAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg11062466	chr8:58055876	NA	0.65	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6835098	0.608	rs2332668	chr4:174163360	A/G	cg08422745	chr4:174089978	GALNT7	-0.78	-13.67	-0.55	1.76e-35	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg15181151	chr6:150070149	PCMT1	0.39	7.76	0.35	6.42e-14	Lung cancer;
LUAD	trans	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg14917512	chr19:3094685	GNA11	0.55	6.65	0.31	9.22e-11	Diabetic kidney disease;
LUAD	cis	rs28595532	1.000	rs73842212	chr4:119638122	A/G	cg14228332	chr4:119757509	SEC24D	0.76	7.06	0.32	7e-12	Cannabis dependence symptom count;
LUAD	cis	rs4713675	0.565	rs9366828	chr6:33672798	G/A	cg14003231	chr6:33640908	ITPR3	0.49	9.53	0.42	1.26e-19	Plateletcrit;
LUAD	trans	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg10755058	chr3:40428713	ENTPD3	0.45	8.42	0.38	6.06e-16	Renal cell carcinoma;
LUAD	cis	rs2224391	0.518	rs17736905	chr6:5291511	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.62	-7.15	-0.33	3.8e-12	Height;
LUAD	cis	rs10493773	1.000	rs55654440	chr1:86176158	G/C	cg17807903	chr1:86174739	ZNHIT6	-0.55	-9.09	-0.4	3.93e-18	Urate levels in overweight individuals;
LUAD	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.26	0.33	1.82e-12	Tonsillectomy;
LUAD	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg20476274	chr7:133979776	SLC35B4	0.84	16.59	0.63	5.64e-48	Mean platelet volume;
LUAD	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg22535103	chr8:58192502	C8orf71	-0.6	-6.5	-0.3	2.23e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg11189052	chr15:85197271	WDR73	0.61	7.55	0.34	2.74e-13	Schizophrenia;
LUAD	cis	rs738322	0.600	rs6001031	chr22:38556260	G/T	cg17652424	chr22:38574118	PLA2G6	0.26	7.18	0.33	3.08e-12	Cutaneous nevi;
LUAD	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg22482690	chr17:47019901	SNF8	0.45	8.58	0.38	1.86e-16	Type 2 diabetes;
LUAD	trans	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg14917512	chr19:3094685	GNA11	-0.57	-6.8	-0.31	3.69e-11	Diabetic kidney disease;
LUAD	cis	rs9473147	0.516	rs9349415	chr6:47551861	T/C	cg02130027	chr6:47444894	CD2AP	0.34	6.61	0.31	1.19e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg12745145	chr7:2261452	MAD1L1	-0.35	-6.57	-0.3	1.48e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06544989	chr22:39130855	UNC84B	0.41	7.59	0.35	2.07e-13	Menopause (age at onset);
LUAD	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	9.45	0.42	2.28e-19	Lung cancer in ever smokers;
LUAD	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg14343924	chr8:8086146	FLJ10661	0.52	8.26	0.37	1.86e-15	Mood instability;
LUAD	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-11.5	-0.49	8.41e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg21963583	chr11:68658836	MRPL21	0.66	11.82	0.5	4.92e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg06713675	chr4:122721982	EXOSC9	-0.84	-18.11	-0.66	1.13e-54	Type 2 diabetes;
LUAD	cis	rs2637266	1.000	rs12251862	chr10:78367929	A/G	cg18941641	chr10:78392320	NA	0.34	7.24	0.33	2.2e-12	Pulmonary function;
LUAD	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.82	-0.47	2.98e-24	Total body bone mineral density;
LUAD	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg02782426	chr3:40428986	ENTPD3	0.42	8.83	0.39	2.81e-17	Renal cell carcinoma;
LUAD	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg19318889	chr4:1322082	MAEA	0.44	7.02	0.32	8.86e-12	Obesity-related traits;
LUAD	cis	rs11112613	0.713	rs73184082	chr12:105951748	T/C	cg03607813	chr12:105948248	NA	0.73	12.68	0.52	1.91e-31	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg05434287	chr7:2030229	MAD1L1	0.38	6.5	0.3	2.29e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	10.91	0.47	1.36e-24	Height;
LUAD	cis	rs1873147	1.000	rs4775601	chr15:63311980	C/T	cg12160578	chr15:63334699	TPM1	0.35	6.57	0.3	1.47e-10	Orofacial clefts;
LUAD	trans	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.59	-10.61	-0.46	1.75e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8049603	0.697	rs12934362	chr16:23196591	T/C	cg09552652	chr16:23197569	SCNN1G	0.39	6.8	0.31	3.62e-11	Multiple sclerosis;
LUAD	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg11822812	chr5:140052017	DND1	0.38	6.84	0.32	2.76e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg13606994	chr1:44402422	ARTN	-0.33	-6.79	-0.31	3.82e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg24675056	chr1:15929824	NA	0.47	8.21	0.37	2.75e-15	Systolic blood pressure;
LUAD	cis	rs11681884	0.892	rs17042810	chr2:113838569	C/T	cg12858261	chr2:113808755	IL1F8	0.57	6.42	0.3	3.69e-10	Stroke;
LUAD	cis	rs6987853	0.787	rs12677427	chr8:42414226	T/A	cg09913449	chr8:42400586	C8orf40	0.51	10.31	0.45	2.16e-22	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg20607798	chr8:58055168	NA	0.58	7.54	0.34	2.94e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.92	-15.22	-0.59	4.77e-42	Homoarginine levels;
LUAD	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.49	0.3	2.38e-10	Cardiac Troponin-T levels;
LUAD	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg09367891	chr1:107599246	PRMT6	-0.52	-8.81	-0.39	3.26e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg00495681	chr13:53174319	NA	0.49	8.57	0.38	1.94e-16	Lewy body disease;
LUAD	trans	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg07211511	chr3:129823064	LOC729375	-0.53	-6.73	-0.31	5.7e-11	Blood pressure (smoking interaction);
LUAD	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg18446336	chr7:2847575	GNA12	-0.35	-6.48	-0.3	2.59e-10	Height;
LUAD	cis	rs701145	0.938	rs355768	chr3:154045001	A/G	cg17054900	chr3:154042577	DHX36	0.61	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs17095355	1.000	rs11194923	chr10:111695762	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.71	-9.56	-0.42	9.93e-20	Biliary atresia;
LUAD	cis	rs57590327	0.555	rs13072957	chr3:81776242	A/G	cg07356753	chr3:81810745	GBE1	0.63	10.2	0.44	5.56e-22	Extraversion;
LUAD	cis	rs7937890	0.559	rs1116739	chr11:14489182	G/C	cg02886208	chr11:14281011	SPON1	-0.34	-6.66	-0.31	8.62e-11	Mitochondrial DNA levels;
LUAD	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg10802521	chr3:52805072	NEK4	-0.45	-7.2	-0.33	2.84e-12	Bipolar disorder;
LUAD	trans	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg01620082	chr3:125678407	NA	-1.04	-10.21	-0.44	4.98e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg06740227	chr12:86229804	RASSF9	0.35	6.48	0.3	2.6e-10	Major depressive disorder;
LUAD	cis	rs4730250	0.707	rs257377	chr7:106801088	G/T	cg02696742	chr7:106810147	HBP1	-0.87	-11.31	-0.48	4.32e-26	Osteoarthritis;
LUAD	trans	rs12517041	1.000	rs6894688	chr5:23312285	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.49	-6.92	-0.32	1.73e-11	Calcium levels;
LUAD	cis	rs7527798	0.592	rs11118337	chr1:207852693	G/C	cg09232269	chr1:207846808	CR1L	-0.35	-6.59	-0.31	1.3100000000000001e-10	Erythrocyte sedimentation rate;
LUAD	cis	rs35146811	0.555	rs1981549	chr7:99541636	A/G	cg22906224	chr7:99728672	NA	0.53	8.6	0.39	1.58e-16	Coronary artery disease;
LUAD	cis	rs12618769	0.597	rs2278206	chr2:99172244	A/G	cg10123293	chr2:99228465	UNC50	0.48	8.45	0.38	4.59e-16	Bipolar disorder;
LUAD	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg16486109	chr11:613632	IRF7	0.48	8.09	0.37	6.28e-15	Systemic lupus erythematosus;
LUAD	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg05304507	chr6:116381966	FRK	0.19	6.62	0.31	1.09e-10	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs6906287	0.647	rs7772214	chr6:118793703	A/T	cg18833306	chr6:118973337	C6orf204	0.46	8.17	0.37	3.65e-15	Electrocardiographic conduction measures;
LUAD	cis	rs6060717	0.536	rs6058356	chr20:34491530	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.81	-0.31	3.35e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg25817165	chr18:72167213	CNDP2	-0.82	-14.17	-0.57	1.39e-37	Refractive error;
LUAD	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg01765077	chr12:122356316	WDR66	0.57	9.81	0.43	1.37e-20	Mean corpuscular volume;
LUAD	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.25	-0.37	2.07e-15	Total body bone mineral density;
LUAD	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg09658497	chr7:2847517	GNA12	-0.55	-9.07	-0.4	4.48e-18	Height;
LUAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg00280220	chr17:61926910	NA	0.37	7.06	0.32	7.05e-12	Prudent dietary pattern;
LUAD	cis	rs807669	0.903	rs1780640	chr22:19174597	C/T	cg24911827	chr22:19170109	CLTCL1	0.45	9.26	0.41	1.07e-18	Metabolite levels;
LUAD	cis	rs449303	1	rs449303	chr14:60605788	A/G	cg06898279	chr14:60629192	DHRS7	0.52	7.81	0.35	4.63e-14	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg02569458	chr12:86230093	RASSF9	-0.41	-7.6	-0.35	1.95e-13	Major depressive disorder;
LUAD	cis	rs72634258	0.503	rs72632055	chr1:7835774	T/G	cg26816564	chr1:7831052	VAMP3	0.8	10.46	0.45	6.12e-23	Inflammatory bowel disease;
LUAD	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg05368731	chr17:41323189	NBR1	0.97	20.9	0.71	3.65e-67	Menopause (age at onset);
LUAD	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg11250194	chr11:61601937	FADS2	-0.63	-8.46	-0.38	4.51e-16	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13696300	chr17:18162128	FLII	-0.46	-7.21	-0.33	2.64e-12	Height;
LUAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg10862848	chr6:42927986	GNMT	-0.32	-9.24	-0.41	1.21e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	9.04	0.4	5.49e-18	Lung cancer in ever smokers;
LUAD	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg07404485	chr7:94953653	PON1	-0.5	-7.13	-0.33	4.51e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4919694	1.000	rs4917986	chr10:104630181	T/C	cg04362960	chr10:104952993	NT5C2	0.65	7.21	0.33	2.67e-12	Arsenic metabolism;
LUAD	trans	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg21775007	chr8:11205619	TDH	-0.37	-6.41	-0.3	3.82e-10	Mood instability;
LUAD	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg19761014	chr17:28927070	LRRC37B2	0.88	8.68	0.39	8.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.75	0.31	4.94e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg07757535	chr4:1339547	NA	0.32	6.47	0.3	2.74e-10	Longevity;
LUAD	cis	rs2997447	0.723	rs2802337	chr1:26474398	G/C	cg00147160	chr1:26503991	CNKSR1	0.34	6.38	0.3	4.53e-10	QRS complex (12-leadsum);
LUAD	cis	rs4523957	0.583	rs2760737	chr17:2024647	C/T	cg16513277	chr17:2031491	SMG6	-0.96	-19.09	-0.68	4.76e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg11663144	chr21:46675770	NA	-0.6	-11.83	-0.5	4.19e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11890956	chr21:40555474	PSMG1	-0.57	-9.24	-0.41	1.24e-18	Cognitive function;
LUAD	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg03477792	chr4:77819574	ANKRD56	0.49	7.59	0.35	2.04e-13	Emphysema distribution in smoking;
LUAD	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18404041	chr3:52824283	ITIH1	-0.6	-12.58	-0.52	4.93e-31	Electroencephalogram traits;
LUAD	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg13010344	chr12:123464640	ARL6IP4	-0.41	-7.13	-0.33	4.33e-12	Platelet count;
LUAD	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg25554036	chr4:6271136	WFS1	0.69	13.88	0.56	2.31e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg03929089	chr4:120376271	NA	0.59	7.47	0.34	4.52e-13	Axial length;
LUAD	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg12908607	chr1:44402522	ARTN	0.52	10.53	0.46	3.42e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg05215272	chr17:6899095	ALOX12	-0.49	-9.37	-0.41	4.46e-19	Tonsillectomy;
LUAD	cis	rs208520	0.874	rs208514	chr6:66945520	G/A	cg07460842	chr6:66804631	NA	-0.98	-14.37	-0.57	2.09e-38	Exhaled nitric oxide output;
LUAD	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg17443473	chr1:3703550	LRRC47	0.47	7.9	0.36	2.39e-14	Red cell distribution width;
LUAD	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg06873352	chr17:61820015	STRADA	0.4	6.84	0.32	2.71e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg15556689	chr8:8085844	FLJ10661	0.41	6.45	0.3	3e-10	Systemic lupus erythematosus;
LUAD	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.38	10.14	0.44	9.34e-22	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg04025307	chr7:1156635	C7orf50	0.71	10.17	0.44	6.79e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg11952622	chr19:58962976	ZNF324B	0.46	6.98	0.32	1.15e-11	Mean platelet volume;
LUAD	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg03885332	chr11:832357	CD151	-0.42	-7.91	-0.36	2.3e-14	Mean platelet volume;
LUAD	cis	rs3823572	0.564	rs2953623	chr7:133659410	C/G	cg03336402	chr7:133662267	EXOC4	-0.4	-7.39	-0.34	7.73e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg10589385	chr1:150898437	SETDB1	0.43	7.93	0.36	1.98e-14	Melanoma;
LUAD	cis	rs4604732	0.578	rs112449432	chr1:247624180	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.4	6.79	0.31	3.78e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.77	-11.37	-0.48	2.61e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg14903685	chr15:70391316	TLE3	-0.74	-6.98	-0.32	1.18e-11	Type 2 diabetes;
LUAD	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.85	0.4	2.39e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg08008072	chr16:1524255	CLCN7	-0.74	-18.55	-0.67	1.23e-56	Bone mineral density;
LUAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg11494091	chr17:61959527	GH2	0.74	18.32	0.67	1.27e-55	Prudent dietary pattern;
LUAD	trans	rs13201294	1	rs13201294	chr6:27556141	A/T	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.38	2.04e-16	Squamous cell lung carcinoma;
LUAD	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg09085632	chr11:111637200	PPP2R1B	0.75	11.78	0.5	6.62e-28	Primary sclerosing cholangitis;
LUAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg01448562	chr3:133502909	NA	-0.67	-12.34	-0.51	4.26e-30	Iron status biomarkers;
LUAD	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.81	-0.39	3.29e-17	Total body bone mineral density;
LUAD	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	8.28	0.37	1.6e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg27411982	chr8:10470053	RP1L1	0.39	6.87	0.32	2.3e-11	Mood instability;
LUAD	cis	rs2294693	0.530	rs11756788	chr6:41082688	G/A	cg14769373	chr6:40998127	UNC5CL	-0.61	-8.4	-0.38	6.96e-16	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs10504073	0.647	rs11785310	chr8:50025035	G/A	cg00325661	chr8:49890786	NA	0.44	9.89	0.43	7.09e-21	Blood metabolite ratios;
LUAD	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg21475434	chr5:93447410	FAM172A	0.74	8.59	0.39	1.72e-16	Diabetic retinopathy;
LUAD	cis	rs41271473	0.526	rs12143098	chr1:228720965	A/C	cg10167378	chr1:228756711	NA	0.68	9.15	0.41	2.52e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs17155006	0.664	rs451252	chr7:107738948	G/A	cg05962710	chr7:107745446	LAMB4	-0.35	-7.27	-0.33	1.78e-12	Pneumococcal bacteremia;
LUAD	cis	rs9487051	0.768	rs435611	chr6:109527755	C/T	cg01475377	chr6:109611718	NA	-0.38	-6.94	-0.32	1.45e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg21028142	chr17:79581711	NPLOC4	0.34	6.76	0.31	4.58e-11	Eye color traits;
LUAD	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.93	-0.36	1.91e-14	Prostate cancer;
LUAD	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg04025307	chr7:1156635	C7orf50	0.52	7.22	0.33	2.37e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs677665	0.537	rs72641832	chr1:9336116	C/A	cg25755851	chr1:9335794	NA	0.79	13.86	0.56	2.71e-36	Eosinophil percentage of white cells;
LUAD	trans	rs7395662	1.000	rs7479498	chr11:48660499	G/A	cg15704280	chr7:45808275	SEPT13	-0.43	-6.68	-0.31	7.35e-11	HDL cholesterol;
LUAD	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg06641503	chr3:48959341	ARIH2	-0.37	-7.31	-0.33	1.38e-12	Menarche (age at onset);
LUAD	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg11189052	chr15:85197271	WDR73	0.68	9.12	0.41	2.97e-18	Schizophrenia;
LUAD	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg17264618	chr3:40429014	ENTPD3	0.35	7.56	0.34	2.56e-13	Renal cell carcinoma;
LUAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg27454412	chr7:1067447	C7orf50	0.48	7.75	0.35	6.7e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg09365446	chr1:150670422	GOLPH3L	0.66	12.57	0.52	5.38e-31	Tonsillectomy;
LUAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg00634984	chr7:65235879	NA	0.54	8.91	0.4	1.58e-17	Calcium levels;
LUAD	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg06221963	chr1:154839813	KCNN3	-0.83	-19.19	-0.68	1.69e-59	Prostate cancer;
LUAD	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg24399712	chr22:39784796	NA	-0.83	-16.51	-0.63	1.25e-47	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.62	9.16	0.41	2.29e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg23711669	chr6:146136114	FBXO30	-0.39	-6.52	-0.3	2.05e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg02012338	chr4:187126139	CYP4V2	-1.0	-10.09	-0.44	1.4e-21	Blood protein levels;
LUAD	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg19875535	chr5:140030758	IK	0.42	7.14	0.33	4.04e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.5	-0.34	3.89e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg03609598	chr5:56110824	MAP3K1	-0.57	-8.01	-0.36	1.11e-14	Initial pursuit acceleration;
LUAD	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg11663144	chr21:46675770	NA	-0.62	-12.16	-0.51	2.28e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7187994	0.614	rs2291649	chr16:84800907	G/A	cg07647771	chr16:84786436	USP10	-0.31	-8.08	-0.37	6.86e-15	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs7241530	0.662	rs6506734	chr18:75888374	A/G	cg14642773	chr18:75888474	NA	0.32	6.61	0.31	1.19e-10	Educational attainment (years of education);
LUAD	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg10544611	chr16:67998164	SLC12A4	-0.58	-7.09	-0.33	5.67e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg18129178	chr5:148520854	ABLIM3	-0.7	-10.23	-0.45	4.1e-22	Breast cancer;
LUAD	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.15	0.48	1.68e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.55	-9.31	-0.41	7.2e-19	Glomerular filtration rate;
LUAD	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg22868518	chr11:507468	RNH1	-0.67	-6.69	-0.31	6.95e-11	Body mass index;
LUAD	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg12310025	chr6:25882481	NA	-0.59	-9.75	-0.43	2.18e-20	Blood metabolite levels;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg25371950	chr2:242786524	NA	-0.5	-6.69	-0.31	7.22e-11	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21582582	chr3:182698605	DCUN1D1	0.62	10.47	0.45	5.6e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg26408565	chr15:76604113	ETFA	-0.56	-9.87	-0.43	8.29e-21	Blood metabolite levels;
LUAD	cis	rs1395	0.744	rs1122227	chr2:27544285	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.46	7.71	0.35	9.17e-14	Blood metabolite levels;
LUAD	cis	rs1232027	0.666	rs1643639	chr5:79952390	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.94	-0.36	1.9e-14	Huntington's disease progression;
LUAD	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg16647868	chr5:131706066	SLC22A5	0.37	6.49	0.3	2.47e-10	Blood metabolite levels;
LUAD	cis	rs375066	0.762	rs1073653	chr19:44411543	G/A	cg12072164	chr19:44306565	LYPD5	-0.32	-6.44	-0.3	3.27e-10	Breast cancer;
LUAD	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.0	-0.32	1.04e-11	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04498971	chr17:56084468	SFRS1	-0.42	-6.54	-0.3	1.79e-10	Height;
LUAD	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11890956	chr21:40555474	PSMG1	0.78	13.83	0.56	3.69e-36	Cognitive function;
LUAD	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	7.05	0.32	7.34e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg12908607	chr1:44402522	ARTN	-0.53	-10.38	-0.45	1.2e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7607369	0.714	rs2272190	chr2:219609995	G/C	cg02176678	chr2:219576539	TTLL4	-0.59	-12.0	-0.5	9.65e-29	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs9341808	0.754	rs978814	chr6:80959912	G/T	cg08355045	chr6:80787529	NA	0.56	10.1	0.44	1.2e-21	Sitting height ratio;
LUAD	cis	rs1595825	0.891	rs16825917	chr2:198805185	C/T	cg00982548	chr2:198649783	BOLL	-0.64	-8.87	-0.4	2.1e-17	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7759001	0.857	rs6915934	chr6:27367887	C/T	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg08027265	chr7:2291960	NA	-0.41	-6.76	-0.31	4.46e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9556958	0.708	rs9513435	chr13:99160334	C/G	cg07423050	chr13:99094983	FARP1	-0.38	-6.72	-0.31	5.91e-11	Educational attainment (years of education);
LUAD	cis	rs6840360	0.517	rs4399967	chr4:152729312	T/A	cg22705602	chr4:152727874	NA	0.46	8.97	0.4	1.01e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg03517284	chr6:25882590	NA	-0.65	-9.53	-0.42	1.22e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg21475434	chr5:93447410	FAM172A	0.73	8.23	0.37	2.31e-15	Diabetic retinopathy;
LUAD	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg06641503	chr3:48959341	ARIH2	-0.38	-7.61	-0.35	1.76e-13	Parkinson's disease;
LUAD	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg00666640	chr1:248458726	OR2T12	0.31	7.6	0.35	1.96e-13	Common traits (Other);
LUAD	trans	rs2018683	0.707	rs4722875	chr7:28969632	A/G	cg19402173	chr7:128379420	CALU	-0.52	-8.44	-0.38	5.22e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg03433033	chr1:76189801	ACADM	0.84	15.2	0.59	5.84e-42	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg09137382	chr11:130731461	NA	0.38	6.53	0.3	1.84e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2637266	0.935	rs2583053	chr10:78402416	A/G	cg18941641	chr10:78392320	NA	0.34	7.04	0.32	7.75e-12	Pulmonary function;
LUAD	trans	rs9393777	0.920	rs34071253	chr6:27391802	C/T	cg01620082	chr3:125678407	NA	-0.79	-8.53	-0.38	2.67e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18404041	chr3:52824283	ITIH1	-0.63	-12.63	-0.52	2.97e-31	Bipolar disorder;
LUAD	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg03929089	chr4:120376271	NA	-0.56	-8.29	-0.37	1.55e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08219700	chr8:58056026	NA	0.7	9.15	0.41	2.48e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	7.82	0.36	4.11e-14	Menopause (age at onset);
LUAD	cis	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-8.12	-0.37	5.05e-15	Neuroticism;
LUAD	trans	rs2018683	0.745	rs917217	chr7:28975025	G/T	cg19402173	chr7:128379420	CALU	0.51	8.32	0.38	1.18e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg16647868	chr5:131706066	SLC22A5	0.38	6.65	0.31	9.27e-11	Blood metabolite levels;
LUAD	cis	rs9517302	0.512	rs9517305	chr13:99097910	G/C	cg22223119	chr13:99095684	FARP1	-0.61	-9.81	-0.43	1.37e-20	Obesity-related traits;
LUAD	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg01802117	chr1:53393560	SCP2	-0.35	-6.85	-0.32	2.67e-11	Monocyte count;
LUAD	cis	rs17095355	0.818	rs7088861	chr10:111775544	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.02	-0.36	1.03e-14	Biliary atresia;
LUAD	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7665090	0.875	rs6813322	chr4:103555619	C/G	cg07973026	chr4:103553119	MANBA	0.48	8.44	0.38	5e-16	Primary biliary cholangitis;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg11516830	chr17:75242950	NA	0.43	6.45	0.3	2.98e-10	QT interval;
LUAD	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15506890	chr2:3487001	NA	-0.45	-7.95	-0.36	1.75e-14	Neurofibrillary tangles;
LUAD	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg02423579	chr7:2872169	GNA12	-0.56	-9.54	-0.42	1.13e-19	Height;
LUAD	cis	rs9811920	0.535	rs793483	chr3:99489825	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-8.54	-0.38	2.53e-16	Axial length;
LUAD	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg25985355	chr7:65971099	NA	-0.56	-6.85	-0.32	2.68e-11	Diabetic kidney disease;
LUAD	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg01689657	chr7:91764605	CYP51A1	-0.3	-7.29	-0.33	1.58e-12	Breast cancer;
LUAD	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.02	0.32	8.87e-12	Hypertriglyceridemia;
LUAD	cis	rs6688613	0.840	rs10918607	chr1:166957803	T/C	cg07049167	chr1:166818506	POGK	0.45	6.66	0.31	8.3e-11	Refractive astigmatism;
LUAD	cis	rs11048434	0.736	rs1805733	chr12:9089272	A/C	cg26114124	chr12:9217669	LOC144571	0.36	6.67	0.31	8.15e-11	Sjögren's syndrome;
LUAD	trans	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg26043149	chr18:55253948	FECH	0.51	8.12	0.37	5.03e-15	Bone mineral density;
LUAD	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg18105134	chr13:113819100	PROZ	-0.85	-14.85	-0.59	1.95e-40	Platelet distribution width;
LUAD	cis	rs7193541	0.662	rs8063458	chr16:74469121	G/T	cg01733217	chr16:74700730	RFWD3	-0.4	-6.64	-0.31	9.71e-11	Multiple myeloma;
LUAD	trans	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	17.47	0.65	7.39e-52	Exhaled nitric oxide output;
LUAD	cis	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg27411982	chr8:10470053	RP1L1	0.4	7.56	0.35	2.47e-13	Myopia (pathological);
LUAD	cis	rs7274811	0.744	rs6141962	chr20:32110312	T/C	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.52	-7.58	-0.35	2.22e-13	Height;
LUAD	cis	rs11229555	1.000	rs12808544	chr11:58373221	C/A	cg15696309	chr11:58395628	NA	-0.73	-10.98	-0.47	7.29e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.61	8.6	0.39	1.61e-16	Gut microbiome composition (summer);
LUAD	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg09491104	chr22:46646882	C22orf40	-0.52	-7.38	-0.34	8.32e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs12576326	1.000	rs12576326	chr11:44980383	A/G	cg07619142	chr11:44971049	TP53I11	-0.41	-6.57	-0.3	1.45e-10	Resting heart rate;
LUAD	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg24675056	chr1:15929824	NA	0.48	8.33	0.38	1.14e-15	Systolic blood pressure;
LUAD	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg02886208	chr11:14281011	SPON1	0.36	7.5	0.34	3.86e-13	Mitochondrial DNA levels;
LUAD	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.37	6.48	0.3	2.53e-10	Type 2 diabetes;
LUAD	cis	rs9584850	0.834	rs8481	chr13:99105395	G/A	cg17380943	chr13:99100506	FARP1	-0.35	-6.59	-0.31	1.3e-10	Neuroticism;
LUAD	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg16680214	chr1:154839983	KCNN3	-0.61	-12.62	-0.52	3.43e-31	Prostate cancer;
LUAD	cis	rs4903604	0.581	rs41347855	chr14:78037909	C/T	cg18872420	chr14:78023429	SPTLC2	0.47	8.61	0.39	1.51e-16	Gut microbiome composition (winter);
LUAD	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg18190219	chr22:46762943	CELSR1	-0.65	-6.92	-0.32	1.65e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg01689657	chr7:91764605	CYP51A1	-0.32	-7.88	-0.36	2.81e-14	Breast cancer;
LUAD	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg14541582	chr5:601475	NA	-0.35	-7.55	-0.34	2.71e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg18446336	chr7:2847575	GNA12	-0.33	-6.81	-0.31	3.41e-11	Height;
LUAD	trans	rs587242	1.000	rs2985639	chr1:96894735	C/T	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs6500395	1.000	rs8059819	chr16:48682834	A/G	cg04672837	chr16:48644449	N4BP1	-0.36	-6.37	-0.3	4.92e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg25427524	chr10:38739819	LOC399744	0.65	10.95	0.47	9.48e-25	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg02891314	chr5:179741120	GFPT2	-0.76	-12.51	-0.52	9.22e-31	Height;
LUAD	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg25173405	chr17:45401733	C17orf57	-0.47	-7.6	-0.35	1.88e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg17971929	chr21:40555470	PSMG1	0.43	6.8	0.31	3.67e-11	Cognitive function;
LUAD	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21028142	chr17:79581711	NPLOC4	0.45	9.78	0.43	1.62e-20	Eye color traits;
LUAD	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg06784218	chr1:46089804	CCDC17	-0.54	-11.66	-0.49	1.91e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg09365446	chr1:150670422	GOLPH3L	0.67	12.19	0.51	1.71e-29	Blood protein levels;
LUAD	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg06636001	chr8:8085503	FLJ10661	0.41	6.67	0.31	8.09e-11	Mood instability;
LUAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg23978390	chr7:1156363	C7orf50	0.46	7.45	0.34	5.45e-13	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.17	0.33	3.44e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11811982	0.793	rs78469866	chr1:227575024	G/A	cg24860534	chr1:227506868	CDC42BPA	0.66	7.2	0.33	2.8e-12	Optic disc area;
LUAD	cis	rs240764	0.658	rs12213201	chr6:101176285	C/A	cg09795085	chr6:101329169	ASCC3	-0.49	-8.67	-0.39	9.43e-17	Neuroticism;
LUAD	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg24069376	chr3:38537580	EXOG	-0.44	-10.57	-0.46	2.43e-23	Electrocardiographic conduction measures;
LUAD	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg12935359	chr14:103987150	CKB	-0.47	-7.75	-0.35	6.87e-14	Body mass index;
LUAD	cis	rs1448094	0.842	rs7309725	chr12:86440612	T/C	cg18827107	chr12:86230957	RASSF9	-0.44	-8.14	-0.37	4.61e-15	Major depressive disorder;
LUAD	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg11833968	chr6:79620685	NA	-0.42	-7.86	-0.36	3.12e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.08	0.33	6.15e-12	Motion sickness;
LUAD	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.52	0.42	1.32e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.76	8.45	0.38	4.6e-16	Yeast infection;
LUAD	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg06766960	chr11:133703094	NA	-0.46	-8.71	-0.39	6.84e-17	Childhood ear infection;
LUAD	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg05725404	chr16:58534157	NDRG4	-0.71	-7.49	-0.34	3.92e-13	Schizophrenia;
LUAD	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg17264618	chr3:40429014	ENTPD3	0.38	8.4	0.38	6.96e-16	Renal cell carcinoma;
LUAD	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg07606381	chr6:8435919	SLC35B3	0.44	7.18	0.33	3.09e-12	Motion sickness;
LUAD	cis	rs8112211	0.598	rs4802351	chr19:38848796	A/G	cg14299480	chr19:38876666	GGN	-0.46	-7.11	-0.33	4.87e-12	Blood protein levels;
LUAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg23029597	chr12:123009494	RSRC2	0.53	8.17	0.37	3.65e-15	Body mass index;
LUAD	cis	rs11229555	0.874	rs17567523	chr11:58354081	G/A	cg15696309	chr11:58395628	NA	-0.72	-10.3	-0.45	2.35e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05901451	chr6:126070800	HEY2	-0.45	-6.65	-0.31	9.3e-11	Endometrial cancer;
LUAD	cis	rs3772130	0.962	rs1920320	chr3:121547527	A/G	cg20356878	chr3:121714668	ILDR1	0.51	8.15	0.37	4.24e-15	Cognitive performance;
LUAD	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg02807482	chr3:125708958	NA	-0.66	-8.57	-0.38	1.91e-16	Blood pressure (smoking interaction);
LUAD	cis	rs9462027	0.628	rs2814967	chr6:34712838	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.04	-0.4	5.87e-18	Systemic lupus erythematosus;
LUAD	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg23758822	chr17:41437982	NA	1.01	20.95	0.71	2.2e-67	Menopause (age at onset);
LUAD	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg09936400	chr10:82049201	MAT1A	0.36	6.58	0.3	1.43e-10	Post bronchodilator FEV1;
LUAD	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg18867708	chr6:26865862	GUSBL1	0.41	6.55	0.3	1.67e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs57994353	0.861	rs13301660	chr9:139340802	C/T	cg14364472	chr9:139394549	NOTCH1	-0.43	-6.5	-0.3	2.25e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg10792982	chr14:105748885	BRF1	0.4	8.83	0.39	2.75e-17	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg05590025	chr7:65112418	INTS4L2	0.74	8.05	0.36	8.39e-15	Diabetic kidney disease;
LUAD	cis	rs9354308	0.834	rs12212376	chr6:66598879	T/C	cg07460842	chr6:66804631	NA	0.49	7.42	0.34	6.6e-13	Metabolite levels;
LUAD	cis	rs2629540	0.882	rs10901813	chr10:126429875	G/A	cg08799069	chr10:126477246	METTL10	-0.46	-6.65	-0.31	8.94e-11	Cocaine dependence;
LUAD	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg22189786	chr22:42395067	WBP2NL	0.46	6.59	0.31	1.3100000000000001e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg03433033	chr1:76189801	ACADM	0.69	9.96	0.44	3.81e-21	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	12.03	0.5	7.1e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs741677	0.586	rs58180134	chr17:499297	C/A	cg15660573	chr17:549704	VPS53	-0.64	-9.51	-0.42	1.45e-19	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs11677416	1.000	rs7570215	chr2:113527660	G/T	cg27083787	chr2:113543245	IL1A	0.38	6.64	0.31	9.56e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs847851	0.630	rs9469905	chr6:34797747	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.56	-0.38	2.05e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4631830	0.600	rs11004324	chr10:51496623	G/T	cg16070123	chr10:51489643	NA	-0.41	-6.6	-0.31	1.21e-10	Prostate-specific antigen levels;
LUAD	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg09365446	chr1:150670422	GOLPH3L	0.63	10.92	0.47	1.27e-24	Melanoma;
LUAD	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg22189786	chr22:42395067	WBP2NL	0.45	6.51	0.3	2.14e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs57502260	0.704	rs12286536	chr11:68290234	C/G	cg16797656	chr11:68205561	LRP5	0.46	6.85	0.32	2.65e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg13010199	chr12:38710504	ALG10B	0.41	6.76	0.31	4.66e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg12193833	chr17:30244370	NA	-0.58	-6.93	-0.32	1.54e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg09184832	chr6:79620586	NA	-0.5	-9.46	-0.42	2.24e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg06640241	chr16:89574553	SPG7	0.72	12.81	0.53	5.6199999999999995e-32	Multiple myeloma (IgH translocation);
LUAD	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg12310025	chr6:25882481	NA	-0.91	-16.12	-0.62	6.18e-46	Uric acid levels;
LUAD	cis	rs8067545	0.750	rs9944451	chr17:20001316	T/C	cg04132472	chr17:19861366	AKAP10	0.31	7.32	0.34	1.25e-12	Schizophrenia;
LUAD	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg02466173	chr16:30829666	NA	-0.74	-13.01	-0.53	8.46e-33	Multiple myeloma;
LUAD	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg04944784	chr2:26401820	FAM59B	-0.72	-10.12	-0.44	1.08e-21	Gut microbiome composition (summer);
LUAD	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg18230493	chr5:56204884	C5orf35	-0.75	-11.07	-0.47	3.45e-25	Initial pursuit acceleration;
LUAD	cis	rs10992471	0.528	rs1924244	chr9:95224952	A/G	cg14631576	chr9:95140430	CENPP	-0.49	-10.13	-0.44	1e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg09359103	chr1:154839909	KCNN3	0.88	20.01	0.7	3.52e-63	Prostate cancer;
LUAD	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg18827107	chr12:86230957	RASSF9	0.54	9.74	0.43	2.24e-20	Major depressive disorder;
LUAD	cis	rs727505	0.721	rs11536526	chr7:124749441	G/A	cg23710748	chr7:124431027	NA	-0.39	-8.05	-0.36	8.48e-15	Lewy body disease;
LUAD	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg26587870	chr6:27730563	NA	0.52	7.48	0.34	4.23e-13	Depression;
LUAD	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.53	9.17	0.41	2.04e-18	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg07636037	chr3:49044803	WDR6	0.35	6.38	0.3	4.61e-10	Resting heart rate;
LUAD	cis	rs4285028	0.948	rs34837785	chr3:121657776	G/A	cg11130432	chr3:121712080	ILDR1	-0.61	-8.56	-0.38	2.16e-16	Multiple sclerosis;
LUAD	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg11247378	chr22:39784982	NA	-0.7	-12.33	-0.51	4.71e-30	Intelligence (multi-trait analysis);
LUAD	trans	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.91	-0.32	1.8e-11	Gout;
LUAD	cis	rs427941	0.694	rs2529094	chr7:101739617	C/T	cg06246474	chr7:101738831	CUX1	0.41	7.25	0.33	1.98e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg13327785	chr12:132219529	SFRS8	-0.38	-7.07	-0.32	6.62e-12	Migraine;
LUAD	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg23933602	chr10:16859644	RSU1	0.63	8.66	0.39	9.76e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg12310025	chr6:25882481	NA	-0.51	-7.72	-0.35	8.48e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13457403	chr21:44313401	NDUFV3	-0.55	-6.97	-0.32	1.21e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs438465	0.853	rs394053	chr6:169808704	T/A	cg11181693	chr6:169825345	NA	-0.65	-8.48	-0.38	3.83e-16	Corneal astigmatism;
LUAD	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg18512352	chr11:47633146	NA	-0.57	-10.14	-0.44	8.77e-22	Subjective well-being;
LUAD	cis	rs9400271	0.632	rs9372205	chr6:109588401	A/T	cg01475377	chr6:109611718	NA	-0.36	-6.37	-0.3	4.9e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-9.02	-0.4	6.41e-18	Total body bone mineral density;
LUAD	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg08999081	chr20:33150536	PIGU	-0.62	-13.96	-0.56	1.08e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs10489202	0.683	rs4657730	chr1:168072738	A/T	cg24449463	chr1:168025552	DCAF6	-0.62	-9.36	-0.41	4.9e-19	Schizophrenia;
LUAD	cis	rs6484504	0.576	rs2756191	chr11:31135882	A/T	cg26647111	chr11:31128758	NA	0.47	8.5	0.38	3.4e-16	Red blood cell count;
LUAD	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg26408565	chr15:76604113	ETFA	-0.46	-7.76	-0.35	6.64e-14	Blood metabolite levels;
LUAD	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg14092571	chr14:90743983	NA	-0.47	-8.39	-0.38	7.42e-16	Mortality in heart failure;
LUAD	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg18944383	chr4:111397179	ENPEP	0.37	6.65	0.31	8.99e-11	Coronary artery disease;
LUAD	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg08280861	chr8:58055591	NA	-0.55	-7.49	-0.34	4.09e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg22681709	chr2:178499509	PDE11A	0.5	8.74	0.39	5.73e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs6908034	0.607	rs12525152	chr6:19809424	A/T	cg02682789	chr6:19804855	NA	0.88	9.2	0.41	1.69e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg14416269	chr4:6271139	WFS1	0.6	12.46	0.52	1.42e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg18876405	chr7:65276391	NA	-0.46	-7.26	-0.33	1.85e-12	Aortic root size;
LUAD	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg04034577	chr2:241836375	C2orf54	-0.51	-11.38	-0.48	2.37e-26	Urinary metabolites;
LUAD	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.73	0.31	5.64e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg04455712	chr21:45112962	RRP1B	0.52	10.45	0.45	6.61e-23	Mean corpuscular volume;
LUAD	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.54	-9.21	-0.41	1.59e-18	Tonsillectomy;
LUAD	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg14008862	chr17:28927542	LRRC37B2	0.75	7.6	0.35	1.94e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs28830936	0.510	rs2412640	chr15:42124082	C/T	cg17847044	chr15:42102381	MAPKBP1	0.55	12.87	0.53	3.25e-32	Diastolic blood pressure;
LUAD	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg02788857	chr8:22132959	PIWIL2	0.57	10.54	0.46	3.17e-23	Hypertriglyceridemia;
LUAD	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg02158880	chr13:53174818	NA	0.6	10.47	0.45	5.95e-23	Lewy body disease;
LUAD	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg24955955	chr5:415729	AHRR	0.8	8.97	0.4	9.42e-18	Fat distribution (HIV);
LUAD	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg00933542	chr6:150070202	PCMT1	0.35	7.24	0.33	2.14e-12	Testicular germ cell tumor;
LUAD	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg02038168	chr22:39784481	NA	0.52	8.63	0.39	1.3e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9902453	0.967	rs12449783	chr17:28527653	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.33	0.38	1.14e-15	Coffee consumption (cups per day);
LUAD	cis	rs7814319	0.700	rs35290014	chr8:97263930	T/C	cg20787634	chr8:97240163	UQCRB	-0.36	-6.69	-0.31	6.88e-11	Lung function (FVC);
LUAD	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg05234568	chr11:5960015	NA	-0.51	-9.3	-0.41	7.88e-19	DNA methylation (variation);
LUAD	cis	rs1595825	1.000	rs73058820	chr2:198864358	A/G	cg10547527	chr2:198650123	BOLL	-0.49	-6.72	-0.31	5.74e-11	Ulcerative colitis;
LUAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg08742575	chr21:47604166	C21orf56	0.42	6.73	0.31	5.61e-11	Testicular germ cell tumor;
LUAD	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.32	0.34	1.24e-12	Menopause (age at onset);
LUAD	cis	rs59698941	0.943	rs57045911	chr5:132272311	T/C	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.2e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg17105886	chr17:28927953	LRRC37B2	0.72	6.57	0.3	1.53e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.66	-0.31	8.57e-11	Neuroticism;
LUAD	cis	rs3772130	0.923	rs13090798	chr3:121482768	C/A	cg20356878	chr3:121714668	ILDR1	0.52	8.17	0.37	3.58e-15	Cognitive performance;
LUAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg16031515	chr1:205743344	RAB7L1	-0.34	-6.81	-0.31	3.44e-11	Monocyte percentage of white cells;
LUAD	cis	rs5758659	0.716	rs5758661	chr22:42624445	A/C	cg15128208	chr22:42549153	NA	-0.39	-7.98	-0.36	1.39e-14	Cognitive function;
LUAD	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg18932078	chr1:2524107	MMEL1	0.37	7.02	0.32	9.11e-12	Inflammatory bowel disease;Ulcerative colitis;
LUAD	trans	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.67	12.05	0.51	6.16e-29	Mean corpuscular volume;
LUAD	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg17724175	chr1:150552817	MCL1	0.34	7.87	0.36	3.01e-14	Melanoma;
LUAD	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg13385794	chr1:248469461	NA	0.26	6.76	0.31	4.7e-11	Common traits (Other);
LUAD	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-7.11	-0.33	4.85e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg25554036	chr4:6271136	WFS1	-0.65	-12.16	-0.51	2.2e-29	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.57	-10.63	-0.46	1.5e-23	Longevity;Endometriosis;
LUAD	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg04036182	chr15:45458818	NA	-0.4	-6.84	-0.32	2.81e-11	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs89107	0.688	rs422833	chr6:118608971	T/C	cg21191810	chr6:118973309	C6orf204	0.48	9.25	0.41	1.13e-18	Cardiac structure and function;
LUAD	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg23029597	chr12:123009494	RSRC2	-0.53	-8.24	-0.37	2.21e-15	Body mass index;
LUAD	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.32	6.65	0.31	9.05e-11	Obesity-related traits;
LUAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg22764044	chr5:178986830	RUFY1	0.64	11.07	0.47	3.43e-25	Lung cancer;
LUAD	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg17644776	chr2:200775616	C2orf69	0.54	7.83	0.36	3.99e-14	Schizophrenia;
LUAD	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.31	0.37	1.35e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg05342682	chr7:94953680	PON1	-0.51	-7.01	-0.32	9.46e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg05313129	chr8:58192883	C8orf71	-0.57	-8.5	-0.38	3.25e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs612683	0.759	rs12722868	chr1:100956478	A/G	cg09408571	chr1:101003634	GPR88	0.34	6.68	0.31	7.46e-11	Breast cancer;
LUAD	trans	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg05926928	chr17:57297772	GDPD1	-0.44	-6.58	-0.3	1.36e-10	Schizophrenia;
LUAD	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.33	-7.6	-0.35	1.88e-13	Lung cancer;
LUAD	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.53	-8.87	-0.4	2.08e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg00431813	chr7:1051703	C7orf50	-0.37	-6.56	-0.3	1.56e-10	Longevity;Endometriosis;
LUAD	cis	rs6987853	0.563	rs2974312	chr8:42455846	C/T	cg09913449	chr8:42400586	C8orf40	0.34	6.4	0.3	4.12e-10	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs748404	0.697	rs579651	chr15:43558376	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.15	0.37	4.19e-15	Lung cancer;
LUAD	trans	rs9784649	0.882	rs72753879	chr5:24947395	C/T	cg11038491	chr20:34638489	LOC647979	-0.63	-7.87	-0.36	2.95e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg05110241	chr16:68378359	PRMT7	-0.81	-8.75	-0.39	5.05e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	8.05	0.36	8.73e-15	Rheumatoid arthritis;
LUAD	cis	rs9372498	0.536	rs62422235	chr6:118971913	G/A	cg07617317	chr6:118971624	C6orf204	0.53	7.7	0.35	9.46e-14	Diastolic blood pressure;
LUAD	cis	rs41311933	0.562	rs72760256	chr9:123937240	G/A	cg13567360	chr9:123745713	C5	-0.71	-8.51	-0.38	3.09e-16	Coronary artery disease;
LUAD	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.59	-8.69	-0.39	7.94e-17	Gut microbiome composition (summer);
LUAD	cis	rs2030746	0.521	rs13021979	chr2:121325454	A/G	cg03661458	chr2:121334411	NA	-0.41	-6.99	-0.32	1.08e-11	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LUAD	cis	rs10129255	0.500	rs8011115	chr14:107194530	T/C	cg23076370	chr14:107095027	NA	-0.42	-8.42	-0.38	5.88e-16	Kawasaki disease;
LUAD	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg25358565	chr5:93447407	FAM172A	0.57	6.74	0.31	5.19e-11	Diabetic retinopathy;
LUAD	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.09	-0.44	1.4e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg09033563	chr22:24373618	LOC391322	-0.58	-9.67	-0.43	4.12e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg00802000	chr16:706648	WDR90	-0.37	-6.86	-0.32	2.45e-11	Height;
LUAD	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	12.05	0.51	6.18e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg18721089	chr20:30220636	NA	-0.48	-6.98	-0.32	1.13e-11	Mean corpuscular hemoglobin;
LUAD	trans	rs225245	0.610	rs321608	chr17:33880636	A/G	cg19694781	chr19:47549865	TMEM160	-0.47	-7.75	-0.35	6.85e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.61	0.52	3.64e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4853036	0.904	rs62152020	chr2:70147664	C/T	cg02498382	chr2:70120550	SNRNP27	-0.55	-8.84	-0.39	2.62e-17	Colorectal or endometrial cancer;
LUAD	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg15462221	chr8:8086144	FLJ10661	-0.44	-7.03	-0.32	8.26e-12	Neuroticism;
LUAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1950500	0.509	rs12888965	chr14:24834291	C/T	cg22990158	chr14:24802150	ADCY4	-0.4	-7.17	-0.33	3.43e-12	Height;
LUAD	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-10.92	-0.47	1.25e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.18	-0.41	1.96e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg00310523	chr12:86230176	RASSF9	0.4	7.92	0.36	2.18e-14	Major depressive disorder;
LUAD	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg02228675	chr17:40259724	DHX58	-0.45	-7.44	-0.34	5.8e-13	Fibrinogen levels;
LUAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg03188948	chr7:1209495	NA	0.62	8.22	0.37	2.45e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg07362569	chr17:61921086	SMARCD2	-0.39	-6.82	-0.31	3.18e-11	Prudent dietary pattern;
LUAD	cis	rs12200560	0.505	rs59296768	chr6:97075535	C/T	cg06623918	chr6:96969491	KIAA0776	0.47	7.32	0.34	1.23e-12	Coronary heart disease;
LUAD	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.77	-10.19	-0.44	6.04e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg15133208	chr4:90757351	SNCA	-0.46	-6.9	-0.32	1.94e-11	Neuroticism;
LUAD	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg27490568	chr2:178487706	NA	0.56	9.26	0.41	1.05e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg21285383	chr16:89894308	SPIRE2	0.4	9.49	0.42	1.77e-19	Vitiligo;
LUAD	cis	rs1788820	0.917	rs1652349	chr18:21142734	A/T	cg14672496	chr18:21087552	C18orf8	0.36	6.8	0.31	3.56e-11	Body mass index;
LUAD	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.4	0.34	7.47e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg00530320	chr1:46809349	NSUN4	0.51	7.92	0.36	2.07e-14	Menopause (age at onset);
LUAD	cis	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg27411982	chr8:10470053	RP1L1	0.38	6.58	0.3	1.4e-10	Neuroticism;
LUAD	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg01528321	chr10:82214614	TSPAN14	0.47	7.51	0.34	3.46e-13	Post bronchodilator FEV1;
LUAD	cis	rs494562	0.892	rs7753711	chr6:86130699	G/T	cg13315970	chr6:86159197	NT5E	-0.74	-8.78	-0.39	4.11e-17	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06623486	chr1:162531613	UAP1	-0.55	-6.84	-0.32	2.83e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6881634	0.501	rs17193552	chr5:77767577	C/T	cg11547950	chr5:77652471	NA	-0.36	-6.6	-0.31	1.25e-10	Hippocampal atrophy;
LUAD	cis	rs9329289	0.510	rs12359941	chr10:2547015	G/A	cg15501526	chr10:2543763	NA	0.55	11.85	0.5	3.64e-28	Age-related hearing impairment;
LUAD	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg00310523	chr12:86230176	RASSF9	0.37	7.76	0.35	6.36e-14	Major depressive disorder;
LUAD	cis	rs4664308	0.875	rs7593593	chr2:160933811	C/T	cg03641300	chr2:160917029	PLA2R1	-0.38	-6.51	-0.3	2.13e-10	Idiopathic membranous nephropathy;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg20141549	chr3:51534298	VPRBP	-0.39	-6.4	-0.3	4.09e-10	Subcortical brain region volumes;
LUAD	trans	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg04565464	chr8:145669602	NFKBIL2	0.45	6.75	0.31	4.87e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg24154853	chr7:158122151	PTPRN2	-0.56	-11.28	-0.48	5.36e-26	Calcium levels;
LUAD	cis	rs6484504	0.576	rs438578	chr11:31222579	A/G	cg14844989	chr11:31128820	NA	0.44	8.21	0.37	2.73e-15	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.12e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg06028605	chr16:24865363	SLC5A11	0.36	6.49	0.3	2.48e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7193541	0.682	rs28681530	chr16:74682496	C/T	cg01733217	chr16:74700730	RFWD3	0.68	13.53	0.55	6.68e-35	Multiple myeloma;
LUAD	trans	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg26043149	chr18:55253948	FECH	0.51	8.36	0.38	8.88e-16	Bone mineral density;
LUAD	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg02269571	chr22:50332266	NA	-0.61	-9.22	-0.41	1.46e-18	Schizophrenia;
LUAD	trans	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.0	-0.4	7.63e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4891159	0.548	rs690082	chr18:74116668	C/T	cg24786174	chr18:74118243	ZNF516	0.9	22.51	0.74	2.36e-74	Longevity;
LUAD	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg01448562	chr3:133502909	NA	-0.54	-9.21	-0.41	1.53e-18	Iron status biomarkers;
LUAD	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg11707310	chr1:2537719	MMEL1	-0.37	-7.89	-0.36	2.64e-14	Ulcerative colitis;
LUAD	cis	rs75920871	0.843	rs12099358	chr11:116726048	C/A	cg04087571	chr11:116723030	SIK3	-0.32	-7.12	-0.33	4.57e-12	Subjective well-being;
LUAD	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.52	-0.38	2.76e-16	Alzheimer's disease (late onset);
LUAD	cis	rs7274811	0.744	rs6141411	chr20:32157934	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.52	-7.8	-0.35	4.82e-14	Height;
LUAD	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.86	-0.36	3.32e-14	Diabetic kidney disease;
LUAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg04025307	chr7:1156635	C7orf50	0.69	12.29	0.51	6.82e-30	Longevity;Endometriosis;
LUAD	cis	rs2535633	0.588	rs2564930	chr3:53017307	T/C	cg18404041	chr3:52824283	ITIH1	0.38	6.66	0.31	8.72e-11	Body mass index;
LUAD	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg09222892	chr1:25734099	RHCE	-0.5	-9.19	-0.41	1.74e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg10360139	chr7:1886902	MAD1L1	-0.41	-6.37	-0.3	5.06e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.95	-0.32	1.43e-11	Retinal vascular caliber;
LUAD	cis	rs10170310	1.000	rs10803568	chr2:139290914	T/C	cg03782584	chr2:139258740	SPOPL	0.32	6.64	0.31	9.79e-11	Response to antipsychotic treatment;
LUAD	cis	rs6430585	0.536	rs3213892	chr2:136552517	G/A	cg07169764	chr2:136633963	MCM6	0.83	9.93	0.43	5.01e-21	Corneal structure;
LUAD	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg12379764	chr21:47803548	PCNT	-0.37	-6.44	-0.3	3.34e-10	Testicular germ cell tumor;
LUAD	trans	rs9784649	1.000	rs9784649	chr5:25011524	G/A	cg08600765	chr20:34638493	LOC647979	-0.64	-8.02	-0.36	1.03e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg15704280	chr7:45808275	SEPT13	0.65	7.65	0.35	1.39e-13	Intraocular pressure;
LUAD	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg23254163	chr1:152506842	NA	0.27	7.32	0.34	1.3e-12	Hair morphology;
LUAD	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg24813613	chr7:1882135	MAD1L1	-0.43	-6.82	-0.31	3.14e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs76419734	0.558	rs28536076	chr4:106527896	T/C	cg05309399	chr4:106552544	FLJ20184	-0.52	-6.89	-0.32	2.06e-11	Post bronchodilator FEV1;
LUAD	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg14227996	chr4:17616232	MED28	0.71	7.38	0.34	8.65e-13	Opioid sensitivity;
LUAD	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg11822812	chr5:140052017	DND1	0.37	6.45	0.3	3.11e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg14917512	chr19:3094685	GNA11	-0.57	-6.7	-0.31	6.72e-11	Diabetic kidney disease;
LUAD	cis	rs757647	1.000	rs12659034	chr5:137773525	C/T	cg10676309	chr5:137685565	NA	0.36	6.88	0.32	2.11e-11	Menarche (age at onset);
LUAD	trans	rs853679	0.607	rs13201308	chr6:28130089	C/T	cg01620082	chr3:125678407	NA	-1.1	-10.38	-0.45	1.25e-22	Depression;
LUAD	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg02176678	chr2:219576539	TTLL4	0.63	12.32	0.51	5.16e-30	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg00504896	chr12:9437009	LOC642846	-0.57	-9.8	-0.43	1.42e-20	Breast size;
LUAD	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg04398451	chr17:18023971	MYO15A	0.69	12.35	0.51	4.08e-30	Total body bone mineral density;
LUAD	cis	rs12681287	0.640	rs6471309	chr8:87387760	C/T	cg27223183	chr8:87520930	FAM82B	-0.67	-9.48	-0.42	1.82e-19	Caudate activity during reward;
LUAD	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg17145862	chr1:211918768	LPGAT1	0.55	11.1	0.47	2.69e-25	Leprosy;
LUAD	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.87	-0.36	2.99e-14	Diabetic kidney disease;
LUAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13732083	chr21:47605072	C21orf56	-0.56	-9.72	-0.43	2.83e-20	Testicular germ cell tumor;
LUAD	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.57	-9.35	-0.41	5.31e-19	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs12144309	0.554	rs2476599	chr1:114363459	G/A	cg03325407	chr1:114423726	BCL2L15	0.39	6.9	0.32	1.91e-11	Coronary artery disease;
LUAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg11062466	chr8:58055876	NA	0.67	8.47	0.38	4.18e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	5e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg25767906	chr1:53392781	SCP2	0.41	7.3	0.33	1.45e-12	Monocyte count;
LUAD	cis	rs7017914	0.902	rs10504481	chr8:71699517	T/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.4	-0.3	4.09e-10	Bone mineral density;
LUAD	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg18811423	chr2:55921094	PNPT1	0.52	8.63	0.39	1.23e-16	Metabolic syndrome;
LUAD	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg17200465	chr3:40428508	ENTPD3	-0.25	-6.39	-0.3	4.28e-10	Renal cell carcinoma;
LUAD	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg21191810	chr6:118973309	C6orf204	-0.52	-8.14	-0.37	4.53e-15	Diastolic blood pressure;
LUAD	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg05043794	chr9:111880884	C9orf5	-0.42	-7.53	-0.34	3.04e-13	Menarche (age at onset);
LUAD	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg21475434	chr5:93447410	FAM172A	0.7	8.26	0.37	1.86e-15	Diabetic retinopathy;
LUAD	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg22681709	chr2:178499509	PDE11A	-0.4	-6.64	-0.31	9.69e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs877282	0.898	rs11253352	chr10:766598	C/A	cg22713356	chr15:30763199	NA	1.27	17.71	0.65	6.62e-53	Uric acid levels;
LUAD	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg13390004	chr1:15929781	NA	0.47	7.76	0.35	6.45e-14	Systolic blood pressure;
LUAD	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.14	-0.41	2.57e-18	Life satisfaction;
LUAD	cis	rs41311933	0.656	rs77934993	chr9:123844845	C/A	cg13567360	chr9:123745713	C5	-0.71	-8.08	-0.37	6.78e-15	Coronary artery disease;
LUAD	cis	rs13112683	0.638	rs6842378	chr4:140785446	G/A	cg02876341	chr4:140783585	MAML3	0.31	6.66	0.31	8.71e-11	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LUAD	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg15997130	chr1:24165203	NA	0.56	9.54	0.42	1.14e-19	Immature fraction of reticulocytes;
LUAD	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.44	0.3	3.17e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg15181151	chr6:150070149	PCMT1	0.4	7.68	0.35	1.14e-13	Lung cancer;
LUAD	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg02782426	chr3:40428986	ENTPD3	-0.43	-9.08	-0.4	4.03e-18	Renal cell carcinoma;
LUAD	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg25985355	chr7:65971099	NA	0.38	7.0	0.32	1.01e-11	Aortic root size;
LUAD	cis	rs3784262	0.934	rs4646611	chr15:58265083	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.45	-9.09	-0.4	3.89e-18	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7250872	0.619	rs2396359	chr19:1819125	T/C	cg10370574	chr19:1840461	REXO1	-0.65	-10.74	-0.46	5.66e-24	Bipolar disorder;
LUAD	cis	rs2224391	0.590	rs2145372	chr6:5245070	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-9.2	-0.41	1.67e-18	Height;
LUAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg08888203	chr3:10149979	C3orf24	0.73	12.71	0.53	1.41e-31	Alzheimer's disease;
LUAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg24503407	chr1:205819492	PM20D1	0.45	7.17	0.33	3.34e-12	Parkinson's disease;
LUAD	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05901451	chr6:126070800	HEY2	-0.65	-11.06	-0.47	3.94e-25	Brugada syndrome;
LUAD	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg13722127	chr7:150037890	RARRES2	0.5	8.67	0.39	9.41e-17	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6733011	0.578	rs1581250	chr2:99500750	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.83	-0.32	2.89e-11	Bipolar disorder;
LUAD	cis	rs62400317	0.762	rs3997499	chr6:44864552	G/T	cg18551225	chr6:44695536	NA	-0.58	-8.81	-0.39	3.22e-17	Total body bone mineral density;
LUAD	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg24397884	chr7:158709396	WDR60	0.46	8.01	0.36	1.12e-14	Height;
LUAD	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg26408565	chr15:76604113	ETFA	-0.44	-7.22	-0.33	2.46e-12	Blood metabolite levels;
LUAD	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg05896524	chr21:47604654	C21orf56	-0.59	-8.96	-0.4	1.08e-17	Testicular germ cell tumor;
LUAD	cis	rs8177876	0.822	rs59685942	chr16:81115139	A/G	cg08591886	chr16:81111003	C16orf46	-0.79	-7.37	-0.34	8.94e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08859206	chr1:53392774	SCP2	-0.76	-15.06	-0.59	2.52e-41	Monocyte count;
LUAD	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg05714579	chr10:131428358	MGMT	-0.45	-7.01	-0.32	9.62e-12	Response to temozolomide;
LUAD	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg01528321	chr10:82214614	TSPAN14	0.66	10.56	0.46	2.66e-23	Post bronchodilator FEV1;
LUAD	cis	rs7189233	0.955	rs7184800	chr16:53509131	G/A	cg04059762	chr16:53544020	NA	-0.41	-6.6	-0.31	1.24e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7072216	0.922	rs6584191	chr10:100152055	C/G	cg26618903	chr10:100175079	PYROXD2	-0.33	-7.09	-0.33	5.81e-12	Metabolite levels;
LUAD	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg19761014	chr17:28927070	LRRC37B2	0.69	6.75	0.31	4.76e-11	Body mass index;
LUAD	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg11833968	chr6:79620685	NA	-0.4	-7.11	-0.33	5.1e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10242455	0.557	rs2404487	chr7:99038057	G/A	cg18809830	chr7:99032528	PTCD1	-0.99	-7.18	-0.33	3.17e-12	Blood metabolite levels;
LUAD	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg04155289	chr7:94953770	PON1	-0.55	-7.41	-0.34	6.89e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg04705435	chr11:17411270	KCNJ11	0.41	6.87	0.32	2.32e-11	Type 2 diabetes;
LUAD	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg13813247	chr22:41461852	NA	-0.46	-7.31	-0.33	1.38e-12	Neuroticism;
LUAD	cis	rs73206853	0.614	rs57154770	chr12:110814415	T/C	cg12870014	chr12:110450643	ANKRD13A	0.61	6.72	0.31	6.02e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs7395662	0.929	rs8186263	chr11:48737935	A/T	cg00717180	chr2:96193071	NA	-0.39	-7.2	-0.33	2.76e-12	HDL cholesterol;
LUAD	cis	rs7843479	0.582	rs11135743	chr8:21803008	A/G	cg03445287	chr8:21823731	XPO7	-0.49	-9.27	-0.41	9.51e-19	Mean corpuscular volume;
LUAD	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg13073564	chr4:8508604	NA	-0.62	-11.37	-0.48	2.46e-26	Response to antineoplastic agents;
LUAD	cis	rs4523957	0.928	rs216198	chr17:2201735	C/T	cg16513277	chr17:2031491	SMG6	0.73	13.69	0.55	1.43e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg04117972	chr1:227635322	NA	0.86	7.78	0.35	5.8e-14	Major depressive disorder;
LUAD	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-13.7	-0.55	1.25e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg00634984	chr7:65235879	NA	0.5	6.73	0.31	5.62e-11	Aortic root size;
LUAD	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.08	-0.4	4.16e-18	Menopause (age at onset);
LUAD	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.66	0.39	1.02e-16	Menopause (age at onset);
LUAD	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg20587970	chr11:113659929	NA	-0.94	-13.11	-0.54	3.5e-33	Hip circumference adjusted for BMI;
LUAD	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.93	0.32	1.55e-11	Cognitive test performance;
LUAD	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.85	-0.36	3.48e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.95	0.32	1.4e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6500395	1.000	rs9930365	chr16:48682154	A/C	cg04672837	chr16:48644449	N4BP1	0.39	6.77	0.31	4.19e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg02038168	chr22:39784481	NA	-0.59	-10.68	-0.46	1.01e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg12419862	chr22:24373484	LOC391322	0.77	14.04	0.56	4.83e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2806561	0.828	rs944509	chr1:23542242	C/T	cg19743168	chr1:23544995	NA	-0.46	-8.4	-0.38	6.84e-16	Height;
LUAD	cis	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg21775007	chr8:11205619	TDH	0.37	6.44	0.3	3.16e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg07679836	chr6:33548423	BAK1	0.63	10.88	0.47	1.76e-24	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
LUAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg27588902	chr6:42928151	GNMT	-0.35	-9.29	-0.41	8.47e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs13064411	0.696	rs6768979	chr3:113204149	G/A	cg10517650	chr3:113235015	CCDC52	-0.56	-9.72	-0.43	2.67e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg16797656	chr11:68205561	LRP5	0.45	8.48	0.38	3.83e-16	Total body bone mineral density;
LUAD	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg24229701	chr12:130821962	PIWIL1	0.39	6.52	0.3	2e-10	Menopause (age at onset);
LUAD	cis	rs4243830	0.850	rs11122043	chr1:6580429	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.73	-9.7	-0.43	3.1e-20	Body mass index;
LUAD	cis	rs7737355	0.947	rs40989	chr5:130992284	T/G	cg06307176	chr5:131281290	NA	0.53	8.34	0.38	1.06e-15	Life satisfaction;
LUAD	cis	rs7582720	1.000	rs72934563	chr2:203995405	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.59	0.42	7.76e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg26384229	chr12:38710491	ALG10B	0.47	7.56	0.35	2.48e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs73416724	0.925	rs79641366	chr6:43279144	T/C	cg26312998	chr6:43337775	ZNF318	0.55	6.58	0.3	1.36e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9296095	0.950	rs5745587	chr6:33545125	A/G	cg07679836	chr6:33548423	BAK1	0.39	6.42	0.3	3.56e-10	Platelet count;
LUAD	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg14847009	chr1:175162515	KIAA0040	-0.33	-8.71	-0.39	7.09e-17	Alcohol dependence;
LUAD	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg19436804	chr8:8560866	CLDN23	0.42	6.35	0.3	5.49e-10	Obesity-related traits;
LUAD	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23158103	chr7:148848205	ZNF398	-0.64	-11.96	-0.5	1.36e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs7395662	0.700	rs11493668	chr11:48727582	G/A	cg15704280	chr7:45808275	SEPT13	-0.41	-6.35	-0.3	5.43e-10	HDL cholesterol;
LUAD	cis	rs2073499	0.935	rs74398439	chr3:50331927	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.63	7.26	0.33	1.85e-12	Schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27304813	chr3:120068385	LRRC58	-0.43	-6.83	-0.32	2.95e-11	Height;
LUAD	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg15181151	chr6:150070149	PCMT1	0.39	8.01	0.36	1.09e-14	Lung cancer;
LUAD	cis	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg23950597	chr19:37808831	NA	-0.62	-7.66	-0.35	1.28e-13	Coronary artery calcification;
LUAD	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg20119798	chr7:94954144	PON1	-0.48	-6.54	-0.3	1.83e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg21823605	chr1:152486609	CRCT1	0.3	6.85	0.32	2.6e-11	Hair morphology;
LUAD	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.54	8.51	0.38	3.13e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs17401966	1.000	rs7530167	chr1:10453374	A/G	cg15208524	chr1:10270712	KIF1B	0.5	7.43	0.34	6.15e-13	Hepatocellular carcinoma;
LUAD	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs6906287	0.625	rs7453914	chr6:118692981	A/T	cg21191810	chr6:118973309	C6orf204	0.53	10.97	0.47	8.19e-25	Electrocardiographic conduction measures;
LUAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg16031515	chr1:205743344	RAB7L1	-0.37	-7.35	-0.34	1.04e-12	Menarche (age at onset);
LUAD	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg11871910	chr12:69753446	YEATS4	0.54	8.54	0.38	2.37e-16	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg00310523	chr12:86230176	RASSF9	0.41	8.05	0.36	8.27e-15	Major depressive disorder;
LUAD	trans	rs970548	0.688	rs2082111	chr10:45931060	A/C	cg14222797	chr10:16859974	RSU1	-0.59	-6.86	-0.32	2.45e-11	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08315959	chr5:98106052	RGMB	-0.38	-6.4	-0.3	4.25e-10	Cancer;
LUAD	cis	rs7524258	0.903	rs4908450	chr1:7292756	T/C	cg07173049	chr1:7289937	CAMTA1	0.55	10.39	0.45	1.12e-22	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.26	0.37	1.82e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg07917127	chr4:99064746	C4orf37	0.43	6.67	0.31	7.85e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs55986470	0.759	rs66636130	chr2:239405748	G/A	cg01134436	chr17:81009848	B3GNTL1	0.7	7.03	0.32	8.37e-12	Chronotype;
LUAD	cis	rs6563943	0.857	rs8053046	chr16:83636775	C/G	cg01935413	chr16:83636749	CDH13	0.37	6.94	0.32	1.52e-11	Height;
LUAD	cis	rs593982	0.920	rs645621	chr11:65490756	T/C	cg08755490	chr11:65554678	OVOL1	1.27	15.24	0.6	3.99e-42	Atopic dermatitis;
LUAD	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23158103	chr7:148848205	ZNF398	-0.66	-12.57	-0.52	4.98e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs1728785	1.000	rs6499181	chr16:68593002	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.31	0.45	2.19e-22	Ulcerative colitis;
LUAD	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg23954153	chr1:44402353	ARTN	-0.34	-6.42	-0.3	3.59e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs114221457	chr7:107019913	C/G	cg02696742	chr7:106810147	HBP1	-0.77	-10.29	-0.45	2.57e-22	Coronary artery disease;
LUAD	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg10591111	chr5:226296	SDHA	-0.55	-7.23	-0.33	2.23e-12	Breast cancer;
LUAD	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg27219399	chr15:67835830	MAP2K5	0.42	6.69	0.31	7.31e-11	Restless legs syndrome;
LUAD	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg02428538	chr16:24856791	SLC5A11	-0.52	-7.09	-0.33	5.68e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs3125734	0.633	rs4979782	chr10:63998527	C/T	cg09941381	chr10:64027924	RTKN2	-0.3	-6.93	-0.32	1.53e-11	Rheumatoid arthritis;
LUAD	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg17264618	chr3:40429014	ENTPD3	0.39	8.26	0.37	1.89e-15	Renal cell carcinoma;
LUAD	cis	rs9389248	0.728	rs1022491	chr6:135259366	C/T	cg22676075	chr6:135203613	NA	-0.55	-9.86	-0.43	8.54e-21	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg02782426	chr3:40428986	ENTPD3	0.34	7.45	0.34	5.36e-13	Renal cell carcinoma;
LUAD	cis	rs2735413	0.837	rs12920830	chr16:78083149	A/C	cg04733911	chr16:78082701	NA	-0.34	-8.17	-0.37	3.53e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg26384229	chr12:38710491	ALG10B	-0.51	-8.42	-0.38	6.1e-16	Heart rate;
LUAD	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg20891283	chr12:69753455	YEATS4	0.44	7.14	0.33	4.18e-12	Blood protein levels;
LUAD	cis	rs11958404	0.860	rs56090852	chr5:157431120	A/G	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg26168224	chr5:2018326	NA	0.78	17.46	0.65	8.56e-52	Gut microbiome composition (winter);
LUAD	cis	rs16854884	0.632	rs62267390	chr3:143644067	A/T	cg01302019	chr3:143689584	C3orf58	-0.39	-6.44	-0.3	3.34e-10	Economic and political preferences (feminism/equality);
LUAD	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg13736514	chr6:26305472	NA	-0.71	-13.18	-0.54	1.76e-33	Educational attainment;
LUAD	cis	rs28655083	0.956	rs7184167	chr16:77069451	T/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.43	-7.31	-0.33	1.33e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18876405	chr7:65276391	NA	-0.58	-9.72	-0.43	2.82e-20	Aortic root size;
LUAD	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg02269571	chr22:50332266	NA	-0.59	-8.95	-0.4	1.16e-17	Schizophrenia;
LUAD	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18404041	chr3:52824283	ITIH1	-0.59	-12.01	-0.5	8.88e-29	Bipolar disorder;
LUAD	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg06740227	chr12:86229804	RASSF9	0.42	7.16	0.33	3.68e-12	Major depressive disorder;
LUAD	cis	rs11809207	1.000	rs11809207	chr1:26521140	G/A	cg00147160	chr1:26503991	CNKSR1	0.43	8.67	0.39	9.31e-17	Height;
LUAD	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg02018176	chr4:1364513	KIAA1530	-0.42	-8.06	-0.36	7.97e-15	Obesity-related traits;
LUAD	cis	rs13315871	1.000	rs13317400	chr3:58408792	T/G	cg20936604	chr3:58311152	NA	-0.69	-7.24	-0.33	2.16e-12	Cholesterol, total;
LUAD	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00802000	chr16:706648	WDR90	-0.42	-7.93	-0.36	2.02e-14	Height;
LUAD	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-8.34	-0.38	1.08e-15	Axial length;
LUAD	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg17200465	chr3:40428508	ENTPD3	0.27	6.58	0.3	1.39e-10	Renal cell carcinoma;
LUAD	cis	rs6541297	1.000	rs2144298	chr1:230280198	T/C	cg20703242	chr1:230279135	GALNT2	0.66	11.65	0.49	2.15e-27	Coronary artery disease;
LUAD	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg23992470	chr4:843637	GAK	0.68	7.19	0.33	2.88e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg07636037	chr3:49044803	WDR6	0.56	10.64	0.46	1.39e-23	Parkinson's disease;
LUAD	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg13319975	chr6:146136371	FBXO30	-0.75	-12.64	-0.52	2.71e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg20503657	chr10:835505	NA	0.78	10.52	0.46	3.65e-23	Eosinophil percentage of granulocytes;
LUAD	cis	rs12900413	0.603	rs12909833	chr15:90301518	G/A	cg24249390	chr15:90295951	MESP1	-0.35	-6.85	-0.32	2.66e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs853679	0.607	rs13197176	chr6:28129232	C/T	cg06606381	chr12:133084897	FBRSL1	-1.22	-10.86	-0.47	2.15e-24	Depression;
LUAD	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg03563238	chr19:33554763	RHPN2	-0.35	-8.27	-0.37	1.76e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.75	-0.31	4.81e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6690583	0.623	rs61768852	chr1:85454613	T/C	cg22153463	chr1:85462885	MCOLN2	0.55	6.37	0.3	4.97e-10	Serum sulfate level;
LUAD	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg22676075	chr6:135203613	NA	0.56	9.95	0.44	4.34e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg13319975	chr6:146136371	FBXO30	-0.55	-8.9	-0.4	1.59e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	9.57	0.42	8.74e-20	Axial length;
LUAD	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg24558204	chr6:135376177	HBS1L	0.46	7.77	0.35	5.88e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7665090	1.000	rs7665090	chr4:103551603	C/T	cg07973026	chr4:103553119	MANBA	-0.47	-8.43	-0.38	5.68e-16	Primary biliary cholangitis;
LUAD	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06022373	chr22:39101656	GTPBP1	0.48	8.0	0.36	1.23e-14	Menopause (age at onset);
LUAD	cis	rs2688608	0.967	rs2633299	chr10:75656754	T/G	cg19442545	chr10:75533431	FUT11	-0.4	-6.92	-0.32	1.67e-11	Inflammatory bowel disease;
LUAD	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.3	-0.37	1.38e-15	Height;
LUAD	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg11584989	chr19:19387371	SF4	0.36	6.38	0.3	4.66e-10	Tonsillectomy;
LUAD	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg18230493	chr5:56204884	C5orf35	0.51	8.29	0.37	1.48e-15	Coronary artery disease;
LUAD	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg19875535	chr5:140030758	IK	-0.39	-6.61	-0.31	1.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.47	-0.34	4.73e-13	Type 2 diabetes;
LUAD	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg18131467	chr2:239335373	ASB1	0.73	12.46	0.52	1.49e-30	Multiple system atrophy;
LUAD	cis	rs3760982	0.585	rs67704568	chr19:44294019	T/C	cg12072164	chr19:44306565	LYPD5	0.42	8.52	0.38	2.78e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg10755058	chr3:40428713	ENTPD3	0.44	8.4	0.38	7.02e-16	Renal cell carcinoma;
LUAD	cis	rs938554	0.784	rs7682751	chr4:9976294	A/G	cg11266682	chr4:10021025	SLC2A9	0.43	7.58	0.35	2.17e-13	Blood metabolite levels;
LUAD	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19717773	chr7:2847554	GNA12	-0.57	-9.81	-0.43	1.36e-20	Height;
LUAD	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg23803603	chr1:2058230	PRKCZ	-0.41	-7.15	-0.33	3.85e-12	Height;
LUAD	cis	rs4077468	1.000	rs4077468	chr1:205914757	A/G	cg26354017	chr1:205819088	PM20D1	-0.36	-6.5	-0.3	2.25e-10	Cystic fibrosis-related diabetes;
LUAD	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg07386859	chr16:1872102	HAGH	0.48	8.32	0.37	1.25e-15	Insulin-like growth factors;
LUAD	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18404041	chr3:52824283	ITIH1	-0.59	-12.0	-0.5	9.05e-29	Bipolar disorder;
LUAD	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg07708487	chr16:89387014	ANKRD11	-0.32	-6.38	-0.3	4.63e-10	Multiple myeloma (IgH translocation);
LUAD	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg26384229	chr12:38710491	ALG10B	0.4	6.44	0.3	3.27e-10	Morning vs. evening chronotype;
LUAD	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg21427119	chr20:30132790	HM13	-0.5	-7.98	-0.36	1.4e-14	Mean corpuscular hemoglobin;
LUAD	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg23533926	chr12:111358616	MYL2	-0.39	-6.72	-0.31	6.07e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg12432903	chr7:1882776	MAD1L1	-0.41	-6.53	-0.3	1.93e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs1997103	0.906	rs6593232	chr7:55402916	C/T	cg20935933	chr6:143382018	AIG1	0.53	7.48	0.34	4.32e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg12454169	chr2:30669597	LCLAT1	0.56	7.45	0.34	5.32e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg08213375	chr14:104286397	PPP1R13B	0.26	6.79	0.31	3.74e-11	Schizophrenia;
LUAD	cis	rs2224391	0.578	rs766339	chr6:5243506	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-8.66	-0.39	1e-16	Height;
LUAD	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23583168	chr7:148888333	NA	-0.94	-19.29	-0.68	5.95e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg03037974	chr15:76606532	NA	0.39	8.29	0.37	1.56e-15	Blood metabolite levels;
LUAD	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg12935359	chr14:103987150	CKB	0.48	7.46	0.34	4.96e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg13736514	chr6:26305472	NA	-0.73	-13.92	-0.56	1.53e-36	Educational attainment;
LUAD	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.46	-7.39	-0.34	8.05e-13	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	trans	rs1728785	1.000	rs1170433	chr16:68606081	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.4	0.45	1.02e-22	Ulcerative colitis;
LUAD	cis	rs240764	0.658	rs7740783	chr6:101263516	C/T	cg09795085	chr6:101329169	ASCC3	0.44	7.73	0.35	8.02e-14	Neuroticism;
LUAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg11494091	chr17:61959527	GH2	0.74	18.18	0.66	5.63e-55	Prudent dietary pattern;
LUAD	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg22467129	chr15:76604101	ETFA	-0.5	-8.59	-0.39	1.73e-16	Blood metabolite levels;
LUAD	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg24558204	chr6:135376177	HBS1L	0.49	8.33	0.38	1.12e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg07538946	chr5:131705188	SLC22A5	0.48	7.86	0.36	3.18e-14	Breast cancer;Mosquito bite size;
LUAD	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.62	-0.35	1.73e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg15181151	chr6:150070149	PCMT1	0.33	6.49	0.3	2.43e-10	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg04546413	chr19:29218101	NA	0.58	7.51	0.34	3.66e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg23262073	chr20:60523788	NA	-0.46	-7.41	-0.34	7.12e-13	Body mass index;
LUAD	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg22532475	chr10:104410764	TRIM8	0.55	10.73	0.46	6.43e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg06640241	chr16:89574553	SPG7	0.72	13.02	0.53	7.74e-33	Multiple myeloma (IgH translocation);
LUAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.51	-9.06	-0.4	4.94e-18	Lymphocyte counts;
LUAD	cis	rs9650657	0.707	rs10097283	chr8:10659406	G/C	cg27411982	chr8:10470053	RP1L1	-0.39	-6.73	-0.31	5.7e-11	Neuroticism;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg26801646	chr10:76970496	VDAC2	-0.46	-8.19	-0.37	3.16e-15	Schizophrenia;
LUAD	cis	rs7017914	0.967	rs17688313	chr8:71683864	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	0.32	6.42	0.3	3.63e-10	Bone mineral density;
LUAD	cis	rs11771526	0.901	rs1530823	chr7:32311420	G/T	cg27532318	chr7:32358331	NA	-0.55	-7.53	-0.34	3.04e-13	Body mass index;
LUAD	cis	rs8060686	0.516	rs10852439	chr16:68288331	T/C	cg05110241	chr16:68378359	PRMT7	-0.6	-7.72	-0.35	8.76e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg12432903	chr7:1882776	MAD1L1	-0.41	-6.57	-0.3	1.46e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs3823572	0.542	rs62470446	chr7:133631002	C/T	cg03336402	chr7:133662267	EXOC4	0.42	7.65	0.35	1.33e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2535633	0.631	rs2581819	chr3:53016552	C/A	cg18404041	chr3:52824283	ITIH1	0.38	6.58	0.3	1.42e-10	Body mass index;
LUAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.52	-7.8	-0.35	4.92e-14	Alzheimer's disease;
LUAD	cis	rs12912251	0.591	rs4924291	chr15:39000484	A/C	cg01338139	chr15:38987640	C15orf53	-0.53	-7.22	-0.33	2.46e-12	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg04944784	chr2:26401820	FAM59B	-0.9	-13.56	-0.55	4.79e-35	Gut microbiome composition (summer);
LUAD	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg11166453	chr1:247681781	NA	-0.4	-8.09	-0.37	6.52e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7000551	0.725	rs2469757	chr8:22360938	C/T	cg12081754	chr8:22256438	SLC39A14	0.46	7.83	0.36	3.94e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-7.86	-0.36	3.32e-14	Lung cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17001531	chr1:16825540	NA	-0.57	-7.08	-0.33	6.22e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg12179176	chr11:130786555	SNX19	0.54	9.07	0.4	4.68e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7827545	0.961	rs4909482	chr8:135564786	G/T	cg17885191	chr8:135476712	NA	0.49	7.78	0.35	5.77e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.73	13.11	0.54	3.56e-33	Breast cancer;
LUAD	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg20587970	chr11:113659929	NA	1.12	15.24	0.6	3.9e-42	Hip circumference adjusted for BMI;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg08333703	chr19:35225315	ZNF181	-0.38	-6.64	-0.31	9.43e-11	Schizophrenia;
LUAD	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.22	-0.54	1.24e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg05966235	chr16:28915196	ATP2A1	0.47	7.61	0.35	1.75e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7487075	0.567	rs4768712	chr12:46811521	T/C	cg23829395	chr12:46796953	NA	0.32	6.98	0.32	1.16e-11	Itch intensity from mosquito bite;
LUAD	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg02734326	chr4:10020555	SLC2A9	-0.55	-9.53	-0.42	1.29e-19	Bone mineral density;
LUAD	cis	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg01251360	chr16:68772225	CDH1	-0.28	-8.9	-0.4	1.63e-17	Colorectal cancer;
LUAD	cis	rs6489882	0.703	rs10774672	chr12:113360737	G/T	cg20102336	chr12:113376681	OAS3	-0.56	-8.49	-0.38	3.51e-16	Chronic lymphocytic leukemia;
LUAD	trans	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg10556349	chr10:835070	NA	0.68	8.17	0.37	3.54e-15	Eosinophil percentage of granulocytes;
LUAD	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs55665837	0.701	rs10766188	chr11:14660826	T/C	cg19336497	chr11:14380999	RRAS2	-0.41	-7.27	-0.33	1.79e-12	Vitamin D levels;
LUAD	cis	rs11214589	0.747	rs7939992	chr11:113229665	T/C	cg14159747	chr11:113255604	NA	0.59	12.14	0.51	2.64e-29	Neuroticism;
LUAD	cis	rs1832871	0.672	rs9457343	chr6:158740567	A/G	cg07165851	chr6:158734300	TULP4	0.72	11.09	0.47	2.99e-25	Height;
LUAD	cis	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.44	-0.34	5.74e-13	Neuroticism;
LUAD	cis	rs7759001	0.857	rs12195788	chr6:27356406	C/T	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.83e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg04414720	chr1:150670196	GOLPH3L	0.7	12.41	0.52	2.25e-30	Melanoma;
LUAD	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg23758822	chr17:41437982	NA	0.99	20.48	0.71	2.94e-65	Menopause (age at onset);
LUAD	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.57	-8.05	-0.36	8.36e-15	Gut microbiome composition (summer);
LUAD	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg00277334	chr10:82204260	NA	-0.63	-10.63	-0.46	1.46e-23	Post bronchodilator FEV1;
LUAD	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg21153622	chr11:89784906	NA	-0.33	-6.45	-0.3	3.14e-10	Coronary artery disease;
LUAD	cis	rs2742234	0.541	rs10793427	chr10:43747443	G/A	cg15436174	chr10:43711423	RASGEF1A	0.48	8.28	0.37	1.64e-15	Hirschsprung disease;
LUAD	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.75	-0.35	6.93e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg03433033	chr1:76189801	ACADM	0.81	14.61	0.58	2.05e-39	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg05872129	chr22:39784769	NA	-0.8	-15.18	-0.59	7.33e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg27284194	chr4:1044797	NA	0.71	10.22	0.44	4.71e-22	Recombination rate (females);
LUAD	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg17173187	chr15:85201210	NMB	0.39	6.36	0.3	5.22e-10	Schizophrenia;
LUAD	trans	rs6940638	1.000	rs12204280	chr6:27033104	T/C	cg06606381	chr12:133084897	FBRSL1	-0.48	-6.36	-0.3	5.18e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4722585	0.533	rs2049843	chr7:26196963	G/A	cg07876897	chr7:26191696	NFE2L3	0.46	7.44	0.34	5.67e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs113835537	0.597	rs11227523	chr11:66305938	C/T	cg24851651	chr11:66362959	CCS	0.58	10.28	0.45	2.81e-22	Airway imaging phenotypes;
LUAD	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg11822812	chr5:140052017	DND1	-0.44	-8.25	-0.37	2.07e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg00071950	chr4:10020882	SLC2A9	0.78	15.84	0.61	1.11e-44	Bone mineral density;
LUAD	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15664640	chr17:80829946	TBCD	-0.85	-17.6	-0.65	2.01e-52	Breast cancer;
LUAD	cis	rs1595825	0.891	rs35817167	chr2:198718928	A/T	cg11031976	chr2:198649780	BOLL	-0.48	-7.13	-0.33	4.37e-12	Ulcerative colitis;
LUAD	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg13770153	chr20:60521292	NA	-0.47	-7.99	-0.36	1.29e-14	Body mass index;
LUAD	cis	rs6500395	0.928	rs4553627	chr16:48708801	A/T	cg04672837	chr16:48644449	N4BP1	-0.38	-6.55	-0.3	1.67e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg18876405	chr7:65276391	NA	0.62	10.9	0.47	1.5e-24	Calcium levels;
LUAD	cis	rs6499255	0.951	rs16958970	chr16:69627793	G/A	cg15192750	chr16:69999425	NA	0.54	8.41	0.38	6.48e-16	IgE levels;
LUAD	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg07138768	chr7:917805	C7orf20	0.39	7.7	0.35	9.43e-14	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs3813948	0.543	rs11120218	chr1:207278451	C/T	cg11070419	chr1:207277210	C4BPA	-0.47	-6.86	-0.32	2.47e-11	C4b binding protein levels;
LUAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg24846343	chr22:24311635	DDTL	-0.58	-9.92	-0.43	5.22e-21	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs1483890	0.723	rs6807930	chr3:69411662	C/T	cg22125112	chr3:69402811	FRMD4B	0.45	7.56	0.35	2.46e-13	Resting heart rate;
LUAD	cis	rs6066825	0.644	rs6066823	chr20:47338768	C/G	cg18078177	chr20:47281410	PREX1	0.39	6.43	0.3	3.36e-10	Colorectal cancer;
LUAD	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg27572855	chr1:25598939	RHD	0.62	14.12	0.57	2.23e-37	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg04025307	chr7:1156635	C7orf50	0.67	7.75	0.35	6.99e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22496380	chr5:211416	CCDC127	-1.22	-15.59	-0.6	1.29e-43	Breast cancer;
LUAD	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg11266682	chr4:10021025	SLC2A9	0.67	15.48	0.6	3.66e-43	Bone mineral density;
LUAD	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03352830	chr11:487213	PTDSS2	0.81	10.74	0.46	5.82e-24	Body mass index;
LUAD	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.41	-0.34	7.13e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.36	-0.3	5.31e-10	Morning vs. evening chronotype;
LUAD	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg08027265	chr7:2291960	NA	-0.41	-7.01	-0.32	9.56e-12	Schizophrenia;
LUAD	cis	rs10992471	0.756	rs3758229	chr9:95078852	G/T	cg14631576	chr9:95140430	CENPP	-0.45	-9.31	-0.41	6.86e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.96	-0.36	1.56e-14	Alzheimer's disease;
LUAD	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg00814883	chr7:100076585	TSC22D4	-0.83	-12.14	-0.51	2.7e-29	Platelet count;
LUAD	cis	rs11098699	0.784	rs13114897	chr4:124247406	T/A	cg09941581	chr4:124220074	SPATA5	0.43	6.83	0.32	2.93e-11	Mosquito bite size;
LUAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg07217954	chr7:1067459	C7orf50	0.46	7.16	0.33	3.55e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg11833968	chr6:79620685	NA	-0.44	-8.33	-0.38	1.11e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg04025307	chr7:1156635	C7orf50	0.55	9.91	0.43	5.74e-21	Longevity;Endometriosis;
LUAD	cis	rs9796	0.870	rs8030306	chr15:41261821	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.4	-7.52	-0.34	3.23e-13	Menopause (age at onset);
LUAD	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg18232548	chr7:50535776	DDC	0.65	8.68	0.39	8.38e-17	Malaria;
LUAD	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg20587970	chr11:113659929	NA	-1.1	-16.3	-0.62	1.03e-46	Hip circumference adjusted for BMI;
LUAD	cis	rs2274273	0.837	rs10141483	chr14:55786871	T/C	cg04306507	chr14:55594613	LGALS3	0.41	8.5	0.38	3.26e-16	Protein biomarker;
LUAD	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg12908607	chr1:44402522	ARTN	-0.45	-8.95	-0.4	1.1e-17	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs4908760	0.757	rs301807	chr1:8484823	A/G	cg01447281	chr1:8482689	RERE	-0.4	-8.34	-0.38	1.08e-15	Vitiligo;
LUAD	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg00383909	chr3:49044727	WDR6	0.88	8.06	0.36	7.76e-15	Cognitive function;
LUAD	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg23281280	chr6:28129359	ZNF389	0.46	6.51	0.3	2.16e-10	Depression;
LUAD	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg23758822	chr17:41437982	NA	0.98	20.3	0.7	1.9e-64	Menopause (age at onset);
LUAD	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg16479474	chr6:28041457	NA	0.48	8.18	0.37	3.31e-15	Depression;
LUAD	cis	rs354225	1.000	rs354225	chr2:54923766	G/A	cg26097391	chr2:54893211	SPTBN1	0.47	8.01	0.36	1.16e-14	Schizophrenia;
LUAD	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg17200465	chr3:40428508	ENTPD3	0.27	6.42	0.3	3.68e-10	Renal cell carcinoma;
LUAD	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg22166914	chr1:53195759	ZYG11B	-0.45	-7.62	-0.35	1.66e-13	Monocyte count;
LUAD	cis	rs2235649	0.833	rs9927047	chr16:1851927	A/C	cg08610935	chr16:1836813	NUBP2	-0.48	-7.19	-0.33	2.87e-12	Blood metabolite levels;
LUAD	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg10909506	chr17:38081995	ORMDL3	0.37	6.52	0.3	1.96e-10	Self-reported allergy;
LUAD	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg03676636	chr4:99064102	C4orf37	0.37	9.54	0.42	1.11e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	10.31	0.45	2.26e-22	Monocyte percentage of white cells;
LUAD	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg00631329	chr6:26305371	NA	-0.69	-13.21	-0.54	1.4e-33	Educational attainment;
LUAD	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03517284	chr6:25882590	NA	-0.56	-8.19	-0.37	3.1e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs4846217	0.920	rs12139158	chr1:10325610	A/G	cg17425144	chr1:10567563	PEX14	-0.52	-7.01	-0.32	9.36e-12	Platelet count;
LUAD	trans	rs1941687	0.797	rs8086041	chr18:31402756	G/A	cg27147174	chr7:100797783	AP1S1	-0.48	-7.94	-0.36	1.88e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg10518543	chr12:38710700	ALG10B	-0.48	-7.96	-0.36	1.64e-14	Morning vs. evening chronotype;
LUAD	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg19536664	chr17:6899085	ALOX12	0.57	11.21	0.48	1.06e-25	Tonsillectomy;
LUAD	cis	rs9473147	0.516	rs10948367	chr6:47585615	A/G	cg02130027	chr6:47444894	CD2AP	0.34	6.68	0.31	7.53e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.46	-8.27	-0.37	1.75e-15	Longevity;Endometriosis;
LUAD	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18876405	chr7:65276391	NA	0.45	7.09	0.33	5.65e-12	Aortic root size;
LUAD	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg20891558	chr2:74357851	NA	0.86	15.02	0.59	3.43e-41	Gestational age at birth (maternal effect);
LUAD	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.5	0.3	2.33e-10	Depression;
LUAD	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg11822812	chr5:140052017	DND1	-0.43	-7.58	-0.35	2.18e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-12.22	-0.51	1.31e-29	Breast cancer;
LUAD	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg13126279	chr21:47581558	C21orf56	-0.44	-7.56	-0.34	2.54e-13	Testicular germ cell tumor;
LUAD	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg18252515	chr7:66147081	NA	0.6	6.68	0.31	7.56e-11	Diabetic kidney disease;
LUAD	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26314531	chr2:26401878	FAM59B	-0.64	-8.7	-0.39	7.27e-17	Gut microbiome composition (summer);
LUAD	cis	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.54	6.48	0.3	2.59e-10	Depression;
LUAD	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27297192	chr10:134578999	INPP5A	-0.36	-6.44	-0.3	3.29e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21582582	chr3:182698605	DCUN1D1	0.6	9.56	0.42	9.67e-20	Resting heart rate;
LUAD	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.67	-9.12	-0.41	2.96e-18	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs4713675	0.565	rs6928010	chr6:33676590	T/C	cg13859433	chr6:33739653	LEMD2	-0.3	-7.07	-0.33	6.5e-12	Plateletcrit;
LUAD	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg01191920	chr7:158217561	PTPRN2	0.61	12.84	0.53	4.18e-32	Obesity-related traits;
LUAD	cis	rs9560113	1.000	rs9555810	chr13:112181437	C/G	cg14154082	chr13:112174009	NA	0.36	6.61	0.31	1.16e-10	Menarche (age at onset);
LUAD	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg19761014	chr17:28927070	LRRC37B2	0.86	8.32	0.38	1.22e-15	Body mass index;
LUAD	cis	rs953387	0.866	rs4954577	chr2:136948711	A/G	cg05194412	chr2:137003533	NA	-0.41	-6.4	-0.3	4.04e-10	Arthritis (juvenile idiopathic);
LUAD	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg07507251	chr3:52567010	NT5DC2	0.39	7.5	0.34	3.78e-13	Bipolar disorder;
LUAD	cis	rs7799006	0.929	rs71525363	chr7:2268792	G/A	cg02951883	chr7:2050386	MAD1L1	-0.51	-7.84	-0.36	3.74e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs11048434	0.761	rs1805765	chr12:9094548	A/G	cg04155231	chr12:9217510	LOC144571	0.39	7.35	0.34	1.04e-12	Sjögren's syndrome;
LUAD	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg07936489	chr17:37558343	FBXL20	0.5	6.77	0.31	4.22e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7731657	0.508	rs6595974	chr5:130327530	C/T	cg08523029	chr5:130500466	HINT1	0.56	7.36	0.34	9.74e-13	Fasting plasma glucose;
LUAD	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg25358565	chr5:93447407	FAM172A	0.6	7.12	0.33	4.62e-12	Diabetic retinopathy;
LUAD	cis	rs4953404	0.613	rs2346877	chr2:46892958	C/G	cg09399716	chr2:46890238	NA	-0.34	-6.63	-0.31	1.03e-10	Pulse pressure (alcohol consumption interaction);
LUAD	cis	rs4378999	0.800	rs10865970	chr3:51357501	C/G	cg12934382	chr3:51741135	GRM2	0.42	6.47	0.3	2.77e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg00310523	chr12:86230176	RASSF9	0.41	8.71	0.39	6.76e-17	Major depressive disorder;
LUAD	cis	rs4072705	0.967	rs4838208	chr9:127528035	C/A	cg13476313	chr9:127244764	NR5A1	0.33	7.94	0.36	1.84e-14	Menarche (age at onset);
LUAD	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg05991184	chr2:219186017	PNKD	0.38	7.24	0.33	2.2e-12	Colorectal cancer;
LUAD	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg09537434	chr19:41945824	ATP5SL	-0.53	-8.29	-0.37	1.55e-15	Height;
LUAD	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg11189052	chr15:85197271	WDR73	0.68	9.15	0.41	2.47e-18	Schizophrenia;
LUAD	trans	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg18187862	chr3:45730750	SACM1L	0.53	7.92	0.36	2.07e-14	Primary sclerosing cholangitis;
LUAD	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.44	-0.34	5.57e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg09359103	chr1:154839909	KCNN3	-0.91	-21.12	-0.72	3.92e-68	Prostate cancer;
LUAD	cis	rs10871290	0.650	rs3760055	chr16:74490529	G/A	cg01733217	chr16:74700730	RFWD3	0.44	6.89	0.32	2.04e-11	Breast cancer;
LUAD	cis	rs62238980	0.614	rs79605389	chr22:32413385	C/A	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg05425664	chr17:57184151	TRIM37	0.43	7.66	0.35	1.28e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4478137	1.000	rs4478137	chr4:164238385	G/A	cg06758707	chr4:164254230	NPY1R	0.48	7.48	0.34	4.28e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs6690583	0.524	rs12045710	chr1:85451765	T/C	cg22153463	chr1:85462885	MCOLN2	0.55	6.37	0.3	4.97e-10	Serum sulfate level;
LUAD	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg17366294	chr4:99064904	C4orf37	0.47	8.4	0.38	6.73e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs438465	0.947	rs438217	chr6:169815949	A/C	cg11181693	chr6:169825345	NA	-0.65	-7.97	-0.36	1.45e-14	Corneal astigmatism;
LUAD	cis	rs346785	0.692	rs8072944	chr17:74291733	T/G	cg09812376	chr17:74270190	QRICH2	-0.3	-6.37	-0.3	4.87e-10	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg06808227	chr14:105710500	BRF1	-0.41	-6.43	-0.3	3.4e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs12791968	1.000	rs10838397	chr11:45009133	A/G	cg11846598	chr11:44996168	LOC221122	0.74	13.08	0.54	4.58e-33	Inhibitory control;
LUAD	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg00310523	chr12:86230176	RASSF9	0.4	7.89	0.36	2.62e-14	Major depressive disorder;
LUAD	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg22153463	chr1:85462885	MCOLN2	-0.56	-7.8	-0.35	4.95e-14	Serum sulfate level;
LUAD	cis	rs10465746	0.780	rs2389648	chr1:84403031	C/T	cg10977910	chr1:84465055	TTLL7	0.6	9.83	0.43	1.14e-20	Obesity-related traits;
LUAD	cis	rs752010	0.523	rs943376	chr1:42122117	A/G	cg06885757	chr1:42089581	HIVEP3	0.51	11.3	0.48	4.88e-26	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.61	0.31	1.15e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1997103	1.000	rs10228182	chr7:55406695	A/T	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg02807482	chr3:125708958	NA	-0.66	-8.85	-0.4	2.44e-17	Blood pressure (smoking interaction);
LUAD	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg15448220	chr1:150897856	SETDB1	0.46	7.98	0.36	1.39e-14	Tonsillectomy;
LUAD	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg12935359	chr14:103987150	CKB	0.48	7.52	0.34	3.37e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.46	7.69	0.35	1.03e-13	Lung cancer in ever smokers;
LUAD	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23583168	chr7:148888333	NA	-0.9	-18.12	-0.66	9.57e-55	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2224391	0.784	rs67285271	chr6:5279267	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-8.25	-0.37	2.02e-15	Height;
LUAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg12419862	chr22:24373484	LOC391322	0.66	11.28	0.48	5.4e-26	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1950626	0.705	rs34991312	chr14:101435167	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.57	0.35	2.35e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18876405	chr7:65276391	NA	0.57	9.4	0.42	3.41e-19	Aortic root size;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19452060	chr12:57914632	DDIT3	-0.61	-7.66	-0.35	1.3e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10992471	0.603	rs7873397	chr9:95205928	G/C	cg14631576	chr9:95140430	CENPP	-0.56	-11.35	-0.48	3.12e-26	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg17031739	chr1:67600172	NA	-0.48	-8.49	-0.38	3.53e-16	Psoriasis;
LUAD	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg08999081	chr20:33150536	PIGU	0.46	8.76	0.39	4.83e-17	Coronary artery disease;
LUAD	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg11070056	chr1:107600091	PRMT6	0.64	10.97	0.47	8.55e-25	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg11062466	chr8:58055876	NA	0.67	8.87	0.4	2.01e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs11700980	0.636	rs35497275	chr21:30275022	G/A	cg14791747	chr16:20752902	THUMPD1	0.61	6.8	0.31	3.62e-11	QRS complex (12-leadsum);
LUAD	cis	rs56161922	0.908	rs113826410	chr1:207849815	C/T	cg11752769	chr1:207818423	CR1L	-0.67	-6.99	-0.32	1.08e-11	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	trans	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg21051086	chr3:73046214	PPP4R2	-0.47	-7.37	-0.34	8.84e-13	Pancreatic cancer;
LUAD	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg00717180	chr2:96193071	NA	-0.4	-7.23	-0.33	2.22e-12	Coronary artery disease;
LUAD	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg05110241	chr16:68378359	PRMT7	-0.7	-7.99	-0.36	1.26e-14	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs8073060	0.586	rs225296	chr17:33924847	C/G	cg19694781	chr19:47549865	TMEM160	-1.22	-19.97	-0.7	5.49e-63	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg00450029	chr8:599525	NA	0.77	8.02	0.36	1.02e-14	IgG glycosylation;
LUAD	cis	rs1832871	0.711	rs9459887	chr6:158696479	C/T	cg07165851	chr6:158734300	TULP4	0.7	10.9	0.47	1.57e-24	Height;
LUAD	trans	rs2898857	0.524	rs2906100	chr17:47372764	C/T	cg11430096	chr6:110968061	CDK19	0.51	7.73	0.35	7.71e-14	Cancer;
LUAD	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg23758822	chr17:41437982	NA	0.99	20.82	0.71	8.69e-67	Menopause (age at onset);
LUAD	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	7.44	0.34	5.48e-13	Glomerular filtration rate;
LUAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg26338869	chr17:61819248	STRADA	-0.39	-6.57	-0.3	1.53e-10	Prudent dietary pattern;
LUAD	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg14092988	chr3:52407081	DNAH1	0.44	8.87	0.4	2.13e-17	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.66	0.31	8.75e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8002861	0.905	rs12430629	chr13:44415919	T/A	cg12856521	chr11:46389249	DGKZ	-0.38	-6.43	-0.3	3.42e-10	Leprosy;
LUAD	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.57	-0.35	2.42e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4631830	0.832	rs10825652	chr10:51510761	G/A	cg20129853	chr10:51489980	NA	0.34	6.7	0.31	6.82e-11	Prostate-specific antigen levels;
LUAD	cis	rs73086581	1.000	rs3746666	chr20:3910861	A/G	cg02187196	chr20:3869020	PANK2	0.49	7.23	0.33	2.23e-12	Response to antidepressants in depression;
LUAD	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.4	7.1	0.33	5.47e-12	Systemic lupus erythematosus;
LUAD	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg17063962	chr7:91808500	NA	0.7	12.64	0.52	2.62e-31	Breast cancer;
LUAD	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg25817165	chr18:72167213	CNDP2	-0.52	-8.52	-0.38	2.79e-16	Refractive error;
LUAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg21782813	chr7:2030301	MAD1L1	0.42	6.82	0.31	3.11e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg23229984	chr5:148520753	ABLIM3	0.4	6.46	0.3	2.97e-10	Breast cancer;
LUAD	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg14789911	chr21:47582049	C21orf56	-0.4	-6.57	-0.3	1.47e-10	Testicular germ cell tumor;
LUAD	cis	rs2953145	0.568	rs1133354	chr2:241522450	A/G	cg07929629	chr2:241523174	NA	0.4	6.84	0.32	2.76e-11	Bipolar disorder;
LUAD	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22307029	chr19:49891270	CCDC155	0.74	11.41	0.49	1.72e-26	Multiple sclerosis;
LUAD	trans	rs5756813	0.584	rs12484820	chr22:38207556	A/G	cg19894588	chr14:64061835	NA	-0.54	-7.52	-0.34	3.34e-13	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg13319975	chr6:146136371	FBXO30	-0.55	-9.27	-0.41	9.75e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg10411590	chr13:21900810	NA	0.46	7.09	0.33	5.5e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg07538946	chr5:131705188	SLC22A5	0.46	7.54	0.34	2.8e-13	Blood metabolite levels;
LUAD	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg13699009	chr12:122356056	WDR66	0.31	7.0	0.32	1.01e-11	Mean corpuscular volume;
LUAD	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg11266682	chr4:10021025	SLC2A9	0.65	14.92	0.59	9.42e-41	Bone mineral density;
LUAD	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg04414720	chr1:150670196	GOLPH3L	0.6	10.27	0.45	2.97e-22	Melanoma;
LUAD	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg16950941	chr11:66035639	RAB1B	0.45	7.57	0.35	2.31e-13	Gout;
LUAD	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg07917127	chr4:99064746	C4orf37	0.42	7.01	0.32	9.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg26811252	chr16:29126840	RRN3P2	0.62	10.59	0.46	2.19e-23	Menopause (age at onset);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg25896967	chr11:86666558	FZD4	-0.65	-6.74	-0.31	5.36e-11	Type 2 diabetes;
LUAD	cis	rs7953508	0.750	rs7310512	chr12:93976703	C/T	cg18151635	chr12:93972918	NA	-0.6	-9.61	-0.42	6.4e-20	Pubertal anthropometrics;
LUAD	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg16486109	chr11:613632	IRF7	0.5	7.66	0.35	1.32e-13	Systemic lupus erythematosus;
LUAD	trans	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg18335740	chr13:41363409	SLC25A15	0.72	13.87	0.56	2.55e-36	Lewy body disease;
LUAD	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg17509989	chr5:176798049	RGS14	0.55	9.68	0.43	3.75e-20	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg10862848	chr6:42927986	GNMT	-0.32	-9.1	-0.4	3.6e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg15123519	chr2:136567270	LCT	0.39	7.26	0.33	1.89e-12	Mosquito bite size;
LUAD	cis	rs4478137	0.824	rs4057791	chr4:164225132	A/C	cg06758707	chr4:164254230	NPY1R	0.43	6.63	0.31	1.05e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.09	-0.33	5.61e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg12179176	chr11:130786555	SNX19	0.45	7.53	0.34	3.19e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg06606381	chr12:133084897	FBRSL1	-1.18	-10.07	-0.44	1.53e-21	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs6921919	0.562	rs13198809	chr6:28323702	G/A	cg01620082	chr3:125678407	NA	-1.11	-10.46	-0.45	6.13e-23	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1003719	0.788	rs4817849	chr21:38469796	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.64	0.39	1.13e-16	Eye color traits;
LUAD	cis	rs2485376	0.842	rs1056890	chr10:104162770	G/A	cg20641465	chr10:103991465	PITX3	-0.53	-9.18	-0.41	1.92e-18	QT interval;
LUAD	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg04450456	chr4:17643702	FAM184B	0.38	7.37	0.34	8.86e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg00634984	chr7:65235879	NA	-0.5	-6.92	-0.32	1.67e-11	Aortic root size;
LUAD	cis	rs7975161	0.506	rs7953434	chr12:104622101	T/G	cg25273343	chr12:104657179	TXNRD1	-0.62	-6.91	-0.32	1.74e-11	Toenail selenium levels;
LUAD	cis	rs7043114	0.525	rs4744136	chr9:95275024	A/G	cg14631576	chr9:95140430	CENPP	0.42	8.72	0.39	6.33e-17	Height;
LUAD	cis	rs9560113	0.919	rs11069896	chr13:112178887	C/T	cg14154082	chr13:112174009	NA	0.37	6.79	0.31	3.87e-11	Menarche (age at onset);
LUAD	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg19622623	chr12:86230825	RASSF9	-0.54	-9.64	-0.42	4.98e-20	Major depressive disorder;
LUAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg22535103	chr8:58192502	C8orf71	-0.65	-6.99	-0.32	1.11e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg17848003	chr1:3704513	LRRC47	0.52	10.59	0.46	2.17e-23	Red cell distribution width;
LUAD	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg11494091	chr17:61959527	GH2	0.39	6.91	0.32	1.76e-11	Height;
LUAD	cis	rs6499255	1.000	rs4078387	chr16:69814047	G/A	cg15192750	chr16:69999425	NA	0.55	8.76	0.39	4.92e-17	IgE levels;
LUAD	cis	rs3806843	0.898	rs3756335	chr5:140213510	A/T	cg19875535	chr5:140030758	IK	0.43	7.13	0.33	4.51e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10840133	1	rs10840133	chr11:8846369	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.42	7.58	0.35	2.21e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs7818345	0.967	rs11204039	chr8:19280442	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.91	0.32	1.8e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg19901468	chr14:105411992	AHNAK2	-0.54	-10.44	-0.45	7.46e-23	Rheumatoid arthritis;
LUAD	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg15445000	chr17:37608096	MED1	-0.44	-7.99	-0.36	1.32e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs1215050	0.660	rs3864229	chr4:98714323	A/G	cg17366294	chr4:99064904	C4orf37	0.43	7.08	0.33	6.18e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4073416	0.510	rs10873190	chr14:65981439	G/T	cg10998611	chr14:65879393	FUT8;LOC645431	-0.43	-6.6	-0.31	1.27e-10	N-glycan levels;
LUAD	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg00603274	chr11:61596626	FADS2	-0.5	-8.59	-0.39	1.64e-16	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02018176	chr4:1364513	KIAA1530	-0.57	-10.09	-0.44	1.33e-21	Obesity-related traits;
LUAD	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg26587870	chr6:27730563	NA	-0.68	-7.21	-0.33	2.63e-12	Depression;
LUAD	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg23229984	chr5:148520753	ABLIM3	0.5	7.8	0.35	4.9e-14	Breast cancer;
LUAD	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg19743168	chr1:23544995	NA	-0.4	-7.02	-0.32	9.09e-12	Height;
LUAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13732083	chr21:47605072	C21orf56	-0.6	-10.54	-0.46	3.12e-23	Testicular germ cell tumor;
LUAD	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg25817165	chr18:72167213	CNDP2	-0.72	-10.76	-0.46	5.07e-24	Refractive error;
LUAD	cis	rs7771547	0.519	rs4713973	chr6:36382044	A/G	cg04289385	chr6:36355825	ETV7	0.49	7.25	0.33	2.03e-12	Platelet distribution width;
LUAD	cis	rs3849570	1.000	rs6548773	chr3:81840222	C/T	cg07356753	chr3:81810745	GBE1	0.7	12.55	0.52	6.06e-31	Waist circumference;Body mass index;
LUAD	cis	rs4253772	0.575	rs9615364	chr22:46797503	G/A	cg00784671	chr22:46762841	CELSR1	-0.61	-7.51	-0.34	3.48e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg15691649	chr6:25882328	NA	-0.46	-6.64	-0.31	9.43e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg13736514	chr6:26305472	NA	0.68	12.97	0.53	1.25e-32	Educational attainment;
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01171360	chr6:293285	DUSP22	-0.74	-13.02	-0.53	7.69e-33	Menopause (age at onset);
LUAD	trans	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg14791747	chr16:20752902	THUMPD1	-0.49	-7.23	-0.33	2.29e-12	Pancreatic cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11636714	chr8:42128950	IKBKB	-0.57	-6.8	-0.31	3.52e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10129255	0.518	rs11847766	chr14:107187425	T/C	cg07958169	chr14:107095056	NA	-0.37	-7.34	-0.34	1.08e-12	Kawasaki disease;
LUAD	cis	rs113835537	0.529	rs11227509	chr11:66281194	T/C	cg24851651	chr11:66362959	CCS	0.57	10.1	0.44	1.25e-21	Airway imaging phenotypes;
LUAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg08132940	chr7:1081526	C7orf50	-0.77	-10.5	-0.45	4.63e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg11859384	chr17:80120422	CCDC57	-0.52	-9.35	-0.41	5.05e-19	Life satisfaction;
LUAD	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.58	-9.74	-0.43	2.35e-20	Hip circumference adjusted for BMI;
LUAD	cis	rs155346	0.947	rs265160	chr5:139390914	A/C	cg01090482	chr5:139365336	NRG2	-0.33	-6.53	-0.3	1.9e-10	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUAD	cis	rs7582720	0.511	rs116219813	chr2:204081675	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.58	0.42	8.55e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg10165071	chr2:217557160	IGFBP5	-0.36	-6.67	-0.31	7.98e-11	Schizophrenia;
LUAD	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg25173405	chr17:45401733	C17orf57	-0.46	-7.57	-0.35	2.29e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs367943	0.604	rs10477502	chr5:113007126	C/T	cg12552261	chr5:112820674	MCC	0.48	8.13	0.37	4.88e-15	Type 2 diabetes;
LUAD	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg27411982	chr8:10470053	RP1L1	-0.41	-7.2	-0.33	2.69e-12	Neuroticism;
LUAD	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg07936489	chr17:37558343	FBXL20	-0.55	-7.31	-0.34	1.31e-12	Glomerular filtration rate (creatinine);
LUAD	trans	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg01620082	chr3:125678407	NA	-0.72	-7.28	-0.33	1.62e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg21214613	chr1:16344536	HSPB7	0.43	7.74	0.35	7.16e-14	Systolic blood pressure;
LUAD	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg24818145	chr4:99064322	C4orf37	-0.41	-6.84	-0.32	2.76e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1018836	0.700	rs10504894	chr8:91516436	G/A	cg16814680	chr8:91681699	NA	-0.7	-11.71	-0.49	1.27e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg06064525	chr11:970664	AP2A2	-0.54	-11.07	-0.47	3.62e-25	Alzheimer's disease (late onset);
LUAD	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg00981070	chr1:2046702	PRKCZ	0.36	6.96	0.32	1.32e-11	Height;
LUAD	cis	rs250585	0.850	rs7186974	chr16:23545478	G/T	cg00143387	chr16:23521605	GGA2	0.63	7.75	0.35	6.84e-14	Egg allergy;
LUAD	cis	rs3743162	0.553	rs12900463	chr15:85415386	T/C	cg17173187	chr15:85201210	NMB	0.4	6.36	0.3	5.12e-10	Alzheimer's disease (age of onset);
LUAD	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg26384229	chr12:38710491	ALG10B	0.49	7.83	0.36	4.09e-14	Morning vs. evening chronotype;
LUAD	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg11822812	chr5:140052017	DND1	-0.41	-7.58	-0.35	2.17e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg20203395	chr5:56204925	C5orf35	-0.81	-11.8	-0.5	5.68e-28	Initial pursuit acceleration;
LUAD	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.94	-0.4	1.24e-17	Total body bone mineral density;
LUAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg10802521	chr3:52805072	NEK4	-0.46	-7.66	-0.35	1.24e-13	Electroencephalogram traits;
LUAD	cis	rs35883536	1.000	rs12409831	chr1:101107670	A/T	cg06223162	chr1:101003688	GPR88	0.35	6.57	0.3	1.53e-10	Monocyte count;
LUAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg22907277	chr7:1156413	C7orf50	0.74	10.98	0.47	7.29e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg20744362	chr22:50050164	C22orf34	0.42	9.31	0.41	6.93e-19	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg26384229	chr12:38710491	ALG10B	0.44	7.11	0.33	5.07e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg00933542	chr6:150070202	PCMT1	0.43	9.24	0.41	1.26e-18	Lung cancer;
LUAD	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.64	8.9	0.4	1.67e-17	Gut microbiome composition (summer);
LUAD	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg02782426	chr3:40428986	ENTPD3	-0.42	-9.22	-0.41	1.45e-18	Renal cell carcinoma;
LUAD	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.47	6.67	0.31	7.88e-11	Platelet count;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg26996874	chr6:158677312	NA	-0.4	-7.17	-0.33	3.38e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg00933542	chr6:150070202	PCMT1	0.43	9.19	0.41	1.82e-18	Lung cancer;
LUAD	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg23544223	chr18:12777786	NA	-0.73	-8.63	-0.39	1.28e-16	Inflammatory skin disease;
LUAD	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg15704280	chr7:45808275	SEPT13	-0.69	-11.05	-0.47	4.28e-25	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.58	0.3	1.37e-10	Cognitive test performance;
LUAD	cis	rs354225	0.544	rs10182836	chr2:54808504	T/G	cg01766943	chr2:54829624	SPTBN1	0.38	7.21	0.33	2.56e-12	Schizophrenia;
LUAD	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.59	-0.35	2.1e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg20607287	chr7:12443886	VWDE	-0.55	-6.8	-0.31	3.51e-11	Coronary artery disease;
LUAD	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23583168	chr7:148888333	NA	-0.93	-18.89	-0.68	3.76e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2274273	0.934	rs10140869	chr14:55795283	G/A	cg04306507	chr14:55594613	LGALS3	0.43	8.92	0.4	1.43e-17	Protein biomarker;
LUAD	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.09	0.33	5.7e-12	Menopause (age at onset);
LUAD	cis	rs7827545	1.000	rs7832857	chr8:135565477	A/G	cg17885191	chr8:135476712	NA	0.5	7.95	0.36	1.72e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg06484146	chr7:12443880	VWDE	-0.58	-7.32	-0.34	1.28e-12	Coronary artery disease;
LUAD	cis	rs10979	1.000	rs12211659	chr6:143898348	G/T	cg25407410	chr6:143891975	LOC285740	-0.64	-10.28	-0.45	2.77e-22	Hypospadias;
LUAD	cis	rs7264396	0.563	rs2425119	chr20:34324216	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2e-15	Total cholesterol levels;
LUAD	cis	rs6494488	0.500	rs72744729	chr15:65038484	G/A	cg08069370	chr15:64387884	SNX1	-0.73	-6.47	-0.3	2.78e-10	Coronary artery disease;
LUAD	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg11166453	chr1:247681781	NA	0.38	7.28	0.33	1.68e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg16647868	chr5:131706066	SLC22A5	-0.49	-7.79	-0.35	5.09e-14	Breast cancer;
LUAD	cis	rs2235649	0.798	rs78540053	chr16:1853275	G/A	cg08610935	chr16:1836813	NUBP2	-0.5	-7.48	-0.34	4.21e-13	Blood metabolite levels;
LUAD	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg23758822	chr17:41437982	NA	1.01	20.95	0.71	2.33e-67	Menopause (age at onset);
LUAD	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.94	-0.32	1.45e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg19077165	chr18:44547161	KATNAL2	0.48	8.27	0.37	1.81e-15	Personality dimensions;
LUAD	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.8	-10.16	-0.44	7.58e-22	Body mass index;
LUAD	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg26924012	chr15:45694286	SPATA5L1	0.57	9.85	0.43	9.8e-21	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg17747265	chr1:1875780	NA	-0.75	-18.62	-0.67	5.85e-57	Body mass index;
LUAD	cis	rs11229555	0.645	rs12273638	chr11:58186335	T/C	cg15696309	chr11:58395628	NA	-0.74	-10.2	-0.44	5.41e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg06221963	chr1:154839813	KCNN3	-0.84	-17.58	-0.65	2.43e-52	Prostate cancer;
LUAD	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg23533926	chr12:111358616	MYL2	-0.43	-7.34	-0.34	1.07e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg04800585	chr6:26043546	HIST1H2BB	0.49	8.41	0.38	6.23e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs17401966	0.867	rs7546364	chr1:10418815	G/A	cg19773385	chr1:10388646	KIF1B	-0.4	-6.47	-0.3	2.64e-10	Hepatocellular carcinoma;
LUAD	trans	rs11039798	0.698	rs78553793	chr11:48947336	C/A	cg15704280	chr7:45808275	SEPT13	0.75	7.53	0.34	2.99e-13	Axial length;
LUAD	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg13319975	chr6:146136371	FBXO30	-0.59	-9.77	-0.43	1.79e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg04944784	chr2:26401820	FAM59B	-0.89	-12.62	-0.52	3.3e-31	Gut microbiome composition (summer);
LUAD	trans	rs7615952	0.546	rs2979338	chr3:125343126	G/T	cg17147758	chr8:6949321	NA	-0.49	-7.45	-0.34	5.27e-13	Blood pressure (smoking interaction);
LUAD	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg18132916	chr6:79620363	NA	-0.47	-8.0	-0.36	1.21e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22496380	chr5:211416	CCDC127	-0.94	-13.36	-0.54	3.21e-34	Breast cancer;
LUAD	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg05234568	chr11:5960015	NA	-0.52	-9.11	-0.4	3.42e-18	DNA methylation (variation);
LUAD	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg03929089	chr4:120376271	NA	-0.83	-15.06	-0.59	2.53e-41	Coronary artery disease;
LUAD	cis	rs9925964	0.967	rs1978487	chr16:31129942	C/T	cg03418659	chr16:31128414	MYST1	-0.43	-7.35	-0.34	1.06e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg06640241	chr16:89574553	SPG7	0.73	13.12	0.54	3.11e-33	Multiple myeloma (IgH translocation);
LUAD	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg25036284	chr2:26402008	FAM59B	-0.58	-8.1	-0.37	6.05e-15	Gut microbiome composition (summer);
LUAD	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg10978503	chr1:24200527	CNR2	0.55	12.07	0.51	5.07e-29	Immature fraction of reticulocytes;
LUAD	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg00933542	chr6:150070202	PCMT1	0.44	9.23	0.41	1.3e-18	Lung cancer;
LUAD	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg18099408	chr3:52552593	STAB1	0.41	7.23	0.33	2.22e-12	Bipolar disorder;
LUAD	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.5	-0.3	2.28e-10	Joint mobility (Beighton score);
LUAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg08219700	chr8:58056026	NA	0.59	7.91	0.36	2.2e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01402448	chr6:136571605	FAM54A	-0.62	-7.54	-0.34	2.95e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10802521	chr3:52805072	NEK4	-0.55	-9.3	-0.41	7.66e-19	Bipolar disorder;
LUAD	cis	rs2688608	0.904	rs2675669	chr10:75653872	C/T	cg23231163	chr10:75533350	FUT11	-0.38	-6.97	-0.32	1.24e-11	Inflammatory bowel disease;
LUAD	cis	rs17401966	0.964	rs17400510	chr1:10290421	T/C	cg15208524	chr1:10270712	KIF1B	0.55	8.28	0.37	1.63e-15	Hepatocellular carcinoma;
LUAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg22535103	chr8:58192502	C8orf71	-0.69	-7.47	-0.34	4.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg07828340	chr4:882639	GAK	-1.05	-10.87	-0.47	1.88e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg02807482	chr3:125708958	NA	-0.66	-8.79	-0.39	3.83e-17	Blood pressure (smoking interaction);
LUAD	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg05665937	chr4:1216051	CTBP1	0.38	6.39	0.3	4.31e-10	Obesity-related traits;
LUAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg08132940	chr7:1081526	C7orf50	-0.79	-10.67	-0.46	1.04e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg02734326	chr4:10020555	SLC2A9	0.65	11.56	0.49	4.62e-27	Bone mineral density;
LUAD	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg03037974	chr15:76606532	NA	0.37	7.94	0.36	1.9e-14	Blood metabolite levels;
LUAD	cis	rs231513	0.906	rs75508812	chr17:42003397	G/A	cg26893861	chr17:41843967	DUSP3	0.67	7.19	0.33	2.97e-12	Cognitive function;
LUAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg13453750	chr1:205783389	SLC41A1	-0.39	-6.95	-0.32	1.4e-11	Menarche (age at onset);
LUAD	trans	rs11039798	1.000	rs3902928	chr11:48581458	A/T	cg03929089	chr4:120376271	NA	0.56	6.46	0.3	2.81e-10	Axial length;
LUAD	cis	rs243505	0.559	rs2072407	chr7:148508833	A/G	cg09806900	chr7:148480153	CUL1	0.5	8.52	0.38	2.91e-16	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2012796	0.704	rs57670850	chr14:81841577	C/T	cg02996355	chr14:81879375	NA	0.56	8.34	0.38	1.03e-15	Night sleep phenotypes;
LUAD	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3096299	0.589	rs3114898	chr16:89392315	C/T	cg07708487	chr16:89387014	ANKRD11	-0.33	-6.73	-0.31	5.53e-11	Multiple myeloma (IgH translocation);
LUAD	trans	rs2665103	0.655	rs1501367	chr15:82522816	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.41	-6.84	-0.32	2.76e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg27446573	chr6:127587934	RNF146	0.46	6.7	0.31	6.88e-11	Breast cancer;
LUAD	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg23758822	chr17:41437982	NA	0.99	19.97	0.7	5.33e-63	Menopause (age at onset);
LUAD	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg00074818	chr8:8560427	CLDN23	0.65	10.06	0.44	1.77e-21	Obesity-related traits;
LUAD	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg15181151	chr6:150070149	PCMT1	0.4	8.22	0.37	2.52e-15	Lung cancer;
LUAD	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg10589385	chr1:150898437	SETDB1	-0.39	-7.79	-0.35	5.32e-14	Tonsillectomy;
LUAD	cis	rs798766	1.000	rs798719	chr4:1698183	C/T	cg03947459	chr4:1685442	FAM53A	0.49	6.69	0.31	7.17e-11	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg02176678	chr2:219576539	TTLL4	0.75	15.21	0.59	5.55e-42	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg01689657	chr7:91764605	CYP51A1	-0.38	-9.25	-0.41	1.12e-18	Breast cancer;
LUAD	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19524238	chr7:2802976	GNA12	-0.32	-6.61	-0.31	1.18e-10	Height;
LUAD	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg06547715	chr2:218990976	CXCR2	-0.31	-7.54	-0.34	2.95e-13	Colorectal cancer;
LUAD	cis	rs11214589	0.774	rs10891544	chr11:113256152	A/C	cg14159747	chr11:113255604	NA	-0.69	-15.35	-0.6	1.4e-42	Neuroticism;
LUAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg08888203	chr3:10149979	C3orf24	0.64	11.16	0.48	1.64e-25	Alzheimer's disease;
LUAD	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg19418458	chr7:158789849	NA	-0.62	-10.97	-0.47	8.46e-25	Facial morphology (factor 20);
LUAD	cis	rs748404	0.723	rs573169	chr15:43550581	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.19	0.37	3.03e-15	Lung cancer;
LUAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.8	-0.31	3.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22857025	chr5:266934	NA	-1.06	-13.35	-0.54	3.53e-34	Breast cancer;
LUAD	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg22906224	chr7:99728672	NA	-0.57	-9.94	-0.44	4.44e-21	Coronary artery disease;
LUAD	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg25754956	chr12:51612065	POU6F1	0.59	9.24	0.41	1.19e-18	Cisplatin-induced ototoxicity;
LUAD	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg20203395	chr5:56204925	C5orf35	-0.84	-11.94	-0.5	1.64e-28	Initial pursuit acceleration;
LUAD	trans	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6426558	0.537	rs56219094	chr1:227340191	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.56	-9.0	-0.4	7.7e-18	Neutrophil percentage of white cells;
LUAD	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-7.4	-0.34	7.31e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg20891283	chr12:69753455	YEATS4	0.46	7.42	0.34	6.64e-13	Blood protein levels;
LUAD	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.52	-0.3	2.02e-10	Alzheimer's disease (late onset);
LUAD	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg23719950	chr11:63933701	MACROD1	0.6	7.42	0.34	6.66e-13	Mean platelet volume;
LUAD	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg15123519	chr2:136567270	LCT	-0.36	-6.56	-0.3	1.56e-10	Mosquito bite size;
LUAD	cis	rs6433857	0.657	rs10209994	chr2:181514955	A/C	cg23363182	chr2:181467187	NA	-0.42	-7.07	-0.33	6.45e-12	Body mass index;
LUAD	cis	rs2657888	0.529	rs11171862	chr12:56871314	C/T	cg23002907	chr12:56915593	RBMS2	-0.38	-6.79	-0.31	3.7e-11	Adiponectin levels;
LUAD	trans	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg03886242	chr7:26192032	NFE2L3	0.36	6.39	0.3	4.32e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs72781680	1.000	rs17763442	chr2:24255991	C/T	cg20701182	chr2:24300061	SF3B14	0.68	7.34	0.34	1.11e-12	Lymphocyte counts;
LUAD	cis	rs909341	0.710	rs6010998	chr20:62294402	A/T	cg04115418	chr20:62273971	STMN3	-0.34	-6.36	-0.3	5.32e-10	Atopic dermatitis;
LUAD	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg15790184	chr11:494944	RNH1	0.53	6.68	0.31	7.74e-11	Body mass index;
LUAD	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg22618164	chr12:122356400	WDR66	0.75	13.72	0.55	1.12e-35	Mean corpuscular volume;
LUAD	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg25753631	chr6:25732923	NA	-0.44	-7.51	-0.34	3.49e-13	Iron status biomarkers;
LUAD	trans	rs2797160	0.967	rs1777224	chr6:126019527	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.54	8.51	0.38	3.12e-16	Endometrial cancer;
LUAD	cis	rs11126435	0.858	rs363629	chr2:74933799	C/G	cg19285774	chr2:74907978	SEMA4F	0.37	6.41	0.3	3.79e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg19622623	chr12:86230825	RASSF9	-0.44	-7.76	-0.35	6.54e-14	Major depressive disorder;
LUAD	cis	rs4786125	0.542	rs2345826	chr16:6916235	G/T	cg03623568	chr16:6915990	A2BP1	-0.49	-10.6	-0.46	1.87e-23	Heart rate variability traits (SDNN);
LUAD	cis	rs1957429	0.808	rs1957436	chr14:65348207	T/G	cg23373153	chr14:65346875	NA	0.55	6.45	0.3	2.99e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs7737355	0.898	rs1016068	chr5:131100246	T/C	cg06307176	chr5:131281290	NA	0.51	8.07	0.37	7.09e-15	Life satisfaction;
LUAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg00106254	chr7:1943704	MAD1L1	-0.46	-6.72	-0.31	5.73e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg22907277	chr7:1156413	C7orf50	0.69	8.05	0.36	8.6e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg02176678	chr2:219576539	TTLL4	-0.8	-16.98	-0.64	1.12e-49	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg23985595	chr17:80112537	CCDC57	-0.53	-9.51	-0.42	1.43e-19	Life satisfaction;
LUAD	trans	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg11693508	chr17:37793320	STARD3	-0.77	-9.9	-0.43	6.38e-21	Bipolar disorder;
LUAD	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg23992470	chr4:843637	GAK	0.64	6.86	0.32	2.38e-11	Parkinson's disease;
LUAD	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22857025	chr5:266934	NA	-0.94	-13.02	-0.53	7.98e-33	Breast cancer;
LUAD	cis	rs8060686	0.516	rs7187202	chr16:68273895	T/C	cg09835421	chr16:68378352	PRMT7	-0.55	-6.84	-0.32	2.78e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg00101154	chr16:420108	MRPL28	-0.67	-12.63	-0.52	3.1e-31	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg14582100	chr15:45693742	SPATA5L1	0.51	9.61	0.42	6.43e-20	Homoarginine levels;
LUAD	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg14895029	chr7:2775587	GNA12	-0.42	-6.82	-0.31	3.22e-11	Height;
LUAD	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg08558340	chr7:100472263	SRRT	0.51	6.39	0.3	4.37e-10	Resting heart rate;
LUAD	cis	rs3800461	0.544	rs41312309	chr6:34498328	C/T	cg14254433	chr6:34482411	PACSIN1	-0.76	-9.94	-0.44	4.76e-21	Chronic lymphocytic leukemia;
LUAD	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg02371401	chr5:676784	TPPP	-0.48	-7.76	-0.35	6.42e-14	Obesity-related traits;
LUAD	cis	rs2294693	0.679	rs12200923	chr6:40970092	T/G	cg14769373	chr6:40998127	UNC5CL	-0.6	-8.74	-0.39	5.41e-17	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs907683	0.559	rs11685408	chr2:220291474	T/C	cg15015639	chr2:220282977	DES	0.48	8.98	0.4	9.01e-18	Resting heart rate;
LUAD	trans	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg26043149	chr18:55253948	FECH	0.41	6.67	0.31	7.87e-11	Bone mineral density;
LUAD	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg15485101	chr11:133734466	NA	0.39	8.69	0.39	8.09e-17	Childhood ear infection;
LUAD	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-15.16	-0.59	8.76e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg00071950	chr4:10020882	SLC2A9	0.74	14.9	0.59	1.18e-40	Bone mineral density;
LUAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg13560548	chr3:10150139	C3orf24	0.45	7.66	0.35	1.27e-13	Alzheimer's disease;
LUAD	cis	rs3790645	1.000	rs3790645	chr1:26884864	G/A	cg23229016	chr1:26872525	RPS6KA1	0.21	6.91	0.32	1.77e-11	Glucose homeostasis traits;
LUAD	cis	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg27411982	chr8:10470053	RP1L1	0.38	6.6	0.31	1.24e-10	Systemic lupus erythematosus;
LUAD	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg18240062	chr17:79603768	NPLOC4	0.45	8.05	0.36	8.72e-15	Eye color traits;
LUAD	cis	rs7665090	1.000	rs4547797	chr4:103557192	C/T	cg07973026	chr4:103553119	MANBA	0.47	8.41	0.38	6.43e-16	Primary biliary cholangitis;
LUAD	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.97	0.32	1.21e-11	Colorectal cancer;
LUAD	cis	rs9549328	0.670	rs3011475	chr13:113616866	T/C	cg17524180	chr13:113633600	MCF2L	0.3	6.49	0.3	2.37e-10	Systolic blood pressure;
LUAD	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21984481	chr17:79567631	NPLOC4	0.65	15.64	0.61	8.05e-44	Eye color traits;
LUAD	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg09137382	chr11:130731461	NA	0.4	7.31	0.34	1.32e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg03929089	chr4:120376271	NA	-0.7	-10.53	-0.46	3.58e-23	Coronary artery disease;
LUAD	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg24550644	chr17:30846204	MYO1D	-0.46	-8.6	-0.39	1.56e-16	Schizophrenia;
LUAD	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.02	-0.32	8.64e-12	Breast cancer;
LUAD	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg25344623	chr2:136566232	LCT	0.34	6.54	0.3	1.8e-10	Mosquito bite size;
LUAD	cis	rs7927771	0.524	rs4752796	chr11:47841862	A/G	cg18512352	chr11:47633146	NA	-0.37	-6.66	-0.31	8.61e-11	Subjective well-being;
LUAD	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg23711669	chr6:146136114	FBXO30	0.37	6.37	0.3	4.98e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg12599982	chr1:44399894	ARTN	0.35	6.98	0.32	1.16e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg02158880	chr13:53174818	NA	0.46	7.6	0.35	1.89e-13	Lewy body disease;
LUAD	cis	rs9972944	0.627	rs28845012	chr17:63760891	G/A	cg07283582	chr17:63770753	CCDC46	-0.51	-11.53	-0.49	6.17e-27	Total body bone mineral density;
LUAD	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg04155289	chr7:94953770	PON1	0.48	6.77	0.31	4.31e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4523957	0.583	rs6503302	chr17:2052704	C/T	cg16513277	chr17:2031491	SMG6	-0.97	-18.99	-0.68	1.4e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.54	0.3	1.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.66	-12.33	-0.51	4.55e-30	Lung cancer;
LUAD	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.01	0.47	5.84e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg19626725	chr5:178986131	RUFY1	0.5	8.55	0.38	2.35e-16	Lung cancer;
LUAD	cis	rs1550582	0.662	rs6981748	chr8:135501309	A/C	cg17885191	chr8:135476712	NA	-0.92	-13.86	-0.56	2.7e-36	Educational attainment;
LUAD	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg12011299	chr4:100065546	ADH4	0.69	12.46	0.52	1.46e-30	Smoking initiation;
LUAD	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg19743168	chr1:23544995	NA	0.36	6.44	0.3	3.23e-10	Height;
LUAD	cis	rs9296095	0.747	rs12206050	chr6:33564296	A/T	cg14003231	chr6:33640908	ITPR3	0.67	11.96	0.5	1.4e-28	Platelet count;
LUAD	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg10876282	chr6:28092338	ZSCAN16	0.46	7.23	0.33	2.35e-12	Cardiac Troponin-T levels;
LUAD	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg05717871	chr11:638507	DRD4	-0.41	-6.47	-0.3	2.72e-10	Systemic lupus erythematosus;
LUAD	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg21951975	chr1:209979733	IRF6	0.58	6.99	0.32	1.06e-11	Coronary artery disease;
LUAD	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27297192	chr10:134578999	INPP5A	0.37	6.39	0.3	4.49e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg23029597	chr12:123009494	RSRC2	-0.5	-7.82	-0.36	4.2e-14	Body mass index;
LUAD	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg02461776	chr11:598696	PHRF1	0.49	6.91	0.32	1.8e-11	Systemic lupus erythematosus;
LUAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg04025307	chr7:1156635	C7orf50	0.65	7.72	0.35	8.22e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6840360	0.530	rs11946622	chr4:152486018	C/T	cg22705602	chr4:152727874	NA	-0.44	-7.53	-0.34	3.05e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg27490568	chr2:178487706	NA	0.41	6.84	0.32	2.79e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg23711669	chr6:146136114	FBXO30	-0.38	-6.39	-0.3	4.45e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6445967	0.569	rs62259330	chr3:58294970	T/C	cg23715586	chr3:58305044	RPP14	0.41	6.67	0.31	8.09e-11	Platelet count;
LUAD	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg09509183	chr1:209979624	IRF6	0.58	6.88	0.32	2.11e-11	Coronary artery disease;
LUAD	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.48	-0.34	4.2e-13	Bipolar disorder;
LUAD	cis	rs1371867	0.846	rs2919471	chr8:101232701	T/C	cg06002616	chr8:101225028	SPAG1	0.43	8.77	0.39	4.35e-17	Atrioventricular conduction;
LUAD	cis	rs10788264	0.518	rs1028632	chr10:124044657	C/G	cg09507567	chr10:124027408	NA	0.48	10.59	0.46	2.18e-23	Total body bone mineral density;
LUAD	cis	rs4280164	0.551	rs12436194	chr14:24804859	C/T	cg07162820	chr14:24837146	NFATC4	0.32	6.39	0.3	4.51e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs11209185	0.563	rs10889733	chr1:68424136	G/A	cg22082780	chr1:68452167	NA	-0.42	-8.86	-0.4	2.19e-17	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg20607798	chr8:58055168	NA	0.67	8.71	0.39	7.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9341808	0.754	rs6916405	chr6:81024188	C/T	cg08355045	chr6:80787529	NA	0.54	9.55	0.42	1.05e-19	Sitting height ratio;
LUAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg24829409	chr8:58192753	C8orf71	-0.62	-8.13	-0.37	4.78e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg22029157	chr1:209979665	IRF6	0.8	11.8	0.5	5.71e-28	Cleft lip with or without cleft palate;
LUAD	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg11645453	chr3:52864694	ITIH4	0.59	11.02	0.47	5.13e-25	Schizophrenia;
LUAD	cis	rs1113500	0.933	rs10881500	chr1:108638895	C/T	cg06207961	chr1:108661230	NA	0.45	8.45	0.38	4.67e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg23758822	chr17:41437982	NA	0.9	18.01	0.66	2.97e-54	Menopause (age at onset);
LUAD	cis	rs10791323	0.517	rs1120247	chr11:133745180	T/G	cg03690763	chr11:133734501	NA	-0.27	-6.41	-0.3	3.86e-10	Childhood ear infection;
LUAD	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg25036284	chr2:26402008	FAM59B	-0.58	-8.07	-0.37	7.42e-15	Gut microbiome composition (summer);
LUAD	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg11618577	chr2:27665543	KRTCAP3	-0.26	-6.53	-0.3	1.89e-10	Total body bone mineral density;
LUAD	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg15448220	chr1:150897856	SETDB1	0.47	8.09	0.37	6.35e-15	Tonsillectomy;
LUAD	cis	rs7107174	1.000	rs2510054	chr11:77959659	A/G	cg19901956	chr11:77921274	USP35	0.51	6.57	0.3	1.44e-10	Testicular germ cell tumor;
LUAD	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg07153921	chr17:41440717	NA	-0.41	-7.02	-0.32	8.69e-12	Menopause (age at onset);
LUAD	cis	rs68170813	0.559	rs78267892	chr7:106823734	C/T	cg23024343	chr7:107201750	COG5	0.5	7.26	0.33	1.92e-12	Coronary artery disease;
LUAD	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg04398451	chr17:18023971	MYO15A	-0.73	-13.45	-0.55	1.39e-34	Total body bone mineral density;
LUAD	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg09165964	chr15:75287851	SCAMP5	-0.53	-7.65	-0.35	1.37e-13	Blood trace element (Zn levels);
LUAD	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.07	-14.66	-0.58	1.25e-39	Schizophrenia;
LUAD	cis	rs7799006	0.929	rs71525363	chr7:2268792	G/A	cg08027265	chr7:2291960	NA	-0.62	-11.19	-0.48	1.21e-25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs4285028	0.656	rs2141487	chr3:121482765	A/G	cg11130432	chr3:121712080	ILDR1	0.57	8.28	0.37	1.63e-15	Multiple sclerosis;
LUAD	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg06002616	chr8:101225028	SPAG1	-0.4	-8.26	-0.37	1.84e-15	Atrioventricular conduction;
LUAD	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg11062466	chr8:58055876	NA	0.45	6.47	0.3	2.66e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs12216545	0.737	rs1568628	chr7:150239286	A/T	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.4	-0.3	4.08e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg06074448	chr4:187884817	NA	0.39	7.9	0.36	2.42e-14	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2806561	1.000	rs1208932	chr1:23429122	T/G	cg12483005	chr1:23474871	LUZP1	-0.4	-6.91	-0.32	1.78e-11	Height;
LUAD	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg17063962	chr7:91808500	NA	0.62	10.4	0.45	1.02e-22	Breast cancer;
LUAD	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg13813247	chr22:41461852	NA	-0.47	-7.51	-0.34	3.54e-13	Neuroticism;
LUAD	trans	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg01620082	chr3:125678407	NA	-0.6	-6.87	-0.32	2.32e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg11822812	chr5:140052017	DND1	0.37	6.75	0.31	4.74e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9581857	0.579	rs3759433	chr13:27997999	C/T	cg22138327	chr13:27999177	GTF3A	0.92	12.99	0.53	1.04e-32	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg17178900	chr1:205818956	PM20D1	0.72	14.62	0.58	1.87e-39	Menarche (age at onset);
LUAD	cis	rs427394	0.582	rs274661	chr5:6704848	C/T	cg10857441	chr5:6722123	POLS	-0.57	-10.05	-0.44	1.83e-21	Menopause (age at onset);
LUAD	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg03517284	chr6:25882590	NA	-0.4	-6.44	-0.3	3.27e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs3935685	1.000	rs4886904	chr15:78027178	C/T	cg25212270	chr15:78015279	NA	0.35	6.55	0.3	1.69e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04915463	chr1:162039957	NOS1AP	-0.43	-6.84	-0.32	2.8e-11	Height;
LUAD	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg16647868	chr5:131706066	SLC22A5	-0.42	-7.27	-0.33	1.8e-12	Blood metabolite levels;
LUAD	cis	rs9341808	0.754	rs1015158	chr6:80945745	C/T	cg08355045	chr6:80787529	NA	0.59	10.67	0.46	1.03e-23	Sitting height ratio;
LUAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg09509183	chr1:209979624	IRF6	0.59	8.93	0.4	1.33e-17	Cleft lip with or without cleft palate;
LUAD	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	7.26	0.33	1.92e-12	Menarche (age at onset);
LUAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg11062466	chr8:58055876	NA	-0.76	-9.52	-0.42	1.29e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	6.9	0.32	1.86e-11	Schizophrenia;
LUAD	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg12927641	chr6:109611667	NA	-0.5	-8.78	-0.39	4.02e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg23625390	chr15:77176239	SCAPER	-0.53	-8.16	-0.37	3.78e-15	Blood metabolite levels;
LUAD	trans	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg03886242	chr7:26192032	NFE2L3	-0.47	-8.31	-0.37	1.36e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs7395662	0.553	rs11040122	chr11:48901038	A/G	cg00717180	chr2:96193071	NA	0.39	7.4	0.34	7.27e-13	HDL cholesterol;
LUAD	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg08885076	chr2:99613938	TSGA10	-0.4	-7.18	-0.33	3.2e-12	Chronic sinus infection;
LUAD	cis	rs427941	0.655	rs201468	chr7:101742673	C/T	cg06246474	chr7:101738831	CUX1	0.41	7.19	0.33	2.88e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg09796270	chr17:17721594	SREBF1	0.36	7.01	0.32	9.37e-12	Total body bone mineral density;
LUAD	trans	rs2797160	0.967	rs1739368	chr6:126011079	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.55	8.66	0.39	1.02e-16	Endometrial cancer;
LUAD	cis	rs476633	0.691	rs28735224	chr15:41537539	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.51	-9.46	-0.42	2.23e-19	Glomerular filtration rate (creatinine);
LUAD	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.62	-0.6	9.38e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg21659725	chr3:3221576	CRBN	-0.49	-8.32	-0.38	1.26e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.45	0.42	2.4e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg23985595	chr17:80112537	CCDC57	0.53	9.65	0.42	4.6e-20	Life satisfaction;
LUAD	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg07952391	chr2:88470173	THNSL2	0.78	8.13	0.37	4.94e-15	Plasma clusterin levels;
LUAD	cis	rs300774	0.920	rs378161	chr2:192983	A/T	cg21211680	chr2:198530	NA	0.57	8.0	0.36	1.22e-14	Suicide attempts in bipolar disorder;
LUAD	cis	rs1997103	1.000	rs6973337	chr7:55411534	T/C	cg17469321	chr7:55412551	NA	0.67	11.37	0.48	2.64e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg09904177	chr6:26538194	HMGN4	0.43	7.21	0.33	2.51e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs758324	0.812	rs13170176	chr5:131138736	G/C	cg25547332	chr5:131281432	NA	0.43	6.95	0.32	1.39e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9972944	0.729	rs6504348	chr17:63763049	C/T	cg07283582	chr17:63770753	CCDC46	-0.51	-11.57	-0.49	4.41e-27	Total body bone mineral density;
LUAD	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg26384229	chr12:38710491	ALG10B	0.4	6.37	0.3	4.82e-10	Morning vs. evening chronotype;
LUAD	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg16735072	chr8:11994639	FAM66D	0.44	6.55	0.3	1.63e-10	Joint mobility (Beighton score);
LUAD	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg17063962	chr7:91808500	NA	0.68	12.31	0.51	5.78e-30	Breast cancer;
LUAD	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg10544611	chr16:67998164	SLC12A4	-0.46	-6.51	-0.3	2.18e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg11859384	chr17:80120422	CCDC57	0.52	9.34	0.41	5.71e-19	Life satisfaction;
LUAD	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.86	12.37	0.52	3.34e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg24421504	chr8:75262575	GDAP1	-0.63	-6.83	-0.32	2.89e-11	Type 2 diabetes;
LUAD	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg12011299	chr4:100065546	ADH4	0.69	12.49	0.52	1.07e-30	Smoking initiation;
LUAD	cis	rs5756391	0.568	rs4821569	chr22:37316873	A/G	cg16356956	chr22:37317934	CSF2RB	0.32	6.75	0.31	5.01e-11	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs2070677	0.935	rs4384343	chr10:135422545	G/C	cg20169779	chr10:135381914	SYCE1	-0.5	-7.85	-0.36	3.57e-14	Gout;
LUAD	cis	rs758324	0.783	rs253941	chr5:131320293	C/T	cg25547332	chr5:131281432	NA	-0.43	-6.43	-0.3	3.55e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.559	rs7794965	chr7:106826439	A/G	cg02696742	chr7:106810147	HBP1	0.78	11.34	0.48	3.38e-26	Coronary artery disease;
LUAD	cis	rs9287719	0.578	rs13425171	chr2:10731966	C/G	cg03983476	chr2:10830698	NOL10	-0.39	-6.48	-0.3	2.58e-10	Prostate cancer;
LUAD	trans	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg26043149	chr18:55253948	FECH	0.47	7.58	0.35	2.15e-13	Bone mineral density;
LUAD	cis	rs4589502	1.000	rs8023363	chr15:67154654	G/A	cg09911534	chr15:67153556	NA	-0.43	-6.35	-0.3	5.46e-10	Lung cancer (smoking interaction);
LUAD	cis	rs2455799	1.000	rs6807029	chr3:15869857	A/C	cg16303742	chr3:15540471	COLQ	-0.38	-6.64	-0.31	9.83e-11	Mean platelet volume;
LUAD	cis	rs427394	0.659	rs274675	chr5:6755319	C/T	cg12316010	chr5:6737918	POLS	0.35	6.7	0.31	6.64e-11	Menopause (age at onset);
LUAD	cis	rs2992756	0.663	rs2992763	chr1:18804386	G/A	cg14356550	chr1:18808102	KLHDC7A	-0.57	-9.92	-0.43	5.4e-21	Breast cancer;
LUAD	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg27539214	chr16:67997921	SLC12A4	-0.72	-9.19	-0.41	1.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg18230493	chr5:56204884	C5orf35	0.67	10.86	0.47	2.13e-24	Coronary artery disease;
LUAD	cis	rs4660214	0.666	rs11205839	chr1:39733733	G/A	cg27567593	chr1:39956653	BMP8A	0.33	6.6	0.31	1.27e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg18230493	chr5:56204884	C5orf35	-0.83	-12.27	-0.51	8.34e-30	Initial pursuit acceleration;
LUAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg04025307	chr7:1156635	C7orf50	0.82	14.72	0.58	6.5e-40	Longevity;Endometriosis;
LUAD	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg09165964	chr15:75287851	SCAMP5	-0.44	-6.72	-0.31	5.95e-11	Blood trace element (Zn levels);
LUAD	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg06784218	chr1:46089804	CCDC17	-0.6	-13.41	-0.55	2.12e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7520050	0.807	rs4660312	chr1:46110572	A/G	cg06784218	chr1:46089804	CCDC17	0.35	7.6	0.35	1.97e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg16070123	chr10:51489643	NA	-0.36	-6.5	-0.3	2.33e-10	Prostate-specific antigen levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12020201	chr12:50017283	PRPF40B	-0.51	-6.41	-0.3	4e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg11502198	chr6:26597334	ABT1	-0.66	-11.59	-0.49	3.59e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg06263672	chr7:65235340	NA	0.57	9.4	0.42	3.6e-19	Calcium levels;
LUAD	cis	rs1950500	0.509	rs12882558	chr14:24819233	G/A	cg22990158	chr14:24802150	ADCY4	-0.43	-7.85	-0.36	3.5e-14	Height;
LUAD	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg00717180	chr2:96193071	NA	-0.4	-7.67	-0.35	1.21e-13	Coronary artery disease;
LUAD	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg12908607	chr1:44402522	ARTN	-0.51	-9.97	-0.44	3.67e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg14092988	chr3:52407081	DNAH1	0.36	7.02	0.32	8.77e-12	Bipolar disorder;
LUAD	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.57	6.5	0.3	2.25e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs6564851	0.935	rs12927647	chr16:81259893	A/C	cg00908271	chr16:81254010	PKD1L2	-0.32	-7.11	-0.33	4.82e-12	Carotenoid and tocopherol levels;
LUAD	cis	rs684232	0.644	rs2657613	chr17:623902	T/C	cg12384639	chr17:618140	VPS53	0.47	8.23	0.37	2.31e-15	Prostate cancer;
LUAD	trans	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg06606381	chr12:133084897	FBRSL1	0.52	6.69	0.31	6.88e-11	Depression;
LUAD	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg06108461	chr20:60628389	TAF4	-0.72	-11.88	-0.5	2.67e-28	Body mass index;
LUAD	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg20487152	chr13:99095054	FARP1	-0.48	-8.18	-0.37	3.47e-15	Longevity;
LUAD	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg08085267	chr17:45401833	C17orf57	-0.6	-10.41	-0.45	9.45e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg02423579	chr7:2872169	GNA12	-0.55	-9.3	-0.41	7.75e-19	Height;
LUAD	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.09	-0.33	5.65e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg06671706	chr8:8559999	CLDN23	0.64	10.98	0.47	7.7e-25	Obesity-related traits;
LUAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg16606324	chr3:10149918	C3orf24	0.68	11.12	0.48	2.23e-25	Alzheimer's disease;
LUAD	trans	rs11638815	0.626	rs1367841	chr15:83310625	A/G	cg18393722	chr15:85113863	UBE2QP1	0.47	7.1	0.33	5.33e-12	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	cis	rs4077515	0.967	rs11794847	chr9:139271747	G/A	cg14019695	chr9:139328340	INPP5E	0.42	7.97	0.36	1.53e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02353165	chr6:42928485	GNMT	0.42	7.41	0.34	6.89e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg17105886	chr17:28927953	LRRC37B2	0.74	7.63	0.35	1.61e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3806843	0.549	rs246012	chr5:140336277	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9469913	0.740	rs2744977	chr6:34563060	A/G	cg14254433	chr6:34482411	PACSIN1	-0.43	-6.67	-0.31	7.91e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg13606994	chr1:44402422	ARTN	0.37	7.48	0.34	4.22e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-6.81	-0.31	3.3e-11	Personality dimensions;
LUAD	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg06064525	chr11:970664	AP2A2	-0.53	-10.75	-0.46	5.28e-24	Alzheimer's disease (late onset);
LUAD	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg12501888	chr15:85177176	SCAND2	-0.46	-7.06	-0.32	7.05e-12	P wave terminal force;
LUAD	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg22823121	chr1:150693482	HORMAD1	-0.35	-6.42	-0.3	3.63e-10	Tonsillectomy;
LUAD	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg12564285	chr5:131593104	PDLIM4	-0.38	-7.27	-0.33	1.72e-12	Acylcarnitine levels;
LUAD	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg27170947	chr2:26402098	FAM59B	0.64	9.03	0.4	6.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs6866614	0.627	rs27437	chr5:131436961	A/G	cg14196790	chr5:131705035	SLC22A5	0.41	6.81	0.31	3.3e-11	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg02990361	chr1:107599529	PRMT6	0.64	10.78	0.46	4.31e-24	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs17135859	0.715	rs2416325	chr5:113018908	A/C	cg12552261	chr5:112820674	MCC	0.53	6.43	0.3	3.54e-10	F-cell distribution;
LUAD	trans	rs9408928	0.778	rs9409230	chr9:123967760	A/T	cg25418748	chr5:178977236	RUFY1	0.66	6.59	0.31	1.34e-10	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs12681288	0.550	rs6989880	chr8:957209	A/G	cg15309053	chr8:964076	NA	0.44	9.86	0.43	8.91e-21	Schizophrenia;
LUAD	cis	rs938554	0.868	rs734553	chr4:9923004	G/T	cg00071950	chr4:10020882	SLC2A9	0.53	8.5	0.38	3.37e-16	Blood metabolite levels;
LUAD	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg21100191	chr22:23484243	RTDR1	0.71	12.84	0.53	4.26e-32	Bone mineral density;
LUAD	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03264133	chr6:25882463	NA	-0.52	-7.62	-0.35	1.7e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.98	-0.32	1.11e-11	Neuroticism;
LUAD	cis	rs853679	0.607	rs13211507	chr6:28257377	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.52	6.44	0.3	3.19e-10	Depression;
LUAD	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg15468180	chr1:107600409	PRMT6	-0.39	-6.76	-0.31	4.49e-11	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs738321	0.725	rs9622738	chr22:38542346	G/A	cg17652424	chr22:38574118	PLA2G6	-0.27	-7.11	-0.33	5.06e-12	Breast cancer;
LUAD	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.62	-0.35	1.73e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg14530993	chr4:882597	GAK	0.73	6.75	0.31	4.96e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.61	-0.31	1.16e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9976767	0.637	rs2277799	chr21:43824123	G/C	cg23042151	chr21:43824109	UBASH3A	-0.32	-6.86	-0.32	2.41e-11	Type 1 diabetes;
LUAD	cis	rs4660214	0.666	rs598415	chr1:39832407	T/C	cg27567593	chr1:39956653	BMP8A	-0.35	-6.99	-0.32	1.08e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg13385794	chr1:248469461	NA	0.26	7.07	0.33	6.48e-12	Common traits (Other);
LUAD	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-6.99	-0.32	1.1e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg09650180	chr20:62225654	GMEB2	-0.46	-6.48	-0.3	2.55e-10	Glioblastoma;
LUAD	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg17640201	chr16:30407289	ZNF48	0.43	6.56	0.3	1.54e-10	Tonsillectomy;
LUAD	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	7.12	0.33	4.76e-12	Menarche (age at onset);
LUAD	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg11502198	chr6:26597334	ABT1	0.68	11.86	0.5	3.38e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg11663144	chr21:46675770	NA	-0.6	-11.57	-0.49	4.42e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.32	0.34	1.29e-12	Bladder cancer;
LUAD	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg06096015	chr1:231504339	EGLN1	-0.34	-6.55	-0.3	1.63e-10	Hemoglobin concentration;
LUAD	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.37	7.5	0.34	3.83e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg15900387	chr1:150738905	CTSS	-0.37	-6.76	-0.31	4.65e-11	Melanoma;
LUAD	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg21918786	chr6:109611834	NA	-0.57	-10.58	-0.46	2.34e-23	Reticulocyte fraction of red cells;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg01158970	chr5:72861249	UTP15;ANKRA2	0.41	6.43	0.3	3.44e-10	Diastolic blood pressure;
LUAD	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg06784218	chr1:46089804	CCDC17	-0.6	-13.33	-0.54	4.38e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg16606324	chr3:10149918	C3orf24	0.56	9.2	0.41	1.64e-18	Alzheimer's disease;
LUAD	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-9.37	-0.41	4.39e-19	Platelet count;
LUAD	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg16647868	chr5:131706066	SLC22A5	0.39	6.8	0.31	3.49e-11	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7202877	0.561	rs2865532	chr16:75350975	A/G	cg03315344	chr16:75512273	CHST6	0.47	6.37	0.3	5.05e-10	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg05805236	chr11:65401703	PCNXL3	-0.61	-9.91	-0.43	5.68e-21	Acne (severe);
LUAD	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg15556689	chr8:8085844	FLJ10661	0.41	6.74	0.31	5.3e-11	Mood instability;
LUAD	trans	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg03929089	chr4:120376271	NA	-0.53	-7.06	-0.32	6.95e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs56161922	0.818	rs111340461	chr1:207870682	A/C	cg11752769	chr1:207818423	CR1L	-0.62	-6.39	-0.3	4.39e-10	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg17105886	chr17:28927953	LRRC37B2	0.79	7.8	0.35	4.95e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg24112000	chr20:60950667	NA	0.69	9.87	0.43	8.03e-21	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg03433033	chr1:76189801	ACADM	-0.71	-11.38	-0.48	2.35e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg15691649	chr6:25882328	NA	0.64	9.9	0.43	6.25e-21	Blood metabolite levels;
LUAD	cis	rs28595532	0.623	rs34531766	chr4:119230339	T/C	cg02775129	chr4:119771670	NA	-0.64	-6.9	-0.32	1.86e-11	Cannabis dependence symptom count;
LUAD	cis	rs10979	1.000	rs9390107	chr6:143892721	A/T	cg25407410	chr6:143891975	LOC285740	-0.64	-10.11	-0.44	1.16e-21	Hypospadias;
LUAD	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg13606994	chr1:44402422	ARTN	0.41	7.55	0.34	2.77e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs16867321	0.614	rs10204086	chr2:181449668	G/T	cg23363182	chr2:181467187	NA	-0.43	-6.97	-0.32	1.22e-11	Obesity;
LUAD	cis	rs59104589	0.617	rs59934670	chr2:242207285	G/C	cg08645257	chr2:242211290	HDLBP	0.5	7.83	0.36	4.04e-14	Fibrinogen levels;
LUAD	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.28	-7.24	-0.33	2.14e-12	Total body bone mineral density;
LUAD	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.77	-14.93	-0.59	8.67e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs11048434	0.736	rs4309200	chr12:9121856	A/C	cg23795048	chr12:9217529	LOC144571	0.41	7.52	0.34	3.34e-13	Sjögren's syndrome;
LUAD	cis	rs4713675	0.649	rs568901	chr6:33710038	A/G	cg07979401	chr6:33739406	LEMD2	0.36	6.8	0.31	3.65e-11	Plateletcrit;
LUAD	cis	rs7937890	0.532	rs2575832	chr11:14488810	A/G	cg06199346	chr11:14280333	SPON1	-0.33	-6.54	-0.3	1.82e-10	Mitochondrial DNA levels;
LUAD	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg21153622	chr11:89784906	NA	-0.32	-6.46	-0.3	2.95e-10	Height;
LUAD	trans	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.0	0.5	9.58e-29	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg07685180	chr8:600429	NA	0.86	8.61	0.39	1.43e-16	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg21475434	chr5:93447410	FAM172A	-0.64	-7.9	-0.36	2.44e-14	Diabetic retinopathy;
LUAD	cis	rs5758511	0.514	rs2899354	chr22:42554409	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.65	11.38	0.48	2.43e-26	Birth weight;
LUAD	cis	rs7223966	0.729	rs9902761	chr17:62010627	A/G	cg11494091	chr17:61959527	GH2	0.46	8.26	0.37	1.9e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7582720	0.943	rs72934546	chr2:203980033	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.69	0.43	3.45e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg00106254	chr7:1943704	MAD1L1	-0.46	-6.66	-0.31	8.55e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs494562	0.892	rs9294335	chr6:86126680	C/T	cg13315970	chr6:86159197	NT5E	0.71	7.86	0.36	3.15e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1904096	0.506	rs13435702	chr4:95167751	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.51	-9.75	-0.43	2.12e-20	Type 2 diabetes;
LUAD	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.33	6.59	0.31	1.3e-10	Obesity-related traits;
LUAD	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg01620082	chr3:125678407	NA	-0.44	-6.7	-0.31	6.82e-11	Parkinson's disease;
LUAD	cis	rs7833986	0.501	rs72653990	chr8:57037115	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.97	17.01	0.64	8.45e-50	Height;
LUAD	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg20933634	chr6:27740509	NA	0.45	7.03	0.32	8.53e-12	Parkinson's disease;
LUAD	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.21	-0.37	2.66e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.49	10.12	0.44	1.03e-21	Monocyte percentage of white cells;
LUAD	cis	rs4253772	0.938	rs41355347	chr22:46637511	G/A	cg09491104	chr22:46646882	C22orf40	-0.5	-6.8	-0.31	3.55e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.49	-0.3	2.39e-10	Prostate cancer;
LUAD	trans	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-7.75	-0.35	6.9e-14	HDL cholesterol;
LUAD	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg18827107	chr12:86230957	RASSF9	0.54	9.74	0.43	2.24e-20	Major depressive disorder;
LUAD	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-10.51	-0.45	4.22e-23	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg20701182	chr2:24300061	SF3B14	0.58	6.83	0.32	2.93e-11	Lymphocyte counts;
LUAD	cis	rs4523957	0.579	rs903160	chr17:2091765	C/T	cg16513277	chr17:2031491	SMG6	-0.86	-16.49	-0.63	1.61e-47	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg06740227	chr12:86229804	RASSF9	0.45	7.92	0.36	2.07e-14	Major depressive disorder;
LUAD	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg22508957	chr16:3507546	NAT15	-0.39	-6.66	-0.31	8.36e-11	Body mass index (adult);
LUAD	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg15962314	chr1:44399869	ARTN	0.31	6.69	0.31	7.03e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg18230493	chr5:56204884	C5orf35	-0.83	-12.22	-0.51	1.26e-29	Initial pursuit acceleration;
LUAD	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg08470875	chr2:26401718	FAM59B	-0.56	-7.77	-0.35	6.1e-14	Gut microbiome composition (summer);
LUAD	cis	rs9837602	0.572	rs13320057	chr3:99584630	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.62	7.48	0.34	4.48e-13	Breast cancer;
LUAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.19	0.54	1.67e-33	Prudent dietary pattern;
LUAD	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	6.48	0.3	2.5e-10	Systolic blood pressure;
LUAD	trans	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg05064044	chr6:292385	DUSP22	-0.79	-13.48	-0.55	1.08e-34	Menopause (age at onset);
LUAD	cis	rs8062405	0.698	rs8046545	chr16:28915217	G/A	cg05966235	chr16:28915196	ATP2A1	-0.54	-8.43	-0.38	5.49e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg21016266	chr12:122356598	WDR66	0.71	12.87	0.53	3.29e-32	Mean corpuscular volume;
LUAD	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg22906224	chr7:99728672	NA	-0.55	-9.51	-0.42	1.43e-19	Coronary artery disease;
LUAD	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.23	-0.33	2.34e-12	Height;
LUAD	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	ch.11.42038R	chr11:967971	AP2A2	0.39	6.88	0.32	2.23e-11	Alzheimer's disease (late onset);
LUAD	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg04896959	chr15:78267971	NA	0.63	12.12	0.51	3.23e-29	Coronary artery disease or large artery stroke;
LUAD	cis	rs853679	0.607	rs13205911	chr6:28124114	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.56	6.53	0.3	1.91e-10	Depression;
LUAD	cis	rs1451375	0.617	rs10276473	chr7:50612997	A/C	cg18232548	chr7:50535776	DDC	-0.61	-8.56	-0.38	2.07e-16	Malaria;
LUAD	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg09323728	chr8:95962352	TP53INP1	-0.29	-6.83	-0.32	2.9e-11	Type 2 diabetes;
LUAD	cis	rs2742417	1.000	rs2742386	chr3:45756310	A/C	cg10512202	chr3:45649293	LIMD1	0.36	6.43	0.3	3.51e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11644478	chr21:40555479	PSMG1	-0.61	-10.31	-0.45	2.11e-22	Cognitive function;
LUAD	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.59	-0.31	1.33e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7945718	0.967	rs4757945	chr11:12808718	A/G	cg25843174	chr11:12811716	TEAD1	-0.24	-7.17	-0.33	3.44e-12	Educational attainment (years of education);
LUAD	cis	rs9902453	0.935	rs7220151	chr17:28334710	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-9.06	-0.4	5.02e-18	Coffee consumption (cups per day);
LUAD	trans	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.67	-0.39	9.2e-17	Endometrial cancer;
LUAD	cis	rs4072705	0.900	rs1931189	chr9:127560653	C/T	cg13476313	chr9:127244764	NR5A1	0.29	6.85	0.32	2.59e-11	Menarche (age at onset);
LUAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02353165	chr6:42928485	GNMT	0.45	8.19	0.37	3.03e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05901451	chr6:126070800	HEY2	-0.49	-7.32	-0.34	1.28e-12	Migraine;
LUAD	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.41	-7.3	-0.33	1.47e-12	Platelet count;
LUAD	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg24397884	chr7:158709396	WDR60	0.61	8.44	0.38	5.04e-16	Height;
LUAD	cis	rs8048589	0.948	rs11648468	chr16:12181510	A/G	cg03816625	chr16:12192430	SNX29	-0.5	-7.46	-0.34	5.02e-13	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06544989	chr22:39130855	UNC84B	0.46	8.51	0.38	3.14e-16	Menopause (age at onset);
LUAD	cis	rs6840360	0.571	rs62327272	chr4:152545090	A/C	cg22705602	chr4:152727874	NA	-0.4	-6.89	-0.32	1.97e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg16989719	chr2:238392110	NA	-0.35	-7.04	-0.32	7.61e-12	Prostate cancer;
LUAD	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.36	-7.67	-0.35	1.21e-13	Hemoglobin concentration;
LUAD	trans	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg24644049	chr4:85504048	CDS1	0.89	7.31	0.33	1.37e-12	Skin colour saturation;
LUAD	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg07828340	chr4:882639	GAK	1.04	11.44	0.49	1.38e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg19318889	chr4:1322082	MAEA	0.47	7.8	0.35	4.92e-14	Obesity-related traits;
LUAD	trans	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg12400702	chr3:12838781	CAND2	0.31	6.41	0.3	3.79e-10	Parkinson's disease;
LUAD	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg25894440	chr7:65020034	NA	-0.7	-7.49	-0.34	4.14e-13	Diabetic kidney disease;
LUAD	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg18446336	chr7:2847575	GNA12	-0.34	-6.99	-0.32	1.1e-11	Height;
LUAD	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg08493051	chr2:3487164	NA	0.46	8.06	0.36	8.05e-15	Neurofibrillary tangles;
LUAD	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg16989719	chr2:238392110	NA	-0.37	-6.86	-0.32	2.41e-11	Prostate cancer;
LUAD	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg21231944	chr12:82153410	PPFIA2	-0.35	-6.48	-0.3	2.61e-10	Resting heart rate;
LUAD	cis	rs863345	0.604	rs12064489	chr1:158499449	T/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg22535103	chr8:58192502	C8orf71	-0.67	-7.38	-0.34	8.42e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs9522267	0.535	rs11069899	chr13:112231553	T/C	cg10483660	chr13:112241077	NA	-0.31	-6.66	-0.31	8.75e-11	Hepatitis;
LUAD	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg19041857	chr6:27730383	NA	-0.4	-6.78	-0.31	4.13e-11	Parkinson's disease;
LUAD	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg25566285	chr7:158114605	PTPRN2	-0.54	-11.9	-0.5	2.25e-28	Calcium levels;
LUAD	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg10792982	chr14:105748885	BRF1	0.44	9.42	0.42	3.03e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg26408565	chr15:76604113	ETFA	-0.56	-9.87	-0.43	8.14e-21	Blood metabolite levels;
LUAD	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg09509183	chr1:209979624	IRF6	0.58	7.98	0.36	1.36e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg22875332	chr1:76189707	ACADM	0.71	11.88	0.5	2.87e-28	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2835872	0.758	rs1787401	chr21:39038893	C/T	cg06728970	chr21:39037746	KCNJ6	0.41	7.79	0.35	5.19e-14	Electroencephalographic traits in alcoholism;
LUAD	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg09796270	chr17:17721594	SREBF1	0.39	7.89	0.36	2.53e-14	Total body bone mineral density;
LUAD	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg04944784	chr2:26401820	FAM59B	-0.89	-12.57	-0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg11502198	chr6:26597334	ABT1	0.65	11.37	0.48	2.51e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg09365446	chr1:150670422	GOLPH3L	-0.57	-9.35	-0.41	5.3e-19	Blood protein levels;
LUAD	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg22532475	chr10:104410764	TRIM8	-0.41	-8.03	-0.36	9.93e-15	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7582720	1.000	rs7582720	chr2:203753072	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.46	0.42	2.24e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg12745145	chr7:2261452	MAD1L1	-0.34	-6.48	-0.3	2.6e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2274273	1.000	rs1047556	chr14:55600282	A/T	cg04306507	chr14:55594613	LGALS3	0.37	7.53	0.34	3.11e-13	Protein biomarker;
LUAD	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg27170947	chr2:26402098	FAM59B	-0.67	-9.34	-0.41	5.42e-19	Gut microbiome composition (summer);
LUAD	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg24768116	chr2:27665128	KRTCAP3	0.26	6.58	0.3	1.43e-10	Oral cavity cancer;
LUAD	cis	rs6840360	0.571	rs12648420	chr4:152543434	G/C	cg22705602	chr4:152727874	NA	-0.4	-6.89	-0.32	1.97e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg00776166	chr8:613548	NA	0.57	6.39	0.3	4.26e-10	IgG glycosylation;
LUAD	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg22532475	chr10:104410764	TRIM8	-0.47	-9.04	-0.4	5.53e-18	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg22009923	chr11:832065	CD151	-0.34	-6.65	-0.31	8.91e-11	Mean platelet volume;
LUAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-7.43	-0.34	5.89e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs12995491	0.933	rs7590305	chr2:88513131	C/T	cg04511125	chr2:88470314	THNSL2	-0.44	-7.37	-0.34	8.95e-13	Response to metformin (IC50);
LUAD	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg01299579	chr2:10830716	NOL10	0.41	7.11	0.33	4.95e-12	Prostate cancer;
LUAD	cis	rs73416724	1.000	rs17209379	chr6:43265231	A/C	cg26312998	chr6:43337775	ZNF318	0.56	6.64	0.31	9.91e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg19761014	chr17:28927070	LRRC37B2	0.7	6.61	0.31	1.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg04414720	chr1:150670196	GOLPH3L	0.58	9.77	0.43	1.8e-20	Melanoma;
LUAD	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg04450456	chr4:17643702	FAM184B	0.37	7.22	0.33	2.4e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg02880119	chr16:3481970	NA	0.57	8.36	0.38	8.83e-16	Body mass index (adult);
LUAD	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg07617317	chr6:118971624	C6orf204	0.54	8.16	0.37	3.78e-15	Diastolic blood pressure;
LUAD	trans	rs11039798	0.541	rs11040166	chr11:48965449	T/C	cg03929089	chr4:120376271	NA	0.68	6.78	0.31	4.18e-11	Axial length;
LUAD	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg00631329	chr6:26305371	NA	-0.52	-9.38	-0.42	3.93e-19	Educational attainment;
LUAD	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg03354898	chr7:1950403	MAD1L1	0.4	7.27	0.33	1.8e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs72634258	0.503	rs71637401	chr1:7837012	G/A	cg26816564	chr1:7831052	VAMP3	0.79	10.01	0.44	2.56e-21	Inflammatory bowel disease;
LUAD	cis	rs758324	0.812	rs30159	chr5:131306535	T/C	cg06307176	chr5:131281290	NA	-0.42	-6.68	-0.31	7.75e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg00701064	chr4:6280414	WFS1	0.65	13.79	0.56	5.41e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg16647868	chr5:131706066	SLC22A5	0.4	6.85	0.32	2.63e-11	Blood metabolite levels;
LUAD	trans	rs3779273	0.965	rs3779274	chr7:77828739	G/A	cg05596911	chr5:118502651	DMXL1	0.38	6.78	0.31	3.99e-11	Body mass index;
LUAD	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg00684032	chr4:1343700	KIAA1530	0.49	7.75	0.35	7.01e-14	Obesity-related traits;
LUAD	cis	rs72845660	1.000	rs3802678	chr10:104115395	A/T	cg20641465	chr10:103991465	PITX3	-0.48	-6.8	-0.31	3.53e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg04287289	chr16:89883240	FANCA	0.71	12.83	0.53	4.58e-32	Vitiligo;
LUAD	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg25452165	chr22:42524984	CYP2D6	0.41	6.7	0.31	6.8e-11	Schizophrenia;
LUAD	cis	rs868036	0.958	rs4261478	chr15:68074084	G/A	cg24579218	chr15:68104479	NA	-0.38	-6.98	-0.32	1.13e-11	Restless legs syndrome;
LUAD	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg20607287	chr7:12443886	VWDE	-0.53	-6.67	-0.31	8.01e-11	Coronary artery disease;
LUAD	cis	rs11650494	0.908	rs78208413	chr17:47398282	G/A	cg08112188	chr17:47440006	ZNF652	0.96	7.93	0.36	2.03e-14	Prostate cancer;
LUAD	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg27494647	chr7:150038898	RARRES2	0.46	8.18	0.37	3.26e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.23	0.48	8.73e-26	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg13047869	chr3:10149882	C3orf24	-0.65	-11.03	-0.47	5.04e-25	Alzheimer's disease;
LUAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg13560548	chr3:10150139	C3orf24	0.45	7.66	0.35	1.27e-13	Alzheimer's disease;
LUAD	cis	rs10761482	0.861	rs10740027	chr10:62159661	T/C	cg18175470	chr10:62150864	ANK3	-0.39	-6.43	-0.3	3.52e-10	Schizophrenia;
LUAD	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg15704280	chr7:45808275	SEPT13	0.78	13.0	0.53	9.44e-33	Coronary artery disease;
LUAD	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg03878208	chr11:72483293	STARD10	0.4	6.47	0.3	2.7e-10	Body mass index;
LUAD	cis	rs4774899	1.000	rs2414494	chr15:57441738	T/C	cg14026238	chr15:57616123	NA	0.37	6.97	0.32	1.21e-11	Urinary tract infection frequency;
LUAD	cis	rs10193935	0.901	rs62142561	chr2:42477808	G/C	cg27598129	chr2:42591480	NA	-0.77	-9.16	-0.41	2.19e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg16049864	chr8:95962084	TP53INP1	0.53	10.43	0.45	7.86e-23	Type 2 diabetes;
LUAD	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg23262073	chr20:60523788	NA	-0.45	-7.04	-0.32	7.82e-12	Body mass index;
LUAD	cis	rs12135894	0.648	rs4648423	chr1:3765678	C/T	cg13057898	chr1:3703894	LRRC47	-0.52	-9.55	-0.42	1.02e-19	Mean corpuscular volume;
LUAD	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg09455208	chr3:40491958	NA	0.52	11.19	0.48	1.21e-25	Renal cell carcinoma;
LUAD	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-7.98	-0.36	1.37e-14	Electroencephalogram traits;
LUAD	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23583168	chr7:148888333	NA	-0.9	-18.04	-0.66	2.28e-54	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7937890	0.631	rs7118886	chr11:14427517	T/C	cg06199346	chr11:14280333	SPON1	-0.33	-6.59	-0.31	1.32e-10	Mitochondrial DNA levels;
LUAD	cis	rs1044826	0.642	rs7652860	chr3:139205818	T/A	cg00490450	chr3:139108681	COPB2	0.41	6.48	0.3	2.63e-10	Obesity-related traits;
LUAD	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg14458575	chr2:238380390	NA	0.65	12.23	0.51	1.13e-29	Prostate cancer;
LUAD	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg22532475	chr10:104410764	TRIM8	-0.44	-8.29	-0.37	1.49e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3617	0.599	rs12487379	chr3:52895785	G/A	cg11645453	chr3:52864694	ITIH4	0.35	6.65	0.31	8.84e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs78456975	0.739	rs11896906	chr2:1519550	A/G	cg12573674	chr2:1569213	NA	-0.6	-7.09	-0.33	5.73e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7665090	0.934	rs6533020	chr4:103558805	T/C	cg07973026	chr4:103553119	MANBA	0.47	8.41	0.38	6.57e-16	Primary biliary cholangitis;
LUAD	cis	rs3790645	1.000	rs444482	chr1:26890648	C/G	cg23229016	chr1:26872525	RPS6KA1	0.2	6.73	0.31	5.66e-11	Glucose homeostasis traits;
LUAD	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg12310025	chr6:25882481	NA	0.46	7.45	0.34	5.16e-13	Blood metabolite levels;
LUAD	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg06547715	chr2:218990976	CXCR2	-0.28	-6.78	-0.31	4.06e-11	Colorectal cancer;
LUAD	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19346786	chr7:2764209	NA	-0.57	-12.27	-0.51	8.19e-30	Height;
LUAD	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg04287289	chr16:89883240	FANCA	0.78	6.93	0.32	1.59e-11	Skin colour saturation;
LUAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.29	0.37	1.55e-15	Alzheimer's disease;
LUAD	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg09658497	chr7:2847517	GNA12	-0.47	-8.79	-0.39	3.88e-17	Height;
LUAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg24642844	chr7:1081250	C7orf50	-0.96	-14.27	-0.57	5.21e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8127571	0.529	rs9306142	chr21:47225575	A/G	cg07529122	chr21:47054539	NA	0.41	6.81	0.31	3.42e-11	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.94	13.66	0.55	1.95e-35	Smoking behavior;
LUAD	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg27535305	chr1:53392650	SCP2	0.31	6.59	0.31	1.33e-10	Monocyte count;
LUAD	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg15247329	chr7:2764246	NA	-0.36	-6.39	-0.3	4.44e-10	Height;
LUAD	trans	rs225245	0.817	rs225297	chr17:33924587	G/A	cg19694781	chr19:47549865	TMEM160	-0.46	-7.58	-0.35	2.14e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20814179	chr4:940893	TMEM175	0.63	9.94	0.44	4.66e-21	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs7465272	1.000	rs36050651	chr8:143681796	A/G	cg10104451	chr8:143696006	ARC	-0.51	-7.0	-0.32	1e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg05368731	chr17:41323189	NBR1	0.97	20.31	0.7	1.61e-64	Menopause (age at onset);
LUAD	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg02683114	chr2:24398427	C2orf84	0.51	8.13	0.37	4.68e-15	Asthma;
LUAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg11416102	chr8:651193	ERICH1	0.97	8.85	0.4	2.33e-17	IgG glycosylation;
LUAD	cis	rs12505328	0.593	rs11132986	chr4:174371781	C/T	cg12145043	chr4:174357286	NA	-0.53	-8.05	-0.36	8.63e-15	Chin dimples;
LUAD	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg25797454	chr6:150327115	RAET1K	0.34	7.56	0.34	2.55e-13	Alopecia areata;
LUAD	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.78	0.53	7.64e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-7.41	-0.34	6.9e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg16479474	chr6:28041457	NA	0.49	8.52	0.38	2.85e-16	Depression;
LUAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08677398	chr8:58056175	NA	0.49	6.53	0.3	1.92e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.79	-0.39	3.78e-17	Alzheimer's disease (late onset);
LUAD	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg07195577	chr17:27052828	TLCD1	0.46	6.42	0.3	3.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg01802117	chr1:53393560	SCP2	-0.38	-7.43	-0.34	6.02e-13	Monocyte count;
LUAD	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg23887609	chr12:130822674	PIWIL1	0.4	6.64	0.31	9.93e-11	Menopause (age at onset);
LUAD	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg25237894	chr2:233734115	C2orf82	0.6	11.6	0.49	3.33e-27	Coronary artery disease;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg22080472	chr1:28176762	PPP1R8	-0.4	-6.51	-0.3	2.1e-10	Anger;
LUAD	cis	rs7216064	1.000	rs12452511	chr17:65832576	A/G	cg08758996	chr17:66097529	LOC651250	0.47	7.14	0.33	3.97e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg16479474	chr6:28041457	NA	0.35	6.36	0.3	5.21e-10	Cardiac Troponin-T levels;
LUAD	cis	rs8078723	0.668	rs56030650	chr17:38131187	C/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.35	-6.77	-0.31	4.23e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.73	0.31	5.44e-11	Motion sickness;
LUAD	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg20476274	chr7:133979776	SLC35B4	0.55	8.97	0.4	1.01e-17	Mean platelet volume;
LUAD	cis	rs6840360	0.967	rs4383600	chr4:152694383	T/C	cg22705602	chr4:152727874	NA	-0.32	-6.42	-0.3	3.61e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs897984	0.542	rs8061047	chr16:31068960	T/C	cg02466173	chr16:30829666	NA	-0.55	-9.43	-0.42	2.64e-19	Dementia with Lewy bodies;
LUAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.68	0.31	7.44e-11	Prudent dietary pattern;
LUAD	cis	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg07460842	chr6:66804631	NA	0.6	7.89	0.36	2.53e-14	Exhaled nitric oxide output;
LUAD	cis	rs77861329	1.000	rs17051977	chr3:52182944	A/G	cg08692210	chr3:52188851	WDR51A	0.8	7.71	0.35	8.78e-14	Macrophage inflammatory protein 1b levels;
LUAD	trans	rs1728785	0.591	rs10775305	chr16:68656460	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.68	10.51	0.46	4.3e-23	Ulcerative colitis;
LUAD	cis	rs354225	0.584	rs9677089	chr2:54794927	A/C	cg01766943	chr2:54829624	SPTBN1	0.36	6.41	0.3	4e-10	Schizophrenia;
LUAD	cis	rs9287719	0.601	rs6751436	chr2:10723862	C/T	cg02196655	chr2:10830764	NOL10	-0.39	-6.74	-0.31	5.27e-11	Prostate cancer;
LUAD	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg06740227	chr12:86229804	RASSF9	0.44	7.61	0.35	1.8e-13	Major depressive disorder;
LUAD	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg04896959	chr15:78267971	NA	-0.53	-10.39	-0.45	1.15e-22	Coronary artery disease or large artery stroke;
LUAD	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg20848291	chr7:100343083	ZAN	0.4	6.9	0.32	1.95e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs6005807	0.582	rs8136767	chr22:29008626	G/A	cg12565055	chr22:29076175	TTC28	0.75	8.76	0.39	4.71e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg27572855	chr1:25598939	RHD	-0.54	-11.45	-0.49	1.29e-26	Erythrocyte sedimentation rate;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg27226861	chr4:71705278	GRSF1	0.45	6.63	0.31	1.02e-10	QT interval;
LUAD	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg22396632	chr1:3079212	PRDM16	0.39	8.75	0.39	5.03e-17	Migraine;
LUAD	cis	rs7587476	0.601	rs6715570	chr2:215673440	T/C	cg04004882	chr2:215674386	BARD1	-0.54	-7.26	-0.33	1.86e-12	Neuroblastoma;
LUAD	cis	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg06360820	chr2:242988706	NA	-0.8	-9.22	-0.41	1.39e-18	Obesity-related traits;
LUAD	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18876405	chr7:65276391	NA	0.43	6.82	0.31	3.13e-11	Aortic root size;
LUAD	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4711350	0.862	rs652049	chr6:33711420	C/T	cg18005901	chr6:33739558	LEMD2	0.5	7.12	0.33	4.54e-12	Schizophrenia;
LUAD	cis	rs4604732	0.631	rs74154675	chr1:247625836	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11644478	chr21:40555479	PSMG1	-0.54	-8.72	-0.39	6.34e-17	Cognitive function;
LUAD	cis	rs61776719	0.810	rs34655914	chr1:38397341	G/A	cg18451016	chr1:38461880	NA	0.54	11.5	0.49	7.96e-27	Coronary artery disease;
LUAD	cis	rs515186	1	rs515186	chr6:36397492	T/G	cg07856975	chr6:36356162	ETV7	0.49	7.77	0.35	6.21e-14	Mean platelet volume;
LUAD	cis	rs367943	0.712	rs10062004	chr5:112694914	T/C	cg12552261	chr5:112820674	MCC	0.48	9.36	0.41	4.84e-19	Type 2 diabetes;
LUAD	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg21138405	chr5:131827807	IRF1	-0.61	-13.68	-0.55	1.59e-35	Asthma (sex interaction);
LUAD	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.3	-7.4	-0.34	7.19e-13	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg24818145	chr4:99064322	C4orf37	0.48	8.16	0.37	3.85e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17253792	0.822	rs75663029	chr14:56092385	T/C	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14159672	chr1:205819179	PM20D1	0.79	16.01	0.61	1.87e-45	Menarche (age at onset);
LUAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6445967	0.554	rs62259769	chr3:58414382	C/T	cg13750441	chr3:58318267	PXK	-0.31	-6.48	-0.3	2.55e-10	Platelet count;
LUAD	cis	rs6496044	0.568	rs11636764	chr15:86079751	G/A	cg13263323	chr15:86062960	AKAP13	-0.52	-9.4	-0.42	3.4e-19	Interstitial lung disease;
LUAD	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg12756686	chr19:29218302	NA	0.62	8.92	0.4	1.44e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg13813247	chr22:41461852	NA	-0.5	-7.91	-0.36	2.3e-14	Neuroticism;
LUAD	cis	rs10129255	0.500	rs10143242	chr14:107137831	C/T	cg07958169	chr14:107095056	NA	-0.34	-6.8	-0.31	3.63e-11	Kawasaki disease;
LUAD	trans	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.7	11.94	0.5	1.63e-28	Mean corpuscular volume;
LUAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	cis	rs17102423	0.731	rs942629	chr14:65539318	A/G	cg11161011	chr14:65562177	MAX	-0.4	-6.66	-0.31	8.3e-11	Obesity-related traits;
LUAD	trans	rs7487075	0.786	rs7965629	chr12:46675066	G/C	cg17341174	chr7:97923834	BAIAP2L1	-0.34	-6.37	-0.3	4.86e-10	Itch intensity from mosquito bite;
LUAD	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg01324343	chr3:183735012	ABCC5	0.92	24.79	0.77	1.99e-84	Anterior chamber depth;
LUAD	cis	rs11247915	0.561	rs11583258	chr1:26624270	C/T	cg15628303	chr1:26608928	UBXN11	0.55	9.8	0.43	1.4e-20	Obesity-related traits;
LUAD	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10802521	chr3:52805072	NEK4	-0.54	-9.05	-0.4	5.3e-18	Bipolar disorder;
LUAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08280861	chr8:58055591	NA	0.67	8.72	0.39	6.27e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg06623918	chr6:96969491	KIAA0776	0.87	17.29	0.64	4.67e-51	Headache;
LUAD	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg17644776	chr2:200775616	C2orf69	0.54	7.22	0.33	2.36e-12	Schizophrenia;
LUAD	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg23711669	chr6:146136114	FBXO30	0.4	6.74	0.31	5.19e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg06532163	chr17:45867833	NA	0.48	8.47	0.38	4.02e-16	IgG glycosylation;
LUAD	cis	rs68170813	0.523	rs7781947	chr7:106902219	A/G	cg23024343	chr7:107201750	COG5	0.48	6.99	0.32	1.11e-11	Coronary artery disease;
LUAD	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.41	6.93	0.32	1.55e-11	Total body bone mineral density;
LUAD	cis	rs2274273	0.840	rs7153110	chr14:55820628	A/G	cg04306507	chr14:55594613	LGALS3	0.41	8.69	0.39	8.26e-17	Protein biomarker;
LUAD	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg05373962	chr22:49881684	NA	-0.51	-11.01	-0.47	6.01e-25	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg09399716	chr2:46890238	NA	-0.46	-9.21	-0.41	1.48e-18	Height;
LUAD	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg20307385	chr11:47447363	PSMC3	0.65	11.05	0.47	4.04e-25	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs300774	0.925	rs300713	chr2:138363	A/G	cg21211680	chr2:198530	NA	-0.43	-6.71	-0.31	6.08e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg11833968	chr6:79620685	NA	-0.45	-8.32	-0.38	1.21e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg24818145	chr4:99064322	C4orf37	0.43	7.18	0.33	3.2e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2795502	0.564	rs72777186	chr10:43430464	C/T	cg27426351	chr10:43362370	NA	0.55	6.86	0.32	2.44e-11	Blood protein levels;
LUAD	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg00802000	chr16:706648	WDR90	0.41	6.48	0.3	2.48e-10	Height;
LUAD	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22307029	chr19:49891270	CCDC155	0.76	11.47	0.49	1.08e-26	Multiple sclerosis;
LUAD	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.38	0.34	8.71e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1784581	0.674	rs3016555	chr6:162391421	T/C	cg17173639	chr6:162384350	PARK2	-0.5	-9.03	-0.4	6.32e-18	Itch intensity from mosquito bite;
LUAD	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg23281280	chr6:28129359	ZNF389	0.46	6.56	0.3	1.55e-10	Depression;
LUAD	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg09455208	chr3:40491958	NA	0.64	14.25	0.57	6.5e-38	Renal cell carcinoma;
LUAD	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg05368731	chr17:41323189	NBR1	0.97	20.52	0.71	1.85e-65	Menopause (age at onset);
LUAD	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg04772025	chr11:68637568	NA	0.56	8.73	0.39	6.13e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg08877624	chr8:141521446	CHRAC1	-0.39	-6.46	-0.3	2.92e-10	Vertical cup-disc ratio;
LUAD	trans	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg13565492	chr6:43139072	SRF	-0.6	-6.4	-0.3	4.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg27446573	chr6:127587934	RNF146	0.44	6.53	0.3	1.89e-10	Breast cancer;
LUAD	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg01475377	chr6:109611718	NA	-0.52	-10.09	-0.44	1.31e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs752010	0.715	rs11807117	chr1:42101206	C/T	cg06885757	chr1:42089581	HIVEP3	0.63	13.77	0.56	6.94e-36	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs367943	0.634	rs2195377	chr5:112973620	G/A	cg12552261	chr5:112820674	MCC	0.45	8.07	0.37	7.37e-15	Type 2 diabetes;
LUAD	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-7.63	-0.35	1.5700000000000001e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg12927641	chr6:109611667	NA	-0.53	-9.46	-0.42	2.15e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg22535103	chr8:58192502	C8orf71	-0.75	-8.88	-0.4	2e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs11078597	0.650	rs62090056	chr17:1645410	C/T	cg18436246	chr17:1640651	WDR81	0.78	12.4	0.52	2.39e-30	Serum albumin level;
LUAD	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg00933542	chr6:150070202	PCMT1	0.46	10.05	0.44	1.89e-21	Lung cancer;
LUAD	cis	rs11893307	0.537	rs7571572	chr2:191553637	C/G	cg27211696	chr2:191398769	TMEM194B	-0.4	-6.36	-0.3	5.23e-10	Mean platelet volume;
LUAD	cis	rs10489202	0.908	rs6692861	chr1:168079553	G/C	cg24449463	chr1:168025552	DCAF6	-0.57	-7.53	-0.34	3.15e-13	Schizophrenia;
LUAD	cis	rs8017423	0.935	rs11159959	chr14:90733656	C/T	cg14092571	chr14:90743983	NA	0.48	7.96	0.36	1.55e-14	Mortality in heart failure;
LUAD	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg17063962	chr7:91808500	NA	0.65	11.01	0.47	5.7e-25	Breast cancer;
LUAD	cis	rs9902453	0.967	rs4325622	chr17:28526475	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	8.14	0.37	4.45e-15	Coffee consumption (cups per day);
LUAD	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg09640425	chr7:158790006	NA	-0.56	-9.71	-0.43	3.02e-20	Facial morphology (factor 20);
LUAD	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg08999081	chr20:33150536	PIGU	0.62	13.98	0.56	9.28e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18876405	chr7:65276391	NA	0.41	6.5	0.3	2.31e-10	Aortic root size;
LUAD	cis	rs17095355	1.000	rs55728195	chr10:111715599	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.68	-9.23	-0.41	1.29e-18	Biliary atresia;
LUAD	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg08514558	chr10:81106712	PPIF	0.49	9.42	0.42	3.07e-19	Height;
LUAD	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg24818145	chr4:99064322	C4orf37	0.46	7.8	0.35	4.86e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35883536	1.000	rs11547648	chr1:101106268	G/T	cg06223162	chr1:101003688	GPR88	0.35	6.57	0.3	1.53e-10	Monocyte count;
LUAD	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg17724175	chr1:150552817	MCL1	0.32	7.42	0.34	6.42e-13	Melanoma;
LUAD	cis	rs28830936	1.000	rs2004162	chr15:41965542	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.32	-6.57	-0.3	1.52e-10	Diastolic blood pressure;
LUAD	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg22906224	chr7:99728672	NA	0.6	10.23	0.45	4.28e-22	Coronary artery disease;
LUAD	cis	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg27411982	chr8:10470053	RP1L1	0.39	6.72	0.31	5.83e-11	Neuroticism;
LUAD	cis	rs11681884	1.000	rs11681884	chr2:113847628	C/T	cg12858261	chr2:113808755	IL1F8	0.52	6.55	0.3	1.67e-10	Stroke;
LUAD	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg00631329	chr6:26305371	NA	-0.73	-14.12	-0.57	2.28e-37	Educational attainment;
LUAD	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14240646	chr10:27532245	ACBD5	-0.93	-12.34	-0.51	4.42e-30	Breast cancer;
LUAD	cis	rs910187	0.678	rs3818013	chr20:45816639	A/G	cg27589058	chr20:45804311	EYA2	-0.31	-7.07	-0.33	6.44e-12	Migraine;
LUAD	cis	rs790123	1.000	rs790117	chr3:122380888	C/T	cg15604389	chr3:122379662	NA	0.48	8.4	0.38	6.84e-16	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg06606381	chr12:133084897	FBRSL1	-1.17	-8.7	-0.39	7.69e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.96	0.53	1.4e-32	Cognitive ability;
LUAD	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg00106254	chr7:1943704	MAD1L1	-0.49	-7.32	-0.34	1.23e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg12432903	chr7:1882776	MAD1L1	-0.44	-6.83	-0.32	2.9e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg01765077	chr12:122356316	WDR66	0.55	9.54	0.42	1.17e-19	Mean corpuscular volume;
LUAD	cis	rs9902453	0.904	rs7225686	chr17:28356744	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.6	-0.46	1.89e-23	Coffee consumption (cups per day);
LUAD	cis	rs317865	0.867	rs73234637	chr4:16178866	C/T	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.63	6.68	0.31	7.73e-11	Kidney disease (early stage) in type 1 diabetes;
LUAD	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg04492858	chr10:133558786	NA	0.39	7.86	0.36	3.33e-14	Survival in rectal cancer;
LUAD	cis	rs2882667	0.931	rs10068237	chr5:138337960	T/A	cg04439458	chr5:138467593	SIL1	-0.39	-7.23	-0.33	2.26e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg05665937	chr4:1216051	CTBP1	0.41	6.73	0.31	5.53e-11	Obesity-related traits;
LUAD	cis	rs6684514	1.000	rs12023704	chr1:156294149	C/A	cg16558208	chr1:156270281	VHLL	0.56	10.15	0.44	8.53e-22	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.5	-0.38	3.38e-16	Height;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg18648122	chr4:105412473	CXXC4	-0.42	-7.28	-0.33	1.65e-12	Schizophrenia;
LUAD	cis	rs34734847	1.000	rs56273049	chr12:121156041	A/T	cg27246729	chr12:121163418	ACADS	0.39	7.41	0.34	6.85e-13	Mean corpuscular volume;
LUAD	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.45	-7.51	-0.34	3.44e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.56	0.34	2.59e-13	Cannabis dependence symptom count;
LUAD	cis	rs300774	1.000	rs436446	chr2:106409	T/C	cg21211680	chr2:198530	NA	-0.46	-6.71	-0.31	6.34e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs6066835	1.000	rs6066828	chr20:47344233	C/T	cg18078177	chr20:47281410	PREX1	0.77	7.04	0.32	7.93e-12	Multiple myeloma;
LUAD	cis	rs6424115	0.790	rs72874118	chr1:24177800	A/G	cg10978503	chr1:24200527	CNR2	-0.57	-11.96	-0.5	1.38e-28	Immature fraction of reticulocytes;
LUAD	cis	rs2404602	0.735	rs437131	chr15:76781051	C/T	cg23625390	chr15:77176239	SCAPER	0.41	6.66	0.31	8.79e-11	Blood metabolite levels;
LUAD	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg03929089	chr4:120376271	NA	-0.93	-17.47	-0.65	7.35e-52	Height;
LUAD	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg26597838	chr10:835615	NA	0.74	9.02	0.4	6.76e-18	Eosinophil percentage of granulocytes;
LUAD	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg11089071	chr1:36397261	EIF2C3	-0.4	-6.46	-0.3	2.95e-10	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg10518543	chr12:38710700	ALG10B	0.49	7.86	0.36	3.24e-14	Morning vs. evening chronotype;
LUAD	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-7.79	-0.35	5.25e-14	Heart rate;
LUAD	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg19336497	chr11:14380999	RRAS2	-0.7	-16.3	-0.62	1.05e-46	Sense of smell;
LUAD	cis	rs7614311	0.731	rs56126667	chr3:63866286	A/G	cg22134162	chr3:63841271	THOC7	-0.55	-8.91	-0.4	1.54e-17	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs3818285	0.504	rs4917547	chr10:111652285	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.67	-10.5	-0.45	4.66e-23	Superior crus of antihelix expression;
LUAD	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg15133208	chr4:90757351	SNCA	-0.48	-7.3	-0.33	1.44e-12	Neuroticism;
LUAD	cis	rs1065656	0.563	rs391546	chr16:1915581	T/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.42	6.84	0.32	2.74e-11	Insulin-like growth factors;
LUAD	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.21	0.33	2.68e-12	Lung cancer;
LUAD	cis	rs17092148	0.836	rs4911157	chr20:33167075	T/C	cg16810054	chr20:33298113	TP53INP2	-0.53	-7.94	-0.36	1.8e-14	Neuroticism;
LUAD	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg02734326	chr4:10020555	SLC2A9	0.5	8.89	0.4	1.79e-17	Bone mineral density;
LUAD	trans	rs11165623	0.792	rs2104236	chr1:96908690	C/T	cg10631902	chr5:14652156	NA	-0.61	-11.89	-0.5	2.46e-28	Hip circumference;Waist circumference;
LUAD	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg13126279	chr21:47581558	C21orf56	0.5	8.31	0.37	1.32e-15	Testicular germ cell tumor;
LUAD	cis	rs4285028	0.948	rs12630486	chr3:121685267	C/T	cg20356878	chr3:121714668	ILDR1	-0.5	-6.76	-0.31	4.51e-11	Multiple sclerosis;
LUAD	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg20848291	chr7:100343083	ZAN	-0.58	-7.9	-0.36	2.41e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg01765077	chr12:122356316	WDR66	0.55	9.59	0.42	7.6e-20	Mean corpuscular volume;
LUAD	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg00981070	chr1:2046702	PRKCZ	-0.33	-7.0	-0.32	1.04e-11	Height;
LUAD	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg21699342	chr2:239360505	ASB1	-0.57	-11.28	-0.48	5.5e-26	Multiple system atrophy;
LUAD	cis	rs11650494	0.808	rs76366926	chr17:47396628	T/C	cg08112188	chr17:47440006	ZNF652	0.96	7.93	0.36	2.03e-14	Prostate cancer;
LUAD	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.87	-0.36	3.06e-14	Height;
LUAD	cis	rs10911363	0.592	rs2275675	chr1:183439483	C/T	cg09173681	chr1:183549694	NCF2	-0.53	-9.93	-0.43	5.05e-21	Systemic lupus erythematosus;
LUAD	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg08085267	chr17:45401833	C17orf57	-0.64	-11.38	-0.48	2.31e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4713675	0.505	rs753890	chr6:33652880	G/A	cg14003231	chr6:33640908	ITPR3	0.52	10.02	0.44	2.31e-21	Plateletcrit;
LUAD	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg27394845	chr17:28928406	LRRC37B2	0.5	6.37	0.3	4.96e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg00316803	chr15:76480434	C15orf27	-0.39	-7.28	-0.33	1.61e-12	Blood metabolite levels;
LUAD	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg25233709	chr10:116636983	FAM160B1	0.44	8.75	0.39	5.28e-17	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	6.56	0.3	1.58e-10	Tonsillectomy;
LUAD	cis	rs4604732	0.536	rs76191272	chr1:247628055	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	9.17	0.41	2.14e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg12034118	chr1:209979487	IRF6	0.55	7.39	0.34	8.17e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg02782426	chr3:40428986	ENTPD3	0.36	7.7	0.35	9.85e-14	Renal cell carcinoma;
LUAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg13047869	chr3:10149882	C3orf24	0.66	9.64	0.42	5.05e-20	Alzheimer's disease;
LUAD	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg05044414	chr3:183734942	ABCC5	0.47	9.97	0.44	3.69e-21	Anterior chamber depth;
LUAD	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg17042849	chr6:26104293	HIST1H4C	-0.48	-6.54	-0.3	1.79e-10	Iron status biomarkers;
LUAD	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg06131755	chr6:160182447	ACAT2	0.43	6.44	0.3	3.18e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs7215564	0.908	rs115148337	chr17:78688545	G/T	cg09596252	chr17:78655493	RPTOR	0.55	6.58	0.3	1.39e-10	Myopia (pathological);
LUAD	trans	rs28735056	0.620	rs12456484	chr18:77677315	C/G	cg05926928	chr17:57297772	GDPD1	0.51	7.63	0.35	1.52e-13	Schizophrenia;
LUAD	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03264133	chr6:25882463	NA	0.58	9.76	0.43	1.94e-20	Blood metabolite levels;
LUAD	cis	rs11676348	0.808	rs61700947	chr2:219046171	C/G	cg06547715	chr2:218990976	CXCR2	-0.28	-6.51	-0.3	2.15e-10	Ulcerative colitis;
LUAD	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.58	-9.92	-0.43	5.43e-21	Electrocardiographic conduction measures;
LUAD	cis	rs11771526	0.748	rs4723142	chr7:32337569	C/A	cg27532318	chr7:32358331	NA	0.55	7.37	0.34	9.34e-13	Body mass index;
LUAD	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg17863274	chr19:49399704	TULP2	-0.54	-8.95	-0.4	1.16e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.66	-0.43	4.31e-20	Bone mineral density;
LUAD	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg16205897	chr5:131564050	P4HA2	0.3	6.56	0.3	1.62e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs117623576	0.680	rs11008756	chr10:32363137	A/G	cg03047570	chr10:32398778	NA	-0.63	-7.67	-0.35	1.2e-13	Anti-saccade response;
LUAD	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg03713592	chr11:72463424	ARAP1	0.6	7.43	0.34	6.23e-13	Type 2 diabetes;
LUAD	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg00280220	chr17:61926910	NA	0.37	7.06	0.32	7.05e-12	Prudent dietary pattern;
LUAD	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.55	-6.4	-0.3	4.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg18105139	chr6:28058856	ZSCAN12L1	0.25	6.4	0.3	4.25e-10	Cardiac Troponin-T levels;
LUAD	cis	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg21775007	chr8:11205619	TDH	0.37	6.43	0.3	3.5e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs7737355	0.773	rs192166	chr5:130852525	T/C	cg25547332	chr5:131281432	NA	0.41	6.56	0.3	1.57e-10	Life satisfaction;
LUAD	cis	rs7818345	1.000	rs11991105	chr8:19290655	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.9	0.32	1.88e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg25456477	chr12:86230367	RASSF9	0.34	6.45	0.3	3.1e-10	Major depressive disorder;
LUAD	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg09085632	chr11:111637200	PPP2R1B	0.63	9.41	0.42	3.31e-19	Primary sclerosing cholangitis;
LUAD	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg12011299	chr4:100065546	ADH4	0.66	12.17	0.51	2.06e-29	Alcohol dependence;
LUAD	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg02421172	chr7:1938701	MAD1L1	0.48	6.8	0.31	3.6e-11	Bipolar disorder;
LUAD	cis	rs9796	0.621	rs58109657	chr15:41471750	A/G	cg18705301	chr15:41695430	NDUFAF1	0.5	9.06	0.4	5.03e-18	Menopause (age at onset);
LUAD	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg18944383	chr4:111397179	ENPEP	0.37	7.54	0.34	2.95e-13	Height;
LUAD	cis	rs3818285	0.544	rs7899805	chr10:111671177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.72	-11.53	-0.49	6.16e-27	Superior crus of antihelix expression;
LUAD	cis	rs9302635	0.550	rs35959677	chr16:72200801	G/T	cg23815491	chr16:72088622	HP	0.5	7.9	0.36	2.38e-14	Blood protein levels;
LUAD	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg00898013	chr13:113819073	PROZ	-0.67	-11.9	-0.5	2.24e-28	Platelet distribution width;
LUAD	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg26384229	chr12:38710491	ALG10B	0.47	7.7	0.35	1e-13	Morning vs. evening chronotype;
LUAD	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg08048268	chr3:133502702	NA	-0.41	-7.96	-0.36	1.57e-14	Iron status biomarkers;
LUAD	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.39	0.42	3.79e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg10596483	chr8:143751796	JRK	0.44	7.08	0.33	6.14e-12	Schizophrenia;
LUAD	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg22467129	chr15:76604101	ETFA	-0.47	-7.78	-0.35	5.7e-14	Blood metabolite levels;
LUAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg21724239	chr8:58056113	NA	0.65	8.41	0.38	6.32e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg18132916	chr6:79620363	NA	0.45	7.79	0.35	5.37e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg08885076	chr2:99613938	TSGA10	-0.4	-7.18	-0.33	3.2e-12	Chronic sinus infection;
LUAD	cis	rs748404	0.697	rs504417	chr15:43554226	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.35	0.34	1.03e-12	Lung cancer;
LUAD	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg23758822	chr17:41437982	NA	1.02	20.77	0.71	1.52e-66	Menopause (age at onset);
LUAD	cis	rs7020830	0.830	rs17487601	chr9:37213641	G/A	cg14294708	chr9:37120828	ZCCHC7	0.88	17.4	0.65	1.52e-51	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.38e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	8.74	0.39	5.55e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg25985355	chr7:65971099	NA	-0.53	-6.69	-0.31	7.18e-11	Diabetic kidney disease;
LUAD	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg11822812	chr5:140052017	DND1	0.38	6.66	0.31	8.67e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg00310523	chr12:86230176	RASSF9	-0.37	-7.43	-0.34	6.02e-13	Major depressive disorder;
LUAD	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.63	-0.42	5.74e-20	Schizophrenia;
LUAD	cis	rs8010715	0.771	rs2277481	chr14:24587545	A/G	cg23112188	chr14:24563095	PCK2	-0.31	-6.5	-0.3	2.21e-10	IgG glycosylation;
LUAD	cis	rs7712401	0.562	rs246267	chr5:122256104	A/T	cg19077854	chr5:122220652	SNX24	0.34	6.56	0.3	1.59e-10	Mean platelet volume;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg15629860	chr1:146715159	CHD1L	-0.39	-6.52	-0.3	1.98e-10	Cancer;
LUAD	cis	rs58804349	0.605	rs72779330	chr10:43522315	C/G	cg20628663	chr10:43360327	NA	0.6	6.73	0.31	5.48e-11	Pediatric bone mineral content (radius);
LUAD	trans	rs9951602	0.512	rs12454617	chr18:76656007	C/T	cg02800362	chr5:177631904	HNRNPAB	0.91	14.4	0.57	1.57e-38	Obesity-related traits;
LUAD	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg15181151	chr6:150070149	PCMT1	0.39	7.8	0.35	5e-14	Lung cancer;
LUAD	cis	rs12049351	0.774	rs6668018	chr1:229629053	T/C	cg11742688	chr1:229674241	ABCB10	-0.42	-6.5	-0.3	2.31e-10	Circulating myeloperoxidase levels (plasma);
LUAD	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg14343924	chr8:8086146	FLJ10661	-0.39	-6.44	-0.3	3.16e-10	Neuroticism;
LUAD	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg11070056	chr1:107600091	PRMT6	0.63	10.96	0.47	9.28e-25	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9399401	0.633	rs1329705	chr6:142753338	G/A	cg04461802	chr6:142623433	GPR126	0.41	7.52	0.34	3.37e-13	Chronic obstructive pulmonary disease;
LUAD	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22481606	chr17:56429567	SUPT4H1	-0.46	-7.28	-0.33	1.68e-12	Height;
LUAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg03354898	chr7:1950403	MAD1L1	-0.39	-7.42	-0.34	6.43e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg03467027	chr4:99064603	C4orf37	0.4	6.46	0.3	2.93e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg23281280	chr6:28129359	ZNF389	0.46	6.45	0.3	3e-10	Depression;
LUAD	cis	rs637571	0.676	rs634534	chr11:65665256	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.47	-8.06	-0.36	7.79e-15	Eosinophil percentage of white cells;
LUAD	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg03396347	chr1:1875803	NA	-0.6	-15.56	-0.6	1.6700000000000001e-43	Body mass index;
LUAD	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg26677194	chr12:130822605	PIWIL1	-0.53	-8.89	-0.4	1.73e-17	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg13319975	chr6:146136371	FBXO30	-0.57	-9.59	-0.42	7.5e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg00339695	chr16:24857497	SLC5A11	0.47	8.76	0.39	4.75e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs796364	0.616	rs7589545	chr2:200676102	T/A	cg23649088	chr2:200775458	C2orf69	0.52	6.43	0.3	3.43e-10	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg22117172	chr7:91764530	CYP51A1	0.35	7.79	0.35	5.22e-14	Breast cancer;
LUAD	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.76	-0.31	4.59e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg12011299	chr4:100065546	ADH4	-0.73	-13.72	-0.55	1.1e-35	Alcohol dependence;
LUAD	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg14983838	chr19:29218262	NA	0.63	9.69	0.43	3.54e-20	Methadone dose in opioid dependence;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg05396178	chr6:27833129	HIST1H2AL	0.42	6.88	0.32	2.14e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.66	-0.43	4.48e-20	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg02450064	chr17:40260053	DHX58	-0.44	-7.55	-0.34	2.65e-13	Fibrinogen levels;
LUAD	cis	rs3784262	0.669	rs12912093	chr15:58332583	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.56	-0.35	2.5e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg20119798	chr7:94954144	PON1	0.48	6.73	0.31	5.54e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2235544	0.579	rs1537322	chr1:54482306	G/T	cg25741118	chr1:54482237	LDLRAD1	-0.25	-6.78	-0.31	3.96e-11	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUAD	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg05234568	chr11:5960015	NA	-0.55	-10.06	-0.44	1.75e-21	DNA methylation (variation);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg21097640	chr13:28195548	POLR1D;LNX2	-0.4	-6.51	-0.3	2.07e-10	Subcortical brain region volumes;
LUAD	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg06618935	chr21:46677482	NA	-0.5	-10.01	-0.44	2.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1160297	0.576	rs12617374	chr2:53107105	C/T	cg07782112	chr2:53107842	NA	0.38	8.17	0.37	3.61e-15	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.71	0.31	6.24e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg26384229	chr12:38710491	ALG10B	0.5	8.11	0.37	5.64e-15	Heart rate;
LUAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg16606324	chr3:10149918	C3orf24	-0.66	-11.05	-0.47	4.01e-25	Alzheimer's disease;
LUAD	cis	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-8.21	-0.37	2.76e-15	Neuroticism;
LUAD	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg08989290	chr16:615782	NHLRC4	0.31	6.81	0.31	3.32e-11	Height;
LUAD	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg01579765	chr21:45077557	HSF2BP	-0.61	-13.65	-0.55	2.15e-35	Mean corpuscular volume;
LUAD	cis	rs12505328	0.966	rs11731804	chr4:174375754	A/T	cg12145043	chr4:174357286	NA	0.56	10.37	0.45	1.36e-22	Chin dimples;
LUAD	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg20290983	chr6:43655470	MRPS18A	0.82	16.37	0.62	5.15e-47	IgG glycosylation;
LUAD	cis	rs853679	0.607	rs13217619	chr6:28306671	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.55	6.45	0.3	3.1e-10	Depression;
LUAD	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12292205	chr6:26970375	C6orf41	-0.49	-6.77	-0.31	4.43e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs11893307	0.509	rs2356126	chr2:191542514	C/T	cg27211696	chr2:191398769	TMEM194B	-0.43	-6.81	-0.31	3.32e-11	Mean platelet volume;
LUAD	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg00981070	chr1:2046702	PRKCZ	-0.35	-7.09	-0.33	5.69e-12	Height;
LUAD	trans	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg26043149	chr18:55253948	FECH	0.49	7.95	0.36	1.69e-14	Bone mineral density;
LUAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg03188948	chr7:1209495	NA	0.83	10.16	0.44	7.81e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg26587870	chr6:27730563	NA	-0.5	-8.25	-0.37	2.08e-15	Parkinson's disease;
LUAD	cis	rs600626	0.636	rs10899110	chr11:75452342	C/G	cg24262691	chr11:75473276	NA	0.55	7.17	0.33	3.42e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.32	6.44	0.3	3.19e-10	Obesity-related traits;
LUAD	trans	rs3960554	0.808	rs2302434	chr7:75630183	C/T	cg19862616	chr7:65841803	NCRNA00174	0.82	11.26	0.48	6.76e-26	Eotaxin levels;
LUAD	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.57	-0.35	2.42e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg26597838	chr10:835615	NA	0.77	10.32	0.45	2e-22	Eosinophil percentage of granulocytes;
LUAD	cis	rs62458065	0.850	rs28677012	chr7:32469811	C/A	cg20159608	chr7:32802032	NA	-0.58	-7.7	-0.35	9.47e-14	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-10.44	-0.45	7.32e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg03388025	chr16:89894329	SPIRE2	0.47	12.17	0.51	2.02e-29	Vitiligo;
LUAD	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg06873352	chr17:61820015	STRADA	-0.65	-12.56	-0.52	5.58e-31	Prudent dietary pattern;
LUAD	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg07677032	chr17:61819896	STRADA	0.48	8.43	0.38	5.39e-16	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.06	0.37	7.62e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg04155289	chr7:94953770	PON1	-0.52	-6.9	-0.32	1.93e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24531977	chr5:56204891	C5orf35	-0.97	-15.04	-0.59	2.86e-41	Initial pursuit acceleration;
LUAD	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg06387496	chr7:2775674	GNA12	-0.38	-6.41	-0.3	3.94e-10	Height;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg21139845	chr12:7053993	C12orf57	-0.44	-7.22	-0.33	2.44e-12	Subcortical brain region volumes;
LUAD	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.8	-0.43	1.47e-20	Schizophrenia;
LUAD	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg17724175	chr1:150552817	MCL1	0.29	6.7	0.31	6.5500000000000006e-11	Melanoma;
LUAD	cis	rs11051970	0.636	rs2651368	chr12:32561506	T/C	cg24626660	chr12:32551988	NA	0.34	7.3	0.33	1.48e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg21963583	chr11:68658836	MRPL21	0.65	11.37	0.48	2.52e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg11057378	chr10:81107060	PPIF	0.37	6.81	0.31	3.31e-11	Height;
LUAD	cis	rs8017423	0.904	rs2149647	chr14:90769539	C/T	cg14092571	chr14:90743983	NA	0.49	8.34	0.38	1.1e-15	Mortality in heart failure;
LUAD	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.61	-8.87	-0.4	2.09e-17	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg17366294	chr4:99064904	C4orf37	0.65	12.39	0.52	2.65e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg16325326	chr1:53192061	ZYG11B	-0.64	-11.82	-0.5	4.6e-28	Monocyte count;
LUAD	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25427524	chr10:38739819	LOC399744	0.78	15.06	0.59	2.47e-41	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg00933542	chr6:150070202	PCMT1	0.45	9.52	0.42	1.34e-19	Lung cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20284440	chr14:52118688	FRMD6	-0.42	-6.72	-0.31	5.71e-11	Height;
LUAD	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.34	6.48	0.3	2.57e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs9341808	0.690	rs9448909	chr6:80909031	G/A	cg08355045	chr6:80787529	NA	0.58	10.52	0.46	3.89e-23	Sitting height ratio;
LUAD	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg13606994	chr1:44402422	ARTN	-0.37	-7.43	-0.34	6.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg02951883	chr7:2050386	MAD1L1	-0.82	-14.16	-0.57	1.63e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.28	0.45	2.94e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-7.52	-0.34	3.31e-13	Morning vs. evening chronotype;
LUAD	cis	rs62229266	0.659	rs2835242	chr21:37413532	A/C	cg08632701	chr21:37451849	NA	-0.38	-6.44	-0.3	3.3e-10	Mitral valve prolapse;
LUAD	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg20701182	chr2:24300061	SF3B14	0.56	6.52	0.3	2.05e-10	Lymphocyte counts;
LUAD	trans	rs62103177	0.525	rs1835410	chr18:77702025	T/C	cg05926928	chr17:57297772	GDPD1	-0.88	-10.91	-0.47	1.44e-24	Opioid sensitivity;
LUAD	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg14582100	chr15:45693742	SPATA5L1	0.64	12.65	0.52	2.43e-31	Homoarginine levels;
LUAD	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg03467027	chr4:99064603	C4orf37	0.46	7.26	0.33	1.84e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12612619	0.732	rs11680032	chr2:27198148	C/T	cg00617064	chr2:27272375	NA	-0.35	-6.88	-0.32	2.12e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg07507251	chr3:52567010	NT5DC2	0.39	7.52	0.34	3.33e-13	Bipolar disorder;
LUAD	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.46	-0.49	1.18e-26	Type 2 diabetes;
LUAD	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg06627628	chr2:24431161	ITSN2	0.43	7.49	0.34	4.01e-13	Asthma;
LUAD	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg06636551	chr8:101224915	SPAG1	-0.38	-6.97	-0.32	1.23e-11	Atrioventricular conduction;
LUAD	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg02734326	chr4:10020555	SLC2A9	0.62	10.71	0.46	7.81e-24	Bone mineral density;
LUAD	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg25797454	chr6:150327115	RAET1K	0.37	7.76	0.35	6.26e-14	Alopecia areata;
LUAD	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg25324976	chr17:61989376	CSHL1	0.37	7.02	0.32	8.95e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg06620762	chr15:76136437	UBE2Q2	0.39	6.36	0.3	5.37e-10	Bilirubin levels;
LUAD	cis	rs4243830	0.850	rs1010584	chr1:6579843	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.74	-10.28	-0.45	2.8e-22	Body mass index;
LUAD	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.74	8.08	0.37	6.92e-15	Initial pursuit acceleration;
LUAD	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg16680214	chr1:154839983	KCNN3	-0.63	-13.23	-0.54	1.11e-33	Prostate cancer;
LUAD	cis	rs2996428	0.628	rs6667526	chr1:3774603	G/A	cg13057898	chr1:3703894	LRRC47	0.62	10.2	0.44	5.33e-22	Red cell distribution width;
LUAD	cis	rs2034088	0.833	rs7219151	chr17:440497	G/A	cg06217071	chr17:408420	NA	0.48	11.22	0.48	9.15e-26	Hip circumference adjusted for BMI;
LUAD	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg09455208	chr3:40491958	NA	-0.5	-10.33	-0.45	1.79e-22	Renal cell carcinoma;
LUAD	cis	rs8014204	0.720	rs34752362	chr14:75232306	G/A	cg06637938	chr14:75390232	RPS6KL1	0.36	6.52	0.3	2.05e-10	Caffeine consumption;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04281649	chr2:98612676	TMEM131	0.43	6.4	0.3	4.03e-10	Gut microbiome composition (summer);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23147149	chr17:2304328	MNT	-0.46	-7.28	-0.33	1.61e-12	Height;
LUAD	cis	rs4774899	0.869	rs2962993	chr15:57344066	A/C	cg14026238	chr15:57616123	NA	0.36	6.73	0.31	5.43e-11	Urinary tract infection frequency;
LUAD	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg05966235	chr16:28915196	ATP2A1	0.47	7.61	0.35	1.75e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg13319975	chr6:146136371	FBXO30	-0.59	-9.82	-0.43	1.2e-20	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs4799710	1.000	rs1941696	chr18:31252129	G/A	cg27147174	chr7:100797783	AP1S1	-0.4	-6.37	-0.3	4.95e-10	Pulmonary function;
LUAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg18402987	chr7:1209562	NA	0.79	9.65	0.42	4.67e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg23758822	chr17:41437982	NA	1.02	21.61	0.72	2.47e-70	Menopause (age at onset);
LUAD	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.31	-0.51	5.5e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	12.04	0.51	6.49e-29	Hip circumference adjusted for BMI;
LUAD	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg19442545	chr10:75533431	FUT11	-0.51	-8.81	-0.39	3.17e-17	Inflammatory bowel disease;
LUAD	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg14530993	chr4:882597	GAK	0.77	7.35	0.34	1.04e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-9.72	-0.43	2.63e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	cis	rs17818399	0.675	rs35949012	chr2:46860401	T/A	cg09399716	chr2:46890238	NA	-0.41	-7.81	-0.35	4.7e-14	Height;
LUAD	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg06199346	chr11:14280333	SPON1	-0.34	-7.14	-0.33	4.22e-12	Mitochondrial DNA levels;
LUAD	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.36	-6.57	-0.3	1.53e-10	Caffeine consumption;
LUAD	cis	rs9364220	0.623	rs6940507	chr6:168493719	T/C	cg02770688	chr6:168491649	NA	-0.37	-7.09	-0.33	5.77e-12	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
LUAD	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg20891283	chr12:69753455	YEATS4	0.46	7.32	0.34	1.25e-12	Blood protein levels;
LUAD	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.38	0.38	7.94e-16	Menopause (age at onset);
LUAD	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg05340658	chr4:99064831	C4orf37	0.51	8.5	0.38	3.34e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg03563238	chr19:33554763	RHPN2	-0.37	-8.57	-0.38	2.01e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10504073	0.584	rs74457150	chr8:49890753	C/G	cg00325661	chr8:49890786	NA	0.5	10.98	0.47	7.3e-25	Blood metabolite ratios;
LUAD	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11644478	chr21:40555479	PSMG1	0.6	9.44	0.42	2.62e-19	Cognitive function;
LUAD	cis	rs10203711	0.966	rs10167210	chr2:239601726	A/C	cg14580085	chr2:239553406	NA	-0.41	-8.97	-0.4	9.92e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg06877462	chr1:205807181	PM20D1	0.39	7.35	0.34	1.01e-12	Menarche (age at onset);
LUAD	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.49	8.22	0.37	2.57e-15	Alzheimer's disease (late onset);
LUAD	cis	rs7680126	0.632	rs78030862	chr4:10150412	G/A	cg00071950	chr4:10020882	SLC2A9	-0.58	-8.25	-0.37	1.97e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg21016266	chr12:122356598	WDR66	-0.68	-12.45	-0.52	1.53e-30	Mean corpuscular volume;
LUAD	cis	rs2637266	1.000	rs2579747	chr10:78327759	C/T	cg18941641	chr10:78392320	NA	0.31	6.38	0.3	4.66e-10	Pulmonary function;
LUAD	cis	rs2686555	0.553	rs1616213	chr12:121077508	C/T	cg18477009	chr12:121087777	CABP1	0.45	7.8	0.35	4.98e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs8014204	0.804	rs2287403	chr14:75259140	C/T	cg06637938	chr14:75390232	RPS6KL1	0.38	6.85	0.32	2.55e-11	Caffeine consumption;
LUAD	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg16060761	chr17:80687452	NA	0.45	6.73	0.31	5.67e-11	Breast cancer;
LUAD	trans	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg20587970	chr11:113659929	NA	0.71	10.79	0.46	3.95e-24	Hip circumference adjusted for BMI;
LUAD	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg06453172	chr10:134556979	INPP5A	-0.78	-10.89	-0.47	1.65e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs77861329	1.000	rs9868101	chr3:52138377	T/C	cg08692210	chr3:52188851	WDR51A	0.83	7.75	0.35	6.7e-14	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs2615252	1	rs2615252	chr15:57473075	T/C	cg14026238	chr15:57616123	NA	0.39	7.41	0.34	7.16e-13	Urinary tract infection frequency;
LUAD	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.5e-19	Life satisfaction;
LUAD	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg13736514	chr6:26305472	NA	0.45	7.32	0.34	1.3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4711336	1.000	rs764752	chr6:33658066	G/C	cg13859433	chr6:33739653	LEMD2	-0.3	-6.85	-0.32	2.65e-11	Height;
LUAD	trans	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg20587970	chr11:113659929	NA	-0.71	-10.98	-0.47	7.36e-25	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg16606324	chr3:10149918	C3orf24	0.65	10.77	0.46	4.51e-24	Alzheimer's disease;
LUAD	cis	rs2067615	0.579	rs7964605	chr12:107205413	C/T	cg15890332	chr12:107067104	RFX4	-0.39	-8.43	-0.38	5.65e-16	Heart rate;
LUAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg08219700	chr8:58056026	NA	0.42	6.56	0.3	1.53e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs753778	1.000	rs753778	chr8:142228909	G/A	cg18755752	chr8:142205143	DENND3	-0.46	-7.55	-0.34	2.75e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7187994	0.848	rs3764333	chr16:84793261	A/G	cg07647771	chr16:84786436	USP10	-0.37	-9.55	-0.42	1.06e-19	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.43	0.3	3.49e-10	Cognitive test performance;
LUAD	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg25985355	chr7:65971099	NA	0.39	7.28	0.33	1.6e-12	Aortic root size;
LUAD	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg15147215	chr3:52552868	STAB1	-0.41	-7.48	-0.34	4.25e-13	Bipolar disorder;
LUAD	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg06740227	chr12:86229804	RASSF9	0.4	7.09	0.33	5.5e-12	Major depressive disorder;
LUAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.42	-0.34	6.41e-13	Electroencephalogram traits;
LUAD	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs220324	0.738	rs9983523	chr21:43578837	C/G	cg09727148	chr21:43560719	UMODL1	0.55	7.82	0.36	4.12e-14	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7586879	0.789	rs13035239	chr2:25134000	T/A	cg04586622	chr2:25135609	ADCY3	0.37	7.49	0.34	3.94e-13	Body mass index;
LUAD	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg17644776	chr2:200775616	C2orf69	0.55	7.23	0.33	2.32e-12	Schizophrenia;
LUAD	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg16325326	chr1:53192061	ZYG11B	-0.5	-8.17	-0.37	3.67e-15	Monocyte count;
LUAD	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg26818010	chr10:134567672	INPP5A	-0.87	-14.94	-0.59	7.49e-41	Migraine;
LUAD	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg19610905	chr11:61596333	FADS2	-0.65	-9.77	-0.43	1.8899999999999998e-20	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg07828340	chr4:882639	GAK	1.0	10.36	0.45	1.47e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs7177699	0.557	rs7164479	chr15:79123054	C/T	cg00540400	chr15:79124168	NA	0.44	9.73	0.43	2.48e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	trans	rs3857536	0.813	rs1029399	chr6:66952476	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.52	-0.3	2.04e-10	Blood trace element (Cu levels);
LUAD	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg26769984	chr7:1090371	C7orf50	0.58	9.72	0.43	2.78e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs10744422	1.000	rs2292134	chr12:123334033	C/G	cg16953816	chr12:123349952	VPS37B	0.59	6.64	0.31	9.46e-11	Schizophrenia;
LUAD	cis	rs5756813	0.754	rs15691	chr22:38172380	C/A	cg06521852	chr22:38141419	TRIOBP	0.49	9.25	0.41	1.1e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	7.28	0.33	1.62e-12	Alzheimer's disease;
LUAD	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg03806693	chr22:41940476	POLR3H	-0.57	-8.44	-0.38	5.1e-16	Vitiligo;
LUAD	trans	rs7395662	0.963	rs6485906	chr11:48651661	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.21	-0.33	2.52e-12	HDL cholesterol;
LUAD	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.38	-0.3	4.53e-10	Mood instability;
LUAD	cis	rs55823223	0.618	rs72860390	chr17:73869914	A/G	cg12714757	chr17:73874637	TRIM47	-0.48	-7.4	-0.34	7.17e-13	Psoriasis;
LUAD	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.41	6.42	0.3	3.71e-10	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-11.68	-0.49	1.6e-27	Bipolar disorder;
LUAD	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg25036284	chr2:26402008	FAM59B	-0.58	-8.17	-0.37	3.48e-15	Gut microbiome composition (summer);
LUAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03452623	chr4:187889614	NA	-0.82	-16.69	-0.63	2.13e-48	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs938554	0.657	rs9994216	chr4:9984541	G/T	cg11266682	chr4:10021025	SLC2A9	0.42	7.88	0.36	2.85e-14	Blood metabolite levels;
LUAD	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.13	-0.37	4.77e-15	Total body bone mineral density;
LUAD	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.11	-0.4	3.42e-18	Total body bone mineral density;
LUAD	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg27454412	chr7:1067447	C7orf50	-0.34	-6.66	-0.31	8.72e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg03579179	chr7:12444095	VWDE	-0.42	-6.39	-0.3	4.29e-10	Coronary artery disease;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg10964887	chr6:84937691	KIAA1009	0.42	6.87	0.32	2.33e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg06808227	chr14:105710500	BRF1	-0.42	-6.36	-0.3	5.13e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs11676348	0.774	rs11683524	chr2:218984604	G/A	cg06547715	chr2:218990976	CXCR2	0.32	7.25	0.33	2.04e-12	Ulcerative colitis;
LUAD	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg10518543	chr12:38710700	ALG10B	0.42	6.47	0.3	2.71e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.41	-0.34	6.98e-13	Coronary artery disease;
LUAD	trans	rs1997103	1.000	rs2177804	chr7:55410302	G/A	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg20587970	chr11:113659929	NA	-1.4	-20.92	-0.71	2.99e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs7010267	0.596	rs4336637	chr8:120016636	C/T	cg01975934	chr8:119970761	NA	-0.35	-6.67	-0.31	7.96e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs11771526	0.901	rs62456038	chr7:32288663	G/A	cg13207630	chr7:32358064	NA	0.64	7.65	0.35	1.33e-13	Body mass index;
LUAD	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg02527881	chr3:46936655	PTH1R	-0.54	-11.17	-0.48	1.47e-25	Colorectal cancer;
LUAD	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.16	0.33	3.68e-12	Motion sickness;
LUAD	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg25767906	chr1:53392781	SCP2	-0.4	-7.08	-0.33	5.97e-12	Monocyte count;
LUAD	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.35	0.34	1e-12	Bipolar disorder;
LUAD	trans	rs9393777	0.778	rs4452638	chr6:27229265	A/G	cg06606381	chr12:133084897	FBRSL1	0.96	9.98	0.44	3.22e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08219700	chr8:58056026	NA	0.67	12.5	0.52	1.03e-30	Developmental language disorder (linguistic errors);
LUAD	cis	rs375066	0.762	rs239943	chr19:44374716	A/T	cg12072164	chr19:44306565	LYPD5	0.33	6.7	0.31	6.63e-11	Breast cancer;
LUAD	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg14895029	chr7:2775587	GNA12	-0.4	-6.45	-0.3	2.98e-10	Height;
LUAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg26516362	chr5:178986906	RUFY1	0.59	10.38	0.45	1.26e-22	Lung cancer;
LUAD	trans	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg25894440	chr7:65020034	NA	-0.63	-6.67	-0.31	8.15e-11	Diabetic kidney disease;
LUAD	trans	rs2262909	0.962	rs12609368	chr19:22263996	T/C	cg05197062	chr11:11642011	GALNTL4	0.6	9.18	0.41	1.96e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9581857	0.547	rs76971629	chr13:28051031	C/T	cg22138327	chr13:27999177	GTF3A	0.85	9.38	0.41	4.05e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg10792982	chr14:105748885	BRF1	0.46	9.91	0.43	5.74e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg27454412	chr7:1067447	C7orf50	0.44	7.07	0.33	6.35e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg22907277	chr7:1156413	C7orf50	0.79	12.13	0.51	2.99e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg11693508	chr17:37793320	STARD3	0.81	10.2	0.44	5.63e-22	Bipolar disorder;
LUAD	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg27446573	chr6:127587934	RNF146	0.45	6.64	0.31	9.54e-11	Breast cancer;
LUAD	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.7	-11.74	-0.5	9.22e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08219700	chr8:58056026	NA	0.69	9.27	0.41	9.62e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg17366294	chr4:99064904	C4orf37	0.65	12.64	0.52	2.71e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.43	6.75	0.31	4.86e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg15445000	chr17:37608096	MED1	0.44	8.19	0.37	3.14e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs2637266	1.000	rs12251568	chr10:78345667	C/T	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.26e-11	Pulmonary function;
LUAD	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg20283391	chr11:68216788	NA	-0.42	-6.63	-0.31	1.01e-10	Total body bone mineral density;
LUAD	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg25754956	chr12:51612065	POU6F1	0.52	7.89	0.36	2.7e-14	Cisplatin-induced ototoxicity;
LUAD	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg05865280	chr17:75406074	SEPT9	0.61	19.3	0.68	5.44e-60	Airflow obstruction;
LUAD	cis	rs711245	0.732	rs848643	chr2:36782387	G/A	cg01206211	chr2:36825736	FEZ2	0.45	8.15	0.37	4.06e-15	Height;
LUAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg05896524	chr21:47604654	C21orf56	-0.77	-13.55	-0.55	5.23e-35	Testicular germ cell tumor;
LUAD	trans	rs17685	0.515	rs111240556	chr7:75600863	T/C	cg19862616	chr7:65841803	NCRNA00174	0.66	11.56	0.49	4.83e-27	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg21194808	chr1:2205498	SKI	0.4	6.36	0.3	5.16e-10	Height;
LUAD	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-6.57	-0.3	1.45e-10	Personality dimensions;
LUAD	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg15468180	chr1:107600409	PRMT6	0.45	7.6	0.35	1.93e-13	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4889911	0.544	rs1294081	chr17:77829864	T/C	cg00646381	chr17:77835854	NA	0.53	8.72	0.39	6.58e-17	Electroencephalogram traits;
LUAD	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	trans	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.52	8.06	0.36	7.83e-15	Platelet count;
LUAD	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01570182	chr17:44337453	NA	-0.94	-13.85	-0.56	3.18e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs7200543	0.884	rs72789542	chr16:15127535	C/A	cg24683922	chr1:11983373	KIAA2013	-0.5	-8.22	-0.37	2.46e-15	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg15448220	chr1:150897856	SETDB1	-0.46	-7.89	-0.36	2.54e-14	Tonsillectomy;
LUAD	cis	rs925255	0.747	rs6547850	chr2:28629343	G/T	cg01273330	chr2:28605224	NA	0.32	7.05	0.32	7.51e-12	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2346177	0.519	rs35509718	chr2:46696793	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-7.95	-0.36	1.7e-14	HDL cholesterol;
LUAD	cis	rs713587	1.000	rs2384054	chr2:25156773	T/C	cg01884057	chr2:25150051	NA	0.39	8.5	0.38	3.36e-16	Body mass index in non-asthmatics;
LUAD	cis	rs7677751	0.806	rs7673027	chr4:55096180	T/A	cg17187183	chr4:55093834	PDGFRA	0.51	8.63	0.39	1.23e-16	Corneal astigmatism;
LUAD	trans	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg14917512	chr19:3094685	GNA11	-0.56	-6.5	-0.3	2.21e-10	Diabetic kidney disease;
LUAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg11494091	chr17:61959527	GH2	0.74	18.58	0.67	9.11e-57	Prudent dietary pattern;
LUAD	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	9.07	0.4	4.47e-18	Tonsillectomy;
LUAD	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg03453431	chr7:157225567	NA	-0.5	-8.93	-0.4	1.36e-17	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg04369109	chr6:150039330	LATS1	-0.44	-7.29	-0.33	1.54e-12	Lung cancer;
LUAD	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12310025	chr6:25882481	NA	-0.55	-8.06	-0.37	7.7e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.46	0.38	4.49e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg08508325	chr11:3079039	CARS	-0.57	-12.48	-0.52	1.14e-30	Longevity;
LUAD	cis	rs9517313	0.523	rs4772104	chr13:99235677	G/A	cg20487152	chr13:99095054	FARP1	-0.49	-8.07	-0.37	7.37e-15	Neuroticism;
LUAD	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18404041	chr3:52824283	ITIH1	-0.61	-12.19	-0.51	1.71e-29	Bipolar disorder;
LUAD	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.24	0.33	2.19e-12	Tonsillectomy;
LUAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00149659	chr3:10157352	C3orf10	0.54	7.55	0.34	2.71e-13	Alzheimer's disease;
LUAD	cis	rs4285028	0.747	rs4048703	chr3:121374361	G/A	cg11130432	chr3:121712080	ILDR1	-0.47	-6.52	-0.3	2e-10	Multiple sclerosis;
LUAD	cis	rs11650175	0.835	rs17695154	chr17:63771970	T/C	cg07283582	chr17:63770753	CCDC46	0.37	7.26	0.33	1.89e-12	Chin dimples;
LUAD	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12756686	chr19:29218302	NA	0.67	9.78	0.43	1.7e-20	Methadone dose in opioid dependence;
LUAD	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg03733263	chr8:22462867	KIAA1967	-0.62	-10.57	-0.46	2.56e-23	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs6835098	1.000	rs10031414	chr4:174084953	A/C	cg27433088	chr4:174089019	GALNT7	0.39	7.5	0.34	3.85e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs7945705	0.776	rs2316865	chr11:8815470	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.49	8.7	0.39	7.25e-17	Hemoglobin concentration;
LUAD	cis	rs12541635	0.966	rs12550587	chr8:106978289	C/T	cg10147462	chr8:107024639	NA	0.47	8.2	0.37	3.01e-15	Age of smoking initiation;
LUAD	cis	rs7493	0.851	rs11770903	chr7:95026327	A/G	cg04155289	chr7:94953770	PON1	-0.55	-7.61	-0.35	1.82e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg12573674	chr2:1569213	NA	-0.59	-8.64	-0.39	1.19e-16	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7809950	0.817	rs10224503	chr7:107075569	A/C	cg23024343	chr7:107201750	COG5	-0.85	-14.48	-0.58	7.24e-39	Coronary artery disease;
LUAD	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08677398	chr8:58056175	NA	0.48	6.38	0.3	4.6e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg09367891	chr1:107599246	PRMT6	-0.51	-8.58	-0.38	1.85e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg17279839	chr7:150038598	RARRES2	0.42	7.13	0.33	4.24e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs2235649	0.833	rs7189070	chr16:1850813	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.4	-6.44	-0.3	3.26e-10	Blood metabolite levels;
LUAD	cis	rs3789045	1.000	rs3789045	chr1:204586812	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.39	-6.6	-0.31	1.23e-10	Educational attainment (college completion);
LUAD	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg14092988	chr3:52407081	DNAH1	0.38	7.77	0.35	5.95e-14	Bipolar disorder;
LUAD	cis	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg07460842	chr6:66804631	NA	1.05	16.39	0.62	4.09e-47	Exhaled nitric oxide output;
LUAD	cis	rs9837602	1.000	rs4075038	chr3:99680086	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	7.29	0.33	1.51e-12	Breast cancer;
LUAD	cis	rs9535307	0.719	rs1198315	chr13:50370168	C/T	cg04663916	chr13:50265991	EBPL	-0.58	-6.57	-0.3	1.5e-10	Obesity-related traits;
LUAD	cis	rs9469913	0.808	rs2744971	chr6:34581636	T/G	cg14254433	chr6:34482411	PACSIN1	-0.43	-6.72	-0.31	6.06e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg08773314	chr2:239334832	ASB1	-0.48	-11.05	-0.47	4.27e-25	Multiple system atrophy;
LUAD	cis	rs9875589	0.509	rs1906538	chr3:14014169	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	7.17	0.33	3.37e-12	Ovarian reserve;
LUAD	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.56	0.52	5.53e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg21433313	chr16:3507492	NAT15	0.76	13.6	0.55	3.44e-35	Tuberculosis;
LUAD	trans	rs12517041	1.000	rs4701219	chr5:23284067	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.47	-0.3	2.73e-10	Calcium levels;
LUAD	cis	rs3761847	0.622	rs4837807	chr9:123792005	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	6.52	0.3	1.95e-10	Rheumatoid arthritis;
LUAD	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg18306943	chr3:40428807	ENTPD3	0.36	6.37	0.3	5.05e-10	Renal cell carcinoma;
LUAD	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg03213289	chr20:61660250	NA	0.69	14.76	0.58	4.6e-40	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs71478720	0.953	rs11606049	chr11:112033129	C/T	cg26534425	chr11:112034925	IL18	0.44	6.61	0.31	1.19e-10	Interleukin-18 levels;
LUAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg18621852	chr3:10150065	C3orf24	0.45	7.08	0.33	5.94e-12	Alzheimer's disease;
LUAD	cis	rs12545109	0.800	rs2576602	chr8:57394495	C/T	cg07080864	chr8:57359956	PENK	-0.37	-6.42	-0.3	3.72e-10	Obesity-related traits;
LUAD	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg23503501	chr22:45809793	SMC1B;RIBC2	0.71	7.83	0.36	4.03e-14	Tonsillectomy;
LUAD	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg27432699	chr2:27873401	GPN1	-0.4	-6.78	-0.31	4.01e-11	Total body bone mineral density;
LUAD	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	18.34	0.67	1.09e-55	Bone mineral density;
LUAD	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg24829409	chr8:58192753	C8orf71	-0.62	-9.38	-0.42	3.98e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs4253772	1.000	rs11705483	chr22:46630544	C/A	cg09491104	chr22:46646882	C22orf40	-0.5	-6.76	-0.31	4.69e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs17152411	1.000	rs61873277	chr10:126619331	C/A	cg07906193	chr10:126599966	NA	0.55	7.61	0.35	1.79e-13	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12810402	chr2:24240148	MFSD2B	0.45	6.49	0.3	2.43e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg04287289	chr16:89883240	FANCA	0.49	7.77	0.35	5.91e-14	Vitiligo;
LUAD	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.19	-0.37	3.2e-15	Cannabis dependence symptom count;
LUAD	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.94	-0.36	1.86e-14	Monocyte chemoattractant protein-1 levels;
LUAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg16606324	chr3:10149918	C3orf24	0.7	11.51	0.49	7.19e-27	Alzheimer's disease;
LUAD	cis	rs752010	0.902	rs60743712	chr1:42076629	G/A	cg06885757	chr1:42089581	HIVEP3	0.47	10.27	0.45	3.09e-22	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg02574844	chr11:5959923	NA	-0.43	-7.51	-0.34	3.61e-13	DNA methylation (variation);
LUAD	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01332181	chr19:47290716	SLC1A5	-0.56	-6.65	-0.31	8.98e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7100689	0.646	rs10736346	chr10:82134281	A/C	cg00277334	chr10:82204260	NA	-0.63	-10.54	-0.46	3.26e-23	Post bronchodilator FEV1;
LUAD	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.77e-11	Depression;
LUAD	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg12011299	chr4:100065546	ADH4	0.68	14.33	0.57	3.03e-38	Alcohol dependence;
LUAD	cis	rs9469913	0.740	rs2814983	chr6:34591207	A/G	cg17674042	chr6:34482479	PACSIN1	-0.42	-6.37	-0.3	4.96e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg17063962	chr7:91808500	NA	-0.61	-10.19	-0.44	6e-22	Breast cancer;
LUAD	cis	rs7680126	0.633	rs11727390	chr4:10296760	C/T	cg02734326	chr4:10020555	SLC2A9	-0.5	-6.66	-0.31	8.46e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg18200150	chr17:30822561	MYO1D	0.44	8.23	0.37	2.39e-15	Schizophrenia;
LUAD	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg00898013	chr13:113819073	PROZ	-0.65	-11.74	-0.5	9.38e-28	Platelet distribution width;
LUAD	trans	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-11.13	-0.48	2.02e-25	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.67	0.31	8.17e-11	Depression;
LUAD	cis	rs7582720	0.943	rs72926800	chr2:203829225	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1448094	0.842	rs10779231	chr12:86462237	T/C	cg02569458	chr12:86230093	RASSF9	-0.37	-7.04	-0.32	8.01e-12	Major depressive disorder;
LUAD	trans	rs75565482	0.793	rs78666229	chr1:168473129	C/T	cg05043794	chr9:111880884	C9orf5	0.75	6.38	0.3	4.61e-10	Emphysema imaging phenotypes;
LUAD	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18404041	chr3:52824283	ITIH1	-0.6	-12.1	-0.51	3.81e-29	Bipolar disorder;
LUAD	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg20628663	chr10:43360327	NA	0.74	11.33	0.48	3.53e-26	Blood protein levels;
LUAD	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg18180107	chr4:99064573	C4orf37	0.47	7.36	0.34	9.69e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2067615	0.579	rs4385986	chr12:107133775	C/T	cg15890332	chr12:107067104	RFX4	0.39	8.34	0.38	1.02e-15	Heart rate;
LUAD	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7584330	0.518	rs74003105	chr2:238446851	T/C	cg14458575	chr2:238380390	NA	0.76	11.07	0.47	3.54e-25	Prostate cancer;
LUAD	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg11915388	chr22:42470451	FAM109B	0.39	6.92	0.32	1.69e-11	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs11039798	0.841	rs7950737	chr11:48590678	T/G	cg02254774	chr11:50257496	LOC441601	0.51	6.56	0.3	1.57e-10	Axial length;
LUAD	cis	rs2735413	0.709	rs9938043	chr16:78091426	A/G	cg04733911	chr16:78082701	NA	-0.37	-8.67	-0.39	9.11e-17	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.66	-0.35	1.3e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs617219	0.550	rs115009495	chr5:78433831	C/T	cg25119155	chr5:78426943	BHMT	0.37	6.53	0.3	1.92e-10	Betaine levels in individuals undergoing cardiac evaluation;
LUAD	cis	rs4604732	0.631	rs12038793	chr1:247624262	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.5	-8.79	-0.39	3.78e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg01620082	chr3:125678407	NA	-0.51	-6.75	-0.31	4.76e-11	Depression;
LUAD	cis	rs11126435	0.858	rs363624	chr2:74930842	A/G	cg19285774	chr2:74907978	SEMA4F	0.37	6.53	0.3	1.92e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs12545109	0.571	rs7002482	chr8:57295200	C/T	cg09654669	chr8:57350985	NA	-0.69	-9.68	-0.43	3.74e-20	Obesity-related traits;
LUAD	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg11915388	chr22:42470451	FAM109B	0.41	7.35	0.34	1.02e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg11584989	chr19:19387371	SF4	0.61	9.06	0.4	5.02e-18	Bipolar disorder;
LUAD	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.55	8.82	0.39	3.13e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12681288	0.963	rs7822955	chr8:1029090	C/T	cg15309053	chr8:964076	NA	-0.31	-6.6	-0.31	1.27e-10	Schizophrenia;
LUAD	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg19743168	chr1:23544995	NA	0.36	6.41	0.3	3.81e-10	Height;
LUAD	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg25358565	chr5:93447407	FAM172A	0.62	7.38	0.34	8.39e-13	Diabetic retinopathy;
LUAD	cis	rs6905628	1	rs6905628	chr6:90344869	C/G	cg23505970	chr6:90529759	MDN1	0.62	8.98	0.4	9.28e-18	Coronary artery disease;
LUAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg13560548	chr3:10150139	C3orf24	0.44	7.44	0.34	5.51e-13	Alzheimer's disease;
LUAD	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.68	12.21	0.51	1.39e-29	Cognitive ability;
LUAD	cis	rs755249	0.501	rs2490945	chr1:39837344	T/C	cg27567593	chr1:39956653	BMP8A	-0.34	-6.68	-0.31	7.48e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg25358565	chr5:93447407	FAM172A	0.62	7.8	0.35	4.92e-14	Diabetic retinopathy;
LUAD	cis	rs986417	0.818	rs10144990	chr14:60927816	T/C	cg27398547	chr14:60952738	C14orf39	0.65	7.69	0.35	1.02e-13	Gut microbiota (bacterial taxa);
LUAD	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.02	-0.36	1.03e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg01620082	chr3:125678407	NA	-0.44	-6.55	-0.3	1.66e-10	Depression;
LUAD	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg05340658	chr4:99064831	C4orf37	0.46	7.05	0.32	7.26e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4285028	0.948	rs34543553	chr3:121675637	C/T	cg11130432	chr3:121712080	ILDR1	-0.59	-8.37	-0.38	8.74e-16	Multiple sclerosis;
LUAD	cis	rs2227564	0.597	rs12256103	chr10:75545251	A/G	cg23231163	chr10:75533350	FUT11	-0.44	-6.87	-0.32	2.33e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg17366294	chr4:99064904	C4orf37	-0.51	-8.97	-0.4	9.47e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs790123	1.000	rs2650950	chr3:122382048	C/T	cg17380795	chr3:122379686	NA	0.48	8.07	0.37	7.2e-15	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs2224391	1.000	rs2753248	chr6:5262154	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-9.86	-0.43	9.13e-21	Height;
LUAD	cis	rs790123	0.581	rs2877628	chr3:122352678	A/G	cg15604389	chr3:122379662	NA	0.41	7.14	0.33	4.12e-12	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg21226059	chr5:178986404	RUFY1	-0.7	-11.89	-0.5	2.54e-28	Lung cancer;
LUAD	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg09367891	chr1:107599246	PRMT6	0.57	9.5	0.42	1.6e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg17724175	chr1:150552817	MCL1	0.38	8.76	0.39	4.72e-17	Melanoma;
LUAD	cis	rs4713675	0.565	rs9368773	chr6:33682541	C/A	cg14003231	chr6:33640908	ITPR3	0.5	9.62	0.42	5.93e-20	Plateletcrit;
LUAD	cis	rs420259	0.516	rs7199108	chr16:23548801	G/A	cg00143387	chr16:23521605	GGA2	-0.73	-10.03	-0.44	2.27e-21	Bipolar disorder;
LUAD	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg14092988	chr3:52407081	DNAH1	0.34	6.88	0.32	2.21e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg02176678	chr2:219576539	TTLL4	0.61	11.85	0.5	3.46e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg00933542	chr6:150070202	PCMT1	0.46	9.36	0.41	4.83e-19	Lung cancer;
LUAD	cis	rs2637266	0.756	rs846623	chr10:78542819	C/T	cg18941641	chr10:78392320	NA	0.31	6.38	0.3	4.68e-10	Pulmonary function;
LUAD	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg22875332	chr1:76189707	ACADM	0.92	19.03	0.68	8.59e-59	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg09658497	chr7:2847517	GNA12	-0.46	-8.5	-0.38	3.25e-16	Height;
LUAD	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg11673840	chr17:47092156	IGF2BP1	-0.37	-7.17	-0.33	3.44e-12	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg17863274	chr19:49399704	TULP2	-0.55	-8.41	-0.38	6.34e-16	Red cell distribution width;
LUAD	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23583168	chr7:148888333	NA	-0.8	-14.01	-0.56	6.95e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs909002	0.830	rs1356803	chr1:32131163	C/G	cg13919466	chr1:32135498	COL16A1	-0.41	-9.64	-0.42	5.23e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs17253792	0.822	rs76264681	chr14:56060447	T/C	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg08888203	chr3:10149979	C3orf24	0.72	12.87	0.53	3.25e-32	Alzheimer's disease;
LUAD	cis	rs62400317	0.859	rs12199256	chr6:45303493	T/G	cg18551225	chr6:44695536	NA	-0.55	-8.55	-0.38	2.2e-16	Total body bone mineral density;
LUAD	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11890956	chr21:40555474	PSMG1	0.77	12.97	0.53	1.27e-32	Cognitive function;
LUAD	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg08885076	chr2:99613938	TSGA10	-0.4	-7.12	-0.33	4.62e-12	Chronic sinus infection;
LUAD	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg00147160	chr1:26503991	CNKSR1	0.38	8.84	0.39	2.66e-17	Height;
LUAD	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg22482690	chr17:47019901	SNF8	0.44	8.37	0.38	8.71e-16	Type 2 diabetes;
LUAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08280861	chr8:58055591	NA	0.67	8.72	0.39	6.27e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg15181151	chr6:150070149	PCMT1	-0.33	-6.55	-0.3	1.67e-10	Testicular germ cell tumor;
LUAD	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg00310523	chr12:86230176	RASSF9	0.37	7.85	0.36	3.51e-14	Major depressive disorder;
LUAD	cis	rs6906287	0.559	rs7751467	chr6:118893861	T/A	cg21191810	chr6:118973309	C6orf204	0.5	9.57	0.42	9.12e-20	Electrocardiographic conduction measures;
LUAD	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg14829155	chr15:31115871	NA	-0.58	-9.5	-0.42	1.56e-19	Huntington's disease progression;
LUAD	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg05340658	chr4:99064831	C4orf37	0.54	8.71	0.39	6.8e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg20673091	chr1:2541236	MMEL1	0.39	8.11	0.37	5.38e-15	Ulcerative colitis;
LUAD	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg03929089	chr4:120376271	NA	-0.64	-10.43	-0.45	7.9399999999999994e-23	Coronary artery disease;
LUAD	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg08213375	chr14:104286397	PPP1R13B	-0.28	-7.14	-0.33	4.19e-12	Schizophrenia;
LUAD	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg06640241	chr16:89574553	SPG7	0.48	7.95	0.36	1.68e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.89	9.56	0.42	9.77e-20	Initial pursuit acceleration;
LUAD	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg00071950	chr4:10020882	SLC2A9	0.74	14.9	0.59	1.18e-40	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.7	-11.62	-0.49	2.7e-27	Primary sclerosing cholangitis;
LUAD	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.35	6.73	0.31	5.64e-11	Depression;
LUAD	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg12292205	chr6:26970375	C6orf41	0.49	8.33	0.38	1.1e-15	Schizophrenia;
LUAD	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.817	rs12051834	chr17:28192785	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.51	0.42	1.41e-19	Coffee consumption (cups per day);
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg04347006	chr1:3688759	LOC388588	0.37	6.58	0.3	1.38e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg26384229	chr12:38710491	ALG10B	0.52	8.42	0.38	5.96e-16	Heart rate;
LUAD	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg07404485	chr7:94953653	PON1	-0.52	-7.3	-0.33	1.43e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs733175	0.855	rs6853437	chr4:10005435	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-6.86	-0.32	2.42e-11	Psychosis and Alzheimer's disease;
LUAD	cis	rs2731664	0.792	rs163199	chr5:176890067	A/G	cg23176889	chr5:176863531	GRK6	-0.75	-14.82	-0.58	2.61e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.17	0.37	3.53e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7809950	0.862	rs2299421	chr7:106946195	C/G	cg23024343	chr7:107201750	COG5	-0.62	-10.27	-0.45	2.94e-22	Coronary artery disease;
LUAD	cis	rs921968	0.528	rs13382651	chr2:219628191	A/G	cg02176678	chr2:219576539	TTLL4	-0.6	-12.18	-0.51	1.92e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7633770	0.710	rs34820891	chr3:46698059	A/G	cg11219411	chr3:46661640	NA	-0.41	-8.58	-0.39	1.79e-16	Coronary artery disease;
LUAD	cis	rs977987	0.806	rs4888390	chr16:75400320	G/A	cg03315344	chr16:75512273	CHST6	0.65	14.03	0.56	5.38e-37	Dupuytren's disease;
LUAD	cis	rs713587	0.563	rs10865315	chr2:25100738	C/A	cg01884057	chr2:25150051	NA	0.31	6.48	0.3	2.56e-10	Body mass index in non-asthmatics;
LUAD	cis	rs208520	1.000	rs208521	chr6:66953625	C/T	cg07460842	chr6:66804631	NA	-0.97	-13.16	-0.54	2.25e-33	Exhaled nitric oxide output;
LUAD	cis	rs10129255	0.500	rs8014529	chr14:107192302	G/A	cg07958169	chr14:107095056	NA	-0.37	-7.36	-0.34	9.91e-13	Kawasaki disease;
LUAD	cis	rs13095912	0.819	rs11918734	chr3:185296602	T/C	cg11274856	chr3:185301563	NA	0.48	8.72	0.39	6.37e-17	Systolic blood pressure;
LUAD	cis	rs9394169	0.536	rs3998115	chr6:33784833	G/C	cg13859433	chr6:33739653	LEMD2	-0.34	-7.83	-0.36	4.09e-14	Essential tremor;
LUAD	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg04545296	chr12:48745243	ZNF641	0.43	10.75	0.46	5.24e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs1559088	0.895	rs7246562	chr19:33546088	T/G	cg03563238	chr19:33554763	RHPN2	-0.38	-8.85	-0.4	2.36e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.56	0.52	5.93e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg21028142	chr17:79581711	NPLOC4	0.37	7.6	0.35	1.91e-13	Eye color traits;
LUAD	cis	rs7178572	0.568	rs1565757	chr15:77657682	C/T	cg15453836	chr15:77711506	NA	-0.36	-6.53	-0.3	1.84e-10	Type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg18621852	chr3:10150065	C3orf24	-0.48	-8.69	-0.39	8.09e-17	Alzheimer's disease;
LUAD	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg17279839	chr7:150038598	RARRES2	0.44	7.25	0.33	1.96e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg18402987	chr7:1209562	NA	0.81	9.91	0.43	6.12e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3772130	0.962	rs11707518	chr3:121496568	G/A	cg20356878	chr3:121714668	ILDR1	0.52	8.02	0.36	1.01e-14	Cognitive performance;
LUAD	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg07432352	chr17:45403706	C17orf57	-0.42	-8.02	-0.36	1.04e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg21782813	chr7:2030301	MAD1L1	0.42	6.93	0.32	1.6e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.42	-6.71	-0.31	6.33e-11	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg24818145	chr4:99064322	C4orf37	0.45	7.55	0.34	2.63e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg18755752	chr8:142205143	DENND3	-0.8	-16.76	-0.63	9.97e-49	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	trans	rs75804782	0.521	rs1123472	chr2:239414355	C/T	cg01134436	chr17:81009848	B3GNTL1	-0.77	-8.36	-0.38	9.08e-16	Morning vs. evening chronotype;Chronotype;
LUAD	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	12.83	0.53	4.87e-32	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.92	-0.36	2.08e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1983170	0.668	rs77687738	chr1:92016191	C/G	cg02896835	chr1:92012615	NA	0.5	6.86	0.32	2.46e-11	Eosinophil percentage of white cells;
LUAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	cis	rs11771526	0.901	rs11773754	chr7:32304801	A/G	cg13207630	chr7:32358064	NA	0.61	7.56	0.35	2.47e-13	Body mass index;
LUAD	cis	rs7202877	0.610	rs11149814	chr16:75332981	T/C	cg03315344	chr16:75512273	CHST6	0.52	7.03	0.32	8.41e-12	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs2282300	0.739	rs1717772	chr11:30340133	C/T	cg25418670	chr11:30344373	C11orf46	-0.52	-7.14	-0.33	4.16e-12	Morning vs. evening chronotype;
LUAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg08027265	chr7:2291960	NA	-0.39	-6.39	-0.3	4.35e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg00255919	chr5:131827918	IRF1	0.49	11.85	0.5	3.74e-28	Asthma (sex interaction);
LUAD	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg21775007	chr8:11205619	TDH	-0.46	-8.11	-0.37	5.51e-15	Retinal vascular caliber;
LUAD	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg23758822	chr17:41437982	NA	0.9	18.32	0.67	1.3e-55	Menopause (age at onset);
LUAD	cis	rs10392	0.543	rs1733	chr20:37581506	G/A	cg27552599	chr20:37590471	DHX35	0.41	7.01	0.32	9.43e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg24813613	chr7:1882135	MAD1L1	-0.44	-6.99	-0.32	1.08e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.44	-0.38	4.96e-16	Total body bone mineral density;
LUAD	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg13722127	chr7:150037890	RARRES2	0.44	7.46	0.34	5.04e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg10909506	chr17:38081995	ORMDL3	0.37	6.76	0.31	4.7e-11	Self-reported allergy;
LUAD	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg14552801	chr7:65878734	NA	0.39	6.77	0.31	4.37e-11	Aortic root size;
LUAD	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3540	0.514	rs2601194	chr15:90937051	T/A	cg10434728	chr15:90938212	IQGAP1	0.4	8.07	0.37	7.42e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs41311933	0.803	rs62578393	chr9:123691750	T/C	cg13567360	chr9:123745713	C5	-0.83	-7.22	-0.33	2.36e-12	Coronary artery disease;
LUAD	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.57	-0.35	2.3e-13	Breast cancer;
LUAD	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg27068330	chr11:65405492	SIPA1	-0.76	-11.29	-0.48	5.05e-26	Acne (severe);
LUAD	cis	rs9487051	0.735	rs455839	chr6:109524221	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.28	-0.33	1.63e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.22	-0.37	2.56e-15	Alzheimer's disease;
LUAD	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg23029597	chr12:123009494	RSRC2	-0.44	-7.0	-0.32	9.84e-12	Body mass index;
LUAD	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg22705602	chr4:152727874	NA	-0.4	-7.04	-0.32	7.6e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg09936400	chr10:82049201	MAT1A	0.37	6.58	0.3	1.43e-10	Post bronchodilator FEV1;
LUAD	cis	rs859767	0.737	rs2280219	chr2:135351764	A/G	cg12500956	chr2:135428796	TMEM163	-0.3	-7.57	-0.35	2.34e-13	Neuroticism;
LUAD	cis	rs89107	0.934	rs281868	chr6:118574061	A/G	cg18833306	chr6:118973337	C6orf204	-0.47	-8.5	-0.38	3.25e-16	Cardiac structure and function;
LUAD	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg25358565	chr5:93447407	FAM172A	0.62	7.68	0.35	1.1e-13	Diabetic retinopathy;
LUAD	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg22431228	chr1:16359049	CLCNKA	-0.63	-12.69	-0.53	1.68e-31	Dilated cardiomyopathy;
LUAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg07677032	chr17:61819896	STRADA	0.57	10.47	0.45	5.92e-23	Prudent dietary pattern;
LUAD	cis	rs7809950	0.953	rs2237670	chr7:107131485	A/G	cg23024343	chr7:107201750	COG5	-0.69	-11.75	-0.5	8.77e-28	Coronary artery disease;
LUAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg03354898	chr7:1950403	MAD1L1	-0.39	-7.09	-0.33	5.8e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg26039829	chr8:22132926	PIWIL2	0.57	10.42	0.45	9.12e-23	Hypertriglyceridemia;
LUAD	cis	rs62229266	0.682	rs11700546	chr21:37371139	A/C	cg12218747	chr21:37451666	NA	-0.43	-6.86	-0.32	2.44e-11	Mitral valve prolapse;
LUAD	cis	rs757081	0.667	rs17560341	chr11:17107163	C/T	cg15432903	chr11:17409602	KCNJ11	-0.41	-6.56	-0.3	1.6e-10	Systolic blood pressure;
LUAD	cis	rs1232027	0.656	rs1677650	chr5:79967164	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.23	-0.33	2.27e-12	Huntington's disease progression;
LUAD	cis	rs1997103	0.871	rs6956733	chr7:55393032	A/C	cg17469321	chr7:55412551	NA	0.64	10.21	0.44	5.15e-22	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg14093570	chr1:16679143	FBXO42	-0.36	-6.66	-0.31	8.76e-11	Schizophrenia;
LUAD	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg11919837	chr8:57350735	NA	-0.43	-6.41	-0.3	3.98e-10	Obesity-related traits;
LUAD	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg03885332	chr11:832357	CD151	-0.41	-7.89	-0.36	2.53e-14	Mean platelet volume;
LUAD	cis	rs657075	0.697	rs3805667	chr5:131646516	A/G	cg21138405	chr5:131827807	IRF1	0.5	6.42	0.3	3.75e-10	Rheumatoid arthritis;
LUAD	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg01299579	chr2:10830716	NOL10	-0.42	-7.42	-0.34	6.53e-13	Prostate cancer;
LUAD	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg06558623	chr16:89946397	TCF25	1.13	10.21	0.44	5.12e-22	Skin colour saturation;
LUAD	cis	rs3812049	0.784	rs2250127	chr5:127388844	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.55	-7.5	-0.34	3.68e-13	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg05082376	chr22:42548792	NA	0.43	7.14	0.33	4.09e-12	Schizophrenia;
LUAD	cis	rs4253772	0.515	rs77797820	chr22:46771270	C/T	cg00784671	chr22:46762841	CELSR1	-0.68	-7.47	-0.34	4.68e-13	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg23533926	chr12:111358616	MYL2	-0.4	-6.77	-0.31	4.23e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg22920501	chr2:26401640	FAM59B	-0.78	-11.14	-0.48	1.92e-25	Gut microbiome composition (summer);
LUAD	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg07741184	chr6:167504864	NA	0.36	8.12	0.37	5.12e-15	Primary biliary cholangitis;
LUAD	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg02773041	chr1:40204384	PPIE	0.51	8.48	0.38	3.67e-16	Blood protein levels;
LUAD	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg18277682	chr1:228362509	C1orf69	-0.38	-6.41	-0.3	3.83e-10	Diastolic blood pressure;
LUAD	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg11494091	chr17:61959527	GH2	0.41	7.75	0.35	6.83e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6714710	0.603	rs34502870	chr2:98405929	A/G	cg26665480	chr2:98280029	ACTR1B	0.5	8.22	0.37	2.6e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21659725	chr3:3221576	CRBN	0.64	11.01	0.47	5.8e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs1832871	0.711	rs9456266	chr6:158714422	A/G	cg07165851	chr6:158734300	TULP4	0.71	11.16	0.48	1.62e-25	Height;
LUAD	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg01689657	chr7:91764605	CYP51A1	-0.31	-7.52	-0.34	3.31e-13	Breast cancer;
LUAD	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg05064044	chr6:292385	DUSP22	-0.55	-9.06	-0.4	4.87e-18	Menopause (age at onset);
LUAD	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg20587970	chr11:113659929	NA	-1.2	-17.86	-0.66	1.36e-53	Hip circumference adjusted for BMI;
LUAD	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg07708487	chr16:89387014	ANKRD11	-0.34	-7.04	-0.32	7.79e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg25703541	chr22:24373054	LOC391322	-0.94	-18.43	-0.67	4.34e-56	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9914988	0.887	rs4795456	chr17:27072463	G/A	cg02049041	chr17:27085579	C17orf63	0.61	7.93	0.36	2.02e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs11676348	0.783	rs13035513	chr2:218960680	C/T	cg06547715	chr2:218990976	CXCR2	0.43	10.04	0.44	2.11e-21	Ulcerative colitis;
LUAD	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg13334819	chr7:99746414	C7orf59	-0.7	-10.81	-0.47	3.31e-24	Coronary artery disease;
LUAD	cis	rs6541297	0.645	rs666718	chr1:230313662	A/G	cg20703242	chr1:230279135	GALNT2	-0.48	-7.11	-0.33	4.9e-12	Coronary artery disease;
LUAD	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg15790184	chr11:494944	RNH1	0.56	6.73	0.31	5.39e-11	Body mass index;
LUAD	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.3	6.93	0.32	1.61e-11	Prostate cancer;
LUAD	cis	rs7771547	0.855	rs4713987	chr6:36599010	T/C	cg07856975	chr6:36356162	ETV7	0.45	6.84	0.32	2.76e-11	Platelet distribution width;
LUAD	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg26446133	chr18:72167187	CNDP2	-0.61	-10.12	-0.44	1.08e-21	Refractive error;
LUAD	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06022373	chr22:39101656	GTPBP1	0.46	7.15	0.33	3.76e-12	Menopause (age at onset);
LUAD	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg09222892	chr1:25734099	RHCE	-0.46	-8.56	-0.38	2.08e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.58	-0.6	1.35e-43	Chronic sinus infection;
LUAD	cis	rs2387326	0.671	rs11016104	chr10:129946512	G/A	cg16087940	chr10:129947807	NA	-0.64	-9.02	-0.4	6.63e-18	Select biomarker traits;
LUAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	6.42	0.3	3.57e-10	Prudent dietary pattern;
LUAD	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg02527881	chr3:46936655	PTH1R	-0.46	-8.94	-0.4	1.19e-17	Colorectal cancer;
LUAD	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg15704280	chr7:45808275	SEPT13	-1.05	-23.49	-0.75	1.05e-78	Height;
LUAD	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg05340658	chr4:99064831	C4orf37	0.45	7.36	0.34	9.65e-13	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11039798	0.687	rs11499938	chr11:48957297	G/A	cg02254774	chr11:50257496	LOC441601	0.52	6.56	0.3	1.62e-10	Axial length;
LUAD	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg19636519	chr7:99541626	NA	0.41	7.33	0.34	1.14e-12	Coronary artery disease;
LUAD	cis	rs11893307	0.537	rs3771319	chr2:191525233	C/G	cg27211696	chr2:191398769	TMEM194B	-0.42	-6.43	-0.3	3.36e-10	Mean platelet volume;
LUAD	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.68	-13.4	-0.55	2.31e-34	Ulcerative colitis;
LUAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00149659	chr3:10157352	C3orf10	0.6	8.51	0.38	3.1e-16	Alzheimer's disease;
LUAD	cis	rs4891159	0.584	rs690397	chr18:74117767	C/T	cg24786174	chr18:74118243	ZNF516	0.9	22.51	0.74	2.36e-74	Longevity;
LUAD	cis	rs4889855	0.530	rs4303599	chr17:78566700	C/T	cg16591659	chr17:78472290	NA	0.44	7.82	0.36	4.27e-14	Fractional excretion of uric acid;
LUAD	cis	rs7149337	0.933	rs28705789	chr14:51713508	C/T	cg23942311	chr14:51606299	NA	0.81	16.96	0.64	1.33e-49	Cancer;
LUAD	cis	rs986417	0.711	rs2224409	chr14:60957216	C/T	cg27398547	chr14:60952738	C14orf39	0.69	8.31	0.37	1.29e-15	Gut microbiota (bacterial taxa);
LUAD	cis	rs2282300	0.739	rs3858428	chr11:30296550	T/C	cg25418670	chr11:30344373	C11orf46	0.52	7.26	0.33	1.87e-12	Morning vs. evening chronotype;
LUAD	cis	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-6.51	-0.3	2.15e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs71478720	0.868	rs5744222	chr11:112037014	G/T	cg26534425	chr11:112034925	IL18	0.43	6.57	0.3	1.47e-10	Interleukin-18 levels;
LUAD	trans	rs7696796	0.909	rs6840036	chr4:183163929	C/T	cg10929758	chr2:54857270	SPTBN1	0.36	6.48	0.3	2.56e-10	Neuroticism;
LUAD	cis	rs7809950	1.000	rs1544336	chr7:107082415	G/C	cg23024343	chr7:107201750	COG5	-0.71	-11.94	-0.5	1.57e-28	Coronary artery disease;
LUAD	cis	rs7945718	0.806	rs11022507	chr11:12829753	A/T	cg25843174	chr11:12811716	TEAD1	0.23	7.08	0.33	6.2e-12	Educational attainment (years of education);
LUAD	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg24920358	chr1:40204285	PPIE	0.7	12.47	0.52	1.29e-30	Blood protein levels;
LUAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg26304593	chr6:42947056	PEX6	-0.47	-7.88	-0.36	2.84e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12667521	chr19:29218732	NA	0.6	8.49	0.38	3.42e-16	Methadone dose in opioid dependence;
LUAD	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18404041	chr3:52824283	ITIH1	-0.58	-12.0	-0.5	9.42e-29	Bipolar disorder;
LUAD	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg15448220	chr1:150897856	SETDB1	0.5	8.45	0.38	4.69e-16	Melanoma;
LUAD	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg00677455	chr12:58241039	CTDSP2	-0.43	-7.09	-0.33	5.76e-12	Multiple sclerosis;
LUAD	trans	rs1997103	1.000	rs10270618	chr7:55396712	T/A	cg20935933	chr6:143382018	AIG1	0.53	7.46	0.34	4.94e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg18180107	chr4:99064573	C4orf37	0.44	7.06	0.32	6.79e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg04398451	chr17:18023971	MYO15A	-0.6	-10.67	-0.46	1.06e-23	Total body bone mineral density;
LUAD	cis	rs752092	0.775	rs4965806	chr15:101752435	G/A	cg19997662	chr15:101784653	CHSY1	-0.44	-8.06	-0.36	8.03e-15	Corneal structure;
LUAD	cis	rs9462027	0.628	rs2814968	chr6:34713138	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.04	-0.4	5.87e-18	Systemic lupus erythematosus;
LUAD	trans	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg04565464	chr8:145669602	NFKBIL2	0.47	7.04	0.32	7.97e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs68170813	0.523	rs12535093	chr7:107020182	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.57	-0.46	2.43e-23	Coronary artery disease;
LUAD	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25427524	chr10:38739819	LOC399744	-0.74	-13.14	-0.54	2.5e-33	Extrinsic epigenetic age acceleration;
LUAD	trans	rs3942852	0.868	rs58407618	chr11:48104167	T/G	cg03929089	chr4:120376271	NA	-0.52	-6.98	-0.32	1.14e-11	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg16647868	chr5:131706066	SLC22A5	-0.51	-8.06	-0.36	8.1e-15	Breast cancer;
LUAD	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-6.87	-0.32	2.32e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg03037974	chr15:76606532	NA	0.37	7.83	0.36	3.87e-14	Blood metabolite levels;
LUAD	cis	rs6495122	0.699	rs4886410	chr15:75065644	G/C	cg14664628	chr15:75095509	CSK	-0.5	-8.28	-0.37	1.67e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.56	-0.42	9.67e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg18721089	chr20:30220636	NA	-0.47	-6.85	-0.32	2.57e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs9419702	0.614	rs7907614	chr10:133532208	T/C	cg04492858	chr10:133558786	NA	0.39	7.56	0.35	2.52e-13	Survival in rectal cancer;
LUAD	cis	rs4588572	0.643	rs10044028	chr5:77794750	C/T	cg11547950	chr5:77652471	NA	0.78	12.46	0.52	1.37e-30	Triglycerides;
LUAD	trans	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	12.51	0.52	9.38e-31	Exhaled nitric oxide output;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg16189722	chr7:73668877	RFC2	-0.66	-6.61	-0.31	1.18e-10	Type 2 diabetes;
LUAD	cis	rs7937890	0.531	rs2575828	chr11:14484192	T/C	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.07e-12	Mitochondrial DNA levels;
LUAD	cis	rs1595825	0.891	rs16866980	chr2:198513009	A/C	cg00982548	chr2:198649783	BOLL	-0.62	-8.88	-0.4	1.95e-17	Ulcerative colitis;
LUAD	cis	rs986417	1.000	rs1254323	chr14:60908378	G/A	cg27398547	chr14:60952738	C14orf39	-0.62	-7.69	-0.35	1.07e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg20814179	chr4:940893	TMEM175	0.56	7.94	0.36	1.79e-14	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18876405	chr7:65276391	NA	-0.43	-6.86	-0.32	2.38e-11	Aortic root size;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23468238	chr5:72861609	UTP15;ANKRA2	-0.41	-6.77	-0.31	4.42e-11	Cancer;
LUAD	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg18230493	chr5:56204884	C5orf35	-0.85	-12.49	-0.52	1.11e-30	Initial pursuit acceleration;
LUAD	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg26373071	chr5:1325741	CLPTM1L	0.37	7.94	0.36	1.9e-14	Lung cancer;
LUAD	cis	rs7903847	0.642	rs61863819	chr10:99142400	T/C	cg08345082	chr10:99160200	RRP12	-0.35	-7.05	-0.32	7.43e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9560113	0.922	rs4773377	chr13:112174152	G/C	cg14154082	chr13:112174009	NA	0.37	6.83	0.32	3.01e-11	Menarche (age at onset);
LUAD	trans	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg14791747	chr16:20752902	THUMPD1	-0.51	-7.12	-0.33	4.73e-12	Selective IgA deficiency;
LUAD	trans	rs9929218	0.954	rs12596834	chr16:68823199	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.72	-0.53	1.32e-31	Colorectal cancer;
LUAD	cis	rs7809950	1.000	rs12668402	chr7:107173020	G/A	cg23024343	chr7:107201750	COG5	-0.7	-11.83	-0.5	4.19e-28	Coronary artery disease;
LUAD	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg03732007	chr1:2071316	PRKCZ	-0.34	-6.49	-0.3	2.38e-10	Height;
LUAD	cis	rs7737355	0.738	rs7734666	chr5:130861456	A/G	cg06307176	chr5:131281290	NA	0.43	7.16	0.33	3.63e-12	Life satisfaction;
LUAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg04267008	chr7:1944627	MAD1L1	-0.75	-11.78	-0.5	6.72e-28	Bipolar disorder and schizophrenia;
LUAD	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg02527881	chr3:46936655	PTH1R	-0.54	-11.14	-0.48	1.92e-25	Colorectal cancer;
LUAD	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs8064299	0.597	rs2166703	chr17:72781812	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.41	6.58	0.3	1.37e-10	Monocyte count;
LUAD	cis	rs13031619	0.607	rs13001751	chr2:3695870	A/G	cg19052272	chr2:3704530	ALLC	-0.39	-6.8	-0.31	3.55e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7737355	0.738	rs10051609	chr5:130877080	G/C	cg06307176	chr5:131281290	NA	0.44	7.18	0.33	3.16e-12	Life satisfaction;
LUAD	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10802521	chr3:52805072	NEK4	0.58	10.63	0.46	1.52e-23	Bipolar disorder;
LUAD	cis	rs34638657	0.702	rs67612167	chr16:82199598	A/G	cg09439754	chr16:82129088	HSD17B2	-0.37	-7.05	-0.32	7.18e-12	Lung adenocarcinoma;
LUAD	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg02931644	chr1:25747376	RHCE	-0.42	-8.5	-0.38	3.29e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg25036284	chr2:26402008	FAM59B	-0.82	-11.37	-0.48	2.62e-26	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg22535103	chr8:58192502	C8orf71	-0.67	-7.28	-0.33	1.66e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs7615952	0.611	rs12488771	chr3:125700526	A/G	cg07211511	chr3:129823064	LOC729375	-0.8	-7.42	-0.34	6.47e-13	Blood pressure (smoking interaction);
LUAD	trans	rs11088226	0.598	rs79634586	chr21:33959363	A/G	cg09050820	chr6:167586206	TCP10L2	0.94	13.22	0.54	1.18e-33	Gastritis;
LUAD	cis	rs2901656	0.934	rs9425311	chr1:172388778	G/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.46	8.84	0.39	2.6e-17	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg17177755	chr1:15930204	NA	0.49	7.6	0.35	1.9e-13	Systolic blood pressure;
LUAD	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.26	-0.45	3.45e-22	Bipolar disorder and schizophrenia;
LUAD	trans	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg17712092	chr4:129076599	LARP1B	-0.65	-10.15	-0.44	8.61e-22	Eosinophil percentage of white cells;
LUAD	cis	rs6867913	0.709	rs891987	chr5:141467196	A/T	cg08523384	chr5:141488047	NDFIP1	0.44	7.21	0.33	2.6e-12	Asthma;
LUAD	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg25173405	chr17:45401733	C17orf57	-0.46	-7.57	-0.35	2.38e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs877282	0.898	rs11253350	chr10:765968	G/A	cg17470449	chr10:769945	NA	0.61	8.47	0.38	4.14e-16	Uric acid levels;
LUAD	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg06608945	chr2:219082296	ARPC2	-0.42	-6.83	-0.32	2.93e-11	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg14458575	chr2:238380390	NA	0.66	12.43	0.52	1.89e-30	Prostate cancer;
LUAD	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg09117114	chr16:67998030	SLC12A4	-0.51	-6.78	-0.31	4.01e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg20701182	chr2:24300061	SF3B14	0.63	7.12	0.33	4.76e-12	Lymphocyte counts;
LUAD	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg11494091	chr17:61959527	GH2	0.4	6.93	0.32	1.63e-11	Height;
LUAD	trans	rs208520	0.690	rs866452	chr6:66849936	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-15.85	-0.61	9.27e-45	Exhaled nitric oxide output;
LUAD	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.52	0.3	1.97e-10	Breast cancer;
LUAD	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg10523679	chr1:76189770	ACADM	0.94	18.6	0.67	7.2e-57	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg06623918	chr6:96969491	KIAA0776	0.83	16.02	0.61	1.77e-45	Headache;
LUAD	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg14664628	chr15:75095509	CSK	-0.43	-6.71	-0.31	6.24e-11	Breast cancer;
LUAD	trans	rs7395662	1.000	rs6485911	chr11:48654784	A/C	cg00717180	chr2:96193071	NA	-0.35	-6.48	-0.3	2.53e-10	HDL cholesterol;
LUAD	cis	rs2882667	0.861	rs7703288	chr5:138366539	C/G	cg04439458	chr5:138467593	SIL1	-0.4	-7.33	-0.34	1.17e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7168353	0.948	rs10520720	chr15:93634724	A/G	cg02918577	chr15:93633145	RGMA	-0.41	-6.42	-0.3	3.73e-10	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUAD	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg01191920	chr7:158217561	PTPRN2	0.62	13.17	0.54	2e-33	Obesity-related traits;
LUAD	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg21775007	chr8:11205619	TDH	-0.53	-9.5	-0.42	1.5700000000000001e-19	Retinal vascular caliber;
LUAD	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg08048268	chr3:133502702	NA	-0.47	-9.75	-0.43	2.15e-20	Ankle injury;
LUAD	trans	rs877282	0.853	rs7069720	chr10:754487	A/G	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg18305652	chr10:134549665	INPP5A	0.61	11.76	0.5	7.82e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-12.34	-0.51	4.29e-30	Breast cancer;
LUAD	cis	rs8060686	0.516	rs7184821	chr16:68270229	T/C	cg09835421	chr16:68378352	PRMT7	-0.56	-7.03	-0.32	8.08e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11048434	0.736	rs11048345	chr12:9123056	T/G	cg04155231	chr12:9217510	LOC144571	0.38	7.09	0.33	5.63e-12	Sjögren's syndrome;
LUAD	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.67	-11.25	-0.48	7.3e-26	Primary sclerosing cholangitis;
LUAD	cis	rs6840360	0.554	rs6849111	chr4:152708874	T/C	cg22705602	chr4:152727874	NA	-0.47	-9.14	-0.41	2.57e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg06781209	chr11:61594997	FADS2	-0.38	-7.2	-0.33	2.8e-12	Trans fatty acid levels;
LUAD	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.8	-10.14	-0.44	8.87e-22	Body mass index;
LUAD	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg23096020	chr7:158799433	NA	-0.37	-6.81	-0.31	3.28e-11	Facial morphology (factor 20);
LUAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg16414030	chr3:133502952	NA	0.69	13.15	0.54	2.34e-33	Iron status biomarkers;
LUAD	cis	rs6761276	0.866	rs12469822	chr2:113830563	C/T	cg10479672	chr2:113810641	IL1F8	-0.34	-6.61	-0.31	1.17e-10	Protein quantitative trait loci;
LUAD	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.68	-0.35	1.13e-13	Total body bone mineral density;
LUAD	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg24558204	chr6:135376177	HBS1L	0.46	7.86	0.36	3.32e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg14582100	chr15:45693742	SPATA5L1	0.59	10.85	0.47	2.33e-24	Homoarginine levels;
LUAD	cis	rs1595825	0.735	rs6434955	chr2:198946551	G/A	cg00361562	chr2:198649771	BOLL	-0.51	-6.98	-0.32	1.15e-11	Ulcerative colitis;
LUAD	trans	rs7944735	1.000	rs7944735	chr11:47955608	G/C	cg03929089	chr4:120376271	NA	0.6	7.62	0.35	1.63e-13	Intraocular pressure;
LUAD	trans	rs10411161	0.702	rs16983200	chr19:52386723	G/A	cg22319618	chr22:45562946	NUP50	-0.64	-8.96	-0.4	1.08e-17	Breast cancer;
LUAD	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg18477163	chr1:228402036	OBSCN	0.44	7.8	0.35	4.92e-14	Diastolic blood pressure;
LUAD	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg04218760	chr10:45406644	TMEM72	-0.3	-7.81	-0.35	4.68e-14	Mean corpuscular volume;
LUAD	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg02734326	chr4:10020555	SLC2A9	-0.56	-9.62	-0.42	5.99e-20	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4774899	0.752	rs2962992	chr15:57346505	T/C	cg14026238	chr15:57616123	NA	0.44	8.43	0.38	5.51e-16	Urinary tract infection frequency;
LUAD	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.82	-0.39	3.1e-17	Initial pursuit acceleration;
LUAD	cis	rs1215050	0.904	rs165246	chr4:98688541	C/T	cg17366294	chr4:99064904	C4orf37	0.4	6.79	0.31	3.83e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg10729496	chr3:10149963	C3orf24	0.58	9.43	0.42	2.66e-19	Alzheimer's disease;
LUAD	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg17644776	chr2:200775616	C2orf69	0.56	7.41	0.34	6.87e-13	Schizophrenia;
LUAD	trans	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg21427119	chr20:30132790	HM13	-0.52	-8.5	-0.38	3.19e-16	Mean corpuscular hemoglobin;
LUAD	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg00530320	chr1:46809349	NSUN4	0.53	8.17	0.37	3.49e-15	Menopause (age at onset);
LUAD	cis	rs921968	0.541	rs933994	chr2:219650616	C/T	cg02176678	chr2:219576539	TTLL4	-0.59	-11.77	-0.5	7.6e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.47	7.35	0.34	1.02e-12	Total body bone mineral density;
LUAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg11494091	chr17:61959527	GH2	0.74	18.52	0.67	1.62e-56	Prudent dietary pattern;
LUAD	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg05110241	chr16:68378359	PRMT7	-0.84	-9.13	-0.41	2.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2274273	0.773	rs10147765	chr14:55827826	G/A	cg04306507	chr14:55594613	LGALS3	0.43	8.99	0.4	8.23e-18	Protein biomarker;
LUAD	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg15133208	chr4:90757351	SNCA	-0.46	-6.83	-0.32	2.88e-11	Neuroticism;
LUAD	trans	rs3219090	0.962	rs2027439	chr1:226575749	T/C	cg27539482	chr13:111589090	NA	0.41	6.71	0.31	6.09e-11	Melanoma;
LUAD	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.23	0.54	1.09e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg15962314	chr1:44399869	ARTN	0.32	6.82	0.31	3.22e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs59104589	0.535	rs73004374	chr2:242378000	T/C	cg08645257	chr2:242211290	HDLBP	0.42	7.0	0.32	9.94e-12	Fibrinogen levels;
LUAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg22535103	chr8:58192502	C8orf71	-0.72	-10.5	-0.45	4.54e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg16486109	chr11:613632	IRF7	0.49	8.14	0.37	4.35e-15	Systemic lupus erythematosus;
LUAD	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.76	8.48	0.38	3.68e-16	Yeast infection;
LUAD	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg16988262	chr1:15930761	NA	0.41	6.84	0.32	2.85e-11	Systolic blood pressure;
LUAD	cis	rs741677	0.963	rs7214033	chr17:472173	C/T	cg13332499	chr17:408570	NA	0.34	6.83	0.32	2.99e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg04772025	chr11:68637568	NA	0.51	8.05	0.36	8.33e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.47	-7.39	-0.34	8.08e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg02527881	chr3:46936655	PTH1R	-0.53	-10.7	-0.46	8.35e-24	Colorectal cancer;
LUAD	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.35	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs11650494	0.901	rs117087923	chr17:47364913	G/A	cg11430096	chr6:110968061	CDK19	0.88	6.6	0.31	1.24e-10	Prostate cancer;
LUAD	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg17177755	chr1:15930204	NA	0.43	6.94	0.32	1.47e-11	Systolic blood pressure;
LUAD	cis	rs7177699	0.557	rs12898452	chr15:79112628	C/A	cg00540400	chr15:79124168	NA	0.43	9.23	0.41	1.27e-18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.44	0.55	1.59e-34	Prudent dietary pattern;
LUAD	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg21890820	chr11:65308645	LTBP3	0.47	7.46	0.34	4.9e-13	Bone mineral density;
LUAD	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg01475377	chr6:109611718	NA	-0.51	-9.43	-0.42	2.74e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg17178900	chr1:205818956	PM20D1	0.84	19.0	0.68	1.14e-58	Menarche (age at onset);
LUAD	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs25645	0.760	rs11870683	chr17:38129841	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.72	14.87	0.59	1.49e-40	Myeloid white cell count;
LUAD	cis	rs4889855	0.530	rs4889863	chr17:78550468	C/T	cg16591659	chr17:78472290	NA	-0.43	-7.59	-0.35	1.99e-13	Fractional excretion of uric acid;
LUAD	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg08761264	chr16:28874980	SH2B1	-0.45	-6.89	-0.32	2.05e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg25535316	chr11:579198	PHRF1	-0.42	-6.54	-0.3	1.73e-10	Systemic lupus erythematosus;
LUAD	cis	rs7671266	0.628	rs11734783	chr4:10240663	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	6.99	0.32	1.07e-11	Cardiovascular disease risk factors;
LUAD	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg23982607	chr1:1823379	GNB1	-0.89	-17.69	-0.65	7.82e-53	Body mass index;
LUAD	cis	rs17102423	0.731	rs998247	chr14:65546299	C/T	cg11161011	chr14:65562177	MAX	-0.4	-6.83	-0.31	3.04e-11	Obesity-related traits;
LUAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7010267	0.935	rs10955915	chr8:119963547	A/G	cg01975934	chr8:119970761	NA	-0.4	-7.58	-0.35	2.23e-13	Total body bone mineral density (age 45-60);
LUAD	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg07917127	chr4:99064746	C4orf37	0.41	6.89	0.32	2.01e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg26408565	chr15:76604113	ETFA	-0.44	-7.12	-0.33	4.65e-12	Blood metabolite levels;
LUAD	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg00071950	chr4:10020882	SLC2A9	0.67	13.14	0.54	2.53e-33	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs11771526	0.686	rs117514532	chr7:32316615	A/G	cg13207630	chr7:32358064	NA	0.67	6.89	0.32	1.98e-11	Body mass index;
LUAD	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg08885076	chr2:99613938	TSGA10	0.41	7.61	0.35	1.84e-13	Chronic sinus infection;
LUAD	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg03340356	chr1:67600835	NA	-0.38	-6.9	-0.32	1.88e-11	Psoriasis;
LUAD	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.71	0.39	6.86e-17	Menopause (age at onset);
LUAD	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg06641503	chr3:48959341	ARIH2	-0.36	-6.69	-0.31	6.9e-11	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg14552801	chr7:65878734	NA	0.38	6.7	0.31	6.53e-11	Aortic root size;
LUAD	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg09904177	chr6:26538194	HMGN4	0.43	7.26	0.33	1.87e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg12016809	chr21:47604291	C21orf56	-0.59	-10.17	-0.44	6.84e-22	Testicular germ cell tumor;
LUAD	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg14582100	chr15:45693742	SPATA5L1	0.64	12.54	0.52	6.55e-31	Homoarginine levels;
LUAD	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg14835575	chr10:16859367	RSU1	0.62	9.9	0.43	6.27e-21	Platelet distribution width;
LUAD	cis	rs877282	0.842	rs12357963	chr10:757562	C/T	cg17470449	chr10:769945	NA	0.59	8.02	0.36	1.07e-14	Uric acid levels;
LUAD	cis	rs11650494	0.908	rs73324323	chr17:47420054	G/T	cg08112188	chr17:47440006	ZNF652	0.91	7.89	0.36	2.56e-14	Prostate cancer;
LUAD	trans	rs1876905	0.680	rs7767302	chr6:111465145	A/G	cg19734536	chr1:160607887	SLAMF1	-0.39	-6.42	-0.3	3.74e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs4148087	0.719	rs9978956	chr21:43599950	T/C	cg08841829	chr21:43638893	ABCG1	-0.5	-6.62	-0.31	1.11e-10	Eating disorder in bipolar disorder;
LUAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg18621852	chr3:10150065	C3orf24	0.45	7.08	0.33	5.94e-12	Alzheimer's disease;
LUAD	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg08632164	chr7:65971372	NA	-0.55	-6.37	-0.3	4.93e-10	Diabetic kidney disease;
LUAD	cis	rs12545109	0.765	rs2576589	chr8:57425647	C/T	cg09654669	chr8:57350985	NA	-0.61	-8.65	-0.39	1.08e-16	Obesity-related traits;
LUAD	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg25358565	chr5:93447407	FAM172A	0.64	7.6	0.35	1.87e-13	Diabetic retinopathy;
LUAD	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.87e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg04539111	chr16:67997858	SLC12A4	-0.54	-7.24	-0.33	2.14e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg00933542	chr6:150070202	PCMT1	0.35	7.41	0.34	7.13e-13	Testicular germ cell tumor;
LUAD	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	3.96e-11	Depression;
LUAD	cis	rs11771526	1.000	rs11770367	chr7:32354319	C/T	cg27532318	chr7:32358331	NA	0.72	8.3	0.37	1.46e-15	Body mass index;
LUAD	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg03929089	chr4:120376271	NA	-0.85	-14.83	-0.58	2.24e-40	Height;
LUAD	cis	rs68092024	0.704	rs704576	chr3:99487154	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-9.41	-0.42	3.1400000000000002e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg26384229	chr12:38710491	ALG10B	0.45	7.4	0.34	7.36e-13	Bladder cancer;
LUAD	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg03806693	chr22:41940476	POLR3H	-0.45	-6.85	-0.32	2.54e-11	Neuroticism;
LUAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.11	-0.4	3.36e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs17818399	0.815	rs17819022	chr2:46850571	G/A	cg09399716	chr2:46890238	NA	-0.41	-7.46	-0.34	5.09e-13	Height;
LUAD	cis	rs10489202	0.657	rs3767478	chr1:168069626	G/A	cg24449463	chr1:168025552	DCAF6	-0.62	-9.28	-0.41	9.2e-19	Schizophrenia;
LUAD	cis	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-7.88	-0.36	2.75e-14	Neuroticism;
LUAD	cis	rs4786125	0.581	rs7194903	chr16:6918194	A/G	cg03623568	chr16:6915990	A2BP1	-0.47	-10.22	-0.44	4.72e-22	Heart rate variability traits (SDNN);
LUAD	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.45	8.19	0.37	3.01e-15	Systemic lupus erythematosus;
LUAD	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg21427119	chr20:30132790	HM13	-0.62	-9.46	-0.42	2.24e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg09904177	chr6:26538194	HMGN4	0.39	6.48	0.3	2.56e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg15704280	chr7:45808275	SEPT13	-0.94	-18.43	-0.67	4.03e-56	Coronary artery disease;
LUAD	cis	rs8192282	0.739	rs4575077	chr1:154495011	C/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.45	-6.92	-0.32	1.67e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.99e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.69	-13.27	-0.54	7.66e-34	Longevity;Endometriosis;
LUAD	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.79	15.49	0.6	3.28e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg07460842	chr6:66804631	NA	0.7	12.73	0.53	1.23e-31	Initial pursuit acceleration in psychotic disorders;
LUAD	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg03929089	chr4:120376271	NA	-0.93	-17.75	-0.65	4.6e-53	Height;
LUAD	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg01851573	chr8:8652454	MFHAS1	0.41	7.25	0.33	2e-12	Schizophrenia;
LUAD	cis	rs4795519	0.701	rs12450905	chr17:22187673	G/A	cg22648282	chr17:21454238	C17orf51	-0.39	-6.42	-0.3	3.61e-10	Chronic myeloid leukemia;
LUAD	cis	rs4642101	0.597	rs2305397	chr3:12857493	C/T	cg24848339	chr3:12840334	CAND2	0.43	8.75	0.39	5.01e-17	QRS complex (12-leadsum);
LUAD	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg06544989	chr22:39130855	UNC84B	0.41	7.58	0.35	2.28e-13	Menopause (age at onset);
LUAD	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg27124370	chr19:33622961	WDR88	0.46	7.15	0.33	3.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs3772130	0.962	rs35679661	chr3:121484763	G/A	cg20356878	chr3:121714668	ILDR1	0.53	8.14	0.37	4.43e-15	Cognitive performance;
LUAD	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg24069376	chr3:38537580	EXOG	-0.45	-11.04	-0.47	4.39e-25	Electrocardiographic conduction measures;
LUAD	cis	rs870825	1.000	rs870823	chr4:185588195	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	9.25	0.41	1.08e-18	Blood protein levels;
LUAD	trans	rs853679	0.556	rs13197633	chr6:28174757	G/A	cg01620082	chr3:125678407	NA	-1.08	-10.27	-0.45	3.17e-22	Depression;
LUAD	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg12935359	chr14:103987150	CKB	-0.44	-7.03	-0.32	8.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.16e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.15	0.33	3.76e-12	Parkinson's disease;
LUAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg15691649	chr6:25882328	NA	0.63	9.68	0.43	3.66e-20	Blood metabolite levels;
LUAD	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg24531977	chr5:56204891	C5orf35	1.11	17.35	0.64	2.47e-51	Initial pursuit acceleration;
LUAD	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg21138405	chr5:131827807	IRF1	0.57	12.02	0.5	7.82e-29	Asthma (sex interaction);
LUAD	cis	rs9652601	0.959	rs9931397	chr16:11177394	G/C	cg04616529	chr16:11181986	CLEC16A	0.37	6.53	0.3	1.89e-10	Systemic lupus erythematosus;
LUAD	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.59e-12	Crohn's disease;
LUAD	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.35	7.34	0.34	1.08e-12	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg24644049	chr4:85504048	CDS1	0.84	7.69	0.35	1.02e-13	Skin colour saturation;
LUAD	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg00745463	chr17:30367425	LRRC37B	0.7	8.4	0.38	6.85e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs877529	0.605	rs139397	chr22:39543371	T/C	cg18708252	chr22:39545030	CBX7	-0.3	-6.46	-0.3	2.84e-10	Multiple myeloma;
LUAD	cis	rs9473147	0.516	rs10948363	chr6:47487762	A/G	cg12968598	chr6:47444699	CD2AP	0.36	6.46	0.3	2.81e-10	Platelet distribution width;Mean platelet volume;
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg02796970	chr10:39023768	NA	-0.48	-7.69	-0.35	1.03e-13	Menopause (age at onset);
LUAD	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg10518543	chr12:38710700	ALG10B	-0.42	-6.89	-0.32	2.01e-11	Bladder cancer;
LUAD	trans	rs747782	0.527	rs2270993	chr11:48145166	G/A	cg15704280	chr7:45808275	SEPT13	0.67	7.22	0.33	2.46e-12	Intraocular pressure;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg13490966	chr1:26496285	ZNF593	-0.46	-6.38	-0.3	4.71e-10	Blood protein levels;
LUAD	trans	rs58106596	0.747	rs6731997	chr2:232560411	A/G	cg01370599	chr3:116745421	NA	0.58	8.59	0.39	1.63e-16	White blood cell count;Lymphocyte counts;
LUAD	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg08470875	chr2:26401718	FAM59B	-0.79	-11.06	-0.47	3.77e-25	Gut microbiome composition (summer);
LUAD	trans	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg26043149	chr18:55253948	FECH	0.52	8.78	0.39	4.19e-17	Bone mineral density;
LUAD	cis	rs11048434	0.761	rs2377675	chr12:9124765	C/T	cg04155231	chr12:9217510	LOC144571	0.42	7.92	0.36	2.14e-14	Sjögren's syndrome;
LUAD	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg06784218	chr1:46089804	CCDC17	0.57	12.74	0.53	1.04e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.49	0.6	3.38e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs912057	1.000	rs912057	chr6:6736931	C/T	cg06612196	chr6:6737390	NA	-0.53	-12.22	-0.51	1.29e-29	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg23352942	chr3:46931381	PTH1R	-0.39	-7.99	-0.36	1.34e-14	Birth weight;
LUAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.54	-10.04	-0.44	2.09e-21	Longevity;Endometriosis;
LUAD	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11644478	chr21:40555479	PSMG1	-0.54	-8.63	-0.39	1.29e-16	Cognitive function;
LUAD	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg17330251	chr7:94953956	PON1	-0.56	-7.75	-0.35	7.07e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7326068	0.610	rs2818985	chr13:21314209	G/T	cg27499820	chr13:21296301	IL17D	0.52	7.74	0.35	7.51e-14	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.9	13.06	0.54	5.6e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00149659	chr3:10157352	C3orf10	0.61	8.49	0.38	3.41e-16	Alzheimer's disease;
LUAD	trans	rs1728785	0.901	rs1728787	chr16:68593042	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.31	0.45	2.19e-22	Ulcerative colitis;
LUAD	cis	rs6960043	0.738	rs4721400	chr7:15059906	G/A	cg19272540	chr7:15055459	NA	0.39	8.79	0.39	3.74e-17	Type 2 diabetes;
LUAD	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg22823121	chr1:150693482	HORMAD1	-0.35	-6.42	-0.3	3.63e-10	Tonsillectomy;
LUAD	cis	rs8067545	0.641	rs4925060	chr17:19863258	C/G	cg04132472	chr17:19861366	AKAP10	0.4	9.33	0.41	5.86e-19	Schizophrenia;
LUAD	cis	rs2364543	0.624	rs61774752	chr1:41847024	T/C	cg08462924	chr1:41848221	NA	0.48	8.92	0.4	1.39e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg27170947	chr2:26402098	FAM59B	-0.71	-10.61	-0.46	1.84e-23	Gut microbiome composition (summer);
LUAD	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg25566285	chr7:158114605	PTPRN2	0.52	11.01	0.47	6.02e-25	Calcium levels;
LUAD	cis	rs4285028	0.948	rs7615571	chr3:121665950	A/C	cg11130432	chr3:121712080	ILDR1	-0.58	-8.12	-0.37	5.33e-15	Multiple sclerosis;
LUAD	cis	rs2840044	0.963	rs225247	chr17:33944590	T/A	cg05299278	chr17:33885742	SLFN14	0.43	8.64	0.39	1.16e-16	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs7122539	0.603	rs508443	chr11:66509369	C/T	cg24851651	chr11:66362959	CCS	-0.38	-6.83	-0.32	2.89e-11	HIV-1 susceptibility;
LUAD	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg25036284	chr2:26402008	FAM59B	-0.81	-12.2	-0.51	1.53e-29	Gut microbiome composition (summer);
LUAD	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg25358565	chr5:93447407	FAM172A	0.66	7.78	0.35	5.63e-14	Diabetic retinopathy;
LUAD	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26314531	chr2:26401878	FAM59B	0.73	9.78	0.43	1.66e-20	Gut microbiome composition (summer);
LUAD	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg20291162	chr17:40259547	DHX58	-0.68	-10.42	-0.45	9.09e-23	Fibrinogen levels;
LUAD	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg18129748	chr3:49941408	MST1R	-0.44	-7.24	-0.33	2.1e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-6.73	-0.31	5.54e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg07967210	chr17:47022446	SNF8	0.35	6.4	0.3	4.22e-10	Type 2 diabetes;
LUAD	cis	rs41311933	0.656	rs41308026	chr9:123792989	A/G	cg13567360	chr9:123745713	C5	-0.75	-9.01	-0.4	7.36e-18	Coronary artery disease;
LUAD	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg27631724	chr1:11040367	C1orf127	0.53	9.65	0.42	4.85e-20	Ewing sarcoma;
LUAD	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg06784218	chr1:46089804	CCDC17	-0.54	-11.8	-0.5	5.62e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-6.84	-0.32	2.83e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg08807101	chr21:30365312	RNF160	-0.47	-7.76	-0.35	6.46e-14	Dental caries;
LUAD	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg25237894	chr2:233734115	C2orf82	0.62	11.87	0.5	3.06e-28	Coronary artery disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14797243	chr11:68671428	IGHMBP2;MRPL21	-0.41	-6.61	-0.31	1.17e-10	Height;
LUAD	cis	rs870825	0.616	rs877276	chr4:185621249	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg22681709	chr2:178499509	PDE11A	-0.42	-6.96	-0.32	1.32e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7705042	0.865	rs4912623	chr5:141505462	T/A	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.92	-0.32	1.65e-11	Asthma;
LUAD	cis	rs2735413	0.918	rs34094825	chr16:78081392	G/C	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg14530993	chr4:882597	GAK	0.78	7.39	0.34	7.74e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg19700328	chr14:106028568	NA	-0.46	-7.78	-0.35	5.58e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg08125733	chr17:73851984	WBP2	0.55	8.3	0.37	1.43e-15	Psoriasis;
LUAD	cis	rs7665090	0.875	rs6813687	chr4:103555612	G/A	cg07973026	chr4:103553119	MANBA	0.47	8.3	0.37	1.41e-15	Primary biliary cholangitis;
LUAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg02524346	chr8:600233	NA	1.18	10.9	0.47	1.52e-24	IgG glycosylation;
LUAD	cis	rs10746514	0.833	rs1888601	chr1:232266922	C/T	cg09506761	chr1:232265262	NA	-0.39	-7.38	-0.34	8.26e-13	Response to statin therapy;
LUAD	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg09640425	chr7:158790006	NA	-0.46	-7.76	-0.35	6.39e-14	Facial morphology (factor 20);
LUAD	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg07930552	chr6:133119739	C6orf192	0.59	7.02	0.32	9.02e-12	Type 2 diabetes nephropathy;
LUAD	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg08807101	chr21:30365312	RNF160	-0.48	-8.33	-0.38	1.12e-15	Dental caries;
LUAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg10729496	chr3:10149963	C3orf24	0.54	9.25	0.41	1.16e-18	Alzheimer's disease;
LUAD	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07636037	chr3:49044803	WDR6	-0.48	-8.01	-0.36	1.15e-14	Menarche (age at onset);
LUAD	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg08508325	chr11:3079039	CARS	-0.59	-12.5	-0.52	1.03e-30	Longevity;
LUAD	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg10802521	chr3:52805072	NEK4	-0.47	-6.76	-0.31	4.53e-11	Schizophrenia;
LUAD	cis	rs12208915	0.731	rs9361473	chr6:79657042	C/T	cg09184832	chr6:79620586	NA	0.53	7.4	0.34	7.51e-13	Left atrial antero-posterior diameter;
LUAD	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.2	-0.41	1.61e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7771547	0.519	rs72852340	chr6:36554804	G/A	cg07856975	chr6:36356162	ETV7	0.52	7.0	0.32	1.04e-11	Platelet distribution width;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg02203542	chr20:305175	SOX12	-0.63	-6.36	-0.3	5.27e-10	Type 2 diabetes;
LUAD	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg00745463	chr17:30367425	LRRC37B	0.66	8.35	0.38	9.53e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs2458413	0.935	rs2514667	chr8:105358590	C/T	cg04554929	chr8:105342491	NA	0.37	7.16	0.33	3.6e-12	Paget's disease;
LUAD	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg24578937	chr1:2090814	PRKCZ	0.79	16.49	0.63	1.56e-47	Height;
LUAD	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21659725	chr3:3221576	CRBN	0.69	11.83	0.5	4.16e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg18404041	chr3:52824283	ITIH1	0.38	7.03	0.32	8.58e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg26536354	chr8:144654954	C8orf73	0.61	6.69	0.31	7.31e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.42	-0.34	6.68e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	9.07	0.4	4.44e-18	Alzheimer's disease;
LUAD	cis	rs11951515	0.508	rs6898866	chr5:43586375	G/A	cg01983248	chr5:43482804	C5orf28	-0.39	-8.41	-0.38	6.21e-16	Metabolite levels  (X-11787);
LUAD	trans	rs7615952	0.546	rs11711150	chr3:125315663	C/T	cg17147758	chr8:6949321	NA	-0.47	-7.03	-0.32	8.49e-12	Blood pressure (smoking interaction);
LUAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08439880	chr3:133502540	NA	-0.5	-9.87	-0.43	8.16e-21	Iron status biomarkers;
LUAD	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg12935359	chr14:103987150	CKB	-0.48	-8.14	-0.37	4.33e-15	Body mass index;
LUAD	cis	rs6542838	0.641	rs6542841	chr2:99489039	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.3	-0.33	1.47e-12	Fear of minor pain;
LUAD	cis	rs750460	0.844	rs28588430	chr15:74223430	C/G	cg23484268	chr15:74220776	LOXL1	0.36	6.88	0.32	2.11e-11	Height;
LUAD	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg20476274	chr7:133979776	SLC35B4	-0.62	-10.8	-0.46	3.48e-24	Mean platelet volume;
LUAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.5	7.02	0.32	8.64e-12	Renal function-related traits (BUN);
LUAD	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg26769984	chr7:1090371	C7orf50	0.65	9.28	0.41	9.03e-19	Bronchopulmonary dysplasia;
LUAD	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-9.74	-0.43	2.31e-20	Height;
LUAD	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.7	-0.35	1e-13	Bipolar disorder;
LUAD	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg13319975	chr6:146136371	FBXO30	-0.58	-9.83	-0.43	1.1e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs354225	0.544	rs13386146	chr2:54802514	G/C	cg01766943	chr2:54829624	SPTBN1	0.38	7.01	0.32	9.47e-12	Schizophrenia;
LUAD	cis	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.04	-0.36	8.84e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7107174	1.000	rs1567890	chr11:78101700	T/C	cg02023728	chr11:77925099	USP35	0.47	7.25	0.33	1.95e-12	Testicular germ cell tumor;
LUAD	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg14779329	chr11:130786720	SNX19	0.39	6.92	0.32	1.65e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4629710	0.545	rs2077490	chr6:131554184	C/T	cg12606694	chr6:131520996	AKAP7	0.48	7.23	0.33	2.23e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg24675658	chr1:53192096	ZYG11B	0.36	6.4	0.3	4.17e-10	Monocyte count;
LUAD	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg15704280	chr7:45808275	SEPT13	0.74	10.89	0.47	1.6e-24	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.18	0.41	1.91e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2735413	0.918	rs2344494	chr16:78078111	C/T	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	trans	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg04565464	chr8:145669602	NFKBIL2	0.45	6.76	0.31	4.61e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs11098699	0.784	rs4833899	chr4:124243971	C/T	cg09941581	chr4:124220074	SPATA5	0.42	6.66	0.31	8.48e-11	Mosquito bite size;
LUAD	cis	rs2067615	0.599	rs12369214	chr12:107198611	G/A	cg15890332	chr12:107067104	RFX4	0.38	8.26	0.37	1.89e-15	Heart rate;
LUAD	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	10.88	0.47	1.74e-24	Hip circumference adjusted for BMI;
LUAD	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg19717773	chr7:2847554	GNA12	-0.53	-10.44	-0.45	7.14e-23	Height;
LUAD	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15664640	chr17:80829946	TBCD	-0.84	-17.15	-0.64	1.93e-50	Breast cancer;
LUAD	cis	rs798766	0.779	rs55895920	chr4:1735930	C/T	cg05874882	chr4:1763078	NA	-0.38	-6.67	-0.31	8.2e-11	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs8014204	0.804	rs34956813	chr14:75254167	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.34	-6.45	-0.3	3.03e-10	Caffeine consumption;
LUAD	cis	rs758324	0.947	rs687816	chr5:131262077	C/T	cg06307176	chr5:131281290	NA	-0.53	-8.39	-0.38	7.1e-16	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs10465746	0.967	rs11163876	chr1:84440605	T/C	cg10977910	chr1:84465055	TTLL7	0.51	8.21	0.37	2.71e-15	Obesity-related traits;
LUAD	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.38	-0.6	1.02e-42	Chronic sinus infection;
LUAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs11696501	0.688	rs6094192	chr20:44297796	G/A	cg11783356	chr20:44313418	WFDC10B	-0.48	-7.97	-0.36	1.45e-14	Brain structure;
LUAD	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg01528321	chr10:82214614	TSPAN14	0.51	8.12	0.37	4.99e-15	Post bronchodilator FEV1;
LUAD	cis	rs7561528	0.501	rs11678744	chr2:127888784	C/G	cg08168897	chr2:127865431	BIN1	-0.43	-6.56	-0.3	1.58e-10	Alzheimer's disease;Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg17366294	chr4:99064904	C4orf37	0.65	12.39	0.52	2.65e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.45	7.63	0.35	1.53e-13	Lung cancer in ever smokers;
LUAD	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg04727924	chr7:799746	HEATR2	-0.53	-7.23	-0.33	2.21e-12	Cerebrospinal P-tau181p levels;
LUAD	trans	rs853679	0.546	rs200949	chr6:27835435	A/G	cg06606381	chr12:133084897	FBRSL1	-0.79	-8.26	-0.37	1.88e-15	Depression;
LUAD	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg27129171	chr3:47204927	SETD2	0.41	6.57	0.3	1.5e-10	Colorectal cancer;
LUAD	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg06046430	chr4:77819534	ANKRD56	0.53	8.59	0.39	1.66e-16	Emphysema distribution in smoking;
LUAD	cis	rs7759001	0.857	rs10946914	chr6:27369892	C/T	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg23992470	chr4:843637	GAK	0.69	7.11	0.33	5.08e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18402987	chr7:1209562	NA	0.41	6.59	0.31	1.32e-10	Longevity;Endometriosis;
LUAD	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg23260525	chr10:116636907	FAM160B1	0.47	11.01	0.47	5.64e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12923728	chr3:195709715	SDHAP1	-0.77	-13.3	-0.54	5.58e-34	Pancreatic cancer;
LUAD	trans	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	15.84	0.61	1.03e-44	Exhaled nitric oxide levels;
LUAD	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg14847009	chr1:175162515	KIAA0040	0.33	8.51	0.38	3e-16	Alcohol dependence;
LUAD	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg11822812	chr5:140052017	DND1	0.38	6.64	0.31	9.37e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg02775129	chr4:119771670	NA	-0.89	-8.03	-0.36	9.85e-15	Cannabis dependence symptom count;
LUAD	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg26818010	chr10:134567672	INPP5A	-0.73	-12.67	-0.52	2.07e-31	Migraine;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg17074213	chr1:92351695	TGFBR3	-0.68	-6.5	-0.3	2.25e-10	Type 2 diabetes;
LUAD	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg11833968	chr6:79620685	NA	-0.44	-8.35	-0.38	9.52e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs17095355	0.584	rs12243027	chr10:111924817	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.5	-0.38	3.4e-16	Biliary atresia;
LUAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08677398	chr8:58056175	NA	0.48	6.84	0.32	2.87e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.91	-0.4	1.51e-17	Total body bone mineral density;
LUAD	cis	rs12545109	0.800	rs1837620	chr8:57399473	C/A	cg21220214	chr8:57350948	NA	-0.63	-9.08	-0.4	4.14e-18	Obesity-related traits;
LUAD	trans	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg27411982	chr8:10470053	RP1L1	0.42	7.76	0.35	6.59e-14	Mood instability;
LUAD	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg13789015	chr9:136890014	NCRNA00094	0.86	14.04	0.56	4.79e-37	Platelet distribution width;
LUAD	cis	rs7173743	0.934	rs7168915	chr15:79128889	C/T	cg15571903	chr15:79123663	NA	0.37	7.34	0.34	1.08e-12	Coronary artery disease;
LUAD	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.99	0.32	1.1e-11	Hypertriglyceridemia;
LUAD	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg07936489	chr17:37558343	FBXL20	0.52	7.03	0.32	8.1e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg07606381	chr6:8435919	SLC35B3	0.41	6.88	0.32	2.13e-11	Motion sickness;
LUAD	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg04398451	chr17:18023971	MYO15A	-0.63	-11.52	-0.49	6.7399999999999993e-27	Total body bone mineral density;
LUAD	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg06781209	chr11:61594997	FADS2	-0.37	-6.93	-0.32	1.62e-11	Trans fatty acid levels;
LUAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02353165	chr6:42928485	GNMT	0.41	7.3	0.33	1.46e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7633770	0.786	rs9845998	chr3:46683710	G/A	cg11219411	chr3:46661640	NA	0.58	12.86	0.53	3.49e-32	Coronary artery disease;
LUAD	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07636037	chr3:49044803	WDR6	-0.48	-7.97	-0.36	1.51e-14	Menarche (age at onset);
LUAD	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg15358701	chr1:161410459	NA	-0.7	-7.09	-0.33	5.57e-12	Rheumatoid arthritis;
LUAD	cis	rs9902453	0.791	rs9904051	chr17:28244122	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	10.1	0.44	1.29e-21	Coffee consumption (cups per day);
LUAD	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg16680214	chr1:154839983	KCNN3	0.58	12.2	0.51	1.47e-29	Prostate cancer;
LUAD	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18876405	chr7:65276391	NA	-0.58	-9.67	-0.43	3.92e-20	Aortic root size;
LUAD	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.89e-14	Depression;
LUAD	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.83	0.36	4.09e-14	Morning vs. evening chronotype;
LUAD	cis	rs4917833	0.700	rs7067691	chr10:100221081	T/C	cg25691326	chr10:100228212	HPSE2	0.36	6.46	0.3	2.93e-10	Pediatric bone mineral density (femoral neck);
LUAD	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.65	0.39	1.09e-16	Menarche (age at onset);
LUAD	cis	rs2742417	1.000	rs2673056	chr3:45737802	C/T	cg10512202	chr3:45649293	LIMD1	0.36	6.49	0.3	2.34e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.54	0.38	2.46e-16	Platelet count;
LUAD	cis	rs2985684	1.000	rs3007031	chr14:50102269	G/C	cg04989706	chr14:50066350	PPIL5	-0.47	-6.9	-0.32	1.93e-11	Carotid intima media thickness;
LUAD	cis	rs7107174	1.000	rs58565853	chr11:78036707	C/T	cg02023728	chr11:77925099	USP35	0.4	6.67	0.31	8.21e-11	Testicular germ cell tumor;
LUAD	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.55	0.3	1.69e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs679087	0.932	rs10843507	chr12:29931056	C/A	cg14258853	chr12:29935411	TMTC1	0.62	11.84	0.5	3.99e-28	Schizophrenia;
LUAD	cis	rs704	0.726	rs11080055	chr17:26649724	A/C	cg10342447	chr17:26645325	TMEM97	-0.34	-6.99	-0.32	1.05e-11	Osteoprotegerin levels;
LUAD	cis	rs11771526	0.818	rs17161140	chr7:32324199	T/C	cg27511599	chr7:32358540	NA	0.53	6.6	0.31	1.26e-10	Body mass index;
LUAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06873352	chr17:61820015	STRADA	0.82	18.45	0.67	3.31e-56	Prudent dietary pattern;
LUAD	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg03714773	chr7:91764589	CYP51A1	0.28	6.44	0.3	3.31e-10	Breast cancer;
LUAD	cis	rs12681287	0.604	rs34227066	chr8:87449366	C/T	cg27223183	chr8:87520930	FAM82B	-0.67	-9.58	-0.42	8.35e-20	Caudate activity during reward;
LUAD	trans	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg03886242	chr7:26192032	NFE2L3	-0.44	-7.64	-0.35	1.51e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14240646	chr10:27532245	ACBD5	-0.66	-9.69	-0.43	3.38e-20	Breast cancer;
LUAD	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg26924012	chr15:45694286	SPATA5L1	0.84	14.33	0.57	3.05e-38	Homoarginine levels;
LUAD	cis	rs11734570	0.581	rs73811714	chr4:38588327	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.45	6.45	0.3	3e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg13685833	chr1:53393034	SCP2	-0.5	-7.95	-0.36	1.7e-14	Monocyte count;
LUAD	cis	rs3741798	1.000	rs61922049	chr12:12497395	C/T	cg08615371	chr12:12503544	MANSC1	0.74	6.8	0.31	3.67e-11	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs2302190	0.882	rs7221464	chr17:56552353	A/T	cg25885038	chr17:56607967	SEPT4	-0.48	-7.55	-0.34	2.65e-13	Vitamin D levels;
LUAD	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg13770153	chr20:60521292	NA	0.65	9.81	0.43	1.29e-20	Body mass index;
LUAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.7	10.66	0.46	1.14e-23	Renal function-related traits (BUN);
LUAD	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg20933634	chr6:27740509	NA	-0.48	-7.29	-0.33	1.5e-12	Parkinson's disease;
LUAD	cis	rs7267979	0.668	rs4815398	chr20:25237338	C/T	cg08601574	chr20:25228251	PYGB	-0.43	-7.96	-0.36	1.65e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs11051970	0.661	rs188979	chr12:32569684	G/T	cg02745156	chr12:32552066	NA	0.3	6.36	0.3	5.27e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg09509183	chr1:209979624	IRF6	0.37	6.4	0.3	4.05e-10	Monobrow;
LUAD	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.57	9.11	0.4	3.43e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9369695	0.842	rs2396825	chr6:47568696	A/G	cg02130027	chr6:47444894	CD2AP	0.35	6.81	0.31	3.44e-11	Reticulocyte count;
LUAD	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg24634471	chr8:143751801	JRK	0.48	7.62	0.35	1.72e-13	Schizophrenia;
LUAD	cis	rs2274273	1.000	rs2075603	chr14:55609955	C/A	cg04306507	chr14:55594613	LGALS3	0.38	7.76	0.35	6.26e-14	Protein biomarker;
LUAD	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.55	-0.3	1.66e-10	Total body bone mineral density;
LUAD	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg13180566	chr4:1052158	NA	-0.39	-6.56	-0.3	1.6e-10	Recombination rate (females);
LUAD	cis	rs2041840	0.538	rs3821142	chr2:37575287	C/T	cg25727520	chr2:37576821	QPCT	-0.33	-7.26	-0.33	1.86e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs72772090	0.539	rs72775818	chr5:96193215	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-6.65	-0.31	8.86e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs367615	0.552	rs7720036	chr5:108710699	A/G	cg17395555	chr5:108820864	NA	-0.53	-10.03	-0.44	2.19e-21	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03517284	chr6:25882590	NA	-0.55	-8.22	-0.37	2.45e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7695732	0.743	rs7680864	chr4:89921899	T/C	cg17769793	chr4:89976368	FAM13A	-0.29	-6.39	-0.3	4.32e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg21138405	chr5:131827807	IRF1	-0.61	-13.69	-0.55	1.42e-35	Asthma (sex interaction);
LUAD	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.89	0.32	2.03e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.947	rs31583	chr5:130992432	T/C	cg25547332	chr5:131281432	NA	0.44	6.61	0.31	1.15e-10	Life satisfaction;
LUAD	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg27539214	chr16:67997921	SLC12A4	-0.72	-9.21	-0.41	1.53e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg26168224	chr5:2018326	NA	0.78	17.46	0.65	8.56e-52	Gut microbiome composition (winter);
LUAD	trans	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.46	0.34	4.99e-13	Resting heart rate;
LUAD	cis	rs3800461	0.544	rs11754548	chr6:34504767	G/C	cg14254433	chr6:34482411	PACSIN1	-0.62	-8.7	-0.39	7.65e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs6961069	0.806	rs1761665	chr7:80242079	A/G	cg04458919	chr7:80252533	CD36	-0.35	-6.79	-0.31	3.92e-11	Platelet count;
LUAD	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg10589385	chr1:150898437	SETDB1	0.43	8.09	0.37	6.38e-15	Melanoma;
LUAD	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.64	0.31	9.47e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7149242	0.500	rs10144381	chr14:101173297	C/T	cg18089426	chr14:101175970	NA	0.41	7.19	0.33	2.89e-12	Platelet count;
LUAD	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23158103	chr7:148848205	ZNF398	-0.64	-11.78	-0.5	6.93e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs870825	0.581	rs7675106	chr4:185652388	C/G	cg04058563	chr4:185651563	MLF1IP	-0.85	-13.61	-0.55	3.09e-35	Blood protein levels;
LUAD	cis	rs6499255	1.000	rs6499255	chr16:69830328	A/G	cg15192750	chr16:69999425	NA	0.47	7.32	0.34	1.26e-12	IgE levels;
LUAD	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.3e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg19635926	chr16:89946313	TCF25	0.74	6.59	0.31	1.32e-10	Skin colour saturation;
LUAD	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg02158880	chr13:53174818	NA	0.53	8.95	0.4	1.12e-17	Lewy body disease;
LUAD	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg18876405	chr7:65276391	NA	-0.66	-11.31	-0.48	4.17e-26	Aortic root size;
LUAD	cis	rs2625529	0.824	rs12595228	chr15:72267215	T/C	cg16672083	chr15:72433130	SENP8	-0.76	-12.75	-0.53	9.75e-32	Red blood cell count;
LUAD	cis	rs1018836	0.923	rs6986001	chr8:91650205	T/C	cg16814680	chr8:91681699	NA	-0.67	-11.54	-0.49	5.52e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg11098525	chr4:1320231	MAEA	-0.39	-6.42	-0.3	3.67e-10	Obesity-related traits;
LUAD	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg07256732	chr16:621771	PIGQ	-0.31	-6.36	-0.3	5.27e-10	Height;
LUAD	trans	rs1997103	0.954	rs1997099	chr7:55405540	T/C	cg20935933	chr6:143382018	AIG1	0.54	7.55	0.34	2.67e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg01028140	chr2:1542097	TPO	-0.5	-6.86	-0.32	2.52e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg09399716	chr2:46890238	NA	-0.38	-6.6	-0.31	1.26e-10	Height;
LUAD	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg00757033	chr12:89920650	WDR51B	0.7	12.14	0.51	2.6e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10802521	chr3:52805072	NEK4	-0.53	-9.1	-0.4	3.69e-18	Bipolar disorder;
LUAD	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.46	0.52	1.4e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.4	-6.62	-0.31	1.11e-10	Longevity;Endometriosis;
LUAD	cis	rs1555895	0.576	rs10904571	chr10:850762	A/G	cg20503657	chr10:835505	NA	0.41	6.6	0.31	1.2e-10	Survival in rectal cancer;
LUAD	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg17366294	chr4:99064904	C4orf37	-0.67	-12.93	-0.53	1.82e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg17848003	chr1:3704513	LRRC47	0.53	10.26	0.45	3.42e-22	Red cell distribution width;
LUAD	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg24818145	chr4:99064322	C4orf37	-0.45	-6.97	-0.32	1.2e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs55665837	1.000	rs10832268	chr11:14465068	C/A	cg19336497	chr11:14380999	RRAS2	-0.51	-10.3	-0.45	2.32e-22	Vitamin D levels;
LUAD	cis	rs28374715	0.787	rs11856169	chr15:41547938	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.96	-18.74	-0.67	1.77e-57	Ulcerative colitis;
LUAD	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.44	7.0	0.32	1.03e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs4853036	0.951	rs6738783	chr2:70120608	A/G	cg02498382	chr2:70120550	SNRNP27	-0.56	-9.13	-0.41	2.85e-18	Colorectal or endometrial cancer;
LUAD	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg20744362	chr22:50050164	C22orf34	0.4	8.62	0.39	1.37e-16	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg05590025	chr7:65112418	INTS4L2	-0.74	-8.01	-0.36	1.16e-14	Diabetic kidney disease;
LUAD	trans	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg14791747	chr16:20752902	THUMPD1	0.48	6.95	0.32	1.4e-11	Pancreatic cancer;
LUAD	cis	rs698833	0.848	rs696596	chr2:44718058	G/A	cg04920474	chr2:44395004	PPM1B	0.36	6.51	0.3	2.19e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.79	0.31	3.76e-11	Rheumatoid arthritis;
LUAD	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg21433313	chr16:3507492	NAT15	0.75	12.69	0.53	1.66e-31	Tuberculosis;
LUAD	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21659725	chr3:3221576	CRBN	0.86	18.38	0.67	7.23e-56	Intelligence (multi-trait analysis);
LUAD	cis	rs921968	0.565	rs7599365	chr2:219620566	G/A	cg02176678	chr2:219576539	TTLL4	-0.59	-12.08	-0.51	4.49e-29	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09832218	chr12:56694334	CS	-0.47	-7.84	-0.36	3.68e-14	Cancer;
LUAD	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg00852783	chr1:26633632	UBXN11	0.46	7.52	0.34	3.21e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2067615	0.579	rs1811458	chr12:107203683	G/A	cg15890332	chr12:107067104	RFX4	0.39	8.38	0.38	7.7e-16	Heart rate;
LUAD	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.62	-10.23	-0.45	4.31e-22	Resting heart rate;
LUAD	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	6.64	0.31	9.66e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.59e-12	Breast cancer;
LUAD	cis	rs10504073	0.584	rs55908480	chr8:49923431	G/A	cg00325661	chr8:49890786	NA	0.47	10.49	0.45	4.96e-23	Blood metabolite ratios;
LUAD	cis	rs2979489	0.891	rs6982511	chr8:30355513	G/T	cg26383811	chr8:30366931	RBPMS	-0.69	-10.84	-0.47	2.58e-24	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg15704280	chr7:45808275	SEPT13	0.62	8.32	0.38	1.25e-15	Axial length;
LUAD	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg26384229	chr12:38710491	ALG10B	0.45	7.42	0.34	6.44e-13	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-10.23	-0.45	4.26e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg07817883	chr1:32538562	TMEM39B	1.16	12.14	0.51	2.67e-29	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.64	8.74	0.39	5.7e-17	Renal function-related traits (BUN);
LUAD	cis	rs300774	0.858	rs300712	chr2:138903	A/T	cg21211680	chr2:198530	NA	-0.47	-7.38	-0.34	8.37e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg09537434	chr19:41945824	ATP5SL	-0.53	-8.38	-0.38	7.95e-16	Height;
LUAD	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg00484396	chr16:3507460	NAT15	0.75	10.0	0.44	2.84e-21	Tuberculosis;
LUAD	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg05340658	chr4:99064831	C4orf37	0.45	6.92	0.32	1.66e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs151234	0.612	rs11641853	chr16:28589719	A/G	cg04609801	chr16:28609176	SULT1A2	0.63	9.02	0.4	6.67e-18	Platelet distribution width;
LUAD	cis	rs859767	0.501	rs10210052	chr2:135417350	C/T	cg12500956	chr2:135428796	TMEM163	-0.27	-7.24	-0.33	2.2e-12	Neuroticism;
LUAD	cis	rs1395	0.778	rs72810794	chr2:27401260	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	8.39	0.38	7.3e-16	Blood metabolite levels;
LUAD	cis	rs58804349	0.581	rs12221397	chr10:43239833	A/G	cg08461752	chr10:43522343	NA	0.7	6.79	0.31	3.85e-11	Pediatric bone mineral content (radius);
LUAD	cis	rs10899021	0.790	rs12288525	chr11:74332589	T/A	cg25880958	chr11:74394337	NA	-0.53	-7.41	-0.34	6.77e-13	Response to metformin (IC50);
LUAD	cis	rs7119	0.651	rs12917044	chr15:77850146	A/G	cg27398640	chr15:77910606	LINGO1	0.34	6.63	0.31	1.01e-10	Type 2 diabetes;
LUAD	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg09184832	chr6:79620586	NA	-0.53	-9.75	-0.43	2.11e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg00750074	chr16:89608354	SPG7	-0.57	-9.95	-0.44	4.33e-21	Multiple myeloma (IgH translocation);
LUAD	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg19761014	chr17:28927070	LRRC37B2	0.7	6.61	0.31	1.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.61	-0.31	1.19e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7020830	0.898	rs12554874	chr9:37073902	C/T	cg14294708	chr9:37120828	ZCCHC7	0.84	16.19	0.62	3.13e-46	Schizophrenia;
LUAD	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg00898013	chr13:113819073	PROZ	-0.68	-12.2	-0.51	1.55e-29	Platelet distribution width;
LUAD	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg11859384	chr17:80120422	CCDC57	-0.48	-8.69	-0.39	7.8e-17	Life satisfaction;
LUAD	cis	rs11622475	0.911	rs55908053	chr14:104386173	T/C	cg12183467	chr14:104352244	NA	-0.41	-7.43	-0.34	6.19e-13	Bipolar disorder;
LUAD	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg09654669	chr8:57350985	NA	-0.66	-10.03	-0.44	2.29e-21	Obesity-related traits;
LUAD	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg03676636	chr4:99064102	C4orf37	0.29	6.95	0.32	1.35e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11811982	0.793	rs11806721	chr1:227514987	A/T	cg24860534	chr1:227506868	CDC42BPA	-0.58	-6.83	-0.32	2.87e-11	Optic disc area;
LUAD	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg17724175	chr1:150552817	MCL1	0.34	7.85	0.36	3.53e-14	Melanoma;
LUAD	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.68	-12.76	-0.53	9.14e-32	Ulcerative colitis;
LUAD	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg08219700	chr8:58056026	NA	0.69	8.98	0.4	9.17e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg27541892	chr1:1571801	CDK11B	-0.45	-7.37	-0.34	9.19e-13	Body mass index;
LUAD	cis	rs28530618	0.580	rs4607010	chr20:31255271	G/C	cg13636640	chr20:31349939	DNMT3B	-0.46	-6.93	-0.32	1.54e-11	Birth weight;
LUAD	cis	rs7937890	0.559	rs2597219	chr11:14530866	C/G	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.25e-11	Mitochondrial DNA levels;
LUAD	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22496380	chr5:211416	CCDC127	0.96	13.17	0.54	1.92e-33	Breast cancer;
LUAD	cis	rs654950	0.806	rs941971	chr1:42040893	T/C	cg06885757	chr1:42089581	HIVEP3	-0.49	-10.99	-0.47	7e-25	Airway imaging phenotypes;
LUAD	cis	rs796364	0.715	rs78988795	chr2:201095739	G/A	cg23649088	chr2:200775458	C2orf69	-0.7	-7.39	-0.34	8.07e-13	Schizophrenia;
LUAD	cis	rs2387326	0.767	rs12264157	chr10:129943271	G/A	cg16087940	chr10:129947807	NA	-0.65	-9.11	-0.4	3.39e-18	Select biomarker traits;
LUAD	cis	rs673604	0.536	rs72657987	chr1:35684267	T/C	cg12633102	chr1:35676489	NA	-0.72	-7.24	-0.33	2.12e-12	Endometrial cancer;
LUAD	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11644478	chr21:40555479	PSMG1	-0.39	-6.37	-0.3	5e-10	Menarche (age at onset);
LUAD	trans	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.56	-9.53	-0.42	1.25e-19	Mean corpuscular volume;
LUAD	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg16049864	chr8:95962084	TP53INP1	0.52	9.62	0.42	6.23e-20	Type 2 diabetes;
LUAD	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg24069376	chr3:38537580	EXOG	-0.33	-7.48	-0.34	4.4e-13	Electrocardiographic conduction measures;
LUAD	trans	rs57046232	0.552	rs6054147	chr20:6336002	A/G	cg21095983	chr6:86352623	SYNCRIP	-0.43	-6.67	-0.31	7.85e-11	Colorectal cancer;
LUAD	cis	rs7274811	0.711	rs291691	chr20:32002878	G/C	cg13403462	chr20:32256071	NECAB3;C20orf134	0.43	6.46	0.3	2.92e-10	Height;
LUAD	cis	rs989128	0.572	rs6504674	chr17:48630814	T/C	cg24438145	chr17:48624694	SPATA20	0.38	6.58	0.3	1.37e-10	Type 2 diabetes;
LUAD	cis	rs4308124	0.708	rs67816163	chr2:111963310	A/G	cg04571233	chr2:111982156	NA	-0.45	-6.41	-0.3	3.78e-10	Vitiligo;
LUAD	cis	rs750460	0.966	rs4243042	chr15:74241624	A/T	cg23484268	chr15:74220776	LOXL1	0.37	7.09	0.33	5.52e-12	Height;
LUAD	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg05044414	chr3:183734942	ABCC5	0.5	9.34	0.41	5.36e-19	Anterior chamber depth;
LUAD	trans	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg19862616	chr7:65841803	NCRNA00174	1.04	26.03	0.78	6.94e-90	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs939584	1.000	rs6744646	chr2:628504	A/G	cg03444855	chr2:621920	NA	-0.4	-6.46	-0.3	2.83e-10	Body mass index;
LUAD	cis	rs739496	0.614	rs9788231	chr12:112385665	A/C	cg10833066	chr12:111807467	FAM109A	0.43	6.96	0.32	1.29e-11	Platelet count;
LUAD	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg14552801	chr7:65878734	NA	-0.37	-6.42	-0.3	3.77e-10	Aortic root size;
LUAD	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg10802521	chr3:52805072	NEK4	-0.46	-6.72	-0.31	6.06e-11	Schizophrenia;
LUAD	cis	rs1232027	0.622	rs1620258	chr5:79982008	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.42	-6.5	-0.3	2.27e-10	Huntington's disease progression;
LUAD	cis	rs3789045	0.560	rs1107339	chr1:204411942	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.6	-9.64	-0.42	5.32e-20	Educational attainment (college completion);
LUAD	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg15782153	chr7:917662	C7orf20	-0.54	-10.37	-0.45	1.34e-22	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs4853525	0.859	rs6434424	chr2:191722126	A/C	cg27211696	chr2:191398769	TMEM194B	-0.37	-6.52	-0.3	2.04e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg19318889	chr4:1322082	MAEA	0.47	7.8	0.35	4.92e-14	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-7.58	-0.35	2.18e-13	Neutrophil percentage of white cells;
LUAD	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg13770153	chr20:60521292	NA	-0.55	-9.25	-0.41	1.11e-18	Body mass index;
LUAD	cis	rs12530845	0.623	rs7798256	chr7:135344211	C/A	cg23117316	chr7:135346802	PL-5283	-0.6	-9.07	-0.4	4.54e-18	Red blood cell traits;
LUAD	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg05043794	chr9:111880884	C9orf5	-0.42	-7.57	-0.35	2.42e-13	Menarche (age at onset);
LUAD	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg11859384	chr17:80120422	CCDC57	0.5	9.01	0.4	7.15e-18	Life satisfaction;
LUAD	cis	rs9394841	0.692	rs9349202	chr6:41805581	A/C	cg25600774	chr6:41776562	USP49	-0.43	-6.54	-0.3	1.74e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg10909506	chr17:38081995	ORMDL3	0.37	6.71	0.31	6.23e-11	Self-reported allergy;
LUAD	cis	rs11077998	0.933	rs3736204	chr17:80530279	C/T	cg10255544	chr17:80519551	FOXK2	0.34	6.65	0.31	8.89e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07157834	chr1:205819609	PM20D1	0.72	13.85	0.56	3.06e-36	Menarche (age at onset);
LUAD	cis	rs9863	0.828	rs11057412	chr12:124489142	G/C	cg17723958	chr12:124429295	CCDC92	-0.41	-6.85	-0.32	2.66e-11	White blood cell count;
LUAD	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg01448562	chr3:133502909	NA	0.65	12.2	0.51	1.57e-29	Iron status biomarkers;
LUAD	cis	rs9400271	0.527	rs60248809	chr6:109640690	A/C	cg21918786	chr6:109611834	NA	0.39	6.41	0.3	3.91e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg12140854	chr5:148520817	ABLIM3	-0.67	-10.58	-0.46	2.33e-23	Breast cancer;
LUAD	trans	rs8002861	0.935	rs1373903	chr13:44475514	G/T	cg17145862	chr1:211918768	LPGAT1	0.75	17.76	0.65	3.78e-53	Leprosy;
LUAD	cis	rs6987853	0.933	rs2974340	chr8:42397731	T/C	cg09913449	chr8:42400586	C8orf40	0.43	7.93	0.36	2.03e-14	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs733175	0.855	rs10018666	chr4:10004805	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.02	0.32	8.75e-12	Psychosis and Alzheimer's disease;
LUAD	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg27279351	chr12:120934652	DYNLL1	0.44	6.68	0.31	7.75e-11	High light scatter reticulocyte count;
LUAD	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg25427524	chr10:38739819	LOC399744	0.7	12.68	0.52	1.82e-31	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.36	0.34	9.68e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs17433780	0.892	rs72726528	chr1:89455980	C/A	cg09516651	chr1:89888402	LOC400759	0.49	8.7	0.39	7.7e-17	Carotid intima media thickness;
LUAD	cis	rs938554	0.784	rs16868246	chr4:9978305	C/G	cg11266682	chr4:10021025	SLC2A9	0.44	7.7	0.35	9.64e-14	Blood metabolite levels;
LUAD	cis	rs56283067	0.886	rs2023311	chr6:44678306	A/T	cg18551225	chr6:44695536	NA	-0.53	-8.88	-0.4	1.92e-17	Total body bone mineral density;
LUAD	cis	rs8048589	0.948	rs35053871	chr16:12182437	G/T	cg03816625	chr16:12192430	SNX29	0.54	7.97	0.36	1.51e-14	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg22764044	chr5:178986830	RUFY1	0.55	9.23	0.41	1.34e-18	Lung cancer;
LUAD	trans	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg20556744	chr2:9614537	IAH1	0.62	6.53	0.3	1.91e-10	Opioid sensitivity;
LUAD	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg17063962	chr7:91808500	NA	-0.67	-12.02	-0.5	7.57e-29	Breast cancer;
LUAD	trans	rs8105895	0.735	rs17554694	chr19:22317148	A/G	cg05197062	chr11:11642011	GALNTL4	0.5	7.34	0.34	1.1e-12	Body mass index (change over time);
LUAD	cis	rs2425143	1.000	rs12479473	chr20:34398628	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.08	-0.33	6.15e-12	Blood protein levels;
LUAD	cis	rs62238980	0.614	rs118073663	chr22:32397610	A/T	cg00543991	chr22:32367038	NA	0.93	8.61	0.39	1.41e-16	Childhood ear infection;
LUAD	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg06558623	chr16:89946397	TCF25	1.15	10.16	0.44	7.69e-22	Skin colour saturation;
LUAD	trans	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-14.88	-0.59	1.42e-40	Exhaled nitric oxide output;
LUAD	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg24813613	chr7:1882135	MAD1L1	-0.53	-8.78	-0.39	4.01e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg04398451	chr17:18023971	MYO15A	0.72	13.26	0.54	8.21e-34	Total body bone mineral density;
LUAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-8.24	-0.37	2.17e-15	Alzheimer's disease;
LUAD	cis	rs7107174	0.901	rs10899473	chr11:78042983	A/C	cg19901956	chr11:77921274	USP35	-0.45	-6.36	-0.3	5.38e-10	Testicular germ cell tumor;
LUAD	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg12011299	chr4:100065546	ADH4	-0.74	-13.66	-0.55	1.89e-35	Alcohol dependence;
LUAD	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg20628663	chr10:43360327	NA	-0.73	-11.33	-0.48	3.61e-26	Blood protein levels;
LUAD	cis	rs2573652	0.698	rs12916269	chr15:100530216	A/T	cg09918751	chr15:100517450	ADAMTS17	0.39	7.29	0.33	1.58e-12	Height;
LUAD	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg12927641	chr6:109611667	NA	-0.54	-9.47	-0.42	2.02e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs1904096	0.506	rs11097408	chr4:95165662	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.5	-9.32	-0.41	6.74e-19	Type 2 diabetes;
LUAD	cis	rs73191547	0.501	rs6986885	chr8:9978471	G/A	cg27411982	chr8:10470053	RP1L1	0.36	6.83	0.32	2.89e-11	Schizophrenia;
LUAD	cis	rs10489202	0.632	rs202273	chr1:167919963	A/G	cg24449463	chr1:168025552	DCAF6	-0.72	-12.11	-0.51	3.47e-29	Schizophrenia;
LUAD	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg09399716	chr2:46890238	NA	-0.38	-6.78	-0.31	4.1e-11	Height;
LUAD	cis	rs2479724	1.000	rs2479724	chr6:41890982	T/C	cg17623882	chr6:41773611	USP49	-0.6	-10.78	-0.46	4.03e-24	Menarche (age at onset);
LUAD	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.27	-6.84	-0.32	2.86e-11	Oral cavity cancer;
LUAD	cis	rs13095912	1.000	rs13340181	chr3:185325612	T/C	cg11274856	chr3:185301563	NA	0.38	7.72	0.35	8.33e-14	Systolic blood pressure;
LUAD	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	12.37	0.52	3.39e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg14196790	chr5:131705035	SLC22A5	0.37	6.77	0.31	4.19e-11	Blood metabolite levels;
LUAD	cis	rs7326068	0.610	rs4769128	chr13:21322682	A/G	cg27499820	chr13:21296301	IL17D	-0.51	-7.79	-0.35	5.39e-14	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs5756813	0.727	rs4821703	chr22:38136676	C/T	cg06521852	chr22:38141419	TRIOBP	0.5	8.98	0.4	8.8e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.89	-0.66	1.08e-53	Height;
LUAD	cis	rs9473147	0.602	rs9296567	chr6:47553402	G/A	cg02130027	chr6:47444894	CD2AP	0.37	6.99	0.32	1.06e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7809615	0.901	rs6947974	chr7:99156506	G/A	cg03133378	chr7:99195931	NA	-0.58	-6.79	-0.31	3.77e-11	Blood metabolite ratios;
LUAD	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg13319975	chr6:146136371	FBXO30	0.84	14.27	0.57	5.2e-38	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg06263672	chr7:65235340	NA	0.57	9.23	0.41	1.35e-18	Calcium levels;
LUAD	trans	rs6495785	0.678	rs71466817	chr15:35925895	C/T	cg04307083	chr4:57521138	HOPX	-0.36	-6.88	-0.32	2.16e-11	Menopause (age at onset);
LUAD	cis	rs727505	0.954	rs67870530	chr7:124591878	A/G	cg23710748	chr7:124431027	NA	-0.44	-8.68	-0.39	8.75e-17	Lewy body disease;
LUAD	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg05425664	chr17:57184151	TRIM37	0.42	6.95	0.32	1.36e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg24634471	chr8:143751801	JRK	-0.47	-7.55	-0.34	2.79e-13	Schizophrenia;
LUAD	cis	rs7851660	0.809	rs10739526	chr9:100662671	T/C	cg13688889	chr9:100608707	NA	-0.54	-9.17	-0.41	2.08e-18	Strep throat;
LUAD	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.47	0.3	2.77e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4689388	0.581	rs4688985	chr4:6285715	A/G	cg25554036	chr4:6271136	WFS1	0.64	10.4	0.45	1.06e-22	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs752010	0.655	rs10890145	chr1:42086290	A/G	cg06885757	chr1:42089581	HIVEP3	0.48	11.11	0.48	2.54e-25	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg19761014	chr17:28927070	LRRC37B2	0.9	8.82	0.39	3.11e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs12541635	0.677	rs1496181	chr8:107027141	C/T	cg10147462	chr8:107024639	NA	0.56	10.08	0.44	1.48e-21	Age of smoking initiation;
LUAD	cis	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg18232548	chr7:50535776	DDC	-0.69	-12.02	-0.5	7.62e-29	Response to zileuton treatment in asthma (FEV1 change interaction);
LUAD	cis	rs877282	0.755	rs2790388	chr10:786084	T/C	cg17470449	chr10:769945	NA	0.48	7.45	0.34	5.32e-13	Uric acid levels;
LUAD	cis	rs2742234	0.541	rs10899782	chr10:43736361	A/T	cg15436174	chr10:43711423	RASGEF1A	0.53	8.88	0.4	1.96e-17	Hirschsprung disease;
LUAD	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg04111992	chr7:158790115	NA	-0.43	-7.21	-0.33	2.66e-12	Facial morphology (factor 20);
LUAD	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg21153622	chr11:89784906	NA	-0.33	-6.54	-0.3	1.83e-10	Coronary artery disease;
LUAD	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg11833968	chr6:79620685	NA	-0.44	-8.23	-0.37	2.36e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7709909	0.967	rs11743909	chr5:80002425	A/G	cg24059623	chr5:79951536	MSH3;DHFR	0.4	6.87	0.32	2.34e-11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	trans	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.59	-10.5	-0.45	4.54e-23	Mean corpuscular volume;
LUAD	trans	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg18187862	chr3:45730750	SACM1L	0.53	8.05	0.36	8.32e-15	Primary sclerosing cholangitis;
LUAD	cis	rs877282	0.898	rs11253343	chr10:765117	C/T	cg17470449	chr10:769945	NA	0.63	9.0	0.4	7.54e-18	Uric acid levels;
LUAD	trans	rs7395662	0.963	rs11039826	chr11:48572398	G/A	cg00717180	chr2:96193071	NA	-0.4	-7.47	-0.34	4.76e-13	HDL cholesterol;
LUAD	cis	rs75920871	0.843	rs4936363	chr11:116972935	A/G	cg04087571	chr11:116723030	SIK3	0.32	6.63	0.31	1.04e-10	Subjective well-being;
LUAD	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg21918786	chr6:109611834	NA	-0.57	-10.58	-0.46	2.38e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs12920732	0.583	rs8058755	chr16:84785203	C/T	cg07647771	chr16:84786436	USP10	-0.24	-6.82	-0.31	3.2e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05665937	chr4:1216051	CTBP1	0.48	7.23	0.33	2.24e-12	Longevity;
LUAD	trans	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.47	0.49	1.07e-26	Mean corpuscular volume;
LUAD	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg12179176	chr11:130786555	SNX19	0.54	9.07	0.4	4.68e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg06484146	chr7:12443880	VWDE	-0.58	-8.54	-0.38	2.41e-16	Coronary artery disease;
LUAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg21226059	chr5:178986404	RUFY1	-0.65	-11.9	-0.5	2.39e-28	Lung cancer;
LUAD	trans	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg06606381	chr12:133084897	FBRSL1	-0.94	-8.88	-0.4	1.91e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.61	-0.52	3.58e-31	Hip circumference adjusted for BMI;
LUAD	trans	rs3960554	0.808	rs112962015	chr7:75659303	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	11.16	0.48	1.65e-25	Eotaxin levels;
LUAD	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg02269571	chr22:50332266	NA	-0.62	-9.28	-0.41	8.6e-19	Schizophrenia;
LUAD	trans	rs3857536	0.813	rs6904511	chr6:66939102	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg07402062	chr16:89894098	SPIRE2	0.44	11.14	0.48	1.96e-25	Vitiligo;
LUAD	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg27432699	chr2:27873401	GPN1	-0.38	-6.44	-0.3	3.21e-10	Total body bone mineral density;
LUAD	cis	rs644148	0.770	rs2571113	chr19:44999814	A/G	cg15540054	chr19:45004280	ZNF180	-0.41	-6.7	-0.31	6.61e-11	Personality dimensions;
LUAD	cis	rs2996428	0.643	rs6424056	chr1:3722486	G/A	cg17443473	chr1:3703550	LRRC47	0.47	8.13	0.37	4.65e-15	Red cell distribution width;
LUAD	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg26677194	chr12:130822605	PIWIL1	0.54	8.98	0.4	8.78e-18	Menopause (age at onset);
LUAD	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg07305463	chr2:136567211	LCT	0.4	7.56	0.35	2.52e-13	Mosquito bite size;
LUAD	trans	rs2018683	0.700	rs13227954	chr7:29017188	A/C	cg19402173	chr7:128379420	CALU	0.54	9.07	0.4	4.65e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3087591	0.960	rs12942397	chr17:29462498	C/A	cg24425628	chr17:29625626	OMG;NF1	0.41	6.66	0.31	8.31e-11	Hip circumference;
LUAD	cis	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg07460842	chr6:66804631	NA	-0.99	-14.76	-0.58	4.38e-40	Exhaled nitric oxide output;
LUAD	cis	rs62238980	0.614	rs74534759	chr22:32383419	T/G	cg00543991	chr22:32367038	NA	0.92	8.48	0.38	3.7e-16	Childhood ear infection;
LUAD	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg06618935	chr21:46677482	NA	-0.45	-8.77	-0.39	4.45e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18876405	chr7:65276391	NA	-0.44	-6.91	-0.32	1.83e-11	Aortic root size;
LUAD	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.76	0.35	6.57e-14	Parkinson's disease;
LUAD	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.55	-0.3	1.66e-10	Total body bone mineral density;
LUAD	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg13263323	chr15:86062960	AKAP13	-0.45	-7.46	-0.34	5e-13	Coronary artery disease;
LUAD	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs758324	0.947	rs60847707	chr5:131252554	C/T	cg25547332	chr5:131281432	NA	-0.44	-6.76	-0.31	4.67e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg26597838	chr10:835615	NA	1.31	20.16	0.7	7.51e-64	Eosinophil percentage of granulocytes;
LUAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08280861	chr8:58055591	NA	0.69	8.39	0.38	7.24e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.04	-0.36	9.24e-15	Cystic fibrosis severity;
LUAD	cis	rs3815700	0.920	rs10426856	chr19:33096406	A/G	cg02997394	chr19:33096574	ANKRD27	0.69	9.46	0.42	2.09e-19	Eosinophilic esophagitis;
LUAD	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg12564285	chr5:131593104	PDLIM4	0.37	7.04	0.32	7.94e-12	Acylcarnitine levels;
LUAD	cis	rs3096299	0.606	rs2965960	chr16:89541795	G/A	cg06640241	chr16:89574553	SPG7	0.52	7.74	0.35	7.54e-14	Multiple myeloma (IgH translocation);
LUAD	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg23533926	chr12:111358616	MYL2	-0.42	-7.25	-0.33	2.01e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg24733560	chr20:60626293	TAF4	0.45	8.03	0.36	1e-14	Body mass index;
LUAD	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg24450063	chr1:156163899	SLC25A44	1.05	16.88	0.63	3.18e-49	Testicular germ cell tumor;
LUAD	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg07234876	chr8:600039	NA	-0.83	-7.96	-0.36	1.59e-14	IgG glycosylation;
LUAD	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg13918804	chr1:2043761	PRKCZ	0.38	6.4	0.3	4.24e-10	Height;
LUAD	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg16989719	chr2:238392110	NA	-0.34	-7.42	-0.34	6.64e-13	Prostate cancer;
LUAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg00080972	chr5:178986291	RUFY1	0.5	8.76	0.39	4.84e-17	Lung cancer;
LUAD	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg18138036	chr10:133769891	PPP2R2D	0.41	6.69	0.31	7.09e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg23887609	chr12:130822674	PIWIL1	0.4	6.56	0.3	1.62e-10	Menopause (age at onset);
LUAD	cis	rs1561288	0.691	rs2384093	chr2:25401627	A/G	cg10045137	chr2:25383940	POMC	-0.39	-6.69	-0.31	7.18e-11	Body mass index;
LUAD	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	9.82	0.43	1.25e-20	Axial length;
LUAD	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg06623918	chr6:96969491	KIAA0776	-0.85	-16.45	-0.62	2.37e-47	Headache;
LUAD	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg24531977	chr5:56204891	C5orf35	-0.45	-7.33	-0.34	1.21e-12	Coronary artery disease;
LUAD	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg05340658	chr4:99064831	C4orf37	0.43	7.26	0.33	1.92e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-9.81	-0.43	1.34e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg23758822	chr17:41437982	NA	0.99	20.11	0.7	1.33e-63	Menopause (age at onset);
LUAD	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg14416269	chr4:6271139	WFS1	0.6	12.15	0.51	2.31e-29	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs12681287	0.640	rs7841690	chr8:87365359	T/C	cg27223183	chr8:87520930	FAM82B	0.69	9.65	0.42	4.81e-20	Caudate activity during reward;
LUAD	cis	rs7799006	0.929	rs6461233	chr7:2261468	G/A	cg02951883	chr7:2050386	MAD1L1	-0.49	-7.76	-0.35	6.41e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg23625390	chr15:77176239	SCAPER	-0.52	-7.87	-0.36	2.92e-14	Blood metabolite levels;
LUAD	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	trans	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.71	-0.35	9.25e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg20291162	chr17:40259547	DHX58	-0.69	-10.45	-0.45	6.85e-23	Fibrinogen levels;
LUAD	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg10755058	chr3:40428713	ENTPD3	-0.38	-7.36	-0.34	9.9e-13	Renal cell carcinoma;
LUAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg11062466	chr8:58055876	NA	0.45	6.45	0.3	3.04e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs11051970	0.636	rs10844198	chr12:32563479	G/T	cg02745156	chr12:32552066	NA	0.31	6.66	0.31	8.77e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4776059	1.000	rs3751614	chr15:52901638	T/C	cg24008177	chr15:52972085	KIAA1370	0.25	6.87	0.32	2.37e-11	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6987853	0.933	rs2974353	chr8:42409165	A/C	cg09913449	chr8:42400586	C8orf40	0.42	7.94	0.36	1.78e-14	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4523957	0.893	rs11078019	chr17:2162121	G/A	cg16513277	chr17:2031491	SMG6	-0.76	-14.68	-0.58	1.05e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6987853	0.966	rs2974342	chr8:42436651	A/C	cg09913449	chr8:42400586	C8orf40	0.41	7.68	0.35	1.15e-13	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6906287	0.718	rs6911035	chr6:118653705	A/T	cg21191810	chr6:118973309	C6orf204	0.35	6.37	0.3	5e-10	Electrocardiographic conduction measures;
LUAD	cis	rs938554	0.744	rs6449137	chr4:9932479	A/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.61	-0.31	1.16e-10	Blood metabolite levels;
LUAD	cis	rs250677	0.522	rs1432798	chr5:148383345	C/G	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.61	-0.35	1.79e-13	Breast cancer;
LUAD	cis	rs7640424	0.620	rs34910554	chr3:107816733	C/T	cg09227934	chr3:107805635	CD47	-0.68	-10.73	-0.46	6.68e-24	Body mass index;
LUAD	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg10755058	chr3:40428713	ENTPD3	0.45	8.5	0.38	3.36e-16	Renal cell carcinoma;
LUAD	cis	rs62400317	0.859	rs62436778	chr6:45120666	A/G	cg20913747	chr6:44695427	NA	-0.4	-6.4	-0.3	4.02e-10	Total body bone mineral density;
LUAD	cis	rs7095607	0.730	rs1900012	chr10:69953942	G/A	cg18986048	chr10:69913749	MYPN	0.42	7.42	0.34	6.49e-13	Lung function (FVC);
LUAD	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.02	0.32	8.71e-12	Renal cell carcinoma;
LUAD	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg06618935	chr21:46677482	NA	-0.49	-9.76	-0.43	1.94e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg02493740	chr2:85810744	VAMP5	0.46	8.4	0.38	6.62e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	trans	rs637571	0.584	rs594689	chr11:65635559	G/A	cg17712092	chr4:129076599	LARP1B	-0.76	-13.1	-0.54	3.74e-33	Eosinophil percentage of white cells;
LUAD	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg12016809	chr21:47604291	C21orf56	0.54	8.64	0.39	1.14e-16	Testicular germ cell tumor;
LUAD	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg24813613	chr7:1882135	MAD1L1	0.44	6.9	0.32	1.9e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7527798	0.592	rs10863437	chr1:207817612	T/C	cg09232269	chr1:207846808	CR1L	-0.34	-6.53	-0.3	1.93e-10	Erythrocyte sedimentation rate;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg04275040	chr17:78936628	RPTOR	0.37	6.53	0.3	1.86e-10	Vertical cup-disc ratio;
LUAD	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg25753631	chr6:25732923	NA	-0.42	-7.46	-0.34	5.13e-13	Iron status biomarkers;
LUAD	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.8	8.85	0.4	2.41e-17	Initial pursuit acceleration;
LUAD	cis	rs17292804	0.527	rs12887734	chr14:104046834	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.42	-0.34	6.37e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg12458913	chr13:53173898	NA	0.41	7.29	0.33	1.53e-12	Lewy body disease;
LUAD	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg13012494	chr21:47604986	C21orf56	0.47	7.75	0.35	6.93e-14	Testicular germ cell tumor;
LUAD	cis	rs1232027	0.656	rs1650663	chr5:79963197	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.15	-0.33	3.76e-12	Huntington's disease progression;
LUAD	cis	rs3845702	0.736	rs72962517	chr2:180861452	G/A	cg01881094	chr2:180872142	CWC22	0.81	8.67	0.39	9.63e-17	Schizophrenia;
LUAD	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg08893839	chr5:154027129	NA	0.56	7.56	0.34	2.55e-13	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	trans	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.06	-0.4	4.77e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs13064411	0.696	rs9814395	chr3:113188885	C/T	cg10517650	chr3:113235015	CCDC52	-0.52	-9.04	-0.4	5.66e-18	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22496380	chr5:211416	CCDC127	-0.93	-13.09	-0.54	4.04e-33	Breast cancer;
LUAD	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg06263672	chr7:65235340	NA	0.49	6.85	0.32	2.64e-11	Aortic root size;
LUAD	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.32	6.4	0.3	4.25e-10	Personality dimensions;
LUAD	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg17264618	chr3:40429014	ENTPD3	0.41	9.07	0.4	4.62e-18	Renal cell carcinoma;
LUAD	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.37	6.76	0.31	4.57e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1712517	0.844	rs4918003	chr10:105044157	C/T	cg05636881	chr10:105038444	INA	0.33	6.6	0.31	1.22e-10	Migraine;
LUAD	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.62	-0.31	1.1e-10	Total body bone mineral density;
LUAD	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg16479474	chr6:28041457	NA	0.36	6.41	0.3	3.8e-10	Cardiac Troponin-T levels;
LUAD	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.61	-0.31	1.16e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2425143	1.000	rs1890470	chr20:34357008	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.6	-0.35	1.96e-13	Blood protein levels;
LUAD	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg16405210	chr4:1374714	KIAA1530	-0.6	-9.27	-0.41	9.62e-19	Longevity;
LUAD	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg23254163	chr1:152506842	NA	0.26	7.18	0.33	3.24e-12	Hair morphology;
LUAD	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg24829409	chr8:58192753	C8orf71	-0.65	-9.71	-0.43	2.94e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs78707713	0.841	rs10998780	chr10:71201735	A/T	cg12610070	chr10:71211762	TSPAN15	-0.4	-7.43	-0.34	5.93e-13	Venous thromboembolism;
LUAD	cis	rs375066	0.592	rs349046	chr19:44300626	C/T	cg12072164	chr19:44306565	LYPD5	-0.39	-8.15	-0.37	4.12e-15	Breast cancer;
LUAD	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg09085632	chr11:111637200	PPP2R1B	0.63	9.1	0.4	3.57e-18	Primary sclerosing cholangitis;
LUAD	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg03732007	chr1:2071316	PRKCZ	0.35	7.01	0.32	9.51e-12	Height;
LUAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.63	9.55	0.42	1.04e-19	Renal function-related traits (BUN);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg17199681	chr17:3540328	CTNS;SHPK	-0.73	-6.88	-0.32	2.12e-11	Type 2 diabetes;
LUAD	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg27087555	chr16:88793112	FAM38A	-0.9	-8.18	-0.37	3.35e-15	Plateletcrit;
LUAD	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.37	-0.34	9.19e-13	Breast cancer;
LUAD	cis	rs13082711	0.911	rs6773733	chr3:27502131	C/A	cg02860705	chr3:27208620	NA	0.61	9.35	0.41	5.18e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs4889855	0.505	rs8082303	chr17:78605012	A/G	cg16591659	chr17:78472290	NA	-0.43	-7.48	-0.34	4.25e-13	Fractional excretion of uric acid;
LUAD	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.46	-0.42	2.11e-19	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.62e-10	Aortic root size;
LUAD	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg25358565	chr5:93447407	FAM172A	0.62	7.3	0.33	1.46e-12	Diabetic retinopathy;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12069248	chr11:65628378	MUS81	-0.41	-6.37	-0.3	5.03e-10	Height;
LUAD	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg08280861	chr8:58055591	NA	0.75	9.0	0.4	7.45e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg16049864	chr8:95962084	TP53INP1	-0.54	-11.51	-0.49	7.69e-27	Type 2 diabetes;
LUAD	trans	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.78	-14.93	-0.59	8.42e-41	Brugada syndrome;
LUAD	cis	rs240764	0.717	rs239236	chr6:101099217	A/G	cg09795085	chr6:101329169	ASCC3	0.4	6.94	0.32	1.44e-11	Neuroticism;
LUAD	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.67	-10.28	-0.45	2.75e-22	Chronic sinus infection;
LUAD	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg10356904	chr22:49881777	NA	-0.33	-6.88	-0.32	2.16e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4072705	1.000	rs10760371	chr9:127452977	T/G	cg13476313	chr9:127244764	NR5A1	0.28	6.81	0.31	3.37e-11	Menarche (age at onset);
LUAD	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20456258	chr4:962124	DGKQ	0.38	6.62	0.31	1.06e-10	Sjögren's syndrome;
LUAD	cis	rs2735413	0.918	rs1922612	chr16:78052983	G/C	cg04733911	chr16:78082701	NA	-0.28	-6.45	-0.3	3.03e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg04450456	chr4:17643702	FAM184B	0.4	7.94	0.36	1.83e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03934478	chr11:495069	RNH1	0.77	8.91	0.4	1.58e-17	Body mass index;
LUAD	cis	rs1865721	0.682	rs3745082	chr18:73142734	G/T	cg26385618	chr18:73139727	C18orf62	-0.5	-10.02	-0.44	2.33e-21	Intelligence;
LUAD	cis	rs7095607	0.538	rs2673796	chr10:69917242	A/G	cg18986048	chr10:69913749	MYPN	0.45	7.77	0.35	6.1e-14	Lung function (FVC);
LUAD	cis	rs7944584	0.563	rs61895112	chr11:47560433	T/C	cg20307385	chr11:47447363	PSMC3	0.52	7.69	0.35	1.04e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg18876405	chr7:65276391	NA	0.43	6.67	0.31	8.14e-11	Aortic root size;
LUAD	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg25985355	chr7:65971099	NA	-0.51	-6.37	-0.3	4.89e-10	Diabetic kidney disease;
LUAD	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.86	12.37	0.52	3.34e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1448094	0.933	rs10779218	chr12:86320053	A/G	cg00310523	chr12:86230176	RASSF9	0.36	7.72	0.35	8.22e-14	Major depressive disorder;
LUAD	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.74e-11	Crohn's disease;
LUAD	cis	rs4604732	0.578	rs12040725	chr1:247644697	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.51	8.74	0.39	5.54e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg01620082	chr3:125678407	NA	-0.44	-6.68	-0.31	7.77e-11	Depression;
LUAD	cis	rs7107174	1.000	rs10899465	chr11:78013588	G/A	cg02023728	chr11:77925099	USP35	0.51	7.71	0.35	9.05e-14	Testicular germ cell tumor;
LUAD	trans	rs9991328	0.727	rs3822075	chr4:89726073	T/A	cg07140885	chr10:99495859	ZFYVE27	0.34	6.35	0.3	5.58e-10	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-10.84	-0.47	2.54e-24	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7617773	0.780	rs34630841	chr3:48343261	G/A	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.43	-0.42	2.72e-19	Life satisfaction;
LUAD	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	7.49	0.34	4.15e-13	Tonsillectomy;
LUAD	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg19000871	chr14:103996768	TRMT61A	-0.53	-9.04	-0.4	5.73e-18	Coronary artery disease;
LUAD	cis	rs62238980	0.614	rs1475996	chr22:32464980	T/C	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs35883536	0.875	rs1970227	chr1:101140723	G/A	cg06223162	chr1:101003688	GPR88	-0.37	-6.84	-0.32	2.76e-11	Monocyte count;
LUAD	cis	rs35146811	0.555	rs1981549	chr7:99541636	A/G	cg19636519	chr7:99541626	NA	0.41	7.32	0.34	1.23e-12	Coronary artery disease;
LUAD	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg11502198	chr6:26597334	ABT1	0.54	9.21	0.41	1.53e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg14582100	chr15:45693742	SPATA5L1	0.51	9.65	0.42	4.88e-20	Homoarginine levels;
LUAD	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.57	-0.35	2.31e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12216545	0.711	rs9632622	chr7:150233219	T/C	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.5	-0.3	2.21e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6060717	0.536	rs6060669	chr20:34480557	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.04	-0.32	8.04e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg00280220	chr17:61926910	NA	0.36	6.9	0.32	1.9e-11	Prudent dietary pattern;
LUAD	trans	rs8073060	0.586	rs226087	chr17:34017652	T/C	cg19694781	chr19:47549865	TMEM160	-1.22	-19.42	-0.69	1.67e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg02527881	chr3:46936655	PTH1R	-0.67	-15.44	-0.6	5.45e-43	Birth weight;
LUAD	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg01299579	chr2:10830716	NOL10	-0.43	-7.55	-0.34	2.68e-13	Prostate cancer;
LUAD	cis	rs7809950	0.817	rs2237678	chr7:107203265	T/G	cg23024343	chr7:107201750	COG5	-0.9	-15.24	-0.6	3.89e-42	Coronary artery disease;
LUAD	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg08893839	chr5:154027129	NA	0.56	7.41	0.34	6.75e-13	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7937890	0.559	rs2034480	chr11:14466923	G/A	cg22961513	chr11:14280813	SPON1	-0.37	-7.07	-0.32	6.56e-12	Mitochondrial DNA levels;
LUAD	cis	rs67072384	1.000	rs61489692	chr11:72445314	T/C	cg04827223	chr11:72435913	ARAP1	-0.63	-7.58	-0.35	2.19e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg06608945	chr2:219082296	ARPC2	0.52	8.96	0.4	1.06e-17	Colorectal cancer;
LUAD	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg27471124	chr11:109292789	C11orf87	-0.35	-7.03	-0.32	8.44e-12	Schizophrenia;
LUAD	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg00852783	chr1:26633632	UBXN11	0.42	7.31	0.34	1.3e-12	Obesity-related traits;
LUAD	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg25019722	chr6:37503610	NA	-0.29	-6.45	-0.3	3.12e-10	Cognitive performance;
LUAD	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg14664628	chr15:75095509	CSK	0.52	8.42	0.38	5.96e-16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg20587970	chr11:113659929	NA	-1.37	-20.14	-0.7	9.73e-64	Hip circumference adjusted for BMI;
LUAD	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	11.25	0.48	7.51e-26	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg07677032	chr17:61819896	STRADA	0.58	10.68	0.46	1e-23	Prudent dietary pattern;
LUAD	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg18404041	chr3:52824283	ITIH1	0.41	7.55	0.34	2.75e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.8	-0.31	3.48e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1448094	0.967	rs7961782	chr12:86326461	T/C	cg00310523	chr12:86230176	RASSF9	0.35	7.56	0.34	2.58e-13	Major depressive disorder;
LUAD	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg12927641	chr6:109611667	NA	-0.53	-9.35	-0.41	5.13e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs7191700	0.509	rs415595	chr16:11363692	A/G	cg00044050	chr16:11439710	C16orf75	0.59	9.32	0.41	6.39e-19	Multiple sclerosis;
LUAD	cis	rs17362650	0.881	rs71437665	chr2:9627978	C/T	cg12832956	chr2:9616023	IAH1	-0.47	-7.41	-0.34	6.96e-13	Alcohol dependence (age at onset);
LUAD	trans	rs75804782	0.630	rs80271258	chr2:239311505	C/T	cg01134436	chr17:81009848	B3GNTL1	0.78	6.92	0.32	1.64e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.25	-0.33	2.06e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg27170947	chr2:26402098	FAM59B	-0.81	-12.21	-0.51	1.46e-29	Gut microbiome composition (summer);
LUAD	cis	rs57920188	0.585	rs12127463	chr1:4079127	C/T	cg10510935	chr1:4059661	NA	0.45	6.94	0.32	1.45e-11	Interleukin-17 levels;
LUAD	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg01579765	chr21:45077557	HSF2BP	0.56	13.02	0.53	8.22e-33	Mean corpuscular volume;
LUAD	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11644478	chr21:40555479	PSMG1	0.69	11.3	0.48	4.52e-26	Cognitive function;
LUAD	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg06671706	chr8:8559999	CLDN23	0.67	11.65	0.49	2.24e-27	Obesity-related traits;
LUAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-9.98	-0.44	3.45e-21	Lymphocyte counts;
LUAD	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg27129171	chr3:47204927	SETD2	0.4	6.37	0.3	5.06e-10	Colorectal cancer;
LUAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.55	-0.42	1.09e-19	Alzheimer's disease;
LUAD	cis	rs9392556	0.829	rs2783073	chr6:4118674	T/C	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.42	-7.32	-0.34	1.25e-12	Blood metabolite levels;
LUAD	cis	rs977987	0.800	rs12922951	chr16:75355096	C/G	cg03315344	chr16:75512273	CHST6	0.62	13.6	0.55	3.29e-35	Dupuytren's disease;
LUAD	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27286337	chr10:134555280	INPP5A	0.72	9.35	0.41	5.1e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-20.48	-0.71	2.79e-65	Coronary artery disease;
LUAD	cis	rs7180079	0.620	rs16948036	chr15:64820679	A/G	cg08069370	chr15:64387884	SNX1	-0.56	-6.77	-0.31	4.25e-11	Monocyte count;
LUAD	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg05340658	chr4:99064831	C4orf37	0.46	7.52	0.34	3.23e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg12011299	chr4:100065546	ADH4	0.72	13.24	0.54	1.02e-33	Alcohol dependence;
LUAD	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg05425664	chr17:57184151	TRIM37	0.43	7.66	0.35	1.28e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg10560079	chr2:191398806	TMEM194B	0.57	7.26	0.33	1.86e-12	Diastolic blood pressure;
LUAD	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.23	0.48	8.73e-26	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg12908607	chr1:44402522	ARTN	-0.52	-10.06	-0.44	1.74e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06544989	chr22:39130855	UNC84B	0.44	8.88	0.4	1.86e-17	Menopause (age at onset);
LUAD	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	-0.34	-7.03	-0.32	8.59e-12	Menopause (age at onset);
LUAD	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg00933542	chr6:150070202	PCMT1	0.35	7.09	0.33	5.57e-12	Testicular germ cell tumor;
LUAD	cis	rs7481584	1.000	rs12804412	chr11:3020782	G/A	cg11201177	chr11:2961805	NA	0.39	6.55	0.3	1.7e-10	Calcium levels;
LUAD	trans	rs62103177	0.673	rs62096717	chr18:77616819	C/T	cg05926928	chr17:57297772	GDPD1	0.87	12.41	0.52	2.25e-30	Opioid sensitivity;
LUAD	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg02551604	chr5:131831745	NA	-0.6	-8.51	-0.38	3e-16	Asthma (sex interaction);
LUAD	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg27432699	chr2:27873401	GPN1	-0.68	-12.12	-0.51	3.18e-29	Oral cavity cancer;
LUAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.31e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg19442545	chr10:75533431	FUT11	-0.47	-7.7	-0.35	1e-13	Inflammatory bowel disease;
LUAD	cis	rs11771526	0.818	rs17161140	chr7:32324199	T/C	cg13207630	chr7:32358064	NA	0.63	7.59	0.35	2.05e-13	Body mass index;
LUAD	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg27490568	chr2:178487706	NA	0.57	8.49	0.38	3.57e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg27411982	chr8:10470053	RP1L1	0.37	6.42	0.3	3.7e-10	Neuroticism;
LUAD	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg05665937	chr4:1216051	CTBP1	0.42	7.04	0.32	7.61e-12	Obesity-related traits;
LUAD	cis	rs68170813	0.917	rs13234124	chr7:107225043	C/T	cg23024343	chr7:107201750	COG5	0.45	6.75	0.31	4.98e-11	Coronary artery disease;
LUAD	cis	rs8060686	0.858	rs8057986	chr16:67893879	A/G	cg26727032	chr16:67993705	SLC12A4	-0.51	-8.51	-0.38	2.95e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-8.12	-0.37	5.09e-15	Alzheimer's disease;
LUAD	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg13319975	chr6:146136371	FBXO30	-0.64	-11.11	-0.48	2.53e-25	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16826753	chr21:34915507	GART;SON	-0.42	-6.47	-0.3	2.71e-10	Height;
LUAD	cis	rs4795519	0.736	rs12941092	chr17:22154100	T/C	cg22648282	chr17:21454238	C17orf51	-0.39	-6.45	-0.3	3.02e-10	Chronic myeloid leukemia;
LUAD	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg03605463	chr16:89740564	NA	0.6	11.06	0.47	3.91e-25	Hemoglobin concentration;
LUAD	cis	rs2579500	0.844	rs1866444	chr2:97172125	A/G	cg23100626	chr2:96804247	ASTL	-0.27	-6.65	-0.31	9.09e-11	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg26513180	chr16:89883248	FANCA	0.68	12.84	0.53	4.43e-32	Vitiligo;
LUAD	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18876405	chr7:65276391	NA	-0.43	-7.04	-0.32	7.76e-12	Aortic root size;
LUAD	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg16006841	chr5:176797999	RGS14	-0.58	-9.02	-0.4	6.61e-18	Urate levels in lean individuals;
LUAD	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg27129171	chr3:47204927	SETD2	-0.41	-6.6	-0.31	1.22e-10	Colorectal cancer;
LUAD	cis	rs9296092	0.517	rs56069946	chr6:33511136	G/A	cg13560919	chr6:33536144	NA	-0.85	-13.9	-0.56	1.98e-36	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.8	-0.31	3.51e-11	Diabetic kidney disease;
LUAD	cis	rs539096	0.692	rs7549094	chr1:44213178	C/A	cg12908607	chr1:44402522	ARTN	-0.37	-7.08	-0.33	6.06e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg15664640	chr17:80829946	TBCD	0.63	8.09	0.37	6.17e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg15704280	chr7:45808275	SEPT13	0.87	16.51	0.63	1.31e-47	Coronary artery disease;
LUAD	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg08029281	chr1:67600428	NA	0.37	7.41	0.34	6.84e-13	Psoriasis;
LUAD	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg27426351	chr10:43362370	NA	-0.51	-8.03	-0.36	9.66e-15	Blood protein levels;
LUAD	cis	rs2795502	0.630	rs4948698	chr10:43539459	A/G	cg08461752	chr10:43522343	NA	0.73	8.69	0.39	8.06e-17	Blood protein levels;
LUAD	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg14983838	chr19:29218262	NA	0.58	7.6	0.35	1.94e-13	Methadone dose in opioid dependence;
LUAD	cis	rs1595825	0.891	rs77032596	chr2:198603185	T/G	cg10547527	chr2:198650123	BOLL	-0.53	-7.05	-0.32	7.2e-12	Ulcerative colitis;
LUAD	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg10591111	chr5:226296	SDHA	-0.55	-7.23	-0.33	2.23e-12	Breast cancer;
LUAD	trans	rs7395662	1.000	rs11039862	chr11:48618306	A/G	cg00717180	chr2:96193071	NA	-0.37	-7.02	-0.32	9.02e-12	HDL cholesterol;
LUAD	cis	rs16910800	0.638	rs12273883	chr11:23164569	C/G	cg20040320	chr11:23191996	NA	0.67	8.59	0.39	1.63e-16	Cancer;
LUAD	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg00071950	chr4:10020882	SLC2A9	0.75	15.36	0.6	1.25e-42	Bone mineral density;
LUAD	cis	rs10465746	0.967	rs12732697	chr1:84349283	A/G	cg10977910	chr1:84465055	TTLL7	0.5	8.12	0.37	5.04e-15	Obesity-related traits;
LUAD	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg12432903	chr7:1882776	MAD1L1	-0.44	-7.12	-0.33	4.54e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg23758822	chr17:41437982	NA	0.99	19.87	0.69	1.51e-62	Menopause (age at onset);
LUAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg13047869	chr3:10149882	C3orf24	0.66	11.09	0.47	2.88e-25	Alzheimer's disease;
LUAD	cis	rs870825	0.655	rs7683556	chr4:185632019	T/A	cg04058563	chr4:185651563	MLF1IP	0.9	14.4	0.57	1.6e-38	Blood protein levels;
LUAD	cis	rs4774899	0.966	rs17819700	chr15:57279185	G/T	cg14026238	chr15:57616123	NA	0.34	6.53	0.3	1.91e-10	Urinary tract infection frequency;
LUAD	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg10589385	chr1:150898437	SETDB1	-0.34	-6.39	-0.3	4.33e-10	Tonsillectomy;
LUAD	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg21204522	chr6:27730016	NA	-0.46	-7.31	-0.33	1.36e-12	Parkinson's disease;
LUAD	cis	rs68170813	0.559	rs1018947	chr7:106851939	A/T	cg02696742	chr7:106810147	HBP1	-0.78	-10.78	-0.46	4.15e-24	Coronary artery disease;
LUAD	cis	rs8067287	1.000	rs55810902	chr17:16816421	A/G	cg26910001	chr17:16838321	NA	-0.49	-6.52	-0.3	2.03e-10	Diabetic kidney disease;
LUAD	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg26769984	chr7:1090371	C7orf50	0.43	7.26	0.33	1.92e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg24733560	chr20:60626293	TAF4	0.47	9.24	0.41	1.25e-18	Body mass index;
LUAD	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg18252515	chr7:66147081	NA	0.61	6.69	0.31	6.92e-11	Diabetic kidney disease;
LUAD	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg03929089	chr4:120376271	NA	-0.94	-17.96	-0.66	4.89e-54	Height;
LUAD	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg17177755	chr1:15930204	NA	0.45	7.37	0.34	9.03e-13	Systolic blood pressure;
LUAD	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg11965913	chr1:205819406	PM20D1	-0.53	-8.04	-0.36	9.08e-15	Menarche (age at onset);
LUAD	trans	rs587242	0.868	rs35869184	chr1:97027749	G/C	cg10631902	chr5:14652156	NA	0.42	6.44	0.3	3.28e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg03929089	chr4:120376271	NA	0.68	9.67	0.43	4e-20	Coronary artery disease;
LUAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg04234412	chr22:24373322	LOC391322	-0.91	-18.16	-0.66	6.37e-55	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg18833306	chr6:118973337	C6orf204	-0.49	-7.22	-0.33	2.39e-12	Renal cell carcinoma;
LUAD	cis	rs6961069	0.868	rs1194179	chr7:80232973	T/C	cg04458919	chr7:80252533	CD36	-0.34	-6.36	-0.3	5.23e-10	Platelet count;
LUAD	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg03605463	chr16:89740564	NA	0.47	7.63	0.35	1.5700000000000001e-13	Vitiligo;
LUAD	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg07636037	chr3:49044803	WDR6	0.61	10.32	0.45	1.97e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs67981189	0.546	rs2810075	chr14:71375080	G/C	cg15910301	chr14:71632612	NA	-0.42	-6.42	-0.3	3.57e-10	Schizophrenia;
LUAD	cis	rs17789174	0.953	rs11149708	chr16:85104919	T/G	cg01715842	chr16:85045600	ZDHHC7	-0.4	-6.7	-0.31	6.77e-11	Dysphagia;
LUAD	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg17480646	chr11:65405466	SIPA1	-0.46	-6.85	-0.32	2.57e-11	Acne (severe);
LUAD	cis	rs4444235	0.838	rs11623717	chr14:54414132	A/G	cg16720578	chr14:54410717	NA	0.49	8.72	0.39	6.2e-17	Colorectal cancer;
LUAD	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg05564831	chr3:52568323	NT5DC2	-0.36	-6.58	-0.3	1.42e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7582720	1.000	rs72934764	chr2:203758521	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	trans	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.73	0.35	8.15e-14	Resting heart rate;
LUAD	cis	rs10419226	0.540	rs6510995	chr19:18770776	G/A	cg22001208	chr19:18782374	NA	-0.48	-8.03	-0.36	9.54e-15	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg01851573	chr8:8652454	MFHAS1	0.4	7.42	0.34	6.44e-13	Mood instability;
LUAD	trans	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.7	0.49	1.43e-27	Mean corpuscular volume;
LUAD	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg09021430	chr5:549028	NA	-0.68	-13.32	-0.54	4.96e-34	Lung disease severity in cystic fibrosis;
LUAD	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg09658497	chr7:2847517	GNA12	-0.52	-8.77	-0.39	4.26e-17	Height;
LUAD	cis	rs6426558	0.537	rs1320494	chr1:227241300	A/T	cg10327440	chr1:227177885	CDC42BPA	0.56	9.16	0.41	2.34e-18	Neutrophil percentage of white cells;
LUAD	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg15605315	chr1:45957053	TESK2	0.49	7.75	0.35	6.74e-14	High light scatter reticulocyte count;
LUAD	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg26384229	chr12:38710491	ALG10B	0.44	7.3	0.33	1.4e-12	Bladder cancer;
LUAD	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg09021430	chr5:549028	NA	-0.69	-14.49	-0.58	6.3e-39	Obesity-related traits;
LUAD	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg18944383	chr4:111397179	ENPEP	0.4	7.96	0.36	1.56e-14	Height;
LUAD	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg23649088	chr2:200775458	C2orf69	0.81	14.74	0.58	5.86e-40	Osteoporosis;
LUAD	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.89	0.53	2.58e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg00431813	chr7:1051703	C7orf50	-0.41	-7.99	-0.36	1.27e-14	Longevity;Endometriosis;
LUAD	cis	rs62238980	0.614	rs117305417	chr22:32400975	T/C	cg00543991	chr22:32367038	NA	0.95	8.87	0.4	2.05e-17	Childhood ear infection;
LUAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg07157834	chr1:205819609	PM20D1	0.41	6.45	0.3	3.04e-10	Parkinson's disease;
LUAD	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg16479474	chr6:28041457	NA	0.35	6.57	0.3	1.44e-10	Parkinson's disease;
LUAD	cis	rs3733418	0.929	rs13120990	chr4:165905118	A/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-6.73	-0.31	5.59e-11	Obesity-related traits;
LUAD	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg04450456	chr4:17643702	FAM184B	0.4	7.79	0.35	5.19e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2224391	0.613	rs17140075	chr6:5282415	A/G	cg26704043	chr6:5282702	FARS2	0.39	6.65	0.31	9.28e-11	Height;
LUAD	cis	rs41271951	0.512	rs79122717	chr1:151093526	G/A	cg11822372	chr1:151115635	SEMA6C	-0.84	-7.09	-0.33	5.75e-12	Blood protein levels;
LUAD	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg20476274	chr7:133979776	SLC35B4	0.83	16.66	0.63	2.87e-48	Mean platelet volume;
LUAD	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.38	6.93	0.32	1.58e-11	Systemic lupus erythematosus;
LUAD	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg00316803	chr15:76480434	C15orf27	0.41	6.46	0.3	2.94e-10	Blood metabolite levels;
LUAD	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg18351406	chr4:77819688	ANKRD56	0.61	9.8	0.43	1.48e-20	Emphysema distribution in smoking;
LUAD	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11890956	chr21:40555474	PSMG1	0.78	13.58	0.55	4.12e-35	Cognitive function;
LUAD	cis	rs9517320	0.967	rs6491430	chr13:99178276	G/A	cg07423050	chr13:99094983	FARP1	0.37	6.55	0.3	1.66e-10	Longevity;
LUAD	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg05697835	chr1:2722811	NA	0.32	6.65	0.31	9.1e-11	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg13385794	chr1:248469461	NA	0.26	6.79	0.31	3.75e-11	Common traits (Other);
LUAD	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg06131755	chr6:160182447	ACAT2	0.44	6.5	0.3	2.24e-10	Age-related macular degeneration (geographic atrophy);
LUAD	trans	rs1997103	1.000	rs6593237	chr7:55411015	T/C	cg20935933	chr6:143382018	AIG1	0.53	7.46	0.34	4.87e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg11871910	chr12:69753446	YEATS4	0.71	12.14	0.51	2.74e-29	Blood protein levels;
LUAD	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg19717773	chr7:2847554	GNA12	-0.54	-10.16	-0.44	7.71e-22	Height;
LUAD	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg15790184	chr11:494944	RNH1	0.56	6.93	0.32	1.6e-11	Body mass index;
LUAD	cis	rs76878669	0.515	rs947978	chr11:66108660	C/T	cg18002602	chr11:66138449	SLC29A2	0.46	9.96	0.44	4.03e-21	Educational attainment (years of education);
LUAD	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg26408565	chr15:76604113	ETFA	0.45	7.35	0.34	1.04e-12	Blood metabolite levels;
LUAD	cis	rs8067545	0.641	rs119672	chr17:19818601	A/G	cg04132472	chr17:19861366	AKAP10	0.37	8.82	0.39	3.01e-17	Schizophrenia;
LUAD	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-8.03	-0.36	9.53e-15	Blood metabolite levels;
LUAD	cis	rs6709815	0.902	rs13020432	chr2:219668211	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-10.19	-0.44	5.99e-22	Reticulocyte count;High light scatter reticulocyte count;
LUAD	cis	rs9341808	0.644	rs62408577	chr6:80942024	T/A	cg08355045	chr6:80787529	NA	-0.48	-8.49	-0.38	3.64e-16	Sitting height ratio;
LUAD	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.91	0.32	1.75e-11	Depression;
LUAD	cis	rs6906287	0.647	rs12199463	chr6:118826695	A/G	cg18833306	chr6:118973337	C6orf204	-0.47	-8.42	-0.38	6.07e-16	Electrocardiographic conduction measures;
LUAD	cis	rs6840360	0.550	rs6535806	chr4:152483906	G/A	cg22705602	chr4:152727874	NA	-0.37	-6.64	-0.31	9.65e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.06	-0.36	7.93e-15	Diabetic kidney disease;
LUAD	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.77	-0.31	4.33e-11	Post bronchodilator FEV1;
LUAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg14159672	chr1:205819179	PM20D1	0.74	14.34	0.57	2.75e-38	Monocyte percentage of white cells;
LUAD	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg27432699	chr2:27873401	GPN1	-0.38	-6.46	-0.3	2.9e-10	Total body bone mineral density;
LUAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg11494091	chr17:61959527	GH2	0.74	18.37	0.67	7.72e-56	Prudent dietary pattern;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05821866	chr1:167905319	DCAF6;BRP44	-0.5	-8.28	-0.37	1.65e-15	Height;
LUAD	cis	rs6906287	0.647	rs11153734	chr6:118726220	A/G	cg21191810	chr6:118973309	C6orf204	0.49	9.45	0.42	2.31e-19	Electrocardiographic conduction measures;
LUAD	cis	rs2004318	1.000	rs78192819	chr19:55080918	G/A	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.96e-13	Blood protein levels;
LUAD	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg20701182	chr2:24300061	SF3B14	0.6	6.91	0.32	1.77e-11	Lymphocyte counts;
LUAD	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg13902645	chr11:5959945	NA	0.49	8.26	0.37	1.94e-15	DNA methylation (variation);
LUAD	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-11.37	-0.48	2.46e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg04851639	chr8:1020857	NA	-0.36	-8.55	-0.38	2.31e-16	Schizophrenia;
LUAD	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg08645402	chr16:4508243	NA	0.58	10.71	0.46	7.53e-24	Schizophrenia;
LUAD	cis	rs7665090	0.936	rs2866412	chr4:103554350	T/A	cg07973026	chr4:103553119	MANBA	0.48	8.5	0.38	3.22e-16	Primary biliary cholangitis;
LUAD	cis	rs4332037	0.508	rs60238952	chr7:1914350	A/G	cg07027305	chr7:2059796	MAD1L1	-0.29	-6.56	-0.3	1.55e-10	Bipolar disorder;
LUAD	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg25237894	chr2:233734115	C2orf82	-0.49	-9.23	-0.41	1.35e-18	Coronary artery disease;
LUAD	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg12311346	chr5:56204834	C5orf35	-0.83	-12.47	-0.52	1.27e-30	Initial pursuit acceleration;
LUAD	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7575217	0.697	rs2582930	chr2:101721369	T/A	cg23907051	chr2:101730305	TBC1D8	-0.27	-6.42	-0.3	3.62e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg17724175	chr1:150552817	MCL1	0.37	8.51	0.38	2.95e-16	Melanoma;
LUAD	cis	rs13315871	1.000	rs1131052	chr3:58411530	A/T	cg12435725	chr3:58293450	RPP14	-0.69	-7.66	-0.35	1.31e-13	Cholesterol, total;
LUAD	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg19717773	chr7:2847554	GNA12	-0.55	-10.96	-0.47	8.8e-25	Height;
LUAD	cis	rs877282	0.853	rs12763400	chr10:763617	C/T	cg06581033	chr10:766294	NA	-0.59	-7.98	-0.36	1.39e-14	Uric acid levels;
LUAD	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg00745463	chr17:30367425	LRRC37B	-1.06	-12.58	-0.52	4.73e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-8.92	-0.4	1.46e-17	Gut microbiome composition (summer);
LUAD	cis	rs35146811	0.586	rs12666107	chr7:99778019	G/C	cg13334819	chr7:99746414	C7orf59	-0.62	-9.22	-0.41	1.44e-18	Coronary artery disease;
LUAD	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg03161606	chr19:29218774	NA	0.6	8.63	0.39	1.3e-16	Methadone dose in opioid dependence;
LUAD	cis	rs806215	0.951	rs327516	chr7:127255795	C/G	cg25922125	chr7:127225783	GCC1	0.45	6.58	0.3	1.44e-10	Type 2 diabetes;
LUAD	cis	rs17401966	0.838	rs12127604	chr1:10352800	T/G	cg15208524	chr1:10270712	KIF1B	0.43	6.74	0.31	5.06e-11	Hepatocellular carcinoma;
LUAD	cis	rs7707921	0.881	rs60733727	chr5:81448283	G/A	cg15871215	chr5:81402204	ATG10	-0.68	-9.68	-0.43	3.74e-20	Breast cancer;
LUAD	cis	rs7647973	1.000	rs6446268	chr3:49445695	G/A	cg07636037	chr3:49044803	WDR6	-0.47	-7.74	-0.35	7.28e-14	Menarche (age at onset);
LUAD	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg09796270	chr17:17721594	SREBF1	0.37	7.39	0.34	7.8e-13	Total body bone mineral density;
LUAD	cis	rs4891159	0.660	rs4891160	chr18:74102135	C/T	cg24786174	chr18:74118243	ZNF516	0.71	14.71	0.58	7.65e-40	Longevity;
LUAD	cis	rs6577655	0.517	rs6983560	chr8:135584553	C/T	cg17885191	chr8:135476712	NA	-0.59	-8.35	-0.38	1.01e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg04267008	chr7:1944627	MAD1L1	0.52	7.8	0.35	4.72e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg13813247	chr22:41461852	NA	-0.5	-7.95	-0.36	1.74e-14	Neuroticism;
LUAD	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg17443473	chr1:3703550	LRRC47	0.44	7.4	0.34	7.47e-13	Red cell distribution width;
LUAD	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg21918786	chr6:109611834	NA	-0.6	-11.11	-0.48	2.44e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg22117172	chr7:91764530	CYP51A1	-0.37	-8.05	-0.36	8.49e-15	Breast cancer;
LUAD	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.62	-0.31	1.12e-10	Bladder cancer;
LUAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg19130645	chr7:65235666	NA	0.43	7.3	0.33	1.44e-12	Calcium levels;
LUAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg09074113	chr2:20870087	GDF7	-0.47	-9.2	-0.41	1.63e-18	Abdominal aortic aneurysm;
LUAD	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg06221963	chr1:154839813	KCNN3	-0.45	-8.25	-0.37	2.03e-15	Schizophrenia;
LUAD	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg02079420	chr8:82753780	SNX16	0.42	8.16	0.37	3.93e-15	Diastolic blood pressure;
LUAD	trans	rs7395662	0.890	rs4882133	chr11:48593450	T/C	cg15704280	chr7:45808275	SEPT13	-0.42	-6.57	-0.3	1.47e-10	HDL cholesterol;
LUAD	cis	rs71478720	0.953	rs5744258	chr11:112021767	C/G	cg04929355	chr11:112034997	IL18	0.45	7.05	0.32	7.42e-12	Interleukin-18 levels;
LUAD	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg05182265	chr7:156933206	UBE3C	-0.81	-17.36	-0.65	2.21e-51	Body mass index;
LUAD	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.57	-0.35	2.44e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4588572	0.688	rs2362829	chr5:77724036	T/A	cg11547950	chr5:77652471	NA	-0.63	-10.93	-0.47	1.19e-24	Triglycerides;
LUAD	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg11301795	chr4:187892539	NA	-0.75	-15.02	-0.59	3.73e-41	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg14668632	chr7:2872130	GNA12	-0.48	-8.48	-0.38	3.89e-16	Height;
LUAD	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg05754148	chr16:3507555	NAT15	-0.49	-8.04	-0.36	9.32e-15	Body mass index (adult);
LUAD	trans	rs4650994	0.544	rs2761469	chr1:178590638	A/C	cg05059571	chr16:84539110	KIAA1609	0.67	11.64	0.49	2.28e-27	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg05725404	chr16:58534157	NDRG4	-0.69	-7.57	-0.35	2.34e-13	Schizophrenia;
LUAD	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg04450003	chr12:50355995	AQP5	0.75	10.25	0.45	3.53e-22	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg09365446	chr1:150670422	GOLPH3L	0.58	10.26	0.45	3.31e-22	Melanoma;
LUAD	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.12e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg27219399	chr15:67835830	MAP2K5	0.41	6.59	0.3	1.34e-10	Restless legs syndrome;
LUAD	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg18477163	chr1:228402036	OBSCN	-0.36	-7.17	-0.33	3.43e-12	Diastolic blood pressure;
LUAD	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg11871910	chr12:69753446	YEATS4	0.7	12.09	0.51	4.21e-29	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs12545109	0.765	rs2438063	chr8:57384360	A/G	cg11919837	chr8:57350735	NA	0.44	6.43	0.3	3.41e-10	Obesity-related traits;
LUAD	trans	rs11039798	1.000	rs7924372	chr11:48556319	T/A	cg15704280	chr7:45808275	SEPT13	0.73	7.32	0.34	1.23e-12	Axial length;
LUAD	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg19318889	chr4:1322082	MAEA	0.82	13.74	0.56	9.09e-36	Longevity;
LUAD	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19748678	chr4:122722346	EXOSC9	0.43	6.81	0.31	3.43e-11	Type 2 diabetes;
LUAD	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-15.13	-0.59	1.17e-41	Chronic sinus infection;
LUAD	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.45	0.3	3.02e-10	Depression;
LUAD	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg23625390	chr15:77176239	SCAPER	0.52	8.3	0.37	1.46e-15	Blood metabolite levels;
LUAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	13.04	0.54	6.86e-33	Prudent dietary pattern;
LUAD	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.87	-9.15	-0.41	2.43e-18	Lung cancer in ever smokers;
LUAD	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg06784218	chr1:46089804	CCDC17	0.6	13.33	0.54	4.38e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.61	0.52	3.64e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg19193384	chr17:30244184	NA	-0.54	-6.35	-0.3	5.44e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1215050	0.791	rs6813619	chr4:98830768	C/T	cg03467027	chr4:99064603	C4orf37	-0.4	-6.41	-0.3	3.84e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.28	6.64	0.31	9.68e-11	Prostate cancer;
LUAD	cis	rs9902453	1.000	rs4074170	chr17:28381141	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.34	-0.41	5.51e-19	Coffee consumption (cups per day);
LUAD	cis	rs17095355	0.539	rs12260509	chr10:111920995	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.45	-0.38	4.74e-16	Biliary atresia;
LUAD	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg21951975	chr1:209979733	IRF6	-0.56	-7.08	-0.33	6.09e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg06641503	chr3:48959341	ARIH2	-0.34	-6.53	-0.3	1.91e-10	Parkinson's disease;
LUAD	cis	rs6906287	0.647	rs11153748	chr6:118773609	A/G	cg18833306	chr6:118973337	C6orf204	0.47	8.38	0.38	7.66e-16	Electrocardiographic conduction measures;
LUAD	cis	rs977987	0.843	rs11860231	chr16:75385159	A/G	cg03315344	chr16:75512273	CHST6	0.64	14.01	0.56	6.8e-37	Dupuytren's disease;
LUAD	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.9	-0.47	1.56e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08219700	chr8:58056026	NA	0.61	8.63	0.39	1.25e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg04772025	chr11:68637568	NA	0.56	8.84	0.4	2.51e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg07507251	chr3:52567010	NT5DC2	0.37	7.35	0.34	1.04e-12	Bipolar disorder;
LUAD	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg17761419	chr8:57350749	NA	-0.52	-7.83	-0.36	4.07e-14	Obesity-related traits;
LUAD	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg01475377	chr6:109611718	NA	-0.51	-9.43	-0.42	2.74e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg26408565	chr15:76604113	ETFA	-0.56	-9.77	-0.43	1.78e-20	Blood metabolite levels;
LUAD	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg15445000	chr17:37608096	MED1	-0.45	-8.38	-0.38	7.9e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg09455208	chr3:40491958	NA	-0.59	-12.9	-0.53	2.46e-32	Renal cell carcinoma;
LUAD	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg27284194	chr4:1044797	NA	0.68	9.93	0.43	4.96e-21	Recombination rate (females);
LUAD	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg15839431	chr19:19639596	YJEFN3	-0.53	-8.65	-0.39	1.11e-16	Bipolar disorder;
LUAD	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg06740227	chr12:86229804	RASSF9	0.45	7.77	0.35	5.9e-14	Major depressive disorder;
LUAD	cis	rs78761021	0.720	rs55872800	chr17:9794823	G/A	cg26853458	chr17:9805074	RCVRN	0.38	7.02	0.32	9.07e-12	Type 2 diabetes;
LUAD	cis	rs6690583	0.623	rs1371140	chr1:85455362	A/C	cg22153463	chr1:85462885	MCOLN2	0.55	6.37	0.3	4.97e-10	Serum sulfate level;
LUAD	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg11189052	chr15:85197271	WDR73	0.6	7.49	0.34	3.97e-13	Schizophrenia;
LUAD	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.47	8.03	0.36	9.84e-15	Birth weight;
LUAD	cis	rs9462027	0.628	rs7756405	chr6:34722659	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.81	-0.39	3.26e-17	Systemic lupus erythematosus;
LUAD	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg01579765	chr21:45077557	HSF2BP	-0.61	-13.75	-0.56	7.77e-36	Mean corpuscular volume;
LUAD	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg20673091	chr1:2541236	MMEL1	-0.46	-10.23	-0.45	4.26e-22	Ulcerative colitis;
LUAD	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg06131755	chr6:160182447	ACAT2	0.42	6.37	0.3	4.98e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg19761014	chr17:28927070	LRRC37B2	0.72	7.35	0.34	1.02e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs701145	0.938	rs701143	chr3:154060047	A/G	cg17054900	chr3:154042577	DHX36	0.65	7.12	0.33	4.61e-12	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6484504	0.652	rs485265	chr11:31407788	G/A	cg14844989	chr11:31128820	NA	0.45	8.13	0.37	4.71e-15	Red blood cell count;
LUAD	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.44	8.0	0.36	1.24e-14	Systemic lupus erythematosus;
LUAD	cis	rs2041840	0.889	rs4670691	chr2:37565276	C/G	cg25727520	chr2:37576821	QPCT	-0.35	-7.1	-0.33	5.44e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs2735413	0.875	rs8055298	chr16:78084868	C/G	cg04733911	chr16:78082701	NA	0.34	8.09	0.37	6.18e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs3760775	1.000	rs3760775	chr19:5841356	A/C	cg25387410	chr19:5844109	FUT3	0.67	8.26	0.37	1.96e-15	Vitamin B12 levels;Elevated serum carcinoembryonic antigen levels;Tumor biomarkers;
LUAD	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg06608945	chr2:219082296	ARPC2	0.52	8.93	0.4	1.35e-17	Colorectal cancer;
LUAD	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg09904177	chr6:26538194	HMGN4	0.44	7.36	0.34	9.71e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg05110241	chr16:68378359	PRMT7	-0.7	-7.92	-0.36	2.1e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg10909506	chr17:38081995	ORMDL3	0.37	6.52	0.3	1.96e-10	Self-reported allergy;
LUAD	cis	rs7659604	0.521	rs9993206	chr4:122686957	A/G	cg06713675	chr4:122721982	EXOSC9	0.42	7.73	0.35	7.74e-14	Type 2 diabetes;
LUAD	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg07169764	chr2:136633963	MCM6	0.63	7.55	0.34	2.62e-13	Corneal structure;
LUAD	cis	rs2282300	0.653	rs67745574	chr11:30234839	C/T	cg06241208	chr11:30344200	C11orf46	-0.57	-7.48	-0.34	4.21e-13	Morning vs. evening chronotype;
LUAD	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg08885076	chr2:99613938	TSGA10	0.35	6.45	0.3	3.08e-10	Chronic sinus infection;
LUAD	cis	rs2580764	0.566	rs2972075	chr2:55292322	T/G	cg09592903	chr2:55203963	RTN4	0.42	9.33	0.41	5.84e-19	Mean platelet volume;
LUAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.51	-8.54	-0.38	2.36e-16	Renal function-related traits (BUN);
LUAD	cis	rs2797160	0.935	rs1739379	chr6:126012593	T/C	cg05901451	chr6:126070800	HEY2	0.47	7.15	0.33	3.77e-12	Endometrial cancer;
LUAD	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg19041857	chr6:27730383	NA	-0.42	-7.09	-0.33	5.73e-12	Parkinson's disease;
LUAD	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	8.86	0.4	2.19e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs8048589	0.527	rs9939383	chr16:12176120	C/T	cg03816625	chr16:12192430	SNX29	0.48	7.18	0.33	3.22e-12	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	trans	rs2018683	0.707	rs4719961	chr7:28969513	C/T	cg19402173	chr7:128379420	CALU	-0.52	-8.41	-0.38	6.26e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.68	-0.31	7.58e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg06627628	chr2:24431161	ITSN2	0.47	6.51	0.3	2.17e-10	Lymphocyte counts;
LUAD	cis	rs55665837	0.701	rs12286408	chr11:14579376	G/A	cg19336497	chr11:14380999	RRAS2	-0.41	-7.4	-0.34	7.63e-13	Vitamin D levels;
LUAD	cis	rs7607369	0.574	rs12990478	chr2:219667463	T/A	cg02176678	chr2:219576539	TTLL4	-0.53	-10.19	-0.44	5.8e-22	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06873352	chr17:61820015	STRADA	0.83	18.42	0.67	4.62e-56	Prudent dietary pattern;
LUAD	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg06671706	chr8:8559999	CLDN23	-0.36	-6.35	-0.3	5.56e-10	Mood instability;
LUAD	cis	rs2041840	0.597	rs4670686	chr2:37536436	C/T	cg25727520	chr2:37576821	QPCT	-0.36	-7.77	-0.35	5.82e-14	Chronic lymphocytic leukemia;
LUAD	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg23262073	chr20:60523788	NA	-0.44	-7.61	-0.35	1.78e-13	Body mass index;
LUAD	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6969780	0.915	rs3807597	chr7:27189195	C/T	cg05579037	chr7:27184853	NA	0.5	6.72	0.31	6.07e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUAD	cis	rs938554	0.779	rs13106991	chr4:9959011	G/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-7.66	-0.35	1.3e-13	Blood metabolite levels;
LUAD	cis	rs6674176	0.932	rs12410334	chr1:44442521	A/C	cg15962314	chr1:44399869	ARTN	0.32	6.66	0.31	8.76e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg26384229	chr12:38710491	ALG10B	0.45	7.13	0.33	4.42e-12	Heart rate;
LUAD	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7089973	0.872	rs7094072	chr10:116627160	T/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.68	0.43	3.68e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg02002194	chr4:3960332	NA	-0.29	-7.01	-0.32	9.46e-12	Mood instability;
LUAD	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg03929089	chr4:120376271	NA	-0.56	-8.34	-0.38	1.05e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg08645402	chr16:4508243	NA	0.57	10.4	0.45	1.01e-22	Schizophrenia;
LUAD	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg03388025	chr16:89894329	SPIRE2	0.32	7.83	0.36	4.08e-14	Vitiligo;
LUAD	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.86	0.36	3.29e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg12311346	chr5:56204834	C5orf35	-0.62	-10.05	-0.44	1.94e-21	Coronary artery disease;
LUAD	trans	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg04565464	chr8:145669602	NFKBIL2	0.46	7.19	0.33	3.05e-12	Schizophrenia;
LUAD	cis	rs796825	0.530	rs4146299	chr3:119999820	A/G	cg21790991	chr3:120137480	FSTL1	0.46	7.81	0.36	4.53e-14	HIV-1 susceptibility;
LUAD	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg05865280	chr17:75406074	SEPT9	0.61	19.3	0.68	5.44e-60	Airflow obstruction;
LUAD	trans	rs7781370	1.000	rs7781370	chr7:96133531	A/G	cg21959181	chr7:150755243	CDK5;SLC4A2	-0.38	-6.37	-0.3	4.82e-10	Bone mineral density (hip);
LUAD	cis	rs220324	0.688	rs9978854	chr21:43567731	G/A	cg09727148	chr21:43560719	UMODL1	0.48	7.55	0.34	2.7e-13	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7107174	0.681	rs10793301	chr11:78020913	G/T	cg02023728	chr11:77925099	USP35	0.52	7.85	0.36	3.49e-14	Testicular germ cell tumor;
LUAD	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg04414720	chr1:150670196	GOLPH3L	-0.47	-7.39	-0.34	7.9e-13	Tonsillectomy;
LUAD	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Parkinson's disease;
LUAD	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg24578937	chr1:2090814	PRKCZ	0.54	11.24	0.48	7.78e-26	Height;
LUAD	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg03806693	chr22:41940476	POLR3H	-0.82	-11.51	-0.49	7.64e-27	Vitiligo;
LUAD	cis	rs597583	0.709	rs7940527	chr11:117398202	C/G	cg27161313	chr11:117392002	DSCAML1	0.49	8.48	0.38	3.79e-16	Putamen volume;
LUAD	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg02158880	chr13:53174818	NA	0.48	8.3	0.37	1.44e-15	Lewy body disease;
LUAD	cis	rs600231	0.508	rs35292734	chr11:65227700	C/T	cg17120908	chr11:65337727	SSSCA1	-0.66	-8.44	-0.38	5.18e-16	Bone mineral density;
LUAD	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg02551604	chr5:131831745	NA	0.63	10.28	0.45	2.73e-22	Asthma (sex interaction);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02654935	chr6:12514489	NA	0.52	6.89	0.32	2.07e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3733418	0.929	rs12512234	chr4:165908865	C/T	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.52	-6.73	-0.31	5.69e-11	Obesity-related traits;
LUAD	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-7.58	-0.35	2.21e-13	Bladder cancer;
LUAD	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12756686	chr19:29218302	NA	0.66	9.7	0.43	3.28e-20	Methadone dose in opioid dependence;
LUAD	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg15448220	chr1:150897856	SETDB1	0.46	7.99	0.36	1.26e-14	Tonsillectomy;
LUAD	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.46	0.34	4.82e-13	Hypertriglyceridemia;
LUAD	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg26022315	chr17:47021804	SNF8	0.41	7.38	0.34	8.45e-13	Type 2 diabetes;
LUAD	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg03929089	chr4:120376271	NA	-0.46	-7.13	-0.33	4.36e-12	HDL cholesterol;
LUAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg26513180	chr16:89883248	FANCA	-0.66	-12.45	-0.52	1.61e-30	Vitiligo;
LUAD	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg07741184	chr6:167504864	NA	0.36	8.32	0.37	1.24e-15	Crohn's disease;
LUAD	cis	rs1448094	1.000	rs4919776	chr12:86353763	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-8.29	-0.37	1.54e-15	Major depressive disorder;
LUAD	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg02196655	chr2:10830764	NOL10	-0.44	-8.05	-0.36	8.34e-15	Prostate cancer;
LUAD	cis	rs17270561	0.541	rs17586946	chr6:25939053	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	7.11	0.33	4.87e-12	Iron status biomarkers;
LUAD	trans	rs208520	0.754	rs851592	chr6:66875175	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-16.07	-0.62	1.09e-45	Exhaled nitric oxide output;
LUAD	trans	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg06606381	chr12:133084897	FBRSL1	-0.85	-8.96	-0.4	1.04e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg12863693	chr15:85201151	NMB	0.38	6.78	0.31	4.1e-11	Schizophrenia;
LUAD	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg12011299	chr4:100065546	ADH4	0.7	12.87	0.53	3.13e-32	Alcohol dependence;
LUAD	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg07741184	chr6:167504864	NA	0.36	8.27	0.37	1.73e-15	Primary biliary cholangitis;
LUAD	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg15691649	chr6:25882328	NA	-0.55	-7.6	-0.35	1.98e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg10319629	chr12:132285459	NA	0.35	7.07	0.32	6.63e-12	Migraine;
LUAD	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	10.39	0.45	1.12e-22	Lung cancer in ever smokers;
LUAD	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg17971929	chr21:40555470	PSMG1	0.57	9.05	0.4	5.18e-18	Cognitive function;
LUAD	cis	rs4378999	0.660	rs7617533	chr3:51355206	A/G	cg12934382	chr3:51741135	GRM2	0.4	6.85	0.32	2.68e-11	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs10979	0.679	rs2275345	chr6:143872960	G/A	cg25407410	chr6:143891975	LOC285740	-0.5	-7.36	-0.34	9.9e-13	Hypospadias;
LUAD	cis	rs6460942	1.000	rs77010200	chr7:12290724	G/A	cg06484146	chr7:12443880	VWDE	-0.55	-6.89	-0.32	2.07e-11	Coronary artery disease;
LUAD	trans	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	2.89e-11	Diabetic kidney disease;
LUAD	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.58	0.49	3.93e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg03959625	chr15:84868606	LOC388152	0.4	6.48	0.3	2.6200000000000003e-10	Schizophrenia;
LUAD	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg18512352	chr11:47633146	NA	-0.55	-9.57	-0.42	9.38e-20	Subjective well-being;
LUAD	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	9.02	0.4	6.57e-18	Multiple sclerosis;
LUAD	cis	rs4604732	0.631	rs12038793	chr1:247624262	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	-0.39	-6.82	-0.31	3.15e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08219700	chr8:58056026	NA	0.61	8.09	0.37	6.26e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg01620082	chr3:125678407	NA	0.43	6.5	0.3	2.23e-10	Depression;
LUAD	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	8.55	0.38	2.29e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg05665937	chr4:1216051	CTBP1	0.38	6.41	0.3	3.9e-10	Obesity-related traits;
LUAD	cis	rs72845660	1.000	rs1890060	chr10:104122842	A/G	cg20641465	chr10:103991465	PITX3	-0.5	-6.97	-0.32	1.21e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg11965913	chr1:205819406	PM20D1	-0.72	-13.59	-0.55	3.62e-35	Menarche (age at onset);
LUAD	cis	rs7586879	0.828	rs2384056	chr2:25092649	G/A	cg04586622	chr2:25135609	ADCY3	0.35	7.06	0.32	6.74e-12	Body mass index;
LUAD	cis	rs2742417	0.603	rs2673062	chr3:45763635	A/G	cg10512202	chr3:45649293	LIMD1	0.47	8.82	0.39	3.03e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg12935359	chr14:103987150	CKB	0.51	7.91	0.36	2.23e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg18105134	chr13:113819100	PROZ	-0.81	-14.33	-0.57	3.07e-38	Platelet distribution width;
LUAD	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg16060761	chr17:80687452	NA	-0.57	-8.23	-0.37	2.29e-15	Glycated hemoglobin levels;
LUAD	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg06552810	chr11:31128660	NA	-0.35	-6.88	-0.32	2.16e-11	Red blood cell count;
LUAD	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg14092988	chr3:52407081	DNAH1	0.45	8.98	0.4	8.87e-18	Bipolar disorder;
LUAD	cis	rs4660214	0.639	rs6699928	chr1:39733499	T/G	cg27567593	chr1:39956653	BMP8A	0.34	6.85	0.32	2.67e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.73	0.31	5.55e-11	Colorectal cancer;
LUAD	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg13770153	chr20:60521292	NA	-0.58	-8.98	-0.4	9.32e-18	Body mass index;
LUAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9902453	0.740	rs2628189	chr17:28088813	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.52	-0.46	3.74e-23	Coffee consumption (cups per day);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26797073	chr2:131129811	PTPN18	-0.68	-6.51	-0.3	2.19e-10	Type 2 diabetes;
LUAD	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.33	7.04	0.32	7.8e-12	Parkinson's disease;
LUAD	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg02421172	chr7:1938701	MAD1L1	0.49	7.16	0.33	3.62e-12	Bipolar disorder;
LUAD	cis	rs9902453	0.730	rs2020939	chr17:28550732	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.44	-7.31	-0.33	1.35e-12	Coffee consumption (cups per day);
LUAD	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	8.67	0.39	9.24e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs367943	0.698	rs2900074	chr5:113000374	A/C	cg12552261	chr5:112820674	MCC	0.51	9.15	0.41	2.45e-18	Type 2 diabetes;
LUAD	trans	rs8002861	0.967	rs7984393	chr13:44484361	T/C	cg17145862	chr1:211918768	LPGAT1	0.75	17.68	0.65	8.51e-53	Leprosy;
LUAD	cis	rs2282300	0.702	rs4379811	chr11:30294760	C/T	cg25418670	chr11:30344373	C11orf46	0.52	7.26	0.33	1.87e-12	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.47	0.3	2.69e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg16797656	chr11:68205561	LRP5	-0.38	-7.28	-0.33	1.62e-12	Bone mineral density (spine);
LUAD	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg23029597	chr12:123009494	RSRC2	0.48	8.18	0.37	3.47e-15	Body mass index;
LUAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07167872	chr1:205819463	PM20D1	0.73	14.28	0.57	4.83e-38	Menarche (age at onset);
LUAD	cis	rs354033	1.000	rs58026905	chr7:149224358	G/A	cg24335155	chr7:149193227	ZNF746	0.39	6.49	0.3	2.43e-10	Multiple sclerosis;
LUAD	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg22029157	chr1:209979665	IRF6	-0.79	-9.94	-0.44	4.57e-21	Cleft lip with or without cleft palate;
LUAD	cis	rs3820068	0.705	rs7533125	chr1:15883744	T/C	cg24675056	chr1:15929824	NA	0.42	6.66	0.31	8.65e-11	Systolic blood pressure;
LUAD	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg16479474	chr6:28041457	NA	0.36	6.69	0.31	7.09e-11	Cardiac Troponin-T levels;
LUAD	cis	rs9972944	0.756	rs6416949	chr17:63767219	A/T	cg07283582	chr17:63770753	CCDC46	-0.5	-11.18	-0.48	1.28e-25	Total body bone mineral density;
LUAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg02951883	chr7:2050386	MAD1L1	-0.94	-18.4	-0.67	5.46e-56	Bipolar disorder and schizophrenia;
LUAD	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg00316803	chr15:76480434	C15orf27	-0.37	-6.82	-0.31	3.07e-11	Blood metabolite levels;
LUAD	cis	rs977987	0.778	rs11862719	chr16:75431708	T/A	cg03315344	chr16:75512273	CHST6	0.64	14.02	0.56	5.99e-37	Dupuytren's disease;
LUAD	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg27432699	chr2:27873401	GPN1	-0.39	-6.62	-0.31	1.11e-10	Total body bone mineral density;
LUAD	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg04450456	chr4:17643702	FAM184B	0.39	7.61	0.35	1.82e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg11062466	chr8:58055876	NA	0.73	9.23	0.41	1.26e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7593730	1.000	rs12692592	chr2:161163381	G/T	cg22609984	chr2:161126801	NA	0.44	7.32	0.34	1.28e-12	Type 2 diabetes;
LUAD	cis	rs6687430	0.526	rs12120962	chr1:10609505	G/A	cg17425144	chr1:10567563	PEX14	0.55	10.65	0.46	1.28e-23	Hand grip strength;
LUAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg11965913	chr1:205819406	PM20D1	0.8	16.72	0.63	1.51e-48	Menarche (age at onset);
LUAD	trans	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg06606381	chr12:133084897	FBRSL1	-1.13	-10.48	-0.45	5.16e-23	Urinary tract infection frequency;
LUAD	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg04944784	chr2:26401820	FAM59B	-0.71	-10.02	-0.44	2.37e-21	Gut microbiome composition (summer);
LUAD	cis	rs701145	0.537	rs357471	chr3:153896403	C/T	cg17054900	chr3:154042577	DHX36	0.6	6.59	0.3	1.34e-10	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.46e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg21138405	chr5:131827807	IRF1	0.6	13.88	0.56	2.35e-36	Asthma (sex interaction);
LUAD	cis	rs295137	0.725	rs1729413	chr2:201086663	T/G	cg23649088	chr2:200775458	C2orf69	0.44	7.54	0.34	2.86e-13	Asthma (bronchodilator response);
LUAD	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg27494647	chr7:150038898	RARRES2	0.52	9.13	0.41	2.79e-18	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg17644776	chr2:200775616	C2orf69	-0.55	-6.66	-0.31	8.69e-11	Schizophrenia;
LUAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg14668632	chr7:2872130	GNA12	-0.7	-12.39	-0.52	2.68e-30	Height;
LUAD	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg02951883	chr7:2050386	MAD1L1	-0.79	-14.31	-0.57	3.6e-38	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg01299579	chr2:10830716	NOL10	0.43	7.65	0.35	1.42e-13	Prostate cancer;
LUAD	cis	rs938554	0.542	rs7678287	chr4:10000501	A/G	cg11266682	chr4:10021025	SLC2A9	0.53	9.24	0.41	1.21e-18	Blood metabolite levels;
LUAD	cis	rs12545109	0.800	rs2576602	chr8:57394495	C/T	cg11919837	chr8:57350735	NA	-0.47	-6.79	-0.31	3.8e-11	Obesity-related traits;
LUAD	cis	rs2224391	0.613	rs11757924	chr6:5282516	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-7.87	-0.36	3.05e-14	Height;
LUAD	cis	rs9843304	0.528	rs12488126	chr3:149192676	G/A	cg08667024	chr3:149219783	TM4SF4	0.37	6.62	0.31	1.07e-10	Gallstone disease;
LUAD	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg14689365	chr7:158441557	NCAPG2	0.46	7.87	0.36	2.98e-14	Height;
LUAD	cis	rs6500395	1.000	rs7185899	chr16:48714101	A/G	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.59	0.31	1.29e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg04842962	chr6:43655489	MRPS18A	1.06	26.53	0.79	4.81e-92	IgG glycosylation;
LUAD	cis	rs921968	0.565	rs1079177	chr2:219605929	G/A	cg02176678	chr2:219576539	TTLL4	-0.59	-12.01	-0.5	8.65e-29	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg00636124	chr16:27215281	JMJD5	0.4	6.56	0.3	1.56e-10	Anger;
LUAD	cis	rs8060686	0.546	rs8047978	chr16:68143598	T/G	cg09835421	chr16:68378352	PRMT7	-0.53	-6.75	-0.31	4.84e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg07806771	chr7:64541737	NA	0.43	6.85	0.32	2.59e-11	Aortic root size;
LUAD	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg06784218	chr1:46089804	CCDC17	-0.58	-12.79	-0.53	6.77e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg02493740	chr2:85810744	VAMP5	0.45	8.46	0.38	4.34e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs4588572	0.561	rs7727592	chr5:77804547	G/A	cg11547950	chr5:77652471	NA	-0.59	-8.94	-0.4	1.22e-17	Triglycerides;
LUAD	cis	rs7737355	0.645	rs184950	chr5:130852847	G/A	cg25547332	chr5:131281432	NA	0.43	6.68	0.31	7.64e-11	Life satisfaction;
LUAD	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg02527881	chr3:46936655	PTH1R	0.46	9.02	0.4	6.52e-18	Colorectal cancer;
LUAD	cis	rs908922	0.676	rs7518654	chr1:152517845	C/G	cg23254163	chr1:152506842	NA	0.26	7.29	0.33	1.49e-12	Hair morphology;
LUAD	cis	rs12545109	0.837	rs4738500	chr8:57356193	G/A	cg17761419	chr8:57350749	NA	-0.58	-8.1	-0.37	6.09e-15	Obesity-related traits;
LUAD	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-9.27	-0.41	9.65e-19	Total body bone mineral density;
LUAD	cis	rs3096299	0.933	rs2930219	chr16:89492049	G/A	cg07708487	chr16:89387014	ANKRD11	-0.33	-6.51	-0.3	2.12e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	6.97	0.32	1.21e-11	Menopause (age at onset);
LUAD	cis	rs6908034	0.546	rs74514942	chr6:19810520	G/A	cg02682789	chr6:19804855	NA	0.9	8.96	0.4	1.03e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg13319975	chr6:146136371	FBXO30	0.67	11.44	0.49	1.39e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg20542592	chr8:11973495	FAM66D	-0.44	-7.32	-0.34	1.25e-12	Neuroticism;
LUAD	cis	rs7799006	0.723	rs2270052	chr7:2291399	C/T	cg08027265	chr7:2291960	NA	-0.76	-16.08	-0.62	9.48e-46	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21582582	chr3:182698605	DCUN1D1	0.62	10.47	0.45	5.6e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs73198271	0.562	rs55961293	chr8:8675478	T/C	cg01851573	chr8:8652454	MFHAS1	0.68	10.11	0.44	1.18e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg10518543	chr12:38710700	ALG10B	0.52	8.56	0.38	2.13e-16	Morning vs. evening chronotype;
LUAD	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-9.67	-0.43	4.11e-20	Coronary artery disease;
LUAD	cis	rs72928364	0.932	rs2576372	chr3:100639636	A/G	cg10123952	chr3:100791384	NA	-0.55	-6.75	-0.31	4.91e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg15557168	chr22:42548783	NA	0.37	6.52	0.3	1.98e-10	Cognitive function;
LUAD	trans	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg18187862	chr3:45730750	SACM1L	0.5	8.02	0.36	1.01e-14	Primary sclerosing cholangitis;
LUAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg08742575	chr21:47604166	C21orf56	-0.56	-9.37	-0.41	4.31e-19	Testicular germ cell tumor;
LUAD	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg05590025	chr7:65112418	INTS4L2	-0.77	-8.16	-0.37	3.81e-15	Diabetic kidney disease;
LUAD	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg08645402	chr16:4508243	NA	0.57	10.13	0.44	9.42e-22	Schizophrenia;
LUAD	cis	rs3951016	0.514	rs283067	chr6:118620030	T/A	cg21191810	chr6:118973309	C6orf204	0.44	8.01	0.36	1.12e-14	Resting heart rate;
LUAD	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.48	0.34	4.32e-13	Hip circumference adjusted for BMI;
LUAD	trans	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	6.07e-11	Depression;
LUAD	cis	rs12579753	0.871	rs12822050	chr12:82183041	C/T	cg07988820	chr12:82153109	PPFIA2	-0.45	-7.26	-0.33	1.85e-12	Resting heart rate;
LUAD	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg08885076	chr2:99613938	TSGA10	-0.39	-6.97	-0.32	1.24e-11	Chronic sinus infection;
LUAD	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg07404485	chr7:94953653	PON1	-0.49	-7.11	-0.33	5.11e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs73206853	0.841	rs56887341	chr12:110947185	T/C	cg12870014	chr12:110450643	ANKRD13A	0.64	7.38	0.34	8.36e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs71478720	0.743	rs71478724	chr11:112082775	A/G	cg04929355	chr11:112034997	IL18	0.39	6.45	0.3	3.04e-10	Interleukin-18 levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg12361290	chr11:129149358	NA	-0.67	-6.8	-0.31	3.66e-11	Type 2 diabetes;
LUAD	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.44	7.45	0.34	5.3e-13	Body mass index (adult);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24353236	chr11:47270908	NR1H3;ACP2	0.42	6.48	0.3	2.54e-10	Gut microbiome composition (summer);
LUAD	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg19336497	chr11:14380999	RRAS2	-0.61	-13.0	-0.53	9.46e-33	Sense of smell;
LUAD	cis	rs7809950	0.817	rs58052742	chr7:107210003	A/G	cg23024343	chr7:107201750	COG5	0.81	13.38	0.55	2.6e-34	Coronary artery disease;
LUAD	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg22482690	chr17:47019901	SNF8	-0.42	-7.75	-0.35	6.83e-14	Type 2 diabetes;
LUAD	cis	rs4660306	0.961	rs11211138	chr1:46015157	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-7.55	-0.34	2.72e-13	Homocysteine levels;
LUAD	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.52	9.09	0.4	3.85e-18	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06331359	chr17:78190755	SGSH	0.46	6.91	0.32	1.8e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9837602	0.507	rs1059905	chr3:99516879	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.54	-9.98	-0.44	3.28e-21	Breast cancer;
LUAD	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg16647868	chr5:131706066	SLC22A5	0.39	6.4	0.3	4.19e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg01579765	chr21:45077557	HSF2BP	-0.63	-14.43	-0.57	1.15e-38	Mean corpuscular volume;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg17675882	chr20:35374068	NDRG3	0.41	6.52	0.3	2.01e-10	Bilirubin levels;
LUAD	cis	rs8017423	0.967	rs7154683	chr14:90700692	A/G	cg14092571	chr14:90743983	NA	-0.5	-8.8	-0.39	3.61e-17	Mortality in heart failure;
LUAD	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg09835421	chr16:68378352	PRMT7	-0.86	-9.2	-0.41	1.7e-18	Schizophrenia;
LUAD	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg25753631	chr6:25732923	NA	-0.37	-6.43	-0.3	3.49e-10	Iron status biomarkers;
LUAD	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg22117172	chr7:91764530	CYP51A1	0.33	7.21	0.33	2.66e-12	Breast cancer;
LUAD	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg10468373	chr11:64009913	FKBP2	0.54	6.71	0.31	6.09e-11	Mean platelet volume;
LUAD	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg17063962	chr7:91808500	NA	-0.68	-12.06	-0.51	5.43e-29	Breast cancer;
LUAD	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg06784218	chr1:46089804	CCDC17	0.6	13.49	0.55	9.23e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7072216	0.691	rs7910973	chr10:100166732	G/A	cg26618903	chr10:100175079	PYROXD2	-0.36	-7.94	-0.36	1.8e-14	Metabolite levels;
LUAD	trans	rs9929218	1.000	rs13334294	chr16:68809278	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.93	-0.56	1.47e-36	Colorectal cancer;
LUAD	cis	rs4730250	0.581	rs3779500	chr7:106792704	T/C	cg23024343	chr7:107201750	COG5	-0.5	-6.87	-0.32	2.3e-11	Osteoarthritis;
LUAD	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	8.57	0.38	1.92e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs11098699	0.821	rs6811839	chr4:124222326	G/A	cg09941581	chr4:124220074	SPATA5	0.49	7.97	0.36	1.52e-14	Mosquito bite size;
LUAD	cis	rs6076065	0.548	rs1112818	chr20:23323936	G/A	cg11657817	chr20:23433608	CST11	0.54	11.39	0.48	2.2e-26	Facial morphology (factor 15, philtrum width);
LUAD	trans	rs10411161	0.810	rs11667971	chr19:52407694	G/A	cg22319618	chr22:45562946	NUP50	-0.61	-6.71	-0.31	6.18e-11	Breast cancer;
LUAD	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.41	-0.38	6.29e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.07	-0.37	7.52e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg15468180	chr1:107600409	PRMT6	0.43	7.35	0.34	1.04e-12	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs36093844	0.747	rs17817314	chr11:85594972	T/C	cg25872744	chr11:85566296	CCDC83	-0.52	-6.47	-0.3	2.69e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUAD	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg07617317	chr6:118971624	C6orf204	0.55	8.57	0.38	2e-16	Diastolic blood pressure;
LUAD	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg23719950	chr11:63933701	MACROD1	-0.62	-7.3	-0.33	1.42e-12	Mean platelet volume;
LUAD	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg11814155	chr7:99998594	ZCWPW1	0.45	7.82	0.36	4.35e-14	Platelet count;
LUAD	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg02269571	chr22:50332266	NA	0.59	9.04	0.4	5.64e-18	Schizophrenia;
LUAD	cis	rs7607369	0.500	rs6712856	chr2:219658617	A/T	cg02176678	chr2:219576539	TTLL4	-0.65	-12.73	-0.53	1.16e-31	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg18806716	chr10:30721971	MAP3K8	-0.6	-11.9	-0.5	2.28e-28	Inflammatory bowel disease;
LUAD	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	15.35	0.6	1.41e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg12940439	chr1:67600707	NA	0.43	8.44	0.38	5.11e-16	Psoriasis;
LUAD	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg27539214	chr16:67997921	SLC12A4	-0.67	-8.45	-0.38	4.73e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7394190	0.748	rs16930909	chr10:75561582	T/C	cg02286717	chr10:75415704	SYNPO2L	-0.36	-6.4	-0.3	4.01e-10	Incident atrial fibrillation;
LUAD	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg07402062	chr16:89894098	SPIRE2	0.41	10.1	0.44	1.21e-21	Vitiligo;
LUAD	cis	rs7394190	0.748	rs2292307	chr10:75549916	C/A	cg02286717	chr10:75415704	SYNPO2L	-0.4	-6.88	-0.32	2.12e-11	Incident atrial fibrillation;
LUAD	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg00666640	chr1:248458726	OR2T12	0.33	7.8	0.35	4.84e-14	Common traits (Other);
LUAD	cis	rs72901758	0.669	rs17641275	chr17:76247796	A/C	cg26068271	chr17:76253126	NA	-0.39	-6.76	-0.31	4.48e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg00086871	chr4:6988644	TBC1D14	0.73	6.85	0.32	2.55e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2629540	0.781	rs11245362	chr10:126458649	T/C	cg08799069	chr10:126477246	METTL10	-0.48	-7.11	-0.33	5.1e-12	Cocaine dependence;
LUAD	cis	rs931127	0.747	rs11820062	chr11:65429936	T/C	cg27068330	chr11:65405492	SIPA1	-0.43	-6.83	-0.31	3.05e-11	Systemic lupus erythematosus;
LUAD	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.17	-0.33	3.4e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03934478	chr11:495069	RNH1	0.75	8.9	0.4	1.64e-17	Body mass index;
LUAD	cis	rs1371614	0.635	rs12714002	chr2:27134925	C/T	cg00617064	chr2:27272375	NA	0.35	6.62	0.31	1.08e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg06671706	chr8:8559999	CLDN23	0.67	11.65	0.49	2.1e-27	Obesity-related traits;
LUAD	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg19346786	chr7:2764209	NA	-0.53	-11.49	-0.49	8.85e-27	Height;
LUAD	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg04398451	chr17:18023971	MYO15A	-0.7	-12.88	-0.53	2.83e-32	Total body bone mineral density;
LUAD	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg11070056	chr1:107600091	PRMT6	-0.65	-11.2	-0.48	1.09e-25	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg26373071	chr5:1325741	CLPTM1L	0.36	7.56	0.35	2.51e-13	Lung cancer;
LUAD	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg00684032	chr4:1343700	KIAA1530	0.42	6.97	0.32	1.2e-11	Obesity-related traits;
LUAD	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg00852783	chr1:26633632	UBXN11	0.4	7.05	0.32	7.38e-12	Obesity-related traits;
LUAD	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.45	-0.52	1.54e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg19635926	chr16:89946313	TCF25	0.74	6.47	0.3	2.79e-10	Skin colour saturation;
LUAD	cis	rs7709909	0.967	rs6151704	chr5:80004718	C/T	cg24059623	chr5:79951536	MSH3;DHFR	0.42	7.1	0.33	5.29e-12	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg08645402	chr16:4508243	NA	0.53	9.45	0.42	2.28e-19	Schizophrenia;
LUAD	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg09835421	chr16:68378352	PRMT7	-0.99	-11.11	-0.48	2.41e-25	Schizophrenia;
LUAD	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg15017067	chr4:17643749	FAM184B	0.37	7.2	0.33	2.74e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg13319975	chr6:146136371	FBXO30	-0.58	-9.94	-0.44	4.55e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4072705	1.000	rs4836985	chr9:127407894	C/T	cg13476313	chr9:127244764	NR5A1	0.3	7.3	0.33	1.46e-12	Menarche (age at onset);
LUAD	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg03929089	chr4:120376271	NA	-0.68	-9.83	-0.43	1.12e-20	Height;
LUAD	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg11301795	chr4:187892539	NA	-0.78	-16.15	-0.62	4.63e-46	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg11266682	chr4:10021025	SLC2A9	0.48	8.74	0.39	5.4e-17	Blood metabolite levels;
LUAD	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg04546413	chr19:29218101	NA	0.71	10.04	0.44	2.11e-21	Methadone dose in opioid dependence;
LUAD	cis	rs1561288	0.729	rs2028195	chr2:25398953	G/T	cg10045137	chr2:25383940	POMC	-0.39	-6.64	-0.31	9.4e-11	Body mass index;
LUAD	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22307029	chr19:49891270	CCDC155	0.81	13.07	0.54	4.9e-33	Multiple sclerosis;
LUAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-10.68	-0.46	9.88e-24	Lymphocyte counts;
LUAD	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05890377	chr2:74357713	NA	0.82	12.68	0.52	1.84e-31	Gestational age at birth (maternal effect);
LUAD	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg09074113	chr2:20870087	GDF7	-0.48	-9.65	-0.42	4.6e-20	Abdominal aortic aneurysm;
LUAD	cis	rs12135894	0.648	rs4648423	chr1:3765678	C/T	cg23277830	chr1:3704460	LRRC47	-0.42	-9.63	-0.42	5.7e-20	Mean corpuscular volume;
LUAD	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg21475434	chr5:93447410	FAM172A	0.78	7.81	0.35	4.69e-14	Diabetic retinopathy;
LUAD	cis	rs7927592	0.546	rs599083	chr11:68192346	T/G	cg16797656	chr11:68205561	LRP5	0.5	10.18	0.44	6.19e-22	Total body bone mineral density;
LUAD	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg06028605	chr16:24865363	SLC5A11	0.53	8.01	0.36	1.15e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg10596483	chr8:143751796	JRK	0.45	7.15	0.33	3.88e-12	Schizophrenia;
LUAD	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.43	7.58	0.35	2.24e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.43	0.34	5.92e-13	Menopause (age at onset);
LUAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	12.53	0.52	7.36e-31	Lymphocyte counts;
LUAD	cis	rs1215050	0.791	rs783969	chr4:98906504	C/T	cg24818145	chr4:99064322	C4orf37	0.4	6.56	0.3	1.56e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.51	-8.12	-0.37	5.01e-15	Total body bone mineral density;
LUAD	trans	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg26043149	chr18:55253948	FECH	1.03	17.07	0.64	4.45e-50	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg20607798	chr8:58055168	NA	0.67	8.87	0.4	2.15e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-9.66	-0.43	4.45e-20	Migraine;Coronary artery disease;
LUAD	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg00277334	chr10:82204260	NA	-0.96	-22.01	-0.73	4.33e-72	Post bronchodilator FEV1;
LUAD	cis	rs4356932	0.967	rs9999755	chr4:76961802	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.52	-0.3	2.05e-10	Blood protein levels;
LUAD	trans	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg03886242	chr7:26192032	NFE2L3	0.37	6.52	0.3	1.98e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6445967	0.554	rs67507131	chr3:58436488	C/T	cg23715586	chr3:58305044	RPP14	0.39	6.35	0.3	5.48e-10	Platelet count;
LUAD	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg12436631	chr1:155007014	DCST1;DCST2	0.29	6.99	0.32	1.07e-11	Prostate cancer;
LUAD	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg06064525	chr11:970664	AP2A2	-0.46	-9.15	-0.41	2.5e-18	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg00383909	chr3:49044727	WDR6	0.88	10.12	0.44	1.03e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	trans	rs75804782	0.521	rs55690022	chr2:239407783	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	8.78	0.39	4.11e-17	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg06641503	chr3:48959341	ARIH2	-0.4	-7.91	-0.36	2.24e-14	Parkinson's disease;
LUAD	cis	rs1894633	0.547	rs6674018	chr1:172340661	T/A	cg13446689	chr1:172328377	DNM3	0.4	6.41	0.3	3.92e-10	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg14598338	chr9:96623480	NA	-0.44	-9.43	-0.42	2.82e-19	DNA methylation (variation);
LUAD	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.7	-0.39	7.18e-17	Total body bone mineral density;
LUAD	trans	rs2544390	1.000	rs2673172	chr2:170204800	A/C	cg09567311	chr17:53316197	NA	-0.37	-6.44	-0.3	3.35e-10	Urate levels;
LUAD	cis	rs4233802	0.708	rs7564743	chr2:151133831	A/G	cg25300694	chr2:151184358	NA	0.78	6.76	0.31	4.73e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs11811982	0.793	rs76859897	chr1:227365040	C/A	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic disc area;
LUAD	cis	rs11048434	0.736	rs933462	chr12:9103665	T/G	cg13575925	chr12:9217583	LOC144571	0.37	6.85	0.32	2.69e-11	Sjögren's syndrome;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16140913	chr4:8430389	ACOX3	-0.45	-7.0	-0.32	1.01e-11	Height;
LUAD	cis	rs7809950	0.817	rs34325395	chr7:107113808	C/G	cg23024343	chr7:107201750	COG5	-0.9	-14.98	-0.59	5.05e-41	Coronary artery disease;
LUAD	cis	rs1595825	0.891	rs73054867	chr2:198700417	C/G	cg00982548	chr2:198649783	BOLL	-0.65	-9.3	-0.41	7.77e-19	Ulcerative colitis;
LUAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg04025307	chr7:1156635	C7orf50	0.66	7.49	0.34	4.17e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	7.84	0.36	3.65e-14	Menopause (age at onset);
LUAD	cis	rs240764	0.817	rs239238	chr6:101094880	G/T	cg09795085	chr6:101329169	ASCC3	0.43	7.37	0.34	9.09e-13	Neuroticism;
LUAD	cis	rs68170813	0.559	rs3801963	chr7:106898036	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.68	-0.46	9.92e-24	Coronary artery disease;
LUAD	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.86	10.76	0.46	4.94e-24	Body mass index;
LUAD	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg07917127	chr4:99064746	C4orf37	-0.43	-7.15	-0.33	3.76e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.36e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2224391	0.628	rs2753244	chr6:5257610	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.61	-9.21	-0.41	1.5e-18	Height;
LUAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08677398	chr8:58056175	NA	0.53	6.86	0.32	2.41e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg22920501	chr2:26401640	FAM59B	-0.96	-14.19	-0.57	1.13e-37	Gut microbiome composition (summer);
LUAD	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg10755058	chr3:40428713	ENTPD3	0.45	8.44	0.38	5.03e-16	Renal cell carcinoma;
LUAD	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06022373	chr22:39101656	GTPBP1	0.45	6.82	0.31	3.2e-11	Menopause (age at onset);
LUAD	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.58	9.85	0.43	9.73e-21	Cognitive ability;
LUAD	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.59	0.52	4.51e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs55788414	0.725	rs55819896	chr16:81188466	G/A	cg06400318	chr16:81190750	PKD1L2	-0.78	-10.51	-0.46	4.01e-23	Left ventricular obstructive tract defect (maternal effect);
LUAD	trans	rs629535	0.665	rs2433331	chr8:70041943	T/C	cg21567404	chr3:27674614	NA	1.01	19.02	0.68	9.6e-59	Dupuytren's disease;
LUAD	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg18180107	chr4:99064573	C4orf37	0.4	6.44	0.3	3.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12216545	0.765	rs2373809	chr7:150249465	A/C	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.39	-0.3	4.27e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg05717871	chr11:638507	DRD4	-0.41	-6.45	-0.3	3.1e-10	Systemic lupus erythematosus;
LUAD	cis	rs2882667	0.964	rs12719517	chr5:138305502	C/T	cg04439458	chr5:138467593	SIL1	-0.47	-8.49	-0.38	3.64e-16	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg09323728	chr8:95962352	TP53INP1	0.3	7.12	0.33	4.75e-12	Type 2 diabetes;
LUAD	cis	rs10080237	0.564	rs2490224	chr6:80809833	G/A	cg08355045	chr6:80787529	NA	0.62	11.4	0.48	2e-26	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUAD	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg09904177	chr6:26538194	HMGN4	0.43	7.31	0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg23649088	chr2:200775458	C2orf69	-0.56	-6.57	-0.3	1.51e-10	Schizophrenia;
LUAD	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.08	-0.51	4.49e-29	Primary sclerosing cholangitis;
LUAD	trans	rs783540	0.934	rs36109438	chr15:83264459	T/G	cg18393722	chr15:85113863	UBE2QP1	-0.44	-7.21	-0.33	2.58e-12	Schizophrenia;
LUAD	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	13.63	0.55	2.48e-35	Lung cancer in ever smokers;
LUAD	cis	rs887829	0.569	rs4294999	chr2:234635467	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-9.12	-0.41	3.08e-18	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs240764	0.621	rs9404052	chr6:101249718	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-7.58	-0.35	2.26e-13	Neuroticism;
LUAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.92	0.32	1.64e-11	Motion sickness;
LUAD	cis	rs1624802	1.000	rs1624802	chr12:130497472	C/T	cg15444478	chr12:130494697	NA	0.28	6.35	0.3	5.56e-10	Obesity-related traits;
LUAD	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.42	7.74	0.35	7.2e-14	Systemic lupus erythematosus;
LUAD	cis	rs2070997	0.586	rs7851994	chr9:133749848	C/T	cg01000188	chr9:133769184	QRFP	0.5	6.64	0.31	9.77e-11	Response to amphetamines;
LUAD	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg01097406	chr16:89675127	NA	0.44	9.47	0.42	2.04e-19	Vitiligo;
LUAD	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg00530320	chr1:46809349	NSUN4	0.51	7.86	0.36	3.16e-14	Menopause (age at onset);
LUAD	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.53	-0.3	1.94e-10	Prostate cancer;
LUAD	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg05791153	chr7:19748676	TWISTNB	0.85	12.54	0.52	7.1e-31	Night sleep phenotypes;
LUAD	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg25358565	chr5:93447407	FAM172A	0.61	7.15	0.33	3.89e-12	Diabetic retinopathy;
LUAD	cis	rs2505998	0.833	rs2505533	chr10:43594453	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.34	-6.39	-0.3	4.42e-10	Hirschsprung disease;
LUAD	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg03733263	chr8:22462867	KIAA1967	0.72	12.14	0.51	2.59e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs7020830	0.571	rs3780335	chr9:37376587	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.59	-8.61	-0.39	1.42e-16	Schizophrenia;
LUAD	trans	rs7746199	0.673	rs72847313	chr6:27730082	C/T	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.05	-0.44	1.91e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg02951883	chr7:2050386	MAD1L1	-0.74	-11.65	-0.49	2.23e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs6541297	0.645	rs612577	chr1:230324364	A/G	cg20703242	chr1:230279135	GALNT2	-0.5	-7.03	-0.32	8.34e-12	Coronary artery disease;
LUAD	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg10755058	chr3:40428713	ENTPD3	0.45	8.44	0.38	5.02e-16	Renal cell carcinoma;
LUAD	cis	rs12545109	0.800	rs2576591	chr8:57423606	A/G	cg07776626	chr8:57350775	NA	-0.58	-8.18	-0.37	3.42e-15	Obesity-related traits;
LUAD	cis	rs6906287	0.647	rs7746778	chr6:118725871	C/A	cg21191810	chr6:118973309	C6orf204	0.5	9.71	0.43	2.95e-20	Electrocardiographic conduction measures;
LUAD	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg15181151	chr6:150070149	PCMT1	0.39	7.8	0.35	5e-14	Lung cancer;
LUAD	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-7.75	-0.35	7.07e-14	Total cholesterol levels;
LUAD	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg05872129	chr22:39784769	NA	-0.83	-15.67	-0.61	5.76e-44	Intelligence (multi-trait analysis);
LUAD	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg02683114	chr2:24398427	C2orf84	-0.43	-6.59	-0.31	1.28e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09223439	chr15:65282374	SPG21	-0.42	-6.64	-0.31	9.81e-11	Height;
LUAD	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.89	-0.5	2.54e-28	Bipolar disorder;
LUAD	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg25036284	chr2:26402008	FAM59B	-0.68	-9.26	-0.41	1.02e-18	Gut microbiome composition (summer);
LUAD	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg23283495	chr1:209979779	IRF6	0.74	10.85	0.47	2.24e-24	Cleft lip with or without cleft palate;
LUAD	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg06064525	chr11:970664	AP2A2	-0.45	-8.81	-0.39	3.29e-17	Alzheimer's disease (late onset);
LUAD	cis	rs5766691	0.644	rs6007607	chr22:47529288	C/G	cg15757745	chr22:47558489	TBC1D22A	-0.67	-11.77	-0.5	7.47e-28	Longevity;
LUAD	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg22117172	chr7:91764530	CYP51A1	0.34	7.6	0.35	1.96e-13	Breast cancer;
LUAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg05434287	chr7:2030229	MAD1L1	0.4	6.49	0.3	2.37e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs10129255	0.500	rs8022547	chr14:107190222	A/T	cg23076370	chr14:107095027	NA	-0.44	-8.71	-0.39	6.72e-17	Kawasaki disease;
LUAD	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg11822812	chr5:140052017	DND1	-0.45	-8.1	-0.37	5.98e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg15962314	chr1:44399869	ARTN	0.35	7.82	0.36	4.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2066819	1.000	rs57279772	chr12:56698960	G/A	cg26714650	chr12:56694279	CS	-0.86	-7.23	-0.33	2.25e-12	Psoriasis vulgaris;
LUAD	cis	rs9283706	0.608	rs13189948	chr5:66355306	A/G	cg11590213	chr5:66331682	MAST4	0.43	7.04	0.32	7.68e-12	Coronary artery disease;
LUAD	cis	rs1832871	0.672	rs7745596	chr6:158732991	T/A	cg07165851	chr6:158734300	TULP4	0.72	10.96	0.47	8.77e-25	Height;
LUAD	cis	rs9341808	0.718	rs9294171	chr6:80839815	C/T	cg08355045	chr6:80787529	NA	0.55	10.02	0.44	2.38e-21	Sitting height ratio;
LUAD	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg27490568	chr2:178487706	NA	0.51	8.1	0.37	5.9e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9341808	0.519	rs660888	chr6:80983212	A/T	cg08355045	chr6:80787529	NA	0.4	6.67	0.31	8.09e-11	Sitting height ratio;
LUAD	trans	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	trans	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg18187862	chr3:45730750	SACM1L	0.53	8.27	0.37	1.71e-15	Primary sclerosing cholangitis;
LUAD	cis	rs6005807	0.719	rs12168765	chr22:29033308	G/C	cg12565055	chr22:29076175	TTC28	0.74	8.71	0.39	6.98e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs2412208	0.509	rs7546792	chr1:7124346	C/T	cg20434152	chr1:7120926	CAMTA1	-0.4	-10.28	-0.45	2.81e-22	Survival in sporadic amyotrophic lateral sclerosis;
LUAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.5e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg24640516	chr1:210004059	C1orf107	0.36	6.45	0.3	3.06e-10	Orofacial clefts;
LUAD	cis	rs9341808	0.600	rs2505930	chr6:80837058	A/G	cg08355045	chr6:80787529	NA	0.51	8.86	0.4	2.23e-17	Sitting height ratio;
LUAD	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.51	-0.42	1.51e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg08807101	chr21:30365312	RNF160	0.52	8.89	0.4	1.83e-17	Dental caries;
LUAD	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg03433033	chr1:76189801	ACADM	0.85	15.75	0.61	2.62e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06873352	chr17:61820015	STRADA	0.82	18.27	0.66	2.09e-55	Prudent dietary pattern;
LUAD	cis	rs4356932	1.000	rs4417995	chr4:76945999	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.49	-0.3	2.36e-10	Blood protein levels;
LUAD	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg07507251	chr3:52567010	NT5DC2	0.39	7.51	0.34	3.59e-13	Bipolar disorder;
LUAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg18621852	chr3:10150065	C3orf24	0.45	7.08	0.33	5.94e-12	Alzheimer's disease;
LUAD	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg12011299	chr4:100065546	ADH4	0.66	13.87	0.56	2.49e-36	Alcohol dependence;
LUAD	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg19997662	chr15:101784653	CHSY1	-0.55	-10.19	-0.44	5.96e-22	Corneal structure;
LUAD	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg17279839	chr7:150038598	RARRES2	0.45	7.63	0.35	1.58e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg24503407	chr1:205819492	PM20D1	0.71	14.05	0.56	4.58e-37	Menarche (age at onset);
LUAD	cis	rs2046867	0.862	rs6805234	chr3:72829869	A/G	cg25664220	chr3:72788482	NA	-0.61	-11.06	-0.47	3.94e-25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07636037	chr3:49044803	WDR6	-0.47	-7.91	-0.36	2.24e-14	Menarche (age at onset);
LUAD	trans	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg18187862	chr3:45730750	SACM1L	-0.54	-7.83	-0.36	4.06e-14	Primary sclerosing cholangitis;
LUAD	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg06784218	chr1:46089804	CCDC17	0.5	10.94	0.47	1.09e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs12210905	1.000	rs9357034	chr6:27243425	C/G	cg11502198	chr6:26597334	ABT1	-0.77	-6.38	-0.3	4.58e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg21545522	chr1:205238299	TMCC2	0.36	6.61	0.31	1.14e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg25237894	chr2:233734115	C2orf82	-0.57	-11.12	-0.48	2.19e-25	Coronary artery disease;
LUAD	cis	rs6693567	0.565	rs1776276	chr1:150293078	A/C	cg15654264	chr1:150340011	RPRD2	0.37	6.56	0.3	1.59e-10	Migraine;
LUAD	cis	rs3772130	0.962	rs1318472	chr3:121556899	G/A	cg20356878	chr3:121714668	ILDR1	0.52	8.45	0.38	4.74e-16	Cognitive performance;
LUAD	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.84	-0.39	2.55e-17	Total body bone mineral density;
LUAD	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.33	0.34	1.19e-12	Tonsillectomy;
LUAD	trans	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-9.81	-0.43	1.29e-20	Brugada syndrome;
LUAD	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg05283184	chr6:79620031	NA	-0.43	-7.53	-0.34	3.01e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs17067123	0.614	rs72712852	chr4:180066270	T/C	cg26610307	chr4:180072759	NA	-0.52	-6.75	-0.31	4.86e-11	Response to hepatitis C treatment;
LUAD	cis	rs9584850	1.000	rs9584850	chr13:99101426	G/C	cg17380943	chr13:99100506	FARP1	-0.35	-6.63	-0.31	1.03e-10	Neuroticism;
LUAD	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg16680214	chr1:154839983	KCNN3	-0.63	-12.89	-0.53	2.59e-32	Prostate cancer;
LUAD	cis	rs4285028	0.948	rs10934565	chr3:121664661	G/A	cg20356878	chr3:121714668	ILDR1	-0.5	-6.73	-0.31	5.44e-11	Multiple sclerosis;
LUAD	cis	rs60733400	0.644	rs28774982	chr1:2621352	C/G	cg18854424	chr1:2615690	NA	-0.41	-8.72	-0.39	6.64e-17	Multiple sclerosis;
LUAD	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg09365446	chr1:150670422	GOLPH3L	0.54	9.57	0.42	9.3e-20	Melanoma;
LUAD	cis	rs1816752	0.870	rs7981480	chr13:25015104	A/G	cg02811702	chr13:24901961	NA	0.45	7.9	0.36	2.5e-14	Obesity-related traits;
LUAD	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22590775	chr19:49891494	CCDC155	0.75	11.91	0.5	2.08e-28	Multiple sclerosis;
LUAD	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg09658497	chr7:2847517	GNA12	-0.51	-8.47	-0.38	4.23e-16	Height;
LUAD	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03264133	chr6:25882463	NA	-0.57	-9.39	-0.42	3.71e-19	Blood metabolite levels;
LUAD	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg11502198	chr6:26597334	ABT1	0.68	11.85	0.5	3.69e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs9393692	0.620	rs9358927	chr6:26330492	T/G	cg00631329	chr6:26305371	NA	-0.52	-9.11	-0.4	3.37e-18	Educational attainment;
LUAD	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.64	0.31	9.69e-11	Depression;
LUAD	cis	rs9788682	0.747	rs2656074	chr15:78741384	T/C	cg18825076	chr15:78729989	IREB2	-0.54	-7.58	-0.35	2.19e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg27454412	chr7:1067447	C7orf50	-0.34	-6.72	-0.31	5.77e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg02160872	chr5:212506	CCDC127	-0.5	-6.42	-0.3	3.72e-10	Breast cancer;
LUAD	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.78	11.0	0.47	6.11e-25	Smoking behavior;
LUAD	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11644478	chr21:40555479	PSMG1	-0.53	-8.5	-0.38	3.27e-16	Cognitive function;
LUAD	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06022373	chr22:39101656	GTPBP1	0.48	7.8	0.35	4.83e-14	Menopause (age at onset);
LUAD	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg10057126	chr4:77819792	ANKRD56	-0.52	-9.19	-0.41	1.78e-18	Emphysema distribution in smoking;
LUAD	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg14582100	chr15:45693742	SPATA5L1	0.64	12.48	0.52	1.16e-30	Homoarginine levels;
LUAD	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-7.03	-0.32	8.23e-12	Lung cancer;
LUAD	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg11707310	chr1:2537719	MMEL1	0.34	7.49	0.34	4.08e-13	Multiple sclerosis;
LUAD	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.45	6.52	0.3	1.96e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1232027	0.588	rs836816	chr5:79994622	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.45	-7.07	-0.33	6.28e-12	Huntington's disease progression;
LUAD	cis	rs7009516	0.625	rs17799264	chr8:24257137	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.41	8.47	0.38	4.09e-16	Hair greying;
LUAD	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg17724175	chr1:150552817	MCL1	-0.4	-9.09	-0.4	3.98e-18	Blood protein levels;
LUAD	cis	rs8027181	0.710	rs34117151	chr15:73097221	T/A	cg25632853	chr15:73088954	NA	0.31	6.78	0.31	4.06e-11	Triglyceride levels;
LUAD	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg18105134	chr13:113819100	PROZ	-0.84	-14.66	-0.58	1.19e-39	Platelet distribution width;
LUAD	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg09222892	chr1:25734099	RHCE	0.5	9.31	0.41	7.01e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg22823121	chr1:150693482	HORMAD1	0.41	7.84	0.36	3.66e-14	Melanoma;
LUAD	cis	rs13112683	0.638	rs7657941	chr4:140784971	A/T	cg02876341	chr4:140783585	MAML3	0.31	6.7	0.31	6.56e-11	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LUAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03452623	chr4:187889614	NA	-0.81	-16.4	-0.62	3.81e-47	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-11.45	-0.49	1.25e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4711336	0.935	rs3818525	chr6:33660779	A/G	cg14003231	chr6:33640908	ITPR3	0.49	9.45	0.42	2.31e-19	Height;
LUAD	cis	rs11048434	0.636	rs7306165	chr12:9059081	T/C	cg13575925	chr12:9217583	LOC144571	0.37	6.89	0.32	2.07e-11	Sjögren's syndrome;
LUAD	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg04025307	chr7:1156635	C7orf50	0.57	8.15	0.37	4.17e-15	Bronchopulmonary dysplasia;
LUAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07167872	chr1:205819463	PM20D1	0.81	16.63	0.63	3.99e-48	Menarche (age at onset);
LUAD	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg11247378	chr22:39784982	NA	-0.73	-13.62	-0.55	2.71e-35	Intelligence (multi-trait analysis);
LUAD	cis	rs7264396	0.563	rs6060580	chr20:34310512	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.26	-0.37	1.94e-15	Total cholesterol levels;
LUAD	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg08645402	chr16:4508243	NA	0.58	10.84	0.47	2.49e-24	Schizophrenia;
LUAD	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21659725	chr3:3221576	CRBN	0.69	11.28	0.48	5.58e-26	Resting heart rate;
LUAD	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg15556689	chr8:8085844	FLJ10661	0.42	6.71	0.31	6.15e-11	Mood instability;
LUAD	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.69	0.31	6.95e-11	Depression;
LUAD	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg17644776	chr2:200775616	C2orf69	-0.57	-7.41	-0.34	6.71e-13	Schizophrenia;
LUAD	cis	rs10744422	1.000	rs4759387	chr12:123377569	C/T	cg16953816	chr12:123349952	VPS37B	0.61	6.97	0.32	1.23e-11	Schizophrenia;
LUAD	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg27535305	chr1:53392650	SCP2	-0.32	-6.56	-0.3	1.62e-10	Monocyte count;
LUAD	trans	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg01620082	chr3:125678407	NA	-0.43	-6.62	-0.31	1.08e-10	Parkinson's disease;
LUAD	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg12011299	chr4:100065546	ADH4	0.68	12.19	0.51	1.62e-29	Smoking initiation;
LUAD	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg20283391	chr11:68216788	NA	-0.42	-6.56	-0.3	1.56e-10	Total body bone mineral density;
LUAD	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg03806693	chr22:41940476	POLR3H	0.74	10.03	0.44	2.26e-21	Vitiligo;
LUAD	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg15790184	chr11:494944	RNH1	0.57	7.06	0.32	7.05e-12	Body mass index;
LUAD	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg19622623	chr12:86230825	RASSF9	-0.56	-9.85	-0.43	9.25e-21	Major depressive disorder;
LUAD	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg17063962	chr7:91808500	NA	0.73	13.23	0.54	1.13e-33	Breast cancer;
LUAD	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg17747265	chr1:1875780	NA	-0.76	-19.18	-0.68	1.85e-59	Body mass index;
LUAD	cis	rs4523957	0.715	rs6503321	chr17:2096580	G/A	cg16513277	chr17:2031491	SMG6	-0.73	-13.72	-0.55	1.09e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg11062466	chr8:58055876	NA	0.58	7.85	0.36	3.46e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.58	-10.27	-0.45	3.07e-22	Electrocardiographic conduction measures;
LUAD	cis	rs7172809	0.573	rs4886865	chr15:77686876	C/T	cg11865553	chr15:77376250	NA	-0.39	-6.46	-0.3	2.91e-10	Glucose homeostasis traits;
LUAD	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg04455712	chr21:45112962	RRP1B	0.37	7.36	0.34	9.58e-13	Mean corpuscular volume;
LUAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg05564831	chr3:52568323	NT5DC2	0.35	6.49	0.3	2.42e-10	Electroencephalogram traits;
LUAD	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg00898013	chr13:113819073	PROZ	0.73	13.12	0.54	3.18e-33	Platelet distribution width;
LUAD	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.33	7.11	0.33	5e-12	Cardiac Troponin-T levels;
LUAD	cis	rs9902453	0.765	rs2467334	chr17:28135508	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.56	-0.46	2.8e-23	Coffee consumption (cups per day);
LUAD	trans	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg19862616	chr7:65841803	NCRNA00174	1.05	26.51	0.79	5.76e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs28595532	0.688	rs116566508	chr4:119619195	G/A	cg02775129	chr4:119771670	NA	-0.84	-7.82	-0.36	4.25e-14	Cannabis dependence symptom count;
LUAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg00106254	chr7:1943704	MAD1L1	0.58	9.13	0.41	2.9e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs4865169	0.560	rs1277312	chr4:57902945	T/A	cg00922110	chr4:57842668	C4orf14	-0.35	-6.43	-0.3	3.43e-10	Breast cancer;
LUAD	cis	rs7267979	0.586	rs1473695	chr20:25186965	A/G	cg08601574	chr20:25228251	PYGB	0.36	6.57	0.3	1.51e-10	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg18402987	chr7:1209562	NA	0.76	9.06	0.4	5.05e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg03388025	chr16:89894329	SPIRE2	-0.33	-7.64	-0.35	1.43e-13	Vitiligo;
LUAD	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg03340356	chr1:67600835	NA	-0.42	-7.34	-0.34	1.08e-12	Psoriasis;
LUAD	cis	rs727505	1.000	rs113394869	chr7:124518172	G/C	cg23710748	chr7:124431027	NA	-0.47	-9.57	-0.42	8.81e-20	Lewy body disease;
LUAD	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17092148	1.000	rs17092148	chr20:33435161	A/C	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.33	-0.38	1.16e-15	Neuroticism;
LUAD	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg09658497	chr7:2847517	GNA12	-0.48	-8.96	-0.4	1.01e-17	Height;
LUAD	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg22117172	chr7:91764530	CYP51A1	0.33	7.11	0.33	4.89e-12	Breast cancer;
LUAD	cis	rs1113500	0.933	rs11185261	chr1:108638703	G/A	cg06207961	chr1:108661230	NA	0.45	8.42	0.38	5.94e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.38	-6.5	-0.3	2.25e-10	Platelet count;
LUAD	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.89	-0.5	2.59e-28	Bipolar disorder;
LUAD	cis	rs738321	0.757	rs4820315	chr22:38518731	C/T	cg25457927	chr22:38595422	NA	-0.52	-11.44	-0.49	1.33e-26	Breast cancer;
LUAD	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg03806693	chr22:41940476	POLR3H	0.74	9.95	0.44	4.33e-21	Vitiligo;
LUAD	cis	rs11126435	0.858	rs363670	chr2:74929833	A/G	cg19285774	chr2:74907978	SEMA4F	0.37	6.49	0.3	2.45e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.14	14.79	0.58	3.43e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22590775	chr19:49891494	CCDC155	0.73	11.7	0.49	1.42e-27	Multiple sclerosis;
LUAD	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg11062466	chr8:58055876	NA	0.59	8.03	0.36	9.43e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg26597838	chr10:835615	NA	1.04	16.91	0.64	2.28e-49	Eosinophil percentage of granulocytes;
LUAD	trans	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg14917512	chr19:3094685	GNA11	0.55	6.45	0.3	3.11e-10	Diabetic kidney disease;
LUAD	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg17330251	chr7:94953956	PON1	-0.57	-7.63	-0.35	1.59e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg13385794	chr1:248469461	NA	0.27	7.28	0.33	1.63e-12	Common traits (Other);
LUAD	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg02574844	chr11:5959923	NA	-0.42	-7.33	-0.34	1.19e-12	DNA methylation (variation);
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg08965527	chr16:84178213	HSDL1;LRRC50	-0.47	-6.52	-0.3	2.03e-10	Testicular germ cell tumor;
LUAD	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg09184832	chr6:79620586	NA	-0.51	-9.74	-0.43	2.33e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg00784671	chr22:46762841	CELSR1	-0.44	-6.76	-0.31	4.58e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2882667	0.858	rs10900856	chr5:138417746	C/T	cg04439458	chr5:138467593	SIL1	0.52	9.68	0.43	3.76e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.45	-8.17	-0.37	3.72e-15	Longevity;Endometriosis;
LUAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg13560548	chr3:10150139	C3orf24	0.45	7.66	0.35	1.27e-13	Alzheimer's disease;
LUAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08677398	chr8:58056175	NA	0.45	6.45	0.3	3.07e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg18477163	chr1:228402036	OBSCN	0.42	8.23	0.37	2.41e-15	Diastolic blood pressure;
LUAD	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg18180107	chr4:99064573	C4orf37	0.43	6.96	0.32	1.27e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4664308	0.935	rs6744567	chr2:160933781	C/G	cg03641300	chr2:160917029	PLA2R1	-0.38	-6.51	-0.3	2.13e-10	Idiopathic membranous nephropathy;
LUAD	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg04282206	chr17:62833786	PLEKHM1P	0.63	9.34	0.41	5.37e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2996428	0.536	rs12126653	chr1:3773815	C/G	cg17443473	chr1:3703550	LRRC47	0.48	7.93	0.36	1.98e-14	Red cell distribution width;
LUAD	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg12645284	chr15:79092878	ADAMTS7	-0.61	-10.35	-0.45	1.52e-22	Diastolic blood pressure;
LUAD	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg03267442	chr10:82210566	NA	-0.36	-6.46	-0.3	2.8e-10	Post bronchodilator FEV1;
LUAD	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg11292332	chr7:45801988	SEPT13	-0.3	-6.58	-0.3	1.38e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs10193935	1.000	rs10193935	chr2:42419829	C/T	cg27598129	chr2:42591480	NA	-0.75	-10.07	-0.44	1.55e-21	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05415724	chr2:113033170	ZC3H6	-0.54	-6.75	-0.31	4.78e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-10.22	-0.44	4.68e-22	Hip circumference adjusted for BMI;
LUAD	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg17147758	chr8:6949321	NA	-0.5	-8.75	-0.39	5.19e-17	Blood pressure (smoking interaction);
LUAD	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg00933542	chr6:150070202	PCMT1	0.43	8.72	0.39	6.33e-17	Lung cancer;
LUAD	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg22482690	chr17:47019901	SNF8	0.45	8.51	0.38	3.15e-16	Type 2 diabetes;
LUAD	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.22	-0.37	2.57e-15	Bipolar disorder;
LUAD	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.4	8.04	0.36	9.08e-15	Depression;
LUAD	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg13319975	chr6:146136371	FBXO30	0.57	9.46	0.42	2.12e-19	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs2548003	0.518	rs1833823	chr5:28741723	A/G	cg12623145	chr2:97778927	ANKRD36	0.46	6.57	0.3	1.5e-10	Hip geometry;
LUAD	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg11901034	chr3:128598214	ACAD9	0.42	6.39	0.3	4.31e-10	IgG glycosylation;
LUAD	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg02371401	chr5:676784	TPPP	-0.36	-6.56	-0.3	1.61e-10	Lung disease severity in cystic fibrosis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20703108	chr2:26364086	NA	0.53	6.49	0.3	2.37e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg09998033	chr7:158218633	PTPRN2	0.37	6.48	0.3	2.55e-10	Obesity-related traits;
LUAD	cis	rs790123	0.553	rs7612991	chr3:122351791	T/C	cg17380795	chr3:122379686	NA	0.48	8.49	0.38	3.5e-16	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs6541297	0.703	rs653523	chr1:230318402	C/T	cg20703242	chr1:230279135	GALNT2	-0.47	-6.97	-0.32	1.21e-11	Coronary artery disease;
LUAD	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg10876282	chr6:28092338	ZSCAN16	0.44	6.75	0.31	4.96e-11	Parkinson's disease;
LUAD	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg09796270	chr17:17721594	SREBF1	-0.37	-7.12	-0.33	4.74e-12	Total body bone mineral density;
LUAD	cis	rs3803170	0.513	rs11065884	chr12:111818701	A/G	cg10833066	chr12:111807467	FAM109A	0.47	8.69	0.39	8.11e-17	Mean corpuscular hemoglobin;
LUAD	trans	rs40363	0.523	rs757270	chr16:3534451	C/T	cg17171325	chr3:10052813	LOC401052	-0.45	-6.73	-0.31	5.55e-11	Tuberculosis;
LUAD	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	9.17	0.41	2.15e-18	Tonsillectomy;
LUAD	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg15181151	chr6:150070149	PCMT1	0.4	8.26	0.37	1.91e-15	Lung cancer;
LUAD	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.91	0.4	1.49e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs4642101	0.535	rs55692304	chr3:12840057	C/T	cg24848339	chr3:12840334	CAND2	0.53	11.23	0.48	8.81e-26	QRS complex (12-leadsum);
LUAD	cis	rs877282	0.945	rs10904550	chr10:774177	C/T	cg17470449	chr10:769945	NA	0.67	10.42	0.45	8.95e-23	Uric acid levels;
LUAD	cis	rs4819852	0.958	rs9606204	chr22:19976510	C/A	cg07821417	chr22:19972146	ARVCF	0.4	7.64	0.35	1.45e-13	Pulse pressure;
LUAD	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg20891283	chr12:69753455	YEATS4	0.42	6.63	0.31	1.02e-10	Blood protein levels;
LUAD	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg05043794	chr9:111880884	C9orf5	-0.44	-7.54	-0.34	2.83e-13	Menarche (age at onset);
LUAD	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg01579765	chr21:45077557	HSF2BP	-0.56	-11.96	-0.5	1.4e-28	Mean corpuscular volume;
LUAD	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg24531977	chr5:56204891	C5orf35	-0.64	-10.34	-0.45	1.65e-22	Coronary artery disease;
LUAD	cis	rs2235649	0.663	rs12596160	chr16:1848784	G/A	cg08610935	chr16:1836813	NUBP2	-0.5	-7.67	-0.35	1.19e-13	Blood metabolite levels;
LUAD	cis	rs7937890	0.559	rs2597201	chr11:14485404	T/C	cg22961513	chr11:14280813	SPON1	-0.38	-7.3	-0.33	1.46e-12	Mitochondrial DNA levels;
LUAD	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06544989	chr22:39130855	UNC84B	0.44	8.88	0.4	1.86e-17	Menopause (age at onset);
LUAD	cis	rs6952808	0.964	rs10950407	chr7:1895666	T/G	cg21782813	chr7:2030301	MAD1L1	0.45	7.17	0.33	3.45e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg25809561	chr17:30822961	MYO1D	0.46	8.39	0.38	7.42e-16	Schizophrenia;
LUAD	cis	rs4389656	0.857	rs274677	chr5:6754402	T/C	cg10857441	chr5:6722123	POLS	-0.46	-8.13	-0.37	4.97e-15	Coronary artery disease;
LUAD	trans	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-8.48	-0.38	3.78e-16	Endometrial cancer;
LUAD	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg13390004	chr1:15929781	NA	0.47	8.33	0.38	1.11e-15	Systolic blood pressure;
LUAD	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg01097406	chr16:89675127	NA	0.3	6.67	0.31	8.07e-11	Hemoglobin concentration;
LUAD	cis	rs3087591	0.960	rs2953000	chr17:29509791	C/T	cg24425628	chr17:29625626	OMG;NF1	0.39	6.36	0.3	5.27e-10	Hip circumference;
LUAD	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg27499820	chr13:21296301	IL17D	-0.41	-7.19	-0.33	2.99e-12	Dental caries;
LUAD	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg02574844	chr11:5959923	NA	0.43	8.04	0.36	9.23e-15	DNA methylation (variation);
LUAD	cis	rs490234	0.588	rs35278449	chr9:128172963	C/G	cg14078157	chr9:128172775	NA	-0.53	-9.48	-0.42	1.89e-19	Mean arterial pressure;
LUAD	cis	rs62238980	0.522	rs117215349	chr22:32412642	A/G	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg14416269	chr4:6271139	WFS1	0.62	12.86	0.53	3.43e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.64	8.9	0.4	1.69e-17	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.786	rs73054839	chr2:198671665	C/A	cg00361562	chr2:198649771	BOLL	-0.48	-6.68	-0.31	7.67e-11	Ulcerative colitis;
LUAD	cis	rs4006360	0.628	rs439075	chr17:39239467	A/C	cg16090541	chr17:39240343	KRTAP4-7	-0.36	-6.43	-0.3	3.52e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.41	-0.38	6.29e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.37	7.39	0.34	7.71e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7120118	0.517	rs56825896	chr11:47326184	A/G	cg13308137	chr11:47528955	CUGBP1	0.37	6.57	0.3	1.51e-10	HDL cholesterol;
LUAD	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.04	23.44	0.75	1.77e-78	Chronic sinus infection;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01171360	chr6:293285	DUSP22	-0.76	-13.45	-0.55	1.43e-34	Menopause (age at onset);
LUAD	trans	rs12310956	0.510	rs7302434	chr12:33886819	G/A	cg10518543	chr12:38710700	ALG10B	0.39	6.4	0.3	4.22e-10	Morning vs. evening chronotype;
LUAD	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg00933542	chr6:150070202	PCMT1	0.44	9.36	0.41	4.68e-19	Lung cancer;
LUAD	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg00316803	chr15:76480434	C15orf27	-0.41	-7.66	-0.35	1.26e-13	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg02569458	chr12:86230093	RASSF9	0.37	7.21	0.33	2.68e-12	Major depressive disorder;
LUAD	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg26769984	chr7:1090371	C7orf50	0.58	9.39	0.42	3.7e-19	Bronchopulmonary dysplasia;
LUAD	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg16479474	chr6:28041457	NA	0.36	6.44	0.3	3.28e-10	Parkinson's disease;
LUAD	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg09904177	chr6:26538194	HMGN4	0.41	6.84	0.32	2.73e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08704250	chr15:31115839	NA	-0.57	-10.0	-0.44	2.75e-21	Huntington's disease progression;
LUAD	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.88	0.5	2.69e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs67311347	0.524	rs7649168	chr3:40356158	T/C	cg09455208	chr3:40491958	NA	0.5	10.61	0.46	1.79e-23	Renal cell carcinoma;
LUAD	cis	rs10871290	0.650	rs28484753	chr16:74489395	G/C	cg01733217	chr16:74700730	RFWD3	0.48	7.48	0.34	4.24e-13	Breast cancer;
LUAD	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg13319975	chr6:146136371	FBXO30	0.65	11.3	0.48	4.8e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-8.9	-0.4	1.69e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg02807482	chr3:125708958	NA	-0.64	-8.47	-0.38	4.01e-16	Blood pressure (smoking interaction);
LUAD	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05890377	chr2:74357713	NA	0.87	12.1	0.51	3.88e-29	Gestational age at birth (maternal effect);
LUAD	cis	rs1595825	0.945	rs1850634	chr2:198827896	T/C	cg11031976	chr2:198649780	BOLL	-0.47	-6.94	-0.32	1.5e-11	Ulcerative colitis;
LUAD	cis	rs7301826	1.000	rs7301826	chr12:131291101	C/T	cg11011512	chr12:131303247	STX2	0.39	6.71	0.31	6.1e-11	Plasma plasminogen activator levels;
LUAD	cis	rs62229266	0.804	rs62230788	chr21:37380337	A/T	cg08632701	chr21:37451849	NA	-0.47	-7.71	-0.35	9.26e-14	Mitral valve prolapse;
LUAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg02353165	chr6:42928485	GNMT	0.46	8.24	0.37	2.23e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg21775007	chr8:11205619	TDH	-0.52	-9.35	-0.41	5.04e-19	Retinal vascular caliber;
LUAD	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.59	-0.3	1.34e-10	Morning vs. evening chronotype;
LUAD	trans	rs564343	0.538	rs1783563	chr11:65789980	T/C	cg26701943	chr11:108369231	KDELC2	-0.49	-8.17	-0.37	3.59e-15	Obesity (early onset extreme);
LUAD	trans	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg07817883	chr1:32538562	TMEM39B	1.52	13.04	0.54	6.47e-33	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg20891558	chr2:74357851	NA	0.97	17.23	0.64	9.16e-51	Gestational age at birth (maternal effect);
LUAD	cis	rs12286929	0.644	rs12099024	chr11:115082142	A/G	cg04055981	chr11:115044050	NA	0.4	7.06	0.32	6.83e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12541635	0.833	rs4099936	chr8:107099297	G/A	cg10147462	chr8:107024639	NA	-0.39	-6.76	-0.31	4.54e-11	Age of smoking initiation;
LUAD	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg05082376	chr22:42548792	NA	-0.44	-7.54	-0.34	2.95e-13	Schizophrenia;
LUAD	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg10356904	chr22:49881777	NA	-0.41	-8.06	-0.36	8e-15	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9902453	0.817	rs1842026	chr17:28188111	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.51	0.42	1.41e-19	Coffee consumption (cups per day);
LUAD	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg06784218	chr1:46089804	CCDC17	0.51	11.23	0.48	8.7e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6546550	0.869	rs6712827	chr2:70156540	C/G	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.13	-0.48	2.03e-25	Prevalent atrial fibrillation;
LUAD	cis	rs2795502	0.564	rs72777186	chr10:43430464	C/T	cg20628663	chr10:43360327	NA	0.59	7.0	0.32	1.04e-11	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.44	0.38	5.18e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06873352	chr17:61820015	STRADA	0.56	9.09	0.4	3.88e-18	Height;
LUAD	cis	rs72772090	0.539	rs10515250	chr5:96150193	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-6.57	-0.3	1.45e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.14	-0.41	2.7e-18	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg24818145	chr4:99064322	C4orf37	0.47	7.89	0.36	2.6e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62400317	0.762	rs10484626	chr6:44882271	A/G	cg18551225	chr6:44695536	NA	-0.59	-8.94	-0.4	1.2e-17	Total body bone mineral density;
LUAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg24503407	chr1:205819492	PM20D1	0.49	7.63	0.35	1.61e-13	Parkinson's disease;
LUAD	cis	rs6772849	0.901	rs9849126	chr3:128312069	C/T	cg16766828	chr3:128327626	NA	0.35	6.41	0.3	3.78e-10	Monocyte percentage of white cells;Monocyte count;
LUAD	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.38	-6.37	-0.3	5.08e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg03526776	chr6:41159608	TREML2	0.36	7.67	0.35	1.19e-13	Alzheimer's disease (late onset);
LUAD	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg25324976	chr17:61989376	CSHL1	0.37	7.11	0.33	4.88e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg17644776	chr2:200775616	C2orf69	0.54	6.96	0.32	1.31e-11	Schizophrenia;
LUAD	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg19318889	chr4:1322082	MAEA	0.56	9.52	0.42	1.3e-19	Longevity;
LUAD	cis	rs2734839	0.537	rs11214603	chr11:113279922	G/A	cg14159747	chr11:113255604	NA	0.63	12.83	0.53	4.82e-32	Information processing speed;
LUAD	cis	rs9479482	0.935	rs9479507	chr6:150366514	T/G	cg08316699	chr6:150357289	NA	0.36	7.31	0.33	1.37e-12	Alopecia areata;
LUAD	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.83	10.01	0.44	2.67e-21	Yeast infection;
LUAD	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08704250	chr15:31115839	NA	-0.56	-10.02	-0.44	2.38e-21	Huntington's disease progression;
LUAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00149659	chr3:10157352	C3orf10	0.57	8.06	0.36	7.87e-15	Alzheimer's disease;
LUAD	cis	rs2425143	0.818	rs35448195	chr20:34542365	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-6.82	-0.31	3.19e-11	Blood protein levels;
LUAD	trans	rs7395662	1.000	rs2221559	chr11:48707973	A/G	cg00717180	chr2:96193071	NA	0.39	7.23	0.33	2.27e-12	HDL cholesterol;
LUAD	cis	rs728616	0.614	rs56147535	chr10:82027625	G/T	cg27171509	chr10:82033454	MAT1A	-0.59	-6.4	-0.3	4.15e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg22431228	chr1:16359049	CLCNKA	0.41	7.66	0.35	1.3e-13	Systolic blood pressure;
LUAD	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg00074818	chr8:8560427	CLDN23	0.61	9.45	0.42	2.27e-19	Obesity-related traits;
LUAD	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg02569458	chr12:86230093	RASSF9	0.38	6.93	0.32	1.58e-11	Major depressive disorder;
LUAD	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg17724175	chr1:150552817	MCL1	0.37	8.55	0.38	2.33e-16	Melanoma;
LUAD	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg21862992	chr11:68658383	NA	0.52	9.52	0.42	1.39e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9486719	1.000	rs12208884	chr6:96885572	G/A	cg06623918	chr6:96969491	KIAA0776	-0.71	-10.02	-0.44	2.32e-21	Migraine;Coronary artery disease;
LUAD	cis	rs494562	0.803	rs727870	chr6:86131156	A/G	cg17966619	chr6:86160162	NT5E	0.59	7.59	0.35	2.01e-13	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.07e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9826463	0.582	rs6769123	chr3:142107897	A/G	cg20824294	chr3:142316082	PLS1	0.38	6.75	0.31	4.78e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7953508	0.506	rs3782415	chr12:93967755	T/C	cg18151635	chr12:93972918	NA	-0.79	-11.91	-0.5	2.05e-28	Pubertal anthropometrics;
LUAD	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg11663144	chr21:46675770	NA	-0.6	-11.83	-0.5	4.19e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg18187862	chr3:45730750	SACM1L	0.51	7.97	0.36	1.49e-14	Primary sclerosing cholangitis;
LUAD	cis	rs6672530	0.518	rs3010196	chr1:227793908	C/T	cg12133451	chr1:227746453	NA	-0.36	-6.39	-0.3	4.32e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs7010267	0.570	rs2326192	chr8:120028855	C/G	cg01975934	chr8:119970761	NA	-0.35	-6.59	-0.31	1.3e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs1403694	0.515	rs710448	chr3:186452885	A/G	cg12454167	chr3:186435060	KNG1	0.4	8.34	0.38	1.09e-15	Blood protein levels;
LUAD	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg12623302	chr6:28058802	ZSCAN12L1	0.46	7.63	0.35	1.55e-13	Lung cancer in ever smokers;
LUAD	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23583168	chr7:148888333	NA	-0.9	-18.3	-0.66	1.59e-55	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-7.01	-0.32	9.68e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs66725070	1	rs66725070	chr15:58267416	GACAT/G	cg12031962	chr15:58353849	ALDH1A2	-0.46	-9.36	-0.41	4.76e-19	Barrett's esophagus;
LUAD	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg22117172	chr7:91764530	CYP51A1	0.3	6.5	0.3	2.24e-10	Breast cancer;
LUAD	cis	rs3849570	0.533	rs6548782	chr3:81993287	T/G	cg07356753	chr3:81810745	GBE1	-0.5	-8.36	-0.38	9.01e-16	Waist circumference;Body mass index;
LUAD	trans	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg01620082	chr3:125678407	NA	-1.04	-10.33	-0.45	1.92e-22	Depression;
LUAD	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg23803603	chr1:2058230	PRKCZ	0.4	7.21	0.33	2.56e-12	Height;
LUAD	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24308560	chr3:49941425	MST1R	-0.59	-9.9	-0.43	6.45e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00166722	chr3:10149974	C3orf24	0.75	10.93	0.47	1.19e-24	Alzheimer's disease;
LUAD	trans	rs2018683	0.770	rs10951208	chr7:29022504	G/T	cg19402173	chr7:128379420	CALU	-0.54	-8.79	-0.39	3.85e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9581857	0.547	rs9581878	chr13:28104552	T/A	cg22138327	chr13:27999177	GTF3A	0.82	8.9	0.4	1.71e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs2839186	0.584	rs2032111	chr21:47904569	G/A	cg05896524	chr21:47604654	C21orf56	0.5	7.64	0.35	1.51e-13	Testicular germ cell tumor;
LUAD	cis	rs953387	0.824	rs4954578	chr2:136958593	T/C	cg05194412	chr2:137003533	NA	-0.41	-6.48	-0.3	2.59e-10	Arthritis (juvenile idiopathic);
LUAD	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.76	-0.39	4.71e-17	Alcohol dependence;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg22267908	chr13:28025227	MTIF3	-0.39	-6.39	-0.3	4.47e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.35	-6.88	-0.32	2.2e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	8.38	0.38	8.17e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs11039798	1.000	rs12225599	chr11:48755868	T/C	cg02254774	chr11:50257496	LOC441601	0.53	6.61	0.31	1.19e-10	Axial length;
LUAD	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg02527881	chr3:46936655	PTH1R	0.67	15.07	0.59	2.27e-41	Birth weight;
LUAD	cis	rs4409675	0.576	rs7536088	chr1:28234325	A/G	cg23691781	chr1:28212827	C1orf38	0.36	9.84	0.43	1e-20	Corneal astigmatism;
LUAD	cis	rs494562	0.892	rs522915	chr6:86116321	A/G	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13126279	chr21:47581558	C21orf56	-0.58	-10.44	-0.45	7.27e-23	Testicular germ cell tumor;
LUAD	cis	rs9826463	0.757	rs77081474	chr3:142294634	T/C	cg20824294	chr3:142316082	PLS1	0.46	8.13	0.37	4.72e-15	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9341808	0.667	rs2505929	chr6:80834208	A/G	cg08355045	chr6:80787529	NA	0.48	8.41	0.38	6.49e-16	Sitting height ratio;
LUAD	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg27284194	chr4:1044797	NA	0.7	10.13	0.44	9.73e-22	Recombination rate (females);
LUAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg04731861	chr2:219085781	ARPC2	0.27	8.19	0.37	3.17e-15	Colorectal cancer;
LUAD	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	7.27	0.33	1.78e-12	Schizophrenia;
LUAD	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg00750074	chr16:89608354	SPG7	-0.57	-9.95	-0.44	4.15e-21	Multiple myeloma (IgH translocation);
LUAD	cis	rs4523957	0.855	rs11078883	chr17:2138828	C/G	cg16513277	chr17:2031491	SMG6	-0.68	-11.8	-0.5	5.84e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg18404041	chr3:52824283	ITIH1	0.41	7.51	0.34	3.52e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6547741	0.775	rs11692692	chr2:27861707	G/A	cg27432699	chr2:27873401	GPN1	-0.67	-11.75	-0.5	8.58e-28	Oral cavity cancer;
LUAD	cis	rs12347191	0.500	rs907580	chr9:100622597	T/C	cg13688889	chr9:100608707	NA	-0.61	-9.98	-0.44	3.24e-21	Orofacial clefts;
LUAD	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.41	-0.52	2.18e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-8.52	-0.38	2.91e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-9.71	-0.43	2.94e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg20556744	chr2:9614537	IAH1	0.66	6.55	0.3	1.66e-10	Opioid sensitivity;
LUAD	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg09163369	chr1:210001066	C1orf107	0.5	7.14	0.33	4.12e-12	Orofacial clefts;
LUAD	cis	rs11809207	0.857	rs11247866	chr1:26517794	A/G	cg00147160	chr1:26503991	CNKSR1	0.42	8.54	0.38	2.47e-16	Height;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01964765	chr12:123869334	SETD8	0.41	6.6	0.31	1.27e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg10556349	chr10:835070	NA	0.51	6.43	0.3	3.39e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg12310025	chr6:25882481	NA	-0.47	-7.08	-0.33	5.89e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6835098	0.924	rs12639929	chr4:174156538	C/T	cg08422745	chr4:174089978	GALNT7	-0.94	-16.98	-0.64	1.11e-49	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs2414856	0.510	rs77109323	chr15:64704941	G/A	cg08069370	chr15:64387884	SNX1	-0.75	-6.65	-0.31	9.29e-11	Pulse pressure;Systolic blood pressure;
LUAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg08888203	chr3:10149979	C3orf24	0.73	12.78	0.53	7.21e-32	Alzheimer's disease;
LUAD	trans	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg14917512	chr19:3094685	GNA11	-0.57	-6.78	-0.31	4.13e-11	Diabetic kidney disease;
LUAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg18621852	chr3:10150065	C3orf24	0.45	7.08	0.33	5.94e-12	Alzheimer's disease;
LUAD	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg12458913	chr13:53173898	NA	0.37	6.77	0.31	4.43e-11	Lewy body disease;
LUAD	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg26384229	chr12:38710491	ALG10B	-0.42	-7.27	-0.33	1.73e-12	Morning vs. evening chronotype;
LUAD	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg21918786	chr6:109611834	NA	-0.6	-11.28	-0.48	5.8e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs80319144	1.000	rs115983109	chr2:159273472	A/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.92	0.32	1.66e-11	Restless legs syndrome;
LUAD	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg18827107	chr12:86230957	RASSF9	-0.69	-12.68	-0.52	1.84e-31	Major depressive disorder;
LUAD	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg21918786	chr6:109611834	NA	-0.55	-10.3	-0.45	2.43e-22	Reticulocyte fraction of red cells;
LUAD	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22968622	chr17:43663579	NA	-1.2	-20.1	-0.7	1.51e-63	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08439880	chr3:133502540	NA	-0.45	-8.94	-0.4	1.24e-17	Iron status biomarkers;
LUAD	cis	rs7107174	0.901	rs10899494	chr11:78122208	G/T	cg02023728	chr11:77925099	USP35	0.43	6.64	0.31	9.77e-11	Testicular germ cell tumor;
LUAD	cis	rs12681287	0.752	rs4463401	chr8:87250309	C/T	cg27223183	chr8:87520930	FAM82B	-0.61	-8.65	-0.39	1.08e-16	Caudate activity during reward;
LUAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg05434287	chr7:2030229	MAD1L1	0.42	6.94	0.32	1.5e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg25319279	chr11:5960081	NA	-0.4	-7.04	-0.32	7.7e-12	DNA methylation (variation);
LUAD	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg08280861	chr8:58055591	NA	0.64	8.25	0.37	1.98e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs3096299	0.934	rs9927904	chr16:89462847	G/A	cg10164272	chr16:89456328	ANKRD11	0.41	6.37	0.3	4.89e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs62064224	0.597	rs7207268	chr17:30725155	T/G	cg25809561	chr17:30822961	MYO1D	0.48	8.61	0.39	1.5e-16	Schizophrenia;
LUAD	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.59	-10.31	-0.45	2.16e-22	Menarche (age at onset);
LUAD	cis	rs10170310	0.872	rs62161711	chr2:139259222	A/G	cg10095539	chr2:139258744	SPOPL	0.32	6.45	0.3	3.11e-10	Response to antipsychotic treatment;
LUAD	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg19318889	chr4:1322082	MAEA	-0.43	-7.34	-0.34	1.07e-12	Obesity-related traits;
LUAD	cis	rs62229266	0.839	rs11702763	chr21:37470704	A/G	cg08632701	chr21:37451849	NA	-0.47	-7.88	-0.36	2.85e-14	Mitral valve prolapse;
LUAD	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg22920501	chr2:26401640	FAM59B	-0.76	-10.97	-0.47	8.37e-25	Gut microbiome composition (summer);
LUAD	cis	rs7705042	0.865	rs4912805	chr5:141493685	A/G	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.53	-0.3	1.85e-10	Asthma;
LUAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg17178900	chr1:205818956	PM20D1	0.67	13.14	0.54	2.54e-33	Monocyte percentage of white cells;
LUAD	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg21399703	chr1:247681439	NA	0.41	8.05	0.36	8.19e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg08470875	chr2:26401718	FAM59B	0.77	9.98	0.44	3.25e-21	Gut microbiome composition (summer);
LUAD	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg09904177	chr6:26538194	HMGN4	0.44	7.31	0.34	1.31e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.76	-0.35	6.43e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg16325326	chr1:53192061	ZYG11B	0.71	13.76	0.56	7.08e-36	Monocyte count;
LUAD	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg02176678	chr2:219576539	TTLL4	0.6	11.68	0.49	1.61e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs926938	0.841	rs11588144	chr1:115239355	G/A	cg12756093	chr1:115239321	AMPD1	-0.5	-9.02	-0.4	6.71e-18	Autism;
LUAD	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg15704280	chr7:45808275	SEPT13	-0.94	-18.32	-0.67	1.35e-55	Coronary artery disease;
LUAD	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.68	12.44	0.52	1.74e-30	Cognitive ability;
LUAD	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg22532475	chr10:104410764	TRIM8	0.35	7.16	0.33	3.7e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.25	-0.41	1.09e-18	Life satisfaction;
LUAD	cis	rs6066825	0.644	rs6019380	chr20:47318845	A/G	cg18078177	chr20:47281410	PREX1	0.39	6.42	0.3	3.61e-10	Colorectal cancer;
LUAD	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg01448562	chr3:133502909	NA	0.56	10.04	0.44	2.1e-21	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.69	-0.35	1.02e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.14	-0.37	4.61e-15	Alzheimer's disease;
LUAD	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg04772025	chr11:68637568	NA	0.58	8.89	0.4	1.75e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.12	-0.54	3.15e-33	Breast cancer;
LUAD	cis	rs4604732	0.578	rs12040725	chr1:247644697	T/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.4	6.4	0.3	4.11e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1595825	0.838	rs73058854	chr2:198885060	G/A	cg00982548	chr2:198649783	BOLL	-0.68	-9.47	-0.42	1.96e-19	Ulcerative colitis;
LUAD	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg12573674	chr2:1569213	NA	-0.59	-6.95	-0.32	1.35e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg14779329	chr11:130786720	SNX19	0.4	6.75	0.31	4.78e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.5700000000000001e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg03605463	chr16:89740564	NA	0.55	9.84	0.43	1e-20	Hemoglobin concentration;
LUAD	cis	rs11051970	0.636	rs2733705	chr12:32561564	T/C	cg02745156	chr12:32552066	NA	0.31	6.66	0.31	8.77e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4243830	1.000	rs12401795	chr1:6594773	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.78	8.54	0.38	2.53e-16	Body mass index;
LUAD	cis	rs727479	0.543	rs12900487	chr15:51523159	T/C	cg19946085	chr15:51559439	CYP19A1	-0.36	-6.45	-0.3	3.09e-10	Estradiol levels;
LUAD	cis	rs56283067	0.887	rs9472365	chr6:44770214	C/G	cg18551225	chr6:44695536	NA	0.47	7.29	0.33	1.49e-12	Total body bone mineral density;
LUAD	cis	rs909002	0.849	rs2271933	chr1:32092525	C/T	cg13919466	chr1:32135498	COL16A1	0.35	8.09	0.37	6.42e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs12995491	0.933	rs13023008	chr2:88530933	G/A	cg04511125	chr2:88470314	THNSL2	-0.45	-7.46	-0.34	4.82e-13	Response to metformin (IC50);
LUAD	cis	rs2279817	0.865	rs35255680	chr1:17981184	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.47	-6.94	-0.32	1.48e-11	Neuroticism;
LUAD	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg02176678	chr2:219576539	TTLL4	0.6	11.68	0.49	1.59e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg23954153	chr1:44402353	ARTN	-0.38	-7.11	-0.33	4.94e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg17644776	chr2:200775616	C2orf69	0.46	7.93	0.36	1.92e-14	Systolic blood pressure;
LUAD	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.38	0.34	8.33e-13	Morning vs. evening chronotype;
LUAD	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.1	-0.4	3.49e-18	HDL cholesterol;
LUAD	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.88	-9.97	-0.44	3.75e-21	Smoking behavior;
LUAD	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg13870426	chr17:30244630	NA	-0.5	-6.39	-0.3	4.33e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1018836	0.628	rs35816262	chr8:91511017	C/G	cg16814680	chr8:91681699	NA	-0.66	-10.84	-0.47	2.59e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg27539214	chr16:67997921	SLC12A4	-0.66	-8.31	-0.37	1.32e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4077515	0.874	rs3812575	chr9:139293259	T/C	cg14169450	chr9:139327907	INPP5E	0.39	7.27	0.33	1.72e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg03609598	chr5:56110824	MAP3K1	-0.63	-8.54	-0.38	2.37e-16	Initial pursuit acceleration;
LUAD	cis	rs4846217	0.920	rs17396340	chr1:10286176	G/A	cg17425144	chr1:10567563	PEX14	-0.56	-7.22	-0.33	2.38e-12	Platelet count;
LUAD	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg02176678	chr2:219576539	TTLL4	0.61	11.75	0.5	8.59e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7945705	0.776	rs2316865	chr11:8815470	A/G	cg12365402	chr11:9010492	NRIP3	0.37	6.46	0.3	2.81e-10	Hemoglobin concentration;
LUAD	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg01689657	chr7:91764605	CYP51A1	0.37	9.06	0.4	5e-18	Breast cancer;
LUAD	cis	rs868036	1.000	rs884202	chr15:68054388	G/A	cg24579218	chr15:68104479	NA	0.36	6.72	0.31	5.78e-11	Restless legs syndrome;
LUAD	cis	rs1595825	0.838	rs6742343	chr2:198666752	C/T	cg10547527	chr2:198650123	BOLL	-0.53	-7.05	-0.32	7.15e-12	Ulcerative colitis;
LUAD	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg07936489	chr17:37558343	FBXL20	0.53	7.57	0.35	2.43e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg15181151	chr6:150070149	PCMT1	0.34	6.66	0.31	8.8e-11	Lung cancer;
LUAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg27454412	chr7:1067447	C7orf50	0.48	7.73	0.35	7.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg10596483	chr8:143751796	JRK	0.44	7.08	0.33	6.14e-12	Schizophrenia;
LUAD	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg25456477	chr12:86230367	RASSF9	0.32	6.47	0.3	2.75e-10	Major depressive disorder;
LUAD	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18404041	chr3:52824283	ITIH1	-0.58	-11.86	-0.5	3.21e-28	Bipolar disorder;
LUAD	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg06740227	chr12:86229804	RASSF9	0.39	6.91	0.32	1.79e-11	Major depressive disorder;
LUAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg05457628	chr5:178986728	RUFY1	0.54	9.21	0.41	1.51e-18	Lung cancer;
LUAD	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg06873352	chr17:61820015	STRADA	0.4	6.59	0.3	1.35e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.64	0.52	2.71e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg18527919	chr2:24398170	C2orf84	0.42	6.53	0.3	1.89e-10	Asthma;
LUAD	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg25208724	chr1:156163844	SLC25A44	1.11	20.78	0.71	1.3e-66	Testicular germ cell tumor;
LUAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg12432903	chr7:1882776	MAD1L1	-0.4	-6.46	-0.3	2.82e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg18944383	chr4:111397179	ENPEP	0.38	7.62	0.35	1.7e-13	Height;
LUAD	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg26384229	chr12:38710491	ALG10B	0.45	7.22	0.33	2.47e-12	Heart rate;
LUAD	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg23625390	chr15:77176239	SCAPER	0.39	6.82	0.31	3.25e-11	Blood metabolite levels;
LUAD	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg27432699	chr2:27873401	GPN1	-0.49	-8.55	-0.38	2.21e-16	Oral cavity cancer;
LUAD	trans	rs7181230	1.000	rs28620926	chr15:40357171	A/G	cg22705835	chr10:65332833	REEP3	-0.41	-8.45	-0.38	4.79e-16	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg13511324	chr14:104056883	C14orf153	-0.26	-6.5	-0.3	2.21e-10	Reticulocyte count;
LUAD	cis	rs1843834	0.898	rs2015099	chr2:225519915	T/C	cg22455342	chr2:225449267	CUL3	0.46	6.8	0.31	3.48e-11	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg06558623	chr16:89946397	TCF25	1.23	12.4	0.52	2.47e-30	Skin colour saturation;
LUAD	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg02421172	chr7:1938701	MAD1L1	0.45	6.38	0.3	4.78e-10	Neuroticism;
LUAD	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg26597838	chr10:835615	NA	0.84	11.56	0.49	4.78e-27	Eosinophil percentage of granulocytes;
LUAD	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg14343924	chr8:8086146	FLJ10661	0.44	6.96	0.32	1.29e-11	Mood instability;
LUAD	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.23	-0.33	2.34e-12	Height;
LUAD	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg22117172	chr7:91764530	CYP51A1	0.35	7.7	0.35	9.61e-14	Breast cancer;
LUAD	trans	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg03929089	chr4:120376271	NA	0.58	7.66	0.35	1.29e-13	Axial length;
LUAD	cis	rs2880765	0.835	rs4536419	chr15:86039471	C/T	cg13263323	chr15:86062960	AKAP13	-0.49	-9.06	-0.4	4.69e-18	Coronary artery disease;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg22385477	chr4:186392754	CCDC110	-0.39	-6.69	-0.31	6.96e-11	Schizophrenia;
LUAD	cis	rs367943	0.712	rs9326884	chr5:112697520	C/A	cg12552261	chr5:112820674	MCC	0.48	9.36	0.41	4.84e-19	Type 2 diabetes;
LUAD	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.62	10.71	0.46	7.56e-24	Electrocardiographic conduction measures;
LUAD	cis	rs1967309	0.625	rs730242	chr16:4070433	C/T	cg00061520	chr16:4070371	ADCY9	0.49	8.93	0.4	1.28e-17	Response to Dalcetrapib treatment in acute coronary syndrome;
LUAD	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg12436631	chr1:155007014	DCST1;DCST2	0.32	7.35	0.34	1.04e-12	Prostate cancer;
LUAD	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg07741184	chr6:167504864	NA	0.35	8.35	0.38	1.02e-15	Primary biliary cholangitis;
LUAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg12016809	chr21:47604291	C21orf56	0.66	11.67	0.49	1.79e-27	Testicular germ cell tumor;
LUAD	cis	rs7809615	0.901	rs6947826	chr7:99156520	C/T	cg12290671	chr7:99195819	NA	-0.67	-7.87	-0.36	2.95e-14	Blood metabolite ratios;
LUAD	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19717773	chr7:2847554	GNA12	-0.57	-9.9	-0.43	6.56e-21	Height;
LUAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.47	-8.5	-0.38	3.39e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg13685833	chr1:53393034	SCP2	-0.46	-7.4	-0.34	7.16e-13	Monocyte count;
LUAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg00280220	chr17:61926910	NA	0.36	6.91	0.32	1.78e-11	Prudent dietary pattern;
LUAD	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg15128208	chr22:42549153	NA	-0.41	-8.52	-0.38	2.82e-16	Cognitive function;
LUAD	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg13556452	chr1:2391241	NA	-0.31	-6.52	-0.3	2.05e-10	Schizophrenia;
LUAD	trans	rs3960554	0.674	rs112742093	chr7:75800597	T/C	cg19862616	chr7:65841803	NCRNA00174	0.81	10.69	0.46	9.3e-24	Eotaxin levels;
LUAD	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg20307385	chr11:47447363	PSMC3	0.53	7.94	0.36	1.89e-14	Diastolic blood pressure;Systolic blood pressure;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg15846643	chr11:94964345	SESN3	-0.52	-6.39	-0.3	4.39e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs977987	0.806	rs4888420	chr16:75462998	G/C	cg03315344	chr16:75512273	CHST6	0.64	13.99	0.56	7.87e-37	Dupuytren's disease;
LUAD	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.72	0.39	6.26e-17	Parkinson's disease;
LUAD	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14829155	chr15:31115871	NA	-0.79	-13.45	-0.55	1.38e-34	Huntington's disease progression;
LUAD	cis	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.98	-0.36	1.37e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.31	0.41	6.89e-19	Colorectal cancer;
LUAD	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg25664220	chr3:72788482	NA	-0.67	-11.72	-0.5	1.14e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg11822812	chr5:140052017	DND1	0.38	6.73	0.31	5.4e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.4	-0.34	7.17e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg11494091	chr17:61959527	GH2	0.41	7.19	0.33	3.01e-12	Height;
LUAD	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg19163074	chr7:65112434	INTS4L2	0.44	6.76	0.31	4.62e-11	Aortic root size;
LUAD	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg01528321	chr10:82214614	TSPAN14	0.53	8.4	0.38	7.03e-16	Post bronchodilator FEV1;
LUAD	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg09517075	chr8:22133004	PIWIL2	0.48	9.16	0.41	2.33e-18	Hypertriglyceridemia;
LUAD	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg12599982	chr1:44399894	ARTN	-0.34	-6.91	-0.32	1.78e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.51	-0.3	2.14e-10	Neuroticism;
LUAD	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg23758822	chr17:41437982	NA	1.0	20.72	0.71	2.45e-66	Menopause (age at onset);
LUAD	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg05368731	chr17:41323189	NBR1	0.96	19.58	0.69	3.22e-61	Menopause (age at onset);
LUAD	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg13393036	chr8:95962371	TP53INP1	-0.35	-7.71	-0.35	8.99e-14	Type 2 diabetes;
LUAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-6.98	-0.32	1.13e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs317865	0.609	rs73234660	chr4:16221047	G/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.86	8.56	0.38	2.05e-16	Kidney disease (early stage) in type 1 diabetes;
LUAD	cis	rs6489882	0.867	rs7958379	chr12:113363284	A/G	cg20102336	chr12:113376681	OAS3	-0.6	-9.14	-0.41	2.59e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs2455601	1.000	rs11042114	chr11:8919889	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-8.34	-0.38	1.07e-15	Schizophrenia;
LUAD	cis	rs497273	0.534	rs9431	chr12:121202664	A/C	cg02419362	chr12:121203948	SPPL3	0.38	7.65	0.35	1.37e-13	Systemic lupus erythematosus;
LUAD	cis	rs13095912	0.785	rs34619288	chr3:185331678	G/C	cg11274856	chr3:185301563	NA	0.5	9.43	0.42	2.76e-19	Systolic blood pressure;
LUAD	cis	rs2637266	0.745	rs2583039	chr10:78440187	A/G	cg18941641	chr10:78392320	NA	0.33	6.6	0.31	1.27e-10	Pulmonary function;
LUAD	cis	rs9905704	0.633	rs2632518	chr17:56512236	T/C	cg19466818	chr17:56409534	MIR142	-0.34	-6.76	-0.31	4.59e-11	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.2	0.37	3.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg13385794	chr1:248469461	NA	0.26	6.97	0.32	1.19e-11	Common traits (Other);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07932290	chr14:74252976	C14orf43	-0.41	-6.46	-0.3	2.85e-10	Height;
LUAD	cis	rs2625529	0.668	rs12914070	chr15:72334279	T/C	cg16672083	chr15:72433130	SENP8	-0.75	-12.66	-0.52	2.33e-31	Red blood cell count;
LUAD	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg27490568	chr2:178487706	NA	0.55	8.91	0.4	1.55e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg01689657	chr7:91764605	CYP51A1	0.33	8.16	0.37	3.76e-15	Breast cancer;
LUAD	cis	rs4964805	0.710	rs1866296	chr12:104187092	G/A	cg02344784	chr12:104178138	NT5DC3	0.45	9.23	0.41	1.34e-18	Attention deficit hyperactivity disorder;
LUAD	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21659725	chr3:3221576	CRBN	-0.64	-11.01	-0.47	5.7e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg06547715	chr2:218990976	CXCR2	0.42	9.83	0.43	1.13e-20	Ulcerative colitis;
LUAD	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.94	-0.32	1.52e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg15208524	chr1:10270712	KIF1B	0.42	6.42	0.3	3.7e-10	Hepatocellular carcinoma;
LUAD	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg19622623	chr12:86230825	RASSF9	-0.39	-7.2	-0.33	2.72e-12	Major depressive disorder;
LUAD	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg15147215	chr3:52552868	STAB1	-0.41	-7.45	-0.34	5.15e-13	Bipolar disorder;
LUAD	cis	rs6594713	0.604	rs34324763	chr5:112937355	T/C	cg12552261	chr5:112820674	MCC	0.51	6.9	0.32	1.91e-11	Brain cytoarchitecture;
LUAD	cis	rs4523957	0.651	rs9898819	chr17:2076352	G/A	cg16513277	chr17:2031491	SMG6	-0.97	-19.34	-0.69	3.5e-60	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg10053473	chr17:62856997	LRRC37A3	0.78	10.73	0.46	6.22e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg06547715	chr2:218990976	CXCR2	-0.29	-6.89	-0.32	2.06e-11	Colorectal cancer;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg26668828	chr6:292823	DUSP22	-0.8	-14.09	-0.57	3.08e-37	Menopause (age at onset);
LUAD	trans	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg14791747	chr16:20752902	THUMPD1	0.73	9.88	0.43	7.26e-21	Cognitive test performance;
LUAD	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg03929089	chr4:120376271	NA	-0.92	-17.61	-0.65	1.82e-52	Height;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg18110333	chr6:292329	DUSP22	-0.77	-12.92	-0.53	1.96e-32	Menopause (age at onset);
LUAD	trans	rs61332075	0.518	rs112649209	chr2:239422814	C/G	cg01134436	chr17:81009848	B3GNTL1	0.75	8.16	0.37	4e-15	Lung function (FEV1/FVC);
LUAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06873352	chr17:61820015	STRADA	0.82	18.31	0.66	1.47e-55	Prudent dietary pattern;
LUAD	cis	rs1113500	0.933	rs11185250	chr1:108616417	A/G	cg06207961	chr1:108661230	NA	0.45	8.39	0.38	7.15e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs9494145	0.680	rs9389269	chr6:135427159	T/C	cg22676075	chr6:135203613	NA	0.59	8.8	0.39	3.45e-17	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUAD	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg17306686	chr7:157230923	NA	0.53	11.08	0.47	3.22e-25	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg02551604	chr5:131831745	NA	-0.61	-9.73	-0.43	2.5e-20	Asthma (sex interaction);
LUAD	cis	rs6489882	0.671	rs4767026	chr12:113359132	A/G	cg20102336	chr12:113376681	OAS3	-0.55	-8.41	-0.38	6.5e-16	Chronic lymphocytic leukemia;
LUAD	cis	rs657075	0.697	rs4646194	chr5:131649062	C/A	cg21138405	chr5:131827807	IRF1	0.5	6.37	0.3	4.99e-10	Rheumatoid arthritis;
LUAD	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg04025307	chr7:1156635	C7orf50	0.55	8.12	0.37	5.01e-15	Bronchopulmonary dysplasia;
LUAD	trans	rs1973993	0.651	rs60776572	chr1:96960121	C/T	cg10631902	chr5:14652156	NA	-0.47	-8.04	-0.36	8.81e-15	Weight;
LUAD	cis	rs847577	0.609	rs7791463	chr7:97819047	G/A	cg21770322	chr7:97807741	LMTK2	0.35	8.24	0.37	2.14e-15	Breast cancer;
LUAD	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	2.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg02450064	chr17:40260053	DHX58	-0.44	-7.32	-0.34	1.24e-12	Fibrinogen levels;
LUAD	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-6.95	-0.32	1.4e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.87	0.47	1.98e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2625529	0.617	rs62023343	chr15:72174963	C/A	cg16672083	chr15:72433130	SENP8	0.6	11.19	0.48	1.23e-25	Red blood cell count;
LUAD	cis	rs7043114	0.563	rs7848391	chr9:95337520	C/T	cg14631576	chr9:95140430	CENPP	-0.37	-7.48	-0.34	4.42e-13	Height;
LUAD	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg01475377	chr6:109611718	NA	-0.51	-9.56	-0.42	1.02e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg10876282	chr6:28092338	ZSCAN16	0.42	6.73	0.31	5.46e-11	Cardiac Troponin-T levels;
LUAD	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-10.59	-0.46	2.06e-23	Gut microbiome composition (summer);
LUAD	cis	rs61990749	0.597	rs59848135	chr14:78129000	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.56	-6.94	-0.32	1.5e-11	Fibroblast growth factor basic levels;
LUAD	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg08997352	chr12:9597637	DDX12	0.66	11.4	0.48	1.9e-26	Breast size;
LUAD	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.51	0.3	2.17e-10	Cardiac Troponin-T levels;
LUAD	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg11494091	chr17:61959527	GH2	0.43	8.13	0.37	4.93e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg07460842	chr6:66804631	NA	0.96	12.87	0.53	3.14e-32	Exhaled nitric oxide output;
LUAD	cis	rs5771069	0.933	rs137845	chr22:50439430	A/G	cg27068297	chr22:50451975	IL17REL	0.37	7.23	0.33	2.35e-12	Ulcerative colitis;
LUAD	cis	rs7028939	0.792	rs7033350	chr9:102992644	C/T	cg14153061	chr9:102669613	STX17	-0.56	-6.41	-0.3	3.79e-10	Preeclampsia;
LUAD	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg23985595	chr17:80112537	CCDC57	0.42	7.51	0.34	3.65e-13	Life satisfaction;
LUAD	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg01689657	chr7:91764605	CYP51A1	-0.36	-8.89	-0.4	1.77e-17	Breast cancer;
LUAD	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12667521	chr19:29218732	NA	0.6	8.95	0.4	1.1e-17	Methadone dose in opioid dependence;
LUAD	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08704250	chr15:31115839	NA	-0.73	-13.42	-0.55	1.81e-34	Huntington's disease progression;
LUAD	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.49	-8.09	-0.37	6.23e-15	Tonsillectomy;
LUAD	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.92	-0.32	1.68e-11	Neuroticism;
LUAD	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg05234568	chr11:5960015	NA	-0.58	-11.13	-0.48	2.05e-25	DNA methylation (variation);
LUAD	cis	rs1595825	0.735	rs113834557	chr2:198611624	A/G	cg00982548	chr2:198649783	BOLL	-0.63	-8.77	-0.39	4.41e-17	Ulcerative colitis;
LUAD	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg04450456	chr4:17643702	FAM184B	0.4	7.72	0.35	8.55e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.74	0.43	2.28e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg23649088	chr2:200775458	C2orf69	0.49	8.59	0.39	1.67e-16	Asthma (bronchodilator response);
LUAD	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg13606994	chr1:44402422	ARTN	-0.38	-7.54	-0.34	2.94e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg22029157	chr1:209979665	IRF6	0.74	10.64	0.46	1.38e-23	Cleft lip with or without cleft palate;
LUAD	cis	rs12530845	0.943	rs78188670	chr7:135335163	T/C	cg23117316	chr7:135346802	PL-5283	-0.49	-9.11	-0.41	3.24e-18	Red blood cell traits;
LUAD	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg23625390	chr15:77176239	SCAPER	0.38	6.78	0.31	4.11e-11	Blood metabolite levels;
LUAD	cis	rs2625529	0.824	rs16956452	chr15:72284092	T/C	cg16672083	chr15:72433130	SENP8	-0.76	-12.76	-0.53	9.28e-32	Red blood cell count;
LUAD	cis	rs2274273	0.624	rs10132453	chr14:55840851	C/T	cg04306507	chr14:55594613	LGALS3	0.41	7.91	0.36	2.24e-14	Protein biomarker;
LUAD	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg04476341	chr5:669733	TPPP	0.41	7.97	0.36	1.44e-14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg27087555	chr16:88793112	FAM38A	-1.24	-14.11	-0.57	2.63e-37	Plateletcrit;
LUAD	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg20848291	chr7:100343083	ZAN	0.39	6.72	0.31	5.83e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs10489202	1.000	rs17557135	chr1:167985888	A/G	cg24449463	chr1:168025552	DCAF6	-0.55	-7.07	-0.33	6.37e-12	Schizophrenia;
LUAD	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg18721089	chr20:30220636	NA	-0.41	-6.45	-0.3	2.98e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg19635926	chr16:89946313	TCF25	0.72	6.43	0.3	3.55e-10	Skin colour saturation;
LUAD	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg14343924	chr8:8086146	FLJ10661	0.45	6.95	0.32	1.36e-11	Neuroticism;
LUAD	trans	rs9951602	0.512	rs12455566	chr18:76655926	A/G	cg02800362	chr5:177631904	HNRNPAB	0.91	14.4	0.57	1.57e-38	Obesity-related traits;
LUAD	cis	rs4774899	0.902	rs11636919	chr15:57465955	G/T	cg14026238	chr15:57616123	NA	0.35	6.41	0.3	3.98e-10	Urinary tract infection frequency;
LUAD	cis	rs2882667	0.931	rs10077896	chr5:138356756	G/A	cg04439458	chr5:138467593	SIL1	-0.41	-7.44	-0.34	5.65e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-10.51	-0.45	4.22e-23	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg11822812	chr5:140052017	DND1	0.37	6.45	0.3	3.11e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6969780	0.915	rs7341470	chr7:27184842	T/C	cg05579037	chr7:27184853	NA	0.47	6.58	0.3	1.41e-10	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUAD	cis	rs7010267	0.935	rs11573829	chr8:119959623	T/C	cg01975934	chr8:119970761	NA	-0.4	-7.57	-0.35	2.29e-13	Total body bone mineral density (age 45-60);
LUAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.91	-0.32	1.75e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg17173187	chr15:85201210	NMB	0.4	6.53	0.3	1.87e-10	Schizophrenia;
LUAD	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg04414720	chr1:150670196	GOLPH3L	-0.54	-9.2	-0.41	1.67e-18	Tonsillectomy;
LUAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-8.83	-0.39	2.85e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2070677	0.935	rs4335491	chr10:135422460	T/G	cg20169779	chr10:135381914	SYCE1	-0.5	-7.85	-0.36	3.57e-14	Gout;
LUAD	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg20848291	chr7:100343083	ZAN	-0.6	-7.9	-0.36	2.48e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg12436631	chr1:155007014	DCST1;DCST2	0.3	6.96	0.32	1.32e-11	Prostate cancer;
LUAD	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.47	-0.38	4.06e-16	Breast cancer;
LUAD	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg01028140	chr2:1542097	TPO	-0.5	-7.0	-0.32	1.01e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg27614445	chr3:179041226	ZNF639	-0.45	-7.58	-0.35	2.19e-13	Schizophrenia;
LUAD	cis	rs877282	0.945	rs10904556	chr10:789429	A/G	cg06581033	chr10:766294	NA	-0.57	-7.64	-0.35	1.5e-13	Uric acid levels;
LUAD	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg23933602	chr10:16859644	RSU1	1.0	21.75	0.73	5.91e-71	Platelet distribution width;
LUAD	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.56	-0.35	2.48e-13	Lung cancer;
LUAD	cis	rs12681287	0.752	rs13255058	chr8:87287445	G/A	cg00550725	chr8:87521180	FAM82B	0.45	6.53	0.3	1.84e-10	Caudate activity during reward;
LUAD	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.25	-0.51	9.53e-30	Platelet count;
LUAD	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg22139774	chr2:100720529	AFF3	-0.36	-6.97	-0.32	1.23e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs13082711	0.911	rs13075550	chr3:27427618	A/G	cg02860705	chr3:27208620	NA	0.59	8.97	0.4	9.69e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg23281280	chr6:28129359	ZNF389	0.44	6.56	0.3	1.55e-10	Depression;
LUAD	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg04731861	chr2:219085781	ARPC2	0.27	8.25	0.37	2.03e-15	Colorectal cancer;
LUAD	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg19610905	chr11:61596333	FADS2	-0.66	-11.28	-0.48	5.78e-26	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.947	rs31254	chr5:130829404	C/T	cg06307176	chr5:131281290	NA	0.49	7.76	0.35	6.34e-14	Life satisfaction;
LUAD	trans	rs2018683	0.707	rs2057957	chr7:28974626	A/C	cg19402173	chr7:128379420	CALU	0.5	8.2	0.37	3e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg05340658	chr4:99064831	C4orf37	0.43	7.25	0.33	2.01e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg19774624	chr17:42201019	HDAC5	0.38	6.67	0.31	8.08e-11	Total body bone mineral density;
LUAD	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg06781209	chr11:61594997	FADS2	-0.49	-8.8	-0.39	3.53e-17	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg01324343	chr3:183735012	ABCC5	0.76	16.67	0.63	2.56e-48	Anterior chamber depth;
LUAD	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg26513180	chr16:89883248	FANCA	0.7	6.73	0.31	5.59e-11	Skin colour saturation;
LUAD	cis	rs12541635	0.801	rs9642802	chr8:107101364	A/T	cg10147462	chr8:107024639	NA	-0.42	-7.43	-0.34	6.09e-13	Age of smoking initiation;
LUAD	cis	rs3936840	0.565	rs8011721	chr14:102986388	C/G	cg18135206	chr14:102964638	TECPR2	-0.48	-7.19	-0.33	2.97e-12	Plateletcrit;
LUAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg08027265	chr7:2291960	NA	-0.41	-6.76	-0.31	4.49e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg02176678	chr2:219576539	TTLL4	0.64	12.4	0.52	2.42e-30	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6138458	0.828	rs6138466	chr20:24997137	A/G	cg26195577	chr20:24973756	C20orf3	0.78	13.7	0.55	1.35e-35	Blood protein levels;
LUAD	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22857025	chr5:266934	NA	-1.06	-13.35	-0.54	3.53e-34	Breast cancer;
LUAD	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg11822812	chr5:140052017	DND1	-0.39	-7.03	-0.32	8.23e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg03859395	chr2:55845619	SMEK2	0.76	14.24	0.57	7.08e-38	Metabolic syndrome;
LUAD	cis	rs117623576	0.941	rs60146023	chr10:32411515	G/A	cg03047570	chr10:32398778	NA	-0.86	-11.48	-0.49	9.52e-27	Anti-saccade response;
LUAD	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.49	8.05	0.36	8.71e-15	Lymphocyte percentage of white cells;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg04481722	chr22:18893717	DGCR6	-0.45	-7.23	-0.33	2.34e-12	Vertical cup-disc ratio;
LUAD	cis	rs4713675	0.546	rs791903	chr6:33702645	G/C	cg13859433	chr6:33739653	LEMD2	0.28	6.76	0.31	4.49e-11	Plateletcrit;
LUAD	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-8.08	-0.37	6.7e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg15181151	chr6:150070149	PCMT1	0.42	8.71	0.39	6.76e-17	Lung cancer;
LUAD	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg21862992	chr11:68658383	NA	-0.41	-7.61	-0.35	1.82e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg21823605	chr1:152486609	CRCT1	0.28	6.39	0.3	4.49e-10	Hair morphology;
LUAD	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg09367891	chr1:107599246	PRMT6	-0.61	-10.31	-0.45	2.15e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg07952391	chr2:88470173	THNSL2	-0.43	-6.95	-0.32	1.39e-11	Response to metformin (IC50);
LUAD	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg00898013	chr13:113819073	PROZ	-0.84	-15.31	-0.6	2.14e-42	Platelet distribution width;
LUAD	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg24579218	chr15:68104479	NA	0.51	8.38	0.38	7.74e-16	Restless legs syndrome;
LUAD	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.58	-9.41	-0.42	3.28e-19	Urate levels;
LUAD	cis	rs300774	0.925	rs300717	chr2:136638	G/A	cg21211680	chr2:198530	NA	-0.47	-7.38	-0.34	8.37e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs6489882	0.966	rs10735079	chr12:113380008	A/G	cg20102336	chr12:113376681	OAS3	0.52	8.27	0.37	1.7e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs28595532	0.800	rs114321375	chr4:119341663	G/A	cg02775129	chr4:119771670	NA	-0.66	-6.48	-0.3	2.5e-10	Cannabis dependence symptom count;
LUAD	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.6	-0.42	7.19e-20	Life satisfaction;
LUAD	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg17757837	chr7:157058334	UBE3C	-0.47	-8.25	-0.37	1.96e-15	Body mass index;
LUAD	cis	rs9469890	0.604	rs11756281	chr6:34503446	T/C	cg17674042	chr6:34482479	PACSIN1	-0.52	-7.26	-0.33	1.93e-12	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg20891558	chr2:74357851	NA	0.96	16.41	0.62	3.6e-47	Gestational age at birth (maternal effect);
LUAD	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg00857998	chr1:205179979	DSTYK	0.4	6.68	0.31	7.41e-11	Red blood cell count;
LUAD	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg05623727	chr3:50126028	RBM5	-0.33	-7.21	-0.33	2.6e-12	Body mass index;
LUAD	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.31	7.69	0.35	1.03e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg25319279	chr11:5960081	NA	-0.41	-7.23	-0.33	2.25e-12	DNA methylation (variation);
LUAD	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg26384229	chr12:38710491	ALG10B	-0.4	-6.87	-0.32	2.36e-11	Heart rate;
LUAD	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg07741184	chr6:167504864	NA	0.3	7.02	0.32	8.9e-12	Crohn's disease;
LUAD	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg06627628	chr2:24431161	ITSN2	0.42	7.16	0.33	3.61e-12	Asthma;
LUAD	cis	rs1034435	0.755	rs5768679	chr22:48892847	T/G	cg05992904	chr22:48892994	FAM19A5	-0.75	-16.59	-0.63	5.86e-48	Late-onset Alzheimer's disease;
LUAD	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg03452623	chr4:187889614	NA	-0.8	-15.64	-0.61	7.8e-44	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.58	-0.42	8.21e-20	Schizophrenia;
LUAD	cis	rs6489882	0.703	rs1051042	chr12:113357237	G/C	cg20102336	chr12:113376681	OAS3	-0.54	-8.29	-0.37	1.52e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg13319975	chr6:146136371	FBXO30	-0.57	-9.8	-0.43	1.43e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg24818145	chr4:99064322	C4orf37	-0.41	-6.82	-0.31	3.2e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg27411982	chr8:10470053	RP1L1	0.41	7.46	0.34	4.96e-13	Retinal vascular caliber;
LUAD	trans	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg18335740	chr13:41363409	SLC25A15	0.6	11.21	0.48	1.07e-25	Lewy body disease;
LUAD	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg00933542	chr6:150070202	PCMT1	0.45	9.64	0.42	5.2e-20	Lung cancer;
LUAD	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.09	13.46	0.55	1.25e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4268898	1.000	rs10195436	chr2:24436112	C/T	cg06627628	chr2:24431161	ITSN2	0.45	7.7	0.35	9.85e-14	Asthma;
LUAD	cis	rs11809207	1.000	rs11247865	chr1:26517773	T/C	cg00300879	chr1:26503847	CNKSR1	0.28	6.81	0.31	3.44e-11	Height;
LUAD	cis	rs6906287	0.552	rs7740645	chr6:118929208	T/A	cg05564266	chr6:118973597	C6orf204	0.37	7.76	0.35	6.44e-14	Electrocardiographic conduction measures;
LUAD	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.34	7.19	0.33	2.98e-12	Obesity-related traits;
LUAD	cis	rs9494145	0.648	rs7758845	chr6:135428537	A/C	cg22676075	chr6:135203613	NA	0.53	8.12	0.37	5.13e-15	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUAD	cis	rs673604	0.881	rs7512559	chr1:35677753	T/C	cg12633102	chr1:35676489	NA	-0.68	-8.35	-0.38	9.84e-16	Endometrial cancer;
LUAD	cis	rs9549328	0.700	rs34890317	chr13:113617245	G/C	cg17524180	chr13:113633600	MCF2L	0.3	6.46	0.3	2.81e-10	Systolic blood pressure;
LUAD	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	15.35	0.6	1.41e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg02782426	chr3:40428986	ENTPD3	0.36	7.65	0.35	1.39e-13	Renal cell carcinoma;
LUAD	cis	rs490234	0.702	rs13287071	chr9:128268224	T/C	cg14078157	chr9:128172775	NA	-0.46	-8.04	-0.36	9.14e-15	Mean arterial pressure;
LUAD	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg19875535	chr5:140030758	IK	0.47	7.74	0.35	7.29e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.18	-0.33	3.09e-12	Glomerular filtration rate;
LUAD	cis	rs9326248	0.539	rs518181	chr11:116772787	C/A	cg20608306	chr11:116969690	SIK3	0.3	6.59	0.3	1.35e-10	Blood protein levels;
LUAD	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg03609598	chr5:56110824	MAP3K1	-0.48	-7.59	-0.35	2.07e-13	Coronary artery disease;
LUAD	cis	rs4713675	0.524	rs4713672	chr6:33705066	G/A	cg13859433	chr6:33739653	LEMD2	-0.3	-7.32	-0.34	1.23e-12	Plateletcrit;
LUAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14893161	chr1:205819251	PM20D1	0.74	14.94	0.59	8.11e-41	Menarche (age at onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26084319	chr14:21905280	CHD8	-0.43	-6.65	-0.31	9.27e-11	Height;
LUAD	cis	rs67180937	0.553	rs2133188	chr1:222813753	G/T	cg09820183	chr1:222886073	C1orf58;AIDA	0.49	6.5	0.3	2.27e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LUAD	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg18944383	chr4:111397179	ENPEP	0.33	6.43	0.3	3.53e-10	Height;
LUAD	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg10518543	chr12:38710700	ALG10B	-0.51	-8.52	-0.38	2.81e-16	Morning vs. evening chronotype;
LUAD	trans	rs875971	0.545	rs801212	chr7:66015630	C/G	cg04775059	chr7:64541387	NA	-0.5	-6.72	-0.31	5.89e-11	Aortic root size;
LUAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.47	0.3	2.75e-10	Depression;
LUAD	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	7.66	0.35	1.28e-13	Schizophrenia;
LUAD	cis	rs10193935	0.901	rs10179237	chr2:42515501	C/T	cg27598129	chr2:42591480	NA	-0.67	-8.74	-0.39	5.42e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7523050	0.730	rs12726126	chr1:109436128	A/G	cg08274380	chr1:109419600	GPSM2	0.71	6.57	0.3	1.49e-10	Fat distribution (HIV);
LUAD	cis	rs4478137	0.931	rs11100488	chr4:164237660	C/A	cg06758707	chr4:164254230	NPY1R	0.48	7.63	0.35	1.6e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	trans	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	10.97	0.47	8.11e-25	Mean corpuscular volume;
LUAD	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg01028140	chr2:1542097	TPO	-0.43	-7.16	-0.33	3.56e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.46	-0.58	8.37e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs897984	0.762	rs12930545	chr16:30938811	A/G	cg02466173	chr16:30829666	NA	0.67	12.44	0.52	1.77e-30	Dementia with Lewy bodies;
LUAD	cis	rs7737355	0.947	rs10463887	chr5:130776854	C/G	cg06307176	chr5:131281290	NA	-0.48	-7.69	-0.35	1.03e-13	Life satisfaction;
LUAD	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	trans	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-10.73	-0.46	6.58e-24	Obesity-related traits;
LUAD	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg08807101	chr21:30365312	RNF160	0.43	6.55	0.3	1.65e-10	Selective IgA deficiency;
LUAD	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27286337	chr10:134555280	INPP5A	0.7	9.14	0.41	2.68e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg25554036	chr4:6271136	WFS1	0.66	13.15	0.54	2.33e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs4908760	0.811	rs301806	chr1:8482078	C/T	cg01447281	chr1:8482689	RERE	-0.4	-8.36	-0.38	8.93e-16	Vitiligo;
LUAD	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg15358701	chr1:161410459	NA	-0.65	-6.7	-0.31	6.74e-11	Rheumatoid arthritis;
LUAD	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg26384229	chr12:38710491	ALG10B	-0.4	-6.75	-0.31	4.85e-11	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg03929089	chr4:120376271	NA	0.84	15.25	0.6	3.65e-42	Coronary artery disease;
LUAD	cis	rs6445967	0.569	rs9862934	chr3:58281676	A/G	cg13750441	chr3:58318267	PXK	-0.31	-6.59	-0.31	1.32e-10	Platelet count;
LUAD	cis	rs500891	0.525	rs36116892	chr6:84087567	T/A	cg08257003	chr6:84140564	ME1	0.35	6.68	0.31	7.73e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg17366294	chr4:99064904	C4orf37	0.6	10.06	0.44	1.69e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg04398451	chr17:18023971	MYO15A	-0.61	-10.4	-0.45	1.06e-22	Total body bone mineral density;
LUAD	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.76	-0.31	4.65e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03264133	chr6:25882463	NA	-0.55	-8.96	-0.4	1.04e-17	Blood metabolite levels;
LUAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg26354017	chr1:205819088	PM20D1	0.8	17.16	0.64	1.74e-50	Menarche (age at onset);
LUAD	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg21798802	chr22:38057573	PDXP	0.45	8.95	0.4	1.13e-17	Fat distribution (HIV);
LUAD	cis	rs17197710	0.673	rs12576461	chr11:47320772	T/C	cg13308137	chr11:47528955	CUGBP1	0.44	7.18	0.33	3.17e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3784262	0.739	rs1530293	chr15:58210398	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.42	-8.25	-0.37	2.04e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg25811766	chr13:21894605	NA	-0.63	-7.62	-0.35	1.67e-13	White matter hyperintensity burden;
LUAD	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg00750074	chr16:89608354	SPG7	0.53	9.18	0.41	1.94e-18	Multiple myeloma (IgH translocation);
LUAD	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg10518543	chr12:38710700	ALG10B	-0.47	-7.81	-0.36	4.46e-14	Morning vs. evening chronotype;
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18000306	chr6:288505	NA	-0.41	-7.66	-0.35	1.26e-13	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg18180107	chr4:99064573	C4orf37	0.43	6.96	0.32	1.27e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg13385794	chr1:248469461	NA	0.26	6.88	0.32	2.12e-11	Common traits (Other);
LUAD	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg15790184	chr11:494944	RNH1	0.55	6.81	0.31	3.31e-11	Body mass index;
LUAD	cis	rs7107174	0.892	rs11237450	chr11:78023356	C/A	cg19901956	chr11:77921274	USP35	-0.53	-6.44	-0.3	3.2e-10	Testicular germ cell tumor;
LUAD	cis	rs10735851	1	rs10735851	chr12:53743064	G/A	cg26875137	chr12:53738046	NA	0.34	7.13	0.33	4.44e-12	Total body bone mineral density;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg24315188	chr7:77428849	PHTF2;TMEM60	0.43	7.14	0.33	4.18e-12	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg23533926	chr12:111358616	MYL2	-0.42	-7.25	-0.33	2.01e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2657888	0.628	rs2638335	chr12:56880672	C/T	cg23002907	chr12:56915593	RBMS2	-0.41	-7.56	-0.35	2.53e-13	Adiponectin levels;
LUAD	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg24399712	chr22:39784796	NA	-0.66	-10.03	-0.44	2.18e-21	IgG glycosylation;
LUAD	trans	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg12400702	chr3:12838781	CAND2	0.31	6.44	0.3	3.34e-10	Parkinson's disease;
LUAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg24642844	chr7:1081250	C7orf50	-0.97	-14.62	-0.58	1.8e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs977987	0.806	rs4887824	chr16:75441613	T/C	cg03315344	chr16:75512273	CHST6	0.64	14.13	0.57	2e-37	Dupuytren's disease;
LUAD	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.02	-0.36	1.08e-14	Diabetic kidney disease;
LUAD	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	8.61	0.39	1.47e-16	Lung cancer in ever smokers;
LUAD	cis	rs6847149	1.000	rs6847149	chr4:110800097	C/T	cg07850274	chr4:110748770	RRH	-0.42	-6.44	-0.3	3.2e-10	Exercise treadmill test traits;
LUAD	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg14582100	chr15:45693742	SPATA5L1	0.64	12.48	0.52	1.23e-30	Homoarginine levels;
LUAD	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg02734326	chr4:10020555	SLC2A9	0.44	7.79	0.35	5.06e-14	Bone mineral density;
LUAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.7e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg07157834	chr1:205819609	PM20D1	-0.46	-6.88	-0.32	2.19e-11	Menarche (age at onset);
LUAD	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg02176678	chr2:219576539	TTLL4	0.74	14.73	0.58	6.1e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	7.84	0.36	3.65e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg03188948	chr7:1209495	NA	0.83	10.1	0.44	1.29e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3750082	0.582	rs6462436	chr7:32970900	T/C	cg05721444	chr7:32995514	FKBP9	0.43	6.93	0.32	1.55e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs62238980	0.614	rs76037448	chr22:32413653	A/T	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	trans	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg03886242	chr7:26192032	NFE2L3	0.43	7.56	0.35	2.56e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12760731	0.517	rs11587387	chr1:178229950	C/T	cg00404053	chr1:178313656	RASAL2	0.73	9.21	0.41	1.48e-18	Obesity-related traits;
LUAD	cis	rs3760982	0.585	rs62116964	chr19:44291986	T/C	cg11993925	chr19:44307056	LYPD5	0.57	11.87	0.5	3.13e-28	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs7843479	0.601	rs9969551	chr8:21860007	T/C	cg03445287	chr8:21823731	XPO7	-0.48	-9.12	-0.41	2.96e-18	Mean corpuscular volume;
LUAD	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-8.5	-0.38	3.2e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg05665937	chr4:1216051	CTBP1	-0.43	-7.86	-0.36	3.33e-14	Obesity-related traits;
LUAD	cis	rs62238980	0.521	rs117792024	chr22:32379444	G/A	cg00543991	chr22:32367038	NA	0.94	8.78	0.39	4.09e-17	Childhood ear infection;
LUAD	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.55	0.42	1.04e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs472402	0.580	rs10060745	chr5:6658003	T/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.42	-6.45	-0.3	3.08e-10	Response to amphetamines;
LUAD	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.94	-0.32	1.52e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg10018233	chr7:150070692	REPIN1	0.48	7.44	0.34	5.78e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6894268	0.762	rs4701136	chr5:179025550	A/G	cg26135573	chr5:179059668	NA	0.64	8.66	0.39	9.84e-17	Eating disorders;
LUAD	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg17264618	chr3:40429014	ENTPD3	-0.36	-7.84	-0.36	3.78e-14	Renal cell carcinoma;
LUAD	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg02527881	chr3:46936655	PTH1R	0.43	8.17	0.37	3.67e-15	Colorectal cancer;
LUAD	cis	rs11958404	0.932	rs7711898	chr5:157430688	A/G	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg10589385	chr1:150898437	SETDB1	0.45	8.26	0.37	1.91e-15	Melanoma;
LUAD	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.59	-0.31	1.33e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-8.44	-0.38	5.13e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg07570687	chr10:102243282	WNT8B	0.43	6.55	0.3	1.62e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02788857	chr8:22132959	PIWIL2	-0.55	-10.18	-0.44	6.26e-22	Hypertriglyceridemia;
LUAD	cis	rs7903847	0.642	rs2275089	chr10:99141205	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-7.18	-0.33	3.18e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg25894440	chr7:65020034	NA	0.53	6.39	0.3	4.47e-10	Diabetic kidney disease;
LUAD	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg19413350	chr8:57351067	NA	-0.42	-6.7	-0.31	6.48e-11	Obesity-related traits;
LUAD	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.87	-9.63	-0.42	5.54e-20	Lung cancer in ever smokers;
LUAD	cis	rs36051895	0.659	rs62541539	chr9:5038180	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-7.23	-0.33	2.27e-12	Pediatric autoimmune diseases;
LUAD	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg17063962	chr7:91808500	NA	-0.61	-10.25	-0.45	3.55e-22	Breast cancer;
LUAD	cis	rs938554	1.000	rs938555	chr4:9926051	A/G	cg00071950	chr4:10020882	SLC2A9	0.54	8.36	0.38	9.34e-16	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23121547	chr11:1593657	HCCA2;LOC338651;DUSP8	-0.56	-6.81	-0.31	3.26e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs36051895	0.664	rs3780377	chr9:5110899	T/C	cg02405213	chr9:5042618	JAK2	-0.48	-6.57	-0.3	1.46e-10	Pediatric autoimmune diseases;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg04709886	chr11:108093754	ATM;NPAT	0.42	6.44	0.3	3.16e-10	QT interval;
LUAD	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg19717773	chr7:2847554	GNA12	-0.53	-10.26	-0.45	3.41e-22	Height;
LUAD	cis	rs2404602	0.530	rs12915184	chr15:76965922	G/A	cg23625390	chr15:77176239	SCAPER	-0.46	-6.55	-0.3	1.71e-10	Blood metabolite levels;
LUAD	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	8.09	0.37	6.29e-15	Rheumatoid arthritis;
LUAD	cis	rs9487051	0.735	rs380774	chr6:109519623	C/T	cg01475377	chr6:109611718	NA	-0.39	-7.33	-0.34	1.18e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs12612619	0.732	rs12616092	chr2:27217228	G/A	cg00617064	chr2:27272375	NA	-0.37	-7.18	-0.33	3.06e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs755249	0.565	rs1809697	chr1:39959085	C/T	cg27567593	chr1:39956653	BMP8A	0.36	7.32	0.34	1.29e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.19	0.54	1.66e-33	Prudent dietary pattern;
LUAD	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg26384229	chr12:38710491	ALG10B	0.46	7.3	0.33	1.43e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08677398	chr8:58056175	NA	0.46	6.54	0.3	1.76e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg01765077	chr12:122356316	WDR66	0.49	8.41	0.38	6.45e-16	Mean corpuscular volume;
LUAD	cis	rs7103648	0.808	rs7103835	chr11:47461693	G/A	cg20307385	chr11:47447363	PSMC3	0.6	9.48	0.42	1.9e-19	Diastolic blood pressure;Systolic blood pressure;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27495444	chr19:2819863	ZNF554	-0.52	-7.01	-0.32	9.69e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg14530993	chr4:882597	GAK	0.68	6.63	0.31	1.05e-10	Parkinson's disease;
LUAD	cis	rs4964805	0.626	rs11111771	chr12:104179271	A/G	cg02344784	chr12:104178138	NT5DC3	-0.37	-6.44	-0.3	3.34e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs500891	0.525	rs6454321	chr6:84050941	A/G	cg08257003	chr6:84140564	ME1	0.34	6.68	0.31	7.45e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08109568	chr15:31115862	NA	-0.6	-10.01	-0.44	2.51e-21	Huntington's disease progression;
LUAD	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg11915388	chr22:42470451	FAM109B	-0.43	-7.47	-0.34	4.65e-13	Schizophrenia;
LUAD	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg17366294	chr4:99064904	C4orf37	-0.48	-8.36	-0.38	9.12e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2033908	0.620	rs1440271	chr11:12852068	A/G	cg25843174	chr11:12811716	TEAD1	-0.21	-6.4	-0.3	4.09e-10	Sitting height ratio;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg12320968	chr22:22337153	TOP3B	-0.4	-6.7	-0.31	6.73e-11	Schizophrenia;
LUAD	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.48	0.3	2.56e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs4478037	0.822	rs9868526	chr3:33124269	A/G	cg19404215	chr3:33155277	CRTAP	-0.51	-6.58	-0.3	1.39e-10	Major depressive disorder;
LUAD	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg03609598	chr5:56110824	MAP3K1	-0.68	-8.56	-0.38	2.07e-16	Initial pursuit acceleration;
LUAD	cis	rs1784581	0.588	rs9295180	chr6:162420579	T/C	cg17173639	chr6:162384350	PARK2	0.43	7.72	0.35	8.36e-14	Itch intensity from mosquito bite;
LUAD	trans	rs225245	0.541	rs321613	chr17:33881718	G/A	cg19694781	chr19:47549865	TMEM160	-0.61	-9.69	-0.43	3.49e-20	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs3806843	0.576	rs246008	chr5:140338485	C/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.38	-0.3	4.59e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1018836	0.828	rs756568	chr8:91557038	G/C	cg16814680	chr8:91681699	NA	-0.6	-10.19	-0.44	5.9e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.28	-6.77	-0.31	4.35e-11	Coronary artery disease;
LUAD	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg00717180	chr2:96193071	NA	-0.37	-6.83	-0.32	3.01e-11	Coronary artery disease;
LUAD	cis	rs12505328	0.931	rs12511985	chr4:174369927	C/A	cg12145043	chr4:174357286	NA	0.55	9.83	0.43	1.09e-20	Chin dimples;
LUAD	cis	rs2485376	1.000	rs2485378	chr10:104059139	A/G	cg20641465	chr10:103991465	PITX3	-0.56	-10.35	-0.45	1.56e-22	QT interval;
LUAD	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg08704250	chr15:31115839	NA	-0.59	-9.83	-0.43	1.11e-20	Huntington's disease progression;
LUAD	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg04414720	chr1:150670196	GOLPH3L	0.62	10.81	0.47	3.17e-24	Melanoma;
LUAD	cis	rs7582720	1.000	rs114520702	chr2:203697092	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.36	0.41	4.68e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs10979	1.000	rs9484767	chr6:143887912	C/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.29	-0.45	2.66e-22	Hypospadias;
LUAD	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18876405	chr7:65276391	NA	-0.43	-6.83	-0.32	3.02e-11	Aortic root size;
LUAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg22963979	chr7:1858916	MAD1L1	0.55	9.5	0.42	1.62e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg20487152	chr13:99095054	FARP1	-0.48	-8.27	-0.37	1.79e-15	Longevity;
LUAD	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg02990361	chr1:107599529	PRMT6	0.52	8.11	0.37	5.63e-15	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg07460842	chr6:66804631	NA	-1.06	-16.7	-0.63	1.92e-48	Exhaled nitric oxide output;
LUAD	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.28	-0.57	5.01e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg03563238	chr19:33554763	RHPN2	-0.39	-9.17	-0.41	2.14e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs7395662	0.622	rs2865620	chr11:48807911	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.37	-0.34	8.98e-13	HDL cholesterol;
LUAD	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg20933634	chr6:27740509	NA	0.46	7.31	0.33	1.38e-12	Parkinson's disease;
LUAD	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg26384229	chr12:38710491	ALG10B	0.48	7.87	0.36	3.06e-14	Bladder cancer;
LUAD	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg22532475	chr10:104410764	TRIM8	-0.45	-8.52	-0.38	2.84e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs877282	1.000	rs34257857	chr10:772993	C/A	cg06581033	chr10:766294	NA	-0.48	-6.77	-0.31	4.2e-11	Uric acid levels;
LUAD	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg17372223	chr3:52568218	NT5DC2	-0.39	-7.1	-0.33	5.19e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg18225595	chr11:63971243	STIP1	-0.37	-6.42	-0.3	3.76e-10	Platelet count;
LUAD	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg26441486	chr22:50317300	CRELD2	0.45	6.68	0.31	7.68e-11	Schizophrenia;
LUAD	cis	rs12541635	0.801	rs1429675	chr8:107101623	A/G	cg10147462	chr8:107024639	NA	-0.42	-7.46	-0.34	5e-13	Age of smoking initiation;
LUAD	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.51	-10.58	-0.46	2.21e-23	Monocyte percentage of white cells;
LUAD	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4786125	0.626	rs6500859	chr16:6914358	A/T	cg03623568	chr16:6915990	A2BP1	-0.46	-10.14	-0.44	8.99e-22	Heart rate variability traits (SDNN);
LUAD	cis	rs8048589	0.750	rs12926900	chr16:12184084	C/G	cg03816625	chr16:12192430	SNX29	0.43	7.0	0.32	9.91e-12	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg21890820	chr11:65308645	LTBP3	0.46	7.38	0.34	8.22e-13	Bone mineral density;
LUAD	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg02505535	chr3:195703920	SDHAP1	-0.35	-7.13	-0.33	4.27e-12	Pancreatic cancer;
LUAD	cis	rs11958404	0.932	rs72816547	chr5:157417820	G/T	cg05962755	chr5:157440814	NA	0.62	8.51	0.38	3e-16	IgG glycosylation;
LUAD	cis	rs4481887	0.927	rs4534422	chr1:248479482	A/G	cg00666640	chr1:248458726	OR2T12	0.31	7.51	0.34	3.65e-13	Common traits (Other);
LUAD	cis	rs4664304	0.629	rs57751799	chr2:160854180	A/T	cg23995753	chr2:160760732	LY75	-0.39	-6.66	-0.31	8.33e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg05872129	chr22:39784769	NA	-0.83	-15.67	-0.61	5.76e-44	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.95	-0.36	1.76e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12541635	0.966	rs6987512	chr8:106998770	C/T	cg10147462	chr8:107024639	NA	0.51	9.34	0.41	5.39e-19	Age of smoking initiation;
LUAD	trans	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg19676328	chr12:49525230	TUBA1B	-0.56	-8.12	-0.37	4.98e-15	Total cholesterol levels;
LUAD	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.61	-7.44	-0.34	5.83e-13	Body mass index;
LUAD	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg12483005	chr1:23474871	LUZP1	0.51	9.0	0.4	7.53e-18	Height;
LUAD	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg14668632	chr7:2872130	GNA12	-0.75	-13.06	-0.54	5.65e-33	Height;
LUAD	cis	rs7705042	0.865	rs2338822	chr5:141503059	T/C	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.84	-0.32	2.75e-11	Asthma;
LUAD	trans	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.93	-0.36	2.03e-14	Depression;
LUAD	cis	rs364477	0.762	rs9299103	chr9:1001231	G/T	cg13952963	chr9:998547	NA	-0.55	-7.58	-0.35	2.2e-13	Major depressive disorder;
LUAD	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.52	8.61	0.39	1.49e-16	Electrocardiographic conduction measures;
LUAD	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg25036284	chr2:26402008	FAM59B	-0.59	-8.2	-0.37	2.91e-15	Gut microbiome composition (summer);
LUAD	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg21856205	chr7:94953877	PON1	-0.54	-7.42	-0.34	6.35e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg15448220	chr1:150897856	SETDB1	0.54	9.52	0.42	1.39e-19	Melanoma;
LUAD	cis	rs41311933	0.656	rs72758198	chr9:123820400	G/T	cg13567360	chr9:123745713	C5	-0.73	-8.79	-0.39	3.86e-17	Coronary artery disease;
LUAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg23978390	chr7:1156363	C7orf50	-0.49	-7.51	-0.34	3.61e-13	Longevity;Endometriosis;
LUAD	cis	rs912057	0.901	rs744056	chr6:6733540	A/G	cg06612196	chr6:6737390	NA	0.53	12.03	0.5	7.1e-29	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs6840360	0.571	rs12647566	chr4:152482525	C/T	cg22705602	chr4:152727874	NA	-0.38	-6.63	-0.31	1.06e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19105961	chr17:4046223	CYB5D2;ZZEF1	-0.57	-7.21	-0.33	2.61e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-20.27	-0.7	2.58e-64	Height;
LUAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg13047869	chr3:10149882	C3orf24	0.59	9.99	0.44	2.95e-21	Alzheimer's disease;
LUAD	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg18721089	chr20:30220636	NA	-0.44	-6.62	-0.31	1.12e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg17063962	chr7:91808500	NA	-0.6	-10.22	-0.44	4.67e-22	Breast cancer;
LUAD	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-20.84	-0.71	6.96e-67	Height;
LUAD	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg05872129	chr22:39784769	NA	-0.78	-14.79	-0.58	3.36e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.17	-0.41	2.13e-18	Total body bone mineral density;
LUAD	cis	rs56346965	0.967	rs11900804	chr2:191533767	T/C	cg27211696	chr2:191398769	TMEM194B	-0.46	-8.39	-0.38	7.19e-16	Bone mineral density (Ward's triangle area);
LUAD	cis	rs4713675	0.565	rs4711340	chr6:33681131	C/T	cg13859433	chr6:33739653	LEMD2	-0.3	-7.18	-0.33	3.16e-12	Plateletcrit;
LUAD	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg23231163	chr10:75533350	FUT11	-0.52	-9.6	-0.42	6.98e-20	Inflammatory bowel disease;
LUAD	cis	rs300774	1.000	rs378456	chr2:119346	C/G	cg21211680	chr2:198530	NA	-0.46	-6.65	-0.31	8.99e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs7827545	0.545	rs1867062	chr8:135559079	G/A	cg17885191	chr8:135476712	NA	0.6	8.1	0.37	5.73e-15	Hypertension (SNP x SNP interaction);
LUAD	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg19622623	chr12:86230825	RASSF9	0.38	6.86	0.32	2.5e-11	Major depressive disorder;
LUAD	cis	rs11051970	0.879	rs2733682	chr12:32574608	G/A	cg24626660	chr12:32551988	NA	0.32	6.55	0.3	1.64e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.65	0.31	8.98e-11	Menarche (age at onset);
LUAD	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg11292332	chr7:45801988	SEPT13	-0.28	-6.36	-0.3	5.26e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4372836	1.000	rs2169748	chr2:28957753	G/A	cg09522027	chr2:28974177	PPP1CB	0.64	9.91	0.43	5.85e-21	Body mass index;
LUAD	trans	rs2840044	1.000	rs225251	chr17:33951228	A/C	cg19694781	chr19:47549865	TMEM160	-0.63	-10.19	-0.44	5.72e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.67	-0.35	1.21e-13	Breast cancer;
LUAD	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-9.63	-0.42	5.65e-20	Gut microbiome composition (summer);
LUAD	cis	rs10207060	0.500	rs7585903	chr2:240682481	A/C	cg07506560	chr2:240697449	NA	0.38	6.69	0.31	6.95e-11	Obesity-related traits;
LUAD	cis	rs2742417	0.603	rs2531755	chr3:45772742	T/C	cg10512202	chr3:45649293	LIMD1	0.47	8.85	0.4	2.46e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg03396347	chr1:1875803	NA	0.54	13.58	0.55	3.99e-35	Body mass index;
LUAD	cis	rs3204270	0.639	rs7216239	chr17:79660187	C/T	cg18367735	chr17:79674897	NA	0.59	7.1	0.33	5.42e-12	Dental caries;
LUAD	cis	rs1595825	0.891	rs73056811	chr2:198766642	T/C	cg00361562	chr2:198649771	BOLL	-0.47	-6.73	-0.31	5.53e-11	Ulcerative colitis;
LUAD	trans	rs629535	0.734	rs659430	chr8:70009988	A/G	cg21567404	chr3:27674614	NA	0.79	14.21	0.57	9.67e-38	Dupuytren's disease;
LUAD	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg19318889	chr4:1322082	MAEA	0.9	15.39	0.6	9.48e-43	Longevity;
LUAD	cis	rs1595825	0.891	rs77029420	chr2:198651492	G/A	cg11031976	chr2:198649780	BOLL	-0.48	-6.54	-0.3	1.74e-10	Ulcerative colitis;
LUAD	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg05283184	chr6:79620031	NA	-0.6	-12.2	-0.51	1.51e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg23281280	chr6:28129359	ZNF389	0.46	6.56	0.3	1.55e-10	Depression;
LUAD	cis	rs35883536	0.647	rs2647325	chr1:101040195	T/C	cg06223162	chr1:101003688	GPR88	0.47	9.15	0.41	2.44e-18	Monocyte count;
LUAD	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg03563238	chr19:33554763	RHPN2	-0.37	-8.56	-0.38	2.12e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7809950	0.798	rs2701684	chr7:107299527	C/T	cg23024343	chr7:107201750	COG5	0.55	9.14	0.41	2.61e-18	Coronary artery disease;
LUAD	trans	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-8.92	-0.4	1.45e-17	Brugada syndrome;
LUAD	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg08470875	chr2:26401718	FAM59B	-0.62	-8.49	-0.38	3.43e-16	Gut microbiome composition (summer);
LUAD	cis	rs6696239	0.531	rs10799423	chr1:227737384	C/G	cg12133451	chr1:227746453	NA	0.37	6.82	0.31	3.08e-11	Height;
LUAD	trans	rs11039798	0.541	rs12283728	chr11:48796407	G/A	cg15704280	chr7:45808275	SEPT13	0.67	7.83	0.36	3.98e-14	Axial length;
LUAD	cis	rs8017423	0.904	rs12433417	chr14:90804028	A/G	cg14092571	chr14:90743983	NA	0.47	8.07	0.37	7.25e-15	Mortality in heart failure;
LUAD	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg12310025	chr6:25882481	NA	-0.68	-10.15	-0.44	8.3e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg22508957	chr16:3507546	NAT15	-0.7	-10.72	-0.46	6.85e-24	Tuberculosis;
LUAD	cis	rs7197653	0.519	rs55757091	chr16:68323654	G/A	cg09835421	chr16:68378352	PRMT7	-0.67	-8.3	-0.37	1.37e-15	Magnesium levels;
LUAD	cis	rs2067615	0.579	rs10861667	chr12:107194776	T/G	cg15890332	chr12:107067104	RFX4	0.39	8.29	0.37	1.57e-15	Heart rate;
LUAD	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-7.34	-0.34	1.07e-12	Tonsillectomy;
LUAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg22535103	chr8:58192502	C8orf71	-0.75	-9.31	-0.41	7.18e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7707921	0.767	rs862242	chr5:81587566	C/T	cg15871215	chr5:81402204	ATG10	-0.59	-9.56	-0.42	9.63e-20	Breast cancer;
LUAD	cis	rs1483890	0.723	rs12629229	chr3:69411222	A/G	cg22125112	chr3:69402811	FRMD4B	0.45	7.71	0.35	8.88e-14	Resting heart rate;
LUAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg11494091	chr17:61959527	GH2	0.74	18.55	0.67	1.16e-56	Prudent dietary pattern;
LUAD	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg16950941	chr11:66035639	RAB1B	0.46	7.7	0.35	9.85e-14	Gout;
LUAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg11494091	chr17:61959527	GH2	0.74	18.54	0.67	1.3e-56	Prudent dietary pattern;
LUAD	cis	rs12618769	0.597	rs2278208	chr2:99154229	C/T	cg10123293	chr2:99228465	UNC50	0.5	8.75	0.39	5.07e-17	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg04944784	chr2:26401820	FAM59B	0.88	11.44	0.49	1.42e-26	Gut microbiome composition (summer);
LUAD	cis	rs7680126	0.596	rs11731652	chr4:10292984	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-7.51	-0.34	3.51e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg04450456	chr4:17643702	FAM184B	0.37	6.77	0.31	4.32e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg25811766	chr13:21894605	NA	0.61	9.95	0.44	4.13e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg18132916	chr6:79620363	NA	-0.46	-7.95	-0.36	1.76e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.79	-0.31	3.84e-11	Height;
LUAD	cis	rs6908034	0.607	rs76413455	chr6:19808964	T/G	cg02682789	chr6:19804855	NA	0.9	8.96	0.4	1.03e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs68170813	0.559	rs7783181	chr7:106977613	A/G	cg02696742	chr7:106810147	HBP1	-0.73	-10.49	-0.45	4.71e-23	Coronary artery disease;
LUAD	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg10591111	chr5:226296	SDHA	-0.56	-7.3	-0.33	1.42e-12	Breast cancer;
LUAD	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1493916	0.905	rs10460051	chr18:31413679	C/T	cg15819921	chr19:927150	ARID3A	-0.48	-8.07	-0.37	7.39e-15	Life satisfaction;
LUAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.66	0.31	8.54e-11	Prudent dietary pattern;
LUAD	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg14834391	chr1:2537342	MMEL1	-0.31	-6.42	-0.3	3.67e-10	Ulcerative colitis;
LUAD	trans	rs11638815	0.581	rs783535	chr15:83250425	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.47	-7.25	-0.33	2.05e-12	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg08027265	chr7:2291960	NA	-0.49	-8.44	-0.38	5.01e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs17818399	0.926	rs13032670	chr2:46830794	C/T	cg09399716	chr2:46890238	NA	-0.41	-7.73	-0.35	8.06e-14	Height;
LUAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08677398	chr8:58056175	NA	0.54	7.04	0.32	7.78e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg15557168	chr22:42548783	NA	0.51	9.58	0.42	8.65e-20	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.76	0.53	9e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg18944383	chr4:111397179	ENPEP	0.37	7.57	0.35	2.29e-13	Height;
LUAD	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg22482690	chr17:47019901	SNF8	0.45	8.58	0.38	1.86e-16	Type 2 diabetes;
LUAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg02951883	chr7:2050386	MAD1L1	-0.73	-11.67	-0.49	1.78e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg14668632	chr7:2872130	GNA12	-0.74	-13.25	-0.54	9.49e-34	Height;
LUAD	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg15704280	chr7:45808275	SEPT13	0.67	10.66	0.46	1.15e-23	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs79911532	0.515	rs114616297	chr7:75719576	T/G	cg19862616	chr7:65841803	NCRNA00174	0.84	8.61	0.39	1.47e-16	Mononucleosis;
LUAD	cis	rs886126	0.684	rs10083213	chr12:111654363	A/G	cg10833066	chr12:111807467	FAM109A	-0.49	-9.08	-0.4	4.05e-18	Coronary heart disease;
LUAD	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg08847533	chr14:75593920	NEK9	-0.41	-6.97	-0.32	1.21e-11	Height;
LUAD	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg24558204	chr6:135376177	HBS1L	0.48	8.88	0.4	1.94e-17	Red blood cell count;
LUAD	cis	rs7809950	0.953	rs1468336	chr7:107208250	T/C	cg23024343	chr7:107201750	COG5	0.74	12.18	0.51	1.89e-29	Coronary artery disease;
LUAD	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg09796270	chr17:17721594	SREBF1	0.38	7.7	0.35	9.64e-14	Total body bone mineral density;
LUAD	cis	rs922692	0.744	rs11072806	chr15:79079074	G/A	cg22753661	chr15:79092743	ADAMTS7	0.5	8.09	0.37	6.33e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg10589385	chr1:150898437	SETDB1	0.39	7.26	0.33	1.9e-12	Tonsillectomy;
LUAD	cis	rs11030122	0.702	rs66503725	chr11:3980998	G/A	cg18678763	chr11:4115507	RRM1	-0.44	-7.33	-0.34	1.14e-12	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs7395662	1.000	rs10838912	chr11:48496477	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.36	-0.34	9.44e-13	HDL cholesterol;
LUAD	trans	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21659725	chr3:3221576	CRBN	-0.51	-8.26	-0.37	1.82e-15	Body mass index;
LUAD	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs2224391	0.910	rs7752203	chr6:5260812	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.67	-11.22	-0.48	9.23e-26	Height;
LUAD	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.45	-0.38	4.65e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.91	-0.36	2.24e-14	Monocyte percentage of white cells;
LUAD	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg23758822	chr17:41437982	NA	1.01	20.86	0.71	5.96e-67	Menopause (age at onset);
LUAD	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg14668632	chr7:2872130	GNA12	-0.47	-8.3	-0.37	1.44e-15	Height;
LUAD	cis	rs7219021	0.739	rs1800632	chr17:46970509	G/A	cg14634687	chr17:47094252	IGF2BP1	0.29	6.39	0.3	4.39e-10	Schizophrenia or bipolar disorder;
LUAD	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg10876282	chr6:28092338	ZSCAN16	0.46	6.64	0.31	9.91e-11	Parkinson's disease;
LUAD	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	12.74	0.53	1.03e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg21433313	chr16:3507492	NAT15	0.76	13.56	0.55	5.15e-35	Tuberculosis;
LUAD	cis	rs3857067	0.806	rs7669168	chr4:95104881	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.38	-6.64	-0.31	9.81e-11	QT interval;
LUAD	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01570182	chr17:44337453	NA	-0.93	-13.69	-0.55	1.39e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg11427898	chr15:38544983	SPRED1	-0.38	-6.67	-0.31	8.01e-11	Schizophrenia;
LUAD	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg07917127	chr4:99064746	C4orf37	0.45	7.36	0.34	9.83e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	14.33	0.57	3.02e-38	Lung cancer in ever smokers;
LUAD	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg13685833	chr1:53393034	SCP2	-0.48	-8.01	-0.36	1.11e-14	Monocyte count;
LUAD	cis	rs17095355	1.000	rs11194920	chr10:111695412	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.72	-9.62	-0.42	6.28e-20	Biliary atresia;
LUAD	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11890956	chr21:40555474	PSMG1	-0.68	-11.94	-0.5	1.6e-28	Cognitive function;
LUAD	cis	rs4766566	0.651	rs933307	chr12:111735537	A/C	cg24530795	chr12:111807189	FAM109A	-0.37	-6.44	-0.3	3.25e-10	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg12620342	chr12:56522011	ESYT1	-0.74	-7.05	-0.32	7.39e-12	Type 2 diabetes;
LUAD	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg26597838	chr10:835615	NA	0.69	9.92	0.43	5.51e-21	Eosinophil percentage of granulocytes;
LUAD	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg18129178	chr5:148520854	ABLIM3	-0.63	-9.64	-0.42	5.18e-20	Breast cancer;
LUAD	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg03948781	chr1:205179583	DSTYK	0.36	6.49	0.3	2.47e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs2235649	0.663	rs12596160	chr16:1848784	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.5	-8.26	-0.37	1.83e-15	Blood metabolite levels;
LUAD	trans	rs7246760	0.867	rs55800282	chr19:9833530	A/G	cg02900749	chr2:68251473	NA	-0.58	-6.58	-0.3	1.37e-10	Pursuit maintenance gain;
LUAD	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22968622	chr17:43663579	NA	0.94	16.27	0.62	1.47e-46	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg22663859	chr13:21900854	NA	0.48	8.07	0.37	7.36e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg17971929	chr21:40555470	PSMG1	0.53	8.41	0.38	6.43e-16	Cognitive function;
LUAD	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06544989	chr22:39130855	UNC84B	0.45	9.0	0.4	7.52e-18	Menopause (age at onset);
LUAD	cis	rs7617773	0.743	rs4632568	chr3:48367819	C/T	cg11946769	chr3:48343235	NME6	0.45	6.89	0.32	2.05e-11	Coronary artery disease;
LUAD	cis	rs10821973	0.550	rs1432416	chr10:63975309	A/T	cg09941381	chr10:64027924	RTKN2	-0.34	-6.74	-0.31	5.22e-11	Hypothyroidism;
LUAD	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg10164272	chr16:89456328	ANKRD11	0.41	6.42	0.3	3.61e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs2692947	0.616	rs2301707	chr2:96931846	T/C	cg23100626	chr2:96804247	ASTL	0.39	9.77	0.43	1.82e-20	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs6430585	0.697	rs6724569	chr2:136516970	G/A	cg07169764	chr2:136633963	MCM6	0.79	8.95	0.4	1.17e-17	Corneal structure;
LUAD	trans	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg01620082	chr3:125678407	NA	-1.08	-10.23	-0.45	4.14e-22	Depression;
LUAD	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg06740227	chr12:86229804	RASSF9	-0.4	-7.13	-0.33	4.34e-12	Major depressive disorder;
LUAD	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg00933542	chr6:150070202	PCMT1	0.46	9.99	0.44	3.13e-21	Lung cancer;
LUAD	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg22878388	chr2:105853796	NA	-0.4	-7.06	-0.32	7.06e-12	Type 2 diabetes;
LUAD	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg02631126	chr6:28058918	ZSCAN12L1	-0.39	-7.97	-0.36	1.53e-14	Parkinson's disease;
LUAD	cis	rs8017423	0.935	rs4904661	chr14:90729332	T/C	cg14092571	chr14:90743983	NA	-0.48	-8.28	-0.37	1.66e-15	Mortality in heart failure;
LUAD	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg25427524	chr10:38739819	LOC399744	-0.46	-7.66	-0.35	1.29e-13	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg08223748	chr5:88179260	MEF2C	-0.41	-6.65	-0.31	8.8e-11	Subcortical brain region volumes;
LUAD	cis	rs16882447	0.607	rs10052279	chr5:53491197	A/G	cg06461071	chr5:53490839	ARL15	0.43	7.66	0.35	1.28e-13	Systolic blood pressure (dietary potassium intake interaction);
LUAD	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg04800585	chr6:26043546	HIST1H2BB	0.37	6.59	0.31	1.33e-10	Blood metabolite levels;
LUAD	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg24838063	chr12:130822603	PIWIL1	0.66	11.12	0.48	2.33e-25	Menopause (age at onset);
LUAD	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg05623727	chr3:50126028	RBM5	0.3	6.59	0.31	1.3e-10	Body mass index;
LUAD	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.97	20.88	0.71	4.9e-67	Chronic sinus infection;
LUAD	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg00204512	chr16:28754710	NA	0.33	7.12	0.33	4.52e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg14917512	chr19:3094685	GNA11	-0.37	-6.44	-0.3	3.18e-10	Aortic root size;
LUAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg00106254	chr7:1943704	MAD1L1	-0.49	-7.28	-0.33	1.62e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4409675	0.576	rs6565	chr1:28213157	T/C	cg23691781	chr1:28212827	C1orf38	0.39	11.36	0.48	2.75e-26	Corneal astigmatism;
LUAD	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18876405	chr7:65276391	NA	-0.41	-6.62	-0.31	1.06e-10	Aortic root size;
LUAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18876405	chr7:65276391	NA	-0.42	-6.46	-0.3	2.85e-10	Aortic root size;
LUAD	trans	rs587242	1.000	rs550739	chr1:96887109	G/A	cg10631902	chr5:14652156	NA	0.43	7.17	0.33	3.28e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs757647	0.723	rs11242424	chr5:137719172	G/T	cg10676309	chr5:137685565	NA	0.43	7.65	0.35	1.41e-13	Menarche (age at onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16917406	chr15:85114159	UBE2QP1	-0.41	-6.38	-0.3	4.58e-10	Height;
LUAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.8	14.78	0.58	3.82e-40	Lymphocyte counts;
LUAD	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg13319975	chr6:146136371	FBXO30	-0.61	-10.24	-0.45	3.94e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1595825	0.945	rs7581202	chr2:198836777	A/G	cg00982548	chr2:198649783	BOLL	-0.63	-8.93	-0.4	1.31e-17	Ulcerative colitis;
LUAD	cis	rs1003719	0.591	rs13046303	chr21:38551976	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.46	-7.7	-0.35	9.4e-14	Eye color traits;
LUAD	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg26587870	chr6:27730563	NA	-0.37	-6.57	-0.3	1.52e-10	Parkinson's disease;
LUAD	cis	rs7903847	0.612	rs72838764	chr10:99142107	T/C	cg20016023	chr10:99160130	RRP12	-0.34	-7.39	-0.34	7.68e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9329221	0.712	rs1962073	chr8:10260553	A/G	cg21775007	chr8:11205619	TDH	-0.36	-6.35	-0.3	5.41e-10	Neuroticism;
LUAD	cis	rs1403694	0.966	rs1656910	chr3:186438993	A/C	cg12454167	chr3:186435060	KNG1	0.42	8.79	0.39	3.75e-17	Blood protein levels;
LUAD	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg17105886	chr17:28927953	LRRC37B2	0.76	7.18	0.33	3.14e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg13010199	chr12:38710504	ALG10B	0.4	6.68	0.31	7.59e-11	Bladder cancer;
LUAD	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg08999081	chr20:33150536	PIGU	0.63	14.09	0.57	3.02e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs6906287	0.647	rs7772214	chr6:118793703	A/T	cg05564266	chr6:118973597	C6orf204	0.34	7.28	0.33	1.64e-12	Electrocardiographic conduction measures;
LUAD	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg20362242	chr5:692897	TPPP	0.5	6.8	0.31	3.51e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg00450029	chr8:599525	NA	0.81	7.94	0.36	1.79e-14	IgG glycosylation;
LUAD	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg15309053	chr8:964076	NA	0.41	8.65	0.39	1.05e-16	Schizophrenia;
LUAD	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06544989	chr22:39130855	UNC84B	-0.4	-7.25	-0.33	2.06e-12	Menopause (age at onset);
LUAD	cis	rs1524976	0.943	rs11720595	chr3:65518274	C/G	cg16238336	chr3:65465873	MAGI1	-0.59	-6.92	-0.32	1.65e-11	PR interval;
LUAD	trans	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg11292332	chr7:45801988	SEPT13	-0.31	-6.76	-0.31	4.53e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02018176	chr4:1364513	KIAA1530	0.69	11.89	0.5	2.46e-28	Longevity;
LUAD	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg15448220	chr1:150897856	SETDB1	0.47	8.09	0.37	6.35e-15	Tonsillectomy;
LUAD	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg07741184	chr6:167504864	NA	0.36	8.11	0.37	5.42e-15	Crohn's disease;
LUAD	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-11.0	-0.47	6.15e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1595825	1.000	rs1440091	chr2:198879457	C/T	cg10547527	chr2:198650123	BOLL	-0.45	-6.41	-0.3	3.84e-10	Ulcerative colitis;
LUAD	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg05754148	chr16:3507555	NAT15	0.48	7.07	0.33	6.38e-12	Body mass index (adult);
LUAD	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg03467027	chr4:99064603	C4orf37	0.42	6.68	0.31	7.49e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21659725	chr3:3221576	CRBN	0.87	18.73	0.67	1.97e-57	Intelligence (multi-trait analysis);
LUAD	cis	rs7527798	0.592	rs6657161	chr1:207847128	C/T	cg09232269	chr1:207846808	CR1L	-0.38	-6.95	-0.32	1.39e-11	Erythrocyte sedimentation rate;
LUAD	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg05665937	chr4:1216051	CTBP1	-0.43	-7.73	-0.35	7.96e-14	Obesity-related traits;
LUAD	cis	rs1595825	0.838	rs73058883	chr2:198896255	C/T	cg00361562	chr2:198649771	BOLL	-0.47	-6.52	-0.3	1.96e-10	Ulcerative colitis;
LUAD	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.67	0.31	7.88e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg05340658	chr4:99064831	C4orf37	-0.45	-7.37	-0.34	8.91e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2425143	1.000	rs2425093	chr20:34306875	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2.04e-15	Blood protein levels;
LUAD	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-11.94	-0.5	1.66e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg22442454	chr1:209979470	IRF6	0.56	6.36	0.3	5.22e-10	Coronary artery disease;
LUAD	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs8192282	0.739	rs6697115	chr1:154499947	C/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.46	-7.08	-0.33	6.18e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7107174	1.000	rs2511158	chr11:77973980	C/T	cg02023728	chr11:77925099	USP35	0.53	8.09	0.37	6.44e-15	Testicular germ cell tumor;
LUAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg02951883	chr7:2050386	MAD1L1	0.9	17.35	0.64	2.69e-51	Bipolar disorder and schizophrenia;
LUAD	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg09509183	chr1:209979624	IRF6	0.61	7.4	0.34	7.58e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.01	-0.5	8.8e-29	Primary sclerosing cholangitis;
LUAD	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg09365446	chr1:150670422	GOLPH3L	0.66	12.3	0.51	6.1e-30	Tonsillectomy;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09588474	chr5:96519644	RIOK2	-0.38	-6.35	-0.3	5.48e-10	Cancer;
LUAD	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg27446573	chr6:127587934	RNF146	0.45	6.59	0.31	1.3100000000000001e-10	Breast cancer;
LUAD	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg24558204	chr6:135376177	HBS1L	0.48	8.87	0.4	2.1e-17	Red blood cell count;
LUAD	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg00981070	chr1:2046702	PRKCZ	-0.36	-7.7	-0.35	9.59e-14	Height;
LUAD	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg08085267	chr17:45401833	C17orf57	-0.8	-14.62	-0.58	1.79e-39	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg21475434	chr5:93447410	FAM172A	0.74	8.28	0.37	1.65e-15	Diabetic retinopathy;
LUAD	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-13.53	-0.55	6.83e-35	Chronic sinus infection;
LUAD	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg25985355	chr7:65971099	NA	-0.54	-6.8	-0.31	3.58e-11	Diabetic kidney disease;
LUAD	cis	rs11958404	0.932	rs56204919	chr5:157431084	C/T	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg25703541	chr22:24373054	LOC391322	0.71	10.93	0.47	1.21e-24	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18099408	chr3:52552593	STAB1	-0.46	-8.09	-0.37	6.6e-15	Bipolar disorder;
LUAD	cis	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg26958806	chr6:27640298	NA	0.67	6.64	0.31	9.45e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg04842962	chr6:43655489	MRPS18A	1.08	27.75	0.8	2.77e-97	IgG glycosylation;
LUAD	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg00316803	chr15:76480434	C15orf27	-0.41	-7.8	-0.35	4.87e-14	Blood metabolite levels;
LUAD	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg16205897	chr5:131564050	P4HA2	-0.36	-8.48	-0.38	3.77e-16	Blood metabolite levels;
LUAD	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg11663144	chr21:46675770	NA	-0.48	-9.12	-0.41	3.1e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg16606324	chr3:10149918	C3orf24	0.65	9.96	0.44	3.78e-21	Alzheimer's disease;
LUAD	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg10589385	chr1:150898437	SETDB1	0.37	7.13	0.33	4.49e-12	Melanoma;
LUAD	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg10523679	chr1:76189770	ACADM	0.77	11.44	0.49	1.34e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs11098699	0.784	rs7661575	chr4:124246339	A/T	cg09941581	chr4:124220074	SPATA5	0.42	6.72	0.31	6.07e-11	Mosquito bite size;
LUAD	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg04944784	chr2:26401820	FAM59B	0.89	12.59	0.52	4.15e-31	Gut microbiome composition (summer);
LUAD	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg17724175	chr1:150552817	MCL1	0.37	8.41	0.38	6.21e-16	Melanoma;
LUAD	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg09365446	chr1:150670422	GOLPH3L	-0.41	-6.63	-0.31	1.02e-10	Tonsillectomy;
LUAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9581857	0.512	rs9581866	chr13:28063176	G/A	cg22138327	chr13:27999177	GTF3A	0.83	9.18	0.41	1.96e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg05425664	chr17:57184151	TRIM37	-0.43	-7.58	-0.35	2.15e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg03929089	chr4:120376271	NA	-0.98	-20.59	-0.71	9.72e-66	Height;
LUAD	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg12310025	chr6:25882481	NA	-0.58	-9.55	-0.42	1.1e-19	Blood metabolite levels;
LUAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg21280719	chr6:42927975	GNMT	-0.4	-12.11	-0.51	3.43e-29	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-12.0	-0.5	9.42e-29	Bipolar disorder;
LUAD	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg09835421	chr16:68378352	PRMT7	-0.77	-8.29	-0.37	1.47e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.44	6.97	0.32	1.22e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9875589	0.509	rs4684174	chr3:14048375	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.37	6.65	0.31	9.21e-11	Ovarian reserve;
LUAD	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg02891314	chr5:179741120	GFPT2	0.68	11.27	0.48	6.03e-26	Height;
LUAD	cis	rs12579753	0.917	rs11610365	chr12:82218108	C/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.0	-0.32	1e-11	Resting heart rate;
LUAD	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg02527881	chr3:46936655	PTH1R	0.42	8.22	0.37	2.46e-15	Colorectal cancer;
LUAD	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg25358565	chr5:93447407	FAM172A	0.61	7.71	0.35	9.25e-14	Diabetic retinopathy;
LUAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.47	0.45	5.92e-23	Prudent dietary pattern;
LUAD	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg11822812	chr5:140052017	DND1	-0.45	-8.16	-0.37	4e-15	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg07393940	chr7:158741817	NA	-0.68	-11.63	-0.49	2.6e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.39	-7.41	-0.34	7.1e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg02951883	chr7:2050386	MAD1L1	-0.8	-14.44	-0.57	1.03e-38	Bipolar disorder and schizophrenia;
LUAD	trans	rs1997103	1.000	rs4628219	chr7:55410449	A/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.82	-0.36	4.23e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.8	0.53	6.31e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg03388025	chr16:89894329	SPIRE2	0.5	12.93	0.53	1.81e-32	Vitiligo;
LUAD	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg11292332	chr7:45801988	SEPT13	-0.28	-6.36	-0.3	5.26e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.56	0.52	5.93e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg03474202	chr17:45855739	NA	-0.39	-9.24	-0.41	1.18e-18	IgG glycosylation;
LUAD	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg21545522	chr1:205238299	TMCC2	0.36	6.61	0.31	1.14e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs73198271	0.562	rs3827810	chr8:8659040	T/G	cg01851573	chr8:8652454	MFHAS1	0.74	11.22	0.48	9.58e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs7395662	0.817	rs1848151	chr11:48692658	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.15	-0.33	3.92e-12	HDL cholesterol;
LUAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg15242686	chr22:24348715	GSTTP1	0.41	6.75	0.31	4.91e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg19041857	chr6:27730383	NA	0.45	6.68	0.31	7.46e-11	Depression;
LUAD	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg02461776	chr11:598696	PHRF1	0.47	6.68	0.31	7.43e-11	Systemic lupus erythematosus;
LUAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg03188948	chr7:1209495	NA	0.8	9.76	0.43	2.04e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4711350	0.862	rs652049	chr6:33711420	C/T	cg07979401	chr6:33739406	LEMD2	0.49	7.88	0.36	2.83e-14	Schizophrenia;
LUAD	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg05991184	chr2:219186017	PNKD	-0.37	-7.46	-0.34	4.89e-13	Colorectal cancer;
LUAD	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg20476274	chr7:133979776	SLC35B4	0.73	12.78	0.53	7.78e-32	Mean platelet volume;
LUAD	cis	rs1387259	0.619	rs2130095	chr12:48638755	G/A	cg04545296	chr12:48745243	ZNF641	-0.26	-6.58	-0.3	1.37e-10	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs7107174	1.000	rs55761949	chr11:77993860	A/G	cg02023728	chr11:77925099	USP35	0.48	7.5	0.34	3.84e-13	Testicular germ cell tumor;
LUAD	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg00776166	chr8:613548	NA	-0.63	-7.29	-0.33	1.56e-12	IgG glycosylation;
LUAD	cis	rs4803468	0.935	rs284660	chr19:41932084	G/T	cg09537434	chr19:41945824	ATP5SL	-0.47	-7.42	-0.34	6.69e-13	Height;
LUAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg15147215	chr3:52552868	STAB1	-0.51	-9.87	-0.43	7.87e-21	Electroencephalogram traits;
LUAD	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg03806693	chr22:41940476	POLR3H	0.77	10.28	0.45	2.78e-22	Vitiligo;
LUAD	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11644478	chr21:40555479	PSMG1	0.69	11.51	0.49	7.13e-27	Cognitive function;
LUAD	cis	rs68170813	0.559	rs76646886	chr7:107034328	T/C	cg23024343	chr7:107201750	COG5	0.52	7.19	0.33	2.96e-12	Coronary artery disease;
LUAD	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg22532475	chr10:104410764	TRIM8	-0.47	-9.04	-0.4	5.53e-18	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.78	0.46	4.23e-24	Mean corpuscular volume;
LUAD	cis	rs10504073	0.584	rs10957337	chr8:49959027	G/T	cg00325661	chr8:49890786	NA	0.49	10.66	0.46	1.15e-23	Blood metabolite ratios;
LUAD	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg19875535	chr5:140030758	IK	-0.4	-6.6	-0.31	1.25e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2286503	0.966	rs6949233	chr7:22858191	T/G	cg06496272	chr7:22895283	SNORD93	-0.41	-7.38	-0.34	8.51e-13	Fibrinogen;
LUAD	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg13012494	chr21:47604986	C21orf56	0.47	7.75	0.35	6.98e-14	Testicular germ cell tumor;
LUAD	trans	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.32	0.45	2.07e-22	Mean corpuscular volume;
LUAD	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg19912559	chr1:40204330	PPIE	0.57	9.73	0.43	2.59e-20	Blood protein levels;
LUAD	cis	rs806215	1.000	rs2106186	chr7:127241352	G/C	cg25922125	chr7:127225783	GCC1	0.48	6.91	0.32	1.85e-11	Type 2 diabetes;
LUAD	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg26513180	chr16:89883248	FANCA	0.84	7.36	0.34	9.58e-13	Skin colour saturation;
LUAD	cis	rs427394	0.659	rs274693	chr5:6734162	G/A	cg12316010	chr5:6737918	POLS	0.39	7.42	0.34	6.35e-13	Menopause (age at onset);
LUAD	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg25894440	chr7:65020034	NA	-0.61	-6.58	-0.3	1.39e-10	Diabetic kidney disease;
LUAD	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg11062466	chr8:58055876	NA	0.45	6.47	0.3	2.66e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg05665937	chr4:1216051	CTBP1	0.48	7.46	0.34	5.04e-13	Longevity;
LUAD	cis	rs752092	0.894	rs8042989	chr15:101770761	T/A	cg19997662	chr15:101784653	CHSY1	-0.48	-8.73	-0.39	5.78e-17	Corneal structure;
LUAD	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg14196790	chr5:131705035	SLC22A5	0.53	9.79	0.43	1.58e-20	Blood metabolite levels;
LUAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg22105103	chr4:187893119	NA	0.57	12.61	0.52	3.6e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg23625390	chr15:77176239	SCAPER	0.46	7.52	0.34	3.38e-13	Blood metabolite levels;
LUAD	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg08859206	chr1:53392774	SCP2	-0.51	-9.15	-0.41	2.47e-18	Monocyte count;
LUAD	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg18811423	chr2:55921094	PNPT1	0.5	8.21	0.37	2.67e-15	Metabolic syndrome;
LUAD	cis	rs6594713	0.744	rs6874175	chr5:112663398	G/A	cg12552261	chr5:112820674	MCC	0.48	7.56	0.35	2.45e-13	Brain cytoarchitecture;
LUAD	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-6.89	-0.32	2.02e-11	Breast cancer;
LUAD	cis	rs9914988	0.887	rs62066838	chr17:27184533	C/T	cg20469991	chr17:27169893	C17orf63	0.5	6.47	0.3	2.72e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2066819	1.000	rs58852079	chr12:56706922	A/C	cg26714650	chr12:56694279	CS	-0.85	-7.1	-0.33	5.17e-12	Psoriasis vulgaris;
LUAD	cis	rs877282	0.853	rs12779017	chr10:763619	T/C	cg17470449	chr10:769945	NA	0.62	8.83	0.39	2.91e-17	Uric acid levels;
LUAD	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg04369109	chr6:150039330	LATS1	-0.46	-7.58	-0.35	2.24e-13	Lung cancer;
LUAD	cis	rs7927592	0.546	rs599083	chr11:68192346	T/G	cg01657329	chr11:68192670	LRP5	-0.54	-9.28	-0.41	8.66e-19	Total body bone mineral density;
LUAD	cis	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg03551406	chr16:56715756	MT1X	0.42	7.37	0.34	8.93e-13	Gambling;
LUAD	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg11266682	chr4:10021025	SLC2A9	0.69	15.79	0.61	1.69e-44	Bone mineral density;
LUAD	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg00204512	chr16:28754710	NA	0.35	7.77	0.35	6.09e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg16841327	chr22:46466183	NA	0.41	6.7	0.31	6.69e-11	Optic cup area;
LUAD	cis	rs3916	0.955	rs34030695	chr12:121156496	G/A	cg27246729	chr12:121163418	ACADS	0.46	7.51	0.34	3.53e-13	Urinary metabolites (H-NMR features);
LUAD	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg05082376	chr22:42548792	NA	-0.38	-6.77	-0.31	4.26e-11	Cognitive function;
LUAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00166722	chr3:10149974	C3orf24	-0.73	-11.1	-0.48	2.6e-25	Alzheimer's disease;
LUAD	cis	rs68170813	0.559	rs78888729	chr7:106940957	G/C	cg02696742	chr7:106810147	HBP1	-0.77	-10.76	-0.46	5.12e-24	Coronary artery disease;
LUAD	cis	rs7394190	0.748	rs12572278	chr10:75504513	C/A	cg02286717	chr10:75415704	SYNPO2L	-0.41	-7.01	-0.32	9.75e-12	Incident atrial fibrillation;
LUAD	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg27144592	chr16:783916	NARFL	0.35	6.38	0.3	4.75e-10	Height;
LUAD	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg11494091	chr17:61959527	GH2	0.45	8.55	0.38	2.21e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg03709012	chr19:19516395	GATAD2A	0.51	6.98	0.32	1.14e-11	Nonalcoholic fatty liver disease;
LUAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg18402987	chr7:1209562	NA	0.41	6.69	0.31	7.16e-11	Longevity;Endometriosis;
LUAD	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.62	-0.35	1.73e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.5	0.3	2.26e-10	Cardiac Troponin-T levels;
LUAD	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg27170947	chr2:26402098	FAM59B	0.72	8.95	0.4	1.1e-17	Gut microbiome composition (summer);
LUAD	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg01579765	chr21:45077557	HSF2BP	0.56	12.91	0.53	2.31e-32	Mean corpuscular volume;
LUAD	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg01874867	chr7:94954059	PON1	-0.5	-6.92	-0.32	1.69e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.38	-6.69	-0.31	6.99e-11	Body mass index (adult);
LUAD	cis	rs9323205	0.765	rs12232228	chr14:51658072	A/G	cg23942311	chr14:51606299	NA	0.5	8.87	0.4	2.06e-17	Cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04870464	chr3:10157252	C3orf10	-0.44	-7.09	-0.33	5.53e-12	Cancer;
LUAD	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.29	0.37	1.55e-15	Alzheimer's disease;
LUAD	cis	rs1003719	0.680	rs2257091	chr21:38522618	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.33	-0.38	1.16e-15	Eye color traits;
LUAD	cis	rs1385374	0.858	rs10847698	chr12:129300222	T/C	cg09035930	chr12:129282057	SLC15A4	-0.62	-6.7	-0.31	6.79e-11	Systemic lupus erythematosus;
LUAD	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg26727032	chr16:67993705	SLC12A4	-0.49	-8.1	-0.37	6.15e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs116095464	1.000	rs61079948	chr5:325503	G/C	cg22857025	chr5:266934	NA	-1.06	-8.48	-0.38	3.81e-16	Breast cancer;
LUAD	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg07570687	chr10:102243282	WNT8B	0.42	6.44	0.3	3.3e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.54	0.3	1.77e-10	Parkinson's disease;
LUAD	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg18404041	chr3:52824283	ITIH1	0.41	7.5	0.34	3.73e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg15017067	chr4:17643749	FAM184B	0.38	7.35	0.34	1.03e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6761276	0.899	rs11693750	chr2:113835602	C/T	cg10479672	chr2:113810641	IL1F8	-0.38	-7.65	-0.35	1.39e-13	Protein quantitative trait loci;
LUAD	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg18200150	chr17:30822561	MYO1D	0.43	8.01	0.36	1.09e-14	Schizophrenia;
LUAD	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.91	0.32	1.75e-11	Colorectal cancer;
LUAD	cis	rs9302635	0.513	rs7198572	chr16:72183220	G/A	cg23815491	chr16:72088622	HP	0.47	7.53	0.34	3.07e-13	Blood protein levels;
LUAD	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg14403583	chr14:105418241	AHNAK2	-0.44	-8.14	-0.37	4.36e-15	Rheumatoid arthritis;
LUAD	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg09117114	chr16:67998030	SLC12A4	-0.6	-7.52	-0.34	3.4e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6835098	1.000	rs2332654	chr4:174088399	C/T	cg27433088	chr4:174089019	GALNT7	0.4	7.63	0.35	1.54e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg12940439	chr1:67600707	NA	0.42	7.83	0.36	3.93e-14	Psoriasis;
LUAD	trans	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg12400702	chr3:12838781	CAND2	0.31	6.36	0.3	5.23e-10	Parkinson's disease;
LUAD	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg18477163	chr1:228402036	OBSCN	-0.35	-6.99	-0.32	1.08e-11	Diastolic blood pressure;
LUAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03452623	chr4:187889614	NA	-0.83	-17.3	-0.64	4.07e-51	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg03388025	chr16:89894329	SPIRE2	0.5	13.36	0.54	3.2e-34	Vitiligo;
LUAD	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg04756594	chr16:24857601	SLC5A11	0.54	10.3	0.45	2.34e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg26343298	chr8:95960752	TP53INP1	0.38	8.07	0.37	7.17e-15	Type 2 diabetes;
LUAD	cis	rs2012796	0.956	rs56161464	chr14:81814749	A/T	cg02996355	chr14:81879375	NA	0.45	6.49	0.3	2.35e-10	Night sleep phenotypes;
LUAD	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg09365446	chr1:150670422	GOLPH3L	-0.41	-6.7	-0.31	6.8e-11	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg06873352	chr17:61820015	STRADA	-0.66	-12.93	-0.53	1.82e-32	Prudent dietary pattern;
LUAD	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg16797656	chr11:68205561	LRP5	0.47	9.16	0.41	2.2e-18	Total body bone mineral density;
LUAD	cis	rs28595532	0.920	rs116091383	chr4:119635518	A/G	cg14228332	chr4:119757509	SEC24D	0.77	7.07	0.33	6.46e-12	Cannabis dependence symptom count;
LUAD	cis	rs6564851	0.506	rs56291739	chr16:81258372	C/T	cg00908271	chr16:81254010	PKD1L2	0.34	6.85	0.32	2.56e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg22532475	chr10:104410764	TRIM8	-0.44	-8.56	-0.38	2.09e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs208520	0.690	rs207112	chr6:66792092	C/T	cg07460842	chr6:66804631	NA	-1.06	-16.63	-0.63	3.97e-48	Exhaled nitric oxide output;
LUAD	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg20503657	chr10:835505	NA	0.65	9.08	0.4	4.27e-18	Eosinophil percentage of granulocytes;
LUAD	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg26022315	chr17:47021804	SNF8	0.41	7.42	0.34	6.32e-13	Type 2 diabetes;
LUAD	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg07930552	chr6:133119739	C6orf192	0.68	8.21	0.37	2.63e-15	Type 2 diabetes nephropathy;
LUAD	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg11494091	chr17:61959527	GH2	0.45	8.79	0.39	3.68e-17	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg10518543	chr12:38710700	ALG10B	0.5	8.48	0.38	3.78e-16	Morning vs. evening chronotype;
LUAD	cis	rs8018808	1.000	rs11844594	chr14:77843814	T/C	cg20045696	chr14:77926864	AHSA1	-0.38	-6.73	-0.31	5.43e-11	Myeloid white cell count;
LUAD	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg17200465	chr3:40428508	ENTPD3	0.27	6.51	0.3	2.08e-10	Renal cell carcinoma;
LUAD	cis	rs7274811	0.652	rs291686	chr20:32010851	T/C	cg03904042	chr20:32255491	NECAB3;C20orf134	0.5	7.58	0.35	2.14e-13	Height;
LUAD	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.29	-0.33	1.54e-12	Lung cancer;
LUAD	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg24848339	chr3:12840334	CAND2	0.44	9.17	0.41	2.15e-18	QRS complex (12-leadsum);
LUAD	cis	rs12541635	0.966	rs4416800	chr8:106996677	T/C	cg10147462	chr8:107024639	NA	0.5	9.03	0.4	6.12e-18	Age of smoking initiation;
LUAD	cis	rs1385374	0.502	rs923077	chr12:129276708	C/A	cg09035930	chr12:129282057	SLC15A4	0.61	7.28	0.33	1.62e-12	Systemic lupus erythematosus;
LUAD	cis	rs6577655	0.517	rs4909294	chr8:135588020	C/T	cg17885191	chr8:135476712	NA	0.61	8.1	0.37	6.05e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg21427119	chr20:30132790	HM13	-0.58	-9.27	-0.41	9.27e-19	Mean corpuscular hemoglobin;
LUAD	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-9.95	-0.44	4.22e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg27124370	chr19:33622961	WDR88	0.46	7.08	0.33	5.94e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs533581	0.866	rs488251	chr16:88972554	G/A	cg11339718	chr16:89000225	CBFA2T3	-0.34	-6.52	-0.3	1.98e-10	Social autistic-like traits;
LUAD	cis	rs317865	0.737	rs55949632	chr4:16207072	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.87	8.45	0.38	4.6e-16	Kidney disease (early stage) in type 1 diabetes;
LUAD	trans	rs75804782	0.625	rs10929279	chr2:239468667	A/G	cg01134436	chr17:81009848	B3GNTL1	0.71	7.28	0.33	1.64e-12	Morning vs. evening chronotype;Chronotype;
LUAD	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg21153622	chr11:89784906	NA	-0.34	-6.71	-0.31	6.11e-11	HDL cholesterol;
LUAD	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg07169764	chr2:136633963	MCM6	0.79	9.26	0.41	1.02e-18	Corneal structure;
LUAD	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg26924012	chr15:45694286	SPATA5L1	1.02	19.01	0.68	1.11e-58	Homoarginine levels;
LUAD	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-14.51	-0.58	5.23e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.87	-8.62	-0.39	1.33e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg14458575	chr2:238380390	NA	0.74	11.22	0.48	9.2e-26	Prostate cancer;
LUAD	cis	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg00745463	chr17:30367425	LRRC37B	-0.89	-8.84	-0.39	2.6e-17	Height;
LUAD	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg17971929	chr21:40555470	PSMG1	-0.47	-7.09	-0.33	5.7e-12	Cognitive function;
LUAD	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg23758822	chr17:41437982	NA	1.01	20.95	0.71	2.33e-67	Menopause (age at onset);
LUAD	cis	rs68170813	0.559	rs9641378	chr7:106868003	T/C	cg02696742	chr7:106810147	HBP1	-0.78	-11.01	-0.47	5.99e-25	Coronary artery disease;
LUAD	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-11.04	-0.47	4.4e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.58e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg00666640	chr1:248458726	OR2T12	0.31	7.53	0.34	3.12e-13	Common traits (Other);
LUAD	cis	rs10489202	1.000	rs12404574	chr1:167961235	C/T	cg24449463	chr1:168025552	DCAF6	0.55	7.3	0.33	1.46e-12	Schizophrenia;
LUAD	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg14582100	chr15:45693742	SPATA5L1	0.64	12.51	0.52	9.2e-31	Homoarginine levels;
LUAD	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg09796270	chr17:17721594	SREBF1	0.4	7.95	0.36	1.75e-14	Total body bone mineral density;
LUAD	cis	rs7116495	1.000	rs2511076	chr11:71783827	A/G	cg07596299	chr11:71824057	C11orf51	-0.77	-6.53	-0.3	1.86e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23158103	chr7:148848205	ZNF398	-0.67	-12.46	-0.52	1.46e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.85	0.32	2.63e-11	Rheumatoid arthritis;
LUAD	cis	rs7818345	0.935	rs7016259	chr8:19277530	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.32	6.99	0.32	1.1e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg21605333	chr4:119757512	SEC24D	0.81	7.78	0.35	5.59e-14	Cannabis dependence symptom count;
LUAD	cis	rs7665090	0.967	rs6533022	chr4:103558951	T/C	cg07973026	chr4:103553119	MANBA	0.47	8.39	0.38	7.09e-16	Primary biliary cholangitis;
LUAD	cis	rs4481233	0.528	rs115776655	chr4:10381329	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-7.74	-0.35	7.59e-14	Metabolic traits;
LUAD	cis	rs7737355	0.738	rs3776011	chr5:130868840	C/T	cg06307176	chr5:131281290	NA	0.44	7.19	0.33	3.02e-12	Life satisfaction;
LUAD	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg20790798	chr5:1857306	NA	-0.47	-7.91	-0.36	2.26e-14	Cardiovascular disease risk factors;
LUAD	cis	rs2742234	0.541	rs1254959	chr10:43700979	C/G	cg15436174	chr10:43711423	RASGEF1A	0.52	8.7	0.39	7.5e-17	Hirschsprung disease;
LUAD	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	6.88	0.32	2.14e-11	Lung cancer in ever smokers;
LUAD	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.51	-0.52	9.09e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-7.21	-0.33	2.65e-12	Lung cancer;
LUAD	cis	rs8192282	0.691	rs4845635	chr1:154474131	C/G	cg16683920	chr1:154474344	TDRD10;SHE	-0.44	-6.81	-0.31	3.33e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg12011299	chr4:100065546	ADH4	-0.74	-13.64	-0.55	2.38e-35	Alcohol dependence;
LUAD	trans	rs3942852	1.000	rs3942852	chr11:48115089	C/T	cg03929089	chr4:120376271	NA	-0.54	-7.34	-0.34	1.08e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.47	8.38	0.38	7.82e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg20673091	chr1:2541236	MMEL1	0.41	8.65	0.39	1.04e-16	Ulcerative colitis;
LUAD	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg03714773	chr7:91764589	CYP51A1	0.27	6.41	0.3	3.9e-10	Breast cancer;
LUAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06873352	chr17:61820015	STRADA	-0.8	-17.4	-0.65	1.61e-51	Prudent dietary pattern;
LUAD	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg27284194	chr4:1044797	NA	0.71	10.29	0.45	2.68e-22	Recombination rate (females);
LUAD	cis	rs751728	0.965	rs2013381	chr6:33763837	C/T	cg13859433	chr6:33739653	LEMD2	-0.38	-8.83	-0.39	2.73e-17	Crohn's disease;
LUAD	cis	rs10489202	1.000	rs7538251	chr1:168001752	C/G	cg24449463	chr1:168025552	DCAF6	-0.55	-6.98	-0.32	1.12e-11	Schizophrenia;
LUAD	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg15017067	chr4:17643749	FAM184B	0.35	6.93	0.32	1.63e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs56283067	0.887	rs7349931	chr6:44783674	C/T	cg00690400	chr1:174992704	MRPS14	0.54	6.74	0.31	5.24e-11	Total body bone mineral density;
LUAD	trans	rs3960554	0.808	rs2286829	chr7:75677739	G/A	cg19862616	chr7:65841803	NCRNA00174	0.82	11.2	0.48	1.15e-25	Eotaxin levels;
LUAD	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg24558204	chr6:135376177	HBS1L	0.49	9.05	0.4	5.45e-18	Red blood cell count;
LUAD	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg04990556	chr1:26633338	UBXN11	-0.42	-6.85	-0.32	2.68e-11	Obesity-related traits;
LUAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg13560548	chr3:10150139	C3orf24	0.42	6.99	0.32	1.09e-11	Alzheimer's disease;
LUAD	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg09491104	chr22:46646882	C22orf40	-0.57	-7.49	-0.34	4.17e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.44	7.26	0.33	1.83e-12	Resistin levels;
LUAD	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg23173402	chr1:227635558	NA	0.85	7.94	0.36	1.78e-14	Major depressive disorder;
LUAD	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.58	-0.52	4.94e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg16486109	chr11:613632	IRF7	0.53	8.8	0.39	3.48e-17	Systemic lupus erythematosus;
LUAD	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg21238619	chr17:78079768	GAA	-0.38	-7.13	-0.33	4.35e-12	Yeast infection;
LUAD	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	trans	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg14791747	chr16:20752902	THUMPD1	0.74	10.2	0.44	5.33e-22	Cognitive test performance;
LUAD	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg00204512	chr16:28754710	NA	0.32	6.69	0.31	7.05e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1003719	0.715	rs7280251	chr21:38567911	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.19	-0.37	3.08e-15	Eye color traits;
LUAD	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg13813247	chr22:41461852	NA	-0.45	-7.19	-0.33	3e-12	Neuroticism;
LUAD	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	7.19	0.33	3.05e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg09455208	chr3:40491958	NA	0.66	14.4	0.57	1.61e-38	Renal cell carcinoma;
LUAD	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg11292332	chr7:45801988	SEPT13	-0.28	-6.37	-0.3	4.86e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs8025790	0.508	rs28673019	chr15:67809823	T/A	cg27219399	chr15:67835830	MAP2K5	0.43	7.61	0.35	1.74e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg14835575	chr10:16859367	RSU1	0.91	12.91	0.53	2.2e-32	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg24101359	chr6:42928495	GNMT	0.6	11.83	0.5	4.23e-28	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs11229555	0.645	rs17474373	chr11:58191243	G/A	cg15696309	chr11:58395628	NA	-0.77	-10.52	-0.46	3.94e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs123509	0.913	rs339686	chr3:42769688	T/C	cg12982090	chr3:42733453	KBTBD5	0.55	9.82	0.43	1.21e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg18305652	chr10:134549665	INPP5A	0.64	12.39	0.52	2.71e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24531977	chr5:56204891	C5orf35	-0.97	-14.62	-0.58	1.72e-39	Initial pursuit acceleration;
LUAD	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.42	6.59	0.31	1.28e-10	Platelet count;
LUAD	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg04398451	chr17:18023971	MYO15A	-0.65	-11.71	-0.49	1.3e-27	Total body bone mineral density;
LUAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg24642844	chr7:1081250	C7orf50	-0.89	-13.77	-0.56	6.55e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.57	8.32	0.37	1.23e-15	Platelet count;
LUAD	trans	rs4718428	1.000	rs4718421	chr7:66350300	C/T	cg18876405	chr7:65276391	NA	0.49	7.89	0.36	2.52e-14	Corneal structure;
LUAD	cis	rs13418410	0.539	rs11695597	chr2:33840024	A/G	cg04131969	chr2:33951647	MYADML	0.63	10.22	0.45	4.5e-22	Non-response to antidepressants and depression;
LUAD	cis	rs6906287	0.647	rs11153767	chr6:118960519	C/T	cg21191810	chr6:118973309	C6orf204	0.5	9.38	0.42	3.97e-19	Electrocardiographic conduction measures;
LUAD	cis	rs12711979	0.509	rs13035992	chr2:3826597	G/A	cg17052675	chr2:3827356	NA	-0.84	-19.77	-0.69	4.21e-62	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs8018808	0.935	rs2091916	chr14:77914752	A/G	cg20045696	chr14:77926864	AHSA1	0.36	6.35	0.3	5.57e-10	Myeloid white cell count;
LUAD	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg25036284	chr2:26402008	FAM59B	-0.78	-10.44	-0.45	7.66e-23	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.85	0.53	3.74e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg20119798	chr7:94954144	PON1	-0.47	-6.53	-0.3	1.91e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg00684032	chr4:1343700	KIAA1530	0.42	6.96	0.32	1.34e-11	Obesity-related traits;
LUAD	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg18306943	chr3:40428807	ENTPD3	0.43	7.12	0.33	4.8e-12	Renal cell carcinoma;
LUAD	cis	rs2625529	0.730	rs2929528	chr15:72269337	C/A	cg16672083	chr15:72433130	SENP8	0.66	11.91	0.5	2.18e-28	Red blood cell count;
LUAD	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg27284194	chr4:1044797	NA	0.69	10.12	0.44	1.1e-21	Recombination rate (females);
LUAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg16606324	chr3:10149918	C3orf24	0.59	9.65	0.42	4.73e-20	Alzheimer's disease;
LUAD	cis	rs7192380	0.651	rs9940548	chr16:69624095	T/A	cg26679644	chr16:69762563	NA	0.42	6.89	0.32	2.05e-11	Sjögren's syndrome;
LUAD	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.76	0.35	6.42e-14	Bladder cancer;
LUAD	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-9.71	-0.43	3.04e-20	Platelet count;
LUAD	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg08885076	chr2:99613938	TSGA10	0.41	7.61	0.35	1.84e-13	Chronic sinus infection;
LUAD	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg22139774	chr2:100720529	AFF3	0.38	7.7	0.35	9.95e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg08601574	chr20:25228251	PYGB	0.42	7.99	0.36	1.33e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs7395662	0.658	rs2865610	chr11:48772617	T/C	cg00717180	chr2:96193071	NA	-0.38	-7.14	-0.33	4.05e-12	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.16e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg07817883	chr1:32538562	TMEM39B	-0.52	-7.21	-0.33	2.53e-12	Monocyte percentage of white cells;
LUAD	cis	rs11811982	0.744	rs114772174	chr1:227564515	T/G	cg24860534	chr1:227506868	CDC42BPA	0.66	7.2	0.33	2.8e-12	Optic disc area;
LUAD	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-7.08	-0.33	5.86e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.43	9.05	0.4	5.46e-18	Total body bone mineral density;
LUAD	cis	rs13082711	0.522	rs640065	chr3:27363937	A/T	cg02860705	chr3:27208620	NA	0.43	6.87	0.32	2.25e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg04111992	chr7:158790115	NA	-0.51	-8.74	-0.39	5.58e-17	Facial morphology (factor 20);
LUAD	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg09222892	chr1:25734099	RHCE	-0.49	-9.17	-0.41	2.11e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg20607798	chr8:58055168	NA	0.78	9.54	0.42	1.16e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	8.4	0.38	6.9e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg03188948	chr7:1209495	NA	0.81	9.99	0.44	3.12e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2742234	0.955	rs2503849	chr10:43672776	G/A	cg02780029	chr10:43622663	RET	-0.45	-7.23	-0.33	2.32e-12	Hirschsprung disease;
LUAD	cis	rs7017914	0.967	rs6998786	chr8:71694630	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.43	-0.3	3.46e-10	Bone mineral density;
LUAD	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg06547715	chr2:218990976	CXCR2	-0.44	-10.72	-0.46	6.78e-24	Ulcerative colitis;
LUAD	cis	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg20542592	chr8:11973495	FAM66D	0.4	6.56	0.3	1.55e-10	Monocyte count;
LUAD	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg10589385	chr1:150898437	SETDB1	0.39	7.42	0.34	6.51e-13	Tonsillectomy;
LUAD	cis	rs2030746	0.521	rs13415147	chr2:121329768	A/G	cg03661458	chr2:121334411	NA	-0.38	-6.45	-0.3	3.09e-10	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LUAD	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.48	-8.8	-0.39	3.46e-17	Menarche (age at onset);
LUAD	cis	rs2387326	0.717	rs10829342	chr10:129944493	C/T	cg16087940	chr10:129947807	NA	-0.63	-8.98	-0.4	9.14e-18	Select biomarker traits;
LUAD	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg22681709	chr2:178499509	PDE11A	-0.43	-7.04	-0.32	7.85e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg15704280	chr7:45808275	SEPT13	-1.05	-25.02	-0.77	1.82e-85	Height;
LUAD	cis	rs7119	0.700	rs60701760	chr15:77888152	G/A	cg27398640	chr15:77910606	LINGO1	0.38	7.53	0.34	3.19e-13	Type 2 diabetes;
LUAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg10819733	chr22:24237672	NA	-0.4	-7.37	-0.34	8.78e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.48	-0.42	1.79e-19	Bipolar disorder and schizophrenia;
LUAD	trans	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17712092	chr4:129076599	LARP1B	0.86	16.26	0.62	1.58e-46	Breast cancer;
LUAD	cis	rs12989701	0.778	rs7583814	chr2:127863029	C/T	cg08168897	chr2:127865431	BIN1	0.41	6.37	0.3	4.85e-10	Alzheimer's disease (late onset);
LUAD	cis	rs6076065	0.723	rs761726	chr20:23401481	G/C	cg11657817	chr20:23433608	CST11	0.47	8.66	0.39	1e-16	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs12431939	1.000	rs56220306	chr14:51648738	A/T	cg23942311	chr14:51606299	NA	-0.58	-8.06	-0.36	8.14e-15	Cancer;
LUAD	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg26408565	chr15:76604113	ETFA	-0.44	-7.16	-0.33	3.51e-12	Blood metabolite levels;
LUAD	trans	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg01620082	chr3:125678407	NA	-0.61	-7.42	-0.34	6.61e-13	Lung cancer in ever smokers;
LUAD	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg01528321	chr10:82214614	TSPAN14	-0.54	-8.69	-0.39	7.85e-17	Post bronchodilator FEV1;
LUAD	cis	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg11266682	chr4:10021025	SLC2A9	0.4	6.73	0.31	5.53e-11	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg24838063	chr12:130822603	PIWIL1	0.66	10.72	0.46	6.71e-24	Menopause (age at onset);
LUAD	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg11833968	chr6:79620685	NA	0.43	8.22	0.37	2.52e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg07217954	chr7:1067459	C7orf50	0.43	6.6	0.31	1.27e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg18806716	chr10:30721971	MAP3K8	0.78	16.3	0.62	1.08e-46	Inflammatory bowel disease;
LUAD	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg02176678	chr2:219576539	TTLL4	0.68	13.54	0.55	6.15e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg00316803	chr15:76480434	C15orf27	0.4	6.83	0.32	2.97e-11	Blood metabolite levels;
LUAD	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg18944383	chr4:111397179	ENPEP	0.38	7.62	0.35	1.66e-13	Height;
LUAD	cis	rs2880765	0.835	rs7180923	chr15:86050890	A/T	cg13263323	chr15:86062960	AKAP13	-0.52	-9.71	-0.43	2.94e-20	Coronary artery disease;
LUAD	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg13385794	chr1:248469461	NA	0.26	6.88	0.32	2.12e-11	Common traits (Other);
LUAD	cis	rs9372498	0.536	rs62422236	chr6:118972633	G/T	cg18833306	chr6:118973337	C6orf204	-0.55	-7.68	-0.35	1.1e-13	Diastolic blood pressure;
LUAD	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg25985355	chr7:65971099	NA	0.53	6.72	0.31	6e-11	Diabetic kidney disease;
LUAD	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg14458575	chr2:238380390	NA	0.62	11.86	0.5	3.27e-28	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg07917127	chr4:99064746	C4orf37	0.41	6.85	0.32	2.55e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2235642	0.601	rs2235647	chr16:1601331	C/A	cg26528668	chr16:1614120	IFT140	0.52	8.89	0.4	1.78e-17	Coronary artery disease;
LUAD	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg12011299	chr4:100065546	ADH4	0.73	13.72	0.55	1.1e-35	Alcohol dependence;
LUAD	cis	rs7394579	1	rs7394579	chr11:61581450	A/G	cg06781209	chr11:61594997	FADS2	-0.42	-6.81	-0.31	3.46e-11	Red cell distribution width;Mean platelet volume;
LUAD	cis	rs4664304	0.802	rs3792175	chr2:160862804	T/A	cg23995753	chr2:160760732	LY75	-0.43	-7.41	-0.34	7.14e-13	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg24801067	chr17:62843696	NA	-0.52	-8.28	-0.37	1.69e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg02696790	chr15:75250997	RPP25	0.4	7.41	0.34	6.94e-13	Breast cancer;
LUAD	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg23029597	chr12:123009494	RSRC2	-0.49	-8.14	-0.37	4.5e-15	Body mass index;
LUAD	cis	rs35883536	0.513	rs4907910	chr1:101013277	T/A	cg09408571	chr1:101003634	GPR88	0.33	6.68	0.31	7.63e-11	Monocyte count;
LUAD	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	8.0	0.36	1.17e-14	Rheumatoid arthritis;
LUAD	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg17063962	chr7:91808500	NA	0.61	10.22	0.44	4.75e-22	Breast cancer;
LUAD	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11644478	chr21:40555479	PSMG1	0.65	10.92	0.47	1.31e-24	Cognitive function;
LUAD	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg08859206	chr1:53392774	SCP2	-0.61	-10.69	-0.46	9.16e-24	Monocyte count;
LUAD	cis	rs73198271	0.562	rs79296712	chr8:8659978	G/A	cg01851573	chr8:8652454	MFHAS1	0.7	10.65	0.46	1.23e-23	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg11494091	chr17:61959527	GH2	0.4	7.1	0.33	5.48e-12	Height;
LUAD	cis	rs4891159	0.584	rs2848958	chr18:74157068	C/T	cg24786174	chr18:74118243	ZNF516	0.87	20.07	0.7	1.88e-63	Longevity;
LUAD	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg21475434	chr5:93447410	FAM172A	0.74	8.23	0.37	2.29e-15	Diabetic retinopathy;
LUAD	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg07538946	chr5:131705188	SLC22A5	0.48	7.93	0.36	2.01e-14	Breast cancer;Mosquito bite size;
LUAD	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs4523957	0.890	rs216218	chr17:2145329	A/G	cg16513277	chr17:2031491	SMG6	0.77	14.59	0.58	2.5e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg24818145	chr4:99064322	C4orf37	-0.48	-8.25	-0.37	2.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.57	0.49	4.41e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg00071950	chr4:10020882	SLC2A9	0.61	11.68	0.49	1.61e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg24531977	chr5:56204891	C5orf35	-0.48	-8.02	-0.36	1.08e-14	Coronary artery disease;
LUAD	cis	rs73198271	0.601	rs11997731	chr8:8649848	C/T	cg01851573	chr8:8652454	MFHAS1	0.5	8.74	0.39	5.53e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs72928364	1.000	rs73143088	chr3:100672587	G/T	cg10123952	chr3:100791384	NA	0.63	7.33	0.34	1.2e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg14779329	chr11:130786720	SNX19	0.39	6.77	0.31	4.23e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.72	-0.31	5.93e-11	Bladder cancer;
LUAD	cis	rs6867032	0.958	rs4975795	chr5:2015390	G/A	cg26168224	chr5:2018326	NA	0.8	18.17	0.66	6.1e-55	Gut microbiome composition (winter);
LUAD	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg00666640	chr1:248458726	OR2T12	0.35	8.48	0.38	3.75e-16	Common traits (Other);
LUAD	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg10544611	chr16:67998164	SLC12A4	0.67	7.89	0.36	2.55e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg17031739	chr1:67600172	NA	0.46	8.47	0.38	4e-16	Psoriasis;
LUAD	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	8.98	0.4	9.27e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg24163613	chr5:75012816	C5orf37	-0.37	-6.37	-0.3	4.84e-10	Subcortical brain region volumes;
LUAD	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.18	-0.37	3.32e-15	Reticulocyte count;
LUAD	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg00933542	chr6:150070202	PCMT1	0.45	9.52	0.42	1.34e-19	Lung cancer;
LUAD	cis	rs6546550	0.901	rs7419837	chr2:70146625	T/C	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.97	-0.47	8.24e-25	Prevalent atrial fibrillation;
LUAD	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg00666640	chr1:248458726	OR2T12	0.32	7.71	0.35	9.24e-14	Common traits (Other);
LUAD	cis	rs6761276	0.868	rs12468224	chr2:113834434	G/C	cg06383401	chr2:113825234	IL1F10	-0.3	-6.48	-0.3	2.6200000000000003e-10	Protein quantitative trait loci;
LUAD	cis	rs2425143	0.915	rs6060597	chr20:34370100	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	7.44	0.34	5.54e-13	Blood protein levels;
LUAD	cis	rs2279817	0.908	rs12137775	chr1:18018927	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.56	8.87	0.4	2.1e-17	Neuroticism;
LUAD	cis	rs17608059	0.545	rs9915045	chr17:13902636	G/T	cg27005118	chr17:13972210	COX10	-0.32	-6.45	-0.3	2.98e-10	Temperament;
LUAD	cis	rs11756438	0.683	rs17349329	chr6:119002644	T/G	cg21191810	chr6:118973309	C6orf204	0.4	7.15	0.33	3.79e-12	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs3106136	0.901	rs17623135	chr4:95213091	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.71	-0.35	8.92e-14	Capecitabine sensitivity;
LUAD	cis	rs7528419	0.617	rs4970834	chr1:109814880	C/T	cg00908766	chr1:109817496	CELSR2	-0.48	-7.6	-0.35	1.87e-13	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13732083	chr21:47605072	C21orf56	0.59	10.18	0.44	6.25e-22	Testicular germ cell tumor;
LUAD	trans	rs2018683	0.624	rs2286219	chr7:28998663	G/A	cg19402173	chr7:128379420	CALU	-0.5	-8.1	-0.37	5.81e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.32	-0.41	6.36e-19	Alzheimer's disease;
LUAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg18538332	chr22:24372958	LOC391322	-0.45	-7.65	-0.35	1.35e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.52	-0.34	3.34e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.98	0.32	1.12e-11	Hypertriglyceridemia;
LUAD	cis	rs2302190	1.000	rs2302190	chr17:56584508	A/G	cg25885038	chr17:56607967	SEPT4	-0.39	-6.44	-0.3	3.23e-10	Vitamin D levels;
LUAD	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.11	-0.51	3.37e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12541635	0.966	rs10955409	chr8:107022586	A/C	cg10147462	chr8:107024639	NA	0.48	8.92	0.4	1.4e-17	Age of smoking initiation;
LUAD	cis	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.87	-0.36	3.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2688608	0.901	rs2664282	chr10:75620757	T/C	cg23231163	chr10:75533350	FUT11	-0.45	-8.36	-0.38	9.13e-16	Inflammatory bowel disease;
LUAD	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg00255919	chr5:131827918	IRF1	-0.5	-11.61	-0.49	3.15e-27	Asthma (sex interaction);
LUAD	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg17644776	chr2:200775616	C2orf69	0.55	7.23	0.33	2.32e-12	Schizophrenia;
LUAD	trans	rs2262909	1.000	rs2359821	chr19:22208314	C/T	cg17074339	chr11:11642133	GALNTL4	-0.43	-6.81	-0.31	3.42e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg25811766	chr13:21894605	NA	0.63	7.39	0.34	8.11e-13	White matter hyperintensity burden;
LUAD	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-11.05	-0.47	4.28e-25	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs1105228	0.679	rs4709933	chr6:165702705	C/T	cg12582777	chr6:165658423	NA	0.31	6.57	0.3	1.48e-10	Number of pregnancies;Number of children;
LUAD	cis	rs6782228	0.509	rs4481172	chr3:128372657	C/A	cg16766828	chr3:128327626	NA	-0.38	-7.15	-0.33	3.83e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	trans	rs459571	0.959	rs378740	chr9:136890876	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.67	-9.82	-0.43	1.26e-20	Platelet distribution width;
LUAD	cis	rs6474412	1.000	rs1451239	chr8:42546542	G/A	cg25026480	chr8:42547641	NA	0.36	6.37	0.3	4.83e-10	Smoking behavior;
LUAD	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	12.15	0.51	2.52e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06873352	chr17:61820015	STRADA	0.54	8.86	0.4	2.24e-17	Height;
LUAD	cis	rs1524927	0.566	rs12704876	chr7:96366342	C/T	cg26619624	chr7:96339434	SHFM1	-0.32	-6.47	-0.3	2.69e-10	Total body bone mineral density;
LUAD	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg11266682	chr4:10021025	SLC2A9	0.69	15.76	0.61	2.27e-44	Bone mineral density;
LUAD	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg21724239	chr8:58056113	NA	0.55	7.39	0.34	7.95e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg27446573	chr6:127587934	RNF146	0.45	6.53	0.3	1.92e-10	Breast cancer;
LUAD	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.29	-0.33	1.49e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg02002194	chr4:3960332	NA	0.28	6.65	0.31	9.35e-11	Mood instability;
LUAD	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.44e-10	Prostate cancer;
LUAD	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg05283184	chr6:79620031	NA	-0.6	-11.89	-0.5	2.57e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.71e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.35	-0.3	5.58e-10	Neuroticism;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg01769037	chr6:15246613	JARID2	-0.41	-7.19	-0.33	3.02e-12	Subcortical brain region volumes;
LUAD	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.55	-9.16	-0.41	2.19e-18	Glomerular filtration rate;
LUAD	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg18129748	chr3:49941408	MST1R	0.44	7.23	0.33	2.24e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	15.97	0.61	2.98e-45	Exhaled nitric oxide levels;
LUAD	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.06e-11	Parkinson's disease;
LUAD	trans	rs11039798	1.000	rs10838918	chr11:48507449	A/G	cg15704280	chr7:45808275	SEPT13	0.65	7.73	0.35	7.69e-14	Axial length;
LUAD	cis	rs9443645	0.588	rs1415310	chr6:79822314	C/T	cg05283184	chr6:79620031	NA	-0.4	-7.04	-0.32	7.97e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7017914	0.967	rs62508819	chr8:71718106	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.43	-0.3	3.45e-10	Bone mineral density;
LUAD	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg05966235	chr16:28915196	ATP2A1	0.4	6.52	0.3	2.04e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg26022315	chr17:47021804	SNF8	0.4	7.29	0.33	1.54e-12	Type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.63	-9.41	-0.42	3.12e-19	Alzheimer's disease;
LUAD	cis	rs6430585	0.697	rs7607174	chr2:136513670	T/A	cg07169764	chr2:136633963	MCM6	0.79	9.03	0.4	6e-18	Corneal structure;
LUAD	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.17	-0.41	2.16e-18	Bipolar disorder;
LUAD	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg15445000	chr17:37608096	MED1	0.35	6.51	0.3	2.09e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg12193833	chr17:30244370	NA	-0.52	-6.39	-0.3	4.41e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg03676636	chr4:99064102	C4orf37	0.28	7.25	0.33	2.03e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs427941	0.632	rs201502	chr7:101759561	C/T	cg06246474	chr7:101738831	CUX1	-0.37	-6.43	-0.3	3.44e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7274811	0.688	rs56234419	chr20:32086447	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.52	-7.65	-0.35	1.39e-13	Height;
LUAD	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg04450456	chr4:17643702	FAM184B	0.43	8.43	0.38	5.52e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg18105134	chr13:113819100	PROZ	0.91	16.46	0.62	2.18e-47	Platelet distribution width;
LUAD	cis	rs9826463	1.000	rs9813377	chr3:142321717	C/T	cg20824294	chr3:142316082	PLS1	0.36	6.39	0.3	4.5e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg08632164	chr7:65971372	NA	-0.38	-6.62	-0.31	1.09e-10	Aortic root size;
LUAD	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg01191920	chr7:158217561	PTPRN2	-0.75	-16.81	-0.63	6.06e-49	Obesity-related traits;
LUAD	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg03467027	chr4:99064603	C4orf37	0.4	6.46	0.3	2.93e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08280861	chr8:58055591	NA	0.55	7.16	0.33	3.53e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg26513180	chr16:89883248	FANCA	0.71	13.81	0.56	4.54e-36	Vitiligo;
LUAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg07362569	chr17:61921086	SMARCD2	0.39	6.76	0.31	4.46e-11	Prudent dietary pattern;
LUAD	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg08470875	chr2:26401718	FAM59B	0.64	8.0	0.36	1.22e-14	Gut microbiome composition (summer);
LUAD	cis	rs6430585	0.702	rs746857	chr2:136554890	G/A	cg07169764	chr2:136633963	MCM6	-0.74	-8.91	-0.4	1.49e-17	Corneal structure;
LUAD	cis	rs1232027	0.700	rs1478835	chr5:79949600	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-8.09	-0.37	6.53e-15	Huntington's disease progression;
LUAD	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg04944784	chr2:26401820	FAM59B	-0.88	-12.58	-0.52	4.91e-31	Gut microbiome composition (summer);
LUAD	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg26343298	chr8:95960752	TP53INP1	0.38	8.14	0.37	4.53e-15	Type 2 diabetes;
LUAD	cis	rs934734	0.752	rs1194849	chr2:65606653	T/C	cg11674355	chr2:65610261	SPRED2	0.36	6.37	0.3	5.01e-10	Rheumatoid arthritis;
LUAD	cis	rs17092148	1.000	rs2425004	chr20:33405956	G/T	cg16810054	chr20:33298113	TP53INP2	0.54	8.57	0.38	1.96e-16	Neuroticism;
LUAD	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.21	0.48	1.03e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.84	-0.5	3.88e-28	Bipolar disorder;
LUAD	cis	rs1215050	0.904	rs1727285	chr4:98978821	G/A	cg17366294	chr4:99064904	C4orf37	-0.42	-7.22	-0.33	2.47e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.68	-13.19	-0.54	1.63e-33	Longevity;Endometriosis;
LUAD	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg15147215	chr3:52552868	STAB1	-0.41	-7.56	-0.35	2.5e-13	Bipolar disorder;
LUAD	trans	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg14917512	chr19:3094685	GNA11	0.56	6.75	0.31	4.81e-11	Diabetic kidney disease;
LUAD	cis	rs11229555	1.000	rs8373	chr11:58378424	A/G	cg15696309	chr11:58395628	NA	-0.73	-10.98	-0.47	7.29e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs656900	0.715	rs1870576	chr15:80107128	T/C	cg02196730	chr15:80188777	MTHFS	0.42	6.91	0.32	1.82e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7593730	0.832	rs10929982	chr2:161236277	A/G	cg22609984	chr2:161126801	NA	-0.45	-7.17	-0.33	3.32e-12	Type 2 diabetes;
LUAD	cis	rs77972916	0.505	rs6736400	chr2:43500804	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-10.44	-0.45	7.2e-23	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2262909	0.849	rs2666447	chr19:22132868	T/A	cg11619707	chr19:22235551	ZNF257	-0.44	-6.75	-0.31	4.91e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg26516362	chr5:178986906	RUFY1	-0.61	-10.43	-0.45	7.78e-23	Lung cancer;
LUAD	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg07537917	chr2:241836409	C2orf54	-0.32	-9.27	-0.41	9.55e-19	Urinary metabolites;
LUAD	cis	rs2279817	1.000	rs2279817	chr1:18021858	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.51	-7.58	-0.35	2.24e-13	Neuroticism;
LUAD	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.42	-0.34	6.4e-13	Glomerular filtration rate;
LUAD	cis	rs6499255	0.857	rs16959035	chr16:69707645	C/A	cg15192750	chr16:69999425	NA	0.49	7.75	0.35	7.03e-14	IgE levels;
LUAD	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22496380	chr5:211416	CCDC127	-0.94	-13.15	-0.54	2.4e-33	Breast cancer;
LUAD	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-7.85	-0.36	3.54e-14	Total cholesterol levels;
LUAD	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-7.42	-0.34	6.65e-13	Personality dimensions;
LUAD	cis	rs9863	0.861	rs11057399	chr12:124425078	A/G	cg17723958	chr12:124429295	CCDC92	-0.44	-7.06	-0.32	6.71e-12	White blood cell count;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg18429685	chr19:59085257	MZF1;LOC100131691	-0.44	-7.4	-0.34	7.52e-13	Subcortical brain region volumes;
LUAD	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg25985355	chr7:65971099	NA	0.36	6.78	0.31	4.17e-11	Aortic root size;
LUAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg18621852	chr3:10150065	C3orf24	0.46	8.31	0.37	1.32e-15	Alzheimer's disease;
LUAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg08027265	chr7:2291960	NA	-0.43	-7.31	-0.33	1.35e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03479529	chr19:1490731	REEP6;PCSK4	-0.44	-6.79	-0.31	3.75e-11	Height;
LUAD	cis	rs28595532	0.748	rs72670258	chr4:119391660	A/T	cg21605333	chr4:119757512	SEC24D	0.67	6.67	0.31	8.2e-11	Cannabis dependence symptom count;
LUAD	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg26384229	chr12:38710491	ALG10B	0.45	7.36	0.34	9.68e-13	Bladder cancer;
LUAD	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg02527881	chr3:46936655	PTH1R	0.45	8.58	0.39	1.78e-16	Colorectal cancer;
LUAD	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg19743168	chr1:23544995	NA	0.44	8.01	0.36	1.09e-14	Height;
LUAD	trans	rs3942852	0.910	rs10742831	chr11:48119691	G/A	cg15704280	chr7:45808275	SEPT13	-0.6	-8.37	-0.38	8.32e-16	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs853679	0.607	rs34396849	chr6:28250955	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.51	6.4	0.3	4.03e-10	Depression;
LUAD	cis	rs7851660	0.839	rs2417575	chr9:100628642	G/A	cg13688889	chr9:100608707	NA	-0.48	-8.26	-0.37	1.87e-15	Strep throat;
LUAD	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg07917127	chr4:99064746	C4orf37	0.41	6.79	0.31	3.71e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.891	rs73058864	chr2:198889587	C/T	cg10547527	chr2:198650123	BOLL	-0.5	-6.91	-0.32	1.76e-11	Ulcerative colitis;
LUAD	cis	rs6840360	0.550	rs4696289	chr4:152621237	C/T	cg22705602	chr4:152727874	NA	-0.48	-8.37	-0.38	8.41e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs1032833	0.732	rs2305170	chr2:179974761	A/C	cg23883738	chr2:179974586	SESTD1	-0.74	-8.23	-0.37	2.29e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-10.42	-0.45	8.72e-23	Chronic sinus infection;
LUAD	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.54	0.42	1.19e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg03806693	chr22:41940476	POLR3H	0.59	8.59	0.39	1.63e-16	Vitiligo;
LUAD	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg11062466	chr8:58055876	NA	0.72	9.0	0.4	7.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1030877	0.960	rs3792047	chr2:105901553	A/G	cg02079111	chr2:105885981	TGFBRAP1	-0.54	-10.43	-0.45	8.41e-23	Obesity-related traits;
LUAD	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg14092988	chr3:52407081	DNAH1	0.51	9.51	0.42	1.5e-19	Bipolar disorder;
LUAD	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg00933542	chr6:150070202	PCMT1	-0.47	-9.94	-0.44	4.55e-21	Lung cancer;
LUAD	cis	rs13315871	0.929	rs71311852	chr3:58298843	G/A	cg12435725	chr3:58293450	RPP14	-0.74	-7.88	-0.36	2.86e-14	Cholesterol, total;
LUAD	cis	rs2041840	0.961	rs2110964	chr2:37479959	A/C	cg25727520	chr2:37576821	QPCT	-0.36	-7.36	-0.34	9.88e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs2742234	0.590	rs1254960	chr10:43699657	C/T	cg15436174	chr10:43711423	RASGEF1A	0.52	8.72	0.39	6.42e-17	Hirschsprung disease;
LUAD	cis	rs2735413	0.957	rs2735414	chr16:78053658	C/A	cg04733911	chr16:78082701	NA	-0.29	-6.66	-0.31	8.76e-11	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.81	-0.31	3.44e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs300703	0.542	rs67993758	chr2:179594	C/T	cg24565620	chr2:194026	NA	0.38	6.67	0.31	8.11e-11	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg07917127	chr4:99064746	C4orf37	0.41	6.89	0.32	2.01e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.04	23.44	0.75	1.77e-78	Chronic sinus infection;
LUAD	cis	rs7590720	0.819	rs6435931	chr2:216892754	C/G	cg12620499	chr2:216877984	MREG	0.57	9.62	0.42	5.88e-20	Alcohol dependence;
LUAD	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg06873352	chr17:61820015	STRADA	0.42	6.91	0.32	1.76e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg11062466	chr8:58055876	NA	-0.63	-8.24	-0.37	2.22e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg08508325	chr11:3079039	CARS	0.59	12.87	0.53	3.16e-32	Longevity;
LUAD	cis	rs2074977	0.530	rs10401784	chr19:3445721	A/C	cg05344495	chr19:3478662	C19orf77	-0.4	-7.35	-0.34	1.06e-12	Height;
LUAD	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg00933542	chr6:150070202	PCMT1	0.44	9.55	0.42	1.04e-19	Lung cancer;
LUAD	cis	rs12505328	0.932	rs11132985	chr4:174359014	A/G	cg12145043	chr4:174357286	NA	-0.59	-10.38	-0.45	1.27e-22	Chin dimples;
LUAD	trans	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg18876405	chr7:65276391	NA	0.48	7.69	0.35	1.07e-13	Corneal structure;
LUAD	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg19761014	chr17:28927070	LRRC37B2	0.7	6.46	0.3	2.93e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4906332	1.000	rs911549	chr14:103984537	T/C	cg13511324	chr14:104056883	C14orf153	-0.26	-6.58	-0.3	1.43e-10	Coronary artery disease;
LUAD	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg04539111	chr16:67997858	SLC12A4	-0.48	-6.4	-0.3	4.18e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12618769	0.625	rs76362434	chr2:99118005	C/T	cg10123293	chr2:99228465	UNC50	0.53	9.12	0.41	2.98e-18	Bipolar disorder;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07067085	chr12:120638762	RPLP0	-0.52	-6.53	-0.3	1.85e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2880765	0.835	rs7162502	chr15:86044473	G/T	cg13263323	chr15:86062960	AKAP13	-0.5	-9.24	-0.41	1.21e-18	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg07917127	chr4:99064746	C4orf37	0.41	6.82	0.31	3.22e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.55	-0.34	2.67e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7107174	1.000	rs10899469	chr11:78018313	T/C	cg19901956	chr11:77921274	USP35	-0.53	-6.45	-0.3	3.15e-10	Testicular germ cell tumor;
LUAD	cis	rs6558530	0.932	rs6558531	chr8:1707566	A/G	cg19131313	chr8:1704013	NA	-0.46	-7.5	-0.34	3.77e-13	Systolic blood pressure;
LUAD	cis	rs4285028	0.948	rs34158925	chr3:121678465	C/A	cg20356878	chr3:121714668	ILDR1	-0.5	-6.76	-0.31	4.51e-11	Multiple sclerosis;
LUAD	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.25	-0.33	2.06e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg18180107	chr4:99064573	C4orf37	0.43	6.94	0.32	1.51e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.46	-0.38	4.38e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.83	0.32	3.02e-11	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26101466	chr14:64108700	WDR89	-0.56	-6.76	-0.31	4.57e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg26384229	chr12:38710491	ALG10B	0.47	7.61	0.35	1.75e-13	Morning vs. evening chronotype;
LUAD	cis	rs6594713	0.642	rs6867579	chr5:112899573	T/C	cg12552261	chr5:112820674	MCC	0.52	7.19	0.33	2.99e-12	Brain cytoarchitecture;
LUAD	cis	rs3750082	0.692	rs34737146	chr7:32935926	G/A	cg06627557	chr7:32535165	LSM5;AVL9	-0.46	-6.53	-0.3	1.88e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9875589	0.509	rs4047237	chr3:14012861	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	6.54	0.3	1.73e-10	Ovarian reserve;
LUAD	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg25554036	chr4:6271136	WFS1	0.66	11.66	0.49	1.88e-27	Cisplatin-induced ototoxicity;
LUAD	cis	rs5756813	0.754	rs4820307	chr22:38175955	G/A	cg06521852	chr22:38141419	TRIOBP	0.5	9.44	0.42	2.49e-19	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg06627628	chr2:24431161	ITSN2	-0.47	-6.66	-0.31	8.79e-11	Lymphocyte counts;
LUAD	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.49	0.3	2.39e-10	Cardiac Troponin-T levels;
LUAD	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg11859384	chr17:80120422	CCDC57	-0.49	-8.82	-0.39	3.14e-17	Life satisfaction;
LUAD	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg08847533	chr14:75593920	NEK9	0.39	6.63	0.31	1.01e-10	Height;
LUAD	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg04450456	chr4:17643702	FAM184B	-0.4	-7.72	-0.35	8.47e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg10636054	chr15:40330586	SRP14	-0.52	-6.77	-0.31	4.36e-11	Response to haloperidol in psychosis;
LUAD	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg17366294	chr4:99064904	C4orf37	0.48	8.42	0.38	5.92e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg26597838	chr10:835615	NA	1.28	19.87	0.69	1.55e-62	Eosinophil percentage of granulocytes;
LUAD	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg05922057	chr17:4047571	ZZEF1;CYB5D2	-0.38	-6.59	-0.31	1.28e-10	Type 2 diabetes;
LUAD	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg06064525	chr11:970664	AP2A2	0.4	7.89	0.36	2.6e-14	Alzheimer's disease (late onset);
LUAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg06074448	chr4:187884817	NA	-0.37	-7.3	-0.33	1.47e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg20476274	chr7:133979776	SLC35B4	0.85	16.69	0.63	1.99e-48	Mean platelet volume;
LUAD	cis	rs6906287	0.647	rs59671368	chr6:118911430	T/A	cg21191810	chr6:118973309	C6orf204	0.5	9.69	0.43	3.54e-20	Electrocardiographic conduction measures;
LUAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg06873352	chr17:61820015	STRADA	-0.77	-15.99	-0.61	2.4e-45	Prudent dietary pattern;
LUAD	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg27068330	chr11:65405492	SIPA1	-0.78	-12.71	-0.53	1.4e-31	Acne (severe);
LUAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00166722	chr3:10149974	C3orf24	0.71	12.36	0.52	3.47e-30	Alzheimer's disease;
LUAD	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg23954153	chr1:44402353	ARTN	-0.33	-6.62	-0.31	1.09e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	7.4	0.34	7.4e-13	Menopause (age at onset);
LUAD	cis	rs67981189	0.821	rs12896370	chr14:71521340	C/T	cg15816911	chr14:71606274	NA	0.36	6.38	0.3	4.63e-10	Schizophrenia;
LUAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg20849893	chr7:64541193	NA	0.56	9.09	0.4	3.74e-18	Calcium levels;
LUAD	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs4253772	0.872	rs45576140	chr22:46638216	C/G	cg09491104	chr22:46646882	C22orf40	-0.54	-7.83	-0.36	4.09e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.56	0.3	1.54e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg05043794	chr9:111880884	C9orf5	-0.42	-7.32	-0.34	1.28e-12	Menarche (age at onset);
LUAD	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.12	-0.37	5.24e-15	Prostate cancer;
LUAD	cis	rs7100689	0.598	rs35353819	chr10:82135737	A/G	cg00277334	chr10:82204260	NA	-0.62	-10.49	-0.45	4.82e-23	Post bronchodilator FEV1;
LUAD	cis	rs9522267	0.535	rs9522298	chr13:112234457	C/A	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.93e-11	Hepatitis;
LUAD	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.91	-18.93	-0.68	2.46e-58	Ulcerative colitis;
LUAD	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg18016565	chr1:150552671	MCL1	-0.41	-6.97	-0.32	1.24e-11	Tonsillectomy;
LUAD	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg14584255	chr6:163149320	PACRG;PARK2	-0.37	-7.03	-0.32	8.54e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2294693	0.685	rs67525613	chr6:41008956	G/T	cg14769373	chr6:40998127	UNC5CL	-0.57	-8.15	-0.37	4.25e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.45	8.13	0.37	4.84e-15	Systemic lupus erythematosus;
LUAD	trans	rs9951602	0.573	rs78623099	chr18:76646228	G/T	cg02800362	chr5:177631904	HNRNPAB	0.92	14.25	0.57	6.75e-38	Obesity-related traits;
LUAD	cis	rs11971779	0.680	rs7792752	chr7:139066196	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.76	0.31	4.63e-11	Diisocyanate-induced asthma;
LUAD	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg01528321	chr10:82214614	TSPAN14	0.44	6.94	0.32	1.48e-11	Post bronchodilator FEV1;
LUAD	cis	rs7202877	0.656	rs4888374	chr16:75322228	T/C	cg03315344	chr16:75512273	CHST6	0.52	7.03	0.32	8.29e-12	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02788857	chr8:22132959	PIWIL2	0.53	9.95	0.44	4.29e-21	Hypertriglyceridemia;
LUAD	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-6.75	-0.31	4.8e-11	Daytime sleep phenotypes;
LUAD	cis	rs11249608	0.548	rs6894076	chr5:178449813	T/C	cg01312482	chr5:178451176	ZNF879	-0.44	-6.83	-0.32	3.01e-11	Pubertal anthropometrics;
LUAD	cis	rs1595825	0.891	rs73061068	chr2:198908439	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-7.06	-0.32	6.73e-12	Ulcerative colitis;
LUAD	cis	rs11958404	0.932	rs6895484	chr5:157429159	T/C	cg05962755	chr5:157440814	NA	0.69	9.52	0.42	1.31e-19	IgG glycosylation;
LUAD	cis	rs113835537	0.529	rs75685325	chr11:66235242	A/G	cg26679405	chr11:66247800	DPP3	-0.46	-6.45	-0.3	3.1e-10	Airway imaging phenotypes;
LUAD	cis	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg27411982	chr8:10470053	RP1L1	-0.35	-6.38	-0.3	4.54e-10	Neuroticism;
LUAD	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg09835421	chr16:68378352	PRMT7	-0.82	-8.75	-0.39	4.94e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs807669	0.586	rs5746671	chr22:19160899	A/G	cg02655711	chr22:19163373	SLC25A1	0.62	12.44	0.52	1.7e-30	Metabolite levels;
LUAD	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg14324370	chr2:177042789	NA	0.39	7.3	0.33	1.43e-12	IgG glycosylation;
LUAD	cis	rs2406342	0.511	rs10469087	chr18:74575538	A/C	cg16472389	chr18:74514291	NA	0.52	9.22	0.41	1.43e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LUAD	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg05340658	chr4:99064831	C4orf37	0.45	7.42	0.34	6.47e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08271918	chr13:73301231	C13orf37;C13orf34	-0.39	-6.62	-0.31	1.11e-10	Cancer;
LUAD	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg15017067	chr4:17643749	FAM184B	-0.37	-7.15	-0.33	3.85e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg05283184	chr6:79620031	NA	-0.6	-12.06	-0.51	5.22e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs1847202	0.859	rs6805260	chr3:72933767	C/T	cg25664220	chr3:72788482	NA	-0.47	-8.13	-0.37	4.87e-15	Motion sickness;
LUAD	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-8.61	-0.39	1.51e-16	Cognitive function;
LUAD	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.5	-10.27	-0.45	3.01e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs17095355	0.818	rs12571773	chr10:111776004	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.43	-0.34	6.26e-13	Biliary atresia;
LUAD	cis	rs4776059	1.000	rs4776059	chr15:52886962	C/T	cg24008177	chr15:52972085	KIAA1370	0.25	6.86	0.32	2.45e-11	Schizophrenia;
LUAD	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg08601574	chr20:25228251	PYGB	-0.44	-8.16	-0.37	3.83e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24639504	chr13:25875833	NUPL1	-0.41	-6.36	-0.3	5.18e-10	Height;
LUAD	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg20203395	chr5:56204925	C5orf35	0.61	9.46	0.42	2.22e-19	Initial pursuit acceleration;
LUAD	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.44	-6.79	-0.31	3.86e-11	Breast cancer;
LUAD	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg02038168	chr22:39784481	NA	-0.5	-6.97	-0.32	1.21e-11	IgG glycosylation;
LUAD	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg08645402	chr16:4508243	NA	-0.55	-10.23	-0.45	4.29e-22	Schizophrenia;
LUAD	trans	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg06175025	chr14:78082992	SPTLC2	-0.43	-6.97	-0.32	1.26e-11	Bone mineral density;
LUAD	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg04181038	chr4:183730758	NA	0.73	10.72	0.46	6.71e-24	Pediatric autoimmune diseases;
LUAD	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.49	8.93	0.4	1.27e-17	Axial length;
LUAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	10.75	0.46	5.23e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.18	-0.37	3.37e-15	Total cholesterol levels;
LUAD	cis	rs7937890	0.559	rs2597187	chr11:14517019	C/G	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.15e-12	Mitochondrial DNA levels;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg00980293	chr6:17987232	KIF13A	-0.44	-6.47	-0.3	2.68e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg09904177	chr6:26538194	HMGN4	0.44	7.31	0.34	1.31e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7539409	0.651	rs910182	chr1:84297117	A/G	cg10977910	chr1:84465055	TTLL7	0.75	8.58	0.38	1.89e-16	Alzheimer's disease;
LUAD	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg14582100	chr15:45693742	SPATA5L1	0.42	8.46	0.38	4.46e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg07917127	chr4:99064746	C4orf37	0.44	6.73	0.31	5.63e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2652834	1.000	rs2652835	chr15:63396408	T/C	cg25406657	chr15:63342033	TPM1	-0.43	-7.01	-0.32	9.62e-12	HDL cholesterol;
LUAD	cis	rs986417	0.901	rs3759688	chr14:60975579	A/C	cg27398547	chr14:60952738	C14orf39	0.66	7.89	0.36	2.63e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs2224391	0.628	rs2753236	chr6:5252214	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-8.64	-0.39	1.14e-16	Height;
LUAD	cis	rs8099014	0.861	rs2277722	chr18:56121280	G/C	cg12907477	chr18:56117327	MIR122	0.47	7.81	0.36	4.41e-14	Platelet count;
LUAD	cis	rs68170813	0.652	rs11532774	chr7:107201579	T/C	cg23024343	chr7:107201750	COG5	0.54	6.82	0.31	3.25e-11	Coronary artery disease;
LUAD	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.52	-0.52	8.38e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg00431813	chr7:1051703	C7orf50	-0.41	-7.51	-0.34	3.51e-13	Longevity;Endometriosis;
LUAD	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-7.0	-0.32	1.04e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs877282	0.945	rs11599043	chr10:777972	C/T	cg06581033	chr10:766294	NA	-0.57	-7.89	-0.36	2.54e-14	Uric acid levels;
LUAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg27454412	chr7:1067447	C7orf50	0.48	7.74	0.35	7.28e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs877282	1.000	rs877282	chr10:771532	G/A	cg06581033	chr10:766294	NA	-0.57	-7.68	-0.35	1.09e-13	Uric acid levels;
LUAD	cis	rs62238980	0.614	rs74321309	chr22:32483022	C/T	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg22681709	chr2:178499509	PDE11A	-0.38	-7.04	-0.32	7.65e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg07460842	chr6:66804631	NA	0.91	12.14	0.51	2.64e-29	Exhaled nitric oxide output;
LUAD	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg03709012	chr19:19516395	GATAD2A	0.52	6.56	0.3	1.6e-10	Nonalcoholic fatty liver disease;
LUAD	cis	rs748404	0.697	rs1814323	chr15:43563237	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.46	-7.32	-0.34	1.25e-12	Lung cancer;
LUAD	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg25358565	chr5:93447407	FAM172A	0.68	8.04	0.36	9.12e-15	Diabetic retinopathy;
LUAD	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg08859206	chr1:53392774	SCP2	0.6	11.01	0.47	5.78e-25	Monocyte count;
LUAD	cis	rs2979489	0.841	rs2015311	chr8:30306989	A/G	cg26383811	chr8:30366931	RBPMS	0.65	10.17	0.44	6.78e-22	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg09455208	chr3:40491958	NA	0.57	12.79	0.53	6.67e-32	Renal cell carcinoma;
LUAD	cis	rs1832871	0.616	rs55675950	chr6:158773994	T/A	cg07165851	chr6:158734300	TULP4	0.72	11.32	0.48	3.97e-26	Height;
LUAD	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs16910800	1.000	rs2468648	chr11:23201494	C/G	cg20040320	chr11:23191996	NA	0.46	7.0	0.32	1.01e-11	Cancer;
LUAD	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg00769240	chr8:12517080	NA	-0.43	-8.39	-0.38	7.61e-16	Blood pressure (smoking interaction);
LUAD	cis	rs9902453	0.704	rs2628179	chr17:28071796	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.51	-8.27	-0.37	1.81e-15	Coffee consumption (cups per day);
LUAD	trans	rs75804782	0.557	rs3769118	chr2:239342542	C/G	cg01134436	chr17:81009848	B3GNTL1	0.57	6.66	0.31	8.3e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg00814883	chr7:100076585	TSC22D4	-0.8	-11.67	-0.49	1.79e-27	Platelet count;
LUAD	cis	rs3823572	0.542	rs2346267	chr7:133639554	T/C	cg03336402	chr7:133662267	EXOC4	0.41	7.57	0.35	2.4e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg08645402	chr16:4508243	NA	0.57	10.48	0.45	5.32e-23	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.32	-0.38	1.21e-15	Breast cancer;
LUAD	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg17366294	chr4:99064904	C4orf37	0.6	11.17	0.48	1.4e-25	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg02551604	chr5:131831745	NA	-0.59	-8.35	-0.38	9.82e-16	Asthma (sex interaction);
LUAD	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.82	0.31	3.13e-11	Cognitive test performance;
LUAD	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg05665937	chr4:1216051	CTBP1	-0.45	-8.1	-0.37	5.76e-15	Obesity-related traits;
LUAD	trans	rs4650994	0.525	rs4457535	chr1:178497186	C/T	cg05059571	chr16:84539110	KIAA1609	0.72	13.11	0.54	3.44e-33	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg04414720	chr1:150670196	GOLPH3L	0.73	13.62	0.55	2.78e-35	Tonsillectomy;
LUAD	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg22532475	chr10:104410764	TRIM8	-0.36	-7.28	-0.33	1.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7975161	0.572	rs7957725	chr12:104574749	A/T	cg25273343	chr12:104657179	TXNRD1	-0.63	-6.82	-0.31	3.18e-11	Toenail selenium levels;
LUAD	cis	rs4321325	0.733	rs4510165	chr2:127936284	C/T	cg11380483	chr2:127933992	NA	0.49	6.45	0.3	3.03e-10	Protein C levels;
LUAD	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg27490568	chr2:178487706	NA	-0.57	-8.85	-0.4	2.4e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2905347	0.520	rs1858936	chr7:22647553	G/C	cg23521230	chr7:22704884	NA	0.46	7.06	0.32	7.07e-12	Major depression and alcohol dependence;
LUAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg08027265	chr7:2291960	NA	-0.43	-6.98	-0.32	1.11e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.87	-0.36	2.99e-14	Diabetic kidney disease;
LUAD	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg00603274	chr11:61596626	FADS2	-0.7	-9.87	-0.43	8.2e-21	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg13319975	chr6:146136371	FBXO30	-0.58	-9.77	-0.43	1.79e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.38	6.56	0.3	1.57e-10	Blood metabolite levels;
LUAD	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg22442454	chr1:209979470	IRF6	0.53	7.04	0.32	8e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.56	-0.3	1.54e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	7.53	0.34	3.18e-13	Resting heart rate;
LUAD	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg16205897	chr5:131564050	P4HA2	-0.43	-9.46	-0.42	2.1e-19	Blood metabolite levels;
LUAD	cis	rs2625529	0.652	rs7497104	chr15:72154000	C/T	cg16672083	chr15:72433130	SENP8	-0.64	-12.09	-0.51	4.28e-29	Red blood cell count;
LUAD	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg18827107	chr12:86230957	RASSF9	-0.68	-12.28	-0.51	7.15e-30	Major depressive disorder;
LUAD	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.98	0.32	1.12e-11	Motion sickness;
LUAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg08132940	chr7:1081526	C7orf50	-0.45	-6.77	-0.31	4.34e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg26043149	chr18:55253948	FECH	1.04	17.74	0.65	5.04e-53	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs9914988	0.943	rs7217547	chr17:27106872	C/G	cg20469991	chr17:27169893	C17orf63	-0.51	-6.58	-0.3	1.43e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7020830	0.867	rs1472169	chr9:37209396	C/T	cg14294708	chr9:37120828	ZCCHC7	0.88	17.74	0.65	4.87e-53	Schizophrenia;
LUAD	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg19774624	chr17:42201019	HDAC5	-0.41	-7.03	-0.32	8.55e-12	Total body bone mineral density;
LUAD	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg08085267	chr17:45401833	C17orf57	-0.49	-8.14	-0.37	4.56e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7202877	0.706	rs247437	chr16:75431275	T/G	cg03315344	chr16:75512273	CHST6	-0.47	-6.46	-0.3	2.84e-10	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.41	0.52	2.33e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg26875233	chr11:93583750	C11orf90	-0.4	-8.88	-0.4	1.95e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg11645453	chr3:52864694	ITIH4	0.34	6.67	0.31	8.04e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6987853	0.814	rs2167338	chr8:42455079	A/G	cg09913449	chr8:42400586	C8orf40	0.44	8.28	0.37	1.67e-15	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg12310025	chr6:25882481	NA	-0.57	-9.16	-0.41	2.33e-18	Blood metabolite levels;
LUAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg08888203	chr3:10149979	C3orf24	0.63	9.56	0.42	9.44e-20	Alzheimer's disease;
LUAD	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg11266682	chr4:10021025	SLC2A9	0.55	11.88	0.5	2.68e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg11494091	chr17:61959527	GH2	0.74	18.32	0.67	1.27e-55	Prudent dietary pattern;
LUAD	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg12179176	chr11:130786555	SNX19	0.53	8.93	0.4	1.35e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7493	0.851	rs11770903	chr7:95026327	A/G	cg05342682	chr7:94953680	PON1	-0.52	-7.4	-0.34	7.54e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs11039798	0.764	rs11039929	chr11:48703289	A/G	cg02254774	chr11:50257496	LOC441601	0.53	6.61	0.31	1.19e-10	Axial length;
LUAD	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg05665937	chr4:1216051	CTBP1	0.44	7.44	0.34	5.59e-13	Obesity-related traits;
LUAD	cis	rs231513	0.911	rs124722	chr17:41956002	T/G	cg26893861	chr17:41843967	DUSP3	-0.55	-6.59	-0.31	1.33e-10	Cognitive function;
LUAD	cis	rs4523957	0.583	rs8067895	chr17:2030234	G/A	cg16513277	chr17:2031491	SMG6	-0.98	-20.08	-0.7	1.79e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2274471	0.716	rs10974911	chr9:5010471	C/A	cg03390472	chr9:5043263	JAK2	-0.56	-8.21	-0.37	2.73e-15	Crohn's disease;
LUAD	cis	rs11971779	0.584	rs34762928	chr7:139113168	T/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.38	-0.3	4.74e-10	Diisocyanate-induced asthma;
LUAD	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg09021430	chr5:549028	NA	-0.67	-14.64	-0.58	1.5e-39	Obesity-related traits;
LUAD	cis	rs1113500	0.814	rs1592282	chr1:108601365	T/C	cg06207961	chr1:108661230	NA	0.35	6.62	0.31	1.07e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg02551604	chr5:131831745	NA	-0.61	-10.02	-0.44	2.39e-21	Asthma (sex interaction);
LUAD	cis	rs6546550	0.901	rs6739780	chr2:70138111	G/A	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.97	-0.47	8.24e-25	Prevalent atrial fibrillation;
LUAD	cis	rs2996428	0.709	rs6667255	chr1:3711689	T/C	cg13057898	chr1:3703894	LRRC47	0.64	10.78	0.46	4.29e-24	Red cell distribution width;
LUAD	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg16950941	chr11:66035639	RAB1B	0.44	7.37	0.34	9.31e-13	Gout;
LUAD	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.69e-18	Life satisfaction;
LUAD	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.57	-0.35	2.32e-13	Heart rate;
LUAD	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg26513180	chr16:89883248	FANCA	0.74	6.64	0.31	9.9e-11	Skin colour saturation;
LUAD	cis	rs1881797	0.527	rs1852908	chr1:247678260	C/T	cg14830002	chr1:247616686	OR2B11	0.5	6.71	0.31	6.12e-11	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs68170813	0.559	rs6967745	chr7:106850548	G/T	cg23024343	chr7:107201750	COG5	0.49	7.03	0.32	8.49e-12	Coronary artery disease;
LUAD	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.33	6.75	0.31	4.82e-11	Obesity-related traits;
LUAD	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08219700	chr8:58056026	NA	0.61	8.09	0.37	6.29e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1595825	0.891	rs2045244	chr2:198506466	C/T	cg10547527	chr2:198650123	BOLL	-0.54	-7.56	-0.35	2.52e-13	Ulcerative colitis;
LUAD	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-14.51	-0.58	5.3e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg02466173	chr16:30829666	NA	-0.85	-17.22	-0.64	9.29e-51	Dementia with Lewy bodies;
LUAD	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg14343924	chr8:8086146	FLJ10661	0.47	7.26	0.33	1.89e-12	Mood instability;
LUAD	cis	rs2070433	0.539	rs56157650	chr21:47957959	T/C	cg12379764	chr21:47803548	PCNT	0.49	7.25	0.33	1.98e-12	Lymphocyte counts;
LUAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00166722	chr3:10149974	C3orf24	0.66	10.69	0.46	8.7e-24	Alzheimer's disease;
LUAD	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg23985595	chr17:80112537	CCDC57	0.52	9.51	0.42	1.48e-19	Life satisfaction;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09444120	chr8:107227878	NA	0.49	6.38	0.3	4.76e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.45	-8.79	-0.39	3.93e-17	Longevity;Endometriosis;
LUAD	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg02993280	chr1:107599747	PRMT6	-0.45	-7.32	-0.34	1.25e-12	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22442454	chr1:209979470	IRF6	0.51	7.31	0.34	1.32e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg27535305	chr1:53392650	SCP2	-0.41	-8.66	-0.39	1.02e-16	Monocyte count;
LUAD	trans	rs1941687	0.563	rs9953034	chr18:31335294	A/G	cg15819921	chr19:927150	ARID3A	-0.48	-8.12	-0.37	5.23e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg17644776	chr2:200775616	C2orf69	-0.53	-7.87	-0.36	3.07e-14	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs6543140	0.964	rs6543143	chr2:103085420	A/C	cg04239558	chr2:103089729	SLC9A4	0.36	7.13	0.33	4.32e-12	Blood protein levels;
LUAD	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg01579765	chr21:45077557	HSF2BP	-0.63	-15.29	-0.6	2.39e-42	Mean corpuscular volume;
LUAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.8	-0.39	3.47e-17	Lymphocyte counts;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg07681156	chr19:56154921	ZNF581	0.45	7.14	0.33	4.08e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg01028140	chr2:1542097	TPO	-0.55	-7.34	-0.34	1.08e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4148883	0.504	rs9307238	chr4:100136182	A/G	cg12011299	chr4:100065546	ADH4	-0.55	-11.43	-0.49	1.45e-26	Alcohol dependence;
LUAD	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg10518543	chr12:38710700	ALG10B	0.4	6.38	0.3	4.53e-10	Bladder cancer;
LUAD	cis	rs13082711	0.911	rs77037289	chr3:27512971	C/T	cg02860705	chr3:27208620	NA	0.61	9.28	0.41	8.99e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7746199	0.736	rs13193542	chr6:27702425	G/T	cg26958806	chr6:27640298	NA	0.64	6.53	0.3	1.91e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg18306943	chr3:40428807	ENTPD3	0.38	6.73	0.31	5.57e-11	Renal cell carcinoma;
LUAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.61	-10.91	-0.47	1.34e-24	Longevity;Endometriosis;
LUAD	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg15549821	chr19:49342101	PLEKHA4	1.14	19.8	0.69	3.04e-62	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs986417	0.818	rs767602	chr14:61098624	G/T	cg27398547	chr14:60952738	C14orf39	0.56	6.48	0.3	2.55e-10	Gut microbiota (bacterial taxa);
LUAD	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-7.24	-0.33	2.14e-12	Platelet count;
LUAD	cis	rs3125734	0.633	rs7100297	chr10:63985100	T/C	cg19640130	chr10:64028056	RTKN2	-0.34	-7.15	-0.33	3.73e-12	Rheumatoid arthritis;
LUAD	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg12311346	chr5:56204834	C5orf35	-0.93	-13.61	-0.55	3.03e-35	Initial pursuit acceleration;
LUAD	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg05342682	chr7:94953680	PON1	-0.49	-6.79	-0.31	3.73e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg26587870	chr6:27730563	NA	-0.64	-6.98	-0.32	1.17e-11	Breast cancer;
LUAD	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg06608945	chr2:219082296	ARPC2	-0.42	-6.83	-0.32	2.93e-11	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg11673840	chr17:47092156	IGF2BP1	-0.38	-7.25	-0.33	1.95e-12	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg07211511	chr3:129823064	LOC729375	-0.81	-11.89	-0.5	2.59e-28	Blood pressure (smoking interaction);
LUAD	cis	rs1395	0.925	rs1659676	chr2:27399294	C/T	cg23587288	chr2:27483067	SLC30A3	0.41	8.32	0.38	1.21e-15	Blood metabolite levels;
LUAD	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg16325326	chr1:53192061	ZYG11B	0.59	10.65	0.46	1.31e-23	Monocyte count;
LUAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg08888203	chr3:10149979	C3orf24	0.73	10.95	0.47	1.01e-24	Alzheimer's disease;
LUAD	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg21963583	chr11:68658836	MRPL21	0.65	11.45	0.49	1.27e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg25319279	chr11:5960081	NA	-0.41	-7.23	-0.33	2.25e-12	DNA methylation (variation);
LUAD	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg07917127	chr4:99064746	C4orf37	0.42	6.96	0.32	1.34e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg16988262	chr1:15930761	NA	0.42	6.96	0.32	1.29e-11	Systolic blood pressure;
LUAD	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.13	0.33	4.42e-12	Motion sickness;
LUAD	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg25237894	chr2:233734115	C2orf82	-0.48	-8.9	-0.4	1.65e-17	Coronary artery disease;
LUAD	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg18016565	chr1:150552671	MCL1	0.41	7.55	0.34	2.78e-13	Tonsillectomy;
LUAD	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.35	7.01	0.32	9.42e-12	Obesity-related traits;
LUAD	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg08219700	chr8:58056026	NA	0.47	6.95	0.32	1.4e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs77972916	0.561	rs72788900	chr2:43559087	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-6.92	-0.32	1.73e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	6.48	0.3	2.6e-10	Schizophrenia;
LUAD	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg25237894	chr2:233734115	C2orf82	-0.57	-11.1	-0.47	2.7e-25	Coronary artery disease;
LUAD	cis	rs494562	0.892	rs7767800	chr6:86124526	G/A	cg13315970	chr6:86159197	NT5E	0.71	7.86	0.36	3.15e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.28	-6.94	-0.32	1.44e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg26597838	chr10:835615	NA	1.01	15.42	0.6	7.14e-43	Eosinophil percentage of granulocytes;
LUAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg20607798	chr8:58055168	NA	0.79	9.76	0.43	1.93e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg09658497	chr7:2847517	GNA12	-0.41	-7.19	-0.33	2.9e-12	Height;
LUAD	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg26513180	chr16:89883248	FANCA	-0.68	-12.53	-0.52	7.76e-31	Vitiligo;
LUAD	cis	rs12765878	0.967	rs11598018	chr10:105661315	C/A	cg11005552	chr10:105648138	OBFC1	0.44	8.33	0.38	1.11e-15	Coronary artery disease;
LUAD	cis	rs10242455	0.702	rs17854665	chr7:99050039	G/A	cg18809830	chr7:99032528	PTCD1	-0.99	-7.18	-0.33	3.17e-12	Blood metabolite levels;
LUAD	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg17366294	chr4:99064904	C4orf37	0.47	8.34	0.38	1.03e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg10518543	chr12:38710700	ALG10B	0.5	8.42	0.38	5.96e-16	Morning vs. evening chronotype;
LUAD	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg09796270	chr17:17721594	SREBF1	-0.39	-7.75	-0.35	6.99e-14	Total body bone mineral density;
LUAD	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07343612	chr16:622815	PIGQ	-0.82	-16.56	-0.63	7.45e-48	Height;
LUAD	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg16205897	chr5:131564050	P4HA2	-0.37	-8.31	-0.37	1.35e-15	Blood metabolite levels;
LUAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg22963979	chr7:1858916	MAD1L1	-0.71	-12.55	-0.52	6.26e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs3106136	0.967	rs66581998	chr4:95196901	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.46	-0.34	5.03e-13	Capecitabine sensitivity;
LUAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg08280861	chr8:58055591	NA	0.52	7.27	0.33	1.77e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg12016809	chr21:47604291	C21orf56	-0.54	-8.66	-0.39	1.04e-16	Testicular germ cell tumor;
LUAD	cis	rs8067287	0.762	rs11650981	chr17:16824038	A/G	cg26910001	chr17:16838321	NA	-0.48	-6.67	-0.31	8.09e-11	Diabetic kidney disease;
LUAD	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg13870426	chr17:30244630	NA	-0.57	-6.49	-0.3	2.43e-10	Hip circumference adjusted for BMI;
LUAD	trans	rs28735056	1.000	rs4798922	chr18:77628953	G/C	cg05926928	chr17:57297772	GDPD1	-0.48	-6.57	-0.3	1.45e-10	Schizophrenia;
LUAD	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg19875535	chr5:140030758	IK	-0.4	-6.79	-0.31	3.79e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg23018236	chr17:30244563	NA	-0.69	-8.34	-0.38	1.07e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg26924012	chr15:45694286	SPATA5L1	0.86	14.67	0.58	1.07e-39	Homoarginine levels;
LUAD	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg27426351	chr10:43362370	NA	0.54	8.35	0.38	1.02e-15	Blood protein levels;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02809263	chr1:70671218	LRRC40;SFRS11	0.42	6.35	0.3	5.45e-10	Gut microbiome composition (summer);
LUAD	cis	rs2227564	0.620	rs3911887	chr10:75548026	A/G	cg23231163	chr10:75533350	FUT11	-0.43	-6.8	-0.31	3.49e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.67	0.43	4.17e-20	Alzheimer's disease;
LUAD	cis	rs7147624	0.882	rs7141367	chr14:65938641	C/T	cg03016385	chr14:66212404	NA	-0.58	-6.78	-0.31	4.04e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg18944383	chr4:111397179	ENPEP	0.4	8.11	0.37	5.57e-15	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02466933	chr2:9770529	YWHAQ	-0.51	-6.66	-0.31	8.38e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.54	-9.24	-0.41	1.18e-18	Glomerular filtration rate;
LUAD	trans	rs853679	0.607	rs67998226	chr6:28238059	T/C	cg01620082	chr3:125678407	NA	-1.06	-10.59	-0.46	2.1e-23	Depression;
LUAD	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.36	6.44	0.3	3.34e-10	Schizophrenia;
LUAD	trans	rs9951602	0.512	rs4799248	chr18:76653459	G/A	cg02800362	chr5:177631904	HNRNPAB	0.91	14.37	0.57	2.07e-38	Obesity-related traits;
LUAD	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg19622623	chr12:86230825	RASSF9	-0.51	-9.06	-0.4	4.82e-18	Major depressive disorder;
LUAD	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg23950597	chr19:37808831	NA	-0.6	-7.46	-0.34	4.88e-13	Coronary artery calcification;
LUAD	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg10164272	chr16:89456328	ANKRD11	0.41	6.39	0.3	4.46e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.86	-0.4	2.31e-17	Lymphocyte counts;
LUAD	cis	rs9503598	0.714	rs11242859	chr6:3454032	G/A	cg00476032	chr6:3446245	SLC22A23	0.37	8.02	0.36	1.06e-14	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs17532515	0.628	rs882930	chr4:141458485	T/G	cg09181644	chr4:141490428	UCP1	-0.31	-6.87	-0.32	2.28e-11	Select biomarker traits;
LUAD	cis	rs758324	0.947	rs13170693	chr5:131187826	T/C	cg25547332	chr5:131281432	NA	0.44	6.7	0.31	6.85e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs11118844	0.843	rs12144586	chr1:221919378	A/G	cg04222084	chr1:221915650	DUSP10	-0.7	-7.96	-0.36	1.59e-14	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23158103	chr7:148848205	ZNF398	-0.67	-12.51	-0.52	9.4e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg25753631	chr6:25732923	NA	-0.43	-7.49	-0.34	3.95e-13	Iron status biomarkers;
LUAD	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg22598563	chr5:131563921	P4HA2	-0.32	-7.94	-0.36	1.8e-14	Blood metabolite levels;
LUAD	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg13319975	chr6:146136371	FBXO30	0.6	10.08	0.44	1.46e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9787249	0.957	rs12074147	chr1:40203722	T/C	cg24920358	chr1:40204285	PPIE	0.7	12.46	0.52	1.43e-30	Blood protein levels;
LUAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07167872	chr1:205819463	PM20D1	0.77	15.81	0.61	1.43e-44	Menarche (age at onset);
LUAD	cis	rs1595825	0.891	rs16826791	chr2:198895133	C/G	cg10547527	chr2:198650123	BOLL	-0.51	-7.05	-0.32	7.36e-12	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.94	0.44	4.72e-21	Ulcerative colitis;
LUAD	cis	rs1832871	0.711	rs9459877	chr6:158692331	G/A	cg07165851	chr6:158734300	TULP4	0.71	11.01	0.47	5.97e-25	Height;
LUAD	cis	rs8044868	0.530	rs3890860	chr16:72103409	A/G	cg23815491	chr16:72088622	HP	0.51	9.34	0.41	5.43e-19	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01516881	chr6:292596	DUSP22	-0.8	-14.01	-0.56	6.5e-37	Menopause (age at onset);
LUAD	cis	rs612683	0.602	rs12565245	chr1:101019326	T/G	cg06223162	chr1:101003688	GPR88	0.53	10.04	0.44	2.03e-21	Breast cancer;
LUAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03647317	chr4:187891568	NA	-0.35	-6.47	-0.3	2.75e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-9.41	-0.42	3.21e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg00495681	chr13:53174319	NA	0.47	8.55	0.38	2.19e-16	Lewy body disease;
LUAD	cis	rs2408955	0.522	rs7139330	chr12:48483484	A/C	cg04545296	chr12:48745243	ZNF641	-0.33	-8.55	-0.38	2.33e-16	Glycated hemoglobin levels;
LUAD	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg08470875	chr2:26401718	FAM59B	-0.62	-8.52	-0.38	2.89e-16	Gut microbiome composition (summer);
LUAD	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.31	-0.33	1.39e-12	Electroencephalogram traits;
LUAD	cis	rs113835537	0.529	rs75003264	chr11:66256099	G/A	cg26679405	chr11:66247800	DPP3	-0.47	-6.58	-0.3	1.41e-10	Airway imaging phenotypes;
LUAD	trans	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg21659725	chr3:3221576	CRBN	-0.49	-6.41	-0.3	3.95e-10	Menarche (age at onset);
LUAD	cis	rs28595532	1.000	rs114912871	chr4:119697004	G/C	cg21605333	chr4:119757512	SEC24D	0.83	7.78	0.35	5.59e-14	Cannabis dependence symptom count;
LUAD	cis	rs4604732	0.631	rs11490201	chr1:247626262	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs12579753	0.917	rs7313521	chr12:82205656	G/A	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.31	-0.34	1.32e-12	Resting heart rate;
LUAD	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg01765077	chr12:122356316	WDR66	0.54	9.35	0.41	5.13e-19	Mean corpuscular volume;
LUAD	cis	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg03315344	chr16:75512273	CHST6	0.61	13.35	0.54	3.5e-34	Dupuytren's disease;
LUAD	cis	rs10883723	0.641	rs80146619	chr10:104405850	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	6.92	0.32	1.73e-11	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg16988262	chr1:15930761	NA	0.41	6.85	0.32	2.61e-11	Systolic blood pressure;
LUAD	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.08	0.37	6.86e-15	Menopause (age at onset);
LUAD	cis	rs2282300	0.739	rs16920406	chr11:30216158	A/C	cg25418670	chr11:30344373	C11orf46	-0.49	-6.91	-0.32	1.81e-11	Morning vs. evening chronotype;
LUAD	cis	rs6076065	1.000	rs2424547	chr20:23392690	A/G	cg11657817	chr20:23433608	CST11	0.45	8.91	0.4	1.48e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg10518543	chr12:38710700	ALG10B	0.42	6.49	0.3	2.37e-10	Bladder cancer;
LUAD	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.57	-9.52	-0.42	1.32e-19	Menarche (age at onset);
LUAD	cis	rs2235649	0.833	rs2011088	chr16:1850091	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.47	-7.85	-0.36	3.57e-14	Blood metabolite levels;
LUAD	cis	rs73086581	0.787	rs73084505	chr20:3856874	C/T	cg02187196	chr20:3869020	PANK2	0.5	6.86	0.32	2.46e-11	Response to antidepressants in depression;
LUAD	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg24818145	chr4:99064322	C4orf37	-0.42	-6.96	-0.32	1.26e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.62	-0.58	1.83e-39	Schizophrenia;
LUAD	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg00049323	chr5:472564	LOC25845	0.44	7.41	0.34	6.88e-13	Cystic fibrosis severity;
LUAD	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	9.16	0.41	2.34e-18	Electrocardiographic conduction measures;
LUAD	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg20503657	chr10:835505	NA	0.65	9.04	0.4	5.68e-18	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg17366294	chr4:99064904	C4orf37	0.65	12.62	0.52	3.18e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg17330251	chr7:94953956	PON1	-0.52	-6.99	-0.32	1.05e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.26	6.66	0.31	8.73e-11	Parkinson's disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07614371	chr15:38746870	FAM98B	-0.43	-6.94	-0.32	1.46e-11	Cancer;
LUAD	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg26769984	chr7:1090371	C7orf50	0.64	9.06	0.4	4.9e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs11811982	0.793	rs116588679	chr1:227535745	C/T	cg24860534	chr1:227506868	CDC42BPA	0.71	7.52	0.34	3.35e-13	Optic disc area;
LUAD	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg19875535	chr5:140030758	IK	0.45	7.49	0.34	4.07e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg05373962	chr22:49881684	NA	-0.5	-10.08	-0.44	1.49e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg20203395	chr5:56204925	C5orf35	-0.49	-7.76	-0.35	6.35e-14	Coronary artery disease;
LUAD	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg18932078	chr1:2524107	MMEL1	0.38	7.06	0.32	6.67e-12	Ulcerative colitis;
LUAD	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.49	7.68	0.35	1.14e-13	Total body bone mineral density;
LUAD	cis	rs354225	0.544	rs28581481	chr2:54812372	T/G	cg01766943	chr2:54829624	SPTBN1	0.37	6.97	0.32	1.22e-11	Schizophrenia;
LUAD	cis	rs7119	0.700	rs2867311	chr15:77902191	A/C	cg27398640	chr15:77910606	LINGO1	0.43	8.52	0.38	2.74e-16	Type 2 diabetes;
LUAD	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.83	-0.36	4.1e-14	Total body bone mineral density;
LUAD	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg05754148	chr16:3507555	NAT15	-0.4	-6.74	-0.31	5.29e-11	Body mass index (adult);
LUAD	cis	rs7107174	0.901	rs901105	chr11:77924607	A/C	cg19901956	chr11:77921274	USP35	-0.54	-6.69	-0.31	7.08e-11	Testicular germ cell tumor;
LUAD	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg17480646	chr11:65405466	SIPA1	-0.46	-6.9	-0.32	1.86e-11	Acne (severe);
LUAD	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg00922110	chr4:57842668	C4orf14	-0.39	-6.64	-0.31	9.91e-11	Response to bleomycin (chromatid breaks);
LUAD	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-7.49	-0.34	4.04e-13	Lung cancer;
LUAD	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg15226275	chr6:116381976	FRK	0.23	7.14	0.33	4.12e-12	Cholesterol, total;LDL cholesterol;
LUAD	trans	rs6049375	1.000	rs6049375	chr20:24058407	A/G	cg15108490	chr11:36177699	LDLRAD3	-0.52	-6.38	-0.3	4.53e-10	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs12545109	1.000	rs1975284	chr8:57314663	A/G	cg17761419	chr8:57350749	NA	-0.53	-7.46	-0.34	5.08e-13	Obesity-related traits;
LUAD	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12667521	chr19:29218732	NA	0.65	8.17	0.37	3.69e-15	Methadone dose in opioid dependence;
LUAD	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg09509183	chr1:209979624	IRF6	0.39	6.96	0.32	1.29e-11	Monobrow;
LUAD	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.58	-0.35	2.2e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs11039798	0.764	rs7294013	chr11:48762416	G/A	cg03929089	chr4:120376271	NA	0.59	6.8	0.31	3.49e-11	Axial length;
LUAD	cis	rs6546550	0.935	rs13017134	chr2:70090579	C/G	cg02498382	chr2:70120550	SNRNP27	-0.55	-10.81	-0.47	3.18e-24	Prevalent atrial fibrillation;
LUAD	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.85e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3845702	0.736	rs12693214	chr2:180825685	G/A	cg01881094	chr2:180872142	CWC22	-0.8	-8.43	-0.38	5.33e-16	Schizophrenia;
LUAD	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg05434287	chr7:2030229	MAD1L1	0.38	6.38	0.3	4.63e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg12310025	chr6:25882481	NA	-0.58	-9.55	-0.42	1.1e-19	Blood metabolite levels;
LUAD	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg04450456	chr4:17643702	FAM184B	0.42	8.4	0.38	7.07e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs760805	0.932	rs1005734	chr1:25262022	C/A	cg22509179	chr1:25234806	RUNX3	-0.82	-15.13	-0.59	1.25e-41	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs8099014	1.000	rs4640266	chr18:56131865	T/G	cg12907477	chr18:56117327	MIR122	0.39	6.48	0.3	2.51e-10	Platelet count;
LUAD	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg06781209	chr11:61594997	FADS2	0.4	7.47	0.34	4.61e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg27144592	chr16:783916	NARFL	0.37	6.73	0.31	5.44e-11	Height;
LUAD	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	6.91	0.32	1.8e-11	Lung cancer in ever smokers;
LUAD	cis	rs2554380	0.943	rs2585040	chr15:84340468	G/C	cg14598478	chr15:84363061	ADAMTSL3	-0.58	-9.04	-0.4	5.81e-18	Height;
LUAD	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg19717773	chr7:2847554	GNA12	-0.5	-9.34	-0.41	5.4e-19	Height;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg16101703	chr5:65440440	SFRS12	-0.66	-6.42	-0.3	3.63e-10	Type 2 diabetes;
LUAD	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg25894440	chr7:65020034	NA	-0.59	-6.36	-0.3	5.16e-10	Diabetic kidney disease;
LUAD	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg09367891	chr1:107599246	PRMT6	0.51	8.67	0.39	9.3e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg02221422	chr11:68192511	LRP5	-0.42	-6.66	-0.31	8.78e-11	Total body bone mineral density;
LUAD	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-9.62	-0.42	5.96e-20	Obesity (extreme);
LUAD	trans	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg04775059	chr7:64541387	NA	0.5	6.72	0.31	5.9e-11	Aortic root size;
LUAD	cis	rs739496	0.602	rs79209359	chr12:111967161	A/T	cg10833066	chr12:111807467	FAM109A	0.41	6.55	0.3	1.68e-10	Platelet count;
LUAD	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg04455712	chr21:45112962	RRP1B	0.52	10.97	0.47	8.51e-25	Mean corpuscular volume;
LUAD	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00166722	chr3:10149974	C3orf24	0.67	8.87	0.4	2.09e-17	Alzheimer's disease;
LUAD	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg02018176	chr4:1364513	KIAA1530	-0.37	-6.99	-0.32	1.08e-11	Obesity-related traits;
LUAD	cis	rs10489202	0.612	rs3820401	chr1:168074753	T/C	cg24449463	chr1:168025552	DCAF6	-0.64	-10.28	-0.45	2.74e-22	Schizophrenia;
LUAD	cis	rs6541297	0.703	rs611701	chr1:230324173	C/T	cg20703242	chr1:230279135	GALNT2	-0.46	-6.97	-0.32	1.2e-11	Coronary artery disease;
LUAD	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg14196790	chr5:131705035	SLC22A5	0.47	8.51	0.38	3.08e-16	Blood metabolite levels;
LUAD	cis	rs9811920	0.809	rs6440967	chr3:99722396	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	12.22	0.51	1.26e-29	Axial length;
LUAD	cis	rs28374715	0.532	rs316607	chr15:41772693	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.1	-22.52	-0.74	2.15e-74	Ulcerative colitis;
LUAD	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.37	-7.88	-0.36	2.87e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.85	-0.36	3.48e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08280861	chr8:58055591	NA	0.63	8.2	0.37	2.89e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg12310025	chr6:25882481	NA	-0.43	-7.15	-0.33	3.89e-12	Height;
LUAD	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg14416269	chr4:6271139	WFS1	-0.63	-13.41	-0.55	1.97e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6740322	0.901	rs2163228	chr2:43549246	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-8.88	-0.4	1.87e-17	Coronary artery disease;
LUAD	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg11189052	chr15:85197271	WDR73	0.58	7.28	0.33	1.65e-12	Schizophrenia;
LUAD	cis	rs10189230	0.904	rs13029372	chr2:222348434	A/G	cg14652038	chr2:222343519	EPHA4	0.43	8.62	0.39	1.34e-16	Urate levels in lean individuals;
LUAD	cis	rs7216064	0.953	rs2086744	chr17:65849275	C/G	cg08758996	chr17:66097529	LOC651250	0.47	7.25	0.33	2.05e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs240764	0.658	rs4840155	chr6:101253942	G/T	cg09795085	chr6:101329169	ASCC3	-0.43	-7.59	-0.35	2.04e-13	Neuroticism;
LUAD	cis	rs877282	0.838	rs34778553	chr10:796865	T/C	cg17470449	chr10:769945	NA	0.63	9.37	0.41	4.25e-19	Uric acid levels;
LUAD	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17095355	0.818	rs11195006	chr10:111903306	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.64	-8.83	-0.39	2.74e-17	Biliary atresia;
LUAD	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg00898013	chr13:113819073	PROZ	-0.66	-11.33	-0.48	3.55e-26	Platelet distribution width;
LUAD	cis	rs977987	0.806	rs12917651	chr16:75466696	G/T	cg03315344	chr16:75512273	CHST6	0.65	14.15	0.57	1.72e-37	Dupuytren's disease;
LUAD	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	8.72	0.39	6.23e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg04455712	chr21:45112962	RRP1B	0.44	8.62	0.39	1.31e-16	Mean corpuscular volume;
LUAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg26516362	chr5:178986906	RUFY1	-0.58	-10.14	-0.44	8.96e-22	Lung cancer;
LUAD	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.21e-19	Life satisfaction;
LUAD	cis	rs11893307	0.509	rs11895262	chr2:191533862	C/T	cg11845111	chr2:191398756	TMEM194B	-0.48	-6.94	-0.32	1.51e-11	Mean platelet volume;
LUAD	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-7.08	-0.33	6.23e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg05925327	chr15:68127851	NA	-0.42	-6.36	-0.3	5.31e-10	Restless legs syndrome;
LUAD	cis	rs59104589	0.617	rs61615527	chr2:242342768	T/A	cg08645257	chr2:242211290	HDLBP	0.43	6.95	0.32	1.4e-11	Fibrinogen levels;
LUAD	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg25809561	chr17:30822961	MYO1D	-0.62	-11.69	-0.49	1.48e-27	Schizophrenia;
LUAD	cis	rs9346649	0.967	rs6920748	chr6:168490047	T/G	cg02770688	chr6:168491649	NA	-0.38	-7.5	-0.34	3.88e-13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs8017423	0.935	rs11628906	chr14:90738002	C/T	cg14092571	chr14:90743983	NA	0.44	7.4	0.34	7.49e-13	Mortality in heart failure;
LUAD	cis	rs89107	0.651	rs2356080	chr6:118609174	G/T	cg21191810	chr6:118973309	C6orf204	0.48	9.13	0.41	2.87e-18	Cardiac structure and function;
LUAD	cis	rs10979	0.931	rs9403509	chr6:143888691	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.3	-0.45	2.33e-22	Hypospadias;
LUAD	cis	rs921968	0.643	rs1850169	chr2:219487299	A/T	cg02176678	chr2:219576539	TTLL4	0.58	10.84	0.47	2.61e-24	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2835872	0.694	rs2835910	chr21:39085907	C/T	cg06728970	chr21:39037746	KCNJ6	-0.4	-6.67	-0.31	8.25e-11	Electroencephalographic traits in alcoholism;
LUAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg08027265	chr7:2291960	NA	0.39	6.9	0.32	1.93e-11	Schizophrenia;
LUAD	cis	rs684232	0.602	rs331014	chr17:532103	C/T	cg15660573	chr17:549704	VPS53	-0.88	-18.33	-0.67	1.14e-55	Prostate cancer;
LUAD	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg09873201	chr16:3507582	NAT15	0.53	7.93	0.36	1.96e-14	Tuberculosis;
LUAD	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18099408	chr3:52552593	STAB1	-0.46	-8.03	-0.36	9.79e-15	Bipolar disorder;
LUAD	cis	rs877282	0.685	rs56234340	chr10:781339	A/G	cg06581033	chr10:766294	NA	-0.52	-7.28	-0.33	1.59e-12	Uric acid levels;
LUAD	cis	rs6484504	0.652	rs674035	chr11:31399014	G/A	cg26647111	chr11:31128758	NA	0.44	7.65	0.35	1.35e-13	Red blood cell count;
LUAD	cis	rs877282	0.700	rs816311	chr10:796490	C/A	cg17470449	chr10:769945	NA	0.48	7.13	0.33	4.5e-12	Uric acid levels;
LUAD	cis	rs1395	0.922	rs11608	chr2:27435374	G/A	cg23587288	chr2:27483067	SLC30A3	0.38	7.83	0.36	3.86e-14	Blood metabolite levels;
LUAD	cis	rs6445967	0.530	rs62259332	chr3:58297874	C/T	cg23715586	chr3:58305044	RPP14	0.4	6.65	0.31	9.31e-11	Platelet count;
LUAD	cis	rs796364	0.577	rs7574287	chr2:200680999	C/T	cg23649088	chr2:200775458	C2orf69	0.52	6.49	0.3	2.4e-10	Schizophrenia;
LUAD	cis	rs7786877	1.000	rs7786877	chr7:100214015	A/G	cg16850897	chr7:100343110	ZAN	-0.56	-8.19	-0.37	3.08e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs3857536	0.741	rs4710582	chr6:66939984	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.98	-0.32	1.15e-11	Height;
LUAD	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-9.24	-0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	trans	rs7615952	0.688	rs4422259	chr3:125545831	C/T	cg07211511	chr3:129823064	LOC729375	-0.67	-9.68	-0.43	3.64e-20	Blood pressure (smoking interaction);
LUAD	cis	rs6867032	0.527	rs9312971	chr5:2012888	C/A	cg26168224	chr5:2018326	NA	0.51	10.54	0.46	3.09e-23	Gut microbiome composition (winter);
LUAD	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg23018236	chr17:30244563	NA	-0.67	-8.21	-0.37	2.74e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg14092988	chr3:52407081	DNAH1	0.37	7.48	0.34	4.47e-13	Bipolar disorder;
LUAD	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25427524	chr10:38739819	LOC399744	-0.79	-14.41	-0.57	1.42e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg18180107	chr4:99064573	C4orf37	0.43	6.94	0.32	1.51e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg10518543	chr12:38710700	ALG10B	0.45	7.61	0.35	1.81e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.04	0.32	7.78e-12	Menopause (age at onset);
LUAD	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.78	0.31	4.09e-11	Parkinson's disease;
LUAD	cis	rs887829	0.609	rs7597496	chr2:234630443	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-8.57	-0.38	1.99e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg14345882	chr6:26364793	BTN3A2	-0.65	-6.82	-0.31	3.15e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg11416102	chr8:651193	ERICH1	1.0	8.85	0.4	2.47e-17	IgG glycosylation;
LUAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg03188948	chr7:1209495	NA	0.81	9.79	0.43	1.52e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.7	-0.35	9.88e-14	Personality dimensions;
LUAD	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72928364	1.000	rs2576377	chr3:100647749	C/T	cg10123952	chr3:100791384	NA	-0.55	-6.71	-0.31	6.2e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg03411270	chr7:8301693	ICA1	-0.66	-6.54	-0.3	1.75e-10	Type 2 diabetes;
LUAD	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg19336497	chr11:14380999	RRAS2	-0.69	-16.34	-0.62	7.36e-47	Sense of smell;
LUAD	trans	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg01620082	chr3:125678407	NA	-0.84	-9.03	-0.4	5.97e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg25173405	chr17:45401733	C17orf57	-0.43	-6.96	-0.32	1.28e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs8013055	0.796	rs28662250	chr14:105996341	C/G	cg19700328	chr14:106028568	NA	-0.44	-7.29	-0.33	1.51e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs752010	0.756	rs943374	chr1:42056194	A/G	cg06885757	chr1:42089581	HIVEP3	0.4	8.63	0.39	1.25e-16	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs7937890	0.559	rs2575823	chr11:14521354	C/A	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.12e-10	Mitochondrial DNA levels;
LUAD	cis	rs1298062	0.790	rs1274604	chr19:50969325	A/G	cg11430371	chr19:50961752	MYBPC2	0.34	6.95	0.32	1.43e-11	Age of smoking initiation;
LUAD	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg06640241	chr16:89574553	SPG7	0.68	11.82	0.5	4.57e-28	Multiple myeloma (IgH translocation);
LUAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg05313129	chr8:58192883	C8orf71	-0.55	-7.15	-0.33	3.91e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg15591513	chr8:142139310	DENND3	0.35	6.41	0.3	3.98e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg06547715	chr2:218990976	CXCR2	0.43	10.34	0.45	1.65e-22	Ulcerative colitis;
LUAD	cis	rs7640424	0.620	rs71321252	chr3:107813107	A/C	cg09227934	chr3:107805635	CD47	-0.66	-10.47	-0.45	5.63e-23	Body mass index;
LUAD	cis	rs4372836	0.754	rs6709674	chr2:28989667	A/G	cg09522027	chr2:28974177	PPP1CB	-0.68	-12.46	-0.52	1.43e-30	Body mass index;
LUAD	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.37	6.54	0.3	1.75e-10	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg05340658	chr4:99064831	C4orf37	0.53	8.93	0.4	1.31e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-7.24	-0.33	2.09e-12	Personality dimensions;
LUAD	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg01849466	chr14:104193079	ZFYVE21	0.47	7.71	0.35	8.93e-14	Body mass index;
LUAD	trans	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg27411982	chr8:10470053	RP1L1	0.41	7.08	0.33	5.85e-12	Mood instability;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21986422	chr20:44519582	CTSA;NEURL2	-0.58	-6.97	-0.32	1.23e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9826463	0.646	rs11711434	chr3:142336362	G/A	cg20824294	chr3:142316082	PLS1	0.45	6.76	0.31	4.71e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13082711	0.519	rs13091109	chr3:27229125	G/A	cg02860705	chr3:27208620	NA	0.64	10.07	0.44	1.6e-21	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	trans	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg25482853	chr8:67687455	SGK3	0.96	15.77	0.61	2.15e-44	Ulcerative colitis;
LUAD	cis	rs73086581	1.000	rs17286349	chr20:3914302	G/A	cg02187196	chr20:3869020	PANK2	0.47	6.59	0.31	1.29e-10	Response to antidepressants in depression;
LUAD	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	9.78	0.43	1.68e-20	Total body bone mineral density;
LUAD	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg17366294	chr4:99064904	C4orf37	0.47	8.27	0.37	1.81e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10992471	0.603	rs7868013	chr9:95240173	G/A	cg14631576	chr9:95140430	CENPP	-0.56	-11.52	-0.49	7.08e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg09873201	chr16:3507582	NAT15	0.51	8.26	0.37	1.84e-15	Tuberculosis;
LUAD	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg07195577	chr17:27052828	TLCD1	-0.46	-6.55	-0.3	1.71e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs55665837	1.000	rs11023246	chr11:14536956	T/C	cg19336497	chr11:14380999	RRAS2	-0.5	-9.97	-0.44	3.71e-21	Vitamin D levels;
LUAD	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg18016565	chr1:150552671	MCL1	0.35	6.4	0.3	4.11e-10	Melanoma;
LUAD	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg24818145	chr4:99064322	C4orf37	0.47	7.99	0.36	1.29e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11640533	0.901	rs11862250	chr16:53415038	C/A	cg08681685	chr16:53407594	NA	0.45	7.77	0.35	5.9e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg14668632	chr7:2872130	GNA12	-0.69	-12.15	-0.51	2.33e-29	Height;
LUAD	cis	rs2274273	0.662	rs2094436	chr14:55661495	C/G	cg04306507	chr14:55594613	LGALS3	0.42	7.82	0.36	4.39e-14	Protein biomarker;
LUAD	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg12193833	chr17:30244370	NA	-0.59	-6.85	-0.32	2.67e-11	Hip circumference adjusted for BMI;
LUAD	trans	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg21659725	chr3:3221576	CRBN	0.5	8.14	0.37	4.6e-15	Body mass index;
LUAD	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg13393036	chr8:95962371	TP53INP1	-0.43	-10.54	-0.46	3.22e-23	Type 2 diabetes;
LUAD	cis	rs7593730	1.000	rs4632293	chr2:161176379	T/C	cg22609984	chr2:161126801	NA	0.44	6.94	0.32	1.51e-11	Type 2 diabetes;
LUAD	cis	rs454510	0.726	rs376910	chr1:120181277	A/C	cg16322792	chr1:120165303	ZNF697	-0.34	-6.48	-0.3	2.6e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg23985595	chr17:80112537	CCDC57	0.53	9.65	0.42	4.6e-20	Life satisfaction;
LUAD	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg10876282	chr6:28092338	ZSCAN16	0.48	7.47	0.34	4.78e-13	Cardiac Troponin-T levels;
LUAD	cis	rs4006360	0.635	rs1848811	chr17:39235963	A/G	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.06	0.36	8.16e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs1547374	1.000	rs1547374	chr21:43778895	C/T	cg09521743	chr10:75415752	SYNPO2L	0.38	6.39	0.3	4.48e-10	Pancreatic cancer;
LUAD	cis	rs7822232	0.908	rs4977164	chr8:145144912	T/G	cg07195118	chr8:145162905	KIAA1875	-0.67	-6.38	-0.3	4.62e-10	Blood metabolite levels;
LUAD	cis	rs2274273	0.967	rs2094102	chr14:55591098	T/C	cg04306507	chr14:55594613	LGALS3	0.36	7.64	0.35	1.51e-13	Protein biomarker;
LUAD	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg14416269	chr4:6271139	WFS1	0.63	13.2	0.54	1.44e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2617583	0.509	rs2937650	chr5:1458018	C/T	cg13982541	chr5:1466431	LPCAT1	-0.6	-9.67	-0.43	4.02e-20	Breast cancer;
LUAD	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg26597838	chr10:835615	NA	0.83	11.28	0.48	5.7e-26	Eosinophil percentage of granulocytes;
LUAD	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg03213289	chr20:61660250	NA	0.69	14.76	0.58	4.6e-40	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg00666640	chr1:248458726	OR2T12	0.3	7.24	0.33	2.14e-12	Common traits (Other);
LUAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg08677398	chr8:58056175	NA	0.43	6.58	0.3	1.42e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.17	0.33	3.34e-12	Motion sickness;
LUAD	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg25024717	chr12:54324583	NA	-0.32	-7.06	-0.32	6.98e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUAD	cis	rs12620999	0.941	rs4663701	chr2:238036884	C/T	cg23555395	chr2:238036564	NA	-0.62	-9.61	-0.42	6.34e-20	Systemic lupus erythematosus;
LUAD	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg19774624	chr17:42201019	HDAC5	-0.38	-6.47	-0.3	2.78e-10	Total body bone mineral density;
LUAD	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg01475377	chr6:109611718	NA	-0.55	-10.61	-0.46	1.71e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs977987	0.843	rs60730309	chr16:75431769	C/G	cg03315344	chr16:75512273	CHST6	0.63	13.81	0.56	4.4e-36	Dupuytren's disease;
LUAD	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg09222892	chr1:25734099	RHCE	-0.46	-8.5	-0.38	3.3e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg07776626	chr8:57350775	NA	-0.65	-9.37	-0.41	4.37e-19	Obesity-related traits;
LUAD	cis	rs4638749	0.677	rs10185601	chr2:108828278	A/G	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.38	-0.34	8.2e-13	Blood pressure;
LUAD	cis	rs72928364	1.000	rs34275644	chr3:100658065	G/A	cg10123952	chr3:100791384	NA	0.65	7.37	0.34	8.86e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-10.98	-0.47	7.26e-25	Hemoglobin concentration;
LUAD	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21028142	chr17:79581711	NPLOC4	-0.44	-9.59	-0.42	7.71e-20	Eye color traits;
LUAD	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg04772025	chr11:68637568	NA	0.55	8.73	0.39	5.88e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg18016565	chr1:150552671	MCL1	0.38	6.56	0.3	1.59e-10	Melanoma;
LUAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg11062466	chr8:58055876	NA	0.82	10.04	0.44	2.11e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg04287289	chr16:89883240	FANCA	0.71	13.11	0.54	3.58e-33	Vitiligo;
LUAD	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg11663144	chr21:46675770	NA	-0.51	-9.36	-0.41	4.86e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg11822812	chr5:140052017	DND1	-0.44	-8.2	-0.37	2.85e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg02527881	chr3:46936655	PTH1R	-0.48	-9.37	-0.41	4.29e-19	Colorectal cancer;
LUAD	cis	rs11030122	0.702	rs10835340	chr11:3960420	A/G	cg18678763	chr11:4115507	RRM1	0.43	7.17	0.33	3.39e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.43	0.38	5.49e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7809950	0.678	rs77395658	chr7:107000651	G/A	cg23024343	chr7:107201750	COG5	-0.82	-13.91	-0.56	1.7e-36	Coronary artery disease;
LUAD	cis	rs6840360	0.615	rs6535822	chr4:152679722	A/G	cg22705602	chr4:152727874	NA	-0.47	-8.99	-0.4	8.15e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs524023	1.000	rs11602903	chr11:64358241	A/T	cg19131476	chr11:64387923	NRXN2	-0.36	-6.91	-0.32	1.8e-11	Urate levels in obese individuals;
LUAD	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg24801067	chr17:62843696	NA	0.53	8.4	0.38	6.98e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg00484396	chr16:3507460	NAT15	0.72	13.02	0.53	7.76e-33	Tuberculosis;
LUAD	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg08645402	chr16:4508243	NA	0.54	9.68	0.43	3.68e-20	Schizophrenia;
LUAD	cis	rs1595825	0.891	rs73058867	chr2:198891568	A/G	cg11031976	chr2:198649780	BOLL	-0.45	-6.56	-0.3	1.62e-10	Ulcerative colitis;
LUAD	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg14345882	chr6:26364793	BTN3A2	0.7	7.1	0.33	5.18e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg21775007	chr8:11205619	TDH	0.54	9.34	0.41	5.55e-19	Retinal vascular caliber;
LUAD	cis	rs6537837	0.701	rs17595368	chr1:110154390	C/T	cg05049280	chr1:110155535	GNAT2	0.57	7.03	0.32	8.57e-12	Major depressive disorder;
LUAD	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg03806693	chr22:41940476	POLR3H	-0.44	-6.66	-0.31	8.47e-11	Neuroticism;
LUAD	cis	rs55823223	0.648	rs66584478	chr17:73870203	G/A	cg08125733	chr17:73851984	WBP2	0.58	8.45	0.38	4.72e-16	Psoriasis;
LUAD	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.54	8.26	0.37	1.88e-15	Birth weight;
LUAD	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg26513180	chr16:89883248	FANCA	0.78	6.72	0.31	5.84e-11	Skin colour saturation;
LUAD	cis	rs807669	0.548	rs885978	chr22:19198226	A/G	cg24911827	chr22:19170109	CLTCL1	0.33	6.94	0.32	1.49e-11	Metabolite levels;
LUAD	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs8038465	0.592	rs1542580	chr15:73935834	C/G	cg15420318	chr15:73925796	NPTN	0.49	8.27	0.37	1.75e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12618769	0.597	rs2278212	chr2:99136266	T/C	cg10123293	chr2:99228465	UNC50	0.47	8.47	0.38	4.2e-16	Bipolar disorder;
LUAD	cis	rs41311933	1.000	rs16910254	chr9:123751661	A/G	cg13567360	chr9:123745713	C5	-0.79	-8.95	-0.4	1.1e-17	Coronary artery disease;
LUAD	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg03433033	chr1:76189801	ACADM	-0.64	-9.71	-0.43	2.97e-20	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6076065	0.644	rs1056394	chr20:23337422	G/A	cg11657817	chr20:23433608	CST11	0.5	9.47	0.42	2.02e-19	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg18854424	chr1:2615690	NA	-0.42	-9.07	-0.4	4.56e-18	Ulcerative colitis;
LUAD	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg00852783	chr1:26633632	UBXN11	0.42	7.4	0.34	7.52e-13	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.6	0.52	3.99e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg09117114	chr16:67998030	SLC12A4	-0.48	-6.82	-0.31	3.06e-11	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
LUAD	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07930192	chr7:1003750	NA	0.39	7.51	0.34	3.51e-13	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08219700	chr8:58056026	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7975161	0.640	rs4477504	chr12:104710465	T/C	cg25273343	chr12:104657179	TXNRD1	-0.6	-7.16	-0.33	3.58e-12	Toenail selenium levels;
LUAD	cis	rs1882538	0.503	rs13240997	chr7:133135373	C/A	cg10665199	chr7:133106180	EXOC4	0.59	9.83	0.43	1.13e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg02869364	chr7:1081709	C7orf50	-0.49	-6.37	-0.3	5.04e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7582720	0.943	rs72932560	chr2:203847417	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.64	0.42	5.27e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg11845111	chr2:191398756	TMEM194B	-0.58	-7.57	-0.35	2.39e-13	Diastolic blood pressure;
LUAD	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.51	-0.34	3.45e-13	Resting heart rate;
LUAD	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg06784218	chr1:46089804	CCDC17	-0.54	-11.8	-0.5	5.62e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05611199	chr16:88637223	ZC3H18	-0.54	-6.77	-0.31	4.32e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3018712	0.522	rs4930593	chr11:68434181	A/C	cg16797656	chr11:68205561	LRP5	-0.34	-6.37	-0.3	4.99e-10	Total body bone mineral density;
LUAD	cis	rs889398	0.510	rs11646575	chr16:69567781	G/A	cg26679644	chr16:69762563	NA	0.47	8.85	0.4	2.5e-17	Body mass index;
LUAD	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg17509989	chr5:176798049	RGS14	0.58	10.16	0.44	7.43e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs56283067	0.887	rs62437968	chr6:44729495	G/A	cg20913747	chr6:44695427	NA	-0.43	-7.17	-0.33	3.35e-12	Total body bone mineral density;
LUAD	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.58	9.49	0.42	1.74e-19	Menarche (age at onset);
LUAD	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06112835	chr11:68658793	MRPL21	0.51	9.25	0.41	1.12e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.2	-38.3	-0.88	1.42e-139	Myeloid white cell count;
LUAD	cis	rs6427508	1	rs6427508	chr1:160238857	T/C	cg02974968	chr1:160236444	NA	-0.54	-9.9	-0.43	6.55e-21	Breast size;
LUAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07167872	chr1:205819463	PM20D1	0.76	15.32	0.6	1.79e-42	Menarche (age at onset);
LUAD	cis	rs4604732	0.527	rs77361748	chr1:247626475	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2996428	0.561	rs2275827	chr1:3746585	T/G	cg17848003	chr1:3704513	LRRC47	0.48	9.69	0.43	3.36e-20	Red cell distribution width;
LUAD	cis	rs6988985	0.594	rs12543598	chr8:143955318	T/G	cg10324643	chr8:143916377	GML	0.31	6.52	0.3	2.04e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg02807482	chr3:125708958	NA	-0.66	-8.54	-0.38	2.43e-16	Blood pressure (smoking interaction);
LUAD	trans	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.0	-0.4	7.63e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg06784218	chr1:46089804	CCDC17	0.6	13.4	0.55	2.3e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs75804782	0.630	rs74404946	chr2:239300772	C/G	cg01134436	chr17:81009848	B3GNTL1	0.77	6.82	0.31	3.19e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg23982607	chr1:1823379	GNB1	-0.92	-19.39	-0.69	2.27e-60	Body mass index;
LUAD	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.16	-0.33	3.72e-12	Total body bone mineral density;
LUAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg10819733	chr22:24237672	NA	-0.39	-7.42	-0.34	6.58e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-7.01	-0.32	9.73e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg20503657	chr10:835505	NA	0.82	11.16	0.48	1.6e-25	Eosinophil percentage of granulocytes;
LUAD	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg18252515	chr7:66147081	NA	-0.59	-6.54	-0.3	1.8e-10	Diabetic kidney disease;
LUAD	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg03433033	chr1:76189801	ACADM	-0.47	-6.85	-0.32	2.61e-11	Daytime sleep phenotypes;
LUAD	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg16850897	chr7:100343110	ZAN	0.43	7.63	0.35	1.55e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg23533926	chr12:111358616	MYL2	-0.42	-7.31	-0.33	1.39e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs477692	0.792	rs12762024	chr10:131441055	G/C	cg05714579	chr10:131428358	MGMT	-0.43	-7.04	-0.32	7.75e-12	Response to temozolomide;
LUAD	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg11822812	chr5:140052017	DND1	0.38	6.84	0.32	2.78e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg05896524	chr21:47604654	C21orf56	0.63	10.82	0.47	2.9e-24	Testicular germ cell tumor;
LUAD	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg10755058	chr3:40428713	ENTPD3	0.39	7.32	0.34	1.27e-12	Renal cell carcinoma;
LUAD	cis	rs10905065	0.965	rs10795541	chr10:5811954	A/G	cg11519256	chr10:5708881	ASB13	-0.4	-6.63	-0.31	1.05e-10	Menopause (age at onset);
LUAD	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.52	0.6	2.57e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs16958440	0.867	rs2117373	chr18:44671834	C/T	cg17192377	chr18:44677553	HDHD2	0.67	6.74	0.31	5.07e-11	Sitting height ratio;
LUAD	cis	rs654950	0.806	rs1815257	chr1:42041479	A/C	cg06885757	chr1:42089581	HIVEP3	-0.5	-11.31	-0.48	4.4e-26	Airway imaging phenotypes;
LUAD	cis	rs2012796	0.785	rs61986593	chr14:81840659	G/A	cg02996355	chr14:81879375	NA	0.55	8.34	0.38	1.03e-15	Night sleep phenotypes;
LUAD	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg14092988	chr3:52407081	DNAH1	0.37	7.46	0.34	5.06e-13	Electroencephalogram traits;
LUAD	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-8.56	-0.38	2.17e-16	Neutrophil percentage of white cells;
LUAD	cis	rs12541635	0.966	rs12544362	chr8:106976344	A/C	cg10147462	chr8:107024639	NA	0.47	8.17	0.37	3.58e-15	Age of smoking initiation;
LUAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg13560548	chr3:10150139	C3orf24	0.45	7.66	0.35	1.27e-13	Alzheimer's disease;
LUAD	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs1594829	0.553	rs17055108	chr8:26160739	G/A	cg13160058	chr8:26243215	BNIP3L	-0.34	-7.45	-0.34	5.21e-13	Height;
LUAD	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg27068330	chr11:65405492	SIPA1	-0.75	-11.29	-0.48	5.29e-26	Acne (severe);
LUAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg21237687	chr17:6899380	ALOX12	0.38	7.1	0.33	5.33e-12	Tonsillectomy;
LUAD	cis	rs3849570	0.533	rs6809792	chr3:81990084	C/T	cg07356753	chr3:81810745	GBE1	-0.5	-8.34	-0.38	1.05e-15	Waist circumference;Body mass index;
LUAD	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg19875535	chr5:140030758	IK	-0.46	-7.61	-0.35	1.84e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6500596	0.570	rs8055628	chr16:4447477	G/A	cg08645402	chr16:4508243	NA	0.47	7.57	0.35	2.35e-13	Schizophrenia;
LUAD	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg21770322	chr7:97807741	LMTK2	0.33	7.47	0.34	4.65e-13	Breast cancer;
LUAD	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg27432699	chr2:27873401	GPN1	-0.38	-6.44	-0.3	3.21e-10	Total body bone mineral density;
LUAD	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg13057898	chr1:3703894	LRRC47	0.62	10.22	0.45	4.63e-22	Red cell distribution width;
LUAD	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21659725	chr3:3221576	CRBN	-0.62	-10.71	-0.46	7.74e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg17299007	chr1:248814626	OR2T27	0.28	6.37	0.3	4.91e-10	Common traits (Other);
LUAD	cis	rs12579753	0.917	rs4842410	chr12:82219225	A/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.37	-0.34	9.09e-13	Resting heart rate;
LUAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg22907277	chr7:1156413	C7orf50	0.66	8.3	0.37	1.38e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg02176678	chr2:219576539	TTLL4	0.68	13.54	0.55	6.08e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg14458575	chr2:238380390	NA	0.73	14.39	0.57	1.75e-38	Prostate cancer;
LUAD	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg26587870	chr6:27730563	NA	-0.69	-7.01	-0.32	9.17e-12	Depression;
LUAD	cis	rs1003719	0.679	rs2835674	chr21:38581522	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.26	-0.37	1.9e-15	Eye color traits;
LUAD	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.17	0.33	3.34e-12	Motion sickness;
LUAD	cis	rs7617773	0.817	rs34728236	chr3:48259108	A/G	cg11946769	chr3:48343235	NME6	0.41	6.35	0.3	5.52e-10	Coronary artery disease;
LUAD	cis	rs775227	0.574	rs34286076	chr3:113269695	G/C	cg10517650	chr3:113235015	CCDC52	-0.48	-6.8	-0.31	3.61e-11	Dental caries;
LUAD	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg15921436	chr17:44337874	NA	-0.72	-9.48	-0.42	1.82e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2274273	0.840	rs10467798	chr14:55724927	C/T	cg04306507	chr14:55594613	LGALS3	0.4	8.48	0.38	3.88e-16	Protein biomarker;
LUAD	cis	rs8044868	0.586	rs8182213	chr16:72080005	C/T	cg23815491	chr16:72088622	HP	0.53	9.68	0.43	3.7799999999999997e-20	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg17173187	chr15:85201210	NMB	0.41	6.52	0.3	2e-10	Schizophrenia;
LUAD	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg26384229	chr12:38710491	ALG10B	0.4	6.37	0.3	4.82e-10	Morning vs. evening chronotype;
LUAD	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg18131467	chr2:239335373	ASB1	0.58	9.23	0.41	1.34e-18	Multiple system atrophy;
LUAD	cis	rs17739167	0.550	rs17687976	chr15:42234824	A/G	cg20935245	chr15:42234343	EHD4	-0.44	-7.68	-0.35	1.13e-13	Monocyte count;
LUAD	cis	rs6445967	0.569	rs62259314	chr3:58284189	G/A	cg13750441	chr3:58318267	PXK	-0.3	-6.44	-0.3	3.31e-10	Platelet count;
LUAD	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg02176678	chr2:219576539	TTLL4	-0.83	-17.39	-0.65	1.79e-51	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.24	0.37	2.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg03216991	chr17:2415620	METT10D	-0.46	-7.55	-0.34	2.77e-13	Schizophrenia;
LUAD	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-9.24	-0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg23649088	chr2:200775458	C2orf69	0.59	8.32	0.37	1.26e-15	Schizophrenia;
LUAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18099408	chr3:52552593	STAB1	-0.52	-9.52	-0.42	1.38e-19	Electroencephalogram traits;
LUAD	cis	rs4629710	0.563	rs9483238	chr6:131567196	A/T	cg12606694	chr6:131520996	AKAP7	0.5	7.27	0.33	1.7e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs2712431	0.554	rs2010054	chr3:128305302	A/G	cg16766828	chr3:128327626	NA	-0.38	-6.92	-0.32	1.73e-11	Monocyte chemoattractant protein-1 levels;
LUAD	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg23231163	chr10:75533350	FUT11	-0.54	-10.19	-0.44	6.17e-22	Inflammatory bowel disease;
LUAD	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg10356904	chr22:49881777	NA	-0.4	-7.47	-0.34	4.58e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg26338869	chr17:61819248	STRADA	-0.39	-6.58	-0.3	1.37e-10	Prudent dietary pattern;
LUAD	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg22907277	chr7:1156413	C7orf50	0.68	7.97	0.36	1.52e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg00310523	chr12:86230176	RASSF9	0.41	8.01	0.36	1.16e-14	Major depressive disorder;
LUAD	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-8.57	-0.38	1.99e-16	Total body bone mineral density;
LUAD	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.46	-0.45	6.09e-23	Total body bone mineral density;
LUAD	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.69	0.39	7.74e-17	Menopause (age at onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05000123	chr14:20937394	PNP	-0.4	-6.47	-0.3	2.68e-10	Height;
LUAD	cis	rs12900413	0.562	rs12898229	chr15:90295960	C/T	cg24249390	chr15:90295951	MESP1	-0.33	-6.63	-0.31	1.03e-10	Coronary artery aneurysm in Kawasaki disease;
LUAD	trans	rs343496	0.877	rs340924	chr9:6088525	T/C	cg16665231	chr1:245741199	KIF26B	-0.41	-6.35	-0.3	5.44e-10	Asthma and hay fever;
LUAD	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg09904177	chr6:26538194	HMGN4	0.44	7.4	0.34	7.22e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.75	-12.69	-0.53	1.69e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18876405	chr7:65276391	NA	0.62	10.91	0.47	1.33e-24	Calcium levels;
LUAD	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-9.19	-0.41	1.83e-18	Gut microbiome composition (summer);
LUAD	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg19912559	chr1:40204330	PPIE	0.57	9.66	0.43	4.34e-20	Blood protein levels;
LUAD	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-23.48	-0.75	1.17e-78	Height;
LUAD	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg03714773	chr7:91764589	CYP51A1	0.27	6.41	0.3	3.9e-10	Breast cancer;
LUAD	cis	rs68170813	0.641	rs12539895	chr7:107091849	C/A	cg02696742	chr7:106810147	HBP1	-0.79	-10.51	-0.45	4.19e-23	Coronary artery disease;
LUAD	cis	rs73058052	0.597	rs10404887	chr19:50096421	C/G	cg21913888	chr19:50084626	PRRG2;NOSIP	0.33	8.58	0.38	1.88e-16	Fibrinogen levels;
LUAD	cis	rs1997103	0.906	rs2177806	chr7:55402609	A/T	cg17469321	chr7:55412551	NA	0.67	11.39	0.48	2.05e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg08798685	chr6:27730294	NA	-0.4	-6.46	-0.3	2.83e-10	Parkinson's disease;
LUAD	trans	rs9348721	0.562	rs9393716	chr6:26376868	A/G	cg06606381	chr12:133084897	FBRSL1	-0.58	-6.68	-0.31	7.35e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6438504	0.883	rs1584398	chr3:118967571	A/T	cg25372693	chr3:118959985	B4GALT4	0.34	6.37	0.3	5.07e-10	Clozapine-induced cytotoxicity;
LUAD	cis	rs62229266	0.740	rs2835233	chr21:37393582	A/G	cg12218747	chr21:37451666	NA	-0.47	-8.1	-0.37	5.89e-15	Mitral valve prolapse;
LUAD	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.1	0.44	1.3e-21	Ileal carcinoids;
LUAD	trans	rs11184708	0.509	rs78632804	chr1:106255014	T/C	cg06936704	chr20:37009829	NA	0.64	6.36	0.3	5.38e-10	Waist-to-hip circumference ratio (ever vs never smoking interaction);
LUAD	cis	rs10203711	1.000	rs907102	chr2:239564503	G/A	cg14580085	chr2:239553406	NA	0.41	8.63	0.39	1.26e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs953387	1.000	rs12616955	chr2:136902666	C/T	cg05194412	chr2:137003533	NA	-0.4	-6.58	-0.3	1.43e-10	Arthritis (juvenile idiopathic);
LUAD	cis	rs13082711	0.554	rs7635958	chr3:27385616	A/C	cg02860705	chr3:27208620	NA	0.72	10.9	0.47	1.5e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs727505	1.000	rs28523990	chr7:124436139	C/T	cg23710748	chr7:124431027	NA	-0.45	-8.93	-0.4	1.33e-17	Lewy body disease;
LUAD	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg25358565	chr5:93447407	FAM172A	0.63	7.75	0.35	6.78e-14	Diabetic retinopathy;
LUAD	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg04414720	chr1:150670196	GOLPH3L	0.72	13.36	0.54	3.28e-34	Tonsillectomy;
LUAD	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg06784218	chr1:46089804	CCDC17	0.35	7.53	0.34	3.09e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs500891	0.525	rs6940284	chr6:84063926	T/G	cg08257003	chr6:84140564	ME1	0.34	6.72	0.31	6.03e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg21100191	chr22:23484243	RTDR1	0.68	11.54	0.49	5.58e-27	Bone mineral density;
LUAD	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg24399712	chr22:39784796	NA	0.82	16.63	0.63	3.91e-48	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17042849	chr6:26104293	HIST1H4C	-0.65	-8.48	-0.38	3.7e-16	Iron status biomarkers;
LUAD	cis	rs938554	0.876	rs6823324	chr4:9932359	T/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.14	-0.37	4.41e-15	Blood metabolite levels;
LUAD	cis	rs6541297	0.703	rs677990	chr1:230320428	G/A	cg20703242	chr1:230279135	GALNT2	-0.45	-6.83	-0.32	3.02e-11	Coronary artery disease;
LUAD	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg09796270	chr17:17721594	SREBF1	-0.36	-6.82	-0.31	3.25e-11	Total body bone mineral density;
LUAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg02869364	chr7:1081709	C7orf50	-0.5	-6.43	-0.3	3.45e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	cis	rs6445967	1.000	rs7640866	chr3:58288362	A/G	cg23715586	chr3:58305044	RPP14	0.42	7.59	0.35	2.06e-13	Platelet count;
LUAD	cis	rs2996428	0.561	rs2275827	chr1:3746585	T/G	cg13057898	chr1:3703894	LRRC47	0.56	9.66	0.43	4.46e-20	Red cell distribution width;
LUAD	trans	rs7395662	1.000	rs11039821	chr11:48562875	T/C	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.81e-10	HDL cholesterol;
LUAD	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.6	-8.6	-0.39	1.57e-16	Gut microbiome composition (summer);
LUAD	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg00290607	chr11:67383545	NA	0.4	6.63	0.31	1.06e-10	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg05340658	chr4:99064831	C4orf37	0.54	9.19	0.41	1.83e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	0.893	rs10788763	chr1:248429070	A/T	cg00666640	chr1:248458726	OR2T12	-0.29	-7.59	-0.35	2e-13	Common traits (Other);
LUAD	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.47	-6.45	-0.3	3.15e-10	Gut microbiome composition (summer);
LUAD	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg02160872	chr5:212506	CCDC127	-0.51	-6.61	-0.31	1.16e-10	Breast cancer;
LUAD	cis	rs2204008	0.694	rs11179394	chr12:38210389	A/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.59	-0.3	1.34e-10	Bladder cancer;
LUAD	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg14835575	chr10:16859367	RSU1	0.97	13.31	0.54	5.2e-34	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg15181151	chr6:150070149	PCMT1	0.38	7.27	0.33	1.78e-12	Lung cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06596743	chr16:77228577	MON1B	0.52	6.35	0.3	5.51e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11958404	0.932	rs72816592	chr5:157435246	A/G	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10802521	chr3:52805072	NEK4	-0.63	-11.16	-0.48	1.65e-25	Bipolar disorder;
LUAD	cis	rs2625529	0.730	rs8182011	chr15:72389948	C/T	cg16672083	chr15:72433130	SENP8	0.69	12.36	0.52	3.54e-30	Red blood cell count;
LUAD	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-7.66	-0.35	1.25e-13	Total cholesterol levels;
LUAD	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg11344533	chr11:111475393	SIK2	0.35	6.55	0.3	1.67e-10	Primary sclerosing cholangitis;
LUAD	cis	rs2235649	0.833	rs9925460	chr16:1849943	C/T	cg08610935	chr16:1836813	NUBP2	-0.45	-6.86	-0.32	2.45e-11	Blood metabolite levels;
LUAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg08027265	chr7:2291960	NA	-0.4	-6.73	-0.31	5.38e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg23254163	chr1:152506842	NA	0.25	7.07	0.33	6.24e-12	Hair morphology;
LUAD	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg18827107	chr12:86230957	RASSF9	-0.68	-12.38	-0.52	3.01e-30	Major depressive disorder;
LUAD	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.39	-0.34	7.8e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2455799	0.613	rs2470538	chr3:15717124	G/C	cg16303742	chr3:15540471	COLQ	-0.5	-9.19	-0.41	1.81e-18	Mean platelet volume;
LUAD	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg23018236	chr17:30244563	NA	0.62	7.79	0.35	5.19e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs17532515	0.628	rs2321272	chr4:141465244	T/C	cg09181644	chr4:141490428	UCP1	-0.32	-7.17	-0.33	3.48e-12	Select biomarker traits;
LUAD	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-13.35	-0.54	3.72e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg14530993	chr4:882597	GAK	0.79	7.92	0.36	2.17e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg01181863	chr3:195395398	SDHAP2	-0.62	-9.43	-0.42	2.78e-19	Pancreatic cancer;
LUAD	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg25237894	chr2:233734115	C2orf82	-0.62	-11.75	-0.5	9.06e-28	Coronary artery disease;
LUAD	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.55	-0.3	1.71e-10	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg03929089	chr4:120376271	NA	-0.64	-8.82	-0.39	3.11e-17	Coronary artery disease;
LUAD	cis	rs1062746	0.683	rs891094	chr16:87378001	C/G	cg02258303	chr16:87377426	FBXO31	0.44	7.57	0.35	2.3e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-8.01	-0.36	1.09e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6738485	0.531	rs72819612	chr2:106846316	T/C	cg00318621	chr2:106887213	NA	-0.54	-7.56	-0.34	2.58e-13	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22515636	chr2:109150313	NA	-0.4	-6.41	-0.3	3.92e-10	Height;
LUAD	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg04398451	chr17:18023971	MYO15A	-0.93	-19.25	-0.68	8.72e-60	Total body bone mineral density;
LUAD	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg06108461	chr20:60628389	TAF4	-0.94	-16.8	-0.63	6.65e-49	Body mass index;
LUAD	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg04398451	chr17:18023971	MYO15A	-0.75	-13.77	-0.56	6.79e-36	Total body bone mineral density;
LUAD	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg07432352	chr17:45403706	C17orf57	-0.4	-7.87	-0.36	3.05e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg18512352	chr11:47633146	NA	-0.5	-8.84	-0.39	2.61e-17	Subjective well-being;
LUAD	cis	rs11048434	0.736	rs7957321	chr12:9120154	C/T	cg23795048	chr12:9217529	LOC144571	0.41	7.51	0.34	3.61e-13	Sjögren's syndrome;
LUAD	cis	rs6906287	0.647	rs6569013	chr6:118681328	G/T	cg18833306	chr6:118973337	C6orf204	-0.55	-9.97	-0.44	3.57e-21	Electrocardiographic conduction measures;
LUAD	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg09137382	chr11:130731461	NA	0.41	7.46	0.34	5e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg15242686	chr22:24348715	GSTTP1	0.47	8.04	0.36	9.14e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs438465	0.947	rs400607	chr6:169808409	C/T	cg11181693	chr6:169825345	NA	-0.65	-8.12	-0.37	5.02e-15	Corneal astigmatism;
LUAD	cis	rs11828289	0.660	rs75816907	chr11:23175126	G/A	cg20040320	chr11:23191996	NA	-0.7	-8.04	-0.36	9.16e-15	Cancer;
LUAD	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg11859384	chr17:80120422	CCDC57	0.49	8.88	0.4	1.97e-17	Life satisfaction;
LUAD	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7177699	0.526	rs7166764	chr15:79123509	T/G	cg15571903	chr15:79123663	NA	0.42	8.82	0.39	3e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21659725	chr3:3221576	CRBN	0.67	11.44	0.49	1.33e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg26924012	chr15:45694286	SPATA5L1	1.03	19.3	0.68	5.41e-60	Homoarginine levels;
LUAD	cis	rs8013055	0.796	rs4075105	chr14:106000231	C/T	cg19700328	chr14:106028568	NA	-0.45	-7.66	-0.35	1.27e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg25173405	chr17:45401733	C17orf57	-0.64	-10.84	-0.47	2.6e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg06627628	chr2:24431161	ITSN2	-0.5	-6.36	-0.3	5.15e-10	Lymphocyte counts;
LUAD	cis	rs7809950	1.000	rs7809950	chr7:107237807	T/C	cg23024343	chr7:107201750	COG5	0.77	12.51	0.52	9.09e-31	Coronary artery disease;
LUAD	cis	rs7680126	0.632	rs6834645	chr4:10150174	G/A	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.33	-0.34	1.14e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg21775007	chr8:11205619	TDH	-0.52	-9.38	-0.42	4.01e-19	Retinal vascular caliber;
LUAD	cis	rs11622475	0.677	rs7145372	chr14:104359121	A/G	cg12183467	chr14:104352244	NA	0.56	10.77	0.46	4.59e-24	Bipolar disorder;
LUAD	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg09455208	chr3:40491958	NA	0.54	11.98	0.5	1.1e-28	Renal cell carcinoma;
LUAD	trans	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg08071915	chr8:12219732	FAM66A	0.43	7.19	0.33	3.03e-12	Joint mobility (Beighton score);
LUAD	cis	rs7274811	0.711	rs291698	chr20:31982250	A/T	cg13403462	chr20:32256071	NECAB3;C20orf134	0.43	6.62	0.31	1.09e-10	Height;
LUAD	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg05084668	chr3:125655381	ALG1L	-0.43	-6.4	-0.3	4.03e-10	Blood pressure (smoking interaction);
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg01738168	chr15:59397053	CCNB2	0.37	6.41	0.3	4e-10	Bipolar disorder;
LUAD	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01570182	chr17:44337453	NA	-0.88	-12.76	-0.53	9.17e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg06623918	chr6:96969491	KIAA0776	-0.78	-13.84	-0.56	3.42e-36	Headache;
LUAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg13732083	chr21:47605072	C21orf56	0.42	6.98	0.32	1.11e-11	Testicular germ cell tumor;
LUAD	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg27124370	chr19:33622961	WDR88	0.43	6.92	0.32	1.67e-11	Bone properties (heel);
LUAD	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.63	-10.58	-0.46	2.33e-23	Glomerular filtration rate;
LUAD	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg27411982	chr8:10470053	RP1L1	0.38	6.88	0.32	2.15e-11	Retinal vascular caliber;
LUAD	cis	rs62400317	0.859	rs11964844	chr6:45258823	T/A	cg18551225	chr6:44695536	NA	-0.53	-8.4	-0.38	7.09e-16	Total body bone mineral density;
LUAD	cis	rs7903847	0.642	rs7092499	chr10:99140313	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-7.23	-0.33	2.32e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg06766960	chr11:133703094	NA	-0.44	-8.25	-0.37	2.1e-15	Childhood ear infection;
LUAD	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	9.52	0.42	1.34e-19	Lung cancer in ever smokers;
LUAD	cis	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg07460842	chr6:66804631	NA	0.61	9.62	0.42	5.93e-20	Type 2 diabetes;
LUAD	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg12311346	chr5:56204834	C5orf35	-0.95	-13.92	-0.56	1.56e-36	Initial pursuit acceleration;
LUAD	trans	rs1959947	0.585	rs8008487	chr14:41534471	A/C	cg27514286	chr3:183892688	AP2M1	0.37	6.53	0.3	1.91e-10	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg07167872	chr1:205819463	PM20D1	0.72	14.48	0.58	7.33e-39	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	1.000	rs35531458	chr7:107249855	G/A	cg02696742	chr7:106810147	HBP1	-0.5	-6.66	-0.31	8.32e-11	Coronary artery disease;
LUAD	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg02221750	chr19:17393354	ANKLE1	-0.74	-11.72	-0.5	1.16e-27	Systemic lupus erythematosus;
LUAD	cis	rs929596	0.785	rs6714634	chr2:234664765	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.73	12.52	0.52	8.52e-31	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs4372836	0.504	rs12714249	chr2:29055916	G/A	cg09522027	chr2:28974177	PPP1CB	-0.6	-10.73	-0.46	6.45e-24	Body mass index;
LUAD	cis	rs2735413	0.837	rs4888734	chr16:78083685	C/G	cg04733911	chr16:78082701	NA	-0.34	-8.17	-0.37	3.53e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg09455208	chr3:40491958	NA	0.63	13.85	0.56	3.24e-36	Renal cell carcinoma;
LUAD	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg25208724	chr1:156163844	SLC25A44	0.98	15.49	0.6	3.55e-43	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg17366294	chr4:99064904	C4orf37	0.64	12.43	0.52	1.89e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg11502198	chr6:26597334	ABT1	0.55	9.09	0.4	3.73e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg16479474	chr6:28041457	NA	0.48	8.22	0.37	2.46e-15	Depression;
LUAD	cis	rs3617	0.599	rs12487379	chr3:52895785	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-7.18	-0.33	3.06e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs629535	0.859	rs55803226	chr8:70108965	T/C	cg21567404	chr3:27674614	NA	-0.93	-16.61	-0.63	4.63e-48	Dupuytren's disease;
LUAD	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.35	-8.95	-0.4	1.1e-17	Total body bone mineral density;
LUAD	cis	rs7520050	0.751	rs2991975	chr1:46024526	A/G	cg06784218	chr1:46089804	CCDC17	-0.36	-7.65	-0.35	1.34e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.89	0.53	2.56e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg17747265	chr1:1875780	NA	-0.77	-19.21	-0.68	1.35e-59	Body mass index;
LUAD	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg12573674	chr2:1569213	NA	-0.59	-8.65	-0.39	1.1e-16	IgG glycosylation;
LUAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg19626725	chr5:178986131	RUFY1	0.44	7.89	0.36	2.63e-14	Lung cancer;
LUAD	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg05340658	chr4:99064831	C4orf37	0.53	9.05	0.4	5.17e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs612683	0.599	rs2809823	chr1:101003762	C/A	cg06223162	chr1:101003688	GPR88	0.55	11.53	0.49	6.14e-27	Breast cancer;
LUAD	cis	rs2839627	0.638	rs60342559	chr21:44310051	T/C	cg03543861	chr21:44258195	NA	0.67	8.08	0.37	6.96e-15	Information processing speed;
LUAD	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03264133	chr6:25882463	NA	-0.56	-8.02	-0.36	1.03e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22968622	chr17:43663579	NA	1.14	19.14	0.68	2.78e-59	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03264133	chr6:25882463	NA	-0.46	-7.0	-0.32	1.01e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9581857	0.579	rs76578450	chr13:27982656	C/A	cg22138327	chr13:27999177	GTF3A	0.99	11.59	0.49	3.81e-27	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg21782813	chr7:2030301	MAD1L1	0.58	10.04	0.44	2.07e-21	Bipolar disorder and schizophrenia;
LUAD	trans	rs7246760	1.000	rs68176351	chr19:9864222	G/A	cg02900749	chr2:68251473	NA	-0.64	-7.04	-0.32	7.78e-12	Pursuit maintenance gain;
LUAD	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg12179176	chr11:130786555	SNX19	0.54	9.0	0.4	7.49e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7017914	0.967	rs34042354	chr8:71730961	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.53	-0.3	1.93e-10	Bone mineral density;
LUAD	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg21918786	chr6:109611834	NA	0.56	10.26	0.45	3.45e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.39	-6.73	-0.31	5.7e-11	Rheumatoid arthritis;
LUAD	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg11266682	chr4:10021025	SLC2A9	0.69	15.75	0.61	2.65e-44	Bone mineral density;
LUAD	cis	rs9473147	0.747	rs9395288	chr6:47598125	C/T	cg02130027	chr6:47444894	CD2AP	0.35	6.4	0.3	4.21e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg25324976	chr17:61989376	CSHL1	0.37	7.17	0.33	3.32e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6516091	0.850	rs62199232	chr20:6050137	T/G	cg25325723	chr20:6104886	FERMT1	-0.59	-6.68	-0.31	7.54e-11	Abdominal aortic aneurysm;
LUAD	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg08999081	chr20:33150536	PIGU	0.54	11.44	0.49	1.38e-26	Coronary artery disease;
LUAD	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg23978390	chr7:1156363	C7orf50	0.57	7.78	0.35	5.62e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	7.03	0.32	8.27e-12	Tonsillectomy;
LUAD	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg00277334	chr10:82204260	NA	-0.62	-8.56	-0.38	2.16e-16	Post bronchodilator FEV1;
LUAD	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg01579765	chr21:45077557	HSF2BP	-0.65	-15.06	-0.59	2.52e-41	Mean corpuscular volume;
LUAD	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg07636037	chr3:49044803	WDR6	0.58	9.36	0.41	4.81e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg15605315	chr1:45957053	TESK2	0.47	7.37	0.34	9.24e-13	High light scatter reticulocyte count;
LUAD	cis	rs68170813	0.559	rs10953536	chr7:107021691	G/A	cg02696742	chr7:106810147	HBP1	-0.76	-10.14	-0.44	8.83e-22	Coronary artery disease;
LUAD	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.69	-0.35	1.03e-13	Personality dimensions;
LUAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg03188948	chr7:1209495	NA	0.42	6.81	0.31	3.36e-11	Longevity;Endometriosis;
LUAD	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-11.29	-0.48	5.27e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs35883536	0.528	rs1542837	chr1:101029768	T/C	cg09408571	chr1:101003634	GPR88	0.34	6.87	0.32	2.32e-11	Monocyte count;
LUAD	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg21220214	chr8:57350948	NA	-0.6	-8.89	-0.4	1.8e-17	Obesity-related traits;
LUAD	cis	rs7107174	0.579	rs10793299	chr11:78018954	T/A	cg19901956	chr11:77921274	USP35	-0.53	-6.45	-0.3	3.15e-10	Testicular germ cell tumor;
LUAD	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.67	-11.17	-0.48	1.4e-25	Urate levels;
LUAD	cis	rs2230307	0.518	rs12046458	chr1:100703069	C/T	cg20868668	chr1:100435035	SLC35A3	-0.49	-6.99	-0.32	1.05e-11	Carotid intima media thickness;
LUAD	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg06641503	chr3:48959341	ARIH2	-0.36	-7.25	-0.33	2.02e-12	Menarche (age at onset);
LUAD	cis	rs10465746	0.657	rs67045520	chr1:84414998	G/T	cg10977910	chr1:84465055	TTLL7	0.54	8.78	0.39	4e-17	Obesity-related traits;
LUAD	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg10523679	chr1:76189770	ACADM	0.8	12.23	0.51	1.21e-29	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg00666640	chr1:248458726	OR2T12	0.34	8.19	0.37	3.11e-15	Common traits (Other);
LUAD	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg13119609	chr19:45449297	APOC2	0.61	13.18	0.54	1.78e-33	Blood protein levels;
LUAD	trans	rs853679	0.546	rs34546986	chr6:28362309	G/A	cg06606381	chr12:133084897	FBRSL1	-1.24	-10.7	-0.46	8.18e-24	Depression;
LUAD	cis	rs4321325	0.733	rs4284779	chr2:127946500	T/C	cg11380483	chr2:127933992	NA	0.47	6.52	0.3	1.99e-10	Protein C levels;
LUAD	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.12	-0.33	4.65e-12	Blood metabolite levels;
LUAD	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03517284	chr6:25882590	NA	-0.53	-7.98	-0.36	1.39e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7274811	0.554	rs35556109	chr20:32133489	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.51	-7.36	-0.34	9.74e-13	Height;
LUAD	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg27411982	chr8:10470053	RP1L1	0.4	7.12	0.33	4.54e-12	Retinal vascular caliber;
LUAD	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg25173405	chr17:45401733	C17orf57	-0.46	-7.61	-0.35	1.75e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs701145	0.938	rs355776	chr3:154035626	A/T	cg17054900	chr3:154042577	DHX36	0.66	7.32	0.34	1.29e-12	Coronary artery disease;
LUAD	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg14458575	chr2:238380390	NA	0.65	12.23	0.51	1.13e-29	Prostate cancer;
LUAD	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg06636001	chr8:8085503	FLJ10661	0.44	7.07	0.33	6.45e-12	Mood instability;
LUAD	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg10802521	chr3:52805072	NEK4	-0.47	-7.63	-0.35	1.53e-13	Bipolar disorder;
LUAD	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg03714773	chr7:91764589	CYP51A1	0.27	6.36	0.3	5.23e-10	Breast cancer;
LUAD	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg09324608	chr17:30823087	MYO1D	0.45	8.4	0.38	7.02e-16	Schizophrenia;
LUAD	cis	rs6087771	0.781	rs6089067	chr20:30358894	G/C	cg21427119	chr20:30132790	HM13	-0.36	-6.46	-0.3	2.92e-10	Subcortical brain region volumes;Putamen volume;
LUAD	cis	rs1953600	0.870	rs2245168	chr10:81921918	T/C	cg00277334	chr10:82204260	NA	-0.41	-6.94	-0.32	1.45e-11	Sarcoidosis;
LUAD	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg25730555	chr22:47059586	GRAMD4	0.38	6.36	0.3	5.28e-10	Urate levels in obese individuals;
LUAD	cis	rs877282	0.945	rs10904556	chr10:789429	A/G	cg17470449	chr10:769945	NA	0.61	8.57	0.38	2.01e-16	Uric acid levels;
LUAD	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg20108693	chr8:143823809	SLURP1	0.33	7.61	0.35	1.78e-13	Urinary tract infection frequency;
LUAD	cis	rs727505	1.000	rs28622327	chr7:124526213	C/T	cg23710748	chr7:124431027	NA	-0.47	-9.57	-0.42	8.81e-20	Lewy body disease;
LUAD	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg12483005	chr1:23474871	LUZP1	0.53	9.2	0.41	1.63e-18	Height;
LUAD	cis	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg26679405	chr11:66247800	DPP3	0.51	7.21	0.33	2.67e-12	Airway imaging phenotypes;
LUAD	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.82	-0.36	4.36e-14	Total body bone mineral density;
LUAD	cis	rs9309473	0.583	rs35885918	chr2:73612234	T/C	cg20560298	chr2:73613845	ALMS1	-0.42	-6.53	-0.3	1.91e-10	Metabolite levels;
LUAD	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.75	16.42	0.62	3.08e-47	White blood cell count;
LUAD	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg01528321	chr10:82214614	TSPAN14	0.64	10.06	0.44	1.71e-21	Post bronchodilator FEV1;
LUAD	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg12935359	chr14:103987150	CKB	-0.49	-7.99	-0.36	1.28e-14	Body mass index;
LUAD	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg06808227	chr14:105710500	BRF1	-0.41	-6.43	-0.3	3.42e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9322817	0.583	rs9391226	chr6:105158405	T/C	cg02098413	chr6:105308735	HACE1	-0.38	-7.91	-0.36	2.29e-14	Thyroid stimulating hormone;
LUAD	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg06108461	chr20:60628389	TAF4	-1.12	-20.54	-0.71	1.59e-65	Body mass index;
LUAD	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg01689657	chr7:91764605	CYP51A1	-0.37	-9.19	-0.41	1.73e-18	Breast cancer;
LUAD	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg12863693	chr15:85201151	NMB	-0.43	-8.03	-0.36	9.78e-15	Schizophrenia;
LUAD	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	5e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2425143	1.000	rs11699793	chr20:34271574	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.26	-0.33	1.92e-12	Blood protein levels;
LUAD	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg25894440	chr7:65020034	NA	-0.62	-6.69	-0.31	7.13e-11	Diabetic kidney disease;
LUAD	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg24634471	chr8:143751801	JRK	0.48	7.84	0.36	3.79e-14	Schizophrenia;
LUAD	cis	rs943466	0.911	rs111352628	chr6:33742490	A/G	cg16010596	chr6:33739607	LEMD2	-0.41	-7.84	-0.36	3.77e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs62064224	0.589	rs6505295	chr17:30687522	G/C	cg25809561	chr17:30822961	MYO1D	0.47	8.6	0.39	1.56e-16	Schizophrenia;
LUAD	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.06	-0.4	4.88e-18	Bipolar disorder;
LUAD	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg16006841	chr5:176797999	RGS14	0.76	14.1	0.57	2.72e-37	Urinary electrolytes (magnesium/calcium ratio);
LUAD	cis	rs7223966	0.810	rs2665838	chr17:61966465	C/G	cg25324976	chr17:61989376	CSHL1	0.35	6.59	0.31	1.32e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4664304	0.966	rs3792198	chr2:160760338	G/A	cg23995753	chr2:160760732	LY75	-0.47	-8.36	-0.38	9.04e-16	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg05234568	chr11:5960015	NA	-0.51	-9.03	-0.4	5.94e-18	DNA methylation (variation);
LUAD	cis	rs9905704	0.633	rs757484	chr17:56457097	C/G	cg19466818	chr17:56409534	MIR142	0.35	6.94	0.32	1.48e-11	Testicular germ cell tumor;
LUAD	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg17147758	chr8:6949321	NA	-0.48	-8.49	-0.38	3.5e-16	Blood pressure (smoking interaction);
LUAD	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-7.76	-0.35	6.51e-14	Fear of minor pain;
LUAD	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.81	0.53	5.5e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg05754148	chr16:3507555	NAT15	0.66	11.46	0.49	1.11e-26	Tuberculosis;
LUAD	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg09184832	chr6:79620586	NA	-0.51	-9.68	-0.43	3.84e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs4953318	0.619	rs10183887	chr2:46361808	T/A	cg12428440	chr2:46370979	PRKCE	0.42	6.7	0.31	6.7e-11	Red blood cell count;Hematocrit;Red blood cell traits;
LUAD	cis	rs7584330	0.554	rs74003110	chr2:238448188	C/T	cg14458575	chr2:238380390	NA	0.55	8.35	0.38	9.55e-16	Prostate cancer;
LUAD	trans	rs853679	0.607	rs72846794	chr6:28137499	G/A	cg06606381	chr12:133084897	FBRSL1	-1.22	-10.86	-0.47	2.15e-24	Depression;
LUAD	cis	rs2625529	0.816	rs8025504	chr15:72294757	C/T	cg16672083	chr15:72433130	SENP8	-0.76	-12.72	-0.53	1.25e-31	Red blood cell count;
LUAD	cis	rs11771526	0.892	rs11764802	chr7:32372978	C/T	cg13207630	chr7:32358064	NA	0.68	7.68	0.35	1.11e-13	Body mass index;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13248847	chr17:7137857	DVL2	-0.55	-6.69	-0.31	7.04e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg22906224	chr7:99728672	NA	0.6	10.34	0.45	1.72e-22	Coronary artery disease;
LUAD	cis	rs2455601	1.000	rs72632952	chr11:8917976	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-8.32	-0.38	1.22e-15	Schizophrenia;
LUAD	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg04703951	chr17:43578652	NA	-0.43	-7.04	-0.32	8.03e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4481887	0.676	rs946764	chr1:248522033	A/C	cg00666640	chr1:248458726	OR2T12	0.29	7.2	0.33	2.69e-12	Common traits (Other);
LUAD	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg03806693	chr22:41940476	POLR3H	-0.46	-6.9	-0.32	1.85e-11	Neuroticism;
LUAD	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg19717773	chr7:2847554	GNA12	-0.49	-8.41	-0.38	6.42e-16	Height;
LUAD	cis	rs6906287	0.647	rs13217710	chr6:118843601	A/G	cg18833306	chr6:118973337	C6orf204	0.46	8.12	0.37	5.19e-15	Electrocardiographic conduction measures;
LUAD	cis	rs138055607	1	rs138055607	chr10:75450901	C/G	cg02286717	chr10:75415704	SYNPO2L	-0.42	-7.32	-0.34	1.27e-12	Initial pursuit acceleration;
LUAD	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg23711669	chr6:146136114	FBXO30	0.39	6.65	0.31	9.17e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7843479	0.601	rs10109521	chr8:21829948	G/A	cg03445287	chr8:21823731	XPO7	-0.49	-9.2	-0.41	1.6e-18	Mean corpuscular volume;
LUAD	cis	rs72928364	0.860	rs13085839	chr3:100797234	G/A	cg10123952	chr3:100791384	NA	0.66	7.65	0.35	1.41e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg05373962	chr22:49881684	NA	-0.54	-11.88	-0.5	2.67e-28	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2274273	0.710	rs67395212	chr14:55591939	T/A	cg04306507	chr14:55594613	LGALS3	0.4	7.44	0.34	5.59e-13	Protein biomarker;
LUAD	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg05368731	chr17:41323189	NBR1	0.98	20.49	0.71	2.59e-65	Menopause (age at onset);
LUAD	cis	rs6908034	0.607	rs76525593	chr6:19809170	G/T	cg02682789	chr6:19804855	NA	0.9	8.96	0.4	1.03e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg20607798	chr8:58055168	NA	0.58	7.54	0.34	2.94e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg13334819	chr7:99746414	C7orf59	-0.67	-10.35	-0.45	1.58e-22	Coronary artery disease;
LUAD	cis	rs3096299	0.838	rs3102376	chr16:89402473	A/C	cg06640241	chr16:89574553	SPG7	0.43	6.93	0.32	1.54e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs9394841	0.646	rs9471676	chr6:41815192	C/T	cg17623882	chr6:41773611	USP49	-0.53	-7.3	-0.33	1.48e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.05	-0.32	7.32e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.84	-0.32	2.81e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9314323	0.964	rs2304300	chr8:26249018	G/A	cg13160058	chr8:26243215	BNIP3L	-0.47	-9.88	-0.43	7.29e-21	Red cell distribution width;
LUAD	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg17063962	chr7:91808500	NA	0.68	12.19	0.51	1.64e-29	Breast cancer;
LUAD	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg14343924	chr8:8086146	FLJ10661	0.43	6.66	0.31	8.72e-11	Mood instability;
LUAD	trans	rs877282	0.898	rs35743076	chr10:758991	C/T	cg22713356	chr15:30763199	NA	1.24	16.5	0.63	1.36e-47	Uric acid levels;
LUAD	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg25358565	chr5:93447407	FAM172A	0.6	7.02	0.32	9.01e-12	Diabetic retinopathy;
LUAD	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg15448220	chr1:150897856	SETDB1	0.56	9.58	0.42	8.12e-20	Melanoma;
LUAD	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg06175025	chr14:78082992	SPTLC2	-0.4	-6.35	-0.3	5.66e-10	Bone mineral density;
LUAD	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.15	0.33	3.76e-12	Parkinson's disease;
LUAD	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg05313129	chr8:58192883	C8orf71	-0.5	-7.57	-0.35	2.42e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg06558623	chr16:89946397	TCF25	1.12	9.85	0.43	9.8e-21	Skin colour saturation;
LUAD	trans	rs2288327	0.643	rs16866334	chr2:179336672	A/G	cg14011486	chr1:26737247	LIN28	0.56	7.92	0.36	2.05e-14	Atrial fibrillation;
LUAD	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.82e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg15147215	chr3:52552868	STAB1	-0.4	-7.24	-0.33	2.2e-12	Bipolar disorder;
LUAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg08888203	chr3:10149979	C3orf24	0.73	11.17	0.48	1.44e-25	Alzheimer's disease;
LUAD	cis	rs7937890	0.598	rs10734225	chr11:14442994	C/G	cg06199346	chr11:14280333	SPON1	-0.35	-6.58	-0.3	1.43e-10	Mitochondrial DNA levels;
LUAD	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg12365402	chr11:9010492	NRIP3	-0.39	-6.86	-0.32	2.44e-11	Hematocrit;
LUAD	cis	rs75920871	0.925	rs4938333	chr11:116930888	A/G	cg04087571	chr11:116723030	SIK3	-0.33	-6.7	-0.31	6.56e-11	Subjective well-being;
LUAD	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.81	-0.31	3.45e-11	Diabetic kidney disease;
LUAD	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.54	-7.83	-0.36	4.06e-14	IgG glycosylation;
LUAD	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg11494091	chr17:61959527	GH2	0.4	7.04	0.32	7.9e-12	Height;
LUAD	cis	rs220324	0.954	rs467589	chr21:43582763	C/T	cg08841829	chr21:43638893	ABCG1	0.41	6.55	0.3	1.72e-10	Idiopathic osteonecrosis of the femoral head;
LUAD	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21582582	chr3:182698605	DCUN1D1	0.59	10.06	0.44	1.77e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs7254114	0.578	rs6511727	chr19:11315817	G/T	cg02815516	chr19:11306319	KANK2	-0.3	-6.4	-0.3	4.03e-10	Immature fraction of reticulocytes;
LUAD	cis	rs13064411	0.696	rs2399479	chr3:113227050	G/A	cg10517650	chr3:113235015	CCDC52	-0.56	-9.45	-0.42	2.29e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg20826792	chr1:29425	WASH5P	0.4	6.8	0.31	3.55e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg11833968	chr6:79620685	NA	-0.43	-8.01	-0.36	1.1e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs11039798	0.841	rs11039760	chr11:48479009	C/T	cg03929089	chr4:120376271	NA	0.65	6.6	0.31	1.21e-10	Axial length;
LUAD	cis	rs9394841	0.692	rs2395795	chr6:41802354	G/A	cg17623882	chr6:41773611	USP49	-0.49	-6.86	-0.32	2.45e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs11756438	0.572	rs2638545	chr6:119000203	G/C	cg21191810	chr6:118973309	C6orf204	0.5	9.59	0.42	7.66e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg25358565	chr5:93447407	FAM172A	0.61	7.12	0.33	4.79e-12	Diabetic retinopathy;
LUAD	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg25554036	chr4:6271136	WFS1	0.67	13.35	0.54	3.63e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg11416102	chr8:651193	ERICH1	0.69	6.84	0.32	2.76e-11	IgG glycosylation;
LUAD	cis	rs989128	0.600	rs2240218	chr17:48630580	A/T	cg24438145	chr17:48624694	SPATA20	0.38	6.58	0.3	1.37e-10	Type 2 diabetes;
LUAD	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg05044414	chr3:183734942	ABCC5	0.39	7.99	0.36	1.28e-14	Anterior chamber depth;
LUAD	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg10523679	chr1:76189770	ACADM	0.95	18.66	0.67	4.06e-57	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg27539214	chr16:67997921	SLC12A4	-0.68	-8.44	-0.38	5.2e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7771547	0.573	rs547026	chr6:36398616	G/A	cg07856975	chr6:36356162	ETV7	0.47	7.31	0.33	1.38e-12	Platelet distribution width;
LUAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg16414030	chr3:133502952	NA	0.65	12.69	0.53	1.67e-31	Iron status biomarkers;
LUAD	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg02423579	chr7:2872169	GNA12	-0.89	-15.75	-0.61	2.72e-44	Height;
LUAD	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.39	-0.34	7.96e-13	Blood metabolite levels;
LUAD	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg23950597	chr19:37808831	NA	-0.64	-7.57	-0.35	2.35e-13	Coronary artery calcification;
LUAD	cis	rs8067287	0.749	rs62065427	chr17:16831560	C/T	cg26910001	chr17:16838321	NA	-0.49	-6.8	-0.31	3.6e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg25811766	chr13:21894605	NA	-0.62	-7.54	-0.34	2.91e-13	White matter hyperintensity burden;
LUAD	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.6	0.52	4.03e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg04944784	chr2:26401820	FAM59B	0.73	9.39	0.42	3.75e-19	Gut microbiome composition (summer);
LUAD	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg02493740	chr2:85810744	VAMP5	0.64	12.28	0.51	7.17e-30	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	trans	rs79911532	0.515	rs79859948	chr7:75679099	A/G	cg19862616	chr7:65841803	NCRNA00174	0.84	8.66	0.39	9.81e-17	Mononucleosis;
LUAD	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-13.72	-0.55	1.07e-35	Chronic sinus infection;
LUAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg04025307	chr7:1156635	C7orf50	0.65	7.34	0.34	1.12e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.78	0.31	4.15e-11	Cardiac Troponin-T levels;
LUAD	trans	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg01620082	chr3:125678407	NA	-0.46	-7.02	-0.32	8.71e-12	Parkinson's disease;
LUAD	cis	rs7107174	1.000	rs11602622	chr11:78010830	A/G	cg19901956	chr11:77921274	USP35	-0.51	-6.46	-0.3	2.9e-10	Testicular germ cell tumor;
LUAD	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg23029597	chr12:123009494	RSRC2	-0.54	-8.2	-0.37	2.98e-15	Body mass index;
LUAD	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	7.97	0.36	1.51e-14	Breast cancer;
LUAD	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-6.53	-0.3	1.84e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7301826	0.651	rs10848206	chr12:131281471	G/C	cg11011512	chr12:131303247	STX2	0.43	7.14	0.33	4.07e-12	Plasma plasminogen activator levels;
LUAD	cis	rs4964805	0.626	rs4964827	chr12:104177081	G/T	cg02344784	chr12:104178138	NT5DC3	0.38	6.53	0.3	1.87e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs59104589	0.521	rs62190414	chr2:242424687	A/G	cg08645257	chr2:242211290	HDLBP	0.39	6.52	0.3	2.06e-10	Fibrinogen levels;
LUAD	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg01448562	chr3:133502909	NA	-0.69	-12.43	-0.52	1.94e-30	Iron status biomarkers;
LUAD	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg00647820	chr17:40259828	DHX58	-0.44	-7.11	-0.33	4.85e-12	Fibrinogen levels;
LUAD	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.85	0.32	2.67e-11	Motion sickness;
LUAD	cis	rs2274273	0.624	rs10146637	chr14:55744810	G/A	cg04306507	chr14:55594613	LGALS3	0.4	7.74	0.35	7.26e-14	Protein biomarker;
LUAD	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg21475434	chr5:93447410	FAM172A	-0.47	-6.53	-0.3	1.84e-10	Diabetic retinopathy;
LUAD	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg06558623	chr16:89946397	TCF25	0.69	7.88	0.36	2.83e-14	Skin colour saturation;
LUAD	cis	rs735539	0.521	rs574139	chr13:21425816	T/G	cg27499820	chr13:21296301	IL17D	0.44	7.29	0.33	1.5e-12	Dental caries;
LUAD	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg10755058	chr3:40428713	ENTPD3	0.38	7.01	0.32	9.48e-12	Renal cell carcinoma;
LUAD	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg14008862	chr17:28927542	LRRC37B2	0.78	7.49	0.34	3.98e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg17200465	chr3:40428508	ENTPD3	0.28	7.27	0.33	1.79e-12	Renal cell carcinoma;
LUAD	cis	rs9469913	0.740	rs2744937	chr6:34557246	C/T	cg14254433	chr6:34482411	PACSIN1	-0.43	-6.59	-0.3	1.34e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.44	-6.8	-0.31	3.48e-11	Breast cancer;
LUAD	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg06784218	chr1:46089804	CCDC17	0.51	11.29	0.48	5.17e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-10.06	-0.44	1.66e-21	Schizophrenia;
LUAD	cis	rs28595532	0.623	rs56324414	chr4:119274655	A/C	cg02775129	chr4:119771670	NA	-0.61	-6.63	-0.31	1.03e-10	Cannabis dependence symptom count;
LUAD	cis	rs11048434	0.761	rs12824380	chr12:9132017	A/G	cg04155231	chr12:9217510	LOC144571	0.42	7.94	0.36	1.85e-14	Sjögren's syndrome;
LUAD	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.62e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg27432699	chr2:27873401	GPN1	-0.4	-6.86	-0.32	2.41e-11	Total body bone mineral density;
LUAD	trans	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg06437703	chr8:37914619	EIF4EBP1	-0.73	-14.14	-0.57	1.86e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg14411612	chr14:23567027	C14orf119	-0.38	-6.37	-0.3	4.86e-10	Response to antipsychotic treatment;
LUAD	trans	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.66	-11.04	-0.47	4.65e-25	Mean corpuscular volume;
LUAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08677398	chr8:58056175	NA	0.46	6.54	0.3	1.76e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg03733263	chr8:22462867	KIAA1967	0.73	12.53	0.52	7.72e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg02887458	chr19:19495540	GATAD2A	-0.43	-6.98	-0.32	1.16e-11	Bipolar disorder;
LUAD	cis	rs877282	0.755	rs2486578	chr10:785227	C/T	cg17470449	chr10:769945	NA	-0.44	-7.15	-0.33	3.96e-12	Uric acid levels;
LUAD	cis	rs10992471	0.603	rs747628	chr9:95289532	A/T	cg14631576	chr9:95140430	CENPP	-0.5	-10.17	-0.44	6.83e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg13010199	chr12:38710504	ALG10B	0.39	6.47	0.3	2.71e-10	Bladder cancer;
LUAD	cis	rs6489882	0.807	rs61266553	chr12:113371977	A/G	cg20102336	chr12:113376681	OAS3	-0.6	-9.42	-0.42	3.07e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.74	10.31	0.45	2.21e-22	Smoking behavior;
LUAD	trans	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg06606381	chr12:133084897	FBRSL1	-0.96	-9.1	-0.4	3.45e-18	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg04025307	chr7:1156635	C7orf50	-0.57	-8.4	-0.38	6.72e-16	Bronchopulmonary dysplasia;
LUAD	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg03340356	chr1:67600835	NA	0.43	7.45	0.34	5.42e-13	Psoriasis;
LUAD	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg24069376	chr3:38537580	EXOG	-0.33	-7.47	-0.34	4.69e-13	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg02569458	chr12:86230093	RASSF9	0.45	8.15	0.37	4.3e-15	Major depressive disorder;
LUAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg04234412	chr22:24373322	LOC391322	-0.8	-14.21	-0.57	9.29e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs873917	0.620	rs784595	chr1:40135017	C/T	cg06209491	chr1:40138402	NT5C1A	-0.5	-7.8	-0.35	5.02e-14	Amyotrophic lateral sclerosis;
LUAD	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg12623302	chr6:28058802	ZSCAN12L1	0.3	6.39	0.3	4.49e-10	Cardiac Troponin-T levels;
LUAD	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg17366294	chr4:99064904	C4orf37	0.62	11.5	0.49	8.03e-27	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg25025879	chr12:53359317	NA	-0.69	-12.66	-0.52	2.33e-31	Prostate cancer;
LUAD	cis	rs9560113	0.550	rs1163632	chr13:112231530	T/C	cg10483660	chr13:112241077	NA	-0.47	-9.9	-0.43	6.42e-21	Menarche (age at onset);
LUAD	cis	rs4852324	0.536	rs71418714	chr2:74219886	G/C	cg20891558	chr2:74357851	NA	0.85	7.89	0.36	2.57e-14	Systemic lupus erythematosus;
LUAD	cis	rs7192380	1.000	rs11647110	chr16:69589363	G/A	cg00738113	chr16:70207722	CLEC18C	-0.33	-6.58	-0.3	1.42e-10	Sjögren's syndrome;
LUAD	cis	rs12545109	0.800	rs1837620	chr8:57399473	C/A	cg17761419	chr8:57350749	NA	-0.56	-8.35	-0.38	1.02e-15	Obesity-related traits;
LUAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg09491104	chr22:46646882	C22orf40	-0.61	-8.13	-0.37	4.75e-15	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2224391	0.628	rs9405261	chr6:5249702	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-8.78	-0.39	4.05e-17	Height;
LUAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg04025307	chr7:1156635	C7orf50	0.75	13.56	0.55	5e-35	Longevity;Endometriosis;
LUAD	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg01868782	chr6:126071099	HEY2	0.31	6.51	0.3	2.12e-10	Brugada syndrome;
LUAD	cis	rs60154123	0.730	rs10863818	chr1:210458007	C/T	cg22029157	chr1:209979665	IRF6	0.56	6.59	0.31	1.3e-10	Coronary artery disease;
LUAD	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.04e-13	Morning vs. evening chronotype;
LUAD	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg23435118	chr5:141488016	NDFIP1	-0.48	-7.32	-0.34	1.28e-12	Crohn's disease;
LUAD	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.64	11.24	0.48	8.16e-26	Birth weight;
LUAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg23131131	chr22:24373011	LOC391322	-0.59	-9.97	-0.44	3.75e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg08601574	chr20:25228251	PYGB	-0.46	-8.65	-0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg20368463	chr18:77673604	PQLC1	0.56	9.28	0.41	8.59e-19	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUAD	cis	rs1215050	0.669	rs783962	chr4:98884473	G/A	cg17366294	chr4:99064904	C4orf37	-0.49	-8.5	-0.38	3.31e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11651000	0.761	rs11079788	chr17:45820723	C/T	cg03474202	chr17:45855739	NA	-0.35	-7.4	-0.34	7.28e-13	IgG glycosylation;
LUAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13732083	chr21:47605072	C21orf56	-0.62	-10.47	-0.45	5.82e-23	Testicular germ cell tumor;
LUAD	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg19761014	chr17:28927070	LRRC37B2	0.83	8.06	0.36	7.92e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs17152411	0.947	rs17152408	chr10:126649007	C/T	cg07906193	chr10:126599966	NA	0.46	6.55	0.3	1.64e-10	Height;
LUAD	cis	rs9297145	0.724	rs6954584	chr7:98766930	G/A	cg05967295	chr7:98741636	SMURF1	0.98	15.62	0.6	9.47e-44	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs9341808	0.667	rs6938280	chr6:80897782	G/A	cg08355045	chr6:80787529	NA	0.5	8.89	0.4	1.75e-17	Sitting height ratio;
LUAD	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg16988262	chr1:15930761	NA	0.44	7.42	0.34	6.38e-13	Systolic blood pressure;
LUAD	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.73	15.67	0.61	5.66e-44	White blood cell count (neutrophil);
LUAD	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.55	-0.34	2.63e-13	Lung cancer;
LUAD	trans	rs4650994	0.544	rs4652301	chr1:178499799	T/C	cg05059571	chr16:84539110	KIAA1609	-0.76	-13.54	-0.55	6.11e-35	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs2067615	0.579	rs1922438	chr12:107085171	C/G	cg15890332	chr12:107067104	RFX4	0.39	8.43	0.38	5.39e-16	Heart rate;
LUAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	6.39	0.3	4.33e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21659725	chr3:3221576	CRBN	-0.61	-9.94	-0.44	4.65e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg22166914	chr1:53195759	ZYG11B	0.47	7.85	0.36	3.33e-14	Monocyte count;
LUAD	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg26647111	chr11:31128758	NA	-0.44	-7.67	-0.35	1.24e-13	Red blood cell count;
LUAD	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg09085632	chr11:111637200	PPP2R1B	0.8	13.05	0.54	5.88e-33	Primary sclerosing cholangitis;
LUAD	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg24069376	chr3:38537580	EXOG	0.37	8.38	0.38	7.74e-16	Schizophrenia;
LUAD	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06028808	chr11:68637592	NA	0.43	6.93	0.32	1.53e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg08213375	chr14:104286397	PPP1R13B	0.29	7.09	0.33	5.73e-12	Schizophrenia;
LUAD	cis	rs12545109	0.842	rs2609975	chr8:57401667	T/C	cg21220214	chr8:57350948	NA	-0.61	-8.71	-0.39	6.85e-17	Obesity-related traits;
LUAD	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg09137382	chr11:130731461	NA	0.38	6.81	0.31	3.46e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg25767906	chr1:53392781	SCP2	0.4	7.19	0.33	2.92e-12	Monocyte count;
LUAD	cis	rs2839627	0.683	rs11555158	chr21:44337914	A/G	cg03543861	chr21:44258195	NA	0.67	7.94	0.36	1.82e-14	Information processing speed;
LUAD	cis	rs41311933	1.000	rs16910253	chr9:123748830	G/C	cg13567360	chr9:123745713	C5	-0.77	-8.98	-0.4	9.26e-18	Coronary artery disease;
LUAD	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.21	-0.44	5.05e-22	Total body bone mineral density;
LUAD	cis	rs9308433	0.529	rs17022608	chr1:214500907	A/C	cg06198575	chr1:214491504	SMYD2	0.45	7.63	0.35	1.53e-13	IgG glycosylation;
LUAD	cis	rs9807989	0.507	rs6706002	chr2:103006104	A/G	cg03938978	chr2:103052716	IL18RAP	0.45	10.24	0.45	3.99e-22	Asthma;
LUAD	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18876405	chr7:65276391	NA	-0.42	-6.65	-0.31	9.07e-11	Aortic root size;
LUAD	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg11502198	chr6:26597334	ABT1	0.68	11.85	0.5	3.69e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs3791556	0.501	rs3791536	chr2:240101713	G/A	cg03281426	chr2:240109471	HDAC4	0.5	9.38	0.41	4.11e-19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg23803603	chr1:2058230	PRKCZ	-0.4	-7.1	-0.33	5.15e-12	Height;
LUAD	cis	rs34734847	1.000	rs34734847	chr12:121154221	T/C	cg21892295	chr12:121157589	UNC119B	-0.45	-8.14	-0.37	4.43e-15	Mean corpuscular volume;
LUAD	cis	rs2066819	1.000	rs77120931	chr12:56646213	A/C	cg26714650	chr12:56694279	CS	-0.84	-7.2	-0.33	2.73e-12	Psoriasis vulgaris;
LUAD	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.23	0.48	8.61e-26	Eosinophil percentage of white cells;
LUAD	cis	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg05635807	chr8:11422167	NA	0.4	6.43	0.3	3.47e-10	Systemic lupus erythematosus;
LUAD	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg15448220	chr1:150897856	SETDB1	0.46	7.98	0.36	1.42e-14	Tonsillectomy;
LUAD	cis	rs1348850	0.597	rs13014512	chr2:178470851	T/A	cg22681709	chr2:178499509	PDE11A	-0.46	-6.6	-0.31	1.22e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7246760	1.000	rs57736549	chr19:9937558	A/G	cg02900749	chr2:68251473	NA	-0.63	-6.76	-0.31	4.67e-11	Pursuit maintenance gain;
LUAD	cis	rs8177876	0.642	rs4454990	chr16:81140155	A/G	cg08591886	chr16:81111003	C16orf46	0.63	6.58	0.3	1.37e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg03929089	chr4:120376271	NA	-0.6	-9.4	-0.42	3.6e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg13736514	chr6:26305472	NA	0.47	7.66	0.35	1.24e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg27661571	chr11:113659931	NA	-0.69	-8.04	-0.36	9.03e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg21724239	chr8:58056113	NA	0.78	9.3	0.41	7.55e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg23758822	chr17:41437982	NA	0.99	20.03	0.7	2.87e-63	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg11663144	chr21:46675770	NA	-0.48	-8.14	-0.37	4.5e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg18180107	chr4:99064573	C4orf37	0.42	6.84	0.32	2.77e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.59e-12	Crohn's disease;
LUAD	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg18811423	chr2:55921094	PNPT1	0.54	9.19	0.41	1.83e-18	Metabolic syndrome;
LUAD	cis	rs62238980	0.614	rs75691061	chr22:32381222	G/A	cg00543991	chr22:32367038	NA	0.94	8.78	0.39	4.09e-17	Childhood ear infection;
LUAD	cis	rs73198271	0.565	rs575920	chr8:8594254	C/T	cg01851573	chr8:8652454	MFHAS1	0.44	8.0	0.36	1.2e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg00310523	chr12:86230176	RASSF9	0.39	7.84	0.36	3.8e-14	Major depressive disorder;
LUAD	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22968622	chr17:43663579	NA	-1.18	-19.73	-0.69	6.31e-62	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3820068	0.580	rs61169376	chr1:16003832	A/G	cg24675056	chr1:15929824	NA	0.49	8.1	0.37	5.9e-15	Systolic blood pressure;
LUAD	cis	rs7737355	0.947	rs7725220	chr5:130877001	C/G	cg25547332	chr5:131281432	NA	0.43	6.49	0.3	2.42e-10	Life satisfaction;
LUAD	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06022373	chr22:39101656	GTPBP1	0.46	7.15	0.33	3.72e-12	Menopause (age at onset);
LUAD	cis	rs6543140	0.964	rs13390895	chr2:103075499	G/A	cg04239558	chr2:103089729	SLC9A4	0.36	7.34	0.34	1.11e-12	Blood protein levels;
LUAD	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg12927641	chr6:109611667	NA	0.52	9.5	0.42	1.62e-19	Reticulocyte fraction of red cells;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16448126	chr12:123921461	RILPL2	-0.41	-6.62	-0.31	1.12e-10	Cancer;
LUAD	trans	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-10.78	-0.46	4.07e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg26354017	chr1:205819088	PM20D1	0.93	23.03	0.75	1.22e-76	Menarche (age at onset);
LUAD	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg13770153	chr20:60521292	NA	-0.59	-9.15	-0.41	2.35e-18	Body mass index;
LUAD	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg19610905	chr11:61596333	FADS2	-0.66	-11.06	-0.47	3.75e-25	Trans fatty acid levels;
LUAD	cis	rs9811920	0.641	rs58704213	chr3:99690331	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-9.79	-0.43	1.6e-20	Axial length;
LUAD	cis	rs10128251	0.962	rs4748018	chr10:5711507	T/A	cg24097872	chr10:5724021	NA	0.45	8.14	0.37	4.31e-15	Childhood ear infection;
LUAD	cis	rs1950500	0.545	rs724165	chr14:24806229	G/A	cg22990158	chr14:24802150	ADCY4	-0.56	-10.49	-0.45	5.08e-23	Height;
LUAD	cis	rs3087591	0.887	rs2905796	chr17:29537586	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	6.7	0.31	6.59e-11	Hip circumference;
LUAD	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg00981070	chr1:2046702	PRKCZ	0.36	6.97	0.32	1.19e-11	Height;
LUAD	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg18932078	chr1:2524107	MMEL1	0.38	7.14	0.33	4.03e-12	Ulcerative colitis;
LUAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.91e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg06532163	chr17:45867833	NA	0.47	7.27	0.33	1.78e-12	IgG glycosylation;
LUAD	cis	rs2224391	0.656	rs68061889	chr6:5292817	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-8.56	-0.38	2.16e-16	Height;
LUAD	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg10755058	chr3:40428713	ENTPD3	0.46	8.49	0.38	3.62e-16	Renal cell carcinoma;
LUAD	trans	rs1493916	0.837	rs1493908	chr18:31411700	G/A	cg27147174	chr7:100797783	AP1S1	-0.62	-10.88	-0.47	1.73e-24	Life satisfaction;
LUAD	cis	rs2274471	0.634	rs913594	chr9:5063199	C/T	cg03390472	chr9:5043263	JAK2	-0.53	-7.77	-0.35	6.16e-14	Crohn's disease;
LUAD	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg21709803	chr11:61594965	FADS2	-0.61	-8.67	-0.39	9.03e-17	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs7582720	1.000	rs4675310	chr2:203880834	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.73	-9.34	-0.41	5.75e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs12545109	0.800	rs1996105	chr8:57413123	A/G	cg09654669	chr8:57350985	NA	-0.66	-9.4	-0.42	3.52e-19	Obesity-related traits;
LUAD	cis	rs7707921	0.881	rs112355050	chr5:81386035	C/T	cg15871215	chr5:81402204	ATG10	-0.68	-9.64	-0.42	5.06e-20	Breast cancer;
LUAD	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg22705602	chr4:152727874	NA	-0.37	-6.64	-0.31	9.65e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9487051	0.735	rs1260595	chr6:109519873	T/G	cg01475377	chr6:109611718	NA	-0.38	-7.31	-0.33	1.36e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg15181151	chr6:150070149	PCMT1	0.41	8.44	0.38	5.07e-16	Lung cancer;
LUAD	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg23172400	chr8:95962367	TP53INP1	0.31	6.55	0.3	1.65e-10	Type 2 diabetes;
LUAD	cis	rs62400317	0.859	rs2093900	chr6:45176683	C/T	cg20913747	chr6:44695427	NA	-0.43	-6.61	-0.31	1.18e-10	Total body bone mineral density;
LUAD	trans	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.17	29.6	0.82	4.18e-105	Colorectal cancer;
LUAD	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	7.05	0.32	7.49e-12	Personality dimensions;
LUAD	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg27394845	chr17:28928406	LRRC37B2	0.53	6.85	0.32	2.67e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2625529	0.824	rs16956328	chr15:72143855	A/T	cg16672083	chr15:72433130	SENP8	-0.76	-12.95	-0.53	1.52e-32	Red blood cell count;
LUAD	cis	rs9837602	1.000	rs9833888	chr3:99723580	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-7.0	-0.32	9.81e-12	Breast cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14195377	chr11:60928647	VPS37C	-0.51	-6.51	-0.3	2.15e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg21427119	chr20:30132790	HM13	-0.62	-9.46	-0.42	2.24e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg06609049	chr19:2785107	THOP1	1.06	20.86	0.71	5.63e-67	Total cholesterol levels;
LUAD	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg00071950	chr4:10020882	SLC2A9	-0.62	-11.98	-0.5	1.1e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg27454412	chr7:1067447	C7orf50	0.36	6.67	0.31	8.27e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs67072384	0.786	rs58424437	chr11:72448256	C/T	cg04827223	chr11:72435913	ARAP1	-0.64	-7.66	-0.35	1.31e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg20607287	chr7:12443886	VWDE	-0.54	-6.85	-0.32	2.59e-11	Coronary artery disease;
LUAD	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg07538946	chr5:131705188	SLC22A5	0.45	7.51	0.34	3.59e-13	Blood metabolite levels;
LUAD	cis	rs1983170	0.935	rs578155	chr1:91976541	G/A	cg25838465	chr1:92012736	NA	-0.49	-7.3	-0.33	1.4e-12	Eosinophil percentage of white cells;
LUAD	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.82	-0.36	4.38e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12200560	0.505	rs211176	chr6:97073821	G/A	cg06623918	chr6:96969491	KIAA0776	0.47	7.26	0.33	1.88e-12	Coronary heart disease;
LUAD	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg19980929	chr12:42632907	YAF2	-0.33	-6.38	-0.3	4.72e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg08888203	chr3:10149979	C3orf24	0.67	11.93	0.5	1.8e-28	Alzheimer's disease;
LUAD	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg02221422	chr11:68192511	LRP5	-0.41	-6.83	-0.31	3.05e-11	Total body bone mineral density;
LUAD	cis	rs7851660	0.805	rs7038998	chr9:100662396	C/G	cg13688889	chr9:100608707	NA	-0.54	-9.17	-0.41	2.08e-18	Strep throat;
LUAD	cis	rs6942407	0.546	rs2108272	chr7:86805399	C/T	cg02420886	chr7:86849541	C7orf23	0.6	6.95	0.32	1.35e-11	Food allergy;
LUAD	cis	rs6961069	0.722	rs13438282	chr7:80262224	C/T	cg04458919	chr7:80252533	CD36	0.37	6.98	0.32	1.12e-11	Platelet count;
LUAD	trans	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.59	0.31	1.27e-10	Neuroticism;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19997236	chr12:121790271	ANAPC5	-0.43	-6.7	-0.31	6.64e-11	Height;
LUAD	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.1	-0.51	3.68e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs9633740	1.000	rs7896832	chr10:82257570	T/C	cg00277334	chr10:82204260	NA	-0.64	-8.79	-0.39	3.69e-17	Post bronchodilator FEV1;
LUAD	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg21775007	chr8:11205619	TDH	-0.5	-9.02	-0.4	6.54e-18	Retinal vascular caliber;
LUAD	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.5	6.93	0.32	1.56e-11	Cognitive test performance;
LUAD	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg14668632	chr7:2872130	GNA12	-0.7	-12.19	-0.51	1.71e-29	Height;
LUAD	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg05110241	chr16:68378359	PRMT7	-0.7	-7.99	-0.36	1.26e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg11247378	chr22:39784982	NA	-0.67	-11.23	-0.48	8.6e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.34	-0.34	1.12e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg01851573	chr8:8652454	MFHAS1	-0.37	-6.82	-0.31	3.21e-11	Neuroticism;
LUAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg08888203	chr3:10149979	C3orf24	0.63	10.73	0.46	6.56e-24	Alzheimer's disease;
LUAD	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg18200150	chr17:30822561	MYO1D	0.44	8.27	0.37	1.7e-15	Schizophrenia;
LUAD	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.25	-0.33	2.06e-12	Total cholesterol levels;
LUAD	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg03684893	chr10:554711	DIP2C	-0.5	-9.54	-0.42	1.19e-19	Psychosis in Alzheimer's disease;
LUAD	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.84	-0.32	2.72e-11	Type 2 diabetes;
LUAD	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.81	-0.71	9.87e-67	Coronary artery disease;
LUAD	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-11.15	-0.48	1.76e-25	Bone mineral density;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01596986	chr13:48611463	NUDT15	-0.42	-7.1	-0.33	5.44e-12	Cancer;
LUAD	cis	rs1697139	0.583	rs1428475	chr5:66543954	G/T	cg11553311	chr5:66541588	NA	0.44	8.25	0.37	2.06e-15	Breast cancer;
LUAD	cis	rs713587	0.713	rs11125884	chr2:25239264	C/T	cg04586622	chr2:25135609	ADCY3	0.32	6.95	0.32	1.42e-11	Body mass index in non-asthmatics;
LUAD	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg04369109	chr6:150039330	LATS1	-0.44	-7.31	-0.34	1.31e-12	Lung cancer;
LUAD	trans	rs2262909	0.962	rs2017521	chr19:22126138	T/C	cg17074339	chr11:11642133	GALNTL4	-0.44	-7.08	-0.33	6.22e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg05991184	chr2:219186017	PNKD	0.37	7.12	0.33	4.55e-12	Colorectal cancer;
LUAD	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg26384229	chr12:38710491	ALG10B	-0.44	-7.57	-0.35	2.32e-13	Heart rate;
LUAD	cis	rs2835872	0.726	rs1515056	chr21:39082585	C/G	cg06728970	chr21:39037746	KCNJ6	-0.39	-6.6	-0.31	1.25e-10	Electroencephalographic traits in alcoholism;
LUAD	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg23281280	chr6:28129359	ZNF389	0.45	6.56	0.3	1.62e-10	Depression;
LUAD	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10802521	chr3:52805072	NEK4	0.54	8.92	0.4	1.38e-17	Bipolar disorder;
LUAD	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg24578937	chr1:2090814	PRKCZ	-0.75	-15.74	-0.61	2.74e-44	Height;
LUAD	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg01579765	chr21:45077557	HSF2BP	-0.65	-14.99	-0.59	4.61e-41	Mean corpuscular volume;
LUAD	cis	rs3823572	0.525	rs2346445	chr7:133717904	T/C	cg03336402	chr7:133662267	EXOC4	-0.43	-7.29	-0.33	1.52e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg06484146	chr7:12443880	VWDE	-0.59	-7.5	-0.34	3.88e-13	Coronary artery disease;
LUAD	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg03806693	chr22:41940476	POLR3H	-0.81	-11.38	-0.48	2.24e-26	Vitiligo;
LUAD	cis	rs9788721	1.000	rs55781567	chr15:78857986	C/G	cg18825076	chr15:78729989	IREB2	-0.53	-8.68	-0.39	8.36e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs6854137	0.758	rs6553150	chr4:169729877	A/C	cg20607169	chr4:169750834	PALLD	0.41	7.42	0.34	6.36e-13	Vein graft stenosis in coronary artery bypass grafting;
LUAD	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg22823121	chr1:150693482	HORMAD1	0.4	7.72	0.35	8.56e-14	Melanoma;
LUAD	cis	rs447921	0.861	rs12949638	chr17:74444758	C/T	cg17201438	chr17:74438067	UBE2O	0.68	8.6	0.39	1.57e-16	Mitochondrial DNA levels;
LUAD	cis	rs7584330	0.554	rs77648388	chr2:238431832	G/C	cg14458575	chr2:238380390	NA	0.86	13.27	0.54	7.83e-34	Prostate cancer;
LUAD	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.41	-6.38	-0.3	4.54e-10	Glycated hemoglobin levels;
LUAD	cis	rs4629710	0.568	rs9492883	chr6:131573872	A/T	cg12606694	chr6:131520996	AKAP7	0.51	7.4	0.34	7.44e-13	Multiple myeloma (IgH translocation);
LUAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.29	-0.37	1.48e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs500891	0.525	rs1591396	chr6:84107897	T/C	cg08257003	chr6:84140564	ME1	0.34	6.49	0.3	2.47e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg12458913	chr13:53173898	NA	0.39	6.94	0.32	1.47e-11	Lewy body disease;
LUAD	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.92	-0.36	2.15e-14	NT-proBNP levels in acute coronary syndrome;
LUAD	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg09184832	chr6:79620586	NA	-0.52	-9.79	-0.43	1.6e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23583168	chr7:148888333	NA	-0.77	-13.24	-0.54	1.06e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg09517075	chr8:22133004	PIWIL2	0.46	8.54	0.38	2.42e-16	Hypertriglyceridemia;
LUAD	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs4372836	0.681	rs4477866	chr2:29009089	C/A	cg09522027	chr2:28974177	PPP1CB	-0.69	-12.5	-0.52	1.01e-30	Body mass index;
LUAD	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg26924012	chr15:45694286	SPATA5L1	1.01	18.53	0.67	1.47e-56	Homoarginine levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14712964	chr3:9773672	BRPF1	-0.46	-7.16	-0.33	3.6e-12	Height;
LUAD	cis	rs7927771	0.542	rs7122217	chr11:47777920	G/C	cg18512352	chr11:47633146	NA	-0.36	-6.5	-0.3	2.29e-10	Subjective well-being;
LUAD	cis	rs4243830	0.522	rs10157142	chr1:6618785	A/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.81	-10.2	-0.44	5.49e-22	Body mass index;
LUAD	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg03526776	chr6:41159608	TREML2	0.33	6.92	0.32	1.73e-11	Alzheimer's disease (late onset);
LUAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.3	0.45	2.42e-22	Prudent dietary pattern;
LUAD	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.48	-0.34	4.38e-13	Electroencephalogram traits;
LUAD	cis	rs68170813	0.559	rs12536485	chr7:106978005	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-10.47	-0.45	5.75e-23	Coronary artery disease;
LUAD	cis	rs910187	0.605	rs3787235	chr20:45803522	C/T	cg27589058	chr20:45804311	EYA2	-0.37	-8.47	-0.38	4.17e-16	Migraine;
LUAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg08219700	chr8:58056026	NA	0.42	6.4	0.3	4.22e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.67	12.76	0.53	9.19e-32	Cognitive ability;
LUAD	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs12760731	0.623	rs2295019	chr1:178451732	A/G	cg00404053	chr1:178313656	RASAL2	0.59	7.62	0.35	1.69e-13	Obesity-related traits;
LUAD	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg16680214	chr1:154839983	KCNN3	-0.61	-12.62	-0.52	3.43e-31	Prostate cancer;
LUAD	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg27266060	chr8:22091797	NA	0.46	8.37	0.38	8.49e-16	Hypertriglyceridemia;
LUAD	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg21238619	chr17:78079768	GAA	-0.33	-6.78	-0.31	4.03e-11	Yeast infection;
LUAD	cis	rs5756813	0.661	rs11703407	chr22:38200124	C/T	cg06521852	chr22:38141419	TRIOBP	0.47	8.47	0.38	4.21e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg00271210	chr6:167070053	RPS6KA2	0.34	6.52	0.3	1.96e-10	Crohn's disease;
LUAD	trans	rs6598955	0.671	rs11247893	chr1:26597086	A/C	cg07461501	chr17:79650226	HGS;ARL16	0.72	10.08	0.44	1.5e-21	Obesity-related traits;
LUAD	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg18016565	chr1:150552671	MCL1	-0.41	-7.14	-0.33	4.04e-12	Tonsillectomy;
LUAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg12016809	chr21:47604291	C21orf56	0.65	11.44	0.49	1.37e-26	Testicular germ cell tumor;
LUAD	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg06002616	chr8:101225028	SPAG1	-0.41	-8.27	-0.37	1.71e-15	Atrioventricular conduction;
LUAD	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg02993280	chr1:107599747	PRMT6	-0.5	-7.82	-0.36	4.32e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.64	11.14	0.48	1.94e-25	Lymphocyte counts;
LUAD	cis	rs7773004	0.905	rs1053860	chr6:26325228	C/T	cg13736514	chr6:26305472	NA	-0.48	-8.04	-0.36	9.15e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg08885076	chr2:99613938	TSGA10	0.36	6.49	0.3	2.45e-10	Chronic sinus infection;
LUAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	7.39	0.34	7.85e-13	Alzheimer's disease;
LUAD	trans	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg26043149	chr18:55253948	FECH	0.51	8.32	0.38	1.2e-15	Bone mineral density;
LUAD	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18876405	chr7:65276391	NA	-0.58	-9.91	-0.43	5.83e-21	Aortic root size;
LUAD	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg15445000	chr17:37608096	MED1	0.45	8.28	0.37	1.66e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs9287719	0.556	rs10168351	chr2:10736810	T/C	cg02196655	chr2:10830764	NOL10	-0.39	-6.78	-0.31	4.13e-11	Prostate cancer;
LUAD	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg11189052	chr15:85197271	WDR73	0.64	8.16	0.37	3.98e-15	Schizophrenia;
LUAD	cis	rs4356932	0.967	rs4478212	chr4:76958899	A/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.52	-0.3	2.05e-10	Blood protein levels;
LUAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg09033563	chr22:24373618	LOC391322	-0.5	-7.85	-0.36	3.34e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3767633	0.528	rs6671373	chr1:161890796	C/G	cg27519958	chr1:161735129	ATF6	-0.43	-7.39	-0.34	7.89e-13	IgG glycosylation;
LUAD	cis	rs7943203	0.525	rs665293	chr11:108142617	G/A	cg04873221	chr11:107992290	ACAT1	-0.49	-7.46	-0.34	4.83e-13	Red blood cell count;Mean corpuscular volume;
LUAD	trans	rs587242	1.000	rs4341405	chr1:96902589	A/G	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs13190036	0.901	rs4631	chr5:176733116	A/G	cg06733329	chr5:176740039	MXD3	-0.53	-6.52	-0.3	1.98e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg21204522	chr6:27730016	NA	-0.44	-6.94	-0.32	1.51e-11	Parkinson's disease;
LUAD	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg02160872	chr5:212506	CCDC127	-0.51	-6.61	-0.31	1.16e-10	Breast cancer;
LUAD	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg23533926	chr12:111358616	MYL2	-0.4	-6.8	-0.31	3.48e-11	Extrinsic epigenetic age acceleration;
LUAD	trans	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.53	8.02	0.36	1.04e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.66	-0.39	9.95e-17	Total body bone mineral density;
LUAD	trans	rs11650494	0.908	rs73340392	chr17:47358308	G/A	cg11430096	chr6:110968061	CDK19	0.9	7.13	0.33	4.33e-12	Prostate cancer;
LUAD	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg16850897	chr7:100343110	ZAN	0.41	7.39	0.34	7.88e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg08999081	chr20:33150536	PIGU	-0.6	-13.2	-0.54	1.47e-33	Glomerular filtration rate (creatinine);
LUAD	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	9.75	0.43	2.15e-20	Ileal carcinoids;
LUAD	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg17366294	chr4:99064904	C4orf37	0.48	8.38	0.38	8.04e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24531977	chr5:56204891	C5orf35	0.78	12.58	0.52	4.62e-31	Initial pursuit acceleration;
LUAD	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg09509183	chr1:209979624	IRF6	0.59	7.24	0.33	2.08e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.73	-14.12	-0.57	2.34e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.74	-0.46	5.85e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.39	0.3	4.48e-10	Cardiac Troponin-T levels;
LUAD	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg06060754	chr5:176797920	RGS14	0.55	10.63	0.46	1.48e-23	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg06713675	chr4:122721982	EXOSC9	-0.85	-18.09	-0.66	1.32e-54	Type 2 diabetes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24701985	chr7:149535383	ZNF862	-0.45	-7.17	-0.33	3.35e-12	Height;
LUAD	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg23985595	chr17:80112537	CCDC57	0.53	9.74	0.43	2.39e-20	Life satisfaction;
LUAD	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19346786	chr7:2764209	NA	-0.57	-12.38	-0.52	2.96e-30	Height;
LUAD	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg21699342	chr2:239360505	ASB1	0.48	8.78	0.39	4.08e-17	Multiple system atrophy;
LUAD	cis	rs10193935	1.000	rs12618105	chr2:42414146	T/G	cg27598129	chr2:42591480	NA	-0.78	-10.28	-0.45	2.87e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	9.85	0.43	9.32e-21	Electrocardiographic conduction measures;
LUAD	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg02782426	chr3:40428986	ENTPD3	0.36	7.98	0.36	1.38e-14	Renal cell carcinoma;
LUAD	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.94	-0.36	1.9e-14	Type 2 diabetes;
LUAD	cis	rs7000551	0.556	rs12674913	chr8:22263617	G/C	cg12081754	chr8:22256438	SLC39A14	0.86	13.46	0.55	1.27e-34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg08999081	chr20:33150536	PIGU	-0.64	-14.36	-0.57	2.16e-38	Glomerular filtration rate (creatinine);
LUAD	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg23281280	chr6:28129359	ZNF389	0.48	6.71	0.31	6.44e-11	Depression;
LUAD	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg26587870	chr6:27730563	NA	-0.69	-7.35	-0.34	1.01e-12	Depression;
LUAD	cis	rs4930561	0.714	rs7130844	chr11:67927517	C/T	cg04465784	chr11:67976953	SUV420H1	-0.36	-11.25	-0.48	7.33e-26	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.36	-6.52	-0.3	2.01e-10	Crohn's disease;
LUAD	cis	rs7727544	0.570	rs7701237	chr5:131534381	C/T	cg14196790	chr5:131705035	SLC22A5	0.42	7.24	0.33	2.07e-12	Blood metabolite levels;
LUAD	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg04154034	chr17:28927549	LRRC37B2	0.66	6.45	0.3	3.01e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.49	-8.15	-0.37	4.07e-15	Tonsillectomy;
LUAD	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-9.54	-0.42	1.17e-19	Bone mineral density;
LUAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.07e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.54	0.42	1.15e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg07817883	chr1:32538562	TMEM39B	1.27	12.17	0.51	1.94e-29	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg05340658	chr4:99064831	C4orf37	0.54	9.18	0.41	1.9e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg17366294	chr4:99064904	C4orf37	0.67	12.89	0.53	2.7e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	12.65	0.52	2.59e-31	Exhaled nitric oxide output;
LUAD	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-8.04	-0.36	9.03e-15	Prostate cancer;
LUAD	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg10295955	chr4:187884368	NA	-1.18	-31.46	-0.84	7.72e-113	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6594713	0.921	rs6887482	chr5:112741433	G/T	cg12552261	chr5:112820674	MCC	-0.52	-8.54	-0.38	2.49e-16	Brain cytoarchitecture;
LUAD	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg09184832	chr6:79620586	NA	-0.51	-9.57	-0.42	9.28e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs35883536	0.647	rs2783702	chr1:101040836	G/A	cg06223162	chr1:101003688	GPR88	0.47	9.14	0.41	2.68e-18	Monocyte count;
LUAD	cis	rs10065203	0.527	rs173948	chr5:14347771	A/G	cg26595256	chr5:14380529	TRIO	-0.43	-7.51	-0.34	3.44e-13	Paclitaxel-induced neuropathy;
LUAD	cis	rs4604732	0.631	rs4411161	chr1:247632374	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.11	0.33	4.96e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg23625390	chr15:77176239	SCAPER	-0.52	-8.05	-0.36	8.71e-15	Blood metabolite levels;
LUAD	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg12310025	chr6:25882481	NA	-0.56	-9.05	-0.4	5.14e-18	Blood metabolite levels;
LUAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02353165	chr6:42928485	GNMT	0.41	7.41	0.34	6.87e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg05110241	chr16:68378359	PRMT7	-0.91	-10.81	-0.47	3.38e-24	Schizophrenia;
LUAD	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg00339695	chr16:24857497	SLC5A11	0.7	11.12	0.48	2.22e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg24558204	chr6:135376177	HBS1L	0.49	9.08	0.4	4.18e-18	Red blood cell count;
LUAD	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg09658497	chr7:2847517	GNA12	-0.44	-7.35	-0.34	1.04e-12	Height;
LUAD	cis	rs12976411	0.575	rs73927590	chr19:32821559	G/C	cg02282382	chr19:32836354	ZNF507	0.71	6.43	0.3	3.54e-10	Coronary artery disease;
LUAD	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg04455712	chr21:45112962	RRP1B	0.43	8.62	0.39	1.4e-16	Mean corpuscular volume;
LUAD	cis	rs10129255	0.536	rs10139058	chr14:107141916	C/T	cg07958169	chr14:107095056	NA	-0.36	-7.06	-0.32	6.91e-12	Kawasaki disease;
LUAD	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg13010199	chr12:38710504	ALG10B	0.41	6.69	0.31	7.05e-11	Bladder cancer;
LUAD	cis	rs116248771	0.739	rs73156428	chr3:158346471	T/C	cg16708174	chr3:158430962	RARRES1	0.47	6.83	0.32	2.98e-11	diarrhoeal disease at age 2;
LUAD	cis	rs8025790	0.508	rs4776370	chr15:67904511	T/C	cg24579218	chr15:68104479	NA	-0.49	-8.04	-0.36	9.26e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs6761276	0.649	rs10181720	chr2:113838608	A/G	cg09040174	chr2:113837401	NA	0.68	12.05	0.51	6.05e-29	Protein quantitative trait loci;
LUAD	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg15448220	chr1:150897856	SETDB1	-0.45	-7.69	-0.35	1.04e-13	Tonsillectomy;
LUAD	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg15445000	chr17:37608096	MED1	0.44	8.19	0.37	3.14e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs7617773	0.780	rs3197223	chr3:48335857	C/T	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.12e-11	Coronary artery disease;
LUAD	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-7.42	-0.34	6.53e-13	Personality dimensions;
LUAD	cis	rs10193935	0.901	rs62142639	chr2:42600019	C/G	cg27598129	chr2:42591480	NA	-0.75	-9.83	-0.43	1.16e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11039798	0.844	rs41431447	chr11:48983199	A/G	cg03929089	chr4:120376271	NA	0.66	6.57	0.3	1.49e-10	Axial length;
LUAD	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg24069376	chr3:38537580	EXOG	0.45	11.0	0.47	6.54e-25	Electrocardiographic conduction measures;
LUAD	cis	rs12618769	0.597	rs17031146	chr2:99036683	A/G	cg10123293	chr2:99228465	UNC50	0.45	8.13	0.37	4.87e-15	Bipolar disorder;
LUAD	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.4	-6.91	-0.32	1.78e-11	Longevity;Endometriosis;
LUAD	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21659725	chr3:3221576	CRBN	0.69	11.44	0.49	1.38e-26	Resting heart rate;
LUAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg09060608	chr5:178986726	RUFY1	0.63	10.15	0.44	8.21e-22	Lung cancer;
LUAD	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg02454025	chr1:11042201	C1orf127	1.04	17.71	0.65	6.82e-53	Ewing sarcoma;
LUAD	cis	rs514406	0.734	rs581118	chr1:53311324	T/C	cg25767906	chr1:53392781	SCP2	-0.41	-7.23	-0.33	2.28e-12	Monocyte count;
LUAD	cis	rs6714710	0.603	rs2044458	chr2:98377512	A/T	cg26665480	chr2:98280029	ACTR1B	0.5	8.27	0.37	1.75e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs2797160	0.967	rs1954360	chr6:126001064	A/G	cg05901451	chr6:126070800	HEY2	-0.44	-6.59	-0.31	1.27e-10	Endometrial cancer;
LUAD	cis	rs1045714	0.943	rs56063345	chr7:2653504	C/G	cg20813462	chr7:2646259	IQCE	0.67	7.19	0.33	2.89e-12	Urate levels in lean individuals;
LUAD	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg00495681	chr13:53174319	NA	-0.59	-10.94	-0.47	1.07e-24	Lewy body disease;
LUAD	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.67	-0.35	1.21e-13	Alzheimer's disease (late onset);
LUAD	cis	rs35883536	0.513	rs4907910	chr1:101013277	T/A	cg06223162	chr1:101003688	GPR88	0.54	11.0	0.47	6.33e-25	Monocyte count;
LUAD	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg10978503	chr1:24200527	CNR2	0.59	12.82	0.53	5.07e-32	Immature fraction of reticulocytes;
LUAD	cis	rs1018836	0.892	rs4735224	chr8:91567046	C/A	cg16814680	chr8:91681699	NA	-0.57	-9.54	-0.42	1.12e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7116495	1.000	rs58991229	chr11:71839878	G/A	cg07596299	chr11:71824057	C11orf51	0.79	6.79	0.31	3.74e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg24558204	chr6:135376177	HBS1L	0.51	8.77	0.39	4.3e-17	High light scatter reticulocyte percentage of red cells;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg06873684	chr19:4472059	HDGF2	0.39	6.65	0.31	9.13e-11	Anger;
LUAD	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.99e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56346965	0.844	rs4853516	chr2:191553931	A/G	cg27211696	chr2:191398769	TMEM194B	-0.43	-7.47	-0.34	4.66e-13	Bone mineral density (Ward's triangle area);
LUAD	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22590775	chr19:49891494	CCDC155	-0.67	-9.92	-0.43	5.65e-21	Multiple sclerosis;
LUAD	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg02221422	chr11:68192511	LRP5	-0.4	-6.63	-0.31	1.01e-10	Total body bone mineral density;
LUAD	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg23954153	chr1:44402353	ARTN	-0.36	-6.4	-0.3	4.21e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg20290983	chr6:43655470	MRPS18A	-1.07	-27.27	-0.8	3.31e-95	IgG glycosylation;
LUAD	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03934478	chr11:495069	RNH1	0.76	8.92	0.4	1.44e-17	Body mass index;
LUAD	cis	rs12286929	0.679	rs11606814	chr11:115042513	G/T	cg04055981	chr11:115044050	NA	0.44	7.93	0.36	2e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg16329650	chr2:213403929	ERBB4	0.6	10.88	0.47	1.72e-24	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg08132940	chr7:1081526	C7orf50	-0.67	-9.51	-0.42	1.43e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg11833968	chr6:79620685	NA	-0.42	-7.95	-0.36	1.77e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg11494091	chr17:61959527	GH2	0.74	18.12	0.66	1.04e-54	Prudent dietary pattern;
LUAD	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.46	-0.42	2.08e-19	Life satisfaction;
LUAD	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	cis	rs68170813	0.652	rs17403088	chr7:107111373	C/A	cg23024343	chr7:107201750	COG5	0.51	6.45	0.3	3.09e-10	Coronary artery disease;
LUAD	cis	rs713477	0.967	rs61976571	chr14:55908774	T/C	cg13175173	chr14:55914753	NA	-0.33	-6.95	-0.32	1.41e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg04990556	chr1:26633338	UBXN11	-0.39	-6.53	-0.3	1.89e-10	Obesity-related traits;
LUAD	cis	rs12612619	0.704	rs6714547	chr2:27321206	T/G	cg00617064	chr2:27272375	NA	-0.38	-7.12	-0.33	4.68e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg13560548	chr3:10150139	C3orf24	0.39	6.41	0.3	3.89e-10	Alzheimer's disease;
LUAD	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg12935359	chr14:103987150	CKB	-0.48	-8.0	-0.36	1.23e-14	Body mass index;
LUAD	cis	rs3803170	0.513	rs4766574	chr12:111832372	C/T	cg10833066	chr12:111807467	FAM109A	0.49	8.87	0.4	2.02e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg16325326	chr1:53192061	ZYG11B	-0.61	-10.92	-0.47	1.24e-24	Monocyte count;
LUAD	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg08859206	chr1:53392774	SCP2	-0.47	-8.68	-0.39	8.63e-17	Monocyte count;
LUAD	cis	rs11811982	0.793	rs75948705	chr1:227510285	G/A	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg23387056	chr11:14280742	SPON1	-0.4	-8.2	-0.37	2.95e-15	Mitochondrial DNA levels;
LUAD	cis	rs11771526	0.892	rs62457539	chr7:32364604	G/A	cg27511599	chr7:32358540	NA	0.59	6.83	0.32	2.88e-11	Body mass index;
LUAD	cis	rs2019216	0.524	rs1518049	chr17:21922055	C/T	cg05591447	chr17:21909280	FLJ36000	-0.27	-6.55	-0.3	1.62e-10	Pelvic organ prolapse;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg11297934	chr3:12705869	RAF1	-0.38	-6.45	-0.3	3.12e-10	Schizophrenia;
LUAD	cis	rs35306767	0.807	rs1013505	chr10:953273	C/T	cg26597838	chr10:835615	NA	0.97	13.5	0.55	8.93e-35	Eosinophil percentage of granulocytes;
LUAD	cis	rs6920965	0.507	rs9401853	chr6:126215197	A/T	cg05901451	chr6:126070800	HEY2	-0.45	-6.75	-0.31	4.99e-11	High light scatter reticulocyte count;
LUAD	cis	rs7487075	0.619	rs4077707	chr12:46858498	T/C	cg23829395	chr12:46796953	NA	0.31	6.56	0.3	1.62e-10	Itch intensity from mosquito bite;
LUAD	cis	rs7020830	0.931	rs9775431	chr9:37130433	G/A	cg14294708	chr9:37120828	ZCCHC7	0.8	15.32	0.6	1.89e-42	Schizophrenia;
LUAD	cis	rs89107	0.688	rs283082	chr6:118605441	A/C	cg18833306	chr6:118973337	C6orf204	0.52	9.35	0.41	5.09e-19	Cardiac structure and function;
LUAD	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg09184832	chr6:79620586	NA	-0.52	-9.78	-0.43	1.71e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg00634984	chr7:65235879	NA	0.5	6.94	0.32	1.51e-11	Aortic root size;
LUAD	trans	rs7395662	0.963	rs2865923	chr11:48724955	G/A	cg15704280	chr7:45808275	SEPT13	-0.41	-6.35	-0.3	5.43e-10	HDL cholesterol;
LUAD	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg07870213	chr5:140052090	DND1	1.0	14.22	0.57	8.88e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08048268	chr3:133502702	NA	-0.53	-10.54	-0.46	3.32e-23	Iron status biomarkers;
LUAD	cis	rs12545109	0.800	rs2609979	chr8:57390066	G/A	cg07776626	chr8:57350775	NA	-0.63	-9.08	-0.4	4.27e-18	Obesity-related traits;
LUAD	trans	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg12400702	chr3:12838781	CAND2	0.31	6.44	0.3	3.34e-10	Parkinson's disease;
LUAD	cis	rs10916814	0.632	rs10916817	chr1:20897294	C/T	cg24502330	chr1:20914028	CDA	-0.36	-7.14	-0.33	4.19e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-20.88	-0.71	4.69e-67	Coronary artery disease;
LUAD	cis	rs28374715	0.662	rs72737792	chr15:41515589	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.9	-16.74	-0.63	1.19e-48	Ulcerative colitis;
LUAD	cis	rs9487051	0.768	rs463503	chr6:109525757	T/C	cg01475377	chr6:109611718	NA	-0.38	-6.9	-0.32	1.9e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs7665090	1.000	rs909349	chr4:103556316	C/T	cg07973026	chr4:103553119	MANBA	-0.47	-8.31	-0.37	1.28e-15	Primary biliary cholangitis;
LUAD	cis	rs9837602	0.810	rs13093776	chr3:99842140	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.56	8.19	0.37	3.1e-15	Breast cancer;
LUAD	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.76	13.93	0.56	1.47e-36	Intelligence (multi-trait analysis);
LUAD	cis	rs7927771	0.524	rs10838777	chr11:47860954	A/C	cg18512352	chr11:47633146	NA	0.36	6.39	0.3	4.37e-10	Subjective well-being;
LUAD	cis	rs7799006	0.929	rs745566	chr7:2256406	T/C	cg02951883	chr7:2050386	MAD1L1	-0.5	-7.4	-0.34	7.6e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg01884057	chr2:25150051	NA	0.33	6.97	0.32	1.2e-11	Body mass index;
LUAD	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg14829155	chr15:31115871	NA	0.5	8.48	0.38	3.92e-16	Huntington's disease progression;
LUAD	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-14.98	-0.59	5.45e-41	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs11088226	0.645	rs78172258	chr21:33936539	T/G	cg09050820	chr6:167586206	TCP10L2	0.91	12.44	0.52	1.65e-30	Gastritis;
LUAD	cis	rs4803468	0.904	rs60781668	chr19:41944842	A/T	cg09537434	chr19:41945824	ATP5SL	0.5	7.89	0.36	2.61e-14	Height;
LUAD	cis	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg02807482	chr3:125708958	NA	-0.6	-6.8	-0.31	3.59e-11	Blood pressure (smoking interaction);
LUAD	cis	rs2806561	0.964	rs1757041	chr1:23506063	G/A	cg12483005	chr1:23474871	LUZP1	0.39	6.86	0.32	2.46e-11	Height;
LUAD	cis	rs59698941	0.943	rs4705978	chr5:132245433	C/T	cg14825688	chr5:132208181	LEAP2	-0.47	-6.41	-0.3	3.91e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.18	0.54	1.73e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg01765077	chr12:122356316	WDR66	0.55	9.47	0.42	1.98e-19	Mean corpuscular volume;
LUAD	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg26924012	chr15:45694286	SPATA5L1	1.02	19.06	0.68	6.2e-59	Homoarginine levels;
LUAD	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg00310523	chr12:86230176	RASSF9	0.37	7.46	0.34	4.93e-13	Major depressive disorder;
LUAD	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg05425664	chr17:57184151	TRIM37	-0.44	-7.88	-0.36	2.83e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6062509	0.965	rs2315008	chr20:62343956	T/G	cg02966332	chr20:62369605	LIME1	-0.46	-7.6	-0.35	1.87e-13	Prostate cancer;
LUAD	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.94	-0.4	1.26e-17	Total body bone mineral density;
LUAD	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg03929089	chr4:120376271	NA	-1.0	-20.66	-0.71	4.34e-66	Height;
LUAD	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg04546413	chr19:29218101	NA	0.72	10.56	0.46	2.7e-23	Methadone dose in opioid dependence;
LUAD	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg11062466	chr8:58055876	NA	0.61	8.01	0.36	1.11e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg18621852	chr3:10150065	C3orf24	0.46	8.07	0.37	7.31e-15	Alzheimer's disease;
LUAD	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg02880119	chr16:3481970	NA	0.63	9.41	0.42	3.25e-19	Body mass index (adult);
LUAD	cis	rs56283067	0.847	rs62435999	chr6:44695273	T/G	cg20913747	chr6:44695427	NA	-0.44	-7.44	-0.34	5.76e-13	Total body bone mineral density;
LUAD	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg00933542	chr6:150070202	PCMT1	0.43	8.92	0.4	1.39e-17	Lung cancer;
LUAD	cis	rs7584330	0.554	rs7587496	chr2:238387632	A/G	cg14458575	chr2:238380390	NA	0.77	11.54	0.49	5.46e-27	Prostate cancer;
LUAD	cis	rs9900062	0.507	rs7225993	chr17:62708284	C/G	cg02598441	chr17:62777298	LOC146880	-0.5	-6.45	-0.3	3.12e-10	QT interval;
LUAD	cis	rs2447097	1.000	rs2447097	chr17:2278064	A/C	cg27406664	chr17:2294951	MNT	0.54	11.22	0.48	9.67e-26	Autism spectrum disorder;
LUAD	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg22875332	chr1:76189707	ACADM	0.85	17.11	0.64	2.88e-50	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg13385794	chr1:248469461	NA	0.25	6.65	0.31	8.98e-11	Common traits (Other);
LUAD	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg10518543	chr12:38710700	ALG10B	-0.46	-7.34	-0.34	1.09e-12	Morning vs. evening chronotype;
LUAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg22907277	chr7:1156413	C7orf50	0.84	13.79	0.56	5.33e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11166629	1.000	rs6981735	chr8:135635730	T/C	cg27224718	chr8:135614730	ZFAT	0.62	10.98	0.47	7.68e-25	Smoking quantity;
LUAD	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg11344533	chr11:111475393	SIK2	-0.35	-6.63	-0.31	1.02e-10	Primary sclerosing cholangitis;
LUAD	trans	rs8073060	0.592	rs225306	chr17:33920036	A/C	cg19694781	chr19:47549865	TMEM160	0.79	13.09	0.54	4.15e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs420259	0.516	rs120963	chr16:23608070	A/G	cg00143387	chr16:23521605	GGA2	0.72	10.06	0.44	1.72e-21	Bipolar disorder;
LUAD	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs8017423	0.935	rs2236403	chr14:90736325	C/T	cg14092571	chr14:90743983	NA	0.44	7.52	0.34	3.39e-13	Mortality in heart failure;
LUAD	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg04287289	chr16:89883240	FANCA	0.83	7.23	0.33	2.24e-12	Skin colour saturation;
LUAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.29	-0.41	8.23e-19	Bipolar disorder and schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20299236	chr22:32870557	FBXO7	-0.43	-6.72	-0.31	5.72e-11	Height;
LUAD	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs62229266	0.659	rs2026259	chr21:37430627	A/G	cg12218747	chr21:37451666	NA	-0.4	-7.02	-0.32	8.62e-12	Mitral valve prolapse;
LUAD	cis	rs3733418	0.929	rs13134940	chr4:165889612	G/A	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.49	-6.39	-0.3	4.34e-10	Obesity-related traits;
LUAD	cis	rs2224391	1.000	rs9504369	chr6:5261575	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-9.75	-0.43	2.08e-20	Height;
LUAD	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg25817165	chr18:72167213	CNDP2	-0.74	-11.74	-0.5	9.44e-28	Refractive error;
LUAD	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg14835575	chr10:16859367	RSU1	0.51	7.69	0.35	1.08e-13	Platelet distribution width;
LUAD	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg11833968	chr6:79620685	NA	-0.43	-8.29	-0.37	1.56e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6445967	0.530	rs4553990	chr3:58381180	T/A	cg23715586	chr3:58305044	RPP14	0.41	6.6	0.31	1.26e-10	Platelet count;
LUAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06873352	chr17:61820015	STRADA	0.82	18.31	0.67	1.36e-55	Prudent dietary pattern;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03232484	chr7:93633800	BET1	-0.39	-6.36	-0.3	5.16e-10	Cancer;
LUAD	cis	rs1524976	1.000	rs7612710	chr3:65476581	C/T	cg16238336	chr3:65465873	MAGI1	-0.59	-7.18	-0.33	3.24e-12	PR interval;
LUAD	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.42	-8.01	-0.36	1.1e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2455799	0.613	rs1976479	chr3:15729714	C/G	cg16303742	chr3:15540471	COLQ	-0.52	-9.69	-0.43	3.38e-20	Mean platelet volume;
LUAD	cis	rs2637266	1.000	rs2395384	chr10:78335329	G/A	cg18941641	chr10:78392320	NA	0.34	6.95	0.32	1.36e-11	Pulmonary function;
LUAD	cis	rs117623576	0.680	rs12269122	chr10:32367864	C/T	cg03047570	chr10:32398778	NA	-0.62	-7.61	-0.35	1.76e-13	Anti-saccade response;
LUAD	cis	rs6011002	0.745	rs2261092	chr20:62353933	A/G	cg21849932	chr20:62369462	LIME1	-0.78	-6.47	-0.3	2.78e-10	Dental caries;
LUAD	cis	rs4786125	0.581	rs7193000	chr16:6918270	G/C	cg03623568	chr16:6915990	A2BP1	-0.47	-10.22	-0.44	4.72e-22	Heart rate variability traits (SDNN);
LUAD	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg23018236	chr17:30244563	NA	-0.69	-8.54	-0.38	2.38e-16	Hip circumference adjusted for BMI;
LUAD	trans	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg18335740	chr13:41363409	SLC25A15	0.63	11.53	0.49	5.96e-27	Lewy body disease;
LUAD	cis	rs4253772	0.592	rs1807600	chr22:46644640	A/G	cg09491104	chr22:46646882	C22orf40	-0.58	-11.53	-0.49	6.24e-27	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs3806843	0.608	rs246042	chr5:140330967	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.41	0.42	3.12e-19	Menarche (age at onset);
LUAD	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg24818145	chr4:99064322	C4orf37	-0.42	-7.06	-0.32	6.78e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.57	-9.87	-0.43	8.2e-21	Electrocardiographic conduction measures;
LUAD	cis	rs7432375	0.566	rs835636	chr3:136674500	A/C	cg15507776	chr3:136538369	TMEM22	0.45	8.01	0.36	1.12e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg06618935	chr21:46677482	NA	0.47	8.22	0.37	2.57e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6445967	0.554	rs4364180	chr3:58452639	C/T	cg23715586	chr3:58305044	RPP14	0.39	6.38	0.3	4.54e-10	Platelet count;
LUAD	cis	rs10751667	0.560	rs10902267	chr11:1007831	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-6.91	-0.32	1.78e-11	Alzheimer's disease (late onset);
LUAD	cis	rs847851	0.834	rs2504164	chr6:34914378	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.29	-6.52	-0.3	2.05e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg25237894	chr2:233734115	C2orf82	0.61	11.68	0.49	1.57e-27	Coronary artery disease;
LUAD	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg03474202	chr17:45855739	NA	-0.39	-9.24	-0.41	1.18e-18	IgG glycosylation;
LUAD	cis	rs11971779	0.616	rs6974907	chr7:139068729	G/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.46	-0.3	2.86e-10	Diisocyanate-induced asthma;
LUAD	cis	rs4903604	0.581	rs4899658	chr14:78035392	A/T	cg18872420	chr14:78023429	SPTLC2	-0.45	-8.15	-0.37	4.13e-15	Gut microbiome composition (winter);
LUAD	cis	rs1595825	0.735	rs6752454	chr2:198938959	T/G	cg10547527	chr2:198650123	BOLL	-0.51	-6.96	-0.32	1.27e-11	Ulcerative colitis;
LUAD	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg04772025	chr11:68637568	NA	0.57	8.89	0.4	1.76e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg00814883	chr7:100076585	TSC22D4	-0.8	-11.2	-0.48	1.15e-25	Platelet count;
LUAD	cis	rs13394619	0.936	rs9789414	chr2:11724684	A/G	cg07314298	chr2:11723111	GREB1	-0.53	-9.82	-0.43	1.19e-20	Endometriosis;
LUAD	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg17480646	chr11:65405466	SIPA1	-0.46	-6.85	-0.32	2.57e-11	Acne (severe);
LUAD	cis	rs1595825	0.891	rs77032596	chr2:198603185	T/G	cg00361562	chr2:198649771	BOLL	-0.5	-6.73	-0.31	5.48e-11	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.0	0.36	1.24e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.6	0.52	4.03e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg22676075	chr6:135203613	NA	0.53	9.5	0.42	1.55e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs791888	0.965	rs791875	chr10:89406088	C/T	cg13926569	chr10:89418898	PAPSS2	-0.46	-8.62	-0.39	1.36e-16	Magnesium levels;
LUAD	cis	rs1403694	0.695	rs1050274	chr3:186435370	G/A	cg12454167	chr3:186435060	KNG1	0.5	10.5	0.45	4.58e-23	Blood protein levels;
LUAD	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg14541582	chr5:601475	NA	-0.36	-7.66	-0.35	1.31e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs9837602	0.938	rs9823908	chr3:99795507	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	9.4	0.42	3.34e-19	Breast cancer;
LUAD	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg09184832	chr6:79620586	NA	-0.53	-9.75	-0.43	2.11e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg15839431	chr19:19639596	YJEFN3	0.54	8.65	0.39	1.06e-16	Bipolar disorder;
LUAD	cis	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg01251360	chr16:68772225	CDH1	-0.3	-9.23	-0.41	1.33e-18	Colorectal cancer;
LUAD	cis	rs7107174	1.000	rs2373009	chr11:77945815	T/A	cg19901956	chr11:77921274	USP35	-0.54	-6.53	-0.3	1.84e-10	Testicular germ cell tumor;
LUAD	cis	rs9611519	1.000	rs2273085	chr22:41615376	C/T	cg13813247	chr22:41461852	NA	-0.43	-7.15	-0.33	3.76e-12	Neuroticism;
LUAD	cis	rs12216545	0.765	rs4725915	chr7:150251752	C/T	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.43	-0.3	3.43e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs921968	0.613	rs2556388	chr2:219541056	T/C	cg02176678	chr2:219576539	TTLL4	-0.59	-11.83	-0.5	4.21e-28	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs1325195	0.920	rs4651013	chr1:179072966	C/T	cg11624085	chr17:8464688	MYH10	-0.44	-6.79	-0.31	3.82e-11	IgE grass sensitization;
LUAD	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg22676075	chr6:135203613	NA	0.39	7.11	0.33	5.07e-12	Red blood cell count;
LUAD	cis	rs703842	0.532	rs238516	chr12:58117355	T/C	cg12615879	chr12:58013172	SLC26A10	0.4	7.95	0.36	1.74e-14	Multiple sclerosis;
LUAD	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg19163074	chr7:65112434	INTS4L2	0.44	6.64	0.31	9.61e-11	Aortic root size;
LUAD	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg06558623	chr16:89946397	TCF25	1.16	10.75	0.46	5.64e-24	Skin colour saturation;
LUAD	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg14779329	chr11:130786720	SNX19	0.38	6.74	0.31	5.2e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-8.75	-0.39	5.26e-17	Gut microbiome composition (summer);
LUAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.56	-6.9	-0.32	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg17063962	chr7:91808500	NA	0.71	12.7	0.53	1.5e-31	Breast cancer;
LUAD	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg21681030	chr2:46777652	RHOQ	0.41	6.96	0.32	1.27e-11	Height;
LUAD	cis	rs375066	0.935	rs10421518	chr19:44381286	A/G	cg12072164	chr19:44306565	LYPD5	0.32	6.49	0.3	2.44e-10	Breast cancer;
LUAD	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg24596788	chr1:163392923	NA	-0.33	-7.12	-0.33	4.79e-12	Motion sickness;
LUAD	cis	rs2224391	0.628	rs2753243	chr6:5256261	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.61	-9.82	-0.43	1.26e-20	Height;
LUAD	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg15448220	chr1:150897856	SETDB1	0.46	7.97	0.36	1.47e-14	Tonsillectomy;
LUAD	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg20848291	chr7:100343083	ZAN	-0.61	-9.91	-0.43	5.92e-21	Other erythrocyte phenotypes;
LUAD	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg02421172	chr7:1938701	MAD1L1	0.43	6.65	0.31	9.35e-11	Bipolar disorder;
LUAD	cis	rs4072705	0.646	rs4838187	chr9:127242076	G/C	cg01786973	chr9:127249749	NR5A1	0.3	6.74	0.31	5.32e-11	Menarche (age at onset);
LUAD	trans	rs1493916	0.837	rs4992177	chr18:31407020	C/T	cg15819921	chr19:927150	ARID3A	-0.42	-6.86	-0.32	2.44e-11	Life satisfaction;
LUAD	cis	rs6424115	1.000	rs4649115	chr1:24155731	A/G	cg15997130	chr1:24165203	NA	-0.57	-10.08	-0.44	1.41e-21	Immature fraction of reticulocytes;
LUAD	cis	rs877282	0.945	rs12776447	chr10:790625	A/G	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg14895029	chr7:2775587	GNA12	0.44	7.09	0.33	5.68e-12	Height;
LUAD	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg08999081	chr20:33150536	PIGU	0.63	14.36	0.57	2.33e-38	Coronary artery disease;
LUAD	cis	rs34172651	0.545	rs8056132	chr16:24716348	A/G	cg04756594	chr16:24857601	SLC5A11	0.45	8.64	0.39	1.19e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.5	6.87	0.32	2.37e-11	Platelet count;
LUAD	cis	rs11676348	0.741	rs12694425	chr2:218942313	A/G	cg06547715	chr2:218990976	CXCR2	-0.28	-6.41	-0.3	3.81e-10	Ulcerative colitis;
LUAD	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23221052	chr5:179740743	GFPT2	-0.66	-10.74	-0.46	6.02e-24	Height;
LUAD	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg03433033	chr1:76189801	ACADM	0.93	19.22	0.68	1.31e-59	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs5758511	0.514	rs5758626	chr22:42572363	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.66	11.45	0.49	1.21e-26	Birth weight;
LUAD	cis	rs12711979	0.765	rs6705742	chr2:3820672	C/T	cg17052675	chr2:3827356	NA	-0.51	-10.45	-0.45	7e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.37	0.41	4.32e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13012494	chr21:47604986	C21orf56	-0.61	-10.53	-0.46	3.62e-23	Testicular germ cell tumor;
LUAD	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg03517284	chr6:25882590	NA	-0.4	-6.41	-0.3	3.89e-10	Height;
LUAD	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg24879335	chr3:133465180	TF	-0.39	-8.32	-0.37	1.26e-15	Iron status biomarkers (transferrin levels);
LUAD	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg18833306	chr6:118973337	C6orf204	-0.49	-7.3	-0.33	1.42e-12	Diastolic blood pressure;
LUAD	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg27129171	chr3:47204927	SETD2	-0.42	-6.63	-0.31	1.02e-10	Colorectal cancer;
LUAD	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg00383909	chr3:49044727	WDR6	0.98	9.1	0.4	3.53e-18	Cognitive function;
LUAD	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg24818145	chr4:99064322	C4orf37	-0.41	-6.88	-0.32	2.23e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg11663144	chr21:46675770	NA	-0.62	-12.5	-0.52	1.02e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13012494	chr21:47604986	C21orf56	0.65	11.3	0.48	4.86e-26	Testicular germ cell tumor;
LUAD	cis	rs7274811	0.901	rs55990870	chr20:32302908	C/T	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.48	-6.79	-0.31	3.88e-11	Height;
LUAD	cis	rs2274273	0.686	rs28631821	chr14:55845987	T/C	cg04306507	chr14:55594613	LGALS3	0.4	8.58	0.38	1.88e-16	Protein biomarker;
LUAD	cis	rs7593730	0.636	rs10170600	chr2:161118687	T/C	cg22609984	chr2:161126801	NA	0.56	10.27	0.45	3.08e-22	Type 2 diabetes;
LUAD	trans	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg26043149	chr18:55253948	FECH	0.47	7.69	0.35	1.03e-13	Bone mineral density;
LUAD	cis	rs11741688	0.557	rs6898923	chr5:178330559	C/T	cg20935368	chr5:178288625	ZNF354B	0.36	6.39	0.3	4.51e-10	Sleep duration;
LUAD	cis	rs11051970	0.879	rs2651379	chr12:32581778	A/G	cg24626660	chr12:32551988	NA	0.32	6.5	0.3	2.23e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7680126	0.596	rs4637402	chr4:10045430	C/T	cg00071950	chr4:10020882	SLC2A9	0.6	9.79	0.43	1.57e-20	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg24531977	chr5:56204891	C5orf35	-0.72	-11.53	-0.49	6.37e-27	Coronary artery disease;
LUAD	cis	rs921968	0.565	rs6436073	chr2:219618237	A/C	cg02176678	chr2:219576539	TTLL4	-0.57	-11.35	-0.48	2.94e-26	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg18335740	chr13:41363409	SLC25A15	0.86	16.89	0.63	2.62e-49	Lewy body disease;
LUAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg15117754	chr3:10150083	C3orf24	0.42	6.7	0.31	6.79e-11	Alzheimer's disease;
LUAD	cis	rs427941	0.703	rs201440	chr7:101735599	C/T	cg06246474	chr7:101738831	CUX1	0.41	7.27	0.33	1.72e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs9837602	1.000	rs2291494	chr3:99781805	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	9.04	0.4	5.82e-18	Breast cancer;
LUAD	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg12623918	chr2:306882	NA	0.34	6.81	0.31	3.38e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.93	0.4	1.35e-17	Endometrial cancer;
LUAD	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg04036182	chr15:45458818	NA	-0.39	-6.91	-0.32	1.8e-11	Glomerular filtration rate;
LUAD	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg16701003	chr16:89028210	CBFA2T3	0.51	10.13	0.44	9.86e-22	Social autistic-like traits;
LUAD	cis	rs3796352	0.527	rs11716506	chr3:52944328	C/T	cg04865290	chr3:52927548	TMEM110	-0.53	-7.17	-0.33	3.32e-12	Immune reponse to smallpox (secreted IL-2);
LUAD	cis	rs4006360	0.629	rs72625995	chr17:39253835	C/T	cg20663846	chr17:39254439	KRTAP4-8	0.37	7.85	0.36	3.46e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg05887092	chr17:76393375	PGS1	0.42	7.44	0.34	5.83e-13	HDL cholesterol levels;
LUAD	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-7.86	-0.36	3.25e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs17608059	0.566	rs5005684	chr17:13910633	T/C	cg27005118	chr17:13972210	COX10	-0.32	-6.59	-0.31	1.28e-10	Temperament;
LUAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.31	-0.41	6.92e-19	Alzheimer's disease;
LUAD	cis	rs9837602	1.000	rs9841186	chr3:99795651	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.44	6.75	0.31	4.83e-11	Breast cancer;
LUAD	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg15992532	chr8:142229932	SLC45A4	-0.48	-8.56	-0.38	2.11e-16	Immature fraction of reticulocytes;
LUAD	cis	rs7267979	0.844	rs869358	chr20:25374674	A/G	cg08601574	chr20:25228251	PYGB	-0.42	-7.75	-0.35	7.03e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg00684032	chr4:1343700	KIAA1530	0.38	6.56	0.3	1.57e-10	Obesity-related traits;
LUAD	trans	rs7395662	0.724	rs10400308	chr11:48891246	G/T	cg00717180	chr2:96193071	NA	-0.39	-7.42	-0.34	6.52e-13	HDL cholesterol;
LUAD	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.57	9.08	0.4	4.25e-18	Platelet count;
LUAD	cis	rs7584330	0.554	rs55919896	chr2:238428823	A/T	cg14458575	chr2:238380390	NA	0.59	9.42	0.42	2.96e-19	Prostate cancer;
LUAD	cis	rs4845570	0.920	rs1521185	chr1:151764049	A/G	cg07092448	chr1:151763213	TDRKH	0.74	9.67	0.43	4.02e-20	Coronary artery disease;
LUAD	trans	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg18834416	chr8:37888184	EIF4EBP1	0.41	6.84	0.32	2.81e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg24684739	chr11:58345702	ZFP91;LPXN;ZFP91-CNTF	0.43	6.39	0.3	4.28e-10	QT interval;
LUAD	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.09	0.33	5.56e-12	Renal cell carcinoma;
LUAD	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg19041857	chr6:27730383	NA	-0.44	-7.61	-0.35	1.82e-13	Parkinson's disease;
LUAD	trans	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.49	0.42	1.72e-19	Mean corpuscular volume;
LUAD	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg15017067	chr4:17643749	FAM184B	0.37	7.26	0.33	1.88e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg18221128	chr13:20735236	GJA3	-0.39	-6.69	-0.31	7.16e-11	Schizophrenia;
LUAD	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	10.05	0.44	1.85e-21	Total body bone mineral density;
LUAD	cis	rs807669	0.869	rs1061325	chr22:19184095	T/C	cg24911827	chr22:19170109	CLTCL1	0.32	6.72	0.31	5.79e-11	Metabolite levels;
LUAD	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.86	0.36	3.24e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg20991723	chr1:152506922	NA	0.34	6.64	0.31	9.55e-11	Hair morphology;
LUAD	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-7.84	-0.36	3.68e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.92	-0.5	1.91e-28	Bipolar disorder;
LUAD	cis	rs6121246	0.609	rs6060652	chr20:30266845	A/G	cg21427119	chr20:30132790	HM13	-0.36	-6.47	-0.3	2.64e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	6.63	0.31	1.05e-10	Rheumatoid arthritis;
LUAD	cis	rs7072216	0.763	rs8181292	chr10:100175477	A/G	cg26618903	chr10:100175079	PYROXD2	-0.4	-8.74	-0.39	5.39e-17	Metabolite levels;
LUAD	cis	rs739496	0.615	rs57072497	chr12:112145217	A/T	cg10833066	chr12:111807467	FAM109A	0.44	7.01	0.32	9.55e-12	Platelet count;
LUAD	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.7	13.09	0.54	4.16e-33	Axial length;
LUAD	cis	rs11971779	0.680	rs6962366	chr7:139043867	G/A	cg23387468	chr7:139079360	LUC7L2	0.28	6.5	0.3	2.31e-10	Diisocyanate-induced asthma;
LUAD	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg07527032	chr15:84868466	LOC388152	0.44	6.63	0.31	1.01e-10	Schizophrenia;
LUAD	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2692947	0.800	rs4332959	chr2:96549121	C/T	cg23100626	chr2:96804247	ASTL	0.29	7.14	0.33	4.03e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg19761014	chr17:28927070	LRRC37B2	0.93	9.19	0.41	1.82e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs77972916	0.536	rs7562101	chr2:43592756	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-7.65	-0.35	1.4e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg05590025	chr7:65112418	INTS4L2	-0.71	-7.61	-0.35	1.84e-13	Diabetic kidney disease;
LUAD	cis	rs897984	0.572	rs112906665	chr16:31040139	T/C	cg02466173	chr16:30829666	NA	-0.56	-9.83	-0.43	1.1e-20	Dementia with Lewy bodies;
LUAD	trans	rs7395662	1.000	rs4882123	chr11:48575739	G/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.55	-0.3	1.71e-10	HDL cholesterol;
LUAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg13047869	chr3:10149882	C3orf24	0.59	10.05	0.44	1.87e-21	Alzheimer's disease;
LUAD	cis	rs7680126	0.633	rs2868937	chr4:10303081	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-7.26	-0.33	1.89e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg14829155	chr15:31115871	NA	0.57	9.48	0.42	1.78e-19	Huntington's disease progression;
LUAD	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg26898376	chr11:64110657	CCDC88B	-0.37	-6.92	-0.32	1.66e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg15242686	chr22:24348715	GSTTP1	0.39	6.78	0.31	3.95e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs67072384	1.000	rs67072384	chr11:72450724	C/T	cg04827223	chr11:72435913	ARAP1	-0.63	-7.29	-0.33	1.54e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs2625529	0.689	rs10851847	chr15:72111760	T/C	cg16672083	chr15:72433130	SENP8	-0.62	-11.56	-0.49	4.69e-27	Red blood cell count;
LUAD	cis	rs76878669	0.561	rs11227465	chr11:66115879	T/A	cg10616300	chr11:66138557	SLC29A2	-0.36	-7.43	-0.34	6.23e-13	Educational attainment (years of education);
LUAD	cis	rs8099014	0.954	rs4559989	chr18:56131869	G/A	cg12907477	chr18:56117327	MIR122	0.39	6.52	0.3	1.97e-10	Platelet count;
LUAD	cis	rs55788414	0.929	rs66463064	chr16:81180995	T/C	cg06400318	chr16:81190750	PKD1L2	-0.72	-8.58	-0.39	1.75e-16	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs12210905	0.920	rs72839468	chr6:27301734	A/G	cg08851530	chr6:28072375	NA	0.76	6.42	0.3	3.73e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07343612	chr16:622815	PIGQ	-0.82	-16.36	-0.62	5.59e-47	Height;
LUAD	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg08470875	chr2:26401718	FAM59B	-0.57	-7.83	-0.36	3.9e-14	Gut microbiome composition (summer);
LUAD	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	trans	rs629535	0.862	rs662725	chr8:70029616	C/T	cg21567404	chr3:27674614	NA	1.0	18.39	0.67	6.15e-56	Dupuytren's disease;
LUAD	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg15145296	chr3:125709740	NA	-0.53	-6.78	-0.31	4.01e-11	Blood pressure (smoking interaction);
LUAD	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.89	-0.36	2.52e-14	Total body bone mineral density;
LUAD	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg10544611	chr16:67998164	SLC12A4	-0.53	-6.77	-0.31	4.32e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs131777	0.545	rs131759	chr22:51015481	G/A	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	0.36	6.45	0.3	3.02e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs7587476	0.601	rs1129804	chr2:215674323	C/G	cg04004882	chr2:215674386	BARD1	-0.53	-7.11	-0.33	5.05e-12	Neuroblastoma;
LUAD	cis	rs80319144	1.000	rs77276698	chr2:159250229	G/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.9	0.32	1.93e-11	Restless legs syndrome;
LUAD	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg07507251	chr3:52567010	NT5DC2	0.34	6.47	0.3	2.76e-10	Bipolar disorder;
LUAD	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg04455712	chr21:45112962	RRP1B	0.43	8.84	0.39	2.55e-17	Mean corpuscular volume;
LUAD	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	6.37	0.3	4.96e-10	Rheumatoid arthritis;
LUAD	cis	rs11078597	0.731	rs8077638	chr17:1640793	C/T	cg18436246	chr17:1640651	WDR81	0.79	12.3	0.51	6.14e-30	Serum albumin level;
LUAD	trans	rs5756813	0.661	rs2285177	chr22:38205894	A/G	cg19894588	chr14:64061835	NA	-0.54	-7.91	-0.36	2.3e-14	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg18099408	chr3:52552593	STAB1	0.41	7.22	0.33	2.36e-12	Bipolar disorder;
LUAD	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg20135002	chr11:47629003	NA	-0.41	-7.19	-0.33	3.02e-12	Subjective well-being;
LUAD	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg00310523	chr12:86230176	RASSF9	-0.35	-7.12	-0.33	4.79e-12	Major depressive disorder;
LUAD	cis	rs57994353	0.897	rs3812594	chr9:139368953	G/A	cg14019695	chr9:139328340	INPP5E	0.39	6.39	0.3	4.44e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs12200782	0.674	rs12207224	chr6:26519280	A/T	cg08851530	chr6:28072375	NA	0.72	6.69	0.31	7.12e-11	Small cell lung carcinoma;
LUAD	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg12927641	chr6:109611667	NA	-0.52	-9.21	-0.41	1.5e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs9473147	0.543	rs4715025	chr6:47483653	C/G	cg02130027	chr6:47444894	CD2AP	0.38	7.1	0.33	5.44e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg14664628	chr15:75095509	CSK	-0.49	-8.23	-0.37	2.37e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg26343298	chr8:95960752	TP53INP1	0.37	8.01	0.36	1.16e-14	Type 2 diabetes;
LUAD	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg17177755	chr1:15930204	NA	0.45	7.26	0.33	1.82e-12	Systolic blood pressure;
LUAD	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-12.75	-0.53	1e-31	Mean corpuscular volume;
LUAD	cis	rs35771425	0.572	rs34552796	chr1:211422229	C/T	cg26515805	chr1:211431828	RCOR3	-0.37	-6.46	-0.3	2.84e-10	Educational attainment (years of education);
LUAD	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.42	6.56	0.3	1.6e-10	Schizophrenia;
LUAD	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg02454025	chr1:11042201	C1orf127	0.99	17.13	0.64	2.49e-50	Ewing sarcoma;
LUAD	cis	rs6782228	0.606	rs7627549	chr3:128353079	G/A	cg16766828	chr3:128327626	NA	-0.38	-7.18	-0.33	3.16e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18876405	chr7:65276391	NA	-0.43	-6.91	-0.32	1.74e-11	Aortic root size;
LUAD	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg18209359	chr17:80159595	CCDC57	0.41	7.02	0.32	8.69e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs3204270	0.684	rs57405099	chr17:79637065	T/C	cg09655341	chr17:79618100	PDE6G	0.53	6.7	0.31	6.5e-11	Dental caries;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg06024135	chr12:27863332	MRPS35	0.39	6.39	0.3	4.43e-10	Bilirubin levels;
LUAD	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg27411982	chr8:10470053	RP1L1	0.42	7.25	0.33	1.94e-12	Retinal vascular caliber;
LUAD	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg09184832	chr6:79620586	NA	-0.53	-9.85	-0.43	9.4499999999999992e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs2377058	0.803	rs13332439	chr16:89730479	A/T	cg04155793	chr16:89752847	CDK10	-0.33	-6.63	-0.31	1.01e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs8102476	0.905	rs7250689	chr19:38753625	C/T	cg14131526	chr19:38747285	PPP1R14A	0.37	6.84	0.32	2.8e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUAD	trans	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.21	-0.41	1.52e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03822003	chr16:30569878	ZNF764	-0.57	-6.93	-0.32	1.6e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9372498	0.536	rs9481825	chr6:118876092	C/T	cg18833306	chr6:118973337	C6orf204	-0.49	-7.16	-0.33	3.61e-12	Diastolic blood pressure;
LUAD	cis	rs208520	0.802	rs208499	chr6:66932146	C/T	cg07460842	chr6:66804631	NA	-0.96	-13.9	-0.56	2e-36	Exhaled nitric oxide output;
LUAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg13047869	chr3:10149882	C3orf24	0.67	11.48	0.49	9.3e-27	Alzheimer's disease;
LUAD	cis	rs12618769	0.652	rs3754871	chr2:99224309	A/T	cg10123293	chr2:99228465	UNC50	0.5	8.84	0.4	2.51e-17	Bipolar disorder;
LUAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg18538332	chr22:24372958	LOC391322	0.47	7.07	0.32	6.55e-12	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs11230563	1.000	rs2074227	chr11:60776781	T/C	cg27098804	chr11:60776124	CD6	0.38	7.06	0.32	7.05e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs10465746	0.967	rs11163879	chr1:84444051	T/C	cg10977910	chr1:84465055	TTLL7	0.51	8.21	0.37	2.71e-15	Obesity-related traits;
LUAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg05896524	chr21:47604654	C21orf56	0.73	12.76	0.53	9.03e-32	Testicular germ cell tumor;
LUAD	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg15181151	chr6:150070149	PCMT1	0.41	8.52	0.38	2.82e-16	Lung cancer;
LUAD	cis	rs317865	0.737	rs73234651	chr4:16196651	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.87	8.45	0.38	4.6e-16	Kidney disease (early stage) in type 1 diabetes;
LUAD	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg09455208	chr3:40491958	NA	0.55	12.06	0.51	5.4e-29	Renal cell carcinoma;
LUAD	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg18105134	chr13:113819100	PROZ	-1.05	-19.34	-0.68	3.82e-60	Platelet distribution width;
LUAD	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg23301539	chr8:142222248	SLC45A4	0.49	8.9	0.4	1.6e-17	Immature fraction of reticulocytes;
LUAD	cis	rs7107174	1.000	rs2256051	chr11:77920457	G/A	cg19901956	chr11:77921274	USP35	-0.49	-6.55	-0.3	1.64e-10	Testicular germ cell tumor;
LUAD	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg25894440	chr7:65020034	NA	-0.67	-7.22	-0.33	2.47e-12	Diabetic kidney disease;
LUAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg04025307	chr7:1156635	C7orf50	0.6	6.74	0.31	5.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.55	0.52	6.47e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08048268	chr3:133502702	NA	-0.53	-10.82	-0.47	3.1e-24	Iron status biomarkers;
LUAD	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12379764	chr21:47803548	PCNT	-0.62	-9.7	-0.43	3.1e-20	Testicular germ cell tumor;
LUAD	cis	rs6840360	0.615	rs1877188	chr4:152607931	T/C	cg22705602	chr4:152727874	NA	-0.47	-8.85	-0.4	2.42e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg00310523	chr12:86230176	RASSF9	0.4	8.0	0.36	1.18e-14	Major depressive disorder;
LUAD	cis	rs929596	0.793	rs2741045	chr2:234580140	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-9.01	-0.4	7.18e-18	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs953387	1.000	rs10179271	chr2:136910834	T/C	cg05194412	chr2:137003533	NA	-0.44	-7.25	-0.33	2.01e-12	Arthritis (juvenile idiopathic);
LUAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08677398	chr8:58056175	NA	0.47	6.55	0.3	1.69e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1003719	0.788	rs1543750	chr21:38446918	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.44	0.38	5.28e-16	Eye color traits;
LUAD	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg05368731	chr17:41323189	NBR1	0.98	20.62	0.71	6.5e-66	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.87	16.77	0.63	8.94e-49	Lymphocyte counts;
LUAD	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg22920501	chr2:26401640	FAM59B	-0.96	-14.21	-0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg17306686	chr7:157230923	NA	0.52	10.41	0.45	9.41e-23	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg10876282	chr6:28092338	ZSCAN16	0.47	7.34	0.34	1.07e-12	Cardiac Troponin-T levels;
LUAD	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg21856205	chr7:94953877	PON1	-0.56	-7.93	-0.36	1.98e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6714710	0.603	rs10432626	chr2:98561153	C/A	cg26665480	chr2:98280029	ACTR1B	0.5	8.18	0.37	3.28e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs727505	1.000	rs3925331	chr7:124446137	C/G	cg23710748	chr7:124431027	NA	-0.43	-9.41	-0.42	3.15e-19	Lewy body disease;
LUAD	cis	rs977987	0.806	rs34996006	chr16:75479434	A/G	cg03315344	chr16:75512273	CHST6	0.65	14.23	0.57	8.11e-38	Dupuytren's disease;
LUAD	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg11584989	chr19:19387371	SF4	0.36	6.45	0.3	3.07e-10	Tonsillectomy;
LUAD	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg00666640	chr1:248458726	OR2T12	0.29	6.79	0.31	3.81e-11	Common traits (Other);
LUAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg02951883	chr7:2050386	MAD1L1	-0.97	-18.67	-0.67	3.53e-57	Bipolar disorder and schizophrenia;
LUAD	trans	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg11693508	chr17:37793320	STARD3	0.58	7.26	0.33	1.84e-12	Neuroticism;
LUAD	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.45	-7.23	-0.33	2.32e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg13722127	chr7:150037890	RARRES2	0.4	6.47	0.3	2.64e-10	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11644478	chr21:40555479	PSMG1	-0.57	-9.24	-0.41	1.2e-18	Cognitive function;
LUAD	cis	rs7147624	0.766	rs11158597	chr14:65913536	T/G	cg03016385	chr14:66212404	NA	-0.61	-7.21	-0.33	2.56e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg15704280	chr7:45808275	SEPT13	-0.6	-9.71	-0.43	2.89e-20	HDL cholesterol;
LUAD	cis	rs12620999	0.774	rs7584900	chr2:237957112	T/G	cg23555395	chr2:238036564	NA	0.53	8.31	0.37	1.33e-15	Systemic lupus erythematosus;
LUAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg21724239	chr8:58056113	NA	0.65	8.35	0.38	9.78e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg09035930	chr12:129282057	SLC15A4	-0.52	-9.73	-0.43	2.51e-20	Systemic lupus erythematosus;
LUAD	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg24397884	chr7:158709396	WDR60	0.66	9.02	0.4	6.54e-18	Height;
LUAD	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg27572855	chr1:25598939	RHD	0.62	14.35	0.57	2.44e-38	Erythrocyte sedimentation rate;
LUAD	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.9	0.4	1.59e-17	Parkinson's disease;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg05489143	chr3:40498640	RPL14	0.42	6.76	0.31	4.58e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg00321850	chr1:175162397	KIAA0040	-0.51	-10.93	-0.47	1.12e-24	Alcohol dependence;
LUAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg11494091	chr17:61959527	GH2	0.73	18.24	0.66	2.84e-55	Prudent dietary pattern;
LUAD	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.17	0.33	3.3e-12	Tonsillectomy;
LUAD	cis	rs6500395	1.000	rs9931123	chr16:48614293	G/T	cg04672837	chr16:48644449	N4BP1	0.39	6.69	0.31	6.99e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12681288	0.550	rs7000482	chr8:958380	T/C	cg15309053	chr8:964076	NA	0.44	9.84	0.43	9.98e-21	Schizophrenia;
LUAD	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg02782426	chr3:40428986	ENTPD3	0.35	7.51	0.34	3.58e-13	Renal cell carcinoma;
LUAD	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg00666640	chr1:248458726	OR2T12	0.32	7.71	0.35	9.24e-14	Common traits (Other);
LUAD	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg09658497	chr7:2847517	GNA12	-0.5	-9.18	-0.41	1.91e-18	Height;
LUAD	cis	rs62400317	0.859	rs10948219	chr6:45229307	A/T	cg18551225	chr6:44695536	NA	-0.56	-8.7	-0.39	7.44e-17	Total body bone mineral density;
LUAD	cis	rs953387	1.000	rs953387	chr2:136907170	A/C	cg05194412	chr2:137003533	NA	-0.39	-6.4	-0.3	4.12e-10	Arthritis (juvenile idiopathic);
LUAD	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.37	7.59	0.35	1.99e-13	Hemoglobin concentration;
LUAD	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg25344623	chr2:136566232	LCT	0.34	6.67	0.31	7.89e-11	Mosquito bite size;
LUAD	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg11502198	chr6:26597334	ABT1	0.68	11.79	0.5	5.93e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg15900387	chr1:150738905	CTSS	-0.36	-6.5	-0.3	2.21e-10	Melanoma;
LUAD	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg03467027	chr4:99064603	C4orf37	0.43	6.88	0.32	2.21e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg18105134	chr13:113819100	PROZ	-0.85	-14.47	-0.58	7.44e-39	Platelet distribution width;
LUAD	cis	rs2953174	0.507	rs34568097	chr2:241540989	A/G	cg07929629	chr2:241523174	NA	0.43	6.5	0.3	2.22e-10	Bipolar disorder;
LUAD	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg15790184	chr11:494944	RNH1	0.56	6.93	0.32	1.6e-11	Body mass index;
LUAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.85	0.56	3.1e-36	Prudent dietary pattern;
LUAD	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg21191810	chr6:118973309	C6orf204	-0.52	-8.17	-0.37	3.68e-15	Diastolic blood pressure;
LUAD	cis	rs7586879	0.929	rs6545807	chr2:25124358	C/T	cg04586622	chr2:25135609	ADCY3	0.34	7.36	0.34	9.36e-13	Body mass index;
LUAD	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg11663144	chr21:46675770	NA	-0.61	-12.18	-0.51	1.76e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3018712	0.532	rs948861	chr11:68420622	C/T	cg16797656	chr11:68205561	LRP5	-0.43	-6.62	-0.31	1.11e-10	Total body bone mineral density;
LUAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg12016809	chr21:47604291	C21orf56	0.45	7.48	0.34	4.43e-13	Testicular germ cell tumor;
LUAD	cis	rs11030122	0.702	rs10835406	chr11:3992954	G/T	cg18678763	chr11:4115507	RRM1	0.42	7.0	0.32	1.01e-11	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs9467711	0.651	rs34555420	chr6:26090270	G/T	cg06606381	chr12:133084897	FBRSL1	-1.16	-8.64	-0.39	1.13e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7189233	0.955	rs11540358	chr16:53503943	C/G	cg04059762	chr16:53544020	NA	-0.41	-6.54	-0.3	1.74e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2692947	0.644	rs1724125	chr2:96831355	G/A	cg23100626	chr2:96804247	ASTL	0.38	9.6	0.42	7.12e-20	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg01251360	chr16:68772225	CDH1	-0.3	-9.08	-0.4	4.12e-18	Colorectal cancer;
LUAD	cis	rs13082711	0.911	rs11718991	chr3:27452944	A/G	cg02860705	chr3:27208620	NA	0.59	8.99	0.4	8.62e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg05368731	chr17:41323189	NBR1	0.97	20.25	0.7	3.08e-64	Menopause (age at onset);
LUAD	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg02389323	chr16:88786976	FAM38A	1.21	11.57	0.49	4.42e-27	Plateletcrit;
LUAD	trans	rs587242	1.000	rs10489740	chr1:96919182	G/A	cg10631902	chr5:14652156	NA	0.46	7.65	0.35	1.36e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	trans	rs7181230	0.885	rs9919974	chr15:40337462	T/G	cg22705835	chr10:65332833	REEP3	-0.36	-6.88	-0.32	2.17e-11	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.01	-0.32	9.32e-12	Response to fenofibrate (adiponectin levels);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04215179	chr7:23719682	C7orf46	-0.54	-6.87	-0.32	2.26e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg07460842	chr6:66804631	NA	0.91	14.45	0.57	9.31e-39	Exhaled nitric oxide levels;
LUAD	cis	rs9302690	1.000	rs41351945	chr16:57446809	C/T	cg27017172	chr16:57497170	POLR2C	1.25	9.71	0.43	3.04e-20	Blood protein levels;
LUAD	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.53	7.65	0.35	1.34e-13	Platelet count;
LUAD	cis	rs7216064	0.953	rs12450907	chr17:65870644	T/G	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs7937890	0.706	rs7115393	chr11:14268378	T/A	cg22961513	chr11:14280813	SPON1	0.32	6.38	0.3	4.68e-10	Mitochondrial DNA levels;
LUAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg16606324	chr3:10149918	C3orf24	0.67	11.43	0.49	1.5e-26	Alzheimer's disease;
LUAD	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	6.68	0.31	7.55e-11	Obesity-related traits;
LUAD	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg14092988	chr3:52407081	DNAH1	0.44	8.86	0.4	2.28e-17	Bipolar disorder;
LUAD	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.2	0.33	2.71e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg27411982	chr8:10470053	RP1L1	-0.36	-6.57	-0.3	1.48e-10	Neuroticism;
LUAD	cis	rs10979	0.931	rs9484770	chr6:143896758	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.26	-0.45	3.46e-22	Hypospadias;
LUAD	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg04287289	chr16:89883240	FANCA	0.76	6.54	0.3	1.8e-10	Skin colour saturation;
LUAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg11062466	chr8:58055876	NA	0.67	8.96	0.4	1.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs17092148	1.000	rs3787220	chr20:33337751	T/C	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.34	-0.38	1.05e-15	Neuroticism;
LUAD	trans	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.32	0.54	4.65e-34	Exhaled nitric oxide output;
LUAD	cis	rs5769707	0.656	rs135875	chr22:50012419	T/G	cg05373962	chr22:49881684	NA	-0.5	-10.41	-0.45	9.2e-23	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg07817883	chr1:32538562	TMEM39B	0.51	6.79	0.31	3.78e-11	Monocyte percentage of white cells;
LUAD	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.53	-0.38	2.66e-16	Alzheimer's disease (late onset);
LUAD	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg05368731	chr17:41323189	NBR1	0.95	19.53	0.69	5.13e-61	Menopause (age at onset);
LUAD	trans	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg04565464	chr8:145669602	NFKBIL2	0.44	6.58	0.3	1.38e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.59	0.52	4.32e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.86	0.32	2.39e-11	Rheumatoid arthritis;
LUAD	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg27211696	chr2:191398769	TMEM194B	0.79	16.76	0.63	1.05e-48	Pulse pressure;
LUAD	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg25456477	chr12:86230367	RASSF9	0.33	6.68	0.31	7.67e-11	Major depressive disorder;
LUAD	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg18446336	chr7:2847575	GNA12	-0.33	-6.65	-0.31	8.98e-11	Height;
LUAD	cis	rs11809207	0.857	rs11247866	chr1:26517794	A/G	cg00300879	chr1:26503847	CNKSR1	0.28	6.73	0.31	5.62e-11	Height;
LUAD	cis	rs7512552	0.839	rs2264418	chr1:150368579	G/A	cg15654264	chr1:150340011	RPRD2	0.58	11.06	0.47	3.88e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg07256732	chr16:621771	PIGQ	-0.32	-6.54	-0.3	1.8e-10	Height;
LUAD	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg17173187	chr15:85201210	NMB	0.41	6.65	0.31	9.22e-11	Schizophrenia;
LUAD	cis	rs123509	0.687	rs73075297	chr3:42832466	A/G	cg12982090	chr3:42733453	KBTBD5	-0.53	-9.02	-0.4	6.41e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg20673091	chr1:2541236	MMEL1	0.38	8.07	0.37	7.33e-15	Ulcerative colitis;
LUAD	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg08470875	chr2:26401718	FAM59B	-0.66	-8.95	-0.4	1.1e-17	Gut microbiome composition (summer);
LUAD	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg11166453	chr1:247681781	NA	0.38	7.28	0.33	1.68e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4372836	1.000	rs4666118	chr2:28951698	C/T	cg09522027	chr2:28974177	PPP1CB	-0.63	-10.04	-0.44	2e-21	Body mass index;
LUAD	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg23283495	chr1:209979779	IRF6	0.67	8.34	0.38	1.05e-15	Coronary artery disease;
LUAD	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg27373749	chr11:63775612	MACROD1	0.39	8.0	0.36	1.24e-14	Pulse pressure;
LUAD	trans	rs11247915	1.000	rs11247915	chr1:26650550	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.39	-6.61	-0.31	1.16e-10	Obesity-related traits;
LUAD	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg02176678	chr2:219576539	TTLL4	-0.66	-13.68	-0.55	1.58e-35	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg21475434	chr5:93447410	FAM172A	0.76	8.62	0.39	1.35e-16	Diabetic retinopathy;
LUAD	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg03690763	chr11:133734501	NA	-0.29	-7.04	-0.32	7.7e-12	Childhood ear infection;
LUAD	cis	rs7191439	0.589	rs11076699	chr16:88756812	A/C	cg09381666	chr16:88757816	NA	-0.68	-6.68	-0.31	7.38e-11	Plateletcrit;
LUAD	trans	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	cis	rs2637266	0.905	rs2579772	chr10:78406555	A/G	cg18941641	chr10:78392320	NA	0.35	7.31	0.34	1.31e-12	Pulmonary function;
LUAD	cis	rs1950500	0.545	rs1950501	chr14:24806800	C/G	cg22990158	chr14:24802150	ADCY4	-0.56	-10.37	-0.45	1.36e-22	Height;
LUAD	cis	rs11048434	0.736	rs7302417	chr12:9091116	G/T	cg04155231	chr12:9217510	LOC144571	0.41	7.88	0.36	2.83e-14	Sjögren's syndrome;
LUAD	cis	rs300703	0.515	rs440617	chr2:189818	A/G	cg24565620	chr2:194026	NA	0.38	6.56	0.3	1.59e-10	Blood protein levels;
LUAD	cis	rs1915146	0.546	rs9422857	chr10:126861278	C/G	cg05090351	chr10:126851162	NA	0.54	10.34	0.45	1.69e-22	Menarche (age at onset);
LUAD	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg25358565	chr5:93447407	FAM172A	0.64	7.57	0.35	2.3e-13	Diabetic retinopathy;
LUAD	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg20744362	chr22:50050164	C22orf34	0.38	7.56	0.35	2.47e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg14092571	chr14:90743983	NA	-0.52	-9.22	-0.41	1.37e-18	Mortality in heart failure;
LUAD	cis	rs4631830	0.863	rs2611507	chr10:51518673	T/C	cg20129853	chr10:51489980	NA	-0.33	-6.47	-0.3	2.67e-10	Prostate-specific antigen levels;
LUAD	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	15.1	0.59	1.66e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg27532560	chr4:187881888	NA	-0.41	-8.11	-0.37	5.45e-15	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg02734326	chr4:10020555	SLC2A9	-0.42	-7.24	-0.33	2.16e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg01788221	chr16:89496183	ANKRD11	-0.37	-7.27	-0.33	1.73e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs6761276	0.866	rs12469822	chr2:113830563	C/T	cg09040174	chr2:113837401	NA	0.67	11.49	0.49	8.48e-27	Protein quantitative trait loci;
LUAD	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg27535305	chr1:53392650	SCP2	0.35	7.33	0.34	1.18e-12	Monocyte count;
LUAD	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.14	-0.33	4.14e-12	Breast cancer;
LUAD	trans	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg26043149	chr18:55253948	FECH	0.43	7.04	0.32	8.04e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg15704280	chr7:45808275	SEPT13	-0.53	-8.36	-0.38	9.04e-16	HDL cholesterol;
LUAD	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.49	0.38	3.47e-16	Menopause (age at onset);
LUAD	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg09904177	chr6:26538194	HMGN4	0.42	6.94	0.32	1.48e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg20670292	chr2:131099506	IMP4;CCDC115	-0.39	-6.48	-0.3	2.53e-10	Cancer;
LUAD	cis	rs62400317	0.859	rs6919998	chr6:45159289	C/T	cg18551225	chr6:44695536	NA	-0.55	-8.44	-0.38	5.14e-16	Total body bone mineral density;
LUAD	cis	rs2732480	0.500	rs11168468	chr12:48612465	C/T	cg04545296	chr12:48745243	ZNF641	0.39	10.0	0.44	2.83e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	trans	rs7395662	0.929	rs10838982	chr11:48640168	C/T	cg00717180	chr2:96193071	NA	-0.43	-8.17	-0.37	3.72e-15	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12612619	0.704	rs2119026	chr2:27310393	A/G	cg00617064	chr2:27272375	NA	0.38	7.18	0.33	3.2e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg09796270	chr17:17721594	SREBF1	0.39	7.87	0.36	2.9e-14	Total body bone mineral density;
LUAD	cis	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg07460842	chr6:66804631	NA	-1.19	-29.76	-0.82	8.64e-106	Exhaled nitric oxide output;
LUAD	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg17724175	chr1:150552817	MCL1	0.34	7.87	0.36	3.01e-14	Melanoma;
LUAD	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs7264396	0.563	rs6058296	chr20:34269225	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.86	-0.36	3.16e-14	Total cholesterol levels;
LUAD	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.34e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3087591	1.000	rs8082020	chr17:29694795	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.42	-6.87	-0.32	2.34e-11	Hip circumference;
LUAD	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg00204512	chr16:28754710	NA	0.3	6.4	0.3	4.08e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.35	-0.34	1.04e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10802521	chr3:52805072	NEK4	-0.62	-11.25	-0.48	7.14e-26	Bipolar disorder;
LUAD	cis	rs367943	1.000	rs348954	chr5:112821716	A/G	cg12552261	chr5:112820674	MCC	-0.59	-11.13	-0.48	2.02e-25	Type 2 diabetes;
LUAD	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg08645402	chr16:4508243	NA	-0.59	-10.88	-0.47	1.85e-24	Schizophrenia;
LUAD	cis	rs35740288	0.770	rs67253156	chr15:86105045	A/G	cg13263323	chr15:86062960	AKAP13	-0.41	-6.7	-0.31	6.77e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs7680126	0.633	rs11727390	chr4:10296760	C/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-7.51	-0.34	3.44e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg08280861	chr8:58055591	NA	0.55	7.36	0.34	9.66e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg09455208	chr3:40491958	NA	0.63	13.61	0.55	3.01e-35	Renal cell carcinoma;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14008524	chr16:2587876	PDPK1	-0.39	-6.41	-0.3	3.86e-10	Cancer;
LUAD	cis	rs3818285	0.655	rs623980	chr10:111646147	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.8	-15.71	-0.61	3.69e-44	Superior crus of antihelix expression;
LUAD	cis	rs12949688	0.967	rs12451748	chr17:55822171	T/C	cg12582317	chr17:55822272	NA	0.36	7.32	0.34	1.29e-12	Schizophrenia;
LUAD	cis	rs526821	0.595	rs485555	chr11:55323570	A/G	cg04317927	chr11:55418816	OR4S2	-0.4	-7.76	-0.35	6.3e-14	Pediatric bone mineral density (spine);
LUAD	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg16950941	chr11:66035639	RAB1B	0.43	7.24	0.33	2.1e-12	Gout;
LUAD	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg04155289	chr7:94953770	PON1	-0.54	-7.39	-0.34	7.98e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.49	-0.38	3.64e-16	Gut microbiome composition (summer);
LUAD	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg21984481	chr17:79567631	NPLOC4	-0.56	-11.77	-0.5	7.1e-28	Eye color traits;
LUAD	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.72	-0.43	2.64e-20	Schizophrenia;
LUAD	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg08601574	chr20:25228251	PYGB	-0.47	-8.82	-0.39	2.94e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs208520	0.742	rs208454	chr6:66907783	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-14.08	-0.56	3.33e-37	Exhaled nitric oxide output;
LUAD	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.1	-0.33	5.25e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg08132940	chr7:1081526	C7orf50	-0.77	-10.35	-0.45	1.63e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1555895	0.576	rs752375	chr10:863329	C/T	cg20503657	chr10:835505	NA	0.4	6.35	0.3	5.55e-10	Survival in rectal cancer;
LUAD	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg06263672	chr7:65235340	NA	0.49	6.44	0.3	3.17e-10	Aortic root size;
LUAD	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.76	-14.46	-0.58	8.26e-39	Intelligence (multi-trait analysis);
LUAD	cis	rs73206853	0.563	rs73194047	chr12:111191926	G/A	cg12870014	chr12:110450643	ANKRD13A	0.57	6.46	0.3	2.96e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg25985355	chr7:65971099	NA	0.38	7.08	0.33	5.94e-12	Aortic root size;
LUAD	cis	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.88	-0.36	2.79e-14	Neuroticism;
LUAD	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.53	0.3	1.88e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg20119798	chr7:94954144	PON1	-0.49	-6.5	-0.3	2.28e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg18811423	chr2:55921094	PNPT1	-0.56	-9.45	-0.42	2.31e-19	Metabolic syndrome;
LUAD	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg23954153	chr1:44402353	ARTN	-0.37	-7.22	-0.33	2.49e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg23950597	chr19:37808831	NA	-0.59	-7.07	-0.33	6.44e-12	Coronary artery calcification;
LUAD	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg00631329	chr6:26305371	NA	0.69	13.41	0.55	2e-34	Educational attainment;
LUAD	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	0.46	6.77	0.31	4.23e-11	Alzheimer's disease (late onset);
LUAD	trans	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.71	-10.15	-0.44	8.05e-22	Obesity-related traits;
LUAD	trans	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg07211511	chr3:129823064	LOC729375	-0.54	-6.98	-0.32	1.14e-11	Blood pressure (smoking interaction);
LUAD	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg07636037	chr3:49044803	WDR6	0.57	10.78	0.46	4.25e-24	Parkinson's disease;
LUAD	cis	rs7301826	0.651	rs2037789	chr12:131288292	C/T	cg11011512	chr12:131303247	STX2	-0.42	-7.11	-0.33	5.12e-12	Plasma plasminogen activator levels;
LUAD	trans	rs853679	0.607	rs13205911	chr6:28124114	C/T	cg06606381	chr12:133084897	FBRSL1	-1.22	-10.86	-0.47	2.15e-24	Depression;
LUAD	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg00383909	chr3:49044727	WDR6	0.44	6.76	0.31	4.51e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs10193935	0.901	rs13375	chr2:42559288	A/G	cg27598129	chr2:42591480	NA	-0.69	-8.67	-0.39	9.01e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg06784218	chr1:46089804	CCDC17	0.6	13.33	0.54	4.46e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg04703951	chr17:43578652	NA	-0.57	-8.13	-0.37	4.65e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs11951515	0.508	rs11958046	chr5:43583389	T/C	cg01983248	chr5:43482804	C5orf28	-0.38	-8.27	-0.37	1.8e-15	Metabolite levels  (X-11787);
LUAD	trans	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg18335740	chr13:41363409	SLC25A15	0.6	11.14	0.48	1.93e-25	Lewy body disease;
LUAD	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg22823121	chr1:150693482	HORMAD1	0.47	9.5	0.42	1.5700000000000001e-19	Melanoma;
LUAD	trans	rs3857536	0.813	rs7768944	chr6:66951088	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg19610905	chr11:61596333	FADS2	-0.67	-11.38	-0.48	2.23e-26	Trans fatty acid levels;
LUAD	cis	rs894734	0.535	rs2366142	chr12:54323148	T/C	cg25024717	chr12:54324583	NA	-0.32	-6.74	-0.31	5.34e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUAD	cis	rs12530845	0.623	rs73721673	chr7:135349573	A/T	cg23117316	chr7:135346802	PL-5283	-0.59	-8.85	-0.4	2.34e-17	Red blood cell traits;
LUAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	cis	rs9473147	0.516	rs13212790	chr6:47576367	T/C	cg02130027	chr6:47444894	CD2AP	0.35	6.7	0.31	6.77e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg02160872	chr5:212506	CCDC127	-0.5	-6.57	-0.3	1.44e-10	Breast cancer;
LUAD	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg10589385	chr1:150898437	SETDB1	0.43	8.23	0.37	2.32e-15	Tonsillectomy;
LUAD	cis	rs892961	1.000	rs1110638	chr17:75400690	T/C	cg05865280	chr17:75406074	SEPT9	0.63	19.87	0.69	1.49e-62	Airflow obstruction;
LUAD	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.55	8.15	0.37	4.16e-15	Gut microbiome composition (summer);
LUAD	cis	rs74181299	0.784	rs2723085	chr2:65297359	C/G	cg05010058	chr2:65284262	CEP68	0.31	6.73	0.31	5.61e-11	Pulse pressure;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05020822	chr8:144373356	ZNF696	-0.56	-6.97	-0.32	1.19e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg00677455	chr12:58241039	CTDSP2	0.45	7.69	0.35	1.04e-13	Multiple sclerosis;
LUAD	cis	rs9463078	0.683	rs1418433	chr6:44752568	C/T	cg25276700	chr6:44698697	NA	0.34	6.38	0.3	4.75e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUAD	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11644478	chr21:40555479	PSMG1	-0.61	-10.47	-0.45	5.74e-23	Cognitive function;
LUAD	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg11344533	chr11:111475393	SIK2	0.37	6.91	0.32	1.78e-11	Primary sclerosing cholangitis;
LUAD	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.01	0.36	1.11e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg23018236	chr17:30244563	NA	-0.69	-8.39	-0.38	7.25e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18876405	chr7:65276391	NA	0.61	10.45	0.45	6.68e-23	Aortic root size;
LUAD	trans	rs11039798	1.000	rs12281162	chr11:48650491	T/C	cg03929089	chr4:120376271	NA	0.58	6.6	0.31	1.22e-10	Axial length;
LUAD	cis	rs2625529	0.824	rs12592044	chr15:72419115	A/G	cg16672083	chr15:72433130	SENP8	-0.78	-13.11	-0.54	3.31e-33	Red blood cell count;
LUAD	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.93	-0.5	1.76e-28	Bipolar disorder;
LUAD	trans	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg07211511	chr3:129823064	LOC729375	-0.53	-6.9	-0.32	1.89e-11	Blood pressure (smoking interaction);
LUAD	cis	rs1018836	0.699	rs13271657	chr8:91474599	C/G	cg16814680	chr8:91681699	NA	-0.63	-10.21	-0.44	5.17e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.74	10.31	0.45	2.21e-22	Smoking behavior;
LUAD	cis	rs7793919	0.726	rs10232008	chr7:4783206	T/G	cg00064840	chr7:4784485	FOXK1	0.35	6.57	0.3	1.49e-10	Mosquito bite size;
LUAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg02951883	chr7:2050386	MAD1L1	-0.96	-18.23	-0.66	3.37e-55	Bipolar disorder and schizophrenia;
LUAD	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg18230493	chr5:56204884	C5orf35	0.52	8.46	0.38	4.45e-16	Coronary artery disease;
LUAD	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg02592271	chr2:27665507	KRTCAP3	0.3	7.89	0.36	2.7e-14	Total body bone mineral density;
LUAD	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg11673840	chr17:47092156	IGF2BP1	-0.33	-6.44	-0.3	3.34e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs9788721	0.836	rs2568494	chr15:78740964	G/A	cg18825076	chr15:78729989	IREB2	-0.57	-10.05	-0.44	1.91e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg10164272	chr16:89456328	ANKRD11	0.41	6.57	0.3	1.48e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg15147215	chr3:52552868	STAB1	0.42	7.5	0.34	3.72e-13	Bipolar disorder;
LUAD	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.67	-8.55	-0.38	2.3e-16	Yeast infection;
LUAD	cis	rs62238980	0.614	rs80321137	chr22:32460767	C/T	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg04511125	chr2:88470314	THNSL2	0.87	9.69	0.43	3.34e-20	Plasma clusterin levels;
LUAD	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.46	0.42	2.24e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs117623576	0.887	rs211411	chr10:32394992	T/C	cg03047570	chr10:32398778	NA	0.86	10.75	0.46	5.38e-24	Anti-saccade response;
LUAD	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg08601574	chr20:25228251	PYGB	0.44	8.12	0.37	5.31e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs587242	1.000	rs2011693	chr1:96884287	G/A	cg10631902	chr5:14652156	NA	0.43	7.13	0.33	4.49e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg04546413	chr19:29218101	NA	0.71	8.95	0.4	1.13e-17	Methadone dose in opioid dependence;
LUAD	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg06064525	chr11:970664	AP2A2	-0.54	-11.03	-0.47	4.75e-25	Alzheimer's disease (late onset);
LUAD	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg22676075	chr6:135203613	NA	-0.41	-7.3	-0.33	1.4e-12	Red blood cell count;
LUAD	cis	rs6748734	0.948	rs6752657	chr2:241840541	G/C	cg07537917	chr2:241836409	C2orf54	-0.3	-8.28	-0.37	1.66e-15	Urinary metabolites;
LUAD	cis	rs7582720	0.832	rs114139737	chr2:203721733	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.71	8.78	0.39	3.94e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs986417	1.000	rs761555	chr14:61109543	T/C	cg27398547	chr14:60952738	C14orf39	0.64	7.22	0.33	2.43e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg02683114	chr2:24398427	C2orf84	-0.54	-7.9	-0.36	2.36e-14	Asthma;
LUAD	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.85	-0.36	3.38e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2387326	0.767	rs11016087	chr10:129940761	A/C	cg16087940	chr10:129947807	NA	-0.62	-8.37	-0.38	8.64e-16	Select biomarker traits;
LUAD	trans	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	1.04e-10	Diabetic kidney disease;
LUAD	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg00321850	chr1:175162397	KIAA0040	-0.52	-11.13	-0.48	2.05e-25	Alcohol dependence;
LUAD	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg16850897	chr7:100343110	ZAN	-0.62	-10.23	-0.45	4.17e-22	Other erythrocyte phenotypes;
LUAD	trans	rs3219090	1.000	rs2793382	chr1:226583417	C/T	cg27539482	chr13:111589090	NA	0.42	7.18	0.33	3.13e-12	Melanoma;
LUAD	trans	rs57046232	0.552	rs6054166	chr20:6348251	A/C	cg21095983	chr6:86352623	SYNCRIP	0.42	6.6	0.31	1.24e-10	Colorectal cancer;
LUAD	cis	rs2109514	0.774	rs6954077	chr7:116129153	G/A	cg12739419	chr7:116140593	CAV2	-0.33	-6.8	-0.31	3.58e-11	Prevalent atrial fibrillation;
LUAD	cis	rs17401966	0.838	rs8019	chr1:10366487	T/G	cg19773385	chr1:10388646	KIF1B	-0.39	-6.36	-0.3	5.13e-10	Hepatocellular carcinoma;
LUAD	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg11645453	chr3:52864694	ITIH4	0.6	11.29	0.48	5.14e-26	Schizophrenia;
LUAD	trans	rs3942852	0.955	rs7117386	chr11:48125371	G/A	cg03929089	chr4:120376271	NA	-0.54	-7.12	-0.33	4.75e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs939658	0.683	rs8038464	chr15:79463036	A/T	cg17916960	chr15:79447300	NA	-0.36	-6.84	-0.32	2.79e-11	Refractive error;
LUAD	cis	rs807669	0.903	rs2800974	chr22:19168087	C/T	cg02655711	chr22:19163373	SLC25A1	0.84	18.66	0.67	3.81e-57	Metabolite levels;
LUAD	trans	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.39	-0.3	4.45e-10	Aortic root size;
LUAD	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg07741184	chr6:167504864	NA	0.4	9.14	0.41	2.58e-18	Crohn's disease;
LUAD	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.56	0.3	1.55e-10	Aortic root size;
LUAD	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18099408	chr3:52552593	STAB1	-0.46	-8.07	-0.37	7.53e-15	Bipolar disorder;
LUAD	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg24690094	chr11:67383802	NA	0.4	7.18	0.33	3.06e-12	Mean corpuscular volume;
LUAD	cis	rs7584330	0.554	rs6739456	chr2:238385092	G/C	cg14458575	chr2:238380390	NA	0.69	10.94	0.47	1.1e-24	Prostate cancer;
LUAD	cis	rs12681287	0.547	rs9942793	chr8:87509091	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-10.12	-0.44	1.07e-21	Caudate activity during reward;
LUAD	cis	rs10924309	0.882	rs10924305	chr1:245856763	A/G	cg00036263	chr1:245852353	KIF26B	0.48	7.52	0.34	3.24e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg11494091	chr17:61959527	GH2	0.74	18.43	0.67	4.34e-56	Prudent dietary pattern;
LUAD	cis	rs4629710	0.592	rs13205441	chr6:131575069	G/A	cg12606694	chr6:131520996	AKAP7	0.51	7.42	0.34	6.3e-13	Multiple myeloma (IgH translocation);
LUAD	cis	rs28374715	0.532	rs28703570	chr15:41679492	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.12	-26.3	-0.79	5.01e-91	Ulcerative colitis;
LUAD	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg11166453	chr1:247681781	NA	0.38	7.28	0.33	1.68e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs12618769	0.597	rs3754892	chr2:99063318	T/A	cg10123293	chr2:99228465	UNC50	0.4	6.49	0.3	2.42e-10	Bipolar disorder;
LUAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg08888203	chr3:10149979	C3orf24	0.63	10.72	0.46	7.04e-24	Alzheimer's disease;
LUAD	cis	rs68170813	0.559	rs11773514	chr7:106958469	T/C	cg23024343	chr7:107201750	COG5	0.49	7.0	0.32	1.03e-11	Coronary artery disease;
LUAD	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg08645402	chr16:4508243	NA	0.54	9.98	0.44	3.37e-21	Schizophrenia;
LUAD	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg05342682	chr7:94953680	PON1	-0.5	-7.01	-0.32	9.29e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7089973	0.872	rs7909566	chr10:116629136	A/G	cg25233709	chr10:116636983	FAM160B1	0.39	7.56	0.35	2.48e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs240764	0.817	rs11155606	chr6:101163915	T/C	cg09795085	chr6:101329169	ASCC3	-0.44	-7.57	-0.35	2.36e-13	Neuroticism;
LUAD	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg14541582	chr5:601475	NA	-0.36	-7.66	-0.35	1.31e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg09640425	chr7:158790006	NA	-0.46	-7.75	-0.35	6.85e-14	Facial morphology (factor 20);
LUAD	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg18854424	chr1:2615690	NA	-0.42	-9.11	-0.41	3.27e-18	Ulcerative colitis;
LUAD	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg22029157	chr1:209979665	IRF6	0.78	9.97	0.44	3.75e-21	Cleft lip with or without cleft palate;
LUAD	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.48	-0.38	3.78e-16	Total body bone mineral density;
LUAD	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg23533926	chr12:111358616	MYL2	-0.41	-7.05	-0.32	7.29e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08280861	chr8:58055591	NA	0.8	9.65	0.42	4.69e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs28595532	0.920	rs116401323	chr4:119721727	C/T	cg14228332	chr4:119757509	SEC24D	0.89	8.15	0.37	4.2e-15	Cannabis dependence symptom count;
LUAD	cis	rs68170813	0.641	rs75639044	chr7:107092631	A/C	cg02696742	chr7:106810147	HBP1	-0.79	-10.51	-0.45	4.19e-23	Coronary artery disease;
LUAD	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.39	0.34	7.92e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg20503657	chr10:835505	NA	0.8	12.27	0.51	8.2e-30	Eosinophil percentage of granulocytes;
LUAD	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg06627628	chr2:24431161	ITSN2	-0.7	-11.15	-0.48	1.69e-25	Asthma;
LUAD	trans	rs1973993	0.717	rs56209707	chr1:96972973	C/A	cg10631902	chr5:14652156	NA	-0.47	-8.11	-0.37	5.5e-15	Weight;
LUAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.66	0.31	8.46e-11	Prudent dietary pattern;
LUAD	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg09835421	chr16:68378352	PRMT7	-0.77	-8.18	-0.37	3.36e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg21918786	chr6:109611834	NA	-0.59	-10.85	-0.47	2.24e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs3733418	0.929	rs12512234	chr4:165908865	C/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.49	-6.8	-0.31	3.51e-11	Obesity-related traits;
LUAD	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg11502198	chr6:26597334	ABT1	0.56	9.36	0.41	4.61e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg03474202	chr17:45855739	NA	-0.33	-7.08	-0.33	6.04e-12	IgG glycosylation;
LUAD	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg24818145	chr4:99064322	C4orf37	0.43	7.18	0.33	3.22e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg00981070	chr1:2046702	PRKCZ	0.35	6.59	0.3	1.34e-10	Height;
LUAD	cis	rs68170813	0.559	rs6946036	chr7:106853659	G/A	cg23024343	chr7:107201750	COG5	0.49	7.02	0.32	9.03e-12	Coronary artery disease;
LUAD	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg20790798	chr5:1857306	NA	-0.45	-7.46	-0.34	4.81e-13	Cardiovascular disease risk factors;
LUAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.54	-9.31	-0.41	6.82e-19	Longevity;Endometriosis;
LUAD	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg15691649	chr6:25882328	NA	0.46	7.53	0.34	3.13e-13	Blood metabolite levels;
LUAD	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.16	0.33	3.64e-12	Menopause (age at onset);
LUAD	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg08029281	chr1:67600428	NA	0.35	6.67	0.31	8.18e-11	Psoriasis;
LUAD	cis	rs6714710	0.603	rs34503448	chr2:98587288	A/G	cg26665480	chr2:98280029	ACTR1B	0.55	9.04	0.4	5.86e-18	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.37	-7.61	-0.35	1.79e-13	Lymphocyte counts;
LUAD	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg04414720	chr1:150670196	GOLPH3L	0.72	12.76	0.53	9.4e-32	Melanoma;
LUAD	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.28	-6.93	-0.32	1.54e-11	Coronary artery disease;
LUAD	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg10057126	chr4:77819792	ANKRD56	0.53	8.9	0.4	1.65e-17	Emphysema distribution in smoking;
LUAD	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg02018176	chr4:1364513	KIAA1530	0.36	6.52	0.3	1.97e-10	Obesity-related traits;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23409613	chr14:53196849	STYX	-0.54	-6.65	-0.31	9.21e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg12863693	chr15:85201151	NMB	-0.38	-6.59	-0.3	1.34e-10	Schizophrenia;
LUAD	trans	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.09	-0.47	3.02e-25	Depression;
LUAD	cis	rs2004318	1.000	rs79359901	chr19:55078603	T/C	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.93e-13	Blood protein levels;
LUAD	cis	rs13315871	0.929	rs1045115	chr3:58305199	C/T	cg20936604	chr3:58311152	NA	-0.74	-7.77	-0.35	5.89e-14	Cholesterol, total;
LUAD	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg18230493	chr5:56204884	C5orf35	-0.72	-11.14	-0.48	1.96e-25	Initial pursuit acceleration;
LUAD	cis	rs3784262	0.565	rs3784264	chr15:58250246	T/G	cg12031962	chr15:58353849	ALDH1A2	0.35	6.52	0.3	1.97e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.34	7.2	0.33	2.77e-12	Cardiac Troponin-T levels;
LUAD	cis	rs13315871	0.929	rs9811074	chr3:58421846	A/G	cg12435725	chr3:58293450	RPP14	-0.69	-7.36	-0.34	9.51e-13	Cholesterol, total;
LUAD	cis	rs6740322	1.000	rs6756736	chr2:43558743	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.72	-10.45	-0.45	6.88e-23	Coronary artery disease;
LUAD	cis	rs250677	0.522	rs1432798	chr5:148383345	C/G	cg12140854	chr5:148520817	ABLIM3	-0.54	-9.15	-0.41	2.47e-18	Breast cancer;
LUAD	trans	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg01620082	chr3:125678407	NA	-1.04	-10.21	-0.44	4.98e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7818345	1.000	rs7818345	chr8:19306618	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.32	7.08	0.33	6.04e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg15557168	chr22:42548783	NA	-0.55	-10.85	-0.47	2.3e-24	Schizophrenia;
LUAD	cis	rs713477	0.967	rs4901570	chr14:55915249	T/C	cg13175173	chr14:55914753	NA	-0.35	-7.4	-0.34	7.41e-13	Pediatric bone mineral content (femoral neck);
LUAD	trans	rs9929218	1.000	rs12446407	chr16:68804068	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.76	-0.56	7.41e-36	Colorectal cancer;
LUAD	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg18230493	chr5:56204884	C5orf35	-0.85	-12.54	-0.52	6.65e-31	Initial pursuit acceleration;
LUAD	cis	rs3833788	1	rs3833788	chr12:121151062	CTCTCTTG/C	cg27246729	chr12:121163418	ACADS	0.39	7.39	0.34	8.03e-13	Mean corpuscular hemoglobin;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg07630564	chr3:128445061	RAB7A	-0.51	-6.47	-0.3	2.79e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs8064299	0.597	rs9893035	chr17:72783798	A/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.43	6.84	0.32	2.84e-11	Monocyte count;
LUAD	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg02527881	chr3:46936655	PTH1R	-0.47	-9.38	-0.42	4e-19	Colorectal cancer;
LUAD	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg24531977	chr5:56204891	C5orf35	-0.65	-10.92	-0.47	1.25e-24	Coronary artery disease;
LUAD	trans	rs225245	0.610	rs321607	chr17:33880584	A/G	cg19694781	chr19:47549865	TMEM160	-0.47	-7.75	-0.35	6.85e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	trans	rs11039798	0.764	rs11040208	chr11:49012509	A/G	cg03929089	chr4:120376271	NA	0.65	6.48	0.3	2.54e-10	Axial length;
LUAD	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg24397884	chr7:158709396	WDR60	0.65	8.94	0.4	1.18e-17	Height;
LUAD	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg00204512	chr16:28754710	NA	0.35	7.53	0.34	3.06e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg08859206	chr1:53392774	SCP2	-0.47	-8.69	-0.39	7.93e-17	Monocyte count;
LUAD	cis	rs6494488	0.500	rs72741303	chr15:64692418	G/T	cg08069370	chr15:64387884	SNX1	-0.75	-6.65	-0.31	9.09e-11	Coronary artery disease;
LUAD	cis	rs9875589	0.509	rs1844108	chr3:14024328	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.38	7.05	0.32	7.24e-12	Ovarian reserve;
LUAD	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03452623	chr4:187889614	NA	-0.84	-18.15	-0.66	7.47e-55	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4660306	1.000	rs2356559	chr1:45981512	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.42	-6.88	-0.32	2.17e-11	Homocysteine levels;
LUAD	cis	rs7493	0.901	rs13226149	chr7:95025600	G/A	cg05342682	chr7:94953680	PON1	-0.51	-7.37	-0.34	9.1e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4790333	0.653	rs2447103	chr17:2262997	A/C	cg27406664	chr17:2294951	MNT	0.4	7.82	0.36	4.25e-14	Proinsulin levels;
LUAD	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg21252483	chr19:49399788	TULP2	-0.68	-10.49	-0.45	4.72e-23	Red cell distribution width;
LUAD	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.56	-0.3	1.6e-10	Total body bone mineral density;
LUAD	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.52	-8.76	-0.39	4.84e-17	Alzheimer's disease (late onset);
LUAD	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg03733263	chr8:22462867	KIAA1967	0.73	12.13	0.51	2.83e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs7010267	0.596	rs1485285	chr8:120036138	T/C	cg01975934	chr8:119970761	NA	-0.34	-6.52	-0.3	2.03e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs6942407	0.592	rs757961	chr7:86849510	T/C	cg02420886	chr7:86849541	C7orf23	0.65	7.51	0.34	3.64e-13	Food allergy;
LUAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg18621852	chr3:10150065	C3orf24	0.49	8.49	0.38	3.57e-16	Alzheimer's disease;
LUAD	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg12863693	chr15:85201151	NMB	0.38	6.78	0.31	4.1e-11	Schizophrenia;
LUAD	cis	rs977987	0.806	rs1109342	chr16:75445675	A/G	cg03315344	chr16:75512273	CHST6	-0.63	-13.64	-0.55	2.29e-35	Dupuytren's disease;
LUAD	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	7.74e-16	Body mass index;
LUAD	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.27e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg01802117	chr1:53393560	SCP2	0.43	7.74	0.35	7.19e-14	Monocyte count;
LUAD	trans	rs60843830	0.661	rs11674477	chr2:105822	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.51	7.75	0.35	6.87e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg06740227	chr12:86229804	RASSF9	0.39	6.8	0.31	3.66e-11	Major depressive disorder;
LUAD	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg12935359	chr14:103987150	CKB	-0.47	-7.75	-0.35	6.85e-14	Body mass index;
LUAD	cis	rs68170813	0.559	rs11769527	chr7:106912948	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.48	-0.45	5.18e-23	Coronary artery disease;
LUAD	cis	rs11048434	0.761	rs12827055	chr12:9130861	G/T	cg23795048	chr12:9217529	LOC144571	0.44	7.9	0.36	2.43e-14	Sjögren's syndrome;
LUAD	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg08807101	chr21:30365312	RNF160	0.5	8.55	0.38	2.28e-16	Dental caries;
LUAD	cis	rs7572644	0.699	rs6738887	chr2:28268467	C/T	cg27432699	chr2:27873401	GPN1	-0.42	-6.51	-0.3	2.11e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUAD	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.89	-0.36	2.67e-14	Personality dimensions;
LUAD	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg13319975	chr6:146136371	FBXO30	-0.75	-12.59	-0.52	4.45e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg20503657	chr10:835505	NA	-0.48	-7.52	-0.34	3.29e-13	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7017914	0.934	rs13274062	chr8:71737087	G/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.68	-0.31	7.6e-11	Bone mineral density;
LUAD	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg22683308	chr4:1340831	KIAA1530	-0.49	-8.13	-0.37	4.82e-15	Longevity;
LUAD	cis	rs698833	0.926	rs786626	chr2:44604066	C/G	cg04920474	chr2:44395004	PPM1B	0.38	6.85	0.32	2.59e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg13271783	chr10:134563150	INPP5A	-0.41	-6.56	-0.3	1.54e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs116248771	0.739	rs73156423	chr3:158345628	C/A	cg16708174	chr3:158430962	RARRES1	0.46	6.8	0.31	3.62e-11	diarrhoeal disease at age 2;
LUAD	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg00666640	chr1:248458726	OR2T12	0.28	6.63	0.31	1.01e-10	Common traits (Other);
LUAD	cis	rs727505	0.866	rs56216989	chr7:124729068	T/A	cg23710748	chr7:124431027	NA	-0.42	-8.51	-0.38	2.97e-16	Lewy body disease;
LUAD	cis	rs4948275	0.550	rs10994749	chr10:63156222	G/C	cg02461363	chr10:63212496	TMEM26	-0.35	-7.33	-0.34	1.18e-12	Night sleep phenotypes;
LUAD	cis	rs7487075	0.619	rs6582657	chr12:46856019	A/C	cg23829395	chr12:46796953	NA	0.3	6.76	0.31	4.71e-11	Itch intensity from mosquito bite;
LUAD	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg05340658	chr4:99064831	C4orf37	0.46	7.53	0.34	3.07e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs601339	1.000	rs645491	chr12:123181661	T/C	cg11919336	chr12:123188078	GPR109A	0.47	7.29	0.33	1.52e-12	Adiponectin levels;
LUAD	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg03289416	chr15:75166202	SCAMP2	-0.4	-6.92	-0.32	1.69e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09503196	chr19:52531867	ZNF614	-0.39	-6.55	-0.3	1.69e-10	Cancer;
LUAD	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg21775007	chr8:11205619	TDH	-0.51	-9.37	-0.41	4.29e-19	Retinal vascular caliber;
LUAD	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10802521	chr3:52805072	NEK4	-0.6	-10.91	-0.47	1.39e-24	Bipolar disorder;
LUAD	cis	rs9381040	0.701	rs722442	chr6:41089681	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.32	-0.37	1.24e-15	Alzheimer's disease (late onset);
LUAD	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg16099169	chr2:106886729	NA	-0.62	-9.6	-0.42	7.3e-20	Facial morphology (factor 23);
LUAD	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg22852734	chr6:133119734	C6orf192	0.78	9.37	0.41	4.27e-19	Type 2 diabetes nephropathy;
LUAD	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg06064525	chr11:970664	AP2A2	-0.53	-10.88	-0.47	1.86e-24	Alzheimer's disease (late onset);
LUAD	cis	rs939658	0.567	rs11631829	chr15:79446529	C/T	cg17916960	chr15:79447300	NA	-0.43	-9.03	-0.4	6.33e-18	Refractive error;
LUAD	cis	rs71478720	1.000	rs71478720	chr11:112009605	C/T	cg26534425	chr11:112034925	IL18	0.47	7.06	0.32	6.84e-12	Interleukin-18 levels;
LUAD	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg12311346	chr5:56204834	C5orf35	-0.45	-7.36	-0.34	9.55e-13	Coronary artery disease;
LUAD	trans	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg01620082	chr3:125678407	NA	-0.89	-9.16	-0.41	2.33e-18	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.47	0.38	4.01e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg01528321	chr10:82214614	TSPAN14	0.46	7.26	0.33	1.9e-12	Post bronchodilator FEV1;
LUAD	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg07507251	chr3:52567010	NT5DC2	-0.37	-7.25	-0.33	2.02e-12	Bipolar disorder;
LUAD	cis	rs494562	0.730	rs9450270	chr6:86114766	A/G	cg13315970	chr6:86159197	NT5E	0.57	6.83	0.32	2.93e-11	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg18827107	chr12:86230957	RASSF9	-0.46	-8.45	-0.38	4.63e-16	Major depressive disorder;
LUAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg18621852	chr3:10150065	C3orf24	0.48	8.43	0.38	5.64e-16	Alzheimer's disease;
LUAD	cis	rs9788721	0.902	rs7180002	chr15:78873993	A/T	cg18825076	chr15:78729989	IREB2	-0.57	-9.23	-0.41	1.31e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg07679836	chr6:33548423	BAK1	0.62	10.97	0.47	8.14e-25	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.07	0.37	7.15e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs654384	0.898	rs13242365	chr7:4175025	G/T	cg26275264	chr7:4183598	SDK1	0.4	7.65	0.35	1.39e-13	Positive affect;
LUAD	cis	rs7215564	0.908	rs35253080	chr17:78700167	G/A	cg09596252	chr17:78655493	RPTOR	0.53	6.54	0.3	1.78e-10	Myopia (pathological);
LUAD	cis	rs300774	0.925	rs1531374	chr2:127773	A/C	cg21211680	chr2:198530	NA	-0.47	-7.36	-0.34	9.48e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg08885076	chr2:99613938	TSGA10	-0.37	-6.49	-0.3	2.36e-10	Chronic sinus infection;
LUAD	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.81	-0.36	4.44e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs516243	0.703	rs284313	chr1:10736434	A/G	cg02903756	chr1:10750680	CASZ1	-0.49	-9.27	-0.41	9.48e-19	Migraine - clinic-based;
LUAD	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.57e-13	Tonsillectomy;
LUAD	cis	rs9486719	1.000	rs12205728	chr6:96891838	T/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.04	-0.44	2.05e-21	Migraine;Coronary artery disease;
LUAD	cis	rs35883536	1.000	rs964906	chr1:101087479	G/A	cg06223162	chr1:101003688	GPR88	0.35	6.38	0.3	4.53e-10	Monocyte count;
LUAD	cis	rs11971779	0.680	rs12154842	chr7:139078484	A/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.45	-0.3	3.05e-10	Diisocyanate-induced asthma;
LUAD	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.98	-0.36	1.42e-14	Schizophrenia;
LUAD	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg24675056	chr1:15929824	NA	0.44	7.8	0.35	4.8e-14	Systolic blood pressure;
LUAD	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg25753631	chr6:25732923	NA	-0.39	-6.67	-0.31	8.23e-11	Iron status biomarkers;
LUAD	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg05132306	chr1:1846340	CALML6	-0.33	-7.21	-0.33	2.57e-12	Body mass index;
LUAD	trans	rs12048904	0.504	rs12132283	chr1:101294036	A/C	cg14530983	chr3:88190749	ZNF654	0.38	6.45	0.3	3.12e-10	Multiple sclerosis;
LUAD	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg02421172	chr7:1938701	MAD1L1	0.49	6.72	0.31	5.79e-11	Bipolar disorder;
LUAD	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	7.43	0.34	6.14e-13	Cognitive test performance;
LUAD	trans	rs853679	0.556	rs13197633	chr6:28174757	G/A	cg06606381	chr12:133084897	FBRSL1	-1.23	-10.98	-0.47	7.29e-25	Depression;
LUAD	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg25554036	chr4:6271136	WFS1	-0.62	-12.2	-0.51	1.52e-29	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.48	0.3	2.56e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.53	8.02	0.36	1.04e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg18512352	chr11:47633146	NA	-0.44	-7.49	-0.34	4.09e-13	Subjective well-being;
LUAD	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg21171335	chr12:122356390	WDR66	-0.75	-13.82	-0.56	4.01e-36	Mean corpuscular volume;
LUAD	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg26566898	chr11:117069891	TAGLN	0.35	6.85	0.32	2.65e-11	Blood protein levels;
LUAD	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg05342682	chr7:94953680	PON1	-0.48	-6.48	-0.3	2.6e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7264396	0.666	rs1536147	chr20:34173046	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.4	6.45	0.3	3.01e-10	Total cholesterol levels;
LUAD	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.79	11.07	0.47	3.34e-25	Smoking behavior;
LUAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.25	-0.33	1.98e-12	Bipolar disorder;
LUAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg08132940	chr7:1081526	C7orf50	-0.44	-6.68	-0.31	7.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs89107	0.688	rs283085	chr6:118603267	C/A	cg18833306	chr6:118973337	C6orf204	0.52	9.55	0.42	1.1e-19	Cardiac structure and function;
LUAD	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.33	0.34	1.21e-12	Menopause (age at onset);
LUAD	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg08798685	chr6:27730294	NA	-0.68	-7.23	-0.33	2.34e-12	Depression;
LUAD	cis	rs36051895	0.626	rs10815149	chr9:5063701	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-6.87	-0.32	2.37e-11	Pediatric autoimmune diseases;
LUAD	cis	rs7267979	0.789	rs1983974	chr20:25530619	A/C	cg08601574	chr20:25228251	PYGB	-0.4	-7.48	-0.34	4.26e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg05835009	chr4:710272	PCGF3	0.58	8.47	0.38	3.98e-16	White blood cell count;
LUAD	cis	rs9479482	0.967	rs3860823	chr6:150356526	A/G	cg25797454	chr6:150327115	RAET1K	0.3	6.69	0.31	7.19e-11	Alopecia areata;
LUAD	cis	rs68170813	0.559	rs79705824	chr7:106848325	T/C	cg02696742	chr7:106810147	HBP1	-0.78	-10.62	-0.46	1.69e-23	Coronary artery disease;
LUAD	cis	rs6831352	0.879	rs4699716	chr4:100066125	G/A	cg12011299	chr4:100065546	ADH4	-0.74	-13.41	-0.55	1.94e-34	Alcohol dependence;
LUAD	cis	rs116248771	0.793	rs6765967	chr3:158347310	T/C	cg16708174	chr3:158430962	RARRES1	0.47	6.88	0.32	2.22e-11	diarrhoeal disease at age 2;
LUAD	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.88	0.53	2.84e-32	Cognitive ability;
LUAD	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3784262	0.967	rs12148907	chr15:58296450	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.47	-9.58	-0.42	8.44e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg12935359	chr14:103987150	CKB	-0.46	-7.96	-0.36	1.55e-14	Body mass index;
LUAD	cis	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.38	-0.34	8.34e-13	Resting heart rate;
LUAD	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.39	7.06	0.32	6.91e-12	Systemic lupus erythematosus;
LUAD	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg16680214	chr1:154839983	KCNN3	-0.61	-12.42	-0.52	2.06e-30	Prostate cancer;
LUAD	cis	rs752092	0.925	rs8032007	chr15:101790817	C/T	cg19997662	chr15:101784653	CHSY1	0.53	9.6	0.42	7.25e-20	Corneal structure;
LUAD	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05776053	chr2:74358815	NA	0.45	6.56	0.3	1.53e-10	Gestational age at birth (maternal effect);
LUAD	cis	rs9443645	0.507	rs1475046	chr6:79461801	G/A	cg05283184	chr6:79620031	NA	-0.39	-7.15	-0.33	3.78e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg12016809	chr21:47604291	C21orf56	0.52	8.37	0.38	8.34e-16	Testicular germ cell tumor;
LUAD	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg02389323	chr16:88786976	FAM38A	1.07	10.61	0.46	1.83e-23	Plateletcrit;
LUAD	cis	rs8027181	1.000	rs7164727	chr15:73093991	C/T	cg25632853	chr15:73088954	NA	0.35	7.66	0.35	1.28e-13	Triglyceride levels;
LUAD	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg17063962	chr7:91808500	NA	-0.7	-12.44	-0.52	1.75e-30	Breast cancer;
LUAD	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg24675056	chr1:15929824	NA	0.5	8.72	0.39	6.23e-17	Systolic blood pressure;
LUAD	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg20203395	chr5:56204925	C5orf35	-0.4	-6.55	-0.3	1.69e-10	Coronary artery disease;
LUAD	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg14784868	chr12:69753453	YEATS4	0.44	7.18	0.33	3.16e-12	Blood protein levels;
LUAD	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg00129232	chr17:37814104	STARD3	-0.44	-7.29	-0.33	1.57e-12	Asthma;
LUAD	cis	rs7527798	0.592	rs1323720	chr1:207823161	T/C	cg09232269	chr1:207846808	CR1L	-0.36	-6.84	-0.32	2.87e-11	Erythrocyte sedimentation rate;
LUAD	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg19622623	chr12:86230825	RASSF9	0.42	7.49	0.34	3.93e-13	Major depressive disorder;
LUAD	trans	rs853679	0.599	rs149943	chr6:28002388	G/A	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.6	-0.35	1.98e-13	Depression;
LUAD	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg12923728	chr3:195709715	SDHAP1	0.44	6.74	0.31	5.32e-11	Mean corpuscular volume;
LUAD	cis	rs10149470	0.549	rs9652403	chr14:104036024	G/C	cg12935359	chr14:103987150	CKB	-0.4	-6.57	-0.3	1.5e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg03676636	chr4:99064102	C4orf37	0.37	9.64	0.42	5.05e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2455799	0.552	rs2470519	chr3:15762847	G/A	cg16303742	chr3:15540471	COLQ	-0.5	-9.23	-0.41	1.35e-18	Mean platelet volume;
LUAD	cis	rs315934	0.664	rs315923	chr2:113864505	G/C	cg09040174	chr2:113837401	NA	-0.6	-7.1	-0.33	5.34e-12	Dysmenorrheic pain;
LUAD	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg11871910	chr12:69753446	YEATS4	0.71	12.0	0.5	9.02e-29	Blood protein levels;
LUAD	trans	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg01620082	chr3:125678407	NA	-0.69	-7.67	-0.35	1.21e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg07266350	chr3:49460521	AMT;NICN1	0.36	6.47	0.3	2.79e-10	Menarche (age at onset);
LUAD	cis	rs11723261	0.582	rs6830247	chr4:150683	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	7.82	0.36	4.25e-14	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10150615	chr22:24372951	LOC391322	-0.54	-8.85	-0.4	2.33e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.8	-16.81	-0.63	6.33e-49	Longevity;Endometriosis;
LUAD	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-20.98	-0.71	1.6e-67	Coronary artery disease;
LUAD	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg03037974	chr15:76606532	NA	0.38	8.14	0.37	4.43e-15	Blood metabolite levels;
LUAD	cis	rs870825	0.616	rs61653735	chr4:185630025	G/A	cg04058563	chr4:185651563	MLF1IP	0.9	14.58	0.58	2.56e-39	Blood protein levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg20963003	chr1:101775007	NA	-0.39	-7.0	-0.32	1.02e-11	Cancer;
LUAD	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg00339695	chr16:24857497	SLC5A11	-0.71	-11.33	-0.48	3.66e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.39	7.07	0.33	6.43e-12	IgG glycosylation;
LUAD	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.92	0.32	1.7e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs807669	0.504	rs8141941	chr22:19166263	G/A	cg02655711	chr22:19163373	SLC25A1	0.6	11.86	0.5	3.3e-28	Metabolite levels;
LUAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	8.94	0.4	1.19e-17	Alzheimer's disease;
LUAD	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg24818145	chr4:99064322	C4orf37	0.45	7.07	0.32	6.59e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.89	0.47	1.68e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg20203395	chr5:56204925	C5orf35	0.93	12.94	0.53	1.73e-32	Initial pursuit acceleration;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg07608032	chr19:21579862	ZNF493	-0.39	-6.5	-0.3	2.31e-10	Subcortical brain region volumes;
LUAD	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg12623918	chr2:306882	NA	0.36	7.22	0.33	2.48e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs3789045	0.688	rs6668637	chr1:204452295	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.44	-7.3	-0.33	1.43e-12	Educational attainment (college completion);
LUAD	cis	rs8027181	0.839	rs7176223	chr15:73077742	T/G	cg25632853	chr15:73088954	NA	0.32	6.97	0.32	1.25e-11	Triglyceride levels;
LUAD	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs17152411	0.895	rs7080330	chr10:126585673	A/G	cg07906193	chr10:126599966	NA	0.54	7.65	0.35	1.34e-13	Height;
LUAD	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg19717773	chr7:2847554	GNA12	0.65	11.91	0.5	2.12e-28	Loneliness (linear analysis);
LUAD	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg11395062	chr17:14139857	CDRT15	-0.56	-9.05	-0.4	5.35e-18	Temperament;
LUAD	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.21e-16	Prostate cancer;
LUAD	cis	rs2281845	0.507	rs942703	chr1:201092979	A/G	cg06714761	chr1:201096289	NA	-0.39	-8.63	-0.39	1.25e-16	Permanent tooth development;
LUAD	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	7.75	0.35	6.88e-14	Rheumatoid arthritis;
LUAD	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg08610935	chr16:1836813	NUBP2	0.45	7.06	0.32	6.95e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs380904	0.519	rs1377663	chr8:144644787	T/A	cg13399544	chr8:144649678	C8orf73	-0.47	-6.76	-0.31	4.5e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs13095912	0.752	rs13061708	chr3:185339984	T/C	cg11274856	chr3:185301563	NA	0.5	9.58	0.42	8.07e-20	Systolic blood pressure;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08664652	chr17:28804287	GOSR1	-0.39	-6.36	-0.3	5.27e-10	Height;
LUAD	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg05373962	chr22:49881684	NA	-0.57	-13.8	-0.56	5.03e-36	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg13319975	chr6:146136371	FBXO30	-0.59	-9.83	-0.43	1.13e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.47	0.3	2.76e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg17177755	chr1:15930204	NA	0.45	7.27	0.33	1.8e-12	Systolic blood pressure;
LUAD	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.8e-11	Crohn's disease;
LUAD	cis	rs9487051	0.704	rs1741930	chr6:109519797	T/A	cg21918786	chr6:109611834	NA	-0.41	-7.53	-0.34	3.1e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.03	-0.36	9.93e-15	Diabetic kidney disease;
LUAD	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.17	0.33	3.34e-12	Motion sickness;
LUAD	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg03676636	chr4:99064102	C4orf37	0.29	7.03	0.32	8.24e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06022373	chr22:39101656	GTPBP1	-0.44	-7.01	-0.32	9.21e-12	Menopause (age at onset);
LUAD	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg21153622	chr11:89784906	NA	-0.33	-6.46	-0.3	2.81e-10	Coronary artery disease;
LUAD	cis	rs6500395	1.000	rs2354579	chr16:48601521	T/C	cg04672837	chr16:48644449	N4BP1	0.38	6.49	0.3	2.41e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg13309027	chr11:47870224	NUP160	-0.39	-6.46	-0.3	2.95e-10	Gait speed in old age;
LUAD	cis	rs2073300	1.000	rs115730610	chr20:23442621	G/A	cg09953122	chr20:23471693	CST8	-0.65	-6.39	-0.3	4.29e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6011002	0.745	rs6011068	chr20:62364885	T/A	cg01176363	chr20:62369445	LIME1	-0.79	-6.63	-0.31	1.05e-10	Dental caries;
LUAD	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.03	0.36	9.52e-15	Menopause (age at onset);
LUAD	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg12310025	chr6:25882481	NA	-0.53	-7.82	-0.36	4.31e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg06640241	chr16:89574553	SPG7	0.41	6.8	0.31	3.66e-11	Multiple myeloma (IgH translocation);
LUAD	trans	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg01620082	chr3:125678407	NA	-0.54	-7.08	-0.33	6.23e-12	Depression;
LUAD	cis	rs9611519	1.000	rs5758264	chr22:41616284	T/G	cg13813247	chr22:41461852	NA	-0.43	-7.27	-0.33	1.75e-12	Neuroticism;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26297431	chr1:46597359	PIK3R3	-0.37	-6.42	-0.3	3.74e-10	Cancer;
LUAD	cis	rs977987	0.778	rs7203157	chr16:75417920	T/C	cg03315344	chr16:75512273	CHST6	0.64	14.07	0.56	3.66e-37	Dupuytren's disease;
LUAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg07217954	chr7:1067459	C7orf50	0.46	7.16	0.33	3.55e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4285028	0.847	rs1986712	chr3:121710986	A/G	cg11130432	chr3:121712080	ILDR1	-0.61	-8.63	-0.39	1.3e-16	Multiple sclerosis;
LUAD	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg11663144	chr21:46675770	NA	0.49	8.15	0.37	4.3e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2235544	0.579	rs11804837	chr1:54482915	G/A	cg25741118	chr1:54482237	LDLRAD1	-0.25	-6.95	-0.32	1.39e-11	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08677398	chr8:58056175	NA	0.46	6.37	0.3	4.87e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4711350	0.765	rs6921772	chr6:33749686	A/G	cg07979401	chr6:33739406	LEMD2	-0.54	-9.79	-0.43	1.6e-20	Schizophrenia;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg25362248	chr1:31192015	MATN1	0.4	6.49	0.3	2.38e-10	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs4714291	0.832	rs761798	chr6:40087514	C/T	cg02267698	chr19:7991119	CTXN1	0.43	6.72	0.31	5.75e-11	Strep throat;
LUAD	cis	rs10901296	0.660	rs2855198	chr9:133764606	T/C	cg13397898	chr9:133768931	QRFP	0.51	6.8	0.31	3.54e-11	Bilirubin levels;
LUAD	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg23435118	chr5:141488016	NDFIP1	-0.5	-7.55	-0.34	2.63e-13	Crohn's disease;
LUAD	cis	rs735539	0.521	rs2585898	chr13:21400301	T/C	cg27499820	chr13:21296301	IL17D	0.43	7.19	0.33	3e-12	Dental caries;
LUAD	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg10544611	chr16:67998164	SLC12A4	-0.54	-6.87	-0.32	2.38e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.86	0.32	2.52e-11	Obesity-related traits;
LUAD	cis	rs7508679	1.000	rs10401485	chr19:7222234	T/C	cg00428638	chr19:7224713	INSR	0.69	14.48	0.58	7e-39	Hypothyroidism;
LUAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.55	-9.71	-0.43	3e-20	Lymphocyte counts;
LUAD	cis	rs3733418	0.929	rs4690797	chr4:165908505	G/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.49	-6.8	-0.31	3.51e-11	Obesity-related traits;
LUAD	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg24531977	chr5:56204891	C5orf35	-0.9	-11.27	-0.48	6.02e-26	Type 2 diabetes;
LUAD	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg27219399	chr15:67835830	MAP2K5	0.4	6.5	0.3	2.24e-10	Restless legs syndrome;
LUAD	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	trans	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg21051086	chr3:73046214	PPP4R2	-0.45	-7.28	-0.33	1.64e-12	Pancreatic cancer;
LUAD	trans	rs208520	0.661	rs207090	chr6:66783963	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.32	-0.64	3.48e-51	Exhaled nitric oxide output;
LUAD	cis	rs2235642	0.507	rs2235645	chr16:1597924	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.55	-8.52	-0.38	2.77e-16	Coronary artery disease;
LUAD	cis	rs8067287	0.708	rs55635506	chr17:16838685	G/A	cg26910001	chr17:16838321	NA	-0.47	-6.4	-0.3	4.25e-10	Diabetic kidney disease;
LUAD	cis	rs1595825	0.891	rs7585709	chr2:198883682	C/T	cg11031976	chr2:198649780	BOLL	-0.45	-6.51	-0.3	2.12e-10	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12760731	0.546	rs6699087	chr1:178433200	G/T	cg00404053	chr1:178313656	RASAL2	0.46	6.56	0.3	1.61e-10	Obesity-related traits;
LUAD	cis	rs904251	0.523	rs10947675	chr6:37479972	G/A	cg25019722	chr6:37503610	NA	-0.32	-7.29	-0.33	1.53e-12	Cognitive performance;
LUAD	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg02158880	chr13:53174818	NA	0.59	10.41	0.45	9.7e-23	Lewy body disease;
LUAD	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03452623	chr4:187889614	NA	-0.82	-16.82	-0.63	5.55e-49	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg05368731	chr17:41323189	NBR1	0.97	20.37	0.7	9.04e-65	Menopause (age at onset);
LUAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05923103	chr1:51701583	RNF11	-0.44	-6.8	-0.31	3.66e-11	Height;
LUAD	cis	rs870825	0.860	rs61165411	chr4:185604461	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	11.22	0.48	9.12e-26	Blood protein levels;
LUAD	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg22868518	chr11:507468	RNH1	-0.66	-6.56	-0.3	1.59e-10	Body mass index;
LUAD	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg03289416	chr15:75166202	SCAMP2	0.45	7.76	0.35	6.23e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg11707310	chr1:2537719	MMEL1	-0.39	-8.3	-0.37	1.43e-15	Ulcerative colitis;
LUAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.49	-9.13	-0.41	2.79e-18	Longevity;Endometriosis;
LUAD	trans	rs11039798	0.764	rs11039929	chr11:48703289	A/G	cg03929089	chr4:120376271	NA	0.59	6.8	0.31	3.49e-11	Axial length;
LUAD	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.04	0.36	9.29e-15	Menopause (age at onset);
LUAD	cis	rs6460942	0.915	rs7803051	chr7:12306904	A/T	cg20607287	chr7:12443886	VWDE	-0.44	-6.41	-0.3	3.94e-10	Coronary artery disease;
LUAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg10729496	chr3:10149963	C3orf24	0.6	10.18	0.44	6.41e-22	Alzheimer's disease;
LUAD	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg05373962	chr22:49881684	NA	-0.5	-10.36	-0.45	1.41e-22	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg03806693	chr22:41940476	POLR3H	-0.81	-11.55	-0.49	5.01e-27	Vitiligo;
LUAD	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg00504896	chr12:9437009	LOC642846	-0.41	-6.53	-0.3	1.9e-10	Breast size;
LUAD	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg02461776	chr11:598696	PHRF1	0.49	6.87	0.32	2.24e-11	Systemic lupus erythematosus;
LUAD	trans	rs800082	1.000	rs1405597	chr3:144314276	A/C	cg24215973	chr2:240111563	HDAC4	-0.44	-7.11	-0.33	5.03e-12	Smoking behavior;
LUAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-9.63	-0.42	5.64e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs17169635	0.765	rs2290360	chr7:134555261	C/G	cg07876788	chr7:134849633	TMEM140	-0.46	-6.84	-0.32	2.77e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs8099014	0.861	rs6566969	chr18:56118999	A/G	cg12907477	chr18:56117327	MIR122	0.48	7.69	0.35	1.05e-13	Platelet count;
LUAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	12.53	0.52	7.51e-31	Lymphocyte counts;
LUAD	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.27	6.55	0.3	1.68e-10	Depression;
LUAD	cis	rs2070677	0.935	rs4350328	chr10:135414948	G/A	cg20169779	chr10:135381914	SYCE1	-0.51	-8.2	-0.37	2.99e-15	Gout;
LUAD	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg15997130	chr1:24165203	NA	0.54	9.26	0.41	1.03e-18	Immature fraction of reticulocytes;
LUAD	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg05368731	chr17:41323189	NBR1	0.95	19.24	0.68	1.03e-59	Menopause (age at onset);
LUAD	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg08632164	chr7:65971372	NA	-0.55	-6.37	-0.3	4.93e-10	Diabetic kidney disease;
LUAD	cis	rs7017914	0.967	rs12679261	chr8:71844649	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.42	-0.3	3.7e-10	Bone mineral density;
LUAD	cis	rs11771526	0.892	rs76035550	chr7:32371359	G/A	cg27532318	chr7:32358331	NA	0.69	8.04	0.36	9.23e-15	Body mass index;
LUAD	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.33	8.29	0.37	1.49e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.71	0.76	1.12e-79	Chronic sinus infection;
LUAD	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.4	-0.34	7.27e-13	Breast cancer;
LUAD	cis	rs2430307	0.556	rs3930019	chr7:76541610	C/T	cg05843312	chr7:76586131	NA	0.46	6.66	0.31	8.69e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs59698941	0.943	rs12515752	chr5:132312960	C/G	cg14825688	chr5:132208181	LEAP2	-0.49	-6.98	-0.32	1.15e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs597583	0.755	rs562422	chr11:117428278	G/A	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.28	-0.37	1.61e-15	Putamen volume;
LUAD	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.79	-0.43	1.52e-20	Schizophrenia;
LUAD	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg11395062	chr17:14139857	CDRT15	0.62	10.24	0.45	4.05e-22	Temperament;
LUAD	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg16797656	chr11:68205561	LRP5	0.45	8.47	0.38	4.1e-16	Total body bone mineral density;
LUAD	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg15704280	chr7:45808275	SEPT13	0.74	10.9	0.47	1.54e-24	Coronary artery disease;
LUAD	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	8.03e-16	Body mass index;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14816748	chr17:74349897	PRPSAP1	-0.4	-6.83	-0.32	3.01e-11	Cancer;
LUAD	cis	rs2282300	0.739	rs10835648	chr11:30320506	A/G	cg06241208	chr11:30344200	C11orf46	0.55	7.2	0.33	2.84e-12	Morning vs. evening chronotype;
LUAD	cis	rs1832871	0.711	rs9457248	chr6:158681204	C/T	cg07165851	chr6:158734300	TULP4	0.71	11.06	0.47	3.81e-25	Height;
LUAD	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg10596483	chr8:143751796	JRK	0.43	6.89	0.32	2.06e-11	Schizophrenia;
LUAD	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.42	-8.09	-0.37	6.29e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg02775129	chr4:119771670	NA	-0.86	-8.15	-0.37	4.09e-15	Cannabis dependence symptom count;
LUAD	cis	rs870825	0.929	rs10027213	chr4:185579871	C/G	cg04058563	chr4:185651563	MLF1IP	0.78	10.35	0.45	1.6e-22	Blood protein levels;
LUAD	trans	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg08071915	chr8:12219732	FAM66A	-0.42	-6.99	-0.32	1.08e-11	Mood instability;
LUAD	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg04287289	chr16:89883240	FANCA	0.49	8.04	0.36	9.12e-15	Vitiligo;
LUAD	cis	rs8027181	0.839	rs4777532	chr15:73041767	A/G	cg25632853	chr15:73088954	NA	0.31	6.69	0.31	7.21e-11	Triglyceride levels;
LUAD	cis	rs7586879	0.765	rs6545758	chr2:25074874	C/T	cg04586622	chr2:25135609	ADCY3	-0.4	-8.71	-0.39	7.11e-17	Body mass index;
LUAD	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg06740227	chr12:86229804	RASSF9	0.4	7.17	0.33	3.38e-12	Major depressive disorder;
LUAD	cis	rs4285028	0.696	rs3915060	chr3:121712980	C/T	cg20356878	chr3:121714668	ILDR1	0.51	7.37	0.34	9e-13	Multiple sclerosis;
LUAD	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.51	8.33	0.38	1.13e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg25985355	chr7:65971099	NA	-0.54	-6.79	-0.31	3.76e-11	Diabetic kidney disease;
LUAD	cis	rs727505	1.000	rs6971909	chr7:124525517	C/T	cg23710748	chr7:124431027	NA	-0.44	-9.38	-0.41	4.11e-19	Lewy body disease;
LUAD	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg11317459	chr13:21872234	NA	-1.09	-14.71	-0.58	7.3e-40	White matter hyperintensity burden;
LUAD	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg04154034	chr17:28927549	LRRC37B2	0.57	6.67	0.31	8.05e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10788264	0.621	rs7907952	chr10:124056774	C/T	cg09507567	chr10:124027408	NA	-0.49	-10.81	-0.47	3.12e-24	Total body bone mineral density;
LUAD	cis	rs7267979	0.546	rs8115804	chr20:25438783	C/T	cg08601574	chr20:25228251	PYGB	-0.36	-6.59	-0.31	1.3e-10	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg02079420	chr8:82753780	SNX16	0.38	7.78	0.35	5.6e-14	Diastolic blood pressure;
LUAD	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg00310523	chr12:86230176	RASSF9	0.39	7.57	0.35	2.3e-13	Major depressive disorder;
LUAD	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	7.41	0.34	7.07e-13	Tonsillectomy;
LUAD	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg18129178	chr5:148520854	ABLIM3	-0.66	-9.11	-0.41	3.24e-18	Breast cancer;
LUAD	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg05665937	chr4:1216051	CTBP1	0.42	7.04	0.32	7.61e-12	Obesity-related traits;
LUAD	cis	rs7095607	0.777	rs7905579	chr10:69926594	G/T	cg18986048	chr10:69913749	MYPN	0.38	6.45	0.3	3.04e-10	Lung function (FVC);
LUAD	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg19717773	chr7:2847554	GNA12	-0.46	-8.25	-0.37	1.96e-15	Height;
LUAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg02869364	chr7:1081709	C7orf50	-0.46	-6.36	-0.3	5.3e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs57994353	0.865	rs34376913	chr9:139378914	T/C	cg14169450	chr9:139327907	INPP5E	0.41	6.51	0.3	2.19e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg07305463	chr2:136567211	LCT	-0.37	-7.03	-0.32	8.26e-12	Mosquito bite size;
LUAD	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg02782426	chr3:40428986	ENTPD3	0.42	8.9	0.4	1.64e-17	Renal cell carcinoma;
LUAD	trans	rs6921919	0.832	rs17312661	chr6:28300336	A/G	cg06606381	chr12:133084897	FBRSL1	-0.6	-7.03	-0.32	8.28e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg23950597	chr19:37808831	NA	-0.54	-6.57	-0.3	1.45e-10	Coronary artery calcification;
LUAD	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.6	-0.39	1.56e-16	Alzheimer's disease (late onset);
LUAD	cis	rs67180937	0.553	rs1498382	chr1:222814837	G/T	cg09820183	chr1:222886073	C1orf58;AIDA	0.5	6.57	0.3	1.47e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LUAD	trans	rs360929	1.000	rs360929	chr4:152907700	C/T	cg20631654	chr20:56285704	PMEPA1	-0.5	-6.42	-0.3	3.72e-10	Volumetric brain MRI;
LUAD	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg13679303	chr9:96623674	NA	-0.37	-7.35	-0.34	1e-12	DNA methylation (variation);
LUAD	cis	rs11051970	0.879	rs2243815	chr12:32576158	C/T	cg24626660	chr12:32551988	NA	0.32	6.48	0.3	2.61e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1032833	0.732	rs4499457	chr2:180003076	T/G	cg23883738	chr2:179974586	SESTD1	-0.7	-7.65	-0.35	1.39e-13	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03264133	chr6:25882463	NA	-0.67	-9.95	-0.44	4.33e-21	Intelligence (multi-trait analysis);
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg09273779	chr9:35605990	TESK1	0.39	6.47	0.3	2.76e-10	Bilirubin levels;
LUAD	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.08	0.33	5.93e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg14779329	chr11:130786720	SNX19	0.37	6.45	0.3	3.03e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg13770153	chr20:60521292	NA	-0.45	-7.37	-0.34	8.79e-13	Body mass index;
LUAD	cis	rs3772130	1.000	rs3772130	chr3:121344140	A/G	cg20356878	chr3:121714668	ILDR1	0.47	7.32	0.34	1.24e-12	Cognitive performance;
LUAD	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg13180566	chr4:1052158	NA	-0.4	-6.78	-0.31	4.04e-11	Recombination rate (females);
LUAD	trans	rs60843830	1.000	rs9213	chr2:218386	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.73	12.0	0.5	9.42e-29	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7582720	1.000	rs114079739	chr2:203825106	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg16049864	chr8:95962084	TP53INP1	-0.39	-7.15	-0.33	3.8e-12	Type 2 diabetes;
LUAD	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg18132916	chr6:79620363	NA	-0.47	-8.19	-0.37	3.04e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs72634258	0.520	rs4908485	chr1:7907984	A/G	cg26816564	chr1:7831052	VAMP3	0.69	9.16	0.41	2.26e-18	Inflammatory bowel disease;
LUAD	cis	rs1949733	0.959	rs2688242	chr4:8429943	T/G	cg13073564	chr4:8508604	NA	-0.61	-11.08	-0.47	3.22e-25	Response to antineoplastic agents;
LUAD	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg00933542	chr6:150070202	PCMT1	-0.35	-7.45	-0.34	5.42e-13	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08219700	chr8:58056026	NA	0.58	8.04	0.36	8.82e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04565464	chr8:145669602	NFKBIL2	0.43	6.56	0.3	1.56e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs10992471	0.603	rs10114912	chr9:95307863	C/A	cg14631576	chr9:95140430	CENPP	-0.5	-10.16	-0.44	7.78e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs986417	1.000	rs11158293	chr14:61109020	G/C	cg27398547	chr14:60952738	C14orf39	0.64	7.22	0.33	2.43e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg15467112	chr14:75489610	MLH3	-0.35	-6.58	-0.3	1.4e-10	Height;
LUAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg05313129	chr8:58192883	C8orf71	-0.53	-8.1	-0.37	5.89e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg22963979	chr7:1858916	MAD1L1	-0.58	-10.13	-0.44	9.92e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg14458575	chr2:238380390	NA	0.77	11.84	0.5	3.84e-28	Prostate cancer;
LUAD	cis	rs4523957	0.583	rs2984940	chr17:2023825	A/G	cg16513277	chr17:2031491	SMG6	-0.95	-19.14	-0.68	2.98e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9788721	0.836	rs7181486	chr15:78741618	C/T	cg18825076	chr15:78729989	IREB2	0.57	9.85	0.43	9.21e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04520396	chr17:1585312	PRPF8	0.43	7.09	0.33	5.7e-12	Height;
LUAD	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg02773041	chr1:40204384	PPIE	0.52	8.78	0.39	3.98e-17	Blood protein levels;
LUAD	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg08645402	chr16:4508243	NA	0.58	11.02	0.47	5.19e-25	Schizophrenia;
LUAD	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.61	-7.35	-0.34	1.01e-12	Body mass index;
LUAD	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg00129232	chr17:37814104	STARD3	-0.45	-7.47	-0.34	4.79e-13	Asthma;
LUAD	cis	rs8060686	0.623	rs7201591	chr16:68086105	A/G	cg26727032	chr16:67993705	SLC12A4	-0.46	-7.78	-0.35	5.63e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.39	-6.72	-0.31	6e-11	Longevity;Endometriosis;
LUAD	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg24069376	chr3:38537580	EXOG	-0.43	-10.43	-0.45	7.99e-23	Electrocardiographic conduction measures;
LUAD	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg26384229	chr12:38710491	ALG10B	-0.45	-7.48	-0.34	4.47e-13	Bladder cancer;
LUAD	cis	rs11167764	0.895	rs13189044	chr5:141471431	A/C	cg08523384	chr5:141488047	NDFIP1	-0.48	-7.18	-0.33	3.22e-12	Crohn's disease;
LUAD	cis	rs738322	0.804	rs2076116	chr22:38517405	A/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-8.52	-0.38	2.77e-16	Cutaneous nevi;
LUAD	cis	rs28655083	0.636	rs7194836	chr16:77066830	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.49	-7.38	-0.34	8.66e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg06547715	chr2:218990976	CXCR2	0.44	10.39	0.45	1.09e-22	Ulcerative colitis;
LUAD	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.03	15.09	0.59	1.88e-41	Schizophrenia;
LUAD	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg04036182	chr15:45458818	NA	-0.4	-6.93	-0.32	1.59e-11	Glomerular filtration rate;
LUAD	cis	rs6499255	0.904	rs12595927	chr16:69716338	C/G	cg15192750	chr16:69999425	NA	0.53	7.7	0.35	9.77e-14	IgE levels;
LUAD	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg08085267	chr17:45401833	C17orf57	0.58	10.41	0.45	9.29e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg05283184	chr6:79620031	NA	-0.61	-12.1	-0.51	3.81e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg17366294	chr4:99064904	C4orf37	-0.47	-8.48	-0.38	3.87e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg17063962	chr7:91808500	NA	0.61	10.05	0.44	1.84e-21	Breast cancer;
LUAD	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg19717773	chr7:2847554	GNA12	-0.51	-9.66	-0.43	4.31e-20	Height;
LUAD	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg13385794	chr1:248469461	NA	0.26	7.07	0.33	6.48e-12	Common traits (Other);
LUAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.37	-7.65	-0.35	1.39e-13	Lymphocyte counts;
LUAD	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg18854424	chr1:2615690	NA	-0.43	-9.38	-0.42	4e-19	Ulcerative colitis;
LUAD	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg07636037	chr3:49044803	WDR6	0.48	8.2	0.37	2.85e-15	Menarche (age at onset);
LUAD	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27286337	chr10:134555280	INPP5A	-0.69	-9.24	-0.41	1.21e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6516091	0.850	rs62199228	chr20:6047655	G/A	cg25325723	chr20:6104886	FERMT1	-0.65	-7.15	-0.33	3.92e-12	Abdominal aortic aneurysm;
LUAD	cis	rs1298908	0.639	rs2993763	chr10:82033594	G/A	cg01528321	chr10:82214614	TSPAN14	0.41	6.43	0.3	3.53e-10	Diabetic kidney disease;
LUAD	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7512552	0.809	rs2794685	chr1:150312268	C/T	cg15654264	chr1:150340011	RPRD2	0.61	11.6	0.49	3.48e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7680126	0.596	rs10022911	chr4:10140551	A/G	cg00071950	chr4:10020882	SLC2A9	-0.6	-8.81	-0.39	3.31e-17	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs4073416	0.542	rs1113962	chr14:66005798	C/T	cg10998611	chr14:65879393	FUT8;LOC645431	-0.42	-6.38	-0.3	4.66e-10	N-glycan levels;
LUAD	cis	rs240764	0.817	rs58266877	chr6:101156284	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-7.39	-0.34	7.89e-13	Neuroticism;
LUAD	cis	rs28493229	0.582	rs78915350	chr19:41160609	A/G	cg21869046	chr19:41225005	ITPKC	0.52	9.04	0.4	5.57e-18	Kawasaki disease;
LUAD	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs806794	0.804	rs9393688	chr6:26207174	A/T	cg00631329	chr6:26305371	NA	-0.48	-7.3	-0.33	1.39e-12	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg10729496	chr3:10149963	C3orf24	0.49	7.88	0.36	2.73e-14	Alzheimer's disease;
LUAD	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06636551	chr8:101224915	SPAG1	-0.37	-6.8	-0.31	3.61e-11	Atrioventricular conduction;
LUAD	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg23649088	chr2:200775458	C2orf69	-0.6	-8.23	-0.37	2.27e-15	Schizophrenia;
LUAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg10150615	chr22:24372951	LOC391322	-0.47	-7.8	-0.35	4.79e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg14092988	chr3:52407081	DNAH1	0.45	9.09	0.4	3.99e-18	Bipolar disorder;
LUAD	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg02896835	chr1:92012615	NA	-0.58	-11.93	-0.5	1.69e-28	Breast cancer;
LUAD	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg20476274	chr7:133979776	SLC35B4	0.79	14.48	0.58	7.37e-39	Mean platelet volume;
LUAD	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg02660097	chr11:68866761	NA	0.46	6.4	0.3	4.08e-10	Blond vs. brown hair color;
LUAD	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg22963979	chr7:1858916	MAD1L1	-0.6	-9.94	-0.44	4.76e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.84	-0.39	2.55e-17	Total body bone mineral density;
LUAD	cis	rs6445967	0.569	rs7624746	chr3:58282500	T/C	cg23715586	chr3:58305044	RPP14	0.39	6.48	0.3	2.5e-10	Platelet count;
LUAD	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg18944383	chr4:111397179	ENPEP	0.37	7.57	0.35	2.4e-13	Height;
LUAD	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22590775	chr19:49891494	CCDC155	0.56	8.65	0.39	1.11e-16	Multiple sclerosis;
LUAD	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg10164272	chr16:89456328	ANKRD11	0.42	6.69	0.31	7.31e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs72634258	0.554	rs4562654	chr1:7934423	A/T	cg26816564	chr1:7831052	VAMP3	0.58	7.97	0.36	1.53e-14	Inflammatory bowel disease;
LUAD	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.49	8.43	0.38	5.36e-16	Alzheimer's disease (late onset);
LUAD	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.75	-0.31	4.87e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-6.91	-0.32	1.75e-11	Total body bone mineral density;
LUAD	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg15704280	chr7:45808275	SEPT13	-0.65	-9.94	-0.44	4.46e-21	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs11078597	0.731	rs12937244	chr17:1646317	T/C	cg18436246	chr17:1640651	WDR81	0.79	12.76	0.53	8.64e-32	Serum albumin level;
LUAD	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.66	-12.5	-0.52	9.81e-31	Ulcerative colitis;
LUAD	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg15704280	chr7:45808275	SEPT13	-0.54	-8.49	-0.38	3.52e-16	HDL cholesterol;
LUAD	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg00504896	chr12:9437009	LOC642846	-0.42	-6.59	-0.31	1.28e-10	Breast size;
LUAD	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg13319975	chr6:146136371	FBXO30	-0.64	-11.18	-0.48	1.31e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg22482690	chr17:47019901	SNF8	0.45	8.6	0.39	1.62e-16	Type 2 diabetes;
LUAD	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg10523679	chr1:76189770	ACADM	0.75	11.55	0.49	5.03e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2422052	0.792	rs4849637	chr2:118645575	A/G	cg22545206	chr2:118617499	NA	0.41	7.08	0.33	5.94e-12	Mosquito bite size;
LUAD	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs2688608	0.967	rs2675663	chr10:75660270	T/G	cg19442545	chr10:75533431	FUT11	-0.4	-6.87	-0.32	2.33e-11	Inflammatory bowel disease;
LUAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.39	-6.55	-0.3	1.67e-10	Longevity;Endometriosis;
LUAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg13047869	chr3:10149882	C3orf24	0.59	9.94	0.44	4.62e-21	Alzheimer's disease;
LUAD	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg26022315	chr17:47021804	SNF8	0.41	7.3	0.33	1.47e-12	Type 2 diabetes;
LUAD	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.44	0.3	3.28e-10	Depression;
LUAD	cis	rs10927875	0.619	rs2013019	chr1:16129320	T/C	cg21385522	chr1:16154831	NA	-0.65	-11.59	-0.49	3.78e-27	Dilated cardiomyopathy;
LUAD	cis	rs733175	0.857	rs3796835	chr4:10011530	C/T	cg02734326	chr4:10020555	SLC2A9	0.5	6.65	0.31	9.2e-11	Psychosis and Alzheimer's disease;
LUAD	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.57	-11.34	-0.48	3.28e-26	Birth weight;
LUAD	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg06558623	chr16:89946397	TCF25	1.15	10.6	0.46	1.96e-23	Skin colour saturation;
LUAD	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.3	-7.75	-0.35	7.05e-14	Total body bone mineral density;
LUAD	cis	rs12681287	0.752	rs12675974	chr8:87247845	T/C	cg27223183	chr8:87520930	FAM82B	-0.58	-8.16	-0.37	3.75e-15	Caudate activity during reward;
LUAD	cis	rs62238980	0.614	rs76161060	chr22:32383153	G/A	cg02631450	chr22:32366979	NA	0.81	6.56	0.3	1.61e-10	Childhood ear infection;
LUAD	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11971779	0.715	rs6943973	chr7:139029893	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.59	0.31	1.28e-10	Diisocyanate-induced asthma;
LUAD	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg10523679	chr1:76189770	ACADM	-0.7	-10.46	-0.45	6.22e-23	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg06636001	chr8:8085503	FLJ10661	0.42	6.86	0.32	2.47e-11	Joint mobility (Beighton score);
LUAD	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg03806693	chr22:41940476	POLR3H	0.58	8.33	0.38	1.15e-15	Vitiligo;
LUAD	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg18252515	chr7:66147081	NA	-0.64	-6.85	-0.32	2.59e-11	Diabetic kidney disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26654771	chr8:22412432	SORBS3	0.47	6.51	0.3	2.08e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg00129232	chr17:37814104	STARD3	-0.47	-7.61	-0.35	1.86e-13	Asthma;
LUAD	cis	rs9462027	0.583	rs2814995	chr6:34621171	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.78	-0.39	4.02e-17	Systemic lupus erythematosus;
LUAD	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.46	-8.65	-0.39	1.07e-16	Cystic fibrosis severity;
LUAD	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.42	6.49	0.3	2.35e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs897984	0.568	rs67456613	chr16:30888295	G/A	cg02466173	chr16:30829666	NA	-0.67	-10.47	-0.45	5.67e-23	Dementia with Lewy bodies;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04117832	chr2:152685230	ARL5A	-0.56	-6.74	-0.31	5.24e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.46	8.04	0.36	9.16e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg18105134	chr13:113819100	PROZ	0.84	15.04	0.59	2.98e-41	Platelet distribution width;
LUAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-7.66	-0.35	1.28e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg20129853	chr10:51489980	NA	-0.36	-7.19	-0.33	2.99e-12	Prostate-specific antigen levels;
LUAD	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg23803603	chr1:2058230	PRKCZ	0.41	6.6	0.31	1.22e-10	Height;
LUAD	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg09455208	chr3:40491958	NA	-0.56	-12.39	-0.52	2.7e-30	Renal cell carcinoma;
LUAD	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg04586622	chr2:25135609	ADCY3	0.37	8.36	0.38	9.08e-16	Body mass index;
LUAD	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg25237894	chr2:233734115	C2orf82	-0.63	-12.04	-0.51	6.29e-29	Coronary artery disease;
LUAD	cis	rs13095912	0.778	rs7651346	chr3:185300395	G/A	cg11274856	chr3:185301563	NA	0.5	9.32	0.41	6.41e-19	Systolic blood pressure;
LUAD	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg26076054	chr5:421317	AHRR	-0.43	-6.38	-0.3	4.66e-10	Cystic fibrosis severity;
LUAD	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg18016565	chr1:150552671	MCL1	0.43	7.95	0.36	1.76e-14	Tonsillectomy;
LUAD	cis	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg14039649	chr22:38352398	POLR2F	0.37	6.73	0.31	5.37e-11	Glioblastoma;Glioma;
LUAD	cis	rs10489202	0.608	rs7553238	chr1:168076768	G/A	cg25738037	chr1:168025549	DCAF6	-0.46	-6.63	-0.31	1.04e-10	Schizophrenia;
LUAD	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg17077180	chr1:38461687	NA	-0.46	-8.12	-0.37	5.28e-15	Coronary artery disease;
LUAD	trans	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs12545109	0.842	rs2582379	chr8:57395243	C/T	cg07776626	chr8:57350775	NA	0.63	8.63	0.39	1.28e-16	Obesity-related traits;
LUAD	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg07617317	chr6:118971624	C6orf204	0.55	8.24	0.37	2.12e-15	Diastolic blood pressure;
LUAD	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-12.41	-0.52	2.16e-30	Schizophrenia;
LUAD	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg20503657	chr10:835505	NA	0.78	10.49	0.45	4.79e-23	Eosinophil percentage of granulocytes;
LUAD	cis	rs3125734	0.633	rs10761616	chr10:64009076	G/A	cg19640130	chr10:64028056	RTKN2	-0.35	-7.59	-0.35	2.03e-13	Rheumatoid arthritis;
LUAD	cis	rs295140	0.803	rs12469091	chr2:201124735	A/T	cg23649088	chr2:200775458	C2orf69	-0.38	-6.63	-0.31	1.01e-10	QT interval;
LUAD	cis	rs6684514	0.922	rs12047994	chr1:156284535	C/A	cg16558208	chr1:156270281	VHLL	0.53	9.66	0.43	4.4e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg00666640	chr1:248458726	OR2T12	0.33	8.05	0.36	8.2e-15	Common traits (Other);
LUAD	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg15017067	chr4:17643749	FAM184B	0.35	6.76	0.31	4.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg01657329	chr11:68192670	LRP5	-0.41	-6.48	-0.3	2.57e-10	Total body bone mineral density;
LUAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg18402987	chr7:1209562	NA	0.42	6.89	0.32	1.98e-11	Longevity;Endometriosis;
LUAD	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg03609598	chr5:56110824	MAP3K1	0.63	8.68	0.39	8.35e-17	Initial pursuit acceleration;
LUAD	cis	rs4664304	0.966	rs925407	chr2:160767502	A/C	cg23995753	chr2:160760732	LY75	-0.46	-8.12	-0.37	5.08e-15	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.87	-0.36	3.03e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.85	0.32	2.58e-11	Rheumatoid arthritis;
LUAD	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg00922110	chr4:57842668	C4orf14	-0.45	-8.62	-0.39	1.39e-16	Response to bleomycin (chromatid breaks);
LUAD	trans	rs11039798	0.764	rs4357721	chr11:48354907	G/A	cg15704280	chr7:45808275	SEPT13	-0.65	-7.73	-0.35	7.92e-14	Axial length;
LUAD	cis	rs7107174	1.000	rs2512538	chr11:77972461	T/G	cg19901956	chr11:77921274	USP35	-0.51	-6.36	-0.3	5.29e-10	Testicular germ cell tumor;
LUAD	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg21963583	chr11:68658836	MRPL21	-0.63	-11.19	-0.48	1.24e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11811982	0.793	rs75322809	chr1:227573821	T/C	cg24860534	chr1:227506868	CDC42BPA	0.66	7.2	0.33	2.8e-12	Optic disc area;
LUAD	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg12483005	chr1:23474871	LUZP1	0.52	9.0	0.4	7.99e-18	Height;
LUAD	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg20701182	chr2:24300061	SF3B14	0.91	13.84	0.56	3.41e-36	Lymphocyte counts;
LUAD	trans	rs1997103	0.871	rs9649855	chr7:55410222	T/C	cg20935933	chr6:143382018	AIG1	0.54	7.63	0.35	1.58e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg18402987	chr7:1209562	NA	0.79	9.79	0.43	1.55e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3806843	0.576	rs246005	chr5:140339884	A/C	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.38	-0.3	4.59e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4638749	0.677	rs13389470	chr2:108806301	C/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.13	-0.33	4.28e-12	Blood pressure;
LUAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg09436375	chr6:42928200	GNMT	-0.29	-8.4	-0.38	6.72e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg15997130	chr1:24165203	NA	0.56	10.01	0.44	2.63e-21	Immature fraction of reticulocytes;
LUAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00149659	chr3:10157352	C3orf10	0.87	11.54	0.49	5.61e-27	Alzheimer's disease;
LUAD	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg01689657	chr7:91764605	CYP51A1	-0.32	-8.09	-0.37	6.59e-15	Breast cancer;
LUAD	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg05082376	chr22:42548792	NA	-0.49	-9.01	-0.4	7.38e-18	Schizophrenia;
LUAD	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg10755058	chr3:40428713	ENTPD3	0.38	7.11	0.33	5.09e-12	Renal cell carcinoma;
LUAD	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg12311346	chr5:56204834	C5orf35	-0.93	-13.76	-0.56	7.63e-36	Initial pursuit acceleration;
LUAD	cis	rs62064224	0.589	rs9903650	chr17:30689370	T/A	cg18200150	chr17:30822561	MYO1D	0.41	7.61	0.35	1.78e-13	Schizophrenia;
LUAD	cis	rs758324	0.898	rs11958749	chr5:131166014	T/C	cg06307176	chr5:131281290	NA	0.51	8.08	0.37	7.01e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7523050	0.558	rs34880940	chr1:109487731	T/C	cg08274380	chr1:109419600	GPSM2	0.76	6.7	0.31	6.67e-11	Fat distribution (HIV);
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg16855422	chr11:63997982	DNAJC4	-0.47	-7.49	-0.34	3.93e-13	Vertical cup-disc ratio;
LUAD	trans	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.33	-0.38	1.18e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs68170813	0.652	rs117775624	chr7:107124113	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-8.96	-0.4	1.05e-17	Coronary artery disease;
LUAD	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg11247378	chr22:39784982	NA	-0.67	-11.17	-0.48	1.43e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg26384229	chr12:38710491	ALG10B	0.5	8.06	0.36	8.11e-15	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15369054	chr17:80825471	TBCD	-0.57	-9.09	-0.4	3.91e-18	Breast cancer;
LUAD	cis	rs6842047	0.611	rs4253421	chr4:187204937	C/T	cg23442198	chr4:187126114	CYP4V2	-0.74	-7.03	-0.32	8.4e-12	Blood protein levels;
LUAD	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-7.76	-0.35	6.64e-14	Blood metabolite levels;
LUAD	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg24558204	chr6:135376177	HBS1L	0.49	8.98	0.4	9.03e-18	Red blood cell count;
LUAD	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg05434287	chr7:2030229	MAD1L1	0.4	6.61	0.31	1.14e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs829880	0.789	rs1096146	chr12:98850966	A/G	cg25150519	chr12:98850993	NA	0.65	11.89	0.5	2.61e-28	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.54	0.34	2.94e-13	Menopause (age at onset);
LUAD	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg00999904	chr2:3704751	ALLC	-0.4	-7.29	-0.33	1.54e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.61	6.77	0.31	4.4e-11	Crohn's disease;
LUAD	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg03806693	chr22:41940476	POLR3H	-0.5	-7.38	-0.34	8.29e-13	Neuroticism;
LUAD	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg12035532	chr1:1886765	KIAA1751	0.42	7.01	0.32	9.75e-12	Body mass index;
LUAD	cis	rs7678296	0.649	rs60691639	chr4:37239925	T/C	cg06805348	chr4:37245195	KIAA1239	0.58	7.0	0.32	9.81e-12	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs11031096	0.754	rs4910886	chr11:4143721	G/T	cg18678763	chr11:4115507	RRM1	-0.42	-7.14	-0.33	4.01e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs7172809	0.548	rs11853625	chr15:77505206	C/T	cg11865553	chr15:77376250	NA	-0.38	-6.36	-0.3	5.39e-10	Glucose homeostasis traits;
LUAD	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg18187862	chr3:45730750	SACM1L	0.52	8.28	0.37	1.61e-15	Primary sclerosing cholangitis;
LUAD	cis	rs7943203	1.000	rs10890839	chr11:108306236	C/A	cg04873221	chr11:107992290	ACAT1	-0.42	-6.72	-0.31	5.79e-11	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg19767477	chr5:127420684	SLC12A2	0.43	6.58	0.3	1.39e-10	Ileal carcinoids;
LUAD	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg06092702	chr1:163392909	NA	-0.39	-8.55	-0.38	2.3e-16	Motion sickness;
LUAD	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg12311346	chr5:56204834	C5orf35	-0.57	-9.04	-0.4	5.78e-18	Coronary artery disease;
LUAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12016809	chr21:47604291	C21orf56	0.64	10.81	0.47	3.24e-24	Testicular germ cell tumor;
LUAD	cis	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg27411982	chr8:10470053	RP1L1	0.41	6.93	0.32	1.55e-11	Neuroticism;
LUAD	cis	rs7027203	1.000	rs34624092	chr9:96523092	G/A	cg14598338	chr9:96623480	NA	0.38	7.51	0.34	3.64e-13	DNA methylation (variation);
LUAD	cis	rs12612619	0.732	rs1866654	chr2:27263122	A/G	cg00617064	chr2:27272375	NA	-0.38	-7.38	-0.34	8.36e-13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs11696501	0.947	rs6073759	chr20:44115498	A/T	cg11783356	chr20:44313418	WFDC10B	-0.47	-7.13	-0.33	4.28e-12	Brain structure;
LUAD	cis	rs12618769	0.652	rs72823801	chr2:99235055	A/G	cg10123293	chr2:99228465	UNC50	0.5	8.94	0.4	1.25e-17	Bipolar disorder;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg04621676	chr1:9599380	SLC25A33	-0.38	-6.44	-0.3	3.16e-10	Schizophrenia;
LUAD	cis	rs7246657	0.943	rs28373708	chr19:37976659	C/T	cg23950597	chr19:37808831	NA	-0.63	-7.86	-0.36	3.17e-14	Coronary artery calcification;
LUAD	trans	rs629535	0.590	rs55988608	chr8:70133619	A/G	cg21567404	chr3:27674614	NA	-1.02	-16.75	-0.63	1.15e-48	Dupuytren's disease;
LUAD	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg07432352	chr17:45403706	C17orf57	-0.39	-7.6	-0.35	1.95e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg14917512	chr19:3094685	GNA11	-0.57	-6.81	-0.31	3.33e-11	Diabetic kidney disease;
LUAD	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg04455712	chr21:45112962	RRP1B	0.43	8.74	0.39	5.45e-17	Mean corpuscular volume;
LUAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	cis	rs4722585	0.533	rs757371	chr7:26199207	A/G	cg07876897	chr7:26191696	NFE2L3	0.45	7.37	0.34	8.97e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	trans	rs6561151	0.681	rs61959998	chr13:44462501	A/T	cg12856521	chr11:46389249	DGKZ	0.85	11.9	0.5	2.2e-28	Crohn's disease;
LUAD	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.51	-10.26	-0.45	3.37e-22	Monocyte percentage of white cells;
LUAD	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.55	7.69	0.35	1.01e-13	Platelet count;
LUAD	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg21153622	chr11:89784906	NA	0.33	6.51	0.3	2.19e-10	Coronary artery disease;
LUAD	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg11861562	chr11:117069780	TAGLN	-0.34	-6.48	-0.3	2.59e-10	Blood protein levels;
LUAD	cis	rs2455799	0.613	rs13080145	chr3:15880060	C/G	cg16303742	chr3:15540471	COLQ	-0.51	-9.38	-0.42	3.99e-19	Mean platelet volume;
LUAD	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs11098699	0.732	rs2132077	chr4:124240638	G/C	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	cis	rs7809950	0.822	rs2712228	chr7:107300340	A/C	cg23024343	chr7:107201750	COG5	0.64	10.7	0.46	8.29e-24	Coronary artery disease;
LUAD	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg04586622	chr2:25135609	ADCY3	0.37	8.35	0.38	1.02e-15	Body mass index in non-asthmatics;
LUAD	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs7584330	0.518	rs11903073	chr2:238432766	C/T	cg14458575	chr2:238380390	NA	0.61	9.68	0.43	3.72e-20	Prostate cancer;
LUAD	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.25	-0.33	1.96e-12	Blood metabolite levels;
LUAD	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22590775	chr19:49891494	CCDC155	0.68	11.01	0.47	5.74e-25	Multiple sclerosis;
LUAD	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg12311346	chr5:56204834	C5orf35	-0.48	-7.98	-0.36	1.37e-14	Coronary artery disease;
LUAD	cis	rs1018836	0.892	rs10105142	chr8:91547420	C/T	cg16814680	chr8:91681699	NA	-0.58	-10.18	-0.44	6.45e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg13385794	chr1:248469461	NA	0.26	6.99	0.32	1.08e-11	Common traits (Other);
LUAD	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Parkinson's disease;
LUAD	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.57	-0.3	1.51e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06028808	chr11:68637592	NA	0.43	7.06	0.32	6.73e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs783540	0.934	rs7182403	chr15:83297613	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.43	-7.01	-0.32	9.26e-12	Schizophrenia;
LUAD	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg10589385	chr1:150898437	SETDB1	0.38	7.28	0.33	1.59e-12	Tonsillectomy;
LUAD	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg03526776	chr6:41159608	TREML2	-0.52	-11.56	-0.49	4.66e-27	Alzheimer's disease (late onset);
LUAD	cis	rs12545109	0.571	rs4314648	chr8:57276937	G/A	cg07776626	chr8:57350775	NA	-0.66	-8.64	-0.39	1.13e-16	Obesity-related traits;
LUAD	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg27411982	chr8:10470053	RP1L1	0.39	6.85	0.32	2.68e-11	Retinal vascular caliber;
LUAD	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-6.95	-0.32	1.38e-11	Morning vs. evening chronotype;
LUAD	cis	rs2735413	0.709	rs4395084	chr16:78088011	C/G	cg04733911	chr16:78082701	NA	-0.39	-9.28	-0.41	8.75e-19	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg16686185	chr17:78078845	GAA	-0.39	-6.39	-0.3	4.45e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.43	-0.6	6.11e-43	Chronic sinus infection;
LUAD	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg26384229	chr12:38710491	ALG10B	0.44	7.15	0.33	3.77e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2806561	0.929	rs9426694	chr1:23539742	T/C	cg12483005	chr1:23474871	LUZP1	0.38	6.49	0.3	2.4e-10	Height;
LUAD	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg25237894	chr2:233734115	C2orf82	0.61	11.73	0.5	1.02e-27	Coronary artery disease;
LUAD	cis	rs4150161	0.656	rs3743642	chr16:84212928	G/A	cg10106505	chr16:84220380	TAF1C	-0.88	-8.02	-0.36	1.05e-14	Systolic blood pressure response to hydrochlorothiazide in hypertension;
LUAD	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.41	0.6	7.52e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg26043149	chr18:55253948	FECH	-0.47	-7.71	-0.35	9.06e-14	Bone mineral density;
LUAD	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg19163074	chr7:65112434	INTS4L2	0.44	6.79	0.31	3.82e-11	Aortic root size;
LUAD	trans	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg06606381	chr12:133084897	FBRSL1	-0.63	-6.81	-0.31	3.44e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2073300	1.000	rs114718317	chr20:23442620	T/C	cg09953122	chr20:23471693	CST8	-0.65	-6.39	-0.3	4.29e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs758324	0.947	rs924434	chr5:131143369	A/C	cg06307176	chr5:131281290	NA	0.5	7.84	0.36	3.6e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg08916839	chr5:415575	AHRR	0.85	9.94	0.44	4.68e-21	Fat distribution (HIV);
LUAD	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg19318889	chr4:1322082	MAEA	0.58	9.76	0.43	1.97e-20	Longevity;
LUAD	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg08989290	chr16:615782	NHLRC4	0.3	6.6	0.31	1.24e-10	Height;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg20372543	chr2:242575850	ATG4B;THAP4	-0.68	-6.82	-0.31	3.25e-11	Type 2 diabetes;
LUAD	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-21.17	-0.72	2.47e-68	Coronary artery disease;
LUAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06873352	chr17:61820015	STRADA	0.82	18.31	0.67	1.36e-55	Prudent dietary pattern;
LUAD	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg17971929	chr21:40555470	PSMG1	-0.41	-6.41	-0.3	3.84e-10	Cognitive function;
LUAD	trans	rs28735056	0.587	rs8093548	chr18:77636451	G/A	cg05926928	chr17:57297772	GDPD1	-0.69	-10.67	-0.46	1.09e-23	Schizophrenia;
LUAD	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg12193833	chr17:30244370	NA	-0.58	-6.97	-0.32	1.25e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs9443645	0.527	rs9343870	chr6:79789473	T/G	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.61	-0.31	1.16e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs7200543	0.848	rs62039480	chr16:15137450	G/A	cg24683922	chr1:11983373	KIAA2013	-0.43	-7.18	-0.33	3.26e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs8099014	1.000	rs4940701	chr18:56110158	A/T	cg12907477	chr18:56117327	MIR122	0.39	6.71	0.31	6.24e-11	Platelet count;
LUAD	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	24.17	0.76	1.04e-81	Chronic sinus infection;
LUAD	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg14092571	chr14:90743983	NA	-0.8	-15.01	-0.59	3.93e-41	Gut microbiota (bacterial taxa);
LUAD	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.38	6.91	0.32	1.8e-11	Systemic lupus erythematosus;
LUAD	cis	rs13315871	1.000	rs28668389	chr3:58323942	G/C	cg20936604	chr3:58311152	NA	-0.78	-8.27	-0.37	1.76e-15	Cholesterol, total;
LUAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg11416102	chr8:651193	ERICH1	0.91	8.49	0.38	3.46e-16	IgG glycosylation;
LUAD	cis	rs7100689	0.646	rs11202724	chr10:82136190	T/C	cg00277334	chr10:82204260	NA	-0.63	-10.54	-0.46	3.26e-23	Post bronchodilator FEV1;
LUAD	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg06740227	chr12:86229804	RASSF9	0.45	7.88	0.36	2.78e-14	Major depressive disorder;
LUAD	trans	rs11165623	0.765	rs12749081	chr1:96970371	A/C	cg10631902	chr5:14652156	NA	-0.57	-11.04	-0.47	4.36e-25	Hip circumference;Waist circumference;
LUAD	cis	rs17818399	0.815	rs35837037	chr2:46861300	C/T	cg09399716	chr2:46890238	NA	-0.41	-7.8	-0.35	4.86e-14	Height;
LUAD	cis	rs367943	0.666	rs10074214	chr5:112702214	A/G	cg12552261	chr5:112820674	MCC	0.45	8.88	0.4	1.89e-17	Type 2 diabetes;
LUAD	cis	rs7493	0.901	rs17882539	chr7:95026408	G/A	cg04871131	chr7:94954202	PON1	-0.47	-6.44	-0.3	3.19e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg22442454	chr1:209979470	IRF6	0.47	6.78	0.31	4.13e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg01448562	chr3:133502909	NA	-0.67	-12.29	-0.51	6.55e-30	Iron status biomarkers;
LUAD	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg23533926	chr12:111358616	MYL2	-0.4	-6.79	-0.31	3.87e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2880765	0.743	rs8032488	chr15:86012768	T/C	cg13263323	chr15:86062960	AKAP13	-0.47	-8.46	-0.38	4.4e-16	Coronary artery disease;
LUAD	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg18105134	chr13:113819100	PROZ	-0.87	-15.55	-0.6	1.91e-43	Platelet distribution width;
LUAD	cis	rs977987	0.843	rs59465235	chr16:75483810	C/G	cg03315344	chr16:75512273	CHST6	0.64	13.81	0.56	4.64e-36	Dupuytren's disease;
LUAD	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.89e-14	Depression;
LUAD	cis	rs7927771	0.524	rs10838740	chr11:47679980	A/G	cg18512352	chr11:47633146	NA	0.39	7.09	0.33	5.55e-12	Subjective well-being;
LUAD	trans	rs10838798	0.563	rs4752894	chr11:48120936	G/A	cg00717180	chr2:96193071	NA	-0.38	-7.1	-0.33	5.44e-12	Height;
LUAD	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg04155289	chr7:94953770	PON1	-0.5	-6.55	-0.3	1.71e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2882667	0.858	rs11949916	chr5:138396277	T/G	cg04439458	chr5:138467593	SIL1	-0.52	-9.22	-0.41	1.45e-18	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.62	0.35	1.73e-13	Platelet count;
LUAD	cis	rs62458065	1.000	rs6462363	chr7:32464759	T/G	cg20159608	chr7:32802032	NA	-0.47	-6.82	-0.31	3.22e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg03579179	chr7:12444095	VWDE	-0.46	-7.21	-0.33	2.57e-12	Coronary artery disease;
LUAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg05434287	chr7:2030229	MAD1L1	0.43	7.1	0.33	5.29e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs3849570	0.514	rs4389498	chr3:82015395	G/A	cg07356753	chr3:81810745	GBE1	-0.51	-8.49	-0.38	3.55e-16	Waist circumference;Body mass index;
LUAD	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.95	-0.36	1.78e-14	Monocyte percentage of white cells;
LUAD	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg15704280	chr7:45808275	SEPT13	-0.76	-12.74	-0.53	1.08e-31	Coronary artery disease;
LUAD	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg08470875	chr2:26401718	FAM59B	-0.79	-11.13	-0.48	2.11e-25	Gut microbiome composition (summer);
LUAD	cis	rs2625529	0.590	rs3803471	chr15:72500786	A/G	cg16672083	chr15:72433130	SENP8	-0.75	-12.72	-0.53	1.31e-31	Red blood cell count;
LUAD	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg21475434	chr5:93447410	FAM172A	0.73	8.58	0.39	1.76e-16	Diabetic retinopathy;
LUAD	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg23933602	chr10:16859644	RSU1	0.58	7.85	0.36	3.55e-14	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs68170813	0.559	rs113211438	chr7:106969198	G/A	cg02696742	chr7:106810147	HBP1	-0.76	-10.22	-0.44	4.83e-22	Coronary artery disease;
LUAD	cis	rs73206853	0.698	rs1018134	chr12:111121119	G/A	cg12870014	chr12:110450643	ANKRD13A	0.6	6.81	0.31	3.36e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24689585	chr15:22957012	CYFIP1	0.58	7.27	0.33	1.73e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-7.8	-0.35	5.04e-14	Electroencephalogram traits;
LUAD	cis	rs6738485	0.930	rs13015630	chr2:106790253	T/C	cg15412446	chr2:106886593	NA	-0.38	-6.4	-0.3	4.12e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs2479724	0.870	rs7766960	chr6:41918190	T/G	cg17623882	chr6:41773611	USP49	-0.57	-10.09	-0.44	1.36e-21	Menarche (age at onset);
LUAD	cis	rs870825	0.929	rs1405939	chr4:185591444	C/T	cg04058563	chr4:185651563	MLF1IP	0.68	8.31	0.37	1.33e-15	Blood protein levels;
LUAD	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-7.1	-0.33	5.15e-12	Morning vs. evening chronotype;
LUAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22496380	chr5:211416	CCDC127	-1.19	-15.83	-0.61	1.11e-44	Breast cancer;
LUAD	cis	rs1832871	0.541	rs17581620	chr6:158880590	A/G	cg07165851	chr6:158734300	TULP4	0.52	7.26	0.33	1.93e-12	Height;
LUAD	cis	rs4481887	0.790	rs4453078	chr1:248411889	A/G	cg00666640	chr1:248458726	OR2T12	-0.28	-7.17	-0.33	3.48e-12	Common traits (Other);
LUAD	cis	rs12765878	1.000	rs34300861	chr10:105643332	A/C	cg11005552	chr10:105648138	OBFC1	0.44	8.26	0.37	1.91e-15	Coronary artery disease;
LUAD	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg19980929	chr12:42632907	YAF2	-0.35	-6.81	-0.31	3.31e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg20203395	chr5:56204925	C5orf35	-0.82	-11.9	-0.5	2.26e-28	Type 2 diabetes;
LUAD	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg08761264	chr16:28874980	SH2B1	-0.46	-7.02	-0.32	8.96e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg00495681	chr13:53174319	NA	0.5	9.11	0.4	3.4e-18	Lewy body disease;
LUAD	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.85	0.53	3.9e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.48	0.3	2.52e-10	Parkinson's disease;
LUAD	cis	rs6714710	0.603	rs717417	chr2:98416850	T/G	cg26665480	chr2:98280029	ACTR1B	0.55	8.98	0.4	8.82e-18	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs9796	0.689	rs11855797	chr15:41434679	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.42	-7.6	-0.35	1.89e-13	Menopause (age at onset);
LUAD	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg09117114	chr16:67998030	SLC12A4	-0.61	-8.15	-0.37	4.12e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs367943	0.666	rs7717422	chr5:112704089	A/G	cg12552261	chr5:112820674	MCC	0.44	8.88	0.4	1.95e-17	Type 2 diabetes;
LUAD	cis	rs7586879	0.789	rs7560156	chr2:25124794	T/C	cg04586622	chr2:25135609	ADCY3	0.36	7.28	0.33	1.68e-12	Body mass index;
LUAD	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg14752069	chr8:11977206	FAM66D	-0.3	-6.72	-0.31	5.8e-11	Neuroticism;
LUAD	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg12179176	chr11:130786555	SNX19	0.44	7.39	0.34	7.83e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg07395648	chr5:131743802	NA	-0.38	-6.43	-0.3	3.35e-10	Breast cancer;
LUAD	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg05313129	chr8:58192883	C8orf71	-0.53	-7.66	-0.35	1.25e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22857025	chr5:266934	NA	-0.99	-14.44	-0.57	1.05e-38	Breast cancer;
LUAD	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-8.6	-0.39	1.59e-16	Menarche (age at onset);
LUAD	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg07061783	chr6:25882402	NA	-0.56	-8.94	-0.4	1.25e-17	Uric acid levels;
LUAD	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	11.59	0.49	3.79e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg23958373	chr8:599963	NA	1.06	10.47	0.45	5.85e-23	IgG glycosylation;
LUAD	cis	rs2262909	0.962	rs11667209	chr19:22259467	A/G	cg11619707	chr19:22235551	ZNF257	0.49	7.57	0.35	2.33e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg16479474	chr6:28041457	NA	0.45	7.73	0.35	7.89e-14	Depression;
LUAD	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.62	-0.35	1.71e-13	Monocyte percentage of white cells;
LUAD	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-7.27	-0.33	1.71e-12	Morning vs. evening chronotype;
LUAD	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23583168	chr7:148888333	NA	-0.93	-19.34	-0.69	3.52e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7089973	0.966	rs36089581	chr10:116623059	G/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.21	0.41	1.56e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg00277334	chr10:82204260	NA	-0.67	-12.18	-0.51	1.8e-29	Post bronchodilator FEV1;
LUAD	cis	rs752010	0.811	rs10749836	chr1:42086860	G/C	cg06885757	chr1:42089581	HIVEP3	0.41	8.38	0.38	7.96e-16	Lupus nephritis in systemic lupus erythematosus;
LUAD	trans	rs62458065	1.000	rs10275978	chr7:32466719	G/T	cg00845942	chr12:64062724	DPY19L2	-0.45	-6.52	-0.3	1.96e-10	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7116495	0.541	rs579320	chr11:71794954	G/T	cg07596299	chr11:71824057	C11orf51	-0.77	-6.53	-0.3	1.86e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg03806693	chr22:41940476	POLR3H	0.7	9.66	0.43	4.44e-20	Vitiligo;
LUAD	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19717773	chr7:2847554	GNA12	-0.58	-10.05	-0.44	1.9e-21	Height;
LUAD	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg12011299	chr4:100065546	ADH4	-0.72	-13.46	-0.55	1.22e-34	Alcohol dependence;
LUAD	cis	rs1065656	0.563	rs391546	chr16:1915581	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.38	6.6	0.31	1.27e-10	Insulin-like growth factors;
LUAD	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg08280861	chr8:58055591	NA	0.74	9.14	0.41	2.65e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg24531977	chr5:56204891	C5orf35	-0.58	-9.25	-0.41	1.15e-18	Coronary artery disease;
LUAD	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	9.92	0.43	5.57e-21	Electrocardiographic conduction measures;
LUAD	cis	rs2742417	0.603	rs2742455	chr3:45767116	A/G	cg10512202	chr3:45649293	LIMD1	0.47	8.85	0.4	2.46e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs11958404	0.858	rs72818142	chr5:157474934	C/T	cg05962755	chr5:157440814	NA	0.65	8.73	0.39	5.78e-17	IgG glycosylation;
LUAD	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg03433033	chr1:76189801	ACADM	-0.47	-6.74	-0.31	5.18e-11	Daytime sleep phenotypes;
LUAD	trans	rs11638815	0.626	rs11633829	chr15:83326938	C/T	cg18393722	chr15:85113863	UBE2QP1	0.49	7.31	0.33	1.37e-12	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg17346650	chr17:80929145	B3GNTL1	-0.39	-7.42	-0.34	6.58e-13	Glycated hemoglobin levels;
LUAD	cis	rs938554	0.784	rs1071988	chr4:9974638	A/G	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.35	-0.38	1.01e-15	Blood metabolite levels;
LUAD	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg08470875	chr2:26401718	FAM59B	-0.77	-10.37	-0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg27129171	chr3:47204927	SETD2	0.4	6.48	0.3	2.5e-10	Colorectal cancer;
LUAD	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.44e-10	Prostate cancer;
LUAD	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg03433033	chr1:76189801	ACADM	0.7	11.12	0.48	2.23e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs754466	0.957	rs61854183	chr10:79698077	T/C	cg17075019	chr10:79541650	NA	-0.8	-12.87	-0.53	3.13e-32	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg17724175	chr1:150552817	MCL1	-0.3	-6.89	-0.32	2.06e-11	Melanoma;
LUAD	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg12365402	chr11:9010492	NRIP3	0.49	9.17	0.41	2.02e-18	Hemoglobin concentration;
LUAD	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg06064525	chr11:970664	AP2A2	-0.55	-11.27	-0.48	6.09e-26	Alzheimer's disease (late onset);
LUAD	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.41	-7.01	-0.32	9.61e-12	Longevity;Endometriosis;
LUAD	trans	rs3930017	1.000	rs3930016	chr7:76720449	A/G	cg05913257	chr4:53525745	USP46	-0.41	-6.68	-0.31	7.62e-11	Body mass index;
LUAD	cis	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg20542592	chr8:11973495	FAM66D	-0.44	-7.26	-0.33	1.93e-12	Neuroticism;
LUAD	cis	rs4728302	0.583	rs1424583	chr7:133159583	T/G	cg10665199	chr7:133106180	EXOC4	0.66	11.45	0.49	1.27e-26	Intelligence;Intelligence (multi-trait analysis);
LUAD	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg16049864	chr8:95962084	TP53INP1	-0.6	-13.21	-0.54	1.29e-33	Type 2 diabetes;
LUAD	cis	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.43	8.28	0.37	1.69e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg05340658	chr4:99064831	C4orf37	0.54	9.17	0.41	2.01e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.58	7.43	0.34	6.25e-13	Gut microbiome composition (summer);
LUAD	cis	rs8112211	0.519	rs117624491	chr19:38808505	A/C	cg14299480	chr19:38876666	GGN	-0.4	-6.83	-0.32	2.9100000000000002e-11	Blood protein levels;
LUAD	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.28	-7.03	-0.32	8.28e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11890956	chr21:40555474	PSMG1	0.76	13.45	0.55	1.35e-34	Cognitive function;
LUAD	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg27170947	chr2:26402098	FAM59B	-0.82	-11.61	-0.49	3.05e-27	Gut microbiome composition (summer);
LUAD	cis	rs524023	0.881	rs544838	chr11:64429059	T/C	cg19131476	chr11:64387923	NRXN2	-0.43	-8.51	-0.38	3.03e-16	Urate levels in obese individuals;
LUAD	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.59	8.37	0.38	8.75e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg06766960	chr11:133703094	NA	-0.44	-8.25	-0.37	2.1e-15	Childhood ear infection;
LUAD	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs72799341	1.000	rs72799341	chr16:30936743	G/A	cg05768032	chr16:30646687	NA	0.41	6.4	0.3	4.23e-10	Diastolic blood pressure;
LUAD	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg02018176	chr4:1364513	KIAA1530	0.38	6.52	0.3	1.95e-10	Obesity-related traits;
LUAD	cis	rs11685299	1	rs11685299	chr2:225391296	C/A	cg12698349	chr2:225449008	CUL3	0.76	13.2	0.54	1.54e-33	Schizophrenia;
LUAD	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg13393036	chr8:95962371	TP53INP1	-0.45	-11.19	-0.48	1.2e-25	Type 2 diabetes;
LUAD	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg09491104	chr22:46646882	C22orf40	-0.74	-13.44	-0.55	1.6e-34	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs113835537	0.529	rs57691879	chr11:66236604	C/T	cg26679405	chr11:66247800	DPP3	-0.44	-6.51	-0.3	2.1e-10	Airway imaging phenotypes;
LUAD	trans	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg19469189	chr11:128781035	KCNJ5	0.44	6.63	0.31	1.03e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.91	-0.36	2.34e-14	HDL cholesterol;
LUAD	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-8.01	-0.36	1.1e-14	Prostate cancer;
LUAD	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg13319975	chr6:146136371	FBXO30	-0.64	-11.13	-0.48	2.07e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs427941	0.703	rs201451	chr7:101739550	G/A	cg06246474	chr7:101738831	CUX1	0.41	7.25	0.33	1.98e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg00310523	chr12:86230176	RASSF9	-0.34	-6.96	-0.32	1.27e-11	Major depressive disorder;
LUAD	cis	rs113835537	0.529	rs57634456	chr11:66250838	A/C	cg24851651	chr11:66362959	CCS	0.56	10.1	0.44	1.28e-21	Airway imaging phenotypes;
LUAD	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg01191920	chr7:158217561	PTPRN2	-0.7	-15.22	-0.59	5.01e-42	Obesity-related traits;
LUAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07157834	chr1:205819609	PM20D1	0.69	13.03	0.54	7.54e-33	Menarche (age at onset);
LUAD	cis	rs4072705	1.000	rs4836980	chr9:127339163	C/T	cg13476313	chr9:127244764	NR5A1	0.3	7.26	0.33	1.87e-12	Menarche (age at onset);
LUAD	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg26022315	chr17:47021804	SNF8	0.41	7.38	0.34	8.45e-13	Type 2 diabetes;
LUAD	cis	rs4919694	1.000	rs3740394	chr10:104634474	A/G	cg04362960	chr10:104952993	NT5C2	0.65	7.12	0.33	4.58e-12	Arsenic metabolism;
LUAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg15117754	chr3:10150083	C3orf24	0.42	6.68	0.31	7.38e-11	Alzheimer's disease;
LUAD	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg21856205	chr7:94953877	PON1	-0.53	-7.34	-0.34	1.09e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.4	-0.38	7.05e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg04414720	chr1:150670196	GOLPH3L	0.62	10.51	0.45	4.26e-23	Melanoma;
LUAD	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg15664640	chr17:80829946	TBCD	-0.69	-8.49	-0.38	3.55e-16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs3743162	0.553	rs12900463	chr15:85415386	T/C	cg11189052	chr15:85197271	WDR73	0.56	6.81	0.31	3.32e-11	Alzheimer's disease (age of onset);
LUAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg22105103	chr4:187893119	NA	0.57	12.62	0.52	3.25e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg03034668	chr16:1723424	CRAMP1L	-0.38	-6.54	-0.3	1.78e-10	Coronary artery disease;
LUAD	cis	rs7927771	0.524	rs12362318	chr11:47682671	T/C	cg18512352	chr11:47633146	NA	0.37	6.47	0.3	2.7e-10	Subjective well-being;
LUAD	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07930192	chr7:1003750	NA	0.37	7.14	0.33	4.09e-12	Longevity;Endometriosis;
LUAD	cis	rs9517320	0.967	rs6491430	chr13:99178276	G/A	cg20487152	chr13:99095054	FARP1	0.36	6.57	0.3	1.47e-10	Longevity;
LUAD	cis	rs1018836	0.923	rs13254212	chr8:91582355	T/C	cg16814680	chr8:91681699	NA	-0.71	-11.98	-0.5	1.15e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7180079	1.000	rs10519228	chr15:64483187	A/G	cg08069370	chr15:64387884	SNX1	-0.5	-6.36	-0.3	5.13e-10	Monocyte count;
LUAD	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.33	0.48	3.51e-26	Height;
LUAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-8.97	-0.4	9.95e-18	Renal function-related traits (BUN);
LUAD	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg17200465	chr3:40428508	ENTPD3	0.28	7.15	0.33	3.84e-12	Renal cell carcinoma;
LUAD	cis	rs2274273	0.638	rs3825614	chr14:55729387	G/A	cg04306507	chr14:55594613	LGALS3	0.43	7.93	0.36	2e-14	Protein biomarker;
LUAD	cis	rs11048434	0.736	rs12812913	chr12:9110836	C/G	cg13575925	chr12:9217583	LOC144571	0.37	7.03	0.32	8.36e-12	Sjögren's syndrome;
LUAD	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg09359103	chr1:154839909	KCNN3	-0.91	-21.12	-0.72	3.92e-68	Prostate cancer;
LUAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg18621852	chr3:10150065	C3orf24	0.47	7.18	0.33	3.19e-12	Alzheimer's disease;
LUAD	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg23985595	chr17:80112537	CCDC57	0.51	9.26	0.41	1.07e-18	Life satisfaction;
LUAD	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg06532163	chr17:45867833	NA	0.48	8.44	0.38	5.28e-16	IgG glycosylation;
LUAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg16606324	chr3:10149918	C3orf24	0.7	11.51	0.49	7.19e-27	Alzheimer's disease;
LUAD	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg18512352	chr11:47633146	NA	-0.57	-10.14	-0.44	8.77e-22	Subjective well-being;
LUAD	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg23985595	chr17:80112537	CCDC57	0.53	9.74	0.43	2.39e-20	Life satisfaction;
LUAD	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03934478	chr11:495069	RNH1	0.77	9.25	0.41	1.11e-18	Body mass index;
LUAD	trans	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg24644049	chr4:85504048	CDS1	0.85	7.17	0.33	3.38e-12	Skin colour saturation;
LUAD	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.71	-0.61	3.75e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs13064411	0.518	rs9870996	chr3:113238375	A/C	cg18753928	chr3:113234510	CCDC52	-0.48	-8.57	-0.38	1.93e-16	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.79	14.74	0.58	5.39e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg18105134	chr13:113819100	PROZ	-1.0	-18.55	-0.67	1.2e-56	Platelet distribution width;
LUAD	cis	rs2668423	0.502	rs7254913	chr19:1388320	A/G	cg02639931	chr19:1387894	NDUFS7	0.74	17.46	0.65	8.1e-52	Nonalcoholic fatty liver disease;
LUAD	trans	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg26043149	chr18:55253948	FECH	0.43	7.14	0.33	4.06e-12	Bone mineral density;
LUAD	cis	rs4900538	0.821	rs2009575	chr14:102820787	C/T	cg18135206	chr14:102964638	TECPR2	-0.97	-19.58	-0.69	3.18e-61	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs494562	0.892	rs4624841	chr6:86130251	G/A	cg17966619	chr6:86160162	NT5E	0.67	7.9	0.36	2.36e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg18932078	chr1:2524107	MMEL1	0.36	6.63	0.31	1.01e-10	Multiple sclerosis;
LUAD	cis	rs10857712	0.687	rs11101742	chr10:135224372	C/G	cg01444801	chr10:135216882	MTG1	-0.43	-6.79	-0.31	3.78e-11	Systemic lupus erythematosus;
LUAD	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg12524338	chr4:183729343	NA	0.54	6.93	0.32	1.62e-11	Pediatric autoimmune diseases;
LUAD	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg04267008	chr7:1944627	MAD1L1	-0.5	-7.74	-0.35	7.57e-14	Schizophrenia;
LUAD	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg15962314	chr1:44399869	ARTN	-0.35	-8.0	-0.36	1.23e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01084379	chr5:179160712	MAML1	-0.53	-6.41	-0.3	3.9e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg09035930	chr12:129282057	SLC15A4	0.75	18.02	0.66	2.82e-54	Systemic lupus erythematosus;
LUAD	cis	rs958025	1	rs958025	chr15:78759348	C/T	cg18825076	chr15:78729989	IREB2	0.56	7.88	0.36	2.9e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs12612619	0.732	rs11126836	chr2:27273128	C/T	cg00617064	chr2:27272375	NA	-0.37	-7.11	-0.33	4.89e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs4911259	0.552	rs62208880	chr20:31463284	T/C	cg13636640	chr20:31349939	DNMT3B	-0.57	-9.36	-0.41	4.71e-19	Inflammatory bowel disease;
LUAD	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg25358565	chr5:93447407	FAM172A	0.61	7.12	0.33	4.79e-12	Diabetic retinopathy;
LUAD	cis	rs28595532	0.920	rs115317002	chr4:119722809	T/C	cg21605333	chr4:119757512	SEC24D	0.92	8.44	0.38	5.27e-16	Cannabis dependence symptom count;
LUAD	cis	rs2629540	0.847	rs10901807	chr10:126384610	G/A	cg08799069	chr10:126477246	METTL10	0.46	6.9	0.32	1.93e-11	Cocaine dependence;
LUAD	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.92	-0.5	1.91e-28	Bipolar disorder;
LUAD	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg02551604	chr5:131831745	NA	0.59	9.62	0.42	6.08e-20	Asthma (sex interaction);
LUAD	cis	rs4730250	0.640	rs7783562	chr7:106917438	G/T	cg23024343	chr7:107201750	COG5	0.55	6.91	0.32	1.83e-11	Osteoarthritis;
LUAD	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg08999081	chr20:33150536	PIGU	0.63	14.53	0.58	4.13e-39	Coronary artery disease;
LUAD	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg14835575	chr10:16859367	RSU1	0.98	14.4	0.57	1.48e-38	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs62238980	0.614	rs74658500	chr22:32410101	C/A	cg00543991	chr22:32367038	NA	0.96	9.05	0.4	5.32e-18	Childhood ear infection;
LUAD	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs2425143	1.000	rs7273174	chr20:34350306	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.15	-0.33	3.78e-12	Blood protein levels;
LUAD	trans	rs75804782	0.641	rs3769124	chr2:239349362	G/A	cg01134436	chr17:81009848	B3GNTL1	0.73	8.02	0.36	1.02e-14	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg01017244	chr2:74357527	NA	0.85	12.44	0.52	1.78e-30	Gestational age at birth (maternal effect);
LUAD	cis	rs2625529	0.652	rs2929525	chr15:72287856	G/A	cg16672083	chr15:72433130	SENP8	0.65	12.02	0.5	7.77e-29	Red blood cell count;
LUAD	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.23	0.54	1.09e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10802521	chr3:52805072	NEK4	-0.62	-11.08	-0.47	3.05e-25	Bipolar disorder;
LUAD	cis	rs1461503	0.966	rs7110154	chr11:122843300	A/G	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg23939001	chr4:940644	TMEM175	0.62	9.13	0.41	2.84e-18	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg03929089	chr4:120376271	NA	0.56	6.5	0.3	2.2e-10	Intraocular pressure;
LUAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg18305652	chr10:134549665	INPP5A	0.62	12.11	0.51	3.6e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg05754148	chr16:3507555	NAT15	0.43	6.52	0.3	2.03e-10	Body mass index (adult);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg27203599	chr10:99161199	RRP12	-0.4	-6.64	-0.31	9.79e-11	Cancer;
LUAD	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.45	6.45	0.3	3.1e-10	Gut microbiome composition (summer);
LUAD	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg04398451	chr17:18023971	MYO15A	0.64	11.74	0.5	9.74e-28	Total body bone mineral density;
LUAD	cis	rs2274471	0.645	rs73639261	chr9:5084215	G/A	cg03390472	chr9:5043263	JAK2	-0.58	-7.8	-0.35	4.87e-14	Crohn's disease;
LUAD	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	7.92	0.36	2.05e-14	Menopause (age at onset);
LUAD	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-19.65	-0.69	1.48e-61	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs4629710	0.592	rs1885641	chr6:131553986	A/G	cg12606694	chr6:131520996	AKAP7	0.52	7.55	0.34	2.64e-13	Multiple myeloma (IgH translocation);
LUAD	cis	rs4619206	1	rs4619206	chr12:1002857	T/C	cg06357748	chr12:1025529	RAD52	0.38	7.44	0.34	5.84e-13	Lung cancer in ever smokers;
LUAD	cis	rs3750082	0.889	rs13244998	chr7:32912910	T/C	cg05721444	chr7:32995514	FKBP9	0.37	6.75	0.31	4.77e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs5771069	0.669	rs137879	chr22:50457041	C/T	cg27467552	chr22:50353597	PIM3	-0.38	-6.68	-0.31	7.32e-11	Ulcerative colitis;
LUAD	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-9.66	-0.43	4.47e-20	Gut microbiome composition (summer);
LUAD	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.04	0.36	8.92e-15	Rheumatoid arthritis;
LUAD	cis	rs4523957	0.553	rs2131702	chr17:2025458	T/C	cg16513277	chr17:2031491	SMG6	-0.98	-19.85	-0.69	1.83e-62	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg03388025	chr16:89894329	SPIRE2	0.33	7.93	0.36	1.96e-14	Vitiligo;
LUAD	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-8.72	-0.39	6.49e-17	Monocyte percentage of white cells;
LUAD	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-8.07	-0.37	7.6e-15	Total body bone mineral density;
LUAD	cis	rs2235649	0.833	rs9933168	chr16:1848361	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-6.72	-0.31	6.01e-11	Blood metabolite levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg27084994	chr5:175875161	FAF2	-0.37	-6.35	-0.3	5.71e-10	Cancer;
LUAD	cis	rs6445967	0.933	rs6796069	chr3:58332508	C/T	cg23715586	chr3:58305044	RPP14	0.44	7.87	0.36	3.05e-14	Platelet count;
LUAD	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.48	0.3	2.53e-10	Breast cancer;
LUAD	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg26384229	chr12:38710491	ALG10B	0.48	7.69	0.35	1.01e-13	Bladder cancer;
LUAD	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg06713675	chr4:122721982	EXOSC9	-0.61	-11.48	-0.49	9.83e-27	Type 2 diabetes;
LUAD	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2302190	0.882	rs7226008	chr17:56644633	T/C	cg25885038	chr17:56607967	SEPT4	-0.52	-8.27	-0.37	1.76e-15	Vitamin D levels;
LUAD	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg07606381	chr6:8435919	SLC35B3	0.41	6.88	0.32	2.21e-11	Motion sickness;
LUAD	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11890956	chr21:40555474	PSMG1	-0.56	-9.87	-0.43	8.24e-21	Menarche (age at onset);
LUAD	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21659725	chr3:3221576	CRBN	0.65	11.52	0.49	6.95e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg00933542	chr6:150070202	PCMT1	0.47	10.11	0.44	1.19e-21	Lung cancer;
LUAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.85	15.9	0.61	5.66e-45	Lymphocyte counts;
LUAD	cis	rs10129255	0.500	rs2027902	chr14:107215393	T/C	cg07958169	chr14:107095056	NA	-0.35	-7.06	-0.32	6.74e-12	Kawasaki disease;
LUAD	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg05731713	chr7:157510257	PTPRN2	0.43	10.04	0.44	2.1e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg00784671	chr22:46762841	CELSR1	-0.43	-6.42	-0.3	3.7e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg23815491	chr16:72088622	HP	0.6	11.55	0.49	5.18e-27	Fibrinogen levels;
LUAD	cis	rs76419734	0.510	rs2553456	chr4:106751028	T/C	cg05309399	chr4:106552544	FLJ20184	0.52	7.5	0.34	3.77e-13	Post bronchodilator FEV1;
LUAD	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08439880	chr3:133502540	NA	0.43	8.63	0.39	1.24e-16	Iron status biomarkers;
LUAD	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg15017067	chr4:17643749	FAM184B	-0.36	-6.93	-0.32	1.53e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg23719950	chr11:63933701	MACROD1	-0.62	-7.41	-0.34	7.01e-13	Mean platelet volume;
LUAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg24101359	chr6:42928495	GNMT	0.46	8.52	0.38	2.85e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg06608945	chr2:219082296	ARPC2	-0.42	-7.2	-0.33	2.73e-12	Colorectal cancer;
LUAD	trans	rs9914544	0.545	rs4510081	chr17:18798846	A/C	cg21372672	chr17:16614065	CCDC144A	-0.36	-6.36	-0.3	5.1e-10	Educational attainment (years of education);
LUAD	cis	rs7727544	0.582	rs3749756	chr5:131534499	C/T	cg07538946	chr5:131705188	SLC22A5	0.41	6.48	0.3	2.61e-10	Blood metabolite levels;
LUAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg21724239	chr8:58056113	NA	0.87	16.11	0.62	6.97e-46	Developmental language disorder (linguistic errors);
LUAD	cis	rs1113500	0.548	rs3853495	chr1:108643245	A/C	cg06207961	chr1:108661230	NA	0.41	6.51	0.3	2.11e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg16647868	chr5:131706066	SLC22A5	-0.39	-6.64	-0.31	9.75e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg02079420	chr8:82753780	SNX16	0.39	7.59	0.35	2.09e-13	Diastolic blood pressure;
LUAD	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg02734326	chr4:10020555	SLC2A9	0.56	10.02	0.44	2.31e-21	Bone mineral density;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg25621096	chr1:151032116	CDC42SE1;MLLT11	0.4	6.39	0.3	4.34e-10	Optic cup area;
LUAD	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg20503657	chr10:835505	NA	-0.44	-6.69	-0.31	7.17e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg24397884	chr7:158709396	WDR60	0.47	8.18	0.37	3.24e-15	Height;
LUAD	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg18404041	chr3:52824283	ITIH1	0.44	8.12	0.37	5.28e-15	Bipolar disorder;
LUAD	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.53	8.41	0.38	6.42e-16	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg11062466	chr8:58055876	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2637266	0.902	rs2583056	chr10:78399498	A/G	cg18941641	chr10:78392320	NA	0.34	7.08	0.33	6.08e-12	Pulmonary function;
LUAD	cis	rs710865	0.723	rs710870	chr1:19549759	G/A	cg13387374	chr1:19411106	UBR4	0.45	7.67	0.35	1.2e-13	Brain structure;
LUAD	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg00814883	chr7:100076585	TSC22D4	-0.82	-11.73	-0.5	1.07e-27	Platelet count;
LUAD	cis	rs9611519	1.000	rs5758268	chr22:41622419	A/T	cg13813247	chr22:41461852	NA	-0.41	-6.94	-0.32	1.5e-11	Neuroticism;
LUAD	cis	rs870825	0.616	rs6552810	chr4:185644143	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	14.03	0.56	5.61e-37	Blood protein levels;
LUAD	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg19336497	chr11:14380999	RRAS2	0.6	12.78	0.53	7.51e-32	Vitamin D levels;
LUAD	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg11148817	chr5:312970	AHRR;PDCD6	0.45	6.62	0.31	1.08e-10	Breast cancer;
LUAD	cis	rs4906332	1.000	rs911549	chr14:103984537	T/C	cg19000871	chr14:103996768	TRMT61A	0.39	6.81	0.31	3.42e-11	Coronary artery disease;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg00437311	chr19:37178174	NA	-0.4	-6.61	-0.31	1.16e-10	Schizophrenia;
LUAD	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.87	-0.36	3.09e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.28	-0.48	5.6e-26	Primary sclerosing cholangitis;
LUAD	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.61e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg17330251	chr7:94953956	PON1	-0.54	-7.31	-0.34	1.32e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg27432699	chr2:27873401	GPN1	0.57	9.99	0.44	3.03e-21	Oral cavity cancer;
LUAD	cis	rs7614311	0.636	rs73117047	chr3:63910779	G/A	cg22134162	chr3:63841271	THOC7	-0.52	-8.4	-0.38	6.82e-16	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs7503807	0.935	rs9910745	chr17:78610543	C/T	cg09596252	chr17:78655493	RPTOR	0.41	7.75	0.35	6.92e-14	Obesity;
LUAD	trans	rs75565482	1.000	rs1304873	chr1:168469600	A/G	cg05043794	chr9:111880884	C9orf5	0.75	6.38	0.3	4.61e-10	Emphysema imaging phenotypes;
LUAD	cis	rs13315871	1.000	rs13327709	chr3:58408767	C/T	cg12435725	chr3:58293450	RPP14	-0.69	-7.64	-0.35	1.47e-13	Cholesterol, total;
LUAD	cis	rs6752107	0.967	rs56049444	chr2:234157688	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.53	8.97	0.4	1e-17	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg14779329	chr11:130786720	SNX19	0.43	7.36	0.34	9.85e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs375066	0.592	rs349048	chr19:44300937	C/T	cg12072164	chr19:44306565	LYPD5	-0.39	-8.16	-0.37	3.99e-15	Breast cancer;
LUAD	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg21709803	chr11:61594965	FADS2	-0.4	-7.26	-0.33	1.89e-12	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.89	0.32	2e-11	Colorectal cancer;
LUAD	trans	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.69	-9.93	-0.43	5.03e-21	Obesity-related traits;
LUAD	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg20587970	chr11:113659929	NA	-1.2	-18.25	-0.66	2.76e-55	Hip circumference adjusted for BMI;
LUAD	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg11861562	chr11:117069780	TAGLN	-0.34	-6.63	-0.31	9.99e-11	Blood protein levels;
LUAD	cis	rs77972916	0.609	rs72790907	chr2:43575195	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-7.12	-0.33	4.77e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00802000	chr16:706648	WDR90	-0.41	-7.73	-0.35	8e-14	Height;
LUAD	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.47e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12711979	0.765	rs7559345	chr2:3818523	G/A	cg17052675	chr2:3827356	NA	-0.51	-10.46	-0.45	6.07e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg05590025	chr7:65112418	INTS4L2	-0.78	-6.94	-0.32	1.5e-11	Diabetic kidney disease;
LUAD	cis	rs6499255	1.000	rs11641521	chr16:69823081	C/G	cg15192750	chr16:69999425	NA	0.55	8.58	0.39	1.78e-16	IgE levels;
LUAD	cis	rs2235649	0.753	rs4316755	chr16:1849916	T/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.47	-7.73	-0.35	7.72e-14	Blood metabolite levels;
LUAD	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg18944383	chr4:111397179	ENPEP	0.41	8.2	0.37	2.89e-15	Height;
LUAD	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg26384229	chr12:38710491	ALG10B	0.47	7.59	0.35	2.07e-13	Morning vs. evening chronotype;
LUAD	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11644478	chr21:40555479	PSMG1	0.69	11.57	0.49	4.34e-27	Cognitive function;
LUAD	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10802521	chr3:52805072	NEK4	0.55	9.49	0.42	1.73e-19	Bipolar disorder;
LUAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg00280220	chr17:61926910	NA	0.37	7.24	0.33	2.17e-12	Prudent dietary pattern;
LUAD	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg23860436	chr12:58378763	NA	-0.36	-6.76	-0.31	4.62e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg19635926	chr16:89946313	TCF25	0.79	6.72	0.31	5.96e-11	Skin colour saturation;
LUAD	trans	rs1997103	1.000	rs12718956	chr7:55407763	A/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg08807101	chr21:30365312	RNF160	0.43	6.36	0.3	5.17e-10	Selective IgA deficiency;
LUAD	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg16850897	chr7:100343110	ZAN	0.42	7.39	0.34	8.04e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg01579765	chr21:45077557	HSF2BP	0.56	12.89	0.53	2.64e-32	Mean corpuscular volume;
LUAD	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg15448220	chr1:150897856	SETDB1	0.53	9.04	0.4	5.55e-18	Melanoma;
LUAD	cis	rs9549328	0.565	rs36145949	chr13:113616608	T/C	cg17524180	chr13:113633600	MCF2L	0.3	6.43	0.3	3.51e-10	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg18180107	chr4:99064573	C4orf37	0.42	6.75	0.31	5e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg06784218	chr1:46089804	CCDC17	-0.54	-11.63	-0.49	2.61e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg02951883	chr7:2050386	MAD1L1	-0.78	-14.17	-0.57	1.41e-37	Schizophrenia;
LUAD	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg07828340	chr4:882639	GAK	1.03	10.76	0.46	5.14e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.95	0.36	1.74e-14	Depression;
LUAD	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg09904177	chr6:26538194	HMGN4	0.41	6.76	0.31	4.59e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg00802000	chr16:706648	WDR90	-0.37	-6.94	-0.32	1.45e-11	Height;
LUAD	cis	rs8099014	0.911	rs8098308	chr18:56130661	A/G	cg12907477	chr18:56117327	MIR122	0.38	6.42	0.3	3.76e-10	Platelet count;
LUAD	cis	rs6920965	0.527	rs7763515	chr6:126174714	C/G	cg05901451	chr6:126070800	HEY2	-0.43	-7.01	-0.32	9.19e-12	High light scatter reticulocyte count;
LUAD	cis	rs887829	0.569	rs871514	chr2:234628529	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-9.27	-0.41	9.28e-19	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.26	0.33	1.89e-12	Lung cancer;
LUAD	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg02466173	chr16:30829666	NA	-0.67	-12.1	-0.51	3.74e-29	Multiple myeloma;
LUAD	trans	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg01620082	chr3:125678407	NA	-0.62	-7.42	-0.34	6.49e-13	Depression;
LUAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08219700	chr8:58056026	NA	0.57	8.08	0.37	6.8e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7937890	0.505	rs4403769	chr11:14450176	C/T	cg06199346	chr11:14280333	SPON1	-0.34	-6.73	-0.31	5.61e-11	Mitochondrial DNA levels;
LUAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22442454	chr1:209979470	IRF6	0.76	16.11	0.62	7.37e-46	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUAD	cis	rs2554380	0.800	rs8034055	chr15:84411895	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.5	-7.78	-0.35	5.73e-14	Height;
LUAD	cis	rs9296092	0.517	rs76361685	chr6:33536458	G/C	cg13560919	chr6:33536144	NA	-0.9	-16.23	-0.62	2.05e-46	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg04450456	chr4:17643702	FAM184B	0.4	7.88	0.36	2.75e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs684232	0.602	rs8064796	chr17:525937	A/C	cg12384639	chr17:618140	VPS53	0.47	8.07	0.37	7.18e-15	Prostate cancer;
LUAD	cis	rs11650175	0.634	rs7221699	chr17:63773919	A/C	cg07283582	chr17:63770753	CCDC46	0.32	6.49	0.3	2.43e-10	Chin dimples;
LUAD	cis	rs2019216	0.542	rs1987424	chr17:21874036	G/A	cg05591447	chr17:21909280	FLJ36000	-0.27	-6.51	-0.3	2.08e-10	Pelvic organ prolapse;
LUAD	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs2629540	0.781	rs2293064	chr10:126396511	C/G	cg08799069	chr10:126477246	METTL10	0.43	6.81	0.31	3.34e-11	Cocaine dependence;
LUAD	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg10645314	chr2:3704589	ALLC	-0.59	-9.36	-0.41	4.68e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg11859384	chr17:80120422	CCDC57	0.41	7.34	0.34	1.09e-12	Life satisfaction;
LUAD	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg19346786	chr7:2764209	NA	-0.53	-11.49	-0.49	8.62e-27	Height;
LUAD	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg24154853	chr7:158122151	PTPRN2	0.58	11.25	0.48	6.97e-26	Calcium levels;
LUAD	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19717773	chr7:2847554	GNA12	-0.58	-10.08	-0.44	1.47e-21	Height;
LUAD	cis	rs7394190	0.748	rs2306327	chr10:75573778	A/T	cg02286717	chr10:75415704	SYNPO2L	-0.37	-6.56	-0.3	1.57e-10	Incident atrial fibrillation;
LUAD	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg00769240	chr8:12517080	NA	-0.43	-8.39	-0.38	7.61e-16	Blood pressure (smoking interaction);
LUAD	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg12310025	chr6:25882481	NA	-0.58	-9.52	-0.42	1.34e-19	Blood metabolite levels;
LUAD	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg11833968	chr6:79620685	NA	-0.44	-8.32	-0.38	1.22e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg01802117	chr1:53393560	SCP2	-0.37	-7.15	-0.33	3.78e-12	Monocyte count;
LUAD	cis	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg07460842	chr6:66804631	NA	-1.07	-16.7	-0.63	1.93e-48	Exhaled nitric oxide output;
LUAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.45e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9972944	0.756	rs6504349	chr17:63764140	G/A	cg07283582	chr17:63770753	CCDC46	-0.5	-11.19	-0.48	1.24e-25	Total body bone mineral density;
LUAD	cis	rs4523957	0.620	rs58187837	chr17:2073272	G/C	cg16513277	chr17:2031491	SMG6	-0.99	-20.0	-0.7	3.94e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2953145	0.545	rs2975755	chr2:241524919	G/A	cg07929629	chr2:241523174	NA	0.41	6.97	0.32	1.22e-11	Bipolar disorder;
LUAD	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg16850897	chr7:100343110	ZAN	-0.64	-10.03	-0.44	2.25e-21	Other erythrocyte phenotypes;
LUAD	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg18827107	chr12:86230957	RASSF9	-0.7	-13.06	-0.54	5.27e-33	Major depressive disorder;
LUAD	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg05283184	chr6:79620031	NA	-0.6	-12.2	-0.51	1.5e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg24733560	chr20:60626293	TAF4	0.46	8.86	0.4	2.21e-17	Body mass index;
LUAD	cis	rs11771526	0.901	rs11761481	chr7:32293994	C/T	cg13207630	chr7:32358064	NA	0.56	7.21	0.33	2.64e-12	Body mass index;
LUAD	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.64	0.31	9.76e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg20607798	chr8:58055168	NA	0.8	9.91	0.43	6.02e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg16797656	chr11:68205561	LRP5	0.46	9.26	0.41	1.04e-18	Bone mineral density (spine);
LUAD	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.88	0.36	2.71e-14	Bladder cancer;
LUAD	cis	rs59104589	0.617	rs59487360	chr2:242270433	A/G	cg08645257	chr2:242211290	HDLBP	0.49	7.74	0.35	7.17e-14	Fibrinogen levels;
LUAD	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs877282	1.000	rs877282	chr10:771532	G/A	cg17470449	chr10:769945	NA	0.65	9.37	0.41	4.28e-19	Uric acid levels;
LUAD	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg23982607	chr1:1823379	GNB1	-0.9	-18.85	-0.68	5.38e-58	Body mass index;
LUAD	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg07305463	chr2:136567211	LCT	-0.37	-7.05	-0.32	7.49e-12	Mosquito bite size;
LUAD	trans	rs783540	0.846	rs783539	chr15:83254070	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.58	-0.3	1.37e-10	Schizophrenia;
LUAD	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg27170947	chr2:26402098	FAM59B	-0.69	-9.46	-0.42	2.12e-19	Gut microbiome composition (summer);
LUAD	cis	rs8192282	0.739	rs6697103	chr1:154499926	C/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.46	-7.08	-0.33	6.18e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.87	-0.36	3.05e-14	Diabetic kidney disease;
LUAD	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs4148883	0.689	rs1154415	chr4:99999033	T/C	cg12011299	chr4:100065546	ADH4	0.66	13.79	0.56	5.58e-36	Alcohol dependence;
LUAD	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg13319975	chr6:146136371	FBXO30	-0.54	-8.68	-0.39	8.52e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.31	6.82	0.31	3.23e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg23533926	chr12:111358616	MYL2	-0.4	-6.77	-0.31	4.23e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg24562669	chr7:97807699	LMTK2	0.34	8.06	0.36	7.78e-15	Breast cancer;
LUAD	cis	rs7771547	0.855	rs1406945	chr6:36562441	C/G	cg07856975	chr6:36356162	ETV7	0.42	6.5	0.3	2.29e-10	Platelet distribution width;
LUAD	cis	rs7607369	0.617	rs12987009	chr2:219658170	A/T	cg02176678	chr2:219576539	TTLL4	-0.68	-13.39	-0.55	2.52e-34	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.785	rs6539941	chr12:86452813	G/T	cg02569458	chr12:86230093	RASSF9	-0.38	-7.24	-0.33	2.1e-12	Major depressive disorder;
LUAD	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.43	-0.42	2.72e-19	Life satisfaction;
LUAD	cis	rs807669	0.934	rs762523	chr22:19180589	A/G	cg24911827	chr22:19170109	CLTCL1	0.45	9.25	0.41	1.13e-18	Metabolite levels;
LUAD	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg04455712	chr21:45112962	RRP1B	0.41	8.18	0.37	3.27e-15	Mean corpuscular volume;
LUAD	cis	rs3125734	0.633	rs4561099	chr10:64041163	T/C	cg09941381	chr10:64027924	RTKN2	-0.32	-7.46	-0.34	4.84e-13	Rheumatoid arthritis;
LUAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-8.31	-0.37	1.28e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9393777	0.778	rs35608615	chr6:27040402	G/C	cg01620082	chr3:125678407	NA	-0.87	-8.9	-0.4	1.69e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7927771	0.524	rs10838769	chr11:47825333	A/G	cg18512352	chr11:47633146	NA	-0.37	-6.66	-0.31	8.61e-11	Subjective well-being;
LUAD	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg23283495	chr1:209979779	IRF6	-0.46	-8.85	-0.4	2.42e-17	Monobrow;
LUAD	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg06873352	chr17:61820015	STRADA	0.41	6.83	0.32	2.88e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs990171	0.538	rs2075193	chr2:103118027	A/G	cg03938978	chr2:103052716	IL18RAP	-0.33	-6.38	-0.3	4.75e-10	Lymphocyte counts;
LUAD	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg01528321	chr10:82214614	TSPAN14	0.69	10.69	0.46	9.28e-24	Post bronchodilator FEV1;
LUAD	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg00814883	chr7:100076585	TSC22D4	-0.87	-13.12	-0.54	3.02e-33	Platelet count;
LUAD	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg15412446	chr2:106886593	NA	-0.67	-10.58	-0.46	2.21e-23	Facial morphology (factor 23);
LUAD	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.5	0.3	2.33e-10	Depression;
LUAD	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07636037	chr3:49044803	WDR6	0.49	8.5	0.38	3.24e-16	Menarche (age at onset);
LUAD	cis	rs9287719	0.745	rs4997810	chr2:10755540	T/A	cg01299579	chr2:10830716	NOL10	-0.41	-7.17	-0.33	3.39e-12	Prostate cancer;
LUAD	cis	rs909341	0.537	rs4809334	chr20:62384972	G/A	cg14758556	chr20:62440591	NA	0.44	6.68	0.31	7.35e-11	Atopic dermatitis;
LUAD	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg21399703	chr1:247681439	NA	0.45	7.92	0.36	2.13e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6490294	0.898	rs4767202	chr12:112354075	T/C	cg10833066	chr12:111807467	FAM109A	0.43	7.11	0.33	4.85e-12	Mean platelet volume;
LUAD	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg06740227	chr12:86229804	RASSF9	-0.41	-7.23	-0.33	2.27e-12	Major depressive disorder;
LUAD	cis	rs4849845	0.637	rs2028147	chr2:121058412	C/T	cg24070213	chr2:121070622	NA	-0.39	-7.47	-0.34	4.63e-13	Mean platelet volume;
LUAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.53	-10.59	-0.46	2.14e-23	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.86	-0.36	3.11e-14	Total body bone mineral density;
LUAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg22535103	chr8:58192502	C8orf71	-0.74	-9.2	-0.41	1.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7759001	0.857	rs1022515	chr6:27365807	C/G	cg18711553	chr6:27366782	ZNF391	0.38	6.41	0.3	3.93e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs2040771	0.804	rs1091013	chr22:19248587	C/T	cg02655711	chr22:19163373	SLC25A1	0.58	10.8	0.46	3.58e-24	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs4727443	0.966	rs66748925	chr7:99589843	A/G	cg22004693	chr7:99632812	ZKSCAN1	0.4	6.77	0.31	4.27e-11	Interstitial lung disease;
LUAD	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg23254163	chr1:152506842	NA	0.26	7.07	0.32	6.59e-12	Hair morphology;
LUAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg04352962	chr1:209979756	IRF6	0.46	6.59	0.31	1.3100000000000001e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs4786125	0.665	rs1565634	chr16:6919370	T/C	cg03623568	chr16:6915990	A2BP1	-0.48	-10.24	-0.45	3.77e-22	Heart rate variability traits (SDNN);
LUAD	cis	rs4638749	0.677	rs7599646	chr2:108852343	C/T	cg25838818	chr2:108905173	SULT1C2	0.37	6.84	0.32	2.83e-11	Blood pressure;
LUAD	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg18230493	chr5:56204884	C5orf35	-0.86	-12.42	-0.52	2.08e-30	Type 2 diabetes;
LUAD	trans	rs8073060	0.545	rs3859282	chr17:34006111	T/C	cg19694781	chr19:47549865	TMEM160	-1.22	-19.55	-0.69	4.14e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7180079	1.000	rs62021612	chr15:64558040	C/G	cg08069370	chr15:64387884	SNX1	-0.51	-6.56	-0.3	1.6e-10	Monocyte count;
LUAD	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg10556349	chr10:835070	NA	0.56	7.03	0.32	8.22e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg23840854	chr1:161414152	NA	-0.86	-11.35	-0.48	2.98e-26	Rheumatoid arthritis;
LUAD	cis	rs7267979	0.899	rs6115213	chr20:25550372	G/A	cg08601574	chr20:25228251	PYGB	0.41	7.61	0.35	1.82e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg26513180	chr16:89883248	FANCA	0.53	8.47	0.38	4.22e-16	Vitiligo;
LUAD	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg05373962	chr22:49881684	NA	-0.5	-10.1	-0.44	1.2e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg04267008	chr7:1944627	MAD1L1	-0.53	-7.96	-0.36	1.65e-14	Schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06506560	chr17:38474741	RARA	-0.7	-6.61	-0.31	1.17e-10	Type 2 diabetes;
LUAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg10862848	chr6:42927986	GNMT	-0.32	-9.26	-0.41	1.08e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg18306943	chr3:40428807	ENTPD3	0.38	6.73	0.31	5.38e-11	Renal cell carcinoma;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg13603510	chr19:3626908	C19orf29	-0.69	-6.62	-0.31	1.08e-10	Type 2 diabetes;
LUAD	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg05132306	chr1:1846340	CALML6	-0.36	-7.79	-0.35	5.37e-14	Body mass index;
LUAD	cis	rs11229555	0.609	rs7928676	chr11:58188022	C/T	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg21963583	chr11:68658836	MRPL21	0.64	11.26	0.48	6.95e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg03161606	chr19:29218774	NA	0.61	7.52	0.34	3.4e-13	Methadone dose in opioid dependence;
LUAD	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg07708487	chr16:89387014	ANKRD11	-0.35	-7.02	-0.32	8.81e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs3087591	0.960	rs4795575	chr17:29452625	A/G	cg24425628	chr17:29625626	OMG;NF1	0.4	6.39	0.3	4.37e-10	Hip circumference;
LUAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.76	0.31	4.72e-11	Obesity-related traits;
LUAD	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.26	0.48	6.91e-26	Eosinophil percentage of white cells;
LUAD	cis	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.73	0.31	5.38e-11	Neuroticism;
LUAD	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg17063962	chr7:91808500	NA	-0.66	-11.47	-0.49	1.07e-26	Breast cancer;
LUAD	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg16325326	chr1:53192061	ZYG11B	-0.74	-14.51	-0.58	5.24e-39	Monocyte count;
LUAD	trans	rs6921919	0.945	rs61289879	chr6:28419162	G/A	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.04	-0.32	7.75e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs2686555	0.502	rs693074	chr12:121077728	A/C	cg24292016	chr12:121087689	CABP1	0.41	6.5	0.3	2.2e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg04455712	chr21:45112962	RRP1B	0.46	9.13	0.41	2.74e-18	Mean corpuscular volume;
LUAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg21226059	chr5:178986404	RUFY1	0.62	9.97	0.44	3.53e-21	Lung cancer;
LUAD	cis	rs1816752	0.713	rs7336357	chr13:25017590	T/C	cg02811702	chr13:24901961	NA	0.46	7.89	0.36	2.6e-14	Obesity-related traits;
LUAD	cis	rs7216064	0.636	rs4638	chr17:66039350	A/G	cg08758996	chr17:66097529	LOC651250	-0.42	-7.09	-0.33	5.49e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs16858210	0.874	rs6792309	chr3:183607661	C/T	cg01324343	chr3:183735012	ABCC5	0.43	6.72	0.31	5.84e-11	Menopause (age at onset);
LUAD	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg10755058	chr3:40428713	ENTPD3	0.38	7.42	0.34	6.38e-13	Renal cell carcinoma;
LUAD	cis	rs6952808	0.964	rs10950407	chr7:1895666	T/G	cg08027265	chr7:2291960	NA	-0.41	-6.55	-0.3	1.71e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs12286929	0.644	rs7942036	chr11:115078356	G/C	cg04055981	chr11:115044050	NA	0.45	8.32	0.38	1.18e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg04287289	chr16:89883240	FANCA	0.75	6.35	0.3	5.56e-10	Skin colour saturation;
LUAD	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.91	0.36	2.27e-14	Bladder cancer;
LUAD	cis	rs6577655	0.517	rs6998749	chr8:135584316	A/G	cg17885191	chr8:135476712	NA	-0.64	-8.36	-0.38	9.15e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg15147215	chr3:52552868	STAB1	-0.39	-7.19	-0.33	2.99e-12	Bipolar disorder;
LUAD	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg05313129	chr8:58192883	C8orf71	-0.53	-7.82	-0.36	4.14e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg11663144	chr21:46675770	NA	-0.58	-11.33	-0.48	3.71e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-7.98	-0.36	1.42e-14	Total cholesterol levels;
LUAD	cis	rs4635969	1.000	rs4635969	chr5:1308552	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.56	-7.35	-0.34	1.02e-12	Testicular germ cell tumor;Testicular germ cell cancer;
LUAD	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg00717180	chr2:96193071	NA	-0.4	-7.39	-0.34	7.86e-13	Height;
LUAD	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg26408565	chr15:76604113	ETFA	-0.45	-7.36	-0.34	9.68e-13	Blood metabolite levels;
LUAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg16606324	chr3:10149918	C3orf24	0.59	9.58	0.42	8.28e-20	Alzheimer's disease;
LUAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.69e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.76	0.31	4.45e-11	Parkinson's disease;
LUAD	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg00784671	chr22:46762841	CELSR1	-0.54	-7.05	-0.32	7.32e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg20135002	chr11:47629003	NA	-0.42	-7.36	-0.34	9.93e-13	Subjective well-being;
LUAD	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg14458575	chr2:238380390	NA	0.67	12.55	0.52	6.43e-31	Prostate cancer;
LUAD	cis	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg05084668	chr3:125655381	ALG1L	-0.59	-9.27	-0.41	9.67e-19	Blood pressure (smoking interaction);
LUAD	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg17971929	chr21:40555470	PSMG1	0.44	7.04	0.32	8.05e-12	Cognitive function;
LUAD	cis	rs1595825	0.891	rs7585709	chr2:198883682	C/T	cg10547527	chr2:198650123	BOLL	-0.5	-6.94	-0.32	1.51e-11	Ulcerative colitis;
LUAD	cis	rs62458065	0.568	rs62463963	chr7:32486691	C/T	cg20159608	chr7:32802032	NA	-0.6	-8.13	-0.37	4.66e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.87	-0.36	3.05e-14	Neutrophil percentage of white cells;
LUAD	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg20135002	chr11:47629003	NA	-0.41	-7.16	-0.33	3.62e-12	Subjective well-being;
LUAD	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg04414720	chr1:150670196	GOLPH3L	0.73	13.64	0.55	2.2e-35	Tonsillectomy;
LUAD	trans	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.19	-0.33	2.87e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg12573674	chr2:1569213	NA	-0.6	-8.67	-0.39	9e-17	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs6489785	0.735	rs11065286	chr12:121271734	C/T	cg02419362	chr12:121203948	SPPL3	-0.34	-6.84	-0.32	2.82e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg15704280	chr7:45808275	SEPT13	-0.93	-17.86	-0.66	1.38e-53	Coronary artery disease;
LUAD	trans	rs6076960	0.682	rs6054065	chr20:6267920	G/A	cg21095983	chr6:86352623	SYNCRIP	0.41	6.5	0.3	2.32e-10	Smooth-surface caries;
LUAD	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.39	6.5	0.3	2.32e-10	Total body bone mineral density;
LUAD	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.24	-0.41	1.25e-18	Total body bone mineral density;
LUAD	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg11871910	chr12:69753446	YEATS4	0.49	7.27	0.33	1.72e-12	Response to diuretic therapy;
LUAD	trans	rs7395662	1.000	rs4882016	chr11:48570125	G/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.53	-0.3	1.89e-10	HDL cholesterol;
LUAD	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg03806693	chr22:41940476	POLR3H	0.58	8.7	0.39	7.68e-17	Vitiligo;
LUAD	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19717773	chr7:2847554	GNA12	-0.56	-9.81	-0.43	1.35e-20	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03591798	chr2:73404524	NA	-0.44	-6.71	-0.31	6.32e-11	Height;
LUAD	cis	rs3862030	0.594	rs7923675	chr10:104235809	G/T	cg22532475	chr10:104410764	TRIM8	-0.34	-6.77	-0.31	4.19e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg07936489	chr17:37558343	FBXL20	0.46	7.0	0.32	1e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg20991723	chr1:152506922	NA	0.35	6.85	0.32	2.62e-11	Hair morphology;
LUAD	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg16797656	chr11:68205561	LRP5	0.45	8.62	0.39	1.34e-16	Total body bone mineral density;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06406294	chr21:34915161	GART;SON	-0.59	-7.19	-0.33	3e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg06608945	chr2:219082296	ARPC2	0.43	7.36	0.34	9.75e-13	Colorectal cancer;
LUAD	cis	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-6.98	-0.32	1.11e-11	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs12431939	1.000	rs12432466	chr14:51638873	T/C	cg23942311	chr14:51606299	NA	-0.63	-8.53	-0.38	2.59e-16	Cancer;
LUAD	cis	rs6446731	0.636	rs2157092	chr4:3273092	G/C	cg08886695	chr4:3369023	RGS12	-0.5	-8.42	-0.38	5.94e-16	Mean platelet volume;
LUAD	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg11859384	chr17:80120422	CCDC57	-0.5	-8.77	-0.39	4.26e-17	Life satisfaction;
LUAD	cis	rs17641971	0.684	rs4873094	chr8:49989578	G/T	cg00325661	chr8:49890786	NA	0.3	6.8	0.31	3.68e-11	Blood metabolite levels;
LUAD	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg00852783	chr1:26633632	UBXN11	0.4	7.14	0.33	4.05e-12	Obesity-related traits;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20032723	chr11:126174041	DCPS	-0.45	-7.15	-0.33	3.82e-12	Height;
LUAD	cis	rs240764	0.680	rs12209777	chr6:101156639	G/A	cg09795085	chr6:101329169	ASCC3	-0.39	-6.76	-0.31	4.71e-11	Neuroticism;
LUAD	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	7.0	0.32	1.01e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs220324	0.688	rs2076788	chr21:43565241	A/G	cg08841829	chr21:43638893	ABCG1	-0.5	-6.7	-0.31	6.85e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs1595825	0.891	rs59617443	chr2:198653204	C/A	cg00982548	chr2:198649783	BOLL	-0.66	-9.3	-0.41	7.6e-19	Ulcerative colitis;
LUAD	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg02733842	chr7:1102375	C7orf50	-0.58	-9.05	-0.4	5.44e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg11707310	chr1:2537719	MMEL1	-0.37	-7.89	-0.36	2.64e-14	Ulcerative colitis;
LUAD	cis	rs4638749	1.000	rs1466213	chr2:108856607	G/A	cg25838818	chr2:108905173	SULT1C2	-0.55	-8.7	-0.39	7.19e-17	Blood pressure;
LUAD	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg15181151	chr6:150070149	PCMT1	0.38	7.27	0.33	1.77e-12	Lung cancer;
LUAD	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg17863274	chr19:49399704	TULP2	-0.53	-7.56	-0.35	2.51e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg26513180	chr16:89883248	FANCA	0.43	6.86	0.32	2.52e-11	Vitiligo;
LUAD	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg15017067	chr4:17643749	FAM184B	0.36	6.98	0.32	1.17e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg09658497	chr7:2847517	GNA12	-0.45	-8.29	-0.37	1.48e-15	Height;
LUAD	cis	rs12545109	0.800	rs1913278	chr8:57403725	T/C	cg21220214	chr8:57350948	NA	-0.61	-8.77	-0.39	4.56e-17	Obesity-related traits;
LUAD	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg00784671	chr22:46762841	CELSR1	-0.68	-8.18	-0.37	3.33e-15	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs669446	0.562	rs4660260	chr1:44195353	A/G	cg12908607	chr1:44402522	ARTN	-0.35	-6.92	-0.32	1.72e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs7851660	0.809	rs10818241	chr9:100661972	A/G	cg13688889	chr9:100608707	NA	-0.54	-9.17	-0.41	2.08e-18	Strep throat;
LUAD	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg12573674	chr2:1569213	NA	-0.58	-6.73	-0.31	5.62e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg15556689	chr8:8085844	FLJ10661	0.41	6.74	0.31	5.34e-11	Mood instability;
LUAD	trans	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs9283706	0.608	rs71626484	chr5:66334502	A/T	cg11590213	chr5:66331682	MAST4	0.41	6.64	0.31	9.84e-11	Coronary artery disease;
LUAD	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.89e-14	Depression;
LUAD	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg09033563	chr22:24373618	LOC391322	-0.49	-7.52	-0.34	3.42e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg15448220	chr1:150897856	SETDB1	0.49	8.54	0.38	2.5e-16	Melanoma;
LUAD	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg07636037	chr3:49044803	WDR6	0.56	8.63	0.39	1.25e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg07636037	chr3:49044803	WDR6	0.54	8.46	0.38	4.46e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg05044414	chr3:183734942	ABCC5	0.47	9.94	0.44	4.59e-21	Anterior chamber depth;
LUAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg10150615	chr22:24372951	LOC391322	-0.47	-7.51	-0.34	3.63e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2795502	0.630	rs1271547	chr10:43507665	C/T	cg20628663	chr10:43360327	NA	0.55	6.69	0.31	6.99e-11	Blood protein levels;
LUAD	cis	rs7731657	0.537	rs72801772	chr5:130341294	G/T	cg08523029	chr5:130500466	HINT1	-0.6	-7.7	-0.35	9.54e-14	Fasting plasma glucose;
LUAD	trans	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg23505145	chr19:12996616	KLF1	0.53	8.65	0.39	1.07e-16	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.04	-0.32	8.02e-12	Electroencephalogram traits;
LUAD	cis	rs9948	0.655	rs62152785	chr2:97459403	A/T	cg20312557	chr2:97357134	FER1L5	-0.63	-7.41	-0.34	7.02e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22765964	chr11:75110494	SNORD15A;RPS3	-0.39	-6.4	-0.3	4.08e-10	Cancer;
LUAD	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg09650180	chr20:62225654	GMEB2	-0.48	-6.84	-0.32	2.87e-11	Glioblastoma;
LUAD	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg27494647	chr7:150038898	RARRES2	0.47	8.32	0.38	1.2e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7927771	0.524	rs7129797	chr11:47667167	G/C	cg18512352	chr11:47633146	NA	0.37	6.44	0.3	3.3e-10	Subjective well-being;
LUAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18402987	chr7:1209562	NA	0.44	7.1	0.33	5.44e-12	Longevity;Endometriosis;
LUAD	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.44	-0.49	1.35e-26	Type 2 diabetes;
LUAD	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.03	-0.4	6.02e-18	Total body bone mineral density;
LUAD	cis	rs56283067	0.847	rs11962872	chr6:44690740	T/G	cg18551225	chr6:44695536	NA	-0.61	-10.14	-0.44	9.33e-22	Total body bone mineral density;
LUAD	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg25753631	chr6:25732923	NA	-0.42	-7.44	-0.34	5.79e-13	Iron status biomarkers;
LUAD	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.3	-0.33	1.42e-12	Height;
LUAD	cis	rs1953600	0.870	rs2788296	chr10:81937889	G/A	cg04850286	chr10:81895943	PLAC9	0.36	6.44	0.3	3.25e-10	Sarcoidosis;
LUAD	cis	rs977987	0.835	rs4888380	chr16:75347690	T/C	cg03315344	chr16:75512273	CHST6	0.62	13.81	0.56	4.46e-36	Dupuytren's disease;
LUAD	cis	rs427941	0.595	rs201477	chr7:101746915	G/A	cg06246474	chr7:101738831	CUX1	0.4	6.85	0.32	2.66e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg18402987	chr7:1209562	NA	0.65	6.52	0.3	2.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6901250	0.851	rs339313	chr6:117179501	C/T	cg12892004	chr6:117198278	RFX6	-0.34	-7.09	-0.33	5.52e-12	C-reactive protein levels;
LUAD	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg25894440	chr7:65020034	NA	-0.59	-6.43	-0.3	3.45e-10	Diabetic kidney disease;
LUAD	cis	rs12681288	0.550	rs60530879	chr8:958381	G/C	cg15309053	chr8:964076	NA	0.44	9.84	0.43	9.98e-21	Schizophrenia;
LUAD	cis	rs4853036	0.502	rs6717068	chr2:70009641	A/T	cg02498382	chr2:70120550	SNRNP27	-0.46	-6.48	-0.3	2.58e-10	Colorectal or endometrial cancer;
LUAD	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg00086871	chr4:6988644	TBC1D14	0.74	6.38	0.3	4.58e-10	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg11693508	chr17:37793320	STARD3	0.76	9.68	0.43	3.65e-20	Bipolar disorder;
LUAD	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.37	9.39	0.42	3.84e-19	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg17712092	chr4:129076599	LARP1B	-0.77	-11.9	-0.5	2.34e-28	Breast cancer;
LUAD	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg06627628	chr2:24431161	ITSN2	-0.7	-11.28	-0.48	5.81e-26	Asthma;
LUAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg05434287	chr7:2030229	MAD1L1	0.39	6.57	0.3	1.52e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs617219	1.000	rs617219	chr5:78429594	G/T	cg25119155	chr5:78426943	BHMT	-0.35	-6.42	-0.3	3.7e-10	Betaine levels in individuals undergoing cardiac evaluation;
LUAD	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg17105886	chr17:28927953	LRRC37B2	0.81	8.0	0.36	1.18e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.86	-0.4	2.23e-17	Total body bone mineral density;
LUAD	cis	rs1045714	0.887	rs73033694	chr7:2637139	G/A	cg20813462	chr7:2646259	IQCE	0.69	7.67	0.35	1.18e-13	Urate levels in lean individuals;
LUAD	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-7.24	-0.33	2.17e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6960043	0.714	rs6976086	chr7:15048611	T/G	cg19272540	chr7:15055459	NA	0.36	7.94	0.36	1.84e-14	Type 2 diabetes;
LUAD	cis	rs72772090	0.539	rs116360011	chr5:96117797	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-7.06	-0.32	6.97e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg00071950	chr4:10020882	SLC2A9	-0.58	-10.52	-0.46	3.71e-23	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	8.0	0.36	1.2e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg07677032	chr17:61819896	STRADA	0.57	10.48	0.45	5.49e-23	Prudent dietary pattern;
LUAD	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg11645453	chr3:52864694	ITIH4	0.36	6.78	0.31	4.03e-11	Body mass index;
LUAD	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg02931644	chr1:25747376	RHCE	0.44	8.98	0.4	9.05e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs6499255	0.904	rs2161631	chr16:69556948	C/A	cg00738113	chr16:70207722	CLEC18C	-0.4	-6.77	-0.31	4.35e-11	IgE levels;
LUAD	cis	rs1595825	0.945	rs7581202	chr2:198836777	A/G	cg11031976	chr2:198649780	BOLL	-0.47	-6.95	-0.32	1.41e-11	Ulcerative colitis;
LUAD	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg17264618	chr3:40429014	ENTPD3	0.39	8.63	0.39	1.28e-16	Renal cell carcinoma;
LUAD	cis	rs7503807	0.905	rs62068345	chr17:78608040	C/T	cg09596252	chr17:78655493	RPTOR	0.41	7.92	0.36	2.15e-14	Obesity;
LUAD	cis	rs60871478	0.636	rs61441144	chr7:897784	C/T	cg13798912	chr7:905769	UNC84A	-0.62	-6.96	-0.32	1.32e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg04944784	chr2:26401820	FAM59B	-0.78	-10.55	-0.46	2.83e-23	Gut microbiome composition (summer);
LUAD	cis	rs8077889	0.917	rs72836559	chr17:41913529	C/T	cg26893861	chr17:41843967	DUSP3	0.94	14.64	0.58	1.42e-39	Triglycerides;
LUAD	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg13722127	chr7:150037890	RARRES2	0.44	7.24	0.33	2.17e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg13606994	chr1:44402422	ARTN	-0.36	-7.41	-0.34	6.96e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg13319975	chr6:146136371	FBXO30	0.64	11.05	0.47	4.31e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg27286337	chr10:134555280	INPP5A	0.7	9.79	0.43	1.6e-20	Migraine;
LUAD	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg07776626	chr8:57350775	NA	-0.59	-9.09	-0.4	3.81e-18	Obesity-related traits;
LUAD	cis	rs1868673	1.000	rs9813752	chr3:150151120	G/A	cg04908077	chr3:150187338	NA	-0.31	-6.35	-0.3	5.53e-10	Waist circumference;
LUAD	trans	rs4650994	0.593	rs12033086	chr1:178540925	C/T	cg05059571	chr16:84539110	KIAA1609	0.43	6.81	0.31	3.45e-11	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs9323205	0.677	rs12589680	chr14:51723138	T/C	cg23942311	chr14:51606299	NA	-0.57	-8.63	-0.39	1.23e-16	Cancer;
LUAD	cis	rs7737355	0.773	rs11242069	chr5:130598318	A/C	cg06307176	chr5:131281290	NA	-0.38	-6.46	-0.3	2.96e-10	Life satisfaction;
LUAD	cis	rs4948275	0.550	rs10994742	chr10:63132240	A/T	cg02461363	chr10:63212496	TMEM26	-0.35	-7.28	-0.33	1.68e-12	Night sleep phenotypes;
LUAD	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg06623918	chr6:96969491	KIAA0776	0.89	17.61	0.65	1.84e-52	Headache;
LUAD	cis	rs2073300	1.000	rs6137966	chr20:23444359	A/T	cg12062639	chr20:23401060	NAPB	0.98	8.35	0.38	9.91e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg03714773	chr7:91764589	CYP51A1	0.29	6.58	0.3	1.4e-10	Breast cancer;
LUAD	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg11887960	chr12:57824829	NA	0.53	6.59	0.31	1.32e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.87	-0.32	2.27e-11	Mood instability;
LUAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.84	0.43	1.07e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs747782	0.528	rs11039669	chr11:48328818	C/T	cg15704280	chr7:45808275	SEPT13	0.65	7.61	0.35	1.79e-13	Intraocular pressure;
LUAD	cis	rs4692589	1.000	rs4692783	chr4:170935407	G/A	cg19918862	chr4:170955249	NA	0.29	6.94	0.32	1.52e-11	Anxiety disorder;
LUAD	trans	rs28735056	0.933	rs499472	chr18:77589759	C/T	cg05926928	chr17:57297772	GDPD1	-0.48	-6.89	-0.32	2.04e-11	Schizophrenia;
LUAD	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg21984481	chr17:79567631	NPLOC4	-0.71	-17.03	-0.64	6.54e-50	Eye color traits;
LUAD	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.51	-0.34	3.54e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg11941060	chr3:133502564	NA	-0.46	-7.71	-0.35	9.23e-14	Iron status biomarkers;
LUAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg23958373	chr8:599963	NA	1.09	10.44	0.45	7.69e-23	IgG glycosylation;
LUAD	cis	rs79839061	0.636	rs76839318	chr4:837810	T/A	cg23992470	chr4:843637	GAK	0.71	6.54	0.3	1.73e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	6.52	0.3	1.96e-10	Schizophrenia;
LUAD	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg18944383	chr4:111397179	ENPEP	0.42	8.22	0.37	2.45e-15	Height;
LUAD	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg12935359	chr14:103987150	CKB	-0.46	-7.75	-0.35	6.75e-14	Body mass index;
LUAD	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg12034118	chr1:209979487	IRF6	0.54	6.53	0.3	1.84e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg22431228	chr1:16359049	CLCNKA	0.42	7.77	0.35	5.82e-14	Systolic blood pressure;
LUAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg12538597	chr11:85906334	NA	-0.41	-6.56	-0.3	1.59e-10	Response to antipsychotic treatment;
LUAD	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg07570687	chr10:102243282	WNT8B	-0.44	-7.16	-0.33	3.62e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg21153622	chr11:89784906	NA	-0.34	-6.78	-0.31	3.97e-11	HDL cholesterol;
LUAD	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg00784671	chr22:46762841	CELSR1	-0.49	-6.46	-0.3	2.95e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg00530320	chr1:46809349	NSUN4	0.51	7.93	0.36	1.92e-14	Menopause (age at onset);
LUAD	cis	rs7828089	0.819	rs7846557	chr8:22243654	T/C	cg12081754	chr8:22256438	SLC39A14	0.52	9.18	0.41	1.9e-18	Verbal declarative memory;
LUAD	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg12179176	chr11:130786555	SNX19	0.53	9.05	0.4	5.35e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg08470875	chr2:26401718	FAM59B	0.64	7.97	0.36	1.49e-14	Gut microbiome composition (summer);
LUAD	cis	rs3818285	0.515	rs12258440	chr10:111676799	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.72	-11.48	-0.49	9.54e-27	Superior crus of antihelix expression;
LUAD	cis	rs6545883	0.783	rs7579651	chr2:61800279	C/G	cg15711740	chr2:61764176	XPO1	-0.42	-6.61	-0.31	1.17e-10	Tuberculosis;
LUAD	cis	rs35264875	0.851	rs7933746	chr11:68867722	A/G	cg02660097	chr11:68866761	NA	0.48	7.48	0.34	4.37e-13	Blond vs. brown hair color;
LUAD	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg01579765	chr21:45077557	HSF2BP	-0.54	-12.12	-0.51	3.07e-29	Mean corpuscular volume;
LUAD	cis	rs7707921	0.881	rs17243791	chr5:81322547	A/G	cg15871215	chr5:81402204	ATG10	-0.7	-9.91	-0.43	6.03e-21	Breast cancer;
LUAD	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg25237894	chr2:233734115	C2orf82	-0.61	-11.78	-0.5	6.52e-28	Coronary artery disease;
LUAD	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg17848003	chr1:3704513	LRRC47	0.53	10.65	0.46	1.3e-23	Red cell distribution width;
LUAD	cis	rs926938	0.783	rs2144428	chr1:115269211	G/A	cg12756093	chr1:115239321	AMPD1	-0.41	-7.27	-0.33	1.74e-12	Autism;
LUAD	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.26	-0.54	8.48e-34	Chronic sinus infection;
LUAD	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg23281280	chr6:28129359	ZNF389	0.45	6.45	0.3	3.1e-10	Depression;
LUAD	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06544989	chr22:39130855	UNC84B	0.48	9.56	0.42	9.49e-20	Menopause (age at onset);
LUAD	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg26818010	chr10:134567672	INPP5A	-0.97	-15.55	-0.6	1.81e-43	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4072980	0.545	rs7519947	chr1:38447725	T/C	cg17077180	chr1:38461687	NA	-0.45	-8.1	-0.37	5.98e-15	Coronary artery disease;
LUAD	cis	rs11771526	0.901	rs17161123	chr7:32305426	G/A	cg27532318	chr7:32358331	NA	0.59	7.51	0.34	3.57e-13	Body mass index;
LUAD	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg12927641	chr6:109611667	NA	-0.53	-9.18	-0.41	2e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs9287719	0.774	rs4997811	chr2:10755538	T/C	cg00105475	chr2:10696890	NA	0.37	6.66	0.31	8.64e-11	Prostate cancer;
LUAD	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg12927641	chr6:109611667	NA	-0.52	-9.29	-0.41	8.1e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs1448094	0.967	rs10863118	chr12:86339232	C/G	cg18827107	chr12:86230957	RASSF9	-0.45	-8.04	-0.36	8.89e-15	Major depressive disorder;
LUAD	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg20701182	chr2:24300061	SF3B14	0.91	13.82	0.56	4e-36	Lymphocyte counts;
LUAD	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg08859206	chr1:53392774	SCP2	0.6	11.03	0.47	4.81e-25	Monocyte count;
LUAD	cis	rs6596100	0.500	rs67904956	chr5:132274044	A/G	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Breast cancer;
LUAD	cis	rs4930561	0.765	rs10896304	chr11:67981714	T/G	cg04465784	chr11:67976953	SUV420H1	-0.27	-7.97	-0.36	1.48e-14	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg22676075	chr6:135203613	NA	0.43	7.86	0.36	3.16e-14	Red blood cell count;
LUAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg04025307	chr7:1156635	C7orf50	0.88	17.17	0.64	1.67e-50	Longevity;Endometriosis;
LUAD	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg05926928	chr17:57297772	GDPD1	1.38	17.68	0.65	9.22e-53	Opioid sensitivity;
LUAD	cis	rs7809950	0.593	rs62482503	chr7:106987988	A/G	cg23024343	chr7:107201750	COG5	-0.81	-13.82	-0.56	4.22e-36	Coronary artery disease;
LUAD	cis	rs7705042	0.865	rs7723666	chr5:141513966	C/T	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.89	-0.32	2.08e-11	Asthma;
LUAD	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg10556349	chr10:835070	NA	0.46	6.42	0.3	3.57e-10	Eosinophil percentage of granulocytes;
LUAD	trans	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg24644049	chr4:85504048	CDS1	0.9	7.64	0.35	1.47e-13	Skin colour saturation;
LUAD	cis	rs17095355	1.000	rs2419313	chr10:111750851	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.67	-8.8	-0.39	3.6e-17	Biliary atresia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19864416	chr19:42498173	ATP1A3	-0.52	-6.45	-0.3	3.03e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs116248771	0.690	rs4459938	chr3:158406075	G/A	cg16708174	chr3:158430962	RARRES1	0.47	6.78	0.31	4.16e-11	diarrhoeal disease at age 2;
LUAD	cis	rs727505	0.517	rs10268372	chr7:124487310	G/A	cg23710748	chr7:124431027	NA	0.42	8.67	0.39	9.61e-17	Lewy body disease;
LUAD	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg15664640	chr17:80829946	TBCD	0.76	14.78	0.58	3.94e-40	Breast cancer;
LUAD	cis	rs6684514	1.000	rs12139321	chr1:156230429	A/G	cg16558208	chr1:156270281	VHLL	0.51	9.3	0.41	7.42e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs10129255	0.500	rs7157975	chr14:107212287	G/A	cg23076370	chr14:107095027	NA	-0.43	-8.64	-0.39	1.18e-16	Kawasaki disease;
LUAD	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg11344533	chr11:111475393	SIK2	-0.37	-6.91	-0.32	1.77e-11	Primary sclerosing cholangitis;
LUAD	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg13057898	chr1:3703894	LRRC47	0.63	10.94	0.47	1.02e-24	Red cell distribution width;
LUAD	cis	rs6761276	1.000	rs6761276	chr2:113832312	C/T	cg10479672	chr2:113810641	IL1F8	0.37	7.66	0.35	1.31e-13	Protein quantitative trait loci;
LUAD	cis	rs6445967	0.966	rs35955376	chr3:58297779	G/A	cg23715586	chr3:58305044	RPP14	0.42	7.59	0.35	2.03e-13	Platelet count;
LUAD	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	8.74	0.39	5.59e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.71	-14.16	-0.57	1.52e-37	Prudent dietary pattern;
LUAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg00106254	chr7:1943704	MAD1L1	-0.5	-7.13	-0.33	4.36e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs551517	0.541	rs496475	chr9:113638236	G/T	cg00374333	chr2:224702156	AP1S3	0.36	6.49	0.3	2.42e-10	Post bronchodilator FEV1 in COPD;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LUAD	trans	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg04775059	chr7:64541387	NA	0.52	7.24	0.33	2.19e-12	Aortic root size;
LUAD	cis	rs8192282	0.646	rs4288587	chr1:154492357	A/T	cg07911225	chr1:154474108	TDRD10;SHE	-0.44	-7.57	-0.35	2.32e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg15691649	chr6:25882328	NA	-0.6	-9.34	-0.41	5.38e-19	Blood metabolite levels;
LUAD	cis	rs10489202	0.583	rs201539	chr1:167995407	A/G	cg25738037	chr1:168025549	DCAF6	-0.51	-7.63	-0.35	1.6e-13	Schizophrenia;
LUAD	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26314531	chr2:26401878	FAM59B	0.61	7.75	0.35	6.74e-14	Gut microbiome composition (summer);
LUAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg04025307	chr7:1156635	C7orf50	0.61	7.37	0.34	8.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4727443	1.000	rs4727443	chr7:99593346	C/A	cg22004693	chr7:99632812	ZKSCAN1	0.4	6.84	0.32	2.8e-11	Interstitial lung disease;
LUAD	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.53	0.3	1.89e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg03676636	chr4:99064102	C4orf37	0.3	7.83	0.36	3.93e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11051970	0.636	rs10844198	chr12:32563479	G/T	cg24626660	chr12:32551988	NA	0.34	7.3	0.33	1.48e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg02463440	chr8:22132932	PIWIL2	0.56	10.1	0.44	1.21e-21	Hypertriglyceridemia;
LUAD	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.35	0.41	5.2e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg19622623	chr12:86230825	RASSF9	-0.52	-9.65	-0.42	4.67e-20	Major depressive disorder;
LUAD	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg10523679	chr1:76189770	ACADM	0.8	12.48	0.52	1.2e-30	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs3752645	1.000	rs11762123	chr7:106748079	T/C	cg02696742	chr7:106810147	HBP1	-0.66	-6.55	-0.3	1.7e-10	Bladder cancer (smoking interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19884546	chr22:38082237	NOL12	-0.44	-6.8	-0.31	3.67e-11	Height;
LUAD	cis	rs7100689	0.599	rs7077847	chr10:82134952	A/G	cg00277334	chr10:82204260	NA	-0.62	-10.06	-0.44	1.66e-21	Post bronchodilator FEV1;
LUAD	cis	rs7786808	0.552	rs12539355	chr7:158187565	C/T	cg01191920	chr7:158217561	PTPRN2	-0.63	-12.98	-0.53	1.11e-32	Obesity-related traits;
LUAD	trans	rs875971	0.545	rs221986	chr7:65570310	T/C	cg04775059	chr7:64541387	NA	-0.5	-6.54	-0.3	1.76e-10	Aortic root size;
LUAD	cis	rs68170813	0.559	rs80017637	chr7:107050660	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-10.37	-0.45	1.35e-22	Coronary artery disease;
LUAD	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg06484146	chr7:12443880	VWDE	-0.52	-6.69	-0.31	7.25e-11	Coronary artery disease;
LUAD	cis	rs9807989	0.801	rs10173193	chr2:102975050	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	6.41	0.3	3.79e-10	Asthma;
LUAD	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg23533926	chr12:111358616	MYL2	-0.43	-7.35	-0.34	1.03e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7107174	0.581	rs11237485	chr11:78126011	G/A	cg02023728	chr11:77925099	USP35	0.42	6.39	0.3	4.44e-10	Testicular germ cell tumor;
LUAD	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.76	-0.35	6.64e-14	Schizophrenia;
LUAD	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg16988262	chr1:15930761	NA	0.41	6.92	0.32	1.65e-11	Systolic blood pressure;
LUAD	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.12	0.33	4.81e-12	Menopause (age at onset);
LUAD	cis	rs7833986	1.000	rs36103212	chr8:57101475	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.76	10.13	0.44	9.58e-22	Height;
LUAD	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg18404041	chr3:52824283	ITIH1	-0.6	-10.44	-0.45	7.18e-23	Schizophrenia;
LUAD	cis	rs1030877	0.924	rs2250658	chr2:105889683	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.6	11.65	0.49	2.12e-27	Obesity-related traits;
LUAD	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg00631329	chr6:26305371	NA	-0.68	-13.36	-0.54	3.29e-34	Educational attainment;
LUAD	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg18477163	chr1:228402036	OBSCN	-0.34	-6.84	-0.32	2.87e-11	Diastolic blood pressure;
LUAD	cis	rs2224391	0.534	rs2773308	chr6:5246833	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.61	-9.47	-0.42	1.99e-19	Height;
LUAD	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg22823121	chr1:150693482	HORMAD1	-0.39	-7.73	-0.35	7.99e-14	Tonsillectomy;
LUAD	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg22875332	chr1:76189707	ACADM	0.87	16.41	0.62	3.45e-47	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.54	-8.09	-0.37	6.51e-15	Gut microbiome composition (summer);
LUAD	cis	rs908922	0.676	rs2105117	chr1:152484129	G/A	cg20991723	chr1:152506922	NA	0.33	6.41	0.3	3.84e-10	Hair morphology;
LUAD	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg18129748	chr3:49941408	MST1R	0.44	7.36	0.34	9.86e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg17178900	chr1:205818956	PM20D1	0.67	13.47	0.55	1.14e-34	Menarche (age at onset);
LUAD	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.71	-0.35	8.94e-14	Total body bone mineral density;
LUAD	cis	rs713587	0.713	rs12466350	chr2:25239969	A/G	cg01884057	chr2:25150051	NA	0.31	6.37	0.3	5.04e-10	Body mass index in non-asthmatics;
LUAD	cis	rs4072705	0.646	rs10120967	chr9:127244134	C/T	cg14219918	chr9:127249562	NR5A1	0.28	6.46	0.3	2.96e-10	Menarche (age at onset);
LUAD	trans	rs7944735	0.517	rs1827503	chr11:48225115	G/T	cg03929089	chr4:120376271	NA	0.61	6.62	0.31	1.07e-10	Intraocular pressure;
LUAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.46	-8.06	-0.36	8.08e-15	Longevity;Endometriosis;
LUAD	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.96	-0.47	8.88e-25	Total body bone mineral density;
LUAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg07677032	chr17:61819896	STRADA	0.55	10.09	0.44	1.41e-21	Prudent dietary pattern;
LUAD	cis	rs2625529	0.824	rs4131630	chr15:72355398	C/T	cg16672083	chr15:72433130	SENP8	-0.74	-12.57	-0.52	5.03e-31	Red blood cell count;
LUAD	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.05	-0.32	7.14e-12	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs743757	0.878	rs12494849	chr3:50524558	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.44	6.39	0.3	4.32e-10	Diastolic blood pressure;
LUAD	cis	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg05643964	chr20:62369504	LIME1	0.4	6.48	0.3	2.6200000000000003e-10	Prostate cancer;
LUAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.49	6.84	0.32	2.73e-11	Renal function-related traits (BUN);
LUAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	10.54	0.46	3.09e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg11494091	chr17:61959527	GH2	0.74	18.44	0.67	3.83e-56	Prudent dietary pattern;
LUAD	trans	rs2735413	0.881	rs12921945	chr16:78080133	G/T	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.82e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg26354017	chr1:205819088	PM20D1	-0.55	-8.62	-0.39	1.33e-16	Parkinson's disease;
LUAD	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg12193833	chr17:30244370	NA	-0.58	-7.16	-0.33	3.71e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs12431939	1.000	rs7148508	chr14:51635137	G/A	cg23942311	chr14:51606299	NA	-0.59	-8.2	-0.37	2.86e-15	Cancer;
LUAD	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg04703951	chr17:43578652	NA	0.42	6.69	0.31	7.26e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg00603274	chr11:61596626	FADS2	-0.39	-6.83	-0.32	2.94e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg14416269	chr4:6271139	WFS1	0.62	12.71	0.53	1.37e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg20487152	chr13:99095054	FARP1	-0.48	-8.14	-0.37	4.34e-15	Longevity;
LUAD	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg23815491	chr16:72088622	HP	0.53	9.69	0.43	3.4e-20	Fibrinogen levels;
LUAD	cis	rs731174	0.959	rs12747993	chr1:38190852	T/C	cg12339802	chr1:38156545	C1orf109	-0.45	-6.93	-0.32	1.55e-11	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs4253772	0.515	rs9615969	chr22:46773592	C/G	cg09491104	chr22:46646882	C22orf40	-0.57	-6.55	-0.3	1.67e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg08859206	chr1:53392774	SCP2	0.59	10.6	0.46	1.98e-23	Monocyte count;
LUAD	cis	rs7301826	0.651	rs10773825	chr12:131298913	G/A	cg11011512	chr12:131303247	STX2	0.44	7.47	0.34	4.63e-13	Plasma plasminogen activator levels;
LUAD	cis	rs68170813	0.559	rs10953532	chr7:106881808	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.4	-0.45	1.07e-22	Coronary artery disease;
LUAD	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg08798685	chr6:27730294	NA	-0.44	-7.08	-0.33	6.2e-12	Parkinson's disease;
LUAD	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg03684893	chr10:554711	DIP2C	-0.53	-9.89	-0.43	6.98e-21	Psychosis in Alzheimer's disease;
LUAD	cis	rs7666738	0.688	rs35739409	chr4:98576934	C/T	cg05340658	chr4:99064831	C4orf37	0.5	7.03	0.32	8.47e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg13319975	chr6:146136371	FBXO30	-0.58	-9.54	-0.42	1.13e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.78	10.59	0.46	2.14e-23	Smoking behavior;
LUAD	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg01028140	chr2:1542097	TPO	-0.41	-6.91	-0.32	1.84e-11	IgG glycosylation;
LUAD	cis	rs9660992	0.662	rs12092492	chr1:205251880	T/C	cg21545522	chr1:205238299	TMCC2	0.38	7.17	0.33	3.32e-12	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs12618769	0.597	rs961242	chr2:99138979	G/A	cg10123293	chr2:99228465	UNC50	0.47	8.47	0.38	4.2e-16	Bipolar disorder;
LUAD	cis	rs8192282	0.739	rs6656395	chr1:154500016	T/C	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.37	-0.34	8.86e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg00684032	chr4:1343700	KIAA1530	0.42	7.04	0.32	7.59e-12	Obesity-related traits;
LUAD	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg08847533	chr14:75593920	NEK9	0.39	6.72	0.31	5.78e-11	Height;
LUAD	cis	rs7586879	0.789	rs17046737	chr2:25127835	C/T	cg04586622	chr2:25135609	ADCY3	0.36	7.26	0.33	1.92e-12	Body mass index;
LUAD	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg08645402	chr16:4508243	NA	-0.51	-9.43	-0.42	2.73e-19	Schizophrenia;
LUAD	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg07741184	chr6:167504864	NA	-0.3	-7.17	-0.33	3.48e-12	Crohn's disease;
LUAD	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg12193833	chr17:30244370	NA	-0.57	-6.85	-0.32	2.63e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs2281558	0.876	rs2274890	chr20:25301022	C/T	cg08601574	chr20:25228251	PYGB	0.44	6.38	0.3	4.6e-10	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUAD	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg00106254	chr7:1943704	MAD1L1	-0.51	-8.02	-0.36	1.08e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg15448220	chr1:150897856	SETDB1	0.58	9.79	0.43	1.54e-20	Melanoma;
LUAD	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.56	-0.3	1.6e-10	Breast cancer;
LUAD	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.47	-7.3	-0.33	1.47e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.9	0.32	1.89e-11	Rheumatoid arthritis;
LUAD	cis	rs4888262	0.545	rs7195499	chr16:74693973	C/G	cg01733217	chr16:74700730	RFWD3	0.52	8.59	0.39	1.73e-16	Testicular germ cell tumor;
LUAD	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg22681709	chr2:178499509	PDE11A	-0.55	-9.71	-0.43	2.87e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg07708487	chr16:89387014	ANKRD11	0.31	6.36	0.3	5.13e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs7264396	0.563	rs6058312	chr20:34324484	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2e-15	Total cholesterol levels;
LUAD	cis	rs807669	0.548	rs5748028	chr22:19172281	G/A	cg02655711	chr22:19163373	SLC25A1	0.7	14.32	0.57	3.33e-38	Metabolite levels;
LUAD	trans	rs11638815	0.603	rs10162807	chr15:83289181	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.51	-7.59	-0.35	2.11e-13	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg05425664	chr17:57184151	TRIM37	0.41	6.86	0.32	2.53e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.77	-0.39	4.43e-17	Total body bone mineral density;
LUAD	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15369054	chr17:80825471	TBCD	0.66	10.92	0.47	1.23e-24	Breast cancer;
LUAD	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg02423579	chr7:2872169	GNA12	-0.89	-16.07	-0.62	1.05e-45	Height;
LUAD	cis	rs7727544	0.582	rs6896703	chr5:131521295	C/G	cg14196790	chr5:131705035	SLC22A5	-0.37	-6.68	-0.31	7.69e-11	Blood metabolite levels;
LUAD	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg07917127	chr4:99064746	C4orf37	0.45	6.49	0.3	2.34e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg00933542	chr6:150070202	PCMT1	0.47	9.84	0.43	1.08e-20	Lung cancer;
LUAD	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg21775007	chr8:11205619	TDH	0.41	7.32	0.34	1.22e-12	Retinal vascular caliber;
LUAD	trans	rs783540	0.967	rs55972423	chr15:83258954	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.45	-7.19	-0.33	3.01e-12	Schizophrenia;
LUAD	cis	rs748404	0.697	rs564946	chr15:43556272	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.06	0.36	7.77e-15	Lung cancer;
LUAD	cis	rs1232027	0.656	rs1650666	chr5:79962439	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg22681709	chr2:178499509	PDE11A	-0.39	-6.99	-0.32	1.07e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs10802346	0.545	rs6662672	chr1:246387611	A/C	cg22732515	chr19:44031385	ETHE1	0.57	9.27	0.41	9.45e-19	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg13047869	chr3:10149882	C3orf24	0.64	9.95	0.44	4.3e-21	Alzheimer's disease;
LUAD	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg06718696	chr17:78121285	EIF4A3	0.61	9.01	0.4	7.35e-18	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg09796270	chr17:17721594	SREBF1	0.37	6.96	0.32	1.33e-11	Total body bone mineral density;
LUAD	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg17200465	chr3:40428508	ENTPD3	0.28	6.63	0.31	1.04e-10	Renal cell carcinoma;
LUAD	cis	rs9826463	0.757	rs79576118	chr3:142244645	A/C	cg20824294	chr3:142316082	PLS1	0.43	7.58	0.35	2.28e-13	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1387259	0.698	rs4579969	chr12:48779562	C/T	cg04545296	chr12:48745243	ZNF641	-0.29	-7.66	-0.35	1.28e-13	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs62458065	0.640	rs10271491	chr7:32530665	C/A	cg20159608	chr7:32802032	NA	-0.61	-8.04	-0.36	9.11e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs11811982	0.546	rs74491441	chr1:227226201	G/C	cg24860534	chr1:227506868	CDC42BPA	0.68	7.12	0.33	4.56e-12	Optic disc area;
LUAD	trans	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg20849893	chr7:64541193	NA	0.49	6.44	0.3	3.17e-10	Aortic root size;
LUAD	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.15	-0.33	3.75e-12	Bipolar disorder;
LUAD	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg14689365	chr7:158441557	NCAPG2	0.42	7.07	0.33	6.35e-12	Height;
LUAD	cis	rs600626	0.947	rs10160784	chr11:75456055	T/C	cg24262691	chr11:75473276	NA	0.43	7.08	0.33	5.86e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg25324976	chr17:61989376	CSHL1	0.38	7.23	0.33	2.22e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs3784262	0.528	rs4646589	chr15:58303165	C/T	cg12031962	chr15:58353849	ALDH1A2	0.35	6.49	0.3	2.44e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg08027265	chr7:2291960	NA	-0.42	-7.24	-0.33	2.18e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg21724239	chr8:58056113	NA	0.79	9.83	0.43	1.17e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2992756	0.663	rs1360919	chr1:18805844	T/C	cg24076588	chr1:18808559	KLHDC7A	-0.46	-7.62	-0.35	1.69e-13	Breast cancer;
LUAD	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.02	-0.4	6.56e-18	Total body bone mineral density;
LUAD	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg08660285	chr1:67390436	MIER1;WDR78	-0.66	-10.04	-0.44	2.01e-21	Lymphocyte percentage of white cells;
LUAD	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg25019722	chr6:37503610	NA	-0.33	-7.64	-0.35	1.45e-13	Cognitive performance;
LUAD	cis	rs4233802	1.000	rs10209398	chr2:151151095	A/G	cg25300694	chr2:151184358	NA	-0.8	-7.09	-0.33	5.51e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs612683	0.518	rs565590	chr1:100846956	T/C	cg06223162	chr1:101003688	GPR88	0.37	6.94	0.32	1.5e-11	Breast cancer;
LUAD	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg13319975	chr6:146136371	FBXO30	-0.59	-9.93	-0.43	5e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg02375832	chr11:62437615	C11orf48	0.3	6.37	0.3	4.98e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9302065	0.529	rs2992904	chr13:95958173	A/C	cg24476569	chr13:95954382	ABCC4	-0.61	-11.19	-0.48	1.22e-25	Blood metabolite levels;
LUAD	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg16325326	chr1:53192061	ZYG11B	0.47	7.97	0.36	1.52e-14	Monocyte count;
LUAD	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11890956	chr21:40555474	PSMG1	0.8	14.04	0.56	5.12e-37	Cognitive function;
LUAD	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg06558623	chr16:89946397	TCF25	1.12	9.78	0.43	1.69e-20	Skin colour saturation;
LUAD	trans	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg02002194	chr4:3960332	NA	-0.32	-7.7	-0.35	9.9e-14	Mood instability;
LUAD	cis	rs2485376	0.842	rs2145308	chr10:104150999	A/G	cg20641465	chr10:103991465	PITX3	-0.51	-8.97	-0.4	9.95e-18	QT interval;
LUAD	cis	rs12681287	0.640	rs7830480	chr8:87403137	T/C	cg00550725	chr8:87521180	FAM82B	-0.44	-6.46	-0.3	2.95e-10	Caudate activity during reward;
LUAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg24642844	chr7:1081250	C7orf50	-0.96	-14.14	-0.57	1.95e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg13385794	chr1:248469461	NA	0.26	7.21	0.33	2.55e-12	Common traits (Other);
LUAD	cis	rs9323205	0.677	rs113612692	chr14:51709461	C/A	cg23942311	chr14:51606299	NA	-0.59	-8.41	-0.38	6.49e-16	Cancer;
LUAD	cis	rs1045714	1.000	rs1045714	chr7:2653582	A/G	cg24848437	chr7:2645542	IQCE	0.76	8.6	0.39	1.56e-16	Urate levels in lean individuals;
LUAD	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg04455712	chr21:45112962	RRP1B	0.47	9.24	0.41	1.19e-18	Mean corpuscular volume;
LUAD	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg17863274	chr19:49399704	TULP2	-0.65	-9.9	-0.43	6.22e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg19875535	chr5:140030758	IK	-0.41	-6.92	-0.32	1.64e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg04267008	chr7:1944627	MAD1L1	-0.74	-11.61	-0.49	3.2e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs1448094	0.874	rs10779219	chr12:86322643	T/G	cg18827107	chr12:86230957	RASSF9	-0.44	-7.93	-0.36	1.94e-14	Major depressive disorder;
LUAD	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.62	-0.35	1.73e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg13385794	chr1:248469461	NA	0.26	6.97	0.32	1.19e-11	Common traits (Other);
LUAD	cis	rs2880765	0.835	rs4514633	chr15:86041017	T/G	cg13263323	chr15:86062960	AKAP13	-0.5	-9.33	-0.41	5.94e-19	Coronary artery disease;
LUAD	cis	rs7705042	0.865	rs2338822	chr5:141503059	T/C	cg08523384	chr5:141488047	NDFIP1	-0.38	-6.55	-0.3	1.64e-10	Asthma;
LUAD	cis	rs2485376	1.000	rs2479552	chr10:104028507	C/A	cg20641465	chr10:103991465	PITX3	-0.57	-10.2	-0.44	5.28e-22	QT interval;
LUAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.61	-0.31	1.16e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.4e-12	Lung cancer;
LUAD	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg02782426	chr3:40428986	ENTPD3	-0.33	-7.16	-0.33	3.56e-12	Renal cell carcinoma;
LUAD	cis	rs12612619	0.685	rs4665937	chr2:27241795	A/T	cg00617064	chr2:27272375	NA	0.35	6.63	0.31	1.04e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg17105886	chr17:28927953	LRRC37B2	0.58	6.66	0.31	8.67e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg20673091	chr1:2541236	MMEL1	-0.41	-8.63	-0.39	1.29e-16	Ulcerative colitis;
LUAD	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg03433033	chr1:76189801	ACADM	0.71	11.48	0.49	9.49e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.84e-26	Alzheimer's disease (late onset);
LUAD	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg22029157	chr1:209979665	IRF6	-0.7	-9.38	-0.41	4.13e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs12024301	0.557	rs12066802	chr1:183647316	A/G	cg19264170	chr1:183622470	APOBEC4;RGL1	-0.58	-6.43	-0.3	3.48e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	8.91	0.4	1.55e-17	Rheumatoid arthritis;
LUAD	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-14.78	-0.58	3.6e-40	Extrinsic epigenetic age acceleration;
LUAD	cis	rs10865541	0.869	rs6548162	chr2:3434332	C/T	cg22182287	chr2:3452347	TTC15	0.46	7.84	0.36	3.76e-14	Obesity-related traits;
LUAD	cis	rs6499255	1.000	rs4985518	chr16:69787158	T/C	cg15192750	chr16:69999425	NA	0.56	8.71	0.39	7e-17	IgE levels;
LUAD	cis	rs239198	0.521	rs13198473	chr6:101337779	C/T	cg09795085	chr6:101329169	ASCC3	0.4	7.01	0.32	9.28e-12	Menarche (age at onset);
LUAD	cis	rs6577655	0.517	rs2315835	chr8:135589854	A/G	cg17885191	chr8:135476712	NA	0.63	8.33	0.38	1.16e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07157834	chr1:205819609	PM20D1	0.54	9.7	0.43	3.27e-20	Menarche (age at onset);
LUAD	cis	rs89107	0.688	rs283087	chr6:118596207	C/T	cg18833306	chr6:118973337	C6orf204	0.53	9.61	0.42	6.65e-20	Cardiac structure and function;
LUAD	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg08470875	chr2:26401718	FAM59B	-0.62	-8.49	-0.38	3.43e-16	Gut microbiome composition (summer);
LUAD	cis	rs7818345	0.967	rs4433156	chr8:19284247	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.32	7.24	0.33	2.11e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg22875332	chr1:76189707	ACADM	0.85	15.8	0.61	1.61e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg18180107	chr4:99064573	C4orf37	0.4	6.45	0.3	3.12e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg12940439	chr1:67600707	NA	0.42	8.17	0.37	3.53e-15	Psoriasis;
LUAD	cis	rs7771547	0.573	rs629721	chr6:36398229	T/C	cg07856975	chr6:36356162	ETV7	0.49	7.77	0.35	6.21e-14	Platelet distribution width;
LUAD	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg19875535	chr5:140030758	IK	0.45	7.49	0.34	3.96e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg17372223	chr3:52568218	NT5DC2	0.39	7.27	0.33	1.7e-12	Electroencephalogram traits;
LUAD	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.0	-0.36	1.2e-14	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2235642	0.601	rs2235647	chr16:1601331	C/A	cg09065629	chr16:1709722	CRAMP1L	0.42	7.02	0.32	8.76e-12	Coronary artery disease;
LUAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.48	-7.5	-0.34	3.75e-13	Longevity;Endometriosis;
LUAD	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg10755058	chr3:40428713	ENTPD3	0.43	8.35	0.38	9.64e-16	Renal cell carcinoma;
LUAD	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg16049864	chr8:95962084	TP53INP1	-0.47	-9.72	-0.43	2.66e-20	Type 2 diabetes;
LUAD	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.74	-8.54	-0.38	2.39e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.68e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg22482690	chr17:47019901	SNF8	0.46	8.94	0.4	1.21e-17	Type 2 diabetes;
LUAD	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg21856205	chr7:94953877	PON1	-0.56	-8.13	-0.37	4.96e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19419581	chr17:79482410	NA	-0.43	-6.84	-0.32	2.87e-11	Height;
LUAD	cis	rs6430585	0.528	rs499483	chr2:136652524	G/A	cg07169764	chr2:136633963	MCM6	0.69	8.2	0.37	2.94e-15	Corneal structure;
LUAD	cis	rs35883536	0.933	rs1409419	chr1:101183396	T/C	cg06223162	chr1:101003688	GPR88	0.37	6.69	0.31	7.15e-11	Monocyte count;
LUAD	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg21016266	chr12:122356598	WDR66	0.7	13.0	0.53	9.64e-33	Mean corpuscular volume;
LUAD	cis	rs11792861	0.566	rs67780641	chr9:111850710	A/G	cg05043794	chr9:111880884	C9orf5	-0.38	-7.24	-0.33	2.2e-12	Menarche (age at onset);
LUAD	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	7.98	0.36	1.38e-14	Menopause (age at onset);
LUAD	trans	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg19862616	chr7:65841803	NCRNA00174	1.04	25.75	0.78	1.24e-88	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg23158103	chr7:148848205	ZNF398	-0.61	-11.1	-0.47	2.7e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs1595825	0.891	rs59617443	chr2:198653204	C/A	cg00361562	chr2:198649771	BOLL	-0.48	-6.76	-0.31	4.54e-11	Ulcerative colitis;
LUAD	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.65	-0.35	1.33e-13	Monocyte percentage of white cells;
LUAD	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg05043794	chr9:111880884	C9orf5	-0.45	-7.87	-0.36	2.98e-14	Menarche (age at onset);
LUAD	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-8.99	-0.4	8.6e-18	Life satisfaction;
LUAD	cis	rs2573652	0.723	rs2573655	chr15:100515709	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.63	-11.45	-0.49	1.25e-26	Height;
LUAD	cis	rs11951515	0.508	rs67261887	chr5:43612441	T/A	cg01983248	chr5:43482804	C5orf28	-0.38	-8.17	-0.37	3.58e-15	Metabolite levels  (X-11787);
LUAD	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs12893668	0.667	rs11844466	chr14:104066422	G/A	cg13511324	chr14:104056883	C14orf153	0.26	6.5	0.3	2.29e-10	Reticulocyte count;
LUAD	cis	rs28374715	0.510	rs8034073	chr15:41545613	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.52	-9.46	-0.42	2.19e-19	Ulcerative colitis;
LUAD	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-9.74	-0.43	2.36e-20	Gut microbiome composition (summer);
LUAD	cis	rs1018836	0.923	rs9643298	chr8:91552502	G/A	cg16814680	chr8:91681699	NA	-0.74	-13.35	-0.54	3.73e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7586879	0.828	rs11675013	chr2:25107208	G/A	cg04586622	chr2:25135609	ADCY3	0.35	7.2	0.33	2.7e-12	Body mass index;
LUAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03452623	chr4:187889614	NA	-0.83	-17.31	-0.64	3.98e-51	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.33	0.45	1.84e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs1298062	0.763	rs921938	chr19:50982086	C/A	cg11430371	chr19:50961752	MYBPC2	0.32	6.47	0.3	2.68e-10	Age of smoking initiation;
LUAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg24503407	chr1:205819492	PM20D1	0.44	7.05	0.32	7.42e-12	Parkinson's disease;
LUAD	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg26384229	chr12:38710491	ALG10B	0.42	7.3	0.33	1.42e-12	Morning vs. evening chronotype;
LUAD	cis	rs459571	0.959	rs467379	chr9:136905474	C/T	cg13789015	chr9:136890014	NCRNA00094	0.79	13.12	0.54	3.19e-33	Platelet distribution width;
LUAD	cis	rs9796	0.870	rs11854472	chr15:41357687	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.37	-6.97	-0.32	1.22e-11	Menopause (age at onset);
LUAD	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg07169764	chr2:136633963	MCM6	0.76	8.9	0.4	1.71e-17	Corneal structure;
LUAD	cis	rs149163995	1	rs149163995	chr2:203777226	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Migraine;
LUAD	trans	rs3219090	0.962	rs3219119	chr1:226556443	A/T	cg27539482	chr13:111589090	NA	-0.4	-6.89	-0.32	2.05e-11	Melanoma;
LUAD	cis	rs9902453	0.765	rs2264302	chr17:28057095	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.3	-0.45	2.34e-22	Coffee consumption (cups per day);
LUAD	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg08085267	chr17:45401833	C17orf57	-0.56	-10.0	-0.44	2.74e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg05535760	chr7:792225	HEATR2	-0.87	-9.84	-0.43	1.03e-20	Cerebrospinal P-tau181p levels;
LUAD	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13732083	chr21:47605072	C21orf56	0.52	8.72	0.39	6.34e-17	Testicular germ cell tumor;
LUAD	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg03037974	chr15:76606532	NA	0.38	8.2	0.37	2.87e-15	Blood metabolite levels;
LUAD	cis	rs4660214	0.568	rs6692769	chr1:39683175	G/C	cg27567593	chr1:39956653	BMP8A	0.33	6.51	0.3	2.1e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg23711669	chr6:146136114	FBXO30	0.38	6.61	0.31	1.13e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.15	-0.33	3.91e-12	Blood metabolite levels;
LUAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg27454412	chr7:1067447	C7orf50	0.42	6.67	0.31	8.07e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	trans	rs3960554	0.808	rs78340819	chr7:75673833	C/G	cg19862616	chr7:65841803	NCRNA00174	0.82	11.2	0.48	1.15e-25	Eotaxin levels;
LUAD	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-9.07	-0.4	4.4e-18	Life satisfaction;
LUAD	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg09509183	chr1:209979624	IRF6	-0.57	-7.17	-0.33	3.32e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg14895029	chr7:2775587	GNA12	-0.39	-6.37	-0.3	4.81e-10	Height;
LUAD	cis	rs1385374	0.858	rs10773578	chr12:129290026	G/C	cg09035930	chr12:129282057	SLC15A4	-0.65	-6.91	-0.32	1.79e-11	Systemic lupus erythematosus;
LUAD	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg22823121	chr1:150693482	HORMAD1	0.42	8.23	0.37	2.33e-15	Melanoma;
LUAD	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.31	-8.05	-0.36	8.35e-15	Total body bone mineral density;
LUAD	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg04455712	chr21:45112962	RRP1B	0.41	8.13	0.37	4.8e-15	Mean corpuscular volume;
LUAD	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg04450456	chr4:17643702	FAM184B	0.41	7.84	0.36	3.7e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs375066	0.592	rs10401203	chr19:44299666	C/T	cg11993925	chr19:44307056	LYPD5	-0.37	-7.34	-0.34	1.12e-12	Breast cancer;
LUAD	cis	rs3733585	0.683	rs3796839	chr4:10009917	G/A	cg02734326	chr4:10020555	SLC2A9	0.63	11.22	0.48	9.75e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs62064224	0.554	rs9894877	chr17:30679517	T/A	cg18200150	chr17:30822561	MYO1D	0.42	7.73	0.35	7.67e-14	Schizophrenia;
LUAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg08132940	chr7:1081526	C7orf50	-0.76	-10.36	-0.45	1.46e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-7.93	-0.36	1.93e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs12210905	0.610	rs72845208	chr6:27395664	C/A	cg08851530	chr6:28072375	NA	1.03	7.52	0.34	3.3e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg05434287	chr7:2030229	MAD1L1	0.39	6.67	0.31	8.01e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs62229266	0.804	rs56279140	chr21:37424361	C/T	cg12218747	chr21:37451666	NA	-0.46	-7.84	-0.36	3.71e-14	Mitral valve prolapse;
LUAD	cis	rs6987853	0.966	rs2974338	chr8:42391945	A/G	cg09913449	chr8:42400586	C8orf40	0.43	7.92	0.36	2.14e-14	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7582720	0.943	rs72932583	chr2:203869847	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.28	0.41	8.55e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1461503	0.932	rs7107575	chr11:122845406	C/T	cg27398637	chr11:122830231	C11orf63	0.35	6.79	0.31	3.78e-11	Menarche (age at onset);
LUAD	cis	rs7180079	1.000	rs59190688	chr15:64516669	G/A	cg08069370	chr15:64387884	SNX1	-0.52	-6.58	-0.3	1.38e-10	Monocyte count;
LUAD	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg01689657	chr7:91764605	CYP51A1	-0.36	-8.76	-0.39	4.7e-17	Breast cancer;
LUAD	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg03388025	chr16:89894329	SPIRE2	0.34	7.59	0.35	2.04e-13	Vitiligo;
LUAD	cis	rs6011002	0.636	rs7267230	chr20:62354572	G/A	cg21849932	chr20:62369462	LIME1	-0.78	-6.47	-0.3	2.78e-10	Dental caries;
LUAD	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg07432352	chr17:45403706	C17orf57	-0.41	-8.02	-0.36	1.06e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg22467129	chr15:76604101	ETFA	-0.49	-8.52	-0.38	2.86e-16	Blood metabolite levels;
LUAD	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg05110241	chr16:68378359	PRMT7	-0.84	-9.13	-0.41	2.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00884529	chr7:16685823	BZW2;ANKMY2	0.42	6.43	0.3	3.47e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs1448094	0.842	rs7301280	chr12:86455752	G/T	cg00310523	chr12:86230176	RASSF9	-0.35	-7.38	-0.34	8.41e-13	Major depressive disorder;
LUAD	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg07936489	chr17:37558343	FBXL20	-0.5	-6.61	-0.31	1.14e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7705042	0.897	rs249681	chr5:141538017	G/C	cg23435118	chr5:141488016	NDFIP1	-0.42	-7.17	-0.33	3.33e-12	Asthma;
LUAD	cis	rs752092	1.000	rs11247277	chr15:101784664	A/G	cg19997662	chr15:101784653	CHSY1	-0.54	-9.86	-0.43	8.8e-21	Corneal structure;
LUAD	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08677398	chr8:58056175	NA	0.49	6.42	0.3	3.69e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg04398451	chr17:18023971	MYO15A	-0.88	-16.88	-0.63	3.11e-49	Total body bone mineral density;
LUAD	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg18932078	chr1:2524107	MMEL1	-0.37	-6.96	-0.32	1.32e-11	Ulcerative colitis;
LUAD	trans	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg27411982	chr8:10470053	RP1L1	0.4	7.15	0.33	3.76e-12	Mood instability;
LUAD	trans	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg14917512	chr19:3094685	GNA11	-0.54	-6.6	-0.31	1.26e-10	Gout;
LUAD	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21659725	chr3:3221576	CRBN	-0.63	-10.09	-0.44	1.37e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7192380	0.639	rs7186296	chr16:69808998	A/G	cg26679644	chr16:69762563	NA	-0.48	-8.87	-0.4	2.13e-17	Sjögren's syndrome;
LUAD	cis	rs6993813	0.843	rs7013722	chr8:120047621	A/T	cg01975934	chr8:119970761	NA	-0.36	-7.03	-0.32	8.2e-12	Bone mineral density (hip);
LUAD	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg11494091	chr17:61959527	GH2	0.41	7.23	0.33	2.34e-12	Height;
LUAD	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg23352942	chr3:46931381	PTH1R	-0.39	-7.97	-0.36	1.51e-14	Birth weight;
LUAD	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg13319975	chr6:146136371	FBXO30	-0.63	-10.93	-0.47	1.18e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3087591	1.000	rs2905884	chr17:29512476	A/G	cg24425628	chr17:29625626	OMG;NF1	0.41	6.63	0.31	1.05e-10	Hip circumference;
LUAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg04025307	chr7:1156635	C7orf50	0.65	7.4	0.34	7.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs734999	0.549	rs867436	chr1:2523723	C/T	cg20673091	chr1:2541236	MMEL1	0.41	8.74	0.39	5.44e-17	Ulcerative colitis;
LUAD	cis	rs68170813	0.523	rs3757713	chr7:107042750	A/C	cg23024343	chr7:107201750	COG5	0.51	7.12	0.33	4.56e-12	Coronary artery disease;
LUAD	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg11663144	chr21:46675770	NA	-0.49	-8.49	-0.38	3.57e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg07757535	chr4:1339547	NA	0.31	6.39	0.3	4.45e-10	Longevity;
LUAD	cis	rs9486719	1.000	rs2472895	chr6:96870387	A/T	cg06623918	chr6:96969491	KIAA0776	0.72	10.01	0.44	2.68e-21	Migraine;Coronary artery disease;
LUAD	trans	rs7181230	1.000	rs9972424	chr15:40365851	A/G	cg22705835	chr10:65332833	REEP3	-0.39	-8.21	-0.37	2.62e-15	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg06582575	chr6:163149167	PACRG;PARK2	1.17	14.83	0.58	2.36e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs1997103	1.000	rs6948112	chr7:55411302	G/A	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs220324	0.688	rs8134831	chr21:43568380	G/A	cg09727148	chr21:43560719	UMODL1	0.48	7.55	0.34	2.7e-13	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02353165	chr6:42928485	GNMT	0.4	7.23	0.33	2.35e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs240764	0.853	rs1875401	chr6:101023588	G/A	cg09795085	chr6:101329169	ASCC3	-0.42	-7.11	-0.33	5.11e-12	Neuroticism;
LUAD	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10802521	chr3:52805072	NEK4	-0.53	-8.93	-0.4	1.3e-17	Bipolar disorder;
LUAD	cis	rs3784262	0.692	rs4646590	chr15:58303137	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.66	-0.35	1.24e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg06046430	chr4:77819534	ANKRD56	0.53	8.44	0.38	5.11e-16	Emphysema distribution in smoking;
LUAD	cis	rs3784262	0.631	rs6493980	chr15:58352290	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.74	-0.35	7.59e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7903847	0.642	rs2275581	chr10:99126249	G/A	cg20016023	chr10:99160130	RRP12	-0.32	-6.99	-0.32	1.04e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg06636001	chr8:8085503	FLJ10661	0.44	7.02	0.32	9.08e-12	Mood instability;
LUAD	cis	rs300774	0.925	rs405258	chr2:145646	T/A	cg21211680	chr2:198530	NA	-0.47	-7.36	-0.34	9.94e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg20119798	chr7:94954144	PON1	-0.5	-6.99	-0.32	1.05e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2686555	0.649	rs1151874	chr12:121092555	T/C	cg13504434	chr12:121088311	CABP1	0.42	7.15	0.33	3.85e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.71	-13.76	-0.56	7.48e-36	Ulcerative colitis;
LUAD	cis	rs6424115	0.557	rs35904775	chr1:24180623	T/C	cg15997130	chr1:24165203	NA	-0.6	-10.49	-0.45	5.02e-23	Immature fraction of reticulocytes;
LUAD	cis	rs9399401	0.626	rs6906468	chr6:142769386	A/G	cg03128060	chr6:142623767	GPR126	0.45	9.17	0.41	2.15e-18	Chronic obstructive pulmonary disease;
LUAD	cis	rs367943	0.712	rs4331889	chr5:112679795	C/T	cg12552261	chr5:112820674	MCC	0.45	8.84	0.39	2.57e-17	Type 2 diabetes;
LUAD	cis	rs6066835	1.000	rs6125446	chr20:47348161	C/G	cg18078177	chr20:47281410	PREX1	0.73	6.85	0.32	2.63e-11	Multiple myeloma;
LUAD	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg01689657	chr7:91764605	CYP51A1	-0.29	-6.88	-0.32	2.23e-11	Breast cancer;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09587503	chr5:134094082	DDX46	0.39	6.63	0.31	1.01e-10	Gut microbiome composition (summer);
LUAD	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg18252515	chr7:66147081	NA	-0.63	-6.89	-0.32	2.07e-11	Diabetic kidney disease;
LUAD	cis	rs1003719	0.751	rs55992706	chr21:38542749	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.44	-0.38	5.25e-16	Eye color traits;
LUAD	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg26818010	chr10:134567672	INPP5A	-0.88	-15.23	-0.6	4.45e-42	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg11859384	chr17:80120422	CCDC57	0.48	8.67	0.39	9.09e-17	Life satisfaction;
LUAD	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg12573674	chr2:1569213	NA	-0.57	-8.25	-0.37	2.06e-15	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.39	6.52	0.3	1.97e-10	Immature fraction of reticulocytes;Schizophrenia;
LUAD	cis	rs2882667	0.756	rs11957953	chr5:138479377	G/T	cg04439458	chr5:138467593	SIL1	-0.55	-10.04	-0.44	2e-21	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg22823121	chr1:150693482	HORMAD1	0.39	7.25	0.33	2.06e-12	Urate levels;
LUAD	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg03929089	chr4:120376271	NA	-0.7	-9.93	-0.43	5.07e-21	Coronary artery disease;
LUAD	cis	rs738322	0.775	rs4375	chr22:38539041	T/C	cg25457927	chr22:38595422	NA	-0.53	-13.13	-0.54	2.82e-33	Cutaneous nevi;
LUAD	cis	rs4698790	0.507	rs17610314	chr4:110682953	A/G	cg07850274	chr4:110748770	RRH	-0.44	-6.56	-0.3	1.61e-10	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUAD	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg26384229	chr12:38710491	ALG10B	0.47	7.77	0.35	6.1e-14	Bladder cancer;
LUAD	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.04	-0.44	2.08e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs877282	1.000	rs11253370	chr10:773712	G/A	cg17470449	chr10:769945	NA	0.68	10.68	0.46	1.01e-23	Uric acid levels;
LUAD	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg02734326	chr4:10020555	SLC2A9	0.44	7.55	0.34	2.65e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7213347	0.707	rs4790323	chr17:2181658	A/G	cg16513277	chr17:2031491	SMG6	-0.42	-6.45	-0.3	3.05e-10	Total body bone mineral density;
LUAD	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.11	-0.4	3.42e-18	Total body bone mineral density;
LUAD	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg02993280	chr1:107599747	PRMT6	-0.56	-9.01	-0.4	7.04e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg04025307	chr7:1156635	C7orf50	0.6	6.78	0.31	3.97e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg00280220	chr17:61926910	NA	0.36	6.97	0.32	1.26e-11	Prudent dietary pattern;
LUAD	cis	rs57590327	0.503	rs11706976	chr3:81899653	C/T	cg07356753	chr3:81810745	GBE1	-0.63	-9.93	-0.43	4.95e-21	Extraversion;
LUAD	cis	rs9392556	0.829	rs676683	chr6:4127253	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.42	-7.19	-0.33	2.95e-12	Blood metabolite levels;
LUAD	cis	rs7224314	1.000	rs8075952	chr17:65381358	C/T	cg01507342	chr17:65387096	PITPNC1	-0.53	-8.67	-0.39	9.14e-17	Diisocyanate-induced asthma;
LUAD	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	trans	rs9467711	0.606	rs9393735	chr6:26582327	A/G	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.41	-0.34	6.85e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg06002616	chr8:101225028	SPAG1	-0.38	-7.83	-0.36	3.85e-14	Atrioventricular conduction;
LUAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18099408	chr3:52552593	STAB1	-0.53	-9.6	-0.42	7.07e-20	Electroencephalogram traits;
LUAD	cis	rs3106136	0.967	rs17310526	chr4:95222227	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.71	-0.35	8.92e-14	Capecitabine sensitivity;
LUAD	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg26924012	chr15:45694286	SPATA5L1	0.88	14.38	0.57	1.85e-38	Homoarginine levels;
LUAD	cis	rs2421770	0.530	rs7945809	chr11:35369253	G/A	cg13971030	chr11:35366721	SLC1A2	-0.47	-8.23	-0.37	2.29e-15	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg14458575	chr2:238380390	NA	0.79	15.69	0.61	4.7e-44	Prostate cancer;
LUAD	cis	rs6906287	0.647	rs12211576	chr6:118872080	G/A	cg21191810	chr6:118973309	C6orf204	0.5	9.83	0.43	1.11e-20	Electrocardiographic conduction measures;
LUAD	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.44	-7.08	-0.33	6e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg10909506	chr17:38081995	ORMDL3	0.37	6.89	0.32	2.09e-11	Self-reported allergy;
LUAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg03188948	chr7:1209495	NA	0.8	9.89	0.43	6.98e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.09	0.33	5.82e-12	Depression;
LUAD	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-16.36	-0.62	5.58e-47	Schizophrenia;
LUAD	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg17031739	chr1:67600172	NA	-0.56	-10.01	-0.44	2.54e-21	Psoriasis;
LUAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg03188948	chr7:1209495	NA	0.55	8.16	0.37	3.82e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg17264618	chr3:40429014	ENTPD3	0.39	8.69	0.39	8.07e-17	Renal cell carcinoma;
LUAD	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg02782426	chr3:40428986	ENTPD3	0.42	8.8	0.39	3.42e-17	Renal cell carcinoma;
LUAD	cis	rs4853036	1.000	rs11902295	chr2:70084599	C/T	cg02498382	chr2:70120550	SNRNP27	-0.51	-8.16	-0.37	3.74e-15	Colorectal or endometrial cancer;
LUAD	cis	rs1723838	0.826	rs118089862	chr11:73428769	G/A	cg10064339	chr11:73693792	UCP2	0.83	6.55	0.3	1.67e-10	Obesity-related traits;
LUAD	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg04731861	chr2:219085781	ARPC2	-0.23	-6.99	-0.32	1.06e-11	Colorectal cancer;
LUAD	cis	rs9394841	0.620	rs9462746	chr6:41816279	T/A	cg25600774	chr6:41776562	USP49	-0.42	-6.47	-0.3	2.77e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs117623576	0.941	rs211424	chr10:32398895	A/G	cg03047570	chr10:32398778	NA	0.79	10.61	0.46	1.82e-23	Anti-saccade response;
LUAD	cis	rs12545109	0.837	rs6474063	chr8:57355545	C/T	cg09654669	chr8:57350985	NA	-0.72	-10.46	-0.45	6.06e-23	Obesity-related traits;
LUAD	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.42	0.34	6.39e-13	Bipolar disorder;
LUAD	cis	rs4588572	0.644	rs9293751	chr5:77778296	A/G	cg11547950	chr5:77652471	NA	-0.58	-9.67	-0.43	4.19e-20	Triglycerides;
LUAD	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg05373962	chr22:49881684	NA	-0.48	-9.99	-0.44	3.08e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg08859206	chr1:53392774	SCP2	-0.58	-10.48	-0.45	5.45e-23	Monocyte count;
LUAD	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg19622623	chr12:86230825	RASSF9	-0.48	-8.25	-0.37	2e-15	Major depressive disorder;
LUAD	cis	rs6546550	0.835	rs3752781	chr2:70124316	T/A	cg02498382	chr2:70120550	SNRNP27	-0.6	-11.37	-0.48	2.57e-26	Prevalent atrial fibrillation;
LUAD	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg11266682	chr4:10021025	SLC2A9	0.68	15.49	0.6	3.32e-43	Bone mineral density;
LUAD	cis	rs1030877	0.515	rs2576742	chr2:105898822	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.41	6.48	0.3	2.51e-10	Obesity-related traits;
LUAD	trans	rs208520	0.754	rs851594	chr6:66876695	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-16.11	-0.62	6.99e-46	Exhaled nitric oxide output;
LUAD	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg14789911	chr21:47582049	C21orf56	0.41	6.86	0.32	2.47e-11	Testicular germ cell tumor;
LUAD	cis	rs9837602	1.000	rs13323143	chr3:99811553	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	9.31	0.41	6.94e-19	Breast cancer;
LUAD	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	12.2	0.51	1.51e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1950626	0.833	rs72700524	chr14:101417309	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.38	7.23	0.33	2.32e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs59698941	0.943	rs17691584	chr5:132284251	A/C	cg14825688	chr5:132208181	LEAP2	-0.49	-6.89	-0.32	2.05e-11	Apolipoprotein A-IV levels;
LUAD	trans	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg07817883	chr1:32538562	TMEM39B	1.27	12.12	0.51	3.14e-29	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg05368731	chr17:41323189	NBR1	0.83	16.43	0.62	2.98e-47	Menopause (age at onset);
LUAD	cis	rs1232027	0.700	rs71578847	chr5:79932504	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg09491104	chr22:46646882	C22orf40	-0.6	-7.39	-0.34	8.1e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs13082711	0.595	rs17317435	chr3:27339326	A/G	cg02860705	chr3:27208620	NA	0.77	12.19	0.51	1.74e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg26384229	chr12:38710491	ALG10B	0.49	8.07	0.37	7.43e-15	Heart rate;
LUAD	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg13679303	chr9:96623674	NA	-0.36	-7.36	-0.34	9.51e-13	DNA methylation (variation);
LUAD	cis	rs16910800	0.731	rs56768542	chr11:23191946	A/G	cg20040320	chr11:23191996	NA	-0.73	-9.81	-0.43	1.32e-20	Cancer;
LUAD	cis	rs1018836	0.923	rs9643308	chr8:91625399	A/C	cg16814680	chr8:91681699	NA	-0.69	-11.67	-0.49	1.77e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-8.5	-0.38	3.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg11344533	chr11:111475393	SIK2	-0.37	-6.92	-0.32	1.7e-11	Primary sclerosing cholangitis;
LUAD	cis	rs6564851	0.506	rs11643509	chr16:81260435	A/C	cg00908271	chr16:81254010	PKD1L2	0.33	6.71	0.31	6.1e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg07776626	chr8:57350775	NA	-0.59	-8.53	-0.38	2.64e-16	Obesity-related traits;
LUAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14893161	chr1:205819251	PM20D1	0.82	17.23	0.64	8.85e-51	Menarche (age at onset);
LUAD	cis	rs12545109	0.836	rs2196586	chr8:57347126	C/T	cg17761419	chr8:57350749	NA	0.55	7.8	0.35	4.74e-14	Obesity-related traits;
LUAD	cis	rs7072216	0.655	rs3830024	chr10:100176106	G/A	cg26618903	chr10:100175079	PYROXD2	-0.4	-8.62	-0.39	1.38e-16	Metabolite levels;
LUAD	cis	rs9469913	0.740	rs2092344	chr6:34570922	G/C	cg14254433	chr6:34482411	PACSIN1	-0.43	-6.67	-0.31	7.91e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg10631373	chr1:89457642	RBMXL1;CCBL2	0.37	6.46	0.3	2.88e-10	Carotid intima media thickness;
LUAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg21226059	chr5:178986404	RUFY1	0.78	13.99	0.56	8.1e-37	Lung cancer;
LUAD	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg07930552	chr6:133119739	C6orf192	0.65	7.91	0.36	2.28e-14	Type 2 diabetes nephropathy;
LUAD	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg06096015	chr1:231504339	EGLN1	0.34	6.6	0.31	1.2e-10	Hemoglobin concentration;
LUAD	cis	rs10504073	0.647	rs62507247	chr8:50013554	T/G	cg00325661	chr8:49890786	NA	0.45	10.04	0.44	2.06e-21	Blood metabolite ratios;
LUAD	cis	rs12949688	0.967	rs12451753	chr17:55822214	T/A	cg12582317	chr17:55822272	NA	0.37	7.41	0.34	6.86e-13	Schizophrenia;
LUAD	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg01416388	chr22:39784598	NA	-0.54	-8.6	-0.39	1.52e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-7.66	-0.35	1.27e-13	Fear of minor pain;
LUAD	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg27144592	chr16:783916	NARFL	0.36	6.44	0.3	3.3e-10	Height;
LUAD	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg14343924	chr8:8086146	FLJ10661	0.49	7.78	0.35	5.47e-14	Mood instability;
LUAD	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.46	0.34	5.12e-13	Bladder cancer;
LUAD	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg05182265	chr7:156933206	UBE3C	0.69	13.37	0.54	3.04e-34	Body mass index;
LUAD	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg24531977	chr5:56204891	C5orf35	0.77	12.37	0.52	3.4e-30	Initial pursuit acceleration;
LUAD	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg27284194	chr4:1044797	NA	0.68	9.95	0.44	4.25e-21	Recombination rate (females);
LUAD	cis	rs11948739	0.610	rs4705882	chr5:130343041	A/G	cg08523029	chr5:130500466	HINT1	0.48	6.61	0.31	1.14e-10	Pediatric bone mineral content (hip);
LUAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.44	-0.3	3.28e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7215564	0.908	rs36100789	chr17:78701117	C/T	cg09596252	chr17:78655493	RPTOR	0.55	6.78	0.31	4.12e-11	Myopia (pathological);
LUAD	cis	rs28595532	0.748	rs115651241	chr4:119363509	C/T	cg21605333	chr4:119757512	SEC24D	0.69	6.79	0.31	3.9e-11	Cannabis dependence symptom count;
LUAD	cis	rs17152411	0.895	rs61872120	chr10:126583588	T/G	cg07906193	chr10:126599966	NA	0.55	7.71	0.35	9.13e-14	Height;
LUAD	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg07636037	chr3:49044803	WDR6	0.53	10.08	0.44	1.51e-21	Menarche (age at onset);
LUAD	trans	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg18187862	chr3:45730750	SACM1L	-0.53	-7.91	-0.36	2.31e-14	Primary sclerosing cholangitis;
LUAD	cis	rs2806561	1.000	rs681753	chr1:23515216	T/C	cg19743168	chr1:23544995	NA	0.41	7.75	0.35	7.1e-14	Height;
LUAD	cis	rs7953508	0.506	rs12425869	chr12:93961353	A/G	cg18151635	chr12:93972918	NA	-0.73	-11.08	-0.47	3.14e-25	Pubertal anthropometrics;
LUAD	cis	rs6545883	0.929	rs2694625	chr2:61616055	G/A	cg15711740	chr2:61764176	XPO1	0.4	6.39	0.3	4.36e-10	Tuberculosis;
LUAD	cis	rs2652834	0.904	rs7175602	chr15:63367032	T/C	cg25406657	chr15:63342033	TPM1	0.43	7.08	0.33	5.95e-12	HDL cholesterol;
LUAD	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.8e-11	Depression;
LUAD	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.41	-0.45	9.77e-23	Total body bone mineral density;
LUAD	cis	rs17092148	1.000	rs1884432	chr20:33342439	A/G	cg16810054	chr20:33298113	TP53INP2	-0.51	-8.24	-0.37	2.19e-15	Neuroticism;
LUAD	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	17.56	0.65	3.09e-52	Bone mineral density;
LUAD	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg21951975	chr1:209979733	IRF6	0.58	7.02	0.32	9.03e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs2213920	0.516	rs71505546	chr9:118158372	G/A	cg13918206	chr9:118159781	DEC1	-0.61	-6.74	-0.31	5.17e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LUAD	cis	rs7809799	0.826	rs73159506	chr7:98881417	G/A	cg12290671	chr7:99195819	NA	-0.79	-6.53	-0.3	1.87e-10	Ulcerative colitis;
LUAD	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg18833306	chr6:118973337	C6orf204	-0.51	-7.4	-0.34	7.2e-13	Diastolic blood pressure;
LUAD	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg14895029	chr7:2775587	GNA12	-0.43	-6.81	-0.31	3.34e-11	Height;
LUAD	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.84	-0.36	3.71e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg15691649	chr6:25882328	NA	0.69	10.46	0.45	6.29e-23	Blood metabolite levels;
LUAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg09640425	chr7:158790006	NA	-0.51	-8.79	-0.39	3.76e-17	Facial morphology (factor 20);
LUAD	cis	rs887829	0.569	rs4663965	chr2:234650604	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-8.77	-0.39	4.57e-17	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg19500851	chr17:37840957	PGAP3	0.33	6.5	0.3	2.22e-10	Asthma;
LUAD	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg14558114	chr2:88469736	THNSL2	-0.41	-6.41	-0.3	3.81e-10	Response to metformin (IC50);
LUAD	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg15395560	chr15:45543142	SLC28A2	0.37	6.36	0.3	5.22e-10	Uric acid levels;
LUAD	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs654950	0.806	rs2759251	chr1:42041749	C/G	cg06885757	chr1:42089581	HIVEP3	-0.5	-11.36	-0.48	2.78e-26	Airway imaging phenotypes;
LUAD	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg23029597	chr12:123009494	RSRC2	-0.53	-8.17	-0.37	3.55e-15	Body mass index;
LUAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg24846343	chr22:24311635	DDTL	0.76	16.95	0.64	1.49e-49	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg01689657	chr7:91764605	CYP51A1	0.33	8.01	0.36	1.13e-14	Breast cancer;
LUAD	cis	rs7116495	0.786	rs610004	chr11:71797939	C/T	cg07596299	chr11:71824057	C11orf51	-0.77	-6.44	-0.3	3.2e-10	Severe influenza A (H1N1) infection;
LUAD	trans	rs7395662	0.963	rs10838967	chr11:48595007	C/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.57	-0.3	1.47e-10	HDL cholesterol;
LUAD	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg26043149	chr18:55253948	FECH	0.51	8.18	0.37	3.32e-15	Bone mineral density;
LUAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg20607798	chr8:58055168	NA	0.57	7.28	0.33	1.6e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9616064	0.520	rs875557	chr22:47034722	C/T	cg05621596	chr22:47072043	GRAMD4	-0.63	-10.44	-0.45	7.33e-23	Urate levels in obese individuals;
LUAD	cis	rs4698036	0.586	rs7672759	chr4:10285015	G/A	cg00071950	chr4:10020882	SLC2A9	0.49	8.24	0.37	2.24e-15	Cardiovascular disease risk factors;
LUAD	cis	rs7027203	1.000	rs34624092	chr9:96523092	G/A	cg14396892	chr9:96623032	NA	0.39	7.05	0.32	7.55e-12	DNA methylation (variation);
LUAD	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.01	-0.32	9.7e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4594175	0.962	rs7157823	chr14:51633170	C/T	cg23942311	chr14:51606299	NA	0.65	11.34	0.48	3.39e-26	Cancer;
LUAD	cis	rs863345	0.625	rs12119672	chr1:158500285	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-10.16	-0.44	7.5e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs9302065	1.000	rs7490267	chr13:95970258	T/C	cg19955956	chr7:72299837	SBDSP;TYW1B	0.39	6.65	0.31	9.16e-11	Blood metabolite levels;
LUAD	trans	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg07211511	chr3:129823064	LOC729375	-0.89	-13.92	-0.56	1.51e-36	Blood pressure (smoking interaction);
LUAD	cis	rs4006360	0.628	rs6416911	chr17:39253311	A/G	cg20663846	chr17:39254439	KRTAP4-8	0.38	8.08	0.37	6.63e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-10.37	-0.45	1.37e-22	Obesity-related traits;
LUAD	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg11814155	chr7:99998594	ZCWPW1	0.4	6.5	0.3	2.31e-10	Platelet count;
LUAD	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg05082376	chr22:42548792	NA	0.44	7.56	0.34	2.59e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg01579765	chr21:45077557	HSF2BP	-0.62	-14.86	-0.59	1.66e-40	Mean corpuscular volume;
LUAD	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.94	-13.5	-0.55	8.44e-35	Red cell distribution width;
LUAD	cis	rs10788264	0.544	rs10788269	chr10:124022870	A/G	cg09507567	chr10:124027408	NA	0.52	11.66	0.49	1.97e-27	Total body bone mineral density;
LUAD	cis	rs10489202	1.000	rs1060041	chr1:167973976	C/T	cg24449463	chr1:168025552	DCAF6	-0.55	-7.34	-0.34	1.07e-12	Schizophrenia;
LUAD	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg10755058	chr3:40428713	ENTPD3	0.46	8.6	0.39	1.57e-16	Renal cell carcinoma;
LUAD	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg25664220	chr3:72788482	NA	-0.66	-11.63	-0.49	2.63e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg21252483	chr19:49399788	TULP2	-0.64	-8.7	-0.39	7.48e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	trans	rs867371	0.502	rs3759800	chr15:82532963	A/C	cg04831495	chr15:85060580	GOLGA6L5	0.41	6.99	0.32	1.06e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LUAD	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07266350	chr3:49460521	AMT;NICN1	-0.37	-6.57	-0.3	1.45e-10	Menarche (age at onset);
LUAD	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19346786	chr7:2764209	NA	-0.54	-11.51	-0.49	7.39e-27	Height;
LUAD	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11644478	chr21:40555479	PSMG1	0.68	11.16	0.48	1.53e-25	Cognitive function;
LUAD	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7524258	0.900	rs12035586	chr1:7273020	C/T	cg07173049	chr1:7289937	CAMTA1	-0.35	-6.46	-0.3	2.92e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg11618577	chr2:27665543	KRTCAP3	-0.26	-7.0	-0.32	1.01e-11	Total body bone mineral density;
LUAD	cis	rs11051970	0.679	rs2651377	chr12:32556919	A/C	cg24626660	chr12:32551988	NA	0.34	7.31	0.33	1.37e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03517284	chr6:25882590	NA	0.6	10.0	0.44	2.93e-21	Blood metabolite levels;
LUAD	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg15704280	chr7:45808275	SEPT13	0.74	10.8	0.46	3.66e-24	Coronary artery disease;
LUAD	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg04586622	chr2:25135609	ADCY3	0.37	8.35	0.38	9.62e-16	Body mass index;
LUAD	trans	rs853679	0.607	rs34166054	chr6:28065801	T/C	cg01620082	chr3:125678407	NA	-1.1	-10.56	-0.46	2.69e-23	Depression;
LUAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.5	-0.45	4.41e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03264133	chr6:25882463	NA	-0.5	-7.47	-0.34	4.68e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.745	rs4997810	chr2:10755540	T/A	cg02196655	chr2:10830764	NOL10	-0.42	-7.5	-0.34	3.7e-13	Prostate cancer;
LUAD	cis	rs11971779	0.680	rs7795520	chr7:139079207	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.82	0.31	3.2e-11	Diisocyanate-induced asthma;
LUAD	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg06784218	chr1:46089804	CCDC17	-0.55	-12.01	-0.5	8.64e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs11677370	0.561	rs12711973	chr2:3825339	C/G	cg17052675	chr2:3827356	NA	-0.62	-10.56	-0.46	2.7e-23	Type 2 diabetes;
LUAD	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg17105886	chr17:28927953	LRRC37B2	0.83	7.92	0.36	2.14e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1997103	1.000	rs1997098	chr7:55405594	G/T	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.88	0.32	2.13e-11	Motion sickness;
LUAD	cis	rs4845570	1.000	rs3790514	chr1:151744168	T/C	cg07092448	chr1:151763213	TDRKH	-0.74	-8.72	-0.39	6.59e-17	Coronary artery disease;
LUAD	cis	rs68170813	0.559	rs74898466	chr7:107053998	C/A	cg02696742	chr7:106810147	HBP1	-0.77	-10.56	-0.46	2.7e-23	Coronary artery disease;
LUAD	cis	rs7737355	0.947	rs11744232	chr5:130911732	A/G	cg06307176	chr5:131281290	NA	0.42	6.73	0.31	5.41e-11	Life satisfaction;
LUAD	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg15704280	chr7:45808275	SEPT13	-1.07	-25.01	-0.77	2.01e-85	Height;
LUAD	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18876405	chr7:65276391	NA	-0.57	-9.66	-0.43	4.25e-20	Aortic root size;
LUAD	cis	rs2997447	0.739	rs3008223	chr1:26389633	T/C	cg00147160	chr1:26503991	CNKSR1	0.36	6.79	0.31	3.9e-11	QRS complex (12-leadsum);
LUAD	cis	rs1403694	0.515	rs1648700	chr3:186449916	C/T	cg12454167	chr3:186435060	KNG1	-0.41	-8.46	-0.38	4.44e-16	Blood protein levels;
LUAD	cis	rs6489882	0.867	rs6489877	chr12:113368079	A/G	cg20102336	chr12:113376681	OAS3	-0.58	-8.86	-0.4	2.19e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg03859395	chr2:55845619	SMEK2	-0.62	-10.86	-0.47	2.2e-24	Metabolic syndrome;
LUAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg16606324	chr3:10149918	C3orf24	0.68	11.01	0.47	5.73e-25	Alzheimer's disease;
LUAD	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg07741184	chr6:167504864	NA	-0.31	-7.36	-0.34	9.42e-13	Crohn's disease;
LUAD	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs17401966	1.000	rs4846210	chr1:10322153	A/G	cg15208524	chr1:10270712	KIF1B	0.56	8.21	0.37	2.64e-15	Hepatocellular carcinoma;
LUAD	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg20469991	chr17:27169893	C17orf63	-0.52	-6.58	-0.3	1.37e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg00922110	chr4:57842668	C4orf14	-0.41	-6.9	-0.32	1.86e-11	Response to bleomycin (chromatid breaks);
LUAD	cis	rs1595825	0.891	rs59938443	chr2:198497105	C/T	cg11031976	chr2:198649780	BOLL	-0.46	-6.9	-0.32	1.91e-11	Ulcerative colitis;
LUAD	cis	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg14348967	chr4:10160060	NA	-0.41	-6.89	-0.32	2.03e-11	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22496380	chr5:211416	CCDC127	-1.21	-16.14	-0.62	5.37e-46	Breast cancer;
LUAD	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.99	-18.75	-0.67	1.62e-57	Homoarginine levels;
LUAD	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg03929089	chr4:120376271	NA	-0.91	-17.08	-0.64	3.84e-50	Coronary artery disease;
LUAD	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.82	-0.47	2.88e-24	Total body bone mineral density;
LUAD	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg19077165	chr18:44547161	KATNAL2	-0.41	-7.02	-0.32	8.93e-12	Personality dimensions;
LUAD	trans	rs8073060	0.586	rs225265	chr17:33961972	C/T	cg19694781	chr19:47549865	TMEM160	-1.24	-19.59	-0.69	2.7e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7607369	0.718	rs6727147	chr2:219639024	G/A	cg02176678	chr2:219576539	TTLL4	-0.58	-11.8	-0.5	5.42e-28	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05060843	chr21:43162018	RIPK4	0.48	6.45	0.3	2.97e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11677370	0.603	rs10198219	chr2:3854600	T/C	cg17052675	chr2:3827356	NA	-0.61	-10.55	-0.46	2.88e-23	Type 2 diabetes;
LUAD	cis	rs1524976	1.000	rs1524976	chr3:65486388	A/G	cg16238336	chr3:65465873	MAGI1	0.64	7.37	0.34	9.02e-13	PR interval;
LUAD	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg20701182	chr2:24300061	SF3B14	0.61	6.77	0.31	4.19e-11	Lymphocyte counts;
LUAD	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg23758822	chr17:41437982	NA	1.02	20.93	0.71	2.75e-67	Menopause (age at onset);
LUAD	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg13770153	chr20:60521292	NA	-0.45	-7.3	-0.33	1.44e-12	Body mass index;
LUAD	cis	rs3916	0.911	rs7313271	chr12:121152667	C/T	cg27246729	chr12:121163418	ACADS	0.46	7.51	0.34	3.46e-13	Urinary metabolites (H-NMR features);
LUAD	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.66	-0.43	4.48e-20	Schizophrenia;
LUAD	cis	rs7394190	0.748	rs11000771	chr10:75524458	T/G	cg02286717	chr10:75415704	SYNPO2L	-0.36	-6.4	-0.3	4.06e-10	Incident atrial fibrillation;
LUAD	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg17366294	chr4:99064904	C4orf37	0.65	12.62	0.52	3.18e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9788682	0.747	rs28511883	chr15:78783683	C/T	cg18825076	chr15:78729989	IREB2	0.53	7.42	0.34	6.65e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	7.76	0.35	6.34e-14	Menopause (age at onset);
LUAD	cis	rs7119	0.604	rs939488	chr15:77867780	T/C	cg27398640	chr15:77910606	LINGO1	0.39	7.18	0.33	3.11e-12	Type 2 diabetes;
LUAD	cis	rs2235649	0.561	rs12599786	chr16:1965257	T/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-7.06	-0.32	6.99e-12	Blood metabolite levels;
LUAD	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.06	0.32	6.7e-12	Platelet count;
LUAD	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg06002616	chr8:101225028	SPAG1	-0.39	-7.91	-0.36	2.23e-14	Atrioventricular conduction;
LUAD	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg05425664	chr17:57184151	TRIM37	-0.44	-7.86	-0.36	3.27e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs79705824	chr7:106848325	T/C	cg23024343	chr7:107201750	COG5	0.5	7.08	0.33	5.93e-12	Coronary artery disease;
LUAD	cis	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg01251360	chr16:68772225	CDH1	-0.28	-8.88	-0.4	1.95e-17	Colorectal cancer;
LUAD	cis	rs3750082	0.754	rs35110377	chr7:32971770	C/G	cg05721444	chr7:32995514	FKBP9	-0.41	-7.33	-0.34	1.2e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.56	-9.52	-0.42	1.38e-19	Glomerular filtration rate;
LUAD	cis	rs921968	0.565	rs3770220	chr2:219619550	C/T	cg02176678	chr2:219576539	TTLL4	-0.59	-12.0	-0.5	9.65e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	-0.41	-6.49	-0.3	2.46e-10	Resistin levels;
LUAD	cis	rs9811920	0.809	rs796976	chr3:99621002	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.61	11.7	0.49	1.32e-27	Axial length;
LUAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg07677032	chr17:61819896	STRADA	0.55	10.2	0.44	5.37e-22	Prudent dietary pattern;
LUAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	7.27	0.33	1.73e-12	Alzheimer's disease;
LUAD	cis	rs2730245	0.550	rs10258339	chr7:158670243	T/C	cg24397884	chr7:158709396	WDR60	0.58	10.38	0.45	1.26e-22	Height;
LUAD	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg03676636	chr4:99064102	C4orf37	0.31	8.24	0.37	2.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg02569458	chr12:86230093	RASSF9	0.45	8.17	0.37	3.54e-15	Major depressive disorder;
LUAD	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-12.13	-0.51	2.78e-29	Breast cancer;
LUAD	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.39	-0.34	7.96e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg23649088	chr2:200775458	C2orf69	-0.62	-7.92	-0.36	2.17e-14	Schizophrenia;
LUAD	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	6.88	0.32	2.17e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg17425144	chr1:10567563	PEX14	0.59	12.24	0.51	1.11e-29	Prostate cancer;
LUAD	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg21854759	chr1:92012499	NA	-0.43	-7.63	-0.35	1.5700000000000001e-13	Breast cancer;
LUAD	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg10544611	chr16:67998164	SLC12A4	-0.63	-7.4	-0.34	7.61e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg05887092	chr17:76393375	PGS1	0.42	7.41	0.34	7.1e-13	HDL cholesterol levels;
LUAD	cis	rs1997103	1.000	rs6593237	chr7:55411015	T/C	cg17469321	chr7:55412551	NA	0.66	11.3	0.48	4.76e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.48	-0.38	3.82e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11722228	0.594	rs10939663	chr4:10032516	T/G	cg00071950	chr4:10020882	SLC2A9	0.54	8.46	0.38	4.31e-16	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs78761021	0.823	rs57690042	chr17:9786783	T/C	cg26853458	chr17:9805074	RCVRN	0.36	7.33	0.34	1.18e-12	Type 2 diabetes;
LUAD	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg06671706	chr8:8559999	CLDN23	0.64	10.95	0.47	9.59e-25	Obesity-related traits;
LUAD	cis	rs3733418	0.929	rs13149738	chr4:165905697	T/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.49	-6.98	-0.32	1.16e-11	Obesity-related traits;
LUAD	cis	rs9486719	0.843	rs2499789	chr6:96844510	T/C	cg06623918	chr6:96969491	KIAA0776	0.71	9.3	0.41	7.58e-19	Migraine;Coronary artery disease;
LUAD	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg05425664	chr17:57184151	TRIM37	-0.42	-7.49	-0.34	4.03e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg06608945	chr2:219082296	ARPC2	-0.41	-6.85	-0.32	2.54e-11	Colorectal cancer;
LUAD	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.88	9.25	0.41	1.09e-18	Initial pursuit acceleration;
LUAD	cis	rs908922	0.676	rs1538082	chr1:152517304	A/G	cg21823605	chr1:152486609	CRCT1	0.29	6.54	0.3	1.74e-10	Hair morphology;
LUAD	cis	rs758324	0.947	rs804059	chr5:131270136	T/C	cg25547332	chr5:131281432	NA	-0.44	-6.67	-0.31	7.91e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg10909506	chr17:38081995	ORMDL3	0.37	6.52	0.3	1.96e-10	Self-reported allergy;
LUAD	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg24308560	chr3:49941425	MST1R	0.53	8.83	0.39	2.85e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs9341808	0.690	rs3805926	chr6:80879280	C/G	cg08355045	chr6:80787529	NA	0.58	10.4	0.45	1.08e-22	Sitting height ratio;
LUAD	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg03948781	chr1:205179583	DSTYK	0.35	6.43	0.3	3.38e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	trans	rs1200821	0.535	rs1208789	chr10:37722472	A/G	cg25427524	chr10:38739819	LOC399744	-0.43	-7.15	-0.33	3.87e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg14893161	chr1:205819251	PM20D1	-0.52	-7.92	-0.36	2.06e-14	Menarche (age at onset);
LUAD	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.82	-0.36	4.36e-14	Total body bone mineral density;
LUAD	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.51	8.48	0.38	3.83e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg08085267	chr17:45401833	C17orf57	-0.65	-11.39	-0.48	2.23e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg11645453	chr3:52864694	ITIH4	-0.35	-6.78	-0.31	4.12e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-9.53	-0.42	1.21e-19	Monocyte percentage of white cells;
LUAD	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg18138036	chr10:133769891	PPP2R2D	0.42	6.86	0.32	2.43e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg27432699	chr2:27873401	GPN1	-0.39	-6.38	-0.3	4.73e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.4e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.18	0.54	1.73e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2835872	0.758	rs7278101	chr21:39035873	T/C	cg06728970	chr21:39037746	KCNJ6	-0.41	-7.79	-0.35	5.13e-14	Electroencephalographic traits in alcoholism;
LUAD	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.02	0.36	1.02e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4077468	0.927	rs1342063	chr1:205912859	C/T	cg07167872	chr1:205819463	PM20D1	-0.38	-6.67	-0.31	7.89e-11	Cystic fibrosis-related diabetes;
LUAD	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.71	0.35	9.36e-14	Lung cancer;
LUAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg22764044	chr5:178986830	RUFY1	0.55	9.43	0.42	2.77e-19	Lung cancer;
LUAD	trans	rs10411161	0.702	rs8110546	chr19:52383556	C/A	cg22319618	chr22:45562946	NUP50	-0.6	-8.32	-0.38	1.24e-15	Breast cancer;
LUAD	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg13770153	chr20:60521292	NA	-0.57	-8.84	-0.4	2.53e-17	Body mass index;
LUAD	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg27446573	chr6:127587934	RNF146	0.44	6.62	0.31	1.06e-10	Breast cancer;
LUAD	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg24397884	chr7:158709396	WDR60	0.66	9.13	0.41	2.82e-18	Height;
LUAD	trans	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg12400702	chr3:12838781	CAND2	0.31	6.44	0.3	3.22e-10	Parkinson's disease;
LUAD	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.86e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg13560548	chr3:10150139	C3orf24	-0.41	-6.78	-0.31	4.08e-11	Alzheimer's disease;
LUAD	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg24562669	chr7:97807699	LMTK2	0.32	7.37	0.34	9.25e-13	Breast cancer;
LUAD	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg18944383	chr4:111397179	ENPEP	0.37	6.65	0.31	8.99e-11	Coronary artery disease;
LUAD	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg11814155	chr7:99998594	ZCWPW1	0.41	6.97	0.32	1.24e-11	Platelet count;
LUAD	cis	rs4253772	0.872	rs45576734	chr22:46638365	A/G	cg09491104	chr22:46646882	C22orf40	-0.54	-7.83	-0.36	4.09e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg14582100	chr15:45693742	SPATA5L1	0.43	8.68	0.39	8.46e-17	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs2274273	1.000	rs2274273	chr14:55614636	A/G	cg04306507	chr14:55594613	LGALS3	-0.36	-7.43	-0.34	5.88e-13	Protein biomarker;
LUAD	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg20469991	chr17:27169893	C17orf63	0.49	6.43	0.3	3.42e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7607369	0.536	rs13013510	chr2:219667227	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-10.25	-0.45	3.54e-22	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	trans	rs1973993	0.662	rs6593607	chr1:96968116	G/A	cg10631902	chr5:14652156	NA	-0.47	-8.11	-0.37	5.5e-15	Weight;
LUAD	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg00666640	chr1:248458726	OR2T12	0.3	7.22	0.33	2.5e-12	Common traits (Other);
LUAD	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg22529645	chr1:3704559	LRRC47	-0.57	-10.56	-0.46	2.8e-23	Red cell distribution width;
LUAD	cis	rs10129255	0.536	rs3944157	chr14:107138303	C/T	cg23076370	chr14:107095027	NA	-0.4	-7.88	-0.36	2.83e-14	Kawasaki disease;
LUAD	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg17524180	chr13:113633600	MCF2L	-0.39	-7.75	-0.35	6.87e-14	Systolic blood pressure;
LUAD	cis	rs732716	0.785	rs11666453	chr19:4368797	G/A	cg21934504	chr19:4445085	UBXN6	0.43	7.05	0.32	7.43e-12	Mean corpuscular volume;
LUAD	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.4	7.38	0.34	8.42e-13	Lung cancer in ever smokers;
LUAD	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg23978390	chr7:1156363	C7orf50	0.55	8.38	0.38	8.02e-16	Bronchopulmonary dysplasia;
LUAD	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg11416102	chr8:651193	ERICH1	-0.8	-7.57	-0.35	2.29e-13	IgG glycosylation;
LUAD	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2985684	0.894	rs4900932	chr14:50022928	A/G	cg04989706	chr14:50066350	PPIL5	-0.5	-7.39	-0.34	8.18e-13	Carotid intima media thickness;
LUAD	cis	rs494562	0.892	rs547052	chr6:86118840	G/A	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910187	0.596	rs6066222	chr20:45801917	G/A	cg27589058	chr20:45804311	EYA2	-0.38	-8.71	-0.39	6.74e-17	Migraine;
LUAD	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg21918786	chr6:109611834	NA	-0.56	-9.93	-0.43	4.94e-21	Reticulocyte fraction of red cells;
LUAD	trans	rs62458065	0.713	rs921406	chr7:32486205	G/C	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.68	-0.35	1.09e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.93	-0.36	2.03e-14	Monocyte percentage of white cells;
LUAD	cis	rs354225	0.626	rs7608414	chr2:54844995	G/A	cg01766943	chr2:54829624	SPTBN1	0.39	7.1	0.33	5.48e-12	Schizophrenia;
LUAD	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15369054	chr17:80825471	TBCD	0.67	11.09	0.47	2.91e-25	Breast cancer;
LUAD	cis	rs9341808	0.718	rs2143887	chr6:80917287	T/C	cg08355045	chr6:80787529	NA	0.59	10.54	0.46	3.21e-23	Sitting height ratio;
LUAD	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-19.65	-0.69	1.48e-61	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg00666640	chr1:248458726	OR2T12	0.34	8.3	0.37	1.4e-15	Common traits (Other);
LUAD	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg22676075	chr6:135203613	NA	0.4	7.46	0.34	4.95e-13	Red blood cell count;
LUAD	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-13.81	-0.56	4.72e-36	Total body bone mineral density;
LUAD	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg27124370	chr19:33622961	WDR88	-0.46	-7.61	-0.35	1.84e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs8112211	0.911	rs2270095	chr19:38840896	A/G	cg14299480	chr19:38876666	GGN	-0.41	-7.21	-0.33	2.57e-12	Blood protein levels;
LUAD	trans	rs6076960	0.652	rs6085441	chr20:6211383	A/G	cg21095983	chr6:86352623	SYNCRIP	0.39	6.53	0.3	1.85e-10	Smooth-surface caries;
LUAD	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg03929089	chr4:120376271	NA	-0.57	-7.25	-0.33	1.94e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2806561	0.929	rs9426694	chr1:23539742	T/C	cg19743168	chr1:23544995	NA	0.45	8.39	0.38	7.42e-16	Height;
LUAD	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg11707310	chr1:2537719	MMEL1	-0.39	-8.24	-0.37	2.24e-15	Ulcerative colitis;
LUAD	cis	rs12478296	0.591	rs4973646	chr2:243001373	C/T	cg06360820	chr2:242988706	NA	0.65	9.61	0.42	6.34e-20	Obesity-related traits;
LUAD	cis	rs367615	0.704	rs7726991	chr5:108847434	C/T	cg17395555	chr5:108820864	NA	0.66	14.33	0.57	3.09e-38	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs9948	0.529	rs2139406	chr2:97366779	A/G	cg20312557	chr2:97357134	FER1L5	-0.54	-6.84	-0.32	2.76e-11	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs8099014	1.000	rs8099014	chr18:56109859	C/A	cg12907477	chr18:56117327	MIR122	0.39	6.74	0.31	5.34e-11	Platelet count;
LUAD	cis	rs7737355	0.812	rs12514547	chr5:130973304	C/G	cg06307176	chr5:131281290	NA	0.44	7.13	0.33	4.3e-12	Life satisfaction;
LUAD	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg08085267	chr17:45401833	C17orf57	0.55	9.41	0.42	3.22e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9473147	0.571	rs9463335	chr6:47479136	G/A	cg12968598	chr6:47444699	CD2AP	0.36	6.35	0.3	5.44e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs790123	1.000	rs790123	chr3:122388993	T/C	cg15604389	chr3:122379662	NA	0.52	9.16	0.41	2.25e-18	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg15147215	chr3:52552868	STAB1	-0.52	-10.2	-0.44	5.59e-22	Electroencephalogram traits;
LUAD	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg10792982	chr14:105748885	BRF1	0.41	8.93	0.4	1.32e-17	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg00339695	chr16:24857497	SLC5A11	0.69	11.19	0.48	1.27e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg14784868	chr12:69753453	YEATS4	0.47	7.92	0.36	2.16e-14	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg11247378	chr22:39784982	NA	0.76	13.15	0.54	2.26e-33	Intelligence (multi-trait analysis);
LUAD	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.66	12.43	0.52	1.82e-30	Cognitive ability;
LUAD	trans	rs9914544	0.545	rs9898426	chr17:18794071	A/G	cg21372672	chr17:16614065	CCDC144A	-0.36	-6.45	-0.3	3.04e-10	Educational attainment (years of education);
LUAD	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03934478	chr11:495069	RNH1	0.75	9.21	0.41	1.52e-18	Body mass index;
LUAD	cis	rs8017423	0.967	rs2277516	chr14:90722824	G/C	cg14092571	chr14:90743983	NA	-0.5	-8.87	-0.4	2.08e-17	Mortality in heart failure;
LUAD	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.21	-0.37	2.62e-15	Bipolar disorder;
LUAD	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23158103	chr7:148848205	ZNF398	-0.66	-12.48	-0.52	1.18e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9911578	0.813	rs12452313	chr17:57129882	C/A	cg05425664	chr17:57184151	TRIM37	0.45	7.28	0.33	1.61e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1018836	0.773	rs7837109	chr8:91639178	C/T	cg16814680	chr8:91681699	NA	-0.69	-11.86	-0.5	3.16e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg03467027	chr4:99064603	C4orf37	0.41	6.65	0.31	9.1e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs796825	0.671	rs6795868	chr3:120001235	G/A	cg21790991	chr3:120137480	FSTL1	-0.39	-6.79	-0.31	3.87e-11	HIV-1 susceptibility;
LUAD	cis	rs1904096	0.506	rs28701470	chr4:95167088	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.51	-9.49	-0.42	1.7e-19	Type 2 diabetes;
LUAD	cis	rs1595825	0.891	rs73054808	chr2:198602283	C/T	cg00982548	chr2:198649783	BOLL	-0.64	-8.9	-0.4	1.6e-17	Ulcerative colitis;
LUAD	cis	rs7520050	0.898	rs4660885	chr1:46243756	C/T	cg06784218	chr1:46089804	CCDC17	-0.31	-6.66	-0.31	8.76e-11	Red blood cell count;Reticulocyte count;
LUAD	cis	rs11048434	0.736	rs2377672	chr12:9112414	A/G	cg13575925	chr12:9217583	LOC144571	0.37	6.92	0.32	1.68e-11	Sjögren's syndrome;
LUAD	cis	rs4077468	1.000	rs4077469	chr1:205914885	C/T	cg14159672	chr1:205819179	PM20D1	-0.39	-6.83	-0.32	3e-11	Cystic fibrosis-related diabetes;
LUAD	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg10356904	chr22:49881777	NA	-0.42	-9.13	-0.41	2.83e-18	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs7395662	0.889	rs1848158	chr11:48697294	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	2.03e-12	HDL cholesterol;
LUAD	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs10465746	0.780	rs1570691	chr1:84370393	A/C	cg10977910	chr1:84465055	TTLL7	0.6	9.81	0.43	1.35e-20	Obesity-related traits;
LUAD	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.54	-9.17	-0.41	2.09e-18	Tonsillectomy;
LUAD	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg05234568	chr11:5960015	NA	-0.52	-9.26	-0.41	1.02e-18	DNA methylation (variation);
LUAD	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.76	14.68	0.58	1.02e-39	Intelligence (multi-trait analysis);
LUAD	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg21918786	chr6:109611834	NA	-0.59	-11.2	-0.48	1.12e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg08645402	chr16:4508243	NA	0.57	9.96	0.44	4.05e-21	Schizophrenia;
LUAD	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18404041	chr3:52824283	ITIH1	-0.6	-12.15	-0.51	2.44e-29	Bipolar disorder;
LUAD	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	9.23	0.41	1.33e-18	Total body bone mineral density;
LUAD	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.93	-0.36	1.91e-14	Prostate cancer;
LUAD	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.33	0.54	4.46e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs897984	0.520	rs4889614	chr16:30862135	G/A	cg02466173	chr16:30829666	NA	0.7	11.28	0.48	5.4e-26	Dementia with Lewy bodies;
LUAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00166722	chr3:10149974	C3orf24	0.63	10.42	0.45	8.88e-23	Alzheimer's disease;
LUAD	cis	rs4604732	0.588	rs7552461	chr1:247628644	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.18	0.33	3.06e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9715521	0.746	rs57464801	chr4:59851169	C/G	cg11281224	chr4:60001000	NA	-0.59	-10.06	-0.44	1.69e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg22223655	chr18:67872902	RTTN	-0.48	-6.87	-0.32	2.32e-11	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs12541635	0.966	rs6469028	chr8:107014552	C/T	cg10147462	chr8:107024639	NA	0.51	9.25	0.41	1.11e-18	Age of smoking initiation;
LUAD	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg25894440	chr7:65020034	NA	-0.61	-6.5	-0.3	2.26e-10	Diabetic kidney disease;
LUAD	cis	rs8177876	0.749	rs2287995	chr16:81095099	C/G	cg08591886	chr16:81111003	C16orf46	-0.74	-6.77	-0.31	4.37e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.61	0.31	1.13e-10	Prudent dietary pattern;
LUAD	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg26587870	chr6:27730563	NA	-0.46	-7.8	-0.35	4.77e-14	Parkinson's disease;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg06694137	chr1:214161720	PROX1	-0.41	-6.35	-0.3	5.6e-10	Blood protein levels;
LUAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg26304593	chr6:42947056	PEX6	-0.39	-6.47	-0.3	2.74e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg15704280	chr7:45808275	SEPT13	0.63	7.5	0.34	3.88e-13	Axial length;
LUAD	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg00933542	chr6:150070202	PCMT1	0.35	7.41	0.34	7.13e-13	Testicular germ cell tumor;
LUAD	cis	rs12545109	0.571	rs4237014	chr8:57284479	C/A	cg07776626	chr8:57350775	NA	-0.67	-9.24	-0.41	1.23e-18	Obesity-related traits;
LUAD	cis	rs7809950	0.731	rs2712196	chr7:107128797	G/T	cg23024343	chr7:107201750	COG5	-0.85	-14.15	-0.57	1.79e-37	Coronary artery disease;
LUAD	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18876405	chr7:65276391	NA	-0.42	-6.58	-0.3	1.41e-10	Aortic root size;
LUAD	trans	rs4650994	0.544	rs6664493	chr1:178494428	C/T	cg05059571	chr16:84539110	KIAA1609	-0.74	-13.46	-0.55	1.26e-34	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-7.44	-0.34	5.82e-13	Neutrophil percentage of white cells;
LUAD	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg24069376	chr3:38537580	EXOG	-0.43	-10.35	-0.45	1.58e-22	Electrocardiographic conduction measures;
LUAD	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg06547715	chr2:218990976	CXCR2	0.44	10.64	0.46	1.38e-23	Ulcerative colitis;
LUAD	cis	rs4911253	0.509	rs66499347	chr20:31448696	C/T	cg13636640	chr20:31349939	DNMT3B	-0.62	-10.42	-0.45	8.5e-23	Lymphocyte counts;
LUAD	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.65	-0.35	1.34e-13	Personality dimensions;
LUAD	cis	rs11811982	0.793	rs11805012	chr1:227221683	G/A	cg24860534	chr1:227506868	CDC42BPA	0.68	7.12	0.33	4.56e-12	Optic disc area;
LUAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	7.01	0.32	9.68e-12	Alzheimer's disease;
LUAD	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg17724175	chr1:150552817	MCL1	0.4	9.53	0.42	1.2e-19	Tonsillectomy;
LUAD	cis	rs9929218	0.559	rs55907909	chr16:68805805	C/T	cg01251360	chr16:68772225	CDH1	-0.26	-8.04	-0.36	9.1e-15	Colorectal cancer;
LUAD	trans	rs4650994	0.544	rs6682815	chr1:178501109	T/C	cg05059571	chr16:84539110	KIAA1609	-0.75	-13.92	-0.56	1.59e-36	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg06671706	chr8:8559999	CLDN23	0.64	10.87	0.47	1.98e-24	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6906287	0.625	rs7764280	chr6:118692514	A/G	cg05564266	chr6:118973597	C6orf204	0.37	8.06	0.36	8.03e-15	Electrocardiographic conduction measures;
LUAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-9.2	-0.41	1.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1997103	1.000	rs2177805	chr7:55404381	T/A	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs8099014	1.000	rs7238719	chr18:56132195	T/C	cg12907477	chr18:56117327	MIR122	0.39	6.64	0.31	9.53e-11	Platelet count;
LUAD	cis	rs752092	1.000	rs11636578	chr15:101787969	T/C	cg19997662	chr15:101784653	CHSY1	-0.54	-9.75	-0.43	2.19e-20	Corneal structure;
LUAD	cis	rs2072499	0.966	rs2853646	chr1:156189626	C/T	cg24450063	chr1:156163899	SLC25A44	1.2	24.2	0.76	7.81e-82	Testicular germ cell tumor;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg01932459	chr6:109703513	CD164	0.39	6.4	0.3	4.01e-10	Optic cup area;
LUAD	cis	rs2224391	0.518	rs17736611	chr6:5283821	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.65	-7.7	-0.35	9.4e-14	Height;
LUAD	cis	rs2979489	0.533	rs62505279	chr8:30447069	C/T	cg26383811	chr8:30366931	RBPMS	-0.55	-8.36	-0.38	8.87e-16	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.67	-10.4	-0.45	1.04e-22	Chronic sinus infection;
LUAD	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg18944383	chr4:111397179	ENPEP	0.38	7.66	0.35	1.24e-13	Height;
LUAD	cis	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.99	-0.36	1.31e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg26811252	chr16:29126840	RRN3P2	0.61	10.48	0.45	5.25e-23	Menopause (age at onset);
LUAD	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22590775	chr19:49891494	CCDC155	0.69	10.97	0.47	8.58e-25	Multiple sclerosis;
LUAD	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg03609598	chr5:56110824	MAP3K1	-0.64	-8.65	-0.39	1.1e-16	Initial pursuit acceleration;
LUAD	cis	rs6988985	0.728	rs4736311	chr8:143952700	A/G	cg10324643	chr8:143916377	GML	0.31	6.42	0.3	3.69e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18099408	chr3:52552593	STAB1	0.46	8.13	0.37	4.83e-15	Bipolar disorder;
LUAD	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs7605378	1.000	rs2689766	chr2:200697539	A/T	cg23649088	chr2:200775458	C2orf69	0.54	8.41	0.38	6.24e-16	Osteoporosis;
LUAD	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg14092988	chr3:52407081	DNAH1	0.32	6.56	0.3	1.54e-10	Bipolar disorder;
LUAD	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg24733560	chr20:60626293	TAF4	0.39	7.52	0.34	3.28e-13	Body mass index;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14431619	chr19:11266544	SPC24	0.4	6.59	0.31	1.34e-10	Bilirubin levels;
LUAD	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg18854424	chr1:2615690	NA	0.34	7.87	0.36	3.09e-14	Ulcerative colitis;
LUAD	cis	rs1953600	0.645	rs2819945	chr10:81952956	G/A	cg00277334	chr10:82204260	NA	0.41	7.0	0.32	9.94e-12	Sarcoidosis;
LUAD	cis	rs7584330	0.695	rs7570882	chr2:238435086	G/A	cg14458575	chr2:238380390	NA	0.57	10.82	0.47	3.09e-24	Prostate cancer;
LUAD	cis	rs2692947	0.537	rs12478605	chr2:96377078	C/T	cg23100626	chr2:96804247	ASTL	0.33	7.94	0.36	1.87e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10242455	0.557	rs77997620	chr7:99070415	G/T	cg18809830	chr7:99032528	PTCD1	-1.0	-7.35	-0.34	1.04e-12	Blood metabolite levels;
LUAD	cis	rs2282300	0.653	rs12800124	chr11:30239865	A/G	cg25418670	chr11:30344373	C11orf46	-0.53	-7.28	-0.33	1.69e-12	Morning vs. evening chronotype;
LUAD	trans	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.2	-0.33	2.85e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.12	-0.51	3.11e-29	Bone mineral density;
LUAD	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg14416269	chr4:6271139	WFS1	0.63	13.04	0.54	6.92e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg11645453	chr3:52864694	ITIH4	0.58	11.08	0.47	3.14e-25	Schizophrenia;
LUAD	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg26924012	chr15:45694286	SPATA5L1	0.99	18.3	0.66	1.64e-55	Homoarginine levels;
LUAD	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18876405	chr7:65276391	NA	-0.42	-6.6	-0.31	1.2e-10	Aortic root size;
LUAD	cis	rs7512552	0.839	rs2794684	chr1:150320571	C/T	cg15654264	chr1:150340011	RPRD2	0.61	11.6	0.49	3.48e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.75	0.39	5.08e-17	Parkinson's disease;
LUAD	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg03651054	chr13:50194643	NA	0.39	7.89	0.36	2.53e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg06558623	chr16:89946397	TCF25	1.12	9.87	0.43	8.04e-21	Skin colour saturation;
LUAD	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg16205897	chr5:131564050	P4HA2	0.29	6.49	0.3	2.41e-10	Breast cancer;
LUAD	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg02018176	chr4:1364513	KIAA1530	0.39	6.73	0.31	5.55e-11	Obesity-related traits;
LUAD	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg02734326	chr4:10020555	SLC2A9	0.57	9.81	0.43	1.35e-20	Bone mineral density;
LUAD	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg23231163	chr10:75533350	FUT11	-0.51	-9.5	-0.42	1.63e-19	Inflammatory bowel disease;
LUAD	cis	rs1395	1.000	rs7593448	chr2:27449293	C/G	cg23587288	chr2:27483067	SLC30A3	-0.39	-7.95	-0.36	1.73e-14	Blood metabolite levels;
LUAD	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg21951975	chr1:209979733	IRF6	0.54	7.46	0.34	4.9e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs6840360	0.571	rs4696270	chr4:152498289	G/A	cg22705602	chr4:152727874	NA	-0.37	-6.64	-0.31	9.93e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg15992532	chr8:142229932	SLC45A4	0.48	8.41	0.38	6.47e-16	Immature fraction of reticulocytes;
LUAD	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg16647868	chr5:131706066	SLC22A5	0.4	6.99	0.32	1.08e-11	Blood metabolite levels;
LUAD	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg16647868	chr5:131706066	SLC22A5	-0.39	-6.79	-0.31	3.83e-11	Blood metabolite levels;
LUAD	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg01528321	chr10:82214614	TSPAN14	0.55	8.92	0.4	1.38e-17	Post bronchodilator FEV1;
LUAD	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg06108461	chr20:60628389	TAF4	-0.95	-16.96	-0.64	1.31e-49	Body mass index;
LUAD	trans	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg18834416	chr8:37888184	EIF4EBP1	-0.51	-8.86	-0.4	2.29e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.41	6.9	0.32	1.88e-11	Total body bone mineral density;
LUAD	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg17644776	chr2:200775616	C2orf69	-0.52	-7.73	-0.35	7.97e-14	LDL cholesterol to HDL cholesterol ratio;
LUAD	cis	rs938554	0.692	rs4428284	chr4:9996392	A/T	cg00071950	chr4:10020882	SLC2A9	0.64	9.51	0.42	1.48e-19	Blood metabolite levels;
LUAD	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg17595323	chr11:93583763	C11orf90	-0.43	-8.88	-0.4	1.95e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.85	16.26	0.62	1.62e-46	Lymphocyte counts;
LUAD	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.49	6.92	0.32	1.73e-11	Cognitive test performance;
LUAD	cis	rs1003719	0.715	rs8126941	chr21:38551542	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.38	-0.38	7.91e-16	Eye color traits;
LUAD	cis	rs10901296	0.660	rs2855199	chr9:133765044	T/C	cg13397898	chr9:133768931	QRFP	0.51	6.99	0.32	1.06e-11	Bilirubin levels;
LUAD	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg11645453	chr3:52864694	ITIH4	0.38	7.25	0.33	2.05e-12	Bipolar disorder;
LUAD	cis	rs1707322	1.000	rs1707303	chr1:46598273	A/C	cg06784218	chr1:46089804	CCDC17	-0.53	-11.35	-0.48	3.08e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs8060686	0.668	rs2418739	chr16:68092850	G/C	cg05110241	chr16:68378359	PRMT7	-0.53	-6.95	-0.32	1.38e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1775715	0.707	rs2799019	chr10:32142850	C/T	cg04359828	chr10:32216031	ARHGAP12	0.31	6.46	0.3	2.94e-10	Bipolar disorder with mood-incongruent psychosis;
LUAD	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg10560079	chr2:191398806	TMEM194B	-0.48	-6.47	-0.3	2.77e-10	Diastolic blood pressure;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg07754938	chr3:48885314	PRKAR2A	0.44	6.59	0.31	1.27e-10	QT interval;
LUAD	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.51	0.38	3.06e-16	Parkinson's disease;
LUAD	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.2	-0.33	2.83e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.43	-7.82	-0.36	4.37e-14	Longevity;Endometriosis;
LUAD	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	8.55	0.38	2.29e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs6684428	0.901	rs11206681	chr1:56364528	T/C	cg11651538	chr1:56320950	NA	-0.4	-6.39	-0.3	4.39e-10	Airflow obstruction;
LUAD	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg00255919	chr5:131827918	IRF1	0.47	10.59	0.46	2.13e-23	Asthma (sex interaction);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01774705	chr17:4447783	MYBBP1A	0.46	6.61	0.31	1.19e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.35	6.96	0.32	1.31e-11	Depression;
LUAD	cis	rs62400317	0.762	rs12193264	chr6:44930793	T/C	cg20913747	chr6:44695427	NA	-0.44	-6.85	-0.32	2.54e-11	Total body bone mineral density;
LUAD	cis	rs7731657	0.537	rs10062336	chr5:130193668	T/A	cg08523029	chr5:130500466	HINT1	-0.58	-7.53	-0.34	3.1400000000000003e-13	Fasting plasma glucose;
LUAD	cis	rs939658	0.935	rs954292	chr15:79449237	C/T	cg17916960	chr15:79447300	NA	0.47	9.76	0.43	2.01e-20	Refractive error;
LUAD	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.64	-9.84	-0.43	1.05e-20	IgG glycosylation;
LUAD	cis	rs752010	1.000	rs6656183	chr1:42094025	A/G	cg06885757	chr1:42089581	HIVEP3	0.44	9.41	0.42	3.2e-19	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg18477163	chr1:228402036	OBSCN	-0.36	-7.13	-0.33	4.29e-12	Diastolic blood pressure;
LUAD	trans	rs1904173	0.800	rs17525070	chr5:25453114	C/T	cg08850729	chr1:60036715	FGGY	-0.62	-6.75	-0.31	4.99e-11	IgG glycosylation;
LUAD	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.36	0.34	9.62e-13	Menopause (age at onset);
LUAD	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.71	-0.39	7.08e-17	Alzheimer's disease (late onset);
LUAD	cis	rs66569888	0.581	rs17271098	chr2:106692818	A/G	cg15412446	chr2:106886593	NA	0.53	7.92	0.36	2.15e-14	Facial morphology (factor 23);
LUAD	trans	rs8002861	0.641	rs2028813	chr13:44422126	G/T	cg17145862	chr1:211918768	LPGAT1	0.67	12.99	0.53	1.03e-32	Leprosy;
LUAD	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg26816564	chr1:7831052	VAMP3	0.79	10.29	0.45	2.52e-22	Inflammatory bowel disease;
LUAD	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg02734326	chr4:10020555	SLC2A9	0.59	10.4	0.45	1.02e-22	Bone mineral density;
LUAD	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg24558204	chr6:135376177	HBS1L	0.5	8.63	0.39	1.23e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg23803603	chr1:2058230	PRKCZ	0.42	7.83	0.36	4.02e-14	Height;
LUAD	trans	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg06175025	chr14:78082992	SPTLC2	-0.41	-6.63	-0.31	1.03e-10	Bone mineral density;
LUAD	cis	rs4774899	0.752	rs2733185	chr15:57361347	G/A	cg14026238	chr15:57616123	NA	0.42	8.02	0.36	1.05e-14	Urinary tract infection frequency;
LUAD	cis	rs375066	0.762	rs62114648	chr19:44414816	T/C	cg12072164	chr19:44306565	LYPD5	-0.31	-6.4	-0.3	4.13e-10	Breast cancer;
LUAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg22963979	chr7:1858916	MAD1L1	-0.71	-12.51	-0.52	9.38e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg04398451	chr17:18023971	MYO15A	0.76	13.21	0.54	1.39e-33	Total body bone mineral density;
LUAD	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg13606994	chr1:44402422	ARTN	-0.37	-7.47	-0.34	4.65e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg00071950	chr4:10020882	SLC2A9	0.45	6.53	0.3	1.89e-10	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs8058578	1.000	rs67128646	chr16:30672097	A/C	cg05768032	chr16:30646687	NA	0.44	7.42	0.34	6.68e-13	Multiple myeloma;
LUAD	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg26597838	chr10:835615	NA	0.87	12.91	0.53	2.23e-32	Eosinophil percentage of granulocytes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01372608	chr1:116185223	VANGL1	-0.48	-7.53	-0.34	3.18e-13	Height;
LUAD	cis	rs10193935	0.901	rs3088290	chr2:42578143	A/G	cg27598129	chr2:42591480	NA	-0.77	-10.05	-0.44	1.94e-21	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs28735056	0.967	rs8091497	chr18:77632565	G/A	cg05926928	chr17:57297772	GDPD1	-0.47	-6.46	-0.3	2.93e-10	Schizophrenia;
LUAD	cis	rs6490294	0.583	rs2339973	chr12:112520883	C/T	cg10833066	chr12:111807467	FAM109A	0.35	6.55	0.3	1.67e-10	Mean platelet volume;
LUAD	cis	rs3818285	0.655	rs588160	chr10:111641538	C/T	cg00817464	chr10:111662876	XPNPEP1	0.82	15.99	0.61	2.43e-45	Superior crus of antihelix expression;
LUAD	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg25753631	chr6:25732923	NA	-0.4	-6.7	-0.31	6.48e-11	Height;
LUAD	cis	rs1953600	0.870	rs2573353	chr10:81940917	A/C	cg00277334	chr10:82204260	NA	-0.4	-6.79	-0.31	3.79e-11	Sarcoidosis;
LUAD	cis	rs4343996	0.902	rs9969270	chr7:3368974	C/T	cg21248987	chr7:3385318	SDK1	-0.35	-6.62	-0.31	1.11e-10	Motion sickness;
LUAD	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11644478	chr21:40555479	PSMG1	0.68	11.18	0.48	1.34e-25	Cognitive function;
LUAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg02869364	chr7:1081709	C7orf50	-0.35	-6.54	-0.3	1.81e-10	Longevity;Endometriosis;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00035945	chr4:75859212	PARM1	-0.4	-6.63	-0.31	1.05e-10	Cancer;
LUAD	cis	rs1595825	0.891	rs16823385	chr2:198602101	G/A	cg11031976	chr2:198649780	BOLL	-0.47	-6.68	-0.31	7.72e-11	Ulcerative colitis;
LUAD	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg10167378	chr1:228756711	NA	0.45	7.41	0.34	6.87e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg11584989	chr19:19387371	SF4	0.36	6.48	0.3	2.52e-10	Tonsillectomy;
LUAD	cis	rs4713675	0.553	rs943465	chr6:33731663	G/A	cg18005901	chr6:33739558	LEMD2	-0.47	-7.27	-0.33	1.73e-12	Plateletcrit;
LUAD	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg07810366	chr2:100720526	AFF3	-0.37	-7.57	-0.35	2.43e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg03563238	chr19:33554763	RHPN2	-0.34	-8.14	-0.37	4.41e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg25237894	chr2:233734115	C2orf82	0.63	11.76	0.5	8.02e-28	Coronary artery disease;
LUAD	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.1	-0.44	1.24e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs4730250	0.707	rs257378	chr7:106801395	C/G	cg02696742	chr7:106810147	HBP1	-0.87	-11.34	-0.48	3.41e-26	Osteoarthritis;
LUAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg08888203	chr3:10149979	C3orf24	0.63	10.73	0.46	6.56e-24	Alzheimer's disease;
LUAD	cis	rs10129255	0.500	rs2027902	chr14:107215393	T/C	cg23076370	chr14:107095027	NA	-0.42	-8.52	-0.38	2.76e-16	Kawasaki disease;
LUAD	cis	rs1509123	0.609	rs11078650	chr17:6704816	T/C	cg12642237	chr17:6703447	TEKT1	-0.51	-7.85	-0.36	3.49e-14	Blood metabolite levels;
LUAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00166722	chr3:10149974	C3orf24	0.7	12.16	0.51	2.19e-29	Alzheimer's disease;
LUAD	cis	rs73198271	0.740	rs10113326	chr8:8647630	A/T	cg01851573	chr8:8652454	MFHAS1	0.48	8.54	0.38	2.53e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4288356	1	rs4288356	chr8:141055724	G/A	cg06693505	chr8:141057453	TRAPPC9	-0.32	-6.75	-0.31	4.95e-11	Pulse pressure;
LUAD	trans	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg01620082	chr3:125678407	NA	-0.44	-6.6	-0.31	1.27e-10	Depression;
LUAD	cis	rs2387326	0.717	rs77277629	chr10:129944462	C/T	cg16087940	chr10:129947807	NA	-0.63	-8.35	-0.38	9.71e-16	Select biomarker traits;
LUAD	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg03714773	chr7:91764589	CYP51A1	0.28	6.51	0.3	2.19e-10	Breast cancer;
LUAD	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg06544989	chr22:39130855	UNC84B	0.41	7.47	0.34	4.61e-13	Menopause (age at onset);
LUAD	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg02269571	chr22:50332266	NA	0.59	8.96	0.4	1.05e-17	Schizophrenia;
LUAD	cis	rs62238980	0.614	rs76177859	chr22:32390135	T/C	cg00543991	chr22:32367038	NA	0.92	8.16	0.37	3.95e-15	Childhood ear infection;
LUAD	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg26384229	chr12:38710491	ALG10B	0.44	7.4	0.34	7.33e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg16479474	chr6:28041457	NA	0.42	7.01	0.32	9.33e-12	Depression;
LUAD	cis	rs17253792	0.822	rs10142757	chr14:56074211	C/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	trans	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	15.46	0.6	4.8e-43	Exhaled nitric oxide levels;
LUAD	trans	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg00953403	chr17:74099816	EXOC7	-0.43	-6.99	-0.32	1.06e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs6005807	0.843	rs9625515	chr22:29024303	T/G	cg12565055	chr22:29076175	TTC28	0.67	6.68	0.31	7.72e-11	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-8.77	-0.39	4.26e-17	Life satisfaction;
LUAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.64	-11.85	-0.5	3.6e-28	Longevity;Endometriosis;
LUAD	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.65	11.53	0.49	6.24e-27	Birth weight;
LUAD	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg22166914	chr1:53195759	ZYG11B	-0.45	-7.62	-0.35	1.66e-13	Monocyte count;
LUAD	cis	rs9346649	0.606	rs7750135	chr6:168490841	C/A	cg02770688	chr6:168491649	NA	0.51	9.56	0.42	9.85e-20	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs11971779	0.680	rs6467846	chr7:139079385	G/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.4	-0.3	4.05e-10	Diisocyanate-induced asthma;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg14443077	chr11:68606701	CPT1A	0.37	6.61	0.31	1.19e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs4285028	0.948	rs35737776	chr3:121677856	G/A	cg20356878	chr3:121714668	ILDR1	-0.5	-6.76	-0.31	4.51e-11	Multiple sclerosis;
LUAD	trans	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg27411982	chr8:10470053	RP1L1	-0.35	-6.47	-0.3	2.64e-10	Joint mobility (Beighton score);
LUAD	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	8.81	0.39	3.15e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg22532475	chr10:104410764	TRIM8	-0.47	-9.04	-0.4	5.53e-18	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	trans	rs343496	0.877	rs340922	chr9:6088815	A/C	cg16665231	chr1:245741199	KIF26B	-0.41	-6.35	-0.3	5.44e-10	Asthma and hay fever;
LUAD	cis	rs3772130	0.962	rs11719093	chr3:121487686	G/A	cg20356878	chr3:121714668	ILDR1	0.52	8.12	0.37	5.09e-15	Cognitive performance;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg17213342	chr10:121485184	INPP5F	-0.63	-6.44	-0.3	3.26e-10	Type 2 diabetes;
LUAD	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg15704280	chr7:45808275	SEPT13	0.68	8.96	0.4	1.02e-17	Axial length;
LUAD	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg09654669	chr8:57350985	NA	-0.65	-10.02	-0.44	2.42e-21	Obesity-related traits;
LUAD	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg08109568	chr15:31115862	NA	0.5	7.13	0.33	4.25e-12	Huntington's disease progression;
LUAD	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg22496339	chr2:162101262	NA	0.73	13.51	0.55	7.61e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	cis	rs9902453	0.935	rs9911794	chr17:28349466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-9.0	-0.4	7.96e-18	Coffee consumption (cups per day);
LUAD	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg14541582	chr5:601475	NA	-0.35	-7.55	-0.34	2.71e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs220324	0.688	rs9983766	chr21:43570667	C/T	cg09727148	chr21:43560719	UMODL1	0.48	7.41	0.34	6.99e-13	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg04455712	chr21:45112962	RRP1B	0.44	8.28	0.37	1.58e-15	Mean corpuscular volume;
LUAD	cis	rs4308124	0.708	rs10179596	chr2:111970380	G/A	cg04571233	chr2:111982156	NA	-0.46	-6.53	-0.3	1.84e-10	Vitiligo;
LUAD	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg02049041	chr17:27085579	C17orf63	-0.65	-8.76	-0.39	4.83e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.69	-11.89	-0.5	2.44e-28	Menarche (age at onset);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12785087	chr11:63705946	NAA40	-0.4	-6.4	-0.3	4.09e-10	Cancer;
LUAD	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg23018236	chr17:30244563	NA	-0.68	-8.33	-0.38	1.14e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg19717773	chr7:2847554	GNA12	-0.53	-10.43	-0.45	8.3e-23	Height;
LUAD	cis	rs1595825	0.945	rs76877032	chr2:198840000	G/A	cg00361562	chr2:198649771	BOLL	-0.47	-6.66	-0.31	8.63e-11	Ulcerative colitis;
LUAD	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg03433033	chr1:76189801	ACADM	-0.49	-7.31	-0.33	1.37e-12	Daytime sleep phenotypes;
LUAD	cis	rs10795061	0.576	rs12219804	chr10:3710626	C/T	cg22632523	chr10:3711048	NA	0.43	7.46	0.34	5.05e-13	Subjective well-being;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg07776409	chr17:27182127	ERAL1	0.42	6.51	0.3	2.14e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg18252515	chr7:66147081	NA	-0.63	-6.84	-0.32	2.86e-11	Diabetic kidney disease;
LUAD	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg03806693	chr22:41940476	POLR3H	-0.51	-7.46	-0.34	4.97e-13	Vitiligo;
LUAD	cis	rs6089584	0.546	rs6089308	chr20:60583529	C/T	cg06108461	chr20:60628389	TAF4	-0.75	-12.97	-0.53	1.22e-32	Body mass index;
LUAD	cis	rs113835537	0.529	rs17147644	chr11:66256660	C/T	cg24851651	chr11:66362959	CCS	0.56	9.79	0.43	1.52e-20	Airway imaging phenotypes;
LUAD	cis	rs2882667	0.858	rs11957633	chr5:138364394	T/C	cg04439458	chr5:138467593	SIL1	-0.51	-9.23	-0.41	1.33e-18	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg21823605	chr1:152486609	CRCT1	0.29	6.39	0.3	4.29e-10	Hair morphology;
LUAD	cis	rs7766641	1	rs7766641	chr6:26184102	G/A	cg13736514	chr6:26305472	NA	-0.47	-7.14	-0.33	4.22e-12	Height;
LUAD	cis	rs57994353	0.865	rs34376913	chr9:139378914	T/C	cg13856295	chr9:139396418	NOTCH1	-0.42	-6.62	-0.31	1.08e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs3936840	0.514	rs8007356	chr14:102975266	G/A	cg18135206	chr14:102964638	TECPR2	0.45	6.76	0.31	4.58e-11	Plateletcrit;
LUAD	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.34	7.35	0.34	1.04e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg21226059	chr5:178986404	RUFY1	0.54	9.07	0.4	4.41e-18	Lung cancer;
LUAD	cis	rs10493773	0.510	rs11161645	chr1:86092872	T/C	cg17807903	chr1:86174739	ZNHIT6	0.45	8.12	0.37	4.98e-15	Urate levels in overweight individuals;
LUAD	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg26384229	chr12:38710491	ALG10B	0.51	8.45	0.38	4.74e-16	Heart rate;
LUAD	cis	rs7937890	0.559	rs2575823	chr11:14521354	C/A	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.25e-11	Mitochondrial DNA levels;
LUAD	cis	rs2797160	1.000	rs1739349	chr6:126014984	G/C	cg05901451	chr6:126070800	HEY2	0.45	6.71	0.31	6.22e-11	Endometrial cancer;
LUAD	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg23254163	chr1:152506842	NA	0.26	7.12	0.33	4.53e-12	Hair morphology;
LUAD	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg12011299	chr4:100065546	ADH4	0.65	13.59	0.55	3.74e-35	Alcohol dependence;
LUAD	trans	rs11039798	1.000	rs10160423	chr11:48457227	G/T	cg15704280	chr7:45808275	SEPT13	0.65	7.66	0.35	1.29e-13	Axial length;
LUAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg08132940	chr7:1081526	C7orf50	-0.76	-10.36	-0.45	1.5e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.19	-0.41	1.77e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs354033	0.837	rs4727075	chr7:149187738	G/T	cg24335155	chr7:149193227	ZNF746	0.38	6.46	0.3	2.84e-10	Multiple sclerosis;
LUAD	trans	rs12439619	0.846	rs7496227	chr15:82567582	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.48	-6.46	-0.3	2.92e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg06784218	chr1:46089804	CCDC17	0.51	11.23	0.48	8.7e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg19862616	chr7:65841803	NCRNA00174	1.07	25.96	0.78	1.48e-89	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg19761014	chr17:28927070	LRRC37B2	-0.77	-9.02	-0.4	6.48e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg24818145	chr4:99064322	C4orf37	-0.48	-8.26	-0.37	1.96e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg26043149	chr18:55253948	FECH	1.05	19.22	0.68	1.19e-59	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg23262073	chr20:60523788	NA	-0.46	-8.02	-0.36	1.04e-14	Body mass index;
LUAD	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg04287289	chr16:89883240	FANCA	0.47	7.36	0.34	9.78e-13	Vitiligo;
LUAD	cis	rs929596	0.561	rs6431625	chr2:234637912	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-10.53	-0.46	3.38e-23	Total bilirubin levels in HIV-1 infection;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg13023681	chr2:10444156	HPCAL1	-0.38	-6.55	-0.3	1.7e-10	Subcortical brain region volumes;
LUAD	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.66	-0.31	8.51e-11	Crohn's disease;
LUAD	cis	rs3736594	0.879	rs4666011	chr2:27980912	G/C	cg27432699	chr2:27873401	GPN1	0.44	6.66	0.31	8.49e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg21770322	chr7:97807741	LMTK2	-0.34	-8.03	-0.36	9.92e-15	Breast cancer;
LUAD	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg13319975	chr6:146136371	FBXO30	-0.59	-9.97	-0.44	3.57e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg16606324	chr3:10149918	C3orf24	0.67	9.78	0.43	1.69e-20	Alzheimer's disease;
LUAD	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08048268	chr3:133502702	NA	-0.54	-10.55	-0.46	2.9e-23	Iron status biomarkers;
LUAD	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.42	6.91	0.32	1.79e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-14.51	-0.58	5.23e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03264133	chr6:25882463	NA	0.45	7.18	0.33	3.19e-12	Blood metabolite levels;
LUAD	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg17063962	chr7:91808500	NA	0.68	11.46	0.49	1.12e-26	Breast cancer;
LUAD	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	7.94e-19	Tonsillectomy;
LUAD	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg14558114	chr2:88469736	THNSL2	0.64	6.83	0.32	2.92e-11	Plasma clusterin levels;
LUAD	cis	rs1030268	0.505	rs80305547	chr7:133259400	A/G	cg10665199	chr7:133106180	EXOC4	0.47	6.59	0.31	1.32e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg09117114	chr16:67998030	SLC12A4	-0.57	-7.62	-0.35	1.68e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg08601574	chr20:25228251	PYGB	0.48	8.92	0.4	1.4e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06873352	chr17:61820015	STRADA	0.82	18.29	0.66	1.68e-55	Prudent dietary pattern;
LUAD	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg08219700	chr8:58056026	NA	0.69	8.97	0.4	9.72e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs8018808	0.870	rs11159264	chr14:77937017	T/C	cg20045696	chr14:77926864	AHSA1	0.36	6.36	0.3	5.3e-10	Myeloid white cell count;
LUAD	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg03037974	chr15:76606532	NA	0.38	8.19	0.37	3.05e-15	Blood metabolite levels;
LUAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg07677032	chr17:61819896	STRADA	0.55	9.97	0.44	3.66e-21	Prudent dietary pattern;
LUAD	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg03859395	chr2:55845619	SMEK2	0.77	14.4	0.57	1.51e-38	Metabolic syndrome;
LUAD	cis	rs73206853	0.841	rs11065663	chr12:110988886	G/T	cg12870014	chr12:110450643	ANKRD13A	0.6	6.94	0.32	1.49e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg04450456	chr4:17643702	FAM184B	0.42	8.3	0.37	1.42e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg02450064	chr17:40260053	DHX58	-0.44	-7.5	-0.34	3.9e-13	Fibrinogen levels;
LUAD	trans	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.59	-10.43	-0.45	7.84e-23	Mean corpuscular volume;
LUAD	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg18490616	chr2:88469792	THNSL2	-0.42	-6.71	-0.31	6.21e-11	Response to metformin (IC50);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00706444	chr3:48594638	PFKFB4	-0.38	-6.43	-0.3	3.44e-10	Cancer;
LUAD	cis	rs240764	0.578	rs6928418	chr6:101175347	T/C	cg09795085	chr6:101329169	ASCC3	0.39	6.48	0.3	2.57e-10	Neuroticism;
LUAD	cis	rs262150	0.625	rs55974535	chr7:158769145	C/G	cg09640425	chr7:158790006	NA	0.54	6.63	0.31	1.03e-10	Facial morphology (factor 20);
LUAD	cis	rs7582720	1.000	rs72936326	chr2:204054141	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.58	0.42	8.55e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg02931644	chr1:25747376	RHCE	0.41	8.5	0.38	3.27e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116161686	0.521	rs701941	chr1:210439529	G/A	cg22029157	chr1:209979665	IRF6	0.57	6.56	0.3	1.59e-10	Coronary artery disease;
LUAD	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg24733560	chr20:60626293	TAF4	-0.48	-9.65	-0.42	4.89e-20	Body mass index;
LUAD	trans	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17712092	chr4:129076599	LARP1B	0.93	17.58	0.65	2.4e-52	Eosinophil percentage of white cells;
LUAD	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21659725	chr3:3221576	CRBN	0.71	11.82	0.5	4.65e-28	Resting heart rate;
LUAD	cis	rs6782228	0.606	rs58977394	chr3:128337917	C/T	cg16766828	chr3:128327626	NA	-0.38	-7.12	-0.33	4.55e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg19774624	chr17:42201019	HDAC5	0.41	7.1	0.33	5.25e-12	Total body bone mineral density;
LUAD	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg06740227	chr12:86229804	RASSF9	0.4	7.14	0.33	4.15e-12	Major depressive disorder;
LUAD	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg11833968	chr6:79620685	NA	-0.44	-8.13	-0.37	4.8e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg15123519	chr2:136567270	LCT	-0.38	-6.76	-0.31	4.71e-11	Mosquito bite size;
LUAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg11941060	chr3:133502564	NA	-0.69	-12.82	-0.53	5.13e-32	Iron status biomarkers;
LUAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.67e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg04287289	chr16:89883240	FANCA	0.8	7.0	0.32	1.01e-11	Skin colour saturation;
LUAD	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg14895029	chr7:2775587	GNA12	-0.43	-6.91	-0.32	1.77e-11	Height;
LUAD	cis	rs9788721	0.836	rs72738732	chr15:78752188	C/G	cg18825076	chr15:78729989	IREB2	-0.6	-10.12	-0.44	1.05e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs10992471	0.528	rs2296666	chr9:95274261	C/T	cg14631576	chr9:95140430	CENPP	0.47	9.66	0.43	4.39e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg15181151	chr6:150070149	PCMT1	0.4	7.71	0.35	9.18e-14	Lung cancer;
LUAD	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg01097406	chr16:89675127	NA	-0.4	-8.06	-0.36	8.08e-15	Vitiligo;
LUAD	cis	rs6500395	0.926	rs8057164	chr16:48563466	A/G	cg04672837	chr16:48644449	N4BP1	0.39	6.69	0.31	6.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg07936489	chr17:37558343	FBXL20	-0.44	-6.78	-0.31	4.09e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs9715521	0.900	rs72634623	chr4:59827419	T/C	cg11281224	chr4:60001000	NA	-0.57	-9.68	-0.43	3.81e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4689388	0.793	rs4234731	chr4:6299914	A/G	cg25554036	chr4:6271136	WFS1	0.67	12.88	0.53	2.92e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg08807101	chr21:30365312	RNF160	-0.44	-7.48	-0.34	4.31e-13	Dental caries;
LUAD	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg26513180	chr16:89883248	FANCA	0.75	6.76	0.31	4.55e-11	Skin colour saturation;
LUAD	cis	rs727505	1.000	rs10246424	chr7:124494861	A/G	cg23710748	chr7:124431027	NA	-0.49	-9.92	-0.43	5.5e-21	Lewy body disease;
LUAD	cis	rs11118844	0.744	rs6655994	chr1:221933888	A/G	cg04222084	chr1:221915650	DUSP10	-0.71	-7.48	-0.34	4.4e-13	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	cis	rs910187	0.605	rs62201430	chr20:45808227	A/T	cg27589058	chr20:45804311	EYA2	-0.37	-8.32	-0.37	1.23e-15	Migraine;
LUAD	cis	rs2274273	0.624	rs8014540	chr14:55841688	C/A	cg04306507	chr14:55594613	LGALS3	0.41	7.91	0.36	2.24e-14	Protein biomarker;
LUAD	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.35	7.33	0.34	1.21e-12	Depression;
LUAD	cis	rs3784262	1.000	rs1372368	chr15:58297363	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.48	-9.73	-0.43	2.52e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs12995491	0.933	rs13008732	chr2:88528771	G/A	cg04511125	chr2:88470314	THNSL2	-0.45	-7.61	-0.35	1.77e-13	Response to metformin (IC50);
LUAD	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg19761014	chr17:28927070	LRRC37B2	0.86	8.61	0.39	1.42e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg05044414	chr3:183734942	ABCC5	-0.41	-8.15	-0.37	4.07e-15	Anterior chamber depth;
LUAD	cis	rs231513	0.954	rs231508	chr17:41967583	G/A	cg26893861	chr17:41843967	DUSP3	-0.54	-6.55	-0.3	1.65e-10	Cognitive function;
LUAD	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.76	0.39	4.7e-17	Menarche (age at onset);
LUAD	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11644478	chr21:40555479	PSMG1	0.72	12.29	0.51	6.89e-30	Cognitive function;
LUAD	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg01874867	chr7:94954059	PON1	-0.53	-7.25	-0.33	2.05e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg23625390	chr15:77176239	SCAPER	-0.58	-9.29	-0.41	8.19e-19	Blood metabolite levels;
LUAD	trans	rs853679	0.546	rs200995	chr6:27813694	C/T	cg06606381	chr12:133084897	FBRSL1	0.75	7.74	0.35	7.35e-14	Depression;
LUAD	cis	rs220324	0.738	rs9975104	chr21:43579344	G/T	cg09727148	chr21:43560719	UMODL1	0.55	7.85	0.36	3.49e-14	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg22963979	chr7:1858916	MAD1L1	0.5	8.32	0.38	1.19e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg22907277	chr7:1156413	C7orf50	0.56	7.13	0.33	4.41e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs77972916	0.536	rs6751209	chr2:43588302	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-8.15	-0.37	4.19e-15	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07167872	chr1:205819463	PM20D1	0.77	15.31	0.6	2.12e-42	Menarche (age at onset);
LUAD	cis	rs6961069	0.806	rs10480808	chr7:80250122	A/T	cg04458919	chr7:80252533	CD36	-0.36	-6.72	-0.31	6.04e-11	Platelet count;
LUAD	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg12011299	chr4:100065546	ADH4	0.71	13.37	0.55	2.87e-34	Alcohol dependence;
LUAD	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg22029157	chr1:209979665	IRF6	0.78	9.41	0.42	3.33e-19	Coronary artery disease;
LUAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg21951975	chr1:209979733	IRF6	0.59	9.47	0.42	1.98e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg22532475	chr10:104410764	TRIM8	0.35	7.19	0.33	2.94e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg15704280	chr7:45808275	SEPT13	0.78	12.15	0.51	2.45e-29	Coronary artery disease;
LUAD	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg11502198	chr6:26597334	ABT1	0.67	11.84	0.5	4.04e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs9837602	0.810	rs35885423	chr3:99813218	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	9.31	0.41	6.94e-19	Breast cancer;
LUAD	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg02734326	chr4:10020555	SLC2A9	-0.45	-7.66	-0.35	1.28e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs738322	0.532	rs9622746	chr22:38564041	C/G	cg25457927	chr22:38595422	NA	-0.5	-11.15	-0.48	1.73e-25	Cutaneous nevi;
LUAD	cis	rs698833	0.926	rs1067367	chr2:44654905	A/G	cg04920474	chr2:44395004	PPM1B	0.41	7.51	0.34	3.64e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg19041857	chr6:27730383	NA	-0.4	-6.7	-0.31	6.73e-11	Parkinson's disease;
LUAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg12373951	chr3:133503437	NA	0.37	7.4	0.34	7.39e-13	Iron status biomarkers;
LUAD	cis	rs4268898	1.000	rs10165445	chr2:24441698	C/T	cg06627628	chr2:24431161	ITSN2	0.46	7.86	0.36	3.11e-14	Asthma;
LUAD	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18876405	chr7:65276391	NA	-0.56	-9.45	-0.42	2.41e-19	Aortic root size;
LUAD	cis	rs17401966	0.931	rs4240911	chr1:10307453	A/G	cg19773385	chr1:10388646	KIF1B	-0.39	-6.42	-0.3	3.58e-10	Hepatocellular carcinoma;
LUAD	cis	rs1832871	0.711	rs9457300	chr6:158714609	G/C	cg07165851	chr6:158734300	TULP4	0.71	11.14	0.48	1.95e-25	Height;
LUAD	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg03878208	chr11:72483293	STARD10	0.48	6.97	0.32	1.2e-11	Type 2 diabetes;
LUAD	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg12311346	chr5:56204834	C5orf35	-0.92	-13.64	-0.55	2.32e-35	Initial pursuit acceleration;
LUAD	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg01191920	chr7:158217561	PTPRN2	0.62	12.93	0.53	1.9e-32	Obesity-related traits;
LUAD	cis	rs4604732	0.588	rs7549955	chr1:247628321	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.17	0.33	3.35e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7771547	0.547	rs1076931	chr6:36562021	G/C	cg07856975	chr6:36356162	ETV7	0.52	6.98	0.32	1.14e-11	Platelet distribution width;
LUAD	trans	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.69	12.19	0.51	1.67e-29	Mean corpuscular volume;
LUAD	cis	rs6460942	1.000	rs17191008	chr7:12417690	T/G	cg06484146	chr7:12443880	VWDE	-0.56	-6.75	-0.31	4.82e-11	Coronary artery disease;
LUAD	cis	rs10744422	0.858	rs7980541	chr12:123379477	C/T	cg16953816	chr12:123349952	VPS37B	0.58	6.57	0.3	1.46e-10	Schizophrenia;
LUAD	cis	rs250585	1.000	rs2040572	chr16:23529886	G/C	cg00143387	chr16:23521605	GGA2	-0.63	-7.49	-0.34	4.01e-13	Egg allergy;
LUAD	cis	rs11971779	0.584	rs17613864	chr7:139095587	C/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs73206853	0.764	rs56273026	chr12:110901691	A/C	cg12870014	chr12:110450643	ANKRD13A	0.6	6.65	0.31	8.93e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg18827107	chr12:86230957	RASSF9	-0.62	-10.97	-0.47	8.2e-25	Major depressive disorder;
LUAD	trans	rs3857536	0.813	rs6931701	chr6:66940905	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg03037974	chr15:76606532	NA	0.39	8.56	0.38	2.12e-16	Blood metabolite levels;
LUAD	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.37	7.33	0.34	1.15e-12	Depression;
LUAD	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg20933634	chr6:27740509	NA	0.53	8.03	0.36	9.56e-15	Parkinson's disease;
LUAD	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg13263323	chr15:86062960	AKAP13	-0.48	-8.84	-0.39	2.67e-17	Coronary artery disease;
LUAD	cis	rs7084921	0.552	rs7098331	chr10:101877961	T/G	cg19754520	chr10:101825118	CPN1	-0.32	-6.73	-0.31	5.43e-11	Bone mineral density;
LUAD	cis	rs17095355	0.818	rs11194981	chr10:111861054	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.64	-8.77	-0.39	4.3e-17	Biliary atresia;
LUAD	cis	rs2688608	0.869	rs2250140	chr10:75612881	T/C	cg23231163	chr10:75533350	FUT11	-0.45	-8.28	-0.37	1.68e-15	Inflammatory bowel disease;
LUAD	cis	rs7223966	0.621	rs72845875	chr17:61639269	T/C	cg11494091	chr17:61959527	GH2	0.36	6.51	0.3	2.14e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg17105886	chr17:28927953	LRRC37B2	0.83	8.14	0.37	4.34e-15	Body mass index;
LUAD	cis	rs7607369	0.637	rs3731866	chr2:219288899	C/T	cg02176678	chr2:219576539	TTLL4	-0.81	-15.69	-0.61	4.66e-44	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	7.55	0.34	2.75e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg23158103	chr7:148848205	ZNF398	-0.48	-8.24	-0.37	2.2e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7107174	1.000	rs2512549	chr11:77940163	A/G	cg19901956	chr11:77921274	USP35	0.48	6.82	0.31	3.1e-11	Testicular germ cell tumor;
LUAD	trans	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg13565492	chr6:43139072	SRF	-0.61	-6.47	-0.3	2.76e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg12193833	chr17:30244370	NA	-0.58	-6.87	-0.32	2.24e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg18230493	chr5:56204884	C5orf35	-0.45	-7.78	-0.35	5.57e-14	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.37	7.95	0.36	1.7e-14	Parkinson's disease;
LUAD	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg10169327	chr19:45448959	APOC2	0.37	7.5	0.34	3.68e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-7.88	-0.36	2.8e-14	Total body bone mineral density;
LUAD	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-6.72	-0.31	5.88e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg13047869	chr3:10149882	C3orf24	0.64	11.02	0.47	5.16e-25	Alzheimer's disease;
LUAD	trans	rs7246760	0.867	rs66943818	chr19:9746367	G/A	cg02900749	chr2:68251473	NA	-0.61	-6.61	-0.31	1.14e-10	Pursuit maintenance gain;
LUAD	trans	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg26043149	chr18:55253948	FECH	0.43	7.01	0.32	9.35e-12	Bone mineral density;
LUAD	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg03037974	chr15:76606532	NA	0.38	8.03	0.36	9.78e-15	Blood metabolite levels;
LUAD	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg13770153	chr20:60521292	NA	-0.48	-8.08	-0.37	6.98e-15	Body mass index;
LUAD	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg04398451	chr17:18023971	MYO15A	0.77	14.04	0.56	4.95e-37	Total body bone mineral density;
LUAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg04025307	chr7:1156635	C7orf50	0.6	6.77	0.31	4.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.39	7.24	0.33	2.11e-12	Lung cancer in ever smokers;
LUAD	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.76	0.31	4.45e-11	Parkinson's disease;
LUAD	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	10.62	0.46	1.7e-23	Blood metabolite levels;
LUAD	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08045932	chr20:61659980	NA	0.51	9.72	0.43	2.71e-20	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg08213375	chr14:104286397	PPP1R13B	0.28	7.23	0.33	2.31e-12	Schizophrenia;
LUAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg22764044	chr5:178986830	RUFY1	0.7	11.96	0.5	1.33e-28	Lung cancer;
LUAD	cis	rs9394841	0.536	rs6899876	chr6:41796970	A/G	cg17623882	chr6:41773611	USP49	-0.44	-6.52	-0.3	2.04e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg06740227	chr12:86229804	RASSF9	0.4	7.02	0.32	8.71e-12	Major depressive disorder;
LUAD	cis	rs35883536	0.626	rs10493933	chr1:101111282	A/G	cg06223162	chr1:101003688	GPR88	-0.41	-7.43	-0.34	6.21e-13	Monocyte count;
LUAD	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg15790184	chr11:494944	RNH1	0.55	6.87	0.32	2.32e-11	Body mass index;
LUAD	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05535760	chr7:792225	HEATR2	1.02	13.07	0.54	5.12e-33	Cerebrospinal P-tau181p levels;
LUAD	cis	rs1476679	0.927	rs2405442	chr7:99971313	T/C	cg22906224	chr7:99728672	NA	-0.48	-7.67	-0.35	1.19e-13	Alzheimer's disease (late onset);
LUAD	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.37	7.84	0.36	3.79e-14	Parkinson's disease;
LUAD	trans	rs11642282	0.558	rs2161727	chr16:79051702	G/T	cg21637392	chr7:5735123	RNF216	0.63	7.42	0.34	6.42e-13	Clozapine-induced cytotoxicity;
LUAD	cis	rs3772130	0.775	rs6769102	chr3:121560722	G/A	cg20356878	chr3:121714668	ILDR1	0.52	8.36	0.38	8.93e-16	Cognitive performance;
LUAD	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg09835421	chr16:68378352	PRMT7	-0.77	-8.33	-0.38	1.17e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9902453	0.689	rs56788338	chr17:28186557	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	10.17	0.44	6.9e-22	Coffee consumption (cups per day);
LUAD	cis	rs654950	0.792	rs625448	chr1:41988541	A/T	cg06885757	chr1:42089581	HIVEP3	0.34	7.17	0.33	3.34e-12	Airway imaging phenotypes;
LUAD	cis	rs870825	0.616	rs28500698	chr4:185627746	A/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg21724239	chr8:58056113	NA	0.75	9.88	0.43	7.48e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs427941	0.703	rs201446	chr7:101738323	C/G	cg06246474	chr7:101738831	CUX1	0.42	7.33	0.34	1.22e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.48	-8.26	-0.37	1.84e-15	Alzheimer's disease (late onset);
LUAD	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg23950597	chr19:37808831	NA	-0.6	-7.52	-0.34	3.32e-13	Coronary artery calcification;
LUAD	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.06	-0.32	6.83e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg16414030	chr3:133502952	NA	-0.52	-9.44	-0.42	2.61e-19	Iron status biomarkers;
LUAD	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg14582100	chr15:45693742	SPATA5L1	0.64	12.43	0.52	1.86e-30	Homoarginine levels;
LUAD	trans	rs7404843	0.789	rs222909	chr16:15499289	A/G	cg02716450	chr16:28638775	NA	0.71	8.5	0.38	3.37e-16	Testicular germ cell tumor;
LUAD	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg15962314	chr1:44399869	ARTN	0.3	6.87	0.32	2.36e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06873352	chr17:61820015	STRADA	0.56	9.08	0.4	4.04e-18	Height;
LUAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg13560548	chr3:10150139	C3orf24	0.44	6.73	0.31	5.62e-11	Alzheimer's disease;
LUAD	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18404041	chr3:52824283	ITIH1	-0.48	-9.77	-0.43	1.76e-20	Bipolar disorder;
LUAD	cis	rs17152411	0.895	rs7914206	chr10:126585397	G/A	cg07906193	chr10:126599966	NA	0.5	6.74	0.31	5.33e-11	Height;
LUAD	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg23262073	chr20:60523788	NA	-0.37	-6.58	-0.3	1.39e-10	Body mass index;
LUAD	cis	rs427941	0.632	rs201469	chr7:101743932	C/G	cg06246474	chr7:101738831	CUX1	0.4	6.89	0.32	1.99e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs6561151	0.718	rs11842000	chr13:44413467	T/C	cg17145862	chr1:211918768	LPGAT1	0.53	6.71	0.31	6.21e-11	Crohn's disease;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg14115740	chr9:98054883	FANCC	-0.4	-6.76	-0.31	4.51e-11	Schizophrenia;
LUAD	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg23985595	chr17:80112537	CCDC57	0.53	9.74	0.43	2.39e-20	Life satisfaction;
LUAD	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg24733560	chr20:60626293	TAF4	0.43	7.59	0.35	2.05e-13	Body mass index;
LUAD	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg18198730	chr1:247681584	NA	-0.42	-7.63	-0.35	1.54e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs62400317	0.859	rs62438864	chr6:45041787	G/A	cg20913747	chr6:44695427	NA	-0.42	-6.69	-0.31	7.19e-11	Total body bone mineral density;
LUAD	cis	rs2066819	1.000	rs75265219	chr12:56640341	G/A	cg26714650	chr12:56694279	CS	-0.84	-7.17	-0.33	3.39e-12	Psoriasis vulgaris;
LUAD	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-13.39	-0.55	2.38e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg05340658	chr4:99064831	C4orf37	0.51	8.5	0.38	3.3e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5756391	0.568	rs7410682	chr22:37317258	A/G	cg16356956	chr22:37317934	CSF2RB	0.31	6.59	0.31	1.29e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	trans	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg05590025	chr7:65112418	INTS4L2	-0.78	-8.16	-0.37	3.75e-15	Gout;
LUAD	cis	rs61897795	0.628	rs174579	chr11:61605613	C/T	cg06781209	chr11:61594997	FADS2	-0.49	-7.75	-0.35	7.01e-14	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs13064411	0.518	rs1471884	chr3:113212041	G/A	cg18753928	chr3:113234510	CCDC52	-0.48	-8.75	-0.39	5.23e-17	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs1832871	0.541	rs56182595	chr6:158895680	T/A	cg07165851	chr6:158734300	TULP4	0.52	7.56	0.34	2.58e-13	Height;
LUAD	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.56	-0.3	1.56e-10	Mood instability;
LUAD	cis	rs9715521	0.835	rs9714848	chr4:59824650	C/T	cg11281224	chr4:60001000	NA	-0.56	-9.51	-0.42	1.5e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg06697600	chr4:7070879	GRPEL1	0.53	7.58	0.35	2.14e-13	Monocyte percentage of white cells;
LUAD	cis	rs12042938	0.507	rs1765776	chr1:231731607	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.41	-7.21	-0.33	2.67e-12	Neuranatomic and neurocognitive phenotypes;
LUAD	cis	rs3125734	0.572	rs3864794	chr10:64041956	A/C	cg19640130	chr10:64028056	RTKN2	-0.36	-7.83	-0.36	4.08e-14	Rheumatoid arthritis;
LUAD	cis	rs7264396	1.000	rs224424	chr20:34147998	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.46	-0.3	2.96e-10	Total cholesterol levels;
LUAD	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg13334819	chr7:99746414	C7orf59	-0.65	-10.47	-0.45	5.66e-23	Coronary artery disease;
LUAD	trans	rs62103177	0.561	rs891488	chr18:77637424	T/C	cg05926928	chr17:57297772	GDPD1	-0.73	-9.69	-0.43	3.58e-20	Opioid sensitivity;
LUAD	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg14582100	chr15:45693742	SPATA5L1	0.43	8.65	0.39	1.11e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg04586622	chr2:25135609	ADCY3	0.38	8.51	0.38	3e-16	Body mass index;
LUAD	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg17173187	chr15:85201210	NMB	0.53	9.33	0.41	6.16e-19	Schizophrenia;
LUAD	cis	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg26958806	chr6:27640298	NA	0.64	6.35	0.3	5.45e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17532515	0.505	rs12645922	chr4:141496237	T/C	cg09181644	chr4:141490428	UCP1	0.36	7.27	0.33	1.81e-12	Select biomarker traits;
LUAD	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg00809820	chr17:80708513	TBCD;FN3K	-0.39	-6.94	-0.32	1.5e-11	Glycated hemoglobin levels;
LUAD	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.46	-7.33	-0.34	1.16e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg10589385	chr1:150898437	SETDB1	0.42	7.73	0.35	8.13e-14	Melanoma;
LUAD	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27286337	chr10:134555280	INPP5A	0.73	9.41	0.42	3.12e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg17366294	chr4:99064904	C4orf37	0.71	13.31	0.54	5.17e-34	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9611519	0.828	rs9611460	chr22:41418297	T/C	cg13813247	chr22:41461852	NA	-0.48	-7.13	-0.33	4.46e-12	Neuroticism;
LUAD	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg26373071	chr5:1325741	CLPTM1L	-0.38	-7.76	-0.35	6.51e-14	Lung cancer;
LUAD	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg00321850	chr1:175162397	KIAA0040	-0.51	-11.11	-0.48	2.56e-25	Alcohol dependence;
LUAD	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg27432699	chr2:27873401	GPN1	-0.4	-6.86	-0.32	2.41e-11	Total body bone mineral density;
LUAD	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg17644776	chr2:200775616	C2orf69	-0.53	-6.66	-0.31	8.36e-11	Schizophrenia;
LUAD	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg15309053	chr8:964076	NA	0.32	6.92	0.32	1.69e-11	Schizophrenia;
LUAD	cis	rs2131877	0.956	rs12631516	chr3:194872631	T/G	cg19760965	chr3:194868843	C3orf21	0.39	6.55	0.3	1.69e-10	Non-small cell lung cancer;
LUAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.16	0.41	2.31e-18	Alzheimer's disease;
LUAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.55e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg05805236	chr11:65401703	PCNXL3	-0.54	-9.14	-0.41	2.59e-18	Acne (severe);
LUAD	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-9.19	-0.41	1.84e-18	Bipolar disorder;
LUAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13732083	chr21:47605072	C21orf56	0.53	9.27	0.41	9.37e-19	Testicular germ cell tumor;
LUAD	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.65	-10.44	-0.45	7.41e-23	IgG glycosylation;
LUAD	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg08601574	chr20:25228251	PYGB	0.46	8.8	0.39	3.41e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs757647	0.723	rs740074	chr5:137684330	C/T	cg10676309	chr5:137685565	NA	0.4	7.24	0.33	2.07e-12	Menarche (age at onset);
LUAD	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg26338869	chr17:61819248	STRADA	-0.39	-6.58	-0.3	1.39e-10	Prudent dietary pattern;
LUAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg24642844	chr7:1081250	C7orf50	-0.98	-14.82	-0.58	2.67e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-20.06	-0.7	2.23e-63	Height;
LUAD	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.71	-12.16	-0.51	2.23e-29	Menarche (age at onset);
LUAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg13560548	chr3:10150139	C3orf24	0.4	6.7	0.31	6.86e-11	Alzheimer's disease;
LUAD	cis	rs7267979	1.000	rs448396	chr20:25440269	G/A	cg08601574	chr20:25228251	PYGB	0.47	8.7	0.39	7.64e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	9.63	0.42	5.79e-20	Electrocardiographic conduction measures;
LUAD	cis	rs2658782	0.789	rs2605574	chr11:93136444	T/G	cg15737290	chr11:93063684	CCDC67	0.49	7.48	0.34	4.37e-13	Pulmonary function decline;
LUAD	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg17366294	chr4:99064904	C4orf37	0.47	8.38	0.38	8.17e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7274811	0.652	rs293732	chr20:31975090	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	0.48	7.21	0.33	2.67e-12	Height;
LUAD	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg00316803	chr15:76480434	C15orf27	-0.42	-8.37	-0.38	8.32e-16	Blood metabolite levels;
LUAD	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg18404041	chr3:52824283	ITIH1	-0.42	-7.75	-0.35	6.88e-14	Electroencephalogram traits;
LUAD	cis	rs12545109	0.800	rs1371936	chr8:57422715	A/G	cg19413350	chr8:57351067	NA	-0.45	-6.84	-0.32	2.72e-11	Obesity-related traits;
LUAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg13271783	chr10:134563150	INPP5A	-0.41	-6.59	-0.31	1.28e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00166722	chr3:10149974	C3orf24	0.67	11.04	0.47	4.43e-25	Alzheimer's disease;
LUAD	cis	rs250677	0.522	rs56309414	chr5:148376026	C/G	cg12140854	chr5:148520817	ABLIM3	-0.56	-8.68	-0.39	8.81e-17	Breast cancer;
LUAD	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg26513180	chr16:89883248	FANCA	0.78	6.74	0.31	5.14e-11	Skin colour saturation;
LUAD	cis	rs9826463	0.757	rs113288103	chr3:142175321	C/T	cg20824294	chr3:142316082	PLS1	0.43	7.37	0.34	9.12e-13	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg00083206	chr6:110721305	DDO	0.43	7.97	0.36	1.45e-14	Platelet distribution width;
LUAD	cis	rs7621025	0.500	rs1965107	chr3:136648643	T/A	cg15507776	chr3:136538369	TMEM22	0.6	9.58	0.42	8.51e-20	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUAD	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg00647820	chr17:40259828	DHX58	-0.42	-6.66	-0.31	8.39e-11	Fibrinogen levels;
LUAD	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06112835	chr11:68658793	MRPL21	0.51	9.42	0.42	2.96e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11650494	0.831	rs73324348	chr17:47455752	G/A	cg08112188	chr17:47440006	ZNF652	0.89	7.83	0.36	3.83e-14	Prostate cancer;
LUAD	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg05425664	chr17:57184151	TRIM37	0.39	6.78	0.31	4.05e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg03806693	chr22:41940476	POLR3H	0.74	9.98	0.44	3.25e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg12016809	chr21:47604291	C21orf56	0.45	7.51	0.34	3.64e-13	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg11062466	chr8:58055876	NA	0.7	8.74	0.39	5.56e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9462027	0.628	rs7739003	chr6:34800329	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.67	-0.39	9.45e-17	Systemic lupus erythematosus;
LUAD	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23221052	chr5:179740743	GFPT2	0.65	10.75	0.46	5.36e-24	Height;
LUAD	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg25358565	chr5:93447407	FAM172A	0.58	6.77	0.31	4.31e-11	Diabetic retinopathy;
LUAD	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.45	-6.5	-0.3	2.23e-10	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg20607798	chr8:58055168	NA	0.72	9.44	0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10207060	0.500	rs72992164	chr2:240711780	G/A	cg07506560	chr2:240697449	NA	0.39	6.52	0.3	1.96e-10	Obesity-related traits;
LUAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg05457628	chr5:178986728	RUFY1	-0.66	-11.38	-0.48	2.28e-26	Lung cancer;
LUAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg13047869	chr3:10149882	C3orf24	0.69	11.84	0.5	3.86e-28	Alzheimer's disease;
LUAD	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.2	-0.33	2.73e-12	Total body bone mineral density;
LUAD	trans	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs7659604	0.540	rs13140070	chr4:122713899	C/T	cg06713675	chr4:122721982	EXOSC9	0.45	8.2	0.37	2.86e-15	Type 2 diabetes;
LUAD	cis	rs4638749	0.627	rs4676185	chr2:108841908	G/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.33	-0.34	1.19e-12	Blood pressure;
LUAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08280861	chr8:58055591	NA	0.78	9.96	0.44	3.9e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg05872129	chr22:39784769	NA	-0.53	-8.88	-0.4	1.92e-17	IgG glycosylation;
LUAD	cis	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.23	-0.33	2.29e-12	Resting heart rate;
LUAD	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.87	-11.22	-0.48	9.14e-26	Lung cancer in ever smokers;
LUAD	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18876405	chr7:65276391	NA	-0.59	-9.97	-0.44	3.68e-21	Aortic root size;
LUAD	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	6.8	0.31	3.62e-11	Tonsillectomy;
LUAD	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg09835421	chr16:68378352	PRMT7	-0.55	-6.92	-0.32	1.72e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg06623918	chr6:96969491	KIAA0776	0.89	17.71	0.65	6.38e-53	Headache;
LUAD	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg21385522	chr1:16154831	NA	-1.02	-20.98	-0.71	1.67e-67	Dilated cardiomyopathy;
LUAD	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03188948	chr7:1209495	NA	0.46	7.66	0.35	1.28e-13	Longevity;Endometriosis;
LUAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06873352	chr17:61820015	STRADA	0.81	17.7	0.65	7.39e-53	Prudent dietary pattern;
LUAD	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.65	-0.39	1.05e-16	Total body bone mineral density;
LUAD	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.6	-8.87	-0.4	2.04e-17	Gut microbiome composition (summer);
LUAD	cis	rs9341808	0.591	rs7741013	chr6:80916330	G/A	cg08355045	chr6:80787529	NA	0.49	8.74	0.39	5.54e-17	Sitting height ratio;
LUAD	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg18180107	chr4:99064573	C4orf37	0.43	6.81	0.31	3.36e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg19729930	chr2:74357872	NA	1.02	18.69	0.67	2.82e-57	Gestational age at birth (maternal effect);
LUAD	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg08470875	chr2:26401718	FAM59B	-0.6	-8.2	-0.37	2.96e-15	Gut microbiome composition (summer);
LUAD	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg25208724	chr1:156163844	SLC25A44	1.01	17.96	0.66	5.19e-54	Testicular germ cell tumor;
LUAD	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg05044414	chr3:183734942	ABCC5	0.48	9.89	0.43	6.73e-21	Anterior chamber depth;
LUAD	cis	rs2361710	0.611	rs12051781	chr17:78074468	A/G	cg06718696	chr17:78121285	EIF4A3	0.44	7.06	0.32	6.67e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18123596	chr17:36956264	PIP4K2B	0.49	7.75	0.35	6.98e-14	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg27490568	chr2:178487706	NA	-0.42	-7.03	-0.32	8.19e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg05926928	chr17:57297772	GDPD1	1.41	19.78	0.69	4.08e-62	Opioid sensitivity;
LUAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg05457628	chr5:178986728	RUFY1	-0.63	-11.24	-0.48	8.14e-26	Lung cancer;
LUAD	trans	rs459571	0.959	rs408307	chr9:136892523	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.6	8.79	0.39	3.82e-17	Platelet distribution width;
LUAD	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-7.18	-0.33	3.18e-12	Monocyte percentage of white cells;
LUAD	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19717773	chr7:2847554	GNA12	-0.52	-8.83	-0.39	2.89e-17	Height;
LUAD	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg13319975	chr6:146136371	FBXO30	0.61	10.58	0.46	2.29e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg20701182	chr2:24300061	SF3B14	0.54	6.56	0.3	1.57e-10	Lymphocyte counts;
LUAD	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg23254163	chr1:152506842	NA	0.26	7.17	0.33	3.28e-12	Hair morphology;
LUAD	cis	rs12413816	0.963	rs10796116	chr10:13762786	C/T	cg16485048	chr10:13749193	FRMD4A	-0.42	-7.62	-0.35	1.74e-13	Red cell distribution width;
LUAD	cis	rs12519773	0.597	rs17360518	chr5:92457899	A/C	cg18783429	chr5:92414398	NA	0.48	8.56	0.38	2.08e-16	Migraine;
LUAD	cis	rs7172118	1	rs7172118	chr15:78862453	C/A	cg18825076	chr15:78729989	IREB2	-0.56	-9.08	-0.4	4.03e-18	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg08888203	chr3:10149979	C3orf24	0.74	12.88	0.53	2.93e-32	Alzheimer's disease;
LUAD	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg02733842	chr7:1102375	C7orf50	-0.7	-10.36	-0.45	1.45e-22	Bronchopulmonary dysplasia;
LUAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg13012494	chr21:47604986	C21orf56	0.46	7.58	0.35	2.26e-13	Testicular germ cell tumor;
LUAD	cis	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg07460842	chr6:66804631	NA	-1.17	-27.85	-0.8	1.03e-97	Exhaled nitric oxide output;
LUAD	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg14092571	chr14:90743983	NA	0.5	8.97	0.4	9.47e-18	Mortality in heart failure;
LUAD	cis	rs7301826	0.651	rs10848210	chr12:131312020	G/A	cg11011512	chr12:131303247	STX2	0.43	7.27	0.33	1.8e-12	Plasma plasminogen activator levels;
LUAD	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg02228675	chr17:40259724	DHX58	-0.45	-7.44	-0.34	5.8e-13	Fibrinogen levels;
LUAD	cis	rs3087591	1.000	rs9904169	chr17:29572518	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.43	-7.0	-0.32	9.88e-12	Hip circumference;
LUAD	trans	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg01620082	chr3:125678407	NA	-0.71	-7.15	-0.33	3.79e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1639906	0.965	rs1637742	chr7:2236432	G/A	cg18044113	chr7:2236405	MAD1L1	-0.39	-7.59	-0.35	2.11e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4638749	0.677	rs13398290	chr2:108833853	G/T	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.41	-0.34	6.95e-13	Blood pressure;
LUAD	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg26818010	chr10:134567672	INPP5A	-0.98	-16.04	-0.61	1.43e-45	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	trans	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg26043149	chr18:55253948	FECH	-0.53	-8.56	-0.38	2.15e-16	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg00933542	chr6:150070202	PCMT1	0.44	9.68	0.43	3.63e-20	Lung cancer;
LUAD	cis	rs6484504	0.576	rs208066	chr11:31156206	C/G	cg14844989	chr11:31128820	NA	-0.46	-8.18	-0.37	3.46e-15	Red blood cell count;
LUAD	cis	rs2629540	0.889	rs4962699	chr10:126477209	A/G	cg08799069	chr10:126477246	METTL10	-0.48	-7.41	-0.34	7.07e-13	Cocaine dependence;
LUAD	cis	rs2073300	1.000	rs12625804	chr20:23441981	G/A	cg12062639	chr20:23401060	NAPB	1.0	9.21	0.41	1.47e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg07208322	chr5:177027175	B4GALT7	-0.37	-6.35	-0.3	5.5e-10	Schizophrenia;
LUAD	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08109568	chr15:31115862	NA	-0.6	-10.13	-0.44	9.9700000000000009e-22	Huntington's disease progression;
LUAD	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg24675056	chr1:15929824	NA	0.5	8.72	0.39	6.23e-17	Systolic blood pressure;
LUAD	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg12011299	chr4:100065546	ADH4	0.7	12.61	0.52	3.55e-31	Smoking initiation;
LUAD	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-7.41	-0.34	7.05e-13	Lung cancer;
LUAD	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg03676636	chr4:99064102	C4orf37	0.32	8.38	0.38	7.84e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg06623918	chr6:96969491	KIAA0776	0.72	11.06	0.47	3.88e-25	Migraine;Coronary artery disease;
LUAD	cis	rs17102423	0.594	rs2781374	chr14:65568563	C/T	cg16583315	chr14:65563665	MAX	-0.36	-6.76	-0.31	4.63e-11	Obesity-related traits;
LUAD	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg05340658	chr4:99064831	C4orf37	0.45	7.47	0.34	4.69e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg06618935	chr21:46677482	NA	0.5	10.11	0.44	1.1e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs877282	0.838	rs11253373	chr10:774857	A/G	cg17470449	chr10:769945	NA	0.66	9.62	0.42	6.29e-20	Uric acid levels;
LUAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs758324	0.812	rs494349	chr5:131260452	C/A	cg25547332	chr5:131281432	NA	-0.42	-6.77	-0.31	4.35e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7659604	0.540	rs11934307	chr4:122677514	G/A	cg06713675	chr4:122721982	EXOSC9	0.42	7.67	0.35	1.17e-13	Type 2 diabetes;
LUAD	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg21775007	chr8:11205619	TDH	-0.39	-6.82	-0.31	3.18e-11	Neuroticism;
LUAD	cis	rs9649213	0.614	rs2240348	chr7:97984077	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.73	-11.0	-0.47	6.41e-25	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.74	-0.35	7.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg04568274	chr7:158649319	WDR60	0.4	6.56	0.3	1.57e-10	Height;
LUAD	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg02158880	chr13:53174818	NA	0.61	10.79	0.46	3.95e-24	Lewy body disease;
LUAD	cis	rs6499255	1.000	rs55992518	chr16:69821407	C/T	cg15192750	chr16:69999425	NA	0.55	8.76	0.39	4.92e-17	IgE levels;
LUAD	cis	rs11771526	0.686	rs62457501	chr7:32329946	A/G	cg13207630	chr7:32358064	NA	0.66	7.9	0.36	2.39e-14	Body mass index;
LUAD	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg06558623	chr16:89946397	TCF25	1.15	10.75	0.46	5.41e-24	Skin colour saturation;
LUAD	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg22532475	chr10:104410764	TRIM8	-0.35	-7.02	-0.32	8.75e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs17169635	0.601	rs1377297	chr7:134546119	A/C	cg07876788	chr7:134849633	TMEM140	-0.38	-6.49	-0.3	2.46e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.2	-0.51	1.59e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs977987	0.806	rs11641587	chr16:75464419	G/T	cg03315344	chr16:75512273	CHST6	0.64	13.99	0.56	7.87e-37	Dupuytren's disease;
LUAD	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.34	6.8	0.31	3.69e-11	Obesity-related traits;
LUAD	trans	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg06606381	chr12:133084897	FBRSL1	-0.95	-9.12	-0.41	3.17e-18	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg04017836	chr7:65315216	NA	-0.42	-6.77	-0.31	4.45e-11	Height;
LUAD	cis	rs2050392	1.000	rs2250714	chr10:30697396	G/C	cg18806716	chr10:30721971	MAP3K8	-0.51	-10.2	-0.44	5.41e-22	Inflammatory bowel disease;
LUAD	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg00933542	chr6:150070202	PCMT1	0.39	8.03	0.36	9.76e-15	Lung cancer;
LUAD	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.28	0.33	1.66e-12	Obesity-related traits;
LUAD	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg00071950	chr4:10020882	SLC2A9	0.74	14.9	0.59	1.18e-40	Bone mineral density;
LUAD	cis	rs77972916	0.505	rs6719754	chr2:43526386	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-10.22	-0.45	4.55e-22	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg07831432	chr5:179125659	CANX	-0.42	-7.13	-0.33	4.42e-12	Subcortical brain region volumes;
LUAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg10729496	chr3:10149963	C3orf24	0.57	9.52	0.42	1.35e-19	Alzheimer's disease;
LUAD	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg15017067	chr4:17643749	FAM184B	0.34	6.44	0.3	3.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs7246760	0.867	rs55846005	chr19:9796709	T/A	cg02900749	chr2:68251473	NA	-0.59	-6.56	-0.3	1.59e-10	Pursuit maintenance gain;
LUAD	cis	rs8017423	0.967	rs4904662	chr14:90729427	G/A	cg14092571	chr14:90743983	NA	-0.48	-8.28	-0.37	1.68e-15	Mortality in heart failure;
LUAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg09509183	chr1:209979624	IRF6	0.59	8.93	0.4	1.33e-17	Cleft lip with or without cleft palate;
LUAD	trans	rs2262909	0.925	rs73019838	chr19:22247732	T/A	cg05197062	chr11:11642011	GALNTL4	0.59	9.06	0.4	4.83e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs55788414	0.932	rs57461213	chr16:81185419	G/C	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.91	-0.36	2.31e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	trans	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg18187862	chr3:45730750	SACM1L	0.5	7.89	0.36	2.55e-14	Primary sclerosing cholangitis;
LUAD	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg09117114	chr16:67998030	SLC12A4	-0.63	-8.46	-0.38	4.25e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg02508848	chr16:68573721	ZFP90	-0.44	-6.61	-0.31	1.19e-10	Ulcerative colitis;
LUAD	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	8.45	0.38	4.91e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.81	0.35	4.6e-14	Depression;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01803856	chr17:650796	GEMIN4	0.47	6.55	0.3	1.64e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7274811	0.901	rs55990870	chr20:32302908	C/T	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.46	-6.37	-0.3	4.92e-10	Height;
LUAD	cis	rs7903847	0.642	rs11189177	chr10:99141663	C/T	cg20016023	chr10:99160130	RRP12	-0.3	-7.12	-0.33	4.78e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg11189052	chr15:85197271	WDR73	0.59	7.61	0.35	1.84e-13	Schizophrenia;
LUAD	trans	rs9929218	1.000	rs28660361	chr16:68800838	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.69	-0.55	1.48e-35	Colorectal cancer;
LUAD	cis	rs9517302	0.615	rs9517306	chr13:99097962	T/C	cg22223119	chr13:99095684	FARP1	-0.69	-10.46	-0.45	6.28e-23	Obesity-related traits;
LUAD	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg04455712	chr21:45112962	RRP1B	0.4	8.3	0.37	1.38e-15	Mean corpuscular volume;
LUAD	cis	rs10899021	1.000	rs10899025	chr11:74367040	G/A	cg25880958	chr11:74394337	NA	-0.62	-8.15	-0.37	4.1e-15	Response to metformin (IC50);
LUAD	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg09117114	chr16:67998030	SLC12A4	-0.49	-6.97	-0.32	1.24e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg18132916	chr6:79620363	NA	-0.46	-7.91	-0.36	2.3e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg17691542	chr6:26056736	HIST1H1C	0.46	6.37	0.3	4.96e-10	Iron status biomarkers;
LUAD	cis	rs1215050	0.791	rs649866	chr4:98738826	T/C	cg05340658	chr4:99064831	C4orf37	0.43	7.24	0.33	2.15e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg06547715	chr2:218990976	CXCR2	0.28	6.56	0.3	1.54e-10	Colorectal cancer;
LUAD	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg18230493	chr5:56204884	C5orf35	-0.58	-9.43	-0.42	2.66e-19	Coronary artery disease;
LUAD	cis	rs71403859	0.502	rs12927006	chr16:71549911	A/G	cg08717414	chr16:71523259	ZNF19	-0.63	-7.84	-0.36	3.79e-14	Post bronchodilator FEV1;
LUAD	cis	rs2235649	0.663	rs113908028	chr16:1848915	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-8.18	-0.37	3.42e-15	Blood metabolite levels;
LUAD	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg22117172	chr7:91764530	CYP51A1	0.38	8.32	0.37	1.24e-15	Breast cancer;
LUAD	cis	rs9875589	0.509	rs6442423	chr3:14016062	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.35	6.43	0.3	3.5e-10	Ovarian reserve;
LUAD	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg08213375	chr14:104286397	PPP1R13B	0.28	7.22	0.33	2.41e-12	Schizophrenia;
LUAD	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.68	-0.39	8.73e-17	Alzheimer's disease (late onset);
LUAD	cis	rs7107174	0.901	rs10899493	chr11:78117534	T/C	cg19901956	chr11:77921274	USP35	-0.47	-6.65	-0.31	9.29e-11	Testicular germ cell tumor;
LUAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg13560548	chr3:10150139	C3orf24	0.42	6.99	0.32	1.09e-11	Alzheimer's disease;
LUAD	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg16988262	chr1:15930761	NA	0.42	6.98	0.32	1.15e-11	Systolic blood pressure;
LUAD	cis	rs4843185	0.769	rs12149168	chr16:85705611	A/C	cg26571870	chr16:85723150	GINS2	0.33	6.79	0.31	3.78e-11	Platelet distribution width;
LUAD	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.11	-0.44	1.2e-21	Migraine;Coronary artery disease;
LUAD	cis	rs1832871	0.512	rs28639499	chr6:158874950	A/G	cg07165851	chr6:158734300	TULP4	0.53	7.53	0.34	3.19e-13	Height;
LUAD	cis	rs7779181	1.000	rs7779181	chr7:32345283	T/C	cg13207630	chr7:32358064	NA	0.44	6.69	0.31	7.17e-11	Body mass index;
LUAD	cis	rs11030122	0.702	rs1452047	chr11:3991648	A/C	cg18678763	chr11:4115507	RRM1	-0.44	-7.15	-0.33	3.88e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg06606381	chr12:133084897	FBRSL1	-1.01	-9.79	-0.43	1.58e-20	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg08873628	chr1:175162347	KIAA0040	0.4	6.73	0.31	5.43e-11	Alcohol dependence;
LUAD	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg05340658	chr4:99064831	C4orf37	0.42	7.01	0.32	9.25e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs943466	1.000	rs6930201	chr6:33738749	A/C	cg16010596	chr6:33739607	LEMD2	-0.42	-8.36	-0.38	8.97e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs12620999	0.878	rs59725626	chr2:237970010	G/A	cg23555395	chr2:238036564	NA	0.59	9.23	0.41	1.29e-18	Systemic lupus erythematosus;
LUAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg07414643	chr4:187882934	NA	0.33	6.73	0.31	5.55e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg06627628	chr2:24431161	ITSN2	-0.67	-10.7	-0.46	7.97e-24	Asthma;
LUAD	cis	rs3790645	0.831	rs873151	chr1:26880989	T/C	cg23229016	chr1:26872525	RPS6KA1	0.21	6.88	0.32	2.22e-11	Glucose homeostasis traits;
LUAD	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg24801067	chr17:62843696	NA	-0.54	-7.47	-0.34	4.7e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg14092988	chr3:52407081	DNAH1	0.45	9.05	0.4	5.24e-18	Bipolar disorder;
LUAD	cis	rs1485395	0.588	rs7969195	chr12:53942789	G/A	cg20730629	chr12:53886622	MAP3K12	-0.46	-6.56	-0.3	1.62e-10	Migraine without aura;
LUAD	cis	rs870825	0.616	rs6552809	chr4:185643984	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	13.97	0.56	9.56e-37	Blood protein levels;
LUAD	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg22166914	chr1:53195759	ZYG11B	0.47	7.78	0.35	5.63e-14	Monocyte count;
LUAD	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.65	0.31	8.87e-11	Joint mobility (Beighton score);
LUAD	cis	rs9972944	0.756	rs2318868	chr17:63767592	G/T	cg07283582	chr17:63770753	CCDC46	-0.5	-11.18	-0.48	1.28e-25	Total body bone mineral density;
LUAD	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg11584989	chr19:19387371	SF4	0.62	9.59	0.42	7.8500000000000006e-20	Bipolar disorder;
LUAD	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg10356904	chr22:49881777	NA	-0.38	-8.22	-0.37	2.44e-15	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs1997103	1.000	rs12718956	chr7:55407763	A/G	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg13073564	chr4:8508604	NA	0.63	11.38	0.48	2.3e-26	Response to antineoplastic agents;
LUAD	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.86	12.35	0.51	4.08e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs644148	0.836	rs2686770	chr19:44998773	A/G	cg15540054	chr19:45004280	ZNF180	-0.43	-6.78	-0.31	4.16e-11	Personality dimensions;
LUAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03407747	chr17:6899364	ALOX12	0.39	7.31	0.33	1.33e-12	Tonsillectomy;
LUAD	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26314531	chr2:26401878	FAM59B	0.72	9.71	0.43	3.04e-20	Gut microbiome composition (summer);
LUAD	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg00071950	chr4:10020882	SLC2A9	-0.76	-15.29	-0.6	2.54e-42	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4700695	0.719	rs36923	chr5:65464783	G/C	cg21114390	chr5:65439923	SFRS12	-0.9	-13.49	-0.55	9.53e-35	Facial morphology (factor 19);
LUAD	cis	rs9811920	0.742	rs2316263	chr3:99900096	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.48	8.94	0.4	1.25e-17	Axial length;
LUAD	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg02176678	chr2:219576539	TTLL4	0.68	13.43	0.55	1.69e-34	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg15445000	chr17:37608096	MED1	-0.44	-8.26	-0.37	1.87e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs7187994	0.848	rs12448489	chr16:84774022	G/A	cg07647771	chr16:84786436	USP10	-0.37	-9.07	-0.4	4.43e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg11584989	chr19:19387371	SF4	-0.39	-6.79	-0.31	3.85e-11	Tonsillectomy;
LUAD	trans	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.78	-0.46	4.08e-24	Obesity-related traits;
LUAD	trans	rs34546498	1	rs34546498	chr6:26961280	C/T	cg01620082	chr3:125678407	NA	-1.01	-8.94	-0.4	1.18e-17	Breast cancer;
LUAD	cis	rs7487075	0.619	rs4768723	chr12:46845724	C/T	cg23829395	chr12:46796953	NA	0.3	6.36	0.3	5.21e-10	Itch intensity from mosquito bite;
LUAD	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg14835575	chr10:16859367	RSU1	0.98	14.24	0.57	7.19e-38	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs12200560	0.505	rs11153095	chr6:97078592	T/C	cg06623918	chr6:96969491	KIAA0776	-0.45	-6.94	-0.32	1.43e-11	Coronary heart disease;
LUAD	cis	rs13082711	0.520	rs2643825	chr3:27562613	A/G	cg02860705	chr3:27208620	NA	0.44	6.61	0.31	1.19e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs9354308	0.901	rs55832318	chr6:66560086	A/G	cg07460842	chr6:66804631	NA	0.51	7.64	0.35	1.5e-13	Metabolite levels;
LUAD	cis	rs3772130	0.962	rs9812137	chr3:121539103	T/G	cg20356878	chr3:121714668	ILDR1	0.53	8.55	0.38	2.2e-16	Cognitive performance;
LUAD	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg13722127	chr7:150037890	RARRES2	0.45	7.68	0.35	1.15e-13	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs7395662	0.963	rs4882002	chr11:48546731	A/C	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.1e-12	HDL cholesterol;
LUAD	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-6.85	-0.32	2.57e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg10589385	chr1:150898437	SETDB1	0.39	7.48	0.34	4.23e-13	Tonsillectomy;
LUAD	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg23602478	chr1:26503979	CNKSR1	0.29	7.01	0.32	9.34e-12	Height;
LUAD	cis	rs7520050	0.966	rs4545281	chr1:46360054	C/T	cg06784218	chr1:46089804	CCDC17	-0.3	-6.36	-0.3	5.38e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	14.46	0.58	8.71e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg11859384	chr17:80120422	CCDC57	0.51	9.22	0.41	1.42e-18	Life satisfaction;
LUAD	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.8	-0.31	3.56e-11	Personality dimensions;
LUAD	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg11859384	chr17:80120422	CCDC57	0.48	8.68	0.39	8.47e-17	Life satisfaction;
LUAD	cis	rs6688613	1.000	rs12130629	chr1:166953284	C/T	cg07049167	chr1:166818506	POGK	0.42	7.04	0.32	7.76e-12	Refractive astigmatism;
LUAD	cis	rs9837602	0.938	rs34922392	chr3:99794730	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-7.46	-0.34	4.9e-13	Breast cancer;
LUAD	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg20933634	chr6:27740509	NA	0.43	6.37	0.3	4.87e-10	Parkinson's disease;
LUAD	cis	rs4812048	0.649	rs3761257	chr20:57618787	C/T	cg14073986	chr20:57617431	SLMO2	0.81	9.97	0.44	3.48e-21	Mean platelet volume;
LUAD	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg01097406	chr16:89675127	NA	0.47	10.0	0.44	2.73e-21	Vitiligo;
LUAD	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg04455712	chr21:45112962	RRP1B	-0.34	-6.78	-0.31	4.06e-11	Mean corpuscular volume;
LUAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg24642844	chr7:1081250	C7orf50	-0.98	-14.49	-0.58	6.65e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg03806693	chr22:41940476	POLR3H	0.63	9.3	0.41	7.4e-19	Vitiligo;
LUAD	cis	rs9796	0.689	rs28409432	chr15:41447454	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.45	-8.34	-0.38	1.05e-15	Menopause (age at onset);
LUAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg15242686	chr22:24348715	GSTTP1	-0.43	-7.25	-0.33	2.03e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2421770	0.530	rs10836375	chr11:35353842	C/T	cg13971030	chr11:35366721	SLC1A2	-0.41	-7.05	-0.32	7.45e-12	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg11050988	chr7:1952600	MAD1L1	-0.38	-7.78	-0.35	5.7e-14	Bipolar disorder and schizophrenia;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg15677368	chr1:245133209	EFCAB2	0.55	9.35	0.41	5.25e-19	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08280861	chr8:58055591	NA	-0.52	-6.95	-0.32	1.42e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs62458065	0.513	rs7788809	chr7:32552622	T/A	cg00845942	chr12:64062724	DPY19L2	-0.55	-7.89	-0.36	2.55e-14	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg12923728	chr3:195709715	SDHAP1	-0.63	-9.79	-0.43	1.51e-20	Pancreatic cancer;
LUAD	cis	rs7394190	0.748	rs11000780	chr10:75559077	G/A	cg02286717	chr10:75415704	SYNPO2L	-0.4	-7.0	-0.32	9.98e-12	Incident atrial fibrillation;
LUAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg13047869	chr3:10149882	C3orf24	0.64	11.02	0.47	5.16e-25	Alzheimer's disease;
LUAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.41	-0.38	6.57e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-9.45	-0.42	2.41e-19	Alzheimer's disease;
LUAD	trans	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg15704280	chr7:45808275	SEPT13	0.66	7.81	0.36	4.59e-14	Intraocular pressure;
LUAD	trans	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg18187862	chr3:45730750	SACM1L	-0.45	-6.47	-0.3	2.64e-10	Primary sclerosing cholangitis;
LUAD	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg17366294	chr4:99064904	C4orf37	0.47	8.38	0.38	8.17e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg06641503	chr3:48959341	ARIH2	-0.37	-6.77	-0.31	4.23e-11	Menarche (age at onset);
LUAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.11	-0.33	4.87e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2692947	0.537	rs1364394	chr2:96195730	A/G	cg23100626	chr2:96804247	ASTL	-0.32	-8.04	-0.36	9.2e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg18200150	chr17:30822561	MYO1D	-0.41	-7.47	-0.34	4.77e-13	Schizophrenia;
LUAD	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg17366294	chr4:99064904	C4orf37	-0.48	-8.51	-0.38	3.07e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4660306	1.000	rs7534467	chr1:45988691	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.5	-7.98	-0.36	1.36e-14	Homocysteine levels;
LUAD	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg26384229	chr12:38710491	ALG10B	-0.43	-7.27	-0.33	1.76e-12	Morning vs. evening chronotype;
LUAD	cis	rs375066	0.592	rs349047	chr19:44300884	G/A	cg11993925	chr19:44307056	LYPD5	-0.37	-7.37	-0.34	9.32e-13	Breast cancer;
LUAD	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10802521	chr3:52805072	NEK4	-0.55	-9.16	-0.41	2.26e-18	Bipolar disorder;
LUAD	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg15704280	chr7:45808275	SEPT13	0.64	8.49	0.38	3.6e-16	Axial length;
LUAD	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg08470875	chr2:26401718	FAM59B	-0.6	-8.23	-0.37	2.38e-15	Gut microbiome composition (summer);
LUAD	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg08645402	chr16:4508243	NA	0.55	9.44	0.42	2.44e-19	Schizophrenia;
LUAD	cis	rs1878931	1.000	rs1878931	chr16:3450907	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.44	7.65	0.35	1.37e-13	Body mass index (adult);
LUAD	cis	rs12413816	0.784	rs11258560	chr10:13770137	A/G	cg16485048	chr10:13749193	FRMD4A	0.39	6.49	0.3	2.35e-10	Red cell distribution width;
LUAD	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.22	-0.33	2.51e-12	Blood metabolite levels;
LUAD	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg04772025	chr11:68637568	NA	0.56	8.69	0.39	7.82e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg02527881	chr3:46936655	PTH1R	-0.58	-12.09	-0.51	4.17e-29	Colorectal cancer;
LUAD	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg02782426	chr3:40428986	ENTPD3	0.43	9.2	0.41	1.69e-18	Renal cell carcinoma;
LUAD	cis	rs7107174	1.000	rs57738705	chr11:77994489	A/G	cg02023728	chr11:77925099	USP35	0.48	7.48	0.34	4.46e-13	Testicular germ cell tumor;
LUAD	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg27494647	chr7:150038898	RARRES2	0.45	7.57	0.35	2.42e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg26384229	chr12:38710491	ALG10B	-0.4	-6.75	-0.31	4.86e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg18404041	chr3:52824283	ITIH1	-0.56	-9.47	-0.42	2.05e-19	Schizophrenia;
LUAD	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.54	-0.34	2.8e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg25319279	chr11:5960081	NA	-0.42	-7.62	-0.35	1.69e-13	DNA methylation (variation);
LUAD	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg11845111	chr2:191398756	TMEM194B	0.66	12.12	0.51	3.23e-29	Pulse pressure;
LUAD	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg10523679	chr1:76189770	ACADM	0.78	11.56	0.49	4.8e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg02269571	chr22:50332266	NA	0.6	9.06	0.4	4.75e-18	Schizophrenia;
LUAD	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg14598338	chr9:96623480	NA	-0.44	-9.49	-0.42	1.73e-19	DNA methylation (variation);
LUAD	trans	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.45	-7.54	-0.34	2.91e-13	Body mass index;
LUAD	cis	rs926938	0.584	rs869990	chr1:115379614	A/G	cg12756093	chr1:115239321	AMPD1	-0.38	-6.71	-0.31	6.13e-11	Autism;
LUAD	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg16479474	chr6:28041457	NA	0.43	7.38	0.34	8.39e-13	Depression;
LUAD	cis	rs72960926	0.590	rs117275111	chr6:74750921	G/A	cg03266952	chr6:74778945	NA	-0.8	-7.36	-0.34	9.73e-13	Metabolite levels (MHPG);
LUAD	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18876405	chr7:65276391	NA	-0.44	-6.95	-0.32	1.43e-11	Aortic root size;
LUAD	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg17077180	chr1:38461687	NA	0.44	9.03	0.4	6.26e-18	Coronary artery disease;
LUAD	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg25344623	chr2:136566232	LCT	0.35	6.8	0.31	3.49e-11	Mosquito bite size;
LUAD	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22590775	chr19:49891494	CCDC155	0.67	10.38	0.45	1.21e-22	Multiple sclerosis;
LUAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg24642844	chr7:1081250	C7orf50	-0.96	-14.27	-0.57	5.21e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg00745463	chr17:30367425	LRRC37B	0.65	8.0	0.36	1.16e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs11971779	0.648	rs28754644	chr7:139065057	C/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.76	0.31	4.63e-11	Diisocyanate-induced asthma;
LUAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.48	-7.94	-0.36	1.88e-14	Longevity;Endometriosis;
LUAD	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg02389323	chr16:88786976	FAM38A	0.94	10.0	0.44	2.81e-21	Plateletcrit;
LUAD	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg15997130	chr1:24165203	NA	0.55	9.5	0.42	1.54e-19	Immature fraction of reticulocytes;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg19871494	chr1:1310280	AURKAIP1	-0.69	-6.53	-0.3	1.94e-10	Type 2 diabetes;
LUAD	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg11148817	chr5:312970	AHRR;PDCD6	-0.47	-6.44	-0.3	3.23e-10	Breast cancer;
LUAD	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg26384229	chr12:38710491	ALG10B	-0.44	-7.26	-0.33	1.82e-12	Morning vs. evening chronotype;
LUAD	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg06505273	chr16:24850292	NA	0.47	6.8	0.31	3.65e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7072216	0.763	rs10883092	chr10:100167276	A/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-8.0	-0.36	1.23e-14	Metabolite levels;
LUAD	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg25767906	chr1:53392781	SCP2	0.41	7.54	0.34	2.94e-13	Monocyte count;
LUAD	trans	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.14	-0.37	4.36e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17767294	0.708	rs9380018	chr6:27740646	A/G	cg08851530	chr6:28072375	NA	1.08	7.9	0.36	2.51e-14	Parkinson's disease;
LUAD	cis	rs870825	0.860	rs72689295	chr4:185600930	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	11.51	0.49	7.31e-27	Blood protein levels;
LUAD	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg09117114	chr16:67998030	SLC12A4	-0.63	-8.22	-0.37	2.59e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.3	6.48	0.3	2.5e-10	Parkinson's disease;
LUAD	trans	rs1864729	1.000	rs2567773	chr8:98279182	G/A	cg08679828	chr8:102218111	ZNF706	-0.78	-7.85	-0.36	3.57e-14	Estradiol plasma levels (breast cancer);
LUAD	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21659725	chr3:3221576	CRBN	-0.66	-10.57	-0.46	2.47e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg06753367	chr22:24256600	NA	-0.41	-7.31	-0.33	1.34e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg23254163	chr1:152506842	NA	0.26	7.05	0.32	7.19e-12	Hair morphology;
LUAD	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg26384229	chr12:38710491	ALG10B	0.47	7.64	0.35	1.49e-13	Morning vs. evening chronotype;
LUAD	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg11344533	chr11:111475393	SIK2	-0.36	-6.75	-0.31	4.82e-11	Primary sclerosing cholangitis;
LUAD	cis	rs656900	0.740	rs1675181	chr15:80111638	C/T	cg02196730	chr15:80188777	MTHFS	-0.38	-6.39	-0.3	4.48e-10	Cerebrospinal P-tau181p levels;
LUAD	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg24818145	chr4:99064322	C4orf37	0.41	6.89	0.32	2.04e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1784581	0.588	rs7453474	chr6:162421736	C/T	cg17173639	chr6:162384350	PARK2	0.43	7.73	0.35	8.1e-14	Itch intensity from mosquito bite;
LUAD	cis	rs7512552	0.839	rs834232	chr1:150354682	T/C	cg15654264	chr1:150340011	RPRD2	0.58	11.07	0.47	3.61e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs938554	0.779	rs7442295	chr4:9966380	A/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.03	-0.36	1e-14	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18283712	chr14:57735581	MUDENG;EXOC5	-0.58	-7.29	-0.33	1.57e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7731657	0.537	rs17621442	chr5:130205555	T/C	cg08523029	chr5:130500466	HINT1	-0.56	-7.13	-0.33	4.46e-12	Fasting plasma glucose;
LUAD	trans	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg26043149	chr18:55253948	FECH	0.49	7.93	0.36	1.92e-14	Bone mineral density;
LUAD	trans	rs853679	0.607	rs34243448	chr6:28193102	C/A	cg01620082	chr3:125678407	NA	-1.1	-10.34	-0.45	1.67e-22	Depression;
LUAD	cis	rs9972944	0.729	rs10083870	chr17:63773272	C/T	cg07283582	chr17:63770753	CCDC46	0.46	10.03	0.44	2.28e-21	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4662945	0.504	rs35568023	chr2:130251812	A/T	cg05903289	chr2:130345205	NA	-0.32	-6.94	-0.32	1.44e-11	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs11756438	0.683	rs11754023	chr6:119005785	A/G	cg18833306	chr6:118973337	C6orf204	0.38	6.43	0.3	3.43e-10	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2629540	0.847	rs12763093	chr10:126395688	C/G	cg08799069	chr10:126477246	METTL10	-0.45	-6.74	-0.31	5.36e-11	Cocaine dependence;
LUAD	trans	rs80264589	1	rs80264589	chr6:26927602	G/A	cg06606381	chr12:133084897	FBRSL1	-1.04	-9.31	-0.41	6.79e-19	Lung cancer;Intelligence (multi-trait analysis);
LUAD	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg22681709	chr2:178499509	PDE11A	-0.44	-6.38	-0.3	4.52e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg10556349	chr10:835070	NA	-0.49	-7.76	-0.35	6.41e-14	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs11247915	0.583	rs66569416	chr1:26659737	C/G	cg15628303	chr1:26608928	UBXN11	0.51	9.28	0.41	8.76e-19	Obesity-related traits;
LUAD	trans	rs7786808	0.530	rs6459875	chr7:158186141	C/T	cg02030672	chr11:45687055	CHST1	-0.41	-7.34	-0.34	1.08e-12	Obesity-related traits;
LUAD	cis	rs4700695	0.545	rs29441	chr5:65509116	G/T	cg21114390	chr5:65439923	SFRS12	-0.83	-12.66	-0.52	2.31e-31	Facial morphology (factor 19);
LUAD	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg04287289	chr16:89883240	FANCA	0.79	7.06	0.32	6.75e-12	Skin colour saturation;
LUAD	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24308560	chr3:49941425	MST1R	0.56	9.53	0.42	1.2e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs2625529	0.668	rs35206011	chr15:72539494	T/C	cg16672083	chr15:72433130	SENP8	-0.82	-13.82	-0.56	4e-36	Red blood cell count;
LUAD	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg21775007	chr8:11205619	TDH	-0.4	-7.11	-0.33	4.85e-12	Retinal vascular caliber;
LUAD	cis	rs73416724	1.000	rs76823934	chr6:43359424	G/A	cg26312998	chr6:43337775	ZNF318	0.53	6.39	0.3	4.32e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.61	-10.51	-0.46	4.03e-23	Melanoma;
LUAD	trans	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg14917512	chr19:3094685	GNA11	-0.57	-6.7	-0.31	6.66e-11	Diabetic kidney disease;
LUAD	trans	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg26043149	chr18:55253948	FECH	0.49	7.86	0.36	3.15e-14	Bone mineral density;
LUAD	cis	rs62400317	0.859	rs17209636	chr6:45142517	T/G	cg20913747	chr6:44695427	NA	-0.4	-6.46	-0.3	2.82e-10	Total body bone mineral density;
LUAD	cis	rs1215050	0.660	rs3864229	chr4:98714323	A/G	cg05340658	chr4:99064831	C4orf37	0.45	6.95	0.32	1.41e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7084921	0.552	rs12780023	chr10:101874829	C/T	cg19754520	chr10:101825118	CPN1	-0.32	-6.73	-0.31	5.69e-11	Bone mineral density;
LUAD	cis	rs1595825	0.891	rs73054817	chr2:198623751	A/G	cg10547527	chr2:198650123	BOLL	-0.53	-7.37	-0.34	8.82e-13	Ulcerative colitis;
LUAD	cis	rs11958404	0.932	rs113264420	chr5:157437779	T/C	cg05962755	chr5:157440814	NA	0.55	8.28	0.37	1.65e-15	IgG glycosylation;
LUAD	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg10426581	chr7:100472382	SRRT	0.76	10.31	0.45	2.2e-22	Resting heart rate;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13064004	chr8:38854350	ADAM9;TM2D2	-0.52	-6.37	-0.3	4.85e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs929596	0.755	rs4148324	chr2:234672722	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.74	-12.83	-0.53	4.52e-32	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs4786125	0.512	rs55818804	chr16:6930199	T/C	cg03623568	chr16:6915990	A2BP1	-0.46	-9.39	-0.42	3.67e-19	Heart rate variability traits (SDNN);
LUAD	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21582582	chr3:182698605	DCUN1D1	0.57	9.61	0.42	6.56e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg00277334	chr10:82204260	NA	-0.62	-8.64	-0.39	1.18e-16	Post bronchodilator FEV1;
LUAD	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg16049864	chr8:95962084	TP53INP1	-0.39	-7.03	-0.32	8.26e-12	Type 2 diabetes;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg16665598	chr19:14316192	LPHN1	-0.65	-6.68	-0.31	7.72e-11	Type 2 diabetes;
LUAD	cis	rs4253772	0.575	rs6008684	chr22:46719100	C/G	cg09491104	chr22:46646882	C22orf40	-0.55	-6.91	-0.32	1.85e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	9.37	0.41	4.27e-19	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg12483005	chr1:23474871	LUZP1	0.52	9.0	0.4	7.74e-18	Height;
LUAD	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18404041	chr3:52824283	ITIH1	-0.59	-11.79	-0.5	5.98e-28	Bipolar disorder;
LUAD	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg14159672	chr1:205819179	PM20D1	-0.53	-7.91	-0.36	2.33e-14	Menarche (age at onset);
LUAD	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.3	6.37	0.3	4.98e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2446066	0.605	rs8938	chr12:53936878	G/T	cg20730629	chr12:53886622	MAP3K12	-0.47	-6.78	-0.31	4.15e-11	Red blood cell count;
LUAD	trans	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-7.04	-0.32	7.89e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7737355	0.812	rs26010	chr5:131013815	G/A	cg06307176	chr5:131281290	NA	0.45	7.42	0.34	6.51e-13	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg15445000	chr17:37608096	MED1	0.44	8.09	0.37	6.48e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg17761419	chr8:57350749	NA	-0.52	-7.83	-0.36	4.07e-14	Obesity-related traits;
LUAD	cis	rs6424115	0.557	rs35904775	chr1:24180623	T/C	cg10978503	chr1:24200527	CNR2	-0.57	-12.13	-0.51	2.87e-29	Immature fraction of reticulocytes;
LUAD	cis	rs9837602	0.938	rs17393059	chr3:99761908	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	9.14	0.41	2.72e-18	Breast cancer;
LUAD	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.7	-0.31	6.49e-11	Total body bone mineral density;
LUAD	cis	rs225245	0.791	rs2285742	chr17:34018682	C/T	cg05299278	chr17:33885742	SLFN14	0.5	11.14	0.48	1.83e-25	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs57920188	0.703	rs10915642	chr1:4089244	T/C	cg20703997	chr1:4087676	NA	0.49	9.36	0.41	4.71e-19	Interleukin-17 levels;
LUAD	cis	rs9811920	0.695	rs793497	chr3:99505610	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.54	-10.04	-0.44	2.07e-21	Axial length;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07077115	chr13:28024429	MTIF3	-0.45	-6.98	-0.32	1.15e-11	Height;
LUAD	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg07810366	chr2:100720526	AFF3	-0.36	-7.48	-0.34	4.39e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs3106136	0.546	rs2664881	chr4:95143484	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.22	-0.44	4.77e-22	Capecitabine sensitivity;
LUAD	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg05043794	chr9:111880884	C9orf5	-0.42	-7.35	-0.34	1.05e-12	Menarche (age at onset);
LUAD	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg13722127	chr7:150037890	RARRES2	0.5	8.29	0.37	1.47e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg07617317	chr6:118971624	C6orf204	-0.55	-8.43	-0.38	5.38e-16	Diastolic blood pressure;
LUAD	cis	rs12530845	0.943	rs3800762	chr7:135347601	T/A	cg23117316	chr7:135346802	PL-5283	-0.5	-8.71	-0.39	7.1e-17	Red blood cell traits;
LUAD	cis	rs7680126	0.596	rs12503603	chr4:10313757	T/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-6.62	-0.31	1.12e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg23719950	chr11:63933701	MACROD1	-0.6	-7.36	-0.34	9.86e-13	Mean platelet volume;
LUAD	cis	rs6499255	1.000	rs12446201	chr16:69815586	T/C	cg15192750	chr16:69999425	NA	0.51	8.15	0.37	4.24e-15	IgE levels;
LUAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.49	6.89	0.32	2.05e-11	Renal function-related traits (BUN);
LUAD	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08536481	chr12:123459152	ABCB9;OGFOD2	-0.53	-6.5	-0.3	2.23e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.56	0.3	1.62e-10	Cognitive test performance;
LUAD	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg06766960	chr11:133703094	NA	0.47	8.53	0.38	2.71e-16	Childhood ear infection;
LUAD	cis	rs2840044	0.534	rs321596	chr17:33885736	C/T	cg05299278	chr17:33885742	SLFN14	-0.55	-13.07	-0.54	5.02e-33	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg01475377	chr6:109611718	NA	-0.52	-10.13	-0.44	9.42e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg16797656	chr11:68205561	LRP5	0.45	8.62	0.39	1.34e-16	Total body bone mineral density;
LUAD	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg20607287	chr7:12443886	VWDE	-0.54	-6.93	-0.32	1.55e-11	Coronary artery disease;
LUAD	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg07936489	chr17:37558343	FBXL20	-0.44	-6.84	-0.32	2.8e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg00255919	chr5:131827918	IRF1	0.49	11.85	0.5	3.74e-28	Asthma (sex interaction);
LUAD	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg19318889	chr4:1322082	MAEA	0.46	7.31	0.34	1.32e-12	Obesity-related traits;
LUAD	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.59	9.71	0.43	3.02e-20	Birth weight;
LUAD	cis	rs9341808	0.618	rs6916507	chr6:80862265	T/C	cg08355045	chr6:80787529	NA	0.54	9.83	0.43	1.16e-20	Sitting height ratio;
LUAD	cis	rs9323205	0.531	rs55928212	chr14:51543439	G/A	cg23942311	chr14:51606299	NA	-0.42	-6.65	-0.31	8.91e-11	Cancer;
LUAD	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg17105886	chr17:28927953	LRRC37B2	0.84	8.08	0.37	6.96e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg06611532	chr13:114900021	NA	0.3	6.81	0.31	3.35e-11	Schizophrenia;
LUAD	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg08508325	chr11:3079039	CARS	-0.62	-13.32	-0.54	4.98e-34	Longevity;
LUAD	cis	rs490234	0.552	rs2841327	chr9:128156503	G/A	cg14078157	chr9:128172775	NA	-0.44	-8.15	-0.37	4.27e-15	Mean arterial pressure;
LUAD	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg07677032	chr17:61819896	STRADA	0.43	6.49	0.3	2.47e-10	Height;
LUAD	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.35	-0.34	1.01e-12	Lung cancer;
LUAD	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg04414720	chr1:150670196	GOLPH3L	0.72	13.23	0.54	1.16e-33	Tonsillectomy;
LUAD	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.56	-0.38	2.16e-16	Total body bone mineral density;
LUAD	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg23840854	chr1:161414152	NA	-0.86	-11.14	-0.48	1.95e-25	Rheumatoid arthritis;
LUAD	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg24112000	chr20:60950667	NA	-0.67	-9.64	-0.42	5.08e-20	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7512552	0.839	rs1260367	chr1:150344514	C/T	cg15654264	chr1:150340011	RPRD2	0.59	11.22	0.48	9.71e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg26043149	chr18:55253948	FECH	0.49	7.86	0.36	3.15e-14	Bone mineral density;
LUAD	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg18230493	chr5:56204884	C5orf35	-0.86	-12.54	-0.52	7.15e-31	Initial pursuit acceleration;
LUAD	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg17652424	chr22:38574118	PLA2G6	-0.33	-10.13	-0.44	9.75e-22	Cutaneous nevi;
LUAD	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg18305652	chr10:134549665	INPP5A	0.56	12.05	0.51	5.95e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs11048434	0.736	rs2041625	chr12:9112005	C/T	cg04155231	chr12:9217510	LOC144571	0.39	7.57	0.35	2.43e-13	Sjögren's syndrome;
LUAD	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.81	-14.07	-0.56	3.58e-37	Chronic sinus infection;
LUAD	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	0.27	6.87	0.32	2.32e-11	Total body bone mineral density;
LUAD	cis	rs12760731	0.565	rs35038893	chr1:178168417	C/T	cg00404053	chr1:178313656	RASAL2	0.73	9.14	0.41	2.66e-18	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg23281280	chr6:28129359	ZNF389	0.48	6.71	0.31	6.44e-11	Depression;
LUAD	cis	rs9392556	0.829	rs660560	chr6:4125941	A/G	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.38	-6.68	-0.31	7.36e-11	Blood metabolite levels;
LUAD	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg23254163	chr1:152506842	NA	-0.24	-6.65	-0.31	9.2e-11	Hair morphology;
LUAD	trans	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg04995722	chr7:26192034	NFE2L3	-0.41	-7.16	-0.33	3.6e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.53	0.3	1.86e-10	Breast cancer;
LUAD	cis	rs7089973	0.836	rs12765350	chr10:116635305	G/A	cg25233709	chr10:116636983	FAM160B1	0.39	7.55	0.34	2.67e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg18335740	chr13:41363409	SLC25A15	0.77	14.95	0.59	6.8e-41	Lewy body disease;
LUAD	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg06547715	chr2:218990976	CXCR2	-0.42	-10.15	-0.44	8.35e-22	Ulcerative colitis;
LUAD	cis	rs2455799	0.573	rs2455833	chr3:15752830	T/C	cg16303742	chr3:15540471	COLQ	-0.51	-9.41	-0.42	3.17e-19	Mean platelet volume;
LUAD	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.5	-8.94	-0.4	1.23e-17	Eosinophil percentage of white cells;
LUAD	cis	rs2840044	1.000	rs225295	chr17:33925755	A/G	cg05299278	chr17:33885742	SLFN14	0.44	8.79	0.39	3.79e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs7937890	0.559	rs2575837	chr11:14498001	A/G	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.01e-10	Mitochondrial DNA levels;
LUAD	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg23625390	chr15:77176239	SCAPER	-0.56	-8.99	-0.4	8.24e-18	Blood metabolite levels;
LUAD	cis	rs7927771	0.832	rs1542321	chr11:47379615	G/A	cg18512352	chr11:47633146	NA	0.43	7.38	0.34	8.28e-13	Subjective well-being;
LUAD	cis	rs9807989	0.524	rs6543126	chr2:103027104	G/A	cg03938978	chr2:103052716	IL18RAP	0.45	10.35	0.45	1.62e-22	Asthma;
LUAD	trans	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg03929089	chr4:120376271	NA	0.53	7.1	0.33	5.39e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2455799	0.634	rs1584326	chr3:15903951	G/A	cg16303742	chr3:15540471	COLQ	-0.5	-9.01	-0.4	7.11e-18	Mean platelet volume;
LUAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-8.07	-0.37	7.12e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.32	-0.34	1.28e-12	Schizophrenia;
LUAD	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg13607699	chr17:42295918	UBTF	-0.45	-6.78	-0.31	4.02e-11	Total body bone mineral density;
LUAD	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg01236616	chr12:121019343	POP5	-1.18	-16.71	-0.63	1.76e-48	Type 1 diabetes nephropathy;
LUAD	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg06713675	chr4:122721982	EXOSC9	0.45	8.08	0.37	6.9e-15	Type 2 diabetes;
LUAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg00431813	chr7:1051703	C7orf50	-0.41	-7.94	-0.36	1.78e-14	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7267979	0.738	rs2892409	chr20:25638138	C/T	cg08601574	chr20:25228251	PYGB	0.38	7.05	0.32	7.36e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg20503657	chr10:835505	NA	-1.24	-19.01	-0.68	1.1e-58	Eosinophil percentage of granulocytes;
LUAD	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.66	-0.71	4.32e-66	Coronary artery disease;
LUAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg09033563	chr22:24373618	LOC391322	-0.5	-7.89	-0.36	2.65e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg12365402	chr11:9010492	NRIP3	-0.52	-10.51	-0.46	4.11e-23	Hemoglobin concentration;
LUAD	cis	rs71636778	0.543	rs36109400	chr1:27247822	G/A	cg12203394	chr1:27248618	NUDC	0.52	6.59	0.31	1.33e-10	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7149337	0.805	rs2999355	chr14:51607084	A/G	cg23942311	chr14:51606299	NA	0.88	20.43	0.7	4.83e-65	Cancer;
LUAD	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg16512390	chr1:228756714	NA	0.66	8.93	0.4	1.28e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg03806693	chr22:41940476	POLR3H	-0.53	-7.55	-0.34	2.63e-13	Vitiligo;
LUAD	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg06627628	chr2:24431161	ITSN2	0.4	6.72	0.31	5.85e-11	Asthma;
LUAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.22	0.54	1.22e-33	Prudent dietary pattern;
LUAD	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05890377	chr2:74357713	NA	0.81	12.61	0.52	3.47e-31	Gestational age at birth (maternal effect);
LUAD	cis	rs12618769	0.597	rs4850875	chr2:99069815	A/G	cg10123293	chr2:99228465	UNC50	0.47	8.39	0.38	7.13e-16	Bipolar disorder;
LUAD	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg00310523	chr12:86230176	RASSF9	0.39	7.76	0.35	6.41e-14	Major depressive disorder;
LUAD	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21659725	chr3:3221576	CRBN	0.68	11.67	0.49	1.85e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg01028140	chr2:1542097	TPO	-0.42	-7.05	-0.32	7.47e-12	IgG glycosylation;
LUAD	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg27490568	chr2:178487706	NA	0.62	9.2	0.41	1.66e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.62	0.31	1.09e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg02146966	chr17:18967117	NA	-0.37	-6.36	-0.3	5.33e-10	Subcortical brain region volumes;
LUAD	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	6.68	0.31	7.55e-11	Obesity-related traits;
LUAD	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg18827107	chr12:86230957	RASSF9	-0.7	-13.06	-0.54	5.27e-33	Major depressive disorder;
LUAD	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	12.72	0.53	1.24e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6028335	0.610	rs67343649	chr20:37557894	A/G	cg27660920	chr20:37554817	FAM83D	0.56	7.31	0.33	1.36e-12	Alcohol and nicotine co-dependence;
LUAD	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg12698349	chr2:225449008	CUL3	-0.66	-9.89	-0.43	6.85e-21	IgE levels in asthmatics (D.p. specific);
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg22696252	chr3:97540975	NA	-0.54	-6.39	-0.3	4.34e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05901451	chr6:126070800	HEY2	0.58	9.15	0.41	2.51e-18	Endometrial cancer;
LUAD	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.75	0.35	6.99e-14	Breast cancer;
LUAD	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.87	0.36	2.95e-14	Depression;
LUAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08677398	chr8:58056175	NA	0.48	6.77	0.31	4.3e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7428	0.545	rs9248	chr2:85537312	G/A	cg24342717	chr2:85555507	TGOLN2	-0.47	-7.69	-0.35	1.03e-13	Ear protrusion;
LUAD	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg18854424	chr1:2615690	NA	0.42	9.17	0.41	2.06e-18	Ulcerative colitis;
LUAD	trans	rs2797160	1.000	rs13328298	chr6:126016580	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.48e-17	Endometrial cancer;
LUAD	cis	rs735539	0.645	rs1052209	chr13:21216850	C/T	cg27499820	chr13:21296301	IL17D	0.5	8.04	0.36	8.82e-15	Dental caries;
LUAD	cis	rs7833986	0.501	rs9650314	chr8:56903610	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	14.5	0.58	5.81e-39	Height;
LUAD	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg18932078	chr1:2524107	MMEL1	-0.37	-6.95	-0.32	1.37e-11	Ulcerative colitis;
LUAD	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg24848339	chr3:12840334	CAND2	0.43	8.43	0.38	5.65e-16	QRS complex (12-leadsum);
LUAD	trans	rs8073060	0.572	rs1634683	chr17:33941560	G/C	cg19694781	chr19:47549865	TMEM160	-1.24	-19.71	-0.69	7.81e-62	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	trans	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg06606381	chr12:133084897	FBRSL1	-0.71	-6.68	-0.31	7.77e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4285028	0.851	rs1986368	chr3:121710969	A/T	cg11130432	chr3:121712080	ILDR1	-0.58	-8.34	-0.38	1.09e-15	Multiple sclerosis;
LUAD	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg03959625	chr15:84868606	LOC388152	0.4	6.48	0.3	2.6200000000000003e-10	Schizophrenia;
LUAD	cis	rs6920965	0.507	rs9385389	chr6:126215486	G/C	cg05901451	chr6:126070800	HEY2	-0.51	-7.49	-0.34	4.18e-13	High light scatter reticulocyte count;
LUAD	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg03714773	chr7:91764589	CYP51A1	0.29	6.76	0.31	4.6e-11	Breast cancer;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	ch.1.1180380F	chr1:37182591	NA	0.43	7.11	0.33	5e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.5	7.95	0.36	1.77e-14	Electrocardiographic conduction measures;
LUAD	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg25427524	chr10:38739819	LOC399744	0.57	10.06	0.44	1.74e-21	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.89	9.22	0.41	1.46e-18	Initial pursuit acceleration;
LUAD	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.09	-0.33	5.49e-12	Total body bone mineral density;
LUAD	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.61	0.31	1.14e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs986417	1.000	rs1254296	chr14:60870389	T/C	cg27398547	chr14:60952738	C14orf39	-0.63	-7.29	-0.33	1.5e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00166722	chr3:10149974	C3orf24	0.71	12.36	0.52	3.47e-30	Alzheimer's disease;
LUAD	cis	rs36051895	0.658	rs10974910	chr9:5010091	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-7.04	-0.32	7.69e-12	Pediatric autoimmune diseases;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg14668821	chr17:77704760	ENPP7	0.34	6.97	0.32	1.2e-11	Menopause (age at onset);
LUAD	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg00631329	chr6:26305371	NA	-0.76	-14.18	-0.57	1.33e-37	Educational attainment;
LUAD	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg07211511	chr3:129823064	LOC729375	-0.57	-7.54	-0.34	2.93e-13	Blood pressure (smoking interaction);
LUAD	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg11494091	chr17:61959527	GH2	0.74	18.63	0.67	5.61e-57	Prudent dietary pattern;
LUAD	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.43	-7.04	-0.32	8.05e-12	Menarche (age at onset);
LUAD	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	7.81	0.36	4.52e-14	Tonsillectomy;
LUAD	cis	rs9902453	0.791	rs28492945	chr17:28223982	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	10.38	0.45	1.18e-22	Coffee consumption (cups per day);
LUAD	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg01874867	chr7:94954059	PON1	-0.48	-6.5	-0.3	2.31e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.87	-0.36	3.1e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3818285	0.679	rs612155	chr10:111630731	C/G	cg00817464	chr10:111662876	XPNPEP1	0.8	15.45	0.6	5.34e-43	Superior crus of antihelix expression;
LUAD	cis	rs6494488	0.500	rs78659827	chr15:64721927	G/T	cg08069370	chr15:64387884	SNX1	-0.75	-6.64	-0.31	9.44e-11	Coronary artery disease;
LUAD	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg00933542	chr6:150070202	PCMT1	0.35	7.4	0.34	7.5e-13	Lung cancer;
LUAD	cis	rs2294693	0.945	rs9462668	chr6:41004194	T/C	cg14769373	chr6:40998127	UNC5CL	-0.51	-7.85	-0.36	3.38e-14	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.15	0.33	3.78e-12	Motion sickness;
LUAD	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg02475777	chr4:1388615	CRIPAK	0.65	9.16	0.41	2.24e-18	Longevity;
LUAD	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg10909506	chr17:38081995	ORMDL3	0.42	7.19	0.33	3.01e-12	Self-reported allergy;
LUAD	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.42	0.3	3.65e-10	Cardiac Troponin-T levels;
LUAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00166722	chr3:10149974	C3orf24	0.7	12.15	0.51	2.46e-29	Alzheimer's disease;
LUAD	cis	rs16958440	0.867	rs78720782	chr18:44664015	A/T	cg17192377	chr18:44677553	HDHD2	0.84	7.76	0.35	6.64e-14	Sitting height ratio;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg23681110	chr8:140847721	TRAPPC9	-0.46	-7.54	-0.34	2.86e-13	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs76419734	0.510	rs961472	chr4:106535062	A/G	cg05309399	chr4:106552544	FLJ20184	-0.59	-7.13	-0.33	4.26e-12	Post bronchodilator FEV1;
LUAD	cis	rs12900413	0.687	rs28493563	chr15:90309505	C/T	cg24249390	chr15:90295951	MESP1	-0.34	-6.55	-0.3	1.64e-10	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg17971929	chr21:40555470	PSMG1	0.54	8.43	0.38	5.63e-16	Cognitive function;
LUAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.16e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg13813247	chr22:41461852	NA	-0.45	-7.2	-0.33	2.76e-12	Neuroticism;
LUAD	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg10523679	chr1:76189770	ACADM	0.92	18.39	0.67	6.1e-56	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg25173405	chr17:45401733	C17orf57	-0.4	-6.73	-0.31	5.64e-11	Multiple sclerosis;Ankylosing spondylitis;
LUAD	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg23750338	chr8:142222470	SLC45A4	0.46	9.25	0.41	1.16e-18	Immature fraction of reticulocytes;
LUAD	trans	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg21659725	chr3:3221576	CRBN	0.38	6.49	0.3	2.45e-10	Resting heart rate;
LUAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg05434287	chr7:2030229	MAD1L1	0.39	6.56	0.3	1.61e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg02002194	chr4:3960332	NA	0.26	6.71	0.31	6.39e-11	Neuroticism;
LUAD	cis	rs12765878	1.000	rs2902639	chr10:105658588	G/C	cg11005552	chr10:105648138	OBFC1	0.44	8.28	0.37	1.65e-15	Coronary artery disease;
LUAD	cis	rs9952991	0.941	rs45450798	chr18:12792940	C/G	cg23598886	chr18:12777645	NA	-0.68	-8.16	-0.37	3.82e-15	Inflammatory skin disease;
LUAD	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg09796270	chr17:17721594	SREBF1	-0.37	-7.04	-0.32	7.66e-12	Total body bone mineral density;
LUAD	cis	rs454510	1.000	rs377033	chr1:120196652	C/G	cg16322792	chr1:120165303	ZNF697	0.46	8.25	0.37	2.08e-15	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24531977	chr5:56204891	C5orf35	-0.98	-15.09	-0.59	1.82e-41	Initial pursuit acceleration;
LUAD	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg18230493	chr5:56204884	C5orf35	-0.57	-9.35	-0.41	4.95e-19	Coronary artery disease;
LUAD	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg02734326	chr4:10020555	SLC2A9	0.65	11.56	0.49	4.62e-27	Bone mineral density;
LUAD	cis	rs11048434	0.736	rs2041624	chr12:9111855	C/G	cg23795048	chr12:9217529	LOC144571	0.41	7.62	0.35	1.72e-13	Sjögren's syndrome;
LUAD	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg12311346	chr5:56204834	C5orf35	-1.09	-16.01	-0.61	1.96e-45	Initial pursuit acceleration;
LUAD	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg02569458	chr12:86230093	RASSF9	0.39	7.46	0.34	5.12e-13	Major depressive disorder;
LUAD	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	10.97	0.47	8.09e-25	Hip circumference adjusted for BMI;
LUAD	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg01299579	chr2:10830716	NOL10	-0.42	-7.38	-0.34	8.52e-13	Prostate cancer;
LUAD	cis	rs7789940	1.000	rs76024966	chr7:75995021	C/T	cg10167463	chr7:75959203	YWHAG	-0.72	-13.04	-0.54	6.79e-33	Multiple sclerosis;
LUAD	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg20608306	chr11:116969690	SIK3	0.29	6.41	0.3	3.83e-10	Blood protein levels;
LUAD	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.13	-0.37	4.78e-15	Cystic fibrosis severity;
LUAD	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg22906224	chr7:99728672	NA	-0.62	-10.86	-0.47	2.08e-24	Coronary artery disease;
LUAD	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg23625390	chr15:77176239	SCAPER	-0.49	-7.97	-0.36	1.53e-14	Blood metabolite levels;
LUAD	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg23544223	chr18:12777786	NA	0.68	8.63	0.39	1.25e-16	Inflammatory skin disease;
LUAD	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.45	0.42	2.43e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg00999904	chr2:3704751	ALLC	0.52	8.94	0.4	1.19e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg23803603	chr1:2058230	PRKCZ	0.4	6.52	0.3	2.05e-10	Height;
LUAD	cis	rs7264396	0.563	rs56941405	chr20:34313426	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2.04e-15	Total cholesterol levels;
LUAD	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg04703951	chr17:43578652	NA	0.62	8.7	0.39	7.3e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg03467027	chr4:99064603	C4orf37	0.41	6.53	0.3	1.87e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg27446573	chr6:127587934	RNF146	0.43	6.54	0.3	1.81e-10	Breast cancer;
LUAD	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg06064525	chr11:970664	AP2A2	-0.54	-11.0	-0.47	6.45e-25	Alzheimer's disease (late onset);
LUAD	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.45	0.34	5.19e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs72928364	1.000	rs36156426	chr3:100646243	T/C	cg10123952	chr3:100791384	NA	0.64	7.32	0.34	1.26e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg17063962	chr7:91808500	NA	0.71	12.72	0.53	1.24e-31	Breast cancer;
LUAD	cis	rs9309473	0.687	rs11693531	chr2:73608614	C/G	cg20560298	chr2:73613845	ALMS1	-0.45	-7.1	-0.33	5.44e-12	Metabolite levels;
LUAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg12373951	chr3:133503437	NA	0.33	6.54	0.3	1.78e-10	Iron status biomarkers;
LUAD	cis	rs2286503	1.000	rs2286498	chr7:22857504	C/T	cg06496272	chr7:22895283	SNORD93	0.38	6.81	0.31	3.45e-11	Fibrinogen;
LUAD	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg02176678	chr2:219576539	TTLL4	0.68	13.49	0.55	9.91e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs11677416	1.000	rs72825514	chr2:113527706	G/T	cg27083787	chr2:113543245	IL1A	0.41	6.91	0.32	1.79e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg03563238	chr19:33554763	RHPN2	-0.3	-7.29	-0.33	1.52e-12	Bone properties (heel);
LUAD	trans	rs2018683	0.899	rs10269454	chr7:28978400	C/T	cg19402173	chr7:128379420	CALU	-0.6	-9.99	-0.44	2.99e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs754466	0.606	rs11002306	chr10:79591519	A/T	cg17075019	chr10:79541650	NA	-0.89	-18.63	-0.67	5.4e-57	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg23281280	chr6:28129359	ZNF389	0.46	6.66	0.31	8.56e-11	Depression;
LUAD	cis	rs6138458	1.000	rs6114984	chr20:24976610	A/G	cg26195577	chr20:24973756	C20orf3	0.98	17.44	0.65	9.94e-52	Blood protein levels;
LUAD	cis	rs2224391	0.628	rs2773313	chr6:5252213	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-8.64	-0.39	1.14e-16	Height;
LUAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg11965913	chr1:205819406	PM20D1	0.82	17.01	0.64	8.32e-50	Menarche (age at onset);
LUAD	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg14835575	chr10:16859367	RSU1	0.98	14.86	0.59	1.69e-40	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg27266060	chr8:22091797	NA	0.41	7.3	0.33	1.4e-12	Hypertriglyceridemia;
LUAD	cis	rs6445967	0.569	rs62259302	chr3:58284005	G/A	cg13750441	chr3:58318267	PXK	-0.31	-6.63	-0.31	1.04e-10	Platelet count;
LUAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08219700	chr8:58056026	NA	0.58	8.03	0.36	9.71e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg27632911	chr20:34205182	SPAG4	0.38	6.38	0.3	4.78e-10	Total cholesterol levels;
LUAD	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg01689657	chr7:91764605	CYP51A1	-0.29	-6.96	-0.32	1.27e-11	Breast cancer;
LUAD	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg26818010	chr10:134567672	INPP5A	-0.82	-14.24	-0.57	7.01e-38	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs11771526	0.792	rs62457499	chr7:32319197	T/C	cg27511599	chr7:32358540	NA	0.52	6.51	0.3	2.12e-10	Body mass index;
LUAD	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg02696790	chr15:75250997	RPP25	-0.35	-6.97	-0.32	1.21e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg09835421	chr16:68378352	PRMT7	-0.83	-8.65	-0.39	1.11e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg10295955	chr4:187884368	NA	-0.99	-20.76	-0.71	1.62e-66	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6499255	0.951	rs7186002	chr16:69751065	C/G	cg15192750	chr16:69999425	NA	0.54	8.22	0.37	2.6e-15	IgE levels;
LUAD	cis	rs2996428	0.561	rs2275833	chr1:3745721	C/T	cg17443473	chr1:3703550	LRRC47	0.44	7.71	0.35	8.99e-14	Red cell distribution width;
LUAD	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg23711669	chr6:146136114	FBXO30	-0.39	-6.43	-0.3	3.55e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg18621852	chr3:10150065	C3orf24	0.46	7.21	0.33	2.58e-12	Alzheimer's disease;
LUAD	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg00316803	chr15:76480434	C15orf27	-0.4	-7.69	-0.35	1.01e-13	Blood metabolite levels;
LUAD	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06544989	chr22:39130855	UNC84B	0.49	9.7	0.43	3.27e-20	Menopause (age at onset);
LUAD	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.83	0.32	3.03e-11	Blood metabolite levels;
LUAD	cis	rs240764	0.658	rs9322182	chr6:101223295	G/A	cg09795085	chr6:101329169	ASCC3	-0.43	-7.48	-0.34	4.47e-13	Neuroticism;
LUAD	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.73e-16	Neutrophil percentage of white cells;
LUAD	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg17264618	chr3:40429014	ENTPD3	0.42	9.09	0.4	3.72e-18	Renal cell carcinoma;
LUAD	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg04944784	chr2:26401820	FAM59B	-0.66	-9.5	-0.42	1.63e-19	Gut microbiome composition (summer);
LUAD	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	13.63	0.55	2.48e-35	Lung cancer in ever smokers;
LUAD	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg04450456	chr4:17643702	FAM184B	0.42	8.33	0.38	1.15e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg13271783	chr10:134563150	INPP5A	-0.41	-6.79	-0.31	3.72e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg11211951	chr8:145729740	GPT	0.37	7.49	0.34	4.05e-13	Age at first birth;
LUAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg02524346	chr8:600233	NA	1.1	10.75	0.46	5.42e-24	IgG glycosylation;
LUAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg04287289	chr16:89883240	FANCA	0.67	12.09	0.51	4.28e-29	Vitiligo;
LUAD	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.41	0.45	9.74e-23	Post bronchodilator FEV1;
LUAD	cis	rs1691799	0.899	rs1168328	chr12:66729250	T/C	cg16791601	chr12:66731901	HELB	-0.36	-6.61	-0.31	1.18e-10	White blood cell count (basophil);
LUAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg07677032	chr17:61819896	STRADA	0.59	10.83	0.47	2.7e-24	Prudent dietary pattern;
LUAD	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg09065629	chr16:1709722	CRAMP1L	0.43	7.31	0.33	1.33e-12	Coronary artery disease;
LUAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.58	-0.42	8.04e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg06618935	chr21:46677482	NA	-0.5	-10.0	-0.44	2.88e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.89	0.53	2.7e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg14024328	chr4:719362	PCGF3	-0.52	-8.57	-0.38	1.92e-16	White blood cell count;
LUAD	cis	rs7589342	0.831	rs13429270	chr2:106453060	C/T	cg16077055	chr2:106428750	NCK2	0.37	6.51	0.3	2.08e-10	Addiction;
LUAD	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg18132916	chr6:79620363	NA	-0.46	-7.81	-0.36	4.44e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs367943	0.666	rs6594704	chr5:112692834	A/T	cg21806985	chr5:112824646	MCC	0.25	6.41	0.3	3.83e-10	Type 2 diabetes;
LUAD	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg17264618	chr3:40429014	ENTPD3	0.42	9.03	0.4	6.15e-18	Renal cell carcinoma;
LUAD	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21582582	chr3:182698605	DCUN1D1	0.49	7.57	0.35	2.29e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg20607798	chr8:58055168	NA	0.63	7.99	0.36	1.27e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg08213375	chr14:104286397	PPP1R13B	0.26	6.84	0.32	2.82e-11	Schizophrenia;
LUAD	cis	rs35995292	0.963	rs7803397	chr7:38905686	C/T	cg19327137	chr7:38886074	VPS41	-0.5	-8.54	-0.38	2.41e-16	Subjective well-being (multi-trait analysis);
LUAD	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08109568	chr15:31115862	NA	-0.79	-13.64	-0.55	2.35e-35	Huntington's disease progression;
LUAD	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg00745463	chr17:30367425	LRRC37B	0.65	7.79	0.35	5.39e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg00204512	chr16:28754710	NA	0.33	7.02	0.32	8.77e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs11958404	0.860	rs72818114	chr5:157440207	A/C	cg05962755	chr5:157440814	NA	0.55	8.28	0.37	1.65e-15	IgG glycosylation;
LUAD	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg07386859	chr16:1872102	HAGH	-0.51	-8.14	-0.37	4.32e-15	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18404041	chr3:52824283	ITIH1	-0.61	-12.29	-0.51	6.97e-30	Bipolar disorder;
LUAD	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg17063962	chr7:91808500	NA	0.67	11.95	0.5	1.49e-28	Breast cancer;
LUAD	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg03929089	chr4:120376271	NA	-0.92	-17.28	-0.64	5.24e-51	Height;
LUAD	cis	rs929596	0.785	rs34352510	chr2:234650562	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.73	-12.68	-0.52	1.87e-31	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg08742575	chr21:47604166	C21orf56	-0.57	-9.43	-0.42	2.79e-19	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg07917127	chr4:99064746	C4orf37	0.4	6.52	0.3	2.05e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg03806693	chr22:41940476	POLR3H	-0.58	-8.35	-0.38	9.94e-16	Vitiligo;
LUAD	cis	rs2742234	0.910	rs2505511	chr10:43641029	T/A	cg15436174	chr10:43711423	RASGEF1A	-0.46	-8.38	-0.38	7.66e-16	Hirschsprung disease;
LUAD	cis	rs59698941	0.943	rs67268447	chr5:132303194	G/A	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs2455601	0.882	rs10840139	chr11:8894838	T/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.53	-8.36	-0.38	9.47e-16	Schizophrenia;
LUAD	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg02158880	chr13:53174818	NA	0.49	8.27	0.37	1.8e-15	Lewy body disease;
LUAD	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg21475434	chr5:93447410	FAM172A	0.74	8.56	0.38	2.15e-16	Diabetic retinopathy;
LUAD	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-6.97	-0.32	1.2e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg03526776	chr6:41159608	TREML2	0.34	7.19	0.33	2.93e-12	Alzheimer's disease (late onset);
LUAD	cis	rs34638657	0.732	rs7205534	chr16:82201618	C/T	cg09439754	chr16:82129088	HSD17B2	-0.39	-7.41	-0.34	6.74e-13	Lung adenocarcinoma;
LUAD	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg07677032	chr17:61819896	STRADA	-0.48	-8.55	-0.38	2.3e-16	Prudent dietary pattern;
LUAD	cis	rs8112211	0.637	rs4804046	chr19:38839732	G/T	cg14299480	chr19:38876666	GGN	-0.43	-6.52	-0.3	1.97e-10	Blood protein levels;
LUAD	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.65	-12.34	-0.51	4.38e-30	Lung cancer;
LUAD	cis	rs10733682	0.659	rs13287548	chr9:129466456	C/T	cg00232160	chr9:129468157	NA	0.53	9.57	0.42	8.96e-20	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2985684	0.948	rs4900925	chr14:50012325	A/G	cg04989706	chr14:50066350	PPIL5	0.51	7.57	0.35	2.34e-13	Carotid intima media thickness;
LUAD	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg18721089	chr20:30220636	NA	-0.44	-6.49	-0.3	2.46e-10	Mean corpuscular hemoglobin;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00850453	chr7:12726919	ARL4A	-0.52	-6.59	-0.31	1.3100000000000001e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg27211696	chr2:191398769	TMEM194B	-0.64	-8.12	-0.37	5.13e-15	Diastolic blood pressure;
LUAD	cis	rs1448094	0.842	rs12809288	chr12:86455427	C/T	cg00310523	chr12:86230176	RASSF9	-0.35	-7.36	-0.34	9.76e-13	Major depressive disorder;
LUAD	cis	rs7089973	0.966	rs61867966	chr10:116584362	T/C	cg23260525	chr10:116636907	FAM160B1	0.41	8.86	0.4	2.16e-17	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg07636037	chr3:49044803	WDR6	0.63	12.09	0.51	4.18e-29	Parkinson's disease;
LUAD	cis	rs11800820	0.557	rs55881259	chr1:246665951	C/T	cg16700716	chr1:246684329	NA	0.38	7.04	0.32	7.67e-12	Obesity-related traits;
LUAD	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg11814155	chr7:99998594	ZCWPW1	0.45	7.61	0.35	1.75e-13	Platelet count;
LUAD	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg14196790	chr5:131705035	SLC22A5	0.37	6.68	0.31	7.73e-11	Breast cancer;
LUAD	cis	rs939658	0.967	rs11629665	chr15:79457133	C/T	cg17916960	chr15:79447300	NA	0.45	9.24	0.41	1.2e-18	Refractive error;
LUAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg16414030	chr3:133502952	NA	0.69	13.48	0.55	1.1e-34	Iron status biomarkers;
LUAD	trans	rs853679	0.607	rs13204012	chr6:28201531	G/A	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.13	-0.48	1.99e-25	Depression;
LUAD	cis	rs9807989	0.507	rs1420094	chr2:103015687	C/T	cg03938978	chr2:103052716	IL18RAP	0.45	10.29	0.45	2.51e-22	Asthma;
LUAD	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg07570687	chr10:102243282	WNT8B	0.46	7.06	0.32	6.89e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg26513180	chr16:89883248	FANCA	0.71	13.52	0.55	7.32e-35	Vitiligo;
LUAD	cis	rs2294693	0.891	rs4714421	chr6:40992837	C/T	cg14769373	chr6:40998127	UNC5CL	-0.52	-7.96	-0.36	1.58e-14	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg06064525	chr11:970664	AP2A2	-0.4	-7.89	-0.36	2.63e-14	Alzheimer's disease (late onset);
LUAD	cis	rs4481887	0.893	rs6587450	chr1:248480496	T/A	cg00666640	chr1:248458726	OR2T12	0.32	7.63	0.35	1.5700000000000001e-13	Common traits (Other);
LUAD	cis	rs10992471	0.580	rs7847534	chr9:95282653	C/T	cg14631576	chr9:95140430	CENPP	-0.51	-10.22	-0.45	4.58e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg18016565	chr1:150552671	MCL1	-0.38	-6.69	-0.31	7.3e-11	Tonsillectomy;
LUAD	cis	rs1595825	0.945	rs61184128	chr2:198843659	C/T	cg10547527	chr2:198650123	BOLL	-0.51	-7.14	-0.33	4.01e-12	Ulcerative colitis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18030545	chr6:107077498	QRSL1;RTN4IP1	-0.42	-6.66	-0.31	8.54e-11	Height;
LUAD	trans	rs28735056	0.592	rs2277725	chr18:77694168	A/C	cg05926928	chr17:57297772	GDPD1	-0.48	-7.07	-0.33	6.51e-12	Schizophrenia;
LUAD	cis	rs889398	0.802	rs12598642	chr16:69848772	A/G	cg00738113	chr16:70207722	CLEC18C	0.36	7.4	0.34	7.33e-13	Body mass index;
LUAD	cis	rs10504073	0.584	rs55838473	chr8:49948281	C/A	cg00325661	chr8:49890786	NA	0.48	10.56	0.46	2.81e-23	Blood metabolite ratios;
LUAD	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg10018233	chr7:150070692	REPIN1	0.48	7.49	0.34	4.02e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg26314531	chr2:26401878	FAM59B	0.62	7.81	0.36	4.51e-14	Gut microbiome composition (summer);
LUAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg27532560	chr4:187881888	NA	-0.35	-6.68	-0.31	7.58e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg21724239	chr8:58056113	NA	0.63	7.99	0.36	1.33e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs6684514	1.000	rs12117951	chr1:156305286	G/A	cg16558208	chr1:156270281	VHLL	0.53	9.58	0.42	8.04e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs4285028	0.948	rs71329246	chr3:121680170	T/C	cg20356878	chr3:121714668	ILDR1	-0.5	-6.76	-0.31	4.51e-11	Multiple sclerosis;
LUAD	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg03690763	chr11:133734501	NA	-0.35	-8.12	-0.37	5.15e-15	Childhood ear infection;
LUAD	cis	rs4372836	0.504	rs6760186	chr2:29087274	T/C	cg09522027	chr2:28974177	PPP1CB	-0.59	-10.6	-0.46	1.85e-23	Body mass index;
LUAD	cis	rs4631830	0.863	rs6481329	chr10:51529746	G/A	cg20129853	chr10:51489980	NA	-0.32	-6.39	-0.3	4.35e-10	Prostate-specific antigen levels;
LUAD	cis	rs62238980	0.614	rs74399071	chr22:32455990	G/T	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg02196655	chr2:10830764	NOL10	0.44	7.87	0.36	3.05e-14	Prostate cancer;
LUAD	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg17264618	chr3:40429014	ENTPD3	0.39	8.75	0.39	5.01e-17	Renal cell carcinoma;
LUAD	cis	rs1497406	0.744	rs12057222	chr1:16508534	A/G	cg20430773	chr1:16534157	ARHGEF19	0.4	6.84	0.32	2.82e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.58	0.38	1.85e-16	Parkinson's disease;
LUAD	trans	rs8002861	0.905	rs9525869	chr13:44467210	A/G	cg17145862	chr1:211918768	LPGAT1	0.77	18.1	0.66	1.21e-54	Leprosy;
LUAD	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs4774899	1.000	rs12899036	chr15:57476452	C/A	cg14026238	chr15:57616123	NA	0.36	6.77	0.31	4.38e-11	Urinary tract infection frequency;
LUAD	trans	rs911186	0.782	rs34569203	chr6:27153984	A/C	cg06606381	chr12:133084897	FBRSL1	-0.64	-7.63	-0.35	1.53e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs752010	0.905	rs10890150	chr1:42095603	A/C	cg06885757	chr1:42089581	HIVEP3	0.48	10.79	0.46	3.86e-24	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs11718455	0.960	rs4682712	chr3:43997971	T/C	cg08738300	chr3:44038990	NA	0.44	6.64	0.31	9.88e-11	Coronary artery disease;
LUAD	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg19318889	chr4:1322082	MAEA	0.46	7.5	0.34	3.82e-13	Obesity-related traits;
LUAD	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg25237894	chr2:233734115	C2orf82	-0.56	-10.75	-0.46	5.57e-24	Coronary artery disease;
LUAD	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg25985355	chr7:65971099	NA	-0.52	-6.46	-0.3	2.91e-10	Diabetic kidney disease;
LUAD	trans	rs7944735	0.578	rs7949985	chr11:48062449	C/T	cg15704280	chr7:45808275	SEPT13	0.65	6.92	0.32	1.63e-11	Intraocular pressure;
LUAD	cis	rs11249608	0.548	rs10479520	chr5:178451447	C/A	cg01312482	chr5:178451176	ZNF879	-0.44	-6.88	-0.32	2.18e-11	Pubertal anthropometrics;
LUAD	cis	rs2734839	0.929	rs7131627	chr11:113299829	G/A	cg14159747	chr11:113255604	NA	0.53	10.04	0.44	2.11e-21	Information processing speed;
LUAD	cis	rs2224391	1.000	rs2753246	chr6:5261845	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-9.82	-0.43	1.26e-20	Height;
LUAD	cis	rs10979	1.000	rs35354710	chr6:143886454	A/G	cg25407410	chr6:143891975	LOC285740	-0.63	-9.97	-0.44	3.68e-21	Hypospadias;
LUAD	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg10755058	chr3:40428713	ENTPD3	0.42	7.95	0.36	1.7e-14	Renal cell carcinoma;
LUAD	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-8.15	-0.37	4.09e-15	Total cholesterol levels;
LUAD	cis	rs123509	0.687	rs6865	chr3:42826041	A/C	cg12982090	chr3:42733453	KBTBD5	-0.52	-9.0	-0.4	7.81e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg21724239	chr8:58056113	NA	0.74	9.62	0.42	5.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs3752645	1.000	rs10272371	chr7:106762847	A/T	cg02696742	chr7:106810147	HBP1	0.71	6.71	0.31	6.16e-11	Bladder cancer (smoking interaction);
LUAD	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg03433033	chr1:76189801	ACADM	0.86	17.43	0.65	1.19e-51	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg03388025	chr16:89894329	SPIRE2	0.31	6.85	0.32	2.66e-11	Vitiligo;
LUAD	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg09417038	chr21:47716443	C21orf57	-0.42	-6.85	-0.32	2.67e-11	Testicular germ cell tumor;
LUAD	cis	rs2421770	0.530	rs4756218	chr11:35370113	G/A	cg13971030	chr11:35366721	SLC1A2	-0.47	-8.29	-0.37	1.48e-15	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg11707310	chr1:2537719	MMEL1	0.39	8.29	0.37	1.49e-15	Ulcerative colitis;
LUAD	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg06784218	chr1:46089804	CCDC17	0.59	13.21	0.54	1.38e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7759001	0.857	rs9468111	chr6:27355083	T/A	cg18711553	chr6:27366782	ZNF391	0.39	6.43	0.3	3.36e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg18402987	chr7:1209562	NA	0.78	9.48	0.42	1.89e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.52	-0.55	7.37e-35	Alcohol dependence;
LUAD	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg12310025	chr6:25882481	NA	-0.63	-9.16	-0.41	2.18e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs2548003	0.518	rs13157411	chr5:28751609	C/T	cg22863700	chr5:28928346	NA	-0.47	-7.21	-0.33	2.54e-12	Hip geometry;
LUAD	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08280861	chr8:58055591	NA	0.69	8.32	0.38	1.21e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03352830	chr11:487213	PTDSS2	0.82	10.59	0.46	2.07e-23	Body mass index;
LUAD	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg22705602	chr4:152727874	NA	-0.39	-6.86	-0.32	2.45e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg03467027	chr4:99064603	C4orf37	0.41	6.69	0.31	7.21e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg00277334	chr10:82204260	NA	-0.53	-8.33	-0.38	1.11e-15	Post bronchodilator FEV1;
LUAD	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg03037974	chr15:76606532	NA	0.38	8.02	0.36	1.06e-14	Blood metabolite levels;
LUAD	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg01236616	chr12:121019343	POP5	1.29	19.09	0.68	4.89e-59	Type 1 diabetes nephropathy;
LUAD	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.23	-0.33	2.23e-12	Breast cancer;
LUAD	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg20019720	chr6:154832845	CNKSR3	0.65	12.98	0.53	1.13e-32	Lipoprotein (a) levels;
LUAD	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg00071950	chr4:10020882	SLC2A9	-0.57	-10.85	-0.47	2.33e-24	Bone mineral density;
LUAD	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg15448220	chr1:150897856	SETDB1	-0.52	-9.05	-0.4	5.15e-18	Melanoma;
LUAD	cis	rs796825	0.530	rs34998142	chr3:119939802	T/C	cg21790991	chr3:120137480	FSTL1	-0.42	-7.26	-0.33	1.88e-12	HIV-1 susceptibility;
LUAD	cis	rs3862030	0.720	rs3740415	chr10:104232716	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.95	-0.36	1.76e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs939584	1.000	rs6744653	chr2:628524	A/G	cg03444855	chr2:621920	NA	-0.4	-6.46	-0.3	2.83e-10	Body mass index;
LUAD	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg23262073	chr20:60523788	NA	-0.47	-8.09	-0.37	6.53e-15	Body mass index;
LUAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg15117754	chr3:10150083	C3orf24	0.45	7.46	0.34	4.87e-13	Alzheimer's disease;
LUAD	cis	rs12210905	0.688	rs12205044	chr6:27478990	A/G	cg08851530	chr6:28072375	NA	1.03	7.92	0.36	2.19e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs6063312	0.935	rs6066827	chr20:47341005	T/C	cg18078177	chr20:47281410	PREX1	0.66	8.42	0.38	5.8e-16	Tonometry;
LUAD	cis	rs7640424	0.649	rs1369555	chr3:107901184	A/G	cg09227934	chr3:107805635	CD47	0.47	8.33	0.38	1.15e-15	Body mass index;
LUAD	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.52	0.3	2.05e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg14784868	chr12:69753453	YEATS4	0.4	6.55	0.3	1.69e-10	Blood protein levels;
LUAD	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-8.01	-0.36	1.14e-14	Monocyte percentage of white cells;
LUAD	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	trans	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg01620082	chr3:125678407	NA	-0.64	-7.87	-0.36	2.96e-14	Depression;
LUAD	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24308560	chr3:49941425	MST1R	-0.59	-10.03	-0.44	2.12e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs12472274	0.941	rs6748440	chr2:239100375	C/T	cg17459225	chr2:239074497	NA	0.68	9.18	0.41	1.97e-18	Phospholipid levels (plasma);
LUAD	cis	rs2425143	1.000	rs113203744	chr20:34253656	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.25	-0.33	2.05e-12	Blood protein levels;
LUAD	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1595825	1.000	rs73058834	chr2:198873779	T/G	cg11031976	chr2:198649780	BOLL	-0.46	-6.68	-0.31	7.38e-11	Ulcerative colitis;
LUAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg05896524	chr21:47604654	C21orf56	0.74	13.22	0.54	1.21e-33	Testicular germ cell tumor;
LUAD	cis	rs317865	0.867	rs73234625	chr4:16166206	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.92	8.74	0.39	5.69e-17	Kidney disease (early stage) in type 1 diabetes;
LUAD	cis	rs7824557	0.602	rs7834139	chr8:11206363	C/G	cg21775007	chr8:11205619	TDH	0.56	9.85	0.43	9.2e-21	Retinal vascular caliber;
LUAD	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg12935359	chr14:103987150	CKB	-0.47	-7.99	-0.36	1.33e-14	Body mass index;
LUAD	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11644478	chr21:40555479	PSMG1	0.72	12.04	0.51	6.38e-29	Cognitive function;
LUAD	cis	rs3106136	0.967	rs12499309	chr4:95171284	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.65	-0.35	1.37e-13	Capecitabine sensitivity;
LUAD	cis	rs7927771	0.524	rs10742824	chr11:47864842	C/T	cg18512352	chr11:47633146	NA	0.36	6.39	0.3	4.37e-10	Subjective well-being;
LUAD	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg18721089	chr20:30220636	NA	-0.45	-6.51	-0.3	2.15e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg26924012	chr15:45694286	SPATA5L1	0.61	10.28	0.45	2.92e-22	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg12927641	chr6:109611667	NA	-0.53	-9.21	-0.41	1.54e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs877282	0.898	rs12357016	chr10:765675	C/T	cg17470449	chr10:769945	NA	0.61	8.47	0.38	4.14e-16	Uric acid levels;
LUAD	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.73	-0.35	7.99e-14	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg05590025	chr7:65112418	INTS4L2	0.75	7.92	0.36	2.07e-14	Diabetic kidney disease;
LUAD	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.44	-8.2	-0.37	2.86e-15	Menopause (age at onset);
LUAD	cis	rs9467160	0.817	rs12194966	chr6:24437611	G/A	cg16211469	chr6:24423932	MRS2	0.47	7.08	0.33	5.95e-12	Liver enzyme levels;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg15383120	chr6:291909	DUSP22	-0.71	-11.88	-0.5	2.64e-28	Menopause (age at onset);
LUAD	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03517284	chr6:25882590	NA	0.57	9.27	0.41	9.86e-19	Blood metabolite levels;
LUAD	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg24596788	chr1:163392923	NA	-0.37	-8.08	-0.37	6.82e-15	Motion sickness;
LUAD	cis	rs9462027	0.628	rs6924898	chr6:34811199	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.89	-0.4	1.84e-17	Systemic lupus erythematosus;
LUAD	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg15181151	chr6:150070149	PCMT1	0.41	8.53	0.38	2.66e-16	Lung cancer;
LUAD	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg21862992	chr11:68658383	NA	0.53	9.64	0.42	5.11e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg11295801	chr6:150039190	LATS1	-0.36	-6.36	-0.3	5.11e-10	Schizophrenia;
LUAD	cis	rs7677751	0.806	rs61320297	chr4:55088175	G/A	cg17187183	chr4:55093834	PDGFRA	0.51	8.63	0.39	1.23e-16	Corneal astigmatism;
LUAD	cis	rs2573652	1.000	rs2581359	chr15:100513707	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.53	-9.69	-0.43	3.43e-20	Height;
LUAD	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.16	0.37	3.86e-15	Rheumatoid arthritis;
LUAD	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs11178918	0.585	rs79892958	chr12:72154155	A/T	cg10168894	chr12:72148281	RAB21	-0.53	-6.58	-0.3	1.39e-10	Economic and political preferences (time);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02289682	chr14:65879007	FUT8;LOC645431	-0.4	-6.68	-0.31	7.73e-11	Cancer;
LUAD	cis	rs2425143	1.000	rs74785978	chr20:34373234	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.09	-0.33	5.52e-12	Blood protein levels;
LUAD	cis	rs7943953	0.714	rs7924822	chr11:59199455	G/T	cg00706994	chr11:59190310	OR5A2	0.34	6.37	0.3	4.95e-10	Odorant perception (&beta-ionone);
LUAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.29	-0.41	8.46e-19	Alzheimer's disease;
LUAD	cis	rs1044826	0.642	rs295470	chr3:139213903	A/G	cg00490450	chr3:139108681	COPB2	0.4	6.41	0.3	3.79e-10	Obesity-related traits;
LUAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg13560548	chr3:10150139	C3orf24	0.42	6.9	0.32	1.95e-11	Alzheimer's disease;
LUAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00149659	chr3:10157352	C3orf10	0.55	7.57	0.35	2.41e-13	Alzheimer's disease;
LUAD	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14829155	chr15:31115871	NA	-0.79	-13.71	-0.55	1.2e-35	Huntington's disease progression;
LUAD	cis	rs4774899	0.752	rs7173936	chr15:57418815	A/C	cg14026238	chr15:57616123	NA	-0.4	-7.71	-0.35	9.3e-14	Urinary tract infection frequency;
LUAD	cis	rs12530845	0.887	rs4492299	chr7:135315690	T/G	cg23117316	chr7:135346802	PL-5283	-0.49	-8.43	-0.38	5.55e-16	Red blood cell traits;
LUAD	cis	rs8064299	0.967	rs7420	chr17:72765215	A/G	cg21922841	chr17:72744131	SLC9A3R1	-0.25	-6.44	-0.3	3.29e-10	Monocyte count;
LUAD	cis	rs12291225	0.877	rs11023160	chr11:14264225	T/A	cg19336497	chr11:14380999	RRAS2	-0.55	-10.89	-0.47	1.58e-24	Sense of smell;
LUAD	cis	rs16854884	0.586	rs4613453	chr3:143735600	C/G	cg01302019	chr3:143689584	C3orf58	-0.37	-6.63	-0.31	1.02e-10	Economic and political preferences (feminism/equality);
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg05819172	chr1:33815750	PHC2	0.45	6.73	0.31	5.54e-11	QT interval;
LUAD	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg20673091	chr1:2541236	MMEL1	0.4	8.57	0.38	1.91e-16	Ulcerative colitis;
LUAD	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg18131467	chr2:239335373	ASB1	0.58	9.03	0.4	5.96e-18	Multiple system atrophy;
LUAD	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg06608945	chr2:219082296	ARPC2	0.5	8.45	0.38	4.75e-16	Colorectal cancer;
LUAD	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.49	-8.57	-0.38	1.97e-16	Alzheimer's disease (late onset);
LUAD	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.69	-0.39	8e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1595825	0.945	rs76510735	chr2:198823095	G/A	cg11031976	chr2:198649780	BOLL	-0.47	-6.94	-0.32	1.5e-11	Ulcerative colitis;
LUAD	cis	rs12791968	1.000	rs12791968	chr11:45001490	C/T	cg11846598	chr11:44996168	LOC221122	0.78	14.22	0.57	8.43e-38	Inhibitory control;
LUAD	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg24069376	chr3:38537580	EXOG	0.34	7.99	0.36	1.32e-14	Electrocardiographic conduction measures;
LUAD	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg26373071	chr5:1325741	CLPTM1L	0.37	7.7	0.35	9.68e-14	Lung cancer;
LUAD	cis	rs6867913	0.561	rs9324864	chr5:141469000	A/G	cg08523384	chr5:141488047	NDFIP1	0.43	7.18	0.33	3.17e-12	Asthma;
LUAD	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg08773314	chr2:239334832	ASB1	-0.44	-10.09	-0.44	1.34e-21	Multiple system atrophy;
LUAD	cis	rs9715521	0.867	rs6840137	chr4:59830872	A/G	cg11281224	chr4:60001000	NA	-0.56	-9.46	-0.42	2.1e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg12458913	chr13:53173898	NA	0.42	7.5	0.34	3.81e-13	Lewy body disease;
LUAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg07414643	chr4:187882934	NA	0.33	6.73	0.31	5.55e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg02269571	chr22:50332266	NA	-0.7	-9.73	-0.43	2.45e-20	Schizophrenia;
LUAD	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg18477163	chr1:228402036	OBSCN	0.38	7.09	0.33	5.54e-12	Diastolic blood pressure;
LUAD	cis	rs9826463	0.582	rs11719737	chr3:142164017	A/G	cg20824294	chr3:142316082	PLS1	0.35	6.38	0.3	4.63e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg09184832	chr6:79620586	NA	-0.51	-9.62	-0.42	6e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs12505328	0.514	rs11723762	chr4:174385978	G/T	cg12145043	chr4:174357286	NA	0.41	6.37	0.3	5.02e-10	Chin dimples;
LUAD	cis	rs6460942	0.544	rs4719292	chr7:12139616	C/T	cg06484146	chr7:12443880	VWDE	-0.55	-6.54	-0.3	1.74e-10	Coronary artery disease;
LUAD	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg04282206	chr17:62833786	PLEKHM1P	0.49	7.44	0.34	5.61e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-15.24	-0.6	3.96e-42	Colorectal cancer;
LUAD	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.71	0.49	1.31e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26314531	chr2:26401878	FAM59B	0.55	7.71	0.35	8.95e-14	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg05340658	chr4:99064831	C4orf37	0.47	6.62	0.31	1.1e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3824867	0.738	rs1228024	chr11:47951353	C/A	cg03929089	chr4:120376271	NA	-0.46	-6.77	-0.31	4.33e-11	Mean corpuscular hemoglobin;
LUAD	trans	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg14917512	chr19:3094685	GNA11	0.38	6.62	0.31	1.1e-10	Aortic root size;
LUAD	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg15485101	chr11:133734466	NA	0.37	7.94	0.36	1.87e-14	Childhood ear infection;
LUAD	cis	rs889398	0.802	rs2291959	chr16:69873992	T/G	cg00738113	chr16:70207722	CLEC18C	-0.35	-7.07	-0.33	6.35e-12	Body mass index;
LUAD	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-9.24	-0.41	1.25e-18	Schizophrenia;
LUAD	cis	rs713587	0.713	rs11682135	chr2:25205377	G/A	cg04586622	chr2:25135609	ADCY3	-0.32	-6.84	-0.32	2.76e-11	Body mass index in non-asthmatics;
LUAD	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg03467027	chr4:99064603	C4orf37	0.45	7.26	0.33	1.9e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.73e-16	Height;Educational attainment;Head circumference (infant);
LUAD	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg00981070	chr1:2046702	PRKCZ	0.33	6.85	0.32	2.54e-11	Height;
LUAD	cis	rs7932354	0.528	rs7937950	chr11:47098445	A/C	cg19486271	chr11:47235900	DDB2	-0.46	-7.47	-0.34	4.58e-13	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg24838063	chr12:130822603	PIWIL1	0.71	11.62	0.49	2.9e-27	Menopause (age at onset);
LUAD	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg17425144	chr1:10567563	PEX14	0.61	12.75	0.53	9.81e-32	Breast size;
LUAD	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg17724175	chr1:150552817	MCL1	0.34	7.87	0.36	3.01e-14	Melanoma;
LUAD	cis	rs4280164	0.945	rs4366641	chr14:24771101	C/T	cg22990158	chr14:24802150	ADCY4	0.44	6.42	0.3	3.65e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg20607798	chr8:58055168	NA	0.67	8.77	0.39	4.44e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg12011299	chr4:100065546	ADH4	0.66	12.17	0.51	2.06e-29	Alcohol dependence;
LUAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg11629889	chr17:40839022	CNTNAP1	0.63	12.92	0.53	2.08e-32	Colorectal or endometrial cancer;
LUAD	cis	rs3806843	0.576	rs246041	chr5:140331128	C/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	9.08e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg19717773	chr7:2847554	GNA12	-0.57	-11.24	-0.48	7.61e-26	Height;
LUAD	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg18230493	chr5:56204884	C5orf35	0.71	11.35	0.48	2.96e-26	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1728785	1.000	rs1728773	chr16:68563644	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.78	0.43	1.69e-20	Ulcerative colitis;
LUAD	cis	rs986417	0.786	rs76632048	chr14:60846934	G/A	cg27398547	chr14:60952738	C14orf39	-0.61	-7.25	-0.33	1.95e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg24578937	chr1:2090814	PRKCZ	-0.5	-9.87	-0.43	8.24e-21	Height;
LUAD	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg25427524	chr10:38739819	LOC399744	0.56	9.71	0.43	2.99e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg07817883	chr1:32538562	TMEM39B	1.16	10.86	0.47	2.09e-24	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg07741184	chr6:167504864	NA	0.4	9.03	0.4	6.13e-18	Crohn's disease;
LUAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9863	0.931	rs6488914	chr12:124447841	C/G	cg17723958	chr12:124429295	CCDC92	0.43	6.95	0.32	1.42e-11	White blood cell count;
LUAD	trans	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg14917512	chr19:3094685	GNA11	0.36	6.5	0.3	2.29e-10	Aortic root size;
LUAD	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.7	10.18	0.44	6.61e-22	IgG glycosylation;
LUAD	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg07507251	chr3:52567010	NT5DC2	0.37	7.32	0.34	1.26e-12	Bipolar disorder;
LUAD	cis	rs7843479	0.965	rs3816786	chr8:21860425	A/T	cg10047019	chr8:21822950	XPO7	-0.37	-6.55	-0.3	1.66e-10	Mean corpuscular volume;
LUAD	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg17845761	chr1:175162550	KIAA0040	-0.34	-8.96	-0.4	1.07e-17	Alcohol dependence;
LUAD	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg26384229	chr12:38710491	ALG10B	0.51	8.34	0.38	1.05e-15	Heart rate;
LUAD	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg04944784	chr2:26401820	FAM59B	-0.7	-9.87	-0.43	7.92e-21	Gut microbiome composition (summer);
LUAD	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg09796270	chr17:17721594	SREBF1	0.38	7.79	0.35	5.3e-14	Total body bone mineral density;
LUAD	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg08847533	chr14:75593920	NEK9	-0.4	-6.78	-0.31	4.07e-11	Height;
LUAD	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-6.88	-0.32	2.16e-11	Personality dimensions;
LUAD	cis	rs67366981	0.720	rs4396457	chr14:77685379	G/A	cg22824376	chr14:77648248	TMEM63C	0.84	9.92	0.43	5.6e-21	Obsessive-compulsive symptoms;
LUAD	cis	rs1595825	0.732	rs7577835	chr2:198378056	T/C	cg00982548	chr2:198649783	BOLL	-0.51	-6.88	-0.32	2.2e-11	Ulcerative colitis;
LUAD	cis	rs4481887	0.800	rs4639798	chr1:248515703	A/G	cg00666640	chr1:248458726	OR2T12	0.28	7.04	0.32	7.73e-12	Common traits (Other);
LUAD	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.44	-0.34	5.73e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg24733560	chr20:60626293	TAF4	0.39	7.52	0.34	3.25e-13	Body mass index;
LUAD	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg00316803	chr15:76480434	C15orf27	0.42	6.67	0.31	8.25e-11	Blood metabolite levels;
LUAD	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg16049864	chr8:95962084	TP53INP1	-0.39	-7.15	-0.33	3.8e-12	Type 2 diabetes;
LUAD	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg06532163	chr17:45867833	NA	0.48	8.43	0.38	5.49e-16	IgG glycosylation;
LUAD	cis	rs2282300	0.739	rs7952339	chr11:30327344	C/T	cg06241208	chr11:30344200	C11orf46	0.54	7.1	0.33	5.36e-12	Morning vs. evening chronotype;
LUAD	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10802521	chr3:52805072	NEK4	-0.59	-10.38	-0.45	1.2e-22	Electroencephalogram traits;
LUAD	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.27	0.33	1.81e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs4964805	0.802	rs11111778	chr12:104185431	G/A	cg02344784	chr12:104178138	NT5DC3	0.4	6.84	0.32	2.72e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs9807989	0.507	rs6749014	chr2:103006448	C/T	cg03938978	chr2:103052716	IL18RAP	0.45	10.24	0.45	3.99e-22	Asthma;
LUAD	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg18016565	chr1:150552671	MCL1	0.41	7.48	0.34	4.43e-13	Tonsillectomy;
LUAD	trans	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg04565464	chr8:145669602	NFKBIL2	0.44	6.95	0.32	1.39e-11	Schizophrenia;
LUAD	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg02733842	chr7:1102375	C7orf50	-0.83	-11.93	-0.5	1.71e-28	Bronchopulmonary dysplasia;
LUAD	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg11673840	chr17:47092156	IGF2BP1	-0.37	-7.21	-0.33	2.68e-12	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg18129748	chr3:49941408	MST1R	0.42	7.01	0.32	9.3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs3806933	0.522	rs13157863	chr5:110470505	G/A	cg04450332	chr5:110408780	TSLP	0.35	6.57	0.3	1.51e-10	Eosinophilic esophagitis;
LUAD	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg05182265	chr7:156933206	UBE3C	-0.81	-17.36	-0.65	2.21e-51	Body mass index;
LUAD	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg13877915	chr19:58951672	ZNF132	0.76	14.31	0.57	3.59e-38	Uric acid clearance;
LUAD	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg15309053	chr8:964076	NA	0.44	9.29	0.41	8.48e-19	Schizophrenia;
LUAD	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg07570687	chr10:102243282	WNT8B	0.44	7.04	0.32	7.86e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs4942242	1.000	rs9533566	chr13:44224691	T/C	cg19169023	chr15:41853346	TYRO3	-0.5	-8.53	-0.38	2.58e-16	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7264396	0.563	rs2425137	chr20:34345396	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.72	-0.31	5.83e-11	Total cholesterol levels;
LUAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg11766577	chr21:47581405	C21orf56	-0.6	-10.89	-0.47	1.67e-24	Testicular germ cell tumor;
LUAD	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg07570687	chr10:102243282	WNT8B	0.46	7.09	0.33	5.53e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs59698941	0.550	rs60042615	chr5:132193220	A/G	cg14825688	chr5:132208181	LEAP2	-0.53	-10.77	-0.46	4.7e-24	Apolipoprotein A-IV levels;
LUAD	cis	rs7395662	1.000	rs6485882	chr11:48592435	C/G	cg21546286	chr11:48923668	NA	0.34	6.94	0.32	1.53e-11	HDL cholesterol;
LUAD	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21214613	chr1:16344536	HSPB7	0.56	9.87	0.43	8.28e-21	Dilated cardiomyopathy;
LUAD	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg19761014	chr17:28927070	LRRC37B2	0.82	8.34	0.38	1.09e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs9951602	1.000	rs1903723	chr18:76646571	A/G	cg02800362	chr5:177631904	HNRNPAB	1.01	12.55	0.52	6.15e-31	Obesity-related traits;
LUAD	cis	rs3784262	1.000	rs7495968	chr15:58244103	C/G	cg12031962	chr15:58353849	ALDH1A2	0.41	8.27	0.37	1.76e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg19541837	chr11:71823834	C11orf51	-0.38	-6.57	-0.3	1.49e-10	Subcortical brain region volumes;
LUAD	trans	rs11088226	0.681	rs2833902	chr21:33940458	A/G	cg09050820	chr6:167586206	TCP10L2	0.92	12.57	0.52	5.36e-31	Gastritis;
LUAD	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg17264618	chr3:40429014	ENTPD3	0.42	8.86	0.4	2.27e-17	Renal cell carcinoma;
LUAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.39	-6.5	-0.3	2.25e-10	Longevity;Endometriosis;
LUAD	trans	rs79911532	0.551	rs74999892	chr7:75756464	T/C	cg19862616	chr7:65841803	NCRNA00174	0.84	8.66	0.39	1.01e-16	Mononucleosis;
LUAD	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg13770153	chr20:60521292	NA	0.49	8.58	0.39	1.76e-16	Body mass index;
LUAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg27588902	chr6:42928151	GNMT	-0.35	-8.95	-0.4	1.16e-17	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs897984	0.609	rs55979739	chr16:31049155	A/G	cg02466173	chr16:30829666	NA	-0.55	-9.65	-0.42	4.9e-20	Dementia with Lewy bodies;
LUAD	trans	rs7395662	1.000	rs10838943	chr11:48557442	T/G	cg15704280	chr7:45808275	SEPT13	-0.41	-6.37	-0.3	4.81e-10	HDL cholesterol;
LUAD	cis	rs2075165	0.901	rs759329	chr1:156230936	A/G	cg20302342	chr1:156215951	PAQR6	0.38	8.63	0.39	1.3e-16	Tonsillectomy;
LUAD	cis	rs7705042	0.865	rs4385236	chr5:141513396	G/A	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.82	-0.31	3.12e-11	Asthma;
LUAD	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg12940439	chr1:67600707	NA	0.44	8.59	0.39	1.7e-16	Psoriasis;
LUAD	cis	rs9837602	0.935	rs9860290	chr3:99839106	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.56	7.68	0.35	1.1e-13	Breast cancer;
LUAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg07217954	chr7:1067459	C7orf50	0.45	7.1	0.33	5.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7147624	1.000	rs4902408	chr14:66111901	A/T	cg03016385	chr14:66212404	NA	-0.55	-6.78	-0.31	4.01e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.34	-0.51	4.3e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs7072216	0.763	rs733346	chr10:100164325	A/C	cg26618903	chr10:100175079	PYROXD2	-0.38	-8.39	-0.38	7.15e-16	Metabolite levels;
LUAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg02869364	chr7:1081709	C7orf50	-0.52	-6.64	-0.31	9.7e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg20673091	chr1:2541236	MMEL1	-0.45	-9.82	-0.43	1.24e-20	Ulcerative colitis;
LUAD	cis	rs427941	0.632	rs201497	chr7:101755928	A/C	cg06246474	chr7:101738831	CUX1	0.38	6.51	0.3	2.14e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs113835537	0.529	rs61561111	chr11:66275923	T/C	cg24851651	chr11:66362959	CCS	0.56	9.98	0.44	3.45e-21	Airway imaging phenotypes;
LUAD	cis	rs7707921	0.881	rs111907176	chr5:81312399	A/G	cg15871215	chr5:81402204	ATG10	-0.7	-9.86	-0.43	8.87e-21	Breast cancer;
LUAD	cis	rs2882667	0.858	rs11242444	chr5:138406379	T/A	cg04439458	chr5:138467593	SIL1	-0.53	-9.54	-0.42	1.18e-19	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg04287289	chr16:89883240	FANCA	0.76	6.72	0.31	5.74e-11	Skin colour saturation;
LUAD	cis	rs9394152	0.781	rs9380362	chr6:33467734	T/C	cg13560919	chr6:33536144	NA	0.5	8.3	0.37	1.4e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs12612619	0.677	rs2053386	chr2:27244712	C/T	cg00617064	chr2:27272375	NA	-0.38	-7.13	-0.33	4.42e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg17279839	chr7:150038598	RARRES2	0.45	7.6	0.35	1.91e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg24558204	chr6:135376177	HBS1L	-0.42	-7.35	-0.34	1.05e-12	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg07870213	chr5:140052090	DND1	-0.83	-11.39	-0.48	2.15e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg19346786	chr7:2764209	NA	-0.31	-6.44	-0.3	3.32e-10	Height;
LUAD	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg07587117	chr16:2239488	CASKIN1	0.37	7.15	0.33	3.8e-12	Height;
LUAD	cis	rs62064224	0.512	rs9912766	chr17:30712780	A/G	cg18200150	chr17:30822561	MYO1D	0.41	7.59	0.35	2.11e-13	Schizophrenia;
LUAD	cis	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg21775007	chr8:11205619	TDH	0.57	10.36	0.45	1.42e-22	Retinal vascular caliber;
LUAD	cis	rs713587	0.521	rs35177510	chr2:25089594	C/A	cg04586622	chr2:25135609	ADCY3	0.39	8.75	0.39	5.11e-17	Body mass index in non-asthmatics;
LUAD	cis	rs72928364	0.929	rs62275197	chr3:100683147	C/T	cg10123952	chr3:100791384	NA	0.64	7.43	0.34	5.93e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg08645402	chr16:4508243	NA	0.52	8.96	0.4	1.03e-17	Schizophrenia;
LUAD	cis	rs113835537	0.529	rs4930378	chr11:66255515	T/C	cg24851651	chr11:66362959	CCS	0.55	9.75	0.43	2.23e-20	Airway imaging phenotypes;
LUAD	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg19418458	chr7:158789849	NA	-0.61	-10.71	-0.46	7.73e-24	Facial morphology (factor 20);
LUAD	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg07917127	chr4:99064746	C4orf37	-0.42	-6.89	-0.32	2.08e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-9.59	-0.42	7.75e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg09365446	chr1:150670422	GOLPH3L	0.61	10.91	0.47	1.39e-24	Melanoma;
LUAD	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg03806693	chr22:41940476	POLR3H	-0.48	-7.17	-0.33	3.36e-12	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs3741798	1.000	rs55865572	chr12:12497333	T/C	cg08615371	chr12:12503544	MANSC1	0.74	6.8	0.31	3.67e-11	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg08873628	chr1:175162347	KIAA0040	0.4	6.94	0.32	1.5e-11	Alcohol dependence;
LUAD	cis	rs4072705	0.586	rs7869042	chr9:127246751	C/T	cg01786973	chr9:127249749	NR5A1	-0.29	-6.4	-0.3	4.13e-10	Menarche (age at onset);
LUAD	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg10544611	chr16:67998164	SLC12A4	-0.67	-8.04	-0.36	9.1e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1032833	0.732	rs75805674	chr2:180059711	T/C	cg23883738	chr2:179974586	SESTD1	-0.71	-7.89	-0.36	2.69e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg14403583	chr14:105418241	AHNAK2	0.4	7.04	0.32	7.64e-12	Rheumatoid arthritis;
LUAD	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.82e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.46	-6.8	-0.31	3.69e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg16978871	chr7:139026114	C7orf55	0.46	7.31	0.33	1.38e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg06108461	chr20:60628389	TAF4	0.78	13.85	0.56	3.03e-36	Body mass index;
LUAD	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg15412446	chr2:106886593	NA	-0.63	-9.67	-0.43	4.16e-20	Facial morphology (factor 23);
LUAD	cis	rs354225	0.673	rs354232	chr2:54916910	C/A	cg26097391	chr2:54893211	SPTBN1	0.41	6.7	0.31	6.84e-11	Schizophrenia;
LUAD	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg13385794	chr1:248469461	NA	0.26	6.93	0.32	1.62e-11	Common traits (Other);
LUAD	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg21191810	chr6:118973309	C6orf204	-0.53	-8.32	-0.38	1.21e-15	Diastolic blood pressure;
LUAD	trans	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg27411982	chr8:10470053	RP1L1	0.37	6.39	0.3	4.28e-10	Mood instability;
LUAD	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg23954153	chr1:44402353	ARTN	0.38	7.18	0.33	3.2e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs8192482	1	rs8192482	chr15:78886198	C/T	cg18825076	chr15:78729989	IREB2	-0.57	-9.2	-0.41	1.66e-18	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg21951975	chr1:209979733	IRF6	0.56	8.06	0.36	7.72e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg19436804	chr8:8560866	CLDN23	0.42	6.45	0.3	3.05e-10	Obesity-related traits;
LUAD	cis	rs7070678	0.505	rs12775988	chr10:29784489	T/C	cg11515215	chr10:29698152	LOC387647	0.43	6.54	0.3	1.78e-10	Platelet thrombus formation;
LUAD	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg17863274	chr19:49399704	TULP2	-0.64	-9.78	-0.43	1.74e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg25894440	chr7:65020034	NA	0.64	6.92	0.32	1.65e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg03676636	chr4:99064102	C4orf37	0.31	7.86	0.36	3.17e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg05966235	chr16:28915196	ATP2A1	-0.46	-7.49	-0.34	4.11e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg04673462	chr1:38461896	NA	0.39	8.08	0.37	6.71e-15	Coronary artery disease;
LUAD	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg15468180	chr1:107600409	PRMT6	-0.46	-7.76	-0.35	6.36e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg18944383	chr4:111397179	ENPEP	0.4	7.96	0.36	1.61e-14	Height;
LUAD	cis	rs870825	0.549	rs7656993	chr4:185635159	T/C	cg04058563	chr4:185651563	MLF1IP	0.9	14.43	0.57	1.19e-38	Blood protein levels;
LUAD	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg25457927	chr22:38595422	NA	-0.54	-14.2	-0.57	1.04e-37	Cutaneous nevi;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04683551	chr10:14880332	HSPA14;CDNF	-0.53	-6.35	-0.3	5.68e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg01802117	chr1:53393560	SCP2	-0.33	-6.35	-0.3	5.43e-10	Monocyte count;
LUAD	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg05340658	chr4:99064831	C4orf37	0.55	9.38	0.41	4.09e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg23422044	chr7:1970798	MAD1L1	0.52	6.43	0.3	3.45e-10	Bipolar disorder;
LUAD	cis	rs752010	0.574	rs6671999	chr1:42120416	G/A	cg06885757	chr1:42089581	HIVEP3	0.4	8.64	0.39	1.15e-16	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg07936489	chr17:37558343	FBXL20	-0.47	-7.35	-0.34	1.06e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs1595825	0.891	rs6733834	chr2:198518709	C/G	cg00982548	chr2:198649783	BOLL	0.58	8.15	0.37	4.13e-15	Ulcerative colitis;
LUAD	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg13798912	chr7:905769	UNC84A	-0.65	-7.22	-0.33	2.48e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4730250	0.707	rs257372	chr7:106796977	T/G	cg23024343	chr7:107201750	COG5	0.51	6.97	0.32	1.25e-11	Osteoarthritis;
LUAD	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg23625390	chr15:77176239	SCAPER	-0.49	-7.4	-0.34	7.54e-13	Blood metabolite levels;
LUAD	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg18512352	chr11:47633146	NA	-0.44	-7.53	-0.34	3.08e-13	Subjective well-being;
LUAD	cis	rs6674970	0.748	rs56299877	chr1:151115645	C/T	cg11822372	chr1:151115635	SEMA6C	-1.15	-19.83	-0.69	2.43e-62	Childhood ear infection;
LUAD	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.15	15.18	0.59	7.19e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg00745463	chr17:30367425	LRRC37B	-0.84	-10.37	-0.45	1.38e-22	Hip circumference adjusted for BMI;
LUAD	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	7.03	0.32	8.27e-12	Lung cancer;
LUAD	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.22	-0.37	2.55e-15	Total cholesterol levels;
LUAD	cis	rs11696501	0.739	rs6032411	chr20:44286542	C/G	cg11783356	chr20:44313418	WFDC10B	-0.4	-7.12	-0.33	4.74e-12	Brain structure;
LUAD	cis	rs427941	0.632	rs201471	chr7:101744145	T/G	cg06246474	chr7:101738831	CUX1	0.4	6.89	0.32	1.99e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.4	-6.61	-0.31	1.13e-10	Birth weight;
LUAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg07234876	chr8:600039	NA	1.03	10.13	0.44	9.72e-22	IgG glycosylation;
LUAD	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg14008862	chr17:28927542	LRRC37B2	0.56	6.76	0.31	4.65e-11	Body mass index;
LUAD	cis	rs2535633	0.631	rs2581803	chr3:52994981	G/A	cg11645453	chr3:52864694	ITIH4	-0.37	-6.91	-0.32	1.75e-11	Body mass index;
LUAD	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg16405210	chr4:1374714	KIAA1530	-0.6	-9.16	-0.41	2.3e-18	Longevity;
LUAD	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg11915388	chr22:42470451	FAM109B	0.41	7.28	0.33	1.64e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-7.04	-0.32	7.87e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6854137	0.556	rs6855574	chr4:169730716	C/T	cg20607169	chr4:169750834	PALLD	0.4	7.1	0.33	5.36e-12	Vein graft stenosis in coronary artery bypass grafting;
LUAD	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg10518543	chr12:38710700	ALG10B	-0.51	-8.33	-0.38	1.11e-15	Morning vs. evening chronotype;
LUAD	cis	rs3820068	0.822	rs2901964	chr1:15792426	C/G	cg24675056	chr1:15929824	NA	0.42	6.51	0.3	2.1e-10	Systolic blood pressure;
LUAD	cis	rs1595825	0.786	rs116046984	chr2:198884413	G/A	cg00982548	chr2:198649783	BOLL	-0.65	-9.14	-0.41	2.63e-18	Ulcerative colitis;
LUAD	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.46	7.62	0.35	1.63e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2235649	0.552	rs8056773	chr16:1959432	G/A	cg07386859	chr16:1872102	HAGH	0.45	6.46	0.3	2.82e-10	Blood metabolite levels;
LUAD	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.82	-0.36	4.23e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15541040	chr2:3486749	NA	-0.43	-7.42	-0.34	6.46e-13	Neurofibrillary tangles;
LUAD	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg07507251	chr3:52567010	NT5DC2	0.37	7.35	0.34	1.06e-12	Bipolar disorder;
LUAD	cis	rs7258465	1.000	rs10413237	chr19:18548249	A/C	cg01065977	chr19:18549689	ISYNA1	-0.41	-7.85	-0.36	3.44e-14	Breast cancer;
LUAD	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.53	-0.34	3.05e-13	Breast cancer;
LUAD	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg25233709	chr10:116636983	FAM160B1	0.41	8.26	0.37	1.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.91	-19.0	-0.68	1.15e-58	Ulcerative colitis;
LUAD	cis	rs405460	0.517	rs443654	chr14:59305709	A/C	cg02291164	chr14:59296302	NA	-0.42	-8.03	-0.36	9.85e-15	Obesity-related traits;
LUAD	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.58	-0.3	1.35e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9649213	0.614	rs1006169	chr7:97938443	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.72	10.81	0.47	3.14e-24	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs4073416	0.542	rs10142283	chr14:66044129	G/A	cg10998611	chr14:65879393	FUT8;LOC645431	-0.42	-6.37	-0.3	5.06e-10	N-glycan levels;
LUAD	cis	rs3760982	0.585	rs8109478	chr19:44298256	C/T	cg11993925	chr19:44307056	LYPD5	0.54	11.2	0.48	1.15e-25	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs2046867	0.818	rs17010204	chr3:72879099	G/A	cg25664220	chr3:72788482	NA	-0.63	-11.53	-0.49	6.27e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7187994	0.848	rs60566983	chr16:84774799	A/G	cg07647771	chr16:84786436	USP10	-0.36	-9.23	-0.41	1.35e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs7680126	0.633	rs4698023	chr4:10304726	A/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.09	-0.33	5.67e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7737355	0.947	rs1468303	chr5:130804400	T/C	cg06307176	chr5:131281290	NA	-0.51	-8.08	-0.37	6.84e-15	Life satisfaction;
LUAD	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg11502198	chr6:26597334	ABT1	0.65	10.59	0.46	2.14e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg27624424	chr6:160112604	SOD2	0.44	6.42	0.3	3.62e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs1697139	0.935	rs1627990	chr5:66513326	C/T	cg16691251	chr5:66510806	NA	0.35	6.67	0.31	8.22e-11	Breast cancer;
LUAD	cis	rs4846217	0.920	rs17400878	chr1:10316729	A/G	cg17425144	chr1:10567563	PEX14	-0.57	-7.31	-0.34	1.31e-12	Platelet count;
LUAD	cis	rs7187994	0.848	rs8044948	chr16:84749734	A/T	cg07647771	chr16:84786436	USP10	-0.38	-9.75	-0.43	2.12e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	8.07	0.37	7.1e-15	Rheumatoid arthritis;
LUAD	cis	rs829880	0.570	rs844205	chr12:98846053	A/G	cg25150519	chr12:98850993	NA	0.73	13.09	0.54	4.08e-33	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs907683	0.635	rs11691617	chr2:220295167	C/T	cg15015639	chr2:220282977	DES	0.46	8.66	0.39	1.01e-16	Resting heart rate;
LUAD	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg18016565	chr1:150552671	MCL1	-0.47	-8.19	-0.37	3.14e-15	Blood protein levels;
LUAD	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg13385794	chr1:248469461	NA	0.26	6.93	0.32	1.62e-11	Common traits (Other);
LUAD	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg26408565	chr15:76604113	ETFA	-0.42	-6.66	-0.31	8.45e-11	Blood metabolite levels;
LUAD	cis	rs9322817	0.583	rs7746856	chr6:105146360	A/C	cg02098413	chr6:105308735	HACE1	0.35	7.08	0.33	5.9e-12	Thyroid stimulating hormone;
LUAD	trans	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg01620082	chr3:125678407	NA	-0.44	-6.66	-0.31	8.39e-11	Depression;
LUAD	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg20991723	chr1:152506922	NA	0.33	6.53	0.3	1.87e-10	Hair morphology;
LUAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00166722	chr3:10149974	C3orf24	0.73	10.8	0.47	3.42e-24	Alzheimer's disease;
LUAD	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg00701064	chr4:6280414	WFS1	0.57	10.74	0.46	6.03e-24	Cisplatin-induced ototoxicity;
LUAD	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.86e-16	Neutrophil percentage of white cells;
LUAD	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg17366294	chr4:99064904	C4orf37	0.48	8.49	0.38	3.49e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg15997130	chr1:24165203	NA	0.57	10.42	0.45	8.73e-23	Immature fraction of reticulocytes;
LUAD	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg02269571	chr22:50332266	NA	-0.68	-9.77	-0.43	1.76e-20	Schizophrenia;
LUAD	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg00684032	chr4:1343700	KIAA1530	0.39	6.55	0.3	1.64e-10	Obesity-related traits;
LUAD	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg12119029	chr16:89752879	CDK10	0.37	7.48	0.34	4.28e-13	Vitiligo;
LUAD	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg03388025	chr16:89894329	SPIRE2	0.49	12.68	0.52	1.9e-31	Vitiligo;
LUAD	cis	rs79839061	0.520	rs2279187	chr4:875529	C/T	cg14530993	chr4:882597	GAK	0.74	6.8	0.31	3.61e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-7.22	-0.33	2.44e-12	Morning vs. evening chronotype;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09133386	chr6:20404188	E2F3	-0.44	-6.87	-0.32	2.29e-11	Height;
LUAD	cis	rs727505	1.000	rs17246404	chr7:124462661	C/T	cg23710748	chr7:124431027	NA	-0.48	-9.87	-0.43	7.99e-21	Lewy body disease;
LUAD	cis	rs427394	0.659	rs419128	chr5:6739791	G/A	cg14682080	chr5:6737778	POLS	0.35	7.56	0.35	2.45e-13	Menopause (age at onset);
LUAD	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg08355456	chr11:67383691	NA	0.46	7.9	0.36	2.41e-14	Mean corpuscular volume;
LUAD	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg16479474	chr6:28041457	NA	0.46	7.67	0.35	1.2e-13	Depression;
LUAD	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg21138405	chr5:131827807	IRF1	0.59	13.55	0.55	5.42e-35	Asthma (sex interaction);
LUAD	trans	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg10518543	chr12:38710700	ALG10B	0.4	6.43	0.3	3.47e-10	Morning vs. evening chronotype;
LUAD	cis	rs6840360	0.593	rs4696106	chr4:152606818	A/G	cg22705602	chr4:152727874	NA	-0.47	-8.6	-0.39	1.58e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg22166914	chr1:53195759	ZYG11B	-0.45	-7.62	-0.35	1.67e-13	Monocyte count;
LUAD	cis	rs1448094	0.967	rs7312144	chr12:86328256	T/C	cg18827107	chr12:86230957	RASSF9	-0.44	-7.93	-0.36	1.94e-14	Major depressive disorder;
LUAD	cis	rs13095912	1.000	rs1823238	chr3:185341970	G/A	cg11274856	chr3:185301563	NA	0.39	7.81	0.36	4.51e-14	Systolic blood pressure;
LUAD	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg12863693	chr15:85201151	NMB	-0.38	-6.74	-0.31	5.07e-11	Schizophrenia;
LUAD	cis	rs7773004	0.905	rs6932584	chr6:26327081	A/C	cg00631329	chr6:26305371	NA	-0.52	-8.97	-0.4	9.44e-18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07685180	chr8:600429	NA	0.8	8.42	0.38	6.08e-16	IgG glycosylation;
LUAD	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg20587970	chr11:113659929	NA	-1.4	-20.82	-0.71	8.72e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs10465746	0.780	rs2147392	chr1:84404154	C/A	cg10977910	chr1:84465055	TTLL7	0.6	9.9	0.43	6.35e-21	Obesity-related traits;
LUAD	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.33	6.78	0.31	4.18e-11	Obesity-related traits;
LUAD	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg09509183	chr1:209979624	IRF6	0.59	8.15	0.37	4.16e-15	Cleft lip with or without cleft palate;
LUAD	trans	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg15133208	chr4:90757351	SNCA	-0.47	-7.11	-0.33	4.85e-12	Neuroticism;
LUAD	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg03526776	chr6:41159608	TREML2	0.31	6.56	0.3	1.59e-10	Alzheimer's disease (late onset);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22212156	chr20:32031449	SNTA1	-0.55	-6.68	-0.31	7.6e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.92	0.32	1.67e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	7.19	0.33	2.97e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg08470875	chr2:26401718	FAM59B	-0.6	-8.12	-0.37	5.14e-15	Gut microbiome composition (summer);
LUAD	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg23985595	chr17:80112537	CCDC57	0.42	7.42	0.34	6.39e-13	Life satisfaction;
LUAD	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg18446336	chr7:2847575	GNA12	-0.36	-6.76	-0.31	4.48e-11	Height;
LUAD	trans	rs4942242	0.602	rs61960076	chr13:44217784	T/C	cg19169023	chr15:41853346	TYRO3	-0.68	-11.48	-0.49	9.54e-27	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.58	-9.97	-0.44	3.65e-21	Electrocardiographic conduction measures;
LUAD	cis	rs11195062	0.766	rs7922679	chr10:112014428	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.4	-6.37	-0.3	5.04e-10	Multiple myeloma;
LUAD	cis	rs4356932	1.000	rs4257674	chr4:76945685	A/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.49	-0.3	2.36e-10	Blood protein levels;
LUAD	cis	rs300774	1.000	rs300777	chr2:112026	T/C	cg21211680	chr2:198530	NA	-0.46	-6.68	-0.31	7.37e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg06609049	chr19:2785107	THOP1	1.06	20.86	0.71	5.63e-67	Total cholesterol levels;
LUAD	cis	rs11126435	0.858	rs363622	chr2:74929001	G/A	cg19285774	chr2:74907978	SEMA4F	0.36	6.41	0.3	3.99e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06544989	chr22:39130855	UNC84B	0.44	8.35	0.38	9.51e-16	Menopause (age at onset);
LUAD	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg21475434	chr5:93447410	FAM172A	0.7	7.81	0.36	4.51e-14	Diabetic retinopathy;
LUAD	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg14631576	chr9:95140430	CENPP	-0.47	-9.59	-0.42	7.84e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs739496	0.843	rs625093	chr12:111988432	A/G	cg10833066	chr12:111807467	FAM109A	0.41	6.57	0.3	1.52e-10	Platelet count;
LUAD	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-8.43	-0.38	5.33e-16	Gut microbiome composition (summer);
LUAD	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg21138405	chr5:131827807	IRF1	0.6	13.77	0.56	6.51e-36	Asthma (sex interaction);
LUAD	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg18110333	chr6:292329	DUSP22	-0.53	-8.66	-0.39	1.04e-16	Menopause (age at onset);
LUAD	cis	rs89107	0.651	rs447193	chr6:118607662	G/A	cg21191810	chr6:118973309	C6orf204	0.49	9.67	0.43	4.09e-20	Cardiac structure and function;
LUAD	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg10589385	chr1:150898437	SETDB1	0.44	8.09	0.37	6.27e-15	Melanoma;
LUAD	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg07708487	chr16:89387014	ANKRD11	-0.33	-6.67	-0.31	8.25e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.06	-0.36	7.85e-15	Breast cancer;
LUAD	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.43	-6.94	-0.32	1.46e-11	Tonsillectomy;
LUAD	cis	rs11671005	0.779	rs3794970	chr19:58986260	C/T	cg13877915	chr19:58951672	ZNF132	-0.52	-6.75	-0.31	4.98e-11	Mean platelet volume;
LUAD	cis	rs240764	0.697	rs846799	chr6:101270345	A/G	cg09795085	chr6:101329169	ASCC3	0.43	7.43	0.34	5.93e-13	Neuroticism;
LUAD	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg04944784	chr2:26401820	FAM59B	-0.88	-12.6	-0.52	4.12e-31	Gut microbiome composition (summer);
LUAD	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg12365402	chr11:9010492	NRIP3	-0.52	-10.51	-0.46	4.11e-23	Hemoglobin concentration;
LUAD	cis	rs7665090	0.934	rs35112949	chr4:103559630	C/T	cg07973026	chr4:103553119	MANBA	0.47	8.23	0.37	2.31e-15	Primary biliary cholangitis;
LUAD	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg13319975	chr6:146136371	FBXO30	0.66	11.45	0.49	1.29e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8067545	0.641	rs169412	chr17:19851875	G/T	cg04132472	chr17:19861366	AKAP10	0.4	9.39	0.42	3.83e-19	Schizophrenia;
LUAD	cis	rs7274811	0.744	rs209665	chr20:32128889	T/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.51	-7.72	-0.35	8.46e-14	Height;
LUAD	cis	rs1160297	0.609	rs12713232	chr2:53108308	A/T	cg07782112	chr2:53107842	NA	-0.43	-9.5	-0.42	1.52e-19	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg01851573	chr8:8652454	MFHAS1	-0.43	-7.56	-0.35	2.48e-13	Mood instability;
LUAD	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg04369109	chr6:150039330	LATS1	-0.46	-7.75	-0.35	6.81e-14	Lung cancer;
LUAD	cis	rs992157	0.672	rs2382829	chr2:219184617	G/A	cg05991184	chr2:219186017	PNKD	-0.41	-7.73	-0.35	8.08e-14	Colorectal cancer;
LUAD	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg04455712	chr21:45112962	RRP1B	0.47	9.24	0.41	1.21e-18	Mean corpuscular volume;
LUAD	cis	rs2030114	0.555	rs34065507	chr16:51595451	G/A	cg03758633	chr16:51611768	NA	0.33	6.9	0.32	1.86e-11	Blood pressure measurement (high sodium and potassium intervention);
LUAD	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg18944383	chr4:111397179	ENPEP	0.39	7.84	0.36	3.75e-14	Height;
LUAD	cis	rs12144309	0.554	rs1970559	chr1:114377148	T/C	cg03325407	chr1:114423726	BCL2L15	0.39	6.9	0.32	1.91e-11	Coronary artery disease;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg13665852	chr10:13146898	OPTN	-0.41	-6.79	-0.31	3.75e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg05901451	chr6:126070800	HEY2	-0.57	-9.1	-0.4	3.53e-18	Brugada syndrome;
LUAD	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg02018176	chr4:1364513	KIAA1530	-0.37	-6.99	-0.32	1.11e-11	Obesity-related traits;
LUAD	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg26384229	chr12:38710491	ALG10B	0.47	7.57	0.35	2.3e-13	Morning vs. evening chronotype;
LUAD	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.59	0.35	2.07e-13	Depression;
LUAD	cis	rs7095607	0.538	rs2634708	chr10:69920013	C/A	cg18986048	chr10:69913749	MYPN	0.46	7.83	0.36	3.87e-14	Lung function (FVC);
LUAD	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg04025307	chr7:1156635	C7orf50	0.52	6.91	0.32	1.82e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs4356932	0.967	rs4386624	chr4:76946139	G/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.49	-0.3	2.36e-10	Blood protein levels;
LUAD	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg24579218	chr15:68104479	NA	-0.56	-9.7	-0.43	3.29e-20	Restless legs syndrome;
LUAD	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg07776626	chr8:57350775	NA	-0.6	-9.01	-0.4	7.35e-18	Obesity-related traits;
LUAD	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg00204512	chr16:28754710	NA	0.35	7.53	0.34	3.19e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	10.01	0.44	2.6e-21	Total body bone mineral density;
LUAD	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg04455712	chr21:45112962	RRP1B	0.47	9.4	0.42	3.42e-19	Mean corpuscular volume;
LUAD	trans	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg06606381	chr12:133084897	FBRSL1	-0.63	-6.48	-0.3	2.56e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg12483005	chr1:23474871	LUZP1	0.52	9.13	0.41	2.93e-18	Height;
LUAD	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.86e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.43	-7.49	-0.34	4.05e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg06784218	chr1:46089804	CCDC17	0.58	13.03	0.54	7.57e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10193935	1.000	rs13411405	chr2:42413811	C/A	cg27598129	chr2:42591480	NA	-0.78	-10.28	-0.45	2.87e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs714515	0.511	rs9425301	chr1:172363815	A/C	cg13446689	chr1:172328377	DNM3	-0.39	-7.79	-0.35	5.18e-14	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07870854	chr16:791252	NARFL	-0.59	-7.13	-0.33	4.45e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7168353	1.000	rs7168353	chr15:93638401	C/G	cg02918577	chr15:93633145	RGMA	0.41	6.57	0.3	1.45e-10	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6906287	0.647	rs973944	chr6:118850956	T/G	cg21191810	chr6:118973309	C6orf204	0.5	9.77	0.43	1.85e-20	Electrocardiographic conduction measures;
LUAD	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg20891558	chr2:74357851	NA	0.97	17.49	0.65	6.25e-52	Gestational age at birth (maternal effect);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19394510	chr12:58068806	NA	0.47	6.37	0.3	4.97e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg21724239	chr8:58056113	NA	0.55	7.36	0.34	9.95e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs6087990	0.735	rs2064350	chr20:31390533	T/C	cg13636640	chr20:31349939	DNMT3B	0.74	13.17	0.54	1.9e-33	Ulcerative colitis;
LUAD	cis	rs1215050	0.743	rs6532692	chr4:98648005	C/A	cg05340658	chr4:99064831	C4orf37	-0.45	-7.31	-0.34	1.3e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg18944383	chr4:111397179	ENPEP	0.39	7.85	0.36	3.57e-14	Height;
LUAD	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg22920501	chr2:26401640	FAM59B	0.76	10.94	0.47	1.09e-24	Gut microbiome composition (summer);
LUAD	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.9	0.36	2.47e-14	Morning vs. evening chronotype;
LUAD	cis	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg00071950	chr4:10020882	SLC2A9	0.47	7.03	0.32	8.23e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg21153622	chr11:89784906	NA	-0.33	-6.55	-0.3	1.7e-10	Coronary artery disease;
LUAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg26818010	chr10:134567672	INPP5A	-0.95	-15.77	-0.61	2.08e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg13679303	chr9:96623674	NA	-0.37	-7.4	-0.34	7.42e-13	DNA methylation (variation);
LUAD	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg05805236	chr11:65401703	PCNXL3	0.4	6.67	0.31	7.88e-11	Acne (severe);
LUAD	cis	rs597539	0.690	rs1249359	chr11:68618279	C/T	cg06112835	chr11:68658793	MRPL21	0.5	8.82	0.39	2.94e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.79	-0.43	1.52e-20	Schizophrenia;
LUAD	cis	rs4965006	0.915	rs7969545	chr12:132419157	C/T	cg00588090	chr12:132412438	PUS1	-0.58	-8.52	-0.38	2.75e-16	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg03732007	chr1:2071316	PRKCZ	-0.34	-6.36	-0.3	5.39e-10	Height;
LUAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg18402987	chr7:1209562	NA	0.85	11.2	0.48	1.16e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62238980	0.614	rs75142210	chr22:32398992	G/A	cg00543991	chr22:32367038	NA	0.95	8.87	0.4	2.05e-17	Childhood ear infection;
LUAD	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg10589385	chr1:150898437	SETDB1	0.45	8.26	0.37	1.91e-15	Melanoma;
LUAD	cis	rs6964587	0.758	rs35963176	chr7:91617115	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	7.15	0.33	3.94e-12	Breast cancer;
LUAD	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg20487152	chr13:99095054	FARP1	-0.47	-8.05	-0.36	8.36e-15	Longevity;
LUAD	cis	rs6076065	1.000	rs6083105	chr20:23368475	C/A	cg11657817	chr20:23433608	CST11	0.44	8.66	0.39	1.03e-16	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg17366294	chr4:99064904	C4orf37	0.61	10.3	0.45	2.47e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg26958806	chr6:27640298	NA	0.58	6.39	0.3	4.46e-10	Depression;
LUAD	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg11584989	chr19:19387371	SF4	0.35	6.4	0.3	4.02e-10	Tonsillectomy;
LUAD	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg24813613	chr7:1882135	MAD1L1	-0.43	-6.83	-0.32	3.01e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg09035930	chr12:129282057	SLC15A4	0.69	15.86	0.61	8.44e-45	Systemic lupus erythematosus;
LUAD	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-6.82	-0.31	3.23e-11	Blood metabolite levels;
LUAD	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg17063962	chr7:91808500	NA	0.71	12.67	0.52	2.11e-31	Breast cancer;
LUAD	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.37	-6.43	-0.3	3.52e-10	Caffeine consumption;
LUAD	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06544989	chr22:39130855	UNC84B	0.45	8.41	0.38	6.52e-16	Menopause (age at onset);
LUAD	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg17063962	chr7:91808500	NA	0.68	12.36	0.52	3.5e-30	Breast cancer;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg14417157	chr15:50646187	GABPB1;FLJ10038;LOC100129387	-0.38	-6.89	-0.32	2.03e-11	Subcortical brain region volumes;
LUAD	cis	rs2282300	0.739	rs35229181	chr11:30241698	A/G	cg06241208	chr11:30344200	C11orf46	-0.57	-7.31	-0.34	1.31e-12	Morning vs. evening chronotype;
LUAD	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-7.48	-0.34	4.42e-13	Total cholesterol levels;
LUAD	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg18252515	chr7:66147081	NA	-0.62	-6.78	-0.31	4.18e-11	Diabetic kidney disease;
LUAD	cis	rs870825	0.616	rs7660064	chr4:185617529	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.32	0.57	3.35e-38	Blood protein levels;
LUAD	cis	rs2282300	0.739	rs34234618	chr11:30241701	T/C	cg06241208	chr11:30344200	C11orf46	-0.57	-7.31	-0.34	1.31e-12	Morning vs. evening chronotype;
LUAD	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg04944784	chr2:26401820	FAM59B	-0.89	-12.76	-0.53	8.87e-32	Gut microbiome composition (summer);
LUAD	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg04944784	chr2:26401820	FAM59B	0.69	9.66	0.43	4.3e-20	Gut microbiome composition (summer);
LUAD	cis	rs12049351	0.774	rs4148760	chr1:229673934	G/C	cg11742688	chr1:229674241	ABCB10	-0.42	-6.91	-0.32	1.78e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg10356904	chr22:49881777	NA	-0.41	-8.08	-0.37	6.61e-15	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.17e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	6.8	0.31	3.47e-11	Platelet count;
LUAD	cis	rs599083	0.744	rs603129	chr11:68186669	A/T	cg16797656	chr11:68205561	LRP5	-0.47	-9.23	-0.41	1.31e-18	Bone mineral density (spine);
LUAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg25703541	chr22:24373054	LOC391322	-0.84	-15.97	-0.61	2.94e-45	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06544989	chr22:39130855	UNC84B	0.44	8.27	0.37	1.7e-15	Menopause (age at onset);
LUAD	cis	rs6717918	0.887	rs6746834	chr2:233158817	C/T	ch.2.233013039R	chr2:233304795	NA	-0.47	-7.08	-0.33	6.19e-12	Height;
LUAD	cis	rs7937890	0.559	rs2597217	chr11:14532883	A/G	cg06199346	chr11:14280333	SPON1	-0.32	-6.41	-0.3	3.86e-10	Mitochondrial DNA levels;
LUAD	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.38	0.38	7.69e-16	Platelet count;
LUAD	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg13319975	chr6:146136371	FBXO30	-0.62	-10.76	-0.46	4.85e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2294693	0.530	rs2073016	chr6:41020922	T/C	cg14769373	chr6:40998127	UNC5CL	-0.58	-8.15	-0.37	4.05e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs7737355	1.000	rs2549018	chr5:130698949	C/T	cg06307176	chr5:131281290	NA	-0.46	-7.32	-0.34	1.29e-12	Life satisfaction;
LUAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg24101359	chr6:42928495	GNMT	0.57	11.15	0.48	1.81e-25	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg13453750	chr1:205783389	SLC41A1	-0.38	-6.67	-0.31	8e-11	Menarche (age at onset);
LUAD	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	7.86	0.36	3.33e-14	Tonsillectomy;
LUAD	cis	rs17401966	1.000	rs2275424	chr1:10356562	C/A	cg15208524	chr1:10270712	KIF1B	0.56	8.31	0.37	1.33e-15	Hepatocellular carcinoma;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16015499	chr1:159888603	TAGLN2	0.52	6.53	0.3	1.86e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11811982	0.793	rs11807068	chr1:227514908	T/G	cg24860534	chr1:227506868	CDC42BPA	0.67	7.32	0.34	1.25e-12	Optic disc area;
LUAD	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg27489772	chr12:121021490	NA	0.58	6.99	0.32	1.07e-11	Type 1 diabetes nephropathy;
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg09563405	chr16:32127656	NA	-0.35	-6.42	-0.3	3.64e-10	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg22683308	chr4:1340831	KIAA1530	-0.47	-7.72	-0.35	8.34e-14	Longevity;
LUAD	cis	rs3820068	0.705	rs951225	chr1:15826292	G/A	cg13390004	chr1:15929781	NA	0.4	6.51	0.3	2.15e-10	Systolic blood pressure;
LUAD	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg22532475	chr10:104410764	TRIM8	0.35	7.0	0.32	1.02e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs17095355	1.000	rs12244557	chr10:111746142	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.7	-9.28	-0.41	8.83e-19	Biliary atresia;
LUAD	cis	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg21775007	chr8:11205619	TDH	-0.38	-6.47	-0.3	2.67e-10	Neuroticism;
LUAD	cis	rs6005807	0.719	rs9625513	chr22:29022172	C/T	cg12565055	chr22:29076175	TTC28	0.75	8.76	0.39	4.71e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	trans	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	26.66	0.79	1.38e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9902453	0.765	rs3115087	chr17:28030267	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.51	0.42	1.45e-19	Coffee consumption (cups per day);
LUAD	cis	rs1865721	0.804	rs59187673	chr18:73143964	A/G	cg26385618	chr18:73139727	C18orf62	-0.51	-10.11	-0.44	1.11e-21	Intelligence;
LUAD	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	6.59	0.3	1.35e-10	Cognitive test performance;
LUAD	cis	rs807669	0.548	rs762522	chr22:19180575	C/T	cg24911827	chr22:19170109	CLTCL1	0.36	7.51	0.34	3.61e-13	Metabolite levels;
LUAD	cis	rs686320	1.000	rs667196	chr11:65247092	A/T	cg21890820	chr11:65308645	LTBP3	0.8	8.55	0.38	2.26e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs13082711	0.911	rs17019809	chr3:27509080	A/G	cg02860705	chr3:27208620	NA	0.56	8.73	0.39	5.84e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg03806693	chr22:41940476	POLR3H	0.67	9.06	0.4	4.69e-18	Vitiligo;
LUAD	cis	rs7680126	0.633	rs74469609	chr4:10294424	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-7.49	-0.34	4.13e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs12200782	1.000	rs12204145	chr6:26600156	C/T	cg11502198	chr6:26597334	ABT1	-0.76	-6.77	-0.31	4.2e-11	Small cell lung carcinoma;
LUAD	cis	rs909002	0.849	rs871634	chr1:32093167	G/C	cg13919466	chr1:32135498	COL16A1	-0.35	-8.14	-0.37	4.43e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6445967	0.530	rs7615468	chr3:58339148	C/T	cg23715586	chr3:58305044	RPP14	0.41	6.58	0.3	1.4e-10	Platelet count;
LUAD	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg01236616	chr12:121019343	POP5	-1.2	-17.93	-0.66	6.87e-54	Type 1 diabetes nephropathy;
LUAD	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg22117172	chr7:91764530	CYP51A1	0.37	8.19	0.37	3.14e-15	Breast cancer;
LUAD	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg24397884	chr7:158709396	WDR60	-0.74	-13.29	-0.54	6.41e-34	Height;
LUAD	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg20487152	chr13:99095054	FARP1	-0.62	-11.87	-0.5	3.03e-28	Neuroticism;
LUAD	trans	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg14917512	chr19:3094685	GNA11	-0.38	-6.43	-0.3	3.47e-10	Aortic root size;
LUAD	cis	rs57502260	0.704	rs2186937	chr11:68256847	G/A	cg16797656	chr11:68205561	LRP5	0.46	6.85	0.32	2.64e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg20203395	chr5:56204925	C5orf35	-0.82	-11.8	-0.5	5.55e-28	Initial pursuit acceleration;
LUAD	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg10544611	chr16:67998164	SLC12A4	-0.68	-8.12	-0.37	5.15e-15	Schizophrenia;
LUAD	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg10018233	chr7:150070692	REPIN1	0.49	7.68	0.35	1.15e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1853665	0.580	rs4242282	chr6:150273346	C/G	cg16301758	chr6:150275521	NA	-0.52	-7.63	-0.35	1.58e-13	Radiation response;
LUAD	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg03806693	chr22:41940476	POLR3H	-0.46	-7.1	-0.33	5.19e-12	Vitiligo;
LUAD	trans	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg26043149	chr18:55253948	FECH	0.51	8.31	0.37	1.35e-15	Bone mineral density;
LUAD	cis	rs11811982	0.793	rs77220222	chr1:227342972	G/T	cg24860534	chr1:227506868	CDC42BPA	0.66	7.22	0.33	2.41e-12	Optic disc area;
LUAD	cis	rs6684514	1.000	rs59468948	chr1:156288058	A/T	cg16558208	chr1:156270281	VHLL	0.53	9.78	0.43	1.71e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs28655083	0.826	rs2134335	chr16:77079272	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.47	-7.22	-0.33	2.51e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9372498	0.505	rs9489493	chr6:118992323	T/C	cg07617317	chr6:118971624	C6orf204	0.51	7.75	0.35	6.73e-14	Diastolic blood pressure;
LUAD	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18404041	chr3:52824283	ITIH1	-0.61	-12.39	-0.52	2.81e-30	Bipolar disorder;
LUAD	trans	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg19862616	chr7:65841803	NCRNA00174	1.06	27.03	0.8	3.44e-94	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg25324976	chr17:61989376	CSHL1	0.38	7.24	0.33	2.09e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg27170947	chr2:26402098	FAM59B	-0.66	-9.36	-0.41	4.92e-19	Gut microbiome composition (summer);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg23973034	chr20:43948422	NA	-0.41	-7.21	-0.33	2.65e-12	Subcortical brain region volumes;
LUAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14893161	chr1:205819251	PM20D1	0.8	16.58	0.63	6.24e-48	Menarche (age at onset);
LUAD	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg21028142	chr17:79581711	NPLOC4	0.34	6.73	0.31	5.48e-11	Eye color traits;
LUAD	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.34	-6.47	-0.3	2.64e-10	Personality dimensions;
LUAD	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg07741184	chr6:167504864	NA	0.39	9.1	0.4	3.59e-18	Primary biliary cholangitis;
LUAD	cis	rs755249	0.614	rs10888798	chr1:39958080	C/G	cg27567593	chr1:39956653	BMP8A	0.35	7.29	0.33	1.57e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg00074818	chr8:8560427	CLDN23	0.67	10.39	0.45	1.14e-22	Obesity-related traits;
LUAD	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg00898013	chr13:113819073	PROZ	0.72	12.87	0.53	3.22e-32	Platelet distribution width;
LUAD	cis	rs68170813	0.559	rs10487271	chr7:106898458	T/C	cg23024343	chr7:107201750	COG5	0.49	7.19	0.33	2.99e-12	Coronary artery disease;
LUAD	cis	rs427394	0.802	rs274698	chr5:6730957	T/G	cg10857441	chr5:6722123	POLS	-0.65	-12.65	-0.52	2.55e-31	Menopause (age at onset);
LUAD	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg23533926	chr12:111358616	MYL2	-0.4	-6.8	-0.31	3.48e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1461503	0.966	rs10892937	chr11:122841904	T/C	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg14416269	chr4:6271139	WFS1	0.63	13.17	0.54	2.05e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg11833968	chr6:79620685	NA	-0.42	-7.81	-0.35	4.68e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs7746199	0.736	rs72845070	chr6:27668300	A/C	cg08344181	chr3:125677491	NA	-0.66	-6.36	-0.3	5.11e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7680126	0.536	rs4484299	chr4:10050451	A/G	cg11266682	chr4:10021025	SLC2A9	0.52	7.51	0.34	3.62e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg02160872	chr5:212506	CCDC127	-0.49	-6.59	-0.31	1.32e-10	Breast cancer;
LUAD	cis	rs2239547	0.603	rs12489490	chr3:53064022	C/A	cg11645453	chr3:52864694	ITIH4	0.56	9.69	0.43	3.49e-20	Schizophrenia;
LUAD	cis	rs17401966	0.838	rs4846209	chr1:10322054	G/A	cg19773385	chr1:10388646	KIF1B	-0.4	-6.54	-0.3	1.73e-10	Hepatocellular carcinoma;
LUAD	cis	rs7811528	0.656	rs58091069	chr7:2705879	C/T	cg11411865	chr7:2701802	TTYH3	0.53	6.51	0.3	2.17e-10	Schizophrenia;
LUAD	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg11189052	chr15:85197271	WDR73	0.63	8.28	0.37	1.59e-15	Schizophrenia;
LUAD	cis	rs4072705	0.967	rs2148787	chr9:127468204	G/A	cg13476313	chr9:127244764	NR5A1	0.29	7.28	0.33	1.65e-12	Menarche (age at onset);
LUAD	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg10434728	chr15:90938212	IQGAP1	0.35	6.73	0.31	5.42e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg23985595	chr17:80112537	CCDC57	-0.51	-9.28	-0.41	8.9e-19	Life satisfaction;
LUAD	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg24818145	chr4:99064322	C4orf37	0.45	7.11	0.33	4.85e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg25358565	chr5:93447407	FAM172A	0.58	6.77	0.31	4.31e-11	Diabetic retinopathy;
LUAD	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg20503657	chr10:835505	NA	0.8	12.36	0.51	3.71e-30	Eosinophil percentage of granulocytes;
LUAD	cis	rs17739794	0.517	rs34109064	chr8:772796	T/C	cg01971667	chr8:817044	NA	-0.34	-6.82	-0.31	3.16e-11	Clozapine-induced cytotoxicity;
LUAD	cis	rs6445967	0.569	rs7615294	chr3:58278785	C/A	cg23715586	chr3:58305044	RPP14	0.4	6.65	0.31	9.11e-11	Platelet count;
LUAD	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg24818145	chr4:99064322	C4orf37	0.46	7.84	0.36	3.83e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg11494091	chr17:61959527	GH2	0.42	7.86	0.36	3.24e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg26022315	chr17:47021804	SNF8	0.41	7.5	0.34	3.85e-13	Type 2 diabetes;
LUAD	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg09021430	chr5:549028	NA	-0.69	-13.71	-0.55	1.23e-35	Lung disease severity in cystic fibrosis;
LUAD	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg03929089	chr4:120376271	NA	-0.92	-17.61	-0.65	1.82e-52	Height;
LUAD	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg11247378	chr22:39784982	NA	-0.75	-14.25	-0.57	6.44e-38	Intelligence (multi-trait analysis);
LUAD	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg03690763	chr11:133734501	NA	-0.34	-7.9	-0.36	2.47e-14	Childhood ear infection;
LUAD	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg03929089	chr4:120376271	NA	-0.67	-9.11	-0.4	3.4e-18	Coronary artery disease;
LUAD	cis	rs12410462	0.748	rs1495853	chr1:227657336	A/G	cg23173402	chr1:227635558	NA	-0.64	-7.64	-0.35	1.49e-13	Major depressive disorder;
LUAD	cis	rs9902453	0.817	rs12941382	chr17:28410124	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-10.07	-0.44	1.64e-21	Coffee consumption (cups per day);
LUAD	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18099408	chr3:52552593	STAB1	-0.46	-8.05	-0.36	8.22e-15	Bipolar disorder;
LUAD	cis	rs74417235	0.684	rs71590150	chr5:154060512	A/T	cg07371521	chr5:154026371	NA	0.48	7.82	0.36	4.17e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg21862992	chr11:68658383	NA	0.55	10.02	0.44	2.34e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg05709478	chr1:6581295	PLEKHG5	0.6	8.24	0.37	2.21e-15	Body mass index;
LUAD	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg23815491	chr16:72088622	HP	0.54	9.77	0.43	1.88e-20	Fibrinogen levels;
LUAD	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg07776626	chr8:57350775	NA	-0.61	-9.04	-0.4	5.77e-18	Obesity-related traits;
LUAD	cis	rs10761482	0.859	rs1599166	chr10:62163729	G/A	cg18175470	chr10:62150864	ANK3	-0.41	-6.91	-0.32	1.78e-11	Schizophrenia;
LUAD	cis	rs2742234	0.541	rs2742235	chr10:43616325	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.5	-8.45	-0.38	4.71e-16	Hirschsprung disease;
LUAD	cis	rs6063312	0.518	rs6122718	chr20:47346225	A/G	cg18078177	chr20:47281410	PREX1	-0.62	-10.33	-0.45	1.86e-22	Tonometry;
LUAD	cis	rs1348850	0.757	rs4893954	chr2:178340520	T/G	cg22681709	chr2:178499509	PDE11A	-0.46	-7.54	-0.34	2.99e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg00204512	chr16:28754710	NA	0.31	6.71	0.31	6.38e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.22	16.48	0.63	1.65e-47	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.43	-7.87	-0.36	2.97e-14	Longevity;Endometriosis;
LUAD	cis	rs737008	0.960	rs949429	chr16:11376029	C/T	cg00044050	chr16:11439710	C16orf75	-0.46	-6.99	-0.32	1.11e-11	Obesity-related traits;
LUAD	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg20744362	chr22:50050164	C22orf34	0.37	7.15	0.33	3.92e-12	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4786125	0.920	rs6500851	chr16:6896521	A/G	cg03623568	chr16:6915990	A2BP1	-0.4	-8.32	-0.37	1.24e-15	Heart rate variability traits (SDNN);
LUAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00149659	chr3:10157352	C3orf10	0.58	8.1	0.37	5.92e-15	Alzheimer's disease;
LUAD	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg12193833	chr17:30244370	NA	-0.57	-6.91	-0.32	1.78e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg25173405	chr17:45401733	C17orf57	-0.46	-7.54	-0.34	2.84e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4852324	1.000	rs4852324	chr2:74202578	A/G	cg01017244	chr2:74357527	NA	0.54	6.37	0.3	4.94e-10	Systemic lupus erythematosus;
LUAD	cis	rs6564851	0.508	rs7199144	chr16:81251846	A/T	cg00908271	chr16:81254010	PKD1L2	-0.4	-8.63	-0.39	1.25e-16	Carotenoid and tocopherol levels;
LUAD	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg18721089	chr20:30220636	NA	-0.48	-6.96	-0.32	1.31e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	12.04	0.51	6.41e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg22491629	chr6:157744540	C6orf35	-0.82	-9.51	-0.42	1.46e-19	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7095607	0.579	rs6480308	chr10:69952953	T/C	cg18986048	chr10:69913749	MYPN	0.41	7.23	0.33	2.34e-12	Lung function (FVC);
LUAD	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.43	0.38	5.49e-16	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.33	0.45	1.88e-22	Mean corpuscular volume;
LUAD	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg07930552	chr6:133119739	C6orf192	0.59	7.02	0.32	9.02e-12	Type 2 diabetes nephropathy;
LUAD	cis	rs2486288	0.656	rs1706767	chr15:45569099	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.35	-6.6	-0.31	1.24e-10	Glomerular filtration rate;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg05712126	chr22:29601860	EMID1	-0.51	-6.98	-0.32	1.15e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs7737355	1.000	rs12517604	chr5:130748500	T/C	cg06307176	chr5:131281290	NA	-0.49	-7.7	-0.35	9.8e-14	Life satisfaction;
LUAD	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg08859206	chr1:53392774	SCP2	0.48	8.48	0.38	3.72e-16	Monocyte count;
LUAD	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg14416269	chr4:6271139	WFS1	0.64	13.7	0.55	1.29e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.27	-6.82	-0.31	3.06e-11	Total body bone mineral density;
LUAD	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg17724175	chr1:150552817	MCL1	0.39	9.43	0.42	2.64e-19	Tonsillectomy;
LUAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg10729496	chr3:10149963	C3orf24	0.49	7.88	0.36	2.73e-14	Alzheimer's disease;
LUAD	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg03264133	chr6:25882463	NA	-0.51	-7.6	-0.35	1.97e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg25036284	chr2:26402008	FAM59B	-0.6	-8.32	-0.37	1.26e-15	Gut microbiome composition (summer);
LUAD	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	7.82	0.36	4.11e-14	Tonsillectomy;
LUAD	cis	rs7617773	0.779	rs9833309	chr3:48327450	C/T	cg11946769	chr3:48343235	NME6	0.43	6.65	0.31	8.89e-11	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg18198730	chr1:247681584	NA	0.44	7.62	0.35	1.71e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg09491104	chr22:46646882	C22orf40	-0.74	-13.44	-0.55	1.6e-34	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg13511324	chr14:104056883	C14orf153	0.28	6.88	0.32	2.12e-11	Reticulocyte count;
LUAD	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg13736514	chr6:26305472	NA	-0.67	-12.81	-0.53	5.57e-32	Educational attainment;
LUAD	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg02269571	chr22:50332266	NA	-0.7	-9.8	-0.43	1.49e-20	Schizophrenia;
LUAD	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg21951975	chr1:209979733	IRF6	0.53	6.97	0.32	1.25e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg05340658	chr4:99064831	C4orf37	0.53	9.06	0.4	4.81e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17102423	0.755	rs7143495	chr14:65546361	C/T	cg11161011	chr14:65562177	MAX	0.46	7.48	0.34	4.48e-13	Obesity-related traits;
LUAD	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg08601574	chr20:25228251	PYGB	0.48	9.0	0.4	7.84e-18	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg04369109	chr6:150039330	LATS1	-0.46	-7.73	-0.35	7.84e-14	Lung cancer;
LUAD	cis	rs6987853	0.787	rs2923441	chr8:42429937	G/T	cg09913449	chr8:42400586	C8orf40	-0.45	-8.77	-0.39	4.51e-17	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1451375	0.617	rs896307	chr7:50569060	T/C	cg18232548	chr7:50535776	DDC	-0.65	-8.96	-0.4	1.02e-17	Malaria;
LUAD	cis	rs78761021	0.898	rs55954208	chr17:9776157	A/C	cg26853458	chr17:9805074	RCVRN	0.35	6.68	0.31	7.5e-11	Type 2 diabetes;
LUAD	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	7.36	0.34	9.89e-13	Schizophrenia;
LUAD	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.36	0.38	8.99e-16	Breast cancer;
LUAD	cis	rs9469913	0.799	rs2814993	chr6:34618893	A/G	cg14254433	chr6:34482411	PACSIN1	0.42	6.47	0.3	2.73e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.71	-9.31	-0.41	6.92e-19	Body mass index;
LUAD	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg08754654	chr5:154026448	NA	0.48	8.08	0.37	7.03e-15	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg01028140	chr2:1542097	TPO	-0.55	-7.02	-0.32	8.73e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.03	0.4	6.03e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs783540	0.967	rs783527	chr15:83285847	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.45	-7.24	-0.33	2.07e-12	Schizophrenia;
LUAD	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg23803603	chr1:2058230	PRKCZ	-0.4	-6.55	-0.3	1.65e-10	Height;
LUAD	cis	rs12893668	0.703	rs4906335	chr14:104021141	C/A	cg13511324	chr14:104056883	C14orf153	0.27	6.65	0.31	9.23e-11	Reticulocyte count;
LUAD	trans	rs7246760	0.867	rs3859512	chr19:9932831	C/T	cg02900749	chr2:68251473	NA	-0.62	-6.64	-0.31	9.88e-11	Pursuit maintenance gain;
LUAD	cis	rs6489882	0.867	rs6489874	chr12:113367895	A/G	cg20102336	chr12:113376681	OAS3	-0.6	-9.37	-0.41	4.39e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs1595825	0.891	rs16823148	chr2:198584209	G/A	cg10547527	chr2:198650123	BOLL	-0.53	-7.69	-0.35	1.04e-13	Ulcerative colitis;
LUAD	cis	rs8067545	0.616	rs203465	chr17:19810720	T/G	cg04132472	chr17:19861366	AKAP10	0.38	8.84	0.39	2.66e-17	Schizophrenia;
LUAD	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg26408565	chr15:76604113	ETFA	-0.45	-7.3	-0.33	1.43e-12	Blood metabolite levels;
LUAD	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.59	-6.84	-0.32	2.87e-11	Lung cancer in ever smokers;
LUAD	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg06671706	chr8:8559999	CLDN23	0.67	11.65	0.49	2.1e-27	Obesity-related traits;
LUAD	cis	rs2658782	0.547	rs3020054	chr11:93055556	C/T	cg15737290	chr11:93063684	CCDC67	0.56	10.12	0.44	1.07e-21	Pulmonary function decline;
LUAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg27532560	chr4:187881888	NA	-0.35	-6.51	-0.3	2.08e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11168351	0.833	rs6580652	chr12:48447105	C/A	cg04545296	chr12:48745243	ZNF641	-0.34	-8.86	-0.4	2.17e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg12179176	chr11:130786555	SNX19	-0.59	-10.14	-0.44	8.74e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2274273	0.712	rs6572999	chr14:55527374	T/C	cg04306507	chr14:55594613	LGALS3	0.32	6.68	0.31	7.65e-11	Protein biomarker;
LUAD	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg09640425	chr7:158790006	NA	0.5	6.53	0.3	1.85e-10	Facial morphology (factor 20);
LUAD	cis	rs12760731	0.565	rs12047117	chr1:178132608	G/A	cg00404053	chr1:178313656	RASAL2	0.7	8.9	0.4	1.65e-17	Obesity-related traits;
LUAD	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg27535305	chr1:53392650	SCP2	-0.4	-8.32	-0.37	1.24e-15	Monocyte count;
LUAD	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg09165964	chr15:75287851	SCAMP5	-0.47	-7.13	-0.33	4.49e-12	Blood trace element (Zn levels);
LUAD	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg17971929	chr21:40555470	PSMG1	0.46	7.63	0.35	1.52e-13	Cognitive function;
LUAD	cis	rs8064454	1.000	rs11651755	chr17:36099840	A/G	cg04198914	chr17:36106025	HNF1B	0.35	6.82	0.31	3.26e-11	Prostate cancer;
LUAD	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg25233709	chr10:116636983	FAM160B1	0.41	8.26	0.37	1.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg08888203	chr3:10149979	C3orf24	0.71	12.43	0.52	1.87e-30	Alzheimer's disease;
LUAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg22907277	chr7:1156413	C7orf50	0.71	8.26	0.37	1.84e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg25753631	chr6:25732923	NA	-0.37	-6.43	-0.3	3.49e-10	Iron status biomarkers;
LUAD	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg00316803	chr15:76480434	C15orf27	0.4	6.43	0.3	3.42e-10	Blood metabolite levels;
LUAD	cis	rs3806843	0.551	rs184996	chr5:140323773	T/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.62e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22496380	chr5:211416	CCDC127	-0.92	-12.71	-0.53	1.43e-31	Breast cancer;
LUAD	cis	rs36051895	0.554	rs11789744	chr9:5134213	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-6.44	-0.3	3.25e-10	Pediatric autoimmune diseases;
LUAD	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.33e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.08	-0.33	6.17e-12	Total cholesterol levels;
LUAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	8.69	0.39	8.31e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg11292332	chr7:45801988	SEPT13	-0.29	-6.4	-0.3	4.19e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6906287	0.647	rs57813349	chr6:118763858	C/A	cg05564266	chr6:118973597	C6orf204	0.32	6.91	0.32	1.76e-11	Electrocardiographic conduction measures;
LUAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-6.98	-0.32	1.18e-11	Mood instability;
LUAD	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.46	8.85	0.4	2.5e-17	Neutrophil percentage of white cells;
LUAD	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg01256987	chr12:42539512	GXYLT1	-0.35	-6.92	-0.32	1.68e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg19130645	chr7:65235666	NA	0.44	7.47	0.34	4.67e-13	Calcium levels;
LUAD	cis	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg07460842	chr6:66804631	NA	0.83	9.8	0.43	1.43e-20	Exhaled nitric oxide output;
LUAD	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg14828511	chr1:107599125	PRMT6	-0.6	-10.5	-0.45	4.64e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs743757	1.000	rs2298955	chr3:50431194	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.45	-6.91	-0.32	1.75e-11	Diastolic blood pressure;
LUAD	cis	rs11677370	0.603	rs11675498	chr2:3850943	G/T	cg17052675	chr2:3827356	NA	-0.62	-10.48	-0.45	5.4e-23	Type 2 diabetes;
LUAD	cis	rs7945718	0.967	rs10831904	chr11:12760937	A/G	cg25843174	chr11:12811716	TEAD1	0.24	7.02	0.32	8.96e-12	Educational attainment (years of education);
LUAD	trans	rs7395662	1.000	rs6485888	chr11:48605339	A/T	cg00717180	chr2:96193071	NA	-0.39	-7.27	-0.33	1.72e-12	HDL cholesterol;
LUAD	cis	rs6076065	0.723	rs1419009	chr20:23365094	G/A	cg11657817	chr20:23433608	CST11	0.49	9.0	0.4	7.9e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg23231163	chr10:75533350	FUT11	-0.51	-9.62	-0.42	6.04e-20	Inflammatory bowel disease;
LUAD	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg27284194	chr4:1044797	NA	0.68	10.1	0.44	1.28e-21	Recombination rate (females);
LUAD	cis	rs7582720	1.000	rs72934707	chr2:203707878	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.26	0.41	1.04e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-6.61	-0.31	1.15e-10	Lung cancer;
LUAD	cis	rs6998277	0.830	rs965661	chr8:103597586	C/T	cg10187029	chr8:103597600	NA	0.87	16.43	0.62	2.8e-47	Migraine;
LUAD	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg14024328	chr4:719362	PCGF3	-0.52	-8.58	-0.39	1.79e-16	White blood cell count;
LUAD	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	6.92	0.32	1.68e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg09184832	chr6:79620586	NA	-0.5	-9.3	-0.41	7.68e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs758324	0.812	rs2133706	chr5:131165216	T/G	cg25547332	chr5:131281432	NA	0.42	6.79	0.31	3.72e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg06558623	chr16:89946397	TCF25	1.12	9.78	0.43	1.69e-20	Skin colour saturation;
LUAD	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg23815491	chr16:72088622	HP	0.51	9.28	0.41	9.1e-19	Fibrinogen levels;
LUAD	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg18512352	chr11:47633146	NA	-0.57	-10.14	-0.44	8.77e-22	Subjective well-being;
LUAD	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11890956	chr21:40555474	PSMG1	-0.58	-9.63	-0.42	5.57e-20	Cognitive function;
LUAD	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg00666640	chr1:248458726	OR2T12	0.32	7.81	0.36	4.46e-14	Common traits (Other);
LUAD	cis	rs863345	0.604	rs12133794	chr1:158506697	C/G	cg12129480	chr1:158549410	OR10X1	-0.24	-6.59	-0.3	1.34e-10	Pneumococcal bacteremia;
LUAD	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg13397359	chr6:42928475	GNMT	0.5	7.81	0.35	4.58e-14	Blood protein levels;
LUAD	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg18755752	chr8:142205143	DENND3	-0.45	-7.89	-0.36	2.55e-14	Immature fraction of reticulocytes;
LUAD	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg20891283	chr12:69753455	YEATS4	0.45	7.41	0.34	6.97e-13	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs4917300	0.743	rs34292923	chr8:143094726	G/C	cg25363559	chr8:143086065	NA	-0.35	-6.65	-0.31	8.96e-11	Amyotrophic lateral sclerosis;
LUAD	cis	rs12893597	0.715	rs34486942	chr14:76831530	G/A	cg20290672	chr14:76816747	NA	-0.45	-7.16	-0.33	3.6e-12	Maximal oxygen uptake response;
LUAD	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg02880119	chr16:3481970	NA	0.62	9.05	0.4	5.22e-18	Body mass index (adult);
LUAD	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg09065629	chr16:1709722	CRAMP1L	0.43	7.41	0.34	6.92e-13	Coronary artery disease;
LUAD	cis	rs8049603	0.812	rs4073291	chr16:23195993	G/T	cg09552652	chr16:23197569	SCNN1G	-0.36	-6.46	-0.3	2.85e-10	Multiple sclerosis;
LUAD	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg26384229	chr12:38710491	ALG10B	0.53	8.64	0.39	1.13e-16	Heart rate;
LUAD	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg19761014	chr17:28927070	LRRC37B2	0.76	8.91	0.4	1.52e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8067545	0.641	rs1479129	chr17:19845769	A/G	cg04132472	chr17:19861366	AKAP10	0.4	9.39	0.42	3.89e-19	Schizophrenia;
LUAD	cis	rs4702	0.611	rs11539637	chr15:91428290	C/T	cg05469396	chr15:91419421	FURIN	0.46	7.92	0.36	2.12e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg17845761	chr1:175162550	KIAA0040	-0.34	-8.91	-0.4	1.5e-17	Alcohol dependence;
LUAD	cis	rs7945718	0.967	rs12417886	chr11:12811731	A/C	cg25843174	chr11:12811716	TEAD1	-0.27	-8.06	-0.36	7.71e-15	Educational attainment (years of education);
LUAD	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg04989706	chr14:50066350	PPIL5	-0.53	-7.71	-0.35	9.38e-14	Carotid intima media thickness;
LUAD	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg25985355	chr7:65971099	NA	-0.55	-6.83	-0.32	2.9e-11	Diabetic kidney disease;
LUAD	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.47	0.3	2.76e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.06e-19	Life satisfaction;
LUAD	cis	rs10193935	0.818	rs2374428	chr2:42667961	T/C	cg27598129	chr2:42591480	NA	0.64	8.39	0.38	7.44e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs953387	1.000	rs950176	chr2:136898078	A/G	cg05194412	chr2:137003533	NA	-0.44	-7.23	-0.33	2.32e-12	Arthritis (juvenile idiopathic);
LUAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg11050988	chr7:1952600	MAD1L1	0.35	7.16	0.33	3.56e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg06064525	chr11:970664	AP2A2	-0.53	-10.8	-0.47	3.4e-24	Alzheimer's disease (late onset);
LUAD	cis	rs6988985	0.626	rs6392	chr8:143956925	T/C	cg10324643	chr8:143916377	GML	0.3	6.36	0.3	5.18e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs1044826	0.619	rs7375091	chr3:139090389	T/A	cg00490450	chr3:139108681	COPB2	-0.43	-6.92	-0.32	1.69e-11	Obesity-related traits;
LUAD	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg00757033	chr12:89920650	WDR51B	0.68	11.59	0.49	3.58e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg22532475	chr10:104410764	TRIM8	0.36	7.27	0.33	1.76e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg27454412	chr7:1067447	C7orf50	0.44	7.01	0.32	9.47e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs34638657	0.732	rs12597534	chr16:82200276	G/T	cg09439754	chr16:82129088	HSD17B2	-0.4	-7.71	-0.35	9.32e-14	Lung adenocarcinoma;
LUAD	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.51	-8.62	-0.39	1.33e-16	Electrocardiographic conduction measures;
LUAD	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03352830	chr11:487213	PTDSS2	0.79	9.94	0.44	4.68e-21	Body mass index;
LUAD	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg02428538	chr16:24856791	SLC5A11	-0.49	-6.96	-0.32	1.31e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg13535736	chr9:111863775	C9orf5	-0.42	-6.45	-0.3	3.09e-10	Menarche (age at onset);
LUAD	cis	rs151234	0.741	rs151230	chr16:28583215	G/A	cg04643524	chr16:28609220	SULT1A2	0.63	9.05	0.4	5.39e-18	Platelet distribution width;
LUAD	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg08847533	chr14:75593920	NEK9	0.43	7.34	0.34	1.07e-12	Height;
LUAD	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg04287289	chr16:89883240	FANCA	-0.63	-6.45	-0.3	3.01e-10	Skin colour saturation;
LUAD	cis	rs7095607	0.777	rs2101483	chr10:69922987	G/A	cg18986048	chr10:69913749	MYPN	0.38	6.57	0.3	1.5e-10	Lung function (FVC);
LUAD	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg17173187	chr15:85201210	NMB	0.42	6.95	0.32	1.39e-11	Schizophrenia;
LUAD	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg00310523	chr12:86230176	RASSF9	0.4	8.19	0.37	3.06e-15	Major depressive disorder;
LUAD	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.89	-0.4	1.72e-17	Initial pursuit acceleration;
LUAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.85	0.56	3.1e-36	Prudent dietary pattern;
LUAD	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg18876405	chr7:65276391	NA	-0.61	-9.99	-0.44	3.13e-21	Aortic root size;
LUAD	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg25894440	chr7:65020034	NA	-0.68	-7.32	-0.34	1.23e-12	Diabetic kidney disease;
LUAD	cis	rs727505	0.721	rs11534064	chr7:124767997	G/T	cg23710748	chr7:124431027	NA	0.34	7.24	0.33	2.1e-12	Lewy body disease;
LUAD	trans	rs1493916	0.905	rs12455290	chr18:31398778	A/G	cg15819921	chr19:927150	ARID3A	-0.49	-8.1	-0.37	6.04e-15	Life satisfaction;
LUAD	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg19442545	chr10:75533431	FUT11	-0.47	-7.7	-0.35	1e-13	Inflammatory bowel disease;
LUAD	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.53	-9.74	-0.43	2.28e-20	Schizophrenia;
LUAD	cis	rs2131877	0.956	rs2279631	chr3:194869328	T/C	cg19760965	chr3:194868843	C3orf21	0.43	7.12	0.33	4.68e-12	Non-small cell lung cancer;
LUAD	cis	rs6782228	0.651	rs9852825	chr3:128387357	C/G	cg16766828	chr3:128327626	NA	-0.39	-7.18	-0.33	3.15e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg18180107	chr4:99064573	C4orf37	0.43	6.73	0.31	5.7e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	9.19	0.41	1.74e-18	Platelet count;
LUAD	cis	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg01251360	chr16:68772225	CDH1	-0.28	-8.81	-0.39	3.21e-17	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-8.23	-0.37	2.34e-15	Blood metabolite levels;
LUAD	cis	rs7665090	0.870	rs228613	chr4:103577465	T/C	cg07973026	chr4:103553119	MANBA	-0.4	-6.99	-0.32	1.11e-11	Primary biliary cholangitis;
LUAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg17178900	chr1:205818956	PM20D1	0.41	6.75	0.31	4.77e-11	Parkinson's disease;
LUAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg08132940	chr7:1081526	C7orf50	-0.76	-10.28	-0.45	2.91e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.11	0.4	3.37e-18	Alzheimer's disease;
LUAD	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11890956	chr21:40555474	PSMG1	-0.56	-9.72	-0.43	2.82e-20	Menarche (age at onset);
LUAD	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	10.41	0.45	9.58e-23	Lung cancer in ever smokers;
LUAD	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.48	7.73	0.35	7.88e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.48	-0.34	4.38e-13	Electroencephalogram traits;
LUAD	cis	rs7705042	0.865	rs449454	chr5:141533062	A/G	cg08523384	chr5:141488047	NDFIP1	-0.4	-6.79	-0.31	3.88e-11	Asthma;
LUAD	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	8.61	0.39	1.44e-16	Menarche (age at onset);
LUAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg08888203	chr3:10149979	C3orf24	0.72	10.93	0.47	1.19e-24	Alzheimer's disease;
LUAD	cis	rs2249625	0.545	rs9791273	chr6:72891016	G/T	cg18830697	chr6:72922368	RIMS1	0.45	8.05	0.36	8.21e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg07936489	chr17:37558343	FBXL20	-0.51	-6.87	-0.32	2.29e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs1595825	0.945	rs16826320	chr2:198845623	T/C	cg10547527	chr2:198650123	BOLL	-0.51	-7.14	-0.33	4.01e-12	Ulcerative colitis;
LUAD	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.44	-6.65	-0.31	9.19e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg27426351	chr10:43362370	NA	0.47	7.57	0.35	2.29e-13	Blood protein levels;
LUAD	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg06108461	chr20:60628389	TAF4	-1.11	-20.45	-0.71	4.01e-65	Body mass index;
LUAD	cis	rs10242455	0.702	rs59240302	chr7:99072991	C/G	cg18809830	chr7:99032528	PTCD1	-1.0	-7.35	-0.34	1.04e-12	Blood metabolite levels;
LUAD	cis	rs2742417	0.603	rs13059502	chr3:45781380	A/G	cg10512202	chr3:45649293	LIMD1	0.48	8.95	0.4	1.16e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs12765878	1.000	rs2273698	chr10:105649158	G/A	cg11005552	chr10:105648138	OBFC1	0.44	8.25	0.37	2.06e-15	Coronary artery disease;
LUAD	cis	rs13064411	0.518	rs7646188	chr3:113219272	C/T	cg18753928	chr3:113234510	CCDC52	-0.48	-8.75	-0.39	5.23e-17	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1113500	0.862	rs11185264	chr1:108640506	T/C	cg06207961	chr1:108661230	NA	0.45	8.43	0.38	5.63e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs12760731	0.720	rs1994233	chr1:178269823	C/T	cg00404053	chr1:178313656	RASAL2	-0.58	-8.14	-0.37	4.46e-15	Obesity-related traits;
LUAD	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg19163074	chr7:65112434	INTS4L2	0.46	6.81	0.31	3.36e-11	Aortic root size;
LUAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-9.3	-0.41	7.88e-19	Alzheimer's disease;
LUAD	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.83	0.32	2.98e-11	Menarche (age at onset);
LUAD	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg25828334	chr19:18545568	ISYNA1	-0.36	-7.22	-0.33	2.35e-12	Breast cancer;
LUAD	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg00074818	chr8:8560427	CLDN23	0.64	9.83	0.43	1.13e-20	Obesity-related traits;
LUAD	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.86	-0.53	3.5e-32	Dilated cardiomyopathy;
LUAD	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg27279351	chr12:120934652	DYNLL1	0.46	6.82	0.31	3.21e-11	High light scatter reticulocyte count;
LUAD	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.62	-0.35	1.65e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg12011299	chr4:100065546	ADH4	-0.74	-13.73	-0.56	9.82e-36	Alcohol dependence;
LUAD	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg26924012	chr15:45694286	SPATA5L1	0.86	14.75	0.58	4.98e-40	Homoarginine levels;
LUAD	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.68	0.52	1.89e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg18252515	chr7:66147081	NA	-0.63	-6.94	-0.32	1.5e-11	Gout;
LUAD	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.54	-7.98	-0.36	1.38e-14	Gut microbiome composition (summer);
LUAD	cis	rs886126	0.901	rs10744770	chr12:111662578	G/A	cg10833066	chr12:111807467	FAM109A	0.62	11.57	0.49	4.27e-27	Coronary heart disease;
LUAD	cis	rs889398	0.771	rs3790080	chr16:69902139	A/G	cg00738113	chr16:70207722	CLEC18C	-0.35	-7.01	-0.32	9.44e-12	Body mass index;
LUAD	cis	rs68170813	0.559	rs3823959	chr7:107009379	T/G	cg23024343	chr7:107201750	COG5	0.51	7.22	0.33	2.44e-12	Coronary artery disease;
LUAD	cis	rs1485395	0.541	rs11170614	chr12:54017647	G/A	cg20730629	chr12:53886622	MAP3K12	-0.46	-6.42	-0.3	3.62e-10	Migraine without aura;
LUAD	cis	rs10128251	0.650	rs4469789	chr10:5712366	A/G	cg24097872	chr10:5724021	NA	0.37	7.07	0.33	6.44e-12	Childhood ear infection;
LUAD	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg25237894	chr2:233734115	C2orf82	0.63	12.02	0.5	7.65e-29	Coronary artery disease;
LUAD	cis	rs897984	0.568	rs8063565	chr16:30883965	G/C	cg05768032	chr16:30646687	NA	-0.41	-6.55	-0.3	1.69e-10	Dementia with Lewy bodies;
LUAD	cis	rs7809950	0.530	rs111865019	chr7:106812246	A/G	cg23024343	chr7:107201750	COG5	-0.75	-12.12	-0.51	3.15e-29	Coronary artery disease;
LUAD	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg03037974	chr15:76606532	NA	0.41	8.82	0.39	2.95e-17	Blood metabolite levels;
LUAD	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg22920501	chr2:26401640	FAM59B	-0.73	-10.44	-0.45	7.58e-23	Gut microbiome composition (summer);
LUAD	cis	rs10911363	0.549	rs12742245	chr1:183446922	T/A	cg09173681	chr1:183549694	NCF2	0.57	10.45	0.45	6.94e-23	Systemic lupus erythematosus;
LUAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg12432903	chr7:1882776	MAD1L1	-0.49	-7.97	-0.36	1.49e-14	Bipolar disorder and schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13784889	chr4:89513377	HERC3	-0.42	-6.45	-0.3	3.04e-10	Height;
LUAD	cis	rs4664308	1.000	rs6707458	chr2:160914540	G/T	cg03641300	chr2:160917029	PLA2R1	-0.37	-6.61	-0.31	1.2e-10	Idiopathic membranous nephropathy;
LUAD	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg26408565	chr15:76604113	ETFA	-0.45	-7.3	-0.33	1.44e-12	Blood metabolite levels;
LUAD	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg27489772	chr12:121021490	NA	-0.53	-6.76	-0.31	4.54e-11	Type 1 diabetes nephropathy;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01399255	chr7:100271274	GNB2	-0.58	-7.01	-0.32	9.48e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg14582100	chr15:45693742	SPATA5L1	0.64	12.54	0.52	6.55e-31	Homoarginine levels;
LUAD	cis	rs8067545	0.717	rs9907788	chr17:20008903	T/C	cg04132472	chr17:19861366	AKAP10	0.3	7.09	0.33	5.69e-12	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2554380	0.628	rs12914377	chr15:84460693	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.37	-6.62	-0.31	1.11e-10	Height;
LUAD	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg17372223	chr3:52568218	NT5DC2	0.38	6.87	0.32	2.26e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9814567	0.806	rs4245903	chr3:134317074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-11.95	-0.5	1.48e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg02918483	chr4:84406202	FAM175A	-0.42	-7.24	-0.33	2.17e-12	Schizophrenia;
LUAD	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg17420585	chr12:42539391	GXYLT1	-0.53	-9.84	-0.43	1.03e-20	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg21427119	chr20:30132790	HM13	-0.58	-9.28	-0.41	8.67e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg04476341	chr5:669733	TPPP	-0.41	-8.0	-0.36	1.25e-14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg14092571	chr14:90743983	NA	-0.48	-8.44	-0.38	5.18e-16	Mortality in heart failure;
LUAD	cis	rs12618769	0.597	rs7585939	chr2:99219206	T/A	cg10123293	chr2:99228465	UNC50	0.5	8.87	0.4	2.09e-17	Bipolar disorder;
LUAD	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs10911363	0.659	rs2275676	chr1:183430822	C/G	cg09173681	chr1:183549694	NCF2	-0.53	-9.88	-0.43	7.55e-21	Systemic lupus erythematosus;
LUAD	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	14.46	0.58	8.66e-39	Smoking behavior;
LUAD	cis	rs735539	0.521	rs2585896	chr13:21398861	A/G	cg27499820	chr13:21296301	IL17D	0.43	7.23	0.33	2.34e-12	Dental caries;
LUAD	trans	rs1728785	1.000	rs3203684	chr16:68600440	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.68	-10.37	-0.45	1.35e-22	Ulcerative colitis;
LUAD	cis	rs524023	1.000	rs10792441	chr11:64360629	C/T	cg19131476	chr11:64387923	NRXN2	-0.37	-7.02	-0.32	8.85e-12	Urate levels in obese individuals;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25218905	chr12:92538613	BTG1	-0.42	-6.44	-0.3	3.33e-10	Height;
LUAD	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg04944784	chr2:26401820	FAM59B	-0.7	-9.93	-0.43	5.07e-21	Gut microbiome composition (summer);
LUAD	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg02176678	chr2:219576539	TTLL4	0.74	14.93	0.59	8.76e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg24531977	chr5:56204891	C5orf35	-0.52	-8.3	-0.37	1.46e-15	Coronary artery disease;
LUAD	cis	rs8044868	1.000	rs10400963	chr16:72184983	A/C	cg23815491	chr16:72088622	HP	0.4	7.13	0.33	4.32e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg04013166	chr16:89971882	TCF25	-0.54	-6.73	-0.31	5.53e-11	Skin colour saturation;
LUAD	cis	rs7236492	0.683	rs78250476	chr18:77198934	G/A	cg15644404	chr18:77186268	NFATC1	-0.61	-6.9	-0.32	1.9e-11	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg27454412	chr7:1067447	C7orf50	-0.43	-7.97	-0.36	1.52e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.79e-18	Life satisfaction;
LUAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08219700	chr8:58056026	NA	0.59	8.24	0.37	2.25e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-7.08	-0.33	5.91e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.51	0.34	3.55e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs11971779	0.680	rs17613690	chr7:139088401	C/T	cg23387468	chr7:139079360	LUC7L2	-0.28	-6.54	-0.3	1.82e-10	Diisocyanate-induced asthma;
LUAD	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg00383909	chr3:49044727	WDR6	0.75	8.6	0.39	1.52e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7274811	0.652	rs293732	chr20:31975090	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.51	7.61	0.35	1.85e-13	Height;
LUAD	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg07828340	chr4:882639	GAK	-1.02	-11.23	-0.48	8.5e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg24813613	chr7:1882135	MAD1L1	-0.47	-7.65	-0.35	1.33e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs1497828	0.956	rs2646834	chr1:217545202	G/C	cg04411442	chr1:217543379	NA	0.38	6.97	0.32	1.24e-11	Dialysis-related mortality;
LUAD	cis	rs7737355	0.773	rs31239	chr5:130813377	G/T	cg06307176	chr5:131281290	NA	-0.43	-7.08	-0.33	6.21e-12	Life satisfaction;
LUAD	trans	rs1493916	0.837	rs9945976	chr18:31409314	C/T	cg15819921	chr19:927150	ARID3A	-0.42	-6.86	-0.32	2.44e-11	Life satisfaction;
LUAD	cis	rs3845702	0.736	rs72958863	chr2:180808144	C/T	cg01881094	chr2:180872142	CWC22	0.79	8.33	0.38	1.15e-15	Schizophrenia;
LUAD	cis	rs6005807	0.719	rs9625521	chr22:29039953	T/G	cg12565055	chr22:29076175	TTC28	0.74	8.71	0.39	6.98e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.38	-6.7	-0.31	6.86e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs9929218	1.000	rs9928847	chr16:68797893	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.72	-0.55	1.08e-35	Colorectal cancer;
LUAD	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg26513180	chr16:89883248	FANCA	0.7	6.73	0.31	5.59e-11	Skin colour saturation;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21868211	chr19:37341078	ZNF345	-0.56	-6.75	-0.31	4.91e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg07460842	chr6:66804631	NA	0.77	10.46	0.45	6.05e-23	Exhaled nitric oxide output;
LUAD	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg19346786	chr7:2764209	NA	-0.3	-6.43	-0.3	3.52e-10	Height;
LUAD	cis	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg21775007	chr8:11205619	TDH	0.39	6.49	0.3	2.41e-10	Neuroticism;
LUAD	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.8	-0.35	5.01e-14	Prostate cancer;
LUAD	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg18132916	chr6:79620363	NA	-0.42	-7.4	-0.34	7.27e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs17641971	0.662	rs1858312	chr8:49996521	G/A	cg00325661	chr8:49890786	NA	0.3	6.71	0.31	6.13e-11	Blood metabolite levels;
LUAD	cis	rs6543140	0.964	rs11886793	chr2:103072220	T/G	cg04239558	chr2:103089729	SLC9A4	0.36	7.34	0.34	1.11e-12	Blood protein levels;
LUAD	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg22823121	chr1:150693482	HORMAD1	-0.39	-7.62	-0.35	1.7e-13	Melanoma;
LUAD	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg18512352	chr11:47633146	NA	-0.48	-8.42	-0.38	5.71e-16	Subjective well-being;
LUAD	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	5e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg21827317	chr3:136751795	NA	0.36	6.58	0.3	1.37e-10	Neuroticism;
LUAD	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07636037	chr3:49044803	WDR6	0.48	8.11	0.37	5.51e-15	Menarche (age at onset);
LUAD	cis	rs7809950	1.000	rs2520271	chr7:107194949	C/T	cg23024343	chr7:107201750	COG5	-0.72	-12.21	-0.51	1.43e-29	Coronary artery disease;
LUAD	cis	rs3764563	0.877	rs4019751	chr19:15740716	T/G	cg20725493	chr19:15740067	CYP4F8	-0.76	-8.82	-0.39	2.92e-17	Inflammatory biomarkers;
LUAD	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.61e-18	Life satisfaction;
LUAD	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08859206	chr1:53392774	SCP2	0.83	15.64	0.61	7.89e-44	Monocyte count;
LUAD	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg11833968	chr6:79620685	NA	-0.42	-7.94	-0.36	1.8e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg08859206	chr1:53392774	SCP2	-0.6	-10.63	-0.46	1.47e-23	Monocyte count;
LUAD	cis	rs2535633	0.588	rs2564930	chr3:53017307	T/C	cg11645453	chr3:52864694	ITIH4	-0.39	-7.46	-0.34	5.12e-13	Body mass index;
LUAD	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg00129232	chr17:37814104	STARD3	-0.45	-7.69	-0.35	1.02e-13	Asthma;
LUAD	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg05340658	chr4:99064831	C4orf37	0.54	9.23	0.41	1.27e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	6.78	0.31	4.15e-11	Personality dimensions;
LUAD	cis	rs2235649	0.833	rs4335769	chr16:1849376	G/A	cg08610935	chr16:1836813	NUBP2	-0.5	-7.64	-0.35	1.49e-13	Blood metabolite levels;
LUAD	cis	rs3820068	0.705	rs41270255	chr1:15892980	G/A	cg24675056	chr1:15929824	NA	0.43	6.77	0.31	4.33e-11	Systolic blood pressure;
LUAD	cis	rs9905704	0.681	rs2531728	chr17:56539792	T/C	cg19466818	chr17:56409534	MIR142	-0.34	-6.68	-0.31	7.51e-11	Testicular germ cell tumor;
LUAD	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg10518543	chr12:38710700	ALG10B	0.43	6.67	0.31	8.23e-11	Bladder cancer;
LUAD	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg08601574	chr20:25228251	PYGB	-0.46	-8.55	-0.38	2.35e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.07	-0.37	7.49e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7937890	0.559	rs1116739	chr11:14489182	G/C	cg06199346	chr11:14280333	SPON1	-0.33	-6.51	-0.3	2.09e-10	Mitochondrial DNA levels;
LUAD	cis	rs8077889	0.869	rs11713	chr17:41845824	A/G	cg26893861	chr17:41843967	DUSP3	-0.86	-14.33	-0.57	3.14e-38	Triglycerides;
LUAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.66	9.93	0.43	5.04e-21	Alzheimer's disease;
LUAD	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg21211680	chr2:198530	NA	0.61	8.3	0.37	1.38e-15	Blood protein levels;
LUAD	cis	rs9948	0.655	rs62156232	chr2:97431161	C/A	cg20312557	chr2:97357134	FER1L5	-0.75	-8.47	-0.38	4.12e-16	Erectile dysfunction and prostate cancer treatment;
LUAD	trans	rs4799710	0.620	rs6507057	chr18:31293981	G/A	cg27147174	chr7:100797783	AP1S1	-0.46	-7.47	-0.34	4.5e-13	Pulmonary function;
LUAD	trans	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg06606381	chr12:133084897	FBRSL1	-1.11	-10.19	-0.44	6.13e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7851660	0.874	rs1955144	chr9:100634589	A/G	cg13688889	chr9:100608707	NA	-0.48	-8.28	-0.37	1.69e-15	Strep throat;
LUAD	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg26384229	chr12:38710491	ALG10B	0.5	8.11	0.37	5.64e-15	Heart rate;
LUAD	cis	rs734999	0.967	rs10797434	chr1:2511280	C/T	cg18854424	chr1:2615690	NA	0.34	7.8	0.35	4.76e-14	Ulcerative colitis;
LUAD	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.42	-0.57	1.25e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7173743	0.784	rs11072811	chr15:79132330	G/T	cg15571903	chr15:79123663	NA	-0.37	-7.25	-0.33	1.93e-12	Coronary artery disease;
LUAD	trans	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg19862616	chr7:65841803	NCRNA00174	1.04	25.8	0.78	7.32e-89	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg17366294	chr4:99064904	C4orf37	0.65	12.58	0.52	4.73e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.44	0.34	5.72e-13	Breast cancer;
LUAD	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg27426351	chr10:43362370	NA	0.43	6.67	0.31	7.81e-11	Blood protein levels;
LUAD	cis	rs750460	0.844	rs2028386	chr15:74226708	C/G	cg23484268	chr15:74220776	LOXL1	0.38	7.52	0.34	3.22e-13	Height;
LUAD	cis	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg08601574	chr20:25228251	PYGB	0.44	7.99	0.36	1.33e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg23018236	chr17:30244563	NA	-0.59	-7.73	-0.35	8.18e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg12458913	chr13:53173898	NA	-0.39	-6.93	-0.32	1.57e-11	Lewy body disease;
LUAD	cis	rs7589342	0.894	rs6736932	chr2:106444854	A/G	cg16077055	chr2:106428750	NCK2	0.37	6.54	0.3	1.79e-10	Addiction;
LUAD	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg22535103	chr8:58192502	C8orf71	-0.65	-6.89	-0.32	2e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7100689	0.560	rs10887891	chr10:82207717	A/C	cg01528321	chr10:82214614	TSPAN14	0.61	9.59	0.42	7.55e-20	Post bronchodilator FEV1;
LUAD	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg16479474	chr6:28041457	NA	0.38	6.72	0.31	5.8e-11	Parkinson's disease;
LUAD	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.64	-0.31	9.95e-11	Schizophrenia;
LUAD	trans	rs75804782	0.521	rs72993044	chr2:239397949	C/T	cg01134436	chr17:81009848	B3GNTL1	0.79	8.62	0.39	1.33e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.6	-0.42	6.91e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg27446573	chr6:127587934	RNF146	0.45	6.59	0.31	1.3100000000000001e-10	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04132851	chr1:85155548	SSX2IP	-0.46	-7.3	-0.33	1.47e-12	Height;
LUAD	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	5.84e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.23	-0.41	1.3e-18	Type 2 diabetes;
LUAD	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg26513180	chr16:89883248	FANCA	-0.47	-8.03	-0.36	9.46e-15	Vitiligo;
LUAD	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg15790184	chr11:494944	RNH1	0.4	6.64	0.31	9.47e-11	Systemic lupus erythematosus;
LUAD	cis	rs7818345	0.845	rs17407039	chr8:19268056	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.34	7.05	0.32	7.17e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg17063962	chr7:91808500	NA	-0.66	-11.47	-0.49	1.07e-26	Breast cancer;
LUAD	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg04414720	chr1:150670196	GOLPH3L	0.6	10.27	0.45	2.97e-22	Melanoma;
LUAD	cis	rs760794	0.728	rs6921778	chr6:19800988	G/A	cg02404759	chr6:19790362	NA	-0.34	-6.42	-0.3	3.6e-10	Endometriosis;
LUAD	cis	rs1448938	0.806	rs291163	chr11:30945164	A/T	cg26647111	chr11:31128758	NA	0.37	6.52	0.3	2.05e-10	Gut microbiome composition (winter);
LUAD	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg14227996	chr4:17616232	MED28	0.7	7.46	0.34	5.01e-13	Opioid sensitivity;
LUAD	cis	rs9479482	0.967	rs3860823	chr6:150356526	A/G	cg08316699	chr6:150357289	NA	0.33	6.99	0.32	1.09e-11	Alopecia areata;
LUAD	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.93	-0.36	1.97e-14	Personality dimensions;
LUAD	cis	rs7833986	0.534	rs2667972	chr8:56906661	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	14.5	0.58	5.81e-39	Height;
LUAD	cis	rs16958440	0.867	rs12326221	chr18:44682893	G/T	cg17192377	chr18:44677553	HDHD2	0.84	7.96	0.36	1.64e-14	Sitting height ratio;
LUAD	cis	rs758324	0.755	rs578637	chr5:131267609	G/A	cg25547332	chr5:131281432	NA	-0.41	-6.62	-0.31	1.07e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.21	-0.41	1.52e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg18404041	chr3:52824283	ITIH1	0.39	7.01	0.32	9.44e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2880765	0.835	rs2170736	chr15:86043398	A/G	cg13263323	chr15:86062960	AKAP13	-0.5	-9.26	-0.41	1.07e-18	Coronary artery disease;
LUAD	cis	rs4372836	0.729	rs4638745	chr2:29093803	A/G	cg09522027	chr2:28974177	PPP1CB	0.65	11.42	0.49	1.69e-26	Body mass index;
LUAD	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg18190219	chr22:46762943	CELSR1	-0.5	-6.45	-0.3	3.12e-10	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs11039798	0.920	rs9667596	chr11:48691193	T/C	cg02254774	chr11:50257496	LOC441601	0.53	6.61	0.31	1.19e-10	Axial length;
LUAD	cis	rs7107174	0.892	rs2510031	chr11:77969956	T/C	cg19901956	chr11:77921274	USP35	-0.46	-6.47	-0.3	2.71e-10	Testicular germ cell tumor;
LUAD	cis	rs977987	0.843	rs11644741	chr16:75466433	C/A	cg03315344	chr16:75512273	CHST6	0.65	14.15	0.57	1.72e-37	Dupuytren's disease;
LUAD	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg06740227	chr12:86229804	RASSF9	0.36	6.67	0.31	7.79e-11	Major depressive disorder;
LUAD	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg17063962	chr7:91808500	NA	-0.66	-11.27	-0.48	6.2e-26	Breast cancer;
LUAD	cis	rs12545109	0.842	rs2609975	chr8:57401667	T/C	cg07776626	chr8:57350775	NA	-0.6	-8.56	-0.38	2.05e-16	Obesity-related traits;
LUAD	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg08742575	chr21:47604166	C21orf56	0.52	8.41	0.38	6.58e-16	Testicular germ cell tumor;
LUAD	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.17	0.37	3.65e-15	Breast cancer;
LUAD	cis	rs6867032	0.839	rs4314451	chr5:2001859	T/C	cg26168224	chr5:2018326	NA	-0.71	-13.87	-0.56	2.46e-36	Gut microbiome composition (winter);
LUAD	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.54	7.54	0.34	2.96e-13	Platelet count;
LUAD	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg01579765	chr21:45077557	HSF2BP	0.62	13.89	0.56	2.02e-36	Mean corpuscular volume;
LUAD	cis	rs986417	1.000	rs7160408	chr14:60977471	A/G	cg27398547	chr14:60952738	C14orf39	0.66	7.86	0.36	3.32e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg04450456	chr4:17643702	FAM184B	0.38	7.34	0.34	1.1e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.6	-9.5	-0.42	1.55e-19	Renal function-related traits (BUN);
LUAD	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg06532163	chr17:45867833	NA	0.47	8.41	0.38	6.49e-16	IgG glycosylation;
LUAD	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	8.12	0.37	5e-15	Tonsillectomy;
LUAD	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg12310025	chr6:25882481	NA	-0.5	-8.04	-0.36	9.14e-15	Blood metabolite levels;
LUAD	cis	rs4660214	0.666	rs596062	chr1:39826005	A/G	cg27567593	chr1:39956653	BMP8A	-0.36	-7.31	-0.33	1.33e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg05340658	chr4:99064831	C4orf37	0.53	8.98	0.4	8.92e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-10.98	-0.47	7.62e-25	Monocyte percentage of white cells;
LUAD	cis	rs4764487	0.735	rs2072370	chr12:6345080	A/G	cg08284733	chr12:6341482	CD9	-0.41	-7.36	-0.34	9.53e-13	Mean platelet volume;
LUAD	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.74	15.81	0.61	1.42e-44	White blood cell count;
LUAD	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg02753203	chr1:228287806	NA	-0.62	-11.23	-0.48	8.46e-26	Parkinson's disease;
LUAD	cis	rs210138	0.706	rs3916279	chr6:33574950	A/C	cg17865955	chr6:33601177	ITPR3	0.51	9.13	0.41	2.76e-18	Testicular germ cell tumor;
LUAD	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg09796270	chr17:17721594	SREBF1	0.38	7.56	0.34	2.61e-13	Total body bone mineral density;
LUAD	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg06671706	chr8:8559999	CLDN23	0.68	11.82	0.5	4.72e-28	Obesity-related traits;
LUAD	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg03929089	chr4:120376271	NA	-0.87	-15.77	-0.61	2.11e-44	Coronary artery disease;
LUAD	cis	rs4481887	0.861	rs1339989	chr1:248511624	C/G	cg00666640	chr1:248458726	OR2T12	0.29	7.19	0.33	2.91e-12	Common traits (Other);
LUAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg16479474	chr6:28041457	NA	0.43	7.38	0.34	8.39e-13	Depression;
LUAD	trans	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.71	-0.31	6.45e-11	Depression;
LUAD	cis	rs1232027	0.700	rs1643657	chr5:79936417	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21665057	chr3:196295764	WDR53;FBXO45	-0.79	-15.25	-0.6	3.63e-42	Blood protein levels;
LUAD	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg00684032	chr4:1343700	KIAA1530	0.4	6.57	0.3	1.47e-10	Obesity-related traits;
LUAD	cis	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg07460842	chr6:66804631	NA	-1.06	-16.77	-0.63	9.25e-49	Exhaled nitric oxide output;
LUAD	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg03929089	chr4:120376271	NA	-0.98	-19.95	-0.7	6.8e-63	Height;
LUAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg07167872	chr1:205819463	PM20D1	-0.53	-8.77	-0.39	4.36e-17	Parkinson's disease;
LUAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14893161	chr1:205819251	PM20D1	0.8	16.65	0.63	2.99e-48	Menarche (age at onset);
LUAD	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.53	-7.86	-0.36	3.17e-14	IgG glycosylation;
LUAD	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg01788221	chr16:89496183	ANKRD11	0.36	7.11	0.33	5.12e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14240646	chr10:27532245	ACBD5	-0.92	-11.97	-0.5	1.2e-28	Breast cancer;
LUAD	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg18477163	chr1:228402036	OBSCN	0.39	7.15	0.33	3.82e-12	Diastolic blood pressure;
LUAD	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg13319975	chr6:146136371	FBXO30	-0.6	-9.93	-0.43	4.83e-21	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs629535	0.773	rs568159	chr8:70032908	C/G	cg21567404	chr3:27674614	NA	1.01	18.57	0.67	9.52e-57	Dupuytren's disease;
LUAD	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg06092702	chr1:163392909	NA	-0.37	-8.22	-0.37	2.55e-15	Motion sickness;
LUAD	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg07917127	chr4:99064746	C4orf37	0.4	6.57	0.3	1.5e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg24011408	chr12:48396354	COL2A1	-0.43	-9.44	-0.42	2.63e-19	Plateletcrit;
LUAD	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg03874509	chr1:107600012	PRMT6	0.53	9.2	0.41	1.62e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.37	-7.88	-0.36	2.87e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg14779329	chr11:130786720	SNX19	0.37	6.49	0.3	2.38e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6489882	0.867	rs10850098	chr12:113362058	C/G	cg20102336	chr12:113376681	OAS3	-0.54	-8.4	-0.38	6.94e-16	Chronic lymphocytic leukemia;
LUAD	cis	rs9837602	1.000	rs10212525	chr3:99713377	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	9.02	0.4	6.64e-18	Breast cancer;
LUAD	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1113500	0.933	rs12035689	chr1:108636756	T/C	cg06207961	chr1:108661230	NA	0.44	8.35	0.38	1.01e-15	Growth-regulated protein alpha levels;
LUAD	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg09626299	chr10:82213104	TSPAN14	-0.3	-6.64	-0.31	9.83e-11	Post bronchodilator FEV1;
LUAD	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.11	0.33	4.87e-12	Menopause (age at onset);
LUAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg07362569	chr17:61921086	SMARCD2	0.39	6.74	0.31	5.29e-11	Prudent dietary pattern;
LUAD	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg06697600	chr4:7070879	GRPEL1	-0.51	-7.35	-0.34	1.03e-12	Monocyte percentage of white cells;
LUAD	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg06608945	chr2:219082296	ARPC2	-0.41	-6.78	-0.31	4.08e-11	Colorectal cancer;
LUAD	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	6.4	0.3	4.19e-10	Menarche (age at onset);
LUAD	cis	rs679087	0.612	rs7970465	chr12:29905251	C/T	cg14258853	chr12:29935411	TMTC1	-0.54	-8.75	-0.39	4.99e-17	Schizophrenia;
LUAD	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg19346786	chr7:2764209	NA	-0.33	-7.01	-0.32	9.43e-12	Height;
LUAD	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg04944784	chr2:26401820	FAM59B	-0.66	-9.54	-0.42	1.11e-19	Gut microbiome composition (summer);
LUAD	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg22618164	chr12:122356400	WDR66	0.68	11.78	0.5	6.75e-28	Mean corpuscular volume;
LUAD	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg05966235	chr16:28915196	ATP2A1	0.47	7.61	0.35	1.75e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg18180107	chr4:99064573	C4orf37	-0.41	-6.51	-0.3	2.08e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg11344533	chr11:111475393	SIK2	-0.35	-6.59	-0.31	1.33e-10	Primary sclerosing cholangitis;
LUAD	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg10295955	chr4:187884368	NA	-1.06	-23.42	-0.75	2.28e-78	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg09253696	chr17:73873529	TRIM47	-0.46	-7.5	-0.34	3.8e-13	Psoriasis;
LUAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg11062466	chr8:58055876	NA	0.65	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg20587970	chr11:113659929	NA	-1.4	-20.93	-0.71	2.68e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs1395	0.778	rs11126918	chr2:27438710	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	8.66	0.39	9.93e-17	Blood metabolite levels;
LUAD	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg18825076	chr15:78729989	IREB2	0.53	7.62	0.35	1.67e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg00684032	chr4:1343700	KIAA1530	0.42	7.04	0.32	7.59e-12	Obesity-related traits;
LUAD	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg18512352	chr11:47633146	NA	0.42	7.53	0.34	3.08e-13	Subjective well-being;
LUAD	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg18306943	chr3:40428807	ENTPD3	0.4	6.78	0.31	4.08e-11	Renal cell carcinoma;
LUAD	cis	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg07460842	chr6:66804631	NA	0.96	12.93	0.53	1.93e-32	Exhaled nitric oxide output;
LUAD	cis	rs12791968	0.765	rs12226848	chr11:45009204	C/T	cg11846598	chr11:44996168	LOC221122	-0.66	-9.74	-0.43	2.35e-20	Inhibitory control;
LUAD	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg17372223	chr3:52568218	NT5DC2	0.38	6.81	0.31	3.3e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg21963583	chr11:68658836	MRPL21	0.65	11.47	0.49	1.1e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg18827107	chr12:86230957	RASSF9	-0.71	-13.08	-0.54	4.38e-33	Major depressive disorder;
LUAD	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06022373	chr22:39101656	GTPBP1	0.46	7.13	0.33	4.32e-12	Menopause (age at onset);
LUAD	cis	rs9914988	1.000	rs9914988	chr17:27183104	G/A	cg02049041	chr17:27085579	C17orf63	-0.6	-8.03	-0.36	9.89e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7120118	0.517	rs10838694	chr11:47351760	G/A	cg13308137	chr11:47528955	CUGBP1	0.37	6.71	0.31	6.42e-11	HDL cholesterol;
LUAD	cis	rs4639966	0.589	rs480958	chr11:118577990	G/A	cg11286122	chr11:118477406	PHLDB1	0.35	6.58	0.3	1.44e-10	Systemic lupus erythematosus;
LUAD	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg05872129	chr22:39784769	NA	0.69	11.54	0.49	5.81e-27	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg26384229	chr12:38710491	ALG10B	-0.42	-7.26	-0.33	1.81e-12	Morning vs. evening chronotype;
LUAD	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg02371401	chr5:676784	TPPP	-0.48	-7.81	-0.36	4.42e-14	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.76	0.39	4.66e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg20762182	chr15:69727293	KIF23	-0.42	-6.37	-0.3	4.8e-10	Height;
LUAD	trans	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg18335740	chr13:41363409	SLC25A15	0.57	10.22	0.45	4.73e-22	Lewy body disease;
LUAD	cis	rs11771526	0.901	rs62457469	chr7:32303052	T/C	cg27532318	chr7:32358331	NA	0.59	7.42	0.34	6.66e-13	Body mass index;
LUAD	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-8.15	-0.37	4.19e-15	Total cholesterol levels;
LUAD	cis	rs10129255	0.500	rs6576232	chr14:107195328	A/G	cg23076370	chr14:107095027	NA	-0.42	-8.54	-0.38	2.45e-16	Kawasaki disease;
LUAD	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	11.55	0.49	5.28e-27	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg26647111	chr11:31128758	NA	-0.45	-7.89	-0.36	2.69e-14	Red blood cell count;
LUAD	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg11871910	chr12:69753446	YEATS4	0.48	7.51	0.34	3.52e-13	Response to diuretic therapy;
LUAD	cis	rs7584330	0.666	rs6760963	chr2:238398268	C/T	cg14458575	chr2:238380390	NA	-0.52	-8.52	-0.38	2.91e-16	Prostate cancer;
LUAD	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg04450456	chr4:17643702	FAM184B	0.43	8.47	0.38	4.05e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs73416724	0.841	rs78415183	chr6:43394041	T/G	cg26312998	chr6:43337775	ZNF318	0.56	6.79	0.31	3.69e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07266350	chr3:49460521	AMT;NICN1	0.37	6.66	0.31	8.8e-11	Menarche (age at onset);
LUAD	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg15704280	chr7:45808275	SEPT13	0.7	11.69	0.49	1.57e-27	Coronary artery disease;
LUAD	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.88	-0.5	2.64e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg22618164	chr12:122356400	WDR66	0.67	11.84	0.5	3.9e-28	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.57e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.42	6.65	0.31	9.33e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22857025	chr5:266934	NA	-0.96	-13.99	-0.56	8.25e-37	Breast cancer;
LUAD	cis	rs7843479	0.562	rs2127206	chr8:21786989	C/T	cg03445287	chr8:21823731	XPO7	-0.5	-9.18	-0.41	1.94e-18	Mean corpuscular volume;
LUAD	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg16486109	chr11:613632	IRF7	0.52	7.79	0.35	5.13e-14	Systemic lupus erythematosus;
LUAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	cis	rs72634258	0.945	rs12748993	chr1:8129507	A/G	cg26816564	chr1:7831052	VAMP3	0.5	6.59	0.31	1.27e-10	Inflammatory bowel disease;
LUAD	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg07936489	chr17:37558343	FBXL20	-0.47	-7.49	-0.34	3.94e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg18402987	chr7:1209562	NA	0.82	11.01	0.47	5.73e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg00383909	chr3:49044727	WDR6	0.54	6.9	0.32	1.9e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08219700	chr8:58056026	NA	0.63	8.82	0.39	2.92e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-9.42	-0.42	2.92e-19	Endometrial cancer;
LUAD	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg10792982	chr14:105748885	BRF1	0.44	9.51	0.42	1.44e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	8.03e-16	Body mass index;
LUAD	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg09359103	chr1:154839909	KCNN3	-0.91	-21.24	-0.72	1.09e-68	Prostate cancer;
LUAD	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21214613	chr1:16344536	HSPB7	0.57	10.41	0.45	9.95e-23	Dilated cardiomyopathy;
LUAD	trans	rs1997103	1.000	rs1997102	chr7:55399322	A/C	cg20935933	chr6:143382018	AIG1	-0.53	-7.66	-0.35	1.24e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2880765	0.835	rs7169632	chr15:86044667	T/G	cg04831495	chr15:85060580	GOLGA6L5	-0.37	-6.35	-0.3	5.56e-10	Coronary artery disease;
LUAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07167872	chr1:205819463	PM20D1	0.6	11.14	0.48	1.86e-25	Menarche (age at onset);
LUAD	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg00321850	chr1:175162397	KIAA0040	-0.51	-10.8	-0.46	3.6e-24	Alcohol dependence;
LUAD	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg20469991	chr17:27169893	C17orf63	-0.51	-6.46	-0.3	2.89e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg12179176	chr11:130786555	SNX19	0.46	7.69	0.35	1.06e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10489202	0.583	rs203777	chr1:167876616	C/T	cg25738037	chr1:168025549	DCAF6	-0.47	-6.83	-0.31	3.06e-11	Schizophrenia;
LUAD	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg02782426	chr3:40428986	ENTPD3	0.43	9.15	0.41	2.49e-18	Renal cell carcinoma;
LUAD	cis	rs9302065	0.565	rs2993584	chr13:95961678	C/A	cg24476569	chr13:95954382	ABCC4	-0.58	-10.65	-0.46	1.27e-23	Blood metabolite levels;
LUAD	cis	rs5756391	0.532	rs4820261	chr22:37316949	G/A	cg16356956	chr22:37317934	CSF2RB	0.31	6.53	0.3	1.84e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs7119	0.717	rs11634174	chr15:77811232	A/T	cg27398640	chr15:77910606	LINGO1	-0.34	-6.55	-0.3	1.63e-10	Type 2 diabetes;
LUAD	cis	rs8067545	0.641	rs203462	chr17:19812541	T/C	cg04132472	chr17:19861366	AKAP10	0.39	9.21	0.41	1.5e-18	Schizophrenia;
LUAD	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg03676636	chr4:99064102	C4orf37	0.29	6.99	0.32	1.09e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg01528321	chr10:82214614	TSPAN14	0.65	10.19	0.44	5.99e-22	Post bronchodilator FEV1;
LUAD	cis	rs12579753	0.917	rs7138651	chr12:82253615	A/G	cg07988820	chr12:82153109	PPFIA2	0.39	6.48	0.3	2.56e-10	Resting heart rate;
LUAD	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.78	0.35	5.45e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg02753203	chr1:228287806	NA	0.77	14.07	0.56	3.73e-37	Diastolic blood pressure;
LUAD	cis	rs2979489	0.891	rs4449748	chr8:30304402	A/G	cg26383811	chr8:30366931	RBPMS	0.64	9.84	0.43	1.06e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	trans	rs60787346	0.883	rs3788070	chr21:45068077	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	7.3	0.33	1.45e-12	Coronary artery disease;
LUAD	cis	rs6543140	0.964	rs6543144	chr2:103092575	A/G	cg04239558	chr2:103089729	SLC9A4	0.35	7.07	0.33	6.42e-12	Blood protein levels;
LUAD	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg12908607	chr1:44402522	ARTN	-0.45	-8.95	-0.4	1.11e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg08885076	chr2:99613938	TSGA10	0.36	6.46	0.3	2.91e-10	Chronic sinus infection;
LUAD	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg12311346	chr5:56204834	C5orf35	-0.93	-13.95	-0.56	1.23e-36	Initial pursuit acceleration;
LUAD	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg03929089	chr4:120376271	NA	-0.84	-14.92	-0.59	9.64e-41	Coronary artery disease;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19517509	chr12:120933726	DYNLL1	0.44	6.55	0.3	1.63e-10	Monocyte percentage of white cells;
LUAD	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg08027265	chr7:2291960	NA	-0.41	-7.0	-0.32	9.89e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2404602	0.735	rs11637490	chr15:76759565	A/G	cg23625390	chr15:77176239	SCAPER	-0.51	-8.24	-0.37	2.18e-15	Blood metabolite levels;
LUAD	cis	rs62238980	0.522	rs118120290	chr22:32399262	T/C	cg00543991	chr22:32367038	NA	0.95	8.87	0.4	2.05e-17	Childhood ear infection;
LUAD	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg07917127	chr4:99064746	C4orf37	0.42	7.02	0.32	9.15e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg03037974	chr15:76606532	NA	0.39	8.74	0.39	5.41e-17	Blood metabolite levels;
LUAD	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.56	-0.3	1.61e-10	Alzheimer's disease (late onset);
LUAD	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg10518543	chr12:38710700	ALG10B	-0.44	-7.2	-0.33	2.71e-12	Bladder cancer;
LUAD	cis	rs7586879	0.719	rs7565468	chr2:25130092	C/T	cg04586622	chr2:25135609	ADCY3	0.36	7.27	0.33	1.74e-12	Body mass index;
LUAD	cis	rs68170813	0.559	rs4730226	chr7:106887274	A/C	cg23024343	chr7:107201750	COG5	0.49	7.03	0.32	8.5e-12	Coronary artery disease;
LUAD	trans	rs7395662	0.929	rs12366252	chr11:48542318	G/A	cg00717180	chr2:96193071	NA	-0.4	-7.55	-0.34	2.65e-13	HDL cholesterol;
LUAD	cis	rs208520	0.690	rs207740	chr6:66764132	T/G	cg07460842	chr6:66804631	NA	1.05	16.39	0.62	4.09e-47	Exhaled nitric oxide output;
LUAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg12432903	chr7:1882776	MAD1L1	-0.53	-8.84	-0.4	2.53e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs73206853	0.563	rs73194046	chr12:111191665	A/G	cg12870014	chr12:110450643	ANKRD13A	0.57	6.46	0.3	2.84e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg06532163	chr17:45867833	NA	0.47	8.28	0.37	1.68e-15	IgG glycosylation;
LUAD	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg06873352	chr17:61820015	STRADA	0.42	7.05	0.32	7.15e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg22166914	chr1:53195759	ZYG11B	-0.41	-6.75	-0.31	4.85e-11	Monocyte count;
LUAD	cis	rs9925964	0.933	rs8050894	chr16:31104509	C/G	cg03418659	chr16:31128414	MYST1	0.41	7.23	0.33	2.31e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.1	0.37	5.93e-15	Menopause (age at onset);
LUAD	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg22117172	chr7:91764530	CYP51A1	-0.32	-6.89	-0.32	2.02e-11	Breast cancer;
LUAD	cis	rs1595825	0.891	rs77029420	chr2:198651492	G/A	cg00361562	chr2:198649771	BOLL	-0.5	-6.54	-0.3	1.75e-10	Ulcerative colitis;
LUAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg06753367	chr22:24256600	NA	-0.38	-6.64	-0.31	9.81e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.92	-0.5	1.91e-28	Bipolar disorder;
LUAD	cis	rs4356932	1.000	rs6828596	chr4:76961373	A/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.52	-0.3	2.05e-10	Blood protein levels;
LUAD	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg27144592	chr16:783916	NARFL	0.35	6.45	0.3	3.13e-10	Height;
LUAD	cis	rs1385374	0.858	rs11059927	chr12:129294333	T/C	cg09035930	chr12:129282057	SLC15A4	-0.65	-6.91	-0.32	1.79e-11	Systemic lupus erythematosus;
LUAD	cis	rs829883	0.714	rs249847	chr12:98867716	C/T	cg25150519	chr12:98850993	NA	0.73	13.96	0.56	1.13e-36	Colorectal adenoma (advanced);
LUAD	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg18512352	chr11:47633146	NA	-0.55	-9.74	-0.43	2.37e-20	Subjective well-being;
LUAD	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24531977	chr5:56204891	C5orf35	-0.99	-15.17	-0.59	8.56e-42	Initial pursuit acceleration;
LUAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00166722	chr3:10149974	C3orf24	0.71	12.36	0.52	3.47e-30	Alzheimer's disease;
LUAD	cis	rs4631830	0.900	rs10763534	chr10:51534920	C/T	cg20129853	chr10:51489980	NA	-0.34	-6.74	-0.31	5.26e-11	Prostate-specific antigen levels;
LUAD	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg00071950	chr4:10020882	SLC2A9	0.78	15.83	0.61	1.14e-44	Bone mineral density;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21515243	chr18:21033072	RIOK3	0.39	6.37	0.3	4.95e-10	Gut microbiome composition (summer);
LUAD	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg09835421	chr16:68378352	PRMT7	-0.91	-9.53	-0.42	1.23e-19	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg27535305	chr1:53392650	SCP2	-0.33	-6.67	-0.31	8.07e-11	Monocyte count;
LUAD	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11644478	chr21:40555479	PSMG1	-0.4	-6.61	-0.31	1.18e-10	Menarche (age at onset);
LUAD	trans	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg26043149	chr18:55253948	FECH	0.53	8.81	0.39	3.19e-17	Bone mineral density;
LUAD	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg03733263	chr8:22462867	KIAA1967	-0.64	-10.66	-0.46	1.16e-23	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs1018836	0.923	rs10956748	chr8:91621537	T/A	cg16814680	chr8:91681699	NA	-0.7	-11.77	-0.5	7.31e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg07570687	chr10:102243282	WNT8B	0.42	6.39	0.3	4.4e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg26384229	chr12:38710491	ALG10B	0.44	7.21	0.33	2.52e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs12976411	0.575	rs6510240	chr19:32820082	A/G	cg18253629	chr19:32836317	ZNF507	0.65	6.84	0.32	2.71e-11	Coronary artery disease;
LUAD	cis	rs2455601	0.638	rs3815991	chr11:9007669	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.44	7.77	0.35	5.88e-14	Schizophrenia;
LUAD	cis	rs8177876	0.822	rs10514515	chr16:81115322	T/C	cg08591886	chr16:81111003	C16orf46	-0.79	-7.37	-0.34	8.94e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg06627628	chr2:24431161	ITSN2	-0.64	-10.0	-0.44	2.73e-21	Asthma;
LUAD	cis	rs6490294	0.659	rs608848	chr12:112146964	C/T	cg10833066	chr12:111807467	FAM109A	0.36	6.73	0.31	5.43e-11	Mean platelet volume;
LUAD	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg08470875	chr2:26401718	FAM59B	-0.59	-7.94	-0.36	1.84e-14	Gut microbiome composition (summer);
LUAD	trans	rs7395662	0.713	rs2865668	chr11:48745046	T/C	cg15704280	chr7:45808275	SEPT13	-0.41	-6.39	-0.3	4.33e-10	HDL cholesterol;
LUAD	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg16797656	chr11:68205561	LRP5	0.45	8.53	0.38	2.72e-16	Total body bone mineral density;
LUAD	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3779273	1.000	rs3779272	chr7:77828991	A/T	cg05596911	chr5:118502651	DMXL1	-0.38	-6.76	-0.31	4.51e-11	Body mass index;
LUAD	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg08859206	chr1:53392774	SCP2	0.54	9.77	0.43	1.78e-20	Monocyte count;
LUAD	cis	rs790123	0.965	rs2133850	chr3:122381696	C/T	cg24850323	chr3:122379709	NA	0.37	6.63	0.31	1.04e-10	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg14728415	chr7:32535168	LSM5;AVL9	-0.56	-8.95	-0.4	1.12e-17	Cognitive ability;
LUAD	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	3.96e-11	Depression;
LUAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.26	0.37	1.85e-15	Alzheimer's disease;
LUAD	cis	rs68170813	0.559	rs75007274	chr7:106814543	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-11.09	-0.47	3.01e-25	Coronary artery disease;
LUAD	cis	rs17739167	0.550	rs11634233	chr15:42224563	G/A	cg20935245	chr15:42234343	EHD4	0.44	7.58	0.35	2.22e-13	Monocyte count;
LUAD	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg10544611	chr16:67998164	SLC12A4	-0.53	-6.66	-0.31	8.69e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.56	0.34	2.59e-13	Cannabis dependence symptom count;
LUAD	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Colorectal cancer;
LUAD	cis	rs7267979	0.753	rs404148	chr20:25447931	A/G	cg08601574	chr20:25228251	PYGB	0.39	7.3	0.33	1.45e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11386818	chr6:86351552	SYNCRIP	-0.39	-6.48	-0.3	2.6e-10	Cancer;
LUAD	cis	rs713587	0.713	rs4665276	chr2:25213333	C/T	cg04586622	chr2:25135609	ADCY3	-0.31	-6.77	-0.31	4.24e-11	Body mass index in non-asthmatics;
LUAD	cis	rs7274811	0.625	rs293734	chr20:31924680	T/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.46	6.57	0.3	1.46e-10	Height;
LUAD	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg20203395	chr5:56204925	C5orf35	-0.81	-11.83	-0.5	4.42e-28	Initial pursuit acceleration;
LUAD	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg22189786	chr22:42395067	WBP2NL	0.46	6.57	0.3	1.53e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg19442545	chr10:75533431	FUT11	-0.46	-7.64	-0.35	1.52e-13	Inflammatory bowel disease;
LUAD	trans	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg11693508	chr17:37793320	STARD3	0.71	9.34	0.41	5.49e-19	Bipolar disorder;
LUAD	cis	rs6906287	0.647	rs10456917	chr6:118779419	A/C	cg18833306	chr6:118973337	C6orf204	0.46	8.16	0.37	3.89e-15	Electrocardiographic conduction measures;
LUAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	9.59	0.42	7.53e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg00933542	chr6:150070202	PCMT1	0.35	7.41	0.34	7.13e-13	Testicular germ cell tumor;
LUAD	cis	rs10504073	0.609	rs17644494	chr8:50019679	T/C	cg00325661	chr8:49890786	NA	0.43	9.82	0.43	1.25e-20	Blood metabolite ratios;
LUAD	trans	rs79911532	0.515	rs117690214	chr7:75718237	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	8.61	0.39	1.47e-16	Mononucleosis;
LUAD	cis	rs4006360	0.577	rs4986669	chr17:39250341	C/A	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.3	0.37	1.43e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	6.59	0.3	1.35e-10	Cognitive test performance;
LUAD	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg22676075	chr6:135203613	NA	0.42	7.79	0.35	5.41e-14	Red blood cell count;
LUAD	cis	rs10037055	0.947	rs10063803	chr5:176667327	C/A	cg06733329	chr5:176740039	MXD3	-0.44	-7.04	-0.32	8.01e-12	Migraine without aura;
LUAD	cis	rs4689388	0.890	rs9993624	chr4:6286528	C/T	cg14416269	chr4:6271139	WFS1	0.65	13.91	0.56	1.71e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6496044	0.568	rs12898783	chr15:86066100	G/C	cg13263323	chr15:86062960	AKAP13	-0.58	-10.79	-0.46	3.87e-24	Interstitial lung disease;
LUAD	cis	rs977987	0.835	rs8057535	chr16:75347941	C/T	cg03315344	chr16:75512273	CHST6	0.63	13.98	0.56	8.47e-37	Dupuytren's disease;
LUAD	cis	rs4604732	0.631	rs10925043	chr1:247627001	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23583168	chr7:148888333	NA	-1.04	-25.58	-0.78	6.99e-88	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg27432699	chr2:27873401	GPN1	-0.39	-6.59	-0.31	1.28e-10	Total body bone mineral density;
LUAD	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26314531	chr2:26401878	FAM59B	-0.66	-9.68	-0.43	3.81e-20	Gut microbiome composition (summer);
LUAD	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg11663144	chr21:46675770	NA	0.59	11.75	0.5	8.92e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg05368731	chr17:41323189	NBR1	0.98	20.62	0.71	6.67e-66	Menopause (age at onset);
LUAD	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg10518543	chr12:38710700	ALG10B	0.52	8.56	0.38	2.13e-16	Morning vs. evening chronotype;
LUAD	cis	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg27411982	chr8:10470053	RP1L1	0.39	7.16	0.33	3.68e-12	Neuroticism;
LUAD	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg05368731	chr17:41323189	NBR1	0.95	19.8	0.69	3.25e-62	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9972944	0.729	rs8067136	chr17:63762995	C/A	cg07283582	chr17:63770753	CCDC46	-0.52	-11.41	-0.49	1.72e-26	Total body bone mineral density;
LUAD	cis	rs113835537	0.559	rs57045447	chr11:66339683	A/G	cg24851651	chr11:66362959	CCS	0.59	10.48	0.45	5.18e-23	Airway imaging phenotypes;
LUAD	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg00310523	chr12:86230176	RASSF9	0.41	8.03	0.36	9.78e-15	Major depressive disorder;
LUAD	cis	rs4853036	0.951	rs3755391	chr2:70141519	C/T	cg02498382	chr2:70120550	SNRNP27	-0.55	-8.85	-0.4	2.44e-17	Colorectal or endometrial cancer;
LUAD	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg00933542	chr6:150070202	PCMT1	0.41	8.36	0.38	9.28e-16	Lung cancer;
LUAD	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg00898013	chr13:113819073	PROZ	-0.68	-12.09	-0.51	3.98e-29	Platelet distribution width;
LUAD	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg09365446	chr1:150670422	GOLPH3L	0.61	10.84	0.47	2.48e-24	Melanoma;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20431080	chr7:149158239	ZNF777	0.54	6.89	0.32	2.09e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7168353	1.000	rs7168353	chr15:93638401	C/G	cg12595281	chr15:93633172	RGMA	0.38	6.5	0.3	2.26e-10	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUAD	cis	rs6842047	1.000	rs9995366	chr4:187131384	T/C	cg09526685	chr4:187126073	CYP4V2	0.89	10.08	0.44	1.48e-21	Blood protein levels;
LUAD	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg00933542	chr6:150070202	PCMT1	0.35	7.41	0.34	7.13e-13	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg08219700	chr8:58056026	NA	0.68	9.03	0.4	6.18e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg02527881	chr3:46936655	PTH1R	-0.55	-11.52	-0.49	6.6e-27	Colorectal cancer;
LUAD	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12667521	chr19:29218732	NA	-0.56	-7.04	-0.32	7.6e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg09117114	chr16:67998030	SLC12A4	-0.61	-8.12	-0.37	5.29e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg05043794	chr9:111880884	C9orf5	0.4	6.81	0.31	3.46e-11	Menarche (age at onset);
LUAD	cis	rs1448094	0.802	rs11117146	chr12:86382870	C/T	cg06740227	chr12:86229804	RASSF9	-0.36	-6.54	-0.3	1.79e-10	Major depressive disorder;
LUAD	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03517284	chr6:25882590	NA	0.6	10.0	0.44	2.93e-21	Blood metabolite levels;
LUAD	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg20701182	chr2:24300061	SF3B14	0.54	6.54	0.3	1.76e-10	Lymphocyte counts;
LUAD	cis	rs62238980	0.614	rs117256264	chr22:32381750	T/C	cg02631450	chr22:32366979	NA	0.79	6.46	0.3	2.9e-10	Childhood ear infection;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg14378659	chr8:8860465	ERI1	-0.39	-6.54	-0.3	1.77e-10	Schizophrenia;
LUAD	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg24558204	chr6:135376177	HBS1L	0.45	7.52	0.34	3.36e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.26e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9462027	0.628	rs2814953	chr6:34697767	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.87	-0.4	2.11e-17	Systemic lupus erythematosus;
LUAD	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg26597838	chr10:835615	NA	1.03	16.35	0.62	6.41e-47	Eosinophil percentage of granulocytes;
LUAD	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.21e-32	Immature fraction of reticulocytes;
LUAD	cis	rs9486719	0.843	rs2205754	chr6:96843134	T/C	cg06623918	chr6:96969491	KIAA0776	0.71	9.3	0.41	7.58e-19	Migraine;Coronary artery disease;
LUAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg22963979	chr7:1858916	MAD1L1	-0.69	-11.72	-0.5	1.17e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs4285028	0.948	rs12488851	chr3:121687192	C/T	cg11130432	chr3:121712080	ILDR1	-0.59	-8.44	-0.38	5.05e-16	Multiple sclerosis;
LUAD	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg11344533	chr11:111475393	SIK2	-0.35	-6.64	-0.31	9.9e-11	Primary sclerosing cholangitis;
LUAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-8.12	-0.37	5.09e-15	Alzheimer's disease;
LUAD	cis	rs11650494	0.908	rs11656535	chr17:47425588	C/T	cg08112188	chr17:47440006	ZNF652	0.91	7.89	0.36	2.56e-14	Prostate cancer;
LUAD	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg17063962	chr7:91808500	NA	0.62	10.4	0.45	1.04e-22	Breast cancer;
LUAD	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.02	0.32	8.9e-12	Hypertriglyceridemia;
LUAD	cis	rs6500395	1.000	rs1477134	chr16:48706973	G/A	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs35883536	0.647	rs12026951	chr1:101046273	C/T	cg06223162	chr1:101003688	GPR88	-0.48	-9.34	-0.41	5.43e-19	Monocyte count;
LUAD	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg03929089	chr4:120376271	NA	0.57	7.53	0.34	3.06e-13	Axial length;
LUAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.06	0.66	1.83e-54	Prudent dietary pattern;
LUAD	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg00316803	chr15:76480434	C15orf27	0.41	6.52	0.3	2.03e-10	Blood metabolite levels;
LUAD	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.12	-0.41	2.98e-18	Total body bone mineral density;
LUAD	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18876405	chr7:65276391	NA	-0.45	-7.15	-0.33	3.74e-12	Aortic root size;
LUAD	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg23649088	chr2:200775458	C2orf69	-0.56	-6.57	-0.3	1.51e-10	Schizophrenia;
LUAD	cis	rs11229555	0.645	rs12226725	chr11:58246332	G/A	cg15696309	chr11:58395628	NA	-0.8	-10.9	-0.47	1.45e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs10927875	0.501	rs61782229	chr1:16220118	G/A	cg21385522	chr1:16154831	NA	-0.96	-13.98	-0.56	8.72e-37	Dilated cardiomyopathy;
LUAD	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg02574844	chr11:5959923	NA	-0.45	-8.24	-0.37	2.23e-15	DNA methylation (variation);
LUAD	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg13385794	chr1:248469461	NA	0.25	6.95	0.32	1.35e-11	Common traits (Other);
LUAD	trans	rs7746199	0.736	rs56405707	chr6:27640246	G/A	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.65	-0.46	1.24e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.31	-0.37	1.32e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11644478	chr21:40555479	PSMG1	0.6	10.32	0.45	1.98e-22	Cognitive function;
LUAD	cis	rs6906287	0.647	rs13192574	chr6:118875258	C/T	cg05564266	chr6:118973597	C6orf204	0.36	7.68	0.35	1.11e-13	Electrocardiographic conduction measures;
LUAD	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg06558623	chr16:89946397	TCF25	1.15	10.6	0.46	1.96e-23	Skin colour saturation;
LUAD	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.47	0.38	4.01e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7000551	0.751	rs2461482	chr8:22382898	C/T	cg12081754	chr8:22256438	SLC39A14	0.47	7.74	0.35	7.3e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg08645402	chr16:4508243	NA	0.59	11.02	0.47	5.37e-25	Schizophrenia;
LUAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg04234412	chr22:24373322	LOC391322	-0.79	-14.41	-0.57	1.4e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18099408	chr3:52552593	STAB1	-0.42	-7.44	-0.34	5.74e-13	Electroencephalogram traits;
LUAD	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.23	0.48	8.73e-26	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.47	7.7	0.35	9.6e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg27411982	chr8:10470053	RP1L1	-0.35	-6.39	-0.3	4.36e-10	Neuroticism;
LUAD	cis	rs7737355	0.947	rs11750739	chr5:130911743	C/T	cg25547332	chr5:131281432	NA	0.4	6.44	0.3	3.31e-10	Life satisfaction;
LUAD	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg06640241	chr16:89574553	SPG7	-0.46	-7.75	-0.35	6.7e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.39	6.38	0.3	4.67e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs2279817	0.863	rs11203441	chr1:18026725	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.52	8.65	0.39	1.08e-16	Neuroticism;
LUAD	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg17724175	chr1:150552817	MCL1	0.39	9.39	0.42	3.82e-19	Tonsillectomy;
LUAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg06263672	chr7:65235340	NA	-0.47	-7.6	-0.35	1.87e-13	Calcium levels;
LUAD	trans	rs66573146	0.803	rs60228659	chr4:7031704	G/A	cg07817883	chr1:32538562	TMEM39B	1.42	11.46	0.49	1.2e-26	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7107174	1.000	rs2450129	chr11:77940385	T/C	cg02023728	chr11:77925099	USP35	0.53	8.11	0.37	5.36e-15	Testicular germ cell tumor;
LUAD	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg10356904	chr22:49881777	NA	-0.39	-8.49	-0.38	3.52e-16	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg01475377	chr6:109611718	NA	-0.49	-8.9	-0.4	1.67e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs35110281	0.540	rs55840436	chr21:45118541	G/T	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.95	-0.5	1.48e-28	Mean corpuscular volume;
LUAD	cis	rs7127129	0.503	rs7105001	chr11:70051949	T/C	cg06159181	chr11:70072977	NA	-0.44	-8.6	-0.39	1.6e-16	Aortic root size;
LUAD	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg10589385	chr1:150898437	SETDB1	-0.44	-8.41	-0.38	6.51e-16	Melanoma;
LUAD	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg25894440	chr7:65020034	NA	-0.61	-6.6	-0.31	1.25e-10	Diabetic kidney disease;
LUAD	cis	rs12545109	0.879	rs893234	chr8:57363885	G/A	cg11919837	chr8:57350735	NA	-0.48	-6.71	-0.31	6.26e-11	Obesity-related traits;
LUAD	cis	rs7254114	0.578	rs12980863	chr19:11309871	C/T	cg02815516	chr19:11306319	KANK2	-0.34	-7.6	-0.35	1.91e-13	Immature fraction of reticulocytes;
LUAD	cis	rs9487051	0.660	rs2884036	chr6:109642916	A/G	cg21918786	chr6:109611834	NA	0.43	7.12	0.33	4.71e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs7107174	1.000	rs2510035	chr11:77953175	A/C	cg02023728	chr11:77925099	USP35	0.5	7.64	0.35	1.46e-13	Testicular germ cell tumor;
LUAD	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg19041857	chr6:27730383	NA	-0.41	-6.94	-0.32	1.46e-11	Parkinson's disease;
LUAD	cis	rs17155006	0.746	rs435125	chr7:107748934	A/G	cg05962710	chr7:107745446	LAMB4	-0.34	-7.31	-0.33	1.37e-12	Pneumococcal bacteremia;
LUAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00166722	chr3:10149974	C3orf24	0.73	10.94	0.47	1.1e-24	Alzheimer's disease;
LUAD	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs7737355	0.947	rs3776027	chr5:130802970	T/C	cg06307176	chr5:131281290	NA	-0.49	-7.83	-0.36	3.85e-14	Life satisfaction;
LUAD	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg09035930	chr12:129282057	SLC15A4	0.71	15.77	0.61	2.18e-44	Systemic lupus erythematosus;
LUAD	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg14345882	chr6:26364793	BTN3A2	0.7	7.17	0.33	3.35e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs59918340	0.509	rs11784862	chr8:142203452	T/C	cg23301539	chr8:142222248	SLC45A4	0.42	6.89	0.32	2.01e-11	Immature fraction of reticulocytes;
LUAD	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg12311346	chr5:56204834	C5orf35	-0.45	-7.37	-0.34	8.81e-13	Coronary artery disease;
LUAD	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg00086871	chr4:6988644	TBC1D14	0.74	6.38	0.3	4.58e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg22482690	chr17:47019901	SNF8	0.44	8.37	0.38	8.71e-16	Type 2 diabetes;
LUAD	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-13.04	-0.54	6.62e-33	Axial length;
LUAD	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg02951883	chr7:2050386	MAD1L1	-0.64	-10.06	-0.44	1.72e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs847577	0.569	rs12674083	chr7:97696334	C/T	cg24562669	chr7:97807699	LMTK2	0.3	7.03	0.32	8.48e-12	Breast cancer;
LUAD	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg04800585	chr6:26043546	HIST1H2BB	-0.38	-6.88	-0.32	2.19e-11	Blood metabolite levels;
LUAD	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg20135002	chr11:47629003	NA	-0.41	-7.21	-0.33	2.63e-12	Subjective well-being;
LUAD	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg13180566	chr4:1052158	NA	-0.38	-6.54	-0.3	1.73e-10	Recombination rate (females);
LUAD	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.07e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10802521	chr3:52805072	NEK4	-0.62	-11.08	-0.47	3.05e-25	Bipolar disorder;
LUAD	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.98	-0.36	1.35e-14	Monocyte percentage of white cells;
LUAD	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg07936489	chr17:37558343	FBXL20	-0.44	-7.03	-0.32	8.4e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg11189052	chr15:85197271	WDR73	0.68	9.05	0.4	5.08e-18	Schizophrenia;
LUAD	cis	rs67981189	0.593	rs2240531	chr14:71553606	A/G	cg15816911	chr14:71606274	NA	0.34	6.4	0.3	4.25e-10	Schizophrenia;
LUAD	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.08	-0.44	1.5e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.67	-0.31	8.19e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9296092	0.538	rs7761268	chr6:33519300	C/T	cg13560919	chr6:33536144	NA	-0.88	-16.13	-0.62	5.99e-46	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs12618769	0.652	rs72821965	chr2:99188783	T/C	cg10123293	chr2:99228465	UNC50	0.48	8.71	0.39	6.82e-17	Bipolar disorder;
LUAD	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg09365446	chr1:150670422	GOLPH3L	-0.4	-6.44	-0.3	3.23e-10	Tonsillectomy;
LUAD	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg05110241	chr16:68378359	PRMT7	-0.83	-9.03	-0.4	6.05e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.08	-0.37	6.63e-15	Bipolar disorder;
LUAD	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-6.84	-0.32	2.75e-11	Lung cancer;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg02718464	chr13:41384019	SUGT1L1;SLC25A15;MIR621	0.41	6.38	0.3	4.52e-10	Prostate cancer (SNP x SNP interaction);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg03051979	chr16:58283909	CCDC113	0.44	7.14	0.33	4.06e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg18306943	chr3:40428807	ENTPD3	0.37	6.67	0.31	8.22e-11	Renal cell carcinoma;
LUAD	trans	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg26043149	chr18:55253948	FECH	-0.41	-6.81	-0.31	3.36e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4853036	0.672	rs13018194	chr2:70025988	G/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-6.75	-0.31	4.88e-11	Colorectal or endometrial cancer;
LUAD	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg23803603	chr1:2058230	PRKCZ	0.43	8.03	0.36	1.01e-14	Height;
LUAD	cis	rs2735413	0.875	rs8053987	chr16:78084834	G/A	cg04733911	chr16:78082701	NA	0.34	8.28	0.37	1.67e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg02527881	chr3:46936655	PTH1R	-0.46	-8.98	-0.4	9.16e-18	Colorectal cancer;
LUAD	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg12927641	chr6:109611667	NA	-0.51	-9.15	-0.41	2.41e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg03948781	chr1:205179583	DSTYK	0.35	6.4	0.3	4.17e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs684232	0.602	rs10521107	chr17:511156	G/A	cg12384639	chr17:618140	VPS53	0.48	8.04	0.36	9.06e-15	Prostate cancer;
LUAD	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg07741184	chr6:167504864	NA	0.39	9.01	0.4	7.23e-18	Primary biliary cholangitis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13063812	chr6:16129305	MYLIP	-0.53	-6.42	-0.3	3.61e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg06558623	chr16:89946397	TCF25	1.2	12.11	0.51	3.39e-29	Skin colour saturation;
LUAD	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg04455712	chr21:45112962	RRP1B	0.47	9.29	0.41	7.99e-19	Mean corpuscular volume;
LUAD	trans	rs853679	0.546	rs200990	chr6:27815823	T/G	cg01620082	chr3:125678407	NA	-0.8	-8.69	-0.39	7.74e-17	Depression;
LUAD	cis	rs3772130	0.962	rs9856641	chr3:121566859	G/A	cg20356878	chr3:121714668	ILDR1	0.52	8.3	0.37	1.39e-15	Cognitive performance;
LUAD	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.37	-0.34	8.77e-13	Total cholesterol levels;
LUAD	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.77e-11	Depression;
LUAD	cis	rs701145	0.585	rs454837	chr3:153915417	T/C	cg17054900	chr3:154042577	DHX36	0.66	7.08	0.33	6.13e-12	Coronary artery disease;
LUAD	cis	rs7326068	0.576	rs34880311	chr13:21329255	A/T	cg27499820	chr13:21296301	IL17D	0.44	7.31	0.33	1.35e-12	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg17724175	chr1:150552817	MCL1	0.39	9.39	0.42	3.82e-19	Tonsillectomy;
LUAD	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.74	-0.35	7.33e-14	Breast cancer;
LUAD	cis	rs9549328	0.642	rs2993343	chr13:113616844	C/G	cg17524180	chr13:113633600	MCF2L	0.3	6.44	0.3	3.18e-10	Systolic blood pressure;
LUAD	cis	rs490234	0.676	rs1129	chr9:128199873	A/G	cg14078157	chr9:128172775	NA	0.5	9.04	0.4	5.89e-18	Mean arterial pressure;
LUAD	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg14668632	chr7:2872130	GNA12	-0.76	-13.69	-0.55	1.36e-35	Height;
LUAD	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-9.0	-0.4	7.89e-18	Bipolar disorder;
LUAD	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg10523679	chr1:76189770	ACADM	-0.49	-6.83	-0.32	3.03e-11	Daytime sleep phenotypes;
LUAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-9.43	-0.42	2.83e-19	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.84e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4774899	0.752	rs7175436	chr15:57418814	T/C	cg14026238	chr15:57616123	NA	-0.4	-7.71	-0.35	9.3e-14	Urinary tract infection frequency;
LUAD	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg02782426	chr3:40428986	ENTPD3	0.34	7.47	0.34	4.59e-13	Renal cell carcinoma;
LUAD	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs10746514	1.000	rs12129814	chr1:232251730	C/A	cg09506761	chr1:232265262	NA	0.38	6.97	0.32	1.26e-11	Response to statin therapy;
LUAD	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg00933542	chr6:150070202	PCMT1	0.42	8.9	0.4	1.63e-17	Lung cancer;
LUAD	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg09365446	chr1:150670422	GOLPH3L	0.63	11.04	0.47	4.38e-25	Melanoma;
LUAD	cis	rs9341808	0.628	rs1892475	chr6:80862213	T/C	cg08355045	chr6:80787529	NA	0.47	8.3	0.37	1.45e-15	Sitting height ratio;
LUAD	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg03929089	chr4:120376271	NA	-0.64	-8.84	-0.39	2.64e-17	Coronary artery disease;
LUAD	cis	rs2066819	1.000	rs76151170	chr12:56659320	C/T	cg26714650	chr12:56694279	CS	-0.84	-7.06	-0.32	6.71e-12	Psoriasis vulgaris;
LUAD	cis	rs1018836	0.892	rs11776824	chr8:91553256	T/C	cg16814680	chr8:91681699	NA	-0.61	-10.5	-0.45	4.68e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs73195822	0.614	rs7975139	chr12:111221131	T/C	cg12870014	chr12:110450643	ANKRD13A	0.57	6.4	0.3	4.24e-10	Itch intensity from mosquito bite;
LUAD	cis	rs17818399	0.926	rs13033177	chr2:46831062	C/A	cg09399716	chr2:46890238	NA	-0.41	-7.73	-0.35	8.06e-14	Height;
LUAD	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg24818145	chr4:99064322	C4orf37	0.48	8.21	0.37	2.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg23887609	chr12:130822674	PIWIL1	-0.41	-7.15	-0.33	3.79e-12	Menopause (age at onset);
LUAD	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21659725	chr3:3221576	CRBN	-0.61	-9.94	-0.44	4.65e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs208520	0.661	rs851466	chr6:66840476	A/G	cg07460842	chr6:66804631	NA	-1.07	-16.78	-0.63	8.61e-49	Exhaled nitric oxide output;
LUAD	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg20362242	chr5:692897	TPPP	0.55	6.82	0.31	3.22e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.01	0.36	1.13e-14	Breast cancer;
LUAD	cis	rs735539	0.521	rs2251031	chr13:21414326	G/T	cg27499820	chr13:21296301	IL17D	0.46	6.9	0.32	1.96e-11	Dental caries;
LUAD	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.46	9.51	0.42	1.49e-19	Monocyte percentage of white cells;
LUAD	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg21475434	chr5:93447410	FAM172A	0.71	8.4	0.38	7.06e-16	Diabetic retinopathy;
LUAD	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg24011408	chr12:48396354	COL2A1	0.42	9.22	0.41	1.36e-18	Plateletcrit;
LUAD	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg07741184	chr6:167504864	NA	0.36	8.12	0.37	5.12e-15	Primary biliary cholangitis;
LUAD	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg00431813	chr7:1051703	C7orf50	-0.52	-10.43	-0.45	7.93e-23	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg08219700	chr8:58056026	NA	0.51	7.6	0.35	1.9e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.11	-0.37	5.65e-15	Total body bone mineral density;
LUAD	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.57	10.95	0.47	9.54e-25	Hemoglobin concentration;
LUAD	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg11062466	chr8:58055876	NA	0.59	8.03	0.36	9.43e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18876405	chr7:65276391	NA	0.53	8.92	0.4	1.39e-17	Aortic root size;
LUAD	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10802521	chr3:52805072	NEK4	-0.6	-10.91	-0.47	1.39e-24	Bipolar disorder;
LUAD	cis	rs877282	0.583	rs12358255	chr10:828626	C/T	cg13775593	chr10:823151	NA	0.38	6.63	0.31	1.06e-10	Uric acid levels;
LUAD	cis	rs11078597	0.767	rs4525526	chr17:1650125	T/C	cg18436246	chr17:1640651	WDR81	0.78	12.53	0.52	7.5e-31	Serum albumin level;
LUAD	cis	rs601339	0.877	rs2649991	chr12:123179461	A/G	cg11919336	chr12:123188078	GPR109A	0.47	7.32	0.34	1.26e-12	Adiponectin levels;
LUAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg04025307	chr7:1156635	C7orf50	0.68	11.69	0.49	1.54e-27	Longevity;Endometriosis;
LUAD	cis	rs698813	0.674	rs6725676	chr2:44497828	T/A	cg00619915	chr2:44497795	NA	-0.44	-6.72	-0.31	5.87e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUAD	cis	rs6484504	0.532	rs11031342	chr11:31309818	G/A	cg26647111	chr11:31128758	NA	-0.46	-8.02	-0.36	1.01e-14	Red blood cell count;
LUAD	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg06713675	chr4:122721982	EXOSC9	-0.81	-16.42	-0.62	3.23e-47	Type 2 diabetes;
LUAD	cis	rs60154123	0.772	rs701944	chr1:210417098	G/A	cg22029157	chr1:209979665	IRF6	0.66	7.16	0.33	3.6e-12	Coronary artery disease;
LUAD	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg09640425	chr7:158790006	NA	0.5	6.56	0.3	1.62e-10	Facial morphology (factor 20);
LUAD	cis	rs4253772	0.938	rs41329344	chr22:46636930	C/T	cg09491104	chr22:46646882	C22orf40	-0.5	-6.8	-0.31	3.55e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg23283495	chr1:209979779	IRF6	0.42	7.56	0.35	2.51e-13	Monobrow;
LUAD	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg13319975	chr6:146136371	FBXO30	0.63	10.84	0.47	2.56e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs68170813	0.599	rs12532849	chr7:106959226	A/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.13	-0.44	9.9700000000000009e-22	Coronary artery disease;
LUAD	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg19717773	chr7:2847554	GNA12	-0.49	-8.34	-0.38	1.02e-15	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19657082	chr1:40724061	ZMPSTE24	-0.42	-6.41	-0.3	3.94e-10	Height;
LUAD	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.39	6.56	0.3	1.55e-10	Total body bone mineral density;
LUAD	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg09455208	chr3:40491958	NA	0.5	10.61	0.46	1.79e-23	Renal cell carcinoma;
LUAD	cis	rs7474896	0.515	rs2738208	chr10:38306128	A/G	cg25427524	chr10:38739819	LOC399744	0.58	8.33	0.38	1.16e-15	Obesity (extreme);
LUAD	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7187994	0.848	rs16974532	chr16:84783310	G/A	cg07647771	chr16:84786436	USP10	-0.34	-8.77	-0.39	4.45e-17	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg06641503	chr3:48959341	ARIH2	-0.4	-7.69	-0.35	1.06e-13	Parkinson's disease;
LUAD	cis	rs1865721	0.839	rs59718187	chr18:73144032	C/T	cg26385618	chr18:73139727	C18orf62	-0.51	-10.11	-0.44	1.11e-21	Intelligence;
LUAD	cis	rs6743376	0.642	rs4849152	chr2:113848574	C/T	cg09040174	chr2:113837401	NA	0.49	7.49	0.34	4.12e-13	Inflammatory biomarkers;
LUAD	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.49	6.63	0.31	1.05e-10	Platelet count;
LUAD	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg24803719	chr17:45855879	NA	-0.32	-6.94	-0.32	1.46e-11	IgG glycosylation;
LUAD	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	trans	rs629535	0.814	rs62513381	chr8:70110991	T/C	cg21567404	chr3:27674614	NA	-0.96	-17.14	-0.64	2.25e-50	Dupuytren's disease;
LUAD	cis	rs9326248	0.581	rs11216267	chr11:116952392	C/T	cg20608306	chr11:116969690	SIK3	0.3	6.74	0.31	5.1e-11	Blood protein levels;
LUAD	cis	rs2073300	1.000	rs2207989	chr20:23446014	T/G	cg12062639	chr20:23401060	NAPB	0.7	6.59	0.31	1.3100000000000001e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.91	-0.36	2.21e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9914544	0.505	rs7503678	chr17:18776020	A/T	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.53	-0.3	1.84e-10	Educational attainment (years of education);
LUAD	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.43	0.34	6.09e-13	Menopause (age at onset);
LUAD	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.96	-0.32	1.27e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs12545109	0.613	rs6998873	chr8:57299697	A/G	cg07776626	chr8:57350775	NA	0.61	8.24	0.37	2.11e-15	Obesity-related traits;
LUAD	cis	rs1595825	1.000	rs73058820	chr2:198864358	A/G	cg11031976	chr2:198649780	BOLL	-0.46	-6.75	-0.31	4.94e-11	Ulcerative colitis;
LUAD	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	trans	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg06175025	chr14:78082992	SPTLC2	-0.41	-6.65	-0.31	9.09e-11	Bone mineral density;
LUAD	trans	rs12517041	1.000	rs6879720	chr5:23312477	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13662262	chr21:30364895	RNF160	-0.49	-7.63	-0.35	1.59e-13	Height;
LUAD	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.81	0.36	4.46e-14	Bladder cancer;
LUAD	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg01802117	chr1:53393560	SCP2	-0.43	-8.33	-0.38	1.1e-15	Monocyte count;
LUAD	cis	rs346785	0.518	rs11077811	chr17:74285242	G/A	cg09812376	chr17:74270190	QRICH2	-0.41	-8.4	-0.38	6.66e-16	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs1018836	0.923	rs2105965	chr8:91537690	T/C	cg16814680	chr8:91681699	NA	-0.74	-13.03	-0.54	7.53e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg10518543	chr12:38710700	ALG10B	0.42	6.44	0.3	3.26e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4481887	0.790	rs7546964	chr1:248414960	A/G	cg00666640	chr1:248458726	OR2T12	0.3	7.35	0.34	1.06e-12	Common traits (Other);
LUAD	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg12908607	chr1:44402522	ARTN	-0.51	-9.99	-0.44	3.01e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4604732	0.631	rs74154676	chr1:247625894	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs11048434	0.736	rs1805724	chr12:9104609	T/C	cg23795048	chr12:9217529	LOC144571	0.43	7.82	0.36	4.26e-14	Sjögren's syndrome;
LUAD	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg11941060	chr3:133502564	NA	-0.64	-11.39	-0.48	2.13e-26	Iron status biomarkers;
LUAD	cis	rs6987853	0.666	rs2923403	chr8:42447748	G/T	cg09913449	chr8:42400586	C8orf40	0.47	8.73	0.39	6.16e-17	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9902453	0.967	rs12450441	chr17:28495021	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	8.41	0.38	6.35e-16	Coffee consumption (cups per day);
LUAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg13047869	chr3:10149882	C3orf24	0.58	9.77	0.43	1.81e-20	Alzheimer's disease;
LUAD	cis	rs525592	1	rs525592	chr11:68195104	C/T	cg02221422	chr11:68192511	LRP5	-0.44	-7.11	-0.33	5.09e-12	Bone mineral density;
LUAD	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg05590025	chr7:65112418	INTS4L2	0.74	8.05	0.36	8.39e-15	Diabetic kidney disease;
LUAD	trans	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg02002194	chr4:3960332	NA	-0.28	-6.78	-0.31	4.06e-11	Mood instability;
LUAD	cis	rs231513	0.906	rs11657681	chr17:42005363	G/A	cg26893861	chr17:41843967	DUSP3	0.6	6.59	0.31	1.32e-10	Cognitive function;
LUAD	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.02	0.36	1.02e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.95	0.36	1.71e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7665090	0.846	rs7690700	chr4:103552068	T/C	cg07973026	chr4:103553119	MANBA	0.48	8.53	0.38	2.63e-16	Primary biliary cholangitis;
LUAD	cis	rs62238980	0.614	rs76161060	chr22:32383153	G/A	cg00543991	chr22:32367038	NA	0.92	8.48	0.38	3.7e-16	Childhood ear infection;
LUAD	cis	rs59104589	0.583	rs57576464	chr2:242240697	C/T	cg08645257	chr2:242211290	HDLBP	0.5	7.88	0.36	2.87e-14	Fibrinogen levels;
LUAD	cis	rs2274273	0.624	rs1972221	chr14:55785381	C/A	cg04306507	chr14:55594613	LGALS3	0.43	8.17	0.37	3.49e-15	Protein biomarker;
LUAD	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.41	0.34	7.08e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg12400702	chr3:12838781	CAND2	0.31	6.45	0.3	3.06e-10	Parkinson's disease;
LUAD	trans	rs1973993	0.967	rs1555543	chr1:96944797	A/C	cg10631902	chr5:14652156	NA	0.57	10.63	0.46	1.45e-23	Weight;
LUAD	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10802521	chr3:52805072	NEK4	-0.55	-9.45	-0.42	2.28e-19	Bipolar disorder;
LUAD	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg07936489	chr17:37558343	FBXL20	-0.47	-7.41	-0.34	6.94e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.64	9.45	0.42	2.26e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg10729496	chr3:10149963	C3orf24	0.64	9.65	0.42	4.77e-20	Alzheimer's disease;
LUAD	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg05110241	chr16:68378359	PRMT7	-0.81	-8.73	-0.39	5.74e-17	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg17063962	chr7:91808500	NA	0.71	12.73	0.53	1.24e-31	Breast cancer;
LUAD	trans	rs1864729	0.892	rs1821134	chr8:98266824	C/T	cg08679828	chr8:102218111	ZNF706	0.76	7.87	0.36	3.04e-14	Estradiol plasma levels (breast cancer);
LUAD	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg10544611	chr16:67998164	SLC12A4	-0.55	-6.98	-0.32	1.14e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.72	-0.31	6e-11	Morning vs. evening chronotype;
LUAD	cis	rs250677	0.522	rs6580590	chr5:148360374	C/T	cg18129178	chr5:148520854	ABLIM3	0.51	7.62	0.35	1.65e-13	Breast cancer;
LUAD	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-8.28	-0.37	1.67e-15	Triglycerides;
LUAD	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.74	-0.31	5.05e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg03188948	chr7:1209495	NA	0.72	6.74	0.31	5.14e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7771547	0.662	rs2001101	chr6:36536448	C/T	cg04289385	chr6:36355825	ETV7	0.49	6.39	0.3	4.43e-10	Platelet distribution width;
LUAD	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg06740227	chr12:86229804	RASSF9	0.45	7.96	0.36	1.65e-14	Major depressive disorder;
LUAD	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.93	0.32	1.55e-11	Cognitive test performance;
LUAD	cis	rs7617773	0.747	rs34076262	chr3:48370416	C/T	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.21e-11	Coronary artery disease;
LUAD	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg18016565	chr1:150552671	MCL1	0.42	7.99	0.36	1.33e-14	Tonsillectomy;
LUAD	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg05665937	chr4:1216051	CTBP1	0.42	6.79	0.31	3.93e-11	Obesity-related traits;
LUAD	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.6	-10.64	-0.46	1.32e-23	Hip circumference adjusted for BMI;
LUAD	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.68	-10.81	-0.47	3.37e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.37	-7.18	-0.33	3.22e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs1044826	0.597	rs1017468	chr3:139145778	A/G	cg00490450	chr3:139108681	COPB2	0.44	6.99	0.32	1.09e-11	Obesity-related traits;
LUAD	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg02158880	chr13:53174818	NA	0.52	9.05	0.4	5.15e-18	Lewy body disease;
LUAD	cis	rs8017423	0.935	rs3742668	chr14:90767759	G/A	cg14092571	chr14:90743983	NA	0.47	8.19	0.37	3.04e-15	Mortality in heart failure;
LUAD	cis	rs4700695	1.000	rs111340	chr5:65420285	C/A	cg21114390	chr5:65439923	SFRS12	-0.65	-8.22	-0.37	2.47e-15	Facial morphology (factor 19);
LUAD	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg15557168	chr22:42548783	NA	0.5	9.29	0.41	8.21e-19	Schizophrenia;
LUAD	trans	rs7246760	0.867	rs57943754	chr19:9841283	G/A	cg02900749	chr2:68251473	NA	-0.65	-6.92	-0.32	1.67e-11	Pursuit maintenance gain;
LUAD	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.93	-0.4	1.29e-17	Bipolar disorder;
LUAD	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg15147215	chr3:52552868	STAB1	-0.39	-7.19	-0.33	2.99e-12	Bipolar disorder;
LUAD	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg11189052	chr15:85197271	WDR73	0.65	8.8	0.39	3.55e-17	Schizophrenia;
LUAD	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg03959625	chr15:84868606	LOC388152	0.4	6.48	0.3	2.6200000000000003e-10	Schizophrenia;
LUAD	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg20503657	chr10:835505	NA	1.02	15.76	0.61	2.33e-44	Eosinophil percentage of granulocytes;
LUAD	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-11.05	-0.47	4.28e-25	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg07507251	chr3:52567010	NT5DC2	0.36	7.04	0.32	7.81e-12	Bipolar disorder;
LUAD	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg11247378	chr22:39784982	NA	-0.76	-14.06	-0.56	3.98e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs4268898	0.552	rs4665663	chr2:24372139	G/C	cg06627628	chr2:24431161	ITSN2	0.45	7.64	0.35	1.52e-13	Asthma;
LUAD	cis	rs2445762	0.659	rs17524318	chr15:51663386	G/A	cg20344442	chr15:51633704	GLDN	0.39	7.0	0.32	1.02e-11	Hormone measurements;
LUAD	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg03037974	chr15:76606532	NA	0.4	8.79	0.39	3.91e-17	Blood metabolite levels;
LUAD	cis	rs1232027	0.700	rs1382541	chr5:79953484	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.94	-0.36	1.9e-14	Huntington's disease progression;
LUAD	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg13393036	chr8:95962371	TP53INP1	0.38	8.28	0.37	1.6e-15	Type 2 diabetes;
LUAD	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg07936489	chr17:37558343	FBXL20	0.43	6.72	0.31	5.78e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg07677032	chr17:61819896	STRADA	0.57	10.3	0.45	2.42e-22	Prudent dietary pattern;
LUAD	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg03467027	chr4:99064603	C4orf37	0.39	6.37	0.3	5.05e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg16486109	chr11:613632	IRF7	0.48	7.43	0.34	5.92e-13	Systemic lupus erythematosus;
LUAD	cis	rs3784262	0.669	rs4646594	chr15:58302386	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.66	-0.35	1.24e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs17102423	0.755	rs8009714	chr14:65573446	G/T	cg11161011	chr14:65562177	MAX	-0.53	-8.31	-0.37	1.28e-15	Obesity-related traits;
LUAD	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg03037974	chr15:76606532	NA	0.39	8.56	0.38	2.17e-16	Blood metabolite levels;
LUAD	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03934478	chr11:495069	RNH1	0.71	8.61	0.39	1.5e-16	Body mass index;
LUAD	cis	rs8014204	0.806	rs11159104	chr14:75293374	A/G	cg06637938	chr14:75390232	RPS6KL1	0.4	7.31	0.33	1.37e-12	Caffeine consumption;
LUAD	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg06671706	chr8:8559999	CLDN23	0.6	10.13	0.44	9.35e-22	Obesity-related traits;
LUAD	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg04727924	chr7:799746	HEATR2	-0.54	-6.4	-0.3	4.22e-10	Cerebrospinal P-tau181p levels;
LUAD	cis	rs6942407	0.546	rs2286268	chr7:86848385	C/T	cg02420886	chr7:86849541	C7orf23	0.65	7.51	0.34	3.64e-13	Food allergy;
LUAD	cis	rs7107174	1.000	rs2512546	chr11:77957276	T/C	cg02023728	chr11:77925099	USP35	0.38	6.42	0.3	3.75e-10	Testicular germ cell tumor;
LUAD	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg06623918	chr6:96969491	KIAA0776	-0.71	-9.93	-0.43	4.94e-21	Migraine;Coronary artery disease;
LUAD	cis	rs6445967	0.530	rs116643404	chr3:58463907	A/G	cg13750441	chr3:58318267	PXK	-0.33	-6.41	-0.3	3.84e-10	Platelet count;
LUAD	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.73	10.55	0.46	2.93e-23	Smoking behavior;
LUAD	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-9.91	-0.43	5.71e-21	Migraine;Coronary artery disease;
LUAD	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11890956	chr21:40555474	PSMG1	0.66	11.72	0.5	1.11e-27	Cognitive function;
LUAD	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg13902645	chr11:5959945	NA	-0.51	-8.7	-0.39	7.55e-17	DNA methylation (variation);
LUAD	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg15557168	chr22:42548783	NA	0.51	9.48	0.42	1.92e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg14664628	chr15:75095509	CSK	-0.49	-8.25	-0.37	2e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs123509	0.913	rs339682	chr3:42791123	A/G	cg10144569	chr3:42726640	KBTBD5	0.49	7.55	0.34	2.72e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg22535103	chr8:58192502	C8orf71	-0.61	-8.94	-0.4	1.21e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg19875535	chr5:140030758	IK	0.45	7.45	0.34	5.43e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg08601574	chr20:25228251	PYGB	0.46	8.51	0.38	3.16e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2073300	1.000	rs6048810	chr20:23446429	G/A	cg12062639	chr20:23401060	NAPB	0.7	6.59	0.31	1.3100000000000001e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg14227996	chr4:17616232	MED28	0.71	7.38	0.34	8.62e-13	Opioid sensitivity;
LUAD	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg06108461	chr20:60628389	TAF4	-1.13	-20.62	-0.71	6.5e-66	Body mass index;
LUAD	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg06784218	chr1:46089804	CCDC17	0.59	13.18	0.54	1.75e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1160297	0.633	rs12477231	chr2:53084648	T/G	cg07782112	chr2:53107842	NA	0.4	8.33	0.38	1.13e-15	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg26043149	chr18:55253948	FECH	1.05	17.66	0.65	1.05e-52	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs4919694	1.000	rs78893207	chr10:104796138	T/C	cg04362960	chr10:104952993	NT5C2	0.73	7.86	0.36	3.28e-14	Arsenic metabolism;
LUAD	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg22683308	chr4:1340831	KIAA1530	-0.47	-7.77	-0.35	5.84e-14	Longevity;
LUAD	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg04155289	chr7:94953770	PON1	-0.54	-7.39	-0.34	8.12e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg15557168	chr22:42548783	NA	-0.36	-6.36	-0.3	5.13e-10	Cognitive function;
LUAD	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg13010199	chr12:38710504	ALG10B	0.39	6.38	0.3	4.74e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs887829	0.569	rs4148326	chr2:234673462	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-8.6	-0.39	1.57e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-16.38	-0.62	4.63e-47	Schizophrenia;
LUAD	cis	rs57920188	0.585	rs12127463	chr1:4079127	C/T	cg20703997	chr1:4087676	NA	0.45	8.31	0.37	1.36e-15	Interleukin-17 levels;
LUAD	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg05110241	chr16:68378359	PRMT7	-0.83	-8.96	-0.4	1.04e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2073300	1.000	rs74273799	chr20:23444492	T/C	cg12062639	chr20:23401060	NAPB	0.98	8.35	0.38	9.91e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg06713675	chr4:122721982	EXOSC9	-0.59	-11.34	-0.48	3.29e-26	Type 2 diabetes;
LUAD	cis	rs4243830	0.737	rs4908923	chr1:6614535	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.75	-9.66	-0.43	4.29e-20	Body mass index;
LUAD	cis	rs78707713	0.535	rs3812705	chr10:71211146	A/G	cg12610070	chr10:71211762	TSPAN15	-0.41	-11.01	-0.47	5.84e-25	Venous thromboembolism;
LUAD	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg22823121	chr1:150693482	HORMAD1	-0.39	-7.71	-0.35	8.88e-14	Tonsillectomy;
LUAD	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26314531	chr2:26401878	FAM59B	-0.55	-7.72	-0.35	8.65e-14	Gut microbiome composition (summer);
LUAD	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg13319975	chr6:146136371	FBXO30	-0.55	-9.33	-0.41	6.07e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2485376	1.000	rs11191245	chr10:104012677	T/C	cg20641465	chr10:103991465	PITX3	0.57	10.4	0.45	1.02e-22	QT interval;
LUAD	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.38	-8.24	-0.37	2.22e-15	Height;
LUAD	cis	rs6005807	0.843	rs12166363	chr22:29000057	C/T	cg12565055	chr22:29076175	TTC28	0.67	6.63	0.31	1.02e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.07	15.65	0.61	7.21e-44	Lung cancer in ever smokers;
LUAD	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg10950924	chr17:47092072	IGF2BP1	0.37	7.41	0.34	6.81e-13	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs7737355	0.773	rs7720194	chr5:130837077	T/C	cg06307176	chr5:131281290	NA	0.43	7.11	0.33	5.02e-12	Life satisfaction;
LUAD	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-12.91	-0.53	2.13e-32	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1595825	0.891	rs6733834	chr2:198518709	C/G	cg10547527	chr2:198650123	BOLL	0.51	7.29	0.33	1.54e-12	Ulcerative colitis;
LUAD	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-7.06	-0.32	6.81e-12	Waist circumference;Hip circumference;
LUAD	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg00784671	chr22:46762841	CELSR1	-0.58	-7.57	-0.35	2.39e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.84	12.21	0.51	1.38e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4409675	0.549	rs72872888	chr1:28239809	G/A	cg23691781	chr1:28212827	C1orf38	0.38	10.83	0.47	2.75e-24	Corneal astigmatism;
LUAD	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg05304507	chr6:116381966	FRK	0.2	6.79	0.31	3.7e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg07217954	chr7:1067459	C7orf50	-0.36	-6.54	-0.3	1.82e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg09367891	chr1:107599246	PRMT6	0.58	9.83	0.43	1.1e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1881797	0.527	rs74227706	chr1:247638315	A/C	cg21399703	chr1:247681439	NA	0.46	6.37	0.3	4.98e-10	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg18854424	chr1:2615690	NA	-0.41	-9.07	-0.4	4.39e-18	Ulcerative colitis;
LUAD	cis	rs72772090	0.539	rs11747179	chr5:96112969	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-7.39	-0.34	8.08e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs11771526	0.901	rs17161084	chr7:32293192	G/C	cg27532318	chr7:32358331	NA	0.56	7.33	0.34	1.19e-12	Body mass index;
LUAD	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs8112211	0.682	rs11671779	chr19:38833350	C/T	cg14299480	chr19:38876666	GGN	-0.45	-6.57	-0.3	1.5e-10	Blood protein levels;
LUAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00166722	chr3:10149974	C3orf24	0.73	10.94	0.47	1.1e-24	Alzheimer's disease;
LUAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg22907277	chr7:1156413	C7orf50	0.52	8.69	0.39	8.25e-17	Longevity;Endometriosis;
LUAD	cis	rs62400317	0.821	rs12206568	chr6:45152747	C/T	cg18551225	chr6:44695536	NA	-0.53	-8.28	-0.37	1.63e-15	Total body bone mineral density;
LUAD	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg00277334	chr10:82204260	NA	-0.45	-7.46	-0.34	4.9e-13	Post bronchodilator FEV1;
LUAD	cis	rs8060686	0.516	rs2290699	chr16:68289059	C/T	cg09835421	chr16:68378352	PRMT7	-0.57	-7.17	-0.33	3.28e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs829880	0.558	rs249820	chr12:98897473	A/G	cg25150519	chr12:98850993	NA	0.42	6.8	0.31	3.61e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg27454412	chr7:1067447	C7orf50	-0.45	-7.92	-0.36	2.13e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg03605463	chr16:89740564	NA	0.66	11.82	0.5	4.59e-28	Vitiligo;
LUAD	cis	rs8099014	0.911	rs4331413	chr18:56133165	T/C	cg12907477	chr18:56117327	MIR122	0.4	6.68	0.31	7.48e-11	Platelet count;
LUAD	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg13755796	chr4:20253514	NA	-0.41	-7.03	-0.32	8.43e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs6445967	0.569	rs1913714	chr3:58307829	G/T	cg13750441	chr3:58318267	PXK	-0.31	-6.4	-0.3	4.07e-10	Platelet count;
LUAD	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg13770153	chr20:60521292	NA	-0.58	-9.03	-0.4	6.25e-18	Body mass index;
LUAD	cis	rs600231	0.665	rs1784858	chr11:65222952	T/C	cg21890820	chr11:65308645	LTBP3	0.48	7.67	0.35	1.21e-13	Bone mineral density;
LUAD	trans	rs4650994	0.525	rs2811295	chr1:178551267	C/T	cg05059571	chr16:84539110	KIAA1609	0.72	13.28	0.54	6.78e-34	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg21427119	chr20:30132790	HM13	-0.6	-9.27	-0.41	9.4e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	6.6	0.31	1.22e-10	Lung cancer in ever smokers;
LUAD	cis	rs68170813	0.523	rs79607134	chr7:107033619	A/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.43	-0.45	8.41e-23	Coronary artery disease;
LUAD	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.41	0.38	6.24e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2455799	0.613	rs1532767	chr3:15733600	A/T	cg16303742	chr3:15540471	COLQ	-0.48	-9.0	-0.4	7.68e-18	Mean platelet volume;
LUAD	cis	rs494562	0.892	rs640093	chr6:86115866	C/T	cg27297263	chr6:86160468	NT5E	0.61	7.06	0.32	7.05e-12	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg06740227	chr12:86229804	RASSF9	0.47	8.09	0.37	6.55e-15	Major depressive disorder;
LUAD	trans	rs75804782	0.521	rs56373856	chr2:239437926	C/T	cg01134436	chr17:81009848	B3GNTL1	0.79	8.6	0.39	1.61e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg21856205	chr7:94953877	PON1	-0.52	-6.99	-0.32	1.09e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4372836	0.504	rs10183665	chr2:28995226	A/G	cg09522027	chr2:28974177	PPP1CB	-0.61	-10.95	-0.47	9.45e-25	Body mass index;
LUAD	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg18230493	chr5:56204884	C5orf35	-0.43	-7.28	-0.33	1.64e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.56	8.14	0.37	4.39e-15	Platelet count;
LUAD	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.48	-0.45	5.41e-23	Total body bone mineral density;
LUAD	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.37	0.38	8.27e-16	Platelet count;
LUAD	cis	rs12893668	0.703	rs4906335	chr14:104021141	C/A	cg01849466	chr14:104193079	ZFYVE21	-0.49	-7.55	-0.34	2.71e-13	Reticulocyte count;
LUAD	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg05754148	chr16:3507555	NAT15	-0.45	-6.97	-0.32	1.19e-11	Body mass index (adult);
LUAD	cis	rs981844	0.740	rs6841173	chr4:154682563	A/G	cg10279832	chr4:154682576	RNF175	0.34	7.17	0.33	3.43e-12	Response to statins (LDL cholesterol change);
LUAD	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg13736514	chr6:26305472	NA	0.45	7.45	0.34	5.41e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs5758511	0.514	rs5758622	chr22:42563933	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.66	11.45	0.49	1.21e-26	Birth weight;
LUAD	cis	rs62238980	0.614	rs1547411	chr22:32443590	T/C	cg00543991	chr22:32367038	NA	0.97	9.16	0.41	2.22e-18	Childhood ear infection;
LUAD	cis	rs367943	1.000	rs348941	chr5:112824166	G/C	cg12552261	chr5:112820674	MCC	-0.58	-10.8	-0.46	3.55e-24	Type 2 diabetes;
LUAD	cis	rs41311933	1.000	rs41311933	chr9:123739560	C/T	cg13567360	chr9:123745713	C5	-0.84	-9.22	-0.41	1.46e-18	Coronary artery disease;
LUAD	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg02176678	chr2:219576539	TTLL4	0.68	13.54	0.55	6.15e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs77741769	0.571	rs989987	chr12:121274062	C/T	cg02419362	chr12:121203948	SPPL3	0.41	8.31	0.37	1.33e-15	Mean corpuscular volume;
LUAD	cis	rs13333054	1.000	rs13333054	chr16:86011033	C/T	cg08215318	chr16:86016387	NA	0.5	8.29	0.37	1.55e-15	Multiple sclerosis;
LUAD	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg13327785	chr12:132219529	SFRS8	-0.42	-7.32	-0.34	1.24e-12	Migraine;
LUAD	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg24069376	chr3:38537580	EXOG	0.43	10.46	0.45	6.06e-23	Electrocardiographic conduction measures;
LUAD	trans	rs17685	0.535	rs41299460	chr7:75600951	G/A	cg19862616	chr7:65841803	NCRNA00174	0.67	11.9	0.5	2.3e-28	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs68170813	0.523	rs79619227	chr7:107025335	T/C	cg23024343	chr7:107201750	COG5	0.51	7.25	0.33	2e-12	Coronary artery disease;
LUAD	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg17279839	chr7:150038598	RARRES2	0.46	7.74	0.35	7.5e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs17095355	0.818	rs72828263	chr10:111785703	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.61	-0.31	1.16e-10	Biliary atresia;
LUAD	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg00383909	chr3:49044727	WDR6	0.91	10.04	0.44	2.07e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg27535305	chr1:53392650	SCP2	-0.32	-6.67	-0.31	8.06e-11	Monocyte count;
LUAD	cis	rs807669	0.525	rs738904	chr22:19167385	C/A	cg02655711	chr22:19163373	SLC25A1	0.58	11.16	0.48	1.65e-25	Metabolite levels;
LUAD	cis	rs863345	0.604	rs12120526	chr1:158498404	T/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.61	-0.31	1.18e-10	Pneumococcal bacteremia;
LUAD	trans	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg26043149	chr18:55253948	FECH	0.43	7.04	0.32	7.77e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-8.16	-0.37	3.79e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg04800585	chr6:26043546	HIST1H2BB	-0.37	-6.61	-0.31	1.13e-10	Blood metabolite levels;
LUAD	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg23992470	chr4:843637	GAK	0.67	7.36	0.34	9.39e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs698813	0.674	rs4952707	chr2:44500683	G/C	cg00619915	chr2:44497795	NA	-0.43	-6.41	-0.3	3.84e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUAD	cis	rs113835537	0.597	rs7116921	chr11:66303854	T/C	cg24851651	chr11:66362959	CCS	0.58	10.28	0.45	2.81e-22	Airway imaging phenotypes;
LUAD	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg04511125	chr2:88470314	THNSL2	0.98	11.41	0.49	1.8e-26	Plasma clusterin levels;
LUAD	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg18230493	chr5:56204884	C5orf35	-0.44	-7.32	-0.34	1.27e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs12900413	0.687	rs7176948	chr15:90315707	A/C	cg24249390	chr15:90295951	MESP1	-0.34	-6.83	-0.32	2.94e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg15123519	chr2:136567270	LCT	-0.39	-7.1	-0.33	5.36e-12	Mosquito bite size;
LUAD	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg13319975	chr6:146136371	FBXO30	0.64	11.06	0.47	3.84e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg06197492	chr11:2016605	H19	0.42	8.46	0.38	4.3e-16	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23583168	chr7:148888333	NA	-0.91	-18.38	-0.67	6.82e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg23985595	chr17:80112537	CCDC57	0.53	9.73	0.43	2.45e-20	Life satisfaction;
LUAD	trans	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.05	0.4	5.44e-18	Mean corpuscular volume;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15371732	chr17:78194151	SLC26A11;SGSH	-0.55	-6.81	-0.31	3.46e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs1997103	1.000	rs6949244	chr7:55411301	C/G	cg20935933	chr6:143382018	AIG1	0.53	7.51	0.34	3.64e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs55788414	0.860	rs9929059	chr16:81182117	G/C	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.9	-0.36	2.46e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.69	10.18	0.44	6.67e-22	Smoking behavior;
LUAD	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg08632164	chr7:65971372	NA	-0.55	-6.42	-0.3	3.67e-10	Diabetic kidney disease;
LUAD	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg21475434	chr5:93447410	FAM172A	0.73	8.22	0.37	2.52e-15	Diabetic retinopathy;
LUAD	cis	rs2882667	0.858	rs11956159	chr5:138408568	T/C	cg04439458	chr5:138467593	SIL1	-0.53	-9.6	-0.42	7.35e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg10589385	chr1:150898437	SETDB1	0.44	8.11	0.37	5.35e-15	Melanoma;
LUAD	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg04450456	chr4:17643702	FAM184B	0.39	7.53	0.34	3.09e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg19006050	chr10:131904236	NA	-0.4	-6.66	-0.31	8.6e-11	Diastolic blood pressure;
LUAD	cis	rs75920871	0.858	rs888245	chr11:116723737	C/G	cg04087571	chr11:116723030	SIK3	-0.33	-6.59	-0.3	1.34e-10	Subjective well-being;
LUAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg27532560	chr4:187881888	NA	-0.35	-6.81	-0.31	3.3e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11048434	0.736	rs11048338	chr12:9121362	C/G	cg04155231	chr12:9217510	LOC144571	0.4	7.5	0.34	3.8e-13	Sjögren's syndrome;
LUAD	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg06740227	chr12:86229804	RASSF9	-0.41	-7.36	-0.34	9.88e-13	Major depressive disorder;
LUAD	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg09491104	chr22:46646882	C22orf40	-0.6	-7.93	-0.36	2.01e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg17178900	chr1:205818956	PM20D1	0.47	7.5	0.34	3.73e-13	Parkinson's disease;
LUAD	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg00277334	chr10:82204260	NA	0.66	11.81	0.5	5.28e-28	Post bronchodilator FEV1;
LUAD	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg13722127	chr7:150037890	RARRES2	0.43	7.48	0.34	4.2e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg02176678	chr2:219576539	TTLL4	0.74	14.98	0.59	5.28e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg13319975	chr6:146136371	FBXO30	-0.59	-9.98	-0.44	3.27e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-8.42	-0.38	5.88e-16	Type 2 diabetes;
LUAD	cis	rs7246657	0.653	rs28701616	chr19:37681098	G/A	cg23950597	chr19:37808831	NA	-0.59	-6.36	-0.3	5.12e-10	Coronary artery calcification;
LUAD	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg02807482	chr3:125708958	NA	-0.63	-8.67	-0.39	9.4e-17	Blood pressure (smoking interaction);
LUAD	cis	rs8060686	0.858	rs7199443	chr16:67841129	T/G	cg26727032	chr16:67993705	SLC12A4	-0.5	-8.45	-0.38	4.74e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg02782426	chr3:40428986	ENTPD3	-0.42	-9.08	-0.4	4.22e-18	Renal cell carcinoma;
LUAD	cis	rs28595532	1.000	rs116030177	chr4:119650768	T/C	cg14228332	chr4:119757509	SEC24D	0.78	7.21	0.33	2.55e-12	Cannabis dependence symptom count;
LUAD	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg02734326	chr4:10020555	SLC2A9	0.55	9.48	0.42	1.8e-19	Bone mineral density;
LUAD	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg13010199	chr12:38710504	ALG10B	-0.38	-6.4	-0.3	4.23e-10	Morning vs. evening chronotype;
LUAD	cis	rs8112211	0.682	rs11672793	chr19:38827357	T/A	cg14299480	chr19:38876666	GGN	-0.43	-6.42	-0.3	3.67e-10	Blood protein levels;
LUAD	cis	rs12681287	0.752	rs1080170	chr8:87310108	C/T	cg27223183	chr8:87520930	FAM82B	-0.62	-8.48	-0.38	3.9e-16	Caudate activity during reward;
LUAD	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg18827107	chr12:86230957	RASSF9	0.53	9.56	0.42	1.01e-19	Major depressive disorder;
LUAD	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg19442545	chr10:75533431	FUT11	-0.5	-8.58	-0.39	1.76e-16	Inflammatory bowel disease;
LUAD	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg13770153	chr20:60521292	NA	-0.47	-8.14	-0.37	4.62e-15	Body mass index;
LUAD	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg05865280	chr17:75406074	SEPT9	0.62	19.31	0.68	4.9e-60	Airflow obstruction;
LUAD	cis	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg02240030	chr7:2089880	MAD1L1	0.35	6.84	0.32	2.72e-11	Neuroticism;
LUAD	cis	rs2131877	0.956	rs10933699	chr3:194869391	G/A	cg19760965	chr3:194868843	C3orf21	0.43	7.12	0.33	4.68e-12	Non-small cell lung cancer;
LUAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg22907277	chr7:1156413	C7orf50	0.7	8.23	0.37	2.35e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2742417	1.000	rs2742437	chr3:45743277	G/A	cg10512202	chr3:45649293	LIMD1	0.38	6.84	0.32	2.8e-11	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg15448220	chr1:150897856	SETDB1	0.5	8.66	0.39	9.83e-17	Melanoma;
LUAD	cis	rs10899021	0.920	rs7112664	chr11:74348426	T/C	cg25880958	chr11:74394337	NA	-0.64	-8.6	-0.39	1.54e-16	Response to metformin (IC50);
LUAD	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg17173187	chr15:85201210	NMB	0.48	8.53	0.38	2.55e-16	Schizophrenia;
LUAD	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg22676075	chr6:135203613	NA	0.39	7.17	0.33	3.44e-12	Red blood cell count;
LUAD	cis	rs240764	0.658	rs10872634	chr6:101199579	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-8.05	-0.36	8.39e-15	Neuroticism;
LUAD	cis	rs2657888	0.965	rs2694909	chr12:56934928	T/C	cg23002907	chr12:56915593	RBMS2	0.35	6.48	0.3	2.57e-10	Adiponectin levels;
LUAD	trans	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg02002194	chr4:3960332	NA	-0.3	-7.18	-0.33	3.15e-12	Mood instability;
LUAD	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg22823121	chr1:150693482	HORMAD1	0.42	8.45	0.38	4.91e-16	Tonsillectomy;
LUAD	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg23758822	chr17:41437982	NA	-1.0	-21.13	-0.72	3.68e-68	Menopause (age at onset);
LUAD	cis	rs9535307	0.719	rs1211304	chr13:50381016	G/A	cg04663916	chr13:50265991	EBPL	-0.62	-6.98	-0.32	1.17e-11	Obesity-related traits;
LUAD	cis	rs1595825	0.786	rs75415672	chr2:198535679	G/A	cg00982548	chr2:198649783	BOLL	-0.63	-8.91	-0.4	1.48e-17	Ulcerative colitis;
LUAD	cis	rs1448094	0.813	rs6539942	chr12:86452969	T/C	cg00310523	chr12:86230176	RASSF9	-0.36	-7.49	-0.34	3.96e-13	Major depressive disorder;
LUAD	cis	rs4812048	0.649	rs6100319	chr20:57626568	A/C	cg14073986	chr20:57617431	SLMO2	0.82	9.89	0.43	6.7e-21	Mean platelet volume;
LUAD	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg09365446	chr1:150670422	GOLPH3L	0.66	12.34	0.51	4.22e-30	Tonsillectomy;
LUAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg17178900	chr1:205818956	PM20D1	0.73	15.21	0.59	5.55e-42	Menarche (age at onset);
LUAD	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.18	-0.33	3.12e-12	Height;
LUAD	cis	rs11585357	1.000	rs11585357	chr1:17601165	C/T	cg08277548	chr1:17600880	PADI3	-0.97	-13.86	-0.56	2.87e-36	Hair shape;
LUAD	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg07936489	chr17:37558343	FBXL20	-0.48	-7.57	-0.35	2.4e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23158103	chr7:148848205	ZNF398	-0.66	-12.59	-0.52	4.25e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs17601876	0.814	rs8029537	chr15:51557698	A/G	cg19946085	chr15:51559439	CYP19A1	-0.37	-6.68	-0.31	7.63e-11	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LUAD	cis	rs8067342	0.611	rs7213842	chr17:21175537	C/T	cg03858720	chr17:21194718	MAP2K3	-0.31	-6.4	-0.3	4.22e-10	Immature fraction of reticulocytes;Red cell distribution width;
LUAD	cis	rs1405069	0.809	rs1046279	chr6:36932571	C/T	cg26433444	chr6:36932349	PI16	-0.43	-8.65	-0.39	1.1e-16	Chemerin levels;
LUAD	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg13902645	chr11:5959945	NA	-0.48	-8.42	-0.38	5.81e-16	DNA methylation (variation);
LUAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13732083	chr21:47605072	C21orf56	0.61	10.31	0.45	2.18e-22	Testicular germ cell tumor;
LUAD	cis	rs113835537	0.597	rs2075792	chr11:66334556	G/A	cg24851651	chr11:66362959	CCS	0.59	10.44	0.45	7.58e-23	Airway imaging phenotypes;
LUAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.49	-7.11	-0.33	5.01e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02475777	chr4:1388615	CRIPAK	0.72	10.4	0.45	1.01e-22	Longevity;
LUAD	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg13902645	chr11:5959945	NA	-0.57	-10.87	-0.47	2.02e-24	DNA methylation (variation);
LUAD	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg06640241	chr16:89574553	SPG7	0.66	11.27	0.48	6.36e-26	Multiple myeloma (IgH translocation);
LUAD	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg06623918	chr6:96969491	KIAA0776	-0.69	-9.56	-0.42	9.89e-20	Migraine;Coronary artery disease;
LUAD	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg07537917	chr2:241836409	C2orf54	-0.31	-8.69	-0.39	8.26e-17	Urinary metabolites;
LUAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg07167872	chr1:205819463	PM20D1	0.52	8.08	0.37	6.85e-15	Parkinson's disease;
LUAD	cis	rs10129255	0.500	rs2105989	chr14:107138216	C/T	cg07958169	chr14:107095056	NA	-0.37	-7.43	-0.34	6.2e-13	Kawasaki disease;
LUAD	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	7.1	0.33	5.41e-12	Cognitive test performance;
LUAD	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg21475434	chr5:93447410	FAM172A	0.58	7.29	0.33	1.58e-12	Diabetic retinopathy;
LUAD	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg06623918	chr6:96969491	KIAA0776	0.87	17.21	0.64	1.04e-50	Headache;
LUAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg10729496	chr3:10149963	C3orf24	0.65	9.65	0.42	4.98e-20	Alzheimer's disease;
LUAD	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg13180566	chr4:1052158	NA	-0.39	-6.69	-0.31	7.15e-11	Recombination rate (females);
LUAD	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-7.08	-0.33	5.95e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2224391	0.534	rs2753228	chr6:5246623	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-8.74	-0.39	5.41e-17	Height;
LUAD	cis	rs6542838	0.641	rs12478574	chr2:99476369	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-7.04	-0.32	7.85e-12	Fear of minor pain;
LUAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg00450029	chr8:599525	NA	0.83	8.17	0.37	3.67e-15	IgG glycosylation;
LUAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg17372223	chr3:52568218	NT5DC2	0.43	8.17	0.37	3.58e-15	Electroencephalogram traits;
LUAD	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg04450456	chr4:17643702	FAM184B	0.43	8.37	0.38	8.65e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs853679	0.607	rs13217984	chr6:28139710	A/T	cg12623302	chr6:28058802	ZSCAN12L1	0.56	6.53	0.3	1.91e-10	Depression;
LUAD	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg08847533	chr14:75593920	NEK9	0.42	7.31	0.33	1.36e-12	Height;
LUAD	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg17551891	chr7:1960795	MAD1L1	-0.38	-6.5	-0.3	2.31e-10	Neuroticism;
LUAD	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs2999052	1.000	rs2811529	chr3:127994160	G/A	cg00340326	chr3:127988088	EEFSEC	0.33	6.44	0.3	3.29e-10	Hypospadias;
LUAD	cis	rs1395	1.000	rs6717980	chr2:27452784	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.41	7.72	0.35	8.39e-14	Blood metabolite levels;
LUAD	cis	rs904251	0.797	rs2776878	chr6:37487273	G/A	cg25019722	chr6:37503610	NA	-0.3	-6.62	-0.31	1.12e-10	Cognitive performance;
LUAD	cis	rs62400317	0.762	rs72865924	chr6:44878943	G/A	cg18551225	chr6:44695536	NA	-0.56	-8.54	-0.38	2.51e-16	Total body bone mineral density;
LUAD	cis	rs9503598	0.636	rs6596975	chr6:3465925	G/A	cg00476032	chr6:3446245	SLC22A23	0.32	6.75	0.31	4.87e-11	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg07305463	chr2:136567211	LCT	0.39	7.34	0.34	1.08e-12	Mosquito bite size;
LUAD	trans	rs12517041	1.000	rs4701364	chr5:23301087	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.49	-0.3	2.42e-10	Calcium levels;
LUAD	trans	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg11693508	chr17:37793320	STARD3	0.59	7.5	0.34	3.67e-13	Neuroticism;
LUAD	cis	rs6738485	0.507	rs72819611	chr2:106845912	G/A	cg23109721	chr2:106886537	NA	-0.53	-6.81	-0.31	3.35e-11	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs7202877	0.706	rs4887813	chr16:75312494	A/G	cg03315344	chr16:75512273	CHST6	0.52	6.94	0.32	1.51e-11	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg19717773	chr7:2847554	GNA12	-0.54	-10.22	-0.44	4.8e-22	Height;
LUAD	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.87	-12.39	-0.52	2.78e-30	Red cell distribution width;
LUAD	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg16479474	chr6:28041457	NA	0.43	7.33	0.34	1.15e-12	Depression;
LUAD	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.43	0.34	6.07e-13	Hypertriglyceridemia;
LUAD	cis	rs7107174	0.892	rs2510042	chr11:77923665	C/T	cg02023728	chr11:77925099	USP35	0.51	7.89	0.36	2.53e-14	Testicular germ cell tumor;
LUAD	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg22532475	chr10:104410764	TRIM8	0.33	6.83	0.32	2.99e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg19318889	chr4:1322082	MAEA	0.45	7.28	0.33	1.61e-12	Obesity-related traits;
LUAD	cis	rs72799341	1.000	rs7185007	chr16:30927509	C/T	cg02466173	chr16:30829666	NA	-0.62	-9.26	-0.41	1.05e-18	Diastolic blood pressure;
LUAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg01448562	chr3:133502909	NA	-0.78	-15.12	-0.59	1.34e-41	Iron status biomarkers;
LUAD	cis	rs7020830	0.898	rs12000309	chr9:37230844	G/A	cg14294708	chr9:37120828	ZCCHC7	0.87	17.68	0.65	8.87e-53	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg01689657	chr7:91764605	CYP51A1	0.34	8.41	0.38	6.45e-16	Breast cancer;
LUAD	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg10518543	chr12:38710700	ALG10B	-0.49	-8.08	-0.37	6.85e-15	Morning vs. evening chronotype;
LUAD	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg24813613	chr7:1882135	MAD1L1	-0.43	-6.66	-0.31	8.34e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs11031096	0.754	rs10742242	chr11:4156851	T/C	cg18678763	chr11:4115507	RRM1	-0.42	-7.4	-0.34	7.44e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg04398451	chr17:18023971	MYO15A	-0.62	-11.41	-0.49	1.82e-26	Total body bone mineral density;
LUAD	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg03034668	chr16:1723424	CRAMP1L	-0.38	-6.67	-0.31	7.81e-11	Coronary artery disease;
LUAD	trans	rs4650994	0.789	rs2476559	chr1:178592919	A/G	cg05059571	chr16:84539110	KIAA1609	0.49	8.17	0.37	3.6e-15	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs4888262	0.526	rs4887776	chr16:74635632	A/G	cg01733217	chr16:74700730	RFWD3	0.51	8.56	0.38	2.04e-16	Testicular germ cell tumor;
LUAD	cis	rs62400317	0.859	rs10456543	chr6:45178907	T/C	cg18551225	chr6:44695536	NA	-0.55	-8.27	-0.37	1.76e-15	Total body bone mineral density;
LUAD	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg24634471	chr8:143751801	JRK	0.48	7.6	0.35	1.86e-13	Schizophrenia;
LUAD	cis	rs2455799	0.613	rs4685264	chr3:15858347	G/A	cg16303742	chr3:15540471	COLQ	-0.53	-9.86	-0.43	8.68e-21	Mean platelet volume;
LUAD	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg16205897	chr5:131564050	P4HA2	-0.44	-10.03	-0.44	2.25e-21	Blood metabolite levels;
LUAD	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg26677194	chr12:130822605	PIWIL1	0.55	9.04	0.4	5.6e-18	Menopause (age at onset);
LUAD	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg08798685	chr6:27730294	NA	-0.65	-7.02	-0.32	8.89e-12	Breast cancer;
LUAD	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg06627628	chr2:24431161	ITSN2	-0.57	-9.58	-0.42	8.4e-20	Asthma;
LUAD	cis	rs7737355	0.812	rs548635	chr5:131055546	G/T	cg25547332	chr5:131281432	NA	-0.41	-6.67	-0.31	7.98e-11	Life satisfaction;
LUAD	cis	rs13095912	0.962	rs11916386	chr3:185308069	G/T	cg11274856	chr3:185301563	NA	0.37	7.49	0.34	3.95e-13	Systolic blood pressure;
LUAD	trans	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg06606381	chr12:133084897	FBRSL1	-0.51	-6.39	-0.3	4.32e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg14416269	chr4:6271139	WFS1	0.63	13.39	0.55	2.42e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs595018	1.000	rs488483	chr11:60592227	A/G	cg07588442	chr11:60673866	PRPF19	-0.49	-6.36	-0.3	5.28e-10	Wegener's granulomatosis;
LUAD	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.12	-0.33	4.76e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	trans	rs877282	0.891	rs10904557	chr10:797490	C/T	cg22713356	chr15:30763199	NA	-1.21	-19.21	-0.68	1.32e-59	Uric acid levels;
LUAD	cis	rs7536201	1.000	rs7550552	chr1:25299602	C/T	cg23273869	chr1:25296894	NA	-0.39	-8.07	-0.37	7.56e-15	Psoriasis vulgaris;
LUAD	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg26022315	chr17:47021804	SNF8	0.41	7.43	0.34	6.03e-13	Type 2 diabetes;
LUAD	cis	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg21775007	chr8:11205619	TDH	0.37	6.49	0.3	2.4e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg00898013	chr13:113819073	PROZ	-0.83	-15.02	-0.59	3.5e-41	Platelet distribution width;
LUAD	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg21475434	chr5:93447410	FAM172A	0.71	8.39	0.38	7.33e-16	Diabetic retinopathy;
LUAD	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03517284	chr6:25882590	NA	-0.6	-9.79	-0.43	1.51e-20	Blood metabolite levels;
LUAD	cis	rs12541635	0.677	rs1429681	chr8:107048808	A/C	cg10147462	chr8:107024639	NA	0.52	9.39	0.42	3.77e-19	Age of smoking initiation;
LUAD	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg13511324	chr14:104056883	C14orf153	0.25	6.38	0.3	4.53e-10	Coronary artery disease;
LUAD	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg17063962	chr7:91808500	NA	0.71	12.79	0.53	6.97e-32	Breast cancer;
LUAD	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg18190219	chr22:46762943	CELSR1	-0.5	-6.46	-0.3	2.8e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.23	-0.33	2.22e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6906287	0.647	rs34479834	chr6:118826244	T/A	cg21191810	chr6:118973309	C6orf204	0.5	9.8	0.43	1.38e-20	Electrocardiographic conduction measures;
LUAD	cis	rs55665837	0.701	rs1522633	chr11:14645238	A/T	cg19336497	chr11:14380999	RRAS2	-0.4	-7.17	-0.33	3.29e-12	Vitamin D levels;
LUAD	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.65	0.52	2.46e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs727505	0.564	rs68107250	chr7:124870200	G/A	cg23710748	chr7:124431027	NA	-0.37	-7.35	-0.34	1.01e-12	Lewy body disease;
LUAD	cis	rs9372498	0.505	rs56406560	chr6:118991787	G/A	cg07617317	chr6:118971624	C6orf204	0.51	7.65	0.35	1.4e-13	Diastolic blood pressure;
LUAD	cis	rs78761021	0.898	rs73257187	chr17:9776719	T/C	cg26853458	chr17:9805074	RCVRN	0.35	6.61	0.31	1.15e-10	Type 2 diabetes;
LUAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.81	0.43	1.32e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27286337	chr10:134555280	INPP5A	-0.72	-9.66	-0.43	4.32e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2455799	0.613	rs13071161	chr3:15958166	C/T	cg16303742	chr3:15540471	COLQ	-0.43	-7.8	-0.35	4.83e-14	Mean platelet volume;
LUAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	6.96	0.32	1.27e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg20283391	chr11:68216788	NA	-0.41	-6.49	-0.3	2.46e-10	Total body bone mineral density;
LUAD	cis	rs60871478	0.645	rs111968669	chr7:856683	C/T	cg05535760	chr7:792225	HEATR2	-0.59	-7.53	-0.34	3.1e-13	Cerebrospinal P-tau181p levels;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg04791162	chr14:62331287	NA	0.4	6.58	0.3	1.38e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	7.05	0.32	7.46e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-7.28	-0.33	1.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2625529	0.775	rs16956273	chr15:72117102	C/T	cg16672083	chr15:72433130	SENP8	-0.67	-11.78	-0.5	6.73e-28	Red blood cell count;
LUAD	cis	rs758324	0.812	rs4705839	chr5:131175258	G/A	cg25547332	chr5:131281432	NA	0.42	6.88	0.32	2.11e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg13535736	chr9:111863775	C9orf5	-0.42	-6.43	-0.3	3.37e-10	Menarche (age at onset);
LUAD	cis	rs15676	0.733	rs2900269	chr9:131569878	G/T	cg00228799	chr9:131580591	ENDOG	0.47	7.27	0.33	1.74e-12	Blood metabolite levels;
LUAD	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg27211696	chr2:191398769	TMEM194B	0.79	16.69	0.63	2.11e-48	Pulse pressure;
LUAD	cis	rs4372836	0.664	rs4233729	chr2:29092679	T/C	cg09522027	chr2:28974177	PPP1CB	0.65	11.4	0.48	2.02e-26	Body mass index;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24810144	chr11:1502134	HCCA2	0.46	6.35	0.3	5.64e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7903847	0.642	rs10882909	chr10:99137998	G/C	cg20016023	chr10:99160130	RRP12	-0.3	-7.2	-0.33	2.81e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs11958404	0.615	rs7724696	chr5:157450852	A/C	cg05962755	chr5:157440814	NA	0.44	8.46	0.38	4.4e-16	IgG glycosylation;
LUAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg22963979	chr7:1858916	MAD1L1	-0.56	-9.51	-0.42	1.51e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs13394619	0.775	rs10165819	chr2:11722102	A/T	cg07314298	chr2:11723111	GREB1	-0.51	-9.63	-0.42	5.63e-20	Endometriosis;
LUAD	trans	rs9393777	0.920	rs35716472	chr6:27406607	C/G	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.12	-0.37	5.18e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg10589385	chr1:150898437	SETDB1	0.41	7.76	0.35	6.59e-14	Tonsillectomy;
LUAD	cis	rs4849845	0.889	rs1065518	chr2:121050989	T/A	cg24070213	chr2:121070622	NA	0.36	6.37	0.3	4.92e-10	Mean platelet volume;
LUAD	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg17105886	chr17:28927953	LRRC37B2	0.73	6.64	0.31	9.66e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3106136	0.872	rs13130583	chr4:95245543	T/C	cg11021082	chr4:95130006	SMARCAD1	0.36	6.39	0.3	4.32e-10	Capecitabine sensitivity;
LUAD	trans	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg26043149	chr18:55253948	FECH	-0.43	-7.15	-0.33	3.74e-12	Bone mineral density;
LUAD	cis	rs131777	0.545	rs140514	chr22:51018579	A/G	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	0.34	6.45	0.3	3.07e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg11905131	chr22:24372483	LOC391322	-0.63	-11.14	-0.48	1.96e-25	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2274273	0.624	rs7159824	chr14:55772536	C/T	cg04306507	chr14:55594613	LGALS3	0.4	7.87	0.36	3.01e-14	Protein biomarker;
LUAD	cis	rs62238980	0.614	rs75426883	chr22:32434795	C/G	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.3	6.66	0.31	8.75e-11	Systemic lupus erythematosus;
LUAD	cis	rs4774899	1.000	rs12914182	chr15:57424454	A/G	cg14026238	chr15:57616123	NA	0.37	7.01	0.32	9.35e-12	Urinary tract infection frequency;
LUAD	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg04398451	chr17:18023971	MYO15A	0.64	11.2	0.48	1.1e-25	Total body bone mineral density;
LUAD	cis	rs752010	0.630	rs11210507	chr1:42105488	T/C	cg06885757	chr1:42089581	HIVEP3	0.38	8.09	0.37	6.48e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs977987	0.741	rs10514393	chr16:75344476	C/T	cg03315344	chr16:75512273	CHST6	0.63	13.92	0.56	1.63e-36	Dupuytren's disease;
LUAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-10.31	-0.45	2.26e-22	Lymphocyte counts;
LUAD	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.5	0.3	2.29e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg20476274	chr7:133979776	SLC35B4	0.61	10.33	0.45	1.81e-22	Mean platelet volume;
LUAD	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg22676075	chr6:135203613	NA	0.5	8.86	0.4	2.21e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs472402	0.580	rs3733773	chr5:6652252	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.41	-6.37	-0.3	4.93e-10	Response to amphetamines;
LUAD	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg06740227	chr12:86229804	RASSF9	0.42	7.3	0.33	1.42e-12	Major depressive disorder;
LUAD	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25427524	chr10:38739819	LOC399744	0.77	14.8	0.58	3.03e-40	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.78	-0.31	4.01e-11	Post bronchodilator FEV1;
LUAD	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg04731861	chr2:219085781	ARPC2	0.27	8.38	0.38	7.82e-16	Colorectal cancer;
LUAD	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg24818145	chr4:99064322	C4orf37	0.45	7.34	0.34	1.12e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.72	-0.31	5.94e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs8002861	0.754	rs7330760	chr13:44403088	A/T	cg17145862	chr1:211918768	LPGAT1	-0.54	-10.65	-0.46	1.25e-23	Leprosy;
LUAD	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg17480646	chr11:65405466	SIPA1	0.43	6.37	0.3	5.02e-10	Acne (severe);
LUAD	cis	rs9902453	0.967	rs56129908	chr17:28421382	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	9.05	0.4	5.4e-18	Coffee consumption (cups per day);
LUAD	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.63	-0.31	1.04e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg19318889	chr4:1322082	MAEA	0.56	9.4	0.42	3.36e-19	Longevity;
LUAD	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	12.75	0.53	9.79e-32	Melanoma;
LUAD	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg15704280	chr7:45808275	SEPT13	-0.99	-20.31	-0.7	1.58e-64	Height;
LUAD	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg21385522	chr1:16154831	NA	0.57	9.57	0.42	8.98e-20	Systolic blood pressure;
LUAD	cis	rs758324	0.773	rs13174385	chr5:131160187	T/G	cg06307176	chr5:131281290	NA	0.43	7.2	0.33	2.68e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7666738	0.688	rs35739409	chr4:98576934	C/T	cg24818145	chr4:99064322	C4orf37	0.52	7.61	0.35	1.84e-13	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03392679	chr3:71773917	EIF4E3	-0.37	-6.46	-0.3	2.86e-10	Cancer;
LUAD	cis	rs6701037	0.522	rs12094153	chr1:175094025	G/A	cg14847009	chr1:175162515	KIAA0040	-0.26	-6.51	-0.3	2.16e-10	Alcohol dependence;
LUAD	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg02569458	chr12:86230093	RASSF9	0.45	8.22	0.37	2.53e-15	Major depressive disorder;
LUAD	cis	rs2046867	0.862	rs35178407	chr3:72799703	C/T	cg25664220	chr3:72788482	NA	-0.62	-11.04	-0.47	4.47e-25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.36	-0.45	1.5e-22	Monocyte percentage of white cells;
LUAD	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg09365446	chr1:150670422	GOLPH3L	0.66	12.52	0.52	8.29e-31	Tonsillectomy;
LUAD	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg27535305	chr1:53392650	SCP2	-0.33	-6.71	-0.31	6.1e-11	Monocyte count;
LUAD	cis	rs7945718	0.870	rs3890064	chr11:12758766	C/A	cg25843174	chr11:12811716	TEAD1	0.24	6.94	0.32	1.43e-11	Educational attainment (years of education);
LUAD	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.52	0.34	3.2e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs730775	0.505	rs324137	chr6:44273546	G/T	cg21130236	chr6:44246755	TMEM151B	0.35	7.45	0.34	5.21e-13	Monocyte percentage of white cells;Monocyte count;
LUAD	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06028808	chr11:68637592	NA	0.44	7.32	0.34	1.3e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg11301795	chr4:187892539	NA	-0.76	-15.36	-0.6	1.28e-42	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3820068	0.677	rs72643691	chr1:15856251	T/C	cg24675056	chr1:15929824	NA	0.42	6.81	0.31	3.38e-11	Systolic blood pressure;
LUAD	cis	rs1461503	0.966	rs11218908	chr11:122841687	A/G	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.86	-0.36	3.15e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg02423579	chr7:2872169	GNA12	-0.83	-14.4	-0.57	1.57e-38	Height;
LUAD	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.59	9.91	0.43	6.12e-21	Electrocardiographic conduction measures;
LUAD	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg01851573	chr8:8652454	MFHAS1	-0.47	-8.3	-0.37	1.38e-15	Mood instability;
LUAD	cis	rs12467847	1.000	rs12467847	chr2:113691404	A/G	cg12858261	chr2:113808755	IL1F8	0.37	6.54	0.3	1.81e-10	Response to amphetamines;
LUAD	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg08999081	chr20:33150536	PIGU	0.58	12.6	0.52	3.99e-31	Coronary artery disease;
LUAD	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg21951975	chr1:209979733	IRF6	-0.41	-8.13	-0.37	4.91e-15	Monobrow;
LUAD	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg00981070	chr1:2046702	PRKCZ	-0.37	-7.73	-0.35	8.11e-14	Height;
LUAD	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg09658497	chr7:2847517	GNA12	-0.5	-8.43	-0.38	5.33e-16	Height;
LUAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.46	-0.34	5.03e-13	Bipolar disorder and schizophrenia;
LUAD	trans	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.64	9.53	0.42	1.23e-19	Platelet distribution width;
LUAD	cis	rs10499694	1.000	rs10499694	chr7:50614173	A/G	cg18232548	chr7:50535776	DDC	-0.47	-8.06	-0.37	7.63e-15	Body mass index;
LUAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg18621852	chr3:10150065	C3orf24	0.42	7.46	0.34	5.08e-13	Alzheimer's disease;
LUAD	cis	rs1942	1.000	rs1942	chr15:41774423	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.4	-7.03	-0.32	8.1e-12	Eosinophil percentage of granulocytes;
LUAD	trans	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg25894440	chr7:65020034	NA	-0.63	-6.94	-0.32	1.48e-11	Gout;
LUAD	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg23815491	chr16:72088622	HP	0.59	11.14	0.48	1.96e-25	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LUAD	cis	rs9469913	0.604	rs11755266	chr6:35162141	A/G	cg14254433	chr6:34482411	PACSIN1	0.51	6.77	0.31	4.31e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs2004318	1.000	rs2363868	chr19:55140934	C/A	cg03320607	chr19:54800032	LILRA3	-0.7	-7.42	-0.34	6.32e-13	Blood protein levels;
LUAD	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg00631329	chr6:26305371	NA	-0.44	-7.46	-0.34	5e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg15181151	chr6:150070149	PCMT1	0.4	8.15	0.37	4.27e-15	Lung cancer;
LUAD	cis	rs3204270	0.759	rs8066217	chr17:79672615	C/G	cg18367735	chr17:79674897	NA	0.54	6.82	0.31	3.06e-11	Dental caries;
LUAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00149659	chr3:10157352	C3orf10	0.57	7.98	0.36	1.34e-14	Alzheimer's disease;
LUAD	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-23.73	-0.76	9.23e-80	Height;
LUAD	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.62	7.46	0.34	4.93e-13	Body mass index;
LUAD	trans	rs4650994	0.525	rs2761463	chr1:178557137	T/C	cg05059571	chr16:84539110	KIAA1609	0.73	13.09	0.54	4.05e-33	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg11189052	chr15:85197271	WDR73	-0.64	-10.66	-0.46	1.17e-23	P wave terminal force;
LUAD	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25427524	chr10:38739819	LOC399744	-0.71	-12.86	-0.53	3.64e-32	Extrinsic epigenetic age acceleration;
LUAD	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg03732007	chr1:2071316	PRKCZ	0.34	6.61	0.31	1.14e-10	Height;
LUAD	cis	rs68170813	0.559	rs12536574	chr7:106810997	A/T	cg02696742	chr7:106810147	HBP1	-0.79	-11.06	-0.47	3.63e-25	Coronary artery disease;
LUAD	trans	rs75804782	0.510	rs10186447	chr2:239467168	C/T	cg01134436	chr17:81009848	B3GNTL1	0.71	7.28	0.33	1.64e-12	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18404041	chr3:52824283	ITIH1	-0.61	-12.19	-0.51	1.71e-29	Bipolar disorder;
LUAD	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg21775007	chr8:11205619	TDH	0.56	9.81	0.43	1.35e-20	Retinal vascular caliber;
LUAD	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-8.21	-0.37	2.77e-15	Height;
LUAD	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-8.17	-0.37	3.57e-15	Bipolar disorder;
LUAD	trans	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	10.81	0.47	3.13e-24	Resting heart rate;
LUAD	cis	rs11771526	1.000	rs6462350	chr7:32342000	G/A	cg13207630	chr7:32358064	NA	0.69	7.93	0.36	1.93e-14	Body mass index;
LUAD	cis	rs4523957	0.928	rs12943566	chr17:2157774	A/G	cg16513277	chr17:2031491	SMG6	0.75	13.82	0.56	4.14e-36	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs67981189	0.519	rs2526879	chr14:71377218	T/C	cg15910301	chr14:71632612	NA	-0.43	-6.65	-0.31	8.94e-11	Schizophrenia;
LUAD	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg01802117	chr1:53393560	SCP2	-0.38	-7.36	-0.34	9.57e-13	Monocyte count;
LUAD	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg24450063	chr1:156163899	SLC25A44	1.04	16.57	0.63	7.22e-48	Testicular germ cell tumor;
LUAD	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	8.08	0.37	6.85e-15	Schizophrenia;
LUAD	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg09365446	chr1:150670422	GOLPH3L	0.66	12.58	0.52	4.9e-31	Tonsillectomy;
LUAD	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg09904177	chr6:26538194	HMGN4	0.43	7.31	0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg16405210	chr4:1374714	KIAA1530	-0.61	-9.71	-0.43	2.85e-20	Longevity;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg27482856	chr7:99214447	ZNF498	0.41	7.32	0.34	1.22e-12	Anger;
LUAD	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg07917127	chr4:99064746	C4orf37	0.5	8.13	0.37	4.76e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg14186256	chr22:23484241	RTDR1	0.47	8.13	0.37	4.63e-15	Bone mineral density;
LUAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg11766577	chr21:47581405	C21orf56	0.64	11.7	0.49	1.35e-27	Testicular germ cell tumor;
LUAD	cis	rs10193935	0.901	rs12619348	chr2:42625586	C/T	cg27598129	chr2:42591480	NA	-0.73	-9.33	-0.41	5.94e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.69	-9.13	-0.41	2.77e-18	Body mass index;
LUAD	cis	rs1065656	0.563	rs391546	chr16:1915581	T/G	cg07386859	chr16:1872102	HAGH	-0.52	-8.02	-0.36	1.07e-14	Insulin-like growth factors;
LUAD	cis	rs8044868	0.530	rs12918956	chr16:72224335	A/G	cg23815491	chr16:72088622	HP	-0.45	-8.41	-0.38	6.5e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-7.89	-0.36	2.54e-14	Blood metabolite levels;
LUAD	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.72	0.31	5.85e-11	Rheumatoid arthritis;
LUAD	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg05110241	chr16:68378359	PRMT7	-0.81	-8.73	-0.39	5.74e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02475777	chr4:1388615	CRIPAK	-0.49	-7.2	-0.33	2.84e-12	Obesity-related traits;
LUAD	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg15921436	chr17:44337874	NA	-0.72	-9.45	-0.42	2.34e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg04025307	chr7:1156635	C7orf50	0.66	8.21	0.37	2.8e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg02551604	chr5:131831745	NA	-0.61	-10.1	-0.44	1.22e-21	Asthma (sex interaction);
LUAD	cis	rs6743376	0.533	rs10206428	chr2:113826475	A/G	cg09040174	chr2:113837401	NA	0.48	7.58	0.35	2.24e-13	Inflammatory biomarkers;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01338834	chr21:40720919	HMGN1	-0.68	-6.47	-0.3	2.68e-10	Type 2 diabetes;
LUAD	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	8.6	0.39	1.54e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01516881	chr6:292596	DUSP22	-0.77	-13.38	-0.55	2.79e-34	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg03467027	chr4:99064603	C4orf37	0.39	6.43	0.3	3.43e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-11.74	-0.5	9.7e-28	Hemoglobin concentration;
LUAD	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg05590025	chr7:65112418	INTS4L2	0.77	8.15	0.37	4.09e-15	Diabetic kidney disease;
LUAD	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg14582100	chr15:45693742	SPATA5L1	0.43	8.59	0.39	1.65e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs7975161	0.572	rs4964226	chr12:104570489	A/G	cg25273343	chr12:104657179	TXNRD1	-0.66	-7.5	-0.34	3.76e-13	Toenail selenium levels;
LUAD	cis	rs7301016	0.901	rs12369961	chr12:62966584	C/T	cg11441379	chr12:63026424	NA	0.61	7.8	0.35	4.99e-14	IgG glycosylation;
LUAD	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg08280861	chr8:58055591	NA	0.57	7.92	0.36	2.15e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	8.05	0.36	8.47e-15	Tonsillectomy;
LUAD	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg03388025	chr16:89894329	SPIRE2	-0.32	-7.4	-0.34	7.48e-13	Vitiligo;
LUAD	cis	rs208520	1.000	rs208527	chr6:66957209	A/C	cg07460842	chr6:66804631	NA	-0.97	-13.16	-0.54	2.25e-33	Exhaled nitric oxide output;
LUAD	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg05340658	chr4:99064831	C4orf37	0.45	7.42	0.34	6.47e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7822232	1.000	rs7822232	chr8:145145687	A/C	cg14631276	chr8:145163102	KIAA1875	-0.64	-6.36	-0.3	5.19e-10	Blood metabolite levels;
LUAD	cis	rs11696845	0.666	rs6103849	chr20:43365687	C/T	cg25301532	chr20:43378953	KCNK15	-0.48	-8.19	-0.37	3.09e-15	Obesity-related traits;
LUAD	cis	rs1451375	0.755	rs3829897	chr7:50629764	G/T	cg18232548	chr7:50535776	DDC	0.49	8.07	0.37	7.14e-15	Malaria;
LUAD	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg22508957	chr16:3507546	NAT15	-0.38	-6.58	-0.3	1.38e-10	Body mass index (adult);
LUAD	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg04450456	chr4:17643702	FAM184B	-0.41	-7.8	-0.35	4.88e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg26384229	chr12:38710491	ALG10B	0.45	7.55	0.34	2.65e-13	Morning vs. evening chronotype;
LUAD	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg03433033	chr1:76189801	ACADM	0.91	18.17	0.66	5.71e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.41	6.67	0.31	8.27e-11	Resistin levels;
LUAD	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg03690763	chr11:133734501	NA	-0.33	-7.83	-0.36	3.85e-14	Childhood ear infection;
LUAD	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs78487399	0.808	rs6728106	chr2:43683885	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.69	-0.31	7.16e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg09253696	chr17:73873529	TRIM47	-0.45	-7.61	-0.35	1.77e-13	Psoriasis;
LUAD	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.18	0.54	1.73e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg15147215	chr3:52552868	STAB1	-0.39	-7.19	-0.33	3.02e-12	Bipolar disorder;
LUAD	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg27124370	chr19:33622961	WDR88	0.44	7.09	0.33	5.67e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs760805	1.000	rs61774728	chr1:25258867	G/C	cg22509179	chr1:25234806	RUNX3	-0.74	-13.46	-0.55	1.27e-34	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs11971779	0.680	rs10085901	chr7:139108989	G/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.38e-10	Diisocyanate-induced asthma;
LUAD	trans	rs4942242	0.663	rs34595450	chr13:44221245	A/G	cg19169023	chr15:41853346	TYRO3	-0.68	-11.49	-0.49	8.83e-27	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg13535736	chr9:111863775	C9orf5	-0.42	-6.49	-0.3	2.47e-10	Menarche (age at onset);
LUAD	cis	rs12541635	0.966	rs4734895	chr8:107002604	A/G	cg10147462	chr8:107024639	NA	0.48	8.5	0.38	3.35e-16	Age of smoking initiation;
LUAD	cis	rs738322	0.555	rs2284063	chr22:38544298	C/T	cg17652424	chr22:38574118	PLA2G6	0.27	7.34	0.34	1.11e-12	Cutaneous nevi;
LUAD	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg07870213	chr5:140052090	DND1	0.73	11.1	0.47	2.61e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg22705602	chr4:152727874	NA	-0.36	-6.49	-0.3	2.46e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.98	-0.4	8.9e-18	Total body bone mineral density;
LUAD	cis	rs67311347	0.544	rs7652439	chr3:40349948	G/T	cg09455208	chr3:40491958	NA	0.38	7.6	0.35	1.93e-13	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg12623918	chr2:306882	NA	0.34	6.76	0.31	4.53e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs11098699	0.784	rs6832894	chr4:124239525	T/C	cg09941581	chr4:124220074	SPATA5	0.42	6.78	0.31	4.1e-11	Mosquito bite size;
LUAD	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg26769984	chr7:1090371	C7orf50	0.7	11.16	0.48	1.57e-25	Bronchopulmonary dysplasia;
LUAD	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg12011299	chr4:100065546	ADH4	0.7	12.59	0.52	4.29e-31	Alcohol dependence;
LUAD	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24531977	chr5:56204891	C5orf35	0.77	12.41	0.52	2.19e-30	Initial pursuit acceleration;
LUAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg00280220	chr17:61926910	NA	0.36	6.83	0.32	3e-11	Prudent dietary pattern;
LUAD	trans	rs853679	0.546	rs35017208	chr6:28345282	C/T	cg01620082	chr3:125678407	NA	-1.09	-10.07	-0.44	1.58e-21	Depression;
LUAD	cis	rs7737355	0.812	rs3756289	chr5:130982194	A/G	cg25547332	chr5:131281432	NA	0.43	6.93	0.32	1.57e-11	Life satisfaction;
LUAD	cis	rs7010267	0.935	rs4319131	chr8:119947651	A/G	cg01975934	chr8:119970761	NA	0.42	8.06	0.36	7.74e-15	Total body bone mineral density (age 45-60);
LUAD	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg04455712	chr21:45112962	RRP1B	0.48	9.34	0.41	5.4e-19	Mean corpuscular volume;
LUAD	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg21220214	chr8:57350948	NA	-0.6	-8.89	-0.4	1.8e-17	Obesity-related traits;
LUAD	cis	rs7705042	0.761	rs10062349	chr5:141509597	G/A	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.78	-0.31	4.1e-11	Asthma;
LUAD	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg26384229	chr12:38710491	ALG10B	0.5	8.07	0.37	7.14e-15	Morning vs. evening chronotype;
LUAD	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg21782813	chr7:2030301	MAD1L1	0.51	8.6	0.39	1.62e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg23231163	chr10:75533350	FUT11	-0.51	-9.33	-0.41	5.87e-19	Inflammatory bowel disease;
LUAD	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg04539111	chr16:67997858	SLC12A4	-0.61	-7.57	-0.35	2.29e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.9	-0.4	1.66e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1595825	0.891	rs16826791	chr2:198895133	C/G	cg00982548	chr2:198649783	BOLL	-0.65	-9.2	-0.41	1.65e-18	Ulcerative colitis;
LUAD	cis	rs12620999	0.555	rs10199274	chr2:238111864	G/C	cg15867307	chr2:238110829	NA	0.4	6.68	0.31	7.64e-11	Systemic lupus erythematosus;
LUAD	cis	rs6076065	0.723	rs16985308	chr20:23359780	A/T	cg11657817	chr20:23433608	CST11	0.47	8.78	0.39	4.17e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg20476274	chr7:133979776	SLC35B4	0.75	12.85	0.53	3.9e-32	Mean platelet volume;
LUAD	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg21918786	chr6:109611834	NA	-0.54	-9.68	-0.43	3.64e-20	Reticulocyte fraction of red cells;
LUAD	cis	rs78707713	0.560	rs61848436	chr10:71247714	C/T	cg12610070	chr10:71211762	TSPAN15	-0.37	-9.08	-0.4	4.16e-18	Venous thromboembolism;
LUAD	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg17747265	chr1:1875780	NA	-0.75	-18.34	-0.67	1.04e-55	Body mass index;
LUAD	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg17420585	chr12:42539391	GXYLT1	-0.5	-9.17	-0.41	2.08e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.41	6.44	0.3	3.27e-10	Schizophrenia;
LUAD	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10802521	chr3:52805072	NEK4	-0.53	-8.93	-0.4	1.34e-17	Bipolar disorder;
LUAD	cis	rs2274273	0.870	rs8023197	chr14:55767395	G/T	cg04306507	chr14:55594613	LGALS3	0.41	8.5	0.38	3.24e-16	Protein biomarker;
LUAD	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg03806693	chr22:41940476	POLR3H	-0.61	-9.02	-0.4	6.58e-18	Vitiligo;
LUAD	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg16797656	chr11:68205561	LRP5	0.47	8.93	0.4	1.36e-17	Total body bone mineral density;
LUAD	cis	rs36051895	0.659	rs58345215	chr9:5043767	A/T	cg02405213	chr9:5042618	JAK2	-0.49	-6.69	-0.31	7.12e-11	Pediatric autoimmune diseases;
LUAD	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.46	0.34	4.84e-13	Morning vs. evening chronotype;
LUAD	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg04756594	chr16:24857601	SLC5A11	0.7	12.01	0.5	8.64e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.4e-15	Prostate cancer;
LUAD	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg19875535	chr5:140030758	IK	-0.46	-7.69	-0.35	1.07e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg03037974	chr15:76606532	NA	0.38	8.0	0.36	1.24e-14	Blood metabolite levels;
LUAD	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.59e-18	Life satisfaction;
LUAD	cis	rs4006360	0.646	rs917635	chr17:39302683	A/G	cg20663846	chr17:39254439	KRTAP4-8	-0.37	-8.1	-0.37	6.07e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg23625390	chr15:77176239	SCAPER	0.38	6.7	0.31	6.51e-11	Blood metabolite levels;
LUAD	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg11502198	chr6:26597334	ABT1	0.65	11.37	0.48	2.44e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.76	-0.31	4.59e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2067615	0.524	rs10778504	chr12:107120424	C/T	cg15890332	chr12:107067104	RFX4	0.4	8.53	0.38	2.72e-16	Heart rate;
LUAD	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg27211696	chr2:191398769	TMEM194B	-0.69	-9.03	-0.4	6.1e-18	Diastolic blood pressure;
LUAD	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg27124370	chr19:33622961	WDR88	0.46	7.44	0.34	5.66e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg14582100	chr15:45693742	SPATA5L1	0.64	12.54	0.52	6.93e-31	Homoarginine levels;
LUAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22029157	chr1:209979665	IRF6	0.79	12.94	0.53	1.63e-32	Cleft lip with or without cleft palate;
LUAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg20607798	chr8:58055168	NA	0.72	9.47	0.42	1.93e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg07527032	chr15:84868466	LOC388152	0.44	6.63	0.31	1.04e-10	Schizophrenia;
LUAD	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg21854759	chr1:92012499	NA	-0.46	-7.23	-0.33	2.22e-12	Eosinophil percentage of white cells;
LUAD	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg12311346	chr5:56204834	C5orf35	-0.41	-6.81	-0.31	3.33e-11	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs11971779	0.648	rs6467849	chr7:139080512	C/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg23625390	chr15:77176239	SCAPER	0.39	6.84	0.32	2.85e-11	Blood metabolite levels;
LUAD	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg17724175	chr1:150552817	MCL1	0.34	7.75	0.35	6.75e-14	Melanoma;
LUAD	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.19	16.34	0.62	7.34e-47	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg05564831	chr3:52568323	NT5DC2	-0.36	-6.64	-0.31	9.59e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17401966	0.838	rs4846207	chr1:10313811	T/C	cg19773385	chr1:10388646	KIF1B	-0.39	-6.46	-0.3	2.89e-10	Hepatocellular carcinoma;
LUAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg04267008	chr7:1944627	MAD1L1	-0.71	-11.13	-0.48	2.01e-25	Bipolar disorder and schizophrenia;
LUAD	trans	rs931812	0.757	rs35569317	chr8:101907971	T/C	cg20993868	chr7:22813445	NA	0.56	11.96	0.5	1.37e-28	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg08280861	chr8:58055591	NA	0.74	8.87	0.4	2.12e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs939658	1.000	rs8031504	chr15:79458589	G/T	cg17916960	chr15:79447300	NA	0.44	9.16	0.41	2.23e-18	Refractive error;
LUAD	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg02390115	chr1:21767211	NBPF3	0.41	6.9	0.32	1.95e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2692947	0.501	rs111397326	chr2:96374796	C/T	cg23100626	chr2:96804247	ASTL	0.4	7.21	0.33	2.64e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03452623	chr4:187889614	NA	-0.82	-16.85	-0.63	4.12e-49	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg22532475	chr10:104410764	TRIM8	-0.48	-9.21	-0.41	1.53e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.85	-0.32	2.6e-11	Breast cancer;
LUAD	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg22491629	chr6:157744540	C6orf35	0.76	9.1	0.4	3.67e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg03808351	chr9:123631620	PHF19	0.4	6.52	0.3	2e-10	Birth weight;
LUAD	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg00277334	chr10:82204260	NA	-0.68	-12.29	-0.51	6.91e-30	Post bronchodilator FEV1;
LUAD	cis	rs11247915	0.600	rs3795686	chr1:26582091	G/A	cg15628303	chr1:26608928	UBXN11	0.54	9.77	0.43	1.77e-20	Obesity-related traits;
LUAD	cis	rs1403694	1.000	rs1656911	chr3:186439373	T/C	cg12454167	chr3:186435060	KNG1	0.42	8.77	0.39	4.5e-17	Blood protein levels;
LUAD	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg16988262	chr1:15930761	NA	0.42	7.01	0.32	9.56e-12	Systolic blood pressure;
LUAD	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.79	-15.26	-0.6	3.22e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs11696501	0.739	rs6104285	chr20:44295416	A/G	cg11783356	chr20:44313418	WFDC10B	-0.54	-8.47	-0.38	4.08e-16	Brain structure;
LUAD	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg21724239	chr8:58056113	NA	0.63	8.09	0.37	6.52e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs9296661	1.000	rs1326589	chr6:51674161	A/G	cg07264792	chr22:38054590	PDXP	0.36	6.37	0.3	4.8e-10	Weight loss (gastric bypass surgery);
LUAD	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25427524	chr10:38739819	LOC399744	-0.78	-14.26	-0.57	6.18e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg23758822	chr17:41437982	NA	0.99	20.01	0.7	3.66e-63	Menopause (age at onset);
LUAD	trans	rs7395662	0.747	rs11040106	chr11:48889126	C/T	cg00717180	chr2:96193071	NA	0.36	6.85	0.32	2.61e-11	HDL cholesterol;
LUAD	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg17425144	chr1:10567563	PEX14	0.62	12.87	0.53	3.36e-32	Breast size;
LUAD	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-8.21	-0.37	2.7e-15	Gut microbiome composition (summer);
LUAD	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg00383909	chr3:49044727	WDR6	0.98	10.41	0.45	9.22e-23	Cognitive function;
LUAD	cis	rs9473147	0.543	rs9473122	chr6:47474962	C/T	cg02130027	chr6:47444894	CD2AP	0.36	6.96	0.32	1.3e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg21951975	chr1:209979733	IRF6	0.61	7.4	0.34	7.44e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs8060686	0.623	rs2418736	chr16:68154862	A/G	cg26727032	chr16:67993705	SLC12A4	0.46	7.93	0.36	2.01e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg22029157	chr1:209979665	IRF6	0.46	8.17	0.37	3.54e-15	Monobrow;
LUAD	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg25324976	chr17:61989376	CSHL1	0.34	6.68	0.31	7.7e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg18180107	chr4:99064573	C4orf37	0.47	7.34	0.34	1.09e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3845702	0.736	rs6433818	chr2:180810264	A/T	cg01881094	chr2:180872142	CWC22	-0.8	-8.46	-0.38	4.39e-16	Schizophrenia;
LUAD	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg23173402	chr1:227635558	NA	0.74	7.94	0.36	1.85e-14	Major depressive disorder;
LUAD	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg08632164	chr7:65971372	NA	0.36	6.41	0.3	3.86e-10	Aortic root size;
LUAD	cis	rs208520	0.874	rs208512	chr6:66943869	C/G	cg07460842	chr6:66804631	NA	-0.97	-14.01	-0.56	6.62e-37	Exhaled nitric oxide output;
LUAD	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg01851573	chr8:8652454	MFHAS1	-0.47	-8.29	-0.37	1.53e-15	Mood instability;
LUAD	cis	rs427941	0.703	rs201441	chr7:101737327	A/C	cg06246474	chr7:101738831	CUX1	0.4	7.04	0.32	7.81e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs4711350	0.765	rs943476	chr6:33750086	A/G	cg18005901	chr6:33739558	LEMD2	-0.56	-8.77	-0.39	4.5e-17	Schizophrenia;
LUAD	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg09658497	chr7:2847517	GNA12	-0.47	-8.54	-0.38	2.39e-16	Height;
LUAD	cis	rs9715521	0.677	rs11944208	chr4:59860652	G/A	cg11281224	chr4:60001000	NA	-0.61	-10.69	-0.46	9.11e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg01416388	chr22:39784598	NA	0.53	8.78	0.39	4.02e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg06191203	chr2:152266755	RIF1	-0.6	-8.94	-0.4	1.2e-17	Lung cancer;
LUAD	cis	rs909002	0.800	rs7529064	chr1:32105192	C/A	cg13919466	chr1:32135498	COL16A1	-0.36	-8.32	-0.38	1.21e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs7615952	0.546	rs2979306	chr3:125312130	C/A	cg17147758	chr8:6949321	NA	-0.44	-6.97	-0.32	1.22e-11	Blood pressure (smoking interaction);
LUAD	cis	rs7809950	1.000	rs2237672	chr7:107131563	A/C	cg23024343	chr7:107201750	COG5	-0.69	-11.69	-0.49	1.48e-27	Coronary artery disease;
LUAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg05896524	chr21:47604654	C21orf56	0.65	11.12	0.48	2.19e-25	Testicular germ cell tumor;
LUAD	cis	rs7665590	1	rs7665590	chr4:99796784	T/C	cg12011299	chr4:100065546	ADH4	-0.51	-9.63	-0.42	5.45e-20	Primary biliary cholangitis;
LUAD	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg06263672	chr7:65235340	NA	0.48	6.39	0.3	4.36e-10	Aortic root size;
LUAD	cis	rs2046867	0.862	rs62251653	chr3:72811827	C/T	cg25664220	chr3:72788482	NA	-0.7	-12.16	-0.51	2.13e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg10591111	chr5:226296	SDHA	-0.55	-7.23	-0.33	2.23e-12	Breast cancer;
LUAD	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg18305652	chr10:134549665	INPP5A	0.59	12.12	0.51	3.04e-29	Migraine;
LUAD	cis	rs6430585	0.527	rs1900306	chr2:136416533	G/A	cg07169764	chr2:136633963	MCM6	0.67	7.65	0.35	1.36e-13	Corneal structure;
LUAD	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.36	0.52	3.62e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg11166453	chr1:247681781	NA	0.38	7.28	0.33	1.68e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7617773	0.780	rs13067450	chr3:48337206	C/T	cg11946769	chr3:48343235	NME6	0.44	6.8	0.31	3.52e-11	Coronary artery disease;
LUAD	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg20587970	chr11:113659929	NA	-1.4	-20.91	-0.71	3.32e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg22105103	chr4:187893119	NA	-0.56	-12.3	-0.51	5.95e-30	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs7395662	0.824	rs12785858	chr11:48778806	A/G	cg00717180	chr2:96193071	NA	-0.38	-7.14	-0.33	4.11e-12	HDL cholesterol;
LUAD	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg15704280	chr7:45808275	SEPT13	0.91	17.63	0.65	1.54e-52	Coronary artery disease;
LUAD	cis	rs7177699	0.557	rs8027833	chr15:79112837	T/C	cg15571903	chr15:79123663	NA	0.37	7.38	0.34	8.32e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03611598	chr17:48586076	MYCBPAP	-0.74	-11.78	-0.5	6.75e-28	Visceral fat;
LUAD	cis	rs6495367	1.000	rs755362	chr15:79376601	C/T	cg17916960	chr15:79447300	NA	-0.33	-6.53	-0.3	1.84e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg14228332	chr4:119757509	SEC24D	0.7	6.72	0.31	5.72e-11	Cannabis dependence symptom count;
LUAD	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg13073564	chr4:8508604	NA	0.61	11.31	0.48	4.14e-26	Response to antineoplastic agents;
LUAD	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg03859395	chr2:55845619	SMEK2	0.76	14.3	0.57	4.07e-38	Metabolic syndrome;
LUAD	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg05731713	chr7:157510257	PTPRN2	-0.32	-6.37	-0.3	4.91e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs939658	0.805	rs59104559	chr15:79438784	A/G	cg17916960	chr15:79447300	NA	-0.53	-11.28	-0.48	5.58e-26	Refractive error;
LUAD	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg03609598	chr5:56110824	MAP3K1	-0.47	-7.34	-0.34	1.09e-12	Coronary artery disease;
LUAD	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg10596483	chr8:143751796	JRK	0.45	7.29	0.33	1.53e-12	Schizophrenia;
LUAD	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg12444411	chr7:2802554	GNA12	-0.36	-6.55	-0.3	1.67e-10	Height;
LUAD	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg25985355	chr7:65971099	NA	0.36	6.55	0.3	1.69e-10	Aortic root size;
LUAD	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg04455712	chr21:45112962	RRP1B	0.43	8.75	0.39	5.29e-17	Mean corpuscular volume;
LUAD	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.53	0.34	3.06e-13	Bipolar disorder;
LUAD	cis	rs7937890	0.559	rs2597206	chr11:14477538	A/C	cg22961513	chr11:14280813	SPON1	-0.37	-7.14	-0.33	4.22e-12	Mitochondrial DNA levels;
LUAD	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg00666640	chr1:248458726	OR2T12	0.32	7.78	0.35	5.79e-14	Common traits (Other);
LUAD	cis	rs7586879	0.964	rs11688665	chr2:25121168	G/T	cg04586622	chr2:25135609	ADCY3	0.33	7.08	0.33	5.95e-12	Body mass index;
LUAD	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg23262073	chr20:60523788	NA	-0.45	-7.0	-0.32	1.02e-11	Body mass index;
LUAD	cis	rs62400317	0.859	rs62436779	chr6:45124911	G/A	cg20913747	chr6:44695427	NA	-0.4	-6.41	-0.3	3.92e-10	Total body bone mineral density;
LUAD	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg03609598	chr5:56110824	MAP3K1	0.47	6.89	0.32	2.04e-11	Initial pursuit acceleration;
LUAD	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg07741184	chr6:167504864	NA	-0.3	-7.23	-0.33	2.28e-12	Crohn's disease;
LUAD	cis	rs9309473	0.718	rs10175529	chr2:73606093	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-6.81	-0.31	3.31e-11	Metabolite levels;
LUAD	cis	rs4711350	1.000	rs751727	chr6:33764158	A/G	cg13859433	chr6:33739653	LEMD2	-0.34	-6.61	-0.31	1.17e-10	Schizophrenia;
LUAD	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.41	-7.25	-0.33	1.94e-12	Platelet count;
LUAD	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg10556349	chr10:835070	NA	-0.68	-8.26	-0.37	1.95e-15	Eosinophil percentage of granulocytes;
LUAD	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg15123519	chr2:136567270	LCT	0.39	7.26	0.33	1.89e-12	Mosquito bite size;
LUAD	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.91	12.99	0.53	1.07e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.25	6.61	0.31	1.17e-10	Parkinson's disease;
LUAD	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.34	7.31	0.34	1.31e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2066819	1.000	rs59295315	chr12:56708576	G/A	cg26714650	chr12:56694279	CS	-0.85	-7.1	-0.33	5.17e-12	Psoriasis vulgaris;
LUAD	cis	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-7.53	-0.34	3e-13	Neuroticism;
LUAD	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg08885076	chr2:99613938	TSGA10	-0.39	-7.33	-0.34	1.15e-12	Chronic sinus infection;
LUAD	cis	rs6028335	0.674	rs66476511	chr20:37605303	T/A	cg27660920	chr20:37554817	FAM83D	0.51	6.46	0.3	2.95e-10	Alcohol and nicotine co-dependence;
LUAD	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg07343612	chr16:622815	PIGQ	-0.79	-15.58	-0.6	1.46e-43	Height;
LUAD	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.33e-13	Menopause (age at onset);
LUAD	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg23985595	chr17:80112537	CCDC57	-0.53	-9.92	-0.43	5.5e-21	Life satisfaction;
LUAD	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg14668632	chr7:2872130	GNA12	-0.68	-11.59	-0.49	3.7e-27	Height;
LUAD	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg10518543	chr12:38710700	ALG10B	0.42	6.42	0.3	3.65e-10	Bladder cancer;
LUAD	cis	rs6500395	1.000	rs7187513	chr16:48591638	T/C	cg04672837	chr16:48644449	N4BP1	0.38	6.49	0.3	2.41e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	6.78	0.31	4.09e-11	Personality dimensions;
LUAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg12432903	chr7:1882776	MAD1L1	-0.45	-7.28	-0.33	1.66e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg26597838	chr10:835615	NA	0.84	11.25	0.48	7.49e-26	Eosinophil percentage of granulocytes;
LUAD	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg18198730	chr1:247681584	NA	0.47	8.04	0.36	9.26e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs1160297	0.576	rs1451458	chr2:53088905	G/C	cg07782112	chr2:53107842	NA	0.39	8.34	0.38	1.09e-15	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg16647868	chr5:131706066	SLC22A5	-0.49	-7.69	-0.35	1.04e-13	Breast cancer;
LUAD	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18404041	chr3:52824283	ITIH1	-0.59	-12.0	-0.5	9.27e-29	Bipolar disorder;
LUAD	cis	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg27411982	chr8:10470053	RP1L1	-0.4	-7.11	-0.33	4.87e-12	Systolic blood pressure;
LUAD	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg25985355	chr7:65971099	NA	-0.55	-6.85	-0.32	2.55e-11	Diabetic kidney disease;
LUAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00149659	chr3:10157352	C3orf10	0.56	7.19	0.33	2.87e-12	Alzheimer's disease;
LUAD	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg11250194	chr11:61601937	FADS2	-0.46	-6.65	-0.31	9.32e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg10295955	chr4:187884368	NA	1.11	26.6	0.79	2.53e-92	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs250585	1.000	rs250589	chr16:23397248	C/T	cg00143387	chr16:23521605	GGA2	0.53	6.62	0.31	1.09e-10	Egg allergy;
LUAD	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg00852783	chr1:26633632	UBXN11	0.46	7.61	0.35	1.83e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2274273	1.000	rs57970196	chr14:55600405	C/T	cg04306507	chr14:55594613	LGALS3	0.38	7.69	0.35	1.07e-13	Protein biomarker;
LUAD	cis	rs117623576	1.000	rs117623576	chr10:32387808	C/T	cg03047570	chr10:32398778	NA	-0.94	-10.27	-0.45	3.15e-22	Anti-saccade response;
LUAD	cis	rs11690462	0.963	rs12471849	chr2:26559825	C/G	cg13255216	chr2:26625047	C2orf39	-0.36	-6.36	-0.3	5.3e-10	Coronary artery disease;
LUAD	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg14343924	chr8:8086146	FLJ10661	-0.44	-7.02	-0.32	8.72e-12	Neuroticism;
LUAD	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg03732007	chr1:2071316	PRKCZ	0.34	6.96	0.32	1.33e-11	Height;
LUAD	cis	rs7633770	0.735	rs12491236	chr3:46688481	C/T	cg11219411	chr3:46661640	NA	-0.48	-10.18	-0.44	6.57e-22	Coronary artery disease;
LUAD	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg00277334	chr10:82204260	NA	0.55	9.13	0.41	2.76e-18	Post bronchodilator FEV1;
LUAD	cis	rs76878669	0.561	rs7125752	chr11:66162419	C/T	cg18002602	chr11:66138449	SLC29A2	-0.5	-10.51	-0.45	4.19e-23	Educational attainment (years of education);
LUAD	cis	rs7177699	0.557	rs7178051	chr15:79118296	A/G	cg15571903	chr15:79123663	NA	0.4	8.0	0.36	1.24e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs2239547	0.525	rs2246556	chr3:53027983	T/C	cg18404041	chr3:52824283	ITIH1	0.43	7.79	0.35	5.34e-14	Schizophrenia;
LUAD	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg16405210	chr4:1374714	KIAA1530	0.47	7.54	0.34	2.98e-13	Obesity-related traits;
LUAD	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg07432352	chr17:45403706	C17orf57	-0.41	-8.03	-0.36	9.67e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6740322	0.841	rs10211126	chr2:43551416	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.76	-11.39	-0.48	2.04e-26	Coronary artery disease;
LUAD	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg24634471	chr8:143751801	JRK	-0.41	-6.45	-0.3	3.06e-10	Schizophrenia;
LUAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg10150615	chr22:24372951	LOC391322	0.4	6.62	0.31	1.1e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11585357	0.895	rs2501795	chr1:17633499	A/G	cg08277548	chr1:17600880	PADI3	-0.8	-12.58	-0.52	4.74e-31	Hair shape;
LUAD	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.13	-0.41	2.77e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs807669	0.525	rs9604934	chr22:19194868	C/T	cg02655711	chr22:19163373	SLC25A1	0.57	10.83	0.47	2.67e-24	Metabolite levels;
LUAD	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg26384229	chr12:38710491	ALG10B	-0.37	-6.37	-0.3	5.07e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg09976142	chr9:130955436	CIZ1	0.45	8.29	0.37	1.57e-15	Attention deficit hyperactivity disorder;
LUAD	cis	rs11677416	1.000	rs4848303	chr2:113552698	A/G	cg27083787	chr2:113543245	IL1A	0.4	6.87	0.32	2.35e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg09658497	chr7:2847517	GNA12	-0.54	-9.09	-0.4	3.74e-18	Height;
LUAD	cis	rs7010267	0.570	rs2326194	chr8:120043960	C/T	cg01975934	chr8:119970761	NA	-0.34	-6.43	-0.3	3.5e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg02018176	chr4:1364513	KIAA1530	0.47	8.54	0.38	2.48e-16	Longevity;
LUAD	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg24531977	chr5:56204891	C5orf35	-0.48	-7.95	-0.36	1.72e-14	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.25	0.37	2.06e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg09324608	chr17:30823087	MYO1D	0.43	7.78	0.35	5.55e-14	Schizophrenia;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27172057	chr12:64616385	C12orf66	0.43	6.62	0.31	1.06e-10	Gut microbiome composition (summer);
LUAD	cis	rs6430585	0.941	rs10496737	chr2:136540083	A/G	cg07169764	chr2:136633963	MCM6	0.63	8.16	0.37	3.82e-15	Corneal structure;
LUAD	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg20891283	chr12:69753455	YEATS4	0.44	7.11	0.33	4.94e-12	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs3942852	0.703	rs11039513	chr11:48107204	C/T	cg15704280	chr7:45808275	SEPT13	0.69	10.15	0.44	8.41e-22	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg06131755	chr6:160182447	ACAT2	0.46	6.96	0.32	1.27e-11	Age-related macular degeneration (geographic atrophy);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg23332732	chr12:26986274	ITPR2	-0.46	-7.7	-0.35	9.97e-14	Schizophrenia;
LUAD	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg27266060	chr8:22091797	NA	0.45	8.23	0.37	2.27e-15	Hypertriglyceridemia;
LUAD	cis	rs7943953	0.714	rs12806001	chr11:59201347	T/C	cg00706994	chr11:59190310	OR5A2	0.34	6.37	0.3	4.95e-10	Odorant perception (&beta-ionone);
LUAD	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg02461776	chr11:598696	PHRF1	0.47	6.66	0.31	8.37e-11	Systemic lupus erythematosus;
LUAD	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg17264618	chr3:40429014	ENTPD3	0.37	8.12	0.37	5.28e-15	Renal cell carcinoma;
LUAD	cis	rs68170813	0.559	rs56933300	chr7:106953278	A/AGGACCTCGGCAGAAGCC	cg23024343	chr7:107201750	COG5	0.52	6.93	0.32	1.55e-11	Coronary artery disease;
LUAD	cis	rs6734238	1.000	rs6734238	chr2:113841030	A/G	cg09040174	chr2:113837401	NA	0.42	6.93	0.32	1.58e-11	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
LUAD	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.87	0.36	3.09e-14	Breast cancer;
LUAD	trans	rs6561151	0.681	rs2121037	chr13:44471317	C/T	cg17145862	chr1:211918768	LPGAT1	0.53	7.4	0.34	7.65e-13	Crohn's disease;
LUAD	cis	rs7827545	1.000	rs62523736	chr8:135560916	A/T	cg17885191	chr8:135476712	NA	0.54	8.64	0.39	1.14e-16	Hypertension (SNP x SNP interaction);
LUAD	cis	rs12545109	0.571	rs1370306	chr8:57299137	C/G	cg21220214	chr8:57350948	NA	-0.64	-8.86	-0.4	2.32e-17	Obesity-related traits;
LUAD	cis	rs300703	0.719	rs446488	chr2:195365	T/C	cg21211680	chr2:198530	NA	0.64	8.73	0.39	5.9e-17	Blood protein levels;
LUAD	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg03037974	chr15:76606532	NA	0.41	8.82	0.39	2.95e-17	Blood metabolite levels;
LUAD	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.55	11.15	0.48	1.69e-25	Monocyte percentage of white cells;
LUAD	cis	rs68170813	0.559	rs3823959	chr7:107009379	T/G	cg02696742	chr7:106810147	HBP1	-0.79	-10.73	-0.46	6.22e-24	Coronary artery disease;
LUAD	trans	rs459571	0.715	rs401826	chr9:136890591	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.66	-9.57	-0.42	8.98e-20	Platelet distribution width;
LUAD	cis	rs1395	0.922	rs13404327	chr2:27519153	G/T	cg23587288	chr2:27483067	SLC30A3	-0.38	-7.42	-0.34	6.57e-13	Blood metabolite levels;
LUAD	trans	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	15.95	0.61	3.53e-45	Exhaled nitric oxide levels;
LUAD	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg25233709	chr10:116636983	FAM160B1	0.41	8.13	0.37	4.89e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg05896524	chr21:47604654	C21orf56	-0.51	-8.6	-0.39	1.62e-16	Testicular germ cell tumor;
LUAD	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg08470875	chr2:26401718	FAM59B	0.64	8.64	0.39	1.15e-16	Gut microbiome composition (summer);
LUAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg24642844	chr7:1081250	C7orf50	-0.96	-14.26	-0.57	6.09e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg27454412	chr7:1067447	C7orf50	-0.37	-6.6	-0.31	1.22e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg08798685	chr6:27730294	NA	-0.42	-6.7	-0.31	6.5500000000000006e-11	Parkinson's disease;
LUAD	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg05991184	chr2:219186017	PNKD	0.37	6.94	0.32	1.48e-11	Colorectal cancer;
LUAD	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg09085632	chr11:111637200	PPP2R1B	0.86	15.23	0.6	4.7e-42	Primary sclerosing cholangitis;
LUAD	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg04851639	chr8:1020857	NA	-0.38	-9.41	-0.42	3.19e-19	Schizophrenia;
LUAD	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg05725404	chr16:58534157	NDRG4	-0.73	-7.59	-0.35	2.1e-13	Schizophrenia;
LUAD	cis	rs1371614	0.635	rs12612520	chr2:27137307	C/T	cg00617064	chr2:27272375	NA	0.35	6.72	0.31	5.8200000000000003e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.94	0.44	4.66e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg24818145	chr4:99064322	C4orf37	0.47	8.01	0.36	1.09e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg26338869	chr17:61819248	STRADA	-0.39	-6.55	-0.3	1.72e-10	Prudent dietary pattern;
LUAD	cis	rs1524976	1.000	rs2177685	chr3:65491171	T/C	cg16238336	chr3:65465873	MAGI1	-0.7	-7.69	-0.35	1.03e-13	PR interval;
LUAD	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg19875535	chr5:140030758	IK	0.48	8.06	0.36	8.14e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg19163074	chr7:65112434	INTS4L2	0.44	6.75	0.31	4.79e-11	Aortic root size;
LUAD	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg14686297	chr22:46650375	NA	-0.38	-6.57	-0.3	1.44e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg12407791	chr17:73824354	UNC13D	-0.32	-6.72	-0.31	6.05e-11	White matter hyperintensity burden;
LUAD	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.79	-0.35	5.27e-14	Neutrophil percentage of white cells;
LUAD	cis	rs2070677	0.935	rs12245634	chr10:135420002	A/G	cg20169779	chr10:135381914	SYCE1	-0.52	-8.14	-0.37	4.47e-15	Gout;
LUAD	cis	rs6688613	0.649	rs2280995	chr1:166846069	A/G	cg07049167	chr1:166818506	POGK	0.58	8.92	0.4	1.39e-17	Refractive astigmatism;
LUAD	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11644478	chr21:40555479	PSMG1	0.7	11.8	0.5	5.71e-28	Cognitive function;
LUAD	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg18138036	chr10:133769891	PPP2R2D	0.4	6.46	0.3	2.85e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg25036284	chr2:26402008	FAM59B	0.7	8.65	0.39	1.05e-16	Gut microbiome composition (summer);
LUAD	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg04414720	chr1:150670196	GOLPH3L	0.67	11.79	0.5	6.3e-28	Melanoma;
LUAD	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg22166914	chr1:53195759	ZYG11B	0.47	7.86	0.36	3.2e-14	Monocyte count;
LUAD	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.86	-0.36	3.15e-14	Diabetic kidney disease;
LUAD	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg13770153	chr20:60521292	NA	-0.49	-8.26	-0.37	1.88e-15	Body mass index;
LUAD	cis	rs10129255	0.500	rs11628999	chr14:107208446	C/T	cg23076370	chr14:107095027	NA	-0.42	-8.53	-0.38	2.62e-16	Kawasaki disease;
LUAD	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg17279839	chr7:150038598	RARRES2	-0.44	-7.61	-0.35	1.81e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg20673091	chr1:2541236	MMEL1	-0.38	-8.07	-0.37	7.32e-15	Ulcerative colitis;
LUAD	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg02775129	chr4:119771670	NA	-0.86	-8.05	-0.36	8.54e-15	Cannabis dependence symptom count;
LUAD	cis	rs3849570	0.922	rs3772895	chr3:81769493	A/G	cg07356753	chr3:81810745	GBE1	-0.71	-12.53	-0.52	7.37e-31	Waist circumference;Body mass index;
LUAD	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg23533926	chr12:111358616	MYL2	-0.42	-7.21	-0.33	2.63e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg18621852	chr3:10150065	C3orf24	0.5	7.65	0.35	1.34e-13	Alzheimer's disease;
LUAD	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	8.8	0.39	3.47e-17	Ileal carcinoids;
LUAD	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00684032	chr4:1343700	KIAA1530	0.48	7.86	0.36	3.31e-14	Obesity-related traits;
LUAD	cis	rs3761847	0.593	rs1468673	chr9:123809890	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	6.68	0.31	7.37e-11	Rheumatoid arthritis;
LUAD	cis	rs4691139	1.000	rs6536883	chr4:165900704	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.45	-8.78	-0.39	3.94e-17	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs7210086	0.821	rs3935123	chr17:70641183	C/T	cg04206342	chr17:70636940	NA	0.34	6.65	0.31	9.31e-11	Ulcerative colitis;
LUAD	cis	rs9393692	0.557	rs6918325	chr6:26327965	T/G	cg00631329	chr6:26305371	NA	-0.53	-8.67	-0.39	9.29e-17	Educational attainment;
LUAD	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg02951883	chr7:2050386	MAD1L1	0.5	6.9	0.32	1.94e-11	Neuroticism;
LUAD	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg04450456	chr4:17643702	FAM184B	-0.42	-7.83	-0.36	3.93e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs714515	0.934	rs2213732	chr1:172333595	G/A	cg14508705	chr1:172360182	DNM3	-0.36	-6.39	-0.3	4.46e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg18932078	chr1:2524107	MMEL1	-0.39	-7.3	-0.33	1.46e-12	Ulcerative colitis;
LUAD	cis	rs7593730	1.000	rs1110209	chr2:161199498	T/C	cg22609984	chr2:161126801	NA	0.45	7.27	0.33	1.73e-12	Type 2 diabetes;
LUAD	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.02	-0.36	1.05e-14	Diabetic kidney disease;
LUAD	cis	rs17253792	0.732	rs28380739	chr14:56088402	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	trans	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg26811252	chr16:29126840	RRN3P2	0.64	10.92	0.47	1.27e-24	Menopause (age at onset);
LUAD	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg15226275	chr6:116381976	FRK	0.23	7.64	0.35	1.43e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs7737355	0.853	rs7730810	chr5:130781179	T/C	cg25547332	chr5:131281432	NA	-0.43	-6.99	-0.32	1.08e-11	Life satisfaction;
LUAD	cis	rs11650175	0.634	rs9989482	chr17:63783219	C/G	cg07283582	chr17:63770753	CCDC46	0.32	6.4	0.3	4.22e-10	Chin dimples;
LUAD	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg02551604	chr5:131831745	NA	-0.61	-10.02	-0.44	2.39e-21	Asthma (sex interaction);
LUAD	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg05340658	chr4:99064831	C4orf37	0.54	9.18	0.41	1.91e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg24558204	chr6:135376177	HBS1L	0.48	8.88	0.4	1.94e-17	Red blood cell count;
LUAD	cis	rs6782228	0.628	rs7641584	chr3:128392630	G/C	cg16766828	chr3:128327626	NA	-0.39	-7.13	-0.33	4.34e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-20.46	-0.71	3.39e-65	Height;
LUAD	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg09359103	chr1:154839909	KCNN3	-0.93	-21.5	-0.72	8.12e-70	Prostate cancer;
LUAD	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg05043794	chr9:111880884	C9orf5	-0.39	-6.49	-0.3	2.39e-10	Menarche (age at onset);
LUAD	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg18132916	chr6:79620363	NA	-0.47	-7.95	-0.36	1.72e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs62458065	0.513	rs7805536	chr7:32573570	T/C	cg20159608	chr7:32802032	NA	-0.68	-10.19	-0.44	5.94e-22	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg11062466	chr8:58055876	NA	0.67	8.94	0.4	1.26e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg05283184	chr6:79620031	NA	-0.6	-12.05	-0.51	5.77e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs7680126	0.633	rs74469609	chr4:10294424	G/A	cg02734326	chr4:10020555	SLC2A9	-0.48	-6.37	-0.3	4.98e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.98	0.32	1.12e-11	Hypertriglyceridemia;
LUAD	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18404041	chr3:52824283	ITIH1	-0.59	-12.0	-0.5	9.27e-29	Bipolar disorder;
LUAD	trans	rs4650994	0.505	rs2811291	chr1:178574217	C/T	cg05059571	chr16:84539110	KIAA1609	0.7	12.13	0.51	2.89e-29	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.7	-0.31	6.51e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg16797656	chr11:68205561	LRP5	0.47	9.3	0.41	7.5e-19	Total body bone mineral density;
LUAD	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.54	-0.38	2.4e-16	Alzheimer's disease (late onset);
LUAD	cis	rs9322817	0.691	rs1933804	chr6:105341969	G/C	cg02098413	chr6:105308735	HACE1	0.42	9.02	0.4	6.69e-18	Thyroid stimulating hormone;
LUAD	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg17644776	chr2:200775616	C2orf69	-0.5	-6.43	-0.3	3.47e-10	Schizophrenia;
LUAD	cis	rs6782228	0.606	rs4857861	chr3:128406767	T/C	cg16766828	chr3:128327626	NA	-0.39	-7.43	-0.34	6.12e-13	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg18806716	chr10:30721971	MAP3K8	-0.77	-16.59	-0.63	5.9e-48	Inflammatory bowel disease;
LUAD	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg04282206	chr17:62833786	PLEKHM1P	-0.54	-8.19	-0.37	3.22e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg10978503	chr1:24200527	CNR2	0.59	12.81	0.53	5.88e-32	Immature fraction of reticulocytes;
LUAD	cis	rs6424115	0.830	rs12744386	chr1:24168019	C/T	cg15997130	chr1:24165203	NA	-0.55	-9.35	-0.41	5.18e-19	Immature fraction of reticulocytes;
LUAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg24813613	chr7:1882135	MAD1L1	-0.46	-7.21	-0.33	2.59e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.46	7.43	0.34	5.91e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73198271	0.562	rs964773	chr8:8651314	T/C	cg01851573	chr8:8652454	MFHAS1	0.7	11.29	0.48	4.91e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2236918	0.687	rs1776176	chr1:242012554	C/T	cg21919602	chr1:242011447	EXO1	-0.41	-6.62	-0.31	1.09e-10	Menopause (age at onset);
LUAD	trans	rs2929451	0.566	rs17658270	chr8:9153619	C/G	cg14343924	chr8:8086146	FLJ10661	0.47	7.06	0.32	7.04e-12	Nose size;
LUAD	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-8.71	-0.39	6.9e-17	Cognitive function;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg25169641	chr17:43225227	HEXIM1	-0.38	-6.49	-0.3	2.34e-10	Cancer;
LUAD	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg27454412	chr7:1067447	C7orf50	-0.42	-7.86	-0.36	3.25e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.58	-10.03	-0.44	2.26e-21	Menarche (age at onset);
LUAD	cis	rs67366981	1.000	rs2287379	chr14:77705411	A/C	cg22824376	chr14:77648248	TMEM63C	0.59	6.45	0.3	3.12e-10	Obsessive-compulsive symptoms;
LUAD	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg11822812	chr5:140052017	DND1	0.37	6.45	0.3	3.11e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg14196790	chr5:131705035	SLC22A5	-0.38	-6.58	-0.3	1.4e-10	Blood metabolite levels;
LUAD	cis	rs9473147	0.543	rs4711880	chr6:47480676	A/G	cg12968598	chr6:47444699	CD2AP	0.36	6.46	0.3	2.81e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18404041	chr3:52824283	ITIH1	-0.6	-12.12	-0.51	3.31e-29	Bipolar disorder;
LUAD	trans	rs853679	0.607	rs72854513	chr6:28265954	A/T	cg01620082	chr3:125678407	NA	-1.07	-10.43	-0.45	8.25e-23	Depression;
LUAD	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg01191920	chr7:158217561	PTPRN2	-0.74	-16.97	-0.64	1.18e-49	Obesity-related traits;
LUAD	cis	rs4253772	0.575	rs9615983	chr22:46793314	G/A	cg00784671	chr22:46762841	CELSR1	-0.62	-7.63	-0.35	1.58e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg23649088	chr2:200775458	C2orf69	0.79	14.7	0.58	7.95e-40	Osteoporosis;
LUAD	cis	rs7122539	0.646	rs627330	chr11:66602099	C/T	cg24851651	chr11:66362959	CCS	0.37	6.79	0.31	3.9e-11	HIV-1 susceptibility;
LUAD	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.54e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18099408	chr3:52552593	STAB1	0.47	8.19	0.37	3.16e-15	Bipolar disorder;
LUAD	trans	rs4145130	1	rs4145130	chr6:95422618	A/T	cg24657206	chr5:115912020	SEMA6A	-0.71	-6.36	-0.3	5.34e-10	Methotrexate phramacokinetics (acute lymphoblastic leukemia);
LUAD	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg14228332	chr4:119757509	SEC24D	-0.83	-7.51	-0.34	3.6e-13	Cannabis dependence symptom count;
LUAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg26554054	chr8:600488	NA	0.81	8.02	0.36	1.02e-14	IgG glycosylation;
LUAD	cis	rs2302190	0.882	rs6503869	chr17:56637461	C/G	cg25885038	chr17:56607967	SEPT4	-0.51	-8.23	-0.37	2.35e-15	Vitamin D levels;
LUAD	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg05036130	chr6:150231994	NA	0.28	6.51	0.3	2.17e-10	Testicular germ cell tumor;
LUAD	cis	rs10979	0.597	rs9496691	chr6:143910970	T/C	cg25407410	chr6:143891975	LOC285740	-0.53	-7.55	-0.34	2.63e-13	Hypospadias;
LUAD	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg16479474	chr6:28041457	NA	0.44	7.44	0.34	5.75e-13	Depression;
LUAD	cis	rs11178918	0.585	rs10879328	chr12:72146140	A/T	cg10168894	chr12:72148281	RAB21	-0.53	-6.46	-0.3	2.87e-10	Economic and political preferences (time);
LUAD	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg20307385	chr11:47447363	PSMC3	0.53	7.91	0.36	2.25e-14	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs1232027	0.656	rs1650737	chr5:80001785	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.45	-7.27	-0.33	1.78e-12	Huntington's disease progression;
LUAD	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.71	-0.35	9.27e-14	Blood metabolite levels;
LUAD	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg25452165	chr22:42524984	CYP2D6	-0.38	-6.36	-0.3	5.15e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs57994353	0.793	rs12552167	chr9:139322927	C/T	cg13611204	chr9:139324423	INPP5E	-0.37	-6.63	-0.31	1.03e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	trans	rs747782	0.528	rs16905753	chr11:48285906	C/T	cg15704280	chr7:45808275	SEPT13	0.65	7.82	0.36	4.34e-14	Intraocular pressure;
LUAD	cis	rs490234	0.616	rs2841325	chr9:128163620	C/G	cg14078157	chr9:128172775	NA	0.43	8.07	0.37	7.44e-15	Mean arterial pressure;
LUAD	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs61869271	0.871	rs12098332	chr10:116728074	A/T	cg23260525	chr10:116636907	FAM160B1	0.34	6.97	0.32	1.23e-11	Tonsillectomy;
LUAD	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg02269571	chr22:50332266	NA	0.61	9.3	0.41	7.6e-19	Schizophrenia;
LUAD	cis	rs2535633	0.594	rs2581789	chr3:53096230	C/T	cg18404041	chr3:52824283	ITIH1	0.42	7.42	0.34	6.2800000000000005e-13	Body mass index;
LUAD	cis	rs13315871	0.929	rs13066351	chr3:58398215	C/T	cg12435725	chr3:58293450	RPP14	-0.71	-7.37	-0.34	8.8e-13	Cholesterol, total;
LUAD	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.61	12.86	0.53	3.5e-32	Monocyte percentage of white cells;
LUAD	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg15445000	chr17:37608096	MED1	0.44	8.24	0.37	2.18e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01570182	chr17:44337453	NA	1.12	17.22	0.64	9.56e-51	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.57	7.65	0.35	1.39e-13	Renal function-related traits (BUN);
LUAD	cis	rs597583	0.671	rs4938401	chr11:117399605	T/G	cg27161313	chr11:117392002	DSCAML1	-0.59	-9.16	-0.41	2.23e-18	Putamen volume;
LUAD	cis	rs11756438	0.572	rs2638551	chr6:118998756	T/C	cg18833306	chr6:118973337	C6orf204	0.54	9.67	0.43	4.03e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03517284	chr6:25882590	NA	-0.5	-7.43	-0.34	6.08e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs6484504	0.625	rs7112412	chr11:31370271	T/C	cg26647111	chr11:31128758	NA	0.43	7.59	0.35	2.11e-13	Red blood cell count;
LUAD	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg05991184	chr2:219186017	PNKD	0.37	7.02	0.32	9.03e-12	Colorectal cancer;
LUAD	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg22906224	chr7:99728672	NA	-0.64	-11.13	-0.48	2e-25	Coronary artery disease;
LUAD	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg01689657	chr7:91764605	CYP51A1	-0.29	-6.85	-0.32	2.66e-11	Breast cancer;
LUAD	cis	rs59698941	0.943	rs12516596	chr5:132273608	C/G	cg14825688	chr5:132208181	LEAP2	-0.48	-6.46	-0.3	2.96e-10	Apolipoprotein A-IV levels;
LUAD	trans	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg18335740	chr13:41363409	SLC25A15	0.53	9.28	0.41	9.2e-19	Lewy body disease;
LUAD	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.6	0.31	1.27e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs6840360	0.593	rs1877186	chr4:152692418	C/G	cg22705602	chr4:152727874	NA	-0.48	-9.24	-0.41	1.25e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs751728	0.965	rs9394165	chr6:33731408	G/A	cg13859433	chr6:33739653	LEMD2	-0.38	-8.99	-0.4	8.51e-18	Crohn's disease;
LUAD	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg09835421	chr16:68378352	PRMT7	-0.64	-6.58	-0.3	1.35e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg09085632	chr11:111637200	PPP2R1B	0.67	9.88	0.43	7.38e-21	Primary sclerosing cholangitis;
LUAD	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg26384229	chr12:38710491	ALG10B	0.49	7.91	0.36	2.27e-14	Bladder cancer;
LUAD	cis	rs60154123	0.686	rs227222	chr1:210191272	T/C	cg22029157	chr1:209979665	IRF6	-0.69	-7.21	-0.33	2.55e-12	Coronary artery disease;
LUAD	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg08754654	chr5:154026448	NA	0.51	8.77	0.39	4.56e-17	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.3	0.33	1.47e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs6988985	0.589	rs6987382	chr8:143987191	G/A	cg10324643	chr8:143916377	GML	0.32	6.75	0.31	5e-11	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg19717773	chr7:2847554	GNA12	-0.53	-9.88	-0.43	7.7e-21	Height;
LUAD	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg24163568	chr5:669837	TPPP	0.36	6.76	0.31	4.52e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg13334819	chr7:99746414	C7orf59	0.64	10.06	0.44	1.7e-21	Coronary artery disease;
LUAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg11062466	chr8:58055876	NA	0.44	6.55	0.3	1.71e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg20203395	chr5:56204925	C5orf35	-0.83	-11.94	-0.5	1.57e-28	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg05340658	chr4:99064831	C4orf37	-0.52	-8.83	-0.39	2.71e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10905065	0.833	rs6602259	chr10:5844628	C/T	cg11519256	chr10:5708881	ASB13	0.41	7.04	0.32	8.02e-12	Menopause (age at onset);
LUAD	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.77	0.39	4.32e-17	Lung cancer in ever smokers;
LUAD	cis	rs28830936	0.510	rs7174099	chr15:42099059	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.57	-13.8	-0.56	4.97e-36	Diastolic blood pressure;
LUAD	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg23758822	chr17:41437982	NA	1.01	21.34	0.72	4.24e-69	Menopause (age at onset);
LUAD	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.84	16.72	0.63	1.51e-48	Birth weight;
LUAD	cis	rs295140	0.803	rs4516415	chr2:201129608	C/G	cg23649088	chr2:200775458	C2orf69	-0.39	-6.42	-0.3	3.63e-10	QT interval;
LUAD	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	7.33	0.34	1.18e-12	Platelet count;
LUAD	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.54	-0.3	1.77e-10	Breast cancer;
LUAD	cis	rs684232	0.602	rs331010	chr17:547124	G/A	cg12384639	chr17:618140	VPS53	0.48	8.26	0.37	1.94e-15	Prostate cancer;
LUAD	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.27	-6.94	-0.32	1.48e-11	Schizophrenia;
LUAD	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg01884057	chr2:25150051	NA	0.36	7.43	0.34	6.1e-13	Body mass index;
LUAD	trans	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg25482853	chr8:67687455	SGK3	1.06	16.65	0.63	2.99e-48	Obesity-related traits;
LUAD	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg04398451	chr17:18023971	MYO15A	0.78	14.11	0.57	2.51e-37	Total body bone mineral density;
LUAD	trans	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg14917512	chr19:3094685	GNA11	-0.58	-6.92	-0.32	1.73e-11	Diabetic kidney disease;
LUAD	cis	rs7178572	0.568	rs11632966	chr15:77621805	A/C	cg15453836	chr15:77711506	NA	-0.36	-6.41	-0.3	3.9e-10	Type 2 diabetes;
LUAD	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg02160872	chr5:212506	CCDC127	-0.51	-6.61	-0.31	1.16e-10	Breast cancer;
LUAD	cis	rs3087591	1.000	rs2952989	chr17:29516113	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	6.85	0.32	2.65e-11	Hip circumference;
LUAD	cis	rs7709909	0.720	rs6864512	chr5:79985947	A/C	cg24059623	chr5:79951536	MSH3;DHFR	0.46	8.58	0.39	1.78e-16	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.97	20.88	0.71	4.9e-67	Chronic sinus infection;
LUAD	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg23750338	chr8:142222470	SLC45A4	0.34	6.63	0.31	1.01e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs12208915	0.731	rs9443630	chr6:79661777	G/T	cg18132916	chr6:79620363	NA	0.52	6.96	0.32	1.33e-11	Left atrial antero-posterior diameter;
LUAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.46	-7.43	-0.34	6.23e-13	Renal function-related traits (BUN);
LUAD	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg24558204	chr6:135376177	HBS1L	0.5	8.7	0.39	7.68e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7680126	0.596	rs10022911	chr4:10140551	A/G	cg02734326	chr4:10020555	SLC2A9	-0.48	-6.64	-0.31	9.6e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9900062	0.519	rs2676293	chr17:62710461	T/C	cg02097616	chr17:62675921	NA	0.7	11.65	0.49	2.18e-27	QT interval;
LUAD	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg04602696	chr16:88846723	FAM38A	-0.5	-8.31	-0.37	1.31e-15	Glycated hemoglobin levels;
LUAD	cis	rs72772090	0.539	rs72773942	chr5:96123366	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-7.06	-0.32	6.88e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg07343612	chr16:622815	PIGQ	-0.82	-16.03	-0.61	1.54e-45	Height;
LUAD	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.1	-0.33	5.25e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg15017067	chr4:17643749	FAM184B	-0.33	-6.42	-0.3	3.67e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg24308560	chr3:49941425	MST1R	0.39	6.46	0.3	2.81e-10	Body mass index;
LUAD	cis	rs6782228	0.606	rs7613073	chr3:128388503	T/G	cg16766828	chr3:128327626	NA	-0.39	-7.19	-0.33	2.87e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs68170813	0.559	rs6951639	chr7:106817639	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-11.09	-0.47	3.01e-25	Coronary artery disease;
LUAD	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg06740227	chr12:86229804	RASSF9	0.38	6.81	0.31	3.4e-11	Major depressive disorder;
LUAD	cis	rs2554380	0.943	rs2562777	chr15:84366066	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.59	-8.76	-0.39	4.89e-17	Height;
LUAD	trans	rs2770228	1.000	rs9582143	chr13:98166750	A/G	cg09782245	chr16:30845959	NA	-0.77	-6.38	-0.3	4.52e-10	Metabolite levels (Dihydroxy docosatrienoic acid);
LUAD	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg10556349	chr10:835070	NA	0.6	7.64	0.35	1.48e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg08873628	chr1:175162347	KIAA0040	0.39	6.64	0.31	9.74e-11	Alcohol dependence;
LUAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg19318889	chr4:1322082	MAEA	-0.44	-7.25	-0.33	1.97e-12	Obesity-related traits;
LUAD	cis	rs4523957	0.855	rs9896535	chr17:2133205	C/T	cg16513277	chr17:2031491	SMG6	-0.82	-15.37	-0.6	1.09e-42	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.64	11.61	0.49	3.16e-27	Lymphocyte counts;
LUAD	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.34	-0.34	1.08e-12	Bipolar disorder;
LUAD	trans	rs8073060	0.586	rs72828038	chr17:33893908	C/A	cg19694781	chr19:47549865	TMEM160	1.23	19.54	0.69	4.86e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs59698941	0.943	rs12520928	chr5:132305891	C/A	cg14825688	chr5:132208181	LEAP2	-0.47	-6.51	-0.3	2.12e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs2274273	0.773	rs8006525	chr14:55813394	T/G	cg04306507	chr14:55594613	LGALS3	0.41	8.6	0.39	1.52e-16	Protein biomarker;
LUAD	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg21017887	chr14:105400489	NA	0.75	14.39	0.57	1.64e-38	Rheumatoid arthritis;
LUAD	cis	rs8099014	0.648	rs4940704	chr18:56115507	A/G	cg12907477	chr18:56117327	MIR122	0.51	7.07	0.33	6.27e-12	Platelet count;
LUAD	cis	rs9796	0.866	rs544744	chr15:41366290	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.38	-7.21	-0.33	2.54e-12	Menopause (age at onset);
LUAD	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg03806693	chr22:41940476	POLR3H	-0.65	-9.76	-0.43	1.97e-20	Vitiligo;
LUAD	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg10356904	chr22:49881777	NA	-0.4	-7.55	-0.34	2.73e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs1451375	0.617	rs2876829	chr7:50566762	A/G	cg18232548	chr7:50535776	DDC	0.62	8.73	0.39	5.99e-17	Malaria;
LUAD	cis	rs4481887	0.830	rs4364913	chr1:248515635	C/A	cg13385794	chr1:248469461	NA	0.26	7.0	0.32	1.01e-11	Common traits (Other);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg06622735	chr5:473452	SLC9A3;LOC25845	-0.38	-6.7	-0.31	6.57e-11	Schizophrenia;
LUAD	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg08027265	chr7:2291960	NA	-0.42	-7.1	-0.33	5.47e-12	Schizophrenia;
LUAD	cis	rs7072216	0.881	rs755126	chr10:100148951	G/A	cg26618903	chr10:100175079	PYROXD2	-0.3	-6.51	-0.3	2.13e-10	Metabolite levels;
LUAD	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.08	-0.33	5.93e-12	Blood metabolite levels;
LUAD	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.75e-26	Alzheimer's disease (late onset);
LUAD	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.94	-0.4	1.26e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg12573674	chr2:1569213	NA	-0.56	-8.41	-0.38	6.55e-16	IgG glycosylation;
LUAD	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg13319975	chr6:146136371	FBXO30	-0.59	-9.79	-0.43	1.49e-20	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg22062239	chr16:31106011	VKORC1	0.41	6.55	0.3	1.72e-10	Diastolic blood pressure;
LUAD	cis	rs7937890	0.532	rs2575827	chr11:14475515	A/G	cg23387056	chr11:14280742	SPON1	-0.34	-6.46	-0.3	2.88e-10	Mitochondrial DNA levels;
LUAD	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.22e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg19442545	chr10:75533431	FUT11	-0.47	-7.77	-0.35	5.91e-14	Inflammatory bowel disease;
LUAD	cis	rs9326248	0.581	rs6589582	chr11:116829200	A/C	cg20608306	chr11:116969690	SIK3	0.31	6.98	0.32	1.17e-11	Blood protein levels;
LUAD	cis	rs9863	0.896	rs7311233	chr12:124475940	C/T	cg17723958	chr12:124429295	CCDC92	0.39	6.42	0.3	3.77e-10	White blood cell count;
LUAD	cis	rs617219	0.889	rs1316776	chr5:78430607	C/A	cg25119155	chr5:78426943	BHMT	0.37	6.49	0.3	2.45e-10	Betaine levels in individuals undergoing cardiac evaluation;
LUAD	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg27284194	chr4:1044797	NA	0.69	9.91	0.43	5.79e-21	Recombination rate (females);
LUAD	cis	rs7771547	0.519	rs6917489	chr6:36368169	C/T	cg07856975	chr6:36356162	ETV7	0.59	8.65	0.39	1.06e-16	Platelet distribution width;
LUAD	cis	rs2637266	0.905	rs3923669	chr10:78375047	T/C	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	cis	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.36	-0.34	9.4e-13	Resting heart rate;
LUAD	cis	rs7215564	0.908	rs34914062	chr17:78655909	C/T	cg09596252	chr17:78655493	RPTOR	0.61	6.63	0.31	1e-10	Myopia (pathological);
LUAD	cis	rs2816062	0.786	rs742486	chr1:18900829	G/A	cg18795169	chr1:18902165	NA	-0.93	-22.32	-0.74	1.77e-73	Urate levels in lean individuals;
LUAD	cis	rs7712401	0.623	rs538424	chr5:122228763	G/A	cg19077854	chr5:122220652	SNX24	0.34	6.51	0.3	2.11e-10	Mean platelet volume;
LUAD	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg22681709	chr2:178499509	PDE11A	-0.54	-9.05	-0.4	5.21e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7731657	0.537	rs6885379	chr5:130345372	C/G	cg08523029	chr5:130500466	HINT1	0.59	7.79	0.35	5.38e-14	Fasting plasma glucose;
LUAD	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg00074818	chr8:8560427	CLDN23	0.66	10.12	0.44	1.07e-21	Obesity-related traits;
LUAD	cis	rs68170813	0.559	rs6963917	chr7:106953427	T/G	cg02696742	chr7:106810147	HBP1	-0.76	-10.33	-0.45	1.92e-22	Coronary artery disease;
LUAD	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.86	0.4	2.32e-17	Parkinson's disease;
LUAD	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg12035532	chr1:1886765	KIAA1751	0.41	6.94	0.32	1.45e-11	Body mass index;
LUAD	cis	rs11811982	0.793	rs11800364	chr1:227353932	T/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic disc area;
LUAD	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg16325326	chr1:53192061	ZYG11B	0.47	7.73	0.35	8e-14	Monocyte count;
LUAD	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-20.11	-0.7	1.33e-63	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14893161	chr1:205819251	PM20D1	0.95	23.22	0.75	1.73e-77	Menarche (age at onset);
LUAD	cis	rs10129255	0.518	rs28378320	chr14:107216845	T/C	cg23076370	chr14:107095027	NA	-0.45	-9.0	-0.4	7.53e-18	Kawasaki disease;
LUAD	cis	rs12208915	0.848	rs7774691	chr6:79505798	C/G	cg05283184	chr6:79620031	NA	0.5	6.74	0.31	5.3e-11	Left atrial antero-posterior diameter;
LUAD	cis	rs11690462	0.926	rs12467721	chr2:26558489	T/G	cg13255216	chr2:26625047	C2orf39	0.38	6.61	0.31	1.14e-10	Coronary artery disease;
LUAD	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg09365446	chr1:150670422	GOLPH3L	0.66	12.57	0.52	5.38e-31	Tonsillectomy;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg24142014	chr2:74734760	PCGF1	-0.43	-6.44	-0.3	3.34e-10	Blood protein levels;
LUAD	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg10319629	chr12:132285459	NA	0.36	6.81	0.31	3.36e-11	Migraine;
LUAD	cis	rs887829	0.588	rs7556676	chr2:234658250	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.55	-9.33	-0.41	5.79e-19	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs1997103	0.911	rs11238361	chr7:55395981	A/G	cg17469321	chr7:55412551	NA	0.67	11.48	0.49	9.4e-27	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg14668632	chr7:2872130	GNA12	-0.48	-8.33	-0.38	1.18e-15	Height;
LUAD	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg25208724	chr1:156163844	SLC25A44	0.99	15.38	0.6	9.82e-43	Testicular germ cell tumor;
LUAD	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg03396347	chr1:1875803	NA	-0.6	-14.96	-0.59	6.19e-41	Body mass index;
LUAD	cis	rs76878669	0.515	rs12576299	chr11:66132286	T/C	cg10616300	chr11:66138557	SLC29A2	0.35	7.3	0.33	1.49e-12	Educational attainment (years of education);
LUAD	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg02269571	chr22:50332266	NA	-0.46	-6.87	-0.32	2.25e-11	Schizophrenia;
LUAD	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg19792802	chr11:65647270	CTSW	0.51	6.95	0.32	1.42e-11	Crohn's disease;
LUAD	cis	rs2050392	0.792	rs303434	chr10:30714440	G/A	cg18806716	chr10:30721971	MAP3K8	-0.54	-10.83	-0.47	2.62e-24	Inflammatory bowel disease;
LUAD	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg12756686	chr19:29218302	NA	0.53	6.83	0.31	3.05e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg21775007	chr8:11205619	TDH	0.54	9.76	0.43	1.97e-20	Retinal vascular caliber;
LUAD	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.5	0.3	2.33e-10	Depression;
LUAD	cis	rs739496	0.895	rs7309325	chr12:111849515	G/T	cg10833066	chr12:111807467	FAM109A	0.46	8.26	0.37	1.9e-15	Platelet count;
LUAD	cis	rs73206853	0.764	rs59527539	chr12:110968119	A/G	cg12870014	chr12:110450643	ANKRD13A	0.63	7.35	0.34	1.05e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs17092148	0.887	rs6059915	chr20:33147737	C/G	cg16810054	chr20:33298113	TP53INP2	-0.49	-7.32	-0.34	1.27e-12	Neuroticism;
LUAD	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg20933634	chr6:27740509	NA	-0.53	-8.32	-0.37	1.26e-15	Parkinson's disease;
LUAD	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg03929089	chr4:120376271	NA	-0.92	-17.61	-0.65	1.82e-52	Height;
LUAD	cis	rs9462027	0.628	rs9469857	chr6:34719793	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-8.57	-0.38	1.98e-16	Systemic lupus erythematosus;
LUAD	trans	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg10518543	chr12:38710700	ALG10B	0.39	6.39	0.3	4.49e-10	Morning vs. evening chronotype;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01253856	chr12:98884920	NA	-0.42	-7.0	-0.32	9.79e-12	Cancer;
LUAD	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	13.75	0.56	8.02e-36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg18834416	chr8:37888184	EIF4EBP1	0.39	6.73	0.31	5.54e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4523957	0.671	rs9910849	chr17:2175768	A/G	cg16513277	chr17:2031491	SMG6	0.63	9.79	0.43	1.59e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10911251	0.528	rs10911266	chr1:183115097	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.68	0.31	7.58e-11	Colorectal cancer;
LUAD	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg18198730	chr1:247681584	NA	0.4	7.33	0.34	1.17e-12	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-8.56	-0.38	2.18e-16	Endometrial cancer;
LUAD	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08219700	chr8:58056026	NA	0.68	8.86	0.4	2.31e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg27411982	chr8:10470053	RP1L1	-0.39	-7.12	-0.33	4.55e-12	Neuroticism;
LUAD	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg12292205	chr6:26970375	C6orf41	-0.56	-6.93	-0.32	1.61e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12776158	0.901	rs12413873	chr10:71212091	C/G	cg12610070	chr10:71211762	TSPAN15	-0.34	-6.45	-0.3	3.12e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg12011299	chr4:100065546	ADH4	0.68	12.05	0.51	6.24e-29	Smoking initiation;
LUAD	cis	rs6060717	0.536	rs6058364	chr20:34507890	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.06	-0.32	7.08e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.94e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11890956	chr21:40555474	PSMG1	0.68	11.91	0.5	2.03e-28	Cognitive function;
LUAD	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg04398451	chr17:18023971	MYO15A	-0.77	-14.08	-0.56	3.36e-37	Total body bone mineral density;
LUAD	trans	rs1997103	0.954	rs1917769	chr7:55392325	T/A	cg20935933	chr6:143382018	AIG1	0.54	7.51	0.34	3.44e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs62103177	0.568	rs2365388	chr18:77973702	G/T	cg05926928	chr17:57297772	GDPD1	0.68	7.94	0.36	1.83e-14	Opioid sensitivity;
LUAD	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg26513180	chr16:89883248	FANCA	0.5	8.74	0.39	5.62e-17	Vitiligo;
LUAD	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg03929089	chr4:120376271	NA	0.57	7.13	0.33	4.42e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs597583	0.664	rs4938395	chr11:117384673	C/T	cg27161313	chr11:117392002	DSCAML1	0.52	8.13	0.37	4.77e-15	Putamen volume;
LUAD	cis	rs7737355	0.812	rs251012	chr5:131030295	A/G	cg06307176	chr5:131281290	NA	-0.44	-7.47	-0.34	4.54e-13	Life satisfaction;
LUAD	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg03929089	chr4:120376271	NA	-0.96	-19.69	-0.69	9.6e-62	Height;
LUAD	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg23625390	chr15:77176239	SCAPER	0.38	6.69	0.31	7.18e-11	Blood metabolite levels;
LUAD	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg10792982	chr14:105748885	BRF1	0.39	8.59	0.39	1.73e-16	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg27631724	chr1:11040367	C1orf127	0.53	9.05	0.4	5.25e-18	Ewing sarcoma;
LUAD	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg07917127	chr4:99064746	C4orf37	0.43	6.96	0.32	1.27e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg06618935	chr21:46677482	NA	-0.48	-9.79	-0.43	1.6e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2282300	0.739	rs1765133	chr11:30339400	C/T	cg25418670	chr11:30344373	C11orf46	-0.52	-6.88	-0.32	2.13e-11	Morning vs. evening chronotype;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg21028463	chr17:74733682	MIR636;SFRS2;MFSD11	-0.47	-6.57	-0.3	1.52e-10	Testicular germ cell tumor;
LUAD	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg26513180	chr16:89883248	FANCA	0.78	6.74	0.31	5.14e-11	Skin colour saturation;
LUAD	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg16482183	chr6:26056742	HIST1H1C	0.39	6.39	0.3	4.34e-10	Height;
LUAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg04287289	chr16:89883240	FANCA	-0.67	-12.22	-0.51	1.3e-29	Vitiligo;
LUAD	cis	rs1595825	0.891	rs35817167	chr2:198718928	A/T	cg10547527	chr2:198650123	BOLL	-0.54	-7.61	-0.35	1.8e-13	Ulcerative colitis;
LUAD	cis	rs4950928	0.774	rs4950931	chr1:203164075	G/A	cg17014757	chr1:203156097	CHI3L1	-0.61	-8.64	-0.39	1.18e-16	YKL-40 levels;
LUAD	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.58	-0.3	1.41e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.63	11.12	0.48	2.23e-25	Birth weight;
LUAD	trans	rs6561151	0.718	rs11842000	chr13:44413467	T/C	cg12856521	chr11:46389249	DGKZ	0.95	12.07	0.51	4.91e-29	Crohn's disease;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27141267	chr11:66175971	NA	0.43	6.49	0.3	2.34e-10	Gut microbiome composition (summer);
LUAD	cis	rs8063761	0.689	rs4785763	chr16:90066936	G/T	cg12064134	chr16:90016061	DEF8	-0.42	-7.24	-0.33	2.16e-12	Squamous cell carcinoma;
LUAD	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7180079	1.000	rs62021599	chr15:64535177	G/A	cg08069370	chr15:64387884	SNX1	-0.51	-6.56	-0.3	1.6e-10	Monocyte count;
LUAD	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.04	23.44	0.75	1.77e-78	Chronic sinus infection;
LUAD	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg11814155	chr7:99998594	ZCWPW1	0.43	7.48	0.34	4.27e-13	Platelet count;
LUAD	cis	rs757110	0.902	rs2074310	chr11:17421886	T/C	cg15432903	chr11:17409602	KCNJ11	0.59	10.96	0.47	9.2e-25	Type 2 diabetes;
LUAD	cis	rs220324	0.738	rs9983523	chr21:43578837	C/G	cg08841829	chr21:43638893	ABCG1	-0.52	-6.89	-0.32	2.03e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs412658	0.535	rs1651558	chr19:22089575	A/G	cg05197062	chr11:11642011	GALNTL4	0.42	7.11	0.33	5.03e-12	Telomere length;
LUAD	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg22963979	chr7:1858916	MAD1L1	-0.57	-9.59	-0.42	7.48e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg01689657	chr7:91764605	CYP51A1	0.37	8.87	0.4	2.13e-17	Breast cancer;
LUAD	cis	rs2224391	0.628	rs2773317	chr6:5254509	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-8.74	-0.39	5.6e-17	Height;
LUAD	cis	rs7210086	0.808	rs8073267	chr17:70639514	G/C	cg04206342	chr17:70636940	NA	-0.38	-6.99	-0.32	1.07e-11	Ulcerative colitis;
LUAD	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.81	-0.39	3.23e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg21709803	chr11:61594965	FADS2	0.4	7.58	0.35	2.15e-13	Trans fatty acid levels;
LUAD	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg00898013	chr13:113819073	PROZ	-0.69	-12.14	-0.51	2.61e-29	Platelet distribution width;
LUAD	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg22884516	chr22:45809543	SMC1B;RIBC2	0.59	6.45	0.3	3.15e-10	Tonsillectomy;
LUAD	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.52e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg25828334	chr19:18545568	ISYNA1	-0.36	-7.2	-0.33	2.77e-12	Breast cancer;
LUAD	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg25753631	chr6:25732923	NA	-0.45	-7.84	-0.36	3.61e-14	Iron status biomarkers;
LUAD	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg22884516	chr22:45809543	SMC1B;RIBC2	0.65	6.39	0.3	4.28e-10	Tonsillectomy;
LUAD	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg12179176	chr11:130786555	SNX19	0.54	9.16	0.41	2.3e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg13902645	chr11:5959945	NA	-0.57	-10.09	-0.44	1.39e-21	DNA methylation (variation);
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg26668828	chr6:292823	DUSP22	-0.77	-13.64	-0.55	2.38e-35	Menopause (age at onset);
LUAD	cis	rs7267979	0.764	rs2474767	chr20:25246733	T/C	cg08601574	chr20:25228251	PYGB	0.42	7.88	0.36	2.87e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs68170813	0.559	rs17349904	chr7:106897237	A/C	cg02696742	chr7:106810147	HBP1	-0.78	-10.89	-0.47	1.6e-24	Coronary artery disease;
LUAD	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-7.33	-0.34	1.18e-12	Morning vs. evening chronotype;
LUAD	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg22117172	chr7:91764530	CYP51A1	0.32	7.08	0.33	5.88e-12	Breast cancer;
LUAD	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg19635926	chr16:89946313	TCF25	0.74	6.97	0.32	1.22e-11	Skin colour saturation;
LUAD	cis	rs12681287	0.640	rs4490816	chr8:87384938	T/C	cg27223183	chr8:87520930	FAM82B	0.68	9.52	0.42	1.34e-19	Caudate activity during reward;
LUAD	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.3	-0.37	1.4e-15	Prostate cancer;
LUAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg15147215	chr3:52552868	STAB1	0.53	10.27	0.45	3.02e-22	Electroencephalogram traits;
LUAD	trans	rs208520	0.837	rs208467	chr6:66914837	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-14.27	-0.57	5.29e-38	Exhaled nitric oxide output;
LUAD	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg14092988	chr3:52407081	DNAH1	0.37	7.49	0.34	4.02e-13	Bipolar disorder;
LUAD	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.47	0.3	2.68e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg00318621	chr2:106887213	NA	0.48	7.52	0.34	3.3e-13	Facial morphology (factor 23);
LUAD	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19346786	chr7:2764209	NA	-0.6	-13.09	-0.54	4.02e-33	Height;
LUAD	cis	rs654950	0.840	rs2810551	chr1:41995402	G/A	cg06885757	chr1:42089581	HIVEP3	-0.32	-6.75	-0.31	4.74e-11	Airway imaging phenotypes;
LUAD	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08677398	chr8:58056175	NA	0.48	6.67	0.31	8.02e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg11062466	chr8:58055876	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404618	0.593	rs7829532	chr8:1485190	C/A	cg02903104	chr8:1507517	DLGAP2	0.32	7.11	0.33	5.03e-12	Lung cancer;
LUAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg11814155	chr7:99998594	ZCWPW1	0.38	6.56	0.3	1.6e-10	Platelet count;
LUAD	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.68	-0.46	9.59e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg21823605	chr1:152486609	CRCT1	0.28	6.4	0.3	4.11e-10	Hair morphology;
LUAD	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg11822812	chr5:140052017	DND1	0.38	6.66	0.31	8.67e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg06558623	chr16:89946397	TCF25	1.12	9.76	0.43	2.05e-20	Skin colour saturation;
LUAD	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg03676636	chr4:99064102	C4orf37	0.37	9.57	0.42	8.85e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg17330251	chr7:94953956	PON1	-0.53	-7.1	-0.33	5.36e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg04775059	chr7:64541387	NA	0.53	8.59	0.39	1.69e-16	Calcium levels;
LUAD	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg11766577	chr21:47581405	C21orf56	-0.45	-7.68	-0.35	1.09e-13	Testicular germ cell tumor;
LUAD	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg05725404	chr16:58534157	NDRG4	-0.79	-8.29	-0.37	1.52e-15	Schizophrenia;
LUAD	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.06	0.36	7.82e-15	Menopause (age at onset);
LUAD	trans	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg27411982	chr8:10470053	RP1L1	0.38	6.68	0.31	7.49e-11	Mood instability;
LUAD	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg12927641	chr6:109611667	NA	-0.5	-8.8	-0.39	3.59e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs7572644	0.679	rs12986980	chr2:28030437	A/G	cg27432699	chr2:27873401	GPN1	0.42	6.37	0.3	4.89e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUAD	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg25173405	chr17:45401733	C17orf57	-0.55	-9.4	-0.42	3.47e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg18944383	chr4:111397179	ENPEP	0.37	7.68	0.35	1.12e-13	Height;
LUAD	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18876405	chr7:65276391	NA	-0.42	-6.6	-0.31	1.21e-10	Aortic root size;
LUAD	trans	rs208520	0.802	rs208516	chr6:66946119	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-14.84	-0.59	2.01e-40	Exhaled nitric oxide output;
LUAD	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg19163074	chr7:65112434	INTS4L2	0.44	6.74	0.31	5.32e-11	Aortic root size;
LUAD	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg00255919	chr5:131827918	IRF1	0.29	6.61	0.31	1.13e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25427524	chr10:38739819	LOC399744	-0.74	-13.24	-0.54	1.03e-33	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg14345882	chr6:26364793	BTN3A2	0.7	7.14	0.33	4.13e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg01620082	chr3:125678407	NA	-0.96	-8.68	-0.39	8.74e-17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg17330251	chr7:94953956	PON1	0.49	7.2	0.33	2.82e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg23262351	chr6:79576851	IRAK1BP1	-0.41	-6.91	-0.32	1.76e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs11585357	0.843	rs72633805	chr1:17617471	A/T	cg08277548	chr1:17600880	PADI3	-0.95	-13.88	-0.56	2.3e-36	Hair shape;
LUAD	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg12311346	chr5:56204834	C5orf35	-0.48	-8.0	-0.36	1.19e-14	Coronary artery disease;
LUAD	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg12062639	chr20:23401060	NAPB	1.09	11.23	0.48	8.38e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg23985595	chr17:80112537	CCDC57	-0.51	-9.14	-0.41	2.72e-18	Life satisfaction;
LUAD	cis	rs72772090	0.710	rs11739280	chr5:96074147	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.54	6.69	0.31	7.18e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs11048434	0.736	rs4309200	chr12:9121856	A/C	cg26114124	chr12:9217669	LOC144571	0.35	6.42	0.3	3.64e-10	Sjögren's syndrome;
LUAD	cis	rs9329221	0.585	rs12550717	chr8:10266706	G/A	cg27411982	chr8:10470053	RP1L1	0.38	6.57	0.3	1.51e-10	Neuroticism;
LUAD	cis	rs7107174	0.901	rs2450137	chr11:77925233	C/G	cg02023728	chr11:77925099	USP35	0.49	7.76	0.35	6.47e-14	Testicular germ cell tumor;
LUAD	cis	rs8048589	1.000	rs12596549	chr16:12183500	C/A	cg03816625	chr16:12192430	SNX29	0.54	7.98	0.36	1.42e-14	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg07719772	chr16:32360419	NA	-0.46	-7.13	-0.33	4.36e-12	Menopause (age at onset);
LUAD	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg14552801	chr7:65878734	NA	0.37	6.37	0.3	5.05e-10	Aortic root size;
LUAD	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21659725	chr3:3221576	CRBN	-0.63	-10.93	-0.47	1.14e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs7809950	0.678	rs7803151	chr7:106934246	G/A	cg23024343	chr7:107201750	COG5	-0.81	-13.45	-0.55	1.35e-34	Coronary artery disease;
LUAD	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg27427491	chr17:78079615	GAA	-0.38	-7.14	-0.33	4.21e-12	Yeast infection;
LUAD	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg11517269	chr6:28058789	ZSCAN12L1	0.26	6.46	0.3	2.88e-10	Cardiac Troponin-T levels;
LUAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08280861	chr8:58055591	NA	0.64	8.44	0.38	5.01e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg22532475	chr10:104410764	TRIM8	-0.48	-9.21	-0.41	1.53e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.04e-13	Morning vs. evening chronotype;
LUAD	cis	rs13223928	0.666	rs9986825	chr7:3151177	C/T	cg19214707	chr7:3157722	NA	0.53	9.45	0.42	2.4e-19	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg09976142	chr9:130955436	CIZ1	-0.61	-12.16	-0.51	2.24e-29	Attention deficit hyperactivity disorder;
LUAD	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg02734326	chr4:10020555	SLC2A9	0.59	10.38	0.45	1.25e-22	Bone mineral density;
LUAD	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg21238619	chr17:78079768	GAA	-0.32	-6.62	-0.31	1.07e-10	Yeast infection;
LUAD	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg17120908	chr11:65337727	SSSCA1	0.68	10.64	0.46	1.4e-23	Bone mineral density;
LUAD	cis	rs1267303	0.675	rs1267309	chr1:46987342	G/A	cg16387850	chr1:46982889	NA	0.47	7.93	0.36	1.95e-14	Monobrow;
LUAD	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg13902645	chr11:5959945	NA	-0.57	-10.09	-0.44	1.39e-21	DNA methylation (variation);
LUAD	cis	rs2455601	0.882	rs10840139	chr11:8894838	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-7.42	-0.34	6.63e-13	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg25985355	chr7:65971099	NA	-0.53	-6.62	-0.31	1.09e-10	Diabetic kidney disease;
LUAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg24846343	chr22:24311635	DDTL	0.79	17.99	0.66	3.76e-54	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.88	-0.32	2.19e-11	Neuroticism;
LUAD	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs4972806	0.849	rs2113561	chr2:177030925	G/A	cg14324370	chr2:177042789	NA	0.42	7.82	0.36	4.15e-14	IgG glycosylation;
LUAD	cis	rs868036	0.681	rs28670272	chr15:68109907	C/T	cg24579218	chr15:68104479	NA	0.58	10.05	0.44	1.91e-21	Restless legs syndrome;
LUAD	cis	rs7010267	0.902	rs10505348	chr8:119972696	A/G	cg01975934	chr8:119970761	NA	-0.41	-7.85	-0.36	3.41e-14	Total body bone mineral density (age 45-60);
LUAD	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg00784671	chr22:46762841	CELSR1	-0.43	-6.69	-0.31	7.18e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg10523679	chr1:76189770	ACADM	0.9	16.24	0.62	1.99e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs71478720	1.000	rs3882892	chr11:112014986	C/T	cg09122223	chr11:112035175	IL18	0.42	6.38	0.3	4.56e-10	Interleukin-18 levels;
LUAD	cis	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg05084668	chr3:125655381	ALG1L	-0.66	-8.86	-0.4	2.19e-17	Blood pressure (smoking interaction);
LUAD	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23583168	chr7:148888333	NA	-0.91	-18.87	-0.68	4.59e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs3219090	0.861	rs2695239	chr1:226605227	T/C	cg27539482	chr13:111589090	NA	0.43	7.26	0.33	1.93e-12	Melanoma;
LUAD	cis	rs490234	0.932	rs577026	chr9:128341023	C/T	cg14078157	chr9:128172775	NA	-0.36	-6.66	-0.31	8.57e-11	Mean arterial pressure;
LUAD	cis	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.87	-0.36	3.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs593982	1.000	rs665191	chr11:65493658	G/A	cg08755490	chr11:65554678	OVOL1	1.31	18.39	0.67	6.31e-56	Atopic dermatitis;
LUAD	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg25173405	chr17:45401733	C17orf57	-0.59	-10.19	-0.44	6.05e-22	Glaucoma (primary open-angle);
LUAD	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg11833968	chr6:79620685	NA	-0.43	-8.08	-0.37	6.94e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05412979	chr6:99873168	SFRS18	-0.54	-6.58	-0.3	1.43e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg07741184	chr6:167504864	NA	0.34	8.08	0.37	6.8e-15	Primary biliary cholangitis;
LUAD	cis	rs938554	0.571	rs7696092	chr4:10025320	C/A	cg00071950	chr4:10020882	SLC2A9	0.61	10.11	0.44	1.17e-21	Blood metabolite levels;
LUAD	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg05579598	chr16:88989069	CBFA2T3	0.33	6.81	0.31	3.45e-11	Social autistic-like traits;
LUAD	cis	rs4372836	0.681	rs6419696	chr2:29010339	G/A	cg09522027	chr2:28974177	PPP1CB	-0.67	-12.28	-0.51	7.75e-30	Body mass index;
LUAD	cis	rs889398	0.904	rs6499244	chr16:69735271	T/A	cg26679644	chr16:69762563	NA	0.37	6.72	0.31	5.75e-11	Body mass index;
LUAD	trans	rs853679	0.546	rs493161	chr6:27850714	A/T	cg01620082	chr3:125678407	NA	-0.87	-8.88	-0.4	1.92e-17	Depression;
LUAD	cis	rs13082711	0.520	rs2724494	chr3:27563920	C/A	cg02860705	chr3:27208620	NA	0.44	6.79	0.31	3.74e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.49	6.57	0.3	1.51e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25427524	chr10:38739819	LOC399744	-0.76	-14.61	-0.58	2.02e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg04450456	chr4:17643702	FAM184B	0.39	7.54	0.34	2.89e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27003951	chr16:11350045	SOCS1	-0.54	-6.51	-0.3	2.15e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4604732	0.631	rs12039642	chr1:247624898	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.45	7.26	0.33	1.85e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs11048434	0.736	rs35870866	chr12:9129091	C/A	cg13575925	chr12:9217583	LOC144571	0.4	7.39	0.34	7.77e-13	Sjögren's syndrome;
LUAD	cis	rs977987	0.843	rs12443834	chr16:75438469	C/T	cg03315344	chr16:75512273	CHST6	0.64	14.14	0.57	1.96e-37	Dupuytren's disease;
LUAD	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg08085267	chr17:45401833	C17orf57	-0.59	-10.35	-0.45	1.55e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg07936489	chr17:37558343	FBXL20	-0.47	-7.35	-0.34	1.04e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg03188948	chr7:1209495	NA	0.92	12.19	0.51	1.66e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs12216545	0.765	rs7801447	chr7:150227281	C/T	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.7	-0.31	6.68e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.66	-0.43	4.48e-20	Schizophrenia;
LUAD	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	10.05	0.44	1.83e-21	Lung cancer in ever smokers;
LUAD	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg25797454	chr6:150327115	RAET1K	0.33	7.23	0.33	2.34e-12	Alopecia areata;
LUAD	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg18306943	chr3:40428807	ENTPD3	0.42	7.05	0.32	7.38e-12	Renal cell carcinoma;
LUAD	cis	rs9487051	0.799	rs351725	chr6:109547939	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.25	-0.33	1.96e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg18825076	chr15:78729989	IREB2	0.47	6.55	0.3	1.69e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs593982	0.920	rs10896044	chr11:65554680	C/G	cg08755490	chr11:65554678	OVOL1	1.35	18.4	0.67	5.74e-56	Atopic dermatitis;
LUAD	cis	rs2282300	0.696	rs12578061	chr11:30249365	T/A	cg06241208	chr11:30344200	C11orf46	-0.64	-8.26	-0.37	1.89e-15	Morning vs. evening chronotype;
LUAD	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg15997130	chr1:24165203	NA	0.56	9.54	0.42	1.11e-19	Immature fraction of reticulocytes;
LUAD	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg02551604	chr5:131831745	NA	-0.6	-9.73	-0.43	2.53e-20	Asthma (sex interaction);
LUAD	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg17105886	chr17:28927953	LRRC37B2	0.8	7.82	0.36	4.29e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.92	-0.36	2.08e-14	Prostate cancer;
LUAD	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg09658497	chr7:2847517	GNA12	-0.53	-8.83	-0.39	2.91e-17	Height;
LUAD	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg12365402	chr11:9010492	NRIP3	0.46	8.5	0.38	3.35e-16	Hemoglobin concentration;
LUAD	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.34	6.96	0.32	1.28e-11	Height;Educational attainment;Head circumference (infant);
LUAD	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg03806693	chr22:41940476	POLR3H	-0.73	-9.73	-0.43	2.47e-20	Vitiligo;
LUAD	cis	rs8077889	0.719	rs2079006	chr17:41865745	C/G	cg26893861	chr17:41843967	DUSP3	1.12	25.28	0.78	1.44e-86	Triglycerides;
LUAD	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg03609598	chr5:56110824	MAP3K1	-0.63	-8.58	-0.39	1.82e-16	Initial pursuit acceleration;
LUAD	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg23649088	chr2:200775458	C2orf69	-0.55	-6.46	-0.3	2.83e-10	Schizophrenia;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg24714709	chr7:95064397	PON2	0.38	6.41	0.3	3.89e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs7582720	1.000	rs72934763	chr2:203758396	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11644478	chr21:40555479	PSMG1	0.65	10.3	0.45	2.47e-22	Cognitive function;
LUAD	cis	rs870825	0.932	rs28702958	chr4:185575562	C/T	cg04058563	chr4:185651563	MLF1IP	0.69	8.62	0.39	1.34e-16	Blood protein levels;
LUAD	cis	rs11696501	0.694	rs6073825	chr20:44258217	T/C	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.2	-0.37	2.91e-15	Brain structure;
LUAD	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg24558204	chr6:135376177	HBS1L	0.45	8.19	0.37	3.12e-15	Red blood cell count;
LUAD	cis	rs7727544	0.582	rs10075459	chr5:131541363	C/G	cg07538946	chr5:131705188	SLC22A5	0.4	6.43	0.3	3.39e-10	Blood metabolite levels;
LUAD	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.25	-0.33	2.02e-12	Coronary artery disease;
LUAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg00431813	chr7:1051703	C7orf50	-0.46	-8.55	-0.38	2.33e-16	Longevity;Endometriosis;
LUAD	cis	rs17152411	1.000	rs2241541	chr10:126671673	T/C	cg07906193	chr10:126599966	NA	0.54	7.54	0.34	2.94e-13	Height;
LUAD	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg13010199	chr12:38710504	ALG10B	0.39	6.38	0.3	4.74e-10	Bladder cancer;
LUAD	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23158103	chr7:148848205	ZNF398	-0.51	-8.9	-0.4	1.6e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9837602	0.688	rs793492	chr3:99499736	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	6.72	0.31	5.83e-11	Breast cancer;
LUAD	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg03806693	chr22:41940476	POLR3H	-0.8	-11.36	-0.48	2.7e-26	Vitiligo;
LUAD	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg11502198	chr6:26597334	ABT1	0.55	9.1	0.4	3.71e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg27170947	chr2:26402098	FAM59B	-0.69	-9.44	-0.42	2.45e-19	Gut microbiome composition (summer);
LUAD	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.66	-11.74	-0.5	9.82e-28	Menarche (age at onset);
LUAD	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg09835421	chr16:68378352	PRMT7	-0.85	-9.1	-0.4	3.55e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12155623	0.834	rs16939055	chr8:49824013	T/G	cg22283653	chr8:49824208	NA	0.5	9.24	0.41	1.22e-18	Sudden cardiac arrest;
LUAD	cis	rs17433780	0.523	rs6701673	chr1:89525812	C/G	cg09516651	chr1:89888402	LOC400759	0.68	13.94	0.56	1.29e-36	Carotid intima media thickness;
LUAD	cis	rs13082711	0.911	rs7625337	chr3:27516853	G/T	cg02860705	chr3:27208620	NA	0.57	8.59	0.39	1.68e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs13315871	0.929	rs13077539	chr3:58267846	T/C	cg20936604	chr3:58311152	NA	-0.58	-6.51	-0.3	2.16e-10	Cholesterol, total;
LUAD	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.47	0.52	1.27e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34172651	0.917	rs12599643	chr16:24832693	C/T	cg04756594	chr16:24857601	SLC5A11	0.52	10.14	0.44	9.29e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg11822812	chr5:140052017	DND1	0.38	7.03	0.32	8.08e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg17747265	chr1:1875780	NA	-0.76	-18.92	-0.68	2.61e-58	Body mass index;
LUAD	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	14.81	0.58	2.75e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg07636037	chr3:49044803	WDR6	0.57	10.67	0.46	1.05e-23	Parkinson's disease;
LUAD	trans	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.68	-10.19	-0.44	5.77e-22	Platelet distribution width;
LUAD	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg21427119	chr20:30132790	HM13	-0.62	-9.47	-0.42	2.02e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	25.69	0.78	2.24e-88	Chronic sinus infection;
LUAD	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg15247329	chr7:2764246	NA	-0.36	-6.8	-0.31	3.65e-11	Height;
LUAD	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg09835421	chr16:68378352	PRMT7	-0.84	-8.89	-0.4	1.74e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg06453172	chr10:134556979	INPP5A	-0.66	-9.98	-0.44	3.4e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg09417038	chr21:47716443	C21orf57	-0.41	-6.49	-0.3	2.37e-10	Testicular germ cell tumor;
LUAD	trans	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg13565492	chr6:43139072	SRF	-0.75	-10.22	-0.45	4.59e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg11663144	chr21:46675770	NA	-0.57	-10.99	-0.47	6.88e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg12573674	chr2:1569213	NA	-0.63	-7.06	-0.32	6.87e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg17264618	chr3:40429014	ENTPD3	0.42	9.13	0.41	2.76e-18	Renal cell carcinoma;
LUAD	cis	rs300774	0.844	rs300728	chr2:131828	G/A	cg21211680	chr2:198530	NA	-0.45	-7.1	-0.33	5.19e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg06873352	chr17:61820015	STRADA	0.43	7.11	0.33	4.92e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.21	0.48	1.04e-25	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	trans	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg18834416	chr8:37888184	EIF4EBP1	0.4	6.58	0.3	1.42e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg24920358	chr1:40204285	PPIE	0.7	12.71	0.53	1.45e-31	Blood protein levels;
LUAD	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg04455712	chr21:45112962	RRP1B	0.38	7.61	0.35	1.84e-13	Mean corpuscular volume;
LUAD	trans	rs7078219	0.743	rs7095953	chr10:101274425	C/T	cg10536398	chr20:56935483	RAB22A	-0.45	-6.78	-0.31	4.17e-11	Dental caries;
LUAD	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-6.78	-0.31	3.99e-11	Total body bone mineral density;
LUAD	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg25324976	chr17:61989376	CSHL1	0.35	6.78	0.31	4.18e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg23533926	chr12:111358616	MYL2	-0.4	-6.79	-0.31	3.7e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9287719	0.699	rs4669602	chr2:10787967	C/T	cg03983476	chr2:10830698	NOL10	-0.39	-6.5	-0.3	2.23e-10	Prostate cancer;
LUAD	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg04833646	chr19:10679720	CDKN2D	-0.76	-12.1	-0.51	3.87e-29	Red cell distribution width;
LUAD	cis	rs240764	0.578	rs6927598	chr6:101232729	T/C	cg09795085	chr6:101329169	ASCC3	0.41	7.17	0.33	3.39e-12	Neuroticism;
LUAD	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg18833306	chr6:118973337	C6orf204	-0.52	-7.62	-0.35	1.69e-13	Diastolic blood pressure;
LUAD	cis	rs6430585	0.528	rs111682961	chr2:136653848	C/T	cg07169764	chr2:136633963	MCM6	0.81	9.45	0.42	2.41e-19	Corneal structure;
LUAD	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg01528321	chr10:82214614	TSPAN14	0.72	11.18	0.48	1.36e-25	Post bronchodilator FEV1;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00920043	chr1:11333412	UBIAD1	-0.45	-7.24	-0.33	2.19e-12	Height;
LUAD	trans	rs2840044	1.000	rs225304	chr17:33921857	G/T	cg19694781	chr19:47549865	TMEM160	-0.64	-10.25	-0.45	3.59e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg02160872	chr5:212506	CCDC127	-0.49	-6.36	-0.3	5.23e-10	Breast cancer;
LUAD	cis	rs1403694	0.515	rs5030058	chr3:186452415	T/G	cg12454167	chr3:186435060	KNG1	0.4	8.34	0.38	1.09e-15	Blood protein levels;
LUAD	cis	rs7809950	1.000	rs2520277	chr7:107130234	C/T	cg23024343	chr7:107201750	COG5	-0.69	-11.75	-0.5	8.77e-28	Coronary artery disease;
LUAD	cis	rs151234	0.800	rs231972	chr16:28538336	A/C	cg04643524	chr16:28609220	SULT1A2	0.57	7.54	0.34	2.99e-13	Platelet distribution width;
LUAD	trans	rs4698048	0.545	rs6811287	chr4:10180823	C/T	cg26043149	chr18:55253948	FECH	-0.51	-8.28	-0.37	1.69e-15	Skin aging (microtopography measurement);
LUAD	cis	rs2455799	0.929	rs2455850	chr3:15782711	A/C	cg16303742	chr3:15540471	COLQ	-0.39	-6.78	-0.31	4.09e-11	Mean platelet volume;
LUAD	cis	rs17095355	1.000	rs12570607	chr10:111696704	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.72	-9.69	-0.43	3.51e-20	Biliary atresia;
LUAD	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg25036284	chr2:26402008	FAM59B	-0.78	-11.9	-0.5	2.35e-28	Gut microbiome composition (summer);
LUAD	cis	rs2880765	0.835	rs4280192	chr15:86043020	G/A	cg13263323	chr15:86062960	AKAP13	-0.5	-9.24	-0.41	1.21e-18	Coronary artery disease;
LUAD	cis	rs9473147	0.516	rs7749167	chr6:47493940	G/A	cg02130027	chr6:47444894	CD2AP	0.36	6.96	0.32	1.3e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs9369695	0.883	rs9473128	chr6:47505010	C/T	cg20196966	chr6:47445060	CD2AP	0.44	7.02	0.32	8.78e-12	Reticulocyte count;
LUAD	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg00277334	chr10:82204260	NA	-0.61	-10.19	-0.44	5.77e-22	Post bronchodilator FEV1;
LUAD	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg00852783	chr1:26633632	UBXN11	0.43	7.62	0.35	1.71e-13	Obesity-related traits;
LUAD	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg02002194	chr4:3960332	NA	-0.26	-6.45	-0.3	3.07e-10	Retinal vascular caliber;
LUAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg07389463	chr12:132296394	NA	0.44	8.36	0.38	9.04e-16	Migraine;
LUAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.85	16.24	0.62	1.9e-46	Lymphocyte counts;
LUAD	cis	rs1784581	0.674	rs1789990	chr6:162406957	G/T	cg17173639	chr6:162384350	PARK2	-0.47	-8.54	-0.38	2.4e-16	Itch intensity from mosquito bite;
LUAD	cis	rs6489882	0.703	rs6489864	chr12:113360025	A/G	cg20102336	chr12:113376681	OAS3	-0.55	-8.33	-0.38	1.13e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs72928364	0.769	rs2713748	chr3:100655579	T/C	cg10123952	chr3:100791384	NA	-0.55	-6.72	-0.31	5.99e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg12311346	chr5:56204834	C5orf35	-0.93	-13.8	-0.56	5.17e-36	Initial pursuit acceleration;
LUAD	trans	rs75804782	0.521	rs72993065	chr2:239409001	C/T	cg01134436	chr17:81009848	B3GNTL1	0.78	8.45	0.38	4.58e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg06618935	chr21:46677482	NA	-0.51	-10.28	-0.45	2.86e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.68	-0.35	1.08e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg05697835	chr1:2722811	NA	0.3	6.37	0.3	4.8e-10	Ulcerative colitis;
LUAD	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg12935359	chr14:103987150	CKB	0.48	7.41	0.34	6.93e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg02269571	chr22:50332266	NA	-0.67	-9.73	-0.43	2.56e-20	Schizophrenia;
LUAD	cis	rs7107174	1.000	rs10793297	chr11:78009660	T/C	cg19901956	chr11:77921274	USP35	-0.55	-6.8	-0.31	3.66e-11	Testicular germ cell tumor;
LUAD	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.66	-0.35	1.32e-13	Menarche (age at onset);
LUAD	cis	rs12545109	1.000	rs1975284	chr8:57314663	A/G	cg21220214	chr8:57350948	NA	-0.57	-7.74	-0.35	7.49e-14	Obesity-related traits;
LUAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg08132940	chr7:1081526	C7orf50	-0.77	-10.31	-0.45	2.21e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg06532163	chr17:45867833	NA	0.45	7.88	0.36	2.89e-14	IgG glycosylation;
LUAD	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11644478	chr21:40555479	PSMG1	0.68	11.24	0.48	7.91e-26	Cognitive function;
LUAD	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg17177755	chr1:15930204	NA	0.46	7.43	0.34	5.89e-13	Systolic blood pressure;
LUAD	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg04455712	chr21:45112962	RRP1B	0.37	7.49	0.34	4.07e-13	Mean corpuscular volume;
LUAD	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	6.94	0.32	1.47e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.0	-0.36	1.17e-14	Diabetic kidney disease;
LUAD	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg00383909	chr3:49044727	WDR6	0.89	8.4	0.38	6.98e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.5	8.1	0.37	5.89e-15	Lung cancer;
LUAD	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.71	0.39	7.1e-17	Menarche (age at onset);
LUAD	cis	rs2282300	0.739	rs1222211	chr11:30362239	A/C	cg06241208	chr11:30344200	C11orf46	-0.57	-7.57	-0.35	2.3e-13	Morning vs. evening chronotype;
LUAD	cis	rs7943203	1.000	rs7952492	chr11:108296680	C/T	cg04873221	chr11:107992290	ACAT1	-0.43	-6.99	-0.32	1.07e-11	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.93	0.32	1.57e-11	Parkinson's disease;
LUAD	cis	rs758324	0.773	rs4540167	chr5:131163022	G/A	cg25547332	chr5:131281432	NA	0.41	6.76	0.31	4.65e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7326068	0.610	rs3924006	chr13:21331779	T/A	cg27499820	chr13:21296301	IL17D	0.54	8.12	0.37	5.33e-15	Schizophrenia, bipolar disorder and depression (combined);
LUAD	trans	rs2797160	0.967	rs1954360	chr6:126001064	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.63	-0.39	1.22e-16	Endometrial cancer;
LUAD	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg06287003	chr12:125626642	AACS	-0.4	-6.43	-0.3	3.37e-10	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg00933542	chr6:150070202	PCMT1	0.43	9.27	0.41	9.82e-19	Lung cancer;
LUAD	cis	rs1160297	0.609	rs6545310	chr2:53103542	T/C	cg07782112	chr2:53107842	NA	0.4	8.39	0.38	7.51e-16	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6456156	1.000	rs6456156	chr6:167522300	T/C	cg07741184	chr6:167504864	NA	0.3	6.86	0.32	2.39e-11	Primary biliary cholangitis;
LUAD	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg04944784	chr2:26401820	FAM59B	0.87	11.61	0.49	3.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs2625529	0.824	rs11072338	chr15:72245447	T/C	cg16672083	chr15:72433130	SENP8	-0.76	-12.74	-0.53	1.11e-31	Red blood cell count;
LUAD	cis	rs10242455	0.557	rs45492501	chr7:99047030	T/A	cg18809830	chr7:99032528	PTCD1	-0.99	-7.18	-0.33	3.17e-12	Blood metabolite levels;
LUAD	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-8.04	-0.36	9.31e-15	Total body bone mineral density;
LUAD	trans	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.89	-0.32	2e-11	Systolic blood pressure;
LUAD	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg21963583	chr11:68658836	MRPL21	0.68	11.79	0.5	6.18e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	7.52	0.34	3.28e-13	Platelet count;
LUAD	cis	rs7187994	0.806	rs11149677	chr16:84748270	C/G	cg07647771	chr16:84786436	USP10	-0.33	-8.54	-0.38	2.36e-16	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg03676636	chr4:99064102	C4orf37	-0.31	-8.09	-0.37	6.51e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7187994	0.515	rs7199123	chr16:84776178	A/T	cg07647771	chr16:84786436	USP10	-0.25	-7.0	-0.32	9.79e-12	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg25767906	chr1:53392781	SCP2	-0.6	-11.24	-0.48	7.69e-26	Monocyte count;
LUAD	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.63	0.42	5.44e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg09021430	chr5:549028	NA	-0.58	-13.15	-0.54	2.27e-33	Obesity-related traits;
LUAD	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg06636551	chr8:101224915	SPAG1	-0.38	-6.97	-0.32	1.23e-11	Atrioventricular conduction;
LUAD	trans	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.9	-0.32	1.86e-11	Gout;
LUAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg22029157	chr1:209979665	IRF6	0.74	12.0	0.5	9.71e-29	Cleft lip with or without cleft palate;
LUAD	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg01849466	chr14:104193079	ZFYVE21	0.51	8.29	0.37	1.56e-15	Body mass index;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25282353	chr6:144416767	SF3B5	-0.53	-6.44	-0.3	3.23e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.97	0.32	1.24e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg07423050	chr13:99094983	FARP1	-0.54	-9.23	-0.41	1.29e-18	Longevity;
LUAD	cis	rs7904368	0.806	rs7899923	chr10:16857394	G/A	cg23933602	chr10:16859644	RSU1	0.55	7.25	0.33	2.03e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg12310025	chr6:25882481	NA	-0.56	-8.14	-0.37	4.49e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03517284	chr6:25882590	NA	0.84	13.96	0.56	1.06e-36	Blood metabolite levels;
LUAD	cis	rs2282300	0.739	rs34044331	chr11:30264486	T/C	cg06241208	chr11:30344200	C11orf46	-0.59	-7.78	-0.35	5.63e-14	Morning vs. evening chronotype;
LUAD	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg08859206	chr1:53392774	SCP2	0.57	10.12	0.44	1.1e-21	Monocyte count;
LUAD	cis	rs9902453	0.967	rs28792710	chr17:28450015	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.72	0.39	6.41e-17	Coffee consumption (cups per day);
LUAD	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-8.58	-0.38	1.87e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg03948781	chr1:205179583	DSTYK	0.34	6.44	0.3	3.28e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07343612	chr16:622815	PIGQ	-0.82	-16.3	-0.62	1.05e-46	Height;
LUAD	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg23281280	chr6:28129359	ZNF389	0.45	6.51	0.3	2.09e-10	Depression;
LUAD	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg11189052	chr15:85197271	WDR73	0.67	9.06	0.4	4.94e-18	Schizophrenia;
LUAD	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg05368731	chr17:41323189	NBR1	0.95	19.19	0.68	1.76e-59	Menopause (age at onset);
LUAD	cis	rs6564851	0.545	rs4889285	chr16:81252258	C/T	cg00908271	chr16:81254010	PKD1L2	-0.41	-8.91	-0.4	1.49e-17	Carotenoid and tocopherol levels;
LUAD	cis	rs6942407	0.546	rs4140847	chr7:86783263	A/T	cg02420886	chr7:86849541	C7orf23	0.63	7.29	0.33	1.55e-12	Food allergy;
LUAD	cis	rs11771526	0.792	rs10249413	chr7:32304259	G/C	cg27532318	chr7:32358331	NA	0.59	7.4	0.34	7.31e-13	Body mass index;
LUAD	cis	rs11958404	0.932	rs10045597	chr5:157451963	T/C	cg05962755	chr5:157440814	NA	0.52	8.68	0.39	8.51e-17	IgG glycosylation;
LUAD	trans	rs1681630	1.000	rs1681630	chr11:47969152	A/G	cg15704280	chr7:45808275	SEPT13	-0.48	-7.24	-0.33	2.12e-12	Height;
LUAD	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg17105886	chr17:28927953	LRRC37B2	0.8	7.82	0.36	4.29e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg08027265	chr7:2291960	NA	-0.41	-6.82	-0.31	3.18e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs4253772	0.872	rs11704508	chr22:46638540	A/G	cg09491104	chr22:46646882	C22orf40	-0.51	-6.99	-0.32	1.11e-11	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21582582	chr3:182698605	DCUN1D1	0.61	9.88	0.43	7.36e-21	Resting heart rate;
LUAD	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg08470875	chr2:26401718	FAM59B	-0.62	-8.49	-0.38	3.43e-16	Gut microbiome composition (summer);
LUAD	cis	rs738322	0.600	rs6001031	chr22:38556260	G/T	cg25457927	chr22:38595422	NA	0.52	12.39	0.52	2.76e-30	Cutaneous nevi;
LUAD	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg25237894	chr2:233734115	C2orf82	0.64	12.02	0.5	7.78e-29	Coronary artery disease;
LUAD	trans	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg01620082	chr3:125678407	NA	-0.45	-6.68	-0.31	7.42e-11	Depression;
LUAD	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg11502198	chr6:26597334	ABT1	0.66	11.38	0.48	2.33e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs2688608	0.967	rs2675663	chr10:75660270	T/G	cg23231163	chr10:75533350	FUT11	-0.38	-7.08	-0.33	5.98e-12	Inflammatory bowel disease;
LUAD	cis	rs2731664	0.740	rs2731670	chr5:176848019	G/T	cg23176889	chr5:176863531	GRK6	0.65	11.86	0.5	3.44e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg25358565	chr5:93447407	FAM172A	0.57	6.74	0.31	5.19e-11	Diabetic retinopathy;
LUAD	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg14558114	chr2:88469736	THNSL2	-0.86	-9.0	-0.4	7.51e-18	Plasma clusterin levels;
LUAD	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg18761221	chr20:60518478	NA	0.39	6.85	0.32	2.62e-11	Body mass index;
LUAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.48	-7.96	-0.36	1.65e-14	Longevity;Endometriosis;
LUAD	trans	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg01620082	chr3:125678407	NA	-0.44	-6.7	-0.31	6.82e-11	Depression;
LUAD	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg08859206	chr1:53392774	SCP2	0.6	11.22	0.48	9.75e-26	Monocyte count;
LUAD	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg05368731	chr17:41323189	NBR1	0.86	16.68	0.63	2.21e-48	Menopause (age at onset);
LUAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg09509183	chr1:209979624	IRF6	0.58	8.84	0.39	2.66e-17	Cleft lip with or without cleft palate;
LUAD	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg00383909	chr3:49044727	WDR6	0.43	6.6	0.31	1.26e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg06618935	chr21:46677482	NA	-0.49	-10.03	-0.44	2.21e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6901250	0.851	rs339362	chr6:117165370	A/C	cg12892004	chr6:117198278	RFX6	-0.34	-7.15	-0.33	3.89e-12	C-reactive protein levels;
LUAD	trans	rs853679	0.607	rs13208096	chr6:28225311	C/G	cg01620082	chr3:125678407	NA	-1.1	-10.35	-0.45	1.59e-22	Depression;
LUAD	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg00071950	chr4:10020882	SLC2A9	0.83	17.73	0.65	5.58e-53	Bone mineral density;
LUAD	cis	rs7095607	0.777	rs10762191	chr10:69920031	C/A	cg18986048	chr10:69913749	MYPN	0.38	6.41	0.3	3.92e-10	Lung function (FVC);
LUAD	cis	rs4148883	0.615	rs2187483	chr4:100134103	G/T	cg12011299	chr4:100065546	ADH4	-0.53	-10.52	-0.46	3.7e-23	Alcohol dependence;
LUAD	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.45	6.7	0.31	6.73e-11	Schizophrenia;
LUAD	cis	rs1034435	0.692	rs6008739	chr22:48892542	T/C	cg05992904	chr22:48892994	FAM19A5	-0.76	-17.16	-0.64	1.77e-50	Late-onset Alzheimer's disease;
LUAD	cis	rs9875589	0.509	rs1844107	chr3:14065319	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	6.61	0.31	1.17e-10	Ovarian reserve;
LUAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg04025307	chr7:1156635	C7orf50	0.66	9.44	0.42	2.48e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs68170813	0.559	rs75932578	chr7:106844694	C/T	cg23024343	chr7:107201750	COG5	0.54	7.29	0.33	1.52e-12	Coronary artery disease;
LUAD	cis	rs9399401	0.626	rs6906468	chr6:142769386	A/G	cg04461802	chr6:142623433	GPR126	0.38	7.28	0.33	1.62e-12	Chronic obstructive pulmonary disease;
LUAD	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg03396347	chr1:1875803	NA	-0.59	-15.0	-0.59	4.21e-41	Body mass index;
LUAD	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg03929089	chr4:120376271	NA	-0.83	-14.65	-0.58	1.31e-39	Height;
LUAD	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg23758822	chr17:41437982	NA	1.01	20.89	0.71	4.34e-67	Menopause (age at onset);
LUAD	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.29	-6.6	-0.31	1.23e-10	Dupuytren's disease;
LUAD	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	6.56	0.3	1.62e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs1348850	0.914	rs2121430	chr2:178318375	A/G	cg27490568	chr2:178487706	NA	0.39	6.41	0.3	4e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.92	11.03	0.47	4.99e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg20933634	chr6:27740509	NA	0.45	7.03	0.32	8.49e-12	Parkinson's disease;
LUAD	cis	rs11696501	0.688	rs59196188	chr20:44278868	C/T	cg11783356	chr20:44313418	WFDC10B	-0.4	-7.08	-0.33	6.13e-12	Brain structure;
LUAD	trans	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.64	-0.31	9.77e-11	Neuroticism;
LUAD	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.87	0.32	2.27e-11	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.39	-7.67	-0.35	1.2e-13	Total body bone mineral density;
LUAD	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg15704280	chr7:45808275	SEPT13	-0.59	-7.89	-0.36	2.59e-14	D-dimer levels;
LUAD	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg13180566	chr4:1052158	NA	0.4	6.69	0.31	7.15e-11	Recombination rate (females);
LUAD	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22857025	chr5:266934	NA	-0.97	-14.59	-0.58	2.33e-39	Breast cancer;
LUAD	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg11502198	chr6:26597334	ABT1	0.55	9.27	0.41	9.37e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg26384229	chr12:38710491	ALG10B	-0.41	-7.05	-0.32	7.11e-12	Heart rate;
LUAD	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg03676636	chr4:99064102	C4orf37	0.32	8.43	0.38	5.55e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg17063962	chr7:91808500	NA	-0.62	-10.61	-0.46	1.82e-23	Breast cancer;
LUAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg04234412	chr22:24373322	LOC391322	-0.78	-14.93	-0.59	8.85e-41	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.18	0.54	1.83e-33	Prudent dietary pattern;
LUAD	cis	rs17102423	0.594	rs4902360	chr14:65546722	A/C	cg16583315	chr14:65563665	MAX	-0.37	-7.0	-0.32	9.86e-12	Obesity-related traits;
LUAD	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	9.19	0.41	1.74e-18	Platelet count;
LUAD	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.62	-0.35	1.68e-13	Fear of minor pain;
LUAD	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.56	-0.3	1.54e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.44	6.65	0.31	9.04e-11	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62400317	0.859	rs6919813	chr6:45159177	C/T	cg18551225	chr6:44695536	NA	-0.57	-8.69	-0.39	8.17e-17	Total body bone mineral density;
LUAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg00280220	chr17:61926910	NA	0.37	7.18	0.33	3.23e-12	Prudent dietary pattern;
LUAD	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg23260525	chr10:116636907	FAM160B1	0.47	11.0	0.47	6.26e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs469568	0.935	rs338875	chr5:178669297	A/G	cg08999896	chr5:178685787	ADAMTS2	-0.34	-7.22	-0.33	2.39e-12	Stroke (pediatric);
LUAD	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg00933542	chr6:150070202	PCMT1	0.45	9.52	0.42	1.34e-19	Lung cancer;
LUAD	trans	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg14791747	chr16:20752902	THUMPD1	0.46	7.1	0.33	5.25e-12	Dental caries;
LUAD	trans	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg26811252	chr16:29126840	RRN3P2	-0.64	-10.71	-0.46	7.75e-24	Menopause (age at onset);
LUAD	cis	rs7709909	0.782	rs3958547	chr5:79995570	T/G	cg24059623	chr5:79951536	MSH3;DHFR	0.46	8.58	0.39	1.77e-16	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg06002616	chr8:101225028	SPAG1	-0.4	-8.06	-0.36	7.99e-15	Atrioventricular conduction;
LUAD	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg24558204	chr6:135376177	HBS1L	-0.47	-8.62	-0.39	1.32e-16	Red blood cell count;
LUAD	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg23887609	chr12:130822674	PIWIL1	0.39	6.48	0.3	2.57e-10	Menopause (age at onset);
LUAD	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg27532560	chr4:187881888	NA	-0.42	-8.33	-0.38	1.13e-15	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg14196790	chr5:131705035	SLC22A5	0.47	8.43	0.38	5.64e-16	Blood metabolite levels;
LUAD	cis	rs72901758	0.768	rs72901762	chr17:76244926	A/G	cg25512537	chr17:76250053	NA	0.39	7.71	0.35	8.87e-14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs9972944	0.657	rs9904302	chr17:63758238	A/G	cg07283582	chr17:63770753	CCDC46	-0.5	-11.44	-0.49	1.33e-26	Total body bone mineral density;
LUAD	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg17724175	chr1:150552817	MCL1	0.34	7.92	0.36	2.09e-14	Melanoma;
LUAD	cis	rs7818345	0.845	rs7821446	chr8:19268822	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.37	-7.85	-0.36	3.37e-14	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06505273	chr16:24850292	NA	0.44	6.39	0.3	4.42e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1472147	1.000	rs6970221	chr7:128511024	A/G	cg00260937	chr7:128520193	KCP	0.41	6.41	0.3	3.91e-10	Calcium levels;
LUAD	cis	rs7633770	0.841	rs11709936	chr3:46680483	C/G	cg11219411	chr3:46661640	NA	0.61	13.36	0.54	3.16e-34	Coronary artery disease;
LUAD	cis	rs6087990	0.806	rs4911108	chr20:31375311	A/G	cg13636640	chr20:31349939	DNMT3B	0.75	13.53	0.55	6.38e-35	Ulcerative colitis;
LUAD	cis	rs7177699	0.557	rs10083697	chr15:79124039	G/A	cg15571903	chr15:79123663	NA	-0.4	-8.06	-0.36	8.07e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	trans	rs9557635	0.766	rs1572591	chr13:102060076	A/G	cg14752429	chr2:26569594	GPR113;SELI	0.38	6.51	0.3	2.08e-10	Non-small cell lung cancer;
LUAD	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.41	-0.42	3.19e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.42	0.3	3.76e-10	Cardiac Troponin-T levels;
LUAD	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg09365446	chr1:150670422	GOLPH3L	0.66	12.34	0.51	4.22e-30	Tonsillectomy;
LUAD	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg17264618	chr3:40429014	ENTPD3	0.42	9.07	0.4	4.5e-18	Renal cell carcinoma;
LUAD	trans	rs875971	0.964	rs778708	chr7:65856319	T/C	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg09945482	chr18:12777974	NA	0.54	6.77	0.31	4.44e-11	Inflammatory skin disease;
LUAD	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.31	-0.51	5.5e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs9826463	0.757	rs73238200	chr3:142204634	C/T	cg20824294	chr3:142316082	PLS1	0.43	7.64	0.35	1.42e-13	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg15962314	chr1:44399869	ARTN	0.34	7.21	0.33	2.51e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg20891558	chr2:74357851	NA	0.97	15.4	0.6	8.24e-43	Gestational age at birth (maternal effect);
LUAD	cis	rs9650315	0.530	rs61334940	chr8:57072570	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.55	7.72	0.35	8.59e-14	Height;
LUAD	cis	rs11674184	0.714	rs16857668	chr2:11723110	G/A	cg07314298	chr2:11723111	GREB1	-0.85	-18.53	-0.67	1.45e-56	Endometriosis;
LUAD	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg05368731	chr17:41323189	NBR1	0.96	20.03	0.7	3.01e-63	Menopause (age at onset);
LUAD	cis	rs877282	0.898	rs34490091	chr10:765800	A/C	cg06581033	chr10:766294	NA	-0.63	-8.41	-0.38	6.17e-16	Uric acid levels;
LUAD	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg14343924	chr8:8086146	FLJ10661	0.43	6.6	0.31	1.2e-10	Joint mobility (Beighton score);
LUAD	cis	rs60733400	0.644	rs28774982	chr1:2621352	C/G	cg18932078	chr1:2524107	MMEL1	-0.36	-6.64	-0.31	9.6e-11	Multiple sclerosis;
LUAD	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg10518543	chr12:38710700	ALG10B	-0.45	-7.31	-0.34	1.32e-12	Morning vs. evening chronotype;
LUAD	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.15	-0.41	2.5e-18	Total body bone mineral density;
LUAD	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg12292205	chr6:26970375	C6orf41	0.37	6.54	0.3	1.83e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9837602	1.000	rs1688766	chr3:99647850	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.61	9.07	0.4	4.67e-18	Breast cancer;
LUAD	cis	rs68170813	0.559	rs12538769	chr7:106984288	C/T	cg02696742	chr7:106810147	HBP1	-0.74	-10.11	-0.44	1.19e-21	Coronary artery disease;
LUAD	cis	rs72829446	0.530	rs9646411	chr17:7398909	A/G	cg07168214	chr17:7380112	ZBTB4	0.36	6.38	0.3	4.71e-10	Androgen levels;
LUAD	cis	rs4372836	0.681	rs6547875	chr2:28997140	G/T	cg09522027	chr2:28974177	PPP1CB	-0.45	-7.46	-0.34	5.08e-13	Body mass index;
LUAD	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg18806716	chr10:30721971	MAP3K8	-0.68	-13.59	-0.55	3.71e-35	Inflammatory bowel disease;
LUAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg01448562	chr3:133502909	NA	-0.71	-13.36	-0.54	3.19e-34	Iron status biomarkers;
LUAD	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg02527881	chr3:46936655	PTH1R	-0.48	-9.43	-0.42	2.66e-19	Colorectal cancer;
LUAD	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg21475434	chr5:93447410	FAM172A	0.76	8.32	0.38	1.2e-15	Diabetic retinopathy;
LUAD	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg03714773	chr7:91764589	CYP51A1	0.29	6.98	0.32	1.14e-11	Breast cancer;
LUAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg26384229	chr12:38710491	ALG10B	0.39	6.65	0.31	9.24e-11	Bladder cancer;
LUAD	trans	rs61332075	0.518	rs56171132	chr2:239378856	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	8.72	0.39	6.55e-17	Lung function (FEV1/FVC);
LUAD	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg18230493	chr5:56204884	C5orf35	-0.86	-12.45	-0.52	1.5e-30	Initial pursuit acceleration;
LUAD	cis	rs7267979	1.000	rs401166	chr20:25446308	C/G	cg08601574	chr20:25228251	PYGB	0.47	8.7	0.39	7.19e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.8	0.39	3.42e-17	Menopause (age at onset);
LUAD	trans	rs877282	0.945	rs10904550	chr10:774177	C/T	cg22713356	chr15:30763199	NA	1.17	16.74	0.63	1.23e-48	Uric acid levels;
LUAD	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg24397884	chr7:158709396	WDR60	-0.74	-13.47	-0.55	1.13e-34	Height;
LUAD	cis	rs4776059	1.000	rs4776068	chr15:52947401	G/A	cg24008177	chr15:52972085	KIAA1370	0.27	7.3	0.33	1.45e-12	Schizophrenia;
LUAD	cis	rs2797160	1.000	rs2797154	chr6:126005197	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.66	-0.31	8.37e-11	Endometrial cancer;
LUAD	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.56	0.3	1.53e-10	Breast cancer;
LUAD	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.46	-7.72	-0.35	8.72e-14	Rheumatoid arthritis;
LUAD	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.7	0.31	6.71e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7705042	0.759	rs3765011	chr5:141517665	G/C	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.83	-0.32	2.88e-11	Asthma;
LUAD	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg11901034	chr3:128598214	ACAD9	-0.43	-6.36	-0.3	5.18e-10	IgG glycosylation;
LUAD	cis	rs2505998	0.833	rs2505536	chr10:43592204	A/T	cg15436174	chr10:43711423	RASGEF1A	0.34	6.46	0.3	2.82e-10	Hirschsprung disease;
LUAD	cis	rs9039	1.000	rs1128001	chr16:9207003	T/C	cg08831531	chr16:9218945	NA	-0.4	-7.28	-0.33	1.62e-12	Menopause (age at onset);
LUAD	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg20578329	chr17:80767326	TBCD	-0.63	-7.26	-0.33	1.82e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg05340658	chr4:99064831	C4orf37	0.54	9.18	0.41	1.9e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.61	-0.31	1.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg27490568	chr2:178487706	NA	0.41	6.82	0.31	3.06e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg12373951	chr3:133503437	NA	-0.34	-6.81	-0.31	3.3e-11	Iron status biomarkers;
LUAD	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg22823121	chr1:150693482	HORMAD1	0.45	8.54	0.38	2.5e-16	Melanoma;
LUAD	cis	rs28374715	0.662	rs28587487	chr15:41495460	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.9	-16.71	-0.63	1.75e-48	Ulcerative colitis;
LUAD	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg12623918	chr2:306882	NA	0.34	6.79	0.31	3.87e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs1784581	0.588	rs10945792	chr6:162423484	C/T	cg17173639	chr6:162384350	PARK2	0.43	7.58	0.35	2.15e-13	Itch intensity from mosquito bite;
LUAD	cis	rs12618769	0.597	rs3769729	chr2:99102810	T/C	cg10123293	chr2:99228465	UNC50	0.46	8.44	0.38	5.15e-16	Bipolar disorder;
LUAD	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg03676636	chr4:99064102	C4orf37	0.3	7.32	0.34	1.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06873352	chr17:61820015	STRADA	0.81	18.02	0.66	2.74e-54	Prudent dietary pattern;
LUAD	cis	rs6005807	0.719	rs9625522	chr22:29045212	C/A	cg12565055	chr22:29076175	TTC28	0.74	8.71	0.39	6.98e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.31	7.91	0.36	2.24e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs735539	0.645	rs6490601	chr13:21245897	G/A	cg27499820	chr13:21296301	IL17D	0.58	9.47	0.42	1.95e-19	Dental caries;
LUAD	cis	rs7737355	0.812	rs2042252	chr5:130980027	A/G	cg06307176	chr5:131281290	NA	-0.45	-7.59	-0.35	2.1e-13	Life satisfaction;
LUAD	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg22029157	chr1:209979665	IRF6	0.76	9.92	0.43	5.4e-21	Cleft lip with or without cleft palate;
LUAD	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg10018233	chr7:150070692	REPIN1	0.49	7.49	0.34	4.15e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1997103	1.000	rs6953494	chr7:55412157	G/A	cg17469321	chr7:55412551	NA	0.67	11.32	0.48	3.95e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs354225	0.544	rs12713264	chr2:54805218	A/C	cg01766943	chr2:54829624	SPTBN1	-0.39	-7.33	-0.34	1.14e-12	Schizophrenia;
LUAD	trans	rs7395662	0.963	rs4882072	chr11:48479891	C/T	cg00717180	chr2:96193071	NA	-0.4	-7.46	-0.34	4.93e-13	HDL cholesterol;
LUAD	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg04727924	chr7:799746	HEATR2	-0.56	-7.52	-0.34	3.29e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7193541	0.585	rs7978	chr16:74486189	T/C	cg01733217	chr16:74700730	RFWD3	-0.49	-8.81	-0.39	3.35e-17	Multiple myeloma;
LUAD	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg23283495	chr1:209979779	IRF6	0.41	7.35	0.34	1.02e-12	Monobrow;
LUAD	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg25036284	chr2:26402008	FAM59B	-0.83	-11.68	-0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.77	0.31	4.44e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09825030	chr2:85568866	NA	-0.54	-7.07	-0.33	6.29e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.67	0.35	1.19e-13	Bladder cancer;
LUAD	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg27284194	chr4:1044797	NA	0.71	10.26	0.45	3.2800000000000002e-22	Recombination rate (females);
LUAD	cis	rs17401966	0.964	rs2027331	chr1:10276718	C/T	cg15208524	chr1:10270712	KIF1B	0.55	7.96	0.36	1.6e-14	Hepatocellular carcinoma;
LUAD	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.27e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11640533	1.000	rs11640533	chr16:53412862	A/G	cg02380802	chr16:53407808	NA	-0.37	-6.59	-0.31	1.3e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg08219700	chr8:58056026	NA	0.41	6.39	0.3	4.44e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg07917127	chr4:99064746	C4orf37	0.42	7.01	0.32	9.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg26043149	chr18:55253948	FECH	-0.51	-8.19	-0.37	3.08e-15	Bone mineral density;
LUAD	trans	rs587242	1.000	rs35729443	chr1:96897468	C/T	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs2580764	0.515	rs4672005	chr2:55246551	C/T	cg09592903	chr2:55203963	RTN4	-0.45	-10.04	-0.44	2.1e-21	Mean platelet volume;
LUAD	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg00316803	chr15:76480434	C15orf27	-0.41	-7.83	-0.36	3.83e-14	Blood metabolite levels;
LUAD	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg09365446	chr1:150670422	GOLPH3L	0.66	12.58	0.52	4.9e-31	Tonsillectomy;
LUAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.86	10.88	0.47	1.71e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg22532475	chr10:104410764	TRIM8	-0.5	-9.07	-0.4	4.57e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg07677032	chr17:61819896	STRADA	0.55	9.85	0.43	9.54e-21	Prudent dietary pattern;
LUAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg07806771	chr7:64541737	NA	0.48	7.67	0.35	1.21e-13	Calcium levels;
LUAD	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg22875332	chr1:76189707	ACADM	-0.68	-10.62	-0.46	1.7e-23	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11644478	chr21:40555479	PSMG1	0.67	10.92	0.47	1.3e-24	Cognitive function;
LUAD	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6854137	0.721	rs34007727	chr4:169731061	A/G	cg20607169	chr4:169750834	PALLD	0.4	7.12	0.33	4.67e-12	Vein graft stenosis in coronary artery bypass grafting;
LUAD	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg08847533	chr14:75593920	NEK9	0.4	6.85	0.32	2.68e-11	Height;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg22559639	chr12:53895182	TARBP2	-0.37	-6.57	-0.3	1.46e-10	Schizophrenia;
LUAD	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg10518543	chr12:38710700	ALG10B	-0.43	-7.16	-0.33	3.7e-12	Bladder cancer;
LUAD	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg13012494	chr21:47604986	C21orf56	0.48	7.96	0.36	1.64e-14	Testicular germ cell tumor;
LUAD	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg26441486	chr22:50317300	CRELD2	0.43	6.45	0.3	3.1e-10	Schizophrenia;
LUAD	cis	rs12893597	0.715	rs12896100	chr14:76825064	C/T	cg20290672	chr14:76816747	NA	-0.43	-7.03	-0.32	8.09e-12	Maximal oxygen uptake response;
LUAD	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg27490568	chr2:178487706	NA	0.41	6.68	0.31	7.71e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg22676075	chr6:135203613	NA	0.39	7.26	0.33	1.9e-12	Red blood cell count;
LUAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08219700	chr8:58056026	NA	0.64	11.82	0.5	4.52e-28	Developmental language disorder (linguistic errors);
LUAD	trans	rs853679	0.607	rs13199906	chr6:27834139	C/G	cg01620082	chr3:125678407	NA	-1.04	-10.25	-0.45	3.6e-22	Depression;
LUAD	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06544989	chr22:39130855	UNC84B	0.48	9.56	0.42	9.49e-20	Menopause (age at onset);
LUAD	cis	rs72766638	0.895	rs11795079	chr9:136930134	T/C	cg13789015	chr9:136890014	NCRNA00094	0.62	7.95	0.36	1.7e-14	Mosquito bite size;
LUAD	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03264133	chr6:25882463	NA	-0.83	-11.71	-0.49	1.28e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.69	-13.55	-0.55	5.36e-35	Longevity;Endometriosis;
LUAD	trans	rs587242	1.000	rs663771	chr1:96891855	C/G	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg12179176	chr11:130786555	SNX19	0.55	9.27	0.41	9.37e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg20119798	chr7:94954144	PON1	-0.48	-6.53	-0.3	1.94e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg19318889	chr4:1322082	MAEA	0.46	7.62	0.35	1.7e-13	Obesity-related traits;
LUAD	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg05373962	chr22:49881684	NA	0.47	10.91	0.47	1.43e-24	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	11.84	0.5	4.09e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg19622623	chr12:86230825	RASSF9	-0.42	-7.36	-0.34	9.55e-13	Major depressive disorder;
LUAD	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg07828340	chr4:882639	GAK	0.99	10.24	0.45	4.03e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs938554	1.000	rs938555	chr4:9926051	A/G	cg11266682	chr4:10021025	SLC2A9	0.43	7.41	0.34	6.82e-13	Blood metabolite levels;
LUAD	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg23252815	chr20:44420276	WFDC3;DNTTIP1	0.38	6.38	0.3	4.59e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg16606324	chr3:10149918	C3orf24	0.64	10.64	0.46	1.38e-23	Alzheimer's disease;
LUAD	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.35	0.38	1e-15	Platelet count;
LUAD	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg04850017	chr11:63683019	RCOR2	0.36	7.84	0.36	3.76e-14	Pulse pressure;
LUAD	cis	rs11971779	0.588	rs6972408	chr7:139071474	T/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.46	-0.3	2.86e-10	Diisocyanate-induced asthma;
LUAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg11062466	chr8:58055876	NA	0.81	10.17	0.44	7.19e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg06753367	chr22:24256600	NA	-0.39	-7.07	-0.33	6.47e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.71	12.28	0.51	7.69e-30	Mean corpuscular volume;
LUAD	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg18230493	chr5:56204884	C5orf35	0.71	11.29	0.48	5.07e-26	Initial pursuit acceleration;
LUAD	cis	rs12367572	0.965	rs7979717	chr12:45242272	A/T	cg04608330	chr12:45269318	NELL2	-0.35	-6.51	-0.3	2.11e-10	Gut microbiome composition (summer);
LUAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg21226059	chr5:178986404	RUFY1	0.68	12.12	0.51	3.27e-29	Lung cancer;
LUAD	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.23	0.54	1.09e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs2735413	0.918	rs12924772	chr16:78083115	T/C	cg01028844	chr5:122736986	CEP120	0.41	6.5	0.3	2.24e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.42	-7.44	-0.34	5.57e-13	Longevity;Endometriosis;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg25008494	chr17:37910528	NA	-0.69	-6.86	-0.32	2.51e-11	Type 2 diabetes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21411757	chr12:93771484	NUDT4;NUDT4P1	-0.43	-6.74	-0.31	5.26e-11	Height;
LUAD	cis	rs11971779	0.618	rs3778931	chr7:139102490	A/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.38e-10	Diisocyanate-induced asthma;
LUAD	cis	rs72928364	1.000	rs13092605	chr3:100620403	G/A	cg10123952	chr3:100791384	NA	0.59	6.95	0.32	1.4e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg08132940	chr7:1081526	C7orf50	-0.71	-10.26	-0.45	3.36e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg05902063	chr12:96794315	CDK17	-0.41	-6.93	-0.32	1.55e-11	Schizophrenia;
LUAD	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg14092988	chr3:52407081	DNAH1	0.44	8.88	0.4	1.99e-17	Bipolar disorder;
LUAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg18305652	chr10:134549665	INPP5A	0.61	11.4	0.48	2.02e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.43	-0.34	6.08e-13	Bipolar disorder;
LUAD	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg03388025	chr16:89894329	SPIRE2	0.31	7.28	0.33	1.6e-12	Vitiligo;
LUAD	cis	rs7737355	0.947	rs193458	chr5:130816284	G/C	cg25547332	chr5:131281432	NA	0.42	6.4	0.3	4.05e-10	Life satisfaction;
LUAD	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg10556349	chr10:835070	NA	-0.45	-6.86	-0.32	2.51e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg27432699	chr2:27873401	GPN1	0.58	10.23	0.45	4.14e-22	Oral cavity cancer;
LUAD	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg14019146	chr3:50243930	SLC38A3	-0.35	-6.47	-0.3	2.66e-10	Body mass index;
LUAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg04025307	chr7:1156635	C7orf50	0.71	12.76	0.53	8.6e-32	Longevity;Endometriosis;
LUAD	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg24838063	chr12:130822603	PIWIL1	0.64	10.68	0.46	9.9899999999999993e-24	Menopause (age at onset);
LUAD	cis	rs3772130	1.000	rs35988617	chr3:121432902	A/G	cg20356878	chr3:121714668	ILDR1	0.5	7.82	0.36	4.36e-14	Cognitive performance;
LUAD	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg06221963	chr1:154839813	KCNN3	-0.85	-20.1	-0.7	1.48e-63	Prostate cancer;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg01936090	chr1:179923733	CEP350	0.39	6.42	0.3	3.61e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs17401966	0.931	rs17410217	chr1:10371854	A/G	cg19773385	chr1:10388646	KIF1B	-0.4	-6.54	-0.3	1.74e-10	Hepatocellular carcinoma;
LUAD	cis	rs7191700	1.000	rs7191700	chr16:11406803	C/T	cg00044050	chr16:11439710	C16orf75	0.68	9.9	0.43	6.54e-21	Multiple sclerosis;
LUAD	cis	rs1997103	1.000	rs4947499	chr7:55407196	T/C	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg10755058	chr3:40428713	ENTPD3	0.43	8.26	0.37	1.93e-15	Renal cell carcinoma;
LUAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.17e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg20607798	chr8:58055168	NA	0.76	9.48	0.42	1.79e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7943203	1.000	rs1960006	chr11:108294107	A/G	cg04873221	chr11:107992290	ACAT1	-0.43	-6.91	-0.32	1.74e-11	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg21890820	chr11:65308645	LTBP3	-0.57	-9.54	-0.42	1.16e-19	Bone mineral density;
LUAD	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg14186256	chr22:23484241	RTDR1	0.46	7.79	0.35	5.4e-14	Bone mineral density;
LUAD	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg24803719	chr17:45855879	NA	-0.33	-7.47	-0.34	4.49e-13	IgG glycosylation;
LUAD	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg20607798	chr8:58055168	NA	0.78	8.57	0.38	1.93e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg03733263	chr8:22462867	KIAA1967	0.66	10.98	0.47	7.32e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg13393036	chr8:95962371	TP53INP1	0.34	6.96	0.32	1.3e-11	Type 2 diabetes;
LUAD	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.82	-0.31	3.18e-11	Morning vs. evening chronotype;
LUAD	cis	rs11098699	0.821	rs4833887	chr4:124208033	T/C	cg09941581	chr4:124220074	SPATA5	0.5	8.07	0.37	7.58e-15	Mosquito bite size;
LUAD	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg22029157	chr1:209979665	IRF6	0.78	10.01	0.44	2.56e-21	Cleft lip with or without cleft palate;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03812994	chr10:81205453	ZCCHC24	-0.39	-6.58	-0.3	1.37e-10	Cancer;
LUAD	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg02466173	chr16:30829666	NA	-0.73	-13.28	-0.54	6.84e-34	Multiple myeloma;
LUAD	cis	rs7789940	0.951	rs7779014	chr7:75975586	C/T	cg10167463	chr7:75959203	YWHAG	-0.71	-12.89	-0.53	2.6e-32	Multiple sclerosis;
LUAD	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg04511125	chr2:88470314	THNSL2	0.96	11.3	0.48	4.88e-26	Plasma clusterin levels;
LUAD	cis	rs889398	0.967	rs7359336	chr16:69733460	G/A	cg26679644	chr16:69762563	NA	0.36	6.56	0.3	1.6e-10	Body mass index;
LUAD	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg05182265	chr7:156933206	UBE3C	-0.68	-13.01	-0.53	8.78e-33	Body mass index;
LUAD	cis	rs7216064	1.000	rs2128792	chr17:65857177	C/T	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs4642101	0.765	rs1985428	chr3:12829315	A/G	cg24848339	chr3:12840334	CAND2	-0.39	-7.92	-0.36	2.11e-14	QRS complex (12-leadsum);
LUAD	cis	rs1451375	0.698	rs11238214	chr7:50636018	A/G	cg18232548	chr7:50535776	DDC	0.51	8.33	0.38	1.12e-15	Malaria;
LUAD	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.55	7.78	0.35	5.54e-14	Platelet count;
LUAD	cis	rs9296092	0.521	rs6929165	chr6:33515958	T/G	cg13560919	chr6:33536144	NA	-0.82	-15.1	-0.59	1.57e-41	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs1784581	0.706	rs9346895	chr6:162431168	T/C	cg17173639	chr6:162384350	PARK2	0.51	9.26	0.41	1.04e-18	Itch intensity from mosquito bite;
LUAD	cis	rs877282	0.945	rs11253397	chr10:789774	A/G	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	trans	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg04995722	chr7:26192034	NFE2L3	-0.41	-7.28	-0.33	1.6e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs344364	0.602	rs8044343	chr16:1881145	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-6.95	-0.32	1.43e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg23625390	chr15:77176239	SCAPER	0.39	7.12	0.33	4.81e-12	Blood metabolite levels;
LUAD	cis	rs1003719	0.591	rs2040125	chr21:38549236	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.43	7.24	0.33	2.2e-12	Eye color traits;
LUAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg23743428	chr13:21893420	NA	-0.49	-8.64	-0.39	1.17e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs76878669	0.561	rs10791876	chr11:66169646	C/T	cg10616300	chr11:66138557	SLC29A2	-0.37	-7.68	-0.35	1.13e-13	Educational attainment (years of education);
LUAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg15117754	chr3:10150083	C3orf24	0.4	6.66	0.31	8.79e-11	Alzheimer's disease;
LUAD	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.38	-0.34	8.39e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg10295955	chr4:187884368	NA	-1.08	-25.09	-0.77	9.02e-86	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg12419862	chr22:24373484	LOC391322	-0.68	-11.57	-0.49	4.33e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs938554	0.737	rs11723439	chr4:9951819	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-9.01	-0.4	6.89e-18	Blood metabolite levels;
LUAD	cis	rs17818399	0.817	rs17767994	chr2:46860079	G/T	cg09399716	chr2:46890238	NA	0.41	7.81	0.35	4.62e-14	Height;
LUAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg21951975	chr1:209979733	IRF6	0.54	8.08	0.37	6.84e-15	Cleft lip with or without cleft palate;
LUAD	trans	rs1493916	0.905	rs4239383	chr18:31401066	T/C	cg13755796	chr4:20253514	NA	-0.44	-7.55	-0.34	2.64e-13	Life satisfaction;
LUAD	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg25554036	chr4:6271136	WFS1	0.66	12.0	0.5	9.08e-29	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs938554	0.779	rs4639073	chr4:9973781	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-7.65	-0.35	1.37e-13	Blood metabolite levels;
LUAD	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg12927641	chr6:109611667	NA	-0.54	-9.62	-0.42	6.19e-20	Reticulocyte fraction of red cells;
LUAD	cis	rs12049351	0.774	rs10449250	chr1:229640771	A/G	cg11742688	chr1:229674241	ABCB10	-0.41	-6.82	-0.31	3.17e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs6906287	0.647	rs12211576	chr6:118872080	G/A	cg18833306	chr6:118973337	C6orf204	0.48	8.54	0.38	2.36e-16	Electrocardiographic conduction measures;
LUAD	cis	rs1448094	0.967	rs7313443	chr12:86332940	G/A	cg18827107	chr12:86230957	RASSF9	-0.44	-7.93	-0.36	1.94e-14	Major depressive disorder;
LUAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg20607798	chr8:58055168	NA	0.58	7.41	0.34	6.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg17633681	chr16:88106987	BANP	0.41	7.03	0.32	8.28e-12	Menopause (age at onset);
LUAD	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.6	-11.6	-0.49	3.49e-27	Schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18247177	chr17:7745472	KDM6B	-0.5	-7.89	-0.36	2.59e-14	Height;
LUAD	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.17	0.33	3.36e-12	Tonsillectomy;
LUAD	cis	rs11893307	0.566	rs62179714	chr2:191567541	G/C	cg27211696	chr2:191398769	TMEM194B	-0.45	-6.92	-0.32	1.68e-11	Mean platelet volume;
LUAD	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg18190219	chr22:46762943	CELSR1	-0.54	-6.66	-0.31	8.41e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.05	0.36	8.6e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.5	-0.34	3.69e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg13047869	chr3:10149882	C3orf24	0.59	9.99	0.44	2.95e-21	Alzheimer's disease;
LUAD	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	7.45	0.34	5.22e-13	Renal cell carcinoma;
LUAD	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg12756686	chr19:29218302	NA	0.54	6.91	0.32	1.85e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs11025523	0.950	rs7952732	chr11:20380048	A/G	cg02900213	chr11:20385756	HTATIP2	0.47	7.27	0.33	1.73e-12	Obesity-related traits;
LUAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg26818010	chr10:134567672	INPP5A	-0.96	-15.8	-0.61	1.63e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg06974483	chr4:124317831	SPRY1	0.55	6.4	0.3	4.16e-10	Lymphocyte counts;
LUAD	cis	rs847577	0.677	rs4729403	chr7:97707841	G/C	cg21770322	chr7:97807741	LMTK2	-0.3	-6.71	-0.31	6.31e-11	Breast cancer;
LUAD	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14240646	chr10:27532245	ACBD5	-0.92	-11.87	-0.5	3.02e-28	Breast cancer;
LUAD	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg04944784	chr2:26401820	FAM59B	-0.89	-13.72	-0.55	1.08e-35	Gut microbiome composition (summer);
LUAD	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.15	0.33	3.87e-12	Menopause (age at onset);
LUAD	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.55	0.34	2.73e-13	Breast cancer;
LUAD	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg05368731	chr17:41323189	NBR1	0.83	16.4	0.62	3.87e-47	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.28	-0.33	1.67e-12	Height;
LUAD	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg03684893	chr10:554711	DIP2C	-0.52	-9.89	-0.43	7.1e-21	Psychosis in Alzheimer's disease;
LUAD	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg18944383	chr4:111397179	ENPEP	0.41	8.26	0.37	1.87e-15	Height;
LUAD	cis	rs4372836	0.964	rs17007191	chr2:28932502	C/T	cg09522027	chr2:28974177	PPP1CB	0.56	8.84	0.39	2.62e-17	Body mass index;
LUAD	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.6	-0.39	1.57e-16	Total body bone mineral density;
LUAD	cis	rs2835872	0.737	rs1787404	chr21:39049362	C/T	cg06728970	chr21:39037746	KCNJ6	-0.37	-6.88	-0.32	2.11e-11	Electroencephalographic traits in alcoholism;
LUAD	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg04282206	chr17:62833786	PLEKHM1P	0.42	6.98	0.32	1.11e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6952808	0.964	rs10950407	chr7:1895666	T/G	cg24813613	chr7:1882135	MAD1L1	-0.54	-8.52	-0.38	2.92e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg24813613	chr7:1882135	MAD1L1	-0.44	-6.98	-0.32	1.16e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs300774	0.925	rs6732024	chr2:148410	A/G	cg21211680	chr2:198530	NA	-0.47	-7.36	-0.34	9.94e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.38	0.34	8.46e-13	Tonsillectomy;
LUAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4711350	1.000	rs2395401	chr6:33759471	T/C	cg13859433	chr6:33739653	LEMD2	-0.34	-6.64	-0.31	9.9e-11	Schizophrenia;
LUAD	cis	rs7000551	0.751	rs1116084	chr8:22395309	C/T	cg12081754	chr8:22256438	SLC39A14	0.43	6.9	0.32	1.93e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9463078	0.739	rs1293457	chr6:44758098	T/C	cg25276700	chr6:44698697	NA	0.34	6.38	0.3	4.67e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg06453172	chr10:134556979	INPP5A	-0.77	-10.93	-0.47	1.16e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg25024717	chr12:54324583	NA	-0.33	-6.72	-0.31	5.84e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg18138036	chr10:133769891	PPP2R2D	0.4	6.53	0.3	1.9e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.62	-0.39	1.31e-16	Alzheimer's disease (late onset);
LUAD	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg11517269	chr6:28058789	ZSCAN12L1	0.26	6.48	0.3	2.58e-10	Cardiac Troponin-T levels;
LUAD	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.57	8.3	0.37	1.39e-15	Platelet count;
LUAD	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg23245007	chr3:195682326	NA	-0.4	-6.63	-0.31	1.04e-10	Pancreatic cancer;
LUAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg20607798	chr8:58055168	NA	0.64	8.11	0.37	5.45e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg07606381	chr6:8435919	SLC35B3	0.41	6.68	0.31	7.42e-11	Motion sickness;
LUAD	cis	rs208520	0.690	rs851465	chr6:66840293	G/A	cg07460842	chr6:66804631	NA	-1.07	-16.78	-0.63	8.61e-49	Exhaled nitric oxide output;
LUAD	cis	rs921968	0.565	rs7599945	chr2:219641528	G/T	cg02176678	chr2:219576539	TTLL4	-0.58	-11.8	-0.5	5.42e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg17761419	chr8:57350749	NA	-0.52	-7.83	-0.36	4.07e-14	Obesity-related traits;
LUAD	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg20500540	chr8:101228448	SPAG1	-0.36	-6.46	-0.3	2.82e-10	Atrioventricular conduction;
LUAD	cis	rs3540	0.533	rs2601197	chr15:90940059	C/A	cg10434728	chr15:90938212	IQGAP1	0.43	8.58	0.38	1.88e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg12935359	chr14:103987150	CKB	-0.49	-7.87	-0.36	3.06e-14	Body mass index;
LUAD	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg04944784	chr2:26401820	FAM59B	0.87	11.58	0.49	3.89e-27	Gut microbiome composition (summer);
LUAD	cis	rs4919694	1.000	rs75691516	chr10:104652045	C/T	cg04362960	chr10:104952993	NT5C2	0.74	8.03	0.36	9.68e-15	Arsenic metabolism;
LUAD	cis	rs9549328	0.616	rs35086993	chr13:113617305	G/A	cg17524180	chr13:113633600	MCF2L	0.3	6.49	0.3	2.4e-10	Systolic blood pressure;
LUAD	cis	rs3733585	0.566	rs35955619	chr4:9918986	T/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-10.58	-0.46	2.34e-23	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.47	-9.71	-0.43	3.03e-20	Total body bone mineral density;
LUAD	trans	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg07817883	chr1:32538562	TMEM39B	1.5	12.94	0.53	1.61e-32	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs62229266	0.633	rs743420	chr21:37387402	A/G	cg08632701	chr21:37451849	NA	-0.4	-6.74	-0.31	5.29e-11	Mitral valve prolapse;
LUAD	cis	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg23950597	chr19:37808831	NA	-0.66	-7.85	-0.36	3.49e-14	Coronary artery calcification;
LUAD	cis	rs11893307	0.509	rs17465200	chr2:191549636	C/T	cg27211696	chr2:191398769	TMEM194B	-0.41	-6.4	-0.3	4.08e-10	Mean platelet volume;
LUAD	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg22823121	chr1:150693482	HORMAD1	0.45	9.13	0.41	2.95e-18	Tonsillectomy;
LUAD	cis	rs654950	0.934	rs662999	chr1:42001160	A/C	cg06885757	chr1:42089581	HIVEP3	0.42	9.24	0.41	1.21e-18	Airway imaging phenotypes;
LUAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06873352	chr17:61820015	STRADA	0.81	18.02	0.66	2.74e-54	Prudent dietary pattern;
LUAD	trans	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg01620082	chr3:125678407	NA	-1.02	-9.91	-0.43	6e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4072705	0.646	rs915034	chr9:127244955	G/A	cg01786973	chr9:127249749	NR5A1	0.3	6.8	0.31	3.54e-11	Menarche (age at onset);
LUAD	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg18490616	chr2:88469792	THNSL2	0.64	6.48	0.3	2.63e-10	Plasma clusterin levels;
LUAD	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg14584255	chr6:163149320	PACRG;PARK2	-0.4	-7.7	-0.35	9.55e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	9.23	0.41	1.28e-18	Electrocardiographic conduction measures;
LUAD	cis	rs11650494	0.908	rs75092916	chr17:47412578	T/C	cg08112188	chr17:47440006	ZNF652	0.94	7.85	0.36	3.51e-14	Prostate cancer;
LUAD	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg03609598	chr5:56110824	MAP3K1	0.5	7.42	0.34	6.53e-13	Initial pursuit acceleration;
LUAD	trans	rs12365397	0.569	rs7926780	chr11:43236755	A/G	cg03416422	chr11:111807767	DIXDC1	0.37	6.47	0.3	2.71e-10	Migraine;
LUAD	cis	rs11756438	0.572	rs2638529	chr6:119006459	T/C	cg18833306	chr6:118973337	C6orf204	0.5	8.95	0.4	1.15e-17	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg15017067	chr4:17643749	FAM184B	0.35	6.84	0.32	2.82e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7274811	0.711	rs291677	chr20:32027915	A/G	cg13403462	chr20:32256071	NECAB3;C20orf134	0.44	6.7	0.31	6.75e-11	Height;
LUAD	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.54	-0.6	2.15e-43	Chronic sinus infection;
LUAD	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg17105886	chr17:28927953	LRRC37B2	0.83	7.9	0.36	2.38e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs11165623	0.602	rs4619021	chr1:97025910	T/C	cg10631902	chr5:14652156	NA	-0.45	-8.08	-0.37	6.73e-15	Hip circumference;Waist circumference;
LUAD	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg06544989	chr22:39130855	UNC84B	0.44	8.94	0.4	1.21e-17	Menopause (age at onset);
LUAD	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg00701064	chr4:6280414	WFS1	0.74	17.06	0.64	4.72e-50	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg16797656	chr11:68205561	LRP5	0.47	8.87	0.4	2.04e-17	Total body bone mineral density;
LUAD	cis	rs3106136	0.967	rs2129595	chr4:95224454	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.71	-0.35	8.92e-14	Capecitabine sensitivity;
LUAD	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg07538946	chr5:131705188	SLC22A5	0.51	8.08	0.37	6.87e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg10382835	chr6:42185730	MRPS10	0.57	7.11	0.33	4.82e-12	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg04155289	chr7:94953770	PON1	-0.54	-7.37	-0.34	9.01e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6426558	0.502	rs6697665	chr1:227474665	T/C	cg10327440	chr1:227177885	CDC42BPA	0.55	8.85	0.4	2.41e-17	Neutrophil percentage of white cells;
LUAD	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg00383909	chr3:49044727	WDR6	0.99	10.63	0.46	1.45e-23	Cognitive function;
LUAD	cis	rs891088	0.622	rs10426094	chr19:7205240	C/T	cg09779027	chr19:7224513	INSR	-0.42	-6.58	-0.3	1.39e-10	Hip circumference adjusted for BMI;Height;
LUAD	cis	rs758324	0.947	rs6596039	chr5:131198652	C/A	cg06307176	chr5:131281290	NA	0.51	8.01	0.36	1.09e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg08132940	chr7:1081526	C7orf50	-0.77	-10.35	-0.45	1.63e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg20320717	chr1:151043708	GABPB2	-0.53	-6.43	-0.3	3.46e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg01028140	chr2:1542097	TPO	-0.55	-7.47	-0.34	4.78e-13	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg03929089	chr4:120376271	NA	-0.92	-17.27	-0.64	5.85e-51	Height;
LUAD	cis	rs11771526	0.551	rs2392053	chr7:32259056	C/T	cg27532318	chr7:32358331	NA	-0.46	-6.57	-0.3	1.51e-10	Body mass index;
LUAD	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.41	0.34	6.78e-13	Tonsillectomy;
LUAD	cis	rs12681287	0.640	rs13280468	chr8:87338452	C/T	cg00550725	chr8:87521180	FAM82B	0.46	6.61	0.31	1.16e-10	Caudate activity during reward;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06435639	chr8:37756942	RAB11FIP1	-0.42	-6.49	-0.3	2.35e-10	Height;
LUAD	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg19980929	chr12:42632907	YAF2	-0.34	-6.54	-0.3	1.76e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-7.5	-0.34	3.87e-13	Lung cancer;
LUAD	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg18129748	chr3:49941408	MST1R	0.39	6.47	0.3	2.78e-10	Body mass index;
LUAD	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg12927641	chr6:109611667	NA	-0.5	-8.35	-0.38	9.62e-16	Reticulocyte fraction of red cells;
LUAD	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg17279839	chr7:150038598	RARRES2	-0.4	-6.89	-0.32	2.03e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg03467027	chr4:99064603	C4orf37	0.4	6.5	0.3	2.21e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2663905	0.611	rs2663924	chr15:81392903	T/G	cg22872349	chr15:81410745	NA	-0.38	-6.88	-0.32	2.17e-11	QT interval (drug interaction);
LUAD	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg22117172	chr7:91764530	CYP51A1	0.38	8.39	0.38	7.56e-16	Breast cancer;
LUAD	cis	rs113835537	0.529	rs2276406	chr11:66283257	C/T	cg26679405	chr11:66247800	DPP3	-0.46	-6.67	-0.31	8.26e-11	Airway imaging phenotypes;
LUAD	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27286337	chr10:134555280	INPP5A	0.67	9.57	0.42	9.13e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg26195577	chr20:24973756	C20orf3	-0.95	-17.34	-0.64	2.83e-51	Blood protein levels;
LUAD	cis	rs17155006	0.746	rs435522	chr7:107748701	A/G	cg05962710	chr7:107745446	LAMB4	-0.34	-7.31	-0.33	1.37e-12	Pneumococcal bacteremia;
LUAD	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg01689657	chr7:91764605	CYP51A1	-0.29	-6.81	-0.31	3.45e-11	Breast cancer;
LUAD	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg26924012	chr15:45694286	SPATA5L1	0.64	10.98	0.47	7.37e-25	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg04398451	chr17:18023971	MYO15A	-0.79	-14.56	-0.58	3.26e-39	Total body bone mineral density;
LUAD	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg09323728	chr8:95962352	TP53INP1	-0.32	-7.71	-0.35	9.23e-14	Type 2 diabetes;
LUAD	cis	rs2116941	1.000	rs8104426	chr19:10338676	G/T	cg01850179	chr19:10340795	S1PR2	0.82	13.8	0.56	5.09e-36	Pulse pressure;
LUAD	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg03806693	chr22:41940476	POLR3H	0.58	8.49	0.38	3.65e-16	Vitiligo;
LUAD	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg06064525	chr11:970664	AP2A2	-0.45	-8.89	-0.4	1.85e-17	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9923856	0.570	rs9652599	chr16:11079161	A/G	cg04616529	chr16:11181986	CLEC16A	-0.41	-6.36	-0.3	5.19e-10	Atopic dermatitis;Adult asthma;
LUAD	trans	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg19862616	chr7:65841803	NCRNA00174	1.03	25.27	0.78	1.46e-86	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg04546413	chr19:29218101	NA	0.67	10.51	0.45	4.19e-23	Methadone dose in opioid dependence;
LUAD	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg02466173	chr16:30829666	NA	-0.84	-17.39	-0.65	1.75e-51	Dementia with Lewy bodies;
LUAD	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg17077180	chr1:38461687	NA	0.46	8.93	0.4	1.34e-17	Coronary artery disease;
LUAD	cis	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg14752069	chr8:11977206	FAM66D	-0.3	-6.5	-0.3	2.3e-10	Triglycerides;
LUAD	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg04225089	chr17:73874465	TRIM47	-0.4	-7.06	-0.32	6.77e-12	Psoriasis;
LUAD	cis	rs4523957	0.583	rs9303251	chr17:2047214	C/T	cg16513277	chr17:2031491	SMG6	-0.99	-20.01	-0.7	3.5e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg03037974	chr15:76606532	NA	0.37	7.83	0.36	3.87e-14	Blood metabolite levels;
LUAD	cis	rs1448094	0.842	rs7966352	chr12:86438705	A/C	cg19622623	chr12:86230825	RASSF9	-0.35	-6.46	-0.3	2.9e-10	Major depressive disorder;
LUAD	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg15448220	chr1:150897856	SETDB1	-0.42	-7.08	-0.33	6.08e-12	Tonsillectomy;
LUAD	cis	rs2625529	0.761	rs4776582	chr15:72207520	A/T	cg16672083	chr15:72433130	SENP8	-0.75	-12.38	-0.52	2.91e-30	Red blood cell count;
LUAD	cis	rs2282300	0.739	rs1933343	chr11:30310992	T/C	cg25418670	chr11:30344373	C11orf46	0.54	7.4	0.34	7.27e-13	Morning vs. evening chronotype;
LUAD	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg05373962	chr22:49881684	NA	-0.53	-12.22	-0.51	1.22e-29	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg19862616	chr7:65841803	NCRNA00174	1.03	25.39	0.78	4.74e-87	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg13732083	chr21:47605072	C21orf56	0.42	6.95	0.32	1.39e-11	Testicular germ cell tumor;
LUAD	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.73	-14.15	-0.57	1.69e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs12530845	0.623	rs76485854	chr7:135352668	T/C	cg23117316	chr7:135346802	PL-5283	-0.6	-8.99	-0.4	8.23e-18	Red blood cell traits;
LUAD	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11644478	chr21:40555479	PSMG1	0.71	11.89	0.5	2.53e-28	Cognitive function;
LUAD	cis	rs3026445	0.832	rs7975364	chr12:110602275	A/T	cg12870014	chr12:110450643	ANKRD13A	0.37	6.78	0.31	3.97e-11	QT interval;
LUAD	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg14582100	chr15:45693742	SPATA5L1	0.64	12.76	0.53	8.95e-32	Homoarginine levels;
LUAD	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-11.16	-0.48	1.62e-25	Monocyte percentage of white cells;
LUAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg27532560	chr4:187881888	NA	-0.35	-6.72	-0.31	5.92e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3733418	0.929	rs12507869	chr4:165895674	T/C	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-6.72	-0.31	5.95e-11	Obesity-related traits;
LUAD	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg23277830	chr1:3704460	LRRC47	0.42	8.49	0.38	3.54e-16	Red cell distribution width;
LUAD	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg07570687	chr10:102243282	WNT8B	0.45	6.88	0.32	2.22e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.55	0.38	2.24e-16	Rheumatoid arthritis;
LUAD	cis	rs9399401	0.601	rs262130	chr6:142853486	C/T	cg03128060	chr6:142623767	GPR126	0.43	7.68	0.35	1.08e-13	Chronic obstructive pulmonary disease;
LUAD	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.45	-0.38	4.61e-16	Schizophrenia;
LUAD	cis	rs17095355	0.605	rs7075964	chr10:111631265	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-7.73	-0.35	7.93e-14	Biliary atresia;
LUAD	cis	rs921968	0.540	rs6746040	chr2:219588890	G/T	cg02176678	chr2:219576539	TTLL4	-0.57	-11.34	-0.48	3.34e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2235642	0.533	rs2667679	chr16:1654946	G/A	cg03034668	chr16:1723424	CRAMP1L	-0.47	-8.07	-0.37	7.35e-15	Coronary artery disease;
LUAD	cis	rs354225	0.544	rs12713266	chr2:54805443	G/T	cg26097391	chr2:54893211	SPTBN1	0.42	6.42	0.3	3.73e-10	Schizophrenia;
LUAD	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg10978503	chr1:24200527	CNR2	0.59	12.81	0.53	5.87e-32	Immature fraction of reticulocytes;
LUAD	cis	rs1451375	0.572	rs745042	chr7:50544138	A/G	cg18232548	chr7:50535776	DDC	-0.65	-9.05	-0.4	5.3e-18	Malaria;
LUAD	cis	rs8067287	0.640	rs62065424	chr17:16828650	A/G	cg26910001	chr17:16838321	NA	-0.5	-7.03	-0.32	8.23e-12	Diabetic kidney disease;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14737592	chr12:57914238	DDIT3	0.48	7.35	0.34	1.04e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg06753367	chr22:24256600	NA	-0.38	-6.62	-0.31	1.12e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.68e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1215050	0.791	rs548892	chr4:98724701	C/T	cg24818145	chr4:99064322	C4orf37	0.41	7.0	0.32	9.84e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs910187	0.678	rs6124967	chr20:45813624	T/C	cg27589058	chr20:45804311	EYA2	-0.31	-7.13	-0.33	4.5e-12	Migraine;
LUAD	trans	rs2018683	0.523	rs1499224	chr7:29029468	T/G	cg19402173	chr7:128379420	CALU	-0.45	-7.05	-0.32	7.28e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6690583	0.524	rs12029690	chr1:85452867	C/G	cg22153463	chr1:85462885	MCOLN2	0.55	6.37	0.3	4.97e-10	Serum sulfate level;
LUAD	cis	rs7945718	0.775	rs10500759	chr11:12822588	A/G	cg25843174	chr11:12811716	TEAD1	-0.21	-6.41	-0.3	3.8e-10	Educational attainment (years of education);
LUAD	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg18404041	chr3:52824283	ITIH1	-0.45	-8.33	-0.38	1.17e-15	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2224391	0.628	rs9392666	chr6:5249888	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.62	-9.46	-0.42	2.2e-19	Height;
LUAD	cis	rs2404602	0.735	rs2468130	chr15:76796496	T/C	cg23625390	chr15:77176239	SCAPER	-0.44	-7.04	-0.32	7.67e-12	Blood metabolite levels;
LUAD	cis	rs6988985	0.693	rs6395	chr8:143956808	A/C	cg10324643	chr8:143916377	GML	0.3	6.56	0.3	1.58e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs733175	0.857	rs3796835	chr4:10011530	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	7.7	0.35	9.54e-14	Psychosis and Alzheimer's disease;
LUAD	trans	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.91	-0.32	1.8e-11	Gout;
LUAD	trans	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.28	-0.33	1.66e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg09873201	chr16:3507582	NAT15	0.55	8.84	0.39	2.55e-17	Tuberculosis;
LUAD	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg06640241	chr16:89574553	SPG7	0.66	11.21	0.48	1.06e-25	Multiple myeloma (IgH translocation);
LUAD	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg04398451	chr17:18023971	MYO15A	0.64	11.42	0.49	1.59e-26	Total body bone mineral density;
LUAD	cis	rs877282	0.891	rs10904557	chr10:797490	C/T	cg17470449	chr10:769945	NA	-0.6	-9.53	-0.42	1.25e-19	Uric acid levels;
LUAD	cis	rs8099014	1.000	rs7241204	chr18:56130246	G/A	cg12907477	chr18:56117327	MIR122	0.38	6.42	0.3	3.76e-10	Platelet count;
LUAD	cis	rs9863	0.861	rs4930723	chr12:124423600	G/C	cg17723958	chr12:124429295	CCDC92	-0.44	-7.02	-0.32	9.09e-12	White blood cell count;
LUAD	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg07305463	chr2:136567211	LCT	0.37	7.15	0.33	3.86e-12	Mosquito bite size;
LUAD	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg08999081	chr20:33150536	PIGU	-0.63	-14.1	-0.57	2.92e-37	Glomerular filtration rate (creatinine);
LUAD	trans	rs783540	0.542	rs62009945	chr15:83299956	T/A	cg16105309	chr15:79090380	ADAMTS7	0.41	6.93	0.32	1.61e-11	Schizophrenia;
LUAD	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg05082376	chr22:42548792	NA	-0.42	-7.07	-0.32	6.6e-12	Schizophrenia;
LUAD	cis	rs72960926	0.590	rs78950961	chr6:74745847	T/C	cg03266952	chr6:74778945	NA	-0.75	-7.41	-0.34	7.01e-13	Metabolite levels (MHPG);
LUAD	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg13327785	chr12:132219529	SFRS8	0.39	7.05	0.32	7.5e-12	Migraine;
LUAD	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-8.54	-0.38	2.47e-16	Type 2 diabetes;
LUAD	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg27446573	chr6:127587934	RNF146	0.44	6.51	0.3	2.11e-10	Breast cancer;
LUAD	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg00666640	chr1:248458726	OR2T12	0.3	7.24	0.33	2.14e-12	Common traits (Other);
LUAD	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.55	0.34	2.73e-13	Platelet count;
LUAD	cis	rs796825	0.671	rs9843220	chr3:120003144	A/G	cg21790991	chr3:120137480	FSTL1	0.38	6.8	0.31	3.59e-11	HIV-1 susceptibility;
LUAD	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	7.1	0.33	5.31e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg19196401	chr6:110721138	DDO	0.49	9.55	0.42	1.03e-19	Platelet distribution width;
LUAD	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.04e-13	Morning vs. evening chronotype;
LUAD	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11890956	chr21:40555474	PSMG1	-0.59	-9.58	-0.42	8.11e-20	Cognitive function;
LUAD	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg14228332	chr4:119757509	SEC24D	0.7	6.72	0.31	5.72e-11	Cannabis dependence symptom count;
LUAD	cis	rs9796	0.775	rs57393155	chr15:41426251	A/G	cg21153102	chr15:41252147	NA	0.27	6.36	0.3	5.25e-10	Menopause (age at onset);
LUAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg11941060	chr3:133502564	NA	-0.7	-12.46	-0.52	1.4e-30	Iron status biomarkers;
LUAD	cis	rs2979489	0.699	rs7840356	chr8:30406251	G/A	cg26383811	chr8:30366931	RBPMS	0.69	10.91	0.47	1.43e-24	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs13064411	0.660	rs11916690	chr3:113012343	A/C	cg10517650	chr3:113235015	CCDC52	-0.44	-7.25	-0.33	2.02e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7833986	0.501	rs72653959	chr8:56996516	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	1.02	18.08	0.66	1.43e-54	Height;
LUAD	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.52	0.42	1.32e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06028808	chr11:68637592	NA	0.45	7.56	0.34	2.53e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7216064	0.953	rs62086043	chr17:65968003	A/G	cg08758996	chr17:66097529	LOC651250	0.42	6.65	0.31	9.31e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.37	-0.41	4.45e-19	Schizophrenia;
LUAD	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg18477163	chr1:228402036	OBSCN	-0.38	-7.64	-0.35	1.5e-13	Diastolic blood pressure;
LUAD	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg26597838	chr10:835615	NA	0.68	9.73	0.43	2.48e-20	Eosinophil percentage of granulocytes;
LUAD	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.21e-16	Prostate cancer;
LUAD	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg17105886	chr17:28927953	LRRC37B2	0.66	7.32	0.34	1.23e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg12011299	chr4:100065546	ADH4	0.58	12.2	0.51	1.58e-29	Alcohol dependence;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17397377	chr1:1334575	CCNL2;LOC148413	-0.39	-6.54	-0.3	1.82e-10	Cancer;
LUAD	cis	rs250677	0.522	rs10050928	chr5:148353463	C/A	cg12140854	chr5:148520817	ABLIM3	0.58	9.27	0.41	9.76e-19	Breast cancer;
LUAD	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg02807482	chr3:125708958	NA	-0.66	-8.57	-0.38	1.91e-16	Blood pressure (smoking interaction);
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg26396086	chr1:247494708	ZNF496	0.39	6.47	0.3	2.69e-10	Optic cup area;
LUAD	cis	rs3760982	0.813	rs8111664	chr19:44295092	G/A	cg11993925	chr19:44307056	LYPD5	-0.42	-8.01	-0.36	1.12e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.65	-0.35	1.34e-13	Triglycerides;
LUAD	trans	rs9914544	0.505	rs4924774	chr17:18794920	A/C	cg21372672	chr17:16614065	CCDC144A	-0.36	-6.45	-0.3	3.04e-10	Educational attainment (years of education);
LUAD	cis	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg07988820	chr12:82153109	PPFIA2	-0.45	-7.28	-0.33	1.69e-12	Resting heart rate;
LUAD	cis	rs10489202	0.608	rs7533646	chr1:168077593	A/C	cg24449463	chr1:168025552	DCAF6	-0.61	-9.36	-0.41	4.75e-19	Schizophrenia;
LUAD	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg26354017	chr1:205819088	PM20D1	-0.53	-8.21	-0.37	2.8e-15	Menarche (age at onset);
LUAD	cis	rs12042938	0.507	rs1765777	chr1:231731742	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.41	-7.23	-0.33	2.23e-12	Neuranatomic and neurocognitive phenotypes;
LUAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg07157834	chr1:205819609	PM20D1	0.69	13.37	0.54	3.05e-34	Menarche (age at onset);
LUAD	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg07741184	chr6:167504864	NA	0.41	9.49	0.42	1.77e-19	Crohn's disease;
LUAD	trans	rs747782	0.527	rs75915859	chr11:48232931	C/T	cg15704280	chr7:45808275	SEPT13	0.7	7.62	0.35	1.73e-13	Intraocular pressure;
LUAD	cis	rs11048434	0.761	rs11494570	chr12:9127147	T/C	cg04155231	chr12:9217510	LOC144571	0.42	7.83	0.36	3.89e-14	Sjögren's syndrome;
LUAD	cis	rs9796	0.870	rs4923890	chr15:41258990	T/C	cg21153102	chr15:41252147	NA	-0.26	-6.39	-0.3	4.35e-10	Menopause (age at onset);
LUAD	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg02733842	chr7:1102375	C7orf50	-0.75	-11.17	-0.48	1.49e-25	Bronchopulmonary dysplasia;
LUAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12379764	chr21:47803548	PCNT	0.41	6.73	0.31	5.65e-11	Testicular germ cell tumor;
LUAD	cis	rs67981189	0.634	rs221898	chr14:71605516	A/G	cg15816911	chr14:71606274	NA	0.37	6.95	0.32	1.42e-11	Schizophrenia;
LUAD	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.56	0.3	1.54e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg06221963	chr1:154839813	KCNN3	-0.85	-20.1	-0.7	1.48e-63	Prostate cancer;
LUAD	cis	rs11811982	0.744	rs73102394	chr1:227576152	C/T	cg24860534	chr1:227506868	CDC42BPA	0.55	6.54	0.3	1.77e-10	Optic disc area;
LUAD	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.18	-0.41	1.92e-18	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg02725872	chr8:58115012	NA	-0.33	-6.46	-0.3	2.9e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg09904177	chr6:26538194	HMGN4	0.43	7.21	0.33	2.56e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7809950	1.000	rs10243340	chr7:107090955	A/G	cg23024343	chr7:107201750	COG5	-0.71	-12.06	-0.51	5.55e-29	Coronary artery disease;
LUAD	trans	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.46e-11	Depression;
LUAD	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.44	-0.34	5.54e-13	Total body bone mineral density;
LUAD	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg02493740	chr2:85810744	VAMP5	-0.47	-8.59	-0.39	1.65e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg23958373	chr8:599963	NA	1.07	10.5	0.45	4.32e-23	IgG glycosylation;
LUAD	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg08645402	chr16:4508243	NA	0.58	9.86	0.43	9.16e-21	Schizophrenia;
LUAD	cis	rs6906287	0.647	rs6569020	chr6:118795522	C/T	cg05564266	chr6:118973597	C6orf204	0.34	7.27	0.33	1.71e-12	Electrocardiographic conduction measures;
LUAD	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg17724175	chr1:150552817	MCL1	0.39	9.28	0.41	9.17e-19	Tonsillectomy;
LUAD	cis	rs868036	1.000	rs4776377	chr15:68103387	T/C	cg24579218	chr15:68104479	NA	-0.4	-7.45	-0.34	5.44e-13	Restless legs syndrome;
LUAD	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg15445000	chr17:37608096	MED1	0.44	8.14	0.37	4.51e-15	Glomerular filtration rate (creatinine);
LUAD	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg22491629	chr6:157744540	C6orf35	-0.83	-9.53	-0.42	1.24e-19	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.26	-0.45	3.41e-22	Migraine;Coronary artery disease;
LUAD	cis	rs7731657	0.588	rs11242054	chr5:130330693	A/C	cg08523029	chr5:130500466	HINT1	0.56	7.46	0.34	4.92e-13	Fasting plasma glucose;
LUAD	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg22920501	chr2:26401640	FAM59B	-0.95	-14.07	-0.56	3.62e-37	Gut microbiome composition (summer);
LUAD	cis	rs939658	0.805	rs11631590	chr15:79446199	C/T	cg17916960	chr15:79447300	NA	-0.5	-10.34	-0.45	1.71e-22	Refractive error;
LUAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg03354898	chr7:1950403	MAD1L1	-0.41	-7.85	-0.36	3.52e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs73198271	0.740	rs10103163	chr8:8650675	T/C	cg01851573	chr8:8652454	MFHAS1	0.52	9.2	0.41	1.6e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg25237894	chr2:233734115	C2orf82	0.58	11.0	0.47	6.22e-25	Coronary artery disease;
LUAD	cis	rs4698036	0.626	rs11737042	chr4:10412350	A/G	cg00071950	chr4:10020882	SLC2A9	-0.43	-6.7	-0.31	6.62e-11	Cardiovascular disease risk factors;
LUAD	cis	rs500891	0.525	rs750384	chr6:84030422	C/T	cg08257003	chr6:84140564	ME1	0.34	6.38	0.3	4.57e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg27539214	chr16:67997921	SLC12A4	-0.68	-8.43	-0.38	5.39e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.7	0.53	1.52e-31	Cognitive ability;
LUAD	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.4	0.52	2.37e-30	Tonsillectomy;
LUAD	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.44	6.68	0.31	7.66e-11	Schizophrenia;
LUAD	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg17177755	chr1:15930204	NA	0.43	7.04	0.32	7.97e-12	Systolic blood pressure;
LUAD	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg17173187	chr15:85201210	NMB	0.53	9.43	0.42	2.71e-19	Schizophrenia;
LUAD	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg03929089	chr4:120376271	NA	-0.85	-15.88	-0.61	6.79e-45	Height;
LUAD	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg10591111	chr5:226296	SDHA	-0.54	-7.01	-0.32	9.49e-12	Breast cancer;
LUAD	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22857025	chr5:266934	NA	-0.97	-14.62	-0.58	1.74e-39	Breast cancer;
LUAD	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg20129853	chr10:51489980	NA	-0.35	-7.09	-0.33	5.5e-12	Prostate-specific antigen levels;
LUAD	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg08677398	chr8:58056175	NA	0.5	6.98	0.32	1.14e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg11833968	chr6:79620685	NA	-0.42	-7.86	-0.36	3.12e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg24101359	chr6:42928495	GNMT	0.53	10.16	0.44	7.68e-22	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg07332563	chr6:291687	DUSP22	-0.7	-12.22	-0.51	1.27e-29	Menopause (age at onset);
LUAD	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.62	0.31	1.09e-10	Depression;
LUAD	cis	rs7074356	0.569	rs17102596	chr10:82035173	T/C	cg27171509	chr10:82033454	MAT1A	-0.46	-6.84	-0.32	2.78e-11	Borderline personality disorder;
LUAD	trans	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	11.02	0.47	5.43e-25	Mean corpuscular volume;
LUAD	cis	rs3774830	0.748	rs17367445	chr4:5464903	C/T	cg26943120	chr4:5472116	STK32B	0.38	7.75	0.35	6.97e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg13319975	chr6:146136371	FBXO30	-0.6	-10.26	-0.45	3.38e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg16479474	chr6:28041457	NA	0.44	7.75	0.35	7.11e-14	Depression;
LUAD	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg06618935	chr21:46677482	NA	-0.45	-8.75	-0.39	5.26e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg27432699	chr2:27873401	GPN1	-0.39	-6.63	-0.31	1e-10	Total body bone mineral density;
LUAD	cis	rs4664304	0.710	rs9636280	chr2:160717852	C/T	cg23995753	chr2:160760732	LY75	-0.38	-6.56	-0.3	1.57e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg13732083	chr21:47605072	C21orf56	0.42	6.97	0.32	1.21e-11	Testicular germ cell tumor;
LUAD	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg03433033	chr1:76189801	ACADM	0.74	11.13	0.48	1.99e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4594175	0.926	rs10498421	chr14:51586412	A/G	cg23942311	chr14:51606299	NA	-0.58	-9.31	-0.41	7.17e-19	Cancer;
LUAD	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.35	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs12545109	0.732	rs1973629	chr8:57429583	A/G	cg07776626	chr8:57350775	NA	-0.65	-8.8	-0.39	3.58e-17	Obesity-related traits;
LUAD	trans	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg07817883	chr1:32538562	TMEM39B	1.27	12.17	0.51	1.94e-29	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs4942242	0.663	rs7985489	chr13:44206148	T/C	cg19169023	chr15:41853346	TYRO3	0.66	11.72	0.5	1.14e-27	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg04025307	chr7:1156635	C7orf50	0.57	8.07	0.37	7.35e-15	Bronchopulmonary dysplasia;
LUAD	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg15128208	chr22:42549153	NA	-0.43	-8.84	-0.39	2.7e-17	Cognitive function;
LUAD	trans	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg18187862	chr3:45730750	SACM1L	0.52	8.16	0.37	3.93e-15	Primary sclerosing cholangitis;
LUAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18099408	chr3:52552593	STAB1	-0.53	-9.69	-0.43	3.55e-20	Electroencephalogram traits;
LUAD	cis	rs6489785	0.509	rs3213570	chr12:121222411	C/G	cg02419362	chr12:121203948	SPPL3	0.41	8.29	0.37	1.54e-15	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg22598563	chr5:131563921	P4HA2	-0.28	-6.71	-0.31	6.15e-11	Blood metabolite levels;
LUAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg06074448	chr4:187884817	NA	-0.36	-7.11	-0.33	4.99e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg13334819	chr7:99746414	C7orf59	0.65	10.47	0.45	5.83e-23	Coronary artery disease;
LUAD	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg05082376	chr22:42548792	NA	-0.5	-9.07	-0.4	4.36e-18	Schizophrenia;
LUAD	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.35	6.94	0.32	1.45e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs240764	0.618	rs846778	chr6:101273147	T/C	cg09795085	chr6:101329169	ASCC3	0.43	7.57	0.35	2.37e-13	Neuroticism;
LUAD	cis	rs3845702	0.800	rs6744281	chr2:180844382	G/A	cg01881094	chr2:180872142	CWC22	-0.74	-7.92	-0.36	2.17e-14	Schizophrenia;
LUAD	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg17443473	chr1:3703550	LRRC47	0.44	7.12	0.33	4.67e-12	Red cell distribution width;
LUAD	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg24531977	chr5:56204891	C5orf35	-0.4	-6.45	-0.3	2.98e-10	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg09033563	chr22:24373618	LOC391322	-0.55	-9.16	-0.41	2.27e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg00666640	chr1:248458726	OR2T12	0.31	7.6	0.35	1.94e-13	Common traits (Other);
LUAD	cis	rs870825	0.698	rs28412823	chr4:185638829	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.12	0.57	2.26e-37	Blood protein levels;
LUAD	trans	rs4650994	1.000	rs4076205	chr1:178534157	G/A	cg05059571	chr16:84539110	KIAA1609	-0.58	-10.23	-0.45	4.16e-22	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00149659	chr3:10157352	C3orf10	0.63	8.82	0.39	2.97e-17	Alzheimer's disease;
LUAD	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg13770153	chr20:60521292	NA	-0.47	-7.77	-0.35	5.89e-14	Body mass index;
LUAD	cis	rs35883536	0.967	rs1984134	chr1:101109307	A/G	cg06223162	chr1:101003688	GPR88	0.35	6.57	0.3	1.52e-10	Monocyte count;
LUAD	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg08601574	chr20:25228251	PYGB	-0.47	-8.86	-0.4	2.28e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg13535736	chr9:111863775	C9orf5	-0.42	-6.47	-0.3	2.77e-10	Menarche (age at onset);
LUAD	cis	rs3752645	1.000	rs28610544	chr7:106771703	C/T	cg02696742	chr7:106810147	HBP1	-0.67	-6.53	-0.3	1.86e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs873917	0.577	rs784599	chr1:40138507	A/G	cg06209491	chr1:40138402	NT5C1A	-0.54	-8.13	-0.37	4.85e-15	Amyotrophic lateral sclerosis;
LUAD	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg07606381	chr6:8435919	SLC35B3	0.4	6.57	0.3	1.48e-10	Motion sickness;
LUAD	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg06640241	chr16:89574553	SPG7	0.72	12.9	0.53	2.38e-32	Multiple myeloma (IgH translocation);
LUAD	cis	rs3790645	0.958	rs12723936	chr1:26872554	A/G	cg23229016	chr1:26872525	RPS6KA1	0.2	6.6	0.31	1.26e-10	Glucose homeostasis traits;
LUAD	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg27535305	chr1:53392650	SCP2	0.36	7.34	0.34	1.09e-12	Monocyte count;
LUAD	cis	rs524023	1.000	rs537246	chr11:64360630	G/A	cg19131476	chr11:64387923	NRXN2	0.35	6.74	0.31	5.25e-11	Urate levels in obese individuals;
LUAD	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg21724239	chr8:58056113	NA	0.81	9.79	0.43	1.56e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg13511324	chr14:104056883	C14orf153	0.27	6.51	0.3	2.15e-10	Reticulocyte count;
LUAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-7.94	-0.36	1.78e-14	Alzheimer's disease;
LUAD	trans	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg01620082	chr3:125678407	NA	-0.69	-7.95	-0.36	1.73e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg22467129	chr15:76604101	ETFA	-0.47	-7.69	-0.35	1.01e-13	Blood metabolite levels;
LUAD	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg18105134	chr13:113819100	PROZ	-0.88	-15.88	-0.61	7.03e-45	Platelet distribution width;
LUAD	cis	rs8177876	0.749	rs10459871	chr16:81093067	C/G	cg08591886	chr16:81111003	C16orf46	-0.77	-6.77	-0.31	4.31e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg05340658	chr4:99064831	C4orf37	0.45	6.93	0.32	1.62e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2731664	0.792	rs335468	chr5:176892349	A/G	cg23176889	chr5:176863531	GRK6	0.71	13.71	0.55	1.23e-35	Intelligence (multi-trait analysis);
LUAD	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg17372223	chr3:52568218	NT5DC2	0.34	6.49	0.3	2.47e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9329221	0.682	rs11786677	chr8:10264260	A/G	cg27411982	chr8:10470053	RP1L1	0.39	7.25	0.33	2.03e-12	Neuroticism;
LUAD	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg26408565	chr15:76604113	ETFA	-0.45	-7.32	-0.34	1.28e-12	Blood metabolite levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08253970	chr12:64615825	C12orf66	-0.44	-6.89	-0.32	1.99e-11	Height;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg04024692	chr11:16760046	C11orf58	0.4	6.39	0.3	4.45e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg17105886	chr17:28927953	LRRC37B2	0.84	8.07	0.37	7.16e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg17200465	chr3:40428508	ENTPD3	0.28	6.63	0.31	1.04e-10	Renal cell carcinoma;
LUAD	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg15467112	chr14:75489610	MLH3	0.36	6.57	0.3	1.44e-10	Height;
LUAD	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-8.24	-0.37	2.22e-15	Height;
LUAD	cis	rs10924309	0.686	rs4658796	chr1:245854680	A/G	cg00036263	chr1:245852353	KIF26B	-0.44	-6.91	-0.32	1.8e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs12908161	0.959	rs61074241	chr15:85333396	C/T	cg11189052	chr15:85197271	WDR73	0.64	8.17	0.37	3.49e-15	Schizophrenia;
LUAD	trans	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.84	0.43	1.03e-20	Mean corpuscular volume;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg15413566	chr7:8301971	ICA1	-0.68	-6.83	-0.32	2.9100000000000002e-11	Type 2 diabetes;
LUAD	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg03433033	chr1:76189801	ACADM	-0.46	-6.77	-0.31	4.45e-11	Daytime sleep phenotypes;
LUAD	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg02734326	chr4:10020555	SLC2A9	0.63	11.35	0.48	3.08e-26	Bone mineral density;
LUAD	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg05368731	chr17:41323189	NBR1	0.96	20.58	0.71	1.05e-65	Menopause (age at onset);
LUAD	cis	rs9875589	0.509	rs6768383	chr3:14076952	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	6.52	0.3	2.01e-10	Ovarian reserve;
LUAD	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.23	0.37	2.31e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs3858145	0.588	rs4142049	chr10:70044452	C/A	cg04882175	chr6:131122610	NA	-0.57	-6.77	-0.31	4.42e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUAD	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg09359103	chr1:154839909	KCNN3	-0.89	-20.08	-0.7	1.82e-63	Prostate cancer;
LUAD	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03517284	chr6:25882590	NA	-0.58	-9.28	-0.41	8.66e-19	Blood metabolite levels;
LUAD	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg02782426	chr3:40428986	ENTPD3	0.43	9.09	0.4	3.96e-18	Renal cell carcinoma;
LUAD	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg20203395	chr5:56204925	C5orf35	-0.82	-11.85	-0.5	3.72e-28	Initial pursuit acceleration;
LUAD	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg05805236	chr11:65401703	PCNXL3	0.39	6.6	0.31	1.27e-10	Acne (severe);
LUAD	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg15691649	chr6:25882328	NA	-0.44	-6.39	-0.3	4.42e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg06606381	chr12:133084897	FBRSL1	-0.87	-9.18	-0.41	1.88e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs300774	0.841	rs2926788	chr2:199410	G/A	cg21211680	chr2:198530	NA	0.63	8.84	0.39	2.69e-17	Suicide attempts in bipolar disorder;
LUAD	cis	rs1595825	0.891	rs16824264	chr2:198675917	T/C	cg11031976	chr2:198649780	BOLL	-0.48	-7.05	-0.32	7.29e-12	Ulcerative colitis;
LUAD	cis	rs4889911	1.000	rs4889911	chr17:77839811	C/T	cg00646381	chr17:77835854	NA	-0.43	-7.08	-0.33	5.91e-12	Electroencephalogram traits;
LUAD	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg25828334	chr19:18545568	ISYNA1	-0.38	-7.61	-0.35	1.77e-13	Breast cancer;
LUAD	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg11062466	chr8:58055876	NA	0.45	6.37	0.3	4.87e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1232027	0.656	rs836802	chr5:79983800	G/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.42	-6.5	-0.3	2.27e-10	Huntington's disease progression;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg01516881	chr6:292596	DUSP22	-0.78	-13.5	-0.55	8.34e-35	Menopause (age at onset);
LUAD	cis	rs859767	0.501	rs1568121	chr2:135406606	G/A	cg12500956	chr2:135428796	TMEM163	-0.28	-7.55	-0.34	2.62e-13	Neuroticism;
LUAD	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg19163074	chr7:65112434	INTS4L2	0.43	6.48	0.3	2.5e-10	Aortic root size;
LUAD	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	9.61	0.42	6.36e-20	Menarche (age at onset);
LUAD	trans	rs1941687	0.831	rs12957087	chr18:31328519	C/T	cg27147174	chr7:100797783	AP1S1	-0.53	-9.2	-0.41	1.67e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg06387496	chr7:2775674	GNA12	-0.4	-6.68	-0.31	7.38e-11	Height;
LUAD	cis	rs4853036	0.672	rs3771542	chr2:70029310	A/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.36	-0.3	5.14e-10	Colorectal or endometrial cancer;
LUAD	cis	rs243505	0.898	rs243544	chr7:148402710	T/A	cg09806900	chr7:148480153	CUL1	-0.43	-7.36	-0.34	9.38e-13	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7680126	0.633	rs11735543	chr4:10251652	G/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.74	-0.31	5.05e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	trans	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg11887960	chr12:57824829	NA	0.58	7.11	0.33	5.07e-12	Obesity-related traits;
LUAD	cis	rs2637266	0.846	rs2637261	chr10:78320593	A/G	cg18941641	chr10:78392320	NA	-0.32	-6.54	-0.3	1.79e-10	Pulmonary function;
LUAD	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-7.78	-0.35	5.59e-14	Blood metabolite levels;
LUAD	trans	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg07211511	chr3:129823064	LOC729375	-0.9	-10.16	-0.44	7.6e-22	Blood pressure (smoking interaction);
LUAD	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg15128208	chr22:42549153	NA	-0.35	-6.88	-0.32	2.14e-11	Cognitive function;
LUAD	cis	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg05084668	chr3:125655381	ALG1L	-0.86	-11.3	-0.48	4.85e-26	Blood pressure (smoking interaction);
LUAD	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg15017067	chr4:17643749	FAM184B	0.36	6.89	0.32	2.08e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg24069376	chr3:38537580	EXOG	-0.42	-10.12	-0.44	1.03e-21	Electrocardiographic conduction measures;
LUAD	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg05896524	chr21:47604654	C21orf56	0.54	9.05	0.4	5.18e-18	Testicular germ cell tumor;
LUAD	cis	rs7737355	0.947	rs31583	chr5:130992432	T/C	cg06307176	chr5:131281290	NA	0.53	8.34	0.38	1.06e-15	Life satisfaction;
LUAD	trans	rs11638815	0.581	rs2870965	chr15:83301029	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.49	-7.29	-0.33	1.52e-12	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg21775007	chr8:11205619	TDH	-0.5	-9.09	-0.4	3.87e-18	Retinal vascular caliber;
LUAD	cis	rs1950626	0.699	rs12880855	chr14:101468382	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.39	6.93	0.32	1.62e-11	Pelvic organ prolapse (moderate/severe);
LUAD	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg18944383	chr4:111397179	ENPEP	0.38	6.49	0.3	2.48e-10	Coronary artery disease;
LUAD	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg12927641	chr6:109611667	NA	-0.52	-9.05	-0.4	5.08e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg19077165	chr18:44547161	KATNAL2	-0.4	-6.93	-0.32	1.6e-11	Personality dimensions;
LUAD	trans	rs10267593	0.516	rs62435159	chr7:1911281	G/A	cg11693508	chr17:37793320	STARD3	0.49	7.09	0.33	5.53e-12	Coronary artery disease;
LUAD	cis	rs367615	0.537	rs10463600	chr5:108663636	G/A	cg17395555	chr5:108820864	NA	0.52	9.8	0.43	1.48e-20	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg20712883	chr12:51590929	POU6F1	0.74	11.16	0.48	1.54e-25	Cisplatin-induced ototoxicity;
LUAD	cis	rs13040088	0.872	rs2295481	chr20:61574727	C/T	cg23096297	chr20:61557774	DIDO1	0.74	9.83	0.43	1.13e-20	Menopause (age at onset);
LUAD	cis	rs6867032	1.000	rs2129471	chr5:2016236	C/G	cg26168224	chr5:2018326	NA	0.8	18.29	0.66	1.76e-55	Gut microbiome composition (winter);
LUAD	cis	rs7617773	0.817	rs13100815	chr3:48287449	A/C	cg11946769	chr3:48343235	NME6	0.43	6.55	0.3	1.71e-10	Coronary artery disease;
LUAD	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg22117172	chr7:91764530	CYP51A1	0.35	7.81	0.35	4.64e-14	Breast cancer;
LUAD	cis	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg07460842	chr6:66804631	NA	-0.99	-14.76	-0.58	4.38e-40	Exhaled nitric oxide output;
LUAD	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg00745463	chr17:30367425	LRRC37B	-1.06	-12.58	-0.52	4.73e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg15226275	chr6:116381976	FRK	0.24	7.67	0.35	1.21e-13	Cholesterol, total;LDL cholesterol;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02049522	chr12:6862726	MLF2	-0.41	-6.82	-0.31	3.13e-11	Cancer;
LUAD	cis	rs870825	0.929	rs10003354	chr4:185589782	G/A	cg04058563	chr4:185651563	MLF1IP	0.74	9.41	0.42	3.18e-19	Blood protein levels;
LUAD	cis	rs7617773	0.676	rs13060020	chr3:48372646	C/T	cg11946769	chr3:48343235	NME6	0.44	6.69	0.31	7.23e-11	Coronary artery disease;
LUAD	cis	rs2742234	0.541	rs10899779	chr10:43723976	C/T	cg15436174	chr10:43711423	RASGEF1A	0.55	9.02	0.4	6.55e-18	Hirschsprung disease;
LUAD	cis	rs3806843	0.576	rs246049	chr5:140327590	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19717773	chr7:2847554	GNA12	-0.56	-9.63	-0.42	5.41e-20	Height;
LUAD	cis	rs977987	0.778	rs35214308	chr16:75476088	C/T	cg03315344	chr16:75512273	CHST6	0.65	14.37	0.57	2.04e-38	Dupuytren's disease;
LUAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.12	0.41	3.18e-18	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.56	-9.52	-0.42	1.38e-19	Glomerular filtration rate;
LUAD	cis	rs1375194	0.509	rs62150473	chr2:33822320	G/A	cg04131969	chr2:33951647	MYADML	-0.55	-8.44	-0.38	5e-16	Response to antidepressants in depression;
LUAD	cis	rs4604732	0.631	rs12031721	chr1:247623773	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.1	0.33	5.29e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg23625390	chr15:77176239	SCAPER	0.39	6.99	0.32	1.06e-11	Blood metabolite levels;
LUAD	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.41	0.34	6.78e-13	Tonsillectomy;
LUAD	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg20848291	chr7:100343083	ZAN	-0.66	-10.43	-0.45	8.31e-23	Other erythrocyte phenotypes;
LUAD	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg10518543	chr12:38710700	ALG10B	-0.43	-7.11	-0.33	5.06e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9811920	0.625	rs9290003	chr3:99906993	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.47	8.68	0.39	8.69e-17	Axial length;
LUAD	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg12573674	chr2:1569213	NA	-0.58	-6.56	-0.3	1.57e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg21775007	chr8:11205619	TDH	-0.42	-7.42	-0.34	6.47e-13	Neuroticism;
LUAD	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg09263875	chr16:632152	PIGQ	0.81	17.48	0.65	6.82e-52	Height;
LUAD	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg24154853	chr7:158122151	PTPRN2	0.56	11.29	0.48	4.93e-26	Calcium levels;
LUAD	cis	rs7107174	1.000	rs1318241	chr11:77930792	C/T	cg19901956	chr11:77921274	USP35	-0.53	-6.48	-0.3	2.61e-10	Testicular germ cell tumor;
LUAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg27454412	chr7:1067447	C7orf50	0.44	7.0	0.32	1.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg07266350	chr3:49460521	AMT;NICN1	-0.36	-6.52	-0.3	2.06e-10	Menarche (age at onset);
LUAD	cis	rs9487051	0.737	rs1260593	chr6:109521400	C/T	cg21918786	chr6:109611834	NA	-0.41	-7.23	-0.33	2.33e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs7149337	1.000	rs4261445	chr14:51723540	G/A	cg23942311	chr14:51606299	NA	0.77	16.04	0.62	1.37e-45	Cancer;
LUAD	cis	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg21775007	chr8:11205619	TDH	0.37	6.44	0.3	3.25e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11890956	chr21:40555474	PSMG1	0.78	13.65	0.55	2.17e-35	Cognitive function;
LUAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg23958373	chr8:599963	NA	1.07	10.45	0.45	6.76e-23	IgG glycosylation;
LUAD	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg22491629	chr6:157744540	C6orf35	-0.8	-9.21	-0.41	1.56e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.12	-0.33	4.61e-12	Morning vs. evening chronotype;
LUAD	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg15208524	chr1:10270712	KIF1B	-0.45	-6.94	-0.32	1.47e-11	Hepatocellular carcinoma;
LUAD	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.61	0.31	1.16e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6028335	0.502	rs7265661	chr20:37586842	G/T	cg27552599	chr20:37590471	DHX35	0.39	6.52	0.3	2.03e-10	Alcohol and nicotine co-dependence;
LUAD	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11890956	chr21:40555474	PSMG1	0.56	9.9	0.43	6.49e-21	Menarche (age at onset);
LUAD	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg03885332	chr11:832357	CD151	-0.41	-7.88	-0.36	2.74e-14	Mean platelet volume;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg06808467	chr18:5237767	LOC339290;C18orf18	-0.38	-6.35	-0.3	5.67e-10	Schizophrenia;
LUAD	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg08296037	chr16:1584118	IFT140;TMEM204	-0.26	-6.36	-0.3	5.13e-10	Coronary artery disease;
LUAD	cis	rs7587476	0.862	rs13001462	chr2:215678346	G/A	cg04004882	chr2:215674386	BARD1	0.54	6.87	0.32	2.26e-11	Neuroblastoma;
LUAD	cis	rs7520050	0.778	rs2934857	chr1:46039612	A/G	cg06784218	chr1:46089804	CCDC17	0.35	7.75	0.35	6.97e-14	Red blood cell count;Reticulocyte count;
LUAD	cis	rs4774899	0.752	rs2733177	chr15:57344581	G/A	cg14026238	chr15:57616123	NA	0.42	8.1	0.37	5.9e-15	Urinary tract infection frequency;
LUAD	cis	rs7809950	1.000	rs4730245	chr7:107087294	C/T	cg23024343	chr7:107201750	COG5	-0.75	-12.77	-0.53	8.3e-32	Coronary artery disease;
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg18000306	chr6:288505	NA	0.4	7.57	0.35	2.43e-13	Menopause (age at onset);
LUAD	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.24	-0.33	2.08e-12	Bipolar disorder;
LUAD	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg20701182	chr2:24300061	SF3B14	0.6	6.61	0.31	1.17e-10	Lymphocyte counts;
LUAD	cis	rs1003719	0.614	rs1053808	chr21:38525356	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.46	-7.78	-0.35	5.53e-14	Eye color traits;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg08333703	chr19:35225315	ZNF181	0.35	6.35	0.3	5.55e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	trans	rs5756813	0.635	rs6000899	chr22:38203796	C/T	cg19894588	chr14:64061835	NA	-0.55	-7.75	-0.35	7e-14	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg23281280	chr6:28129359	ZNF389	0.47	6.6	0.31	1.22e-10	Depression;
LUAD	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg05082376	chr22:42548792	NA	0.44	7.63	0.35	1.53e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs727505	1.000	rs7791430	chr7:124429953	G/T	cg23710748	chr7:124431027	NA	-0.44	-8.64	-0.39	1.13e-16	Lewy body disease;
LUAD	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg23649088	chr2:200775458	C2orf69	-0.61	-7.13	-0.33	4.3e-12	Schizophrenia;
LUAD	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg16205897	chr5:131564050	P4HA2	-0.31	-6.84	-0.32	2.74e-11	Acylcarnitine levels;
LUAD	cis	rs4478137	0.931	rs7687423	chr4:164250797	C/T	cg06758707	chr4:164254230	NPY1R	-0.4	-6.5	-0.3	2.21e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg21775007	chr8:11205619	TDH	-0.51	-9.25	-0.41	1.09e-18	Retinal vascular caliber;
LUAD	cis	rs7771547	0.519	rs2057351	chr6:36361682	G/A	cg07856975	chr6:36356162	ETV7	0.51	7.64	0.35	1.48e-13	Platelet distribution width;
LUAD	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg18171855	chr10:2543474	NA	0.34	6.68	0.31	7.69e-11	Age-related hearing impairment;
LUAD	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg13010199	chr12:38710504	ALG10B	-0.38	-6.43	-0.3	3.53e-10	Bladder cancer;
LUAD	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg02475777	chr4:1388615	CRIPAK	0.65	9.05	0.4	5.35e-18	Longevity;
LUAD	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs6546550	0.901	rs11126251	chr2:70163434	A/C	cg02498382	chr2:70120550	SNRNP27	-0.59	-11.33	-0.48	3.58e-26	Prevalent atrial fibrillation;
LUAD	cis	rs10916814	0.589	rs7416238	chr1:20897240	A/G	cg24502330	chr1:20914028	CDA	-0.36	-7.14	-0.33	4.19e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg26597838	chr10:835615	NA	1.0	15.77	0.61	2.05e-44	Eosinophil percentage of granulocytes;
LUAD	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg11859384	chr17:80120422	CCDC57	0.49	8.88	0.4	1.9e-17	Life satisfaction;
LUAD	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg11344533	chr11:111475393	SIK2	-0.36	-6.69	-0.31	7.26e-11	Primary sclerosing cholangitis;
LUAD	cis	rs10489202	1.000	rs7520232	chr1:168011995	T/C	cg24449463	chr1:168025552	DCAF6	-0.58	-7.23	-0.33	2.34e-12	Schizophrenia;
LUAD	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06112835	chr11:68658793	MRPL21	0.5	9.05	0.4	5.44e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg03929089	chr4:120376271	NA	-0.72	-10.77	-0.46	4.42e-24	Coronary artery disease;
LUAD	cis	rs929596	0.793	rs2602376	chr2:234582051	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-8.94	-0.4	1.2e-17	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg26384229	chr12:38710491	ALG10B	-0.43	-7.36	-0.34	9.67e-13	Morning vs. evening chronotype;
LUAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.65	-0.42	4.84e-20	Alzheimer's disease;
LUAD	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg22117172	chr7:91764530	CYP51A1	0.33	7.17	0.33	3.3e-12	Breast cancer;
LUAD	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.68	-0.58	1.03e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg17595323	chr11:93583763	C11orf90	-0.43	-8.99	-0.4	8.17e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs986417	0.901	rs1955693	chr14:61012331	T/C	cg27398547	chr14:60952738	C14orf39	0.66	7.65	0.35	1.38e-13	Gut microbiota (bacterial taxa);
LUAD	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg18944383	chr4:111397179	ENPEP	0.41	8.2	0.37	2.89e-15	Height;
LUAD	cis	rs2762353	0.574	rs4419666	chr6:25693274	C/T	cg03517284	chr6:25882590	NA	0.89	14.59	0.58	2.36e-39	Blood metabolite levels;
LUAD	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg25036284	chr2:26402008	FAM59B	0.84	12.29	0.51	6.99e-30	Gut microbiome composition (summer);
LUAD	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg17105886	chr17:28927953	LRRC37B2	0.79	7.88	0.36	2.81e-14	Body mass index;
LUAD	cis	rs10203711	0.705	rs4663946	chr2:239610287	C/T	cg14580085	chr2:239553406	NA	-0.31	-7.13	-0.33	4.49e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	9.83	0.43	1.09e-20	Lung cancer in ever smokers;
LUAD	trans	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs62400317	0.859	rs4443508	chr6:45235952	C/T	cg20913747	chr6:44695427	NA	-0.41	-6.57	-0.3	1.44e-10	Total body bone mineral density;
LUAD	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg06784218	chr1:46089804	CCDC17	-0.6	-13.44	-0.55	1.56e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs758324	0.755	rs2221674	chr5:131242218	T/A	cg25547332	chr5:131281432	NA	-0.42	-6.76	-0.31	4.48e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4700695	0.841	rs27132	chr5:65288791	A/G	cg21114390	chr5:65439923	SFRS12	0.63	7.3	0.33	1.45e-12	Facial morphology (factor 19);
LUAD	cis	rs5756391	0.568	rs11705504	chr22:37317493	G/A	cg16356956	chr22:37317934	CSF2RB	0.32	6.75	0.31	5.02e-11	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg11143507	chr3:125485238	NA	-0.44	-7.39	-0.34	7.83e-13	Blood pressure (smoking interaction);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04425820	chr19:52408336	ZNF649	-0.55	-6.64	-0.31	9.81e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	6.94	0.32	1.44e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.4	0.45	1.02e-22	Mean corpuscular volume;
LUAD	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg00814883	chr7:100076585	TSC22D4	-0.8	-11.67	-0.49	1.79e-27	Platelet count;
LUAD	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg18755752	chr8:142205143	DENND3	-0.69	-13.94	-0.56	1.29e-36	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2625529	0.627	rs11858015	chr15:72552492	G/A	cg16672083	chr15:72433130	SENP8	-0.77	-13.19	-0.54	1.59e-33	Red blood cell count;
LUAD	cis	rs4588572	0.601	rs10070202	chr5:77792462	A/C	cg11547950	chr5:77652471	NA	-0.77	-12.4	-0.52	2.57e-30	Triglycerides;
LUAD	cis	rs7621025	0.500	rs12629000	chr3:136643571	T/A	cg15507776	chr3:136538369	TMEM22	0.6	9.52	0.42	1.3e-19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg26354017	chr1:205819088	PM20D1	0.48	8.14	0.37	4.49e-15	Parkinson's disease;
LUAD	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg16681516	chr19:46297285	DMWD	0.39	7.76	0.35	6.3e-14	Coronary artery disease;
LUAD	cis	rs6496044	0.611	rs6496055	chr15:86070688	A/G	cg13263323	chr15:86062960	AKAP13	-0.57	-10.63	-0.46	1.49e-23	Interstitial lung disease;
LUAD	cis	rs738322	0.555	rs5750548	chr22:38547016	C/A	cg25457927	chr22:38595422	NA	-0.59	-13.99	-0.56	8.04e-37	Cutaneous nevi;
LUAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg07677032	chr17:61819896	STRADA	0.57	10.34	0.45	1.78e-22	Prudent dietary pattern;
LUAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg07414643	chr4:187882934	NA	0.33	6.56	0.3	1.55e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1497828	0.912	rs2815231	chr1:217538165	T/G	cg04411442	chr1:217543379	NA	-0.35	-6.59	-0.31	1.33e-10	Dialysis-related mortality;
LUAD	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.39	6.53	0.3	1.89e-10	Type 2 diabetes;
LUAD	cis	rs8072548	1	rs8072548	chr17:38164025	T/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.48	-9.8	-0.43	1.45e-20	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg12011299	chr4:100065546	ADH4	0.76	15.49	0.6	3.51e-43	Alcohol dependence;
LUAD	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg03233332	chr7:66118400	NA	-0.46	-6.88	-0.32	2.22e-11	Aortic root size;
LUAD	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg21385522	chr1:16154831	NA	-1.06	-23.5	-0.75	9.82e-79	Dilated cardiomyopathy;
LUAD	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg06808227	chr14:105710500	BRF1	-0.45	-7.15	-0.33	3.9e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg15181151	chr6:150070149	PCMT1	0.39	7.68	0.35	1.12e-13	Lung cancer;
LUAD	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	6.43	0.3	3.5e-10	Obesity-related traits;
LUAD	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg11266682	chr4:10021025	SLC2A9	0.68	15.49	0.6	3.32e-43	Bone mineral density;
LUAD	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg21399703	chr1:247681439	NA	-0.42	-7.65	-0.35	1.37e-13	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg07540722	chr2:70056697	GMCL1	0.42	6.57	0.3	1.5e-10	QT interval;
LUAD	cis	rs7009516	0.625	rs1056222	chr8:24263345	A/G	cg01759110	chr8:24241694	ADAMDEC1	0.43	8.83	0.39	2.75e-17	Hair greying;
LUAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg08219700	chr8:58056026	NA	0.41	6.51	0.3	2.17e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg00074818	chr8:8560427	CLDN23	0.68	10.5	0.45	4.32e-23	Obesity-related traits;
LUAD	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg23533926	chr12:111358616	MYL2	-0.42	-7.17	-0.33	3.32e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg00318621	chr2:106887213	NA	-0.43	-6.78	-0.31	4.06e-11	Facial morphology (factor 23);
LUAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg00080972	chr5:178986291	RUFY1	0.51	8.77	0.39	4.33e-17	Lung cancer;
LUAD	cis	rs6489882	0.867	rs7132404	chr12:113368605	A/G	cg20102336	chr12:113376681	OAS3	-0.59	-9.26	-0.41	1.05e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.68	0.31	7.6e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg23985595	chr17:80112537	CCDC57	0.54	9.86	0.43	8.73e-21	Life satisfaction;
LUAD	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.58	0.3	1.42e-10	Cardiac Troponin-T levels;
LUAD	cis	rs4711350	0.862	rs602399	chr6:33713779	C/T	cg18005901	chr6:33739558	LEMD2	0.5	7.06	0.32	6.72e-12	Schizophrenia;
LUAD	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg06781209	chr11:61594997	FADS2	-0.44	-7.45	-0.34	5.23e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs7516138	1.000	rs7518602	chr1:9711344	T/C	cg26573321	chr1:9711663	PIK3CD	0.76	13.16	0.54	2.23e-33	Monocyte count;
LUAD	cis	rs61990749	0.597	rs117131659	chr14:78131126	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.54	-6.78	-0.31	4.03e-11	Fibroblast growth factor basic levels;
LUAD	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg14844989	chr11:31128820	NA	-0.46	-8.37	-0.38	8.24e-16	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.59	0.42	7.79e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.947	rs4996522	chr5:130761470	G/A	cg25547332	chr5:131281432	NA	-0.43	-6.41	-0.3	3.85e-10	Life satisfaction;
LUAD	cis	rs35740288	0.770	rs34058174	chr15:86174462	G/T	cg13263323	chr15:86062960	AKAP13	-0.45	-7.28	-0.33	1.61e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-9.79	-0.43	1.52e-20	Platelet count;
LUAD	cis	rs6714710	0.557	rs17490429	chr2:98449024	G/A	cg26665480	chr2:98280029	ACTR1B	0.5	8.16	0.37	3.83e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs7015263	0.715	rs6999022	chr8:87523170	C/T	cg27223183	chr8:87520930	FAM82B	-0.4	-6.42	-0.3	3.66e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs17362650	0.653	rs10929581	chr2:9552379	C/T	cg12832956	chr2:9616023	IAH1	-0.48	-8.19	-0.37	3.08e-15	Alcohol dependence (age at onset);
LUAD	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg05754148	chr16:3507555	NAT15	0.67	11.12	0.48	2.23e-25	Tuberculosis;
LUAD	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg11247378	chr22:39784982	NA	-0.53	-9.0	-0.4	7.53e-18	IgG glycosylation;
LUAD	trans	rs9951602	1.000	rs7232284	chr18:76667529	A/G	cg02800362	chr5:177631904	HNRNPAB	0.72	9.21	0.41	1.54e-18	Obesity-related traits;
LUAD	cis	rs11951515	0.966	rs11741797	chr5:43379792	A/G	cg01983248	chr5:43482804	C5orf28	-0.31	-6.44	-0.3	3.33e-10	Metabolite levels  (X-11787);
LUAD	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg04772025	chr11:68637568	NA	0.58	8.91	0.4	1.55e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg22907277	chr7:1156413	C7orf50	0.68	7.93	0.36	1.94e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg00280220	chr17:61926910	NA	0.36	6.97	0.32	1.24e-11	Prudent dietary pattern;
LUAD	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg01528321	chr10:82214614	TSPAN14	0.54	8.72	0.39	6.3e-17	Post bronchodilator FEV1;
LUAD	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg02269571	chr22:50332266	NA	-0.61	-9.41	-0.42	3.27e-19	Schizophrenia;
LUAD	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg03433033	chr1:76189801	ACADM	-0.48	-7.05	-0.32	7.31e-12	Daytime sleep phenotypes;
LUAD	cis	rs2455799	0.964	rs7611203	chr3:15886992	A/T	cg16303742	chr3:15540471	COLQ	-0.38	-6.69	-0.31	7.24e-11	Mean platelet volume;
LUAD	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-6.87	-0.32	2.35e-11	Total body bone mineral density;
LUAD	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg09904177	chr6:26538194	HMGN4	0.4	6.74	0.31	5.08e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-8.31	-0.37	1.32e-15	Neuroticism;
LUAD	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.7	-0.31	6.77e-11	Menopause (age at onset);
LUAD	trans	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg03929089	chr4:120376271	NA	0.6	6.67	0.31	7.98e-11	Intraocular pressure;
LUAD	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg20991723	chr1:152506922	NA	0.34	6.65	0.31	9.03e-11	Hair morphology;
LUAD	cis	rs4280164	0.551	rs2295300	chr14:24805117	C/T	cg07162820	chr14:24837146	NFATC4	0.33	6.74	0.31	5.29e-11	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg14558114	chr2:88469736	THNSL2	-0.43	-6.94	-0.32	1.47e-11	Response to metformin (IC50);
LUAD	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg25985355	chr7:65971099	NA	0.38	7.04	0.32	7.77e-12	Aortic root size;
LUAD	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg04455712	chr21:45112962	RRP1B	-0.46	-8.83	-0.39	2.86e-17	Mean corpuscular volume;
LUAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.51	-9.58	-0.42	8.69e-20	Longevity;Endometriosis;
LUAD	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg08997352	chr12:9597637	DDX12	-0.61	-10.55	-0.46	2.98e-23	Breast size;
LUAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg18402987	chr7:1209562	NA	0.78	9.52	0.42	1.37e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs41311933	0.656	rs72760231	chr9:123896948	G/A	cg13567360	chr9:123745713	C5	-0.73	-8.46	-0.38	4.36e-16	Coronary artery disease;
LUAD	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg02951883	chr7:2050386	MAD1L1	-0.83	-14.7	-0.58	8e-40	Bipolar disorder and schizophrenia;
LUAD	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg15309053	chr8:964076	NA	0.41	8.57	0.38	1.91e-16	Schizophrenia;
LUAD	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs6545883	0.965	rs1562308	chr2:61768421	A/C	cg15711740	chr2:61764176	XPO1	-0.44	-6.92	-0.32	1.66e-11	Tuberculosis;
LUAD	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg02734326	chr4:10020555	SLC2A9	0.56	9.7	0.43	3.27e-20	Bone mineral density;
LUAD	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg00321850	chr1:175162397	KIAA0040	-0.51	-10.93	-0.47	1.15e-24	Alcohol dependence;
LUAD	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-11.77	-0.5	7.06e-28	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.96	-0.36	1.65e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg27454412	chr7:1067447	C7orf50	-0.34	-6.66	-0.31	8.51e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs36051895	0.632	rs62541944	chr9:5159318	G/T	cg02405213	chr9:5042618	JAK2	-0.49	-6.5	-0.3	2.23e-10	Pediatric autoimmune diseases;
LUAD	cis	rs1030877	1.000	rs1030877	chr2:105910513	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.59	11.32	0.48	3.9e-26	Obesity-related traits;
LUAD	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg03605463	chr16:89740564	NA	0.63	11.01	0.47	5.65e-25	Vitiligo;
LUAD	cis	rs11809180	0.546	rs12059132	chr1:169401824	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.1	-7.5	-0.34	3.77e-13	Electrocardiographic traits;
LUAD	cis	rs13315871	0.929	rs13080398	chr3:58300282	A/G	cg20936604	chr3:58311152	NA	-0.75	-7.61	-0.35	1.82e-13	Cholesterol, total;
LUAD	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg05665937	chr4:1216051	CTBP1	0.42	7.01	0.32	9.75e-12	Obesity-related traits;
LUAD	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs77861329	0.660	rs6778442	chr3:52148483	T/C	cg08692210	chr3:52188851	WDR51A	0.55	7.03	0.32	8.1e-12	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg22166914	chr1:53195759	ZYG11B	0.4	6.57	0.3	1.5e-10	Monocyte count;
LUAD	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg23625390	chr15:77176239	SCAPER	-0.52	-8.08	-0.37	7.02e-15	Blood metabolite levels;
LUAD	cis	rs11809207	0.855	rs17257155	chr1:26526439	C/T	cg00147160	chr1:26503991	CNKSR1	-0.42	-8.32	-0.37	1.24e-15	Height;
LUAD	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg08085267	chr17:45401833	C17orf57	0.58	10.39	0.45	1.09e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19346786	chr7:2764209	NA	0.56	12.33	0.51	4.81e-30	Height;
LUAD	cis	rs11811982	0.655	rs114221628	chr1:227530286	A/G	cg24860534	chr1:227506868	CDC42BPA	0.71	7.52	0.34	3.35e-13	Optic disc area;
LUAD	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.48	-8.83	-0.39	2.75e-17	Menopause (age at onset);
LUAD	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.38	-6.84	-0.32	2.84e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg18252515	chr7:66147081	NA	-0.62	-6.75	-0.31	5.02e-11	Diabetic kidney disease;
LUAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg18402987	chr7:1209562	NA	0.77	9.52	0.42	1.34e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62238980	0.614	rs74450143	chr22:32416692	A/G	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12016809	chr21:47604291	C21orf56	-0.64	-10.77	-0.46	4.66e-24	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg08280861	chr8:58055591	NA	0.64	8.29	0.37	1.49e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.99	-0.36	1.3e-14	Diabetic kidney disease;
LUAD	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-9.68	-0.43	3.66e-20	Platelet count;
LUAD	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg03388025	chr16:89894329	SPIRE2	-0.48	-12.67	-0.52	2.16e-31	Vitiligo;
LUAD	cis	rs4691139	0.557	rs4485779	chr4:165924029	G/A	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.4	-7.39	-0.34	7.95e-13	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs7945718	0.875	rs7105783	chr11:12719794	A/G	cg25843174	chr11:12811716	TEAD1	0.22	6.54	0.3	1.82e-10	Educational attainment (years of education);
LUAD	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg23018236	chr17:30244563	NA	-0.58	-7.62	-0.35	1.7e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg06740227	chr12:86229804	RASSF9	0.46	8.04	0.36	9.23e-15	Major depressive disorder;
LUAD	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	5.75e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs71478720	0.953	rs5744249	chr11:112025306	A/C	cg04929355	chr11:112034997	IL18	0.47	7.3	0.33	1.44e-12	Interleukin-18 levels;
LUAD	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg14458575	chr2:238380390	NA	0.99	19.42	0.69	1.55e-60	Prostate cancer;
LUAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.4	0.45	1.04e-22	Prudent dietary pattern;
LUAD	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-8.24	-0.37	2.21e-15	Total body bone mineral density;
LUAD	cis	rs6495367	1.000	rs13380104	chr15:79378821	C/T	cg17916960	chr15:79447300	NA	0.33	6.47	0.3	2.65e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.47	-7.41	-0.34	6.92e-13	Tonsillectomy;
LUAD	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg09137382	chr11:130731461	NA	-0.35	-6.37	-0.3	4.97e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg02527881	chr3:46936655	PTH1R	-0.45	-8.6	-0.39	1.61e-16	Colorectal cancer;
LUAD	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-7.11	-0.33	4.89e-12	Heart rate;
LUAD	cis	rs78487399	0.808	rs72865297	chr2:43743248	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.89	-0.32	2.04e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs9296092	0.538	rs9461875	chr6:33516644	C/T	cg13560919	chr6:33536144	NA	-0.87	-15.37	-0.6	1.19e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs986417	0.901	rs7150630	chr14:61019458	T/A	cg27398547	chr14:60952738	C14orf39	0.64	7.62	0.35	1.68e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs941408	0.963	rs1640267	chr19:2789337	T/C	cg06609049	chr19:2785107	THOP1	0.79	12.65	0.52	2.38e-31	Total cholesterol levels;
LUAD	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg17691542	chr6:26056736	HIST1H1C	0.47	6.46	0.3	2.93e-10	Iron status biomarkers;
LUAD	trans	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg04995722	chr7:26192034	NFE2L3	0.41	6.87	0.32	2.29e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg04565464	chr8:145669602	NFKBIL2	0.44	6.57	0.3	1.45e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg23649088	chr2:200775458	C2orf69	-0.62	-7.79	-0.35	5.11e-14	Schizophrenia;
LUAD	cis	rs4150161	0.656	rs2230131	chr16:84212779	G/A	cg10106505	chr16:84220380	TAF1C	-0.71	-6.78	-0.31	4e-11	Systolic blood pressure response to hydrochlorothiazide in hypertension;
LUAD	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg19635926	chr16:89946313	TCF25	0.74	6.93	0.32	1.62e-11	Skin colour saturation;
LUAD	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg03605463	chr16:89740564	NA	-0.65	-11.43	-0.49	1.51e-26	Vitiligo;
LUAD	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg04896959	chr15:78267971	NA	-0.7	-14.63	-0.58	1.61e-39	Diastolic blood pressure;
LUAD	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg00666640	chr1:248458726	OR2T12	0.31	7.62	0.35	1.64e-13	Common traits (Other);
LUAD	cis	rs62045849	0.557	rs3743982	chr16:89181139	T/G	cg26950739	chr16:89183275	ACSF3	0.58	6.5	0.3	2.23e-10	Red blood cell count;
LUAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg23131131	chr22:24373011	LOC391322	-0.62	-10.52	-0.46	3.73e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg20476274	chr7:133979776	SLC35B4	0.74	13.03	0.54	7.1e-33	Mean platelet volume;
LUAD	trans	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg26043149	chr18:55253948	FECH	0.51	8.32	0.38	1.2e-15	Bone mineral density;
LUAD	cis	rs7903847	0.642	rs11189191	chr10:99148796	T/C	cg20016023	chr10:99160130	RRP12	-0.34	-8.05	-0.36	8.19e-15	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg26513180	chr16:89883248	FANCA	0.66	12.24	0.51	1.1e-29	Vitiligo;
LUAD	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg18180107	chr4:99064573	C4orf37	0.42	6.71	0.31	6.4e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.31	-0.33	1.36e-12	Bone mineral density;
LUAD	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.5	-0.38	3.38e-16	Height;
LUAD	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.54	0.3	1.8e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.59	-0.35	2.06e-13	Platelet count;
LUAD	cis	rs9952991	0.941	rs60735058	chr18:12795470	T/A	cg09945482	chr18:12777974	NA	-0.57	-6.82	-0.31	3.19e-11	Inflammatory skin disease;
LUAD	cis	rs4988958	0.584	rs7559845	chr2:103046214	T/G	cg03938978	chr2:103052716	IL18RAP	0.46	10.49	0.45	4.89e-23	Asthma (childhood onset);
LUAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08219700	chr8:58056026	NA	0.63	8.82	0.39	2.92e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg17863274	chr19:49399704	TULP2	-0.66	-10.02	-0.44	2.43e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.52	7.11	0.33	5.05e-12	Renal function-related traits (BUN);
LUAD	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg18180107	chr4:99064573	C4orf37	-0.4	-6.49	-0.3	2.38e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.812	rs798406	chr5:130689163	T/C	cg06307176	chr5:131281290	NA	-0.39	-6.57	-0.3	1.46e-10	Life satisfaction;
LUAD	trans	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg01620082	chr3:125678407	NA	-1.0	-8.95	-0.4	1.14e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs13631	0.728	rs7466635	chr9:139980417	T/C	cg14289826	chr9:140003911	NA	-0.33	-6.39	-0.3	4.29e-10	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg03609598	chr5:56110824	MAP3K1	-0.67	-9.03	-0.4	6.33e-18	Initial pursuit acceleration;
LUAD	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg01200585	chr1:228362443	C1orf69	0.42	6.82	0.31	3.17e-11	Diastolic blood pressure;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27279809	chr12:49183212	ADCY6	-0.53	-6.5	-0.3	2.22e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.41	7.03	0.32	8.11e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg16205897	chr5:131564050	P4HA2	0.39	8.71	0.39	6.93e-17	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.09	0.37	6.42e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	6.94	0.32	1.46e-11	Menopause (age at onset);
LUAD	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg21028142	chr17:79581711	NPLOC4	0.37	7.54	0.34	2.8e-13	Eye color traits;
LUAD	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg03714773	chr7:91764589	CYP51A1	0.31	7.19	0.33	2.93e-12	Breast cancer;
LUAD	cis	rs7731657	0.537	rs10060101	chr5:130319652	A/T	cg08523029	chr5:130500466	HINT1	-0.58	-7.46	-0.34	4.82e-13	Fasting plasma glucose;
LUAD	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg17063962	chr7:91808500	NA	0.72	12.75	0.53	9.92e-32	Breast cancer;
LUAD	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg23625390	chr15:77176239	SCAPER	0.4	6.86	0.32	2.39e-11	Blood metabolite levels;
LUAD	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.51	-8.87	-0.4	2.08e-17	Alzheimer's disease (late onset);
LUAD	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg10755058	chr3:40428713	ENTPD3	-0.4	-7.67	-0.35	1.22e-13	Renal cell carcinoma;
LUAD	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg21191810	chr6:118973309	C6orf204	-0.53	-8.04	-0.36	9.38e-15	Diastolic blood pressure;
LUAD	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg08601574	chr20:25228251	PYGB	0.48	8.97	0.4	1.01e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg01802117	chr1:53393560	SCP2	-0.38	-7.48	-0.34	4.27e-13	Monocyte count;
LUAD	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	12.2	0.51	1.5e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs28374715	0.532	rs28584379	chr15:41670408	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.12	-23.63	-0.75	2.58e-79	Ulcerative colitis;
LUAD	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg02951883	chr7:2050386	MAD1L1	-0.73	-11.82	-0.5	4.52e-28	Bipolar disorder and schizophrenia;
LUAD	cis	rs7737355	0.853	rs10051003	chr5:131072410	C/T	cg06307176	chr5:131281290	NA	0.46	7.77	0.35	5.92e-14	Life satisfaction;
LUAD	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg25237894	chr2:233734115	C2orf82	0.64	12.02	0.5	7.78e-29	Coronary artery disease;
LUAD	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg18827107	chr12:86230957	RASSF9	-0.62	-10.89	-0.47	1.59e-24	Major depressive disorder;
LUAD	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.85	-0.5	3.7e-28	Bipolar disorder;
LUAD	cis	rs929596	0.785	rs17862875	chr2:234649302	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.76	-12.85	-0.53	3.98e-32	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg23625390	chr15:77176239	SCAPER	-0.56	-8.91	-0.4	1.56e-17	Blood metabolite levels;
LUAD	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14240646	chr10:27532245	ACBD5	0.95	13.73	0.56	9.8e-36	Breast cancer;
LUAD	trans	rs7395662	0.895	rs1121000	chr11:48711790	A/T	cg00717180	chr2:96193071	NA	-0.39	-7.24	-0.33	2.16e-12	HDL cholesterol;
LUAD	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.42	6.64	0.31	9.56e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg02696790	chr15:75250997	RPP25	0.37	7.31	0.34	1.32e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg04287289	chr16:89883240	FANCA	0.76	6.37	0.3	4.97e-10	Skin colour saturation;
LUAD	cis	rs1476679	1.000	rs1476679	chr7:100004446	C/T	cg19116668	chr7:99932089	PMS2L1	0.33	6.9	0.32	1.95e-11	Alzheimer's disease (late onset);
LUAD	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg05182265	chr7:156933206	UBE3C	-0.8	-17.25	-0.64	7.2e-51	Body mass index;
LUAD	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg13722127	chr7:150037890	RARRES2	-0.49	-8.46	-0.38	4.39e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6867032	1.000	rs4413568	chr5:2016894	A/G	cg26168224	chr5:2018326	NA	0.83	19.31	0.68	5.13e-60	Gut microbiome composition (winter);
LUAD	cis	rs367943	0.634	rs6594701	chr5:112685743	C/T	cg12552261	chr5:112820674	MCC	0.47	9.07	0.4	4.59e-18	Type 2 diabetes;
LUAD	cis	rs12620999	0.941	rs62183343	chr2:237979163	T/C	cg23555395	chr2:238036564	NA	0.59	9.08	0.4	4.27e-18	Systemic lupus erythematosus;
LUAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg18402987	chr7:1209562	NA	0.8	9.84	0.43	1.03e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg05340658	chr4:99064831	C4orf37	-0.46	-7.51	-0.34	3.57e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg02527881	chr3:46936655	PTH1R	0.4	7.6	0.35	1.91e-13	Colorectal cancer;
LUAD	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg13010199	chr12:38710504	ALG10B	0.4	6.39	0.3	4.41e-10	Bladder cancer;
LUAD	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg22431228	chr1:16359049	CLCNKA	-0.41	-6.95	-0.32	1.42e-11	Dilated cardiomyopathy;
LUAD	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg23281280	chr6:28129359	ZNF389	0.46	6.64	0.31	9.47e-11	Depression;
LUAD	trans	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg14791747	chr16:20752902	THUMPD1	0.47	6.82	0.31	3.24e-11	Cognitive test performance;
LUAD	cis	rs12995491	0.933	rs12995212	chr2:88527184	C/T	cg04511125	chr2:88470314	THNSL2	-0.45	-7.44	-0.34	5.57e-13	Response to metformin (IC50);
LUAD	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg03929089	chr4:120376271	NA	0.53	6.89	0.32	2.02e-11	Axial length;
LUAD	trans	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg04775059	chr7:64541387	NA	0.52	6.78	0.31	3.98e-11	Aortic root size;
LUAD	cis	rs1497828	1.000	rs2646823	chr1:217537011	C/A	cg04411442	chr1:217543379	NA	-0.35	-6.53	-0.3	1.91e-10	Dialysis-related mortality;
LUAD	cis	rs8027181	1.000	rs3850986	chr15:73091283	G/T	cg25632853	chr15:73088954	NA	0.36	7.99	0.36	1.3e-14	Triglyceride levels;
LUAD	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg19318889	chr4:1322082	MAEA	0.54	9.09	0.4	3.82e-18	Longevity;
LUAD	cis	rs28735056	1.000	rs4798923	chr18:77629373	G/A	cg20368463	chr18:77673604	PQLC1	-0.43	-6.41	-0.3	3.79e-10	Schizophrenia;
LUAD	cis	rs9283706	0.623	rs1159201	chr5:66311339	C/T	cg11590213	chr5:66331682	MAST4	-0.42	-6.84	-0.32	2.77e-11	Coronary artery disease;
LUAD	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg04546413	chr19:29218101	NA	0.72	11.5	0.49	8.28e-27	Methadone dose in opioid dependence;
LUAD	cis	rs17683430	0.702	rs117079807	chr22:32407021	A/G	cg00543991	chr22:32367038	NA	0.96	9.05	0.4	5.32e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LUAD	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg24562669	chr7:97807699	LMTK2	0.34	8.05	0.36	8.28e-15	Breast cancer;
LUAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg10411590	chr13:21900810	NA	0.46	7.65	0.35	1.37e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg14664628	chr15:75095509	CSK	-0.51	-8.4	-0.38	7.08e-16	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg17845761	chr1:175162550	KIAA0040	0.36	9.48	0.42	1.82e-19	Alcohol dependence;
LUAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg16606324	chr3:10149918	C3orf24	0.68	11.41	0.49	1.78e-26	Alzheimer's disease;
LUAD	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg00634984	chr7:65235879	NA	0.5	7.06	0.32	6.76e-12	Aortic root size;
LUAD	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.6	11.35	0.48	3.07e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg00071950	chr4:10020882	SLC2A9	0.47	7.03	0.32	8.23e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs490234	0.841	rs548793	chr9:128301931	C/T	cg14078157	chr9:128172775	NA	0.43	7.95	0.36	1.76e-14	Mean arterial pressure;
LUAD	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg02176678	chr2:219576539	TTLL4	0.61	11.75	0.5	8.79e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg00083206	chr6:110721305	DDO	-0.42	-7.57	-0.35	2.41e-13	Platelet distribution width;
LUAD	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg24675056	chr1:15929824	NA	0.46	7.97	0.36	1.49e-14	Systolic blood pressure;
LUAD	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg15557168	chr22:42548783	NA	-0.5	-9.4	-0.42	3.39e-19	Schizophrenia;
LUAD	cis	rs877282	0.898	rs11253339	chr10:759640	C/T	cg06581033	chr10:766294	NA	-0.59	-8.02	-0.36	1.06e-14	Uric acid levels;
LUAD	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11890956	chr21:40555474	PSMG1	-0.59	-10.29	-0.45	2.55e-22	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.75	0.31	4.81e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.43	8.16	0.37	3.96e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg08798685	chr6:27730294	NA	-0.67	-6.73	-0.31	5.63e-11	Depression;
LUAD	cis	rs9399401	0.601	rs171891	chr6:142850612	G/A	cg03128060	chr6:142623767	GPR126	0.46	8.06	0.36	7.78e-15	Chronic obstructive pulmonary disease;
LUAD	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg05991184	chr2:219186017	PNKD	0.35	6.93	0.32	1.58e-11	Colorectal cancer;
LUAD	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg04586622	chr2:25135609	ADCY3	0.37	8.33	0.38	1.14e-15	Body mass index;
LUAD	cis	rs7107174	1.000	rs10899492	chr11:78109810	G/A	cg19901956	chr11:77921274	USP35	-0.48	-6.73	-0.31	5.5e-11	Testicular germ cell tumor;
LUAD	cis	rs3784262	0.679	rs8031578	chr15:58369145	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.68	-0.35	1.12e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1483890	0.723	rs2007578	chr3:69408982	T/A	cg22125112	chr3:69402811	FRMD4B	0.46	7.66	0.35	1.26e-13	Resting heart rate;
LUAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg11941060	chr3:133502564	NA	0.69	12.4	0.52	2.51e-30	Iron status biomarkers;
LUAD	cis	rs2425143	1.000	rs2295356	chr20:34252856	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.25	-0.33	2.05e-12	Blood protein levels;
LUAD	cis	rs870825	0.616	rs7659201	chr4:185632013	G/A	cg04058563	chr4:185651563	MLF1IP	0.9	14.38	0.57	1.85e-38	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05815958	chr11:63606719	MARK2	-0.6	-6.35	-0.3	5.46e-10	Type 2 diabetes;
LUAD	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11644478	chr21:40555479	PSMG1	-0.41	-6.73	-0.31	5.67e-11	Menarche (age at onset);
LUAD	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22455342	chr2:225449267	CUL3	0.64	10.04	0.44	2.05e-21	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg08999081	chr20:33150536	PIGU	-0.6	-13.39	-0.55	2.42e-34	Glomerular filtration rate (creatinine);
LUAD	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg11235426	chr6:292522	DUSP22	-0.57	-9.4	-0.42	3.4e-19	Menopause (age at onset);
LUAD	cis	rs17102423	0.760	rs2781375	chr14:65569597	A/G	cg11161011	chr14:65562177	MAX	-0.42	-6.99	-0.32	1.05e-11	Obesity-related traits;
LUAD	cis	rs35883536	1.000	rs17403905	chr1:101107358	T/C	cg06223162	chr1:101003688	GPR88	0.35	6.57	0.3	1.53e-10	Monocyte count;
LUAD	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg14582100	chr15:45693742	SPATA5L1	0.62	12.11	0.51	3.4e-29	Homoarginine levels;
LUAD	cis	rs933688	0.527	rs6898622	chr5:90578292	G/T	cg17503389	chr5:90575422	NA	-0.6	-8.02	-0.36	1.05e-14	Smoking behavior;
LUAD	cis	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.72	-0.35	8.21e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs71478720	0.953	rs4988359	chr11:112025915	T/C	cg04929355	chr11:112034997	IL18	0.45	6.94	0.32	1.45e-11	Interleukin-18 levels;
LUAD	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.33	-0.45	1.83e-22	Monocyte percentage of white cells;
LUAD	cis	rs9462027	0.628	rs11759151	chr6:34747603	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.0	-0.4	7.78e-18	Systemic lupus erythematosus;
LUAD	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg15704280	chr7:45808275	SEPT13	0.69	9.32	0.41	6.27e-19	Axial length;
LUAD	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg07741184	chr6:167504864	NA	-0.3	-7.23	-0.33	2.35e-12	Crohn's disease;
LUAD	trans	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.07	-27.13	-0.8	1.26e-94	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs941898	0.957	rs2181102	chr14:100583949	A/G	cg26002632	chr14:100625216	DEGS2	0.37	6.68	0.31	7.48e-11	White matter hyperintensity burden;
LUAD	cis	rs9473147	0.543	rs1872505	chr6:47480975	C/G	cg12968598	chr6:47444699	CD2AP	0.35	6.35	0.3	5.46e-10	Platelet distribution width;Mean platelet volume;
LUAD	trans	rs8073060	0.586	rs2626625	chr17:34027607	C/G	cg19694781	chr19:47549865	TMEM160	-1.22	-18.88	-0.68	3.96e-58	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7707921	0.767	rs6880209	chr5:81574182	C/T	cg15871215	chr5:81402204	ATG10	-0.65	-10.26	-0.45	3.2e-22	Breast cancer;
LUAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg24813613	chr7:1882135	MAD1L1	-0.42	-6.52	-0.3	2.04e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs11077998	0.967	rs4789788	chr17:80510285	C/T	cg10255544	chr17:80519551	FOXK2	-0.35	-7.0	-0.32	9.94e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.15	0.33	3.76e-12	Parkinson's disease;
LUAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03452623	chr4:187889614	NA	0.82	16.97	0.64	1.22e-49	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg06873352	chr17:61820015	STRADA	0.42	6.89	0.32	2.05e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs490234	0.702	rs5016056	chr9:128310807	C/T	cg14078157	chr9:128172775	NA	-0.47	-8.43	-0.38	5.48e-16	Mean arterial pressure;
LUAD	cis	rs13323323	0.652	rs9825080	chr3:44251270	C/T	cg21672276	chr3:44754072	ZNF502	-0.41	-6.44	-0.3	3.26e-10	IgG glycosylation;
LUAD	cis	rs17102423	0.755	rs35769504	chr14:65576857	G/A	cg11161011	chr14:65562177	MAX	-0.52	-8.13	-0.37	4.65e-15	Obesity-related traits;
LUAD	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg23758822	chr17:41437982	NA	1.02	21.24	0.72	1.15e-68	Menopause (age at onset);
LUAD	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg11833968	chr6:79620685	NA	-0.45	-8.32	-0.37	1.26e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg12940439	chr1:67600707	NA	0.45	8.82	0.39	2.94e-17	Psoriasis;
LUAD	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.48	8.04	0.36	9.05e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs11696501	0.688	rs6104293	chr20:44326298	T/C	cg11783356	chr20:44313418	WFDC10B	-0.51	-8.38	-0.38	8.12e-16	Brain structure;
LUAD	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg00074818	chr8:8560427	CLDN23	0.66	10.16	0.44	7.62e-22	Obesity-related traits;
LUAD	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg04731861	chr2:219085781	ARPC2	-0.23	-7.09	-0.33	5.71e-12	Colorectal cancer;
LUAD	cis	rs1595825	0.891	rs16825188	chr2:198741134	G/C	cg00361562	chr2:198649771	BOLL	-0.5	-6.89	-0.32	2.1e-11	Ulcerative colitis;
LUAD	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.06	0.32	7e-12	Lung cancer in ever smokers;
LUAD	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg12564285	chr5:131593104	PDLIM4	0.38	6.42	0.3	3.63e-10	Blood metabolite levels;
LUAD	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg23281280	chr6:28129359	ZNF389	0.46	6.65	0.31	9.18e-11	Depression;
LUAD	cis	rs59698941	0.550	rs12652469	chr5:132182765	A/G	cg14825688	chr5:132208181	LEAP2	-0.52	-10.6	-0.46	2.01e-23	Apolipoprotein A-IV levels;
LUAD	cis	rs2282300	0.739	rs1222211	chr11:30362239	A/C	cg25418670	chr11:30344373	C11orf46	-0.53	-7.47	-0.34	4.53e-13	Morning vs. evening chronotype;
LUAD	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg17761419	chr8:57350749	NA	-0.52	-7.89	-0.36	2.64e-14	Obesity-related traits;
LUAD	cis	rs7705042	0.897	rs4912807	chr5:141519296	G/C	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.66	-0.31	8.39e-11	Asthma;
LUAD	trans	rs587242	1.000	rs2011694	chr1:96884286	T/A	cg10631902	chr5:14652156	NA	0.43	7.13	0.33	4.49e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.56	8.25	0.37	1.99e-15	Platelet count;
LUAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.58	0.3	1.38e-10	Platelet count;
LUAD	cis	rs6445967	1.000	rs3796215	chr3:58316657	A/G	cg23715586	chr3:58305044	RPP14	0.46	8.22	0.37	2.61e-15	Platelet count;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg18000306	chr6:288505	NA	0.43	8.03	0.36	9.89e-15	Menopause (age at onset);
LUAD	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg05340658	chr4:99064831	C4orf37	-0.46	-7.51	-0.34	3.57e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg03233332	chr7:66118400	NA	-0.43	-6.56	-0.3	1.62e-10	Aortic root size;
LUAD	cis	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg07460842	chr6:66804631	NA	0.91	14.33	0.57	2.92e-38	Exhaled nitric oxide levels;
LUAD	cis	rs4711336	1.000	rs2296738	chr6:33656850	C/T	cg13859433	chr6:33739653	LEMD2	-0.29	-6.64	-0.31	9.77e-11	Height;
LUAD	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.09	-0.33	5.5e-12	Total body bone mineral density;
LUAD	cis	rs447921	0.861	rs17596582	chr17:74438120	A/T	cg17201438	chr17:74438067	UBE2O	-0.68	-8.95	-0.4	1.13e-17	Mitochondrial DNA levels;
LUAD	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg10518543	chr12:38710700	ALG10B	0.42	6.37	0.3	5.07e-10	Heart rate;
LUAD	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg24154853	chr7:158122151	PTPRN2	0.6	11.85	0.5	3.67e-28	Calcium levels;
LUAD	cis	rs10821973	0.527	rs1432414	chr10:63977069	A/T	cg09941381	chr10:64027924	RTKN2	-0.34	-6.74	-0.31	5.22e-11	Hypothyroidism;
LUAD	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg00255919	chr5:131827918	IRF1	0.5	11.9	0.5	2.21e-28	Asthma (sex interaction);
LUAD	cis	rs35740288	0.731	rs35085180	chr15:86102612	T/C	cg13263323	chr15:86062960	AKAP13	-0.45	-7.14	-0.33	4.09e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	trans	rs9408928	0.778	rs9409230	chr9:123967760	A/T	cg10583683	chr15:23034700	NIPA2	0.66	6.44	0.3	3.29e-10	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg10802521	chr3:52805072	NEK4	-0.46	-7.7	-0.35	9.55e-14	Electroencephalogram traits;
LUAD	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg17724175	chr1:150552817	MCL1	0.31	7.16	0.33	3.56e-12	Melanoma;
LUAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg09509183	chr1:209979624	IRF6	0.55	7.86	0.36	3.25e-14	Cleft lip with or without cleft palate;
LUAD	trans	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg12400702	chr3:12838781	CAND2	0.31	6.36	0.3	5.19e-10	Parkinson's disease;
LUAD	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg14828511	chr1:107599125	PRMT6	-0.59	-10.44	-0.45	7.47e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs11229555	0.645	rs11229460	chr11:58208343	T/C	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg09263875	chr16:632152	PIGQ	0.81	17.39	0.65	1.66e-51	Height;
LUAD	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs1595825	0.636	rs111540926	chr2:198885578	G/A	cg11031976	chr2:198649780	BOLL	-0.45	-6.56	-0.3	1.62e-10	Ulcerative colitis;
LUAD	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg27490568	chr2:178487706	NA	0.44	7.12	0.33	4.69e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4077468	0.963	rs1342064	chr1:205913073	T/C	cg26354017	chr1:205819088	PM20D1	-0.36	-6.5	-0.3	2.25e-10	Cystic fibrosis-related diabetes;
LUAD	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.67	0.31	7.84e-11	Hypertriglyceridemia;
LUAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-10.02	-0.44	2.48e-21	Lymphocyte counts;
LUAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg07677032	chr17:61819896	STRADA	0.58	10.57	0.46	2.42e-23	Prudent dietary pattern;
LUAD	trans	rs114934997	1.000	rs56119268	chr5:40389552	A/G	cg19995539	chr12:120539137	RAB35	-0.61	-6.6	-0.31	1.22e-10	Psoriasis;
LUAD	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg11859384	chr17:80120422	CCDC57	0.49	8.88	0.4	1.9e-17	Life satisfaction;
LUAD	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg03474202	chr17:45855739	NA	-0.39	-9.24	-0.41	1.18e-18	IgG glycosylation;
LUAD	cis	rs73206853	0.841	rs56017652	chr12:110931054	C/T	cg12870014	chr12:110450643	ANKRD13A	0.61	6.93	0.32	1.62e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7267979	0.789	rs6083810	chr20:25329759	T/A	cg08601574	chr20:25228251	PYGB	-0.38	-7.14	-0.33	3.98e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg10518543	chr12:38710700	ALG10B	0.5	8.34	0.38	1.05e-15	Morning vs. evening chronotype;
LUAD	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg03396347	chr1:1875803	NA	-0.5	-12.49	-0.52	1.1e-30	Body mass index;
LUAD	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg11663144	chr21:46675770	NA	-0.57	-11.36	-0.48	2.77e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg17264618	chr3:40429014	ENTPD3	0.41	9.16	0.41	2.27e-18	Renal cell carcinoma;
LUAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg20276088	chr3:133502917	NA	-0.43	-7.75	-0.35	7.01e-14	Iron status biomarkers;
LUAD	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.28	-6.42	-0.3	3.71e-10	Dupuytren's disease;
LUAD	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.02	0.32	8.9e-12	Colorectal cancer;
LUAD	cis	rs7010267	0.602	rs7822098	chr8:120020129	A/T	cg01975934	chr8:119970761	NA	-0.34	-6.51	-0.3	2.19e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg05579598	chr16:88989069	CBFA2T3	-0.36	-7.82	-0.36	4.23e-14	Social autistic-like traits;
LUAD	cis	rs870825	0.549	rs28542773	chr4:185617935	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg13722127	chr7:150037890	RARRES2	0.5	8.16	0.37	3.99e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.71e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.72	-14.78	-0.58	3.63e-40	Urate levels in overweight individuals;
LUAD	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08704250	chr15:31115839	NA	-0.55	-9.88	-0.43	7.65e-21	Huntington's disease progression;
LUAD	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.67	-0.39	9.17e-17	Alzheimer's disease (late onset);
LUAD	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg19318889	chr4:1322082	MAEA	0.49	8.12	0.37	5.11e-15	Obesity-related traits;
LUAD	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg15226275	chr6:116381976	FRK	0.23	7.63	0.35	1.5700000000000001e-13	Cholesterol, total;LDL cholesterol;
LUAD	trans	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.98	-0.36	1.4e-14	Gout;
LUAD	cis	rs7737355	0.947	rs10073137	chr5:131091089	A/G	cg06307176	chr5:131281290	NA	0.52	8.13	0.37	4.67e-15	Life satisfaction;
LUAD	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.97	20.88	0.71	4.9e-67	Chronic sinus infection;
LUAD	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg20933634	chr6:27740509	NA	0.46	7.26	0.33	1.9e-12	Parkinson's disease;
LUAD	cis	rs250677	0.559	rs17109198	chr5:148369712	C/T	cg12140854	chr5:148520817	ABLIM3	-0.56	-8.68	-0.39	8.81e-17	Breast cancer;
LUAD	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06544989	chr22:39130855	UNC84B	0.45	8.25	0.37	1.96e-15	Menopause (age at onset);
LUAD	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg26384229	chr12:38710491	ALG10B	0.38	6.52	0.3	2.06e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg08470875	chr2:26401718	FAM59B	0.57	7.78	0.35	5.5e-14	Gut microbiome composition (summer);
LUAD	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg02423579	chr7:2872169	GNA12	-0.82	-14.19	-0.57	1.14e-37	Height;
LUAD	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg10978503	chr1:24200527	CNR2	0.6	12.84	0.53	4.37e-32	Immature fraction of reticulocytes;
LUAD	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg03037974	chr15:76606532	NA	0.38	8.03	0.36	1.01e-14	Blood metabolite levels;
LUAD	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg25809561	chr17:30822961	MYO1D	0.61	11.77	0.5	7.06e-28	Schizophrenia;
LUAD	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg13722127	chr7:150037890	RARRES2	0.47	8.38	0.38	7.87e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.59	-0.52	4.21e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg07432352	chr17:45403706	C17orf57	-0.4	-7.73	-0.35	8.06e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg18833306	chr6:118973337	C6orf204	-0.51	-7.4	-0.34	7.2e-13	Diastolic blood pressure;
LUAD	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg18446336	chr7:2847575	GNA12	-0.38	-7.05	-0.32	7.49e-12	Height;
LUAD	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg15017067	chr4:17643749	FAM184B	0.37	7.18	0.33	3.25e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.38	0.34	8.27e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16944159	chr2:62132759	COMMD1	-0.4	-6.4	-0.3	4.25e-10	Height;
LUAD	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg11822812	chr5:140052017	DND1	-0.39	-7.02	-0.32	9.09e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.59	-0.31	1.33e-10	Prostate cancer;
LUAD	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.84	-0.5	3.91e-28	Coronary artery disease;
LUAD	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg12311346	chr5:56204834	C5orf35	-1.0	-15.59	-0.6	1.34e-43	Type 2 diabetes;
LUAD	cis	rs7614311	1.000	rs7614311	chr3:63813654	A/C	cg22134162	chr3:63841271	THOC7	-0.38	-7.93	-0.36	1.97e-14	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-7.81	-0.36	4.43e-14	Blood metabolite levels;
LUAD	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg26446133	chr18:72167187	CNDP2	-0.81	-12.14	-0.51	2.6e-29	Refractive error;
LUAD	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg19635926	chr16:89946313	TCF25	0.79	6.89	0.32	2.08e-11	Skin colour saturation;
LUAD	trans	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg03886242	chr7:26192032	NFE2L3	0.37	6.55	0.3	1.63e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11252926	0.627	rs10751997	chr10:561952	C/T	cg03684893	chr10:554711	DIP2C	-0.4	-7.08	-0.33	6.21e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs4285028	0.948	rs2332033	chr3:121699548	C/T	cg11130432	chr3:121712080	ILDR1	-0.58	-8.2	-0.37	2.83e-15	Multiple sclerosis;
LUAD	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg10164272	chr16:89456328	ANKRD11	0.45	7.21	0.33	2.56e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs12505328	0.593	rs880962	chr4:174362201	G/A	cg12145043	chr4:174357286	NA	-0.53	-7.84	-0.36	3.68e-14	Chin dimples;
LUAD	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg02176678	chr2:219576539	TTLL4	0.74	14.87	0.59	1.63e-40	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs909685	1.000	rs2069235	chr22:39747780	C/T	cg24268161	chr22:39747459	SYNGR1	-0.43	-8.85	-0.4	2.35e-17	Rheumatoid arthritis;
LUAD	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg16797656	chr11:68205561	LRP5	0.45	8.41	0.38	6.15e-16	Total body bone mineral density;
LUAD	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.73	0.31	5.43e-11	Neuroticism;
LUAD	cis	rs1062746	0.777	rs34400756	chr16:87372078	A/G	cg02258303	chr16:87377426	FBXO31	-0.46	-8.01	-0.36	1.16e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	trans	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg01620082	chr3:125678407	NA	-0.88	-9.02	-0.4	6.74e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg22508957	chr16:3507546	NAT15	-0.5	-8.29	-0.37	1.56e-15	Body mass index (adult);
LUAD	cis	rs4713675	0.565	rs4711340	chr6:33681131	C/T	cg14003231	chr6:33640908	ITPR3	0.5	9.59	0.42	7.73e-20	Plateletcrit;
LUAD	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs1595825	0.891	rs7592344	chr2:198572461	C/T	cg10547527	chr2:198650123	BOLL	-0.55	-7.95	-0.36	1.74e-14	Ulcerative colitis;
LUAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg07755735	chr2:20870362	GDF7	-0.52	-9.43	-0.42	2.68e-19	Abdominal aortic aneurysm;
LUAD	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg19163074	chr7:65112434	INTS4L2	-0.45	-6.87	-0.32	2.37e-11	Aortic root size;
LUAD	cis	rs11771526	0.901	rs62457470	chr7:32303516	A/G	cg13207630	chr7:32358064	NA	0.6	7.32	0.34	1.27e-12	Body mass index;
LUAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg20607798	chr8:58055168	NA	0.64	8.19	0.37	3.13e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg17105886	chr17:28927953	LRRC37B2	0.74	6.77	0.31	4.37e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg15123519	chr2:136567270	LCT	0.36	6.36	0.3	5.29e-10	Mosquito bite size;
LUAD	cis	rs7107174	1.000	rs10793303	chr11:78060750	G/A	cg02023728	chr11:77925099	USP35	0.46	7.1	0.33	5.22e-12	Testicular germ cell tumor;
LUAD	cis	rs1371614	0.635	rs34803465	chr2:27138285	G/A	cg00617064	chr2:27272375	NA	0.35	6.72	0.31	5.99e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs10905065	0.862	rs9423948	chr10:5742491	G/A	cg11519256	chr10:5708881	ASB13	0.39	6.36	0.3	5.1e-10	Menopause (age at onset);
LUAD	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg15506890	chr2:3487001	NA	-0.49	-8.48	-0.38	3.9e-16	Neurofibrillary tangles;
LUAD	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.91	-0.36	2.3e-14	Blood metabolite levels;
LUAD	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg22968622	chr17:43663579	NA	-0.98	-16.8	-0.63	7e-49	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg05896524	chr21:47604654	C21orf56	0.54	9.05	0.4	5.18e-18	Testicular germ cell tumor;
LUAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg11494091	chr17:61959527	GH2	-0.73	-18.11	-0.66	1.11e-54	Prudent dietary pattern;
LUAD	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg05044414	chr3:183734942	ABCC5	0.4	7.84	0.36	3.69e-14	Anterior chamber depth;
LUAD	trans	rs1493916	0.905	rs34165207	chr18:31400153	G/A	cg13755796	chr4:20253514	NA	-0.41	-6.79	-0.31	3.81e-11	Life satisfaction;
LUAD	cis	rs6881634	0.501	rs11958920	chr5:77763891	T/C	cg11547950	chr5:77652471	NA	-0.35	-6.38	-0.3	4.74e-10	Hippocampal atrophy;
LUAD	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg22431228	chr1:16359049	CLCNKA	-0.54	-9.67	-0.43	4.07e-20	Dilated cardiomyopathy;
LUAD	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg25344623	chr2:136566232	LCT	-0.33	-6.46	-0.3	2.86e-10	Mosquito bite size;
LUAD	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03517284	chr6:25882590	NA	0.59	9.78	0.43	1.63e-20	Blood metabolite levels;
LUAD	cis	rs3784262	0.528	rs34556514	chr15:58333769	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-7.21	-0.33	2.52e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00149659	chr3:10157352	C3orf10	0.58	7.98	0.36	1.43e-14	Alzheimer's disease;
LUAD	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg08601574	chr20:25228251	PYGB	-0.47	-8.84	-0.39	2.62e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg14024328	chr4:719362	PCGF3	-0.52	-8.62	-0.39	1.31e-16	White blood cell count;
LUAD	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg02527881	chr3:46936655	PTH1R	-0.45	-8.63	-0.39	1.25e-16	Colorectal cancer;
LUAD	cis	rs7432375	0.610	rs60574021	chr3:136520281	C/G	cg15507776	chr3:136538369	TMEM22	0.39	6.96	0.32	1.3e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg02524346	chr8:600233	NA	-1.16	-9.91	-0.43	5.72e-21	IgG glycosylation;
LUAD	cis	rs7241530	0.636	rs34068602	chr18:75898236	C/T	cg14642773	chr18:75888474	NA	0.35	6.35	0.3	5.46e-10	Educational attainment (years of education);
LUAD	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg00277334	chr10:82204260	NA	-0.43	-7.24	-0.33	2.14e-12	Post bronchodilator FEV1;
LUAD	cis	rs10979	1.000	rs9376763	chr6:143887386	C/T	cg25407410	chr6:143891975	LOC285740	-0.64	-10.14	-0.44	8.82e-22	Hypospadias;
LUAD	cis	rs8017423	0.967	rs4904657	chr14:90721600	A/G	cg14092571	chr14:90743983	NA	-0.5	-8.78	-0.39	4.22e-17	Mortality in heart failure;
LUAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg22907277	chr7:1156413	C7orf50	0.48	7.87	0.36	2.97e-14	Longevity;Endometriosis;
LUAD	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.27	0.37	1.77e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg21226059	chr5:178986404	RUFY1	0.45	7.8	0.35	5e-14	Lung cancer;
LUAD	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg25173405	chr17:45401733	C17orf57	-0.47	-7.63	-0.35	1.56e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	9.3	0.41	7.83e-19	Alzheimer's disease;
LUAD	trans	rs79911532	0.515	rs80171070	chr7:75636868	T/C	cg19862616	chr7:65841803	NCRNA00174	0.83	8.64	0.39	1.21e-16	Mononucleosis;
LUAD	cis	rs427941	0.703	rs201454	chr7:101740056	A/G	cg06246474	chr7:101738831	CUX1	0.41	7.29	0.33	1.54e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg23649088	chr2:200775458	C2orf69	0.57	8.15	0.37	4.3e-15	Schizophrenia;
LUAD	trans	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg25215298	chr1:860022	SAMD11	0.49	6.61	0.31	1.19e-10	Leprosy;
LUAD	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg06627628	chr2:24431161	ITSN2	0.42	7.09	0.33	5.83e-12	Asthma;
LUAD	trans	rs7395662	0.929	rs10838956	chr11:48581765	T/C	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.76e-10	HDL cholesterol;
LUAD	cis	rs9811920	0.690	rs7623587	chr3:99906751	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.47	8.98	0.4	8.78e-18	Axial length;
LUAD	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg13319975	chr6:146136371	FBXO30	0.68	11.6	0.49	3.24e-27	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs8129326	0.754	rs9974541	chr21:35806004	C/T	cg07474852	chr4:123073612	NA	-0.4	-6.43	-0.3	3.53e-10	Cancer;
LUAD	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.8	-0.35	5.01e-14	Prostate cancer;
LUAD	cis	rs2554380	0.891	rs2554383	chr15:84356316	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.58	-8.8	-0.39	3.5e-17	Height;
LUAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg13560548	chr3:10150139	C3orf24	0.39	6.47	0.3	2.71e-10	Alzheimer's disease;
LUAD	cis	rs4795519	0.736	rs2879768	chr17:22201257	T/C	cg22648282	chr17:21454238	C17orf51	-0.41	-6.7	-0.31	6.51e-11	Chronic myeloid leukemia;
LUAD	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg08632164	chr7:65971372	NA	-0.37	-6.45	-0.3	3.09e-10	Aortic root size;
LUAD	cis	rs2235649	0.552	rs7203361	chr16:1963085	G/A	cg08610935	chr16:1836813	NUBP2	-0.49	-7.25	-0.33	2.06e-12	Blood metabolite levels;
LUAD	cis	rs11971779	0.680	rs10261557	chr7:139099037	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg26384229	chr12:38710491	ALG10B	0.48	7.82	0.36	4.17e-14	Bladder cancer;
LUAD	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg04398451	chr17:18023971	MYO15A	-0.65	-11.74	-0.5	1e-27	Total body bone mineral density;
LUAD	cis	rs910187	0.605	rs6063079	chr20:45804275	C/G	cg27589058	chr20:45804311	EYA2	-0.37	-8.61	-0.39	1.42e-16	Migraine;
LUAD	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08704250	chr15:31115839	NA	-0.6	-10.93	-0.47	1.21e-24	Huntington's disease progression;
LUAD	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg25457927	chr22:38595422	NA	-0.53	-13.76	-0.56	7.23e-36	Cutaneous nevi;
LUAD	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg09359103	chr1:154839909	KCNN3	-0.91	-21.13	-0.72	3.5e-68	Prostate cancer;
LUAD	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg22907277	chr7:1156413	C7orf50	-0.47	-7.93	-0.36	1.94e-14	Longevity;Endometriosis;
LUAD	trans	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg01620082	chr3:125678407	NA	-0.77	-8.42	-0.38	6.03e-16	Breast cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13211287	chr8:144700128	TSTA3	-0.56	-6.8	-0.31	3.66e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs739496	0.947	rs2285520	chr12:111867487	C/T	cg10833066	chr12:111807467	FAM109A	0.42	6.75	0.31	5.03e-11	Platelet count;
LUAD	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg19678392	chr7:94953810	PON1	-0.57	-7.73	-0.35	7.93e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg02660097	chr11:68866761	NA	0.51	7.12	0.33	4.63e-12	Blond vs. brown hair color;
LUAD	cis	rs11229555	0.645	rs12794534	chr11:58179568	C/A	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg00204512	chr16:28754710	NA	0.31	6.79	0.31	3.76e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs12681288	0.523	rs111782857	chr8:962486	T/C	cg04851639	chr8:1020857	NA	-0.31	-7.23	-0.33	2.26e-12	Schizophrenia;
LUAD	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg21100191	chr22:23484243	RTDR1	0.69	12.13	0.51	2.85e-29	Bone mineral density;
LUAD	cis	rs2554380	0.891	rs1426164	chr15:84301836	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.52	-8.13	-0.37	4.74e-15	Height;
LUAD	trans	rs783540	0.542	rs62009945	chr15:83299956	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.58	-8.6	-0.39	1.56e-16	Schizophrenia;
LUAD	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg06547715	chr2:218990976	CXCR2	0.29	6.77	0.31	4.32e-11	Colorectal cancer;
LUAD	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.46	0.52	1.37e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14893161	chr1:205819251	PM20D1	0.75	15.32	0.6	1.87e-42	Monocyte percentage of white cells;
LUAD	cis	rs10489202	1.000	rs4656564	chr1:167928992	T/C	cg24449463	chr1:168025552	DCAF6	-0.56	-7.25	-0.33	1.98e-12	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg09455208	chr3:40491958	NA	0.56	12.35	0.51	3.79e-30	Renal cell carcinoma;
LUAD	cis	rs4280164	0.551	rs3212242	chr14:24810401	C/T	cg07162820	chr14:24837146	NFATC4	0.32	6.51	0.3	2.13e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs7474896	0.537	rs2505255	chr10:38359642	C/A	cg25427524	chr10:38739819	LOC399744	-0.57	-7.93	-0.36	1.94e-14	Obesity (extreme);
LUAD	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg23758822	chr17:41437982	NA	1.01	21.51	0.72	7.05e-70	Menopause (age at onset);
LUAD	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg26384229	chr12:38710491	ALG10B	0.48	7.74	0.35	7.17e-14	Bladder cancer;
LUAD	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg07549590	chr16:15018862	NA	-0.58	-10.92	-0.47	1.29e-24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs13315871	0.929	rs9837903	chr3:58301906	A/T	cg20936604	chr3:58311152	NA	-0.75	-7.61	-0.35	1.82e-13	Cholesterol, total;
LUAD	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.41	0.38	6.44e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-7.15	-0.33	3.91e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg27454412	chr7:1067447	C7orf50	0.44	7.0	0.32	1.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.87	0.32	2.35e-11	Depression;
LUAD	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg18944383	chr4:111397179	ENPEP	-0.55	-10.61	-0.46	1.71e-23	Height;
LUAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08280861	chr8:58055591	NA	0.63	8.31	0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg03651054	chr13:50194643	NA	0.4	8.02	0.36	1.03e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs8060686	0.858	rs1476306	chr16:67973171	C/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-8.86	-0.4	2.3e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg09658497	chr7:2847517	GNA12	-0.4	-7.02	-0.32	8.6e-12	Height;
LUAD	trans	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg14917512	chr19:3094685	GNA11	-0.54	-6.56	-0.3	1.59e-10	Diabetic kidney disease;
LUAD	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg23625390	chr15:77176239	SCAPER	-0.45	-7.19	-0.33	2.94e-12	Blood metabolite levels;
LUAD	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg18477163	chr1:228402036	OBSCN	0.4	7.19	0.33	3e-12	Diastolic blood pressure;
LUAD	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.94	0.4	1.25e-17	Menarche (age at onset);
LUAD	cis	rs367943	0.576	rs10074024	chr5:112980820	G/A	cg12552261	chr5:112820674	MCC	0.42	7.78	0.35	5.7e-14	Type 2 diabetes;
LUAD	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-12.68	-0.52	1.89e-31	Mean corpuscular volume;
LUAD	cis	rs829883	0.966	rs249818	chr12:98896994	A/C	cg25150519	chr12:98850993	NA	0.68	11.26	0.48	6.78e-26	Colorectal adenoma (advanced);
LUAD	cis	rs116095464	1.000	rs3936676	chr5:353677	T/C	cg22496380	chr5:211416	CCDC127	-1.0	-7.94	-0.36	1.8e-14	Breast cancer;
LUAD	cis	rs8177876	0.570	rs11863158	chr16:81068130	A/T	cg08591886	chr16:81111003	C16orf46	-0.72	-6.81	-0.31	3.38e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-9.75	-0.43	2.08e-20	Lymphocyte counts;
LUAD	cis	rs73198271	0.681	rs35457364	chr8:8649790	T/A	cg01851573	chr8:8652454	MFHAS1	0.5	8.74	0.39	5.53e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4604732	0.631	rs12038880	chr1:247624603	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.49	8.09	0.37	6.36e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg23711669	chr6:146136114	FBXO30	0.38	6.41	0.3	4e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7834588	0.539	rs6472071	chr8:63999990	T/A	cg04220482	chr8:63952370	GGH	0.34	7.13	0.33	4.41e-12	Response to Vitamin E supplementation;
LUAD	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg25036284	chr2:26402008	FAM59B	0.84	12.38	0.52	3.08e-30	Gut microbiome composition (summer);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg04924415	chr12:100661456	SCYL2;DEPDC4	-0.7	-7.06	-0.32	6.92e-12	Type 2 diabetes;
LUAD	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg15744005	chr10:104629667	AS3MT	-0.36	-7.18	-0.33	3.06e-12	Arsenic metabolism;
LUAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg25703541	chr22:24373054	LOC391322	-0.79	-13.81	-0.56	4.67e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6121246	0.609	rs6089054	chr20:30323141	A/G	cg21427119	chr20:30132790	HM13	-0.35	-6.44	-0.3	3.34e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs2637266	0.714	rs4475870	chr10:78450724	T/A	cg18941641	chr10:78392320	NA	0.32	6.63	0.31	1.05e-10	Pulmonary function;
LUAD	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg06784218	chr1:46089804	CCDC17	0.6	13.41	0.55	2.08e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7274811	0.681	rs186026	chr20:31951993	G/T	cg14921437	chr20:32255988	NECAB3;C20orf134	0.5	7.72	0.35	8.74e-14	Height;
LUAD	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg05283184	chr6:79620031	NA	-0.44	-7.62	-0.35	1.63e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg05754148	chr16:3507555	NAT15	0.81	10.67	0.46	1.11e-23	Tuberculosis;
LUAD	cis	rs4891159	0.548	rs689902	chr18:74119969	C/T	cg24786174	chr18:74118243	ZNF516	-0.92	-23.54	-0.75	6.54e-79	Longevity;
LUAD	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg09455208	chr3:40491958	NA	-0.56	-12.24	-0.51	1.02e-29	Renal cell carcinoma;
LUAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08280861	chr8:58055591	NA	0.61	8.0	0.36	1.18e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7843479	0.930	rs4871903	chr8:21827833	C/T	cg10047019	chr8:21822950	XPO7	0.38	6.49	0.3	2.39e-10	Mean corpuscular volume;
LUAD	trans	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg21659725	chr3:3221576	CRBN	-0.58	-9.21	-0.41	1.58e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs68170813	0.527	rs75382408	chr7:107010406	C/T	cg02696742	chr7:106810147	HBP1	-0.73	-10.16	-0.44	7.69e-22	Coronary artery disease;
LUAD	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.86	0.36	3.32e-14	Depression;
LUAD	cis	rs6500395	1.000	rs8052196	chr16:48691644	C/T	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.07e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg06547715	chr2:218990976	CXCR2	-0.3	-7.09	-0.33	5.63e-12	Colorectal cancer;
LUAD	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg02569458	chr12:86230093	RASSF9	0.43	8.13	0.37	4.77e-15	Major depressive disorder;
LUAD	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.97	13.67	0.55	1.78e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08219700	chr8:58056026	NA	0.63	8.82	0.39	2.92e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10174077	0.874	rs10186656	chr2:152475938	T/G	cg06191203	chr2:152266755	RIF1	-0.54	-8.1	-0.37	5.79e-15	Squamous cell lung carcinoma;
LUAD	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-11.29	-0.48	5.3e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg10518543	chr12:38710700	ALG10B	-0.45	-7.34	-0.34	1.11e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs977987	0.705	rs4888377	chr16:75325686	C/G	cg03315344	chr16:75512273	CHST6	0.65	13.5	0.55	8.36e-35	Dupuytren's disease;
LUAD	cis	rs469568	0.674	rs173104	chr5:178686928	C/T	cg08999896	chr5:178685787	ADAMTS2	-0.34	-7.35	-0.34	1.02e-12	Stroke (pediatric);
LUAD	cis	rs74181299	0.890	rs2723062	chr2:65280220	G/A	cg05010058	chr2:65284262	CEP68	0.3	6.5	0.3	2.33e-10	Pulse pressure;
LUAD	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg17509989	chr5:176798049	RGS14	-0.58	-8.98	-0.4	8.95e-18	Urate levels in lean individuals;
LUAD	cis	rs1595825	0.891	rs73054808	chr2:198602283	C/T	cg10547527	chr2:198650123	BOLL	-0.53	-7.31	-0.33	1.35e-12	Ulcerative colitis;
LUAD	cis	rs1865721	0.804	rs35653478	chr18:73212546	C/T	cg26385618	chr18:73139727	C18orf62	-0.38	-7.01	-0.32	9.65e-12	Intelligence;
LUAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18404041	chr3:52824283	ITIH1	-0.39	-7.46	-0.34	5.04e-13	Electroencephalogram traits;
LUAD	cis	rs4242434	0.672	rs7830206	chr8:22485375	C/T	cg03733263	chr8:22462867	KIAA1967	0.59	9.84	0.43	9.97e-21	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg18110333	chr6:292329	DUSP22	-0.55	-9.17	-0.41	2.11e-18	Menopause (age at onset);
LUAD	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg02990361	chr1:107599529	PRMT6	0.53	8.85	0.4	2.43e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7809950	1.000	rs2237676	chr7:107198079	C/A	cg23024343	chr7:107201750	COG5	-0.72	-12.24	-0.51	1.08e-29	Coronary artery disease;
LUAD	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg00049323	chr5:472564	LOC25845	0.46	7.58	0.35	2.25e-13	Cystic fibrosis severity;
LUAD	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.44	7.1	0.33	5.4e-12	Resistin levels;
LUAD	cis	rs11958404	0.932	rs55943686	chr5:157439591	G/C	cg05962755	chr5:157440814	NA	0.71	9.95	0.44	4.36e-21	IgG glycosylation;
LUAD	cis	rs12210905	0.688	rs72841398	chr6:27489114	A/C	cg08851530	chr6:28072375	NA	1.07	7.73	0.35	8.1e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg06640241	chr16:89574553	SPG7	0.66	11.51	0.49	7.57e-27	Multiple myeloma (IgH translocation);
LUAD	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg24803719	chr17:45855879	NA	0.33	7.6	0.35	1.87e-13	IgG glycosylation;
LUAD	cis	rs9868809	0.764	rs2633958	chr3:48635432	A/G	cg00383909	chr3:49044727	WDR6	-0.73	-6.87	-0.32	2.3e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg18490616	chr2:88469792	THNSL2	-0.44	-6.98	-0.32	1.16e-11	Response to metformin (IC50);
LUAD	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.57	-0.35	2.39e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	12.45	0.52	1.53e-30	Homoarginine levels;
LUAD	cis	rs12681287	0.640	rs10098356	chr8:87442667	A/G	cg00550725	chr8:87521180	FAM82B	-0.45	-6.63	-0.31	1.02e-10	Caudate activity during reward;
LUAD	cis	rs7193541	0.684	rs7201320	chr16:74694058	T/G	cg01733217	chr16:74700730	RFWD3	0.68	13.39	0.55	2.55e-34	Multiple myeloma;
LUAD	cis	rs12760731	0.720	rs16852717	chr1:178309723	T/C	cg00404053	chr1:178313656	RASAL2	0.65	8.47	0.38	4.11e-16	Obesity-related traits;
LUAD	cis	rs3784262	0.512	rs4646571	chr15:58343137	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.5	-9.85	-0.43	9.22e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg05665937	chr4:1216051	CTBP1	0.44	7.51	0.34	3.64e-13	Obesity-related traits;
LUAD	cis	rs35306767	0.855	rs12770190	chr10:951262	C/T	cg26597838	chr10:835615	NA	0.97	13.55	0.55	5.63e-35	Eosinophil percentage of granulocytes;
LUAD	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg17551891	chr7:1960795	MAD1L1	-0.44	-7.33	-0.34	1.2e-12	Bipolar disorder;
LUAD	cis	rs4700695	0.925	rs4700692	chr5:65396279	T/C	cg21114390	chr5:65439923	SFRS12	-0.65	-8.42	-0.38	5.95e-16	Facial morphology (factor 19);
LUAD	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18876405	chr7:65276391	NA	-0.56	-9.42	-0.42	2.99e-19	Aortic root size;
LUAD	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.53	0.3	1.89e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg22681709	chr2:178499509	PDE11A	-0.51	-8.24	-0.37	2.12e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.51	0.42	1.41e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3007168	1.000	rs2999356	chr14:51606543	A/G	cg23942311	chr14:51606299	NA	0.54	7.39	0.34	8.02e-13	Cancer;
LUAD	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.94	-0.4	1.17e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4253772	0.938	rs77378083	chr22:46639386	G/A	cg09491104	chr22:46646882	C22orf40	-0.51	-6.97	-0.32	1.22e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg11663144	chr21:46675770	NA	-0.58	-11.53	-0.49	6.06e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.6	-7.85	-0.36	3.46e-14	Iron status biomarkers;
LUAD	cis	rs6987853	0.933	rs2974341	chr8:42398302	T/A	cg09913449	chr8:42400586	C8orf40	0.43	7.93	0.36	2.03e-14	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg14668632	chr7:2872130	GNA12	-0.45	-7.95	-0.36	1.71e-14	Height;
LUAD	cis	rs35771425	0.518	rs1055565	chr1:211605697	G/A	cg26515805	chr1:211431828	RCOR3	-0.42	-8.12	-0.37	5.09e-15	Educational attainment (years of education);
LUAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg19130645	chr7:65235666	NA	0.48	8.14	0.37	4.46e-15	Calcium levels;
LUAD	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg15128208	chr22:42549153	NA	-0.43	-8.88	-0.4	1.91e-17	Cognitive function;
LUAD	trans	rs7200543	1.000	rs1136001	chr16:15131974	G/T	cg24683922	chr1:11983373	KIAA2013	-0.48	-8.09	-0.37	6.22e-15	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg11663144	chr21:46675770	NA	-0.61	-11.65	-0.49	2.12e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg01516881	chr6:292596	DUSP22	-0.51	-8.53	-0.38	2.59e-16	Menopause (age at onset);
LUAD	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg03037974	chr15:76606532	NA	0.37	7.74	0.35	7.19e-14	Blood metabolite levels;
LUAD	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg06064525	chr11:970664	AP2A2	-0.54	-11.1	-0.48	2.57e-25	Alzheimer's disease (late onset);
LUAD	cis	rs6987853	0.787	rs2974351	chr8:42407047	A/T	cg09913449	chr8:42400586	C8orf40	0.52	10.42	0.45	8.46e-23	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9369695	0.842	rs9395262	chr6:47465267	T/C	cg20196966	chr6:47445060	CD2AP	0.45	6.99	0.32	1.04e-11	Reticulocyte count;
LUAD	cis	rs17685	0.740	rs2286821	chr7:75611355	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.42	8.06	0.36	8.01e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.41e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2651899	0.865	rs2817126	chr1:3083246	T/G	cg22674798	chr1:3096360	PRDM16	0.38	9.78	0.43	1.66e-20	Migraine;
LUAD	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg15704280	chr7:45808275	SEPT13	0.63	8.08	0.37	6.77e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7264396	0.561	rs6060741	chr20:34571484	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.45	6.48	0.3	2.56e-10	Total cholesterol levels;
LUAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.44	-0.3	3.34e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03517284	chr6:25882590	NA	-0.58	-9.54	-0.42	1.16e-19	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg09491104	chr22:46646882	C22orf40	-0.57	-8.37	-0.38	8.25e-16	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9902453	0.817	rs2321333	chr17:28140857	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	10.56	0.46	2.72e-23	Coffee consumption (cups per day);
LUAD	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg10523679	chr1:76189770	ACADM	0.89	15.76	0.61	2.28e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg02466173	chr16:30829666	NA	0.82	16.48	0.63	1.73e-47	Dementia with Lewy bodies;
LUAD	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg02228675	chr17:40259724	DHX58	-0.44	-7.03	-0.32	8.22e-12	Fibrinogen levels;
LUAD	trans	rs208520	0.874	rs208473	chr6:66917265	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-14.3	-0.57	3.95e-38	Exhaled nitric oxide output;
LUAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg21782813	chr7:2030301	MAD1L1	0.42	6.98	0.32	1.14e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9302635	0.513	rs7184169	chr16:72152933	C/T	cg23815491	chr16:72088622	HP	0.48	7.59	0.35	2.06e-13	Blood protein levels;
LUAD	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg05991184	chr2:219186017	PNKD	0.38	7.39	0.34	7.96e-13	Colorectal cancer;
LUAD	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg04398451	chr17:18023971	MYO15A	-0.63	-11.4	-0.48	2.01e-26	Total body bone mineral density;
LUAD	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	7.11	0.33	5.12e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg12863693	chr15:85201151	NMB	0.38	6.96	0.32	1.31e-11	Schizophrenia;
LUAD	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.43	-0.3	3.53e-10	Total body bone mineral density;
LUAD	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg03929089	chr4:120376271	NA	-0.91	-17.22	-0.64	9.71e-51	Coronary artery disease;
LUAD	cis	rs877282	0.947	rs957642	chr10:773966	C/T	cg06581033	chr10:766294	NA	-0.45	-6.47	-0.3	2.7e-10	Uric acid levels;
LUAD	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	0.47	7.69	0.35	1.07e-13	Resistin levels;
LUAD	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg26513180	chr16:89883248	FANCA	0.46	7.57	0.35	2.32e-13	Vitiligo;
LUAD	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg27446573	chr6:127587934	RNF146	0.43	6.47	0.3	2.72e-10	Breast cancer;
LUAD	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg09658497	chr7:2847517	GNA12	-0.45	-8.26	-0.37	1.95e-15	Height;
LUAD	trans	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg24644049	chr4:85504048	CDS1	0.7	6.87	0.32	2.34e-11	Skin colour saturation;
LUAD	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg18446336	chr7:2847575	GNA12	-0.33	-6.72	-0.31	5.75e-11	Height;
LUAD	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg18230493	chr5:56204884	C5orf35	-0.84	-12.43	-0.52	1.82e-30	Initial pursuit acceleration;
LUAD	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.56	-0.3	1.58e-10	Longevity;
LUAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg27454412	chr7:1067447	C7orf50	0.48	7.72	0.35	8.28e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg24154853	chr7:158122151	PTPRN2	0.57	11.34	0.48	3.37e-26	Calcium levels;
LUAD	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg09222892	chr1:25734099	RHCE	0.5	9.36	0.41	4.65e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.62	-11.86	-0.5	3.28e-28	Longevity;Endometriosis;
LUAD	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg05340658	chr4:99064831	C4orf37	-0.45	-7.37	-0.34	8.91e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg27494647	chr7:150038898	RARRES2	-0.37	-6.6	-0.31	1.21e-10	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4689388	0.647	rs9997824	chr4:6283253	T/C	cg00701064	chr4:6280414	WFS1	0.58	10.8	0.46	3.68e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7769051	0.522	rs56908272	chr6:133102165	G/C	cg22852734	chr6:133119734	C6orf192	0.89	6.93	0.32	1.56e-11	Type 2 diabetes nephropathy;
LUAD	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg12927641	chr6:109611667	NA	0.5	8.93	0.4	1.27e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg18477163	chr1:228402036	OBSCN	0.44	8.93	0.4	1.3e-17	Diastolic blood pressure;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06858855	chr19:14017133	CC2D1A;C19orf57	-0.66	-6.35	-0.3	5.7e-10	Type 2 diabetes;
LUAD	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg15448220	chr1:150897856	SETDB1	0.51	8.81	0.39	3.2e-17	Melanoma;
LUAD	cis	rs7072216	0.726	rs4474372	chr10:100164571	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-8.45	-0.38	4.62e-16	Metabolite levels;
LUAD	cis	rs6543140	1.000	rs6543140	chr2:103074274	G/T	cg03938978	chr2:103052716	IL18RAP	0.35	6.8	0.31	3.6e-11	Blood protein levels;
LUAD	cis	rs2070677	0.935	rs11101885	chr10:135417088	T/C	cg20169779	chr10:135381914	SYCE1	-0.47	-7.61	-0.35	1.74e-13	Gout;
LUAD	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.65	-0.35	1.38e-13	Lung cancer;
LUAD	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg21709803	chr11:61594965	FADS2	-0.36	-6.69	-0.31	6.92e-11	Trans fatty acid levels;
LUAD	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.0	0.32	1.03e-11	Menopause (age at onset);
LUAD	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.35	0.34	1.05e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs12765878	0.934	rs11191841	chr10:105639611	C/T	cg11005552	chr10:105648138	OBFC1	-0.43	-8.23	-0.37	2.39e-15	Coronary artery disease;
LUAD	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg27411982	chr8:10470053	RP1L1	-0.36	-6.62	-0.31	1.06e-10	Morning vs. evening chronotype;
LUAD	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg04369109	chr6:150039330	LATS1	-0.4	-6.64	-0.31	9.64e-11	Lung cancer;
LUAD	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg13390004	chr1:15929781	NA	0.48	8.23	0.37	2.32e-15	Systolic blood pressure;
LUAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg10862848	chr6:42927986	GNMT	-0.32	-9.26	-0.41	1.07e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg00933542	chr6:150070202	PCMT1	0.35	7.41	0.34	7.13e-13	Testicular germ cell tumor;
LUAD	cis	rs17253792	0.822	rs76918910	chr14:56058762	T/C	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg15448220	chr1:150897856	SETDB1	0.52	8.89	0.4	1.79e-17	Melanoma;
LUAD	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.42	-7.14	-0.33	4.1e-12	Tonsillectomy;
LUAD	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg04398451	chr17:18023971	MYO15A	0.61	10.85	0.47	2.34e-24	Total body bone mineral density;
LUAD	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg21951975	chr1:209979733	IRF6	0.58	7.3	0.33	1.45e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg00106254	chr7:1943704	MAD1L1	-0.53	-7.96	-0.36	1.62e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs7771547	0.519	rs6457912	chr6:36373794	C/A	cg04289385	chr6:36355825	ETV7	0.48	7.09	0.33	5.81e-12	Platelet distribution width;
LUAD	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg15445000	chr17:37608096	MED1	-0.43	-8.03	-0.36	9.65e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs4642101	0.855	rs9873475	chr3:12845422	A/G	cg24848339	chr3:12840334	CAND2	0.39	7.81	0.35	4.65e-14	QRS complex (12-leadsum);
LUAD	cis	rs1105228	0.731	rs1547709	chr6:165705488	T/C	cg12582777	chr6:165658423	NA	0.32	6.56	0.3	1.59e-10	Number of pregnancies;Number of children;
LUAD	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.7	14.48	0.58	6.73e-39	White blood cell count;
LUAD	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg25828334	chr19:18545568	ISYNA1	-0.38	-7.75	-0.35	7.14e-14	Breast cancer;
LUAD	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.48	-8.46	-0.38	4.4e-16	Alzheimer's disease (late onset);
LUAD	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14240646	chr10:27532245	ACBD5	-0.88	-13.84	-0.56	3.3e-36	Breast cancer;
LUAD	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg21951975	chr1:209979733	IRF6	0.57	8.28	0.37	1.58e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.74	10.31	0.45	2.21e-22	Smoking behavior;
LUAD	cis	rs11724804	0.532	rs62295557	chr4:855708	G/A	cg23939001	chr4:940644	TMEM175	0.6	9.54	0.42	1.16e-19	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs887829	0.531	rs4338954	chr2:234593931	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.67	-0.43	4e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs6500395	1.000	rs2080508	chr16:48690665	G/C	cg04672837	chr16:48644449	N4BP1	-0.39	-6.64	-0.31	9.37e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs3823572	0.542	rs11773892	chr7:133626334	G/T	cg03336402	chr7:133662267	EXOC4	0.46	8.09	0.37	6.27e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.73	0.31	5.55e-11	Depression;
LUAD	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg15017067	chr4:17643749	FAM184B	0.36	7.17	0.33	3.37e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs847851	1.000	rs847859	chr6:34937472	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-7.37	-0.34	8.86e-13	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22968622	chr17:43663579	NA	-0.86	-14.81	-0.58	2.75e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg08859206	chr1:53392774	SCP2	-0.65	-11.68	-0.49	1.67e-27	Monocyte count;
LUAD	cis	rs7119	0.666	rs2516302	chr15:77879842	C/G	cg27398640	chr15:77910606	LINGO1	0.42	8.16	0.37	3.96e-15	Type 2 diabetes;
LUAD	trans	rs9784649	0.771	rs72755810	chr5:25039139	A/C	cg11038491	chr20:34638489	LOC647979	-0.8	-10.88	-0.47	1.8e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs35883536	0.588	rs17403878	chr1:101105310	C/T	cg06223162	chr1:101003688	GPR88	0.38	6.84	0.32	2.73e-11	Monocyte count;
LUAD	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg16479474	chr6:28041457	NA	0.38	6.57	0.3	1.51e-10	Parkinson's disease;
LUAD	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg21138405	chr5:131827807	IRF1	0.6	13.88	0.56	2.35e-36	Asthma (sex interaction);
LUAD	cis	rs11098699	0.821	rs6830451	chr4:124230386	G/A	cg09941581	chr4:124220074	SPATA5	0.46	7.3	0.33	1.42e-12	Mosquito bite size;
LUAD	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg10755058	chr3:40428713	ENTPD3	0.43	8.31	0.37	1.28e-15	Renal cell carcinoma;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16402894	chr11:11864017	USP47	-0.39	-6.53	-0.3	1.92e-10	Cancer;
LUAD	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg00074818	chr8:8560427	CLDN23	0.67	10.39	0.45	1.08e-22	Obesity-related traits;
LUAD	cis	rs757647	0.723	rs3734168	chr5:137685690	C/A	cg10676309	chr5:137685565	NA	0.39	7.19	0.33	2.95e-12	Menarche (age at onset);
LUAD	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg16479474	chr6:28041457	NA	0.44	7.4	0.34	7.22e-13	Depression;
LUAD	cis	rs2637266	1.000	rs2637270	chr10:78336901	C/T	cg18941641	chr10:78392320	NA	0.33	6.8	0.31	3.48e-11	Pulmonary function;
LUAD	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00934597	chr7:893267	UNC84A	-0.57	-9.17	-0.41	2.03e-18	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs12545109	0.876	rs1992120	chr8:57337112	G/A	cg19413350	chr8:57351067	NA	-0.47	-6.73	-0.31	5.71e-11	Obesity-related traits;
LUAD	cis	rs1003719	0.715	rs2156078	chr21:38546473	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.43	-0.38	5.44e-16	Eye color traits;
LUAD	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg18446336	chr7:2847575	GNA12	-0.35	-7.34	-0.34	1.1e-12	Height;
LUAD	cis	rs4642101	0.793	rs3889513	chr3:12844070	G/A	cg24848339	chr3:12840334	CAND2	0.39	7.98	0.36	1.4e-14	QRS complex (12-leadsum);
LUAD	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg05182265	chr7:156933206	UBE3C	-0.79	-16.91	-0.64	2.32e-49	Body mass index;
LUAD	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg22508957	chr16:3507546	NAT15	0.79	10.6	0.46	1.87e-23	Tuberculosis;
LUAD	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.76	10.48	0.45	5.33e-23	Smoking behavior;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00777555	chr3:57583074	ARF4	-0.41	-6.65	-0.31	9.07e-11	Height;
LUAD	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg06623918	chr6:96969491	KIAA0776	0.89	17.71	0.65	6.38e-53	Headache;
LUAD	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg06558623	chr16:89946397	TCF25	-1.12	-10.74	-0.46	6.05e-24	Skin colour saturation;
LUAD	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg13319975	chr6:146136371	FBXO30	0.63	10.94	0.47	1.08e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7727544	0.582	rs3792894	chr5:131547271	C/T	cg14196790	chr5:131705035	SLC22A5	0.37	6.43	0.3	3.36e-10	Blood metabolite levels;
LUAD	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg14008862	chr17:28927542	LRRC37B2	0.7	6.8	0.31	3.51e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg06784218	chr1:46089804	CCDC17	-0.51	-11.34	-0.48	3.25e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg22618164	chr12:122356400	WDR66	0.72	13.08	0.54	4.57e-33	Mean corpuscular volume;
LUAD	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.39	-0.3	4.41e-10	Morning vs. evening chronotype;
LUAD	cis	rs61897795	0.628	rs174585	chr11:61611694	G/A	cg00603274	chr11:61596626	FADS2	-0.49	-7.37	-0.34	8.91e-13	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg14828511	chr1:107599125	PRMT6	-0.61	-10.8	-0.46	3.58e-24	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg17724175	chr1:150552817	MCL1	0.37	8.37	0.38	8.58e-16	Melanoma;
LUAD	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.39	-7.5	-0.34	3.73e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.2	0.54	1.48e-33	Prudent dietary pattern;
LUAD	cis	rs1448094	0.842	rs10779231	chr12:86462237	T/C	cg19622623	chr12:86230825	RASSF9	0.36	6.46	0.3	2.93e-10	Major depressive disorder;
LUAD	cis	rs76878669	0.561	rs1784029	chr11:66099987	C/T	cg18002602	chr11:66138449	SLC29A2	0.46	9.76	0.43	1.95e-20	Educational attainment (years of education);
LUAD	cis	rs2239547	0.522	rs9311485	chr3:52987645	T/G	cg18404041	chr3:52824283	ITIH1	0.51	8.74	0.39	5.54e-17	Schizophrenia;
LUAD	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg01191920	chr7:158217561	PTPRN2	-0.67	-14.35	-0.57	2.53e-38	Obesity-related traits;
LUAD	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.42	-8.07	-0.37	7.3e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.06	0.36	7.92e-15	Rheumatoid arthritis;
LUAD	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg01689657	chr7:91764605	CYP51A1	0.39	9.69	0.43	3.54e-20	Breast cancer;
LUAD	cis	rs7677751	0.806	rs4864860	chr4:55090021	T/C	cg17187183	chr4:55093834	PDGFRA	0.51	8.63	0.39	1.23e-16	Corneal astigmatism;
LUAD	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg04455712	chr21:45112962	RRP1B	0.4	7.79	0.35	5.34e-14	Mean corpuscular volume;
LUAD	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg24733560	chr20:60626293	TAF4	0.47	8.25	0.37	2.03e-15	Body mass index;
LUAD	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg11887960	chr12:57824829	NA	0.56	7.16	0.33	3.64e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg05590025	chr7:65112418	INTS4L2	0.74	7.9	0.36	2.39e-14	Diabetic kidney disease;
LUAD	trans	rs2797160	0.522	rs6925158	chr6:125940188	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.47	-7.49	-0.34	4.12e-13	Endometrial cancer;
LUAD	cis	rs4660214	0.666	rs7538300	chr1:39652764	C/A	cg27567593	chr1:39956653	BMP8A	0.35	6.75	0.31	4.95e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg25767906	chr1:53392781	SCP2	-0.41	-7.48	-0.34	4.19e-13	Monocyte count;
LUAD	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg05368731	chr17:41323189	NBR1	0.95	19.31	0.68	5.01e-60	Menopause (age at onset);
LUAD	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21659725	chr3:3221576	CRBN	-0.48	-7.84	-0.36	3.62e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg21248554	chr2:27665150	KRTCAP3	-0.33	-9.1	-0.4	3.46e-18	Total body bone mineral density;
LUAD	cis	rs6499255	0.951	rs10852457	chr16:69607853	C/T	cg15192750	chr16:69999425	NA	0.49	7.68	0.35	1.14e-13	IgE levels;
LUAD	cis	rs698833	0.506	rs713448	chr2:44504877	T/C	cg00619915	chr2:44497795	NA	-0.44	-6.44	-0.3	3.27e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs2795502	0.564	rs11239826	chr10:43403097	T/C	cg27426351	chr10:43362370	NA	0.53	6.44	0.3	3.32e-10	Blood protein levels;
LUAD	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg02423579	chr7:2872169	GNA12	-0.87	-15.23	-0.6	4.59e-42	Height;
LUAD	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg13385794	chr1:248469461	NA	-0.25	-7.08	-0.33	6.01e-12	Common traits (Other);
LUAD	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg00071950	chr4:10020882	SLC2A9	-0.72	-14.64	-0.58	1.47e-39	Bone mineral density;
LUAD	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.58	-8.55	-0.38	2.32e-16	Gut microbiome composition (summer);
LUAD	cis	rs438465	0.945	rs9371133	chr6:169846264	T/C	cg11181693	chr6:169825345	NA	0.61	7.71	0.35	9.14e-14	Corneal astigmatism;
LUAD	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg26384229	chr12:38710491	ALG10B	0.48	7.81	0.36	4.52e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg16205897	chr5:131564050	P4HA2	-0.33	-7.44	-0.34	5.83e-13	Blood metabolite levels;
LUAD	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.48	0.3	2.56e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg07741184	chr6:167504864	NA	0.4	9.25	0.41	1.15e-18	Crohn's disease;
LUAD	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg18230493	chr5:56204884	C5orf35	0.7	11.22	0.48	9.18e-26	Initial pursuit acceleration;
LUAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg04775059	chr7:64541387	NA	-0.5	-8.18	-0.37	3.42e-15	Calcium levels;
LUAD	cis	rs41271473	0.526	rs10916343	chr1:228727961	C/T	cg10167378	chr1:228756711	NA	0.68	9.14	0.41	2.59e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg21475434	chr5:93447410	FAM172A	0.77	8.72	0.39	6.64e-17	Diabetic retinopathy;
LUAD	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg15181151	chr6:150070149	PCMT1	0.41	8.75	0.39	5.18e-17	Lung cancer;
LUAD	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg21214613	chr1:16344536	HSPB7	0.6	11.59	0.49	3.61e-27	Dilated cardiomyopathy;
LUAD	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg11859384	chr17:80120422	CCDC57	0.5	8.95	0.4	1.12e-17	Life satisfaction;
LUAD	cis	rs847851	0.833	rs3817473	chr6:34949451	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.33	7.19	0.33	2.99e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.655	rs59605679	chr1:15863796	T/G	cg13390004	chr1:15929781	NA	0.41	6.58	0.3	1.43e-10	Systolic blood pressure;
LUAD	cis	rs9658691	0.607	rs9658766	chr10:90771612	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-7.32	-0.34	1.29e-12	Mosquito bite size;
LUAD	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg24531977	chr5:56204891	C5orf35	-0.41	-6.74	-0.31	5.13e-11	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg24399712	chr22:39784796	NA	0.74	14.38	0.57	1.84e-38	IgG glycosylation;
LUAD	cis	rs3849570	0.615	rs35779564	chr3:81982771	G/A	cg07356753	chr3:81810745	GBE1	-0.55	-8.99	-0.4	8.24e-18	Waist circumference;Body mass index;
LUAD	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27297192	chr10:134578999	INPP5A	0.37	6.41	0.3	3.78e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2882667	0.964	rs11739351	chr5:138311742	A/G	cg04439458	chr5:138467593	SIL1	-0.41	-7.72	-0.35	8.35e-14	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg09537434	chr19:41945824	ATP5SL	-0.49	-7.87	-0.36	3.05e-14	Height;
LUAD	cis	rs11126435	0.858	rs363620	chr2:74928350	G/T	cg19285774	chr2:74907978	SEMA4F	0.36	6.47	0.3	2.67e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7107174	0.892	rs11237463	chr11:78060464	A/G	cg02023728	chr11:77925099	USP35	0.45	7.07	0.33	6.32e-12	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg20607798	chr8:58055168	NA	0.78	9.96	0.44	4.05e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs9326248	0.581	rs7120963	chr11:116830261	C/T	cg20608306	chr11:116969690	SIK3	-0.3	-6.8	-0.31	3.57e-11	Blood protein levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg24322333	chr6:151646584	AKAP12	-0.67	-6.46	-0.3	2.85e-10	Type 2 diabetes;
LUAD	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.04	0.32	7.98e-12	Colorectal cancer;
LUAD	trans	rs877282	0.947	rs7475589	chr10:767479	C/G	cg22713356	chr15:30763199	NA	1.31	18.0	0.66	3.48e-54	Uric acid levels;
LUAD	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg00074818	chr8:8560427	CLDN23	0.67	10.2	0.44	5.63e-22	Obesity-related traits;
LUAD	cis	rs4889855	0.530	rs9914854	chr17:78598662	A/G	cg16591659	chr17:78472290	NA	-0.43	-7.48	-0.34	4.38e-13	Fractional excretion of uric acid;
LUAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.51	-9.15	-0.41	2.37e-18	Lymphocyte counts;
LUAD	cis	rs2686555	0.649	rs2686556	chr12:121095331	C/T	cg18477009	chr12:121087777	CABP1	0.42	7.75	0.35	6.69e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.9	0.36	2.47e-14	Morning vs. evening chronotype;
LUAD	cis	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg08601574	chr20:25228251	PYGB	-0.46	-8.66	-0.39	1.04e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg04450456	chr4:17643702	FAM184B	0.38	7.43	0.34	6.18e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4660214	0.666	rs10888788	chr1:39937696	G/A	cg27567593	chr1:39956653	BMP8A	0.34	6.85	0.32	2.64e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg21385522	chr1:16154831	NA	-0.57	-9.04	-0.4	5.9e-18	Systolic blood pressure;
LUAD	cis	rs910187	0.678	rs6066229	chr20:45815341	A/G	cg27589058	chr20:45804311	EYA2	0.3	6.79	0.31	3.92e-11	Migraine;
LUAD	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg00204512	chr16:28754710	NA	0.32	6.92	0.32	1.72e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg07570687	chr10:102243282	WNT8B	0.45	6.96	0.32	1.28e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.46	-7.12	-0.33	4.59e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg03396347	chr1:1875803	NA	0.59	15.41	0.6	7.84e-43	Body mass index;
LUAD	cis	rs7166081	0.672	rs3865018	chr15:67892766	A/G	cg27219399	chr15:67835830	MAP2K5	-0.43	-7.64	-0.35	1.5e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs62229266	0.804	rs12483151	chr21:37419578	C/T	cg12218747	chr21:37451666	NA	-0.48	-8.26	-0.37	1.92e-15	Mitral valve prolapse;
LUAD	trans	rs11039798	0.920	rs12279378	chr11:48571030	A/C	cg03929089	chr4:120376271	NA	0.55	6.36	0.3	5.18e-10	Axial length;
LUAD	cis	rs12765878	1.000	rs2067832	chr10:105643134	G/A	cg11005552	chr10:105648138	OBFC1	0.44	8.26	0.37	1.91e-15	Coronary artery disease;
LUAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg10729496	chr3:10149963	C3orf24	0.58	9.63	0.42	5.67e-20	Alzheimer's disease;
LUAD	cis	rs736801	0.964	rs17622656	chr5:131820997	A/G	cg14196790	chr5:131705035	SLC22A5	-0.41	-6.95	-0.32	1.42e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg13271783	chr10:134563150	INPP5A	-0.41	-6.55	-0.3	1.63e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg25427524	chr10:38739819	LOC399744	-0.46	-7.68	-0.35	1.14e-13	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs17152411	0.895	rs61872118	chr10:126583450	C/T	cg07906193	chr10:126599966	NA	0.54	7.64	0.35	1.52e-13	Height;
LUAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg08219700	chr8:58056026	NA	0.52	7.89	0.36	2.59e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs12291225	0.535	rs11023203	chr11:14409815	G/A	cg19336497	chr11:14380999	RRAS2	-0.61	-13.3	-0.54	5.58e-34	Sense of smell;
LUAD	trans	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17712092	chr4:129076599	LARP1B	0.92	17.29	0.64	4.59e-51	Eosinophil percentage of white cells;
LUAD	cis	rs2908197	0.843	rs1076437	chr7:75939721	A/G	cg24580635	chr7:76178542	LOC100133091	-0.42	-6.54	-0.3	1.74e-10	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs6906287	0.647	rs12215793	chr6:118956857	A/T	cg18833306	chr6:118973337	C6orf204	0.48	8.35	0.38	9.92e-16	Electrocardiographic conduction measures;
LUAD	cis	rs1595825	1.000	rs2165237	chr2:198875003	C/T	cg10547527	chr2:198650123	BOLL	-0.47	-6.59	-0.31	1.34e-10	Ulcerative colitis;
LUAD	cis	rs89107	0.688	rs422833	chr6:118608971	T/C	cg18833306	chr6:118973337	C6orf204	0.51	9.2	0.41	1.68e-18	Cardiac structure and function;
LUAD	trans	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.53	0.42	1.26e-19	Mean corpuscular volume;
LUAD	cis	rs986417	0.901	rs12436953	chr14:61001546	C/T	cg27398547	chr14:60952738	C14orf39	0.64	8.01	0.36	1.1e-14	Gut microbiota (bacterial taxa);
LUAD	trans	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.29	0.45	2.56e-22	Mean corpuscular volume;
LUAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.14	-0.37	4.61e-15	Alzheimer's disease;
LUAD	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg07917127	chr4:99064746	C4orf37	0.49	7.05	0.32	7.17e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2882667	0.931	rs10074461	chr5:138319815	G/T	cg04439458	chr5:138467593	SIL1	-0.4	-7.62	-0.35	1.73e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg19622623	chr12:86230825	RASSF9	-0.55	-9.81	-0.43	1.29e-20	Major depressive disorder;
LUAD	cis	rs6687430	0.562	rs12139169	chr1:10635328	C/T	cg17425144	chr1:10567563	PEX14	0.53	10.14	0.44	9.16e-22	Hand grip strength;
LUAD	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06022373	chr22:39101656	GTPBP1	0.46	7.07	0.33	6.52e-12	Menopause (age at onset);
LUAD	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg00495681	chr13:53174319	NA	0.48	8.61	0.39	1.49e-16	Lewy body disease;
LUAD	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg16988262	chr1:15930761	NA	0.42	6.96	0.32	1.29e-11	Systolic blood pressure;
LUAD	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg00802000	chr16:706648	WDR90	-0.38	-7.14	-0.33	4.15e-12	Height;
LUAD	cis	rs8177876	0.731	rs77145371	chr16:81118660	A/G	cg08591886	chr16:81111003	C16orf46	-0.8	-7.39	-0.34	7.72e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15664640	chr17:80829946	TBCD	-0.84	-17.1	-0.64	3.32e-50	Breast cancer;
LUAD	trans	rs4650994	1.000	rs4511075	chr1:178518636	G/A	cg05059571	chr16:84539110	KIAA1609	-0.62	-10.63	-0.46	1.49e-23	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg04218760	chr10:45406644	TMEM72	-0.32	-8.0	-0.36	1.17e-14	Mean corpuscular volume;
LUAD	cis	rs10751667	0.580	rs7396041	chr11:1001607	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-6.75	-0.31	4.96e-11	Alzheimer's disease (late onset);
LUAD	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23158103	chr7:148848205	ZNF398	-0.61	-11.13	-0.48	2.06e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg20607798	chr8:58055168	NA	0.65	8.45	0.38	4.6e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg19761014	chr17:28927070	LRRC37B2	0.94	8.9	0.4	1.71e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9329289	0.510	rs11251283	chr10:2555784	C/G	cg15501526	chr10:2543763	NA	0.54	11.37	0.48	2.61e-26	Age-related hearing impairment;
LUAD	cis	rs7258465	0.965	rs10409003	chr19:18543054	C/T	cg01065977	chr19:18549689	ISYNA1	-0.37	-7.04	-0.32	7.99e-12	Breast cancer;
LUAD	cis	rs4988958	0.565	rs12712146	chr2:103008714	C/T	cg03938978	chr2:103052716	IL18RAP	0.45	10.24	0.45	3.99e-22	Asthma (childhood onset);
LUAD	trans	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.75	12.47	0.52	1.32e-30	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs6138458	1.000	rs227629	chr20:24913551	G/T	cg06937882	chr20:24974362	C20orf3	-0.32	-6.35	-0.3	5.42e-10	Blood protein levels;
LUAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg05896524	chr21:47604654	C21orf56	-0.69	-12.05	-0.51	6.21e-29	Testicular germ cell tumor;
LUAD	cis	rs4919694	1.000	rs112240253	chr10:104753726	C/T	cg04362960	chr10:104952993	NT5C2	0.79	8.21	0.37	2.63e-15	Arsenic metabolism;
LUAD	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg07936489	chr17:37558343	FBXL20	0.51	7.52	0.34	3.27e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs68170813	0.605	rs74632724	chr7:107136759	A/G	cg23024343	chr7:107201750	COG5	0.49	6.83	0.32	3.01e-11	Coronary artery disease;
LUAD	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg23758822	chr17:41437982	NA	0.88	13.61	0.55	3.07e-35	Menopause (age at onset);
LUAD	cis	rs9948	0.786	rs62156230	chr2:97424915	A/G	cg20312557	chr2:97357134	FER1L5	-0.57	-7.12	-0.33	4.76e-12	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	9.78	0.43	1.67e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg20628663	chr10:43360327	NA	0.69	10.93	0.47	1.18e-24	Blood protein levels;
LUAD	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg21285383	chr16:89894308	SPIRE2	0.43	10.33	0.45	1.86e-22	Vitiligo;
LUAD	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07266350	chr3:49460521	AMT;NICN1	-0.35	-6.41	-0.3	3.93e-10	Menarche (age at onset);
LUAD	cis	rs7100689	0.646	rs7077712	chr10:82134894	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	10.26	0.45	3.26e-22	Post bronchodilator FEV1;
LUAD	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-6.69	-0.31	7.24e-11	IgG glycosylation;
LUAD	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.38	6.38	0.3	4.65e-10	Colorectal cancer;
LUAD	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg22676075	chr6:135203613	NA	0.39	7.05	0.32	7.26e-12	Red blood cell count;
LUAD	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg22875332	chr1:76189707	ACADM	0.87	16.7	0.63	1.92e-48	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg13722127	chr7:150037890	RARRES2	0.44	7.57	0.35	2.4e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg07402062	chr16:89894098	SPIRE2	-0.45	-11.25	-0.48	7.13e-26	Vitiligo;
LUAD	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg03929089	chr4:120376271	NA	-0.45	-6.91	-0.32	1.78e-11	HDL cholesterol;
LUAD	cis	rs1018836	0.884	rs2073640	chr8:91594853	A/G	cg16814680	chr8:91681699	NA	-0.66	-11.21	-0.48	1.04e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7593730	0.537	rs10803762	chr2:161105876	G/A	cg22609984	chr2:161126801	NA	0.49	8.99	0.4	8.15e-18	Type 2 diabetes;
LUAD	cis	rs1215050	0.782	rs6532693	chr4:98655815	T/C	cg24818145	chr4:99064322	C4orf37	-0.41	-6.77	-0.31	4.2e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-7.25	-0.33	2.05e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs11677416	0.885	rs4849119	chr2:113523463	G/C	cg27083787	chr2:113543245	IL1A	0.41	6.91	0.32	1.79e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg13906792	chr15:75199810	C15orf17	-0.35	-6.59	-0.3	1.35e-10	Breast cancer;
LUAD	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg04450456	chr4:17643702	FAM184B	0.43	8.5	0.38	3.4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg22467129	chr15:76604101	ETFA	-0.47	-7.9	-0.36	2.44e-14	Blood metabolite levels;
LUAD	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg08645402	chr16:4508243	NA	0.54	9.55	0.42	1.06e-19	Schizophrenia;
LUAD	cis	rs62238980	0.614	rs79173736	chr22:32379966	T/C	cg00543991	chr22:32367038	NA	0.94	8.78	0.39	4.09e-17	Childhood ear infection;
LUAD	cis	rs2262909	0.962	rs56369285	chr19:22267185	T/C	cg11619707	chr19:22235551	ZNF257	0.49	7.5	0.34	3.67e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2073300	1.000	rs115730610	chr20:23442621	G/A	cg12062639	chr20:23401060	NAPB	1.0	9.21	0.41	1.47e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg08885076	chr2:99613938	TSGA10	-0.4	-7.02	-0.32	9.01e-12	Chronic sinus infection;
LUAD	trans	rs11650494	0.803	rs117801358	chr17:47447950	C/A	cg11430096	chr6:110968061	CDK19	0.89	6.74	0.31	5.21e-11	Prostate cancer;
LUAD	cis	rs2835872	0.758	rs1787395	chr21:39036478	A/C	cg06728970	chr21:39037746	KCNJ6	0.4	7.69	0.35	1.05e-13	Electroencephalographic traits in alcoholism;
LUAD	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg08085267	chr17:45401833	C17orf57	-0.51	-8.61	-0.39	1.44e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.64	-0.58	1.54e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs10744422	1.000	rs7972447	chr12:123354545	C/G	cg16953816	chr12:123349952	VPS37B	0.59	6.77	0.31	4.4e-11	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05901451	chr6:126070800	HEY2	-0.82	-15.61	-0.6	1.08e-43	Brugada syndrome;
LUAD	cis	rs12618769	0.597	rs56197140	chr2:99113740	T/C	cg10123293	chr2:99228465	UNC50	0.47	8.47	0.38	4.18e-16	Bipolar disorder;
LUAD	cis	rs1448094	0.967	rs10779222	chr12:86330775	G/A	cg18827107	chr12:86230957	RASSF9	-0.44	-7.93	-0.36	1.94e-14	Major depressive disorder;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg24720442	chr19:56154855	ZNF581	-0.4	-6.74	-0.31	5.25e-11	Subcortical brain region volumes;
LUAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg23301539	chr8:142222248	SLC45A4	-0.46	-8.44	-0.38	5.16e-16	Immature fraction of reticulocytes;
LUAD	cis	rs1997103	0.911	rs6949931	chr7:55391081	T/C	cg17469321	chr7:55412551	NA	0.68	11.53	0.49	6.39e-27	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-14.76	-0.58	4.51e-40	Schizophrenia;
LUAD	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg22532475	chr10:104410764	TRIM8	-0.5	-9.46	-0.42	2.13e-19	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1032833	0.732	rs77593278	chr2:180029855	A/G	cg23883738	chr2:179974586	SESTD1	-0.65	-7.31	-0.34	1.32e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	trans	rs28735056	0.572	rs4799100	chr18:77640207	A/G	cg05926928	chr17:57297772	GDPD1	-0.69	-10.61	-0.46	1.72e-23	Schizophrenia;
LUAD	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg03526776	chr6:41159608	TREML2	0.32	7.01	0.32	9.2e-12	Alzheimer's disease (late onset);
LUAD	cis	rs9581857	0.547	rs77005033	chr13:28109793	A/G	cg22138327	chr13:27999177	GTF3A	0.81	8.47	0.38	4.13e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	trans	rs10411161	0.702	rs11878580	chr19:52388485	C/T	cg22319618	chr22:45562946	NUP50	-0.65	-9.45	-0.42	2.39e-19	Breast cancer;
LUAD	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg17757837	chr7:157058334	UBE3C	-0.48	-8.55	-0.38	2.28e-16	Body mass index;
LUAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg26516362	chr5:178986906	RUFY1	0.52	8.99	0.4	8.4e-18	Lung cancer;
LUAD	cis	rs208520	0.742	rs208454	chr6:66907783	T/C	cg07460842	chr6:66804631	NA	-1.0	-13.92	-0.56	1.58e-36	Exhaled nitric oxide output;
LUAD	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg05368731	chr17:41323189	NBR1	0.95	19.41	0.69	1.68e-60	Menopause (age at onset);
LUAD	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg06092702	chr1:163392909	NA	-0.41	-9.27	-0.41	9.41e-19	Motion sickness;
LUAD	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg15790184	chr11:494944	RNH1	0.4	6.64	0.31	9.47e-11	Systemic lupus erythematosus;
LUAD	cis	rs13082711	0.522	rs543882	chr3:27331854	T/C	cg02860705	chr3:27208620	NA	0.52	8.55	0.38	2.27e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7301826	0.651	rs1973834	chr12:131280157	C/T	cg11011512	chr12:131303247	STX2	0.43	7.14	0.33	4.04e-12	Plasma plasminogen activator levels;
LUAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg09060608	chr5:178986726	RUFY1	0.56	9.61	0.42	6.41e-20	Lung cancer;
LUAD	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg14092988	chr3:52407081	DNAH1	0.32	6.46	0.3	2.88e-10	Bipolar disorder;
LUAD	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg01475377	chr6:109611718	NA	-0.54	-10.46	-0.45	6.18e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg12863693	chr15:85201151	NMB	0.4	7.54	0.34	2.82e-13	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg22117172	chr7:91764530	CYP51A1	0.34	7.55	0.34	2.69e-13	Breast cancer;
LUAD	cis	rs911186	0.509	rs6934329	chr6:27158033	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-6.38	-0.3	4.61e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11811982	0.793	rs78634790	chr1:227610481	C/G	cg24860534	chr1:227506868	CDC42BPA	0.64	6.77	0.31	4.39e-11	Optic disc area;
LUAD	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.54	8.81	0.39	3.19e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg12432903	chr7:1882776	MAD1L1	-0.43	-6.78	-0.31	3.96e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs863345	0.604	rs1578761	chr1:158497572	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.39	-0.3	4.26e-10	Pneumococcal bacteremia;
LUAD	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg14196790	chr5:131705035	SLC22A5	0.38	6.89	0.32	2.04e-11	Blood metabolite levels;
LUAD	cis	rs11948739	0.501	rs2419755	chr5:130252835	A/G	cg08523029	chr5:130500466	HINT1	0.59	7.61	0.35	1.84e-13	Pediatric bone mineral content (hip);
LUAD	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg01416388	chr22:39784598	NA	-0.5	-8.34	-0.38	1.04e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg25358565	chr5:93447407	FAM172A	0.63	7.81	0.35	4.61e-14	Diabetic retinopathy;
LUAD	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg14416269	chr4:6271139	WFS1	0.61	12.65	0.52	2.42e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1113500	0.933	rs61797344	chr1:108622580	C/T	cg06207961	chr1:108661230	NA	0.45	8.48	0.38	3.73e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08280861	chr8:58055591	NA	0.55	7.04	0.32	8.03e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.27	0.37	1.73e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12801636	0.512	rs2075660	chr11:65414709	C/A	cg24147428	chr11:65409760	SIPA1	-0.54	-7.9	-0.36	2.39e-14	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs2235649	0.753	rs7200472	chr16:1849669	T/C	cg08610935	chr16:1836813	NUBP2	-0.5	-7.7	-0.35	9.53e-14	Blood metabolite levels;
LUAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg21724239	chr8:58056113	NA	0.74	9.62	0.42	5.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg12311346	chr5:56204834	C5orf35	-0.44	-7.21	-0.33	2.57e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs9972944	0.729	rs7211481	chr17:63766434	A/C	cg07283582	chr17:63770753	CCDC46	-0.5	-11.3	-0.48	4.85e-26	Total body bone mineral density;
LUAD	cis	rs938554	1.000	rs938554	chr4:9925692	C/G	cg11266682	chr4:10021025	SLC2A9	0.43	7.52	0.34	3.25e-13	Blood metabolite levels;
LUAD	cis	rs12122100	0.913	rs35811591	chr1:146515238	C/T	cg03526459	chr1:146549940	NA	-0.37	-6.88	-0.32	2.17e-11	HIV-1 control;
LUAD	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg21775007	chr8:11205619	TDH	0.52	9.27	0.41	9.46e-19	Retinal vascular caliber;
LUAD	cis	rs4774899	0.867	rs978274	chr15:57528500	C/T	cg14026238	chr15:57616123	NA	0.35	6.65	0.31	9.31e-11	Urinary tract infection frequency;
LUAD	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg18230493	chr5:56204884	C5orf35	-0.84	-12.5	-0.52	9.69e-31	Initial pursuit acceleration;
LUAD	cis	rs68170813	0.559	rs78404515	chr7:106909126	G/A	cg23024343	chr7:107201750	COG5	0.5	7.25	0.33	1.98e-12	Coronary artery disease;
LUAD	cis	rs7561273	0.609	rs2339945	chr2:24348096	G/A	cg20701182	chr2:24300061	SF3B14	0.47	7.63	0.35	1.6e-13	Quantitative traits;
LUAD	cis	rs6906287	0.647	rs2213856	chr6:118806793	C/T	cg05564266	chr6:118973597	C6orf204	0.34	7.28	0.33	1.63e-12	Electrocardiographic conduction measures;
LUAD	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg18404041	chr3:52824283	ITIH1	-0.41	-7.27	-0.33	1.8e-12	Body mass index;
LUAD	cis	rs250677	1.000	rs36069	chr5:148417253	G/C	cg12140854	chr5:148520817	ABLIM3	-0.62	-10.31	-0.45	2.15e-22	Breast cancer;
LUAD	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg27490568	chr2:178487706	NA	0.4	6.66	0.31	8.3e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg01620082	chr3:125678407	NA	-0.65	-8.09	-0.37	6.52e-15	Depression;
LUAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg04025307	chr7:1156635	C7orf50	0.6	6.81	0.31	3.43e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg00280220	chr17:61926910	NA	0.37	7.18	0.33	3.23e-12	Prudent dietary pattern;
LUAD	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg07527032	chr15:84868466	LOC388152	0.45	6.69	0.31	7.26e-11	Schizophrenia;
LUAD	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg18827107	chr12:86230957	RASSF9	0.54	9.63	0.42	5.64e-20	Major depressive disorder;
LUAD	cis	rs7737355	0.947	rs32113	chr5:131049585	G/T	cg25547332	chr5:131281432	NA	-0.47	-7.17	-0.33	3.28e-12	Life satisfaction;
LUAD	cis	rs7000551	0.725	rs2461483	chr8:22386479	C/T	cg12081754	chr8:22256438	SLC39A14	0.42	7.0	0.32	9.85e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg14668632	chr7:2872130	GNA12	-0.72	-13.01	-0.53	8.41e-33	Height;
LUAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg11062466	chr8:58055876	NA	0.67	8.87	0.4	2.01e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9888739	0.800	rs7200615	chr16:31337155	G/A	cg15817542	chr16:31343056	ITGAM	-0.46	-7.54	-0.34	2.87e-13	Systemic lupus erythematosus;
LUAD	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg27068330	chr11:65405492	SIPA1	0.56	8.88	0.4	1.87e-17	Acne (severe);
LUAD	cis	rs859767	0.741	rs1104802	chr2:135436366	A/C	cg12500956	chr2:135428796	TMEM163	-0.31	-8.02	-0.36	1.06e-14	Neuroticism;
LUAD	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg12927641	chr6:109611667	NA	-0.54	-9.49	-0.42	1.77e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg20203395	chr5:56204925	C5orf35	-0.47	-7.34	-0.34	1.07e-12	Coronary artery disease;
LUAD	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg03929089	chr4:120376271	NA	-0.92	-17.83	-0.66	2.01e-53	Height;
LUAD	cis	rs758324	0.898	rs510434	chr5:131292503	C/T	cg06307176	chr5:131281290	NA	-0.5	-7.85	-0.36	3.43e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.57	-8.37	-0.38	8.22e-16	Platelet count;
LUAD	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg26924012	chr15:45694286	SPATA5L1	0.84	14.33	0.57	3.05e-38	Homoarginine levels;
LUAD	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg26384229	chr12:38710491	ALG10B	0.5	7.98	0.36	1.43e-14	Bladder cancer;
LUAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg11494091	chr17:61959527	GH2	0.74	18.23	0.66	3.11e-55	Prudent dietary pattern;
LUAD	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg25036284	chr2:26402008	FAM59B	-0.56	-7.93	-0.36	1.96e-14	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg24818145	chr4:99064322	C4orf37	0.47	7.66	0.35	1.28e-13	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05848120	chr18:44676992	HDHD2	-0.41	-6.66	-0.31	8.65e-11	Cancer;
LUAD	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.39	0.34	7.7e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2688608	0.725	rs2688623	chr10:75689615	C/T	cg19442545	chr10:75533431	FUT11	-0.37	-6.36	-0.3	5.23e-10	Inflammatory bowel disease;
LUAD	cis	rs6543140	0.964	rs6543144	chr2:103092575	A/G	cg03938978	chr2:103052716	IL18RAP	0.35	6.89	0.32	2.01e-11	Blood protein levels;
LUAD	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg01657329	chr11:68192670	LRP5	0.47	8.53	0.38	2.56e-16	Total body bone mineral density;
LUAD	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs7814319	0.966	rs10095443	chr8:97269738	C/T	cg20787634	chr8:97240163	UQCRB	-0.39	-7.56	-0.34	2.55e-13	Lung function (FVC);
LUAD	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.33	-7.61	-0.35	1.78e-13	Lung cancer;
LUAD	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24531977	chr5:56204891	C5orf35	-0.98	-14.71	-0.58	7.48e-40	Initial pursuit acceleration;
LUAD	trans	rs10411161	0.702	rs17835311	chr19:52386781	A/C	cg22319618	chr22:45562946	NUP50	-0.64	-8.96	-0.4	1.08e-17	Breast cancer;
LUAD	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg23758822	chr17:41437982	NA	0.99	21.62	0.72	2.28e-70	Menopause (age at onset);
LUAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg10862848	chr6:42927986	GNMT	-0.32	-9.3	-0.41	7.37e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs12711979	0.740	rs6715434	chr2:3820862	T/G	cg17052675	chr2:3827356	NA	-0.51	-10.53	-0.46	3.55e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg22532475	chr10:104410764	TRIM8	-0.44	-8.6	-0.39	1.53e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg00106254	chr7:1943704	MAD1L1	-0.45	-6.92	-0.32	1.71e-11	Schizophrenia;
LUAD	cis	rs1003719	0.680	rs2835619	chr21:38505380	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-9.06	-0.4	4.94e-18	Eye color traits;
LUAD	cis	rs4523957	0.786	rs216213	chr17:2134225	G/A	cg16513277	chr17:2031491	SMG6	0.79	14.52	0.58	4.81e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs12618769	0.597	rs3754879	chr2:99164541	G/T	cg10123293	chr2:99228465	UNC50	0.5	8.68	0.39	8.87e-17	Bipolar disorder;
LUAD	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg23018236	chr17:30244563	NA	-0.66	-8.04	-0.36	9.02e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs7584330	0.541	rs10202181	chr2:238352099	A/G	cg16989719	chr2:238392110	NA	-0.34	-6.74	-0.31	5.14e-11	Prostate cancer;
LUAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg25811766	chr13:21894605	NA	0.56	8.46	0.38	4.54e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg04450456	chr4:17643702	FAM184B	0.36	6.97	0.32	1.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.56	0.3	1.55e-10	Menarche (age at onset);
LUAD	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg04546413	chr19:29218101	NA	0.67	10.41	0.45	9.91e-23	Methadone dose in opioid dependence;
LUAD	cis	rs1018836	0.608	rs10111060	chr8:91491152	T/C	cg16814680	chr8:91681699	NA	-0.52	-8.53	-0.38	2.65e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg25036284	chr2:26402008	FAM59B	-0.83	-11.81	-0.5	5.26e-28	Gut microbiome composition (summer);
LUAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.53	-9.94	-0.44	4.65e-21	Longevity;Endometriosis;
LUAD	cis	rs11681884	1.000	rs11688270	chr2:113845191	G/A	cg12858261	chr2:113808755	IL1F8	0.51	6.43	0.3	3.48e-10	Stroke;
LUAD	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08280861	chr8:58055591	NA	0.72	8.44	0.38	4.98e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs3784262	0.669	rs12915989	chr15:58315736	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.47	-0.34	4.5e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg17031739	chr1:67600172	NA	0.52	9.37	0.41	4.48e-19	Psoriasis;
LUAD	trans	rs7395662	0.895	rs8186350	chr11:48739261	G/C	cg00717180	chr2:96193071	NA	-0.39	-7.18	-0.33	3.14e-12	HDL cholesterol;
LUAD	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg00933542	chr6:150070202	PCMT1	0.44	9.44	0.42	2.47e-19	Lung cancer;
LUAD	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.44	0.3	3.17e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg21862992	chr11:68658383	NA	0.52	9.42	0.42	3.02e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7771547	0.573	rs522179	chr6:36391605	G/A	cg04289385	chr6:36355825	ETV7	0.42	6.53	0.3	1.85e-10	Platelet distribution width;
LUAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg21724239	chr8:58056113	NA	0.78	9.32	0.41	6.41e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg06784218	chr1:46089804	CCDC17	0.51	11.23	0.48	8.7e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26118713	chr7:148580496	EZH2	-0.42	-6.75	-0.31	4.96e-11	Height;
LUAD	cis	rs7189233	1.000	rs7194519	chr16:53535276	C/G	cg04059762	chr16:53544020	NA	-0.42	-6.79	-0.31	3.76e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg11416102	chr8:651193	ERICH1	0.94	8.61	0.39	1.51e-16	IgG glycosylation;
LUAD	cis	rs67072384	0.901	rs58076660	chr11:72441495	G/A	cg04827223	chr11:72435913	ARAP1	-0.67	-8.18	-0.37	3.35e-15	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg15017067	chr4:17643749	FAM184B	0.37	7.23	0.33	2.28e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg02269571	chr22:50332266	NA	0.59	8.91	0.4	1.49e-17	Schizophrenia;
LUAD	cis	rs2249625	0.844	rs2496502	chr6:72885412	G/A	cg18830697	chr6:72922368	RIMS1	-0.35	-6.66	-0.31	8.28e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg18252515	chr7:66147081	NA	-0.62	-6.68	-0.31	7.75e-11	Diabetic kidney disease;
LUAD	trans	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg18187862	chr3:45730750	SACM1L	0.5	7.89	0.36	2.55e-14	Primary sclerosing cholangitis;
LUAD	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg10426581	chr7:100472382	SRRT	0.76	10.02	0.44	2.48e-21	Resting heart rate;
LUAD	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg23649088	chr2:200775458	C2orf69	-0.62	-7.77	-0.35	6.15e-14	Schizophrenia;
LUAD	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg09998033	chr7:158218633	PTPRN2	-0.55	-10.11	-0.44	1.18e-21	Obesity-related traits;
LUAD	cis	rs9039	1.000	rs67302637	chr16:9221100	C/T	cg08831531	chr16:9218945	NA	-0.42	-7.12	-0.33	4.59e-12	Menopause (age at onset);
LUAD	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg12714757	chr17:73874637	TRIM47	-0.43	-6.69	-0.31	7.14e-11	Psoriasis;
LUAD	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg16797656	chr11:68205561	LRP5	0.45	8.7	0.39	7.53e-17	Total body bone mineral density;
LUAD	trans	rs877282	0.891	rs11599917	chr10:762288	G/A	cg22713356	chr15:30763199	NA	1.26	17.39	0.65	1.65e-51	Uric acid levels;
LUAD	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg16989719	chr2:238392110	NA	-0.38	-8.07	-0.37	7.25e-15	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg03983476	chr2:10830698	NOL10	0.39	6.88	0.32	2.23e-11	Prostate cancer;
LUAD	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg02683114	chr2:24398427	C2orf84	-0.54	-8.04	-0.36	9.16e-15	Asthma;
LUAD	trans	rs208520	0.609	rs208436	chr6:66897470	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.68	-10.15	-0.44	8.45e-22	Exhaled nitric oxide output;
LUAD	cis	rs11811982	0.793	rs75053784	chr1:227443324	C/T	cg24860534	chr1:227506868	CDC42BPA	0.63	6.86	0.32	2.45e-11	Optic disc area;
LUAD	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg05234568	chr11:5960015	NA	0.57	11.08	0.47	3.14e-25	DNA methylation (variation);
LUAD	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg19196401	chr6:110721138	DDO	-0.42	-7.76	-0.35	6.47e-14	Platelet distribution width;
LUAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg07507251	chr3:52567010	NT5DC2	0.48	10.25	0.45	3.71e-22	Hemoglobin concentration;
LUAD	trans	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg07817883	chr1:32538562	TMEM39B	-0.54	-7.64	-0.35	1.51e-13	Monocyte percentage of white cells;
LUAD	cis	rs56283067	0.887	rs12200892	chr6:44768925	T/C	cg18551225	chr6:44695536	NA	-0.61	-9.23	-0.41	1.31e-18	Total body bone mineral density;
LUAD	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg01119278	chr6:110721349	DDO	-0.46	-8.59	-0.39	1.72e-16	Platelet distribution width;
LUAD	cis	rs9393692	0.620	rs9366650	chr6:26335997	G/A	cg13736514	chr6:26305472	NA	-0.49	-8.35	-0.38	9.51e-16	Educational attainment;
LUAD	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.21	-0.33	2.54e-12	Total body bone mineral density;
LUAD	cis	rs12620999	0.941	rs4663240	chr2:238036632	G/T	cg23555395	chr2:238036564	NA	-0.6	-9.2	-0.41	1.66e-18	Systemic lupus erythematosus;
LUAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg04025307	chr7:1156635	C7orf50	0.6	6.81	0.31	3.43e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9322817	0.691	rs4946648	chr6:105329422	G/T	cg02098413	chr6:105308735	HACE1	0.4	8.75	0.39	5.07e-17	Thyroid stimulating hormone;
LUAD	cis	rs7017914	0.967	rs10448014	chr8:71688165	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.46	-0.3	2.82e-10	Bone mineral density;
LUAD	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	8.03e-16	Body mass index;
LUAD	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg14343924	chr8:8086146	FLJ10661	-0.51	-8.18	-0.37	3.32e-15	Mood instability;
LUAD	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg00933542	chr6:150070202	PCMT1	0.45	9.91	0.43	6.13e-21	Lung cancer;
LUAD	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-13.12	-0.54	3.04e-33	Hemoglobin concentration;
LUAD	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.56e-12	Crohn's disease;
LUAD	cis	rs12579753	0.917	rs7138533	chr12:82187885	C/G	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.35	-0.34	1.02e-12	Resting heart rate;
LUAD	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.39	7.55	0.34	2.68e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1595825	0.891	rs4491721	chr2:198521407	C/G	cg10547527	chr2:198650123	BOLL	-0.54	-7.66	-0.35	1.3e-13	Ulcerative colitis;
LUAD	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg25237894	chr2:233734115	C2orf82	0.59	11.07	0.47	3.45e-25	Coronary artery disease;
LUAD	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.8	-0.35	5.01e-14	Prostate cancer;
LUAD	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg20290983	chr6:43655470	MRPS18A	0.83	16.8	0.63	6.62e-49	IgG glycosylation;
LUAD	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg08773314	chr2:239334832	ASB1	0.44	9.54	0.42	1.19e-19	Multiple system atrophy;
LUAD	cis	rs7568458	0.905	rs10198569	chr2:85794415	C/T	cg23752985	chr2:85803571	VAMP8	-0.35	-6.84	-0.32	2.79e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs4072705	0.967	rs4287038	chr9:127369679	A/G	cg13476313	chr9:127244764	NR5A1	-0.3	-7.13	-0.33	4.49e-12	Menarche (age at onset);
LUAD	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25427524	chr10:38739819	LOC399744	-0.78	-14.36	-0.57	2.24e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg10755058	chr3:40428713	ENTPD3	0.37	7.21	0.33	2.55e-12	Renal cell carcinoma;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22126032	chr7:116166529	CAV1	-0.42	-7.08	-0.33	6.14e-12	Cancer;
LUAD	cis	rs7107174	1.000	rs10899457	chr11:78001163	T/A	cg19901956	chr11:77921274	USP35	-0.53	-6.64	-0.31	9.69e-11	Testicular germ cell tumor;
LUAD	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg00316803	chr15:76480434	C15orf27	-0.41	-7.9	-0.36	2.49e-14	Blood metabolite levels;
LUAD	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg26513180	chr16:89883248	FANCA	0.72	6.9	0.32	1.86e-11	Skin colour saturation;
LUAD	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg18196295	chr10:418757	DIP2C	-0.52	-8.53	-0.38	2.63e-16	Psychosis in Alzheimer's disease;
LUAD	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg04842962	chr6:43655489	MRPS18A	1.06	26.88	0.79	1.57e-93	IgG glycosylation;
LUAD	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg21918786	chr6:109611834	NA	-0.56	-10.45	-0.45	6.69e-23	Reticulocyte fraction of red cells;
LUAD	trans	rs12719740	1.000	rs12591872	chr15:99072457	C/G	cg13805001	chr9:89555718	NA	0.44	6.66	0.31	8.71e-11	Arthritis (juvenile idiopathic);
LUAD	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg02734326	chr4:10020555	SLC2A9	0.49	7.44	0.34	5.57e-13	Blood metabolite levels;
LUAD	cis	rs1003719	0.680	rs2835664	chr21:38573429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.2	-0.37	2.89e-15	Eye color traits;
LUAD	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg11663144	chr21:46675770	NA	-0.36	-6.43	-0.3	3.4e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-10.9	-0.47	1.53e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg25566285	chr7:158114605	PTPRN2	0.45	8.07	0.37	7.34e-15	Response to amphetamines;
LUAD	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.8	-0.39	3.43e-17	Alcohol dependence;
LUAD	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg14664628	chr15:75095509	CSK	-0.52	-8.25	-0.37	2.02e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs2573652	1.000	rs2727199	chr15:100514417	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.53	-9.87	-0.43	8.24e-21	Height;
LUAD	cis	rs11677416	0.961	rs1894399	chr2:113540177	C/T	cg27083787	chr2:113543245	IL1A	0.39	6.7	0.31	6.77e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.6	11.3	0.48	4.57e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6028335	0.610	rs6729	chr20:37668272	A/G	cg27660920	chr20:37554817	FAM83D	0.52	6.51	0.3	2.14e-10	Alcohol and nicotine co-dependence;
LUAD	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg02527881	chr3:46936655	PTH1R	-0.52	-10.62	-0.46	1.69e-23	Colorectal cancer;
LUAD	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg21856205	chr7:94953877	PON1	-0.55	-7.79	-0.35	5.13e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg02527881	chr3:46936655	PTH1R	0.54	11.03	0.47	4.8e-25	Colorectal cancer;
LUAD	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg23625390	chr15:77176239	SCAPER	0.55	9.11	0.41	3.27e-18	Blood metabolite levels;
LUAD	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg02551604	chr5:131831745	NA	-0.61	-9.92	-0.43	5.39e-21	Asthma (sex interaction);
LUAD	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg02221422	chr11:68192511	LRP5	-0.42	-6.82	-0.31	3.18e-11	Total body bone mineral density;
LUAD	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg18230493	chr5:56204884	C5orf35	-0.75	-10.95	-0.47	9.47e-25	Initial pursuit acceleration;
LUAD	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg15181151	chr6:150070149	PCMT1	0.37	7.29	0.33	1.52e-12	Lung cancer;
LUAD	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg11317459	chr13:21872234	NA	-1.09	-14.71	-0.58	7.3e-40	White matter hyperintensity burden;
LUAD	cis	rs6782228	0.675	rs4443194	chr3:128383446	T/A	cg16766828	chr3:128327626	NA	-0.39	-7.0	-0.32	1.01e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg21017887	chr14:105400489	NA	0.65	12.11	0.51	3.41e-29	Rheumatoid arthritis;
LUAD	cis	rs3018712	0.532	rs2513294	chr11:68421194	C/T	cg16797656	chr11:68205561	LRP5	-0.41	-6.39	-0.3	4.35e-10	Total body bone mineral density;
LUAD	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	trans	rs9951602	1.000	rs9951602	chr18:76657779	C/T	cg02800362	chr5:177631904	HNRNPAB	0.96	11.47	0.49	1.08e-26	Obesity-related traits;
LUAD	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg25251562	chr2:3704773	ALLC	-0.49	-8.11	-0.37	5.7e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.52	-0.34	3.36e-13	Bipolar disorder;
LUAD	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg04287289	chr16:89883240	FANCA	0.78	6.99	0.32	1.1e-11	Skin colour saturation;
LUAD	cis	rs6740322	0.895	rs10166994	chr2:43557977	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.78	-11.2	-0.48	1.15e-25	Coronary artery disease;
LUAD	cis	rs7833986	0.501	rs72653941	chr8:56942247	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.89	15.59	0.6	1.26e-43	Height;
LUAD	cis	rs2742234	0.541	rs1254958	chr10:43702143	C/T	cg15436174	chr10:43711423	RASGEF1A	0.52	8.7	0.39	7.5e-17	Hirschsprung disease;
LUAD	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg26384229	chr12:38710491	ALG10B	0.5	8.11	0.37	5.5e-15	Heart rate;
LUAD	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05901451	chr6:126070800	HEY2	-0.84	-16.04	-0.61	1.42e-45	Brugada syndrome;
LUAD	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg10518543	chr12:38710700	ALG10B	-0.42	-6.79	-0.31	3.86e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs72827839	0.516	rs111630961	chr17:45938097	T/G	cg02219949	chr17:45927392	SP6	0.46	7.09	0.33	5.56e-12	Ease of getting up in the morning;
LUAD	trans	rs3779273	1.000	rs3807649	chr7:77828340	G/A	cg05596911	chr5:118502651	DMXL1	-0.4	-6.96	-0.32	1.29e-11	Body mass index;
LUAD	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg24596788	chr1:163392923	NA	-0.33	-7.48	-0.34	4.41e-13	Motion sickness;
LUAD	cis	rs4604732	0.588	rs12045675	chr1:247623915	C/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	9.14	0.41	2.55e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg03188948	chr7:1209495	NA	0.76	6.91	0.32	1.78e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7975161	0.535	rs6539138	chr12:104735928	G/A	cg25273343	chr12:104657179	TXNRD1	-0.59	-7.11	-0.33	4.99e-12	Toenail selenium levels;
LUAD	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg02079420	chr8:82753780	SNX16	0.38	7.51	0.34	3.45e-13	Diastolic blood pressure;
LUAD	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.52	7.12	0.33	4.57e-12	Platelet count;
LUAD	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg19196401	chr6:110721138	DDO	0.49	9.37	0.41	4.43e-19	Platelet distribution width;
LUAD	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg11247378	chr22:39784982	NA	-0.73	-13.21	-0.54	1.33e-33	Intelligence (multi-trait analysis);
LUAD	cis	rs7192380	1.000	rs7192380	chr16:69704342	T/C	cg00738113	chr16:70207722	CLEC18C	-0.34	-6.87	-0.32	2.32e-11	Sjögren's syndrome;
LUAD	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg10518543	chr12:38710700	ALG10B	0.51	8.45	0.38	4.85e-16	Morning vs. evening chronotype;
LUAD	cis	rs4588572	0.643	rs3922654	chr5:77684726	G/A	cg11547950	chr5:77652471	NA	0.75	11.58	0.49	3.99e-27	Triglycerides;
LUAD	cis	rs56283067	0.847	rs1283948	chr6:44691702	C/T	cg18551225	chr6:44695536	NA	-0.6	-9.91	-0.43	5.92e-21	Total body bone mineral density;
LUAD	cis	rs1712517	0.771	rs10883857	chr10:105127587	A/C	cg05636881	chr10:105038444	INA	-0.34	-6.6	-0.31	1.23e-10	Migraine;
LUAD	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg05340658	chr4:99064831	C4orf37	0.49	6.95	0.32	1.39e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7843479	0.601	rs11135764	chr8:21814004	A/G	cg03445287	chr8:21823731	XPO7	-0.5	-9.32	-0.41	6.27e-19	Mean corpuscular volume;
LUAD	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg00310523	chr12:86230176	RASSF9	0.38	7.67	0.35	1.19e-13	Major depressive disorder;
LUAD	cis	rs11971779	0.680	rs6978680	chr7:139112048	A/G	cg24109934	chr7:139138155	KLRG2	0.31	6.37	0.3	5.07e-10	Diisocyanate-induced asthma;
LUAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg07677032	chr17:61819896	STRADA	0.57	10.54	0.46	3.21e-23	Prudent dietary pattern;
LUAD	trans	rs7395662	0.963	rs11039773	chr11:48513931	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.51	-0.3	2.08e-10	HDL cholesterol;
LUAD	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg06784218	chr1:46089804	CCDC17	0.51	11.28	0.48	5.4e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg22532475	chr10:104410764	TRIM8	0.4	8.11	0.37	5.37e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.58	-0.38	1.86e-16	Breast cancer;
LUAD	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg27068330	chr11:65405492	SIPA1	0.54	8.6	0.39	1.6e-16	Acne (severe);
LUAD	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg08885076	chr2:99613938	TSGA10	0.37	6.74	0.31	5.11e-11	Chronic sinus infection;
LUAD	cis	rs4853036	0.951	rs6718298	chr2:70145450	A/C	cg02498382	chr2:70120550	SNRNP27	-0.51	-8.3	-0.37	1.42e-15	Colorectal or endometrial cancer;
LUAD	cis	rs7737355	0.947	rs6859469	chr5:130962546	C/T	cg06307176	chr5:131281290	NA	0.49	7.59	0.35	2.02e-13	Life satisfaction;
LUAD	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18876405	chr7:65276391	NA	-0.4	-6.36	-0.3	5.11e-10	Aortic root size;
LUAD	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.55	9.42	0.42	2.99e-19	Breast cancer;
LUAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg16590910	chr6:42928470	GNMT	0.34	6.45	0.3	3.08e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10823500	1.000	rs10823500	chr10:72005190	A/G	cg02100629	chr10:71892760	AIFM2	-0.32	-6.48	-0.3	2.54e-10	Blood protein levels;
LUAD	cis	rs6758955	1.000	rs1558629	chr2:10478364	C/T	cg15773312	chr2:10472214	HPCAL1	-0.4	-6.55	-0.3	1.71e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg02569458	chr12:86230093	RASSF9	0.42	7.99	0.36	1.29e-14	Major depressive disorder;
LUAD	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg02734326	chr4:10020555	SLC2A9	-0.56	-9.54	-0.42	1.14e-19	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg08761264	chr16:28874980	SH2B1	-0.44	-6.44	-0.3	3.28e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs8048589	0.612	rs2869808	chr16:12176864	A/C	cg03816625	chr16:12192430	SNX29	0.48	7.28	0.33	1.69e-12	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg26513180	chr16:89883248	FANCA	0.69	13.09	0.54	4.06e-33	Vitiligo;
LUAD	cis	rs17641971	0.599	rs818555	chr8:49999211	A/G	cg00325661	chr8:49890786	NA	-0.38	-8.49	-0.38	3.49e-16	Blood metabolite levels;
LUAD	cis	rs67072384	0.818	rs12287481	chr11:72472336	A/C	cg04827223	chr11:72435913	ARAP1	0.54	6.75	0.31	4.93e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg11673840	chr17:47092156	IGF2BP1	-0.35	-6.72	-0.31	6.01e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs698813	0.674	rs6759891	chr2:44496005	C/T	cg00619915	chr2:44497795	NA	-0.43	-6.42	-0.3	3.6e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUAD	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg17372223	chr3:52568218	NT5DC2	0.34	6.64	0.31	9.65e-11	Bipolar disorder;
LUAD	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs8060686	0.623	rs74024145	chr16:68153382	G/C	cg26727032	chr16:67993705	SLC12A4	-0.46	-7.71	-0.35	9.28e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg04450456	chr4:17643702	FAM184B	0.39	7.37	0.34	8.87e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19748678	chr4:122722346	EXOSC9	0.43	6.84	0.32	2.83e-11	Type 2 diabetes;
LUAD	trans	rs4942242	0.663	rs1390371	chr13:44211727	A/G	cg19169023	chr15:41853346	TYRO3	0.67	11.99	0.5	1.03e-28	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg15123519	chr2:136567270	LCT	-0.37	-6.68	-0.31	7.4e-11	Mosquito bite size;
LUAD	cis	rs2073300	1.000	rs6137957	chr20:23437384	G/A	cg09953122	chr20:23471693	CST8	-0.65	-6.37	-0.3	4.9e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4308124	0.708	rs28871990	chr2:111962441	G/A	cg04571233	chr2:111982156	NA	-0.45	-6.41	-0.3	3.78e-10	Vitiligo;
LUAD	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg16405210	chr4:1374714	KIAA1530	0.46	7.25	0.33	1.99e-12	Obesity-related traits;
LUAD	cis	rs7833986	1.000	rs61690651	chr8:57096661	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.66	9.12	0.41	3.07e-18	Height;
LUAD	cis	rs240764	0.853	rs2398132	chr6:100981200	A/C	cg09795085	chr6:101329169	ASCC3	-0.39	-6.84	-0.32	2.84e-11	Neuroticism;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22541143	chr4:84377292	HELQ;MRPS18C	-0.55	-6.89	-0.32	2.07e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.25	-0.33	1.95e-12	Lung cancer;
LUAD	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg06740227	chr12:86229804	RASSF9	-0.4	-7.17	-0.33	3.37e-12	Major depressive disorder;
LUAD	cis	rs7089973	0.872	rs35010779	chr10:116631816	A/C	cg25233709	chr10:116636983	FAM160B1	0.39	7.52	0.34	3.3e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg20607798	chr8:58055168	NA	0.57	7.78	0.35	5.64e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg22286687	chr17:43238757	HEXIM2	-0.59	-6.37	-0.3	4.86e-10	Type 2 diabetes;
LUAD	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg09835421	chr16:68378352	PRMT7	-0.85	-9.1	-0.4	3.52e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2637266	1.000	rs12260492	chr10:78365242	C/A	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.72e-11	Pulmonary function;
LUAD	cis	rs35740288	0.770	rs12907126	chr15:86171357	A/G	cg13263323	chr15:86062960	AKAP13	-0.44	-6.9	-0.32	1.93e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg21231944	chr12:82153410	PPFIA2	-0.36	-6.65	-0.31	8.98e-11	Resting heart rate;
LUAD	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg03396347	chr1:1875803	NA	-0.6	-15.0	-0.59	4.16e-41	Body mass index;
LUAD	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg24578937	chr1:2090814	PRKCZ	0.55	11.53	0.49	6.17e-27	Height;
LUAD	cis	rs11771526	0.901	rs10264511	chr7:32304170	T/C	cg27532318	chr7:32358331	NA	0.59	7.4	0.34	7.31e-13	Body mass index;
LUAD	cis	rs877426	0.681	rs7317369	chr13:114816738	C/G	cg21461300	chr13:114830702	RASA3	-0.43	-6.36	-0.3	5.29e-10	Facial morphology (factor 14, intercanthal width);
LUAD	cis	rs6138458	1.000	rs227621	chr20:24910528	A/C	cg26195577	chr20:24973756	C20orf3	0.96	16.32	0.62	8.79e-47	Blood protein levels;
LUAD	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg12193833	chr17:30244370	NA	0.52	6.52	0.3	2.01e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs904251	0.600	rs11756241	chr6:37445101	C/T	cg25019722	chr6:37503610	NA	-0.31	-6.93	-0.32	1.62e-11	Cognitive performance;
LUAD	cis	rs7731657	0.567	rs10074477	chr5:130315505	T/C	cg08523029	chr5:130500466	HINT1	-0.57	-7.3	-0.33	1.47e-12	Fasting plasma glucose;
LUAD	cis	rs7614311	0.555	rs58676857	chr3:63903883	G/A	cg22134162	chr3:63841271	THOC7	-0.41	-7.42	-0.34	6.32e-13	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs11955175	0.717	rs41271053	chr5:40835393	A/C	cg05478818	chr5:40835740	RPL37	0.78	6.65	0.31	9.3e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs4077468	1.000	rs4077469	chr1:205914885	C/T	cg14893161	chr1:205819251	PM20D1	-0.37	-6.56	-0.3	1.53e-10	Cystic fibrosis-related diabetes;
LUAD	cis	rs6840360	0.571	rs4696278	chr4:152558978	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.73	-0.31	5.55e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg07606381	chr6:8435919	SLC35B3	0.42	6.98	0.32	1.14e-11	Motion sickness;
LUAD	cis	rs8044868	1.000	rs6499562	chr16:72162855	G/A	cg23815491	chr16:72088622	HP	0.41	7.52	0.34	3.34e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg27661571	chr11:113659931	NA	-0.7	-8.17	-0.37	3.56e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs8018808	1.000	rs12101153	chr14:77863091	A/C	cg20045696	chr14:77926864	AHSA1	-0.36	-6.52	-0.3	1.95e-10	Myeloid white cell count;
LUAD	cis	rs9326248	0.539	rs660443	chr11:116760693	T/C	cg20608306	chr11:116969690	SIK3	0.3	6.52	0.3	2.07e-10	Blood protein levels;
LUAD	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg02574844	chr11:5959923	NA	-0.46	-8.29	-0.37	1.49e-15	DNA methylation (variation);
LUAD	cis	rs752010	0.574	rs10890161	chr1:42121623	T/C	cg06885757	chr1:42089581	HIVEP3	0.4	8.6	0.39	1.6e-16	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg08888203	chr3:10149979	C3orf24	0.73	11.17	0.48	1.44e-25	Alzheimer's disease;
LUAD	cis	rs7712401	0.755	rs27740	chr5:122204772	A/T	cg19077854	chr5:122220652	SNX24	-0.31	-6.47	-0.3	2.74e-10	Mean platelet volume;
LUAD	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg17509989	chr5:176798049	RGS14	-0.57	-10.24	-0.45	3.99e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg08601574	chr20:25228251	PYGB	-0.44	-8.16	-0.37	4e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs3820068	0.822	rs2901964	chr1:15792426	C/G	cg13390004	chr1:15929781	NA	0.44	6.86	0.32	2.47e-11	Systolic blood pressure;
LUAD	cis	rs6499255	1.000	rs4464069	chr16:69816284	C/T	cg15192750	chr16:69999425	NA	0.51	7.99	0.36	1.32e-14	IgE levels;
LUAD	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg08999081	chr20:33150536	PIGU	0.48	9.17	0.41	2.08e-18	Coronary artery disease;
LUAD	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.56	7.91	0.36	2.24e-14	Platelet count;
LUAD	trans	rs875971	0.545	rs316305	chr7:65617971	G/A	cg04775059	chr7:64541387	NA	-0.49	-6.73	-0.31	5.69e-11	Aortic root size;
LUAD	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	7.93	0.36	2.03e-14	Breast cancer;
LUAD	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg27529037	chr20:44575021	PCIF1	0.46	8.21	0.37	2.69e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg09873201	chr16:3507582	NAT15	-0.48	-6.7	-0.31	6.51e-11	Tuberculosis;
LUAD	cis	rs11190604	1.000	rs76683169	chr10:102358397	A/T	cg07570687	chr10:102243282	WNT8B	0.46	6.86	0.32	2.45e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg24813613	chr7:1882135	MAD1L1	-0.57	-9.36	-0.41	4.89e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg11845111	chr2:191398756	TMEM194B	0.7	12.86	0.53	3.71e-32	Pulse pressure;
LUAD	cis	rs1003719	0.788	rs7275582	chr21:38451130	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.52	8.83	0.39	2.84e-17	Eye color traits;
LUAD	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23158103	chr7:148848205	ZNF398	-0.5	-8.99	-0.4	8.6e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg00666640	chr1:248458726	OR2T12	0.34	8.27	0.37	1.76e-15	Common traits (Other);
LUAD	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg03563238	chr19:33554763	RHPN2	-0.36	-8.39	-0.38	7.32e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg04155289	chr7:94953770	PON1	0.52	6.83	0.32	2.92e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs921968	0.565	rs6704575	chr2:219589594	C/T	cg02176678	chr2:219576539	TTLL4	0.58	11.81	0.5	4.98e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg17063962	chr7:91808500	NA	0.72	12.73	0.53	1.17e-31	Breast cancer;
LUAD	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg27170947	chr2:26402098	FAM59B	0.84	12.42	0.52	1.97e-30	Gut microbiome composition (summer);
LUAD	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg18016565	chr1:150552671	MCL1	-0.4	-7.46	-0.34	4.85e-13	Tonsillectomy;
LUAD	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg00530320	chr1:46809349	NSUN4	0.53	8.23	0.37	2.33e-15	Menopause (age at onset);
LUAD	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.01	-0.36	1.14e-14	Diabetic kidney disease;
LUAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg19318889	chr4:1322082	MAEA	0.45	7.43	0.34	6.17e-13	Obesity-related traits;
LUAD	cis	rs10489202	0.612	rs3820401	chr1:168074753	T/C	cg25738037	chr1:168025549	DCAF6	-0.45	-6.76	-0.31	4.51e-11	Schizophrenia;
LUAD	cis	rs751837	0.591	rs2896462	chr14:103434739	A/G	cg10087771	chr14:103399429	CDC42BPB	0.65	7.34	0.34	1.07e-12	Large B-cell lymphoma;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00436174	chr2:128051630	ERCC3	-0.58	-7.05	-0.32	7.29e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs8002861	0.935	rs9533678	chr13:44463409	C/T	cg17145862	chr1:211918768	LPGAT1	0.77	18.24	0.66	2.97e-55	Leprosy;
LUAD	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg05590025	chr7:65112418	INTS4L2	0.73	7.85	0.36	3.36e-14	Diabetic kidney disease;
LUAD	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg15123519	chr2:136567270	LCT	-0.37	-6.78	-0.31	3.94e-11	Mosquito bite size;
LUAD	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg06697600	chr4:7070879	GRPEL1	-0.51	-8.46	-0.38	4.45e-16	Monocyte percentage of white cells;
LUAD	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg04772025	chr11:68637568	NA	0.59	9.37	0.41	4.25e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg22467129	chr15:76604101	ETFA	-0.6	-11.02	-0.47	5.18e-25	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.39	0.52	2.65e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs752010	0.619	rs6703992	chr1:42115888	G/A	cg06885757	chr1:42089581	HIVEP3	0.56	12.43	0.52	1.92e-30	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs11650175	0.835	rs764819	chr17:63755541	T/A	cg07283582	chr17:63770753	CCDC46	0.4	7.95	0.36	1.76e-14	Chin dimples;
LUAD	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg27170947	chr2:26402098	FAM59B	-0.82	-11.49	-0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg21138405	chr5:131827807	IRF1	0.6	13.77	0.56	6.51e-36	Asthma (sex interaction);
LUAD	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg07917127	chr4:99064746	C4orf37	0.45	7.34	0.34	1.1e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.35	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	trans	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg27411982	chr8:10470053	RP1L1	0.4	7.05	0.32	7.19e-12	Neuroticism;
LUAD	cis	rs2224391	0.656	rs17140118	chr6:5291334	G/A	cg26704043	chr6:5282702	FARS2	0.39	6.4	0.3	4.24e-10	Height;
LUAD	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	7.98	0.36	1.37e-14	Menopause (age at onset);
LUAD	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg18099408	chr3:52552593	STAB1	-0.44	-7.8	-0.35	4.78e-14	Bipolar disorder;
LUAD	cis	rs8060686	0.516	rs9939821	chr16:68167787	T/A	cg09835421	chr16:68378352	PRMT7	-0.56	-6.96	-0.32	1.32e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.26	-0.33	1.89e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	trans	rs800082	0.698	rs800070	chr3:144346614	A/T	cg24215973	chr2:240111563	HDAC4	-0.67	-10.87	-0.47	1.99e-24	Smoking behavior;
LUAD	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg11766577	chr21:47581405	C21orf56	-0.46	-7.75	-0.35	7.11e-14	Testicular germ cell tumor;
LUAD	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg00757033	chr12:89920650	WDR51B	0.69	12.15	0.51	2.5e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs73195822	0.527	rs73194059	chr12:111221740	G/A	cg12870014	chr12:110450643	ANKRD13A	0.58	6.51	0.3	2.11e-10	Itch intensity from mosquito bite;
LUAD	cis	rs4903604	0.581	rs11159279	chr14:78036358	C/T	cg18872420	chr14:78023429	SPTLC2	0.46	8.47	0.38	4.01e-16	Gut microbiome composition (winter);
LUAD	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.62	-0.31	1.09e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs8049603	0.715	rs76013074	chr16:23191178	T/C	cg09552652	chr16:23197569	SCNN1G	0.37	6.36	0.3	5.29e-10	Multiple sclerosis;
LUAD	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg05805236	chr11:65401703	PCNXL3	-0.61	-9.79	-0.43	1.61e-20	Acne (severe);
LUAD	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg02733842	chr7:1102375	C7orf50	-0.76	-10.94	-0.47	1.06e-24	Bronchopulmonary dysplasia;
LUAD	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg19761014	chr17:28927070	LRRC37B2	0.8	9.45	0.42	2.41e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.67	-0.31	7.97e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg07936489	chr17:37558343	FBXL20	-0.46	-7.29	-0.33	1.58e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg07460842	chr6:66804631	NA	-1.2	-30.41	-0.83	1.72e-108	Exhaled nitric oxide output;
LUAD	cis	rs2458413	0.522	rs2514657	chr8:105331215	T/C	cg04554929	chr8:105342491	NA	-0.45	-8.75	-0.39	4.97e-17	Paget's disease;
LUAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg13047869	chr3:10149882	C3orf24	0.63	11.01	0.47	5.82e-25	Alzheimer's disease;
LUAD	cis	rs62400317	0.762	rs756	chr6:44795772	C/T	cg20913747	chr6:44695427	NA	-0.45	-7.13	-0.33	4.45e-12	Total body bone mineral density;
LUAD	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg13798912	chr7:905769	UNC84A	-0.62	-7.11	-0.33	5.02e-12	Cerebrospinal P-tau181p levels;
LUAD	trans	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg11693508	chr17:37793320	STARD3	0.55	7.79	0.35	5.3e-14	Neuroticism;
LUAD	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg02569458	chr12:86230093	RASSF9	-0.41	-7.6	-0.35	1.95e-13	Major depressive disorder;
LUAD	cis	rs9513627	0.915	rs9585070	chr13:100118843	G/C	cg25919922	chr13:100150906	NA	-0.69	-6.6	-0.31	1.25e-10	Obesity-related traits;
LUAD	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg11502198	chr6:26597334	ABT1	0.68	11.32	0.48	3.86e-26	Intelligence (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09558224	chr1:33430421	RNF19B	-0.61	-6.36	-0.3	5.32e-10	Type 2 diabetes;
LUAD	cis	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg17551891	chr7:1960795	MAD1L1	-0.44	-7.27	-0.33	1.72e-12	Bipolar disorder;
LUAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.12	0.41	3.18e-18	Alzheimer's disease;
LUAD	cis	rs9473147	0.516	rs9296561	chr6:47488938	G/A	cg12968598	chr6:47444699	CD2AP	0.35	6.35	0.3	5.46e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs3806843	0.517	rs246031	chr5:140333107	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg04450456	chr4:17643702	FAM184B	0.4	7.89	0.36	2.56e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs367615	0.660	rs4632850	chr5:108832883	C/G	cg17395555	chr5:108820864	NA	0.67	14.5	0.58	5.81e-39	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg14458575	chr2:238380390	NA	0.65	12.6	0.52	4.05e-31	Prostate cancer;
LUAD	cis	rs2067615	0.542	rs4433659	chr12:107082496	G/T	cg15890332	chr12:107067104	RFX4	0.4	8.41	0.38	6.41e-16	Heart rate;
LUAD	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg05182265	chr7:156933206	UBE3C	0.81	17.35	0.64	2.66e-51	Body mass index;
LUAD	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg24818145	chr4:99064322	C4orf37	0.49	8.3	0.37	1.38e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7731657	0.537	rs7709977	chr5:130367086	A/T	cg08523029	chr5:130500466	HINT1	-0.6	-7.67	-0.35	1.17e-13	Fasting plasma glucose;
LUAD	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg25457927	chr22:38595422	NA	-0.53	-13.87	-0.56	2.48e-36	Cutaneous nevi;
LUAD	cis	rs11811982	0.793	rs79766410	chr1:227289103	T/C	cg24860534	chr1:227506868	CDC42BPA	0.66	7.16	0.33	3.6e-12	Optic disc area;
LUAD	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg07917127	chr4:99064746	C4orf37	0.42	6.98	0.32	1.11e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg02018176	chr4:1364513	KIAA1530	0.38	6.85	0.32	2.61e-11	Obesity-related traits;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24715473	chr16:50059017	TMEM188	-0.42	-6.51	-0.3	2.18e-10	Height;
LUAD	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg17724175	chr1:150552817	MCL1	0.31	7.16	0.33	3.56e-12	Melanoma;
LUAD	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg09359103	chr1:154839909	KCNN3	0.91	20.93	0.71	2.73e-67	Prostate cancer;
LUAD	cis	rs113084984	0.816	rs4669749	chr2:11692664	A/C	cg07314298	chr2:11723111	GREB1	-0.45	-7.84	-0.36	3.67e-14	Breast cancer;
LUAD	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	8.99	0.4	8.07e-18	Tonsillectomy;
LUAD	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg14530993	chr4:882597	GAK	0.7	6.74	0.31	5.15e-11	Parkinson's disease;
LUAD	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg09998033	chr7:158218633	PTPRN2	0.41	7.19	0.33	3.04e-12	Obesity-related traits;
LUAD	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.62	-11.52	-0.49	6.81e-27	Schizophrenia;
LUAD	cis	rs7614311	0.681	rs10510903	chr3:63970192	C/G	cg22134162	chr3:63841271	THOC7	-0.51	-8.95	-0.4	1.15e-17	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.64	0.55	2.2e-35	Tonsillectomy;
LUAD	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg19346786	chr7:2764209	NA	-0.52	-11.29	-0.48	5.14e-26	Height;
LUAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg08677398	chr8:58056175	NA	0.43	6.64	0.31	9.9e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9462027	0.628	rs2744961	chr6:34655000	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-8.44	-0.38	5.27e-16	Systemic lupus erythematosus;
LUAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg24642844	chr7:1081250	C7orf50	-0.98	-14.8	-0.58	2.97e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg03690763	chr11:133734501	NA	-0.34	-8.04	-0.36	9.16e-15	Childhood ear infection;
LUAD	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg01689657	chr7:91764605	CYP51A1	-0.32	-7.86	-0.36	3.28e-14	Breast cancer;
LUAD	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg14458575	chr2:238380390	NA	0.67	12.54	0.52	6.99e-31	Prostate cancer;
LUAD	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg15133208	chr4:90757351	SNCA	-0.46	-6.81	-0.31	3.26e-11	Neuroticism;
LUAD	cis	rs2412208	0.608	rs6656489	chr1:7122276	C/T	cg20434152	chr1:7120926	CAMTA1	-0.35	-7.85	-0.36	3.47e-14	Survival in sporadic amyotrophic lateral sclerosis;
LUAD	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.08	15.37	0.6	1.14e-42	Lung cancer in ever smokers;
LUAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg13319975	chr6:146136371	FBXO30	-0.65	-11.06	-0.47	3.69e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg00383909	chr3:49044727	WDR6	0.93	9.59	0.42	7.48e-20	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg23758822	chr17:41437982	NA	1.01	20.78	0.71	1.32e-66	Menopause (age at onset);
LUAD	trans	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.78	-0.46	4.08e-24	Obesity-related traits;
LUAD	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg14324370	chr2:177042789	NA	0.38	7.11	0.33	5.02e-12	IgG glycosylation;
LUAD	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.42	0.3	3.56e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs16854884	0.586	rs7611326	chr3:143736374	C/T	cg01302019	chr3:143689584	C3orf58	-0.37	-6.5	-0.3	2.28e-10	Economic and political preferences (feminism/equality);
LUAD	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg14196790	chr5:131705035	SLC22A5	0.39	7.1	0.33	5.44e-12	Blood metabolite levels;
LUAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg19626725	chr5:178986131	RUFY1	0.49	9.22	0.41	1.43e-18	Lung cancer;
LUAD	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.4	6.55	0.3	1.71e-10	Platelet count;
LUAD	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg23758822	chr17:41437982	NA	1.0	20.84	0.71	7.13e-67	Menopause (age at onset);
LUAD	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.55	-0.3	1.65e-10	Breast cancer;
LUAD	cis	rs11166629	1.000	rs11166629	chr8:135636964	C/T	cg27224718	chr8:135614730	ZFAT	0.61	11.04	0.47	4.33e-25	Smoking quantity;
LUAD	cis	rs7213347	0.707	rs216196	chr17:2202943	T/C	cg16513277	chr17:2031491	SMG6	0.43	6.62	0.31	1.11e-10	Total body bone mineral density;
LUAD	cis	rs11048434	0.673	rs2159961	chr12:9061456	G/T	cg26114124	chr12:9217669	LOC144571	0.35	6.4	0.3	4.05e-10	Sjögren's syndrome;
LUAD	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.81	0.36	4.53e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9329289	0.610	rs10903783	chr10:2540623	C/T	cg15501526	chr10:2543763	NA	0.57	12.4	0.52	2.43e-30	Age-related hearing impairment;
LUAD	trans	rs1941687	0.831	rs62091190	chr18:31387700	C/T	cg27147174	chr7:100797783	AP1S1	-0.54	-9.19	-0.41	1.78e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs6761276	0.899	rs11677088	chr2:113835603	A/G	cg10479672	chr2:113810641	IL1F8	-0.38	-7.65	-0.35	1.39e-13	Protein quantitative trait loci;
LUAD	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg05368731	chr17:41323189	NBR1	0.95	19.1	0.68	4.31e-59	Menopause (age at onset);
LUAD	cis	rs7189233	0.955	rs72801817	chr16:53474568	C/T	cg04059762	chr16:53544020	NA	-0.41	-6.61	-0.31	1.13e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs3750082	0.889	rs4437549	chr7:32914965	C/T	cg05721444	chr7:32995514	FKBP9	0.37	6.75	0.31	4.77e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg00074818	chr8:8560427	CLDN23	-0.6	-9.24	-0.41	1.18e-18	Obesity-related traits;
LUAD	cis	rs4523957	0.583	rs2641442	chr17:2035071	C/T	cg16513277	chr17:2031491	SMG6	-0.98	-19.94	-0.7	7.73e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10493773	0.618	rs17394091	chr1:86075098	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.47	-7.28	-0.33	1.61e-12	Urate levels in overweight individuals;
LUAD	cis	rs8077889	0.917	rs9894873	chr17:41911832	A/G	cg26893861	chr17:41843967	DUSP3	0.85	13.82	0.56	4.26e-36	Triglycerides;
LUAD	cis	rs28595532	1.000	rs73842212	chr4:119638122	A/G	cg02775129	chr4:119771670	NA	-0.82	-7.67	-0.35	1.18e-13	Cannabis dependence symptom count;
LUAD	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg17366294	chr4:99064904	C4orf37	0.47	8.21	0.37	2.76e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12681287	0.640	rs34794500	chr8:87449995	G/A	cg00550725	chr8:87521180	FAM82B	0.45	6.63	0.31	1.02e-10	Caudate activity during reward;
LUAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg09436375	chr6:42928200	GNMT	-0.25	-7.15	-0.33	3.81e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg05368731	chr17:41323189	NBR1	0.89	17.59	0.65	2.29e-52	Menopause (age at onset);
LUAD	cis	rs494562	0.892	rs515980	chr6:86119917	C/T	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg23758822	chr17:41437982	NA	1.01	20.92	0.71	3.08e-67	Menopause (age at onset);
LUAD	cis	rs89107	0.640	rs281864	chr6:118576233	A/C	cg21191810	chr6:118973309	C6orf204	0.49	9.52	0.42	1.36e-19	Cardiac structure and function;
LUAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg20607798	chr8:58055168	NA	0.58	7.54	0.34	2.94e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg00204512	chr16:28754710	NA	-0.34	-7.25	-0.33	2.03e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg03188948	chr7:1209495	NA	0.81	10.04	0.44	2.12e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs57994353	0.828	rs11146021	chr9:139327858	A/G	cg13611204	chr9:139324423	INPP5E	0.36	6.81	0.31	3.43e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg22117172	chr7:91764530	CYP51A1	0.33	7.34	0.34	1.11e-12	Breast cancer;
LUAD	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg26647111	chr11:31128758	NA	-0.47	-8.08	-0.37	6.75e-15	Red blood cell count;
LUAD	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg25985355	chr7:65971099	NA	-0.51	-6.4	-0.3	4.13e-10	Diabetic kidney disease;
LUAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg16031515	chr1:205743344	RAB7L1	-0.37	-7.39	-0.34	7.74e-13	Menarche (age at onset);
LUAD	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg11871910	chr12:69753446	YEATS4	0.7	12.04	0.51	6.52e-29	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg26384229	chr12:38710491	ALG10B	0.46	7.6	0.35	1.99e-13	Morning vs. evening chronotype;
LUAD	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg22753661	chr15:79092743	ADAMTS7	0.57	8.75	0.39	4.94e-17	Coronary artery disease or large artery stroke;
LUAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.55	-9.72	-0.43	2.83e-20	Lymphocyte counts;
LUAD	cis	rs2882667	0.858	rs13177503	chr5:138432759	G/C	cg04439458	chr5:138467593	SIL1	-0.54	-9.75	-0.43	2.23e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs738322	0.753	rs2267372	chr22:38598234	A/G	cg17652424	chr22:38574118	PLA2G6	0.24	6.42	0.3	3.77e-10	Cutaneous nevi;
LUAD	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	25.68	0.78	2.46e-88	Chronic sinus infection;
LUAD	cis	rs11048434	0.736	rs11048264	chr12:9113581	C/T	cg23795048	chr12:9217529	LOC144571	-0.44	-8.29	-0.37	1.5e-15	Sjögren's syndrome;
LUAD	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg18477163	chr1:228402036	OBSCN	0.41	8.25	0.37	2.09e-15	Diastolic blood pressure;
LUAD	cis	rs78487399	0.665	rs72867023	chr2:43763166	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-6.6	-0.31	1.23e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg18944383	chr4:111397179	ENPEP	0.4	7.96	0.36	1.61e-14	Height;
LUAD	cis	rs10242455	0.571	rs41258334	chr7:99271808	T/C	cg18809830	chr7:99032528	PTCD1	-1.07	-8.35	-0.38	1e-15	Blood metabolite levels;
LUAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg24642844	chr7:1081250	C7orf50	-0.96	-14.39	-0.57	1.62e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06544989	chr22:39130855	UNC84B	0.45	8.37	0.38	8.58e-16	Menopause (age at onset);
LUAD	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg20503657	chr10:835505	NA	0.95	14.05	0.56	4.68e-37	Eosinophil percentage of granulocytes;
LUAD	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg19622623	chr12:86230825	RASSF9	0.44	7.94	0.36	1.83e-14	Major depressive disorder;
LUAD	cis	rs9768139	0.658	rs28425474	chr7:158116360	C/T	cg24154853	chr7:158122151	PTPRN2	0.56	11.04	0.47	4.45e-25	Calcium levels;
LUAD	cis	rs1595825	0.891	rs892512	chr2:198905910	C/A	cg00982548	chr2:198649783	BOLL	-0.58	-8.21	-0.37	2.66e-15	Ulcerative colitis;
LUAD	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.51	-0.34	3.54e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs59698941	0.943	rs67806898	chr5:132296771	A/G	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg12483005	chr1:23474871	LUZP1	0.52	9.12	0.41	2.97e-18	Height;
LUAD	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg09137382	chr11:130731461	NA	0.4	7.43	0.34	6.19e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg11189052	chr15:85197271	WDR73	-0.63	-10.44	-0.45	7.47e-23	P wave terminal force;
LUAD	cis	rs9807989	0.507	rs4479442	chr2:103054074	A/T	cg03938978	chr2:103052716	IL18RAP	0.46	10.65	0.46	1.32e-23	Asthma;
LUAD	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg02176678	chr2:219576539	TTLL4	-0.6	-11.67	-0.49	1.81e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg12179176	chr11:130786555	SNX19	0.55	9.39	0.42	3.82e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs754466	0.606	rs11002310	chr10:79596030	A/C	cg17075019	chr10:79541650	NA	-0.88	-18.6	-0.67	6.94e-57	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4911259	0.552	rs11700082	chr20:31460244	A/G	cg13636640	chr20:31349939	DNMT3B	-0.59	-9.73	-0.43	2.58e-20	Inflammatory bowel disease;
LUAD	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg10356904	chr22:49881777	NA	-0.41	-8.14	-0.37	4.58e-15	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg26408565	chr15:76604113	ETFA	-0.44	-7.1	-0.33	5.19e-12	Blood metabolite levels;
LUAD	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg19622623	chr12:86230825	RASSF9	0.42	7.44	0.34	5.78e-13	Major depressive disorder;
LUAD	cis	rs7536201	0.934	rs10903119	chr1:25294902	A/G	cg23273869	chr1:25296894	NA	-0.35	-7.01	-0.32	9.46e-12	Psoriasis vulgaris;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23300659	chr7:136553822	CHRM2	-0.38	-6.51	-0.3	2.12e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Parkinson's disease;
LUAD	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg00316803	chr15:76480434	C15orf27	-0.41	-7.65	-0.35	1.37e-13	Blood metabolite levels;
LUAD	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg18252515	chr7:66147081	NA	-0.62	-6.9	-0.32	1.96e-11	Diabetic kidney disease;
LUAD	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg00757033	chr12:89920650	WDR51B	0.69	12.2	0.51	1.54e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.44	-0.3	3.35e-10	Triglycerides;
LUAD	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.69	0.31	6.95e-11	Depression;
LUAD	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg05368731	chr17:41323189	NBR1	0.97	20.59	0.71	9.16e-66	Menopause (age at onset);
LUAD	cis	rs11971779	0.715	rs10954646	chr7:139061069	C/G	cg23387468	chr7:139079360	LUC7L2	-0.3	-6.92	-0.32	1.73e-11	Diisocyanate-induced asthma;
LUAD	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg00933542	chr6:150070202	PCMT1	0.43	9.25	0.41	1.15e-18	Lung cancer;
LUAD	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg00852783	chr1:26633632	UBXN11	0.41	7.14	0.33	4.2e-12	Obesity-related traits;
LUAD	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-7.35	-0.34	1.04e-12	Morning vs. evening chronotype;
LUAD	cis	rs2425143	1.000	rs1970357	chr20:34339200	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.61	7.18	0.33	3.2e-12	Blood protein levels;
LUAD	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12760731	0.920	rs61109337	chr1:178484674	A/G	cg00404053	chr1:178313656	RASAL2	0.59	6.91	0.32	1.78e-11	Obesity-related traits;
LUAD	trans	rs12517041	1.000	rs7737479	chr5:23288235	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.53	-0.3	1.92e-10	Calcium levels;
LUAD	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg21605333	chr4:119757512	SEC24D	0.93	8.7	0.39	7.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg09365446	chr1:150670422	GOLPH3L	-0.43	-7.22	-0.33	2.48e-12	Tonsillectomy;
LUAD	cis	rs9326248	0.581	rs12225187	chr11:116793231	G/A	cg20608306	chr11:116969690	SIK3	0.32	7.09	0.33	5.71e-12	Blood protein levels;
LUAD	cis	rs7680126	0.633	rs28378345	chr4:10209897	A/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.42	-0.3	3.62e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg01689657	chr7:91764605	CYP51A1	0.29	6.93	0.32	1.6e-11	Breast cancer;
LUAD	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg06784218	chr1:46089804	CCDC17	0.51	11.24	0.48	8.18e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg25834613	chr7:1915315	MAD1L1	0.39	6.38	0.3	4.61e-10	Bipolar disorder;
LUAD	cis	rs6438504	0.885	rs34549395	chr3:118957544	C/A	cg25372693	chr3:118959985	B4GALT4	0.35	6.43	0.3	3.5e-10	Clozapine-induced cytotoxicity;
LUAD	cis	rs3806933	0.522	rs12515367	chr5:110447853	A/G	cg17157872	chr5:110408788	TSLP	0.34	6.39	0.3	4.43e-10	Eosinophilic esophagitis;
LUAD	cis	rs11696501	0.739	rs6073821	chr20:44251791	A/G	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.16	-0.37	3.85e-15	Brain structure;
LUAD	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	0.32	8.01	0.36	1.1e-14	Total body bone mineral density;
LUAD	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg10189605	chr6:58287430	GUSBL2	-0.38	-6.85	-0.32	2.61e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
LUAD	cis	rs10493773	0.862	rs12075929	chr1:86248138	A/C	cg17807903	chr1:86174739	ZNHIT6	0.56	9.62	0.42	5.92e-20	Urate levels in overweight individuals;
LUAD	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg23803603	chr1:2058230	PRKCZ	-0.39	-6.85	-0.32	2.63e-11	Height;
LUAD	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg22920501	chr2:26401640	FAM59B	-0.96	-14.2	-0.57	1.07e-37	Gut microbiome composition (summer);
LUAD	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg03161606	chr19:29218774	NA	0.59	7.36	0.34	9.6e-13	Methadone dose in opioid dependence;
LUAD	trans	rs116939006	1.000	rs6530770	chr8:14264027	A/G	cg16330849	chr6:10694809	C6orf52;PAK1IP1	0.82	7.15	0.33	3.78e-12	Response to paliperidone in schizophrenia (negative Marder score);
LUAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg11822812	chr5:140052017	DND1	0.37	6.55	0.3	1.66e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.53	7.58	0.35	2.19e-13	Platelet count;
LUAD	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg22105103	chr4:187893119	NA	-0.54	-12.03	-0.5	7.27e-29	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg22920501	chr2:26401640	FAM59B	-0.96	-14.21	-0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg20135002	chr11:47629003	NA	-0.38	-6.42	-0.3	3.66e-10	Subjective well-being;
LUAD	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03264133	chr6:25882463	NA	-0.58	-9.45	-0.42	2.29e-19	Blood metabolite levels;
LUAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg26338869	chr17:61819248	STRADA	-0.39	-6.55	-0.3	1.72e-10	Prudent dietary pattern;
LUAD	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg10518543	chr12:38710700	ALG10B	-0.42	-6.97	-0.32	1.24e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6743376	0.556	rs2515397	chr2:113819258	T/C	cg21378206	chr2:113817043	IL1F5	-0.4	-6.48	-0.3	2.52e-10	Inflammatory biomarkers;
LUAD	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg05373962	chr22:49881684	NA	-0.49	-11.46	-0.49	1.16e-26	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2279817	0.675	rs1416853	chr1:18024880	G/C	cg21791023	chr1:18019539	ARHGEF10L	0.56	9.44	0.42	2.5e-19	Neuroticism;
LUAD	cis	rs2880765	0.743	rs6497194	chr15:86014116	C/T	cg13263323	chr15:86062960	AKAP13	-0.48	-8.65	-0.39	1.07e-16	Coronary artery disease;
LUAD	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg02158880	chr13:53174818	NA	-0.48	-8.3	-0.37	1.45e-15	Lewy body disease;
LUAD	cis	rs9309473	0.607	rs7567017	chr2:73596270	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-6.87	-0.32	2.36e-11	Metabolite levels;
LUAD	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg06784218	chr1:46089804	CCDC17	0.59	13.18	0.54	1.75e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7289126	1.000	rs7290372	chr22:38628388	T/G	cg25457927	chr22:38595422	NA	-0.43	-10.3	-0.45	2.31e-22	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs3823572	0.564	rs2346276	chr7:133664901	G/T	cg03336402	chr7:133662267	EXOC4	-0.43	-7.76	-0.35	6.28e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg13319975	chr6:146136371	FBXO30	-0.58	-9.73	-0.43	2.48e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10465746	0.901	rs17534614	chr1:84383079	G/A	cg10977910	chr1:84465055	TTLL7	0.49	7.92	0.36	2.16e-14	Obesity-related traits;
LUAD	cis	rs17092148	0.895	rs4417778	chr20:33350987	T/C	cg16810054	chr20:33298113	TP53INP2	-0.52	-8.14	-0.37	4.36e-15	Neuroticism;
LUAD	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg24069376	chr3:38537580	EXOG	0.45	11.0	0.47	6.54e-25	Electrocardiographic conduction measures;
LUAD	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg22875332	chr1:76189707	ACADM	0.61	9.42	0.42	2.88e-19	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12519773	0.526	rs7714485	chr5:92515301	A/C	cg18783429	chr5:92414398	NA	0.44	7.75	0.35	6.95e-14	Migraine;
LUAD	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg25173405	chr17:45401733	C17orf57	-0.59	-10.31	-0.45	2.17e-22	Glaucoma (primary open-angle);
LUAD	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg16989719	chr2:238392110	NA	-0.36	-7.43	-0.34	5.95e-13	Prostate cancer;
LUAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg25324976	chr17:61989376	CSHL1	0.34	6.72	0.31	6.02e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg17200465	chr3:40428508	ENTPD3	0.28	7.18	0.33	3.23e-12	Renal cell carcinoma;
LUAD	cis	rs240764	0.725	rs239193	chr6:101131848	T/C	cg09795085	chr6:101329169	ASCC3	0.43	7.14	0.33	4.1e-12	Neuroticism;
LUAD	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg21304211	chr1:112281877	C1orf183	0.41	6.71	0.31	6.18e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs16958440	0.867	rs79395141	chr18:44695680	A/G	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg20476274	chr7:133979776	SLC35B4	0.55	9.03	0.4	6.03e-18	Mean platelet volume;
LUAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg00280220	chr17:61926910	NA	0.36	7.04	0.32	8.04e-12	Prudent dietary pattern;
LUAD	cis	rs79349575	0.756	rs2291726	chr17:47039254	T/C	cg22482690	chr17:47019901	SNF8	-0.4	-7.7	-0.35	9.81e-14	Type 2 diabetes;
LUAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg11494091	chr17:61959527	GH2	0.73	17.78	0.65	3.27e-53	Prudent dietary pattern;
LUAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg08888203	chr3:10149979	C3orf24	0.73	12.78	0.53	7.21e-32	Alzheimer's disease;
LUAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg11494091	chr17:61959527	GH2	0.75	18.54	0.67	1.39e-56	Prudent dietary pattern;
LUAD	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06505273	chr16:24850292	NA	-0.47	-6.83	-0.32	2.87e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg02423579	chr7:2872169	GNA12	-0.57	-9.65	-0.42	4.67e-20	Height;
LUAD	cis	rs7937890	0.535	rs2575857	chr11:14501296	C/T	cg06199346	chr11:14280333	SPON1	-0.32	-6.43	-0.3	3.42e-10	Mitochondrial DNA levels;
LUAD	cis	rs6490294	0.659	rs737280	chr12:112194976	T/C	cg10833066	chr12:111807467	FAM109A	0.35	6.46	0.3	2.97e-10	Mean platelet volume;
LUAD	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg01475377	chr6:109611718	NA	-0.53	-10.41	-0.45	9.34e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.16e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1561198	0.523	rs2118177	chr2:85890293	A/G	cg02493740	chr2:85810744	VAMP5	-0.43	-7.43	-0.34	5.9e-13	Coronary artery disease;
LUAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg02869364	chr7:1081709	C7orf50	-0.51	-6.67	-0.31	7.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2797160	1.000	rs1739367	chr6:126004720	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-8.89	-0.4	1.78e-17	Endometrial cancer;
LUAD	cis	rs938554	0.744	rs7675964	chr4:9941434	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.81	-0.39	3.32e-17	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01027365	chr2:191184571	HIBCH	-0.58	-7.1	-0.33	5.21e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg05896524	chr21:47604654	C21orf56	0.54	9.05	0.4	5.18e-18	Testicular germ cell tumor;
LUAD	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg02782426	chr3:40428986	ENTPD3	-0.42	-9.26	-0.41	1.06e-18	Renal cell carcinoma;
LUAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.97	0.47	8.47e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg15900387	chr1:150738905	CTSS	-0.35	-6.36	-0.3	5.11e-10	Melanoma;
LUAD	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg06060754	chr5:176797920	RGS14	0.56	10.4	0.45	1.03e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs7779181	1.000	rs12531858	chr7:32340099	G/T	cg13207630	chr7:32358064	NA	0.44	6.9	0.32	1.96e-11	Body mass index;
LUAD	cis	rs2637266	1.000	rs2579746	chr10:78327674	C/T	cg18941641	chr10:78392320	NA	0.32	6.57	0.3	1.5e-10	Pulmonary function;
LUAD	cis	rs2732480	0.577	rs2634681	chr12:48733084	C/T	cg04545296	chr12:48745243	ZNF641	-0.34	-8.88	-0.4	1.96e-17	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg16479474	chr6:28041457	NA	0.38	6.57	0.3	1.51e-10	Parkinson's disease;
LUAD	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.83	0.32	2.93e-11	Hypertriglyceridemia;
LUAD	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg25036284	chr2:26402008	FAM59B	0.83	11.58	0.49	4.07e-27	Gut microbiome composition (summer);
LUAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg07092213	chr7:1199455	ZFAND2A	0.49	8.24	0.37	2.21e-15	Longevity;Endometriosis;
LUAD	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24531977	chr5:56204891	C5orf35	-0.96	-14.69	-0.58	9.31e-40	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.09	0.33	5.6e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.07e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg27490568	chr2:178487706	NA	0.52	7.99	0.36	1.31e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg12193833	chr17:30244370	NA	-0.55	-7.16	-0.33	3.68e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg22535103	chr8:58192502	C8orf71	-0.75	-10.61	-0.46	1.85e-23	Developmental language disorder (linguistic errors);
LUAD	trans	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg21659725	chr3:3221576	CRBN	-0.6	-9.61	-0.42	6.76e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg24399712	chr22:39784796	NA	-0.8	-15.37	-0.6	1.09e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs332507	0.830	rs35816663	chr3:124405513	G/T	cg05980111	chr3:124395277	KALRN	0.45	7.01	0.32	9.57e-12	Plateletcrit;
LUAD	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg19678392	chr7:94953810	PON1	-0.57	-7.78	-0.35	5.51e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg26958806	chr6:27640298	NA	0.66	6.53	0.3	1.94e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.29	0.33	1.54e-12	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg26043149	chr18:55253948	FECH	0.48	7.66	0.35	1.26e-13	Bone mineral density;
LUAD	cis	rs9462027	0.606	rs6906129	chr6:34801160	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.7	-0.39	7.23e-17	Systemic lupus erythematosus;
LUAD	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	9.92	0.43	5.22e-21	Post bronchodilator FEV1;
LUAD	cis	rs7833986	0.534	rs17759244	chr8:57033768	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.97	17.46	0.65	8.22e-52	Height;
LUAD	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.08	-0.33	6.16e-12	Lung cancer;
LUAD	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg14086364	chr5:150678334	SLC36A3	0.59	13.3	0.54	5.65e-34	Skin aging (microtopography measurement);
LUAD	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.36	0.34	9.88e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg07169764	chr2:136633963	MCM6	0.77	9.09	0.4	3.89e-18	Corneal structure;
LUAD	trans	rs7395662	0.609	rs10839190	chr11:48957008	T/C	cg00717180	chr2:96193071	NA	0.36	6.87	0.32	2.36e-11	HDL cholesterol;
LUAD	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg00204512	chr16:28754710	NA	0.33	7.12	0.33	4.52e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg27471124	chr11:109292789	C11orf87	0.34	6.93	0.32	1.61e-11	Schizophrenia;
LUAD	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg10518543	chr12:38710700	ALG10B	0.41	6.41	0.3	3.89e-10	Bladder cancer;
LUAD	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg22868518	chr11:507468	RNH1	-0.69	-6.83	-0.32	3.02e-11	Body mass index;
LUAD	trans	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg21775007	chr8:11205619	TDH	0.39	6.79	0.31	3.8e-11	Mood instability;
LUAD	cis	rs12519773	0.549	rs11738974	chr5:92537336	G/A	cg18783429	chr5:92414398	NA	0.46	8.05	0.36	8.75e-15	Migraine;
LUAD	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.67	-9.52	-0.42	1.4e-19	Gut microbiome composition (summer);
LUAD	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg17063962	chr7:91808500	NA	-0.64	-10.86	-0.47	2.12e-24	Breast cancer;
LUAD	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.54	-8.11	-0.37	5.52e-15	Gut microbiome composition (summer);
LUAD	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg05673287	chr15:77411982	SGK269	0.43	7.52	0.34	3.32e-13	Type 2 diabetes;
LUAD	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg13813247	chr22:41461852	NA	-0.49	-7.97	-0.36	1.52e-14	Neuroticism;
LUAD	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg09117114	chr16:67998030	SLC12A4	-0.51	-6.64	-0.31	9.55e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg19676328	chr12:49525230	TUBA1B	-0.68	-11.31	-0.48	4.38e-26	Total cholesterol levels;
LUAD	cis	rs9788721	1.000	rs10519203	chr15:78814046	C/T	cg18825076	chr15:78729989	IREB2	0.54	8.91	0.4	1.55e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg21963583	chr11:68658836	MRPL21	0.68	12.1	0.51	3.68e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3784262	0.669	rs2197092	chr15:58247781	C/T	cg12031962	chr15:58353849	ALDH1A2	0.37	7.2	0.33	2.82e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00166722	chr3:10149974	C3orf24	0.73	12.65	0.52	2.57e-31	Alzheimer's disease;
LUAD	trans	rs4650994	0.571	rs6676507	chr1:178508743	C/G	cg05059571	chr16:84539110	KIAA1609	0.46	6.92	0.32	1.67e-11	HDL cholesterol levels;HDL cholesterol;
LUAD	trans	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg19862616	chr7:65841803	NCRNA00174	1.05	26.49	0.79	7.26e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg01148728	chr11:117198424	CEP164	-0.38	-6.42	-0.3	3.76e-10	Subcortical brain region volumes;
LUAD	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg06640241	chr16:89574553	SPG7	0.72	13.14	0.54	2.67e-33	Multiple myeloma (IgH translocation);
LUAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg27454412	chr7:1067447	C7orf50	0.43	7.44	0.34	5.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.43	-7.67	-0.35	1.2e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg27411982	chr8:10470053	RP1L1	0.39	6.87	0.32	2.25e-11	Neuroticism;
LUAD	cis	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg14039649	chr22:38352398	POLR2F	0.37	6.62	0.31	1.12e-10	Glioblastoma;Glioma;
LUAD	cis	rs12612619	0.732	rs11897106	chr2:27196299	A/G	cg00617064	chr2:27272375	NA	0.36	6.91	0.32	1.82e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg01148728	chr11:117198424	CEP164	0.42	6.66	0.31	8.75e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26894311	chr10:104153930	NFKB2	-0.67	-6.37	-0.3	4.95e-10	Type 2 diabetes;
LUAD	cis	rs2455799	0.593	rs2062823	chr3:15732256	G/T	cg16303742	chr3:15540471	COLQ	-0.53	-9.83	-0.43	1.12e-20	Mean platelet volume;
LUAD	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg23229984	chr5:148520753	ABLIM3	-0.46	-7.33	-0.34	1.16e-12	Breast cancer;
LUAD	cis	rs1395	0.922	rs4665376	chr2:27509032	T/C	cg23587288	chr2:27483067	SLC30A3	-0.39	-7.55	-0.34	2.69e-13	Blood metabolite levels;
LUAD	trans	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg04775059	chr7:64541387	NA	-0.49	-6.73	-0.31	5.38e-11	Aortic root size;
LUAD	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.85	-0.61	9.96e-45	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-7.39	-0.34	7.98e-13	Schizophrenia;
LUAD	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg24799795	chr11:5959658	NA	0.35	6.92	0.32	1.66e-11	DNA methylation (variation);
LUAD	cis	rs9486719	0.843	rs1009597	chr6:96843540	A/T	cg06623918	chr6:96969491	KIAA0776	0.71	9.3	0.41	7.58e-19	Migraine;Coronary artery disease;
LUAD	cis	rs3823572	0.525	rs2346443	chr7:133706383	C/T	cg03336402	chr7:133662267	EXOC4	-0.42	-7.25	-0.33	2.01e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg02176678	chr2:219576539	TTLL4	-0.76	-15.88	-0.61	6.84e-45	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs7258465	1.000	rs34746918	chr19:18539744	C/T	cg01065977	chr19:18549689	ISYNA1	-0.36	-6.8	-0.31	3.54e-11	Breast cancer;
LUAD	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg05340658	chr4:99064831	C4orf37	0.53	9.02	0.4	6.84e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.6	0.31	1.25e-10	Breast cancer;
LUAD	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.39	6.51	0.3	2.1e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs947211	0.752	rs1572931	chr1:205744218	C/T	cg11965913	chr1:205819406	PM20D1	-0.54	-6.57	-0.3	1.45e-10	Parkinson's disease;
LUAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg14789911	chr21:47582049	C21orf56	0.5	9.07	0.4	4.45e-18	Testicular germ cell tumor;
LUAD	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.47	0.38	4.1e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.36	0.34	9.99e-13	Blood metabolite levels;
LUAD	cis	rs17095355	0.818	rs10884921	chr10:111776248	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.43	-0.34	6.26e-13	Biliary atresia;
LUAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg20607798	chr8:58055168	NA	0.58	7.41	0.34	6.76e-13	Developmental language disorder (linguistic errors);
LUAD	trans	rs12200782	1.000	rs72844496	chr6:26611608	G/A	cg08851530	chr6:28072375	NA	0.72	6.56	0.3	1.6e-10	Small cell lung carcinoma;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26634885	chr17:43209687	PLCD3;ACBD4	-0.54	-6.49	-0.3	2.39e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg02683114	chr2:24398427	C2orf84	0.42	6.5	0.3	2.3e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg10434947	chr21:47706788	C21orf57	-0.39	-6.77	-0.31	4.38e-11	Subcortical brain region volumes;
LUAD	cis	rs500891	0.525	rs12198419	chr6:84105865	A/T	cg08257003	chr6:84140564	ME1	0.33	6.42	0.3	3.56e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs7737355	0.773	rs27450	chr5:131006082	A/G	cg25547332	chr5:131281432	NA	0.42	6.87	0.32	2.28e-11	Life satisfaction;
LUAD	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg23840854	chr1:161414152	NA	-0.86	-11.14	-0.48	1.95e-25	Rheumatoid arthritis;
LUAD	trans	rs877282	0.891	rs34383514	chr10:800181	T/C	cg22713356	chr15:30763199	NA	1.29	18.54	0.67	1.35e-56	Uric acid levels;
LUAD	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.37	7.53	0.34	3.01e-13	Lung cancer in ever smokers;
LUAD	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg11663144	chr21:46675770	NA	-0.62	-12.6	-0.52	4.12e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2657888	0.931	rs2939312	chr12:56932554	G/A	cg23002907	chr12:56915593	RBMS2	0.37	6.74	0.31	5.12e-11	Adiponectin levels;
LUAD	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg26587870	chr6:27730563	NA	-0.49	-8.18	-0.37	3.36e-15	Parkinson's disease;
LUAD	cis	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg08601574	chr20:25228251	PYGB	0.46	8.43	0.38	5.62e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg25767906	chr1:53392781	SCP2	-0.38	-6.9	-0.32	1.86e-11	Monocyte count;
LUAD	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.43e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg24579218	chr15:68104479	NA	-0.52	-9.0	-0.4	8e-18	Restless legs syndrome;
LUAD	trans	rs800082	0.671	rs800099	chr3:144398547	A/T	cg24215973	chr2:240111563	HDAC4	-0.68	-10.71	-0.46	7.84e-24	Smoking behavior;
LUAD	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg18016565	chr1:150552671	MCL1	-0.41	-7.36	-0.34	9.83e-13	Tonsillectomy;
LUAD	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg26441486	chr22:50317300	CRELD2	0.45	6.78	0.31	4.03e-11	Schizophrenia;
LUAD	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-16.36	-0.62	5.58e-47	Schizophrenia;
LUAD	cis	rs1873147	1.000	rs4774469	chr15:63311927	G/A	cg12160578	chr15:63334699	TPM1	-0.35	-6.37	-0.3	4.94e-10	Orofacial clefts;
LUAD	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.8	0.39	3.42e-17	Menopause (age at onset);
LUAD	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg25985355	chr7:65971099	NA	-0.53	-6.53	-0.3	1.87e-10	Diabetic kidney disease;
LUAD	cis	rs490234	0.812	rs4838284	chr9:128446365	G/T	cg14078157	chr9:128172775	NA	-0.46	-8.57	-0.38	1.9e-16	Mean arterial pressure;
LUAD	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg22166914	chr1:53195759	ZYG11B	0.42	7.32	0.34	1.25e-12	Monocyte count;
LUAD	trans	rs1728785	1.000	rs698712	chr16:68561879	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	9.51	0.42	1.44e-19	Ulcerative colitis;
LUAD	cis	rs757081	0.667	rs12577388	chr11:17101155	C/T	cg15432903	chr11:17409602	KCNJ11	-0.4	-6.49	-0.3	2.45e-10	Systolic blood pressure;
LUAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	12.01	0.5	8.66e-29	Prudent dietary pattern;
LUAD	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.46	-8.02	-0.36	1.06e-14	Caffeine consumption;
LUAD	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg02734326	chr4:10020555	SLC2A9	0.61	10.83	0.47	2.68e-24	Bone mineral density;
LUAD	cis	rs853679	0.585	rs201001	chr6:27808899	T/C	cg21204522	chr6:27730016	NA	-0.48	-7.25	-0.33	1.96e-12	Depression;
LUAD	cis	rs7193541	0.684	rs4888264	chr16:74681632	T/G	cg01733217	chr16:74700730	RFWD3	0.68	13.53	0.55	6.68e-35	Multiple myeloma;
LUAD	cis	rs17532515	0.505	rs1430579	chr4:141492685	C/G	cg09181644	chr4:141490428	UCP1	-0.33	-6.91	-0.32	1.83e-11	Select biomarker traits;
LUAD	cis	rs2279817	1.000	rs2354290	chr1:18019861	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.56	9.62	0.42	6.31e-20	Neuroticism;
LUAD	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg26408565	chr15:76604113	ETFA	-0.45	-7.31	-0.33	1.37e-12	Blood metabolite levels;
LUAD	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg04673462	chr1:38461896	NA	0.42	8.17	0.37	3.67e-15	Coronary artery disease;
LUAD	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg07636037	chr3:49044803	WDR6	0.58	9.39	0.42	3.71e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.01	-0.36	1.09e-14	Diabetic kidney disease;
LUAD	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.8	-0.31	3.47e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg01765077	chr12:122356316	WDR66	0.59	10.21	0.44	5.1e-22	Mean corpuscular volume;
LUAD	cis	rs1997103	1.000	rs1997103	chr7:55395390	C/G	cg17469321	chr7:55412551	NA	0.67	11.35	0.48	2.98e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08219700	chr8:58056026	NA	-0.66	-9.17	-0.41	2.09e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.23	-0.33	2.24e-12	Breast cancer;
LUAD	cis	rs4233802	1.000	rs10165225	chr2:151121736	C/T	cg25300694	chr2:151184358	NA	0.77	6.63	0.31	1.04e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg19318889	chr4:1322082	MAEA	-0.41	-6.77	-0.31	4.27e-11	Obesity-related traits;
LUAD	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg10556349	chr10:835070	NA	0.67	7.91	0.36	2.27e-14	Eosinophil percentage of granulocytes;
LUAD	cis	rs2742234	0.541	rs7073849	chr10:43740474	G/C	cg15436174	chr10:43711423	RASGEF1A	0.53	9.1	0.4	3.7e-18	Hirschsprung disease;
LUAD	cis	rs3916	0.911	rs3999408	chr12:121167387	C/T	cg27246729	chr12:121163418	ACADS	0.47	7.71	0.35	9.24e-14	Urinary metabolites (H-NMR features);
LUAD	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg08885076	chr2:99613938	TSGA10	0.37	6.65	0.31	9.32e-11	Chronic sinus infection;
LUAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03760483	chr17:6899297	ALOX12	-0.36	-6.83	-0.32	2.95e-11	Tonsillectomy;
LUAD	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg03859395	chr2:55845619	SMEK2	0.7	12.47	0.52	1.26e-30	Metabolic syndrome;
LUAD	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg01416388	chr22:39784598	NA	-0.53	-8.93	-0.4	1.31e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg26043149	chr18:55253948	FECH	0.48	7.7	0.35	9.82e-14	Bone mineral density;
LUAD	cis	rs4862307	0.836	rs6829678	chr4:185001631	C/T	cg06737308	chr4:185021514	ENPP6	-0.55	-9.03	-0.4	6.36e-18	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs3902035	0.964	rs1891713	chr6:119009564	A/G	cg07617317	chr6:118971624	C6orf204	-0.38	-6.38	-0.3	4.76e-10	QT interval;
LUAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg11062466	chr8:58055876	NA	0.65	8.7	0.39	7.28e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg26513180	chr16:89883248	FANCA	0.65	6.67	0.31	7.99e-11	Skin colour saturation;
LUAD	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.78	0.35	5.45e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.516	rs4640173	chr16:68163602	C/A	cg09835421	chr16:68378352	PRMT7	-0.55	-6.91	-0.32	1.76e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24531977	chr5:56204891	C5orf35	-0.87	-13.12	-0.54	3.26e-33	Initial pursuit acceleration;
LUAD	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg20933634	chr6:27740509	NA	0.43	6.44	0.3	3.24e-10	Parkinson's disease;
LUAD	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.51	-10.68	-0.46	9.44e-24	Monocyte percentage of white cells;
LUAD	cis	rs7683537	0.887	rs7678412	chr4:185648611	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Systemic lupus erythematosus;
LUAD	cis	rs8030485	0.756	rs2102999	chr15:79410710	C/T	cg17916960	chr15:79447300	NA	-0.35	-6.48	-0.3	2.48e-10	Left ventricle wall thickness;
LUAD	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg18252515	chr7:66147081	NA	-0.61	-6.79	-0.31	3.86e-11	Diabetic kidney disease;
LUAD	trans	rs9302065	0.529	rs2992904	chr13:95958173	A/C	cg19955956	chr7:72299837	SBDSP;TYW1B	0.55	9.35	0.41	5.18e-19	Blood metabolite levels;
LUAD	cis	rs7010267	0.596	rs6999476	chr8:120032259	C/G	cg01975934	chr8:119970761	NA	-0.33	-6.43	-0.3	3.48e-10	Total body bone mineral density (age 45-60);
LUAD	trans	rs9393777	0.778	rs13212921	chr6:27205422	C/T	cg06606381	chr12:133084897	FBRSL1	-1.01	-10.43	-0.45	7.84e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg24818145	chr4:99064322	C4orf37	0.45	7.62	0.35	1.65e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg12365402	chr11:9010492	NRIP3	0.47	8.8	0.39	3.52e-17	Hemoglobin concentration;
LUAD	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg02454025	chr1:11042201	C1orf127	1.03	17.37	0.65	2.15e-51	Male-pattern baldness;
LUAD	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg02807482	chr3:125708958	NA	-0.62	-8.38	-0.38	7.71e-16	Blood pressure (smoking interaction);
LUAD	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg18876405	chr7:65276391	NA	-0.42	-6.71	-0.31	6.18e-11	Aortic root size;
LUAD	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg00431813	chr7:1051703	C7orf50	-0.67	-14.08	-0.56	3.38e-37	Longevity;Endometriosis;
LUAD	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg00814883	chr7:100076585	TSC22D4	-0.8	-11.67	-0.49	1.79e-27	Platelet count;
LUAD	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg22823121	chr1:150693482	HORMAD1	0.41	7.96	0.36	1.57e-14	Melanoma;
LUAD	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg04703951	chr17:43578652	NA	-0.56	-8.08	-0.37	6.96e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs35883536	0.647	rs2783696	chr1:101044089	G/A	cg06223162	chr1:101003688	GPR88	0.48	9.28	0.41	8.73e-19	Monocyte count;
LUAD	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg03806693	chr22:41940476	POLR3H	0.56	7.94	0.36	1.89e-14	Vitiligo;
LUAD	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg18833306	chr6:118973337	C6orf204	-0.52	-7.5	-0.34	3.77e-13	Diastolic blood pressure;
LUAD	cis	rs6446731	0.593	rs6446726	chr4:3274214	T/C	cg08886695	chr4:3369023	RGS12	-0.5	-8.38	-0.38	7.72e-16	Mean platelet volume;
LUAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg02136620	chr5:178986620	RUFY1	-0.43	-6.92	-0.32	1.67e-11	Lung cancer;
LUAD	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg18944383	chr4:111397179	ENPEP	0.34	6.62	0.31	1.08e-10	Height;
LUAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg18404041	chr3:52824283	ITIH1	-0.45	-8.55	-0.38	2.26e-16	Electroencephalogram traits;
LUAD	cis	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg06360820	chr2:242988706	NA	-0.93	-9.19	-0.41	1.85e-18	Obesity-related traits;
LUAD	cis	rs6460942	0.915	rs6460907	chr7:12304449	G/A	cg20607287	chr7:12443886	VWDE	-0.44	-6.55	-0.3	1.68e-10	Coronary artery disease;
LUAD	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg22907277	chr7:1156413	C7orf50	0.66	8.0	0.36	1.2e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7651039	0.846	rs2174267	chr3:15645835	T/C	cg16303742	chr3:15540471	COLQ	0.49	8.77	0.39	4.5e-17	Coronary heart disease;
LUAD	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg13732083	chr21:47605072	C21orf56	0.41	6.82	0.31	3.15e-11	Testicular germ cell tumor;
LUAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg11905131	chr22:24372483	LOC391322	-0.57	-9.51	-0.42	1.44e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6499255	1.000	rs4985523	chr16:69797192	T/A	cg15192750	chr16:69999425	NA	0.55	8.58	0.39	1.81e-16	IgE levels;
LUAD	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg14728415	chr7:32535168	LSM5;AVL9	0.62	10.16	0.44	7.69e-22	Cognitive ability;
LUAD	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	trans	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg14791747	chr16:20752902	THUMPD1	-0.44	-6.46	-0.3	2.9e-10	Pancreatic cancer;
LUAD	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.48	-0.34	4.41e-13	Menarche (age at onset);
LUAD	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg08999081	chr20:33150536	PIGU	-0.36	-7.18	-0.33	3.18e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg09365446	chr1:150670422	GOLPH3L	-0.43	-7.24	-0.33	2.14e-12	Tonsillectomy;
LUAD	cis	rs11030122	0.632	rs714380	chr11:4059653	A/T	cg18678763	chr11:4115507	RRM1	-0.45	-7.43	-0.34	5.96e-13	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7707921	0.522	rs9293290	chr5:81474225	A/T	cg15871215	chr5:81402204	ATG10	-0.63	-11.19	-0.48	1.27e-25	Breast cancer;
LUAD	cis	rs11098699	0.821	rs4833891	chr4:124231454	A/G	cg09941581	chr4:124220074	SPATA5	0.45	7.2	0.33	2.83e-12	Mosquito bite size;
LUAD	trans	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.82	-0.31	3.22e-11	Diabetic kidney disease;
LUAD	cis	rs8044995	0.501	rs73613952	chr16:68352808	G/C	cg09835421	chr16:68378352	PRMT7	-1.05	-11.97	-0.5	1.24e-28	Schizophrenia;
LUAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27286337	chr10:134555280	INPP5A	0.73	9.71	0.43	2.92e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1030877	0.515	rs2576735	chr2:105888839	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.43	6.89	0.32	1.99e-11	Obesity-related traits;
LUAD	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg01028140	chr2:1542097	TPO	-0.53	-7.35	-0.34	1.05e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg04851639	chr8:1020857	NA	-0.33	-7.68	-0.35	1.15e-13	Schizophrenia;
LUAD	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-6.56	-0.3	1.54e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg02196655	chr2:10830764	NOL10	0.46	8.39	0.38	7.24e-16	Prostate cancer;
LUAD	cis	rs977987	0.843	rs8056080	chr16:75410798	C/A	cg03315344	chr16:75512273	CHST6	0.64	13.93	0.56	1.43e-36	Dupuytren's disease;
LUAD	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg04450456	chr4:17643702	FAM184B	0.4	8.18	0.37	3.37e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg15595755	chr5:1867978	NA	0.37	6.76	0.31	4.47e-11	Cardiovascular disease risk factors;
LUAD	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg17330251	chr7:94953956	PON1	-0.52	-6.83	-0.32	2.89e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg13148469	chr1:28969864	TAF12	-0.68	-6.48	-0.3	2.6e-10	Type 2 diabetes;
LUAD	trans	rs877282	0.898	rs11253346	chr10:765313	A/G	cg22713356	chr15:30763199	NA	1.27	17.4	0.65	1.56e-51	Uric acid levels;
LUAD	cis	rs9503598	0.636	rs7775474	chr6:3468224	T/C	cg00476032	chr6:3446245	SLC22A23	0.31	6.57	0.3	1.48e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs1950626	0.743	rs12887333	chr14:101462612	C/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.29	0.33	1.49e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg21724239	chr8:58056113	NA	0.62	7.89	0.36	2.54e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs3820068	0.705	rs4646110	chr1:15817318	A/T	cg17177755	chr1:15930204	NA	0.45	6.66	0.31	8.56e-11	Systolic blood pressure;
LUAD	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg15704280	chr7:45808275	SEPT13	-0.66	-10.05	-0.44	1.81e-21	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00166722	chr3:10149974	C3orf24	0.63	10.46	0.45	6.5e-23	Alzheimer's disease;
LUAD	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg21823605	chr1:152486609	CRCT1	0.3	6.85	0.32	2.6e-11	Hair morphology;
LUAD	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg15445000	chr17:37608096	MED1	-0.45	-8.34	-0.38	1.02e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg05623727	chr3:50126028	RBM5	0.31	6.57	0.3	1.48e-10	Body mass index;
LUAD	cis	rs71478720	0.953	rs5744258	chr11:112021767	C/G	cg09122223	chr11:112035175	IL18	0.42	6.55	0.3	1.7e-10	Interleukin-18 levels;
LUAD	cis	rs6500395	1.000	rs28577888	chr16:48673281	T/G	cg04672837	chr16:48644449	N4BP1	0.39	6.77	0.31	4.2e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg27170947	chr2:26402098	FAM59B	-0.83	-11.47	-0.49	1.06e-26	Gut microbiome composition (summer);
LUAD	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg26384229	chr12:38710491	ALG10B	-0.4	-6.93	-0.32	1.58e-11	Heart rate;
LUAD	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg18016565	chr1:150552671	MCL1	0.42	7.76	0.35	6.5e-14	Tonsillectomy;
LUAD	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg03684893	chr10:554711	DIP2C	0.4	6.92	0.32	1.7e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs78487399	0.731	rs13408697	chr2:43706244	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-6.92	-0.32	1.71e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg12863693	chr15:85201151	NMB	0.39	7.17	0.33	3.42e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg06784218	chr1:46089804	CCDC17	-0.53	-11.84	-0.5	3.99e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs736801	0.521	rs41525648	chr5:131827775	A/G	cg21138405	chr5:131827807	IRF1	-0.45	-9.6	-0.42	7.07e-20	Breast cancer;Mosquito bite size;
LUAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg24829409	chr8:58192753	C8orf71	-0.63	-8.09	-0.37	6.49e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs977987	0.843	rs4888372	chr16:75313485	G/A	cg03315344	chr16:75512273	CHST6	0.6	12.85	0.53	3.96e-32	Dupuytren's disease;
LUAD	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg18827107	chr12:86230957	RASSF9	-0.7	-12.99	-0.53	1.05e-32	Major depressive disorder;
LUAD	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg10909506	chr17:38081995	ORMDL3	0.37	6.58	0.3	1.38e-10	Self-reported allergy;
LUAD	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-11.0	-0.47	6.19e-25	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg03929089	chr4:120376271	NA	-0.92	-17.61	-0.65	1.82e-52	Height;
LUAD	cis	rs250585	0.736	rs250559	chr16:23452824	G/A	cg00143387	chr16:23521605	GGA2	0.62	9.01	0.4	7.09e-18	Egg allergy;
LUAD	cis	rs6484504	0.576	rs158140	chr11:31212971	T/C	cg06552810	chr11:31128660	NA	-0.32	-6.38	-0.3	4.77e-10	Red blood cell count;
LUAD	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.47	0.3	2.64e-10	Breast cancer;
LUAD	cis	rs68170813	0.641	rs12538848	chr7:106984569	G/T	cg23024343	chr7:107201750	COG5	0.46	6.74	0.31	5.2e-11	Coronary artery disease;
LUAD	cis	rs6840360	0.554	rs58751443	chr4:152709905	A/G	cg22705602	chr4:152727874	NA	-0.46	-9.09	-0.4	3.77e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	7.1	0.33	5.39e-12	Rheumatoid arthritis;
LUAD	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg21214613	chr1:16344536	HSPB7	0.6	11.59	0.49	3.61e-27	Dilated cardiomyopathy;
LUAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs78761021	0.867	rs62067561	chr17:9785912	C/T	cg26853458	chr17:9805074	RCVRN	0.37	7.42	0.34	6.6e-13	Type 2 diabetes;
LUAD	cis	rs7932354	0.502	rs10769233	chr11:47072655	T/C	cg19486271	chr11:47235900	DDB2	-0.46	-7.28	-0.33	1.6e-12	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg15691649	chr6:25882328	NA	-0.45	-7.06	-0.32	6.69e-12	Blood metabolite levels;
LUAD	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg18230493	chr5:56204884	C5orf35	-0.69	-11.01	-0.47	5.86e-25	Initial pursuit acceleration;
LUAD	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg12935359	chr14:103987150	CKB	0.45	6.98	0.32	1.14e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg11814155	chr7:99998594	ZCWPW1	0.4	6.47	0.3	2.68e-10	Platelet count;
LUAD	cis	rs6500395	1.000	rs11643264	chr16:48558462	A/G	cg04672837	chr16:48644449	N4BP1	0.38	6.71	0.31	6.4e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg17724175	chr1:150552817	MCL1	0.39	9.4	0.42	3.42e-19	Tonsillectomy;
LUAD	cis	rs9644630	0.696	rs7828025	chr8:19314693	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.35	6.54	0.3	1.74e-10	Oropharynx cancer;
LUAD	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg10755058	chr3:40428713	ENTPD3	0.38	7.46	0.34	4.98e-13	Renal cell carcinoma;
LUAD	cis	rs9462027	0.628	rs9469909	chr6:34813077	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.84	-0.39	2.61e-17	Systemic lupus erythematosus;
LUAD	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg04111992	chr7:158790115	NA	-0.39	-6.55	-0.3	1.69e-10	Facial morphology (factor 20);
LUAD	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg15445000	chr17:37608096	MED1	0.43	7.72	0.35	8.27e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.77	0.31	4.27e-11	Parkinson's disease;
LUAD	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg24399712	chr22:39784796	NA	-0.82	-15.92	-0.61	4.72e-45	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24531977	chr5:56204891	C5orf35	-1.0	-15.19	-0.59	6.67e-42	Initial pursuit acceleration;
LUAD	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg09455208	chr3:40491958	NA	0.59	12.83	0.53	4.63e-32	Renal cell carcinoma;
LUAD	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	6.64	0.31	9.66e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9296092	0.560	rs3846853	chr6:33528194	C/G	cg13560919	chr6:33536144	NA	-0.9	-16.72	-0.63	1.49e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg00898013	chr13:113819073	PROZ	0.58	10.59	0.46	2.1e-23	Platelet distribution width;
LUAD	cis	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg08601574	chr20:25228251	PYGB	-0.45	-8.21	-0.37	2.73e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg04305134	chr10:75173374	ANXA7	-0.39	-6.65	-0.31	9.1e-11	Subcortical brain region volumes;
LUAD	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10802521	chr3:52805072	NEK4	-0.51	-9.02	-0.4	6.75e-18	Bipolar disorder;
LUAD	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg11645453	chr3:52864694	ITIH4	-0.39	-7.57	-0.35	2.44e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs877282	0.898	rs11253352	chr10:766598	C/A	cg06581033	chr10:766294	NA	-0.57	-7.74	-0.35	7.42e-14	Uric acid levels;
LUAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-10.39	-0.45	1.11e-22	Lymphocyte counts;
LUAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg22963979	chr7:1858916	MAD1L1	-0.68	-12.17	-0.51	2.08e-29	Bipolar disorder and schizophrenia;
LUAD	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg19413350	chr8:57351067	NA	-0.42	-6.7	-0.31	6.48e-11	Obesity-related traits;
LUAD	cis	rs10489202	1.000	rs1846416	chr1:167905411	G/A	cg24449463	chr1:168025552	DCAF6	-0.56	-7.33	-0.34	1.19e-12	Schizophrenia;
LUAD	cis	rs9863	0.931	rs11831913	chr12:124446898	T/C	cg17723958	chr12:124429295	CCDC92	-0.43	-6.91	-0.32	1.75e-11	White blood cell count;
LUAD	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg16950941	chr11:66035639	RAB1B	0.46	7.73	0.35	7.86e-14	Gout;
LUAD	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg14829155	chr15:31115871	NA	-0.58	-9.5	-0.42	1.56e-19	Huntington's disease progression;
LUAD	cis	rs2932538	0.922	rs7527076	chr1:113150481	G/A	cg22162597	chr1:113214053	CAPZA1	0.46	6.92	0.32	1.67e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11644478	chr21:40555479	PSMG1	0.7	11.81	0.5	5.1e-28	Cognitive function;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg02249930	chr10:70166207	RUFY2	0.4	6.38	0.3	4.64e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg21280719	chr6:42927975	GNMT	-0.35	-10.99	-0.47	7.14e-25	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg11707310	chr1:2537719	MMEL1	-0.4	-8.61	-0.39	1.51e-16	Ulcerative colitis;
LUAD	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg03806693	chr22:41940476	POLR3H	0.54	7.9	0.36	2.36e-14	Vitiligo;
LUAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.34	-6.43	-0.3	3.51e-10	Longevity;Endometriosis;
LUAD	trans	rs8002861	0.846	rs12428314	chr13:44476011	C/T	cg17145862	chr1:211918768	LPGAT1	-0.67	-14.04	-0.56	4.8e-37	Leprosy;
LUAD	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25427524	chr10:38739819	LOC399744	-0.77	-14.8	-0.58	3.03e-40	Extrinsic epigenetic age acceleration;
LUAD	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg16322792	chr1:120165303	ZNF697	0.72	19.35	0.69	3.24e-60	Systemic lupus erythematosus;
LUAD	cis	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg07460842	chr6:66804631	NA	1.04	16.32	0.62	8.24e-47	Exhaled nitric oxide output;
LUAD	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg21918786	chr6:109611834	NA	-0.6	-11.14	-0.48	1.86e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs3739034	0.823	rs17321713	chr2:135480363	C/T	cg12500956	chr2:135428796	TMEM163	0.37	6.79	0.31	3.71e-11	Gut microbiome composition (winter);
LUAD	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg16329197	chr12:53359506	NA	-0.84	-14.15	-0.57	1.71e-37	Cancer (pleiotropy);
LUAD	cis	rs7771547	0.603	rs6913530	chr6:36598209	A/G	cg02952361	chr6:36355661	ETV7	-0.47	-6.42	-0.3	3.64e-10	Platelet distribution width;
LUAD	cis	rs9902453	0.838	rs9646437	chr17:28209065	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.92	0.4	1.41e-17	Coffee consumption (cups per day);
LUAD	cis	rs68170813	0.559	rs2395880	chr7:107074264	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-10.76	-0.46	5.12e-24	Coronary artery disease;
LUAD	cis	rs73206853	0.764	rs970228	chr12:111070169	G/C	cg12870014	chr12:110450643	ANKRD13A	0.62	7.13	0.33	4.29e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg07211511	chr3:129823064	LOC729375	-0.84	-12.28	-0.51	7.3e-30	Blood pressure (smoking interaction);
LUAD	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg05342682	chr7:94953680	PON1	-0.52	-7.43	-0.34	6.16e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.61	-10.2	-0.44	5.5e-22	Glomerular filtration rate;
LUAD	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg02018176	chr4:1364513	KIAA1530	0.48	8.81	0.39	3.17e-17	Longevity;
LUAD	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg16262614	chr3:133464971	TF	0.42	8.54	0.38	2.5e-16	Iron status biomarkers (transferrin levels);
LUAD	trans	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg18335740	chr13:41363409	SLC25A15	0.49	8.6	0.39	1.57e-16	Lewy body disease;
LUAD	cis	rs7833986	0.534	rs2667980	chr8:56896541	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	14.57	0.58	2.96e-39	Height;
LUAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg14926445	chr8:58193284	C8orf71	-0.48	-7.05	-0.32	7.13e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6942407	0.546	rs3747807	chr7:86800351	A/G	cg02420886	chr7:86849541	C7orf23	0.61	7.18	0.33	3.08e-12	Food allergy;
LUAD	cis	rs1816752	0.870	rs9318529	chr13:24998328	A/G	cg02811702	chr13:24901961	NA	0.41	7.27	0.33	1.72e-12	Obesity-related traits;
LUAD	cis	rs11696501	0.793	rs1883520	chr20:44130777	T/C	cg11783356	chr20:44313418	WFDC10B	-0.46	-7.15	-0.33	3.84e-12	Brain structure;
LUAD	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg14728415	chr7:32535168	LSM5;AVL9	0.62	10.2	0.44	5.32e-22	Cognitive ability;
LUAD	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg26384229	chr12:38710491	ALG10B	0.52	8.54	0.38	2.47e-16	Heart rate;
LUAD	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg09904177	chr6:26538194	HMGN4	0.41	6.84	0.32	2.73e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg26408565	chr15:76604113	ETFA	-0.45	-7.71	-0.35	9.22e-14	Blood metabolite levels;
LUAD	cis	rs11209185	0.509	rs9436789	chr1:68441456	G/A	cg22082780	chr1:68452167	NA	0.5	10.51	0.46	3.9699999999999997e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg15147215	chr3:52552868	STAB1	-0.42	-7.48	-0.34	4.46e-13	Bipolar disorder;
LUAD	cis	rs72634258	0.519	rs744001	chr1:7934557	G/A	cg26816564	chr1:7831052	VAMP3	0.61	8.35	0.38	9.83e-16	Inflammatory bowel disease;
LUAD	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg21427119	chr20:30132790	HM13	-0.5	-7.98	-0.36	1.4e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg09367891	chr1:107599246	PRMT6	0.58	9.74	0.43	2.24e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg06547715	chr2:218990976	CXCR2	0.28	6.68	0.31	7.35e-11	Colorectal cancer;
LUAD	cis	rs68170813	0.617	rs7797791	chr7:107197222	T/C	cg23024343	chr7:107201750	COG5	0.55	6.7	0.31	6.5500000000000006e-11	Coronary artery disease;
LUAD	cis	rs7731657	0.510	rs11748136	chr5:130343725	G/C	cg08523029	chr5:130500466	HINT1	0.59	7.79	0.35	5.38e-14	Fasting plasma glucose;
LUAD	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg19635926	chr16:89946313	TCF25	0.74	6.55	0.3	1.7e-10	Skin colour saturation;
LUAD	trans	rs1493916	0.967	rs34341086	chr18:31400141	C/T	cg27147174	chr7:100797783	AP1S1	-0.66	-11.37	-0.48	2.57e-26	Life satisfaction;
LUAD	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg22467129	chr15:76604101	ETFA	-0.49	-8.5	-0.38	3.2e-16	Blood metabolite levels;
LUAD	cis	rs2455799	0.573	rs2062824	chr3:15757901	T/C	cg16303742	chr3:15540471	COLQ	-0.51	-9.38	-0.41	4.18e-19	Mean platelet volume;
LUAD	cis	rs5771069	0.896	rs137862	chr22:50446550	C/A	cg27467552	chr22:50353597	PIM3	-0.46	-8.39	-0.38	7.25e-16	Ulcerative colitis;
LUAD	cis	rs17532515	0.652	rs1346927	chr4:141388975	T/C	cg03645522	chr4:141391200	NA	0.41	6.66	0.31	8.74e-11	Select biomarker traits;
LUAD	cis	rs7178572	0.524	rs1473922	chr15:77656798	G/T	cg15453836	chr15:77711506	NA	-0.37	-6.54	-0.3	1.76e-10	Type 2 diabetes;
LUAD	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg21475434	chr5:93447410	FAM172A	0.58	7.39	0.34	8.07e-13	Diabetic retinopathy;
LUAD	cis	rs7010267	0.740	rs6993910	chr8:119950781	C/T	cg01975934	chr8:119970761	NA	0.36	6.9	0.32	1.86e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg00666640	chr1:248458726	OR2T12	0.3	7.22	0.33	2.47e-12	Common traits (Other);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07700258	chr1:228327729	GUK1	-0.65	-6.41	-0.3	3.86e-10	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg26043149	chr18:55253948	FECH	0.44	7.26	0.33	1.81e-12	Bone mineral density;
LUAD	trans	rs7200543	1.000	rs35574015	chr16:15146061	T/C	cg24683922	chr1:11983373	KIAA2013	-0.48	-7.94	-0.36	1.9e-14	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg23815491	chr16:72088622	HP	-0.4	-7.1	-0.33	5.32e-12	Prostate cancer;
LUAD	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg00933542	chr6:150070202	PCMT1	0.46	9.97	0.44	3.54e-21	Lung cancer;
LUAD	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.48	-0.3	2.52e-10	Aortic root size;
LUAD	cis	rs1073160	1.000	rs1073160	chr12:9058562	A/G	cg04155231	chr12:9217510	LOC144571	-0.36	-6.77	-0.31	4.42e-11	Small cell lung carcinoma;
LUAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg07685180	chr8:600429	NA	1.0	9.41	0.42	3.33e-19	IgG glycosylation;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg00280761	chr22:19132003	DGCR14	0.39	6.61	0.31	1.19e-10	Bipolar disorder;
LUAD	trans	rs9354308	0.901	rs12197136	chr6:66590953	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.52	7.7	0.35	9.56e-14	Metabolite levels;
LUAD	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg20503657	chr10:835505	NA	0.77	12.03	0.5	6.99e-29	Eosinophil percentage of granulocytes;
LUAD	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg22166914	chr1:53195759	ZYG11B	0.4	6.6	0.31	1.26e-10	Monocyte count;
LUAD	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	8.12	0.37	5e-15	Tonsillectomy;
LUAD	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg03806693	chr22:41940476	POLR3H	-0.77	-10.21	-0.44	5e-22	Vitiligo;
LUAD	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.91	0.36	2.29e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg04568274	chr7:158649319	WDR60	-0.44	-6.77	-0.31	4.44e-11	Height;
LUAD	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg07570687	chr10:102243282	WNT8B	0.43	6.53	0.3	1.86e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg05082376	chr22:42548792	NA	-0.39	-6.95	-0.32	1.38e-11	Cognitive function;
LUAD	trans	rs11039798	0.920	rs116109043	chr11:48976940	C/T	cg02254774	chr11:50257496	LOC441601	0.52	6.56	0.3	1.62e-10	Axial length;
LUAD	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg13870426	chr17:30244630	NA	-0.56	-6.62	-0.31	1.12e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg18016565	chr1:150552671	MCL1	-0.4	-6.95	-0.32	1.36e-11	Tonsillectomy;
LUAD	trans	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg04775059	chr7:64541387	NA	-0.5	-6.93	-0.32	1.62e-11	Aortic root size;
LUAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08677398	chr8:58056175	NA	0.47	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg22963979	chr7:1858916	MAD1L1	-0.48	-7.98	-0.36	1.38e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.49	7.73	0.35	8.17e-14	Total body bone mineral density;
LUAD	cis	rs713477	0.935	rs4901567	chr14:55912698	C/T	cg13175173	chr14:55914753	NA	-0.34	-7.09	-0.33	5.67e-12	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg03909863	chr11:638404	DRD4	-0.47	-6.51	-0.3	2.1e-10	Systemic lupus erythematosus;
LUAD	cis	rs758324	0.504	rs55764014	chr5:131170905	G/T	cg06307176	chr5:131281290	NA	0.45	7.44	0.34	5.55e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg01206211	chr2:36825736	FEZ2	0.66	13.62	0.55	2.9e-35	Height;
LUAD	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.45	-0.34	5.36e-13	Type 2 diabetes;
LUAD	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.43	0.34	6.13e-13	Rheumatoid arthritis;
LUAD	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg26384229	chr12:38710491	ALG10B	0.46	7.49	0.34	4.17e-13	Bladder cancer;
LUAD	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg05043794	chr9:111880884	C9orf5	-0.44	-7.48	-0.34	4.23e-13	Menarche (age at onset);
LUAD	cis	rs8067545	0.750	rs4925072	chr17:19956899	C/T	cg04132472	chr17:19861366	AKAP10	-0.27	-6.52	-0.3	2.03e-10	Schizophrenia;
LUAD	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg11502198	chr6:26597334	ABT1	0.54	9.1	0.4	3.68e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg06263672	chr7:65235340	NA	-0.47	-6.4	-0.3	4.15e-10	Aortic root size;
LUAD	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg17346650	chr17:80929145	B3GNTL1	0.39	6.77	0.31	4.39e-11	Glycated hemoglobin levels;
LUAD	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg10523679	chr1:76189770	ACADM	-0.72	-11.47	-0.49	1.02e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs28712821	0.930	rs11940694	chr4:39414993	C/T	cg12062995	chr4:39368212	RFC1	-0.46	-7.59	-0.35	2.03e-13	Alcohol consumption;
LUAD	cis	rs7040024	0.716	rs10815892	chr9:859401	G/A	cg14021170	chr9:826657	NA	-0.43	-6.61	-0.31	1.17e-10	Testicular germ cell tumor;Testicular cancer;
LUAD	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg05373962	chr22:49881684	NA	-0.57	-13.84	-0.56	3.35e-36	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg14092988	chr3:52407081	DNAH1	0.39	7.85	0.36	3.56e-14	Bipolar disorder;
LUAD	cis	rs7903847	0.619	rs9888116	chr10:99159482	G/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.66	-0.35	1.24e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg25237894	chr2:233734115	C2orf82	-0.61	-11.64	-0.49	2.35e-27	Coronary artery disease;
LUAD	cis	rs7107174	1.000	rs10899474	chr11:78043636	T/C	cg19901956	chr11:77921274	USP35	-0.49	-6.44	-0.3	3.16e-10	Testicular germ cell tumor;
LUAD	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg22823121	chr1:150693482	HORMAD1	0.47	9.3	0.41	7.48e-19	Melanoma;
LUAD	cis	rs11051970	0.679	rs2651366	chr12:32560431	T/C	cg02745156	chr12:32552066	NA	0.31	6.79	0.31	3.73e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6005807	0.719	rs73430118	chr22:28913950	C/T	cg12565055	chr22:29076175	TTC28	0.75	8.6	0.39	1.54e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05714926	chr2:166810417	TTC21B	-0.4	-6.64	-0.31	9.7e-11	Cancer;
LUAD	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.4	8.05	0.36	8.72e-15	Platelet count;
LUAD	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg06046430	chr4:77819534	ANKRD56	0.53	8.59	0.39	1.66e-16	Emphysema distribution in smoking;
LUAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.5e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs12216545	0.737	rs7788188	chr7:150226669	G/A	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.7	-0.31	6.68e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg23281280	chr6:28129359	ZNF389	-0.47	-6.72	-0.31	5.76e-11	Depression;
LUAD	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg02493740	chr2:85810744	VAMP5	-0.4	-7.18	-0.33	3.08e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg10523679	chr1:76189770	ACADM	0.79	11.9	0.5	2.27e-28	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg00074818	chr8:8560427	CLDN23	-0.62	-9.45	-0.42	2.31e-19	Obesity-related traits;
LUAD	cis	rs870825	0.616	rs28649620	chr4:185648997	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg09263875	chr16:632152	PIGQ	0.81	17.39	0.65	1.66e-51	Height;
LUAD	trans	rs1728785	0.681	rs4783647	chr16:68558048	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-9.4	-0.42	3.41e-19	Ulcerative colitis;
LUAD	cis	rs12505328	0.898	rs2119791	chr4:174381632	A/T	cg12145043	chr4:174357286	NA	0.49	8.53	0.38	2.6e-16	Chin dimples;
LUAD	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg13271783	chr10:134563150	INPP5A	-0.41	-6.4	-0.3	4.03e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg03806693	chr22:41940476	POLR3H	0.58	8.54	0.38	2.42e-16	Vitiligo;
LUAD	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	15.84	0.61	1.02e-44	Bone mineral density;
LUAD	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg23950597	chr19:37808831	NA	-0.65	-7.63	-0.35	1.61e-13	Coronary artery calcification;
LUAD	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.71	0.31	6.08e-11	Depression;
LUAD	cis	rs4321325	0.733	rs74707659	chr2:127945469	T/C	cg11380483	chr2:127933992	NA	0.5	6.52	0.3	2.05e-10	Protein C levels;
LUAD	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg12908607	chr1:44402522	ARTN	-0.45	-8.95	-0.4	1.1e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.48	-0.3	2.55e-10	Depression;
LUAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg18402987	chr7:1209562	NA	0.8	9.76	0.43	1.92e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg03690763	chr11:133734501	NA	-0.35	-8.38	-0.38	7.92e-16	Childhood ear infection;
LUAD	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg00074818	chr8:8560427	CLDN23	-0.63	-9.35	-0.41	5.14e-19	Obesity-related traits;
LUAD	cis	rs669446	0.562	rs11210907	chr1:44191759	C/T	cg12908607	chr1:44402522	ARTN	-0.35	-7.12	-0.33	4.64e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	trans	rs7395662	0.963	rs60772766	chr11:48721011	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.24	-0.33	2.12e-12	HDL cholesterol;
LUAD	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg26597838	chr10:835615	NA	-0.78	-10.86	-0.47	2.2e-24	Eosinophil percentage of granulocytes;
LUAD	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg00898013	chr13:113819073	PROZ	-0.65	-11.74	-0.5	9.38e-28	Platelet distribution width;
LUAD	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg22166914	chr1:53195759	ZYG11B	-0.51	-8.82	-0.39	2.94e-17	Monocyte count;
LUAD	trans	rs66573146	1.000	rs55913461	chr4:7017509	C/T	cg07817883	chr1:32538562	TMEM39B	1.51	12.54	0.52	6.81e-31	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg24397884	chr7:158709396	WDR60	0.66	9.02	0.4	6.54e-18	Height;
LUAD	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg24578937	chr1:2090814	PRKCZ	0.78	16.33	0.62	7.67e-47	Height;
LUAD	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg13319975	chr6:146136371	FBXO30	-0.55	-9.38	-0.41	4.03e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11677370	0.561	rs10191326	chr2:3827524	G/C	cg17052675	chr2:3827356	NA	-0.64	-10.65	-0.46	1.23e-23	Type 2 diabetes;
LUAD	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.38	6.41	0.3	3.84e-10	Rheumatoid arthritis;
LUAD	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg06740227	chr12:86229804	RASSF9	0.44	7.66	0.35	1.25e-13	Major depressive disorder;
LUAD	cis	rs9372498	0.536	rs10484286	chr6:118956447	T/C	cg18833306	chr6:118973337	C6orf204	-0.55	-7.61	-0.35	1.84e-13	Diastolic blood pressure;
LUAD	cis	rs2235649	0.663	rs12596160	chr16:1848784	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.43	-6.84	-0.32	2.82e-11	Blood metabolite levels;
LUAD	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg08859206	chr1:53392774	SCP2	-0.47	-8.69	-0.39	7.93e-17	Monocyte count;
LUAD	cis	rs2996428	0.561	rs72640913	chr1:3747023	C/G	cg13057898	chr1:3703894	LRRC47	0.56	9.69	0.43	3.43e-20	Red cell distribution width;
LUAD	cis	rs938554	0.736	rs11734219	chr4:9977154	C/T	cg00071950	chr4:10020882	SLC2A9	0.53	8.24	0.37	2.24e-15	Blood metabolite levels;
LUAD	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg03733263	chr8:22462867	KIAA1967	0.64	10.82	0.47	2.97e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg12193833	chr17:30244370	NA	-0.5	-6.57	-0.3	1.51e-10	Hip circumference adjusted for BMI;
LUAD	trans	rs2235573	0.625	rs10427673	chr22:38427551	G/C	cg19894588	chr14:64061835	NA	0.44	6.81	0.31	3.26e-11	Glioblastoma;Glioma;
LUAD	cis	rs877282	1.000	rs12775643	chr10:773242	G/A	cg06581033	chr10:766294	NA	-0.48	-6.82	-0.31	3.23e-11	Uric acid levels;
LUAD	cis	rs12681287	0.752	rs1436628	chr8:87313345	C/G	cg27223183	chr8:87520930	FAM82B	0.61	8.38	0.38	8.04e-16	Caudate activity during reward;
LUAD	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg04414720	chr1:150670196	GOLPH3L	-0.5	-8.34	-0.38	1.05e-15	Tonsillectomy;
LUAD	trans	rs3857536	0.776	rs1002764	chr6:66945760	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg05340658	chr4:99064831	C4orf37	-0.45	-7.53	-0.34	3.07e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.19	0.54	1.67e-33	Prudent dietary pattern;
LUAD	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg23172400	chr8:95962367	TP53INP1	-0.3	-6.91	-0.32	1.74e-11	Type 2 diabetes;
LUAD	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg00933542	chr6:150070202	PCMT1	0.44	9.62	0.42	6.29e-20	Lung cancer;
LUAD	cis	rs6426558	0.537	rs4351610	chr1:227325245	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.55	-8.93	-0.4	1.3e-17	Neutrophil percentage of white cells;
LUAD	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	9.58	0.42	8.07e-20	Colorectal cancer;
LUAD	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg08493051	chr2:3487164	NA	-0.45	-7.81	-0.35	4.63e-14	Neurofibrillary tangles;
LUAD	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg09509183	chr1:209979624	IRF6	0.38	6.65	0.31	9.34e-11	Monobrow;
LUAD	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg10518543	chr12:38710700	ALG10B	-0.48	-7.69	-0.35	1.02e-13	Morning vs. evening chronotype;
LUAD	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg25233709	chr10:116636983	FAM160B1	0.43	8.6	0.39	1.54e-16	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg19774624	chr17:42201019	HDAC5	-0.39	-6.66	-0.31	8.5e-11	Total body bone mineral density;
LUAD	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg06064525	chr11:970664	AP2A2	-0.55	-11.27	-0.48	6.09e-26	Alzheimer's disease (late onset);
LUAD	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg02775129	chr4:119771670	NA	-0.78	-7.95	-0.36	1.74e-14	Cannabis dependence symptom count;
LUAD	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg27535305	chr1:53392650	SCP2	0.36	7.39	0.34	7.85e-13	Monocyte count;
LUAD	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	trans	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.26	0.45	3.25e-22	Mean corpuscular volume;
LUAD	cis	rs7582720	1.000	rs74421437	chr2:203831252	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6684514	0.922	rs12128785	chr1:156269389	A/G	cg16558208	chr1:156270281	VHLL	0.53	9.65	0.42	4.74e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs3739034	0.938	rs730946	chr2:135465249	C/G	cg12500956	chr2:135428796	TMEM163	0.33	6.36	0.3	5.3e-10	Gut microbiome composition (winter);
LUAD	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg09359103	chr1:154839909	KCNN3	-0.91	-21.24	-0.72	1.09e-68	Prostate cancer;
LUAD	cis	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg07460842	chr6:66804631	NA	-0.7	-9.71	-0.43	2.98e-20	Exhaled nitric oxide output;
LUAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg06532163	chr17:45867833	NA	0.47	8.36	0.38	8.93e-16	IgG glycosylation;
LUAD	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg11663144	chr21:46675770	NA	-0.62	-12.41	-0.52	2.26e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2224391	0.656	rs68007503	chr6:5292616	G/A	cg26704043	chr6:5282702	FARS2	0.39	6.38	0.3	4.71e-10	Height;
LUAD	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg14835575	chr10:16859367	RSU1	0.49	7.39	0.34	8.08e-13	Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35740288	0.770	rs11631386	chr15:86191995	A/G	cg13263323	chr15:86062960	AKAP13	-0.44	-7.1	-0.33	5.14e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs7017914	0.869	rs11987511	chr8:71645871	C/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs315934	0.664	rs1665186	chr2:113852338	T/C	cg09040174	chr2:113837401	NA	-0.62	-7.43	-0.34	6.15e-13	Dysmenorrheic pain;
LUAD	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21659725	chr3:3221576	CRBN	0.7	11.49	0.49	8.54e-27	Resting heart rate;
LUAD	cis	rs751728	0.605	rs1535950	chr6:33785827	A/G	cg13859433	chr6:33739653	LEMD2	-0.31	-6.42	-0.3	3.61e-10	Crohn's disease;
LUAD	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg19622623	chr12:86230825	RASSF9	-0.55	-9.95	-0.44	4.23e-21	Major depressive disorder;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17265073	chr10:38265539	ZNF25	-0.39	-6.49	-0.3	2.37e-10	Cancer;
LUAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg21724239	chr8:58056113	NA	0.72	9.35	0.41	5.22e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7116495	1.000	rs4945434	chr11:71759087	A/G	cg07596299	chr11:71824057	C11orf51	0.78	6.69	0.31	7.05e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs1723838	0.510	rs2471904	chr11:73690599	G/A	cg10064339	chr11:73693792	UCP2	1.34	10.89	0.47	1.67e-24	Obesity-related traits;
LUAD	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg09904177	chr6:26538194	HMGN4	0.42	6.92	0.32	1.68e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.19	0.33	2.87e-12	Platelet count;
LUAD	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg20476274	chr7:133979776	SLC35B4	0.84	17.09	0.64	3.63e-50	Mean platelet volume;
LUAD	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.25	-0.37	2.02e-15	Total body bone mineral density;
LUAD	cis	rs57590327	0.503	rs9880844	chr3:81507217	C/T	cg07356753	chr3:81810745	GBE1	0.48	7.59	0.35	2e-13	Extraversion;
LUAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg21733973	chr7:65235735	NA	-0.51	-8.2	-0.37	2.81e-15	Calcium levels;
LUAD	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg13722127	chr7:150037890	RARRES2	0.44	7.62	0.35	1.69e-13	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg03929089	chr4:120376271	NA	0.56	6.41	0.3	3.9e-10	Axial length;
LUAD	cis	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg27411982	chr8:10470053	RP1L1	0.41	7.64	0.35	1.44e-13	Neuroticism;
LUAD	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg24088639	chr11:34937564	PDHX;APIP	0.43	7.07	0.33	6.42e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.51	8.61	0.39	1.51e-16	Electrocardiographic conduction measures;
LUAD	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg20476274	chr7:133979776	SLC35B4	0.84	16.21	0.62	2.71e-46	Mean platelet volume;
LUAD	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	6.59	0.31	1.29e-10	Aortic root size;
LUAD	cis	rs2652834	1.000	rs2729833	chr15:63397044	G/A	cg25406657	chr15:63342033	TPM1	-0.42	-6.68	-0.31	7.53e-11	HDL cholesterol;
LUAD	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg18129178	chr5:148520854	ABLIM3	-0.64	-9.81	-0.43	1.35e-20	Breast cancer;
LUAD	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.39	6.36	0.3	5.26e-10	Total body bone mineral density;
LUAD	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg18944383	chr4:111397179	ENPEP	0.34	6.8	0.31	3.66e-11	Coronary artery disease;
LUAD	cis	rs2274273	1.000	rs10140857	chr14:55619611	G/C	cg04306507	chr14:55594613	LGALS3	0.35	7.07	0.32	6.64e-12	Protein biomarker;
LUAD	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg26587870	chr6:27730563	NA	-0.69	-7.38	-0.34	8.29e-13	Depression;
LUAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.52	-9.38	-0.41	4.07e-19	Lymphocyte counts;
LUAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.54	0.55	5.99e-35	Prudent dietary pattern;
LUAD	cis	rs7903847	0.642	rs1537645	chr10:99149914	T/C	cg20016023	chr10:99160130	RRP12	-0.31	-7.42	-0.34	6.64e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.8	-0.5	5.61e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg05991184	chr2:219186017	PNKD	-0.38	-7.43	-0.34	5.91e-13	Colorectal cancer;
LUAD	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg14343924	chr8:8086146	FLJ10661	-0.4	-6.35	-0.3	5.5e-10	Neuroticism;
LUAD	trans	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg07923666	chr12:49932857	KCNH3	-0.5	-6.42	-0.3	3.76e-10	Resting heart rate;
LUAD	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg09904177	chr6:26538194	HMGN4	0.43	7.18	0.33	3.25e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg16988262	chr1:15930761	NA	0.41	6.87	0.32	2.34e-11	Systolic blood pressure;
LUAD	cis	rs2692947	0.770	rs2579552	chr2:96737083	A/G	cg23100626	chr2:96804247	ASTL	0.35	8.83	0.39	2.83e-17	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg06640241	chr16:89574553	SPG7	0.47	7.88	0.36	2.74e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg23262073	chr20:60523788	NA	0.38	6.61	0.31	1.17e-10	Body mass index;
LUAD	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg05313129	chr8:58192883	C8orf71	-0.57	-8.11	-0.37	5.7e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg04234412	chr22:24373322	LOC391322	-0.84	-15.84	-0.61	1.05e-44	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs62064224	0.675	rs4795693	chr17:30636727	A/G	cg25809561	chr17:30822961	MYO1D	0.46	8.28	0.37	1.69e-15	Schizophrenia;
LUAD	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg11859384	chr17:80120422	CCDC57	-0.49	-8.65	-0.39	1.11e-16	Life satisfaction;
LUAD	cis	rs4888262	0.716	rs6564157	chr16:74710254	T/C	cg01733217	chr16:74700730	RFWD3	0.61	11.19	0.48	1.22e-25	Testicular germ cell tumor;
LUAD	trans	rs1997103	0.954	rs940880	chr7:55392619	C/G	cg20935933	chr6:143382018	AIG1	0.53	7.46	0.34	4.98e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg05368731	chr17:41323189	NBR1	0.97	20.43	0.7	5.06e-65	Menopause (age at onset);
LUAD	trans	rs9747201	0.890	rs12946944	chr17:80061748	C/T	cg07393940	chr7:158741817	NA	-0.72	-11.81	-0.5	5.03e-28	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7630877	0.719	rs73057311	chr3:179664197	A/G	cg18765712	chr3:179670323	PEX5L	0.54	8.78	0.39	4.24e-17	Type 2 diabetes;
LUAD	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg15900387	chr1:150738905	CTSS	-0.36	-6.44	-0.3	3.24e-10	Melanoma;
LUAD	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg16482183	chr6:26056742	HIST1H1C	0.56	7.77	0.35	6.14e-14	Iron status biomarkers;
LUAD	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg11645453	chr3:52864694	ITIH4	0.39	7.95	0.36	1.69e-14	Bipolar disorder;
LUAD	cis	rs4689388	0.793	rs4234731	chr4:6299914	A/G	cg14416269	chr4:6271139	WFS1	0.62	12.6	0.52	3.78e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg22535103	chr8:58192502	C8orf71	-0.68	-7.42	-0.34	6.61e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs9811920	0.809	rs6802817	chr3:99779264	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-11.25	-0.48	7.03e-26	Axial length;
LUAD	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.39	0.34	7.71e-13	Hypertriglyceridemia;
LUAD	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg15704280	chr7:45808275	SEPT13	-1.04	-23.88	-0.76	2.08e-80	Height;
LUAD	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.11	-0.33	5.02e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08439880	chr3:133502540	NA	-0.45	-8.85	-0.4	2.46e-17	Iron status biomarkers;
LUAD	cis	rs1707322	0.613	rs1473840	chr1:46601197	A/G	cg06784218	chr1:46089804	CCDC17	-0.45	-9.64	-0.42	5.04e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg08470875	chr2:26401718	FAM59B	0.78	10.87	0.47	1.94e-24	Gut microbiome composition (summer);
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22776125	chr6:167041314	RPS6KA2	0.43	6.53	0.3	1.87e-10	Monocyte percentage of white cells;
LUAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg24642844	chr7:1081250	C7orf50	-0.96	-14.36	-0.57	2.34e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7193541	0.684	rs9923145	chr16:74686166	G/A	cg01733217	chr16:74700730	RFWD3	0.68	13.53	0.55	6.68e-35	Multiple myeloma;
LUAD	cis	rs3750082	0.632	rs35165932	chr7:32926260	T/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.47	-6.67	-0.31	8.25e-11	Glomerular filtration rate (creatinine);
LUAD	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg22491629	chr6:157744540	C6orf35	-0.79	-8.96	-0.4	1.06e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg03859395	chr2:55845619	SMEK2	0.76	14.4	0.57	1.5e-38	Metabolic syndrome;
LUAD	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg06387496	chr7:2775674	GNA12	-0.4	-6.68	-0.31	7.68e-11	Height;
LUAD	cis	rs1505368	0.567	rs2054617	chr2:213355890	T/C	cg16329650	chr2:213403929	ERBB4	0.46	7.5	0.34	3.7e-13	Symmetrical dimethylarginine levels;
LUAD	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg07917127	chr4:99064746	C4orf37	0.42	7.02	0.32	8.76e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.94	-0.36	1.89e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02475777	chr4:1388615	CRIPAK	-0.63	-8.68	-0.39	8.85e-17	Longevity;
LUAD	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg23281280	chr6:28129359	ZNF389	0.43	6.36	0.3	5.13e-10	Depression;
LUAD	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.47	-7.72	-0.35	8.21e-14	Total body bone mineral density;
LUAD	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg25797454	chr6:150327115	RAET1K	0.35	7.59	0.35	2.03e-13	Alopecia areata;
LUAD	cis	rs75920871	0.702	rs11216162	chr11:116728277	A/G	cg04087571	chr11:116723030	SIK3	0.34	7.06	0.32	7.03e-12	Subjective well-being;
LUAD	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg21862992	chr11:68658383	NA	-0.4	-7.48	-0.34	4.45e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7178572	0.568	rs3743479	chr15:77406396	A/G	cg15453836	chr15:77711506	NA	0.37	6.57	0.3	1.48e-10	Type 2 diabetes;
LUAD	cis	rs1451375	0.572	rs11575463	chr7:50547173	A/G	cg18232548	chr7:50535776	DDC	-0.66	-9.01	-0.4	7.17e-18	Malaria;
LUAD	cis	rs17155006	0.655	rs437336	chr7:107728634	G/T	cg05962710	chr7:107745446	LAMB4	-0.3	-6.53	-0.3	1.85e-10	Pneumococcal bacteremia;
LUAD	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg19875535	chr5:140030758	IK	-0.41	-6.92	-0.32	1.64e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs67311347	0.544	rs6787516	chr3:40355616	C/T	cg02782426	chr3:40428986	ENTPD3	0.35	7.51	0.34	3.61e-13	Renal cell carcinoma;
LUAD	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg06064525	chr11:970664	AP2A2	-0.54	-10.89	-0.47	1.58e-24	Alzheimer's disease (late onset);
LUAD	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.54	7.71	0.35	9.31e-14	Platelet count;
LUAD	cis	rs7224314	1.000	rs8072471	chr17:65367062	C/T	cg01507342	chr17:65387096	PITPNC1	-0.56	-8.64	-0.39	1.16e-16	Diisocyanate-induced asthma;
LUAD	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg06618935	chr21:46677482	NA	-0.5	-10.34	-0.45	1.65e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17344932	chr17:38183730	MED24;SNORD124	0.34	6.6	0.31	1.26e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg23803603	chr1:2058230	PRKCZ	-0.41	-7.15	-0.33	3.85e-12	Height;
LUAD	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg25566285	chr7:158114605	PTPRN2	0.51	10.91	0.47	1.38e-24	Calcium levels;
LUAD	cis	rs9469890	0.604	rs77186075	chr6:34504478	C/T	cg17674042	chr6:34482479	PACSIN1	-0.53	-7.05	-0.32	7.13e-12	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg08422745	chr4:174089978	GALNT7	-0.93	-16.52	-0.63	1.15e-47	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg07917127	chr4:99064746	C4orf37	0.42	6.82	0.31	3.15e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-9.0	-0.4	7.88e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg26677194	chr12:130822605	PIWIL1	0.53	8.82	0.39	3.08e-17	Menopause (age at onset);
LUAD	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg12564285	chr5:131593104	PDLIM4	0.34	6.51	0.3	2.19e-10	Blood metabolite levels;
LUAD	trans	rs6964492	0.510	rs6956766	chr7:134436349	C/T	cg26187342	chr17:65713858	NOL11	0.41	6.56	0.3	1.58e-10	Tonsillectomy;
LUAD	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.86e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs11671005	0.735	rs11670871	chr19:58940514	C/T	cg25952890	chr19:58913133	NA	-0.45	-6.45	-0.3	3.15e-10	Mean platelet volume;
LUAD	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-7.18	-0.33	3.21e-12	Lung cancer;
LUAD	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.49	-0.3	2.47e-10	Aortic root size;
LUAD	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg23649088	chr2:200775458	C2orf69	-0.57	-6.71	-0.31	6.25e-11	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg10755058	chr3:40428713	ENTPD3	-0.44	-8.54	-0.38	2.5e-16	Renal cell carcinoma;
LUAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg21782813	chr7:2030301	MAD1L1	0.41	6.85	0.32	2.62e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6489882	0.966	rs6489879	chr12:113377822	G/A	cg20102336	chr12:113376681	OAS3	-0.57	-8.89	-0.4	1.76e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs7582720	0.887	rs115600411	chr2:204121145	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.56	0.42	9.74e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	9.09	0.4	3.81e-18	Tonsillectomy;
LUAD	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg02176678	chr2:219576539	TTLL4	0.75	15.06	0.59	2.35e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg08085267	chr17:45401833	C17orf57	-0.53	-8.87	-0.4	2.12e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17401966	1.000	rs1536263	chr1:10378914	T/C	cg15208524	chr1:10270712	KIF1B	0.55	8.16	0.37	3.97e-15	Hepatocellular carcinoma;
LUAD	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg15467112	chr14:75489610	MLH3	-0.36	-6.48	-0.3	2.58e-10	Height;
LUAD	cis	rs7084921	0.578	rs12765808	chr10:101872687	A/C	cg19754520	chr10:101825118	CPN1	-0.35	-6.99	-0.32	1.08e-11	Bone mineral density;
LUAD	cis	rs6594713	0.921	rs10051115	chr5:112719597	T/C	cg12552261	chr5:112820674	MCC	0.54	8.33	0.38	1.11e-15	Brain cytoarchitecture;
LUAD	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg09537434	chr19:41945824	ATP5SL	-0.45	-7.06	-0.32	6.84e-12	Height;
LUAD	cis	rs7705042	0.761	rs10062349	chr5:141509597	G/A	cg08523384	chr5:141488047	NDFIP1	-0.38	-6.49	-0.3	2.41e-10	Asthma;
LUAD	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg11266682	chr4:10021025	SLC2A9	0.66	14.85	0.59	1.95e-40	Bone mineral density;
LUAD	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.42	-0.34	6.32e-13	Lung cancer;
LUAD	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg21433313	chr16:3507492	NAT15	-0.74	-13.9	-0.56	1.88e-36	Tuberculosis;
LUAD	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg12863693	chr15:85201151	NMB	0.38	6.8	0.31	3.49e-11	Schizophrenia;
LUAD	cis	rs17253792	0.822	rs2296181	chr14:56107051	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.38	-0.3	4.79e-10	Putamen volume;
LUAD	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg01689657	chr7:91764605	CYP51A1	-0.29	-6.88	-0.32	2.23e-11	Breast cancer;
LUAD	cis	rs2004318	1.000	rs2781760	chr19:55140609	C/T	cg03320607	chr19:54800032	LILRA3	-0.7	-7.88	-0.36	2.81e-14	Blood protein levels;
LUAD	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-6.99	-0.32	1.05e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs73086581	1.000	rs73086581	chr20:3977325	T/C	cg02187196	chr20:3869020	PANK2	0.45	6.45	0.3	3.09e-10	Response to antidepressants in depression;
LUAD	cis	rs2070677	1.000	rs2070677	chr10:135351174	A/T	cg20169779	chr10:135381914	SYCE1	-0.51	-7.88	-0.36	2.7e-14	Gout;
LUAD	cis	rs7818345	0.967	rs4617172	chr8:19273362	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.32	6.96	0.32	1.33e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg23982607	chr1:1823379	GNB1	-0.89	-19.32	-0.68	4.41e-60	Body mass index;
LUAD	trans	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg26043149	chr18:55253948	FECH	-0.39	-6.42	-0.3	3.57e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3823572	0.542	rs11764961	chr7:133631142	C/A	cg03336402	chr7:133662267	EXOC4	0.41	7.57	0.35	2.29e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg23649088	chr2:200775458	C2orf69	0.62	7.77	0.35	6.15e-14	Schizophrenia;
LUAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg06753367	chr22:24256600	NA	-0.37	-6.66	-0.31	8.4e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs17532515	0.628	rs3113193	chr4:141462892	T/A	cg09181644	chr4:141490428	UCP1	-0.33	-7.07	-0.32	6.57e-12	Select biomarker traits;
LUAD	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg22681709	chr2:178499509	PDE11A	-0.5	-8.42	-0.38	5.79e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs7395662	0.963	rs8189397	chr11:48711870	A/T	cg15704280	chr7:45808275	SEPT13	-0.41	-6.35	-0.3	5.44e-10	HDL cholesterol;
LUAD	cis	rs9837602	1.000	rs9832186	chr3:99728503	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.98	-0.32	1.12e-11	Breast cancer;
LUAD	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg27490568	chr2:178487706	NA	0.39	6.49	0.3	2.34e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.89	0.4	1.76e-17	Cognitive ability;
LUAD	cis	rs4409675	0.576	rs12070659	chr1:28227175	G/A	cg23691781	chr1:28212827	C1orf38	0.37	10.81	0.47	3.38e-24	Corneal astigmatism;
LUAD	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg07414643	chr4:187882934	NA	0.34	6.89	0.32	2.06e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg23283495	chr1:209979779	IRF6	0.68	10.35	0.45	1.53e-22	Cleft lip with or without cleft palate;
LUAD	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg03188948	chr7:1209495	NA	0.73	6.82	0.31	3.18e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.6	8.4	0.38	6.97e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs240764	0.817	rs240154	chr6:101065792	G/T	cg09795085	chr6:101329169	ASCC3	0.42	7.27	0.33	1.79e-12	Neuroticism;
LUAD	trans	rs412658	0.776	rs12460025	chr19:22318230	A/G	cg05197062	chr11:11642011	GALNTL4	-0.53	-9.57	-0.42	8.8e-20	Telomere length;
LUAD	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg05727186	chr17:43697356	MGC57346	-0.54	-6.76	-0.31	4.6e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg01299579	chr2:10830716	NOL10	-0.42	-7.34	-0.34	1.13e-12	Prostate cancer;
LUAD	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg24675056	chr1:15929824	NA	0.48	8.37	0.38	8.52e-16	Systolic blood pressure;
LUAD	cis	rs7132746	0.553	rs12829972	chr12:86174249	T/C	cg18827107	chr12:86230957	RASSF9	-0.46	-6.53	-0.3	1.84e-10	Lewy body disease;
LUAD	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21659725	chr3:3221576	CRBN	-0.66	-10.52	-0.46	3.7e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs870825	0.616	rs2141258	chr4:185609576	A/C	cg04058563	chr4:185651563	MLF1IP	-0.81	-11.78	-0.5	6.48e-28	Blood protein levels;
LUAD	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg23601416	chr22:19950040	COMT	-0.39	-8.35	-0.38	1.01e-15	Blood metabolite levels;
LUAD	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg25036284	chr2:26402008	FAM59B	-0.57	-7.99	-0.36	1.33e-14	Gut microbiome composition (summer);
LUAD	cis	rs7103648	0.567	rs12287076	chr11:47606865	G/C	cg20307385	chr11:47447363	PSMC3	-0.47	-7.11	-0.33	5.09e-12	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg25535316	chr11:579198	PHRF1	-0.38	-6.67	-0.31	7.81e-11	Systemic lupus erythematosus;
LUAD	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg10523679	chr1:76189770	ACADM	-0.75	-11.68	-0.49	1.67e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs490234	0.769	rs519812	chr9:128348790	T/G	cg14078157	chr9:128172775	NA	0.41	7.76	0.35	6.45e-14	Mean arterial pressure;
LUAD	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg12179176	chr11:130786555	SNX19	-0.43	-7.09	-0.33	5.66e-12	Schizophrenia;
LUAD	cis	rs2279817	1.000	rs4920620	chr1:18023154	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.59	9.47	0.42	2.06e-19	Neuroticism;
LUAD	cis	rs12681287	0.608	rs13270090	chr8:87553297	T/A	cg00550725	chr8:87521180	FAM82B	-0.44	-6.37	-0.3	5.07e-10	Caudate activity during reward;
LUAD	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg05564831	chr3:52568323	NT5DC2	-0.35	-6.37	-0.3	4.92e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg21699342	chr2:239360505	ASB1	0.5	9.6	0.42	7.41e-20	Multiple system atrophy;
LUAD	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg06074448	chr4:187884817	NA	-0.36	-7.09	-0.33	5.68e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-7.91	-0.36	2.25e-14	Height;Educational attainment;Head circumference (infant);
LUAD	cis	rs2235649	0.843	rs9932890	chr16:1847868	G/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	0.42	6.87	0.32	2.34e-11	Blood metabolite levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25018755	chr22:43506952	BIK	-0.4	-6.64	-0.31	9.83e-11	Height;
LUAD	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg10556349	chr10:835070	NA	0.62	7.9	0.36	2.49e-14	Eosinophil percentage of granulocytes;
LUAD	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg03929089	chr4:120376271	NA	-0.51	-8.03	-0.36	9.65e-15	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg17366294	chr4:99064904	C4orf37	0.66	12.73	0.53	1.17e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg00071950	chr4:10020882	SLC2A9	0.68	13.91	0.56	1.8e-36	Bone mineral density;
LUAD	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg01416388	chr22:39784598	NA	-0.47	-7.75	-0.35	6.79e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	0.963	rs9667588	chr11:48730337	C/T	cg15704280	chr7:45808275	SEPT13	0.43	6.75	0.31	5.04e-11	HDL cholesterol;
LUAD	cis	rs57590327	0.503	rs9874184	chr3:81505439	C/T	cg07356753	chr3:81810745	GBE1	0.48	7.59	0.35	2e-13	Extraversion;
LUAD	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg03289416	chr15:75166202	SCAMP2	-0.39	-6.82	-0.31	3.11e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg00318621	chr2:106887213	NA	-0.51	-7.51	-0.34	3.56e-13	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg20607287	chr7:12443886	VWDE	-0.54	-6.93	-0.32	1.55e-11	Coronary artery disease;
LUAD	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg07404485	chr7:94953653	PON1	-0.49	-7.17	-0.33	3.35e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs986417	0.901	rs1955698	chr14:61029936	C/T	cg27398547	chr14:60952738	C14orf39	0.51	6.56	0.3	1.54e-10	Gut microbiota (bacterial taxa);
LUAD	cis	rs1865721	0.804	rs3745084	chr18:73142510	T/G	cg26385618	chr18:73139727	C18orf62	-0.51	-10.04	-0.44	1.99e-21	Intelligence;
LUAD	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7267979	0.816	rs405822	chr20:25501314	A/G	cg08601574	chr20:25228251	PYGB	0.4	7.44	0.34	5.58e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg13012494	chr21:47604986	C21orf56	0.42	6.48	0.3	2.57e-10	Testicular germ cell tumor;
LUAD	cis	rs11048434	0.673	rs2159961	chr12:9061456	G/T	cg23795048	chr12:9217529	LOC144571	0.4	7.31	0.34	1.32e-12	Sjögren's syndrome;
LUAD	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.56	0.3	1.55e-10	Platelet count;
LUAD	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.71	-0.53	1.43e-31	Breast cancer;
LUAD	cis	rs1018836	0.923	rs7013893	chr8:91563137	G/A	cg16814680	chr8:91681699	NA	-0.73	-12.59	-0.52	4.27e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg03929089	chr4:120376271	NA	-0.66	-11.02	-0.47	5.24e-25	Coronary artery disease;
LUAD	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg27535305	chr1:53392650	SCP2	-0.42	-8.54	-0.38	2.52e-16	Monocyte count;
LUAD	cis	rs7582720	1.000	rs75324925	chr2:203698300	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.41	0.42	3.29e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg00376283	chr12:123451042	ABCB9	0.41	6.65	0.31	9.24e-11	Platelet count;
LUAD	cis	rs11112613	0.609	rs11112636	chr12:106047204	G/A	cg03607813	chr12:105948248	NA	0.51	6.81	0.31	3.36e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs68092024	0.731	rs792840	chr3:99471251	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.51	9.62	0.42	6.18e-20	Cleft lip with or without cleft palate;
LUAD	cis	rs73198271	0.653	rs3827811	chr8:8659038	C/T	cg01851573	chr8:8652454	MFHAS1	0.45	8.0	0.36	1.21e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg23758822	chr17:41437982	NA	1.01	20.95	0.71	2.33e-67	Menopause (age at onset);
LUAD	trans	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg05590025	chr7:65112418	INTS4L2	-0.74	-8.14	-0.37	4.55e-15	Gout;
LUAD	trans	rs11638815	0.626	rs4779041	chr15:83337059	G/A	cg18393722	chr15:85113863	UBE2QP1	0.47	7.19	0.33	2.87e-12	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg21724239	chr8:58056113	NA	-0.6	-7.61	-0.35	1.85e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg09137382	chr11:130731461	NA	0.4	7.43	0.34	6.19e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg05991184	chr2:219186017	PNKD	-0.42	-7.93	-0.36	2e-14	Colorectal cancer;
LUAD	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg20283391	chr11:68216788	NA	-0.42	-6.56	-0.3	1.56e-10	Total body bone mineral density;
LUAD	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.32e-15	Prostate cancer;
LUAD	cis	rs3789045	0.560	rs2271424	chr1:204403311	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.53	-8.95	-0.4	1.14e-17	Educational attainment (college completion);
LUAD	cis	rs12446632	0.551	rs56344690	chr16:19742230	G/A	cg01578585	chr16:19721878	C16orf88	0.55	6.38	0.3	4.74e-10	BMI in smokers;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index (joint analysis main effects and smoking interaction);Waist circumference;Obesity;Body mass index in physically active individuals;Childhood body mass index;Menarche (age at onset);Body mass index;Hip circumference;
LUAD	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg04287289	chr16:89883240	FANCA	0.69	12.84	0.53	4.31e-32	Vitiligo;
LUAD	cis	rs6500395	1.000	rs7188741	chr16:48607966	T/C	cg04672837	chr16:48644449	N4BP1	0.38	6.47	0.3	2.73e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7000551	0.751	rs2449338	chr8:22369232	A/G	cg12081754	chr8:22256438	SLC39A14	0.44	7.35	0.34	1.05e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg11663144	chr21:46675770	NA	-0.6	-11.84	-0.5	4.01e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg17644776	chr2:200775616	C2orf69	0.56	7.41	0.34	6.87e-13	Schizophrenia;
LUAD	cis	rs12519773	0.526	rs4551051	chr5:92518724	T/C	cg18783429	chr5:92414398	NA	0.43	7.66	0.35	1.26e-13	Migraine;
LUAD	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg13732083	chr21:47605072	C21orf56	0.41	6.79	0.31	3.84e-11	Testicular germ cell tumor;
LUAD	cis	rs11077815	0.733	rs7219524	chr17:74442440	C/G	cg06840243	chr17:74442338	UBE2O	-0.42	-7.69	-0.35	1.04e-13	Lymphocyte counts;
LUAD	cis	rs2735413	0.875	rs4888737	chr16:78083819	A/G	cg04733911	chr16:78082701	NA	-0.34	-8.17	-0.37	3.53e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs897984	0.806	rs1046276	chr16:30914626	A/G	cg02466173	chr16:30829666	NA	0.64	10.88	0.47	1.79e-24	Dementia with Lewy bodies;
LUAD	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg07606381	chr6:8435919	SLC35B3	-0.41	-6.72	-0.31	5.86e-11	Motion sickness;
LUAD	cis	rs7945705	1.000	rs7937298	chr11:8867509	G/C	cg09997546	chr11:8931473	C11orf17;ST5	0.35	7.03	0.32	8.28e-12	Hemoglobin concentration;
LUAD	cis	rs4790333	0.537	rs898750	chr17:2255193	A/G	cg02569219	chr17:2266849	SGSM2	0.53	9.98	0.44	3.29e-21	Proinsulin levels;
LUAD	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg05896524	chr21:47604654	C21orf56	0.53	8.94	0.4	1.22e-17	Testicular germ cell tumor;
LUAD	cis	rs10865541	0.902	rs13399186	chr2:3423201	G/T	cg13173536	chr2:3403300	TTC15	-0.34	-6.62	-0.31	1.08e-10	Obesity-related traits;
LUAD	cis	rs9902453	0.933	rs7221154	chr17:28505024	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-8.83	-0.39	2.72e-17	Coffee consumption (cups per day);
LUAD	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg25036284	chr2:26402008	FAM59B	-0.56	-7.93	-0.36	2e-14	Gut microbiome composition (summer);
LUAD	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.51	-8.27	-0.37	1.7e-15	Menarche (age at onset);
LUAD	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg05110241	chr16:68378359	PRMT7	-0.77	-8.81	-0.39	3.32e-17	Magnesium levels;
LUAD	cis	rs2535633	0.602	rs2581816	chr3:53014657	C/T	cg05564831	chr3:52568323	NT5DC2	0.37	6.49	0.3	2.45e-10	Body mass index;
LUAD	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26314531	chr2:26401878	FAM59B	-0.7	-9.53	-0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg03762505	chr1:171750926	METTL13	0.39	6.5	0.3	2.25e-10	Schizophrenia;
LUAD	cis	rs10203711	0.531	rs10181391	chr2:239565575	C/T	cg14580085	chr2:239553406	NA	0.32	6.46	0.3	2.84e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg26893861	chr17:41843967	DUSP3	0.63	8.81	0.39	3.34e-17	Triglycerides;
LUAD	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18876405	chr7:65276391	NA	-0.42	-6.7	-0.31	6.62e-11	Aortic root size;
LUAD	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg17366294	chr4:99064904	C4orf37	0.47	8.38	0.38	8.17e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg11494091	chr17:61959527	GH2	0.46	8.19	0.37	3.07e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg07570687	chr10:102243282	WNT8B	0.44	6.8	0.31	3.5e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg08761264	chr16:28874980	SH2B1	-0.44	-6.62	-0.31	1.09e-10	Tonsillectomy;Mean corpuscular volume;
LUAD	cis	rs1018836	0.651	rs2339175	chr8:91565805	A/T	cg16814680	chr8:91681699	NA	-0.72	-12.34	-0.51	4.34e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2455601	0.529	rs2653569	chr11:8986978	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.44	-8.12	-0.37	5.08e-15	Schizophrenia;
LUAD	cis	rs9473147	0.516	rs9395286	chr6:47575332	T/C	cg20196966	chr6:47445060	CD2AP	0.45	7.08	0.33	5.86e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg00784671	chr22:46762841	CELSR1	-0.6	-7.91	-0.36	2.21e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.59	-0.35	2.1e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg05040210	chr1:18807594	KLHDC7A	-0.55	-11.08	-0.47	3.3e-25	Breast cancer;
LUAD	cis	rs1497828	0.956	rs2132994	chr1:217548036	A/G	cg04411442	chr1:217543379	NA	-0.37	-6.63	-0.31	1.03e-10	Dialysis-related mortality;
LUAD	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.86	0.32	2.4e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs28735056	0.933	rs499260	chr18:77589689	G/A	cg05926928	chr17:57297772	GDPD1	-0.48	-6.89	-0.32	2.04e-11	Schizophrenia;
LUAD	cis	rs41311933	1.000	rs12685289	chr9:123755383	T/A	cg13567360	chr9:123745713	C5	-0.79	-8.62	-0.39	1.31e-16	Coronary artery disease;
LUAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg25811766	chr13:21894605	NA	0.57	8.63	0.39	1.24e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.69	-9.16	-0.41	2.31e-18	Yeast infection;
LUAD	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.85	-0.32	2.66e-11	Height;
LUAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg21724239	chr8:58056113	NA	0.64	8.16	0.37	3.84e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg20701182	chr2:24300061	SF3B14	0.62	6.89	0.32	2e-11	Lymphocyte counts;
LUAD	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg13385794	chr1:248469461	NA	0.25	6.46	0.3	2.84e-10	Common traits (Other);
LUAD	cis	rs11971779	0.648	rs6467852	chr7:139112591	A/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.85	0.32	2.66e-11	Diisocyanate-induced asthma;
LUAD	cis	rs2070677	0.935	rs11101869	chr10:135400631	C/T	cg20169779	chr10:135381914	SYCE1	-0.51	-8.29	-0.37	1.52e-15	Gout;
LUAD	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg09365446	chr1:150670422	GOLPH3L	0.67	12.69	0.53	1.67e-31	Tonsillectomy;
LUAD	cis	rs59104589	0.617	rs3755400	chr2:242379795	A/C	cg08645257	chr2:242211290	HDLBP	-0.45	-7.21	-0.33	2.59e-12	Fibrinogen levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg08930741	chr1:59369549	NA	-0.38	-6.4	-0.3	4.21e-10	Schizophrenia;
LUAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg22963979	chr7:1858916	MAD1L1	-0.68	-12.3	-0.51	6.42e-30	Bipolar disorder and schizophrenia;
LUAD	cis	rs76878669	0.561	rs1039594	chr11:66131149	C/T	cg10616300	chr11:66138557	SLC29A2	0.33	7.1	0.33	5.39e-12	Educational attainment (years of education);
LUAD	cis	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.73	-0.31	5.37e-11	Triglycerides;
LUAD	cis	rs6684514	1.000	rs7522948	chr1:156275308	C/T	cg16558208	chr1:156270281	VHLL	0.51	9.88	0.43	7.38e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs6076065	0.723	rs6083104	chr20:23366038	C/T	cg11657817	chr20:23433608	CST11	0.46	8.72	0.39	6.35e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg23649088	chr2:200775458	C2orf69	0.62	8.24	0.37	2.17e-15	Schizophrenia;
LUAD	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03934478	chr11:495069	RNH1	0.74	8.58	0.38	1.87e-16	Body mass index;
LUAD	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg24829409	chr8:58192753	C8orf71	-0.54	-8.28	-0.37	1.69e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs10499694	0.933	rs12538938	chr7:50592313	A/G	cg18232548	chr7:50535776	DDC	-0.45	-7.58	-0.35	2.21e-13	Body mass index;
LUAD	cis	rs4481887	0.927	rs4427440	chr1:248480337	T/A	cg00666640	chr1:248458726	OR2T12	0.31	7.6	0.35	1.96e-13	Common traits (Other);
LUAD	cis	rs4713675	0.584	rs7739505	chr6:33670370	G/A	cg14003231	chr6:33640908	ITPR3	0.49	9.43	0.42	2.79e-19	Plateletcrit;
LUAD	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg09455208	chr3:40491958	NA	0.65	14.22	0.57	8.45e-38	Renal cell carcinoma;
LUAD	cis	rs28374715	0.635	rs112547435	chr15:41648737	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.94	-20.28	-0.7	2.27e-64	Ulcerative colitis;
LUAD	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg23649088	chr2:200775458	C2orf69	-0.8	-14.99	-0.59	4.7e-41	Osteoporosis;
LUAD	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg22676075	chr6:135203613	NA	0.52	9.4	0.42	3.38e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg26513180	chr16:89883248	FANCA	0.68	6.47	0.3	2.66e-10	Skin colour saturation;
LUAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg21681030	chr2:46777652	RHOQ	0.4	7.26	0.33	1.91e-12	Height;
LUAD	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg12292205	chr6:26970375	C6orf41	0.38	6.73	0.31	5.43e-11	Schizophrenia;
LUAD	cis	rs4692589	0.965	rs7657455	chr4:170958843	C/G	cg19918862	chr4:170955249	NA	0.31	7.38	0.34	8.39e-13	Anxiety disorder;
LUAD	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.28	-0.54	7.08e-34	Chronic sinus infection;
LUAD	cis	rs4372836	0.897	rs6707130	chr2:28973276	A/G	cg09522027	chr2:28974177	PPP1CB	-0.6	-9.68	-0.43	3.73e-20	Body mass index;
LUAD	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg22868518	chr11:507468	RNH1	-0.66	-6.56	-0.3	1.54e-10	Body mass index;
LUAD	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg18306943	chr3:40428807	ENTPD3	0.42	7.04	0.32	7.93e-12	Renal cell carcinoma;
LUAD	trans	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg26043149	chr18:55253948	FECH	-0.39	-6.36	-0.3	5.31e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg06641503	chr3:48959341	ARIH2	-0.37	-6.78	-0.31	4e-11	Menarche (age at onset);
LUAD	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg16205897	chr5:131564050	P4HA2	0.31	6.77	0.31	4.22e-11	Blood metabolite levels;
LUAD	cis	rs12893668	0.703	rs34026011	chr14:104050883	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.76	-0.35	6.38e-14	Reticulocyte count;
LUAD	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg26384229	chr12:38710491	ALG10B	0.5	8.27	0.37	1.71e-15	Heart rate;
LUAD	cis	rs7582720	0.943	rs72928610	chr2:203838961	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.64	0.42	5.27e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs10901296	0.660	rs11789055	chr9:133766295	T/C	cg03924115	chr9:133768966	QRFP	0.49	6.63	0.31	1.02e-10	Bilirubin levels;
LUAD	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg13319975	chr6:146136371	FBXO30	-0.58	-9.74	-0.43	2.4e-20	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs459571	0.959	rs456205	chr9:136911146	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-10.19	-0.44	6.18e-22	Platelet distribution width;
LUAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.31	0.37	1.27e-15	Platelet count;
LUAD	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg22963979	chr7:1858916	MAD1L1	-0.48	-7.98	-0.36	1.43e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.51	-9.19	-0.41	1.84e-18	Lymphocyte counts;
LUAD	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.58	8.59	0.39	1.72e-16	Platelet count;
LUAD	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg13180566	chr4:1052158	NA	-0.4	-6.84	-0.32	2.82e-11	Recombination rate (females);
LUAD	cis	rs9487051	0.724	rs13196219	chr6:109635787	A/T	cg01475377	chr6:109611718	NA	-0.39	-6.39	-0.3	4.27e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg02734326	chr4:10020555	SLC2A9	0.51	8.92	0.4	1.47e-17	Bone mineral density;
LUAD	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg22166914	chr1:53195759	ZYG11B	0.46	7.53	0.34	3.08e-13	Monocyte count;
LUAD	cis	rs9515203	0.596	rs9521731	chr13:111032699	C/G	cg15455643	chr13:111040242	COL4A2	0.37	6.86	0.32	2.41e-11	Coronary artery disease;
LUAD	cis	rs7301016	0.948	rs7303825	chr12:62921978	A/G	cg11441379	chr12:63026424	NA	0.56	7.07	0.32	6.57e-12	IgG glycosylation;
LUAD	cis	rs9503598	0.610	rs1328687	chr6:3468377	A/C	cg00476032	chr6:3446245	SLC22A23	0.31	6.69	0.31	7.01e-11	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs4594175	0.926	rs4617765	chr14:51598843	T/C	cg23942311	chr14:51606299	NA	0.64	11.09	0.47	3e-25	Cancer;
LUAD	cis	rs889398	0.771	rs11075732	chr16:69766038	A/G	cg26679644	chr16:69762563	NA	-0.36	-6.36	-0.3	5.36e-10	Body mass index;
LUAD	cis	rs9672608	1.000	rs9672608	chr15:78797463	T/A	cg18825076	chr15:78729989	IREB2	0.55	7.51	0.34	3.64e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs4900538	0.928	rs1190551	chr14:102911508	A/G	cg18135206	chr14:102964638	TECPR2	-1.06	-24.02	-0.76	4.9e-81	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg07460842	chr6:66804631	NA	1.08	16.94	0.64	1.67e-49	Exhaled nitric oxide output;
LUAD	cis	rs17608059	0.710	rs8080167	chr17:13949828	G/A	cg27005118	chr17:13972210	COX10	-0.41	-8.9	-0.4	1.68e-17	Temperament;
LUAD	trans	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg17712092	chr4:129076599	LARP1B	-0.77	-11.85	-0.5	3.74e-28	Breast cancer;
LUAD	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg23758822	chr17:41437982	NA	1.02	20.97	0.71	1.82e-67	Menopause (age at onset);
LUAD	cis	rs7593730	0.636	rs6743795	chr2:161122134	A/G	cg22609984	chr2:161126801	NA	0.57	10.38	0.45	1.22e-22	Type 2 diabetes;
LUAD	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg12483005	chr1:23474871	LUZP1	0.54	9.11	0.41	3.3e-18	Height;
LUAD	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg25344623	chr2:136566232	LCT	0.34	6.67	0.31	7.91e-11	Mosquito bite size;
LUAD	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg07570687	chr10:102243282	WNT8B	0.48	7.39	0.34	8.08e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7614311	0.731	rs3774719	chr3:63950338	C/A	cg22134162	chr3:63841271	THOC7	-0.55	-9.36	-0.41	4.71e-19	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs12478296	0.515	rs13412492	chr2:243000583	T/G	cg06360820	chr2:242988706	NA	-0.69	-9.73	-0.43	2.48e-20	Obesity-related traits;
LUAD	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg13870426	chr17:30244630	NA	-0.57	-6.72	-0.31	5.93e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg04455712	chr21:45112962	RRP1B	0.47	9.27	0.41	9.4e-19	Mean corpuscular volume;
LUAD	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg17105886	chr17:28927953	LRRC37B2	0.83	7.92	0.36	2.14e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg07776626	chr8:57350775	NA	-0.61	-9.05	-0.4	5.25e-18	Obesity-related traits;
LUAD	cis	rs758324	0.853	rs10051653	chr5:131248894	G/A	cg25547332	chr5:131281432	NA	-0.41	-6.65	-0.31	9.21e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg17264618	chr3:40429014	ENTPD3	0.42	8.93	0.4	1.35e-17	Renal cell carcinoma;
LUAD	cis	rs938554	0.784	rs13102218	chr4:9976113	G/T	cg11266682	chr4:10021025	SLC2A9	0.43	7.58	0.35	2.17e-13	Blood metabolite levels;
LUAD	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg03037974	chr15:76606532	NA	0.39	8.19	0.37	3.19e-15	Blood metabolite levels;
LUAD	cis	rs250677	0.687	rs250679	chr5:148434952	A/T	cg12140854	chr5:148520817	ABLIM3	0.52	8.18	0.37	3.24e-15	Breast cancer;
LUAD	cis	rs11048434	0.761	rs12828902	chr12:9132231	C/T	cg23795048	chr12:9217529	LOC144571	0.46	8.38	0.38	8.08e-16	Sjögren's syndrome;
LUAD	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg27535305	chr1:53392650	SCP2	-0.32	-6.46	-0.3	2.82e-10	Monocyte count;
LUAD	cis	rs7107174	0.892	rs2511167	chr11:77964698	C/T	cg02023728	chr11:77925099	USP35	0.5	7.52	0.34	3.35e-13	Testicular germ cell tumor;
LUAD	cis	rs12618769	0.625	rs3769726	chr2:99105827	G/C	cg10123293	chr2:99228465	UNC50	0.46	8.12	0.37	5.1e-15	Bipolar disorder;
LUAD	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg21252483	chr19:49399788	TULP2	-0.87	-14.24	-0.57	6.96e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.59	0.52	4.48e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	14.19	0.57	1.22e-37	Lung cancer in ever smokers;
LUAD	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18876405	chr7:65276391	NA	-0.43	-6.85	-0.32	2.55e-11	Aortic root size;
LUAD	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg09365446	chr1:150670422	GOLPH3L	0.65	12.11	0.51	3.47e-29	Tonsillectomy;
LUAD	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg02269571	chr22:50332266	NA	0.59	8.88	0.4	1.92e-17	Schizophrenia;
LUAD	cis	rs9560113	1.000	rs9560110	chr13:112181233	C/T	cg14154082	chr13:112174009	NA	0.36	6.64	0.31	9.5e-11	Menarche (age at onset);
LUAD	trans	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg24644049	chr4:85504048	CDS1	0.91	7.84	0.36	3.76e-14	Skin colour saturation;
LUAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.48	-9.53	-0.42	1.27e-19	Longevity;Endometriosis;
LUAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg04775059	chr7:64541387	NA	-0.58	-9.43	-0.42	2.75e-19	Calcium levels;
LUAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg00450029	chr8:599525	NA	0.84	8.1	0.37	6e-15	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.91	0.32	1.78e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg24578937	chr1:2090814	PRKCZ	0.78	16.25	0.62	1.67e-46	Height;
LUAD	cis	rs739496	0.542	rs12423926	chr12:111781055	C/T	cg10833066	chr12:111807467	FAM109A	-0.66	-13.25	-0.54	9.34e-34	Platelet count;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05989100	chr16:46655373	SHCBP1	-0.63	-6.37	-0.3	5.01e-10	Type 2 diabetes;
LUAD	cis	rs10189230	0.967	rs13026659	chr2:222353014	C/T	cg14652038	chr2:222343519	EPHA4	0.42	8.33	0.38	1.17e-15	Urate levels in lean individuals;
LUAD	trans	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg18335740	chr13:41363409	SLC25A15	0.73	14.02	0.56	6.18e-37	Lewy body disease;
LUAD	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg05340658	chr4:99064831	C4orf37	0.45	6.76	0.31	4.66e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08280861	chr8:58055591	NA	0.63	8.31	0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg21475434	chr5:93447410	FAM172A	0.74	8.17	0.37	3.69e-15	Diabetic retinopathy;
LUAD	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg04450456	chr4:17643702	FAM184B	0.43	8.51	0.38	2.96e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg04989706	chr14:50066350	PPIL5	-0.51	-7.55	-0.34	2.76e-13	Carotid intima media thickness;
LUAD	cis	rs75920871	0.843	rs61905713	chr11:116909429	C/T	cg04087571	chr11:116723030	SIK3	-0.33	-6.71	-0.31	6.1e-11	Subjective well-being;
LUAD	cis	rs6748734	0.947	rs6752787	chr2:241840647	G/A	cg07537917	chr2:241836409	C2orf54	-0.3	-8.39	-0.38	7.37e-16	Urinary metabolites;
LUAD	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.95	0.4	1.14e-17	Menopause (age at onset);
LUAD	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg11502198	chr6:26597334	ABT1	-0.55	-9.14	-0.41	2.72e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.44	-8.02	-0.36	1.03e-14	Longevity;Endometriosis;
LUAD	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg01851573	chr8:8652454	MFHAS1	0.41	7.38	0.34	8.7e-13	Mood instability;
LUAD	cis	rs10193935	0.901	rs1439231	chr2:42542884	G/A	cg27598129	chr2:42591480	NA	-0.64	-8.58	-0.38	1.85e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg17105886	chr17:28927953	LRRC37B2	-0.81	-7.83	-0.36	4.05e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg18187862	chr3:45730750	SACM1L	-0.51	-7.91	-0.36	2.2e-14	Primary sclerosing cholangitis;
LUAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg07414643	chr4:187882934	NA	0.33	6.73	0.31	5.55e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9807989	0.507	rs2041739	chr2:102994333	A/G	cg03938978	chr2:103052716	IL18RAP	-0.43	-9.95	-0.44	4.29e-21	Asthma;
LUAD	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg13393036	chr8:95962371	TP53INP1	-0.33	-7.39	-0.34	7.96e-13	Type 2 diabetes;
LUAD	cis	rs113835537	0.935	rs3867133	chr11:66451962	A/G	cg24851651	chr11:66362959	CCS	-0.55	-8.09	-0.37	6.53e-15	Airway imaging phenotypes;
LUAD	cis	rs35771425	0.509	rs3120782	chr1:211419700	A/T	cg25617285	chr1:211431773	RCOR3	-0.51	-9.91	-0.43	5.72e-21	Educational attainment (years of education);
LUAD	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg02176678	chr2:219576539	TTLL4	-0.8	-16.82	-0.63	5.43e-49	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg24644049	chr4:85504048	CDS1	-0.83	-7.38	-0.34	8.71e-13	Skin colour saturation;
LUAD	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg03929089	chr4:120376271	NA	-0.69	-10.26	-0.45	3.21e-22	Height;
LUAD	cis	rs2735413	0.881	rs4888727	chr16:78077038	T/C	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg18944383	chr4:111397179	ENPEP	0.38	7.63	0.35	1.61e-13	Height;
LUAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg11062466	chr8:58055876	NA	0.48	6.73	0.31	5.55e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9512730	0.553	rs1040986	chr13:28051352	G/T	cg04070771	chr13:27998621	GTF3A	0.5	7.34	0.34	1.09e-12	Schizophrenia;
LUAD	cis	rs3739034	0.759	rs4430991	chr2:135491932	C/T	cg12500956	chr2:135428796	TMEM163	0.38	6.8	0.31	3.63e-11	Gut microbiome composition (winter);
LUAD	cis	rs6761276	0.899	rs13389457	chr2:113834885	T/C	cg06383401	chr2:113825234	IL1F10	-0.3	-6.48	-0.3	2.6200000000000003e-10	Protein quantitative trait loci;
LUAD	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg13010199	chr12:38710504	ALG10B	0.41	6.73	0.31	5.69e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg00321850	chr1:175162397	KIAA0040	0.49	10.47	0.45	5.78e-23	Alcohol dependence;
LUAD	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	7.46	0.34	5.09e-13	Platelet count;
LUAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg10862848	chr6:42927986	GNMT	-0.33	-9.42	-0.42	2.87e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs73086581	1.000	rs17215054	chr20:3944779	T/C	cg02187196	chr20:3869020	PANK2	0.46	6.49	0.3	2.34e-10	Response to antidepressants in depression;
LUAD	trans	rs7615952	0.546	rs2979307	chr3:125309574	C/T	cg17147758	chr8:6949321	NA	0.46	7.05	0.32	7.44e-12	Blood pressure (smoking interaction);
LUAD	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg11663144	chr21:46675770	NA	-0.61	-12.21	-0.51	1.37e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg00898013	chr13:113819073	PROZ	-0.71	-12.89	-0.53	2.63e-32	Platelet distribution width;
LUAD	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.43	-7.84	-0.36	3.68e-14	Longevity;Endometriosis;
LUAD	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.01	-0.5	8.8e-29	Primary sclerosing cholangitis;
LUAD	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg26384229	chr12:38710491	ALG10B	0.43	7.18	0.33	3.07e-12	Morning vs. evening chronotype;
LUAD	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg05768032	chr16:30646687	NA	0.4	6.69	0.31	7.16e-11	Multiple myeloma;
LUAD	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.91	0.36	2.24e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg25703541	chr22:24373054	LOC391322	-0.79	-13.86	-0.56	2.86e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2274273	0.624	rs72717738	chr14:55842761	C/G	cg04306507	chr14:55594613	LGALS3	0.4	7.68	0.35	1.1e-13	Protein biomarker;
LUAD	cis	rs4660214	0.789	rs1180375	chr1:39881040	G/C	cg27567593	chr1:39956653	BMP8A	-0.36	-7.11	-0.33	5.08e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.93	-0.4	1.3e-17	Bipolar disorder;
LUAD	cis	rs986417	1.000	rs12895784	chr14:60980116	G/T	cg27398547	chr14:60952738	C14orf39	0.66	7.88	0.36	2.78e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs6445967	1.000	rs6777105	chr3:58307644	A/G	cg23715586	chr3:58305044	RPP14	0.43	7.93	0.36	1.99e-14	Platelet count;
LUAD	cis	rs7100689	0.580	rs10736366	chr10:82207921	C/T	cg00277334	chr10:82204260	NA	-0.83	-15.73	-0.61	3.22e-44	Post bronchodilator FEV1;
LUAD	cis	rs10916814	0.546	rs7547998	chr1:20903192	C/T	cg24502330	chr1:20914028	CDA	-0.36	-7.02	-0.32	8.98e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs240764	0.658	rs11155618	chr6:101181811	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.55	-0.38	2.24e-16	Neuroticism;
LUAD	cis	rs912057	0.526	rs1294400	chr6:6733421	A/G	cg06612196	chr6:6737390	NA	-0.64	-15.66	-0.61	6.61e-44	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg10556349	chr10:835070	NA	0.49	6.71	0.31	6.42e-11	Eosinophil percentage of granulocytes;
LUAD	cis	rs9487051	0.724	rs13200047	chr6:109633244	T/C	cg01475377	chr6:109611718	NA	-0.4	-6.66	-0.31	8.61e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg03676636	chr4:99064102	C4orf37	0.29	7.02	0.32	8.91e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg14791747	chr16:20752902	THUMPD1	-0.49	-7.36	-0.34	9.41e-13	Pancreatic cancer;
LUAD	cis	rs10193935	0.786	rs72796504	chr2:42406728	T/C	cg27598129	chr2:42591480	NA	-0.75	-9.73	-0.43	2.49e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73198271	0.565	rs575895	chr8:8594247	G/A	cg01851573	chr8:8652454	MFHAS1	0.44	8.0	0.36	1.2e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	14.99	0.59	4.6e-41	Smoking behavior;
LUAD	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg08355456	chr11:67383691	NA	0.38	6.45	0.3	3.11e-10	Mean corpuscular volume;
LUAD	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg07636037	chr3:49044803	WDR6	0.61	11.68	0.49	1.67e-27	Parkinson's disease;
LUAD	trans	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg07393940	chr7:158741817	NA	0.68	11.3	0.48	4.77e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg18180107	chr4:99064573	C4orf37	0.43	6.65	0.31	9.08e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2734839	0.537	rs6277	chr11:113283459	G/A	cg14159747	chr11:113255604	NA	0.63	12.94	0.53	1.66e-32	Information processing speed;
LUAD	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg02196655	chr2:10830764	NOL10	0.45	8.11	0.37	5.49e-15	Prostate cancer;
LUAD	cis	rs7590720	1.000	rs1991533	chr2:216908910	T/C	cg12620499	chr2:216877984	MREG	0.57	8.95	0.4	1.12e-17	Alcohol dependence;
LUAD	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.12	-0.33	4.66e-12	Coronary artery disease;
LUAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.19	0.54	1.67e-33	Prudent dietary pattern;
LUAD	cis	rs6489882	0.867	rs4767036	chr12:113369177	T/G	cg20102336	chr12:113376681	OAS3	-0.61	-9.47	-0.42	1.96e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg12935359	chr14:103987150	CKB	0.5	7.69	0.35	1.03e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs55665837	1.000	rs10766182	chr11:14499536	A/G	cg19336497	chr11:14380999	RRAS2	-0.5	-9.97	-0.44	3.71e-21	Vitamin D levels;
LUAD	cis	rs3820068	0.705	rs6656907	chr1:15896984	A/G	cg13390004	chr1:15929781	NA	0.42	6.66	0.31	8.64e-11	Systolic blood pressure;
LUAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg16031515	chr1:205743344	RAB7L1	-0.36	-7.23	-0.33	2.24e-12	Menarche (age at onset);
LUAD	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg05110241	chr16:68378359	PRMT7	-0.82	-8.85	-0.4	2.46e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3733418	0.929	rs12510464	chr4:165919040	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.49	-6.8	-0.31	3.51e-11	Obesity-related traits;
LUAD	cis	rs9462027	0.628	rs2815004	chr6:34636268	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.67	-0.39	9.05e-17	Systemic lupus erythematosus;
LUAD	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.87	10.11	0.44	1.17e-21	Initial pursuit acceleration;
LUAD	cis	rs7481584	1.000	rs756693	chr11:3027889	A/G	cg11201177	chr11:2961805	NA	0.4	6.66	0.31	8.42e-11	Calcium levels;
LUAD	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.64	11.94	0.5	1.58e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01570182	chr17:44337453	NA	1.15	17.18	0.64	1.43e-50	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg10164272	chr16:89456328	ANKRD11	0.42	6.37	0.3	4.97e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg06074448	chr4:187884817	NA	-0.36	-7.15	-0.33	3.87e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.2	-0.37	2.88e-15	Total cholesterol levels;
LUAD	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3125734	0.633	rs4561099	chr10:64041163	T/C	cg19640130	chr10:64028056	RTKN2	-0.36	-7.7	-0.35	9.74e-14	Rheumatoid arthritis;
LUAD	cis	rs9878978	1.000	rs17194392	chr3:2487275	A/G	cg21928760	chr3:2462534	CNTN4	-0.33	-6.61	-0.31	1.15e-10	Blood pressure (smoking interaction);
LUAD	trans	rs11039798	0.841	rs10839174	chr11:48931185	G/A	cg02254774	chr11:50257496	LOC441601	0.52	6.56	0.3	1.62e-10	Axial length;
LUAD	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg02880119	chr16:3481970	NA	0.54	8.09	0.37	6.34e-15	Body mass index (adult);
LUAD	cis	rs12545109	0.800	rs1530217	chr8:57408097	C/T	cg17761419	chr8:57350749	NA	-0.53	-7.51	-0.34	3.48e-13	Obesity-related traits;
LUAD	cis	rs4948275	0.530	rs2139778	chr10:63134943	A/T	cg02461363	chr10:63212496	TMEM26	-0.33	-7.05	-0.32	7.56e-12	Night sleep phenotypes;
LUAD	trans	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg03886242	chr7:26192032	NFE2L3	-0.47	-8.41	-0.38	6.58e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18876405	chr7:65276391	NA	0.41	6.5	0.3	2.24e-10	Aortic root size;
LUAD	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg12599982	chr1:44399894	ARTN	0.38	7.37	0.34	9.31e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg09835421	chr16:68378352	PRMT7	-0.72	-7.96	-0.36	1.56e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7584330	0.518	rs113812061	chr2:238447934	T/C	cg14458575	chr2:238380390	NA	0.72	10.67	0.46	1.03e-23	Prostate cancer;
LUAD	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-9.17	-0.41	2.16e-18	Bipolar disorder;
LUAD	cis	rs2279817	0.818	rs883379	chr1:17983789	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.45	-6.75	-0.31	4.83e-11	Neuroticism;
LUAD	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg10792982	chr14:105748885	BRF1	0.43	9.18	0.41	1.94e-18	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg00310523	chr12:86230176	RASSF9	0.37	7.46	0.34	4.93e-13	Major depressive disorder;
LUAD	cis	rs977987	0.806	rs12051326	chr16:75437887	G/A	cg03315344	chr16:75512273	CHST6	0.64	14.15	0.57	1.75e-37	Dupuytren's disease;
LUAD	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg21385522	chr1:16154831	NA	0.45	6.89	0.32	2.07e-11	Dilated cardiomyopathy;
LUAD	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21659725	chr3:3221576	CRBN	0.86	18.28	0.66	1.96e-55	Intelligence (multi-trait analysis);
LUAD	cis	rs16866061	1.000	rs11686590	chr2:225334070	A/G	cg12698349	chr2:225449008	CUL3	0.75	13.18	0.54	1.75e-33	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg14668632	chr7:2872130	GNA12	-0.75	-13.89	-0.56	2.02e-36	Height;
LUAD	trans	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg21284400	chr1:149981654	OTUD7B	-0.37	-6.48	-0.3	2.52e-10	Longevity;Endometriosis;
LUAD	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg02569458	chr12:86230093	RASSF9	-0.41	-7.69	-0.35	1.05e-13	Major depressive disorder;
LUAD	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg20203395	chr5:56204925	C5orf35	-0.39	-6.39	-0.3	4.31e-10	Coronary artery disease;
LUAD	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-24.86	-0.77	9.72e-85	Height;
LUAD	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-7.69	-0.35	1.04e-13	Bladder cancer;
LUAD	trans	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg07211511	chr3:129823064	LOC729375	-0.56	-7.24	-0.33	2.14e-12	Blood pressure (smoking interaction);
LUAD	cis	rs2282300	0.667	rs10734405	chr11:30273750	T/C	cg25418670	chr11:30344373	C11orf46	0.53	7.35	0.34	1.02e-12	Morning vs. evening chronotype;
LUAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg21782813	chr7:2030301	MAD1L1	0.59	10.08	0.44	1.42e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg27433088	chr4:174089019	GALNT7	0.41	7.65	0.35	1.4e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg11062466	chr8:58055876	NA	0.67	8.96	0.4	1.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg24324837	chr19:49891574	CCDC155	0.58	9.03	0.4	6.07e-18	Multiple sclerosis;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11270233	chr8:146277426	C8orf33	-0.41	-6.86	-0.32	2.49e-11	Cancer;
LUAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03452623	chr4:187889614	NA	-0.83	-17.31	-0.64	3.98e-51	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7617773	0.780	rs71323395	chr3:48374077	G/A	cg11946769	chr3:48343235	NME6	0.44	6.68	0.31	7.75e-11	Coronary artery disease;
LUAD	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg25208724	chr1:156163844	SLC25A44	1.19	27.28	0.8	2.87e-95	Testicular germ cell tumor;
LUAD	cis	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg25834613	chr7:1915315	MAD1L1	-0.4	-6.51	-0.3	2.1e-10	Bipolar disorder;
LUAD	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg17264618	chr3:40429014	ENTPD3	0.42	9.16	0.41	2.25e-18	Renal cell carcinoma;
LUAD	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.68	0.31	7.44e-11	Parkinson's disease;
LUAD	cis	rs7707921	0.881	rs73136777	chr5:81434479	T/A	cg15871215	chr5:81402204	ATG10	-0.68	-9.63	-0.42	5.59e-20	Breast cancer;
LUAD	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg15462221	chr8:8086144	FLJ10661	0.45	6.93	0.32	1.56e-11	Neuroticism;
LUAD	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg20503657	chr10:835505	NA	1.02	15.3	0.6	2.28e-42	Eosinophil percentage of granulocytes;
LUAD	cis	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg27411982	chr8:10470053	RP1L1	0.37	6.48	0.3	2.56e-10	Morning vs. evening chronotype;
LUAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19626725	chr5:178986131	RUFY1	-0.61	-11.97	-0.5	1.27e-28	Lung cancer;
LUAD	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg27494647	chr7:150038898	RARRES2	0.46	8.41	0.38	6.57e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9314323	0.862	rs7813520	chr8:26263260	C/T	cg13160058	chr8:26243215	BNIP3L	-0.46	-9.55	-0.42	1.09e-19	Red cell distribution width;
LUAD	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg18180107	chr4:99064573	C4orf37	0.46	6.4	0.3	4.24e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg23173402	chr1:227635558	NA	0.9	8.65	0.39	1.05e-16	Major depressive disorder;
LUAD	cis	rs300703	0.542	rs443419	chr2:189800	C/T	cg24565620	chr2:194026	NA	0.37	6.58	0.3	1.37e-10	Blood protein levels;
LUAD	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg25809561	chr17:30822961	MYO1D	0.74	15.54	0.6	2e-43	Schizophrenia;
LUAD	cis	rs35883536	1.000	rs35883536	chr1:101106534	G/A	cg06223162	chr1:101003688	GPR88	0.35	6.57	0.3	1.53e-10	Monocyte count;
LUAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.19	-0.33	2.91e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.39	-6.75	-0.31	4.92e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg25457927	chr22:38595422	NA	-0.53	-13.76	-0.56	7.23e-36	Cutaneous nevi;
LUAD	cis	rs1395	0.778	rs4665960	chr2:27467598	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.52	9.18	0.41	1.89e-18	Blood metabolite levels;
LUAD	cis	rs12541635	0.902	rs59123253	chr8:107006365	C/T	cg10147462	chr8:107024639	NA	0.51	9.21	0.41	1.57e-18	Age of smoking initiation;
LUAD	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg23625390	chr15:77176239	SCAPER	-0.55	-8.82	-0.39	3.09e-17	Blood metabolite levels;
LUAD	cis	rs7584330	0.617	rs28725355	chr2:238372824	T/G	cg14458575	chr2:238380390	NA	0.69	12.68	0.52	1.94e-31	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4072705	1.000	rs4836991	chr9:127512040	A/G	cg13476313	chr9:127244764	NR5A1	-0.32	-7.63	-0.35	1.61e-13	Menarche (age at onset);
LUAD	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg07936489	chr17:37558343	FBXL20	0.51	6.94	0.32	1.48e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7937890	0.559	rs10766184	chr11:14542577	A/G	cg22961513	chr11:14280813	SPON1	-0.36	-7.02	-0.32	8.74e-12	Mitochondrial DNA levels;
LUAD	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.83	0.32	3.02e-11	Blood metabolite levels;
LUAD	cis	rs9341808	0.527	rs2505946	chr6:80810683	A/G	cg08355045	chr6:80787529	NA	0.69	13.87	0.56	2.67e-36	Sitting height ratio;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg11702503	chr19:6215254	MLLT1	-0.39	-6.41	-0.3	3.88e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs7043114	0.544	rs4302908	chr9:95321641	A/G	cg14631576	chr9:95140430	CENPP	-0.38	-7.86	-0.36	3.28e-14	Height;
LUAD	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg10518543	chr12:38710700	ALG10B	0.42	6.38	0.3	4.61e-10	Bladder cancer;
LUAD	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg07169764	chr2:136633963	MCM6	0.63	7.5	0.34	3.79e-13	Corneal structure;
LUAD	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg22920501	chr2:26401640	FAM59B	-0.76	-10.97	-0.47	8.37e-25	Gut microbiome composition (summer);
LUAD	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg03563238	chr19:33554763	RHPN2	-0.33	-8.03	-0.36	1e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg06028605	chr16:24865363	SLC5A11	-0.4	-6.86	-0.32	2.49e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs17532515	0.652	rs67308919	chr4:141385647	T/A	cg03645522	chr4:141391200	NA	0.39	6.35	0.3	5.46e-10	Select biomarker traits;
LUAD	cis	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg07460842	chr6:66804631	NA	-0.64	-10.69	-0.46	9.19e-24	Blood trace element (Cu levels);
LUAD	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg15181151	chr6:150070149	PCMT1	0.38	7.75	0.35	7.12e-14	Lung cancer;
LUAD	cis	rs7107174	0.901	rs10899498	chr11:78124575	C/G	cg19901956	chr11:77921274	USP35	-0.47	-6.58	-0.3	1.38e-10	Testicular germ cell tumor;
LUAD	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg24818145	chr4:99064322	C4orf37	-0.51	-8.23	-0.37	2.37e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11638815	0.626	rs4779039	chr15:83317767	C/G	cg18393722	chr15:85113863	UBE2QP1	0.47	7.18	0.33	3.13e-12	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-7.44	-0.34	5.52e-13	Bladder cancer;
LUAD	cis	rs12541635	1.000	rs4734897	chr8:107075518	G/A	cg10147462	chr8:107024639	NA	-0.43	-7.62	-0.35	1.65e-13	Age of smoking initiation;
LUAD	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.15	0.33	3.83e-12	Motion sickness;
LUAD	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg09509183	chr1:209979624	IRF6	-0.61	-7.44	-0.34	5.69e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs7187994	0.848	rs16974527	chr16:84782822	C/T	cg07647771	chr16:84786436	USP10	-0.35	-9.02	-0.4	6.39e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs8077889	0.917	rs72836556	chr17:41911824	G/T	cg26893861	chr17:41843967	DUSP3	0.94	15.02	0.59	3.51e-41	Triglycerides;
LUAD	cis	rs72634258	0.945	rs34157438	chr1:8023586	C/T	cg26816564	chr1:7831052	VAMP3	0.53	6.75	0.31	5.01e-11	Inflammatory bowel disease;
LUAD	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg03676636	chr4:99064102	C4orf37	0.32	8.46	0.38	4.26e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6665290	0.904	rs6677602	chr1:227187838	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.1	-26.57	-0.79	3.2e-92	Myeloid white cell count;
LUAD	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg02493740	chr2:85810744	VAMP5	-0.4	-7.18	-0.33	3.16e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg15664640	chr17:80829946	TBCD	-0.65	-7.97	-0.36	1.53e-14	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13126279	chr21:47581558	C21orf56	-0.54	-9.11	-0.41	3.25e-18	Testicular germ cell tumor;
LUAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02353165	chr6:42928485	GNMT	0.4	7.16	0.33	3.71e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6546550	0.935	rs10202159	chr2:70062454	G/T	cg02498382	chr2:70120550	SNRNP27	-0.57	-10.69	-0.46	9.03e-24	Prevalent atrial fibrillation;
LUAD	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg04727924	chr7:799746	HEATR2	-0.56	-6.93	-0.32	1.6e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg11707310	chr1:2537719	MMEL1	0.37	7.79	0.35	5.38e-14	Ulcerative colitis;
LUAD	trans	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.53	-0.3	1.93e-10	Neuroticism;
LUAD	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-7.26	-0.33	1.87e-12	Personality dimensions;
LUAD	trans	rs360929	0.511	rs360942	chr4:152855407	G/T	cg09675889	chr19:912839	C19orf22	-0.5	-6.49	-0.3	2.45e-10	Volumetric brain MRI;
LUAD	trans	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg19862616	chr7:65841803	NCRNA00174	1.06	27.29	0.8	2.67e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs11971779	0.715	rs11772771	chr7:139058803	T/C	cg23387468	chr7:139079360	LUC7L2	0.3	6.92	0.32	1.72e-11	Diisocyanate-induced asthma;
LUAD	trans	rs4714291	0.963	rs1767672	chr6:40104107	G/T	cg02267698	chr19:7991119	CTXN1	0.43	6.52	0.3	1.98e-10	Strep throat;
LUAD	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg02423579	chr7:2872169	GNA12	-0.87	-14.74	-0.58	5.79e-40	Height;
LUAD	cis	rs72634258	0.945	rs441597	chr1:8080895	A/G	cg26816564	chr1:7831052	VAMP3	0.47	6.59	0.31	1.34e-10	Inflammatory bowel disease;
LUAD	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg23281280	chr6:28129359	ZNF389	0.46	6.45	0.3	3.06e-10	Depression;
LUAD	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg11494091	chr17:61959527	GH2	0.45	8.58	0.39	1.76e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg00310523	chr12:86230176	RASSF9	0.39	7.84	0.36	3.8e-14	Major depressive disorder;
LUAD	cis	rs2421770	0.530	rs6484784	chr11:35368347	A/C	cg13971030	chr11:35366721	SLC1A2	0.49	8.56	0.38	2.06e-16	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs938554	0.956	rs6828184	chr4:9936400	G/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-7.03	-0.32	8.24e-12	Blood metabolite levels;
LUAD	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg06784218	chr1:46089804	CCDC17	-0.54	-11.87	-0.5	3e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1816752	0.819	rs4770664	chr13:24988833	C/T	cg02811702	chr13:24901961	NA	0.43	7.33	0.34	1.2e-12	Obesity-related traits;
LUAD	cis	rs524023	0.874	rs518053	chr11:64456099	C/T	cg19131476	chr11:64387923	NRXN2	-0.42	-8.19	-0.37	3.1e-15	Urate levels in obese individuals;
LUAD	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg11833968	chr6:79620685	NA	-0.45	-8.32	-0.37	1.26e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs1018836	0.774	rs35159732	chr8:91633094	A/G	cg16814680	chr8:91681699	NA	-0.75	-12.03	-0.5	7.05e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg09796270	chr17:17721594	SREBF1	-0.36	-7.09	-0.33	5.58e-12	Total body bone mineral density;
LUAD	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-14.9	-0.59	1.12e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg13385794	chr1:248469461	NA	0.26	6.94	0.32	1.46e-11	Common traits (Other);
LUAD	cis	rs57994353	0.897	rs12551527	chr9:139358425	C/G	cg14364472	chr9:139394549	NOTCH1	-0.44	-6.57	-0.3	1.45e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg21427119	chr20:30132790	HM13	-0.48	-7.66	-0.35	1.3e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg11965913	chr1:205819406	PM20D1	0.5	8.06	0.36	7.82e-15	Parkinson's disease;
LUAD	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg17509989	chr5:176798049	RGS14	0.88	15.06	0.59	2.53e-41	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg13073564	chr4:8508604	NA	-0.54	-10.06	-0.44	1.78e-21	Response to antineoplastic agents;
LUAD	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06544989	chr22:39130855	UNC84B	0.46	8.92	0.4	1.47e-17	Menopause (age at onset);
LUAD	cis	rs68170813	0.605	rs2299428	chr7:107134384	A/G	cg23024343	chr7:107201750	COG5	0.5	7.02	0.32	8.67e-12	Coronary artery disease;
LUAD	cis	rs2625529	0.824	rs2415130	chr15:72242554	G/A	cg16672083	chr15:72433130	SENP8	-0.72	-12.15	-0.51	2.52e-29	Red blood cell count;
LUAD	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg04117972	chr1:227635322	NA	0.65	6.6	0.31	1.24e-10	Major depressive disorder;
LUAD	cis	rs7680126	0.633	rs11727390	chr4:10296760	C/T	cg00071950	chr4:10020882	SLC2A9	-0.6	-8.38	-0.38	8.06e-16	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs13095912	1.000	rs34965813	chr3:185333012	T/C	cg11274856	chr3:185301563	NA	0.38	7.6	0.35	1.99e-13	Systolic blood pressure;
LUAD	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg18252515	chr7:66147081	NA	-0.63	-6.84	-0.32	2.86e-11	Diabetic kidney disease;
LUAD	trans	rs2018683	1.000	rs4719962	chr7:28999237	G/A	cg19402173	chr7:128379420	CALU	-0.62	-10.41	-0.45	9.45e-23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg18180107	chr4:99064573	C4orf37	0.4	6.49	0.3	2.34e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4714291	0.802	rs911818	chr6:39988816	C/A	cg02267698	chr19:7991119	CTXN1	-0.45	-7.15	-0.33	3.82e-12	Strep throat;
LUAD	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg12140854	chr5:148520817	ABLIM3	-0.7	-10.48	-0.45	5.41e-23	Breast cancer;
LUAD	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg07917127	chr4:99064746	C4orf37	0.41	6.87	0.32	2.24e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg11822812	chr5:140052017	DND1	0.38	6.73	0.31	5.42e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9902453	0.808	rs56088359	chr17:28173659	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.61	0.42	6.54e-20	Coffee consumption (cups per day);
LUAD	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.28	0.37	1.65e-15	Rheumatoid arthritis;
LUAD	cis	rs8099014	0.861	rs4940706	chr18:56121803	C/T	cg12907477	chr18:56117327	MIR122	-0.5	-7.92	-0.36	2.15e-14	Platelet count;
LUAD	cis	rs7759001	0.857	rs6936539	chr6:27358917	C/G	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs3774830	0.811	rs2654501	chr4:5432416	T/C	cg26943120	chr4:5472116	STK32B	-0.33	-6.45	-0.3	3.11e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19717773	chr7:2847554	GNA12	-0.56	-9.82	-0.43	1.2e-20	Height;
LUAD	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg02782426	chr3:40428986	ENTPD3	0.42	9.34	0.41	5.7e-19	Renal cell carcinoma;
LUAD	trans	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg14917512	chr19:3094685	GNA11	-0.55	-6.53	-0.3	1.87e-10	Gout;
LUAD	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg17971929	chr21:40555470	PSMG1	0.42	6.77	0.31	4.2e-11	Cognitive function;
LUAD	cis	rs9329221	0.576	rs1986972	chr8:10268805	C/T	cg27411982	chr8:10470053	RP1L1	0.38	6.52	0.3	1.99e-10	Neuroticism;
LUAD	cis	rs8067545	0.641	rs203481	chr17:19828728	C/T	cg04132472	chr17:19861366	AKAP10	0.39	9.25	0.41	1.13e-18	Schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	ch.13.721274R	chr13:51955414	INTS6	-0.62	-6.36	-0.3	5.2400000000000005e-10	Type 2 diabetes;
LUAD	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg02569458	chr12:86230093	RASSF9	0.39	7.27	0.33	1.77e-12	Major depressive disorder;
LUAD	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg05966235	chr16:28915196	ATP2A1	0.47	7.55	0.34	2.62e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7542375	0.683	rs7546886	chr1:221099995	G/A	cg16008148	chr1:221062819	NA	0.39	6.39	0.3	4.41e-10	Obesity-related traits;
LUAD	cis	rs8060686	0.546	rs8047343	chr16:68143745	G/A	cg05110241	chr16:68378359	PRMT7	-0.58	-7.5	-0.34	3.88e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg14784868	chr12:69753453	YEATS4	0.44	7.17	0.33	3.41e-12	Blood protein levels;
LUAD	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg22681709	chr2:178499509	PDE11A	-0.43	-7.13	-0.33	4.39e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg21782813	chr7:2030301	MAD1L1	0.61	10.5	0.45	4.63e-23	Bipolar disorder and schizophrenia;
LUAD	trans	rs75804782	0.521	rs72993056	chr2:239404671	G/T	cg01134436	chr17:81009848	B3GNTL1	0.8	8.78	0.39	4.11e-17	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.96	-0.32	1.27e-11	Waist circumference;Hip circumference;
LUAD	cis	rs4006360	0.657	rs6503588	chr17:39235453	A/G	cg20663846	chr17:39254439	KRTAP4-8	0.35	7.65	0.35	1.39e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg00666640	chr1:248458726	OR2T12	0.29	6.79	0.31	3.81e-11	Common traits (Other);
LUAD	cis	rs11030122	0.702	rs12281293	chr11:3963814	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.35	-0.34	1.05e-12	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs4073416	0.542	rs10144979	chr14:65997638	G/A	cg10998611	chr14:65879393	FUT8;LOC645431	-0.42	-6.35	-0.3	5.42e-10	N-glycan levels;
LUAD	trans	rs853679	0.546	rs13195291	chr6:28169241	G/A	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.05	-0.47	4.18e-25	Depression;
LUAD	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg15448220	chr1:150897856	SETDB1	0.42	7.28	0.33	1.59e-12	Tonsillectomy;
LUAD	trans	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg03886242	chr7:26192032	NFE2L3	-0.44	-7.64	-0.35	1.51e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg22815214	chr1:201083145	CACNA1S	0.57	9.8	0.43	1.4e-20	Permanent tooth development;
LUAD	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.32	0.34	1.26e-12	Lung cancer in ever smokers;
LUAD	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.48	-0.42	1.86e-19	Life satisfaction;
LUAD	cis	rs17197710	0.608	rs41304347	chr11:47330991	A/G	cg13308137	chr11:47528955	CUGBP1	0.45	7.2	0.33	2.81e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg16680214	chr1:154839983	KCNN3	-0.6	-12.59	-0.52	4.45e-31	Prostate cancer;
LUAD	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg13789015	chr9:136890014	NCRNA00094	0.87	14.45	0.57	9.69e-39	Platelet distribution width;
LUAD	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg07211511	chr3:129823064	LOC729375	-0.84	-12.25	-0.51	9.76e-30	Blood pressure (smoking interaction);
LUAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg15117754	chr3:10150083	C3orf24	0.42	7.02	0.32	8.83e-12	Alzheimer's disease;
LUAD	trans	rs10411161	0.721	rs1433082	chr19:52390726	A/C	cg22319618	chr22:45562946	NUP50	0.54	8.22	0.37	2.46e-15	Breast cancer;
LUAD	cis	rs4689388	0.647	rs9997824	chr4:6283253	T/C	cg25554036	chr4:6271136	WFS1	0.66	11.62	0.49	2.7e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs4285028	0.699	rs1920297	chr3:121598000	T/C	cg11130432	chr3:121712080	ILDR1	-0.56	-8.01	-0.36	1.13e-14	Multiple sclerosis;
LUAD	cis	rs4638749	0.677	rs10208945	chr2:108838593	G/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.32	-0.34	1.25e-12	Blood pressure;
LUAD	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	7.12	0.33	4.75e-12	Platelet count;
LUAD	cis	rs7119	0.634	rs2682922	chr15:77865006	A/C	cg27398640	chr15:77910606	LINGO1	0.37	7.07	0.32	6.61e-12	Type 2 diabetes;
LUAD	cis	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg08601574	chr20:25228251	PYGB	-0.44	-8.22	-0.37	2.51e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg24813613	chr7:1882135	MAD1L1	0.58	9.39	0.42	3.8e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.43	-0.45	7.96e-23	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg07917127	chr4:99064746	C4orf37	0.53	8.45	0.38	4.69e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg06028605	chr16:24865363	SLC5A11	0.39	6.79	0.31	3.75e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg25358565	chr5:93447407	FAM172A	0.65	7.69	0.35	1.07e-13	Diabetic retinopathy;
LUAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg05434287	chr7:2030229	MAD1L1	0.45	7.36	0.34	9.76e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg02527881	chr3:46936655	PTH1R	0.44	8.65	0.39	1.1e-16	Colorectal cancer;
LUAD	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg02896835	chr1:92012615	NA	-0.47	-9.11	-0.4	3.4e-18	Breast cancer;
LUAD	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-7.98	-0.36	1.38e-14	Morning vs. evening chronotype;
LUAD	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg22029157	chr1:209979665	IRF6	0.79	11.6	0.49	3.43e-27	Cleft lip with or without cleft palate;
LUAD	cis	rs9326248	0.520	rs1446105	chr11:116798544	C/T	cg20608306	chr11:116969690	SIK3	0.32	7.24	0.33	2.08e-12	Blood protein levels;
LUAD	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-18.26	-0.66	2.49e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg19052272	chr2:3704530	ALLC	0.43	7.39	0.34	8.11e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg11941060	chr3:133502564	NA	0.7	13.44	0.55	1.59e-34	Iron status biomarkers;
LUAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg03188948	chr7:1209495	NA	0.67	9.78	0.43	1.63e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7818345	0.595	rs12155539	chr8:19316086	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.31	-6.75	-0.31	4.84e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg18306943	chr3:40428807	ENTPD3	0.37	6.41	0.3	3.92e-10	Renal cell carcinoma;
LUAD	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg10253484	chr15:75165896	SCAMP2	-0.41	-6.36	-0.3	5.13e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs2692947	0.740	rs59076415	chr2:96393944	A/G	cg23100626	chr2:96804247	ASTL	0.35	8.25	0.37	2.08e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs494562	0.892	rs521005	chr6:86116542	A/G	cg27297263	chr6:86160468	NT5E	0.59	6.42	0.3	3.6e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs6840360	0.593	rs1366907	chr4:152682749	T/C	cg22705602	chr4:152727874	NA	-0.48	-9.27	-0.41	9.87e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg18527919	chr2:24398170	C2orf84	0.4	6.72	0.31	5.95e-11	Asthma;
LUAD	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg20476274	chr7:133979776	SLC35B4	0.74	12.91	0.53	2.3e-32	Mean platelet volume;
LUAD	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg22117172	chr7:91764530	CYP51A1	0.36	7.84	0.36	3.66e-14	Breast cancer;
LUAD	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg11494091	chr17:61959527	GH2	0.42	7.88	0.36	2.8e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.61	10.01	0.44	2.58e-21	Colorectal cancer;
LUAD	cis	rs9399401	0.710	rs12197866	chr6:142706063	C/T	cg04461802	chr6:142623433	GPR126	0.46	8.57	0.38	1.91e-16	Chronic obstructive pulmonary disease;
LUAD	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg20503657	chr10:835505	NA	0.79	10.82	0.47	2.9e-24	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.44	0.38	5.18e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg11584989	chr19:19387371	SF4	-0.36	-6.45	-0.3	3e-10	Tonsillectomy;
LUAD	cis	rs4730250	0.707	rs257372	chr7:106796977	T/G	cg02696742	chr7:106810147	HBP1	-0.83	-11.03	-0.47	4.82e-25	Osteoarthritis;
LUAD	cis	rs71478720	0.953	rs5744249	chr11:112025306	A/C	cg09122223	chr11:112035175	IL18	0.43	6.71	0.31	6.38e-11	Interleukin-18 levels;
LUAD	trans	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg03886242	chr7:26192032	NFE2L3	-0.46	-7.86	-0.36	3.19e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg01849466	chr14:104193079	ZFYVE21	0.52	9.68	0.43	3.73e-20	Schizophrenia;
LUAD	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg02049041	chr17:27085579	C17orf63	0.66	8.8	0.39	3.49e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg12011299	chr4:100065546	ADH4	0.67	13.99	0.56	8.44e-37	Alcohol dependence;
LUAD	cis	rs9902453	0.904	rs10853136	chr17:28406018	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-9.85	-0.43	9.5e-21	Coffee consumption (cups per day);
LUAD	cis	rs9837602	1.000	rs62285462	chr3:99769834	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.87	-0.32	2.26e-11	Breast cancer;
LUAD	cis	rs4889911	0.544	rs1285271	chr17:77834197	C/T	cg00646381	chr17:77835854	NA	-0.5	-8.15	-0.37	4.16e-15	Electroencephalogram traits;
LUAD	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg27490568	chr2:178487706	NA	0.39	6.44	0.3	3.3e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7903847	0.642	rs10882915	chr10:99142184	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-7.12	-0.33	4.78e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06544989	chr22:39130855	UNC84B	0.43	8.03	0.36	9.95e-15	Menopause (age at onset);
LUAD	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg26408565	chr15:76604113	ETFA	-0.46	-7.72	-0.35	8.45e-14	Blood metabolite levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07341818	chr12:132379266	ULK1	-0.69	-6.84	-0.32	2.8e-11	Type 2 diabetes;
LUAD	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.58	-0.6	1.34e-43	Eye color traits;
LUAD	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg11822812	chr5:140052017	DND1	0.39	7.09	0.33	5.52e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg26769984	chr7:1090371	C7orf50	0.63	9.99	0.44	3.03e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs4889855	0.556	rs61096326	chr17:78543796	G/C	cg16591659	chr17:78472290	NA	0.44	7.75	0.35	6.89e-14	Fractional excretion of uric acid;
LUAD	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg18451016	chr1:38461880	NA	-0.46	-8.08	-0.37	6.76e-15	Coronary artery disease;
LUAD	trans	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg21775007	chr8:11205619	TDH	0.38	6.41	0.3	3.87e-10	Mood instability;
LUAD	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg04025307	chr7:1156635	C7orf50	0.57	8.07	0.37	7.54e-15	Bronchopulmonary dysplasia;
LUAD	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg25427524	chr10:38739819	LOC399744	0.59	8.6	0.39	1.61e-16	Obesity (extreme);
LUAD	cis	rs62238980	0.614	rs75386630	chr22:32380975	G/C	cg00543991	chr22:32367038	NA	0.94	8.78	0.39	4.09e-17	Childhood ear infection;
LUAD	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg18827107	chr12:86230957	RASSF9	-0.69	-12.92	-0.53	2.02e-32	Major depressive disorder;
LUAD	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11644478	chr21:40555479	PSMG1	0.69	11.07	0.47	3.39e-25	Cognitive function;
LUAD	cis	rs11771526	0.901	rs11767773	chr7:32272342	T/G	cg27532318	chr7:32358331	NA	0.53	7.03	0.32	8.38e-12	Body mass index;
LUAD	trans	rs2262909	0.962	rs73021832	chr19:22316144	G/C	cg05197062	chr11:11642011	GALNTL4	0.6	9.29	0.41	8.39e-19	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7582720	1.000	rs72936838	chr2:203772984	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg21220214	chr8:57350948	NA	-0.59	-8.73	-0.39	6.17e-17	Obesity-related traits;
LUAD	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg09998033	chr7:158218633	PTPRN2	0.43	7.67	0.35	1.19e-13	Obesity-related traits;
LUAD	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg09904177	chr6:26538194	HMGN4	0.43	7.21	0.33	2.51e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg02971882	chr4:71554083	UTP3	-0.4	-6.71	-0.31	6.14e-11	Subcortical brain region volumes;
LUAD	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.19	0.41	1.83e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg18446336	chr7:2847575	GNA12	-0.32	-6.52	-0.3	1.96e-10	Height;
LUAD	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg22532475	chr10:104410764	TRIM8	0.44	8.38	0.38	8.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.55	-0.34	2.71e-13	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-8.69	-0.39	7.92e-17	Menarche (age at onset);
LUAD	cis	rs4706831	0.647	rs627240	chr6:80985885	C/A	cg08355045	chr6:80787529	NA	-0.48	-8.36	-0.38	9.29e-16	Joint mobility (Beighton score);
LUAD	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg25985355	chr7:65971099	NA	0.39	7.23	0.33	2.25e-12	Aortic root size;
LUAD	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.79	-0.35	5.18e-14	Type 2 diabetes;
LUAD	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg18132916	chr6:79620363	NA	-0.45	-7.81	-0.36	4.45e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.64	9.83	0.43	1.14e-20	Lymphocyte percentage of white cells;
LUAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.41	0.55	2.12e-34	Prudent dietary pattern;
LUAD	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	12.86	0.53	3.61e-32	Monocyte percentage of white cells;
LUAD	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg11344533	chr11:111475393	SIK2	-0.37	-6.96	-0.32	1.28e-11	Primary sclerosing cholangitis;
LUAD	trans	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg07817883	chr1:32538562	TMEM39B	1.26	12.1	0.51	3.85e-29	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9399401	0.589	rs2294775	chr6:142766347	C/G	cg03128060	chr6:142623767	GPR126	0.41	8.66	0.39	9.98e-17	Chronic obstructive pulmonary disease;
LUAD	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11644478	chr21:40555479	PSMG1	-0.54	-8.73	-0.39	5.78e-17	Cognitive function;
LUAD	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21659725	chr3:3221576	CRBN	0.66	11.46	0.49	1.18e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg02725872	chr8:58115012	NA	-0.33	-6.46	-0.3	2.9e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg16797656	chr11:68205561	LRP5	0.46	9.5	0.42	1.58e-19	Total body bone mineral density;
LUAD	cis	rs7107174	0.892	rs2511167	chr11:77964698	C/T	cg19901956	chr11:77921274	USP35	-0.53	-6.57	-0.3	1.52e-10	Testicular germ cell tumor;
LUAD	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.94	0.32	1.44e-11	Aortic root size;
LUAD	cis	rs7542375	0.683	rs61819203	chr1:221090010	A/G	cg16008148	chr1:221062819	NA	0.41	6.54	0.3	1.73e-10	Obesity-related traits;
LUAD	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg04539111	chr16:67997858	SLC12A4	-0.51	-6.36	-0.3	5.12e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg14458575	chr2:238380390	NA	0.8	11.87	0.5	3.05e-28	Prostate cancer;
LUAD	cis	rs2692947	0.770	rs62153678	chr2:96558346	C/T	cg23100626	chr2:96804247	ASTL	0.31	7.61	0.35	1.75e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.57	8.34	0.38	1.02e-15	Platelet count;
LUAD	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg18252515	chr7:66147081	NA	-0.59	-6.52	-0.3	1.95e-10	Diabetic kidney disease;
LUAD	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg10523679	chr1:76189770	ACADM	0.94	18.54	0.67	1.32e-56	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7582720	1.000	rs75141346	chr2:203685119	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.32	0.41	6.71e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs11971779	0.680	rs7804388	chr7:139086413	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.18	-0.33	3.17e-12	Total body bone mineral density;
LUAD	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg26898376	chr11:64110657	CCDC88B	0.38	7.19	0.33	3.01e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg06608945	chr2:219082296	ARPC2	-0.42	-6.84	-0.32	2.73e-11	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg24579218	chr15:68104479	NA	-0.57	-9.44	-0.42	2.47e-19	Restless legs syndrome;
LUAD	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg07952391	chr2:88470173	THNSL2	0.78	8.44	0.38	5.29e-16	Plasma clusterin levels;
LUAD	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.63	-0.31	1.04e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg27411982	chr8:10470053	RP1L1	0.4	7.03	0.32	8.26e-12	Neuroticism;
LUAD	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-20.27	-0.7	2.52e-64	Height;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02704927	chr5:65440543	SFRS12	-0.38	-6.41	-0.3	3.92e-10	Cancer;
LUAD	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg02018176	chr4:1364513	KIAA1530	0.65	11.07	0.47	3.41e-25	Longevity;
LUAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg23131131	chr22:24373011	LOC391322	-0.47	-7.49	-0.34	3.99e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00149659	chr3:10157352	C3orf10	0.87	11.54	0.49	5.61e-27	Alzheimer's disease;
LUAD	cis	rs9811920	0.660	rs11719468	chr3:99671848	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-9.77	-0.43	1.87e-20	Axial length;
LUAD	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg23598886	chr18:12777645	NA	0.64	8.0	0.36	1.22e-14	Inflammatory skin disease;
LUAD	cis	rs72949976	0.898	rs6732233	chr2:214022834	C/T	cg08319019	chr2:214017104	IKZF2	-0.54	-8.07	-0.37	7.32e-15	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.15	0.33	3.78e-12	Motion sickness;
LUAD	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg18351406	chr4:77819688	ANKRD56	0.62	10.48	0.45	5.2e-23	Emphysema distribution in smoking;
LUAD	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg08989290	chr16:615782	NHLRC4	0.32	6.82	0.31	3.13e-11	Height;
LUAD	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg06287003	chr12:125626642	AACS	-0.39	-6.37	-0.3	5.07e-10	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-14.51	-0.58	5.36e-39	Schizophrenia;
LUAD	trans	rs258892	0.947	rs250517	chr5:72200626	G/C	cg14879065	chr14:104662468	NA	-0.35	-6.39	-0.3	4.45e-10	Small cell lung carcinoma;
LUAD	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg17173187	chr15:85201210	NMB	0.42	6.86	0.32	2.51e-11	Schizophrenia;
LUAD	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg14008862	chr17:28927542	LRRC37B2	0.59	7.06	0.32	6.94e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg12365402	chr11:9010492	NRIP3	-0.52	-10.53	-0.46	3.47e-23	Hemoglobin concentration;
LUAD	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg03859395	chr2:55845619	SMEK2	0.77	14.53	0.58	4.18e-39	Metabolic syndrome;
LUAD	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg15900387	chr1:150738905	CTSS	-0.38	-6.85	-0.32	2.62e-11	Melanoma;
LUAD	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.59	10.15	0.44	8.36e-22	Electrocardiographic conduction measures;
LUAD	cis	rs13064411	0.518	rs9842559	chr3:113252705	A/C	cg18753928	chr3:113234510	CCDC52	-0.47	-8.41	-0.38	6.23e-16	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs539096	0.692	rs6669157	chr1:44216876	T/C	cg12908607	chr1:44402522	ARTN	-0.36	-7.07	-0.32	6.58e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg18306943	chr3:40428807	ENTPD3	0.4	6.78	0.31	4.06e-11	Renal cell carcinoma;
LUAD	cis	rs7659604	0.540	rs4075065	chr4:122683906	A/G	cg06713675	chr4:122721982	EXOSC9	0.4	7.32	0.34	1.3e-12	Type 2 diabetes;
LUAD	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg22467129	chr15:76604101	ETFA	-0.6	-10.94	-0.47	1.09e-24	Blood metabolite levels;
LUAD	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg10523679	chr1:76189770	ACADM	0.77	11.41	0.49	1.79e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg13047869	chr3:10149882	C3orf24	0.66	10.16	0.44	7.56e-22	Alzheimer's disease;
LUAD	cis	rs904251	0.828	rs2797803	chr6:37487340	T/C	cg25019722	chr6:37503610	NA	-0.3	-6.63	-0.31	1.06e-10	Cognitive performance;
LUAD	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22496380	chr5:211416	CCDC127	-0.93	-12.79	-0.53	6.86e-32	Breast cancer;
LUAD	cis	rs11585357	0.947	rs2977304	chr1:17611615	T/C	cg08277548	chr1:17600880	PADI3	0.84	12.79	0.53	7.02e-32	Hair shape;
LUAD	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg06671706	chr8:8559999	CLDN23	0.62	10.8	0.47	3.45e-24	Obesity-related traits;
LUAD	cis	rs6499255	0.953	rs3811349	chr16:69791266	T/G	cg15192750	chr16:69999425	NA	0.46	7.16	0.33	3.64e-12	IgE levels;
LUAD	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.7	-0.31	6.63e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7072216	0.666	rs11598689	chr10:100156027	G/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-6.36	-0.3	5.3e-10	Metabolite levels;
LUAD	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg05043794	chr9:111880884	C9orf5	-0.44	-7.56	-0.35	2.52e-13	Menarche (age at onset);
LUAD	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg14779329	chr11:130786720	SNX19	0.39	6.84	0.32	2.74e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg12575136	chr18:32820987	ZNF397	0.44	6.96	0.32	1.34e-11	White blood cell count;
LUAD	cis	rs7737355	0.853	rs6873582	chr5:130892741	A/G	cg06307176	chr5:131281290	NA	0.52	8.29	0.37	1.5e-15	Life satisfaction;
LUAD	cis	rs7737355	0.947	rs251014	chr5:131029463	A/G	cg06307176	chr5:131281290	NA	0.54	8.38	0.38	7.79e-16	Life satisfaction;
LUAD	cis	rs7809950	1.000	rs2808	chr7:107260856	A/G	cg23024343	chr7:107201750	COG5	0.73	12.1	0.51	3.8e-29	Coronary artery disease;
LUAD	cis	rs3733418	0.929	rs1401399	chr4:165927906	G/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.52	-6.73	-0.31	5.67e-11	Obesity-related traits;
LUAD	cis	rs739496	0.579	rs11066051	chr12:112301760	G/C	cg10833066	chr12:111807467	FAM109A	0.43	6.95	0.32	1.4e-11	Platelet count;
LUAD	cis	rs11696501	0.688	rs6104247	chr20:44244938	C/T	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.17	-0.37	3.67e-15	Brain structure;
LUAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.82	10.33	0.45	1.93e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg02527881	chr3:46936655	PTH1R	-0.44	-8.46	-0.38	4.44e-16	Colorectal cancer;
LUAD	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg18876405	chr7:65276391	NA	-0.41	-6.5	-0.3	2.25e-10	Aortic root size;
LUAD	cis	rs61897795	0.628	rs174579	chr11:61605613	C/T	cg21709803	chr11:61594965	FADS2	-0.47	-7.22	-0.33	2.36e-12	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs2016266	0.859	rs10747668	chr12:53737461	C/T	cg26875137	chr12:53738046	NA	0.33	6.93	0.32	1.53e-11	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg10523679	chr1:76189770	ACADM	-1.05	-25.1	-0.77	8.35e-86	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg00530320	chr1:46809349	NSUN4	0.51	7.93	0.36	1.92e-14	Menopause (age at onset);
LUAD	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.53	0.52	7.6e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg07460842	chr6:66804631	NA	1.08	16.94	0.64	1.67e-49	Exhaled nitric oxide output;
LUAD	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg12568669	chr8:11666485	FDFT1	0.26	6.89	0.32	1.99e-11	Myopia (pathological);
LUAD	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.12	-0.37	5.16e-15	Diabetic kidney disease;
LUAD	cis	rs12681288	0.676	rs2701901	chr8:1017816	G/C	cg04851639	chr8:1020857	NA	-0.42	-9.87	-0.43	8.37e-21	Schizophrenia;
LUAD	cis	rs12618769	0.597	rs3769741	chr2:99068204	G/T	cg10123293	chr2:99228465	UNC50	0.47	8.7	0.39	7.51e-17	Bipolar disorder;
LUAD	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg18944383	chr4:111397179	ENPEP	0.41	8.24	0.37	2.19e-15	Height;
LUAD	cis	rs790123	1.000	rs790113	chr3:122383276	T/A	cg17380795	chr3:122379686	NA	0.46	7.87	0.36	3.04e-14	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg25535316	chr11:579198	PHRF1	-0.42	-6.54	-0.3	1.73e-10	Systemic lupus erythematosus;
LUAD	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg21770322	chr7:97807741	LMTK2	0.33	7.47	0.34	4.65e-13	Breast cancer;
LUAD	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg17366294	chr4:99064904	C4orf37	0.47	8.38	0.38	8.17e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg19041857	chr6:27730383	NA	-0.37	-6.76	-0.31	4.69e-11	Parkinson's disease;
LUAD	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.53	-0.34	3.18e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs9467603	0.925	rs35436081	chr6:25700342	G/A	cg06606381	chr12:133084897	FBRSL1	-0.75	-6.37	-0.3	4.81e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	0.617	rs1976509	chr11:48964603	C/T	cg15704280	chr7:45808275	SEPT13	0.42	6.53	0.3	1.87e-10	HDL cholesterol;
LUAD	cis	rs11958404	0.932	rs72816564	chr5:157427484	T/C	cg05962755	chr5:157440814	NA	0.69	9.52	0.42	1.31e-19	IgG glycosylation;
LUAD	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg17279839	chr7:150038598	RARRES2	0.43	7.24	0.33	2.19e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs3784262	1.000	rs4646638	chr15:58248783	C/T	cg12031962	chr15:58353849	ALDH1A2	0.45	9.32	0.41	6.38e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg10523679	chr1:76189770	ACADM	-0.75	-11.95	-0.5	1.5e-28	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg10518543	chr12:38710700	ALG10B	-0.43	-7.02	-0.32	8.75e-12	Heart rate;
LUAD	cis	rs9394169	0.709	rs6919321	chr6:33724004	G/A	cg07979401	chr6:33739406	LEMD2	-0.35	-6.96	-0.32	1.33e-11	Essential tremor;
LUAD	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg00310523	chr12:86230176	RASSF9	0.39	7.71	0.35	8.83e-14	Major depressive disorder;
LUAD	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg17971929	chr21:40555470	PSMG1	0.53	8.25	0.37	2e-15	Cognitive function;
LUAD	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.52	0.3	1.95e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2882667	0.858	rs6596460	chr5:138414180	G/A	cg04439458	chr5:138467593	SIL1	-0.5	-9.15	-0.41	2.36e-18	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04509559	chr14:69864994	ERH;SLC39A9	0.44	6.35	0.3	5.52e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs7607369	0.536	rs13033409	chr2:219666509	T/G	cg02176678	chr2:219576539	TTLL4	-0.53	-10.47	-0.45	5.54e-23	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs6835098	0.816	rs13111572	chr4:174159788	G/A	cg27433088	chr4:174089019	GALNT7	-0.4	-7.39	-0.34	7.71e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg04703951	chr17:43578652	NA	0.61	8.32	0.38	1.22e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg10909506	chr17:38081995	ORMDL3	0.39	7.0	0.32	1.02e-11	Self-reported allergy;
LUAD	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.74	-0.61	2.73e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg23954153	chr1:44402353	ARTN	-0.34	-6.71	-0.31	6.34e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs11098699	0.821	rs2047585	chr4:124231984	C/T	cg09941581	chr4:124220074	SPATA5	-0.44	-7.05	-0.32	7.47e-12	Mosquito bite size;
LUAD	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	12.39	0.52	2.73e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.63	-12.05	-0.51	6.04e-29	Ulcerative colitis;
LUAD	trans	rs1973993	0.691	rs1980683	chr1:96890379	A/G	cg10631902	chr5:14652156	NA	0.64	12.73	0.53	1.17e-31	Weight;
LUAD	cis	rs7737355	0.812	rs40991	chr5:131000654	C/A	cg06307176	chr5:131281290	NA	0.54	8.39	0.38	7.46e-16	Life satisfaction;
LUAD	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg15181151	chr6:150070149	PCMT1	0.41	8.39	0.38	7.38e-16	Lung cancer;
LUAD	cis	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg14039649	chr22:38352398	POLR2F	0.37	6.74	0.31	5.12e-11	Glioblastoma;Glioma;
LUAD	cis	rs13185787	1	rs13185787	chr5:130627884	A/G	cg06307176	chr5:131281290	NA	0.39	6.59	0.31	1.33e-10	Subjective well-being;
LUAD	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-8.01	-0.36	1.14e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg26384229	chr12:38710491	ALG10B	0.51	8.37	0.38	8.2e-16	Heart rate;
LUAD	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1559088	1.000	rs11672313	chr19:33563190	C/T	cg03563238	chr19:33554763	RHPN2	-0.38	-8.89	-0.4	1.73e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9341808	0.727	rs4706834	chr6:81012605	G/T	cg08355045	chr6:80787529	NA	0.54	9.67	0.43	3.92e-20	Sitting height ratio;
LUAD	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg04154034	chr17:28927549	LRRC37B2	0.69	6.82	0.31	3.21e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg12927641	chr6:109611667	NA	-0.51	-8.93	-0.4	1.28e-17	Reticulocyte fraction of red cells;
LUAD	trans	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg06606381	chr12:133084897	FBRSL1	-0.62	-7.37	-0.34	9.02e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg21890820	chr11:65308645	LTBP3	1.29	10.83	0.47	2.66e-24	Height;
LUAD	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg27432699	chr2:27873401	GPN1	0.59	10.0	0.44	2.77e-21	Oral cavity cancer;
LUAD	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg11693508	chr17:37793320	STARD3	-0.79	-10.16	-0.44	7.93e-22	Bipolar disorder;
LUAD	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.44	-0.49	1.38e-26	Primary sclerosing cholangitis;
LUAD	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg21153622	chr11:89784906	NA	0.33	6.64	0.31	9.45e-11	Coronary artery disease;
LUAD	trans	rs11039798	1.000	rs10769370	chr11:48515430	A/G	cg03929089	chr4:120376271	NA	0.57	6.65	0.31	9.07e-11	Axial length;
LUAD	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.6	0.31	1.22e-10	Parkinson's disease;
LUAD	cis	rs7512552	0.839	rs12045304	chr1:150399818	G/A	cg15654264	chr1:150340011	RPRD2	0.59	11.31	0.48	4.17e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg22117172	chr7:91764530	CYP51A1	0.34	7.55	0.34	2.79e-13	Breast cancer;
LUAD	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg22508957	chr16:3507546	NAT15	0.81	10.78	0.46	4.29e-24	Tuberculosis;
LUAD	cis	rs750460	1.000	rs750460	chr15:74241506	G/A	cg23484268	chr15:74220776	LOXL1	-0.36	-6.95	-0.32	1.38e-11	Height;
LUAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23375783	chr17:73008576	ICT1	0.41	6.52	0.3	2.05e-10	Response to antipsychotic treatment;
LUAD	cis	rs2425143	1.000	rs2425149	chr20:34359587	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.53	-0.34	3.09e-13	Blood protein levels;
LUAD	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg13770153	chr20:60521292	NA	-0.47	-7.88	-0.36	2.86e-14	Body mass index;
LUAD	trans	rs2262909	1.000	rs2017962	chr19:22208751	T/C	cg17074339	chr11:11642133	GALNTL4	-0.43	-6.81	-0.31	3.42e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs829883	0.724	rs11109507	chr12:98904160	C/T	cg25150519	chr12:98850993	NA	0.53	8.53	0.38	2.58e-16	Colorectal adenoma (advanced);
LUAD	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg12935359	chr14:103987150	CKB	-0.47	-7.87	-0.36	2.9e-14	Body mass index;
LUAD	cis	rs79839061	0.636	rs76839318	chr4:837810	T/A	cg07828340	chr4:882639	GAK	1.08	9.58	0.42	8.08e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg02569458	chr12:86230093	RASSF9	0.41	7.95	0.36	1.77e-14	Major depressive disorder;
LUAD	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg04731861	chr2:219085781	ARPC2	0.27	8.17	0.37	3.51e-15	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs8017423	0.967	rs28424204	chr14:90705669	G/C	cg14092571	chr14:90743983	NA	-0.49	-8.75	-0.39	5.11e-17	Mortality in heart failure;
LUAD	cis	rs11229555	0.609	rs12291791	chr11:58186290	C/T	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg21681030	chr2:46777652	RHOQ	0.38	6.63	0.31	1.03e-10	Height;
LUAD	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-9.89	-0.43	6.75e-21	Bipolar disorder and schizophrenia;
LUAD	trans	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.6	-0.35	1.9e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08048268	chr3:133502702	NA	0.49	9.83	0.43	1.14e-20	Iron status biomarkers;
LUAD	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05901451	chr6:126070800	HEY2	-0.49	-7.44	-0.34	5.84e-13	Endometrial cancer;
LUAD	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg17074396	chr22:49843754	NA	-0.3	-6.43	-0.3	3.4e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.6	-10.33	-0.45	1.83e-22	Menarche (age at onset);
LUAD	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg17042849	chr6:26104293	HIST1H4C	-0.47	-6.52	-0.3	1.96e-10	Iron status biomarkers;
LUAD	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg18705301	chr15:41695430	NDUFAF1	0.6	10.9	0.47	1.52e-24	Ulcerative colitis;
LUAD	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.38	6.6	0.31	1.25e-10	Type 2 diabetes;
LUAD	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg19436804	chr8:8560866	CLDN23	0.42	6.51	0.3	2.18e-10	Obesity-related traits;
LUAD	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg11822812	chr5:140052017	DND1	-0.46	-8.4	-0.38	6.84e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.37	-6.6	-0.31	1.21e-10	Caffeine consumption;
LUAD	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.58	0.3	1.39e-10	Cardiac Troponin-T levels;
LUAD	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg01236616	chr12:121019343	POP5	1.24	19.33	0.68	3.83e-60	Type 1 diabetes nephropathy;
LUAD	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-7.08	-0.33	6e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs8073060	0.586	rs225298	chr17:33923946	T/G	cg19694781	chr19:47549865	TMEM160	-1.26	-20.4	-0.7	6.28e-65	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg07936489	chr17:37558343	FBXL20	0.45	7.17	0.33	3.43e-12	Glomerular filtration rate (creatinine);
LUAD	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg27661571	chr11:113659931	NA	-0.62	-7.99	-0.36	1.29e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs11771526	0.748	rs4723142	chr7:32337569	C/A	cg13207630	chr7:32358064	NA	0.53	6.84	0.32	2.86e-11	Body mass index;
LUAD	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg00933542	chr6:150070202	PCMT1	0.44	9.55	0.42	1.08e-19	Lung cancer;
LUAD	cis	rs7301016	0.817	rs7302456	chr12:62997643	G/T	cg11441379	chr12:63026424	NA	0.6	7.65	0.35	1.36e-13	IgG glycosylation;
LUAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg07677032	chr17:61819896	STRADA	-0.57	-10.5	-0.45	4.62e-23	Prudent dietary pattern;
LUAD	cis	rs1832871	0.655	rs4273715	chr6:158722847	T/C	cg07165851	chr6:158734300	TULP4	0.7	10.92	0.47	1.23e-24	Height;
LUAD	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg18867708	chr6:26865862	GUSBL1	0.44	7.07	0.32	6.58e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg03929089	chr4:120376271	NA	-0.92	-17.23	-0.64	8.64e-51	Height;
LUAD	cis	rs877282	0.891	rs11253355	chr10:768367	C/G	cg17470449	chr10:769945	NA	0.61	8.66	0.39	9.93e-17	Uric acid levels;
LUAD	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg12863693	chr15:85201151	NMB	0.43	7.91	0.36	2.31e-14	Schizophrenia;
LUAD	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg06453172	chr10:134556979	INPP5A	-0.63	-9.93	-0.43	4.98e-21	Migraine;
LUAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg10862848	chr6:42927986	GNMT	-0.31	-8.8	-0.39	3.42e-17	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg24813613	chr7:1882135	MAD1L1	-0.43	-6.69	-0.31	6.89e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2637266	0.935	rs7900900	chr10:78367383	A/T	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg22535103	chr8:58192502	C8orf71	-0.72	-8.94	-0.4	1.24e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.6	-0.35	1.87e-13	Personality dimensions;
LUAD	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg22906224	chr7:99728672	NA	-0.56	-9.73	-0.43	2.45e-20	Coronary artery disease;
LUAD	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg13606994	chr1:44402422	ARTN	-0.35	-7.17	-0.33	3.41e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9644630	1.000	rs9644630	chr8:19370598	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.3	-7.19	-0.33	2.98e-12	Oropharynx cancer;
LUAD	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg09365446	chr1:150670422	GOLPH3L	0.54	9.47	0.42	1.97e-19	Melanoma;
LUAD	cis	rs2455799	0.613	rs7633542	chr3:15816326	C/T	cg16303742	chr3:15540471	COLQ	-0.49	-9.16	-0.41	2.21e-18	Mean platelet volume;
LUAD	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-8.34	-0.38	1.09e-15	Total cholesterol levels;
LUAD	trans	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	cis	rs4845570	1.000	rs6683364	chr1:151746202	T/A	cg07092448	chr1:151763213	TDRKH	-0.74	-8.71	-0.39	7.01e-17	Coronary artery disease;
LUAD	trans	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg07211511	chr3:129823064	LOC729375	-0.55	-7.31	-0.33	1.39e-12	Blood pressure (smoking interaction);
LUAD	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.52	0.3	1.97e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.732	rs77615390	chr2:198454790	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.89	-0.32	2.01e-11	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.91	0.32	1.75e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg13699009	chr12:122356056	WDR66	0.29	6.5	0.3	2.33e-10	Mean corpuscular volume;
LUAD	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg17063962	chr7:91808500	NA	0.66	11.14	0.48	1.94e-25	Breast cancer;
LUAD	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg18402987	chr7:1209562	NA	0.79	9.73	0.43	2.52e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05901451	chr6:126070800	HEY2	0.45	7.09	0.33	5.73e-12	Endometrial cancer;
LUAD	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg10434728	chr15:90938212	IQGAP1	0.37	7.33	0.34	1.2e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs71636778	0.543	rs11810321	chr1:27220521	T/G	cg12203394	chr1:27248618	NUDC	0.54	6.83	0.32	2.92e-11	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	6.45	0.3	2.98e-10	Aortic root size;
LUAD	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.85	-0.32	2.7e-11	Breast cancer;
LUAD	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg08508325	chr11:3079039	CARS	-0.61	-13.4	-0.55	2.29e-34	Longevity;
LUAD	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.06	-0.54	5.68e-33	Chronic sinus infection;
LUAD	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg17105886	chr17:28927953	LRRC37B2	0.59	6.72	0.31	6.02e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg26043149	chr18:55253948	FECH	0.42	6.89	0.32	2.1e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.68	-10.37	-0.45	1.38e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg06627628	chr2:24431161	ITSN2	0.54	8.9	0.4	1.61e-17	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12379764	chr21:47803548	PCNT	0.61	9.72	0.43	2.74e-20	Testicular germ cell tumor;
LUAD	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.6	10.59	0.46	2.07e-23	Birth weight;
LUAD	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg15557168	chr22:42548783	NA	0.35	6.48	0.3	2.52e-10	Cognitive function;
LUAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg24846343	chr22:24311635	DDTL	0.78	17.8	0.65	2.76e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg07507251	chr3:52567010	NT5DC2	0.39	7.68	0.35	1.14e-13	Electroencephalogram traits;
LUAD	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg10589385	chr1:150898437	SETDB1	0.41	7.54	0.34	2.92e-13	Melanoma;
LUAD	cis	rs877282	0.891	rs11253406	chr10:796297	G/A	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg26769984	chr7:1090371	C7orf50	0.44	7.49	0.34	3.93e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg03733263	chr8:22462867	KIAA1967	0.63	9.98	0.44	3.41e-21	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs4713675	0.565	rs9469566	chr6:33667605	G/T	cg14003231	chr6:33640908	ITPR3	0.47	9.2	0.41	1.69e-18	Plateletcrit;
LUAD	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg01324343	chr3:183735012	ABCC5	0.96	25.54	0.78	9.69e-88	Anterior chamber depth;
LUAD	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg06108461	chr20:60628389	TAF4	-1.12	-20.51	-0.71	2.18e-65	Body mass index;
LUAD	cis	rs977987	0.843	rs67409275	chr16:75457212	T/C	cg03315344	chr16:75512273	CHST6	0.63	13.75	0.56	7.87e-36	Dupuytren's disease;
LUAD	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg14092571	chr14:90743983	NA	-0.49	-8.69	-0.39	7.97e-17	Mortality in heart failure;
LUAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03452623	chr4:187889614	NA	-0.81	-16.4	-0.62	3.81e-47	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3760982	0.845	rs62116962	chr19:44287234	A/G	cg11993925	chr19:44307056	LYPD5	-0.43	-8.41	-0.38	6.24e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg23387056	chr11:14280742	SPON1	0.38	7.69	0.35	1.05e-13	Mitochondrial DNA levels;
LUAD	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.81	-0.5	5.28e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.51	0.3	2.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22496380	chr5:211416	CCDC127	-1.21	-16.15	-0.62	4.82e-46	Breast cancer;
LUAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03647317	chr4:187891568	NA	-0.36	-6.64	-0.31	9.4e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg23283495	chr1:209979779	IRF6	0.71	10.26	0.45	3.29e-22	Cleft lip with or without cleft palate;
LUAD	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg15017067	chr4:17643749	FAM184B	0.36	7.07	0.33	6.47e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg08742575	chr21:47604166	C21orf56	0.63	11.07	0.47	3.4e-25	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg03676636	chr4:99064102	C4orf37	-0.32	-8.12	-0.37	5.3e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg20578329	chr17:80767326	TBCD	-0.64	-7.57	-0.35	2.36e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.07	-0.37	7.46e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs10504073	0.647	rs4873096	chr8:49995201	A/G	cg00325661	chr8:49890786	NA	0.45	10.09	0.44	1.39e-21	Blood metabolite ratios;
LUAD	cis	rs11718455	0.960	rs3843372	chr3:43997666	C/T	cg08738300	chr3:44038990	NA	0.42	6.37	0.3	4.87e-10	Coronary artery disease;
LUAD	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg04450456	chr4:17643702	FAM184B	0.37	7.03	0.32	8.49e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg14092571	chr14:90743983	NA	-0.49	-8.78	-0.39	4.11e-17	Mortality in heart failure;
LUAD	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg02733842	chr7:1102375	C7orf50	-0.59	-9.29	-0.41	8.41e-19	Bronchopulmonary dysplasia;
LUAD	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg07917127	chr4:99064746	C4orf37	0.45	7.26	0.33	1.93e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2235649	0.798	rs9922462	chr16:1848011	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.5	-8.38	-0.38	8.03e-16	Blood metabolite levels;
LUAD	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.68	-12.79	-0.53	7.1e-32	Ulcerative colitis;
LUAD	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.62	-0.35	1.67e-13	Personality dimensions;
LUAD	cis	rs2404602	0.552	rs11636612	chr15:76959530	C/T	cg23625390	chr15:77176239	SCAPER	-0.46	-6.4	-0.3	4.14e-10	Blood metabolite levels;
LUAD	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg10523679	chr1:76189770	ACADM	0.83	13.24	0.54	9.72e-34	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg03806693	chr22:41940476	POLR3H	-0.49	-7.34	-0.34	1.1e-12	Vitiligo;
LUAD	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg19077165	chr18:44547161	KATNAL2	0.41	7.19	0.33	3.04e-12	Personality dimensions;
LUAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.26	0.37	1.85e-15	Alzheimer's disease;
LUAD	cis	rs3768617	0.510	rs3768616	chr1:183103551	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.38	6.4	0.3	4.17e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg16031515	chr1:205743344	RAB7L1	-0.37	-7.48	-0.34	4.4e-13	Menarche (age at onset);
LUAD	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg02269571	chr22:50332266	NA	0.59	8.96	0.4	1.05e-17	Schizophrenia;
LUAD	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg03713592	chr11:72463424	ARAP1	0.63	7.98	0.36	1.43e-14	Type 2 diabetes;
LUAD	cis	rs6840360	0.571	rs4696110	chr4:152671325	G/A	cg22705602	chr4:152727874	NA	-0.47	-9.17	-0.41	2.02e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg22875332	chr1:76189707	ACADM	0.84	16.83	0.63	4.9e-49	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg18932078	chr1:2524107	MMEL1	0.37	7.06	0.32	6.75e-12	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg20607798	chr8:58055168	NA	0.77	9.29	0.41	8.01e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.8	0.76	4.34e-80	Chronic sinus infection;
LUAD	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg11822372	chr1:151115635	SEMA6C	0.48	6.7	0.31	6.8e-11	Childhood ear infection;
LUAD	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg26874164	chr19:58962979	ZNF324B	0.43	6.9	0.32	1.86e-11	Uric acid clearance;
LUAD	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg16060761	chr17:80687452	NA	-0.46	-6.9	-0.32	1.9e-11	Breast cancer;
LUAD	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg02734326	chr4:10020555	SLC2A9	-0.42	-7.27	-0.33	1.75e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12618769	0.652	rs3769701	chr2:99195111	A/C	cg10123293	chr2:99228465	UNC50	0.49	8.79	0.39	3.82e-17	Bipolar disorder;
LUAD	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-8.62	-0.39	1.31e-16	Gut microbiome composition (summer);
LUAD	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg17200465	chr3:40428508	ENTPD3	0.27	6.57	0.3	1.51e-10	Renal cell carcinoma;
LUAD	cis	rs12541635	1.000	rs11992752	chr8:107083122	G/A	cg10147462	chr8:107024639	NA	-0.43	-7.62	-0.35	1.71e-13	Age of smoking initiation;
LUAD	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.06	-0.44	1.77e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg23992470	chr4:843637	GAK	-0.7	-7.37	-0.34	9.33e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2274273	1.000	rs8011834	chr14:55625977	A/C	cg04306507	chr14:55594613	LGALS3	0.37	7.82	0.36	4.2e-14	Protein biomarker;
LUAD	cis	rs10493773	0.649	rs17398321	chr1:86084493	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.46	-7.0	-0.32	1.03e-11	Urate levels in overweight individuals;
LUAD	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg08027265	chr7:2291960	NA	-0.42	-7.33	-0.34	1.14e-12	Schizophrenia;
LUAD	cis	rs2282300	0.739	rs2225909	chr11:30329744	T/C	cg06241208	chr11:30344200	C11orf46	0.57	7.31	0.33	1.33e-12	Morning vs. evening chronotype;
LUAD	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg05368731	chr17:41323189	NBR1	0.96	20.23	0.7	3.7e-64	Menopause (age at onset);
LUAD	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.39	6.5	0.3	2.29e-10	Systemic lupus erythematosus;
LUAD	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.76	14.22	0.57	8.66e-38	Intelligence (multi-trait analysis);
LUAD	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg03709012	chr19:19516395	GATAD2A	0.51	6.63	0.31	1.05e-10	Nonalcoholic fatty liver disease;
LUAD	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg03983476	chr2:10830698	NOL10	-0.45	-7.87	-0.36	3.08e-14	Prostate cancer;
LUAD	cis	rs2131877	0.913	rs9825498	chr3:194848021	G/C	cg19760965	chr3:194868843	C3orf21	0.39	6.49	0.3	2.37e-10	Non-small cell lung cancer;
LUAD	cis	rs12900413	0.687	rs28653538	chr15:90304964	T/C	cg24249390	chr15:90295951	MESP1	-0.34	-6.45	-0.3	2.97e-10	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg17863274	chr19:49399704	TULP2	-0.58	-9.09	-0.4	3.86e-18	Red cell distribution width;
LUAD	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10802521	chr3:52805072	NEK4	-0.54	-9.1	-0.4	3.51e-18	Bipolar disorder;
LUAD	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.1	-24.16	-0.76	1.18e-81	Ulcerative colitis;
LUAD	cis	rs8014204	0.836	rs7150254	chr14:75299101	G/A	cg06637938	chr14:75390232	RPS6KL1	0.39	7.17	0.33	3.37e-12	Caffeine consumption;
LUAD	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg00802000	chr16:706648	WDR90	-0.38	-7.14	-0.33	4.15e-12	Height;
LUAD	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06028808	chr11:68637592	NA	0.49	8.15	0.37	4.17e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs68170813	0.559	rs74898466	chr7:107053998	C/A	cg23024343	chr7:107201750	COG5	0.47	6.77	0.31	4.38e-11	Coronary artery disease;
LUAD	cis	rs7267979	1.000	rs6050555	chr20:25328543	A/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.74	-0.39	5.45e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg03948781	chr1:205179583	DSTYK	0.33	6.43	0.3	3.48e-10	Red blood cell count;
LUAD	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg18190219	chr22:46762943	CELSR1	-0.46	-6.84	-0.32	2.82e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs13064411	0.696	rs7610638	chr3:113139656	A/G	cg10517650	chr3:113235015	CCDC52	-0.52	-8.68	-0.39	8.89e-17	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg27535305	chr1:53392650	SCP2	0.35	7.34	0.34	1.12e-12	Monocyte count;
LUAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg08132940	chr7:1081526	C7orf50	-0.77	-10.36	-0.45	1.49e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg07870213	chr5:140052090	DND1	0.72	9.89	0.43	7.1e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg12011299	chr4:100065546	ADH4	0.67	13.98	0.56	8.99e-37	Alcohol dependence;
LUAD	cis	rs7824557	0.602	rs7828711	chr8:11205665	G/C	cg21775007	chr8:11205619	TDH	0.55	9.82	0.43	1.24e-20	Retinal vascular caliber;
LUAD	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg03034668	chr16:1723424	CRAMP1L	-0.39	-6.64	-0.31	9.47e-11	Coronary artery disease;
LUAD	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg26408565	chr15:76604113	ETFA	-0.56	-9.81	-0.43	1.27e-20	Blood metabolite levels;
LUAD	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	7.14	0.33	4.16e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg19743168	chr1:23544995	NA	0.36	6.44	0.3	3.23e-10	Height;
LUAD	cis	rs6723108	0.616	rs6752634	chr2:135407355	G/A	cg12500956	chr2:135428796	TMEM163	-0.29	-7.6	-0.35	1.87e-13	Type 2 diabetes;
LUAD	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22968622	chr17:43663579	NA	-1.18	-19.73	-0.69	6.31e-62	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs62238980	0.614	rs78907591	chr22:32459673	T/C	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs123509	0.874	rs339683	chr3:42788511	G/T	cg10144569	chr3:42726640	KBTBD5	0.5	7.78	0.35	5.42e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2932538	0.922	rs6537744	chr1:113096746	C/G	cg22162597	chr1:113214053	CAPZA1	0.46	6.93	0.32	1.62e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg02221422	chr11:68192511	LRP5	0.41	6.82	0.31	3.13e-11	Total body bone mineral density;
LUAD	cis	rs4664308	1.000	rs2175416	chr2:160904021	G/A	cg03641300	chr2:160917029	PLA2R1	-0.4	-6.91	-0.32	1.76e-11	Idiopathic membranous nephropathy;
LUAD	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg23533926	chr12:111358616	MYL2	-0.4	-6.77	-0.31	4.23e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg18477163	chr1:228402036	OBSCN	-0.35	-6.99	-0.32	1.08e-11	Diastolic blood pressure;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05446994	chr1:20960538	PINK1	-0.42	-6.39	-0.3	4.35e-10	Height;
LUAD	trans	rs78049276	0.736	rs72957606	chr4:148400011	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.57	-6.64	-0.31	9.73e-11	Pulse pressure;
LUAD	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg21285383	chr16:89894308	SPIRE2	0.42	10.43	0.45	7.82e-23	Vitiligo;
LUAD	cis	rs11671005	0.779	rs11670125	chr19:58987390	G/T	cg13877915	chr19:58951672	ZNF132	0.57	7.09	0.33	5.68e-12	Mean platelet volume;
LUAD	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg05872129	chr22:39784769	NA	-0.72	-11.31	-0.48	4.34e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg24803719	chr17:45855879	NA	-0.35	-7.96	-0.36	1.57e-14	IgG glycosylation;
LUAD	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.45	-0.34	5.42e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg26384229	chr12:38710491	ALG10B	0.45	7.34	0.34	1.09e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg04455712	chr21:45112962	RRP1B	0.47	9.24	0.41	1.21e-18	Mean corpuscular volume;
LUAD	cis	rs7215564	0.822	rs2340769	chr17:78755271	C/T	cg09596252	chr17:78655493	RPTOR	-0.62	-6.83	-0.32	3.01e-11	Myopia (pathological);
LUAD	cis	rs7799006	1.000	rs7787274	chr7:2275993	G/A	cg08027265	chr7:2291960	NA	-0.59	-10.9	-0.47	1.54e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs9902453	0.904	rs8071742	chr17:28361669	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.26	-0.41	1e-18	Coffee consumption (cups per day);
LUAD	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg08508325	chr11:3079039	CARS	0.44	9.16	0.41	2.2e-18	Calcium levels;
LUAD	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.3	-0.33	1.47e-12	Resting heart rate;
LUAD	cis	rs657075	0.697	rs35948329	chr5:131686452	T/A	cg21138405	chr5:131827807	IRF1	0.52	6.46	0.3	2.93e-10	Rheumatoid arthritis;
LUAD	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg03233332	chr7:66118400	NA	-0.46	-6.89	-0.32	2e-11	Aortic root size;
LUAD	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg00376283	chr12:123451042	ABCB9	0.41	6.58	0.3	1.41e-10	Platelet count;
LUAD	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg25358565	chr5:93447407	FAM172A	0.61	7.54	0.34	2.97e-13	Diabetic retinopathy;
LUAD	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg16486109	chr11:613632	IRF7	0.54	9.0	0.4	7.62e-18	Systemic lupus erythematosus;
LUAD	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg11766577	chr21:47581405	C21orf56	-0.5	-8.16	-0.37	3.94e-15	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1045714	0.836	rs56246161	chr7:2644679	G/A	cg24848437	chr7:2645542	IQCE	0.66	7.52	0.34	3.23e-13	Urate levels in lean individuals;
LUAD	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg18240062	chr17:79603768	NPLOC4	0.36	6.35	0.3	5.42e-10	Eye color traits;
LUAD	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg25767906	chr1:53392781	SCP2	0.65	11.96	0.5	1.3e-28	Monocyte count;
LUAD	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg11339718	chr16:89000225	CBFA2T3	-0.33	-6.48	-0.3	2.54e-10	Social autistic-like traits;
LUAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg22963979	chr7:1858916	MAD1L1	-0.71	-12.55	-0.52	6.26e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs2932538	0.922	rs12750621	chr1:113206502	G/C	cg22162597	chr1:113214053	CAPZA1	0.45	6.53	0.3	1.89e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs1595825	0.891	rs111340803	chr2:198612877	A/G	cg10547527	chr2:198650123	BOLL	-0.55	-7.76	-0.35	6.31e-14	Ulcerative colitis;
LUAD	cis	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg12964065	chr18:77638022	KCNG2	0.54	6.71	0.31	6.14e-11	Opioid sensitivity;
LUAD	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19717773	chr7:2847554	GNA12	-0.56	-9.38	-0.41	4.15e-19	Height;
LUAD	trans	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg14791747	chr16:20752902	THUMPD1	0.48	7.3	0.33	1.46e-12	Pancreatic cancer;
LUAD	cis	rs3760982	0.935	rs10422990	chr19:44295273	C/T	cg11993925	chr19:44307056	LYPD5	0.42	8.42	0.38	5.9e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg03213289	chr20:61660250	NA	0.69	15.05	0.59	2.55e-41	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg08754654	chr5:154026448	NA	0.48	8.23	0.37	2.29e-15	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.41	0.45	9.8e-23	Prudent dietary pattern;
LUAD	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg27490568	chr2:178487706	NA	0.4	6.82	0.31	3.1e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6011002	0.745	rs2261092	chr20:62353933	A/G	cg01176363	chr20:62369445	LIME1	-0.79	-6.64	-0.31	9.47e-11	Dental caries;
LUAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg14789911	chr21:47582049	C21orf56	0.48	8.6	0.39	1.62e-16	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08280861	chr8:58055591	NA	0.63	8.31	0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs775227	0.574	rs13086266	chr3:113083535	T/A	cg10517650	chr3:113235015	CCDC52	-0.5	-6.61	-0.31	1.19e-10	Dental caries;
LUAD	cis	rs7927592	0.830	rs11228240	chr11:68218290	C/T	cg16797656	chr11:68205561	LRP5	0.49	9.21	0.41	1.59e-18	Total body bone mineral density;
LUAD	cis	rs7659604	0.521	rs4240263	chr4:122683623	C/T	cg06713675	chr4:122721982	EXOSC9	0.42	7.61	0.35	1.79e-13	Type 2 diabetes;
LUAD	cis	rs62400317	0.859	rs12196217	chr6:45204921	C/T	cg20913747	chr6:44695427	NA	-0.41	-6.37	-0.3	5.05e-10	Total body bone mineral density;
LUAD	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg21545522	chr1:205238299	TMCC2	0.38	6.98	0.32	1.14e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-7.14	-0.33	4.07e-12	Bipolar disorder;
LUAD	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg20291162	chr17:40259547	DHX58	-0.7	-10.99	-0.47	6.82e-25	Fibrinogen levels;
LUAD	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg16414030	chr3:133502952	NA	-0.52	-9.33	-0.41	5.81e-19	Iron status biomarkers;
LUAD	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg24838063	chr12:130822603	PIWIL1	0.66	10.78	0.46	4.28e-24	Menopause (age at onset);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07704495	chr21:43916519	RSPH1	-0.55	-6.59	-0.31	1.33e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg01620082	chr3:125678407	NA	-0.41	-6.44	-0.3	3.26e-10	Parkinson's disease;
LUAD	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg08885076	chr2:99613938	TSGA10	0.37	6.74	0.31	5.35e-11	Chronic sinus infection;
LUAD	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.48	-8.64	-0.39	1.15e-16	Menarche (age at onset);
LUAD	cis	rs427394	0.743	rs274716	chr5:6722289	T/C	cg10857441	chr5:6722123	POLS	-0.67	-12.79	-0.53	6.62e-32	Menopause (age at onset);
LUAD	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.57	-10.88	-0.47	1.84e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3736594	0.918	rs9967838	chr2:27968454	A/C	cg27432699	chr2:27873401	GPN1	-0.48	-7.41	-0.34	7.11e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.43	-0.38	5.57e-16	Total body bone mineral density;
LUAD	cis	rs755249	0.565	rs12138051	chr1:39948224	A/G	cg27567593	chr1:39956653	BMP8A	0.35	7.18	0.33	3.13e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg26924012	chr15:45694286	SPATA5L1	0.87	14.95	0.59	7.46e-41	Homoarginine levels;
LUAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.8	0.56	4.98e-36	Prudent dietary pattern;
LUAD	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg27535305	chr1:53392650	SCP2	0.35	7.34	0.34	1.12e-12	Monocyte count;
LUAD	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg09165964	chr15:75287851	SCAMP5	-0.48	-7.18	-0.33	3.22e-12	Blood trace element (Zn levels);
LUAD	trans	rs8073060	0.559	rs17550632	chr17:33890883	G/C	cg19694781	chr19:47549865	TMEM160	1.23	19.23	0.68	1.15e-59	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg09137382	chr11:130731461	NA	0.4	7.42	0.34	6.48e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1395	0.744	rs11679220	chr2:27476378	G/A	cg23587288	chr2:27483067	SLC30A3	-0.41	-7.48	-0.34	4.33e-13	Blood metabolite levels;
LUAD	trans	rs225245	0.791	rs4796103	chr17:34025182	A/G	cg19694781	chr19:47549865	TMEM160	-0.48	-7.93	-0.36	1.99e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg02421172	chr7:1938701	MAD1L1	0.45	6.61	0.31	1.17e-10	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4660306	1.000	rs6667191	chr1:45982844	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-8.11	-0.37	5.72e-15	Homocysteine levels;
LUAD	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg00277334	chr10:82204260	NA	-0.6	-10.02	-0.44	2.48e-21	Post bronchodilator FEV1;
LUAD	cis	rs8044868	0.548	rs3909541	chr16:72201119	C/T	cg23815491	chr16:72088622	HP	-0.45	-8.4	-0.38	6.71e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs2657888	0.529	rs71459376	chr12:56889139	C/G	cg23002907	chr12:56915593	RBMS2	-0.4	-7.06	-0.32	7.01e-12	Adiponectin levels;
LUAD	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg18827107	chr12:86230957	RASSF9	-0.56	-9.88	-0.43	7.31e-21	Major depressive disorder;
LUAD	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg23018236	chr17:30244563	NA	-0.68	-8.31	-0.37	1.3e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg11965913	chr1:205819406	PM20D1	0.49	6.89	0.32	2.04e-11	Parkinson's disease;
LUAD	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg23229984	chr5:148520753	ABLIM3	-0.46	-7.58	-0.35	2.25e-13	Breast cancer;
LUAD	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg01579765	chr21:45077557	HSF2BP	-0.64	-15.2	-0.59	5.96e-42	Mean corpuscular volume;
LUAD	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg20607287	chr7:12443886	VWDE	-0.54	-6.85	-0.32	2.59e-11	Coronary artery disease;
LUAD	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg11871910	chr12:69753446	YEATS4	0.68	11.27	0.48	6e-26	Blood protein levels;
LUAD	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg15704280	chr7:45808275	SEPT13	0.63	8.35	0.38	9.95e-16	Axial length;
LUAD	cis	rs10426930	0.700	rs10407399	chr19:5009466	A/C	cg25246084	chr19:4971487	KDM4B	0.44	7.94	0.36	1.8e-14	Monocyte percentage of white cells;
LUAD	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg03433033	chr1:76189801	ACADM	0.85	15.16	0.59	9.2e-42	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg12365402	chr11:9010492	NRIP3	0.48	8.91	0.4	1.48e-17	Hemoglobin concentration;
LUAD	trans	rs8002861	0.967	rs7999434	chr13:44482961	T/C	cg17145862	chr1:211918768	LPGAT1	0.75	17.76	0.65	3.8e-53	Leprosy;
LUAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.71e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg06641503	chr3:48959341	ARIH2	-0.4	-7.97	-0.36	1.52e-14	Parkinson's disease;
LUAD	trans	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.44	-0.34	5.79e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg20607287	chr7:12443886	VWDE	-0.54	-6.82	-0.31	3.25e-11	Coronary artery disease;
LUAD	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg02734326	chr4:10020555	SLC2A9	0.64	11.35	0.48	3.04e-26	Bone mineral density;
LUAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg21724239	chr8:58056113	NA	0.64	8.19	0.37	3.04e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg23992470	chr4:843637	GAK	0.7	7.28	0.33	1.65e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7614311	0.681	rs6776209	chr3:63858633	G/C	cg22134162	chr3:63841271	THOC7	-0.43	-7.45	-0.34	5.39e-13	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg14583973	chr4:3374767	RGS12	0.28	6.83	0.32	2.95e-11	Serum sulfate level;
LUAD	cis	rs2286503	0.839	rs2270105	chr7:22862467	G/A	cg06496272	chr7:22895283	SNORD93	-0.41	-7.27	-0.33	1.74e-12	Fibrinogen;
LUAD	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg07741184	chr6:167504864	NA	0.29	7.0	0.32	9.82e-12	Crohn's disease;
LUAD	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg26408565	chr15:76604113	ETFA	0.59	9.98	0.44	3.3e-21	Blood metabolite levels;
LUAD	trans	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg03886242	chr7:26192032	NFE2L3	-0.44	-7.57	-0.35	2.44e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs354225	0.544	rs11892443	chr2:54805776	A/G	cg01766943	chr2:54829624	SPTBN1	0.4	7.41	0.34	6.73e-13	Schizophrenia;
LUAD	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg06060754	chr5:176797920	RGS14	-0.54	-8.96	-0.4	1.08e-17	Urate levels in lean individuals;
LUAD	cis	rs834811	0.505	rs7789711	chr7:135938979	C/T	cg01726295	chr7:135938950	NA	-0.32	-8.28	-0.37	1.58e-15	Post-traumatic stress disorder;
LUAD	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg10589385	chr1:150898437	SETDB1	0.39	7.42	0.34	6.51e-13	Tonsillectomy;
LUAD	cis	rs295140	0.546	rs842830	chr2:201131124	C/T	cg17644776	chr2:200775616	C2orf69	-0.38	-6.53	-0.3	1.84e-10	QT interval;
LUAD	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs4714291	0.802	rs2984430	chr6:39983741	A/G	cg02267698	chr19:7991119	CTXN1	-0.46	-7.2	-0.33	2.78e-12	Strep throat;
LUAD	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg09904177	chr6:26538194	HMGN4	0.4	6.45	0.3	3.09e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4638749	0.773	rs4676190	chr2:108858619	A/G	cg25838818	chr2:108905173	SULT1C2	-0.57	-8.52	-0.38	2.93e-16	Blood pressure;
LUAD	cis	rs938554	0.692	rs13111638	chr4:9996890	A/G	cg00071950	chr4:10020882	SLC2A9	0.6	8.73	0.39	6.14e-17	Blood metabolite levels;
LUAD	trans	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg14791747	chr16:20752902	THUMPD1	0.9	16.14	0.62	5.21e-46	Cognitive test performance;
LUAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg11965913	chr1:205819406	PM20D1	0.95	23.07	0.75	8.19e-77	Menarche (age at onset);
LUAD	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.61	-0.35	1.83e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9768139	0.658	rs896778	chr7:158113270	A/G	cg25566285	chr7:158114605	PTPRN2	0.51	10.7	0.46	8.35e-24	Calcium levels;
LUAD	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.41e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg09085632	chr11:111637200	PPP2R1B	0.64	10.82	0.47	2.95e-24	Primary sclerosing cholangitis;
LUAD	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.57	10.44	0.45	7.49e-23	Axial length;
LUAD	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.53	-11.01	-0.47	6.06e-25	Monocyte percentage of white cells;
LUAD	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg26384229	chr12:38710491	ALG10B	-0.42	-7.08	-0.33	5.95e-12	Morning vs. evening chronotype;
LUAD	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.66	-0.35	1.27e-13	Alzheimer's disease (late onset);
LUAD	cis	rs2386661	0.826	rs7092383	chr10:5671101	A/C	cg26603656	chr10:5671107	NA	0.42	7.18	0.33	3.16e-12	Breast cancer;
LUAD	cis	rs6430585	0.583	rs60253740	chr2:136571852	G/T	cg07169764	chr2:136633963	MCM6	0.73	8.81	0.39	3.26e-17	Corneal structure;
LUAD	cis	rs4594175	0.926	rs10145287	chr14:51626808	G/T	cg23942311	chr14:51606299	NA	0.65	11.27	0.48	5.93e-26	Cancer;
LUAD	cis	rs13082711	0.522	rs574955	chr3:27351000	T/C	cg02860705	chr3:27208620	NA	0.51	8.57	0.38	1.96e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs17152411	0.895	rs7084646	chr10:126585738	T/C	cg07906193	chr10:126599966	NA	0.54	7.65	0.35	1.34e-13	Height;
LUAD	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg22868518	chr11:507468	RNH1	-0.66	-6.65	-0.31	8.81e-11	Body mass index;
LUAD	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg14552801	chr7:65878734	NA	0.37	6.47	0.3	2.64e-10	Aortic root size;
LUAD	cis	rs11229555	0.957	rs10896796	chr11:58394256	A/G	cg15696309	chr11:58395628	NA	-0.73	-10.98	-0.47	7.29e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11890956	chr21:40555474	PSMG1	0.7	11.5	0.49	8.26e-27	Cognitive function;
LUAD	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg03467027	chr4:99064603	C4orf37	0.39	6.45	0.3	3.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg14092988	chr3:52407081	DNAH1	0.44	8.86	0.4	2.28e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg17366294	chr4:99064904	C4orf37	-0.67	-13.09	-0.54	4.18e-33	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg23625390	chr15:77176239	SCAPER	-0.5	-7.82	-0.36	4.16e-14	Blood metabolite levels;
LUAD	cis	rs7215564	0.908	rs9972968	chr17:78652569	T/C	cg09596252	chr17:78655493	RPTOR	0.51	6.48	0.3	2.6200000000000003e-10	Myopia (pathological);
LUAD	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg27129171	chr3:47204927	SETD2	0.39	6.42	0.3	3.68e-10	Colorectal cancer;
LUAD	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.09	-0.37	6.38e-15	Personality dimensions;
LUAD	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-11.13	-0.48	2.03e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg02733842	chr7:1102375	C7orf50	-0.55	-8.68	-0.39	8.68e-17	Bronchopulmonary dysplasia;
LUAD	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23583168	chr7:148888333	NA	-0.91	-18.15	-0.66	7.25e-55	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7937890	0.559	rs4369365	chr11:14444515	C/G	cg23387056	chr11:14280742	SPON1	-0.35	-6.71	-0.31	6.2e-11	Mitochondrial DNA levels;
LUAD	cis	rs9902453	0.935	rs4310926	chr17:28433275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.69	0.43	3.37e-20	Coffee consumption (cups per day);
LUAD	cis	rs367615	0.842	rs2578484	chr5:108950808	G/A	cg17395555	chr5:108820864	NA	-0.41	-6.89	-0.32	1.98e-11	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26314531	chr2:26401878	FAM59B	-0.56	-7.73	-0.35	7.77e-14	Gut microbiome composition (summer);
LUAD	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg05673287	chr15:77411982	SGK269	-0.41	-7.23	-0.33	2.27e-12	Type 2 diabetes;
LUAD	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg26528668	chr16:1614120	IFT140	0.57	10.23	0.45	4.11e-22	Coronary artery disease;
LUAD	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg13699009	chr12:122356056	WDR66	0.33	7.08	0.33	6.01e-12	Mean corpuscular volume;
LUAD	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg21798802	chr22:38057573	PDXP	0.38	7.78	0.35	5.57e-14	Fat distribution (HIV);
LUAD	cis	rs11051970	0.636	rs2733704	chr12:32567858	C/T	cg02745156	chr12:32552066	NA	0.31	6.79	0.31	3.9e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.76	0.39	4.66e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs220324	0.688	rs73223565	chr21:43567682	G/A	cg08841829	chr21:43638893	ABCG1	-0.47	-6.78	-0.31	3.99e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg21823605	chr1:152486609	CRCT1	-0.3	-6.9	-0.32	1.89e-11	Hair morphology;
LUAD	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg10556349	chr10:835070	NA	0.68	8.13	0.37	4.75e-15	Eosinophil percentage of granulocytes;
LUAD	cis	rs7809799	0.571	rs740160	chr7:98957880	C/T	cg12290671	chr7:99195819	NA	-0.77	-6.61	-0.31	1.16e-10	Ulcerative colitis;
LUAD	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg00757033	chr12:89920650	WDR51B	0.7	12.14	0.51	2.6e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg04703951	chr17:43578652	NA	0.6	8.11	0.37	5.63e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg25324976	chr17:61989376	CSHL1	0.34	6.68	0.31	7.47e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9905704	0.633	rs8068455	chr17:56589381	C/T	cg19466818	chr17:56409534	MIR142	0.35	6.78	0.31	4.16e-11	Testicular germ cell tumor;
LUAD	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg13385794	chr1:248469461	NA	0.26	6.96	0.32	1.28e-11	Common traits (Other);
LUAD	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg15704280	chr7:45808275	SEPT13	-0.95	-18.42	-0.67	4.42e-56	Coronary artery disease;
LUAD	cis	rs7432375	0.580	rs4678442	chr3:136532971	A/G	cg15507776	chr3:136538369	TMEM22	0.39	6.96	0.32	1.3e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg01191920	chr7:158217561	PTPRN2	-0.62	-12.73	-0.53	1.23e-31	Obesity-related traits;
LUAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08677398	chr8:58056175	NA	0.48	6.83	0.32	2.94e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-6.47	-0.3	2.77e-10	Bipolar disorder;
LUAD	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg19678392	chr7:94953810	PON1	-0.57	-7.78	-0.35	5.51e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	7.8	0.35	4.75e-14	Menopause (age at onset);
LUAD	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg10802521	chr3:52805072	NEK4	-0.46	-7.53	-0.34	3e-13	Bipolar disorder;
LUAD	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-8.28	-0.37	1.61e-15	Gut microbiome composition (summer);
LUAD	trans	rs12517041	0.935	rs6894054	chr5:23305356	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.57	-0.3	1.48e-10	Calcium levels;
LUAD	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.46	0.34	5.06e-13	Electroencephalogram traits;
LUAD	cis	rs57502260	0.651	rs3781586	chr11:68199393	C/A	cg16797656	chr11:68205561	LRP5	0.42	6.47	0.3	2.69e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08677398	chr8:58056175	NA	0.47	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg27170947	chr2:26402098	FAM59B	-0.78	-11.45	-0.49	1.31e-26	Gut microbiome composition (summer);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00566492	chr22:39096679	JOSD1	-0.49	-6.41	-0.3	3.79e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg22852734	chr6:133119734	C6orf192	0.73	8.56	0.38	2.14e-16	Type 2 diabetes nephropathy;
LUAD	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg03467027	chr4:99064603	C4orf37	0.43	7.04	0.32	7.81e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg05110241	chr16:68378359	PRMT7	0.85	9.25	0.41	1.09e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2479724	0.636	rs41273794	chr6:41755708	C/T	cg17623882	chr6:41773611	USP49	0.53	7.81	0.35	4.57e-14	Menarche (age at onset);
LUAD	trans	rs7395662	1.000	rs7944356	chr11:48610154	C/G	cg00717180	chr2:96193071	NA	-0.4	-7.47	-0.34	4.78e-13	HDL cholesterol;
LUAD	trans	rs7181230	0.961	rs7183977	chr15:40377092	C/T	cg22705835	chr10:65332833	REEP3	0.4	8.18	0.37	3.45e-15	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs1723838	0.826	rs17244671	chr11:73574422	A/C	cg10064339	chr11:73693792	UCP2	1.02	8.04	0.36	8.78e-15	Obesity-related traits;
LUAD	cis	rs13082711	0.522	rs646577	chr3:27352225	A/G	cg02860705	chr3:27208620	NA	0.5	8.4	0.38	6.85e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs3760982	0.585	rs11673490	chr19:44298885	C/A	cg21496419	chr19:44306685	LYPD5	0.34	7.59	0.35	2.1e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs9322817	0.691	rs12203954	chr6:105295647	C/T	cg02098413	chr6:105308735	HACE1	0.42	9.01	0.4	7.24e-18	Thyroid stimulating hormone;
LUAD	cis	rs2070488	1.000	rs3792528	chr3:38493303	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	10.44	0.45	7.26e-23	Electrocardiographic conduction measures;
LUAD	trans	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.92	-15.54	-0.6	2.01e-43	Colorectal cancer;
LUAD	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg08085267	chr17:45401833	C17orf57	-0.66	-11.91	-0.5	2.18e-28	Glaucoma (primary open-angle);
LUAD	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18876405	chr7:65276391	NA	-0.4	-6.4	-0.3	4.19e-10	Aortic root size;
LUAD	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.29	6.76	0.31	4.57e-11	Prostate cancer;
LUAD	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg23950597	chr19:37808831	NA	-0.61	-6.78	-0.31	3.96e-11	Coronary artery calcification;
LUAD	cis	rs2278491	0.502	rs10095889	chr8:117758844	C/T	cg23513447	chr8:117778558	UTP23	-0.54	-7.59	-0.35	2.12e-13	Body mass index;
LUAD	cis	rs57994353	0.659	rs76259794	chr9:139377405	C/A	cg14364472	chr9:139394549	NOTCH1	-0.45	-6.87	-0.32	2.24e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg10523679	chr1:76189770	ACADM	-0.48	-6.7	-0.31	6.56e-11	Daytime sleep phenotypes;
LUAD	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg12863693	chr15:85201151	NMB	0.37	6.8	0.31	3.5e-11	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg20607798	chr8:58055168	NA	-0.68	-9.04	-0.4	5.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg05368731	chr17:41323189	NBR1	0.95	20.43	0.7	4.85e-65	Menopause (age at onset);
LUAD	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg24578937	chr1:2090814	PRKCZ	0.56	11.83	0.5	4.47e-28	Height;
LUAD	cis	rs8066384	1	rs8066384	chr17:78625756	T/C	cg16591659	chr17:78472290	NA	-0.44	-7.62	-0.35	1.65e-13	Schizophrenia;
LUAD	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg26924012	chr15:45694286	SPATA5L1	1.03	19.32	0.68	4.39e-60	Homoarginine levels;
LUAD	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg00484396	chr16:3507460	NAT15	0.71	12.43	0.52	1.91e-30	Tuberculosis;
LUAD	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg13319975	chr6:146136371	FBXO30	0.66	11.45	0.49	1.27e-26	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01078248	chr7:123197661	NDUFA5	-0.44	-6.99	-0.32	1.1e-11	Height;
LUAD	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg24579218	chr15:68104479	NA	-0.56	-9.73	-0.43	2.42e-20	Restless legs syndrome;
LUAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg21782813	chr7:2030301	MAD1L1	0.42	6.99	0.32	1.09e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg26587870	chr6:27730563	NA	-0.48	-7.86	-0.36	3.11e-14	Parkinson's disease;
LUAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg22963979	chr7:1858916	MAD1L1	-0.53	-9.06	-0.4	4.89e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs9341808	0.559	rs7762895	chr6:81061431	C/T	cg08355045	chr6:80787529	NA	0.48	8.33	0.38	1.16e-15	Sitting height ratio;
LUAD	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg18404041	chr3:52824283	ITIH1	-0.64	-11.58	-0.49	3.9e-27	Bipolar disorder;
LUAD	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg03806693	chr22:41940476	POLR3H	-0.79	-11.01	-0.47	5.64e-25	Vitiligo;
LUAD	cis	rs4604732	0.578	rs112449432	chr1:247624180	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.43	6.97	0.32	1.22e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg24112000	chr20:60950667	NA	0.71	9.51	0.42	1.46e-19	Colorectal cancer;
LUAD	cis	rs1728785	1.000	rs11075680	chr16:68565700	G/C	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.3100000000000001e-10	Ulcerative colitis;
LUAD	cis	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.75	-0.35	6.92e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs11229555	0.645	rs10896774	chr11:58175837	T/G	cg15696309	chr11:58395628	NA	-0.73	-10.3	-0.45	2.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7017914	0.902	rs1373480	chr8:71686967	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.46	-0.3	2.82e-10	Bone mineral density;
LUAD	cis	rs74417235	0.610	rs13178134	chr5:154063032	A/T	cg08754654	chr5:154026448	NA	-0.47	-8.06	-0.36	7.97e-15	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs71478720	0.953	rs4988359	chr11:112025915	T/C	cg09122223	chr11:112035175	IL18	0.42	6.53	0.3	1.89e-10	Interleukin-18 levels;
LUAD	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.67	-0.46	1.05e-23	Migraine;Coronary artery disease;
LUAD	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	8.17	0.37	3.58e-15	Parkinson's disease;
LUAD	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg11833968	chr6:79620685	NA	-0.44	-8.13	-0.37	4.79e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg02951883	chr7:2050386	MAD1L1	-0.82	-14.06	-0.56	4.14e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs3087591	0.960	rs2905802	chr17:29520084	T/C	cg24425628	chr17:29625626	OMG;NF1	0.43	7.0	0.32	1.03e-11	Hip circumference;
LUAD	cis	rs80319144	1.000	rs7601440	chr2:159223180	T/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.36	6.72	0.31	5.85e-11	Restless legs syndrome;
LUAD	cis	rs11958404	1.000	rs72816529	chr5:157411454	G/C	cg05962755	chr5:157440814	NA	0.61	8.25	0.37	2.05e-15	IgG glycosylation;
LUAD	cis	rs4523957	0.651	rs7223390	chr17:2085653	T/C	cg16513277	chr17:2031491	SMG6	-0.95	-18.82	-0.68	7.48e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg19442545	chr10:75533431	FUT11	-0.47	-7.7	-0.35	1e-13	Inflammatory bowel disease;
LUAD	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg04398451	chr17:18023971	MYO15A	-0.77	-14.05	-0.56	4.36e-37	Total body bone mineral density;
LUAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg04025307	chr7:1156635	C7orf50	0.66	7.49	0.34	4.17e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4356932	1.000	rs6532121	chr4:76962606	A/T	cg24176760	chr4:76958061	ART3;CXCL11	0.36	6.62	0.31	1.09e-10	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.19	0.41	1.83e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs367943	0.576	rs2972673	chr5:112980671	C/T	cg12552261	chr5:112820674	MCC	-0.44	-7.99	-0.36	1.26e-14	Type 2 diabetes;
LUAD	cis	rs4594175	0.926	rs10873044	chr14:51615856	T/C	cg23942311	chr14:51606299	NA	0.64	11.15	0.48	1.76e-25	Cancer;
LUAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.84	0.43	1.07e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg09904177	chr6:26538194	HMGN4	0.43	7.26	0.33	1.87e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg13180566	chr4:1052158	NA	-0.4	-6.92	-0.32	1.71e-11	Recombination rate (females);
LUAD	cis	rs62458065	0.850	rs62458098	chr7:32471129	G/A	cg20159608	chr7:32802032	NA	-0.56	-7.36	-0.34	9.55e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg08125733	chr17:73851984	WBP2	0.67	9.86	0.43	8.6e-21	Psoriasis;
LUAD	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18404041	chr3:52824283	ITIH1	-0.61	-12.19	-0.51	1.71e-29	Bipolar disorder;
LUAD	cis	rs9902453	0.765	rs2250320	chr17:28128657	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.56	-0.46	2.8e-23	Coffee consumption (cups per day);
LUAD	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg04944784	chr2:26401820	FAM59B	-0.89	-12.57	-0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs4372836	0.704	rs966250	chr2:28974139	G/T	cg09522027	chr2:28974177	PPP1CB	-0.68	-12.57	-0.52	4.97e-31	Body mass index;
LUAD	cis	rs9039	1.000	rs56193985	chr16:9207199	C/A	cg08831531	chr16:9218945	NA	-0.38	-6.65	-0.31	8.83e-11	Menopause (age at onset);
LUAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg02951883	chr7:2050386	MAD1L1	-0.83	-14.27	-0.57	5.66e-38	Bipolar disorder and schizophrenia;
LUAD	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg06618935	chr21:46677482	NA	-0.49	-10.01	-0.44	2.56e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4662945	0.603	rs1453147	chr2:130271510	A/C	cg05962382	chr2:130345044	NA	-0.38	-7.07	-0.32	6.62e-12	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg06740227	chr12:86229804	RASSF9	-0.41	-7.36	-0.34	9.88e-13	Major depressive disorder;
LUAD	cis	rs9581857	0.547	rs76435345	chr13:28107638	G/A	cg22138327	chr13:27999177	GTF3A	0.82	8.9	0.4	1.7e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg26384229	chr12:38710491	ALG10B	0.45	7.34	0.34	1.09e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs16958440	0.867	rs74346439	chr18:44677467	G/C	cg17192377	chr18:44677553	HDHD2	0.84	7.97	0.36	1.52e-14	Sitting height ratio;
LUAD	cis	rs2073300	1.000	rs6048811	chr20:23446719	G/C	cg12062639	chr20:23401060	NAPB	0.7	6.55	0.3	1.66e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs853679	0.546	rs175597	chr6:27810626	T/C	cg06606381	chr12:133084897	FBRSL1	-0.81	-8.05	-0.36	8.5e-15	Depression;
LUAD	cis	rs8099014	0.906	rs9953884	chr18:56093448	A/C	cg12907477	chr18:56117327	MIR122	0.41	6.47	0.3	2.68e-10	Platelet count;
LUAD	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg08869376	chr19:10226304	EIF3G	-0.37	-7.62	-0.35	1.71e-13	Narcolepsy;
LUAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg11494091	chr17:61959527	GH2	0.74	18.42	0.67	4.77e-56	Prudent dietary pattern;
LUAD	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg08645402	chr16:4508243	NA	-0.53	-9.66	-0.43	4.3e-20	Schizophrenia;
LUAD	cis	rs4493873	0.869	rs12542178	chr8:92107070	A/G	cg16814680	chr8:91681699	NA	0.42	6.73	0.31	5.54e-11	Migraine - clinic-based;
LUAD	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg15309053	chr8:964076	NA	-0.45	-9.94	-0.43	4.78e-21	Schizophrenia;
LUAD	cis	rs2282300	0.739	rs34951229	chr11:30265166	C/G	cg06241208	chr11:30344200	C11orf46	-0.59	-7.63	-0.35	1.53e-13	Morning vs. evening chronotype;
LUAD	cis	rs8192282	0.698	rs6427729	chr1:154518874	G/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.44	-7.31	-0.34	1.31e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg07402062	chr16:89894098	SPIRE2	0.47	12.0	0.5	9.31e-29	Vitiligo;
LUAD	cis	rs6908034	0.607	rs73376681	chr6:19808175	A/G	cg02682789	chr6:19804855	NA	0.84	8.71	0.39	6.87e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.34	-0.34	1.11e-12	Resting heart rate;
LUAD	cis	rs9513627	1.000	rs9513627	chr13:100196952	G/A	cg25919922	chr13:100150906	NA	0.66	6.7	0.31	6.5e-11	Obesity-related traits;
LUAD	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg12927641	chr6:109611667	NA	-0.51	-8.72	-0.39	6.51e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg16006841	chr5:176797999	RGS14	0.56	10.37	0.45	1.33e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg19729930	chr2:74357872	NA	0.9	16.26	0.62	1.54e-46	Gestational age at birth (maternal effect);
LUAD	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg13902645	chr11:5959945	NA	-0.41	-7.21	-0.33	2.53e-12	DNA methylation (variation);
LUAD	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg11517269	chr6:28058789	ZSCAN12L1	0.26	6.61	0.31	1.14e-10	Parkinson's disease;
LUAD	trans	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.09	-0.33	5.57e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg26384229	chr12:38710491	ALG10B	0.39	6.79	0.31	3.77e-11	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs3219090	0.962	rs1417765	chr1:226591243	T/G	cg27539482	chr13:111589090	NA	0.41	6.8	0.31	3.59e-11	Melanoma;
LUAD	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg15181151	chr6:150070149	PCMT1	0.42	8.61	0.39	1.48e-16	Lung cancer;
LUAD	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-6.37	-0.3	5.02e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs6460942	0.915	rs2216051	chr7:12304054	G/A	cg06484146	chr7:12443880	VWDE	-0.48	-7.33	-0.34	1.2e-12	Coronary artery disease;
LUAD	cis	rs1595825	0.891	rs59990242	chr2:198895868	G/A	cg00982548	chr2:198649783	BOLL	-0.65	-9.18	-0.41	1.88e-18	Ulcerative colitis;
LUAD	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg17177755	chr1:15930204	NA	0.46	7.43	0.34	5.89e-13	Systolic blood pressure;
LUAD	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg14789911	chr21:47582049	C21orf56	0.41	6.9	0.32	1.85e-11	Testicular germ cell tumor;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15457276	chr19:4832024	TICAM1	-0.41	-6.71	-0.31	6.39e-11	Height;
LUAD	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.41	0.57	1.44e-38	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg17330251	chr7:94953956	PON1	-0.56	-7.72	-0.35	8.41e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs943466	0.956	rs1075379	chr6:33737800	T/C	cg16010596	chr6:33739607	LEMD2	-0.41	-8.11	-0.37	5.36e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs4343996	0.870	rs6974257	chr7:3392195	A/G	cg21248987	chr7:3385318	SDK1	-0.36	-6.84	-0.32	2.73e-11	Motion sickness;
LUAD	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22496380	chr5:211416	CCDC127	-0.94	-13.34	-0.54	4.12e-34	Breast cancer;
LUAD	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg09904177	chr6:26538194	HMGN4	0.44	7.53	0.34	3.11e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs13190036	0.515	rs2878686	chr5:176633749	C/T	cg06733329	chr5:176740039	MXD3	0.44	6.52	0.3	2.04e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	trans	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg01017244	chr2:74357527	NA	0.91	13.81	0.56	4.6e-36	Gestational age at birth (maternal effect);
LUAD	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg02696790	chr15:75250997	RPP25	0.39	7.27	0.33	1.73e-12	Breast cancer;
LUAD	cis	rs904251	0.561	rs1757189	chr6:37483727	G/C	cg25019722	chr6:37503610	NA	-0.34	-7.72	-0.35	8.37e-14	Cognitive performance;
LUAD	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg09359103	chr1:154839909	KCNN3	-0.51	-8.9	-0.4	1.65e-17	Schizophrenia;
LUAD	cis	rs11178918	0.585	rs7308393	chr12:72145621	A/C	cg10168894	chr12:72148281	RAB21	-0.53	-6.46	-0.3	2.87e-10	Economic and political preferences (time);
LUAD	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg19717773	chr7:2847554	GNA12	-0.51	-9.54	-0.42	1.14e-19	Height;
LUAD	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-16.29	-0.62	1.21e-46	Height;
LUAD	trans	rs853679	1.000	rs853694	chr6:28279100	A/T	cg06606381	chr12:133084897	FBRSL1	-0.61	-7.3	-0.33	1.43e-12	Depression;
LUAD	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg08999081	chr20:33150536	PIGU	0.46	8.82	0.39	3.04e-17	Coronary artery disease;
LUAD	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg16797656	chr11:68205561	LRP5	-0.38	-7.18	-0.33	3.14e-12	Bone mineral density (spine);
LUAD	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg02569458	chr12:86230093	RASSF9	0.42	7.9	0.36	2.42e-14	Major depressive disorder;
LUAD	cis	rs977987	0.645	rs34904236	chr16:75498253	G/T	cg03315344	chr16:75512273	CHST6	0.66	14.5	0.58	5.78e-39	Dupuytren's disease;
LUAD	cis	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg21775007	chr8:11205619	TDH	0.55	10.1	0.44	1.26e-21	Retinal vascular caliber;
LUAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg04234412	chr22:24373322	LOC391322	-0.85	-16.57	-0.63	7.05e-48	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg14926445	chr8:58193284	C8orf71	-0.48	-6.49	-0.3	2.45e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg13902645	chr11:5959945	NA	-0.57	-10.46	-0.45	6.38e-23	DNA methylation (variation);
LUAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg14893161	chr1:205819251	PM20D1	0.48	7.69	0.35	1.05e-13	Parkinson's disease;
LUAD	cis	rs55665837	0.523	rs10832301	chr11:14788964	G/A	cg19336497	chr11:14380999	RRAS2	-0.4	-7.56	-0.34	2.59e-13	Vitamin D levels;
LUAD	cis	rs11671005	0.693	rs11668821	chr19:58955813	G/A	cg13877915	chr19:58951672	ZNF132	0.57	7.42	0.34	6.63e-13	Mean platelet volume;
LUAD	cis	rs1448094	0.802	rs12369634	chr12:86406792	C/G	cg00310523	chr12:86230176	RASSF9	0.39	8.34	0.38	1.03e-15	Major depressive disorder;
LUAD	cis	rs2487048	0.761	rs2980083	chr9:107691362	A/C	cg14019050	chr9:107690770	ABCA1	-0.37	-6.71	-0.31	6.43e-11	Intraocular pressure;
LUAD	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.7	-12.97	-0.53	1.24e-32	Ulcerative colitis;
LUAD	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg12292205	chr6:26970375	C6orf41	0.39	6.86	0.32	2.42e-11	Schizophrenia;
LUAD	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg01191920	chr7:158217561	PTPRN2	0.75	16.91	0.64	2.32e-49	Obesity-related traits;
LUAD	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg27490568	chr2:178487706	NA	0.4	6.78	0.31	3.95e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg05368731	chr17:41323189	NBR1	0.95	19.8	0.69	3.25e-62	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg02993280	chr1:107599747	PRMT6	-0.55	-8.99	-0.4	8.44e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg04111992	chr7:158790115	NA	-0.44	-7.39	-0.34	8.03e-13	Facial morphology (factor 20);
LUAD	cis	rs11811982	0.793	rs75714930	chr1:227318676	T/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic disc area;
LUAD	cis	rs6138458	1.000	rs7269416	chr20:24976196	T/G	cg06937882	chr20:24974362	C20orf3	-0.34	-6.81	-0.31	3.26e-11	Blood protein levels;
LUAD	cis	rs7737355	0.947	rs31587	chr5:131000711	A/T	cg06307176	chr5:131281290	NA	0.54	8.39	0.38	7.46e-16	Life satisfaction;
LUAD	trans	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg27411982	chr8:10470053	RP1L1	0.37	6.44	0.3	3.33e-10	Neuroticism;
LUAD	cis	rs77861329	0.748	rs4687805	chr3:52123313	A/G	cg08692210	chr3:52188851	WDR51A	0.55	6.95	0.32	1.36e-11	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg11909912	chr17:43974919	MAPT;LOC100130148	0.39	6.51	0.3	2.18e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2230307	0.536	rs11166409	chr1:100641411	T/C	cg20868668	chr1:100435035	SLC35A3	-0.53	-7.78	-0.35	5.6e-14	Carotid intima media thickness;
LUAD	cis	rs708547	0.697	rs67479587	chr4:57878884	A/G	cg00922110	chr4:57842668	C4orf14	-0.44	-8.13	-0.37	4.7e-15	Response to bleomycin (chromatid breaks);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg25827351	chr3:38066270	PLCD1	-0.44	-7.07	-0.33	6.47e-12	Cancer;
LUAD	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg00933542	chr6:150070202	PCMT1	0.44	9.46	0.42	2.17e-19	Lung cancer;
LUAD	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs7677751	0.806	rs7679903	chr4:55097373	T/C	cg17187183	chr4:55093834	PDGFRA	0.51	8.63	0.39	1.23e-16	Corneal astigmatism;
LUAD	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg27219399	chr15:67835830	MAP2K5	0.42	6.91	0.32	1.84e-11	Restless legs syndrome;
LUAD	trans	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg26043149	chr18:55253948	FECH	0.43	7.03	0.32	8.56e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.42	-8.44	-0.38	5.29e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg13385794	chr1:248469461	NA	0.26	6.72	0.31	5.84e-11	Common traits (Other);
LUAD	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg25237894	chr2:233734115	C2orf82	-0.61	-11.36	-0.48	2.79e-26	Coronary artery disease;
LUAD	cis	rs6546550	0.835	rs13002091	chr2:70118388	C/T	cg02498382	chr2:70120550	SNRNP27	-0.59	-11.21	-0.48	1.02e-25	Prevalent atrial fibrillation;
LUAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.51	-9.09	-0.4	3.77e-18	Longevity;Endometriosis;
LUAD	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg00784671	chr22:46762841	CELSR1	-0.61	-7.51	-0.34	3.65e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg24642844	chr7:1081250	C7orf50	-0.98	-14.73	-0.58	6.34e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35740288	0.770	rs11635587	chr15:86173633	C/T	cg13263323	chr15:86062960	AKAP13	-0.45	-7.28	-0.33	1.61e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg14664628	chr15:75095509	CSK	-0.49	-8.24	-0.37	2.18e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg17063962	chr7:91808500	NA	0.61	10.33	0.45	1.88e-22	Breast cancer;
LUAD	cis	rs3956705	1.000	rs12701265	chr7:32971236	G/A	cg05721444	chr7:32995514	FKBP9	-0.37	-6.45	-0.3	3.06e-10	Red cell distribution width;
LUAD	cis	rs4478137	0.931	rs4057797	chr4:164245053	T/A	cg06758707	chr4:164254230	NPY1R	0.42	6.73	0.31	5.7e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg10434728	chr15:90938212	IQGAP1	0.35	6.82	0.31	3.07e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg18351406	chr4:77819688	ANKRD56	0.52	8.22	0.37	2.5e-15	Emphysema distribution in smoking;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25757740	chr10:72647938	PCBD1	-0.55	-6.66	-0.31	8.73e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg17264618	chr3:40429014	ENTPD3	0.41	8.92	0.4	1.4e-17	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg27144592	chr16:783916	NARFL	0.35	6.47	0.3	2.75e-10	Height;
LUAD	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11890956	chr21:40555474	PSMG1	-0.57	-9.97	-0.44	3.6e-21	Menarche (age at onset);
LUAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.07e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg02527881	chr3:46936655	PTH1R	-0.56	-11.57	-0.49	4.2e-27	Colorectal cancer;
LUAD	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg12179176	chr11:130786555	SNX19	0.55	9.29	0.41	8.21e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg23803603	chr1:2058230	PRKCZ	0.42	6.65	0.31	8.99e-11	Height;
LUAD	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg00431813	chr7:1051703	C7orf50	-0.53	-10.53	-0.46	3.43e-23	Longevity;Endometriosis;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05587853	chr3:135914748	MSL2	-0.7	-7.17	-0.33	3.34e-12	Type 2 diabetes;
LUAD	cis	rs6961069	0.868	rs1194178	chr7:80234607	C/T	cg04458919	chr7:80252533	CD36	-0.34	-6.47	-0.3	2.75e-10	Platelet count;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg19709878	chr17:47440040	ZNF652	-0.4	-6.88	-0.32	2.22e-11	Subcortical brain region volumes;
LUAD	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg01689657	chr7:91764605	CYP51A1	0.37	9.02	0.4	6.75e-18	Breast cancer;
LUAD	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11890956	chr21:40555474	PSMG1	-0.55	-9.61	-0.42	6.76e-20	Menarche (age at onset);
LUAD	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.76	0.31	4.58e-11	Aortic root size;
LUAD	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg09904177	chr6:26538194	HMGN4	0.41	6.84	0.32	2.73e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg21475434	chr5:93447410	FAM172A	0.74	8.32	0.37	1.26e-15	Diabetic retinopathy;
LUAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg27454412	chr7:1067447	C7orf50	0.48	7.73	0.35	7.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg13319975	chr6:146136371	FBXO30	0.58	9.95	0.44	4.12e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1018836	0.851	rs7007129	chr8:91629790	T/G	cg16814680	chr8:91681699	NA	-0.69	-11.84	-0.5	3.9e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg14092988	chr3:52407081	DNAH1	0.37	7.53	0.34	3.09e-13	Bipolar disorder;
LUAD	cis	rs9473147	0.543	rs4715019	chr6:47447041	T/A	cg02130027	chr6:47444894	CD2AP	0.37	6.9	0.32	1.88e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg08470875	chr2:26401718	FAM59B	0.76	9.99	0.44	2.96e-21	Gut microbiome composition (summer);
LUAD	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg17177755	chr1:15930204	NA	0.45	7.26	0.33	1.92e-12	Systolic blood pressure;
LUAD	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg09117114	chr16:67998030	SLC12A4	-0.54	-7.32	-0.34	1.3e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg03467027	chr4:99064603	C4orf37	0.47	7.38	0.34	8.26e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg08132940	chr7:1081526	C7orf50	-0.71	-7.39	-0.34	7.88e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg24289452	chr6:170231220	NA	-0.59	-6.36	-0.3	5.17e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-13.3	-0.54	5.8e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg13319975	chr6:146136371	FBXO30	0.64	11.11	0.48	2.52e-25	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12417590	chr20:42086612	SFRS6	-0.45	-7.12	-0.33	4.55e-12	Height;
LUAD	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.36	-0.6	1.23e-42	Chronic sinus infection;
LUAD	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg14634687	chr17:47094252	IGF2BP1	0.27	6.83	0.32	2.89e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg04414720	chr1:150670196	GOLPH3L	0.61	10.24	0.45	3.84e-22	Melanoma;
LUAD	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg07167872	chr1:205819463	PM20D1	0.48	7.84	0.36	3.74e-14	Parkinson's disease;
LUAD	cis	rs735539	0.521	rs2585906	chr13:21407492	C/G	cg27499820	chr13:21296301	IL17D	0.44	7.36	0.34	9.94e-13	Dental caries;
LUAD	cis	rs11811982	0.793	rs11808696	chr1:227563680	C/T	cg24860534	chr1:227506868	CDC42BPA	0.66	7.2	0.33	2.8e-12	Optic disc area;
LUAD	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg27490568	chr2:178487706	NA	0.41	6.92	0.32	1.7e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg11965913	chr1:205819406	PM20D1	0.46	7.28	0.33	1.68e-12	Parkinson's disease;
LUAD	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg07570687	chr10:102243282	WNT8B	0.47	7.15	0.33	3.78e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs12286929	0.687	rs6589485	chr11:115083875	G/A	cg04055981	chr11:115044050	NA	-0.44	-7.81	-0.35	4.62e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2066819	1.000	rs111885088	chr12:56657216	A/C	cg26714650	chr12:56694279	CS	-0.84	-7.06	-0.32	6.71e-12	Psoriasis vulgaris;
LUAD	cis	rs2625529	0.818	rs2246225	chr15:72115230	C/T	cg16672083	chr15:72433130	SENP8	0.64	10.14	0.44	8.83e-22	Red blood cell count;
LUAD	cis	rs12620999	0.555	rs4073396	chr2:238111471	A/C	cg15867307	chr2:238110829	NA	-0.41	-7.06	-0.32	6.92e-12	Systemic lupus erythematosus;
LUAD	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg22598563	chr5:131563921	P4HA2	-0.34	-8.88	-0.4	1.99e-17	Blood metabolite levels;
LUAD	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg20891283	chr12:69753455	YEATS4	0.44	7.14	0.33	4.04e-12	Blood protein levels;
LUAD	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg00255919	chr5:131827918	IRF1	-0.29	-6.4	-0.3	4.15e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs68170813	0.559	rs7804979	chr7:106999453	C/G	cg02696742	chr7:106810147	HBP1	-0.76	-10.49	-0.45	4.71e-23	Coronary artery disease;
LUAD	cis	rs72772090	0.539	rs111237997	chr5:96114953	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.33	-0.34	1.19e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs12949688	1.000	rs7212186	chr17:55818454	C/A	cg12582317	chr17:55822272	NA	0.36	7.26	0.33	1.91e-12	Schizophrenia;
LUAD	cis	rs469568	0.712	rs467604	chr5:178667984	A/G	cg08999896	chr5:178685787	ADAMTS2	-0.32	-6.68	-0.31	7.58e-11	Stroke (pediatric);
LUAD	cis	rs78456975	0.739	rs28913003	chr2:1519620	A/T	cg01028140	chr2:1542097	TPO	-0.49	-6.79	-0.31	3.89e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg07806771	chr7:64541737	NA	0.46	7.32	0.34	1.23e-12	Calcium levels;
LUAD	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg11845111	chr2:191398756	TMEM194B	0.85	11.3	0.48	4.86e-26	Diastolic blood pressure;
LUAD	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg18252515	chr7:66147081	NA	0.6	6.68	0.31	7.56e-11	Diabetic kidney disease;
LUAD	cis	rs2425143	0.818	rs12481545	chr20:34407698	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.58	-0.3	1.44e-10	Blood protein levels;
LUAD	cis	rs7132746	0.570	rs61930067	chr12:86210441	A/G	cg18827107	chr12:86230957	RASSF9	-0.49	-6.56	-0.3	1.55e-10	Lewy body disease;
LUAD	cis	rs7617773	0.815	rs7624450	chr3:48350375	A/G	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg05717871	chr11:638507	DRD4	-0.41	-6.45	-0.3	3.12e-10	Systemic lupus erythematosus;
LUAD	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg13126279	chr21:47581558	C21orf56	-0.46	-7.5	-0.34	3.89e-13	Testicular germ cell tumor;
LUAD	trans	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg21659725	chr3:3221576	CRBN	0.38	6.45	0.3	3.09e-10	Resting heart rate;
LUAD	trans	rs11039798	0.920	rs12279378	chr11:48571030	A/C	cg15704280	chr7:45808275	SEPT13	0.63	7.45	0.34	5.19e-13	Axial length;
LUAD	cis	rs16866061	1.000	rs72974263	chr2:225447371	C/T	cg12698349	chr2:225449008	CUL3	0.78	13.76	0.56	7.46e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs2479724	0.875	rs2253961	chr6:41827011	A/G	cg17623882	chr6:41773611	USP49	-0.64	-11.86	-0.5	3.15e-28	Menarche (age at onset);
LUAD	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.47	-0.52	1.29e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg02038168	chr22:39784481	NA	-0.61	-10.85	-0.47	2.23e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg18512352	chr11:47633146	NA	-0.39	-6.87	-0.32	2.25e-11	Subjective well-being;
LUAD	cis	rs1997103	1.000	rs6966183	chr7:55407546	A/C	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7177699	0.525	rs56076311	chr15:79115120	A/G	cg15571903	chr15:79123663	NA	-0.38	-7.39	-0.34	7.99e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg08999081	chr20:33150536	PIGU	-0.38	-7.5	-0.34	3.81e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg21854759	chr1:92012499	NA	-0.5	-9.14	-0.41	2.73e-18	Breast cancer;
LUAD	trans	rs75804782	0.521	rs72993074	chr2:239413582	T/G	cg01134436	chr17:81009848	B3GNTL1	0.79	8.63	0.39	1.24e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg07636037	chr3:49044803	WDR6	0.57	9.16	0.41	2.33e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg12927641	chr6:109611667	NA	-0.5	-8.63	-0.39	1.26e-16	Reticulocyte fraction of red cells;
LUAD	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg11292332	chr7:45801988	SEPT13	-0.3	-6.63	-0.31	1.05e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.9	-0.36	2.45e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12519773	0.717	rs67779882	chr5:92488009	A/G	cg18783429	chr5:92414398	NA	0.39	6.75	0.31	4.83e-11	Migraine;
LUAD	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg06640241	chr16:89574553	SPG7	0.66	11.61	0.49	3.05e-27	Multiple myeloma (IgH translocation);
LUAD	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.64	-0.35	1.48e-13	Personality dimensions;
LUAD	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg21427119	chr20:30132790	HM13	0.6	9.26	0.41	1.02e-18	Mean corpuscular hemoglobin;
LUAD	cis	rs7107174	1.000	rs2512541	chr11:77981747	A/T	cg19901956	chr11:77921274	USP35	-0.51	-6.56	-0.3	1.54e-10	Testicular germ cell tumor;
LUAD	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg21854759	chr1:92012499	NA	0.48	6.76	0.31	4.55e-11	Eosinophil percentage of white cells;
LUAD	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg03874509	chr1:107600012	PRMT6	0.47	8.48	0.38	3.93e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg07636037	chr3:49044803	WDR6	0.62	12.04	0.51	6.41e-29	Parkinson's disease;
LUAD	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg23442198	chr4:187126114	CYP4V2	-0.99	-10.12	-0.44	1.05e-21	Blood protein levels;
LUAD	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg09904177	chr6:26538194	HMGN4	0.43	7.21	0.33	2.51e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs354225	0.544	rs12713268	chr2:54808845	C/G	cg01766943	chr2:54829624	SPTBN1	-0.38	-7.22	-0.33	2.38e-12	Schizophrenia;
LUAD	cis	rs11811982	0.793	rs116404973	chr1:227389640	A/G	cg24860534	chr1:227506868	CDC42BPA	0.67	7.2	0.33	2.84e-12	Optic disc area;
LUAD	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg00717180	chr2:96193071	NA	-0.4	-7.4	-0.34	7.24e-13	HDL cholesterol;
LUAD	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg10755058	chr3:40428713	ENTPD3	0.45	8.46	0.38	4.38e-16	Renal cell carcinoma;
LUAD	cis	rs7731657	0.537	rs2419936	chr5:130316560	T/C	cg08523029	chr5:130500466	HINT1	-0.57	-7.33	-0.34	1.2e-12	Fasting plasma glucose;
LUAD	cis	rs1448094	0.872	rs4919777	chr12:86358491	C/T	cg18827107	chr12:86230957	RASSF9	-0.47	-8.48	-0.38	3.7e-16	Major depressive disorder;
LUAD	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg12311346	chr5:56204834	C5orf35	-0.92	-13.36	-0.54	3.34e-34	Initial pursuit acceleration;
LUAD	cis	rs7843479	0.562	rs11774629	chr8:21859315	C/T	cg03445287	chr8:21823731	XPO7	-0.48	-8.99	-0.4	8.21e-18	Mean corpuscular volume;
LUAD	cis	rs727505	0.563	rs73227531	chr7:124800221	T/A	cg23710748	chr7:124431027	NA	-0.39	-7.91	-0.36	2.22e-14	Lewy body disease;
LUAD	cis	rs5758511	0.773	rs62240999	chr22:42355563	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.38	6.49	0.3	2.37e-10	Birth weight;
LUAD	trans	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg01620082	chr3:125678407	NA	0.66	6.91	0.32	1.75e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.73	0.35	8.02e-14	Breast cancer;
LUAD	cis	rs7833986	0.501	rs2719233	chr8:56886156	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.93	14.47	0.58	7.79e-39	Height;
LUAD	cis	rs12545109	0.800	rs2610058	chr8:57409120	G/A	cg09654669	chr8:57350985	NA	-0.65	-9.15	-0.41	2.44e-18	Obesity-related traits;
LUAD	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg13126279	chr21:47581558	C21orf56	-0.43	-7.41	-0.34	6.82e-13	Testicular germ cell tumor;
LUAD	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.54	0.34	2.94e-13	Menopause (age at onset);
LUAD	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg26354017	chr1:205819088	PM20D1	0.49	7.05	0.32	7.15e-12	Parkinson's disease;
LUAD	cis	rs11247915	0.622	rs36024412	chr1:26670444	G/T	cg15628303	chr1:26608928	UBXN11	0.5	8.99	0.4	8.46e-18	Obesity-related traits;
LUAD	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-10.64	-0.46	1.4e-23	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg23029597	chr12:123009494	RSRC2	-0.59	-8.91	-0.4	1.52e-17	Body mass index;
LUAD	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-9.13	-0.41	2.76e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00149659	chr3:10157352	C3orf10	0.55	7.57	0.35	2.41e-13	Alzheimer's disease;
LUAD	trans	rs5756813	0.661	rs2285178	chr22:38205989	T/C	cg19894588	chr14:64061835	NA	-0.54	-7.7	-0.35	9.97e-14	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs8067287	0.645	rs55770108	chr17:16841424	A/G	cg26910001	chr17:16838321	NA	-0.47	-6.52	-0.3	2e-10	Diabetic kidney disease;
LUAD	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-8.74	-0.39	5.53e-17	Gut microbiome composition (summer);
LUAD	cis	rs494562	0.892	rs7753711	chr6:86130699	G/T	cg21730993	chr6:86159210	NT5E	-0.72	-8.4	-0.38	6.92e-16	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	10.19	0.44	6.1e-22	Lung cancer in ever smokers;
LUAD	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg06263672	chr7:65235340	NA	0.49	6.42	0.3	3.61e-10	Aortic root size;
LUAD	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg03806693	chr22:41940476	POLR3H	-0.75	-9.98	-0.44	3.39e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg02371401	chr5:676784	TPPP	-0.4	-6.81	-0.31	3.28e-11	Obesity-related traits;
LUAD	cis	rs977987	0.843	rs11149820	chr16:75422760	G/A	cg03315344	chr16:75512273	CHST6	0.64	14.03	0.56	5.56e-37	Dupuytren's disease;
LUAD	cis	rs6754311	0.593	rs6755383	chr2:136416941	C/T	cg07305463	chr2:136567211	LCT	-0.34	-6.42	-0.3	3.67e-10	Mosquito bite size;
LUAD	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg23029597	chr12:123009494	RSRC2	-0.57	-9.07	-0.4	4.45e-18	Body mass index;
LUAD	cis	rs7336332	0.569	rs57724994	chr13:28010389	T/C	cg22138327	chr13:27999177	GTF3A	0.67	9.32	0.41	6.3e-19	Weight;
LUAD	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg20503657	chr10:835505	NA	0.98	14.74	0.58	5.48e-40	Eosinophil percentage of granulocytes;
LUAD	cis	rs3784262	0.669	rs4646554	chr15:58355437	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.66	-0.35	1.3e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg01528321	chr10:82214614	TSPAN14	0.76	10.14	0.44	9.05e-22	Post bronchodilator FEV1;
LUAD	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.09	-28.82	-0.81	8.09e-102	Myeloid white cell count;
LUAD	trans	rs701145	0.585	rs401162	chr3:153905988	T/A	cg14299572	chr10:34021103	NA	-0.4	-6.44	-0.3	3.23e-10	Coronary artery disease;
LUAD	cis	rs938554	0.577	rs4591605	chr4:10002719	T/C	cg11266682	chr4:10021025	SLC2A9	0.54	9.37	0.41	4.46e-19	Blood metabolite levels;
LUAD	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg08316699	chr6:150357289	NA	0.35	7.16	0.33	3.59e-12	Alopecia areata;
LUAD	cis	rs68170813	0.559	rs79543528	chr7:106891090	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-10.78	-0.46	4.16e-24	Coronary artery disease;
LUAD	cis	rs3812831	0.572	rs3118896	chr13:114931769	C/G	cg15896084	chr13:114927664	NA	0.35	6.61	0.31	1.17e-10	Schizophrenia;
LUAD	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg12119029	chr16:89752879	CDK10	0.34	6.97	0.32	1.2e-11	Vitiligo;
LUAD	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg00999904	chr2:3704751	ALLC	-0.51	-8.76	-0.39	4.82e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.93	0.5	1.78e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs11958404	0.932	rs72816540	chr5:157414500	T/C	cg05962755	chr5:157440814	NA	0.44	7.02	0.32	9.06e-12	IgG glycosylation;
LUAD	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	9.1	0.4	3.57e-18	Lymphocyte percentage of white cells;
LUAD	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg16850897	chr7:100343110	ZAN	0.41	7.39	0.34	7.88e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg02990361	chr1:107599529	PRMT6	0.62	10.29	0.45	2.53e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg23758822	chr17:41437982	NA	1.01	20.57	0.71	1.2e-65	Menopause (age at onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26146184	chr11:124637008	C11orf61	0.44	6.97	0.32	1.21e-11	Height;
LUAD	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg02734326	chr4:10020555	SLC2A9	-0.55	-9.41	-0.42	3.29e-19	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7274811	0.711	rs291680	chr20:32022251	A/C	cg14921437	chr20:32255988	NECAB3;C20orf134	0.48	7.32	0.34	1.28e-12	Height;
LUAD	cis	rs9796	0.870	rs8023345	chr15:41338348	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.37	-7.02	-0.32	8.98e-12	Menopause (age at onset);
LUAD	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg10560079	chr2:191398806	TMEM194B	-0.48	-6.49	-0.3	2.35e-10	Diastolic blood pressure;
LUAD	cis	rs9863	0.861	rs75321546	chr12:124447465	T/A	cg17723958	chr12:124429295	CCDC92	-0.42	-6.88	-0.32	2.19e-11	White blood cell count;
LUAD	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg15691649	chr6:25882328	NA	0.46	7.53	0.34	3.13e-13	Blood metabolite levels;
LUAD	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs8073060	0.533	rs178736	chr17:33928158	G/T	cg19694781	chr19:47549865	TMEM160	-1.26	-19.89	-0.7	1.23e-62	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg26597838	chr10:835615	NA	0.69	9.77	0.43	1.77e-20	Eosinophil percentage of granulocytes;
LUAD	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.63	-0.31	1.03e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6988985	0.703	rs6995180	chr8:143946429	C/G	cg10324643	chr8:143916377	GML	0.3	6.53	0.3	1.94e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg18132916	chr6:79620363	NA	-0.44	-7.64	-0.35	1.5e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs11771526	1.000	rs11764617	chr7:32339102	T/C	cg27532318	chr7:32358331	NA	0.7	8.31	0.37	1.28e-15	Body mass index;
LUAD	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.43	0.38	5.48e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg03605463	chr16:89740564	NA	0.67	12.12	0.51	3.08e-29	Vitiligo;
LUAD	cis	rs9902453	0.791	rs3098950	chr17:27998385	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.34	0.45	1.66e-22	Coffee consumption (cups per day);
LUAD	trans	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.76	-0.31	4.56e-11	Joint mobility (Beighton score);
LUAD	cis	rs57590327	0.503	rs2372906	chr3:81504673	G/A	cg07356753	chr3:81810745	GBE1	0.48	7.57	0.35	2.42e-13	Extraversion;
LUAD	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23158103	chr7:148848205	ZNF398	-0.49	-8.67	-0.39	9.14e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7408868	1.000	rs10422818	chr19:15285272	A/G	cg14696996	chr19:15285081	NOTCH3	0.85	10.37	0.45	1.38e-22	Pulse pressure;
LUAD	cis	rs7828089	0.582	rs13282084	chr8:22266280	T/C	cg12081754	chr8:22256438	SLC39A14	0.74	12.3	0.51	5.98e-30	Verbal declarative memory;
LUAD	cis	rs11677416	1.000	rs2856841	chr2:113537339	A/G	cg27083787	chr2:113543245	IL1A	0.4	6.82	0.31	3.18e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg09035930	chr12:129282057	SLC15A4	0.75	18.06	0.66	1.86e-54	Systemic lupus erythematosus;
LUAD	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23583168	chr7:148888333	NA	-0.93	-19.27	-0.68	7.54e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.78	-0.39	4.19e-17	Total body bone mineral density;
LUAD	cis	rs2070997	0.715	rs11244164	chr9:133736116	A/G	cg01000188	chr9:133769184	QRFP	0.53	7.05	0.32	7.51e-12	Response to amphetamines;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg21001214	chr12:56497920	PA2G4	0.4	7.1	0.33	5.42e-12	Bipolar disorder;
LUAD	cis	rs11687659	0.515	rs6725611	chr2:191579025	G/A	cg11845111	chr2:191398756	TMEM194B	-0.46	-7.45	-0.34	5.27e-13	Immature fraction of reticulocytes;
LUAD	cis	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.89	-0.32	2e-11	Triglycerides;
LUAD	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg13944838	chr5:179740914	GFPT2	-0.74	-12.27	-0.51	7.98e-30	Height;
LUAD	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg26441486	chr22:50317300	CRELD2	0.42	6.38	0.3	4.68e-10	Schizophrenia;
LUAD	cis	rs4917300	0.647	rs4917223	chr8:143115548	C/T	cg25363559	chr8:143086065	NA	-0.44	-8.79	-0.39	3.83e-17	Amyotrophic lateral sclerosis;
LUAD	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.96	0.32	1.29e-11	Cognitive test performance;
LUAD	cis	rs4378999	0.800	rs4974105	chr3:51369574	A/G	cg12934382	chr3:51741135	GRM2	0.42	6.52	0.3	2.02e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs7177699	0.557	rs10083696	chr15:79124016	G/A	cg15571903	chr15:79123663	NA	-0.4	-8.06	-0.36	8.07e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg22166914	chr1:53195759	ZYG11B	0.45	7.34	0.34	1.12e-12	Monocyte count;
LUAD	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs11771526	0.786	rs28670858	chr7:32293126	G/A	cg27532318	chr7:32358331	NA	0.56	7.33	0.34	1.19e-12	Body mass index;
LUAD	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg26168224	chr5:2018326	NA	-0.8	-18.31	-0.66	1.45e-55	Gut microbiome composition (winter);
LUAD	trans	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg14917512	chr19:3094685	GNA11	-0.55	-6.54	-0.3	1.83e-10	Diabetic kidney disease;
LUAD	cis	rs757647	0.680	rs60271703	chr5:137758927	T/G	cg10676309	chr5:137685565	NA	0.43	7.63	0.35	1.58e-13	Menarche (age at onset);
LUAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg22907277	chr7:1156413	C7orf50	0.7	8.29	0.37	1.53e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs17532515	0.652	rs17005971	chr4:141388029	A/G	cg03645522	chr4:141391200	NA	0.4	6.46	0.3	2.91e-10	Select biomarker traits;
LUAD	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03452623	chr4:187889614	NA	0.54	10.03	0.44	2.17e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg02493740	chr2:85810744	VAMP5	-0.64	-11.78	-0.5	6.79e-28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs6987853	0.966	rs2923439	chr8:42429122	A/G	cg09913449	chr8:42400586	C8orf40	0.41	7.6	0.35	1.93e-13	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs3736594	0.840	rs57238885	chr2:27974260	C/G	cg27432699	chr2:27873401	GPN1	0.45	6.91	0.32	1.78e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg14416269	chr4:6271139	WFS1	0.59	10.95	0.47	9.39e-25	Cisplatin-induced ototoxicity;
LUAD	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg23625390	chr15:77176239	SCAPER	0.35	6.35	0.3	5.5e-10	Blood metabolite levels;
LUAD	cis	rs11677370	0.561	rs10084170	chr2:3820204	G/C	cg17052675	chr2:3827356	NA	-0.64	-10.81	-0.47	3.18e-24	Type 2 diabetes;
LUAD	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg10802521	chr3:52805072	NEK4	-0.46	-7.9	-0.36	2.43e-14	Bipolar disorder;
LUAD	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg19717773	chr7:2847554	GNA12	0.52	10.4	0.45	1.03e-22	Height;
LUAD	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg02398342	chr17:80708632	TBCD;FN3K	0.56	6.63	0.31	9.96e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21659725	chr3:3221576	CRBN	-0.64	-10.18	-0.44	6.25e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg20203395	chr5:56204925	C5orf35	-0.82	-11.88	-0.5	2.87e-28	Initial pursuit acceleration;
LUAD	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg03433033	chr1:76189801	ACADM	-0.49	-7.31	-0.33	1.37e-12	Daytime sleep phenotypes;
LUAD	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.04	15.2	0.59	5.78e-42	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2262909	0.962	rs422344	chr19:22230956	C/G	cg11619707	chr19:22235551	ZNF257	0.44	6.73	0.31	5.57e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg22256960	chr15:77711686	NA	0.41	6.95	0.32	1.43e-11	Anger;
LUAD	trans	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg06606381	chr12:133084897	FBRSL1	-1.16	-10.37	-0.45	1.35e-22	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4460629	0.521	rs12039316	chr1:155073221	C/T	cg23973274	chr1:155060172	NA	-0.45	-7.89	-0.36	2.55e-14	Serum magnesium levels;
LUAD	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg10434728	chr15:90938212	IQGAP1	-0.37	-7.16	-0.33	3.71e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	8.04	0.36	8.97e-15	Tonsillectomy;
LUAD	cis	rs7799006	0.755	rs12534131	chr7:2294123	C/T	cg02951883	chr7:2050386	MAD1L1	-0.42	-6.58	-0.3	1.42e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.06	-27.31	-0.8	2.2199999999999998e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.68	-0.58	1.03e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs8027181	0.839	rs7176235	chr15:72999104	A/G	cg25632853	chr15:73088954	NA	0.32	6.83	0.32	3e-11	Triglyceride levels;
LUAD	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg21548813	chr6:291882	DUSP22	-0.54	-8.68	-0.39	8.51e-17	Menopause (age at onset);
LUAD	cis	rs8077889	0.917	rs28694735	chr17:41912144	A/G	cg26893861	chr17:41843967	DUSP3	0.85	13.82	0.56	4.26e-36	Triglycerides;
LUAD	cis	rs57994353	0.802	rs12002854	chr9:139377499	G/A	cg14169450	chr9:139327907	INPP5E	0.41	6.51	0.3	2.19e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs4887067	1	rs4887067	chr15:78886947	G/A	cg18825076	chr15:78729989	IREB2	-0.57	-9.2	-0.41	1.66e-18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs2657888	0.628	rs2638334	chr12:56882528	A/C	cg23002907	chr12:56915593	RBMS2	0.43	7.95	0.36	1.75e-14	Adiponectin levels;
LUAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08280861	chr8:58055591	NA	0.8	9.65	0.42	4.6e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg04731861	chr2:219085781	ARPC2	0.23	6.97	0.32	1.22e-11	Colorectal cancer;
LUAD	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.4	6.92	0.32	1.72e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg20503657	chr10:835505	NA	1.24	18.49	0.67	2.18e-56	Eosinophil percentage of granulocytes;
LUAD	cis	rs17154702	0.506	rs2427	chr8:8641125	A/G	cg01851573	chr8:8652454	MFHAS1	-0.59	-7.95	-0.36	1.73e-14	Neurocognitive impairment in HIV-1 infection (continuous);
LUAD	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg08132940	chr7:1081526	C7orf50	-0.74	-10.04	-0.44	2.06e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg08859206	chr1:53392774	SCP2	-0.73	-14.07	-0.56	3.82e-37	Monocyte count;
LUAD	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg22676075	chr6:135203613	NA	0.38	6.9	0.32	1.88e-11	Red blood cell count;
LUAD	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg13768953	chr17:7114967	DLG4	-0.38	-6.76	-0.31	4.53e-11	Diastolic blood pressure;
LUAD	cis	rs9914544	0.583	rs11078422	chr17:18804413	C/T	cg25390199	chr17:18761479	PRPSAP2	-0.37	-6.36	-0.3	5.37e-10	Educational attainment (years of education);
LUAD	cis	rs13095912	0.785	rs6807927	chr3:185324933	A/G	cg11274856	chr3:185301563	NA	-0.51	-9.6	-0.42	7.4e-20	Systolic blood pressure;
LUAD	cis	rs7833986	0.501	rs2976038	chr8:57028864	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.99	17.72	0.65	6.2e-53	Height;
LUAD	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7100689	0.646	rs9804233	chr10:82134667	T/C	cg00277334	chr10:82204260	NA	-0.63	-10.54	-0.46	3.26e-23	Post bronchodilator FEV1;
LUAD	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-16.16	-0.62	4.1e-46	Chronic sinus infection;
LUAD	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg03983476	chr2:10830698	NOL10	-0.47	-8.22	-0.37	2.49e-15	Prostate cancer;
LUAD	cis	rs1595825	0.945	rs73056890	chr2:198831260	A/G	cg00982548	chr2:198649783	BOLL	-0.63	-8.93	-0.4	1.34e-17	Ulcerative colitis;
LUAD	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-8.24	-0.37	2.22e-15	Height;
LUAD	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.74	-12.22	-0.51	1.3e-29	Primary sclerosing cholangitis;
LUAD	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg03396347	chr1:1875803	NA	-0.62	-16.09	-0.62	8.65e-46	Body mass index;
LUAD	cis	rs2840044	1.000	rs9900378	chr17:33911302	C/T	cg05299278	chr17:33885742	SLFN14	-0.44	-8.85	-0.4	2.34e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.81	9.55	0.42	1.09e-19	Yeast infection;
LUAD	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.8	-0.31	3.47e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26270066	chr15:43941407	CATSPER2	0.56	6.75	0.31	4.75e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg14828511	chr1:107599125	PRMT6	-0.6	-10.52	-0.46	3.81e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg23625390	chr15:77176239	SCAPER	-0.52	-8.04	-0.36	8.85e-15	Blood metabolite levels;
LUAD	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg05283184	chr6:79620031	NA	-0.62	-12.38	-0.52	3.03e-30	Intelligence (multi-trait analysis);
LUAD	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.41	-18.29	-0.66	1.83e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg20108693	chr8:143823809	SLURP1	-0.32	-7.74	-0.35	7.18e-14	Urinary tract infection frequency;
LUAD	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17712092	chr4:129076599	LARP1B	0.92	17.32	0.64	3.6e-51	Eosinophil percentage of white cells;
LUAD	cis	rs7527798	0.571	rs12045913	chr1:207844625	A/G	cg09232269	chr1:207846808	CR1L	-0.39	-7.29	-0.33	1.51e-12	Erythrocyte sedimentation rate;
LUAD	cis	rs1509123	0.609	rs79021555	chr17:6719367	T/C	cg12642237	chr17:6703447	TEKT1	-0.46	-6.66	-0.31	8.47e-11	Blood metabolite levels;
LUAD	trans	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	11.99	0.5	1.05e-28	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg27494647	chr7:150038898	RARRES2	0.41	6.64	0.31	9.5e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg16680214	chr1:154839983	KCNN3	-0.67	-14.14	-0.57	1.87e-37	Prostate cancer;
LUAD	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.6	11.51	0.49	7.61e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg04450456	chr4:17643702	FAM184B	0.4	8.21	0.37	2.78e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg14835575	chr10:16859367	RSU1	-0.52	-7.85	-0.36	3.46e-14	Platelet distribution width;
LUAD	cis	rs11800820	0.517	rs12022808	chr1:246659163	C/A	cg16700716	chr1:246684329	NA	0.37	6.77	0.31	4.37e-11	Obesity-related traits;
LUAD	cis	rs7107174	1.000	rs1017908	chr11:77948095	A/G	cg19901956	chr11:77921274	USP35	-0.53	-6.51	-0.3	2.2e-10	Testicular germ cell tumor;
LUAD	cis	rs6669072	0.669	rs712031	chr1:91243395	A/G	cg08895590	chr1:91227319	NA	-0.32	-6.59	-0.31	1.33e-10	Cognitive function;
LUAD	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg09537434	chr19:41945824	ATP5SL	-0.49	-7.9	-0.36	2.37e-14	Height;
LUAD	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08704250	chr15:31115839	NA	-0.56	-9.94	-0.44	4.62e-21	Huntington's disease progression;
LUAD	cis	rs11048434	0.761	rs2377675	chr12:9124765	C/T	cg13575925	chr12:9217583	LOC144571	0.4	7.3	0.33	1.44e-12	Sjögren's syndrome;
LUAD	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs1044826	0.642	rs295478	chr3:139223135	G/A	cg00490450	chr3:139108681	COPB2	0.4	6.42	0.3	3.59e-10	Obesity-related traits;
LUAD	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg02421172	chr7:1938701	MAD1L1	0.46	6.59	0.31	1.3100000000000001e-10	Bipolar disorder;
LUAD	cis	rs3125734	0.633	rs1873685	chr10:64032126	C/T	cg19640130	chr10:64028056	RTKN2	-0.36	-7.8	-0.35	4.73e-14	Rheumatoid arthritis;
LUAD	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-9.89	-0.43	6.75e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg17644776	chr2:200775616	C2orf69	0.4	6.95	0.32	1.36e-11	Asthma (bronchodilator response);
LUAD	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-7.14	-0.33	3.99e-12	Neuroticism;
LUAD	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.71	-0.35	8.94e-14	Total body bone mineral density;
LUAD	cis	rs4820539	0.966	rs3788350	chr22:23468468	C/T	cg21100191	chr22:23484243	RTDR1	0.67	11.33	0.48	3.6e-26	Bone mineral density;
LUAD	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg25985355	chr7:65971099	NA	0.52	6.53	0.3	1.86e-10	Diabetic kidney disease;
LUAD	cis	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.87	-0.36	3.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9814567	0.752	rs4605591	chr3:134328361	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.95	-0.53	1.52e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg03806693	chr22:41940476	POLR3H	-0.47	-6.93	-0.32	1.6e-11	Neuroticism;
LUAD	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg12714757	chr17:73874637	TRIM47	-0.43	-6.51	-0.3	2.15e-10	Psoriasis;
LUAD	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg02734326	chr4:10020555	SLC2A9	0.65	11.56	0.49	4.62e-27	Bone mineral density;
LUAD	cis	rs11723261	0.582	rs3747693	chr4:124375	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.44	7.57	0.35	2.34e-13	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.55	-9.38	-0.41	4.08e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg14416269	chr4:6271139	WFS1	0.62	12.7	0.53	1.51e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7527798	0.592	rs11118281	chr1:207832102	C/T	cg09232269	chr1:207846808	CR1L	-0.36	-6.84	-0.32	2.85e-11	Erythrocyte sedimentation rate;
LUAD	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.6	7.54	0.34	2.95e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6901250	0.587	rs339357	chr6:117198291	G/C	cg12892004	chr6:117198278	RFX6	-0.33	-6.77	-0.31	4.37e-11	C-reactive protein levels;
LUAD	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg09085632	chr11:111637200	PPP2R1B	0.64	9.96	0.44	4.07e-21	Primary sclerosing cholangitis;
LUAD	cis	rs1784581	1.000	rs1784582	chr6:162400712	A/G	cg17173639	chr6:162384350	PARK2	-0.57	-10.38	-0.45	1.24e-22	Itch intensity from mosquito bite;
LUAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg21280719	chr6:42927975	GNMT	-0.4	-12.0	-0.5	9.66e-29	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs72928364	1.000	rs2576369	chr3:100618155	G/A	cg10123952	chr3:100791384	NA	-0.54	-6.76	-0.31	4.69e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7267979	0.586	rs11087505	chr20:25196520	T/A	cg08601574	chr20:25228251	PYGB	0.38	6.87	0.32	2.25e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg01620082	chr3:125678407	NA	-1.04	-10.34	-0.45	1.67e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg26811252	chr16:29126840	RRN3P2	0.62	10.56	0.46	2.68e-23	Menopause (age at onset);
LUAD	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg26408565	chr15:76604113	ETFA	-0.47	-7.94	-0.36	1.83e-14	Blood metabolite levels;
LUAD	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg03388025	chr16:89894329	SPIRE2	0.5	12.9	0.53	2.41e-32	Vitiligo;
LUAD	cis	rs11951515	0.509	rs12521249	chr5:43558629	T/C	cg01983248	chr5:43482804	C5orf28	0.4	8.61	0.39	1.41e-16	Metabolite levels  (X-11787);
LUAD	cis	rs4737010	0.501	rs7000282	chr8:41647493	A/C	cg08923054	chr8:41654455	ANK1	0.4	6.49	0.3	2.46e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs807669	0.548	rs885979	chr22:19198375	T/C	cg02655711	chr22:19163373	SLC25A1	0.68	13.8	0.56	4.82e-36	Metabolite levels;
LUAD	trans	rs1997103	0.954	rs6593236	chr7:55410992	C/T	cg20935933	chr6:143382018	AIG1	0.52	7.21	0.33	2.61e-12	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7640424	0.649	rs62262420	chr3:107909940	C/T	cg09227934	chr3:107805635	CD47	-0.48	-8.5	-0.38	3.19e-16	Body mass index;
LUAD	trans	rs629535	0.551	rs62513429	chr8:70149995	A/C	cg21567404	chr3:27674614	NA	-1.01	-16.41	-0.62	3.43e-47	Dupuytren's disease;
LUAD	trans	rs2018683	0.711	rs917213	chr7:28968204	A/G	cg19402173	chr7:128379420	CALU	-0.58	-9.3	-0.41	7.85e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03934478	chr11:495069	RNH1	0.71	8.66	0.39	1e-16	Body mass index;
LUAD	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg08859206	chr1:53392774	SCP2	0.56	10.15	0.44	8.44e-22	Monocyte count;
LUAD	cis	rs4889855	0.614	rs7208670	chr17:78494220	T/G	cg16591659	chr17:78472290	NA	-0.53	-8.08	-0.37	7.01e-15	Fractional excretion of uric acid;
LUAD	cis	rs295140	0.605	rs3769471	chr2:201195403	G/A	cg23649088	chr2:200775458	C2orf69	-0.43	-7.33	-0.34	1.15e-12	QT interval;
LUAD	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg07570687	chr10:102243282	WNT8B	0.46	7.06	0.32	6.77e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs525592	1	rs525592	chr11:68195104	C/T	cg16797656	chr11:68205561	LRP5	0.52	10.96	0.47	9.09e-25	Bone mineral density;
LUAD	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.46e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg10544611	chr16:67998164	SLC12A4	-0.56	-6.92	-0.32	1.64e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg22823121	chr1:150693482	HORMAD1	-0.39	-7.72	-0.35	8.38e-14	Melanoma;
LUAD	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14829155	chr15:31115871	NA	0.76	12.77	0.53	8.12e-32	Huntington's disease progression;
LUAD	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg11502198	chr6:26597334	ABT1	0.63	10.35	0.45	1.62e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	trans	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg17712092	chr4:129076599	LARP1B	-0.65	-10.19	-0.44	6.06e-22	Eosinophil percentage of white cells;
LUAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08219700	chr8:58056026	NA	0.68	8.84	0.39	2.62e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10129255	0.500	rs7161740	chr14:107184358	G/T	cg23076370	chr14:107095027	NA	-0.43	-8.68	-0.39	8.58e-17	Kawasaki disease;
LUAD	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg15445000	chr17:37608096	MED1	-0.44	-8.07	-0.37	7.38e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg03714773	chr7:91764589	CYP51A1	0.28	6.6	0.31	1.2e-10	Breast cancer;
LUAD	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg23260525	chr10:116636907	FAM160B1	0.47	11.0	0.47	6.26e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs55788414	0.789	rs4630561	chr16:81183108	T/C	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.87	-0.36	3.02e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs7089973	0.872	rs17092497	chr10:116612628	G/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.5	0.42	1.55e-19	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9462027	0.628	rs9462009	chr6:34716330	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.85	-0.4	2.5e-17	Systemic lupus erythematosus;
LUAD	cis	rs17095355	0.901	rs72828247	chr10:111750960	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.71	-8.4	-0.38	6.63e-16	Biliary atresia;
LUAD	cis	rs12765878	0.967	rs10883940	chr10:105650598	G/A	cg11005552	chr10:105648138	OBFC1	0.44	8.34	0.38	1.04e-15	Coronary artery disease;
LUAD	cis	rs10733682	0.524	rs10987422	chr9:129462687	C/A	cg00232160	chr9:129468157	NA	0.47	8.29	0.37	1.49e-15	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9487051	0.768	rs1766814	chr6:109526696	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.0	-0.32	1.02e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg10411590	chr13:21900810	NA	0.44	7.13	0.33	4.45e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.74	0.39	5.73e-17	Menarche (age at onset);
LUAD	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.35	0.34	1e-12	Bipolar disorder;
LUAD	cis	rs908922	0.676	rs1053590	chr1:152488428	T/C	cg23254163	chr1:152506842	NA	0.26	7.12	0.33	4.75e-12	Hair morphology;
LUAD	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg16647868	chr5:131706066	SLC22A5	-0.5	-7.8	-0.35	4.99e-14	Breast cancer;
LUAD	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.55	0.34	2.65e-13	Morning vs. evening chronotype;
LUAD	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg03609598	chr5:56110824	MAP3K1	0.62	7.86	0.36	3.14e-14	Initial pursuit acceleration;
LUAD	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.47	-9.89	-0.43	7.09e-21	Total body bone mineral density;
LUAD	cis	rs4604732	0.536	rs78019731	chr1:247626430	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.83	-0.32	2.94e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs526821	0.595	rs551665	chr11:55343268	G/A	cg04317927	chr11:55418816	OR4S2	0.39	7.44	0.34	5.51e-13	Pediatric bone mineral density (spine);
LUAD	cis	rs3806843	0.576	rs246009	chr5:140338069	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.32	6.71	0.31	6.43e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4900538	0.855	rs762105	chr14:102830175	A/G	cg18135206	chr14:102964638	TECPR2	-1.01	-20.99	-0.71	1.51e-67	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs11098699	0.821	rs11098705	chr4:124229644	C/T	cg09941581	chr4:124220074	SPATA5	0.43	6.96	0.32	1.33e-11	Mosquito bite size;
LUAD	cis	rs7267979	0.966	rs416745	chr20:25438868	T/C	cg08601574	chr20:25228251	PYGB	0.47	8.7	0.39	7.19e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg15744005	chr10:104629667	AS3MT	-0.33	-6.55	-0.3	1.7e-10	Immature fraction of reticulocytes;Schizophrenia;
LUAD	cis	rs28830936	1.000	rs17678767	chr15:42096422	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.34	-6.92	-0.32	1.67e-11	Diastolic blood pressure;
LUAD	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg16486109	chr11:613632	IRF7	0.49	8.14	0.37	4.35e-15	Systemic lupus erythematosus;
LUAD	cis	rs6500395	1.000	rs904818	chr16:48622582	T/C	cg04672837	chr16:48644449	N4BP1	0.38	6.57	0.3	1.46e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs727505	1.000	rs10233385	chr7:124498707	C/G	cg23710748	chr7:124431027	NA	-0.47	-9.56	-0.42	9.77e-20	Lewy body disease;
LUAD	cis	rs9837602	0.810	rs35777905	chr3:99690970	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.61	7.7	0.35	9.45e-14	Breast cancer;
LUAD	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg18190219	chr22:46762943	CELSR1	-0.54	-6.36	-0.3	5.26e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs11229555	0.645	rs12800531	chr11:58180099	C/T	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg18351406	chr4:77819688	ANKRD56	0.61	9.8	0.43	1.48e-20	Emphysema distribution in smoking;
LUAD	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg04851639	chr8:1020857	NA	-0.42	-10.67	-0.46	1.07e-23	Schizophrenia;
LUAD	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg25173405	chr17:45401733	C17orf57	0.52	8.89	0.4	1.75e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7017914	0.902	rs34882924	chr8:71566308	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.52	-0.3	1.99e-10	Bone mineral density;
LUAD	cis	rs758324	0.947	rs4705903	chr5:131206594	A/C	cg06307176	chr5:131281290	NA	0.54	8.66	0.39	9.9900000000000006e-17	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg00953403	chr17:74099816	EXOC7	0.43	6.76	0.31	4.51e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs7818345	0.904	rs6997164	chr8:19287856	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.33	7.08	0.33	6.03e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.52	-8.7	-0.39	7.48e-17	Electrocardiographic conduction measures;
LUAD	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02475777	chr4:1388615	CRIPAK	-0.63	-8.68	-0.39	8.85e-17	Longevity;
LUAD	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs11811982	0.793	rs77116170	chr1:227577717	C/A	cg24860534	chr1:227506868	CDC42BPA	0.62	6.93	0.32	1.55e-11	Optic disc area;
LUAD	cis	rs17401966	0.838	rs34565762	chr1:10300119	T/C	cg15208524	chr1:10270712	KIF1B	0.42	6.45	0.3	3.05e-10	Hepatocellular carcinoma;
LUAD	cis	rs7177699	0.557	rs4433781	chr15:79121835	A/T	cg00540400	chr15:79124168	NA	-0.45	-9.69	-0.43	3.59e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg27284194	chr4:1044797	NA	-0.67	-9.85	-0.43	9.69e-21	Recombination rate (females);
LUAD	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10802521	chr3:52805072	NEK4	-0.62	-11.22	-0.48	9.81e-26	Electroencephalogram traits;
LUAD	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg03037974	chr15:76606532	NA	0.4	8.91	0.4	1.51e-17	Blood metabolite levels;
LUAD	trans	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg02030672	chr11:45687055	CHST1	0.38	6.54	0.3	1.78e-10	Obesity-related traits;
LUAD	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg10518543	chr12:38710700	ALG10B	0.41	6.37	0.3	4.9e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs11249608	0.548	rs7709054	chr5:178462757	C/T	cg01312482	chr5:178451176	ZNF879	-0.45	-7.07	-0.33	6.26e-12	Pubertal anthropometrics;
LUAD	cis	rs68170813	0.917	rs13234124	chr7:107225043	C/T	cg02696742	chr7:106810147	HBP1	-0.52	-6.97	-0.32	1.25e-11	Coronary artery disease;
LUAD	cis	rs75920871	1.000	rs11820814	chr11:116765700	T/C	cg04087571	chr11:116723030	SIK3	-0.32	-6.61	-0.31	1.19e-10	Subjective well-being;
LUAD	trans	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg27411982	chr8:10470053	RP1L1	0.39	7.08	0.33	5.94e-12	Mood instability;
LUAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg23131131	chr22:24373011	LOC391322	-0.59	-9.95	-0.44	4.17e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg17031739	chr1:67600172	NA	0.42	7.4	0.34	7.19e-13	Psoriasis;
LUAD	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg03433033	chr1:76189801	ACADM	0.85	15.12	0.59	1.38e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg01620082	chr3:125678407	NA	-1.1	-10.22	-0.45	4.5e-22	Depression;
LUAD	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.53	-10.01	-0.44	2.68e-21	Schizophrenia;
LUAD	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg04731861	chr2:219085781	ARPC2	0.23	7.05	0.32	7.47e-12	Colorectal cancer;
LUAD	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03452623	chr4:187889614	NA	-0.82	-16.34	-0.62	6.83e-47	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg00106254	chr7:1943704	MAD1L1	-0.62	-9.38	-0.41	4.19e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg04287289	chr16:89883240	FANCA	0.72	13.23	0.54	1.08e-33	Vitiligo;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15470736	chr7:157056012	UBE3C	0.57	6.93	0.32	1.57e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.35	0.54	3.74e-34	Prudent dietary pattern;
LUAD	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg09184832	chr6:79620586	NA	-0.5	-9.34	-0.41	5.53e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg16988262	chr1:15930761	NA	-0.41	-6.91	-0.32	1.83e-11	Systolic blood pressure;
LUAD	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg06547715	chr2:218990976	CXCR2	-0.27	-6.49	-0.3	2.44e-10	Colorectal cancer;
LUAD	cis	rs9487051	0.768	rs351742	chr6:109527325	C/T	cg21918786	chr6:109611834	NA	0.43	7.45	0.34	5.37e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg00071950	chr4:10020882	SLC2A9	-0.62	-11.82	-0.5	4.54e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08219700	chr8:58056026	NA	0.57	8.08	0.37	6.8e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs727505	1.000	rs34986416	chr7:124441017	A/G	cg23710748	chr7:124431027	NA	-0.47	-9.56	-0.42	1.01e-19	Lewy body disease;
LUAD	cis	rs3820068	0.705	rs2145396	chr1:15875184	A/G	cg24675056	chr1:15929824	NA	0.43	6.79	0.31	3.76e-11	Systolic blood pressure;
LUAD	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg03806693	chr22:41940476	POLR3H	-0.58	-8.35	-0.38	9.94e-16	Vitiligo;
LUAD	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg09537434	chr19:41945824	ATP5SL	-0.49	-7.94	-0.36	1.84e-14	Height;
LUAD	cis	rs9300255	0.722	rs12322888	chr12:123825559	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-6.87	-0.32	2.34e-11	Neutrophil percentage of white cells;
LUAD	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.3	-0.41	7.63e-19	Total body bone mineral density;
LUAD	cis	rs6433857	0.657	rs6756509	chr2:181500273	T/C	cg23363182	chr2:181467187	NA	-0.43	-7.22	-0.33	2.47e-12	Body mass index;
LUAD	cis	rs56390833	1	rs56390833	chr15:78877381	C/A	cg18825076	chr15:78729989	IREB2	-0.58	-9.26	-0.41	1.02e-18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00149659	chr3:10157352	C3orf10	0.57	8.06	0.36	7.87e-15	Alzheimer's disease;
LUAD	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg00074818	chr8:8560427	CLDN23	0.76	11.75	0.5	8.6e-28	Obesity-related traits;
LUAD	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg13393036	chr8:95962371	TP53INP1	-0.4	-9.67	-0.43	3.92e-20	Type 2 diabetes;
LUAD	cis	rs7264396	1.000	rs224429	chr20:34152018	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.61	-0.31	1.15e-10	Total cholesterol levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg11424665	chr3:129158811	IFT122;MBD4	-0.41	-6.82	-0.31	3.08e-11	Schizophrenia;
LUAD	cis	rs13315871	1.000	rs28668389	chr3:58323942	G/C	cg12435725	chr3:58293450	RPP14	-0.76	-8.4	-0.38	6.7e-16	Cholesterol, total;
LUAD	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg21724239	chr8:58056113	NA	0.73	8.94	0.4	1.25e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs986417	1.000	rs10143118	chr14:61066043	G/A	cg27398547	chr14:60952738	C14orf39	0.56	6.69	0.31	7.28e-11	Gut microbiota (bacterial taxa);
LUAD	cis	rs7731657	0.537	rs2188957	chr5:130253459	C/T	cg08523029	chr5:130500466	HINT1	0.58	7.53	0.34	3.15e-13	Fasting plasma glucose;
LUAD	cis	rs4911259	0.552	rs6058925	chr20:31465374	G/A	cg13636640	chr20:31349939	DNMT3B	-0.58	-9.52	-0.42	1.4e-19	Inflammatory bowel disease;
LUAD	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg11062466	chr8:58055876	NA	0.75	9.19	0.41	1.75e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg10556830	chr5:68462986	CCNB1	0.42	6.81	0.31	3.32e-11	Bilirubin levels;
LUAD	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg11645453	chr3:52864694	ITIH4	0.37	6.91	0.32	1.82e-11	Bipolar disorder;
LUAD	trans	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.71	-0.35	8.88e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg11344533	chr11:111475393	SIK2	-0.34	-6.49	-0.3	2.44e-10	Primary sclerosing cholangitis;
LUAD	cis	rs2274471	0.645	rs58346692	chr9:5001204	G/A	cg03390472	chr9:5043263	JAK2	-0.52	-7.92	-0.36	2.16e-14	Crohn's disease;
LUAD	cis	rs28655083	1.000	rs1843455	chr16:77072343	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-7.14	-0.33	4.13e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs71636778	0.543	rs17162333	chr1:27236757	C/G	cg12203394	chr1:27248618	NUDC	0.51	6.39	0.3	4.44e-10	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs775227	0.574	rs16861158	chr3:113261709	G/T	cg18753928	chr3:113234510	CCDC52	-0.7	-9.53	-0.42	1.25e-19	Dental caries;
LUAD	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.43	6.66	0.31	8.77e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07157834	chr1:205819609	PM20D1	0.72	14.03	0.56	5.47e-37	Menarche (age at onset);
LUAD	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg01191920	chr7:158217561	PTPRN2	-0.74	-16.11	-0.62	6.79e-46	Obesity-related traits;
LUAD	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg17724175	chr1:150552817	MCL1	0.36	8.29	0.37	1.55e-15	Melanoma;
LUAD	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23158103	chr7:148848205	ZNF398	-0.63	-11.65	-0.49	2.07e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg06784218	chr1:46089804	CCDC17	-0.38	-8.46	-0.38	4.3e-16	Red blood cell count;Reticulocyte count;
LUAD	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg00666640	chr1:248458726	OR2T12	0.34	7.92	0.36	2.05e-14	Common traits (Other);
LUAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06873352	chr17:61820015	STRADA	0.83	18.44	0.67	3.61e-56	Prudent dietary pattern;
LUAD	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg10589385	chr1:150898437	SETDB1	0.43	7.95	0.36	1.76e-14	Melanoma;
LUAD	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11644478	chr21:40555479	PSMG1	0.7	11.8	0.5	5.71e-28	Cognitive function;
LUAD	cis	rs701145	0.878	rs355774	chr3:154036196	A/G	cg17054900	chr3:154042577	DHX36	0.66	7.32	0.34	1.29e-12	Coronary artery disease;
LUAD	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.44	-6.93	-0.32	1.53e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg26384229	chr12:38710491	ALG10B	0.43	7.19	0.33	2.92e-12	Morning vs. evening chronotype;
LUAD	cis	rs1448094	0.845	rs10863123	chr12:86346254	G/A	cg02569458	chr12:86230093	RASSF9	0.35	6.67	0.31	8.03e-11	Major depressive disorder;
LUAD	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.36	-0.34	9.67e-13	Bipolar disorder;
LUAD	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg09365446	chr1:150670422	GOLPH3L	0.61	10.91	0.47	1.39e-24	Melanoma;
LUAD	cis	rs6537837	0.701	rs12021920	chr1:110147287	C/T	cg05049280	chr1:110155535	GNAT2	0.56	7.0	0.32	9.83e-12	Major depressive disorder;
LUAD	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.93	0.36	2.03e-14	Morning vs. evening chronotype;
LUAD	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18404041	chr3:52824283	ITIH1	-0.61	-12.36	-0.52	3.51e-30	Bipolar disorder;
LUAD	cis	rs9326248	0.581	rs7121898	chr11:116796846	A/T	cg20608306	chr11:116969690	SIK3	0.32	7.24	0.33	2.08e-12	Blood protein levels;
LUAD	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg25358565	chr5:93447407	FAM172A	-0.65	-7.8	-0.35	4.77e-14	Diabetic retinopathy;
LUAD	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg00717180	chr2:96193071	NA	-0.42	-7.79	-0.35	5.09e-14	HDL cholesterol;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg23282051	chr2:239067613	NA	-0.65	-6.93	-0.32	1.63e-11	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg19717773	chr7:2847554	GNA12	-0.44	-7.59	-0.35	2.06e-13	Height;
LUAD	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg23625390	chr15:77176239	SCAPER	0.38	6.76	0.31	4.66e-11	Blood metabolite levels;
LUAD	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg13902645	chr11:5959945	NA	-0.56	-9.94	-0.44	4.74e-21	DNA methylation (variation);
LUAD	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.61e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs89107	0.967	rs6912208	chr6:118566516	A/G	cg21191810	chr6:118973309	C6orf204	-0.46	-8.9	-0.4	1.6e-17	Cardiac structure and function;
LUAD	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg27284194	chr4:1044797	NA	-0.56	-9.15	-0.41	2.52e-18	Recombination rate (males);
LUAD	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg21775007	chr8:11205619	TDH	-0.51	-9.25	-0.41	1.09e-18	Neuroticism;
LUAD	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.35	-6.87	-0.32	2.32e-11	Glomerular filtration rate;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06852250	chr1:171750693	METTL13	-0.58	-7.09	-0.33	5.7e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.64	-10.78	-0.46	4.26e-24	Glomerular filtration rate;
LUAD	cis	rs62064224	0.597	rs7207268	chr17:30725155	T/G	cg18200150	chr17:30822561	MYO1D	0.41	7.52	0.34	3.25e-13	Schizophrenia;
LUAD	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg24596788	chr1:163392923	NA	0.32	7.31	0.34	1.31e-12	Motion sickness;
LUAD	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg06640241	chr16:89574553	SPG7	0.49	8.04	0.36	9.39e-15	Multiple myeloma (IgH translocation);
LUAD	cis	rs4072705	0.614	rs7020027	chr9:127241414	G/A	cg01786973	chr9:127249749	NR5A1	-0.3	-6.45	-0.3	3.07e-10	Menarche (age at onset);
LUAD	cis	rs11229555	0.645	rs7117080	chr11:58178677	C/G	cg15696309	chr11:58395628	NA	-0.7	-10.05	-0.44	1.94e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs17102423	0.594	rs1953232	chr14:65570386	A/C	cg16583315	chr14:65563665	MAX	0.36	6.73	0.31	5.43e-11	Obesity-related traits;
LUAD	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg16988262	chr1:15930761	NA	0.42	7.16	0.33	3.64e-12	Systolic blood pressure;
LUAD	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.59	-10.2	-0.44	5.5e-22	Adiponectin levels;
LUAD	trans	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg18335740	chr13:41363409	SLC25A15	0.72	14.14	0.57	1.97e-37	Lewy body disease;
LUAD	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg11833968	chr6:79620685	NA	-0.43	-7.96	-0.36	1.58e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg06453172	chr10:134556979	INPP5A	-0.65	-10.28	-0.45	2.8e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg20701182	chr2:24300061	SF3B14	0.88	13.43	0.55	1.71e-34	Lymphocyte counts;
LUAD	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg24069376	chr3:38537580	EXOG	0.37	8.6	0.39	1.52e-16	Electrocardiographic conduction measures;
LUAD	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg08422745	chr4:174089978	GALNT7	-0.83	-14.65	-0.58	1.28e-39	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs863345	0.604	rs6697656	chr1:158520737	A/G	cg12129480	chr1:158549410	OR10X1	-0.25	-6.41	-0.3	3.95e-10	Pneumococcal bacteremia;
LUAD	cis	rs4332037	0.707	rs11763813	chr7:1896690	C/T	cg02421172	chr7:1938701	MAD1L1	0.5	7.01	0.32	9.7e-12	Bipolar disorder;
LUAD	cis	rs12079745	0.623	rs12091844	chr1:169433273	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.92	-6.69	-0.31	6.99e-11	QT interval;
LUAD	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg10755058	chr3:40428713	ENTPD3	-0.42	-7.82	-0.36	4.32e-14	Renal cell carcinoma;
LUAD	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg20607287	chr7:12443886	VWDE	-0.53	-6.7	-0.31	6.78e-11	Coronary artery disease;
LUAD	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg11919837	chr8:57350735	NA	-0.43	-6.52	-0.3	1.97e-10	Obesity-related traits;
LUAD	cis	rs67366981	0.800	rs55939042	chr14:77691186	T/A	cg22824376	chr14:77648248	TMEM63C	0.67	7.16	0.33	3.5e-12	Obsessive-compulsive symptoms;
LUAD	cis	rs9549328	0.544	rs66893681	chr13:113617499	A/G	cg17524180	chr13:113633600	MCF2L	0.31	6.61	0.31	1.16e-10	Systolic blood pressure;
LUAD	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.62	0.31	1.09e-10	Depression;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01653422	chr8:48920818	UBE2V2	-0.54	-6.41	-0.3	3.82e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg02221750	chr19:17393354	ANKLE1	-0.74	-11.77	-0.5	7.51e-28	Systemic lupus erythematosus;
LUAD	cis	rs35883536	0.967	rs2783689	chr1:101092411	C/G	cg06223162	chr1:101003688	GPR88	-0.37	-6.81	-0.31	3.45e-11	Monocyte count;
LUAD	trans	rs1406428	0.573	rs12613632	chr2:51705755	C/G	cg12951224	chr8:38126910	PPAPDC1B	0.44	6.36	0.3	5.38e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg10819733	chr22:24237672	NA	-0.39	-7.2	-0.33	2.78e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.41	-18.27	-0.66	2.11e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-6.99	-0.32	1.1e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.42	-0.34	6.68e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.15e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg22944662	chr1:178062847	LOC100302401;RASAL2	-0.37	-6.53	-0.3	1.86e-10	Schizophrenia;
LUAD	cis	rs1595825	0.838	rs58576043	chr2:198524149	C/T	cg10547527	chr2:198650123	BOLL	-0.54	-7.66	-0.35	1.3e-13	Ulcerative colitis;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	ch.2.195648145F	chr2:195939902	NA	-0.39	-6.96	-0.32	1.33e-11	Cancer;
LUAD	trans	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg06606381	chr12:133084897	FBRSL1	-0.94	-8.88	-0.4	1.91e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18876405	chr7:65276391	NA	0.55	9.22	0.41	1.46e-18	Aortic root size;
LUAD	cis	rs6489882	0.902	rs4767040	chr12:113374017	C/G	cg20102336	chr12:113376681	OAS3	-0.6	-9.57	-0.42	9.32e-20	Chronic lymphocytic leukemia;
LUAD	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg10518543	chr12:38710700	ALG10B	0.42	6.52	0.3	2.05e-10	Heart rate;
LUAD	cis	rs72681920	0.881	rs28914775	chr4:100233126	C/T	cg12011299	chr4:100065546	ADH4	-0.64	-6.41	-0.3	3.86e-10	Alcohol dependence;
LUAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg02725872	chr8:58115012	NA	-0.33	-6.46	-0.3	2.9e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7009516	0.846	rs13257546	chr8:24218697	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.43	8.73	0.39	5.89e-17	Hair greying;
LUAD	cis	rs28493229	0.708	rs73546845	chr19:41158717	C/T	cg21869046	chr19:41225005	ITPKC	0.52	9.16	0.41	2.18e-18	Kawasaki disease;
LUAD	cis	rs2274273	1.000	rs4644	chr14:55604935	C/A	cg04306507	chr14:55594613	LGALS3	0.38	7.76	0.35	6.22e-14	Protein biomarker;
LUAD	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg27433088	chr4:174089019	GALNT7	0.39	7.58	0.35	2.25e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs4776059	1.000	rs34431049	chr15:52940538	G/C	cg24008177	chr15:52972085	KIAA1370	0.24	6.7	0.31	6.87e-11	Schizophrenia;
LUAD	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg19336497	chr11:14380999	RRAS2	-0.36	-7.19	-0.33	3e-12	Mitochondrial DNA levels;
LUAD	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg01874867	chr7:94954059	PON1	-0.48	-6.41	-0.3	3.98e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7177699	0.557	rs4380028	chr15:79111093	C/T	cg00540400	chr15:79124168	NA	-0.46	-9.71	-0.43	2.93e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs758324	1.000	rs758324	chr5:131109545	G/T	cg06307176	chr5:131281290	NA	0.51	8.07	0.37	7.09e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6545883	0.929	rs12617911	chr2:61740825	A/G	cg15711740	chr2:61764176	XPO1	-0.39	-6.4	-0.3	4.21e-10	Tuberculosis;
LUAD	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg03929089	chr4:120376271	NA	-0.92	-17.34	-0.64	2.83e-51	Coronary artery disease;
LUAD	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg18811423	chr2:55921094	PNPT1	-0.48	-8.01	-0.36	1.11e-14	Metabolic syndrome;
LUAD	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.49	-0.52	1.08e-30	Breast cancer;
LUAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg26338869	chr17:61819248	STRADA	0.4	6.71	0.31	6.14e-11	Prudent dietary pattern;
LUAD	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg09324608	chr17:30823087	MYO1D	0.47	8.67	0.39	9.54e-17	Schizophrenia;
LUAD	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.9	-0.36	2.45e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg03106288	chr1:43424767	SLC2A1	-0.57	-6.35	-0.3	5.46e-10	Monocyte count;
LUAD	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg25233709	chr10:116636983	FAM160B1	0.43	8.65	0.39	1.08e-16	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg23173402	chr1:227635558	NA	0.75	8.07	0.37	7.47e-15	Major depressive disorder;
LUAD	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg17848003	chr1:3704513	LRRC47	0.54	10.9	0.47	1.46e-24	Red cell distribution width;
LUAD	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg15962314	chr1:44399869	ARTN	0.32	6.82	0.31	3.22e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg26384229	chr12:38710491	ALG10B	-0.43	-7.15	-0.33	3.84e-12	Bladder cancer;
LUAD	cis	rs4268898	0.722	rs7563958	chr2:24422381	C/A	cg02683114	chr2:24398427	C2orf84	0.4	6.87	0.32	2.29e-11	Asthma;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg03169527	chr3:11888582	C3orf31	-0.45	-7.66	-0.35	1.29e-13	Subcortical brain region volumes;
LUAD	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg18129748	chr3:49941408	MST1R	-0.43	-7.02	-0.32	8.7e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg25809561	chr17:30822961	MYO1D	0.48	8.74	0.39	5.64e-17	Schizophrenia;
LUAD	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg05368731	chr17:41323189	NBR1	0.96	20.57	0.71	1.16e-65	Menopause (age at onset);
LUAD	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg00495681	chr13:53174319	NA	0.86	17.84	0.66	1.71e-53	Lewy body disease;
LUAD	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.54	-9.1	-0.4	3.65e-18	Glomerular filtration rate;
LUAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-9.2	-0.41	1.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11890956	chr21:40555474	PSMG1	-0.55	-9.61	-0.42	6.76e-20	Menarche (age at onset);
LUAD	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg00634984	chr7:65235879	NA	-0.47	-6.45	-0.3	3.11e-10	Aortic root size;
LUAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg17178900	chr1:205818956	PM20D1	0.73	15.18	0.59	7.22e-42	Menarche (age at onset);
LUAD	cis	rs4631830	0.720	rs2125770	chr10:51514824	T/C	cg20129853	chr10:51489980	NA	-0.34	-6.8	-0.31	3.67e-11	Prostate-specific antigen levels;
LUAD	cis	rs6542838	0.611	rs1878589	chr2:99517979	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.81	-0.31	3.44e-11	Fear of minor pain;
LUAD	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg19622623	chr12:86230825	RASSF9	0.42	7.49	0.34	3.93e-13	Major depressive disorder;
LUAD	cis	rs67366981	0.925	rs66846709	chr14:77692812	G/A	cg22824376	chr14:77648248	TMEM63C	0.67	7.22	0.33	2.42e-12	Obsessive-compulsive symptoms;
LUAD	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.64	0.55	2.2e-35	Tonsillectomy;
LUAD	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg02782426	chr3:40428986	ENTPD3	-0.38	-8.16	-0.37	3.97e-15	Renal cell carcinoma;
LUAD	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg05966235	chr16:28915196	ATP2A1	0.46	7.48	0.34	4.21e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4889855	0.530	rs75398920	chr17:78544540	C/T	cg16591659	chr17:78472290	NA	0.45	7.85	0.36	3.39e-14	Fractional excretion of uric acid;
LUAD	cis	rs1483890	0.723	rs12631128	chr3:69411416	G/T	cg22125112	chr3:69402811	FRMD4B	0.45	7.66	0.35	1.31e-13	Resting heart rate;
LUAD	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg15605315	chr1:45957053	TESK2	-0.41	-6.48	-0.3	2.5e-10	High light scatter reticulocyte count;
LUAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg10729496	chr3:10149963	C3orf24	0.57	9.51	0.42	1.49e-19	Alzheimer's disease;
LUAD	cis	rs2882667	0.858	rs11948429	chr5:138458584	G/A	cg04439458	chr5:138467593	SIL1	-0.54	-9.82	-0.43	1.2e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.69	-0.35	1.05e-13	Bipolar disorder;
LUAD	cis	rs28374715	0.609	rs8043237	chr15:41514298	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.91	-16.93	-0.64	1.89e-49	Ulcerative colitis;
LUAD	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg02269571	chr22:50332266	NA	0.59	8.91	0.4	1.52e-17	Schizophrenia;
LUAD	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg10560079	chr2:191398806	TMEM194B	0.56	7.27	0.33	1.78e-12	Diastolic blood pressure;
LUAD	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg04756594	chr16:24857601	SLC5A11	0.76	13.34	0.54	4.09e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs35883536	0.967	rs3904673	chr1:101137162	A/C	cg06223162	chr1:101003688	GPR88	0.35	6.5	0.3	2.2e-10	Monocyte count;
LUAD	cis	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg07460842	chr6:66804631	NA	0.61	9.56	0.42	9.66e-20	Type 2 diabetes;
LUAD	cis	rs1696756	0.759	rs1298563	chr17:77834703	G/A	cg00646381	chr17:77835854	NA	0.53	9.03	0.4	6.36e-18	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg25985355	chr7:65971099	NA	-0.54	-6.7	-0.31	6.56e-11	Diabetic kidney disease;
LUAD	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-20.27	-0.7	2.52e-64	Height;
LUAD	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg27539214	chr16:67997921	SLC12A4	-0.69	-8.88	-0.4	1.97e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg20203395	chr5:56204925	C5orf35	-0.81	-11.68	-0.49	1.6e-27	Initial pursuit acceleration;
LUAD	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.17	-0.33	3.29e-12	Total body bone mineral density;
LUAD	cis	rs34734847	0.787	rs7976497	chr12:121135467	T/C	cg13914990	chr12:121174878	ACADS	0.4	7.67	0.35	1.16e-13	Mean corpuscular volume;
LUAD	cis	rs1232027	0.700	rs836818	chr5:79947956	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-8.07	-0.37	7.25e-15	Huntington's disease progression;
LUAD	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg08859206	chr1:53392774	SCP2	-0.66	-11.68	-0.49	1.66e-27	Monocyte count;
LUAD	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg03396347	chr1:1875803	NA	-0.6	-15.47	-0.6	4.17e-43	Body mass index;
LUAD	cis	rs6474412	1.000	rs6474412	chr8:42550498	C/T	cg25026480	chr8:42547641	NA	0.36	6.36	0.3	5.16e-10	Smoking behavior;
LUAD	cis	rs9902453	0.935	rs9898424	chr17:28392946	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.28	-0.41	9.11e-19	Coffee consumption (cups per day);
LUAD	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg06784218	chr1:46089804	CCDC17	-0.59	-13.26	-0.54	8.61e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg25036284	chr2:26402008	FAM59B	-0.58	-8.29	-0.37	1.53e-15	Gut microbiome composition (summer);
LUAD	cis	rs8067287	0.762	rs11649835	chr17:16823541	C/G	cg26910001	chr17:16838321	NA	-0.48	-6.67	-0.31	8.09e-11	Diabetic kidney disease;
LUAD	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg22117172	chr7:91764530	CYP51A1	0.32	7.07	0.33	6.34e-12	Breast cancer;
LUAD	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg00981070	chr1:2046702	PRKCZ	0.36	6.86	0.32	2.49e-11	Height;
LUAD	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.59	8.87	0.4	2.08e-17	Total cholesterol levels;
LUAD	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg23018236	chr17:30244563	NA	-0.69	-8.39	-0.38	7.53e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg20908204	chr19:46285434	DMPK	-0.42	-9.32	-0.41	6.56e-19	Coronary artery disease;
LUAD	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg15557168	chr22:42548783	NA	0.57	11.22	0.48	9.18e-26	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg07570687	chr10:102243282	WNT8B	0.45	6.97	0.32	1.25e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg09658497	chr7:2847517	GNA12	-0.44	-7.94	-0.36	1.82e-14	Height;
LUAD	cis	rs12620999	1.000	rs12620999	chr2:238036367	C/T	cg23555395	chr2:238036564	NA	-0.6	-9.2	-0.41	1.66e-18	Systemic lupus erythematosus;
LUAD	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg16512390	chr1:228756714	NA	0.72	10.26	0.45	3.24e-22	Chronic lymphocytic leukemia;
LUAD	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11644478	chr21:40555479	PSMG1	-0.54	-8.63	-0.39	1.29e-16	Cognitive function;
LUAD	cis	rs208520	0.690	rs851458	chr6:66813279	T/G	cg07460842	chr6:66804631	NA	-1.09	-17.22	-0.64	1.01e-50	Exhaled nitric oxide output;
LUAD	cis	rs72928364	1.000	rs62275199	chr3:100695413	A/G	cg10123952	chr3:100791384	NA	0.64	7.47	0.34	4.74e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1044826	0.642	rs2071388	chr3:139236683	C/T	cg00490450	chr3:139108681	COPB2	-0.4	-6.41	-0.3	3.97e-10	Obesity-related traits;
LUAD	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg13319975	chr6:146136371	FBXO30	0.58	9.84	0.43	1.05e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4862307	0.836	rs4507404	chr4:185003767	C/T	cg06737308	chr4:185021514	ENPP6	-0.56	-9.11	-0.4	3.4e-18	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg08601574	chr20:25228251	PYGB	-0.44	-8.16	-0.37	3.82e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2735413	0.709	rs1319049	chr16:78084610	T/G	cg04733911	chr16:78082701	NA	0.37	8.75	0.39	5.07e-17	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.56	8.28	0.37	1.59e-15	Platelet count;
LUAD	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18876405	chr7:65276391	NA	-0.43	-6.97	-0.32	1.24e-11	Aortic root size;
LUAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg08027265	chr7:2291960	NA	-0.41	-6.94	-0.32	1.49e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg17652424	chr22:38574118	PLA2G6	-0.33	-10.14	-0.44	8.96e-22	Cutaneous nevi;
LUAD	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg22166914	chr1:53195759	ZYG11B	-0.39	-6.38	-0.3	4.59e-10	Monocyte count;
LUAD	cis	rs1595825	0.891	rs75163179	chr2:198895402	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-7.0	-0.32	1.02e-11	Ulcerative colitis;
LUAD	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg03806693	chr22:41940476	POLR3H	-0.56	-8.08	-0.37	6.76e-15	Vitiligo;
LUAD	cis	rs12545109	0.842	rs2582379	chr8:57395243	C/T	cg17761419	chr8:57350749	NA	0.54	7.39	0.34	8.15e-13	Obesity-related traits;
LUAD	cis	rs986417	0.818	rs4278669	chr14:60982075	T/C	cg27398547	chr14:60952738	C14orf39	0.66	7.7	0.35	9.92e-14	Gut microbiota (bacterial taxa);
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg16103275	chr6:290800	DUSP22	0.36	6.57	0.3	1.44e-10	Menopause (age at onset);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg08125972	chr19:36705377	ZNF565;ZNF146	-0.39	-6.83	-0.32	2.97e-11	Subcortical brain region volumes;
LUAD	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2425143	1.000	rs6060588	chr20:34337480	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.17	-0.33	3.31e-12	Blood protein levels;
LUAD	trans	rs4650994	0.593	rs10753180	chr1:178520653	A/G	cg05059571	chr16:84539110	KIAA1609	0.48	7.48	0.34	4.39e-13	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs2286885	1.000	rs10987296	chr9:129245316	C/T	cg15282417	chr9:129245246	FAM125B	0.43	8.66	0.39	1.03e-16	Intraocular pressure;
LUAD	cis	rs2742417	0.624	rs2673029	chr3:45758867	A/G	cg10512202	chr3:45649293	LIMD1	0.49	9.18	0.41	1.97e-18	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg25024717	chr12:54324583	NA	-0.32	-6.97	-0.32	1.19e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUAD	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg18825076	chr15:78729989	IREB2	0.48	6.64	0.31	9.68e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg24069376	chr3:38537580	EXOG	-0.43	-10.44	-0.45	7.4e-23	Electrocardiographic conduction measures;
LUAD	trans	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-10.48	-0.45	5.4e-23	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19346786	chr7:2764209	NA	-0.56	-12.11	-0.51	3.61e-29	Height;
LUAD	cis	rs7917772	0.604	rs11191358	chr10:104399250	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.63	-0.31	1e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs8040855	0.579	rs28521166	chr15:85728032	C/T	cg04831495	chr15:85060580	GOLGA6L5	0.41	6.94	0.32	1.52e-11	Bulimia nervosa;
LUAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.56	-10.19	-0.44	5.93e-22	Longevity;Endometriosis;
LUAD	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.42	-0.38	5.93e-16	Total cholesterol levels;
LUAD	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg06131755	chr6:160182447	ACAT2	0.43	6.48	0.3	2.57e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg22705602	chr4:152727874	NA	-0.5	-9.54	-0.42	1.14e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg23758822	chr17:41437982	NA	1.0	20.5	0.71	2.25e-65	Menopause (age at onset);
LUAD	trans	rs931812	0.829	rs13266662	chr8:101916156	C/T	cg20993868	chr7:22813445	NA	0.5	10.16	0.44	7.37e-22	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.56	0.34	2.59e-13	Breast cancer;
LUAD	cis	rs4243830	1.000	rs34757678	chr1:6583270	C/G	cg05709478	chr1:6581295	PLEKHG5	0.59	6.86	0.32	2.52e-11	Body mass index;
LUAD	cis	rs1497828	0.956	rs9441482	chr1:217571282	T/A	cg04411442	chr1:217543379	NA	0.37	6.59	0.31	1.3e-10	Dialysis-related mortality;
LUAD	cis	rs9364220	0.662	rs2087570	chr6:168494037	C/T	cg02770688	chr6:168491649	NA	-0.36	-6.92	-0.32	1.64e-11	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
LUAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	ch.5.2644049F	chr5:141245237	PCDH1	-0.4	-6.75	-0.31	4.93e-11	Cancer;
LUAD	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.53	-0.3	1.89e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg21231944	chr12:82153410	PPFIA2	-0.35	-6.42	-0.3	3.59e-10	Resting heart rate;
LUAD	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg21433313	chr16:3507492	NAT15	-0.74	-11.72	-0.5	1.12e-27	Tuberculosis;
LUAD	cis	rs6906287	0.537	rs13192336	chr6:118875162	A/T	cg21191810	chr6:118973309	C6orf204	0.51	9.86	0.43	9.17e-21	Electrocardiographic conduction measures;
LUAD	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg20487152	chr13:99095054	FARP1	-0.44	-7.81	-0.36	4.41e-14	Longevity;
LUAD	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-18.28	-0.66	1.9e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7267979	0.789	rs6083820	chr20:25354178	G/A	cg08601574	chr20:25228251	PYGB	-0.38	-7.16	-0.33	3.56e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.4e-13	Menopause (age at onset);
LUAD	cis	rs752010	0.714	rs6600384	chr1:42085141	A/G	cg06885757	chr1:42089581	HIVEP3	-0.41	-9.45	-0.42	2.41e-19	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07157834	chr1:205819609	PM20D1	0.67	12.66	0.52	2.23e-31	Menarche (age at onset);
LUAD	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg15704280	chr7:45808275	SEPT13	-0.71	-11.99	-0.5	1.02e-28	Height;
LUAD	cis	rs2880765	0.546	rs35316253	chr15:86065560	T/C	cg13263323	chr15:86062960	AKAP13	-0.52	-8.76	-0.39	4.73e-17	Coronary artery disease;
LUAD	cis	rs12519773	0.597	rs4308464	chr5:92468867	G/C	cg18783429	chr5:92414398	NA	0.49	8.69	0.39	8.01e-17	Migraine;
LUAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg04025307	chr7:1156635	C7orf50	0.52	8.9	0.4	1.62e-17	Longevity;Endometriosis;
LUAD	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg22823121	chr1:150693482	HORMAD1	0.44	8.72	0.39	6.52e-17	Tonsillectomy;
LUAD	cis	rs10799445	0.508	rs10916165	chr1:227754935	C/T	cg12133451	chr1:227746453	NA	0.37	6.55	0.3	1.65e-10	Height;
LUAD	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg05896524	chr21:47604654	C21orf56	0.54	9.09	0.4	3.93e-18	Testicular germ cell tumor;
LUAD	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg19318889	chr4:1322082	MAEA	0.57	9.88	0.43	7.69e-21	Longevity;
LUAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg18621852	chr3:10150065	C3orf24	0.48	8.32	0.38	1.2e-15	Alzheimer's disease;
LUAD	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg18876405	chr7:65276391	NA	-0.45	-7.19	-0.33	2.89e-12	Aortic root size;
LUAD	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg20701182	chr2:24300061	SF3B14	0.53	6.44	0.3	3.28e-10	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.13	0.37	4.79e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg23029597	chr12:123009494	RSRC2	-0.57	-8.9	-0.4	1.6e-17	Body mass index;
LUAD	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg14416269	chr4:6271139	WFS1	0.66	14.1	0.57	2.73e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg06108461	chr20:60628389	TAF4	-0.82	-13.97	-0.56	9.79e-37	Body mass index;
LUAD	trans	rs1728785	1.000	rs7195979	chr16:68586801	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.74	10.96	0.47	9.26e-25	Ulcerative colitis;
LUAD	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03517284	chr6:25882590	NA	0.91	15.29	0.6	2.38e-42	Blood metabolite levels;
LUAD	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg02176678	chr2:219576539	TTLL4	0.58	11.11	0.48	2.39e-25	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4148087	0.929	rs4148084	chr21:43620250	A/C	cg08841829	chr21:43638893	ABCG1	-0.55	-7.52	-0.34	3.25e-13	Eating disorder in bipolar disorder;
LUAD	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg10295955	chr4:187884368	NA	1.14	30.21	0.83	1.1e-107	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.78e-19	Life satisfaction;
LUAD	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg08742575	chr21:47604166	C21orf56	0.43	7.15	0.33	3.84e-12	Testicular germ cell tumor;
LUAD	cis	rs6545883	0.899	rs12473030	chr2:61720497	T/A	cg15711740	chr2:61764176	XPO1	-0.4	-6.44	-0.3	3.33e-10	Tuberculosis;
LUAD	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	6.81	0.31	3.43e-11	Personality dimensions;
LUAD	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg22906224	chr7:99728672	NA	-0.56	-9.68	-0.43	3.82e-20	Coronary artery disease;
LUAD	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg24558204	chr6:135376177	HBS1L	0.5	8.63	0.39	1.23e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg04225089	chr17:73874465	TRIM47	-0.43	-7.33	-0.34	1.15e-12	Psoriasis;
LUAD	cis	rs300774	0.925	rs300709	chr2:139743	C/T	cg21211680	chr2:198530	NA	0.45	7.13	0.33	4.29e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs3750965	1.000	rs3750965	chr11:68840160	A/G	cg06818126	chr11:68850279	TPCN2	-0.49	-7.25	-0.33	2.06e-12	Hair color;
LUAD	cis	rs367943	0.608	rs7705084	chr5:112990748	G/A	cg12552261	chr5:112820674	MCC	0.41	7.49	0.34	4.19e-13	Type 2 diabetes;
LUAD	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg14584255	chr6:163149320	PACRG;PARK2	-0.39	-7.46	-0.34	5e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg12011299	chr4:100065546	ADH4	0.69	12.46	0.52	1.49e-30	Smoking initiation;
LUAD	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg20891558	chr2:74357851	NA	0.88	15.35	0.6	1.44e-42	Gestational age at birth (maternal effect);
LUAD	cis	rs6486730	0.508	rs7133440	chr12:129269244	A/C	cg09035930	chr12:129282057	SLC15A4	-0.33	-6.42	-0.3	3.66e-10	Systemic lupus erythematosus;
LUAD	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg09184832	chr6:79620586	NA	-0.51	-9.72	-0.43	2.75e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2230307	0.656	rs2274569	chr1:100435079	T/C	cg20868668	chr1:100435035	SLC35A3	0.63	7.71	0.35	9.07e-14	Carotid intima media thickness;
LUAD	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.02	0.32	8.64e-12	Parkinson's disease;
LUAD	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	9.59	0.42	7.93e-20	Electrocardiographic conduction measures;
LUAD	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg18446336	chr7:2847575	GNA12	-0.33	-6.7	-0.31	6.5500000000000006e-11	Height;
LUAD	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg25457927	chr22:38595422	NA	0.6	16.25	0.62	1.69e-46	Cutaneous nevi;
LUAD	cis	rs9925964	0.869	rs2288004	chr16:31054040	G/C	cg03418659	chr16:31128414	MYST1	0.4	7.05	0.32	7.16e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg01851573	chr8:8652454	MFHAS1	0.43	7.81	0.35	4.7e-14	Mood instability;
LUAD	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg12310025	chr6:25882481	NA	-0.56	-9.13	-0.41	2.75e-18	Blood metabolite levels;
LUAD	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs7107174	1.000	rs2510049	chr11:77985459	G/T	cg02023728	chr11:77925099	USP35	0.52	7.84	0.36	3.69e-14	Testicular germ cell tumor;
LUAD	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg02753203	chr1:228287806	NA	-0.46	-8.57	-0.38	2e-16	Diastolic blood pressure;
LUAD	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg08761264	chr16:28874980	SH2B1	-0.45	-6.85	-0.32	2.59e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7843479	0.601	rs4872209	chr8:21848832	A/T	cg03445287	chr8:21823731	XPO7	-0.48	-9.13	-0.41	2.88e-18	Mean corpuscular volume;
LUAD	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.41	-0.34	6.98e-13	Coronary artery disease;
LUAD	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	6.43	0.3	3.41e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg15181151	chr6:150070149	PCMT1	0.36	7.14	0.33	4.13e-12	Lung cancer;
LUAD	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.89e-14	Depression;
LUAD	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg07936489	chr17:37558343	FBXL20	-0.51	-6.97	-0.32	1.23e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg07917127	chr4:99064746	C4orf37	0.44	7.34	0.34	1.07e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.559	rs17350182	chr7:106909637	T/A	cg23024343	chr7:107201750	COG5	0.49	7.09	0.33	5.67e-12	Coronary artery disease;
LUAD	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.61	12.76	0.53	9.29e-32	Monocyte percentage of white cells;
LUAD	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg06641503	chr3:48959341	ARIH2	-0.37	-7.35	-0.34	1.06e-12	Parkinson's disease;
LUAD	cis	rs9768139	0.696	rs4909177	chr7:158117047	A/T	cg25566285	chr7:158114605	PTPRN2	0.53	11.11	0.48	2.47e-25	Calcium levels;
LUAD	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg09796270	chr17:17721594	SREBF1	0.37	6.74	0.31	5.2e-11	Total body bone mineral density;
LUAD	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg00074818	chr8:8560427	CLDN23	0.68	10.5	0.45	4.32e-23	Obesity-related traits;
LUAD	cis	rs11083475	0.686	rs73040728	chr19:39257601	C/G	cg07905965	chr19:39260460	NA	0.47	8.7	0.39	7.34e-17	Heart rate;
LUAD	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg18180107	chr4:99064573	C4orf37	0.43	6.9	0.32	1.88e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10727759	chr12:50017361	PRPF40B	-0.57	-6.84	-0.32	2.81e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg22442454	chr1:209979470	IRF6	0.56	7.49	0.34	4.15e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.16	-31.84	-0.84	2.25e-114	Myeloid white cell count;
LUAD	cis	rs739496	0.894	rs10849947	chr12:111864684	T/C	cg10833066	chr12:111807467	FAM109A	0.45	8.23	0.37	2.37e-15	Platelet count;
LUAD	trans	rs7395662	1.000	rs4882017	chr11:48570182	C/T	cg00717180	chr2:96193071	NA	0.39	7.28	0.33	1.63e-12	HDL cholesterol;
LUAD	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg03609598	chr5:56110824	MAP3K1	0.44	6.54	0.3	1.74e-10	Initial pursuit acceleration;
LUAD	cis	rs9826463	0.702	rs55994893	chr3:142304694	G/C	cg20824294	chr3:142316082	PLS1	0.48	8.34	0.38	1.02e-15	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.8	-0.35	5.01e-14	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.82e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg25566285	chr7:158114605	PTPRN2	0.51	10.7	0.46	8.6e-24	Calcium levels;
LUAD	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg25427524	chr10:38739819	LOC399744	0.56	9.75	0.43	2.12e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs877282	0.947	rs12358875	chr10:757531	T/C	cg06581033	chr10:766294	NA	-0.56	-7.21	-0.33	2.57e-12	Uric acid levels;
LUAD	cis	rs7809950	0.817	rs11535285	chr7:107143866	A/G	cg23024343	chr7:107201750	COG5	-0.88	-14.68	-0.58	1e-39	Coronary artery disease;
LUAD	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.77	0.31	4.42e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg08885076	chr2:99613938	TSGA10	-0.39	-6.96	-0.32	1.28e-11	Chronic sinus infection;
LUAD	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg15028436	chr7:37888078	TXNDC3	0.38	7.69	0.35	1.03e-13	Alzheimer's disease (late onset);
LUAD	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg04944784	chr2:26401820	FAM59B	0.68	9.95	0.44	4.16e-21	Gut microbiome composition (summer);
LUAD	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg26818010	chr10:134567672	INPP5A	-0.76	-13.26	-0.54	8.24e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7870753	0.628	rs10820598	chr9:99189255	A/G	cg13563390	chr9:99253610	HABP4	-0.38	-6.36	-0.3	5.38e-10	Height;
LUAD	cis	rs9814567	0.727	rs9809344	chr3:134342758	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.42	-0.52	2.1000000000000002e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs601339	1.000	rs7969523	chr12:123168636	T/G	cg11919336	chr12:123188078	GPR109A	0.48	7.18	0.33	3.25e-12	Adiponectin levels;
LUAD	cis	rs4947962	0.617	rs1558543	chr7:55135512	C/T	cg23757825	chr7:55092271	EGFR	-0.49	-6.4	-0.3	4.19e-10	Subjective response to lithium treatment;
LUAD	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg00383909	chr3:49044727	WDR6	0.58	7.56	0.34	2.55e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg18187862	chr3:45730750	SACM1L	0.51	7.76	0.35	6.52e-14	Primary sclerosing cholangitis;
LUAD	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.53	0.52	7.6e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs758324	0.947	rs4705835	chr5:131116899	T/C	cg06307176	chr5:131281290	NA	0.51	8.07	0.37	7.09e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.41	-0.34	7e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg06606381	chr12:133084897	FBRSL1	-0.85	-8.34	-0.38	1.03e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg03467027	chr4:99064603	C4orf37	0.4	6.46	0.3	2.84e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg18306943	chr3:40428807	ENTPD3	0.4	7.05	0.32	7.55e-12	Renal cell carcinoma;
LUAD	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.79	-0.35	5.27e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	8.59	0.39	1.69e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.53	-0.34	3.08e-13	Blood metabolite levels;
LUAD	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg27284194	chr4:1044797	NA	0.7	10.18	0.44	6.52e-22	Recombination rate (females);
LUAD	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg20933634	chr6:27740509	NA	0.48	7.68	0.35	1.09e-13	Parkinson's disease;
LUAD	cis	rs739496	0.542	rs7399113	chr12:111792848	G/A	cg10833066	chr12:111807467	FAM109A	0.7	14.03	0.56	5.39e-37	Platelet count;
LUAD	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-14.51	-0.58	5.23e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1997103	1.000	rs9642580	chr7:55400359	G/A	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.19e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg27454412	chr7:1067447	C7orf50	0.32	6.37	0.3	4.84e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg24642844	chr7:1081250	C7orf50	-0.61	-9.9	-0.43	6.56e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.81	-0.36	4.47e-14	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
LUAD	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg07061783	chr6:25882402	NA	-0.6	-9.49	-0.42	1.72e-19	Urate levels;
LUAD	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg13699009	chr12:122356056	WDR66	0.29	6.36	0.3	5.33e-10	Mean corpuscular volume;
LUAD	cis	rs3772130	0.962	rs11715951	chr3:121522968	T/C	cg20356878	chr3:121714668	ILDR1	0.53	8.5	0.38	3.31e-16	Cognitive performance;
LUAD	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.44	-0.38	4.99e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg25985355	chr7:65971099	NA	-0.37	-6.87	-0.32	2.33e-11	Aortic root size;
LUAD	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg10755058	chr3:40428713	ENTPD3	0.35	6.41	0.3	3.83e-10	Renal cell carcinoma;
LUAD	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg05697835	chr1:2722811	NA	0.32	6.65	0.31	9.1e-11	Ulcerative colitis;
LUAD	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg21016266	chr12:122356598	WDR66	-0.46	-7.51	-0.34	3.49e-13	Mean corpuscular volume;
LUAD	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24531977	chr5:56204891	C5orf35	-0.97	-15.03	-0.59	3.34e-41	Initial pursuit acceleration;
LUAD	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg03733263	chr8:22462867	KIAA1967	-0.69	-11.15	-0.48	1.75e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg06074448	chr4:187884817	NA	-0.36	-7.22	-0.33	2.49e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9473147	0.516	rs6903331	chr6:47562915	A/G	cg20196966	chr6:47445060	CD2AP	0.44	6.97	0.32	1.22e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs17401966	1.000	rs60743860	chr1:10442926	G/C	cg15208524	chr1:10270712	KIF1B	0.52	7.66	0.35	1.31e-13	Hepatocellular carcinoma;
LUAD	cis	rs6591182	0.503	rs11227241	chr11:65389890	G/C	cg05805236	chr11:65401703	PCNXL3	-0.48	-8.12	-0.37	5.13e-15	Non-alcoholic fatty liver disease histology (lobular);
LUAD	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg01868782	chr6:126071099	HEY2	0.32	6.74	0.31	5.27e-11	Brugada syndrome;
LUAD	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.75	16.0	0.61	2.03e-45	White blood cell count;
LUAD	cis	rs6693567	0.565	rs832621	chr1:150392909	G/C	cg15654264	chr1:150340011	RPRD2	0.37	6.56	0.3	1.57e-10	Migraine;
LUAD	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg23985595	chr17:80112537	CCDC57	-0.51	-9.27	-0.41	9.48e-19	Life satisfaction;
LUAD	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg18944383	chr4:111397179	ENPEP	0.39	7.84	0.36	3.75e-14	Height;
LUAD	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg20503657	chr10:835505	NA	0.65	9.08	0.4	4.27e-18	Eosinophil percentage of granulocytes;
LUAD	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg17971929	chr21:40555470	PSMG1	0.57	9.0	0.4	7.52e-18	Cognitive function;
LUAD	cis	rs13315871	1.000	rs9869276	chr3:58401076	G/A	cg12435725	chr3:58293450	RPP14	-0.69	-7.38	-0.34	8.65e-13	Cholesterol, total;
LUAD	cis	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg05901451	chr6:126070800	HEY2	0.43	6.43	0.3	3.37e-10	Endometrial cancer;
LUAD	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg18306943	chr3:40428807	ENTPD3	0.4	7.11	0.33	4.86e-12	Renal cell carcinoma;
LUAD	cis	rs4642101	0.824	rs9825233	chr3:12843368	A/G	cg24848339	chr3:12840334	CAND2	-0.38	-7.74	-0.35	7.48e-14	QRS complex (12-leadsum);
LUAD	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg27529037	chr20:44575021	PCIF1	0.46	8.19	0.37	3.2e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg13393036	chr8:95962371	TP53INP1	-0.3	-6.53	-0.3	1.83e-10	Type 2 diabetes;
LUAD	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg22618164	chr12:122356400	WDR66	0.65	11.13	0.48	2.08e-25	Mean corpuscular volume;
LUAD	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg18404041	chr3:52824283	ITIH1	-0.57	-11.53	-0.49	6.35e-27	Bipolar disorder;
LUAD	cis	rs2179367	0.881	rs2744432	chr6:149743871	A/C	cg16235748	chr6:149772707	ZC3H12D	0.33	6.98	0.32	1.18e-11	Dupuytren's disease;
LUAD	cis	rs912057	0.833	rs1294426	chr6:6744477	T/C	cg06612196	chr6:6737390	NA	0.55	12.63	0.52	3e-31	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg03433033	chr1:76189801	ACADM	-0.68	-10.87	-0.47	1.92e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs11032090	1	rs11032090	chr11:4417129	A/G	cg09983885	chr11:4415245	TRIM21	0.43	7.8	0.35	4.79e-14	Lung cancer;
LUAD	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg07757535	chr4:1339547	NA	0.32	7.17	0.33	3.43e-12	Longevity;
LUAD	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg14092988	chr3:52407081	DNAH1	0.45	8.97	0.4	9.48e-18	Bipolar disorder;
LUAD	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg16325326	chr1:53192061	ZYG11B	0.59	10.65	0.46	1.31e-23	Monocyte count;
LUAD	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg17074396	chr22:49843754	NA	-0.3	-6.65	-0.31	9e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg00074818	chr8:8560427	CLDN23	0.68	10.52	0.46	3.85e-23	Obesity-related traits;
LUAD	cis	rs943466	0.955	rs11757524	chr6:33766212	A/G	cg16010596	chr6:33739607	LEMD2	-0.41	-7.76	-0.35	6.49e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg18105134	chr13:113819100	PROZ	-0.81	-14.41	-0.57	1.46e-38	Platelet distribution width;
LUAD	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg05754148	chr16:3507555	NAT15	0.81	10.7	0.46	8.55e-24	Tuberculosis;
LUAD	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.55	-0.3	1.72e-10	Aortic root size;
LUAD	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-7.4	-0.34	7.28e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg14784868	chr12:69753453	YEATS4	0.47	7.91	0.36	2.23e-14	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	7.38	0.34	8.7e-13	Alzheimer's disease;
LUAD	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg01448562	chr3:133502909	NA	-0.52	-9.08	-0.4	4.02e-18	Iron status biomarkers;
LUAD	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.09	-0.37	6.17e-15	Personality dimensions;
LUAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.66	-12.33	-0.51	4.68e-30	Lymphocyte counts;
LUAD	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg22963979	chr7:1858916	MAD1L1	-0.46	-7.88	-0.36	2.78e-14	Schizophrenia;
LUAD	cis	rs9581857	0.685	rs60787915	chr13:28022298	C/T	cg22138327	chr13:27999177	GTF3A	0.78	9.68	0.43	3.81e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13126513	0.510	rs10516445	chr4:100524679	C/G	cg05468953	chr4:100565104	NA	0.37	7.52	0.34	3.29e-13	Metabolite levels (MHPG);
LUAD	cis	rs13095912	0.597	rs112800013	chr3:185313807	A/G	cg11274856	chr3:185301563	NA	0.49	9.3	0.41	7.49e-19	Systolic blood pressure;
LUAD	cis	rs669446	0.561	rs559575	chr1:44089940	A/G	cg12908607	chr1:44402522	ARTN	-0.35	-6.38	-0.3	4.79e-10	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.57	-0.3	1.45e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6840360	0.550	rs7675818	chr4:152690777	C/G	cg22705602	chr4:152727874	NA	-0.48	-9.13	-0.41	2.75e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs701145	0.643	rs453699	chr3:153924784	A/G	cg17054900	chr3:154042577	DHX36	0.66	7.08	0.33	6.13e-12	Coronary artery disease;
LUAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg10687131	chr2:20871002	GDF7	-0.5	-9.18	-0.41	1.97e-18	Abdominal aortic aneurysm;
LUAD	trans	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	11.18	0.48	1.31e-25	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.54	-9.65	-0.42	4.62e-20	Lymphocyte counts;
LUAD	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg04282206	chr17:62833786	PLEKHM1P	0.58	8.83	0.39	2.82e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg15017067	chr4:17643749	FAM184B	0.34	6.44	0.3	3.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg27211696	chr2:191398769	TMEM194B	-0.59	-7.9	-0.36	2.5e-14	Diastolic blood pressure;
LUAD	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg07423050	chr13:99094983	FARP1	-0.56	-9.29	-0.41	8.43e-19	Longevity;
LUAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg02869364	chr7:1081709	C7orf50	-0.51	-6.57	-0.3	1.48e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg07305463	chr2:136567211	LCT	0.38	7.09	0.33	5.49e-12	Mosquito bite size;
LUAD	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg17200465	chr3:40428508	ENTPD3	0.27	6.49	0.3	2.44e-10	Renal cell carcinoma;
LUAD	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.13	-0.33	4.34e-12	Glomerular filtration rate;
LUAD	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg24558204	chr6:135376177	HBS1L	0.5	8.7	0.39	7.68e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg06640241	chr16:89574553	SPG7	0.72	12.82	0.53	5.34e-32	Multiple myeloma (IgH translocation);
LUAD	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg00339695	chr16:24857497	SLC5A11	0.52	9.51	0.42	1.42e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs2882667	0.931	rs10070021	chr5:138324706	A/G	cg04439458	chr5:138467593	SIL1	-0.38	-7.02	-0.32	8.99e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg19187155	chr2:232395269	NMUR1	0.56	10.17	0.44	7.12e-22	Height;
LUAD	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg14552801	chr7:65878734	NA	-0.39	-6.64	-0.31	9.75e-11	Aortic root size;
LUAD	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.85	0.36	3.48e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg17366294	chr4:99064904	C4orf37	0.53	9.82	0.43	1.25e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg24642844	chr7:1081250	C7orf50	-0.96	-14.22	-0.57	8.46e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.9	11.03	0.47	4.94e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg05182265	chr7:156933206	UBE3C	-0.79	-16.91	-0.64	2.32e-49	Body mass index;
LUAD	cis	rs2302190	0.882	rs11650105	chr17:56588072	C/T	cg25885038	chr17:56607967	SEPT4	-0.51	-8.2	-0.37	2.86e-15	Vitamin D levels;
LUAD	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg05434287	chr7:2030229	MAD1L1	0.42	6.78	0.31	4.09e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg21970626	chr13:21893289	NA	-0.49	-8.76	-0.39	4.8e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg08885076	chr2:99613938	TSGA10	0.38	6.84	0.32	2.82e-11	Chronic sinus infection;
LUAD	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg10589385	chr1:150898437	SETDB1	-0.41	-7.89	-0.36	2.68e-14	Melanoma;
LUAD	cis	rs12200782	1.000	rs12205909	chr6:26630999	G/A	cg11502198	chr6:26597334	ABT1	-0.77	-6.69	-0.31	7.16e-11	Small cell lung carcinoma;
LUAD	trans	rs11088226	0.758	rs2833864	chr21:33888393	A/C	cg09050820	chr6:167586206	TCP10L2	0.53	7.33	0.34	1.19e-12	Gastritis;
LUAD	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.07e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg02782426	chr3:40428986	ENTPD3	0.43	9.04	0.4	5.74e-18	Renal cell carcinoma;
LUAD	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.36	-6.57	-0.3	1.51e-10	Caffeine consumption;
LUAD	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.99	-18.4	-0.67	5.44e-56	Homoarginine levels;
LUAD	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22307029	chr19:49891270	CCDC155	0.77	11.6	0.49	3.2e-27	Multiple sclerosis;
LUAD	cis	rs6426558	0.537	rs6685823	chr1:227270835	A/G	cg10327440	chr1:227177885	CDC42BPA	0.57	9.36	0.41	4.88e-19	Neutrophil percentage of white cells;
LUAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg09060608	chr5:178986726	RUFY1	-0.78	-13.97	-0.56	9.48e-37	Lung cancer;
LUAD	trans	rs931812	0.895	rs965625	chr8:101909749	T/C	cg20993868	chr7:22813445	NA	0.63	13.34	0.54	4.03e-34	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg01884057	chr2:25150051	NA	0.32	6.65	0.31	8.96e-11	Body mass index;
LUAD	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg01689657	chr7:91764605	CYP51A1	0.38	9.36	0.41	4.69e-19	Breast cancer;
LUAD	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg18306943	chr3:40428807	ENTPD3	-0.44	-7.38	-0.34	8.59e-13	Renal cell carcinoma;
LUAD	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg13770153	chr20:60521292	NA	-0.56	-8.99	-0.4	8.14e-18	Body mass index;
LUAD	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	7.99	0.36	1.33e-14	Rheumatoid arthritis;
LUAD	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.43	-0.34	5.94e-13	Type 2 diabetes;
LUAD	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg01874867	chr7:94954059	PON1	0.48	6.49	0.3	2.46e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg15704280	chr7:45808275	SEPT13	-1.03	-20.62	-0.71	7.01e-66	Height;
LUAD	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg11317459	chr13:21872234	NA	-1.15	-15.24	-0.6	4.06e-42	White matter hyperintensity burden;
LUAD	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg08470875	chr2:26401718	FAM59B	-0.67	-8.64	-0.39	1.13e-16	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg23625390	chr15:77176239	SCAPER	0.39	6.94	0.32	1.47e-11	Blood metabolite levels;
LUAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg02869364	chr7:1081709	C7orf50	-0.5	-6.4	-0.3	4.23e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg14092988	chr3:52407081	DNAH1	0.37	7.42	0.34	6.35e-13	Electroencephalogram traits;
LUAD	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg26924012	chr15:45694286	SPATA5L1	0.64	11.01	0.47	5.78e-25	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg16606324	chr3:10149918	C3orf24	0.57	7.3	0.33	1.46e-12	Alzheimer's disease;
LUAD	cis	rs12144309	0.554	rs1217375	chr1:114346904	G/A	cg03325407	chr1:114423726	BCL2L15	0.4	6.99	0.32	1.06e-11	Coronary artery disease;
LUAD	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg02931644	chr1:25747376	RHCE	0.41	8.6	0.39	1.58e-16	Erythrocyte sedimentation rate;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26856322	chr1:169076014	ATP1B1	-0.65	-6.53	-0.3	1.92e-10	Type 2 diabetes;
LUAD	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg06191203	chr2:152266755	RIF1	-0.55	-8.28	-0.37	1.64e-15	Squamous cell lung carcinoma;
LUAD	cis	rs7536201	0.967	rs6600247	chr1:25305114	T/C	cg23273869	chr1:25296894	NA	-0.36	-7.35	-0.34	1.06e-12	Psoriasis vulgaris;
LUAD	cis	rs10484885	0.887	rs17764308	chr6:90602268	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.69	-8.58	-0.38	1.87e-16	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs4077515	0.935	rs3088081	chr9:139270149	A/G	cg14019695	chr9:139328340	INPP5E	0.39	7.44	0.34	5.54e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1475718	0.526	rs7848481	chr9:137120661	T/C	cg21243944	chr9:137118148	NA	-0.32	-6.72	-0.31	5.98e-11	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7107174	0.892	rs11601866	chr11:78011153	G/A	cg02023728	chr11:77925099	USP35	0.49	7.35	0.34	1.02e-12	Testicular germ cell tumor;
LUAD	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06221963	chr1:154839813	KCNN3	-0.88	-21.13	-0.72	3.68e-68	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02353165	chr6:42928485	GNMT	0.45	8.19	0.37	3.03e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg13537196	chr9:15553060	C9orf93	-0.39	-6.45	-0.3	3.09e-10	Subcortical brain region volumes;
LUAD	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg15147215	chr3:52552868	STAB1	-0.37	-6.9	-0.32	1.91e-11	Bipolar disorder;
LUAD	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg15181151	chr6:150070149	PCMT1	0.42	8.79	0.39	3.93e-17	Lung cancer;
LUAD	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg13385794	chr1:248469461	NA	0.26	7.14	0.33	4.14e-12	Common traits (Other);
LUAD	cis	rs1524976	0.891	rs1404551	chr3:65491913	T/G	cg16238336	chr3:65465873	MAGI1	0.62	7.5	0.34	3.67e-13	PR interval;
LUAD	cis	rs735539	0.645	rs7995773	chr13:21251235	T/C	cg27499820	chr13:21296301	IL17D	0.54	9.1	0.4	3.66e-18	Dental caries;
LUAD	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11890956	chr21:40555474	PSMG1	0.79	14.0	0.56	7.52e-37	Cognitive function;
LUAD	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24531977	chr5:56204891	C5orf35	0.77	12.56	0.52	5.45e-31	Initial pursuit acceleration;
LUAD	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg09365446	chr1:150670422	GOLPH3L	0.61	10.91	0.47	1.39e-24	Melanoma;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg24158363	chr17:73401717	GRB2	-0.42	-6.76	-0.31	4.66e-11	Vertical cup-disc ratio;
LUAD	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg20607798	chr8:58055168	NA	0.58	7.95	0.36	1.75e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg14345882	chr6:26364793	BTN3A2	0.7	7.14	0.33	4.13e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2236521	0.617	rs2236520	chr20:60892172	T/C	cg12382846	chr20:60892121	LAMA5	0.45	6.38	0.3	4.69e-10	Pelvic organ prolapse;
LUAD	cis	rs4774899	0.752	rs2703580	chr15:57353034	C/T	cg14026238	chr15:57616123	NA	0.41	7.88	0.36	2.72e-14	Urinary tract infection frequency;
LUAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg22907277	chr7:1156413	C7orf50	0.77	11.15	0.48	1.79e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	7.25	0.33	1.94e-12	Schizophrenia;
LUAD	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg15147215	chr3:52552868	STAB1	-0.41	-7.49	-0.34	4.08e-13	Bipolar disorder;
LUAD	cis	rs6752107	0.846	rs7559194	chr2:234206799	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	9.36	0.41	4.87e-19	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg18230493	chr5:56204884	C5orf35	-0.44	-7.4	-0.34	7.5e-13	Coronary artery disease;
LUAD	cis	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg23950597	chr19:37808831	NA	-0.64	-7.57	-0.35	2.43e-13	Coronary artery calcification;
LUAD	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg22681709	chr2:178499509	PDE11A	-0.45	-7.65	-0.35	1.36e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg17264618	chr3:40429014	ENTPD3	0.4	8.92	0.4	1.39e-17	Renal cell carcinoma;
LUAD	cis	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.99	-0.36	1.34e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg21153622	chr11:89784906	NA	-0.34	-6.39	-0.3	4.49e-10	Height;
LUAD	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.4e-12	Lung cancer;
LUAD	cis	rs6684514	0.922	rs2075166	chr1:156215562	G/A	cg16558208	chr1:156270281	VHLL	0.51	9.07	0.4	4.45e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs2692947	0.637	rs72492201	chr2:96630201	G/A	cg23100626	chr2:96804247	ASTL	0.31	7.75	0.35	6.69e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.43	-0.34	5.94e-13	Type 2 diabetes;
LUAD	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg12310025	chr6:25882481	NA	0.57	9.66	0.42	4.55e-20	Blood metabolite levels;
LUAD	cis	rs10499694	0.901	rs6975453	chr7:50585211	A/T	cg18232548	chr7:50535776	DDC	-0.44	-7.39	-0.34	7.81e-13	Body mass index;
LUAD	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg20290983	chr6:43655470	MRPS18A	-0.92	-17.76	-0.65	3.95e-53	IgG glycosylation;
LUAD	cis	rs2286503	0.839	rs2270108	chr7:22862131	A/C	cg06496272	chr7:22895283	SNORD93	-0.41	-7.27	-0.33	1.74e-12	Fibrinogen;
LUAD	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.56	0.3	1.55e-10	Depression;
LUAD	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg06221963	chr1:154839813	KCNN3	-0.71	-14.69	-0.58	9.15e-40	Prostate cancer;
LUAD	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03264133	chr6:25882463	NA	-0.47	-6.72	-0.31	5.71e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs13082711	0.555	rs73038733	chr3:27263537	C/G	cg02860705	chr3:27208620	NA	0.61	9.28	0.41	9.01e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	trans	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.66	-0.35	1.26e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg02743256	chr7:2109353	MAD1L1	-0.45	-6.7	-0.31	6.49e-11	Neuroticism;
LUAD	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg00339695	chr16:24857497	SLC5A11	-0.71	-11.62	-0.49	2.92e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs4523957	0.651	rs898748	chr17:2085475	G/T	cg16513277	chr17:2031491	SMG6	-0.95	-18.95	-0.68	2.08e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg17063962	chr7:91808500	NA	-0.6	-9.94	-0.44	4.76e-21	Breast cancer;
LUAD	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg11189052	chr15:85197271	WDR73	0.71	9.51	0.42	1.48e-19	Schizophrenia;
LUAD	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg06671706	chr8:8559999	CLDN23	0.66	11.42	0.49	1.63e-26	Obesity-related traits;
LUAD	cis	rs790123	0.666	rs28666491	chr3:122389184	G/A	cg15604389	chr3:122379662	NA	0.44	7.26	0.33	1.9e-12	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11559952	chr10:112064744	SMNDC1	-0.59	-7.34	-0.34	1.13e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg15704280	chr7:45808275	SEPT13	-0.58	-9.52	-0.42	1.3e-19	Coronary artery disease;
LUAD	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg10876282	chr6:28092338	ZSCAN16	0.46	7.29	0.33	1.52e-12	Parkinson's disease;
LUAD	cis	rs4764487	0.685	rs2268010	chr12:6339856	T/C	cg08284733	chr12:6341482	CD9	0.37	6.58	0.3	1.41e-10	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7580658	0.545	rs13001184	chr2:127952206	A/G	cg16751203	chr2:127950803	CYP27C1	0.4	6.73	0.31	5.63e-11	Protein C levels;
LUAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg22764044	chr5:178986830	RUFY1	0.59	8.81	0.39	3.29e-17	Lung cancer;
LUAD	trans	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04565464	chr8:145669602	NFKBIL2	0.43	6.52	0.3	2.01e-10	Schizophrenia;
LUAD	cis	rs1451375	0.669	rs4469404	chr7:50647062	C/T	cg18232548	chr7:50535776	DDC	-0.52	-8.42	-0.38	5.7e-16	Malaria;
LUAD	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg12863693	chr15:85201151	NMB	0.42	7.59	0.35	2.09e-13	Schizophrenia;
LUAD	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg05926928	chr17:57297772	GDPD1	1.39	17.2	0.64	1.21e-50	Opioid sensitivity;
LUAD	cis	rs4604732	0.642	rs4266925	chr1:247639165	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.36	6.39	0.3	4.46e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs494562	0.892	rs575477	chr6:86118064	A/G	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs12681287	0.752	rs7822268	chr8:87306440	G/T	cg00550725	chr8:87521180	FAM82B	0.46	6.67	0.31	8.01e-11	Caudate activity during reward;
LUAD	cis	rs7149337	0.804	rs4131981	chr14:51667504	A/T	cg23942311	chr14:51606299	NA	-0.83	-18.43	-0.67	4.36e-56	Cancer;
LUAD	cis	rs7192380	0.639	rs12448486	chr16:69802878	G/A	cg26679644	chr16:69762563	NA	-0.47	-8.72	-0.39	6.65e-17	Sjögren's syndrome;
LUAD	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg27170947	chr2:26402098	FAM59B	0.57	8.08	0.37	7.02e-15	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg27068330	chr11:65405492	SIPA1	-0.78	-12.83	-0.53	4.72e-32	Acne (severe);
LUAD	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.91	0.76	1.53e-80	Chronic sinus infection;
LUAD	trans	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg18335740	chr13:41363409	SLC25A15	-0.59	-10.55	-0.46	3.06e-23	Lewy body disease;
LUAD	trans	rs7944735	0.832	rs7130876	chr11:48050995	A/G	cg03929089	chr4:120376271	NA	0.63	7.82	0.36	4.23e-14	Intraocular pressure;
LUAD	cis	rs17152411	0.895	rs7094116	chr10:126587644	T/G	cg07906193	chr10:126599966	NA	0.53	7.47	0.34	4.69e-13	Height;
LUAD	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg14037413	chr11:9482594	ZNF143	0.37	6.61	0.31	1.19e-10	Schizophrenia;
LUAD	cis	rs432925	0.600	rs385862	chr16:344659	A/G	cg06233593	chr16:337645	AXIN1	0.31	6.8	0.31	3.55e-11	Morning vs. evening chronotype;
LUAD	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg26168224	chr5:2018326	NA	-0.65	-12.07	-0.51	5.2e-29	Gut microbiome composition (winter);
LUAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg04025307	chr7:1156635	C7orf50	0.63	7.72	0.35	8.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs859767	0.501	rs6724777	chr2:135407292	C/T	cg12500956	chr2:135428796	TMEM163	-0.29	-7.6	-0.35	1.87e-13	Neuroticism;
LUAD	cis	rs3087591	0.960	rs7212264	chr17:29454766	C/T	cg24425628	chr17:29625626	OMG;NF1	0.45	7.17	0.33	3.37e-12	Hip circumference;
LUAD	cis	rs7659604	0.540	rs9998385	chr4:122676673	C/T	cg06713675	chr4:122721982	EXOSC9	0.42	7.68	0.35	1.11e-13	Type 2 diabetes;
LUAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.74	-0.35	7.29e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.4e-12	Lung cancer;
LUAD	cis	rs4664304	0.903	rs72957578	chr2:160754133	G/C	cg06573604	chr2:160760825	LY75	-0.39	-6.52	-0.3	2.06e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.67	9.9	0.43	6.61e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-14.51	-0.58	5.36e-39	Schizophrenia;
LUAD	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg19418458	chr7:158789849	NA	-0.66	-11.63	-0.49	2.65e-27	Facial morphology (factor 20);
LUAD	cis	rs4795519	0.736	rs3964488	chr17:22180324	A/G	cg22648282	chr17:21454238	C17orf51	-0.4	-6.63	-0.31	1.01e-10	Chronic myeloid leukemia;
LUAD	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03264133	chr6:25882463	NA	-0.57	-9.39	-0.42	3.71e-19	Blood metabolite levels;
LUAD	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21582582	chr3:182698605	DCUN1D1	-0.47	-7.8	-0.35	5.02e-14	Body mass index;
LUAD	trans	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-10.7	-0.46	8.12e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg25554036	chr4:6271136	WFS1	0.65	12.73	0.53	1.18e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg10518543	chr12:38710700	ALG10B	-0.42	-6.8	-0.31	3.57e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg20203395	chr5:56204925	C5orf35	-0.82	-11.72	-0.5	1.16e-27	Initial pursuit acceleration;
LUAD	cis	rs921968	0.565	rs6436083	chr2:219639719	C/T	cg02176678	chr2:219576539	TTLL4	-0.58	-11.8	-0.5	5.42e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg02423579	chr7:2872169	GNA12	-0.41	-6.83	-0.32	3.03e-11	Height;
LUAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.77	-0.31	4.38e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg12573674	chr2:1569213	NA	-0.59	-6.95	-0.32	1.36e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs490234	0.841	rs10123054	chr9:128452054	C/T	cg14078157	chr9:128172775	NA	-0.42	-7.73	-0.35	7.9e-14	Mean arterial pressure;
LUAD	cis	rs7737355	0.947	rs3776007	chr5:130875085	C/G	cg06307176	chr5:131281290	NA	-0.49	-7.86	-0.36	3.22e-14	Life satisfaction;
LUAD	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg23262073	chr20:60523788	NA	-0.44	-7.61	-0.35	1.78e-13	Body mass index;
LUAD	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg06221963	chr1:154839813	KCNN3	-0.8	-17.36	-0.64	2.35e-51	Prostate cancer;
LUAD	trans	rs7395662	0.963	rs7125110	chr11:48545507	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.1e-12	HDL cholesterol;
LUAD	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg13319975	chr6:146136371	FBXO30	-0.6	-10.07	-0.44	1.6e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg02782426	chr3:40428986	ENTPD3	0.45	9.39	0.42	3.89e-19	Renal cell carcinoma;
LUAD	cis	rs7659604	0.540	rs4361412	chr4:122669403	C/T	cg06713675	chr4:122721982	EXOSC9	0.41	7.5	0.34	3.81e-13	Type 2 diabetes;
LUAD	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.51	-0.34	3.55e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg10876282	chr6:28092338	ZSCAN16	0.46	7.11	0.33	5.07e-12	Cardiac Troponin-T levels;
LUAD	cis	rs863345	0.604	rs59427353	chr1:158500621	A/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.77	14.75	0.58	4.99e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs9427116	0.702	rs884618	chr1:154601157	A/G	cg17218026	chr1:154582156	ADAR	0.51	9.86	0.43	8.55e-21	Blood protein levels;
LUAD	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg20476274	chr7:133979776	SLC35B4	0.69	11.89	0.5	2.6e-28	Mean platelet volume;
LUAD	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg02423579	chr7:2872169	GNA12	-0.83	-14.87	-0.59	1.56e-40	Height;
LUAD	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg26677194	chr12:130822605	PIWIL1	0.55	9.07	0.4	4.52e-18	Menopause (age at onset);
LUAD	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg27068330	chr11:65405492	SIPA1	-0.78	-12.63	-0.52	2.88e-31	Acne (severe);
LUAD	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg04025307	chr7:1156635	C7orf50	0.63	10.59	0.46	2.11e-23	Longevity;Endometriosis;
LUAD	trans	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg04565464	chr8:145669602	NFKBIL2	0.45	6.5	0.3	2.22e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7584330	0.554	rs11892169	chr2:238432809	G/A	cg14458575	chr2:238380390	NA	0.61	9.68	0.43	3.72e-20	Prostate cancer;
LUAD	cis	rs4812048	0.602	rs59637156	chr20:57619618	T/C	cg14073986	chr20:57617431	SLMO2	0.81	10.0	0.44	2.85e-21	Mean platelet volume;
LUAD	cis	rs12545109	0.800	rs2609979	chr8:57390066	G/A	cg07080864	chr8:57359956	PENK	-0.37	-6.38	-0.3	4.64e-10	Obesity-related traits;
LUAD	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg03233332	chr7:66118400	NA	-0.45	-6.66	-0.31	8.52e-11	Aortic root size;
LUAD	cis	rs2742417	0.603	rs2742398	chr3:45759036	A/G	cg10512202	chr3:45649293	LIMD1	0.48	9.09	0.4	3.99e-18	Response to anti-depressant treatment in major depressive disorder;
LUAD	trans	rs1493916	0.905	rs34910379	chr18:31400047	A/G	cg15819921	chr19:927150	ARID3A	-0.46	-7.68	-0.35	1.09e-13	Life satisfaction;
LUAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg02951883	chr7:2050386	MAD1L1	-0.94	-17.03	-0.64	6.9e-50	Bipolar disorder and schizophrenia;
LUAD	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg19077165	chr18:44547161	KATNAL2	-0.41	-7.13	-0.33	4.43e-12	Personality dimensions;
LUAD	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.32	-8.31	-0.37	1.3e-15	Total body bone mineral density;
LUAD	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg11871910	chr12:69753446	YEATS4	0.71	12.13	0.51	2.78e-29	Blood protein levels;
LUAD	cis	rs2625529	0.607	rs2912231	chr15:72567957	G/T	cg16672083	chr15:72433130	SENP8	-0.74	-13.05	-0.54	6.23e-33	Red blood cell count;
LUAD	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg14343924	chr8:8086146	FLJ10661	0.47	7.27	0.33	1.8e-12	Systolic blood pressure;
LUAD	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg06221963	chr1:154839813	KCNN3	-0.85	-20.64	-0.71	5.34e-66	Prostate cancer;
LUAD	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg02505535	chr3:195703920	SDHAP1	-0.35	-7.37	-0.34	9.05e-13	Pancreatic cancer;
LUAD	cis	rs7178375	0.607	rs71474639	chr15:31213257	A/G	cg15020726	chr15:31196382	MTMR15	0.65	7.21	0.33	2.55e-12	Hypertriglyceridemia;
LUAD	trans	rs12517041	1.000	rs16892388	chr5:23306240	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg21285383	chr16:89894308	SPIRE2	0.42	10.2	0.44	5.39e-22	Vitiligo;
LUAD	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19717773	chr7:2847554	GNA12	-0.56	-9.61	-0.42	6.63e-20	Height;
LUAD	trans	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg03886242	chr7:26192032	NFE2L3	0.44	7.74	0.35	7.22e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs7944735	0.507	rs7934659	chr11:48066374	C/T	cg03929089	chr4:120376271	NA	0.6	8.62	0.39	1.38e-16	Intraocular pressure;
LUAD	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06112835	chr11:68658793	MRPL21	0.53	9.96	0.44	3.86e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6714710	0.535	rs62158274	chr2:98621060	T/A	cg26665480	chr2:98280029	ACTR1B	0.5	8.05	0.36	8.21e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg10207240	chr12:122356781	WDR66	0.44	7.52	0.34	3.2e-13	Mean corpuscular volume;
LUAD	cis	rs1018836	0.847	rs4735225	chr8:91569100	G/C	cg16814680	chr8:91681699	NA	-0.7	-11.99	-0.5	1.04e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.81	-0.35	4.63e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg08807101	chr21:30365312	RNF160	-0.44	-7.48	-0.34	4.31e-13	Dental caries;
LUAD	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg07636037	chr3:49044803	WDR6	0.64	12.59	0.52	4.15e-31	Parkinson's disease;
LUAD	trans	rs258892	0.947	rs266443	chr5:72180377	C/T	cg14879065	chr14:104662468	NA	-0.35	-6.39	-0.3	4.45e-10	Small cell lung carcinoma;
LUAD	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg11887960	chr12:57824829	NA	0.59	7.34	0.34	1.1e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs727505	0.866	rs73227503	chr7:124721044	A/G	cg23710748	chr7:124431027	NA	-0.42	-8.51	-0.38	2.97e-16	Lewy body disease;
LUAD	cis	rs68170813	0.559	rs74387778	chr7:106963213	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-10.36	-0.45	1.49e-22	Coronary artery disease;
LUAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs208520	0.779	rs208446	chr6:66903515	T/C	cg07460842	chr6:66804631	NA	-1.0	-13.92	-0.56	1.58e-36	Exhaled nitric oxide output;
LUAD	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg20290983	chr6:43655470	MRPS18A	0.84	16.9	0.63	2.56e-49	IgG glycosylation;
LUAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg22535103	chr8:58192502	C8orf71	0.69	8.78	0.39	4.08e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	-0.36	-7.38	-0.34	8.63e-13	Menopause (age at onset);
LUAD	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg03467027	chr4:99064603	C4orf37	0.42	6.92	0.32	1.67e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02359409	chr6:42947317	PEX6	-0.39	-6.84	-0.32	2.76e-11	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-9.02	-0.4	6.43e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs7395662	0.889	rs11517696	chr11:48940073	C/A	cg00717180	chr2:96193071	NA	-0.4	-7.58	-0.35	2.23e-13	HDL cholesterol;
LUAD	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg13722127	chr7:150037890	RARRES2	0.46	7.84	0.36	3.66e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg22117172	chr7:91764530	CYP51A1	-0.35	-7.59	-0.35	2.08e-13	Breast cancer;
LUAD	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg16049864	chr8:95962084	TP53INP1	-0.41	-8.16	-0.37	3.88e-15	Alzheimer's disease (late onset);
LUAD	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg27661571	chr11:113659931	NA	-0.56	-6.95	-0.32	1.38e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11644478	chr21:40555479	PSMG1	0.66	11.23	0.48	8.52e-26	Cognitive function;
LUAD	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg13010199	chr12:38710504	ALG10B	0.39	6.38	0.3	4.65e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs8017423	0.967	rs8021881	chr14:90722276	T/C	cg14092571	chr14:90743983	NA	-0.5	-8.89	-0.4	1.76e-17	Mortality in heart failure;
LUAD	cis	rs10203711	1.000	rs6707795	chr2:239555580	T/C	cg14580085	chr2:239553406	NA	0.41	8.55	0.38	2.33e-16	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg18187862	chr3:45730750	SACM1L	-0.47	-6.94	-0.32	1.49e-11	Primary sclerosing cholangitis;
LUAD	cis	rs4594175	0.962	rs4254242	chr14:51599184	A/C	cg23942311	chr14:51606299	NA	0.64	10.96	0.47	8.86e-25	Cancer;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg27279652	chr12:26986506	ITPR2	0.41	6.51	0.3	2.16e-10	Diastolic blood pressure;
LUAD	cis	rs123509	0.687	rs73077214	chr3:42838020	G/A	cg10144569	chr3:42726640	KBTBD5	-0.48	-7.11	-0.33	5.06e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2295359	0.643	rs1569922	chr1:67664963	C/T	cg03340356	chr1:67600835	NA	0.36	6.66	0.31	8.78e-11	Psoriasis;
LUAD	trans	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.06	-0.32	7.09e-12	Pancreatic cancer;
LUAD	cis	rs62238980	0.614	rs117509300	chr22:32502206	C/T	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs2688608	0.839	rs2633311	chr10:75598099	C/T	cg19442545	chr10:75533431	FUT11	0.43	7.1	0.33	5.32e-12	Inflammatory bowel disease;
LUAD	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg03690763	chr11:133734501	NA	-0.35	-8.1	-0.37	5.76e-15	Childhood ear infection;
LUAD	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-23.73	-0.76	9.7e-80	Height;
LUAD	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg08859206	chr1:53392774	SCP2	-0.58	-10.64	-0.46	1.43e-23	Monocyte count;
LUAD	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg08027265	chr7:2291960	NA	-0.43	-7.07	-0.33	6.5e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg00701064	chr4:6280414	WFS1	0.71	15.96	0.61	3.15e-45	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs57590327	0.679	rs13094809	chr3:81666806	G/A	cg07356753	chr3:81810745	GBE1	-0.5	-6.65	-0.31	8.91e-11	Extraversion;
LUAD	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg18404041	chr3:52824283	ITIH1	-0.57	-10.53	-0.46	3.43e-23	Bipolar disorder;
LUAD	cis	rs17401966	0.867	rs6696056	chr1:10305992	C/A	cg15208524	chr1:10270712	KIF1B	0.42	6.42	0.3	3.64e-10	Hepatocellular carcinoma;
LUAD	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.66	-11.62	-0.49	2.89e-27	Melanoma;
LUAD	cis	rs12369635	1.000	rs9645723	chr12:129554501	C/T	cg01909103	chr12:129572610	TMEM132D	-0.65	-6.87	-0.32	2.24e-11	Schizophrenia (inflammation and infection response interaction);
LUAD	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg02269571	chr22:50332266	NA	0.59	9.04	0.4	5.64e-18	Schizophrenia;
LUAD	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg02782426	chr3:40428986	ENTPD3	0.35	7.55	0.34	2.73e-13	Renal cell carcinoma;
LUAD	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg02421172	chr7:1938701	MAD1L1	0.49	6.74	0.31	5.07e-11	Bipolar disorder;
LUAD	cis	rs6674176	0.542	rs2906468	chr1:44319007	A/G	cg12908607	chr1:44402522	ARTN	-0.44	-8.42	-0.38	6.06e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.77	-0.46	4.38e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs12545109	0.837	rs4738500	chr8:57356193	G/A	cg09654669	chr8:57350985	NA	-0.71	-9.99	-0.44	3e-21	Obesity-related traits;
LUAD	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg18016565	chr1:150552671	MCL1	-0.39	-6.75	-0.31	5.01e-11	Tonsillectomy;
LUAD	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg00020340	chr7:910388	UNC84A	0.63	6.89	0.32	2.03e-11	Initial pursuit acceleration;
LUAD	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg16049864	chr8:95962084	TP53INP1	-0.46	-8.51	-0.38	2.95e-16	Type 2 diabetes;
LUAD	cis	rs500891	0.525	rs7774996	chr6:84073387	A/G	cg08257003	chr6:84140564	ME1	0.35	6.72	0.31	5.8e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg19318889	chr4:1322082	MAEA	0.55	9.29	0.41	8.54e-19	Longevity;
LUAD	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg06640241	chr16:89574553	SPG7	-0.69	-12.38	-0.52	2.9e-30	Multiple myeloma (IgH translocation);
LUAD	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.42	0.34	6.2800000000000005e-13	Menopause (age at onset);
LUAD	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg26924012	chr15:45694286	SPATA5L1	0.62	10.65	0.46	1.32e-23	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs7731657	0.537	rs4705851	chr5:130220592	A/G	cg08523029	chr5:130500466	HINT1	0.55	7.16	0.33	3.58e-12	Fasting plasma glucose;
LUAD	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	7.92	0.36	2.16e-14	Menarche (age at onset);
LUAD	cis	rs654950	0.806	rs1535505	chr1:42026152	A/G	cg06885757	chr1:42089581	HIVEP3	0.48	10.31	0.45	2.26e-22	Airway imaging phenotypes;
LUAD	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-8.57	-0.38	1.92e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4700695	0.841	rs251306	chr5:65252453	C/T	cg21114390	chr5:65439923	SFRS12	0.62	7.49	0.34	4.12e-13	Facial morphology (factor 19);
LUAD	cis	rs6782228	0.675	rs9841987	chr3:128385142	G/T	cg16766828	chr3:128327626	NA	-0.39	-7.15	-0.33	3.8e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs892961	1.000	rs11077909	chr17:75403480	T/C	cg05865280	chr17:75406074	SEPT9	0.62	19.15	0.68	2.56e-59	Airflow obstruction;
LUAD	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg19336497	chr11:14380999	RRAS2	0.36	7.47	0.34	4.5e-13	Mitochondrial DNA levels;
LUAD	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg09365446	chr1:150670422	GOLPH3L	0.59	10.33	0.45	1.85e-22	Melanoma;
LUAD	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg02466173	chr16:30829666	NA	-0.7	-12.62	-0.52	3.27e-31	Multiple myeloma;
LUAD	cis	rs72772090	0.539	rs11750464	chr5:96113031	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.65	7.46	0.34	4.92e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4713118	0.581	rs200504	chr6:27785820	T/C	cg08798685	chr6:27730294	NA	-0.44	-6.68	-0.31	7.63e-11	Parkinson's disease;
LUAD	cis	rs13082711	0.911	rs35532045	chr3:27515870	A/G	cg02860705	chr3:27208620	NA	0.57	8.79	0.39	3.72e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.37	-7.87	-0.36	2.98e-14	Lung cancer;
LUAD	cis	rs4986172	0.726	rs12946454	chr17:43208121	A/T	cg10701640	chr17:43249399	NA	0.57	10.03	0.44	2.29e-21	Height;
LUAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg11766577	chr21:47581405	C21orf56	-0.46	-7.89	-0.36	2.65e-14	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08280861	chr8:58055591	NA	0.6	7.67	0.35	1.18e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs3750082	0.889	rs970673	chr7:32927727	A/G	cg05721444	chr7:32995514	FKBP9	0.37	6.69	0.31	7.2e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs28830936	1.000	rs17676742	chr15:41903048	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.71	-0.31	6.21e-11	Diastolic blood pressure;
LUAD	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg07432352	chr17:45403706	C17orf57	0.45	8.49	0.38	3.53e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11971779	0.752	rs4732371	chr7:139077317	T/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.52	0.3	1.97e-10	Diisocyanate-induced asthma;
LUAD	cis	rs6594713	0.642	rs17389165	chr5:112796598	A/C	cg12552261	chr5:112820674	MCC	-0.53	-7.5	-0.34	3.68e-13	Brain cytoarchitecture;
LUAD	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg02493740	chr2:85810744	VAMP5	-0.63	-11.44	-0.49	1.4e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06022373	chr22:39101656	GTPBP1	0.45	7.0	0.32	1.02e-11	Menopause (age at onset);
LUAD	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg23711669	chr6:146136114	FBXO30	0.37	6.37	0.3	4.85e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2880765	0.835	rs7169429	chr15:86036648	C/T	cg13263323	chr15:86062960	AKAP13	-0.48	-8.81	-0.39	3.31e-17	Coronary artery disease;
LUAD	cis	rs3125734	0.719	rs10821972	chr10:64043735	G/A	cg19640130	chr10:64028056	RTKN2	-0.33	-7.06	-0.32	6.96e-12	Rheumatoid arthritis;
LUAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg13047869	chr3:10149882	C3orf24	0.65	11.01	0.47	5.64e-25	Alzheimer's disease;
LUAD	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg19163074	chr7:65112434	INTS4L2	0.45	6.9	0.32	1.94e-11	Aortic root size;
LUAD	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg18016565	chr1:150552671	MCL1	0.42	7.72	0.35	8.76e-14	Tonsillectomy;
LUAD	cis	rs977987	0.806	rs11644306	chr16:75490053	T/C	cg03315344	chr16:75512273	CHST6	0.64	14.02	0.56	5.96e-37	Dupuytren's disease;
LUAD	cis	rs4285028	0.747	rs9824235	chr3:121432177	G/T	cg11130432	chr3:121712080	ILDR1	-0.47	-6.82	-0.31	3.11e-11	Multiple sclerosis;
LUAD	cis	rs9487051	0.768	rs1766814	chr6:109526696	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.68	-0.31	7.52e-11	Reticulocyte fraction of red cells;
LUAD	trans	rs7395662	0.709	rs11040113	chr11:48895653	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.42	-0.34	6.52e-13	HDL cholesterol;
LUAD	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.53	8.18	0.37	3.41e-15	Platelet count;
LUAD	trans	rs4942242	0.740	rs6561137	chr13:44231965	A/T	cg19169023	chr15:41853346	TYRO3	-0.39	-6.87	-0.32	2.37e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.78	-0.5	6.9e-28	Mean corpuscular volume;
LUAD	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.23	-0.41	1.3e-18	Type 2 diabetes;
LUAD	cis	rs921968	0.565	rs62191658	chr2:219630294	A/G	cg02176678	chr2:219576539	TTLL4	-0.59	-12.06	-0.51	5.24e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs3204270	0.639	rs79193599	chr17:79651490	C/A	cg18367735	chr17:79674897	NA	0.58	6.92	0.32	1.72e-11	Dental caries;
LUAD	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg23283495	chr1:209979779	IRF6	-0.46	-8.6	-0.39	1.52e-16	Orofacial clefts;
LUAD	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg21775007	chr8:11205619	TDH	-0.49	-9.04	-0.4	5.61e-18	Retinal vascular caliber;
LUAD	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.47	0.3	2.64e-10	Depression;
LUAD	cis	rs6906287	0.647	rs3890198	chr6:118706447	T/C	cg21191810	chr6:118973309	C6orf204	0.5	9.63	0.42	5.39e-20	Electrocardiographic conduction measures;
LUAD	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18876405	chr7:65276391	NA	-0.41	-6.43	-0.3	3.5e-10	Aortic root size;
LUAD	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg14671364	chr1:107599128	PRMT6	-0.5	-8.08	-0.37	6.89e-15	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg13319975	chr6:146136371	FBXO30	-0.59	-9.97	-0.44	3.57e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13315871	1.000	rs35792042	chr3:58409668	C/T	cg12435725	chr3:58293450	RPP14	-0.71	-7.65	-0.35	1.36e-13	Cholesterol, total;
LUAD	cis	rs938554	0.737	rs11723439	chr4:9951819	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-8.69	-0.39	8.05e-17	Blood metabolite levels;
LUAD	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg23260525	chr10:116636907	FAM160B1	0.53	12.46	0.52	1.45e-30	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg15900387	chr1:150738905	CTSS	-0.37	-6.71	-0.31	6.41e-11	Melanoma;
LUAD	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14240646	chr10:27532245	ACBD5	-0.89	-12.01	-0.5	8.41e-29	Breast cancer;
LUAD	cis	rs62400317	0.859	rs114017772	chr6:45113862	T/C	cg20913747	chr6:44695427	NA	-0.42	-6.74	-0.31	5.14e-11	Total body bone mineral density;
LUAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg08888203	chr3:10149979	C3orf24	0.74	12.98	0.53	1.18e-32	Alzheimer's disease;
LUAD	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg25358565	chr5:93447407	FAM172A	0.64	7.54	0.34	2.91e-13	Diabetic retinopathy;
LUAD	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	6.9	0.32	1.91e-11	Aortic root size;
LUAD	cis	rs7771547	0.573	rs584418	chr6:36395437	G/A	cg07856975	chr6:36356162	ETV7	0.49	7.77	0.35	6.21e-14	Platelet distribution width;
LUAD	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg24733560	chr20:60626293	TAF4	0.47	8.36	0.38	9.26e-16	Body mass index;
LUAD	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg20673091	chr1:2541236	MMEL1	0.45	9.95	0.44	4.29e-21	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg00784671	chr22:46762841	CELSR1	-0.41	-6.36	-0.3	5.22e-10	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg07817883	chr1:32538562	TMEM39B	-0.51	-6.83	-0.32	2.98e-11	Monocyte percentage of white cells;
LUAD	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg17420585	chr12:42539391	GXYLT1	0.39	6.89	0.32	2.08e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg26354017	chr1:205819088	PM20D1	-0.54	-8.26	-0.37	1.88e-15	Menarche (age at onset);
LUAD	cis	rs12431939	1.000	rs58225416	chr14:51662196	C/T	cg23942311	chr14:51606299	NA	-0.6	-7.91	-0.36	2.29e-14	Cancer;
LUAD	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.01	-0.36	1.1e-14	Personality dimensions;
LUAD	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg09253696	chr17:73873529	TRIM47	-0.45	-7.61	-0.35	1.77e-13	Psoriasis;
LUAD	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-11.07	-0.47	3.41e-25	Monocyte percentage of white cells;
LUAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg02782426	chr3:40428986	ENTPD3	0.42	8.9	0.4	1.64e-17	Renal cell carcinoma;
LUAD	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg05132306	chr1:1846340	CALML6	-0.37	-7.94	-0.36	1.88e-14	Body mass index;
LUAD	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06505273	chr16:24850292	NA	0.47	6.98	0.32	1.14e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg08085267	chr17:45401833	C17orf57	-0.65	-11.46	-0.49	1.2e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.88	0.4	1.93e-17	Menopause (age at onset);
LUAD	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg07636037	chr3:49044803	WDR6	0.51	7.53	0.34	3.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg04663057	chr3:46933782	PTH1R	-0.25	-6.47	-0.3	2.78e-10	Birth weight;
LUAD	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.4	0.42	3.51e-19	Tonsillectomy;
LUAD	cis	rs250677	0.522	rs12520924	chr5:148349149	C/T	cg12140854	chr5:148520817	ABLIM3	0.56	8.46	0.38	4.48e-16	Breast cancer;
LUAD	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.75	-0.35	6.93e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg08645402	chr16:4508243	NA	0.58	10.76	0.46	5.15e-24	Schizophrenia;
LUAD	cis	rs701145	0.878	rs355753	chr3:153968846	T/C	cg17054900	chr3:154042577	DHX36	0.65	6.94	0.32	1.51e-11	Coronary artery disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16919567	chr17:19015961	NA	-0.44	-7.17	-0.33	3.41e-12	Cancer;
LUAD	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg15208524	chr1:10270712	KIF1B	0.43	6.49	0.3	2.44e-10	Hepatocellular carcinoma;
LUAD	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg27411982	chr8:10470053	RP1L1	0.41	7.4	0.34	7.17e-13	Triglycerides;
LUAD	cis	rs36093844	0.800	rs17817326	chr11:85595213	C/T	cg25872744	chr11:85566296	CCDC83	-0.51	-6.42	-0.3	3.71e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUAD	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg11494091	chr17:61959527	GH2	0.45	8.73	0.39	5.96e-17	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs68170813	0.559	rs1989814	chr7:107045076	A/G	cg23024343	chr7:107201750	COG5	0.52	7.22	0.33	2.44e-12	Coronary artery disease;
LUAD	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg10876282	chr6:28092338	ZSCAN16	0.42	6.85	0.32	2.64e-11	Parkinson's disease;
LUAD	trans	rs7395662	1.000	rs7481308	chr11:48600067	T/A	cg00717180	chr2:96193071	NA	-0.38	-7.23	-0.33	2.3e-12	HDL cholesterol;
LUAD	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg08508325	chr11:3079039	CARS	0.44	9.16	0.41	2.3e-18	Calcium levels;
LUAD	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg05283184	chr6:79620031	NA	-0.59	-11.93	-0.5	1.78e-28	Intelligence (multi-trait analysis);
LUAD	trans	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-10.64	-0.46	1.35e-23	Ulcerative colitis;
LUAD	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.21	-0.33	2.57e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg15208524	chr1:10270712	KIF1B	0.54	7.96	0.36	1.59e-14	Hepatocellular carcinoma;
LUAD	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg25173405	chr17:45401733	C17orf57	-0.57	-9.77	-0.43	1.84e-20	Glaucoma (primary open-angle);
LUAD	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg13607699	chr17:42295918	UBTF	0.52	8.47	0.38	4.22e-16	Total body bone mineral density;
LUAD	trans	rs9929218	0.954	rs4552018	chr16:68822854	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.72	-0.53	1.32e-31	Colorectal cancer;
LUAD	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg14343924	chr8:8086146	FLJ10661	-0.46	-7.32	-0.34	1.24e-12	Joint mobility (Beighton score);
LUAD	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg23245007	chr3:195682326	NA	-0.39	-6.5	-0.3	2.31e-10	Pancreatic cancer;
LUAD	cis	rs67311347	0.544	rs7644181	chr3:40355665	A/G	cg09455208	chr3:40491958	NA	-0.49	-10.36	-0.45	1.48e-22	Renal cell carcinoma;
LUAD	cis	rs713587	0.626	rs62140636	chr2:25233811	T/C	cg04586622	chr2:25135609	ADCY3	-0.31	-6.91	-0.32	1.8e-11	Body mass index in non-asthmatics;
LUAD	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg00071950	chr4:10020882	SLC2A9	0.83	18.1	0.66	1.26e-54	Bone mineral density;
LUAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg04234412	chr22:24373322	LOC391322	-0.86	-15.98	-0.61	2.65e-45	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1003719	0.591	rs2835633	chr21:38525019	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.46	-7.78	-0.35	5.53e-14	Eye color traits;
LUAD	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.57	0.3	1.45e-10	Parkinson's disease;
LUAD	cis	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg00071950	chr4:10020882	SLC2A9	0.49	7.02	0.32	9.03e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs10823500	0.545	rs7082562	chr10:71945684	A/G	cg02100629	chr10:71892760	AIFM2	-0.37	-7.58	-0.35	2.22e-13	Blood protein levels;
LUAD	cis	rs34245846	0.769	rs12084791	chr1:154824973	A/G	cg06221963	chr1:154839813	KCNN3	0.47	7.24	0.33	2.13e-12	Atrial fibrillation;
LUAD	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg02158880	chr13:53174818	NA	0.48	8.32	0.37	1.23e-15	Lewy body disease;
LUAD	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg27124370	chr19:33622961	WDR88	0.46	7.15	0.33	3.92e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg00316803	chr15:76480434	C15orf27	0.42	6.56	0.3	1.61e-10	Blood metabolite levels;
LUAD	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg06641503	chr3:48959341	ARIH2	-0.39	-7.73	-0.35	7.88e-14	Parkinson's disease;
LUAD	cis	rs4356932	1.000	rs6532093	chr4:76948032	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.49	-0.3	2.36e-10	Blood protein levels;
LUAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06873352	chr17:61820015	STRADA	0.83	18.6	0.67	7.24e-57	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12545109	0.800	rs2609978	chr8:57394467	T/C	cg07776626	chr8:57350775	NA	-0.66	-9.27	-0.41	9.25e-19	Obesity-related traits;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10359030	chr19:17326115	USE1	-0.44	-6.76	-0.31	4.52e-11	Height;
LUAD	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-9.61	-0.42	6.48e-20	Life satisfaction;
LUAD	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg08885076	chr2:99613938	TSGA10	0.41	7.58	0.35	2.17e-13	Chronic sinus infection;
LUAD	cis	rs758324	0.947	rs9327622	chr5:131125080	T/A	cg25547332	chr5:131281432	NA	0.46	6.98	0.32	1.16e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4523957	0.559	rs170040	chr17:2165714	C/T	cg16513277	chr17:2031491	SMG6	0.63	9.79	0.43	1.55e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.03	-0.4	6.16e-18	Total body bone mineral density;
LUAD	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg01851573	chr8:8652454	MFHAS1	0.4	7.29	0.33	1.57e-12	Mood instability;
LUAD	cis	rs250585	0.736	rs727238	chr16:23521066	C/T	cg00143387	chr16:23521605	GGA2	-0.74	-10.17	-0.44	6.93e-22	Egg allergy;
LUAD	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	9.86	0.43	9.17e-21	Ileal carcinoids;
LUAD	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg00933542	chr6:150070202	PCMT1	0.45	9.78	0.43	1.64e-20	Lung cancer;
LUAD	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg13012494	chr21:47604986	C21orf56	0.47	7.75	0.35	6.93e-14	Testicular germ cell tumor;
LUAD	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg27446573	chr6:127587934	RNF146	0.44	6.53	0.3	1.84e-10	Breast cancer;
LUAD	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg09640425	chr7:158790006	NA	-0.46	-7.92	-0.36	2.14e-14	Facial morphology (factor 20);
LUAD	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg24675658	chr1:53192096	ZYG11B	-0.38	-6.48	-0.3	2.49e-10	Monocyte count;
LUAD	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	8.79	0.39	3.66e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg12935359	chr14:103987150	CKB	-0.47	-7.75	-0.35	6.87e-14	Body mass index;
LUAD	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.62	0.55	2.87e-35	Tonsillectomy;
LUAD	cis	rs6446731	0.500	rs2858085	chr4:3271226	T/G	cg08886695	chr4:3369023	RGS12	0.46	7.81	0.35	4.66e-14	Mean platelet volume;
LUAD	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	13.87	0.56	2.54e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg03859395	chr2:55845619	SMEK2	0.73	13.41	0.55	2.1e-34	Metabolic syndrome;
LUAD	cis	rs7903847	0.620	rs61863813	chr10:99112786	T/C	cg08345082	chr10:99160200	RRP12	-0.33	-6.57	-0.3	1.51e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg05342682	chr7:94953680	PON1	-0.58	-10.15	-0.44	7.96e-22	Paraoxonase activity;
LUAD	trans	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg06606381	chr12:133084897	FBRSL1	0.51	7.07	0.33	6.26e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg25208724	chr1:156163844	SLC25A44	1.01	18.01	0.66	3.13e-54	Testicular germ cell tumor;
LUAD	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg25554036	chr4:6271136	WFS1	0.69	13.72	0.55	1.11e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg01528321	chr10:82214614	TSPAN14	0.46	7.26	0.33	1.9e-12	Post bronchodilator FEV1;
LUAD	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.13	-0.33	4.26e-12	Breast cancer;
LUAD	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg02038168	chr22:39784481	NA	-0.53	-8.38	-0.38	7.93e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg13334819	chr7:99746414	C7orf59	-0.64	-9.44	-0.42	2.51e-19	Coronary artery disease;
LUAD	cis	rs3803170	0.513	rs10774622	chr12:111833348	C/T	cg10833066	chr12:111807467	FAM109A	0.48	8.95	0.4	1.13e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg21856205	chr7:94953877	PON1	-0.55	-7.87	-0.36	3.02e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2282300	0.696	rs1222214	chr11:30347695	C/G	cg06241208	chr11:30344200	C11orf46	-0.55	-6.99	-0.32	1.07e-11	Morning vs. evening chronotype;
LUAD	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg05914723	chr15:78953907	NA	0.56	7.27	0.33	1.78e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg13057898	chr1:3703894	LRRC47	0.63	10.72	0.46	6.9e-24	Red cell distribution width;
LUAD	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg01884057	chr2:25150051	NA	0.33	7.16	0.33	3.69e-12	Body mass index;
LUAD	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.46	0.52	1.4e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg04731861	chr2:219085781	ARPC2	-0.22	-6.78	-0.31	4.09e-11	Colorectal cancer;
LUAD	cis	rs9902453	0.904	rs9900112	chr17:28282910	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	10.12	0.44	1.1e-21	Coffee consumption (cups per day);
LUAD	trans	rs11650494	0.831	rs73324348	chr17:47455752	G/A	cg11430096	chr6:110968061	CDK19	0.82	6.59	0.31	1.28e-10	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.94e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	10.71	0.46	7.56e-24	Resting heart rate;
LUAD	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	10.82	0.47	2.96e-24	Smoking behavior;
LUAD	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	6.97	0.32	1.2e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12568771	0.650	rs3766298	chr1:17602087	A/T	cg08277548	chr1:17600880	PADI3	0.35	6.4	0.3	4.19e-10	IgA nephropathy;
LUAD	cis	rs829883	0.763	rs249843	chr12:98870987	G/A	cg25150519	chr12:98850993	NA	0.76	14.14	0.57	1.86e-37	Colorectal adenoma (advanced);
LUAD	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg23145915	chr12:58146234	CDK4	0.41	6.46	0.3	2.96e-10	Response to antipsychotic treatment;
LUAD	cis	rs7582720	1.000	rs77931721	chr2:203763076	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.55	7.64	0.35	1.43e-13	Platelet count;
LUAD	cis	rs977987	0.806	rs11862095	chr16:75385418	T/A	cg03315344	chr16:75512273	CHST6	0.64	13.93	0.56	1.48e-36	Dupuytren's disease;
LUAD	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg00530320	chr1:46809349	NSUN4	0.53	8.17	0.37	3.63e-15	Menopause (age at onset);
LUAD	cis	rs933688	0.532	rs13164949	chr5:90538489	C/T	cg17503389	chr5:90575422	NA	-0.42	-6.63	-0.31	1.05e-10	Smoking behavior;
LUAD	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg24308560	chr3:49941425	MST1R	-0.54	-9.12	-0.41	3.18e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg22431228	chr1:16359049	CLCNKA	0.43	8.28	0.37	1.66e-15	Systolic blood pressure;
LUAD	cis	rs2108225	0.934	rs4730269	chr7:107455719	T/G	cg18560240	chr7:107437656	SLC26A3	-0.41	-6.67	-0.31	7.85e-11	Ulcerative colitis;
LUAD	cis	rs4711336	0.967	rs4713658	chr6:33667117	C/G	cg14003231	chr6:33640908	ITPR3	0.46	8.93	0.4	1.31e-17	Height;
LUAD	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg10591111	chr5:226296	SDHA	-0.54	-6.84	-0.32	2.87e-11	Breast cancer;
LUAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg00280220	chr17:61926910	NA	0.36	7.0	0.32	9.86e-12	Prudent dietary pattern;
LUAD	cis	rs11741688	0.557	rs6898923	chr5:178330559	C/T	cg09339527	chr5:178322752	ZFP2	-0.35	-7.37	-0.34	8.84e-13	Sleep duration;
LUAD	cis	rs7598759	0.548	rs11693738	chr2:232360484	C/T	cg19187155	chr2:232395269	NMUR1	0.51	9.63	0.42	5.68e-20	Noise-induced hearing loss;
LUAD	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg14196790	chr5:131705035	SLC22A5	0.55	9.95	0.44	4.1e-21	Blood metabolite levels;
LUAD	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg03929089	chr4:120376271	NA	0.58	7.46	0.34	4.81e-13	Axial length;
LUAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08677398	chr8:58056175	NA	0.46	6.54	0.3	1.76e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg20587970	chr11:113659929	NA	-1.38	-20.92	-0.71	3.05e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs2230307	0.656	rs12145880	chr1:100446008	C/G	cg20868668	chr1:100435035	SLC35A3	0.63	7.58	0.35	2.21e-13	Carotid intima media thickness;
LUAD	cis	rs9462027	0.628	rs3734268	chr6:34716028	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.76	-0.39	4.62e-17	Systemic lupus erythematosus;
LUAD	cis	rs2073300	1.000	rs6132621	chr20:23442180	C/T	cg12062639	chr20:23401060	NAPB	1.0	9.21	0.41	1.47e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2267137	0.903	rs2283850	chr22:29772391	G/C	cg07256473	chr22:29710276	RASL10A	0.42	7.97	0.36	1.46e-14	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs4722585	0.533	rs3753097	chr7:26198207	A/G	cg07876897	chr7:26191696	NFE2L3	0.47	7.54	0.34	2.93e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg08754654	chr5:154026448	NA	0.48	8.06	0.36	8.01e-15	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs11031096	0.782	rs10767845	chr11:4156922	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.58	-0.35	2.19e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1595825	0.628	rs6760078	chr2:198563742	A/T	cg11031976	chr2:198649780	BOLL	-0.45	-6.9	-0.32	1.91e-11	Ulcerative colitis;
LUAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg22105103	chr4:187893119	NA	0.56	12.53	0.52	7.69e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs751837	0.591	rs28368893	chr14:103433263	C/T	cg10087771	chr14:103399429	CDC42BPB	0.69	6.9	0.32	1.97e-11	Large B-cell lymphoma;
LUAD	trans	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg13565492	chr6:43139072	SRF	-0.65	-7.36	-0.34	9.75e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg15790184	chr11:494944	RNH1	0.56	6.95	0.32	1.4e-11	Body mass index;
LUAD	cis	rs6494488	0.500	rs72741329	chr15:64736091	A/G	cg08069370	chr15:64387884	SNX1	-0.75	-6.73	-0.31	5.58e-11	Coronary artery disease;
LUAD	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	7.67	0.35	1.18e-13	Schizophrenia;
LUAD	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg05425664	chr17:57184151	TRIM37	-0.43	-7.68	-0.35	1.13e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4700695	0.534	rs152999	chr5:65213108	G/T	cg21114390	chr5:65439923	SFRS12	0.61	6.61	0.31	1.19e-10	Facial morphology (factor 19);
LUAD	cis	rs9925964	0.933	rs881929	chr16:31079371	G/T	cg03418659	chr16:31128414	MYST1	0.37	6.36	0.3	5.27e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-20.37	-0.7	8.9e-65	Height;
LUAD	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg06618935	chr21:46677482	NA	-0.5	-10.05	-0.44	1.93e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1003719	0.751	rs2835585	chr21:38460488	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.36e-16	Eye color traits;
LUAD	cis	rs743757	1.000	rs2282754	chr3:50436827	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.45	7.17	0.33	3.42e-12	Diastolic blood pressure;
LUAD	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg07870213	chr5:140052090	DND1	-0.91	-12.43	-0.52	1.84e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19260885	chr1:113162159	ST7L;CAPZA1	-0.56	-6.76	-0.31	4.67e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg07917127	chr4:99064746	C4orf37	0.45	7.5	0.34	3.78e-13	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01585723	chr16:33734837	NA	0.35	6.39	0.3	4.49e-10	Menopause (age at onset);
LUAD	cis	rs733175	0.857	rs7666545	chr4:10012372	C/T	cg11266682	chr4:10021025	SLC2A9	0.44	7.21	0.33	2.52e-12	Psychosis and Alzheimer's disease;
LUAD	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24531977	chr5:56204891	C5orf35	-0.99	-15.17	-0.59	8.56e-42	Initial pursuit acceleration;
LUAD	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg03563238	chr19:33554763	RHPN2	-0.33	-8.11	-0.37	5.39e-15	Colorectal cancer;
LUAD	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg16989719	chr2:238392110	NA	-0.34	-6.74	-0.31	5.14e-11	Prostate cancer;
LUAD	cis	rs977987	0.835	rs8046109	chr16:75360096	A/G	cg03315344	chr16:75512273	CHST6	0.61	13.34	0.54	3.85e-34	Dupuytren's disease;
LUAD	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg25319279	chr11:5960081	NA	-0.39	-6.87	-0.32	2.26e-11	DNA methylation (variation);
LUAD	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg07936489	chr17:37558343	FBXL20	0.45	7.09	0.33	5.62e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs11958404	0.932	rs72816581	chr5:157432591	T/A	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs3772130	0.603	rs10470410	chr3:121434977	G/T	cg20356878	chr3:121714668	ILDR1	0.6	11.32	0.48	3.83e-26	Cognitive performance;
LUAD	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg22431228	chr1:16359049	CLCNKA	-0.54	-10.39	-0.45	1.1e-22	Dilated cardiomyopathy;
LUAD	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg09165964	chr15:75287851	SCAMP5	0.52	8.51	0.38	3.04e-16	Blood trace element (Zn levels);
LUAD	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg20701182	chr2:24300061	SF3B14	0.46	7.28	0.33	1.66e-12	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg21775007	chr8:11205619	TDH	-0.39	-6.53	-0.3	1.89e-10	Retinal vascular caliber;
LUAD	cis	rs733175	0.830	rs6834555	chr4:10062326	G/A	cg00071950	chr4:10020882	SLC2A9	0.47	7.26	0.33	1.82e-12	Psychosis and Alzheimer's disease;
LUAD	cis	rs59698941	0.943	rs67843388	chr5:132288007	C/T	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs9469578	1.000	rs73743323	chr6:33705355	C/T	cg18708504	chr6:33715942	IP6K3	0.75	8.23	0.37	2.34e-15	Phosphorus levels;
LUAD	cis	rs921968	0.565	rs1541777	chr2:219587291	A/G	cg02176678	chr2:219576539	TTLL4	-0.59	-11.99	-0.5	1.06e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg21016266	chr12:122356598	WDR66	0.7	12.76	0.53	8.7e-32	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7107174	0.901	rs2512522	chr11:77925855	G/C	cg19901956	chr11:77921274	USP35	-0.54	-6.72	-0.31	5.73e-11	Testicular germ cell tumor;
LUAD	cis	rs1003719	0.680	rs7275984	chr21:38505696	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-9.06	-0.4	4.8e-18	Eye color traits;
LUAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00166722	chr3:10149974	C3orf24	0.74	12.65	0.52	2.48e-31	Alzheimer's disease;
LUAD	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg15145296	chr3:125709740	NA	-0.53	-6.39	-0.3	4.37e-10	Blood pressure (smoking interaction);
LUAD	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg09796270	chr17:17721594	SREBF1	0.37	7.1	0.33	5.38e-12	Total body bone mineral density;
LUAD	trans	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg14343924	chr8:8086146	FLJ10661	0.46	6.93	0.32	1.62e-11	Neuroticism;
LUAD	cis	rs10992471	0.756	rs10992303	chr9:95082804	A/G	cg14631576	chr9:95140430	CENPP	-0.48	-9.8	-0.43	1.39e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-10.6	-0.46	1.91e-23	Chronic sinus infection;
LUAD	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg21770322	chr7:97807741	LMTK2	0.31	7.34	0.34	1.12e-12	Breast cancer;
LUAD	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg12564285	chr5:131593104	PDLIM4	-0.38	-6.69	-0.31	7.09e-11	Breast cancer;
LUAD	trans	rs258892	0.947	rs62360681	chr5:72187013	T/G	cg14879065	chr14:104662468	NA	-0.35	-6.39	-0.3	4.45e-10	Small cell lung carcinoma;
LUAD	cis	rs710865	0.966	rs709683	chr1:19565344	C/G	cg13387374	chr1:19411106	UBR4	0.41	6.76	0.31	4.64e-11	Brain structure;
LUAD	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg01689657	chr7:91764605	CYP51A1	0.36	8.43	0.38	5.4e-16	Breast cancer;
LUAD	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg11189052	chr15:85197271	WDR73	0.58	7.54	0.34	2.97e-13	Schizophrenia;
LUAD	cis	rs10159302	0.636	rs267644	chr1:57790529	C/G	cg23691223	chr1:57785036	DAB1	-0.5	-9.19	-0.41	1.76e-18	HIV-1 control;
LUAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.48	6.79	0.31	3.89e-11	Renal function-related traits (BUN);
LUAD	trans	rs75804782	0.630	rs75921156	chr2:239279633	C/T	cg01134436	chr17:81009848	B3GNTL1	0.72	6.35	0.3	5.68e-10	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg16680214	chr1:154839983	KCNN3	-0.65	-12.5	-0.52	9.59e-31	Prostate cancer;
LUAD	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg18252515	chr7:66147081	NA	0.61	6.67	0.31	7.98e-11	Diabetic kidney disease;
LUAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg08027265	chr7:2291960	NA	-0.43	-7.21	-0.33	2.54e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg10295955	chr4:187884368	NA	-1.11	-27.49	-0.8	3.64e-96	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7727544	0.625	rs3091338	chr5:131402738	C/T	cg14196790	chr5:131705035	SLC22A5	0.45	7.67	0.35	1.2e-13	Blood metabolite levels;
LUAD	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg04414720	chr1:150670196	GOLPH3L	0.67	11.79	0.5	6.3e-28	Melanoma;
LUAD	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg10164272	chr16:89456328	ANKRD11	0.42	6.98	0.32	1.16e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg24838063	chr12:130822603	PIWIL1	0.64	10.68	0.46	9.9899999999999993e-24	Menopause (age at onset);
LUAD	cis	rs3540	0.514	rs2601192	chr15:90936704	G/A	cg10434728	chr15:90938212	IQGAP1	0.39	7.82	0.36	4.11e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.98	-0.32	1.15e-11	Height;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06931245	chr8:28351501	FZD3	-0.66	-6.4	-0.3	4.03e-10	Type 2 diabetes;
LUAD	cis	rs7589728	1.000	rs11893832	chr2:88507537	G/C	cg04511125	chr2:88470314	THNSL2	0.79	8.37	0.38	8.39e-16	Plasma clusterin levels;
LUAD	cis	rs150647904	1	rs150647904	chr1:54839485	T/TCAG	cg17417004	chr1:54819992	SSBP3	0.56	7.97	0.36	1.52e-14	Platelet distribution width;
LUAD	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg02896835	chr1:92012615	NA	0.6	12.4	0.52	2.46e-30	Breast cancer;
LUAD	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.43	8.02	0.36	1.07e-14	Neutrophil percentage of white cells;
LUAD	cis	rs6987853	0.787	rs2923436	chr8:42425298	G/A	cg09913449	chr8:42400586	C8orf40	0.48	9.36	0.41	4.67e-19	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs13064411	0.518	rs6438160	chr3:113217591	A/C	cg18753928	chr3:113234510	CCDC52	-0.48	-8.75	-0.39	5.23e-17	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg12311346	chr5:56204834	C5orf35	-0.61	-10.11	-0.44	1.15e-21	Coronary artery disease;
LUAD	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg05043794	chr9:111880884	C9orf5	-0.42	-7.05	-0.32	7.23e-12	Menarche (age at onset);
LUAD	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg01802117	chr1:53393560	SCP2	-0.35	-7.0	-0.32	1.01e-11	Monocyte count;
LUAD	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22968622	chr17:43663579	NA	-1.16	-20.26	-0.7	2.9e-64	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7107174	1.000	rs2512541	chr11:77981747	A/T	cg02023728	chr11:77925099	USP35	0.49	7.57	0.35	2.43e-13	Testicular germ cell tumor;
LUAD	trans	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.19	-0.37	3.2e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.89	0.36	2.62e-14	Bladder cancer;
LUAD	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.93	0.36	2.01e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg18105134	chr13:113819100	PROZ	0.73	12.84	0.53	4.25e-32	Platelet distribution width;
LUAD	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg15181151	chr6:150070149	PCMT1	0.42	8.57	0.38	1.98e-16	Lung cancer;
LUAD	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg03233332	chr7:66118400	NA	-0.46	-6.93	-0.32	1.63e-11	Aortic root size;
LUAD	cis	rs9788721	0.900	rs72740964	chr15:78868636	G/A	cg18825076	chr15:78729989	IREB2	-0.55	-8.9	-0.4	1.67e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg24818145	chr4:99064322	C4orf37	0.41	6.91	0.32	1.78e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12681287	0.647	rs2953510	chr8:87341914	T/C	cg27223183	chr8:87520930	FAM82B	-0.68	-9.57	-0.42	8.82e-20	Caudate activity during reward;
LUAD	cis	rs1497828	0.913	rs2810778	chr1:217542793	G/A	cg04411442	chr1:217543379	NA	0.35	6.39	0.3	4.37e-10	Dialysis-related mortality;
LUAD	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg06484146	chr7:12443880	VWDE	-0.59	-7.7	-0.35	1e-13	Coronary artery disease;
LUAD	cis	rs17253792	0.822	rs77599953	chr14:56058905	C/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg21214613	chr1:16344536	HSPB7	0.56	10.11	0.44	1.14e-21	Dilated cardiomyopathy;
LUAD	cis	rs9807989	0.839	rs11695627	chr2:102970105	A/G	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.05e-10	Asthma;
LUAD	cis	rs7017914	0.870	rs34282253	chr8:71582366	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.47	-0.3	2.79e-10	Bone mineral density;
LUAD	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.73	-13.47	-0.55	1.11e-34	Tonsillectomy;
LUAD	cis	rs2274273	0.682	rs10145268	chr14:55504514	T/C	cg04306507	chr14:55594613	LGALS3	0.33	6.76	0.31	4.62e-11	Protein biomarker;
LUAD	cis	rs4243830	1.000	rs11809957	chr1:6584420	C/A	cg05709478	chr1:6581295	PLEKHG5	0.58	6.78	0.31	4.09e-11	Body mass index;
LUAD	cis	rs11971779	0.553	rs11973507	chr7:139099461	A/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.29	0.37	1.55e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg09509183	chr1:209979624	IRF6	0.56	6.65	0.31	8.98e-11	Coronary artery disease;
LUAD	cis	rs7009516	0.669	rs13280953	chr8:24250161	C/T	cg01759110	chr8:24241694	ADAMDEC1	-0.43	-8.51	-0.38	3.06e-16	Hair greying;
LUAD	cis	rs4523957	0.651	rs9895342	chr17:2081647	T/C	cg16513277	chr17:2031491	SMG6	-0.95	-19.02	-0.68	9.65e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg04565464	chr8:145669602	NFKBIL2	0.43	6.56	0.3	1.61e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg11189052	chr15:85197271	WDR73	-0.61	-10.14	-0.44	8.63e-22	P wave terminal force;
LUAD	cis	rs4589502	1.000	rs79390908	chr15:67130924	C/T	cg09911534	chr15:67153556	NA	-0.5	-6.5	-0.3	2.25e-10	Lung cancer (smoking interaction);
LUAD	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg00603274	chr11:61596626	FADS2	-0.37	-6.54	-0.3	1.82e-10	Trans fatty acid levels;
LUAD	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg03467027	chr4:99064603	C4orf37	0.4	6.49	0.3	2.41e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg27532560	chr4:187881888	NA	-0.35	-6.66	-0.31	8.44e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2677744	0.626	rs868547	chr15:91498760	G/A	cg23684204	chr15:91497937	RCCD1	0.42	7.2	0.33	2.78e-12	Attention deficit hyperactivity disorder;
LUAD	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg27211696	chr2:191398769	TMEM194B	-0.68	-8.6	-0.39	1.57e-16	Diastolic blood pressure;
LUAD	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.74	0.31	5.26e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9826463	0.757	rs73240309	chr3:142240223	A/G	cg20824294	chr3:142316082	PLS1	0.42	7.57	0.35	2.42e-13	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg05340658	chr4:99064831	C4orf37	-0.46	-7.51	-0.34	3.57e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg26513180	chr16:89883248	FANCA	0.7	13.2	0.54	1.49e-33	Vitiligo;
LUAD	cis	rs7773004	0.875	rs6456713	chr6:26325843	A/G	cg13736514	chr6:26305472	NA	-0.48	-8.04	-0.36	9.15e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg26408565	chr15:76604113	ETFA	-0.45	-7.42	-0.34	6.37e-13	Blood metabolite levels;
LUAD	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg11663144	chr21:46675770	NA	-0.6	-11.58	-0.49	4.09e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg13012494	chr21:47604986	C21orf56	0.47	7.26	0.33	1.84e-12	Testicular germ cell tumor;
LUAD	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg19000871	chr14:103996768	TRMT61A	0.42	7.25	0.33	1.99e-12	Coronary artery disease;
LUAD	cis	rs7680126	0.633	rs2024280	chr4:10291813	A/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-6.78	-0.31	4.04e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs8112211	0.731	rs3745952	chr19:38818299	C/T	cg01275006	chr19:38876250	GGN	-0.5	-6.47	-0.3	2.77e-10	Blood protein levels;
LUAD	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg03433033	chr1:76189801	ACADM	-0.48	-6.81	-0.31	3.43e-11	Daytime sleep phenotypes;
LUAD	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.68	-0.43	3.74e-20	Life satisfaction;
LUAD	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg08280861	chr8:58055591	NA	0.56	7.53	0.34	3e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19748678	chr4:122722346	EXOSC9	0.43	6.76	0.31	4.64e-11	Type 2 diabetes;
LUAD	cis	rs41271951	0.512	rs12058128	chr1:151106113	C/T	cg11822372	chr1:151115635	SEMA6C	-0.84	-6.98	-0.32	1.14e-11	Blood protein levels;
LUAD	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg07870213	chr5:140052090	DND1	-0.83	-11.39	-0.48	2.15e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg14343924	chr8:8086146	FLJ10661	0.45	7.17	0.33	3.46e-12	Joint mobility (Beighton score);
LUAD	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg02807482	chr3:125708958	NA	-0.67	-9.19	-0.41	1.74e-18	Blood pressure (smoking interaction);
LUAD	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.13	-0.37	4.77e-15	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.3	0.51	6.29e-30	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs5756813	0.705	rs6000886	chr22:38176670	T/C	cg19894588	chr14:64061835	NA	0.55	8.22	0.37	2.5e-15	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs2625529	0.824	rs4411469	chr15:72421689	A/G	cg16672083	chr15:72433130	SENP8	-0.76	-12.77	-0.53	8.31e-32	Red blood cell count;
LUAD	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.92	-0.36	2.08e-14	Prostate cancer;
LUAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg15147215	chr3:52552868	STAB1	-0.41	-7.44	-0.34	5.71e-13	Bipolar disorder;
LUAD	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg15133208	chr4:90757351	SNCA	-0.47	-7.17	-0.33	3.34e-12	Neuroticism;
LUAD	cis	rs9788721	0.836	rs17483721	chr15:78733731	C/T	cg18825076	chr15:78729989	IREB2	0.56	9.89	0.43	7e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg15181151	chr6:150070149	PCMT1	0.39	8.13	0.37	4.7e-15	Lung cancer;
LUAD	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg10876282	chr6:28092338	ZSCAN16	0.46	7.43	0.34	6.22e-13	Parkinson's disease;
LUAD	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg26924012	chr15:45694286	SPATA5L1	0.99	18.3	0.66	1.64e-55	Homoarginine levels;
LUAD	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22857025	chr5:266934	NA	-0.96	-14.33	-0.57	2.98e-38	Breast cancer;
LUAD	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg10544611	chr16:67998164	SLC12A4	-0.62	-7.32	-0.34	1.26e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6076065	0.723	rs1936013	chr20:23363989	A/G	cg11657817	chr20:23433608	CST11	0.49	8.97	0.4	9.79e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg05590025	chr7:65112418	INTS4L2	0.74	7.9	0.36	2.39e-14	Diabetic kidney disease;
LUAD	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg00316803	chr15:76480434	C15orf27	-0.43	-8.54	-0.38	2.45e-16	Blood metabolite levels;
LUAD	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg07741184	chr6:167504864	NA	0.39	8.77	0.39	4.52e-17	Rheumatoid arthritis;
LUAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg11062466	chr8:58055876	NA	0.57	7.96	0.36	1.64e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg21782813	chr7:2030301	MAD1L1	0.55	9.22	0.41	1.44e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-6.9	-0.32	1.88e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg18200150	chr17:30822561	MYO1D	0.72	15.55	0.6	1.93e-43	Schizophrenia;
LUAD	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg10556349	chr10:835070	NA	0.62	8.11	0.37	5.57e-15	Eosinophil percentage of granulocytes;
LUAD	cis	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.9	-0.32	1.93e-11	Triglycerides;
LUAD	trans	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg02030672	chr11:45687055	CHST1	-0.42	-7.76	-0.35	6.26e-14	Obesity-related traits;
LUAD	cis	rs8067545	0.641	rs860335	chr17:19837679	A/G	cg04132472	chr17:19861366	AKAP10	0.39	9.33	0.41	6.2e-19	Schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg22378614	chr19:10981704	CARM1	-0.68	-6.72	-0.31	5.84e-11	Type 2 diabetes;
LUAD	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg10755058	chr3:40428713	ENTPD3	-0.43	-8.32	-0.37	1.26e-15	Renal cell carcinoma;
LUAD	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg21475434	chr5:93447410	FAM172A	0.77	8.06	0.36	7.71e-15	Diabetic retinopathy;
LUAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg14820908	chr5:178986412	RUFY1	0.62	10.71	0.46	7.32e-24	Lung cancer;
LUAD	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg03806693	chr22:41940476	POLR3H	-0.61	-8.58	-0.38	1.88e-16	Vitiligo;
LUAD	trans	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg26043149	chr18:55253948	FECH	-0.49	-8.18	-0.37	3.41e-15	Bone mineral density;
LUAD	cis	rs1387259	0.839	rs7487682	chr12:48579665	A/C	cg04545296	chr12:48745243	ZNF641	-0.35	-9.36	-0.41	4.84e-19	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg19678392	chr7:94953810	PON1	-0.57	-7.86	-0.36	3.15e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2220004	0.507	rs11231560	chr11:55689699	C/G	cg22937354	chr11:55606216	OR5D16	-0.39	-7.22	-0.33	2.44e-12	Odorant perception (&beta-damascenone);
LUAD	trans	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.81	-0.39	3.3e-17	Endometrial cancer;
LUAD	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg06002616	chr8:101225028	SPAG1	-0.37	-7.66	-0.35	1.28e-13	Atrioventricular conduction;
LUAD	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg04455712	chr21:45112962	RRP1B	0.41	8.2	0.37	2.97e-15	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg03676636	chr4:99064102	C4orf37	0.25	6.57	0.3	1.49e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg03709012	chr19:19516395	GATAD2A	0.53	7.04	0.32	7.7e-12	Nonalcoholic fatty liver disease;
LUAD	cis	rs6906287	0.647	rs12207209	chr6:118850375	T/G	cg18833306	chr6:118973337	C6orf204	0.46	8.12	0.37	5.19e-15	Electrocardiographic conduction measures;
LUAD	cis	rs834811	0.831	rs834810	chr7:135879825	T/C	cg01726295	chr7:135938950	NA	0.28	6.89	0.32	2.01e-11	Post-traumatic stress disorder;
LUAD	cis	rs698833	0.852	rs4953092	chr2:44565293	C/T	cg04920474	chr2:44395004	PPM1B	0.4	7.07	0.32	6.62e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg13385794	chr1:248469461	NA	0.25	6.72	0.31	5.89e-11	Common traits (Other);
LUAD	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg06640241	chr16:89574553	SPG7	0.72	12.91	0.53	2.14e-32	Multiple myeloma (IgH translocation);
LUAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.58	-9.47	-0.42	2.01e-19	Renal function-related traits (BUN);
LUAD	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg10518543	chr12:38710700	ALG10B	0.42	6.41	0.3	3.94e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg02221750	chr19:17393354	ANKLE1	-0.78	-12.18	-0.51	1.78e-29	Systemic lupus erythematosus;
LUAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg23978390	chr7:1156363	C7orf50	0.54	8.36	0.38	9.14e-16	Longevity;Endometriosis;
LUAD	trans	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg08071915	chr8:12219732	FAM66A	-0.39	-6.39	-0.3	4.29e-10	Joint mobility (Beighton score);
LUAD	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg10434728	chr15:90938212	IQGAP1	-0.36	-7.29	-0.33	1.57e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs2230307	0.572	rs2810419	chr1:100643968	C/A	cg20868668	chr1:100435035	SLC35A3	-0.52	-7.49	-0.34	3.93e-13	Carotid intima media thickness;
LUAD	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg00634984	chr7:65235879	NA	0.52	7.08	0.33	5.86e-12	Aortic root size;
LUAD	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg05368731	chr17:41323189	NBR1	0.86	16.85	0.63	4.23e-49	Menopause (age at onset);
LUAD	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-14.18	-0.57	1.28e-37	Headache;
LUAD	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg05283184	chr6:79620031	NA	-0.43	-7.66	-0.35	1.28e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg10544611	chr16:67998164	SLC12A4	-0.6	-7.52	-0.34	3.35e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg21226059	chr5:178986404	RUFY1	0.54	9.05	0.4	5.3e-18	Lung cancer;
LUAD	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.32	-0.34	1.22e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs11650175	0.778	rs2024274	chr17:63768955	G/A	cg07283582	chr17:63770753	CCDC46	0.39	7.99	0.36	1.3e-14	Chin dimples;
LUAD	cis	rs12530845	0.945	rs12540273	chr7:135333854	T/G	cg23117316	chr7:135346802	PL-5283	-0.5	-9.21	-0.41	1.49e-18	Red blood cell traits;
LUAD	cis	rs597583	0.806	rs12224853	chr11:117394822	A/G	cg27161313	chr11:117392002	DSCAML1	0.54	9.03	0.4	5.99e-18	Putamen volume;
LUAD	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg24768116	chr2:27665128	KRTCAP3	-0.3	-6.61	-0.31	1.17e-10	Blood metabolite levels;
LUAD	cis	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg02508848	chr16:68573721	ZFP90	-0.42	-6.6	-0.31	1.22e-10	Ulcerative colitis;
LUAD	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg24818145	chr4:99064322	C4orf37	0.42	7.02	0.32	8.66e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg05368731	chr17:41323189	NBR1	0.96	19.61	0.69	2.37e-61	Menopause (age at onset);
LUAD	cis	rs757647	1.000	rs740077	chr5:137760083	A/C	cg10676309	chr5:137685565	NA	0.37	7.05	0.32	7.34e-12	Menarche (age at onset);
LUAD	cis	rs1800682	0.528	rs3903454	chr10:90743434	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.65	11.11	0.48	2.38e-25	Chronic lymphocytic leukemia;
LUAD	cis	rs10411161	0.752	rs10404812	chr19:52400691	T/C	cg22472290	chr19:52391480	ZNF577	0.5	6.46	0.3	2.88e-10	Breast cancer;
LUAD	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg08508325	chr11:3079039	CARS	-0.51	-10.7	-0.46	8.26e-24	Type 2 diabetes;
LUAD	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg27366882	chr3:133540807	NA	0.35	6.36	0.3	5.16e-10	Ankle injury;
LUAD	cis	rs12612619	0.732	rs11679681	chr2:27298479	C/A	cg00617064	chr2:27272375	NA	-0.37	-7.14	-0.33	4.18e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72781680	0.821	rs17045981	chr2:24109316	A/G	cg20701182	chr2:24300061	SF3B14	0.49	6.39	0.3	4.3e-10	Lymphocyte counts;
LUAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg04025307	chr7:1156635	C7orf50	0.62	6.92	0.32	1.72e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg18230493	chr5:56204884	C5orf35	-0.85	-12.28	-0.51	7.32e-30	Initial pursuit acceleration;
LUAD	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg10356904	chr22:49881777	NA	-0.42	-9.06	-0.4	4.97e-18	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg15358701	chr1:161410459	NA	-0.62	-6.46	-0.3	2.89e-10	Rheumatoid arthritis;
LUAD	cis	rs57590327	0.503	rs7618973	chr3:81619588	C/T	cg07356753	chr3:81810745	GBE1	0.52	7.92	0.36	2.15e-14	Extraversion;
LUAD	cis	rs89107	0.551	rs2078383	chr6:118706643	C/T	cg21191810	chr6:118973309	C6orf204	0.4	7.42	0.34	6.55e-13	Cardiac structure and function;
LUAD	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs4713675	0.565	rs1555965	chr6:33677400	A/G	cg13859433	chr6:33739653	LEMD2	-0.3	-7.09	-0.33	5.85e-12	Plateletcrit;
LUAD	cis	rs3791556	0.853	rs12623679	chr2:240126789	G/A	cg03281426	chr2:240109471	HDAC4	0.39	6.95	0.32	1.39e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg09021430	chr5:549028	NA	-0.49	-12.35	-0.51	3.79e-30	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg23625390	chr15:77176239	SCAPER	0.38	6.9	0.32	1.86e-11	Blood metabolite levels;
LUAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-6.99	-0.32	1.06e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg09021430	chr5:549028	NA	-0.68	-13.32	-0.54	4.96e-34	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10992471	1.000	rs10992471	chr9:95559505	A/G	cg14631576	chr9:95140430	CENPP	0.36	7.64	0.35	1.48e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg17264618	chr3:40429014	ENTPD3	0.37	8.09	0.37	6.23e-15	Renal cell carcinoma;
LUAD	cis	rs7833986	0.501	rs2719261	chr8:56941982	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.89	15.59	0.6	1.26e-43	Height;
LUAD	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg04450456	chr4:17643702	FAM184B	0.37	6.96	0.32	1.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg01689657	chr7:91764605	CYP51A1	0.34	8.38	0.38	7.66e-16	Breast cancer;
LUAD	cis	rs7127900	0.583	rs11043142	chr11:2234042	A/G	cg25635251	chr11:2234043	NA	1.04	20.99	0.71	1.44e-67	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
LUAD	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.21e-19	Life satisfaction;
LUAD	cis	rs7192380	0.965	rs7187634	chr16:69663371	T/C	cg00738113	chr16:70207722	CLEC18C	-0.33	-6.75	-0.31	4.75e-11	Sjögren's syndrome;
LUAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg07685180	chr8:600429	NA	0.88	8.7	0.39	7.28e-17	IgG glycosylation;
LUAD	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg13511324	chr14:104056883	C14orf153	0.26	6.49	0.3	2.44e-10	Reticulocyte count;
LUAD	trans	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17712092	chr4:129076599	LARP1B	0.89	17.05	0.64	5.21e-50	Eosinophil percentage of white cells;
LUAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27286337	chr10:134555280	INPP5A	0.73	9.71	0.43	2.92e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg11814155	chr7:99998594	ZCWPW1	0.39	6.82	0.31	3.11e-11	Platelet count;
LUAD	trans	rs9393777	0.920	rs72839445	chr6:27249686	G/A	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.43	-0.45	7.86e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs9902453	0.765	rs34585141	chr17:28336432	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-10.35	-0.45	1.54e-22	Coffee consumption (cups per day);
LUAD	trans	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg14791747	chr16:20752902	THUMPD1	-0.47	-7.21	-0.33	2.68e-12	Dental caries;
LUAD	cis	rs16867321	0.588	rs1919156	chr2:181456978	C/T	cg23363182	chr2:181467187	NA	-0.44	-7.22	-0.33	2.44e-12	Obesity;
LUAD	cis	rs4601821	0.895	rs2155464	chr11:113242448	T/C	cg14159747	chr11:113255604	NA	0.48	8.88	0.4	1.96e-17	Alcoholic chronic pancreatitis;
LUAD	cis	rs4774899	0.934	rs12903578	chr15:57452681	G/A	cg14026238	chr15:57616123	NA	0.34	6.37	0.3	4.8e-10	Urinary tract infection frequency;
LUAD	cis	rs7241530	0.636	rs11875760	chr18:75897285	C/G	cg14642773	chr18:75888474	NA	0.35	6.35	0.3	5.46e-10	Educational attainment (years of education);
LUAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg11062466	chr8:58055876	NA	0.64	8.38	0.38	7.84e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	10.57	0.46	2.51e-23	Type 2 diabetes;
LUAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg08027265	chr7:2291960	NA	-0.43	-7.07	-0.33	6.3e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.38	6.56	0.3	1.55e-10	Type 2 diabetes;
LUAD	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.61	-0.31	1.19e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4072705	1.000	rs7874367	chr9:127377780	A/T	cg13476313	chr9:127244764	NR5A1	-0.32	-7.67	-0.35	1.22e-13	Menarche (age at onset);
LUAD	cis	rs155076	0.666	rs4770128	chr13:21881922	A/G	cg25811766	chr13:21894605	NA	0.62	8.46	0.38	4.33e-16	White matter hyperintensity burden;
LUAD	cis	rs7124681	0.584	rs10769285	chr11:47709212	C/T	cg18512352	chr11:47633146	NA	0.37	6.63	0.31	9.96e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs3784262	1.000	rs4646622	chr15:58257199	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.46	-9.55	-0.42	1.04e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg14345882	chr6:26364793	BTN3A2	0.7	7.15	0.33	3.76e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.22e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg26373071	chr5:1325741	CLPTM1L	0.36	7.54	0.34	2.84e-13	Lung cancer;
LUAD	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg24558204	chr6:135376177	HBS1L	-0.37	-6.4	-0.3	4.03e-10	Red blood cell count;
LUAD	cis	rs1232027	0.656	rs836801	chr5:79984956	A/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.4	-6.4	-0.3	4.25e-10	Huntington's disease progression;
LUAD	cis	rs11650494	0.908	rs74830554	chr17:47431950	G/A	cg08112188	chr17:47440006	ZNF652	0.93	7.85	0.36	3.56e-14	Prostate cancer;
LUAD	cis	rs7647973	1.000	rs6446268	chr3:49445695	G/A	cg07266350	chr3:49460521	AMT;NICN1	0.36	6.41	0.3	3.93e-10	Menarche (age at onset);
LUAD	cis	rs677665	0.722	rs10746487	chr1:9338689	T/C	cg25755851	chr1:9335794	NA	-0.63	-10.13	-0.44	9.83e-22	Eosinophil percentage of white cells;
LUAD	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	13.02	0.53	7.9e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.69	0.31	6.95e-11	Parkinson's disease;
LUAD	trans	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.27	-0.37	1.72e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg18621852	chr3:10150065	C3orf24	0.48	8.38	0.38	8.14e-16	Alzheimer's disease;
LUAD	cis	rs113835537	0.808	rs10896128	chr11:66324529	G/A	cg24851651	chr11:66362959	CCS	0.57	8.27	0.37	1.71e-15	Airway imaging phenotypes;
LUAD	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-11.55	-0.49	5.01e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg18110333	chr6:292329	DUSP22	-0.79	-13.37	-0.55	2.86e-34	Menopause (age at onset);
LUAD	cis	rs7267979	0.932	rs1985737	chr20:25591468	T/A	cg08601574	chr20:25228251	PYGB	0.45	8.21	0.37	2.63e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg21211680	chr2:198530	NA	-0.53	-6.45	-0.3	3.15e-10	Blood protein levels;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg03639675	chr16:46723204	ORC6L;VPS35	-0.47	-6.86	-0.32	2.47e-11	Blood protein levels;
LUAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.75	-9.22	-0.41	1.39e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg22029157	chr1:209979665	IRF6	0.8	9.71	0.43	3.05e-20	Cleft lip with or without cleft palate;
LUAD	cis	rs8017423	0.967	rs2149655	chr14:90707246	T/C	cg14092571	chr14:90743983	NA	-0.49	-8.75	-0.39	5.11e-17	Mortality in heart failure;
LUAD	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg15704280	chr7:45808275	SEPT13	-0.6	-9.72	-0.43	2.68e-20	Coronary artery disease;
LUAD	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg20503657	chr10:835505	NA	0.74	9.6	0.42	7.42e-20	Eosinophil percentage of granulocytes;
LUAD	cis	rs80319144	1.000	rs76136261	chr2:159274969	G/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.9	0.32	1.88e-11	Restless legs syndrome;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25886382	chr13:26760664	NA	-0.53	-6.44	-0.3	3.17e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg21433313	chr16:3507492	NAT15	0.78	8.03	0.36	1.01e-14	Tuberculosis;
LUAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg11062466	chr8:58055876	NA	0.86	10.51	0.45	4.28e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.48	-0.34	4.28e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3849570	0.533	rs6809793	chr3:81990089	C/T	cg07356753	chr3:81810745	GBE1	-0.5	-8.34	-0.38	1.05e-15	Waist circumference;Body mass index;
LUAD	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg21252483	chr19:49399788	TULP2	-0.88	-14.31	-0.57	3.61e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg15485101	chr11:133734466	NA	0.34	7.63	0.35	1.59e-13	Childhood ear infection;
LUAD	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg02782426	chr3:40428986	ENTPD3	0.44	9.18	0.41	1.96e-18	Renal cell carcinoma;
LUAD	cis	rs55728055	0.661	rs16989334	chr22:32016092	A/G	cg01338084	chr22:32026380	PISD	0.8	6.61	0.31	1.18e-10	Age-related hearing impairment;
LUAD	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg23992470	chr4:843637	GAK	0.66	6.99	0.32	1.06e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg00316803	chr15:76480434	C15orf27	0.41	7.75	0.35	6.97e-14	Blood metabolite levels;
LUAD	cis	rs2835872	0.965	rs2835850	chr21:39012977	A/G	cg06728970	chr21:39037746	KCNJ6	-0.35	-6.41	-0.3	3.89e-10	Electroencephalographic traits in alcoholism;
LUAD	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg00898013	chr13:113819073	PROZ	-0.68	-11.86	-0.5	3.38e-28	Platelet distribution width;
LUAD	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg05340658	chr4:99064831	C4orf37	0.46	7.52	0.34	3.28e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs151234	0.741	rs11074908	chr16:28608356	C/T	cg04643524	chr16:28609220	SULT1A2	0.57	7.61	0.35	1.77e-13	Platelet distribution width;
LUAD	cis	rs2016266	0.684	rs4759021	chr12:53714868	G/A	cg26875137	chr12:53738046	NA	-0.34	-6.64	-0.31	9.49e-11	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.81	0.35	4.68e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg18110333	chr6:292329	DUSP22	-0.76	-12.84	-0.53	4.13e-32	Menopause (age at onset);
LUAD	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg18132916	chr6:79620363	NA	-0.45	-7.68	-0.35	1.11e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs454510	1.000	rs422647	chr1:120195840	T/C	cg16322792	chr1:120165303	ZNF697	0.45	8.06	0.36	7.98e-15	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg06547715	chr2:218990976	CXCR2	0.4	9.22	0.41	1.41e-18	Ulcerative colitis;
LUAD	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg02975922	chr3:195473998	MUC4	-0.42	-7.09	-0.33	5.51e-12	Pancreatic cancer;
LUAD	cis	rs62025270	0.547	rs1026722	chr15:86119399	C/T	cg13263323	chr15:86062960	AKAP13	-0.45	-6.98	-0.32	1.14e-11	Idiopathic pulmonary fibrosis;
LUAD	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg17971929	chr21:40555470	PSMG1	-0.41	-6.51	-0.3	2.08e-10	Cognitive function;
LUAD	cis	rs2230307	0.656	rs531174	chr1:100485988	G/T	cg20868668	chr1:100435035	SLC35A3	0.63	7.58	0.35	2.23e-13	Carotid intima media thickness;
LUAD	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.39	-0.38	7.54e-16	Neutrophil percentage of white cells;
LUAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg11062466	chr8:58055876	NA	0.82	10.33	0.45	1.79e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs8038465	0.622	rs62004587	chr15:73859016	A/C	cg15420318	chr15:73925796	NPTN	0.46	7.44	0.34	5.8e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg11663144	chr21:46675770	NA	-0.62	-12.13	-0.51	2.97e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg00510787	chr6:151772946	C6orf211;RMND1	0.47	7.77	0.35	6.19e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2224391	0.628	rs2773299	chr6:5242169	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.92	-0.36	2.11e-14	Height;
LUAD	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg08645402	chr16:4508243	NA	0.57	10.82	0.47	2.99e-24	Schizophrenia;
LUAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.71e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg03929089	chr4:120376271	NA	-0.45	-6.95	-0.32	1.38e-11	HDL cholesterol;
LUAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg18621852	chr3:10150065	C3orf24	0.48	8.47	0.38	4.1e-16	Alzheimer's disease;
LUAD	cis	rs79349575	0.716	rs595767	chr17:46957987	A/G	cg22482690	chr17:47019901	SNF8	0.4	7.41	0.34	7.14e-13	Type 2 diabetes;
LUAD	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg07606381	chr6:8435919	SLC35B3	0.42	7.12	0.33	4.65e-12	Motion sickness;
LUAD	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.42	-8.26	-0.37	1.85e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg08601574	chr20:25228251	PYGB	-0.46	-8.79	-0.39	3.76e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg27124370	chr19:33622961	WDR88	-0.4	-6.42	-0.3	3.58e-10	Bone properties (heel);
LUAD	cis	rs929596	0.561	rs7564935	chr2:234645186	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.64	-11.29	-0.48	5.31e-26	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs17683430	0.681	rs12157575	chr22:32543338	T/C	cg00543991	chr22:32367038	NA	0.64	6.95	0.32	1.37e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LUAD	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg15017067	chr4:17643749	FAM184B	0.36	7.16	0.33	3.57e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7731657	0.537	rs6595978	chr5:130335009	G/A	cg08523029	chr5:130500466	HINT1	0.56	7.39	0.34	7.72e-13	Fasting plasma glucose;
LUAD	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg21918786	chr6:109611834	NA	-0.6	-11.01	-0.47	5.62e-25	Reticulocyte fraction of red cells;
LUAD	trans	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg24644049	chr4:85504048	CDS1	0.88	7.16	0.33	3.55e-12	Skin colour saturation;
LUAD	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg06627628	chr2:24431161	ITSN2	0.54	9.21	0.41	1.55e-18	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00166722	chr3:10149974	C3orf24	0.75	12.76	0.53	9.16e-32	Alzheimer's disease;
LUAD	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg14668632	chr7:2872130	GNA12	-0.47	-8.32	-0.38	1.2e-15	Height;
LUAD	cis	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg02240030	chr7:2089880	MAD1L1	0.32	6.43	0.3	3.36e-10	Neuroticism;
LUAD	cis	rs59698941	0.943	rs73259116	chr5:132218461	A/G	cg14825688	chr5:132208181	LEAP2	-0.47	-6.7	-0.31	6.62e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06544989	chr22:39130855	UNC84B	0.37	6.93	0.32	1.54e-11	Menopause (age at onset);
LUAD	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.0	-0.4	7.52e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.24	0.33	2.07e-12	Tonsillectomy;
LUAD	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.3	7.65	0.35	1.38e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg14092988	chr3:52407081	DNAH1	0.44	8.86	0.4	2.16e-17	Bipolar disorder;
LUAD	trans	rs8002861	0.727	rs9525852	chr13:44405197	G/C	cg12856521	chr11:46389249	DGKZ	-0.48	-8.35	-0.38	9.67e-16	Leprosy;
LUAD	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg03929089	chr4:120376271	NA	-0.92	-17.46	-0.65	8.02e-52	Coronary artery disease;
LUAD	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.22	-0.54	1.18e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs62283056	0.512	rs1079215	chr4:6282393	A/G	cg14416269	chr4:6271139	WFS1	0.59	11.04	0.47	4.49e-25	Cisplatin-induced ototoxicity;
LUAD	cis	rs367615	0.918	rs10054960	chr5:108866448	C/A	cg17395555	chr5:108820864	NA	0.55	9.29	0.41	7.95e-19	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg26384229	chr12:38710491	ALG10B	0.48	7.69	0.35	1.02e-13	Bladder cancer;
LUAD	cis	rs4786125	0.920	rs6500852	chr16:6896649	A/G	cg03623568	chr16:6915990	A2BP1	-0.4	-8.32	-0.37	1.24e-15	Heart rate variability traits (SDNN);
LUAD	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-8.66	-0.39	1.03e-16	Hemoglobin concentration;
LUAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg12365402	chr11:9010492	NRIP3	-0.49	-9.83	-0.43	1.16e-20	Hemoglobin concentration;
LUAD	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg03948781	chr1:205179583	DSTYK	0.34	6.47	0.3	2.79e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	9.26	0.41	1.04e-18	Melanoma;
LUAD	cis	rs9372498	0.505	rs9489462	chr6:118927855	C/T	cg07617317	chr6:118971624	C6orf204	0.55	8.33	0.38	1.11e-15	Diastolic blood pressure;
LUAD	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg18132916	chr6:79620363	NA	-0.44	-7.57	-0.35	2.42e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg22906224	chr7:99728672	NA	0.57	9.34	0.41	5.6e-19	Coronary artery disease;
LUAD	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg21153622	chr11:89784906	NA	-0.33	-6.38	-0.3	4.78e-10	Coronary artery disease;
LUAD	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg00383909	chr3:49044727	WDR6	0.76	8.62	0.39	1.32e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg07952391	chr2:88470173	THNSL2	0.78	8.44	0.38	5.29e-16	Plasma clusterin levels;
LUAD	cis	rs3784262	0.565	rs9635346	chr15:58298118	C/G	cg12031962	chr15:58353849	ALDH1A2	0.37	7.15	0.33	3.78e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg14664628	chr15:75095509	CSK	-0.6	-9.58	-0.42	8.39e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs10739663	0.520	rs2819624	chr9:128156519	A/G	cg14078157	chr9:128172775	NA	-0.45	-8.53	-0.38	2.72e-16	Resting heart rate;
LUAD	cis	rs12348691	0.503	rs894672	chr9:100612185	C/T	cg13688889	chr9:100608707	NA	-0.63	-10.31	-0.45	2.22e-22	Alopecia areata;
LUAD	cis	rs11958404	0.615	rs7737601	chr5:157448269	C/T	cg05962755	chr5:157440814	NA	-0.43	-8.16	-0.37	3.76e-15	IgG glycosylation;
LUAD	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg15428835	chr7:75027521	TRIM73;TRIM74	0.38	6.44	0.3	3.17e-10	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg16102102	chr5:83017553	HAPLN1	-0.77	-13.03	-0.54	7.49e-33	Prostate cancer;
LUAD	cis	rs11811982	0.793	rs114312101	chr1:227303589	T/A	cg24860534	chr1:227506868	CDC42BPA	0.68	6.7	0.31	6.73e-11	Optic disc area;
LUAD	cis	rs17433780	0.928	rs10922533	chr1:89456659	C/G	cg09516651	chr1:89888402	LOC400759	0.49	8.75	0.39	5.06e-17	Carotid intima media thickness;
LUAD	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg26384229	chr12:38710491	ALG10B	0.45	7.33	0.34	1.18e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2019216	0.542	rs3829569	chr17:21909222	T/C	cg22648282	chr17:21454238	C17orf51	-0.43	-7.73	-0.35	7.92e-14	Pelvic organ prolapse;
LUAD	cis	rs9814567	0.752	rs4955544	chr3:134332776	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.95	-0.53	1.52e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-10.06	-0.44	1.69e-21	Platelet distribution width;
LUAD	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22857025	chr5:266934	NA	-0.95	-14.05	-0.56	4.32e-37	Breast cancer;
LUAD	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg10591111	chr5:226296	SDHA	-0.54	-7.03	-0.32	8.29e-12	Breast cancer;
LUAD	cis	rs3815700	1.000	rs8109768	chr19:33095463	A/G	cg02997394	chr19:33096574	ANKRD27	0.66	8.61	0.39	1.5e-16	Eosinophilic esophagitis;
LUAD	cis	rs829883	1.000	rs249839	chr12:98872364	T/C	cg25150519	chr12:98850993	NA	0.67	11.18	0.48	1.3e-25	Colorectal adenoma (advanced);
LUAD	trans	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.63	10.53	0.46	3.6e-23	Endometrial cancer;
LUAD	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.98	0.36	1.38e-14	Lung cancer;
LUAD	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg22920501	chr2:26401640	FAM59B	0.65	9.37	0.41	4.52e-19	Gut microbiome composition (summer);
LUAD	cis	rs1595825	0.838	rs57437055	chr2:198782617	A/C	cg10547527	chr2:198650123	BOLL	-0.53	-7.64	-0.35	1.45e-13	Ulcerative colitis;
LUAD	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg25208724	chr1:156163844	SLC25A44	1.16	25.93	0.78	1.9e-89	Testicular germ cell tumor;
LUAD	cis	rs9467160	1.000	rs9467160	chr6:24441746	C/T	cg16211469	chr6:24423932	MRS2	0.41	6.65	0.31	8.93e-11	Liver enzyme levels;
LUAD	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg07332563	chr6:291687	DUSP22	-0.48	-8.22	-0.37	2.6e-15	Menopause (age at onset);
LUAD	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg14227996	chr4:17616232	MED28	0.71	7.38	0.34	8.62e-13	Opioid sensitivity;
LUAD	cis	rs7192380	0.756	rs12596945	chr16:69780819	C/A	cg26679644	chr16:69762563	NA	-0.45	-8.32	-0.37	1.27e-15	Sjögren's syndrome;
LUAD	cis	rs7107174	1.000	rs10899478	chr11:78052238	C/T	cg19901956	chr11:77921274	USP35	-0.51	-7.12	-0.33	4.81e-12	Testicular germ cell tumor;
LUAD	cis	rs8099014	1.000	rs3744868	chr18:56123059	C/T	cg12907477	chr18:56117327	MIR122	0.39	6.69	0.31	7.15e-11	Platelet count;
LUAD	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.16	-0.33	3.64e-12	Breast cancer;
LUAD	cis	rs8017423	0.935	rs4643251	chr14:90669256	C/T	cg14092571	chr14:90743983	NA	0.47	8.07	0.37	7.17e-15	Mortality in heart failure;
LUAD	cis	rs3540	0.960	rs1505936	chr15:91010776	T/C	cg10434728	chr15:90938212	IQGAP1	0.36	6.65	0.31	9.18e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-6.97	-0.32	1.24e-11	Personality dimensions;
LUAD	cis	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg08601574	chr20:25228251	PYGB	-0.46	-8.53	-0.38	2.58e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg00071950	chr4:10020882	SLC2A9	0.85	18.34	0.67	1.08e-55	Bone mineral density;
LUAD	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.13	-0.37	4.77e-15	Total body bone mineral density;
LUAD	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg02049041	chr17:27085579	C17orf63	0.66	8.78	0.39	4.02e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg26343298	chr8:95960752	TP53INP1	0.4	8.5	0.38	3.22e-16	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1215050	0.791	rs6813619	chr4:98830768	C/T	cg24818145	chr4:99064322	C4orf37	-0.42	-7.07	-0.32	6.56e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg18827107	chr12:86230957	RASSF9	-0.49	-8.67	-0.39	9.15e-17	Major depressive disorder;
LUAD	cis	rs7192380	0.965	rs3848278	chr16:69640867	T/C	cg26679644	chr16:69762563	NA	0.48	9.43	0.42	2.8e-19	Sjögren's syndrome;
LUAD	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg17264618	chr3:40429014	ENTPD3	0.37	7.89	0.36	2.69e-14	Renal cell carcinoma;
LUAD	cis	rs1395	0.813	rs11685326	chr2:27453679	A/G	cg23587288	chr2:27483067	SLC30A3	-0.4	-7.68	-0.35	1.12e-13	Blood metabolite levels;
LUAD	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg25237894	chr2:233734115	C2orf82	-0.41	-7.76	-0.35	6.23e-14	Coronary artery disease;
LUAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg08027265	chr7:2291960	NA	-0.43	-7.17	-0.33	3.36e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7827545	1.000	rs6578229	chr8:135562453	T/G	cg17885191	chr8:135476712	NA	0.49	7.76	0.35	6.59e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs757647	0.680	rs4835789	chr5:137739040	A/T	cg10676309	chr5:137685565	NA	0.42	7.17	0.33	3.4e-12	Menarche (age at onset);
LUAD	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg11693508	chr17:37793320	STARD3	0.83	10.52	0.46	3.78e-23	Bipolar disorder;
LUAD	cis	rs2637266	1.000	rs7080883	chr10:78361200	A/G	cg18941641	chr10:78392320	NA	0.33	6.84	0.32	2.74e-11	Pulmonary function;
LUAD	cis	rs6881634	0.501	rs6453392	chr5:77757544	G/T	cg11547950	chr5:77652471	NA	-0.35	-6.38	-0.3	4.74e-10	Hippocampal atrophy;
LUAD	cis	rs89107	0.531	rs1690662	chr6:118612354	A/G	cg21191810	chr6:118973309	C6orf204	0.53	10.85	0.47	2.28e-24	Cardiac structure and function;
LUAD	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg01028140	chr2:1542097	TPO	-0.41	-6.8	-0.31	3.67e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs1044826	0.619	rs57357132	chr3:139118358	A/T	cg00490450	chr3:139108681	COPB2	-0.44	-6.99	-0.32	1.07e-11	Obesity-related traits;
LUAD	cis	rs898097	0.567	rs8076119	chr17:80910061	A/G	cg15664640	chr17:80829946	TBCD	0.59	11.1	0.48	2.63e-25	Breast cancer;
LUAD	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg02428538	chr16:24856791	SLC5A11	-0.51	-7.11	-0.33	4.98e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg18512352	chr11:47633146	NA	-0.42	-7.26	-0.33	1.89e-12	Subjective well-being;
LUAD	cis	rs13315871	1.000	rs9862969	chr3:58341917	A/G	cg12435725	chr3:58293450	RPP14	-0.71	-7.89	-0.36	2.57e-14	Cholesterol, total;
LUAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg01246254	chr10:124134882	PLEKHA1	-0.43	-7.01	-0.32	9.49e-12	Schizophrenia;
LUAD	cis	rs6594713	0.533	rs67693282	chr5:112980912	C/T	cg12552261	chr5:112820674	MCC	0.51	6.51	0.3	2.19e-10	Brain cytoarchitecture;
LUAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg00106254	chr7:1943704	MAD1L1	-0.63	-9.73	-0.43	2.52e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs7000551	0.751	rs2449348	chr8:22359572	C/T	cg12081754	chr8:22256438	SLC39A14	0.44	7.34	0.34	1.11e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg02782426	chr3:40428986	ENTPD3	0.42	9.39	0.42	3.69e-19	Renal cell carcinoma;
LUAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.62	0.55	2.7e-35	Prudent dietary pattern;
LUAD	cis	rs9394841	0.667	rs9357366	chr6:41786976	T/G	cg25600774	chr6:41776562	USP49	-0.42	-6.56	-0.3	1.58e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs2992756	0.663	rs2992764	chr1:18804144	A/G	cg14356550	chr1:18808102	KLHDC7A	0.57	10.15	0.44	8.57e-22	Breast cancer;
LUAD	cis	rs2731664	0.721	rs2450333	chr5:176899546	G/A	cg23176889	chr5:176863531	GRK6	-0.72	-13.89	-0.56	2.08e-36	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg22907277	chr7:1156413	C7orf50	0.71	8.31	0.37	1.29e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg13616963	chr3:57583610	ARF4	0.41	6.65	0.31	8.85e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.22	0.33	2.51e-12	Menopause (age at onset);
LUAD	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg22166914	chr1:53195759	ZYG11B	-0.4	-6.61	-0.31	1.17e-10	Monocyte count;
LUAD	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg24069376	chr3:38537580	EXOG	0.45	10.91	0.47	1.33e-24	Electrocardiographic conduction measures;
LUAD	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg12365402	chr11:9010492	NRIP3	0.47	8.88	0.4	1.96e-17	Hemoglobin concentration;
LUAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	7.81	0.36	4.52e-14	Alzheimer's disease;
LUAD	trans	rs1406428	0.573	rs12613632	chr2:51705755	C/G	cg25485084	chr12:118809325	TAOK3	0.42	6.79	0.31	3.7e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg06558623	chr16:89946397	TCF25	1.18	10.49	0.45	4.78e-23	Skin colour saturation;
LUAD	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg15704280	chr7:45808275	SEPT13	0.65	8.59	0.39	1.68e-16	Axial length;
LUAD	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg02807482	chr3:125708958	NA	-0.64	-8.53	-0.38	2.56e-16	Blood pressure (smoking interaction);
LUAD	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg00666640	chr1:248458726	OR2T12	0.31	7.6	0.35	1.96e-13	Common traits (Other);
LUAD	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg24503407	chr1:205819492	PM20D1	-0.56	-9.98	-0.44	3.43e-21	Menarche (age at onset);
LUAD	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg26597838	chr10:835615	NA	0.95	14.09	0.57	2.97e-37	Eosinophil percentage of granulocytes;
LUAD	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.5	-0.3	2.29e-10	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.65	11.98	0.5	1.15e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6484504	0.532	rs2774403	chr11:31320530	A/T	cg26647111	chr11:31128758	NA	0.43	7.55	0.34	2.63e-13	Red blood cell count;
LUAD	cis	rs2692947	0.727	rs893173	chr2:96789787	T/C	cg23100626	chr2:96804247	ASTL	0.37	10.31	0.45	2.19e-22	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg25753631	chr6:25732923	NA	-0.44	-7.76	-0.35	6.26e-14	Iron status biomarkers;
LUAD	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11890956	chr21:40555474	PSMG1	0.72	11.96	0.5	1.29e-28	Cognitive function;
LUAD	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg20503657	chr10:835505	NA	1.25	18.94	0.68	2.28e-58	Eosinophil percentage of granulocytes;
LUAD	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg12179176	chr11:130786555	SNX19	0.55	9.29	0.41	8.21e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg08999081	chr20:33150536	PIGU	0.47	9.21	0.41	1.56e-18	Coronary artery disease;
LUAD	cis	rs11229555	0.645	rs4579945	chr11:58190873	T/C	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg15485101	chr11:133734466	NA	0.37	7.97	0.36	1.52e-14	Childhood ear infection;
LUAD	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg20476274	chr7:133979776	SLC35B4	0.82	16.5	0.63	1.4e-47	Mean platelet volume;
LUAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs13315871	1.000	rs4075403	chr3:58411445	G/C	cg12435725	chr3:58293450	RPP14	-0.69	-7.66	-0.35	1.31e-13	Cholesterol, total;
LUAD	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg07617317	chr6:118971624	C6orf204	0.54	8.46	0.38	4.34e-16	Renal cell carcinoma;
LUAD	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg23231163	chr10:75533350	FUT11	-0.53	-9.69	-0.43	3.44e-20	Inflammatory bowel disease;
LUAD	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg15445000	chr17:37608096	MED1	0.45	8.28	0.37	1.62e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs4689388	0.793	rs4234731	chr4:6299914	A/G	cg00701064	chr4:6280414	WFS1	0.66	13.82	0.56	4.15e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg04352962	chr1:209979756	IRF6	0.51	6.5	0.3	2.21e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg13385794	chr1:248469461	NA	0.25	6.81	0.31	3.26e-11	Common traits (Other);
LUAD	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg00922110	chr4:57842668	C4orf14	-0.41	-6.78	-0.31	3.97e-11	Response to bleomycin (chromatid breaks);
LUAD	cis	rs7173743	0.756	rs4551997	chr15:79130433	G/A	cg15571903	chr15:79123663	NA	0.42	8.39	0.38	7.27e-16	Coronary artery disease;
LUAD	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg08999081	chr20:33150536	PIGU	0.46	8.87	0.4	2.03e-17	Coronary artery disease;
LUAD	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg08761264	chr16:28874980	SH2B1	-0.45	-6.87	-0.32	2.34e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.06	0.32	6.98e-12	Menopause (age at onset);
LUAD	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg02880119	chr16:3481970	NA	-0.54	-8.31	-0.37	1.34e-15	Body mass index (adult);
LUAD	cis	rs4730250	0.707	rs6960148	chr7:106786142	A/G	cg02696742	chr7:106810147	HBP1	0.82	10.9	0.47	1.49e-24	Osteoarthritis;
LUAD	cis	rs2404618	0.624	rs28439223	chr8:1476901	C/G	cg02903104	chr8:1507517	DLGAP2	0.33	7.05	0.32	7.43e-12	Lung cancer;
LUAD	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg08999081	chr20:33150536	PIGU	-0.63	-13.99	-0.56	7.79e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs11098699	0.784	rs13150998	chr4:124245073	T/C	cg09941581	chr4:124220074	SPATA5	0.42	6.66	0.31	8.48e-11	Mosquito bite size;
LUAD	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg11901034	chr3:128598214	ACAD9	-0.55	-8.75	-0.39	5.24e-17	IgG glycosylation;
LUAD	cis	rs2268241	0.938	rs17878783	chr21:34779185	G/A	cg14850771	chr21:34775459	IFNGR2	0.58	6.78	0.31	4.11e-11	Obesity-related traits;
LUAD	cis	rs8177876	0.642	rs12445303	chr16:81115573	A/G	cg08591886	chr16:81111003	C16orf46	0.68	6.61	0.31	1.17e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs131777	0.545	rs131759	chr22:51015481	G/A	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	0.36	6.62	0.31	1.07e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg13352455	chr3:53230110	NA	-0.65	-6.64	-0.31	9.82e-11	Type 2 diabetes;
LUAD	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.31	-7.33	-0.34	1.21e-12	Prostate cancer;
LUAD	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg03806693	chr22:41940476	POLR3H	-0.46	-6.51	-0.3	2.13e-10	Vitiligo;
LUAD	cis	rs8099014	0.906	rs4940693	chr18:56101171	T/G	cg12907477	chr18:56117327	MIR122	0.51	8.13	0.37	4.94e-15	Platelet count;
LUAD	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg14019146	chr3:50243930	SLC38A3	0.55	11.05	0.47	3.98e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs11971779	0.680	rs6467840	chr7:139065401	A/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.76	0.31	4.63e-11	Diisocyanate-induced asthma;
LUAD	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg22875332	chr1:76189707	ACADM	-0.68	-10.73	-0.46	6.68e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg02176678	chr2:219576539	TTLL4	0.6	11.68	0.49	1.61e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg24579218	chr15:68104479	NA	-0.53	-8.53	-0.38	2.6e-16	Obesity;
LUAD	cis	rs11048434	0.736	rs2041625	chr12:9112005	C/T	cg13575925	chr12:9217583	LOC144571	0.38	7.22	0.33	2.49e-12	Sjögren's syndrome;
LUAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg10360139	chr7:1886902	MAD1L1	-0.39	-6.35	-0.3	5.45e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6761276	0.899	rs11693750	chr2:113835602	C/T	cg06383401	chr2:113825234	IL1F10	-0.3	-6.41	-0.3	3.97e-10	Protein quantitative trait loci;
LUAD	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg25036284	chr2:26402008	FAM59B	0.65	8.22	0.37	2.51e-15	Gut microbiome composition (summer);
LUAD	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.47	-0.34	4.72e-13	Bipolar disorder;
LUAD	cis	rs1595825	1.000	rs6434950	chr2:198869979	A/G	cg10547527	chr2:198650123	BOLL	-0.47	-6.63	-0.31	1.03e-10	Ulcerative colitis;
LUAD	trans	rs62458065	0.850	rs10273165	chr7:32460840	G/A	cg00845942	chr12:64062724	DPY19L2	-0.51	-6.72	-0.31	5.85e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg00898013	chr13:113819073	PROZ	0.82	14.9	0.59	1.17e-40	Platelet distribution width;
LUAD	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs11811982	0.744	rs115766366	chr1:227520001	C/T	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic disc area;
LUAD	cis	rs7561273	0.609	rs2160943	chr2:24288775	G/A	cg20701182	chr2:24300061	SF3B14	0.41	6.81	0.31	3.33e-11	Quantitative traits;
LUAD	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg18512352	chr11:47633146	NA	-0.56	-9.94	-0.44	4.49e-21	Subjective well-being;
LUAD	cis	rs13082711	0.522	rs7651661	chr3:27362773	G/C	cg02860705	chr3:27208620	NA	0.51	8.48	0.38	3.94e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.45e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.76	-0.31	4.69e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg19610905	chr11:61596333	FADS2	-0.67	-11.24	-0.48	7.79e-26	Trans fatty acid levels;
LUAD	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg00383909	chr3:49044727	WDR6	0.91	10.01	0.44	2.64e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs57920188	0.513	rs4290031	chr1:4094701	A/G	cg10510935	chr1:4059661	NA	0.44	6.8	0.31	3.6e-11	Interleukin-17 levels;
LUAD	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.32	7.46	0.34	5.09e-13	Prostate cancer;
LUAD	cis	rs62400317	0.859	rs12201555	chr6:45294400	T/A	cg18551225	chr6:44695536	NA	-0.55	-8.69	-0.39	7.9e-17	Total body bone mineral density;
LUAD	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg03929089	chr4:120376271	NA	0.82	13.09	0.54	4.3e-33	Height;
LUAD	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg10556349	chr10:835070	NA	0.57	7.07	0.33	6.4e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg20019720	chr6:154832845	CNKSR3	0.54	11.44	0.49	1.36e-26	Lipoprotein (a) levels;
LUAD	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg17366294	chr4:99064904	C4orf37	-0.51	-9.03	-0.4	5.91e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg07266350	chr3:49460521	AMT;NICN1	-0.38	-6.68	-0.31	7.47e-11	Menarche (age at onset);
LUAD	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg25427524	chr10:38739819	LOC399744	0.56	9.97	0.44	3.59e-21	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs8060686	0.858	rs7187289	chr16:67967878	A/C	cg27539214	chr16:67997921	SLC12A4	-0.44	-6.57	-0.3	1.44e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg13180566	chr4:1052158	NA	0.4	6.59	0.31	1.27e-10	Recombination rate (females);
LUAD	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg00495681	chr13:53174319	NA	0.7	13.82	0.56	4.14e-36	Lewy body disease;
LUAD	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.06e-11	Depression;
LUAD	cis	rs12208915	0.945	rs12214796	chr6:79561068	T/C	cg09184832	chr6:79620586	NA	0.53	6.42	0.3	3.56e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg23649088	chr2:200775458	C2orf69	0.62	7.74	0.35	7.23e-14	Schizophrenia;
LUAD	cis	rs73206853	0.841	rs56324794	chr12:111086449	T/A	cg12870014	chr12:110450643	ANKRD13A	0.61	6.8	0.31	3.68e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs8002861	0.905	rs12875768	chr13:44428305	C/T	cg12856521	chr11:46389249	DGKZ	-0.38	-6.41	-0.3	3.83e-10	Leprosy;
LUAD	cis	rs1232027	0.666	rs1650701	chr5:79944431	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-7.99	-0.36	1.31e-14	Huntington's disease progression;
LUAD	cis	rs2455601	0.786	rs3751064	chr11:8958903	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-7.66	-0.35	1.28e-13	Schizophrenia;
LUAD	cis	rs3087591	0.960	rs4263003	chr17:29438508	G/T	cg24425628	chr17:29625626	OMG;NF1	0.46	7.28	0.33	1.68e-12	Hip circumference;
LUAD	cis	rs494562	0.730	rs313204	chr6:86114296	C/A	cg21730993	chr6:86159210	NT5E	0.58	6.79	0.31	3.76e-11	Blood metabolite levels;Metabolic traits;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18342900	chr16:46865048	C16orf87	-0.43	-6.78	-0.31	3.95e-11	Height;
LUAD	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg18811423	chr2:55921094	PNPT1	0.53	8.85	0.4	2.43e-17	Metabolic syndrome;
LUAD	cis	rs7737355	0.773	rs31589	chr5:131004646	G/A	cg06307176	chr5:131281290	NA	0.44	7.25	0.33	2e-12	Life satisfaction;
LUAD	cis	rs9399401	0.961	rs7774095	chr6:142670862	C/A	cg03128060	chr6:142623767	GPR126	0.3	6.56	0.3	1.55e-10	Chronic obstructive pulmonary disease;
LUAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.39	-0.38	7.58e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg21856205	chr7:94953877	PON1	-0.53	-7.18	-0.33	3.2e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg01657329	chr11:68192670	LRP5	-0.47	-8.27	-0.37	1.71e-15	Total body bone mineral density;
LUAD	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg06547715	chr2:218990976	CXCR2	0.43	10.51	0.45	4.22e-23	Ulcerative colitis;
LUAD	cis	rs10979	0.597	rs9484776	chr6:143906325	T/C	cg25407410	chr6:143891975	LOC285740	-0.56	-7.81	-0.35	4.66e-14	Hypospadias;
LUAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg09033563	chr22:24373618	LOC391322	-0.55	-8.83	-0.39	2.85e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4462272	0.503	rs11596076	chr10:101845434	A/G	cg19754520	chr10:101825118	CPN1	-0.33	-7.14	-0.33	4.17e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg15557168	chr22:42548783	NA	-0.56	-10.95	-0.47	1e-24	Schizophrenia;
LUAD	cis	rs74181299	0.964	rs2540948	chr2:65284623	T/C	cg05010058	chr2:65284262	CEP68	0.31	6.65	0.31	8.82e-11	Pulse pressure;
LUAD	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg14092571	chr14:90743983	NA	0.47	8.0	0.36	1.18e-14	Mortality in heart failure;
LUAD	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg24675056	chr1:15929824	NA	-0.47	-8.38	-0.38	8.11e-16	Systolic blood pressure;
LUAD	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.4e-15	Prostate cancer;
LUAD	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03264133	chr6:25882463	NA	-0.5	-7.5	-0.34	3.78e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg02753203	chr1:228287806	NA	0.81	15.57	0.6	1.51e-43	Diastolic blood pressure;
LUAD	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg23815491	chr16:72088622	HP	0.58	10.85	0.47	2.3e-24	Fibrinogen levels;
LUAD	cis	rs62229266	0.647	rs59397717	chr21:37451725	C/T	cg08632701	chr21:37451849	NA	-0.68	-12.37	-0.52	3.19e-30	Mitral valve prolapse;
LUAD	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg01802117	chr1:53393560	SCP2	0.41	7.84	0.36	3.77e-14	Monocyte count;
LUAD	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg16479474	chr6:28041457	NA	0.44	7.4	0.34	7.22e-13	Parkinson's disease;
LUAD	trans	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg06606381	chr12:133084897	FBRSL1	-0.54	-7.39	-0.34	7.79e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg21724239	chr8:58056113	NA	0.66	8.13	0.37	4.93e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-8.24	-0.37	2.13e-15	Alzheimer's disease (late onset);
LUAD	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg09177884	chr7:1199841	ZFAND2A	0.47	7.39	0.34	7.96e-13	Longevity;Endometriosis;
LUAD	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg19336497	chr11:14380999	RRAS2	-0.66	-14.15	-0.57	1.73e-37	Sense of smell;
LUAD	cis	rs6062509	1.000	rs6062509	chr20:62362563	G/T	cg01176363	chr20:62369445	LIME1	-0.5	-8.03	-0.36	9.72e-15	Prostate cancer;
LUAD	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg16680214	chr1:154839983	KCNN3	-0.61	-12.42	-0.52	2.13e-30	Prostate cancer;
LUAD	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg05966235	chr16:28915196	ATP2A1	0.47	7.71	0.35	8.82e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg20503657	chr10:835505	NA	0.84	12.93	0.53	1.85e-32	Eosinophil percentage of granulocytes;
LUAD	cis	rs7843479	0.601	rs2306645	chr8:21845428	C/T	cg03445287	chr8:21823731	XPO7	0.48	9.12	0.41	3.06e-18	Mean corpuscular volume;
LUAD	cis	rs62238980	0.614	rs10483163	chr22:32459451	A/G	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23583168	chr7:148888333	NA	-0.91	-18.42	-0.67	4.8e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.63	-0.35	1.62e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1882538	0.538	rs9649587	chr7:133104569	A/C	cg10665199	chr7:133106180	EXOC4	0.62	10.83	0.47	2.64e-24	Intelligence (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg21117678	chr7:101459024	CUX1	-0.68	-6.5	-0.3	2.33e-10	Type 2 diabetes;
LUAD	cis	rs7009516	0.819	rs11986557	chr8:24221339	G/A	cg01759110	chr8:24241694	ADAMDEC1	-0.41	-8.18	-0.37	3.29e-15	Hair greying;
LUAD	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg09323728	chr8:95962352	TP53INP1	-0.35	-8.47	-0.38	4.12e-16	Type 2 diabetes;
LUAD	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg27535305	chr1:53392650	SCP2	-0.38	-7.89	-0.36	2.7e-14	Monocyte count;
LUAD	cis	rs2019216	0.542	rs1987424	chr17:21874036	G/A	cg22648282	chr17:21454238	C17orf51	-0.48	-8.4	-0.38	7.05e-16	Pelvic organ prolapse;
LUAD	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg27432699	chr2:27873401	GPN1	0.57	9.96	0.44	3.98e-21	Oral cavity cancer;
LUAD	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.94	0.47	1.05e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg11766577	chr21:47581405	C21orf56	0.59	10.64	0.46	1.44e-23	Testicular germ cell tumor;
LUAD	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg11344533	chr11:111475393	SIK2	-0.35	-6.5	-0.3	2.29e-10	Primary sclerosing cholangitis;
LUAD	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21659725	chr3:3221576	CRBN	0.86	18.28	0.66	1.96e-55	Intelligence (multi-trait analysis);
LUAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08048268	chr3:133502702	NA	-0.52	-10.3	-0.45	2.34e-22	Iron status biomarkers;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11038604	chr10:14996337	DCLRE1C	-0.4	-6.73	-0.31	5.49e-11	Cancer;
LUAD	trans	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg04995722	chr7:26192034	NFE2L3	-0.41	-7.17	-0.33	3.4e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4268898	0.965	rs13033241	chr2:24476118	G/C	cg02683114	chr2:24398427	C2orf84	0.42	6.97	0.32	1.19e-11	Asthma;
LUAD	cis	rs6564851	0.506	rs56053403	chr16:81259025	T/C	cg00908271	chr16:81254010	PKD1L2	0.32	6.66	0.31	8.33e-11	Carotenoid and tocopherol levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03092607	chr2:96068514	FAHD2A	-0.55	-6.73	-0.31	5.51e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2535633	0.631	rs2581819	chr3:53016552	C/A	cg05564831	chr3:52568323	NT5DC2	-0.37	-6.44	-0.3	3.29e-10	Body mass index;
LUAD	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg11502198	chr6:26597334	ABT1	0.55	9.09	0.4	3.73e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23583168	chr7:148888333	NA	-0.91	-18.75	-0.67	1.54e-57	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg15181151	chr6:150070149	PCMT1	0.32	6.4	0.3	4.25e-10	Testicular germ cell tumor;
LUAD	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-7.3	-0.33	1.45e-12	Personality dimensions;
LUAD	trans	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17712092	chr4:129076599	LARP1B	0.88	16.4	0.62	3.75e-47	Eosinophil percentage of white cells;
LUAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg21280719	chr6:42927975	GNMT	-0.4	-12.45	-0.52	1.6e-30	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg13319975	chr6:146136371	FBXO30	-0.67	-11.67	-0.49	1.81e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs72928364	1.000	rs2713764	chr3:100663567	A/G	cg10123952	chr3:100791384	NA	-0.56	-6.9	-0.32	1.86e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg11494091	chr17:61959527	GH2	0.4	7.16	0.33	3.68e-12	Height;
LUAD	cis	rs6484504	0.532	rs1475558	chr11:31263428	A/G	cg14844989	chr11:31128820	NA	-0.43	-7.92	-0.36	2.11e-14	Red blood cell count;
LUAD	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg08999081	chr20:33150536	PIGU	0.54	11.44	0.49	1.38e-26	Coronary artery disease;
LUAD	cis	rs193541	0.545	rs12518979	chr5:122181787	G/T	cg19077854	chr5:122220652	SNX24	-0.35	-6.58	-0.3	1.39e-10	Glucose homeostasis traits;
LUAD	cis	rs76419734	0.558	rs73837046	chr4:106523319	G/A	cg05309399	chr4:106552544	FLJ20184	-0.54	-6.61	-0.31	1.13e-10	Post bronchodilator FEV1;
LUAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg08219700	chr8:58056026	NA	0.44	6.49	0.3	2.37e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs1973993	0.672	rs17367240	chr1:96960057	G/A	cg10631902	chr5:14652156	NA	-0.47	-8.04	-0.36	8.81e-15	Weight;
LUAD	cis	rs12681287	0.547	rs13249177	chr8:87513034	A/G	cg27223183	chr8:87520930	FAM82B	-0.72	-10.13	-0.44	1.01e-21	Caudate activity during reward;
LUAD	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg09658497	chr7:2847517	GNA12	-0.54	-9.26	-0.41	1.03e-18	Height;
LUAD	cis	rs10489202	0.583	rs203777	chr1:167876616	C/T	cg24449463	chr1:168025552	DCAF6	-0.74	-11.86	-0.5	3.41e-28	Schizophrenia;
LUAD	cis	rs34638657	0.732	rs11859473	chr16:82201072	T/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.95	-0.32	1.43e-11	Lung adenocarcinoma;
LUAD	cis	rs7809615	1.000	rs7809615	chr7:99184778	G/T	cg12290671	chr7:99195819	NA	-0.64	-7.24	-0.33	2.15e-12	Blood metabolite ratios;
LUAD	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg12310025	chr6:25882481	NA	0.59	9.68	0.43	3.79e-20	Blood metabolite levels;
LUAD	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.4	-6.84	-0.32	2.7e-11	Coronary artery disease;
LUAD	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg26958806	chr6:27640298	NA	0.57	6.35	0.3	5.5e-10	Depression;
LUAD	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg03467027	chr4:99064603	C4orf37	0.41	6.64	0.31	9.62e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg20290983	chr6:43655470	MRPS18A	0.93	17.21	0.64	1.07e-50	IgG glycosylation;
LUAD	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg01228410	chr5:493893	SLC9A3	-0.53	-7.03	-0.32	8.23e-12	Cystic fibrosis severity;
LUAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg20607798	chr8:58055168	NA	0.72	9.44	0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs11971779	0.680	rs10229358	chr7:139052545	C/T	cg23387468	chr7:139079360	LUC7L2	-0.27	-6.39	-0.3	4.46e-10	Diisocyanate-induced asthma;
LUAD	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg27661571	chr11:113659931	NA	-0.69	-8.12	-0.37	5.29e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg26597838	chr10:835615	NA	1.08	17.08	0.64	4.2e-50	Eosinophil percentage of granulocytes;
LUAD	cis	rs9300255	0.543	rs1260294	chr12:123560289	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.39	6.46	0.3	2.87e-10	Neutrophil percentage of white cells;
LUAD	cis	rs2637266	0.783	rs4980006	chr10:78477993	G/C	cg18941641	chr10:78392320	NA	0.32	6.83	0.32	2.98e-11	Pulmonary function;
LUAD	cis	rs7193541	0.695	rs7199490	chr16:74716026	G/A	cg01733217	chr16:74700730	RFWD3	0.48	7.57	0.35	2.32e-13	Multiple myeloma;
LUAD	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg23262351	chr6:79576851	IRAK1BP1	0.39	6.41	0.3	3.84e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg13385794	chr1:248469461	NA	0.24	6.52	0.3	2.05e-10	Common traits (Other);
LUAD	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg15557168	chr22:42548783	NA	-0.45	-8.38	-0.38	7.81e-16	Cognitive function;
LUAD	cis	rs4911259	0.552	rs6058926	chr20:31465450	T/C	cg13636640	chr20:31349939	DNMT3B	-0.58	-9.52	-0.42	1.4e-19	Inflammatory bowel disease;
LUAD	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg05234568	chr11:5960015	NA	-0.56	-10.07	-0.44	1.61e-21	DNA methylation (variation);
LUAD	cis	rs11098699	0.718	rs4833902	chr4:124245388	G/A	cg09941581	chr4:124220074	SPATA5	0.42	6.66	0.31	8.48e-11	Mosquito bite size;
LUAD	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg00757033	chr12:89920650	WDR51B	0.68	11.21	0.48	1.02e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.79	0.35	5.13e-14	Morning vs. evening chronotype;
LUAD	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg22823121	chr1:150693482	HORMAD1	0.39	7.64	0.35	1.5e-13	Melanoma;
LUAD	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg23887609	chr12:130822674	PIWIL1	0.4	6.64	0.31	9.93e-11	Menopause (age at onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01174096	chr2:196521556	SLC39A10	-0.5	-7.97	-0.36	1.46e-14	Height;
LUAD	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15369054	chr17:80825471	TBCD	0.66	10.8	0.46	3.46e-24	Breast cancer;
LUAD	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06544989	chr22:39130855	UNC84B	0.43	7.89	0.36	2.69e-14	Menopause (age at onset);
LUAD	cis	rs7044106	0.791	rs4836831	chr9:123496570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	12.06	0.51	5.37e-29	Hip circumference adjusted for BMI;
LUAD	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg15017067	chr4:17643749	FAM184B	-0.34	-6.55	-0.3	1.69e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg26039829	chr8:22132926	PIWIL2	0.57	10.67	0.46	1.03e-23	Hypertriglyceridemia;
LUAD	cis	rs7809950	0.723	rs62483634	chr7:106878516	G/A	cg23024343	chr7:107201750	COG5	-0.76	-13.04	-0.54	6.73e-33	Coronary artery disease;
LUAD	cis	rs3806933	0.522	rs13157863	chr5:110470505	G/A	cg17157872	chr5:110408788	TSLP	0.36	6.84	0.32	2.87e-11	Eosinophilic esophagitis;
LUAD	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.1	0.33	5.43e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg04267008	chr7:1944627	MAD1L1	0.52	7.92	0.36	2.14e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg11663144	chr21:46675770	NA	-0.6	-11.63	-0.49	2.47e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg08508325	chr11:3079039	CARS	0.42	8.59	0.39	1.72e-16	Calcium levels;
LUAD	cis	rs10129255	0.556	rs6576222	chr14:107184681	G/A	cg23076370	chr14:107095027	NA	-0.43	-8.68	-0.39	8.58e-17	Kawasaki disease;
LUAD	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-9.21	-0.41	1.57e-18	Schizophrenia;
LUAD	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg14324370	chr2:177042789	NA	-0.42	-7.26	-0.33	1.92e-12	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs7493	0.901	rs13226149	chr7:95025600	G/A	cg17330251	chr7:94953956	PON1	-0.57	-8.03	-0.36	9.82e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6547631	0.622	rs10203826	chr2:85926190	A/C	cg21473183	chr2:85925749	GNLY	0.35	7.49	0.34	4.02e-13	Blood protein levels;
LUAD	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg18105139	chr6:28058856	ZSCAN12L1	-0.27	-6.38	-0.3	4.58e-10	Depression;
LUAD	cis	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg07460842	chr6:66804631	NA	1.06	16.63	0.63	3.65e-48	Exhaled nitric oxide output;
LUAD	cis	rs2016266	0.855	rs1056692	chr12:53687387	A/G	cg26875137	chr12:53738046	NA	-0.35	-6.76	-0.31	4.66e-11	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06505273	chr16:24850292	NA	-0.46	-6.74	-0.31	5.23e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg19000871	chr14:103996768	TRMT61A	0.43	7.41	0.34	6.93e-13	Coronary artery disease;
LUAD	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.36	-6.51	-0.3	2.12e-10	Tonsillectomy;
LUAD	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.53	-0.38	2.65e-16	Breast cancer;
LUAD	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg00757033	chr12:89920650	WDR51B	0.69	12.15	0.51	2.33e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg03392900	chr1:1167310	SDF4;B3GALT6	-0.68	-6.87	-0.32	2.29e-11	Type 2 diabetes;
LUAD	cis	rs1816752	0.669	rs7984513	chr13:25019255	A/G	cg02811702	chr13:24901961	NA	-0.39	-6.81	-0.31	3.3e-11	Obesity-related traits;
LUAD	cis	rs12216545	0.765	rs10235836	chr7:150231373	C/T	cg08960815	chr7:150264767	GIMAP4	0.3	6.54	0.3	1.8e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg22705602	chr4:152727874	NA	-0.4	-7.07	-0.33	6.3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.78e-19	Life satisfaction;
LUAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg05650719	chr12:132293520	NA	-0.39	-6.98	-0.32	1.16e-11	Migraine;
LUAD	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-8.46	-0.38	4.39e-16	Alzheimer's disease (late onset);
LUAD	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg00757033	chr12:89920650	WDR51B	0.67	11.51	0.49	7.53e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs151349	1.000	rs151344	chr20:57585301	A/G	cg23907860	chr20:57583709	CTSZ	-0.56	-10.39	-0.45	1.17e-22	Platelet distribution width;
LUAD	trans	rs8073060	0.586	rs17638867	chr17:34052513	C/T	cg19694781	chr19:47549865	TMEM160	1.17	18.76	0.67	1.35e-57	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg07460842	chr6:66804631	NA	-1.04	-16.27	-0.62	1.46e-46	Exhaled nitric oxide output;
LUAD	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg11502198	chr6:26597334	ABT1	-0.52	-8.78	-0.39	4.23e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs9900497	0.536	rs4646785	chr17:19651902	A/G	cg22552966	chr17:19620595	SLC47A2	-0.37	-7.59	-0.35	2.01e-13	Response to paliperidone in schizophrenia (CGI-S score);
LUAD	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg23649088	chr2:200775458	C2orf69	-0.6	-7.2	-0.33	2.84e-12	Schizophrenia;
LUAD	cis	rs3760982	0.585	rs11673534	chr19:44298884	G/A	cg12072164	chr19:44306565	LYPD5	0.42	8.71	0.39	6.99e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06563686	chr12:8234806	NECAP1	-0.62	-6.37	-0.3	4.84e-10	Type 2 diabetes;
LUAD	cis	rs654950	0.505	rs2475839	chr1:42006005	A/G	cg06885757	chr1:42089581	HIVEP3	-0.31	-6.82	-0.31	3.24e-11	Airway imaging phenotypes;
LUAD	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-10.54	-0.46	3.12e-23	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg19052272	chr2:3704530	ALLC	-0.63	-10.72	-0.46	7.27e-24	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs4700695	0.614	rs153388	chr5:65422308	G/T	cg21114390	chr5:65439923	SFRS12	-0.79	-7.16	-0.33	3.62e-12	Facial morphology (factor 19);
LUAD	trans	rs853679	0.546	rs13213152	chr6:28349698	A/G	cg01620082	chr3:125678407	NA	-1.11	-10.16	-0.44	7.53e-22	Depression;
LUAD	cis	rs9462027	0.539	rs2814963	chr6:34708908	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.15	-0.41	2.51e-18	Systemic lupus erythematosus;
LUAD	cis	rs6906287	0.647	rs10456917	chr6:118779419	A/C	cg05564266	chr6:118973597	C6orf204	0.34	7.18	0.33	3.1e-12	Electrocardiographic conduction measures;
LUAD	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15369054	chr17:80825471	TBCD	0.66	11.05	0.47	4.05e-25	Breast cancer;
LUAD	cis	rs10950821	0.530	rs6950224	chr7:20688109	G/C	cg02470904	chr7:20686108	ABCB5	0.41	7.27	0.33	1.75e-12	Response to statin therapy;
LUAD	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.74	-9.16	-0.41	2.19e-18	Lung cancer in ever smokers;
LUAD	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg06608945	chr2:219082296	ARPC2	0.51	8.69	0.39	8.22e-17	Colorectal cancer;
LUAD	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg16342193	chr10:102329863	NA	-0.36	-6.44	-0.3	3.28e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg18827107	chr12:86230957	RASSF9	-0.54	-9.54	-0.42	1.12e-19	Major depressive disorder;
LUAD	cis	rs7975161	0.671	rs4475991	chr12:104596756	A/G	cg04063896	chr12:104565784	NA	0.36	6.58	0.3	1.38e-10	Toenail selenium levels;
LUAD	trans	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	17.04	0.64	5.78e-50	Exhaled nitric oxide output;
LUAD	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg07636037	chr3:49044803	WDR6	0.57	8.87	0.4	2e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs16958440	0.867	rs75287977	chr18:44686823	G/A	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	trans	rs13086611	1	rs13086611	chr3:49385417	A/T	cg21659725	chr3:3221576	CRBN	-0.56	-8.75	-0.39	5.26e-17	Educational attainment;
LUAD	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg09796270	chr17:17721594	SREBF1	-0.4	-7.88	-0.36	2.8e-14	Total body bone mineral density;
LUAD	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg02421172	chr7:1938701	MAD1L1	0.45	6.76	0.31	4.6e-11	Neuroticism;
LUAD	cis	rs7707921	1.000	rs17245188	chr5:81469082	A/C	cg15871215	chr5:81402204	ATG10	0.64	9.44	0.42	2.52e-19	Breast cancer;
LUAD	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.06e-11	Parkinson's disease;
LUAD	cis	rs6785206	0.527	rs9844706	chr3:128380781	G/A	cg16766828	chr3:128327626	NA	-0.64	-7.58	-0.35	2.28e-13	Lymphocyte percentage of white cells;
LUAD	cis	rs239198	0.602	rs9390698	chr6:101296389	G/A	cg09795085	chr6:101329169	ASCC3	0.41	7.01	0.32	9.6e-12	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg18180107	chr4:99064573	C4orf37	0.43	6.96	0.32	1.31e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg22442454	chr1:209979470	IRF6	0.54	7.18	0.33	3.09e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg27446573	chr6:127587934	RNF146	0.43	6.55	0.3	1.7e-10	Breast cancer;
LUAD	cis	rs4776059	1.000	rs11070909	chr15:52931601	A/G	cg24008177	chr15:52972085	KIAA1370	0.24	6.61	0.31	1.18e-10	Schizophrenia;
LUAD	cis	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.51	-7.24	-0.33	2.11e-12	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg08029281	chr1:67600428	NA	0.33	6.37	0.3	4.83e-10	Psoriasis;
LUAD	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg07936489	chr17:37558343	FBXL20	0.45	6.91	0.32	1.76e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs3772130	0.962	rs9848027	chr3:121551227	T/C	cg20356878	chr3:121714668	ILDR1	0.51	8.3	0.37	1.41e-15	Cognitive performance;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00881440	chr7:2595255	C7orf27	-0.57	-7.21	-0.33	2.61e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg08687137	chr11:62389499	B3GAT3	0.39	6.43	0.3	3.52e-10	Optic cup area;
LUAD	trans	rs7395662	1.000	rs6485875	chr11:48581034	T/C	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.76e-10	HDL cholesterol;
LUAD	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg16006841	chr5:176797999	RGS14	0.56	10.15	0.44	8.02e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs854765	0.587	rs12936927	chr17:17726965	C/T	cg04398451	chr17:18023971	MYO15A	0.61	10.55	0.46	2.99e-23	Total body bone mineral density;
LUAD	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-13.6	-0.55	3.45e-35	Chronic sinus infection;
LUAD	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg14668632	chr7:2872130	GNA12	-0.47	-8.39	-0.38	7.23e-16	Height;
LUAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24503407	chr1:205819492	PM20D1	0.91	21.28	0.72	7.73e-69	Menarche (age at onset);
LUAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg00106254	chr7:1943704	MAD1L1	-0.56	-8.3	-0.37	1.46e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg27411982	chr8:10470053	RP1L1	0.42	7.53	0.34	3.06e-13	Mood instability;
LUAD	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs963731	0.649	rs297147	chr2:39322942	C/T	cg09527680	chr8:49747745	NA	-0.48	-6.37	-0.3	5.02e-10	Corticobasal degeneration;
LUAD	cis	rs2996428	0.561	rs2275827	chr1:3746585	T/G	cg10555106	chr1:3691387	LOC388588	0.4	6.45	0.3	3.05e-10	Red cell distribution width;
LUAD	cis	rs2932538	0.961	rs4839257	chr1:113219388	A/T	cg22162597	chr1:113214053	CAPZA1	-0.43	-6.79	-0.31	3.92e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	7.55	0.34	2.76e-13	Rheumatoid arthritis;
LUAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg14159672	chr1:205819179	PM20D1	-0.51	-7.74	-0.35	7.34e-14	Parkinson's disease;
LUAD	trans	rs11039798	0.764	rs11040030	chr11:48800985	C/T	cg15704280	chr7:45808275	SEPT13	0.67	7.83	0.36	3.98e-14	Axial length;
LUAD	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	7.05	0.32	7.11e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7833986	0.501	rs2976044	chr8:56986737	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.82	14.69	0.58	9.27e-40	Height;
LUAD	cis	rs9314323	0.535	rs1055479	chr8:26240646	A/G	cg13160058	chr8:26243215	BNIP3L	-0.38	-8.04	-0.36	8.92e-15	Red cell distribution width;
LUAD	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08109568	chr15:31115862	NA	-0.54	-9.18	-0.41	1.98e-18	Huntington's disease progression;
LUAD	cis	rs1448094	0.842	rs7966352	chr12:86438705	A/C	cg06740227	chr12:86229804	RASSF9	0.35	6.45	0.3	3.09e-10	Major depressive disorder;
LUAD	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg12403142	chr1:92012408	NA	0.36	6.68	0.31	7.49e-11	Breast cancer;
LUAD	cis	rs11681884	1.000	rs55888413	chr2:113844518	C/T	cg12858261	chr2:113808755	IL1F8	0.51	6.36	0.3	5.26e-10	Stroke;
LUAD	cis	rs1595825	0.786	rs74652956	chr2:198754247	C/T	cg11031976	chr2:198649780	BOLL	-0.48	-7.19	-0.33	2.89e-12	Ulcerative colitis;
LUAD	trans	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg22153745	chr1:153894579	GATAD2B	-0.53	-8.0	-0.36	1.21e-14	Total cholesterol levels;
LUAD	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg04731861	chr2:219085781	ARPC2	0.23	7.05	0.32	7.47e-12	Colorectal cancer;
LUAD	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg26384229	chr12:38710491	ALG10B	0.48	7.78	0.35	5.77e-14	Bladder cancer;
LUAD	cis	rs2535633	0.631	rs2336670	chr3:52998504	T/G	cg11645453	chr3:52864694	ITIH4	-0.37	-6.99	-0.32	1.08e-11	Body mass index;
LUAD	trans	rs8002861	0.664	rs1466005	chr13:44424210	T/C	cg12856521	chr11:46389249	DGKZ	0.48	8.03	0.36	1e-14	Leprosy;
LUAD	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.48	7.73	0.35	7.88e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg14061069	chr19:46274453	DMPK	-0.47	-9.7	-0.43	3.14e-20	Coronary artery disease;
LUAD	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg23758822	chr17:41437982	NA	1.01	20.57	0.71	1.2e-65	Menopause (age at onset);
LUAD	cis	rs7274811	0.744	rs6120309	chr20:32169600	A/G	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.48	-7.34	-0.34	1.12e-12	Height;
LUAD	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.0	-0.44	2.79e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg16606324	chr3:10149918	C3orf24	0.68	11.19	0.48	1.24e-25	Alzheimer's disease;
LUAD	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	7.0	0.32	1.03e-11	Rheumatoid arthritis;
LUAD	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.45	-0.38	4.88e-16	Total body bone mineral density;
LUAD	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg22482690	chr17:47019901	SNF8	0.44	8.32	0.37	1.25e-15	Type 2 diabetes;
LUAD	cis	rs4774899	0.966	rs12901671	chr15:57514268	A/G	cg14026238	chr15:57616123	NA	0.35	6.71	0.31	6.18e-11	Urinary tract infection frequency;
LUAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.25	0.41	1.08e-18	Alzheimer's disease;
LUAD	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg15181151	chr6:150070149	PCMT1	0.41	8.51	0.38	3.14e-16	Lung cancer;
LUAD	cis	rs7809950	0.678	rs12670688	chr7:106821016	A/G	cg23024343	chr7:107201750	COG5	0.8	12.41	0.52	2.26e-30	Coronary artery disease;
LUAD	cis	rs4911259	0.552	rs2014837	chr20:31461082	C/T	cg13636640	chr20:31349939	DNMT3B	0.57	9.67	0.43	3.99e-20	Inflammatory bowel disease;
LUAD	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg05340658	chr4:99064831	C4orf37	0.54	9.18	0.41	1.91e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg06925179	chr17:43578568	NA	0.45	6.37	0.3	4.83e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs75920871	0.920	rs4316540	chr11:116819241	C/T	cg04087571	chr11:116723030	SIK3	-0.32	-6.5	-0.3	2.33e-10	Subjective well-being;
LUAD	cis	rs7737355	0.812	rs31591	chr5:131005638	C/T	cg25547332	chr5:131281432	NA	0.43	7.02	0.32	8.82e-12	Life satisfaction;
LUAD	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.87	-0.36	2.92e-14	Type 2 diabetes;
LUAD	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg25036284	chr2:26402008	FAM59B	0.69	10.13	0.44	9.54e-22	Gut microbiome composition (summer);
LUAD	cis	rs7191700	0.583	rs243314	chr16:11385104	G/C	cg00044050	chr16:11439710	C16orf75	0.66	10.91	0.47	1.38e-24	Multiple sclerosis;
LUAD	trans	rs877282	0.797	rs11253329	chr10:753200	A/T	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg02660097	chr11:68866761	NA	0.46	6.52	0.3	2.02e-10	Blond vs. brown hair color;
LUAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06873352	chr17:61820015	STRADA	0.81	18.3	0.66	1.61e-55	Prudent dietary pattern;
LUAD	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.15	-0.41	2.5e-18	Bipolar disorder;
LUAD	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg08677398	chr8:58056175	NA	0.47	6.51	0.3	2.18e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg25769590	chr7:158789503	NA	-0.38	-6.94	-0.32	1.48e-11	Facial morphology (factor 20);
LUAD	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg10792982	chr14:105748885	BRF1	0.39	8.73	0.39	6.12e-17	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg04025307	chr7:1156635	C7orf50	0.8	14.87	0.59	1.54e-40	Longevity;Endometriosis;
LUAD	cis	rs926938	0.618	rs3121506	chr1:115363207	T/G	cg12756093	chr1:115239321	AMPD1	0.37	6.58	0.3	1.36e-10	Autism;
LUAD	cis	rs1873147	0.569	rs11071710	chr15:63309193	A/G	cg12160578	chr15:63334699	TPM1	0.52	7.9	0.36	2.5e-14	Orofacial clefts;
LUAD	cis	rs2455601	0.935	rs12049908	chr11:8919309	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-8.28	-0.37	1.68e-15	Schizophrenia;
LUAD	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.2	-0.37	2.92e-15	Total body bone mineral density;
LUAD	cis	rs220324	0.688	rs2076788	chr21:43565241	A/G	cg09727148	chr21:43560719	UMODL1	0.57	8.6	0.39	1.52e-16	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg09222892	chr1:25734099	RHCE	0.51	9.26	0.41	1.02e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg05617483	chr15:76483344	C15orf27	0.36	6.43	0.3	3.45e-10	Blood metabolite levels;
LUAD	cis	rs7937890	0.507	rs4463820	chr11:14556342	A/G	cg02886208	chr11:14281011	SPON1	-0.33	-6.43	-0.3	3.37e-10	Mitochondrial DNA levels;
LUAD	cis	rs11677370	0.603	rs10174064	chr2:3849806	C/T	cg17052675	chr2:3827356	NA	-0.63	-10.9	-0.47	1.56e-24	Type 2 diabetes;
LUAD	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg12062639	chr20:23401060	NAPB	1.09	11.21	0.48	1.06e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg20203395	chr5:56204925	C5orf35	0.8	11.67	0.49	1.75e-27	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg24818145	chr4:99064322	C4orf37	0.47	8.02	0.36	1.08e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9560113	1.000	rs9560103	chr13:112174253	G/A	cg14154082	chr13:112174009	NA	0.37	6.83	0.32	3.01e-11	Menarche (age at onset);
LUAD	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.73	-0.31	5.54e-11	Longevity;
LUAD	cis	rs524023	0.837	rs12362590	chr11:64352540	T/A	cg19131476	chr11:64387923	NRXN2	-0.36	-6.88	-0.32	2.12e-11	Urate levels in obese individuals;
LUAD	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg27170947	chr2:26402098	FAM59B	-0.82	-11.58	-0.49	4.09e-27	Gut microbiome composition (summer);
LUAD	cis	rs11168351	0.864	rs12228750	chr12:48496997	G/A	cg04545296	chr12:48745243	ZNF641	-0.33	-8.58	-0.38	1.86e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg05368731	chr17:41323189	NBR1	0.96	20.39	0.7	7.37e-65	Menopause (age at onset);
LUAD	cis	rs7107174	1.000	rs10899455	chr11:77999163	T/C	cg02023728	chr11:77925099	USP35	0.45	7.25	0.33	1.98e-12	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.67	-0.31	8.19e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26303861	chr1:20988122	DDOST	-0.65	-6.6	-0.31	1.21e-10	Type 2 diabetes;
LUAD	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg03714773	chr7:91764589	CYP51A1	0.31	7.28	0.33	1.61e-12	Breast cancer;
LUAD	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg02269571	chr22:50332266	NA	-0.61	-9.41	-0.42	3.27e-19	Schizophrenia;
LUAD	cis	rs526821	0.595	rs532278	chr11:55344983	A/G	cg04317927	chr11:55418816	OR4S2	0.39	7.45	0.34	5.36e-13	Pediatric bone mineral density (spine);
LUAD	cis	rs6688613	0.840	rs6695609	chr1:166953866	A/C	cg07049167	chr1:166818506	POGK	-0.46	-6.85	-0.32	2.7e-11	Refractive astigmatism;
LUAD	cis	rs9902453	0.765	rs2729447	chr17:28099002	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.61	-0.46	1.8e-23	Coffee consumption (cups per day);
LUAD	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg00083206	chr6:110721305	DDO	-0.37	-6.82	-0.31	3.08e-11	Platelet distribution width;
LUAD	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg10057126	chr4:77819792	ANKRD56	0.52	8.78	0.39	3.94e-17	Emphysema distribution in smoking;
LUAD	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg14019695	chr9:139328340	INPP5E	0.39	6.42	0.3	3.62e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg18806716	chr10:30721971	MAP3K8	-0.63	-12.74	-0.53	1.12e-31	Inflammatory bowel disease;
LUAD	cis	rs1595825	0.786	rs73054839	chr2:198671665	C/A	cg10547527	chr2:198650123	BOLL	-0.53	-7.35	-0.34	1.04e-12	Ulcerative colitis;
LUAD	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg15704280	chr7:45808275	SEPT13	0.72	10.91	0.47	1.33e-24	Coronary artery disease;
LUAD	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01570182	chr17:44337453	NA	0.96	14.16	0.57	1.54e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg07617317	chr6:118971624	C6orf204	0.54	8.46	0.38	4.34e-16	Diastolic blood pressure;
LUAD	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	7.03	0.32	8.22e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg16205897	chr5:131564050	P4HA2	-0.33	-7.41	-0.34	7.14e-13	Blood metabolite levels;
LUAD	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg25985355	chr7:65971099	NA	-0.56	-6.91	-0.32	1.79e-11	Gout;
LUAD	cis	rs7274811	0.723	rs6120329	chr20:32210238	T/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.49	-7.15	-0.33	3.77e-12	Height;
LUAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg11301795	chr4:187892539	NA	-0.76	-15.26	-0.6	3.3e-42	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg23950597	chr19:37808831	NA	-0.64	-7.57	-0.35	2.43e-13	Coronary artery calcification;
LUAD	trans	rs7395662	1.000	rs10742862	chr11:48649316	T/C	cg00717180	chr2:96193071	NA	-0.35	-6.45	-0.3	3.01e-10	HDL cholesterol;
LUAD	cis	rs12681287	0.640	rs12549332	chr8:87353392	G/A	cg00550725	chr8:87521180	FAM82B	0.47	6.84	0.32	2.79e-11	Caudate activity during reward;
LUAD	cis	rs1509123	0.609	rs56286838	chr17:6718830	C/T	cg12642237	chr17:6703447	TEKT1	-0.45	-6.4	-0.3	4.24e-10	Blood metabolite levels;
LUAD	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg02733842	chr7:1102375	C7orf50	-0.7	-10.32	-0.45	2.07e-22	Bronchopulmonary dysplasia;
LUAD	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg03433033	chr1:76189801	ACADM	0.73	11.07	0.47	3.54e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs250585	0.850	rs250588	chr16:23400054	T/C	cg00143387	chr16:23521605	GGA2	0.54	7.76	0.35	6.41e-14	Egg allergy;
LUAD	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg23254163	chr1:152506842	NA	-0.26	-7.1	-0.33	5.44e-12	Hair morphology;
LUAD	cis	rs2625529	0.824	rs4777470	chr15:72207518	T/A	cg16672083	chr15:72433130	SENP8	-0.75	-12.38	-0.52	2.91e-30	Red blood cell count;
LUAD	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg15997130	chr1:24165203	NA	0.54	9.47	0.42	2.03e-19	Immature fraction of reticulocytes;
LUAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-6.7	-0.31	6.83e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7811528	0.520	rs2286690	chr7:2695617	A/G	cg11411865	chr7:2701802	TTYH3	-0.49	-6.59	-0.31	1.3e-10	Schizophrenia;
LUAD	cis	rs748404	0.650	rs518234	chr15:43573421	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.01	0.36	1.13e-14	Lung cancer;
LUAD	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg26343298	chr8:95960752	TP53INP1	0.35	7.36	0.34	9.67e-13	Type 2 diabetes;
LUAD	cis	rs2346177	0.542	rs1900591	chr2:46697968	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.46	-7.48	-0.34	4.36e-13	HDL cholesterol;
LUAD	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg17105886	chr17:28927953	LRRC37B2	0.79	7.79	0.35	5.23e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9875589	0.509	rs28865280	chr3:14064958	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	7.23	0.33	2.3e-12	Ovarian reserve;
LUAD	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg23533926	chr12:111358616	MYL2	0.4	6.98	0.32	1.15e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs12681287	0.752	rs9297861	chr8:87254730	G/C	cg00550725	chr8:87521180	FAM82B	0.44	6.39	0.3	4.38e-10	Caudate activity during reward;
LUAD	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg11859384	chr17:80120422	CCDC57	-0.5	-9.07	-0.4	4.4e-18	Life satisfaction;
LUAD	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg25358565	chr5:93447407	FAM172A	0.64	7.66	0.35	1.24e-13	Diabetic retinopathy;
LUAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.76e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg24733560	chr20:60626293	TAF4	0.47	9.19	0.41	1.77e-18	Body mass index;
LUAD	cis	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg27411982	chr8:10470053	RP1L1	-0.39	-7.27	-0.33	1.76e-12	Neuroticism;
LUAD	cis	rs6867913	0.561	rs9324864	chr5:141469000	A/G	cg23435118	chr5:141488016	NDFIP1	0.42	6.97	0.32	1.2e-11	Asthma;
LUAD	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg08807101	chr21:30365312	RNF160	-0.45	-7.84	-0.36	3.59e-14	Dental caries;
LUAD	cis	rs3752645	1.000	rs2191917	chr7:106773708	T/G	cg02696742	chr7:106810147	HBP1	-0.68	-6.61	-0.31	1.13e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg01528321	chr10:82214614	TSPAN14	0.55	8.76	0.39	4.69e-17	Post bronchodilator FEV1;
LUAD	cis	rs35740288	0.770	rs55740125	chr15:86155736	G/A	cg13263323	chr15:86062960	AKAP13	-0.44	-7.07	-0.33	6.4e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg22705602	chr4:152727874	NA	-0.48	-9.12	-0.41	3.05e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs727479	0.543	rs2414096	chr15:51529779	G/A	cg19946085	chr15:51559439	CYP19A1	-0.35	-6.35	-0.3	5.53e-10	Estradiol levels;
LUAD	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg22079354	chr11:130786696	SNX19	0.39	6.37	0.3	4.95e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg14828511	chr1:107599125	PRMT6	0.57	10.16	0.44	7.58e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg26587870	chr6:27730563	NA	-0.43	-7.08	-0.33	6.01e-12	Parkinson's disease;
LUAD	cis	rs55665837	0.539	rs12794714	chr11:14913575	G/A	cg19336497	chr11:14380999	RRAS2	-0.38	-7.1	-0.33	5.16e-12	Vitamin D levels;
LUAD	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg18944383	chr4:111397179	ENPEP	0.51	9.3	0.41	7.87e-19	Coronary artery disease;
LUAD	cis	rs7089973	0.966	rs12775180	chr10:116639754	T/C	cg23260525	chr10:116636907	FAM160B1	0.42	8.97	0.4	9.41e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9486719	1.000	rs4262195	chr6:96929475	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.17	-0.44	6.97e-22	Migraine;Coronary artery disease;
LUAD	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg02527881	chr3:46936655	PTH1R	-0.44	-8.42	-0.38	5.72e-16	Colorectal cancer;
LUAD	cis	rs1232027	0.700	rs73765838	chr5:79947822	G/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-8.03	-0.36	1.01e-14	Huntington's disease progression;
LUAD	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg06346307	chr22:19949965	COMT	-0.4	-8.02	-0.36	1.08e-14	Blood metabolite levels;
LUAD	cis	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg08601574	chr20:25228251	PYGB	-0.46	-8.59	-0.39	1.74e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg21285383	chr16:89894308	SPIRE2	0.42	10.1	0.44	1.28e-21	Vitiligo;
LUAD	cis	rs1371867	0.810	rs3020182	chr8:101233008	T/C	cg20500540	chr8:101228448	SPAG1	-0.38	-6.73	-0.31	5.38e-11	Atrioventricular conduction;
LUAD	trans	rs4698048	0.510	rs12509714	chr4:10107091	C/G	cg26043149	chr18:55253948	FECH	0.44	7.26	0.33	1.92e-12	Skin aging (microtopography measurement);
LUAD	trans	rs6076960	0.684	rs3909086	chr20:6251639	A/G	cg21095983	chr6:86352623	SYNCRIP	0.45	7.05	0.32	7.33e-12	Smooth-surface caries;
LUAD	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg00310523	chr12:86230176	RASSF9	0.35	7.44	0.34	5.68e-13	Major depressive disorder;
LUAD	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg27494647	chr7:150038898	RARRES2	0.53	9.53	0.42	1.25e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg19825600	chr2:3704501	ALLC	-0.39	-7.53	-0.34	3.2e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7119038	0.818	rs7942535	chr11:118681464	C/T	cg19308663	chr11:118741387	NA	-0.43	-6.47	-0.3	2.76e-10	Sjögren's syndrome;
LUAD	cis	rs7614311	0.906	rs832198	chr3:63870352	T/G	cg22134162	chr3:63841271	THOC7	-0.37	-7.52	-0.34	3.28e-13	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs782590	0.870	rs2586950	chr2:55868966	T/G	cg18811423	chr2:55921094	PNPT1	0.5	8.38	0.38	8.12e-16	Metabolic syndrome;
LUAD	cis	rs1232027	0.700	rs1643647	chr5:79938568	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.33e-13	Tonsillectomy;
LUAD	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg16006841	chr5:176797999	RGS14	0.56	10.14	0.44	8.67e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg27454412	chr7:1067447	C7orf50	0.48	7.64	0.35	1.43e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs56283067	0.847	rs12208621	chr6:44752003	G/C	cg18551225	chr6:44695536	NA	-0.59	-9.73	-0.43	2.62e-20	Total body bone mineral density;
LUAD	cis	rs4638749	0.501	rs6733637	chr2:108804564	A/G	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.52	-0.34	3.35e-13	Blood pressure;
LUAD	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.8	-0.31	3.58e-11	Post bronchodilator FEV1;
LUAD	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg18932078	chr1:2524107	MMEL1	0.39	7.28	0.33	1.66e-12	Ulcerative colitis;
LUAD	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.85	-0.36	3.56e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2456568	0.867	rs4753111	chr11:93658410	A/G	cg26875233	chr11:93583750	C11orf90	-0.29	-6.36	-0.3	5.25e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg13535736	chr9:111863775	C9orf5	-0.43	-6.74	-0.31	5.32e-11	Menarche (age at onset);
LUAD	trans	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg13565492	chr6:43139072	SRF	-0.6	-6.37	-0.3	4.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7833986	0.501	rs72653953	chr8:56970795	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	1.01	18.27	0.66	2.1e-55	Height;
LUAD	cis	rs733592	0.931	rs765260	chr12:48431936	C/T	cg24011408	chr12:48396354	COL2A1	-0.35	-7.3	-0.33	1.4e-12	Plateletcrit;
LUAD	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg04287289	chr16:89883240	FANCA	0.78	6.99	0.32	1.1e-11	Skin colour saturation;
LUAD	cis	rs8077889	0.917	rs58080788	chr17:41902909	A/G	cg26893861	chr17:41843967	DUSP3	0.9	14.95	0.59	7.33e-41	Triglycerides;
LUAD	trans	rs9929218	0.953	rs28608872	chr16:68802038	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.69	-0.55	1.48e-35	Colorectal cancer;
LUAD	cis	rs250585	0.920	rs391662	chr16:23454121	T/C	cg00143387	chr16:23521605	GGA2	0.63	7.62	0.35	1.66e-13	Egg allergy;
LUAD	cis	rs9517313	0.584	rs9556974	chr13:99216302	G/C	cg07423050	chr13:99094983	FARP1	-0.58	-9.89	-0.43	7.16e-21	Neuroticism;
LUAD	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.5	0.3	2.27e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs9394841	0.667	rs9471667	chr6:41776681	T/C	cg25600774	chr6:41776562	USP49	-0.43	-6.56	-0.3	1.55e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs990171	0.538	rs11682754	chr2:103117095	A/G	cg03938978	chr2:103052716	IL18RAP	0.33	6.54	0.3	1.76e-10	Lymphocyte counts;
LUAD	cis	rs6743376	0.556	rs1530550	chr2:113817513	A/T	cg09040174	chr2:113837401	NA	0.52	8.07	0.37	7.1e-15	Inflammatory biomarkers;
LUAD	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg09117114	chr16:67998030	SLC12A4	-0.51	-6.78	-0.31	4.01e-11	Schizophrenia;
LUAD	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg10253484	chr15:75165896	SCAMP2	0.4	6.39	0.3	4.5e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg23311108	chr5:115387951	NA	0.39	6.59	0.31	1.29e-10	Hepatitis;
LUAD	cis	rs10100465	0.961	rs10093382	chr8:118640159	C/T	cg09430518	chr8:118662568	NA	0.32	6.54	0.3	1.74e-10	Leprosy;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23104823	chr14:45553408	PRPF39	-0.43	-6.98	-0.32	1.18e-11	Height;
LUAD	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg17971929	chr21:40555470	PSMG1	0.41	6.75	0.31	4.75e-11	Cognitive function;
LUAD	cis	rs17094222	0.504	rs11190661	chr10:102452136	C/T	cg26540559	chr10:102447443	NA	0.45	8.96	0.4	1.04e-17	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9314323	0.558	rs7828560	chr8:26188998	G/A	cg13160058	chr8:26243215	BNIP3L	-0.38	-7.89	-0.36	2.65e-14	Red cell distribution width;
LUAD	trans	rs79976124	0.879	rs78012385	chr6:66618091	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	10.21	0.44	5.13e-22	Type 2 diabetes;
LUAD	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	7.48	0.34	4.19e-13	Platelet count;
LUAD	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg02733842	chr7:1102375	C7orf50	-0.69	-10.3	-0.45	2.3e-22	Bronchopulmonary dysplasia;
LUAD	cis	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg07460842	chr6:66804631	NA	1.06	16.74	0.63	1.3e-48	Exhaled nitric oxide output;
LUAD	cis	rs6906287	0.647	rs12192682	chr6:118863594	A/G	cg05564266	chr6:118973597	C6orf204	0.35	7.43	0.34	6.24e-13	Electrocardiographic conduction measures;
LUAD	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg11871910	chr12:69753446	YEATS4	0.48	7.43	0.34	5.99e-13	Response to diuretic therapy;
LUAD	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg27433088	chr4:174089019	GALNT7	0.41	7.69	0.35	1.06e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05959577	chr3:48129425	MAP4	-0.39	-6.39	-0.3	4.3e-10	Cancer;
LUAD	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg24578937	chr1:2090814	PRKCZ	-0.58	-11.42	-0.49	1.62e-26	Height;
LUAD	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg26677194	chr12:130822605	PIWIL1	0.57	9.03	0.4	5.99e-18	Menopause (age at onset);
LUAD	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06636551	chr8:101224915	SPAG1	-0.37	-6.8	-0.31	3.61e-11	Atrioventricular conduction;
LUAD	cis	rs243505	1.000	rs243511	chr7:148430148	A/C	cg09806900	chr7:148480153	CUL1	-0.43	-7.3	-0.33	1.42e-12	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg22467129	chr15:76604101	ETFA	-0.45	-6.38	-0.3	4.71e-10	Blood metabolite levels;
LUAD	cis	rs12580035	0.568	rs7315298	chr12:1912880	C/T	cg04012082	chr12:1905096	CACNA2D4	0.3	6.4	0.3	4.01e-10	Urate levels in lean individuals;
LUAD	cis	rs7191700	0.712	rs7187741	chr16:11433103	C/G	cg00044050	chr16:11439710	C16orf75	-0.67	-11.47	-0.49	1.08e-26	Multiple sclerosis;
LUAD	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg06784218	chr1:46089804	CCDC17	0.6	13.37	0.55	2.89e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg14664628	chr15:75095509	CSK	0.52	8.49	0.38	3.62e-16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.38	6.56	0.3	1.57e-10	Blood metabolite levels;
LUAD	trans	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg02002194	chr4:3960332	NA	-0.29	-7.04	-0.32	7.63e-12	Mood instability;
LUAD	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.84	-0.32	2.72e-11	Type 2 diabetes;
LUAD	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg03929089	chr4:120376271	NA	-0.68	-9.72	-0.43	2.74e-20	Coronary artery disease;
LUAD	cis	rs13418410	0.539	rs11677468	chr2:33839053	T/C	cg04131969	chr2:33951647	MYADML	-0.63	-10.17	-0.44	6.73e-22	Non-response to antidepressants and depression;
LUAD	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg15208524	chr1:10270712	KIF1B	0.42	6.38	0.3	4.77e-10	Hepatocellular carcinoma;
LUAD	cis	rs11696501	0.688	rs6073834	chr20:44279989	C/A	cg11783356	chr20:44313418	WFDC10B	-0.49	-8.22	-0.37	2.53e-15	Brain structure;
LUAD	trans	rs7944735	0.545	rs4752805	chr11:48018355	A/G	cg03929089	chr4:120376271	NA	0.57	7.95	0.36	1.74e-14	Intraocular pressure;
LUAD	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg21017887	chr14:105400489	NA	0.75	14.25	0.57	6.57e-38	Rheumatoid arthritis;
LUAD	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg08761264	chr16:28874980	SH2B1	-0.45	-6.9	-0.32	1.88e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.4	-0.3	4.09e-10	Alzheimer's disease (late onset);
LUAD	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.7e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg01299579	chr2:10830716	NOL10	-0.43	-7.65	-0.35	1.36e-13	Prostate cancer;
LUAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg07234876	chr8:600039	NA	1.0	9.65	0.42	4.71e-20	IgG glycosylation;
LUAD	cis	rs13082711	0.640	rs35903173	chr3:27287751	T/C	cg02860705	chr3:27208620	NA	0.85	12.69	0.53	1.75e-31	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7010267	0.570	rs7009768	chr8:120041303	G/A	cg01975934	chr8:119970761	NA	-0.34	-6.4	-0.3	4.07e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.08	-0.33	6.17e-12	Total cholesterol levels;
LUAD	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg08805041	chr16:621841	PIGQ	-0.32	-6.57	-0.3	1.5e-10	Height;
LUAD	trans	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.98	-0.36	1.4e-14	Gout;
LUAD	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-7.98	-0.36	1.4e-14	Electroencephalogram traits;
LUAD	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg12365402	chr11:9010492	NRIP3	0.48	8.89	0.4	1.78e-17	Hemoglobin concentration;
LUAD	trans	rs75804782	0.641	rs56000747	chr2:239318541	T/G	cg01134436	chr17:81009848	B3GNTL1	0.8	8.66	0.39	1.02e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs1113500	0.862	rs2336128	chr1:108640739	G/T	cg06207961	chr1:108661230	NA	0.44	8.29	0.37	1.53e-15	Growth-regulated protein alpha levels;
LUAD	trans	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	9.83	0.43	1.09e-20	Mean corpuscular hemoglobin;
LUAD	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg18196295	chr10:418757	DIP2C	-0.43	-6.47	-0.3	2.71e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs7799006	0.722	rs33981648	chr7:2288669	T/C	cg08027265	chr7:2291960	NA	-0.74	-14.89	-0.59	1.3e-40	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.58	0.42	8.17e-20	Cognitive ability;
LUAD	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg06115741	chr20:33292138	TP53INP2	0.4	6.37	0.3	4.86e-10	Coronary artery disease;
LUAD	cis	rs7172809	0.643	rs61097729	chr15:77834358	C/G	cg11865553	chr15:77376250	NA	-0.41	-7.06	-0.32	6.95e-12	Glucose homeostasis traits;
LUAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg26338869	chr17:61819248	STRADA	-0.39	-6.55	-0.3	1.72e-10	Prudent dietary pattern;
LUAD	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg02049041	chr17:27085579	C17orf63	0.64	8.52	0.38	2.81e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg19622623	chr12:86230825	RASSF9	-0.4	-7.0	-0.32	9.82e-12	Major depressive disorder;
LUAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg18621852	chr3:10150065	C3orf24	0.48	8.37	0.38	8.75e-16	Alzheimer's disease;
LUAD	cis	rs208520	0.955	rs208532	chr6:66961280	T/A	cg07460842	chr6:66804631	NA	-0.97	-13.16	-0.54	2.25e-33	Exhaled nitric oxide output;
LUAD	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg05283184	chr6:79620031	NA	-0.42	-7.53	-0.34	3.19e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg24838063	chr12:130822603	PIWIL1	-0.64	-10.8	-0.46	3.49e-24	Menopause (age at onset);
LUAD	cis	rs9503598	0.605	rs9968900	chr6:3457687	C/T	cg00476032	chr6:3446245	SLC22A23	0.34	7.46	0.34	5.09e-13	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg23260525	chr10:116636907	FAM160B1	0.45	10.23	0.45	4.43e-22	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.93	0.4	1.35e-17	Endometrial cancer;
LUAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg23131131	chr22:24373011	LOC391322	-0.53	-8.88	-0.4	1.97e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7737355	0.812	rs11242070	chr5:130626621	A/G	cg06307176	chr5:131281290	NA	0.39	6.59	0.31	1.33e-10	Life satisfaction;
LUAD	cis	rs231513	0.911	rs231515	chr17:41964083	A/G	cg26893861	chr17:41843967	DUSP3	-0.54	-6.55	-0.3	1.7e-10	Cognitive function;
LUAD	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg26597838	chr10:835615	NA	1.3	20.16	0.7	7.85e-64	Eosinophil percentage of granulocytes;
LUAD	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg06002616	chr8:101225028	SPAG1	-0.39	-7.79	-0.35	5.23e-14	Atrioventricular conduction;
LUAD	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg10523679	chr1:76189770	ACADM	0.72	10.11	0.44	1.18e-21	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg03281426	chr2:240109471	HDAC4	0.6	13.74	0.56	8.72e-36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7561273	0.586	rs12477718	chr2:24330539	A/G	cg20701182	chr2:24300061	SF3B14	0.5	8.15	0.37	4.11e-15	Quantitative traits;
LUAD	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg15017067	chr4:17643749	FAM184B	0.36	7.0	0.32	1.03e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.43	-0.34	5.93e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg26446133	chr18:72167187	CNDP2	-0.79	-11.99	-0.5	1.01e-28	Refractive error;
LUAD	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg22491629	chr6:157744540	C6orf35	-0.8	-8.82	-0.39	3.01e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg05535760	chr7:792225	HEATR2	0.81	10.06	0.44	1.75e-21	Cerebrospinal P-tau181p levels;
LUAD	cis	rs13631	0.965	rs9411307	chr9:139994947	C/T	cg14289826	chr9:140003911	NA	0.44	9.09	0.4	3.81e-18	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg12365402	chr11:9010492	NRIP3	-0.49	-9.7	-0.43	3.22e-20	Hemoglobin concentration;
LUAD	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg06558623	chr16:89946397	TCF25	1.23	12.4	0.52	2.47e-30	Skin colour saturation;
LUAD	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	8.89	0.4	1.84e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg14186256	chr22:23484241	RTDR1	0.47	7.93	0.36	1.97e-14	Bone mineral density;
LUAD	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg09323728	chr8:95962352	TP53INP1	-0.38	-9.3	-0.41	7.54e-19	Type 2 diabetes;
LUAD	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg14895029	chr7:2775587	GNA12	-0.45	-7.38	-0.34	8.4e-13	Height;
LUAD	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.64	0.31	9.82e-11	Parkinson's disease;
LUAD	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg25036284	chr2:26402008	FAM59B	-0.62	-8.66	-0.39	9.71e-17	Gut microbiome composition (summer);
LUAD	cis	rs2455826	0.959	rs2471807	chr3:15676565	G/A	cg16303742	chr3:15540471	COLQ	0.45	7.39	0.34	7.84e-13	Inflammatory skin disease;
LUAD	cis	rs62400317	0.859	rs28583363	chr6:45231336	T/A	cg20913747	chr6:44695427	NA	-0.41	-6.57	-0.3	1.44e-10	Total body bone mineral density;
LUAD	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg17063962	chr7:91808500	NA	-0.62	-10.69	-0.46	9.03e-24	Breast cancer;
LUAD	cis	rs8099014	0.906	rs11152071	chr18:56087417	T/C	cg12907477	chr18:56117327	MIR122	0.41	6.67	0.31	8e-11	Platelet count;
LUAD	cis	rs17255340	0.577	rs12192297	chr6:84070966	T/C	cg08257003	chr6:84140564	ME1	0.34	6.71	0.31	6.19e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs476633	0.708	rs28547298	chr15:41446951	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.6	-10.76	-0.46	4.89e-24	Glomerular filtration rate (creatinine);
LUAD	cis	rs295140	0.605	rs10931893	chr2:201114652	A/G	cg23649088	chr2:200775458	C2orf69	-0.48	-8.2	-0.37	2.97e-15	QT interval;
LUAD	cis	rs7132746	0.553	rs7399277	chr12:86189246	A/G	cg18827107	chr12:86230957	RASSF9	-0.46	-6.5	-0.3	2.25e-10	Lewy body disease;
LUAD	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg13393036	chr8:95962371	TP53INP1	-0.43	-10.35	-0.45	1.6e-22	Type 2 diabetes;
LUAD	cis	rs4711350	0.911	rs9461907	chr6:33726990	A/C	cg07979401	chr6:33739406	LEMD2	-0.44	-7.31	-0.33	1.33e-12	Schizophrenia;
LUAD	cis	rs8060686	0.858	rs1476306	chr16:67973171	C/T	cg27539214	chr16:67997921	SLC12A4	-0.44	-6.54	-0.3	1.76e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.27	6.49	0.3	2.39e-10	Depression;
LUAD	trans	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg21775007	chr8:11205619	TDH	0.38	6.6	0.31	1.25e-10	Mood instability;
LUAD	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.15	-0.44	8.13e-22	Monocyte percentage of white cells;
LUAD	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg12863693	chr15:85201151	NMB	0.42	7.98	0.36	1.39e-14	Schizophrenia;
LUAD	cis	rs17155006	0.664	rs378962	chr7:107739538	A/C	cg05962710	chr7:107745446	LAMB4	-0.35	-7.26	-0.33	1.91e-12	Pneumococcal bacteremia;
LUAD	cis	rs9399401	0.677	rs6925979	chr6:142651052	G/A	cg03128060	chr6:142623767	GPR126	0.49	8.98	0.4	9.32e-18	Chronic obstructive pulmonary disease;
LUAD	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg15448220	chr1:150897856	SETDB1	-0.42	-7.08	-0.33	6.1e-12	Tonsillectomy;
LUAD	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg26384229	chr12:38710491	ALG10B	-0.38	-6.43	-0.3	3.41e-10	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg00717180	chr2:96193071	NA	-0.45	-8.72	-0.39	6.64e-17	HDL cholesterol;
LUAD	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06028605	chr16:24865363	SLC5A11	-0.56	-8.72	-0.39	6.51e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs4786125	0.512	rs55694271	chr16:6930378	G/A	cg03623568	chr16:6915990	A2BP1	-0.46	-9.39	-0.42	3.67e-19	Heart rate variability traits (SDNN);
LUAD	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg20503657	chr10:835505	NA	1.22	17.94	0.66	6.16e-54	Eosinophil percentage of granulocytes;
LUAD	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg12193833	chr17:30244370	NA	-0.58	-7.0	-0.32	1.03e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs4711350	0.862	rs597723	chr6:33694079	C/T	cg18005901	chr6:33739558	LEMD2	0.43	6.43	0.3	3.37e-10	Schizophrenia;
LUAD	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg25894440	chr7:65020034	NA	-0.71	-6.56	-0.3	1.56e-10	Diabetic kidney disease;
LUAD	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg02975922	chr3:195473998	MUC4	-0.45	-7.37	-0.34	8.89e-13	Pancreatic cancer;
LUAD	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg26587870	chr6:27730563	NA	-0.47	-7.66	-0.35	1.28e-13	Parkinson's disease;
LUAD	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03517284	chr6:25882590	NA	-0.54	-7.92	-0.36	2.13e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg23254163	chr1:152506842	NA	-0.23	-6.4	-0.3	4.08e-10	Hair morphology;
LUAD	cis	rs7192380	1.000	rs7191292	chr16:69669427	G/A	cg00738113	chr16:70207722	CLEC18C	-0.34	-6.87	-0.32	2.34e-11	Sjögren's syndrome;
LUAD	trans	rs6076960	0.684	rs6054049	chr20:6254909	A/G	cg17788362	chr6:86352627	SYNCRIP	-0.42	-6.62	-0.31	1.1e-10	Smooth-surface caries;
LUAD	trans	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg04775059	chr7:64541387	NA	0.51	6.82	0.31	3.14e-11	Aortic root size;
LUAD	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg13699009	chr12:122356056	WDR66	0.39	8.66	0.39	1.03e-16	Mean corpuscular volume;
LUAD	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg23719950	chr11:63933701	MACROD1	-0.62	-7.4	-0.34	7.57e-13	Mean platelet volume;
LUAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19626725	chr5:178986131	RUFY1	0.6	11.2	0.48	1.1e-25	Lung cancer;
LUAD	cis	rs2425143	1.000	rs78877130	chr20:34344947	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.08	-0.33	6e-12	Blood protein levels;
LUAD	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg09491104	chr22:46646882	C22orf40	-0.63	-10.99	-0.47	6.71e-25	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs757647	1.000	rs12514133	chr5:137742465	T/C	cg10676309	chr5:137685565	NA	0.37	6.98	0.32	1.16e-11	Menarche (age at onset);
LUAD	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg15691649	chr6:25882328	NA	-0.45	-7.12	-0.33	4.63e-12	Blood metabolite levels;
LUAD	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg05865280	chr17:75406074	SEPT9	-0.63	-21.05	-0.72	8.33e-68	Airflow obstruction;
LUAD	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg25665528	chr16:2260870	C16orf79	0.35	7.13	0.33	4.3e-12	Height;
LUAD	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg17031739	chr1:67600172	NA	0.45	8.18	0.37	3.35e-15	Psoriasis;
LUAD	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg15704280	chr7:45808275	SEPT13	-0.62	-8.34	-0.38	1.07e-15	Axial length;
LUAD	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg15208524	chr1:10270712	KIF1B	0.43	6.59	0.31	1.33e-10	Hepatocellular carcinoma;
LUAD	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg04154034	chr17:28927549	LRRC37B2	-0.58	-6.94	-0.32	1.47e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.41	0.3	3.89e-10	Cognitive test performance;
LUAD	cis	rs1003719	0.788	rs2835584	chr21:38460338	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.52	0.38	2.92e-16	Eye color traits;
LUAD	cis	rs7512552	0.839	rs2647373	chr1:150320570	G/C	cg15654264	chr1:150340011	RPRD2	0.61	11.6	0.49	3.48e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg06784218	chr1:46089804	CCDC17	-0.53	-11.59	-0.49	3.65e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg01236616	chr12:121019343	POP5	1.24	19.33	0.68	3.83e-60	Type 1 diabetes nephropathy;
LUAD	cis	rs9287719	0.601	rs1861300	chr2:10763961	A/G	cg02196655	chr2:10830764	NOL10	-0.38	-6.54	-0.3	1.76e-10	Prostate cancer;
LUAD	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg00339695	chr16:24857497	SLC5A11	0.49	9.15	0.41	2.46e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs2046867	0.818	rs6792109	chr3:72867091	C/T	cg25664220	chr3:72788482	NA	-0.63	-11.2	-0.48	1.15e-25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3087591	0.960	rs1124918	chr17:29492423	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.4	-6.53	-0.3	1.83e-10	Hip circumference;
LUAD	cis	rs494562	0.892	rs618448	chr6:86121324	G/A	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg09555818	chr19:45449301	APOC2	0.63	13.28	0.54	6.7e-34	Blood protein levels;
LUAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07167872	chr1:205819463	PM20D1	0.78	15.77	0.61	2.14e-44	Menarche (age at onset);
LUAD	cis	rs113835537	0.529	rs60358007	chr11:66222353	G/A	cg26679405	chr11:66247800	DPP3	-0.46	-6.45	-0.3	3.02e-10	Airway imaging phenotypes;
LUAD	cis	rs17362650	0.960	rs12475630	chr2:9634381	C/T	cg12832956	chr2:9616023	IAH1	-0.47	-7.42	-0.34	6.45e-13	Alcohol dependence (age at onset);
LUAD	cis	rs7274811	0.744	rs2071054	chr20:32265839	A/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.47	-7.23	-0.33	2.25e-12	Height;
LUAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg07217954	chr7:1067459	C7orf50	0.42	7.01	0.32	9.21e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg03467027	chr4:99064603	C4orf37	0.46	7.3	0.33	1.43e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17155006	0.664	rs1735499	chr7:107738882	G/A	cg05962710	chr7:107745446	LAMB4	-0.35	-7.27	-0.33	1.78e-12	Pneumococcal bacteremia;
LUAD	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg14784868	chr12:69753453	YEATS4	-0.45	-7.64	-0.35	1.49e-13	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg00318621	chr2:106887213	NA	-0.46	-6.82	-0.31	3.17e-11	Facial morphology (factor 23);
LUAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg07217954	chr7:1067459	C7orf50	0.4	6.51	0.3	2.07e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2227564	0.620	rs12783161	chr10:75572201	G/C	cg23231163	chr10:75533350	FUT11	-0.43	-6.78	-0.31	4.12e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21028142	chr17:79581711	NPLOC4	-0.45	-9.79	-0.43	1.54e-20	Eye color traits;
LUAD	cis	rs300703	0.654	rs401364	chr2:119493	G/A	cg24565620	chr2:194026	NA	0.46	6.8	0.31	3.58e-11	Blood protein levels;
LUAD	cis	rs12681287	0.517	rs34596274	chr8:87517679	C/T	cg27223183	chr8:87520930	FAM82B	-0.72	-9.98	-0.44	3.43e-21	Caudate activity during reward;
LUAD	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg09184832	chr6:79620586	NA	-0.49	-9.11	-0.41	3.3e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02353165	chr6:42928485	GNMT	0.45	8.12	0.37	5.07e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs738321	0.762	rs4820321	chr22:38579569	T/A	cg25457927	chr22:38595422	NA	-0.55	-12.34	-0.51	4.24e-30	Breast cancer;
LUAD	cis	rs7291412	0.540	rs9627391	chr22:46447097	C/T	cg05468064	chr22:46423449	NA	0.42	8.84	0.39	2.66e-17	Dupuytren's disease;Subjective well-being;
LUAD	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg15704280	chr7:45808275	SEPT13	-1.05	-23.48	-0.75	1.23e-78	Height;
LUAD	cis	rs1232027	0.700	rs865645	chr5:79944104	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-7.95	-0.36	1.74e-14	Huntington's disease progression;
LUAD	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.93	-0.36	1.91e-14	Prostate cancer;
LUAD	cis	rs12208915	0.731	rs9448581	chr6:79553378	A/G	cg11833968	chr6:79620685	NA	-0.49	-7.22	-0.33	2.48e-12	Left atrial antero-posterior diameter;
LUAD	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.38	0.34	8.61e-13	Bladder cancer;
LUAD	cis	rs698833	0.828	rs3738984	chr2:44531484	A/G	cg04920474	chr2:44395004	PPM1B	-0.41	-7.53	-0.34	3.1400000000000003e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs4409675	0.527	rs12067053	chr1:28227122	T/G	cg23691781	chr1:28212827	C1orf38	0.39	11.36	0.48	2.72e-26	Corneal astigmatism;
LUAD	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg15997130	chr1:24165203	NA	0.57	10.18	0.44	6.52e-22	Immature fraction of reticulocytes;
LUAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.55	7.51	0.34	3.49e-13	Renal function-related traits (BUN);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10137463	chr15:23085908	NIPA1	-0.54	-6.6	-0.31	1.23e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7503807	1.000	rs4889775	chr17:78592287	A/G	cg09596252	chr17:78655493	RPTOR	0.39	7.61	0.35	1.84e-13	Obesity;
LUAD	cis	rs7512552	0.839	rs12040949	chr1:150447462	C/T	cg15654264	chr1:150340011	RPRD2	0.6	11.56	0.49	4.75e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg00321850	chr1:175162397	KIAA0040	-0.52	-11.1	-0.48	2.61e-25	Alcohol dependence;
LUAD	cis	rs12049351	0.719	rs10916492	chr1:229634396	G/T	cg11742688	chr1:229674241	ABCB10	-0.42	-6.42	-0.3	3.7e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs9473147	0.516	rs7749271	chr6:47485002	T/C	cg02130027	chr6:47444894	CD2AP	0.37	7.09	0.33	5.65e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg05709478	chr1:6581295	PLEKHG5	-0.58	-7.44	-0.34	5.62e-13	Body mass index;
LUAD	cis	rs877282	0.891	rs12767043	chr10:797943	C/T	cg06581033	chr10:766294	NA	-0.55	-7.71	-0.35	9.26e-14	Uric acid levels;
LUAD	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg06740227	chr12:86229804	RASSF9	-0.42	-7.34	-0.34	1.1e-12	Major depressive disorder;
LUAD	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg12698349	chr2:225449008	CUL3	0.85	16.95	0.64	1.55e-49	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.73	-0.31	5.51e-11	Breast cancer;
LUAD	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg23758822	chr17:41437982	NA	1.01	20.92	0.71	3.1e-67	Menopause (age at onset);
LUAD	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg04727924	chr7:799746	HEATR2	-0.58	-7.45	-0.34	5.2e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg01579765	chr21:45077557	HSF2BP	-0.62	-13.68	-0.55	1.61e-35	Mean corpuscular volume;
LUAD	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg11871910	chr12:69753446	YEATS4	0.5	7.34	0.34	1.09e-12	Response to diuretic therapy;
LUAD	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg12698349	chr2:225449008	CUL3	0.69	10.26	0.45	3.35e-22	IgE levels in asthmatics (D.p. specific);
LUAD	trans	rs4714291	0.832	rs9471247	chr6:40105318	A/G	cg02267698	chr19:7991119	CTXN1	-0.43	-6.68	-0.31	7.34e-11	Strep throat;
LUAD	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg21770322	chr7:97807741	LMTK2	0.35	8.36	0.38	9.22e-16	Breast cancer;
LUAD	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.66	-0.39	1e-16	Total body bone mineral density;
LUAD	cis	rs12760731	0.720	rs10913557	chr1:178442190	C/T	cg00404053	chr1:178313656	RASAL2	0.65	8.28	0.37	1.67e-15	Obesity-related traits;
LUAD	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg11663144	chr21:46675770	NA	0.6	11.79	0.5	6.3e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7937890	0.869	rs2915404	chr11:14404825	A/G	cg06199346	chr11:14280333	SPON1	-0.35	-7.14	-0.33	4.06e-12	Mitochondrial DNA levels;
LUAD	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.33	6.42	0.3	3.57e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg26958806	chr6:27640298	NA	0.65	6.37	0.3	5.04e-10	Depression;
LUAD	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg26513180	chr16:89883248	FANCA	0.78	6.74	0.31	5.14e-11	Skin colour saturation;
LUAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12016809	chr21:47604291	C21orf56	0.64	10.94	0.47	1.04e-24	Testicular germ cell tumor;
LUAD	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.33	6.55	0.3	1.65e-10	Obesity-related traits;
LUAD	cis	rs7737355	0.947	rs1422081	chr5:130776053	A/C	cg06307176	chr5:131281290	NA	0.48	7.75	0.35	6.76e-14	Life satisfaction;
LUAD	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.8	-10.85	-0.47	2.32e-24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg08798685	chr6:27730294	NA	-0.43	-6.97	-0.32	1.23e-11	Parkinson's disease;
LUAD	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg03732007	chr1:2071316	PRKCZ	0.35	6.95	0.32	1.39e-11	Height;
LUAD	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.75	0.31	4.75e-11	Cardiac Troponin-T levels;
LUAD	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg27446573	chr6:127587934	RNF146	0.44	6.7	0.31	6.65e-11	Breast cancer;
LUAD	cis	rs2041840	1.000	rs2160393	chr2:37516950	A/G	cg25727520	chr2:37576821	QPCT	-0.37	-7.51	-0.34	3.52e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs3791556	0.741	rs3791542	chr2:240103955	A/G	cg03281426	chr2:240109471	HDAC4	-0.48	-8.78	-0.39	4.17e-17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg26343298	chr8:95960752	TP53INP1	0.38	8.18	0.37	3.47e-15	Type 2 diabetes;
LUAD	cis	rs17253792	0.822	rs76267907	chr14:56066969	C/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	12.82	0.53	5.33e-32	Melanoma;
LUAD	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg03806693	chr22:41940476	POLR3H	0.71	10.25	0.45	3.48e-22	Vitiligo;
LUAD	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg01851573	chr8:8652454	MFHAS1	-0.37	-6.85	-0.32	2.65e-11	Mood instability;
LUAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14159672	chr1:205819179	PM20D1	0.83	17.14	0.64	2.12e-50	Menarche (age at onset);
LUAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-7.02	-0.32	9.03e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg10792982	chr14:105748885	BRF1	0.44	9.4	0.42	3.61e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg11645453	chr3:52864694	ITIH4	-0.33	-6.47	-0.3	2.64e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg11822812	chr5:140052017	DND1	-0.43	-7.96	-0.36	1.64e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11214589	0.747	rs11214582	chr11:113218050	C/T	cg14159747	chr11:113255604	NA	0.59	12.14	0.51	2.58e-29	Neuroticism;
LUAD	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg13073564	chr4:8508604	NA	-0.62	-11.39	-0.48	2.07e-26	Response to antineoplastic agents;
LUAD	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.57	-0.46	2.41e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg10523679	chr1:76189770	ACADM	-0.89	-16.12	-0.62	6.66e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2692947	0.711	rs56791141	chr2:96587496	C/T	cg23100626	chr2:96804247	ASTL	0.3	7.72	0.35	8.29e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg00083206	chr6:110721305	DDO	-0.37	-6.82	-0.31	3.08e-11	Platelet distribution width;
LUAD	cis	rs7927771	0.524	rs1563821	chr11:47756568	C/T	cg18512352	chr11:47633146	NA	0.37	6.44	0.3	3.24e-10	Subjective well-being;
LUAD	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg21854759	chr1:92012499	NA	-0.49	-9.08	-0.4	4.27e-18	Breast cancer;
LUAD	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg04731861	chr2:219085781	ARPC2	0.27	8.31	0.37	1.36e-15	Colorectal cancer;
LUAD	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg18190219	chr22:46762943	CELSR1	-0.51	-6.65	-0.31	9.05e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg12034118	chr1:209979487	IRF6	0.56	7.39	0.34	8.12e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg08742575	chr21:47604166	C21orf56	0.43	7.18	0.33	3.07e-12	Testicular germ cell tumor;
LUAD	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg10518543	chr12:38710700	ALG10B	-0.47	-7.57	-0.35	2.3e-13	Morning vs. evening chronotype;
LUAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg11050988	chr7:1952600	MAD1L1	0.32	6.59	0.3	1.34e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg14159672	chr1:205819179	PM20D1	0.5	7.67	0.35	1.2e-13	Parkinson's disease;
LUAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg22535103	chr8:58192502	C8orf71	-0.72	-8.94	-0.4	1.24e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1912483	0.545	rs35161461	chr17:45401757	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.63	-0.31	1.05e-10	Coronary artery disease;
LUAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg08132940	chr7:1081526	C7orf50	-0.79	-10.67	-0.46	1.04e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12667521	chr19:29218732	NA	0.61	8.57	0.38	1.89e-16	Methadone dose in opioid dependence;
LUAD	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg08213375	chr14:104286397	PPP1R13B	0.26	6.82	0.31	3.13e-11	Schizophrenia;
LUAD	trans	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	8.6	0.39	1.51e-16	Mean corpuscular volume;
LUAD	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.25	0.33	1.96e-12	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs13067306	1.000	rs35602488	chr3:94246319	T/C	cg02491787	chr7:102739136	ARMC10	-0.45	-6.39	-0.3	4.46e-10	Blood pressure measurement (high sodium intervention);
LUAD	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg09222892	chr1:25734099	RHCE	-0.5	-9.1	-0.4	3.52e-18	Erythrocyte sedimentation rate;
LUAD	trans	rs11088226	1.000	rs11088226	chr21:33925531	C/G	cg09050820	chr6:167586206	TCP10L2	0.57	8.03	0.36	1.01e-14	Gastritis;
LUAD	cis	rs6960043	0.875	rs2215382	chr7:15055010	C/G	cg19272540	chr7:15055459	NA	0.37	8.41	0.38	6.37e-16	Type 2 diabetes;
LUAD	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg09997546	chr11:8931473	C11orf17;ST5	0.37	7.84	0.36	3.66e-14	Hemoglobin concentration;
LUAD	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg05791153	chr7:19748676	TWISTNB	0.65	7.16	0.33	3.5e-12	Thyroid stimulating hormone;
LUAD	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg15320075	chr8:145703422	NA	-0.4	-6.61	-0.31	1.19e-10	Age at first birth;
LUAD	cis	rs3857067	0.806	rs28408270	chr4:95114572	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.36	-6.48	-0.3	2.6200000000000003e-10	QT interval;
LUAD	cis	rs4604732	0.631	rs35046441	chr1:247626812	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg27454412	chr7:1067447	C7orf50	0.44	6.98	0.32	1.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg24634471	chr8:143751801	JRK	0.49	7.89	0.36	2.53e-14	Schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26714410	chr13:45150072	TSC22D1	-0.4	-6.56	-0.3	1.6e-10	Height;
LUAD	cis	rs7123876	0.553	rs10898868	chr11:72431679	A/G	cg04827223	chr11:72435913	ARAP1	-0.55	-10.44	-0.45	7.34e-23	Body mass index;
LUAD	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.66	0.31	8.63e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.52e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4588572	0.643	rs9293747	chr5:77705567	A/G	cg11547950	chr5:77652471	NA	-0.78	-12.76	-0.53	8.98e-32	Triglycerides;
LUAD	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg14507445	chr22:49886340	NA	-0.33	-6.36	-0.3	5.3e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg17372223	chr3:52568218	NT5DC2	0.38	6.83	0.32	2.94e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.38	-8.34	-0.38	1.02e-15	Hemoglobin concentration;
LUAD	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg20587970	chr11:113659929	NA	-1.38	-20.5	-0.71	2.42e-65	Hip circumference adjusted for BMI;
LUAD	cis	rs939658	0.728	rs11637459	chr15:79413554	A/G	cg17916960	chr15:79447300	NA	-0.48	-9.59	-0.42	7.9e-20	Refractive error;
LUAD	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg24818145	chr4:99064322	C4orf37	0.49	8.38	0.38	7.99e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg22442454	chr1:209979470	IRF6	0.54	6.48	0.3	2.54e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Hypertriglyceridemia;
LUAD	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg24578937	chr1:2090814	PRKCZ	-0.58	-12.17	-0.51	1.98e-29	Height;
LUAD	cis	rs10193935	1.000	rs10195776	chr2:42425098	G/A	cg27598129	chr2:42591480	NA	-0.78	-10.21	-0.44	5.19e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11890956	chr21:40555474	PSMG1	0.83	14.75	0.58	5.05e-40	Cognitive function;
LUAD	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg17173187	chr15:85201210	NMB	0.41	6.69	0.31	7e-11	Schizophrenia;
LUAD	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg09455208	chr3:40491958	NA	-0.53	-11.67	-0.49	1.73e-27	Renal cell carcinoma;
LUAD	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.72	0.31	5.81e-11	Motion sickness;
LUAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg08132940	chr7:1081526	C7orf50	-0.7	-10.1	-0.44	1.3e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	8.5	0.38	3.2e-16	Breast cancer;
LUAD	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg09796270	chr17:17721594	SREBF1	-0.37	-7.04	-0.32	7.94e-12	Schizophrenia;
LUAD	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-10.27	-0.45	3.02e-22	Electrocardiographic conduction measures;
LUAD	cis	rs12618769	0.652	rs11896729	chr2:99225645	T/C	cg10123293	chr2:99228465	UNC50	0.5	8.97	0.4	9.88e-18	Bipolar disorder;
LUAD	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg19761014	chr17:28927070	LRRC37B2	-0.84	-8.21	-0.37	2.74e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs752010	0.714	rs2182606	chr1:42082375	T/C	cg06885757	chr1:42089581	HIVEP3	0.47	11.08	0.47	3.17e-25	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg01657329	chr11:68192670	LRP5	-0.47	-8.28	-0.37	1.64e-15	Total body bone mineral density;
LUAD	cis	rs12893597	1.000	rs12587221	chr14:76809864	G/A	cg20290672	chr14:76816747	NA	-0.44	-6.84	-0.32	2.71e-11	Maximal oxygen uptake response;
LUAD	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg16205897	chr5:131564050	P4HA2	-0.33	-7.52	-0.34	3.38e-13	Blood metabolite levels;
LUAD	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg15744005	chr10:104629667	AS3MT	-0.35	-6.83	-0.32	3.01e-11	Arsenic metabolism;
LUAD	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg04025307	chr7:1156635	C7orf50	0.5	7.19	0.33	2.92e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.98	-0.36	1.35e-14	Monocyte percentage of white cells;
LUAD	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg17264618	chr3:40429014	ENTPD3	0.44	9.58	0.42	8.39e-20	Renal cell carcinoma;
LUAD	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg16989719	chr2:238392110	NA	-0.33	-6.66	-0.31	8.68e-11	Prostate cancer;
LUAD	cis	rs4523957	0.651	rs4790315	chr17:2070529	T/C	cg16513277	chr17:2031491	SMG6	-0.96	-19.02	-0.68	9.74e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs910187	0.631	rs2228	chr20:45809941	G/A	cg27589058	chr20:45804311	EYA2	-0.34	-7.63	-0.35	1.61e-13	Migraine;
LUAD	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg25985355	chr7:65971099	NA	-0.54	-6.64	-0.31	9.78e-11	Diabetic kidney disease;
LUAD	cis	rs7017914	0.902	rs13269513	chr8:71578079	A/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.52	-0.3	1.98e-10	Bone mineral density;
LUAD	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg19302996	chr17:73780495	UNK	-0.4	-6.79	-0.31	3.81e-11	White matter hyperintensity burden;
LUAD	cis	rs6906287	0.718	rs6906332	chr6:118653336	C/T	cg21191810	chr6:118973309	C6orf204	0.35	6.37	0.3	4.99e-10	Electrocardiographic conduction measures;
LUAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg23131131	chr22:24373011	LOC391322	0.52	8.68	0.39	8.44e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7043114	0.525	rs710162	chr9:95059790	A/T	cg14631576	chr9:95140430	CENPP	0.4	8.06	0.36	8.03e-15	Height;
LUAD	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg14552801	chr7:65878734	NA	0.38	6.7	0.31	6.53e-11	Aortic root size;
LUAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	cis	rs1113500	0.787	rs12047429	chr1:108633239	C/T	cg06207961	chr1:108661230	NA	0.34	6.47	0.3	2.68e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg07606381	chr6:8435919	SLC35B3	-0.39	-6.55	-0.3	1.63e-10	Motion sickness;
LUAD	cis	rs1003719	0.586	rs2298685	chr21:38533390	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.43	-0.38	5.42e-16	Eye color traits;
LUAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.63	-10.91	-0.47	1.32e-24	Lymphocyte counts;
LUAD	cis	rs877282	0.842	rs7092986	chr10:756373	G/A	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg11344533	chr11:111475393	SIK2	-0.36	-6.78	-0.31	4.18e-11	Primary sclerosing cholangitis;
LUAD	cis	rs6993813	0.872	rs7813486	chr8:120032525	T/C	cg01975934	chr8:119970761	NA	-0.37	-7.2	-0.33	2.7e-12	Bone mineral density (hip);
LUAD	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15664640	chr17:80829946	TBCD	-0.84	-16.95	-0.64	1.43e-49	Breast cancer;
LUAD	cis	rs6908034	0.505	rs77880623	chr6:19819454	T/C	cg02682789	chr6:19804855	NA	0.93	8.5	0.38	3.17e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs68170813	0.559	rs10953530	chr7:106827796	A/C	cg23024343	chr7:107201750	COG5	0.45	6.78	0.31	3.97e-11	Coronary artery disease;
LUAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg11062466	chr8:58055876	NA	0.67	8.84	0.39	2.69e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.4	8.3	0.37	1.46e-15	Hemoglobin concentration;
LUAD	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg12573674	chr2:1569213	NA	-0.57	-8.39	-0.38	7.1e-16	IgG glycosylation;
LUAD	cis	rs3752645	1.000	rs12055946	chr7:106782086	G/A	cg02696742	chr7:106810147	HBP1	-0.71	-6.65	-0.31	8.82e-11	Bladder cancer (smoking interaction);
LUAD	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg09184832	chr6:79620586	NA	-0.52	-9.78	-0.43	1.75e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.56	-0.38	2.16e-16	Total body bone mineral density;
LUAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg11814155	chr7:99998594	ZCWPW1	0.4	6.91	0.32	1.8e-11	Platelet count;
LUAD	cis	rs17152411	1.000	rs61873263	chr10:126589202	G/A	cg07906193	chr10:126599966	NA	0.53	7.55	0.34	2.67e-13	Height;
LUAD	cis	rs2281845	0.859	rs58364051	chr1:201077667	A/G	cg17810781	chr1:201082982	CACNA1S	0.39	6.87	0.32	2.28e-11	Permanent tooth development;
LUAD	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg14668632	chr7:2872130	GNA12	-0.37	-6.42	-0.3	3.56e-10	Height;
LUAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg02951883	chr7:2050386	MAD1L1	-0.9	-16.5	-0.63	1.47e-47	Bipolar disorder and schizophrenia;
LUAD	cis	rs7241530	0.636	rs12961788	chr18:75897998	C/T	cg14642773	chr18:75888474	NA	0.35	6.35	0.3	5.46e-10	Educational attainment (years of education);
LUAD	cis	rs9341808	0.667	rs1575541	chr6:80917485	T/A	cg08355045	chr6:80787529	NA	0.49	8.8	0.39	3.62e-17	Sitting height ratio;
LUAD	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg16647868	chr5:131706066	SLC22A5	-0.41	-7.0	-0.32	9.83e-12	Blood metabolite levels;
LUAD	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg08859206	chr1:53392774	SCP2	-0.46	-8.54	-0.38	2.51e-16	Monocyte count;
LUAD	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg22166914	chr1:53195759	ZYG11B	0.41	6.79	0.31	3.7e-11	Monocyte count;
LUAD	trans	rs8073060	0.544	rs225249	chr17:33942540	T/C	cg19694781	chr19:47549865	TMEM160	-1.26	-20.33	-0.7	1.31e-64	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.4	0.45	1.01e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11890956	chr21:40555474	PSMG1	-0.54	-9.46	-0.42	2.09e-19	Menarche (age at onset);
LUAD	cis	rs2839627	0.598	rs2246573	chr21:44253016	C/T	cg03543861	chr21:44258195	NA	-0.64	-9.65	-0.42	4.64e-20	Information processing speed;
LUAD	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg20744362	chr22:50050164	C22orf34	0.44	9.46	0.42	2.23e-19	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg03929089	chr4:120376271	NA	-0.96	-19.59	-0.69	2.73e-61	Height;
LUAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-9.22	-0.41	1.37e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg25208724	chr1:156163844	SLC25A44	1.13	24.85	0.77	1.01e-84	Testicular germ cell tumor;
LUAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg07414643	chr4:187882934	NA	0.32	6.46	0.3	2.88e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg11833968	chr6:79620685	NA	-0.41	-7.84	-0.36	3.81e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs938554	0.876	rs7670751	chr4:9938773	A/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-7.14	-0.33	4.18e-12	Blood metabolite levels;
LUAD	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-11.68	-0.49	1.6e-27	Bipolar disorder;
LUAD	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.55	-6.93	-0.32	1.6e-11	Body mass index;
LUAD	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg09365446	chr1:150670422	GOLPH3L	0.66	12.34	0.51	4.22e-30	Tonsillectomy;
LUAD	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27286337	chr10:134555280	INPP5A	0.72	9.35	0.41	5.1e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg13180566	chr4:1052158	NA	-0.4	-6.72	-0.31	5.87e-11	Recombination rate (females);
LUAD	cis	rs6601327	0.613	rs12547642	chr8:9493927	T/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.76	-0.31	4.66e-11	Multiple myeloma (hyperdiploidy);
LUAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg00431813	chr7:1051703	C7orf50	-0.45	-8.55	-0.38	2.33e-16	Longevity;Endometriosis;
LUAD	cis	rs6546550	0.901	rs7573442	chr2:70154037	G/A	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.0	-0.47	6.47e-25	Prevalent atrial fibrillation;
LUAD	trans	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.2	-0.33	2.83e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03226425	chr6:170151538	C6orf70;TCTE3	-0.48	-7.25	-0.33	2.05e-12	Height;
LUAD	cis	rs72634258	0.503	rs697675	chr1:7838113	A/C	cg26816564	chr1:7831052	VAMP3	0.66	9.18	0.41	1.98e-18	Inflammatory bowel disease;
LUAD	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg04673462	chr1:38461896	NA	0.47	9.85	0.43	9.96e-21	Coronary artery disease;
LUAD	cis	rs6430585	0.527	rs1446586	chr2:136407445	C/T	cg07169764	chr2:136633963	MCM6	-0.53	-6.42	-0.3	3.6e-10	Corneal structure;
LUAD	trans	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg14917512	chr19:3094685	GNA11	-0.58	-6.84	-0.32	2.72e-11	Diabetic kidney disease;
LUAD	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg04225089	chr17:73874465	TRIM47	-0.39	-6.93	-0.32	1.54e-11	Psoriasis;
LUAD	trans	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-10.29	-0.45	2.51e-22	Obesity-related traits;
LUAD	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg07936489	chr17:37558343	FBXL20	0.51	6.78	0.31	4.02e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs758324	0.812	rs1875176	chr5:131202457	A/G	cg25547332	chr5:131281432	NA	-0.4	-6.49	-0.3	2.4e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg09654669	chr8:57350985	NA	-0.66	-10.06	-0.44	1.76e-21	Obesity-related traits;
LUAD	trans	rs2840044	1.000	rs11656138	chr17:33910218	T/C	cg19694781	chr19:47549865	TMEM160	0.64	10.25	0.45	3.59e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.4	-6.8	-0.31	3.67e-11	Prudent dietary pattern;
LUAD	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.46	-0.3	2.87e-10	Height;
LUAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06873352	chr17:61820015	STRADA	0.83	18.59	0.67	8.47e-57	Prudent dietary pattern;
LUAD	cis	rs11671005	0.735	rs35652377	chr19:58929200	A/C	cg13877915	chr19:58951672	ZNF132	0.56	7.42	0.34	6.67e-13	Mean platelet volume;
LUAD	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg13319975	chr6:146136371	FBXO30	-0.55	-9.26	-0.41	1.06e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs870825	0.872	rs12506750	chr4:185571123	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	9.17	0.41	2.05e-18	Blood protein levels;
LUAD	cis	rs67072384	0.818	rs2291290	chr11:72465877	T/C	cg04827223	chr11:72435913	ARAP1	-0.57	-6.98	-0.32	1.14e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs7923452	0.938	rs753173	chr10:30778738	T/C	cg18806716	chr10:30721971	MAP3K8	0.54	7.57	0.35	2.31e-13	Itch intensity from mosquito bite;
LUAD	trans	rs7395662	0.929	rs11039903	chr11:48679705	G/T	cg15704280	chr7:45808275	SEPT13	-0.45	-6.94	-0.32	1.44e-11	HDL cholesterol;
LUAD	trans	rs62103177	0.564	rs1715230	chr18:77848002	C/T	cg05926928	chr17:57297772	GDPD1	0.8	10.13	0.44	9.9e-22	Opioid sensitivity;
LUAD	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg24531977	chr5:56204891	C5orf35	-0.69	-11.01	-0.47	5.69e-25	Coronary artery disease;
LUAD	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg12863693	chr15:85201151	NMB	0.37	6.5	0.3	2.28e-10	Schizophrenia;
LUAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg12373951	chr3:133503437	NA	0.39	7.86	0.36	3.11e-14	Iron status biomarkers;
LUAD	cis	rs6665290	0.904	rs3738729	chr1:227191227	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.2	-39.11	-0.89	1.42e-142	Myeloid white cell count;
LUAD	cis	rs12618769	0.597	rs1961651	chr2:99049674	G/C	cg10123293	chr2:99228465	UNC50	0.47	8.58	0.38	1.83e-16	Bipolar disorder;
LUAD	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg25358565	chr5:93447407	FAM172A	0.64	7.4	0.34	7.22e-13	Diabetic retinopathy;
LUAD	cis	rs123509	0.687	rs73077214	chr3:42838020	G/A	cg12982090	chr3:42733453	KBTBD5	-0.53	-9.02	-0.4	6.41e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg11814155	chr7:99998594	ZCWPW1	0.45	7.82	0.36	4.35e-14	Platelet count;
LUAD	cis	rs2235642	0.592	rs743963	chr16:1657350	A/T	cg03034668	chr16:1723424	CRAMP1L	-0.43	-7.37	-0.34	9.34e-13	Coronary artery disease;
LUAD	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24531977	chr5:56204891	C5orf35	-0.99	-14.94	-0.59	8.01e-41	Initial pursuit acceleration;
LUAD	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg22823121	chr1:150693482	HORMAD1	-0.45	-9.02	-0.4	6.73e-18	Tonsillectomy;
LUAD	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg26384229	chr12:38710491	ALG10B	0.51	8.38	0.38	7.67e-16	Heart rate;
LUAD	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg16405210	chr4:1374714	KIAA1530	0.48	7.79	0.35	5.09e-14	Obesity-related traits;
LUAD	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg10518543	chr12:38710700	ALG10B	-0.49	-8.16	-0.37	3.79e-15	Morning vs. evening chronotype;
LUAD	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg06484146	chr7:12443880	VWDE	-0.59	-7.62	-0.35	1.72e-13	Coronary artery disease;
LUAD	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg01251548	chr11:17372745	DKFZp686O24166	-0.37	-6.75	-0.31	4.85e-11	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg18180107	chr4:99064573	C4orf37	0.42	6.76	0.31	4.61e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg26043149	chr18:55253948	FECH	-0.44	-7.34	-0.34	1.11e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg07741184	chr6:167504864	NA	0.34	7.87	0.36	2.94e-14	Crohn's disease;
LUAD	cis	rs8044995	0.636	rs9888986	chr16:68297228	G/A	cg05110241	chr16:68378359	PRMT7	-0.84	-8.93	-0.4	1.32e-17	Schizophrenia;
LUAD	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg04398451	chr17:18023971	MYO15A	0.6	10.53	0.46	3.49e-23	Total body bone mineral density;
LUAD	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08109568	chr15:31115862	NA	-0.6	-9.99	-0.44	3.02e-21	Huntington's disease progression;
LUAD	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg05697835	chr1:2722811	NA	0.31	6.48	0.3	2.6200000000000003e-10	Ulcerative colitis;
LUAD	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.57e-12	Crohn's disease;
LUAD	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-20.32	-0.7	1.56e-64	Coronary artery disease;
LUAD	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.95	0.4	1.14e-17	Menopause (age at onset);
LUAD	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg11822812	chr5:140052017	DND1	-0.38	-7.07	-0.32	6.63e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg06608945	chr2:219082296	ARPC2	-0.45	-7.37	-0.34	8.97e-13	Colorectal cancer;
LUAD	cis	rs11048434	0.666	rs12371786	chr12:9090086	G/A	cg23795048	chr12:9217529	LOC144571	0.44	8.06	0.37	7.66e-15	Sjögren's syndrome;
LUAD	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg26513180	chr16:89883248	FANCA	-0.47	-7.92	-0.36	2.07e-14	Vitiligo;
LUAD	cis	rs7301016	0.846	rs7297093	chr12:63033387	C/T	cg11441379	chr12:63026424	NA	0.64	7.76	0.35	6.61e-14	IgG glycosylation;
LUAD	cis	rs733175	0.855	rs10016075	chr4:10006663	G/T	cg00071950	chr4:10020882	SLC2A9	0.6	9.55	0.42	1.1e-19	Psychosis and Alzheimer's disease;
LUAD	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.32	-0.34	1.28e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg12035532	chr1:1886765	KIAA1751	0.4	6.73	0.31	5.39e-11	Body mass index;
LUAD	cis	rs7274811	0.744	rs3213183	chr20:32262962	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.49	-7.06	-0.32	6.87e-12	Height;
LUAD	cis	rs4711350	0.765	rs1318691	chr6:33761884	G/A	cg13859433	chr6:33739653	LEMD2	-0.34	-7.01	-0.32	9.73e-12	Schizophrenia;
LUAD	cis	rs711245	0.637	rs11894187	chr2:36781708	T/A	cg01206211	chr2:36825736	FEZ2	0.48	8.64	0.39	1.18e-16	Height;
LUAD	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg03233332	chr7:66118400	NA	0.41	6.55	0.3	1.68e-10	Aortic root size;
LUAD	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.29	0.37	1.53e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6906287	0.647	rs6569020	chr6:118795522	C/T	cg21191810	chr6:118973309	C6orf204	0.49	9.56	0.42	9.63e-20	Electrocardiographic conduction measures;
LUAD	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.55	7.46	0.34	4.96e-13	Gut microbiome composition (summer);
LUAD	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg03233332	chr7:66118400	NA	-0.44	-6.8	-0.31	3.53e-11	Aortic root size;
LUAD	cis	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg21775007	chr8:11205619	TDH	-0.41	-7.22	-0.33	2.41e-12	Retinal vascular caliber;
LUAD	cis	rs6920965	0.507	rs12203025	chr6:126192034	C/T	cg05901451	chr6:126070800	HEY2	-0.49	-7.29	-0.33	1.54e-12	High light scatter reticulocyte count;
LUAD	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.88e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs78487399	0.808	rs6544664	chr2:43729108	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.46	-0.3	2.91e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.36	7.31	0.34	1.31e-12	Parkinson's disease;
LUAD	cis	rs10752881	1.000	rs10797812	chr1:182984597	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.38	-6.73	-0.31	5.67e-11	Colorectal cancer;
LUAD	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg20135002	chr11:47629003	NA	-0.42	-7.32	-0.34	1.22e-12	Subjective well-being;
LUAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg03188948	chr7:1209495	NA	0.82	9.99	0.44	3.14e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2230307	0.656	rs571697	chr1:100478755	T/C	cg20868668	chr1:100435035	SLC35A3	0.63	7.58	0.35	2.23e-13	Carotid intima media thickness;
LUAD	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg16405210	chr4:1374714	KIAA1530	-0.61	-9.37	-0.41	4.47e-19	Longevity;
LUAD	cis	rs116248771	0.739	rs4680456	chr3:158397842	C/T	cg16708174	chr3:158430962	RARRES1	0.47	6.78	0.31	4.16e-11	diarrhoeal disease at age 2;
LUAD	cis	rs2046867	0.661	rs28599586	chr3:72907185	A/G	cg25664220	chr3:72788482	NA	-0.56	-10.21	-0.44	5.17e-22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7072216	0.763	rs3814142	chr10:100171104	C/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.68	-0.39	8.56e-17	Metabolite levels;
LUAD	trans	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg06175025	chr14:78082992	SPTLC2	-0.42	-6.76	-0.31	4.73e-11	Bone mineral density;
LUAD	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.82	-0.36	4.17e-14	Schizophrenia;
LUAD	cis	rs9814567	0.964	rs10935113	chr3:134173091	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-14.76	-0.58	4.55e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg08888203	chr3:10149979	C3orf24	0.73	11.17	0.48	1.44e-25	Alzheimer's disease;
LUAD	cis	rs17152411	0.895	rs61872119	chr10:126583534	A/G	cg07906193	chr10:126599966	NA	0.55	7.71	0.35	9.13e-14	Height;
LUAD	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.21	-0.33	2.56e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg08742575	chr21:47604166	C21orf56	0.56	9.62	0.42	5.84e-20	Testicular germ cell tumor;
LUAD	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg18512352	chr11:47633146	NA	-0.57	-10.14	-0.44	8.77e-22	Subjective well-being;
LUAD	cis	rs68170813	0.559	rs76534758	chr7:106963262	T/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.2	-0.44	5.49e-22	Coronary artery disease;
LUAD	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg03806693	chr22:41940476	POLR3H	0.66	9.04	0.4	5.8e-18	Vitiligo;
LUAD	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	3.96e-11	Depression;
LUAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg14159672	chr1:205819179	PM20D1	0.45	7.15	0.33	3.92e-12	Parkinson's disease;
LUAD	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg26446133	chr18:72167187	CNDP2	-0.78	-11.81	-0.5	5.17e-28	Refractive error;
LUAD	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg26528668	chr16:1614120	IFT140	0.58	10.45	0.45	6.58e-23	Coronary artery disease;
LUAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.61	-10.67	-0.46	1.06e-23	Lymphocyte counts;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16627807	chr19:40596541	ZNF780A	-0.44	-6.79	-0.31	3.9e-11	Height;
LUAD	cis	rs71478720	1.000	rs5744276	chr11:112016871	C/G	cg26534425	chr11:112034925	IL18	0.47	7.07	0.32	6.6e-12	Interleukin-18 levels;
LUAD	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.91	-0.32	1.84e-11	Diabetic kidney disease;
LUAD	trans	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.76	13.73	0.56	9.51e-36	Mean corpuscular volume;
LUAD	cis	rs2932538	0.885	rs7516421	chr1:113089696	T/C	cg22162597	chr1:113214053	CAPZA1	0.42	6.6	0.31	1.25e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs4460629	0.710	rs11264318	chr1:155083717	A/T	cg23973274	chr1:155060172	NA	-0.37	-6.37	-0.3	4.85e-10	Serum magnesium levels;
LUAD	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg11822812	chr5:140052017	DND1	0.38	6.65	0.31	9.33e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7192380	1.000	rs11640319	chr16:69633515	G/A	cg00738113	chr16:70207722	CLEC18C	-0.34	-6.93	-0.32	1.61e-11	Sjögren's syndrome;
LUAD	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg07432352	chr17:45403706	C17orf57	0.38	7.2	0.33	2.73e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.5e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg01620082	chr3:125678407	NA	-0.45	-6.71	-0.31	6.45e-11	Depression;
LUAD	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.32	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg22963979	chr7:1858916	MAD1L1	-0.57	-10.02	-0.44	2.33e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs11771526	0.901	rs10252303	chr7:32304438	C/T	cg13207630	chr7:32358064	NA	0.59	7.32	0.34	1.23e-12	Body mass index;
LUAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg09033563	chr22:24373618	LOC391322	-0.49	-7.53	-0.34	3.18e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1832871	0.672	rs9456285	chr6:158732819	T/G	cg07165851	chr6:158734300	TULP4	0.72	10.99	0.47	7.18e-25	Height;
LUAD	trans	rs1816537	0.904	rs1369818	chr11:112986192	A/G	cg01289020	chr16:71323706	FTSJD1	-0.37	-6.35	-0.3	5.51e-10	Body mass index;
LUAD	cis	rs1497406	0.744	rs4233540	chr1:16507384	A/G	cg20430773	chr1:16534157	ARHGEF19	-0.43	-7.54	-0.34	2.83e-13	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.69	-0.35	1.07e-13	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs753274	0.650	rs28497965	chr19:14417402	T/G	cg25450033	chr19:14444658	NA	0.4	7.29	0.33	1.55e-12	Tumor necrosis factor beta levels;
LUAD	trans	rs7395662	0.963	rs1588068	chr11:48671745	C/G	cg00717180	chr2:96193071	NA	-0.35	-6.49	-0.3	2.47e-10	HDL cholesterol;
LUAD	cis	rs977987	0.832	rs37597	chr16:75500275	T/G	cg03315344	chr16:75512273	CHST6	-0.65	-14.0	-0.56	7.07e-37	Dupuytren's disease;
LUAD	cis	rs240764	0.755	rs12206564	chr6:100987009	A/G	cg09795085	chr6:101329169	ASCC3	-0.39	-6.77	-0.31	4.37e-11	Neuroticism;
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg21548813	chr6:291882	DUSP22	-0.76	-13.01	-0.53	8.37e-33	Menopause (age at onset);
LUAD	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03264133	chr6:25882463	NA	0.83	13.82	0.56	4.24e-36	Blood metabolite levels;
LUAD	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg08558340	chr7:100472263	SRRT	0.51	6.39	0.3	4.37e-10	Resting heart rate;
LUAD	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.6	-10.73	-0.46	6.43e-24	Melanoma;
LUAD	cis	rs12541635	0.639	rs6415444	chr8:107043797	G/A	cg10147462	chr8:107024639	NA	0.54	9.59	0.42	7.78e-20	Age of smoking initiation;
LUAD	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg15448220	chr1:150897856	SETDB1	0.54	9.21	0.41	1.57e-18	Melanoma;
LUAD	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg07636037	chr3:49044803	WDR6	0.48	8.04	0.36	9.27e-15	Menarche (age at onset);
LUAD	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg17031739	chr1:67600172	NA	0.42	7.55	0.34	2.68e-13	Psoriasis;
LUAD	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg06287003	chr12:125626642	AACS	-0.4	-6.43	-0.3	3.37e-10	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs698833	0.962	rs1067386	chr2:44644257	G/T	cg04920474	chr2:44395004	PPM1B	0.36	6.44	0.3	3.33e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	trans	rs1493916	0.837	rs4997493	chr18:31407302	C/T	cg27147174	chr7:100797783	AP1S1	-0.62	-10.88	-0.47	1.73e-24	Life satisfaction;
LUAD	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg13319975	chr6:146136371	FBXO30	0.63	10.91	0.47	1.4e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg20933634	chr6:27740509	NA	0.46	7.28	0.33	1.62e-12	Parkinson's disease;
LUAD	cis	rs9322817	0.669	rs4079063	chr6:105266118	A/G	cg02098413	chr6:105308735	HACE1	-0.41	-8.84	-0.39	2.67e-17	Thyroid stimulating hormone;
LUAD	cis	rs9902453	1.000	rs55971458	chr17:28427016	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	9.05	0.4	5.4e-18	Coffee consumption (cups per day);
LUAD	cis	rs261532	0.817	rs261534	chr5:138943690	T/C	cg12205435	chr5:138714322	SLC23A1	-0.44	-7.44	-0.34	5.71e-13	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	trans	rs11039798	0.844	rs7126949	chr11:48972166	A/G	cg02254774	chr11:50257496	LOC441601	0.52	6.56	0.3	1.62e-10	Axial length;
LUAD	cis	rs11048434	0.636	rs7306161	chr12:9059075	T/A	cg23795048	chr12:9217529	LOC144571	0.41	7.43	0.34	6.06e-13	Sjögren's syndrome;
LUAD	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg03959625	chr15:84868606	LOC388152	0.42	6.74	0.31	5.29e-11	Schizophrenia;
LUAD	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg05234568	chr11:5960015	NA	-0.57	-10.97	-0.47	8.22e-25	DNA methylation (variation);
LUAD	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.35e-11	Breast cancer;
LUAD	cis	rs9300255	0.602	rs1727317	chr12:123618942	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-6.52	-0.3	2.05e-10	Neutrophil percentage of white cells;
LUAD	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg22508957	chr16:3507546	NAT15	0.82	10.84	0.47	2.44e-24	Tuberculosis;
LUAD	cis	rs2224391	0.656	rs17140096	chr6:5287255	G/A	cg26704043	chr6:5282702	FARS2	0.39	6.43	0.3	3.54e-10	Height;
LUAD	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg09455208	chr3:40491958	NA	0.65	13.48	0.55	1.04e-34	Renal cell carcinoma;
LUAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg21724239	chr8:58056113	NA	0.74	9.62	0.42	5.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg02683114	chr2:24398427	C2orf84	-0.43	-6.69	-0.31	6.9e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs2658782	0.826	rs2925355	chr11:93090887	T/C	cg15737290	chr11:93063684	CCDC67	0.54	7.51	0.34	3.49e-13	Pulmonary function decline;
LUAD	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19346786	chr7:2764209	NA	-0.57	-12.63	-0.52	3.08e-31	Height;
LUAD	trans	rs4650994	0.571	rs11588907	chr1:178509462	C/T	cg05059571	chr16:84539110	KIAA1609	0.43	6.51	0.3	2.1e-10	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg21545522	chr1:205238299	TMCC2	0.35	6.37	0.3	5.05e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs4664304	0.714	rs66496937	chr2:160738509	A/G	cg23995753	chr2:160760732	LY75	-0.45	-7.66	-0.35	1.24e-13	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg18827107	chr12:86230957	RASSF9	-0.45	-8.2	-0.37	2.91e-15	Major depressive disorder;
LUAD	trans	rs208520	0.802	rs208496	chr6:66930786	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-14.43	-0.57	1.18e-38	Exhaled nitric oxide output;
LUAD	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.41	0.34	6.78e-13	Tonsillectomy;
LUAD	trans	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs597583	0.806	rs10892135	chr11:117392826	G/A	cg27161313	chr11:117392002	DSCAML1	-0.49	-8.17	-0.37	3.55e-15	Putamen volume;
LUAD	cis	rs41278232	0.920	rs7265923	chr20:62677395	G/C	cg03065311	chr20:62601662	ZNF512B	0.44	6.38	0.3	4.6e-10	Tonsillectomy;
LUAD	cis	rs7213347	0.780	rs1555568	chr17:2149505	T/C	cg16513277	chr17:2031491	SMG6	-0.43	-6.4	-0.3	4.12e-10	Total body bone mineral density;
LUAD	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg01579765	chr21:45077557	HSF2BP	-0.62	-14.49	-0.58	6.2e-39	Mean corpuscular volume;
LUAD	cis	rs2408955	0.501	rs8716	chr12:48539482	T/G	cg04545296	chr12:48745243	ZNF641	0.31	8.03	0.36	9.51e-15	Glycated hemoglobin levels;
LUAD	cis	rs7589342	0.929	rs1465640	chr2:106439103	C/T	cg16077055	chr2:106428750	NCK2	0.36	6.52	0.3	1.95e-10	Addiction;
LUAD	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg03340356	chr1:67600835	NA	0.45	7.77	0.35	6.06e-14	Psoriasis;
LUAD	trans	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg18187862	chr3:45730750	SACM1L	-0.53	-7.93	-0.36	2e-14	Primary sclerosing cholangitis;
LUAD	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.69	-12.75	-0.53	1e-31	Ulcerative colitis;
LUAD	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg11822812	chr5:140052017	DND1	0.38	6.84	0.32	2.78e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg11292385	chr22:29138453	CHEK2;HSCB	0.39	6.49	0.3	2.36e-10	Schizophrenia;
LUAD	cis	rs4925114	0.568	rs941448	chr17:17654542	C/G	cg09796270	chr17:17721594	SREBF1	-0.36	-6.96	-0.32	1.28e-11	Body mass index;
LUAD	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg24558204	chr6:135376177	HBS1L	0.45	8.09	0.37	6.49e-15	Red blood cell count;
LUAD	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg25457927	chr22:38595422	NA	-0.54	-13.88	-0.56	2.31e-36	Cutaneous nevi;
LUAD	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg27170947	chr2:26402098	FAM59B	0.83	11.56	0.49	4.58e-27	Gut microbiome composition (summer);
LUAD	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-7.48	-0.34	4.27e-13	Alzheimer's disease (late onset);
LUAD	cis	rs11958404	0.932	rs6870115	chr5:157436960	T/C	cg05962755	chr5:157440814	NA	0.71	9.95	0.44	4.36e-21	IgG glycosylation;
LUAD	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg18252515	chr7:66147081	NA	-0.62	-6.85	-0.32	2.7e-11	Diabetic kidney disease;
LUAD	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg25319279	chr11:5960081	NA	-0.38	-6.78	-0.31	4.05e-11	DNA methylation (variation);
LUAD	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.7	-10.19	-0.44	6.07e-22	IgG glycosylation;
LUAD	cis	rs3087591	0.879	rs4795591	chr17:29612410	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.68	-0.31	7.75e-11	Hip circumference;
LUAD	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.62	0.31	1.12e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs8018808	0.902	rs147316	chr14:77888664	C/T	cg20045696	chr14:77926864	AHSA1	0.36	6.4	0.3	4.14e-10	Myeloid white cell count;
LUAD	cis	rs758324	0.947	rs60847707	chr5:131252554	C/T	cg06307176	chr5:131281290	NA	-0.53	-8.44	-0.38	4.99e-16	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.71	-0.43	2.88e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.48	-0.45	5.35e-23	Monocyte percentage of white cells;
LUAD	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg21427119	chr20:30132790	HM13	-0.61	-8.97	-0.4	1e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg00634984	chr7:65235879	NA	-0.5	-6.96	-0.32	1.27e-11	Aortic root size;
LUAD	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg23018236	chr17:30244563	NA	-0.59	-7.73	-0.35	8.18e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg17761419	chr8:57350749	NA	-0.52	-7.86	-0.36	3.16e-14	Obesity-related traits;
LUAD	trans	rs12200782	1.000	rs10456330	chr6:26436692	C/T	cg08851530	chr6:28072375	NA	0.72	6.5	0.3	2.27e-10	Small cell lung carcinoma;
LUAD	cis	rs2688608	0.839	rs2633311	chr10:75598099	C/T	cg23231163	chr10:75533350	FUT11	0.46	8.41	0.38	6.45e-16	Inflammatory bowel disease;
LUAD	trans	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.7	-0.46	8.37e-24	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg18016565	chr1:150552671	MCL1	0.42	7.77	0.35	5.93e-14	Tonsillectomy;
LUAD	trans	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg01620082	chr3:125678407	NA	-0.45	-6.69	-0.31	7.07e-11	Depression;
LUAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg11941060	chr3:133502564	NA	-0.69	-12.37	-0.52	3.12e-30	Iron status biomarkers;
LUAD	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	9.1	0.4	3.47e-18	Parkinson's disease;
LUAD	cis	rs10493773	1.000	rs2274738	chr1:86119898	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.54	-8.95	-0.4	1.17e-17	Urate levels in overweight individuals;
LUAD	cis	rs2425143	1.000	rs11696527	chr20:34245379	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.18	-0.33	3.07e-12	Blood protein levels;
LUAD	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg18230493	chr5:56204884	C5orf35	-0.45	-7.51	-0.34	3.62e-13	Coronary artery disease;
LUAD	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06028808	chr11:68637592	NA	0.49	8.09	0.37	6.36e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1509123	0.609	rs55935995	chr17:6718429	A/G	cg12642237	chr17:6703447	TEKT1	-0.45	-6.4	-0.3	4.24e-10	Blood metabolite levels;
LUAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.63	-11.7	-0.49	1.33e-27	Longevity;Endometriosis;
LUAD	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg17177755	chr1:15930204	NA	0.44	7.13	0.33	4.49e-12	Systolic blood pressure;
LUAD	cis	rs4372836	0.615	rs61407258	chr2:29046909	A/G	cg09522027	chr2:28974177	PPP1CB	-0.66	-11.57	-0.49	4.27e-27	Body mass index;
LUAD	cis	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg07460842	chr6:66804631	NA	-1.2	-30.18	-0.83	1.56e-107	Exhaled nitric oxide output;
LUAD	trans	rs9951602	0.512	rs7234283	chr18:76640552	T/G	cg02800362	chr5:177631904	HNRNPAB	0.92	14.19	0.57	1.12e-37	Obesity-related traits;
LUAD	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg09455208	chr3:40491958	NA	0.57	12.54	0.52	6.86e-31	Renal cell carcinoma;
LUAD	cis	rs870825	0.616	rs2310108	chr4:185639475	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	14.12	0.57	2.26e-37	Blood protein levels;
LUAD	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg01689657	chr7:91764605	CYP51A1	-0.3	-7.12	-0.33	4.61e-12	Breast cancer;
LUAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg16031515	chr1:205743344	RAB7L1	-0.34	-6.79	-0.31	3.79e-11	Menarche (age at onset);
LUAD	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg06641503	chr3:48959341	ARIH2	-0.39	-7.73	-0.35	7.88e-14	Parkinson's disease;
LUAD	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.75e-18	Life satisfaction;
LUAD	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg21918786	chr6:109611834	NA	-0.53	-9.24	-0.41	1.2e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs7731657	0.588	rs6595977	chr5:130334642	T/G	cg08523029	chr5:130500466	HINT1	0.56	7.39	0.34	7.72e-13	Fasting plasma glucose;
LUAD	cis	rs10781543	0.839	rs7863766	chr9:139381314	T/G	cg14169450	chr9:139327907	INPP5E	0.43	7.78	0.35	5.44e-14	Monocyte percentage of white cells;
LUAD	trans	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg26043149	chr18:55253948	FECH	1.07	18.3	0.66	1.6e-55	Gout;Urate levels;Serum uric acid levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08317834	chr8:26148868	PPP2R2A	-0.52	-6.4	-0.3	4.17e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg17595323	chr11:93583763	C11orf90	-0.43	-9.08	-0.4	4.14e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg06873352	chr17:61820015	STRADA	0.42	7.07	0.33	6.49e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs7831697	0.911	rs13273964	chr8:138138088	G/A	cg10329579	chr1:17754830	RCC2	-0.32	-6.39	-0.3	4.47e-10	Pediatric autoimmune diseases;
LUAD	cis	rs714027	1.000	rs4823074	chr22:30512478	G/A	cg00539347	chr22:30592296	NA	-0.28	-6.6	-0.31	1.26e-10	Lymphocyte counts;
LUAD	cis	rs13095912	1.000	rs6762208	chr3:185331165	A/C	cg11274856	chr3:185301563	NA	-0.36	-7.22	-0.33	2.41e-12	Systolic blood pressure;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09544279	chr5:179921349	CNOT6	-0.67	-6.46	-0.3	2.84e-10	Type 2 diabetes;
LUAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg04025307	chr7:1156635	C7orf50	0.66	7.49	0.34	4.17e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg11814155	chr7:99998594	ZCWPW1	0.45	7.28	0.33	1.68e-12	Platelet count;
LUAD	cis	rs4776059	0.958	rs35505902	chr15:52888493	A/G	cg24008177	chr15:52972085	KIAA1370	0.25	6.84	0.32	2.77e-11	Schizophrenia;
LUAD	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26314531	chr2:26401878	FAM59B	-0.73	-9.97	-0.44	3.74e-21	Gut microbiome composition (summer);
LUAD	cis	rs2882667	0.537	rs11743534	chr5:138409007	G/T	cg04439458	chr5:138467593	SIL1	-0.36	-6.78	-0.31	4.18e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.1e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg12143784	chr7:64541923	NA	0.44	7.29	0.33	1.53e-12	Calcium levels;
LUAD	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg11663144	chr21:46675770	NA	-0.57	-11.36	-0.48	2.71e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg04995722	chr7:26192034	NFE2L3	0.39	6.53	0.3	1.91e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg23533926	chr12:111358616	MYL2	-0.43	-7.33	-0.34	1.19e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg27411982	chr8:10470053	RP1L1	-0.36	-6.57	-0.3	1.5e-10	Neuroticism;
LUAD	cis	rs1018836	0.637	rs7843684	chr8:91470035	G/C	cg16814680	chr8:91681699	NA	-0.52	-8.51	-0.38	3.04e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18876405	chr7:65276391	NA	-0.42	-6.64	-0.31	9.59e-11	Aortic root size;
LUAD	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg26752003	chr8:145688521	CYHR1	-0.47	-8.1	-0.37	5.78e-15	Age at first birth;
LUAD	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg18827107	chr12:86230957	RASSF9	-0.61	-10.51	-0.45	4.17e-23	Major depressive disorder;
LUAD	cis	rs12681288	0.782	rs2123055	chr8:1029500	T/G	cg04851639	chr8:1020857	NA	-0.41	-9.72	-0.43	2.68e-20	Schizophrenia;
LUAD	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg05340658	chr4:99064831	C4orf37	0.55	9.38	0.41	4.12e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg04827223	chr11:72435913	ARAP1	-0.68	-13.08	-0.54	4.73e-33	Body mass index;
LUAD	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg23649088	chr2:200775458	C2orf69	-0.63	-9.48	-0.42	1.89e-19	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.5	0.3	2.21e-10	Breast cancer;
LUAD	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg17063962	chr7:91808500	NA	0.68	12.22	0.51	1.33e-29	Breast cancer;
LUAD	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg01028140	chr2:1542097	TPO	-0.48	-6.65	-0.31	8.87e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs8048589	0.948	rs35318501	chr16:12182531	A/C	cg03816625	chr16:12192430	SNX29	0.52	7.44	0.34	5.56e-13	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs5756391	0.568	rs10222238	chr22:37318014	G/T	cg16356956	chr22:37317934	CSF2RB	0.31	6.51	0.3	2.07e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs68170813	0.559	rs3823960	chr7:107009349	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-10.73	-0.46	6.22e-24	Coronary artery disease;
LUAD	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg06623918	chr6:96969491	KIAA0776	-0.89	-17.65	-0.65	1.21e-52	Headache;
LUAD	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg01884057	chr2:25150051	NA	0.32	6.89	0.32	1.99e-11	Body mass index in non-asthmatics;
LUAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24503407	chr1:205819492	PM20D1	0.91	20.47	0.71	3.35e-65	Menarche (age at onset);
LUAD	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg10523679	chr1:76189770	ACADM	-0.45	-6.43	-0.3	3.48e-10	Daytime sleep phenotypes;
LUAD	cis	rs2742234	0.590	rs2435377	chr10:43683600	A/G	cg15436174	chr10:43711423	RASGEF1A	0.5	8.61	0.39	1.51e-16	Hirschsprung disease;
LUAD	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg03517284	chr6:25882590	NA	-0.55	-8.25	-0.37	2.01e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7584330	0.740	rs13404177	chr2:238441412	T/C	cg14458575	chr2:238380390	NA	0.54	9.92	0.43	5.57e-21	Prostate cancer;
LUAD	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg16479474	chr6:28041457	NA	0.37	6.69	0.31	7.27e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.3	1.35e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-7.28	-0.33	1.61e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg08029281	chr1:67600428	NA	0.36	7.13	0.33	4.24e-12	Psoriasis;
LUAD	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg01657329	chr11:68192670	LRP5	-0.4	-6.41	-0.3	3.83e-10	Total body bone mineral density;
LUAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg22907277	chr7:1156413	C7orf50	0.68	8.0	0.36	1.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-6.93	-0.32	1.56e-11	Personality dimensions;
LUAD	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg06108461	chr20:60628389	TAF4	0.93	14.14	0.57	1.95e-37	Body mass index;
LUAD	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg22467129	chr15:76604101	ETFA	-0.47	-7.84	-0.36	3.67e-14	Blood metabolite levels;
LUAD	cis	rs7020830	0.898	rs2790063	chr9:37287405	G/A	cg14294708	chr9:37120828	ZCCHC7	0.79	15.07	0.59	2.22e-41	Schizophrenia;
LUAD	cis	rs2004318	1.000	rs7257210	chr19:55080699	A/C	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.96e-13	Blood protein levels;
LUAD	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg15468180	chr1:107600409	PRMT6	0.43	7.27	0.33	1.72e-12	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.65	0.31	9.11e-11	Depression;
LUAD	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg18129748	chr3:49941408	MST1R	-0.44	-7.3	-0.33	1.45e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2806561	0.704	rs7532266	chr1:23551623	A/C	cg12483005	chr1:23474871	LUZP1	-0.52	-8.68	-0.39	8.6e-17	Height;
LUAD	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg18404041	chr3:52824283	ITIH1	-0.53	-9.0	-0.4	7.75e-18	Schizophrenia;
LUAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs62400317	0.723	rs755	chr6:44795790	C/T	cg18551225	chr6:44695536	NA	-0.51	-7.85	-0.36	3.37e-14	Total body bone mineral density;
LUAD	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg26408565	chr15:76604113	ETFA	-0.46	-7.29	-0.33	1.54e-12	Blood metabolite levels;
LUAD	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg01028140	chr2:1542097	TPO	-0.52	-7.06	-0.32	6.8e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.87	-0.36	3.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18867708	chr6:26865862	GUSBL1	-0.41	-6.47	-0.3	2.73e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg14983838	chr19:29218262	NA	0.6	9.4	0.42	3.37e-19	Methadone dose in opioid dependence;
LUAD	cis	rs977987	0.872	rs10781976	chr16:75314838	G/T	cg03315344	chr16:75512273	CHST6	0.57	12.42	0.52	2.11e-30	Dupuytren's disease;
LUAD	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg01448562	chr3:133502909	NA	-0.62	-10.25	-0.45	3.56e-22	Iron status biomarkers;
LUAD	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg13385794	chr1:248469461	NA	-0.25	-6.72	-0.31	5.83e-11	Common traits (Other);
LUAD	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg07936489	chr17:37558343	FBXL20	0.47	7.5	0.34	3.91e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs3845702	1.000	rs3845702	chr2:180848488	A/C	cg01881094	chr2:180872142	CWC22	0.58	7.71	0.35	8.81e-14	Schizophrenia;
LUAD	cis	rs28493229	0.708	rs10408309	chr19:41161189	T/G	cg21869046	chr19:41225005	ITPKC	0.51	8.76	0.39	4.75e-17	Kawasaki disease;
LUAD	cis	rs7523875	0.516	rs6682599	chr1:211522427	G/A	cg25617285	chr1:211431773	RCOR3	0.45	7.99	0.36	1.29e-14	Mean corpuscular volume;
LUAD	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg14159672	chr1:205819179	PM20D1	0.47	6.63	0.31	1.04e-10	Parkinson's disease;
LUAD	cis	rs6906287	0.573	rs11153732	chr6:118704967	C/T	cg05564266	chr6:118973597	C6orf204	0.33	7.03	0.32	8.39e-12	Electrocardiographic conduction measures;
LUAD	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg01788221	chr16:89496183	ANKRD11	-0.35	-6.68	-0.31	7.46e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.32	6.44	0.3	3.19e-10	Obesity-related traits;
LUAD	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg06547715	chr2:218990976	CXCR2	0.28	6.76	0.31	4.64e-11	Colorectal cancer;
LUAD	cis	rs4692589	1.000	rs12643956	chr4:170932819	A/C	cg19918862	chr4:170955249	NA	0.27	6.5	0.3	2.22e-10	Anxiety disorder;
LUAD	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.53	-0.34	3.1400000000000003e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg19052272	chr2:3704530	ALLC	0.48	7.4	0.34	7.61e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs977987	0.806	rs4888416	chr16:75449176	C/G	cg03315344	chr16:75512273	CHST6	0.64	14.06	0.56	4.12e-37	Dupuytren's disease;
LUAD	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg11645453	chr3:52864694	ITIH4	-0.35	-6.83	-0.32	2.88e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7737355	0.812	rs12513768	chr5:130616792	G/A	cg06307176	chr5:131281290	NA	0.39	6.59	0.31	1.33e-10	Life satisfaction;
LUAD	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.44	0.3	3.28e-10	Depression;
LUAD	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.34	-0.48	3.19e-26	Type 2 diabetes;
LUAD	cis	rs12541635	0.966	rs114386112	chr8:107036340	G/A	cg10147462	chr8:107024639	NA	0.49	8.76	0.39	4.9e-17	Age of smoking initiation;
LUAD	trans	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg01620082	chr3:125678407	NA	-0.4	-6.36	-0.3	5.13e-10	Parkinson's disease;
LUAD	trans	rs11088226	0.681	rs2833897	chr21:33931792	T/C	cg09050820	chr6:167586206	TCP10L2	0.91	12.37	0.52	3.13e-30	Gastritis;
LUAD	cis	rs7267979	0.816	rs422148	chr20:25512604	G/C	cg08601574	chr20:25228251	PYGB	0.37	6.9	0.32	1.97e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg12935359	chr14:103987150	CKB	0.49	8.11	0.37	5.43e-15	Bone mineral density;
LUAD	cis	rs2224391	0.518	rs17140102	chr6:5288618	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.65	-8.11	-0.37	5.45e-15	Height;
LUAD	cis	rs3813948	0.543	rs2808466	chr1:207273751	T/C	cg11070419	chr1:207277210	C4BPA	-0.47	-6.87	-0.32	2.27e-11	C4b binding protein levels;
LUAD	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg18190219	chr22:46762943	CELSR1	-0.46	-6.52	-0.3	2.02e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg15448220	chr1:150897856	SETDB1	-0.47	-8.02	-0.36	1.02e-14	Tonsillectomy;
LUAD	cis	rs4901869	0.931	rs12891570	chr14:59334338	T/A	cg02291164	chr14:59296302	NA	0.65	15.74	0.61	2.91e-44	Panic disorder;
LUAD	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08859206	chr1:53392774	SCP2	0.8	15.19	0.59	6.73e-42	Monocyte count;
LUAD	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg22117172	chr7:91764530	CYP51A1	0.33	7.53	0.34	3.18e-13	Breast cancer;
LUAD	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg04772025	chr11:68637568	NA	0.58	9.06	0.4	4.96e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7216064	1.000	rs62085993	chr17:65923152	T/C	cg08758996	chr17:66097529	LOC651250	0.46	7.13	0.33	4.35e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg19336497	chr11:14380999	RRAS2	-0.35	-7.39	-0.34	7.68e-13	Mitochondrial DNA levels;
LUAD	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.5	0.3	2.24e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06022373	chr22:39101656	GTPBP1	0.38	6.47	0.3	2.76e-10	Menopause (age at onset);
LUAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.57	-8.31	-0.37	1.33e-15	Alzheimer's disease;
LUAD	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.81	-0.35	4.63e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs5167	0.583	rs7252480	chr19:45458925	C/T	cg09555818	chr19:45449301	APOC2	0.37	6.64	0.31	9.63e-11	Blood protein levels;
LUAD	cis	rs7172809	0.500	rs17385059	chr15:77637812	T/C	cg11865553	chr15:77376250	NA	-0.39	-6.68	-0.31	7.48e-11	Glucose homeostasis traits;
LUAD	cis	rs76878669	0.519	rs10791869	chr11:66117113	C/T	cg18002602	chr11:66138449	SLC29A2	-0.48	-10.35	-0.45	1.6e-22	Educational attainment (years of education);
LUAD	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg04705435	chr11:17411270	KCNJ11	0.41	6.84	0.32	2.74e-11	Type 2 diabetes;
LUAD	trans	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.53	0.46	3.58e-23	Mean corpuscular volume;
LUAD	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg25324976	chr17:61989376	CSHL1	0.37	7.34	0.34	1.13e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg19318889	chr4:1322082	MAEA	-0.42	-7.09	-0.33	5.73e-12	Obesity-related traits;
LUAD	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg24558204	chr6:135376177	HBS1L	0.48	8.05	0.36	8.27e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7843479	0.562	rs6988010	chr8:21859084	G/A	cg03445287	chr8:21823731	XPO7	-0.48	-9.1	-0.4	3.6e-18	Mean corpuscular volume;
LUAD	cis	rs7927592	0.546	rs683978	chr11:68192421	T/C	cg01657329	chr11:68192670	LRP5	-0.54	-9.28	-0.41	8.66e-19	Total body bone mineral density;
LUAD	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg16988262	chr1:15930761	NA	0.41	6.83	0.32	2.98e-11	Systolic blood pressure;
LUAD	cis	rs7010267	0.543	rs6469796	chr8:120018042	G/A	cg01975934	chr8:119970761	NA	-0.35	-6.65	-0.31	9.03e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs10924309	0.882	rs10924306	chr1:245857065	G/A	cg00036263	chr1:245852353	KIF26B	-0.51	-7.7	-0.35	9.66e-14	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg04155289	chr7:94953770	PON1	-0.5	-6.54	-0.3	1.81e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs783540	0.656	rs783524	chr15:83284144	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.55	-8.58	-0.39	1.82e-16	Schizophrenia;
LUAD	cis	rs12986413	0.651	rs2238609	chr19:2146629	C/T	cg09261902	chr19:2140048	AP3D1	0.34	6.78	0.31	4.16e-11	Height;
LUAD	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.15	16.61	0.63	4.84e-48	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2735413	0.914	rs1922608	chr16:78065139	A/G	cg04733911	chr16:78082701	NA	-0.33	-7.67	-0.35	1.2e-13	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg09658497	chr7:2847517	GNA12	-0.56	-9.64	-0.42	5.07e-20	Height;
LUAD	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg05283184	chr6:79620031	NA	-0.45	-7.83	-0.36	3.88e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3820068	0.734	rs6674806	chr1:15902656	A/G	cg24675056	chr1:15929824	NA	0.42	6.64	0.31	9.87e-11	Systolic blood pressure;
LUAD	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg05665937	chr4:1216051	CTBP1	0.41	6.73	0.31	5.63e-11	Obesity-related traits;
LUAD	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg01802117	chr1:53393560	SCP2	0.33	6.38	0.3	4.57e-10	Monocyte count;
LUAD	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.98	0.36	1.38e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7818345	0.845	rs11785649	chr8:19268233	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.33	7.03	0.32	8.46e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg13010199	chr12:38710504	ALG10B	0.39	6.59	0.31	1.32e-10	Bladder cancer;
LUAD	cis	rs6714710	0.603	rs2044459	chr2:98447004	T/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.16	0.37	3.83e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs1550582	0.662	rs4909628	chr8:135502380	A/T	cg17885191	chr8:135476712	NA	-0.93	-14.27	-0.57	5.32e-38	Educational attainment;
LUAD	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg11189052	chr15:85197271	WDR73	-0.78	-13.44	-0.55	1.51e-34	P wave terminal force;
LUAD	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg09491104	chr22:46646882	C22orf40	-0.54	-7.7	-0.35	1e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs12541635	0.966	rs2345070	chr8:107072027	A/G	cg10147462	chr8:107024639	NA	-0.48	-8.64	-0.39	1.2e-16	Age of smoking initiation;
LUAD	cis	rs67072384	1.000	rs55957377	chr11:72445476	A/G	cg04827223	chr11:72435913	ARAP1	-0.62	-7.6	-0.35	1.96e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg09184832	chr6:79620586	NA	-0.5	-9.3	-0.41	7.68e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg03713592	chr11:72463424	ARAP1	0.62	7.92	0.36	2.19e-14	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg03806693	chr22:41940476	POLR3H	0.73	9.81	0.43	1.33e-20	Vitiligo;
LUAD	trans	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg01620082	chr3:125678407	NA	-0.45	-6.65	-0.31	8.99e-11	Depression;
LUAD	cis	rs10821973	0.527	rs7896953	chr10:64025653	C/A	cg09941381	chr10:64027924	RTKN2	-0.36	-6.91	-0.32	1.79e-11	Hypothyroidism;
LUAD	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg07936489	chr17:37558343	FBXL20	0.52	7.04	0.32	7.68e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07636037	chr3:49044803	WDR6	0.47	7.88	0.36	2.79e-14	Menarche (age at onset);
LUAD	cis	rs4774899	0.752	rs2733188	chr15:57370507	C/T	cg14026238	chr15:57616123	NA	0.43	8.13	0.37	4.7e-15	Urinary tract infection frequency;
LUAD	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg05623727	chr3:50126028	RBM5	0.31	6.62	0.31	1.11e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.98	-0.36	1.41e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4691139	1.000	rs10007789	chr4:165890377	C/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.45	-8.87	-0.4	2.13e-17	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg04398451	chr17:18023971	MYO15A	0.69	12.34	0.51	4.37e-30	Total body bone mineral density;
LUAD	cis	rs1983170	0.736	rs11164909	chr1:92002506	T/C	cg25838465	chr1:92012736	NA	0.5	6.5	0.3	2.26e-10	Eosinophil percentage of white cells;
LUAD	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg24818145	chr4:99064322	C4orf37	-0.41	-6.9	-0.32	1.96e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg22875332	chr1:76189707	ACADM	0.73	10.79	0.46	3.93e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.34	6.45	0.3	3.14e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.4	-6.57	-0.3	1.51e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg04287289	chr16:89883240	FANCA	-0.48	-7.72	-0.35	8.53e-14	Vitiligo;
LUAD	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg18833306	chr6:118973337	C6orf204	-0.54	-7.55	-0.34	2.74e-13	Diastolic blood pressure;
LUAD	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg25233709	chr10:116636983	FAM160B1	0.46	9.32	0.41	6.3e-19	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.54	0.3	1.76e-10	Cardiac Troponin-T levels;
LUAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg04025307	chr7:1156635	C7orf50	0.65	8.08	0.37	6.8e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	8.0	0.36	1.24e-14	Tonsillectomy;
LUAD	cis	rs4853036	0.904	rs12713683	chr2:70156321	G/A	cg02498382	chr2:70120550	SNRNP27	-0.48	-7.72	-0.35	8.29e-14	Colorectal or endometrial cancer;
LUAD	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-7.88	-0.36	2.74e-14	Breast cancer;
LUAD	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19346786	chr7:2764209	NA	-0.56	-12.15	-0.51	2.5e-29	Height;
LUAD	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.42	-7.53	-0.34	3.12e-13	Tonsillectomy;
LUAD	cis	rs7216064	1.000	rs59950564	chr17:65860859	A/G	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg05865280	chr17:75406074	SEPT9	-0.61	-19.0	-0.68	1.15e-58	Airflow obstruction;
LUAD	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg16049864	chr8:95962084	TP53INP1	0.52	10.19	0.44	6.09e-22	Type 2 diabetes;
LUAD	cis	rs7084921	0.552	rs1324693	chr10:101890617	A/G	cg19754520	chr10:101825118	CPN1	-0.34	-6.87	-0.32	2.29e-11	Bone mineral density;
LUAD	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg15133208	chr4:90757351	SNCA	-0.44	-6.74	-0.31	5.05e-11	Neuroticism;
LUAD	cis	rs7474896	0.515	rs662928	chr10:38316216	G/T	cg25427524	chr10:38739819	LOC399744	0.58	8.35	0.38	9.55e-16	Obesity (extreme);
LUAD	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg03676636	chr4:99064102	C4orf37	0.29	6.9	0.32	1.93e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.08e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.82	-0.36	4.27e-14	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs2797160	1.000	rs983543	chr6:126005767	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-8.89	-0.4	1.78e-17	Endometrial cancer;
LUAD	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg23422044	chr7:1970798	MAD1L1	-0.45	-6.8	-0.31	3.47e-11	Bipolar disorder;
LUAD	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.55	10.9	0.47	1.57e-24	Hemoglobin concentration;
LUAD	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg18876405	chr7:65276391	NA	0.61	10.47	0.45	5.87e-23	Aortic root size;
LUAD	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg11344533	chr11:111475393	SIK2	-0.36	-6.75	-0.31	4.82e-11	Primary sclerosing cholangitis;
LUAD	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg06131755	chr6:160182447	ACAT2	0.42	6.38	0.3	4.63e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs16958440	0.867	rs79712753	chr18:44676727	C/A	cg17192377	chr18:44677553	HDHD2	0.84	8.03	0.36	1e-14	Sitting height ratio;
LUAD	cis	rs17067123	0.614	rs35522192	chr4:180064376	C/A	cg26610307	chr4:180072759	NA	-0.52	-6.75	-0.31	4.86e-11	Response to hepatitis C treatment;
LUAD	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg22482690	chr17:47019901	SNF8	0.44	8.37	0.38	8.71e-16	Type 2 diabetes;
LUAD	cis	rs925255	0.817	rs12624279	chr2:28634790	G/A	cg01273330	chr2:28605224	NA	0.41	8.61	0.39	1.49e-16	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2651899	0.902	rs1798246	chr1:3080855	A/C	cg22674798	chr1:3096360	PRDM16	0.4	10.37	0.45	1.38e-22	Migraine;
LUAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.61	8.3	0.37	1.44e-15	Renal function-related traits (BUN);
LUAD	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.91	-0.36	2.33e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.38	8.47	0.38	4.04e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4285028	0.747	rs7648343	chr3:121426195	G/A	cg11130432	chr3:121712080	ILDR1	-0.57	-7.88	-0.36	2.73e-14	Multiple sclerosis;
LUAD	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg01620082	chr3:125678407	NA	-0.99	-9.64	-0.42	5.04e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs73416724	1.000	rs74690967	chr6:43370915	C/T	cg26312998	chr6:43337775	ZNF318	0.55	6.55	0.3	1.66e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg17173187	chr15:85201210	NMB	0.41	6.43	0.3	3.37e-10	Schizophrenia;
LUAD	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg12257156	chr7:158823799	VIPR2	0.49	7.25	0.33	1.94e-12	Facial morphology (factor 20);
LUAD	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg07636037	chr3:49044803	WDR6	0.49	8.25	0.37	2.06e-15	Childhood ear infection;
LUAD	cis	rs7903847	0.642	rs9888117	chr10:99159963	C/G	cg20016023	chr10:99160130	RRP12	-0.31	-7.44	-0.34	5.64e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2996428	0.628	rs6667526	chr1:3774603	G/A	cg17443473	chr1:3703550	LRRC47	0.48	7.87	0.36	2.96e-14	Red cell distribution width;
LUAD	cis	rs78707713	0.841	rs2033372	chr10:71212333	C/G	cg12610070	chr10:71211762	TSPAN15	-0.4	-7.22	-0.33	2.45e-12	Venous thromboembolism;
LUAD	cis	rs13315871	0.929	rs77487951	chr3:58290892	G/A	cg20936604	chr3:58311152	NA	-0.75	-7.61	-0.35	1.82e-13	Cholesterol, total;
LUAD	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg06002616	chr8:101225028	SPAG1	-0.38	-7.83	-0.36	3.85e-14	Atrioventricular conduction;
LUAD	cis	rs2073300	1.000	rs6137960	chr20:23442886	G/A	cg12062639	chr20:23401060	NAPB	0.98	8.71	0.39	7.03e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.05	-0.56	4.73e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs11971779	0.648	rs9642121	chr7:139092621	G/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg05110241	chr16:68378359	PRMT7	-0.7	-7.99	-0.36	1.26e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11677416	1.000	rs6542091	chr2:113525311	G/A	cg27083787	chr2:113543245	IL1A	0.38	6.64	0.31	9.56e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg12193833	chr17:30244370	NA	-0.58	-6.95	-0.32	1.35e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg00280220	chr17:61926910	NA	0.36	6.9	0.32	1.9e-11	Prudent dietary pattern;
LUAD	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-6.76	-0.31	4.61e-11	Alzheimer's disease (late onset);
LUAD	cis	rs13064411	0.696	rs13325046	chr3:113104444	C/T	cg18753928	chr3:113234510	CCDC52	-0.7	-10.69	-0.46	8.83e-24	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs151234	0.741	rs11644791	chr16:28601186	G/C	cg04643524	chr16:28609220	SULT1A2	0.64	8.99	0.4	8.25e-18	Platelet distribution width;
LUAD	cis	rs2455601	0.882	rs11042105	chr11:8894510	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.52	-8.29	-0.37	1.49e-15	Schizophrenia;
LUAD	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg21775007	chr8:11205619	TDH	0.48	8.25	0.37	2.05e-15	Retinal vascular caliber;
LUAD	cis	rs16866061	1.000	rs72974238	chr2:225432470	C/A	cg12698349	chr2:225449008	CUL3	0.77	13.43	0.55	1.69e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg26924012	chr15:45694286	SPATA5L1	0.88	14.11	0.57	2.44e-37	Homoarginine levels;
LUAD	cis	rs375066	0.762	rs10424336	chr19:44392100	C/T	cg12072164	chr19:44306565	LYPD5	0.32	6.48	0.3	2.6e-10	Breast cancer;
LUAD	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg27284194	chr4:1044797	NA	0.44	6.8	0.31	3.66e-11	Obesity-related traits;
LUAD	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg12667521	chr19:29218732	NA	0.65	8.06	0.36	7.93e-15	Methadone dose in opioid dependence;
LUAD	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.3	6.36	0.3	5.19e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg26958806	chr6:27640298	NA	0.58	6.44	0.3	3.31e-10	Depression;
LUAD	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg00784671	chr22:46762841	CELSR1	-0.44	-6.74	-0.31	5.35e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1232027	0.622	rs1824838	chr5:79961312	C/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg02931644	chr1:25747376	RHCE	0.52	11.38	0.48	2.37e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg26597838	chr10:835615	NA	-1.3	-20.91	-0.71	3.42e-67	Eosinophil percentage of granulocytes;
LUAD	cis	rs41311933	0.710	rs78176134	chr9:123702338	C/T	cg13567360	chr9:123745713	C5	-0.83	-7.22	-0.33	2.36e-12	Coronary artery disease;
LUAD	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg07636037	chr3:49044803	WDR6	0.55	10.3	0.45	2.39e-22	Menarche (age at onset);
LUAD	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg21399703	chr1:247681439	NA	0.41	7.55	0.34	2.75e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg14686297	chr22:46650375	NA	-0.38	-6.57	-0.3	1.44e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg16205897	chr5:131564050	P4HA2	-0.32	-7.07	-0.32	6.59e-12	Breast cancer;
LUAD	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg23649088	chr2:200775458	C2orf69	-0.52	-8.32	-0.37	1.23e-15	Osteoporosis;
LUAD	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg13319975	chr6:146136371	FBXO30	-0.61	-10.64	-0.46	1.36e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2066819	1.000	rs59626664	chr12:56636975	C/G	cg26714650	chr12:56694279	CS	-0.83	-6.99	-0.32	1.05e-11	Psoriasis vulgaris;
LUAD	cis	rs11756438	0.683	rs57237379	chr6:119018319	G/A	cg21191810	chr6:118973309	C6orf204	0.41	7.4	0.34	7.35e-13	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg22166914	chr1:53195759	ZYG11B	0.44	7.3	0.33	1.4e-12	Monocyte count;
LUAD	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg15605315	chr1:45957053	TESK2	0.44	6.79	0.31	3.74e-11	High light scatter reticulocyte count;
LUAD	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg05187965	chr10:45406764	TMEM72	-0.49	-9.72	-0.43	2.64e-20	Mean corpuscular volume;
LUAD	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg04705435	chr11:17411270	KCNJ11	0.41	6.87	0.32	2.32e-11	Type 2 diabetes;
LUAD	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg04731861	chr2:219085781	ARPC2	0.23	7.18	0.33	3.25e-12	Colorectal cancer;
LUAD	cis	rs1232027	0.656	rs836799	chr5:79985768	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.41	-6.5	-0.3	2.3e-10	Huntington's disease progression;
LUAD	cis	rs11811982	0.557	rs76599385	chr1:227318924	A/T	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic disc area;
LUAD	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg02423579	chr7:2872169	GNA12	-0.41	-6.83	-0.32	2.99e-11	Height;
LUAD	cis	rs9902453	0.934	rs4343336	chr17:28488236	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.45	0.38	4.58e-16	Coffee consumption (cups per day);
LUAD	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg14828511	chr1:107599125	PRMT6	0.5	8.5	0.38	3.2e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6750795	0.746	rs2916579	chr2:232421159	A/G	cg19187155	chr2:232395269	NMUR1	0.66	12.44	0.52	1.75e-30	Height;
LUAD	cis	rs2688608	0.967	rs1815076	chr10:75659886	C/T	cg23231163	chr10:75533350	FUT11	-0.38	-7.08	-0.33	5.98e-12	Inflammatory bowel disease;
LUAD	cis	rs34734847	0.842	rs696337	chr12:121159380	T/C	cg21892295	chr12:121157589	UNC119B	-0.37	-6.47	-0.3	2.64e-10	Mean corpuscular volume;
LUAD	cis	rs6546550	0.901	rs6725425	chr2:70150674	T/C	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.97	-0.47	8.24e-25	Prevalent atrial fibrillation;
LUAD	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg12193833	chr17:30244370	NA	-0.51	-6.78	-0.31	4.13e-11	Hip circumference adjusted for BMI;
LUAD	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg05926928	chr17:57297772	GDPD1	1.38	17.09	0.64	3.49e-50	Opioid sensitivity;
LUAD	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg07507251	chr3:52567010	NT5DC2	-0.37	-6.99	-0.32	1.07e-11	Bipolar disorder;
LUAD	cis	rs9633740	1.000	rs1870138	chr10:82269611	A/G	cg00277334	chr10:82204260	NA	-0.62	-8.51	-0.38	3.14e-16	Post bronchodilator FEV1;
LUAD	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg18132916	chr6:79620363	NA	-0.42	-7.4	-0.34	7.27e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg07636037	chr3:49044803	WDR6	0.54	8.11	0.37	5.43e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs7512552	0.582	rs834233	chr1:150354276	G/A	cg15654264	chr1:150340011	RPRD2	0.56	10.49	0.45	4.94e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7799006	0.757	rs2398668	chr7:2298227	A/G	cg08027265	chr7:2291960	NA	0.66	13.71	0.55	1.15e-35	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2262909	0.962	rs12609368	chr19:22263996	T/C	cg11619707	chr19:22235551	ZNF257	0.49	7.5	0.34	3.89e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg11871910	chr12:69753446	YEATS4	0.55	8.68	0.39	8.51e-17	Blood protein levels;
LUAD	cis	rs300774	0.925	rs300779	chr2:111486	G/A	cg21211680	chr2:198530	NA	-0.46	-6.68	-0.31	7.37e-11	Suicide attempts in bipolar disorder;
LUAD	trans	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg11693508	chr17:37793320	STARD3	0.53	7.38	0.34	8.23e-13	Bipolar disorder;
LUAD	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.81	0.36	4.46e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg04772025	chr11:68637568	NA	0.57	8.84	0.39	2.63e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg03433033	chr1:76189801	ACADM	-0.69	-10.78	-0.46	4.25e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg20933634	chr6:27740509	NA	0.5	7.98	0.36	1.4e-14	Parkinson's disease;
LUAD	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg11247378	chr22:39784982	NA	-0.72	-12.73	-0.53	1.17e-31	Intelligence (multi-trait analysis);
LUAD	cis	rs11756438	0.572	rs2638550	chr6:118998481	C/G	cg18833306	chr6:118973337	C6orf204	0.54	9.67	0.43	4.03e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg08470875	chr2:26401718	FAM59B	-0.57	-7.83	-0.36	3.9e-14	Gut microbiome composition (summer);
LUAD	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg06873352	chr17:61820015	STRADA	0.43	7.09	0.33	5.74e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg02569458	chr12:86230093	RASSF9	0.46	8.31	0.37	1.27e-15	Major depressive disorder;
LUAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-8.96	-0.4	1.02e-17	Lymphocyte counts;
LUAD	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.31	-8.61	-0.39	1.47e-16	Total body bone mineral density;
LUAD	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg14668632	chr7:2872130	GNA12	-0.36	-6.39	-0.3	4.31e-10	Height;
LUAD	cis	rs7731657	0.538	rs2107335	chr5:130292853	C/A	cg08523029	chr5:130500466	HINT1	-0.57	-7.43	-0.34	5.98e-13	Fasting plasma glucose;
LUAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-8.19	-0.37	3.03e-15	Alzheimer's disease;
LUAD	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg19761014	chr17:28927070	LRRC37B2	0.86	8.32	0.38	1.22e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg01236616	chr12:121019343	POP5	1.2	18.7	0.67	2.54e-57	Type 1 diabetes nephropathy;
LUAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg03188948	chr7:1209495	NA	0.45	7.28	0.33	1.64e-12	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg08280861	chr8:58055591	NA	0.56	7.74	0.35	7.37e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.91	-0.36	2.21e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06112835	chr11:68658793	MRPL21	0.5	9.12	0.41	3.02e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7617773	0.817	rs9311421	chr3:48293078	G/A	cg11946769	chr3:48343235	NME6	0.42	6.81	0.31	3.32e-11	Coronary artery disease;
LUAD	cis	rs6005807	0.843	rs9625477	chr22:28858248	T/C	cg12565055	chr22:29076175	TTC28	0.67	6.48	0.3	2.57e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs6684514	0.922	rs12037778	chr1:156284864	A/G	cg16558208	chr1:156270281	VHLL	0.53	9.66	0.43	4.4e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	8.7	0.39	7.34e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg11822812	chr5:140052017	DND1	-0.38	-7.03	-0.32	8.08e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg06547715	chr2:218990976	CXCR2	0.28	6.56	0.3	1.54e-10	Colorectal cancer;
LUAD	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg06453172	chr10:134556979	INPP5A	-0.76	-11.04	-0.47	4.37e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg18129748	chr3:49941408	MST1R	-0.41	-6.58	-0.3	1.39e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs500891	0.574	rs7757427	chr6:84131300	T/A	cg08257003	chr6:84140564	ME1	0.34	6.4	0.3	4.08e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-8.52	-0.38	2.74e-16	Heart rate;
LUAD	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg09184832	chr6:79620586	NA	-0.51	-9.57	-0.42	9.28e-20	Intelligence (multi-trait analysis);
LUAD	trans	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04565464	chr8:145669602	NFKBIL2	0.45	6.65	0.31	8.99e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg25767906	chr1:53392781	SCP2	-0.34	-6.37	-0.3	4.84e-10	Monocyte count;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	ch.15.23362502F	chr15:25811411	NA	-0.42	-6.8	-0.31	3.5e-11	Cancer;
LUAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.72	-0.35	8.28e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs10465746	0.725	rs1359331	chr1:84360301	C/A	cg10977910	chr1:84465055	TTLL7	0.61	9.92	0.43	5.3e-21	Obesity-related traits;
LUAD	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs9362426	0.708	rs7744793	chr6:88102040	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.41	7.21	0.33	2.51e-12	Depressive episodes in bipolar disorder;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg08096038	chr6:99861729	SFRS18	0.39	6.42	0.3	3.62e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg24531977	chr5:56204891	C5orf35	0.45	7.41	0.34	6.72e-13	Coronary artery disease;
LUAD	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg17177755	chr1:15930204	NA	0.44	7.11	0.33	5.08e-12	Systolic blood pressure;
LUAD	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg09137382	chr11:130731461	NA	0.42	7.95	0.36	1.66e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1448094	0.967	rs10863118	chr12:86339232	C/G	cg02569458	chr12:86230093	RASSF9	0.37	7.15	0.33	3.76e-12	Major depressive disorder;
LUAD	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg08470875	chr2:26401718	FAM59B	-0.74	-10.21	-0.44	5.09e-22	Gut microbiome composition (summer);
LUAD	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg00129232	chr17:37814104	STARD3	-0.45	-7.7	-0.35	9.43e-14	Asthma;
LUAD	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg12179176	chr11:130786555	SNX19	0.55	9.29	0.41	8.21e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9948	0.655	rs76653480	chr2:97375549	C/T	cg20312557	chr2:97357134	FER1L5	-0.65	-7.48	-0.34	4.23e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs13064411	0.542	rs1463643	chr3:113215447	A/G	cg18753928	chr3:113234510	CCDC52	-0.55	-9.73	-0.43	2.58e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg01689657	chr7:91764605	CYP51A1	-0.31	-7.58	-0.35	2.22e-13	Breast cancer;
LUAD	cis	rs12618769	0.625	rs3769736	chr2:99089119	C/T	cg10123293	chr2:99228465	UNC50	0.47	8.34	0.38	1.05e-15	Bipolar disorder;
LUAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.6	9.19	0.41	1.79e-18	Alzheimer's disease;
LUAD	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg05727186	chr17:43697356	MGC57346	-0.55	-6.88	-0.32	2.22e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07167872	chr1:205819463	PM20D1	0.78	15.77	0.61	2.14e-44	Menarche (age at onset);
LUAD	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg24818145	chr4:99064322	C4orf37	0.5	8.11	0.37	5.69e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg02782426	chr3:40428986	ENTPD3	0.35	7.43	0.34	6.16e-13	Renal cell carcinoma;
LUAD	trans	rs11154851	0.826	rs4896197	chr6:136351296	C/A	cg06647930	chr22:45135965	PRR5-ARHGAP8	0.69	6.37	0.3	5.03e-10	Alzheimer's disease (cognitive decline);
LUAD	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg13175981	chr1:150552382	MCL1	0.4	6.39	0.3	4.4e-10	Tonsillectomy;
LUAD	trans	rs629535	0.814	rs488231	chr8:70064993	T/C	cg21567404	chr3:27674614	NA	1.01	18.48	0.67	2.54e-56	Dupuytren's disease;
LUAD	cis	rs854765	0.647	rs854817	chr17:18021882	T/C	cg04398451	chr17:18023971	MYO15A	-0.91	-18.1	-0.66	1.23e-54	Total body bone mineral density;
LUAD	cis	rs7010267	0.551	rs6469801	chr8:120025675	T/C	cg01975934	chr8:119970761	NA	-0.35	-6.55	-0.3	1.69e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs4308124	0.679	rs7600458	chr2:111963590	G/C	cg04571233	chr2:111982156	NA	-0.45	-6.42	-0.3	3.76e-10	Vitiligo;
LUAD	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-7.04	-0.32	7.57e-12	Personality dimensions;
LUAD	cis	rs829883	0.604	rs249841	chr12:98871743	A/G	cg25150519	chr12:98850993	NA	0.43	7.04	0.32	7.71e-12	Colorectal adenoma (advanced);
LUAD	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	6.52	0.3	2.07e-10	Personality dimensions;
LUAD	cis	rs367943	0.712	rs255861	chr5:112745327	G/A	cg12552261	chr5:112820674	MCC	0.49	9.7	0.43	3.09e-20	Type 2 diabetes;
LUAD	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-19.92	-0.7	9.21e-63	Height;
LUAD	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg01181863	chr3:195395398	SDHAP2	-0.61	-9.22	-0.41	1.4e-18	Pancreatic cancer;
LUAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg11494091	chr17:61959527	GH2	0.74	18.22	0.66	3.56e-55	Prudent dietary pattern;
LUAD	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg19773385	chr1:10388646	KIF1B	-0.42	-6.95	-0.32	1.37e-11	Hepatocellular carcinoma;
LUAD	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg20578329	chr17:80767326	TBCD	-0.62	-7.68	-0.35	1.15e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.81	-0.36	4.47e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs344364	0.602	rs7188401	chr16:1876949	G/C	cg08610935	chr16:1836813	NUBP2	-0.49	-7.42	-0.34	6.45e-13	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg27411982	chr8:10470053	RP1L1	0.39	7.37	0.34	9.14e-13	Triglycerides;
LUAD	cis	rs231513	0.954	rs231501	chr17:41972303	C/T	cg26893861	chr17:41843967	DUSP3	-0.55	-6.67	-0.31	7.95e-11	Cognitive function;
LUAD	cis	rs4730250	0.707	rs6946931	chr7:106788621	G/T	cg23024343	chr7:107201750	COG5	0.5	6.88	0.32	2.15e-11	Osteoarthritis;
LUAD	trans	rs3960554	0.808	rs78811105	chr7:75702795	G/A	cg19862616	chr7:65841803	NCRNA00174	0.81	11.08	0.47	3.11e-25	Eotaxin levels;
LUAD	cis	rs9467160	1.000	rs12198188	chr6:24442482	A/G	cg16211469	chr6:24423932	MRS2	0.44	7.06	0.32	6.93e-12	Liver enzyme levels;
LUAD	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg25456477	chr12:86230367	RASSF9	0.33	6.37	0.3	5e-10	Major depressive disorder;
LUAD	trans	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.67	11.45	0.49	1.31e-26	Mean corpuscular volume;
LUAD	cis	rs9473147	0.516	rs9395283	chr6:47551444	T/C	cg20196966	chr6:47445060	CD2AP	0.44	6.97	0.32	1.22e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg07538946	chr5:131705188	SLC22A5	0.51	8.37	0.38	8.28e-16	Blood metabolite levels;
LUAD	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg18512352	chr11:47633146	NA	0.52	9.34	0.41	5.65e-19	Subjective well-being;
LUAD	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg00933542	chr6:150070202	PCMT1	0.45	9.52	0.42	1.34e-19	Lung cancer;
LUAD	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg14024328	chr4:719362	PCGF3	-0.54	-8.73	-0.39	5.94e-17	White blood cell count;
LUAD	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg13319975	chr6:146136371	FBXO30	0.59	9.88	0.43	7.79e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	6.7	0.31	6.69e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg26043149	chr18:55253948	FECH	-0.42	-6.99	-0.32	1.11e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs300703	0.719	rs446488	chr2:195365	T/C	cg24565620	chr2:194026	NA	-0.45	-7.19	-0.33	2.96e-12	Blood protein levels;
LUAD	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg27539214	chr16:67997921	SLC12A4	-0.73	-9.42	-0.42	3.03e-19	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg05800723	chr4:79103126	FRAS1	-0.37	-6.74	-0.31	5.35e-11	Schizophrenia;
LUAD	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-16.49	-0.63	1.61e-47	Schizophrenia;
LUAD	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg08213375	chr14:104286397	PPP1R13B	0.26	6.88	0.32	2.15e-11	Schizophrenia;
LUAD	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg02493740	chr2:85810744	VAMP5	-0.45	-8.1	-0.37	5.93e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg11301795	chr4:187892539	NA	-0.75	-15.13	-0.59	1.21e-41	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs80319144	1.000	rs79928267	chr2:159288179	G/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.9	0.32	1.88e-11	Restless legs syndrome;
LUAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08439880	chr3:133502540	NA	-0.48	-9.46	-0.42	2.22e-19	Iron status biomarkers;
LUAD	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg21194808	chr1:2205498	SKI	0.41	6.45	0.3	3.13e-10	Height;
LUAD	cis	rs1957429	0.808	rs7144718	chr14:65333831	G/A	cg23373153	chr14:65346875	NA	0.61	6.73	0.31	5.42e-11	Pediatric areal bone mineral density (radius);
LUAD	cis	rs7617773	0.817	rs3731513	chr3:48219537	A/G	cg11946769	chr3:48343235	NME6	0.42	6.39	0.3	4.49e-10	Coronary artery disease;
LUAD	cis	rs6564851	0.935	rs12931255	chr16:81259756	T/A	cg00908271	chr16:81254010	PKD1L2	-0.32	-7.12	-0.33	4.54e-12	Carotenoid and tocopherol levels;
LUAD	cis	rs1997103	1.000	rs2331067	chr7:55408232	A/T	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg02736602	chr1:197744226	DENND1B	-0.39	-6.64	-0.31	9.78e-11	Schizophrenia;
LUAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg22907277	chr7:1156413	C7orf50	0.51	8.33	0.38	1.11e-15	Longevity;Endometriosis;
LUAD	cis	rs9341808	0.718	rs9448908	chr6:80898069	C/T	cg08355045	chr6:80787529	NA	0.58	10.56	0.46	2.76e-23	Sitting height ratio;
LUAD	cis	rs9807989	0.801	rs11123925	chr2:102977511	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	6.38	0.3	4.58e-10	Asthma;
LUAD	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg17264618	chr3:40429014	ENTPD3	0.38	8.26	0.37	1.83e-15	Renal cell carcinoma;
LUAD	trans	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.8	-0.31	3.69e-11	Diabetic kidney disease;
LUAD	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg20744362	chr22:50050164	C22orf34	0.4	8.65	0.39	1.08e-16	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7617773	0.780	rs35190747	chr3:48343290	C/T	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11644478	chr21:40555479	PSMG1	0.65	10.05	0.44	1.9e-21	Cognitive function;
LUAD	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.15e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8018808	1.000	rs8018808	chr14:77858336	A/G	cg20045696	chr14:77926864	AHSA1	-0.37	-6.54	-0.3	1.83e-10	Myeloid white cell count;
LUAD	cis	rs55823223	0.648	rs56901103	chr17:73865667	C/A	cg04225089	chr17:73874465	TRIM47	-0.38	-6.54	-0.3	1.79e-10	Psoriasis;
LUAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.62	-10.42	-0.45	8.73e-23	Longevity;Endometriosis;
LUAD	cis	rs7731657	0.537	rs6595979	chr5:130335192	C/G	cg08523029	chr5:130500466	HINT1	0.56	7.39	0.34	7.72e-13	Fasting plasma glucose;
LUAD	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg12292205	chr6:26970375	C6orf41	-0.46	-6.49	-0.3	2.37e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8067287	0.554	rs56035746	chr17:16841433	C/T	cg26910001	chr17:16838321	NA	-0.47	-6.52	-0.3	2e-10	Diabetic kidney disease;
LUAD	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg05754148	chr16:3507555	NAT15	-0.39	-6.64	-0.31	9.57e-11	Body mass index (adult);
LUAD	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg25753631	chr6:25732923	NA	-0.41	-7.3	-0.33	1.46e-12	Iron status biomarkers;
LUAD	cis	rs3784262	0.669	rs12915821	chr15:58315685	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.47	-0.34	4.5e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg22681709	chr2:178499509	PDE11A	-0.43	-6.99	-0.32	1.08e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg17863274	chr19:49399704	TULP2	-0.52	-7.16	-0.33	3.53e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg20503657	chr10:835505	NA	1.25	18.77	0.67	1.21e-57	Eosinophil percentage of granulocytes;
LUAD	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg01145583	chr6:160211477	TCP1;MRPL18	-0.44	-6.36	-0.3	5.17e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs11190604	0.767	rs11190520	chr10:102175309	T/C	cg07570687	chr10:102243282	WNT8B	0.44	6.39	0.3	4.35e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg19413350	chr8:57351067	NA	-0.4	-6.35	-0.3	5.5e-10	Obesity-related traits;
LUAD	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg22508957	chr16:3507546	NAT15	0.84	10.62	0.46	1.58e-23	Tuberculosis;
LUAD	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	0.44	7.34	0.34	1.12e-12	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg21775007	chr8:11205619	TDH	0.55	9.85	0.43	9.62e-21	Retinal vascular caliber;
LUAD	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg10792982	chr14:105748885	BRF1	0.46	9.92	0.43	5.22e-21	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg01620082	chr3:125678407	NA	-0.7	-7.18	-0.33	3.11e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg13047869	chr3:10149882	C3orf24	0.55	8.46	0.38	4.33e-16	Alzheimer's disease;
LUAD	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg07404485	chr7:94953653	PON1	-0.52	-7.59	-0.35	2.07e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11890956	chr21:40555474	PSMG1	-0.57	-10.14	-0.44	9.29e-22	Menarche (age at onset);
LUAD	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg03388025	chr16:89894329	SPIRE2	-0.48	-12.37	-0.52	3.24e-30	Vitiligo;
LUAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg24503407	chr1:205819492	PM20D1	0.5	8.16	0.37	3.79e-15	Parkinson's disease;
LUAD	cis	rs58804349	0.685	rs9422671	chr10:43288626	T/G	cg20628663	chr10:43360327	NA	0.62	6.46	0.3	2.86e-10	Pediatric bone mineral content (radius);
LUAD	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg12373951	chr3:133503437	NA	0.36	7.04	0.32	7.73e-12	Iron status biomarkers;
LUAD	cis	rs7264396	1.000	rs224433	chr20:34153850	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-6.41	-0.3	3.78e-10	Total cholesterol levels;
LUAD	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02018176	chr4:1364513	KIAA1530	-0.58	-10.44	-0.45	7.59e-23	Obesity-related traits;
LUAD	cis	rs6960043	0.818	rs10950546	chr7:15050391	C/T	cg19272540	chr7:15055459	NA	0.38	8.5	0.38	3.33e-16	Type 2 diabetes;
LUAD	cis	rs72928364	1.000	rs13060166	chr3:100742822	T/C	cg10123952	chr3:100791384	NA	0.64	7.49	0.34	4.12e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg13319975	chr6:146136371	FBXO30	-0.57	-9.52	-0.42	1.35e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg18446336	chr7:2847575	GNA12	-0.35	-7.03	-0.32	8.36e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs28595532	0.920	rs17257945	chr4:119666465	T/A	cg14228332	chr4:119757509	SEC24D	0.82	7.5	0.34	3.71e-13	Cannabis dependence symptom count;
LUAD	cis	rs933688	0.509	rs2941895	chr5:90520510	A/G	cg17503389	chr5:90575422	NA	-0.43	-6.91	-0.32	1.76e-11	Smoking behavior;
LUAD	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg15557168	chr22:42548783	NA	0.43	8.39	0.38	7.19e-16	Cognitive function;
LUAD	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12756686	chr19:29218302	NA	0.64	9.96	0.44	3.97e-21	Methadone dose in opioid dependence;
LUAD	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg02375832	chr11:62437615	C11orf48	-0.38	-7.36	-0.34	9.38e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg25456477	chr12:86230367	RASSF9	0.32	6.48	0.3	2.59e-10	Major depressive disorder;
LUAD	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg05043794	chr9:111880884	C9orf5	-0.44	-7.55	-0.34	2.73e-13	Menarche (age at onset);
LUAD	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg22963979	chr7:1858916	MAD1L1	-0.47	-8.08	-0.37	6.62e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg08508325	chr11:3079039	CARS	-0.61	-13.41	-0.55	2e-34	Longevity;
LUAD	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.73	0.35	7.65e-14	Breast cancer;
LUAD	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg04731861	chr2:219085781	ARPC2	-0.23	-7.14	-0.33	4.12e-12	Colorectal cancer;
LUAD	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.08	-0.33	5.99e-12	Total body bone mineral density;
LUAD	cis	rs12541635	0.966	rs12681183	chr8:107007156	T/A	cg10147462	chr8:107024639	NA	0.51	9.21	0.41	1.48e-18	Age of smoking initiation;
LUAD	cis	rs354225	0.544	rs12713265	chr2:54805409	C/T	cg01766943	chr2:54829624	SPTBN1	0.4	7.49	0.34	3.95e-13	Schizophrenia;
LUAD	cis	rs910187	0.678	rs3818006	chr20:45816328	A/G	cg27589058	chr20:45804311	EYA2	-0.31	-7.08	-0.33	6.04e-12	Migraine;
LUAD	trans	rs208520	0.661	rs207099	chr6:66796373	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-17.47	-0.65	7.65e-52	Exhaled nitric oxide output;
LUAD	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg13393036	chr8:95962371	TP53INP1	-0.4	-9.71	-0.43	2.96e-20	Type 2 diabetes;
LUAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg04234412	chr22:24373322	LOC391322	0.67	10.07	0.44	1.63e-21	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs3806843	0.576	rs246028	chr5:140333513	C/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.71	-12.28	-0.51	7.7e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg17264618	chr3:40429014	ENTPD3	-0.41	-9.04	-0.4	5.62e-18	Renal cell carcinoma;
LUAD	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg10523679	chr1:76189770	ACADM	0.93	18.6	0.67	7.05e-57	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg21016266	chr12:122356598	WDR66	0.6	10.87	0.47	1.97e-24	Mean corpuscular volume;
LUAD	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg13770153	chr20:60521292	NA	-0.56	-9.28	-0.41	8.69e-19	Body mass index;
LUAD	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg09117114	chr16:67998030	SLC12A4	-0.47	-6.75	-0.31	4.93e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4774899	0.752	rs2951906	chr15:57337969	G/C	cg14026238	chr15:57616123	NA	0.42	8.03	0.36	9.57e-15	Urinary tract infection frequency;
LUAD	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg05425664	chr17:57184151	TRIM37	0.44	7.84	0.36	3.77e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg21171335	chr12:122356390	WDR66	0.76	13.98	0.56	8.96e-37	Mean corpuscular volume;
LUAD	cis	rs367943	0.698	rs12719164	chr5:112960802	A/C	cg12552261	chr5:112820674	MCC	0.44	7.83	0.36	3.94e-14	Type 2 diabetes;
LUAD	cis	rs1535500	1.000	rs35099099	chr6:39284857	G/A	cg06347083	chr6:39282316	KCNK17	-0.36	-7.6	-0.35	1.89e-13	Type 2 diabetes;
LUAD	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg14828511	chr1:107599125	PRMT6	0.53	9.32	0.41	6.61e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs494562	0.892	rs573737	chr6:86118233	A/G	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.37	6.59	0.31	1.33e-10	Blood metabolite levels;
LUAD	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg02886208	chr11:14281011	SPON1	0.36	7.39	0.34	7.79e-13	Mitochondrial DNA levels;
LUAD	trans	rs7395662	0.963	rs6485900	chr11:48637415	C/T	cg00717180	chr2:96193071	NA	-0.4	-7.4	-0.34	7.56e-13	HDL cholesterol;
LUAD	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	7.11	0.33	4.84e-12	Schizophrenia;
LUAD	trans	rs11039798	0.920	rs11040015	chr11:48783130	G/T	cg15704280	chr7:45808275	SEPT13	0.67	7.82	0.36	4.38e-14	Axial length;
LUAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06873352	chr17:61820015	STRADA	0.83	18.42	0.67	4.62e-56	Prudent dietary pattern;
LUAD	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.66	-0.31	8.51e-11	Crohn's disease;
LUAD	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg09872104	chr7:134855509	C7orf49	-0.53	-6.51	-0.3	2.16e-10	Colorectal cancer;
LUAD	cis	rs6942407	0.546	rs765968	chr7:86794724	G/A	cg02420886	chr7:86849541	C7orf23	0.63	7.29	0.33	1.55e-12	Food allergy;
LUAD	cis	rs12545109	0.800	rs1440763	chr8:57410481	C/A	cg07776626	chr8:57350775	NA	-0.61	-8.51	-0.38	3.13e-16	Obesity-related traits;
LUAD	trans	rs1945213	0.694	rs67394518	chr11:55855303	G/A	cg15704280	chr7:45808275	SEPT13	0.67	8.1	0.37	5.99e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.41	-0.38	6.27e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.85	0.56	3.1e-36	Prudent dietary pattern;
LUAD	trans	rs4942242	0.763	rs7326281	chr13:44233186	G/A	cg19169023	chr15:41853346	TYRO3	-0.69	-12.15	-0.51	2.31e-29	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7202877	0.656	rs8048677	chr16:75392028	C/G	cg03315344	chr16:75512273	CHST6	0.49	6.82	0.31	3.2e-11	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg26384229	chr12:38710491	ALG10B	0.47	7.54	0.34	2.89e-13	Heart rate;
LUAD	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg08048268	chr3:133502702	NA	-0.48	-8.69	-0.39	7.82e-17	Iron status biomarkers;
LUAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	6.9	0.32	1.92e-11	Alzheimer's disease;
LUAD	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg11645453	chr3:52864694	ITIH4	0.51	10.18	0.44	6.41e-22	Bipolar disorder;
LUAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27286337	chr10:134555280	INPP5A	0.73	9.71	0.43	2.92e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg06046430	chr4:77819534	ANKRD56	0.55	8.97	0.4	1e-17	Emphysema distribution in smoking;
LUAD	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-6.61	-0.31	1.15e-10	Personality dimensions;
LUAD	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg12011299	chr4:100065546	ADH4	0.69	12.46	0.52	1.49e-30	Smoking initiation;
LUAD	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.32	6.99	0.32	1.06e-11	Parkinson's disease;
LUAD	cis	rs490234	0.651	rs13291556	chr9:128240922	T/C	cg14078157	chr9:128172775	NA	-0.46	-8.03	-0.36	9.8e-15	Mean arterial pressure;
LUAD	cis	rs12216545	0.737	rs4725911	chr7:150237328	A/G	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.4	-0.3	4.08e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg00316803	chr15:76480434	C15orf27	-0.39	-7.14	-0.33	4.18e-12	Blood metabolite levels;
LUAD	cis	rs2067615	0.579	rs9651957	chr12:107170128	A/G	cg15890332	chr12:107067104	RFX4	0.4	8.75	0.39	5e-17	Heart rate;
LUAD	trans	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	trans	rs9951602	0.512	rs7237214	chr18:76657394	C/G	cg02800362	chr5:177631904	HNRNPAB	0.92	14.21	0.57	9.51e-38	Obesity-related traits;
LUAD	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.3	-0.51	6.25e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg18306943	chr3:40428807	ENTPD3	0.41	7.02	0.32	9.06e-12	Renal cell carcinoma;
LUAD	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg19052272	chr2:3704530	ALLC	-0.63	-10.7	-0.46	8.35e-24	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg03030879	chr14:75389066	RPS6KL1	0.37	6.7	0.31	6.87e-11	Caffeine consumption;
LUAD	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg06784218	chr1:46089804	CCDC17	-0.53	-11.84	-0.5	3.99e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg04287289	chr16:89883240	FANCA	-0.73	-6.7	-0.31	6.75e-11	Skin colour saturation;
LUAD	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg05340658	chr4:99064831	C4orf37	-0.44	-6.68	-0.31	7.32e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg02951883	chr7:2050386	MAD1L1	0.79	13.75	0.56	7.96e-36	Bipolar disorder and schizophrenia;
LUAD	trans	rs9784649	0.574	rs7702369	chr5:25026602	A/G	cg08600765	chr20:34638493	LOC647979	-0.52	-7.54	-0.34	2.87e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-7.61	-0.35	1.75e-13	Lung cancer;
LUAD	trans	rs11252926	0.797	rs61837235	chr10:489363	G/A	cg00953403	chr17:74099816	EXOC7	-0.52	-7.49	-0.34	3.94e-13	Psychosis in Alzheimer's disease;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14875093	chr19:38398164	WDR87;SIPA1L3	0.42	6.61	0.31	1.16e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.83	-0.32	2.89e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg06064525	chr11:970664	AP2A2	-0.43	-8.47	-0.38	3.98e-16	Alzheimer's disease (late onset);
LUAD	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg00277334	chr10:82204260	NA	-0.69	-10.84	-0.47	2.42e-24	Post bronchodilator FEV1;
LUAD	cis	rs80319144	0.535	rs11686340	chr2:159392957	A/G	cg24986868	chr2:159312599	PKP4;CCDC148	-0.37	-7.58	-0.35	2.15e-13	Restless legs syndrome;
LUAD	cis	rs6460942	0.915	rs17324858	chr7:12305792	G/T	cg06484146	chr7:12443880	VWDE	-0.47	-7.06	-0.32	6.82e-12	Coronary artery disease;
LUAD	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg00290607	chr11:67383545	NA	-0.48	-6.49	-0.3	2.4e-10	Mean corpuscular volume;
LUAD	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.62	10.98	0.47	7.41e-25	Birth weight;
LUAD	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg20283391	chr11:68216788	NA	0.4	6.55	0.3	1.68e-10	Total body bone mineral density;
LUAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg21724239	chr8:58056113	NA	0.47	6.78	0.31	4.11e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11958404	1.000	rs9686690	chr5:157412103	C/T	cg05962755	chr5:157440814	NA	0.4	6.38	0.3	4.66e-10	IgG glycosylation;
LUAD	cis	rs7709909	0.755	rs6883090	chr5:79976388	T/C	cg24059623	chr5:79951536	MSH3;DHFR	0.46	8.62	0.39	1.32e-16	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05665937	chr4:1216051	CTBP1	-0.46	-7.43	-0.34	6.11e-13	Obesity-related traits;
LUAD	cis	rs7095607	0.813	rs7895717	chr10:69924100	A/G	cg18986048	chr10:69913749	MYPN	0.38	6.56	0.3	1.58e-10	Lung function (FVC);
LUAD	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg14092988	chr3:52407081	DNAH1	0.39	7.9	0.36	2.5e-14	Electroencephalogram traits;
LUAD	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.59	-0.42	7.64e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19717773	chr7:2847554	GNA12	-0.57	-9.89	-0.43	6.9299999999999992e-21	Height;
LUAD	cis	rs67072384	1.000	rs72964198	chr11:72446464	C/T	cg04827223	chr11:72435913	ARAP1	-0.61	-7.26	-0.33	1.82e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg27202037	chr11:130298544	ADAMTS8	0.44	7.19	0.33	3.03e-12	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06780703	chr1:161358133	NA	0.5	6.42	0.3	3.69e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.32	6.97	0.32	1.21e-11	Parkinson's disease;
LUAD	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg22508957	chr16:3507546	NAT15	0.52	7.2	0.33	2.78e-12	Body mass index (adult);
LUAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14893161	chr1:205819251	PM20D1	0.8	16.41	0.62	3.36e-47	Menarche (age at onset);
LUAD	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11644478	chr21:40555479	PSMG1	-0.4	-6.6	-0.31	1.22e-10	Menarche (age at onset);
LUAD	cis	rs220324	0.688	rs11700704	chr21:43564103	C/T	cg09727148	chr21:43560719	UMODL1	0.57	8.61	0.39	1.42e-16	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg26343298	chr8:95960752	TP53INP1	0.38	8.01	0.36	1.13e-14	Type 2 diabetes;
LUAD	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg13319975	chr6:146136371	FBXO30	0.58	9.75	0.43	2.15e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10927875	0.526	rs35340817	chr1:16178917	T/C	cg21385522	chr1:16154831	NA	-0.95	-13.82	-0.56	4.2e-36	Dilated cardiomyopathy;
LUAD	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg25036284	chr2:26402008	FAM59B	0.75	10.03	0.44	2.17e-21	Gut microbiome composition (summer);
LUAD	cis	rs2625529	0.816	rs4777467	chr15:72138478	T/C	cg16672083	chr15:72433130	SENP8	-0.73	-11.77	-0.5	7.19e-28	Red blood cell count;
LUAD	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg09904177	chr6:26538194	HMGN4	0.42	6.92	0.32	1.73e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg07757535	chr4:1339547	NA	0.29	6.51	0.3	2.14e-10	Longevity;
LUAD	cis	rs9900062	1.000	rs2521879	chr17:62742678	A/G	cg02598441	chr17:62777298	LOC146880	-0.57	-6.55	-0.3	1.68e-10	QT interval;
LUAD	cis	rs3820068	0.705	rs72643683	chr1:15824905	C/A	cg13390004	chr1:15929781	NA	0.4	6.41	0.3	3.8e-10	Systolic blood pressure;
LUAD	cis	rs8060686	0.516	rs7193701	chr16:68185160	A/G	cg05110241	chr16:68378359	PRMT7	0.55	7.43	0.34	6.12e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2274273	0.934	rs10139337	chr14:55742113	C/T	cg04306507	chr14:55594613	LGALS3	0.44	9.13	0.41	2.91e-18	Protein biomarker;
LUAD	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg08048268	chr3:133502702	NA	-0.41	-7.97	-0.36	1.54e-14	Iron status biomarkers;
LUAD	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg15448220	chr1:150897856	SETDB1	0.53	9.29	0.41	7.97e-19	Melanoma;
LUAD	cis	rs4077515	0.874	rs35670379	chr9:139270606	T/C	cg14019695	chr9:139328340	INPP5E	0.39	7.43	0.34	5.95e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9715521	0.646	rs6819464	chr4:59841935	T/C	cg11281224	chr4:60001000	NA	-0.46	-7.37	-0.34	8.81e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg23649088	chr2:200775458	C2orf69	0.63	8.4	0.38	6.67e-16	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg08027265	chr7:2291960	NA	-0.5	-8.6	-0.39	1.62e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7737355	0.812	rs10040442	chr5:130753077	C/G	cg06307176	chr5:131281290	NA	-0.41	-6.97	-0.32	1.26e-11	Life satisfaction;
LUAD	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg17063962	chr7:91808500	NA	0.67	11.45	0.49	1.31e-26	Breast cancer;
LUAD	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg14008862	chr17:28927542	LRRC37B2	0.77	7.66	0.35	1.29e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs629535	0.547	rs62513420	chr8:70122597	G/A	cg21567404	chr3:27674614	NA	-0.98	-15.94	-0.61	3.78e-45	Dupuytren's disease;
LUAD	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	10.92	0.47	1.27e-24	Hip circumference adjusted for BMI;
LUAD	cis	rs2302190	0.882	rs1974586	chr17:56640731	C/T	cg25885038	chr17:56607967	SEPT4	-0.52	-8.28	-0.37	1.66e-15	Vitamin D levels;
LUAD	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.34	-0.41	5.73e-19	Schizophrenia;
LUAD	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg11915388	chr22:42470451	FAM109B	0.39	7.02	0.32	9.11e-12	Schizophrenia;
LUAD	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg08071915	chr8:12219732	FAM66A	0.45	7.34	0.34	1.14e-12	Joint mobility (Beighton score);
LUAD	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg03560586	chr2:239334908	ASB1	0.3	6.61	0.31	1.14e-10	Multiple system atrophy;
LUAD	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg02993280	chr1:107599747	PRMT6	0.43	7.1	0.33	5.15e-12	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg15900387	chr1:150738905	CTSS	-0.38	-6.9	-0.32	1.89e-11	Melanoma;
LUAD	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg03037974	chr15:76606532	NA	0.38	8.15	0.37	4.16e-15	Blood metabolite levels;
LUAD	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg05925327	chr15:68127851	NA	0.36	6.67	0.31	7.93e-11	Restless legs syndrome;
LUAD	cis	rs58804349	0.685	rs9422671	chr10:43288626	T/G	cg08461752	chr10:43522343	NA	-0.83	-8.18	-0.37	3.4e-15	Pediatric bone mineral content (radius);
LUAD	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg17105886	chr17:28927953	LRRC37B2	0.83	8.0	0.36	1.18e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2046867	0.908	rs62251634	chr3:72788705	A/C	cg04365224	chr3:72788183	NA	-0.49	-7.38	-0.34	8.72e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10821973	0.527	rs7099161	chr10:63969311	C/T	cg09941381	chr10:64027924	RTKN2	-0.34	-6.58	-0.3	1.4e-10	Hypothyroidism;
LUAD	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg04545296	chr12:48745243	ZNF641	0.44	10.87	0.47	2.01e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs4253772	0.530	rs28528366	chr22:46680696	G/A	cg00784671	chr22:46762841	CELSR1	-0.61	-7.23	-0.33	2.27e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg16060761	chr17:80687452	NA	0.69	11.31	0.48	4.24e-26	Glycated hemoglobin levels;
LUAD	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg13334819	chr7:99746414	C7orf59	-0.65	-10.47	-0.45	5.66e-23	Coronary artery disease;
LUAD	cis	rs9322817	0.691	rs2400072	chr6:105344116	C/T	cg02098413	chr6:105308735	HACE1	0.41	8.84	0.4	2.54e-17	Thyroid stimulating hormone;
LUAD	cis	rs113835537	0.529	rs17580784	chr11:66214859	T/A	cg26679405	chr11:66247800	DPP3	-0.46	-6.45	-0.3	3.02e-10	Airway imaging phenotypes;
LUAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg21471580	chr8:22132874	PIWIL2	0.47	8.47	0.38	4.17e-16	Hypertriglyceridemia;
LUAD	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	8.18	0.37	3.24e-15	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg06784218	chr1:46089804	CCDC17	0.55	11.77	0.5	7.42e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg26384229	chr12:38710491	ALG10B	0.47	7.55	0.34	2.64e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.44	0.38	5.18e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3812111	0.510	rs1569824	chr6:116590802	T/A	cg18828861	chr6:116576566	TSPYL4	0.37	7.15	0.33	3.81e-12	Age-related macular degeneration;
LUAD	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg11663144	chr21:46675770	NA	-0.59	-11.45	-0.49	1.29e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg21138405	chr5:131827807	IRF1	-0.6	-13.42	-0.55	1.83e-34	Asthma (sex interaction);
LUAD	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg18854424	chr1:2615690	NA	0.43	9.44	0.42	2.62e-19	Ulcerative colitis;
LUAD	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg18932078	chr1:2524107	MMEL1	0.36	6.82	0.31	3.16e-11	Ulcerative colitis;
LUAD	cis	rs11971779	0.618	rs3778931	chr7:139102490	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	7.16e-11	Diisocyanate-induced asthma;
LUAD	cis	rs4930561	0.714	rs1540209	chr11:67928520	A/C	cg04465784	chr11:67976953	SUV420H1	-0.36	-11.41	-0.49	1.78e-26	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs4691139	1.000	rs4691139	chr4:165908721	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.46	-8.99	-0.4	8.18e-18	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs739496	0.615	rs2285727	chr12:112093078	G/T	cg10833066	chr12:111807467	FAM109A	0.42	6.86	0.32	2.38e-11	Platelet count;
LUAD	cis	rs7119	0.651	rs12902449	chr15:77850926	A/G	cg27398640	chr15:77910606	LINGO1	-0.35	-6.46	-0.3	2.96e-10	Type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14049615	chr4:87928107	AFF1	-0.56	-6.82	-0.31	3.1e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg23470272	chr19:14640395	TECR;MIR639	-0.7	-7.07	-0.33	6.44e-12	Type 2 diabetes;
LUAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.45e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8060686	0.546	rs8047978	chr16:68143598	T/G	cg26727032	chr16:67993705	SLC12A4	-0.46	-7.71	-0.35	9.28e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg23254163	chr1:152506842	NA	0.24	6.62	0.31	1.11e-10	Hair morphology;
LUAD	cis	rs16958440	0.867	rs79420880	chr18:44663687	C/T	cg17192377	chr18:44677553	HDHD2	0.84	7.76	0.35	6.64e-14	Sitting height ratio;
LUAD	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg15395560	chr15:45543142	SLC28A2	0.37	6.36	0.3	5.22e-10	Uric acid levels;
LUAD	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.51	-8.45	-0.38	4.58e-16	Multiple sclerosis;
LUAD	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg05887092	chr17:76393375	PGS1	0.55	11.19	0.48	1.23e-25	HDL cholesterol levels;
LUAD	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.01	-0.32	9.39e-12	Total body bone mineral density;
LUAD	cis	rs6582630	0.538	rs12304844	chr12:38335870	C/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.25	-0.33	1.94e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg08601574	chr20:25228251	PYGB	0.47	8.77	0.39	4.36e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs240764	0.853	rs2001102	chr6:100978351	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-7.19	-0.33	2.99e-12	Neuroticism;
LUAD	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg02782426	chr3:40428986	ENTPD3	0.36	7.82	0.36	4.32e-14	Renal cell carcinoma;
LUAD	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18404041	chr3:52824283	ITIH1	-0.56	-11.7	-0.49	1.41e-27	Bipolar disorder;
LUAD	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg01028140	chr2:1542097	TPO	-0.53	-7.34	-0.34	1.1e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg23029597	chr12:123009494	RSRC2	-0.51	-8.17	-0.37	3.64e-15	Body mass index;
LUAD	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.85e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2470578	0.716	rs2733514	chr3:17323931	A/G	cg03333267	chr4:6577084	MAN2B2	-0.39	-6.38	-0.3	4.71e-10	Schizophrenia;
LUAD	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-7.08	-0.33	5.91e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs1950626	0.577	rs61991118	chr14:101441974	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.37	7.43	0.34	5.92e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs62400317	0.859	rs6920046	chr6:45159431	A/C	cg18551225	chr6:44695536	NA	-0.56	-8.57	-0.38	1.91e-16	Total body bone mineral density;
LUAD	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.93	13.34	0.54	4.14e-34	Smoking behavior;
LUAD	trans	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg18335740	chr13:41363409	SLC25A15	0.76	14.82	0.58	2.58e-40	Lewy body disease;
LUAD	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg20503657	chr10:835505	NA	0.79	10.59	0.46	2.15e-23	Eosinophil percentage of granulocytes;
LUAD	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03517284	chr6:25882590	NA	0.85	14.41	0.57	1.36e-38	Blood metabolite levels;
LUAD	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.41e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9341808	0.538	rs623048	chr6:80981916	C/T	cg08355045	chr6:80787529	NA	-0.42	-7.36	-0.34	9.97e-13	Sitting height ratio;
LUAD	cis	rs735539	0.645	rs3825444	chr13:21173926	A/G	cg27499820	chr13:21296301	IL17D	0.53	8.7	0.39	7.64e-17	Dental caries;
LUAD	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06505273	chr16:24850292	NA	0.45	6.63	0.31	1.01e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg06784218	chr1:46089804	CCDC17	0.5	11.13	0.48	2.11e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.51	-0.38	3.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	6.87	0.32	2.25e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg02461776	chr11:598696	PHRF1	0.47	6.69	0.31	6.95e-11	Systemic lupus erythematosus;
LUAD	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26689765	chr5:52083512	ITGA1;PELO	0.41	6.68	0.31	7.4e-11	Survival in pancreatic cancer;
LUAD	trans	rs1728785	0.748	rs889560	chr16:68605784	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.4	0.45	1.02e-22	Ulcerative colitis;
LUAD	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg12501888	chr15:85177176	SCAND2	-0.43	-6.42	-0.3	3.72e-10	P wave terminal force;
LUAD	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg11645453	chr3:52864694	ITIH4	-0.55	-9.82	-0.43	1.25e-20	Schizophrenia;
LUAD	cis	rs12200782	1.000	rs72844496	chr6:26611608	G/A	cg11502198	chr6:26597334	ABT1	-0.78	-6.78	-0.31	4.17e-11	Small cell lung carcinoma;
LUAD	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.24	0.37	2.25e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg01851573	chr8:8652454	MFHAS1	-0.45	-8.12	-0.37	5.13e-15	Mood instability;
LUAD	cis	rs9486719	0.741	rs2499799	chr6:96851676	T/C	cg06623918	chr6:96969491	KIAA0776	0.73	9.56	0.42	9.85e-20	Migraine;Coronary artery disease;
LUAD	trans	rs190945449	1	rs190945449	chr6:26828359	C/T	cg06606381	chr12:133084897	FBRSL1	-0.96	-9.17	-0.41	2.04e-18	Urinary tract infection frequency;
LUAD	cis	rs7851660	0.935	rs4460498	chr9:100620412	T/C	cg13688889	chr9:100608707	NA	-0.53	-9.47	-0.42	1.96e-19	Strep throat;
LUAD	cis	rs7633770	0.786	rs4234464	chr3:46679675	C/T	cg11219411	chr3:46661640	NA	-0.58	-13.1	-0.54	3.74e-33	Coronary artery disease;
LUAD	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg03806693	chr22:41940476	POLR3H	0.72	9.67	0.43	4e-20	Vitiligo;
LUAD	trans	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	cis	rs2901656	0.591	rs9425304	chr1:172371151	C/A	cg03748243	chr1:172413542	C1orf105;PIGC	0.35	6.46	0.3	2.87e-10	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg16049864	chr8:95962084	TP53INP1	-0.57	-12.3	-0.51	6.35e-30	Type 2 diabetes;
LUAD	cis	rs1045714	0.895	rs61729413	chr7:2646796	G/A	cg24848437	chr7:2645542	IQCE	0.74	8.63	0.39	1.25e-16	Urate levels in lean individuals;
LUAD	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg08798685	chr6:27730294	NA	-0.44	-7.07	-0.32	6.64e-12	Parkinson's disease;
LUAD	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg10544611	chr16:67998164	SLC12A4	-0.51	-6.66	-0.31	8.32e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4478037	0.822	rs9865342	chr3:33118631	G/A	cg19404215	chr3:33155277	CRTAP	0.61	6.74	0.31	5.22e-11	Major depressive disorder;
LUAD	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg21153622	chr11:89784906	NA	0.33	6.71	0.31	6.23e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg03474202	chr17:45855739	NA	-0.38	-9.03	-0.4	6.29e-18	IgG glycosylation;
LUAD	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs2637266	1.000	rs12783273	chr10:78353221	T/C	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	trans	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.57	-9.19	-0.41	1.84e-18	Mean corpuscular hemoglobin;
LUAD	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg15181151	chr6:150070149	PCMT1	0.32	6.48	0.3	2.63e-10	Testicular germ cell tumor;
LUAD	cis	rs3925075	0.903	rs36100148	chr16:31345023	C/T	cg02846316	chr16:31340340	ITGAM	0.32	6.49	0.3	2.44e-10	IgA nephropathy;
LUAD	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg00784671	chr22:46762841	CELSR1	-0.61	-7.55	-0.34	2.66e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-7.01	-0.32	9.51e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7000551	0.619	rs2443506	chr8:22373383	T/C	cg12081754	chr8:22256438	SLC39A14	0.47	7.63	0.35	1.62e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7107174	1.000	rs2510040	chr11:77944548	T/A	cg19901956	chr11:77921274	USP35	-0.54	-6.63	-0.31	9.99e-11	Testicular germ cell tumor;
LUAD	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg26513180	chr16:89883248	FANCA	0.47	7.66	0.35	1.24e-13	Vitiligo;
LUAD	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg06740227	chr12:86229804	RASSF9	-0.41	-7.34	-0.34	1.13e-12	Major depressive disorder;
LUAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.22	0.54	1.26e-33	Prudent dietary pattern;
LUAD	cis	rs11811982	0.793	rs79014060	chr1:227509081	T/C	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7584330	0.504	rs6712927	chr2:238427808	G/A	cg14458575	chr2:238380390	NA	0.52	8.36	0.38	9.07e-16	Prostate cancer;
LUAD	cis	rs7683537	0.725	rs28837443	chr4:185641497	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	14.17	0.57	1.49e-37	Systemic lupus erythematosus;
LUAD	cis	rs7851660	0.933	rs1867277	chr9:100615914	A/G	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg08085267	chr17:45401833	C17orf57	0.53	9.02	0.4	6.66e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-8.03	-0.36	9.52e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-9.54	-0.42	1.13e-19	Bipolar disorder;
LUAD	cis	rs1843834	0.858	rs6731785	chr2:225491143	A/G	cg22455342	chr2:225449267	CUL3	0.46	6.76	0.31	4.65e-11	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs6960043	0.738	rs10950549	chr7:15057829	G/A	cg19272540	chr7:15055459	NA	0.39	8.81	0.39	3.28e-17	Type 2 diabetes;
LUAD	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg03806693	chr22:41940476	POLR3H	-0.71	-9.43	-0.42	2.66e-19	Vitiligo;
LUAD	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg03433033	chr1:76189801	ACADM	-0.67	-10.83	-0.47	2.8e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06022373	chr22:39101656	GTPBP1	-0.46	-7.21	-0.33	2.59e-12	Menopause (age at onset);
LUAD	cis	rs55788414	0.932	rs9929066	chr16:81182157	G/A	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.9	-0.36	2.46e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.58	10.09	0.44	1.35e-21	Eosinophil percentage of white cells;
LUAD	cis	rs6076065	1.000	rs2405231	chr20:23342239	A/C	cg11657817	chr20:23433608	CST11	0.48	9.75	0.43	2.21e-20	Facial morphology (factor 15, philtrum width);
LUAD	trans	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg01620082	chr3:125678407	NA	-0.44	-6.6	-0.31	1.27e-10	Depression;
LUAD	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg15605315	chr1:45957053	TESK2	0.49	7.79	0.35	5.37e-14	High light scatter reticulocyte count;
LUAD	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg17757837	chr7:157058334	UBE3C	0.47	8.43	0.38	5.65e-16	Body mass index;
LUAD	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.4e-15	Prostate cancer;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg01171360	chr6:293285	DUSP22	-0.75	-13.13	-0.54	2.85e-33	Menopause (age at onset);
LUAD	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10865541	1.000	rs11684337	chr2:3395287	A/G	cg22182287	chr2:3452347	TTC15	-0.38	-6.39	-0.3	4.38e-10	Obesity-related traits;
LUAD	trans	rs11700980	0.636	rs61735765	chr21:30255347	C/A	cg14791747	chr16:20752902	THUMPD1	0.63	6.94	0.32	1.44e-11	QRS complex (12-leadsum);
LUAD	cis	rs17253792	0.822	rs75437558	chr14:56066798	C/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg25535316	chr11:579198	PHRF1	-0.41	-6.45	-0.3	3.09e-10	Systemic lupus erythematosus;
LUAD	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg04218760	chr10:45406644	TMEM72	-0.31	-7.9	-0.36	2.47e-14	Mean corpuscular volume;
LUAD	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg00071950	chr4:10020882	SLC2A9	0.69	13.49	0.55	9.82e-35	Bone mineral density;
LUAD	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg15147215	chr3:52552868	STAB1	0.37	6.92	0.32	1.7e-11	Bipolar disorder;
LUAD	cis	rs28655083	0.636	rs61117898	chr16:77050736	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.43	-6.71	-0.31	6.36e-11	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg00717180	chr2:96193071	NA	-0.36	-6.53	-0.3	1.92e-10	Coronary artery disease;
LUAD	cis	rs10465746	0.747	rs34155960	chr1:84447539	T/G	cg10977910	chr1:84465055	TTLL7	0.6	9.87	0.43	7.84e-21	Obesity-related traits;
LUAD	trans	rs2270927	0.790	rs4566770	chr5:75576313	A/G	cg13563193	chr19:33072644	PDCD5	-0.72	-8.81	-0.39	3.36e-17	Mean corpuscular volume;
LUAD	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06505273	chr16:24850292	NA	0.47	6.94	0.32	1.45e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg09658497	chr7:2847517	GNA12	-0.46	-8.4	-0.38	6.79e-16	Height;
LUAD	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg19077165	chr18:44547161	KATNAL2	0.46	7.95	0.36	1.73e-14	Personality dimensions;
LUAD	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg19622623	chr12:86230825	RASSF9	-0.4	-7.05	-0.32	7.16e-12	Major depressive disorder;
LUAD	cis	rs13064411	0.518	rs1471883	chr3:113211828	C/T	cg10517650	chr3:113235015	CCDC52	-0.38	-7.21	-0.33	2.52e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs1904096	0.506	rs114312933	chr4:95216802	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.54	-10.28	-0.45	2.85e-22	Type 2 diabetes;
LUAD	trans	rs10838798	0.584	rs17198859	chr11:48140354	C/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.5	-0.34	3.72e-13	Height;
LUAD	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg14343924	chr8:8086146	FLJ10661	0.42	6.35	0.3	5.71e-10	Neuroticism;
LUAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg11301795	chr4:187892539	NA	-0.76	-15.26	-0.6	3.46e-42	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1728785	1.000	rs1645938	chr16:68595197	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.31	0.45	2.19e-22	Ulcerative colitis;
LUAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg24813613	chr7:1882135	MAD1L1	-0.59	-9.43	-0.42	2.78e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg18806716	chr10:30721971	MAP3K8	0.65	13.03	0.54	7.43e-33	Inflammatory bowel disease;
LUAD	trans	rs877282	0.898	rs11253339	chr10:759640	C/T	cg22713356	chr15:30763199	NA	1.24	16.94	0.64	1.67e-49	Uric acid levels;
LUAD	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg21475434	chr5:93447410	FAM172A	0.82	8.73	0.39	5.76e-17	Diabetic retinopathy;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg10483393	chr16:18573498	NOMO2	-0.66	-6.42	-0.3	3.6e-10	Type 2 diabetes;
LUAD	cis	rs2880765	0.743	rs16940052	chr15:86006674	G/A	cg13263323	chr15:86062960	AKAP13	-0.48	-8.89	-0.4	1.72e-17	Coronary artery disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06466203	chr10:89623360	PTEN;KILLIN	-0.54	-6.6	-0.31	1.21e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.81	0.43	1.28e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3087591	0.960	rs2905790	chr17:29476110	A/G	cg24425628	chr17:29625626	OMG;NF1	0.41	6.7	0.31	6.69e-11	Hip circumference;
LUAD	cis	rs17401966	1.000	rs3753037	chr1:10355834	C/T	cg15208524	chr1:10270712	KIF1B	0.56	8.54	0.38	2.44e-16	Hepatocellular carcinoma;
LUAD	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.09	0.33	5.82e-12	Depression;
LUAD	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg20848291	chr7:100343083	ZAN	0.39	6.72	0.31	5.83e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg04756594	chr16:24857601	SLC5A11	-0.54	-10.25	-0.45	3.5e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.64e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg05727186	chr17:43697356	MGC57346	-0.5	-6.54	-0.3	1.81e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg10979631	chr13:21714325	SAP18	-0.65	-6.41	-0.3	3.88e-10	Type 2 diabetes;
LUAD	cis	rs4072980	0.545	rs7519947	chr1:38447725	T/C	cg04673462	chr1:38461896	NA	-0.4	-7.17	-0.33	3.28e-12	Coronary artery disease;
LUAD	cis	rs7487075	0.619	rs7486495	chr12:46826336	A/G	cg23829395	chr12:46796953	NA	0.32	7.14	0.33	3.97e-12	Itch intensity from mosquito bite;
LUAD	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg13736514	chr6:26305472	NA	0.46	7.62	0.35	1.67e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.39	6.85	0.32	2.6e-11	Blood metabolite levels;
LUAD	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg23260525	chr10:116636907	FAM160B1	0.52	12.31	0.51	5.77e-30	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs10838798	0.563	rs11039516	chr11:48124157	T/A	cg21153622	chr11:89784906	NA	-0.35	-7.05	-0.32	7.39e-12	Height;
LUAD	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg24558204	chr6:135376177	HBS1L	0.49	9.02	0.4	6.61e-18	Red blood cell count;
LUAD	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg13813247	chr22:41461852	NA	-0.5	-7.94	-0.36	1.78e-14	Neuroticism;
LUAD	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg07432352	chr17:45403706	C17orf57	-0.4	-7.86	-0.36	3.28e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg14343924	chr8:8086146	FLJ10661	-0.52	-8.38	-0.38	7.84e-16	Neuroticism;
LUAD	trans	rs79911532	0.515	rs10245109	chr7:75846115	G/T	cg19862616	chr7:65841803	NCRNA00174	0.82	8.56	0.38	2.1e-16	Mononucleosis;
LUAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg09436375	chr6:42928200	GNMT	-0.29	-8.19	-0.37	3.21e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs684232	0.602	rs379998	chr17:556884	A/G	cg12384639	chr17:618140	VPS53	0.48	8.22	0.37	2.6e-15	Prostate cancer;
LUAD	cis	rs6005807	0.563	rs12170637	chr22:28675098	A/G	cg12565055	chr22:29076175	TTC28	0.69	7.9	0.36	2.4e-14	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs3106136	0.933	rs34383543	chr4:95163792	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.44	-0.34	5.56e-13	Capecitabine sensitivity;
LUAD	trans	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.54	9.45	0.42	2.43e-19	Brugada syndrome;
LUAD	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg00814883	chr7:100076585	TSC22D4	-0.8	-11.3	-0.48	4.78e-26	Platelet count;
LUAD	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01570182	chr17:44337453	NA	-0.76	-12.31	-0.51	5.77e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg18132916	chr6:79620363	NA	-0.45	-7.76	-0.35	6.61e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-6.98	-0.32	1.11e-11	Breast cancer;
LUAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-9.2	-0.41	1.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg01475377	chr6:109611718	NA	-0.52	-9.97	-0.44	3.66e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg09184832	chr6:79620586	NA	-0.5	-9.46	-0.42	2.24e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs713587	0.563	rs1529897	chr2:25086827	T/G	cg01884057	chr2:25150051	NA	0.33	6.91	0.32	1.79e-11	Body mass index in non-asthmatics;
LUAD	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg20291162	chr17:40259547	DHX58	-0.68	-10.5	-0.45	4.51e-23	Fibrinogen levels;
LUAD	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg23758822	chr17:41437982	NA	0.9	18.31	0.66	1.43e-55	Menopause (age at onset);
LUAD	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.82	-0.36	4.36e-14	Total body bone mineral density;
LUAD	cis	rs9948	0.655	rs75763821	chr2:97392694	G/A	cg20312557	chr2:97357134	FER1L5	-0.73	-8.14	-0.37	4.45e-15	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg09455208	chr3:40491958	NA	0.65	14.31	0.57	3.52e-38	Renal cell carcinoma;
LUAD	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg06028605	chr16:24865363	SLC5A11	0.52	7.91	0.36	2.2e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg02869364	chr7:1081709	C7orf50	-0.51	-6.67	-0.31	7.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg27170947	chr2:26402098	FAM59B	-0.69	-9.44	-0.42	2.56e-19	Gut microbiome composition (summer);
LUAD	cis	rs7744392	0.557	rs9658083	chr6:35337291	G/C	cg03355690	chr6:35265616	DEF6	0.63	6.36	0.3	5.32e-10	Cataracts in type 2 diabetes;
LUAD	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	9.76	0.43	1.97e-20	Electrocardiographic conduction measures;
LUAD	trans	rs1493916	0.905	rs7239283	chr18:31395397	G/A	cg13755796	chr4:20253514	NA	-0.43	-7.27	-0.33	1.74e-12	Life satisfaction;
LUAD	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.47	-8.1	-0.37	5.86e-15	Rheumatoid arthritis;
LUAD	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-24.12	-0.76	1.69e-81	Height;
LUAD	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.62	0.31	1.12e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs1691799	0.899	rs1168351	chr12:66752505	A/G	cg16791601	chr12:66731901	HELB	-0.36	-6.52	-0.3	2.02e-10	White blood cell count (basophil);
LUAD	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06028605	chr16:24865363	SLC5A11	0.56	8.67	0.39	9.26e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg02038168	chr22:39784481	NA	0.38	6.78	0.31	3.97e-11	IgG glycosylation;
LUAD	trans	rs2797160	1.000	rs2797161	chr6:126010789	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.5e-17	Endometrial cancer;
LUAD	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg20848291	chr7:100343083	ZAN	-0.61	-9.85	-0.43	9.78e-21	Other erythrocyte phenotypes;
LUAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg11965913	chr1:205819406	PM20D1	-0.52	-8.52	-0.38	2.83e-16	Parkinson's disease;
LUAD	cis	rs738322	0.805	rs11570734	chr22:38518622	A/G	cg25457927	chr22:38595422	NA	-0.51	-12.24	-0.51	1.08e-29	Cutaneous nevi;
LUAD	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	9.69	0.43	3.36e-20	Monocyte percentage of white cells;
LUAD	trans	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg26043149	chr18:55253948	FECH	1.05	17.81	0.65	2.29e-53	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs939658	0.626	rs11636901	chr15:79446292	T/C	cg17916960	chr15:79447300	NA	-0.4	-8.07	-0.37	7.27e-15	Refractive error;
LUAD	trans	rs701145	0.585	rs436852	chr3:153913403	G/A	cg14299572	chr10:34021103	NA	-0.39	-6.35	-0.3	5.72e-10	Coronary artery disease;
LUAD	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg11189052	chr15:85197271	WDR73	0.57	6.95	0.32	1.43e-11	Schizophrenia;
LUAD	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.86	-0.36	3.26e-14	Menopause (age at onset);
LUAD	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg21709803	chr11:61594965	FADS2	-0.4	-7.21	-0.33	2.61e-12	Trans fatty acid levels;
LUAD	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11890956	chr21:40555474	PSMG1	0.58	10.06	0.44	1.68e-21	Cognitive function;
LUAD	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.07	0.32	6.55e-12	Hypertriglyceridemia;
LUAD	cis	rs7567389	0.704	rs4662714	chr2:127995213	A/G	cg09760422	chr2:128146352	NA	-0.39	-6.52	-0.3	1.96e-10	Self-rated health;
LUAD	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs7173743	0.756	rs8035039	chr15:79129823	A/G	cg15571903	chr15:79123663	NA	0.39	7.76	0.35	6.38e-14	Coronary artery disease;
LUAD	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.43	-0.49	1.47e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg03676636	chr4:99064102	C4orf37	0.31	8.03	0.36	1.01e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg25817165	chr18:72167213	CNDP2	-0.78	-13.34	-0.54	4.05e-34	Refractive error;
LUAD	cis	rs6840360	0.593	rs1429558	chr4:152685406	A/T	cg22705602	chr4:152727874	NA	-0.48	-9.27	-0.41	9.37e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-11.41	-0.49	1.85e-26	Brugada syndrome;
LUAD	cis	rs2839627	0.561	rs6586248	chr21:44257812	C/T	cg03543861	chr21:44258195	NA	0.64	9.3	0.41	7.48e-19	Information processing speed;
LUAD	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg01788221	chr16:89496183	ANKRD11	-0.36	-6.88	-0.32	2.23e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17362650	0.653	rs35968355	chr2:9551713	G/A	cg12832956	chr2:9616023	IAH1	-0.47	-8.14	-0.37	4.31e-15	Alcohol dependence (age at onset);
LUAD	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg03676636	chr4:99064102	C4orf37	0.32	8.21	0.37	2.66e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2735413	0.709	rs8051521	chr16:78088156	G/C	cg04733911	chr16:78082701	NA	0.38	8.88	0.4	1.95e-17	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7909074	0.531	rs879344	chr10:45400667	G/C	cg05187965	chr10:45406764	TMEM72	-0.42	-7.57	-0.35	2.39e-13	Mean corpuscular volume;
LUAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg26304593	chr6:42947056	PEX6	-0.46	-7.96	-0.36	1.65e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg06197492	chr11:2016605	H19	0.4	8.02	0.36	1.06e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19744773	chr1:22110159	USP48	-0.43	-6.9	-0.32	1.92e-11	Height;
LUAD	cis	rs9863	0.861	rs7132655	chr12:124438973	G/C	cg17723958	chr12:124429295	CCDC92	-0.41	-6.81	-0.31	3.35e-11	White blood cell count;
LUAD	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18876405	chr7:65276391	NA	0.55	9.44	0.42	2.5e-19	Aortic root size;
LUAD	cis	rs1448094	0.872	rs7975457	chr12:86410404	C/T	cg18827107	chr12:86230957	RASSF9	-0.49	-8.86	-0.4	2.26e-17	Major depressive disorder;
LUAD	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg06608945	chr2:219082296	ARPC2	-0.52	-9.03	-0.4	6.14e-18	Colorectal cancer;
LUAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg18621852	chr3:10150065	C3orf24	0.44	7.78	0.35	5.58e-14	Alzheimer's disease;
LUAD	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg21545522	chr1:205238299	TMCC2	0.36	6.61	0.31	1.14e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	trans	rs2262909	0.924	rs4290587	chr19:22164646	A/G	cg17074339	chr11:11642133	GALNTL4	-0.43	-6.93	-0.32	1.6e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg03433033	chr1:76189801	ACADM	-0.52	-7.69	-0.35	1.04e-13	Daytime sleep phenotypes;
LUAD	trans	rs6076960	0.629	rs6054031	chr20:6233657	C/G	cg21095983	chr6:86352623	SYNCRIP	0.46	7.13	0.33	4.25e-12	Smooth-surface caries;
LUAD	cis	rs738322	0.555	rs5750547	chr22:38546700	A/G	cg17652424	chr22:38574118	PLA2G6	0.26	6.96	0.32	1.28e-11	Cutaneous nevi;
LUAD	cis	rs2732480	0.500	rs7966829	chr12:48615603	G/T	cg04545296	chr12:48745243	ZNF641	0.38	9.55	0.42	1.03e-19	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11890956	chr21:40555474	PSMG1	0.79	13.76	0.56	7.13e-36	Cognitive function;
LUAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.63	-10.15	-0.44	7.98e-22	Renal function-related traits (BUN);
LUAD	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg00310523	chr12:86230176	RASSF9	0.4	7.99	0.36	1.33e-14	Major depressive disorder;
LUAD	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg18854424	chr1:2615690	NA	0.42	9.09	0.4	3.81e-18	Ulcerative colitis;
LUAD	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg07741184	chr6:167504864	NA	0.35	8.14	0.37	4.46e-15	Primary biliary cholangitis;
LUAD	trans	rs2840044	1.000	rs1671656	chr17:33939661	C/T	cg19694781	chr19:47549865	TMEM160	-0.63	-10.09	-0.44	1.32e-21	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg21475434	chr5:93447410	FAM172A	0.72	8.49	0.38	3.54e-16	Diabetic retinopathy;
LUAD	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg18252515	chr7:66147081	NA	0.61	6.98	0.32	1.11e-11	Diabetic kidney disease;
LUAD	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg24829409	chr8:58192753	C8orf71	-0.62	-9.16	-0.41	2.26e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9948	0.655	rs6576981	chr2:97394406	G/C	cg20312557	chr2:97357134	FER1L5	-0.61	-7.54	-0.34	2.98e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg00666640	chr1:248458726	OR2T12	0.33	7.92	0.36	2.11e-14	Common traits (Other);
LUAD	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg20848291	chr7:100343083	ZAN	-0.59	-8.07	-0.37	7.22e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg27170947	chr2:26402098	FAM59B	0.83	11.56	0.49	4.58e-27	Gut microbiome composition (summer);
LUAD	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg21984481	chr17:79567631	NPLOC4	-0.55	-11.59	-0.49	3.81e-27	Eye color traits;
LUAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.13	-0.37	4.78e-15	Cystic fibrosis severity;
LUAD	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg21280719	chr6:42927975	GNMT	-0.39	-11.88	-0.5	2.64e-28	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	2.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10899021	1.000	rs7102084	chr11:74358132	T/C	cg25880958	chr11:74394337	NA	-0.61	-8.23	-0.37	2.32e-15	Response to metformin (IC50);
LUAD	cis	rs7779181	0.812	rs7779130	chr7:32346958	G/T	cg13207630	chr7:32358064	NA	0.43	6.61	0.31	1.14e-10	Body mass index;
LUAD	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg02423579	chr7:2872169	GNA12	-0.61	-10.49	-0.45	4.86e-23	Height;
LUAD	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg26441486	chr22:50317300	CRELD2	0.45	6.78	0.31	4.03e-11	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.04e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg16989719	chr2:238392110	NA	-0.36	-7.75	-0.35	7e-14	Prostate cancer;
LUAD	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg26875233	chr11:93583750	C11orf90	-0.39	-8.81	-0.39	3.26e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	trans	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg07211511	chr3:129823064	LOC729375	-0.87	-10.58	-0.46	2.2e-23	Blood pressure (smoking interaction);
LUAD	cis	rs3784262	0.565	rs12595410	chr15:58293040	A/G	cg12031962	chr15:58353849	ALDH1A2	0.39	7.45	0.34	5.41e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg25319279	chr11:5960081	NA	-0.41	-7.25	-0.33	1.96e-12	DNA methylation (variation);
LUAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg22535103	chr8:58192502	C8orf71	-0.78	-10.74	-0.46	5.73e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	6.89	0.32	2.05e-11	Lung cancer in ever smokers;
LUAD	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg18446336	chr7:2847575	GNA12	-0.38	-6.99	-0.32	1.05e-11	Height;
LUAD	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg00666640	chr1:248458726	OR2T12	-0.34	-8.22	-0.37	2.57e-15	Common traits (Other);
LUAD	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg00666640	chr1:248458726	OR2T12	0.3	7.46	0.34	5.08e-13	Common traits (Other);
LUAD	cis	rs654384	0.898	rs11766511	chr7:4173613	A/G	cg26275264	chr7:4183598	SDK1	0.4	7.6	0.35	1.92e-13	Positive affect;
LUAD	cis	rs11671005	0.735	rs12977592	chr19:58961056	C/G	cg13877915	chr19:58951672	ZNF132	0.55	7.85	0.36	3.53e-14	Mean platelet volume;
LUAD	cis	rs11112613	0.762	rs17037308	chr12:105949847	T/G	cg03607813	chr12:105948248	NA	0.81	13.83	0.56	3.89e-36	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg22598563	chr5:131563921	P4HA2	-0.28	-6.97	-0.32	1.24e-11	Blood metabolite levels;
LUAD	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg00750074	chr16:89608354	SPG7	-0.4	-6.61	-0.31	1.17e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.86	-0.36	3.31e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs4650994	0.517	rs2761473	chr1:178609758	A/C	cg05059571	chr16:84539110	KIAA1609	0.46	7.3	0.33	1.4e-12	HDL cholesterol levels;HDL cholesterol;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22959236	chr5:52856869	NDUFS4	-0.43	-7.06	-0.32	6.86e-12	Cancer;
LUAD	cis	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.12	-0.37	5.26e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7746082	0.595	rs6908450	chr6:106489708	C/T	cg02270332	chr6:106475062	NA	-0.38	-6.43	-0.3	3.51e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.49	-0.34	4.12e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2735413	0.711	rs12921476	chr16:78079846	G/C	cg04733911	chr16:78082701	NA	-0.38	-8.9	-0.4	1.68e-17	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg18180107	chr4:99064573	C4orf37	0.42	6.63	0.31	1.05e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg19875535	chr5:140030758	IK	-0.48	-8.05	-0.36	8.29e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4889911	0.544	rs2587498	chr17:77830737	G/A	cg01306824	chr17:77834118	NA	0.42	6.71	0.31	6.24e-11	Electroencephalogram traits;
LUAD	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg03233332	chr7:66118400	NA	-0.45	-6.6	-0.31	1.22e-10	Aortic root size;
LUAD	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg17105886	chr17:28927953	LRRC37B2	0.66	7.53	0.34	3.01e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg20673091	chr1:2541236	MMEL1	0.41	8.62	0.39	1.35e-16	Ulcerative colitis;
LUAD	cis	rs12579753	0.917	rs7132732	chr12:82206053	C/G	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.29	-0.33	1.59e-12	Resting heart rate;
LUAD	cis	rs7089973	0.966	rs12772800	chr10:116630962	A/G	cg23260525	chr10:116636907	FAM160B1	0.42	8.97	0.4	9.99e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs28655083	0.673	rs2220233	chr16:77050294	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.45	-6.95	-0.32	1.39e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg22532475	chr10:104410764	TRIM8	-0.34	-6.93	-0.32	1.58e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg18827107	chr12:86230957	RASSF9	-0.48	-8.54	-0.38	2.38e-16	Major depressive disorder;
LUAD	cis	rs6761276	0.899	rs12711750	chr2:113835380	C/A	cg02343335	chr2:113785852	IL1F8	-0.35	-7.01	-0.32	9.26e-12	Protein quantitative trait loci;
LUAD	cis	rs758324	0.773	rs13174385	chr5:131160187	T/G	cg25547332	chr5:131281432	NA	0.41	6.61	0.31	1.15e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg05340658	chr4:99064831	C4orf37	0.56	9.63	0.42	5.44e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11622475	1.000	rs56060232	chr14:104386165	G/C	cg12183467	chr14:104352244	NA	-0.42	-7.58	-0.35	2.28e-13	Bipolar disorder;
LUAD	cis	rs12541635	0.707	rs2099150	chr8:107109408	A/T	cg10147462	chr8:107024639	NA	-0.39	-6.81	-0.31	3.4e-11	Age of smoking initiation;
LUAD	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg11814155	chr7:99998594	ZCWPW1	0.43	7.37	0.34	9.23e-13	Platelet count;
LUAD	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06112835	chr11:68658793	MRPL21	0.52	9.3	0.41	7.37e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs7786808	0.527	rs62478405	chr7:158188528	G/A	cg02030672	chr11:45687055	CHST1	0.43	7.64	0.35	1.45e-13	Obesity-related traits;
LUAD	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06636551	chr8:101224915	SPAG1	0.47	8.84	0.4	2.54e-17	Atrioventricular conduction;
LUAD	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg04414720	chr1:150670196	GOLPH3L	0.72	12.5	0.52	9.56e-31	Melanoma;
LUAD	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg23985595	chr17:80112537	CCDC57	0.51	9.38	0.41	4.18e-19	Life satisfaction;
LUAD	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg02176678	chr2:219576539	TTLL4	0.75	15.16	0.59	8.94e-42	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	10.54	0.46	3.14e-23	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg10518543	chr12:38710700	ALG10B	0.43	6.43	0.3	3.37e-10	Bladder cancer;
LUAD	cis	rs7759001	0.817	rs6920362	chr6:27351239	A/G	cg18711553	chr6:27366782	ZNF391	0.39	6.39	0.3	4.29e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	cis	rs938554	0.779	rs4639073	chr4:9973781	T/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-7.23	-0.33	2.31e-12	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg21605333	chr4:119757512	SEC24D	-0.73	-7.33	-0.34	1.16e-12	Cannabis dependence symptom count;
LUAD	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.35	6.88	0.32	2.15e-11	Depression;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg12314527	chr22:19110193	DGCR2	0.37	6.59	0.31	1.29e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg18827107	chr12:86230957	RASSF9	-0.46	-8.45	-0.38	4.87e-16	Major depressive disorder;
LUAD	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg26677194	chr12:130822605	PIWIL1	0.57	9.17	0.41	2.05e-18	Menopause (age at onset);
LUAD	trans	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg21659725	chr3:3221576	CRBN	0.4	6.71	0.31	6.2e-11	Resting heart rate;
LUAD	cis	rs1448094	0.935	rs10746355	chr12:86330227	A/T	cg19622623	chr12:86230825	RASSF9	-0.36	-6.43	-0.3	3.42e-10	Major depressive disorder;
LUAD	trans	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg04565464	chr8:145669602	NFKBIL2	0.45	6.58	0.3	1.36e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6761276	0.934	rs11682107	chr2:113835522	G/A	cg09040174	chr2:113837401	NA	0.8	15.64	0.61	7.95e-44	Protein quantitative trait loci;
LUAD	cis	rs11031096	0.727	rs7940013	chr11:4138304	C/T	cg18678763	chr11:4115507	RRM1	-0.41	-7.1	-0.33	5.26e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11644478	chr21:40555479	PSMG1	0.7	11.8	0.5	5.71e-28	Cognitive function;
LUAD	cis	rs12545109	0.800	rs1530217	chr8:57408097	C/T	cg09654669	chr8:57350985	NA	-0.65	-9.15	-0.41	2.44e-18	Obesity-related traits;
LUAD	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.62	9.76	0.43	1.99e-20	Lymphocyte percentage of white cells;
LUAD	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg11965913	chr1:205819406	PM20D1	-0.6	-10.83	-0.47	2.72e-24	Menarche (age at onset);
LUAD	cis	rs57590327	0.503	rs1464790	chr3:81852923	A/T	cg07356753	chr3:81810745	GBE1	0.6	9.7	0.43	3.22e-20	Extraversion;
LUAD	cis	rs9473147	0.543	rs9473122	chr6:47474962	C/T	cg20196966	chr6:47445060	CD2AP	0.45	7.08	0.33	6.11e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg12035532	chr1:1886765	KIAA1751	0.41	6.81	0.31	3.36e-11	Body mass index;
LUAD	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg27068330	chr11:65405492	SIPA1	-0.75	-11.29	-0.48	4.96e-26	Acne (severe);
LUAD	cis	rs4862307	0.836	rs4643860	chr4:184997945	T/C	cg06737308	chr4:185021514	ENPP6	-0.61	-9.97	-0.44	3.62e-21	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg05110241	chr16:68378359	PRMT7	-0.95	-10.82	-0.47	2.86e-24	Magnesium levels;
LUAD	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg23649088	chr2:200775458	C2orf69	-0.57	-6.71	-0.31	6.25e-11	Schizophrenia;
LUAD	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.43	6.6	0.31	1.24e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg06484146	chr7:12443880	VWDE	-0.6	-7.71	-0.35	9.27e-14	Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	trans	rs9784649	0.882	rs2201296	chr5:24967119	G/A	cg11038491	chr20:34638489	LOC647979	-0.62	-7.9	-0.36	2.47e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg11494091	chr17:61959527	GH2	0.45	8.68	0.39	8.42e-17	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg22963979	chr7:1858916	MAD1L1	-0.55	-9.46	-0.42	2.22e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg06221963	chr1:154839813	KCNN3	-0.84	-19.51	-0.69	6.48e-61	Prostate cancer;
LUAD	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg15744005	chr10:104629667	AS3MT	-0.38	-7.4	-0.34	7.36e-13	Arsenic metabolism;
LUAD	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg23254163	chr1:152506842	NA	0.25	7.07	0.33	6.24e-12	Hair morphology;
LUAD	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg19875535	chr5:140030758	IK	0.43	7.4	0.34	7.47e-13	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg26384229	chr12:38710491	ALG10B	0.41	6.52	0.3	2.02e-10	Morning vs. evening chronotype;
LUAD	cis	rs6542838	0.641	rs6741166	chr2:99534926	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-7.48	-0.34	4.22e-13	Fear of minor pain;
LUAD	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-12.48	-0.52	1.19e-30	Coronary artery disease;
LUAD	cis	rs4730250	0.654	rs6947857	chr7:106787266	T/G	cg23024343	chr7:107201750	COG5	-0.5	-6.79	-0.31	3.73e-11	Osteoarthritis;
LUAD	cis	rs9393692	0.577	rs9358914	chr6:26262063	G/T	cg00631329	chr6:26305371	NA	-0.5	-7.79	-0.35	5.12e-14	Educational attainment;
LUAD	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg09658497	chr7:2847517	GNA12	-0.41	-7.25	-0.33	2.06e-12	Height;
LUAD	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18099408	chr3:52552593	STAB1	-0.43	-7.69	-0.35	1.05e-13	Bipolar disorder;
LUAD	cis	rs12079745	0.793	rs3737683	chr1:169438180	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-1.1	-7.65	-0.35	1.38e-13	QT interval;
LUAD	cis	rs1403694	0.695	rs1851664	chr3:186436503	T/A	cg12454167	chr3:186435060	KNG1	0.51	10.81	0.47	3.31e-24	Blood protein levels;
LUAD	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.09	-0.57	2.99e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg02993280	chr1:107599747	PRMT6	0.56	9.11	0.4	3.4e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg04455712	chr21:45112962	RRP1B	0.4	8.21	0.37	2.61e-15	Mean corpuscular volume;
LUAD	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.4	-6.95	-0.32	1.36e-11	Coronary artery disease;
LUAD	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg17757837	chr7:157058334	UBE3C	0.47	8.39	0.38	7.42e-16	Body mass index;
LUAD	cis	rs12519773	0.597	rs10514370	chr5:92435481	G/T	cg18783429	chr5:92414398	NA	0.5	8.5	0.38	3.18e-16	Migraine;
LUAD	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg05709478	chr1:6581295	PLEKHG5	0.54	6.63	0.31	1e-10	Body mass index;
LUAD	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg18230493	chr5:56204884	C5orf35	-0.68	-10.81	-0.47	3.33e-24	Initial pursuit acceleration;
LUAD	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg27284194	chr4:1044797	NA	0.7	10.18	0.44	6.52e-22	Recombination rate (females);
LUAD	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-8.01	-0.36	1.12e-14	Monocyte percentage of white cells;
LUAD	cis	rs13315871	1.000	rs13317835	chr3:58383275	C/T	cg20936604	chr3:58311152	NA	-0.68	-7.09	-0.33	5.75e-12	Cholesterol, total;
LUAD	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg27427491	chr17:78079615	GAA	-0.39	-7.24	-0.33	2.14e-12	Yeast infection;
LUAD	cis	rs9467160	1.000	rs9295624	chr6:24439600	A/G	cg20631270	chr6:24437470	GPLD1	-0.46	-6.42	-0.3	3.69e-10	Liver enzyme levels;
LUAD	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg10755058	chr3:40428713	ENTPD3	0.47	8.69	0.39	7.92e-17	Renal cell carcinoma;
LUAD	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg15335139	chr3:50242325	SLC38A3	-0.38	-6.66	-0.31	8.39e-11	Menarche (age at onset);
LUAD	cis	rs62400317	0.762	rs1329711	chr6:44963401	A/G	cg18551225	chr6:44695536	NA	-0.59	-9.0	-0.4	7.54e-18	Total body bone mineral density;
LUAD	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg24818145	chr4:99064322	C4orf37	0.42	7.05	0.32	7.54e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg27411982	chr8:10470053	RP1L1	0.37	6.61	0.31	1.13e-10	Retinal vascular caliber;
LUAD	trans	rs9503551	0.642	rs4479986	chr6:3327647	T/C	cg13915676	chr9:139305538	SDCCAG3;PMPCA	0.48	6.4	0.3	4.21e-10	Nicotine dependence;
LUAD	cis	rs1832871	1.000	rs827856	chr6:158705887	G/A	cg07165851	chr6:158734300	TULP4	0.37	6.39	0.3	4.42e-10	Height;
LUAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg12432903	chr7:1882776	MAD1L1	-0.41	-6.69	-0.31	7.09e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg24076588	chr1:18808559	KLHDC7A	-0.42	-7.18	-0.33	3.11e-12	Breast cancer;
LUAD	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg12444411	chr7:2802554	GNA12	-0.35	-6.44	-0.3	3.32e-10	Height;
LUAD	cis	rs7210086	0.808	rs72849443	chr17:70637437	G/A	cg04206342	chr17:70636940	NA	-0.38	-6.93	-0.32	1.6e-11	Ulcerative colitis;
LUAD	cis	rs773506	0.628	rs10733740	chr9:93933158	G/T	cg14446406	chr9:93919335	NA	0.38	7.02	0.32	9.04e-12	Type 2 diabetes nephropathy;
LUAD	trans	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg27411982	chr8:10470053	RP1L1	-0.42	-7.5	-0.34	3.79e-13	Joint mobility (Beighton score);
LUAD	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-14.78	-0.58	3.6e-40	Extrinsic epigenetic age acceleration;
LUAD	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg04025307	chr7:1156635	C7orf50	0.52	8.75	0.39	5.03e-17	Longevity;Endometriosis;
LUAD	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg11845111	chr2:191398756	TMEM194B	-0.72	-9.67	-0.43	4.24e-20	Diastolic blood pressure;
LUAD	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg04944784	chr2:26401820	FAM59B	-0.76	-10.5	-0.45	4.4e-23	Gut microbiome composition (summer);
LUAD	cis	rs9525916	0.967	rs9533775	chr13:44697956	C/T	cg04068111	chr13:44716778	NA	0.31	6.8	0.31	3.53e-11	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUAD	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg12011299	chr4:100065546	ADH4	0.77	15.68	0.61	5e-44	Alcohol dependence;
LUAD	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-9.91	-0.43	5.71e-21	Migraine;Coronary artery disease;
LUAD	cis	rs2447097	1.000	rs2447097	chr17:2278064	A/C	cg02569219	chr17:2266849	SGSM2	0.41	7.34	0.34	1.11e-12	Autism spectrum disorder;
LUAD	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg27661571	chr11:113659931	NA	-0.71	-8.32	-0.38	1.21e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg06627628	chr2:24431161	ITSN2	-0.48	-6.63	-0.31	1.03e-10	Lymphocyte counts;
LUAD	cis	rs859767	0.501	rs6742638	chr2:135407360	T/G	cg12500956	chr2:135428796	TMEM163	-0.29	-7.6	-0.35	1.87e-13	Neuroticism;
LUAD	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg00277334	chr10:82204260	NA	-0.46	-7.64	-0.35	1.47e-13	Post bronchodilator FEV1;
LUAD	cis	rs62229266	0.659	rs2835258	chr21:37424365	G/A	cg12218747	chr21:37451666	NA	-0.41	-7.04	-0.32	7.69e-12	Mitral valve prolapse;
LUAD	trans	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg19469189	chr11:128781035	KCNJ5	-0.43	-6.63	-0.31	1.04e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs977987	0.835	rs3851733	chr16:75370263	G/C	cg03315344	chr16:75512273	CHST6	0.65	13.88	0.56	2.25e-36	Dupuytren's disease;
LUAD	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg13319975	chr6:146136371	FBXO30	0.67	11.4	0.48	2.04e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.57	-0.3	1.45e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6543140	0.964	rs10196334	chr2:103090041	T/C	cg04239558	chr2:103089729	SLC9A4	0.36	7.19	0.33	2.93e-12	Blood protein levels;
LUAD	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg24069376	chr3:38537580	EXOG	0.31	7.15	0.33	3.92e-12	Electrocardiographic conduction measures;
LUAD	cis	rs427394	0.582	rs274667	chr5:6710771	A/G	cg12316010	chr5:6737918	POLS	-0.36	-6.87	-0.32	2.25e-11	Menopause (age at onset);
LUAD	cis	rs3744061	0.520	rs4322697	chr17:74648642	C/T	cg27546012	chr17:74684504	MXRA7	-0.37	-6.73	-0.31	5.42e-11	Retinal arteriolar caliber;
LUAD	cis	rs7739264	0.602	rs6925511	chr6:19773553	C/T	cg02404759	chr6:19790362	NA	0.35	6.78	0.31	4.04e-11	Endometriosis;
LUAD	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.16	0.48	1.61e-25	Height;
LUAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08677398	chr8:58056175	NA	0.53	6.67	0.31	7.86e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg03388025	chr16:89894329	SPIRE2	0.49	12.82	0.53	4.99e-32	Vitiligo;
LUAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg04025307	chr7:1156635	C7orf50	0.66	9.34	0.41	5.5e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg04944784	chr2:26401820	FAM59B	-0.87	-12.6	-0.52	3.82e-31	Gut microbiome composition (summer);
LUAD	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.47	-0.3	2.74e-10	Breast cancer;
LUAD	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg13736514	chr6:26305472	NA	-0.71	-13.2	-0.54	1.51e-33	Educational attainment;
LUAD	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg08758996	chr17:66097529	LOC651250	-0.43	-7.31	-0.34	1.32e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg11189052	chr15:85197271	WDR73	-0.61	-7.71	-0.35	8.79e-14	Schizophrenia;
LUAD	cis	rs220324	0.688	rs11700704	chr21:43564103	C/T	cg08841829	chr21:43638893	ABCG1	-0.5	-6.91	-0.32	1.85e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg18016565	chr1:150552671	MCL1	0.41	7.6	0.35	1.93e-13	Tonsillectomy;
LUAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg13560548	chr3:10150139	C3orf24	0.4	6.61	0.31	1.14e-10	Alzheimer's disease;
LUAD	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.91	0.4	1.5e-17	Cognitive ability;
LUAD	cis	rs887829	0.570	rs13002774	chr2:234593706	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-9.76	-0.43	2.03e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg14008862	chr17:28927542	LRRC37B2	0.74	7.4	0.34	7.53e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7094131	0.523	rs10741008	chr10:22882344	T/G	cg19500236	chr10:22911537	PIP4K2A	0.4	7.22	0.33	2.42e-12	Obesity-related traits;
LUAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg22907277	chr7:1156413	C7orf50	0.75	11.16	0.48	1.64e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg02018176	chr4:1364513	KIAA1530	-0.37	-6.99	-0.32	1.08e-11	Obesity-related traits;
LUAD	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.98	0.36	1.42e-14	Parkinson's disease;
LUAD	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg08523384	chr5:141488047	NDFIP1	-0.48	-7.32	-0.34	1.25e-12	Crohn's disease;
LUAD	trans	rs208520	0.690	rs207077	chr6:66769855	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.03	-0.64	6.75e-50	Exhaled nitric oxide output;
LUAD	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18876405	chr7:65276391	NA	-0.44	-6.91	-0.32	1.83e-11	Aortic root size;
LUAD	cis	rs6076065	0.630	rs2424558	chr20:23429344	A/G	cg11657817	chr20:23433608	CST11	0.64	13.27	0.54	7.34e-34	Facial morphology (factor 15, philtrum width);
LUAD	trans	rs116939006	1.000	rs7008279	chr8:14268284	A/C	cg16330849	chr6:10694809	C6orf52;PAK1IP1	0.78	6.43	0.3	3.49e-10	Response to paliperidone in schizophrenia (negative Marder score);
LUAD	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg12940439	chr1:67600707	NA	-0.5	-9.53	-0.42	1.2e-19	Psoriasis;
LUAD	cis	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg07460842	chr6:66804631	NA	0.58	9.03	0.4	6.19e-18	Type 2 diabetes;
LUAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.5	9.03	0.4	6.13e-18	Lymphocyte counts;
LUAD	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg14092988	chr3:52407081	DNAH1	0.35	6.96	0.32	1.31e-11	Bipolar disorder;
LUAD	cis	rs10392	0.516	rs3752293	chr20:37570725	A/G	cg27552599	chr20:37590471	DHX35	-0.38	-6.45	-0.3	3.12e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.14	-0.64	2.18e-50	Height;
LUAD	cis	rs78487399	0.808	rs13416978	chr2:43705265	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.59	7.11	0.33	4.97e-12	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg14582100	chr15:45693742	SPATA5L1	0.52	9.82	0.43	1.2e-20	Homoarginine levels;
LUAD	cis	rs6500395	1.000	rs36077931	chr16:48594221	A/G	cg04672837	chr16:48644449	N4BP1	0.38	6.49	0.3	2.41e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12620999	0.941	rs7593758	chr2:237980920	G/T	cg23555395	chr2:238036564	NA	-0.54	-8.5	-0.38	3.31e-16	Systemic lupus erythematosus;
LUAD	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg27411982	chr8:10470053	RP1L1	0.4	6.92	0.32	1.66e-11	Retinal vascular caliber;
LUAD	cis	rs7737355	0.773	rs192166	chr5:130852525	T/C	cg06307176	chr5:131281290	NA	0.43	7.1	0.33	5.41e-12	Life satisfaction;
LUAD	cis	rs11671005	0.735	rs34511020	chr19:58921296	A/G	cg13877915	chr19:58951672	ZNF132	0.55	7.27	0.33	1.75e-12	Mean platelet volume;
LUAD	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg14582100	chr15:45693742	SPATA5L1	0.64	12.5	0.52	9.64e-31	Homoarginine levels;
LUAD	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg17173187	chr15:85201210	NMB	0.39	6.51	0.3	2.17e-10	Schizophrenia;
LUAD	cis	rs727479	0.543	rs1065778	chr15:51520206	T/C	cg19946085	chr15:51559439	CYP19A1	-0.36	-6.45	-0.3	3.09e-10	Estradiol levels;
LUAD	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-16.17	-0.62	3.71e-46	Schizophrenia;
LUAD	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg18350739	chr11:68623251	NA	0.37	6.47	0.3	2.7e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18404041	chr3:52824283	ITIH1	-0.6	-12.15	-0.51	2.52e-29	Bipolar disorder;
LUAD	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg01256987	chr12:42539512	GXYLT1	0.34	6.62	0.31	1.08e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg20966513	chr17:4736714	MINK1	0.41	6.73	0.31	5.7e-11	Optic cup area;
LUAD	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg07305463	chr2:136567211	LCT	0.38	7.15	0.33	3.93e-12	Mosquito bite size;
LUAD	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg08885076	chr2:99613938	TSGA10	-0.38	-6.83	-0.32	2.9e-11	Chronic sinus infection;
LUAD	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg01765077	chr12:122356316	WDR66	0.58	10.13	0.44	9.85e-22	Mean corpuscular volume;
LUAD	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg08893839	chr5:154027129	NA	0.56	7.41	0.34	6.75e-13	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg22875332	chr1:76189707	ACADM	-0.83	-16.86	-0.63	3.62e-49	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2979489	0.945	rs13250272	chr8:30294942	A/G	cg26383811	chr8:30366931	RBPMS	0.65	10.01	0.44	2.52e-21	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs3806843	0.576	rs155359	chr5:140315425	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.66	-0.31	8.54e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.61e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg17971929	chr21:40555470	PSMG1	0.54	8.55	0.38	2.34e-16	Cognitive function;
LUAD	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg02049041	chr17:27085579	C17orf63	0.64	8.52	0.38	2.81e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg00129232	chr17:37814104	STARD3	-0.46	-8.01	-0.36	1.13e-14	Asthma;
LUAD	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg25985355	chr7:65971099	NA	-0.38	-6.89	-0.32	2.02e-11	Aortic root size;
LUAD	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg15017067	chr4:17643749	FAM184B	0.37	7.26	0.33	1.88e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2412208	0.527	rs4436414	chr1:7120915	G/A	cg20434152	chr1:7120926	CAMTA1	-0.4	-10.28	-0.45	2.81e-22	Survival in sporadic amyotrophic lateral sclerosis;
LUAD	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg05768032	chr16:30646687	NA	0.41	7.02	0.32	9.09e-12	Multiple myeloma;
LUAD	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12016809	chr21:47604291	C21orf56	0.47	6.74	0.31	5.24e-11	Testicular germ cell tumor;
LUAD	cis	rs7586879	0.639	rs6722022	chr2:25098859	A/G	cg01884057	chr2:25150051	NA	0.33	6.79	0.31	3.87e-11	Body mass index;
LUAD	cis	rs10865541	0.902	rs7593978	chr2:3415544	C/T	cg22182287	chr2:3452347	TTC15	0.39	6.4	0.3	4.18e-10	Obesity-related traits;
LUAD	cis	rs35740288	0.770	rs11633893	chr15:86148438	A/G	cg13263323	chr15:86062960	AKAP13	0.44	7.15	0.33	3.85e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg23029597	chr12:123009494	RSRC2	-0.57	-9.03	-0.4	6.03e-18	Body mass index;
LUAD	cis	rs8060686	0.623	rs12599178	chr16:68128104	A/G	cg09835421	chr16:68378352	PRMT7	-0.53	-6.83	-0.31	3.06e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs438465	1.000	rs368028	chr6:169811294	A/G	cg11181693	chr6:169825345	NA	0.64	8.09	0.37	6.53e-15	Corneal astigmatism;
LUAD	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.66	0.31	8.55e-11	Schizophrenia;
LUAD	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg04450456	chr4:17643702	FAM184B	0.42	8.29	0.37	1.54e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs35995292	0.500	rs6945239	chr7:38932208	C/T	cg19327137	chr7:38886074	VPS41	0.71	14.35	0.57	2.43e-38	Subjective well-being (multi-trait analysis);
LUAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg22907277	chr7:1156413	C7orf50	0.51	8.92	0.4	1.42e-17	Longevity;Endometriosis;
LUAD	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.94	-0.32	1.5e-11	Crohn's disease;
LUAD	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg09455208	chr3:40491958	NA	0.57	11.82	0.5	4.6e-28	Renal cell carcinoma;
LUAD	cis	rs17608059	0.679	rs9898056	chr17:13951966	C/G	cg11395062	chr17:14139857	CDRT15	0.45	7.29	0.33	1.52e-12	Temperament;
LUAD	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg18306943	chr3:40428807	ENTPD3	0.4	6.99	0.32	1.07e-11	Renal cell carcinoma;
LUAD	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg22467129	chr15:76604101	ETFA	-0.5	-8.81	-0.39	3.19e-17	Blood metabolite levels;
LUAD	cis	rs7274811	0.711	rs291669	chr20:31945364	C/T	cg13403462	chr20:32256071	NECAB3;C20orf134	0.47	7.36	0.34	9.46e-13	Height;
LUAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg00684032	chr4:1343700	KIAA1530	0.39	6.51	0.3	2.14e-10	Obesity-related traits;
LUAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg00106254	chr7:1943704	MAD1L1	-0.56	-8.71	-0.39	7.14e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg15432903	chr11:17409602	KCNJ11	0.55	10.29	0.45	2.55e-22	Type 2 diabetes;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg03705947	chr1:68152081	GADD45A	0.39	6.47	0.3	2.75e-10	Diastolic blood pressure;
LUAD	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg09222892	chr1:25734099	RHCE	0.51	9.47	0.42	2.04e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.39	0.34	7.85e-13	Tonsillectomy;
LUAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg11344533	chr11:111475393	SIK2	-0.36	-6.82	-0.31	3.18e-11	Primary sclerosing cholangitis;
LUAD	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg14847009	chr1:175162515	KIAA0040	-0.32	-8.45	-0.38	4.75e-16	Alcohol dependence;
LUAD	trans	rs7395662	0.784	rs79037165	chr11:48865464	G/T	cg15704280	chr7:45808275	SEPT13	0.43	6.81	0.31	3.41e-11	HDL cholesterol;
LUAD	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg06618935	chr21:46677482	NA	-0.5	-10.01	-0.44	2.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1385374	0.858	rs12298615	chr12:129286756	G/A	cg09035930	chr12:129282057	SLC15A4	-0.65	-6.91	-0.32	1.78e-11	Systemic lupus erythematosus;
LUAD	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg15557168	chr22:42548783	NA	0.5	9.22	0.41	1.4e-18	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1448094	0.872	rs7311150	chr12:86435989	A/T	cg19622623	chr12:86230825	RASSF9	-0.36	-6.58	-0.3	1.41e-10	Major depressive disorder;
LUAD	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg12432903	chr7:1882776	MAD1L1	-0.41	-6.55	-0.3	1.63e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs10489202	0.608	rs10918826	chr1:168075316	C/T	cg25738037	chr1:168025549	DCAF6	-0.45	-6.76	-0.31	4.51e-11	Schizophrenia;
LUAD	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg05182265	chr7:156933206	UBE3C	-0.8	-17.26	-0.64	6.54e-51	Body mass index;
LUAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg18621852	chr3:10150065	C3orf24	0.51	9.11	0.4	3.39e-18	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.51	0.42	1.48e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.83	0.32	3e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3204270	0.639	rs7216239	chr17:79660187	C/T	cg09655341	chr17:79618100	PDE6G	0.52	6.49	0.3	2.38e-10	Dental caries;
LUAD	cis	rs17641971	0.619	rs6983929	chr8:49984896	T/C	cg00325661	chr8:49890786	NA	0.31	6.97	0.32	1.19e-11	Blood metabolite levels;
LUAD	cis	rs9443645	0.527	rs36128361	chr6:79684340	C/G	cg05283184	chr6:79620031	NA	-0.44	-7.66	-0.35	1.26e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs494562	0.892	rs547052	chr6:86118840	G/A	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7000551	0.715	rs2461478	chr8:22378236	A/G	cg12081754	chr8:22256438	SLC39A14	0.46	7.62	0.35	1.73e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg25703541	chr22:24373054	LOC391322	-0.82	-15.79	-0.61	1.78e-44	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.68	-12.7	-0.53	1.6e-31	Ulcerative colitis;
LUAD	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.72	-0.35	8.72e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg07570687	chr10:102243282	WNT8B	0.44	6.63	0.31	1.06e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg14835575	chr10:16859367	RSU1	0.5	7.6	0.35	1.97e-13	Platelet distribution width;
LUAD	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg00666640	chr1:248458726	OR2T12	-0.29	-7.0	-0.32	9.96e-12	Common traits (Other);
LUAD	cis	rs909002	0.962	rs10798883	chr1:32140305	C/T	cg13919466	chr1:32135498	COL16A1	-0.44	-10.86	-0.47	2.07e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg00814883	chr7:100076585	TSC22D4	-0.51	-6.93	-0.32	1.63e-11	Lung function (FEV1/FVC);
LUAD	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg27087555	chr16:88793112	FAM38A	-1.23	-11.22	-0.48	9.75e-26	Plateletcrit;
LUAD	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg19717773	chr7:2847554	GNA12	-0.54	-10.45	-0.45	6.81e-23	Height;
LUAD	cis	rs55665837	1.000	rs12804549	chr11:14437758	A/T	cg19336497	chr11:14380999	RRAS2	-0.49	-9.88	-0.43	7.54e-21	Vitamin D levels;
LUAD	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg10589385	chr1:150898437	SETDB1	0.45	8.27	0.37	1.8e-15	Melanoma;
LUAD	cis	rs16958440	0.867	rs75228657	chr18:44741063	A/G	cg17192377	chr18:44677553	HDHD2	0.85	8.05	0.36	8.76e-15	Sitting height ratio;
LUAD	cis	rs7614311	1.000	rs2637983	chr3:63821632	G/A	cg22134162	chr3:63841271	THOC7	-0.35	-6.92	-0.32	1.65e-11	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs6743376	0.556	rs2515398	chr2:113819334	A/C	cg09040174	chr2:113837401	NA	0.51	7.96	0.36	1.61e-14	Inflammatory biomarkers;
LUAD	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.79	-0.31	3.84e-11	Height;
LUAD	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg09137382	chr11:130731461	NA	0.4	7.42	0.34	6.48e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg22875332	chr1:76189707	ACADM	0.73	11.26	0.48	6.62e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs4650994	0.525	rs4993304	chr1:178535144	A/G	cg05059571	chr16:84539110	KIAA1609	-0.73	-13.07	-0.54	5.1e-33	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg07256732	chr16:621771	PIGQ	-0.32	-6.5	-0.3	2.31e-10	Height;
LUAD	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs938554	0.571	rs7696092	chr4:10025320	C/A	cg11266682	chr4:10021025	SLC2A9	0.53	10.04	0.44	2.08e-21	Blood metabolite levels;
LUAD	cis	rs10781543	0.845	rs10781542	chr9:139327439	A/G	cg14019695	chr9:139328340	INPP5E	0.55	10.82	0.47	3.09e-24	Monocyte percentage of white cells;
LUAD	cis	rs7586879	0.828	rs1865688	chr2:25108245	C/G	cg04586622	chr2:25135609	ADCY3	0.36	7.26	0.33	1.82e-12	Body mass index;
LUAD	cis	rs4660306	0.961	rs12145526	chr1:45969036	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-8.04	-0.36	8.88e-15	Homocysteine levels;
LUAD	cis	rs859767	0.704	rs6750788	chr2:135362981	A/G	cg12500956	chr2:135428796	TMEM163	-0.31	-8.19	-0.37	3.22e-15	Neuroticism;
LUAD	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.54	-0.38	2.4e-16	Alzheimer's disease (late onset);
LUAD	trans	rs2018683	0.683	rs12538606	chr7:28969408	T/C	cg19402173	chr7:128379420	CALU	-0.54	-8.75	-0.39	5.23e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7737355	0.812	rs244738	chr5:130851170	A/G	cg06307176	chr5:131281290	NA	0.43	7.1	0.33	5.41e-12	Life satisfaction;
LUAD	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg15117754	chr3:10150083	C3orf24	0.45	7.46	0.34	4.87e-13	Alzheimer's disease;
LUAD	cis	rs7539409	0.915	rs1977119	chr1:84275509	A/G	cg10977910	chr1:84465055	TTLL7	0.69	6.82	0.31	3.07e-11	Alzheimer's disease;
LUAD	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18404041	chr3:52824283	ITIH1	-0.59	-12.0	-0.5	9.27e-29	Bipolar disorder;
LUAD	cis	rs76297747	1	rs76297747	chr18:44665657	A/G	cg17192377	chr18:44677553	HDHD2	0.84	7.76	0.35	6.64e-14	Response to paliperidone in schizophrenia (Multivariate);
LUAD	cis	rs17095355	1.000	rs11194941	chr10:111744810	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.69	-9.27	-0.41	9.35e-19	Biliary atresia;
LUAD	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg14668632	chr7:2872130	GNA12	0.72	12.79	0.53	6.66e-32	Height;
LUAD	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	6.63	0.31	1.03e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00149659	chr3:10157352	C3orf10	0.61	8.49	0.38	3.41e-16	Alzheimer's disease;
LUAD	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11644478	chr21:40555479	PSMG1	0.62	9.59	0.42	7.96e-20	Cognitive function;
LUAD	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg15448220	chr1:150897856	SETDB1	0.47	8.18	0.37	3.4e-15	Tonsillectomy;
LUAD	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg22868518	chr11:507468	RNH1	-0.68	-6.83	-0.32	3.02e-11	Body mass index;
LUAD	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg20542592	chr8:11973495	FAM66D	0.42	6.51	0.3	2.17e-10	Joint mobility (Beighton score);
LUAD	cis	rs11048434	0.723	rs2080116	chr12:9138183	A/G	cg13575925	chr12:9217583	LOC144571	0.38	7.04	0.32	7.72e-12	Sjögren's syndrome;
LUAD	cis	rs807669	1.000	rs807670	chr22:19154608	A/C	cg24911827	chr22:19170109	CLTCL1	0.36	7.46	0.34	5.11e-13	Metabolite levels;
LUAD	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg15147215	chr3:52552868	STAB1	-0.39	-7.19	-0.33	2.99e-12	Bipolar disorder;
LUAD	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.24	-0.37	2.22e-15	Prostate cancer;
LUAD	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg17749961	chr2:30669863	LCLAT1	1.21	12.42	0.52	2.02e-30	Midgestational circulating levels of PBDEs (fetal genetic effect);
LUAD	trans	rs877282	1.000	rs12779159	chr10:772143	T/C	cg22713356	chr15:30763199	NA	1.31	18.49	0.67	2.15e-56	Uric acid levels;
LUAD	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg11586189	chr1:201857591	SHISA4	0.29	7.5	0.34	3.79e-13	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUAD	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg11645453	chr3:52864694	ITIH4	0.57	10.77	0.46	4.76e-24	Schizophrenia;
LUAD	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg24397884	chr7:158709396	WDR60	0.63	8.63	0.39	1.22e-16	Height;
LUAD	cis	rs17641971	0.645	rs341806	chr8:50034028	A/C	cg00325661	chr8:49890786	NA	0.31	6.77	0.31	4.28e-11	Blood metabolite levels;
LUAD	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6490294	0.748	rs6489820	chr12:112328503	T/C	cg10833066	chr12:111807467	FAM109A	0.42	6.99	0.32	1.08e-11	Mean platelet volume;
LUAD	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg01028140	chr2:1542097	TPO	-0.55	-8.47	-0.38	4.07e-16	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg07414643	chr4:187882934	NA	0.32	6.59	0.31	1.33e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9929218	0.954	rs35794312	chr16:68827785	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.73	-0.53	1.24e-31	Colorectal cancer;
LUAD	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.95	-0.4	1.16e-17	Gut microbiome composition (summer);
LUAD	cis	rs35740288	0.770	rs745191	chr15:86123170	G/T	cg13263323	chr15:86062960	AKAP13	-0.42	-6.52	-0.3	1.98e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg17264618	chr3:40429014	ENTPD3	0.41	8.83	0.39	2.84e-17	Renal cell carcinoma;
LUAD	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-6.55	-0.3	1.71e-10	Tonsillectomy;
LUAD	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg04287289	chr16:89883240	FANCA	0.71	6.66	0.31	8.69e-11	Skin colour saturation;
LUAD	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg22117172	chr7:91764530	CYP51A1	0.38	8.26	0.37	1.94e-15	Breast cancer;
LUAD	cis	rs12208915	0.708	rs9361481	chr6:79726750	T/A	cg05283184	chr6:79620031	NA	0.46	6.49	0.3	2.47e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg02975922	chr3:195473998	MUC4	-0.42	-7.04	-0.32	7.91e-12	Pancreatic cancer;
LUAD	cis	rs13315871	0.722	rs3952239	chr3:58312057	G/T	cg12435725	chr3:58293450	RPP14	-0.73	-8.21	-0.37	2.72e-15	Cholesterol, total;
LUAD	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.68	-12.76	-0.53	9.14e-32	Ulcerative colitis;
LUAD	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.06	0.32	7.01e-12	Hypertriglyceridemia;
LUAD	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg21475434	chr5:93447410	FAM172A	0.78	8.6	0.39	1.62e-16	Diabetic retinopathy;
LUAD	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg06623918	chr6:96969491	KIAA0776	0.71	10.12	0.44	1.08e-21	Migraine;Coronary artery disease;
LUAD	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.25	-6.35	-0.3	5.51e-10	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg19729930	chr2:74357872	NA	0.99	16.86	0.63	3.82e-49	Gestational age at birth (maternal effect);
LUAD	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	7.86	0.36	3.33e-14	Tonsillectomy;
LUAD	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg23254163	chr1:152506842	NA	0.26	7.07	0.33	6.36e-12	Hair morphology;
LUAD	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.54	-8.43	-0.38	5.63e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg00383909	chr3:49044727	WDR6	0.7	7.57	0.35	2.39e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg04772025	chr11:68637568	NA	0.59	9.29	0.41	7.91e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg02683114	chr2:24398427	C2orf84	-0.51	-7.34	-0.34	1.1e-12	Asthma;
LUAD	cis	rs12545109	0.879	rs2576580	chr8:57365828	G/C	cg09654669	chr8:57350985	NA	-0.7	-9.91	-0.43	5.83e-21	Obesity-related traits;
LUAD	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg09184832	chr6:79620586	NA	-0.39	-6.69	-0.31	7.16e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1595825	0.636	rs111540926	chr2:198885578	G/A	cg00361562	chr2:198649771	BOLL	-0.47	-6.5	-0.3	2.29e-10	Ulcerative colitis;
LUAD	cis	rs17401966	0.838	rs12132134	chr1:10378428	A/G	cg15208524	chr1:10270712	KIF1B	0.42	6.53	0.3	1.86e-10	Hepatocellular carcinoma;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg12796498	chr2:1276796	SNTG2	-0.35	-7.31	-0.33	1.38e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs3750965	0.575	rs3018691	chr11:68884543	C/T	cg06818126	chr11:68850279	TPCN2	-0.46	-6.75	-0.31	5.04e-11	Hair color;
LUAD	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg27411982	chr8:10470053	RP1L1	0.39	7.08	0.33	6.19e-12	Retinal vascular caliber;
LUAD	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg08859206	chr1:53392774	SCP2	-0.58	-10.52	-0.46	3.75e-23	Monocyte count;
LUAD	cis	rs240764	0.697	rs9485411	chr6:101261352	A/C	cg09795085	chr6:101329169	ASCC3	0.41	6.81	0.31	3.27e-11	Neuroticism;
LUAD	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-14.51	-0.58	5.36e-39	Schizophrenia;
LUAD	cis	rs2742417	0.603	rs2742370	chr3:45782098	T/C	cg10512202	chr3:45649293	LIMD1	0.48	8.95	0.4	1.16e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs8051149	0.688	rs3815559	chr16:87871366	G/C	cg10099957	chr16:87869757	SLC7A5	0.44	7.15	0.33	3.94e-12	Blood metabolite levels;
LUAD	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg04944784	chr2:26401820	FAM59B	-0.88	-12.6	-0.52	4.12e-31	Gut microbiome composition (summer);
LUAD	cis	rs6685188	0.843	rs1775139	chr1:205672357	C/G	cg14893161	chr1:205819251	PM20D1	0.41	6.82	0.31	3.19e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg05665937	chr4:1216051	CTBP1	0.38	6.45	0.3	3e-10	Obesity-related traits;
LUAD	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg14584255	chr6:163149320	PACRG;PARK2	-0.38	-7.15	-0.33	3.87e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg16606324	chr3:10149918	C3orf24	0.69	9.99	0.44	3.03e-21	Alzheimer's disease;
LUAD	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-8.22	-0.37	2.44e-15	Monocyte percentage of white cells;
LUAD	cis	rs10992471	0.597	rs11789163	chr9:95234973	T/C	cg14631576	chr9:95140430	CENPP	-0.43	-8.65	-0.39	1.11e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg14416269	chr4:6271139	WFS1	0.64	13.51	0.55	7.7e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs4243830	1.000	rs12046884	chr1:6594561	G/A	cg05709478	chr1:6581295	PLEKHG5	0.57	6.42	0.3	3.7e-10	Body mass index;
LUAD	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.67e-15	Bipolar disorder;
LUAD	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg25767906	chr1:53392781	SCP2	-0.35	-6.6	-0.31	1.26e-10	Monocyte count;
LUAD	cis	rs4460629	0.742	rs11264314	chr1:155078423	C/G	cg23973274	chr1:155060172	NA	-0.37	-6.42	-0.3	3.57e-10	Serum magnesium levels;
LUAD	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg24818145	chr4:99064322	C4orf37	-0.42	-6.96	-0.32	1.26e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2235642	0.505	rs56359342	chr16:1654948	G/A	cg09065629	chr16:1709722	CRAMP1L	0.38	6.4	0.3	4.19e-10	Coronary artery disease;
LUAD	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.67	0.35	1.24e-13	Platelet count;
LUAD	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg06484146	chr7:12443880	VWDE	-0.6	-7.82	-0.36	4.23e-14	Coronary artery disease;
LUAD	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg24505687	chr6:33548425	BAK1	0.61	10.63	0.46	1.45e-23	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LUAD	trans	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	6.07e-11	Depression;
LUAD	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11890956	chr21:40555474	PSMG1	0.78	13.65	0.55	2.17e-35	Cognitive function;
LUAD	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg06623918	chr6:96969491	KIAA0776	0.88	17.14	0.64	2.14e-50	Headache;
LUAD	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.4	-7.9	-0.36	2.47e-14	Glomerular filtration rate;
LUAD	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-8.17	-0.37	3.62e-15	Alzheimer's disease (late onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06613666	chr12:46123163	ARID2;LOC400027	-0.43	-6.73	-0.31	5.38e-11	Height;
LUAD	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg24163568	chr5:669837	TPPP	-0.35	-6.69	-0.31	7.09e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg03605463	chr16:89740564	NA	0.67	12.06	0.51	5.46e-29	Vitiligo;
LUAD	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg19717773	chr7:2847554	GNA12	-0.51	-9.71	-0.43	2.95e-20	Height;
LUAD	cis	rs2637266	1.000	rs17384253	chr10:78342391	A/G	cg18941641	chr10:78392320	NA	0.33	6.82	0.31	3.24e-11	Pulmonary function;
LUAD	cis	rs7072216	0.770	rs942810	chr10:100167860	G/C	cg26618903	chr10:100175079	PYROXD2	-0.33	-7.29	-0.33	1.56e-12	Metabolite levels;
LUAD	cis	rs934734	0.752	rs2661797	chr2:65633190	G/A	cg11674355	chr2:65610261	SPRED2	0.37	6.53	0.3	1.84e-10	Rheumatoid arthritis;
LUAD	cis	rs868036	0.681	rs13329567	chr15:68104367	C/T	cg24579218	chr15:68104479	NA	-0.56	-9.84	-0.43	1.01e-20	Restless legs syndrome;
LUAD	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg02574844	chr11:5959923	NA	-0.45	-8.37	-0.38	8.63e-16	DNA methylation (variation);
LUAD	cis	rs9633740	0.773	rs7080009	chr10:82269461	T/C	cg01528321	chr10:82214614	TSPAN14	0.75	9.84	0.43	1.08e-20	Post bronchodilator FEV1;
LUAD	cis	rs17601876	0.814	rs749292	chr15:51558731	A/G	cg19946085	chr15:51559439	CYP19A1	0.37	6.78	0.31	3.95e-11	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LUAD	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg01874867	chr7:94954059	PON1	-0.48	-6.47	-0.3	2.7e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1113500	0.897	rs10785832	chr1:108638899	G/A	cg06207961	chr1:108661230	NA	0.45	8.45	0.38	4.67e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg18190219	chr22:46762943	CELSR1	-0.6	-7.36	-0.34	9.6e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.55	7.82	0.36	4.12e-14	Platelet count;
LUAD	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg06263672	chr7:65235340	NA	0.47	6.62	0.31	1.07e-10	Aortic root size;
LUAD	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg00102166	chr1:43425337	SLC2A1	-0.84	-11.26	-0.48	6.77e-26	Monocyte count;
LUAD	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-15.13	-0.59	1.16e-41	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11644478	chr21:40555479	PSMG1	-0.42	-6.98	-0.32	1.13e-11	Menarche (age at onset);
LUAD	cis	rs10193935	0.901	rs871045	chr2:42609431	G/C	cg27598129	chr2:42591480	NA	-0.77	-10.16	-0.44	7.53e-22	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg26043149	chr18:55253948	FECH	-0.43	-7.02	-0.32	8.61e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs986417	1.000	rs6573316	chr14:61058029	C/A	cg27398547	chr14:60952738	C14orf39	0.64	7.12	0.33	4.64e-12	Gut microbiota (bacterial taxa);
LUAD	trans	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.21	-0.41	1.52e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg22681709	chr2:178499509	PDE11A	0.5	8.19	0.37	3.04e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg06671706	chr8:8559999	CLDN23	0.61	10.5	0.45	4.45e-23	Obesity-related traits;
LUAD	cis	rs4700695	0.841	rs251300	chr5:65299715	C/G	cg21114390	chr5:65439923	SFRS12	-0.68	-8.16	-0.37	3.74e-15	Facial morphology (factor 19);
LUAD	cis	rs6484504	0.625	rs6484501	chr11:31373100	G/T	cg06552810	chr11:31128660	NA	0.32	6.37	0.3	4.81e-10	Red blood cell count;
LUAD	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg01181863	chr3:195395398	SDHAP2	0.6	9.17	0.41	2.13e-18	Pancreatic cancer;
LUAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg24503407	chr1:205819492	PM20D1	0.79	16.11	0.62	7.35e-46	Menarche (age at onset);
LUAD	cis	rs11229555	0.645	rs1986404	chr11:58194614	T/C	cg15696309	chr11:58395628	NA	-0.77	-10.55	-0.46	2.93e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07611812	chr8:53627203	RB1CC1	-0.41	-6.5	-0.3	2.31e-10	Height;
LUAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg08219700	chr8:58056026	NA	0.42	6.6	0.31	1.2e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg03467027	chr4:99064603	C4orf37	0.39	6.43	0.3	3.42e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.31	-0.45	2.13e-22	Platelet count;
LUAD	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg12035532	chr1:1886765	KIAA1751	0.41	6.8	0.31	3.56e-11	Body mass index;
LUAD	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg26384229	chr12:38710491	ALG10B	0.47	7.55	0.34	2.64e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.85	-0.36	3.46e-14	Total body bone mineral density;
LUAD	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg25894440	chr7:65020034	NA	-0.67	-7.19	-0.33	3.02e-12	Diabetic kidney disease;
LUAD	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg24450063	chr1:156163899	SLC25A44	1.01	16.55	0.63	8.92e-48	Testicular germ cell tumor;
LUAD	cis	rs11126435	0.858	rs3026000	chr2:74930094	A/T	cg19285774	chr2:74907978	SEMA4F	0.36	6.43	0.3	3.37e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs1941687	0.563	rs7232237	chr18:31324934	C/T	cg27147174	chr7:100797783	AP1S1	0.68	12.35	0.51	4.05e-30	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg00316803	chr15:76480434	C15orf27	-0.38	-6.47	-0.3	2.72e-10	Blood metabolite levels;
LUAD	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg18306943	chr3:40428807	ENTPD3	0.42	7.04	0.32	7.93e-12	Renal cell carcinoma;
LUAD	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg15445000	chr17:37608096	MED1	0.38	7.04	0.32	7.99e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.62	0.31	1.09e-10	Depression;
LUAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.93	-0.32	1.56e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs4372836	0.729	rs10166861	chr2:29061111	A/G	cg09522027	chr2:28974177	PPP1CB	-0.68	-12.2	-0.51	1.49e-29	Body mass index;
LUAD	cis	rs4950928	0.823	rs7541061	chr1:203163367	G/T	cg17014757	chr1:203156097	CHI3L1	0.59	8.32	0.37	1.25e-15	YKL-40 levels;
LUAD	cis	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg26587870	chr6:27730563	NA	-0.59	-6.56	-0.3	1.54e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs11229555	0.645	rs11229489	chr11:58244917	A/G	cg15696309	chr11:58395628	NA	-0.8	-10.9	-0.47	1.45e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.63	-0.31	1.06e-10	Breast cancer;
LUAD	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg18932078	chr1:2524107	MMEL1	0.35	6.49	0.3	2.34e-10	Ulcerative colitis;
LUAD	cis	rs1595825	0.891	rs75946628	chr2:198546239	C/T	cg11031976	chr2:198649780	BOLL	-0.49	-7.19	-0.33	2.98e-12	Ulcerative colitis;
LUAD	cis	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg20368463	chr18:77673604	PQLC1	0.52	6.89	0.32	2.08e-11	Opioid sensitivity;
LUAD	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg20135002	chr11:47629003	NA	-0.41	-7.19	-0.33	3.02e-12	Subjective well-being;
LUAD	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21659725	chr3:3221576	CRBN	-0.65	-10.47	-0.45	5.95e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.79e-18	Life satisfaction;
LUAD	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08109568	chr15:31115862	NA	-0.59	-10.16	-0.44	7.56e-22	Huntington's disease progression;
LUAD	cis	rs4767364	0.848	rs10774649	chr12:112539516	A/G	cg10833066	chr12:111807467	FAM109A	0.35	6.66	0.31	8.34e-11	Oral cavity and pharyngeal cancer;
LUAD	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg05425664	chr17:57184151	TRIM37	-0.42	-7.62	-0.35	1.65e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7737355	0.947	rs7724769	chr5:130954943	C/T	cg06307176	chr5:131281290	NA	0.5	7.58	0.35	2.25e-13	Life satisfaction;
LUAD	cis	rs34375054	0.660	rs57491100	chr12:125593010	C/T	cg06287003	chr12:125626642	AACS	-0.43	-6.4	-0.3	4.08e-10	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg00431813	chr7:1051703	C7orf50	-0.39	-7.12	-0.33	4.6e-12	Longevity;Endometriosis;
LUAD	cis	rs62238980	0.614	rs76349379	chr22:32415063	A/G	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs3087591	0.960	rs1013947	chr17:29530362	C/T	cg24425628	chr17:29625626	OMG;NF1	0.41	6.73	0.31	5.61e-11	Hip circumference;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26580576	chr4:6675790	LOC93622	-0.38	-6.44	-0.3	3.32e-10	Cancer;
LUAD	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg15704280	chr7:45808275	SEPT13	-1.0	-20.02	-0.7	3.37e-63	Height;
LUAD	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg05182265	chr7:156933206	UBE3C	-0.79	-17.12	-0.64	2.63e-50	Body mass index;
LUAD	cis	rs735539	0.645	rs9550662	chr13:21141552	C/T	cg27499820	chr13:21296301	IL17D	0.54	8.74	0.39	5.71e-17	Dental caries;
LUAD	cis	rs60871478	0.645	rs111968669	chr7:856683	C/T	cg15782153	chr7:917662	C7orf20	0.47	6.74	0.31	5.12e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg17366294	chr4:99064904	C4orf37	-0.51	-9.11	-0.4	3.41e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg06558623	chr16:89946397	TCF25	1.17	10.78	0.46	4.32e-24	Skin colour saturation;
LUAD	cis	rs9902453	0.933	rs9908901	chr17:28469713	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.72	0.39	6.6e-17	Coffee consumption (cups per day);
LUAD	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg13390004	chr1:15929781	NA	0.47	8.34	0.38	1.09e-15	Systolic blood pressure;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg02796970	chr10:39023768	NA	-0.46	-7.29	-0.33	1.55e-12	Menopause (age at onset);
LUAD	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg06453172	chr10:134556979	INPP5A	-0.67	-10.0	-0.44	2.94e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs806795	0.580	rs811041	chr6:26226032	C/G	cg00631329	chr6:26305371	NA	-0.51	-8.33	-0.38	1.1e-15	Mosquito bite size;
LUAD	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg11941060	chr3:133502564	NA	-0.46	-7.71	-0.35	8.93e-14	Iron status biomarkers;
LUAD	cis	rs240764	0.658	rs60658003	chr6:101201191	C/A	cg09795085	chr6:101329169	ASCC3	-0.47	-8.24	-0.37	2.14e-15	Neuroticism;
LUAD	cis	rs6840360	0.571	rs7678080	chr4:152557350	A/G	cg22705602	chr4:152727874	NA	-0.37	-6.45	-0.3	2.99e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg15309053	chr8:964076	NA	0.35	7.48	0.34	4.31e-13	Schizophrenia;
LUAD	cis	rs11640533	0.901	rs11862250	chr16:53415038	C/A	cg04653913	chr16:53407753	NA	0.5	9.06	0.4	4.92e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs2274273	0.840	rs28493647	chr14:55824463	T/C	cg04306507	chr14:55594613	LGALS3	0.44	9.11	0.4	3.39e-18	Protein biomarker;
LUAD	cis	rs367943	0.698	rs11741887	chr5:112959315	T/C	cg12552261	chr5:112820674	MCC	0.38	6.68	0.31	7.39e-11	Type 2 diabetes;
LUAD	cis	rs116248771	0.739	rs16829290	chr3:158392278	T/C	cg16708174	chr3:158430962	RARRES1	0.47	6.8	0.31	3.56e-11	diarrhoeal disease at age 2;
LUAD	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg02423579	chr7:2872169	GNA12	-0.86	-15.02	-0.59	3.61e-41	Height;
LUAD	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	13.06	0.54	5.6e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs75920871	1.000	rs61905706	chr11:116883777	G/T	cg04087571	chr11:116723030	SIK3	-0.32	-6.42	-0.3	3.6e-10	Subjective well-being;
LUAD	cis	rs938554	0.784	rs16868246	chr4:9978305	C/G	cg00071950	chr4:10020882	SLC2A9	0.53	8.32	0.37	1.27e-15	Blood metabolite levels;
LUAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg13560548	chr3:10150139	C3orf24	0.45	6.61	0.31	1.19e-10	Alzheimer's disease;
LUAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg22105103	chr4:187893119	NA	0.57	12.61	0.52	3.6e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg23758822	chr17:41437982	NA	0.97	20.57	0.71	1.1000000000000001e-65	Menopause (age at onset);
LUAD	cis	rs713477	1.000	rs8014621	chr14:55906849	A/C	cg13175173	chr14:55914753	NA	-0.34	-6.94	-0.32	1.48e-11	Pediatric bone mineral content (femoral neck);
LUAD	trans	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg26043149	chr18:55253948	FECH	-0.42	-6.77	-0.31	4.44e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg08885076	chr2:99613938	TSGA10	-0.41	-7.21	-0.33	2.63e-12	Chronic sinus infection;
LUAD	cis	rs727505	0.721	rs67817822	chr7:124769572	A/G	cg23710748	chr7:124431027	NA	-0.38	-7.85	-0.36	3.56e-14	Lewy body disease;
LUAD	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg25208724	chr1:156163844	SLC25A44	1.18	26.28	0.79	5.88e-91	Testicular germ cell tumor;
LUAD	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg10356904	chr22:49881777	NA	-0.4	-8.53	-0.38	2.72e-16	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg12011299	chr4:100065546	ADH4	0.73	13.72	0.55	1.1e-35	Alcohol dependence;
LUAD	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.43	-6.35	-0.3	5.51e-10	Colorectal cancer;
LUAD	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg10544611	chr16:67998164	SLC12A4	0.59	6.59	0.31	1.32e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1559088	1.000	rs11672313	chr19:33563190	C/T	cg27124370	chr19:33622961	WDR88	0.45	6.89	0.32	1.99e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs11622475	1.000	rs2269186	chr14:104379912	C/T	cg12183467	chr14:104352244	NA	-0.42	-7.65	-0.35	1.35e-13	Bipolar disorder;
LUAD	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg06781209	chr11:61594997	FADS2	0.4	7.76	0.35	6.57e-14	Trans fatty acid levels;
LUAD	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg25809561	chr17:30822961	MYO1D	-0.48	-8.72	-0.39	6.23e-17	Schizophrenia;
LUAD	cis	rs775227	0.574	rs16861158	chr3:113261709	G/T	cg10517650	chr3:113235015	CCDC52	-0.51	-7.17	-0.33	3.42e-12	Dental caries;
LUAD	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg00647820	chr17:40259828	DHX58	-0.44	-7.14	-0.33	4.01e-12	Fibrinogen levels;
LUAD	cis	rs6541297	1.000	rs4846838	chr1:230281618	G/A	cg20703242	chr1:230279135	GALNT2	0.64	10.49	0.45	5.01e-23	Coronary artery disease;
LUAD	cis	rs3789045	0.520	rs2010432	chr1:204462619	G/T	cg17419461	chr1:204415978	PIK3C2B	-0.43	-7.13	-0.33	4.25e-12	Educational attainment (college completion);
LUAD	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg07917127	chr4:99064746	C4orf37	0.4	6.6	0.31	1.22e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12612619	0.732	rs1866655	chr2:27208867	A/T	cg00617064	chr2:27272375	NA	0.34	6.59	0.31	1.32e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	trans	rs1200821	0.535	rs1938417	chr10:37687520	A/C	cg25427524	chr10:38739819	LOC399744	0.45	7.5	0.34	3.81e-13	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs75804782	0.521	rs55713398	chr2:239419933	A/G	cg01134436	chr17:81009848	B3GNTL1	0.78	8.45	0.38	4.89e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg12119029	chr16:89752879	CDK10	0.34	6.99	0.32	1.1e-11	Vitiligo;
LUAD	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg13679303	chr9:96623674	NA	-0.37	-7.36	-0.34	9.56e-13	DNA methylation (variation);
LUAD	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.12	0.37	5.17e-15	Breast cancer;
LUAD	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg14092988	chr3:52407081	DNAH1	-0.45	-8.78	-0.39	4.03e-17	Bipolar disorder;
LUAD	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg13175981	chr1:150552382	MCL1	0.4	6.39	0.3	4.4e-10	Tonsillectomy;
LUAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg22535103	chr8:58192502	C8orf71	-0.59	-7.08	-0.33	5.93e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.42	-0.34	6.65e-13	Total body bone mineral density;
LUAD	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg06199346	chr11:14280333	SPON1	-0.32	-6.38	-0.3	4.65e-10	Mitochondrial DNA levels;
LUAD	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.38	6.85	0.32	2.6e-11	Systemic lupus erythematosus;
LUAD	cis	rs9905704	0.633	rs2526369	chr17:56469113	T/C	cg19466818	chr17:56409534	MIR142	0.35	7.08	0.33	6.17e-12	Testicular germ cell tumor;
LUAD	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.6	0.39	1.62e-16	Menopause (age at onset);
LUAD	cis	rs3772130	0.923	rs28674947	chr3:121529421	C/T	cg20356878	chr3:121714668	ILDR1	0.53	8.58	0.39	1.77e-16	Cognitive performance;
LUAD	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs3760982	0.585	rs11673490	chr19:44298885	C/A	cg12072164	chr19:44306565	LYPD5	0.42	8.71	0.39	6.99e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11971779	0.680	rs10085901	chr7:139108989	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	7.16e-11	Diisocyanate-induced asthma;
LUAD	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg22868518	chr11:507468	RNH1	-0.65	-6.45	-0.3	2.99e-10	Body mass index;
LUAD	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg02951883	chr7:2050386	MAD1L1	-0.79	-12.72	-0.53	1.28e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg25382214	chr1:3105252	PRDM16	0.33	6.59	0.31	1.3100000000000001e-10	Migraine;
LUAD	cis	rs89107	0.688	rs283088	chr6:118592191	T/C	cg21191810	chr6:118973309	C6orf204	0.5	9.88	0.43	7.35e-21	Cardiac structure and function;
LUAD	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg10518543	chr12:38710700	ALG10B	0.42	6.42	0.3	3.68e-10	Bladder cancer;
LUAD	cis	rs2282300	0.739	rs35229181	chr11:30241698	A/G	cg25418670	chr11:30344373	C11orf46	-0.53	-7.09	-0.33	5.5e-12	Morning vs. evening chronotype;
LUAD	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	8.3	0.37	1.37e-15	Parkinson's disease;
LUAD	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg21171335	chr12:122356390	WDR66	0.66	11.63	0.49	2.46e-27	Mean corpuscular volume;
LUAD	cis	rs2041840	0.503	rs3770756	chr2:37573897	T/C	cg25727520	chr2:37576821	QPCT	-0.34	-7.44	-0.34	5.84e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs10242455	0.702	rs73397499	chr7:99039627	T/C	cg18809830	chr7:99032528	PTCD1	-0.99	-7.18	-0.33	3.17e-12	Blood metabolite levels;
LUAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.67	-0.31	8.19e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg09222892	chr1:25734099	RHCE	-0.49	-9.22	-0.41	1.41e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs7149337	0.805	rs7146561	chr14:51608889	C/G	cg23942311	chr14:51606299	NA	0.88	20.43	0.7	4.83e-65	Cancer;
LUAD	cis	rs36051895	0.659	rs57299248	chr9:5062932	C/G	cg02405213	chr9:5042618	JAK2	-0.47	-7.03	-0.32	8.5e-12	Pediatric autoimmune diseases;
LUAD	cis	rs73110464	0.505	rs2638503	chr12:53307369	C/G	cg05393297	chr12:53359155	NA	-0.44	-7.18	-0.33	3.23e-12	Cancer (pleiotropy);
LUAD	cis	rs10037055	0.636	rs13166688	chr5:176583966	T/C	cg06733329	chr5:176740039	MXD3	0.46	6.73	0.31	5.48e-11	Migraine without aura;
LUAD	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.67e-16	Neutrophil percentage of white cells;
LUAD	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.01	-0.5	8.8e-29	Primary sclerosing cholangitis;
LUAD	cis	rs9487051	0.676	rs9386774	chr6:109561646	C/T	cg21918786	chr6:109611834	NA	-0.42	-7.2	-0.33	2.71e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs6674176	0.932	rs4660761	chr1:44440146	G/A	cg12908607	chr1:44402522	ARTN	-0.55	-10.13	-0.44	9.75e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg06606381	chr12:133084897	FBRSL1	-0.78	-8.1	-0.37	5.95e-15	Depression;
LUAD	trans	rs7395662	1.000	rs7925955	chr11:48647533	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.26	-0.33	1.82e-12	HDL cholesterol;
LUAD	cis	rs10979	1.000	rs9386033	chr6:143888520	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-10.3	-0.45	2.33e-22	Hypospadias;
LUAD	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06112835	chr11:68658793	MRPL21	0.49	8.84	0.39	2.55e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs17255340	0.577	rs6937273	chr6:84095513	A/G	cg08257003	chr6:84140564	ME1	0.34	6.5	0.3	2.31e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs367943	0.965	rs644154	chr5:112799080	G/T	cg12552261	chr5:112820674	MCC	-0.58	-11.0	-0.47	6.33e-25	Type 2 diabetes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg25807061	chr7:74306919	PMS2L5;STAG3L2	-0.44	-7.73	-0.35	7.8e-14	Cancer;
LUAD	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg03690763	chr11:133734501	NA	-0.3	-7.1	-0.33	5.37e-12	Childhood ear infection;
LUAD	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.54	-0.6	2.1e-43	Chronic sinus infection;
LUAD	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg10518543	chr12:38710700	ALG10B	0.48	8.1	0.37	5.96e-15	Morning vs. evening chronotype;
LUAD	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg12564285	chr5:131593104	PDLIM4	0.37	6.96	0.32	1.33e-11	Acylcarnitine levels;
LUAD	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg16325326	chr1:53192061	ZYG11B	0.51	8.74	0.39	5.66e-17	Monocyte count;
LUAD	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg16797656	chr11:68205561	LRP5	0.48	10.1	0.44	1.3e-21	Total body bone mineral density;
LUAD	trans	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg00953403	chr17:74099816	EXOC7	0.52	8.03	0.36	9.83e-15	Psychosis in Alzheimer's disease;
LUAD	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg02176678	chr2:219576539	TTLL4	0.74	14.96	0.59	6.21e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg03609598	chr5:56110824	MAP3K1	-0.67	-9.24	-0.41	1.25e-18	Initial pursuit acceleration;
LUAD	cis	rs11771526	0.892	rs76035550	chr7:32371359	G/A	cg27511599	chr7:32358540	NA	0.61	7.05	0.32	7.29e-12	Body mass index;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg11235426	chr6:292522	DUSP22	-0.8	-13.66	-0.55	1.87e-35	Menopause (age at onset);
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg23666278	chr2:171785822	GORASP2	0.4	6.98	0.32	1.17e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01021488	chr15:99395581	IGF1R	0.37	6.54	0.3	1.75e-10	Cancer;
LUAD	cis	rs17739794	0.677	rs17739674	chr8:801584	G/T	cg20652464	chr8:752313	NA	-0.33	-7.17	-0.33	3.47e-12	Clozapine-induced cytotoxicity;
LUAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04267008	chr7:1944627	MAD1L1	-0.69	-10.49	-0.45	5.04e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs1190596	0.525	rs8004474	chr14:102756498	T/C	cg18135206	chr14:102964638	TECPR2	0.44	6.42	0.3	3.68e-10	Behavioural disinhibition (generation interaction);
LUAD	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg27210415	chr4:713949	PCGF3	0.62	9.16	0.41	2.32e-18	White blood cell count;
LUAD	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg22920501	chr2:26401640	FAM59B	-0.76	-10.89	-0.47	1.61e-24	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg22535103	chr8:58192502	C8orf71	-0.59	-7.13	-0.33	4.28e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg00280220	chr17:61926910	NA	-0.36	-6.95	-0.32	1.4e-11	Prudent dietary pattern;
LUAD	cis	rs2535633	0.631	rs2710346	chr3:52974152	C/T	cg11645453	chr3:52864694	ITIH4	-0.39	-7.21	-0.33	2.67e-12	Body mass index;
LUAD	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg10560079	chr2:191398806	TMEM194B	-0.47	-6.35	-0.3	5.56e-10	Diastolic blood pressure;
LUAD	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg05043794	chr9:111880884	C9orf5	-0.42	-7.51	-0.34	3.48e-13	Menarche (age at onset);
LUAD	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg09359103	chr1:154839909	KCNN3	-0.91	-21.11	-0.72	4.36e-68	Prostate cancer;
LUAD	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg13012494	chr21:47604986	C21orf56	0.42	6.46	0.3	2.91e-10	Testicular germ cell tumor;
LUAD	cis	rs9649213	1.000	rs9649213	chr7:98021211	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.52	-8.51	-0.38	3.1e-16	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs9902453	0.933	rs8074028	chr17:28461687	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.72	0.39	6.41e-17	Coffee consumption (cups per day);
LUAD	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg15921436	chr17:44337874	NA	-0.72	-9.45	-0.42	2.34e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7127129	0.872	rs3740720	chr11:70053547	C/T	cg06159181	chr11:70072977	NA	-0.35	-6.8	-0.31	3.65e-11	Aortic root size;
LUAD	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg03859395	chr2:55845619	SMEK2	-0.73	-13.32	-0.54	4.67e-34	Metabolic syndrome;
LUAD	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-7.95	-0.36	1.78e-14	Total body bone mineral density;
LUAD	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.45	0.3	2.98e-10	Aortic root size;
LUAD	trans	rs1973993	0.691	rs6658131	chr1:96889314	C/T	cg10631902	chr5:14652156	NA	0.68	14.06	0.56	4.16e-37	Weight;
LUAD	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.02	0.36	1.02e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs758324	0.853	rs6865911	chr5:131204659	A/G	cg06307176	chr5:131281290	NA	0.52	8.26	0.37	1.86e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7187994	0.790	rs16974508	chr16:84781075	G/A	cg07647771	chr16:84786436	USP10	-0.37	-9.57	-0.42	9.21e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg06808227	chr14:105710500	BRF1	-0.45	-7.12	-0.33	4.79e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17095355	0.642	rs4130278	chr10:111913522	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.03	-0.36	9.93e-15	Biliary atresia;
LUAD	cis	rs13064411	0.518	rs7637618	chr3:113176122	G/A	cg10517650	chr3:113235015	CCDC52	-0.38	-7.31	-0.33	1.35e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7493	0.950	rs11977702	chr7:95029767	C/T	cg05342682	chr7:94953680	PON1	-0.47	-6.53	-0.3	1.9e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg14582100	chr15:45693742	SPATA5L1	0.51	9.7	0.43	3.27e-20	Homoarginine levels;
LUAD	cis	rs9462027	0.606	rs4513788	chr6:34694779	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-9.0	-0.4	7.61e-18	Systemic lupus erythematosus;
LUAD	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg15790184	chr11:494944	RNH1	0.57	7.06	0.32	7.02e-12	Body mass index;
LUAD	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg21471580	chr8:22132874	PIWIL2	0.45	8.14	0.37	4.35e-15	Hypertriglyceridemia;
LUAD	cis	rs9814567	0.537	rs9879993	chr3:134162559	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	9.98	0.44	3.36e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg25797454	chr6:150327115	RAET1K	0.31	6.79	0.31	3.72e-11	Alopecia areata;
LUAD	cis	rs1569328	0.793	rs7150622	chr14:75723538	T/G	cg18117039	chr14:75741733	NA	0.51	8.49	0.38	3.47e-16	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2235649	0.585	rs238679	chr16:1872479	A/G	cg07386859	chr16:1872102	HAGH	-0.49	-6.69	-0.31	7.14e-11	Blood metabolite levels;
LUAD	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.36	-0.38	9.35e-16	Total body bone mineral density;
LUAD	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.16	0.33	3.63e-12	Prostate cancer;
LUAD	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.22	-0.37	2.55e-15	Breast cancer;
LUAD	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg19622623	chr12:86230825	RASSF9	-0.41	-7.37	-0.34	8.81e-13	Major depressive disorder;
LUAD	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg25324976	chr17:61989376	CSHL1	0.38	7.42	0.34	6.33e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs8062405	1.000	rs8061590	chr16:28895130	A/G	cg08761264	chr16:28874980	SH2B1	-0.44	-6.76	-0.31	4.65e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs16854884	0.657	rs1979910	chr3:143710268	A/C	cg01302019	chr3:143689584	C3orf58	-0.39	-6.58	-0.3	1.36e-10	Economic and political preferences (feminism/equality);
LUAD	cis	rs6782228	0.606	rs4857919	chr3:128407495	C/T	cg16766828	chr3:128327626	NA	-0.39	-7.43	-0.34	6.12e-13	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs4774899	0.752	rs2957574	chr15:57336825	C/T	cg14026238	chr15:57616123	NA	0.4	7.57	0.35	2.42e-13	Urinary tract infection frequency;
LUAD	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg02466173	chr16:30829666	NA	-0.75	-13.31	-0.54	5.41e-34	Multiple myeloma;
LUAD	cis	rs6992820	0.967	rs13254746	chr8:56719430	C/G	cg06880721	chr8:56792545	LYN	-0.45	-7.43	-0.34	6.09e-13	Mean platelet volume;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03915945	chr6:155635934	TFB1M	-0.53	-6.43	-0.3	3.37e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2073300	1.000	rs6132623	chr20:23442324	T/A	cg09953122	chr20:23471693	CST8	-0.65	-6.39	-0.3	4.29e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg10589385	chr1:150898437	SETDB1	0.43	8.21	0.37	2.74e-15	Melanoma;
LUAD	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg09455208	chr3:40491958	NA	0.65	14.15	0.57	1.7e-37	Renal cell carcinoma;
LUAD	cis	rs2692947	0.630	rs1168966	chr2:96798510	G/A	cg23100626	chr2:96804247	ASTL	0.36	9.64	0.42	5.08e-20	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7300001	0.667	rs7302198	chr12:110506280	T/C	cg12870014	chr12:110450643	ANKRD13A	0.89	8.48	0.38	3.77e-16	Headache;
LUAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg07677032	chr17:61819896	STRADA	0.55	9.91	0.43	5.73e-21	Prudent dietary pattern;
LUAD	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.58	8.26	0.37	1.84e-15	Platelet count;
LUAD	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg24450063	chr1:156163899	SLC25A44	1.02	18.39	0.67	6e-56	Testicular germ cell tumor;
LUAD	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg09455208	chr3:40491958	NA	-0.53	-11.53	-0.49	6.41e-27	Renal cell carcinoma;
LUAD	cis	rs2066819	1.000	rs76466034	chr12:56719450	G/A	cg26714650	chr12:56694279	CS	-0.85	-7.1	-0.33	5.17e-12	Psoriasis vulgaris;
LUAD	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg10518543	chr12:38710700	ALG10B	-0.43	-7.08	-0.33	5.85e-12	Morning vs. evening chronotype;
LUAD	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.39	8.04	0.36	9.41e-15	Hemoglobin concentration;
LUAD	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg07636037	chr3:49044803	WDR6	0.57	8.9	0.4	1.64e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	9.43	0.42	2.81e-19	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs11585357	0.895	rs72646798	chr1:17614422	C/T	cg08277548	chr1:17600880	PADI3	-0.94	-13.77	-0.56	6.9e-36	Hair shape;
LUAD	cis	rs7640424	0.750	rs13074183	chr3:107851467	G/A	cg09227934	chr3:107805635	CD47	-0.55	-9.65	-0.42	4.79e-20	Body mass index;
LUAD	cis	rs9837602	1.000	rs793499	chr3:99565576	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.6	-8.67	-0.39	9.32e-17	Breast cancer;
LUAD	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs2455799	0.613	rs13071303	chr3:15958203	C/T	cg16303742	chr3:15540471	COLQ	-0.43	-7.8	-0.35	4.83e-14	Mean platelet volume;
LUAD	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg02221750	chr19:17393354	ANKLE1	-0.79	-12.76	-0.53	9.1e-32	Systemic lupus erythematosus;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg04533881	chr14:50583218	C14orf138	0.4	7.04	0.32	7.89e-12	Anger;
LUAD	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg14092571	chr14:90743983	NA	-0.51	-8.83	-0.39	2.79e-17	Mortality in heart failure;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg20323509	chr8:114389479	CSMD3	0.36	6.58	0.3	1.36e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg09455208	chr3:40491958	NA	0.58	12.56	0.52	5.61e-31	Renal cell carcinoma;
LUAD	cis	rs1509123	0.609	rs56066996	chr17:6718844	T/G	cg12642237	chr17:6703447	TEKT1	-0.45	-6.4	-0.3	4.24e-10	Blood metabolite levels;
LUAD	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg03929089	chr4:120376271	NA	0.71	11.46	0.49	1.14e-26	Coronary artery disease;
LUAD	cis	rs7394190	0.748	rs4746139	chr10:75407649	A/C	cg02286717	chr10:75415704	SYNPO2L	-0.39	-6.99	-0.32	1.08e-11	Incident atrial fibrillation;
LUAD	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg22906224	chr7:99728672	NA	-0.56	-9.68	-0.43	3.82e-20	Coronary artery disease;
LUAD	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg14668632	chr7:2872130	GNA12	-0.72	-13.2	-0.54	1.47e-33	Height;
LUAD	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg22508957	chr16:3507546	NAT15	-0.49	-8.08	-0.37	6.88e-15	Body mass index (adult);
LUAD	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg19875535	chr5:140030758	IK	-0.48	-8.01	-0.36	1.16e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs28595532	0.623	rs71608363	chr4:119227259	T/C	cg02775129	chr4:119771670	NA	-0.64	-6.89	-0.32	2.02e-11	Cannabis dependence symptom count;
LUAD	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25427524	chr10:38739819	LOC399744	-0.76	-13.65	-0.55	2.11e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg07460842	chr6:66804631	NA	0.93	11.7	0.49	1.34e-27	Exhaled nitric oxide output;
LUAD	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg11859384	chr17:80120422	CCDC57	-0.52	-9.35	-0.41	5.05e-19	Life satisfaction;
LUAD	trans	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg07817883	chr1:32538562	TMEM39B	1.25	11.92	0.5	1.9e-28	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg01579765	chr21:45077557	HSF2BP	-0.58	-13.49	-0.55	9.68e-35	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg07917127	chr4:99064746	C4orf37	0.4	6.56	0.3	1.54e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg22676075	chr6:135203613	NA	0.59	11.08	0.47	3.26e-25	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg27411982	chr8:10470053	RP1L1	0.38	6.8	0.31	3.53e-11	Neuroticism;
LUAD	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg22920501	chr2:26401640	FAM59B	-0.77	-11.14	-0.48	1.92e-25	Gut microbiome composition (summer);
LUAD	cis	rs11971779	0.680	rs7805767	chr7:139111415	A/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.38e-10	Diisocyanate-induced asthma;
LUAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg18621852	chr3:10150065	C3orf24	0.45	7.08	0.33	5.94e-12	Alzheimer's disease;
LUAD	cis	rs3774830	0.714	rs17464616	chr4:5465004	G/A	cg26943120	chr4:5472116	STK32B	0.38	7.73	0.35	8.01e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg11693508	chr17:37793320	STARD3	0.82	10.6	0.46	1.87e-23	Bipolar disorder;
LUAD	cis	rs7805747	0.961	rs55779150	chr7:151406449	A/T	cg17611936	chr7:151411526	PRKAG2	0.46	6.72	0.31	5.99e-11	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LUAD	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg15432903	chr11:17409602	KCNJ11	0.55	10.57	0.46	2.43e-23	Type 2 diabetes;
LUAD	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg15691649	chr6:25882328	NA	0.43	6.96	0.32	1.3e-11	Blood metabolite levels;
LUAD	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg05234568	chr11:5960015	NA	-0.53	-9.29	-0.41	8e-19	DNA methylation (variation);
LUAD	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18876405	chr7:65276391	NA	-0.41	-6.49	-0.3	2.38e-10	Aortic root size;
LUAD	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.34	-6.42	-0.3	3.77e-10	Crohn's disease;
LUAD	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg00495681	chr13:53174319	NA	0.46	7.88	0.36	2.78e-14	Lewy body disease;
LUAD	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.77	-0.35	6.02e-14	Monocyte count;
LUAD	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg16205897	chr5:131564050	P4HA2	0.31	6.92	0.32	1.73e-11	Blood metabolite levels;
LUAD	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02475777	chr4:1388615	CRIPAK	0.59	8.36	0.38	9.1e-16	Longevity;
LUAD	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg12011299	chr4:100065546	ADH4	0.68	12.19	0.51	1.62e-29	Smoking initiation;
LUAD	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg05991184	chr2:219186017	PNKD	-0.36	-6.89	-0.32	2.05e-11	Colorectal cancer;
LUAD	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.84e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	7.67	0.35	1.23e-13	Breast cancer;
LUAD	trans	rs9393777	0.720	rs13217285	chr6:26999845	C/T	cg01620082	chr3:125678407	NA	-0.83	-8.76	-0.39	4.8e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs758324	0.947	rs6596040	chr5:131198777	C/T	cg06307176	chr5:131281290	NA	0.51	8.01	0.36	1.09e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg07917127	chr4:99064746	C4orf37	0.4	6.62	0.31	1.09e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4964805	0.657	rs11111787	chr12:104189499	C/T	cg02344784	chr12:104178138	NT5DC3	0.45	9.3	0.41	7.73e-19	Attention deficit hyperactivity disorder;
LUAD	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg21475434	chr5:93447410	FAM172A	-0.59	-7.59	-0.35	2.03e-13	Diabetic retinopathy;
LUAD	cis	rs3931020	0.688	rs405445	chr1:75221150	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.49	-6.66	-0.31	8.54e-11	Resistin levels;
LUAD	cis	rs68170813	0.559	rs12535081	chr7:106979291	C/T	cg02696742	chr7:106810147	HBP1	-0.77	-10.4	-0.45	1.05e-22	Coronary artery disease;
LUAD	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg21214613	chr1:16344536	HSPB7	0.62	11.9	0.5	2.26e-28	Dilated cardiomyopathy;
LUAD	cis	rs7089973	0.624	rs61867965	chr10:116574794	A/T	cg25233709	chr10:116636983	FAM160B1	0.4	7.69	0.35	1.02e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg04565464	chr8:145669602	NFKBIL2	0.42	6.47	0.3	2.71e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7107174	1.000	rs2511177	chr11:77922960	C/T	cg02023728	chr11:77925099	USP35	0.38	6.37	0.3	4.82e-10	Testicular germ cell tumor;
LUAD	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg00717180	chr2:96193071	NA	-0.42	-7.86	-0.36	3.31e-14	HDL cholesterol;
LUAD	cis	rs2455799	0.533	rs924754	chr3:15756215	A/T	cg16303742	chr3:15540471	COLQ	-0.46	-8.31	-0.37	1.32e-15	Mean platelet volume;
LUAD	cis	rs977987	0.806	rs11862684	chr16:75461746	T/G	cg03315344	chr16:75512273	CHST6	0.64	13.87	0.56	2.59e-36	Dupuytren's disease;
LUAD	cis	rs4372836	0.964	rs4408686	chr2:28940526	T/C	cg09522027	chr2:28974177	PPP1CB	0.58	9.12	0.41	3.1e-18	Body mass index;
LUAD	cis	rs7937890	0.559	rs2597201	chr11:14485404	T/C	cg23387056	chr11:14280742	SPON1	-0.35	-6.87	-0.32	2.3e-11	Mitochondrial DNA levels;
LUAD	cis	rs12216545	0.737	rs1522598	chr7:150239836	G/A	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.38	-0.3	4.64e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg13319975	chr6:146136371	FBXO30	-0.59	-9.82	-0.43	1.2e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs758324	0.812	rs10042334	chr5:131114979	A/T	cg25547332	chr5:131281432	NA	0.44	7.03	0.32	8.34e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg12935359	chr14:103987150	CKB	-0.48	-7.84	-0.36	3.72e-14	Body mass index;
LUAD	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg17173187	chr15:85201210	NMB	0.4	6.43	0.3	3.4e-10	Schizophrenia;
LUAD	cis	rs954108	0.809	rs1592059	chr13:29368961	G/A	cg11788234	chr13:29393811	NA	-0.33	-6.78	-0.31	4.07e-11	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg18000306	chr6:288505	NA	0.42	7.84	0.36	3.58e-14	Menopause (age at onset);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00053086	chr1:233119296	NA	0.53	6.67	0.31	7.92e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.66	-0.35	1.31e-13	Breast cancer;
LUAD	cis	rs7178572	0.568	rs7176302	chr15:77671216	C/G	cg15453836	chr15:77711506	NA	-0.36	-6.43	-0.3	3.41e-10	Type 2 diabetes;
LUAD	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg10518543	chr12:38710700	ALG10B	0.5	8.45	0.38	4.81e-16	Morning vs. evening chronotype;
LUAD	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.49	0.34	4.02e-13	Breast cancer;
LUAD	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg15181151	chr6:150070149	PCMT1	0.42	8.68	0.39	8.63e-17	Lung cancer;
LUAD	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24308560	chr3:49941425	MST1R	0.56	9.48	0.42	1.8e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg12863693	chr15:85201151	NMB	0.42	7.61	0.35	1.85e-13	Schizophrenia;
LUAD	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg27129171	chr3:47204927	SETD2	0.43	6.92	0.32	1.71e-11	Colorectal cancer;
LUAD	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg27454412	chr7:1067447	C7orf50	0.42	6.67	0.31	7.84e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg25767906	chr1:53392781	SCP2	-0.42	-7.87	-0.36	2.96e-14	Monocyte count;
LUAD	trans	rs4942242	0.763	rs7327129	chr13:44233014	T/C	cg19169023	chr15:41853346	TYRO3	-0.68	-11.95	-0.5	1.49e-28	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs8077889	1.000	rs2066725	chr17:41891473	A/G	cg26893861	chr17:41843967	DUSP3	0.93	15.61	0.6	1.09e-43	Triglycerides;
LUAD	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg14196790	chr5:131705035	SLC22A5	0.37	6.57	0.3	1.44e-10	Blood metabolite levels;
LUAD	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg01528321	chr10:82214614	TSPAN14	0.7	10.74	0.46	5.95e-24	Post bronchodilator FEV1;
LUAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02353165	chr6:42928485	GNMT	0.45	8.26	0.37	1.86e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg14458575	chr2:238380390	NA	0.96	18.16	0.66	6.33e-55	Prostate cancer;
LUAD	cis	rs4664308	0.967	rs17241973	chr2:160918601	A/G	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.8	-0.31	3.6e-11	Idiopathic membranous nephropathy;
LUAD	trans	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg01620082	chr3:125678407	NA	-0.75	-7.59	-0.35	2e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg07636037	chr3:49044803	WDR6	0.6	11.55	0.49	5.41e-27	Parkinson's disease;
LUAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08677398	chr8:58056175	NA	0.48	6.77	0.31	4.3e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg15704280	chr7:45808275	SEPT13	-0.75	-10.99	-0.47	6.85e-25	Coronary artery disease;
LUAD	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06221963	chr1:154839813	KCNN3	-0.86	-20.28	-0.7	2.2e-64	Prostate cancer;
LUAD	cis	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg25427524	chr10:38739819	LOC399744	0.6	8.58	0.39	1.79e-16	Obesity (extreme);
LUAD	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg15468180	chr1:107600409	PRMT6	0.47	7.98	0.36	1.34e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg03188948	chr7:1209495	NA	0.83	10.13	0.44	9.87e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22857025	chr5:266934	NA	-0.97	-14.67	-0.58	1.11e-39	Breast cancer;
LUAD	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg06623918	chr6:96969491	KIAA0776	-0.71	-9.93	-0.43	4.94e-21	Migraine;Coronary artery disease;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg05673432	chr3:15919505	NA	-0.42	-6.61	-0.31	1.15e-10	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02084834	chr2:201983708	CFLAR	-0.4	-6.44	-0.3	3.31e-10	Height;
LUAD	cis	rs2455601	0.744	rs11042107	chr11:8905871	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-6.76	-0.31	4.73e-11	Schizophrenia;
LUAD	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11890956	chr21:40555474	PSMG1	0.68	11.94	0.5	1.6e-28	Cognitive function;
LUAD	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg15133208	chr4:90757351	SNCA	-0.46	-7.08	-0.33	5.94e-12	Neuroticism;
LUAD	cis	rs877282	0.842	rs7092986	chr10:756373	G/A	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg26022315	chr17:47021804	SNF8	0.35	6.44	0.3	3.28e-10	Type 2 diabetes;
LUAD	trans	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg26043149	chr18:55253948	FECH	0.51	8.31	0.37	1.34e-15	Bone mineral density;
LUAD	cis	rs7587476	0.784	rs17424051	chr2:215688992	G/C	cg04004882	chr2:215674386	BARD1	0.51	6.51	0.3	2.15e-10	Neuroblastoma;
LUAD	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg21856205	chr7:94953877	PON1	-0.57	-8.07	-0.37	7.41e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg16647868	chr5:131706066	SLC22A5	-0.48	-7.72	-0.35	8.7e-14	Breast cancer;
LUAD	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg18105134	chr13:113819100	PROZ	-0.85	-14.95	-0.59	7.28e-41	Platelet distribution width;
LUAD	cis	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg23950597	chr19:37808831	NA	-0.59	-7.46	-0.34	4.88e-13	Coronary artery calcification;
LUAD	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.8	-0.31	3.5e-11	Longevity;
LUAD	cis	rs4285028	0.948	rs73855480	chr3:121676646	A/G	cg20356878	chr3:121714668	ILDR1	-0.5	-6.76	-0.31	4.51e-11	Multiple sclerosis;
LUAD	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg25457927	chr22:38595422	NA	-0.53	-13.87	-0.56	2.48e-36	Cutaneous nevi;
LUAD	trans	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg01620082	chr3:125678407	NA	-0.71	-7.22	-0.33	2.44e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17685	0.753	rs8200	chr7:75696606	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.41	7.99	0.36	1.32e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs6066825	0.644	rs1040559	chr20:47314445	A/G	cg18078177	chr20:47281410	PREX1	0.41	6.88	0.32	2.23e-11	Colorectal cancer;
LUAD	cis	rs62238980	0.614	rs4820058	chr22:32345733	A/G	cg00543991	chr22:32367038	NA	0.9	8.22	0.37	2.57e-15	Childhood ear infection;
LUAD	cis	rs3784262	0.565	rs4646607	chr15:58285388	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-6.74	-0.31	5.27e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg25237894	chr2:233734115	C2orf82	0.61	11.69	0.49	1.45e-27	Coronary artery disease;
LUAD	trans	rs2288327	0.673	rs6723399	chr2:179381715	G/C	cg14011486	chr1:26737247	LIN28	0.4	6.36	0.3	5.21e-10	Atrial fibrillation;
LUAD	cis	rs1594829	0.553	rs11135933	chr8:26162364	A/G	cg13160058	chr8:26243215	BNIP3L	-0.34	-7.45	-0.34	5.21e-13	Height;
LUAD	trans	rs8002861	0.626	rs9533634	chr13:44397815	T/C	cg12856521	chr11:46389249	DGKZ	-0.48	-7.94	-0.36	1.78e-14	Leprosy;
LUAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg25703541	chr22:24373054	LOC391322	-0.85	-16.45	-0.62	2.43e-47	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg26384229	chr12:38710491	ALG10B	0.44	7.19	0.33	2.87e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg02428538	chr16:24856791	SLC5A11	-0.56	-7.82	-0.36	4.37e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs17253792	0.822	rs10083499	chr14:56066590	T/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.15	-0.37	4.24e-15	Cannabis dependence symptom count;
LUAD	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg04398451	chr17:18023971	MYO15A	-0.87	-16.56	-0.63	7.97e-48	Total body bone mineral density;
LUAD	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg05368731	chr17:41323189	NBR1	0.95	19.49	0.69	8.14e-61	Menopause (age at onset);
LUAD	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03264133	chr6:25882463	NA	0.54	8.74	0.39	5.72e-17	Blood metabolite levels;
LUAD	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.43	7.0	0.32	1e-11	Resistin levels;
LUAD	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03352830	chr11:487213	PTDSS2	0.82	10.66	0.46	1.21e-23	Body mass index;
LUAD	trans	rs2665103	0.715	rs7403041	chr15:82580182	A/C	cg18393722	chr15:85113863	UBE2QP1	0.49	7.98	0.36	1.34e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.8	0.39	3.54e-17	Menopause (age at onset);
LUAD	cis	rs41271473	0.948	rs12082771	chr1:228830777	C/T	cg16512390	chr1:228756714	NA	0.49	6.44	0.3	3.29e-10	Chronic lymphocytic leukemia;
LUAD	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg18180107	chr4:99064573	C4orf37	0.42	6.72	0.31	5.84e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg25767906	chr1:53392781	SCP2	-0.46	-8.44	-0.38	5.12e-16	Monocyte count;
LUAD	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg18305652	chr10:134549665	INPP5A	0.56	12.26	0.51	8.96e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27470027	chr11:63684601	RCOR2	-0.51	-7.17	-0.33	3.38e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs941408	1.000	rs941406	chr19:2803623	A/G	cg06609049	chr19:2785107	THOP1	0.7	11.53	0.49	6.19e-27	Total cholesterol levels;
LUAD	cis	rs10979	1.000	rs1416208	chr6:143889241	T/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.24	-0.45	4.09e-22	Hypospadias;
LUAD	trans	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.94	0.44	4.72e-21	Ulcerative colitis;
LUAD	cis	rs1003719	0.667	rs73201942	chr21:38475164	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.46	7.62	0.35	1.71e-13	Eye color traits;
LUAD	cis	rs4006360	0.524	rs6503601	chr17:39280487	A/C	cg20663846	chr17:39254439	KRTAP4-8	0.36	7.35	0.34	1.01e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs738322	0.805	rs11570734	chr22:38518622	A/G	cg17652424	chr22:38574118	PLA2G6	-0.27	-7.64	-0.35	1.52e-13	Cutaneous nevi;
LUAD	cis	rs6445967	0.530	rs72624863	chr3:58365300	A/G	cg13750441	chr3:58318267	PXK	-0.32	-6.63	-0.31	1.03e-10	Platelet count;
LUAD	cis	rs13082711	0.911	rs34981505	chr3:27437322	A/T	cg02860705	chr3:27208620	NA	0.55	8.61	0.39	1.49e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg00204512	chr16:28754710	NA	0.35	7.65	0.35	1.39e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg08807101	chr21:30365312	RNF160	0.52	8.87	0.4	2.05e-17	Dental caries;
LUAD	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg01689657	chr7:91764605	CYP51A1	0.35	8.72	0.39	6.53e-17	Breast cancer;
LUAD	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg03929089	chr4:120376271	NA	0.55	6.96	0.32	1.28e-11	D-dimer levels;
LUAD	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg01689657	chr7:91764605	CYP51A1	0.29	6.82	0.31	3.23e-11	Breast cancer;
LUAD	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg22431228	chr1:16359049	CLCNKA	0.47	8.22	0.37	2.46e-15	Dilated cardiomyopathy;
LUAD	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg16205897	chr5:131564050	P4HA2	-0.33	-7.52	-0.34	3.38e-13	Blood metabolite levels;
LUAD	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg14343924	chr8:8086146	FLJ10661	0.46	7.37	0.34	8.85e-13	Systolic blood pressure;
LUAD	cis	rs986417	1.000	rs986417	chr14:60858761	C/T	cg27398547	chr14:60952738	C14orf39	-0.62	-7.31	-0.33	1.35e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg12062639	chr20:23401060	NAPB	1.1	11.14	0.48	1.95e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg22875332	chr1:76189707	ACADM	0.84	16.61	0.63	4.46e-48	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs3942852	0.955	rs7117386	chr11:48125371	G/A	cg15704280	chr7:45808275	SEPT13	-0.6	-8.16	-0.37	3.87e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs752010	0.684	rs10789402	chr1:42084649	A/G	cg06885757	chr1:42089581	HIVEP3	0.47	10.79	0.46	3.75e-24	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg03037974	chr15:76606532	NA	0.38	7.94	0.36	1.9e-14	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.9	0.53	2.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-6.5	-0.3	2.31e-10	Height;
LUAD	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg01689657	chr7:91764605	CYP51A1	0.34	8.74	0.39	5.39e-17	Breast cancer;
LUAD	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg18225595	chr11:63971243	STIP1	0.49	8.57	0.38	1.91e-16	Platelet count;
LUAD	cis	rs35740288	0.770	rs1157519	chr15:86161658	T/G	cg13263323	chr15:86062960	AKAP13	-0.44	-7.08	-0.33	6.03e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs420259	0.516	rs430208	chr16:23458485	A/G	cg00143387	chr16:23521605	GGA2	0.68	9.67	0.43	4.07e-20	Bipolar disorder;
LUAD	cis	rs12681287	0.647	rs2953510	chr8:87341914	T/C	cg00550725	chr8:87521180	FAM82B	0.47	6.75	0.31	5.01e-11	Caudate activity during reward;
LUAD	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.54	-9.05	-0.4	5.41e-18	Electrocardiographic conduction measures;
LUAD	cis	rs4901869	0.966	rs425764	chr14:59334997	A/G	cg02291164	chr14:59296302	NA	0.61	15.09	0.59	1.73e-41	Panic disorder;
LUAD	cis	rs7274811	0.779	rs34145153	chr20:32159067	C/T	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.47	-7.02	-0.32	9.11e-12	Height;
LUAD	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg26384229	chr12:38710491	ALG10B	-0.44	-7.18	-0.33	3.09e-12	Morning vs. evening chronotype;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg13616963	chr3:57583610	ARF4	0.41	6.91	0.32	1.77e-11	Anger;
LUAD	cis	rs2882667	0.894	rs1433008	chr5:138333664	T/C	cg04439458	chr5:138467593	SIL1	-0.4	-7.37	-0.34	9e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18404041	chr3:52824283	ITIH1	-0.59	-11.79	-0.5	5.98e-28	Bipolar disorder;
LUAD	cis	rs10129255	0.500	rs8021941	chr14:107189727	C/T	cg07958169	chr14:107095056	NA	-0.36	-7.15	-0.33	3.89e-12	Kawasaki disease;
LUAD	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg17063962	chr7:91808500	NA	0.7	12.68	0.52	1.96e-31	Breast cancer;
LUAD	cis	rs8014204	0.804	rs35641442	chr14:75207263	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.36	-6.68	-0.31	7.36e-11	Caffeine consumption;
LUAD	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg16205897	chr5:131564050	P4HA2	-0.35	-7.66	-0.35	1.25e-13	Acylcarnitine levels;
LUAD	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg08219700	chr8:58056026	NA	0.6	8.22	0.37	2.5e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4280164	0.945	rs2224122	chr14:24783414	G/C	cg22990158	chr14:24802150	ADCY4	0.5	6.98	0.32	1.12e-11	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs11811982	0.793	rs11808674	chr1:227516077	G/T	cg24860534	chr1:227506868	CDC42BPA	0.65	7.18	0.33	3.17e-12	Optic disc area;
LUAD	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg04287289	chr16:89883240	FANCA	0.78	6.98	0.32	1.15e-11	Skin colour saturation;
LUAD	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg08999081	chr20:33150536	PIGU	0.6	13.32	0.54	4.57e-34	Glomerular filtration rate (creatinine);
LUAD	cis	rs7394579	1	rs7394579	chr11:61581450	A/G	cg11250194	chr11:61601937	FADS2	-0.44	-6.65	-0.31	8.94e-11	Red cell distribution width;Mean platelet volume;
LUAD	cis	rs68170813	0.559	rs80307895	chr7:106907781	T/A	cg02696742	chr7:106810147	HBP1	-0.77	-10.66	-0.46	1.2e-23	Coronary artery disease;
LUAD	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22857025	chr5:266934	NA	-1.02	-12.88	-0.53	2.98e-32	Breast cancer;
LUAD	cis	rs10821973	0.527	rs3852405	chr10:64012554	G/A	cg09941381	chr10:64027924	RTKN2	-0.36	-7.15	-0.33	3.85e-12	Hypothyroidism;
LUAD	cis	rs7465272	1.000	rs35476574	chr8:143683784	C/A	cg10104451	chr8:143696006	ARC	-0.58	-7.93	-0.36	1.94e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg03948781	chr1:205179583	DSTYK	0.34	6.4	0.3	4.25e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	trans	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg03929089	chr4:120376271	NA	-0.62	-9.13	-0.41	2.78e-18	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg18944383	chr4:111397179	ENPEP	-0.41	-8.07	-0.37	7.28e-15	Coronary artery disease;
LUAD	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.48	-0.45	5.41e-23	Total body bone mineral density;
LUAD	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg26384229	chr12:38710491	ALG10B	0.52	8.54	0.38	2.47e-16	Heart rate;
LUAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg08280861	chr8:58055591	NA	0.52	7.15	0.33	3.77e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg15485101	chr11:133734466	NA	-0.33	-7.49	-0.34	4.15e-13	Childhood ear infection;
LUAD	cis	rs7799006	0.929	rs35791351	chr7:2269248	C/T	cg12745145	chr7:2261452	MAD1L1	-0.35	-6.81	-0.31	3.37e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs6960043	0.818	rs10238161	chr7:15053827	A/T	cg19272540	chr7:15055459	NA	0.36	8.22	0.37	2.53e-15	Type 2 diabetes;
LUAD	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg14552801	chr7:65878734	NA	0.38	6.38	0.3	4.7e-10	Aortic root size;
LUAD	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg09359103	chr1:154839909	KCNN3	-0.91	-20.92	-0.71	2.94e-67	Prostate cancer;
LUAD	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg20744362	chr22:50050164	C22orf34	0.42	9.18	0.41	1.95e-18	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg03929089	chr4:120376271	NA	0.9	16.41	0.62	3.5e-47	Height;
LUAD	cis	rs7593730	1.000	rs10209870	chr2:161192545	T/C	cg22609984	chr2:161126801	NA	0.45	7.27	0.33	1.79e-12	Type 2 diabetes;
LUAD	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg15704280	chr7:45808275	SEPT13	0.63	8.34	0.38	1.06e-15	Axial length;
LUAD	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg03806693	chr22:41940476	POLR3H	0.51	7.5	0.34	3.82e-13	Vitiligo;
LUAD	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11644478	chr21:40555479	PSMG1	-0.6	-10.16	-0.44	7.92e-22	Cognitive function;
LUAD	cis	rs12900413	0.687	rs11629590	chr15:90304644	A/G	cg24249390	chr15:90295951	MESP1	0.33	6.64	0.31	9.43e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.54e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6684514	1.000	rs12117903	chr1:156311165	G/T	cg16558208	chr1:156270281	VHLL	0.53	9.64	0.42	5e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs1997103	1.000	rs6593233	chr7:55406200	C/T	cg17469321	chr7:55412551	NA	-0.66	-11.4	-0.48	2.02e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs11756438	0.683	rs17349329	chr6:119002644	T/G	cg18833306	chr6:118973337	C6orf204	0.4	6.59	0.31	1.32e-10	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs3125734	0.572	rs7896627	chr10:64046354	T/G	cg19640130	chr10:64028056	RTKN2	-0.36	-7.7	-0.35	9.51e-14	Rheumatoid arthritis;
LUAD	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.47	9.14	0.41	2.64e-18	White blood cell count (basophil);White blood cell count;
LUAD	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg25036284	chr2:26402008	FAM59B	-0.59	-8.23	-0.37	2.32e-15	Gut microbiome composition (summer);
LUAD	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg04282206	chr17:62833786	PLEKHM1P	0.64	9.52	0.42	1.32e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.51	6.93	0.32	1.6e-11	Platelet count;
LUAD	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg07917127	chr4:99064746	C4orf37	0.41	6.89	0.32	2.01e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62238980	0.614	rs78017579	chr22:32381234	T/G	cg00543991	chr22:32367038	NA	0.94	8.78	0.39	4.09e-17	Childhood ear infection;
LUAD	cis	rs2581828	0.656	rs2581787	chr3:53127677	G/T	cg24530246	chr3:53118167	NA	0.3	6.41	0.3	3.78e-10	Crohn's disease;
LUAD	cis	rs9875589	0.509	rs1601870	chr3:14024162	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.35	6.44	0.3	3.22e-10	Ovarian reserve;
LUAD	cis	rs6500602	0.592	rs8051780	chr16:4434374	G/A	cg08645402	chr16:4508243	NA	0.47	7.68	0.35	1.15e-13	Schizophrenia;
LUAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg23283495	chr1:209979779	IRF6	0.71	11.41	0.49	1.83e-26	Cleft lip with or without cleft palate;
LUAD	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg12311346	chr5:56204834	C5orf35	-0.92	-13.64	-0.55	2.32e-35	Initial pursuit acceleration;
LUAD	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1160297	0.576	rs12990843	chr2:53108688	A/G	cg07782112	chr2:53107842	NA	0.41	8.73	0.39	6.07e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs4711336	0.935	rs754404	chr6:33664730	T/C	cg13859433	chr6:33739653	LEMD2	-0.31	-7.28	-0.33	1.62e-12	Height;
LUAD	cis	rs12893597	0.821	rs12896434	chr14:76816746	C/T	cg20290672	chr14:76816747	NA	-0.45	-7.46	-0.34	4.88e-13	Maximal oxygen uptake response;
LUAD	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg05754148	chr16:3507555	NAT15	0.46	7.21	0.33	2.59e-12	Body mass index (adult);
LUAD	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11890956	chr21:40555474	PSMG1	-0.59	-9.65	-0.42	4.84e-20	Cognitive function;
LUAD	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg13119609	chr19:45449297	APOC2	-0.63	-12.81	-0.53	5.65e-32	Blood protein levels;
LUAD	cis	rs9469913	0.740	rs2744964	chr6:34591320	G/C	cg17674042	chr6:34482479	PACSIN1	-0.42	-6.37	-0.3	4.96e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12766770	chr17:77982340	TBC1D16	-0.38	-6.42	-0.3	3.68e-10	Cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06434972	chr7:44122219	POLM	-0.4	-6.38	-0.3	4.71e-10	Height;
LUAD	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg03467027	chr4:99064603	C4orf37	0.43	6.94	0.32	1.5e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2997447	0.655	rs55820521	chr1:26374286	C/T	cg19633962	chr1:26362018	EXTL1	-0.63	-6.96	-0.32	1.29e-11	QRS complex (12-leadsum);
LUAD	cis	rs62064224	0.614	rs4795700	chr17:30763794	A/G	cg18200150	chr17:30822561	MYO1D	0.41	7.45	0.34	5.3e-13	Schizophrenia;
LUAD	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	10.55	0.46	3.04e-23	Bone mineral density;
LUAD	cis	rs7100689	0.599	rs7077847	chr10:82134952	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	9.93	0.43	5.05e-21	Post bronchodilator FEV1;
LUAD	cis	rs4460629	0.650	rs11264319	chr1:155083942	T/C	cg23973274	chr1:155060172	NA	-0.37	-6.53	-0.3	1.84e-10	Serum magnesium levels;
LUAD	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg17757837	chr7:157058334	UBE3C	0.48	8.53	0.38	2.66e-16	Body mass index;
LUAD	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg05373962	chr22:49881684	NA	-0.5	-10.33	-0.45	1.88e-22	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg23352942	chr3:46931381	PTH1R	-0.38	-7.65	-0.35	1.35e-13	Birth weight;
LUAD	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg07741184	chr6:167504864	NA	0.29	7.03	0.32	8.43e-12	Crohn's disease;
LUAD	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg07917127	chr4:99064746	C4orf37	0.41	6.81	0.31	3.28e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg03676636	chr4:99064102	C4orf37	0.32	8.43	0.38	5.49e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.37	7.14	0.33	4.09e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs346785	0.692	rs3803737	chr17:74289500	G/A	cg09812376	chr17:74270190	QRICH2	-0.3	-6.39	-0.3	4.46e-10	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg21681030	chr2:46777652	RHOQ	0.43	7.11	0.33	4.97e-12	Height;
LUAD	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg16535667	chr11:65410126	SIPA1	-0.48	-7.01	-0.32	9.64e-12	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-7.15	-0.33	3.79e-12	Personality dimensions;
LUAD	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg19875535	chr5:140030758	IK	-0.46	-7.55	-0.34	2.75e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2742417	0.603	rs2673075	chr3:45778288	C/A	cg10512202	chr3:45649293	LIMD1	0.47	8.74	0.39	5.39e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7737355	0.812	rs10078640	chr5:131071246	C/G	cg25547332	chr5:131281432	NA	0.41	6.51	0.3	2.14e-10	Life satisfaction;
LUAD	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg14895029	chr7:2775587	GNA12	0.4	6.46	0.3	2.8e-10	Height;
LUAD	cis	rs10821973	0.527	rs6479790	chr10:63980298	A/G	cg09941381	chr10:64027924	RTKN2	-0.35	-6.94	-0.32	1.48e-11	Hypothyroidism;
LUAD	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg04455712	chr21:45112962	RRP1B	-0.5	-9.95	-0.44	4.23e-21	Mean corpuscular volume;
LUAD	cis	rs367615	0.918	rs10055528	chr5:108861129	G/T	cg17395555	chr5:108820864	NA	0.56	9.32	0.41	6.37e-19	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg08859206	chr1:53392774	SCP2	-0.69	-12.96	-0.53	1.39e-32	Monocyte count;
LUAD	cis	rs6835098	0.816	rs13111572	chr4:174159788	G/A	cg08422745	chr4:174089978	GALNT7	0.95	17.16	0.64	1.8e-50	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs62238980	0.614	rs2899174	chr22:32458789	T/C	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.07	-0.33	6.25e-12	Height;
LUAD	cis	rs62064224	0.614	rs4795700	chr17:30763794	A/G	cg25809561	chr17:30822961	MYO1D	0.47	8.5	0.38	3.22e-16	Schizophrenia;
LUAD	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg08470875	chr2:26401718	FAM59B	-0.67	-8.92	-0.4	1.43e-17	Gut microbiome composition (summer);
LUAD	cis	rs68092024	0.704	rs704575	chr3:99486075	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	7.8	0.35	4.73e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg22117172	chr7:91764530	CYP51A1	-0.37	-8.01	-0.36	1.11e-14	Breast cancer;
LUAD	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg27661571	chr11:113659931	NA	-0.69	-8.12	-0.37	5.29e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg04155289	chr7:94953770	PON1	-0.55	-7.52	-0.34	3.35e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs8073060	0.521	rs225254	chr17:33953384	G/A	cg05299278	chr17:33885742	SLFN14	0.44	8.9	0.4	1.61e-17	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs2580764	0.540	rs10174838	chr2:55241216	A/T	cg09592903	chr2:55203963	RTN4	-0.46	-10.59	-0.46	2.0500000000000001e-23	Mean platelet volume;
LUAD	cis	rs4853036	1.000	rs4853036	chr2:70059824	G/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.26	-0.33	1.88e-12	Colorectal or endometrial cancer;
LUAD	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg15358701	chr1:161410459	NA	-0.68	-6.91	-0.32	1.85e-11	Rheumatoid arthritis;
LUAD	cis	rs57994353	0.897	rs66477686	chr9:139372224	T/C	cg14169450	chr9:139327907	INPP5E	0.4	6.39	0.3	4.48e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs1232027	0.700	rs1650692	chr5:79953393	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-7.98	-0.36	1.39e-14	Huntington's disease progression;
LUAD	cis	rs738322	0.640	rs738321	chr22:38568833	C/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-8.26	-0.37	1.83e-15	Cutaneous nevi;
LUAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00149659	chr3:10157352	C3orf10	0.59	8.33	0.38	1.16e-15	Alzheimer's disease;
LUAD	cis	rs71478720	0.779	rs34006273	chr11:112083096	C/T	cg04929355	chr11:112034997	IL18	0.4	6.45	0.3	3.14e-10	Interleukin-18 levels;
LUAD	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg25817165	chr18:72167213	CNDP2	-0.67	-9.69	-0.43	3.41e-20	Refractive error;
LUAD	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg20587970	chr11:113659929	NA	-1.38	-20.3	-0.7	1.89e-64	Hip circumference adjusted for BMI;
LUAD	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg09184832	chr6:79620586	NA	-0.52	-9.78	-0.43	1.74e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs684232	0.583	rs17677436	chr17:520314	T/C	cg15660573	chr17:549704	VPS53	-0.88	-17.95	-0.66	5.87e-54	Prostate cancer;
LUAD	cis	rs71636778	0.543	rs17162330	chr1:27236212	A/G	cg12203394	chr1:27248618	NUDC	0.52	6.61	0.31	1.15e-10	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs654950	0.841	rs2759247	chr1:41991756	G/C	cg06885757	chr1:42089581	HIVEP3	-0.35	-7.35	-0.34	1.04e-12	Airway imaging phenotypes;
LUAD	cis	rs225245	0.541	rs321613	chr17:33881718	G/A	cg05299278	chr17:33885742	SLFN14	0.37	7.28	0.33	1.65e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	14.82	0.58	2.66e-40	Smoking behavior;
LUAD	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.13	-0.37	4.66e-15	Total body bone mineral density;
LUAD	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg01028140	chr2:1542097	TPO	-0.41	-6.84	-0.32	2.84e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg11301795	chr4:187892539	NA	-0.77	-15.55	-0.6	1.98e-43	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs928736	0.599	rs1000005	chr21:34433051	C/G	cg00274965	chr21:34405681	NA	0.32	6.5	0.3	2.32e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg01802117	chr1:53393560	SCP2	0.37	7.29	0.33	1.53e-12	Monocyte count;
LUAD	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg00106254	chr7:1943704	MAD1L1	0.51	7.77	0.35	5.88e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs713587	0.806	rs6737082	chr2:25138040	A/C	cg04586622	chr2:25135609	ADCY3	0.31	6.77	0.31	4.2e-11	Body mass index in non-asthmatics;
LUAD	cis	rs953387	0.956	rs4954396	chr2:136927557	A/C	cg05194412	chr2:137003533	NA	-0.45	-7.27	-0.33	1.7e-12	Arthritis (juvenile idiopathic);
LUAD	cis	rs2795502	0.630	rs4948698	chr10:43539459	A/G	cg15903213	chr10:43522190	NA	0.6	6.69	0.31	7.11e-11	Blood protein levels;
LUAD	cis	rs4660306	1.000	rs2356561	chr1:45980862	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-6.64	-0.31	9.94e-11	Homocysteine levels;
LUAD	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg03477792	chr4:77819574	ANKRD56	0.48	7.17	0.33	3.33e-12	Emphysema distribution in smoking;
LUAD	cis	rs4845570	0.920	rs3811414	chr1:151763246	A/G	cg07092448	chr1:151763213	TDRKH	-0.76	-10.37	-0.45	1.35e-22	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg17366294	chr4:99064904	C4orf37	0.65	12.62	0.52	3.33e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg19336497	chr11:14380999	RRAS2	-0.66	-14.28	-0.57	5.02e-38	Sense of smell;
LUAD	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg06627628	chr2:24431161	ITSN2	-0.48	-6.64	-0.31	9.87e-11	Lymphocyte counts;
LUAD	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	9.45	0.42	2.31e-19	Electrocardiographic conduction measures;
LUAD	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg10909506	chr17:38081995	ORMDL3	0.37	6.57	0.3	1.47e-10	Self-reported allergy;
LUAD	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.49	0.38	3.47e-16	Menopause (age at onset);
LUAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg16606324	chr3:10149918	C3orf24	0.59	9.58	0.42	8.28e-20	Alzheimer's disease;
LUAD	cis	rs6489882	0.902	rs4767037	chr12:113372804	A/C	cg20102336	chr12:113376681	OAS3	-0.61	-9.51	-0.42	1.51e-19	Chronic lymphocytic leukemia;
LUAD	trans	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg21659725	chr3:3221576	CRBN	0.39	6.56	0.3	1.59e-10	Resting heart rate;
LUAD	cis	rs1595825	0.786	rs1902246	chr2:198492827	C/T	cg00982548	chr2:198649783	BOLL	-0.54	-7.84	-0.36	3.83e-14	Ulcerative colitis;
LUAD	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.72	0.31	5.81e-11	Motion sickness;
LUAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.46	-0.34	5.03e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs1957429	0.808	rs6573580	chr14:65331766	C/G	cg23373153	chr14:65346875	NA	0.6	6.6	0.31	1.2e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22857025	chr5:266934	NA	-1.03	-13.36	-0.54	3.39e-34	Breast cancer;
LUAD	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg21471580	chr8:22132874	PIWIL2	0.46	8.28	0.37	1.65e-15	Hypertriglyceridemia;
LUAD	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg13319975	chr6:146136371	FBXO30	0.58	8.26	0.37	1.93e-15	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg15997130	chr1:24165203	NA	0.53	9.28	0.41	8.66e-19	Immature fraction of reticulocytes;
LUAD	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.54	0.42	1.19e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs80319144	1.000	rs112505400	chr2:159217187	C/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.36	6.72	0.31	5.85e-11	Restless legs syndrome;
LUAD	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg06214716	chr4:10118677	WDR1	-0.43	-6.8	-0.31	3.68e-11	Bone mineral density;
LUAD	cis	rs12208915	0.945	rs116984077	chr6:79583325	A/G	cg05283184	chr6:79620031	NA	0.52	6.35	0.3	5.41e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg22618164	chr12:122356400	WDR66	0.76	14.18	0.57	1.34e-37	Mean platelet volume;
LUAD	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-11.52	-0.49	6.75e-27	Hemoglobin concentration;
LUAD	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg12310025	chr6:25882481	NA	-0.48	-6.88	-0.32	2.22e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg02931644	chr1:25747376	RHCE	0.52	11.38	0.48	2.38e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg13334819	chr7:99746414	C7orf59	-0.65	-10.44	-0.45	7.37e-23	Coronary artery disease;
LUAD	trans	rs9929218	0.559	rs55907909	chr16:68805805	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.0	21.09	0.72	5.52e-68	Colorectal cancer;
LUAD	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg24503407	chr1:205819492	PM20D1	-0.41	-6.7	-0.31	6.58e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg05340658	chr4:99064831	C4orf37	0.46	7.74	0.35	7.58e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg06784218	chr1:46089804	CCDC17	0.55	12.03	0.51	6.86e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.67	0.35	1.18e-13	Platelet count;
LUAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.48e-10	Prudent dietary pattern;
LUAD	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg00383909	chr3:49044727	WDR6	0.9	10.0	0.44	2.92e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg11070056	chr1:107600091	PRMT6	0.53	8.51	0.38	2.94e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg20476274	chr7:133979776	SLC35B4	-0.78	-14.4	-0.57	1.59e-38	Mean platelet volume;
LUAD	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg17724175	chr1:150552817	MCL1	-0.3	-6.88	-0.32	2.23e-11	Melanoma;
LUAD	cis	rs10242455	0.717	rs58649180	chr7:99336045	C/T	cg18809830	chr7:99032528	PTCD1	-0.81	-7.29	-0.33	1.53e-12	Blood metabolite levels;
LUAD	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg10596483	chr8:143751796	JRK	0.45	7.29	0.33	1.53e-12	Schizophrenia;
LUAD	cis	rs807669	0.835	rs698423	chr22:19197896	T/C	cg02655711	chr22:19163373	SLC25A1	0.85	18.35	0.67	9.62e-56	Metabolite levels;
LUAD	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg25344623	chr2:136566232	LCT	0.34	6.72	0.31	5.83e-11	Mosquito bite size;
LUAD	cis	rs7095607	0.813	rs4746732	chr10:69931881	C/T	cg18986048	chr10:69913749	MYPN	0.37	6.44	0.3	3.29e-10	Lung function (FVC);
LUAD	cis	rs9902453	0.845	rs7218113	chr17:28372130	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.53	-0.46	3.46e-23	Coffee consumption (cups per day);
LUAD	cis	rs6546550	0.901	rs12613947	chr2:70161342	A/G	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.07	-0.47	3.61e-25	Prevalent atrial fibrillation;
LUAD	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg27535305	chr1:53392650	SCP2	-0.4	-8.38	-0.38	7.66e-16	Monocyte count;
LUAD	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg04414720	chr1:150670196	GOLPH3L	0.71	12.53	0.52	7.57e-31	Melanoma;
LUAD	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg04398451	chr17:18023971	MYO15A	-0.69	-12.41	-0.52	2.19e-30	Total body bone mineral density;
LUAD	cis	rs9837602	1.000	rs35669453	chr3:99766063	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	9.22	0.41	1.46e-18	Breast cancer;
LUAD	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg09945482	chr18:12777974	NA	0.54	6.8	0.31	3.53e-11	Inflammatory skin disease;
LUAD	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg12292205	chr6:26970375	C6orf41	0.39	6.98	0.32	1.17e-11	Schizophrenia;
LUAD	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg25358565	chr5:93447407	FAM172A	0.65	7.76	0.35	6.38e-14	Diabetic retinopathy;
LUAD	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg25208724	chr1:156163844	SLC25A44	1.1	20.68	0.71	3.69e-66	Testicular germ cell tumor;
LUAD	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg01324343	chr3:183735012	ABCC5	0.83	19.19	0.68	1.65e-59	Anterior chamber depth;
LUAD	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg25036284	chr2:26402008	FAM59B	0.84	12.31	0.51	5.55e-30	Gut microbiome composition (summer);
LUAD	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg13012494	chr21:47604986	C21orf56	0.46	7.57	0.35	2.43e-13	Testicular germ cell tumor;
LUAD	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.79	0.31	3.75e-11	Rheumatoid arthritis;
LUAD	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.64	-0.49	2.39e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs240764	0.746	rs239197	chr6:101133600	T/C	cg09795085	chr6:101329169	ASCC3	0.45	7.85	0.36	3.51e-14	Neuroticism;
LUAD	cis	rs7737355	0.812	rs644964	chr5:131056809	T/C	cg06307176	chr5:131281290	NA	0.46	7.76	0.35	6.24e-14	Life satisfaction;
LUAD	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg22535103	chr8:58192502	C8orf71	-0.75	-10.56	-0.46	2.65e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs35883536	0.626	rs34752753	chr1:101045193	T/G	cg06223162	chr1:101003688	GPR88	-0.47	-9.2	-0.41	1.72e-18	Monocyte count;
LUAD	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg03874509	chr1:107600012	PRMT6	-0.48	-8.54	-0.38	2.47e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs564343	0.966	rs486311	chr11:65907242	T/A	cg26701943	chr11:108369231	KDELC2	-0.47	-7.79	-0.35	5.29e-14	Obesity (early onset extreme);
LUAD	cis	rs7843479	0.511	rs4379446	chr8:21777595	C/G	cg03445287	chr8:21823731	XPO7	-0.49	-9.12	-0.41	2.97e-18	Mean corpuscular volume;
LUAD	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-7.01	-0.32	9.51e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg06618935	chr21:46677482	NA	-0.51	-10.29	-0.45	2.52e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg03037974	chr15:76606532	NA	0.47	10.83	0.47	2.85e-24	Blood metabolite levels;
LUAD	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	11.53	0.49	6.19e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg00277334	chr10:82204260	NA	-0.71	-13.04	-0.54	6.45e-33	Post bronchodilator FEV1;
LUAD	cis	rs6546550	0.867	rs1551374	chr2:70079633	C/T	cg02498382	chr2:70120550	SNRNP27	-0.56	-10.53	-0.46	3.52e-23	Prevalent atrial fibrillation;
LUAD	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg11766577	chr21:47581405	C21orf56	-0.45	-7.76	-0.35	6.43e-14	Testicular germ cell tumor;
LUAD	cis	rs2004318	1.000	rs80051736	chr19:55078160	C/G	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.93e-13	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg18180107	chr4:99064573	C4orf37	0.42	6.79	0.31	3.87e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg25894440	chr7:65020034	NA	0.59	6.5	0.3	2.21e-10	Diabetic kidney disease;
LUAD	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg25208724	chr1:156163844	SLC25A44	1.15	25.87	0.78	3.72e-89	Testicular germ cell tumor;
LUAD	cis	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-7.17	-0.33	3.47e-12	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg09365446	chr1:150670422	GOLPH3L	0.63	11.03	0.47	4.99e-25	Melanoma;
LUAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg26516362	chr5:178986906	RUFY1	-0.63	-10.88	-0.47	1.81e-24	Lung cancer;
LUAD	cis	rs1298908	0.639	rs2994388	chr10:82034262	A/G	cg01528321	chr10:82214614	TSPAN14	-0.4	-6.36	-0.3	5.28e-10	Diabetic kidney disease;
LUAD	cis	rs9427116	0.840	rs9427113	chr1:154626477	A/G	cg17218026	chr1:154582156	ADAR	0.43	8.35	0.38	1.02e-15	Blood protein levels;
LUAD	cis	rs9796	0.621	rs2578655	chr15:41462809	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.6	-0.39	1.59e-16	Menopause (age at onset);
LUAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg20607798	chr8:58055168	NA	0.58	7.3	0.33	1.46e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	6.92	0.32	1.65e-11	Schizophrenia;
LUAD	cis	rs6494488	0.500	rs72741307	chr15:64700223	G/A	cg08069370	chr15:64387884	SNX1	-0.75	-6.65	-0.31	9.29e-11	Coronary artery disease;
LUAD	cis	rs12618769	0.652	rs2230388	chr2:99193496	C/T	cg10123293	chr2:99228465	UNC50	0.49	8.53	0.38	2.62e-16	Bipolar disorder;
LUAD	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.29	0.54	6.06e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1595825	0.891	rs7583917	chr2:198576950	A/G	cg11031976	chr2:198649780	BOLL	-0.45	-6.87	-0.32	2.28e-11	Ulcerative colitis;
LUAD	trans	rs629535	0.679	rs62511660	chr8:70157089	G/A	cg21567404	chr3:27674614	NA	-0.99	-15.76	-0.61	2.44e-44	Dupuytren's disease;
LUAD	cis	rs2387326	1.000	rs12252465	chr10:129932395	G/A	cg16087940	chr10:129947807	NA	-0.5	-6.59	-0.31	1.29e-10	Select biomarker traits;
LUAD	trans	rs7944735	0.786	rs7123436	chr11:48013484	G/A	cg15704280	chr7:45808275	SEPT13	0.69	8.82	0.39	3.1e-17	Intraocular pressure;
LUAD	cis	rs1497828	0.956	rs2646818	chr1:217525655	A/T	cg04411442	chr1:217543379	NA	-0.38	-6.91	-0.32	1.78e-11	Dialysis-related mortality;
LUAD	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.3	-7.89	-0.36	2.54e-14	Total body bone mineral density;
LUAD	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg11266682	chr4:10021025	SLC2A9	0.69	15.76	0.61	2.25e-44	Bone mineral density;
LUAD	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg16205897	chr5:131564050	P4HA2	-0.3	-6.74	-0.31	5.28e-11	Breast cancer;
LUAD	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.3	-0.33	1.41e-12	Height;
LUAD	cis	rs7937890	0.869	rs2915404	chr11:14404825	A/G	cg23387056	chr11:14280742	SPON1	-0.38	-7.71	-0.35	8.81e-14	Mitochondrial DNA levels;
LUAD	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02475777	chr4:1388615	CRIPAK	0.67	9.49	0.42	1.75e-19	Longevity;
LUAD	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg20744362	chr22:50050164	C22orf34	0.42	9.17	0.41	2.07e-18	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg14582100	chr15:45693742	SPATA5L1	0.63	12.48	0.52	1.21e-30	Homoarginine levels;
LUAD	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg00495681	chr13:53174319	NA	0.7	13.78	0.56	6.25e-36	Lewy body disease;
LUAD	cis	rs243505	0.732	rs10255478	chr7:148501985	C/G	cg09806900	chr7:148480153	CUL1	0.46	7.89	0.36	2.63e-14	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6060717	0.536	rs6060699	chr20:34523833	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-6.6	-0.31	1.2e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg02421172	chr7:1938701	MAD1L1	-0.42	-6.55	-0.3	1.66e-10	Bipolar disorder;
LUAD	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg01299579	chr2:10830716	NOL10	-0.43	-7.66	-0.35	1.31e-13	Prostate cancer;
LUAD	cis	rs6971211	0.669	rs12113208	chr7:155670937	A/C	cg14601210	chr7:155671264	NA	0.29	6.78	0.31	4.17e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg03474202	chr17:45855739	NA	-0.36	-7.25	-0.33	1.95e-12	IgG glycosylation;
LUAD	cis	rs9399401	0.667	rs6903424	chr6:142699948	A/C	cg04461802	chr6:142623433	GPR126	0.44	8.53	0.38	2.55e-16	Chronic obstructive pulmonary disease;
LUAD	cis	rs7020830	0.931	rs6476613	chr9:37084340	A/G	cg14294708	chr9:37120828	ZCCHC7	0.81	15.84	0.61	1.09e-44	Schizophrenia;
LUAD	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.35	6.88	0.32	2.23e-11	Lung cancer in ever smokers;
LUAD	cis	rs4481887	0.927	rs12039929	chr1:248482018	G/A	cg00666640	chr1:248458726	OR2T12	0.32	7.65	0.35	1.33e-13	Common traits (Other);
LUAD	cis	rs7149242	0.696	rs7141210	chr14:101182470	T/C	cg08175591	chr14:101176152	NA	0.39	6.87	0.32	2.33e-11	Platelet count;
LUAD	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg02002194	chr4:3960332	NA	-0.26	-6.47	-0.3	2.76e-10	Systemic lupus erythematosus;
LUAD	trans	rs8073060	0.544	rs225244	chr17:33946581	A/G	cg19694781	chr19:47549865	TMEM160	1.23	19.29	0.68	6.26e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03517284	chr6:25882590	NA	0.85	14.0	0.56	7.68e-37	Blood metabolite levels;
LUAD	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg27661571	chr11:113659931	NA	-0.73	-8.27	-0.37	1.78e-15	Hip circumference adjusted for BMI;
LUAD	trans	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg01620082	chr3:125678407	NA	-0.71	-7.15	-0.33	3.79e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-12.03	-0.5	7.38e-29	Bipolar disorder;
LUAD	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg13385794	chr1:248469461	NA	0.26	6.88	0.32	2.12e-11	Common traits (Other);
LUAD	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg09796270	chr17:17721594	SREBF1	-0.38	-7.58	-0.35	2.2e-13	Total body bone mineral density;
LUAD	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg00717180	chr2:96193071	NA	-0.38	-7.01	-0.32	9.76e-12	Height;
LUAD	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.69	-13.21	-0.54	1.4e-33	Cognitive ability;
LUAD	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg22117172	chr7:91764530	CYP51A1	0.38	8.23	0.37	2.38e-15	Breast cancer;
LUAD	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg24818145	chr4:99064322	C4orf37	0.44	6.95	0.32	1.39e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4594175	0.707	rs4901102	chr14:51746605	C/T	cg23942311	chr14:51606299	NA	-0.5	-8.66	-0.39	1.04e-16	Cancer;
LUAD	cis	rs354225	0.584	rs6706263	chr2:54815240	C/T	cg01766943	chr2:54829624	SPTBN1	0.39	7.22	0.33	2.47e-12	Schizophrenia;
LUAD	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg14668632	chr7:2872130	GNA12	-0.7	-12.17	-0.51	1.94e-29	Height;
LUAD	cis	rs4285028	0.747	rs3732407	chr3:121416623	G/C	cg11130432	chr3:121712080	ILDR1	-0.57	-7.89	-0.36	2.66e-14	Multiple sclerosis;
LUAD	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg17264618	chr3:40429014	ENTPD3	-0.4	-8.66	-0.39	9.89e-17	Renal cell carcinoma;
LUAD	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg20476274	chr7:133979776	SLC35B4	-0.79	-14.67	-0.58	1.12e-39	Mean platelet volume;
LUAD	cis	rs11048434	0.673	rs11611106	chr12:9060204	A/C	cg13575925	chr12:9217583	LOC144571	-0.35	-6.4	-0.3	4.03e-10	Sjögren's syndrome;
LUAD	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg21427119	chr20:30132790	HM13	-0.49	-7.88	-0.36	2.77e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg13511324	chr14:104056883	C14orf153	0.25	6.51	0.3	2.14e-10	Coronary artery disease;
LUAD	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.82	7.26	0.33	1.88e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-9.61	-0.42	6.76e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4253772	0.745	rs9626823	chr22:46645148	G/A	cg09491104	chr22:46646882	C22orf40	-0.54	-7.51	-0.34	3.52e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg21285383	chr16:89894308	SPIRE2	0.39	9.34	0.41	5.67e-19	Vitiligo;
LUAD	cis	rs2806561	0.514	rs7414010	chr1:23543929	T/C	cg19743168	chr1:23544995	NA	0.6	10.62	0.46	1.61e-23	Height;
LUAD	cis	rs7180079	0.620	rs936689	chr15:64735527	G/A	cg08069370	chr15:64387884	SNX1	0.49	6.47	0.3	2.73e-10	Monocyte count;
LUAD	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg21775007	chr8:11205619	TDH	0.48	8.31	0.37	1.31e-15	Retinal vascular caliber;
LUAD	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg02569458	chr12:86230093	RASSF9	0.45	8.24	0.37	2.25e-15	Major depressive disorder;
LUAD	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs739496	0.542	rs7312913	chr12:111793552	A/G	cg10833066	chr12:111807467	FAM109A	0.7	14.08	0.56	3.39e-37	Platelet count;
LUAD	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg18721089	chr20:30220636	NA	-0.41	-6.41	-0.3	3.87e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg24803719	chr17:45855879	NA	-0.33	-7.27	-0.33	1.71e-12	IgG glycosylation;
LUAD	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg10295955	chr4:187884368	NA	-1.12	-27.71	-0.8	3.92e-97	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg10057126	chr4:77819792	ANKRD56	0.53	9.01	0.4	7.02e-18	Emphysema distribution in smoking;
LUAD	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.38	6.56	0.3	1.57e-10	Blood metabolite levels;
LUAD	cis	rs9811920	0.535	rs792831	chr3:99473720	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.61	-0.39	1.45e-16	Axial length;
LUAD	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg10978503	chr1:24200527	CNR2	0.6	12.84	0.53	4.37e-32	Immature fraction of reticulocytes;
LUAD	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.63	0.52	2.94e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs870825	0.616	rs28666955	chr4:185631338	A/G	cg04058563	chr4:185651563	MLF1IP	0.9	14.37	0.57	2.08e-38	Blood protein levels;
LUAD	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg21918786	chr6:109611834	NA	-0.59	-11.21	-0.48	1.01e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg03948781	chr1:205179583	DSTYK	0.34	6.46	0.3	2.92e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs3806843	0.547	rs246033	chr5:140332115	A/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.66	-0.31	8.76e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6840360	0.533	rs13121178	chr4:152729047	T/C	cg22705602	chr4:152727874	NA	0.44	8.57	0.38	1.89e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg19748678	chr4:122722346	EXOSC9	0.44	6.93	0.32	1.55e-11	Type 2 diabetes;
LUAD	cis	rs7527798	0.592	rs12563520	chr1:207844062	C/T	cg09232269	chr1:207846808	CR1L	-0.39	-7.29	-0.33	1.51e-12	Erythrocyte sedimentation rate;
LUAD	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg24558204	chr6:135376177	HBS1L	0.48	8.14	0.37	4.6e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg01884057	chr2:25150051	NA	0.33	7.15	0.33	3.84e-12	Body mass index;
LUAD	cis	rs7202877	0.610	rs4888381	chr16:75356847	C/A	cg03315344	chr16:75512273	CHST6	0.47	6.38	0.3	4.66e-10	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs3806843	0.547	rs246048	chr5:140327900	G/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-9.49	-0.42	1.67e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19717773	chr7:2847554	GNA12	-0.57	-9.97	-0.44	3.58e-21	Height;
LUAD	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-7.38	-0.34	8.49e-13	Platelet count;
LUAD	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg15445000	chr17:37608096	MED1	-0.45	-8.3	-0.37	1.41e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs698833	0.892	rs786618	chr2:44593929	C/T	cg04920474	chr2:44395004	PPM1B	0.38	6.88	0.32	2.19e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg15704280	chr7:45808275	SEPT13	-0.69	-9.7	-0.43	3.25e-20	Coronary artery disease;
LUAD	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg17724175	chr1:150552817	MCL1	0.41	9.93	0.43	5.12e-21	Tonsillectomy;
LUAD	cis	rs7737355	0.812	rs798407	chr5:130688378	C/G	cg06307176	chr5:131281290	NA	-0.39	-6.6	-0.31	1.23e-10	Life satisfaction;
LUAD	cis	rs2882667	0.858	rs11959803	chr5:138451315	G/A	cg04439458	chr5:138467593	SIL1	-0.54	-9.7	-0.43	3.25e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg25767906	chr1:53392781	SCP2	-0.4	-7.3	-0.33	1.42e-12	Monocyte count;
LUAD	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	6.95	0.32	1.41e-11	Motion sickness;
LUAD	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg18827107	chr12:86230957	RASSF9	-0.43	-7.83	-0.36	3.84e-14	Major depressive disorder;
LUAD	cis	rs57994353	0.861	rs3812591	chr9:139341612	C/T	cg13856295	chr9:139396418	NOTCH1	0.41	6.74	0.31	5.29e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	trans	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg06606381	chr12:133084897	FBRSL1	-0.71	-6.72	-0.31	5.76e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg00933542	chr6:150070202	PCMT1	0.44	9.68	0.43	3.63e-20	Lung cancer;
LUAD	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11890956	chr21:40555474	PSMG1	0.55	9.49	0.42	1.73e-19	Menarche (age at onset);
LUAD	trans	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04565464	chr8:145669602	NFKBIL2	0.48	7.19	0.33	3.03e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg22907277	chr7:1156413	C7orf50	0.7	8.28	0.37	1.67e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7584330	0.554	rs74001386	chr2:238425333	T/A	cg14458575	chr2:238380390	NA	0.6	9.74	0.43	2.36e-20	Prostate cancer;
LUAD	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg23029597	chr12:123009494	RSRC2	-0.43	-7.24	-0.33	2.07e-12	Body mass index;
LUAD	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg12756686	chr19:29218302	NA	0.7	9.93	0.43	4.89e-21	Methadone dose in opioid dependence;
LUAD	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg21204522	chr6:27730016	NA	-0.48	-7.59	-0.35	2.13e-13	Parkinson's disease;
LUAD	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg09085632	chr11:111637200	PPP2R1B	0.68	10.36	0.45	1.51e-22	Primary sclerosing cholangitis;
LUAD	cis	rs6671926	1	rs6671926	chr1:227386971	G/A	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic cup area;Optic disc area;
LUAD	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg01191920	chr7:158217561	PTPRN2	-0.58	-12.04	-0.51	6.46e-29	Obesity-related traits;
LUAD	trans	rs7200543	0.961	rs3803573	chr16:15138413	C/T	cg24683922	chr1:11983373	KIAA2013	-0.48	-7.98	-0.36	1.41e-14	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg12193833	chr17:30244370	NA	0.52	6.52	0.3	2.01e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg15147215	chr3:52552868	STAB1	-0.39	-7.19	-0.33	2.99e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-9.2	-0.41	1.69e-18	Alzheimer's disease;
LUAD	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21582582	chr3:182698605	DCUN1D1	0.72	14.1	0.57	2.78e-37	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg21153622	chr11:89784906	NA	-0.32	-6.46	-0.3	2.95e-10	Height;
LUAD	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.18	0.33	3.16e-12	Motion sickness;
LUAD	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg24813613	chr7:1882135	MAD1L1	-0.52	-8.45	-0.38	4.77e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs9787249	0.957	rs12074147	chr1:40203722	T/C	cg02773041	chr1:40204384	PPIE	0.51	8.33	0.38	1.12e-15	Blood protein levels;
LUAD	cis	rs4975616	0.807	rs28379291	chr5:1313701	A/G	cg07493874	chr5:1342172	CLPTM1L	0.34	7.36	0.34	9.39e-13	Lung cancer;
LUAD	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg09658497	chr7:2847517	GNA12	0.42	7.35	0.34	1.03e-12	Loneliness (linear analysis);
LUAD	cis	rs295140	0.605	rs34693942	chr2:201184348	T/C	cg23649088	chr2:200775458	C2orf69	-0.45	-7.67	-0.35	1.23e-13	QT interval;
LUAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-7.09	-0.33	5.61e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg13047869	chr3:10149882	C3orf24	0.66	11.19	0.48	1.19e-25	Alzheimer's disease;
LUAD	cis	rs2019216	0.903	rs1817415	chr17:21893338	C/G	cg05591447	chr17:21909280	FLJ36000	-0.29	-7.6	-0.35	1.99e-13	Pelvic organ prolapse;
LUAD	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg03859395	chr2:55845619	SMEK2	-0.49	-7.83	-0.36	3.95e-14	Metabolic syndrome;
LUAD	cis	rs2637266	1.000	rs7474960	chr10:78359021	C/T	cg18941641	chr10:78392320	NA	0.33	6.83	0.32	3.02e-11	Pulmonary function;
LUAD	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg03676636	chr4:99064102	C4orf37	0.3	7.25	0.33	2.02e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg27210415	chr4:713949	PCGF3	0.62	9.3	0.41	7.86e-19	White blood cell count;
LUAD	trans	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	25.94	0.78	1.75e-89	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg19622623	chr12:86230825	RASSF9	-0.39	-7.02	-0.32	9.09e-12	Major depressive disorder;
LUAD	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.4	-7.31	-0.33	1.37e-12	Urate levels in overweight individuals;
LUAD	trans	rs1997103	1.000	rs9642578	chr7:55400320	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.1	0.33	5.27e-12	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg10729496	chr3:10149963	C3orf24	0.58	9.5	0.42	1.63e-19	Alzheimer's disease;
LUAD	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg20916646	chr4:852691	GAK	0.65	8.48	0.38	3.75e-16	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg27129171	chr3:47204927	SETD2	0.43	7.08	0.33	6.04e-12	Colorectal cancer;
LUAD	cis	rs597539	0.690	rs1272609	chr11:68618182	T/C	cg21963583	chr11:68658836	MRPL21	0.63	11.02	0.47	5.39e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs12042107	0.818	rs12046000	chr1:91192396	G/T	cg13456504	chr1:91191583	NA	0.33	6.61	0.31	1.14e-10	Educational attainment;
LUAD	cis	rs112990264	0.568	rs3006239	chr1:212985840	A/G	cg01785514	chr1:212988523	TATDN3	-0.47	-6.81	-0.31	3.4e-11	Itch intensity from mosquito bite;
LUAD	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	2.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7107174	1.000	rs2510048	chr11:77987464	T/C	cg02023728	chr11:77925099	USP35	0.52	7.84	0.36	3.69e-14	Testicular germ cell tumor;
LUAD	cis	rs7241530	0.662	rs9951456	chr18:75888704	A/G	cg14642773	chr18:75888474	NA	0.32	6.55	0.3	1.65e-10	Educational attainment (years of education);
LUAD	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg03929089	chr4:120376271	NA	-0.49	-6.46	-0.3	2.87e-10	D-dimer levels;
LUAD	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg17366294	chr4:99064904	C4orf37	0.61	11.3	0.48	4.59e-26	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs79349575	0.679	rs9894239	chr17:46997959	C/T	cg22482690	chr17:47019901	SNF8	-0.4	-7.74	-0.35	7.15e-14	Type 2 diabetes;
LUAD	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg03806693	chr22:41940476	POLR3H	-0.82	-11.63	-0.49	2.55e-27	Vitiligo;
LUAD	cis	rs13095912	0.719	rs7625483	chr3:185297113	T/C	cg11274856	chr3:185301563	NA	0.48	9.02	0.4	6.55e-18	Systolic blood pressure;
LUAD	cis	rs12545109	0.800	rs1968551	chr8:57407760	T/C	cg07776626	chr8:57350775	NA	-0.61	-8.52	-0.38	2.94e-16	Obesity-related traits;
LUAD	cis	rs1595825	0.891	rs73056811	chr2:198766642	T/C	cg00982548	chr2:198649783	BOLL	-0.63	-9.1	-0.4	3.47e-18	Ulcerative colitis;
LUAD	cis	rs6138458	1.000	rs6114980	chr20:24974288	A/G	cg26195577	chr20:24973756	C20orf3	0.98	17.44	0.65	9.94e-52	Blood protein levels;
LUAD	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-7.17	-0.33	3.36e-12	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg14039649	chr22:38352398	POLR2F	0.37	6.75	0.31	5.01e-11	Glioblastoma;Glioma;
LUAD	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg18811423	chr2:55921094	PNPT1	0.5	8.27	0.37	1.81e-15	Metabolic syndrome;
LUAD	cis	rs4766566	0.609	rs933305	chr12:111738287	G/A	cg10833066	chr12:111807467	FAM109A	0.59	10.26	0.45	3.22e-22	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUAD	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.41	-0.34	6.93e-13	Breast cancer;
LUAD	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg04989706	chr14:50066350	PPIL5	-0.55	-7.77	-0.35	6.06e-14	Carotid intima media thickness;
LUAD	cis	rs7301016	0.846	rs17732182	chr12:63026131	C/T	cg11441379	chr12:63026424	NA	0.62	7.54	0.34	2.93e-13	IgG glycosylation;
LUAD	cis	rs7107174	1.000	rs7127187	chr11:77995188	G/A	cg19901956	chr11:77921274	USP35	-0.52	-6.76	-0.31	4.63e-11	Testicular germ cell tumor;
LUAD	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg23649088	chr2:200775458	C2orf69	-0.62	-7.79	-0.35	5.38e-14	Schizophrenia;
LUAD	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg09184832	chr6:79620586	NA	-0.5	-9.64	-0.42	5.1e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg10729496	chr3:10149963	C3orf24	0.6	10.05	0.44	1.82e-21	Alzheimer's disease;
LUAD	cis	rs225245	0.782	rs225272	chr17:33969911	T/C	cg05299278	chr17:33885742	SLFN14	0.52	12.05	0.51	5.83e-29	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs4700695	0.925	rs6449799	chr5:65394476	A/G	cg21114390	chr5:65439923	SFRS12	-0.62	-8.13	-0.37	4.87e-15	Facial morphology (factor 19);
LUAD	cis	rs4713675	0.546	rs3818521	chr6:33657246	C/T	cg14003231	chr6:33640908	ITPR3	0.5	9.61	0.42	6.84e-20	Plateletcrit;
LUAD	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg27211696	chr2:191398769	TMEM194B	-0.59	-8.05	-0.36	8.73e-15	Diastolic blood pressure;
LUAD	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.21e-19	Life satisfaction;
LUAD	cis	rs910187	0.678	rs1046664	chr20:45817223	G/A	cg27589058	chr20:45804311	EYA2	-0.3	-6.92	-0.32	1.66e-11	Migraine;
LUAD	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-8.21	-0.37	2.68e-15	Hemoglobin concentration;
LUAD	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26314531	chr2:26401878	FAM59B	-0.67	-8.83	-0.39	2.75e-17	Gut microbiome composition (summer);
LUAD	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	7.0	0.32	1.02e-11	Depression;
LUAD	cis	rs8063160	0.561	rs12922197	chr16:89744809	G/C	cg07984980	chr16:89898383	SPIRE2	0.82	8.86	0.4	2.22e-17	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LUAD	cis	rs1865721	0.771	rs72975986	chr18:73127649	A/G	cg26385618	chr18:73139727	C18orf62	-0.51	-10.13	-0.44	9.43e-22	Intelligence;
LUAD	cis	rs6087990	0.966	rs1883730	chr20:31337487	T/A	cg13636640	chr20:31349939	DNMT3B	0.84	16.01	0.61	1.9e-45	Ulcerative colitis;
LUAD	cis	rs11030122	0.702	rs4910868	chr11:3980224	A/C	cg18678763	chr11:4115507	RRM1	-0.44	-7.33	-0.34	1.14e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7818345	1.000	rs6981898	chr8:19305705	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.3	6.6	0.31	1.24e-10	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.38	-7.98	-0.36	1.36e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg00316803	chr15:76480434	C15orf27	0.39	6.61	0.31	1.13e-10	Blood metabolite levels;
LUAD	trans	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg21153622	chr11:89784906	NA	-0.34	-6.79	-0.31	3.7e-11	Height;
LUAD	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg11502198	chr6:26597334	ABT1	-0.64	-10.96	-0.47	9.36e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg14416269	chr4:6271139	WFS1	0.58	11.09	0.47	2.88e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs9462027	0.606	rs7341253	chr6:34726838	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.84	-0.39	2.55e-17	Systemic lupus erythematosus;
LUAD	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg22823121	chr1:150693482	HORMAD1	0.44	8.91	0.4	1.55e-17	Tonsillectomy;
LUAD	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg06092702	chr1:163392909	NA	0.38	8.05	0.36	8.6e-15	Motion sickness;
LUAD	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-9.7	-0.43	3.29e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg09904177	chr6:26538194	HMGN4	0.44	7.39	0.34	7.96e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs701145	1.000	rs355784	chr3:153986371	A/C	cg17054900	chr3:154042577	DHX36	0.64	7.1	0.33	5.4e-12	Coronary artery disease;
LUAD	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.97	0.32	1.23e-11	Blood metabolite levels;
LUAD	cis	rs17092148	0.636	rs2295096	chr20:33464710	A/G	cg16810054	chr20:33298113	TP53INP2	0.43	7.62	0.35	1.73e-13	Neuroticism;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04830409	chr12:64615927	C12orf66	-0.51	-7.89	-0.36	2.62e-14	Height;
LUAD	cis	rs13064411	0.518	rs6438160	chr3:113217591	A/C	cg10517650	chr3:113235015	CCDC52	-0.38	-7.21	-0.33	2.52e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs11039798	0.925	rs12277669	chr11:48925316	A/T	cg15704280	chr7:45808275	SEPT13	0.67	7.8	0.35	4.95e-14	Axial length;
LUAD	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg05368731	chr17:41323189	NBR1	0.96	20.46	0.71	3.7e-65	Menopause (age at onset);
LUAD	trans	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.43	0.55	1.68e-34	Exhaled nitric oxide output;
LUAD	cis	rs1030877	0.515	rs1866038	chr2:105878522	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.41	6.5	0.3	2.25e-10	Obesity-related traits;
LUAD	trans	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg01620082	chr3:125678407	NA	-0.44	-6.67	-0.31	7.84e-11	Depression;
LUAD	cis	rs4722404	0.620	rs6978200	chr7:3118835	A/G	cg19214707	chr7:3157722	NA	-0.41	-6.64	-0.31	9.51e-11	Atopic dermatitis;
LUAD	cis	rs17135859	1.000	rs10447258	chr5:113005906	T/C	cg12552261	chr5:112820674	MCC	0.54	6.68	0.31	7.58e-11	F-cell distribution;
LUAD	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg23254163	chr1:152506842	NA	0.26	7.17	0.33	3.28e-12	Hair morphology;
LUAD	cis	rs6840360	0.762	rs62327352	chr4:152670780	C/A	cg22705602	chr4:152727874	NA	-0.32	-6.35	-0.3	5.42e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7943953	0.714	rs35630700	chr11:59196449	A/C	cg00706994	chr11:59190310	OR5A2	0.34	6.37	0.3	4.95e-10	Odorant perception (&beta-ionone);
LUAD	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.55	-7.94	-0.36	1.86e-14	IgG glycosylation;
LUAD	cis	rs7705042	0.727	rs1062158	chr5:141523000	C/T	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.73	-0.31	5.55e-11	Asthma;
LUAD	trans	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg03886242	chr7:26192032	NFE2L3	-0.41	-6.84	-0.32	2.81e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg12908607	chr1:44402522	ARTN	-0.45	-8.95	-0.4	1.1e-17	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs7737355	0.947	rs6882552	chr5:130841493	A/G	cg06307176	chr5:131281290	NA	0.51	8.0	0.36	1.18e-14	Life satisfaction;
LUAD	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg03859395	chr2:55845619	SMEK2	0.75	13.91	0.56	1.8e-36	Metabolic syndrome;
LUAD	cis	rs12532214	1.000	rs12532214	chr7:3169890	C/G	cg19214707	chr7:3157722	NA	-0.54	-8.25	-0.37	2.04e-15	Itch intensity from mosquito bite;
LUAD	cis	rs1395	0.778	rs62128747	chr2:27412605	T/C	cg23587288	chr2:27483067	SLC30A3	-0.42	-7.84	-0.36	3.81e-14	Blood metabolite levels;
LUAD	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.89	0.32	1.99e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg18621852	chr3:10150065	C3orf24	0.5	8.73	0.39	5.78e-17	Alzheimer's disease;
LUAD	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg11766577	chr21:47581405	C21orf56	-0.45	-7.73	-0.35	7.82e-14	Testicular germ cell tumor;
LUAD	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg17724175	chr1:150552817	MCL1	0.37	8.55	0.38	2.26e-16	Melanoma;
LUAD	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg02176678	chr2:219576539	TTLL4	0.74	14.85	0.59	1.92e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg00684032	chr4:1343700	KIAA1530	0.39	6.45	0.3	3.05e-10	Obesity-related traits;
LUAD	cis	rs2880765	0.835	rs7178991	chr15:86050944	G/C	cg13263323	chr15:86062960	AKAP13	-0.52	-9.6	-0.42	6.92e-20	Coronary artery disease;
LUAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg13047869	chr3:10149882	C3orf24	0.66	11.09	0.47	2.88e-25	Alzheimer's disease;
LUAD	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg23758822	chr17:41437982	NA	0.99	21.5	0.72	7.71e-70	Menopause (age at onset);
LUAD	cis	rs9905704	0.560	rs2680701	chr17:56438301	G/A	cg19466818	chr17:56409534	MIR142	-0.38	-7.28	-0.33	1.65e-12	Testicular germ cell tumor;
LUAD	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg07636037	chr3:49044803	WDR6	0.56	7.97	0.36	1.48e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.16	-0.33	3.64e-12	Bladder cancer;
LUAD	cis	rs4700695	0.719	rs1643415	chr5:65447087	T/C	cg21114390	chr5:65439923	SFRS12	-0.93	-14.52	-0.58	4.67e-39	Facial morphology (factor 19);
LUAD	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.33	0.34	1.2e-12	Tonsillectomy;
LUAD	cis	rs6840360	0.615	rs6535816	chr4:152614264	T/C	cg22705602	chr4:152727874	NA	-0.5	-9.72	-0.43	2.71e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs10129255	0.518	rs2006284	chr14:107132201	G/A	cg23076370	chr14:107095027	NA	-0.42	-8.22	-0.37	2.59e-15	Kawasaki disease;
LUAD	cis	rs6494488	0.500	rs72744741	chr15:65050514	T/C	cg08069370	chr15:64387884	SNX1	-0.72	-6.64	-0.31	9.61e-11	Coronary artery disease;
LUAD	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg18209359	chr17:80159595	CCDC57	0.4	6.91	0.32	1.79e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg12667521	chr19:29218732	NA	0.56	7.06	0.32	6.68e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg01475377	chr6:109611718	NA	-0.46	-8.64	-0.39	1.14e-16	Reticulocyte fraction of red cells;
LUAD	cis	rs3823572	0.525	rs7785128	chr7:133684991	T/C	cg03336402	chr7:133662267	EXOC4	-0.43	-7.37	-0.34	8.92e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.89	13.0	0.53	1e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs17095355	1.000	rs958086	chr10:111752548	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.67	-8.54	-0.38	2.46e-16	Biliary atresia;
LUAD	cis	rs9972944	0.651	rs8080916	chr17:63816368	G/C	cg07283582	chr17:63770753	CCDC46	-0.46	-9.85	-0.43	9.34e-21	Total body bone mineral density;
LUAD	cis	rs2249625	0.523	rs2496501	chr6:72885364	A/G	cg18830697	chr6:72922368	RIMS1	-0.44	-8.04	-0.36	8.97e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg09658497	chr7:2847517	GNA12	-0.4	-7.04	-0.32	7.93e-12	Height;
LUAD	cis	rs7267979	0.586	rs6083776	chr20:25186116	G/A	cg08601574	chr20:25228251	PYGB	0.36	6.57	0.3	1.51e-10	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.55	-10.67	-0.46	1.03e-23	Longevity;Endometriosis;
LUAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg18621852	chr3:10150065	C3orf24	0.42	6.78	0.31	4.02e-11	Alzheimer's disease;
LUAD	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.64	-0.31	9.58e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg25753631	chr6:25732923	NA	-0.45	-7.99	-0.36	1.32e-14	Iron status biomarkers;
LUAD	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg24768116	chr2:27665128	KRTCAP3	0.25	6.35	0.3	5.5e-10	Oral cavity cancer;
LUAD	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg03929089	chr4:120376271	NA	0.83	15.07	0.59	2.15e-41	Coronary artery disease;
LUAD	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg20587970	chr11:113659929	NA	-1.39	-20.74	-0.71	1.91e-66	Hip circumference adjusted for BMI;
LUAD	trans	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-8.96	-0.4	1.07e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.57	8.2	0.37	3.01e-15	Platelet count;
LUAD	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg11814155	chr7:99998594	ZCWPW1	0.43	7.54	0.34	2.96e-13	Platelet count;
LUAD	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg10596483	chr8:143751796	JRK	0.45	7.29	0.33	1.53e-12	Schizophrenia;
LUAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg20607798	chr8:58055168	NA	-0.58	-7.31	-0.34	1.31e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs11051970	0.636	rs1045751	chr12:32569496	T/C	cg24626660	chr12:32551988	NA	0.34	7.17	0.33	3.46e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs332507	0.830	rs11718359	chr3:124395987	G/A	cg05980111	chr3:124395277	KALRN	0.45	7.17	0.33	3.31e-12	Plateletcrit;
LUAD	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-10.02	-0.44	2.39e-21	Lymphocyte counts;
LUAD	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19717773	chr7:2847554	GNA12	-0.57	-9.84	-0.43	1.03e-20	Height;
LUAD	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg05182265	chr7:156933206	UBE3C	-0.8	-17.24	-0.64	8.1e-51	Body mass index;
LUAD	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.75e-11	Crohn's disease;
LUAD	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11214589	0.774	rs877137	chr11:113256330	C/T	cg14159747	chr11:113255604	NA	0.68	14.84	0.59	2.01e-40	Neuroticism;
LUAD	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg26384229	chr12:38710491	ALG10B	0.46	7.36	0.34	9.42e-13	Bladder cancer;
LUAD	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg16486109	chr11:613632	IRF7	0.5	7.61	0.35	1.75e-13	Systemic lupus erythematosus;
LUAD	cis	rs13315871	0.929	rs76226186	chr3:58318499	C/T	cg20936604	chr3:58311152	NA	-0.74	-7.4	-0.34	7.57e-13	Cholesterol, total;
LUAD	cis	rs6761276	0.899	rs11677088	chr2:113835603	A/G	cg09040174	chr2:113837401	NA	0.81	15.75	0.61	2.68e-44	Protein quantitative trait loci;
LUAD	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg17177755	chr1:15930204	NA	0.45	7.21	0.33	2.63e-12	Systolic blood pressure;
LUAD	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg00769240	chr8:12517080	NA	-0.39	-6.54	-0.3	1.78e-10	Blood pressure (smoking interaction);
LUAD	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.21	0.33	2.57e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs9837602	0.938	rs9814359	chr3:99797013	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-7.41	-0.34	6.85e-13	Breast cancer;
LUAD	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06505273	chr16:24850292	NA	0.51	7.59	0.35	2.04e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg01849466	chr14:104193079	ZFYVE21	0.5	8.21	0.37	2.68e-15	Body mass index;
LUAD	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg18854424	chr1:2615690	NA	0.42	9.17	0.41	2.06e-18	Ulcerative colitis;
LUAD	cis	rs6484504	0.532	rs2616799	chr11:31319044	T/C	cg26647111	chr11:31128758	NA	0.46	8.02	0.36	1.01e-14	Red blood cell count;
LUAD	cis	rs870825	0.616	rs1401362	chr4:185643775	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	14.03	0.56	5.61e-37	Blood protein levels;
LUAD	cis	rs4950928	0.823	rs2153101	chr1:203168474	A/T	cg17014757	chr1:203156097	CHI3L1	-0.61	-8.69	-0.39	8.17e-17	YKL-40 levels;
LUAD	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg03806693	chr22:41940476	POLR3H	-0.8	-11.37	-0.48	2.6e-26	Vitiligo;
LUAD	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg17644776	chr2:200775616	C2orf69	0.54	7.21	0.33	2.62e-12	Schizophrenia;
LUAD	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg07917127	chr4:99064746	C4orf37	0.43	6.6	0.31	1.23e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.67	10.21	0.44	5.02e-22	Renal function-related traits (BUN);
LUAD	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg09359103	chr1:154839909	KCNN3	-0.9	-19.89	-0.7	1.32e-62	Prostate cancer;
LUAD	cis	rs12472274	0.648	rs67102443	chr2:239084602	A/G	cg17459225	chr2:239074497	NA	0.53	7.67	0.35	1.23e-13	Phospholipid levels (plasma);
LUAD	cis	rs9826463	0.757	rs73240310	chr3:142240459	T/C	cg20824294	chr3:142316082	PLS1	0.42	7.56	0.35	2.53e-13	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg09365446	chr1:150670422	GOLPH3L	0.55	9.46	0.42	2.18e-19	Melanoma;
LUAD	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg11871910	chr12:69753446	YEATS4	0.7	12.22	0.51	1.31e-29	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg27366882	chr3:133540807	NA	0.41	7.67	0.35	1.23e-13	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg25358565	chr5:93447407	FAM172A	-0.54	-6.68	-0.31	7.65e-11	Diabetic retinopathy;
LUAD	cis	rs6881634	0.768	rs4704495	chr5:77624910	C/T	cg11547950	chr5:77652471	NA	-0.37	-6.85	-0.32	2.55e-11	Hippocampal atrophy;
LUAD	trans	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg01620082	chr3:125678407	NA	-0.42	-6.78	-0.31	4.12e-11	Parkinson's disease;
LUAD	trans	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	10.53	0.46	3.36e-23	Type 2 diabetes;
LUAD	cis	rs7274811	0.625	rs293725	chr20:31929643	C/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.46	6.56	0.3	1.6e-10	Height;
LUAD	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg12935359	chr14:103987150	CKB	0.45	6.99	0.32	1.06e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs698833	0.518	rs2033951	chr2:44556298	T/C	cg04920474	chr2:44395004	PPM1B	0.41	6.71	0.31	6.08e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg07167872	chr1:205819463	PM20D1	0.49	7.88	0.36	2.71e-14	Parkinson's disease;
LUAD	cis	rs13064411	0.518	rs1471884	chr3:113212041	G/A	cg10517650	chr3:113235015	CCDC52	-0.38	-7.21	-0.33	2.52e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs698833	0.780	rs2005203	chr2:44541725	C/T	cg04920474	chr2:44395004	PPM1B	0.4	7.15	0.33	3.96e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg27124370	chr19:33622961	WDR88	0.45	7.33	0.34	1.17e-12	Bone properties (heel);
LUAD	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg15704280	chr7:45808275	SEPT13	-0.54	-8.49	-0.38	3.62e-16	HDL cholesterol;
LUAD	cis	rs80319144	1.000	rs77432849	chr2:159234529	T/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.85	0.32	2.58e-11	Restless legs syndrome;
LUAD	cis	rs12545109	0.837	rs4738500	chr8:57356193	G/A	cg11919837	chr8:57350735	NA	-0.47	-6.55	-0.3	1.7e-10	Obesity-related traits;
LUAD	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.62	0.35	1.73e-13	Platelet count;
LUAD	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg01448562	chr3:133502909	NA	0.45	8.09	0.37	6.22e-15	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg10523679	chr1:76189770	ACADM	0.97	19.58	0.69	2.94e-61	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg15017067	chr4:17643749	FAM184B	0.35	6.93	0.32	1.58e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg20607287	chr7:12443886	VWDE	-0.5	-6.43	-0.3	3.48e-10	Coronary artery disease;
LUAD	cis	rs11126435	0.858	rs11126439	chr2:74928301	A/G	cg19285774	chr2:74907978	SEMA4F	0.36	6.47	0.3	2.75e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg16647868	chr5:131706066	SLC22A5	-0.39	-6.75	-0.31	5e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg17644776	chr2:200775616	C2orf69	0.56	7.5	0.34	3.75e-13	Schizophrenia;
LUAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22029157	chr1:209979665	IRF6	-0.77	-12.64	-0.52	2.84e-31	Cleft lip with or without cleft palate;
LUAD	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg24531977	chr5:56204891	C5orf35	-0.45	-7.32	-0.34	1.23e-12	Coronary artery disease;
LUAD	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.4	7.12	0.33	4.54e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7561273	0.586	rs9309225	chr2:24292863	T/C	cg20701182	chr2:24300061	SF3B14	0.41	6.85	0.32	2.59e-11	Quantitative traits;
LUAD	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg01065977	chr19:18549689	ISYNA1	-0.38	-7.28	-0.33	1.66e-12	Breast cancer;
LUAD	cis	rs2274273	0.712	rs17832311	chr14:55534466	A/G	cg04306507	chr14:55594613	LGALS3	0.32	6.69	0.31	7.18e-11	Protein biomarker;
LUAD	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg21951975	chr1:209979733	IRF6	0.57	8.27	0.37	1.76e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg22907277	chr7:1156413	C7orf50	0.64	7.45	0.34	5.33e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.64	-0.42	4.99e-20	Alzheimer's disease;
LUAD	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg14835575	chr10:16859367	RSU1	0.89	12.77	0.53	8.19e-32	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg03929089	chr4:120376271	NA	-0.91	-17.04	-0.64	6.2e-50	Coronary artery disease;
LUAD	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg05110241	chr16:68378359	PRMT7	-0.8	-8.86	-0.4	2.28e-17	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg06606381	chr12:133084897	FBRSL1	-0.71	-6.79	-0.31	3.91e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	13.06	0.54	5.6e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg03188948	chr7:1209495	NA	0.83	10.13	0.44	9.87e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg15485101	chr11:133734466	NA	0.38	7.98	0.36	1.42e-14	Childhood ear infection;
LUAD	cis	rs7177699	0.550	rs7182103	chr15:79123946	G/T	cg15571903	chr15:79123663	NA	0.42	8.82	0.39	3e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg11416102	chr8:651193	ERICH1	0.84	8.45	0.38	4.89e-16	IgG glycosylation;
LUAD	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg00784671	chr22:46762841	CELSR1	-0.62	-7.47	-0.34	4.72e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1215050	0.765	rs1588018	chr4:98756324	G/C	cg17366294	chr4:99064904	C4orf37	0.48	8.68	0.39	8.6e-17	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg04398451	chr17:18023971	MYO15A	-0.64	-11.37	-0.48	2.48e-26	Total body bone mineral density;
LUAD	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg02176678	chr2:219576539	TTLL4	0.58	11.12	0.48	2.34e-25	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs12541635	0.677	rs2880950	chr8:106983624	C/A	cg10147462	chr8:107024639	NA	0.54	9.84	0.43	1.07e-20	Age of smoking initiation;
LUAD	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03352830	chr11:487213	PTDSS2	0.82	10.64	0.46	1.36e-23	Body mass index;
LUAD	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg15664640	chr17:80829946	TBCD	-0.68	-8.35	-0.38	1e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19346786	chr7:2764209	NA	-0.56	-12.23	-0.51	1.21e-29	Height;
LUAD	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg09796270	chr17:17721594	SREBF1	0.36	6.74	0.31	5.14e-11	Total body bone mineral density;
LUAD	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17972606	chr19:9251437	ZNF317	0.43	6.58	0.3	1.4e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.02	0.32	8.9e-12	Hypertriglyceridemia;
LUAD	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg00784671	chr22:46762841	CELSR1	0.42	6.64	0.31	9.54e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs240764	0.644	rs4329121	chr6:101087507	G/C	cg09795085	chr6:101329169	ASCC3	0.38	6.42	0.3	3.74e-10	Neuroticism;
LUAD	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.53	0.3	1.89e-10	Cognitive test performance;
LUAD	cis	rs2274273	1.000	rs72718804	chr14:55630610	G/A	cg04306507	chr14:55594613	LGALS3	0.38	7.58	0.35	2.19e-13	Protein biomarker;
LUAD	cis	rs2235649	0.663	rs6600167	chr16:1848912	A/G	cg08610935	chr16:1836813	NUBP2	-0.5	-7.71	-0.35	8.96e-14	Blood metabolite levels;
LUAD	cis	rs7216064	1.000	rs58122682	chr17:65876915	T/C	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg14196790	chr5:131705035	SLC22A5	-0.46	-8.36	-0.38	9.09e-16	Breast cancer;Mosquito bite size;
LUAD	cis	rs9462027	0.628	rs6457795	chr6:34819366	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.89	-0.4	1.84e-17	Systemic lupus erythematosus;
LUAD	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.32	-0.34	1.29e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2224391	0.628	rs2773314	chr6:5253800	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-8.57	-0.38	1.9e-16	Height;
LUAD	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg10876282	chr6:28092338	ZSCAN16	0.42	6.85	0.32	2.64e-11	Parkinson's disease;
LUAD	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	8.8	0.39	3.45e-17	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	10.43	0.45	8.24e-23	Ileal carcinoids;
LUAD	cis	rs7301826	0.651	rs10848209	chr12:131311272	A/G	cg11011512	chr12:131303247	STX2	0.42	7.1	0.33	5.28e-12	Plasma plasminogen activator levels;
LUAD	cis	rs1018836	0.575	rs17635255	chr8:91518135	A/T	cg16814680	chr8:91681699	NA	-0.57	-7.31	-0.33	1.32e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg10518543	chr12:38710700	ALG10B	-0.5	-8.41	-0.38	6.29e-16	Morning vs. evening chronotype;
LUAD	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg14530993	chr4:882597	GAK	0.74	6.84	0.32	2.76e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg18252515	chr7:66147081	NA	-0.61	-6.59	-0.31	1.32e-10	Diabetic kidney disease;
LUAD	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg25036284	chr2:26402008	FAM59B	-0.61	-8.43	-0.38	5.33e-16	Gut microbiome composition (summer);
LUAD	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg25173405	chr17:45401733	C17orf57	-0.52	-8.85	-0.4	2.35e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg00634984	chr7:65235879	NA	0.49	6.82	0.31	3.18e-11	Aortic root size;
LUAD	cis	rs6543140	0.964	rs13390895	chr2:103075499	G/A	cg03938978	chr2:103052716	IL18RAP	0.35	6.8	0.31	3.6e-11	Blood protein levels;
LUAD	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg11845111	chr2:191398756	TMEM194B	-0.84	-11.22	-0.48	9.26e-26	Diastolic blood pressure;
LUAD	cis	rs73416724	1.000	rs77529883	chr6:43364634	C/G	cg26312998	chr6:43337775	ZNF318	0.53	6.41	0.3	3.83e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7799006	0.755	rs2256545	chr7:2291943	G/A	cg08027265	chr7:2291960	NA	-0.77	-16.28	-0.62	1.33e-46	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.08	0.33	6.16e-12	Parkinson's disease;
LUAD	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.56	-7.0	-0.32	9.95e-12	Body mass index;
LUAD	trans	rs17715887	0.522	rs17714087	chr5:158224075	A/G	cg14989164	chr1:180205157	LHX4	-0.51	-6.73	-0.31	5.4e-11	Interleukin-2 levels;
LUAD	cis	rs1904096	0.513	rs2632405	chr4:95152215	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.15	-0.44	8.27e-22	Type 2 diabetes;
LUAD	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.47	-0.3	2.69e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg11266682	chr4:10021025	SLC2A9	0.6	12.94	0.53	1.75e-32	Bone mineral density;
LUAD	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg22496339	chr2:162101262	NA	0.43	6.78	0.31	4.08e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg13736514	chr6:26305472	NA	0.47	7.62	0.35	1.7e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs11078917	1	rs11078917	chr17:37746359	A/C	cg15445000	chr17:37608096	MED1	0.42	7.49	0.34	4.1e-13	Mean corpuscular volume;
LUAD	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg02527881	chr3:46936655	PTH1R	-0.47	-9.42	-0.42	2.99e-19	Colorectal cancer;
LUAD	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg01145583	chr6:160211477	TCP1;MRPL18	-0.45	-6.55	-0.3	1.7e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg24476569	chr13:95954382	ABCC4	-0.56	-10.44	-0.45	7.28e-23	Blood metabolite levels;
LUAD	cis	rs7089973	0.966	rs749649	chr10:116641999	G/A	cg25233709	chr10:116636983	FAM160B1	0.37	7.01	0.32	9.76e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4481887	0.751	rs28607212	chr1:248520358	T/C	cg00666640	chr1:248458726	OR2T12	0.27	6.85	0.32	2.69e-11	Common traits (Other);
LUAD	cis	rs7827545	1.000	rs6578234	chr8:135566363	A/G	cg17885191	chr8:135476712	NA	0.45	7.14	0.33	4.23e-12	Hypertension (SNP x SNP interaction);
LUAD	cis	rs7680126	0.596	rs11722185	chr4:10317482	C/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-7.87	-0.36	2.95e-14	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg22508957	chr16:3507546	NAT15	-0.44	-6.82	-0.31	3.22e-11	Body mass index (adult);
LUAD	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg16342193	chr10:102329863	NA	-0.38	-6.52	-0.3	1.99e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg00814883	chr7:100076585	TSC22D4	-0.85	-12.48	-0.52	1.24e-30	Platelet count;
LUAD	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg21890820	chr11:65308645	LTBP3	-0.6	-9.55	-0.42	1.07e-19	Bone mineral density;
LUAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.57	-9.87	-0.43	8.07e-21	Lymphocyte counts;
LUAD	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg03433033	chr1:76189801	ACADM	-0.79	-12.98	-0.53	1.15e-32	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22857025	chr5:266934	NA	-0.96	-14.3	-0.57	3.96e-38	Breast cancer;
LUAD	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg15448220	chr1:150897856	SETDB1	0.47	7.97	0.36	1.52e-14	Tonsillectomy;
LUAD	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.4	-6.89	-0.32	2.05e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	11.99	0.5	1.05e-28	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg21782813	chr7:2030301	MAD1L1	0.41	6.61	0.31	1.15e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg23649088	chr2:200775458	C2orf69	-0.59	-7.63	-0.35	1.59e-13	Schizophrenia;
LUAD	cis	rs8018808	0.875	rs176781	chr14:77887681	C/T	cg20045696	chr14:77926864	AHSA1	0.36	6.4	0.3	4.19e-10	Myeloid white cell count;
LUAD	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg04398451	chr17:18023971	MYO15A	0.78	14.15	0.57	1.76e-37	Total body bone mineral density;
LUAD	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.22	16.1	0.62	8.09e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg18876405	chr7:65276391	NA	0.42	6.87	0.32	2.29e-11	Calcium levels;
LUAD	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.33	-0.41	5.91e-19	Dilated cardiomyopathy;
LUAD	cis	rs6743376	0.556	rs2441376	chr2:113817755	T/C	cg09040174	chr2:113837401	NA	0.52	8.04	0.36	9.12e-15	Inflammatory biomarkers;
LUAD	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg26528668	chr16:1614120	IFT140	0.57	10.31	0.45	2.22e-22	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg17063962	chr7:91808500	NA	-0.63	-11.03	-0.47	4.87e-25	Breast cancer;
LUAD	cis	rs2806561	0.606	rs218341	chr1:23294153	G/C	cg12483005	chr1:23474871	LUZP1	0.48	8.18	0.37	3.33e-15	Height;
LUAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-7.12	-0.33	4.53e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg24112000	chr20:60950667	NA	0.72	12.09	0.51	3.99e-29	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	trans	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg04995722	chr7:26192034	NFE2L3	-0.41	-7.2	-0.33	2.82e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.26	-0.33	1.9e-12	Morning vs. evening chronotype;
LUAD	cis	rs941873	0.772	rs2000404	chr10:81109708	T/C	cg11057378	chr10:81107060	PPIF	0.38	6.84	0.32	2.7e-11	Height;
LUAD	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-10.64	-0.46	1.43e-23	Gut microbiome composition (summer);
LUAD	cis	rs2154319	0.887	rs61780435	chr1:41475571	C/T	cg02290550	chr1:41487317	SLFNL1	0.38	6.44	0.3	3.24e-10	Height;
LUAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs4853525	0.522	rs62179715	chr2:191570072	C/T	cg27211696	chr2:191398769	TMEM194B	-0.42	-7.04	-0.32	7.75e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs68170813	0.559	rs80341862	chr7:106934731	C/G	cg23024343	chr7:107201750	COG5	0.45	6.56	0.3	1.56e-10	Coronary artery disease;
LUAD	cis	rs113835537	0.529	rs11227510	chr11:66281220	T/C	cg26679405	chr11:66247800	DPP3	-0.46	-6.67	-0.31	8.26e-11	Airway imaging phenotypes;
LUAD	trans	rs3857536	0.813	rs9360190	chr6:66942302	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.42	-0.3	3.59e-10	Blood trace element (Cu levels);
LUAD	cis	rs6993813	0.786	rs1872423	chr8:120048320	G/A	cg01975934	chr8:119970761	NA	-0.36	-7.01	-0.32	9.29e-12	Bone mineral density (hip);
LUAD	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg10792982	chr14:105748885	BRF1	0.41	9.19	0.41	1.76e-18	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg23422044	chr7:1970798	MAD1L1	-0.59	-7.31	-0.33	1.34e-12	Bipolar disorder;
LUAD	cis	rs7945718	0.935	rs11022501	chr11:12809314	T/C	cg25843174	chr11:12811716	TEAD1	0.24	7.34	0.34	1.07e-12	Educational attainment (years of education);
LUAD	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg06784218	chr1:46089804	CCDC17	0.6	13.42	0.55	1.86e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg20607798	chr8:58055168	NA	0.58	7.31	0.34	1.31e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg27588902	chr6:42928151	GNMT	-0.35	-9.33	-0.41	5.82e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg17105886	chr17:28927953	LRRC37B2	0.85	8.26	0.37	1.91e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	11.56	0.49	4.85e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs922182	0.663	rs7180057	chr15:64263795	G/A	cg02919090	chr15:64263738	DAPK2	0.36	6.83	0.31	3.06e-11	Blood protein levels;
LUAD	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg10518543	chr12:38710700	ALG10B	-0.43	-7.13	-0.33	4.4e-12	Bladder cancer;
LUAD	cis	rs12545109	0.800	rs2582401	chr8:57401656	A/G	cg19413350	chr8:57351067	NA	-0.44	-6.66	-0.31	8.41e-11	Obesity-related traits;
LUAD	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg11517269	chr6:28058789	ZSCAN12L1	0.25	6.37	0.3	4.89e-10	Parkinson's disease;
LUAD	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg00802000	chr16:706648	WDR90	-0.38	-6.99	-0.32	1.11e-11	Height;
LUAD	cis	rs2046867	0.908	rs62251654	chr3:72816488	C/T	cg04365224	chr3:72788183	NA	-0.48	-7.23	-0.33	2.2e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg12908607	chr1:44402522	ARTN	0.5	9.79	0.43	1.61e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg12193833	chr17:30244370	NA	-0.57	-6.87	-0.32	2.32e-11	Hip circumference adjusted for BMI;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg27199172	chr10:6186668	PFKFB3	-0.65	-6.75	-0.31	4.78e-11	Type 2 diabetes;
LUAD	cis	rs9633740	0.842	rs1870140	chr10:82246749	A/G	cg01528321	chr10:82214614	TSPAN14	0.72	8.13	0.37	4.81e-15	Post bronchodilator FEV1;
LUAD	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg04756594	chr16:24857601	SLC5A11	-0.54	-10.38	-0.45	1.18e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	7.49	0.34	3.93e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg02196655	chr2:10830764	NOL10	0.47	8.53	0.38	2.71e-16	Prostate cancer;
LUAD	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg07917127	chr4:99064746	C4orf37	0.44	7.21	0.33	2.66e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg01689657	chr7:91764605	CYP51A1	-0.37	-8.98	-0.4	8.88e-18	Breast cancer;
LUAD	cis	rs17102423	0.731	rs7145112	chr14:65534084	A/C	cg11161011	chr14:65562177	MAX	-0.39	-6.62	-0.31	1.08e-10	Obesity-related traits;
LUAD	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg12311346	chr5:56204834	C5orf35	-0.46	-7.74	-0.35	7.63e-14	Coronary artery disease;
LUAD	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg21153622	chr11:89784906	NA	-0.35	-6.88	-0.32	2.23e-11	Coronary artery disease;
LUAD	trans	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg07211511	chr3:129823064	LOC729375	-0.87	-8.9	-0.4	1.7e-17	Blood pressure (smoking interaction);
LUAD	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg21699342	chr2:239360505	ASB1	0.51	9.24	0.41	1.18e-18	Multiple system atrophy;
LUAD	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg06697600	chr4:7070879	GRPEL1	-0.51	-8.31	-0.37	1.34e-15	Monocyte percentage of white cells;
LUAD	cis	rs12541635	0.967	rs11997513	chr8:107093325	C/T	cg10147462	chr8:107024639	NA	-0.42	-7.54	-0.34	2.91e-13	Age of smoking initiation;
LUAD	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg16405210	chr4:1374714	KIAA1530	-0.39	-6.37	-0.3	4.81e-10	Obesity-related traits;
LUAD	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg26384229	chr12:38710491	ALG10B	0.44	7.22	0.33	2.4e-12	Bladder cancer;
LUAD	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg22029157	chr1:209979665	IRF6	0.71	8.78	0.39	3.98e-17	Coronary artery disease;
LUAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg00450029	chr8:599525	NA	0.83	8.13	0.37	4.73e-15	IgG glycosylation;
LUAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg22907277	chr7:1156413	C7orf50	0.62	10.56	0.46	2.78e-23	Longevity;Endometriosis;
LUAD	cis	rs8067545	0.750	rs4925085	chr17:20000131	G/T	cg04132472	chr17:19861366	AKAP10	0.3	7.25	0.33	2.03e-12	Schizophrenia;
LUAD	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg18367735	chr17:79674897	NA	0.53	6.81	0.31	3.31e-11	Dental caries;
LUAD	cis	rs62400317	0.762	rs12198308	chr6:44911886	C/T	cg20913747	chr6:44695427	NA	-0.45	-7.05	-0.32	7.13e-12	Total body bone mineral density;
LUAD	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg08601574	chr20:25228251	PYGB	0.46	8.73	0.39	6.1e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg21775007	chr8:11205619	TDH	0.55	9.87	0.43	8.13e-21	Retinal vascular caliber;
LUAD	cis	rs9796	0.553	rs7171437	chr15:41315168	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.49	-8.89	-0.4	1.77e-17	Menopause (age at onset);
LUAD	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg27532560	chr4:187881888	NA	-0.41	-8.19	-0.37	3.15e-15	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs62229266	0.682	rs2835224	chr21:37370030	A/T	cg12218747	chr21:37451666	NA	-0.43	-6.84	-0.32	2.74e-11	Mitral valve prolapse;
LUAD	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs701145	0.938	rs355752	chr3:153970796	A/G	cg17054900	chr3:154042577	DHX36	0.65	6.98	0.32	1.13e-11	Coronary artery disease;
LUAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg12419862	chr22:24373484	LOC391322	-0.66	-10.94	-0.47	1.03e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7224685	0.501	rs897026	chr17:3980318	T/C	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.41	7.17	0.33	3.43e-12	Type 2 diabetes;
LUAD	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg16479474	chr6:28041457	NA	0.46	7.94	0.36	1.8e-14	Depression;
LUAD	trans	rs8073060	0.963	rs4795082	chr17:33873501	C/T	cg19694781	chr19:47549865	TMEM160	0.79	12.36	0.52	3.72e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg21017887	chr14:105400489	NA	0.75	14.36	0.57	2.19e-38	Rheumatoid arthritis;
LUAD	cis	rs10821973	0.527	rs7085402	chr10:64020896	C/T	cg09941381	chr10:64027924	RTKN2	-0.36	-7.16	-0.33	3.58e-12	Hypothyroidism;
LUAD	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.81	-0.36	4.47e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg06623918	chr6:96969491	KIAA0776	-0.77	-12.43	-0.52	1.96e-30	Migraine;Coronary artery disease;
LUAD	cis	rs1775715	0.707	rs2808079	chr10:32167385	C/T	cg04359828	chr10:32216031	ARHGAP12	0.31	6.36	0.3	5.19e-10	Bipolar disorder with mood-incongruent psychosis;
LUAD	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg01689657	chr7:91764605	CYP51A1	-0.3	-7.31	-0.33	1.37e-12	Breast cancer;
LUAD	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg14092988	chr3:52407081	DNAH1	0.34	6.76	0.31	4.69e-11	Bipolar disorder;
LUAD	cis	rs13315871	0.929	rs13066351	chr3:58398215	C/T	cg20936604	chr3:58311152	NA	-0.69	-6.83	-0.32	2.88e-11	Cholesterol, total;
LUAD	cis	rs1595825	0.891	rs41468149	chr2:198910107	C/G	cg11031976	chr2:198649780	BOLL	0.46	6.59	0.31	1.27e-10	Ulcerative colitis;
LUAD	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	trans	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg26043149	chr18:55253948	FECH	0.47	7.65	0.35	1.39e-13	Bone mineral density;
LUAD	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg00316803	chr15:76480434	C15orf27	-0.39	-7.55	-0.34	2.77e-13	Blood metabolite levels;
LUAD	cis	rs6577655	0.561	rs6577654	chr8:135593610	G/A	cg17885191	chr8:135476712	NA	0.65	8.47	0.38	4.17e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg17063962	chr7:91808500	NA	0.67	11.92	0.5	1.89e-28	Breast cancer;
LUAD	trans	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg11693508	chr17:37793320	STARD3	0.69	9.36	0.41	4.91e-19	Neuroticism;
LUAD	trans	rs12517041	1.000	rs16892316	chr5:23282819	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.52	-0.3	2e-10	Calcium levels;
LUAD	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg18105134	chr13:113819100	PROZ	-0.84	-14.58	-0.58	2.6e-39	Platelet distribution width;
LUAD	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg23978390	chr7:1156363	C7orf50	0.58	8.11	0.37	5.64e-15	Bronchopulmonary dysplasia;
LUAD	cis	rs7903847	0.620	rs3737194	chr10:99130127	A/G	cg20016023	chr10:99160130	RRP12	-0.29	-6.96	-0.32	1.29e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25427524	chr10:38739819	LOC399744	-0.74	-13.14	-0.54	2.5e-33	Extrinsic epigenetic age acceleration;
LUAD	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg11189052	chr15:85197271	WDR73	0.65	8.78	0.39	4.13e-17	Schizophrenia;
LUAD	cis	rs11048434	0.673	rs1124402	chr12:9062606	C/T	cg04155231	chr12:9217510	LOC144571	0.38	6.96	0.32	1.29e-11	Sjögren's syndrome;
LUAD	cis	rs4846217	1.000	rs58036267	chr1:10383445	G/A	cg17425144	chr1:10567563	PEX14	-0.5	-6.57	-0.3	1.5e-10	Platelet count;
LUAD	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg19193384	chr17:30244184	NA	-0.52	-6.64	-0.31	9.57e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg26343298	chr8:95960752	TP53INP1	0.37	7.77	0.35	6.16e-14	Type 2 diabetes;
LUAD	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.8	-0.35	5.01e-14	Prostate cancer;
LUAD	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	9.77	0.43	1.83e-20	Ileal carcinoids;
LUAD	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg22868518	chr11:507468	RNH1	-0.68	-6.71	-0.31	6.38e-11	Body mass index;
LUAD	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.52e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg02569458	chr12:86230093	RASSF9	0.42	7.75	0.35	7.12e-14	Major depressive disorder;
LUAD	trans	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg06606381	chr12:133084897	FBRSL1	-0.96	-9.32	-0.41	6.68e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg00933542	chr6:150070202	PCMT1	-0.45	-9.36	-0.41	4.88e-19	Lung cancer;
LUAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04267008	chr7:1944627	MAD1L1	0.69	11.04	0.47	4.38e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg09184832	chr6:79620586	NA	-0.51	-9.54	-0.42	1.11e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg04565464	chr8:145669602	NFKBIL2	0.42	6.39	0.3	4.34e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg12863693	chr15:85201151	NMB	0.37	6.48	0.3	2.6200000000000003e-10	Schizophrenia;
LUAD	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg04756594	chr16:24857601	SLC5A11	0.53	10.26	0.45	3.45e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.58	0.3	1.42e-10	Cardiac Troponin-T levels;
LUAD	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.43	0.52	1.89e-30	Cognitive ability;
LUAD	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg10978503	chr1:24200527	CNR2	0.59	12.8	0.53	6.11e-32	Immature fraction of reticulocytes;
LUAD	cis	rs4372836	0.543	rs6747852	chr2:29009840	A/T	cg09522027	chr2:28974177	PPP1CB	-0.62	-10.83	-0.47	2.72e-24	Body mass index;
LUAD	cis	rs17155006	0.711	rs379821	chr7:107751232	T/C	cg05962710	chr7:107745446	LAMB4	-0.37	-7.6	-0.35	1.87e-13	Pneumococcal bacteremia;
LUAD	cis	rs7737355	0.812	rs171523	chr5:130844946	A/G	cg06307176	chr5:131281290	NA	0.42	6.89	0.32	2.09e-11	Life satisfaction;
LUAD	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg00310523	chr12:86230176	RASSF9	0.35	7.28	0.33	1.65e-12	Major depressive disorder;
LUAD	cis	rs10203711	1.000	rs10191070	chr2:239565413	A/G	cg14580085	chr2:239553406	NA	0.42	8.89	0.4	1.8e-17	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19722041	chr7:75987438	YWHAG	-0.41	-6.64	-0.31	9.37e-11	Cancer;
LUAD	cis	rs3784262	0.765	rs8026952	chr15:58276950	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.56	-0.35	2.49e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg08888203	chr3:10149979	C3orf24	0.63	10.73	0.46	6.56e-24	Alzheimer's disease;
LUAD	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg12193833	chr17:30244370	NA	-0.57	-6.86	-0.32	2.52e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-7.6	-0.35	1.91e-13	Tonsillectomy;
LUAD	cis	rs6564851	0.506	rs72831377	chr16:81257141	A/T	cg00908271	chr16:81254010	PKD1L2	0.34	6.89	0.32	2.09e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.41	8.74	0.39	5.7e-17	Hemoglobin concentration;
LUAD	cis	rs9652601	0.959	rs9934969	chr16:11166002	G/A	cg04616529	chr16:11181986	CLEC16A	0.39	6.92	0.32	1.72e-11	Systemic lupus erythematosus;
LUAD	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg22920501	chr2:26401640	FAM59B	-0.96	-14.32	-0.57	3.46e-38	Gut microbiome composition (summer);
LUAD	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg07741184	chr6:167504864	NA	0.36	8.17	0.37	3.66e-15	Primary biliary cholangitis;
LUAD	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg15017067	chr4:17643749	FAM184B	0.36	6.93	0.32	1.59e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg23254163	chr1:152506842	NA	-0.25	-6.94	-0.32	1.51e-11	Hair morphology;
LUAD	cis	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg23950597	chr19:37808831	NA	-0.62	-7.79	-0.35	5.29e-14	Coronary artery calcification;
LUAD	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg11822812	chr5:140052017	DND1	0.43	8.12	0.37	5.18e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3925075	0.966	rs7195915	chr16:31344455	A/G	cg02846316	chr16:31340340	ITGAM	0.32	6.51	0.3	2.17e-10	IgA nephropathy;
LUAD	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg27068330	chr11:65405492	SIPA1	-0.75	-11.15	-0.48	1.68e-25	Acne (severe);
LUAD	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg03929089	chr4:120376271	NA	-0.43	-6.69	-0.31	7.13e-11	HDL cholesterol;
LUAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg07217954	chr7:1067459	C7orf50	0.43	6.66	0.31	8.41e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.06	0.32	7.06e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg03188948	chr7:1209495	NA	0.39	6.46	0.3	2.92e-10	Longevity;Endometriosis;
LUAD	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.35	-7.12	-0.33	4.72e-12	Glomerular filtration rate;
LUAD	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg14834391	chr1:2537342	MMEL1	0.3	6.59	0.31	1.3100000000000001e-10	Multiple sclerosis;
LUAD	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg09263875	chr16:632152	PIGQ	0.81	17.39	0.65	1.66e-51	Height;
LUAD	cis	rs2736345	0.535	rs4366049	chr8:11398504	A/G	cg27411982	chr8:10470053	RP1L1	0.37	6.67	0.31	8.23e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LUAD	cis	rs1113500	0.573	rs10748507	chr1:108631521	G/A	cg06207961	chr1:108661230	NA	0.42	6.74	0.31	5.12e-11	Growth-regulated protein alpha levels;
LUAD	cis	rs1816752	0.875	rs1050110	chr13:25009485	C/G	cg02811702	chr13:24901961	NA	0.44	7.42	0.34	6.49e-13	Obesity-related traits;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg02399570	chr3:156877196	CCNL1	-0.47	-6.65	-0.31	8.84e-11	Testicular germ cell tumor;
LUAD	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg03354898	chr7:1950403	MAD1L1	-0.43	-8.14	-0.37	4.41e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs12545109	0.800	rs2582404	chr8:57387368	C/T	cg07776626	chr8:57350775	NA	-0.63	-8.91	-0.4	1.55e-17	Obesity-related traits;
LUAD	cis	rs17401966	0.964	rs6674843	chr1:10458378	A/T	cg15208524	chr1:10270712	KIF1B	0.51	7.65	0.35	1.37e-13	Hepatocellular carcinoma;
LUAD	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.65	-0.35	1.41e-13	Menopause (age at onset);
LUAD	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg16325326	chr1:53192061	ZYG11B	0.62	10.76	0.46	4.77e-24	Monocyte count;
LUAD	cis	rs2425143	1.000	rs11907811	chr20:34428078	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-6.58	-0.3	1.38e-10	Blood protein levels;
LUAD	cis	rs11971779	0.680	rs7805824	chr7:139111169	C/G	cg23387468	chr7:139079360	LUC7L2	-0.28	-6.6	-0.31	1.25e-10	Diisocyanate-induced asthma;
LUAD	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6987853	0.814	rs2923411	chr8:42455206	T/C	cg09913449	chr8:42400586	C8orf40	0.44	8.36	0.38	9.13e-16	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs6076960	0.684	rs6054059	chr20:6262472	G/T	cg21095983	chr6:86352623	SYNCRIP	0.43	7.05	0.32	7.2e-12	Smooth-surface caries;
LUAD	cis	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg01251360	chr16:68772225	CDH1	-0.29	-8.99	-0.4	8.34e-18	Colorectal cancer;
LUAD	cis	rs3760982	0.585	rs11083724	chr19:44298988	A/G	cg11993925	chr19:44307056	LYPD5	0.54	11.3	0.48	4.71e-26	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs116248771	0.739	rs116045655	chr3:158335368	G/A	cg16708174	chr3:158430962	RARRES1	0.47	6.81	0.31	3.29e-11	diarrhoeal disease at age 2;
LUAD	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg21724239	chr8:58056113	NA	0.72	8.9	0.4	1.64e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.67	-9.44	-0.42	2.63e-19	Lymphocyte percentage of white cells;
LUAD	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg14668632	chr7:2872130	GNA12	-0.73	-13.31	-0.54	5.39e-34	Height;
LUAD	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg16615211	chr3:44902933	MIR564;TMEM42	0.38	7.3	0.33	1.45e-12	Depressive symptoms;
LUAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg18402987	chr7:1209562	NA	0.7	9.14	0.41	2.58e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs89107	0.641	rs376875	chr6:118611592	C/T	cg21191810	chr6:118973309	C6orf204	0.5	10.17	0.44	6.74e-22	Cardiac structure and function;
LUAD	cis	rs220324	0.688	rs9976212	chr21:43567270	G/A	cg09727148	chr21:43560719	UMODL1	0.48	7.57	0.35	2.29e-13	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg08027265	chr7:2291960	NA	-0.52	-8.99	-0.4	8.03e-18	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUAD	trans	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg24644049	chr4:85504048	CDS1	0.86	7.4	0.34	7.43e-13	Skin colour saturation;
LUAD	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.55	7.94	0.36	1.78e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg20019720	chr6:154832845	CNKSR3	0.65	12.84	0.53	4.41e-32	Lipoprotein (a) levels;
LUAD	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg10518543	chr12:38710700	ALG10B	-0.44	-7.18	-0.33	3.22e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.89	0.32	2.07e-11	Rheumatoid arthritis;
LUAD	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg04568274	chr7:158649319	WDR60	0.42	6.64	0.31	9.95e-11	Height;
LUAD	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg02733842	chr7:1102375	C7orf50	-0.83	-11.94	-0.5	1.61e-28	Bronchopulmonary dysplasia;
LUAD	cis	rs7707921	0.646	rs226208	chr5:81603444	G/A	cg15871215	chr5:81402204	ATG10	0.55	8.66	0.39	1.04e-16	Breast cancer;
LUAD	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg11965913	chr1:205819406	PM20D1	-0.55	-8.34	-0.38	1.1e-15	Menarche (age at onset);
LUAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg12432903	chr7:1882776	MAD1L1	-0.44	-7.05	-0.32	7.32e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs526821	0.595	rs624478	chr11:55340778	C/G	cg04317927	chr11:55418816	OR4S2	0.39	7.51	0.34	3.54e-13	Pediatric bone mineral density (spine);
LUAD	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.22	0.37	2.59e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg17845761	chr1:175162550	KIAA0040	0.37	9.82	0.43	1.2e-20	Alcohol dependence;
LUAD	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg08523384	chr5:141488047	NDFIP1	-0.48	-7.3	-0.33	1.42e-12	Crohn's disease;
LUAD	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-14.86	-0.59	1.7e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.63	-0.31	1.02e-10	Neutrophil percentage of white cells;
LUAD	cis	rs7827545	0.545	rs6578228	chr8:135562422	G/A	cg17885191	chr8:135476712	NA	0.55	7.51	0.34	3.5e-13	Hypertension (SNP x SNP interaction);
LUAD	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg15208524	chr1:10270712	KIF1B	0.45	6.79	0.31	3.71e-11	Hepatocellular carcinoma;
LUAD	cis	rs1965732	0.588	rs4849976	chr2:3717567	A/C	cg10645314	chr2:3704589	ALLC	-0.44	-7.82	-0.36	4.16e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg16479474	chr6:28041457	NA	0.39	6.86	0.32	2.49e-11	Parkinson's disease;
LUAD	cis	rs422249	0.727	rs174606	chr11:61626973	G/T	cg19610905	chr11:61596333	FADS2	-0.38	-6.48	-0.3	2.63e-10	Trans fatty acid levels;
LUAD	cis	rs2455601	0.608	rs59025804	chr11:8870301	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.43	-8.14	-0.37	4.47e-15	Schizophrenia;
LUAD	trans	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-10.19	-0.44	6.18e-22	Brugada syndrome;
LUAD	cis	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg00495681	chr13:53174319	NA	-0.44	-7.85	-0.36	3.38e-14	Lewy body disease;
LUAD	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg11814155	chr7:99998594	ZCWPW1	0.43	7.49	0.34	4e-13	Platelet count;
LUAD	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg12373951	chr3:133503437	NA	-0.35	-6.74	-0.31	5.05e-11	Iron status biomarkers;
LUAD	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg00034003	chr16:88779146	CTU2	0.64	9.56	0.42	9.86e-20	Autism spectrum disorder-related traits;
LUAD	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs3784262	0.565	rs12914414	chr15:58318757	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.37	-7.07	-0.32	6.64e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg00647820	chr17:40259828	DHX58	-0.44	-6.9	-0.32	1.94e-11	Fibrinogen levels;
LUAD	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg27490568	chr2:178487706	NA	0.42	6.94	0.32	1.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg08085267	chr17:45401833	C17orf57	-0.65	-11.57	-0.49	4.32e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg17264618	chr3:40429014	ENTPD3	-0.4	-8.8	-0.39	3.44e-17	Renal cell carcinoma;
LUAD	cis	rs7737355	0.898	rs31590	chr5:131005181	A/G	cg25547332	chr5:131281432	NA	0.44	6.65	0.31	9.13e-11	Life satisfaction;
LUAD	cis	rs6499255	0.638	rs57824734	chr16:69811995	C/T	cg15192750	chr16:69999425	NA	0.51	8.51	0.38	2.97e-16	IgE levels;
LUAD	cis	rs7705042	0.865	rs166079	chr5:141528959	C/T	cg08523384	chr5:141488047	NDFIP1	-0.4	-6.85	-0.32	2.58e-11	Asthma;
LUAD	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	9.39	0.42	3.73e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs7705042	0.897	rs7718955	chr5:141521459	A/G	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.67	-0.31	8.17e-11	Asthma;
LUAD	trans	rs7395662	1.000	rs7948486	chr11:48912140	C/G	cg00717180	chr2:96193071	NA	0.36	6.85	0.32	2.62e-11	HDL cholesterol;
LUAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs250585	0.833	rs30018	chr16:23408591	A/G	cg00143387	chr16:23521605	GGA2	0.55	6.92	0.32	1.72e-11	Egg allergy;
LUAD	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.43	7.54	0.34	2.86e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6076065	0.707	rs2024746	chr20:23356862	G/A	cg11657817	chr20:23433608	CST11	0.57	12.0	0.5	9.36e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1609391	0.543	rs6800690	chr3:136623026	G/A	cg15507776	chr3:136538369	TMEM22	0.5	8.93	0.4	1.36e-17	Neuroticism;
LUAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.4	-6.54	-0.3	1.76e-10	Longevity;Endometriosis;
LUAD	cis	rs832540	0.806	rs10039322	chr5:56260259	A/C	cg24531977	chr5:56204891	C5orf35	-0.43	-6.85	-0.32	2.56e-11	Coronary artery disease;
LUAD	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg13385794	chr1:248469461	NA	0.24	6.49	0.3	2.46e-10	Common traits (Other);
LUAD	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg03433033	chr1:76189801	ACADM	-0.84	-15.54	-0.6	2.11e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg04731861	chr2:219085781	ARPC2	0.23	7.14	0.33	4.01e-12	Colorectal cancer;
LUAD	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg25817165	chr18:72167213	CNDP2	-0.68	-10.28	-0.45	2.84e-22	Refractive error;
LUAD	cis	rs3772130	0.649	rs57636696	chr3:121619464	A/T	cg20356878	chr3:121714668	ILDR1	0.52	8.56	0.38	2.16e-16	Cognitive performance;
LUAD	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.37	7.07	0.33	6.39e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6500395	0.925	rs16946342	chr16:48668542	G/A	cg04672837	chr16:48644449	N4BP1	0.37	6.42	0.3	3.63e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.61	9.57	0.42	8.83e-20	Platelet count;
LUAD	cis	rs7520050	0.807	rs28378621	chr1:46189554	T/C	cg06784218	chr1:46089804	CCDC17	0.35	7.53	0.34	3.02e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs7927592	0.513	rs607887	chr11:68196961	C/T	cg01657329	chr11:68192670	LRP5	-0.55	-9.7	-0.43	3.15e-20	Total body bone mineral density;
LUAD	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg05697835	chr1:2722811	NA	-0.3	-6.4	-0.3	4.22e-10	Ulcerative colitis;
LUAD	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg10755058	chr3:40428713	ENTPD3	0.35	6.55	0.3	1.66e-10	Renal cell carcinoma;
LUAD	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg17264618	chr3:40429014	ENTPD3	0.39	8.74	0.39	5.33e-17	Renal cell carcinoma;
LUAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08677398	chr8:58056175	NA	-0.49	-6.46	-0.3	2.94e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg25452165	chr22:42524984	CYP2D6	-0.38	-6.42	-0.3	3.59e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	11.22	0.48	9.4e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg17366294	chr4:99064904	C4orf37	0.61	10.27	0.45	3.11e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2455799	0.613	rs11706879	chr3:15957130	A/C	cg16303742	chr3:15540471	COLQ	-0.43	-7.72	-0.35	8.68e-14	Mean platelet volume;
LUAD	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg04851639	chr8:1020857	NA	-0.37	-9.23	-0.41	1.36e-18	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg25985355	chr7:65971099	NA	-0.52	-6.56	-0.3	1.57e-10	Diabetic kidney disease;
LUAD	cis	rs2063714	0.967	rs913971	chr6:157197802	C/T	cg23222435	chr6:157204239	ARID1B	-0.36	-6.52	-0.3	2.04e-10	Sitting height ratio;
LUAD	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.68	0.31	7.32e-11	Menarche (age at onset);
LUAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.48	-9.09	-0.4	3.95e-18	Lymphocyte counts;
LUAD	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg13535736	chr9:111863775	C9orf5	-0.44	-6.87	-0.32	2.33e-11	Menarche (age at onset);
LUAD	cis	rs10193935	0.748	rs12467253	chr2:42697588	A/C	cg27598129	chr2:42591480	NA	0.78	9.37	0.41	4.23e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg09462578	chr12:12878428	APOLD1	-0.57	-8.86	-0.4	2.2e-17	Lymphocyte counts;
LUAD	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg25554036	chr4:6271136	WFS1	0.72	14.31	0.57	3.72e-38	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg00717180	chr2:96193071	NA	-0.4	-7.54	-0.34	2.94e-13	Height;
LUAD	cis	rs4372836	0.504	rs6737027	chr2:29070805	A/G	cg09522027	chr2:28974177	PPP1CB	0.57	10.21	0.44	4.88e-22	Body mass index;
LUAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg27094323	chr7:1216898	NA	-0.37	-6.44	-0.3	3.24e-10	Longevity;Endometriosis;
LUAD	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg24503407	chr1:205819492	PM20D1	-0.5	-7.64	-0.35	1.5e-13	Menarche (age at onset);
LUAD	cis	rs7192380	0.964	rs55780735	chr16:69740374	A/G	cg00738113	chr16:70207722	CLEC18C	0.37	7.49	0.34	4.16e-13	Sjögren's syndrome;
LUAD	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg11494091	chr17:61959527	GH2	0.41	7.18	0.33	3.13e-12	Height;
LUAD	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.28	0.54	7.14e-34	Prudent dietary pattern;
LUAD	cis	rs12681287	0.752	rs13277670	chr8:87259920	T/G	cg27223183	chr8:87520930	FAM82B	-0.62	-8.59	-0.39	1.71e-16	Caudate activity during reward;
LUAD	cis	rs4774899	0.966	rs6493901	chr15:57405451	A/G	cg14026238	chr15:57616123	NA	0.35	6.61	0.31	1.14e-10	Urinary tract infection frequency;
LUAD	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg13770153	chr20:60521292	NA	-0.57	-8.9	-0.4	1.64e-17	Body mass index;
LUAD	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg17971929	chr21:40555470	PSMG1	0.49	7.13	0.33	4.39e-12	Cognitive function;
LUAD	cis	rs6066835	1.000	rs6063314	chr20:47353106	T/C	cg18078177	chr20:47281410	PREX1	0.69	6.41	0.3	3.84e-10	Multiple myeloma;
LUAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-7.09	-0.33	5.61e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9393692	0.620	rs9358916	chr6:26283185	G/A	cg13736514	chr6:26305472	NA	-0.54	-9.23	-0.41	1.31e-18	Educational attainment;
LUAD	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg12573674	chr2:1569213	NA	-0.56	-8.45	-0.38	4.63e-16	IgG glycosylation;
LUAD	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg07386859	chr16:1872102	HAGH	0.53	7.81	0.35	4.64e-14	Insulin-like growth factors;
LUAD	cis	rs4144027	0.935	rs8008020	chr14:104355883	T/C	cg12183467	chr14:104352244	NA	-0.36	-6.94	-0.32	1.5e-11	Blood metabolite levels;
LUAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg07234876	chr8:600039	NA	1.15	10.49	0.45	5.03e-23	IgG glycosylation;
LUAD	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg19163074	chr7:65112434	INTS4L2	0.43	6.59	0.31	1.29e-10	Aortic root size;
LUAD	cis	rs3760982	0.626	rs12463370	chr19:44292166	G/A	cg12072164	chr19:44306565	LYPD5	0.39	7.79	0.35	5.24e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.34	0.38	1.06e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6688613	0.649	rs11584352	chr1:166850372	T/C	cg07049167	chr1:166818506	POGK	0.57	8.9	0.4	1.62e-17	Refractive astigmatism;
LUAD	cis	rs3790645	1.000	rs383913	chr1:26893306	A/G	cg23229016	chr1:26872525	RPS6KA1	0.21	6.96	0.32	1.31e-11	Glucose homeostasis traits;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10807698	chr14:103243805	TRAF3	-0.61	-7.39	-0.34	7.88e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs708547	0.874	rs1315006	chr4:57858193	C/T	cg00922110	chr4:57842668	C4orf14	-0.4	-6.35	-0.3	5.43e-10	Response to bleomycin (chromatid breaks);
LUAD	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg12373951	chr3:133503437	NA	-0.37	-7.42	-0.34	6.51e-13	Iron status biomarkers;
LUAD	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.71	-0.31	6.43e-11	Bladder cancer;
LUAD	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.62	-0.35	1.72e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08280861	chr8:58055591	NA	0.63	8.24	0.37	2.25e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg00933542	chr6:150070202	PCMT1	0.36	7.5	0.34	3.75e-13	Testicular germ cell tumor;
LUAD	cis	rs5756813	0.754	rs4820308	chr22:38176216	G/A	cg06521852	chr22:38141419	TRIOBP	0.5	9.41	0.42	3.13e-19	Optic cup area;Vertical cup-disc ratio;
LUAD	trans	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg27411982	chr8:10470053	RP1L1	-0.36	-6.44	-0.3	3.17e-10	Mood instability;
LUAD	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg02269571	chr22:50332266	NA	-0.54	-8.11	-0.37	5.5e-15	Schizophrenia;
LUAD	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg21214613	chr1:16344536	HSPB7	-0.56	-10.13	-0.44	9.52e-22	Dilated cardiomyopathy;
LUAD	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.4	-6.75	-0.31	4.96e-11	Colorectal cancer;
LUAD	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg00981070	chr1:2046702	PRKCZ	-0.34	-6.92	-0.32	1.66e-11	Height;
LUAD	trans	rs877282	0.898	rs11253349	chr10:765897	C/G	cg22713356	chr15:30763199	NA	1.28	17.3	0.64	4.19e-51	Uric acid levels;
LUAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.62	-10.36	-0.45	1.49e-22	Longevity;Endometriosis;
LUAD	cis	rs17155006	0.561	rs22783	chr7:107743243	G/T	cg05962710	chr7:107745446	LAMB4	-0.35	-7.4	-0.34	7.44e-13	Pneumococcal bacteremia;
LUAD	cis	rs12976411	0.575	rs35555788	chr19:32820544	C/T	cg02282382	chr19:32836354	ZNF507	0.71	6.43	0.3	3.54e-10	Coronary artery disease;
LUAD	cis	rs6543140	0.964	rs1523206	chr2:103070175	A/T	cg03938978	chr2:103052716	IL18RAP	0.35	6.7	0.31	6.76e-11	Blood protein levels;
LUAD	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg20476274	chr7:133979776	SLC35B4	0.79	14.48	0.58	7.37e-39	Mean platelet volume;
LUAD	cis	rs62238980	0.614	rs117517889	chr22:32469452	C/T	cg00543991	chr22:32367038	NA	0.92	8.7	0.39	7.27e-17	Childhood ear infection;
LUAD	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.22	-0.57	8.38e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6688613	1.000	rs6688613	chr1:166951869	A/G	cg07049167	chr1:166818506	POGK	-0.43	-7.26	-0.33	1.92e-12	Refractive astigmatism;
LUAD	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg04369109	chr6:150039330	LATS1	-0.44	-7.43	-0.34	5.91e-13	Lung cancer;
LUAD	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-14.86	-0.59	1.7e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06544989	chr22:39130855	UNC84B	0.42	7.76	0.35	6.43e-14	Menopause (age at onset);
LUAD	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg23172400	chr8:95962367	TP53INP1	0.33	7.07	0.32	6.56e-12	Type 2 diabetes;
LUAD	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.7	0.31	6.49e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg04234412	chr22:24373322	LOC391322	-0.8	-14.19	-0.57	1.15e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs250585	0.703	rs7204605	chr16:23553580	T/G	cg00143387	chr16:23521605	GGA2	-0.65	-7.97	-0.36	1.47e-14	Egg allergy;
LUAD	cis	rs1524976	1.000	rs2030732	chr3:65465766	T/C	cg16238336	chr3:65465873	MAGI1	0.64	7.57	0.35	2.44e-13	PR interval;
LUAD	cis	rs8102137	0.706	rs7250389	chr19:30325332	G/T	cg27475126	chr19:30303651	CCNE1	-0.39	-6.42	-0.3	3.65e-10	Bladder cancer;
LUAD	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.65	-0.35	1.33e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2548003	0.541	rs1160444	chr5:28763652	G/A	cg22863700	chr5:28928346	NA	0.42	6.45	0.3	3.08e-10	Hip geometry;
LUAD	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	8.1	0.37	5.82e-15	Parkinson's disease;
LUAD	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg06697600	chr4:7070879	GRPEL1	-0.56	-8.94	-0.4	1.19e-17	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.06	0.32	7.06e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg17178900	chr1:205818956	PM20D1	0.72	14.71	0.58	7.4e-40	Menarche (age at onset);
LUAD	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg03563238	chr19:33554763	RHPN2	-0.34	-8.22	-0.37	2.47e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.39	6.36	0.3	5.12e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg26384229	chr12:38710491	ALG10B	0.48	7.82	0.36	4.31e-14	Bladder cancer;
LUAD	cis	rs12368653	0.840	rs10877020	chr12:58188014	G/A	cg12615879	chr12:58013172	SLC26A10	0.38	7.6	0.35	1.91e-13	Multiple sclerosis;
LUAD	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02353165	chr6:42928485	GNMT	0.43	7.53	0.34	3.11e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg01657329	chr11:68192670	LRP5	-0.41	-6.64	-0.31	9.69e-11	Total body bone mineral density;
LUAD	cis	rs7640424	0.721	rs326355	chr3:107824663	T/C	cg09227934	chr3:107805635	CD47	0.36	6.51	0.3	2.12e-10	Body mass index;
LUAD	trans	rs11165623	0.564	rs9887897	chr1:96996671	T/C	cg10631902	chr5:14652156	NA	-0.4	-7.25	-0.33	1.98e-12	Hip circumference;Waist circumference;
LUAD	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.34	7.4	0.34	7.6e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg11062466	chr8:58055876	NA	0.67	9.01	0.4	7.2e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg13319975	chr6:146136371	FBXO30	-0.82	-14.39	-0.57	1.64e-38	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg25173405	chr17:45401733	C17orf57	0.45	7.82	0.36	4.37e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.04	0.36	9.11e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs877282	0.945	rs71491303	chr10:772884	G/T	cg17470449	chr10:769945	NA	0.68	10.67	0.46	1.06e-23	Uric acid levels;
LUAD	cis	rs12519773	0.526	rs4632783	chr5:92528309	A/G	cg18783429	chr5:92414398	NA	0.44	7.78	0.35	5.47e-14	Migraine;
LUAD	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03762994	chr17:6899332	ALOX12	0.36	6.79	0.31	3.88e-11	Tonsillectomy;
LUAD	cis	rs459571	0.916	rs467303	chr9:136904835	C/T	cg13789015	chr9:136890014	NCRNA00094	0.86	14.59	0.58	2.38e-39	Platelet distribution width;
LUAD	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg00898013	chr13:113819073	PROZ	-0.65	-11.54	-0.49	5.69e-27	Platelet distribution width;
LUAD	cis	rs13064411	0.542	rs11537650	chr3:113222036	G/A	cg10517650	chr3:113235015	CCDC52	-0.45	-8.28	-0.37	1.61e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs853679	0.546	rs34871267	chr6:28364232	G/A	cg06606381	chr12:133084897	FBRSL1	-1.24	-10.7	-0.46	8.18e-24	Depression;
LUAD	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg24675056	chr1:15929824	NA	-0.46	-8.28	-0.37	1.68e-15	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg01620082	chr3:125678407	NA	-0.44	-6.6	-0.31	1.27e-10	Parkinson's disease;
LUAD	cis	rs11030122	0.702	rs4910866	chr11:3950554	A/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.2	-0.33	2.7e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg12623918	chr2:306882	NA	0.35	7.1	0.33	5.18e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7617773	0.643	rs78159520	chr3:48349023	T/C	cg11946769	chr3:48343235	NME6	0.44	6.78	0.31	4.04e-11	Coronary artery disease;
LUAD	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg20469991	chr17:27169893	C17orf63	-0.52	-6.61	-0.31	1.19e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.33	-0.34	1.15e-12	Resting heart rate;
LUAD	trans	rs877282	0.891	rs12767043	chr10:797943	C/T	cg22713356	chr15:30763199	NA	1.29	19.16	0.68	2.3e-59	Uric acid levels;
LUAD	cis	rs11771526	0.901	rs11767773	chr7:32272342	T/G	cg13207630	chr7:32358064	NA	0.53	6.87	0.32	2.25e-11	Body mass index;
LUAD	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.56	-8.19	-0.37	3.06e-15	Gut microbiome composition (summer);
LUAD	cis	rs7588746	0.621	rs1816541	chr2:201151011	T/C	cg23649088	chr2:200775458	C2orf69	-0.47	-7.29	-0.33	1.59e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
LUAD	cis	rs7539409	0.604	rs6689821	chr1:84316605	A/G	cg10977910	chr1:84465055	TTLL7	0.76	8.86	0.4	2.22e-17	Alzheimer's disease;
LUAD	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg16486109	chr11:613632	IRF7	0.5	7.89	0.36	2.54e-14	Systemic lupus erythematosus;
LUAD	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg00204512	chr16:28754710	NA	0.31	6.75	0.31	4.81e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6752107	0.936	rs10192702	chr2:234206750	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	9.36	0.41	4.87e-19	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	13.81	0.56	4.52e-36	Intelligence (multi-trait analysis);
LUAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg02136620	chr5:178986620	RUFY1	-0.48	-8.19	-0.37	3.14e-15	Lung cancer;
LUAD	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg07414643	chr4:187882934	NA	0.34	6.95	0.32	1.42e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs367943	0.712	rs9326888	chr5:112731133	A/C	cg12552261	chr5:112820674	MCC	0.47	9.25	0.41	1.15e-18	Type 2 diabetes;
LUAD	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg10544611	chr16:67998164	SLC12A4	-0.56	-7.33	-0.34	1.19e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg10755058	chr3:40428713	ENTPD3	0.45	8.45	0.38	4.64e-16	Renal cell carcinoma;
LUAD	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Colorectal cancer;
LUAD	trans	rs4714291	0.832	rs3008839	chr6:40052660	G/A	cg02267698	chr19:7991119	CTXN1	-0.46	-7.22	-0.33	2.42e-12	Strep throat;
LUAD	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg08999081	chr20:33150536	PIGU	0.63	14.41	0.57	1.46e-38	Coronary artery disease;
LUAD	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.68	-0.31	7.75e-11	Diabetic kidney disease;
LUAD	cis	rs2019216	0.524	rs1518049	chr17:21922055	C/T	cg22648282	chr17:21454238	C17orf51	-0.43	-7.74	-0.35	7.37e-14	Pelvic organ prolapse;
LUAD	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg02753203	chr1:228287806	NA	0.56	10.28	0.45	2.76e-22	Diastolic blood pressure;
LUAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg15117754	chr3:10150083	C3orf24	0.42	6.83	0.32	2.98e-11	Alzheimer's disease;
LUAD	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg04450456	chr4:17643702	FAM184B	0.4	7.73	0.35	7.91e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg13685833	chr1:53393034	SCP2	-0.46	-7.66	-0.35	1.3e-13	Monocyte count;
LUAD	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg15017067	chr4:17643749	FAM184B	-0.35	-6.63	-0.31	1.05e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg27124370	chr19:33622961	WDR88	0.43	6.62	0.31	1.1e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10489202	0.913	rs380753	chr1:168035273	G/T	cg24449463	chr1:168025552	DCAF6	-0.7	-9.83	-0.43	1.15e-20	Schizophrenia;
LUAD	trans	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg20542592	chr8:11973495	FAM66D	-0.42	-6.67	-0.31	7.91e-11	Mood instability;
LUAD	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg05754148	chr16:3507555	NAT15	0.66	11.43	0.49	1.49e-26	Tuberculosis;
LUAD	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg02493740	chr2:85810744	VAMP5	-0.4	-7.3	-0.33	1.41e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg00271210	chr6:167070053	RPS6KA2	0.35	6.8	0.31	3.53e-11	Crohn's disease;
LUAD	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg16205897	chr5:131564050	P4HA2	-0.45	-10.82	-0.47	2.88e-24	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs877282	0.853	rs10904544	chr10:756966	A/G	cg06581033	chr10:766294	NA	-0.56	-7.2	-0.33	2.69e-12	Uric acid levels;
LUAD	cis	rs1697139	0.583	rs1428474	chr5:66544015	C/A	cg11553311	chr5:66541588	NA	0.44	8.25	0.37	2e-15	Breast cancer;
LUAD	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg27284194	chr4:1044797	NA	0.7	10.25	0.45	3.53e-22	Recombination rate (females);
LUAD	cis	rs4713675	0.565	rs2281829	chr6:33675642	A/G	cg14003231	chr6:33640908	ITPR3	0.49	9.53	0.42	1.26e-19	Plateletcrit;
LUAD	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg07810366	chr2:100720526	AFF3	-0.37	-7.5	-0.34	3.68e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg05754148	chr16:3507555	NAT15	0.5	7.35	0.34	1.07e-12	Body mass index (adult);
LUAD	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg23758822	chr17:41437982	NA	1.0	20.94	0.71	2.46e-67	Menopause (age at onset);
LUAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg07677032	chr17:61819896	STRADA	0.58	10.68	0.46	1e-23	Prudent dietary pattern;
LUAD	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-9.3	-0.41	7.55e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.59	0.42	7.97e-20	Cognitive ability;
LUAD	cis	rs57590327	0.504	rs4856348	chr3:81502923	T/G	cg07356753	chr3:81810745	GBE1	0.48	7.52	0.34	3.38e-13	Extraversion;
LUAD	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg22963979	chr7:1858916	MAD1L1	-0.49	-8.18	-0.37	3.26e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg03806693	chr22:41940476	POLR3H	0.75	10.1	0.44	1.23e-21	Vitiligo;
LUAD	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.06	-0.7	2.23e-63	Height;
LUAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05901451	chr6:126070800	HEY2	0.44	6.38	0.3	4.64e-10	Endometrial cancer;
LUAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg10053473	chr17:62856997	LRRC37A3	0.79	11.32	0.48	3.79e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4853036	0.951	rs6710444	chr2:70120632	G/A	cg02498382	chr2:70120550	SNRNP27	-0.51	-8.36	-0.38	9.18e-16	Colorectal or endometrial cancer;
LUAD	cis	rs7149337	1.000	rs4901103	chr14:51746873	C/T	cg23942311	chr14:51606299	NA	0.78	16.03	0.61	1.62e-45	Cancer;
LUAD	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg19318889	chr4:1322082	MAEA	0.91	15.61	0.6	1.02e-43	Longevity;
LUAD	cis	rs2274471	0.645	rs57291545	chr9:5001205	A/T	cg03390472	chr9:5043263	JAK2	-0.52	-7.92	-0.36	2.16e-14	Crohn's disease;
LUAD	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg06740227	chr12:86229804	RASSF9	0.46	8.06	0.37	7.67e-15	Major depressive disorder;
LUAD	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg23260525	chr10:116636907	FAM160B1	0.47	11.0	0.47	6.26e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11750116	chr1:155057442	EFNA3	-0.43	-6.43	-0.3	3.36e-10	Height;
LUAD	cis	rs757647	1.000	rs12514669	chr5:137757571	G/C	cg10676309	chr5:137685565	NA	0.37	7.06	0.32	6.92e-12	Menarche (age at onset);
LUAD	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg03433033	chr1:76189801	ACADM	0.86	15.87	0.61	8.18e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9902453	0.967	rs7212741	chr17:28322941	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.98	0.4	8.78e-18	Coffee consumption (cups per day);
LUAD	cis	rs250585	1.000	rs457964	chr16:23587924	G/A	cg00143387	chr16:23521605	GGA2	0.66	7.87	0.36	2.91e-14	Egg allergy;
LUAD	cis	rs654950	0.934	rs665223	chr1:42000654	A/T	cg06885757	chr1:42089581	HIVEP3	-0.45	-10.04	-0.44	2.08e-21	Airway imaging phenotypes;
LUAD	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg06558623	chr16:89946397	TCF25	1.22	12.45	0.52	1.56e-30	Skin colour saturation;
LUAD	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06112835	chr11:68658793	MRPL21	0.52	9.87	0.43	8.24e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg26384229	chr12:38710491	ALG10B	0.48	7.74	0.35	7.17e-14	Bladder cancer;
LUAD	cis	rs9788682	0.706	rs2568493	chr15:78740233	G/A	cg18825076	chr15:78729989	IREB2	-0.54	-7.58	-0.35	2.19e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs2019216	0.872	rs6565384	chr17:21897456	T/C	cg05591447	chr17:21909280	FLJ36000	-0.29	-7.6	-0.35	1.97e-13	Pelvic organ prolapse;
LUAD	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.11	0.33	5.05e-12	Menopause (age at onset);
LUAD	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg09658497	chr7:2847517	GNA12	-0.53	-8.84	-0.4	2.53e-17	Height;
LUAD	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg22618164	chr12:122356400	WDR66	0.67	12.03	0.5	7.17e-29	Mean corpuscular volume;
LUAD	cis	rs1018836	0.631	rs2205158	chr8:91472515	C/T	cg16814680	chr8:91681699	NA	-0.56	-9.31	-0.41	6.85e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg22823121	chr1:150693482	HORMAD1	0.46	9.24	0.41	1.2e-18	Tonsillectomy;
LUAD	cis	rs870825	0.616	rs56844261	chr4:185632478	T/C	cg04058563	chr4:185651563	MLF1IP	0.9	14.41	0.57	1.39e-38	Blood protein levels;
LUAD	cis	rs758324	0.773	rs4705901	chr5:131146993	T/C	cg06307176	chr5:131281290	NA	0.43	7.11	0.33	5.11e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg12292205	chr6:26970375	C6orf41	0.56	9.52	0.42	1.3e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2412208	0.816	rs2186090	chr1:7062426	C/T	cg20434152	chr1:7120926	CAMTA1	-0.3	-6.44	-0.3	3.34e-10	Survival in sporadic amyotrophic lateral sclerosis;
LUAD	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg08761264	chr16:28874980	SH2B1	0.46	7.06	0.32	6.76e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1997103	1.000	rs2331068	chr7:55408220	G/A	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg14019146	chr3:50243930	SLC38A3	-0.4	-6.57	-0.3	1.46e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08219700	chr8:58056026	NA	0.56	7.71	0.35	9.33e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg07362569	chr17:61921086	SMARCD2	0.37	6.42	0.3	3.69e-10	Prudent dietary pattern;
LUAD	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg02461776	chr11:598696	PHRF1	0.47	6.87	0.32	2.31e-11	Systemic lupus erythematosus;
LUAD	cis	rs9522267	0.535	rs7329118	chr13:112232693	C/T	cg10483660	chr13:112241077	NA	-0.31	-6.73	-0.31	5.53e-11	Hepatitis;
LUAD	cis	rs6840360	0.615	rs7669761	chr4:152609304	G/A	cg22705602	chr4:152727874	NA	-0.48	-9.07	-0.4	4.4e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg23758822	chr17:41437982	NA	0.99	20.9	0.71	3.79e-67	Menopause (age at onset);
LUAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg13732083	chr21:47605072	C21orf56	0.47	7.53	0.34	3.15e-13	Testicular germ cell tumor;
LUAD	cis	rs10193935	0.901	rs9808509	chr2:42479644	T/C	cg27598129	chr2:42591480	NA	-0.79	-9.24	-0.41	1.25e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.57	-8.88	-0.4	1.91e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.01e-10	Skin colour saturation;
LUAD	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg14844989	chr11:31128820	NA	-0.47	-8.58	-0.39	1.76e-16	Red blood cell count;
LUAD	cis	rs9616064	0.889	rs7284276	chr22:46996137	G/C	cg25730555	chr22:47059586	GRAMD4	0.4	6.66	0.31	8.59e-11	Urate levels in obese individuals;
LUAD	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.51	-10.84	-0.47	2.43e-24	Longevity;Endometriosis;
LUAD	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg04545296	chr12:48745243	ZNF641	0.39	9.79	0.43	1.54e-20	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs6684514	0.961	rs11264469	chr1:156276746	A/G	cg16558208	chr1:156270281	VHLL	0.53	9.69	0.43	3.36e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg04756594	chr16:24857601	SLC5A11	-0.77	-13.48	-0.55	1.02e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg17724175	chr1:150552817	MCL1	0.41	9.36	0.41	4.92e-19	Urate levels;
LUAD	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg00530320	chr1:46809349	NSUN4	0.53	8.09	0.37	6.25e-15	Menopause (age at onset);
LUAD	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.61	-0.31	1.15e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7870753	0.628	rs7857610	chr9:99189953	C/T	cg13563390	chr9:99253610	HABP4	-0.38	-6.36	-0.3	5.38e-10	Height;
LUAD	trans	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg02002194	chr4:3960332	NA	-0.3	-7.27	-0.33	1.73e-12	Neuroticism;
LUAD	cis	rs9287719	0.649	rs11684537	chr2:10734832	C/T	cg03983476	chr2:10830698	NOL10	-0.39	-6.75	-0.31	5.01e-11	Prostate cancer;
LUAD	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg08071915	chr8:12219732	FAM66A	0.44	7.17	0.33	3.36e-12	Joint mobility (Beighton score);
LUAD	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg23719950	chr11:63933701	MACROD1	-0.63	-7.49	-0.34	4.01e-13	Mean platelet volume;
LUAD	cis	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg26587870	chr6:27730563	NA	-0.59	-6.5	-0.3	2.23e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg14668632	chr7:2872130	GNA12	-0.47	-8.15	-0.37	4.03e-15	Height;
LUAD	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg03690763	chr11:133734501	NA	-0.29	-7.04	-0.32	7.7e-12	Childhood ear infection;
LUAD	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg14345882	chr6:26364793	BTN3A2	0.67	6.91	0.32	1.77e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.57	0.3	1.45e-10	Cardiac Troponin-T levels;
LUAD	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.32	0.34	1.3e-12	Obesity-related traits;
LUAD	cis	rs2404602	0.655	rs10444809	chr15:77124536	G/C	cg23625390	chr15:77176239	SCAPER	-0.44	-7.72	-0.35	8.69e-14	Blood metabolite levels;
LUAD	cis	rs6460942	1.000	rs73053531	chr7:12317474	T/C	cg06484146	chr7:12443880	VWDE	-0.55	-6.55	-0.3	1.69e-10	Coronary artery disease;
LUAD	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg27494647	chr7:150038898	RARRES2	0.45	8.27	0.37	1.74e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg13319975	chr6:146136371	FBXO30	-0.59	-9.82	-0.43	1.21e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg15242686	chr22:24348715	GSTTP1	0.42	7.14	0.33	4.22e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-8.09	-0.37	6.6e-15	Bipolar disorder;
LUAD	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-8.24	-0.37	2.22e-15	Height;
LUAD	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-8.03	-0.36	9.8e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg05922057	chr17:4047571	ZZEF1;CYB5D2	-0.38	-6.64	-0.31	9.45e-11	Type 2 diabetes;
LUAD	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg15147215	chr3:52552868	STAB1	-0.42	-7.99	-0.36	1.3e-14	Bipolar disorder;
LUAD	cis	rs9322817	0.691	rs2486135	chr6:105282263	C/T	cg02098413	chr6:105308735	HACE1	0.41	8.96	0.4	1.08e-17	Thyroid stimulating hormone;
LUAD	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg25208724	chr1:156163844	SLC25A44	0.98	15.05	0.59	2.71e-41	Testicular germ cell tumor;
LUAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00166722	chr3:10149974	C3orf24	0.68	11.27	0.48	6.07e-26	Alzheimer's disease;
LUAD	cis	rs2985684	0.802	rs8015368	chr14:50020510	G/A	cg04989706	chr14:50066350	PPIL5	-0.49	-7.31	-0.33	1.35e-12	Carotid intima media thickness;
LUAD	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg13010199	chr12:38710504	ALG10B	0.39	6.48	0.3	2.49e-10	Bladder cancer;
LUAD	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg13334819	chr7:99746414	C7orf59	-0.65	-10.47	-0.45	5.66e-23	Coronary artery disease;
LUAD	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg22535103	chr8:58192502	C8orf71	-0.78	-10.18	-0.44	6.29e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs295140	0.585	rs4233996	chr2:201131228	A/T	cg17644776	chr2:200775616	C2orf69	-0.39	-6.77	-0.31	4.34e-11	QT interval;
LUAD	trans	rs2735413	0.881	rs12919818	chr16:78082862	C/T	cg01028844	chr5:122736986	CEP120	0.4	6.43	0.3	3.4e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg27211696	chr2:191398769	TMEM194B	-0.67	-9.05	-0.4	5.3e-18	Diastolic blood pressure;
LUAD	cis	rs73195822	0.614	rs73194061	chr12:111221941	T/C	cg12870014	chr12:110450643	ANKRD13A	0.58	6.51	0.3	2.11e-10	Itch intensity from mosquito bite;
LUAD	cis	rs11098699	0.732	rs4833898	chr4:124243863	C/A	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	trans	rs3219090	0.962	rs2793376	chr1:226602921	A/G	cg27539482	chr13:111589090	NA	0.43	7.22	0.33	2.5e-12	Melanoma;
LUAD	cis	rs9633740	0.947	rs1878036	chr10:82280137	T/G	cg01528321	chr10:82214614	TSPAN14	0.75	9.67	0.43	4.08e-20	Post bronchodilator FEV1;
LUAD	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg17644776	chr2:200775616	C2orf69	0.58	9.01	0.4	7.14e-18	Schizophrenia;
LUAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	12.68	0.52	1.84e-31	Prudent dietary pattern;
LUAD	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-11.93	-0.5	1.81e-28	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12016809	chr21:47604291	C21orf56	-0.58	-8.66	-0.39	1e-16	Testicular germ cell tumor;
LUAD	cis	rs11811982	0.793	rs11808670	chr1:227516011	G/A	cg24860534	chr1:227506868	CDC42BPA	0.65	7.18	0.33	3.17e-12	Optic disc area;
LUAD	cis	rs6445967	0.569	rs2280166	chr3:58309602	C/T	cg23715586	chr3:58305044	RPP14	0.4	6.55	0.3	1.67e-10	Platelet count;
LUAD	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14893161	chr1:205819251	PM20D1	0.53	9.75	0.43	2.22e-20	Menarche (age at onset);
LUAD	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg10792982	chr14:105748885	BRF1	0.45	9.93	0.43	5.19e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg07741184	chr6:167504864	NA	0.27	6.6	0.31	1.22e-10	Crohn's disease;
LUAD	cis	rs9535307	0.584	rs61961500	chr13:50392624	G/C	cg04663916	chr13:50265991	EBPL	-0.63	-6.49	-0.3	2.41e-10	Obesity-related traits;
LUAD	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.73	-14.15	-0.57	1.72e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg12011299	chr4:100065546	ADH4	-0.77	-13.22	-0.54	1.27e-33	Alcohol dependence;
LUAD	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg00981070	chr1:2046702	PRKCZ	-0.35	-6.78	-0.31	4.18e-11	Height;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06666157	chr19:4791552	FEM1A	0.4	6.38	0.3	4.65e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg04155289	chr7:94953770	PON1	-0.52	-6.83	-0.32	2.94e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.73	15.58	0.6	1.44e-43	Myeloid white cell count;
LUAD	cis	rs6752107	0.936	rs10187822	chr2:234206474	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	9.36	0.41	4.79e-19	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg18811423	chr2:55921094	PNPT1	-0.57	-9.68	-0.43	3.8e-20	Metabolic syndrome;
LUAD	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg06263672	chr7:65235340	NA	0.5	7.06	0.32	6.99e-12	Aortic root size;
LUAD	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg18944383	chr4:111397179	ENPEP	0.39	7.69	0.35	1.06e-13	Height;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg16920189	chr15:100105709	MEF2A	-0.4	-6.6	-0.31	1.23e-10	Schizophrenia;
LUAD	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg26384229	chr12:38710491	ALG10B	0.46	7.4	0.34	7.17e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg21699342	chr2:239360505	ASB1	0.51	9.08	0.4	4.16e-18	Multiple system atrophy;
LUAD	cis	rs6674176	0.932	rs12410334	chr1:44442521	A/C	cg13606994	chr1:44402422	ARTN	-0.4	-7.5	-0.34	3.81e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7017914	0.967	rs7013657	chr8:71637559	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs72793342	0.651	rs8050463	chr16:30554159	A/G	cg02466173	chr16:30829666	NA	0.49	7.19	0.33	2.98e-12	RANTES levels;
LUAD	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg15181151	chr6:150070149	PCMT1	0.36	7.14	0.33	4.13e-12	Lung cancer;
LUAD	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.41	-0.34	6.99e-13	Type 2 diabetes;
LUAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg18402987	chr7:1209562	NA	0.79	9.87	0.43	7.97e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.57	-0.3	1.44e-10	Breast cancer;
LUAD	trans	rs7395662	0.833	rs1963073	chr11:48975094	T/A	cg15704280	chr7:45808275	SEPT13	-0.44	-6.97	-0.32	1.21e-11	HDL cholesterol;
LUAD	cis	rs829661	0.532	rs2363073	chr2:30796008	A/C	cg12454169	chr2:30669597	LCLAT1	-0.44	-6.74	-0.31	5.18e-11	Midgestational circulating levels of PBDEs (fetal genetic effect);
LUAD	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.57	0.3	1.48e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg14458575	chr2:238380390	NA	0.85	12.81	0.53	5.76e-32	Prostate cancer;
LUAD	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg09455208	chr3:40491958	NA	0.54	11.7	0.49	1.41e-27	Renal cell carcinoma;
LUAD	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.36	-0.45	1.4e-22	Platelet count;
LUAD	trans	rs28735056	0.875	rs62103176	chr18:77623611	G/C	cg05926928	chr17:57297772	GDPD1	0.5	7.59	0.35	2e-13	Schizophrenia;
LUAD	cis	rs9469913	0.799	rs2744947	chr6:34657809	A/T	cg14254433	chr6:34482411	PACSIN1	-0.43	-6.83	-0.32	2.93e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.62	-0.39	1.31e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.2	0.48	1.08e-25	Height;
LUAD	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg05425664	chr17:57184151	TRIM37	0.39	6.91	0.32	1.76e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18404041	chr3:52824283	ITIH1	-0.64	-13.14	-0.54	2.6e-33	Bipolar disorder;
LUAD	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg10544611	chr16:67998164	SLC12A4	-0.69	-8.21	-0.37	2.79e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1997103	1.000	rs9649857	chr7:55411777	C/T	cg17469321	chr7:55412551	NA	0.67	11.32	0.48	3.95e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.5	-0.3	2.21e-10	Neuroticism;
LUAD	trans	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs877282	0.853	rs12763400	chr10:763617	C/T	cg22713356	chr15:30763199	NA	1.26	17.41	0.65	1.4e-51	Uric acid levels;
LUAD	cis	rs7520050	0.966	rs10890363	chr1:46356148	C/T	cg06784218	chr1:46089804	CCDC17	0.31	6.54	0.3	1.75e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg03605463	chr16:89740564	NA	-0.61	-11.4	-0.48	2.01e-26	Hemoglobin concentration;
LUAD	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg14582100	chr15:45693742	SPATA5L1	0.43	8.71	0.39	7.16e-17	Response to fenofibrate (adiponectin levels);
LUAD	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg18944383	chr4:111397179	ENPEP	-0.38	-6.57	-0.3	1.5e-10	Coronary artery disease;
LUAD	cis	rs7274811	0.744	rs6120316	chr20:32177079	T/C	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.44	-6.52	-0.3	2.02e-10	Height;
LUAD	cis	rs2573652	1.000	rs2727198	chr15:100513722	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.48	-8.68	-0.39	8.62e-17	Height;
LUAD	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-8.22	-0.37	2.5e-15	Hemoglobin concentration;
LUAD	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	9.48	0.42	1.86e-19	Hip circumference adjusted for BMI;
LUAD	cis	rs6432018	1.000	rs3951115	chr2:9740561	T/C	cg12832956	chr2:9616023	IAH1	-0.36	-6.45	-0.3	3.14e-10	Heart rate variability traits;
LUAD	cis	rs2235649	0.833	rs7189070	chr16:1850813	G/A	cg08610935	chr16:1836813	NUBP2	-0.48	-7.37	-0.34	8.86e-13	Blood metabolite levels;
LUAD	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	7.99	0.36	1.28e-14	Tonsillectomy;
LUAD	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg18129178	chr5:148520854	ABLIM3	-0.57	-8.6	-0.39	1.6e-16	Breast cancer;
LUAD	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg05340658	chr4:99064831	C4orf37	0.56	9.6	0.42	6.97e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.53	-0.34	3.09e-13	Platelet count;
LUAD	cis	rs7809615	0.901	rs11981478	chr7:99163950	C/T	cg12290671	chr7:99195819	NA	-0.71	-7.8	-0.35	4.76e-14	Blood metabolite ratios;
LUAD	cis	rs41271473	0.526	rs56043220	chr1:228783474	G/C	cg16512390	chr1:228756714	NA	0.69	8.88	0.4	1.93e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg07414643	chr4:187882934	NA	0.34	6.96	0.32	1.27e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.95	-0.44	4.09e-21	Monocyte percentage of white cells;
LUAD	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.43	-0.6	6.51e-43	Chronic sinus infection;
LUAD	cis	rs1448094	0.935	rs11117108	chr12:86322310	T/A	cg18827107	chr12:86230957	RASSF9	-0.44	-7.93	-0.36	1.94e-14	Major depressive disorder;
LUAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg22764044	chr5:178986830	RUFY1	-0.66	-11.05	-0.47	4.07e-25	Lung cancer;
LUAD	cis	rs7818345	0.967	rs12543061	chr8:19286181	G/T	cg11303988	chr8:19266685	CSGALNACT1	-0.3	-6.74	-0.31	5.09e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs4619206	1	rs4619206	chr12:1002857	T/C	cg14602222	chr12:1025663	RAD52	0.39	7.22	0.33	2.5e-12	Lung cancer in ever smokers;
LUAD	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg22906224	chr7:99728672	NA	0.65	10.86	0.47	2.06e-24	Coronary artery disease;
LUAD	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg07404485	chr7:94953653	PON1	-0.48	-6.76	-0.31	4.69e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs208520	0.690	rs207081	chr6:66773742	A/G	cg07460842	chr6:66804631	NA	-1.08	-16.75	-0.63	1.18e-48	Exhaled nitric oxide output;
LUAD	cis	rs7707921	0.587	rs17247678	chr5:81652773	C/T	cg15871215	chr5:81402204	ATG10	-0.54	-7.56	-0.34	2.57e-13	Breast cancer;
LUAD	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg08219700	chr8:58056026	NA	0.55	7.71	0.35	8.86e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg02569458	chr12:86230093	RASSF9	0.42	7.94	0.36	1.82e-14	Major depressive disorder;
LUAD	trans	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-11.48	-0.49	9.87e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7737355	0.836	rs10900800	chr5:130914946	G/A	cg25547332	chr5:131281432	NA	0.41	6.47	0.3	2.75e-10	Life satisfaction;
LUAD	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg13385794	chr1:248469461	NA	0.26	7.14	0.33	4.14e-12	Common traits (Other);
LUAD	cis	rs7149242	0.696	rs7141210	chr14:101182470	T/C	cg18089426	chr14:101175970	NA	-0.39	-6.87	-0.32	2.26e-11	Platelet count;
LUAD	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg18876405	chr7:65276391	NA	0.62	10.9	0.47	1.5e-24	Calcium levels;
LUAD	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg11645453	chr3:52864694	ITIH4	-0.33	-6.36	-0.3	5.38e-10	Body mass index;
LUAD	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg03806693	chr22:41940476	POLR3H	-0.77	-10.9	-0.47	1.48e-24	Vitiligo;
LUAD	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg25838465	chr1:92012736	NA	-0.69	-15.11	-0.59	1.51e-41	Breast cancer;
LUAD	cis	rs11756438	0.572	rs902779	chr6:119000593	A/C	cg21191810	chr6:118973309	C6orf204	0.5	9.49	0.42	1.66e-19	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg00204512	chr16:28754710	NA	0.35	7.49	0.34	4.06e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg05896524	chr21:47604654	C21orf56	0.53	8.63	0.39	1.3e-16	Testicular germ cell tumor;
LUAD	cis	rs220324	0.688	rs11701255	chr21:43577614	C/G	cg09727148	chr21:43560719	UMODL1	0.52	7.57	0.35	2.29e-13	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs733175	0.857	rs751092	chr4:10005897	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	6.92	0.32	1.71e-11	Psychosis and Alzheimer's disease;
LUAD	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.22	-0.37	2.49e-15	Total body bone mineral density;
LUAD	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg14196790	chr5:131705035	SLC22A5	0.37	6.46	0.3	2.95e-10	Breast cancer;
LUAD	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg09537434	chr19:41945824	ATP5SL	-0.52	-8.17	-0.37	3.59e-15	Height;
LUAD	cis	rs8027181	0.740	rs8038247	chr15:73096573	A/G	cg25632853	chr15:73088954	NA	0.31	7.02	0.32	8.86e-12	Triglyceride levels;
LUAD	cis	rs2797160	1.000	rs2747725	chr6:126012397	A/C	cg05901451	chr6:126070800	HEY2	0.44	6.41	0.3	3.78e-10	Endometrial cancer;
LUAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg13560548	chr3:10150139	C3orf24	0.44	7.65	0.35	1.41e-13	Alzheimer's disease;
LUAD	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg25767906	chr1:53392781	SCP2	0.54	9.95	0.44	4.19e-21	Monocyte count;
LUAD	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.44	8.15	0.37	4.29e-15	Age at first birth;
LUAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg14893161	chr1:205819251	PM20D1	0.75	15.52	0.6	2.67e-43	Menarche (age at onset);
LUAD	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg01475377	chr6:109611718	NA	-0.53	-9.95	-0.44	4.1e-21	Reticulocyte fraction of red cells;
LUAD	trans	rs7712671	0.840	rs11241418	chr5:116527405	C/T	cg10130401	chr17:46970032	ATP5G1	0.4	6.36	0.3	5.25e-10	Schizophrenia;
LUAD	cis	rs654950	0.901	rs607586	chr1:42004379	C/T	cg06885757	chr1:42089581	HIVEP3	-0.49	-10.67	-0.46	1.03e-23	Airway imaging phenotypes;
LUAD	trans	rs853679	0.546	rs36092177	chr6:28357807	C/T	cg01620082	chr3:125678407	NA	-1.08	-9.99	-0.44	3.19e-21	Depression;
LUAD	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg04727924	chr7:799746	HEATR2	-0.53	-6.77	-0.31	4.29e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg02951883	chr7:2050386	MAD1L1	0.69	11.3	0.48	4.84e-26	Bipolar disorder and schizophrenia;
LUAD	cis	rs4253772	0.575	rs6008684	chr22:46719100	C/G	cg00784671	chr22:46762841	CELSR1	-0.63	-7.67	-0.35	1.19e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg14345882	chr6:26364793	BTN3A2	0.69	7.14	0.33	4.14e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.3	-0.51	6.25e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg12756686	chr19:29218302	NA	0.72	9.15	0.41	2.45e-18	Methadone dose in opioid dependence;
LUAD	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg00316803	chr15:76480434	C15orf27	-0.4	-7.36	-0.34	9.97e-13	Blood metabolite levels;
LUAD	trans	rs7507204	0.530	rs4807470	chr19:3443470	A/T	cg08382705	chr11:45687319	CHST1	-0.43	-7.33	-0.34	1.15e-12	Height;
LUAD	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-10.31	-0.45	2.22e-22	Electroencephalogram traits;
LUAD	cis	rs61990749	0.597	rs1048147	chr14:78139988	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.5	-6.43	-0.3	3.42e-10	Fibroblast growth factor basic levels;
LUAD	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg14416269	chr4:6271139	WFS1	0.64	13.51	0.55	7.7e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7766641	1	rs7766641	chr6:26184102	G/A	cg00631329	chr6:26305371	NA	-0.47	-7.22	-0.33	2.36e-12	Height;
LUAD	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.84	0.36	3.79e-14	Lung cancer;
LUAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13012494	chr21:47604986	C21orf56	-0.7	-12.0	-0.5	9.67e-29	Testicular germ cell tumor;
LUAD	cis	rs7520050	0.931	rs11211189	chr1:46261584	A/T	cg06784218	chr1:46089804	CCDC17	-0.3	-6.35	-0.3	5.54e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.49	6.57	0.3	1.51e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg06064525	chr11:970664	AP2A2	-0.45	-8.89	-0.4	1.79e-17	Alzheimer's disease (late onset);
LUAD	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg06028605	chr16:24865363	SLC5A11	-0.39	-6.86	-0.32	2.45e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg00310523	chr12:86230176	RASSF9	0.39	8.24	0.37	2.18e-15	Major depressive disorder;
LUAD	cis	rs11958404	1.000	rs72816527	chr5:157409633	C/T	cg05962755	chr5:157440814	NA	0.6	8.17	0.37	3.58e-15	IgG glycosylation;
LUAD	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg27446573	chr6:127587934	RNF146	0.45	6.59	0.31	1.3100000000000001e-10	Breast cancer;
LUAD	trans	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg18335740	chr13:41363409	SLC25A15	0.5	8.87	0.4	2.1e-17	Lewy body disease;
LUAD	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	7.97	0.36	1.5e-14	Menarche (age at onset);
LUAD	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg02782426	chr3:40428986	ENTPD3	0.43	9.01	0.4	7.24e-18	Renal cell carcinoma;
LUAD	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg17724175	chr1:150552817	MCL1	0.32	7.3	0.33	1.42e-12	Melanoma;
LUAD	trans	rs11885103	0.543	rs1320365	chr2:563182	A/G	cg12228919	chr15:44955936	SPG11	-0.41	-6.35	-0.3	5.55e-10	Heschl's gyrus morphology;
LUAD	cis	rs12530845	1.000	rs56060450	chr7:135331777	C/T	cg23117316	chr7:135346802	PL-5283	-0.5	-9.3	-0.41	7.55e-19	Red blood cell traits;
LUAD	cis	rs2688608	0.967	rs1815076	chr10:75659886	C/T	cg19442545	chr10:75533431	FUT11	-0.4	-6.87	-0.32	2.33e-11	Inflammatory bowel disease;
LUAD	cis	rs4774899	0.752	rs2951901	chr15:57336750	A/T	cg14026238	chr15:57616123	NA	0.42	7.86	0.36	3.23e-14	Urinary tract infection frequency;
LUAD	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.43	-6.9	-0.32	1.96e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs12545109	0.842	rs2670050	chr8:57402914	T/G	cg09654669	chr8:57350985	NA	-0.62	-9.18	-0.41	1.93e-18	Obesity-related traits;
LUAD	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.43	7.17	0.33	3.48e-12	Body mass index (adult);
LUAD	trans	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg01620082	chr3:125678407	NA	-0.59	-7.43	-0.34	5.91e-13	Depression;
LUAD	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9925964	0.748	rs11640961	chr16:30979818	C/T	cg02466173	chr16:30829666	NA	0.45	7.87	0.36	3.1e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.64	-8.71	-0.39	7.06e-17	Yeast infection;
LUAD	cis	rs57920188	0.535	rs77116992	chr1:4095498	T/A	cg20703997	chr1:4087676	NA	0.48	9.11	0.41	3.3e-18	Interleukin-17 levels;
LUAD	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg08999081	chr20:33150536	PIGU	0.61	13.7	0.55	1.32e-35	Glomerular filtration rate (creatinine);
LUAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg08742575	chr21:47604166	C21orf56	-0.51	-7.6	-0.35	1.99e-13	Testicular germ cell tumor;
LUAD	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg21963583	chr11:68658836	MRPL21	0.65	11.47	0.49	1.06e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11893307	0.537	rs3771319	chr2:191525233	C/G	cg11845111	chr2:191398756	TMEM194B	-0.47	-6.81	-0.31	3.33e-11	Mean platelet volume;
LUAD	cis	rs1044826	0.642	rs295481	chr3:139228811	C/T	cg00490450	chr3:139108681	COPB2	0.4	6.39	0.3	4.51e-10	Obesity-related traits;
LUAD	cis	rs3790645	1.000	rs364977	chr1:26893836	G/A	cg23229016	chr1:26872525	RPS6KA1	0.2	6.58	0.3	1.41e-10	Glucose homeostasis traits;
LUAD	cis	rs67072384	1.000	rs7124056	chr11:72444747	C/T	cg04827223	chr11:72435913	ARAP1	0.58	7.5	0.34	3.85e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs2282300	0.739	rs1933342	chr11:30312825	C/T	cg25418670	chr11:30344373	C11orf46	0.54	7.39	0.34	7.69e-13	Morning vs. evening chronotype;
LUAD	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg23992470	chr4:843637	GAK	0.67	7.09	0.33	5.62e-12	Parkinson's disease;
LUAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg07211511	chr3:129823064	LOC729375	-0.55	-7.0	-0.32	1e-11	Blood pressure (smoking interaction);
LUAD	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg03859395	chr2:55845619	SMEK2	0.7	12.48	0.52	1.17e-30	Metabolic syndrome;
LUAD	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-8.26	-0.37	1.94e-15	Monocyte percentage of white cells;
LUAD	cis	rs2224391	0.628	rs2753233	chr6:5250982	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-8.78	-0.39	3.97e-17	Height;
LUAD	cis	rs4280164	0.887	rs2748543	chr14:24778674	C/A	cg22990158	chr14:24802150	ADCY4	0.5	7.1	0.33	5.33e-12	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg20701182	chr2:24300061	SF3B14	0.62	6.94	0.32	1.45e-11	Lymphocyte counts;
LUAD	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg09455208	chr3:40491958	NA	0.65	14.16	0.57	1.5e-37	Renal cell carcinoma;
LUAD	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg03289416	chr15:75166202	SCAMP2	0.5	8.57	0.38	2.02e-16	Breast cancer;
LUAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.47	0.45	6e-23	Prudent dietary pattern;
LUAD	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg17264618	chr3:40429014	ENTPD3	0.35	7.43	0.34	6.23e-13	Renal cell carcinoma;
LUAD	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg05966235	chr16:28915196	ATP2A1	0.47	7.71	0.35	8.82e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg05283184	chr6:79620031	NA	-0.45	-7.81	-0.35	4.68e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-9.24	-0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs7833986	0.501	rs72653986	chr8:57035048	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.99	17.76	0.65	4.05e-53	Height;
LUAD	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.7	0.39	7.29e-17	Menopause (age at onset);
LUAD	cis	rs4268898	0.760	rs55863105	chr2:24570695	C/T	cg06627628	chr2:24431161	ITSN2	0.39	6.94	0.32	1.48e-11	Asthma;
LUAD	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg11859384	chr17:80120422	CCDC57	0.51	9.28	0.41	9.02e-19	Life satisfaction;
LUAD	cis	rs12519773	0.526	rs4264926	chr5:92518686	C/T	cg18783429	chr5:92414398	NA	0.43	7.66	0.35	1.26e-13	Migraine;
LUAD	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg05535760	chr7:792225	HEATR2	0.85	11.32	0.48	3.81e-26	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7833986	0.501	rs2976012	chr8:56974343	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	1.01	18.4	0.67	5.68e-56	Height;
LUAD	cis	rs7932354	0.528	rs12796744	chr11:47132724	A/T	cg19486271	chr11:47235900	DDB2	0.47	7.39	0.34	7.95e-13	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-6.93	-0.32	1.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs981844	0.714	rs6822142	chr4:154683524	C/T	cg10279832	chr4:154682576	RNF175	0.34	7.15	0.33	3.79e-12	Response to statins (LDL cholesterol change);
LUAD	cis	rs2742234	0.541	rs11238483	chr10:43728780	A/G	cg15436174	chr10:43711423	RASGEF1A	0.54	8.98	0.4	8.99e-18	Hirschsprung disease;
LUAD	cis	rs2354432	0.825	rs10900347	chr1:146800107	G/C	cg25205988	chr1:146714368	CHD1L	0.51	6.38	0.3	4.79e-10	Mitochondrial DNA levels;
LUAD	cis	rs12348691	0.503	rs7849497	chr9:100615660	G/C	cg13688889	chr9:100608707	NA	-0.63	-10.31	-0.45	2.22e-22	Alopecia areata;
LUAD	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg18230493	chr5:56204884	C5orf35	0.71	11.33	0.48	3.55e-26	Initial pursuit acceleration;
LUAD	cis	rs7481584	0.924	rs4758502	chr11:2998461	C/T	cg11201177	chr11:2961805	NA	0.39	6.47	0.3	2.69e-10	Calcium levels;
LUAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.42	0.38	6.07e-16	Alzheimer's disease;
LUAD	cis	rs9902453	0.817	rs2729435	chr17:28121532	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.34	-0.41	5.38e-19	Coffee consumption (cups per day);
LUAD	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg21963583	chr11:68658836	MRPL21	0.66	11.7	0.49	1.4e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg07157834	chr1:205819609	PM20D1	-0.47	-6.94	-0.32	1.46e-11	Menarche (age at onset);
LUAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08677398	chr8:58056175	NA	0.48	6.84	0.32	2.73e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23583168	chr7:148888333	NA	-1.07	-26.82	-0.79	2.65e-93	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.04	0.32	7.78e-12	Menopause (age at onset);
LUAD	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg00316803	chr15:76480434	C15orf27	0.41	6.93	0.32	1.6e-11	Blood metabolite levels;
LUAD	trans	rs7395662	1.000	rs4882010	chr11:48559173	T/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.75e-10	HDL cholesterol;
LUAD	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg24818145	chr4:99064322	C4orf37	0.48	8.09	0.37	6.3e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg05590025	chr7:65112418	INTS4L2	-0.71	-7.61	-0.35	1.84e-13	Diabetic kidney disease;
LUAD	cis	rs1232027	0.700	rs1643658	chr5:79936341	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.5	-9.46	-0.42	2.2e-19	Lymphocyte counts;
LUAD	trans	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.51	0.52	8.81e-31	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs11811982	0.793	rs11809113	chr1:227374357	C/T	cg24860534	chr1:227506868	CDC42BPA	0.67	7.33	0.34	1.22e-12	Optic disc area;
LUAD	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-8.49	-0.38	3.64e-16	Reticulocyte count;
LUAD	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg05579598	chr16:88989069	CBFA2T3	0.3	6.5	0.3	2.28e-10	Social autistic-like traits;
LUAD	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg19318889	chr4:1322082	MAEA	0.48	8.19	0.37	3.16e-15	Obesity-related traits;
LUAD	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg13319975	chr6:146136371	FBXO30	-0.64	-11.06	-0.47	3.69e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg02569458	chr12:86230093	RASSF9	0.43	7.7	0.35	9.88e-14	Major depressive disorder;
LUAD	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg19875535	chr5:140030758	IK	0.42	7.32	0.34	1.23e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg24818145	chr4:99064322	C4orf37	0.47	7.83	0.36	4.1e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg18827107	chr12:86230957	RASSF9	0.54	9.69	0.43	3.44e-20	Major depressive disorder;
LUAD	cis	rs642803	0.933	rs644740	chr11:65561468	C/T	cg27068330	chr11:65405492	SIPA1	0.46	7.17	0.33	3.4e-12	Urate levels;
LUAD	cis	rs1167827	0.680	rs1167800	chr7:75176196	G/A	cg16384552	chr7:74938386	SPDYE8P	-0.62	-9.65	-0.42	4.84e-20	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg04731861	chr2:219085781	ARPC2	0.27	8.22	0.37	2.53e-15	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs13315871	1.000	rs11706420	chr3:58392411	C/T	cg12435725	chr3:58293450	RPP14	0.58	6.51	0.3	2.17e-10	Cholesterol, total;
LUAD	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06022373	chr22:39101656	GTPBP1	0.48	8.13	0.37	4.93e-15	Menopause (age at onset);
LUAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg14893161	chr1:205819251	PM20D1	0.48	7.89	0.36	2.69e-14	Parkinson's disease;
LUAD	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg25769590	chr7:158789503	NA	-0.38	-7.04	-0.32	7.61e-12	Facial morphology (factor 20);
LUAD	cis	rs9341808	0.754	rs1324121	chr6:80946077	A/G	cg08355045	chr6:80787529	NA	0.57	10.41	0.45	9.39e-23	Sitting height ratio;
LUAD	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11890956	chr21:40555474	PSMG1	0.82	14.66	0.58	1.25e-39	Cognitive function;
LUAD	cis	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg02508848	chr16:68573721	ZFP90	-0.42	-6.55	-0.3	1.72e-10	Ulcerative colitis;
LUAD	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06873352	chr17:61820015	STRADA	0.55	9.0	0.4	7.84e-18	Height;
LUAD	cis	rs2797160	1.000	rs2747723	chr6:126010790	C/T	cg05901451	chr6:126070800	HEY2	0.45	6.69	0.31	7.03e-11	Endometrial cancer;
LUAD	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg26408565	chr15:76604113	ETFA	-0.44	-7.54	-0.34	2.93e-13	Blood metabolite levels;
LUAD	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg10518543	chr12:38710700	ALG10B	-0.44	-7.44	-0.34	5.8e-13	Morning vs. evening chronotype;
LUAD	trans	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg11915388	chr22:42470451	FAM109B	-0.4	-7.1	-0.33	5.35e-12	Schizophrenia;
LUAD	cis	rs11734570	0.581	rs73811715	chr4:38590569	A/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.45	6.43	0.3	3.48e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9469913	0.799	rs6938239	chr6:34683635	G/A	cg14254433	chr6:34482411	PACSIN1	0.43	6.71	0.31	6.41e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.17	0.33	3.34e-12	Motion sickness;
LUAD	cis	rs9837602	0.935	rs9810235	chr3:99736538	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.65	9.43	0.42	2.64e-19	Breast cancer;
LUAD	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg17911788	chr17:44343683	NA	-0.48	-6.55	-0.3	1.7e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9902453	0.933	rs9303628	chr17:28527228	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.55	0.42	1.1e-19	Coffee consumption (cups per day);
LUAD	cis	rs7851660	0.809	rs12006522	chr9:100652711	G/C	cg13688889	chr9:100608707	NA	-0.54	-9.08	-0.4	4.17e-18	Strep throat;
LUAD	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg01017244	chr2:74357527	NA	0.88	14.3	0.57	4.16e-38	Gestational age at birth (maternal effect);
LUAD	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg23950597	chr19:37808831	NA	-0.59	-7.0	-0.32	9.87e-12	Coronary artery calcification;
LUAD	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg19622623	chr12:86230825	RASSF9	-0.36	-6.43	-0.3	3.45e-10	Major depressive disorder;
LUAD	cis	rs9462027	0.628	rs10807141	chr6:34693111	A/G	cg07306190	chr6:34760872	UHRF1BP1	0.35	9.0	0.4	7.61e-18	Systemic lupus erythematosus;
LUAD	cis	rs490234	0.871	rs13288032	chr9:128255582	T/A	cg14078157	chr9:128172775	NA	-0.4	-7.1	-0.33	5.37e-12	Mean arterial pressure;
LUAD	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg20891283	chr12:69753455	YEATS4	0.44	7.13	0.33	4.26e-12	Blood protein levels;
LUAD	cis	rs12530845	0.561	rs73725182	chr7:135291001	C/T	cg23117316	chr7:135346802	PL-5283	-0.52	-8.39	-0.38	7.53e-16	Red blood cell traits;
LUAD	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.31	-0.34	1.31e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.51	8.21	0.37	2.76e-15	Total body bone mineral density;
LUAD	trans	rs11088226	0.681	rs8131384	chr21:33944127	C/T	cg09050820	chr6:167586206	TCP10L2	0.93	12.71	0.53	1.39e-31	Gastritis;
LUAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg11494091	chr17:61959527	GH2	0.74	18.33	0.67	1.21e-55	Prudent dietary pattern;
LUAD	trans	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-16.48	-0.63	1.75e-47	Exhaled nitric oxide output;
LUAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg20607798	chr8:58055168	NA	0.7	9.18	0.41	1.86e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6484504	0.600	rs10835763	chr11:31345574	G/A	cg26647111	chr11:31128758	NA	0.44	7.83	0.36	4.05e-14	Red blood cell count;
LUAD	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2839627	0.564	rs7278765	chr21:44279848	A/G	cg03543861	chr21:44258195	NA	0.64	7.59	0.35	2e-13	Information processing speed;
LUAD	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg27489772	chr12:121021490	NA	0.57	6.9	0.32	1.97e-11	Type 1 diabetes nephropathy;
LUAD	cis	rs2742234	0.590	rs2505557	chr10:43666016	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.53	-8.94	-0.4	1.2e-17	Hirschsprung disease;
LUAD	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg12432903	chr7:1882776	MAD1L1	-0.41	-6.67	-0.31	7.87e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg20712883	chr12:51590929	POU6F1	0.75	11.0	0.47	6.42e-25	Cisplatin-induced ototoxicity;
LUAD	cis	rs35306767	0.668	rs35657988	chr10:1103590	A/G	cg10556349	chr10:835070	NA	0.51	6.9	0.32	1.9e-11	Eosinophil percentage of granulocytes;
LUAD	trans	rs1997103	1.000	rs1997098	chr7:55405594	G/T	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.06	0.32	6.7e-12	Platelet count;
LUAD	cis	rs6496044	0.568	rs12899946	chr15:86066082	C/T	cg13263323	chr15:86062960	AKAP13	-0.58	-10.79	-0.46	3.87e-24	Interstitial lung disease;
LUAD	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg18132916	chr6:79620363	NA	-0.44	-7.56	-0.34	2.59e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7173743	0.756	rs8032771	chr15:79126059	A/G	cg00540400	chr15:79124168	NA	0.43	8.89	0.4	1.79e-17	Coronary artery disease;
LUAD	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-7.64	-0.35	1.46e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.74	10.28	0.45	2.79e-22	Smoking behavior;
LUAD	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.39	-0.45	1.15e-22	Monocyte percentage of white cells;
LUAD	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg09796270	chr17:17721594	SREBF1	-0.39	-7.56	-0.35	2.45e-13	Total body bone mineral density;
LUAD	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg23752985	chr2:85803571	VAMP8	0.33	6.54	0.3	1.76e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg23625390	chr15:77176239	SCAPER	0.37	6.46	0.3	2.95e-10	Blood metabolite levels;
LUAD	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg19825600	chr2:3704501	ALLC	-0.57	-9.55	-0.42	1.05e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs75804782	0.521	rs56087929	chr2:239455564	G/A	cg01134436	chr17:81009848	B3GNTL1	0.72	8.06	0.36	8.16e-15	Morning vs. evening chronotype;Chronotype;
LUAD	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21659725	chr3:3221576	CRBN	0.67	11.7	0.49	1.33e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs7590720	1.000	rs934156	chr2:216901482	C/T	cg12620499	chr2:216877984	MREG	-0.54	-8.49	-0.38	3.47e-16	Alcohol dependence;
LUAD	trans	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	26.66	0.79	1.38e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.99	0.47	7.04e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2395909	1	rs2395909	chr7:107292663	G/A	cg23024343	chr7:107201750	COG5	0.56	9.31	0.41	7.25e-19	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg06641503	chr3:48959341	ARIH2	-0.37	-7.22	-0.33	2.37e-12	Parkinson's disease;
LUAD	cis	rs601339	0.878	rs7956284	chr12:123183017	G/A	cg11919336	chr12:123188078	GPR109A	0.47	7.1	0.33	5.42e-12	Adiponectin levels;
LUAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg09033563	chr22:24373618	LOC391322	-0.58	-9.62	-0.42	6.04e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.35	-0.41	4.99e-19	Life satisfaction;
LUAD	cis	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg07460842	chr6:66804631	NA	0.8	9.91	0.43	6.06e-21	Exhaled nitric oxide output;
LUAD	cis	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-7.04	-0.32	7.83e-12	Neuroticism;
LUAD	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg06484146	chr7:12443880	VWDE	-0.53	-6.76	-0.31	4.56e-11	Coronary artery disease;
LUAD	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg25324976	chr17:61989376	CSHL1	0.37	7.35	0.34	1e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10419226	0.555	rs757350	chr19:18774810	G/A	cg22001208	chr19:18782374	NA	-0.47	-7.78	-0.35	5.78e-14	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg07776626	chr8:57350775	NA	-0.6	-9.01	-0.4	7.35e-18	Obesity-related traits;
LUAD	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg00666640	chr1:248458726	OR2T12	0.32	7.66	0.35	1.32e-13	Common traits (Other);
LUAD	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg12310025	chr6:25882481	NA	-0.74	-10.44	-0.45	7.6e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg01802117	chr1:53393560	SCP2	-0.34	-6.73	-0.31	5.63e-11	Monocyte count;
LUAD	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg10589385	chr1:150898437	SETDB1	0.39	7.42	0.34	6.51e-13	Tonsillectomy;
LUAD	cis	rs13126513	0.519	rs7659550	chr4:100554402	G/T	cg05468953	chr4:100565104	NA	0.41	8.28	0.37	1.64e-15	Metabolite levels (MHPG);
LUAD	cis	rs1595825	0.891	rs73058876	chr2:198895022	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-7.05	-0.32	7.36e-12	Ulcerative colitis;
LUAD	cis	rs616402	0.564	rs7419116	chr1:10578606	G/A	cg17425144	chr1:10567563	PEX14	0.61	13.15	0.54	2.47e-33	Breast size;
LUAD	cis	rs7827545	0.960	rs1372661	chr8:135566859	A/G	cg17885191	chr8:135476712	NA	0.5	8.03	0.36	9.54e-15	Hypertension (SNP x SNP interaction);
LUAD	cis	rs7017914	0.934	rs35214141	chr8:71574564	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.52	-0.3	1.98e-10	Bone mineral density;
LUAD	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs57590327	0.503	rs1461611	chr3:81512061	C/A	cg07356753	chr3:81810745	GBE1	0.49	7.65	0.35	1.33e-13	Extraversion;
LUAD	cis	rs684232	0.602	rs4968057	chr17:517521	T/A	cg15660573	chr17:549704	VPS53	-0.87	-17.95	-0.66	5.55e-54	Prostate cancer;
LUAD	cis	rs2637266	0.714	rs1965156	chr10:78450559	G/A	cg18941641	chr10:78392320	NA	0.32	6.63	0.31	1.05e-10	Pulmonary function;
LUAD	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg08027265	chr7:2291960	NA	-0.48	-8.48	-0.38	3.73e-16	Bipolar disorder and schizophrenia;
LUAD	trans	rs1941687	0.510	rs1452649	chr18:31410858	A/G	cg15819921	chr19:927150	ARID3A	-0.42	-6.86	-0.32	2.44e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs16854884	0.586	rs6795008	chr3:143738421	A/G	cg01302019	chr3:143689584	C3orf58	-0.37	-6.65	-0.31	9.18e-11	Economic and political preferences (feminism/equality);
LUAD	cis	rs501916	0.634	rs1561479	chr15:48070157	C/G	cg16110827	chr15:48056943	SEMA6D	-0.35	-6.4	-0.3	4.18e-10	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg00280220	chr17:61926910	NA	0.36	6.91	0.32	1.8e-11	Prudent dietary pattern;
LUAD	cis	rs1003719	0.679	rs1133001	chr21:38512956	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.51	-8.6	-0.39	1.58e-16	Eye color traits;
LUAD	cis	rs3772130	0.962	rs11707504	chr3:121496734	C/T	cg20356878	chr3:121714668	ILDR1	0.51	8.1	0.37	5.81e-15	Cognitive performance;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18654971	chr5:54469363	MIR449C;CDC20B	-0.46	-7.37	-0.34	8.97e-13	Height;
LUAD	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.08	-0.44	1.49e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs7705042	0.897	rs4912807	chr5:141519296	G/C	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.81	-0.31	3.41e-11	Asthma;
LUAD	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg20290983	chr6:43655470	MRPS18A	1.07	26.7	0.79	8.83e-93	IgG glycosylation;
LUAD	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07266350	chr3:49460521	AMT;NICN1	-0.36	-6.49	-0.3	2.46e-10	Menarche (age at onset);
LUAD	cis	rs938554	0.910	rs6837336	chr4:9932510	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.27	-0.33	1.73e-12	Blood metabolite levels;
LUAD	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg22852734	chr6:133119734	C6orf192	-0.7	-8.81	-0.39	3.31e-17	Type 2 diabetes nephropathy;
LUAD	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg22496339	chr2:162101262	NA	0.52	8.41	0.38	6.16e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs4662945	0.603	rs13002385	chr2:130276865	T/C	cg05962382	chr2:130345044	NA	-0.39	-7.3	-0.33	1.46e-12	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg21204522	chr6:27730016	NA	-0.48	-7.59	-0.35	2.13e-13	Parkinson's disease;
LUAD	cis	rs4711336	1.000	rs2296741	chr6:33659557	C/T	cg13859433	chr6:33739653	LEMD2	-0.28	-6.48	-0.3	2.5e-10	Height;
LUAD	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg15691649	chr6:25882328	NA	0.46	7.48	0.34	4.26e-13	Blood metabolite levels;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg07077507	chr14:89290791	TTC8	-0.36	-6.35	-0.3	5.49e-10	Subcortical brain region volumes;
LUAD	cis	rs2554380	0.600	rs6602986	chr15:84447099	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.4	-7.08	-0.33	6.17e-12	Height;
LUAD	cis	rs58749629	1.000	rs3827066	chr20:44586023	C/T	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.54	-6.7	-0.31	6.75e-11	Abdominal aortic aneurysm;
LUAD	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs6906287	0.647	rs3798420	chr6:118786486	T/C	cg21191810	chr6:118973309	C6orf204	0.49	9.66	0.42	4.59e-20	Electrocardiographic conduction measures;
LUAD	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.61e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs68170813	0.559	rs17429118	chr7:106964052	C/T	cg02696742	chr7:106810147	HBP1	-0.77	-10.54	-0.46	3.29e-23	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.27e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg03563238	chr19:33554763	RHPN2	-0.38	-8.86	-0.4	2.3e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1957429	0.808	rs4902325	chr14:65330843	A/G	cg23373153	chr14:65346875	NA	-0.6	-6.6	-0.31	1.26e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs354225	0.584	rs10206143	chr2:54817453	A/T	cg01766943	chr2:54829624	SPTBN1	0.4	7.49	0.34	4.04e-13	Schizophrenia;
LUAD	cis	rs758324	0.898	rs11956351	chr5:131137224	G/A	cg25547332	chr5:131281432	NA	0.44	6.71	0.31	6.38e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs236907	0.859	rs12730717	chr1:171756515	C/T	cg13482142	chr2:234261155	NA	0.5	6.49	0.3	2.43e-10	Mean platelet volume;
LUAD	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21984481	chr17:79567631	NPLOC4	-0.64	-15.17	-0.59	8.38e-42	Eye color traits;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg08197531	chr12:12878211	APOLD1	-0.38	-6.65	-0.31	9.33e-11	Schizophrenia;
LUAD	cis	rs12545109	0.800	rs2609978	chr8:57394467	T/C	cg11919837	chr8:57350735	NA	-0.47	-6.61	-0.31	1.18e-10	Obesity-related traits;
LUAD	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg04287289	chr16:89883240	FANCA	-0.69	-12.45	-0.52	1.52e-30	Vitiligo;
LUAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg20607798	chr8:58055168	NA	0.58	7.41	0.34	6.76e-13	Developmental language disorder (linguistic errors);
LUAD	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg03929089	chr4:120376271	NA	-0.51	-6.7	-0.31	6.86e-11	Axial length;
LUAD	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	7.55	0.34	2.68e-13	Tonsillectomy;
LUAD	cis	rs113835537	0.935	rs76228630	chr11:66458676	T/C	cg24851651	chr11:66362959	CCS	0.6	8.09	0.37	6.39e-15	Airway imaging phenotypes;
LUAD	cis	rs2839627	0.561	rs8126478	chr21:44318668	C/A	cg03543861	chr21:44258195	NA	0.63	8.72	0.39	6.32e-17	Information processing speed;
LUAD	cis	rs11630290	1.000	rs72750990	chr15:64005333	C/T	cg12036633	chr15:63758958	NA	-0.51	-6.86	-0.32	2.47e-11	Iris characteristics;
LUAD	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10802521	chr3:52805072	NEK4	-0.62	-11.22	-0.48	9.81e-26	Electroencephalogram traits;
LUAD	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg24531977	chr5:56204891	C5orf35	-0.48	-7.83	-0.36	4.07e-14	Coronary artery disease;
LUAD	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg07936489	chr17:37558343	FBXL20	-0.56	-7.46	-0.34	5.1e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.3	-0.45	2.43e-22	Total body bone mineral density;
LUAD	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg12179176	chr11:130786555	SNX19	0.48	7.92	0.36	2.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23583168	chr7:148888333	NA	-0.8	-13.82	-0.56	3.96e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs62400317	0.614	rs12210292	chr6:44925293	A/G	cg18551225	chr6:44695536	NA	-0.52	-7.38	-0.34	8.26e-13	Total body bone mineral density;
LUAD	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg03037974	chr15:76606532	NA	0.38	8.13	0.37	4.68e-15	Blood metabolite levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg23001456	chr17:2615074	KIAA0664	-0.65	-7.12	-0.33	4.79e-12	Type 2 diabetes;
LUAD	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	9.17	0.41	2.15e-18	Tonsillectomy;
LUAD	cis	rs864537	0.618	rs1214595	chr1:167427557	G/A	cg22356347	chr1:167427500	CD247	-0.5	-9.99	-0.44	3.05e-21	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg10518543	chr12:38710700	ALG10B	-0.4	-6.62	-0.31	1.11e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg06740227	chr12:86229804	RASSF9	0.38	6.87	0.32	2.37e-11	Major depressive disorder;
LUAD	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11644478	chr21:40555479	PSMG1	0.61	10.33	0.45	1.88e-22	Cognitive function;
LUAD	cis	rs11249608	0.636	rs13361077	chr5:178449174	G/C	cg01312482	chr5:178451176	ZNF879	-0.45	-6.98	-0.32	1.14e-11	Pubertal anthropometrics;
LUAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08280861	chr8:58055591	NA	0.77	9.51	0.42	1.4e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	12.95	0.53	1.47e-32	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs684232	0.602	rs401592	chr17:551316	T/C	cg12384639	chr17:618140	VPS53	0.48	8.26	0.37	1.85e-15	Prostate cancer;
LUAD	cis	rs877282	0.853	rs7092805	chr10:756246	G/A	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg04539111	chr16:67997858	SLC12A4	-0.51	-6.42	-0.3	3.75e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg27454412	chr7:1067447	C7orf50	0.48	7.71	0.35	8.96e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2992756	0.663	rs2992764	chr1:18804144	A/G	cg24076588	chr1:18808559	KLHDC7A	0.45	7.69	0.35	1.03e-13	Breast cancer;
LUAD	trans	rs10248839	0.518	rs1317741	chr7:29711149	T/C	cg27349345	chr7:35225932	NA	-0.46	-6.56	-0.3	1.58e-10	Facial emotion recognition (angry faces);
LUAD	cis	rs7481584	0.926	rs10833024	chr11:3010390	C/T	cg11201177	chr11:2961805	NA	0.38	6.47	0.3	2.71e-10	Calcium levels;
LUAD	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.48	6.52	0.3	2.03e-10	Platelet count;
LUAD	cis	rs55788414	1.000	rs7499792	chr16:81184318	C/T	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.91	-0.36	2.31e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg04218760	chr10:45406644	TMEM72	-0.31	-7.65	-0.35	1.42e-13	Mean corpuscular volume;
LUAD	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.98	-0.4	8.9e-18	Total body bone mineral density;
LUAD	cis	rs4713675	0.584	rs2966	chr6:33689520	C/T	cg14003231	chr6:33640908	ITPR3	0.48	9.41	0.42	3.26e-19	Plateletcrit;
LUAD	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6906287	0.609	rs11153759	chr6:118920860	T/A	cg18833306	chr6:118973337	C6orf204	0.48	8.36	0.38	9e-16	Electrocardiographic conduction measures;
LUAD	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg07757535	chr4:1339547	NA	0.31	6.9	0.32	1.91e-11	Longevity;
LUAD	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg04450456	chr4:17643702	FAM184B	0.39	7.72	0.35	8.31e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11771526	0.551	rs1008652	chr7:32254403	A/G	cg27532318	chr7:32358331	NA	-0.46	-6.67	-0.31	7.79e-11	Body mass index;
LUAD	cis	rs7833986	1.000	rs34480844	chr8:57092973	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.65	8.99	0.4	8.17e-18	Height;
LUAD	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg06784218	chr1:46089804	CCDC17	0.57	12.98	0.53	1.21e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7561273	0.561	rs35268318	chr2:24352824	A/T	cg20701182	chr2:24300061	SF3B14	0.47	7.59	0.35	2.11e-13	Quantitative traits;
LUAD	cis	rs72928364	0.929	rs35850913	chr3:100775080	T/A	cg10123952	chr3:100791384	NA	0.72	7.92	0.36	2.15e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg19678392	chr7:94953810	PON1	-0.55	-7.3	-0.33	1.4e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs11229555	0.834	rs7925560	chr11:58263036	G/A	cg15696309	chr11:58395628	NA	-0.75	-10.6	-0.46	1.97e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs10838798	0.517	rs1967210	chr11:48096692	G/T	cg15704280	chr7:45808275	SEPT13	-0.68	-8.56	-0.38	2.13e-16	Height;
LUAD	cis	rs1018836	0.818	rs2285232	chr8:91546162	C/G	cg16814680	chr8:91681699	NA	-0.61	-10.48	-0.45	5.28e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6738485	0.895	rs13030981	chr2:106816021	A/C	cg16099169	chr2:106886729	NA	-0.4	-6.62	-0.31	1.11e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg10755058	chr3:40428713	ENTPD3	0.45	8.72	0.39	6.19e-17	Renal cell carcinoma;
LUAD	cis	rs500891	0.525	rs6454320	chr6:84050814	C/T	cg08257003	chr6:84140564	ME1	0.34	6.68	0.31	7.45e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs7630877	0.962	rs4146789	chr3:179656495	C/T	cg18765712	chr3:179670323	PEX5L	0.37	6.98	0.32	1.16e-11	Type 2 diabetes;
LUAD	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg07021052	chr2:20871279	NA	-0.46	-8.3	-0.37	1.4e-15	Abdominal aortic aneurysm;
LUAD	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg00634984	chr7:65235879	NA	0.49	6.54	0.3	1.75e-10	Aortic root size;
LUAD	cis	rs62064224	0.614	rs6505294	chr17:30687415	C/T	cg25809561	chr17:30822961	MYO1D	0.48	8.36	0.38	9.36e-16	Schizophrenia;
LUAD	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg00383909	chr3:49044727	WDR6	0.99	10.63	0.46	1.45e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg18898632	chr2:242989856	NA	-0.51	-6.36	-0.3	5.15e-10	Obesity-related traits;
LUAD	cis	rs56159542	1	rs56159542	chr19:19682971	T/C	cg11584989	chr19:19387371	SF4	-0.52	-7.95	-0.36	1.73e-14	Attention deficit hyperactivity disorder symptom score;
LUAD	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.11	0.33	5.06e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11893307	0.509	rs12611764	chr2:191537143	T/C	cg11845111	chr2:191398756	TMEM194B	-0.47	-6.76	-0.31	4.48e-11	Mean platelet volume;
LUAD	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	9.08	0.4	4.18e-18	Menarche (age at onset);
LUAD	trans	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.36	-0.3	5.18e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg07741184	chr6:167504864	NA	0.29	6.73	0.31	5.69e-11	Crohn's disease;
LUAD	cis	rs68170813	0.559	rs11769861	chr7:106979559	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-10.47	-0.45	5.75e-23	Coronary artery disease;
LUAD	cis	rs9811920	0.695	rs1287284	chr3:99516962	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	6.52	0.3	2.06e-10	Axial length;
LUAD	trans	rs2018683	0.739	rs10233884	chr7:28972307	A/G	cg19402173	chr7:128379420	CALU	-0.52	-8.37	-0.38	8.4e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.16	0.33	3.67e-12	Prostate cancer;
LUAD	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg23803603	chr1:2058230	PRKCZ	-0.41	-7.4	-0.34	7.65e-13	Height;
LUAD	cis	rs7000551	0.725	rs4871998	chr8:22308150	A/T	cg12081754	chr8:22256438	SLC39A14	0.53	9.24	0.41	1.23e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs6906287	0.647	rs10457330	chr6:118731468	A/T	cg18833306	chr6:118973337	C6orf204	0.45	8.08	0.37	6.9e-15	Electrocardiographic conduction measures;
LUAD	cis	rs35740288	0.770	rs11638379	chr15:86111290	G/T	cg13263323	chr15:86062960	AKAP13	-0.44	-7.01	-0.32	9.43e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg15128208	chr22:42549153	NA	0.36	7.04	0.32	8.02e-12	Cognitive function;
LUAD	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg15962314	chr1:44399869	ARTN	0.32	7.14	0.33	4.12e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg24531977	chr5:56204891	C5orf35	-0.64	-10.6	-0.46	1.89e-23	Coronary artery disease;
LUAD	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg03388025	chr16:89894329	SPIRE2	0.35	8.42	0.38	5.94e-16	Vitiligo;
LUAD	cis	rs7520050	0.966	rs785479	chr1:46492144	C/T	cg06784218	chr1:46089804	CCDC17	-0.3	-6.4	-0.3	4.19e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg10518543	chr12:38710700	ALG10B	-0.51	-8.31	-0.37	1.35e-15	Morning vs. evening chronotype;
LUAD	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg22868518	chr11:507468	RNH1	-0.68	-6.75	-0.31	4.82e-11	Body mass index;
LUAD	cis	rs6499255	0.951	rs8054096	chr16:69695886	G/A	cg15192750	chr16:69999425	NA	0.49	7.7	0.35	9.68e-14	IgE levels;
LUAD	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg00666640	chr1:248458726	OR2T12	0.34	8.1	0.37	6e-15	Common traits (Other);
LUAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg05313129	chr8:58192883	C8orf71	-0.54	-6.73	-0.31	5.66e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg17173187	chr15:85201210	NMB	0.52	9.28	0.41	9.1e-19	Schizophrenia;
LUAD	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.74	0.43	2.28e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1595825	0.838	rs6742343	chr2:198666752	C/T	cg11031976	chr2:198649780	BOLL	-0.49	-6.89	-0.32	2.05e-11	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg14343924	chr8:8086146	FLJ10661	0.42	6.58	0.3	1.42e-10	Joint mobility (Beighton score);
LUAD	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg08470875	chr2:26401718	FAM59B	-0.64	-8.68	-0.39	8.69e-17	Gut microbiome composition (summer);
LUAD	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02018176	chr4:1364513	KIAA1530	0.68	11.7	0.49	1.41e-27	Longevity;
LUAD	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg21475434	chr5:93447410	FAM172A	0.78	8.63	0.39	1.23e-16	Diabetic retinopathy;
LUAD	trans	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.94	-0.32	1.46e-11	Mood instability;
LUAD	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg11189052	chr15:85197271	WDR73	0.62	7.86	0.36	3.11e-14	Schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08647641	chr7:91763896	CYP51A1	-0.56	-6.71	-0.31	6.45e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.64	-0.39	1.15e-16	Alzheimer's disease (late onset);
LUAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.8	-0.31	3.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg03714773	chr7:91764589	CYP51A1	0.29	6.84	0.32	2.84e-11	Breast cancer;
LUAD	cis	rs679087	1.000	rs302321	chr12:29928388	A/C	cg14258853	chr12:29935411	TMTC1	0.58	10.3	0.45	2.48e-22	Schizophrenia;
LUAD	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg01528321	chr10:82214614	TSPAN14	0.52	8.17	0.37	3.48e-15	Post bronchodilator FEV1;
LUAD	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg03467027	chr4:99064603	C4orf37	0.39	6.37	0.3	5.05e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.27	6.53	0.3	1.87e-10	Parkinson's disease;
LUAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.59	8.2	0.37	2.96e-15	Renal function-related traits (BUN);
LUAD	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-12.03	-0.5	7.27e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs208520	0.779	rs208451	chr6:66906155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-14.08	-0.56	3.33e-37	Exhaled nitric oxide output;
LUAD	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg09085632	chr11:111637200	PPP2R1B	0.64	9.91	0.43	5.93e-21	Primary sclerosing cholangitis;
LUAD	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg14458575	chr2:238380390	NA	0.71	12.85	0.53	3.88e-32	Prostate cancer;
LUAD	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg25985355	chr7:65971099	NA	0.54	6.74	0.31	5.2e-11	Diabetic kidney disease;
LUAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg22764044	chr5:178986830	RUFY1	0.56	8.91	0.4	1.48e-17	Lung cancer;
LUAD	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg17509989	chr5:176798049	RGS14	-0.61	-9.59	-0.42	7.53e-20	Urate levels in lean individuals;
LUAD	cis	rs6479527	0.625	rs1933667	chr9:96744109	G/C	cg14459158	chr9:96720562	NA	0.48	8.47	0.38	4.17e-16	Esophageal adenocarcinoma;
LUAD	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg00339695	chr16:24857497	SLC5A11	0.71	11.4	0.48	2.04e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg08859206	chr1:53392774	SCP2	-0.65	-12.2	-0.51	1.56e-29	Monocyte count;
LUAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg14893161	chr1:205819251	PM20D1	0.52	8.17	0.37	3.66e-15	Parkinson's disease;
LUAD	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg12062639	chr20:23401060	NAPB	1.08	10.86	0.47	2.14e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10392	0.543	rs3752292	chr20:37570475	G/A	cg27552599	chr20:37590471	DHX35	0.4	6.89	0.32	1.97e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs3018712	0.532	rs2510396	chr11:68417652	G/C	cg16797656	chr11:68205561	LRP5	-0.42	-6.39	-0.3	4.31e-10	Total body bone mineral density;
LUAD	cis	rs6960043	0.782	rs10228456	chr7:15063926	C/T	cg19272540	chr7:15055459	NA	-0.36	-7.78	-0.35	5.57e-14	Type 2 diabetes;
LUAD	trans	rs8002861	0.664	rs9533686	chr13:44468494	A/G	cg12856521	chr11:46389249	DGKZ	0.46	7.81	0.36	4.41e-14	Leprosy;
LUAD	cis	rs57143961	1	rs57143961	chr19:16533225	C/CT	cg05286348	chr19:16641544	CHERP	-0.55	-6.85	-0.32	2.56e-11	Lymphocyte percentage of white cells;
LUAD	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg04455712	chr21:45112962	RRP1B	0.52	10.85	0.47	2.27e-24	Mean corpuscular volume;
LUAD	cis	rs1032833	0.732	rs17454024	chr2:179972833	C/G	cg23883738	chr2:179974586	SESTD1	-0.72	-8.3	-0.37	1.39e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs9972944	0.756	rs7207587	chr17:63766307	C/T	cg07283582	chr17:63770753	CCDC46	-0.5	-11.18	-0.48	1.28e-25	Total body bone mineral density;
LUAD	cis	rs6496044	0.568	rs3743321	chr15:86064968	A/G	cg13263323	chr15:86062960	AKAP13	-0.59	-11.11	-0.48	2.51e-25	Interstitial lung disease;
LUAD	cis	rs6076065	0.692	rs6083111	chr20:23374667	A/G	cg11657817	chr20:23433608	CST11	0.46	8.72	0.39	6.57e-17	Facial morphology (factor 15, philtrum width);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07454192	chr8:74888262	TMEM70	-0.4	-6.43	-0.3	3.47e-10	Height;
LUAD	cis	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg07460842	chr6:66804631	NA	-1.2	-30.41	-0.83	1.72e-108	Exhaled nitric oxide output;
LUAD	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.92	0.32	1.67e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs77106637	0.722	rs11605691	chr11:72419514	C/T	cg03713592	chr11:72463424	ARAP1	0.94	11.32	0.48	3.89e-26	Type 2 diabetes;
LUAD	trans	rs1493916	1.000	rs1493916	chr18:31392577	T/G	cg13755796	chr4:20253514	NA	-0.41	-6.89	-0.32	2.07e-11	Life satisfaction;
LUAD	cis	rs6005807	0.640	rs2013784	chr22:28923933	C/T	cg12565055	chr22:29076175	TTC28	-0.72	-8.42	-0.38	6e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs28595532	1.000	rs73842212	chr4:119638122	A/G	cg21605333	chr4:119757512	SEC24D	0.82	7.55	0.34	2.67e-13	Cannabis dependence symptom count;
LUAD	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg22676075	chr6:135203613	NA	0.57	10.21	0.44	4.84e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg04455712	chr21:45112962	RRP1B	0.5	10.63	0.46	1.56e-23	Mean corpuscular volume;
LUAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg13047869	chr3:10149882	C3orf24	0.65	10.93	0.47	1.17e-24	Alzheimer's disease;
LUAD	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.75	-15.71	-0.61	3.87e-44	Lung cancer;
LUAD	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg07936489	chr17:37558343	FBXL20	-0.51	-6.73	-0.31	5.6e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg08508325	chr11:3079039	CARS	0.43	8.83	0.39	2.73e-17	Calcium levels;
LUAD	cis	rs1949733	0.554	rs4259044	chr4:8536188	A/G	cg13073564	chr4:8508604	NA	0.4	6.97	0.32	1.21e-11	Response to antineoplastic agents;
LUAD	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg18252515	chr7:66147081	NA	-0.63	-6.94	-0.32	1.5e-11	Gout;
LUAD	trans	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg26043149	chr18:55253948	FECH	-0.41	-6.78	-0.31	4.14e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1127311	0.846	rs61811388	chr1:154581231	G/C	cg17218026	chr1:154582156	ADAR	0.5	9.67	0.43	4.01e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs1113500	0.897	rs2336127	chr1:108640870	G/A	cg06207961	chr1:108661230	NA	0.44	8.29	0.37	1.57e-15	Growth-regulated protein alpha levels;
LUAD	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg17105886	chr17:28927953	LRRC37B2	0.83	8.0	0.36	1.18e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg07606381	chr6:8435919	SLC35B3	0.41	6.68	0.31	7.42e-11	Motion sickness;
LUAD	cis	rs9487051	0.698	rs35849756	chr6:109644610	G/A	cg21918786	chr6:109611834	NA	-0.45	-6.86	-0.32	2.43e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg14343924	chr8:8086146	FLJ10661	0.45	7.1	0.33	5.43e-12	Mood instability;
LUAD	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg04287289	chr16:89883240	FANCA	0.73	13.35	0.54	3.54e-34	Vitiligo;
LUAD	cis	rs7147624	1.000	rs10083363	chr14:66200768	G/A	cg03016385	chr14:66212404	NA	-0.58	-6.96	-0.32	1.31e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg01528321	chr10:82214614	TSPAN14	0.59	9.2	0.41	1.68e-18	Post bronchodilator FEV1;
LUAD	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg16479474	chr6:28041457	NA	0.48	8.18	0.37	3.31e-15	Depression;
LUAD	cis	rs12900413	0.603	rs2351493	chr15:90299536	A/G	cg24249390	chr15:90295951	MESP1	-0.35	-7.02	-0.32	8.96e-12	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg06873352	chr17:61820015	STRADA	0.42	7.11	0.33	5.1e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg05283184	chr6:79620031	NA	-0.6	-12.13	-0.51	2.8e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs4268898	0.932	rs7577964	chr2:24598279	A/G	cg06627628	chr2:24431161	ITSN2	0.42	7.14	0.33	4.12e-12	Asthma;
LUAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg03354898	chr7:1950403	MAD1L1	-0.39	-7.09	-0.33	5.54e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs12517041	1.000	rs6889624	chr5:23304501	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.57	-0.3	1.47e-10	Calcium levels;
LUAD	cis	rs3736594	0.513	rs62131882	chr2:27765480	T/C	cg27432699	chr2:27873401	GPN1	0.47	6.42	0.3	3.74e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.46	-7.28	-0.33	1.62e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	-0.45	-7.32	-0.34	1.24e-12	Resistin levels;
LUAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00149659	chr3:10157352	C3orf10	0.64	9.0	0.4	7.43e-18	Alzheimer's disease;
LUAD	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg04218760	chr10:45406644	TMEM72	-0.31	-7.56	-0.35	2.51e-13	Mean corpuscular volume;
LUAD	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg26597838	chr10:835615	NA	0.84	11.58	0.49	3.93e-27	Eosinophil percentage of granulocytes;
LUAD	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg05590025	chr7:65112418	INTS4L2	-0.69	-8.09	-0.37	6.24e-15	Diabetic kidney disease;
LUAD	cis	rs798766	1.000	rs2166580	chr4:1743169	G/A	cg05874882	chr4:1763078	NA	-0.38	-6.7	-0.31	6.48e-11	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs6496044	0.568	rs1982743	chr15:86068759	A/T	cg13263323	chr15:86062960	AKAP13	-0.57	-10.75	-0.46	5.52e-24	Interstitial lung disease;
LUAD	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg12458913	chr13:53173898	NA	0.42	7.53	0.34	3.1400000000000003e-13	Lewy body disease;
LUAD	cis	rs1451375	1.000	rs10250513	chr7:50621488	T/G	cg18232548	chr7:50535776	DDC	0.58	9.5	0.42	1.6e-19	Malaria;
LUAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.68	-0.35	1.15e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg11189052	chr15:85197271	WDR73	-0.61	-7.65	-0.35	1.39e-13	Schizophrenia;
LUAD	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg00316803	chr15:76480434	C15orf27	0.4	6.48	0.3	2.58e-10	Blood metabolite levels;
LUAD	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg21545522	chr1:205238299	TMCC2	0.37	6.8	0.31	3.59e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs12410462	1.000	rs1587158	chr1:227658753	G/A	cg23173402	chr1:227635558	NA	-0.64	-7.64	-0.35	1.49e-13	Major depressive disorder;
LUAD	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg26587870	chr6:27730563	NA	-0.38	-6.81	-0.31	3.38e-11	Hepatitis A;
LUAD	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg05535760	chr7:792225	HEATR2	0.86	11.25	0.48	6.98e-26	Cerebrospinal P-tau181p levels;
LUAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-7.04	-0.32	7.62e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg15181151	chr6:150070149	PCMT1	0.43	8.71	0.39	6.74e-17	Lung cancer;
LUAD	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg24818145	chr4:99064322	C4orf37	0.46	7.85	0.36	3.34e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg17971929	chr21:40555470	PSMG1	0.51	7.99	0.36	1.31e-14	Cognitive function;
LUAD	cis	rs8078723	0.510	rs3087852	chr17:38137364	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.47	9.14	0.41	2.64e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs62238980	0.614	rs17744899	chr22:32406766	G/C	cg00543991	chr22:32367038	NA	0.96	9.05	0.4	5.32e-18	Childhood ear infection;
LUAD	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.35	7.44	0.34	5.72e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg24147428	chr11:65409760	SIPA1	-0.55	-8.82	-0.39	3.13e-17	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg03806693	chr22:41940476	POLR3H	-0.49	-7.23	-0.33	2.35e-12	Vitiligo;
LUAD	trans	rs1941687	0.509	rs6507060	chr18:31322278	C/T	cg15819921	chr19:927150	ARID3A	0.44	7.29	0.33	1.5e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg21798802	chr22:38057573	PDXP	0.49	9.84	0.43	1.05e-20	Fat distribution (HIV);
LUAD	cis	rs2979489	0.891	rs2979508	chr8:30388444	C/T	cg26383811	chr8:30366931	RBPMS	-0.69	-10.69	-0.46	9.38e-24	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg18721089	chr20:30220636	NA	-0.45	-6.47	-0.3	2.74e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUAD	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg09455208	chr3:40491958	NA	-0.47	-9.94	-0.44	4.58e-21	Renal cell carcinoma;
LUAD	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg05616858	chr17:37843591	ERBB2;PGAP3	0.32	6.56	0.3	1.6e-10	Asthma;
LUAD	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg05768032	chr16:30646687	NA	0.44	7.84	0.36	3.63e-14	Multiple myeloma;
LUAD	cis	rs1215050	0.765	rs588851	chr4:98678247	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.94	0.36	1.86e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg06636001	chr8:8085503	FLJ10661	0.42	6.36	0.3	5.23e-10	Mean corpuscular volume;
LUAD	cis	rs11696501	0.739	rs6073784	chr20:44201931	T/A	cg11783356	chr20:44313418	WFDC10B	-0.46	-7.27	-0.33	1.8e-12	Brain structure;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg25346576	chr17:28443852	CCDC55;MIR423	-0.48	-6.76	-0.31	4.55e-11	Testicular germ cell tumor;
LUAD	cis	rs300774	0.858	rs300736	chr2:168466	C/G	cg21211680	chr2:198530	NA	-0.49	-7.83	-0.36	4.07e-14	Suicide attempts in bipolar disorder;
LUAD	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg05872129	chr22:39784769	NA	-0.84	-16.37	-0.62	5.13e-47	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs751837	0.591	rs10138133	chr14:103424897	A/G	cg10087771	chr14:103399429	CDC42BPB	0.64	7.54	0.34	2.87e-13	Large B-cell lymphoma;
LUAD	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg00852783	chr1:26633632	UBXN11	0.42	7.46	0.34	5.04e-13	Obesity-related traits;
LUAD	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg16479474	chr6:28041457	NA	0.37	6.97	0.32	1.25e-11	Parkinson's disease;
LUAD	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-12.01	-0.5	8.63e-29	Bipolar disorder;
LUAD	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg17845761	chr1:175162550	KIAA0040	0.37	9.78	0.43	1.7e-20	Alcohol dependence;
LUAD	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg20991723	chr1:152506922	NA	0.34	6.66	0.31	8.77e-11	Hair morphology;
LUAD	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg27432699	chr2:27873401	GPN1	-0.4	-6.84	-0.32	2.76e-11	Menopause (age at onset);
LUAD	trans	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg09872104	chr7:134855509	C7orf49	0.72	6.52	0.3	1.97e-10	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs73416724	1.000	rs111408004	chr6:43326139	T/A	cg26312998	chr6:43337775	ZNF318	0.55	6.69	0.31	7.26e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10489202	0.632	rs12401555	chr1:168069473	G/C	cg24449463	chr1:168025552	DCAF6	-0.62	-9.28	-0.41	9.2e-19	Schizophrenia;
LUAD	trans	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg26043149	chr18:55253948	FECH	0.46	7.36	0.34	9.42e-13	Bone mineral density;
LUAD	trans	rs6499188	0.571	rs1645975	chr16:68564448	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.78	0.43	1.69e-20	Ulcerative colitis;
LUAD	trans	rs7395662	0.963	rs4882094	chr11:48532460	T/C	cg15704280	chr7:45808275	SEPT13	-0.41	-6.41	-0.3	3.84e-10	HDL cholesterol;
LUAD	cis	rs9868809	0.881	rs13324142	chr3:48669447	C/T	cg00383909	chr3:49044727	WDR6	0.63	7.03	0.32	8.51e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg07952391	chr2:88470173	THNSL2	-0.43	-7.01	-0.32	9.31e-12	Response to metformin (IC50);
LUAD	trans	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg26043149	chr18:55253948	FECH	0.43	7.03	0.32	8.56e-12	Bone mineral density;
LUAD	cis	rs1692580	0.777	rs12136830	chr1:2189196	A/T	cg24578937	chr1:2090814	PRKCZ	0.54	10.58	0.46	2.37e-23	Coronary artery disease;
LUAD	cis	rs6906287	0.573	rs12198461	chr6:118880640	T/G	cg21191810	chr6:118973309	C6orf204	0.52	10.12	0.44	1.09e-21	Electrocardiographic conduction measures;
LUAD	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22857025	chr5:266934	NA	-0.99	-14.78	-0.58	3.85e-40	Breast cancer;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg10065162	chr1:27018897	NA	-0.46	-6.57	-0.3	1.5e-10	Blood protein levels;
LUAD	cis	rs1018836	0.923	rs7840846	chr8:91565501	T/A	cg16814680	chr8:91681699	NA	-0.71	-12.25	-0.51	9.82e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg24818145	chr4:99064322	C4orf37	0.49	8.07	0.37	7.57e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg08132940	chr7:1081526	C7orf50	-0.78	-10.58	-0.46	2.29e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg02423579	chr7:2872169	GNA12	-0.58	-9.71	-0.43	2.85e-20	Height;
LUAD	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg14829155	chr15:31115871	NA	-0.65	-10.13	-0.44	1.01e-21	Huntington's disease progression;
LUAD	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.42e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13315871	0.929	rs77178267	chr3:58320657	T/G	cg12435725	chr3:58293450	RPP14	-0.73	-7.68	-0.35	1.11e-13	Cholesterol, total;
LUAD	cis	rs9473147	0.543	rs9369716	chr6:47552180	A/T	cg20196966	chr6:47445060	CD2AP	0.43	6.61	0.31	1.13e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13126279	chr21:47581558	C21orf56	0.54	9.09	0.4	3.93e-18	Testicular germ cell tumor;
LUAD	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg12179176	chr11:130786555	SNX19	0.44	7.11	0.33	5.01e-12	Schizophrenia;
LUAD	cis	rs6087990	0.835	rs4911106	chr20:31331330	A/G	cg13636640	chr20:31349939	DNMT3B	0.78	14.26	0.57	5.69e-38	Ulcerative colitis;
LUAD	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg23758822	chr17:41437982	NA	1.01	20.98	0.71	1.71e-67	Menopause (age at onset);
LUAD	trans	rs8073060	0.586	rs7214250	chr17:33981704	C/G	cg19694781	chr19:47549865	TMEM160	-1.23	-19.31	-0.68	4.77e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs1595825	0.891	rs1030796	chr2:198674673	A/G	cg00361562	chr2:198649771	BOLL	-0.48	-6.68	-0.31	7.67e-11	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg18180107	chr4:99064573	C4orf37	0.42	6.77	0.31	4.28e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18402987	chr7:1209562	NA	0.48	8.51	0.38	3.05e-16	Longevity;Endometriosis;
LUAD	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg12698349	chr2:225449008	CUL3	0.62	9.02	0.4	6.81e-18	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg05132306	chr1:1846340	CALML6	-0.35	-7.51	-0.34	3.51e-13	Body mass index;
LUAD	trans	rs3733589	0.744	rs13122112	chr4:10021404	C/T	cg12980692	chr19:51142613	SYT3	-0.57	-6.35	-0.3	5.54e-10	Renal overload gout;
LUAD	cis	rs6494488	0.500	rs72741379	chr15:64804763	T/C	cg08069370	chr15:64387884	SNX1	-0.75	-6.73	-0.31	5.69e-11	Coronary artery disease;
LUAD	cis	rs6076065	0.748	rs6076055	chr20:23333917	G/C	cg11657817	chr20:23433608	CST11	0.59	12.13	0.51	3.02e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg22482690	chr17:47019901	SNF8	0.44	8.37	0.38	8.71e-16	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.12	0.33	4.56e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg16479474	chr6:28041457	NA	0.34	6.46	0.3	2.88e-10	Parkinson's disease;
LUAD	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg14552801	chr7:65878734	NA	-0.38	-6.37	-0.3	4.96e-10	Aortic root size;
LUAD	cis	rs3849570	0.925	rs9841087	chr3:81907949	A/G	cg07356753	chr3:81810745	GBE1	-0.61	-10.74	-0.46	5.87e-24	Waist circumference;Body mass index;
LUAD	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg05044414	chr3:183734942	ABCC5	0.48	10.07	0.44	1.64e-21	Anterior chamber depth;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg08843538	chr2:210288784	MAP2	-0.42	-7.31	-0.33	1.31e-12	Schizophrenia;
LUAD	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg04455712	chr21:45112962	RRP1B	0.51	10.36	0.45	1.47e-22	Mean corpuscular volume;
LUAD	cis	rs7818345	0.967	rs12679712	chr8:19271032	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.78	0.31	3.95e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg22532475	chr10:104410764	TRIM8	-0.45	-8.83	-0.39	2.7e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	7.4	0.34	7.24e-13	Cognitive test performance;
LUAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg27454412	chr7:1067447	C7orf50	0.48	7.74	0.35	7.28e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8060686	0.516	rs2290699	chr16:68289059	C/T	cg26727032	chr16:67993705	SLC12A4	-0.48	-7.86	-0.36	3.31e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg20701182	chr2:24300061	SF3B14	0.52	6.39	0.3	4.48e-10	Lymphocyte counts;
LUAD	cis	rs367943	0.698	rs2115206	chr5:112999058	A/T	cg12552261	chr5:112820674	MCC	0.45	8.21	0.37	2.63e-15	Type 2 diabetes;
LUAD	cis	rs12765878	1.000	rs35223321	chr10:105646395	C/T	cg11005552	chr10:105648138	OBFC1	0.44	8.25	0.37	2.04e-15	Coronary artery disease;
LUAD	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.87	-0.5	3.07e-28	Mean corpuscular volume;
LUAD	cis	rs7561528	0.501	rs11685593	chr2:127888121	C/T	cg08168897	chr2:127865431	BIN1	-0.43	-6.47	-0.3	2.78e-10	Alzheimer's disease;Alzheimer's disease (late onset);
LUAD	cis	rs7213347	0.707	rs216182	chr17:2173063	A/G	cg02569219	chr17:2266849	SGSM2	0.45	7.09	0.33	5.63e-12	Total body bone mineral density;
LUAD	trans	rs149866169	1	rs149866169	chr6:27441723	T/A	cg01620082	chr3:125678407	NA	-0.76	-8.17	-0.37	3.61e-15	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg06937882	chr20:24974362	C20orf3	-0.35	-6.82	-0.31	3.11e-11	Blood protein levels;
LUAD	cis	rs9811920	0.555	rs68092024	chr3:99691522	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-10.6	-0.46	1.96e-23	Axial length;
LUAD	cis	rs78487399	0.519	rs11124929	chr2:43582103	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-8.08	-0.37	7.06e-15	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg19875535	chr5:140030758	IK	-0.4	-6.7	-0.31	6.72e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7705042	0.865	rs4912804	chr5:141493614	T/C	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.63	-0.31	1.01e-10	Asthma;
LUAD	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	9.82	0.43	1.2e-20	Lung cancer in ever smokers;
LUAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08219700	chr8:58056026	NA	0.67	8.51	0.38	3.09e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg06108461	chr20:60628389	TAF4	-0.96	-17.2	-0.64	1.13e-50	Body mass index;
LUAD	cis	rs4713118	0.581	rs200504	chr6:27785820	T/C	cg20933634	chr6:27740509	NA	0.5	7.48	0.34	4.29e-13	Parkinson's disease;
LUAD	cis	rs2294693	0.945	rs9369260	chr6:41010368	C/G	cg14769373	chr6:40998127	UNC5CL	0.5	7.58	0.35	2.21e-13	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg18306943	chr3:40428807	ENTPD3	0.42	7.02	0.32	9.01e-12	Renal cell carcinoma;
LUAD	cis	rs9902453	0.933	rs9898353	chr17:28451865	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.72	0.39	6.41e-17	Coffee consumption (cups per day);
LUAD	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg22508957	chr16:3507546	NAT15	0.76	13.32	0.54	4.68e-34	Tuberculosis;
LUAD	cis	rs4730250	0.655	rs4727671	chr7:106876045	A/G	cg23024343	chr7:107201750	COG5	0.5	7.42	0.34	6.37e-13	Osteoarthritis;
LUAD	cis	rs72928364	1.000	rs13079002	chr3:100630141	C/T	cg10123952	chr3:100791384	NA	0.59	7.1	0.33	5.18e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg04546413	chr19:29218101	NA	0.71	10.51	0.45	4.18e-23	Methadone dose in opioid dependence;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26566046	chr12:80083628	PAWR	-0.57	-6.93	-0.32	1.61e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg19894588	chr14:64061835	NA	0.53	8.2	0.37	2.89e-15	Glioblastoma;Glioma;
LUAD	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.62	0.35	1.65e-13	Breast cancer;
LUAD	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.53	-0.3	1.87e-10	Total body bone mineral density;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06589161	chr5:180618230	NA	-0.44	-6.81	-0.31	3.38e-11	Height;
LUAD	trans	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.67	-11.21	-0.48	9.93e-26	Mean corpuscular volume;
LUAD	cis	rs2742417	1.000	rs2673058	chr3:45735618	A/C	cg10512202	chr3:45649293	LIMD1	0.37	6.59	0.31	1.3100000000000001e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg07952391	chr2:88470173	THNSL2	0.78	8.13	0.37	4.94e-15	Plasma clusterin levels;
LUAD	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.43	-8.5	-0.38	3.17e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7786808	0.579	rs55701656	chr7:158188812	G/A	cg09998033	chr7:158218633	PTPRN2	-0.44	-7.63	-0.35	1.61e-13	Obesity-related traits;
LUAD	cis	rs9902453	0.900	rs9910970	chr17:28478329	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.89	0.43	7.13e-21	Coffee consumption (cups per day);
LUAD	cis	rs10189230	0.967	rs1864460	chr2:222347655	A/C	cg14652038	chr2:222343519	EPHA4	0.44	8.7	0.39	7.64e-17	Urate levels in lean individuals;
LUAD	cis	rs3772130	0.923	rs7649092	chr3:121561950	C/A	cg20356878	chr3:121714668	ILDR1	0.52	8.36	0.38	8.93e-16	Cognitive performance;
LUAD	trans	rs9393777	0.513	rs13194053	chr6:27143883	T/C	cg06606381	chr12:133084897	FBRSL1	-0.65	-7.68	-0.35	1.11e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg07538946	chr5:131705188	SLC22A5	0.49	7.84	0.36	3.76e-14	Breast cancer;Mosquito bite size;
LUAD	cis	rs654950	0.841	rs2810549	chr1:41991761	C/T	cg06885757	chr1:42089581	HIVEP3	-0.35	-7.35	-0.34	1.04e-12	Airway imaging phenotypes;
LUAD	cis	rs4321325	0.733	rs78516281	chr2:127944564	G/C	cg11380483	chr2:127933992	NA	0.49	6.65	0.31	9.08e-11	Protein C levels;
LUAD	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg11247378	chr22:39784982	NA	-0.72	-13.76	-0.56	7.65e-36	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-16.49	-0.63	1.61e-47	Schizophrenia;
LUAD	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.62	-7.25	-0.33	1.95e-12	Lung cancer in ever smokers;
LUAD	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg18129748	chr3:49941408	MST1R	0.42	7.01	0.32	9.5e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.5	-9.08	-0.4	4.1e-18	Longevity;Endometriosis;
LUAD	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-6.46	-0.3	2.94e-10	IgG glycosylation;
LUAD	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-10.39	-0.45	1.17e-22	Gut microbiome composition (summer);
LUAD	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.56e-12	Crohn's disease;
LUAD	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg16325326	chr1:53192061	ZYG11B	-0.7	-12.82	-0.53	4.93e-32	Monocyte count;
LUAD	cis	rs9811920	0.809	rs4577503	chr3:99657922	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	7.27	0.33	1.71e-12	Axial length;
LUAD	cis	rs7903847	0.673	rs3818908	chr10:99132701	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-7.16	-0.33	3.52e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg26408565	chr15:76604113	ETFA	-0.47	-7.63	-0.35	1.59e-13	Blood metabolite levels;
LUAD	cis	rs1045714	0.895	rs4721860	chr7:2639994	C/T	cg24848437	chr7:2645542	IQCE	0.69	7.99	0.36	1.27e-14	Urate levels in lean individuals;
LUAD	cis	rs10489202	0.954	rs11586522	chr1:168091031	G/T	cg24449463	chr1:168025552	DCAF6	-0.53	-6.98	-0.32	1.16e-11	Schizophrenia;
LUAD	cis	rs62238980	0.614	rs116982428	chr22:32381272	G/C	cg02631450	chr22:32366979	NA	0.79	6.46	0.3	2.9e-10	Childhood ear infection;
LUAD	cis	rs1691799	0.867	rs1168348	chr12:66757168	G/A	cg16791601	chr12:66731901	HELB	-0.37	-6.68	-0.31	7.4e-11	White blood cell count (basophil);
LUAD	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg16647868	chr5:131706066	SLC22A5	0.39	6.6	0.31	1.23e-10	Acylcarnitine levels;
LUAD	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg24565620	chr2:194026	NA	-0.44	-6.98	-0.32	1.12e-11	Blood protein levels;
LUAD	cis	rs68170813	0.559	rs113422695	chr7:107070208	T/A	cg02696742	chr7:106810147	HBP1	-0.78	-10.16	-0.44	7.57e-22	Coronary artery disease;
LUAD	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg02734326	chr4:10020555	SLC2A9	0.61	10.64	0.46	1.4e-23	Bone mineral density;
LUAD	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg01503450	chr10:980765	NA	-0.37	-6.37	-0.3	4.95e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs8017423	0.967	rs4904658	chr14:90721640	C/T	cg14092571	chr14:90743983	NA	-0.5	-8.78	-0.39	4.22e-17	Mortality in heart failure;
LUAD	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.71	9.73	0.43	2.55e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs1595825	0.891	rs1992313	chr2:198896766	T/C	cg11031976	chr2:198649780	BOLL	-0.45	-6.53	-0.3	1.84e-10	Ulcerative colitis;
LUAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.71	-0.35	9.06e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs1941023	0.584	rs2014121	chr11:60156297	T/C	cg08716584	chr11:60157161	MS4A7	-0.48	-9.26	-0.41	1.07e-18	Congenital heart disease (maternal effect);
LUAD	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg26727032	chr16:67993705	SLC12A4	-0.46	-6.54	-0.3	1.78e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.83	0.39	2.81e-17	Parkinson's disease;
LUAD	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.47	2.75e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg23950597	chr19:37808831	NA	-0.6	-7.52	-0.34	3.32e-13	Coronary artery calcification;
LUAD	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.59	-0.35	2.13e-13	Personality dimensions;
LUAD	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg06636551	chr8:101224915	SPAG1	-0.37	-6.76	-0.31	4.62e-11	Atrioventricular conduction;
LUAD	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg05639522	chr1:247681581	NA	-0.35	-6.37	-0.3	5.06e-10	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.13	0.48	2.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg03929089	chr4:120376271	NA	-0.82	-14.26	-0.57	5.99e-38	Height;
LUAD	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg12016809	chr21:47604291	C21orf56	-0.51	-8.42	-0.38	5.8e-16	Testicular germ cell tumor;
LUAD	cis	rs57561814	0.510	rs1524107	chr7:22768219	C/T	cg01770232	chr7:22766155	IL6	0.8	7.7	0.35	9.95e-14	Tonsillectomy;
LUAD	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg16797656	chr11:68205561	LRP5	0.45	9.32	0.41	6.38e-19	Total body bone mineral density;
LUAD	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg14186256	chr22:23484241	RTDR1	0.46	7.94	0.36	1.85e-14	Bone mineral density;
LUAD	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg23229984	chr5:148520753	ABLIM3	0.4	6.38	0.3	4.57e-10	Breast cancer;
LUAD	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-7.95	-0.36	1.72e-14	Bladder cancer;
LUAD	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg24562669	chr7:97807699	LMTK2	0.31	7.5	0.34	3.69e-13	Breast cancer;
LUAD	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg24818145	chr4:99064322	C4orf37	0.45	7.67	0.35	1.16e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg06641503	chr3:48959341	ARIH2	-0.39	-6.85	-0.32	2.58e-11	Menarche (age at onset);
LUAD	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg09399716	chr2:46890238	NA	-0.37	-6.96	-0.32	1.26e-11	Height;
LUAD	cis	rs4846217	1.000	rs12141192	chr1:10431132	C/T	cg17425144	chr1:10567563	PEX14	-0.49	-6.4	-0.3	4.04e-10	Platelet count;
LUAD	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg18944383	chr4:111397179	ENPEP	0.41	8.19	0.37	3.15e-15	Height;
LUAD	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg12564285	chr5:131593104	PDLIM4	-0.37	-6.39	-0.3	4.43e-10	Breast cancer;
LUAD	cis	rs7107174	0.892	rs2512540	chr11:77979299	A/G	cg02023728	chr11:77925099	USP35	0.52	7.84	0.36	3.69e-14	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg00277334	chr10:82204260	NA	-0.45	-7.41	-0.34	6.97e-13	Post bronchodilator FEV1;
LUAD	cis	rs782590	0.902	rs4672052	chr2:55732018	A/C	cg03859395	chr2:55845619	SMEK2	0.73	13.45	0.55	1.44e-34	Metabolic syndrome;
LUAD	trans	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	10.56	0.46	2.7e-23	Type 2 diabetes;
LUAD	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg18404041	chr3:52824283	ITIH1	-0.5	-8.67	-0.39	9.27e-17	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.87	-0.36	2.99e-14	Diabetic kidney disease;
LUAD	cis	rs490234	0.545	rs10117700	chr9:128250651	C/T	cg14078157	chr9:128172775	NA	-0.38	-6.93	-0.32	1.59e-11	Mean arterial pressure;
LUAD	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg03929089	chr4:120376271	NA	-0.6	-9.4	-0.42	3.6e-19	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs1728785	0.688	rs7203363	chr16:68587692	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.3	0.45	2.33e-22	Ulcerative colitis;
LUAD	cis	rs9560113	1.000	rs60374273	chr13:112179206	A/T	cg14154082	chr13:112174009	NA	0.37	6.79	0.31	3.76e-11	Menarche (age at onset);
LUAD	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.39	7.8	0.35	4.96e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs8060686	0.516	rs7189794	chr16:68277727	T/C	cg26727032	chr16:67993705	SLC12A4	-0.48	-7.9	-0.36	2.37e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs701145	0.938	rs2596630	chr3:153992586	A/G	cg17054900	chr3:154042577	DHX36	0.64	7.1	0.33	5.16e-12	Coronary artery disease;
LUAD	trans	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg00769240	chr8:12517080	NA	-0.44	-7.46	-0.34	5e-13	Blood pressure (smoking interaction);
LUAD	cis	rs9549367	0.673	rs3024735	chr13:113819513	G/A	cg00898013	chr13:113819073	PROZ	-0.81	-14.74	-0.58	5.61e-40	Platelet distribution width;
LUAD	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg02158880	chr13:53174818	NA	0.62	10.75	0.46	5.49e-24	Lewy body disease;
LUAD	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56283067	0.847	rs62435998	chr6:44695206	C/T	cg20913747	chr6:44695427	NA	-0.44	-7.45	-0.34	5.39e-13	Total body bone mineral density;
LUAD	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg09184832	chr6:79620586	NA	-0.4	-6.72	-0.31	5.86e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg23262073	chr20:60523788	NA	-0.46	-7.96	-0.36	1.65e-14	Body mass index;
LUAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg21782813	chr7:2030301	MAD1L1	0.59	10.37	0.45	1.29e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg16797656	chr11:68205561	LRP5	0.48	10.44	0.45	7.15e-23	Total body bone mineral density;
LUAD	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg01689657	chr7:91764605	CYP51A1	0.36	8.77	0.39	4.37e-17	Breast cancer;
LUAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.45	-6.77	-0.31	4.31e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs113835537	0.559	rs74933537	chr11:66274958	A/C	cg26679405	chr11:66247800	DPP3	-0.44	-6.38	-0.3	4.55e-10	Airway imaging phenotypes;
LUAD	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.33	-0.38	1.14e-15	Neutrophil percentage of white cells;
LUAD	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg18132916	chr6:79620363	NA	-0.45	-7.72	-0.35	8.48e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg02466173	chr16:30829666	NA	-0.85	-17.06	-0.64	4.87e-50	Dementia with Lewy bodies;
LUAD	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg03983476	chr2:10830698	NOL10	0.47	8.2	0.37	2.86e-15	Prostate cancer;
LUAD	cis	rs1003719	0.654	rs764175	chr21:38517058	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.51	-8.6	-0.39	1.57e-16	Eye color traits;
LUAD	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg15181151	chr6:150070149	PCMT1	0.33	6.45	0.3	3.08e-10	Lung cancer;
LUAD	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg17264618	chr3:40429014	ENTPD3	0.43	9.1	0.4	3.59e-18	Renal cell carcinoma;
LUAD	trans	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg26811252	chr16:29126840	RRN3P2	0.64	10.55	0.46	3.01e-23	Menopause (age at onset);
LUAD	cis	rs877282	1.000	rs10904552	chr10:774326	A/G	cg17470449	chr10:769945	NA	0.67	10.42	0.45	8.95e-23	Uric acid levels;
LUAD	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg10483660	chr13:112241077	NA	-0.32	-6.97	-0.32	1.23e-11	Hepatitis;
LUAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg11416102	chr8:651193	ERICH1	0.95	9.02	0.4	6.52e-18	IgG glycosylation;
LUAD	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-10.22	-0.45	4.59e-22	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3916	0.794	rs3021337	chr12:121163261	C/T	cg27246729	chr12:121163418	ACADS	0.43	7.65	0.35	1.4e-13	Urinary metabolites (H-NMR features);
LUAD	trans	rs7395662	1.000	rs7945192	chr11:48580737	C/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.57	-0.3	1.5e-10	HDL cholesterol;
LUAD	cis	rs2692947	0.770	rs2315417	chr2:96500289	T/C	cg23100626	chr2:96804247	ASTL	0.3	7.62	0.35	1.7e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs9346649	0.630	rs4708643	chr6:168491681	A/G	cg02770688	chr6:168491649	NA	0.55	10.32	0.45	2.07e-22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	trans	rs1973993	0.567	rs2800433	chr1:96998126	T/A	cg10631902	chr5:14652156	NA	0.6	11.6	0.49	3.38e-27	Weight;
LUAD	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg16325326	chr1:53192061	ZYG11B	0.69	12.54	0.52	6.6e-31	Monocyte count;
LUAD	cis	rs7527798	0.592	rs12119104	chr1:207861207	A/G	cg09232269	chr1:207846808	CR1L	-0.39	-7.22	-0.33	2.45e-12	Erythrocyte sedimentation rate;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg19520115	chr1:19811759	CAPZB	-0.7	-6.82	-0.31	3.1e-11	Type 2 diabetes;
LUAD	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg22676075	chr6:135203613	NA	0.37	6.88	0.32	2.21e-11	Red blood cell count;
LUAD	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg14019146	chr3:50243930	SLC38A3	-0.42	-6.78	-0.31	4.09e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs36051895	0.659	rs7045491	chr9:5045658	G/A	cg02405213	chr9:5042618	JAK2	-0.44	-6.43	-0.3	3.42e-10	Pediatric autoimmune diseases;
LUAD	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.78	-0.61	1.99e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.62e-12	Crohn's disease;
LUAD	cis	rs4849845	0.889	rs3931840	chr2:121041347	A/C	cg24070213	chr2:121070622	NA	0.39	6.81	0.31	3.4e-11	Mean platelet volume;
LUAD	cis	rs10979	1.000	rs6570565	chr6:143899531	C/T	cg25407410	chr6:143891975	LOC285740	-0.63	-10.08	-0.44	1.52e-21	Hypospadias;
LUAD	cis	rs4604732	1.000	rs4604732	chr1:247623872	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.35	-6.37	-0.3	4.99e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7809615	0.901	rs10215765	chr7:99101280	G/C	cg12290671	chr7:99195819	NA	-0.7	-8.25	-0.37	2.01e-15	Blood metabolite ratios;
LUAD	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13560760	chr9:139308792	PMPCA	-0.46	-6.84	-0.32	2.79e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg06606381	chr12:133084897	FBRSL1	0.81	8.45	0.38	4.72e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg06074448	chr4:187884817	NA	-0.38	-7.54	-0.34	2.9e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg11901034	chr3:128598214	ACAD9	-0.54	-8.54	-0.38	2.53e-16	IgG glycosylation;
LUAD	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg13385794	chr1:248469461	NA	0.26	7.04	0.32	7.92e-12	Common traits (Other);
LUAD	trans	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg02030672	chr11:45687055	CHST1	-0.39	-6.88	-0.32	2.13e-11	Obesity-related traits;
LUAD	trans	rs2735413	0.918	rs7190752	chr16:78077430	T/C	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7586879	0.789	rs13404163	chr2:25126616	A/G	cg04586622	chr2:25135609	ADCY3	0.36	7.28	0.33	1.68e-12	Body mass index;
LUAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg24503407	chr1:205819492	PM20D1	0.77	15.51	0.6	2.75e-43	Menarche (age at onset);
LUAD	cis	rs68170813	0.559	rs74745121	chr7:106958037	T/C	cg02696742	chr7:106810147	HBP1	-0.76	-10.41	-0.45	9.42e-23	Coronary artery disease;
LUAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg24642844	chr7:1081250	C7orf50	-0.98	-14.8	-0.58	2.97e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.12	-0.33	4.82e-12	Schizophrenia;
LUAD	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08109568	chr15:31115862	NA	-0.6	-10.06	-0.44	1.67e-21	Huntington's disease progression;
LUAD	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg18446336	chr7:2847575	GNA12	-0.38	-7.0	-0.32	9.86e-12	Height;
LUAD	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg10596483	chr8:143751796	JRK	0.45	7.28	0.33	1.6e-12	Schizophrenia;
LUAD	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg04944784	chr2:26401820	FAM59B	0.88	12.18	0.51	1.8e-29	Gut microbiome composition (summer);
LUAD	cis	rs7523050	0.730	rs41279678	chr1:109440215	G/A	cg08274380	chr1:109419600	GPSM2	0.71	6.57	0.3	1.49e-10	Fat distribution (HIV);
LUAD	cis	rs7771547	0.603	rs72852338	chr6:36554240	A/C	cg02952361	chr6:36355661	ETV7	0.48	6.63	0.31	1.05e-10	Platelet distribution width;
LUAD	cis	rs35771425	0.956	rs35014256	chr1:211587701	A/G	cg25617285	chr1:211431773	RCOR3	-0.44	-6.46	-0.3	2.92e-10	Educational attainment (years of education);
LUAD	cis	rs4072705	0.967	rs4836986	chr9:127408059	C/T	cg13476313	chr9:127244764	NR5A1	0.34	8.01	0.36	1.13e-14	Menarche (age at onset);
LUAD	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.47	7.43	0.34	5.94e-13	Total body bone mineral density;
LUAD	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg13390004	chr1:15929781	NA	0.49	8.64	0.39	1.13e-16	Systolic blood pressure;
LUAD	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg12311346	chr5:56204834	C5orf35	-0.44	-7.35	-0.34	1.02e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27286337	chr10:134555280	INPP5A	0.72	9.35	0.41	5.1e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg07217954	chr7:1067459	C7orf50	0.45	7.1	0.33	5.28e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg19792802	chr11:65647270	CTSW	-0.42	-6.58	-0.3	1.36e-10	Crohn's disease;
LUAD	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.46	-0.34	5.07e-13	Bipolar disorder;
LUAD	cis	rs9389248	0.728	rs1022491	chr6:135259366	C/T	cg24558204	chr6:135376177	HBS1L	-0.4	-6.53	-0.3	1.92e-10	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg25456477	chr12:86230367	RASSF9	0.34	6.58	0.3	1.42e-10	Major depressive disorder;
LUAD	cis	rs4853036	0.629	rs13428251	chr2:70014561	G/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-6.62	-0.31	1.07e-10	Colorectal or endometrial cancer;
LUAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg18876405	chr7:65276391	NA	0.41	6.71	0.31	6.27e-11	Calcium levels;
LUAD	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg00647820	chr17:40259828	DHX58	-0.44	-6.95	-0.32	1.41e-11	Fibrinogen levels;
LUAD	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg06784218	chr1:46089804	CCDC17	0.6	13.3	0.54	5.55e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg19318889	chr4:1322082	MAEA	0.44	7.3	0.33	1.42e-12	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs151349	0.743	rs151353	chr20:57604343	A/C	cg23907860	chr20:57583709	CTSZ	-0.46	-8.1	-0.37	5.75e-15	Platelet distribution width;
LUAD	cis	rs11893307	0.507	rs1465305	chr2:191585392	C/G	cg11845111	chr2:191398756	TMEM194B	-0.44	-7.13	-0.33	4.28e-12	Mean platelet volume;
LUAD	trans	rs1493916	0.655	rs4534926	chr18:31349072	G/C	cg13755796	chr4:20253514	NA	-0.42	-7.07	-0.33	6.65e-12	Life satisfaction;
LUAD	trans	rs800082	0.839	rs62275528	chr3:144293687	T/C	cg24215973	chr2:240111563	HDAC4	-0.45	-6.97	-0.32	1.25e-11	Smoking behavior;
LUAD	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg11663144	chr21:46675770	NA	-0.52	-9.41	-0.42	3.16e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg12682607	chr3:32634705	NA	-0.42	-7.25	-0.33	2.05e-12	Schizophrenia;
LUAD	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21659725	chr3:3221576	CRBN	0.67	10.91	0.47	1.41e-24	Resting heart rate;
LUAD	trans	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg14791747	chr16:20752902	THUMPD1	-0.5	-7.29	-0.33	1.52e-12	Pancreatic cancer;
LUAD	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg06784218	chr1:46089804	CCDC17	0.59	13.33	0.54	4.4e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg21285383	chr16:89894308	SPIRE2	-0.44	-10.52	-0.46	3.81e-23	Vitiligo;
LUAD	trans	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg14917512	chr19:3094685	GNA11	-0.58	-6.89	-0.32	2.01e-11	Diabetic kidney disease;
LUAD	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.8	0.31	3.68e-11	Hypertriglyceridemia;
LUAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00166722	chr3:10149974	C3orf24	0.68	10.57	0.46	2.49e-23	Alzheimer's disease;
LUAD	trans	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg20587970	chr11:113659929	NA	0.87	12.6	0.52	3.98e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs7180079	1.000	rs55868267	chr15:64541470	G/A	cg08069370	chr15:64387884	SNX1	-0.54	-6.68	-0.31	7.61e-11	Monocyte count;
LUAD	cis	rs7589728	0.688	rs76734941	chr2:88530454	T/C	cg04511125	chr2:88470314	THNSL2	0.72	6.44	0.3	3.24e-10	Plasma clusterin levels;
LUAD	cis	rs2629540	0.924	rs1545910	chr10:126428145	G/C	cg08799069	chr10:126477246	METTL10	-0.47	-6.8	-0.31	3.5e-11	Cocaine dependence;
LUAD	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg16647868	chr5:131706066	SLC22A5	0.48	7.68	0.35	1.15e-13	Breast cancer;
LUAD	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg00631329	chr6:26305371	NA	-0.68	-13.21	-0.54	1.41e-33	Educational attainment;
LUAD	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg24801067	chr17:62843696	NA	0.65	8.8	0.39	3.54e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4389656	0.857	rs274715	chr5:6723429	C/T	cg10857441	chr5:6722123	POLS	0.46	7.81	0.35	4.63e-14	Coronary artery disease;
LUAD	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg10596483	chr8:143751796	JRK	0.45	7.22	0.33	2.42e-12	Schizophrenia;
LUAD	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.83	0.31	3.04e-11	Cognitive test performance;
LUAD	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg23625390	chr15:77176239	SCAPER	0.41	7.01	0.32	9.23e-12	Blood metabolite levels;
LUAD	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-23.84	-0.76	2.99e-80	Height;
LUAD	cis	rs62400317	0.762	rs3997499	chr6:44864552	G/T	cg20913747	chr6:44695427	NA	-0.44	-6.92	-0.32	1.68e-11	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6546550	0.901	rs3732266	chr2:70057448	T/G	cg02498382	chr2:70120550	SNRNP27	-0.57	-10.75	-0.46	5.57e-24	Prevalent atrial fibrillation;
LUAD	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs9379945	1	rs9379945	chr6:26907831	T/C	cg06606381	chr12:133084897	FBRSL1	-0.7	-6.96	-0.32	1.29e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg24644049	chr4:85504048	CDS1	0.85	7.17	0.33	3.38e-12	Skin colour saturation;
LUAD	cis	rs7582720	1.000	rs114395475	chr2:203769112	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg08085267	chr17:45401833	C17orf57	-0.49	-8.26	-0.37	1.86e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4356932	1.000	rs6825045	chr4:76957558	C/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.54	-0.3	1.78e-10	Blood protein levels;
LUAD	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg12923728	chr3:195709715	SDHAP1	-0.67	-10.0	-0.44	2.83e-21	Pancreatic cancer;
LUAD	cis	rs9469890	0.604	rs78121911	chr6:34503739	T/C	cg14254433	chr6:34482411	PACSIN1	-0.64	-8.79	-0.39	3.93e-17	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg27454412	chr7:1067447	C7orf50	-0.43	-7.99	-0.36	1.31e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg09085632	chr11:111637200	PPP2R1B	0.63	9.41	0.42	3.31e-19	Primary sclerosing cholangitis;
LUAD	cis	rs6960043	0.818	rs6947830	chr7:15064984	A/G	cg19272540	chr7:15055459	NA	0.35	7.75	0.35	6.71e-14	Type 2 diabetes;
LUAD	cis	rs2282300	0.739	rs34224414	chr11:30251041	T/G	cg06241208	chr11:30344200	C11orf46	-0.58	-7.6	-0.35	1.91e-13	Morning vs. evening chronotype;
LUAD	cis	rs11030122	0.702	rs17279635	chr11:3973083	A/C	cg18678763	chr11:4115507	RRM1	0.43	7.12	0.33	4.71e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs67981189	0.513	rs2526856	chr14:71412717	A/G	cg15332261	chr14:71375349	PCNX	-0.43	-7.15	-0.33	3.94e-12	Schizophrenia;
LUAD	cis	rs733592	0.929	rs4760678	chr12:48461581	T/C	cg24011408	chr12:48396354	COL2A1	-0.35	-7.2	-0.33	2.84e-12	Plateletcrit;
LUAD	cis	rs4713675	0.565	rs9469566	chr6:33667605	G/T	cg13859433	chr6:33739653	LEMD2	-0.27	-6.38	-0.3	4.53e-10	Plateletcrit;
LUAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg22907277	chr7:1156413	C7orf50	0.51	8.94	0.4	1.2e-17	Longevity;Endometriosis;
LUAD	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg05373962	chr22:49881684	NA	-0.49	-10.09	-0.44	1.36e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg02158880	chr13:53174818	NA	0.59	10.67	0.46	1.04e-23	Lewy body disease;
LUAD	cis	rs847851	1.000	rs847846	chr6:34925371	G/T	cg07306190	chr6:34760872	UHRF1BP1	0.3	6.88	0.32	2.19e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.71	0.31	6.25e-11	Breast cancer;
LUAD	cis	rs8017423	0.935	rs11624295	chr14:90695612	T/G	cg14092571	chr14:90743983	NA	-0.49	-8.66	-0.39	1.02e-16	Mortality in heart failure;
LUAD	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.78	-0.35	5.6e-14	Diabetic kidney disease;
LUAD	cis	rs9392556	0.829	rs612022	chr6:4126916	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.42	-7.19	-0.33	2.95e-12	Blood metabolite levels;
LUAD	cis	rs60154123	0.772	rs628908	chr1:210428002	C/T	cg22029157	chr1:209979665	IRF6	0.62	7.27	0.33	1.73e-12	Coronary artery disease;
LUAD	cis	rs4713675	0.584	rs4711339	chr6:33667199	A/G	cg14003231	chr6:33640908	ITPR3	0.48	9.26	0.41	1.06e-18	Plateletcrit;
LUAD	cis	rs9462027	0.606	rs2395606	chr6:34778486	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.76	-0.39	4.66e-17	Systemic lupus erythematosus;
LUAD	cis	rs2992756	0.663	rs2992757	chr1:18807137	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.57	-9.96	-0.44	3.94e-21	Breast cancer;
LUAD	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg12311346	chr5:56204834	C5orf35	0.74	11.75	0.5	8.75e-28	Initial pursuit acceleration;
LUAD	cis	rs1870323	0.527	rs2446224	chr11:86183416	T/C	cg01663953	chr11:86133777	CCDC81	0.37	6.77	0.31	4.25e-11	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule);
LUAD	cis	rs13191362	0.573	rs9365499	chr6:163271833	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.68	9.79	0.43	1.61e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg07234876	chr8:600039	NA	1.06	10.26	0.45	3.32e-22	IgG glycosylation;
LUAD	cis	rs76419734	0.510	rs2553463	chr4:106730663	C/T	cg05309399	chr4:106552544	FLJ20184	0.47	6.53	0.3	1.89e-10	Post bronchodilator FEV1;
LUAD	cis	rs7528419	1.000	rs12740374	chr1:109817590	G/T	cg00908766	chr1:109817496	CELSR2	-0.75	-14.32	-0.57	3.49e-38	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUAD	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg09658497	chr7:2847517	GNA12	-0.48	-8.89	-0.4	1.76e-17	Height;
LUAD	cis	rs11811982	0.793	rs80311310	chr1:227415803	G/T	cg24860534	chr1:227506868	CDC42BPA	0.64	7.2	0.33	2.69e-12	Optic disc area;
LUAD	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg21211680	chr2:198530	NA	0.6	8.48	0.38	3.71e-16	Blood protein levels;
LUAD	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.74	-0.31	5.36e-11	Crohn's disease;
LUAD	cis	rs9581857	0.685	rs9319371	chr13:28042564	A/G	cg22138327	chr13:27999177	GTF3A	0.84	9.65	0.42	4.63e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.07	0.33	6.44e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4148087	1.000	rs9975740	chr21:43620485	A/T	cg08841829	chr21:43638893	ABCG1	-0.56	-7.68	-0.35	1.09e-13	Eating disorder in bipolar disorder;
LUAD	cis	rs6087990	0.871	rs4911252	chr20:31330115	A/G	cg13636640	chr20:31349939	DNMT3B	-0.78	-14.25	-0.57	6.46e-38	Ulcerative colitis;
LUAD	cis	rs6993813	0.843	rs1485312	chr8:120043935	T/C	cg01975934	chr8:119970761	NA	-0.37	-7.22	-0.33	2.41e-12	Bone mineral density (hip);
LUAD	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg14895029	chr7:2775587	GNA12	-0.39	-6.39	-0.3	4.45e-10	Height;
LUAD	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg00277334	chr10:82204260	NA	-0.61	-10.28	-0.45	2.82e-22	Post bronchodilator FEV1;
LUAD	cis	rs28735056	0.563	rs12968139	chr18:77685520	A/G	cg20368463	chr18:77673604	PQLC1	-0.59	-10.27	-0.45	2.96e-22	Schizophrenia;
LUAD	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg00717180	chr2:96193071	NA	-0.41	-7.6	-0.35	1.95e-13	HDL cholesterol;
LUAD	cis	rs72772090	0.539	rs35898772	chr5:96179685	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-6.77	-0.31	4.44e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg00933542	chr6:150070202	PCMT1	0.44	9.45	0.42	2.26e-19	Lung cancer;
LUAD	cis	rs116248771	0.739	rs73156455	chr3:158367557	A/G	cg16708174	chr3:158430962	RARRES1	0.46	6.8	0.31	3.58e-11	diarrhoeal disease at age 2;
LUAD	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg00757033	chr12:89920650	WDR51B	0.68	11.57	0.49	4.53e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs74181299	0.892	rs2249105	chr2:65287896	C/T	cg05010058	chr2:65284262	CEP68	-0.28	-6.36	-0.3	5.34e-10	Pulse pressure;
LUAD	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	7.47	0.34	4.55e-13	Rheumatoid arthritis;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07897448	chr8:95907691	CCNE2	-0.66	-6.88	-0.32	2.18e-11	Type 2 diabetes;
LUAD	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.05	-0.36	8.53e-15	Cystic fibrosis severity;
LUAD	cis	rs17401966	0.838	rs61775885	chr1:10281445	T/C	cg15208524	chr1:10270712	KIF1B	0.42	6.5	0.3	2.28e-10	Hepatocellular carcinoma;
LUAD	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.45	0.3	3.02e-10	Depression;
LUAD	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.98	-0.36	1.41e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg11494091	chr17:61959527	GH2	0.41	7.81	0.36	4.51e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/C	cg00631329	chr6:26305371	NA	-0.56	-9.44	-0.42	2.62e-19	Educational attainment;
LUAD	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.8	-10.58	-0.46	2.23e-23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg18277682	chr1:228362509	C1orf69	-0.39	-6.42	-0.3	3.74e-10	Diastolic blood pressure;
LUAD	cis	rs9811920	0.555	rs68092024	chr3:99691522	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	8.97	0.4	9.59e-18	Axial length;
LUAD	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg06636551	chr8:101224915	SPAG1	-0.4	-7.33	-0.34	1.17e-12	Atrioventricular conduction;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13947272	chr1:154909579	PMVK	-0.42	-6.94	-0.32	1.52e-11	Cancer;
LUAD	cis	rs1018836	0.923	rs4735256	chr8:91612145	C/G	cg16814680	chr8:91681699	NA	-0.71	-12.06	-0.51	5.47e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg14202850	chr17:43974869	MAPT;LOC100130148	0.4	6.68	0.31	7.6e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg27210415	chr4:713949	PCGF3	0.62	9.08	0.4	4.04e-18	White blood cell count;
LUAD	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg06627628	chr2:24431161	ITSN2	-0.61	-9.99	-0.44	3.1e-21	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00166722	chr3:10149974	C3orf24	0.64	9.71	0.43	2.92e-20	Alzheimer's disease;
LUAD	cis	rs4901869	0.966	rs1820557	chr14:59334863	C/G	cg02291164	chr14:59296302	NA	0.64	15.6	0.6	1.19e-43	Panic disorder;
LUAD	cis	rs262150	0.501	rs1017034	chr7:158820460	A/G	cg19418458	chr7:158789849	NA	-0.64	-11.14	-0.48	1.93e-25	Facial morphology (factor 20);
LUAD	trans	rs800082	0.839	rs11714177	chr3:144312862	T/C	cg24215973	chr2:240111563	HDAC4	-0.44	-6.76	-0.31	4.53e-11	Smoking behavior;
LUAD	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	11.42	0.49	1.68e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg19875535	chr5:140030758	IK	-0.48	-8.01	-0.36	1.09e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg07967210	chr17:47022446	SNF8	0.36	6.4	0.3	4.19e-10	Type 2 diabetes;
LUAD	cis	rs240764	0.697	rs239195	chr6:101132368	T/C	cg09795085	chr6:101329169	ASCC3	0.42	7.08	0.33	6.07e-12	Neuroticism;
LUAD	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg22852734	chr6:133119734	C6orf192	0.79	9.78	0.43	1.67e-20	Type 2 diabetes nephropathy;
LUAD	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21028142	chr17:79581711	NPLOC4	0.45	9.8	0.43	1.44e-20	Eye color traits;
LUAD	cis	rs7937890	0.559	rs2575837	chr11:14498001	A/G	cg22961513	chr11:14280813	SPON1	-0.37	-7.06	-0.32	6.82e-12	Mitochondrial DNA levels;
LUAD	cis	rs977987	0.800	rs4888378	chr16:75332041	A/G	cg03315344	chr16:75512273	CHST6	0.63	13.75	0.56	7.95e-36	Dupuytren's disease;
LUAD	cis	rs921968	0.565	rs6436070	chr2:219597960	A/G	cg02176678	chr2:219576539	TTLL4	-0.59	-11.89	-0.5	2.42e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs28374715	0.662	rs521890	chr15:41473143	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.86	-15.74	-0.61	2.77e-44	Ulcerative colitis;
LUAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27286337	chr10:134555280	INPP5A	0.72	9.58	0.42	8.08e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg04455712	chr21:45112962	RRP1B	0.44	8.94	0.4	1.17e-17	Mean corpuscular volume;
LUAD	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg02820040	chr2:241836501	C2orf54	-0.31	-6.35	-0.3	5.51e-10	Urinary metabolites;
LUAD	trans	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-11.04	-0.47	4.51e-25	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg25554036	chr4:6271136	WFS1	0.72	14.3	0.57	4.2e-38	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs3935685	1.000	rs10851896	chr15:78026325	C/T	cg25212270	chr15:78015279	NA	0.36	6.97	0.32	1.21e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs3823572	0.542	rs2346269	chr7:133643066	C/T	cg03336402	chr7:133662267	EXOC4	-0.43	-7.74	-0.35	7.14e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg09658497	chr7:2847517	GNA12	-0.47	-7.95	-0.36	1.7e-14	Height;
LUAD	cis	rs13082711	0.911	rs2370995	chr3:27428216	C/T	cg02860705	chr3:27208620	NA	0.55	8.48	0.38	3.8e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg18105134	chr13:113819100	PROZ	-0.87	-15.14	-0.59	1.1e-41	Platelet distribution width;
LUAD	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08564027	chr20:61660810	NA	0.88	18.83	0.68	6.9e-58	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg20203395	chr5:56204925	C5orf35	0.61	9.35	0.41	5.08e-19	Initial pursuit acceleration;
LUAD	trans	rs4650994	0.593	rs2811309	chr1:178607684	A/G	cg05059571	chr16:84539110	KIAA1609	0.41	6.38	0.3	4.68e-10	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg08742575	chr21:47604166	C21orf56	0.42	7.06	0.32	6.84e-12	Testicular germ cell tumor;
LUAD	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03452623	chr4:187889614	NA	-0.82	-16.82	-0.63	5.55e-49	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg23029597	chr12:123009494	RSRC2	-0.51	-7.81	-0.36	4.54e-14	Body mass index;
LUAD	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg24450063	chr1:156163899	SLC25A44	0.72	6.69	0.31	7.05e-11	Paclitaxel disposition in epithelial ovarian cancer;
LUAD	trans	rs405795	1.000	rs2774180	chr13:89786288	C/T	cg24897320	chr1:110042528	CYB561D1	0.62	6.43	0.3	3.43e-10	Yeast infection;
LUAD	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg26446133	chr18:72167187	CNDP2	-0.81	-12.13	-0.51	2.77e-29	Refractive error;
LUAD	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg17200465	chr3:40428508	ENTPD3	0.27	6.39	0.3	4.4e-10	Renal cell carcinoma;
LUAD	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.91	12.8	0.53	6.17e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg06221963	chr1:154839813	KCNN3	-0.84	-19.89	-0.7	1.25e-62	Prostate cancer;
LUAD	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.58e-13	Menopause (age at onset);
LUAD	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.14	-0.51	2.65e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4523957	0.928	rs4790321	chr17:2173499	C/T	cg16513277	chr17:2031491	SMG6	-0.77	-14.65	-0.58	1.36e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs113835537	0.529	rs17065	chr11:66277035	G/A	cg26679405	chr11:66247800	DPP3	-0.47	-6.6	-0.31	1.26e-10	Airway imaging phenotypes;
LUAD	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg13010199	chr12:38710504	ALG10B	0.4	6.39	0.3	4.41e-10	Bladder cancer;
LUAD	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	10.88	0.47	1.82e-24	Hip circumference adjusted for BMI;
LUAD	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg11919837	chr8:57350735	NA	-0.43	-6.52	-0.3	1.99e-10	Obesity-related traits;
LUAD	cis	rs1032833	0.732	rs10497533	chr2:179999215	A/G	cg23883738	chr2:179974586	SESTD1	-0.7	-7.67	-0.35	1.2e-13	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg00074818	chr8:8560427	CLDN23	0.66	10.16	0.44	7.55e-22	Obesity-related traits;
LUAD	cis	rs753778	0.962	rs4961341	chr8:142235154	G/T	cg18755752	chr8:142205143	DENND3	-0.45	-7.31	-0.34	1.31e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.38	-0.34	8.59e-13	Bipolar disorder;
LUAD	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg18827107	chr12:86230957	RASSF9	-0.71	-13.13	-0.54	2.89e-33	Major depressive disorder;
LUAD	cis	rs13064411	0.696	rs2399479	chr3:113227050	G/A	cg18753928	chr3:113234510	CCDC52	-0.73	-12.34	-0.51	4.22e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.03	-0.36	9.99e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs747782	0.528	rs4370963	chr11:48433943	C/G	cg15704280	chr7:45808275	SEPT13	0.63	7.52	0.34	3.3e-13	Intraocular pressure;
LUAD	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.87	0.4	2.11e-17	Menopause (age at onset);
LUAD	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.14	0.33	4.16e-12	Parkinson's disease;
LUAD	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.13	-0.33	4.3e-12	Blood metabolite levels;
LUAD	cis	rs76878669	0.561	rs12794121	chr11:66126169	G/T	cg18002602	chr11:66138449	SLC29A2	0.47	10.16	0.44	7.74e-22	Educational attainment (years of education);
LUAD	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg27532560	chr4:187881888	NA	-0.34	-6.41	-0.3	3.8e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs751728	0.638	rs4607416	chr6:33784998	G/C	cg13859433	chr6:33739653	LEMD2	-0.32	-6.46	-0.3	2.86e-10	Crohn's disease;
LUAD	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11890956	chr21:40555474	PSMG1	-0.54	-9.42	-0.42	3.07e-19	Menarche (age at onset);
LUAD	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18876405	chr7:65276391	NA	0.44	6.89	0.32	2.1e-11	Aortic root size;
LUAD	cis	rs2952156	0.916	rs903506	chr17:37879762	G/A	cg00129232	chr17:37814104	STARD3	-0.44	-7.37	-0.34	9.29e-13	Asthma;
LUAD	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg12062639	chr20:23401060	NAPB	1.0	10.48	0.45	5.27e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg14847009	chr1:175162515	KIAA0040	0.32	8.12	0.37	5.25e-15	Alcohol dependence;
LUAD	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg27284194	chr4:1044797	NA	0.71	10.35	0.45	1.54e-22	Recombination rate (females);
LUAD	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg09165964	chr15:75287851	SCAMP5	-0.48	-7.18	-0.33	3.22e-12	Blood trace element (Zn levels);
LUAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg11905131	chr22:24372483	LOC391322	-0.49	-7.98	-0.36	1.41e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg17330251	chr7:94953956	PON1	-0.54	-7.51	-0.34	3.57e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-7.41	-0.34	6.91e-13	Schizophrenia;
LUAD	trans	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg26043149	chr18:55253948	FECH	1.12	20.86	0.71	5.78e-67	Gout;Urate levels;Serum uric acid levels;
LUAD	trans	rs587242	0.956	rs12030748	chr1:96904404	G/A	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg03714773	chr7:91764589	CYP51A1	0.27	6.48	0.3	2.59e-10	Breast cancer;
LUAD	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg04450456	chr4:17643702	FAM184B	0.4	7.98	0.36	1.35e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg04267008	chr7:1944627	MAD1L1	-0.68	-10.2	-0.44	5.51e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg21963583	chr11:68658836	MRPL21	0.66	11.52	0.49	6.67e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10392	0.571	rs4812350	chr20:37631192	C/T	cg27552599	chr20:37590471	DHX35	0.39	6.5	0.3	2.21e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs1395	1.000	rs1659695	chr2:27406944	T/A	cg23587288	chr2:27483067	SLC30A3	0.4	8.12	0.37	5.07e-15	Blood metabolite levels;
LUAD	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg08029281	chr1:67600428	NA	0.33	6.42	0.3	3.74e-10	Psoriasis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22614265	chr7:100425456	EPHB4	-0.4	-6.39	-0.3	4.44e-10	Height;
LUAD	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg15557168	chr22:42548783	NA	0.37	6.85	0.32	2.61e-11	Cognitive function;
LUAD	cis	rs3760982	1.000	rs12460161	chr19:44293986	C/A	cg12072164	chr19:44306565	LYPD5	0.4	7.95	0.36	1.76e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	trans	rs10838798	0.584	rs4752899	chr11:48141855	T/G	cg21153622	chr11:89784906	NA	-0.35	-6.91	-0.32	1.82e-11	Height;
LUAD	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg25894440	chr7:65020034	NA	-0.64	-6.89	-0.32	2.03e-11	Diabetic kidney disease;
LUAD	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg27247225	chr6:26970382	C6orf41	-0.42	-6.41	-0.3	3.94e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg22705602	chr4:152727874	NA	-0.4	-6.95	-0.32	1.38e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9517302	0.615	rs2274053	chr13:99098318	C/T	cg22223119	chr13:99095684	FARP1	-0.7	-10.52	-0.46	3.73e-23	Obesity-related traits;
LUAD	cis	rs10504073	0.584	rs11784268	chr8:49956339	T/G	cg00325661	chr8:49890786	NA	0.48	10.61	0.46	1.72e-23	Blood metabolite ratios;
LUAD	cis	rs35995292	1.000	rs56098802	chr7:38913730	T/C	cg19327137	chr7:38886074	VPS41	0.5	8.23	0.37	2.41e-15	Subjective well-being (multi-trait analysis);
LUAD	cis	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg05084668	chr3:125655381	ALG1L	-0.62	-9.93	-0.43	5.08e-21	Blood pressure (smoking interaction);
LUAD	cis	rs9393692	0.557	rs2893820	chr6:26295686	G/A	cg00631329	chr6:26305371	NA	-0.57	-9.51	-0.42	1.4e-19	Educational attainment;
LUAD	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg05340658	chr4:99064831	C4orf37	0.53	9.05	0.4	5.32e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg18854424	chr1:2615690	NA	-0.41	-9.28	-0.41	8.98e-19	Ulcerative colitis;
LUAD	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg10518543	chr12:38710700	ALG10B	-0.49	-8.19	-0.37	3.07e-15	Morning vs. evening chronotype;
LUAD	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg00484396	chr16:3507460	NAT15	0.76	8.05	0.36	8.39e-15	Tuberculosis;
LUAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg00106254	chr7:1943704	MAD1L1	-0.62	-9.31	-0.41	7.26e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	7.99e-19	Tonsillectomy;
LUAD	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.07	0.33	6.5e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg04731861	chr2:219085781	ARPC2	-0.24	-7.56	-0.35	2.5e-13	Colorectal cancer;
LUAD	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.73	0.35	7.97e-14	Breast cancer;
LUAD	cis	rs2387326	0.717	rs10829339	chr10:129943681	C/T	cg16087940	chr10:129947807	NA	-0.65	-9.09	-0.4	3.81e-18	Select biomarker traits;
LUAD	cis	rs4380275	1.000	rs4450634	chr2:773257	G/A	cg21665850	chr2:731073	NA	0.5	8.94	0.4	1.24e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUAD	cis	rs7264396	0.563	rs2425132	chr20:34338390	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-7.94	-0.36	1.78e-14	Total cholesterol levels;
LUAD	cis	rs17095355	0.818	rs35096721	chr10:111775907	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.43	-0.34	6.26e-13	Biliary atresia;
LUAD	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg04989706	chr14:50066350	PPIL5	-0.52	-7.55	-0.34	2.64e-13	Carotid intima media thickness;
LUAD	cis	rs41311933	0.803	rs74322175	chr9:123695650	C/T	cg13567360	chr9:123745713	C5	-0.83	-7.22	-0.33	2.36e-12	Coronary artery disease;
LUAD	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.75	0.31	5.03e-11	Platelet count;
LUAD	cis	rs9394438	0.628	rs2153947	chr6:37544930	A/G	cg00985040	chr6:37553208	NA	-0.42	-9.05	-0.4	5.26e-18	IgG glycosylation;
LUAD	cis	rs1847202	0.859	rs4490296	chr3:72949197	C/A	cg25664220	chr3:72788482	NA	-0.43	-7.56	-0.34	2.54e-13	Motion sickness;
LUAD	cis	rs6840360	0.571	rs10026670	chr4:152539212	C/T	cg22705602	chr4:152727874	NA	-0.38	-6.72	-0.31	6.06e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-10.81	-0.47	3.34e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg08085267	chr17:45401833	C17orf57	0.59	10.65	0.46	1.32e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12545109	0.876	rs1992120	chr8:57337112	G/A	cg09654669	chr8:57350985	NA	-0.72	-9.88	-0.43	7.52e-21	Obesity-related traits;
LUAD	trans	rs72766638	0.895	rs11795079	chr9:136930134	T/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.54	-6.47	-0.3	2.77e-10	Mosquito bite size;
LUAD	cis	rs11170631	0.507	rs12307701	chr12:54090724	A/C	cg23533419	chr12:54090519	NA	-0.34	-6.38	-0.3	4.6e-10	Height;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg25418748	chr5:178977236	RUFY1	0.45	7.33	0.34	1.2e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg00204512	chr16:28754710	NA	0.36	7.72	0.35	8.6e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg01620082	chr3:125678407	NA	-1.1	-10.3	-0.45	2.37e-22	Lung cancer in ever smokers;
LUAD	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg05425664	chr17:57184151	TRIM37	0.41	7.28	0.33	1.63e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg20587970	chr11:113659929	NA	-1.41	-20.86	-0.71	5.65e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg06558623	chr16:89946397	TCF25	1.12	9.76	0.43	2.05e-20	Skin colour saturation;
LUAD	cis	rs870825	0.616	rs7692104	chr4:185650895	T/G	cg04058563	chr4:185651563	MLF1IP	0.9	14.58	0.58	2.63e-39	Blood protein levels;
LUAD	trans	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg18335740	chr13:41363409	SLC25A15	0.85	16.73	0.63	1.35e-48	Lewy body disease;
LUAD	cis	rs10392	0.571	rs4812335	chr20:37537612	C/T	cg27552599	chr20:37590471	DHX35	0.38	6.42	0.3	3.78e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg21475434	chr5:93447410	FAM172A	0.76	8.43	0.38	5.66e-16	Diabetic retinopathy;
LUAD	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg18230493	chr5:56204884	C5orf35	-0.5	-8.03	-0.36	9.78e-15	Coronary artery disease;
LUAD	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg09323728	chr8:95962352	TP53INP1	-0.32	-7.74	-0.35	7.28e-14	Type 2 diabetes;
LUAD	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg01802117	chr1:53393560	SCP2	0.42	7.83	0.36	3.85e-14	Monocyte count;
LUAD	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg18827107	chr12:86230957	RASSF9	-0.71	-13.06	-0.54	5.39e-33	Major depressive disorder;
LUAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs300703	0.719	rs385909	chr2:199678	A/G	cg24565620	chr2:194026	NA	-0.41	-6.36	-0.3	5.34e-10	Blood protein levels;
LUAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg15117754	chr3:10150083	C3orf24	0.41	6.59	0.31	1.3100000000000001e-10	Alzheimer's disease;
LUAD	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.54	0.34	2.94e-13	Menopause (age at onset);
LUAD	cis	rs35883536	0.528	rs1542837	chr1:101029768	T/C	cg06223162	chr1:101003688	GPR88	0.56	11.36	0.48	2.74e-26	Monocyte count;
LUAD	cis	rs654950	0.875	rs687766	chr1:41998849	C/G	cg06885757	chr1:42089581	HIVEP3	0.33	6.73	0.31	5.55e-11	Airway imaging phenotypes;
LUAD	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg23950597	chr19:37808831	NA	-0.65	-7.64	-0.35	1.43e-13	Coronary artery calcification;
LUAD	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg06623918	chr6:96969491	KIAA0776	-0.88	-17.4	-0.65	1.63e-51	Headache;
LUAD	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg00784671	chr22:46762841	CELSR1	-0.54	-7.05	-0.32	7.22e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg22875332	chr1:76189707	ACADM	0.73	11.04	0.47	4.47e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs3789045	0.729	rs61817460	chr1:204543579	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.44	-7.36	-0.34	9.84e-13	Educational attainment (college completion);
LUAD	cis	rs7264396	0.508	rs6060739	chr20:34567592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.49	-0.3	2.43e-10	Total cholesterol levels;
LUAD	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10802521	chr3:52805072	NEK4	-0.6	-10.55	-0.46	3.04e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs12681287	0.752	rs4288357	chr8:87251833	C/T	cg27223183	chr8:87520930	FAM82B	-0.59	-8.21	-0.37	2.75e-15	Caudate activity during reward;
LUAD	cis	rs977987	0.750	rs4888407	chr16:75432390	T/C	cg03315344	chr16:75512273	CHST6	0.62	13.59	0.55	3.57e-35	Dupuytren's disease;
LUAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg21951975	chr1:209979733	IRF6	0.55	8.95	0.4	1.1e-17	Cleft lip with or without cleft palate;
LUAD	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg03563238	chr19:33554763	RHPN2	-0.39	-9.13	-0.41	2.87e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs62400317	0.859	rs10948204	chr6:45124300	T/C	cg20913747	chr6:44695427	NA	-0.4	-6.41	-0.3	3.92e-10	Total body bone mineral density;
LUAD	cis	rs4409675	0.576	rs6703851	chr1:28237556	G/A	cg23691781	chr1:28212827	C1orf38	0.37	10.38	0.45	1.28e-22	Corneal astigmatism;
LUAD	trans	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg12400702	chr3:12838781	CAND2	0.31	6.38	0.3	4.7e-10	Parkinson's disease;
LUAD	trans	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg12400702	chr3:12838781	CAND2	0.31	6.4	0.3	4.18e-10	Parkinson's disease;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg06168050	chr17:30677336	ZNF207	0.39	6.48	0.3	2.58e-10	Anger;
LUAD	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg13918804	chr1:2043761	PRKCZ	0.41	6.92	0.32	1.72e-11	Height;
LUAD	cis	rs3821902	0.646	rs56359789	chr3:64016911	T/C	cg22134162	chr3:63841271	THOC7	-0.42	-6.86	-0.32	2.5e-11	Breast cancer;
LUAD	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg27539214	chr16:67997921	SLC12A4	-0.69	-8.51	-0.38	3.16e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1598856	0.932	rs230530	chr4:103453980	A/G	cg07973026	chr4:103553119	MANBA	-0.39	-6.38	-0.3	4.78e-10	Primary biliary cholangitis;
LUAD	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg02466173	chr16:30829666	NA	-0.67	-12.11	-0.51	3.39e-29	Multiple myeloma;
LUAD	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.08	-0.33	6.17e-12	Total cholesterol levels;
LUAD	cis	rs713587	0.563	rs11686663	chr2:25107759	C/T	cg01884057	chr2:25150051	NA	0.33	7.09	0.33	5.71e-12	Body mass index in non-asthmatics;
LUAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg08888203	chr3:10149979	C3orf24	0.63	10.73	0.46	6.56e-24	Alzheimer's disease;
LUAD	cis	rs807669	0.903	rs762527	chr22:19183470	A/G	cg02655711	chr22:19163373	SLC25A1	0.87	18.96	0.68	1.73e-58	Metabolite levels;
LUAD	cis	rs7903847	0.642	rs7896100	chr10:99156994	C/T	cg20016023	chr10:99160130	RRP12	-0.32	-7.78	-0.35	5.57e-14	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg22442454	chr1:209979470	IRF6	0.54	7.28	0.33	1.63e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs9902453	0.845	rs2321331	chr17:28025528	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.32	0.41	6.74e-19	Coffee consumption (cups per day);
LUAD	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg25767906	chr1:53392781	SCP2	0.42	7.89	0.36	2.53e-14	Monocyte count;
LUAD	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg05425664	chr17:57184151	TRIM37	0.42	7.55	0.34	2.67e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18099408	chr3:52552593	STAB1	0.43	7.84	0.36	3.74e-14	Electroencephalogram traits;
LUAD	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg05926928	chr17:57297772	GDPD1	1.39	17.2	0.64	1.21e-50	Opioid sensitivity;
LUAD	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-8.05	-0.36	8.48e-15	Tonsillectomy;
LUAD	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg04352962	chr1:209979756	IRF6	0.51	6.57	0.3	1.51e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs73195822	0.614	rs73194057	chr12:111216913	T/C	cg12870014	chr12:110450643	ANKRD13A	0.66	9.06	0.4	5.01e-18	Itch intensity from mosquito bite;
LUAD	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg08508325	chr11:3079039	CARS	0.41	8.52	0.38	2.79e-16	Calcium levels;
LUAD	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg17724175	chr1:150552817	MCL1	0.39	9.43	0.42	2.64e-19	Tonsillectomy;
LUAD	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.56	-7.73	-0.35	8.03e-14	Gut microbiome composition (summer);
LUAD	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg01849466	chr14:104193079	ZFYVE21	0.46	7.69	0.35	1.04e-13	Body mass index;
LUAD	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.46	-8.13	-0.37	4.74e-15	Rheumatoid arthritis;
LUAD	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-8.03	-0.36	9.63e-15	Body mass index;
LUAD	cis	rs28655083	0.957	rs7185514	chr16:77070129	T/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-7.51	-0.34	3.44e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg07917127	chr4:99064746	C4orf37	0.43	6.67	0.31	7.85e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg10295955	chr4:187884368	NA	-1.1	-25.54	-0.78	9.5e-88	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6906287	0.647	rs13220480	chr6:118916627	G/A	cg18833306	chr6:118973337	C6orf204	0.48	8.4	0.38	7.08e-16	Electrocardiographic conduction measures;
LUAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg20607798	chr8:58055168	NA	0.57	7.28	0.33	1.6e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg17200465	chr3:40428508	ENTPD3	0.27	6.48	0.3	2.51e-10	Renal cell carcinoma;
LUAD	cis	rs78487399	0.808	rs13419380	chr2:43739184	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.52	-0.3	2.06e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs7123876	0.504	rs1157343	chr11:72429141	A/G	cg04827223	chr11:72435913	ARAP1	0.53	10.21	0.44	5.07e-22	Body mass index;
LUAD	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.92	0.32	1.71e-11	Rheumatoid arthritis;
LUAD	cis	rs7582720	1.000	rs72934513	chr2:203927587	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.83	0.43	1.1e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs3766606	0.505	rs72633047	chr1:7935440	G/A	cg26816564	chr1:7831052	VAMP3	0.61	8.28	0.37	1.61e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg11859384	chr17:80120422	CCDC57	0.51	9.22	0.41	1.42e-18	Life satisfaction;
LUAD	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg05564831	chr3:52568323	NT5DC2	-0.37	-6.71	-0.31	6.41e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg18827107	chr12:86230957	RASSF9	-0.7	-12.95	-0.53	1.6e-32	Major depressive disorder;
LUAD	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg05590025	chr7:65112418	INTS4L2	0.72	7.59	0.35	2.03e-13	Diabetic kidney disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17308151	chr11:8703888	RPL27A	-0.42	-6.57	-0.3	1.48e-10	Height;
LUAD	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg24531977	chr5:56204891	C5orf35	-0.51	-8.06	-0.36	8.09e-15	Coronary artery disease;
LUAD	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg03340356	chr1:67600835	NA	0.41	7.35	0.34	1e-12	Psoriasis;
LUAD	cis	rs9905704	0.671	rs2531733	chr17:56548811	A/G	cg19466818	chr17:56409534	MIR142	0.33	6.58	0.3	1.38e-10	Testicular germ cell tumor;
LUAD	cis	rs6496932	0.563	rs2344083	chr15:85897432	T/C	cg19183879	chr15:85880815	NA	-0.34	-7.52	-0.34	3.37e-13	Central corneal thickness;Corneal structure;
LUAD	cis	rs12900413	0.687	rs7176981	chr15:90315757	A/G	cg24249390	chr15:90295951	MESP1	-0.34	-6.83	-0.32	2.94e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs11098699	0.784	rs11930165	chr4:124236979	C/G	cg09941581	chr4:124220074	SPATA5	0.43	6.87	0.32	2.27e-11	Mosquito bite size;
LUAD	cis	rs26868	0.740	rs26869	chr16:2248786	T/C	cg25665528	chr16:2260870	C16orf79	-0.35	-6.81	-0.31	3.37e-11	Height;
LUAD	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg06713675	chr4:122721982	EXOSC9	-0.8	-16.16	-0.62	4.12e-46	Type 2 diabetes;
LUAD	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.4	-0.45	1.03e-22	Glomerular filtration rate;
LUAD	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg07404485	chr7:94953653	PON1	-0.48	-6.65	-0.31	9.26e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs931127	0.658	rs7926512	chr11:65464487	T/A	cg27068330	chr11:65405492	SIPA1	-0.4	-6.38	-0.3	4.61e-10	Systemic lupus erythematosus;
LUAD	cis	rs9902453	0.730	rs4583306	chr17:28538715	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.39	-6.38	-0.3	4.53e-10	Coffee consumption (cups per day);
LUAD	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg17105886	chr17:28927953	LRRC37B2	-0.71	-6.69	-0.31	7.29e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	10.46	0.45	6.08e-23	Birth weight;
LUAD	cis	rs4604732	0.631	rs75320597	chr1:247626751	T/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs7395662	1.000	rs7121992	chr11:48592582	C/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.55	-0.3	1.67e-10	HDL cholesterol;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02053340	chr20:49348184	PARD6B	-0.52	-6.45	-0.3	3.04e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg07169764	chr2:136633963	MCM6	0.82	9.6	0.42	7.17e-20	Corneal structure;
LUAD	cis	rs2455826	0.520	rs2470518	chr3:15759491	A/G	cg16303742	chr3:15540471	COLQ	-0.39	-6.66	-0.31	8.77e-11	Inflammatory skin disease;
LUAD	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg04414720	chr1:150670196	GOLPH3L	0.68	11.93	0.5	1.82e-28	Melanoma;
LUAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg11494091	chr17:61959527	GH2	0.73	18.21	0.66	4.08e-55	Prudent dietary pattern;
LUAD	cis	rs938554	0.784	rs13145758	chr4:9981997	G/A	cg00071950	chr4:10020882	SLC2A9	0.52	8.13	0.37	4.77e-15	Blood metabolite levels;
LUAD	cis	rs113835537	0.597	rs10896129	chr11:66338300	T/C	cg24851651	chr11:66362959	CCS	0.59	10.48	0.45	5.18e-23	Airway imaging phenotypes;
LUAD	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg21475434	chr5:93447410	FAM172A	0.77	8.48	0.38	3.85e-16	Diabetic retinopathy;
LUAD	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg08027265	chr7:2291960	NA	-0.44	-7.2	-0.33	2.83e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs79911532	0.551	rs41301427	chr7:75614557	G/A	cg19862616	chr7:65841803	NCRNA00174	0.82	8.29	0.37	1.5e-15	Mononucleosis;
LUAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.67	-12.22	-0.51	1.27e-29	Longevity;Endometriosis;
LUAD	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg23173402	chr1:227635558	NA	0.74	7.93	0.36	1.94e-14	Major depressive disorder;
LUAD	cis	rs738321	0.762	rs5995543	chr22:38579026	G/A	cg25457927	chr22:38595422	NA	-0.53	-11.71	-0.49	1.22e-27	Breast cancer;
LUAD	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg20701182	chr2:24300061	SF3B14	0.54	6.54	0.3	1.76e-10	Lymphocyte counts;
LUAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13012494	chr21:47604986	C21orf56	-0.66	-11.79	-0.5	6.0500000000000004e-28	Testicular germ cell tumor;
LUAD	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg13813247	chr22:41461852	NA	-0.5	-8.0	-0.36	1.18e-14	Neuroticism;
LUAD	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.63	-10.56	-0.46	2.82e-23	Glomerular filtration rate;
LUAD	cis	rs62400317	0.787	rs10456547	chr6:45219526	T/C	cg20913747	chr6:44695427	NA	-0.43	-6.8	-0.31	3.64e-11	Total body bone mineral density;
LUAD	trans	rs3857536	0.842	rs2188590	chr6:66939534	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs11077998	0.901	rs4789798	chr17:80531643	C/G	cg10255544	chr17:80519551	FOXK2	0.33	6.51	0.3	2.16e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg22166914	chr1:53195759	ZYG11B	-0.44	-7.62	-0.35	1.73e-13	Monocyte count;
LUAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg14893161	chr1:205819251	PM20D1	0.49	7.9	0.36	2.44e-14	Parkinson's disease;
LUAD	cis	rs2731664	0.756	rs335433	chr5:176867207	T/C	cg23176889	chr5:176863531	GRK6	-0.74	-14.44	-0.57	1.03e-38	Intelligence (multi-trait analysis);
LUAD	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg21138405	chr5:131827807	IRF1	0.31	6.35	0.3	5.54e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs9329221	0.509	rs3088186	chr8:10226355	C/T	cg27411982	chr8:10470053	RP1L1	0.43	7.15	0.33	3.79e-12	Neuroticism;
LUAD	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg12140854	chr5:148520817	ABLIM3	0.64	10.54	0.46	3.22e-23	Breast cancer;
LUAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.8	0.56	4.95e-36	Prudent dietary pattern;
LUAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs28493229	0.522	rs2287692	chr19:41289756	G/A	cg21869046	chr19:41225005	ITPKC	0.54	8.87	0.4	2.08e-17	Kawasaki disease;
LUAD	cis	rs501916	0.833	rs11855134	chr15:48047676	A/G	cg16110827	chr15:48056943	SEMA6D	-0.38	-6.76	-0.31	4.66e-11	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs757647	0.723	rs17171808	chr5:137699199	C/T	cg10676309	chr5:137685565	NA	-0.39	-7.3	-0.33	1.43e-12	Menarche (age at onset);
LUAD	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.3	-6.6	-0.31	1.26e-10	Type 2 diabetes;
LUAD	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	8.08	0.37	6.7e-15	Rheumatoid arthritis;
LUAD	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.46	0.34	5.11e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7593730	0.832	rs72969008	chr2:161123335	G/A	cg22609984	chr2:161126801	NA	-0.46	-6.5	-0.3	2.27e-10	Type 2 diabetes;
LUAD	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg20891558	chr2:74357851	NA	0.93	16.28	0.62	1.26e-46	Gestational age at birth (maternal effect);
LUAD	cis	rs2806561	1.000	rs2746553	chr1:23493246	T/C	cg12483005	chr1:23474871	LUZP1	0.41	7.19	0.33	2.95e-12	Height;
LUAD	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg04398451	chr17:18023971	MYO15A	-0.88	-16.85	-0.63	4.25e-49	Total body bone mineral density;
LUAD	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg06618935	chr21:46677482	NA	-0.49	-9.66	-0.43	4.4e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.65	-0.31	8.9e-11	Morning vs. evening chronotype;
LUAD	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg02018176	chr4:1364513	KIAA1530	0.69	11.77	0.5	7.56e-28	Longevity;
LUAD	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg16989719	chr2:238392110	NA	-0.35	-7.4	-0.34	7.24e-13	Prostate cancer;
LUAD	trans	rs6495785	0.678	rs956362	chr15:35927655	A/G	cg04307083	chr4:57521138	HOPX	-0.37	-7.01	-0.32	9.28e-12	Menopause (age at onset);
LUAD	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	9.55	0.42	1.08e-19	Axial length;
LUAD	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg26384229	chr12:38710491	ALG10B	0.45	7.33	0.34	1.18e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.74	-0.35	7.57e-14	Total body bone mineral density;
LUAD	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg01448562	chr3:133502909	NA	-0.61	-10.32	-0.45	2.03e-22	Iron status biomarkers;
LUAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.87	16.74	0.63	1.29e-48	Lymphocyte counts;
LUAD	trans	rs11088226	0.681	rs2833899	chr21:33933263	T/C	cg09050820	chr6:167586206	TCP10L2	0.91	12.43	0.52	1.85e-30	Gastritis;
LUAD	cis	rs2242073	0.733	rs62194805	chr2:209027278	A/G	cg06181187	chr2:209010896	CRYGB	0.47	7.72	0.35	8.57e-14	Attention deficit hyperactivity disorder;
LUAD	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.78	-9.9	-0.43	6.33e-21	Lung cancer in ever smokers;
LUAD	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg22681709	chr2:178499509	PDE11A	-0.55	-9.55	-0.42	1.02e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg14847009	chr1:175162515	KIAA0040	0.32	8.52	0.38	2.83e-16	Alcohol dependence;
LUAD	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg18451016	chr1:38461880	NA	0.45	8.26	0.37	1.92e-15	Coronary artery disease;
LUAD	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	9.91	0.43	5.85e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg21984481	chr17:79567631	NPLOC4	-0.71	-17.18	-0.64	1.46e-50	Eye color traits;
LUAD	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg11645453	chr3:52864694	ITIH4	0.6	11.24	0.48	8.27e-26	Schizophrenia;
LUAD	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg26597838	chr10:835615	NA	0.53	8.38	0.38	8.06e-16	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs12478296	1.000	rs55814222	chr2:243041166	C/T	cg06360820	chr2:242988706	NA	-0.84	-9.69	-0.43	3.39e-20	Obesity-related traits;
LUAD	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg26384229	chr12:38710491	ALG10B	0.49	7.9	0.36	2.47e-14	Morning vs. evening chronotype;
LUAD	cis	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg21775007	chr8:11205619	TDH	-0.38	-6.47	-0.3	2.67e-10	Neuroticism;
LUAD	cis	rs10979	0.597	rs9403515	chr6:143908013	A/G	cg25407410	chr6:143891975	LOC285740	-0.55	-7.69	-0.35	1.05e-13	Hypospadias;
LUAD	cis	rs9807989	0.507	rs11465721	chr2:103063240	T/G	cg03938978	chr2:103052716	IL18RAP	0.46	10.57	0.46	2.39e-23	Asthma;
LUAD	cis	rs7289126	0.868	rs2267377	chr22:38629519	T/C	cg25457927	chr22:38595422	NA	-0.39	-9.08	-0.4	4.3e-18	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs9811920	0.898	rs7636776	chr3:99840446	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.61	11.29	0.48	4.96e-26	Axial length;
LUAD	cis	rs7731657	0.537	rs10051616	chr5:130315631	A/G	cg08523029	chr5:130500466	HINT1	-0.57	-7.3	-0.33	1.47e-12	Fasting plasma glucose;
LUAD	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg23283495	chr1:209979779	IRF6	0.68	10.92	0.47	1.24e-24	Cleft lip with or without cleft palate;
LUAD	cis	rs7605378	1.000	rs797163	chr2:200696387	G/A	cg23649088	chr2:200775458	C2orf69	0.53	8.48	0.38	3.74e-16	Osteoporosis;
LUAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg24846343	chr22:24311635	DDTL	0.78	17.8	0.65	2.74e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg26384229	chr12:38710491	ALG10B	0.51	8.08	0.37	6.85e-15	Bladder cancer;
LUAD	cis	rs9902453	0.791	rs2729451	chr17:28131334	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.06	-0.4	4.92e-18	Coffee consumption (cups per day);
LUAD	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg11645453	chr3:52864694	ITIH4	0.34	6.82	0.31	3.2e-11	Bipolar disorder;
LUAD	cis	rs250677	0.522	rs3763022	chr5:148381078	A/G	cg12140854	chr5:148520817	ABLIM3	-0.54	-9.07	-0.4	4.42e-18	Breast cancer;
LUAD	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg02775129	chr4:119771670	NA	-0.87	-7.95	-0.36	1.73e-14	Cannabis dependence symptom count;
LUAD	cis	rs9503598	0.636	rs6596976	chr6:3466022	C/T	cg00476032	chr6:3446245	SLC22A23	0.31	6.52	0.3	2.04e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg04586622	chr2:25135609	ADCY3	0.37	8.41	0.38	6.25e-16	Body mass index;
LUAD	cis	rs1799949	0.757	rs9915489	chr17:41173226	A/T	cg05368731	chr17:41323189	NBR1	0.83	15.85	0.61	9.75e-45	Menopause (age at onset);
LUAD	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	8.01	0.36	1.15e-14	Menopause (age at onset);
LUAD	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg11062466	chr8:58055876	NA	0.68	7.36	0.34	9.85e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2485376	1.000	rs3758552	chr10:103992964	T/C	cg20641465	chr10:103991465	PITX3	0.56	10.3	0.45	2.45e-22	QT interval;
LUAD	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.28	-0.33	1.62e-12	Total body bone mineral density;
LUAD	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.21e-16	Prostate cancer;
LUAD	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg22875332	chr1:76189707	ACADM	0.7	10.27	0.45	3.14e-22	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg07677032	chr17:61819896	STRADA	0.57	10.38	0.45	1.2e-22	Prudent dietary pattern;
LUAD	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	13.66	0.55	1.93e-35	Lung cancer in ever smokers;
LUAD	cis	rs7512552	0.839	rs1625468	chr1:150321486	G/A	cg15654264	chr1:150340011	RPRD2	0.61	11.6	0.49	3.48e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6684514	1.000	rs12132794	chr1:156281020	C/G	cg16558208	chr1:156270281	VHLL	-0.51	-9.52	-0.42	1.4e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs7851660	0.874	rs10818175	chr9:100633386	T/C	cg13688889	chr9:100608707	NA	-0.48	-8.27	-0.37	1.72e-15	Strep throat;
LUAD	cis	rs2073300	1.000	rs6132625	chr20:23444671	C/T	cg12062639	chr20:23401060	NAPB	0.98	8.35	0.38	9.91e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06873352	chr17:61820015	STRADA	0.82	18.18	0.66	5.66e-55	Prudent dietary pattern;
LUAD	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.37	0.34	9.3e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs8008758	1.000	rs915379	chr14:101689392	T/C	cg26224664	chr14:101693935	NA	-0.32	-6.54	-0.3	1.73e-10	Body mass index (alcohol intake interaction);
LUAD	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg08048268	chr3:133502702	NA	-0.42	-7.82	-0.36	4.22e-14	Iron status biomarkers;
LUAD	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg22532475	chr10:104410764	TRIM8	0.44	8.37	0.38	8.6e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg21918786	chr6:109611834	NA	-0.58	-10.65	-0.46	1.24e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs6076065	0.723	rs6137924	chr20:23366171	C/G	cg11657817	chr20:23433608	CST11	0.48	8.94	0.4	1.23e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg12011299	chr4:100065546	ADH4	0.63	13.05	0.54	5.85e-33	Alcohol dependence;
LUAD	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.59	10.52	0.46	3.91e-23	Birth weight;
LUAD	cis	rs1832871	0.644	rs56180963	chr6:158773990	G/A	cg07165851	chr6:158734300	TULP4	0.72	11.32	0.48	3.97e-26	Height;
LUAD	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg11517269	chr6:28058789	ZSCAN12L1	0.39	7.37	0.34	8.95e-13	Lung cancer in ever smokers;
LUAD	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg17401720	chr7:158221031	PTPRN2	-0.32	-6.58	-0.3	1.38e-10	Obesity-related traits;
LUAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg00945038	chr17:61921165	SMARCD2	-0.35	-6.37	-0.3	4.93e-10	Prudent dietary pattern;
LUAD	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg06221963	chr1:154839813	KCNN3	-0.7	-14.82	-0.58	2.5e-40	Prostate cancer;
LUAD	cis	rs9517313	0.523	rs4772104	chr13:99235677	G/A	cg07423050	chr13:99094983	FARP1	-0.54	-8.68	-0.39	8.46e-17	Neuroticism;
LUAD	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.33	0.38	1.13e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.26	-6.95	-0.32	1.42e-11	Total body bone mineral density;
LUAD	cis	rs9814567	0.702	rs9871226	chr3:134331466	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2046867	0.908	rs62251655	chr3:72821708	T/C	cg04365224	chr3:72788183	NA	-0.48	-7.25	-0.33	1.98e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7274811	0.744	rs34489266	chr20:32223040	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.49	-7.14	-0.33	4.09e-12	Height;
LUAD	trans	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg26043149	chr18:55253948	FECH	0.41	6.69	0.31	7.04e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06873352	chr17:61820015	STRADA	0.81	18.2	0.66	4.63e-55	Prudent dietary pattern;
LUAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg10819733	chr22:24237672	NA	-0.4	-7.35	-0.34	1.03e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2712381	0.517	rs62273237	chr3:128310107	T/C	cg16766828	chr3:128327626	NA	-0.42	-7.78	-0.35	5.57e-14	Monocyte count;
LUAD	trans	rs10802346	0.545	rs4478780	chr1:246372241	T/C	cg22732515	chr19:44031385	ETHE1	0.59	9.53	0.42	1.28e-19	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.02	0.32	8.93e-12	Motion sickness;
LUAD	cis	rs12760731	0.720	rs10798606	chr1:178372965	G/A	cg00404053	chr1:178313656	RASAL2	0.49	6.85	0.32	2.6e-11	Obesity-related traits;
LUAD	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg00933542	chr6:150070202	PCMT1	0.44	9.42	0.42	3.03e-19	Lung cancer;
LUAD	cis	rs17401966	0.931	rs12409754	chr1:10457540	T/C	cg19773385	chr1:10388646	KIF1B	-0.42	-6.69	-0.31	7.02e-11	Hepatocellular carcinoma;
LUAD	cis	rs864537	0.676	rs1773560	chr1:167421763	A/G	cg22356347	chr1:167427500	CD247	-0.46	-9.62	-0.42	6.1e-20	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg21475434	chr5:93447410	FAM172A	0.53	7.1	0.33	5.17e-12	Diabetic retinopathy;
LUAD	cis	rs12541635	0.966	rs56352125	chr8:107041831	G/T	cg10147462	chr8:107024639	NA	0.49	8.68	0.39	8.49e-17	Age of smoking initiation;
LUAD	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62400317	0.859	rs72870950	chr6:45154779	A/G	cg18551225	chr6:44695536	NA	-0.53	-8.23	-0.37	2.37e-15	Total body bone mineral density;
LUAD	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.44	0.57	1.08e-38	Schizophrenia;
LUAD	cis	rs977987	0.806	rs12930768	chr16:75464500	T/C	cg03315344	chr16:75512273	CHST6	0.64	13.99	0.56	7.87e-37	Dupuytren's disease;
LUAD	cis	rs12210905	0.688	rs72843151	chr6:27359268	A/C	cg08851530	chr6:28072375	NA	1.09	7.95	0.36	1.69e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11890956	chr21:40555474	PSMG1	0.8	13.94	0.56	1.31e-36	Cognitive function;
LUAD	cis	rs28493229	0.522	rs17713068	chr19:41270055	A/C	cg21869046	chr19:41225005	ITPKC	0.57	10.11	0.44	1.17e-21	Kawasaki disease;
LUAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg07402062	chr16:89894098	SPIRE2	0.43	10.96	0.47	8.85e-25	Vitiligo;
LUAD	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg06064525	chr11:970664	AP2A2	0.56	11.49	0.49	8.47e-27	Alzheimer's disease (late onset);
LUAD	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-14.51	-0.58	5.23e-39	Extrinsic epigenetic age acceleration;
LUAD	trans	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg18335740	chr13:41363409	SLC25A15	-0.63	-11.52	-0.49	7e-27	Lewy body disease;
LUAD	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg11833968	chr6:79620685	NA	-0.43	-8.2	-0.37	2.84e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6840360	0.571	rs7674244	chr4:152488302	T/C	cg22705602	chr4:152727874	NA	-0.37	-6.64	-0.31	9.65e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs490234	0.841	rs2793135	chr9:128338620	A/G	cg14078157	chr9:128172775	NA	0.35	6.46	0.3	2.89e-10	Mean arterial pressure;
LUAD	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.48	0.38	3.78e-16	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg15704280	chr7:45808275	SEPT13	0.63	8.06	0.36	7.82e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7771547	0.603	rs9357218	chr6:36549858	G/A	cg07856975	chr6:36356162	ETV7	0.53	7.09	0.33	5.56e-12	Platelet distribution width;
LUAD	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12923728	chr3:195709715	SDHAP1	-0.77	-13.34	-0.54	4.01e-34	Pancreatic cancer;
LUAD	cis	rs10193935	0.786	rs13416119	chr2:42462930	A/G	cg27598129	chr2:42591480	NA	-0.74	-7.16	-0.33	3.6e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg00898013	chr13:113819073	PROZ	0.59	10.85	0.47	2.23e-24	Platelet distribution width;
LUAD	cis	rs7771547	0.642	rs628213	chr6:36508646	T/C	cg07856975	chr6:36356162	ETV7	0.42	6.43	0.3	3.5e-10	Platelet distribution width;
LUAD	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg06873352	chr17:61820015	STRADA	0.42	6.89	0.32	2.09e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg05564831	chr3:52568323	NT5DC2	0.48	9.54	0.42	1.19e-19	Electroencephalogram traits;
LUAD	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg18230493	chr5:56204884	C5orf35	-0.86	-12.47	-0.52	1.31e-30	Initial pursuit acceleration;
LUAD	trans	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-7.78	-0.35	5.5e-14	Endometrial cancer;
LUAD	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg21823605	chr1:152486609	CRCT1	0.28	6.53	0.3	1.87e-10	Hair morphology;
LUAD	cis	rs4819852	0.958	rs756653	chr22:19976845	G/A	cg07821417	chr22:19972146	ARVCF	0.4	7.64	0.35	1.45e-13	Pulse pressure;
LUAD	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.61	12.1	0.51	3.74e-29	Hemoglobin concentration;
LUAD	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.85	-14.42	-0.57	1.32e-38	IgG glycosylation;
LUAD	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg18138036	chr10:133769891	PPP2R2D	-0.39	-6.45	-0.3	3.1e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg14343924	chr8:8086146	FLJ10661	0.49	7.82	0.36	4.25e-14	Mood instability;
LUAD	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18876405	chr7:65276391	NA	-0.41	-6.5	-0.3	2.24e-10	Aortic root size;
LUAD	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg00383909	chr3:49044727	WDR6	0.94	9.32	0.41	6.36e-19	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	trans	rs5756813	0.727	rs13055462	chr22:38184685	A/G	cg19894588	chr14:64061835	NA	-0.47	-6.77	-0.31	4.38e-11	Optic cup area;Vertical cup-disc ratio;
LUAD	trans	rs7395662	0.895	rs3903506	chr11:48718513	G/A	cg15704280	chr7:45808275	SEPT13	0.43	6.75	0.31	5.04e-11	HDL cholesterol;
LUAD	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18876405	chr7:65276391	NA	0.42	6.7	0.31	6.8e-11	Aortic root size;
LUAD	trans	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.26	-0.37	1.93e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7671266	0.518	rs16895984	chr4:10284727	C/T	cg11266682	chr4:10021025	SLC2A9	0.38	7.21	0.33	2.52e-12	Cardiovascular disease risk factors;
LUAD	cis	rs953387	1.000	rs4954569	chr2:136913375	C/T	cg05194412	chr2:137003533	NA	-0.4	-6.57	-0.3	1.5e-10	Arthritis (juvenile idiopathic);
LUAD	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg16989719	chr2:238392110	NA	-0.31	-6.55	-0.3	1.68e-10	Prostate cancer;
LUAD	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg16325326	chr1:53192061	ZYG11B	0.62	10.85	0.47	2.38e-24	Monocyte count;
LUAD	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22857025	chr5:266934	NA	-1.03	-13.04	-0.54	6.77e-33	Breast cancer;
LUAD	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.78	-0.35	5.45e-14	Blood trace element (Zn levels);
LUAD	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg26354017	chr1:205819088	PM20D1	0.53	9.24	0.41	1.18e-18	Menarche (age at onset);
LUAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.18	0.54	1.83e-33	Prudent dietary pattern;
LUAD	cis	rs6690583	0.623	rs75918067	chr1:85453413	T/C	cg22153463	chr1:85462885	MCOLN2	0.55	6.37	0.3	4.97e-10	Serum sulfate level;
LUAD	cis	rs4148087	0.530	rs221953	chr21:43608656	A/G	cg08841829	chr21:43638893	ABCG1	0.43	6.7	0.31	6.71e-11	Eating disorder in bipolar disorder;
LUAD	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg17264618	chr3:40429014	ENTPD3	-0.35	-7.51	-0.34	3.51e-13	Renal cell carcinoma;
LUAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.09	0.4	3.83e-18	Alzheimer's disease;
LUAD	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg25985355	chr7:65971099	NA	0.38	7.06	0.32	6.76e-12	Aortic root size;
LUAD	trans	rs3942852	0.955	rs1503190	chr11:48117873	A/G	cg15704280	chr7:45808275	SEPT13	-0.59	-8.06	-0.36	8.1e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg18306943	chr3:40428807	ENTPD3	0.39	6.43	0.3	3.44e-10	Renal cell carcinoma;
LUAD	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg18932078	chr1:2524107	MMEL1	0.38	7.09	0.33	5.76e-12	Ulcerative colitis;
LUAD	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg18196295	chr10:418757	DIP2C	0.51	7.99	0.36	1.31e-14	Psychosis in Alzheimer's disease;
LUAD	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg23649088	chr2:200775458	C2orf69	0.58	8.24	0.37	2.2e-15	Schizophrenia;
LUAD	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	7.94e-19	Tonsillectomy;
LUAD	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27297192	chr10:134578999	INPP5A	0.38	6.75	0.31	4.96e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg11901034	chr3:128598214	ACAD9	-0.5	-7.8	-0.35	4.76e-14	IgG glycosylation;
LUAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg21733973	chr7:65235735	NA	0.55	8.84	0.39	2.67e-17	Calcium levels;
LUAD	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg02931644	chr1:25747376	RHCE	0.51	11.19	0.48	1.27e-25	Erythrocyte sedimentation rate;
LUAD	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg23018236	chr17:30244563	NA	-0.61	-7.75	-0.35	7.02e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg05425664	chr17:57184151	TRIM37	0.44	7.88	0.36	2.83e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg22963979	chr7:1858916	MAD1L1	0.48	8.18	0.37	3.25e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs57590327	0.508	rs1973805	chr3:81946539	C/A	cg07356753	chr3:81810745	GBE1	-0.51	-8.57	-0.38	2.03e-16	Extraversion;
LUAD	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg14582100	chr15:45693742	SPATA5L1	0.46	9.06	0.4	4.85e-18	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg00339695	chr16:24857497	SLC5A11	0.7	11.16	0.48	1.58e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg12310025	chr6:25882481	NA	-0.4	-6.62	-0.31	1.12e-10	Height;
LUAD	cis	rs3733418	0.929	rs12510464	chr4:165919040	A/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-6.99	-0.32	1.08e-11	Obesity-related traits;
LUAD	trans	rs9354308	0.838	rs9445595	chr6:66537559	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.76	-0.31	4.63e-11	Metabolite levels;
LUAD	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg08847533	chr14:75593920	NEK9	0.39	6.85	0.32	2.65e-11	Height;
LUAD	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-8.13	-0.37	4.9e-15	Menarche (age at onset);
LUAD	cis	rs9948	0.786	rs62156233	chr2:97434061	C/G	cg20312557	chr2:97357134	FER1L5	-0.57	-7.16	-0.33	3.66e-12	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg10729496	chr3:10149963	C3orf24	0.49	7.87	0.36	2.94e-14	Alzheimer's disease;
LUAD	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg19041857	chr6:27730383	NA	-0.43	-7.28	-0.33	1.6e-12	Parkinson's disease;
LUAD	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08859206	chr1:53392774	SCP2	0.83	15.65	0.61	6.87e-44	Monocyte count;
LUAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg23131131	chr22:24373011	LOC391322	-0.59	-9.83	-0.43	1.11e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg21051086	chr3:73046214	PPP4R2	0.42	7.4	0.34	7.61e-13	Pancreatic cancer;
LUAD	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg13319975	chr6:146136371	FBXO30	0.57	9.44	0.42	2.48e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11209185	0.602	rs1926282	chr1:68448753	C/G	cg22082780	chr1:68452167	NA	-0.38	-7.67	-0.35	1.18e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg27411982	chr8:10470053	RP1L1	0.4	7.01	0.32	9.33e-12	Retinal vascular caliber;
LUAD	trans	rs877282	0.945	rs12767287	chr10:787310	A/G	cg22713356	chr15:30763199	NA	1.34	18.73	0.67	1.85e-57	Uric acid levels;
LUAD	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg17330251	chr7:94953956	PON1	-0.52	-6.82	-0.31	3.21e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs11811982	0.655	rs7547092	chr1:227413438	T/C	cg24860534	chr1:227506868	CDC42BPA	0.71	7.67	0.35	1.22e-13	Optic disc area;
LUAD	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg10556349	chr10:835070	NA	0.59	7.47	0.34	4.5e-13	Eosinophil percentage of granulocytes;
LUAD	trans	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg01620082	chr3:125678407	NA	-1.01	-9.19	-0.41	1.75e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08219700	chr8:58056026	NA	0.57	7.89	0.36	2.64e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-6.48	-0.3	2.58e-10	Tonsillectomy;
LUAD	cis	rs758324	0.773	rs6870930	chr5:131110125	A/C	cg06307176	chr5:131281290	NA	-0.45	-7.48	-0.34	4.36e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs75804782	0.935	rs61332075	chr2:239316560	G/C	cg01134436	chr17:81009848	B3GNTL1	0.77	8.23	0.37	2.29e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg01181863	chr3:195395398	SDHAP2	-0.61	-9.21	-0.41	1.48e-18	Pancreatic cancer;
LUAD	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.7	-0.35	9.97e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg10729496	chr3:10149963	C3orf24	0.58	9.34	0.41	5.58e-19	Alzheimer's disease;
LUAD	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg12310025	chr6:25882481	NA	-0.58	-9.53	-0.42	1.24e-19	Blood metabolite levels;
LUAD	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.51	0.3	2.1e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4891159	0.548	rs11150952	chr18:74128188	T/C	cg24786174	chr18:74118243	ZNF516	0.9	22.44	0.74	5.04e-74	Longevity;
LUAD	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.8	-0.31	3.47e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7000551	0.581	rs4872487	chr8:22256414	C/T	cg12081754	chr8:22256438	SLC39A14	0.91	15.77	0.61	2.14e-44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.51	-0.42	1.51e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9948	0.786	rs62156231	chr2:97425603	G/A	cg20312557	chr2:97357134	FER1L5	-0.62	-7.27	-0.33	1.7e-12	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.45	0.45	7.07e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg17366294	chr4:99064904	C4orf37	-0.66	-12.53	-0.52	7.53e-31	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg05610740	chr12:96794311	CDK17	-0.42	-7.32	-0.34	1.28e-12	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.76	0.31	4.57e-11	Cognitive test performance;
LUAD	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg17200465	chr3:40428508	ENTPD3	0.27	6.45	0.3	3.01e-10	Renal cell carcinoma;
LUAD	cis	rs757647	0.723	rs3756761	chr5:137671058	G/A	cg10676309	chr5:137685565	NA	0.4	7.17	0.33	3.38e-12	Menarche (age at onset);
LUAD	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg08085267	chr17:45401833	C17orf57	0.63	11.0	0.47	6.34e-25	Coronary artery disease;
LUAD	cis	rs3857067	0.806	rs6817795	chr4:95127716	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.37	-6.69	-0.31	6.92e-11	QT interval;
LUAD	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.79	-0.31	3.93e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7027203	0.964	rs7854075	chr9:96571211	G/A	cg14396892	chr9:96623032	NA	0.41	7.49	0.34	4.11e-13	DNA methylation (variation);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20645649	chr9:127624485	RPL35	-0.43	-6.83	-0.32	2.98e-11	Height;
LUAD	cis	rs9486719	0.948	rs2499813	chr6:96875338	T/C	cg06623918	chr6:96969491	KIAA0776	0.72	10.01	0.44	2.61e-21	Migraine;Coronary artery disease;
LUAD	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	ch.11.42038R	chr11:967971	AP2A2	0.42	7.35	0.34	1.06e-12	Alzheimer's disease (late onset);
LUAD	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg13606994	chr1:44402422	ARTN	-0.32	-6.9	-0.32	1.91e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg16414030	chr3:133502952	NA	-0.51	-9.04	-0.4	5.76e-18	Iron status biomarkers;
LUAD	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.39	0.34	7.76e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg07828340	chr4:882639	GAK	1.05	10.84	0.47	2.47e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs2274471	0.591	rs7034539	chr9:5081585	C/T	cg03390472	chr9:5043263	JAK2	0.6	8.94	0.4	1.21e-17	Crohn's disease;
LUAD	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg24558204	chr6:135376177	HBS1L	0.46	8.39	0.38	7.13e-16	Red blood cell count;
LUAD	cis	rs7010267	0.935	rs11573824	chr8:119959925	A/T	cg01975934	chr8:119970761	NA	-0.4	-7.57	-0.35	2.29e-13	Total body bone mineral density (age 45-60);
LUAD	cis	rs3772130	0.926	rs13072767	chr3:121504098	A/G	cg20356878	chr3:121714668	ILDR1	0.51	8.1	0.37	5.81e-15	Cognitive performance;
LUAD	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg26384229	chr12:38710491	ALG10B	0.46	7.52	0.34	3.25e-13	Bladder cancer;
LUAD	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-8.58	-0.39	1.78e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg23260525	chr10:116636907	FAM160B1	0.47	11.0	0.47	6.26e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9392556	0.600	rs611500	chr6:4126763	C/G	cg10424681	chr6:4079350	C6orf201;C6orf146	0.28	6.95	0.32	1.36e-11	Blood metabolite levels;
LUAD	cis	rs7737355	0.812	rs2549017	chr5:130692045	A/G	cg06307176	chr5:131281290	NA	0.4	6.64	0.31	9.48e-11	Life satisfaction;
LUAD	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.32	-0.34	1.22e-12	Blood metabolite levels;
LUAD	cis	rs7945705	0.776	rs11042069	chr11:8817315	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.33	6.42	0.3	3.63e-10	Hemoglobin concentration;
LUAD	cis	rs9487051	0.738	rs449850	chr6:109525045	A/G	cg21918786	chr6:109611834	NA	-0.42	-7.32	-0.34	1.29e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs7116495	0.619	rs7116188	chr11:71841753	A/G	cg07596299	chr11:71824057	C11orf51	0.77	6.69	0.31	7.27e-11	Severe influenza A (H1N1) infection;
LUAD	trans	rs208520	0.874	rs208518	chr6:66948501	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	14.52	0.58	4.88e-39	Exhaled nitric oxide output;
LUAD	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg15147215	chr3:52552868	STAB1	-0.39	-7.26	-0.33	1.88e-12	Bipolar disorder;
LUAD	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg19773385	chr1:10388646	KIF1B	-0.43	-6.9	-0.32	1.92e-11	Hepatocellular carcinoma;
LUAD	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2688608	0.672	rs2633321	chr10:75693695	C/T	cg23231163	chr10:75533350	FUT11	-0.36	-6.68	-0.31	7.59e-11	Inflammatory bowel disease;
LUAD	trans	rs877282	1.000	rs11253369	chr10:773610	C/G	cg22713356	chr15:30763199	NA	0.99	14.41	0.57	1.39e-38	Uric acid levels;
LUAD	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg01475377	chr6:109611718	NA	-0.51	-9.48	-0.42	1.79e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs10504073	0.584	rs56134839	chr8:49918899	C/T	cg00325661	chr8:49890786	NA	0.48	10.53	0.46	3.35e-23	Blood metabolite ratios;
LUAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg16606324	chr3:10149918	C3orf24	-0.64	-10.42	-0.45	8.52e-23	Alzheimer's disease;
LUAD	trans	rs2262909	0.889	rs61268244	chr19:22310130	C/T	cg05197062	chr11:11642011	GALNTL4	0.6	9.3	0.41	7.59e-19	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg01324343	chr3:183735012	ABCC5	0.94	25.19	0.77	3.48e-86	Anterior chamber depth;
LUAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg18099408	chr3:52552593	STAB1	-0.51	-9.14	-0.41	2.64e-18	Electroencephalogram traits;
LUAD	cis	rs62064224	0.614	rs11656445	chr17:30694164	T/C	cg25809561	chr17:30822961	MYO1D	0.48	8.6	0.39	1.57e-16	Schizophrenia;
LUAD	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg10792982	chr14:105748885	BRF1	-0.36	-8.25	-0.37	2.07e-15	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2479724	0.840	rs10498752	chr6:41768510	T/C	cg17623882	chr6:41773611	USP49	0.67	12.8	0.53	6.1e-32	Menarche (age at onset);
LUAD	cis	rs17362650	0.960	rs66995158	chr2:9639826	G/A	cg12832956	chr2:9616023	IAH1	-0.47	-7.42	-0.34	6.45e-13	Alcohol dependence (age at onset);
LUAD	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg02269571	chr22:50332266	NA	-0.67	-9.6	-0.42	7.15e-20	Schizophrenia;
LUAD	cis	rs243505	0.762	rs734004	chr7:148505460	C/G	cg09806900	chr7:148480153	CUL1	0.44	7.7	0.35	9.64e-14	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg25233709	chr10:116636983	FAM160B1	0.41	8.08	0.37	6.73e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01576737	chr19:11924996	ZNF440	-0.46	-7.1	-0.33	5.22e-12	Height;
LUAD	cis	rs2282300	0.910	rs528292	chr11:30389710	A/G	cg25418670	chr11:30344373	C11orf46	0.48	6.42	0.3	3.65e-10	Morning vs. evening chronotype;
LUAD	cis	rs7192380	0.651	rs12447326	chr16:69630853	C/T	cg26679644	chr16:69762563	NA	0.42	6.85	0.32	2.61e-11	Sjögren's syndrome;
LUAD	cis	rs526821	0.595	rs608964	chr11:55339266	G/A	cg04317927	chr11:55418816	OR4S2	0.4	7.72	0.35	8.53e-14	Pediatric bone mineral density (spine);
LUAD	cis	rs3774830	0.743	rs195127	chr4:5429650	C/T	cg26943120	chr4:5472116	STK32B	-0.32	-6.42	-0.3	3.67e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.57	-8.81	-0.39	3.21e-17	Alzheimer's disease (late onset);
LUAD	cis	rs494562	0.892	rs544403	chr6:86119116	G/T	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg03433033	chr1:76189801	ACADM	-0.48	-7.04	-0.32	7.67e-12	Daytime sleep phenotypes;
LUAD	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg04450456	chr4:17643702	FAM184B	-0.4	-7.72	-0.35	8.25e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.44	-0.49	1.35e-26	Type 2 diabetes;
LUAD	cis	rs250677	0.522	rs62378210	chr5:148384885	G/A	cg12140854	chr5:148520817	ABLIM3	-0.55	-8.5	-0.38	3.24e-16	Breast cancer;
LUAD	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg17595323	chr11:93583763	C11orf90	-0.43	-9.09	-0.4	3.96e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs2953145	0.617	rs7557192	chr2:241541274	T/C	cg07929629	chr2:241523174	NA	0.4	6.55	0.3	1.64e-10	Bipolar disorder;
LUAD	cis	rs684232	0.623	rs391002	chr17:535441	T/G	cg15660573	chr17:549704	VPS53	-0.88	-18.18	-0.66	5.65e-55	Prostate cancer;
LUAD	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.0	-0.4	7.66e-18	Total body bone mineral density;
LUAD	cis	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg07460842	chr6:66804631	NA	-1.07	-16.68	-0.63	2.3e-48	Exhaled nitric oxide output;
LUAD	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg18569988	chr3:195679450	NA	0.43	6.63	0.31	1.02e-10	Pancreatic cancer;
LUAD	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg22338127	chr1:209979572	IRF6	0.5	6.39	0.3	4.46e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.88	-0.36	2.73e-14	Total body bone mineral density;
LUAD	trans	rs1973993	0.507	rs2759670	chr1:97002864	A/G	cg10631902	chr5:14652156	NA	0.61	11.68	0.49	1.69e-27	Weight;
LUAD	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg02569458	chr12:86230093	RASSF9	0.42	7.58	0.35	2.16e-13	Major depressive disorder;
LUAD	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg19875535	chr5:140030758	IK	-0.42	-7.05	-0.32	7.56e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs986417	0.579	rs1254281	chr14:60854300	T/C	cg27398547	chr14:60952738	C14orf39	-0.61	-7.38	-0.34	8.37e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs4774899	0.752	rs2951899	chr15:57381851	G/A	cg14026238	chr15:57616123	NA	0.43	8.12	0.37	5.16e-15	Urinary tract infection frequency;
LUAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.45	-7.86	-0.36	3.27e-14	Longevity;Endometriosis;
LUAD	cis	rs2735413	0.918	rs4888733	chr16:78080523	C/T	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg21475434	chr5:93447410	FAM172A	0.74	8.59	0.39	1.67e-16	Diabetic retinopathy;
LUAD	cis	rs7524258	0.868	rs2412153	chr1:7272412	C/T	cg07173049	chr1:7289937	CAMTA1	0.49	9.35	0.41	5.03e-19	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs12122100	0.651	rs12728300	chr1:146542184	T/C	cg03526459	chr1:146549940	NA	-0.4	-7.36	-0.34	9.82e-13	HIV-1 control;
LUAD	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg20307385	chr11:47447363	PSMC3	0.53	7.87	0.36	3.1e-14	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg11214544	chr1:2391121	NA	-0.56	-11.22	-0.48	9.42e-26	Non-obstructive azoospermia;
LUAD	cis	rs2625529	0.652	rs11072350	chr15:72464609	T/G	cg16672083	chr15:72433130	SENP8	0.63	11.45	0.49	1.31e-26	Red blood cell count;
LUAD	cis	rs7903847	0.642	rs10882910	chr10:99138043	G/A	cg20016023	chr10:99160130	RRP12	-0.3	-7.2	-0.33	2.8e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1003719	0.646	rs7276711	chr21:38578189	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.2	-0.37	2.89e-15	Eye color traits;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06767701	chr1:152008878	S100A11	-0.42	-6.54	-0.3	1.76e-10	Height;
LUAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08677398	chr8:58056175	NA	0.46	6.54	0.3	1.76e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg19318889	chr4:1322082	MAEA	-0.44	-7.53	-0.34	2.99e-13	Obesity-related traits;
LUAD	trans	rs1941687	0.732	rs3744888	chr18:31402594	A/G	cg27147174	chr7:100797783	AP1S1	-0.51	-8.82	-0.39	3.04e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg24733560	chr20:60626293	TAF4	0.47	9.21	0.41	1.55e-18	Body mass index;
LUAD	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03264133	chr6:25882463	NA	-0.97	-17.3	-0.64	4.23e-51	Urate levels;
LUAD	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg08999081	chr20:33150536	PIGU	0.63	14.54	0.58	3.89e-39	Glomerular filtration rate (creatinine);
LUAD	cis	rs4604732	0.631	rs12036460	chr1:247626928	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.43	7.36	0.34	9.62e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.51	-0.42	1.44e-19	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.81	0.35	4.62e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	ch.11.42038R	chr11:967971	AP2A2	0.4	6.99	0.32	1.11e-11	Alzheimer's disease (late onset);
LUAD	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg20476274	chr7:133979776	SLC35B4	0.76	13.19	0.54	1.59e-33	Mean platelet volume;
LUAD	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg09323728	chr8:95962352	TP53INP1	-0.33	-7.97	-0.36	1.45e-14	Type 2 diabetes;
LUAD	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.13	-31.15	-0.83	1.5e-111	Myeloid white cell count;
LUAD	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg26513180	chr16:89883248	FANCA	0.65	6.63	0.31	1.02e-10	Skin colour saturation;
LUAD	cis	rs7707921	0.881	rs12108833	chr5:81371755	A/G	cg15871215	chr5:81402204	ATG10	-0.69	-9.86	-0.43	9.05e-21	Breast cancer;
LUAD	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg08989290	chr16:615782	NHLRC4	0.32	7.0	0.32	1.03e-11	Height;
LUAD	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.71	0.31	6.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg00255919	chr5:131827918	IRF1	-0.48	-11.13	-0.48	2.12e-25	Asthma (sex interaction);
LUAD	cis	rs7180079	1.000	rs55700118	chr15:64529455	G/T	cg08069370	chr15:64387884	SNX1	-0.51	-6.56	-0.3	1.6e-10	Monocyte count;
LUAD	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.39	7.7	0.35	9.82e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9811920	0.660	rs7619512	chr3:99729132	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	6.76	0.31	4.48e-11	Axial length;
LUAD	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg03806693	chr22:41940476	POLR3H	0.54	7.99	0.36	1.29e-14	Vitiligo;
LUAD	cis	rs4604732	0.631	rs34443739	chr1:247626913	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	9.02	0.4	6.67e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11890956	chr21:40555474	PSMG1	0.66	10.58	0.46	2.35e-23	Cognitive function;
LUAD	trans	rs2270927	0.510	rs13188781	chr5:75580409	C/A	cg13563193	chr19:33072644	PDCD5	1.02	9.42	0.42	3.02e-19	Mean corpuscular volume;
LUAD	cis	rs1018836	0.923	rs756569	chr8:91610957	G/A	cg16814680	chr8:91681699	NA	-0.68	-11.59	-0.49	3.75e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg08847533	chr14:75593920	NEK9	0.43	7.33	0.34	1.19e-12	Height;
LUAD	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg19875535	chr5:140030758	IK	-0.47	-7.82	-0.36	4.4e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1692580	0.807	rs12040414	chr1:2192948	T/C	cg21194808	chr1:2205498	SKI	0.4	6.63	0.31	9.98e-11	Coronary artery disease;
LUAD	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg00784671	chr22:46762841	CELSR1	-0.53	-7.29	-0.33	1.52e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg02428538	chr16:24856791	SLC5A11	0.54	7.48	0.34	4.26e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg17724175	chr1:150552817	MCL1	0.33	7.55	0.34	2.62e-13	Melanoma;
LUAD	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg07917127	chr4:99064746	C4orf37	0.42	7.0	0.32	1.02e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg25358565	chr5:93447407	FAM172A	0.62	6.98	0.32	1.13e-11	Diabetic retinopathy;
LUAD	cis	rs453301	0.631	rs7843789	chr8:8800561	G/C	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.12	-0.33	4.78e-12	Joint mobility (Beighton score);
LUAD	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.13	0.33	4.37e-12	Hypertriglyceridemia;
LUAD	cis	rs7818345	0.935	rs6990217	chr8:19276661	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.3	6.61	0.31	1.15e-10	Language performance in older adults (adjusted for episodic memory);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10538494	chr14:97263716	VRK1	-0.52	-6.63	-0.31	1.05e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.06	-0.36	7.8e-15	Gout;
LUAD	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18404041	chr3:52824283	ITIH1	-0.6	-12.58	-0.52	4.93e-31	Electroencephalogram traits;
LUAD	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11890956	chr21:40555474	PSMG1	-0.6	-9.99	-0.44	2.99e-21	Cognitive function;
LUAD	cis	rs9584850	0.874	rs9168	chr13:99101583	C/A	cg17380943	chr13:99100506	FARP1	-0.36	-6.84	-0.32	2.74e-11	Neuroticism;
LUAD	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg02775129	chr4:119771670	NA	-0.86	-8.06	-0.36	7.93e-15	Cannabis dependence symptom count;
LUAD	trans	rs1268789	0.571	rs949507	chr4:79394086	C/T	cg00427086	chr15:52861396	ARPP19	-0.42	-6.79	-0.31	3.71e-11	Hair shape;Hair morphology;
LUAD	cis	rs71478720	0.859	rs12796114	chr11:112049140	A/C	cg04929355	chr11:112034997	IL18	0.43	6.83	0.32	2.96e-11	Interleukin-18 levels;
LUAD	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg18016565	chr1:150552671	MCL1	0.41	7.4	0.34	7.61e-13	Blood protein levels;
LUAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.18	0.54	1.8e-33	Prudent dietary pattern;
LUAD	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg06784218	chr1:46089804	CCDC17	-0.36	-7.84	-0.36	3.8e-14	Red blood cell count;Reticulocyte count;
LUAD	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg03690763	chr11:133734501	NA	-0.35	-7.99	-0.36	1.31e-14	Childhood ear infection;
LUAD	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg21475434	chr5:93447410	FAM172A	-0.64	-7.9	-0.36	2.44e-14	Diabetic retinopathy;
LUAD	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg10295955	chr4:187884368	NA	0.86	17.34	0.64	2.99e-51	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28595532	0.800	rs114321375	chr4:119341663	G/A	cg21605333	chr4:119757512	SEC24D	0.69	6.75	0.31	4.82e-11	Cannabis dependence symptom count;
LUAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.8	-0.31	3.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg27211696	chr2:191398769	TMEM194B	-0.67	-9.01	-0.4	7.04e-18	Diastolic blood pressure;
LUAD	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg27490568	chr2:178487706	NA	-0.54	-7.89	-0.36	2.57e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.42	0.45	8.62e-23	Post bronchodilator FEV1;
LUAD	cis	rs4691139	0.611	rs11100590	chr4:165924787	C/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.42	-7.78	-0.35	5.48e-14	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs11209185	0.509	rs9436790	chr1:68447044	G/A	cg22082780	chr1:68452167	NA	0.51	10.69	0.46	9.35e-24	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg04398451	chr17:18023971	MYO15A	0.64	11.42	0.49	1.7e-26	Total body bone mineral density;
LUAD	cis	rs8077889	0.917	rs72836545	chr17:41892602	A/G	cg26893861	chr17:41843967	DUSP3	0.94	14.77	0.58	4.11e-40	Triglycerides;
LUAD	cis	rs4343996	0.869	rs6974577	chr7:3511350	G/T	cg21248987	chr7:3385318	SDK1	0.35	6.43	0.3	3.45e-10	Motion sickness;
LUAD	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-7.17	-0.33	3.34e-12	Daytime sleep phenotypes;
LUAD	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg03929089	chr4:120376271	NA	-0.92	-17.83	-0.66	2.01e-53	Height;
LUAD	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg01874867	chr7:94954059	PON1	-0.48	-6.47	-0.3	2.74e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.62	9.24	0.41	1.2e-18	Platelet count;
LUAD	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg09936142	chr19:10668400	KRI1	0.46	6.75	0.31	4.95e-11	Red cell distribution width;
LUAD	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg12379764	chr21:47803548	PCNT	-0.38	-6.45	-0.3	2.99e-10	Testicular germ cell tumor;
LUAD	cis	rs4774899	0.966	rs12904321	chr15:57507579	A/T	cg14026238	chr15:57616123	NA	0.36	6.76	0.31	4.72e-11	Urinary tract infection frequency;
LUAD	cis	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg00086871	chr4:6988644	TBC1D14	0.74	6.35	0.3	5.45e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2046867	0.908	rs2679208	chr3:72787440	G/A	cg04365224	chr3:72788183	NA	0.42	6.51	0.3	2.16e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4072705	0.869	rs2416951	chr9:127550603	C/G	cg13476313	chr9:127244764	NR5A1	0.33	7.71	0.35	8.95e-14	Menarche (age at onset);
LUAD	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg20790798	chr5:1857306	NA	-0.45	-7.46	-0.34	4.81e-13	Cardiovascular disease risk factors;
LUAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg13047869	chr3:10149882	C3orf24	0.66	11.11	0.48	2.5e-25	Alzheimer's disease;
LUAD	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg27426351	chr10:43362370	NA	0.52	7.89	0.36	2.67e-14	Blood protein levels;
LUAD	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg17863274	chr19:49399704	TULP2	-0.64	-9.78	-0.43	1.74e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg21890820	chr11:65308645	LTBP3	-0.59	-9.72	-0.43	2.84e-20	Bone mineral density;
LUAD	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg11871910	chr12:69753446	YEATS4	0.48	7.47	0.34	4.6e-13	Response to diuretic therapy;
LUAD	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Colorectal cancer;
LUAD	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg06740227	chr12:86229804	RASSF9	-0.41	-7.34	-0.34	1.08e-12	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.16e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs332507	0.789	rs11928787	chr3:124408149	C/T	cg05980111	chr3:124395277	KALRN	0.43	6.86	0.32	2.41e-11	Plateletcrit;
LUAD	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg04414720	chr1:150670196	GOLPH3L	0.66	11.41	0.49	1.76e-26	Melanoma;
LUAD	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14490972	chr6:43484812	POLR1C;YIPF3	-0.44	-7.03	-0.32	8.48e-12	Height;
LUAD	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg03806693	chr22:41940476	POLR3H	-0.6	-8.4	-0.38	6.7e-16	Vitiligo;
LUAD	cis	rs2730260	0.611	rs73169221	chr7:158846316	T/A	cg02254261	chr7:158964346	NA	-0.54	-6.43	-0.3	3.39e-10	Myopia (pathological);
LUAD	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg25767906	chr1:53392781	SCP2	0.65	11.98	0.5	1.12e-28	Monocyte count;
LUAD	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg06627628	chr2:24431161	ITSN2	0.4	6.86	0.32	2.39e-11	Asthma;
LUAD	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg13126279	chr21:47581558	C21orf56	-0.44	-7.56	-0.35	2.46e-13	Testicular germ cell tumor;
LUAD	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg06608945	chr2:219082296	ARPC2	-0.42	-7.02	-0.32	8.73e-12	Colorectal cancer;
LUAD	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.33	0.38	1.15e-15	Rheumatoid arthritis;
LUAD	cis	rs7705042	0.793	rs10463348	chr5:141502035	G/T	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.8	-0.31	3.48e-11	Asthma;
LUAD	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg00129232	chr17:37814104	STARD3	-0.48	-8.73	-0.39	5.85e-17	Asthma;
LUAD	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.62	11.89	0.5	2.53e-28	Schizophrenia;
LUAD	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg17105886	chr17:28927953	LRRC37B2	0.85	8.14	0.37	4.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.43	-7.61	-0.35	1.76e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg26554054	chr8:600488	NA	0.82	8.02	0.36	1.08e-14	IgG glycosylation;
LUAD	cis	rs2735413	0.875	rs12924402	chr16:78083477	C/G	cg04733911	chr16:78082701	NA	-0.34	-8.15	-0.37	4.05e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.33	6.58	0.3	1.39e-10	Obesity-related traits;
LUAD	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg26769984	chr7:1090371	C7orf50	0.53	8.41	0.38	6.28e-16	Bronchopulmonary dysplasia;
LUAD	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg15147215	chr3:52552868	STAB1	-0.38	-7.06	-0.32	7.06e-12	Electroencephalogram traits;
LUAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg12432903	chr7:1882776	MAD1L1	-0.43	-6.83	-0.32	3e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg05896524	chr21:47604654	C21orf56	0.54	9.05	0.4	5.18e-18	Testicular germ cell tumor;
LUAD	cis	rs863345	0.504	rs857698	chr1:158561166	A/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.5	-0.3	2.25e-10	Pneumococcal bacteremia;
LUAD	cis	rs2282300	0.739	rs1222219	chr11:30344345	G/C	cg25418670	chr11:30344373	C11orf46	-0.51	-6.8	-0.31	3.56e-11	Morning vs. evening chronotype;
LUAD	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg18755752	chr8:142205143	DENND3	0.65	12.73	0.53	1.21e-31	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2067615	0.524	rs4275715	chr12:107062246	C/T	cg15890332	chr12:107067104	RFX4	0.41	8.8	0.39	3.44e-17	Heart rate;
LUAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg05896524	chr21:47604654	C21orf56	-0.78	-13.61	-0.55	3.1e-35	Testicular germ cell tumor;
LUAD	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg14829155	chr15:31115871	NA	-0.52	-8.59	-0.39	1.68e-16	Huntington's disease progression;
LUAD	cis	rs151234	0.676	rs554206	chr16:28576369	G/A	cg04643524	chr16:28609220	SULT1A2	0.63	8.98	0.4	8.68e-18	Platelet distribution width;
LUAD	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg25894440	chr7:65020034	NA	-0.65	-6.98	-0.32	1.13e-11	Diabetic kidney disease;
LUAD	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg09537434	chr19:41945824	ATP5SL	-0.54	-8.55	-0.38	2.35e-16	Height;
LUAD	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24308560	chr3:49941425	MST1R	-0.59	-9.9	-0.43	6.45e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg22920501	chr2:26401640	FAM59B	-0.76	-10.88	-0.47	1.74e-24	Gut microbiome composition (summer);
LUAD	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg13073564	chr4:8508604	NA	-0.55	-10.09	-0.44	1.36e-21	Response to antineoplastic agents;
LUAD	cis	rs1595825	1.000	rs2165237	chr2:198875003	C/T	cg00982548	chr2:198649783	BOLL	-0.6	-8.68	-0.39	8.65e-17	Ulcerative colitis;
LUAD	cis	rs12286929	0.617	rs11607801	chr11:115077367	A/C	cg04055981	chr11:115044050	NA	0.44	8.26	0.37	1.91e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg15448220	chr1:150897856	SETDB1	0.49	8.48	0.38	3.81e-16	Tonsillectomy;
LUAD	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg20503657	chr10:835505	NA	0.8	12.32	0.51	5.22e-30	Eosinophil percentage of granulocytes;
LUAD	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg03037974	chr15:76606532	NA	0.38	8.02	0.36	1.06e-14	Blood metabolite levels;
LUAD	cis	rs12900413	0.645	rs28407340	chr15:90311864	C/T	cg24249390	chr15:90295951	MESP1	-0.33	-6.49	-0.3	2.4e-10	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs427941	0.667	rs34247954	chr7:101740993	C/T	cg06246474	chr7:101738831	CUX1	0.41	7.29	0.33	1.57e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08282784	chr12:121454133	C12orf43	-0.52	-6.43	-0.3	3.5e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg03433033	chr1:76189801	ACADM	0.86	15.41	0.6	7.24e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg26587870	chr6:27730563	NA	-0.57	-6.4	-0.3	4.18e-10	Depression;
LUAD	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg13606994	chr1:44402422	ARTN	0.36	7.32	0.34	1.27e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06544989	chr22:39130855	UNC84B	0.41	7.56	0.34	2.61e-13	Menopause (age at onset);
LUAD	cis	rs9469890	0.604	rs77186075	chr6:34504478	C/T	cg14254433	chr6:34482411	PACSIN1	-0.62	-8.72	-0.39	6.26e-17	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg09517075	chr8:22133004	PIWIL2	0.49	9.09	0.4	3.78e-18	Hypertriglyceridemia;
LUAD	cis	rs4730250	0.707	rs80095766	chr7:106901394	G/T	cg23024343	chr7:107201750	COG5	0.45	6.6	0.31	1.24e-10	Osteoarthritis;
LUAD	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg18129748	chr3:49941408	MST1R	-0.4	-6.42	-0.3	3.56e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7593730	1.000	rs10929978	chr2:161169956	G/C	cg22609984	chr2:161126801	NA	0.44	7.24	0.33	2.15e-12	Type 2 diabetes;
LUAD	trans	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg04565464	chr8:145669602	NFKBIL2	-0.43	-6.74	-0.31	5.14e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg22532475	chr10:104410764	TRIM8	0.44	8.38	0.38	8.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7633770	0.841	rs6442010	chr3:46669500	A/T	cg11219411	chr3:46661640	NA	0.63	14.17	0.57	1.4e-37	Coronary artery disease;
LUAD	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg06808227	chr14:105710500	BRF1	-0.42	-6.66	-0.31	8.4e-11	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg27471124	chr11:109292789	C11orf87	-0.36	-7.28	-0.33	1.64e-12	Schizophrenia;
LUAD	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg16606324	chr3:10149918	C3orf24	0.68	11.37	0.48	2.59e-26	Alzheimer's disease;
LUAD	cis	rs4372836	0.729	rs10174533	chr2:28968928	G/A	cg09522027	chr2:28974177	PPP1CB	-0.69	-12.77	-0.53	8.17e-32	Body mass index;
LUAD	cis	rs6733011	0.600	rs1568213	chr2:99432063	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.67	-0.31	7.94e-11	Bipolar disorder;
LUAD	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg17063962	chr7:91808500	NA	0.7	12.44	0.52	1.66e-30	Breast cancer;
LUAD	cis	rs3784262	0.512	rs4646572	chr15:58343021	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.51	-10.04	-0.44	1.99e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg11941060	chr3:133502564	NA	-0.64	-11.47	-0.49	1.07e-26	Iron status biomarkers;
LUAD	cis	rs7289126	1.000	rs4820328	chr22:38635679	C/T	cg17652424	chr22:38574118	PLA2G6	-0.25	-7.15	-0.33	3.82e-12	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs7177699	0.557	rs9806363	chr15:79110302	A/G	cg00540400	chr15:79124168	NA	-0.46	-9.71	-0.43	2.93e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	6.73	0.31	5.52e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs6761276	0.899	rs13389457	chr2:113834885	T/C	cg02343335	chr2:113785852	IL1F8	-0.35	-7.01	-0.32	9.57e-12	Protein quantitative trait loci;
LUAD	cis	rs9322817	0.691	rs2400071	chr6:105344075	C/T	cg02098413	chr6:105308735	HACE1	0.41	8.84	0.4	2.54e-17	Thyroid stimulating hormone;
LUAD	trans	rs11890236	0.579	rs35397650	chr2:104729432	G/A	cg11430077	chr10:8099018	GATA3	-0.62	-6.56	-0.3	1.57e-10	Obesity-related traits;
LUAD	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg25894440	chr7:65020034	NA	-0.68	-7.36	-0.34	9.49e-13	Diabetic kidney disease;
LUAD	cis	rs6782228	0.585	rs2811492	chr3:128356279	A/G	cg16766828	chr3:128327626	NA	-0.38	-7.2	-0.33	2.79e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg15900387	chr1:150738905	CTSS	0.35	6.49	0.3	2.34e-10	Melanoma;
LUAD	cis	rs7843479	0.582	rs7818254	chr8:21798316	C/T	cg03445287	chr8:21823731	XPO7	-0.5	-9.44	-0.42	2.62e-19	Mean corpuscular volume;
LUAD	cis	rs2777491	0.507	rs34040639	chr15:41760807	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.1	-23.93	-0.76	1.2e-80	Ulcerative colitis;
LUAD	trans	rs4332037	0.715	rs57234495	chr7:1906466	G/A	cg11693508	chr17:37793320	STARD3	0.77	9.79	0.43	1.61e-20	Bipolar disorder;
LUAD	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18876405	chr7:65276391	NA	0.53	8.83	0.39	2.89e-17	Aortic root size;
LUAD	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg10518543	chr12:38710700	ALG10B	-0.46	-7.6	-0.35	1.98e-13	Morning vs. evening chronotype;
LUAD	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg05110241	chr16:68378359	PRMT7	-0.66	-8.34	-0.38	1.08e-15	Schizophrenia;
LUAD	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19346786	chr7:2764209	NA	-0.57	-12.15	-0.51	2.51e-29	Height;
LUAD	cis	rs17685	0.753	rs869804	chr7:75688954	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.77	-0.35	5.96e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg19318889	chr4:1322082	MAEA	-0.45	-7.83	-0.36	3.9e-14	Obesity-related traits;
LUAD	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg20701182	chr2:24300061	SF3B14	0.6	6.86	0.32	2.39e-11	Lymphocyte counts;
LUAD	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg12935359	chr14:103987150	CKB	-0.46	-7.41	-0.34	6.93e-13	Body mass index;
LUAD	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.42	0.57	1.29e-38	Schizophrenia;
LUAD	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.01	-0.32	9.59e-12	Mood instability;
LUAD	cis	rs870825	1.000	rs9995633	chr4:185584441	C/T	cg04058563	chr4:185651563	MLF1IP	0.74	10.23	0.45	4.21e-22	Blood protein levels;
LUAD	cis	rs1232027	0.622	rs1677644	chr5:79963976	A/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.15	-0.33	3.76e-12	Huntington's disease progression;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10210571	chr1:231664364	TSNAX-DISC1;TSNAX	-0.52	-6.4	-0.3	4.23e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg17372223	chr3:52568218	NT5DC2	-0.39	-7.1	-0.33	5.19e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9811920	0.809	rs7649349	chr3:99725629	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	6.69	0.31	6.92e-11	Axial length;
LUAD	cis	rs2279817	0.820	rs924686	chr1:18027726	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.51	8.42	0.38	5.93e-16	Neuroticism;
LUAD	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg16205897	chr5:131564050	P4HA2	-0.3	-6.39	-0.3	4.38e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11890956	chr21:40555474	PSMG1	-0.54	-9.27	-0.41	9.59e-19	Menarche (age at onset);
LUAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg06753367	chr22:24256600	NA	-0.38	-6.82	-0.31	3.19e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg22349387	chr12:9600060	DDX12	-0.5	-8.95	-0.4	1.15e-17	Breast size;
LUAD	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg03474202	chr17:45855739	NA	-0.39	-9.21	-0.41	1.58e-18	IgG glycosylation;
LUAD	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg10523679	chr1:76189770	ACADM	0.91	16.3	0.62	1.1e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg00280220	chr17:61926910	NA	0.36	6.98	0.32	1.12e-11	Prudent dietary pattern;
LUAD	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	trans	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg06606381	chr12:133084897	FBRSL1	0.49	6.49	0.3	2.39e-10	Depression;
LUAD	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg25237894	chr2:233734115	C2orf82	-0.61	-11.47	-0.49	1.09e-26	Coronary artery disease;
LUAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg27094323	chr7:1216898	NA	-0.36	-6.97	-0.32	1.23e-11	Longevity;Endometriosis;
LUAD	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg13902645	chr11:5959945	NA	-0.57	-10.45	-0.45	6.71e-23	DNA methylation (variation);
LUAD	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg11189052	chr15:85197271	WDR73	0.68	8.92	0.4	1.38e-17	Schizophrenia;
LUAD	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg14343924	chr8:8086146	FLJ10661	-0.51	-8.04	-0.36	9.34e-15	Mood instability;
LUAD	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg26441486	chr22:50317300	CRELD2	0.45	6.78	0.31	4.03e-11	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.71	-12.35	-0.51	3.76e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs870825	0.616	rs7682557	chr4:185640773	A/G	cg04058563	chr4:185651563	MLF1IP	0.88	14.17	0.57	1.49e-37	Blood protein levels;
LUAD	cis	rs11229555	0.645	rs12289985	chr11:58185436	C/G	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg15557168	chr22:42548783	NA	-0.57	-11.21	-0.48	1.01e-25	Schizophrenia;
LUAD	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg17105886	chr17:28927953	LRRC37B2	0.86	8.3	0.37	1.42e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.99	0.32	1.07e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg06221963	chr1:154839813	KCNN3	0.44	8.07	0.37	7.48e-15	Schizophrenia;
LUAD	cis	rs4280164	0.551	rs3212243	chr14:24810370	T/C	cg07162820	chr14:24837146	NFATC4	0.32	6.51	0.3	2.13e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24838063	chr12:130822603	PIWIL1	0.65	10.86	0.47	2.13e-24	Menopause (age at onset);
LUAD	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg15445000	chr17:37608096	MED1	-0.45	-8.25	-0.37	1.96e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1032833	0.732	rs4101465	chr2:179960550	T/C	cg23883738	chr2:179974586	SESTD1	-0.72	-8.26	-0.37	1.86e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg04063615	chr12:132293388	NA	-0.38	-6.72	-0.31	5.76e-11	Migraine;
LUAD	cis	rs10979	1.000	rs9386038	chr6:143896358	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.28	-0.45	2.77e-22	Hypospadias;
LUAD	cis	rs6445967	0.530	rs62258132	chr3:58398070	T/C	cg13750441	chr3:58318267	PXK	-0.32	-6.7	-0.31	6.83e-11	Platelet count;
LUAD	cis	rs346785	0.692	rs6501883	chr17:74289908	A/G	cg09812376	chr17:74270190	QRICH2	-0.3	-6.39	-0.3	4.46e-10	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs1957429	0.808	rs1951492	chr14:65346895	G/A	cg23373153	chr14:65346875	NA	0.56	6.42	0.3	3.57e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25427524	chr10:38739819	LOC399744	-0.78	-13.94	-0.56	1.32e-36	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg24397884	chr7:158709396	WDR60	0.66	9.05	0.4	5.42e-18	Height;
LUAD	cis	rs6748734	0.948	rs9973366	chr2:241838151	T/C	cg07537917	chr2:241836409	C2orf54	-0.31	-8.84	-0.39	2.58e-17	Urinary metabolites;
LUAD	cis	rs12618769	0.543	rs4851132	chr2:99042782	T/C	cg10123293	chr2:99228465	UNC50	0.46	8.24	0.37	2.11e-15	Bipolar disorder;
LUAD	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg12292205	chr6:26970375	C6orf41	0.38	6.83	0.32	3.01e-11	Schizophrenia;
LUAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08048268	chr3:133502702	NA	-0.52	-10.46	-0.45	6.34e-23	Iron status biomarkers;
LUAD	cis	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg21775007	chr8:11205619	TDH	0.56	10.38	0.45	1.26e-22	Retinal vascular caliber;
LUAD	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg07741184	chr6:167504864	NA	-0.3	-7.15	-0.33	3.79e-12	Crohn's disease;
LUAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg07677032	chr17:61819896	STRADA	0.56	10.08	0.44	1.43e-21	Prudent dietary pattern;
LUAD	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg23625390	chr15:77176239	SCAPER	-0.52	-8.08	-0.37	6.91e-15	Blood metabolite levels;
LUAD	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg24558204	chr6:135376177	HBS1L	0.46	8.42	0.38	6.07e-16	Red blood cell count;
LUAD	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg01028140	chr2:1542097	TPO	-0.44	-7.34	-0.34	1.1e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg26818010	chr10:134567672	INPP5A	-0.93	-15.41	-0.6	7.68e-43	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg16606324	chr3:10149918	C3orf24	0.68	11.41	0.49	1.78e-26	Alzheimer's disease;
LUAD	cis	rs68170813	0.559	rs77013162	chr7:107071674	A/C	cg23024343	chr7:107201750	COG5	0.51	7.06	0.32	6.78e-12	Coronary artery disease;
LUAD	cis	rs12711979	0.509	rs10195596	chr2:3824222	T/G	cg17052675	chr2:3827356	NA	-0.84	-19.39	-0.69	2.24e-60	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6840360	0.593	rs10022023	chr4:152560731	A/G	cg22705602	chr4:152727874	NA	-0.36	-6.37	-0.3	4.98e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs73086581	0.687	rs73082600	chr20:3844365	G/A	cg02187196	chr20:3869020	PANK2	0.49	6.82	0.31	3.23e-11	Response to antidepressants in depression;
LUAD	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.09	-22.29	-0.73	2.36e-73	Ulcerative colitis;
LUAD	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.52	-0.34	3.38e-13	Breast cancer;
LUAD	cis	rs11166629	1.000	rs4909331	chr8:135644540	T/C	cg27224718	chr8:135614730	ZFAT	0.59	10.6	0.46	1.91e-23	Smoking quantity;
LUAD	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg11941060	chr3:133502564	NA	0.5	8.2	0.37	2.91e-15	Iron status biomarkers;
LUAD	cis	rs13315871	1.000	rs9869940	chr3:58401523	G/A	cg12435725	chr3:58293450	RPP14	-0.69	-7.35	-0.34	1.05e-12	Cholesterol, total;
LUAD	cis	rs12210905	0.688	rs12374607	chr6:27343620	A/G	cg08851530	chr6:28072375	NA	1.09	7.97	0.36	1.45e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs684232	0.602	rs331008	chr17:544617	C/T	cg12384639	chr17:618140	VPS53	0.48	8.26	0.37	1.94e-15	Prostate cancer;
LUAD	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg25554036	chr4:6271136	WFS1	0.67	13.34	0.54	3.79e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs12545109	0.765	rs2576589	chr8:57425647	C/T	cg07776626	chr8:57350775	NA	-0.59	-8.44	-0.38	5.23e-16	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.26	0.37	1.91e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.61	8.88	0.4	1.91e-17	Gut microbiome composition (summer);
LUAD	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg00409905	chr10:38381863	ZNF37A	-0.4	-6.47	-0.3	2.66e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg14779329	chr11:130786720	SNX19	0.37	6.49	0.3	2.38e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs62400317	0.859	rs56283067	chr6:45100330	T/C	cg20913747	chr6:44695427	NA	-0.42	-6.6	-0.31	1.21e-10	Total body bone mineral density;
LUAD	trans	rs1973993	0.691	rs11165623	chr1:96893000	G/A	cg10631902	chr5:14652156	NA	0.71	14.77	0.58	4.18e-40	Weight;
LUAD	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg21427119	chr20:30132790	HM13	-0.61	-9.18	-0.41	1.99e-18	Mean corpuscular hemoglobin;
LUAD	cis	rs938554	1.000	rs6832456	chr4:9924336	A/C	cg00071950	chr4:10020882	SLC2A9	0.54	8.53	0.38	2.63e-16	Blood metabolite levels;
LUAD	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.04	0.32	7.7e-12	Motion sickness;
LUAD	cis	rs757081	0.636	rs214934	chr11:17193475	T/A	cg15432903	chr11:17409602	KCNJ11	-0.4	-6.39	-0.3	4.46e-10	Systolic blood pressure;
LUAD	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg15133208	chr4:90757351	SNCA	-0.47	-7.54	-0.34	2.98e-13	Neuroticism;
LUAD	cis	rs1865721	0.755	rs3813081	chr18:73185096	A/G	cg26385618	chr18:73139727	C18orf62	-0.38	-7.42	-0.34	6.66e-13	Intelligence;
LUAD	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg04586622	chr2:25135609	ADCY3	0.37	8.46	0.38	4.51e-16	Body mass index;
LUAD	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.97	20.88	0.71	4.9e-67	Chronic sinus infection;
LUAD	trans	rs1406428	0.573	rs12613632	chr2:51705755	C/G	cg11654769	chr5:148206180	ADRB2	0.43	6.51	0.3	2.07e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg18451016	chr1:38461880	NA	0.46	8.84	0.39	2.69e-17	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg16512390	chr1:228756714	NA	0.49	8.07	0.37	7.43e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg00933542	chr6:150070202	PCMT1	0.44	9.72	0.43	2.64e-20	Lung cancer;
LUAD	cis	rs17095355	0.901	rs17126938	chr10:111761351	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.14	-0.33	4.12e-12	Biliary atresia;
LUAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg09033563	chr22:24373618	LOC391322	-0.6	-9.63	-0.42	5.83e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7737355	0.773	rs31239	chr5:130813377	G/T	cg25547332	chr5:131281432	NA	-0.4	-6.5	-0.3	2.33e-10	Life satisfaction;
LUAD	cis	rs10203711	0.966	rs4998694	chr2:239564713	C/T	cg14580085	chr2:239553406	NA	0.42	8.95	0.4	1.12e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg24829409	chr8:58192753	C8orf71	-0.66	-7.94	-0.36	1.84e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs3849570	0.615	rs6778265	chr3:81985745	C/T	cg07356753	chr3:81810745	GBE1	0.46	7.7	0.35	9.9e-14	Waist circumference;Body mass index;
LUAD	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg07157834	chr1:205819609	PM20D1	-0.47	-6.91	-0.32	1.8e-11	Menarche (age at onset);
LUAD	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg10544611	chr16:67998164	SLC12A4	-0.69	-8.01	-0.36	1.12e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg04025307	chr7:1156635	C7orf50	0.6	6.77	0.31	4.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg27426351	chr10:43362370	NA	-0.53	-8.12	-0.37	5e-15	Blood protein levels;
LUAD	cis	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.44	8.38	0.38	8.16e-16	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg20135002	chr11:47629003	NA	-0.42	-7.38	-0.34	8.73e-13	Subjective well-being;
LUAD	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg24634471	chr8:143751801	JRK	0.47	7.45	0.34	5.2e-13	Schizophrenia;
LUAD	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11890956	chr21:40555474	PSMG1	0.8	14.04	0.56	4.88e-37	Cognitive function;
LUAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg07677032	chr17:61819896	STRADA	0.55	9.92	0.43	5.41e-21	Prudent dietary pattern;
LUAD	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg03690763	chr11:133734501	NA	-0.34	-8.04	-0.36	9.3e-15	Childhood ear infection;
LUAD	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg13319975	chr6:146136371	FBXO30	-0.8	-13.5	-0.55	8.3e-35	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg11429632	chr9:123964581	RAB14	0.42	6.75	0.31	4.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg18827107	chr12:86230957	RASSF9	0.54	9.63	0.42	5.64e-20	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg18180107	chr4:99064573	C4orf37	0.42	6.68	0.31	7.55e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg15888301	chr15:73344233	NEO1	-0.53	-6.37	-0.3	5e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1005224	0.963	rs11623813	chr14:76138194	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.43	-6.41	-0.3	3.84e-10	Large artery stroke;
LUAD	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg08888203	chr3:10149979	C3orf24	0.62	8.63	0.39	1.23e-16	Alzheimer's disease;
LUAD	cis	rs758324	0.812	rs4705839	chr5:131175258	G/A	cg06307176	chr5:131281290	NA	0.44	7.4	0.34	7.55e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs220324	0.647	rs9981668	chr21:43559780	G/T	cg09727148	chr21:43560719	UMODL1	0.55	8.31	0.37	1.33e-15	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs6494488	0.500	rs77463022	chr15:65064841	G/A	cg08069370	chr15:64387884	SNX1	-0.72	-6.64	-0.31	9.61e-11	Coronary artery disease;
LUAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg22907277	chr7:1156413	C7orf50	0.68	8.04	0.36	9.36e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg14926445	chr8:58193284	C8orf71	-0.48	-6.95	-0.32	1.43e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.43	-7.37	-0.34	8.82e-13	Colorectal cancer;
LUAD	cis	rs7759001	0.857	rs2393932	chr6:27353197	T/C	cg18711553	chr6:27366782	ZNF391	0.39	6.43	0.3	3.36e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs4285028	0.948	rs73855480	chr3:121676646	A/G	cg11130432	chr3:121712080	ILDR1	-0.59	-8.44	-0.38	5.05e-16	Multiple sclerosis;
LUAD	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg03233332	chr7:66118400	NA	0.45	6.93	0.32	1.57e-11	Aortic root size;
LUAD	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg12193833	chr17:30244370	NA	-0.58	-7.0	-0.32	1.03e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.19	0.54	1.67e-33	Prudent dietary pattern;
LUAD	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg26597838	chr10:835615	NA	-0.51	-7.94	-0.36	1.78e-14	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs2625529	0.641	rs11852789	chr15:72265494	G/C	cg16672083	chr15:72433130	SENP8	-0.75	-12.42	-0.52	1.98e-30	Red blood cell count;
LUAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg03188948	chr7:1209495	NA	0.72	9.9	0.43	6.32e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8072100	0.720	rs4794057	chr17:45786452	C/T	cg25173405	chr17:45401733	C17orf57	-0.41	-6.89	-0.32	1.99e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs909002	0.925	rs10798882	chr1:32108547	C/G	cg13919466	chr1:32135498	COL16A1	0.34	8.01	0.36	1.12e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg00339695	chr16:24857497	SLC5A11	0.54	9.81	0.43	1.35e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg23978390	chr7:1156363	C7orf50	0.57	7.81	0.36	4.5e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.81	0.36	4.49e-14	Depression;
LUAD	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg27284194	chr4:1044797	NA	0.55	8.99	0.4	8.16e-18	Recombination rate (males);
LUAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06873352	chr17:61820015	STRADA	-0.73	-15.77	-0.61	2.05e-44	Prudent dietary pattern;
LUAD	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg00255919	chr5:131827918	IRF1	0.28	6.43	0.3	3.47e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg23131131	chr22:24373011	LOC391322	0.49	7.16	0.33	3.5e-12	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg03354898	chr7:1950403	MAD1L1	-0.38	-6.86	-0.32	2.52e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.48	7.73	0.35	7.88e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15369054	chr17:80825471	TBCD	0.66	11.02	0.47	5.38e-25	Breast cancer;
LUAD	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg16329650	chr2:213403929	ERBB4	0.6	10.88	0.47	1.72e-24	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs9408928	0.778	rs9409230	chr9:123967760	A/T	cg18493069	chr6:108582623	SNX3	0.7	6.8	0.31	3.69e-11	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg23752985	chr2:85803571	VAMP8	0.34	6.72	0.31	5.89e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg12483005	chr1:23474871	LUZP1	0.51	8.66	0.39	1.02e-16	Height;
LUAD	cis	rs9399401	0.626	rs9373347	chr6:142779885	C/T	cg03128060	chr6:142623767	GPR126	0.38	7.56	0.34	2.56e-13	Chronic obstructive pulmonary disease;
LUAD	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg02782426	chr3:40428986	ENTPD3	0.42	8.84	0.4	2.52e-17	Renal cell carcinoma;
LUAD	cis	rs6499255	0.857	rs8060588	chr16:69656500	A/G	cg15192750	chr16:69999425	NA	0.53	8.31	0.37	1.36e-15	IgE levels;
LUAD	cis	rs250677	0.522	rs6872701	chr5:148359086	C/G	cg18129178	chr5:148520854	ABLIM3	0.49	7.32	0.34	1.23e-12	Breast cancer;
LUAD	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg25767906	chr1:53392781	SCP2	0.4	7.19	0.33	2.87e-12	Monocyte count;
LUAD	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg22166914	chr1:53195759	ZYG11B	0.41	7.32	0.34	1.25e-12	Monocyte count;
LUAD	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg11166453	chr1:247681781	NA	0.38	7.12	0.33	4.72e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4285028	0.948	rs1920291	chr3:121672440	C/T	cg20356878	chr3:121714668	ILDR1	-0.5	-6.77	-0.31	4.2e-11	Multiple sclerosis;
LUAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg05564831	chr3:52568323	NT5DC2	-0.44	-8.57	-0.38	1.95e-16	Electroencephalogram traits;
LUAD	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-8.62	-0.39	1.37e-16	Height;
LUAD	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1816752	0.905	rs7571	chr13:25000617	C/G	cg02811702	chr13:24901961	NA	0.39	6.72	0.31	6.06e-11	Obesity-related traits;
LUAD	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg19875535	chr5:140030758	IK	0.46	7.6	0.35	1.99e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg21782813	chr7:2030301	MAD1L1	0.52	8.98	0.4	8.98e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs11971779	0.680	rs6467843	chr7:139070523	A/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.46	-0.3	2.86e-10	Diisocyanate-induced asthma;
LUAD	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg23533926	chr12:111358616	MYL2	-0.42	-7.16	-0.33	3.69e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.4	-6.67	-0.31	8.19e-11	Total body bone mineral density;
LUAD	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg11189052	chr15:85197271	WDR73	0.59	7.48	0.34	4.22e-13	Schizophrenia;
LUAD	cis	rs17152411	1.000	rs17152374	chr10:126592644	T/C	cg07906193	chr10:126599966	NA	0.58	7.52	0.34	3.21e-13	Height;
LUAD	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.74	10.33	0.45	1.82e-22	Body mass index;
LUAD	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	6.45	0.3	3.13e-10	Tonsillectomy;
LUAD	cis	rs4891159	0.790	rs72973773	chr18:74115176	T/C	cg24786174	chr18:74118243	ZNF516	-0.81	-15.12	-0.59	1.37e-41	Longevity;
LUAD	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	6.87	0.32	2.31e-11	Tonsillectomy;
LUAD	cis	rs2131877	0.827	rs6784890	chr3:194842145	A/C	cg19760965	chr3:194868843	C3orf21	0.36	6.41	0.3	3.79e-10	Non-small cell lung cancer;
LUAD	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg09085632	chr11:111637200	PPP2R1B	0.76	11.76	0.5	7.95e-28	Primary sclerosing cholangitis;
LUAD	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	15.8	0.61	1.55e-44	Bone mineral density;
LUAD	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg15448220	chr1:150897856	SETDB1	-0.41	-7.03	-0.32	8.36e-12	Tonsillectomy;
LUAD	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.81e-12	Colorectal cancer;
LUAD	cis	rs13064411	0.542	rs4396864	chr3:113212562	C/T	cg10517650	chr3:113235015	CCDC52	-0.45	-8.25	-0.37	2.01e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs240764	0.853	rs12374612	chr6:100955752	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-7.47	-0.34	4.62e-13	Neuroticism;
LUAD	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26314531	chr2:26401878	FAM59B	-0.64	-8.72	-0.39	6.19e-17	Gut microbiome composition (summer);
LUAD	cis	rs11677370	0.561	rs13003140	chr2:3816759	G/T	cg17052675	chr2:3827356	NA	-0.56	-8.51	-0.38	3.11e-16	Type 2 diabetes;
LUAD	cis	rs11209185	0.602	rs6662249	chr1:68447214	C/A	cg22082780	chr1:68452167	NA	0.38	7.54	0.34	2.8e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs3806843	0.576	rs155358	chr5:140297032	A/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.61	-0.31	1.17e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg01475377	chr6:109611718	NA	-0.55	-10.6	-0.46	1.93e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs9473147	0.571	rs9369717	chr6:47554468	T/G	cg02130027	chr6:47444894	CD2AP	0.37	6.97	0.32	1.24e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs752092	0.894	rs8036083	chr15:101767822	T/G	cg19997662	chr15:101784653	CHSY1	-0.47	-8.65	-0.39	1.06e-16	Corneal structure;
LUAD	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg09835421	chr16:68378352	PRMT7	-0.74	-8.48	-0.38	3.69e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3020333	0.875	rs2941742	chr6:152012988	A/G	cg22157087	chr6:152012887	ESR1	0.37	6.59	0.31	1.28e-10	Total body bone mineral density;
LUAD	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg19980929	chr12:42632907	YAF2	-0.34	-6.58	-0.3	1.43e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.6	0.31	1.21e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs13082711	0.953	rs13096477	chr3:27490194	T/C	cg02860705	chr3:27208620	NA	0.66	9.7	0.43	3.24e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg23649088	chr2:200775458	C2orf69	-0.62	-7.77	-0.35	6.15e-14	Schizophrenia;
LUAD	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.43	0.3	3.43e-10	Schizophrenia;
LUAD	trans	rs853679	0.607	rs34765154	chr6:28130450	G/A	cg06606381	chr12:133084897	FBRSL1	-1.22	-10.86	-0.47	2.15e-24	Depression;
LUAD	cis	rs4523957	0.583	rs7503141	chr17:2044645	T/C	cg16513277	chr17:2031491	SMG6	-0.98	-20.08	-0.7	1.79e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg26384229	chr12:38710491	ALG10B	0.46	7.49	0.34	4.17e-13	Bladder cancer;
LUAD	cis	rs7707921	0.752	rs2897554	chr5:81276241	C/T	cg15871215	chr5:81402204	ATG10	0.62	10.09	0.44	1.35e-21	Breast cancer;
LUAD	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg23625390	chr15:77176239	SCAPER	0.39	6.96	0.32	1.33e-11	Blood metabolite levels;
LUAD	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg12908607	chr1:44402522	ARTN	-0.49	-9.32	-0.41	6.52e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg22907277	chr7:1156413	C7orf50	0.67	10.22	0.44	4.72e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg24920358	chr1:40204285	PPIE	0.7	12.71	0.53	1.45e-31	Blood protein levels;
LUAD	cis	rs1298062	0.756	rs2463241	chr19:50996961	C/T	cg11430371	chr19:50961752	MYBPC2	-0.32	-6.57	-0.3	1.49e-10	Age of smoking initiation;
LUAD	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.41	6.4	0.3	4.22e-10	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg01416388	chr22:39784598	NA	0.53	9.15	0.41	2.48e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.56	-9.84	-0.43	1.06e-20	Longevity;Endometriosis;
LUAD	cis	rs2692947	0.537	rs11679899	chr2:96378162	A/G	cg23100626	chr2:96804247	ASTL	0.3	7.47	0.34	4.73e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg13047869	chr3:10149882	C3orf24	0.65	11.01	0.47	5.64e-25	Alzheimer's disease;
LUAD	cis	rs405460	0.557	rs388374	chr14:59308433	A/G	cg02291164	chr14:59296302	NA	0.39	7.46	0.34	5.12e-13	Obesity-related traits;
LUAD	trans	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.5	0.52	1.02e-30	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs7395662	1.000	rs10838944	chr11:48559571	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.32	-0.34	1.25e-12	HDL cholesterol;
LUAD	cis	rs68170813	0.641	rs77487103	chr7:107078793	T/C	cg02696742	chr7:106810147	HBP1	-0.78	-10.1	-0.44	1.23e-21	Coronary artery disease;
LUAD	cis	rs17095355	1.000	rs921348	chr10:111707498	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.7	-9.4	-0.42	3.53e-19	Biliary atresia;
LUAD	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg24397884	chr7:158709396	WDR60	0.45	7.78	0.35	5.76e-14	Height;
LUAD	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.53	-9.88	-0.43	7.6e-21	Schizophrenia;
LUAD	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg12432903	chr7:1882776	MAD1L1	-0.43	-6.98	-0.32	1.18e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg01324343	chr3:183735012	ABCC5	0.82	17.95	0.66	5.73e-54	Anterior chamber depth;
LUAD	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg14558114	chr2:88469736	THNSL2	-0.42	-6.63	-0.31	1.04e-10	Response to metformin (IC50);
LUAD	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.99e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	ch.5.3079640F	chr5:163067975	NA	-0.35	-6.56	-0.3	1.61e-10	Migraine with aura;
LUAD	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23158103	chr7:148848205	ZNF398	-0.62	-11.09	-0.47	2.83e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg26408565	chr15:76604113	ETFA	-0.45	-7.3	-0.33	1.42e-12	Blood metabolite levels;
LUAD	cis	rs12545109	0.613	rs10958480	chr8:57278717	A/T	cg17761419	chr8:57350749	NA	-0.56	-7.73	-0.35	7.92e-14	Obesity-related traits;
LUAD	cis	rs9581857	0.512	rs9507886	chr13:27957286	G/A	cg22138327	chr13:27999177	GTF3A	0.87	9.59	0.42	7.91e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	trans	rs875971	0.929	rs778712	chr7:65849978	C/T	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg19761014	chr17:28927070	LRRC37B2	0.81	8.13	0.37	4.79e-15	Body mass index;
LUAD	cis	rs7593730	1.000	rs4278892	chr2:161158738	A/G	cg22609984	chr2:161126801	NA	0.44	6.96	0.32	1.27e-11	Type 2 diabetes;
LUAD	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2282300	0.739	rs7952339	chr11:30327344	C/T	cg25418670	chr11:30344373	C11orf46	0.49	6.88	0.32	2.11e-11	Morning vs. evening chronotype;
LUAD	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg11247378	chr22:39784982	NA	-0.65	-10.41	-0.45	9.76e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9522267	0.535	rs4773393	chr13:112229755	A/G	cg10483660	chr13:112241077	NA	-0.32	-6.76	-0.31	4.51e-11	Hepatitis;
LUAD	cis	rs6088590	1.000	rs11698996	chr20:33449739	C/G	cg08999081	chr20:33150536	PIGU	0.45	8.06	0.36	8.03e-15	Coronary artery disease;
LUAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg25703541	chr22:24373054	LOC391322	-0.79	-14.25	-0.57	6.57e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.72	-0.39	6.26e-17	Menopause (age at onset);
LUAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11905131	chr22:24372483	LOC391322	-0.53	-8.78	-0.39	4.05e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg24503407	chr1:205819492	PM20D1	-0.48	-7.98	-0.36	1.38e-14	Parkinson's disease;
LUAD	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg13685833	chr1:53393034	SCP2	-0.5	-8.27	-0.37	1.73e-15	Monocyte count;
LUAD	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg20503657	chr10:835505	NA	0.79	10.78	0.46	4.15e-24	Eosinophil percentage of granulocytes;
LUAD	cis	rs9902453	0.933	rs60694493	chr17:28473256	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.5	0.38	3.23e-16	Coffee consumption (cups per day);
LUAD	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg21214613	chr1:16344536	HSPB7	0.46	7.83	0.36	3.89e-14	Dilated cardiomyopathy;
LUAD	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03264133	chr6:25882463	NA	-0.57	-9.39	-0.42	3.87e-19	Blood metabolite levels;
LUAD	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg10518543	chr12:38710700	ALG10B	0.44	7.52	0.34	3.32e-13	Heart rate;
LUAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.07e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg05340658	chr4:99064831	C4orf37	0.56	9.7	0.43	3.15e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.99	-0.32	1.1e-11	Parkinson's disease;
LUAD	cis	rs367943	0.712	rs6896650	chr5:112681048	T/C	cg12552261	chr5:112820674	MCC	0.46	8.86	0.4	2.27e-17	Type 2 diabetes;
LUAD	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg02734326	chr4:10020555	SLC2A9	0.63	11.28	0.48	5.66e-26	Bone mineral density;
LUAD	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg26597838	chr10:835615	NA	1.0	15.74	0.61	2.95e-44	Eosinophil percentage of granulocytes;
LUAD	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg09503522	chr19:53445286	ZNF321	-0.38	-6.41	-0.3	3.86e-10	Psoriasis;
LUAD	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06028808	chr11:68637592	NA	0.48	7.98	0.36	1.4e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2742417	0.967	rs2742462	chr3:45774696	G/A	cg10512202	chr3:45649293	LIMD1	0.36	6.4	0.3	4.03e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg02527881	chr3:46936655	PTH1R	0.44	8.44	0.38	5.27e-16	Colorectal cancer;
LUAD	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg06558623	chr16:89946397	TCF25	1.14	10.37	0.45	1.38e-22	Skin colour saturation;
LUAD	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.68	-10.38	-0.45	1.22e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs4604732	0.536	rs12074913	chr1:247631607	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	9.35	0.41	5.08e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs10203711	0.673	rs9677610	chr2:239621531	G/A	cg14580085	chr2:239553406	NA	0.32	7.09	0.33	5.74e-12	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21659725	chr3:3221576	CRBN	0.68	11.21	0.48	1.03e-25	Resting heart rate;
LUAD	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg01528321	chr10:82214614	TSPAN14	0.74	11.17	0.48	1.43e-25	Post bronchodilator FEV1;
LUAD	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg14092571	chr14:90743983	NA	-0.51	-8.93	-0.4	1.27e-17	Mortality in heart failure;
LUAD	cis	rs4711350	1.000	rs2182659	chr6:33751767	A/G	cg16010596	chr6:33739607	LEMD2	-0.38	-6.58	-0.3	1.43e-10	Schizophrenia;
LUAD	cis	rs3862030	0.594	rs7923675	chr10:104235809	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	7.57	0.35	2.34e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.2	-37.35	-0.88	5.34e-136	Myeloid white cell count;
LUAD	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg12935359	chr14:103987150	CKB	0.51	7.92	0.36	2.11e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg14582100	chr15:45693742	SPATA5L1	0.49	9.08	0.4	4.29e-18	Homoarginine levels;
LUAD	cis	rs7584330	0.504	rs11890307	chr2:238434705	A/G	cg14458575	chr2:238380390	NA	0.6	9.62	0.42	6.18e-20	Prostate cancer;
LUAD	cis	rs3106136	0.967	rs3106135	chr4:95138308	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.6	-0.35	1.89e-13	Capecitabine sensitivity;
LUAD	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg06784218	chr1:46089804	CCDC17	0.5	10.98	0.47	7.29e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg07741184	chr6:167504864	NA	0.35	8.14	0.37	4.46e-15	Primary biliary cholangitis;
LUAD	cis	rs2625529	0.617	rs3784313	chr15:72187519	G/T	cg16672083	chr15:72433130	SENP8	0.62	11.83	0.5	4.29e-28	Red blood cell count;
LUAD	cis	rs1232027	0.656	rs11950480	chr5:79957113	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.09	-0.33	5.53e-12	Huntington's disease progression;
LUAD	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg15790184	chr11:494944	RNH1	0.57	7.07	0.33	6.25e-12	Body mass index;
LUAD	cis	rs1448094	0.872	rs7305869	chr12:86440114	A/G	cg02569458	chr12:86230093	RASSF9	0.35	6.82	0.31	3.12e-11	Major depressive disorder;
LUAD	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg26408565	chr15:76604113	ETFA	-0.43	-6.98	-0.32	1.18e-11	Blood metabolite levels;
LUAD	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	8.03e-16	Body mass index;
LUAD	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18404041	chr3:52824283	ITIH1	-0.6	-12.58	-0.52	4.93e-31	Electroencephalogram traits;
LUAD	cis	rs7659604	0.540	rs7699289	chr4:122671553	G/A	cg06713675	chr4:122721982	EXOSC9	0.41	7.45	0.34	5.18e-13	Type 2 diabetes;
LUAD	cis	rs5756391	0.546	rs2899276	chr22:37312173	A/G	cg16356956	chr22:37317934	CSF2RB	0.33	6.86	0.32	2.51e-11	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.91	-0.36	2.34e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg13319975	chr6:146136371	FBXO30	0.66	11.45	0.49	1.21e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg03467027	chr4:99064603	C4orf37	-0.41	-6.75	-0.31	4.93e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg24308560	chr3:49941425	MST1R	-0.54	-9.08	-0.4	4.18e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.51	-0.34	3.66e-13	Breast cancer;
LUAD	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03517284	chr6:25882590	NA	-0.5	-7.47	-0.34	4.75e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs7916697	0.520	rs4745957	chr10:70044702	A/G	cg04882175	chr6:131122610	NA	0.48	6.39	0.3	4.33e-10	Optic disc area;
LUAD	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9581857	1.000	rs9581857	chr13:28027714	A/C	cg22138327	chr13:27999177	GTF3A	0.9	10.53	0.46	3.42e-23	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg26677194	chr12:130822605	PIWIL1	0.55	9.07	0.4	4.52e-18	Menopause (age at onset);
LUAD	cis	rs12600053	0.687	rs8058664	chr16:84849100	A/G	cg09249803	chr16:84846936	NA	0.39	6.78	0.31	4.08e-11	Asthma (childhood onset);
LUAD	cis	rs13064411	0.735	rs722392	chr3:113228294	A/G	cg10517650	chr3:113235015	CCDC52	-0.55	-9.36	-0.41	4.63e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.53	-8.99	-0.4	8.23e-18	Tonsillectomy;
LUAD	cis	rs7527798	0.592	rs11118360	chr1:207858586	G/A	cg09232269	chr1:207846808	CR1L	-0.38	-7.14	-0.33	4.04e-12	Erythrocyte sedimentation rate;
LUAD	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg04455712	chr21:45112962	RRP1B	0.45	9.01	0.4	7.04e-18	Mean corpuscular volume;
LUAD	trans	rs11039798	1.000	rs7928243	chr11:48589192	A/T	cg03929089	chr4:120376271	NA	0.56	6.54	0.3	1.78e-10	Axial length;
LUAD	cis	rs4372836	0.796	rs7580078	chr2:28997001	G/C	cg09522027	chr2:28974177	PPP1CB	-0.55	-8.32	-0.37	1.23e-15	Body mass index;
LUAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg15242686	chr22:24348715	GSTTP1	0.4	6.75	0.31	4.88e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-8.5	-0.38	3.39e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9473147	0.516	rs9349416	chr6:47551938	G/A	cg20196966	chr6:47445060	CD2AP	0.43	6.86	0.32	2.39e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs1451375	0.617	rs11772714	chr7:50542843	G/A	cg18232548	chr7:50535776	DDC	-0.65	-9.19	-0.41	1.82e-18	Malaria;
LUAD	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.37	0.38	8.26e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg01324343	chr3:183735012	ABCC5	0.95	25.99	0.78	1.11e-89	Anterior chamber depth;
LUAD	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs7737355	0.812	rs7729787	chr5:131066577	A/C	cg25547332	chr5:131281432	NA	0.43	6.91	0.32	1.82e-11	Life satisfaction;
LUAD	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg09873201	chr16:3507582	NAT15	0.51	7.85	0.36	3.49e-14	Tuberculosis;
LUAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-10.82	-0.47	2.97e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs68170813	0.559	rs59782202	chr7:107032766	G/T	cg23024343	chr7:107201750	COG5	0.47	6.65	0.31	8.92e-11	Coronary artery disease;
LUAD	cis	rs4589502	1.000	rs2414925	chr15:67129986	A/G	cg09911534	chr15:67153556	NA	-0.45	-6.67	-0.31	7.94e-11	Lung cancer (smoking interaction);
LUAD	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg01475377	chr6:109611718	NA	-0.55	-10.6	-0.46	1.93e-23	Reticulocyte fraction of red cells;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27088449	chr22:21272634	CRKL	-0.56	-6.69	-0.31	7.01e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12667521	chr19:29218732	NA	0.55	8.29	0.37	1.55e-15	Methadone dose in opioid dependence;
LUAD	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg09324608	chr17:30823087	MYO1D	0.39	6.97	0.32	1.21e-11	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.08	0.33	6.01e-12	Motion sickness;
LUAD	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg03690763	chr11:133734501	NA	0.3	7.47	0.34	4.49e-13	Childhood ear infection;
LUAD	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11644478	chr21:40555479	PSMG1	0.69	11.38	0.48	2.41e-26	Cognitive function;
LUAD	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg15181151	chr6:150070149	PCMT1	0.38	7.38	0.34	8.18e-13	Lung cancer;
LUAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg07677032	chr17:61819896	STRADA	0.58	10.55	0.46	3.04e-23	Prudent dietary pattern;
LUAD	cis	rs1395	0.778	rs4665959	chr2:27443256	C/T	cg23587288	chr2:27483067	SLC30A3	-0.39	-7.45	-0.34	5.22e-13	Blood metabolite levels;
LUAD	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg06641503	chr3:48959341	ARIH2	-0.36	-6.42	-0.3	3.64e-10	Menarche (age at onset);
LUAD	cis	rs55665837	0.519	rs10832297	chr11:14757737	C/A	cg19336497	chr11:14380999	RRAS2	-0.41	-7.8	-0.35	4.76e-14	Vitamin D levels;
LUAD	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg05966235	chr16:28915196	ATP2A1	0.42	6.74	0.31	5.16e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7617773	0.743	rs6804986	chr3:48363595	A/G	cg11946769	chr3:48343235	NME6	0.44	7.02	0.32	8.83e-12	Coronary artery disease;
LUAD	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg23625390	chr15:77176239	SCAPER	-0.49	-7.2	-0.33	2.76e-12	Blood metabolite levels;
LUAD	cis	rs9972944	0.729	rs62065062	chr17:63777383	G/A	cg07283582	chr17:63770753	CCDC46	0.48	10.48	0.45	5.49e-23	Total body bone mineral density;
LUAD	cis	rs11723261	0.582	rs11735742	chr4:142550	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	-0.42	-7.96	-0.36	1.64e-14	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg22508957	chr16:3507546	NAT15	-0.73	-10.8	-0.46	3.62e-24	Tuberculosis;
LUAD	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.46	0.3	2.86e-10	Cognitive test performance;
LUAD	cis	rs10489202	0.657	rs201540	chr1:167992883	G/A	cg24449463	chr1:168025552	DCAF6	-0.75	-12.25	-0.51	9.59e-30	Schizophrenia;
LUAD	cis	rs317865	0.737	rs73234629	chr4:16169776	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.89	8.57	0.38	1.94e-16	Kidney disease (early stage) in type 1 diabetes;
LUAD	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg15017067	chr4:17643749	FAM184B	0.37	7.28	0.33	1.64e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg14227996	chr4:17616232	MED28	0.71	7.38	0.34	8.62e-13	Opioid sensitivity;
LUAD	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.54	-9.55	-0.42	1.08e-19	Axial length;
LUAD	cis	rs898097	0.567	rs8076119	chr17:80910061	A/G	cg15369054	chr17:80825471	TBCD	-0.47	-7.88	-0.36	2.89e-14	Breast cancer;
LUAD	cis	rs863345	0.604	rs2873595	chr1:158508382	G/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.6	-0.31	1.21e-10	Pneumococcal bacteremia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04439696	chr6:36954195	MTCH1	-0.57	-7.02	-0.32	8.66e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.42	-7.76	-0.35	6.48e-14	IgG glycosylation;
LUAD	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21659725	chr3:3221576	CRBN	-0.64	-10.26	-0.45	3.27e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs11190604	0.731	rs10883480	chr10:102163821	G/T	cg07570687	chr10:102243282	WNT8B	-0.42	-6.37	-0.3	4.92e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs17532515	0.652	rs55755384	chr4:141387350	C/T	cg03645522	chr4:141391200	NA	0.4	6.43	0.3	3.41e-10	Select biomarker traits;
LUAD	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg03233332	chr7:66118400	NA	-0.43	-6.54	-0.3	1.79e-10	Aortic root size;
LUAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg00450029	chr8:599525	NA	-0.84	-7.17	-0.33	3.43e-12	IgG glycosylation;
LUAD	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	8.56	0.38	2.15e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg05110241	chr16:68378359	PRMT7	-0.83	-9.03	-0.4	6.05e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1865721	0.804	rs62089468	chr18:73158850	C/T	cg26385618	chr18:73139727	C18orf62	-0.51	-9.7	-0.43	3.15e-20	Intelligence;
LUAD	cis	rs8044868	0.893	rs3909543	chr16:72183543	G/A	cg23815491	chr16:72088622	HP	0.36	6.38	0.3	4.58e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg18827107	chr12:86230957	RASSF9	-0.54	-9.3	-0.41	7.62e-19	Major depressive disorder;
LUAD	cis	rs4285028	0.747	rs9820511	chr3:121361345	G/A	cg11130432	chr3:121712080	ILDR1	-0.44	-6.41	-0.3	3.82e-10	Multiple sclerosis;
LUAD	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg21918786	chr6:109611834	NA	-0.58	-11.06	-0.47	3.91e-25	Reticulocyte fraction of red cells;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02931753	chr4:154074737	TRIM2	-0.46	-8.0	-0.36	1.2e-14	Cancer;
LUAD	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg24829409	chr8:58192753	C8orf71	-0.56	-6.89	-0.32	2e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg18129748	chr3:49941408	MST1R	0.42	6.93	0.32	1.58e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg08280861	chr8:58055591	NA	0.74	8.9	0.4	1.61e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1267303	0.675	rs7519040	chr1:46986641	A/G	cg16387850	chr1:46982889	NA	-0.47	-7.82	-0.36	4.34e-14	Monobrow;
LUAD	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg19346786	chr7:2764209	NA	0.48	9.75	0.43	2.14e-20	Height;
LUAD	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	9.28	0.41	8.6e-19	Hip circumference adjusted for BMI;
LUAD	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg13393036	chr8:95962371	TP53INP1	0.3	6.65	0.31	9.14e-11	Type 2 diabetes;
LUAD	cis	rs2637266	1.000	rs1907317	chr10:78337849	C/A	cg18941641	chr10:78392320	NA	0.32	6.61	0.31	1.15e-10	Pulmonary function;
LUAD	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg02018176	chr4:1364513	KIAA1530	0.37	6.44	0.3	3.21e-10	Obesity-related traits;
LUAD	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg25173405	chr17:45401733	C17orf57	0.51	8.86	0.4	2.26e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg11645453	chr3:52864694	ITIH4	0.41	8.52	0.38	2.81e-16	Bipolar disorder;
LUAD	cis	rs7582720	1.000	rs72932588	chr2:203883193	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.22	0.41	1.41e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6740322	1.000	rs4128209	chr2:43554729	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-10.88	-0.47	1.79e-24	Coronary artery disease;
LUAD	cis	rs250677	0.522	rs1007400	chr5:148382635	C/T	cg12140854	chr5:148520817	ABLIM3	0.51	8.24	0.37	2.1e-15	Breast cancer;
LUAD	cis	rs427941	0.632	rs201478	chr7:101746964	G/C	cg06246474	chr7:101738831	CUX1	0.39	6.81	0.31	3.27e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.5	9.09	0.4	3.75e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg00277334	chr10:82204260	NA	-0.69	-12.63	-0.52	3.08e-31	Post bronchodilator FEV1;
LUAD	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg07507251	chr3:52567010	NT5DC2	0.37	7.36	0.34	9.66e-13	Bipolar disorder;
LUAD	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg04731861	chr2:219085781	ARPC2	0.23	7.05	0.32	7.47e-12	Colorectal cancer;
LUAD	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg19318889	chr4:1322082	MAEA	0.47	8.11	0.37	5.6e-15	Obesity-related traits;
LUAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg21724239	chr8:58056113	NA	0.72	9.49	0.42	1.73e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs870825	0.616	rs4594761	chr4:185643002	A/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.03	0.56	5.61e-37	Blood protein levels;
LUAD	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg13319975	chr6:146136371	FBXO30	-0.58	-9.74	-0.43	2.38e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11811982	0.793	rs77973381	chr1:227432753	C/T	cg24860534	chr1:227506868	CDC42BPA	0.7	7.34	0.34	1.13e-12	Optic disc area;
LUAD	cis	rs12760731	0.720	rs10913545	chr1:178360201	G/A	cg00404053	chr1:178313656	RASAL2	0.64	8.33	0.38	1.15e-15	Obesity-related traits;
LUAD	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg12458913	chr13:53173898	NA	0.4	7.13	0.33	4.34e-12	Lewy body disease;
LUAD	trans	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.71	-0.31	6.46e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs12517041	1.000	rs1560177	chr5:23322987	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.49	-6.85	-0.32	2.55e-11	Calcium levels;
LUAD	cis	rs240764	0.717	rs1039031	chr6:101161812	A/G	cg09795085	chr6:101329169	ASCC3	0.4	7.03	0.32	8.08e-12	Neuroticism;
LUAD	cis	rs9467773	1.000	rs1001687	chr6:26573218	C/G	cg09904177	chr6:26538194	HMGN4	0.44	7.03	0.32	8.25e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	0.963	rs10769389	chr11:48618011	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.27	-0.33	1.72e-12	HDL cholesterol;
LUAD	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg05804949	chr7:23719620	C7orf46	0.38	6.47	0.3	2.78e-10	Schizophrenia;
LUAD	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg09367891	chr1:107599246	PRMT6	-0.56	-9.13	-0.41	2.95e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs10129255	0.500	rs4774008	chr14:107137290	A/T	cg07958169	chr14:107095056	NA	-0.38	-7.52	-0.34	3.35e-13	Kawasaki disease;
LUAD	trans	rs3812049	0.737	rs1993878	chr5:127476971	C/A	cg16011800	chr17:1958478	HIC1	-0.57	-8.03	-0.36	9.68e-15	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg08222618	chr4:941054	TMEM175	0.73	12.39	0.52	2.65e-30	Sjögren's syndrome;
LUAD	cis	rs9560113	0.960	rs950891	chr13:112173992	G/A	cg14154082	chr13:112174009	NA	-0.4	-7.74	-0.35	7.43e-14	Menarche (age at onset);
LUAD	cis	rs941764	0.965	rs941765	chr14:91841358	G/C	cg10511902	chr14:91842949	CCDC88C	0.51	12.01	0.5	8.32e-29	Breast cancer;
LUAD	trans	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg14917512	chr19:3094685	GNA11	-0.56	-6.56	-0.3	1.62e-10	Diabetic kidney disease;
LUAD	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg23978390	chr7:1156363	C7orf50	0.57	8.01	0.36	1.15e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs9878978	0.519	rs1502570	chr3:2477066	G/A	cg21928760	chr3:2462534	CNTN4	0.37	7.74	0.35	7.27e-14	Blood pressure (smoking interaction);
LUAD	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2485376	1.000	rs2485374	chr10:104049150	G/A	cg20641465	chr10:103991465	PITX3	-0.57	-10.34	-0.45	1.65e-22	QT interval;
LUAD	cis	rs4711350	1.000	rs2182659	chr6:33751767	A/G	cg18005901	chr6:33739558	LEMD2	-0.52	-7.6	-0.35	1.97e-13	Schizophrenia;
LUAD	cis	rs4700695	0.719	rs40176	chr5:65464965	C/T	cg21114390	chr5:65439923	SFRS12	-0.9	-13.54	-0.55	5.73e-35	Facial morphology (factor 19);
LUAD	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg25985355	chr7:65971099	NA	-0.38	-6.89	-0.32	2.02e-11	Aortic root size;
LUAD	cis	rs9807989	0.507	rs7584093	chr2:102997721	C/T	cg03938978	chr2:103052716	IL18RAP	0.45	10.24	0.45	3.99e-22	Asthma;
LUAD	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23583168	chr7:148888333	NA	-0.91	-19.03	-0.68	9.05e-59	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	10.06	0.44	1.69e-21	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg12016809	chr21:47604291	C21orf56	0.45	7.39	0.34	8.01e-13	Testicular germ cell tumor;
LUAD	trans	rs7944735	0.817	rs6485784	chr11:47832260	C/T	cg15704280	chr7:45808275	SEPT13	0.52	7.07	0.33	6.44e-12	Intraocular pressure;
LUAD	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.08	-0.37	6.91e-15	Diabetic kidney disease;
LUAD	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg03690763	chr11:133734501	NA	0.38	8.96	0.4	1.05e-17	Childhood ear infection;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg22829908	chr10:21814466	C10orf140	0.38	6.49	0.3	2.48e-10	Bipolar disorder;
LUAD	cis	rs7274811	0.681	rs293733	chr20:31975976	C/T	cg14921437	chr20:32255988	NECAB3;C20orf134	0.48	7.37	0.34	8.76e-13	Height;
LUAD	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg14582100	chr15:45693742	SPATA5L1	0.43	8.59	0.39	1.65e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs4700695	0.764	rs152941	chr5:65241446	A/G	cg21114390	chr5:65439923	SFRS12	0.61	7.41	0.34	6.88e-13	Facial morphology (factor 19);
LUAD	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	8.75e-12	Aortic root size;
LUAD	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg07936489	chr17:37558343	FBXL20	-0.48	-7.57	-0.35	2.31e-13	Glomerular filtration rate (creatinine);
LUAD	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg23854747	chr20:62612705	PRPF6	-0.34	-6.36	-0.3	5.28e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
LUAD	cis	rs6445967	0.898	rs4336086	chr3:58297390	C/T	cg23715586	chr3:58305044	RPP14	0.42	7.59	0.35	2.03e-13	Platelet count;
LUAD	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg03676636	chr4:99064102	C4orf37	0.32	8.43	0.38	5.49e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.54	-0.34	2.81e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.12	-0.33	4.54e-12	Total cholesterol levels;
LUAD	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg00898013	chr13:113819073	PROZ	0.63	10.88	0.47	1.75e-24	Platelet distribution width;
LUAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg21724239	chr8:58056113	NA	0.74	9.62	0.42	5.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg11663144	chr21:46675770	NA	-0.62	-12.49	-0.52	1.11e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg16647868	chr5:131706066	SLC22A5	0.39	6.6	0.31	1.23e-10	Acylcarnitine levels;
LUAD	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg08999081	chr20:33150536	PIGU	0.62	13.92	0.56	1.54e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs7084921	0.526	rs11595928	chr10:101888640	C/T	cg19754520	chr10:101825118	CPN1	-0.31	-6.46	-0.3	2.88e-10	Bone mineral density;
LUAD	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.58	-0.42	8.21e-20	Schizophrenia;
LUAD	trans	rs225245	0.817	rs225299	chr17:33922742	T/C	cg19694781	chr19:47549865	TMEM160	-0.47	-7.68	-0.35	1.13e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs2932538	0.922	rs34531155	chr1:113141550	C/T	cg22162597	chr1:113214053	CAPZA1	0.45	6.56	0.3	1.59e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	9.36	0.41	4.65e-19	Ileal carcinoids;
LUAD	cis	rs13082711	0.911	rs73050094	chr3:27519552	T/A	cg02860705	chr3:27208620	NA	0.61	9.15	0.41	2.45e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg17191109	chr10:126851326	NA	-0.32	-6.42	-0.3	3.74e-10	Menarche (age at onset);
LUAD	cis	rs62458065	1.000	rs6462364	chr7:32464776	C/T	cg20159608	chr7:32802032	NA	-0.47	-6.82	-0.31	3.22e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.59	0.42	7.97e-20	Cognitive ability;
LUAD	trans	rs10838798	0.563	rs4752902	chr11:48148779	G/A	cg15704280	chr7:45808275	SEPT13	-0.47	-7.42	-0.34	6.58e-13	Height;
LUAD	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg04111992	chr7:158790115	NA	0.39	6.45	0.3	3.04e-10	Facial morphology (factor 20);
LUAD	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1113500	0.897	rs55980437	chr1:108639498	G/A	cg06207961	chr1:108661230	NA	0.45	8.45	0.38	4.75e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg11189052	chr15:85197271	WDR73	-0.57	-9.18	-0.41	1.87e-18	P wave terminal force;
LUAD	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.45	7.47	0.34	4.63e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg01181863	chr3:195395398	SDHAP2	-0.62	-9.36	-0.41	4.78e-19	Pancreatic cancer;
LUAD	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg12935359	chr14:103987150	CKB	0.47	7.34	0.34	1.07e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9296092	0.517	rs62405895	chr6:33471969	G/T	cg13560919	chr6:33536144	NA	-0.84	-13.19	-0.54	1.67e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg21724239	chr8:58056113	NA	0.47	6.82	0.31	3.15e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg16606324	chr3:10149918	C3orf24	0.7	11.54	0.49	5.63e-27	Alzheimer's disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08135327	chr2:134877962	NA	-0.69	-7.0	-0.32	1.03e-11	Type 2 diabetes;
LUAD	cis	rs6993813	0.814	rs4617188	chr8:120024764	G/A	cg01975934	chr8:119970761	NA	-0.37	-7.15	-0.33	3.82e-12	Bone mineral density (hip);
LUAD	trans	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-16.81	-0.63	6.12e-49	Exhaled nitric oxide output;
LUAD	cis	rs9467160	1.000	rs9467157	chr6:24440644	C/T	cg16211469	chr6:24423932	MRS2	0.42	6.83	0.32	2.9100000000000002e-11	Liver enzyme levels;
LUAD	cis	rs7927771	0.560	rs4752858	chr11:47685829	C/T	cg18512352	chr11:47633146	NA	-0.37	-6.65	-0.31	9.12e-11	Subjective well-being;
LUAD	cis	rs3087591	0.960	rs12603885	chr17:29466722	C/T	cg24425628	chr17:29625626	OMG;NF1	0.39	6.37	0.3	4.86e-10	Hip circumference;
LUAD	cis	rs68170813	0.559	rs76145119	chr7:107052368	C/T	cg23024343	chr7:107201750	COG5	0.52	7.19	0.33	2.96e-12	Coronary artery disease;
LUAD	cis	rs6688613	1.000	rs6699520	chr1:166955405	G/C	cg07049167	chr1:166818506	POGK	0.41	6.9	0.32	1.92e-11	Refractive astigmatism;
LUAD	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg14983838	chr19:29218262	NA	0.67	9.38	0.41	4.21e-19	Methadone dose in opioid dependence;
LUAD	cis	rs9378688	0.654	rs62392609	chr6:2258345	A/C	cg12303981	chr6:2244766	GMDS	-0.41	-6.37	-0.3	4.95e-10	Caudate nucleus volume;
LUAD	cis	rs13064411	0.696	rs6438159	chr3:113217341	T/C	cg18753928	chr3:113234510	CCDC52	-0.73	-12.43	-0.52	1.82e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs10129255	0.518	rs8010020	chr14:107186255	A/G	cg07958169	chr14:107095056	NA	-0.37	-7.35	-0.34	1.03e-12	Kawasaki disease;
LUAD	cis	rs8062405	0.755	rs62031607	chr16:28631530	A/T	cg00204512	chr16:28754710	NA	0.32	6.71	0.31	6.37e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg21782813	chr7:2030301	MAD1L1	0.4	6.55	0.3	1.69e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg13012494	chr21:47604986	C21orf56	0.47	7.91	0.36	2.33e-14	Testicular germ cell tumor;
LUAD	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg14541582	chr5:601475	NA	-0.36	-7.58	-0.35	2.19e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.48	0.38	3.78e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs713587	0.967	rs6752378	chr2:25150116	C/A	cg04586622	chr2:25135609	ADCY3	0.32	7.04	0.32	7.79e-12	Body mass index in non-asthmatics;
LUAD	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg18196295	chr10:418757	DIP2C	-0.45	-7.49	-0.34	3.94e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25427524	chr10:38739819	LOC399744	-0.75	-13.55	-0.55	5.43e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs490234	0.651	rs13301073	chr9:128284378	G/A	cg14078157	chr9:128172775	NA	-0.46	-8.1	-0.37	6e-15	Mean arterial pressure;
LUAD	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg03161606	chr19:29218774	NA	0.58	7.97	0.36	1.5e-14	Methadone dose in opioid dependence;
LUAD	cis	rs2797160	1.000	rs9401843	chr6:126004124	T/C	cg05901451	chr6:126070800	HEY2	-0.45	-6.6	-0.31	1.23e-10	Endometrial cancer;
LUAD	cis	rs1873147	1.000	rs1873147	chr15:63312632	G/A	cg12160578	chr15:63334699	TPM1	-0.34	-6.36	-0.3	5.28e-10	Orofacial clefts;
LUAD	cis	rs4523957	0.928	rs452363	chr17:2194028	T/C	cg16513277	chr17:2031491	SMG6	0.77	14.42	0.57	1.26e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4380275	0.782	rs60367761	chr2:766414	C/T	cg21665850	chr2:731073	NA	0.36	6.38	0.3	4.56e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUAD	cis	rs77741769	0.529	rs7137504	chr12:121221628	C/T	cg02419362	chr12:121203948	SPPL3	0.41	8.37	0.38	8.59e-16	Mean corpuscular volume;
LUAD	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.57e-13	Tonsillectomy;
LUAD	cis	rs6062509	0.732	rs6062304	chr20:62351539	A/T	cg02966332	chr20:62369605	LIME1	-0.46	-7.5	-0.34	3.83e-13	Prostate cancer;
LUAD	trans	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg07211511	chr3:129823064	LOC729375	-0.88	-10.45	-0.45	6.57e-23	Blood pressure (smoking interaction);
LUAD	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg15704280	chr7:45808275	SEPT13	0.67	10.66	0.46	1.14e-23	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs12900413	0.603	rs12905689	chr15:90301343	G/A	cg24249390	chr15:90295951	MESP1	-0.35	-6.96	-0.32	1.27e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	trans	rs9929218	1.000	rs28549017	chr16:68758828	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-14.91	-0.59	1.05e-40	Colorectal cancer;
LUAD	cis	rs55665837	0.701	rs2007361	chr11:14662722	A/G	cg19336497	chr11:14380999	RRAS2	-0.41	-7.23	-0.33	2.28e-12	Vitamin D levels;
LUAD	cis	rs7677751	0.767	rs6831380	chr4:55076345	G/A	cg17187183	chr4:55093834	PDGFRA	0.44	7.19	0.33	2.92e-12	Corneal astigmatism;
LUAD	cis	rs904251	0.864	rs2797801	chr6:37487161	A/G	cg25019722	chr6:37503610	NA	-0.3	-6.62	-0.31	1.12e-10	Cognitive performance;
LUAD	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg04824913	chr4:887549	GAK	0.42	6.36	0.3	5.27e-10	Systemic sclerosis;
LUAD	cis	rs7843479	1.000	rs17615788	chr8:21814739	C/T	cg03445287	chr8:21823731	XPO7	-0.47	-8.64	-0.39	1.2e-16	Mean corpuscular volume;
LUAD	cis	rs7089973	0.844	rs10510007	chr10:116636721	A/G	cg25233709	chr10:116636983	FAM160B1	0.37	6.96	0.32	1.32e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6952808	0.964	rs10950407	chr7:1895666	T/G	cg12432903	chr7:1882776	MAD1L1	-0.56	-8.89	-0.4	1.76e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg26043149	chr18:55253948	FECH	0.51	8.31	0.37	1.35e-15	Bone mineral density;
LUAD	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg00071950	chr4:10020882	SLC2A9	0.79	15.97	0.61	2.94e-45	Bone mineral density;
LUAD	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	7.26	0.33	1.82e-12	Schizophrenia;
LUAD	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg00981070	chr1:2046702	PRKCZ	-0.35	-6.67	-0.31	8.26e-11	Height;
LUAD	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.0	-0.32	1.04e-11	Breast cancer;
LUAD	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg05082376	chr22:42548792	NA	-0.44	-7.79	-0.35	5.4e-14	Schizophrenia;
LUAD	cis	rs870825	0.616	rs6818447	chr4:185650154	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	14.31	0.57	3.59e-38	Blood protein levels;
LUAD	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg17644776	chr2:200775616	C2orf69	-0.55	-6.7	-0.31	6.74e-11	Schizophrenia;
LUAD	cis	rs7394190	0.748	rs4082339	chr10:75539812	C/T	cg02286717	chr10:75415704	SYNPO2L	0.4	7.23	0.33	2.31e-12	Incident atrial fibrillation;
LUAD	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg15128208	chr22:42549153	NA	0.41	6.37	0.3	4.92e-10	Birth weight;
LUAD	cis	rs6460942	0.915	rs17444044	chr7:12458736	A/G	cg20607287	chr7:12443886	VWDE	-0.54	-6.71	-0.31	6.11e-11	Coronary artery disease;
LUAD	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg14835575	chr10:16859367	RSU1	0.97	14.43	0.57	1.1e-38	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg24675056	chr1:15929824	NA	0.49	8.34	0.38	1.1e-15	Systolic blood pressure;
LUAD	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg24558204	chr6:135376177	HBS1L	0.49	8.98	0.4	9.03e-18	Red blood cell count;
LUAD	cis	rs4730250	0.707	rs10953537	chr7:107027905	G/A	cg02696742	chr7:106810147	HBP1	-0.8	-10.68	-0.46	9.46e-24	Osteoarthritis;
LUAD	cis	rs3125734	0.571	rs7100401	chr10:64024417	C/G	cg19640130	chr10:64028056	RTKN2	-0.35	-7.46	-0.34	4.81e-13	Rheumatoid arthritis;
LUAD	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26314531	chr2:26401878	FAM59B	-0.55	-7.71	-0.35	9.38e-14	Gut microbiome composition (summer);
LUAD	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19346786	chr7:2764209	NA	-0.56	-12.17	-0.51	1.94e-29	Height;
LUAD	cis	rs897984	0.762	rs4889604	chr16:30985994	G/T	cg02466173	chr16:30829666	NA	0.65	11.99	0.5	1.06e-28	Dementia with Lewy bodies;
LUAD	cis	rs4919694	0.808	rs80020194	chr10:105035954	A/G	cg04362960	chr10:104952993	NT5C2	0.69	6.86	0.32	2.45e-11	Arsenic metabolism;
LUAD	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg14828511	chr1:107599125	PRMT6	-0.6	-10.53	-0.46	3.48e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs10189230	0.967	rs12479119	chr2:222354213	C/T	cg14652038	chr2:222343519	EPHA4	0.43	8.56	0.38	2.14e-16	Urate levels in lean individuals;
LUAD	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg10755058	chr3:40428713	ENTPD3	0.45	8.49	0.38	3.48e-16	Renal cell carcinoma;
LUAD	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.52	-0.3	2.02e-10	Mood instability;
LUAD	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg01851573	chr8:8652454	MFHAS1	-0.46	-8.52	-0.38	2.9e-16	Mood instability;
LUAD	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg03609598	chr5:56110824	MAP3K1	-0.45	-7.08	-0.33	5.89e-12	Coronary artery disease;
LUAD	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg21153622	chr11:89784906	NA	-0.35	-6.95	-0.32	1.39e-11	HDL cholesterol;
LUAD	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	6.59	0.3	1.35e-10	Cognitive test performance;
LUAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg11965913	chr1:205819406	PM20D1	0.86	18.17	0.66	5.94e-55	Menarche (age at onset);
LUAD	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.74	15.81	0.61	1.42e-44	White blood cell count;
LUAD	trans	rs11088226	0.581	rs2016103	chr21:33878030	G/A	cg09050820	chr6:167586206	TCP10L2	0.49	8.31	0.37	1.29e-15	Gastritis;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg00584530	chr21:43373897	C2CD2	0.32	6.66	0.31	8.54e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg02176678	chr2:219576539	TTLL4	0.63	11.94	0.5	1.55e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg16322792	chr1:120165303	ZNF697	0.71	19.05	0.68	6.95e-59	Systemic lupus erythematosus;
LUAD	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg08807101	chr21:30365312	RNF160	-0.44	-7.67	-0.35	1.22e-13	Dental caries;
LUAD	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.93	13.29	0.54	6.52e-34	Smoking behavior;
LUAD	cis	rs4144027	0.904	rs10438242	chr14:104345075	C/T	cg12183467	chr14:104352244	NA	-0.37	-7.15	-0.33	3.77e-12	Blood metabolite levels;
LUAD	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg00495681	chr13:53174319	NA	0.49	8.83	0.39	2.78e-17	Lewy body disease;
LUAD	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg25204440	chr1:209979598	IRF6	0.48	6.38	0.3	4.65e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs7107174	1.000	rs7116698	chr11:77995191	T/C	cg02023728	chr11:77925099	USP35	0.5	7.71	0.35	8.87e-14	Testicular germ cell tumor;
LUAD	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg21963583	chr11:68658836	MRPL21	0.68	12.12	0.51	3.24e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04105453	chr2:27440337	CAD	-0.52	-6.39	-0.3	4.33e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg03467027	chr4:99064603	C4orf37	0.39	6.45	0.3	3.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1493916	0.805	rs1452648	chr18:31411003	G/T	cg27147174	chr7:100797783	AP1S1	-0.62	-10.88	-0.47	1.73e-24	Life satisfaction;
LUAD	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg26043149	chr18:55253948	FECH	-0.43	-7.01	-0.32	9.62e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs75920871	0.748	rs12225230	chr11:116728630	G/C	cg04087571	chr11:116723030	SIK3	-0.34	-7.08	-0.33	5.88e-12	Subjective well-being;
LUAD	cis	rs6445967	0.569	rs73081581	chr3:58313077	G/A	cg13750441	chr3:58318267	PXK	-0.32	-6.52	-0.3	1.99e-10	Platelet count;
LUAD	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg15147215	chr3:52552868	STAB1	-0.42	-7.54	-0.34	2.85e-13	Bipolar disorder;
LUAD	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg09796270	chr17:17721594	SREBF1	-0.39	-7.84	-0.36	3.76e-14	Strep throat;
LUAD	cis	rs76878669	0.561	rs7110944	chr11:66118217	C/T	cg18002602	chr11:66138449	SLC29A2	-0.48	-10.35	-0.45	1.6e-22	Educational attainment (years of education);
LUAD	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.39	7.01	0.32	9.37e-12	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs657075	0.697	rs34034297	chr5:131691176	C/T	cg21138405	chr5:131827807	IRF1	0.52	6.47	0.3	2.69e-10	Rheumatoid arthritis;
LUAD	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg23758822	chr17:41437982	NA	1.01	20.86	0.71	5.96e-67	Menopause (age at onset);
LUAD	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg17372223	chr3:52568218	NT5DC2	0.38	6.87	0.32	2.26e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg25985355	chr7:65971099	NA	-0.56	-6.85	-0.32	2.68e-11	Diabetic kidney disease;
LUAD	cis	rs62229266	0.773	rs878606	chr21:37406692	G/A	cg12218747	chr21:37451666	NA	-0.49	-8.46	-0.38	4.55e-16	Mitral valve prolapse;
LUAD	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg26384229	chr12:38710491	ALG10B	0.47	7.78	0.35	5.79e-14	Bladder cancer;
LUAD	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00802000	chr16:706648	WDR90	-0.4	-7.61	-0.35	1.85e-13	Height;
LUAD	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg02423579	chr7:2872169	GNA12	-0.56	-9.45	-0.42	2.41e-19	Height;
LUAD	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg15448220	chr1:150897856	SETDB1	0.46	7.97	0.36	1.47e-14	Tonsillectomy;
LUAD	cis	rs4604732	0.631	rs12031694	chr1:247623653	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.73	0.43	2.54e-20	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.49	0.38	3.54e-16	Breast cancer;
LUAD	trans	rs3858145	0.588	rs7081284	chr10:70044792	C/G	cg04882175	chr6:131122610	NA	-0.57	-6.77	-0.31	4.42e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUAD	cis	rs72827839	0.516	rs111630961	chr17:45938097	T/G	cg23391107	chr17:45924227	SP6	0.43	6.82	0.31	3.2e-11	Ease of getting up in the morning;
LUAD	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg09796270	chr17:17721594	SREBF1	0.38	7.56	0.34	2.61e-13	Total body bone mineral density;
LUAD	trans	rs800082	0.668	rs6805395	chr3:144292116	T/C	cg24215973	chr2:240111563	HDAC4	-0.6	-9.81	-0.43	1.33e-20	Smoking behavior;
LUAD	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg21709803	chr11:61594965	FADS2	-0.38	-7.21	-0.33	2.56e-12	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18876405	chr7:65276391	NA	0.42	6.5	0.3	2.21e-10	Aortic root size;
LUAD	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg23029597	chr12:123009494	RSRC2	-0.5	-7.6	-0.35	1.93e-13	Body mass index;
LUAD	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.13	-0.41	2.86e-18	Total body bone mineral density;
LUAD	cis	rs17102423	0.768	rs8005829	chr14:65576165	C/T	cg16583315	chr14:65563665	MAX	0.36	6.73	0.31	5.6e-11	Obesity-related traits;
LUAD	cis	rs3125734	0.633	rs10740068	chr10:63982254	A/C	cg09941381	chr10:64027924	RTKN2	-0.3	-6.92	-0.32	1.7e-11	Rheumatoid arthritis;
LUAD	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.81	-0.31	3.32e-11	Breast cancer;
LUAD	cis	rs10979	0.562	rs9399446	chr6:143874639	G/C	cg25407410	chr6:143891975	LOC285740	-0.45	-6.77	-0.31	4.4e-11	Hypospadias;
LUAD	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg17031739	chr1:67600172	NA	0.52	9.32	0.41	6.75e-19	Psoriasis;
LUAD	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg02931644	chr1:25747376	RHCE	0.51	11.17	0.48	1.52e-25	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs12900413	0.603	rs2351494	chr15:90299541	C/T	cg24249390	chr15:90295951	MESP1	-0.36	-6.9	-0.32	1.85e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs2227564	0.620	rs10740418	chr10:75519322	T/C	cg23231163	chr10:75533350	FUT11	-0.41	-6.52	-0.3	2.07e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg18209359	chr17:80159595	CCDC57	0.39	6.73	0.31	5.46e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg15133208	chr4:90757351	SNCA	-0.47	-7.05	-0.32	7.21e-12	Neuroticism;
LUAD	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.43	0.34	5.92e-13	Menopause (age at onset);
LUAD	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg16797656	chr11:68205561	LRP5	-0.38	-7.04	-0.32	7.77e-12	Bone mineral density (spine);
LUAD	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg23018236	chr17:30244563	NA	-0.67	-7.87	-0.36	3.04e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs9929218	0.529	rs17715450	chr16:68729785	C/A	cg01251360	chr16:68772225	CDH1	-0.26	-8.19	-0.37	3.06e-15	Colorectal cancer;
LUAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10150615	chr22:24372951	LOC391322	-0.49	-8.0	-0.36	1.21e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9796	0.866	rs2928148	chr15:41401550	G/A	cg18705301	chr15:41695430	NDUFAF1	0.38	7.07	0.33	6.29e-12	Menopause (age at onset);
LUAD	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	6.93	0.32	1.58e-11	Schizophrenia;
LUAD	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg24818145	chr4:99064322	C4orf37	0.45	7.55	0.34	2.63e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	12.41	0.52	2.26e-30	Homoarginine levels;
LUAD	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.18	-0.33	3.23e-12	Bipolar disorder;
LUAD	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.32	-0.34	1.27e-12	Total body bone mineral density;
LUAD	cis	rs986417	1.000	rs1474999	chr14:60905920	T/C	cg27398547	chr14:60952738	C14orf39	-0.61	-7.56	-0.34	2.6e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg18230493	chr5:56204884	C5orf35	-0.69	-10.93	-0.47	1.14e-24	Initial pursuit acceleration;
LUAD	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg08798685	chr6:27730294	NA	-0.44	-7.07	-0.33	6.4e-12	Parkinson's disease;
LUAD	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg17366294	chr4:99064904	C4orf37	0.65	10.34	0.45	1.77e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.03e-19	Life satisfaction;
LUAD	trans	rs961253	0.522	rs2225115	chr20:6360465	C/T	cg21095983	chr6:86352623	SYNCRIP	0.43	6.63	0.31	1.04e-10	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.85	0.53	3.74e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg06046430	chr4:77819534	ANKRD56	0.53	8.39	0.38	7.35e-16	Emphysema distribution in smoking;
LUAD	trans	rs7395662	0.857	rs116589099	chr11:48786205	A/T	cg00717180	chr2:96193071	NA	0.36	6.78	0.31	3.97e-11	HDL cholesterol;
LUAD	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg07404485	chr7:94953653	PON1	-0.49	-7.02	-0.32	8.61e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2625529	0.590	rs2607090	chr15:72496011	C/A	cg16672083	chr15:72433130	SENP8	-0.76	-12.9	-0.53	2.37e-32	Red blood cell count;
LUAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg12373951	chr3:133503437	NA	0.37	7.58	0.35	2.2e-13	Iron status biomarkers;
LUAD	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg00106254	chr7:1943704	MAD1L1	-0.53	-8.07	-0.37	7.12e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs7395662	1.000	rs11039817	chr11:48561480	A/T	cg00717180	chr2:96193071	NA	-0.39	-7.31	-0.33	1.32e-12	HDL cholesterol;
LUAD	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-9.23	-0.41	1.28e-18	Gut microbiome composition (summer);
LUAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg21782813	chr7:2030301	MAD1L1	0.53	8.75	0.39	5.31e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg18306943	chr3:40428807	ENTPD3	0.43	7.14	0.33	4.04e-12	Renal cell carcinoma;
LUAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.2	-0.41	1.61e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7607369	0.536	rs7600248	chr2:219665963	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-10.42	-0.45	8.52e-23	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg03188948	chr7:1209495	NA	0.39	6.57	0.3	1.49e-10	Longevity;Endometriosis;
LUAD	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg10295955	chr4:187884368	NA	-1.18	-31.46	-0.84	7.72e-113	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3981351	0.797	rs12414006	chr10:115461485	A/G	cg24846397	chr10:115438155	CASP7	-0.39	-6.39	-0.3	4.45e-10	Obesity-related traits;
LUAD	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg14092988	chr3:52407081	DNAH1	0.39	7.9	0.36	2.52e-14	Bipolar disorder;
LUAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg07362569	chr17:61921086	SMARCD2	0.39	6.78	0.31	3.96e-11	Prudent dietary pattern;
LUAD	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg05368731	chr17:41323189	NBR1	-0.91	-17.31	-0.64	3.79e-51	Menopause (age at onset);
LUAD	cis	rs8062405	0.573	rs6565300	chr16:28993049	G/T	cg05966235	chr16:28915196	ATP2A1	0.45	7.11	0.33	4.84e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg08601574	chr20:25228251	PYGB	-0.44	-8.16	-0.37	3.83e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg00278107	chr5:1061253	SLC12A7	0.46	8.45	0.38	4.69e-16	QT interval;
LUAD	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs250677	0.687	rs2963485	chr5:148452043	A/G	cg12140854	chr5:148520817	ABLIM3	0.62	10.3	0.45	2.38e-22	Breast cancer;
LUAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.47	0.55	1.14e-34	Prudent dietary pattern;
LUAD	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg21775007	chr8:11205619	TDH	-0.5	-9.13	-0.41	2.84e-18	Retinal vascular caliber;
LUAD	trans	rs7395662	0.963	rs2135680	chr11:48728425	T/C	cg15704280	chr7:45808275	SEPT13	-0.41	-6.35	-0.3	5.43e-10	HDL cholesterol;
LUAD	cis	rs9535307	0.858	rs6561553	chr13:50261089	A/G	cg04663916	chr13:50265991	EBPL	0.59	6.89	0.32	1.99e-11	Obesity-related traits;
LUAD	cis	rs9826463	0.757	rs75100831	chr3:142244647	T/C	cg20824294	chr3:142316082	PLS1	0.43	7.58	0.35	2.28e-13	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg27211696	chr2:191398769	TMEM194B	-0.57	-7.57	-0.35	2.32e-13	Diastolic blood pressure;
LUAD	cis	rs59698941	0.550	rs11748737	chr5:132201070	C/T	cg16419906	chr5:132167176	NA	-0.33	-6.55	-0.3	1.67e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs6500395	0.963	rs6500404	chr16:48690083	C/T	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.07e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12541635	0.966	rs34177605	chr8:107065105	G/A	cg10147462	chr8:107024639	NA	0.48	8.58	0.39	1.79e-16	Age of smoking initiation;
LUAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg20607798	chr8:58055168	NA	0.67	8.77	0.39	4.44e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	6.42	0.3	3.69e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62103177	0.564	rs59188178	chr18:77723435	T/C	cg02751453	chr18:77725136	HSBP1L1	-0.42	-7.34	-0.34	1.1e-12	Opioid sensitivity;
LUAD	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg24399712	chr22:39784796	NA	-0.84	-16.51	-0.63	1.31e-47	Intelligence (multi-trait analysis);
LUAD	cis	rs999943	0.846	rs10947420	chr6:33611061	C/G	cg14003231	chr6:33640908	ITPR3	0.81	16.2	0.62	2.93e-46	Obesity (extreme);
LUAD	cis	rs938554	0.735	rs11942223	chr4:9962765	T/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.26	-0.37	1.84e-15	Blood metabolite levels;
LUAD	cis	rs939658	0.805	rs2177056	chr15:79441489	T/C	cg17916960	chr15:79447300	NA	-0.53	-11.26	-0.48	6.91e-26	Refractive error;
LUAD	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg10556349	chr10:835070	NA	0.46	6.42	0.3	3.57e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg17177755	chr1:15930204	NA	-0.45	-7.47	-0.34	4.5e-13	Systolic blood pressure;
LUAD	cis	rs7267979	0.780	rs6050679	chr20:25537827	A/T	cg08601574	chr20:25228251	PYGB	0.38	7.01	0.32	9.34e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg02773041	chr1:40204384	PPIE	0.52	8.65	0.39	1.05e-16	Blood protein levels;
LUAD	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg01475377	chr6:109611718	NA	-0.52	-9.91	-0.43	6.04e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs4285028	0.747	rs77570895	chr3:121384565	C/T	cg11130432	chr3:121712080	ILDR1	-0.57	-7.87	-0.36	2.93e-14	Multiple sclerosis;
LUAD	cis	rs606458	0.920	rs17146121	chr11:64386526	A/G	cg27243166	chr11:64479496	NRXN2	0.51	6.5	0.3	2.24e-10	Urate levels;
LUAD	cis	rs2230307	0.536	rs473759	chr1:100557282	C/G	cg20868668	chr1:100435035	SLC35A3	0.5	7.48	0.34	4.31e-13	Carotid intima media thickness;
LUAD	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg01579765	chr21:45077557	HSF2BP	0.54	12.19	0.51	1.64e-29	Mean corpuscular volume;
LUAD	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg05110241	chr16:68378359	PRMT7	-0.87	-9.29	-0.41	7.97e-19	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7264396	0.563	rs6060569	chr20:34290731	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.26	-0.37	1.85e-15	Total cholesterol levels;
LUAD	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07266350	chr3:49460521	AMT;NICN1	0.37	6.66	0.31	8.8e-11	Menarche (age at onset);
LUAD	cis	rs7095607	0.813	rs960773	chr10:69931720	G/T	cg18986048	chr10:69913749	MYPN	0.37	6.44	0.3	3.17e-10	Lung function (FVC);
LUAD	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg16797656	chr11:68205561	LRP5	0.45	8.41	0.38	6.15e-16	Total body bone mineral density;
LUAD	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.78	0.35	5.77e-14	Bladder cancer;
LUAD	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg07157834	chr1:205819609	PM20D1	-0.4	-6.49	-0.3	2.44e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs4523957	0.583	rs2760745	chr17:2035591	T/C	cg16513277	chr17:2031491	SMG6	-0.98	-20.08	-0.7	1.79e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg04842962	chr6:43655489	MRPS18A	1.06	26.84	0.79	2.17e-93	IgG glycosylation;
LUAD	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg12935359	chr14:103987150	CKB	0.48	7.48	0.34	4.4e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11992992	chr3:71633216	FOXP1	-0.42	-6.65	-0.31	8.88e-11	Height;
LUAD	cis	rs9308433	0.505	rs6695148	chr1:214497861	G/T	cg06198575	chr1:214491504	SMYD2	0.47	7.92	0.36	2.18e-14	IgG glycosylation;
LUAD	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg07537917	chr2:241836409	C2orf54	0.32	9.13	0.41	2.76e-18	Urinary metabolites;
LUAD	trans	rs877282	0.898	rs34490091	chr10:765800	A/C	cg22713356	chr15:30763199	NA	1.28	17.2	0.64	1.17e-50	Uric acid levels;
LUAD	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.77e-11	Depression;
LUAD	cis	rs2242073	0.935	rs12464552	chr2:209002060	G/A	cg24664470	chr2:208976933	NA	0.45	6.52	0.3	2.03e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg27494647	chr7:150038898	RARRES2	0.42	7.0	0.32	1.02e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18099408	chr3:52552593	STAB1	-0.51	-9.06	-0.4	4.71e-18	Electroencephalogram traits;
LUAD	cis	rs6541297	0.703	rs585361	chr1:230314954	G/A	cg20703242	chr1:230279135	GALNT2	-0.48	-7.06	-0.32	6.74e-12	Coronary artery disease;
LUAD	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg00933542	chr6:150070202	PCMT1	0.36	7.51	0.34	3.52e-13	Testicular germ cell tumor;
LUAD	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs7759001	0.857	rs9468116	chr6:27366812	G/A	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg23758822	chr17:41437982	NA	1.0	20.4	0.7	6.27e-65	Menopause (age at onset);
LUAD	cis	rs8027181	0.959	rs11631352	chr15:73086473	A/G	cg25632853	chr15:73088954	NA	-0.33	-7.42	-0.34	6.48e-13	Triglyceride levels;
LUAD	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg08085267	chr17:45401833	C17orf57	0.57	10.26	0.45	3.41e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg22105103	chr4:187893119	NA	0.54	11.6	0.49	3.33e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg00745463	chr17:30367425	LRRC37B	-0.64	-8.3	-0.37	1.43e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg21724239	chr8:58056113	NA	0.73	9.6	0.42	7.28e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg25985355	chr7:65971099	NA	-0.55	-6.75	-0.31	4.77e-11	Diabetic kidney disease;
LUAD	cis	rs494562	0.892	rs498289	chr6:86116721	A/G	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.21	0.33	2.66e-12	Rheumatoid arthritis;
LUAD	cis	rs11893307	0.566	rs7558832	chr2:191560589	T/C	cg11845111	chr2:191398756	TMEM194B	-0.45	-6.58	-0.3	1.39e-10	Mean platelet volume;
LUAD	trans	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	17.44	0.65	9.9e-52	Exhaled nitric oxide output;
LUAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg08027265	chr7:2291960	NA	-0.41	-6.93	-0.32	1.59e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg06671706	chr8:8559999	CLDN23	-0.59	-10.09	-0.44	1.4e-21	Obesity-related traits;
LUAD	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.67	-9.48	-0.42	1.81e-19	Lymphocyte percentage of white cells;
LUAD	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg01251548	chr11:17372745	DKFZp686O24166	-0.37	-6.71	-0.31	6.22e-11	Type 2 diabetes;
LUAD	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg14092988	chr3:52407081	DNAH1	0.45	9.07	0.4	4.6e-18	Bipolar disorder;
LUAD	cis	rs375066	0.620	rs349049	chr19:44301400	T/C	cg12072164	chr19:44306565	LYPD5	-0.39	-7.96	-0.36	1.56e-14	Breast cancer;
LUAD	cis	rs1595825	0.945	rs7426250	chr2:198837358	G/A	cg00361562	chr2:198649771	BOLL	-0.47	-6.66	-0.31	8.63e-11	Ulcerative colitis;
LUAD	cis	rs490234	0.616	rs2648318	chr9:128163447	T/C	cg13590414	chr9:128173245	NA	-0.34	-6.59	-0.31	1.34e-10	Mean arterial pressure;
LUAD	cis	rs3816788	0.596	rs4872083	chr8:21770372	C/T	cg03445287	chr8:21823731	XPO7	-0.38	-6.86	-0.32	2.43e-11	Lung cancer in ever smokers;
LUAD	cis	rs1784581	0.802	rs9458430	chr6:162426517	G/T	cg17173639	chr6:162384350	PARK2	-0.39	-7.12	-0.33	4.74e-12	Itch intensity from mosquito bite;
LUAD	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg00701064	chr4:6280414	WFS1	0.58	11.17	0.48	1.44e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08534679	chr3:135913333	MSL2	-0.39	-6.59	-0.31	1.3e-10	Cancer;
LUAD	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs727505	1.000	rs56313563	chr7:124507003	G/A	cg23710748	chr7:124431027	NA	-0.47	-9.61	-0.42	6.83e-20	Lewy body disease;
LUAD	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.25	-0.33	2e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg12062639	chr20:23401060	NAPB	1.11	11.56	0.49	4.76e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs711245	0.698	rs848642	chr2:36782886	G/A	cg09467607	chr2:36825704	FEZ2	0.59	12.07	0.51	4.97e-29	Height;
LUAD	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.08	0.33	6.05e-12	Motion sickness;
LUAD	trans	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg24644049	chr4:85504048	CDS1	0.84	7.6	0.35	1.9e-13	Skin colour saturation;
LUAD	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg24733560	chr20:60626293	TAF4	0.47	9.21	0.41	1.55e-18	Body mass index;
LUAD	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-13.98	-0.56	8.87e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg16606324	chr3:10149918	C3orf24	0.67	9.97	0.44	3.59e-21	Alzheimer's disease;
LUAD	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg26752003	chr8:145688521	CYHR1	0.47	8.35	0.38	9.55e-16	Age at first birth;
LUAD	cis	rs12579753	0.917	rs10778833	chr12:82197983	G/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.28	-0.33	1.6e-12	Resting heart rate;
LUAD	cis	rs12545109	0.800	rs1530217	chr8:57408097	C/T	cg19413350	chr8:57351067	NA	-0.44	-6.64	-0.31	9.91e-11	Obesity-related traits;
LUAD	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-12.04	-0.51	6.46e-29	Coronary artery disease;
LUAD	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.65	-7.22	-0.33	2.35e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-9.03	-0.4	6.3e-18	Lymphocyte counts;
LUAD	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.48	0.34	4.46e-13	Tonsillectomy;
LUAD	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	13.63	0.55	2.48e-35	Lung cancer in ever smokers;
LUAD	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.34	-6.49	-0.3	2.39e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg01579765	chr21:45077557	HSF2BP	-0.57	-13.24	-0.54	1e-33	Mean corpuscular volume;
LUAD	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.39	0.38	7.1e-16	Platelet count;
LUAD	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg13319975	chr6:146136371	FBXO30	-0.54	-9.34	-0.41	5.64e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19346786	chr7:2764209	NA	-0.57	-12.36	-0.52	3.56e-30	Height;
LUAD	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg16325326	chr1:53192061	ZYG11B	0.65	11.44	0.49	1.36e-26	Monocyte count;
LUAD	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg12310025	chr6:25882481	NA	-0.59	-9.66	-0.43	4.48e-20	Blood metabolite levels;
LUAD	cis	rs6908034	0.660	rs76322282	chr6:19801660	G/A	cg02682789	chr6:19804855	NA	0.95	9.37	0.41	4.34e-19	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-20.54	-0.71	1.61e-65	Coronary artery disease;
LUAD	trans	rs9929218	1.000	rs12921546	chr16:68780069	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.89	-15.39	-0.6	9.03e-43	Colorectal cancer;
LUAD	cis	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg08601574	chr20:25228251	PYGB	-0.44	-8.16	-0.37	3.82e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg24642844	chr7:1081250	C7orf50	-0.96	-14.33	-0.57	2.98e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg00431813	chr7:1051703	C7orf50	-0.45	-8.67	-0.39	9.35e-17	Longevity;Endometriosis;
LUAD	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	8.47	0.38	4.03e-16	Rheumatoid arthritis;
LUAD	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.39	-0.38	7.35e-16	Total body bone mineral density;
LUAD	trans	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg11693508	chr17:37793320	STARD3	0.55	7.66	0.35	1.32e-13	Bipolar disorder;
LUAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg22535103	chr8:58192502	C8orf71	-0.65	-7.2	-0.33	2.85e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7474896	0.515	rs2505233	chr10:38340265	C/T	cg25427524	chr10:38739819	LOC399744	-0.58	-8.46	-0.38	4.45e-16	Obesity (extreme);
LUAD	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg24848339	chr3:12840334	CAND2	0.42	8.76	0.39	4.65e-17	QRS complex (12-leadsum);
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg15386877	chr6:161258456	NA	-0.43	-6.57	-0.3	1.47e-10	Blood protein levels;
LUAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg24846343	chr22:24311635	DDTL	-0.62	-13.61	-0.55	2.92e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6867032	0.527	rs13162781	chr5:2012235	C/T	cg26168224	chr5:2018326	NA	0.52	10.61	0.46	1.85e-23	Gut microbiome composition (winter);
LUAD	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg06131755	chr6:160182447	ACAT2	0.46	6.9	0.32	1.86e-11	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg26338869	chr17:61819248	STRADA	-0.38	-6.35	-0.3	5.48e-10	Prudent dietary pattern;
LUAD	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg15147215	chr3:52552868	STAB1	0.44	8.46	0.38	4.38e-16	Electroencephalogram traits;
LUAD	cis	rs6761276	0.868	rs13386602	chr2:113834820	A/C	cg06383401	chr2:113825234	IL1F10	-0.3	-6.48	-0.3	2.6200000000000003e-10	Protein quantitative trait loci;
LUAD	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg04398451	chr17:18023971	MYO15A	-0.63	-11.39	-0.48	2.08e-26	Total body bone mineral density;
LUAD	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg09835421	chr16:68378352	PRMT7	-0.8	-8.63	-0.39	1.3e-16	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg03929089	chr4:120376271	NA	0.67	9.81	0.43	1.37e-20	Coronary artery disease;
LUAD	cis	rs7607369	0.536	rs12623007	chr2:219665335	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-10.47	-0.45	5.54e-23	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs9888739	0.668	rs9933520	chr16:31343386	A/G	cg15817542	chr16:31343056	ITGAM	-0.47	-7.77	-0.35	6.21e-14	Systemic lupus erythematosus;
LUAD	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg02753203	chr1:228287806	NA	0.68	12.63	0.52	2.92e-31	Diastolic blood pressure;
LUAD	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg18811423	chr2:55921094	PNPT1	0.52	8.63	0.39	1.23e-16	Metabolic syndrome;
LUAD	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg04772025	chr11:68637568	NA	0.56	8.96	0.4	1.03e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg19901468	chr14:105411992	AHNAK2	0.51	9.39	0.42	3.75e-19	Rheumatoid arthritis;
LUAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg03188948	chr7:1209495	NA	0.81	9.78	0.43	1.65e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg11189052	chr15:85197271	WDR73	0.56	6.95	0.32	1.43e-11	Schizophrenia;
LUAD	cis	rs62400317	0.821	rs62400269	chr6:45200634	C/T	cg20913747	chr6:44695427	NA	-0.43	-6.59	-0.31	1.3e-10	Total body bone mineral density;
LUAD	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg03948781	chr1:205179583	DSTYK	0.35	6.43	0.3	3.38e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs8067545	0.641	rs1638525	chr17:19848594	G/C	cg04132472	chr17:19861366	AKAP10	0.4	9.28	0.41	8.67e-19	Schizophrenia;
LUAD	cis	rs68170813	0.559	rs12538769	chr7:106984288	C/T	cg23024343	chr7:107201750	COG5	0.47	6.83	0.32	2.92e-11	Coronary artery disease;
LUAD	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.0	0.32	9.82e-12	Prostate cancer;
LUAD	cis	rs2235649	0.663	rs6600168	chr16:1848927	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-6.73	-0.31	5.59e-11	Blood metabolite levels;
LUAD	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg14844989	chr11:31128820	NA	-0.47	-8.51	-0.38	3.14e-16	Red blood cell count;
LUAD	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.54	-0.6	2.13e-43	Chronic sinus infection;
LUAD	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg14343924	chr8:8086146	FLJ10661	0.44	6.65	0.31	9.24e-11	Joint mobility (Beighton score);
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg23162967	chr3:105587981	CBLB	0.38	6.47	0.3	2.64e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg14458575	chr2:238380390	NA	0.79	14.36	0.57	2.28e-38	Prostate cancer;
LUAD	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg00129232	chr17:37814104	STARD3	-0.45	-7.75	-0.35	6.99e-14	Asthma;
LUAD	cis	rs938554	1.000	rs938554	chr4:9925692	C/G	cg00071950	chr4:10020882	SLC2A9	0.54	8.54	0.38	2.48e-16	Blood metabolite levels;
LUAD	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg08344181	chr3:125677491	NA	-0.61	-6.39	-0.3	4.32e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7428	0.502	rs3184781	chr2:85549527	T/C	cg24342717	chr2:85555507	TGOLN2	-0.47	-7.74	-0.35	7.28e-14	Ear protrusion;
LUAD	cis	rs7000551	0.751	rs2449329	chr8:22374794	G/T	cg12081754	chr8:22256438	SLC39A14	0.48	7.89	0.36	2.6e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.17	-0.41	2.02e-18	Life satisfaction;
LUAD	cis	rs11771526	0.681	rs78534662	chr7:32406022	A/T	cg13207630	chr7:32358064	NA	0.65	6.71	0.31	6.11e-11	Body mass index;
LUAD	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.67	-0.35	1.22e-13	Alzheimer's disease (late onset);
LUAD	cis	rs8067287	0.554	rs56092540	chr17:16841417	C/T	cg26910001	chr17:16838321	NA	-0.47	-6.52	-0.3	2e-10	Diabetic kidney disease;
LUAD	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg15557168	chr22:42548783	NA	0.51	9.48	0.42	1.92e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg12908607	chr1:44402522	ARTN	-0.46	-9.16	-0.41	2.34e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg19163074	chr7:65112434	INTS4L2	0.43	6.5	0.3	2.33e-10	Aortic root size;
LUAD	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg20119798	chr7:94954144	PON1	-0.48	-6.66	-0.31	8.53e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7739264	0.544	rs6456266	chr6:19791284	C/T	cg02404759	chr6:19790362	NA	-0.35	-6.65	-0.31	9.08e-11	Endometriosis;
LUAD	cis	rs6840360	0.571	rs62327275	chr4:152548238	G/T	cg22705602	chr4:152727874	NA	-0.43	-7.31	-0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs447921	0.861	rs67873924	chr17:74429992	C/G	cg17201438	chr17:74438067	UBE2O	0.69	8.85	0.4	2.48e-17	Mitochondrial DNA levels;
LUAD	cis	rs4523957	0.614	rs7208638	chr17:2061334	G/C	cg16513277	chr17:2031491	SMG6	-0.96	-18.89	-0.68	3.82e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2455799	0.573	rs2255248	chr3:15754849	A/G	cg16303742	chr3:15540471	COLQ	0.48	8.85	0.4	2.35e-17	Mean platelet volume;
LUAD	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg02574844	chr11:5959923	NA	-0.43	-7.36	-0.34	9.66e-13	DNA methylation (variation);
LUAD	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.83	0.36	4.07e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.34	-6.43	-0.3	3.42e-10	Crohn's disease;
LUAD	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24531977	chr5:56204891	C5orf35	-0.99	-15.18	-0.59	7.37e-42	Initial pursuit acceleration;
LUAD	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg12863693	chr15:85201151	NMB	0.37	6.53	0.3	1.91e-10	Schizophrenia;
LUAD	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-11.03	-0.47	4.82e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg09033563	chr22:24373618	LOC391322	-0.67	-11.61	-0.49	3.1e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg04450456	chr4:17643702	FAM184B	0.4	8.19	0.37	3.12e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6906287	0.647	rs13219555	chr6:118816364	G/A	cg21191810	chr6:118973309	C6orf204	0.49	9.59	0.42	7.62e-20	Electrocardiographic conduction measures;
LUAD	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg17120908	chr11:65337727	SSSCA1	-0.61	-9.6	-0.42	7.36e-20	Bone mineral density;
LUAD	cis	rs2262909	0.962	rs4932952	chr19:22246788	G/A	cg11619707	chr19:22235551	ZNF257	0.49	7.61	0.35	1.84e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	trans	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg06606381	chr12:133084897	FBRSL1	-0.54	-7.32	-0.34	1.27e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9369695	0.881	rs9349409	chr6:47463126	G/T	cg02130027	chr6:47444894	CD2AP	0.36	6.87	0.32	2.33e-11	Reticulocyte count;
LUAD	trans	rs629535	0.862	rs2178955	chr8:70045303	C/T	cg21567404	chr3:27674614	NA	1.01	18.57	0.67	9.52e-57	Dupuytren's disease;
LUAD	cis	rs6723108	0.651	rs35215000	chr2:135367656	C/A	cg12500956	chr2:135428796	TMEM163	-0.28	-7.43	-0.34	6.25e-13	Type 2 diabetes;
LUAD	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.45	-7.81	-0.35	4.66e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9837602	1.000	rs35521705	chr3:99716690	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.98	-0.32	1.18e-11	Breast cancer;
LUAD	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg00310523	chr12:86230176	RASSF9	0.39	7.7	0.35	9.64e-14	Major depressive disorder;
LUAD	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg00933542	chr6:150070202	PCMT1	0.42	8.87	0.4	2.1e-17	Lung cancer;
LUAD	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg03433033	chr1:76189801	ACADM	-0.71	-11.31	-0.48	4.33e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	12.46	0.52	1.39e-30	Monocyte percentage of white cells;
LUAD	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg14582100	chr15:45693742	SPATA5L1	0.52	9.72	0.43	2.84e-20	Homoarginine levels;
LUAD	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg00745463	chr17:30367425	LRRC37B	0.83	9.67	0.43	4.02e-20	Hip circumference adjusted for BMI;
LUAD	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg15691649	chr6:25882328	NA	-0.45	-7.12	-0.33	4.63e-12	Blood metabolite levels;
LUAD	cis	rs72634258	0.503	rs707457	chr1:7831064	C/A	cg26816564	chr1:7831052	VAMP3	0.78	10.53	0.46	3.38e-23	Inflammatory bowel disease;
LUAD	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg11915388	chr22:42470451	FAM109B	0.41	7.28	0.33	1.64e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg02030672	chr11:45687055	CHST1	-0.38	-6.89	-0.32	1.99e-11	Obesity-related traits;
LUAD	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg07741184	chr6:167504864	NA	0.31	7.1	0.33	5.48e-12	Crohn's disease;
LUAD	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg22920501	chr2:26401640	FAM59B	-0.76	-10.87	-0.47	1.93e-24	Gut microbiome composition (summer);
LUAD	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg25237894	chr2:233734115	C2orf82	0.58	11.21	0.48	9.97e-26	Coronary artery disease;
LUAD	cis	rs11811982	0.793	rs115769147	chr1:227488343	G/C	cg24860534	chr1:227506868	CDC42BPA	0.64	7.02	0.32	8.81e-12	Optic disc area;
LUAD	trans	rs459571	0.959	rs416390	chr9:136908549	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.69	9.91	0.43	6.06e-21	Platelet distribution width;
LUAD	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg25358565	chr5:93447407	FAM172A	0.61	7.26	0.33	1.89e-12	Diabetic retinopathy;
LUAD	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg19052272	chr2:3704530	ALLC	-0.47	-6.6	-0.31	1.26e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs4594175	0.926	rs9323206	chr14:51621800	C/T	cg23942311	chr14:51606299	NA	0.64	11.37	0.48	2.48e-26	Cancer;
LUAD	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg17063962	chr7:91808500	NA	0.7	12.5	0.52	9.77e-31	Breast cancer;
LUAD	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg00701064	chr4:6280414	WFS1	0.65	13.69	0.55	1.41e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg14917512	chr19:3094685	GNA11	-0.54	-6.52	-0.3	2.03e-10	Diabetic kidney disease;
LUAD	cis	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg02951883	chr7:2050386	MAD1L1	0.53	7.48	0.34	4.26e-13	Neuroticism;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23036426	chr1:10093530	UBE4B	-0.47	-7.2	-0.33	2.73e-12	Height;
LUAD	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23158103	chr7:148848205	ZNF398	-0.6	-10.93	-0.47	1.2e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	15.35	0.6	1.41e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.06	-27.46	-0.8	4.59e-96	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7000551	0.751	rs2469775	chr8:22373238	T/C	cg12081754	chr8:22256438	SLC39A14	0.45	7.4	0.34	7.17e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg00898013	chr13:113819073	PROZ	0.72	12.65	0.52	2.43e-31	Platelet distribution width;
LUAD	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg00495681	chr13:53174319	NA	0.71	13.88	0.56	2.25e-36	Lewy body disease;
LUAD	cis	rs16910800	0.689	rs7101737	chr11:23165031	C/T	cg20040320	chr11:23191996	NA	-0.69	-8.94	-0.4	1.18e-17	Cancer;
LUAD	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg26039829	chr8:22132926	PIWIL2	0.57	10.57	0.46	2.52e-23	Hypertriglyceridemia;
LUAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg27454412	chr7:1067447	C7orf50	0.48	7.75	0.35	6.7e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2554380	0.800	rs1544876	chr15:84375801	T/A	cg14598478	chr15:84363061	ADAMTSL3	-0.47	-7.24	-0.33	2.08e-12	Height;
LUAD	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg12311346	chr5:56204834	C5orf35	-0.94	-13.82	-0.56	4.26e-36	Initial pursuit acceleration;
LUAD	trans	rs701145	0.537	rs446144	chr3:153922154	T/C	cg14299572	chr10:34021103	NA	-0.39	-6.35	-0.3	5.43e-10	Coronary artery disease;
LUAD	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg21475434	chr5:93447410	FAM172A	0.75	8.29	0.37	1.48e-15	Diabetic retinopathy;
LUAD	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23221052	chr5:179740743	GFPT2	-0.7	-11.74	-0.5	9.97e-28	Height;
LUAD	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg00310523	chr12:86230176	RASSF9	0.4	8.01	0.36	1.13e-14	Major depressive disorder;
LUAD	cis	rs8192282	0.739	rs10908844	chr1:154500857	G/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.37	-0.34	8.86e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg18350739	chr11:68623251	NA	-0.37	-6.44	-0.3	3.28e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg22166914	chr1:53195759	ZYG11B	-0.45	-7.74	-0.35	7.59e-14	Monocyte count;
LUAD	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs1595825	0.891	rs73054827	chr2:198649905	G/A	cg10547527	chr2:198650123	BOLL	-0.53	-7.46	-0.34	5.12e-13	Ulcerative colitis;
LUAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg10729496	chr3:10149963	C3orf24	0.49	7.88	0.36	2.73e-14	Alzheimer's disease;
LUAD	cis	rs990171	0.538	rs4851606	chr2:103120889	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	6.54	0.3	1.83e-10	Lymphocyte counts;
LUAD	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.34	-9.22	-0.41	1.45e-18	Total body bone mineral density;
LUAD	cis	rs3764563	0.799	rs7249233	chr19:15723591	T/C	cg20725493	chr19:15740067	CYP4F8	-0.67	-7.71	-0.35	8.96e-14	Inflammatory biomarkers;
LUAD	cis	rs4727443	0.691	rs6975827	chr7:99585798	C/G	cg22004693	chr7:99632812	ZKSCAN1	-0.4	-6.93	-0.32	1.6e-11	Interstitial lung disease;
LUAD	trans	rs853679	0.607	rs35902873	chr6:28058949	G/C	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.09	-0.47	3.02e-25	Depression;
LUAD	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg04450456	chr4:17643702	FAM184B	0.41	7.96	0.36	1.59e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	11.36	0.48	2.87e-26	Hip circumference adjusted for BMI;
LUAD	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg09455208	chr3:40491958	NA	0.63	13.64	0.55	2.34e-35	Renal cell carcinoma;
LUAD	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg14828511	chr1:107599125	PRMT6	0.53	9.32	0.41	6.55e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs17532515	0.652	rs17005995	chr4:141390110	A/G	cg03645522	chr4:141391200	NA	0.44	6.91	0.32	1.8e-11	Select biomarker traits;
LUAD	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg11189052	chr15:85197271	WDR73	0.59	7.48	0.34	4.22e-13	Schizophrenia;
LUAD	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg03037974	chr15:76606532	NA	0.37	7.74	0.35	7.19e-14	Blood metabolite levels;
LUAD	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.38	0.55	2.81e-34	Tonsillectomy;
LUAD	cis	rs6445967	0.530	rs62258104	chr3:58379984	G/C	cg23715586	chr3:58305044	RPP14	0.39	6.43	0.3	3.54e-10	Platelet count;
LUAD	trans	rs9951602	0.512	rs9949512	chr18:76641845	T/C	cg02800362	chr5:177631904	HNRNPAB	0.92	14.18	0.57	1.25e-37	Obesity-related traits;
LUAD	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg22467129	chr15:76604101	ETFA	-0.39	-6.43	-0.3	3.52e-10	Blood metabolite levels;
LUAD	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg18105134	chr13:113819100	PROZ	-0.86	-15.06	-0.59	2.42e-41	Platelet distribution width;
LUAD	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg11494091	chr17:61959527	GH2	-0.73	-16.75	-0.63	1.12e-48	Prudent dietary pattern;
LUAD	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg10755058	chr3:40428713	ENTPD3	0.45	8.24	0.37	2.17e-15	Renal cell carcinoma;
LUAD	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg04398451	chr17:18023971	MYO15A	-0.84	-15.84	-0.61	1.07e-44	Total body bone mineral density;
LUAD	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg05340658	chr4:99064831	C4orf37	0.53	8.41	0.38	6.44e-16	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25184507	chr17:7760147	CYB5D1;LSMD1	-0.41	-6.53	-0.3	1.86e-10	Height;
LUAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	cis	rs7665090	0.967	rs228611	chr4:103561709	G/A	cg07973026	chr4:103553119	MANBA	-0.42	-7.27	-0.33	1.75e-12	Primary biliary cholangitis;
LUAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg11062466	chr8:58055876	NA	0.66	8.64	0.39	1.2e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs11153730	0.503	rs283046	chr6:118627503	T/C	cg21191810	chr6:118973309	C6orf204	0.49	9.51	0.42	1.43e-19	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26314531	chr2:26401878	FAM59B	-0.72	-9.81	-0.43	1.33e-20	Gut microbiome composition (summer);
LUAD	trans	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg04565464	chr8:145669602	NFKBIL2	0.47	7.41	0.34	6.99e-13	Schizophrenia;
LUAD	cis	rs9308433	0.553	rs9308435	chr1:214500166	C/T	cg06198575	chr1:214491504	SMYD2	0.45	7.63	0.35	1.53e-13	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.59	0.52	4.34e-31	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3219090	0.962	rs2249844	chr1:226601135	A/G	cg27539482	chr13:111589090	NA	0.42	7.09	0.33	5.78e-12	Melanoma;
LUAD	trans	rs11165623	0.564	rs7525803	chr1:97000791	T/C	cg10631902	chr5:14652156	NA	-0.41	-7.48	-0.34	4.48e-13	Hip circumference;Waist circumference;
LUAD	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg10556349	chr10:835070	NA	0.55	6.83	0.32	3e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs8067545	0.750	rs4925079	chr17:19986861	T/A	cg04132472	chr17:19861366	AKAP10	0.28	6.61	0.31	1.17e-10	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg05340658	chr4:99064831	C4orf37	0.53	8.38	0.38	7.77e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg21204522	chr6:27730016	NA	-0.48	-7.59	-0.35	2.08e-13	Parkinson's disease;
LUAD	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg04414720	chr1:150670196	GOLPH3L	0.74	13.84	0.56	3.45e-36	Melanoma;
LUAD	cis	rs11811982	0.793	rs75085172	chr1:227513630	T/C	cg24860534	chr1:227506868	CDC42BPA	0.71	7.41	0.34	6.93e-13	Optic disc area;
LUAD	cis	rs10992471	0.639	rs10125587	chr9:95499882	G/A	cg14631576	chr9:95140430	CENPP	-0.48	-9.83	-0.43	1.09e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg06640241	chr16:89574553	SPG7	0.71	12.58	0.52	4.58e-31	Multiple myeloma (IgH translocation);
LUAD	cis	rs4846217	1.000	rs4846217	chr1:10451799	C/T	cg17425144	chr1:10567563	PEX14	-0.49	-6.43	-0.3	3.39e-10	Platelet count;
LUAD	cis	rs7274811	0.711	rs657040	chr20:32001292	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.48	7.17	0.33	3.33e-12	Height;
LUAD	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg21862992	chr11:68658383	NA	0.52	9.64	0.42	5.3e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg17420585	chr12:42539391	GXYLT1	-0.37	-6.63	-0.31	1.03e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg10978503	chr1:24200527	CNR2	-0.46	-8.64	-0.39	1.16e-16	Immature fraction of reticulocytes;
LUAD	cis	rs12586317	0.531	rs60049741	chr14:35719842	G/A	cg07166546	chr14:35805898	NA	-0.26	-6.39	-0.3	4.31e-10	Psoriasis;
LUAD	cis	rs2625529	0.938	rs4776579	chr15:72132608	C/T	cg16672083	chr15:72433130	SENP8	-0.64	-11.04	-0.47	4.68e-25	Red blood cell count;
LUAD	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	13.0	0.53	9.28e-33	Lymphocyte counts;
LUAD	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg06697600	chr4:7070879	GRPEL1	-0.48	-7.82	-0.36	4.39e-14	Monocyte percentage of white cells;
LUAD	cis	rs13223928	0.538	rs10951042	chr7:3139417	T/C	cg19214707	chr7:3157722	NA	-0.43	-7.55	-0.34	2.73e-13	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg20607798	chr8:58055168	NA	0.57	7.89	0.36	2.56e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg26924012	chr15:45694286	SPATA5L1	0.63	10.89	0.47	1.57e-24	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg12310025	chr6:25882481	NA	0.83	13.79	0.56	5.57e-36	Blood metabolite levels;
LUAD	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg08316699	chr6:150357289	NA	0.36	7.56	0.34	2.59e-13	Alopecia areata;
LUAD	cis	rs6138458	1.000	rs6707	chr20:24944166	C/T	cg26195577	chr20:24973756	C20orf3	0.96	16.54	0.63	9.47e-48	Blood protein levels;
LUAD	trans	rs1997103	1.000	rs6968966	chr7:55411356	A/G	cg20935933	chr6:143382018	AIG1	0.53	7.45	0.34	5.24e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.69	0.35	1.02e-13	Bladder cancer;
LUAD	cis	rs1044826	0.619	rs6439856	chr3:139134868	A/T	cg00490450	chr3:139108681	COPB2	-0.44	-6.99	-0.32	1.07e-11	Obesity-related traits;
LUAD	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11890956	chr21:40555474	PSMG1	-0.61	-10.3	-0.45	2.45e-22	Cognitive function;
LUAD	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg01802117	chr1:53393560	SCP2	-0.38	-7.35	-0.34	1.03e-12	Monocyte count;
LUAD	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg17158414	chr2:27665306	KRTCAP3	0.33	8.81	0.39	3.34e-17	Total body bone mineral density;
LUAD	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg19193384	chr17:30244184	NA	-0.49	-6.43	-0.3	3.52e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs78707713	0.560	rs55668536	chr10:71242655	A/G	cg12610070	chr10:71211762	TSPAN15	-0.38	-9.33	-0.41	5.85e-19	Venous thromboembolism;
LUAD	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg15790184	chr11:494944	RNH1	0.57	7.09	0.33	5.69e-12	Body mass index;
LUAD	cis	rs864745	0.690	rs849140	chr7:28183702	T/C	cg22892036	chr7:28189139	JAZF1	0.41	6.9	0.32	1.96e-11	Crohn's disease;Type 2 diabetes;
LUAD	cis	rs28374715	0.532	rs316606	chr15:41772202	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.1	-22.48	-0.74	3.34e-74	Ulcerative colitis;
LUAD	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg15448220	chr1:150897856	SETDB1	0.46	7.97	0.36	1.47e-14	Tonsillectomy;
LUAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg24642844	chr7:1081250	C7orf50	-0.96	-14.27	-0.57	5.21e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	9.55	0.42	1.05e-19	Lung cancer in ever smokers;
LUAD	cis	rs68092024	0.731	rs793479	chr3:99488232	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	7.85	0.36	3.55e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-11.49	-0.49	8.67e-27	Migraine;Coronary artery disease;
LUAD	cis	rs6906287	0.647	rs10457338	chr6:118784018	T/C	cg18833306	chr6:118973337	C6orf204	0.45	8.13	0.37	4.95e-15	Electrocardiographic conduction measures;
LUAD	cis	rs12541635	0.934	rs7008840	chr8:107016404	T/C	cg10147462	chr8:107024639	NA	0.49	8.58	0.39	1.81e-16	Age of smoking initiation;
LUAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08280861	chr8:58055591	NA	0.64	10.8	0.47	3.46e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.05	-0.32	7.1e-12	Pancreatic cancer;
LUAD	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg00316803	chr15:76480434	C15orf27	0.39	6.4	0.3	4.19e-10	Blood metabolite levels;
LUAD	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg21496419	chr19:44306685	LYPD5	0.32	7.29	0.33	1.5e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs13064411	0.542	rs2087130	chr3:113226983	T/A	cg18753928	chr3:113234510	CCDC52	-0.55	-9.71	-0.43	3e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg05340658	chr4:99064831	C4orf37	0.53	8.55	0.38	2.23e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg25036284	chr2:26402008	FAM59B	-0.83	-11.79	-0.5	6.2e-28	Gut microbiome composition (summer);
LUAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.69	-13.58	-0.55	4.05e-35	Prudent dietary pattern;
LUAD	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg21385522	chr1:16154831	NA	0.52	8.67	0.39	9.03e-17	Systolic blood pressure;
LUAD	cis	rs6138458	1.000	rs227615	chr20:24908721	T/C	cg26195577	chr20:24973756	C20orf3	0.96	16.32	0.62	8.79e-47	Blood protein levels;
LUAD	cis	rs73206853	0.764	rs3026447	chr12:110724272	C/T	cg12870014	chr12:110450643	ANKRD13A	0.53	6.93	0.32	1.55e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg21214613	chr1:16344536	HSPB7	-0.45	-7.77	-0.35	5.81e-14	Dilated cardiomyopathy;
LUAD	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg07599136	chr5:415885	AHRR	0.79	8.32	0.37	1.22e-15	Fat distribution (HIV);
LUAD	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg27286337	chr10:134555280	INPP5A	-0.93	-18.67	-0.67	3.69e-57	Migraine;
LUAD	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg23649088	chr2:200775458	C2orf69	-0.57	-6.48	-0.3	2.57e-10	Schizophrenia;
LUAD	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.48	7.66	0.35	1.31e-13	Cognitive ability;
LUAD	trans	rs12200782	1.000	rs72845509	chr6:26639865	T/C	cg08851530	chr6:28072375	NA	0.72	6.56	0.3	1.53e-10	Small cell lung carcinoma;
LUAD	cis	rs300703	0.542	rs300696	chr2:183330	G/A	cg21211680	chr2:198530	NA	-0.52	-7.05	-0.32	7.17e-12	Blood protein levels;
LUAD	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11890956	chr21:40555474	PSMG1	-0.5	-8.02	-0.36	1.05e-14	Menarche (age at onset);
LUAD	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg05340658	chr4:99064831	C4orf37	0.46	7.56	0.34	2.56e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg16647868	chr5:131706066	SLC22A5	-0.43	-7.37	-0.34	8.85e-13	Blood metabolite levels;
LUAD	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg25894440	chr7:65020034	NA	-0.63	-6.67	-0.31	8.15e-11	Diabetic kidney disease;
LUAD	cis	rs3812049	1.000	rs3812049	chr5:127418850	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	8.34	0.38	1.07e-15	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg17264618	chr3:40429014	ENTPD3	0.36	7.37	0.34	9.08e-13	Renal cell carcinoma;
LUAD	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg22532475	chr10:104410764	TRIM8	-0.46	-8.86	-0.4	2.18e-17	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs62025270	0.547	rs338540	chr15:86195731	C/T	cg13263323	chr15:86062960	AKAP13	-0.43	-7.01	-0.32	9.74e-12	Idiopathic pulmonary fibrosis;
LUAD	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg10057126	chr4:77819792	ANKRD56	0.55	9.71	0.43	2.92e-20	Emphysema distribution in smoking;
LUAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg24642844	chr7:1081250	C7orf50	-0.98	-14.87	-0.59	1.54e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg18252515	chr7:66147081	NA	-0.63	-6.96	-0.32	1.34e-11	Diabetic kidney disease;
LUAD	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg07432352	chr17:45403706	C17orf57	0.4	7.48	0.34	4.28e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg25985355	chr7:65971099	NA	-0.51	-6.38	-0.3	4.78e-10	Diabetic kidney disease;
LUAD	cis	rs12681287	0.605	rs2953509	chr8:87343194	C/T	cg00550725	chr8:87521180	FAM82B	0.47	6.75	0.31	5.01e-11	Caudate activity during reward;
LUAD	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg10755058	chr3:40428713	ENTPD3	0.46	8.6	0.39	1.57e-16	Renal cell carcinoma;
LUAD	trans	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg17145862	chr1:211918768	LPGAT1	-0.74	-17.83	-0.66	1.87e-53	Leprosy;
LUAD	cis	rs2282300	0.739	rs34855782	chr11:30225470	G/A	cg25418670	chr11:30344373	C11orf46	-0.52	-7.12	-0.33	4.57e-12	Morning vs. evening chronotype;
LUAD	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg22532475	chr10:104410764	TRIM8	0.34	7.02	0.32	8.97e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11048434	0.736	rs2041624	chr12:9111855	C/G	cg04155231	chr12:9217510	LOC144571	0.38	7.26	0.33	1.82e-12	Sjögren's syndrome;
LUAD	trans	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg07211511	chr3:129823064	LOC729375	-0.93	-14.06	-0.56	3.97e-37	Blood pressure (smoking interaction);
LUAD	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg00316803	chr15:76480434	C15orf27	0.39	6.41	0.3	3.94e-10	Blood metabolite levels;
LUAD	cis	rs4631830	0.600	rs11004324	chr10:51496623	G/T	cg20129853	chr10:51489980	NA	-0.44	-8.16	-0.37	3.77e-15	Prostate-specific antigen levels;
LUAD	cis	rs123509	0.863	rs339662	chr3:42752093	T/C	cg12982090	chr3:42733453	KBTBD5	0.54	9.24	0.41	1.24e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg11919837	chr8:57350735	NA	-0.43	-6.52	-0.3	1.99e-10	Obesity-related traits;
LUAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08219700	chr8:58056026	NA	0.61	8.61	0.39	1.43e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.38	-7.0	-0.32	1.01e-11	Systemic lupus erythematosus;
LUAD	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg12140854	chr5:148520817	ABLIM3	0.64	10.3	0.45	2.37e-22	Breast cancer;
LUAD	cis	rs1395	0.925	rs1659676	chr2:27399294	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.41	-7.49	-0.34	3.95e-13	Blood metabolite levels;
LUAD	cis	rs11809207	0.501	rs2232654	chr1:26496870	A/G	cg23602478	chr1:26503979	CNKSR1	0.28	6.65	0.31	9.33e-11	Height;
LUAD	cis	rs7512552	0.803	rs2454286	chr1:150355538	G/A	cg15654264	chr1:150340011	RPRD2	0.58	11.06	0.47	3.83e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2235649	0.798	rs9922462	chr16:1848011	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-6.85	-0.32	2.64e-11	Blood metabolite levels;
LUAD	cis	rs68170813	0.559	rs17428071	chr7:106878200	C/G	cg02696742	chr7:106810147	HBP1	-0.76	-10.5	-0.45	4.56e-23	Coronary artery disease;
LUAD	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg16479474	chr6:28041457	NA	0.43	7.33	0.34	1.21e-12	Depression;
LUAD	cis	rs593982	0.920	rs1151500	chr11:65481166	T/C	cg08755490	chr11:65554678	OVOL1	1.23	14.73	0.58	6.17e-40	Atopic dermatitis;
LUAD	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11644478	chr21:40555479	PSMG1	0.69	11.54	0.49	5.84e-27	Cognitive function;
LUAD	cis	rs6494488	0.500	rs72744790	chr15:65100005	C/T	cg08069370	chr15:64387884	SNX1	-0.74	-6.64	-0.31	9.68e-11	Coronary artery disease;
LUAD	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg23301539	chr8:142222248	SLC45A4	0.38	6.64	0.31	9.39e-11	Immature fraction of reticulocytes;
LUAD	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg05182265	chr7:156933206	UBE3C	-0.8	-17.25	-0.64	7.2e-51	Body mass index;
LUAD	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-9.24	-0.41	1.23e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7737355	0.947	rs2108869	chr5:131086880	A/G	cg25547332	chr5:131281432	NA	0.44	6.74	0.31	5.19e-11	Life satisfaction;
LUAD	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg06064525	chr11:970664	AP2A2	-0.54	-11.05	-0.47	3.99e-25	Alzheimer's disease (late onset);
LUAD	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg15557168	chr22:42548783	NA	0.37	6.62	0.31	1.11e-10	Cognitive function;
LUAD	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg18105134	chr13:113819100	PROZ	0.91	16.5	0.63	1.4e-47	Platelet distribution width;
LUAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03188948	chr7:1209495	NA	0.47	7.64	0.35	1.42e-13	Longevity;Endometriosis;
LUAD	cis	rs1215050	0.782	rs6853916	chr4:98653387	C/T	cg24818145	chr4:99064322	C4orf37	-0.41	-6.77	-0.31	4.2e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs11165623	0.564	rs7541109	chr1:96995960	C/A	cg10631902	chr5:14652156	NA	-0.41	-7.58	-0.35	2.27e-13	Hip circumference;Waist circumference;
LUAD	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08704250	chr15:31115839	NA	-0.55	-10.01	-0.44	2.63e-21	Huntington's disease progression;
LUAD	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg09509183	chr1:209979624	IRF6	-0.56	-6.68	-0.31	7.65e-11	Coronary artery disease;
LUAD	trans	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg13565492	chr6:43139072	SRF	-0.6	-6.4	-0.3	4.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg14847009	chr1:175162515	KIAA0040	0.31	8.11	0.37	5.64e-15	Alcohol dependence;
LUAD	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg13902645	chr11:5959945	NA	-0.52	-9.07	-0.4	4.47e-18	DNA methylation (variation);
LUAD	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg22166914	chr1:53195759	ZYG11B	-0.51	-8.66	-0.39	1.03e-16	Monocyte count;
LUAD	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg14416269	chr4:6271139	WFS1	-0.59	-12.14	-0.51	2.59e-29	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs3743162	0.553	rs4842994	chr15:85415799	A/G	cg11189052	chr15:85197271	WDR73	-0.5	-6.37	-0.3	4.87e-10	Alzheimer's disease (age of onset);
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg21548813	chr6:291882	DUSP22	-0.77	-13.08	-0.54	4.74e-33	Menopause (age at onset);
LUAD	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg24399712	chr22:39784796	NA	-0.8	-15.37	-0.6	1.09e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs6842047	1.000	rs4862665	chr4:187136142	C/T	cg23442198	chr4:187126114	CYP4V2	-0.83	-8.85	-0.4	2.49e-17	Blood protein levels;
LUAD	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg06131755	chr6:160182447	ACAT2	0.46	6.88	0.32	2.17e-11	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs6577655	0.517	rs4909295	chr8:135588042	G/A	cg17885191	chr8:135476712	NA	0.62	8.22	0.37	2.45e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg07460842	chr6:66804631	NA	-1.21	-30.68	-0.83	1.28e-109	Exhaled nitric oxide output;
LUAD	cis	rs877282	0.898	rs12357016	chr10:765675	C/T	cg06581033	chr10:766294	NA	-0.62	-8.35	-0.38	1.02e-15	Uric acid levels;
LUAD	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.46	9.47	0.42	2.02e-19	Monocyte percentage of white cells;
LUAD	cis	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-7.14	-0.33	4.21e-12	Neuroticism;
LUAD	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg14530993	chr4:882597	GAK	0.73	6.9	0.32	1.89e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg06191203	chr2:152266755	RIF1	0.58	8.66	0.39	1.02e-16	Lung cancer;
LUAD	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg05283184	chr6:79620031	NA	-0.62	-12.45	-0.52	1.52e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs34976449	1	rs34976449	chr1:8498326	T/TG	cg01447281	chr1:8482689	RERE	-0.4	-8.1	-0.37	5.95e-15	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.52e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.39	-6.37	-0.3	4.93e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg12935359	chr14:103987150	CKB	0.47	7.88	0.36	2.85e-14	Body mass index;
LUAD	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg09184832	chr6:79620586	NA	-0.53	-9.91	-0.43	5.95e-21	Intelligence (multi-trait analysis);
LUAD	trans	rs12266096	0.680	rs11201403	chr10:86900524	A/T	cg11357369	chr6:164506268	NA	-0.34	-6.54	-0.3	1.79e-10	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LUAD	cis	rs7289126	0.966	rs4820329	chr22:38646063	G/A	cg25457927	chr22:38595422	NA	-0.45	-10.43	-0.45	7.76e-23	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg08798685	chr6:27730294	NA	-0.44	-7.04	-0.32	8e-12	Parkinson's disease;
LUAD	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg27068330	chr11:65405492	SIPA1	-0.75	-11.25	-0.48	7.53e-26	Acne (severe);
LUAD	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg26384229	chr12:38710491	ALG10B	0.52	8.52	0.38	2.74e-16	Heart rate;
LUAD	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg27535305	chr1:53392650	SCP2	-0.39	-8.11	-0.37	5.57e-15	Monocyte count;
LUAD	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03352830	chr11:487213	PTDSS2	0.82	10.59	0.46	2.07e-23	Body mass index;
LUAD	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg05805236	chr11:65401703	PCNXL3	0.44	7.48	0.34	4.24e-13	Acne (severe);
LUAD	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg09658497	chr7:2847517	GNA12	-0.41	-7.21	-0.33	2.54e-12	Height;
LUAD	cis	rs2016266	0.787	rs61928080	chr12:53752204	G/A	cg26875137	chr12:53738046	NA	-0.34	-6.75	-0.31	4.77e-11	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs7072216	0.727	rs942807	chr10:100168219	G/A	cg26618903	chr10:100175079	PYROXD2	-0.36	-7.93	-0.36	2.01e-14	Metabolite levels;
LUAD	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg07741184	chr6:167504864	NA	-0.31	-7.32	-0.34	1.29e-12	Crohn's disease;
LUAD	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	11.31	0.48	4.35e-26	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg16479474	chr6:28041457	NA	0.46	7.67	0.35	1.2e-13	Depression;
LUAD	trans	rs6601327	0.670	rs10092751	chr8:9426325	T/C	cg27411982	chr8:10470053	RP1L1	0.37	6.86	0.32	2.48e-11	Multiple myeloma (hyperdiploidy);
LUAD	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg17644776	chr2:200775616	C2orf69	0.5	7.25	0.33	2.02e-12	Schizophrenia;
LUAD	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg13319975	chr6:146136371	FBXO30	-0.58	-9.74	-0.43	2.4e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg11822812	chr5:140052017	DND1	0.38	6.7	0.31	6.85e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg22189786	chr22:42395067	WBP2NL	0.45	6.51	0.3	2.09e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg01528321	chr10:82214614	TSPAN14	0.68	10.35	0.45	1.6e-22	Post bronchodilator FEV1;
LUAD	cis	rs8062405	0.573	rs8045689	chr16:28988269	C/T	cg05966235	chr16:28915196	ATP2A1	-0.46	-7.07	-0.33	6.48e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs35995292	0.534	rs11980627	chr7:38907533	T/C	cg19327137	chr7:38886074	VPS41	0.75	15.84	0.61	1.09e-44	Subjective well-being (multi-trait analysis);
LUAD	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg08219700	chr8:58056026	NA	0.41	6.42	0.3	3.64e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg02569458	chr12:86230093	RASSF9	0.39	7.16	0.33	3.57e-12	Major depressive disorder;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg01861096	chr22:19279212	CLTCL1	-0.38	-6.44	-0.3	3.21e-10	Schizophrenia;
LUAD	cis	rs427941	0.668	rs201438	chr7:101735236	G/A	cg06246474	chr7:101738831	CUX1	0.41	7.21	0.33	2.52e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs1595825	0.786	rs73054839	chr2:198671665	C/A	cg00982548	chr2:198649783	BOLL	-0.65	-9.06	-0.4	4.97e-18	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.76	0.31	4.57e-11	Menarche (age at onset);
LUAD	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg10755058	chr3:40428713	ENTPD3	0.39	7.72	0.35	8.65e-14	Renal cell carcinoma;
LUAD	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg21153622	chr11:89784906	NA	-0.33	-6.48	-0.3	2.53e-10	Height;
LUAD	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg21204522	chr6:27730016	NA	-0.48	-7.57	-0.35	2.38e-13	Parkinson's disease;
LUAD	cis	rs7192380	0.639	rs2917666	chr16:69763960	C/G	cg00738113	chr16:70207722	CLEC18C	0.36	7.1	0.33	5.47e-12	Sjögren's syndrome;
LUAD	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg05340658	chr4:99064831	C4orf37	0.45	7.46	0.34	4.86e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7809615	0.901	rs11555142	chr7:99032593	G/T	cg03133378	chr7:99195931	NA	-0.56	-6.47	-0.3	2.64e-10	Blood metabolite ratios;
LUAD	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg26647111	chr11:31128758	NA	-0.45	-7.92	-0.36	2.14e-14	Red blood cell count;
LUAD	cis	rs4638749	1.000	rs10209928	chr2:108863898	C/T	cg25838818	chr2:108905173	SULT1C2	-0.56	-8.82	-0.39	3.05e-17	Blood pressure;
LUAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg08132940	chr7:1081526	C7orf50	-0.44	-6.62	-0.31	1.08e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.43	-0.45	7.96e-23	Monocyte percentage of white cells;
LUAD	cis	rs758324	0.947	rs1604080	chr5:131176644	A/G	cg25547332	chr5:131281432	NA	-0.48	-7.5	-0.34	3.87e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg00603274	chr11:61596626	FADS2	-0.37	-6.44	-0.3	3.26e-10	Trans fatty acid levels;
LUAD	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg24450063	chr1:156163899	SLC25A44	1.23	30.44	0.83	1.21e-108	Testicular germ cell tumor;
LUAD	cis	rs6782228	0.527	rs2811491	chr3:128353950	C/A	cg16766828	chr3:128327626	NA	-0.38	-7.06	-0.32	6.9e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.27	-0.41	9.55e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg23587288	chr2:27483067	SLC30A3	0.44	8.77	0.39	4.33e-17	Blood metabolite levels;
LUAD	cis	rs300703	0.515	rs364431	chr2:191399	C/A	cg21211680	chr2:198530	NA	0.54	7.93	0.36	1.94e-14	Blood protein levels;
LUAD	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg03929089	chr4:120376271	NA	-0.83	-15.3	-0.6	2.17e-42	Coronary artery disease;
LUAD	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-8.56	-0.38	2.04e-16	Platelet count;
LUAD	cis	rs7264396	0.563	rs1970577	chr20:34336737	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.05	-0.36	8.75e-15	Total cholesterol levels;
LUAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg22535103	chr8:58192502	C8orf71	0.58	6.73	0.31	5.42e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg01236616	chr12:121019343	POP5	1.29	19.31	0.68	4.78e-60	Type 1 diabetes nephropathy;
LUAD	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs9354308	0.866	rs2814092	chr6:66547346	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.52	8.07	0.37	7.58e-15	Metabolite levels;
LUAD	cis	rs16867321	0.639	rs12466864	chr2:181441417	C/G	cg23363182	chr2:181467187	NA	0.44	7.29	0.33	1.52e-12	Obesity;
LUAD	cis	rs3772130	0.962	rs6768621	chr3:121530274	C/A	cg20356878	chr3:121714668	ILDR1	0.53	8.5	0.38	3.24e-16	Cognitive performance;
LUAD	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg03690763	chr11:133734501	NA	-0.36	-8.52	-0.38	2.94e-16	Childhood ear infection;
LUAD	cis	rs7771547	0.574	rs9368943	chr6:36566575	C/T	cg12173498	chr6:36355764	ETV7	0.49	6.49	0.3	2.41e-10	Platelet distribution width;
LUAD	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.55	-0.3	1.67e-10	Total body bone mineral density;
LUAD	cis	rs494562	1.000	rs494562	chr6:86117129	A/G	cg17966619	chr6:86160162	NT5E	0.67	8.16	0.37	3.76e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-8.17	-0.37	3.54e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg18105134	chr13:113819100	PROZ	0.75	13.2	0.54	1.48e-33	Platelet distribution width;
LUAD	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.54	-0.34	2.97e-13	Diabetic kidney disease;
LUAD	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg10755058	chr3:40428713	ENTPD3	0.39	7.44	0.34	5.51e-13	Renal cell carcinoma;
LUAD	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg08798685	chr6:27730294	NA	0.62	6.87	0.32	2.34e-11	Depression;
LUAD	cis	rs7617773	0.710	rs36064160	chr3:48243101	C/G	cg11946769	chr3:48343235	NME6	0.41	6.35	0.3	5.52e-10	Coronary artery disease;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20273774	chr5:180671298	GNB2L1;SNORD95	0.45	6.88	0.32	2.15e-11	Gut microbiome composition (summer);
LUAD	trans	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg01620082	chr3:125678407	NA	-0.71	-7.15	-0.33	3.78e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg18105134	chr13:113819100	PROZ	-0.87	-15.27	-0.6	3.07e-42	Platelet distribution width;
LUAD	cis	rs12912251	0.948	rs34281605	chr15:38989674	G/A	cg01338139	chr15:38987640	C15orf53	-0.57	-8.92	-0.4	1.47e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs7809950	0.834	rs3801946	chr7:107242995	T/A	cg23024343	chr7:107201750	COG5	0.77	12.62	0.52	3.31e-31	Coronary artery disease;
LUAD	trans	rs4714291	0.925	rs847747	chr6:40080069	G/T	cg02267698	chr19:7991119	CTXN1	0.43	6.48	0.3	2.63e-10	Strep throat;
LUAD	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	8.55	0.38	2.23e-16	Ileal carcinoids;
LUAD	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.4	-7.3	-0.33	1.44e-12	Urate levels in overweight individuals;
LUAD	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg08132940	chr7:1081526	C7orf50	-0.59	-6.49	-0.3	2.47e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	14.27	0.57	5.43e-38	Schizophrenia;
LUAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg22764044	chr5:178986830	RUFY1	-0.65	-10.72	-0.46	7.05e-24	Lung cancer;
LUAD	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg02269571	chr22:50332266	NA	0.66	9.82	0.43	1.19e-20	Schizophrenia;
LUAD	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg05535760	chr7:792225	HEATR2	0.86	11.74	0.5	9.56e-28	Cerebrospinal P-tau181p levels;
LUAD	cis	rs713477	1.000	rs12887846	chr14:55911139	T/C	cg13175173	chr14:55914753	NA	-0.33	-6.95	-0.32	1.4e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs55823223	0.680	rs3744017	chr17:73871467	G/A	cg12714757	chr17:73874637	TRIM47	-0.48	-7.39	-0.34	8.02e-13	Psoriasis;
LUAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg03354898	chr7:1950403	MAD1L1	0.38	7.17	0.33	3.47e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg20290983	chr6:43655470	MRPS18A	-1.04	-26.2	-0.79	1.3e-90	IgG glycosylation;
LUAD	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg22875332	chr1:76189707	ACADM	-0.84	-14.92	-0.59	9.77e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4691139	0.582	rs9993113	chr4:165940728	G/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.36	-6.8	-0.31	3.63e-11	Ovarian cancer in BRCA1 mutation carriers;
LUAD	trans	rs877282	0.945	rs71489301	chr10:770191	A/G	cg22713356	chr15:30763199	NA	1.21	16.91	0.64	2.28e-49	Uric acid levels;
LUAD	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg24531977	chr5:56204891	C5orf35	-0.41	-6.59	-0.31	1.3e-10	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg21862992	chr11:68658383	NA	0.52	9.54	0.42	1.11e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg21609526	chr1:3105151	PRDM16	-0.34	-7.02	-0.32	8.94e-12	Migraine;
LUAD	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg02734326	chr4:10020555	SLC2A9	0.59	10.24	0.45	3.87e-22	Bone mineral density;
LUAD	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.8	0.39	3.48e-17	Menopause (age at onset);
LUAD	cis	rs1832871	0.643	rs9456282	chr6:158724743	A/G	cg07165851	chr6:158734300	TULP4	0.67	9.73	0.43	2.59e-20	Height;
LUAD	cis	rs4889855	0.530	rs4889865	chr17:78568447	A/T	cg16591659	chr17:78472290	NA	0.45	7.93	0.36	2.03e-14	Fractional excretion of uric acid;
LUAD	trans	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg26043149	chr18:55253948	FECH	-0.49	-7.98	-0.36	1.42e-14	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3736594	0.513	rs62141278	chr2:27768381	C/T	cg27432699	chr2:27873401	GPN1	0.47	6.42	0.3	3.74e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.93	-0.36	2.01e-14	Prostate cancer;
LUAD	cis	rs6684514	0.961	rs12048077	chr1:156299916	T/A	cg16558208	chr1:156270281	VHLL	0.53	9.64	0.42	5e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg05187965	chr10:45406764	TMEM72	-0.43	-8.78	-0.39	4.06e-17	Mean corpuscular volume;
LUAD	trans	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg03929089	chr4:120376271	NA	-0.57	-7.71	-0.35	9.16e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg12140854	chr5:148520817	ABLIM3	-0.66	-10.7	-0.46	8.17e-24	Breast cancer;
LUAD	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.76	0.31	4.49e-11	Platelet count;
LUAD	cis	rs7107174	0.579	rs10793299	chr11:78018954	T/A	cg02023728	chr11:77925099	USP35	0.52	7.85	0.36	3.49e-14	Testicular germ cell tumor;
LUAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg18538332	chr22:24372958	LOC391322	-0.57	-9.86	-0.43	8.57e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7799006	0.782	rs2159044	chr7:2262941	C/A	cg08027265	chr7:2291960	NA	-0.43	-7.89	-0.36	2.54e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg26022315	chr17:47021804	SNF8	0.4	7.28	0.33	1.64e-12	Type 2 diabetes;
LUAD	cis	rs9341808	0.667	rs1408292	chr6:80883906	G/T	cg08355045	chr6:80787529	NA	0.54	9.57	0.42	9.1e-20	Sitting height ratio;
LUAD	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg12436631	chr1:155007014	DCST1;DCST2	-0.3	-6.99	-0.32	1.06e-11	Prostate cancer;
LUAD	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.39	-0.34	7.83e-13	Bone mineral density;
LUAD	cis	rs757110	0.900	rs2074314	chr11:17411821	C/T	cg15432903	chr11:17409602	KCNJ11	0.6	11.17	0.48	1.43e-25	Type 2 diabetes;
LUAD	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg12740337	chr6:28058973	ZSCAN12L1	0.35	6.69	0.31	7.16e-11	Lung cancer in ever smokers;
LUAD	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg21475434	chr5:93447410	FAM172A	0.76	8.5	0.38	3.41e-16	Diabetic retinopathy;
LUAD	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg01802117	chr1:53393560	SCP2	0.43	8.07	0.37	7.39e-15	Monocyte count;
LUAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg07217954	chr7:1067459	C7orf50	0.43	6.61	0.31	1.14e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2797160	0.967	rs1578793	chr6:126015057	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.71	0.31	6.22e-11	Endometrial cancer;
LUAD	cis	rs12760731	0.720	rs35905053	chr1:178441618	A/T	cg00404053	chr1:178313656	RASAL2	0.65	8.3	0.37	1.43e-15	Obesity-related traits;
LUAD	cis	rs2455799	0.613	rs12485852	chr3:15914511	G/C	cg16303742	chr3:15540471	COLQ	-0.5	-9.01	-0.4	7.11e-18	Mean platelet volume;
LUAD	cis	rs1595825	1.000	rs59441945	chr2:198879645	T/A	cg10547527	chr2:198650123	BOLL	-0.47	-6.62	-0.31	1.11e-10	Ulcerative colitis;
LUAD	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg18105134	chr13:113819100	PROZ	0.77	13.72	0.55	1.09e-35	Platelet distribution width;
LUAD	cis	rs6545883	0.931	rs778768	chr2:61790289	C/G	cg15711740	chr2:61764176	XPO1	-0.43	-6.93	-0.32	1.6e-11	Tuberculosis;
LUAD	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg01874867	chr7:94954059	PON1	-0.48	-6.47	-0.3	2.74e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7551222	0.752	rs16853865	chr1:204465659	A/G	cg20240347	chr1:204465584	NA	-0.33	-6.37	-0.3	4.96e-10	Schizophrenia;
LUAD	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg18132916	chr6:79620363	NA	-0.46	-7.89	-0.36	2.64e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.74	0.46	5.74e-24	Exhaled nitric oxide output;
LUAD	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg11098525	chr4:1320231	MAEA	-0.38	-6.62	-0.31	1.09e-10	Obesity-related traits;
LUAD	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.54	8.63	0.39	1.23e-16	Total body bone mineral density;
LUAD	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg07606381	chr6:8435919	SLC35B3	0.44	7.22	0.33	2.48e-12	Motion sickness;
LUAD	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg17074396	chr22:49843754	NA	-0.34	-6.95	-0.32	1.4e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg03909863	chr11:638404	DRD4	-0.5	-6.56	-0.3	1.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.58	-0.35	2.18e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg17200465	chr3:40428508	ENTPD3	0.27	6.4	0.3	4.21e-10	Renal cell carcinoma;
LUAD	cis	rs397969	0.646	rs203454	chr17:19821513	G/C	cg04132472	chr17:19861366	AKAP10	0.33	6.91	0.32	1.83e-11	Platelet count;
LUAD	cis	rs9914988	1.000	rs901975	chr17:27189774	A/G	cg02049041	chr17:27085579	C17orf63	-0.61	-8.14	-0.37	4.58e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs4824093	0.544	rs73443951	chr22:50301251	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-7.52	-0.34	3.38e-13	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs3806843	0.576	rs246011	chr5:140336405	G/C	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.42	-6.99	-0.32	1.07e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs7017914	0.967	rs62530792	chr8:71618767	T/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg21724239	chr8:58056113	NA	0.72	9.56	0.42	1.01e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-7.43	-0.34	6.12e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18876405	chr7:65276391	NA	-0.43	-6.84	-0.32	2.83e-11	Aortic root size;
LUAD	cis	rs13064411	0.735	rs6778800	chr3:113149236	A/G	cg10517650	chr3:113235015	CCDC52	-0.49	-8.25	-0.37	2.09e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs4653767	1.000	rs708775	chr1:226923264	G/A	cg05049329	chr1:226924846	ITPKB	0.45	7.85	0.36	3.44e-14	Parkinson's disease;
LUAD	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg15704280	chr7:45808275	SEPT13	-1.03	-22.98	-0.75	2.05e-76	Height;
LUAD	cis	rs9522267	0.737	rs9515448	chr13:112229526	A/T	cg10483660	chr13:112241077	NA	-0.32	-6.54	-0.3	1.76e-10	Hepatitis;
LUAD	cis	rs9341808	0.935	rs1535825	chr6:80938586	C/T	cg08355045	chr6:80787529	NA	-0.5	-9.28	-0.41	8.6e-19	Sitting height ratio;
LUAD	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg11663144	chr21:46675770	NA	-0.51	-8.82	-0.39	3.03e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg24069376	chr3:38537580	EXOG	-0.32	-7.28	-0.33	1.67e-12	Electrocardiographic conduction measures;
LUAD	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg12863693	chr15:85201151	NMB	0.37	6.44	0.3	3.16e-10	Schizophrenia;
LUAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg00431813	chr7:1051703	C7orf50	-0.34	-6.48	-0.3	2.48e-10	Longevity;Endometriosis;
LUAD	cis	rs2073300	1.000	rs6132623	chr20:23442324	T/A	cg12062639	chr20:23401060	NAPB	1.0	9.21	0.41	1.47e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.31	-0.33	1.33e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24531977	chr5:56204891	C5orf35	-0.99	-15.17	-0.59	8.56e-42	Initial pursuit acceleration;
LUAD	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg21153622	chr11:89784906	NA	-0.34	-6.76	-0.31	4.53e-11	HDL cholesterol;
LUAD	cis	rs12760731	0.720	rs12022646	chr1:178355821	A/G	cg00404053	chr1:178313656	RASAL2	0.65	8.38	0.38	8.19e-16	Obesity-related traits;
LUAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg07217954	chr7:1067459	C7orf50	0.46	7.16	0.33	3.62e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg01579765	chr21:45077557	HSF2BP	-0.54	-12.64	-0.52	2.81e-31	Mean corpuscular volume;
LUAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18402987	chr7:1209562	NA	0.43	7.14	0.33	4.18e-12	Longevity;Endometriosis;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09465149	chr10:97416066	ALDH18A1	-0.41	-6.73	-0.31	5.43e-11	Cancer;
LUAD	cis	rs9715521	0.775	rs67846233	chr4:59848576	G/A	cg11281224	chr4:60001000	NA	-0.6	-10.24	-0.45	3.85e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg27284194	chr4:1044797	NA	0.71	10.44	0.45	7.55e-23	Recombination rate (females);
LUAD	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06505273	chr16:24850292	NA	0.48	6.9	0.32	1.97e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs117623576	0.816	rs72784871	chr10:32445169	T/A	cg03047570	chr10:32398778	NA	-0.79	-9.3	-0.41	7.82e-19	Anti-saccade response;
LUAD	cis	rs4462272	0.558	rs35614792	chr10:101934235	C/T	cg19754520	chr10:101825118	CPN1	-0.31	-6.49	-0.3	2.36e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg19622623	chr12:86230825	RASSF9	0.53	9.83	0.43	1.11e-20	Major depressive disorder;
LUAD	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.45	-0.52	1.54e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg17863274	chr19:49399704	TULP2	-0.66	-10.15	-0.44	8.49e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs6489882	0.867	rs6489876	chr12:113368055	G/A	cg20102336	chr12:113376681	OAS3	-0.58	-8.95	-0.4	1.09e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg04607235	chr12:12878440	APOLD1	-0.53	-8.3	-0.37	1.42e-15	Lymphocyte counts;
LUAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.41	-6.45	-0.3	3.12e-10	Longevity;Endometriosis;
LUAD	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg05926928	chr17:57297772	GDPD1	1.37	17.07	0.64	4.62e-50	Opioid sensitivity;
LUAD	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.63	0.42	5.44e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8192282	0.739	rs4845636	chr1:154486370	A/G	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.35	-0.34	1.05e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs17683430	0.702	rs117983733	chr22:32387606	C/T	cg00543991	chr22:32367038	NA	0.92	8.15	0.37	4.03e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUAD	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.39	-7.69	-0.35	1.07e-13	Total body bone mineral density;
LUAD	cis	rs6754311	0.517	rs1469996	chr2:136542560	A/G	cg07169764	chr2:136633963	MCM6	0.65	8.18	0.37	3.43e-15	Mosquito bite size;
LUAD	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg24069376	chr3:38537580	EXOG	0.41	9.93	0.43	4.85e-21	Electrocardiographic conduction measures;
LUAD	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg18944383	chr4:111397179	ENPEP	0.39	7.71	0.35	8.8e-14	Height;
LUAD	cis	rs2070997	0.715	rs11244164	chr9:133736116	A/G	cg03924115	chr9:133768966	QRFP	0.52	7.17	0.33	3.37e-12	Response to amphetamines;
LUAD	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.2	-0.51	1.59e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg07169764	chr2:136633963	MCM6	0.63	8.0	0.36	1.22e-14	Corneal structure;
LUAD	cis	rs9814567	0.752	rs7633868	chr3:134331048	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg02527881	chr3:46936655	PTH1R	-0.48	-9.56	-0.42	9.98e-20	Colorectal cancer;
LUAD	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg27129171	chr3:47204927	SETD2	0.42	6.79	0.31	3.86e-11	Colorectal cancer;
LUAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg13271783	chr10:134563150	INPP5A	-0.42	-6.65	-0.31	9.14e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs11809207	0.810	rs17356937	chr1:26504036	G/A	cg00147160	chr1:26503991	CNKSR1	0.46	9.25	0.41	1.15e-18	Height;
LUAD	cis	rs6906287	0.647	rs2356183	chr6:118770264	A/G	cg21191810	chr6:118973309	C6orf204	0.49	9.55	0.42	1.1e-19	Electrocardiographic conduction measures;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg22596738	chr1:236688128	LGALS8	-0.39	-6.47	-0.3	2.78e-10	Subcortical brain region volumes;
LUAD	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg14582100	chr15:45693742	SPATA5L1	0.53	10.03	0.44	2.19e-21	Homoarginine levels;
LUAD	cis	rs68170813	0.559	rs78064065	chr7:106967440	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-9.97	-0.44	3.56e-21	Coronary artery disease;
LUAD	cis	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg08601574	chr20:25228251	PYGB	-0.46	-8.76	-0.39	4.9e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg13606994	chr1:44402422	ARTN	-0.34	-6.82	-0.31	3.19e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg23978390	chr7:1156363	C7orf50	0.44	6.89	0.32	1.98e-11	Longevity;Endometriosis;
LUAD	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-7.33	-0.34	1.2e-12	Lung cancer;
LUAD	cis	rs62458065	0.850	rs7808992	chr7:32470677	C/T	cg20159608	chr7:32802032	NA	-0.56	-7.34	-0.34	1.11e-12	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg23625390	chr15:77176239	SCAPER	0.38	6.76	0.31	4.66e-11	Blood metabolite levels;
LUAD	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg13126279	chr21:47581558	C21orf56	-0.48	-7.97	-0.36	1.5e-14	Testicular germ cell tumor;
LUAD	cis	rs4638749	0.677	rs7581595	chr2:108847885	A/G	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.18	-0.33	3.22e-12	Blood pressure;
LUAD	cis	rs1003719	0.715	rs2251952	chr21:38559711	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-8.08	-0.37	6.81e-15	Eye color traits;
LUAD	cis	rs11756438	0.572	rs2798328	chr6:119005378	C/T	cg21191810	chr6:118973309	C6orf204	0.47	9.13	0.41	2.74e-18	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg00339695	chr16:24857497	SLC5A11	-0.56	-8.96	-0.4	1.07e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.77e-11	Depression;
LUAD	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg07570687	chr10:102243282	WNT8B	0.45	6.8	0.31	3.68e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg02734326	chr4:10020555	SLC2A9	0.64	11.33	0.48	3.73e-26	Bone mineral density;
LUAD	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg01657329	chr11:68192670	LRP5	0.48	8.57	0.38	1.95e-16	Total body bone mineral density;
LUAD	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg11266682	chr4:10021025	SLC2A9	-0.55	-12.09	-0.51	4.19e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7020830	0.931	rs13293916	chr9:37136359	C/G	cg14294708	chr9:37120828	ZCCHC7	0.86	16.92	0.64	2.07e-49	Schizophrenia;
LUAD	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg11247378	chr22:39784982	NA	-0.64	-10.33	-0.45	1.9e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	8.58	0.38	1.87e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs151234	0.676	rs508022	chr16:28573963	C/T	cg04643524	chr16:28609220	SULT1A2	0.63	8.98	0.4	8.68e-18	Platelet distribution width;
LUAD	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg07343612	chr16:622815	PIGQ	-0.8	-15.66	-0.61	6.37e-44	Height;
LUAD	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11890956	chr21:40555474	PSMG1	-0.61	-9.9	-0.43	6.61e-21	Cognitive function;
LUAD	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg06640241	chr16:89574553	SPG7	0.48	7.96	0.36	1.58e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg26354017	chr1:205819088	PM20D1	-0.73	-14.37	-0.57	2.01e-38	Menarche (age at onset);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg01089060	chr10:97050836	PDLIM1	-0.36	-6.65	-0.31	8.83e-11	Schizophrenia;
LUAD	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.17	-0.37	3.51e-15	Total body bone mineral density;
LUAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.35	0.38	9.93e-16	Alzheimer's disease;
LUAD	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.48	6.83	0.32	2.93e-11	Platelet count;
LUAD	cis	rs41271473	0.526	rs28593014	chr1:228743576	G/A	cg10167378	chr1:228756711	NA	0.66	8.87	0.4	2.13e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs4389656	0.740	rs274706	chr5:6726629	T/C	cg10857441	chr5:6722123	POLS	-0.47	-8.0	-0.36	1.18e-14	Coronary artery disease;
LUAD	cis	rs12545109	0.879	rs1581129	chr8:57377476	T/C	cg17761419	chr8:57350749	NA	-0.59	-8.28	-0.37	1.66e-15	Obesity-related traits;
LUAD	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg18446336	chr7:2847575	GNA12	-0.34	-6.76	-0.31	4.5e-11	Height;
LUAD	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg20744362	chr22:50050164	C22orf34	0.43	9.34	0.41	5.61e-19	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg21475434	chr5:93447410	FAM172A	0.7	8.36	0.38	8.84e-16	Diabetic retinopathy;
LUAD	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg02450064	chr17:40260053	DHX58	-0.44	-7.55	-0.34	2.65e-13	Fibrinogen levels;
LUAD	trans	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.54	0.49	5.78e-27	Mean corpuscular volume;
LUAD	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg25985355	chr7:65971099	NA	0.38	7.02	0.32	8.89e-12	Aortic root size;
LUAD	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg23172400	chr8:95962367	TP53INP1	-0.34	-7.86	-0.36	3.3e-14	Type 2 diabetes;
LUAD	cis	rs4481887	0.676	rs7524978	chr1:248527319	A/T	cg00666640	chr1:248458726	OR2T12	0.27	6.65	0.31	9.21e-11	Common traits (Other);
LUAD	cis	rs8060686	0.546	rs8047343	chr16:68143745	G/A	cg26727032	chr16:67993705	SLC12A4	-0.46	-7.76	-0.35	6.45e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg19610905	chr11:61596333	FADS2	-0.69	-11.15	-0.48	1.71e-25	Trans fatty acid levels;
LUAD	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg08085267	chr17:45401833	C17orf57	0.63	11.27	0.48	5.92e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19650814	chr6:100016539	CCNC	-0.6	-7.19	-0.33	3.02e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg09455208	chr3:40491958	NA	-0.53	-11.11	-0.48	2.46e-25	Renal cell carcinoma;
LUAD	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg23795048	chr12:9217529	LOC144571	0.45	8.27	0.37	1.81e-15	Sjögren's syndrome;
LUAD	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg25319279	chr11:5960081	NA	-0.4	-7.48	-0.34	4.36e-13	DNA methylation (variation);
LUAD	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg05062854	chr22:32435553	NA	-0.38	-6.45	-0.3	3.02e-10	Brain structure;
LUAD	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg13319975	chr6:146136371	FBXO30	-0.81	-14.29	-0.57	4.52e-38	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6782228	0.565	rs11719239	chr3:128419054	A/G	cg16766828	chr3:128327626	NA	-0.39	-7.28	-0.33	1.6e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs17532515	0.652	rs1346926	chr4:141385284	C/A	cg03645522	chr4:141391200	NA	0.4	6.47	0.3	2.75e-10	Select biomarker traits;
LUAD	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg17177755	chr1:15930204	NA	0.44	7.1	0.33	5.43e-12	Systolic blood pressure;
LUAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg09253696	chr17:73873529	TRIM47	-0.46	-7.72	-0.35	8.73e-14	Psoriasis;
LUAD	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg03676636	chr4:99064102	C4orf37	0.35	8.97	0.4	9.49e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg00277334	chr10:82204260	NA	-0.67	-12.18	-0.51	1.8e-29	Post bronchodilator FEV1;
LUAD	cis	rs863345	0.604	rs7533071	chr1:158504479	T/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.61	0.58	1.91e-39	Schizophrenia;
LUAD	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.38	-0.42	4e-19	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg25007680	chr1:8021821	PARK7	-0.43	-7.39	-0.34	8.02e-13	Cancer;
LUAD	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg18132916	chr6:79620363	NA	-0.44	-7.67	-0.35	1.16e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg15448220	chr1:150897856	SETDB1	0.56	9.39	0.42	3.87e-19	Melanoma;
LUAD	cis	rs59698941	0.527	rs11742089	chr5:132178930	G/A	cg14825688	chr5:132208181	LEAP2	-0.52	-10.6	-0.46	1.93e-23	Apolipoprotein A-IV levels;
LUAD	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-7.48	-0.34	4.35e-13	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg22029157	chr1:209979665	IRF6	0.73	10.62	0.46	1.59e-23	Cleft lip with or without cleft palate;
LUAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg04025307	chr7:1156635	C7orf50	0.68	12.13	0.51	2.8e-29	Longevity;Endometriosis;
LUAD	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg00933542	chr6:150070202	PCMT1	0.46	10.0	0.44	2.73e-21	Lung cancer;
LUAD	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg03929089	chr4:120376271	NA	0.54	7.17	0.33	3.34e-12	Axial length;
LUAD	cis	rs3106136	0.527	rs2865345	chr4:95156565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.52	-9.86	-0.43	8.49e-21	Capecitabine sensitivity;
LUAD	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg11189052	chr15:85197271	WDR73	0.65	8.19	0.37	3.21e-15	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg03676636	chr4:99064102	C4orf37	0.3	8.04	0.36	9.34e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.46	6.53	0.3	1.84e-10	Renal function-related traits (BUN);
LUAD	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg02176678	chr2:219576539	TTLL4	0.64	12.68	0.52	1.91e-31	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs6897795	1.000	rs72648830	chr5:177608542	C/T	cg19598605	chr2:70056955	GMCL1	-0.57	-7.0	-0.32	1.04e-11	Plateletcrit;
LUAD	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg00933542	chr6:150070202	PCMT1	0.4	8.25	0.37	2.07e-15	Lung cancer;
LUAD	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.65	0.31	9.24e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17102423	0.768	rs2151755	chr14:65578874	T/C	cg11161011	chr14:65562177	MAX	0.39	6.53	0.3	1.87e-10	Obesity-related traits;
LUAD	trans	rs6561151	0.957	rs1932990	chr13:44460242	C/T	cg17145862	chr1:211918768	LPGAT1	0.55	9.18	0.41	1.88e-18	Crohn's disease;
LUAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg06138931	chr13:21896616	NA	0.41	6.81	0.31	3.34e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg11859384	chr17:80120422	CCDC57	-0.52	-9.33	-0.41	5.79e-19	Life satisfaction;
LUAD	cis	rs10992471	0.603	rs1535755	chr9:95202031	G/T	cg14631576	chr9:95140430	CENPP	-0.56	-11.41	-0.49	1.8e-26	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs8014204	0.748	rs12889277	chr14:75229376	A/T	cg06637938	chr14:75390232	RPS6KL1	0.36	6.51	0.3	2.17e-10	Caffeine consumption;
LUAD	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg04586622	chr2:25135609	ADCY3	-0.33	-7.21	-0.33	2.54e-12	Body mass index;
LUAD	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.55	0.38	2.34e-16	Menopause (age at onset);
LUAD	cis	rs6733011	0.578	rs10169003	chr2:99508866	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.43	6.9	0.32	1.96e-11	Bipolar disorder;
LUAD	cis	rs11229555	0.645	rs36019763	chr11:58232283	G/T	cg15696309	chr11:58395628	NA	-0.8	-10.75	-0.46	5.45e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg14847009	chr1:175162515	KIAA0040	-0.32	-8.38	-0.38	7.96e-16	Alcohol dependence;
LUAD	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg20503657	chr10:835505	NA	1.25	17.96	0.66	5.3e-54	Eosinophil percentage of granulocytes;
LUAD	cis	rs752010	0.806	rs943375	chr1:42092152	A/G	cg06885757	chr1:42089581	HIVEP3	0.48	10.86	0.47	2.15e-24	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs7193541	0.684	rs8062783	chr16:74691264	C/T	cg01733217	chr16:74700730	RFWD3	-0.66	-13.08	-0.54	4.63e-33	Multiple myeloma;
LUAD	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg09263875	chr16:632152	PIGQ	0.81	17.66	0.65	1.06e-52	Height;
LUAD	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg18811423	chr2:55921094	PNPT1	-0.43	-7.06	-0.32	6.79e-12	Metabolic syndrome;
LUAD	cis	rs13315871	1.000	rs13066269	chr3:58449244	T/C	cg12435725	chr3:58293450	RPP14	-0.69	-7.45	-0.34	5.2e-13	Cholesterol, total;
LUAD	cis	rs11893307	0.507	rs1465304	chr2:191585398	A/G	cg27211696	chr2:191398769	TMEM194B	-0.41	-6.86	-0.32	2.41e-11	Mean platelet volume;
LUAD	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg13535736	chr9:111863775	C9orf5	-0.43	-6.76	-0.31	4.49e-11	Menarche (age at onset);
LUAD	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg22166914	chr1:53195759	ZYG11B	0.4	6.7	0.31	6.84e-11	Monocyte count;
LUAD	cis	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg02421172	chr7:1938701	MAD1L1	0.41	6.45	0.3	3.08e-10	Bipolar disorder;
LUAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14893161	chr1:205819251	PM20D1	-0.52	-8.65	-0.39	1.11e-16	Parkinson's disease;
LUAD	cis	rs4072705	1.000	rs4838207	chr9:127519134	G/A	cg13476313	chr9:127244764	NR5A1	0.3	7.19	0.33	3.01e-12	Menarche (age at onset);
LUAD	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.01e-10	Skin colour saturation;
LUAD	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg12011299	chr4:100065546	ADH4	0.7	12.61	0.52	3.55e-31	Smoking initiation;
LUAD	cis	rs1461503	0.780	rs75981430	chr11:122842469	A/C	cg27398637	chr11:122830231	C11orf63	-0.36	-6.91	-0.32	1.74e-11	Menarche (age at onset);
LUAD	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg18446336	chr7:2847575	GNA12	-0.33	-6.96	-0.32	1.31e-11	Height;
LUAD	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg20476274	chr7:133979776	SLC35B4	0.85	17.33	0.64	3.02e-51	Mean platelet volume;
LUAD	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.08	-0.37	6.77e-15	Bipolar disorder;
LUAD	cis	rs2485376	0.967	rs772014	chr10:104062494	A/G	cg20641465	chr10:103991465	PITX3	-0.53	-9.9	-0.43	6.32e-21	QT interval;
LUAD	cis	rs2485376	1.000	rs3758553	chr10:103992599	C/T	cg20641465	chr10:103991465	PITX3	0.56	10.32	0.45	1.97e-22	QT interval;
LUAD	cis	rs76878669	0.516	rs7104570	chr11:66159098	A/G	cg10616300	chr11:66138557	SLC29A2	0.36	7.65	0.35	1.39e-13	Educational attainment (years of education);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22860137	chr2:216878466	MREG	-0.39	-6.46	-0.3	2.81e-10	Cancer;
LUAD	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg05340658	chr4:99064831	C4orf37	0.56	9.55	0.42	1.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8112211	1.000	rs8112211	chr19:38824581	C/T	cg14299480	chr19:38876666	GGN	-0.44	-7.73	-0.35	7.81e-14	Blood protein levels;
LUAD	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg15181151	chr6:150070149	PCMT1	0.42	8.7	0.39	7.56e-17	Lung cancer;
LUAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg11062466	chr8:58055876	NA	0.67	8.84	0.39	2.69e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.54e-10	Prudent dietary pattern;
LUAD	cis	rs7833986	0.501	rs2719227	chr8:57043794	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.89	-15.51	-0.6	2.7e-43	Height;
LUAD	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11644478	chr21:40555479	PSMG1	-0.59	-9.75	-0.43	2.15e-20	Cognitive function;
LUAD	cis	rs6499255	0.951	rs8046314	chr16:69697922	T/A	cg15192750	chr16:69999425	NA	0.49	7.7	0.35	9.68e-14	IgE levels;
LUAD	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg09085632	chr11:111637200	PPP2R1B	0.76	12.02	0.5	7.97e-29	Primary sclerosing cholangitis;
LUAD	cis	rs7737355	0.812	rs31591	chr5:131005638	C/T	cg06307176	chr5:131281290	NA	0.45	7.42	0.34	6.51e-13	Life satisfaction;
LUAD	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg16486109	chr11:613632	IRF7	0.53	8.04	0.36	9.25e-15	Systemic lupus erythematosus;
LUAD	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg02421172	chr7:1938701	MAD1L1	0.46	6.44	0.3	3.31e-10	Bipolar disorder;
LUAD	cis	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg07460842	chr6:66804631	NA	-1.06	-16.56	-0.63	7.57e-48	Exhaled nitric oxide output;
LUAD	cis	rs1113500	0.614	rs6677839	chr1:108599341	G/T	cg06207961	chr1:108661230	NA	-0.41	-6.9	-0.32	1.95e-11	Growth-regulated protein alpha levels;
LUAD	trans	rs12439619	0.846	rs62010071	chr15:82581783	G/C	cg04831495	chr15:85060580	GOLGA6L5	-0.47	-6.41	-0.3	3.88e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs6561151	0.681	rs2121037	chr13:44471317	C/T	cg12856521	chr11:46389249	DGKZ	0.87	12.17	0.51	2.07e-29	Crohn's disease;
LUAD	trans	rs1941687	0.797	rs9963397	chr18:31395015	A/T	cg27147174	chr7:100797783	AP1S1	-0.51	-8.35	-0.38	9.95e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg07870213	chr5:140052090	DND1	0.93	12.56	0.52	5.55e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24531977	chr5:56204891	C5orf35	-0.99	-15.17	-0.59	8.56e-42	Initial pursuit acceleration;
LUAD	trans	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.39	0.45	1.1e-22	Mean corpuscular volume;
LUAD	cis	rs7737355	0.812	rs11242084	chr5:130935777	T/C	cg06307176	chr5:131281290	NA	0.42	6.77	0.31	4.37e-11	Life satisfaction;
LUAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg22907277	chr7:1156413	C7orf50	0.74	11.05	0.47	4.15e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg21775007	chr8:11205619	TDH	0.54	9.73	0.43	2.61e-20	Retinal vascular caliber;
LUAD	cis	rs11030122	0.702	rs10767702	chr11:3934132	T/C	cg18678763	chr11:4115507	RRM1	-0.44	-7.2	-0.33	2.81e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg07677032	chr17:61819896	STRADA	0.58	10.68	0.46	1e-23	Prudent dietary pattern;
LUAD	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11644478	chr21:40555479	PSMG1	0.7	11.72	0.5	1.17e-27	Cognitive function;
LUAD	cis	rs7671266	0.628	rs11734783	chr4:10240663	C/T	cg11266682	chr4:10021025	SLC2A9	0.45	6.47	0.3	2.71e-10	Cardiovascular disease risk factors;
LUAD	cis	rs4285028	0.948	rs7640872	chr3:121697168	C/A	cg11130432	chr3:121712080	ILDR1	-0.59	-8.35	-0.38	9.53e-16	Multiple sclerosis;
LUAD	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg03467027	chr4:99064603	C4orf37	0.4	6.48	0.3	2.59e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg22532475	chr10:104410764	TRIM8	-0.58	-10.78	-0.46	4.14e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12681287	0.640	rs13261901	chr8:87478717	G/C	cg27223183	chr8:87520930	FAM82B	-0.67	-9.61	-0.42	6.38e-20	Caudate activity during reward;
LUAD	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	9.19	0.41	1.74e-18	Platelet count;
LUAD	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg14895029	chr7:2775587	GNA12	-0.4	-6.42	-0.3	3.71e-10	Height;
LUAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.45e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2357013	0.780	rs57627862	chr2:53239883	C/T	cg07782112	chr2:53107842	NA	-0.36	-7.18	-0.33	3.18e-12	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.87	0.47	1.87e-24	Mean corpuscular volume;
LUAD	cis	rs57994353	0.897	rs11999532	chr9:139371405	G/C	cg14019695	chr9:139328340	INPP5E	0.39	6.35	0.3	5.54e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg24399712	chr22:39784796	NA	-0.77	-15.42	-0.6	6.89e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.1	0.33	5.27e-12	Platelet count;
LUAD	trans	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	7.6	0.35	1.9e-13	Resting heart rate;
LUAD	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg12119029	chr16:89752879	CDK10	0.33	6.52	0.3	2.02e-10	Vitiligo;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11793562	chr13:52027124	INTS6	-0.41	-6.95	-0.32	1.42e-11	Cancer;
LUAD	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg13319975	chr6:146136371	FBXO30	-0.58	-9.82	-0.43	1.23e-20	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.14	-0.37	4.36e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9796	0.653	rs28516683	chr15:41446645	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.45	-8.34	-0.38	1.05e-15	Menopause (age at onset);
LUAD	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	9.44	0.42	2.51e-19	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.26	-6.49	-0.3	2.34e-10	Coronary artery disease;
LUAD	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg13685833	chr1:53393034	SCP2	-0.49	-8.01	-0.36	1.09e-14	Monocyte count;
LUAD	cis	rs4711350	0.723	rs684119	chr6:33662667	C/T	cg18005901	chr6:33739558	LEMD2	0.54	6.53	0.3	1.91e-10	Schizophrenia;
LUAD	trans	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.74	11.11	0.48	2.39e-25	Ulcerative colitis;
LUAD	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.41	0.3	3.92e-10	Breast cancer;
LUAD	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg02683114	chr2:24398427	C2orf84	-0.55	-8.2	-0.37	2.96e-15	Asthma;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg06742493	chr19:13056745	RAD23A	-0.37	-6.35	-0.3	5.46e-10	Schizophrenia;
LUAD	trans	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg25894440	chr7:65020034	NA	-0.63	-6.71	-0.31	6.35e-11	Gout;
LUAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg07677032	chr17:61819896	STRADA	0.58	10.68	0.46	1e-23	Prudent dietary pattern;
LUAD	cis	rs332507	0.830	rs1846892	chr3:124399293	A/G	cg05980111	chr3:124395277	KALRN	0.45	7.11	0.33	4.86e-12	Plateletcrit;
LUAD	trans	rs2262909	0.962	rs12610034	chr19:22314528	G/A	cg05197062	chr11:11642011	GALNTL4	0.6	9.26	0.41	1.04e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs62229266	0.659	rs62230814	chr21:37403546	G/A	cg12218747	chr21:37451666	NA	-0.44	-7.55	-0.34	2.64e-13	Mitral valve prolapse;
LUAD	cis	rs11048434	0.761	rs2110190	chr12:9128289	A/C	cg13575925	chr12:9217583	LOC144571	0.38	6.92	0.32	1.66e-11	Sjögren's syndrome;
LUAD	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-7.05	-0.32	7.32e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg22875332	chr1:76189707	ACADM	0.78	12.94	0.53	1.69e-32	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4771122	0.500	rs1049302	chr13:27998769	T/C	cg22138327	chr13:27999177	GTF3A	-0.99	-17.02	-0.64	7.56e-50	Body mass index;
LUAD	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg12927641	chr6:109611667	NA	-0.54	-9.71	-0.43	3.04e-20	Reticulocyte fraction of red cells;
LUAD	cis	rs10465746	0.967	rs1475263	chr1:84339497	A/T	cg10977910	chr1:84465055	TTLL7	0.5	8.19	0.37	3.07e-15	Obesity-related traits;
LUAD	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	11.14	0.48	1.95e-25	Lung cancer in ever smokers;
LUAD	cis	rs10992471	0.580	rs7869521	chr9:95411059	G/T	cg14631576	chr9:95140430	CENPP	-0.46	-8.7	-0.39	7.3e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.53	7.58	0.35	2.19e-13	Platelet count;
LUAD	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg20701182	chr2:24300061	SF3B14	0.57	6.89	0.32	1.98e-11	Lymphocyte counts;
LUAD	cis	rs992157	0.764	rs62183964	chr2:219186592	G/A	cg05991184	chr2:219186017	PNKD	-0.41	-7.84	-0.36	3.78e-14	Colorectal cancer;
LUAD	cis	rs8067287	0.749	rs62065421	chr17:16827887	T/C	cg26910001	chr17:16838321	NA	-0.48	-6.74	-0.31	5.17e-11	Diabetic kidney disease;
LUAD	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	11.85	0.5	3.73e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.97	13.67	0.55	1.78e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11048434	0.736	rs11048264	chr12:9113581	C/T	cg04155231	chr12:9217510	LOC144571	-0.4	-7.75	-0.35	6.81e-14	Sjögren's syndrome;
LUAD	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg12483005	chr1:23474871	LUZP1	0.53	9.3	0.41	7.45e-19	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14212983	chr1:21985742	RAP1GAP	-0.61	-7.62	-0.35	1.64e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.62e-18	Life satisfaction;
LUAD	cis	rs757647	0.680	rs12517974	chr5:137744369	A/C	cg10676309	chr5:137685565	NA	0.42	7.46	0.34	4.81e-13	Menarche (age at onset);
LUAD	cis	rs4919694	1.000	rs12245343	chr10:104774050	A/G	cg04362960	chr10:104952993	NT5C2	0.75	7.94	0.36	1.86e-14	Arsenic metabolism;
LUAD	cis	rs6494488	0.500	rs72744704	chr15:65011507	G/A	cg08069370	chr15:64387884	SNX1	-0.76	-6.77	-0.31	4.43e-11	Coronary artery disease;
LUAD	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg01689657	chr7:91764605	CYP51A1	-0.35	-8.68	-0.39	8.39e-17	Breast cancer;
LUAD	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg09835421	chr16:68378352	PRMT7	-0.82	-8.78	-0.39	4.06e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg06873352	chr17:61820015	STRADA	0.42	6.76	0.31	4.56e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs72772090	0.539	rs72775807	chr5:96179761	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-6.5	-0.3	2.32e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg09626299	chr10:82213104	TSPAN14	-0.33	-7.49	-0.34	4.19e-13	Post bronchodilator FEV1;
LUAD	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg05342682	chr7:94953680	PON1	-0.48	-6.46	-0.3	2.97e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg08999081	chr20:33150536	PIGU	0.61	13.69	0.55	1.37e-35	Glomerular filtration rate (creatinine);
LUAD	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.08	14.41	0.57	1.41e-38	Lung cancer in ever smokers;
LUAD	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.34	0.51	4.22e-30	Tonsillectomy;
LUAD	cis	rs73206853	0.534	rs73205059	chr12:110509947	G/A	cg12870014	chr12:110450643	ANKRD13A	0.8	8.02	0.36	1.03e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg13770153	chr20:60521292	NA	-0.59	-9.15	-0.41	2.51e-18	Body mass index;
LUAD	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg22532475	chr10:104410764	TRIM8	-0.43	-8.53	-0.38	2.67e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs60733400	0.644	rs28774982	chr1:2621352	C/G	cg11707310	chr1:2537719	MMEL1	-0.38	-8.01	-0.36	1.1e-14	Multiple sclerosis;
LUAD	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05901451	chr6:126070800	HEY2	0.74	13.07	0.54	5.05e-33	Brugada syndrome;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg10157203	chr11:43702128	HSD17B12	-0.52	-6.55	-0.3	1.64e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg17105886	chr17:28927953	LRRC37B2	0.72	7.18	0.33	3.25e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg03433033	chr1:76189801	ACADM	-0.71	-11.56	-0.49	4.64e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10992471	0.603	rs7872610	chr9:95299137	G/C	cg14631576	chr9:95140430	CENPP	-0.52	-10.42	-0.45	8.54e-23	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg22823121	chr1:150693482	HORMAD1	0.42	8.31	0.37	1.28e-15	Melanoma;
LUAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg15117754	chr3:10150083	C3orf24	0.41	6.6	0.31	1.22e-10	Alzheimer's disease;
LUAD	cis	rs10992471	0.603	rs9299405	chr9:95284873	A/G	cg14631576	chr9:95140430	CENPP	-0.51	-10.22	-0.45	4.58e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.96	-0.32	1.27e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg13560548	chr3:10150139	C3orf24	0.43	6.94	0.32	1.47e-11	Alzheimer's disease;
LUAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.7	-9.0	-0.4	7.58e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18876405	chr7:65276391	NA	0.43	6.74	0.31	5.21e-11	Aortic root size;
LUAD	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg10518543	chr12:38710700	ALG10B	0.41	6.37	0.3	5.02e-10	Bladder cancer;
LUAD	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg23815491	chr16:72088622	HP	0.52	9.67	0.43	3.96e-20	Fibrinogen levels;
LUAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg21724239	chr8:58056113	NA	0.72	9.49	0.42	1.73e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs62238980	0.614	rs4821022	chr22:32414335	A/G	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.18	-0.41	2.01e-18	Life satisfaction;
LUAD	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg17971929	chr21:40555470	PSMG1	0.39	6.42	0.3	3.61e-10	Cognitive function;
LUAD	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg17063962	chr7:91808500	NA	0.63	10.49	0.45	5e-23	Breast cancer;
LUAD	trans	rs1406428	0.573	rs12613632	chr2:51705755	C/G	cg20878095	chr19:49298744	BCAT2	0.45	6.56	0.3	1.59e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg06740227	chr12:86229804	RASSF9	0.46	8.07	0.37	7.28e-15	Major depressive disorder;
LUAD	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg04756594	chr16:24857601	SLC5A11	0.74	13.12	0.54	3.23e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg08132940	chr7:1081526	C7orf50	-0.79	-10.66	-0.46	1.14e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg00080972	chr5:178986291	RUFY1	-0.5	-8.64	-0.39	1.16e-16	Lung cancer;
LUAD	trans	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.64	-10.27	-0.45	3.11e-22	Mean corpuscular volume;
LUAD	cis	rs6564851	0.506	rs56389940	chr16:81259152	C/A	cg00908271	chr16:81254010	PKD1L2	0.32	6.66	0.31	8.33e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs6484504	0.652	rs494464	chr11:31386150	C/T	cg26647111	chr11:31128758	NA	0.43	7.59	0.35	2.05e-13	Red blood cell count;
LUAD	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.52	-0.3	2.01e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg23954153	chr1:44402353	ARTN	-0.38	-7.14	-0.33	4.22e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg15744005	chr10:104629667	AS3MT	-0.33	-6.49	-0.3	2.4e-10	Immature fraction of reticulocytes;Schizophrenia;
LUAD	cis	rs28712821	0.930	rs11940694	chr4:39414993	C/T	cg16714752	chr4:39368184	RFC1	-0.43	-6.66	-0.31	8.67e-11	Alcohol consumption;
LUAD	cis	rs2579519	0.556	rs4907302	chr2:96217197	C/G	cg23100626	chr2:96804247	ASTL	0.3	7.26	0.33	1.88e-12	Diastolic blood pressure;
LUAD	cis	rs16867321	0.588	rs2368175	chr2:181493763	G/C	cg23363182	chr2:181467187	NA	-0.46	-7.55	-0.34	2.65e-13	Obesity;
LUAD	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg04842962	chr6:43655489	MRPS18A	1.05	26.45	0.79	1.09e-91	IgG glycosylation;
LUAD	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg08859206	chr1:53392774	SCP2	0.59	10.66	0.46	1.19e-23	Monocyte count;
LUAD	cis	rs4072705	0.967	rs4836986	chr9:127408059	C/T	cg01786973	chr9:127249749	NR5A1	0.3	6.37	0.3	4.87e-10	Menarche (age at onset);
LUAD	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg21252483	chr19:49399788	TULP2	-0.88	-14.3	-0.57	3.88e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg13877915	chr19:58951672	ZNF132	-0.72	-13.68	-0.55	1.61e-35	Uric acid clearance;
LUAD	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg16389456	chr12:123636548	NA	-0.35	-6.35	-0.3	5.51e-10	Neutrophil percentage of white cells;
LUAD	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg12923728	chr3:195709715	SDHAP1	0.44	6.74	0.31	5.32e-11	Mean corpuscular volume;
LUAD	cis	rs1160297	0.518	rs1348781	chr2:53220422	C/T	cg07782112	chr2:53107842	NA	-0.33	-6.62	-0.31	1.07e-10	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs11671005	0.735	rs3826682	chr19:58918748	C/T	cg13877915	chr19:58951672	ZNF132	0.54	7.15	0.33	3.97e-12	Mean platelet volume;
LUAD	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg21100191	chr22:23484243	RTDR1	0.71	12.76	0.53	8.89e-32	Bone mineral density;
LUAD	cis	rs9611519	1.000	rs5751069	chr22:41627775	C/G	cg13813247	chr22:41461852	NA	-0.41	-6.9	-0.32	1.88e-11	Neuroticism;
LUAD	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg03233332	chr7:66118400	NA	0.45	6.58	0.3	1.36e-10	Aortic root size;
LUAD	cis	rs796825	0.530	rs13091848	chr3:119986024	T/G	cg21790991	chr3:120137480	FSTL1	-0.47	-8.09	-0.37	6.17e-15	HIV-1 susceptibility;
LUAD	cis	rs2235649	0.592	rs2429186	chr16:1969939	C/T	cg07386859	chr16:1872102	HAGH	0.45	6.62	0.31	1.1e-10	Blood metabolite levels;
LUAD	cis	rs6761276	0.899	rs11677043	chr2:113835520	A/G	cg10479672	chr2:113810641	IL1F8	-0.37	-7.65	-0.35	1.38e-13	Protein quantitative trait loci;
LUAD	cis	rs2386661	0.826	rs4749834	chr10:5671808	G/A	cg26603656	chr10:5671107	NA	0.42	7.17	0.33	3.41e-12	Breast cancer;
LUAD	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-19.66	-0.69	1.34e-61	Height;
LUAD	cis	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.93	-0.32	1.62e-11	Neuroticism;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg07306088	chr12:46777190	NA	-0.48	-6.46	-0.3	2.82e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg21733973	chr7:65235735	NA	-0.45	-7.22	-0.33	2.37e-12	Calcium levels;
LUAD	cis	rs73206853	0.764	rs73206857	chr12:110767721	T/A	cg12870014	chr12:110450643	ANKRD13A	0.65	7.52	0.34	3.34e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs1941687	0.563	rs9947894	chr18:31328720	G/T	cg13755796	chr4:20253514	NA	0.4	6.89	0.32	2.05e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg06002616	chr8:101225028	SPAG1	-0.39	-7.82	-0.36	4.19e-14	Atrioventricular conduction;
LUAD	cis	rs7659604	0.502	rs11098640	chr4:122675875	G/A	cg06713675	chr4:122721982	EXOSC9	0.42	7.68	0.35	1.11e-13	Type 2 diabetes;
LUAD	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg12935359	chr14:103987150	CKB	-0.44	-7.0	-0.32	1.03e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6756513	0.509	rs11686934	chr2:70172116	C/T	cg02498382	chr2:70120550	SNRNP27	0.56	10.55	0.46	3.07e-23	Breast cancer;Platelet count;
LUAD	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg14689365	chr7:158441557	NCAPG2	0.41	6.89	0.32	2.09e-11	Height;
LUAD	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06112835	chr11:68658793	MRPL21	0.53	9.6	0.42	7.18e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg22681709	chr2:178499509	PDE11A	0.42	6.48	0.3	2.51e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08280861	chr8:58055591	NA	0.54	6.91	0.32	1.81e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs62458065	0.850	rs28693551	chr7:32469387	G/A	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.41	-0.34	7.16e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.79	0.39	3.89e-17	Menopause (age at onset);
LUAD	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg17366294	chr4:99064904	C4orf37	0.58	9.8	0.43	1.38e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2992756	0.663	rs1316327	chr1:18802387	G/A	cg14356550	chr1:18808102	KLHDC7A	-0.57	-9.76	-0.43	1.96e-20	Breast cancer;
LUAD	cis	rs6060717	0.536	rs6060704	chr20:34530270	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.12	-0.33	4.72e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs116248771	0.739	rs73156488	chr3:158413942	C/G	cg16708174	chr3:158430962	RARRES1	0.46	6.76	0.31	4.73e-11	diarrhoeal disease at age 2;
LUAD	cis	rs6960043	0.620	rs11760782	chr7:15064788	A/T	cg19272540	chr7:15055459	NA	0.35	7.52	0.34	3.35e-13	Type 2 diabetes;
LUAD	trans	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg26043149	chr18:55253948	FECH	-0.42	-6.93	-0.32	1.56e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8062405	0.755	rs62034325	chr16:28538640	A/G	cg00204512	chr16:28754710	NA	0.31	6.65	0.31	9.06e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg24397884	chr7:158709396	WDR60	0.66	9.05	0.4	5.38e-18	Height;
LUAD	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg27129171	chr3:47204927	SETD2	0.42	6.78	0.31	4.09e-11	Colorectal cancer;
LUAD	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg23985595	chr17:80112537	CCDC57	0.53	9.74	0.43	2.39e-20	Life satisfaction;
LUAD	trans	rs7200543	0.883	rs4985148	chr16:15147788	A/C	cg24683922	chr1:11983373	KIAA2013	-0.46	-7.53	-0.34	3.11e-13	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg11494091	chr17:61959527	GH2	0.44	8.61	0.39	1.44e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg18335740	chr13:41363409	SLC25A15	-0.59	-10.61	-0.46	1.83e-23	Lewy body disease;
LUAD	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09263875	chr16:632152	PIGQ	0.82	17.86	0.66	1.43e-53	Height;
LUAD	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg11915388	chr22:42470451	FAM109B	0.41	7.36	0.34	9.67e-13	Schizophrenia;
LUAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg11494091	chr17:61959527	GH2	0.8	22.26	0.73	3.1e-73	Prudent dietary pattern;
LUAD	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg02450064	chr17:40260053	DHX58	-0.45	-7.48	-0.34	4.26e-13	Fibrinogen levels;
LUAD	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg27005118	chr17:13972210	COX10	-0.48	-10.31	-0.45	2.26e-22	Temperament;
LUAD	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg21775007	chr8:11205619	TDH	-0.57	-9.97	-0.44	3.66e-21	Retinal vascular caliber;
LUAD	cis	rs1044826	0.642	rs9859864	chr3:139091219	G/T	cg00490450	chr3:139108681	COPB2	-0.42	-6.8	-0.31	3.59e-11	Obesity-related traits;
LUAD	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg00981070	chr1:2046702	PRKCZ	0.37	6.81	0.31	3.43e-11	Height;
LUAD	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.5	-7.64	-0.35	1.44e-13	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs3785574	0.650	rs8077653	chr17:62008965	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-8.19	-0.37	3.03e-15	Height;
LUAD	trans	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg03929089	chr4:120376271	NA	-0.45	-7.08	-0.33	5.99e-12	Height;
LUAD	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.78	10.52	0.46	3.66e-23	Smoking behavior;
LUAD	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.0	0.44	2.81e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6138458	1.000	rs7269416	chr20:24976196	T/G	cg26195577	chr20:24973756	C20orf3	0.98	17.44	0.65	9.94e-52	Blood protein levels;
LUAD	cis	rs28374715	0.662	rs28493087	chr15:41486504	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.89	-16.47	-0.63	1.85e-47	Ulcerative colitis;
LUAD	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg00310523	chr12:86230176	RASSF9	0.4	8.31	0.37	1.33e-15	Major depressive disorder;
LUAD	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg25237894	chr2:233734115	C2orf82	0.63	11.93	0.5	1.83e-28	Coronary artery disease;
LUAD	cis	rs6499129	0.558	rs28711261	chr16:67617186	A/G	cg26727032	chr16:67993705	SLC12A4	-0.41	-6.47	-0.3	2.65e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg08645402	chr16:4508243	NA	-0.55	-10.33	-0.45	1.81e-22	Schizophrenia;
LUAD	trans	rs10802346	0.545	rs10924545	chr1:246364592	C/T	cg13514129	chr1:39547527	MACF1	-0.61	-11.01	-0.47	5.7e-25	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg10523679	chr1:76189770	ACADM	0.82	12.99	0.53	1.04e-32	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs758324	0.898	rs7725041	chr5:131188503	C/A	cg25547332	chr5:131281432	NA	0.44	6.7	0.31	6.85e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg02527881	chr3:46936655	PTH1R	-0.41	-7.93	-0.36	1.92e-14	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg24818145	chr4:99064322	C4orf37	0.44	7.37	0.34	9.22e-13	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg04775059	chr7:64541387	NA	-0.51	-6.68	-0.31	7.63e-11	Aortic root size;
LUAD	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg19052272	chr2:3704530	ALLC	0.6	9.93	0.43	4.85e-21	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg14086364	chr5:150678334	SLC36A3	0.57	12.44	0.52	1.75e-30	Skin aging (microtopography measurement);
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg24533690	chr10:103880622	LDB1	0.41	6.71	0.31	6.29e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	trans	rs629535	0.767	rs72654073	chr8:70081231	G/A	cg21567404	chr3:27674614	NA	-0.99	-17.99	-0.66	3.78e-54	Dupuytren's disease;
LUAD	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg18016565	chr1:150552671	MCL1	0.43	7.94	0.36	1.82e-14	Tonsillectomy;
LUAD	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg21609526	chr1:3105151	PRDM16	-0.32	-6.67	-0.31	8.18e-11	Migraine;
LUAD	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg02176678	chr2:219576539	TTLL4	0.8	16.08	0.62	9.24e-46	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.85	0.32	2.62e-11	Cognitive test performance;
LUAD	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg05754148	chr16:3507555	NAT15	0.47	6.91	0.32	1.81e-11	Body mass index (adult);
LUAD	trans	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg06606381	chr12:133084897	FBRSL1	-1.16	-10.34	-0.45	1.67e-22	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs41271473	0.526	rs1925720	chr1:228728377	G/C	cg16512390	chr1:228756714	NA	0.69	9.2	0.41	1.65e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg19875535	chr5:140030758	IK	-0.39	-6.53	-0.3	1.89e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg25358565	chr5:93447407	FAM172A	0.6	6.96	0.32	1.3e-11	Diabetic retinopathy;
LUAD	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.21	0.51	1.43e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg10636054	chr15:40330586	SRP14	0.75	8.23	0.37	2.36e-15	Response to haloperidol in psychosis;
LUAD	cis	rs1692580	0.807	rs260508	chr1:2187085	T/G	cg21194808	chr1:2205498	SKI	0.4	6.83	0.32	2.96e-11	Coronary artery disease;
LUAD	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.41	-0.34	6.99e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg05373962	chr22:49881684	NA	-0.49	-9.89	-0.43	6.84e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs11039798	1.000	rs12280020	chr11:48618844	G/C	cg02254774	chr11:50257496	LOC441601	0.51	6.53	0.3	1.86e-10	Axial length;
LUAD	cis	rs1865721	0.804	rs3826652	chr18:73142153	C/T	cg26385618	chr18:73139727	C18orf62	0.48	9.55	0.42	1.05e-19	Intelligence;
LUAD	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg03929089	chr4:120376271	NA	-0.83	-15.07	-0.59	2.22e-41	Coronary artery disease;
LUAD	trans	rs11165623	0.564	rs7523597	chr1:97000989	A/G	cg10631902	chr5:14652156	NA	-0.41	-7.48	-0.34	4.48e-13	Hip circumference;Waist circumference;
LUAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg00106254	chr7:1943704	MAD1L1	-0.61	-9.07	-0.4	4.6e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg00204512	chr16:28754710	NA	0.35	7.6	0.35	1.99e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg13319975	chr6:146136371	FBXO30	-0.57	-9.69	-0.43	3.47e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7680126	0.596	rs4697714	chr4:10143786	A/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-7.92	-0.36	2.12e-14	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs904251	0.523	rs12202055	chr6:37486080	A/T	cg25019722	chr6:37503610	NA	-0.34	-7.65	-0.35	1.37e-13	Cognitive performance;
LUAD	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg14343924	chr8:8086146	FLJ10661	-0.4	-6.38	-0.3	4.53e-10	Neuroticism;
LUAD	cis	rs4711350	0.765	rs1318691	chr6:33761884	G/A	cg16010596	chr6:33739607	LEMD2	-0.42	-7.77	-0.35	6.07e-14	Schizophrenia;
LUAD	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg24069376	chr3:38537580	EXOG	0.37	8.44	0.38	5.22e-16	Electrocardiographic conduction measures;
LUAD	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg12016809	chr21:47604291	C21orf56	0.53	8.43	0.38	5.55e-16	Testicular germ cell tumor;
LUAD	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg00603274	chr11:61596626	FADS2	-0.37	-6.48	-0.3	2.49e-10	Trans fatty acid levels;
LUAD	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg05368731	chr17:41323189	NBR1	0.96	20.46	0.71	3.7e-65	Menopause (age at onset);
LUAD	cis	rs67981189	0.821	rs34257131	chr14:71520440	A/G	cg15816911	chr14:71606274	NA	0.36	6.38	0.3	4.63e-10	Schizophrenia;
LUAD	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg05805236	chr11:65401703	PCNXL3	0.39	6.6	0.31	1.27e-10	Acne (severe);
LUAD	cis	rs56283067	0.847	rs10807302	chr6:44710152	G/C	cg18551225	chr6:44695536	NA	-0.58	-9.66	-0.43	4.4e-20	Total body bone mineral density;
LUAD	cis	rs10129255	0.536	rs10139058	chr14:107141916	C/T	cg23076370	chr14:107095027	NA	-0.42	-8.31	-0.37	1.31e-15	Kawasaki disease;
LUAD	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg05082376	chr22:42548792	NA	0.45	7.85	0.36	3.38e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg25344623	chr2:136566232	LCT	0.34	6.56	0.3	1.59e-10	Mosquito bite size;
LUAD	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg14343924	chr8:8086146	FLJ10661	0.45	7.03	0.32	8.49e-12	Mood instability;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13488557	chr1:25574588	C1orf63	-0.39	-6.43	-0.3	3.36e-10	Cancer;
LUAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs57920188	0.640	rs4311852	chr1:4085353	C/A	cg10510935	chr1:4059661	NA	0.48	7.07	0.33	6.25e-12	Interleukin-17 levels;
LUAD	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg25894440	chr7:65020034	NA	0.61	6.56	0.3	1.55e-10	Diabetic kidney disease;
LUAD	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg07870213	chr5:140052090	DND1	-0.83	-11.35	-0.48	2.92e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg22907277	chr7:1156413	C7orf50	0.7	8.23	0.37	2.27e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1451375	0.652	rs10265930	chr7:50627449	C/T	cg18232548	chr7:50535776	DDC	0.49	6.81	0.31	3.32e-11	Malaria;
LUAD	cis	rs4930561	0.714	rs7126326	chr11:67947275	T/G	cg04465784	chr11:67976953	SUV420H1	-0.35	-11.19	-0.48	1.19e-25	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs72781680	0.752	rs55806536	chr2:23912697	A/G	cg20701182	chr2:24300061	SF3B14	0.6	6.57	0.3	1.5e-10	Lymphocyte counts;
LUAD	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg09835421	chr16:68378352	PRMT7	-0.72	-8.15	-0.37	4.27e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg04772025	chr11:68637568	NA	0.55	8.48	0.38	3.8e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg04358685	chr3:12598421	MKRN2	-0.42	-6.66	-0.31	8.34e-11	Vertical cup-disc ratio;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11453546	chr21:43990049	SLC37A1	0.54	6.58	0.3	1.35e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg22508957	chr16:3507546	NAT15	0.82	10.86	0.47	2.13e-24	Tuberculosis;
LUAD	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg08470875	chr2:26401718	FAM59B	-0.64	-8.76	-0.39	4.92e-17	Gut microbiome composition (summer);
LUAD	cis	rs932287	1.000	rs932287	chr11:9044767	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-8.3	-0.37	1.4e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg23750338	chr8:142222470	SLC45A4	-0.6	-13.9	-0.56	1.87e-36	Immature fraction of reticulocytes;
LUAD	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg16235748	chr6:149772707	ZC3H12D	0.29	6.67	0.31	7.82e-11	Dupuytren's disease;
LUAD	cis	rs68170813	0.605	rs4730227	chr7:106904031	G/C	cg23024343	chr7:107201750	COG5	0.44	6.45	0.3	3.1e-10	Coronary artery disease;
LUAD	trans	rs7395662	0.857	rs3902433	chr11:48733324	C/T	cg15704280	chr7:45808275	SEPT13	0.43	6.75	0.31	5.04e-11	HDL cholesterol;
LUAD	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.35	-7.04	-0.32	7.77e-12	IgG glycosylation;
LUAD	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.54e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg21918786	chr6:109611834	NA	-0.6	-11.35	-0.48	3.11e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg00310523	chr12:86230176	RASSF9	0.41	8.02	0.36	1.08e-14	Major depressive disorder;
LUAD	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg09796270	chr17:17721594	SREBF1	-0.39	-7.79	-0.35	5.06e-14	Total body bone mineral density;
LUAD	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.46	-6.7	-0.31	6.84e-11	Height;
LUAD	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg05043794	chr9:111880884	C9orf5	0.4	7.09	0.33	5.8e-12	Menarche (age at onset);
LUAD	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg15147215	chr3:52552868	STAB1	-0.39	-7.17	-0.33	3.31e-12	Bipolar disorder;
LUAD	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg05434287	chr7:2030229	MAD1L1	0.39	6.5	0.3	2.32e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg22823121	chr1:150693482	HORMAD1	0.44	8.99	0.4	8.42e-18	Tonsillectomy;
LUAD	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg08847533	chr14:75593920	NEK9	0.4	6.76	0.31	4.6e-11	Height;
LUAD	cis	rs7072216	0.881	rs4345897	chr10:100147060	A/G	cg26618903	chr10:100175079	PYROXD2	-0.29	-6.39	-0.3	4.27e-10	Metabolite levels;
LUAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg22963979	chr7:1858916	MAD1L1	-0.58	-10.06	-0.44	1.77e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07343612	chr16:622815	PIGQ	-0.84	-16.92	-0.64	2.11e-49	Height;
LUAD	cis	rs2932538	0.961	rs2932534	chr1:113200797	A/G	cg22162597	chr1:113214053	CAPZA1	0.45	6.81	0.31	3.41e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg22681709	chr2:178499509	PDE11A	-0.51	-8.6	-0.39	1.58e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg26441486	chr22:50317300	CRELD2	0.44	6.67	0.31	8.26e-11	Schizophrenia;
LUAD	cis	rs7671266	0.668	rs6834055	chr4:10158511	A/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-7.9	-0.36	2.49e-14	Cardiovascular disease risk factors;
LUAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg22907277	chr7:1156413	C7orf50	0.7	8.2	0.37	2.97e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9644630	1.000	rs9644631	chr8:19370830	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.31	-7.27	-0.33	1.77e-12	Oropharynx cancer;
LUAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg03188948	chr7:1209495	NA	0.81	9.85	0.43	9.72e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg11845111	chr2:191398756	TMEM194B	-0.71	-9.44	-0.42	2.48e-19	Diastolic blood pressure;
LUAD	cis	rs6011002	0.564	rs2260045	chr20:62343013	T/C	cg21849932	chr20:62369462	LIME1	-0.78	-6.45	-0.3	3.09e-10	Dental caries;
LUAD	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg15017067	chr4:17643749	FAM184B	0.34	6.49	0.3	2.41e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg21724239	chr8:58056113	NA	0.75	9.83	0.43	1.17e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs698833	0.926	rs1067353	chr2:44666626	G/A	cg04920474	chr2:44395004	PPM1B	0.4	7.29	0.33	1.58e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs17270561	0.609	rs760698	chr6:25685889	A/G	cg25753631	chr6:25732923	NA	-0.39	-6.92	-0.32	1.66e-11	Iron status biomarkers;
LUAD	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg11859384	chr17:80120422	CCDC57	-0.47	-8.54	-0.38	2.49e-16	Life satisfaction;
LUAD	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25427524	chr10:38739819	LOC399744	-0.78	-14.31	-0.57	3.65e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.58e-12	Breast cancer;
LUAD	trans	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg04775059	chr7:64541387	NA	0.48	6.45	0.3	3.1e-10	Aortic root size;
LUAD	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg08859206	chr1:53392774	SCP2	-0.5	-8.93	-0.4	1.35e-17	Monocyte count;
LUAD	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg23978390	chr7:1156363	C7orf50	0.47	6.4	0.3	4.17e-10	Bronchopulmonary dysplasia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11970458	chr16:31213481	PYCARD	-0.4	-6.63	-0.31	1.03e-10	Height;
LUAD	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg21782813	chr7:2030301	MAD1L1	0.51	8.75	0.39	4.96e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg20587970	chr11:113659929	NA	0.88	11.67	0.49	1.83e-27	Hip circumference adjusted for BMI;
LUAD	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.63	-0.31	9.95e-11	Neuroticism;
LUAD	cis	rs7809950	1.000	rs7793613	chr7:107250484	C/T	cg23024343	chr7:107201750	COG5	-0.65	-10.88	-0.47	1.84e-24	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08280861	chr8:58055591	NA	0.78	9.33	0.41	6.16e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2425143	0.730	rs2095819	chr20:34353278	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.43	-0.34	5.93e-13	Blood protein levels;
LUAD	cis	rs494562	0.892	rs522915	chr6:86116321	A/G	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg08508325	chr11:3079039	CARS	0.43	8.94	0.4	1.26e-17	Calcium levels;
LUAD	cis	rs7072216	0.770	rs7896828	chr10:100170507	A/T	cg26618903	chr10:100175079	PYROXD2	-0.31	-7.03	-0.32	8.24e-12	Metabolite levels;
LUAD	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg15017067	chr4:17643749	FAM184B	0.34	6.55	0.3	1.66e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1003719	0.553	rs1063948	chr21:38574674	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.2	-0.37	2.89e-15	Eye color traits;
LUAD	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg10356904	chr22:49881777	NA	-0.41	-8.01	-0.36	1.09e-14	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs877282	0.945	rs17293517	chr10:778770	C/T	cg22713356	chr15:30763199	NA	1.36	20.1	0.7	1.41e-63	Uric acid levels;
LUAD	cis	rs3784262	0.904	rs12901462	chr15:58316487	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.46	-9.39	-0.42	3.76e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	trans	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg07211511	chr3:129823064	LOC729375	-0.55	-7.08	-0.33	5.92e-12	Blood pressure (smoking interaction);
LUAD	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg24818145	chr4:99064322	C4orf37	0.43	7.34	0.34	1.08e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10788264	0.504	rs1034533	chr10:124032434	A/G	cg09507567	chr10:124027408	NA	0.53	12.02	0.5	7.82e-29	Total body bone mineral density;
LUAD	cis	rs758324	0.947	rs1846650	chr5:131158767	C/T	cg25547332	chr5:131281432	NA	0.42	6.51	0.3	2.18e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs137699	1.000	rs5757632	chr22:39756097	A/C	cg11247378	chr22:39784982	NA	-0.53	-9.0	-0.4	7.53e-18	IgG glycosylation;
LUAD	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg17105886	chr17:28927953	LRRC37B2	0.82	8.04	0.36	8.91e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg17971929	chr21:40555470	PSMG1	0.56	8.87	0.4	2.04e-17	Cognitive function;
LUAD	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-20.52	-0.71	1.83e-65	Height;
LUAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.64	0.35	1.46e-13	Electroencephalogram traits;
LUAD	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg11645453	chr3:52864694	ITIH4	-0.38	-7.55	-0.34	2.68e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg19635926	chr16:89946313	TCF25	0.66	6.51	0.3	2.15e-10	Skin colour saturation;
LUAD	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg12140854	chr5:148520817	ABLIM3	-0.68	-10.95	-0.47	9.61e-25	Breast cancer;
LUAD	cis	rs4660214	0.666	rs1180384	chr1:39892774	T/C	cg27567593	chr1:39956653	BMP8A	-0.36	-7.23	-0.33	2.26e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg22963979	chr7:1858916	MAD1L1	-0.59	-10.07	-0.44	1.53e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs10493773	0.962	rs6698578	chr1:86236676	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.53	-8.67	-0.39	9.3e-17	Urate levels in overweight individuals;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17365369	chr19:52773256	ZNF766	-0.54	-6.81	-0.31	3.4e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg05896524	chr21:47604654	C21orf56	0.52	7.21	0.33	2.53e-12	Testicular germ cell tumor;
LUAD	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg19318889	chr4:1322082	MAEA	0.44	7.07	0.33	6.32e-12	Obesity-related traits;
LUAD	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg10560079	chr2:191398806	TMEM194B	0.54	7.14	0.33	4.2e-12	Diastolic blood pressure;
LUAD	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg14343924	chr8:8086146	FLJ10661	0.4	6.45	0.3	3.15e-10	Neuroticism;
LUAD	cis	rs3789045	0.560	rs4553256	chr1:204411144	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.6	-9.5	-0.42	1.61e-19	Educational attainment (college completion);
LUAD	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg10556349	chr10:835070	NA	0.51	6.6	0.31	1.22e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg02421172	chr7:1938701	MAD1L1	0.48	6.81	0.31	3.27e-11	Bipolar disorder;
LUAD	trans	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg02002194	chr4:3960332	NA	-0.29	-7.09	-0.33	5.59e-12	Mood instability;
LUAD	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg08213375	chr14:104286397	PPP1R13B	0.27	7.12	0.33	4.78e-12	Schizophrenia;
LUAD	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg20119798	chr7:94954144	PON1	-0.49	-6.85	-0.32	2.67e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg18876405	chr7:65276391	NA	-0.4	-6.49	-0.3	2.36e-10	Calcium levels;
LUAD	cis	rs13315871	0.929	rs13082278	chr3:58318224	A/G	cg20936604	chr3:58311152	NA	-0.79	-8.4	-0.38	7.01e-16	Cholesterol, total;
LUAD	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg25985355	chr7:65971099	NA	0.55	6.84	0.32	2.8e-11	Diabetic kidney disease;
LUAD	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.22	-0.41	1.46e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs35883536	0.967	rs2297713	chr1:101092766	T/G	cg06223162	chr1:101003688	GPR88	0.34	6.43	0.3	3.36e-10	Monocyte count;
LUAD	cis	rs12681287	0.752	rs10092651	chr8:87247678	A/C	cg27223183	chr8:87520930	FAM82B	-0.59	-8.28	-0.37	1.58e-15	Caudate activity during reward;
LUAD	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg04365224	chr3:72788183	NA	-0.44	-6.39	-0.3	4.26e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg18944383	chr4:111397179	ENPEP	0.42	8.31	0.37	1.3e-15	Height;
LUAD	cis	rs7210086	0.808	rs3935122	chr17:70641315	C/T	cg04206342	chr17:70636940	NA	-0.37	-6.98	-0.32	1.16e-11	Ulcerative colitis;
LUAD	cis	rs2274273	1.000	rs10149435	chr14:55627489	C/T	cg04306507	chr14:55594613	LGALS3	0.37	7.48	0.34	4.25e-13	Protein biomarker;
LUAD	cis	rs10193935	1.000	rs10210866	chr2:42387879	A/G	cg27598129	chr2:42591480	NA	-0.68	-8.92	-0.4	1.44e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.768	rs458740	chr6:109525527	C/T	cg21918786	chr6:109611834	NA	-0.41	-7.11	-0.33	4.87e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg11814155	chr7:99998594	ZCWPW1	0.41	6.97	0.32	1.25e-11	Platelet count;
LUAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg11062466	chr8:58055876	NA	0.56	7.87	0.36	2.93e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.72	-9.4	-0.42	3.49e-19	Obesity-related traits;
LUAD	cis	rs4285028	0.948	rs10934565	chr3:121664661	G/A	cg11130432	chr3:121712080	ILDR1	-0.58	-8.12	-0.37	5.33e-15	Multiple sclerosis;
LUAD	cis	rs754466	0.651	rs11002316	chr10:79617511	C/G	cg17075019	chr10:79541650	NA	-0.86	-18.11	-0.66	1.14e-54	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10788972	0.903	rs7537946	chr1:54538700	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.23	-6.44	-0.3	3.31e-10	Parkinson disease and lewy body pathology;
LUAD	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg16322792	chr1:120165303	ZNF697	0.72	19.25	0.68	9.59e-60	Systemic lupus erythematosus;
LUAD	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg15445000	chr17:37608096	MED1	0.44	8.24	0.37	2.12e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.53	-8.98	-0.4	9e-18	Electrocardiographic conduction measures;
LUAD	cis	rs4664308	0.967	rs17241792	chr2:160915205	C/T	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.79	-0.31	3.88e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs16854884	0.586	rs6440212	chr3:143748526	T/C	cg01302019	chr3:143689584	C3orf58	-0.38	-6.85	-0.32	2.69e-11	Economic and political preferences (feminism/equality);
LUAD	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-7.92	-0.36	2.19e-14	Electroencephalogram traits;
LUAD	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg13535736	chr9:111863775	C9orf5	-0.43	-6.66	-0.31	8.37e-11	Menarche (age at onset);
LUAD	cis	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg08601574	chr20:25228251	PYGB	-0.44	-8.05	-0.36	8.28e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs733592	0.723	rs10875766	chr12:48593580	G/C	cg24011408	chr12:48396354	COL2A1	0.38	8.24	0.37	2.15e-15	Plateletcrit;
LUAD	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg08885076	chr2:99613938	TSGA10	0.4	7.55	0.34	2.79e-13	Chronic sinus infection;
LUAD	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg05754148	chr16:3507555	NAT15	0.67	11.12	0.48	2.23e-25	Tuberculosis;
LUAD	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.77	0.46	4.7e-24	Colorectal cancer;
LUAD	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg25894440	chr7:65020034	NA	-0.66	-7.1	-0.33	5.28e-12	Diabetic kidney disease;
LUAD	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.34	6.45	0.3	3.14e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	8.48	0.38	3.71e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.19	0.33	2.95e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.67	-10.96	-0.47	9.06e-25	Primary sclerosing cholangitis;
LUAD	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg12292205	chr6:26970375	C6orf41	0.38	6.63	0.31	1.02e-10	Schizophrenia;
LUAD	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg26384229	chr12:38710491	ALG10B	0.39	6.71	0.31	6.34e-11	Bladder cancer;
LUAD	cis	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg08601574	chr20:25228251	PYGB	-0.45	-8.22	-0.37	2.49e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4713675	0.553	rs943465	chr6:33731663	G/A	cg07979401	chr6:33739406	LEMD2	-0.46	-8.13	-0.37	4.96e-15	Plateletcrit;
LUAD	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg19678392	chr7:94953810	PON1	-0.58	-8.05	-0.36	8.63e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3820068	0.580	rs12760698	chr1:16009814	G/A	cg17177755	chr1:15930204	NA	0.49	7.65	0.35	1.38e-13	Systolic blood pressure;
LUAD	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg27170947	chr2:26402098	FAM59B	-0.8	-11.36	-0.48	2.88e-26	Gut microbiome composition (summer);
LUAD	cis	rs7512552	0.839	rs834229	chr1:150384665	G/C	cg15654264	chr1:150340011	RPRD2	0.61	11.71	0.49	1.23e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg21724239	chr8:58056113	NA	0.7	9.1	0.4	3.56e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9807989	0.839	rs7603730	chr2:102974371	A/C	cg03938978	chr2:103052716	IL18RAP	0.32	6.64	0.31	9.48e-11	Asthma;
LUAD	cis	rs10979	0.679	rs9403510	chr6:143892174	C/T	cg25407410	chr6:143891975	LOC285740	-0.52	-7.75	-0.35	7.08e-14	Hypospadias;
LUAD	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg00495681	chr13:53174319	NA	0.49	8.75	0.39	5.22e-17	Lewy body disease;
LUAD	trans	rs853679	0.546	rs200490	chr6:27796935	G/T	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.79	-0.35	5.33e-14	Depression;
LUAD	cis	rs713477	0.967	rs10150617	chr14:55916225	A/C	cg13175173	chr14:55914753	NA	0.35	7.31	0.33	1.37e-12	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg10792982	chr14:105748885	BRF1	-0.38	-8.45	-0.38	4.69e-16	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00614832	chr16:73092394	ZFHX3	-0.51	-6.41	-0.3	3.83e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs1493916	0.967	rs1389532	chr18:31392323	C/T	cg27147174	chr7:100797783	AP1S1	-0.67	-11.84	-0.5	4.11e-28	Life satisfaction;
LUAD	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg13870426	chr17:30244630	NA	-0.55	-6.58	-0.3	1.43e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.4	7.89	0.36	2.57e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs853679	0.505	rs200992	chr6:27814677	A/G	cg01620082	chr3:125678407	NA	-0.81	-8.67	-0.39	9.01e-17	Depression;
LUAD	cis	rs4692589	0.772	rs34642369	chr4:170973469	G/A	cg19918862	chr4:170955249	NA	0.33	6.91	0.32	1.75e-11	Anxiety disorder;
LUAD	cis	rs73416724	1.000	rs1214762	chr6:43355151	C/T	cg26312998	chr6:43337775	ZNF318	-0.52	-6.61	-0.31	1.14e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9902453	0.967	rs7222685	chr17:28496430	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	8.41	0.38	6.12e-16	Coffee consumption (cups per day);
LUAD	cis	rs438034	0.967	rs7289	chr1:214837110	C/G	cg16144317	chr1:214725524	PTPN14	-0.35	-6.42	-0.3	3.62e-10	Response to antineoplastic agents;
LUAD	cis	rs1448094	0.967	rs10746357	chr12:86341044	A/T	cg19622623	chr12:86230825	RASSF9	-0.35	-6.45	-0.3	3.03e-10	Major depressive disorder;
LUAD	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg17366294	chr4:99064904	C4orf37	0.59	9.95	0.44	4.29e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg11247378	chr22:39784982	NA	-0.75	-14.16	-0.57	1.52e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs9322817	0.691	rs56075147	chr6:105337494	T/A	cg02098413	chr6:105308735	HACE1	0.42	9.12	0.41	3.1e-18	Thyroid stimulating hormone;
LUAD	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg05340658	chr4:99064831	C4orf37	0.47	6.62	0.31	1.1e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg15900387	chr1:150738905	CTSS	-0.36	-6.5	-0.3	2.21e-10	Melanoma;
LUAD	cis	rs10193935	0.901	rs2118889	chr2:42451683	G/T	cg27598129	chr2:42591480	NA	-0.73	-9.29	-0.41	8.52e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56283067	0.887	rs12215971	chr6:44784566	A/G	cg18551225	chr6:44695536	NA	-0.49	-7.59	-0.35	2.09e-13	Total body bone mineral density;
LUAD	cis	rs1372520	0.684	rs356188	chr4:90691537	T/C	cg15133208	chr4:90757351	SNCA	0.47	6.86	0.32	2.44e-11	Neuroticism;
LUAD	cis	rs6604026	0.740	rs10874747	chr1:93352491	A/G	cg17283838	chr1:93427260	FAM69A	-0.41	-6.53	-0.3	1.83e-10	Multiple sclerosis;
LUAD	cis	rs868036	0.958	rs12593813	chr15:68036852	C/T	cg24579218	chr15:68104479	NA	-0.41	-7.47	-0.34	4.78e-13	Restless legs syndrome;
LUAD	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg22153463	chr1:85462885	MCOLN2	0.62	9.24	0.41	1.21e-18	Serum sulfate level;
LUAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg22907277	chr7:1156413	C7orf50	0.68	8.03	0.36	9.93e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs427394	0.632	rs2279656	chr5:6737576	G/A	cg14682080	chr5:6737778	POLS	0.35	7.68	0.35	1.1e-13	Menopause (age at onset);
LUAD	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.58	-0.3	1.41e-10	Height;
LUAD	cis	rs6840360	0.593	rs28602726	chr4:152499788	T/C	cg22705602	chr4:152727874	NA	-0.37	-6.64	-0.31	9.65e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg04800585	chr6:26043546	HIST1H2BB	-0.35	-6.36	-0.3	5.13e-10	Blood metabolite levels;
LUAD	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg25985355	chr7:65971099	NA	-0.54	-6.62	-0.31	1.09e-10	Diabetic kidney disease;
LUAD	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg12501888	chr15:85177176	SCAND2	-0.47	-7.09	-0.33	5.52e-12	Schizophrenia;
LUAD	cis	rs36051895	0.695	rs10974922	chr9:5028813	C/T	cg02405213	chr9:5042618	JAK2	-0.48	-7.11	-0.33	5.07e-12	Pediatric autoimmune diseases;
LUAD	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg00933542	chr6:150070202	PCMT1	0.35	7.24	0.33	2.14e-12	Testicular germ cell tumor;
LUAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg13397359	chr6:42928475	GNMT	0.58	11.02	0.47	5.53e-25	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2637266	0.783	rs2583070	chr10:78518555	C/T	cg18941641	chr10:78392320	NA	0.31	6.38	0.3	4.77e-10	Pulmonary function;
LUAD	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg06608945	chr2:219082296	ARPC2	-0.5	-8.55	-0.38	2.33e-16	Colorectal cancer;
LUAD	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg11859384	chr17:80120422	CCDC57	0.48	8.64	0.39	1.17e-16	Life satisfaction;
LUAD	cis	rs2840044	1.000	rs11656138	chr17:33910218	T/C	cg05299278	chr17:33885742	SLFN14	-0.44	-8.85	-0.4	2.34e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-7.53	-0.34	3.19e-13	Tonsillectomy;
LUAD	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg06873352	chr17:61820015	STRADA	0.41	6.56	0.3	1.53e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg02423579	chr7:2872169	GNA12	-0.81	-14.08	-0.56	3.38e-37	Height;
LUAD	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg11502198	chr6:26597334	ABT1	0.54	9.14	0.41	2.56e-18	Intelligence (multi-trait analysis);
LUAD	trans	rs8073060	0.586	rs4796100	chr17:33997657	G/T	cg19694781	chr19:47549865	TMEM160	1.21	18.96	0.68	1.81e-58	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs6500602	1.000	rs11648292	chr16:4462897	C/A	cg08645402	chr16:4508243	NA	0.55	9.82	0.43	1.24e-20	Schizophrenia;
LUAD	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg15128208	chr22:42549153	NA	0.42	6.71	0.31	6.27e-11	Birth weight;
LUAD	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg13180566	chr4:1052158	NA	0.38	6.39	0.3	4.37e-10	Recombination rate (females);
LUAD	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg24675056	chr1:15929824	NA	0.49	8.48	0.38	3.92e-16	Systolic blood pressure;
LUAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg24503407	chr1:205819492	PM20D1	0.72	14.27	0.57	5.27e-38	Monocyte percentage of white cells;
LUAD	cis	rs11644601	1	rs11644601	chr16:15172118	T/C	cg27102117	chr16:15229624	NA	0.45	6.94	0.32	1.47e-11	Metabolite levels (lipid measures);
LUAD	cis	rs17767294	0.541	rs72845042	chr6:27568734	A/T	cg08851530	chr6:28072375	NA	1.01	7.47	0.34	4.71e-13	Parkinson's disease;
LUAD	cis	rs7617773	0.780	rs13082859	chr3:48344675	C/T	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg07570687	chr10:102243282	WNT8B	0.48	7.28	0.33	1.6e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg12432903	chr7:1882776	MAD1L1	-0.53	-8.65	-0.39	1.1e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2637266	0.967	rs12246605	chr10:78352994	G/A	cg18941641	chr10:78392320	NA	0.33	6.82	0.31	3.25e-11	Pulmonary function;
LUAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.47	0.34	4.58e-13	Electroencephalogram traits;
LUAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg04025307	chr7:1156635	C7orf50	0.6	6.77	0.31	4.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg14092571	chr14:90743983	NA	-0.47	-8.27	-0.37	1.74e-15	Mortality in heart failure;
LUAD	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-12.31	-0.51	5.5e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18876405	chr7:65276391	NA	-0.58	-9.91	-0.43	5.85e-21	Aortic root size;
LUAD	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg19761014	chr17:28927070	LRRC37B2	0.85	8.54	0.38	2.46e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg24675056	chr1:15929824	NA	0.47	8.3	0.37	1.37e-15	Systolic blood pressure;
LUAD	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7264396	0.561	rs66483315	chr20:34573575	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.5	-0.3	2.23e-10	Total cholesterol levels;
LUAD	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg03806693	chr22:41940476	POLR3H	-0.81	-11.28	-0.48	5.61e-26	Vitiligo;
LUAD	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg06740227	chr12:86229804	RASSF9	0.37	6.74	0.31	5.34e-11	Major depressive disorder;
LUAD	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg18827107	chr12:86230957	RASSF9	-0.69	-12.77	-0.53	8.43e-32	Major depressive disorder;
LUAD	cis	rs892961	0.965	rs2411111	chr17:75402540	A/T	cg05865280	chr17:75406074	SEPT9	0.61	18.2	0.66	4.26e-55	Airflow obstruction;
LUAD	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg16989719	chr2:238392110	NA	-0.36	-7.75	-0.35	7e-14	Prostate cancer;
LUAD	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.95	-0.36	1.78e-14	Monocyte percentage of white cells;
LUAD	cis	rs7173743	0.967	rs28694044	chr15:79134718	A/T	cg15571903	chr15:79123663	NA	-0.37	-6.98	-0.32	1.16e-11	Coronary artery disease;
LUAD	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg17105886	chr17:28927953	LRRC37B2	0.62	6.94	0.32	1.44e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs11229555	1.000	rs7102510	chr11:58371283	T/G	cg15696309	chr11:58395628	NA	-0.73	-10.98	-0.47	7.29e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.48	-0.42	1.91e-19	Life satisfaction;
LUAD	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg21017887	chr14:105400489	NA	0.75	14.43	0.57	1.2e-38	Rheumatoid arthritis;
LUAD	trans	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg18834416	chr8:37888184	EIF4EBP1	0.39	6.39	0.3	4.39e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg11941060	chr3:133502564	NA	0.61	11.03	0.47	4.75e-25	Iron status biomarkers;
LUAD	cis	rs727505	0.537	rs10235657	chr7:124487309	A/G	cg23710748	chr7:124431027	NA	0.42	8.67	0.39	9.61e-17	Lewy body disease;
LUAD	cis	rs7731657	0.509	rs6595984	chr5:130335884	A/G	cg08523029	chr5:130500466	HINT1	0.5	6.78	0.31	4.13e-11	Fasting plasma glucose;
LUAD	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg17264618	chr3:40429014	ENTPD3	0.42	9.01	0.4	6.93e-18	Renal cell carcinoma;
LUAD	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg03676636	chr4:99064102	C4orf37	0.36	8.18	0.37	3.28e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.31	-0.48	4.47e-26	Type 2 diabetes;
LUAD	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.82	0.31	3.13e-11	Cognitive test performance;
LUAD	cis	rs11811982	0.793	rs115128840	chr1:227422406	T/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.58	0.35	2.27e-13	Optic disc area;
LUAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.46	-0.38	4.38e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg00784671	chr22:46762841	CELSR1	-0.45	-6.88	-0.32	2.16e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs10924309	0.889	rs10802247	chr1:245858508	G/A	cg00036263	chr1:245852353	KIF26B	-0.48	-7.49	-0.34	4.11e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg10356904	chr22:49881777	NA	-0.4	-8.57	-0.38	2.01e-16	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00166722	chr3:10149974	C3orf24	0.63	10.52	0.46	3.77e-23	Alzheimer's disease;
LUAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.34	-6.36	-0.3	5.31e-10	Longevity;Endometriosis;
LUAD	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.2	-0.33	2.72e-12	Heart rate;
LUAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-9.76	-0.43	2.03e-20	Lymphocyte counts;
LUAD	cis	rs7843479	1.000	rs13276082	chr8:21823184	A/G	cg10047019	chr8:21822950	XPO7	-0.38	-6.45	-0.3	2.98e-10	Mean corpuscular volume;
LUAD	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.74	-0.31	5.2e-11	Total body bone mineral density;
LUAD	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25427524	chr10:38739819	LOC399744	-0.75	-13.39	-0.55	2.38e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6761276	0.934	rs11682107	chr2:113835522	G/A	cg06383401	chr2:113825234	IL1F10	-0.29	-6.38	-0.3	4.71e-10	Protein quantitative trait loci;
LUAD	cis	rs6906287	0.647	rs4027880	chr6:118734134	A/T	cg05564266	chr6:118973597	C6orf204	0.34	7.2	0.33	2.73e-12	Electrocardiographic conduction measures;
LUAD	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22857025	chr5:266934	NA	-0.9	-13.99	-0.56	8.23e-37	Breast cancer;
LUAD	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.8	-13.93	-0.56	1.39e-36	Chronic sinus infection;
LUAD	cis	rs9364220	0.646	rs2029489	chr6:168496038	A/G	cg02770688	chr6:168491649	NA	-0.39	-7.38	-0.34	8.72e-13	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
LUAD	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg02782426	chr3:40428986	ENTPD3	0.44	9.29	0.41	8.24e-19	Renal cell carcinoma;
LUAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg04025307	chr7:1156635	C7orf50	0.76	13.75	0.56	7.77e-36	Longevity;Endometriosis;
LUAD	trans	rs11083241	0.570	rs7243677	chr18:25558198	C/T	cg15677368	chr1:245133209	EFCAB2	-0.41	-6.55	-0.3	1.62e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg05283184	chr6:79620031	NA	-0.6	-12.04	-0.51	6.38e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs10924309	0.737	rs4378245	chr1:245852727	G/A	cg00036263	chr1:245852353	KIF26B	-0.53	-9.0	-0.4	7.82e-18	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.64	-0.31	9.73e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs12549902	0.966	rs12544241	chr8:41514888	G/A	cg17182837	chr8:41585554	ANK1	-0.36	-7.49	-0.34	4.16e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUAD	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg03929089	chr4:120376271	NA	-0.97	-20.29	-0.7	2.1e-64	Height;
LUAD	cis	rs10254118	0.757	rs13241123	chr7:133135507	A/T	cg10665199	chr7:133106180	EXOC4	0.59	9.83	0.43	1.13e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00166722	chr3:10149974	C3orf24	-0.74	-12.73	-0.53	1.15e-31	Alzheimer's disease;
LUAD	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg04455712	chr21:45112962	RRP1B	0.43	8.69	0.39	7.86e-17	Mean corpuscular volume;
LUAD	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg22681709	chr2:178499509	PDE11A	-0.5	-8.48	-0.38	3.73e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	7.7	0.35	9.56e-14	Alzheimer's disease;
LUAD	trans	rs360929	0.935	rs360907	chr4:152900634	A/G	cg22822647	chr19:16771056	TMEM38A;C19orf42	-0.52	-6.43	-0.3	3.5e-10	Volumetric brain MRI;
LUAD	cis	rs7937890	0.507	rs4463820	chr11:14556342	A/G	cg06199346	chr11:14280333	SPON1	-0.32	-6.4	-0.3	4.16e-10	Mitochondrial DNA levels;
LUAD	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg05621596	chr22:47072043	GRAMD4	0.64	10.65	0.46	1.27e-23	Urate levels in obese individuals;
LUAD	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg21475434	chr5:93447410	FAM172A	0.73	8.58	0.39	1.76e-16	Diabetic retinopathy;
LUAD	trans	rs2735413	0.918	rs12598024	chr16:78079114	G/A	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs9549367	0.569	rs3024738	chr13:113819921	T/A	cg18105134	chr13:113819100	PROZ	0.97	17.5	0.65	5.46e-52	Platelet distribution width;
LUAD	cis	rs7980687	0.550	rs1727324	chr12:123698603	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-6.52	-0.3	1.99e-10	Height;Educational attainment;Head circumference (infant);
LUAD	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10802521	chr3:52805072	NEK4	-0.59	-10.38	-0.45	1.2e-22	Electroencephalogram traits;
LUAD	trans	rs911555	0.755	rs2756122	chr14:103983033	C/G	cg18022926	chr10:70093071	PBLD;HNRNPH3	-0.41	-6.99	-0.32	1.1e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg12311346	chr5:56204834	C5orf35	-0.93	-13.76	-0.56	7.29e-36	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.27e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs758324	0.773	rs11951407	chr5:131142661	T/C	cg25547332	chr5:131281432	NA	0.41	6.63	0.31	1.01e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9951602	0.920	rs3859334	chr18:76684193	G/A	cg00806245	chr18:76673096	NA	-0.39	-6.57	-0.3	1.51e-10	Obesity-related traits;
LUAD	cis	rs12545109	0.879	rs1975285	chr8:57358682	G/C	cg07776626	chr8:57350775	NA	-0.67	-9.24	-0.41	1.2e-18	Obesity-related traits;
LUAD	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg21918786	chr6:109611834	NA	-0.57	-10.58	-0.46	2.38e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Depression;
LUAD	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg10792982	chr14:105748885	BRF1	0.46	9.89	0.43	7.03e-21	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16714605	chr19:10765132	ILF3;LOC147727	-0.57	-7.06	-0.32	6.9e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg03433033	chr1:76189801	ACADM	0.85	15.15	0.59	9.5e-42	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg06191203	chr2:152266755	RIF1	0.51	7.88	0.36	2.83e-14	Lung cancer;
LUAD	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg25344623	chr2:136566232	LCT	0.33	6.49	0.3	2.34e-10	Mosquito bite size;
LUAD	cis	rs9487051	0.735	rs459956	chr6:109524760	A/G	cg21918786	chr6:109611834	NA	-0.42	-7.35	-0.34	1.01e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg26314531	chr2:26401878	FAM59B	-0.54	-7.59	-0.35	2.07e-13	Gut microbiome composition (summer);
LUAD	trans	rs931812	0.757	rs4734492	chr8:101901901	C/T	cg20993868	chr7:22813445	NA	-0.53	-11.69	-0.49	1.5e-27	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs28595532	1.000	rs114682099	chr4:119702004	C/T	cg02775129	chr4:119771670	NA	-0.84	-8.0	-0.36	1.2e-14	Cannabis dependence symptom count;
LUAD	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg04450456	chr4:17643702	FAM184B	0.37	6.89	0.32	1.99e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg23939166	chr14:55032812	NA	-0.38	-6.51	-0.3	2.08e-10	Schizophrenia;
LUAD	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.67	-10.84	-0.47	2.6e-24	Height;
LUAD	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.44e-10	Prostate cancer;
LUAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg05313129	chr8:58192883	C8orf71	-0.57	-8.42	-0.38	5.89e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg02399570	chr3:156877196	CCNL1	-0.4	-6.79	-0.31	3.92e-11	Subcortical brain region volumes;
LUAD	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg26513180	chr16:89883248	FANCA	0.76	6.92	0.32	1.64e-11	Skin colour saturation;
LUAD	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg21918786	chr6:109611834	NA	-0.6	-11.43	-0.49	1.57e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs9287719	0.639	rs2357650	chr2:10696877	C/T	cg00105475	chr2:10696890	NA	0.41	7.13	0.33	4.39e-12	Prostate cancer;
LUAD	cis	rs3784262	0.565	rs12914603	chr15:58350896	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.59	-0.35	2.05e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg09455208	chr3:40491958	NA	-0.59	-12.84	-0.53	4.41e-32	Renal cell carcinoma;
LUAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg12311346	chr5:56204834	C5orf35	-0.9	-13.78	-0.56	5.78e-36	Initial pursuit acceleration;
LUAD	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg16325326	chr1:53192061	ZYG11B	0.63	12.18	0.51	1.9e-29	Monocyte count;
LUAD	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23583168	chr7:148888333	NA	0.89	17.82	0.65	2.18e-53	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs713477	1.000	rs2185036	chr14:55907710	A/G	cg13175173	chr14:55914753	NA	-0.33	-6.94	-0.32	1.52e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg09365446	chr1:150670422	GOLPH3L	-0.62	-11.09	-0.47	2.96e-25	Melanoma;
LUAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg09033563	chr22:24373618	LOC391322	0.56	9.03	0.4	6.21e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg23933602	chr10:16859644	RSU1	0.61	8.34	0.38	1.04e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg13902645	chr11:5959945	NA	-0.55	-10.69	-0.46	9.23e-24	DNA methylation (variation);
LUAD	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg20135002	chr11:47629003	NA	-0.41	-7.15	-0.33	3.87e-12	Subjective well-being;
LUAD	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg17063962	chr7:91808500	NA	-0.65	-11.65	-0.49	2.09e-27	Breast cancer;
LUAD	trans	rs3219090	0.861	rs1341333	chr1:226604638	A/G	cg27539482	chr13:111589090	NA	0.43	7.26	0.33	1.82e-12	Melanoma;
LUAD	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg12645284	chr15:79092878	ADAMTS7	0.45	7.18	0.33	3.1e-12	Coronary artery disease or large artery stroke;
LUAD	cis	rs6906287	0.647	rs7758614	chr6:118889894	T/C	cg21191810	chr6:118973309	C6orf204	0.51	9.76	0.43	2.04e-20	Electrocardiographic conduction measures;
LUAD	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg09658497	chr7:2847517	GNA12	-0.5	-9.56	-0.42	1.01e-19	Height;
LUAD	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg20607798	chr8:58055168	NA	0.57	7.89	0.36	2.56e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs12208915	0.848	rs9352654	chr6:79500281	A/G	cg05283184	chr6:79620031	NA	0.52	6.53	0.3	1.87e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11811982	0.793	rs116389194	chr1:227302921	T/C	cg24860534	chr1:227506868	CDC42BPA	0.68	7.31	0.33	1.35e-12	Optic disc area;
LUAD	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg15704280	chr7:45808275	SEPT13	0.72	11.03	0.47	4.8e-25	Coronary artery disease;
LUAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg07677032	chr17:61819896	STRADA	0.56	10.36	0.45	1.45e-22	Prudent dietary pattern;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11105980	chr13:37393381	RFXAP	-0.56	-6.68	-0.31	7.75e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg23803603	chr1:2058230	PRKCZ	0.41	6.74	0.31	5.32e-11	Height;
LUAD	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg18490616	chr2:88469792	THNSL2	0.62	6.83	0.32	2.98e-11	Plasma clusterin levels;
LUAD	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg06640241	chr16:89574553	SPG7	-0.56	-9.48	-0.42	1.79e-19	Multiple myeloma (IgH translocation);
LUAD	cis	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg05901451	chr6:126070800	HEY2	-0.45	-6.78	-0.31	4.12e-11	Endometrial cancer;
LUAD	cis	rs116248771	0.690	rs73156490	chr3:158416484	G/A	cg16708174	chr3:158430962	RARRES1	0.47	6.9	0.32	1.94e-11	diarrhoeal disease at age 2;
LUAD	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.19	-0.37	3.12e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs12365397	0.526	rs11037263	chr11:43161203	A/C	cg03447554	chr11:43094025	NA	0.41	7.4	0.34	7.22e-13	Migraine;
LUAD	cis	rs10504073	0.584	rs62507177	chr8:49937306	C/A	cg00325661	chr8:49890786	NA	0.45	10.09	0.44	1.34e-21	Blood metabolite ratios;
LUAD	cis	rs2479724	0.901	rs10947987	chr6:41754370	C/T	cg17623882	chr6:41773611	USP49	0.63	11.38	0.48	2.32e-26	Menarche (age at onset);
LUAD	cis	rs4285028	0.747	rs9850439	chr3:121393075	T/C	cg11130432	chr3:121712080	ILDR1	-0.47	-6.81	-0.31	3.39e-11	Multiple sclerosis;
LUAD	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.8	-0.39	3.43e-17	Alzheimer's disease (late onset);
LUAD	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.4	-0.38	7.03e-16	Prostate cancer;
LUAD	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg09455208	chr3:40491958	NA	0.6	12.65	0.52	2.51e-31	Renal cell carcinoma;
LUAD	cis	rs6714710	0.603	rs17489454	chr2:98407350	C/T	cg26665480	chr2:98280029	ACTR1B	0.49	8.14	0.37	4.38e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.62	8.33	0.38	1.1e-15	Renal function-related traits (BUN);
LUAD	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg16989719	chr2:238392110	NA	-0.36	-7.81	-0.36	4.42e-14	Prostate cancer;
LUAD	cis	rs758324	0.812	rs10042334	chr5:131114979	A/T	cg06307176	chr5:131281290	NA	0.46	7.56	0.35	2.5e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs3800461	0.544	rs11754548	chr6:34504767	G/C	cg17674042	chr6:34482479	PACSIN1	-0.53	-7.02	-0.32	8.77e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg13073564	chr4:8508604	NA	-0.55	-10.15	-0.44	8.07e-22	Response to antineoplastic agents;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg07306088	chr12:46777190	NA	-0.52	-6.47	-0.3	2.65e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2806561	0.780	rs4655142	chr1:23333728	T/C	cg19743168	chr1:23544995	NA	-0.35	-6.38	-0.3	4.68e-10	Height;
LUAD	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg26769984	chr7:1090371	C7orf50	0.64	9.1	0.4	3.51e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs1143633	0.579	rs4849132	chr2:113673471	G/A	cg12858261	chr2:113808755	IL1F8	-0.36	-6.53	-0.3	1.85e-10	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg27539214	chr16:67997921	SLC12A4	0.66	8.3	0.37	1.39e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg14668632	chr7:2872130	GNA12	-0.48	-8.56	-0.38	2.03e-16	Height;
LUAD	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg23281280	chr6:28129359	ZNF389	-0.46	-6.81	-0.31	3.28e-11	Depression;
LUAD	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg07978099	chr16:83986941	OSGIN1	0.52	7.04	0.32	7.65e-12	Pursuit maintenance gain;
LUAD	cis	rs73206853	0.764	rs7966591	chr12:110644045	G/A	cg12870014	chr12:110450643	ANKRD13A	0.67	8.14	0.37	4.6e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg09904177	chr6:26538194	HMGN4	0.44	7.36	0.34	9.71e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg11645453	chr3:52864694	ITIH4	-0.38	-7.5	-0.34	3.84e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg08027265	chr7:2291960	NA	-0.44	-7.93	-0.36	1.98e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.25	-0.33	2.06e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg26394196	chr10:1453818	ADARB2	-0.33	-6.45	-0.3	3.05e-10	Radiation response;
LUAD	cis	rs6500596	0.506	rs1530088	chr16:4439131	C/T	cg08645402	chr16:4508243	NA	0.43	7.14	0.33	4.14e-12	Schizophrenia;
LUAD	trans	rs2270927	0.790	rs4613682	chr5:75576455	G/C	cg13563193	chr19:33072644	PDCD5	0.72	8.37	0.38	8.8e-16	Mean corpuscular volume;
LUAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs813218	0.647	rs6788750	chr3:99774720	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.35	-6.59	-0.31	1.3100000000000001e-10	Orofacial clefts;
LUAD	cis	rs59104589	0.570	rs3771569	chr2:242382606	A/T	cg08645257	chr2:242211290	HDLBP	0.43	7.03	0.32	8.36e-12	Fibrinogen levels;
LUAD	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg00933542	chr6:150070202	PCMT1	0.44	9.47	0.42	2.03e-19	Lung cancer;
LUAD	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg11301795	chr4:187892539	NA	-0.79	-16.53	-0.63	1.06e-47	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11625487	0.957	rs7156032	chr14:77951364	G/A	cg20045696	chr14:77926864	AHSA1	-0.52	-7.14	-0.33	4.12e-12	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18099408	chr3:52552593	STAB1	-0.51	-9.32	-0.41	6.42e-19	Electroencephalogram traits;
LUAD	cis	rs9837602	0.882	rs6807176	chr3:99760864	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	8.97	0.4	9.69e-18	Breast cancer;
LUAD	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.66	-10.84	-0.47	2.59e-24	Height;
LUAD	cis	rs8192282	0.739	rs10752642	chr1:154481624	C/T	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.35	-0.34	1.05e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg05042697	chr2:10830656	NOL10	-0.39	-6.8	-0.31	3.61e-11	Prostate cancer;
LUAD	cis	rs1788820	0.917	rs1788825	chr18:21109250	T/C	cg14672496	chr18:21087552	C18orf8	0.34	6.36	0.3	5.1e-10	Body mass index;
LUAD	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	9.47	0.42	1.98e-19	Axial length;
LUAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03452623	chr4:187889614	NA	-0.82	-17.59	-0.65	2.28e-52	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.58	11.01	0.47	5.78e-25	Hemoglobin concentration;
LUAD	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-13.5	-0.55	8.3e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg18016565	chr1:150552671	MCL1	0.42	7.83	0.36	3.99e-14	Melanoma;
LUAD	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg11344533	chr11:111475393	SIK2	-0.36	-6.67	-0.31	7.9e-11	Primary sclerosing cholangitis;
LUAD	trans	rs877282	0.853	rs12777155	chr10:754731	G/C	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	cis	rs494562	0.892	rs7750970	chr6:86128570	A/T	cg17966619	chr6:86160162	NT5E	0.67	7.9	0.36	2.36e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg00106254	chr7:1943704	MAD1L1	-0.55	-7.95	-0.36	1.69e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs926938	0.520	rs6663115	chr1:115272254	G/A	cg12756093	chr1:115239321	AMPD1	-0.4	-6.47	-0.3	2.68e-10	Autism;
LUAD	cis	rs6906287	0.647	rs12203006	chr6:118917086	C/T	cg18833306	chr6:118973337	C6orf204	0.47	8.27	0.37	1.82e-15	Electrocardiographic conduction measures;
LUAD	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg11344533	chr11:111475393	SIK2	-0.36	-6.69	-0.31	7.26e-11	Primary sclerosing cholangitis;
LUAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg06453172	chr10:134556979	INPP5A	-0.77	-10.93	-0.47	1.16e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg21475434	chr5:93447410	FAM172A	-0.48	-6.49	-0.3	2.46e-10	Diabetic retinopathy;
LUAD	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg01851573	chr8:8652454	MFHAS1	-0.44	-8.26	-0.37	1.9e-15	Mood instability;
LUAD	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg08859206	chr1:53392774	SCP2	0.59	10.45	0.45	6.72e-23	Monocyte count;
LUAD	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg26384229	chr12:38710491	ALG10B	0.44	6.8	0.31	3.64e-11	Heart rate;
LUAD	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08704250	chr15:31115839	NA	0.68	12.72	0.53	1.33e-31	Huntington's disease progression;
LUAD	cis	rs7851660	0.594	rs28703314	chr9:100660145	A/T	cg13688889	chr9:100608707	NA	-0.55	-9.27	-0.41	9.41e-19	Strep throat;
LUAD	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg14343924	chr8:8086146	FLJ10661	-0.51	-8.31	-0.37	1.31e-15	Mood instability;
LUAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg13560548	chr3:10150139	C3orf24	0.39	6.47	0.3	2.71e-10	Alzheimer's disease;
LUAD	cis	rs12410462	0.502	rs75429875	chr1:227957200	A/C	cg23173402	chr1:227635558	NA	0.66	6.41	0.3	3.8e-10	Major depressive disorder;
LUAD	cis	rs1595825	0.891	rs80178661	chr2:198582442	A/G	cg00982548	chr2:198649783	BOLL	-0.62	-9.12	-0.41	3e-18	Ulcerative colitis;
LUAD	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg11344533	chr11:111475393	SIK2	-0.35	-6.6	-0.31	1.23e-10	Primary sclerosing cholangitis;
LUAD	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg11707310	chr1:2537719	MMEL1	0.38	7.91	0.36	2.33e-14	Ulcerative colitis;
LUAD	cis	rs501916	0.634	rs8037600	chr15:48060331	A/G	cg16110827	chr15:48056943	SEMA6D	-0.35	-6.43	-0.3	3.41e-10	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg13319975	chr6:146136371	FBXO30	-0.55	-9.27	-0.41	9.28e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs62458065	0.713	rs1597560	chr7:32493886	C/G	cg20159608	chr7:32802032	NA	-0.56	-7.99	-0.36	1.25e-14	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs733592	0.507	rs7138917	chr12:48455255	G/A	cg24011408	chr12:48396354	COL2A1	-0.42	-9.25	-0.41	1.09e-18	Plateletcrit;
LUAD	cis	rs35883536	0.900	rs7520474	chr1:101091376	T/C	cg06223162	chr1:101003688	GPR88	-0.36	-6.68	-0.31	7.33e-11	Monocyte count;
LUAD	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21582582	chr3:182698605	DCUN1D1	0.72	14.09	0.57	3.19e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg04034577	chr2:241836375	C2orf54	-0.49	-10.87	-0.47	1.98e-24	Urinary metabolites;
LUAD	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg07636037	chr3:49044803	WDR6	-0.53	-10.25	-0.45	3.75e-22	Menarche (age at onset);
LUAD	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg11833968	chr6:79620685	NA	-0.44	-8.15	-0.37	4.07e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg12011299	chr4:100065546	ADH4	-0.8	-19.68	-0.69	1.05e-61	Alcohol dependence;
LUAD	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg26168224	chr5:2018326	NA	-0.61	-10.47	-0.45	5.6e-23	Gut microbiome composition (winter);
LUAD	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg12573674	chr2:1569213	NA	-0.58	-6.56	-0.3	1.57e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg14791747	chr16:20752902	THUMPD1	0.9	16.02	0.61	1.82e-45	Cognitive test performance;
LUAD	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10802521	chr3:52805072	NEK4	-0.53	-9.02	-0.4	6.58e-18	Bipolar disorder;
LUAD	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23583168	chr7:148888333	NA	-0.88	-17.72	-0.65	5.81e-53	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9929218	0.559	rs11642362	chr16:68811307	T/C	cg01251360	chr16:68772225	CDH1	-0.26	-8.03	-0.36	9.77e-15	Colorectal cancer;
LUAD	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg00750074	chr16:89608354	SPG7	-0.54	-9.1	-0.4	3.65e-18	Multiple myeloma (IgH translocation);
LUAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg26818010	chr10:134567672	INPP5A	-0.96	-15.8	-0.61	1.63e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10129255	0.536	rs17113249	chr14:107134290	A/G	cg07958169	chr14:107095056	NA	-0.35	-7.04	-0.32	8.01e-12	Kawasaki disease;
LUAD	cis	rs1475911	0.947	rs67055914	chr21:43510427	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.58	-8.9	-0.4	1.6e-17	IgG glycosylation;
LUAD	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg00484396	chr16:3507460	NAT15	0.74	13.66	0.55	1.96e-35	Tuberculosis;
LUAD	cis	rs7737355	0.947	rs3776005	chr5:130879003	T/C	cg06307176	chr5:131281290	NA	0.49	7.86	0.36	3.33e-14	Life satisfaction;
LUAD	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg17063962	chr7:91808500	NA	0.64	10.65	0.46	1.26e-23	Breast cancer;
LUAD	cis	rs9486719	1.000	rs2472882	chr6:96863474	C/T	cg06623918	chr6:96969491	KIAA0776	0.71	9.96	0.44	3.8e-21	Migraine;Coronary artery disease;
LUAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg16606324	chr3:10149918	C3orf24	0.65	10.77	0.46	4.51e-24	Alzheimer's disease;
LUAD	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg20380214	chr12:9217688	LOC144571	0.34	6.49	0.3	2.45e-10	Sjögren's syndrome;
LUAD	cis	rs17152411	0.843	rs7896051	chr10:126583119	T/C	cg07906193	chr10:126599966	NA	0.53	7.49	0.34	4.12e-13	Height;
LUAD	cis	rs2235649	0.592	rs2429186	chr16:1969939	C/T	cg08610935	chr16:1836813	NUBP2	-0.52	-7.8	-0.35	4.83e-14	Blood metabolite levels;
LUAD	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg07423050	chr13:99094983	FARP1	-0.86	-18.36	-0.67	8.98e-56	Neuroticism;
LUAD	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2806561	0.929	rs6660880	chr1:23540302	T/C	cg19743168	chr1:23544995	NA	-0.45	-8.3	-0.37	1.4e-15	Height;
LUAD	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7633770	0.769	rs3796371	chr3:46667224	C/T	cg11219411	chr3:46661640	NA	0.63	14.46	0.58	8.68e-39	Coronary artery disease;
LUAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg11965913	chr1:205819406	PM20D1	0.63	11.73	0.5	1.06e-27	Menarche (age at onset);
LUAD	cis	rs62229266	0.804	rs880221	chr21:37420785	C/T	cg08632701	chr21:37451849	NA	-0.44	-7.27	-0.33	1.8e-12	Mitral valve prolapse;
LUAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg19626725	chr5:178986131	RUFY1	0.43	7.85	0.36	3.42e-14	Lung cancer;
LUAD	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg17644776	chr2:200775616	C2orf69	0.55	7.32	0.34	1.3e-12	Schizophrenia;
LUAD	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg12756686	chr19:29218302	NA	0.52	6.71	0.31	6.31e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg22906224	chr7:99728672	NA	0.64	10.95	0.47	9.82e-25	Coronary artery disease;
LUAD	cis	rs2688608	1.000	rs2688608	chr10:75658349	G/T	cg23231163	chr10:75533350	FUT11	-0.38	-7.0	-0.32	1.03e-11	Inflammatory bowel disease;
LUAD	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg06618935	chr21:46677482	NA	-0.47	-9.68	-0.43	3.68e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.83	-0.5	4.14e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs231513	0.906	rs11653808	chr17:42005366	A/T	cg26893861	chr17:41843967	DUSP3	0.6	6.59	0.31	1.32e-10	Cognitive function;
LUAD	cis	rs6430585	0.702	rs1042712	chr2:136545844	C/G	cg07169764	chr2:136633963	MCM6	-0.73	-8.76	-0.39	4.76e-17	Corneal structure;
LUAD	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg00530320	chr1:46809349	NSUN4	0.52	8.13	0.37	4.66e-15	Menopause (age at onset);
LUAD	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg07741184	chr6:167504864	NA	0.3	7.27	0.33	1.79e-12	Crohn's disease;
LUAD	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg03859395	chr2:55845619	SMEK2	0.75	13.91	0.56	1.8e-36	Metabolic syndrome;
LUAD	cis	rs7000551	0.556	rs35359294	chr8:22249755	G/A	cg12081754	chr8:22256438	SLC39A14	0.89	14.91	0.59	1.01e-40	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg21823605	chr1:152486609	CRCT1	0.28	6.59	0.31	1.3e-10	Hair morphology;
LUAD	trans	rs10838798	0.584	rs17198859	chr11:48140354	C/A	cg21153622	chr11:89784906	NA	-0.35	-6.9	-0.32	1.89e-11	Height;
LUAD	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg22875332	chr1:76189707	ACADM	0.86	15.92	0.61	4.96e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg26446827	chr20:18268978	ZNF133	-0.47	-6.58	-0.3	1.4e-10	Testicular germ cell tumor;
LUAD	cis	rs17095355	0.818	rs12573187	chr10:111856077	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.69	-0.31	6.95e-11	Biliary atresia;
LUAD	cis	rs10129255	0.500	rs2027903	chr14:107215283	A/C	cg23076370	chr14:107095027	NA	-0.45	-9.0	-0.4	7.53e-18	Kawasaki disease;
LUAD	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-8.76	-0.39	4.61e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7943203	1.000	rs10431061	chr11:108288808	G/T	cg04873221	chr11:107992290	ACAT1	-0.43	-6.98	-0.32	1.12e-11	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg02734326	chr4:10020555	SLC2A9	0.53	8.97	0.4	9.89e-18	Bone mineral density;
LUAD	cis	rs7524258	1.000	rs7524258	chr1:7292229	T/C	cg07173049	chr1:7289937	CAMTA1	0.38	6.96	0.32	1.29e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06028808	chr11:68637592	NA	0.45	7.5	0.34	3.89e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11958404	0.860	rs7730844	chr5:157461208	C/T	cg05962755	chr5:157440814	NA	0.66	9.15	0.41	2.39e-18	IgG glycosylation;
LUAD	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg08632164	chr7:65971372	NA	-0.37	-6.46	-0.3	2.83e-10	Aortic root size;
LUAD	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg03676636	chr4:99064102	C4orf37	0.32	8.34	0.38	1.06e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7149242	0.662	rs4905998	chr14:101181781	A/G	cg10189261	chr14:101176105	NA	0.39	7.34	0.34	1.11e-12	Platelet count;
LUAD	cis	rs807669	0.548	rs5746685	chr22:19192596	C/G	cg24911827	chr22:19170109	CLTCL1	-0.32	-6.54	-0.3	1.75e-10	Metabolite levels;
LUAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg13560548	chr3:10150139	C3orf24	0.45	6.61	0.31	1.19e-10	Alzheimer's disease;
LUAD	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg11663144	chr21:46675770	NA	-0.57	-11.28	-0.48	5.59e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg04731861	chr2:219085781	ARPC2	-0.24	-7.51	-0.34	3.45e-13	Colorectal cancer;
LUAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.7	-14.63	-0.58	1.62e-39	Longevity;Endometriosis;
LUAD	cis	rs4889911	0.544	rs2587498	chr17:77830737	G/A	cg02876276	chr17:77834299	NA	0.49	7.72	0.35	8.29e-14	Electroencephalogram traits;
LUAD	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg09365446	chr1:150670422	GOLPH3L	0.63	11.72	0.49	1.19e-27	Tonsillectomy;
LUAD	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg07741184	chr6:167504864	NA	0.34	7.8	0.35	4.78e-14	Crohn's disease;
LUAD	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg16325326	chr1:53192061	ZYG11B	0.5	8.58	0.39	1.82e-16	Monocyte count;
LUAD	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg00071950	chr4:10020882	SLC2A9	0.86	18.37	0.67	7.73e-56	Bone mineral density;
LUAD	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg17849569	chr6:28058911	ZSCAN12L1	0.31	6.61	0.31	1.13e-10	Depression;
LUAD	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg11663144	chr21:46675770	NA	-0.59	-11.66	-0.49	1.96e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10979	1.000	rs9390104	chr6:143890978	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-10.14	-0.44	8.91e-22	Hypospadias;
LUAD	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.59	10.29	0.45	2.64e-22	Eosinophil percentage of white cells;
LUAD	cis	rs926938	0.520	rs2007231	chr1:115266306	C/T	cg12756093	chr1:115239321	AMPD1	-0.4	-6.61	-0.31	1.15e-10	Autism;
LUAD	cis	rs2046867	0.774	rs62249873	chr3:72907115	G/A	cg25664220	chr3:72788482	NA	-0.59	-9.89	-0.43	7.21e-21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.39	-0.34	7.96e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00149659	chr3:10157352	C3orf10	0.63	8.82	0.39	2.97e-17	Alzheimer's disease;
LUAD	cis	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg08601574	chr20:25228251	PYGB	-0.44	-8.07	-0.37	7.53e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2625529	0.824	rs12899485	chr15:72143215	A/G	cg16672083	chr15:72433130	SENP8	0.78	12.96	0.53	1.35e-32	Red blood cell count;
LUAD	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg12444411	chr7:2802554	GNA12	-0.36	-6.5	-0.3	2.3e-10	Height;
LUAD	cis	rs61774743	0.754	rs11578963	chr1:41834183	A/G	cg08462924	chr1:41848221	NA	-0.4	-6.98	-0.32	1.18e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg05434287	chr7:2030229	MAD1L1	0.41	6.63	0.31	1.01e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9469890	0.604	rs7754038	chr6:34505194	T/G	cg17674042	chr6:34482479	PACSIN1	-0.52	-6.94	-0.32	1.49e-11	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg00982548	chr2:198649783	BOLL	0.64	9.23	0.41	1.26e-18	Ulcerative colitis;
LUAD	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.1	-0.51	3.76e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12049351	0.774	rs6673421	chr1:229636388	A/G	cg11742688	chr1:229674241	ABCB10	-0.42	-6.96	-0.32	1.27e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg16606324	chr3:10149918	C3orf24	0.7	11.51	0.49	7.19e-27	Alzheimer's disease;
LUAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg27454412	chr7:1067447	C7orf50	0.48	7.7	0.35	9.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs59698941	0.882	rs68171951	chr5:132290711	T/C	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25631650	chr19:633157	POLRMT	-0.4	-6.39	-0.3	4.48e-10	Height;
LUAD	cis	rs494562	0.892	rs544408	chr6:86119110	A/T	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg13319975	chr6:146136371	FBXO30	0.57	9.43	0.42	2.73e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg12034118	chr1:209979487	IRF6	0.58	6.46	0.3	2.92e-10	Coronary artery disease;
LUAD	trans	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	11.04	0.47	4.69e-25	Mean corpuscular volume;
LUAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg13560548	chr3:10150139	C3orf24	0.41	6.74	0.31	5.13e-11	Alzheimer's disease;
LUAD	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg05082376	chr22:42548792	NA	-0.37	-6.5	-0.3	2.26e-10	Cognitive function;
LUAD	cis	rs11249608	0.548	rs6880315	chr5:178452502	G/A	cg01312482	chr5:178451176	ZNF879	-0.43	-6.64	-0.31	9.38e-11	Pubertal anthropometrics;
LUAD	cis	rs4372836	0.930	rs4233727	chr2:28977244	T/C	cg09522027	chr2:28974177	PPP1CB	-0.58	-9.15	-0.41	2.49e-18	Body mass index;
LUAD	cis	rs4774899	0.752	rs2703576	chr15:57355156	A/G	cg14026238	chr15:57616123	NA	0.42	7.96	0.36	1.6e-14	Urinary tract infection frequency;
LUAD	cis	rs7614311	0.639	rs73119035	chr3:63993966	A/G	cg22134162	chr3:63841271	THOC7	-0.48	-7.44	-0.34	5.53e-13	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs2997447	0.723	rs2259849	chr1:26474251	A/T	cg00147160	chr1:26503991	CNKSR1	0.34	6.38	0.3	4.53e-10	QRS complex (12-leadsum);
LUAD	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg00530320	chr1:46809349	NSUN4	0.53	8.23	0.37	2.33e-15	Menopause (age at onset);
LUAD	trans	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg07211511	chr3:129823064	LOC729375	-0.51	-7.34	-0.34	1.14e-12	Blood pressure (smoking interaction);
LUAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg20607798	chr8:58055168	NA	0.72	9.44	0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2880765	0.743	rs8028240	chr15:86013248	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.37	-0.3	4.84e-10	Coronary artery disease;
LUAD	cis	rs4845570	0.920	rs1196456	chr1:151737349	T/A	cg07092448	chr1:151763213	TDRKH	0.68	8.99	0.4	8.42e-18	Coronary artery disease;
LUAD	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg11235426	chr6:292522	DUSP22	-0.57	-9.3	-0.41	7.34e-19	Menopause (age at onset);
LUAD	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.45	0.34	5.35e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg00020340	chr7:910388	UNC84A	0.63	6.68	0.31	7.5e-11	Initial pursuit acceleration;
LUAD	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.8	-10.16	-0.44	7.58e-22	Body mass index;
LUAD	cis	rs7786808	0.530	rs7780796	chr7:158183330	C/T	cg09998033	chr7:158218633	PTPRN2	0.45	7.88	0.36	2.76e-14	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.56	0.3	1.61e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg10518543	chr12:38710700	ALG10B	0.41	6.38	0.3	4.59e-10	Bladder cancer;
LUAD	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg17366294	chr4:99064904	C4orf37	0.66	12.74	0.53	1.07e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg25828334	chr19:18545568	ISYNA1	-0.35	-7.18	-0.33	3.11e-12	Breast cancer;
LUAD	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg21775007	chr8:11205619	TDH	-0.5	-8.95	-0.4	1.12e-17	Neuroticism;
LUAD	trans	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg19862616	chr7:65841803	NCRNA00174	1.06	27.22	0.8	5.29e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21607453	chr9:98783545	NCRNA00092	-0.38	-6.47	-0.3	2.72e-10	Height;
LUAD	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg03874509	chr1:107600012	PRMT6	0.52	9.13	0.41	2.9e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs75920871	0.925	rs76523703	chr11:116749509	T/G	cg04087571	chr11:116723030	SIK3	-0.34	-6.86	-0.32	2.53e-11	Subjective well-being;
LUAD	cis	rs240764	0.853	rs2062634	chr6:101002618	G/C	cg09795085	chr6:101329169	ASCC3	-0.42	-7.03	-0.32	8.47e-12	Neuroticism;
LUAD	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg08132940	chr7:1081526	C7orf50	-0.74	-7.52	-0.34	3.36e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg02176678	chr2:219576539	TTLL4	0.75	15.49	0.6	3.6e-43	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs73206853	0.764	rs56205958	chr12:111027361	G/C	cg12870014	chr12:110450643	ANKRD13A	0.62	6.79	0.31	3.92e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg05368731	chr17:41323189	NBR1	0.95	19.41	0.69	1.72e-60	Menopause (age at onset);
LUAD	trans	rs75804782	0.641	rs72985387	chr2:239336589	G/A	cg01134436	chr17:81009848	B3GNTL1	0.75	8.31	0.37	1.3e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg20135002	chr11:47629003	NA	-0.36	-6.43	-0.3	3.53e-10	Subjective well-being;
LUAD	cis	rs847851	1.000	rs4646949	chr6:34845449	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.3	-6.95	-0.32	1.41e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7680126	0.633	rs2024280	chr4:10291813	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-7.46	-0.34	5.1e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg18944383	chr4:111397179	ENPEP	0.37	7.39	0.34	7.95e-13	Height;
LUAD	trans	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.49	0.52	1.12e-30	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03125394	chr5:102091191	NA	-0.44	-6.73	-0.31	5.47e-11	Height;
LUAD	cis	rs13088645	0.652	rs13074557	chr3:134153526	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.47	7.42	0.34	6.64e-13	Coronary artery disease;
LUAD	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg05616858	chr17:37843591	ERBB2;PGAP3	0.32	6.56	0.3	1.6e-10	Asthma;
LUAD	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg05368731	chr17:41323189	NBR1	0.86	17.3	0.64	4.07e-51	Menopause (age at onset);
LUAD	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.54	-0.38	2.48e-16	Neutrophil percentage of white cells;
LUAD	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg18721089	chr20:30220636	NA	-0.48	-6.98	-0.32	1.13e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs1595825	0.945	rs2139050	chr2:198852636	A/G	cg00982548	chr2:198649783	BOLL	-0.64	-9.07	-0.4	4.57e-18	Ulcerative colitis;
LUAD	trans	rs2262909	0.849	rs2666447	chr19:22132868	T/A	cg05197062	chr11:11642011	GALNTL4	-0.54	-8.23	-0.37	2.28e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	12.47	0.52	1.27e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2625529	0.586	rs59975112	chr15:72423710	G/T	cg16672083	chr15:72433130	SENP8	0.63	11.93	0.5	1.72e-28	Red blood cell count;
LUAD	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg09491104	chr22:46646882	C22orf40	-0.57	-11.24	-0.48	7.96e-26	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.67	-11.19	-0.48	1.19e-25	Primary sclerosing cholangitis;
LUAD	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-10.97	-0.47	8.16e-25	Hemoglobin concentration;
LUAD	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg03467027	chr4:99064603	C4orf37	0.4	6.43	0.3	3.45e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg04369109	chr6:150039330	LATS1	-0.44	-7.51	-0.34	3.44e-13	Lung cancer;
LUAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg23131131	chr22:24373011	LOC391322	-0.49	-8.08	-0.37	6.7e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.39	0.55	2.41e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.65	-0.31	8.9e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7336332	0.598	rs75439483	chr13:28010512	A/G	cg22138327	chr13:27999177	GTF3A	0.77	10.1	0.44	1.22e-21	Weight;
LUAD	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg12444411	chr7:2802554	GNA12	-0.35	-6.43	-0.3	3.45e-10	Height;
LUAD	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg03806693	chr22:41940476	POLR3H	-0.43	-6.55	-0.3	1.69e-10	Neuroticism;
LUAD	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg11148817	chr5:312970	AHRR;PDCD6	-0.47	-6.44	-0.3	3.23e-10	Breast cancer;
LUAD	cis	rs4372836	0.504	rs7601413	chr2:29032238	C/T	cg09522027	chr2:28974177	PPP1CB	-0.61	-10.6	-0.46	2.01e-23	Body mass index;
LUAD	cis	rs7707921	0.767	rs226202	chr5:81571669	C/T	cg15871215	chr5:81402204	ATG10	0.66	10.46	0.45	6.42e-23	Breast cancer;
LUAD	cis	rs250677	0.522	rs10477400	chr5:148359598	T/C	cg18129178	chr5:148520854	ABLIM3	0.47	6.82	0.31	3.23e-11	Breast cancer;
LUAD	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.38	6.56	0.3	1.57e-10	Blood metabolite levels;
LUAD	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.71e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1298062	0.563	rs2445828	chr19:50941807	A/G	cg11430371	chr19:50961752	MYBPC2	0.37	7.57	0.35	2.37e-13	Age of smoking initiation;
LUAD	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg19761014	chr17:28927070	LRRC37B2	0.86	8.32	0.38	1.22e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs829883	0.639	rs829898	chr12:98857675	A/C	cg25150519	chr12:98850993	NA	0.75	14.01	0.56	6.58e-37	Colorectal adenoma (advanced);
LUAD	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg25358565	chr5:93447407	FAM172A	0.6	7.02	0.32	9.01e-12	Diabetic retinopathy;
LUAD	cis	rs11756438	0.546	rs9489497	chr6:118999636	T/C	cg21191810	chr6:118973309	C6orf204	0.5	9.59	0.42	7.66e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs986417	0.748	rs10142927	chr14:61041956	A/G	cg27398547	chr14:60952738	C14orf39	0.52	6.64	0.31	9.65e-11	Gut microbiota (bacterial taxa);
LUAD	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg04287289	chr16:89883240	FANCA	-0.69	-12.81	-0.53	5.78e-32	Vitiligo;
LUAD	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.19	-0.33	3.02e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg06064525	chr11:970664	AP2A2	-0.55	-11.26	-0.48	6.74e-26	Alzheimer's disease (late onset);
LUAD	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.64	-10.04	-0.44	1.97e-21	Lymphocyte percentage of white cells;
LUAD	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26314531	chr2:26401878	FAM59B	0.63	8.41	0.38	6.51e-16	Gut microbiome composition (summer);
LUAD	cis	rs2637266	0.935	rs2579727	chr10:78395497	A/C	cg18941641	chr10:78392320	NA	0.34	7.1	0.33	5.37e-12	Pulmonary function;
LUAD	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg14008862	chr17:28927542	LRRC37B2	0.63	6.68	0.31	7.52e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9788682	0.747	rs12101809	chr15:78779801	C/T	cg18825076	chr15:78729989	IREB2	0.53	7.42	0.34	6.65e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.45	-0.34	5.31e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg01475377	chr6:109611718	NA	-0.53	-10.01	-0.44	2.69e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs1232027	0.632	rs1650718	chr5:79930276	G/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg07757535	chr4:1339547	NA	0.33	6.42	0.3	3.74e-10	Longevity;
LUAD	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg26384229	chr12:38710491	ALG10B	0.39	6.74	0.31	5.32e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg07936489	chr17:37558343	FBXL20	0.49	6.41	0.3	3.81e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg23544223	chr18:12777786	NA	0.67	8.51	0.38	3e-16	Inflammatory skin disease;
LUAD	cis	rs4372836	0.894	rs55877710	chr2:28929308	C/T	cg09522027	chr2:28974177	PPP1CB	0.61	9.06	0.4	4.86e-18	Body mass index;
LUAD	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg04731861	chr2:219085781	ARPC2	0.27	8.31	0.37	1.36e-15	Colorectal cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05989775	chr11:2906934	CDKN1C	-0.55	-6.6	-0.31	1.23e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg23625390	chr15:77176239	SCAPER	0.37	6.62	0.31	1.12e-10	Blood metabolite levels;
LUAD	cis	rs1509123	0.609	rs12103645	chr17:6721216	A/G	cg12642237	chr17:6703447	TEKT1	0.43	6.63	0.31	9.96e-11	Blood metabolite levels;
LUAD	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg07636037	chr3:49044803	WDR6	0.64	12.54	0.52	7.08e-31	Parkinson's disease;
LUAD	cis	rs4072705	0.562	rs7855918	chr9:127239939	T/C	cg01786973	chr9:127249749	NR5A1	0.3	6.68	0.31	7.72e-11	Menarche (age at onset);
LUAD	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.82	-0.36	4.14e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg25809561	chr17:30822961	MYO1D	0.74	15.36	0.6	1.24e-42	Schizophrenia;
LUAD	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg12310025	chr6:25882481	NA	-0.55	-8.02	-0.36	1.01e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg04450456	chr4:17643702	FAM184B	0.41	8.21	0.37	2.74e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg04455712	chr21:45112962	RRP1B	0.47	9.25	0.41	1.1e-18	Mean corpuscular volume;
LUAD	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg02574844	chr11:5959923	NA	-0.43	-8.3	-0.37	1.4e-15	DNA methylation (variation);
LUAD	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.68e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg24503407	chr1:205819492	PM20D1	0.49	7.87	0.36	2.95e-14	Parkinson's disease;
LUAD	cis	rs4253772	0.626	rs113658408	chr22:46646019	C/G	cg09491104	chr22:46646882	C22orf40	-0.66	-8.77	-0.39	4.41e-17	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs3960554	0.867	rs76408713	chr7:75829540	G/A	cg19862616	chr7:65841803	NCRNA00174	0.82	10.8	0.46	3.67e-24	Eotaxin levels;
LUAD	cis	rs2625529	0.627	rs1037680	chr15:72514319	T/C	cg16672083	chr15:72433130	SENP8	-0.76	-13.01	-0.53	9.08e-33	Red blood cell count;
LUAD	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg10876282	chr6:28092338	ZSCAN16	0.43	6.65	0.31	9.32e-11	Cardiac Troponin-T levels;
LUAD	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg05283184	chr6:79620031	NA	-0.62	-12.47	-0.52	1.34e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs2274273	0.638	rs3759667	chr14:55658421	A/G	cg04306507	chr14:55594613	LGALS3	0.41	7.63	0.35	1.53e-13	Protein biomarker;
LUAD	cis	rs68170813	0.559	rs4730226	chr7:106887274	A/C	cg02696742	chr7:106810147	HBP1	-0.78	-10.8	-0.46	3.69e-24	Coronary artery disease;
LUAD	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg23533926	chr12:111358616	MYL2	0.42	7.03	0.32	8.33e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4372836	0.729	rs11684695	chr2:29088450	G/T	cg09522027	chr2:28974177	PPP1CB	0.66	11.61	0.49	3.08e-27	Body mass index;
LUAD	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	cis	rs2072438	0.505	rs7034074	chr9:123923029	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.38	6.54	0.3	1.76e-10	Rheumatoid arthritis;
LUAD	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.6	9.32	0.41	6.56e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs8063160	0.533	rs58656226	chr16:89745091	T/G	cg07984980	chr16:89898383	SPIRE2	0.82	8.86	0.4	2.22e-17	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01939664	chr1:33722135	ZNF362	-0.55	-6.67	-0.31	7.92e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg05342682	chr7:94953680	PON1	-0.48	-6.49	-0.3	2.46e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1018836	0.608	rs6982329	chr8:91467488	A/G	cg16814680	chr8:91681699	NA	-0.54	-8.89	-0.4	1.73e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg21194808	chr1:2205498	SKI	0.42	6.64	0.31	9.43e-11	Height;
LUAD	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg24562669	chr7:97807699	LMTK2	0.32	7.45	0.34	5.41e-13	Breast cancer;
LUAD	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg04287289	chr16:89883240	FANCA	-0.49	-7.98	-0.36	1.43e-14	Vitiligo;
LUAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg08027265	chr7:2291960	NA	-0.4	-6.46	-0.3	2.82e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7512552	0.839	rs17597088	chr1:150475772	A/G	cg15654264	chr1:150340011	RPRD2	0.58	11.1	0.47	2.69e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4253772	0.626	rs12169526	chr22:46763846	C/T	cg00784671	chr22:46762841	CELSR1	-0.64	-7.4	-0.34	7.37e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg26924012	chr15:45694286	SPATA5L1	1.02	19.16	0.68	2.32e-59	Homoarginine levels;
LUAD	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg08508325	chr11:3079039	CARS	0.42	8.63	0.39	1.26e-16	Calcium levels;
LUAD	cis	rs4786125	0.769	rs4129042	chr16:6901398	G/T	cg03623568	chr16:6915990	A2BP1	0.37	8.11	0.37	5.43e-15	Heart rate variability traits (SDNN);
LUAD	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg25358565	chr5:93447407	FAM172A	0.65	7.69	0.35	1.07e-13	Diabetic retinopathy;
LUAD	cis	rs10193935	1.000	rs13419669	chr2:42387254	T/C	cg27598129	chr2:42591480	NA	-0.69	-9.04	-0.4	5.85e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg22676075	chr6:135203613	NA	0.41	7.66	0.35	1.26e-13	Red blood cell count;
LUAD	cis	rs3785574	0.650	rs2005132	chr17:62008232	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-8.5	-0.38	3.19e-16	Height;
LUAD	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg21385522	chr1:16154831	NA	0.88	14.56	0.58	3.14e-39	Dilated cardiomyopathy;
LUAD	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg03467027	chr4:99064603	C4orf37	0.42	6.48	0.3	2.5e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg17177755	chr1:15930204	NA	0.43	6.94	0.32	1.47e-11	Systolic blood pressure;
LUAD	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg06784218	chr1:46089804	CCDC17	0.52	11.44	0.49	1.42e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg27661571	chr11:113659931	NA	-0.7	-8.14	-0.37	4.58e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg11416102	chr8:651193	ERICH1	0.95	9.06	0.4	4.77e-18	IgG glycosylation;
LUAD	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.67	0.39	9.53e-17	Parkinson's disease;
LUAD	cis	rs17092148	1.000	rs62211612	chr20:33386156	C/T	cg16810054	chr20:33298113	TP53INP2	0.53	8.34	0.38	1.05e-15	Neuroticism;
LUAD	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.36	7.54	0.34	2.84e-13	Parkinson's disease;
LUAD	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg08125733	chr17:73851984	WBP2	0.57	8.41	0.38	6.47e-16	Psoriasis;
LUAD	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg03433033	chr1:76189801	ACADM	0.72	10.95	0.47	9.75e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs11696501	0.688	rs6130897	chr20:44330004	C/T	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.35	-0.38	1.01e-15	Brain structure;
LUAD	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg00255919	chr5:131827918	IRF1	-0.3	-6.73	-0.31	5.66e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs57590327	0.503	rs6764261	chr3:81620370	T/G	cg07356753	chr3:81810745	GBE1	-0.52	-7.92	-0.36	2.15e-14	Extraversion;
LUAD	cis	rs7527798	0.592	rs2025372	chr1:207829653	T/G	cg09232269	chr1:207846808	CR1L	-0.37	-7.13	-0.33	4.43e-12	Erythrocyte sedimentation rate;
LUAD	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-7.55	-0.34	2.72e-13	Monocyte percentage of white cells;
LUAD	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg23260525	chr10:116636907	FAM160B1	0.47	10.84	0.47	2.48e-24	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg14458575	chr2:238380390	NA	0.82	13.01	0.53	8.54e-33	Prostate cancer;
LUAD	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08045932	chr20:61659980	NA	0.51	9.67	0.43	4.09e-20	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs4925114	0.532	rs11655029	chr17:17649172	T/C	cg09796270	chr17:17721594	SREBF1	-0.37	-7.23	-0.33	2.29e-12	Body mass index;
LUAD	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg13770153	chr20:60521292	NA	-0.59	-9.15	-0.41	2.51e-18	Body mass index;
LUAD	cis	rs240764	0.658	rs2050549	chr6:101216645	A/G	cg09795085	chr6:101329169	ASCC3	-0.42	-7.37	-0.34	9.31e-13	Neuroticism;
LUAD	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg05110241	chr16:68378359	PRMT7	-0.59	-7.49	-0.34	4.02e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg14196790	chr5:131705035	SLC22A5	0.5	8.86	0.4	2.31e-17	Blood metabolite levels;
LUAD	cis	rs11771526	1.000	rs11771526	chr7:32342618	A/G	cg27532318	chr7:32358331	NA	0.71	8.54	0.38	2.48e-16	Body mass index;
LUAD	cis	rs7020830	0.898	rs308523	chr9:37338785	C/T	cg14294708	chr9:37120828	ZCCHC7	0.8	15.47	0.6	4.3e-43	Schizophrenia;
LUAD	cis	rs73195822	0.506	rs61440260	chr12:111142855	G/T	cg12870014	chr12:110450643	ANKRD13A	0.62	7.09	0.33	5.55e-12	Itch intensity from mosquito bite;
LUAD	cis	rs8099014	0.834	rs4940699	chr18:56109007	A/C	cg12907477	chr18:56117327	MIR122	0.39	6.71	0.31	6.24e-11	Platelet count;
LUAD	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg20848291	chr7:100343083	ZAN	-0.58	-7.89	-0.36	2.53e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg25036284	chr2:26402008	FAM59B	-0.6	-8.37	-0.38	8.7e-16	Gut microbiome composition (summer);
LUAD	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg14779329	chr11:130786720	SNX19	0.37	6.49	0.3	2.38e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3125734	0.633	rs1368157	chr10:64001114	T/C	cg09941381	chr10:64027924	RTKN2	-0.3	-7.01	-0.32	9.62e-12	Rheumatoid arthritis;
LUAD	cis	rs751728	1.000	rs943477	chr6:33750931	T/C	cg13859433	chr6:33739653	LEMD2	-0.39	-9.21	-0.41	1.58e-18	Crohn's disease;
LUAD	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.58	0.35	2.14e-13	Tonsillectomy;
LUAD	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.11	-14.52	-0.58	4.61e-39	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg02734326	chr4:10020555	SLC2A9	0.62	10.71	0.46	7.84e-24	Bone mineral density;
LUAD	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg11901034	chr3:128598214	ACAD9	-0.49	-7.63	-0.35	1.52e-13	IgG glycosylation;
LUAD	cis	rs753274	0.650	rs72998945	chr19:14418441	C/A	cg25450033	chr19:14444658	NA	0.4	7.49	0.34	4.1e-13	Tumor necrosis factor beta levels;
LUAD	cis	rs3784262	0.692	rs3784256	chr15:58263046	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.41	-0.34	7.02e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	trans	rs11650494	0.908	rs79768864	chr17:47446968	C/A	cg11430096	chr6:110968061	CDK19	0.89	6.73	0.31	5.69e-11	Prostate cancer;
LUAD	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg14582100	chr15:45693742	SPATA5L1	0.62	12.04	0.51	6.38e-29	Homoarginine levels;
LUAD	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg08798685	chr6:27730294	NA	0.48	7.92	0.36	2.09e-14	Parkinson's disease;
LUAD	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg25173405	chr17:45401733	C17orf57	-0.49	-8.05	-0.36	8.31e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg07256732	chr16:621771	PIGQ	-0.32	-6.49	-0.3	2.47e-10	Height;
LUAD	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.67	-0.35	1.19e-13	Personality dimensions;
LUAD	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.0	-0.32	1.01e-11	Height;
LUAD	cis	rs68170813	0.559	rs3801959	chr7:106955666	A/G	cg23024343	chr7:107201750	COG5	0.5	7.2	0.33	2.84e-12	Coronary artery disease;
LUAD	cis	rs2652822	0.530	rs7165016	chr15:63439590	T/A	cg25406657	chr15:63342033	TPM1	-0.33	-6.44	-0.3	3.27e-10	Metabolic traits;
LUAD	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.45	-0.34	5.22e-13	Bipolar disorder;
LUAD	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.4	-7.16	-0.33	3.51e-12	Tonsillectomy;
LUAD	trans	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.16	0.54	2.23e-33	Exhaled nitric oxide output;
LUAD	cis	rs3087591	0.960	rs9896041	chr17:29571326	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.43	-7.0	-0.32	9.88e-12	Hip circumference;
LUAD	trans	rs11088226	1.000	rs78679088	chr21:33910827	G/A	cg09050820	chr6:167586206	TCP10L2	0.55	7.28	0.33	1.62e-12	Gastritis;
LUAD	cis	rs6494488	0.500	rs72742987	chr15:64993757	T/C	cg08069370	chr15:64387884	SNX1	-0.76	-6.84	-0.32	2.71e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg14008862	chr17:28927542	LRRC37B2	0.75	7.6	0.35	1.94e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg05717871	chr11:638507	DRD4	-0.44	-6.48	-0.3	2.57e-10	Systemic lupus erythematosus;
LUAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.5	-8.99	-0.4	8.19e-18	Lymphocyte counts;
LUAD	cis	rs10193935	0.901	rs10169971	chr2:42602189	G/A	cg27598129	chr2:42591480	NA	-0.78	-9.61	-0.42	6.4e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs853679	0.607	rs13205211	chr6:28203056	T/G	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.13	-0.48	1.99e-25	Depression;
LUAD	cis	rs11771526	0.681	rs117559022	chr7:32405120	C/T	cg13207630	chr7:32358064	NA	0.65	6.71	0.31	6.11e-11	Body mass index;
LUAD	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.61	0.31	1.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.31	-0.45	2.13e-22	Platelet count;
LUAD	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg19875535	chr5:140030758	IK	-0.43	-7.38	-0.34	8.61e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg07393940	chr7:158741817	NA	0.67	11.58	0.49	3.85e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg26373071	chr5:1325741	CLPTM1L	0.37	7.69	0.35	1.07e-13	Lung cancer;
LUAD	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.14	-0.37	4.42e-15	Bipolar disorder;
LUAD	cis	rs6087990	0.842	rs4911253	chr20:31352585	A/G	cg13636640	chr20:31349939	DNMT3B	0.77	14.2	0.57	1.05e-37	Ulcerative colitis;
LUAD	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg23985595	chr17:80112537	CCDC57	0.52	9.43	0.42	2.76e-19	Life satisfaction;
LUAD	cis	rs12472274	0.618	rs12477307	chr2:239110514	G/T	cg17459225	chr2:239074497	NA	0.56	8.04	0.36	9.16e-15	Phospholipid levels (plasma);
LUAD	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg05340658	chr4:99064831	C4orf37	-0.48	-8.06	-0.36	8.1e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	12.62	0.52	3.3e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg12193833	chr17:30244370	NA	-0.47	-6.35	-0.3	5.54e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs986417	1.000	rs1254324	chr14:60908551	C/T	cg27398547	chr14:60952738	C14orf39	-0.62	-7.69	-0.35	1.07e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg09365446	chr1:150670422	GOLPH3L	0.6	11.44	0.49	1.38e-26	Tonsillectomy;
LUAD	cis	rs17152411	1.000	rs7082846	chr10:126593310	C/A	cg07906193	chr10:126599966	NA	0.53	7.6	0.35	1.95e-13	Height;
LUAD	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg21427119	chr20:30132790	HM13	-0.62	-9.29	-0.41	8.03e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg05368731	chr17:41323189	NBR1	0.84	17.02	0.64	7.47e-50	Menopause (age at onset);
LUAD	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg04450456	chr4:17643702	FAM184B	0.4	8.01	0.36	1.15e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2932538	0.883	rs7549547	chr1:113086717	A/T	cg22162597	chr1:113214053	CAPZA1	0.46	6.96	0.32	1.28e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg07677032	chr17:61819896	STRADA	0.56	10.3	0.45	2.48e-22	Prudent dietary pattern;
LUAD	cis	rs7481584	1.000	rs12789474	chr11:3024139	T/G	cg11201177	chr11:2961805	NA	0.39	6.61	0.31	1.15e-10	Calcium levels;
LUAD	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg15691649	chr6:25882328	NA	-0.44	-7.04	-0.32	7.83e-12	Blood metabolite levels;
LUAD	cis	rs7465272	1.000	rs7017842	chr8:143685116	G/A	cg10104451	chr8:143696006	ARC	-0.58	-7.88	-0.36	2.75e-14	Bipolar disorder and schizophrenia;
LUAD	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21582582	chr3:182698605	DCUN1D1	0.6	10.38	0.45	1.19e-22	Intelligence (multi-trait analysis);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26851410	chr19:2785307	THOP1	0.43	6.74	0.31	5.35e-11	Gut microbiome composition (summer);
LUAD	cis	rs6743376	0.556	rs2515396	chr2:113819175	G/A	cg09040174	chr2:113837401	NA	0.5	7.7	0.35	9.54e-14	Inflammatory biomarkers;
LUAD	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.19	-0.41	1.81e-18	Bipolar disorder;
LUAD	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.4	0.45	1.01e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg03563238	chr19:33554763	RHPN2	-0.39	-9.12	-0.41	3.17e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs738322	0.555	rs5750549	chr22:38547172	C/T	cg17652424	chr22:38574118	PLA2G6	-0.28	-7.41	-0.34	6.81e-13	Cutaneous nevi;
LUAD	cis	rs7582720	1.000	rs72934704	chr2:203706433	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.39	0.42	3.83e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg11766577	chr21:47581405	C21orf56	-0.53	-9.34	-0.41	5.53e-19	Testicular germ cell tumor;
LUAD	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.42	0.34	6.43e-13	Bipolar disorder;
LUAD	trans	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg26043149	chr18:55253948	FECH	0.49	8.03	0.36	9.84e-15	Bone mineral density;
LUAD	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg11189052	chr15:85197271	WDR73	-0.6	-9.97	-0.44	3.69e-21	P wave terminal force;
LUAD	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Depression;
LUAD	trans	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg26811252	chr16:29126840	RRN3P2	0.6	10.2	0.44	5.32e-22	Menopause (age at onset);
LUAD	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.66	-12.37	-0.52	3.4e-30	Tonsillectomy;
LUAD	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg26408565	chr15:76604113	ETFA	-0.43	-6.92	-0.32	1.66e-11	Blood metabolite levels;
LUAD	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg25237894	chr2:233734115	C2orf82	0.52	9.89	0.43	7.1e-21	Coronary artery disease;
LUAD	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg21782813	chr7:2030301	MAD1L1	0.46	7.81	0.35	4.7e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.92	-0.36	2.14e-14	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00373665	chr1:234735703	NA	-0.43	-6.61	-0.31	1.17e-10	Height;
LUAD	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg12564285	chr5:131593104	PDLIM4	-0.39	-6.66	-0.31	8.41e-11	Breast cancer;
LUAD	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.67	-0.31	8.07e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg08999081	chr20:33150536	PIGU	0.63	14.12	0.57	2.34e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg20578329	chr17:80767326	TBCD	-0.57	-7.18	-0.33	3.19e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.19	-0.37	3.2e-15	Cannabis dependence symptom count;
LUAD	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.43	-0.52	1.89e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	16.71	0.63	1.66e-48	Homoarginine levels;
LUAD	cis	rs12681288	0.550	rs58295701	chr8:962136	T/C	cg04851639	chr8:1020857	NA	-0.31	-7.23	-0.33	2.26e-12	Schizophrenia;
LUAD	cis	rs67072384	0.818	rs1872128	chr11:72465526	C/T	cg04827223	chr11:72435913	ARAP1	-0.57	-7.0	-0.32	9.99e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22857025	chr5:266934	NA	-0.97	-14.47	-0.58	7.55e-39	Breast cancer;
LUAD	cis	rs11756438	0.683	rs72962906	chr6:119008305	C/T	cg18833306	chr6:118973337	C6orf204	0.41	6.84	0.32	2.74e-11	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg05727186	chr17:43697356	MGC57346	-0.52	-6.46	-0.3	2.86e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg22482690	chr17:47019901	SNF8	0.43	8.19	0.37	3.05e-15	Type 2 diabetes;
LUAD	cis	rs1847202	0.563	rs13095184	chr3:72951008	A/G	cg25664220	chr3:72788482	NA	-0.42	-7.32	-0.34	1.24e-12	Motion sickness;
LUAD	cis	rs669446	0.561	rs571862	chr1:44083110	C/T	cg12908607	chr1:44402522	ARTN	-0.36	-6.63	-0.31	1.03e-10	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg02423579	chr7:2872169	GNA12	-0.86	-14.87	-0.59	1.59e-40	Height;
LUAD	cis	rs4481233	0.528	rs115776655	chr4:10381329	C/T	cg02734326	chr4:10020555	SLC2A9	-0.5	-6.53	-0.3	1.91e-10	Metabolic traits;
LUAD	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.17	-0.33	3.34e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg07917127	chr4:99064746	C4orf37	0.39	6.45	0.3	3.03e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg23750338	chr8:142222470	SLC45A4	0.47	10.05	0.44	1.93e-21	Immature fraction of reticulocytes;
LUAD	cis	rs13082711	0.911	rs35262121	chr3:27508277	G/A	cg02860705	chr3:27208620	NA	0.57	8.69	0.39	8.2e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6076065	0.644	rs2424535	chr20:23381196	T/C	cg11657817	chr20:23433608	CST11	0.44	8.23	0.37	2.32e-15	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2274273	0.934	rs8021940	chr14:55719715	G/A	cg04306507	chr14:55594613	LGALS3	0.42	8.69	0.39	7.81e-17	Protein biomarker;
LUAD	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02475777	chr4:1388615	CRIPAK	-0.52	-7.64	-0.35	1.51e-13	Obesity-related traits;
LUAD	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg13870426	chr17:30244630	NA	-0.54	-6.36	-0.3	5.18e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4285028	0.747	rs3732410	chr3:121415720	T/C	cg11130432	chr3:121712080	ILDR1	-0.49	-6.93	-0.32	1.59e-11	Multiple sclerosis;
LUAD	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg24558204	chr6:135376177	HBS1L	0.43	7.33	0.34	1.21e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg25753631	chr6:25732923	NA	-0.38	-6.51	-0.3	2.18e-10	Iron status biomarkers;
LUAD	cis	rs9354308	0.899	rs2802057	chr6:66548093	A/C	cg07460842	chr6:66804631	NA	0.49	7.47	0.34	4.73e-13	Metabolite levels;
LUAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg07217954	chr7:1067459	C7orf50	0.43	6.63	0.31	1.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-7.33	-0.34	1.22e-12	IgG glycosylation;
LUAD	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg18721089	chr20:30220636	NA	-0.5	-7.09	-0.33	5.77e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.19	-0.41	1.84e-18	Bipolar disorder and schizophrenia;
LUAD	trans	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg27600084	chr12:12264075	NA	0.4	7.52	0.34	3.32e-13	Breast size;
LUAD	trans	rs11989744	0.843	rs10481331	chr8:23559257	T/C	cg03492747	chr16:86543808	FOXF1	0.43	6.89	0.32	2e-11	Waist-hip ratio;
LUAD	cis	rs1816752	0.870	rs9511261	chr13:25012018	C/T	cg02811702	chr13:24901961	NA	0.46	7.93	0.36	2.03e-14	Obesity-related traits;
LUAD	cis	rs6489882	0.966	rs4767044	chr12:113402899	C/A	cg20102336	chr12:113376681	OAS3	-0.48	-7.1	-0.33	5.47e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg11645453	chr3:52864694	ITIH4	-0.53	-10.03	-0.44	2.17e-21	Schizophrenia;
LUAD	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg03878208	chr11:72483293	STARD10	0.58	8.45	0.38	4.84e-16	Type 2 diabetes;
LUAD	cis	rs367615	0.704	rs6889301	chr5:108835181	C/T	cg17395555	chr5:108820864	NA	0.66	14.39	0.57	1.61e-38	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg17077180	chr1:38461687	NA	0.44	8.63	0.39	1.24e-16	Coronary artery disease;
LUAD	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg16606324	chr3:10149918	C3orf24	0.56	7.39	0.34	8.04e-13	Alzheimer's disease;
LUAD	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg27494647	chr7:150038898	RARRES2	0.55	9.78	0.43	1.7e-20	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06873352	chr17:61820015	STRADA	-0.53	-8.84	-0.39	2.57e-17	Height;
LUAD	cis	rs3820068	0.580	rs61169376	chr1:16003832	A/G	cg13390004	chr1:15929781	NA	0.47	7.96	0.36	1.6e-14	Systolic blood pressure;
LUAD	cis	rs7809615	0.581	rs11760993	chr7:99009014	T/G	cg12290671	chr7:99195819	NA	-0.71	-6.85	-0.32	2.59e-11	Blood metabolite ratios;
LUAD	cis	rs7274811	0.711	rs291677	chr20:32027915	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.49	7.38	0.34	8.57e-13	Height;
LUAD	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg14895029	chr7:2775587	GNA12	-0.42	-6.76	-0.31	4.67e-11	Height;
LUAD	cis	rs12549902	0.966	rs10504042	chr8:41515993	G/A	cg17182837	chr8:41585554	ANK1	-0.36	-7.43	-0.34	5.92e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUAD	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg04511125	chr2:88470314	THNSL2	-0.53	-8.95	-0.4	1.15e-17	Response to metformin (IC50);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00026222	chr1:2144244	NA	-0.53	-6.82	-0.31	3.26e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.85	0.4	2.46e-17	Menopause (age at onset);
LUAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg21724239	chr8:58056113	NA	0.72	9.56	0.42	1.01e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs863345	0.604	rs11265024	chr1:158513255	A/G	cg12129480	chr1:158549410	OR10X1	-0.25	-6.51	-0.3	2.13e-10	Pneumococcal bacteremia;
LUAD	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg09796270	chr17:17721594	SREBF1	-0.37	-6.95	-0.32	1.35e-11	Total body bone mineral density;
LUAD	trans	rs9393777	0.920	rs35768595	chr6:27141904	C/T	cg01620082	chr3:125678407	NA	-1.01	-9.07	-0.4	4.55e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs346785	0.692	rs2279052	chr17:74287204	C/G	cg09812376	chr17:74270190	QRICH2	-0.31	-6.53	-0.3	1.94e-10	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.71	0.31	6.25e-11	Breast cancer;
LUAD	cis	rs9467773	1.000	rs6913462	chr6:26577530	A/G	cg11502198	chr6:26597334	ABT1	0.61	10.06	0.44	1.76e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06873352	chr17:61820015	STRADA	0.81	18.22	0.66	3.7e-55	Prudent dietary pattern;
LUAD	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg15704280	chr7:45808275	SEPT13	0.64	8.22	0.37	2.58e-15	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg17327406	chr4:6303265	WFS1	0.5	6.71	0.31	6.42e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs11677370	0.603	rs10178523	chr2:3854169	G/A	cg17052675	chr2:3827356	NA	-0.63	-10.62	-0.46	1.69e-23	Type 2 diabetes;
LUAD	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-12.42	-0.52	2.14e-30	Bone mineral density;
LUAD	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08564027	chr20:61660810	NA	0.88	18.83	0.68	6.9e-58	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs78487399	0.710	rs6544665	chr2:43729212	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.46	-0.3	2.91e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs7789940	0.904	rs6953281	chr7:75946943	C/T	cg10167463	chr7:75959203	YWHAG	-0.7	-12.51	-0.52	9.14e-31	Multiple sclerosis;
LUAD	cis	rs427941	0.632	rs201470	chr7:101744045	G/A	cg06246474	chr7:101738831	CUX1	0.4	6.89	0.32	1.99e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg06873352	chr17:61820015	STRADA	-0.39	-6.63	-0.31	1.02e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg01851573	chr8:8652454	MFHAS1	0.43	7.72	0.35	8.39e-14	Neuroticism;
LUAD	cis	rs2249625	0.967	rs2056756	chr6:72916638	G/A	cg18830697	chr6:72922368	RIMS1	-0.36	-6.51	-0.3	2.15e-10	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg19980929	chr12:42632907	YAF2	-0.34	-6.5	-0.3	2.27e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg03929089	chr4:120376271	NA	-0.98	-21.12	-0.72	4.05e-68	Height;
LUAD	cis	rs4692589	0.802	rs2877501	chr4:170955277	G/T	cg19918862	chr4:170955249	NA	0.33	7.51	0.34	3.49e-13	Anxiety disorder;
LUAD	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg02527881	chr3:46936655	PTH1R	0.44	8.41	0.38	6.51e-16	Colorectal cancer;
LUAD	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg10523679	chr1:76189770	ACADM	0.9	15.86	0.61	8.88e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6981523	0.500	rs4412337	chr8:11072020	C/T	cg27411982	chr8:10470053	RP1L1	0.36	6.38	0.3	4.66e-10	Neuroticism;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg00013441	chr12:123258908	CCDC62	0.41	6.49	0.3	2.35e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	6.91	0.32	1.77e-11	Motion sickness;
LUAD	cis	rs7945705	0.875	rs4929914	chr11:8824388	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-9.46	-0.42	2.24e-19	Hemoglobin concentration;
LUAD	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.82	-14.19	-0.57	1.2e-37	Chronic sinus infection;
LUAD	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.38	-6.49	-0.3	2.34e-10	Hematocrit;
LUAD	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg07570687	chr10:102243282	WNT8B	0.44	6.4	0.3	4.17e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.97	0.47	8.47e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7593730	1.000	rs4077463	chr2:161166234	A/G	cg22609984	chr2:161126801	NA	0.45	7.36	0.34	9.97e-13	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg20607798	chr8:58055168	NA	0.67	8.84	0.39	2.61e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7659604	0.502	rs28435300	chr4:122709412	T/C	cg06713675	chr4:122721982	EXOSC9	0.45	8.28	0.37	1.65e-15	Type 2 diabetes;
LUAD	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg09137382	chr11:130731461	NA	0.41	7.51	0.34	3.57e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9283706	0.689	rs12517976	chr5:66321579	G/A	cg11590213	chr5:66331682	MAST4	0.4	6.37	0.3	5.07e-10	Coronary artery disease;
LUAD	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	9.45	0.42	2.37e-19	Electrocardiographic conduction measures;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13393195	chr12:113659153	TPCN1;IQCD	-0.48	-7.51	-0.34	3.48e-13	Height;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg25177113	chr1:955463	AGRN	-0.56	-6.95	-0.32	1.4e-11	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg17173187	chr15:85201210	NMB	0.47	7.82	0.36	4.25e-14	Schizophrenia;
LUAD	cis	rs2282300	0.653	rs67745574	chr11:30234839	C/T	cg25418670	chr11:30344373	C11orf46	-0.52	-7.09	-0.33	5.5e-12	Morning vs. evening chronotype;
LUAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg07806771	chr7:64541737	NA	0.44	6.87	0.32	2.31e-11	Calcium levels;
LUAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg27454412	chr7:1067447	C7orf50	0.4	6.8	0.31	3.65e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.76	-0.5	8.41e-28	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg05340658	chr4:99064831	C4orf37	0.54	9.11	0.4	3.36e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4268898	0.862	rs11125549	chr2:24576240	C/T	cg06627628	chr2:24431161	ITSN2	0.47	8.13	0.37	4.96e-15	Asthma;
LUAD	cis	rs757647	1.000	rs757647	chr5:137707315	A/G	cg10676309	chr5:137685565	NA	-0.34	-6.42	-0.3	3.58e-10	Menarche (age at onset);
LUAD	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg13755796	chr4:20253514	NA	-0.42	-7.21	-0.33	2.53e-12	Life satisfaction;
LUAD	cis	rs926938	0.584	rs360606	chr1:115391769	C/T	cg12756093	chr1:115239321	AMPD1	0.36	6.5	0.3	2.26e-10	Autism;
LUAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg18538332	chr22:24372958	LOC391322	-0.53	-8.88	-0.4	1.87e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg10518543	chr12:38710700	ALG10B	0.43	6.37	0.3	5.06e-10	Bladder cancer;
LUAD	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg21823605	chr1:152486609	CRCT1	0.29	6.42	0.3	3.64e-10	Hair morphology;
LUAD	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.05	-0.36	8.53e-15	Cystic fibrosis severity;
LUAD	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg17644776	chr2:200775616	C2orf69	-0.45	-7.2	-0.33	2.71e-12	Osteoporosis;
LUAD	cis	rs12989701	1.000	rs13004848	chr2:127887560	C/T	cg08168897	chr2:127865431	BIN1	-0.47	-7.13	-0.33	4.42e-12	Alzheimer's disease (late onset);
LUAD	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg27219399	chr15:67835830	MAP2K5	0.4	6.78	0.31	4.09e-11	Obesity;
LUAD	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg00634984	chr7:65235879	NA	-0.47	-6.46	-0.3	2.81e-10	Aortic root size;
LUAD	cis	rs9807989	0.507	rs4851579	chr2:103028984	G/A	cg03938978	chr2:103052716	IL18RAP	0.44	9.94	0.44	4.72e-21	Asthma;
LUAD	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	9.16	0.41	2.3e-18	Menarche (age at onset);
LUAD	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg08798685	chr6:27730294	NA	-0.69	-7.35	-0.34	1.03e-12	Depression;
LUAD	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.2	-0.33	2.75e-12	Lung cancer;
LUAD	trans	rs1973993	0.745	rs6686016	chr1:96948002	G/A	cg10631902	chr5:14652156	NA	-0.51	-8.65	-0.39	1.09e-16	Weight;
LUAD	trans	rs941408	1.000	rs941406	chr19:2803623	A/G	cg22153745	chr1:153894579	GATAD2B	-0.48	-7.03	-0.32	8.6e-12	Total cholesterol levels;
LUAD	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg00316803	chr15:76480434	C15orf27	0.41	6.4	0.3	4.23e-10	Blood metabolite levels;
LUAD	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05776053	chr2:74358815	NA	0.45	7.06	0.32	6.96e-12	Gestational age at birth (maternal effect);
LUAD	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg02807482	chr3:125708958	NA	-0.56	-7.76	-0.35	6.24e-14	Blood pressure (smoking interaction);
LUAD	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg03340356	chr1:67600835	NA	0.44	7.53	0.34	3.03e-13	Psoriasis;
LUAD	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg22117172	chr7:91764530	CYP51A1	0.35	7.91	0.36	2.2e-14	Breast cancer;
LUAD	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg15485101	chr11:133734466	NA	-0.34	-7.08	-0.33	5.98e-12	Childhood ear infection;
LUAD	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg18944383	chr4:111397179	ENPEP	0.38	7.71	0.35	8.85e-14	Height;
LUAD	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg27211696	chr2:191398769	TMEM194B	-0.47	-6.43	-0.3	3.43e-10	Diastolic blood pressure;
LUAD	cis	rs7737355	0.947	rs2108869	chr5:131086880	A/G	cg06307176	chr5:131281290	NA	0.52	8.16	0.37	3.77e-15	Life satisfaction;
LUAD	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg09365446	chr1:150670422	GOLPH3L	0.66	12.56	0.52	5.78e-31	Tonsillectomy;
LUAD	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg27284194	chr4:1044797	NA	0.7	10.13	0.44	9.73e-22	Recombination rate (females);
LUAD	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.52	-0.42	1.3e-19	Life satisfaction;
LUAD	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg00339695	chr16:24857497	SLC5A11	0.52	9.25	0.41	1.08e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.21	0.44	4.99e-22	Ileal carcinoids;
LUAD	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg07537917	chr2:241836409	C2orf54	-0.32	-9.1	-0.4	3.47e-18	Urinary metabolites;
LUAD	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg25566285	chr7:158114605	PTPRN2	0.52	10.93	0.47	1.2e-24	Calcium levels;
LUAD	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg12573674	chr2:1569213	NA	-0.55	-6.78	-0.31	4.08e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs5756391	0.568	rs4821570	chr22:37317177	C/G	cg16356956	chr22:37317934	CSF2RB	0.31	6.53	0.3	1.85e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs2652834	1.000	rs36116701	chr15:63397494	T/C	cg25406657	chr15:63342033	TPM1	-0.43	-6.91	-0.32	1.84e-11	HDL cholesterol;
LUAD	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg00852783	chr1:26633632	UBXN11	0.46	7.61	0.35	1.83e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg03188948	chr7:1209495	NA	0.69	6.59	0.31	1.32e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs5756391	0.546	rs1807546	chr22:37311425	A/C	cg16356956	chr22:37317934	CSF2RB	0.35	7.55	0.34	2.79e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs17153755	0.931	rs12677897	chr8:11612963	G/A	cg12568669	chr8:11666485	FDFT1	-0.26	-6.47	-0.3	2.75e-10	Testicular germ cell tumor;
LUAD	cis	rs77861329	0.748	rs2334961	chr3:52173625	G/C	cg08692210	chr3:52188851	WDR51A	0.55	6.93	0.32	1.54e-11	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs6487679	0.526	rs7305336	chr12:9375089	C/A	cg08997352	chr12:9597637	DDX12	-0.48	-7.37	-0.34	9.16e-13	Non-alcoholic fatty liver disease histology (AST);
LUAD	cis	rs1497828	0.956	rs2815232	chr1:217538336	A/G	cg04411442	chr1:217543379	NA	-0.38	-6.81	-0.31	3.43e-11	Dialysis-related mortality;
LUAD	cis	rs7809950	1.000	rs2894475	chr7:107262558	A/T	cg23024343	chr7:107201750	COG5	-0.69	-11.63	-0.49	2.52e-27	Coronary artery disease;
LUAD	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg11887960	chr12:57824829	NA	-0.55	-7.0	-0.32	9.91e-12	Obesity-related traits;
LUAD	cis	rs9826463	0.582	rs56370391	chr3:142084647	A/G	cg20824294	chr3:142316082	PLS1	0.41	7.13	0.33	4.47e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.66	-0.35	1.29e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs739496	0.947	rs2339816	chr12:111912188	T/C	cg10833066	chr12:111807467	FAM109A	0.42	6.76	0.31	4.72e-11	Platelet count;
LUAD	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg20203395	chr5:56204925	C5orf35	-0.82	-11.8	-0.5	5.55e-28	Initial pursuit acceleration;
LUAD	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.68	-0.39	8.87e-17	Alzheimer's disease (late onset);
LUAD	cis	rs8067545	0.750	rs9915758	chr17:19964775	A/G	cg04132472	chr17:19861366	AKAP10	0.27	6.37	0.3	4.92e-10	Schizophrenia;
LUAD	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22857025	chr5:266934	NA	-0.96	-14.33	-0.57	2.98e-38	Breast cancer;
LUAD	cis	rs7493	0.901	rs17882539	chr7:95026408	G/A	cg05342682	chr7:94953680	PON1	-0.52	-7.52	-0.34	3.38e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs494562	0.892	rs550499	chr6:86115602	G/C	cg13315970	chr6:86159197	NT5E	0.71	8.06	0.36	8.06e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs11229555	0.874	rs11229512	chr11:58286105	T/C	cg15696309	chr11:58395628	NA	-0.73	-10.34	-0.45	1.67e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.83	-0.32	3e-11	Retinal vascular caliber;
LUAD	cis	rs4604732	0.588	rs9943231	chr1:247629829	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.18	0.33	3.06e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2692947	0.727	rs2692950	chr2:96673524	T/C	cg23100626	chr2:96804247	ASTL	0.3	7.53	0.34	3.1400000000000003e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.74	13.45	0.55	1.43e-34	Axial length;
LUAD	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg07679836	chr6:33548423	BAK1	0.63	10.88	0.47	1.76e-24	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
LUAD	cis	rs11048434	0.736	rs11048345	chr12:9123056	T/G	cg23795048	chr12:9217529	LOC144571	0.41	7.51	0.34	3.5e-13	Sjögren's syndrome;
LUAD	cis	rs243505	0.898	rs243535	chr7:148410123	A/C	cg09806900	chr7:148480153	CUL1	-0.44	-7.37	-0.34	9.24e-13	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs738322	0.574	rs28653361	chr22:38570700	C/A	cg17652424	chr22:38574118	PLA2G6	-0.3	-7.98	-0.36	1.38e-14	Cutaneous nevi;
LUAD	cis	rs6426558	0.537	rs2718193	chr1:227404672	C/G	cg10327440	chr1:227177885	CDC42BPA	0.54	8.83	0.39	2.79e-17	Neutrophil percentage of white cells;
LUAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.6	8.17	0.37	3.58e-15	Renal function-related traits (BUN);
LUAD	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg01874867	chr7:94954059	PON1	-0.5	-6.95	-0.32	1.37e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9811920	0.535	rs704574	chr3:99483773	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.45	8.53	0.38	2.68e-16	Axial length;
LUAD	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs2688608	0.836	rs2675668	chr10:75636148	G/A	cg19442545	chr10:75533431	FUT11	-0.42	-7.0	-0.32	9.91e-12	Inflammatory bowel disease;
LUAD	cis	rs4961252	0.505	rs6990155	chr8:142098977	C/T	cg09914555	chr8:142094789	NA	0.43	7.49	0.34	4.04e-13	Isovolumetric relaxation time;Response to interferon beta therapy;
LUAD	cis	rs76878669	0.561	rs4930363	chr11:66169676	C/T	cg10616300	chr11:66138557	SLC29A2	0.35	7.56	0.35	2.48e-13	Educational attainment (years of education);
LUAD	cis	rs6733011	0.518	rs12992214	chr2:99466337	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.69	-0.31	6.96e-11	Bipolar disorder;
LUAD	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg05042697	chr2:10830656	NOL10	0.38	6.64	0.31	9.42e-11	Prostate cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg11602459	chr20:39765965	PLCG1	-0.63	-6.39	-0.3	4.5e-10	Type 2 diabetes;
LUAD	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg25233709	chr10:116636983	FAM160B1	0.42	8.56	0.38	2.16e-16	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.32	-6.36	-0.3	5.31e-10	Longevity;Endometriosis;
LUAD	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg10755058	chr3:40428713	ENTPD3	0.45	8.44	0.38	5.03e-16	Renal cell carcinoma;
LUAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.07e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg08493051	chr2:3487164	NA	-0.44	-7.66	-0.35	1.25e-13	Neurofibrillary tangles;
LUAD	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg12573674	chr2:1569213	NA	-0.56	-8.3	-0.37	1.39e-15	IgG glycosylation;
LUAD	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg04450456	chr4:17643702	FAM184B	0.4	7.84	0.36	3.69e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs1832871	0.711	rs7770047	chr6:158685696	A/G	cg07165851	chr6:158734300	TULP4	0.71	11.07	0.47	3.54e-25	Height;
LUAD	trans	rs7395662	1.000	rs7129386	chr11:48616694	A/G	cg00717180	chr2:96193071	NA	-0.4	-7.41	-0.34	7.11e-13	HDL cholesterol;
LUAD	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg18230493	chr5:56204884	C5orf35	-0.44	-7.31	-0.33	1.38e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg03806693	chr22:41940476	POLR3H	-0.61	-8.73	-0.39	6.07e-17	Vitiligo;
LUAD	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg09117114	chr16:67998030	SLC12A4	-0.54	-7.02	-0.32	9.13e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.47	0.3	2.76e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg02683114	chr2:24398427	C2orf84	0.53	8.21	0.37	2.76e-15	Asthma;
LUAD	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg12193833	chr17:30244370	NA	-0.58	-7.03	-0.32	8.14e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg05564831	chr3:52568323	NT5DC2	-0.36	-6.63	-0.31	1.03e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs62238980	0.614	rs79738052	chr22:32455812	G/A	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs11971779	0.584	rs34762928	chr7:139113168	T/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.85	0.32	2.66e-11	Diisocyanate-induced asthma;
LUAD	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg25767906	chr1:53392781	SCP2	-0.54	-10.24	-0.45	4.01e-22	Monocyte count;
LUAD	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg20607798	chr8:58055168	NA	0.77	9.36	0.41	4.82e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs1941687	0.527	rs2000945	chr18:31365336	A/G	cg27147174	chr7:100797783	AP1S1	-0.71	-13.15	-0.54	2.36e-33	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.88	-0.36	2.85e-14	Type 2 diabetes;
LUAD	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg27170947	chr2:26402098	FAM59B	-0.81	-12.2	-0.51	1.54e-29	Gut microbiome composition (summer);
LUAD	cis	rs62229266	0.804	rs56279140	chr21:37424361	C/T	cg08632701	chr21:37451849	NA	-0.42	-6.8	-0.31	3.64e-11	Mitral valve prolapse;
LUAD	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg15181151	chr6:150070149	PCMT1	0.41	8.53	0.38	2.66e-16	Lung cancer;
LUAD	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg05082376	chr22:42548792	NA	-0.39	-7.01	-0.32	9.19e-12	Cognitive function;
LUAD	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Parkinson's disease;
LUAD	cis	rs758324	0.947	rs7734536	chr5:131162124	C/T	cg06307176	chr5:131281290	NA	0.49	7.77	0.35	5.88e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs8073060	0.586	rs2523114	chr17:34023762	G/A	cg19694781	chr19:47549865	TMEM160	-1.22	-19.43	-0.69	1.51e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg24813613	chr7:1882135	MAD1L1	-0.49	-8.0	-0.36	1.24e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg24112000	chr20:60950667	NA	0.68	11.17	0.48	1.46e-25	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs55788414	0.932	rs28583467	chr16:81186428	G/C	cg06400318	chr16:81190750	PKD1L2	-0.68	-8.75	-0.39	5.09e-17	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22857025	chr5:266934	NA	-1.03	-13.4	-0.55	2.25e-34	Breast cancer;
LUAD	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg16647868	chr5:131706066	SLC22A5	0.39	6.6	0.31	1.23e-10	Acylcarnitine levels;
LUAD	cis	rs4849845	0.598	rs11690576	chr2:121019800	A/G	cg24070213	chr2:121070622	NA	-0.39	-7.31	-0.33	1.33e-12	Mean platelet volume;
LUAD	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.45	-0.45	6.63e-23	Monocyte percentage of white cells;
LUAD	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg19442545	chr10:75533431	FUT11	0.51	8.71	0.39	6.68e-17	Inflammatory bowel disease;
LUAD	cis	rs9868809	0.881	rs7620853	chr3:48666503	G/A	cg00383909	chr3:49044727	WDR6	0.63	7.04	0.32	7.77e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs6960043	0.791	rs2191346	chr7:15053878	C/G	cg19272540	chr7:15055459	NA	-0.37	-8.41	-0.38	6.18e-16	Type 2 diabetes;
LUAD	cis	rs2625529	0.617	rs8557	chr15:72115733	T/C	cg16672083	chr15:72433130	SENP8	-0.61	-10.95	-0.47	1.01e-24	Red blood cell count;
LUAD	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.96e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg03806693	chr22:41940476	POLR3H	0.69	9.6	0.42	7.05e-20	Vitiligo;
LUAD	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs4689388	0.581	rs4688985	chr4:6285715	A/G	cg14416269	chr4:6271139	WFS1	0.59	10.05	0.44	1.82e-21	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg07414643	chr4:187882934	NA	0.34	6.96	0.32	1.27e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs738322	0.753	rs2267372	chr22:38598234	A/G	cg25457927	chr22:38595422	NA	0.68	18.69	0.67	3.01e-57	Cutaneous nevi;
LUAD	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg14343924	chr8:8086146	FLJ10661	0.46	6.92	0.32	1.67e-11	Mood instability;
LUAD	trans	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg25482853	chr8:67687455	SGK3	1.03	16.44	0.62	2.46e-47	Obesity-related traits;
LUAD	cis	rs7771547	0.662	rs2001101	chr6:36536448	C/T	cg02952361	chr6:36355661	ETV7	0.49	6.46	0.3	2.81e-10	Platelet distribution width;
LUAD	cis	rs9925964	0.748	rs4889603	chr16:30982225	C/T	cg02466173	chr16:30829666	NA	-0.45	-7.91	-0.36	2.25e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs8192282	0.739	rs6427720	chr1:154501756	G/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.37	-0.34	8.86e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg15181151	chr6:150070149	PCMT1	0.4	7.83	0.36	3.99e-14	Lung cancer;
LUAD	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg16060761	chr17:80687452	NA	-0.57	-8.19	-0.37	3.03e-15	Glycated hemoglobin levels;
LUAD	cis	rs758324	0.812	rs9327621	chr5:131118943	T/C	cg06307176	chr5:131281290	NA	0.46	7.56	0.35	2.5e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.7	10.44	0.45	7.71e-23	IgG glycosylation;
LUAD	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg23711669	chr6:146136114	FBXO30	-0.39	-6.4	-0.3	4.12e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg15242686	chr22:24348715	GSTTP1	0.39	6.6	0.31	1.24e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.21	-0.41	1.52e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4774899	0.752	rs2615231	chr15:57405674	A/G	cg14026238	chr15:57616123	NA	-0.4	-7.7	-0.35	9.97e-14	Urinary tract infection frequency;
LUAD	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19346786	chr7:2764209	NA	-0.57	-12.16	-0.51	2.25e-29	Height;
LUAD	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg21475434	chr5:93447410	FAM172A	0.74	8.2	0.37	2.81e-15	Diabetic retinopathy;
LUAD	trans	rs225245	0.782	rs321618	chr17:33912404	A/G	cg19694781	chr19:47549865	TMEM160	-0.46	-7.58	-0.35	2.14e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08843538	chr2:210288784	MAP2	0.43	6.35	0.3	5.51e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs758324	0.891	rs652839	chr5:131281106	G/C	cg06307176	chr5:131281290	NA	-0.53	-8.48	-0.38	3.69e-16	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-8.11	-0.37	5.55e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs673604	1.000	rs668092	chr1:35687203	A/G	cg12633102	chr1:35676489	NA	-0.61	-8.86	-0.4	2.26e-17	Endometrial cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg19442647	chr3:126194923	ZXDC	-0.38	-6.59	-0.31	1.3e-10	Schizophrenia;
LUAD	trans	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg14917512	chr19:3094685	GNA11	-0.54	-6.36	-0.3	5.37e-10	Diabetic kidney disease;
LUAD	cis	rs6424115	1.000	rs7521961	chr1:24157634	C/T	cg10978503	chr1:24200527	CNR2	-0.56	-12.2	-0.51	1.52e-29	Immature fraction of reticulocytes;
LUAD	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg23625390	chr15:77176239	SCAPER	0.37	6.48	0.3	2.58e-10	Blood metabolite levels;
LUAD	cis	rs12618769	0.597	rs72821924	chr2:99114924	C/T	cg10123293	chr2:99228465	UNC50	0.46	8.39	0.38	7.48e-16	Bipolar disorder;
LUAD	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg02018176	chr4:1364513	KIAA1530	-0.39	-7.25	-0.33	2.06e-12	Obesity-related traits;
LUAD	cis	rs13315871	1.000	rs13071688	chr3:58398730	G/A	cg12435725	chr3:58293450	RPP14	-0.69	-7.35	-0.34	1.05e-12	Cholesterol, total;
LUAD	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg00361562	chr2:198649771	BOLL	-0.5	-7.13	-0.33	4.47e-12	Ulcerative colitis;
LUAD	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg03433033	chr1:76189801	ACADM	-0.48	-7.01	-0.32	9.46e-12	Daytime sleep phenotypes;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg15846643	chr11:94964345	SESN3	-0.4	-6.84	-0.32	2.77e-11	Schizophrenia;
LUAD	cis	rs782590	0.721	rs782641	chr2:55929294	C/T	cg18811423	chr2:55921094	PNPT1	0.52	8.58	0.39	1.8e-16	Metabolic syndrome;
LUAD	cis	rs62400317	0.762	rs62436375	chr6:44875818	T/C	cg20913747	chr6:44695427	NA	-0.41	-6.44	-0.3	3.28e-10	Total body bone mineral density;
LUAD	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg08085267	chr17:45401833	C17orf57	0.5	8.36	0.38	9.34e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg10589385	chr1:150898437	SETDB1	0.43	7.95	0.36	1.73e-14	Melanoma;
LUAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg17178900	chr1:205818956	PM20D1	0.4	6.63	0.31	1.02e-10	Parkinson's disease;
LUAD	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg11189052	chr15:85197271	WDR73	0.68	9.04	0.4	5.49e-18	Schizophrenia;
LUAD	cis	rs12348691	0.503	rs1348386	chr9:100612807	A/G	cg13688889	chr9:100608707	NA	-0.6	-9.8	-0.43	1.48e-20	Alopecia areata;
LUAD	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.04	23.44	0.75	1.77e-78	Chronic sinus infection;
LUAD	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg27490568	chr2:178487706	NA	0.62	9.2	0.41	1.66e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.44	0.3	3.17e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg19622623	chr12:86230825	RASSF9	-0.36	-6.63	-0.31	1.01e-10	Major depressive disorder;
LUAD	trans	rs7944735	0.938	rs59185955	chr11:47961566	G/C	cg15704280	chr7:45808275	SEPT13	0.67	8.77	0.39	4.5e-17	Intraocular pressure;
LUAD	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg22508957	chr16:3507546	NAT15	-0.71	-11.67	-0.49	1.86e-27	Tuberculosis;
LUAD	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.42e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg08885076	chr2:99613938	TSGA10	0.41	7.62	0.35	1.67e-13	Chronic sinus infection;
LUAD	cis	rs7274811	0.711	rs373618	chr20:31992639	C/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.49	7.2	0.33	2.75e-12	Height;
LUAD	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg14092988	chr3:52407081	DNAH1	0.44	8.87	0.4	2.04e-17	Bipolar disorder;
LUAD	cis	rs6922632	1.000	rs28921123	chr6:24126112	G/A	cg26194775	chr6:24126114	NRSN1	-0.69	-10.36	-0.45	1.46e-22	Information processing speed;
LUAD	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg15462221	chr8:8086144	FLJ10661	0.45	7.15	0.33	3.86e-12	Neuroticism;
LUAD	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.48	7.0	0.32	9.9e-12	Alzheimer's disease (late onset);
LUAD	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg27535305	chr1:53392650	SCP2	-0.33	-6.81	-0.31	3.34e-11	Monocyte count;
LUAD	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg11344533	chr11:111475393	SIK2	0.37	6.61	0.31	1.16e-10	Primary sclerosing cholangitis;
LUAD	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg17063962	chr7:91808500	NA	0.65	11.27	0.48	6.36e-26	Breast cancer;
LUAD	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg06641503	chr3:48959341	ARIH2	-0.37	-7.33	-0.34	1.17e-12	Parkinson's disease;
LUAD	cis	rs68170813	0.559	rs58663672	chr7:106949444	T/C	cg23024343	chr7:107201750	COG5	0.45	6.47	0.3	2.69e-10	Coronary artery disease;
LUAD	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg14582100	chr15:45693742	SPATA5L1	0.51	9.63	0.42	5.43e-20	Homoarginine levels;
LUAD	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg09904177	chr6:26538194	HMGN4	0.41	6.84	0.32	2.73e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg17105886	chr17:28927953	LRRC37B2	0.84	8.08	0.37	6.96e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg12927641	chr6:109611667	NA	-0.51	-8.76	-0.39	4.9e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg03037974	chr15:76606532	NA	0.33	6.66	0.31	8.49e-11	Blood metabolite levels;
LUAD	cis	rs6998277	0.830	rs12543008	chr8:103603747	C/T	cg10187029	chr8:103597600	NA	0.88	16.6	0.63	5.3e-48	Migraine;
LUAD	cis	rs116248771	0.696	rs16847123	chr3:158416137	C/T	cg16708174	chr3:158430962	RARRES1	0.47	6.81	0.31	3.44e-11	diarrhoeal disease at age 2;
LUAD	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-9.43	-0.42	2.66e-19	Obesity (extreme);
LUAD	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	6.05e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.03	-0.36	9.69e-15	Diabetic kidney disease;
LUAD	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg17264618	chr3:40429014	ENTPD3	-0.39	-8.52	-0.38	2.79e-16	Renal cell carcinoma;
LUAD	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg05623727	chr3:50126028	RBM5	0.31	6.74	0.31	5.1e-11	Body mass index;
LUAD	cis	rs10489202	1.000	rs7538581	chr1:167979347	A/G	cg24449463	chr1:168025552	DCAF6	-0.55	-7.04	-0.32	7.9e-12	Schizophrenia;
LUAD	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg18477163	chr1:228402036	OBSCN	-0.35	-7.1	-0.33	5.32e-12	Diastolic blood pressure;
LUAD	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.51	-0.34	3.54e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6984449	0.508	rs62496184	chr8:19319423	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.4	7.3	0.33	1.42e-12	Educational attainment;
LUAD	trans	rs6678622	0.863	rs12742653	chr1:78339481	A/T	cg20826526	chr3:156266748	SSR3	-0.45	-6.85	-0.32	2.63e-11	Hip circumference;
LUAD	cis	rs7180079	1.000	rs11855072	chr15:64538524	C/T	cg08069370	chr15:64387884	SNX1	-0.5	-6.35	-0.3	5.46e-10	Monocyte count;
LUAD	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg23260525	chr10:116636907	FAM160B1	0.47	10.84	0.47	2.48e-24	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs68170813	0.559	rs1002935	chr7:106832361	G/A	cg23024343	chr7:107201750	COG5	0.5	7.26	0.33	1.92e-12	Coronary artery disease;
LUAD	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg05340658	chr4:99064831	C4orf37	0.44	7.33	0.34	1.15e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs34311866	0.808	rs748483	chr4:952409	A/G	cg23992470	chr4:843637	GAK	0.68	7.12	0.33	4.78e-12	Parkinson's disease;
LUAD	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22307029	chr19:49891270	CCDC155	0.81	12.98	0.53	1.14e-32	Multiple sclerosis;
LUAD	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg05872129	chr22:39784769	NA	-0.68	-9.98	-0.44	3.32e-21	IgG glycosylation;
LUAD	cis	rs1832871	0.683	rs56197409	chr6:158684338	A/G	cg07165851	chr6:158734300	TULP4	0.71	10.97	0.47	7.89e-25	Height;
LUAD	cis	rs986417	0.818	rs12883272	chr14:61015153	A/G	cg27398547	chr14:60952738	C14orf39	0.66	7.65	0.35	1.38e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg26924012	chr15:45694286	SPATA5L1	0.86	14.52	0.58	5e-39	Homoarginine levels;
LUAD	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg04455712	chr21:45112962	RRP1B	0.45	8.85	0.4	2.4e-17	Mean corpuscular volume;
LUAD	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg21775007	chr8:11205619	TDH	-0.5	-9.11	-0.4	3.31e-18	Retinal vascular caliber;
LUAD	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	trans	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg17551891	chr7:1960795	MAD1L1	-0.39	-6.76	-0.31	4.6e-11	Neuroticism;
LUAD	cis	rs755249	0.510	rs582883	chr1:39835540	T/C	cg27567593	chr1:39956653	BMP8A	-0.34	-6.8	-0.31	3.63e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs12505328	0.514	rs7699342	chr4:174390593	G/A	cg12145043	chr4:174357286	NA	0.43	7.04	0.32	7.81e-12	Chin dimples;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00964137	chr5:93905358	MIR1974;C5orf36	0.44	6.86	0.32	2.45e-11	Height;
LUAD	cis	rs4356932	1.000	rs4356932	chr4:76955194	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.37	-6.63	-0.31	1.03e-10	Blood protein levels;
LUAD	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg21548813	chr6:291882	DUSP22	-0.53	-8.59	-0.39	1.69e-16	Menopause (age at onset);
LUAD	cis	rs12519773	0.502	rs67862943	chr5:92529268	G/A	cg18783429	chr5:92414398	NA	0.46	8.13	0.37	4.75e-15	Migraine;
LUAD	cis	rs4700695	0.614	rs2561241	chr5:65206565	C/T	cg21114390	chr5:65439923	SFRS12	0.65	7.47	0.34	4.77e-13	Facial morphology (factor 19);
LUAD	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg05082376	chr22:42548792	NA	0.45	7.8	0.35	4.73e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg17366294	chr4:99064904	C4orf37	-0.48	-8.41	-0.38	6.54e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.65	-0.35	1.37e-13	Monocyte count;
LUAD	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg11845111	chr2:191398756	TMEM194B	0.66	12.15	0.51	2.49e-29	Pulse pressure;
LUAD	cis	rs35883536	0.566	rs10783141	chr1:101043897	G/A	cg06223162	chr1:101003688	GPR88	-0.47	-9.18	-0.41	1.88e-18	Monocyte count;
LUAD	cis	rs80319144	0.904	rs77571593	chr2:159300402	T/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.9	0.32	1.88e-11	Restless legs syndrome;
LUAD	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.79	-10.36	-0.45	1.41e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs10901296	0.660	rs2855199	chr9:133765044	T/C	cg03924115	chr9:133768966	QRFP	0.51	6.64	0.31	9.82e-11	Bilirubin levels;
LUAD	cis	rs9296092	0.538	rs9469488	chr6:33517117	G/T	cg13560919	chr6:33536144	NA	-0.87	-15.45	-0.6	4.9e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg03388025	chr16:89894329	SPIRE2	0.52	13.84	0.56	3.52e-36	Vitiligo;
LUAD	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg06784218	chr1:46089804	CCDC17	0.51	11.23	0.48	8.7e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.1e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.39	-0.34	7.83e-13	Bone mineral density;
LUAD	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.27	-6.61	-0.31	1.15e-10	Menopause (age at onset);
LUAD	cis	rs72766638	0.895	rs55924785	chr9:136929586	C/T	cg13789015	chr9:136890014	NCRNA00094	0.61	7.76	0.35	6.25e-14	Mosquito bite size;
LUAD	trans	rs1959947	0.585	rs8008487	chr14:41534471	A/C	cg07097265	chr17:17727093	SREBF1	0.35	6.37	0.3	4.89e-10	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg04731861	chr2:219085781	ARPC2	0.23	7.08	0.33	6.05e-12	Colorectal cancer;
LUAD	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg18277682	chr1:228362509	C1orf69	-0.4	-6.62	-0.31	1.09e-10	Diastolic blood pressure;
LUAD	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg04450456	chr4:17643702	FAM184B	0.4	8.06	0.36	7.87e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.03	-15.29	-0.6	2.48e-42	Schizophrenia;
LUAD	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.71	0.31	6.24e-11	Aortic root size;
LUAD	cis	rs1609391	0.543	rs9828009	chr3:136631275	C/T	cg15507776	chr3:136538369	TMEM22	0.49	8.7	0.39	7.41e-17	Neuroticism;
LUAD	trans	rs10504906	1.000	rs13273795	chr8:92438919	C/T	cg10665438	chr10:134049549	STK32C	0.73	6.38	0.3	4.59e-10	Fat distribution (HIV);
LUAD	cis	rs12618769	0.597	rs11902825	chr2:99129137	T/C	cg10123293	chr2:99228465	UNC50	0.46	8.21	0.37	2.77e-15	Bipolar disorder;
LUAD	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg15445000	chr17:37608096	MED1	-0.44	-8.25	-0.37	1.99e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs7590720	1.000	rs934154	chr2:216901933	C/T	cg12620499	chr2:216877984	MREG	0.56	8.95	0.4	1.09e-17	Alcohol dependence;
LUAD	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.5e-19	Life satisfaction;
LUAD	cis	rs887829	0.569	rs3755319	chr2:234667582	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.04	-0.36	9.28e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs2294693	0.530	rs9394761	chr6:41033640	A/C	cg14769373	chr6:40998127	UNC5CL	-0.57	-8.08	-0.37	6.94e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	trans	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg07211511	chr3:129823064	LOC729375	0.56	7.35	0.34	1.04e-12	Blood pressure (smoking interaction);
LUAD	cis	rs10916814	1.000	rs72649163	chr1:20900592	G/C	cg24502330	chr1:20914028	CDA	-0.38	-7.12	-0.33	4.7e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7647973	1.000	rs6446268	chr3:49445695	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.48	-8.61	-0.39	1.44e-16	Menarche (age at onset);
LUAD	cis	rs3849570	1.000	rs3772882	chr3:81808602	C/A	cg07356753	chr3:81810745	GBE1	-0.63	-10.94	-0.47	1.02e-24	Waist circumference;Body mass index;
LUAD	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg13271783	chr10:134563150	INPP5A	-0.4	-6.83	-0.31	3.05e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4268898	1.000	rs6707781	chr2:24441883	T/G	cg02683114	chr2:24398427	C2orf84	0.42	7.07	0.33	6.25e-12	Asthma;
LUAD	cis	rs1595825	0.891	rs16825917	chr2:198805185	C/T	cg00361562	chr2:198649771	BOLL	-0.49	-6.75	-0.31	5.04e-11	Ulcerative colitis;
LUAD	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg24818145	chr4:99064322	C4orf37	0.48	7.86	0.36	3.31e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg21704491	chr20:388519	RBCK1	-0.37	-6.69	-0.31	7.02e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg11822812	chr5:140052017	DND1	-0.39	-6.9	-0.32	1.95e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-8.35	-0.38	1.02e-15	Endometrial cancer;
LUAD	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg22467129	chr15:76604101	ETFA	-0.58	-10.58	-0.46	2.22e-23	Blood metabolite levels;
LUAD	cis	rs11771526	0.901	rs62457503	chr7:32330980	A/C	cg13207630	chr7:32358064	NA	0.66	7.91	0.36	2.24e-14	Body mass index;
LUAD	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg21856205	chr7:94953877	PON1	-0.55	-7.7	-0.35	9.5e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1816752	0.719	rs11841989	chr13:24997698	C/A	cg02811702	chr13:24901961	NA	0.42	7.15	0.33	3.93e-12	Obesity-related traits;
LUAD	trans	rs73193808	0.639	rs2832237	chr21:30547683	C/G	cg14791747	chr16:20752902	THUMPD1	-0.48	-6.95	-0.32	1.39e-11	Coronary artery disease;
LUAD	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg08508325	chr11:3079039	CARS	-0.59	-12.54	-0.52	7.04e-31	Longevity;
LUAD	cis	rs7561273	0.565	rs6545275	chr2:24331860	A/G	cg20701182	chr2:24300061	SF3B14	0.5	8.15	0.37	4.11e-15	Quantitative traits;
LUAD	cis	rs17102423	0.760	rs2781375	chr14:65569597	A/G	cg16583315	chr14:65563665	MAX	-0.35	-6.6	-0.31	1.22e-10	Obesity-related traits;
LUAD	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg21204522	chr6:27730016	NA	-0.51	-7.61	-0.35	1.84e-13	Breast cancer;
LUAD	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg20848291	chr7:100343083	ZAN	0.37	6.38	0.3	4.68e-10	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs41311933	0.706	rs72760229	chr9:123889817	G/T	cg13567360	chr9:123745713	C5	-0.74	-8.57	-0.38	1.89e-16	Coronary artery disease;
LUAD	cis	rs834811	0.829	rs834818	chr7:135895070	A/G	cg01726295	chr7:135938950	NA	0.28	7.04	0.32	7.81e-12	Post-traumatic stress disorder;
LUAD	cis	rs12618769	0.545	rs3769710	chr2:99153756	C/T	cg10123293	chr2:99228465	UNC50	0.51	6.79	0.31	3.76e-11	Bipolar disorder;
LUAD	cis	rs6564851	0.506	rs7186423	chr16:81257161	A/G	cg00908271	chr16:81254010	PKD1L2	0.31	6.36	0.3	5.35e-10	Carotenoid and tocopherol levels;
LUAD	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg17063962	chr7:91808500	NA	0.7	12.6	0.52	4.03e-31	Breast cancer;
LUAD	cis	rs4730250	0.708	rs3801965	chr7:106825628	G/T	cg23024343	chr7:107201750	COG5	0.49	7.09	0.33	5.65e-12	Osteoarthritis;
LUAD	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg25767906	chr1:53392781	SCP2	-0.55	-10.32	-0.45	2.04e-22	Monocyte count;
LUAD	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg13606994	chr1:44402422	ARTN	-0.37	-7.33	-0.34	1.19e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg18110333	chr6:292329	DUSP22	-0.79	-13.33	-0.54	4.41e-34	Menopause (age at onset);
LUAD	cis	rs870825	0.860	rs72703527	chr4:185605997	C/A	cg04058563	chr4:185651563	MLF1IP	0.78	10.21	0.44	4.85e-22	Blood protein levels;
LUAD	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg05590025	chr7:65112418	INTS4L2	-0.71	-7.48	-0.34	4.27e-13	Diabetic kidney disease;
LUAD	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg03477792	chr4:77819574	ANKRD56	0.49	7.42	0.34	6.57e-13	Emphysema distribution in smoking;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg05064044	chr6:292385	DUSP22	-0.83	-14.26	-0.57	5.82e-38	Menopause (age at onset);
LUAD	cis	rs10089	0.953	rs758180	chr5:127354423	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	10.04	0.44	2e-21	Ileal carcinoids;
LUAD	cis	rs62400317	0.859	rs56357385	chr6:45203591	C/T	cg20913747	chr6:44695427	NA	-0.43	-6.65	-0.31	9.07e-11	Total body bone mineral density;
LUAD	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg01416388	chr22:39784598	NA	-0.53	-9.0	-0.4	7.79e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg19318889	chr4:1322082	MAEA	0.47	7.75	0.35	6.82e-14	Obesity-related traits;
LUAD	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22857025	chr5:266934	NA	-0.96	-14.42	-0.57	1.32e-38	Breast cancer;
LUAD	cis	rs4372836	0.504	rs3768666	chr2:29005870	C/T	cg09522027	chr2:28974177	PPP1CB	-0.62	-10.96	-0.47	9.05e-25	Body mass index;
LUAD	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs7536201	1.000	rs7523412	chr1:25294264	G/A	cg23273869	chr1:25296894	NA	-0.35	-6.97	-0.32	1.22e-11	Psoriasis vulgaris;
LUAD	cis	rs12200560	0.505	rs211174	chr6:97071120	C/T	cg06623918	chr6:96969491	KIAA0776	0.46	7.02	0.32	8.74e-12	Coronary heart disease;
LUAD	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg14582100	chr15:45693742	SPATA5L1	0.64	12.54	0.52	6.61e-31	Homoarginine levels;
LUAD	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg21951975	chr1:209979733	IRF6	-0.42	-8.22	-0.37	2.57e-15	Orofacial clefts;
LUAD	cis	rs9902453	0.934	rs7213902	chr17:28322935	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.92	0.4	1.45e-17	Coffee consumption (cups per day);
LUAD	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg25319279	chr11:5960081	NA	-0.39	-6.94	-0.32	1.44e-11	DNA methylation (variation);
LUAD	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg00049323	chr5:472564	LOC25845	0.46	7.58	0.35	2.25e-13	Cystic fibrosis severity;
LUAD	cis	rs2414856	0.510	rs10400921	chr15:64661937	C/T	cg08069370	chr15:64387884	SNX1	-0.81	-7.3	-0.33	1.4e-12	Pulse pressure;Systolic blood pressure;
LUAD	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.34	-0.41	5.58e-19	Life satisfaction;
LUAD	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg18306943	chr3:40428807	ENTPD3	0.42	7.04	0.32	7.91e-12	Renal cell carcinoma;
LUAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-9.62	-0.42	6.15e-20	Alzheimer's disease;
LUAD	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg21890820	chr11:65308645	LTBP3	0.48	7.66	0.35	1.27e-13	Bone mineral density;
LUAD	cis	rs12701220	0.595	rs12532837	chr7:1122851	T/A	cg07217954	chr7:1067459	C7orf50	-0.37	-6.49	-0.3	2.47e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs7677751	0.806	rs7673984	chr4:55088761	C/T	cg17187183	chr4:55093834	PDGFRA	0.49	8.23	0.37	2.34e-15	Corneal astigmatism;
LUAD	cis	rs739496	0.947	rs1029388	chr12:111926901	A/G	cg10833066	chr12:111807467	FAM109A	0.46	8.24	0.37	2.18e-15	Platelet count;
LUAD	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg00933542	chr6:150070202	PCMT1	0.44	9.38	0.41	4.12e-19	Lung cancer;
LUAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg00106254	chr7:1943704	MAD1L1	-0.64	-9.77	-0.43	1.8e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg12311346	chr5:56204834	C5orf35	-0.94	-13.82	-0.56	4.26e-36	Initial pursuit acceleration;
LUAD	cis	rs8027181	1.000	rs7166595	chr15:73094204	A/G	cg25632853	chr15:73088954	NA	0.34	7.4	0.34	7.32e-13	Triglyceride levels;
LUAD	cis	rs3125734	0.633	rs3765002	chr10:64006124	G/T	cg19640130	chr10:64028056	RTKN2	-0.34	-7.29	-0.33	1.55e-12	Rheumatoid arthritis;
LUAD	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06022373	chr22:39101656	GTPBP1	0.43	6.75	0.31	5.03e-11	Menopause (age at onset);
LUAD	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.78	0.35	5.76e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg23625390	chr15:77176239	SCAPER	-0.53	-8.13	-0.37	4.71e-15	Blood metabolite levels;
LUAD	cis	rs7017914	0.840	rs13254851	chr8:71689034	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.46	-0.3	2.82e-10	Bone mineral density;
LUAD	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.61	0.35	1.8e-13	Cannabis dependence symptom count;
LUAD	cis	rs17152411	1.000	rs7092008	chr10:126638226	G/A	cg07906193	chr10:126599966	NA	0.55	7.71	0.35	8.92e-14	Height;
LUAD	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg04800585	chr6:26043546	HIST1H2BB	0.34	6.38	0.3	4.77e-10	Blood metabolite levels;
LUAD	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg06271696	chr7:157225062	NA	-0.64	-14.7	-0.58	7.89e-40	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg19761014	chr17:28927070	LRRC37B2	0.8	9.42	0.42	2.99e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs11676855	1.000	rs729866	chr2:235899359	G/A	cg14917874	chr2:235941519	SH3BP4	0.4	6.84	0.32	2.71e-11	Dialysis-related mortality;
LUAD	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg18252515	chr7:66147081	NA	0.6	6.68	0.31	7.56e-11	Diabetic kidney disease;
LUAD	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg02421172	chr7:1938701	MAD1L1	0.46	6.61	0.31	1.15e-10	Bipolar disorder;
LUAD	cis	rs6499255	0.951	rs9921045	chr16:69708698	C/T	cg15192750	chr16:69999425	NA	0.53	8.31	0.37	1.29e-15	IgE levels;
LUAD	cis	rs9462027	0.628	rs2814959	chr6:34705947	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.02	-0.4	6.62e-18	Systemic lupus erythematosus;
LUAD	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.56	-0.3	1.62e-10	Breast cancer;
LUAD	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg03806693	chr22:41940476	POLR3H	-0.82	-11.63	-0.49	2.55e-27	Vitiligo;
LUAD	cis	rs2455799	1.000	rs35226891	chr3:15887668	G/A	cg16303742	chr3:15540471	COLQ	-0.38	-6.69	-0.31	7.24e-11	Mean platelet volume;
LUAD	cis	rs2996428	0.561	rs2275833	chr1:3745721	C/T	cg10555106	chr1:3691387	LOC388588	0.4	6.46	0.3	2.87e-10	Red cell distribution width;
LUAD	cis	rs77741769	0.534	rs58918988	chr12:121332953	G/A	cg02419362	chr12:121203948	SPPL3	0.42	8.6	0.39	1.59e-16	Mean corpuscular volume;
LUAD	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg02049041	chr17:27085579	C17orf63	0.66	8.72	0.39	6.27e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7336332	0.598	rs12018313	chr13:28012266	C/A	cg22138327	chr13:27999177	GTF3A	0.77	9.95	0.44	4.34e-21	Weight;
LUAD	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg02807482	chr3:125708958	NA	-0.66	-8.81	-0.39	3.32e-17	Blood pressure (smoking interaction);
LUAD	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg26354017	chr1:205819088	PM20D1	0.54	8.51	0.38	3.06e-16	Parkinson's disease;
LUAD	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg15017067	chr4:17643749	FAM184B	0.35	6.84	0.32	2.75e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg17366294	chr4:99064904	C4orf37	0.61	11.32	0.48	3.77e-26	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg03289416	chr15:75166202	SCAMP2	0.43	7.31	0.33	1.33e-12	Caffeine consumption;
LUAD	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg04539111	chr16:67997858	SLC12A4	-0.51	-6.36	-0.3	5.34e-10	HDL cholesterol;
LUAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg18402987	chr7:1209562	NA	0.78	9.54	0.42	1.15e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg14092988	chr3:52407081	DNAH1	0.45	8.97	0.4	9.82e-18	Bipolar disorder;
LUAD	cis	rs3849570	0.961	rs3772912	chr3:81698481	A/G	cg07356753	chr3:81810745	GBE1	-0.58	-9.91	-0.43	5.69e-21	Waist circumference;Body mass index;
LUAD	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.48	0.34	4.46e-13	Tonsillectomy;
LUAD	cis	rs6761276	1.000	rs6761276	chr2:113832312	C/T	cg06383401	chr2:113825234	IL1F10	0.3	6.46	0.3	2.85e-10	Protein quantitative trait loci;
LUAD	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.26	0.37	1.91e-15	Breast cancer;
LUAD	cis	rs4072705	0.967	rs4240486	chr9:127341110	C/T	cg13476313	chr9:127244764	NR5A1	0.32	7.56	0.34	2.58e-13	Menarche (age at onset);
LUAD	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg00316803	chr15:76480434	C15orf27	0.43	6.78	0.31	3.97e-11	Blood metabolite levels;
LUAD	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.41	-0.6	7.61e-43	Chronic sinus infection;
LUAD	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg26384229	chr12:38710491	ALG10B	0.48	7.81	0.36	4.47e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg05283184	chr6:79620031	NA	-0.61	-12.41	-0.52	2.26e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg18252515	chr7:66147081	NA	0.57	6.4	0.3	4.13e-10	Diabetic kidney disease;
LUAD	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg19875535	chr5:140030758	IK	0.45	7.45	0.34	5.43e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg06611532	chr13:114900021	NA	0.37	8.7	0.39	7.7e-17	Schizophrenia;
LUAD	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg18404041	chr3:52824283	ITIH1	0.43	7.94	0.36	1.85e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	12.61	0.52	3.74e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.54	8.15	0.37	4.14e-15	Alzheimer's disease;
LUAD	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg22676075	chr6:135203613	NA	0.41	7.69	0.35	1.08e-13	Red blood cell count;
LUAD	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.9	-0.36	2.47e-14	Blood metabolite levels;
LUAD	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg24069376	chr3:38537580	EXOG	0.45	10.92	0.47	1.28e-24	Electrocardiographic conduction measures;
LUAD	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg14458575	chr2:238380390	NA	0.86	12.94	0.53	1.72e-32	Prostate cancer;
LUAD	cis	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg26587870	chr6:27730563	NA	-0.59	-6.5	-0.3	2.32e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg12011299	chr4:100065546	ADH4	0.73	13.53	0.55	6.48e-35	Alcohol dependence;
LUAD	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg16850897	chr7:100343110	ZAN	-0.59	-8.14	-0.37	4.31e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7267979	0.844	rs4423675	chr20:25402778	A/G	cg08601574	chr20:25228251	PYGB	-0.42	-7.91	-0.36	2.34e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg10755058	chr3:40428713	ENTPD3	0.37	7.13	0.33	4.45e-12	Renal cell carcinoma;
LUAD	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg15448220	chr1:150897856	SETDB1	0.52	8.66	0.39	9.68e-17	Melanoma;
LUAD	cis	rs7737355	1.000	rs798416	chr5:130693100	T/C	cg06307176	chr5:131281290	NA	-0.46	-7.32	-0.34	1.29e-12	Life satisfaction;
LUAD	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg00814883	chr7:100076585	TSC22D4	-0.85	-12.48	-0.52	1.24e-30	Platelet count;
LUAD	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg01689657	chr7:91764605	CYP51A1	0.3	7.37	0.34	9.23e-13	Breast cancer;
LUAD	cis	rs9341808	0.667	rs2490239	chr6:80826289	G/A	cg08355045	chr6:80787529	NA	0.51	9.02	0.4	6.58e-18	Sitting height ratio;
LUAD	cis	rs977987	0.806	rs1544810	chr16:75411163	A/T	cg03315344	chr16:75512273	CHST6	0.65	14.18	0.57	1.32e-37	Dupuytren's disease;
LUAD	cis	rs62238980	0.522	rs117246042	chr22:32454080	T/C	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs72928364	1.000	rs34509910	chr3:100717467	T/C	cg10123952	chr3:100791384	NA	0.63	7.31	0.33	1.34e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg01299579	chr2:10830716	NOL10	-0.43	-7.64	-0.35	1.45e-13	Prostate cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01151424	chr11:17411006	KCNJ11	-0.69	-6.66	-0.31	8.63e-11	Type 2 diabetes;
LUAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg16606324	chr3:10149918	C3orf24	0.67	9.78	0.43	1.69e-20	Alzheimer's disease;
LUAD	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg25233709	chr10:116636983	FAM160B1	-0.42	-8.31	-0.37	1.31e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg27454412	chr7:1067447	C7orf50	-0.39	-7.53	-0.34	3.04e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs2479724	0.905	rs2149274	chr6:41839092	T/C	cg17623882	chr6:41773611	USP49	-0.68	-12.76	-0.53	8.8e-32	Menarche (age at onset);
LUAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.22	0.54	1.26e-33	Prudent dietary pattern;
LUAD	cis	rs6543140	0.964	rs4851593	chr2:103089227	C/T	cg04239558	chr2:103089729	SLC9A4	-0.36	-7.28	-0.33	1.66e-12	Blood protein levels;
LUAD	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg11822812	chr5:140052017	DND1	-0.36	-6.51	-0.3	2.17e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg16606324	chr3:10149918	C3orf24	0.67	10.97	0.47	8.41e-25	Alzheimer's disease;
LUAD	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg07936489	chr17:37558343	FBXL20	0.43	6.66	0.31	8.58e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	6.8	0.31	3.53e-11	Multiple sclerosis;
LUAD	cis	rs6489882	0.836	rs12322160	chr12:113368505	A/G	cg20102336	chr12:113376681	OAS3	-0.6	-9.38	-0.42	4.01e-19	Chronic lymphocytic leukemia;
LUAD	trans	rs1973993	0.669	rs510552	chr1:96891671	A/G	cg10631902	chr5:14652156	NA	0.73	15.35	0.6	1.33e-42	Weight;
LUAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg03188948	chr7:1209495	NA	0.38	6.51	0.3	2.12e-10	Longevity;Endometriosis;
LUAD	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg14671364	chr1:107599128	PRMT6	0.49	7.96	0.36	1.62e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs68170813	0.523	rs4730241	chr7:107057361	G/A	cg02696742	chr7:106810147	HBP1	-0.8	-10.68	-0.46	9.78e-24	Coronary artery disease;
LUAD	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg19980929	chr12:42632907	YAF2	-0.33	-6.43	-0.3	3.44e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg19318889	chr4:1322082	MAEA	0.91	15.65	0.61	6.99e-44	Longevity;
LUAD	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg27366882	chr3:133540807	NA	-0.47	-8.78	-0.39	4.23e-17	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg25804541	chr17:80189381	SLC16A3	0.3	6.39	0.3	4.26e-10	Life satisfaction;
LUAD	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg05717871	chr11:638507	DRD4	-0.41	-6.45	-0.3	3.12e-10	Systemic lupus erythematosus;
LUAD	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07343612	chr16:622815	PIGQ	-0.83	-17.0	-0.64	9.1e-50	Height;
LUAD	cis	rs2455799	1.000	rs6805928	chr3:15893237	T/C	cg16303742	chr3:15540471	COLQ	-0.38	-6.69	-0.31	7.24e-11	Mean platelet volume;
LUAD	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg03806693	chr22:41940476	POLR3H	0.58	8.46	0.38	4.56e-16	Vitiligo;
LUAD	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18404041	chr3:52824283	ITIH1	-0.61	-12.24	-0.51	1.1e-29	Bipolar disorder;
LUAD	cis	rs2580764	0.565	rs6545466	chr2:55228392	C/T	cg09592903	chr2:55203963	RTN4	-0.46	-10.65	-0.46	1.24e-23	Mean platelet volume;
LUAD	cis	rs13082711	0.911	rs7637211	chr3:27419868	C/T	cg02860705	chr3:27208620	NA	0.62	9.32	0.41	6.5e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg21171335	chr12:122356390	WDR66	0.66	11.56	0.49	4.73e-27	Mean corpuscular volume;
LUAD	cis	rs786425	0.682	rs34586028	chr12:124187082	T/C	cg02460419	chr12:124198876	ATP6V0A2	0.32	6.36	0.3	5.33e-10	Pubertal anthropometrics;
LUAD	cis	rs9372253	0.509	rs2057149	chr6:110717493	C/T	cg01119278	chr6:110721349	DDO	-0.38	-6.41	-0.3	3.8e-10	Platelet distribution width;
LUAD	cis	rs11077998	0.933	rs4239021	chr17:80531826	T/C	cg10255544	chr17:80519551	FOXK2	0.34	6.66	0.31	8.42e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.55e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg03806693	chr22:41940476	POLR3H	-0.42	-6.54	-0.3	1.75e-10	Neuroticism;
LUAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07157834	chr1:205819609	PM20D1	0.72	14.16	0.57	1.63e-37	Menarche (age at onset);
LUAD	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg02158880	chr13:53174818	NA	0.48	8.31	0.37	1.28e-15	Lewy body disease;
LUAD	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg02569458	chr12:86230093	RASSF9	0.42	7.9	0.36	2.43e-14	Major depressive disorder;
LUAD	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg01579765	chr21:45077557	HSF2BP	-0.58	-13.5	-0.55	8.82e-35	Mean corpuscular volume;
LUAD	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg18854424	chr1:2615690	NA	-0.41	-9.03	-0.4	6.14e-18	Ulcerative colitis;
LUAD	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	6.92	0.32	1.64e-11	Schizophrenia;
LUAD	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg15448220	chr1:150897856	SETDB1	0.57	9.84	0.43	1e-20	Melanoma;
LUAD	cis	rs17767294	0.541	rs72845051	chr6:27610545	G/A	cg08851530	chr6:28072375	NA	0.9	6.76	0.31	4.72e-11	Parkinson's disease;
LUAD	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg02782426	chr3:40428986	ENTPD3	0.42	9.43	0.42	2.85e-19	Renal cell carcinoma;
LUAD	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg25208724	chr1:156163844	SLC25A44	1.13	25.37	0.78	5.68e-87	Testicular germ cell tumor;
LUAD	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg04545296	chr12:48745243	ZNF641	0.39	9.84	0.43	1.02e-20	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg09365446	chr1:150670422	GOLPH3L	0.55	9.62	0.42	6.27e-20	Melanoma;
LUAD	cis	rs1595825	0.945	rs1518369	chr2:198859183	C/T	cg10547527	chr2:198650123	BOLL	-0.5	-7.09	-0.33	5.64e-12	Ulcerative colitis;
LUAD	cis	rs7709909	0.553	rs41097	chr5:80019172	A/G	cg24059623	chr5:79951536	MSH3;DHFR	0.49	7.44	0.34	5.8e-13	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg04851639	chr8:1020857	NA	-0.33	-7.68	-0.35	1.15e-13	Schizophrenia;
LUAD	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg00255919	chr5:131827918	IRF1	0.5	11.9	0.5	2.21e-28	Asthma (sex interaction);
LUAD	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg20203395	chr5:56204925	C5orf35	-0.82	-11.8	-0.5	5.55e-28	Initial pursuit acceleration;
LUAD	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg26169700	chr22:42538906	CYP2D7P1	-0.51	-6.88	-0.32	2.21e-11	Birth weight;
LUAD	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg04989706	chr14:50066350	PPIL5	-0.51	-7.56	-0.35	2.51e-13	Carotid intima media thickness;
LUAD	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.21	0.33	2.52e-12	Rheumatoid arthritis;
LUAD	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg22815214	chr1:201083145	CACNA1S	0.56	9.68	0.43	3.75e-20	Permanent tooth development;
LUAD	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.26e-12	Tonsillectomy;
LUAD	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	15.35	0.6	1.41e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg15181151	chr6:150070149	PCMT1	0.39	7.84	0.36	3.65e-14	Lung cancer;
LUAD	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg14008862	chr17:28927542	LRRC37B2	0.75	7.6	0.35	1.91e-13	Body mass index;
LUAD	cis	rs7617773	0.817	rs4131362	chr3:48329036	A/C	cg11946769	chr3:48343235	NME6	0.42	6.48	0.3	2.48e-10	Coronary artery disease;
LUAD	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.35	-6.87	-0.32	2.32e-11	Glomerular filtration rate;
LUAD	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg04414720	chr1:150670196	GOLPH3L	0.6	10.68	0.46	9.76e-24	Melanoma;
LUAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg24813613	chr7:1882135	MAD1L1	-0.44	-6.89	-0.32	2.05e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg27532560	chr4:187881888	NA	-0.36	-6.59	-0.3	1.34e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg03929089	chr4:120376271	NA	-0.84	-14.95	-0.59	7.16e-41	Height;
LUAD	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg11494091	chr17:61959527	GH2	0.41	7.2	0.33	2.78e-12	Height;
LUAD	cis	rs12210905	0.925	rs12214640	chr6:26762080	G/A	cg11502198	chr6:26597334	ABT1	-0.78	-6.74	-0.31	5.09e-11	Hip circumference adjusted for BMI;
LUAD	trans	rs853679	0.556	rs67297533	chr6:28141253	G/T	cg01620082	chr3:125678407	NA	-1.1	-10.38	-0.45	1.25e-22	Depression;
LUAD	cis	rs11771526	0.892	rs62457541	chr7:32372566	G/A	cg27532318	chr7:32358331	NA	0.68	7.97	0.36	1.44e-14	Body mass index;
LUAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg07677032	chr17:61819896	STRADA	0.57	10.47	0.45	5.87e-23	Prudent dietary pattern;
LUAD	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg11663144	chr21:46675770	NA	-0.61	-12.21	-0.51	1.37e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg16060761	chr17:80687452	NA	-0.53	-7.55	-0.34	2.79e-13	Glycated hemoglobin levels;
LUAD	cis	rs72928364	0.932	rs9832195	chr3:100622392	A/C	cg10123952	chr3:100791384	NA	-0.55	-6.85	-0.32	2.57e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs250585	1.000	rs4968018	chr16:23543131	G/A	cg00143387	chr16:23521605	GGA2	-0.68	-7.99	-0.36	1.27e-14	Egg allergy;
LUAD	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg14668632	chr7:2872130	GNA12	-0.49	-8.56	-0.38	2.17e-16	Height;
LUAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg18099408	chr3:52552593	STAB1	0.53	9.77	0.43	1.8899999999999998e-20	Electroencephalogram traits;
LUAD	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg10560079	chr2:191398806	TMEM194B	0.45	7.95	0.36	1.75e-14	Pulse pressure;
LUAD	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.84	-0.36	3.71e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2275906	0.557	rs62394317	chr6:25882977	T/A	cg03264133	chr6:25882463	NA	-0.54	-6.44	-0.3	3.2e-10	Urate levels in lean individuals;
LUAD	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	11.9	0.5	2.21e-28	Smoking behavior;
LUAD	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg24801067	chr17:62843696	NA	0.65	8.81	0.39	3.22e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6499255	0.904	rs60010276	chr16:69674805	C/T	cg15192750	chr16:69999425	NA	0.49	7.68	0.35	1.15e-13	IgE levels;
LUAD	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg00383909	chr3:49044727	WDR6	0.67	8.49	0.38	3.58e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs447921	0.861	rs62084971	chr17:74425318	T/G	cg17201438	chr17:74438067	UBE2O	-0.63	-8.58	-0.38	1.85e-16	Mitochondrial DNA levels;
LUAD	cis	rs758324	0.812	rs11750031	chr5:131171251	G/A	cg06307176	chr5:131281290	NA	0.45	7.44	0.34	5.55e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	ch.11.42038R	chr11:967971	AP2A2	0.39	6.88	0.32	2.23e-11	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.76	0.31	4.64e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg00184235	chr8:126442434	TRIB1	-0.71	-7.36	-0.34	9.98e-13	Type 2 diabetes;
LUAD	cis	rs12681287	0.640	rs6471314	chr8:87400459	G/A	cg00550725	chr8:87521180	FAM82B	-0.46	-6.66	-0.31	8.62e-11	Caudate activity during reward;
LUAD	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg21211367	chr2:162094118	NA	0.45	7.97	0.36	1.46e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg01028140	chr2:1542097	TPO	-0.48	-7.78	-0.35	5.73e-14	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs17092148	0.887	rs6058104	chr20:33271052	G/A	cg16810054	chr20:33298113	TP53INP2	-0.54	-7.61	-0.35	1.75e-13	Neuroticism;
LUAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg11050988	chr7:1952600	MAD1L1	-0.34	-6.87	-0.32	2.36e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg27411982	chr8:10470053	RP1L1	-0.39	-6.83	-0.32	2.93e-11	Morning vs. evening chronotype;
LUAD	cis	rs758324	0.738	rs648304	chr5:131286708	T/C	cg06307176	chr5:131281290	NA	-0.43	-7.2	-0.33	2.78e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg22681709	chr2:178499509	PDE11A	-0.53	-9.1	-0.4	3.45e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs7395662	0.853	rs10769356	chr11:48444654	T/G	cg00717180	chr2:96193071	NA	-0.38	-7.03	-0.32	8.6e-12	HDL cholesterol;
LUAD	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg24112000	chr20:60950667	NA	-0.87	-15.18	-0.59	7.09e-42	Colorectal cancer;
LUAD	cis	rs7084921	0.520	rs2902377	chr10:101876770	G/A	cg19754520	chr10:101825118	CPN1	-0.32	-6.73	-0.31	5.43e-11	Bone mineral density;
LUAD	cis	rs11811982	0.793	rs111314111	chr1:227569838	C/T	cg24860534	chr1:227506868	CDC42BPA	0.66	7.2	0.33	2.8e-12	Optic disc area;
LUAD	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg03714773	chr7:91764589	CYP51A1	0.3	6.83	0.32	2.9e-11	Breast cancer;
LUAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg10729496	chr3:10149963	C3orf24	0.51	7.98	0.36	1.36e-14	Alzheimer's disease;
LUAD	cis	rs870825	0.929	rs72689261	chr4:185590897	C/A	cg04058563	chr4:185651563	MLF1IP	0.74	9.52	0.42	1.37e-19	Blood protein levels;
LUAD	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg09365446	chr1:150670422	GOLPH3L	0.67	12.58	0.52	4.67e-31	Tonsillectomy;
LUAD	cis	rs9560113	0.959	rs9555803	chr13:112179560	G/T	cg14154082	chr13:112174009	NA	0.36	6.75	0.31	4.77e-11	Menarche (age at onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25654619	chr2:85555411	TGOLN2	-0.42	-6.51	-0.3	2.13e-10	Height;
LUAD	cis	rs1448094	0.872	rs7305869	chr12:86440114	A/G	cg00310523	chr12:86230176	RASSF9	0.34	7.14	0.33	4.03e-12	Major depressive disorder;
LUAD	cis	rs2137111	0.579	rs116951852	chr15:77721319	A/T	cg11865553	chr15:77376250	NA	-0.39	-6.43	-0.3	3.37e-10	Anticoagulant levels;
LUAD	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg01819759	chr13:79234251	RNF219	0.58	8.19	0.37	3.18e-15	Large artery stroke;
LUAD	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg06781209	chr11:61594997	FADS2	-0.41	-7.83	-0.36	4.04e-14	Trans fatty acid levels;
LUAD	cis	rs986417	1.000	rs1269984	chr14:60898138	C/G	cg27398547	chr14:60952738	C14orf39	-0.65	-7.78	-0.35	5.47e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs1950500	0.585	rs8003339	chr14:24817817	T/C	cg22990158	chr14:24802150	ADCY4	-0.47	-8.28	-0.37	1.62e-15	Height;
LUAD	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg04851639	chr8:1020857	NA	-0.41	-10.23	-0.45	4.11e-22	Schizophrenia;
LUAD	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.56	-0.3	1.58e-10	Aortic root size;
LUAD	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg27284194	chr4:1044797	NA	0.71	10.19	0.44	6.08e-22	Recombination rate (females);
LUAD	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg06784218	chr1:46089804	CCDC17	0.6	13.36	0.54	3.41e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg14458575	chr2:238380390	NA	0.99	19.48	0.69	8.86e-61	Prostate cancer;
LUAD	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26314531	chr2:26401878	FAM59B	-0.74	-10.68	-0.46	1.02e-23	Gut microbiome composition (summer);
LUAD	cis	rs240764	0.817	rs239232	chr6:101103038	G/A	cg09795085	chr6:101329169	ASCC3	0.43	7.36	0.34	9.84e-13	Neuroticism;
LUAD	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg03037974	chr15:76606532	NA	0.4	9.01	0.4	7.12e-18	Blood metabolite levels;
LUAD	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg15110403	chr19:17392923	ANKLE1	-0.46	-7.45	-0.34	5.43e-13	Systemic lupus erythematosus;
LUAD	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg13271783	chr10:134563150	INPP5A	-0.41	-6.63	-0.31	9.98e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs17102423	0.723	rs8181937	chr14:65555707	A/C	cg11161011	chr14:65562177	MAX	-0.49	-7.84	-0.36	3.69e-14	Obesity-related traits;
LUAD	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg09455208	chr3:40491958	NA	0.55	12.21	0.51	1.43e-29	Renal cell carcinoma;
LUAD	cis	rs2860975	0.905	rs10786182	chr10:96789775	C/T	cg09036531	chr10:96991505	NA	-0.44	-6.4	-0.3	4.01e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs10821973	0.527	rs4979777	chr10:63981896	C/T	cg09941381	chr10:64027924	RTKN2	-0.34	-6.75	-0.31	4.77e-11	Hypothyroidism;
LUAD	cis	rs3736594	0.802	rs9678824	chr2:27964328	G/C	cg27432699	chr2:27873401	GPN1	0.46	6.99	0.32	1.07e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg22467129	chr15:76604101	ETFA	-0.47	-7.91	-0.36	2.26e-14	Blood metabolite levels;
LUAD	cis	rs9296092	0.517	rs55683509	chr6:33471077	A/G	cg13560919	chr6:33536144	NA	-0.78	-12.25	-0.51	9.84e-30	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg20587970	chr11:113659929	NA	-1.21	-18.1	-0.66	1.21e-54	Hip circumference adjusted for BMI;
LUAD	cis	rs938554	0.910	rs6837336	chr4:9932510	G/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.06	-0.36	8.01e-15	Blood metabolite levels;
LUAD	trans	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.2	-0.33	2.83e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg00074818	chr8:8560427	CLDN23	0.53	8.43	0.38	5.38e-16	Obesity-related traits;
LUAD	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.57	9.99	0.44	3.19e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.57	-8.76	-0.39	4.87e-17	Alzheimer's disease (late onset);
LUAD	cis	rs11031096	0.782	rs4910904	chr11:4165529	C/T	cg18678763	chr11:4115507	RRM1	0.43	7.66	0.35	1.24e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22857025	chr5:266934	NA	-0.99	-14.44	-0.57	1.05e-38	Breast cancer;
LUAD	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg12311346	chr5:56204834	C5orf35	-0.91	-13.41	-0.55	2.07e-34	Initial pursuit acceleration;
LUAD	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg06781209	chr11:61594997	FADS2	0.39	7.56	0.35	2.49e-13	Trans fatty acid levels;
LUAD	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg01689657	chr7:91764605	CYP51A1	0.32	8.17	0.37	3.69e-15	Breast cancer;
LUAD	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg25753631	chr6:25732923	NA	-0.42	-7.44	-0.34	5.79e-13	Iron status biomarkers;
LUAD	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg03388025	chr16:89894329	SPIRE2	0.34	7.68	0.35	1.14e-13	Vitiligo;
LUAD	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg04414720	chr1:150670196	GOLPH3L	-0.49	-8.13	-0.37	4.8e-15	Tonsillectomy;
LUAD	cis	rs2637266	1.000	rs4979784	chr10:78355476	T/A	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs7072216	0.621	rs11189595	chr10:100167322	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-7.43	-0.34	6.01e-13	Metabolite levels;
LUAD	cis	rs6840360	0.967	rs10028961	chr4:152668224	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.44	-0.3	3.26e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1003719	0.788	rs2835605	chr21:38490734	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.47	0.38	4.04e-16	Eye color traits;
LUAD	cis	rs7707921	0.881	rs1428940	chr5:81447995	A/G	cg15871215	chr5:81402204	ATG10	-0.68	-9.67	-0.43	4.17e-20	Breast cancer;
LUAD	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg15147215	chr3:52552868	STAB1	-0.41	-7.43	-0.34	6.14e-13	Bipolar disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09528111	chr14:31495531	AP4S1;STRN3	-0.41	-6.56	-0.3	1.6e-10	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25008156	chr6:170893875	PDCD2	-0.48	-7.29	-0.33	1.55e-12	Height;
LUAD	cis	rs6541297	0.703	rs638116	chr1:230310740	C/T	cg20703242	chr1:230279135	GALNT2	-0.48	-6.99	-0.32	1.08e-11	Coronary artery disease;
LUAD	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg08923669	chr16:420230	MRPL28	-0.47	-6.59	-0.31	1.28e-10	Bone mineral density (spine);Bone mineral density;
LUAD	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22968622	chr17:43663579	NA	1.4	25.89	0.78	2.93e-89	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs12517041	1.000	rs16892385	chr5:23306170	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs6028335	0.610	rs3752291	chr20:37570404	G/T	cg27660920	chr20:37554817	FAM83D	0.55	7.24	0.33	2.18e-12	Alcohol and nicotine co-dependence;
LUAD	cis	rs67981189	0.593	rs7154437	chr14:71441385	A/G	cg15332261	chr14:71375349	PCNX	-0.39	-6.38	-0.3	4.65e-10	Schizophrenia;
LUAD	cis	rs7709909	0.967	rs7712332	chr5:79957835	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.76	-0.31	4.47e-11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs12760731	0.720	rs12047646	chr1:178274083	G/A	cg00404053	chr1:178313656	RASAL2	0.75	9.48	0.42	1.85e-19	Obesity-related traits;
LUAD	cis	rs4268898	1.000	rs1203	chr2:24443330	A/G	cg06627628	chr2:24431161	ITSN2	0.45	7.84	0.36	3.66e-14	Asthma;
LUAD	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg12011299	chr4:100065546	ADH4	-0.74	-13.68	-0.55	1.58e-35	Alcohol dependence;
LUAD	cis	rs11112613	0.713	rs11112588	chr12:105943801	A/C	cg03607813	chr12:105948248	NA	0.84	14.12	0.57	2.41e-37	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg20701182	chr2:24300061	SF3B14	0.57	6.89	0.32	1.98e-11	Lymphocyte counts;
LUAD	cis	rs13112683	0.638	rs4863693	chr4:140786061	T/C	cg02876341	chr4:140783585	MAML3	0.33	7.04	0.32	8e-12	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LUAD	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg06360820	chr2:242988706	NA	-0.88	-11.77	-0.5	7.25e-28	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.87	0.36	2.95e-14	Depression;
LUAD	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg16797656	chr11:68205561	LRP5	0.49	9.04	0.4	5.54e-18	Total body bone mineral density;
LUAD	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.64	12.12	0.51	3.09e-29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs897984	0.762	rs12931046	chr16:30987144	G/A	cg02466173	chr16:30829666	NA	0.65	11.99	0.5	1.06e-28	Dementia with Lewy bodies;
LUAD	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg22491629	chr6:157744540	C6orf35	-0.8	-9.2	-0.41	1.65e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg00981070	chr1:2046702	PRKCZ	-0.36	-7.39	-0.34	7.71e-13	Height;
LUAD	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg10434728	chr15:90938212	IQGAP1	0.36	7.03	0.32	8.46e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg17372223	chr3:52568218	NT5DC2	0.41	7.82	0.36	4.16e-14	Electroencephalogram traits;
LUAD	cis	rs7851660	0.901	rs7873389	chr9:100609230	C/T	cg13688889	chr9:100608707	NA	-0.52	-9.51	-0.42	1.42e-19	Strep throat;
LUAD	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg26958806	chr6:27640298	NA	0.57	6.39	0.3	4.46e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11677416	1.000	rs4848304	chr2:113552737	T/C	cg27083787	chr2:113543245	IL1A	0.4	6.8	0.31	3.52e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg19346786	chr7:2764209	NA	-0.53	-11.58	-0.49	4.02e-27	Height;
LUAD	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg13073564	chr4:8508604	NA	0.6	11.11	0.48	2.43e-25	Response to antineoplastic agents;
LUAD	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg01236616	chr12:121019343	POP5	1.24	19.33	0.68	3.83e-60	Type 1 diabetes nephropathy;
LUAD	cis	rs6087990	0.735	rs2424913	chr20:31374259	C/T	cg13636640	chr20:31349939	DNMT3B	0.68	12.45	0.52	1.5e-30	Ulcerative colitis;
LUAD	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg08997352	chr12:9597637	DDX12	-0.68	-12.05	-0.51	5.86e-29	Breast size;
LUAD	cis	rs59104589	0.617	rs16843642	chr2:242351379	T/G	cg08645257	chr2:242211290	HDLBP	0.46	7.44	0.34	5.86e-13	Fibrinogen levels;
LUAD	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg17757837	chr7:157058334	UBE3C	0.46	8.22	0.37	2.54e-15	Body mass index;
LUAD	cis	rs62400317	0.859	rs10456546	chr6:45217424	C/T	cg20913747	chr6:44695427	NA	-0.4	-6.43	-0.3	3.41e-10	Total body bone mineral density;
LUAD	trans	rs258892	0.947	rs266435	chr5:72174432	C/G	cg14879065	chr14:104662468	NA	-0.35	-6.39	-0.3	4.45e-10	Small cell lung carcinoma;
LUAD	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg11189052	chr15:85197271	WDR73	0.59	7.52	0.34	3.32e-13	Schizophrenia;
LUAD	cis	rs9394169	1.000	rs9394169	chr6:33778964	A/G	cg07979401	chr6:33739406	LEMD2	-0.35	-7.07	-0.33	6.41e-12	Essential tremor;
LUAD	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-8.43	-0.38	5.32e-16	Alzheimer's disease (late onset);
LUAD	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.45	-9.2	-0.41	1.6e-18	Total body bone mineral density;
LUAD	cis	rs7191700	0.674	rs12597893	chr16:11426331	A/G	cg00044050	chr16:11439710	C16orf75	0.71	11.98	0.5	1.17e-28	Multiple sclerosis;
LUAD	cis	rs3819817	0.642	rs4762255	chr12:96348191	G/A	cg07236190	chr12:96338038	AMDHD1	0.41	6.47	0.3	2.78e-10	Vitamin D levels;
LUAD	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.65	-8.48	-0.38	3.7e-16	Iron status biomarkers;
LUAD	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg17063962	chr7:91808500	NA	0.68	12.44	0.52	1.7e-30	Breast cancer;
LUAD	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg06558623	chr16:89946397	TCF25	1.15	10.41	0.45	9.62e-23	Skin colour saturation;
LUAD	cis	rs752010	0.645	rs1109254	chr1:42091770	T/C	cg06885757	chr1:42089581	HIVEP3	0.63	14.03	0.56	5.47e-37	Lupus nephritis in systemic lupus erythematosus;
LUAD	trans	rs1941687	0.563	rs1565784	chr18:31358491	G/T	cg15819921	chr19:927150	ARID3A	0.44	7.42	0.34	6.41e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg09509183	chr1:209979624	IRF6	0.55	8.27	0.37	1.7e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs9826463	0.702	rs73228762	chr3:142325220	A/C	cg20824294	chr3:142316082	PLS1	0.46	6.66	0.31	8.58e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg24399712	chr22:39784796	NA	-0.81	-15.52	-0.6	2.6e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs494562	0.730	rs9362209	chr6:86114491	C/T	cg21730993	chr6:86159210	NT5E	0.57	6.44	0.3	3.16e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs3087591	0.960	rs2269855	chr17:29482878	G/A	cg24425628	chr17:29625626	OMG;NF1	0.41	6.58	0.3	1.36e-10	Hip circumference;
LUAD	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg03037974	chr15:76606532	NA	0.38	8.06	0.36	7.95e-15	Blood metabolite levels;
LUAD	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11890956	chr21:40555474	PSMG1	0.82	14.9	0.59	1.17e-40	Cognitive function;
LUAD	trans	rs7953508	0.711	rs10492321	chr12:93980088	T/A	cg13553693	chr8:26261744	BNIP3L	0.46	6.42	0.3	3.56e-10	Pubertal anthropometrics;
LUAD	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg00757033	chr12:89920650	WDR51B	0.69	12.15	0.51	2.5e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs41311933	0.656	rs80195731	chr9:123827963	G/T	cg13567360	chr9:123745713	C5	-0.72	-8.54	-0.38	2.52e-16	Coronary artery disease;
LUAD	cis	rs10744422	1.000	rs10847869	chr12:123328359	C/G	cg16953816	chr12:123349952	VPS37B	0.62	7.17	0.33	3.34e-12	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg13834670	chr9:129677390	RALGPS1	-0.48	-7.68	-0.35	1.12e-13	Vertical cup-disc ratio;
LUAD	cis	rs28595532	1.000	rs55634130	chr4:119655093	C/T	cg14228332	chr4:119757509	SEC24D	0.78	7.21	0.33	2.55e-12	Cannabis dependence symptom count;
LUAD	cis	rs11255291	0.668	rs719748	chr10:7731885	A/G	cg13340899	chr10:7670827	ITIH5	0.39	6.85	0.32	2.58e-11	Ovarian reserve;
LUAD	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg08859206	chr1:53392774	SCP2	-0.53	-9.41	-0.42	3.17e-19	Monocyte count;
LUAD	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg05665937	chr4:1216051	CTBP1	0.42	6.99	0.32	1.06e-11	Obesity-related traits;
LUAD	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg18306943	chr3:40428807	ENTPD3	0.41	6.84	0.32	2.75e-11	Renal cell carcinoma;
LUAD	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg23533926	chr12:111358616	MYL2	-0.43	-7.34	-0.34	1.07e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.51e-10	Prudent dietary pattern;
LUAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg22907277	chr7:1156413	C7orf50	0.7	8.24	0.37	2.2e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.26e-12	Tonsillectomy;
LUAD	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg26850624	chr5:429559	AHRR	-0.42	-6.65	-0.31	9.24e-11	Cystic fibrosis severity;
LUAD	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg00310523	chr12:86230176	RASSF9	0.42	8.35	0.38	9.88e-16	Major depressive disorder;
LUAD	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg16479474	chr6:28041457	NA	0.44	7.44	0.34	5.83e-13	Depression;
LUAD	cis	rs477692	0.544	rs7904404	chr10:131447612	G/A	cg05714579	chr10:131428358	MGMT	-0.45	-7.03	-0.32	8.15e-12	Response to temozolomide;
LUAD	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs9354308	0.901	rs2814096	chr6:66566131	G/A	cg07460842	chr6:66804631	NA	0.49	7.25	0.33	1.99e-12	Metabolite levels;
LUAD	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg14196790	chr5:131705035	SLC22A5	0.53	9.48	0.42	1.78e-19	Blood metabolite levels;
LUAD	cis	rs9902453	0.704	rs1972305	chr17:28533880	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.42	6.75	0.31	5.03e-11	Coffee consumption (cups per day);
LUAD	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg05340658	chr4:99064831	C4orf37	0.54	9.23	0.41	1.3e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg06636001	chr8:8085503	FLJ10661	0.45	7.0	0.32	1e-11	Systolic blood pressure;
LUAD	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06022373	chr22:39101656	GTPBP1	0.46	7.11	0.33	4.84e-12	Menopause (age at onset);
LUAD	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg06608945	chr2:219082296	ARPC2	-0.52	-8.92	-0.4	1.38e-17	Colorectal cancer;
LUAD	cis	rs397969	0.646	rs427033	chr17:19803244	C/T	cg04132472	chr17:19861366	AKAP10	0.34	6.95	0.32	1.39e-11	Platelet count;
LUAD	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg10518543	chr12:38710700	ALG10B	-0.49	-7.94	-0.36	1.87e-14	Morning vs. evening chronotype;
LUAD	cis	rs977987	0.806	rs8050059	chr16:75388731	C/T	cg03315344	chr16:75512273	CHST6	0.66	14.28	0.57	4.83e-38	Dupuytren's disease;
LUAD	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg24308560	chr3:49941425	MST1R	-0.48	-7.99	-0.36	1.25e-14	Body mass index;
LUAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg08132940	chr7:1081526	C7orf50	-0.77	-10.29	-0.45	2.49e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.41	0.55	2.12e-34	Prudent dietary pattern;
LUAD	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg06558623	chr16:89946397	TCF25	1.15	12.15	0.51	2.46e-29	Skin colour saturation;
LUAD	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg22823121	chr1:150693482	HORMAD1	0.42	8.31	0.37	1.28e-15	Tonsillectomy;
LUAD	cis	rs1595825	0.891	rs74965164	chr2:198499162	C/T	cg11031976	chr2:198649780	BOLL	-0.46	-6.81	-0.31	3.32e-11	Ulcerative colitis;
LUAD	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg00339695	chr16:24857497	SLC5A11	0.48	8.84	0.39	2.58e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.85	0.32	2.55e-11	Blood metabolite levels;
LUAD	cis	rs55665837	1.000	rs10832264	chr11:14459982	T/A	cg19336497	chr11:14380999	RRAS2	-0.5	-10.1	-0.44	1.27e-21	Vitamin D levels;
LUAD	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-13.58	-0.55	4.08e-35	Chronic sinus infection;
LUAD	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg12062639	chr20:23401060	NAPB	1.09	11.27	0.48	6.24e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7953508	0.636	rs10859535	chr12:93979892	A/G	cg18151635	chr12:93972918	NA	-0.73	-11.26	-0.48	6.48e-26	Pubertal anthropometrics;
LUAD	cis	rs67072384	1.000	rs12294368	chr11:72451239	G/A	cg04827223	chr11:72435913	ARAP1	-0.61	-7.31	-0.33	1.35e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs59104589	0.583	rs61689231	chr2:242244583	G/A	cg08645257	chr2:242211290	HDLBP	0.5	7.88	0.36	2.87e-14	Fibrinogen levels;
LUAD	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.77	-0.31	4.27e-11	Height;
LUAD	cis	rs8077889	1.000	rs8077889	chr17:41878166	G/T	cg26893861	chr17:41843967	DUSP3	-0.88	-14.0	-0.56	7.32e-37	Triglycerides;
LUAD	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg22683308	chr4:1340831	KIAA1530	-0.42	-6.71	-0.31	6.42e-11	Longevity;
LUAD	cis	rs7116495	0.786	rs10736785	chr11:71718912	C/A	cg07596299	chr11:71824057	C11orf51	-0.76	-6.52	-0.3	2.03e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg00634984	chr7:65235879	NA	0.47	6.44	0.3	3.28e-10	Aortic root size;
LUAD	cis	rs11955175	1.000	rs75929994	chr5:40821816	T/C	cg05478818	chr5:40835740	RPL37	0.79	6.65	0.31	8.94e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs300774	0.925	rs300720	chr2:134472	A/G	cg21211680	chr2:198530	NA	-0.47	-7.38	-0.34	8.37e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs6840360	0.533	rs13121190	chr4:152729072	T/G	cg22705602	chr4:152727874	NA	0.46	9.0	0.4	7.59e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs889398	0.802	rs8050414	chr16:69886813	T/A	cg00738113	chr16:70207722	CLEC18C	-0.34	-6.82	-0.31	3.21e-11	Body mass index;
LUAD	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg15128208	chr22:42549153	NA	0.4	6.48	0.3	2.5e-10	Birth weight;
LUAD	cis	rs2749592	0.918	rs4934590	chr10:37877569	T/C	cg25427524	chr10:38739819	LOC399744	0.6	8.98	0.4	8.8e-18	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	trans	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg14917512	chr19:3094685	GNA11	0.56	6.72	0.31	6.04e-11	Diabetic kidney disease;
LUAD	cis	rs11771526	1.000	rs11771526	chr7:32342618	A/G	cg27511599	chr7:32358540	NA	0.58	6.91	0.32	1.81e-11	Body mass index;
LUAD	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg18190219	chr22:46762943	CELSR1	-0.5	-6.45	-0.3	3.12e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23158103	chr7:148848205	ZNF398	-0.63	-11.28	-0.48	5.49e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg24644049	chr4:85504048	CDS1	0.84	6.88	0.32	2.23e-11	Skin colour saturation;
LUAD	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg08999081	chr20:33150536	PIGU	0.63	14.03	0.56	5.5e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.39	-0.34	7.8e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg10596483	chr8:143751796	JRK	0.44	6.99	0.32	1.1e-11	Schizophrenia;
LUAD	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg10556349	chr10:835070	NA	0.6	7.63	0.35	1.55e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs4481887	0.893	rs7538645	chr1:248478137	C/T	cg13385794	chr1:248469461	NA	0.26	7.0	0.32	1.01e-11	Common traits (Other);
LUAD	cis	rs2677744	0.626	rs2001216	chr15:91498130	T/C	cg23684204	chr15:91497937	RCCD1	0.44	7.36	0.34	9.59e-13	Attention deficit hyperactivity disorder;
LUAD	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg01017244	chr2:74357527	NA	-0.76	-10.57	-0.46	2.46e-23	Gestational age at birth (maternal effect);
LUAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg11062466	chr8:58055876	NA	0.68	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7680126	0.644	rs4697703	chr4:10107431	A/G	cg02734326	chr4:10020555	SLC2A9	-0.47	-6.47	-0.3	2.67e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs11809207	1.000	rs4659412	chr1:26518470	C/T	cg00147160	chr1:26503991	CNKSR1	0.42	8.45	0.38	4.84e-16	Height;
LUAD	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg18252515	chr7:66147081	NA	-0.61	-6.78	-0.31	4.07e-11	Diabetic kidney disease;
LUAD	cis	rs7633770	0.841	rs11709020	chr3:46680063	A/G	cg11219411	chr3:46661640	NA	-0.62	-12.85	-0.53	3.74e-32	Coronary artery disease;
LUAD	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-7.43	-0.34	6.04e-13	Alzheimer's disease (late onset);
LUAD	cis	rs4722404	0.502	rs13223548	chr7:3110446	T/C	cg19214707	chr7:3157722	NA	-0.44	-6.97	-0.32	1.21e-11	Atopic dermatitis;
LUAD	cis	rs89107	0.651	rs2356080	chr6:118609174	G/T	cg18833306	chr6:118973337	C6orf204	0.51	9.15	0.41	2.42e-18	Cardiac structure and function;
LUAD	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg12310025	chr6:25882481	NA	-0.53	-7.81	-0.35	4.65e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg26343298	chr8:95960752	TP53INP1	0.38	7.96	0.36	1.64e-14	Type 2 diabetes;
LUAD	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg19163074	chr7:65112434	INTS4L2	0.45	6.83	0.32	3e-11	Aortic root size;
LUAD	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.66	-10.7	-0.46	8.08e-24	IgG glycosylation;
LUAD	cis	rs2637266	1.000	rs7914880	chr10:78363693	A/G	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	cis	rs4906332	0.966	rs7159665	chr14:103984616	C/T	cg13511324	chr14:104056883	C14orf153	0.26	6.39	0.3	4.38e-10	Coronary artery disease;
LUAD	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-8.38	-0.38	8.11e-16	Alzheimer's disease (late onset);
LUAD	trans	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg11693508	chr17:37793320	STARD3	0.7	9.28	0.41	8.95e-19	Bipolar disorder;
LUAD	cis	rs4664308	0.935	rs6739867	chr2:160942818	G/A	cg03641300	chr2:160917029	PLA2R1	-0.37	-6.43	-0.3	3.44e-10	Idiopathic membranous nephropathy;
LUAD	trans	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg01620082	chr3:125678407	NA	-0.72	-7.28	-0.33	1.62e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs75920871	0.925	rs61903418	chr11:116956665	G/A	cg04087571	chr11:116723030	SIK3	-0.33	-6.69	-0.31	7.14e-11	Subjective well-being;
LUAD	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg00666640	chr1:248458726	OR2T12	0.32	7.67	0.35	1.2e-13	Common traits (Other);
LUAD	cis	rs2274273	0.743	rs13379159	chr14:55540801	C/T	cg04306507	chr14:55594613	LGALS3	0.31	6.53	0.3	1.85e-10	Protein biomarker;
LUAD	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg02993280	chr1:107599747	PRMT6	-0.46	-7.72	-0.35	8.72e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg00310523	chr12:86230176	RASSF9	0.42	8.42	0.38	6.08e-16	Major depressive disorder;
LUAD	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg25457927	chr22:38595422	NA	0.59	15.53	0.6	2.38e-43	Cutaneous nevi;
LUAD	cis	rs2797160	0.935	rs60515555	chr6:126000638	T/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.73	-0.31	5.6e-11	Endometrial cancer;
LUAD	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.67	0.35	1.19e-13	Bladder cancer;
LUAD	cis	rs7851660	0.809	rs35324451	chr9:100660136	A/T	cg13688889	chr9:100608707	NA	-0.56	-9.38	-0.42	3.93e-19	Strep throat;
LUAD	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18876405	chr7:65276391	NA	0.44	6.96	0.32	1.33e-11	Aortic root size;
LUAD	cis	rs250677	0.522	rs6580589	chr5:148360335	C/G	cg12140854	chr5:148520817	ABLIM3	0.57	8.98	0.4	9.03e-18	Breast cancer;
LUAD	cis	rs12618769	0.543	rs72819971	chr2:99034846	T/G	cg10123293	chr2:99228465	UNC50	0.45	7.99	0.36	1.3e-14	Bipolar disorder;
LUAD	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.37	7.71	0.35	9.06e-14	Hemoglobin concentration;
LUAD	trans	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.76	-0.35	6.63e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17102423	0.740	rs35520739	chr14:65577612	T/C	cg16583315	chr14:65563665	MAX	0.35	6.59	0.31	1.34e-10	Obesity-related traits;
LUAD	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg25985355	chr7:65971099	NA	-0.52	-6.56	-0.3	1.57e-10	Diabetic kidney disease;
LUAD	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg17366294	chr4:99064904	C4orf37	0.47	8.34	0.38	1.03e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg21385606	chr21:47601150	C21orf56	0.36	6.47	0.3	2.75e-10	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg08219700	chr8:58056026	NA	0.5	7.25	0.33	1.99e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg10729496	chr3:10149963	C3orf24	-0.54	-8.82	-0.39	3.05e-17	Alzheimer's disease;
LUAD	trans	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg01620082	chr3:125678407	NA	-1.08	-10.31	-0.45	2.2e-22	Depression;
LUAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.55	-0.42	1.06e-19	Alzheimer's disease;
LUAD	trans	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg27411982	chr8:10470053	RP1L1	0.44	7.9	0.36	2.44e-14	Mood instability;
LUAD	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg08761264	chr16:28874980	SH2B1	-0.45	-6.9	-0.32	1.88e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg15147215	chr3:52552868	STAB1	-0.38	-6.87	-0.32	2.28e-11	Bipolar disorder;
LUAD	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg16797656	chr11:68205561	LRP5	0.47	9.41	0.42	3.17e-19	Total body bone mineral density;
LUAD	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg00106254	chr7:1943704	MAD1L1	-0.57	-8.8	-0.39	3.43e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg17120908	chr11:65337727	SSSCA1	-0.6	-9.51	-0.42	1.41e-19	Bone mineral density;
LUAD	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs7520050	0.966	rs11810993	chr1:46478793	A/G	cg06784218	chr1:46089804	CCDC17	-0.3	-6.4	-0.3	4.02e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs1941023	0.584	rs10897057	chr11:60172273	A/T	cg08716584	chr11:60157161	MS4A7	-0.45	-8.55	-0.38	2.29e-16	Congenital heart disease (maternal effect);
LUAD	cis	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.87	-0.36	3.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.51	-0.34	3.45e-13	Resting heart rate;
LUAD	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	cg06064525	chr11:970664	AP2A2	-0.37	-7.02	-0.32	8.76e-12	Alzheimer's disease (late onset);
LUAD	cis	rs7147624	1.000	rs10135969	chr14:65982345	C/T	cg03016385	chr14:66212404	NA	-0.6	-7.12	-0.33	4.61e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs7927592	0.546	rs599083	chr11:68192346	T/G	cg02221422	chr11:68192511	LRP5	-0.46	-7.29	-0.33	1.56e-12	Total body bone mineral density;
LUAD	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg27144592	chr16:783916	NARFL	0.74	12.74	0.53	1.08e-31	Height;
LUAD	cis	rs7043114	0.525	rs7026361	chr9:95138564	A/C	cg14631576	chr9:95140430	CENPP	0.39	7.62	0.35	1.63e-13	Height;
LUAD	trans	rs7944735	0.567	rs7111404	chr11:48011283	C/G	cg15704280	chr7:45808275	SEPT13	0.6	6.61	0.31	1.16e-10	Intraocular pressure;
LUAD	cis	rs6942407	0.546	rs7810647	chr7:86805961	C/A	cg02420886	chr7:86849541	C7orf23	0.61	7.06	0.32	6.67e-12	Food allergy;
LUAD	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.68	-0.58	1.03e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg03037974	chr15:76606532	NA	-0.35	-7.7	-0.35	9.4e-14	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg11062466	chr8:58055876	NA	0.65	8.81	0.39	3.35e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg25985355	chr7:65971099	NA	-0.53	-6.55	-0.3	1.66e-10	Diabetic kidney disease;
LUAD	cis	rs727505	1.000	rs7790856	chr7:124459852	C/T	cg23710748	chr7:124431027	NA	-0.44	-9.43	-0.42	2.78e-19	Lewy body disease;
LUAD	cis	rs10170310	0.608	rs10928657	chr2:139291769	G/A	cg03782584	chr2:139258740	SPOPL	0.32	6.48	0.3	2.52e-10	Response to antipsychotic treatment;
LUAD	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg23262351	chr6:79576851	IRAK1BP1	0.41	6.83	0.32	2.92e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg25251562	chr2:3704773	ALLC	-0.43	-7.63	-0.35	1.5700000000000001e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg21427119	chr20:30132790	HM13	-0.5	-8.0	-0.36	1.21e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg13047869	chr3:10149882	C3orf24	-0.55	-7.93	-0.36	2e-14	Alzheimer's disease;
LUAD	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.08	-0.33	6.16e-12	Lung cancer;
LUAD	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21659725	chr3:3221576	CRBN	-0.5	-8.3	-0.37	1.38e-15	Body mass index;
LUAD	cis	rs9837602	0.810	rs9854260	chr3:99850212	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.58	8.3	0.37	1.37e-15	Breast cancer;
LUAD	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.55e-11	Crohn's disease;
LUAD	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg15432903	chr11:17409602	KCNJ11	0.51	9.52	0.42	1.38e-19	Type 2 diabetes;
LUAD	cis	rs244899	0.935	rs2445786	chr5:167930877	G/A	cg06604206	chr5:167912465	RARS	-0.4	-6.94	-0.32	1.46e-11	Response to platinum-based chemotherapy (carboplatin);
LUAD	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg20587970	chr11:113659929	NA	-1.4	-20.93	-0.71	2.68e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg06453172	chr10:134556979	INPP5A	-0.77	-10.9	-0.47	1.5e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7681423	0.951	rs6050	chr4:155507590	C/T	cg20735720	chr4:155535218	FGG	0.48	7.33	0.34	1.17e-12	Fibrinogen;
LUAD	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg01579765	chr21:45077557	HSF2BP	-0.59	-13.77	-0.56	6.72e-36	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg05340658	chr4:99064831	C4orf37	-0.46	-7.21	-0.33	2.66e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs587242	0.528	rs77824669	chr1:97205475	T/C	cg10631902	chr5:14652156	NA	0.39	6.65	0.31	9.33e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg23283495	chr1:209979779	IRF6	0.41	7.35	0.34	1.02e-12	Monobrow;
LUAD	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-7.43	-0.34	6.11e-13	Neutrophil percentage of white cells;
LUAD	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.49	7.95	0.36	1.67e-14	Lymphocyte percentage of white cells;
LUAD	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.32	6.97	0.32	1.23e-11	Cardiac Troponin-T levels;
LUAD	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg27471124	chr11:109292789	C11orf87	0.36	7.11	0.33	4.87e-12	Schizophrenia;
LUAD	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg21775007	chr8:11205619	TDH	0.47	8.11	0.37	5.36e-15	Retinal vascular caliber;
LUAD	trans	rs7939886	0.920	rs1482009	chr11:55884690	T/G	cg15704280	chr7:45808275	SEPT13	0.67	6.56	0.3	1.59e-10	Myopia (pathological);
LUAD	cis	rs9914988	0.576	rs11080075	chr17:27322441	A/C	cg02049041	chr17:27085579	C17orf63	-0.51	-6.48	-0.3	2.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg15181151	chr6:150070149	PCMT1	0.39	7.91	0.36	2.31e-14	Lung cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23365392	chr7:99970074	PILRA	-0.47	-6.95	-0.32	1.39e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4737010	0.501	rs55694640	chr8:41649439	T/G	cg08923054	chr8:41654455	ANK1	0.4	6.47	0.3	2.64e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.41	-0.34	7.13e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7589728	0.748	rs3791357	chr2:88478664	C/T	cg14558114	chr2:88469736	THNSL2	0.75	7.23	0.33	2.23e-12	Plasma clusterin levels;
LUAD	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg14343924	chr8:8086146	FLJ10661	0.51	8.09	0.37	6.55e-15	Systolic blood pressure;
LUAD	cis	rs2425143	1.000	rs73902908	chr20:34365112	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.01	-0.32	9.67e-12	Blood protein levels;
LUAD	cis	rs9972944	0.756	rs7215462	chr17:63770498	T/C	cg07283582	chr17:63770753	CCDC46	-0.51	-11.6	-0.49	3.32e-27	Total body bone mineral density;
LUAD	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg08470875	chr2:26401718	FAM59B	0.76	10.08	0.44	1.47e-21	Gut microbiome composition (summer);
LUAD	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg00316803	chr15:76480434	C15orf27	-0.37	-7.28	-0.33	1.69e-12	Blood metabolite levels;
LUAD	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.54	-9.58	-0.42	8.2e-20	Prudent dietary pattern;
LUAD	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg09835421	chr16:68378352	PRMT7	-0.79	-8.59	-0.39	1.63e-16	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs3219090	0.861	rs1858548	chr1:226607774	A/G	cg27539482	chr13:111589090	NA	0.41	6.61	0.31	1.18e-10	Melanoma;
LUAD	cis	rs6062509	0.965	rs6062504	chr20:62348907	A/G	cg01176363	chr20:62369445	LIME1	-0.48	-7.78	-0.35	5.67e-14	Prostate cancer;
LUAD	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-7.27	-0.33	1.77e-12	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg07917127	chr4:99064746	C4orf37	0.4	6.66	0.31	8.78e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg22681709	chr2:178499509	PDE11A	-0.49	-8.35	-0.38	9.75e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.79e-18	Life satisfaction;
LUAD	cis	rs12681287	0.546	rs11539113	chr8:87497176	G/A	cg27223183	chr8:87520930	FAM82B	-0.71	-10.12	-0.44	1.05e-21	Caudate activity during reward;
LUAD	cis	rs7927771	0.524	rs2869024	chr11:47674101	G/A	cg18512352	chr11:47633146	NA	-0.37	-6.56	-0.3	1.54e-10	Subjective well-being;
LUAD	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg15017067	chr4:17643749	FAM184B	0.35	6.8	0.31	3.54e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4588572	0.643	rs6874309	chr5:77774498	A/T	cg11547950	chr5:77652471	NA	0.76	12.44	0.52	1.64e-30	Triglycerides;
LUAD	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg24813613	chr7:1882135	MAD1L1	-0.55	-9.08	-0.4	4.08e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg17264618	chr3:40429014	ENTPD3	0.42	8.99	0.4	8.15e-18	Renal cell carcinoma;
LUAD	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg27284194	chr4:1044797	NA	0.71	10.33	0.45	1.88e-22	Recombination rate (females);
LUAD	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.51	-0.3	2.1e-10	Neutrophil percentage of white cells;
LUAD	cis	rs13191362	0.507	rs13210000	chr6:163176944	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.42	6.6	0.31	1.2e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg04000281	chr11:63949212	NA	-0.29	-6.71	-0.31	6.24e-11	Platelet count;
LUAD	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg20556744	chr2:9614537	IAH1	0.66	6.56	0.3	1.55e-10	Opioid sensitivity;
LUAD	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg04944784	chr2:26401820	FAM59B	-0.7	-9.93	-0.43	5.07e-21	Gut microbiome composition (summer);
LUAD	cis	rs1032833	0.732	rs79839178	chr2:180031881	C/T	cg23883738	chr2:179974586	SESTD1	-0.65	-7.31	-0.34	1.32e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.1	-24.16	-0.76	1.18e-81	Ulcerative colitis;
LUAD	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg02753203	chr1:228287806	NA	0.77	14.07	0.56	3.73e-37	Diastolic blood pressure;
LUAD	cis	rs250677	0.687	rs2963485	chr5:148452043	A/G	cg23229984	chr5:148520753	ABLIM3	-0.42	-6.71	-0.31	6.43e-11	Breast cancer;
LUAD	cis	rs701145	0.640	rs357495	chr3:153939099	A/G	cg17054900	chr3:154042577	DHX36	0.66	7.56	0.34	2.6e-13	Coronary artery disease;
LUAD	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg25985355	chr7:65971099	NA	0.39	7.3	0.33	1.48e-12	Aortic root size;
LUAD	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg23173402	chr1:227635558	NA	0.74	7.94	0.36	1.85e-14	Major depressive disorder;
LUAD	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg16479474	chr6:28041457	NA	0.44	7.4	0.34	7.22e-13	Depression;
LUAD	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg03714773	chr7:91764589	CYP51A1	0.3	7.09	0.33	5.66e-12	Breast cancer;
LUAD	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21582582	chr3:182698605	DCUN1D1	0.59	10.06	0.44	1.75e-21	Intelligence (multi-trait analysis);
LUAD	trans	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.57	0.42	8.93e-20	Mean corpuscular volume;
LUAD	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11890956	chr21:40555474	PSMG1	-0.64	-11.07	-0.47	3.36e-25	Cognitive function;
LUAD	cis	rs870825	0.616	rs7682505	chr4:185640648	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	14.17	0.57	1.49e-37	Blood protein levels;
LUAD	trans	rs2235573	0.625	rs1883471	chr22:38417510	T/C	cg19894588	chr14:64061835	NA	0.43	6.67	0.31	8.13e-11	Glioblastoma;Glioma;
LUAD	cis	rs2806561	0.894	rs598438	chr1:23531563	C/T	cg19743168	chr1:23544995	NA	0.45	8.29	0.37	1.5e-15	Height;
LUAD	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg01579765	chr21:45077557	HSF2BP	-0.62	-15.05	-0.59	2.68e-41	Mean corpuscular volume;
LUAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg18402987	chr7:1209562	NA	0.63	9.2	0.41	1.63e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg07636037	chr3:49044803	WDR6	0.65	12.67	0.52	2.08e-31	Parkinson's disease;
LUAD	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg03684893	chr10:554711	DIP2C	-0.39	-6.9	-0.32	1.92e-11	Psychosis in Alzheimer's disease;
LUAD	trans	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg07817883	chr1:32538562	TMEM39B	-0.52	-7.19	-0.33	2.98e-12	Monocyte percentage of white cells;
LUAD	cis	rs4653767	1.000	rs4653767	chr1:226916078	T/C	cg05049329	chr1:226924846	ITPKB	0.47	8.18	0.37	3.38e-15	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	7.09	0.33	5.66e-12	Parkinson's disease;
LUAD	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg07570687	chr10:102243282	WNT8B	0.44	6.63	0.31	1e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.61	-0.35	1.86e-13	Lung cancer;
LUAD	cis	rs9473147	0.516	rs9296564	chr6:47494759	A/G	cg12968598	chr6:47444699	CD2AP	0.35	6.4	0.3	4.2e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg02683114	chr2:24398427	C2orf84	-0.53	-7.78	-0.35	5.67e-14	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs12545109	0.879	rs2670015	chr8:57376607	T/A	cg19413350	chr8:57351067	NA	-0.47	-7.07	-0.33	6.31e-12	Obesity-related traits;
LUAD	cis	rs1113500	0.805	rs11185244	chr1:108601147	C/T	cg06207961	chr1:108661230	NA	0.35	6.62	0.31	1.07e-10	Growth-regulated protein alpha levels;
LUAD	trans	rs800082	1.000	rs12637885	chr3:144291254	G/T	cg24215973	chr2:240111563	HDAC4	-0.41	-6.35	-0.3	5.53e-10	Smoking behavior;
LUAD	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.75	0.39	5.3e-17	Menarche (age at onset);
LUAD	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.4	0.34	7.47e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7592578	0.603	rs12476782	chr2:191472880	G/A	cg10560079	chr2:191398806	TMEM194B	-0.49	-6.38	-0.3	4.69e-10	Diastolic blood pressure;
LUAD	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg09904177	chr6:26538194	HMGN4	0.44	7.41	0.34	6.96e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg23711669	chr6:146136114	FBXO30	0.38	6.39	0.3	4.39e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11051970	0.636	rs2651368	chr12:32561506	T/C	cg02745156	chr12:32552066	NA	0.31	6.66	0.31	8.77e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.84	-11.57	-0.49	4.45e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg11822812	chr5:140052017	DND1	-0.41	-7.48	-0.34	4.24e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs13064411	0.627	rs28710051	chr3:113143531	G/A	cg18753928	chr3:113234510	CCDC52	-0.69	-11.23	-0.48	8.99e-26	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg08989290	chr16:615782	NHLRC4	0.33	7.06	0.32	6.93e-12	Height;
LUAD	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg02079420	chr8:82753780	SNX16	0.42	8.61	0.39	1.49e-16	Diastolic blood pressure;
LUAD	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg26384229	chr12:38710491	ALG10B	-0.43	-7.23	-0.33	2.32e-12	Morning vs. evening chronotype;
LUAD	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.59	-0.31	1.33e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg17425144	chr1:10567563	PEX14	0.62	12.75	0.53	1.03e-31	Breast cancer;
LUAD	cis	rs2479724	0.792	rs7739064	chr6:41834037	C/A	cg17623882	chr6:41773611	USP49	-0.67	-12.45	-0.52	1.5e-30	Menarche (age at onset);
LUAD	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg05872129	chr22:39784769	NA	-0.8	-15.59	-0.6	1.31e-43	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg26677194	chr12:130822605	PIWIL1	0.55	9.04	0.4	5.6e-18	Menopause (age at onset);
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg15383120	chr6:291909	DUSP22	-0.68	-11.51	-0.49	7.41e-27	Menopause (age at onset);
LUAD	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg00495681	chr13:53174319	NA	-0.53	-9.79	-0.43	1.51e-20	Lewy body disease;
LUAD	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg15704280	chr7:45808275	SEPT13	-0.9	-16.76	-0.63	1.06e-48	Height;
LUAD	cis	rs7927771	0.524	rs7936948	chr11:47704200	T/G	cg18512352	chr11:47633146	NA	0.37	6.63	0.31	9.96e-11	Subjective well-being;
LUAD	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg01200585	chr1:228362443	C1orf69	-0.38	-7.08	-0.33	6.11e-12	Diastolic blood pressure;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg19898230	chr1:37980216	MEAF6	-0.68	-7.0	-0.32	1.02e-11	Type 2 diabetes;
LUAD	cis	rs89107	0.576	rs12661338	chr6:118794690	C/A	cg21191810	chr6:118973309	C6orf204	0.4	7.43	0.34	6.21e-13	Cardiac structure and function;
LUAD	cis	rs68170813	0.559	rs12536603	chr7:107002573	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-10.32	-0.45	2.03e-22	Coronary artery disease;
LUAD	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg16325326	chr1:53192061	ZYG11B	0.63	12.35	0.51	3.9e-30	Monocyte count;
LUAD	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg11645453	chr3:52864694	ITIH4	0.36	6.59	0.31	1.3100000000000001e-10	Bipolar disorder;
LUAD	cis	rs9287719	0.747	rs1534400	chr2:10696833	T/C	cg03983476	chr2:10830698	NOL10	-0.45	-7.51	-0.34	3.62e-13	Prostate cancer;
LUAD	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.45	7.46	0.34	4.96e-13	Fear of minor pain;
LUAD	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.64	-0.35	1.46e-13	Lung cancer;
LUAD	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg09137382	chr11:130731461	NA	0.44	8.16	0.37	3.81e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs60154123	0.772	rs664072	chr1:210422160	G/A	cg22029157	chr1:209979665	IRF6	0.65	7.07	0.32	6.63e-12	Coronary artery disease;
LUAD	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg22442454	chr1:209979470	IRF6	0.55	7.3	0.33	1.44e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg02423579	chr7:2872169	GNA12	-0.57	-9.81	-0.43	1.32e-20	Height;
LUAD	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg00814883	chr7:100076585	TSC22D4	-0.77	-10.37	-0.45	1.3e-22	Platelet count;
LUAD	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg20701182	chr2:24300061	SF3B14	0.57	6.9	0.32	1.9e-11	Lymphocyte counts;
LUAD	cis	rs78487399	0.808	rs10200815	chr2:43673273	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-6.47	-0.3	2.75e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.57	-9.16	-0.41	2.28e-18	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs2996428	0.628	rs6667526	chr1:3774603	G/A	cg23277830	chr1:3704460	LRRC47	0.4	7.92	0.36	2.09e-14	Red cell distribution width;
LUAD	trans	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg02002194	chr4:3960332	NA	-0.3	-7.1	-0.33	5.28e-12	Mood instability;
LUAD	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-6.82	-0.31	3.23e-11	Personality dimensions;
LUAD	trans	rs208520	0.837	rs208471	chr6:66916749	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-14.3	-0.57	3.95e-38	Exhaled nitric oxide output;
LUAD	cis	rs5756813	0.754	rs5750495	chr22:38179120	T/A	cg06521852	chr22:38141419	TRIOBP	-0.48	-9.08	-0.4	4.33e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08677398	chr8:58056175	NA	-0.49	-6.76	-0.31	4.72e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg02782426	chr3:40428986	ENTPD3	0.35	7.39	0.34	7.9e-13	Renal cell carcinoma;
LUAD	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg01028140	chr2:1542097	TPO	-0.48	-6.67	-0.31	8.26e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg20587970	chr11:113659929	NA	-1.44	-20.69	-0.71	3.22e-66	Hip circumference adjusted for BMI;
LUAD	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.95	13.05	0.54	6.31e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg04287289	chr16:89883240	FANCA	0.84	7.21	0.33	2.62e-12	Skin colour saturation;
LUAD	cis	rs889398	0.641	rs7200258	chr16:69897469	T/G	cg00738113	chr16:70207722	CLEC18C	-0.34	-6.99	-0.32	1.06e-11	Body mass index;
LUAD	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.84	12.21	0.51	1.38e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg11189052	chr15:85197271	WDR73	0.57	6.95	0.32	1.43e-11	Schizophrenia;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg08728825	chr12:44152210	PUS7L;IRAK4	-0.39	-6.58	-0.3	1.43e-10	Subcortical brain region volumes;
LUAD	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg23803603	chr1:2058230	PRKCZ	-0.4	-6.86	-0.32	2.53e-11	Height;
LUAD	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.83	-10.72	-0.46	6.89e-24	Body mass index;
LUAD	cis	rs1595825	0.891	rs60129872	chr2:198653192	A/G	cg00982548	chr2:198649783	BOLL	-0.66	-9.48	-0.42	1.89e-19	Ulcerative colitis;
LUAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.53	7.43	0.34	6.06e-13	Renal function-related traits (BUN);
LUAD	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg06064525	chr11:970664	AP2A2	-0.55	-11.27	-0.48	5.91e-26	Alzheimer's disease (late onset);
LUAD	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg27661571	chr11:113659931	NA	-0.56	-6.92	-0.32	1.69e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs34172651	0.545	rs7185291	chr16:24714679	C/T	cg04756594	chr16:24857601	SLC5A11	-0.45	-8.6	-0.39	1.53e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg08989290	chr16:615782	NHLRC4	0.31	6.8	0.31	3.6e-11	Height;
LUAD	cis	rs2425143	1.000	rs8115150	chr20:34397189	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.08	-0.33	6.15e-12	Blood protein levels;
LUAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	9.13	0.41	2.88e-18	Platelet count;
LUAD	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg24879335	chr3:133465180	TF	0.39	8.15	0.37	4.08e-15	Iron status biomarkers (transferrin levels);
LUAD	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg02421172	chr7:1938701	MAD1L1	0.44	6.4	0.3	4.14e-10	Bipolar disorder;
LUAD	cis	rs62229266	0.771	rs2835232	chr21:37393427	G/A	cg08632701	chr21:37451849	NA	-0.44	-7.29	-0.33	1.51e-12	Mitral valve prolapse;
LUAD	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg12193833	chr17:30244370	NA	-0.58	-6.8	-0.31	3.55e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs11247915	0.622	rs4072445	chr1:26664219	T/C	cg15628303	chr1:26608928	UBXN11	0.49	8.71	0.39	7.07e-17	Obesity-related traits;
LUAD	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.53	-0.34	3.07e-13	Schizophrenia;
LUAD	cis	rs3087591	0.960	rs757384	chr17:29596135	C/T	cg24425628	chr17:29625626	OMG;NF1	0.42	6.89	0.32	2e-11	Hip circumference;
LUAD	cis	rs28595532	1.000	rs114912871	chr4:119697004	G/C	cg14228332	chr4:119757509	SEC24D	0.8	7.57	0.35	2.28e-13	Cannabis dependence symptom count;
LUAD	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg03929089	chr4:120376271	NA	-0.72	-11.29	-0.48	5.31e-26	Coronary artery disease;
LUAD	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.21e-19	Life satisfaction;
LUAD	cis	rs2880765	0.743	rs8028240	chr15:86013248	A/G	cg13263323	chr15:86062960	AKAP13	-0.47	-8.47	-0.38	4.04e-16	Coronary artery disease;
LUAD	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-11.42	-0.49	1.6e-26	Schizophrenia;
LUAD	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg23649088	chr2:200775458	C2orf69	0.51	7.95	0.36	1.7e-14	Osteoporosis;
LUAD	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.31	-6.94	-0.32	1.46e-11	Dupuytren's disease;
LUAD	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.51	0.3	2.18e-10	Depression;
LUAD	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg01765077	chr12:122356316	WDR66	0.52	8.73	0.39	6.18e-17	Mean corpuscular volume;
LUAD	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg10523679	chr1:76189770	ACADM	0.95	18.66	0.67	4.06e-57	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg07404485	chr7:94953653	PON1	-0.5	-7.13	-0.33	4.26e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs877282	0.853	rs11595507	chr10:756703	C/T	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	cis	rs6489882	0.763	rs1859329	chr12:113376452	C/T	cg20102336	chr12:113376681	OAS3	-0.58	-8.91	-0.4	1.57e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs4713675	0.565	rs9394161	chr6:33669793	G/C	cg13859433	chr6:33739653	LEMD2	-0.31	-7.23	-0.33	2.25e-12	Plateletcrit;
LUAD	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg15147215	chr3:52552868	STAB1	-0.37	-6.8	-0.31	3.47e-11	Bipolar disorder;
LUAD	cis	rs12681287	0.752	rs13277670	chr8:87259920	T/G	cg00550725	chr8:87521180	FAM82B	0.45	6.5	0.3	2.28e-10	Caudate activity during reward;
LUAD	trans	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg04995722	chr7:26192034	NFE2L3	0.38	6.62	0.31	1.07e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg25036284	chr2:26402008	FAM59B	-0.83	-11.78	-0.5	6.58e-28	Gut microbiome composition (summer);
LUAD	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg05727186	chr17:43697356	MGC57346	-0.57	-6.95	-0.32	1.42e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg05340658	chr4:99064831	C4orf37	0.45	6.94	0.32	1.5e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7107174	0.892	rs10899487	chr11:78085474	G/A	cg19901956	chr11:77921274	USP35	-0.5	-6.51	-0.3	2.07e-10	Testicular germ cell tumor;
LUAD	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg22823121	chr1:150693482	HORMAD1	0.41	7.83	0.36	3.99e-14	Melanoma;
LUAD	trans	rs28735056	0.935	rs72980082	chr18:77630170	G/T	cg05926928	chr17:57297772	GDPD1	-0.5	-6.99	-0.32	1.1e-11	Schizophrenia;
LUAD	cis	rs1232027	0.622	rs1677653	chr5:79968271	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.81	-0.31	3.33e-11	Huntington's disease progression;
LUAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00149659	chr3:10157352	C3orf10	0.63	8.82	0.39	2.97e-17	Alzheimer's disease;
LUAD	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.77	-0.53	7.92e-32	Monocyte count;
LUAD	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg10792982	chr14:105748885	BRF1	0.44	9.57	0.42	9.2e-20	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7107174	0.786	rs4945269	chr11:78047077	A/G	cg19901956	chr11:77921274	USP35	-0.51	-7.07	-0.33	6.49e-12	Testicular germ cell tumor;
LUAD	cis	rs57502260	0.764	rs7105218	chr11:68222461	C/A	cg16797656	chr11:68205561	LRP5	0.51	8.18	0.37	3.31e-15	Total body bone mineral density (age 45-60);
LUAD	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg18016565	chr1:150552671	MCL1	0.41	7.48	0.34	4.31e-13	Tonsillectomy;
LUAD	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.56	0.38	2.11e-16	Menopause (age at onset);
LUAD	cis	rs2274273	0.905	rs2075601	chr14:55609234	C/T	cg04306507	chr14:55594613	LGALS3	0.41	8.51	0.38	2.97e-16	Protein biomarker;
LUAD	cis	rs524023	0.957	rs538737	chr11:64355772	C/G	cg19131476	chr11:64387923	NRXN2	0.37	7.0	0.32	1.01e-11	Urate levels in obese individuals;
LUAD	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg18230493	chr5:56204884	C5orf35	-0.85	-12.54	-0.52	6.65e-31	Initial pursuit acceleration;
LUAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24030630	chr11:67806668	TCIRG1	-0.4	-6.73	-0.31	5.61e-11	Cancer;
LUAD	cis	rs9837602	0.938	rs9823908	chr3:99795507	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.45	-6.74	-0.31	5.22e-11	Breast cancer;
LUAD	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg02569458	chr12:86230093	RASSF9	0.41	7.48	0.34	4.2e-13	Major depressive disorder;
LUAD	cis	rs9787249	0.957	rs12074147	chr1:40203722	T/C	cg19912559	chr1:40204330	PPIE	0.56	9.57	0.42	9.03e-20	Blood protein levels;
LUAD	trans	rs853679	0.607	rs13205211	chr6:28203056	T/G	cg01620082	chr3:125678407	NA	-1.1	-10.34	-0.45	1.67e-22	Depression;
LUAD	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg18132916	chr6:79620363	NA	-0.45	-7.76	-0.35	6.62e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08677398	chr8:58056175	NA	0.48	6.85	0.32	2.64e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2274273	0.870	rs11625001	chr14:55758160	T/C	cg04306507	chr14:55594613	LGALS3	0.43	8.91	0.4	1.57e-17	Protein biomarker;
LUAD	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg02221422	chr11:68192511	LRP5	-0.4	-6.6	-0.31	1.26e-10	Total body bone mineral density;
LUAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg24813613	chr7:1882135	MAD1L1	-0.57	-9.32	-0.41	6.26e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs7737355	0.504	rs31256	chr5:130828749	T/C	cg06307176	chr5:131281290	NA	0.49	7.73	0.35	8.02e-14	Life satisfaction;
LUAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14159672	chr1:205819179	PM20D1	0.72	14.15	0.57	1.68e-37	Menarche (age at onset);
LUAD	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg08761264	chr16:28874980	SH2B1	-0.46	-7.07	-0.33	6.45e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg19193384	chr17:30244184	NA	-0.5	-6.43	-0.3	3.42e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg08085267	chr17:45401833	C17orf57	0.52	8.67	0.39	9.53e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg21582582	chr3:182698605	DCUN1D1	0.46	7.6	0.35	1.89e-13	Body mass index;
LUAD	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.71	-11.04	-0.47	4.46e-25	Primary sclerosing cholangitis;
LUAD	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	14.33	0.57	3.02e-38	Lung cancer in ever smokers;
LUAD	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg02423579	chr7:2872169	GNA12	-0.58	-9.75	-0.43	2.07e-20	Height;
LUAD	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-7.13	-0.33	4.29e-12	Daytime sleep phenotypes;
LUAD	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg05373962	chr22:49881684	NA	-0.54	-12.76	-0.53	9.38e-32	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7769051	0.522	rs6930703	chr6:133111266	C/T	cg22852734	chr6:133119734	C6orf192	0.89	7.59	0.35	2.13e-13	Type 2 diabetes nephropathy;
LUAD	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg00750074	chr16:89608354	SPG7	-0.55	-9.41	-0.42	3.3e-19	Multiple myeloma (IgH translocation);
LUAD	cis	rs4523957	0.859	rs9891227	chr17:2164311	G/A	cg16513277	chr17:2031491	SMG6	-0.76	-14.68	-0.58	1.05e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg16342193	chr10:102329863	NA	-0.4	-6.81	-0.31	3.31e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs3096299	0.967	rs2965937	chr16:89488779	A/T	cg01788221	chr16:89496183	ANKRD11	-0.35	-6.74	-0.31	5.15e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg06671706	chr8:8559999	CLDN23	0.66	11.33	0.48	3.46e-26	Obesity-related traits;
LUAD	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg18446336	chr7:2847575	GNA12	-0.36	-6.63	-0.31	1.02e-10	Height;
LUAD	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	10.06	0.44	1.76e-21	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg21285383	chr16:89894308	SPIRE2	0.43	10.43	0.45	7.96e-23	Vitiligo;
LUAD	trans	rs1997103	1.000	rs6593233	chr7:55406200	C/T	cg20935933	chr6:143382018	AIG1	-0.52	-7.43	-0.34	5.88e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7394190	0.748	rs60632610	chr10:75415677	C/T	cg02286717	chr10:75415704	SYNPO2L	-0.37	-6.75	-0.31	4.84e-11	Incident atrial fibrillation;
LUAD	cis	rs758324	0.947	rs72793241	chr5:131240885	C/T	cg06307176	chr5:131281290	NA	-0.54	-8.63	-0.39	1.29e-16	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg07570687	chr10:102243282	WNT8B	0.45	6.88	0.32	2.22e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs758324	0.947	rs58016983	chr5:131235275	T/C	cg25547332	chr5:131281432	NA	-0.44	-6.62	-0.31	1.12e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs75804782	0.641	rs72987315	chr2:239348474	C/T	cg01134436	chr17:81009848	B3GNTL1	0.81	8.33	0.38	1.17e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-7.54	-0.34	2.85e-13	Lung cancer;
LUAD	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg23752985	chr2:85803571	VAMP8	0.33	6.39	0.3	4.31e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg00631329	chr6:26305371	NA	-0.69	-13.08	-0.54	4.46e-33	Educational attainment;
LUAD	cis	rs494562	0.892	rs544408	chr6:86119110	A/T	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12756686	chr19:29218302	NA	0.67	9.78	0.43	1.7e-20	Methadone dose in opioid dependence;
LUAD	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11644478	chr21:40555479	PSMG1	0.57	8.57	0.38	1.9e-16	Cognitive function;
LUAD	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg25233709	chr10:116636983	FAM160B1	0.42	8.46	0.38	4.34e-16	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs151349	1.000	rs151345	chr20:57586849	G/C	cg23907860	chr20:57583709	CTSZ	-0.56	-10.35	-0.45	1.6e-22	Platelet distribution width;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13766096	chr13:111365492	ING1	-0.42	-6.88	-0.32	2.2e-11	Cancer;
LUAD	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg08645402	chr16:4508243	NA	0.49	8.55	0.38	2.31e-16	Schizophrenia;
LUAD	cis	rs62238980	0.614	rs17683471	chr22:32487815	C/G	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-7.47	-0.34	4.71e-13	Tonsillectomy;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05360422	chr6:74363449	SLC17A5	-0.63	-6.44	-0.3	3.32e-10	Type 2 diabetes;
LUAD	cis	rs427394	0.632	rs169285	chr5:6736587	G/C	cg14682080	chr5:6737778	POLS	0.35	7.67	0.35	1.22e-13	Menopause (age at onset);
LUAD	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.73e-16	Neutrophil percentage of white cells;
LUAD	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg04586622	chr2:25135609	ADCY3	0.38	8.69	0.39	8.05e-17	Body mass index;
LUAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg11301795	chr4:187892539	NA	-0.76	-15.14	-0.59	1.1e-41	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.44	0.3	3.26e-10	Lung cancer;
LUAD	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg17264618	chr3:40429014	ENTPD3	-0.4	-8.7	-0.39	7.22e-17	Renal cell carcinoma;
LUAD	cis	rs10203711	1.000	rs907112	chr2:239566603	C/G	cg14580085	chr2:239553406	NA	0.42	9.07	0.4	4.66e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg04036182	chr15:45458818	NA	-0.41	-7.19	-0.33	3e-12	Glomerular filtration rate;
LUAD	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg27411982	chr8:10470053	RP1L1	0.37	6.75	0.31	4.93e-11	Neuroticism;
LUAD	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg23719950	chr11:63933701	MACROD1	-0.55	-6.65	-0.31	9.08e-11	Mean platelet volume;
LUAD	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.45	-0.34	5.31e-13	Breast cancer;
LUAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg27532560	chr4:187881888	NA	-0.34	-6.38	-0.3	4.56e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10802521	chr3:52805072	NEK4	-0.52	-8.85	-0.4	2.49e-17	Bipolar disorder;
LUAD	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg02753203	chr1:228287806	NA	0.58	10.77	0.46	4.76e-24	Diastolic blood pressure;
LUAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.58	8.84	0.39	2.67e-17	Renal function-related traits (BUN);
LUAD	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg09658497	chr7:2847517	GNA12	0.56	9.55	0.42	1.07e-19	Height;
LUAD	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg08859206	chr1:53392774	SCP2	0.63	11.73	0.5	1.01e-27	Monocyte count;
LUAD	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-7.79	-0.35	5.3e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6906287	0.647	rs7758614	chr6:118889894	T/C	cg05564266	chr6:118973597	C6orf204	0.36	7.7	0.35	9.99e-14	Electrocardiographic conduction measures;
LUAD	cis	rs2070677	0.935	rs11812637	chr10:135413418	A/G	cg20169779	chr10:135381914	SYCE1	-0.51	-8.2	-0.37	2.99e-15	Gout;
LUAD	cis	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg27411982	chr8:10470053	RP1L1	-0.4	-7.24	-0.33	2.1e-12	Systolic blood pressure;
LUAD	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg24768116	chr2:27665128	KRTCAP3	0.26	6.53	0.3	1.87e-10	Oral cavity cancer;
LUAD	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg21823605	chr1:152486609	CRCT1	0.28	6.39	0.3	4.3e-10	Plantar warts;
LUAD	trans	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg18834416	chr8:37888184	EIF4EBP1	-0.46	-7.7	-0.35	1.01e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.51e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs15676	0.783	rs2997917	chr9:131586918	G/A	cg00228799	chr9:131580591	ENDOG	0.47	7.35	0.34	1.03e-12	Blood metabolite levels;
LUAD	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.62	0.31	1.08e-10	Menarche (age at onset);
LUAD	cis	rs7107174	1.000	rs2512532	chr11:77968641	T/C	cg19901956	chr11:77921274	USP35	-0.52	-6.64	-0.31	9.56e-11	Testicular germ cell tumor;
LUAD	cis	rs9473147	0.516	rs9395283	chr6:47551444	T/C	cg02130027	chr6:47444894	CD2AP	0.35	6.68	0.31	7.35e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.83	0.53	4.51e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg12292205	chr6:26970375	C6orf41	0.39	6.8	0.31	3.65e-11	Schizophrenia;
LUAD	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg02753203	chr1:228287806	NA	-0.46	-8.41	-0.38	6.15e-16	Diastolic blood pressure;
LUAD	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.35	-7.48	-0.34	4.31e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs925255	0.810	rs1396733	chr2:28642747	A/C	cg01273330	chr2:28605224	NA	0.34	6.81	0.31	3.32e-11	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9923856	0.611	rs7192393	chr16:11087096	C/T	cg04616529	chr16:11181986	CLEC16A	0.42	6.37	0.3	4.96e-10	Atopic dermatitis;Adult asthma;
LUAD	cis	rs4889911	0.544	rs1285271	chr17:77834197	C/T	cg02876276	chr17:77834299	NA	-0.49	-7.32	-0.34	1.23e-12	Electroencephalogram traits;
LUAD	trans	rs11227306	0.934	rs11227313	chr11:65588938	C/T	cg17712092	chr4:129076599	LARP1B	0.68	10.64	0.46	1.36e-23	DNA methylation (variation);
LUAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg21226059	chr5:178986404	RUFY1	-0.59	-10.07	-0.44	1.6e-21	Lung cancer;
LUAD	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20684973	chr10:105127632	TAF5	0.38	6.36	0.3	5.3e-10	Survival in pancreatic cancer;
LUAD	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg10755058	chr3:40428713	ENTPD3	0.45	8.22	0.37	2.47e-15	Renal cell carcinoma;
LUAD	cis	rs4711336	1.000	rs4711336	chr6:33659046	A/G	cg14003231	chr6:33640908	ITPR3	-0.51	-9.75	-0.43	2.08e-20	Height;
LUAD	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.66	0.31	8.79e-11	Parkinson's disease;
LUAD	cis	rs12612619	0.732	rs12613822	chr2:27217102	A/T	cg00617064	chr2:27272375	NA	-0.38	-7.44	-0.34	5.7e-13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg02018176	chr4:1364513	KIAA1530	0.58	10.92	0.47	1.21e-24	Longevity;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg18970754	chr14:74079533	NA	0.4	6.4	0.3	4.24e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs4888262	0.564	rs8062404	chr16:74611675	T/C	cg01733217	chr16:74700730	RFWD3	0.51	8.62	0.39	1.3e-16	Testicular germ cell tumor;
LUAD	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg25985355	chr7:65971099	NA	-0.56	-6.94	-0.32	1.49e-11	Diabetic kidney disease;
LUAD	trans	rs6561151	0.957	rs9316058	chr13:44485076	G/C	cg12856521	chr11:46389249	DGKZ	0.65	10.2	0.44	5.48e-22	Crohn's disease;
LUAD	cis	rs1448094	0.842	rs10863155	chr12:86446416	T/C	cg00310523	chr12:86230176	RASSF9	-0.35	-7.61	-0.35	1.77e-13	Major depressive disorder;
LUAD	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg06627628	chr2:24431161	ITSN2	-0.56	-9.57	-0.42	8.78e-20	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs6901250	0.851	rs339322	chr6:117193356	T/C	cg12892004	chr6:117198278	RFX6	-0.32	-6.86	-0.32	2.44e-11	C-reactive protein levels;
LUAD	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg23954153	chr1:44402353	ARTN	-0.37	-7.16	-0.33	3.61e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs13315871	1.000	rs11715445	chr3:58343888	T/C	cg20936604	chr3:58311152	NA	-0.7	-7.13	-0.33	4.47e-12	Cholesterol, total;
LUAD	cis	rs243505	0.762	rs2007404	chr7:148487395	A/G	cg09806900	chr7:148480153	CUL1	0.42	7.18	0.33	3.1e-12	Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.15	-0.37	4.21e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg21775007	chr8:11205619	TDH	-0.53	-9.71	-0.43	2.96e-20	Retinal vascular caliber;
LUAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg11416102	chr8:651193	ERICH1	0.95	9.02	0.4	6.39e-18	IgG glycosylation;
LUAD	trans	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg11693508	chr17:37793320	STARD3	0.6	7.45	0.34	5.33e-13	Neuroticism;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07469408	chr14:75894384	JDP2	-0.67	-6.8	-0.31	3.68e-11	Type 2 diabetes;
LUAD	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg23649088	chr2:200775458	C2orf69	0.65	10.65	0.46	1.28e-23	Schizophrenia;
LUAD	trans	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg21051086	chr3:73046214	PPP4R2	-0.46	-6.99	-0.32	1.07e-11	Pancreatic cancer;
LUAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg09509183	chr1:209979624	IRF6	0.54	8.26	0.37	1.94e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg14092988	chr3:52407081	DNAH1	0.46	9.12	0.41	3e-18	Bipolar disorder;
LUAD	trans	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg01620082	chr3:125678407	NA	-0.45	-6.71	-0.31	6.33e-11	Depression;
LUAD	cis	rs4077468	1.000	rs4077469	chr1:205914885	C/T	cg26354017	chr1:205819088	PM20D1	-0.36	-6.5	-0.3	2.25e-10	Cystic fibrosis-related diabetes;
LUAD	cis	rs55665837	1.000	rs11023214	chr11:14436259	G/C	cg19336497	chr11:14380999	RRAS2	-0.5	-10.21	-0.44	5.18e-22	Vitamin D levels;
LUAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg21724239	chr8:58056113	NA	0.65	8.41	0.38	6.32e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg22681709	chr2:178499509	PDE11A	-0.46	-7.67	-0.35	1.18e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2860975	0.501	rs602941	chr10:96961184	G/A	cg09036531	chr10:96991505	NA	-0.74	-13.61	-0.55	3.09e-35	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs3087591	0.960	rs2905803	chr17:29520056	T/C	cg24425628	chr17:29625626	OMG;NF1	0.43	7.0	0.32	1.03e-11	Hip circumference;
LUAD	cis	rs1348850	0.602	rs1453373	chr2:178221668	G/A	cg22681709	chr2:178499509	PDE11A	-0.41	-7.49	-0.34	4.04e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg18190219	chr22:46762943	CELSR1	-0.5	-6.58	-0.3	1.36e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.63	-0.35	1.62e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.62	8.3	0.37	1.44e-15	Renal function-related traits (BUN);
LUAD	trans	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg07211511	chr3:129823064	LOC729375	-0.53	-7.34	-0.34	1.08e-12	Blood pressure (smoking interaction);
LUAD	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg16989719	chr2:238392110	NA	-0.38	-8.28	-0.37	1.58e-15	Prostate cancer;
LUAD	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.31	6.38	0.3	4.64e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10992471	0.603	rs10761160	chr9:95208701	A/T	cg14631576	chr9:95140430	CENPP	-0.56	-11.38	-0.48	2.42e-26	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg09796270	chr17:17721594	SREBF1	0.37	7.08	0.33	6.06e-12	Total body bone mineral density;
LUAD	cis	rs10203711	1.000	rs10203711	chr2:239553368	C/T	cg14580085	chr2:239553406	NA	0.4	8.5	0.38	3.34e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg23954153	chr1:44402353	ARTN	-0.36	-6.74	-0.31	5.22e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg05535760	chr7:792225	HEATR2	0.84	11.21	0.48	1.04e-25	Cerebrospinal P-tau181p levels;
LUAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.38	0.55	2.75e-34	Prudent dietary pattern;
LUAD	trans	rs1941687	0.527	rs1493914	chr18:31362327	C/T	cg13755796	chr4:20253514	NA	-0.42	-7.09	-0.33	5.59e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs12541635	0.639	rs10095827	chr8:106984403	A/G	cg10147462	chr8:107024639	NA	0.54	9.84	0.43	1.07e-20	Age of smoking initiation;
LUAD	trans	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg01620082	chr3:125678407	NA	-0.98	-9.65	-0.42	4.92e-20	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10203711	0.705	rs4286234	chr2:239616695	G/C	cg14580085	chr2:239553406	NA	0.32	7.09	0.33	5.74e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4285028	0.747	rs1463736	chr3:121400725	G/A	cg11130432	chr3:121712080	ILDR1	-0.47	-6.81	-0.31	3.39e-11	Multiple sclerosis;
LUAD	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-7.01	-0.32	9.69e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg04731861	chr2:219085781	ARPC2	-0.24	-7.44	-0.34	5.64e-13	Colorectal cancer;
LUAD	cis	rs12765878	1.000	rs11191848	chr10:105650837	T/C	cg11005552	chr10:105648138	OBFC1	0.44	8.34	0.38	1.04e-15	Coronary artery disease;
LUAD	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18099408	chr3:52552593	STAB1	-0.46	-8.12	-0.37	5e-15	Bipolar disorder;
LUAD	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg02734326	chr4:10020555	SLC2A9	-0.42	-7.31	-0.33	1.33e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06544989	chr22:39130855	UNC84B	0.43	7.97	0.36	1.5e-14	Menopause (age at onset);
LUAD	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg17200465	chr3:40428508	ENTPD3	0.27	6.48	0.3	2.51e-10	Renal cell carcinoma;
LUAD	cis	rs12791968	0.917	rs11038238	chr11:45002010	A/G	cg11846598	chr11:44996168	LOC221122	-0.78	-14.01	-0.56	6.94e-37	Inhibitory control;
LUAD	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg11845111	chr2:191398756	TMEM194B	0.71	13.16	0.54	2.16e-33	Pulse pressure;
LUAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg03188948	chr7:1209495	NA	0.39	6.4	0.3	4.19e-10	Longevity;Endometriosis;
LUAD	cis	rs6494488	0.500	rs72741336	chr15:64757917	T/C	cg08069370	chr15:64387884	SNX1	-0.75	-6.73	-0.31	5.58e-11	Coronary artery disease;
LUAD	cis	rs4243830	0.826	rs12565181	chr1:6620545	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	0.8	9.99	0.44	3.05e-21	Body mass index;
LUAD	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg14196790	chr5:131705035	SLC22A5	0.47	8.34	0.38	1.07e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg01849466	chr14:104193079	ZFYVE21	0.47	7.59	0.35	2.08e-13	Body mass index;
LUAD	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg00316803	chr15:76480434	C15orf27	0.4	6.8	0.31	3.52e-11	Blood metabolite levels;
LUAD	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg21827317	chr3:136751795	NA	0.34	6.37	0.3	5.03e-10	Neuroticism;
LUAD	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg05665937	chr4:1216051	CTBP1	0.48	7.32	0.34	1.26e-12	Longevity;
LUAD	cis	rs57920188	0.584	rs12068729	chr1:4091650	A/G	cg20703997	chr1:4087676	NA	0.48	8.99	0.4	8.23e-18	Interleukin-17 levels;
LUAD	cis	rs977987	0.898	rs12918974	chr16:75493943	T/A	cg03315344	chr16:75512273	CHST6	0.66	14.93	0.59	8.3e-41	Dupuytren's disease;
LUAD	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg17724175	chr1:150552817	MCL1	0.33	7.64	0.35	1.47e-13	Melanoma;
LUAD	cis	rs10979	0.965	rs9376759	chr6:143886959	G/A	cg25407410	chr6:143891975	LOC285740	-0.59	-9.26	-0.41	1.07e-18	Hypospadias;
LUAD	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg20108693	chr8:143823809	SLURP1	0.32	7.27	0.33	1.71e-12	Urinary tract infection frequency;
LUAD	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg00898013	chr13:113819073	PROZ	-0.67	-11.56	-0.49	4.96e-27	Platelet distribution width;
LUAD	cis	rs300703	0.872	rs300752	chr2:209292	A/G	cg21211680	chr2:198530	NA	0.58	6.37	0.3	4.83e-10	Blood protein levels;
LUAD	cis	rs6446731	0.517	rs2798221	chr4:3270488	T/C	cg08886695	chr4:3369023	RGS12	0.46	7.66	0.35	1.25e-13	Mean platelet volume;
LUAD	cis	rs4285028	0.747	rs7623901	chr3:121529011	A/G	cg11130432	chr3:121712080	ILDR1	0.58	8.69	0.39	8.16e-17	Multiple sclerosis;
LUAD	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg13319975	chr6:146136371	FBXO30	-0.59	-10.0	-0.44	2.78e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg02524346	chr8:600233	NA	1.09	11.07	0.47	3.48e-25	IgG glycosylation;
LUAD	cis	rs2554380	0.628	rs7177929	chr15:84478679	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.38	-6.64	-0.31	9.87e-11	Height;
LUAD	cis	rs9399401	0.626	rs12664563	chr6:142785201	A/G	cg04461802	chr6:142623433	GPR126	0.38	6.88	0.32	2.15e-11	Chronic obstructive pulmonary disease;
LUAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg08027265	chr7:2291960	NA	-0.42	-6.81	-0.31	3.39e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs986417	0.901	rs1955690	chr14:61000492	A/G	cg27398547	chr14:60952738	C14orf39	-0.59	-7.47	-0.34	4.49e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs9517302	0.615	rs7983522	chr13:99098055	C/T	cg22223119	chr13:99095684	FARP1	-0.62	-10.01	-0.44	2.59e-21	Obesity-related traits;
LUAD	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-8.13	-0.37	4.71e-15	Morning vs. evening chronotype;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg23982527	chr11:884807	CHID1	-0.36	-6.39	-0.3	4.36e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg21427119	chr20:30132790	HM13	-0.57	-8.64	-0.39	1.17e-16	Mean corpuscular hemoglobin;
LUAD	cis	rs7705042	0.759	rs3765011	chr5:141517665	G/C	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.63	-0.31	1.06e-10	Asthma;
LUAD	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg04944784	chr2:26401820	FAM59B	0.87	12.16	0.51	2.29e-29	Gut microbiome composition (summer);
LUAD	trans	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.69	0.43	3.38e-20	Mean corpuscular volume;
LUAD	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg19622623	chr12:86230825	RASSF9	-0.52	-9.06	-0.4	4.9e-18	Major depressive disorder;
LUAD	cis	rs28374715	0.662	rs691907	chr15:41474657	C/G	cg18705301	chr15:41695430	NDUFAF1	0.86	15.72	0.61	3.57e-44	Ulcerative colitis;
LUAD	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg12863693	chr15:85201151	NMB	0.4	7.19	0.33	2.89e-12	Schizophrenia;
LUAD	cis	rs8177876	0.731	rs7188508	chr16:81113702	T/C	cg08591886	chr16:81111003	C16orf46	-0.76	-7.01	-0.32	9.76e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.91	0.4	1.48e-17	Cognitive ability;
LUAD	cis	rs68170813	0.523	rs75999022	chr7:107017135	C/T	cg23024343	chr7:107201750	COG5	0.51	7.19	0.33	3.03e-12	Coronary artery disease;
LUAD	trans	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg07211511	chr3:129823064	LOC729375	0.7	7.8	0.35	4.97e-14	Blood pressure (smoking interaction);
LUAD	cis	rs738321	0.757	rs3788535	chr22:38534045	T/C	cg25457927	chr22:38595422	NA	-0.5	-11.11	-0.48	2.55e-25	Breast cancer;
LUAD	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg04000281	chr11:63949212	NA	-0.28	-6.8	-0.31	3.55e-11	Platelet count;
LUAD	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg03188948	chr7:1209495	NA	0.73	7.39	0.34	7.89e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg10978503	chr1:24200527	CNR2	0.59	12.8	0.53	6.02e-32	Immature fraction of reticulocytes;
LUAD	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg08027265	chr7:2291960	NA	-0.52	-9.1	-0.4	3.53e-18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs1997103	1.000	rs10224446	chr7:55413147	C/G	cg17469321	chr7:55412551	NA	0.66	11.21	0.48	1.05e-25	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs3820068	0.637	rs4646080	chr1:15826627	A/T	cg24675056	chr1:15929824	NA	0.41	6.58	0.3	1.39e-10	Systolic blood pressure;
LUAD	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg11189052	chr15:85197271	WDR73	0.61	7.58	0.35	2.19e-13	Schizophrenia;
LUAD	cis	rs2735413	0.837	rs4888735	chr16:78083742	C/T	cg04733911	chr16:78082701	NA	-0.34	-8.17	-0.37	3.53e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02475777	chr4:1388615	CRIPAK	0.71	10.27	0.45	3.13e-22	Longevity;
LUAD	cis	rs11214589	0.651	rs17600713	chr11:113259947	C/T	cg14159747	chr11:113255604	NA	0.65	13.58	0.55	4.21e-35	Neuroticism;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21407906	chr20:61427925	C20orf20	-0.55	-6.79	-0.31	3.7e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg24801067	chr17:62843696	NA	0.66	9.0	0.4	7.77e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	6.7	0.31	6.69e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs11030122	0.673	rs11030639	chr11:4039056	A/G	cg18678763	chr11:4115507	RRM1	-0.42	-7.11	-0.33	5.04e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg09365446	chr1:150670422	GOLPH3L	0.61	10.84	0.47	2.45e-24	Melanoma;
LUAD	cis	rs332507	0.830	rs333355	chr3:124393595	A/G	cg05980111	chr3:124395277	KALRN	0.41	6.57	0.3	1.46e-10	Plateletcrit;
LUAD	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg15704280	chr7:45808275	SEPT13	-0.87	-15.22	-0.59	5.22e-42	Height;
LUAD	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	12.15	0.51	2.52e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs17067123	0.614	rs7698554	chr4:180053504	T/C	cg26610307	chr4:180072759	NA	-0.52	-6.78	-0.31	3.96e-11	Response to hepatitis C treatment;
LUAD	trans	rs1941687	0.563	rs7238931	chr18:31334993	G/A	cg15819921	chr19:927150	ARID3A	-0.49	-8.35	-0.38	9.82e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg05776053	chr2:74358815	NA	0.46	6.8	0.31	3.55e-11	Gestational age at birth (maternal effect);
LUAD	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg01028140	chr2:1542097	TPO	-0.53	-6.97	-0.32	1.21e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00149659	chr3:10157352	C3orf10	0.86	11.57	0.49	4.56e-27	Alzheimer's disease;
LUAD	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg08859206	chr1:53392774	SCP2	0.58	10.52	0.46	3.78e-23	Monocyte count;
LUAD	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-12.01	-0.5	8.63e-29	Bipolar disorder;
LUAD	cis	rs12701220	0.595	rs12532837	chr7:1122851	T/A	cg02733842	chr7:1102375	C7orf50	-0.75	-11.29	-0.48	5.19e-26	Bronchopulmonary dysplasia;
LUAD	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg12072164	chr19:44306565	LYPD5	0.43	8.63	0.39	1.23e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg11833968	chr6:79620685	NA	-0.44	-8.17	-0.37	3.57e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs3849570	0.555	rs6548783	chr3:81993621	G/A	cg07356753	chr3:81810745	GBE1	-0.54	-8.99	-0.4	8.44e-18	Waist circumference;Body mass index;
LUAD	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg22431228	chr1:16359049	CLCNKA	0.43	7.57	0.35	2.36e-13	Dilated cardiomyopathy;
LUAD	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.14	0.37	4.33e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg05084668	chr3:125655381	ALG1L	-0.61	-8.79	-0.39	3.91e-17	Blood pressure (smoking interaction);
LUAD	cis	rs7192380	0.964	rs8055756	chr16:69648653	A/G	cg26679644	chr16:69762563	NA	-0.49	-9.46	-0.42	2.15e-19	Sjögren's syndrome;
LUAD	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.37	6.59	0.3	1.34e-10	Blood metabolite levels;
LUAD	cis	rs11771526	0.901	rs62457470	chr7:32303516	A/G	cg27532318	chr7:32358331	NA	0.59	7.42	0.34	6.66e-13	Body mass index;
LUAD	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.58	-0.35	2.14e-13	Personality dimensions;
LUAD	trans	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg26043149	chr18:55253948	FECH	0.5	7.99	0.36	1.31e-14	Bone mineral density;
LUAD	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg02993280	chr1:107599747	PRMT6	-0.57	-9.31	-0.41	7.18e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2580764	0.566	rs2968827	chr2:55297629	C/G	cg09592903	chr2:55203963	RTN4	0.41	9.03	0.4	5.98e-18	Mean platelet volume;
LUAD	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg20991723	chr1:152506922	NA	0.32	6.43	0.3	3.42e-10	Hair morphology;
LUAD	cis	rs6684514	1.000	rs12141236	chr1:156302575	A/C	cg16558208	chr1:156270281	VHLL	0.53	9.64	0.42	5e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg02887458	chr19:19495540	GATAD2A	-0.44	-6.82	-0.31	3.23e-11	Bipolar disorder;
LUAD	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg08470875	chr2:26401718	FAM59B	-0.77	-10.45	-0.45	7e-23	Gut microbiome composition (summer);
LUAD	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11890956	chr21:40555474	PSMG1	0.76	13.4	0.55	2.25e-34	Cognitive function;
LUAD	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.34	0.38	1.06e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12989701	0.877	rs34854727	chr2:127855392	C/T	cg08168897	chr2:127865431	BIN1	0.45	6.51	0.3	2.15e-10	Alzheimer's disease (late onset);
LUAD	cis	rs11030122	0.604	rs10835557	chr11:4083121	A/G	cg18678763	chr11:4115507	RRM1	-0.44	-7.0	-0.32	9.91e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2806561	0.578	rs6702719	chr1:23302576	T/C	cg19743168	chr1:23544995	NA	0.38	6.45	0.3	3.07e-10	Height;
LUAD	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.71	0.39	6.86e-17	Menopause (age at onset);
LUAD	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg00316803	chr15:76480434	C15orf27	-0.41	-7.59	-0.35	2.03e-13	Blood metabolite levels;
LUAD	cis	rs4462272	0.557	rs11597086	chr10:101953705	A/C	cg19754520	chr10:101825118	CPN1	-0.3	-6.44	-0.3	3.25e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.15	0.33	3.88e-12	Motion sickness;
LUAD	cis	rs921968	0.565	rs6733892	chr2:219616002	C/A	cg02176678	chr2:219576539	TTLL4	-0.62	-12.97	-0.53	1.33e-32	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg19318889	chr4:1322082	MAEA	0.48	7.87	0.36	3.08e-14	Obesity-related traits;
LUAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-10.98	-0.47	7.29e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs4888262	0.526	rs8055803	chr16:74615190	A/G	cg01733217	chr16:74700730	RFWD3	0.51	8.53	0.38	2.69e-16	Testicular germ cell tumor;
LUAD	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.42	-0.49	1.6e-26	Primary sclerosing cholangitis;
LUAD	cis	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg08601574	chr20:25228251	PYGB	0.46	8.71	0.39	7.05e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg03929089	chr4:120376271	NA	-0.52	-7.67	-0.35	1.2e-13	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24475744	chr19:10829423	DNM2	-0.42	-6.86	-0.32	2.39e-11	Cancer;
LUAD	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg25319279	chr11:5960081	NA	-0.41	-7.23	-0.33	2.25e-12	DNA methylation (variation);
LUAD	cis	rs12681287	0.752	rs10956786	chr8:87301237	T/C	cg00550725	chr8:87521180	FAM82B	0.45	6.54	0.3	1.75e-10	Caudate activity during reward;
LUAD	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg15448220	chr1:150897856	SETDB1	0.47	8.09	0.37	6.35e-15	Tonsillectomy;
LUAD	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg09796270	chr17:17721594	SREBF1	0.39	8.0	0.36	1.17e-14	Total body bone mineral density;
LUAD	cis	rs9486719	0.895	rs4486019	chr6:96883814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.71	-10.02	-0.44	2.32e-21	Migraine;Coronary artery disease;
LUAD	cis	rs4954585	0.762	rs12986776	chr2:136991517	C/G	cg05194412	chr2:137003533	NA	0.61	10.78	0.46	4.17e-24	Colorectal cancer;
LUAD	cis	rs62458065	0.713	rs28421905	chr7:32489501	G/A	cg20159608	chr7:32802032	NA	-0.59	-8.09	-0.37	6.3e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg26022315	chr17:47021804	SNF8	0.4	7.3	0.33	1.46e-12	Type 2 diabetes;
LUAD	cis	rs7932354	0.528	rs7121418	chr11:47165106	G/A	cg19486271	chr11:47235900	DDB2	-0.4	-6.51	-0.3	2.09e-10	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs870825	0.587	rs58332461	chr4:185639742	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	14.12	0.57	2.26e-37	Blood protein levels;
LUAD	cis	rs4604732	0.536	rs12037221	chr1:247631212	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	9.33	0.41	5.82e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs68170813	0.559	rs75672288	chr7:107031549	G/C	cg02696742	chr7:106810147	HBP1	-0.78	-10.36	-0.45	1.4e-22	Coronary artery disease;
LUAD	cis	rs2067615	0.579	rs7975576	chr12:107132501	A/G	cg15890332	chr12:107067104	RFX4	0.38	8.21	0.37	2.67e-15	Heart rate;
LUAD	trans	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg07211511	chr3:129823064	LOC729375	-0.55	-7.31	-0.33	1.39e-12	Blood pressure (smoking interaction);
LUAD	cis	rs72772090	0.539	rs17405676	chr5:96182615	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-6.74	-0.31	5.17e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg07404485	chr7:94953653	PON1	-0.49	-7.11	-0.33	5.11e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg26384229	chr12:38710491	ALG10B	0.43	7.23	0.33	2.23e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg27129171	chr3:47204927	SETD2	0.43	6.96	0.32	1.28e-11	Colorectal cancer;
LUAD	cis	rs6547631	0.622	rs1561284	chr2:85924295	C/A	cg21473183	chr2:85925749	GNLY	0.35	7.59	0.35	2.1e-13	Blood protein levels;
LUAD	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg04398451	chr17:18023971	MYO15A	0.65	11.64	0.49	2.38e-27	Total body bone mineral density;
LUAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.75	-0.39	5.05e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg13334819	chr7:99746414	C7orf59	-0.67	-10.35	-0.45	1.58e-22	Coronary artery disease;
LUAD	trans	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg24644049	chr4:85504048	CDS1	0.81	7.77	0.35	5.85e-14	Skin colour saturation;
LUAD	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg10556349	chr10:835070	NA	-0.47	-7.36	-0.34	9.49e-13	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.67	0.31	8.26e-11	Cardiac Troponin-T levels;
LUAD	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.04	0.32	7.98e-12	Colorectal cancer;
LUAD	cis	rs17095355	1.000	rs12571674	chr10:111717608	C/T	cg00817464	chr10:111662876	XPNPEP1	0.64	8.09	0.37	6.18e-15	Biliary atresia;
LUAD	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg00383909	chr3:49044727	WDR6	0.85	8.38	0.38	7.84e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg18180107	chr4:99064573	C4orf37	-0.42	-6.79	-0.31	3.79e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2540226	0.844	rs1035138	chr2:39999341	G/A	cg22354234	chr2:40006543	THUMPD2	0.36	6.38	0.3	4.68e-10	Personality dimensions;
LUAD	cis	rs13064411	0.696	rs7610638	chr3:113139656	A/G	cg18753928	chr3:113234510	CCDC52	-0.68	-11.11	-0.48	2.51e-25	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.52	0.46	3.84e-23	Mean corpuscular volume;
LUAD	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.77	0.39	4.32e-17	Lung cancer in ever smokers;
LUAD	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg22676075	chr6:135203613	NA	0.44	8.15	0.37	4.2e-15	Red blood cell count;
LUAD	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg21782813	chr7:2030301	MAD1L1	0.43	7.31	0.33	1.33e-12	Schizophrenia;
LUAD	cis	rs2625529	0.775	rs2723342	chr15:72107699	G/C	cg16672083	chr15:72433130	SENP8	-0.71	-10.87	-0.47	2.02e-24	Red blood cell count;
LUAD	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	8.49	0.38	3.5e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg03983476	chr2:10830698	NOL10	-0.46	-7.87	-0.36	3e-14	Prostate cancer;
LUAD	cis	rs59698941	0.943	rs59484796	chr5:132293543	C/T	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs117623576	0.618	rs211416	chr10:32397591	T/A	cg03047570	chr10:32398778	NA	0.68	8.59	0.39	1.66e-16	Anti-saccade response;
LUAD	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.49	0.38	3.47e-16	Menopause (age at onset);
LUAD	cis	rs9399401	0.667	rs11155242	chr6:142691549	A/C	cg03128060	chr6:142623767	GPR126	0.5	9.83	0.43	1.15e-20	Chronic obstructive pulmonary disease;
LUAD	cis	rs9302635	0.513	rs12928732	chr16:72188683	C/T	cg23815491	chr16:72088622	HP	0.49	7.93	0.36	2.04e-14	Blood protein levels;
LUAD	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg09491104	chr22:46646882	C22orf40	-0.56	-7.72	-0.35	8.26e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6906287	0.647	rs7769001	chr6:118934509	A/G	cg05564266	chr6:118973597	C6orf204	0.37	7.68	0.35	1.08e-13	Electrocardiographic conduction measures;
LUAD	cis	rs11126435	0.858	rs363608	chr2:74901602	C/T	cg19285774	chr2:74907978	SEMA4F	0.39	6.97	0.32	1.23e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg10018233	chr7:150070692	REPIN1	0.56	9.89	0.43	7.08e-21	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs3784262	0.740	rs12917536	chr15:58288247	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-8.27	-0.37	1.79e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9372498	0.764	rs4593396	chr6:118722514	A/G	cg07617317	chr6:118971624	C6orf204	0.53	6.59	0.31	1.3e-10	Diastolic blood pressure;
LUAD	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg04539111	chr16:67997858	SLC12A4	-0.52	-6.38	-0.3	4.62e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05901451	chr6:126070800	HEY2	-0.66	-11.19	-0.48	1.18e-25	Brugada syndrome;
LUAD	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg08645402	chr16:4508243	NA	0.52	8.89	0.4	1.77e-17	Schizophrenia;
LUAD	trans	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg21775007	chr8:11205619	TDH	0.38	6.64	0.31	9.65e-11	Mood instability;
LUAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg20607798	chr8:58055168	NA	0.54	7.55	0.34	2.72e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.48	0.42	1.89e-19	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs34734847	0.933	rs998727	chr12:121149064	T/G	cg27246729	chr12:121163418	ACADS	0.41	7.78	0.35	5.42e-14	Mean corpuscular volume;
LUAD	cis	rs6688613	1.000	rs6682062	chr1:166949979	C/G	cg07049167	chr1:166818506	POGK	-0.38	-6.36	-0.3	5.1e-10	Refractive astigmatism;
LUAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg06753367	chr22:24256600	NA	-0.39	-6.99	-0.32	1.07e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg11266682	chr4:10021025	SLC2A9	0.54	11.54	0.49	5.69e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8053891	0.585	rs12926804	chr16:71994932	A/G	cg04254540	chr16:71951199	KIAA0174	-0.71	-7.08	-0.33	5.88e-12	Coronary artery disease;
LUAD	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	14.91	0.59	1.01e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12292205	chr6:26970375	C6orf41	-0.47	-6.57	-0.3	1.47e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs8017423	0.935	rs3783838	chr14:90733012	A/G	cg14092571	chr14:90743983	NA	0.45	7.83	0.36	4.06e-14	Mortality in heart failure;
LUAD	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	cis	rs67385638	1.000	rs2855121	chr11:5277291	C/T	cg12559170	chr11:5275217	HBG2	0.32	6.46	0.3	2.95e-10	Hemoglobin levels;
LUAD	cis	rs1595825	0.945	rs6736825	chr2:198854224	C/T	cg00982548	chr2:198649783	BOLL	-0.64	-9.07	-0.4	4.57e-18	Ulcerative colitis;
LUAD	cis	rs4846217	0.833	rs4846214	chr1:10400718	A/G	cg17425144	chr1:10567563	PEX14	-0.5	-6.59	-0.31	1.3e-10	Platelet count;
LUAD	cis	rs4853525	0.522	rs1860167	chr2:191582387	G/A	cg27211696	chr2:191398769	TMEM194B	-0.41	-6.8	-0.31	3.62e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg13856295	chr9:139396418	NOTCH1	-0.36	-6.45	-0.3	3.11e-10	Monocyte percentage of white cells;
LUAD	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg06484146	chr7:12443880	VWDE	-0.58	-7.37	-0.34	9.17e-13	Coronary artery disease;
LUAD	cis	rs17401966	0.838	rs12737239	chr1:10323973	C/G	cg15208524	chr1:10270712	KIF1B	0.44	6.83	0.32	2.9100000000000002e-11	Hepatocellular carcinoma;
LUAD	cis	rs10992471	0.603	rs11788523	chr9:95256593	G/A	cg14631576	chr9:95140430	CENPP	-0.56	-11.54	-0.49	5.9e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs6901250	1.000	rs993394	chr6:117117143	G/A	cg12892004	chr6:117198278	RFX6	0.35	7.15	0.33	3.73e-12	C-reactive protein levels;
LUAD	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15506890	chr2:3487001	NA	-0.45	-7.76	-0.35	6.38e-14	Neurofibrillary tangles;
LUAD	cis	rs1043515	0.607	rs4795318	chr17:36949053	C/T	cg20826740	chr17:37024042	NA	0.4	6.88	0.32	2.14e-11	Height;
LUAD	cis	rs10924309	0.765	rs1122735	chr1:245853299	G/A	cg00036263	chr1:245852353	KIF26B	-0.49	-7.85	-0.36	3.36e-14	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg21475434	chr5:93447410	FAM172A	0.75	8.28	0.37	1.67e-15	Diabetic retinopathy;
LUAD	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg17366294	chr4:99064904	C4orf37	-0.48	-8.53	-0.38	2.59e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9902453	0.808	rs8069669	chr17:28239502	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	10.59	0.46	2.12e-23	Coffee consumption (cups per day);
LUAD	trans	rs7939886	0.920	rs7115395	chr11:55877116	G/A	cg15704280	chr7:45808275	SEPT13	0.66	6.56	0.3	1.56e-10	Myopia (pathological);
LUAD	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	cis	rs977987	0.806	rs4888389	chr16:75395228	T/C	cg03315344	chr16:75512273	CHST6	0.64	14.02	0.56	5.88e-37	Dupuytren's disease;
LUAD	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg21252483	chr19:49399788	TULP2	-0.89	-14.64	-0.58	1.52e-39	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs6992820	0.902	rs13274826	chr8:56764794	G/T	cg06880721	chr8:56792545	LYN	-0.5	-8.35	-0.38	9.66e-16	Mean platelet volume;
LUAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08677398	chr8:58056175	NA	0.47	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4711336	0.967	rs4713658	chr6:33667117	C/G	cg13859433	chr6:33739653	LEMD2	-0.31	-7.44	-0.34	5.74e-13	Height;
LUAD	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg20628663	chr10:43360327	NA	0.71	11.03	0.47	5.05e-25	Blood protein levels;
LUAD	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg16325326	chr1:53192061	ZYG11B	0.47	7.66	0.35	1.3e-13	Monocyte count;
LUAD	cis	rs9473147	0.571	rs9463335	chr6:47479136	G/A	cg02130027	chr6:47444894	CD2AP	0.38	7.22	0.33	2.38e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00149659	chr3:10157352	C3orf10	0.63	8.82	0.39	2.97e-17	Alzheimer's disease;
LUAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00149659	chr3:10157352	C3orf10	0.84	11.27	0.48	6.37e-26	Alzheimer's disease;
LUAD	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.67	-11.73	-0.5	1.07e-27	Menarche (age at onset);
LUAD	cis	rs2421770	0.504	rs7943314	chr11:35363823	A/G	cg13971030	chr11:35366721	SLC1A2	-0.46	-7.98	-0.36	1.36e-14	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs377457	0.623	rs1053328	chr16:85711860	A/G	cg02758499	chr16:85682440	KIAA0182	-0.35	-6.45	-0.3	2.98e-10	Type 2 diabetes;
LUAD	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.39	6.58	0.3	1.43e-10	Systemic lupus erythematosus;
LUAD	cis	rs500891	0.525	rs9800770	chr6:84070313	C/T	cg08257003	chr6:84140564	ME1	0.34	6.71	0.31	6.19e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs7524258	0.868	rs1304711	chr1:7270320	G/T	cg07173049	chr1:7289937	CAMTA1	-0.49	-9.54	-0.42	1.15e-19	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg13722127	chr7:150037890	RARRES2	0.41	6.66	0.31	8.7e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	6.65	0.31	8.9e-11	Multiple sclerosis;
LUAD	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-13.73	-0.56	9.38e-36	Chronic sinus infection;
LUAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-9.23	-0.41	1.32e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg06108461	chr20:60628389	TAF4	-0.74	-12.35	-0.51	4e-30	Body mass index;
LUAD	cis	rs4253772	0.626	rs113658408	chr22:46646019	C/G	cg00784671	chr22:46762841	CELSR1	-0.61	-7.59	-0.35	2.1e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg01097406	chr16:89675127	NA	-0.32	-6.37	-0.3	4.86e-10	Vitiligo;
LUAD	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg14664628	chr15:75095509	CSK	-0.53	-8.61	-0.39	1.5e-16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.72	0.39	6.5e-17	Parkinson's disease;
LUAD	cis	rs4285028	0.948	rs79103597	chr3:121667629	C/T	cg11130432	chr3:121712080	ILDR1	-0.58	-8.12	-0.37	5.33e-15	Multiple sclerosis;
LUAD	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg27124370	chr19:33622961	WDR88	0.45	6.95	0.32	1.36e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.81	-14.3	-0.57	4.17e-38	Chronic sinus infection;
LUAD	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg00922110	chr4:57842668	C4orf14	-0.43	-7.13	-0.33	4.47e-12	Response to bleomycin (chromatid breaks);
LUAD	cis	rs12791968	0.659	rs12808379	chr11:45009273	C/G	cg11846598	chr11:44996168	LOC221122	-0.68	-10.14	-0.44	9.12e-22	Inhibitory control;
LUAD	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg13902645	chr11:5959945	NA	-0.57	-10.09	-0.44	1.39e-21	DNA methylation (variation);
LUAD	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg05340658	chr4:99064831	C4orf37	0.54	9.16	0.41	2.27e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg01689657	chr7:91764605	CYP51A1	-0.32	-7.98	-0.36	1.43e-14	Breast cancer;
LUAD	cis	rs11955175	1.000	rs77394428	chr5:40743517	A/G	cg05478818	chr5:40835740	RPL37	0.77	6.56	0.3	1.61e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg25753631	chr6:25732923	NA	-0.45	-7.9	-0.36	2.47e-14	Iron status biomarkers;
LUAD	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.61	-0.35	1.85e-13	Blood metabolite levels;
LUAD	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg07169764	chr2:136633963	MCM6	0.68	8.32	0.37	1.23e-15	Corneal structure;
LUAD	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg08807101	chr21:30365312	RNF160	0.43	7.16	0.33	3.5e-12	Dental caries;
LUAD	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg16615211	chr3:44902933	MIR564;TMEM42	0.38	7.12	0.33	4.81e-12	Depressive symptoms;
LUAD	cis	rs3849570	0.533	rs6548784	chr3:81995889	G/A	cg07356753	chr3:81810745	GBE1	-0.49	-8.25	-0.37	2.01e-15	Waist circumference;Body mass index;
LUAD	cis	rs12791968	0.765	rs12790121	chr11:45001089	G/A	cg11846598	chr11:44996168	LOC221122	-0.65	-9.6	-0.42	7.13e-20	Inhibitory control;
LUAD	cis	rs7617773	0.817	rs936427	chr3:48301074	A/G	cg11946769	chr3:48343235	NME6	-0.43	-6.69	-0.31	7.09e-11	Coronary artery disease;
LUAD	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg14844989	chr11:31128820	NA	-0.47	-8.48	-0.38	3.84e-16	Red blood cell count;
LUAD	trans	rs8002861	0.905	rs12874535	chr13:44433565	A/G	cg17145862	chr1:211918768	LPGAT1	-0.68	-14.9	-0.59	1.12e-40	Leprosy;
LUAD	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg11941060	chr3:133502564	NA	-0.66	-11.57	-0.49	4.39e-27	Iron status biomarkers;
LUAD	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg23231163	chr10:75533350	FUT11	-0.52	-9.54	-0.42	1.19e-19	Inflammatory bowel disease;
LUAD	cis	rs6541297	1.000	rs6682741	chr1:230279090	T/C	cg20703242	chr1:230279135	GALNT2	0.66	12.22	0.51	1.23e-29	Coronary artery disease;
LUAD	cis	rs938554	0.779	rs11735831	chr4:9951591	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.33	-0.34	1.21e-12	Blood metabolite levels;
LUAD	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg27286337	chr10:134555280	INPP5A	0.94	18.97	0.68	1.71e-58	Migraine;
LUAD	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.32	-0.34	1.26e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg21252483	chr19:49399788	TULP2	-0.63	-9.0	-0.4	7.84e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg01579765	chr21:45077557	HSF2BP	-0.6	-13.37	-0.54	3.06e-34	Mean corpuscular volume;
LUAD	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.71	-0.31	6.23e-11	Electroencephalogram traits;
LUAD	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg19729930	chr2:74357872	NA	1.05	16.92	0.64	2.06e-49	Gestational age at birth (maternal effect);
LUAD	cis	rs78487399	0.808	rs13414140	chr2:43671176	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-6.74	-0.31	5.08e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.44	8.5	0.38	3.33e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.12	0.37	5.31e-15	Menopause (age at onset);
LUAD	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg18811423	chr2:55921094	PNPT1	0.5	8.21	0.37	2.67e-15	Metabolic syndrome;
LUAD	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg14092988	chr3:52407081	DNAH1	0.37	7.49	0.34	4.02e-13	Bipolar disorder;
LUAD	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg19622623	chr12:86230825	RASSF9	-0.53	-9.55	-0.42	1.05e-19	Major depressive disorder;
LUAD	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg02569458	chr12:86230093	RASSF9	0.42	7.75	0.35	7.12e-14	Major depressive disorder;
LUAD	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg11247378	chr22:39784982	NA	-0.73	-13.35	-0.54	3.65e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg10518543	chr12:38710700	ALG10B	-0.44	-7.26	-0.33	1.87e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg03452623	chr4:187889614	NA	-0.8	-15.79	-0.61	1.67e-44	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06022373	chr22:39101656	GTPBP1	0.48	8.0	0.36	1.23e-14	Menopause (age at onset);
LUAD	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.5	0.3	2.29e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs57046232	0.552	rs6085497	chr20:6315937	A/G	cg21095983	chr6:86352623	SYNCRIP	0.42	6.59	0.31	1.29e-10	Colorectal cancer;
LUAD	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-9.44	-0.42	2.53e-19	Monocyte percentage of white cells;
LUAD	cis	rs7166081	0.688	rs4776361	chr15:67762056	G/A	cg27219399	chr15:67835830	MAP2K5	0.41	7.47	0.34	4.68e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23248424	chr5:179741104	GFPT2	-0.72	-12.06	-0.51	5.46e-29	Height;
LUAD	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg23649088	chr2:200775458	C2orf69	0.64	8.44	0.38	5.1e-16	Schizophrenia;
LUAD	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg14779329	chr11:130786720	SNX19	0.37	6.53	0.3	1.91e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg22823121	chr1:150693482	HORMAD1	0.44	8.91	0.4	1.55e-17	Tonsillectomy;
LUAD	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg11070056	chr1:107600091	PRMT6	0.65	11.24	0.48	7.86e-26	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg20607798	chr8:58055168	NA	0.72	9.44	0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg02782426	chr3:40428986	ENTPD3	0.43	8.99	0.4	8.01e-18	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.97	0.32	1.21e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.77	-0.35	5.97e-14	Prostate cancer;
LUAD	cis	rs9487051	0.768	rs458740	chr6:109525527	C/T	cg01475377	chr6:109611718	NA	-0.38	-6.93	-0.32	1.59e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	7.86	0.36	3.28e-14	Tonsillectomy;
LUAD	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg03453431	chr7:157225567	NA	-0.4	-6.79	-0.31	3.74e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg25894440	chr7:65020034	NA	-0.68	-7.32	-0.34	1.29e-12	Diabetic kidney disease;
LUAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg26338869	chr17:61819248	STRADA	-0.39	-6.51	-0.3	2.08e-10	Prudent dietary pattern;
LUAD	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg15485101	chr11:133734466	NA	0.38	8.25	0.37	2.01e-15	Childhood ear infection;
LUAD	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	10.53	0.46	3.4e-23	Electrocardiographic conduction measures;
LUAD	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05901451	chr6:126070800	HEY2	-0.67	-11.43	-0.49	1.5e-26	Brugada syndrome;
LUAD	cis	rs7274811	0.595	rs13045068	chr20:32133484	G/C	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.48	-7.02	-0.32	9.05e-12	Height;
LUAD	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg17173187	chr15:85201210	NMB	0.41	6.69	0.31	7.16e-11	Schizophrenia;
LUAD	cis	rs12618769	0.652	rs13402379	chr2:99209314	G/A	cg10123293	chr2:99228465	UNC50	0.46	8.48	0.38	3.92e-16	Bipolar disorder;
LUAD	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg09184832	chr6:79620586	NA	-0.52	-9.58	-0.42	8.05e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg11707310	chr1:2537719	MMEL1	0.4	8.5	0.38	3.22e-16	Ulcerative colitis;
LUAD	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg02683114	chr2:24398427	C2orf84	0.4	6.37	0.3	4.89e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs13040088	0.935	rs3787513	chr20:61573736	G/A	cg23096297	chr20:61557774	DIDO1	0.74	9.83	0.43	1.13e-20	Menopause (age at onset);
LUAD	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.4	7.29	0.33	1.54e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.16	0.37	3.86e-15	Rheumatoid arthritis;
LUAD	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg04944784	chr2:26401820	FAM59B	-0.76	-10.5	-0.45	4.4e-23	Gut microbiome composition (summer);
LUAD	cis	rs1232027	0.700	rs1222809	chr5:79917517	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.48	-7.67	-0.35	1.16e-13	Huntington's disease progression;
LUAD	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg17330251	chr7:94953956	PON1	-0.53	-7.21	-0.33	2.66e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2404618	0.561	rs9918765	chr8:1484467	C/T	cg02903104	chr8:1507517	DLGAP2	0.33	7.25	0.33	2.02e-12	Lung cancer;
LUAD	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg11919837	chr8:57350735	NA	-0.43	-6.53	-0.3	1.83e-10	Obesity-related traits;
LUAD	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg07636037	chr3:49044803	WDR6	0.63	12.36	0.52	3.5e-30	Parkinson's disease;
LUAD	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg22467129	chr15:76604101	ETFA	-0.47	-7.92	-0.36	2.07e-14	Blood metabolite levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg04246357	chr6:158589294	SERAC1;GTF2H5	-0.43	-7.3	-0.33	1.41e-12	Schizophrenia;
LUAD	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg16988262	chr1:15930761	NA	0.42	7.04	0.32	7.77e-12	Systolic blood pressure;
LUAD	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg16797656	chr11:68205561	LRP5	-0.47	-10.41	-0.45	9.31e-23	Total body bone mineral density;
LUAD	trans	rs9951602	0.512	rs7232551	chr18:76650702	G/A	cg02800362	chr5:177631904	HNRNPAB	0.92	14.03	0.56	5.64e-37	Obesity-related traits;
LUAD	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg21782813	chr7:2030301	MAD1L1	0.41	6.89	0.32	2e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2880765	0.835	rs4842884	chr15:86035174	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.5	-0.3	2.29e-10	Coronary artery disease;
LUAD	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg00204512	chr16:28754710	NA	0.32	6.88	0.32	2.15e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg13736514	chr6:26305472	NA	0.52	9.06	0.4	4.83e-18	Educational attainment;
LUAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg17178900	chr1:205818956	PM20D1	0.74	15.46	0.6	4.86e-43	Menarche (age at onset);
LUAD	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg03684893	chr10:554711	DIP2C	-0.39	-6.81	-0.31	3.42e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg01579765	chr21:45077557	HSF2BP	-0.61	-13.33	-0.54	4.18e-34	Mean corpuscular volume;
LUAD	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg06671706	chr8:8559999	CLDN23	0.65	11.03	0.47	5.09e-25	Obesity-related traits;
LUAD	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-11.03	-0.47	4.97e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg21823605	chr1:152486609	CRCT1	0.29	6.58	0.3	1.36e-10	Hair morphology;
LUAD	cis	rs367615	0.506	rs2914684	chr5:108775110	C/T	cg17395555	chr5:108820864	NA	-0.62	-13.07	-0.54	4.77e-33	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	7.37	0.34	9.33e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg07169764	chr2:136633963	MCM6	0.83	9.72	0.43	2.69e-20	Corneal structure;
LUAD	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.15	0.37	4.14e-15	Menopause (age at onset);
LUAD	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-8.07	-0.37	7.28e-15	Alzheimer's disease (late onset);
LUAD	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg22920501	chr2:26401640	FAM59B	-0.96	-14.21	-0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs73198271	0.531	rs11985640	chr8:8652504	C/T	cg01851573	chr8:8652454	MFHAS1	0.71	11.31	0.48	4.43e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg02931644	chr1:25747376	RHCE	0.43	8.85	0.4	2.5e-17	Erythrocyte sedimentation rate;
LUAD	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.75	0.31	4.86e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7187994	0.551	rs8050719	chr16:84780468	G/A	cg07647771	chr16:84786436	USP10	-0.27	-7.52	-0.34	3.35e-13	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs2073300	1.000	rs78000067	chr20:23439507	A/G	cg12062639	chr20:23401060	NAPB	1.0	9.23	0.41	1.27e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05890377	chr2:74357713	NA	0.83	12.56	0.52	5.95e-31	Gestational age at birth (maternal effect);
LUAD	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg09117114	chr16:67998030	SLC12A4	-0.51	-6.64	-0.31	9.55e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg03732007	chr1:2071316	PRKCZ	0.35	7.05	0.32	7.1e-12	Height;
LUAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg02353165	chr6:42928485	GNMT	0.49	9.04	0.4	5.64e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg23978390	chr7:1156363	C7orf50	0.46	7.25	0.33	2.05e-12	Longevity;Endometriosis;
LUAD	cis	rs4664304	0.739	rs2162500	chr2:160708645	C/G	cg23995753	chr2:160760732	LY75	0.37	6.48	0.3	2.51e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg15358701	chr1:161410459	NA	-0.68	-6.93	-0.32	1.58e-11	Rheumatoid arthritis;
LUAD	trans	rs7944735	0.671	rs1228044	chr11:48011180	A/G	cg15704280	chr7:45808275	SEPT13	0.64	8.84	0.39	2.55e-17	Intraocular pressure;
LUAD	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.5	7.82	0.36	4.19e-14	Total body bone mineral density;
LUAD	cis	rs6087990	0.735	rs2424920	chr20:31385452	T/C	cg13636640	chr20:31349939	DNMT3B	0.74	13.28	0.54	6.78e-34	Ulcerative colitis;
LUAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg24642844	chr7:1081250	C7orf50	-0.98	-14.8	-0.58	2.97e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg19678392	chr7:94953810	PON1	-0.57	-7.74	-0.35	7.18e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs225245	0.755	rs226432	chr17:34043825	G/A	cg05299278	chr17:33885742	SLFN14	-0.49	-11.15	-0.48	1.79e-25	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14240646	chr10:27532245	ACBD5	0.93	12.22	0.51	1.24e-29	Breast cancer;
LUAD	cis	rs10193935	0.582	rs13394853	chr2:42630900	T/C	cg27598129	chr2:42591480	NA	-0.69	-8.78	-0.39	4.07e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg24642844	chr7:1081250	C7orf50	-0.87	-9.3	-0.41	7.43e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg14343924	chr8:8086146	FLJ10661	-0.47	-7.53	-0.34	3.06e-13	Joint mobility (Beighton score);
LUAD	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg21951975	chr1:209979733	IRF6	0.58	6.98	0.32	1.14e-11	Coronary artery disease;
LUAD	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg27446573	chr6:127587934	RNF146	0.43	6.54	0.3	1.81e-10	Breast cancer;
LUAD	cis	rs1595825	0.945	rs73056890	chr2:198831260	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-7.1	-0.33	5.43e-12	Ulcerative colitis;
LUAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.25	0.41	1.08e-18	Alzheimer's disease;
LUAD	cis	rs877282	0.947	rs7904978	chr10:768078	C/T	cg06581033	chr10:766294	NA	-0.62	-8.34	-0.38	1.08e-15	Uric acid levels;
LUAD	cis	rs438465	1.000	rs2997878	chr6:169883429	T/G	cg11181693	chr6:169825345	NA	-0.64	-8.4	-0.38	6.74e-16	Corneal astigmatism;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg20811730	chr1:150293902	PRPF3	-0.51	-6.63	-0.31	1e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs4776059	1.000	rs8026800	chr15:52933548	C/G	cg24008177	chr15:52972085	KIAA1370	0.26	7.12	0.33	4.68e-12	Schizophrenia;
LUAD	cis	rs2658782	0.789	rs3020076	chr11:93141058	C/T	cg15737290	chr11:93063684	CCDC67	0.49	7.14	0.33	4.21e-12	Pulmonary function decline;
LUAD	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg17971929	chr21:40555470	PSMG1	0.56	8.88	0.4	1.97e-17	Cognitive function;
LUAD	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg01251548	chr11:17372745	DKFZp686O24166	-0.37	-6.71	-0.31	6.22e-11	Type 2 diabetes;
LUAD	cis	rs67072384	0.818	rs2291291	chr11:72466897	T/C	cg04827223	chr11:72435913	ARAP1	-0.57	-6.98	-0.32	1.14e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs9372498	0.536	rs9489460	chr6:118925754	C/T	cg21191810	chr6:118973309	C6orf204	-0.53	-8.22	-0.37	2.44e-15	Diastolic blood pressure;
LUAD	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg18132916	chr6:79620363	NA	0.41	6.66	0.31	8.44e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg20307385	chr11:47447363	PSMC3	0.68	11.84	0.5	3.98e-28	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg02951883	chr7:2050386	MAD1L1	-0.73	-12.97	-0.53	1.28e-32	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.72	0.53	1.27e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg24829409	chr8:58192753	C8orf71	-0.66	-8.19	-0.37	3.04e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	7.62	0.35	1.73e-13	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.77	-0.31	4.39e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	cis	rs2235649	0.798	rs4100646	chr16:1850446	C/T	cg08610935	chr16:1836813	NUBP2	-0.44	-6.78	-0.31	4.02e-11	Blood metabolite levels;
LUAD	cis	rs2282300	0.739	rs1222216	chr11:30346052	C/T	cg06241208	chr11:30344200	C11orf46	-0.55	-7.0	-0.32	1.04e-11	Morning vs. evening chronotype;
LUAD	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-7.42	-0.34	6.34e-13	Alzheimer's disease (late onset);
LUAD	trans	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg26043149	chr18:55253948	FECH	0.51	8.31	0.37	1.35e-15	Bone mineral density;
LUAD	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg22496339	chr2:162101262	NA	-0.46	-6.63	-0.31	1.05e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LUAD	cis	rs4691139	0.658	rs4691142	chr4:165926786	C/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.39	-7.54	-0.34	2.83e-13	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.06e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg02683114	chr2:24398427	C2orf84	-0.52	-7.75	-0.35	7.03e-14	Asthma;
LUAD	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg09658497	chr7:2847517	GNA12	-0.51	-8.56	-0.38	2.1e-16	Height;
LUAD	cis	rs7586879	0.796	rs11684619	chr2:25078859	G/A	cg04586622	chr2:25135609	ADCY3	0.35	7.12	0.33	4.77e-12	Body mass index;
LUAD	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg01097406	chr16:89675127	NA	-0.45	-9.71	-0.43	2.93e-20	Vitiligo;
LUAD	cis	rs938554	0.779	rs6449173	chr4:9966105	A/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.21	-0.37	2.75e-15	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6546550	0.901	rs12475412	chr2:70167197	C/T	cg02498382	chr2:70120550	SNRNP27	-0.61	-11.47	-0.49	1.05e-26	Prevalent atrial fibrillation;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg15067401	chr12:88536400	TMTC3;CEP290	-0.39	-6.69	-0.31	7.31e-11	Subcortical brain region volumes;
LUAD	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.36	7.38	0.34	8.38e-13	Platelet count;
LUAD	cis	rs2302190	0.882	rs7209650	chr17:56674905	C/T	cg25885038	chr17:56607967	SEPT4	-0.51	-8.09	-0.37	6.59e-15	Vitamin D levels;
LUAD	trans	rs1728785	1.000	rs11647432	chr16:68565426	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.78	0.43	1.69e-20	Ulcerative colitis;
LUAD	cis	rs35771425	0.619	rs6689078	chr1:211476423	C/G	cg26515805	chr1:211431828	RCOR3	-0.42	-7.91	-0.36	2.29e-14	Educational attainment (years of education);
LUAD	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg14092988	chr3:52407081	DNAH1	0.39	7.9	0.36	2.5e-14	Electroencephalogram traits;
LUAD	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg22029157	chr1:209979665	IRF6	0.74	11.93	0.5	1.75e-28	Cleft lip with or without cleft palate;
LUAD	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	9.15	0.41	2.52e-18	Multiple sclerosis;
LUAD	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg22676075	chr6:135203613	NA	0.43	7.96	0.36	1.64e-14	Red blood cell count;
LUAD	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg09658497	chr7:2847517	GNA12	-0.49	-9.08	-0.4	4.23e-18	Height;
LUAD	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.55	-0.3	1.65e-10	Prostate cancer;
LUAD	cis	rs9902453	0.791	rs6505141	chr17:27998187	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.34	0.45	1.66e-22	Coffee consumption (cups per day);
LUAD	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg23029597	chr12:123009494	RSRC2	-0.54	-8.18	-0.37	3.25e-15	Body mass index;
LUAD	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg23649088	chr2:200775458	C2orf69	0.56	9.77	0.43	1.88e-20	Systolic blood pressure;
LUAD	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg20607287	chr7:12443886	VWDE	-0.53	-6.79	-0.31	3.74e-11	Coronary artery disease;
LUAD	cis	rs9972944	0.729	rs2024275	chr17:63768913	C/T	cg07283582	chr17:63770753	CCDC46	-0.51	-11.6	-0.49	3.32e-27	Total body bone mineral density;
LUAD	cis	rs13082711	0.595	rs62255583	chr3:27309704	G/T	cg02860705	chr3:27208620	NA	0.78	12.01	0.5	8.59e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg24829409	chr8:58192753	C8orf71	0.59	7.71	0.35	8.94e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg07636037	chr3:49044803	WDR6	0.55	10.44	0.45	7.55e-23	Menarche (age at onset);
LUAD	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg11833968	chr6:79620685	NA	-0.42	-7.87	-0.36	2.92e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg08470875	chr2:26401718	FAM59B	-0.67	-8.95	-0.4	1.1e-17	Gut microbiome composition (summer);
LUAD	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg25894440	chr7:65020034	NA	-0.69	-7.31	-0.33	1.34e-12	Diabetic kidney disease;
LUAD	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg26384229	chr12:38710491	ALG10B	0.48	7.82	0.36	4.31e-14	Bladder cancer;
LUAD	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg23711669	chr6:146136114	FBXO30	0.39	6.48	0.3	2.57e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9443645	0.527	rs9343870	chr6:79789473	T/G	cg05283184	chr6:79620031	NA	-0.46	-7.94	-0.36	1.83e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7737355	0.812	rs11750704	chr5:130911578	C/A	cg25547332	chr5:131281432	NA	0.4	6.44	0.3	3.31e-10	Life satisfaction;
LUAD	cis	rs597583	0.951	rs599411	chr11:117422262	T/G	cg27161313	chr11:117392002	DSCAML1	-0.42	-7.27	-0.33	1.79e-12	Putamen volume;
LUAD	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg14228332	chr4:119757509	SEC24D	0.87	8.17	0.37	3.71e-15	Cannabis dependence symptom count;
LUAD	cis	rs2281845	0.859	rs4915217	chr1:201077470	T/A	cg17810781	chr1:201082982	CACNA1S	0.37	6.63	0.31	1.01e-10	Permanent tooth development;
LUAD	cis	rs2066819	1.000	rs80317430	chr12:56727705	G/A	cg26714650	chr12:56694279	CS	-0.86	-7.09	-0.33	5.59e-12	Psoriasis vulgaris;
LUAD	cis	rs1182436	1	rs1182436	chr7:157027753	T/C	cg05182265	chr7:156933206	UBE3C	0.57	7.69	0.35	1.08e-13	Type 2 diabetes;
LUAD	cis	rs7575217	0.767	rs6543018	chr2:101730288	A/G	cg23907051	chr2:101730305	TBC1D8	0.28	6.61	0.31	1.18e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs17789174	0.953	rs11149708	chr16:85104919	T/G	cg27466129	chr16:85060822	KIAA0513	0.33	6.94	0.32	1.53e-11	Dysphagia;
LUAD	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg10164272	chr16:89456328	ANKRD11	0.41	6.52	0.3	1.97e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg05805236	chr11:65401703	PCNXL3	0.4	6.67	0.31	7.88e-11	Acne (severe);
LUAD	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg15309053	chr8:964076	NA	0.38	8.3	0.37	1.37e-15	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.38e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg15445000	chr17:37608096	MED1	0.44	8.17	0.37	3.6e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.45	-0.52	1.54e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg21984481	chr17:79567631	NPLOC4	-0.54	-11.53	-0.49	6.01e-27	Eye color traits;
LUAD	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs4523957	0.890	rs216191	chr17:2188639	C/T	cg16513277	chr17:2031491	SMG6	0.77	14.32	0.57	3.26e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7524258	0.903	rs6577424	chr1:7292417	C/T	cg07173049	chr1:7289937	CAMTA1	-0.55	-10.25	-0.45	3.61e-22	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.58	-0.3	1.42e-10	Height;
LUAD	trans	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg14791747	chr16:20752902	THUMPD1	0.9	16.1	0.62	7.79e-46	Cognitive test performance;
LUAD	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.42	-8.33	-0.38	1.1e-15	Glomerular filtration rate;
LUAD	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23583168	chr7:148888333	NA	-0.91	-18.68	-0.67	3.08e-57	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg02527881	chr3:46936655	PTH1R	-0.46	-8.89	-0.4	1.78e-17	Colorectal cancer;
LUAD	cis	rs9584850	0.874	rs4584	chr13:99101869	G/C	cg15168958	chr13:99100528	FARP1	-0.38	-6.6	-0.31	1.2e-10	Neuroticism;
LUAD	cis	rs2932538	0.922	rs6690169	chr1:113114974	A/G	cg22162597	chr1:113214053	CAPZA1	0.46	6.88	0.32	2.1e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg16647868	chr5:131706066	SLC22A5	0.39	6.43	0.3	3.5e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg11618577	chr2:27665543	KRTCAP3	0.26	6.82	0.31	3.24e-11	Total body bone mineral density;
LUAD	cis	rs9814567	0.806	rs4074521	chr3:134325536	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.75	13.61	0.55	3.02e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7953508	0.711	rs3825198	chr12:93977465	T/A	cg18151635	chr12:93972918	NA	-0.67	-10.57	-0.46	2.51e-23	Pubertal anthropometrics;
LUAD	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg19717773	chr7:2847554	GNA12	-0.46	-8.23	-0.37	2.33e-15	Height;
LUAD	cis	rs868036	0.718	rs4776985	chr15:68123021	T/G	cg24579218	chr15:68104479	NA	-0.53	-9.23	-0.41	1.3e-18	Restless legs syndrome;
LUAD	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.11	0.37	5.52e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs11971779	0.648	rs6467849	chr7:139080512	C/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	trans	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.53	-0.3	1.84e-10	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs11165623	0.543	rs60982887	chr1:96989155	T/G	cg10631902	chr5:14652156	NA	-0.42	-7.58	-0.35	2.21e-13	Hip circumference;Waist circumference;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06722144	chr3:128206790	GATA2	-0.62	-6.41	-0.3	3.86e-10	Type 2 diabetes;
LUAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg08888203	chr3:10149979	C3orf24	0.63	10.63	0.46	1.52e-23	Alzheimer's disease;
LUAD	cis	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg12964065	chr18:77638022	KCNG2	0.55	6.84	0.32	2.85e-11	Opioid sensitivity;
LUAD	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs9394841	0.692	rs35085306	chr6:41856002	A/G	cg17623882	chr6:41773611	USP49	-0.51	-6.9	-0.32	1.88e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg15448220	chr1:150897856	SETDB1	0.56	9.56	0.42	9.56e-20	Melanoma;
LUAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg11965913	chr1:205819406	PM20D1	0.82	17.12	0.64	2.68e-50	Menarche (age at onset);
LUAD	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg11663144	chr21:46675770	NA	-0.61	-12.12	-0.51	3.26e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg00129232	chr17:37814104	STARD3	-0.43	-7.44	-0.34	5.79e-13	Asthma;
LUAD	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg01657329	chr11:68192670	LRP5	-0.4	-6.42	-0.3	3.69e-10	Total body bone mineral density;
LUAD	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.38	6.85	0.32	2.59e-11	Systemic lupus erythematosus;
LUAD	cis	rs2279817	0.863	rs12139706	chr1:18026435	G/A	cg21791023	chr1:18019539	ARHGEF10L	0.53	8.94	0.4	1.25e-17	Neuroticism;
LUAD	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg06108461	chr20:60628389	TAF4	-0.78	-13.22	-0.54	1.23e-33	Body mass index;
LUAD	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg13511324	chr14:104056883	C14orf153	0.26	6.52	0.3	1.95e-10	Coronary artery disease;
LUAD	cis	rs89107	0.550	rs17226667	chr6:118721628	A/G	cg21191810	chr6:118973309	C6orf204	0.41	7.48	0.34	4.21e-13	Cardiac structure and function;
LUAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg10819733	chr22:24237672	NA	-0.38	-7.35	-0.34	1.05e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg04565464	chr8:145669602	NFKBIL2	0.46	6.7	0.31	6.79e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs932287	0.651	rs1111010	chr11:9049935	A/G	cg12365402	chr11:9010492	NRIP3	0.37	6.55	0.3	1.72e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-8.1	-0.37	5.87e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.47	7.84	0.36	3.66e-14	Tonsillectomy;
LUAD	cis	rs977987	0.872	rs2161648	chr16:75314629	T/G	cg03315344	chr16:75512273	CHST6	0.62	13.13	0.54	2.79e-33	Dupuytren's disease;
LUAD	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg27129171	chr3:47204927	SETD2	0.41	6.74	0.31	5.21e-11	Colorectal cancer;
LUAD	cis	rs17362650	1.000	rs34137501	chr2:9674852	T/G	cg12832956	chr2:9616023	IAH1	-0.47	-7.4	-0.34	7.6e-13	Alcohol dependence (age at onset);
LUAD	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg25985355	chr7:65971099	NA	-0.39	-7.17	-0.33	3.4e-12	Aortic root size;
LUAD	trans	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.49	0.42	1.72e-19	Mean corpuscular volume;
LUAD	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg03526776	chr6:41159608	TREML2	0.32	6.55	0.3	1.71e-10	Alzheimer's disease (late onset);
LUAD	cis	rs9303280	0.685	rs9916765	chr17:38005595	T/C	cg10909506	chr17:38081995	ORMDL3	0.38	6.96	0.32	1.27e-11	Self-reported allergy;
LUAD	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg18932078	chr1:2524107	MMEL1	0.36	6.72	0.31	5.94e-11	Ulcerative colitis;
LUAD	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-8.66	-0.39	1.03e-16	Hemoglobin concentration;
LUAD	cis	rs2357013	0.658	rs13423867	chr2:53047108	C/T	cg07782112	chr2:53107842	NA	0.35	7.19	0.33	2.94e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9796	0.870	rs2925342	chr15:41305733	A/G	cg21153102	chr15:41252147	NA	-0.26	-6.38	-0.3	4.62e-10	Menopause (age at onset);
LUAD	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	9.77	0.43	1.77e-20	Lung cancer in ever smokers;
LUAD	cis	rs68170813	0.876	rs34523267	chr7:107226156	C/T	cg23024343	chr7:107201750	COG5	0.45	6.7	0.31	6.65e-11	Coronary artery disease;
LUAD	cis	rs2235649	0.592	rs2429186	chr16:1969939	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.42	-6.69	-0.31	7.07e-11	Blood metabolite levels;
LUAD	cis	rs11229555	0.645	rs4347409	chr11:58176252	C/T	cg15696309	chr11:58395628	NA	0.73	10.52	0.46	3.74e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg23435118	chr5:141488016	NDFIP1	-0.5	-7.65	-0.35	1.33e-13	Crohn's disease;
LUAD	cis	rs7671266	0.622	rs11943276	chr4:10403545	A/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.56	-0.35	2.51e-13	Cardiovascular disease risk factors;
LUAD	cis	rs9341808	0.556	rs10455370	chr6:81040867	A/G	cg08355045	chr6:80787529	NA	-0.46	-7.89	-0.36	2.54e-14	Sitting height ratio;
LUAD	cis	rs4786125	0.587	rs1473515	chr16:6923092	T/G	cg03623568	chr16:6915990	A2BP1	-0.48	-10.22	-0.45	4.47e-22	Heart rate variability traits (SDNN);
LUAD	cis	rs2274273	0.624	rs67795323	chr14:55797833	G/A	cg04306507	chr14:55594613	LGALS3	0.42	8.12	0.37	5.25e-15	Protein biomarker;
LUAD	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg16032841	chr13:111522222	C13orf29	-0.49	-7.13	-0.33	4.38e-12	Sitting height ratio;
LUAD	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.59	-8.23	-0.37	2.37e-15	Gut microbiome composition (summer);
LUAD	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg04539111	chr16:67997858	SLC12A4	-0.59	-6.92	-0.32	1.67e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg06636551	chr8:101224915	SPAG1	-0.37	-6.84	-0.32	2.83e-11	Atrioventricular conduction;
LUAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg18621852	chr3:10150065	C3orf24	0.44	7.78	0.35	5.58e-14	Alzheimer's disease;
LUAD	cis	rs4988958	0.584	rs7589142	chr2:103024660	T/C	cg03938978	chr2:103052716	IL18RAP	0.45	10.29	0.45	2.7e-22	Asthma (childhood onset);
LUAD	cis	rs9616064	0.520	rs875557	chr22:47034722	C/T	cg25730555	chr22:47059586	GRAMD4	0.4	6.64	0.31	9.69e-11	Urate levels in obese individuals;
LUAD	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.02	-0.36	1.02e-14	Height;
LUAD	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg09455208	chr3:40491958	NA	-0.52	-11.48	-0.49	9.62e-27	Renal cell carcinoma;
LUAD	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg14364472	chr9:139394549	NOTCH1	-0.45	-6.8	-0.31	3.65e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs9372498	0.764	rs4599686	chr6:118722118	T/A	cg07617317	chr6:118971624	C6orf204	0.53	6.59	0.31	1.3e-10	Diastolic blood pressure;
LUAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg11494091	chr17:61959527	GH2	-0.74	-18.44	-0.67	3.66e-56	Prudent dietary pattern;
LUAD	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg22029157	chr1:209979665	IRF6	0.77	10.09	0.44	1.34e-21	Cleft lip with or without cleft palate;
LUAD	cis	rs6028335	0.674	rs57993460	chr20:37662068	C/A	cg27660920	chr20:37554817	FAM83D	0.52	6.5	0.3	2.24e-10	Alcohol and nicotine co-dependence;
LUAD	cis	rs6743376	0.556	rs12475161	chr2:113823626	T/C	cg09040174	chr2:113837401	NA	0.48	7.37	0.34	8.97e-13	Inflammatory biomarkers;
LUAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.74	-0.35	7.2e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg14784868	chr12:69753453	YEATS4	0.44	7.22	0.33	2.42e-12	Blood protein levels;
LUAD	trans	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg04775059	chr7:64541387	NA	-0.5	-6.56	-0.3	1.56e-10	Aortic root size;
LUAD	cis	rs6087990	0.899	rs4911262	chr20:31393352	G/A	cg13636640	chr20:31349939	DNMT3B	0.81	15.14	0.59	1.14e-41	Ulcerative colitis;
LUAD	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg27661571	chr11:113659931	NA	-0.52	-6.49	-0.3	2.37e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1949733	0.701	rs2631754	chr4:8449233	A/G	cg13073564	chr4:8508604	NA	-0.55	-10.14	-0.44	8.86e-22	Response to antineoplastic agents;
LUAD	cis	rs2742234	0.541	rs60845448	chr10:43721462	C/T	cg15436174	chr10:43711423	RASGEF1A	0.55	9.02	0.4	6.55e-18	Hirschsprung disease;
LUAD	cis	rs977987	0.671	rs9922008	chr16:75335406	T/C	cg03315344	chr16:75512273	CHST6	0.63	12.99	0.53	1.07e-32	Dupuytren's disease;
LUAD	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.84	0.39	2.66e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs9341808	0.644	rs59371711	chr6:80942027	G/T	cg08355045	chr6:80787529	NA	-0.48	-8.49	-0.38	3.64e-16	Sitting height ratio;
LUAD	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.9	-0.36	2.45e-14	Total body bone mineral density;
LUAD	trans	rs11039798	0.858	rs11039730	chr11:48440495	A/G	cg03929089	chr4:120376271	NA	0.66	6.71	0.31	6.24e-11	Axial length;
LUAD	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10802521	chr3:52805072	NEK4	-0.53	-9.01	-0.4	6.95e-18	Bipolar disorder;
LUAD	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg06740227	chr12:86229804	RASSF9	0.4	7.0	0.32	9.89e-12	Major depressive disorder;
LUAD	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg20503657	chr10:835505	NA	0.74	9.76	0.43	2.03e-20	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg25237894	chr2:233734115	C2orf82	0.6	11.22	0.48	9.39e-26	Coronary artery disease;
LUAD	cis	rs7149242	0.697	rs12882815	chr14:101183142	C/G	cg18089426	chr14:101175970	NA	-0.38	-6.63	-0.31	1.03e-10	Platelet count;
LUAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg21775007	chr8:11205619	TDH	0.53	9.62	0.42	6.07e-20	Retinal vascular caliber;
LUAD	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg18240062	chr17:79603768	NPLOC4	0.39	6.85	0.32	2.59e-11	Eye color traits;
LUAD	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg07195577	chr17:27052828	TLCD1	0.46	6.44	0.3	3.17e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs68170813	0.527	rs78133594	chr7:107025260	T/C	cg23024343	chr7:107201750	COG5	0.47	6.84	0.32	2.86e-11	Coronary artery disease;
LUAD	trans	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg11693508	chr17:37793320	STARD3	0.55	7.76	0.35	6.48e-14	Bipolar disorder;
LUAD	cis	rs2046867	0.862	rs58538718	chr3:72800563	C/A	cg04365224	chr3:72788183	NA	-0.45	-6.7	-0.31	6.75e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4285028	0.948	rs6790281	chr3:121665543	C/A	cg11130432	chr3:121712080	ILDR1	-0.59	-8.23	-0.37	2.32e-15	Multiple sclerosis;
LUAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg14893161	chr1:205819251	PM20D1	0.76	15.17	0.59	8.21e-42	Monocyte percentage of white cells;
LUAD	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22496380	chr5:211416	CCDC127	-0.94	-13.36	-0.54	3.21e-34	Breast cancer;
LUAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg03188948	chr7:1209495	NA	0.83	10.15	0.44	8.5e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg03886242	chr7:26192032	NFE2L3	-0.42	-7.29	-0.33	1.55e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg02158880	chr13:53174818	NA	0.47	8.19	0.37	3.2e-15	Lewy body disease;
LUAD	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg01119278	chr6:110721349	DDO	-0.42	-7.77	-0.35	6.08e-14	Platelet distribution width;
LUAD	cis	rs9584850	0.834	rs2031239	chr13:99111560	C/T	cg20750642	chr13:99100586	FARP1	-0.33	-6.85	-0.32	2.67e-11	Neuroticism;
LUAD	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg09184832	chr6:79620586	NA	-0.51	-9.66	-0.43	4.26e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg22907277	chr7:1156413	C7orf50	0.51	6.5	0.3	2.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1595825	0.891	rs114426561	chr2:198698891	A/G	cg11031976	chr2:198649780	BOLL	-0.47	-7.07	-0.32	6.55e-12	Ulcerative colitis;
LUAD	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06022373	chr22:39101656	GTPBP1	0.47	7.37	0.34	9.13e-13	Menopause (age at onset);
LUAD	cis	rs6456156	0.967	rs150108	chr6:167513153	C/T	cg07741184	chr6:167504864	NA	0.28	6.53	0.3	1.89e-10	Primary biliary cholangitis;
LUAD	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	6.61	0.31	1.16e-10	Cognitive test performance;
LUAD	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg05340658	chr4:99064831	C4orf37	0.53	9.05	0.4	5.27e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg22963979	chr7:1858916	MAD1L1	-0.62	-10.72	-0.46	7.16e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs17253792	0.822	rs10148122	chr14:56146694	G/T	cg01858014	chr14:56050164	KTN1	-0.6	-6.41	-0.3	3.99e-10	Putamen volume;
LUAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg08888203	chr3:10149979	C3orf24	0.73	12.78	0.53	7.21e-32	Alzheimer's disease;
LUAD	cis	rs4664304	0.597	rs979129	chr2:160840151	T/C	cg23995753	chr2:160760732	LY75	-0.37	-6.35	-0.3	5.54e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.66	0.35	1.25e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg13770153	chr20:60521292	NA	-0.55	-9.01	-0.4	6.91e-18	Body mass index;
LUAD	cis	rs1045714	0.895	rs1107690	chr7:2640595	G/T	cg20813462	chr7:2646259	IQCE	0.67	7.45	0.34	5.28e-13	Urate levels in lean individuals;
LUAD	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg12310025	chr6:25882481	NA	-0.57	-9.35	-0.41	5.19e-19	Blood metabolite levels;
LUAD	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg26769984	chr7:1090371	C7orf50	0.66	10.07	0.44	1.65e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs12541635	0.639	rs10955408	chr8:107020789	G/A	cg10147462	chr8:107024639	NA	0.56	10.42	0.45	8.94e-23	Age of smoking initiation;
LUAD	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg09455208	chr3:40491958	NA	-0.5	-10.56	-0.46	2.67e-23	Renal cell carcinoma;
LUAD	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.19	-0.41	1.75e-18	Total body bone mineral density;
LUAD	cis	rs7851660	0.874	rs1955145	chr9:100634751	A/C	cg13688889	chr9:100608707	NA	0.51	8.84	0.39	2.66e-17	Strep throat;
LUAD	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg24531977	chr5:56204891	C5orf35	-1.06	-17.23	-0.64	8.7e-51	Type 2 diabetes;
LUAD	cis	rs1832871	0.521	rs62437409	chr6:158820221	G/C	cg07165851	chr6:158734300	TULP4	0.46	6.94	0.32	1.48e-11	Height;
LUAD	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.23	0.33	2.25e-12	Blood metabolite levels;
LUAD	cis	rs1832871	0.521	rs62437411	chr6:158823211	G/A	cg07165851	chr6:158734300	TULP4	0.47	7.0	0.32	1.02e-11	Height;
LUAD	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg05872129	chr22:39784769	NA	-0.8	-15.01	-0.59	3.96e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg24733560	chr20:60626293	TAF4	0.47	8.42	0.38	5.78e-16	Body mass index;
LUAD	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg17644776	chr2:200775616	C2orf69	0.56	7.41	0.34	6.87e-13	Schizophrenia;
LUAD	cis	rs9616064	0.506	rs11705341	chr22:47066294	T/C	cg05621596	chr22:47072043	GRAMD4	-0.72	-12.02	-0.5	7.74e-29	Urate levels in obese individuals;
LUAD	cis	rs7584330	0.518	rs74003109	chr2:238448150	C/T	cg14458575	chr2:238380390	NA	0.73	10.75	0.46	5.43e-24	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08219700	chr8:58056026	NA	-0.54	-7.72	-0.35	8.45e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.747	rs1534400	chr2:10696833	T/C	cg01299579	chr2:10830716	NOL10	-0.41	-7.04	-0.32	7.71e-12	Prostate cancer;
LUAD	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg00321850	chr1:175162397	KIAA0040	0.52	11.41	0.49	1.84e-26	Alcohol dependence;
LUAD	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg23649088	chr2:200775458	C2orf69	0.61	8.2	0.37	2.87e-15	Schizophrenia;
LUAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg21724239	chr8:58056113	NA	0.67	8.55	0.38	2.23e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg14725641	chr11:61582763	MIR1908;FADS1	0.43	6.67	0.31	7.9e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg03037974	chr15:76606532	NA	0.38	7.97	0.36	1.46e-14	Blood metabolite levels;
LUAD	trans	rs28735056	0.933	rs72980085	chr18:77631679	A/C	cg05926928	chr17:57297772	GDPD1	-0.48	-6.49	-0.3	2.35e-10	Schizophrenia;
LUAD	trans	rs1728785	0.901	rs1170420	chr16:68635877	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.3	0.45	2.3e-22	Ulcerative colitis;
LUAD	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg04492858	chr10:133558786	NA	0.4	8.01	0.36	1.1e-14	Survival in rectal cancer;
LUAD	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg05991184	chr2:219186017	PNKD	-0.37	-7.19	-0.33	2.99e-12	Colorectal cancer;
LUAD	cis	rs3540	1.000	rs6496678	chr15:91034456	A/G	cg10434728	chr15:90938212	IQGAP1	0.36	6.62	0.31	1.09e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg09323728	chr8:95962352	TP53INP1	0.35	7.66	0.35	1.25e-13	Type 2 diabetes;
LUAD	cis	rs7927771	0.524	rs4752865	chr11:47759841	G/A	cg18512352	chr11:47633146	NA	-0.37	-6.64	-0.31	9.54e-11	Subjective well-being;
LUAD	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg26384229	chr12:38710491	ALG10B	0.49	7.97	0.36	1.49e-14	Heart rate;
LUAD	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	7.06	0.32	7.02e-12	Breast cancer;
LUAD	cis	rs72772090	0.539	rs67140788	chr5:96116286	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.3	-0.33	1.4e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs654950	0.774	rs941972	chr1:42040740	T/C	cg06885757	chr1:42089581	HIVEP3	-0.45	-10.16	-0.44	7.36e-22	Airway imaging phenotypes;
LUAD	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg26513180	chr16:89883248	FANCA	0.69	12.94	0.53	1.61e-32	Vitiligo;
LUAD	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.56	-0.3	1.59e-10	Bladder cancer;
LUAD	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg26408565	chr15:76604113	ETFA	-0.43	-6.96	-0.32	1.31e-11	Blood metabolite levels;
LUAD	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.34e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg13010199	chr12:38710504	ALG10B	0.39	6.42	0.3	3.59e-10	Bladder cancer;
LUAD	trans	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg04146151	chr16:2155961	PKD1	-0.52	-9.48	-0.42	1.91e-19	Triglycerides;
LUAD	cis	rs1003719	0.680	rs2187577	chr21:38533341	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.42	-0.38	5.78e-16	Eye color traits;
LUAD	cis	rs1832871	0.672	rs1342211	chr6:158759496	G/T	cg07165851	chr6:158734300	TULP4	0.72	11.06	0.47	3.85e-25	Height;
LUAD	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.3	-6.78	-0.31	4.08e-11	Dupuytren's disease;
LUAD	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg04398451	chr17:18023971	MYO15A	-0.65	-11.64	-0.49	2.27e-27	Total body bone mineral density;
LUAD	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg25173405	chr17:45401733	C17orf57	0.44	7.6	0.35	1.92e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg16606324	chr3:10149918	C3orf24	0.59	9.65	0.42	4.73e-20	Alzheimer's disease;
LUAD	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.39	7.2	0.33	2.7e-12	IgG glycosylation;
LUAD	cis	rs2282300	0.739	rs35883696	chr11:30246407	A/C	cg25418670	chr11:30344373	C11orf46	-0.53	-7.26	-0.33	1.89e-12	Morning vs. evening chronotype;
LUAD	trans	rs4650994	0.816	rs2209169	chr1:178601492	C/T	cg05059571	chr16:84539110	KIAA1609	0.5	8.26	0.37	1.84e-15	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.8	-0.35	4.77e-14	Diabetic kidney disease;
LUAD	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg17173187	chr15:85201210	NMB	0.41	6.63	0.31	1.05e-10	Schizophrenia;
LUAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg11941060	chr3:133502564	NA	0.64	11.42	0.49	1.59e-26	Iron status biomarkers;
LUAD	cis	rs12135894	0.562	rs6688969	chr1:3743391	C/T	cg17848003	chr1:3704513	LRRC47	0.44	9.5	0.42	1.64e-19	Mean corpuscular volume;
LUAD	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03517284	chr6:25882590	NA	-0.58	-9.55	-0.42	1.09e-19	Blood metabolite levels;
LUAD	cis	rs7927771	0.524	rs10458915	chr11:47864392	T/A	cg18512352	chr11:47633146	NA	0.36	6.39	0.3	4.37e-10	Subjective well-being;
LUAD	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-10.93	-0.47	1.15e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg05340658	chr4:99064831	C4orf37	0.54	9.16	0.41	2.18e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg09436375	chr6:42928200	GNMT	-0.29	-7.91	-0.36	2.33e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.51	-8.27	-0.37	1.78e-15	Platelet count;
LUAD	cis	rs7903847	0.642	rs61863819	chr10:99142400	T/C	cg20016023	chr10:99160130	RRP12	-0.34	-8.08	-0.37	6.95e-15	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs909002	0.789	rs56074668	chr1:32123801	T/C	cg13919466	chr1:32135498	COL16A1	-0.41	-9.6	-0.42	7.12e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg01528321	chr10:82214614	TSPAN14	0.46	7.38	0.34	8.42e-13	Post bronchodilator FEV1;
LUAD	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg17644776	chr2:200775616	C2orf69	0.56	7.41	0.34	6.87e-13	Schizophrenia;
LUAD	cis	rs13266463	0.830	rs7014552	chr8:143410423	A/G	cg16886403	chr8:143471632	TSNARE1	0.44	6.84	0.32	2.82e-11	Schizophrenia;
LUAD	cis	rs11971779	0.680	rs111461944	chr7:139077903	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.82	0.31	3.2e-11	Diisocyanate-induced asthma;
LUAD	cis	rs11112613	0.938	rs2374513	chr12:106007300	C/T	cg03607813	chr12:105948248	NA	0.61	8.76	0.39	4.77e-17	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs10170310	1.000	rs6720716	chr2:139268802	A/G	cg03782584	chr2:139258740	SPOPL	0.32	6.68	0.31	7.72e-11	Response to antipsychotic treatment;
LUAD	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg12311346	chr5:56204834	C5orf35	-0.43	-7.22	-0.33	2.43e-12	Coronary artery disease;
LUAD	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg16950941	chr11:66035639	RAB1B	0.45	7.52	0.34	3.42e-13	Gout;
LUAD	cis	rs7712401	0.601	rs1990890	chr5:122182970	C/T	cg19077854	chr5:122220652	SNX24	0.34	6.48	0.3	2.57e-10	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.6	0.52	4.03e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg23758822	chr17:41437982	NA	1.01	20.42	0.7	5.25e-65	Menopause (age at onset);
LUAD	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.44	-7.29	-0.33	1.52e-12	Longevity;Endometriosis;
LUAD	cis	rs6430585	0.759	rs12467770	chr2:136536095	G/A	cg07169764	chr2:136633963	MCM6	0.79	8.99	0.4	8.57e-18	Corneal structure;
LUAD	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	8.42	0.38	5.97e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs9837602	0.623	rs56339461	chr3:99466531	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.57	6.82	0.31	3.25e-11	Breast cancer;
LUAD	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22857025	chr5:266934	NA	-0.96	-14.33	-0.57	2.98e-38	Breast cancer;
LUAD	cis	rs6688613	0.765	rs56229522	chr1:166816108	T/A	cg07049167	chr1:166818506	POGK	0.61	9.8	0.43	1.38e-20	Refractive astigmatism;
LUAD	cis	rs2637266	0.935	rs751770	chr10:78393956	A/G	cg18941641	chr10:78392320	NA	0.32	6.72	0.31	5.72e-11	Pulmonary function;
LUAD	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg14844989	chr11:31128820	NA	-0.44	-8.1	-0.37	5.76e-15	Red blood cell count;
LUAD	cis	rs28595532	1.000	rs115915387	chr4:119640854	C/T	cg21605333	chr4:119757512	SEC24D	0.87	8.03	0.36	1.01e-14	Cannabis dependence symptom count;
LUAD	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg27490568	chr2:178487706	NA	0.4	6.61	0.31	1.16e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg04565464	chr8:145669602	NFKBIL2	0.44	6.57	0.3	1.45e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.27	0.37	1.77e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg06558623	chr16:89946397	TCF25	1.16	10.95	0.47	9.98e-25	Skin colour saturation;
LUAD	cis	rs10781543	0.810	rs11145756	chr9:139364585	A/G	cg13856295	chr9:139396418	NOTCH1	-0.36	-6.57	-0.3	1.51e-10	Monocyte percentage of white cells;
LUAD	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.14	0.48	1.82e-25	Height;
LUAD	trans	rs61332075	0.518	rs72993031	chr2:239380028	A/G	cg01134436	chr17:81009848	B3GNTL1	0.8	8.72	0.39	6.43e-17	Lung function (FEV1/FVC);
LUAD	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg21433313	chr16:3507492	NAT15	-0.4	-6.43	-0.3	3.42e-10	Body mass index (adult);
LUAD	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg06191203	chr2:152266755	RIF1	-0.51	-7.88	-0.36	2.83e-14	Lung cancer;
LUAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.51e-10	Prudent dietary pattern;
LUAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg18621852	chr3:10150065	C3orf24	0.48	8.45	0.38	4.89e-16	Alzheimer's disease;
LUAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.62	-0.31	1.1e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7119038	0.818	rs11217032	chr11:118669605	T/A	cg19308663	chr11:118741387	NA	0.45	6.47	0.3	2.7e-10	Sjögren's syndrome;
LUAD	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.37	-0.41	4.45e-19	Schizophrenia;
LUAD	cis	rs11255291	0.668	rs6602265	chr10:7732939	A/G	cg13340899	chr10:7670827	ITIH5	0.4	6.9	0.32	1.92e-11	Ovarian reserve;
LUAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg17372223	chr3:52568218	NT5DC2	0.52	10.58	0.46	2.2e-23	Electroencephalogram traits;
LUAD	trans	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg01620082	chr3:125678407	NA	-0.71	-7.15	-0.33	3.79e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg22189786	chr22:42395067	WBP2NL	0.46	6.56	0.3	1.58e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs6594713	0.533	rs71577455	chr5:112953197	C/T	cg12552261	chr5:112820674	MCC	0.51	6.36	0.3	5.09e-10	Brain cytoarchitecture;
LUAD	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.38	6.56	0.3	1.55e-10	Type 2 diabetes;
LUAD	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg13385794	chr1:248469461	NA	-0.27	-7.26	-0.33	1.88e-12	Common traits (Other);
LUAD	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg02951883	chr7:2050386	MAD1L1	-0.83	-14.73	-0.58	6.15e-40	Bipolar disorder and schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05967123	chr1:156737250	PRCC	-0.42	-6.46	-0.3	2.87e-10	Height;
LUAD	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.65	0.31	9.15e-11	Depression;
LUAD	trans	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg17712092	chr4:129076599	LARP1B	-0.76	-11.71	-0.49	1.31e-27	Breast cancer;
LUAD	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg03467027	chr4:99064603	C4orf37	0.4	6.46	0.3	2.93e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7224314	1.000	rs8072527	chr17:65367220	A/G	cg01507342	chr17:65387096	PITPNC1	-0.56	-8.64	-0.39	1.2e-16	Diisocyanate-induced asthma;
LUAD	cis	rs7017914	0.967	rs34677078	chr8:71617715	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs1003719	0.715	rs2835613	chr21:38496883	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.52	-8.79	-0.39	3.93e-17	Eye color traits;
LUAD	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg26384229	chr12:38710491	ALG10B	-0.4	-6.66	-0.31	8.65e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg03354898	chr7:1950403	MAD1L1	-0.38	-6.87	-0.32	2.29e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.61	0.31	1.14e-10	Prudent dietary pattern;
LUAD	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.07	-0.44	1.66e-21	Migraine;Coronary artery disease;
LUAD	cis	rs4588572	0.686	rs10078289	chr5:77670793	T/G	cg11547950	chr5:77652471	NA	0.78	11.81	0.5	4.99e-28	Triglycerides;
LUAD	cis	rs758324	0.704	rs31480	chr5:131396332	C/T	cg06307176	chr5:131281290	NA	-0.42	-6.94	-0.32	1.51e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs41271473	0.607	rs10916361	chr1:228859971	A/T	cg16512390	chr1:228756714	NA	0.42	6.66	0.31	8.28e-11	Chronic lymphocytic leukemia;
LUAD	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg17264618	chr3:40429014	ENTPD3	0.41	8.83	0.39	2.84e-17	Renal cell carcinoma;
LUAD	cis	rs72781680	1.000	rs72781689	chr2:24256349	C/T	cg06627628	chr2:24431161	ITSN2	-0.57	-6.48	-0.3	2.54e-10	Lymphocyte counts;
LUAD	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05926928	chr17:57297772	GDPD1	1.38	17.76	0.65	3.85e-53	Opioid sensitivity;
LUAD	cis	rs7937890	0.572	rs2597202	chr11:14484645	C/T	cg23387056	chr11:14280742	SPON1	-0.34	-6.38	-0.3	4.7e-10	Mitochondrial DNA levels;
LUAD	cis	rs7246657	0.891	rs7253114	chr19:37988725	G/A	cg23950597	chr19:37808831	NA	-0.58	-7.19	-0.33	3.04e-12	Coronary artery calcification;
LUAD	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg17177755	chr1:15930204	NA	0.44	7.18	0.33	3.09e-12	Systolic blood pressure;
LUAD	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg04772025	chr11:68637568	NA	0.56	8.71	0.39	6.96e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs8192282	0.739	rs7513603	chr1:154481158	T/C	cg16683920	chr1:154474344	TDRD10;SHE	-0.45	-6.78	-0.31	4.08e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2882667	0.858	rs11750382	chr5:138456994	A/G	cg04439458	chr5:138467593	SIL1	0.52	9.69	0.43	3.51e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs89107	0.688	rs281867	chr6:118575808	C/T	cg18833306	chr6:118973337	C6orf204	0.52	9.36	0.41	4.64e-19	Cardiac structure and function;
LUAD	cis	rs12618769	0.625	rs56240302	chr2:99148970	C/T	cg10123293	chr2:99228465	UNC50	0.47	8.19	0.37	3.24e-15	Bipolar disorder;
LUAD	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg23625390	chr15:77176239	SCAPER	0.39	6.89	0.32	1.97e-11	Blood metabolite levels;
LUAD	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18876405	chr7:65276391	NA	0.42	6.7	0.31	6.8e-11	Aortic root size;
LUAD	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg24818145	chr4:99064322	C4orf37	-0.46	-7.67	-0.35	1.22e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg19318889	chr4:1322082	MAEA	-0.73	-12.56	-0.52	5.44e-31	Obesity-related traits;
LUAD	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg24154853	chr7:158122151	PTPRN2	-0.47	-8.09	-0.37	6.43e-15	Response to amphetamines;
LUAD	cis	rs657075	0.643	rs71583471	chr5:131654167	C/T	cg21138405	chr5:131827807	IRF1	0.5	6.42	0.3	3.76e-10	Rheumatoid arthritis;
LUAD	trans	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg01620082	chr3:125678407	NA	-0.88	-8.94	-0.4	1.19e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg20991723	chr1:152506922	NA	0.34	6.66	0.31	8.76e-11	Hair morphology;
LUAD	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg01657329	chr11:68192670	LRP5	0.47	8.32	0.38	1.2e-15	Total body bone mineral density;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08724901	chr15:89089781	DET1	-0.44	-6.87	-0.32	2.26e-11	Height;
LUAD	cis	rs7731657	0.509	rs9327583	chr5:130333614	T/A	cg08523029	chr5:130500466	HINT1	0.56	7.35	0.34	1.03e-12	Fasting plasma glucose;
LUAD	cis	rs7737355	0.947	rs6596007	chr5:130588550	A/G	cg06307176	chr5:131281290	NA	-0.41	-6.89	-0.32	2.03e-11	Life satisfaction;
LUAD	cis	rs4711350	0.765	rs1318691	chr6:33761884	G/A	cg07979401	chr6:33739406	LEMD2	-0.54	-9.65	-0.42	4.69e-20	Schizophrenia;
LUAD	cis	rs701145	0.938	rs1515653	chr3:154076654	A/G	cg17054900	chr3:154042577	DHX36	0.63	7.08	0.33	6.16e-12	Coronary artery disease;
LUAD	cis	rs4631830	0.720	rs7090326	chr10:51503375	A/T	cg20129853	chr10:51489980	NA	-0.32	-6.5	-0.3	2.31e-10	Prostate-specific antigen levels;
LUAD	cis	rs3789045	0.774	rs12039365	chr1:204488687	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.43	-7.28	-0.33	1.68e-12	Educational attainment (college completion);
LUAD	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.52	0.3	2.05e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11048434	0.736	rs11048264	chr12:9113581	C/T	cg26114124	chr12:9217669	LOC144571	-0.36	-6.85	-0.32	2.56e-11	Sjögren's syndrome;
LUAD	cis	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg07460842	chr6:66804631	NA	0.94	15.0	0.59	4.2e-41	Exhaled nitric oxide levels;
LUAD	cis	rs7561273	0.586	rs11896092	chr2:24317827	G/A	cg20701182	chr2:24300061	SF3B14	0.52	8.29	0.37	1.52e-15	Quantitative traits;
LUAD	cis	rs7264396	0.563	rs7264869	chr20:34346502	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-7.78	-0.35	5.77e-14	Total cholesterol levels;
LUAD	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg06191203	chr2:152266755	RIF1	-0.46	-7.18	-0.33	3.15e-12	Lung cancer;
LUAD	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg08493051	chr2:3487164	NA	-0.42	-7.27	-0.33	1.72e-12	Neurofibrillary tangles;
LUAD	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.71	0.31	6.33e-11	Cardiac Troponin-T levels;
LUAD	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg11845111	chr2:191398756	TMEM194B	-0.6	-11.02	-0.47	5.46e-25	Pulse pressure;
LUAD	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg23954153	chr1:44402353	ARTN	0.37	7.11	0.33	5.11e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9394841	0.667	rs1891453	chr6:41765265	T/C	cg17623882	chr6:41773611	USP49	-0.52	-7.34	-0.34	1.1e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg06808227	chr14:105710500	BRF1	-0.42	-6.71	-0.31	6.43e-11	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg11822812	chr5:140052017	DND1	-0.44	-7.92	-0.36	2.18e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11890956	chr21:40555474	PSMG1	-0.56	-9.73	-0.43	2.54e-20	Menarche (age at onset);
LUAD	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.27	7.14	0.33	4.14e-12	Schizophrenia;
LUAD	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.55	-9.39	-0.42	3.8e-19	Electrocardiographic conduction measures;
LUAD	cis	rs7192380	0.893	rs1469908	chr16:69764412	C/T	cg26679644	chr16:69762563	NA	-0.51	-9.65	-0.42	4.84e-20	Sjögren's syndrome;
LUAD	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg11494091	chr17:61959527	GH2	0.75	18.63	0.67	5.39e-57	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg10356904	chr22:49881777	NA	-0.4	-8.44	-0.38	4.97e-16	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.78	-14.84	-0.59	2.01e-40	Brugada syndrome;
LUAD	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg15181151	chr6:150070149	PCMT1	0.39	7.6	0.35	1.93e-13	Lung cancer;
LUAD	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-15.51	-0.6	2.94e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg05234568	chr11:5960015	NA	-0.55	-9.91	-0.43	6.02e-21	DNA methylation (variation);
LUAD	cis	rs977987	0.806	rs766521	chr16:75424154	A/G	cg03315344	chr16:75512273	CHST6	-0.62	-13.59	-0.55	3.69e-35	Dupuytren's disease;
LUAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg19626725	chr5:178986131	RUFY1	0.52	8.35	0.38	1.01e-15	Lung cancer;
LUAD	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.58	0.3	1.35e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	cis	rs11098699	0.821	rs6830258	chr4:124230345	A/G	cg09941581	chr4:124220074	SPATA5	-0.45	-7.33	-0.34	1.15e-12	Mosquito bite size;
LUAD	cis	rs8017423	0.935	rs7144070	chr14:90753047	T/C	cg14092571	chr14:90743983	NA	-0.46	-7.92	-0.36	2.08e-14	Mortality in heart failure;
LUAD	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg13319975	chr6:146136371	FBXO30	-0.63	-11.11	-0.48	2.53e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg17120908	chr11:65337727	SSSCA1	0.69	10.97	0.47	8.42e-25	Bone mineral density;
LUAD	trans	rs2262909	0.889	rs61268244	chr19:22310130	C/T	cg17074339	chr11:11642133	GALNTL4	0.46	7.55	0.34	2.8e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26314531	chr2:26401878	FAM59B	-0.69	-9.9	-0.43	6.32e-21	Gut microbiome composition (summer);
LUAD	cis	rs11230563	1.000	rs2074227	chr11:60776781	T/C	cg10158843	chr11:60776172	CD6	0.41	7.31	0.34	1.31e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.31	0.33	1.37e-12	Tonsillectomy;
LUAD	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg07936489	chr17:37558343	FBXL20	-0.48	-7.46	-0.34	4.95e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg15017067	chr4:17643749	FAM184B	0.35	6.9	0.32	1.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg17063962	chr7:91808500	NA	0.71	12.74	0.53	1.03e-31	Breast cancer;
LUAD	cis	rs35740288	0.770	rs1382538	chr15:86165896	G/C	cg13263323	chr15:86062960	AKAP13	-0.45	-6.91	-0.32	1.83e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs9394169	0.533	rs4713675	chr6:33718418	C/T	cg07979401	chr6:33739406	LEMD2	-0.34	-6.6	-0.31	1.23e-10	Essential tremor;
LUAD	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg21252483	chr19:49399788	TULP2	-0.73	-11.68	-0.49	1.67e-27	Red cell distribution width;
LUAD	cis	rs1728785	1.000	rs12918861	chr16:68566508	G/A	cg02508848	chr16:68573721	ZFP90	-0.43	-6.68	-0.31	7.74e-11	Ulcerative colitis;
LUAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg12432903	chr7:1882776	MAD1L1	-0.52	-8.62	-0.39	1.4e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg03874509	chr1:107600012	PRMT6	-0.57	-9.96	-0.44	3.98e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.05	13.15	0.54	2.26e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs3135063	0.504	rs3129315	chr4:3290600	C/T	cg08817983	chr4:3391423	RGS12	-0.51	-7.34	-0.34	1.1e-12	Blood protein levels;
LUAD	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg18512352	chr11:47633146	NA	-0.57	-10.26	-0.45	3.42e-22	Subjective well-being;
LUAD	trans	rs8073060	0.586	rs225300	chr17:33922428	C/T	cg19694781	chr19:47549865	TMEM160	-1.22	-19.67	-0.69	1.28e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs1784581	0.802	rs7768986	chr6:162427890	G/C	cg17173639	chr6:162384350	PARK2	0.49	8.83	0.39	2.89e-17	Itch intensity from mosquito bite;
LUAD	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11644478	chr21:40555479	PSMG1	0.62	9.7	0.43	3.19e-20	Cognitive function;
LUAD	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg10589385	chr1:150898437	SETDB1	0.4	7.26	0.33	1.82e-12	Melanoma;
LUAD	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg13736514	chr6:26305472	NA	-0.68	-12.99	-0.53	1.1e-32	Educational attainment;
LUAD	cis	rs12681288	0.723	rs35425201	chr8:971062	C/T	cg15309053	chr8:964076	NA	0.43	9.85	0.43	9.82e-21	Schizophrenia;
LUAD	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg08645402	chr16:4508243	NA	0.6	10.69	0.46	9.36e-24	Schizophrenia;
LUAD	trans	rs61332075	0.518	rs72994950	chr2:239422993	T/C	cg01134436	chr17:81009848	B3GNTL1	0.78	8.37	0.38	8.79e-16	Lung function (FEV1/FVC);
LUAD	cis	rs713477	1.000	rs12888361	chr14:55906187	A/G	cg13175173	chr14:55914753	NA	-0.33	-6.94	-0.32	1.49e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg18446336	chr7:2847575	GNA12	0.37	7.06	0.32	6.8e-12	Height;
LUAD	cis	rs77106637	0.789	rs76550717	chr11:72428172	A/G	cg04827223	chr11:72435913	ARAP1	-0.46	-6.38	-0.3	4.65e-10	Type 2 diabetes;
LUAD	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg03526776	chr6:41159608	TREML2	0.33	6.85	0.32	2.67e-11	Alzheimer's disease (late onset);
LUAD	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.08	0.47	3.28e-25	Eosinophil percentage of white cells;
LUAD	cis	rs10744422	1.000	rs4759355	chr12:123316566	A/G	cg16953816	chr12:123349952	VPS37B	0.62	6.97	0.32	1.2e-11	Schizophrenia;
LUAD	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg09904177	chr6:26538194	HMGN4	0.42	6.93	0.32	1.58e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg13770153	chr20:60521292	NA	-0.47	-7.97	-0.36	1.54e-14	Body mass index;
LUAD	cis	rs2019216	0.521	rs6565386	chr17:21901755	A/G	cg22648282	chr17:21454238	C17orf51	0.4	7.09	0.33	5.73e-12	Pelvic organ prolapse;
LUAD	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg23283495	chr1:209979779	IRF6	0.7	9.13	0.41	2.8e-18	Cleft lip with or without cleft palate;
LUAD	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg04036182	chr15:45458818	NA	-0.41	-7.19	-0.33	3e-12	Glomerular filtration rate;
LUAD	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg00071950	chr4:10020882	SLC2A9	-0.62	-12.0	-0.5	9.66e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg09491104	chr22:46646882	C22orf40	-0.64	-8.7	-0.39	7.27e-17	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs12912251	1.000	rs34356257	chr15:38989605	T/C	cg01338139	chr15:38987640	C15orf53	-0.57	-8.92	-0.4	1.47e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg19318889	chr4:1322082	MAEA	0.44	7.07	0.33	6.32e-12	Obesity-related traits;
LUAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg27588902	chr6:42928151	GNMT	-0.37	-9.75	-0.43	2.07e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg00993799	chr7:104653126	LOC100216545	-0.5	-6.91	-0.32	1.84e-11	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg19622623	chr12:86230825	RASSF9	-0.47	-8.19	-0.37	3.1e-15	Major depressive disorder;
LUAD	cis	rs1784581	0.802	rs9365355	chr6:162414604	A/G	cg17173639	chr6:162384350	PARK2	0.49	9.07	0.4	4.47e-18	Itch intensity from mosquito bite;
LUAD	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg02753203	chr1:228287806	NA	0.56	10.22	0.45	4.52e-22	Diastolic blood pressure;
LUAD	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg19875535	chr5:140030758	IK	-0.49	-8.12	-0.37	5.05e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9512730	0.553	rs6491211	chr13:28049533	A/G	cg04070771	chr13:27998621	GTF3A	0.48	7.09	0.33	5.76e-12	Schizophrenia;
LUAD	cis	rs55728055	0.661	rs62237772	chr22:31964975	A/C	cg01338084	chr22:32026380	PISD	0.9	6.84	0.32	2.75e-11	Age-related hearing impairment;
LUAD	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05665937	chr4:1216051	CTBP1	0.47	7.05	0.32	7.17e-12	Longevity;
LUAD	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg25767906	chr1:53392781	SCP2	-0.4	-7.27	-0.33	1.7e-12	Monocyte count;
LUAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg03188948	chr7:1209495	NA	0.65	9.52	0.42	1.35e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11890956	chr21:40555474	PSMG1	0.66	8.51	0.38	3.03e-16	Cognitive function;
LUAD	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg00300879	chr1:26503847	CNKSR1	0.29	8.24	0.37	2.25e-15	Height;
LUAD	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	trans	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg19862616	chr7:65841803	NCRNA00174	1.04	24.95	0.77	3.66e-85	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.99	-18.6	-0.67	7.55e-57	Homoarginine levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg12214534	chr11:64851506	CDCA5;ZFPL1	-0.66	-6.64	-0.31	9.38e-11	Type 2 diabetes;
LUAD	cis	rs9902453	1.000	rs4465649	chr17:28394747	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.25	-0.41	1.09e-18	Coffee consumption (cups per day);
LUAD	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg03929089	chr4:120376271	NA	-0.92	-17.61	-0.65	1.82e-52	Height;
LUAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.7	-0.39	7.63e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs367943	0.626	rs7718480	chr5:112704486	G/T	cg21806985	chr5:112824646	MCC	0.24	6.51	0.3	2.17e-10	Type 2 diabetes;
LUAD	cis	rs8060686	0.858	rs7187289	chr16:67967878	A/C	cg26727032	chr16:67993705	SLC12A4	-0.52	-8.68	-0.39	8.72e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg18721089	chr20:30220636	NA	-0.46	-6.57	-0.3	1.47e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	10.26	0.45	3.34e-22	Lung cancer in ever smokers;
LUAD	cis	rs7617773	0.780	rs6442111	chr3:48312060	G/C	cg11946769	chr3:48343235	NME6	0.43	6.76	0.31	4.52e-11	Coronary artery disease;
LUAD	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg12667521	chr19:29218732	NA	0.61	7.66	0.35	1.3e-13	Methadone dose in opioid dependence;
LUAD	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18876405	chr7:65276391	NA	0.45	7.19	0.33	2.9e-12	Aortic root size;
LUAD	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg02160872	chr5:212506	CCDC127	-0.51	-6.59	-0.31	1.3100000000000001e-10	Breast cancer;
LUAD	cis	rs2275731	0.673	rs2000202	chr10:16522790	A/G	cg04254609	chr10:16479192	PTER	-0.41	-6.57	-0.3	1.45e-10	Bone fracture in osteoporosis;
LUAD	cis	rs367943	0.637	rs10039956	chr5:113010928	G/A	cg12552261	chr5:112820674	MCC	0.44	7.53	0.34	3.03e-13	Type 2 diabetes;
LUAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg08027265	chr7:2291960	NA	-0.46	-7.57	-0.35	2.4e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs12893668	0.667	rs8017628	chr14:104047428	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.49	-7.72	-0.35	8.58e-14	Reticulocyte count;
LUAD	cis	rs13064411	0.696	rs2087129	chr3:113142769	T/A	cg18753928	chr3:113234510	CCDC52	-0.67	-11.01	-0.47	5.69e-25	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg09263875	chr16:632152	PIGQ	0.81	17.39	0.65	1.66e-51	Height;
LUAD	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg09085632	chr11:111637200	PPP2R1B	0.64	9.96	0.44	3.84e-21	Primary sclerosing cholangitis;
LUAD	cis	rs6740322	0.748	rs6755601	chr2:43483044	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-10.54	-0.46	3.19e-23	Coronary artery disease;
LUAD	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg11189052	chr15:85197271	WDR73	0.59	7.59	0.35	2.04e-13	Schizophrenia;
LUAD	trans	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg22153745	chr1:153894579	GATAD2B	-0.49	-7.48	-0.34	4.24e-13	Total cholesterol levels;
LUAD	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg23533926	chr12:111358616	MYL2	-0.42	-7.18	-0.33	3.2e-12	Extrinsic epigenetic age acceleration;
LUAD	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg26384229	chr12:38710491	ALG10B	0.44	7.36	0.34	9.42e-13	Morning vs. evening chronotype;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08614659	chr21:45553336	C21orf33	-0.57	-6.71	-0.31	6.38e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg08773314	chr2:239334832	ASB1	0.47	10.83	0.47	2.66e-24	Multiple system atrophy;
LUAD	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg15445000	chr17:37608096	MED1	0.45	8.28	0.37	1.62e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.4	-6.56	-0.3	1.58e-10	Longevity;Endometriosis;
LUAD	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg20119798	chr7:94954144	PON1	-0.49	-6.84	-0.32	2.78e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs62238980	0.614	rs75091642	chr22:32449078	C/A	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg09365446	chr1:150670422	GOLPH3L	-0.42	-7.27	-0.33	1.7e-12	Tonsillectomy;
LUAD	cis	rs2797160	1.000	rs1739347	chr6:126014157	C/T	cg05901451	chr6:126070800	HEY2	0.44	6.51	0.3	2.16e-10	Endometrial cancer;
LUAD	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.44	-0.49	1.38e-26	Primary sclerosing cholangitis;
LUAD	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.94	-0.36	1.83e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4899554	0.509	rs78368951	chr14:75730348	A/G	cg18117039	chr14:75741733	NA	0.65	9.26	0.41	1.07e-18	Inflammatory bowel disease;
LUAD	trans	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg04565464	chr8:145669602	NFKBIL2	0.44	6.49	0.3	2.37e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs3017493	0.685	rs78711146	chr11:70671687	G/A	cg11479156	chr11:70672388	SHANK2	-0.56	-6.5	-0.3	2.22e-10	Renal transplant outcome;
LUAD	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg22852734	chr6:133119734	C6orf192	0.79	9.98	0.44	3.43e-21	Type 2 diabetes nephropathy;
LUAD	cis	rs2688608	0.967	rs72814394	chr10:75656325	C/T	cg23231163	chr10:75533350	FUT11	-0.38	-7.12	-0.33	4.67e-12	Inflammatory bowel disease;
LUAD	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg09835421	chr16:68378352	PRMT7	-0.62	-7.13	-0.33	4.44e-12	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg14668821	chr17:77704760	ENPP7	0.34	6.9	0.32	1.96e-11	Menopause (age at onset);
LUAD	cis	rs3823572	0.564	rs2953626	chr7:133657458	A/G	cg03336402	chr7:133662267	EXOC4	-0.43	-7.75	-0.35	6.93e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg20703242	chr1:230279135	GALNT2	-0.63	-10.86	-0.47	2.12e-24	Coronary artery disease;
LUAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg05457628	chr5:178986728	RUFY1	0.62	9.87	0.43	8.2e-21	Lung cancer;
LUAD	cis	rs1018836	0.923	rs6986689	chr8:91626709	A/C	cg16814680	chr8:91681699	NA	-0.71	-12.1	-0.51	3.8e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg18335740	chr13:41363409	SLC25A15	0.59	10.72	0.46	7.1e-24	Lewy body disease;
LUAD	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.91	0.32	1.79e-11	Aortic root size;
LUAD	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg12908607	chr1:44402522	ARTN	-0.52	-10.53	-0.46	3.46e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg16680214	chr1:154839983	KCNN3	-0.67	-14.14	-0.57	1.87e-37	Prostate cancer;
LUAD	cis	rs9302690	0.557	rs223875	chr16:57506915	C/T	cg16753122	chr16:57506917	DOK4	0.59	7.12	0.33	4.6e-12	Blood protein levels;
LUAD	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.76	0.31	4.49e-11	Platelet count;
LUAD	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.48	-0.45	5.44e-23	Total body bone mineral density;
LUAD	cis	rs75920871	0.920	rs4938336	chr11:116948442	A/G	cg04087571	chr11:116723030	SIK3	-0.33	-6.73	-0.31	5.65e-11	Subjective well-being;
LUAD	cis	rs2797685	1.000	rs707467	chr1:7861684	A/C	cg04725166	chr1:7887271	PER3	-0.47	-6.82	-0.31	3.25e-11	Crohn's disease;
LUAD	cis	rs1816752	0.652	rs2902356	chr13:24988471	C/T	cg02811702	chr13:24901961	NA	0.43	7.27	0.33	1.76e-12	Obesity-related traits;
LUAD	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg27284194	chr4:1044797	NA	0.7	10.1	0.44	1.21e-21	Recombination rate (females);
LUAD	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	6.86	0.32	2.42e-11	Motion sickness;
LUAD	cis	rs6754311	0.589	rs11681659	chr2:136820960	C/T	cg05194412	chr2:137003533	NA	0.43	6.57	0.3	1.52e-10	Mosquito bite size;
LUAD	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg16647868	chr5:131706066	SLC22A5	0.39	6.64	0.31	9.48e-11	Blood metabolite levels;
LUAD	cis	rs13315871	0.929	rs28659863	chr3:58328072	C/T	cg20936604	chr3:58311152	NA	-0.75	-7.82	-0.36	4.24e-14	Cholesterol, total;
LUAD	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg05187965	chr10:45406764	TMEM72	-0.47	-9.05	-0.4	5.46e-18	Mean corpuscular volume;
LUAD	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.33	-0.34	1.15e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.86	-0.53	3.5e-32	Dilated cardiomyopathy;
LUAD	trans	rs889122	0.765	rs889162	chr19:9951916	C/T	cg05991743	chr2:56412380	CCDC85A	0.38	6.36	0.3	5.35e-10	Menarche (age at onset);
LUAD	cis	rs68170813	0.559	rs3823960	chr7:107009349	T/C	cg23024343	chr7:107201750	COG5	0.51	7.22	0.33	2.44e-12	Coronary artery disease;
LUAD	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.98	0.4	8.85e-18	Parkinson's disease;
LUAD	cis	rs684232	0.666	rs425961	chr17:573714	G/A	cg15660573	chr17:549704	VPS53	-0.79	-15.18	-0.59	7.57e-42	Prostate cancer;
LUAD	trans	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg01620082	chr3:125678407	NA	-1.09	-10.7	-0.46	8.55e-24	Depression;
LUAD	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg19912559	chr1:40204330	PPIE	0.58	9.95	0.44	4.12e-21	Blood protein levels;
LUAD	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg02569458	chr12:86230093	RASSF9	0.43	7.76	0.35	6.51e-14	Major depressive disorder;
LUAD	cis	rs9902453	0.817	rs62068625	chr17:28176581	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.55	0.42	1.09e-19	Coffee consumption (cups per day);
LUAD	cis	rs929596	0.614	rs10929302	chr2:234665782	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.76	-12.93	-0.53	1.88e-32	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs16854884	0.586	rs4616638	chr3:143735423	A/T	cg01302019	chr3:143689584	C3orf58	0.39	6.94	0.32	1.5e-11	Economic and political preferences (feminism/equality);
LUAD	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg11292332	chr7:45801988	SEPT13	-0.28	-6.36	-0.3	5.15e-10	Extrinsic epigenetic age acceleration;
LUAD	trans	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04565464	chr8:145669602	NFKBIL2	0.45	6.88	0.32	2.12e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs12122100	0.955	rs12141289	chr1:146509468	A/G	cg03526459	chr1:146549940	NA	-0.39	-7.41	-0.34	6.85e-13	HIV-1 control;
LUAD	cis	rs7264396	0.563	rs6060592	chr20:34352414	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.97	-0.36	1.45e-14	Total cholesterol levels;
LUAD	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg00750074	chr16:89608354	SPG7	-0.61	-10.67	-0.46	1.1e-23	Multiple myeloma (IgH translocation);
LUAD	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.06	-0.47	3.76e-25	Type 2 diabetes;
LUAD	cis	rs7582720	0.943	rs72932556	chr2:203845996	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.64	0.42	5.27e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7903847	0.619	rs76094900	chr10:99158164	G/A	cg20016023	chr10:99160130	RRP12	-0.31	-7.24	-0.33	2.16e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg05425664	chr17:57184151	TRIM37	-0.43	-7.64	-0.35	1.47e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg12034118	chr1:209979487	IRF6	0.56	7.45	0.34	5.39e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-11.11	-0.48	2.44e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg00495681	chr13:53174319	NA	0.6	11.29	0.48	4.91e-26	Lewy body disease;
LUAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02359409	chr6:42947317	PEX6	-0.38	-6.82	-0.31	3.12e-11	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs367943	1.000	rs348956	chr5:112821464	C/T	cg12552261	chr5:112820674	MCC	0.59	11.13	0.48	2.02e-25	Type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15289517	chr15:65809633	DPP8	-0.56	-6.81	-0.31	3.43e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10911363	0.592	rs2782411	chr1:183476929	G/A	cg09173681	chr1:183549694	NCF2	0.56	10.16	0.44	7.62e-22	Systemic lupus erythematosus;
LUAD	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg24733560	chr20:60626293	TAF4	0.41	8.16	0.37	3.96e-15	Body mass index;
LUAD	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg24675056	chr1:15929824	NA	0.48	8.35	0.38	9.97e-16	Systolic blood pressure;
LUAD	cis	rs6594713	0.837	rs7714221	chr5:112751378	A/C	cg12552261	chr5:112820674	MCC	0.56	8.75	0.39	5e-17	Brain cytoarchitecture;
LUAD	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.59	-0.35	2.06e-13	Personality dimensions;
LUAD	trans	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg26043149	chr18:55253948	FECH	-0.41	-6.74	-0.31	5.31e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs11971779	0.680	rs4732376	chr7:139098024	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	trans	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg18187862	chr3:45730750	SACM1L	0.52	8.16	0.37	3.93e-15	Primary sclerosing cholangitis;
LUAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.11	0.54	3.28e-33	Prudent dietary pattern;
LUAD	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg21153622	chr11:89784906	NA	-0.37	-7.37	-0.34	9.34e-13	HDL cholesterol;
LUAD	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg12011299	chr4:100065546	ADH4	0.7	12.66	0.52	2.33e-31	Smoking initiation;
LUAD	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs752010	0.619	rs1123483	chr1:42114198	C/T	cg06885757	chr1:42089581	HIVEP3	-0.59	-13.4	-0.55	2.22e-34	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg23752985	chr2:85803571	VAMP8	0.33	6.38	0.3	4.55e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	trans	rs800082	0.934	rs1007566	chr3:144311752	G/A	cg24215973	chr2:240111563	HDAC4	-0.44	-6.85	-0.32	2.59e-11	Smoking behavior;
LUAD	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs72634501	0.568	rs6679564	chr1:39617080	A/G	cg27567593	chr1:39956653	BMP8A	0.35	7.0	0.32	9.93e-12	HDL cholesterol;
LUAD	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg23533926	chr12:111358616	MYL2	-0.39	-6.54	-0.3	1.82e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7561273	0.609	rs1056122	chr2:24342505	C/T	cg20701182	chr2:24300061	SF3B14	-0.48	-7.84	-0.36	3.68e-14	Quantitative traits;
LUAD	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.46	-7.39	-0.34	7.66e-13	Body mass index;
LUAD	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg15017067	chr4:17643749	FAM184B	-0.35	-6.77	-0.31	4.3e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-9.24	-0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.06	-24.41	-0.76	9.18e-83	Chronic sinus infection;
LUAD	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg25985355	chr7:65971099	NA	-0.53	-6.6	-0.31	1.22e-10	Diabetic kidney disease;
LUAD	cis	rs1873147	0.569	rs12593573	chr15:63309919	G/A	cg12160578	chr15:63334699	TPM1	0.52	7.89	0.36	2.56e-14	Orofacial clefts;
LUAD	cis	rs116095464	1.000	rs6879758	chr5:350277	G/C	cg22496380	chr5:211416	CCDC127	-1.0	-8.07	-0.37	7.3e-15	Breast cancer;
LUAD	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg24733560	chr20:60626293	TAF4	0.39	7.52	0.34	3.25e-13	Body mass index;
LUAD	cis	rs791888	0.760	rs10788561	chr10:89423245	A/G	cg13926569	chr10:89418898	PAPSS2	0.49	9.34	0.41	5.5e-19	Magnesium levels;
LUAD	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08109568	chr15:31115862	NA	-0.65	-10.25	-0.45	3.61e-22	Huntington's disease progression;
LUAD	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg27494647	chr7:150038898	RARRES2	0.48	8.39	0.38	7.22e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.98	0.36	1.42e-14	Parkinson's disease;
LUAD	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg26446133	chr18:72167187	CNDP2	-0.79	-11.32	-0.48	4.11e-26	Refractive error;
LUAD	cis	rs2932538	0.922	rs7522110	chr1:113072914	A/C	cg22162597	chr1:113214053	CAPZA1	0.44	6.69	0.31	7.03e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs7737355	0.853	rs6873582	chr5:130892741	A/G	cg25547332	chr5:131281432	NA	0.44	6.62	0.31	1.07e-10	Life satisfaction;
LUAD	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg26769984	chr7:1090371	C7orf50	0.6	9.99	0.44	2.97e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs4072705	1.000	rs10760374	chr9:127495508	C/T	cg13476313	chr9:127244764	NR5A1	0.29	7.11	0.33	5.05e-12	Menarche (age at onset);
LUAD	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs2268241	0.877	rs17885509	chr21:34779630	C/T	cg14850771	chr21:34775459	IFNGR2	0.58	6.78	0.31	4e-11	Obesity-related traits;
LUAD	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-9.88	-0.43	7.7e-21	Schizophrenia;
LUAD	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg00786952	chr1:21763130	NA	0.35	6.94	0.32	1.5e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11890956	chr21:40555474	PSMG1	0.74	11.89	0.5	2.43e-28	Cognitive function;
LUAD	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.53	0.34	3.11e-13	Breast cancer;
LUAD	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg22681709	chr2:178499509	PDE11A	-0.49	-8.29	-0.37	1.56e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg01620082	chr3:125678407	NA	-1.07	-10.11	-0.44	1.15e-21	Depression;
LUAD	cis	rs17021463	0.966	rs10856908	chr4:95222755	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.52	-9.92	-0.43	5.42e-21	Testicular germ cell tumor;
LUAD	cis	rs11229555	0.645	rs34794607	chr11:58188401	A/T	cg15696309	chr11:58395628	NA	-0.77	-10.52	-0.46	3.94e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs12900413	0.687	rs34484228	chr15:90304067	A/G	cg24249390	chr15:90295951	MESP1	-0.36	-7.12	-0.33	4.66e-12	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg26195577	chr20:24973756	C20orf3	0.95	16.46	0.62	2.05e-47	Blood protein levels;
LUAD	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18876405	chr7:65276391	NA	0.56	9.38	0.41	4.1e-19	Aortic root size;
LUAD	cis	rs1385374	0.642	rs10847691	chr12:129287449	G/A	cg09035930	chr12:129282057	SLC15A4	-0.65	-6.94	-0.32	1.52e-11	Systemic lupus erythematosus;
LUAD	cis	rs17362650	0.960	rs12464398	chr2:9674809	T/C	cg12832956	chr2:9616023	IAH1	-0.47	-7.4	-0.34	7.6e-13	Alcohol dependence (age at onset);
LUAD	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.03	-0.36	9.53e-15	Bipolar disorder;
LUAD	cis	rs9796	0.689	rs576336	chr15:41452771	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.42	-7.54	-0.34	2.91e-13	Menopause (age at onset);
LUAD	cis	rs2880765	0.527	rs1483578	chr15:86075417	A/G	cg13263323	chr15:86062960	AKAP13	-0.51	-8.68	-0.39	8.73e-17	Coronary artery disease;
LUAD	cis	rs7744392	1.000	rs6939017	chr6:35280858	A/G	cg00237391	chr6:35265643	DEF6	0.78	6.54	0.3	1.81e-10	Cataracts in type 2 diabetes;
LUAD	cis	rs12144309	0.577	rs11102660	chr1:114150717	C/T	cg03325407	chr1:114423726	BCL2L15	-0.43	-6.54	-0.3	1.76e-10	Coronary artery disease;
LUAD	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg06046430	chr4:77819534	ANKRD56	0.55	8.84	0.4	2.52e-17	Emphysema distribution in smoking;
LUAD	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg02569458	chr12:86230093	RASSF9	0.45	8.15	0.37	4.06e-15	Major depressive disorder;
LUAD	cis	rs12472274	0.646	rs2305171	chr2:239097140	G/A	cg17459225	chr2:239074497	NA	0.65	7.19	0.33	2.87e-12	Phospholipid levels (plasma);
LUAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-8.07	-0.37	7.12e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg02158880	chr13:53174818	NA	0.76	13.51	0.55	8.07e-35	Lewy body disease;
LUAD	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg24503407	chr1:205819492	PM20D1	0.48	6.74	0.31	5.35e-11	Parkinson's disease;
LUAD	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg23985595	chr17:80112537	CCDC57	0.52	9.4	0.42	3.57e-19	Life satisfaction;
LUAD	cis	rs11255291	1.000	rs10905219	chr10:7738411	C/T	cg13340899	chr10:7670827	ITIH5	0.38	6.36	0.3	5.35e-10	Ovarian reserve;
LUAD	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg14664628	chr15:75095509	CSK	-0.6	-9.69	-0.43	3.37e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg06074448	chr4:187884817	NA	-0.42	-8.79	-0.39	3.83e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.59	0.31	1.32e-10	Prudent dietary pattern;
LUAD	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg00933542	chr6:150070202	PCMT1	0.35	7.23	0.33	2.24e-12	Testicular germ cell tumor;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg14728310	chr19:9879317	ZNF846	-0.66	-6.36	-0.3	5.3e-10	Type 2 diabetes;
LUAD	cis	rs600626	0.529	rs57188913	chr11:75473294	T/C	cg24262691	chr11:75473276	NA	0.61	8.77	0.39	4.33e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7771547	0.519	rs12190911	chr6:36378487	C/T	cg02952361	chr6:36355661	ETV7	-0.46	-6.78	-0.31	4.18e-11	Platelet distribution width;
LUAD	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg18446336	chr7:2847575	GNA12	0.41	7.74	0.35	7.49e-14	Height;
LUAD	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg02734326	chr4:10020555	SLC2A9	-0.49	-8.51	-0.38	2.98e-16	Bone mineral density;
LUAD	cis	rs4824093	0.544	rs73443957	chr22:50305515	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	6.92	0.32	1.72e-11	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg05304507	chr6:116381966	FRK	0.2	6.91	0.32	1.84e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg27446573	chr6:127587934	RNF146	0.44	6.62	0.31	1.06e-10	Breast cancer;
LUAD	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg27284194	chr4:1044797	NA	0.7	10.13	0.44	9.73e-22	Recombination rate (females);
LUAD	cis	rs57590327	0.555	rs3821551	chr3:81710179	A/T	cg07356753	chr3:81810745	GBE1	-0.63	-9.86	-0.43	8.69e-21	Extraversion;
LUAD	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.34	-0.34	1.1e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.68	-0.46	1.01e-23	Total body bone mineral density;
LUAD	cis	rs7680126	0.596	rs10939835	chr4:10313750	A/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-6.62	-0.31	1.12e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg13126279	chr21:47581558	C21orf56	-0.51	-8.99	-0.4	8.29e-18	Testicular germ cell tumor;
LUAD	trans	rs78049276	0.688	rs56024659	chr4:148378604	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.64	-7.82	-0.36	4.18e-14	Pulse pressure;
LUAD	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.36	0.34	9.77e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs4660214	0.666	rs12025847	chr1:39766649	G/A	cg27567593	chr1:39956653	BMP8A	0.35	7.1	0.33	5.19e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6011002	0.636	rs1758199	chr20:62352827	T/C	cg01176363	chr20:62369445	LIME1	-0.79	-6.64	-0.31	9.47e-11	Dental caries;
LUAD	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.74	-0.43	2.27e-20	Schizophrenia;
LUAD	cis	rs6565180	1.000	rs8049108	chr16:30376486	A/G	cg17640201	chr16:30407289	ZNF48	-0.4	-6.45	-0.3	3.04e-10	Tonsillectomy;
LUAD	cis	rs6894268	0.762	rs6892309	chr5:179031198	T/A	cg26135573	chr5:179059668	NA	0.64	8.66	0.39	1.02e-16	Eating disorders;
LUAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg00280220	chr17:61926910	NA	0.35	6.74	0.31	5.18e-11	Prudent dietary pattern;
LUAD	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg05182265	chr7:156933206	UBE3C	0.81	17.11	0.64	2.83e-50	Body mass index;
LUAD	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg22532475	chr10:104410764	TRIM8	-0.44	-8.56	-0.38	2.19e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg14835575	chr10:16859367	RSU1	0.57	9.07	0.4	4.43e-18	Platelet distribution width;
LUAD	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg24399712	chr22:39784796	NA	-0.79	-14.92	-0.59	9.14e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg04267008	chr7:1944627	MAD1L1	-0.75	-12.08	-0.51	4.54e-29	Bipolar disorder and schizophrenia;
LUAD	cis	rs910187	0.678	rs3818014	chr20:45816649	C/T	cg27589058	chr20:45804311	EYA2	-0.31	-7.07	-0.33	6.44e-12	Migraine;
LUAD	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg08999081	chr20:33150536	PIGU	0.47	8.85	0.4	2.36e-17	Coronary artery disease;
LUAD	cis	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg27411982	chr8:10470053	RP1L1	0.46	8.63	0.39	1.25e-16	Neuroticism;
LUAD	trans	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-10.17	-0.44	7.26e-22	Brugada syndrome;
LUAD	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg19046167	chr17:80928561	B3GNTL1	0.41	6.5	0.3	2.25e-10	Breast cancer;
LUAD	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg01503450	chr10:980765	NA	-0.39	-6.89	-0.32	2.08e-11	Eosinophil percentage of granulocytes;
LUAD	cis	rs11640533	0.901	rs2908790	chr16:53412161	T/C	cg09744766	chr16:53407421	NA	0.41	6.98	0.32	1.15e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg22681709	chr2:178499509	PDE11A	-0.42	-7.0	-0.32	9.91e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs698833	0.852	rs698768	chr2:44576549	C/T	cg04920474	chr2:44395004	PPM1B	0.43	7.91	0.36	2.22e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg09873201	chr16:3507582	NAT15	0.51	7.86	0.36	3.17e-14	Tuberculosis;
LUAD	cis	rs7575217	0.767	rs796056	chr2:101735276	A/C	cg23907051	chr2:101730305	TBC1D8	-0.28	-6.39	-0.3	4.44e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7586879	0.828	rs9631062	chr2:25110084	C/T	cg04586622	chr2:25135609	ADCY3	0.35	7.22	0.33	2.48e-12	Body mass index;
LUAD	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg26384229	chr12:38710491	ALG10B	0.44	7.3	0.33	1.48e-12	Morning vs. evening chronotype;
LUAD	cis	rs10203711	0.933	rs10180937	chr2:239597184	A/G	cg14580085	chr2:239553406	NA	0.41	8.63	0.39	1.26e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg00634984	chr7:65235879	NA	0.47	6.37	0.3	4.91e-10	Aortic root size;
LUAD	trans	rs75804782	0.630	rs13024052	chr2:239308456	T/G	cg01134436	chr17:81009848	B3GNTL1	0.7	6.52	0.3	2.05e-10	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg15110403	chr19:17392923	ANKLE1	-0.46	-7.39	-0.34	7.83e-13	Systemic lupus erythematosus;
LUAD	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg06623918	chr6:96969491	KIAA0776	-0.69	-10.11	-0.44	1.12e-21	Migraine;Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs2239908	0.718	rs241776	chr17:26644308	C/T	cg10342447	chr17:26645325	TMEM97	0.38	7.64	0.35	1.44e-13	Blood protein levels;
LUAD	cis	rs6906287	0.647	rs7772921	chr6:118964623	C/G	cg18833306	chr6:118973337	C6orf204	0.47	8.21	0.37	2.75e-15	Electrocardiographic conduction measures;
LUAD	cis	rs877282	1.000	rs71491304	chr10:772982	C/T	cg17470449	chr10:769945	NA	0.68	10.67	0.46	1.06e-23	Uric acid levels;
LUAD	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg27490568	chr2:178487706	NA	0.6	8.73	0.39	6.08e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg27490568	chr2:178487706	NA	0.42	7.05	0.32	7.32e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs11971779	0.715	rs7787398	chr7:139061846	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.57	0.3	1.49e-10	Diisocyanate-induced asthma;
LUAD	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg18230493	chr5:56204884	C5orf35	0.46	7.73	0.35	8.14e-14	Coronary artery disease;
LUAD	cis	rs7010267	0.570	rs4495458	chr8:120042780	G/T	cg01975934	chr8:119970761	NA	-0.34	-6.4	-0.3	4.23e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg21285383	chr16:89894308	SPIRE2	0.41	9.79	0.43	1.52e-20	Vitiligo;
LUAD	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-10.64	-0.46	1.43e-23	Schizophrenia;
LUAD	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg18944383	chr4:111397179	ENPEP	0.39	7.84	0.36	3.75e-14	Height;
LUAD	trans	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg18187862	chr3:45730750	SACM1L	-0.47	-6.81	-0.31	3.41e-11	Primary sclerosing cholangitis;
LUAD	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.58	-0.35	2.18e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg09517075	chr8:22133004	PIWIL2	0.48	8.99	0.4	8.43e-18	Hypertriglyceridemia;
LUAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.66	-12.11	-0.51	3.61e-29	Longevity;Endometriosis;
LUAD	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg08601574	chr20:25228251	PYGB	-0.47	-8.9	-0.4	1.66e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg25985355	chr7:65971099	NA	-0.38	-6.85	-0.32	2.64e-11	Aortic root size;
LUAD	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg06671706	chr8:8559999	CLDN23	0.64	10.98	0.47	7.7e-25	Obesity-related traits;
LUAD	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg25358565	chr5:93447407	FAM172A	0.56	6.62	0.31	1.11e-10	Diabetic retinopathy;
LUAD	cis	rs7759001	0.857	rs6934748	chr6:27354781	T/G	cg18711553	chr6:27366782	ZNF391	0.39	6.5	0.3	2.21e-10	Glomerular filtration rate (creatinine);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07466433	chr2:7005728	CMPK2	-0.54	-6.42	-0.3	3.62e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs938554	0.612	rs28592748	chr4:9998605	T/C	cg00071950	chr4:10020882	SLC2A9	0.6	9.35	0.41	5.05e-19	Blood metabolite levels;
LUAD	cis	rs11166629	1.000	rs966659	chr8:135639045	C/T	cg27224718	chr8:135614730	ZFAT	-0.57	-10.3	-0.45	2.46e-22	Smoking quantity;
LUAD	cis	rs12122100	0.689	rs12129419	chr1:146546703	A/G	cg03526459	chr1:146549940	NA	-0.36	-6.58	-0.3	1.35e-10	HIV-1 control;
LUAD	cis	rs62400317	0.762	rs10948176	chr6:44833913	A/G	cg20913747	chr6:44695427	NA	-0.43	-6.76	-0.31	4.47e-11	Total body bone mineral density;
LUAD	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.49	0.34	4.05e-13	Bipolar disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01880404	chr19:44079527	XRCC1	-0.42	-6.44	-0.3	3.22e-10	Height;
LUAD	cis	rs909002	0.772	rs12740754	chr1:32083273	G/C	cg13919466	chr1:32135498	COL16A1	-0.34	-7.88	-0.36	2.89e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4889911	0.544	rs1294081	chr17:77829864	T/C	cg01306824	chr17:77834118	NA	0.46	7.03	0.32	8.08e-12	Electroencephalogram traits;
LUAD	trans	rs7712671	0.840	rs11241418	chr5:116527405	C/T	cg02931753	chr4:154074737	TRIM2	0.39	6.5	0.3	2.28e-10	Schizophrenia;
LUAD	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21659725	chr3:3221576	CRBN	0.67	11.58	0.49	4.09e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs870825	0.929	rs72689258	chr4:185590550	G/C	cg04058563	chr4:185651563	MLF1IP	0.74	9.52	0.42	1.37e-19	Blood protein levels;
LUAD	trans	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.44	-0.3	3.35e-10	Aortic root size;
LUAD	cis	rs739496	0.579	rs6489810	chr12:112277406	T/C	cg10833066	chr12:111807467	FAM109A	0.43	7.12	0.33	4.7e-12	Platelet count;
LUAD	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg12011299	chr4:100065546	ADH4	0.72	13.38	0.55	2.81e-34	Alcohol dependence;
LUAD	cis	rs4819852	1.000	rs1034566	chr22:19984277	C/T	cg07821417	chr22:19972146	ARVCF	0.41	7.78	0.35	5.67e-14	Pulse pressure;
LUAD	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg23018236	chr17:30244563	NA	0.62	7.79	0.35	5.19e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg26536354	chr8:144654954	C8orf73	0.6	6.62	0.31	1.08e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg03878208	chr11:72483293	STARD10	0.56	7.89	0.36	2.53e-14	Type 2 diabetes;
LUAD	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.47	7.97	0.36	1.45e-14	Lung cancer in ever smokers;
LUAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.64	-12.16	-0.51	2.13e-29	Longevity;Endometriosis;
LUAD	cis	rs4786125	0.665	rs1492371	chr16:6921285	A/C	cg03623568	chr16:6915990	A2BP1	-0.47	-10.22	-0.44	4.65e-22	Heart rate variability traits (SDNN);
LUAD	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg21605333	chr4:119757512	SEC24D	0.93	8.74	0.39	5.54e-17	Cannabis dependence symptom count;
LUAD	cis	rs8177876	0.731	rs4889227	chr16:81109181	T/C	cg08591886	chr16:81111003	C16orf46	0.63	6.45	0.3	3.15e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg26043149	chr18:55253948	FECH	1.06	18.0	0.66	3.43e-54	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs9512730	0.553	rs9507904	chr13:28049506	C/T	cg04070771	chr13:27998621	GTF3A	0.52	7.9	0.36	2.43e-14	Schizophrenia;
LUAD	cis	rs1113500	0.548	rs11185269	chr1:108647636	T/C	cg06207961	chr1:108661230	NA	0.42	6.61	0.31	1.18e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.34e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg21280719	chr6:42927975	GNMT	-0.38	-11.72	-0.5	1.17e-27	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg21427119	chr20:30132790	HM13	-0.5	-8.02	-0.36	1.04e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg07570687	chr10:102243282	WNT8B	0.44	6.5	0.3	2.22e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg23815491	chr16:72088622	HP	-0.59	-11.33	-0.48	3.49e-26	Fibrinogen levels;
LUAD	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.57	9.98	0.44	3.34e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg24829409	chr8:58192753	C8orf71	-0.59	-6.98	-0.32	1.15e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	9.05e-12	Aortic root size;
LUAD	cis	rs494562	0.892	rs638745	chr6:86115587	C/G	cg17966619	chr6:86160162	NT5E	0.65	7.88	0.36	2.78e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg24558204	chr6:135376177	HBS1L	0.46	8.41	0.38	6.49e-16	Red blood cell count;
LUAD	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg04414720	chr1:150670196	GOLPH3L	0.75	13.51	0.55	7.53e-35	Blood protein levels;
LUAD	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg01416388	chr22:39784598	NA	-0.49	-8.29	-0.37	1.54e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg23283495	chr1:209979779	IRF6	0.73	10.61	0.46	1.8e-23	Cleft lip with or without cleft palate;
LUAD	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg11871910	chr12:69753446	YEATS4	-0.66	-11.4	-0.48	1.92e-26	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg06558623	chr16:89946397	TCF25	1.1	11.03	0.47	5.02e-25	Skin colour saturation;
LUAD	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg17644776	chr2:200775616	C2orf69	0.53	7.56	0.34	2.61e-13	Schizophrenia;
LUAD	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	cis	rs2742234	0.541	rs4648313	chr10:43716739	G/A	cg15436174	chr10:43711423	RASGEF1A	0.55	9.02	0.4	6.55e-18	Hirschsprung disease;
LUAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04267008	chr7:1944627	MAD1L1	0.61	9.33	0.41	6.13e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs1497828	0.956	rs1013386	chr1:217566215	C/T	cg04411442	chr1:217543379	NA	0.36	6.47	0.3	2.74e-10	Dialysis-related mortality;
LUAD	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05901451	chr6:126070800	HEY2	-0.84	-16.04	-0.62	1.37e-45	Brugada syndrome;
LUAD	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg05340658	chr4:99064831	C4orf37	-0.45	-7.32	-0.34	1.28e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg18944383	chr4:111397179	ENPEP	0.38	7.63	0.35	1.52e-13	Height;
LUAD	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg25173405	chr17:45401733	C17orf57	0.46	7.78	0.35	5.59e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.96	-0.32	1.35e-11	Height;
LUAD	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg22349387	chr12:9600060	DDX12	-0.5	-8.96	-0.4	1.01e-17	Breast size;
LUAD	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22857025	chr5:266934	NA	-0.96	-14.42	-0.57	1.32e-38	Breast cancer;
LUAD	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg05283184	chr6:79620031	NA	-0.44	-7.76	-0.35	6.6e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg21252483	chr19:49399788	TULP2	-0.69	-11.02	-0.47	5.34e-25	Red cell distribution width;
LUAD	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg18129748	chr3:49941408	MST1R	0.41	6.82	0.31	3.21e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg18180107	chr4:99064573	C4orf37	0.42	6.81	0.31	3.47e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.786	rs74484541	chr2:198894223	T/C	cg00361562	chr2:198649771	BOLL	-0.47	-6.52	-0.3	1.96e-10	Ulcerative colitis;
LUAD	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg03563238	chr19:33554763	RHPN2	-0.37	-8.57	-0.38	2.01e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg11062466	chr8:58055876	NA	0.45	6.43	0.3	3.43e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg18240062	chr17:79603768	NPLOC4	0.46	8.18	0.37	3.36e-15	Eye color traits;
LUAD	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg00999904	chr2:3704751	ALLC	-0.74	-11.67	-0.49	1.74e-27	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg18190219	chr22:46762943	CELSR1	-0.46	-6.74	-0.31	5.35e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg00129232	chr17:37814104	STARD3	-0.49	-8.92	-0.4	1.37e-17	Asthma;
LUAD	cis	rs2286885	1.000	rs2286886	chr9:129246177	T/C	cg15282417	chr9:129245246	FAM125B	0.45	9.27	0.41	9.37e-19	Intraocular pressure;
LUAD	cis	rs4523957	0.552	rs2760742	chr17:2019037	A/G	cg16513277	chr17:2031491	SMG6	-0.95	-19.21	-0.68	1.41e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg10755058	chr3:40428713	ENTPD3	0.47	8.66	0.39	1.03e-16	Renal cell carcinoma;
LUAD	cis	rs7336332	0.628	rs9581855	chr13:28018014	G/A	cg22138327	chr13:27999177	GTF3A	0.72	9.64	0.42	5.05e-20	Weight;
LUAD	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg19163074	chr7:65112434	INTS4L2	0.43	6.41	0.3	3.9e-10	Aortic root size;
LUAD	cis	rs4700695	0.668	rs36837	chr5:65480007	C/A	cg21114390	chr5:65439923	SFRS12	-0.91	-14.07	-0.56	3.59e-37	Facial morphology (factor 19);
LUAD	cis	rs2230307	0.536	rs6577152	chr1:100434610	A/G	cg20868668	chr1:100435035	SLC35A3	0.55	7.87	0.36	3.02e-14	Carotid intima media thickness;
LUAD	cis	rs76878669	0.561	rs10896111	chr11:66115690	T/C	cg18002602	chr11:66138449	SLC29A2	-0.48	-10.35	-0.45	1.6e-22	Educational attainment (years of education);
LUAD	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg01802117	chr1:53393560	SCP2	0.33	6.62	0.31	1.12e-10	Monocyte count;
LUAD	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg23978390	chr7:1156363	C7orf50	0.53	6.6	0.31	1.2e-10	Bronchopulmonary dysplasia;
LUAD	trans	rs853679	0.607	rs34662244	chr6:28073881	G/A	cg01620082	chr3:125678407	NA	-1.1	-10.56	-0.46	2.69e-23	Depression;
LUAD	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg09658497	chr7:2847517	GNA12	-0.54	-9.14	-0.41	2.65e-18	Height;
LUAD	cis	rs6460942	1.000	rs75564554	chr7:12319362	A/C	cg06484146	chr7:12443880	VWDE	-0.54	-6.44	-0.3	3.32e-10	Coronary artery disease;
LUAD	cis	rs1065852	0.510	rs5758666	chr22:42632833	G/A	cg15128208	chr22:42549153	NA	0.37	6.44	0.3	3.3e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg12698349	chr2:225449008	CUL3	0.85	16.93	0.64	1.86e-49	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.42	0.3	3.75e-10	Parkinson's disease;
LUAD	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	15.43	0.6	6.29e-43	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg18477163	chr1:228402036	OBSCN	-0.37	-7.32	-0.34	1.26e-12	Diastolic blood pressure;
LUAD	cis	rs354225	0.626	rs6740893	chr2:54834380	G/A	cg01766943	chr2:54829624	SPTBN1	0.4	7.29	0.33	1.51e-12	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	trans	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.08	25.67	0.78	2.82e-88	Colorectal cancer;
LUAD	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg02450064	chr17:40260053	DHX58	-0.45	-7.6	-0.35	1.87e-13	Fibrinogen levels;
LUAD	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg08400316	chr16:204221	HBZ	-0.49	-7.72	-0.35	8.32e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg03433033	chr1:76189801	ACADM	0.85	15.18	0.59	7.66e-42	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs11031096	0.676	rs7120125	chr11:3941264	C/T	cg18678763	chr11:4115507	RRM1	0.39	7.09	0.33	5.74e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.52	-0.38	2.84e-16	Neutrophil percentage of white cells;
LUAD	cis	rs11098699	0.821	rs13148385	chr4:124206117	A/G	cg09941581	chr4:124220074	SPATA5	0.49	8.02	0.36	1.05e-14	Mosquito bite size;
LUAD	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg02782426	chr3:40428986	ENTPD3	0.4	8.73	0.39	6.13e-17	Renal cell carcinoma;
LUAD	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg15395560	chr15:45543142	SLC28A2	0.37	6.36	0.3	5.22e-10	Uric acid levels;
LUAD	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg12193833	chr17:30244370	NA	-0.58	-6.97	-0.32	1.19e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.65	0.31	8.98e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56346965	0.967	rs2293765	chr2:191520845	C/A	cg11845111	chr2:191398756	TMEM194B	0.47	7.93	0.36	1.97e-14	Bone mineral density (Ward's triangle area);
LUAD	cis	rs7072216	0.770	rs3830020	chr10:100176615	C/G	cg26618903	chr10:100175079	PYROXD2	0.33	7.59	0.35	2e-13	Metabolite levels;
LUAD	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg09998033	chr7:158218633	PTPRN2	0.42	7.55	0.34	2.77e-13	Obesity-related traits;
LUAD	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg23719950	chr11:63933701	MACROD1	-0.58	-6.91	-0.32	1.75e-11	Mean platelet volume;
LUAD	cis	rs11771526	0.901	rs62457472	chr7:32306885	A/G	cg27511599	chr7:32358540	NA	0.5	6.36	0.3	5.2400000000000005e-10	Body mass index;
LUAD	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg17366294	chr4:99064904	C4orf37	0.65	12.46	0.52	1.45e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg21191810	chr6:118973309	C6orf204	-0.48	-7.66	-0.35	1.28e-13	Diastolic blood pressure;
LUAD	cis	rs2295359	0.643	rs1569922	chr1:67664963	C/T	cg12940439	chr1:67600707	NA	0.33	6.6	0.31	1.27e-10	Psoriasis;
LUAD	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg24818145	chr4:99064322	C4orf37	0.4	6.6	0.31	1.26e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg18621852	chr3:10150065	C3orf24	0.5	9.06	0.4	5.05e-18	Alzheimer's disease;
LUAD	cis	rs9394169	0.613	rs7774682	chr6:33722644	C/T	cg13859433	chr6:33739653	LEMD2	-0.32	-6.94	-0.32	1.45e-11	Essential tremor;
LUAD	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg26750617	chr12:132293702	NA	-0.38	-6.46	-0.3	2.97e-10	Migraine;
LUAD	cis	rs7843479	0.601	rs1058486	chr8:21862551	A/G	cg03445287	chr8:21823731	XPO7	-0.49	-9.17	-0.41	2.05e-18	Mean corpuscular volume;
LUAD	cis	rs61897795	0.628	rs174579	chr11:61605613	C/T	cg00603274	chr11:61596626	FADS2	-0.52	-7.89	-0.36	2.56e-14	Neutrophil count;Sum basophil neutrophil counts;
LUAD	trans	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg06606381	chr12:133084897	FBRSL1	-0.67	-8.01	-0.36	1.11e-14	Depression;
LUAD	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	10.43	0.45	8.34e-23	Monocyte percentage of white cells;
LUAD	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18876405	chr7:65276391	NA	-0.42	-6.6	-0.31	1.21e-10	Aortic root size;
LUAD	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg12588279	chr6:26043732	HIST1H2BB	0.39	6.43	0.3	3.47e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4713675	0.584	rs9368776	chr6:33696405	A/G	cg13859433	chr6:33739653	LEMD2	-0.31	-7.48	-0.34	4.29e-13	Plateletcrit;
LUAD	cis	rs6011002	0.745	rs6011068	chr20:62364885	T/A	cg21849932	chr20:62369462	LIME1	-0.78	-6.45	-0.3	3.09e-10	Dental caries;
LUAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-9.75	-0.43	2.16e-20	Lymphocyte counts;
LUAD	cis	rs11741688	0.557	rs6897783	chr5:178330574	G/A	cg20935368	chr5:178288625	ZNF354B	0.36	6.39	0.3	4.51e-10	Sleep duration;
LUAD	cis	rs12286929	0.606	rs11823428	chr11:115071222	C/A	cg04055981	chr11:115044050	NA	0.47	8.66	0.39	1.04e-16	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg02569458	chr12:86230093	RASSF9	0.38	6.93	0.32	1.58e-11	Major depressive disorder;
LUAD	trans	rs1728785	1.000	rs1728765	chr16:68589433	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.3	0.45	2.43e-22	Ulcerative colitis;
LUAD	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.98	-0.4	8.78e-18	Total body bone mineral density;
LUAD	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg14583973	chr4:3374767	RGS12	0.31	7.77	0.35	5.91e-14	Serum sulfate level;
LUAD	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg17177755	chr1:15930204	NA	0.44	7.18	0.33	3.09e-12	Systolic blood pressure;
LUAD	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg27661571	chr11:113659931	NA	-0.53	-6.86	-0.32	2.53e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs123509	0.874	rs339683	chr3:42788511	G/T	cg12982090	chr3:42733453	KBTBD5	0.55	9.86	0.43	8.56e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg07636037	chr3:49044803	WDR6	0.55	8.29	0.37	1.53e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.62	0.31	1.09e-10	Depression;
LUAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg14159672	chr1:205819179	PM20D1	0.56	9.88	0.43	7.74e-21	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12545109	0.800	rs1837620	chr8:57399473	C/A	cg19413350	chr8:57351067	NA	-0.44	-6.83	-0.32	3.03e-11	Obesity-related traits;
LUAD	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg04450456	chr4:17643702	FAM184B	-0.39	-7.76	-0.35	6.48e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs75804782	0.521	rs56340711	chr2:239440080	A/T	cg01134436	chr17:81009848	B3GNTL1	0.79	8.6	0.39	1.61e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-6.97	-0.32	1.22e-11	Morning vs. evening chronotype;
LUAD	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg03609598	chr5:56110824	MAP3K1	0.48	7.11	0.33	4.92e-12	Initial pursuit acceleration;
LUAD	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.87	0.4	2.05e-17	Parkinson's disease;
LUAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.36	-6.69	-0.31	7.07e-11	Longevity;Endometriosis;
LUAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg16414030	chr3:133502952	NA	-0.64	-12.5	-0.52	9.88e-31	Iron status biomarkers;
LUAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg27454412	chr7:1067447	C7orf50	0.45	7.09	0.33	5.53e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg14752069	chr8:11977206	FAM66D	-0.29	-6.44	-0.3	3.22e-10	Triglycerides;
LUAD	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg15900387	chr1:150738905	CTSS	-0.37	-6.71	-0.31	6.41e-11	Melanoma;
LUAD	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21659725	chr3:3221576	CRBN	0.64	11.14	0.48	1.9e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg15133208	chr4:90757351	SNCA	-0.46	-6.81	-0.31	3.26e-11	Neuroticism;
LUAD	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg17173187	chr15:85201210	NMB	0.51	8.68	0.39	8.86e-17	Schizophrenia;
LUAD	cis	rs9341808	0.754	rs9343973	chr6:80913216	A/G	cg08355045	chr6:80787529	NA	0.58	10.53	0.46	3.59e-23	Sitting height ratio;
LUAD	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg13685833	chr1:53393034	SCP2	-0.51	-8.15	-0.37	4.07e-15	Monocyte count;
LUAD	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00802000	chr16:706648	WDR90	-0.4	-7.41	-0.34	7.11e-13	Height;
LUAD	trans	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg14791747	chr16:20752902	THUMPD1	0.46	7.1	0.33	5.2e-12	Pancreatic cancer;
LUAD	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.37	-10.2	-0.44	5.58e-22	Total body bone mineral density;
LUAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.5	-8.31	-0.37	1.28e-15	Renal function-related traits (BUN);
LUAD	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg11247378	chr22:39784982	NA	-0.7	-13.29	-0.54	6.24e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg16262614	chr3:133464971	TF	0.33	6.39	0.3	4.51e-10	Iron status biomarkers;
LUAD	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg00277334	chr10:82204260	NA	-0.59	-9.77	-0.43	1.8899999999999998e-20	Post bronchodilator FEV1;
LUAD	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg16797656	chr11:68205561	LRP5	-0.38	-7.14	-0.33	4.14e-12	Bone mineral density (spine);
LUAD	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.81	-0.47	3.34e-24	Migraine;Coronary artery disease;
LUAD	cis	rs9900062	1.000	rs9900062	chr17:62739574	G/A	cg02097616	chr17:62675921	NA	0.6	8.38	0.38	8.11e-16	QT interval;
LUAD	cis	rs790123	1.000	rs790113	chr3:122383276	T/A	cg15604389	chr3:122379662	NA	0.51	8.98	0.4	8.73e-18	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg24558204	chr6:135376177	HBS1L	-0.41	-6.96	-0.32	1.34e-11	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg07460842	chr6:66804631	NA	1.03	15.95	0.61	3.43e-45	Exhaled nitric oxide output;
LUAD	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg09085632	chr11:111637200	PPP2R1B	0.67	10.09	0.44	1.39e-21	Primary sclerosing cholangitis;
LUAD	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg04450456	chr4:17643702	FAM184B	-0.37	-6.99	-0.32	1.08e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg22349387	chr12:9600060	DDX12	-0.41	-7.06	-0.32	7.08e-12	Breast size;
LUAD	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.7	0.39	7.31e-17	Parkinson's disease;
LUAD	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg05313129	chr8:58192883	C8orf71	-0.59	-8.7	-0.39	7.45e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs17054480	0.614	rs17054487	chr4:169623117	A/G	cg23372723	chr17:1015100	ABR	0.54	6.44	0.3	3.21e-10	Advanced glycation end-product levels;
LUAD	trans	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg14791747	chr16:20752902	THUMPD1	0.47	7.15	0.33	3.94e-12	Dental caries;
LUAD	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11890956	chr21:40555474	PSMG1	0.79	13.85	0.56	3.18e-36	Cognitive function;
LUAD	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.54	-0.38	2.36e-16	Height;
LUAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg11050988	chr7:1952600	MAD1L1	-0.38	-7.88	-0.36	2.74e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs886126	0.671	rs7952972	chr12:111646519	A/T	cg10833066	chr12:111807467	FAM109A	-0.53	-8.5	-0.38	3.29e-16	Coronary heart disease;
LUAD	cis	rs12540874	1.000	rs12540874	chr7:50664922	A/G	cg18232548	chr7:50535776	DDC	-0.48	-8.13	-0.37	4.66e-15	Systemic sclerosis;
LUAD	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg26513180	chr16:89883248	FANCA	0.73	14.01	0.56	6.47e-37	Vitiligo;
LUAD	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg05991184	chr2:219186017	PNKD	0.37	7.18	0.33	3.25e-12	Colorectal cancer;
LUAD	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg14343924	chr8:8086146	FLJ10661	0.46	7.32	0.34	1.23e-12	Mood instability;
LUAD	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg04369109	chr6:150039330	LATS1	-0.46	-7.45	-0.34	5.16e-13	Lung cancer;
LUAD	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg07169764	chr2:136633963	MCM6	0.81	9.43	0.42	2.76e-19	Corneal structure;
LUAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13126279	chr21:47581558	C21orf56	-0.56	-10.34	-0.45	1.75e-22	Testicular germ cell tumor;
LUAD	cis	rs6688613	1.000	rs1327866	chr1:166952910	C/T	cg07049167	chr1:166818506	POGK	-0.45	-7.68	-0.35	1.09e-13	Refractive astigmatism;
LUAD	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg17177755	chr1:15930204	NA	0.46	7.41	0.34	6.87e-13	Systolic blood pressure;
LUAD	cis	rs9487051	0.768	rs427960	chr6:109524939	C/T	cg21918786	chr6:109611834	NA	-0.42	-7.35	-0.34	1.01e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs11195062	0.521	rs4562740	chr10:111951930	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.49	-7.97	-0.36	1.51e-14	Multiple myeloma;
LUAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg13453750	chr1:205783389	SLC41A1	-0.37	-6.52	-0.3	1.96e-10	Menarche (age at onset);
LUAD	cis	rs4589502	0.512	rs4395023	chr15:67097208	G/A	cg12317470	chr15:67143691	NA	0.52	7.69	0.35	1.02e-13	Lung cancer (smoking interaction);
LUAD	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg00316803	chr15:76480434	C15orf27	-0.41	-7.63	-0.35	1.56e-13	Blood metabolite levels;
LUAD	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2281558	1.000	rs2281558	chr20:25240189	G/T	cg08601574	chr20:25228251	PYGB	0.49	6.97	0.32	1.23e-11	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUAD	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg25237894	chr2:233734115	C2orf82	0.61	11.52	0.49	7.04e-27	Coronary artery disease;
LUAD	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg09365446	chr1:150670422	GOLPH3L	0.61	10.63	0.46	1.51e-23	Melanoma;
LUAD	cis	rs72772090	1.000	rs72772095	chr5:96053853	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.54	-6.42	-0.3	3.73e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs11920354	0.642	rs9812878	chr3:47182787	T/C	cg02527881	chr3:46936655	PTH1R	-0.38	-7.19	-0.33	2.87e-12	Granulocyte count;Sum neutrophil eosinophil counts;
LUAD	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-7.03	-0.32	8.43e-12	Lung cancer;
LUAD	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg00981070	chr1:2046702	PRKCZ	-0.34	-6.68	-0.31	7.4e-11	Height;
LUAD	trans	rs1973993	0.662	rs2057427	chr1:96888897	C/G	cg10631902	chr5:14652156	NA	-0.48	-8.03	-0.36	9.65e-15	Weight;
LUAD	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg13010199	chr12:38710504	ALG10B	0.4	6.73	0.31	5.55e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg26384229	chr12:38710491	ALG10B	-0.42	-6.99	-0.32	1.06e-11	Morning vs. evening chronotype;
LUAD	cis	rs3791556	1.000	rs3791558	chr2:240113255	G/A	cg03281426	chr2:240109471	HDAC4	0.47	8.1	0.37	5.76e-15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs6840360	1.000	rs9995704	chr4:152619069	C/A	cg22705602	chr4:152727874	NA	-0.33	-6.49	-0.3	2.42e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.65	9.1	0.4	3.61e-18	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs4730250	0.654	rs12705405	chr7:106792517	C/T	cg02696742	chr7:106810147	HBP1	0.82	10.81	0.47	3.2e-24	Osteoarthritis;
LUAD	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg09359103	chr1:154839909	KCNN3	0.5	8.73	0.39	6.07e-17	Schizophrenia;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg17952549	chr19:58983050	ZNF324	-0.45	-7.14	-0.33	4e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs73206853	0.686	rs60439011	chr12:110909179	T/C	cg12870014	chr12:110450643	ANKRD13A	0.6	6.61	0.31	1.14e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg18225595	chr11:63971243	STIP1	0.52	8.91	0.4	1.54e-17	Platelet count;
LUAD	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg05110241	chr16:68378359	PRMT7	-0.95	-10.72	-0.46	7.15e-24	Schizophrenia;
LUAD	trans	rs7181230	0.813	rs4924417	chr15:40366939	G/C	cg22705835	chr10:65332833	REEP3	-0.38	-7.26	-0.33	1.85e-12	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs7814319	0.870	rs2292836	chr8:97239613	A/C	cg20787634	chr8:97240163	UQCRB	-0.39	-7.8	-0.35	4.86e-14	Lung function (FVC);
LUAD	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg23602478	chr1:26503979	CNKSR1	0.28	7.0	0.32	1.03e-11	Height;
LUAD	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg18446336	chr7:2847575	GNA12	-0.31	-6.39	-0.3	4.4e-10	Height;
LUAD	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg00603274	chr11:61596626	FADS2	-0.37	-6.4	-0.3	4.18e-10	Trans fatty acid levels;
LUAD	cis	rs1550582	0.548	rs7828645	chr8:135497385	A/G	cg17885191	chr8:135476712	NA	-1.0	-15.1	-0.59	1.69e-41	Educational attainment;
LUAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-9.73	-0.43	2.62e-20	Lymphocyte counts;
LUAD	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.44	-6.96	-0.32	1.33e-11	Primary sclerosing cholangitis;
LUAD	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.58e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg09365446	chr1:150670422	GOLPH3L	0.6	10.73	0.46	6.2e-24	Melanoma;
LUAD	cis	rs4948275	0.550	rs10994742	chr10:63132240	A/T	cg03237606	chr10:63212265	TMEM26	-0.34	-6.97	-0.32	1.26e-11	Night sleep phenotypes;
LUAD	trans	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.98	-0.36	1.4e-14	Gout;
LUAD	cis	rs2070488	0.560	rs1381798	chr3:38437471	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-6.71	-0.31	6.15e-11	Electrocardiographic conduction measures;
LUAD	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.53	0.38	2.71e-16	Breast cancer;
LUAD	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg05991184	chr2:219186017	PNKD	0.34	6.53	0.3	1.85e-10	Colorectal cancer;
LUAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07157834	chr1:205819609	PM20D1	0.73	14.24	0.57	7.28e-38	Menarche (age at onset);
LUAD	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg16325326	chr1:53192061	ZYG11B	-0.62	-11.02	-0.47	5.19e-25	Monocyte count;
LUAD	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg05872129	chr22:39784769	NA	-0.77	-13.86	-0.56	2.74e-36	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg10589385	chr1:150898437	SETDB1	0.43	8.21	0.37	2.66e-15	Melanoma;
LUAD	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg12193833	chr17:30244370	NA	-0.58	-6.95	-0.32	1.35e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.77	-0.43	1.88e-20	Schizophrenia;
LUAD	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.25	6.37	0.3	4.8e-10	Parkinson's disease;
LUAD	trans	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg26043149	chr18:55253948	FECH	1.01	16.77	0.63	9.58e-49	Gout;Urate levels;Serum uric acid levels;
LUAD	trans	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg18834416	chr8:37888184	EIF4EBP1	0.44	7.47	0.34	4.75e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg08888203	chr3:10149979	C3orf24	0.75	13.03	0.54	7.01e-33	Alzheimer's disease;
LUAD	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.88	0.4	1.91e-17	Menopause (age at onset);
LUAD	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.63	-0.35	1.58e-13	Blood metabolite levels;
LUAD	cis	rs8067545	0.717	rs34401389	chr17:19989436	A/T	cg04132472	chr17:19861366	AKAP10	0.3	7.12	0.33	4.63e-12	Schizophrenia;
LUAD	trans	rs3960554	0.867	rs11489553	chr7:75843062	G/A	cg19862616	chr7:65841803	NCRNA00174	0.81	10.44	0.45	7.66e-23	Eotaxin levels;
LUAD	cis	rs12753569	0.837	rs1251490	chr1:76518693	T/C	cg00791851	chr1:76518896	NA	-0.32	-7.12	-0.33	4.78e-12	Personality dimensions;
LUAD	cis	rs7903847	0.642	rs4635018	chr10:99137839	C/G	cg20016023	chr10:99160130	RRP12	0.31	7.07	0.33	6.34e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs938554	0.956	rs874432	chr4:9920606	A/T	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.63	-0.31	1.02e-10	Blood metabolite levels;
LUAD	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.42	2.49e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg21399703	chr1:247681439	NA	0.41	7.65	0.35	1.34e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg24069376	chr3:38537580	EXOG	0.32	6.82	0.31	3.16e-11	Electrocardiographic conduction measures;
LUAD	trans	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg01620082	chr3:125678407	NA	-1.03	-9.32	-0.41	6.67e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg12863693	chr15:85201151	NMB	0.42	7.59	0.35	2.09e-13	Schizophrenia;
LUAD	cis	rs10129255	0.518	rs8010020	chr14:107186255	A/G	cg23076370	chr14:107095027	NA	-0.44	-8.73	-0.39	6.02e-17	Kawasaki disease;
LUAD	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg15704280	chr7:45808275	SEPT13	0.63	8.53	0.38	2.65e-16	Axial length;
LUAD	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg07967210	chr17:47022446	SNF8	0.35	6.38	0.3	4.54e-10	Type 2 diabetes;
LUAD	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-7.33	-0.34	1.15e-12	Morning vs. evening chronotype;
LUAD	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg15123519	chr2:136567270	LCT	-0.38	-7.08	-0.33	6.05e-12	Mosquito bite size;
LUAD	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg24531977	chr5:56204891	C5orf35	-0.49	-8.15	-0.37	4.3e-15	Coronary artery disease;
LUAD	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg15557168	chr22:42548783	NA	0.51	9.41	0.42	3.33e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12216545	0.765	rs12538773	chr7:150250055	A/G	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.37	-0.3	5.02e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg14343924	chr8:8086146	FLJ10661	0.53	8.32	0.38	1.22e-15	Mood instability;
LUAD	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg09085632	chr11:111637200	PPP2R1B	0.52	8.66	0.39	1.03e-16	Primary sclerosing cholangitis;
LUAD	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.57	-0.3	1.45e-10	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21659725	chr3:3221576	CRBN	-0.62	-10.8	-0.46	3.47e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.24	-0.51	1.07e-29	Hip circumference adjusted for BMI;
LUAD	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg15147215	chr3:52552868	STAB1	-0.4	-7.17	-0.33	3.31e-12	Bipolar disorder;
LUAD	cis	rs870825	0.860	rs60022249	chr4:185600772	T/C	cg04058563	chr4:185651563	MLF1IP	0.79	10.49	0.45	4.72e-23	Blood protein levels;
LUAD	cis	rs9486719	0.843	rs2103539	chr6:96844342	T/A	cg06623918	chr6:96969491	KIAA0776	0.71	9.3	0.41	7.58e-19	Migraine;Coronary artery disease;
LUAD	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg06784218	chr1:46089804	CCDC17	0.35	7.69	0.35	1.03e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs714027	1.000	rs2412973	chr22:30529631	C/A	cg11564601	chr22:30592435	NA	-0.4	-8.55	-0.38	2.23e-16	Lymphocyte counts;
LUAD	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg25036284	chr2:26402008	FAM59B	-0.57	-7.97	-0.36	1.5e-14	Gut microbiome composition (summer);
LUAD	cis	rs9814567	0.752	rs6764764	chr3:134331167	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.71	11.45	0.49	1.21e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg12310025	chr6:25882481	NA	-0.56	-9.04	-0.4	5.83e-18	Blood metabolite levels;
LUAD	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg11247378	chr22:39784982	NA	-0.73	-13.28	-0.54	6.86e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs733175	0.855	rs10022499	chr4:10006537	C/A	cg00071950	chr4:10020882	SLC2A9	0.6	9.55	0.42	1.1e-19	Psychosis and Alzheimer's disease;
LUAD	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg06627628	chr2:24431161	ITSN2	-0.46	-6.49	-0.3	2.42e-10	Lymphocyte counts;
LUAD	cis	rs6782228	0.606	rs6787559	chr3:128381086	T/C	cg16766828	chr3:128327626	NA	-0.38	-6.98	-0.32	1.14e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	trans	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg00953403	chr17:74099816	EXOC7	0.45	7.05	0.32	7.22e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs1448094	0.935	rs4919775	chr12:86339985	T/C	cg06740227	chr12:86229804	RASSF9	0.36	6.53	0.3	1.91e-10	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.76e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg13319975	chr6:146136371	FBXO30	0.66	11.14	0.48	1.84e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg02734326	chr4:10020555	SLC2A9	0.46	8.0	0.36	1.2e-14	Bone mineral density;
LUAD	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19717773	chr7:2847554	GNA12	-0.56	-9.48	-0.42	1.82e-19	Height;
LUAD	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg13789015	chr9:136890014	NCRNA00094	0.88	14.67	0.58	1.06e-39	Platelet distribution width;
LUAD	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg17173187	chr15:85201210	NMB	0.41	6.42	0.3	3.77e-10	Schizophrenia;
LUAD	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.48	-0.3	2.48e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22455342	chr2:225449267	CUL3	0.72	11.12	0.48	2.28e-25	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg25894440	chr7:65020034	NA	-0.61	-6.5	-0.3	2.26e-10	Diabetic kidney disease;
LUAD	cis	rs7177699	0.557	rs8035093	chr15:79120670	T/C	cg00540400	chr15:79124168	NA	0.44	9.58	0.42	8.3e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs1881797	0.527	rs79724455	chr1:247646957	T/C	cg21399703	chr1:247681439	NA	0.47	6.49	0.3	2.47e-10	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs984440	0.524	rs10111139	chr8:139084283	C/T	cg03334052	chr1:168888044	NA	-0.44	-7.46	-0.34	5.02e-13	Obesity-related traits;
LUAD	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg21220214	chr8:57350948	NA	-0.6	-8.9	-0.4	1.68e-17	Obesity-related traits;
LUAD	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.01	-0.36	1.14e-14	Diabetic kidney disease;
LUAD	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg06641503	chr3:48959341	ARIH2	-0.36	-7.04	-0.32	7.9e-12	Menarche (age at onset);
LUAD	cis	rs56283067	0.671	rs1028608	chr6:44681721	C/T	cg18551225	chr6:44695536	NA	-0.5	-8.32	-0.37	1.23e-15	Total body bone mineral density;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14491479	chr8:144623711	ZC3H3	-0.58	-7.03	-0.32	8.29e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs5417	0.775	rs222852	chr17:7140606	A/G	cg15655154	chr3:113604241	GRAMD1C	0.58	10.95	0.47	9.43e-25	Diastolic blood pressure;
LUAD	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg10755058	chr3:40428713	ENTPD3	-0.47	-8.72	-0.39	6.18e-17	Renal cell carcinoma;
LUAD	trans	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg10208301	chr11:6592745	DNHD1	0.49	6.45	0.3	3.03e-10	Coronary artery calcification;
LUAD	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg27124370	chr19:33622961	WDR88	0.45	6.98	0.32	1.11e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1497828	0.956	rs2646799	chr1:217522196	T/C	cg04411442	chr1:217543379	NA	-0.39	-6.91	-0.32	1.73e-11	Dialysis-related mortality;
LUAD	cis	rs8027181	1.000	rs2162269	chr15:73090262	C/T	cg25632853	chr15:73088954	NA	0.36	7.99	0.36	1.3e-14	Triglyceride levels;
LUAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.84	0.43	1.06e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22029157	chr1:209979665	IRF6	0.78	12.71	0.53	1.38e-31	Cleft lip with or without cleft palate;
LUAD	cis	rs7116495	1.000	rs3750908	chr11:71822401	A/G	cg07596299	chr11:71824057	C11orf51	0.78	6.44	0.3	3.19e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	14.34	0.57	2.63e-38	Smoking behavior;
LUAD	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-10.08	-0.44	1.46e-21	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg07234876	chr8:600039	NA	-1.13	-9.63	-0.42	5.76e-20	IgG glycosylation;
LUAD	cis	rs1524976	1.000	rs62255277	chr3:65470507	A/G	cg16238336	chr3:65465873	MAGI1	-0.67	-7.62	-0.35	1.69e-13	PR interval;
LUAD	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg25767906	chr1:53392781	SCP2	0.65	11.98	0.5	1.12e-28	Monocyte count;
LUAD	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.69	0.35	1.02e-13	Bladder cancer;
LUAD	cis	rs11771526	0.901	rs28709683	chr7:32301989	A/G	cg27532318	chr7:32358331	NA	0.59	7.42	0.34	6.66e-13	Body mass index;
LUAD	cis	rs12976411	0.867	rs12985626	chr19:32828993	A/G	cg02282382	chr19:32836354	ZNF507	-0.69	-6.69	-0.31	7.28e-11	Coronary artery disease;
LUAD	trans	rs2262909	0.962	rs408687	chr19:22231123	T/C	cg05197062	chr11:11642011	GALNTL4	-0.58	-9.0	-0.4	7.43e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg02018176	chr4:1364513	KIAA1530	0.55	10.34	0.45	1.68e-22	Longevity;
LUAD	trans	rs1422110	0.513	rs987280	chr5:85448604	C/T	cg01787110	chr1:109008453	NBPF6	-0.49	-8.41	-0.38	6.56e-16	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.1	-0.33	5.47e-12	Joint mobility (Beighton score);
LUAD	cis	rs2074585	0.708	rs2601190	chr15:90932966	A/C	cg10434728	chr15:90938212	IQGAP1	0.39	7.79	0.35	5.33e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs77861329	1.000	rs9841469	chr3:52166596	C/A	cg08692210	chr3:52188851	WDR51A	0.83	7.75	0.35	6.7e-14	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg12964065	chr18:77638022	KCNG2	0.55	6.84	0.32	2.85e-11	Opioid sensitivity;
LUAD	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg26513180	chr16:89883248	FANCA	0.79	7.28	0.33	1.68e-12	Skin colour saturation;
LUAD	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg05132306	chr1:1846340	CALML6	-0.36	-7.71	-0.35	9.19e-14	Body mass index;
LUAD	cis	rs3007168	1.000	rs3007068	chr14:51597196	T/C	cg23942311	chr14:51606299	NA	0.52	7.19	0.33	3.04e-12	Cancer;
LUAD	cis	rs1065852	0.861	rs5758627	chr22:42572547	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.66	11.45	0.49	1.21e-26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.75	0.43	2.1e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg21028142	chr17:79581711	NPLOC4	0.45	9.74	0.43	2.39e-20	Eye color traits;
LUAD	cis	rs240764	0.658	rs1039030	chr6:101198707	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-8.33	-0.38	1.15e-15	Neuroticism;
LUAD	trans	rs6540	1.000	rs12274855	chr11:262234	C/T	cg01022370	chr8:8749074	MFHAS1	0.64	6.6	0.31	1.24e-10	Endometriosis;
LUAD	trans	rs877282	0.583	rs11595057	chr10:819203	A/C	cg22713356	chr15:30763199	NA	0.73	9.42	0.42	3.03e-19	Uric acid levels;
LUAD	cis	rs7166081	0.738	rs28399271	chr15:67710011	G/A	cg24579218	chr15:68104479	NA	-0.48	-7.89	-0.36	2.62e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs7191439	0.858	rs2290902	chr16:88782676	A/G	cg27087555	chr16:88793112	FAM38A	-0.87	-8.07	-0.37	7.13e-15	Plateletcrit;
LUAD	cis	rs9443645	0.527	rs9343870	chr6:79789473	T/G	cg09184832	chr6:79620586	NA	-0.39	-6.52	-0.3	2.03e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg16440638	chr2:11887120	LPIN1	-0.7	-6.88	-0.32	2.2e-11	Type 2 diabetes;
LUAD	cis	rs669446	0.531	rs673485	chr1:44087496	C/T	cg12908607	chr1:44402522	ARTN	-0.37	-6.55	-0.3	1.72e-10	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs59698941	0.943	rs66628697	chr5:132252561	C/T	cg14825688	chr5:132208181	LEAP2	-0.49	-6.85	-0.32	2.6e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg23254163	chr1:152506842	NA	0.26	7.05	0.32	7.19e-12	Hair morphology;
LUAD	cis	rs7180079	0.925	rs56101352	chr15:64534299	C/T	cg08069370	chr15:64387884	SNX1	-0.51	-6.56	-0.3	1.6e-10	Monocyte count;
LUAD	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg04586622	chr2:25135609	ADCY3	0.38	8.67	0.39	9.23e-17	Body mass index in non-asthmatics;
LUAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.49	6.93	0.32	1.6e-11	Renal function-related traits (BUN);
LUAD	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg04455712	chr21:45112962	RRP1B	0.4	7.92	0.36	2.05e-14	Mean corpuscular volume;
LUAD	cis	rs438465	1.000	rs9371114	chr6:169849887	A/C	cg11181693	chr6:169825345	NA	0.64	7.83	0.36	3.87e-14	Corneal astigmatism;
LUAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg08132940	chr7:1081526	C7orf50	-0.76	-10.27	-0.45	3.19e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg00814883	chr7:100076585	TSC22D4	-0.85	-12.48	-0.52	1.24e-30	Platelet count;
LUAD	cis	rs7731657	0.537	rs4637539	chr5:130311944	T/C	cg08523029	chr5:130500466	HINT1	-0.57	-7.22	-0.33	2.41e-12	Fasting plasma glucose;
LUAD	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg18811423	chr2:55921094	PNPT1	0.5	8.31	0.37	1.27e-15	Metabolic syndrome;
LUAD	cis	rs6547631	0.622	rs4240202	chr2:85925680	T/G	cg21473183	chr2:85925749	GNLY	0.35	7.47	0.34	4.68e-13	Blood protein levels;
LUAD	cis	rs796825	0.671	rs9875613	chr3:119995092	C/T	cg21790991	chr3:120137480	FSTL1	-0.4	-6.91	-0.32	1.79e-11	HIV-1 susceptibility;
LUAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08677398	chr8:58056175	NA	0.46	6.54	0.3	1.76e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg11062466	chr8:58055876	NA	0.53	7.33	0.34	1.2e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg20302342	chr1:156215951	PAQR6	0.38	8.64	0.39	1.2e-16	Tonsillectomy;
LUAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs28830936	1.000	rs4923905	chr15:41909889	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.74	-0.31	5.27e-11	Diastolic blood pressure;
LUAD	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg10978503	chr1:24200527	CNR2	-0.56	-12.29	-0.51	6.9e-30	Immature fraction of reticulocytes;
LUAD	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03517284	chr6:25882590	NA	-0.58	-9.56	-0.42	1.02e-19	Blood metabolite levels;
LUAD	cis	rs250585	0.736	rs465193	chr16:23596983	A/G	cg00143387	chr16:23521605	GGA2	0.7	9.83	0.43	1.16e-20	Egg allergy;
LUAD	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg04450456	chr4:17643702	FAM184B	0.39	7.85	0.36	3.54e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg13319975	chr6:146136371	FBXO30	-0.6	-10.26	-0.45	3.38e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg26384229	chr12:38710491	ALG10B	0.38	6.56	0.3	1.61e-10	Heart rate;
LUAD	cis	rs2235649	0.663	rs6600167	chr16:1848912	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-8.18	-0.37	3.42e-15	Blood metabolite levels;
LUAD	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg01689657	chr7:91764605	CYP51A1	-0.28	-6.55	-0.3	1.66e-10	Breast cancer;
LUAD	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg17042849	chr6:26104293	HIST1H4C	-0.49	-6.54	-0.3	1.82e-10	Iron status biomarkers;
LUAD	cis	rs2235649	0.833	rs9927047	chr16:1851927	A/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.47	-7.76	-0.35	6.56e-14	Blood metabolite levels;
LUAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00166722	chr3:10149974	C3orf24	0.62	10.45	0.45	6.55e-23	Alzheimer's disease;
LUAD	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg05368731	chr17:41323189	NBR1	0.96	19.54	0.69	4.53e-61	Menopause (age at onset);
LUAD	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg09085632	chr11:111637200	PPP2R1B	0.64	9.62	0.42	6.17e-20	Primary sclerosing cholangitis;
LUAD	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg15017067	chr4:17643749	FAM184B	0.36	7.28	0.33	1.69e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.75	0.31	4.93e-11	Colorectal cancer;
LUAD	cis	rs6445967	0.554	rs67507131	chr3:58436488	C/T	cg13750441	chr3:58318267	PXK	-0.32	-6.59	-0.31	1.3e-10	Platelet count;
LUAD	trans	rs587242	1.000	rs12740202	chr1:96905594	G/A	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.6	11.47	0.49	1.06e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg23422044	chr7:1970798	MAD1L1	0.5	7.21	0.33	2.53e-12	Bipolar disorder;
LUAD	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg27170947	chr2:26402098	FAM59B	0.84	11.84	0.5	4e-28	Gut microbiome composition (summer);
LUAD	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg26597838	chr10:835615	NA	1.04	15.82	0.61	1.27e-44	Eosinophil percentage of granulocytes;
LUAD	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg13385794	chr1:248469461	NA	0.26	6.91	0.32	1.82e-11	Common traits (Other);
LUAD	cis	rs13315871	0.929	rs35376204	chr3:58325563	T/C	cg20936604	chr3:58311152	NA	-0.72	-7.22	-0.33	2.51e-12	Cholesterol, total;
LUAD	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg19875535	chr5:140030758	IK	-0.4	-6.65	-0.31	8.99e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08677398	chr8:58056175	NA	0.54	7.21	0.33	2.66e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg03676636	chr4:99064102	C4orf37	0.27	6.95	0.32	1.39e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00149659	chr3:10157352	C3orf10	0.64	8.92	0.4	1.38e-17	Alzheimer's disease;
LUAD	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg02891314	chr5:179741120	GFPT2	-0.75	-12.64	-0.52	2.82e-31	Height;
LUAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg13047869	chr3:10149882	C3orf24	0.63	10.94	0.47	1.1e-24	Alzheimer's disease;
LUAD	cis	rs775227	1.000	rs41271355	chr3:113004155	G/A	cg18753928	chr3:113234510	CCDC52	-0.47	-6.47	-0.3	2.64e-10	Dental caries;
LUAD	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg05590025	chr7:65112418	INTS4L2	-0.72	-7.71	-0.35	8.83e-14	Diabetic kidney disease;
LUAD	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19717773	chr7:2847554	GNA12	-0.56	-9.62	-0.42	6.15e-20	Height;
LUAD	cis	rs2742234	0.541	rs61268333	chr10:43721370	G/A	cg15436174	chr10:43711423	RASGEF1A	0.55	9.02	0.4	6.55e-18	Hirschsprung disease;
LUAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg04025307	chr7:1156635	C7orf50	0.6	6.75	0.31	4.88e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs60154123	0.730	rs679042	chr1:210457122	A/G	cg22029157	chr1:209979665	IRF6	0.55	6.53	0.3	1.94e-10	Coronary artery disease;
LUAD	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg27170947	chr2:26402098	FAM59B	-0.69	-9.41	-0.42	3.19e-19	Gut microbiome composition (summer);
LUAD	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg23815491	chr16:72088622	HP	0.52	9.56	0.42	9.44e-20	Fibrinogen levels;
LUAD	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.4	6.6	0.31	1.24e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs868943	0.743	rs13213124	chr6:116335637	A/G	cg15226275	chr6:116381976	FRK	0.23	6.53	0.3	1.88e-10	Total cholesterol levels;
LUAD	cis	rs863345	0.504	rs857714	chr1:158566972	C/T	cg12129480	chr1:158549410	OR10X1	0.25	6.72	0.31	6.02e-11	Pneumococcal bacteremia;
LUAD	cis	rs9487051	0.768	rs427960	chr6:109524939	C/T	cg01475377	chr6:109611718	NA	-0.38	-6.89	-0.32	1.98e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg21984481	chr17:79567631	NPLOC4	0.56	11.78	0.5	6.74e-28	Eye color traits;
LUAD	cis	rs62400317	0.762	rs10484626	chr6:44882271	A/G	cg20913747	chr6:44695427	NA	-0.45	-6.92	-0.32	1.63e-11	Total body bone mineral density;
LUAD	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg00666640	chr1:248458726	OR2T12	-0.34	-8.58	-0.39	1.79e-16	Common traits (Other);
LUAD	trans	rs4650994	1.000	rs10798616	chr1:178515642	G/C	cg05059571	chr16:84539110	KIAA1609	-0.62	-10.68	-0.46	9.74e-24	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg15445000	chr17:37608096	MED1	0.44	8.09	0.37	6.48e-15	Lung function (FEV1);
LUAD	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg14558114	chr2:88469736	THNSL2	-0.43	-6.99	-0.32	1.07e-11	Response to metformin (IC50);
LUAD	cis	rs7119	0.689	rs12916833	chr15:77819778	G/A	cg27398640	chr15:77910606	LINGO1	-0.34	-6.35	-0.3	5.54e-10	Type 2 diabetes;
LUAD	cis	rs8067545	0.750	rs11867585	chr17:19992607	A/G	cg04132472	chr17:19861366	AKAP10	0.29	6.9	0.32	1.87e-11	Schizophrenia;
LUAD	cis	rs6490294	0.659	rs7294578	chr12:112197837	A/C	cg10833066	chr12:111807467	FAM109A	0.35	6.46	0.3	2.97e-10	Mean platelet volume;
LUAD	cis	rs11167764	0.945	rs7720832	chr5:141473097	T/G	cg23435118	chr5:141488016	NDFIP1	-0.48	-7.25	-0.33	2.06e-12	Crohn's disease;
LUAD	cis	rs4711350	0.862	rs688209	chr6:33700376	G/T	cg07979401	chr6:33739406	LEMD2	-0.4	-6.61	-0.31	1.13e-10	Schizophrenia;
LUAD	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	8.55	0.38	2.23e-16	Ileal carcinoids;
LUAD	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg25828334	chr19:18545568	ISYNA1	-0.39	-7.83	-0.36	4.05e-14	Breast cancer;
LUAD	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg02269571	chr22:50332266	NA	-0.93	-9.77	-0.43	1.77e-20	Schizophrenia;
LUAD	cis	rs10489202	0.657	rs201541	chr1:167992344	T/A	cg24449463	chr1:168025552	DCAF6	-0.75	-12.22	-0.51	1.31e-29	Schizophrenia;
LUAD	cis	rs754466	0.606	rs10824581	chr10:79599501	A/G	cg17075019	chr10:79541650	NA	-0.89	-18.66	-0.67	3.84e-57	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6500395	0.928	rs723807	chr16:48691443	A/G	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.07e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg04565464	chr8:145669602	NFKBIL2	0.47	7.45	0.34	5.43e-13	Schizophrenia;
LUAD	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg18132916	chr6:79620363	NA	-0.46	-7.9	-0.36	2.42e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg19469189	chr11:128781035	KCNJ5	-0.43	-6.58	-0.3	1.41e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg07343612	chr16:622815	PIGQ	-0.79	-15.58	-0.6	1.46e-43	Height;
LUAD	cis	rs757647	0.717	rs1859466	chr5:137775081	C/T	cg10676309	chr5:137685565	NA	0.42	7.3	0.33	1.41e-12	Menarche (age at onset);
LUAD	cis	rs55823223	0.752	rs34974290	chr17:73888354	G/A	cg12714757	chr17:73874637	TRIM47	-0.45	-6.87	-0.32	2.35e-11	Psoriasis;
LUAD	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg05991184	chr2:219186017	PNKD	-0.36	-6.89	-0.32	2.05e-11	Colorectal cancer;
LUAD	trans	rs7395662	0.611	rs11040073	chr11:48855624	G/A	cg00717180	chr2:96193071	NA	0.36	6.65	0.31	9.18e-11	HDL cholesterol;
LUAD	cis	rs9902453	0.967	rs62070344	chr17:28476997	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.62	0.39	1.4e-16	Coffee consumption (cups per day);
LUAD	cis	rs9443645	0.527	rs36128361	chr6:79684340	C/G	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.79	-0.31	3.69e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1032833	0.732	rs1048026	chr2:179973467	T/C	cg23883738	chr2:179974586	SESTD1	-0.72	-8.3	-0.37	1.39e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg10589385	chr1:150898437	SETDB1	0.39	7.39	0.34	8e-13	Tonsillectomy;
LUAD	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06221963	chr1:154839813	KCNN3	-0.84	-19.64	-0.69	1.6e-61	Prostate cancer;
LUAD	cis	rs34684276	1	rs34684276	chr15:78813155	G/A	cg18825076	chr15:78729989	IREB2	-0.58	-9.28	-0.41	8.78e-19	Nicotine dependence;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00166722	chr3:10149974	C3orf24	0.65	11.0	0.47	6.09e-25	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.1	0.33	5.24e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.02	-0.32	8.74e-12	Dental caries;
LUAD	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg21951975	chr1:209979733	IRF6	0.52	6.49	0.3	2.44e-10	Coronary artery disease;
LUAD	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.4	6.37	0.3	5.07e-10	Schizophrenia;
LUAD	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg06199346	chr11:14280333	SPON1	0.34	6.93	0.32	1.63e-11	Mitochondrial DNA levels;
LUAD	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg13685833	chr1:53393034	SCP2	-0.49	-8.11	-0.37	5.4e-15	Monocyte count;
LUAD	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.5	-0.3	2.3e-10	Total body bone mineral density;
LUAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs1997103	0.765	rs55686950	chr7:55396552	A/C	cg20935933	chr6:143382018	AIG1	0.53	7.48	0.34	4.34e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs420259	0.516	rs2369013	chr16:23496346	T/C	cg00143387	chr16:23521605	GGA2	-0.7	-10.02	-0.44	2.41e-21	Bipolar disorder;
LUAD	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg24579218	chr15:68104479	NA	-0.6	-9.48	-0.42	1.81e-19	Restless legs syndrome;
LUAD	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg07080864	chr8:57359956	PENK	-0.37	-6.35	-0.3	5.4e-10	Obesity-related traits;
LUAD	cis	rs8177876	0.642	rs56032321	chr16:81117906	A/C	cg08591886	chr16:81111003	C16orf46	-0.81	-7.47	-0.34	4.56e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg12255698	chr17:1953305	MIR132	0.46	6.66	0.31	8.32e-11	QT interval;
LUAD	trans	rs1997103	1.000	rs6951294	chr7:55400835	C/T	cg20935933	chr6:143382018	AIG1	0.53	7.48	0.34	4.32e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs61990749	0.597	rs11623088	chr14:78137735	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.49	-6.48	-0.3	2.54e-10	Fibroblast growth factor basic levels;
LUAD	trans	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg14343924	chr8:8086146	FLJ10661	0.45	7.25	0.33	1.98e-12	Mood instability;
LUAD	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.08e-11	Depression;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg23179321	chr10:15138793	C10orf111;RPP38	-0.39	-6.64	-0.31	9.9e-11	Subcortical brain region volumes;
LUAD	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg03714773	chr7:91764589	CYP51A1	0.29	6.68	0.31	7.77e-11	Breast cancer;
LUAD	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.73	0.31	5.59e-11	Cognitive test performance;
LUAD	trans	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg21051086	chr3:73046214	PPP4R2	-0.44	-7.15	-0.33	3.78e-12	Pancreatic cancer;
LUAD	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg00310523	chr12:86230176	RASSF9	0.36	7.27	0.33	1.73e-12	Major depressive disorder;
LUAD	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.85	-0.36	3.56e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7193541	0.673	rs12716769	chr16:74652537	T/C	cg01733217	chr16:74700730	RFWD3	0.68	13.05	0.54	6.15e-33	Multiple myeloma;
LUAD	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg11822812	chr5:140052017	DND1	0.37	6.54	0.3	1.75e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg21153622	chr11:89784906	NA	-0.33	-6.55	-0.3	1.7e-10	Coronary artery disease;
LUAD	cis	rs220324	0.688	rs9980786	chr21:43562535	C/T	cg08841829	chr21:43638893	ABCG1	-0.51	-6.84	-0.32	2.87e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg23254163	chr1:152506842	NA	0.25	7.07	0.33	6.24e-12	Hair morphology;
LUAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg12432903	chr7:1882776	MAD1L1	-0.41	-6.7	-0.31	6.5500000000000006e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg15704280	chr7:45808275	SEPT13	-0.84	-13.72	-0.55	1.05e-35	Coronary artery disease;
LUAD	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg14186256	chr22:23484241	RTDR1	-0.46	-7.96	-0.36	1.56e-14	Bone mineral density;
LUAD	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg00020340	chr7:910388	UNC84A	0.65	7.03	0.32	8.11e-12	Initial pursuit acceleration;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg27514703	chr19:50380514	AKT1S1;TBC1D17	-0.66	-6.5	-0.3	2.27e-10	Type 2 diabetes;
LUAD	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg16049864	chr8:95962084	TP53INP1	0.53	11.34	0.48	3.24e-26	Type 2 diabetes;
LUAD	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.24	-0.37	2.17e-15	Resting heart rate;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24294857	chr1:20812821	CAMK2N1	-0.52	-6.44	-0.3	3.2e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11671005	0.735	rs11671591	chr19:58918337	A/G	cg13877915	chr19:58951672	ZNF132	-0.55	-7.44	-0.34	5.65e-13	Mean platelet volume;
LUAD	cis	rs12711979	0.513	rs7566217	chr2:3851381	A/C	cg17052675	chr2:3827356	NA	-0.38	-7.05	-0.32	7.48e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.38	-0.38	8.11e-16	Total body bone mineral density;
LUAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg22105103	chr4:187893119	NA	0.57	12.62	0.52	3.25e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3818285	0.556	rs941864	chr10:111656948	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.69	-10.81	-0.47	3.32e-24	Superior crus of antihelix expression;
LUAD	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg06002616	chr8:101225028	SPAG1	-0.39	-7.92	-0.36	2.06e-14	Atrioventricular conduction;
LUAD	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg09365446	chr1:150670422	GOLPH3L	0.61	10.91	0.47	1.39e-24	Melanoma;
LUAD	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg08645402	chr16:4508243	NA	0.53	9.61	0.42	6.44e-20	Schizophrenia;
LUAD	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg03929089	chr4:120376271	NA	-0.56	-8.29	-0.37	1.55e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs832540	0.806	rs10039322	chr5:56260259	A/C	cg12311346	chr5:56204834	C5orf35	-0.43	-6.86	-0.32	2.41e-11	Coronary artery disease;
LUAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg12143784	chr7:64541923	NA	0.45	7.21	0.33	2.58e-12	Calcium levels;
LUAD	cis	rs7903847	0.642	rs11189179	chr10:99143320	T/C	cg20016023	chr10:99160130	RRP12	-0.3	-7.12	-0.33	4.78e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg21775007	chr8:11205619	TDH	-0.46	-8.22	-0.37	2.44e-15	Retinal vascular caliber;
LUAD	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00934597	chr7:893267	UNC84A	-0.53	-8.78	-0.39	4.07e-17	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs758324	0.898	rs7725041	chr5:131188503	C/A	cg06307176	chr5:131281290	NA	0.5	7.95	0.36	1.76e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg17264618	chr3:40429014	ENTPD3	-0.4	-8.83	-0.39	2.89e-17	Renal cell carcinoma;
LUAD	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg08885076	chr2:99613938	TSGA10	0.39	7.37	0.34	8.93e-13	Chronic sinus infection;
LUAD	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg10518543	chr12:38710700	ALG10B	0.42	6.97	0.32	1.25e-11	Heart rate;
LUAD	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg12714757	chr17:73874637	TRIM47	-0.41	-6.47	-0.3	2.69e-10	Psoriasis;
LUAD	trans	rs1941687	0.797	rs7227708	chr18:31393091	A/G	cg27147174	chr7:100797783	AP1S1	-0.5	-8.26	-0.37	1.93e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg23231163	chr10:75533350	FUT11	-0.51	-9.37	-0.41	4.29e-19	Inflammatory bowel disease;
LUAD	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.42	0.38	5.75e-16	Platelet count;
LUAD	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg18132916	chr6:79620363	NA	-0.44	-7.64	-0.35	1.47e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg20933634	chr6:27740509	NA	0.47	7.32	0.34	1.22e-12	Parkinson's disease;
LUAD	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg02423579	chr7:2872169	GNA12	-0.85	-14.56	-0.58	3.08e-39	Height;
LUAD	cis	rs657075	0.697	rs34754328	chr5:131688074	G/T	cg21138405	chr5:131827807	IRF1	0.53	6.55	0.3	1.66e-10	Rheumatoid arthritis;
LUAD	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg11833968	chr6:79620685	NA	0.41	7.37	0.34	8.75e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg03609598	chr5:56110824	MAP3K1	-0.68	-9.21	-0.41	1.59e-18	Initial pursuit acceleration;
LUAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg08132940	chr7:1081526	C7orf50	-0.79	-10.71	-0.46	7.69e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02249930	chr10:70166207	RUFY2	-0.43	-6.68	-0.31	7.73e-11	Height;
LUAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg11416102	chr8:651193	ERICH1	0.91	8.49	0.38	3.47e-16	IgG glycosylation;
LUAD	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg11941060	chr3:133502564	NA	-0.62	-10.86	-0.47	2.19e-24	Iron status biomarkers;
LUAD	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg03467027	chr4:99064603	C4orf37	-0.44	-7.17	-0.33	3.39e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg05064044	chr6:292385	DUSP22	-0.56	-9.19	-0.41	1.81e-18	Menopause (age at onset);
LUAD	trans	rs1728785	1.000	rs1170431	chr16:68605639	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.4	0.45	1.02e-22	Ulcerative colitis;
LUAD	cis	rs7215564	0.908	rs7503757	chr17:78685599	A/G	cg09596252	chr17:78655493	RPTOR	0.62	6.61	0.31	1.17e-10	Myopia (pathological);
LUAD	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg16797656	chr11:68205561	LRP5	-0.48	-10.47	-0.45	5.56e-23	Total body bone mineral density;
LUAD	cis	rs877282	0.945	rs11599043	chr10:777972	C/T	cg17470449	chr10:769945	NA	0.63	9.21	0.41	1.56e-18	Uric acid levels;
LUAD	cis	rs911555	0.723	rs12436956	chr14:103852607	G/T	cg12935359	chr14:103987150	CKB	0.48	7.31	0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4824093	0.610	rs73443974	chr22:50314316	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.64	6.43	0.3	3.47e-10	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg12072164	chr19:44306565	LYPD5	0.42	8.5	0.38	3.37e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg08798685	chr6:27730294	NA	-0.4	-6.6	-0.31	1.22e-10	Parkinson's disease;
LUAD	cis	rs6842047	0.611	rs4253421	chr4:187204937	C/T	cg02012338	chr4:187126139	CYP4V2	-0.71	-6.59	-0.31	1.27e-10	Blood protein levels;
LUAD	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-10.5	-0.45	4.44e-23	Gut microbiome composition (summer);
LUAD	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg06671706	chr8:8559999	CLDN23	0.57	10.36	0.45	1.5e-22	Obesity-related traits;
LUAD	trans	rs783540	0.592	rs2567632	chr15:83284804	A/G	cg16105309	chr15:79090380	ADAMTS7	0.42	7.6	0.35	1.93e-13	Schizophrenia;
LUAD	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg20203395	chr5:56204925	C5orf35	-0.83	-11.79	-0.5	6.25e-28	Initial pursuit acceleration;
LUAD	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs8038465	0.592	rs899981	chr15:73935329	G/A	cg15420318	chr15:73925796	NPTN	0.47	7.75	0.35	6.87e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2625529	0.689	rs12898728	chr15:72112853	C/T	cg16672083	chr15:72433130	SENP8	-0.59	-10.35	-0.45	1.54e-22	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg03929089	chr4:120376271	NA	-0.91	-17.24	-0.64	7.83e-51	Coronary artery disease;
LUAD	cis	rs6547631	0.622	rs1866141	chr2:85925386	T/C	cg21473183	chr2:85925749	GNLY	0.35	7.47	0.34	4.78e-13	Blood protein levels;
LUAD	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg08213375	chr14:104286397	PPP1R13B	0.26	6.85	0.32	2.6e-11	Schizophrenia;
LUAD	trans	rs7246760	0.867	rs55914342	chr19:9824447	A/T	cg02900749	chr2:68251473	NA	-0.6	-6.64	-0.31	9.52e-11	Pursuit maintenance gain;
LUAD	trans	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg06606381	chr12:133084897	FBRSL1	-0.65	-7.74	-0.35	7.22e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg17063962	chr7:91808500	NA	0.7	12.51	0.52	8.87e-31	Breast cancer;
LUAD	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg18252515	chr7:66147081	NA	0.6	6.65	0.31	9.28e-11	Diabetic kidney disease;
LUAD	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg07936489	chr17:37558343	FBXL20	-0.43	-6.75	-0.31	4.74e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg27411982	chr8:10470053	RP1L1	-0.39	-7.13	-0.33	4.48e-12	Neuroticism;
LUAD	cis	rs1448094	0.785	rs7955173	chr12:86447214	G/A	cg19622623	chr12:86230825	RASSF9	0.36	6.64	0.31	9.78e-11	Major depressive disorder;
LUAD	cis	rs1595825	0.891	rs7584475	chr2:198577424	A/C	cg00982548	chr2:198649783	BOLL	-0.6	-8.42	-0.38	5.86e-16	Ulcerative colitis;
LUAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg02869364	chr7:1081709	C7orf50	-0.51	-6.61	-0.31	1.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg09184832	chr6:79620586	NA	-0.53	-9.85	-0.43	9.5e-21	Intelligence (multi-trait analysis);
LUAD	trans	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg08071915	chr8:12219732	FAM66A	0.44	7.33	0.34	1.17e-12	Joint mobility (Beighton score);
LUAD	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg22535103	chr8:58192502	C8orf71	-0.6	-7.1	-0.33	5.22e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg18131467	chr2:239335373	ASB1	0.65	10.9	0.47	1.47e-24	Multiple system atrophy;
LUAD	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg06713675	chr4:122721982	EXOSC9	-0.81	-16.47	-0.63	1.87e-47	Type 2 diabetes;
LUAD	cis	rs9393692	0.557	rs6918325	chr6:26327965	T/G	cg13736514	chr6:26305472	NA	-0.5	-7.9	-0.36	2.48e-14	Educational attainment;
LUAD	cis	rs7116495	1.000	rs11235440	chr11:71826644	A/G	cg07596299	chr11:71824057	C11orf51	0.73	6.64	0.31	9.52e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg25894440	chr7:65020034	NA	-0.68	-7.31	-0.33	1.38e-12	Diabetic kidney disease;
LUAD	cis	rs7705042	0.865	rs6580223	chr5:141489027	G/T	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.56	-0.3	1.58e-10	Asthma;
LUAD	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg16102102	chr5:83017553	HAPLN1	-0.77	-13.03	-0.54	7.49e-33	Prostate cancer;
LUAD	cis	rs7799006	0.862	rs3757439	chr7:2272122	C/T	cg08027265	chr7:2291960	NA	-0.58	-10.8	-0.46	3.47e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg17346650	chr17:80929145	B3GNTL1	-0.4	-7.51	-0.34	3.43e-13	Glycated hemoglobin levels;
LUAD	cis	rs6761276	0.899	rs11677043	chr2:113835520	A/G	cg09040174	chr2:113837401	NA	0.8	15.64	0.61	7.95e-44	Protein quantitative trait loci;
LUAD	cis	rs13064411	0.696	rs6766615	chr3:113219342	T/C	cg10517650	chr3:113235015	CCDC52	-0.55	-9.41	-0.42	3.3e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg04977983	chr14:39572202	SEC23A	-0.66	-6.38	-0.3	4.53e-10	Type 2 diabetes;
LUAD	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg07414643	chr4:187882934	NA	0.34	6.87	0.32	2.28e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg18621852	chr3:10150065	C3orf24	0.5	9.1	0.4	3.52e-18	Alzheimer's disease;
LUAD	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg15226275	chr6:116381976	FRK	0.24	7.7	0.35	9.56e-14	Cholesterol, total;LDL cholesterol;
LUAD	trans	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg19163074	chr7:65112434	INTS4L2	-0.44	-6.68	-0.31	7.75e-11	Aortic root size;
LUAD	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg21823605	chr1:152486609	CRCT1	0.28	6.35	0.3	5.48e-10	Hair morphology;
LUAD	cis	rs10743315	0.732	rs16915309	chr12:19430632	G/A	cg16731194	chr12:19336481	PLEKHA5	-0.58	-6.37	-0.3	4.97e-10	Gut microbiota (bacterial taxa);
LUAD	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg00495681	chr13:53174319	NA	0.57	10.82	0.47	2.87e-24	Lewy body disease;
LUAD	cis	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg27411982	chr8:10470053	RP1L1	-0.4	-7.34	-0.34	1.13e-12	Morning vs. evening chronotype;
LUAD	cis	rs9948	0.529	rs62156208	chr2:97383686	A/G	cg20312557	chr2:97357134	FER1L5	-0.65	-7.42	-0.34	6.6e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs870825	0.616	rs10025167	chr4:185649551	A/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg14227996	chr4:17616232	MED28	0.72	8.02	0.36	1.06e-14	Opioid sensitivity;
LUAD	cis	rs3813948	0.543	rs2808468	chr1:207280703	A/G	cg11153969	chr1:207277031	C4BPA	-0.69	-9.2	-0.41	1.62e-18	C4b binding protein levels;
LUAD	trans	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg06606381	chr12:133084897	FBRSL1	-0.95	-9.12	-0.41	3.17e-18	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.36	0.38	9.35e-16	Breast cancer;
LUAD	cis	rs2554380	0.628	rs963690	chr15:84439820	G/C	cg14598478	chr15:84363061	ADAMTSL3	-0.4	-7.11	-0.33	5.03e-12	Height;
LUAD	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-8.0	-0.36	1.24e-14	Electroencephalogram traits;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg18000306	chr6:288505	NA	0.43	8.03	0.36	9.61e-15	Menopause (age at onset);
LUAD	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg02990361	chr1:107599529	PRMT6	0.6	9.98	0.44	3.3e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11644478	chr21:40555479	PSMG1	0.69	11.3	0.48	4.84e-26	Cognitive function;
LUAD	cis	rs7274811	0.634	rs4911356	chr20:32255034	T/C	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.5	-7.51	-0.34	3.47e-13	Height;
LUAD	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14829155	chr15:31115871	NA	-0.77	-12.75	-0.53	9.51e-32	Huntington's disease progression;
LUAD	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg17761419	chr8:57350749	NA	-0.52	-7.89	-0.36	2.69e-14	Obesity-related traits;
LUAD	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg11189052	chr15:85197271	WDR73	0.65	8.6	0.39	1.62e-16	Schizophrenia;
LUAD	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg21138405	chr5:131827807	IRF1	0.6	13.77	0.56	6.51e-36	Asthma (sex interaction);
LUAD	cis	rs7937890	0.559	rs2597197	chr11:14489832	G/A	cg02886208	chr11:14281011	SPON1	-0.34	-6.52	-0.3	2.05e-10	Mitochondrial DNA levels;
LUAD	trans	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg13698153	chr12:118541722	VSIG10	-0.43	-6.74	-0.31	5.16e-11	Vitiligo;
LUAD	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg06387496	chr7:2775674	GNA12	-0.4	-6.69	-0.31	7.08e-11	Height;
LUAD	cis	rs2455601	0.671	rs10840135	chr11:8879794	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.44	-8.1	-0.37	6.07e-15	Schizophrenia;
LUAD	cis	rs68170813	0.652	rs17482543	chr7:107169174	C/G	cg02696742	chr7:106810147	HBP1	-0.77	-9.09	-0.4	3.86e-18	Coronary artery disease;
LUAD	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg06608945	chr2:219082296	ARPC2	0.47	8.09	0.37	6.3e-15	High light scatter reticulocyte percentage of red cells;Plateletcrit;
LUAD	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg11822812	chr5:140052017	DND1	0.38	6.73	0.31	5.4e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs72901758	0.700	rs1109279	chr17:76248130	T/C	cg25512537	chr17:76250053	NA	0.34	6.64	0.31	9.45e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg15900387	chr1:150738905	CTSS	-0.36	-6.48	-0.3	2.61e-10	Melanoma;
LUAD	cis	rs62238980	0.614	rs1475996	chr22:32464980	T/C	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs877426	0.681	rs113130895	chr13:114806184	C/T	cg21461300	chr13:114830702	RASA3	-0.43	-6.48	-0.3	2.53e-10	Facial morphology (factor 14, intercanthal width);
LUAD	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg01528321	chr10:82214614	TSPAN14	0.55	8.4	0.38	6.92e-16	Post bronchodilator FEV1;
LUAD	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10802521	chr3:52805072	NEK4	-0.5	-8.89	-0.4	1.75e-17	Bipolar disorder;
LUAD	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg02423579	chr7:2872169	GNA12	-0.39	-6.51	-0.3	2.16e-10	Height;
LUAD	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg02454025	chr1:11042201	C1orf127	0.99	17.14	0.64	2.22e-50	Ewing sarcoma;
LUAD	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg13906792	chr15:75199810	C15orf17	-0.35	-6.54	-0.3	1.74e-10	Breast cancer;
LUAD	cis	rs10203711	0.933	rs11695877	chr2:239585797	T/A	cg14580085	chr2:239553406	NA	0.4	8.62	0.39	1.39e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg18721089	chr20:30220636	NA	-0.5	-7.09	-0.33	5.77e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg17178900	chr1:205818956	PM20D1	0.74	15.46	0.6	4.86e-43	Menarche (age at onset);
LUAD	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.53	0.3	1.94e-10	Parkinson's disease;
LUAD	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg15147215	chr3:52552868	STAB1	-0.42	-7.51	-0.34	3.46e-13	Bipolar disorder;
LUAD	cis	rs909002	0.811	rs11575883	chr1:32085485	G/A	cg13919466	chr1:32135498	COL16A1	-0.35	-8.11	-0.37	5.43e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs3106136	0.527	rs2883	chr4:95158610	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.19	-0.44	5.86e-22	Capecitabine sensitivity;
LUAD	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg17366294	chr4:99064904	C4orf37	0.48	8.44	0.38	5.11e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg11822812	chr5:140052017	DND1	0.39	6.95	0.32	1.4e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg00933542	chr6:150070202	PCMT1	0.33	7.1	0.33	5.19e-12	Testicular germ cell tumor;
LUAD	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-6.64	-0.31	9.5e-11	Height;
LUAD	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg14343924	chr8:8086146	FLJ10661	-0.4	-6.37	-0.3	5e-10	Mood instability;
LUAD	trans	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.43	-0.3	3.49e-10	Educational attainment (years of education);
LUAD	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg17366294	chr4:99064904	C4orf37	0.66	12.68	0.52	1.83e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2735413	0.914	rs2707604	chr16:78054853	A/G	cg04733911	chr16:78082701	NA	-0.28	-6.42	-0.3	3.59e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08736216	chr1:53307985	ZYG11A	0.33	6.43	0.3	3.37e-10	Monocyte count;
LUAD	cis	rs1018836	0.828	rs10091275	chr8:91559751	A/G	cg16814680	chr8:91681699	NA	-0.61	-10.34	-0.45	1.75e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg11494091	chr17:61959527	GH2	0.75	18.49	0.67	2.35e-56	Prudent dietary pattern;
LUAD	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg12501888	chr15:85177176	SCAND2	-0.45	-6.89	-0.32	1.98e-11	P wave terminal force;
LUAD	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03517284	chr6:25882590	NA	-0.51	-7.51	-0.34	3.58e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06873352	chr17:61820015	STRADA	-0.82	-18.5	-0.67	2.09e-56	Prudent dietary pattern;
LUAD	cis	rs7771547	0.519	rs28371845	chr6:36377709	C/T	cg04289385	chr6:36355825	ETV7	0.5	7.45	0.34	5.42e-13	Platelet distribution width;
LUAD	cis	rs6906287	0.625	rs7764280	chr6:118692514	A/G	cg21191810	chr6:118973309	C6orf204	0.54	11.21	0.48	1e-25	Electrocardiographic conduction measures;
LUAD	cis	rs7737355	0.947	rs9885286	chr5:130883270	C/T	cg25547332	chr5:131281432	NA	0.43	6.57	0.3	1.45e-10	Life satisfaction;
LUAD	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23583168	chr7:148888333	NA	-0.89	-18.54	-0.67	1.31e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg23978390	chr7:1156363	C7orf50	0.56	7.65	0.35	1.38e-13	Bronchopulmonary dysplasia;
LUAD	trans	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.45	-0.3	3.04e-10	Aortic root size;
LUAD	trans	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg21659725	chr3:3221576	CRBN	0.38	6.53	0.3	1.85e-10	Resting heart rate;
LUAD	trans	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg02030672	chr11:45687055	CHST1	0.45	8.22	0.37	2.51e-15	Obesity-related traits;
LUAD	cis	rs10916814	0.610	rs10799641	chr1:20897250	G/A	cg24502330	chr1:20914028	CDA	-0.36	-7.14	-0.33	4.19e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs57590327	0.716	rs4352391	chr3:81802318	T/C	cg07356753	chr3:81810745	GBE1	-0.58	-8.39	-0.38	7.38e-16	Extraversion;
LUAD	cis	rs7264396	0.563	rs2425071	chr20:34292961	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.61	8.14	0.37	4.32e-15	Total cholesterol levels;
LUAD	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg07917127	chr4:99064746	C4orf37	0.52	8.33	0.38	1.11e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg24768116	chr2:27665128	KRTCAP3	0.25	6.35	0.3	5.5e-10	Oral cavity cancer;
LUAD	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg12011299	chr4:100065546	ADH4	0.7	12.61	0.52	3.55e-31	Smoking initiation;
LUAD	cis	rs2046867	0.818	rs62249866	chr3:72878632	T/C	cg25664220	chr3:72788482	NA	-0.67	-11.89	-0.5	2.62e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg05966235	chr16:28915196	ATP2A1	0.4	6.52	0.3	2.04e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7759001	0.817	rs2206250	chr6:27355842	A/C	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.83e-10	Glomerular filtration rate (creatinine);
LUAD	trans	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17712092	chr4:129076599	LARP1B	0.81	14.99	0.59	4.61e-41	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg05590025	chr7:65112418	INTS4L2	-0.71	-7.61	-0.35	1.84e-13	Diabetic kidney disease;
LUAD	cis	rs11030122	0.702	rs1349583	chr11:3972236	G/A	cg18678763	chr11:4115507	RRM1	-0.45	-7.51	-0.34	3.49e-13	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg11317459	chr13:21872234	NA	-1.12	-14.6	-0.58	2.15e-39	White matter hyperintensity burden;
LUAD	cis	rs1215050	0.791	rs165241	chr4:98681112	C/T	cg24818145	chr4:99064322	C4orf37	0.41	6.77	0.31	4.2e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6446731	0.593	rs6446728	chr4:3275650	A/G	cg08886695	chr4:3369023	RGS12	-0.5	-8.4	-0.38	6.6e-16	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg11301795	chr4:187892539	NA	0.77	15.79	0.61	1.71e-44	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11771526	0.901	rs62456036	chr7:32266182	C/T	cg27532318	chr7:32358331	NA	0.52	7.05	0.32	7.15e-12	Body mass index;
LUAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.18	-0.33	3.1e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs35740288	0.770	rs11635711	chr15:86126486	C/G	cg13263323	chr15:86062960	AKAP13	-0.42	-6.71	-0.31	6.33e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.5	6.99	0.32	1.08e-11	Cognitive test performance;
LUAD	cis	rs7712401	0.601	rs257813	chr5:122217168	G/A	cg19077854	chr5:122220652	SNX24	0.34	6.44	0.3	3.19e-10	Mean platelet volume;
LUAD	cis	rs7107174	1.000	rs948662	chr11:77979829	A/G	cg19901956	chr11:77921274	USP35	-0.53	-6.67	-0.31	8.26e-11	Testicular germ cell tumor;
LUAD	cis	rs4594175	0.926	rs72688717	chr14:51614493	C/T	cg23942311	chr14:51606299	NA	0.63	10.48	0.45	5.43e-23	Cancer;
LUAD	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg15017067	chr4:17643749	FAM184B	0.38	7.45	0.34	5.26e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00149659	chr3:10157352	C3orf10	0.6	8.3	0.37	1.46e-15	Alzheimer's disease;
LUAD	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg06740227	chr12:86229804	RASSF9	0.44	7.61	0.35	1.8e-13	Major depressive disorder;
LUAD	cis	rs748404	0.723	rs560134	chr15:43555699	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.35	0.34	1.03e-12	Lung cancer;
LUAD	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg08859206	chr1:53392774	SCP2	-0.56	-10.01	-0.44	2.58e-21	Monocyte count;
LUAD	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg06641503	chr3:48959341	ARIH2	-0.4	-7.97	-0.36	1.46e-14	Parkinson's disease;
LUAD	cis	rs427941	0.703	rs201435	chr7:101732865	G/C	cg06246474	chr7:101738831	CUX1	0.41	7.03	0.32	8.54e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg24397884	chr7:158709396	WDR60	0.47	8.09	0.37	6.22e-15	Height;
LUAD	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg13073564	chr4:8508604	NA	-0.63	-11.49	-0.49	8.95e-27	Response to antineoplastic agents;
LUAD	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg00631329	chr6:26305371	NA	0.47	7.91	0.36	2.23e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs175714	0.845	rs175702	chr14:75971133	G/T	cg01624173	chr14:75981868	NA	-0.68	-14.2	-0.57	1.05e-37	Lymphocyte counts;
LUAD	cis	rs11098699	0.750	rs2132075	chr4:124243487	A/G	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg06784218	chr1:46089804	CCDC17	0.35	7.53	0.34	3.05e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs752010	0.715	rs4083592	chr1:42099522	A/G	cg06885757	chr1:42089581	HIVEP3	0.63	13.68	0.55	1.56e-35	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg10909506	chr17:38081995	ORMDL3	0.41	7.19	0.33	3.04e-12	Self-reported allergy;
LUAD	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg00316803	chr15:76480434	C15orf27	0.4	6.38	0.3	4.6e-10	Blood metabolite levels;
LUAD	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	8.98	0.4	9.29e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08733960	chr6:52529248	LOC730101	-0.4	-6.75	-0.31	5e-11	Cancer;
LUAD	cis	rs1865721	1.000	rs8094181	chr18:73193976	T/A	cg26385618	chr18:73139727	C18orf62	-0.41	-7.48	-0.34	4.31e-13	Intelligence;
LUAD	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg09085632	chr11:111637200	PPP2R1B	0.8	13.1	0.54	3.71e-33	Primary sclerosing cholangitis;
LUAD	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	cis	rs7937890	0.559	rs2575831	chr11:14486194	A/T	cg06199346	chr11:14280333	SPON1	-0.33	-6.53	-0.3	1.94e-10	Mitochondrial DNA levels;
LUAD	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08109568	chr15:31115862	NA	-0.65	-10.31	-0.45	2.28e-22	Huntington's disease progression;
LUAD	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg27490568	chr2:178487706	NA	0.4	6.73	0.31	5.59e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg19163074	chr7:65112434	INTS4L2	0.43	6.59	0.31	1.29e-10	Aortic root size;
LUAD	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg12311346	chr5:56204834	C5orf35	-0.96	-13.95	-0.56	1.13e-36	Initial pursuit acceleration;
LUAD	trans	rs7246760	0.867	rs66880218	chr19:9774155	A/G	cg02900749	chr2:68251473	NA	-0.59	-6.43	-0.3	3.44e-10	Pursuit maintenance gain;
LUAD	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg26384229	chr12:38710491	ALG10B	0.44	7.38	0.34	8.37e-13	Morning vs. evening chronotype;
LUAD	cis	rs72928364	1.000	rs2713793	chr3:100619174	A/G	cg10123952	chr3:100791384	NA	-0.54	-6.76	-0.31	4.69e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.76	-0.39	4.88e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.7	-0.61	4.39e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg12419862	chr22:24373484	LOC391322	-0.63	-10.73	-0.46	6.43e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.55	0.34	2.78e-13	Tonsillectomy;
LUAD	cis	rs7737355	0.812	rs31241	chr5:130808198	T/C	cg25547332	chr5:131281432	NA	0.41	6.63	0.31	1.03e-10	Life satisfaction;
LUAD	cis	rs7809950	1.000	rs2520249	chr7:107146748	A/G	cg23024343	chr7:107201750	COG5	-0.71	-11.99	-0.5	1.07e-28	Coronary artery disease;
LUAD	trans	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg14917512	chr19:3094685	GNA11	-0.58	-6.85	-0.32	2.54e-11	Diabetic kidney disease;
LUAD	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-10.48	-0.45	5.48e-23	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs877282	0.853	rs7083589	chr10:754494	G/A	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg03579179	chr7:12444095	VWDE	0.42	6.58	0.3	1.37e-10	Coronary artery disease;
LUAD	trans	rs11184708	0.509	rs76718429	chr1:106252718	G/A	cg06936704	chr20:37009829	NA	0.64	6.36	0.3	5.38e-10	Waist-to-hip circumference ratio (ever vs never smoking interaction);
LUAD	cis	rs1843834	0.931	rs10170573	chr2:225552916	A/G	cg22455342	chr2:225449267	CUL3	0.46	6.39	0.3	4.42e-10	IgE levels in asthmatics (D.p. specific);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13069535	chr11:66406744	RBM4	-0.4	-6.65	-0.31	9.2e-11	Cancer;
LUAD	cis	rs9302635	0.688	rs763665	chr16:72078043	C/T	cg23815491	chr16:72088622	HP	0.49	6.41	0.3	3.79e-10	Blood protein levels;
LUAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.63	-10.91	-0.47	1.32e-24	Lymphocyte counts;
LUAD	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-12.06	-0.51	5.29e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg01236616	chr12:121019343	POP5	-1.22	-18.88	-0.68	4.21e-58	Type 1 diabetes nephropathy;
LUAD	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg06640241	chr16:89574553	SPG7	0.59	8.74	0.39	5.67e-17	Multiple myeloma (IgH translocation);
LUAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13012494	chr21:47604986	C21orf56	0.61	10.54	0.46	3.1e-23	Testicular germ cell tumor;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25486615	chr20:5591870	RP5-1022P6.2	-0.43	-6.65	-0.31	9.33e-11	Height;
LUAD	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.26e-12	Tonsillectomy;
LUAD	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.15	0.44	8.52e-22	Lung cancer in ever smokers;
LUAD	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg25208724	chr1:156163844	SLC25A44	1.19	27.44	0.8	6.1e-96	Testicular germ cell tumor;
LUAD	cis	rs753778	0.570	rs6578154	chr8:142210057	G/A	cg18755752	chr8:142205143	DENND3	-0.71	-14.23	-0.57	7.83e-38	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg21724239	chr8:58056113	NA	0.74	9.62	0.42	5.86e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs8073060	0.963	rs11080354	chr17:33872407	A/G	cg19694781	chr19:47549865	TMEM160	-0.77	-12.1	-0.51	3.88e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg09835421	chr16:68378352	PRMT7	-0.85	-9.1	-0.4	3.55e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13095912	1.000	rs10937226	chr3:185302885	G/A	cg11274856	chr3:185301563	NA	0.37	7.51	0.34	3.5e-13	Systolic blood pressure;
LUAD	cis	rs7953508	0.506	rs10777530	chr12:93961110	C/T	cg18151635	chr12:93972918	NA	-0.78	-11.73	-0.5	1.05e-27	Pubertal anthropometrics;
LUAD	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg07870213	chr5:140052090	DND1	-0.81	-11.5	-0.49	8.43e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg06544989	chr22:39130855	UNC84B	0.45	8.01	0.36	1.09e-14	Menopause (age at onset);
LUAD	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	8.03	0.36	9.57e-15	Tonsillectomy;
LUAD	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg09658497	chr7:2847517	GNA12	-0.45	-8.34	-0.38	1.08e-15	Height;
LUAD	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.32	-0.34	1.24e-12	Total body bone mineral density;
LUAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg00280220	chr17:61926910	NA	0.36	6.98	0.32	1.17e-11	Prudent dietary pattern;
LUAD	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19346786	chr7:2764209	NA	-0.54	-11.82	-0.5	4.76e-28	Height;
LUAD	cis	rs12541635	1.000	rs1540420	chr8:107088426	C/T	cg10147462	chr8:107024639	NA	-0.42	-7.59	-0.35	2.12e-13	Age of smoking initiation;
LUAD	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg04944784	chr2:26401820	FAM59B	-0.71	-10.02	-0.44	2.37e-21	Gut microbiome composition (summer);
LUAD	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg21399703	chr1:247681439	NA	0.43	7.77	0.35	5.82e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs1595825	0.891	rs59617443	chr2:198653204	C/A	cg11031976	chr2:198649780	BOLL	-0.48	-7.05	-0.32	7.3e-12	Ulcerative colitis;
LUAD	trans	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg18335740	chr13:41363409	SLC25A15	-0.5	-9.07	-0.4	4.58e-18	Lewy body disease;
LUAD	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.89	-0.32	2.08e-11	Bipolar disorder;
LUAD	cis	rs7122539	0.646	rs569818	chr11:66570749	G/A	cg24851651	chr11:66362959	CCS	0.37	6.77	0.31	4.28e-11	HIV-1 susceptibility;
LUAD	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.41	-6.71	-0.31	6.21e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.95	-0.36	1.78e-14	Monocyte percentage of white cells;
LUAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg21724239	chr8:58056113	NA	0.72	9.56	0.42	1.01e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24531977	chr5:56204891	C5orf35	-1.0	-15.36	-0.6	1.21e-42	Initial pursuit acceleration;
LUAD	cis	rs35740288	0.770	rs34048547	chr15:86181067	A/G	cg13263323	chr15:86062960	AKAP13	-0.44	-7.09	-0.33	5.8e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs68170813	0.559	rs12536574	chr7:106810997	A/T	cg23024343	chr7:107201750	COG5	0.49	7.14	0.33	4.02e-12	Coronary artery disease;
LUAD	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg27284194	chr4:1044797	NA	0.7	10.1	0.44	1.21e-21	Recombination rate (females);
LUAD	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg02574844	chr11:5959923	NA	-0.4	-7.05	-0.32	7.43e-12	DNA methylation (variation);
LUAD	cis	rs7731657	0.537	rs10066004	chr5:130304689	G/A	cg08523029	chr5:130500466	HINT1	-0.58	-7.52	-0.34	3.28e-13	Fasting plasma glucose;
LUAD	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-8.99	-0.4	8.24e-18	Blood metabolite levels;
LUAD	cis	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg00071950	chr4:10020882	SLC2A9	0.49	7.02	0.32	8.88e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.74	-0.35	7.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg20556744	chr2:9614537	IAH1	0.66	6.56	0.3	1.55e-10	Opioid sensitivity;
LUAD	trans	rs7181230	0.885	rs17723133	chr15:40365418	A/G	cg22705835	chr10:65332833	REEP3	0.37	7.13	0.33	4.38e-12	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs1448094	1.000	rs1448094	chr12:86343135	G/T	cg00310523	chr12:86230176	RASSF9	0.36	7.45	0.34	5.13e-13	Major depressive disorder;
LUAD	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.94	-15.64	-0.61	7.8e-44	Homoarginine levels;
LUAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.69	0.35	1.06e-13	Depression;
LUAD	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.3	-0.33	1.41e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg08132940	chr7:1081526	C7orf50	-0.77	-10.35	-0.45	1.63e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.78	10.25	0.45	3.48e-22	Smoking behavior;
LUAD	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg04398451	chr17:18023971	MYO15A	0.76	13.79	0.56	5.35e-36	Total body bone mineral density;
LUAD	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg02551604	chr5:131831745	NA	0.62	9.95	0.44	4.36e-21	Asthma (sex interaction);
LUAD	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg01475377	chr6:109611718	NA	-0.52	-10.08	-0.44	1.42e-21	Reticulocyte fraction of red cells;
LUAD	trans	rs867371	0.502	rs28610286	chr15:82525655	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.4	-6.82	-0.31	3.19e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LUAD	cis	rs1865721	0.804	rs1319789	chr18:73161157	C/A	cg26385618	chr18:73139727	C18orf62	-0.49	-9.42	-0.42	2.94e-19	Intelligence;
LUAD	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg02569458	chr12:86230093	RASSF9	0.41	7.42	0.34	6.57e-13	Major depressive disorder;
LUAD	trans	rs12439619	0.508	rs8042665	chr15:82481349	A/T	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.37	-0.3	5.05e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg03609598	chr5:56110824	MAP3K1	0.67	8.58	0.38	1.88e-16	Initial pursuit acceleration;
LUAD	cis	rs240764	0.817	rs239249	chr6:101087081	G/A	cg09795085	chr6:101329169	ASCC3	0.43	7.3	0.33	1.46e-12	Neuroticism;
LUAD	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg11822812	chr5:140052017	DND1	0.37	6.95	0.32	1.41e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.74	13.7	0.55	1.33e-35	Axial length;
LUAD	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg07507251	chr3:52567010	NT5DC2	0.38	7.34	0.34	1.1e-12	Bipolar disorder;
LUAD	cis	rs2455799	0.613	rs2470536	chr3:15715156	G/C	cg16303742	chr3:15540471	COLQ	-0.5	-9.19	-0.41	1.84e-18	Mean platelet volume;
LUAD	cis	rs11696501	0.688	rs4810465	chr20:44311354	A/G	cg11783356	chr20:44313418	WFDC10B	0.51	8.54	0.38	2.36e-16	Brain structure;
LUAD	cis	rs12422267	0.536	rs12423631	chr12:132606886	C/T	cg09764611	chr12:132620959	NA	-0.66	-10.97	-0.47	8.57e-25	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg08219700	chr8:58056026	NA	0.6	8.47	0.38	3.98e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg21862992	chr11:68658383	NA	0.54	9.87	0.43	8.2e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs13082711	0.863	rs77135084	chr3:27423549	A/C	cg02860705	chr3:27208620	NA	0.59	9.05	0.4	5.16e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs3806843	0.576	rs246034	chr5:140332064	A/C	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.41	-0.3	3.86e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs494562	0.892	rs7767800	chr6:86124526	G/A	cg17966619	chr6:86160162	NT5E	0.66	7.83	0.36	4.05e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg09904177	chr6:26538194	HMGN4	0.43	7.31	0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg07332563	chr6:291687	DUSP22	-0.45	-7.68	-0.35	1.08e-13	Menopause (age at onset);
LUAD	cis	rs6256	0.860	rs74932445	chr11:13500645	G/A	cg11976911	chr11:13509032	NA	-0.52	-6.4	-0.3	4.06e-10	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
LUAD	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	13.89	0.56	2.2e-36	Smoking behavior;
LUAD	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg04827223	chr11:72435913	ARAP1	-0.49	-6.69	-0.31	6.9e-11	Type 2 diabetes;
LUAD	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg05425664	chr17:57184151	TRIM37	-0.43	-7.67	-0.35	1.17e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9814567	0.727	rs4435681	chr3:134344435	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.42	-0.52	2.1000000000000002e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7072216	0.881	rs2274247	chr10:100150148	G/C	cg26618903	chr10:100175079	PYROXD2	-0.31	-6.68	-0.31	7.75e-11	Metabolite levels;
LUAD	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg04731861	chr2:219085781	ARPC2	-0.24	-7.47	-0.34	4.71e-13	Colorectal cancer;
LUAD	cis	rs10504073	0.647	rs11997959	chr8:50014044	C/T	cg00325661	chr8:49890786	NA	0.43	9.81	0.43	1.34e-20	Blood metabolite ratios;
LUAD	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg11645453	chr3:52864694	ITIH4	-0.39	-7.64	-0.35	1.42e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.67	-9.08	-0.4	4.14e-18	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs9715521	0.900	rs6819160	chr4:59834879	A/G	cg11281224	chr4:60001000	NA	-0.56	-9.45	-0.42	2.39e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9487051	0.768	rs398944	chr6:109523444	T/G	cg21918786	chr6:109611834	NA	-0.41	-7.28	-0.33	1.59e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs1962073	0.667	rs4521760	chr8:10274188	C/A	cg27411982	chr8:10470053	RP1L1	-0.35	-6.39	-0.3	4.5e-10	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LUAD	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg13679303	chr9:96623674	NA	0.37	7.59	0.35	2.01e-13	DNA methylation (variation);
LUAD	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg02196655	chr2:10830764	NOL10	0.46	8.41	0.38	6.18e-16	Prostate cancer;
LUAD	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.15e-16	Prostate cancer;
LUAD	trans	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.38	-0.38	7.69e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg06064525	chr11:970664	AP2A2	-0.53	-10.86	-0.47	2.05e-24	Alzheimer's disease (late onset);
LUAD	cis	rs427941	0.703	rs10953358	chr7:101738226	T/C	cg06246474	chr7:101738831	CUX1	-0.41	-7.26	-0.33	1.87e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	9.15	0.41	2.48e-18	Total body bone mineral density;
LUAD	trans	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg22598563	chr5:131563921	P4HA2	-0.27	-6.61	-0.31	1.14e-10	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg03676636	chr4:99064102	C4orf37	-0.33	-8.73	-0.39	5.82e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg19699088	chr1:15930386	NA	-0.38	-6.92	-0.32	1.69e-11	Systolic blood pressure;
LUAD	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg00684032	chr4:1343700	KIAA1530	0.42	7.04	0.32	7.89e-12	Obesity-related traits;
LUAD	trans	rs12200782	1.000	rs12207181	chr6:26431285	C/T	cg08851530	chr6:28072375	NA	0.72	6.5	0.3	2.27e-10	Small cell lung carcinoma;
LUAD	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg23281280	chr6:28129359	ZNF389	0.47	6.6	0.31	1.22e-10	Depression;
LUAD	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.23	-0.37	2.38e-15	Bipolar disorder;
LUAD	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg19163074	chr7:65112434	INTS4L2	0.44	6.76	0.31	4.56e-11	Aortic root size;
LUAD	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg04225089	chr17:73874465	TRIM47	-0.39	-6.81	-0.31	3.26e-11	Psoriasis;
LUAD	cis	rs9308433	0.553	rs1048791	chr1:214511519	T/C	cg06198575	chr1:214491504	SMYD2	0.43	7.1	0.33	5.33e-12	IgG glycosylation;
LUAD	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg16479474	chr6:28041457	NA	0.46	7.82	0.36	4.18e-14	Depression;
LUAD	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.53	6.61	0.31	1.17e-10	Body mass index;
LUAD	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg21214613	chr1:16344536	HSPB7	0.62	11.9	0.5	2.26e-28	Dilated cardiomyopathy;
LUAD	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.87	-0.32	2.37e-11	Height;
LUAD	cis	rs7598759	0.527	rs12987949	chr2:232367511	A/G	cg19187155	chr2:232395269	NMUR1	0.5	9.58	0.42	8.22e-20	Noise-induced hearing loss;
LUAD	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.41	0.38	6.44e-16	Body mass index;
LUAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg11766577	chr21:47581405	C21orf56	-0.45	-7.79	-0.35	5.32e-14	Testicular germ cell tumor;
LUAD	trans	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg06606381	chr12:133084897	FBRSL1	-1.22	-11.0	-0.47	6.18e-25	Depression;
LUAD	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg04267008	chr7:1944627	MAD1L1	-0.69	-10.93	-0.47	1.17e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.41	-8.09	-0.37	6.58e-15	Glomerular filtration rate;
LUAD	cis	rs6499255	0.951	rs12596823	chr16:69634757	A/C	cg15192750	chr16:69999425	NA	0.5	7.89	0.36	2.58e-14	IgE levels;
LUAD	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg25173405	chr17:45401733	C17orf57	-0.4	-6.54	-0.3	1.75e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4790333	1.000	rs4790332	chr17:2262611	G/A	cg27406664	chr17:2294951	MNT	0.42	8.35	0.38	9.59e-16	Proinsulin levels;
LUAD	cis	rs11674184	0.659	rs11679605	chr2:11722468	G/A	cg07314298	chr2:11723111	GREB1	-0.77	-14.25	-0.57	6.63e-38	Endometriosis;
LUAD	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg21100191	chr22:23484243	RTDR1	0.65	11.35	0.48	2.93e-26	Bone mineral density;
LUAD	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg03806693	chr22:41940476	POLR3H	0.59	8.59	0.39	1.63e-16	Vitiligo;
LUAD	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg05304507	chr6:116381966	FRK	0.2	6.79	0.31	3.81e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg10518543	chr12:38710700	ALG10B	-0.51	-8.41	-0.38	6.57e-16	Morning vs. evening chronotype;
LUAD	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.33	0.34	1.2e-12	Tonsillectomy;
LUAD	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg21153622	chr11:89784906	NA	-0.32	-6.46	-0.3	2.95e-10	Height;
LUAD	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg03929089	chr4:120376271	NA	-0.82	-13.13	-0.54	2.73e-33	Height;
LUAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08677398	chr8:58056175	NA	0.47	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg11235426	chr6:292522	DUSP22	-0.81	-13.91	-0.56	1.77e-36	Menopause (age at onset);
LUAD	cis	rs9462027	0.628	rs9469863	chr6:34739649	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.94	-0.4	1.27e-17	Systemic lupus erythematosus;
LUAD	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg11645453	chr3:52864694	ITIH4	0.32	6.5	0.3	2.31e-10	Bipolar disorder;
LUAD	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg07538946	chr5:131705188	SLC22A5	0.45	7.32	0.34	1.28e-12	Blood metabolite levels;
LUAD	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.18	-0.41	1.87e-18	Total body bone mineral density;
LUAD	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg15147215	chr3:52552868	STAB1	-0.4	-7.49	-0.34	3.92e-13	Electroencephalogram traits;
LUAD	trans	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg14791747	chr16:20752902	THUMPD1	-0.45	-6.83	-0.32	3.06e-11	Dental caries;
LUAD	cis	rs6542838	0.611	rs7423519	chr2:99518319	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.94	-0.32	1.46e-11	Fear of minor pain;
LUAD	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg24818145	chr4:99064322	C4orf37	0.54	7.94	0.36	1.83e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11644478	chr21:40555479	PSMG1	-0.42	-6.94	-0.32	1.46e-11	Menarche (age at onset);
LUAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08677398	chr8:58056175	NA	0.46	6.54	0.3	1.76e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs7939886	0.844	rs2512784	chr11:55894186	G/A	cg15704280	chr7:45808275	SEPT13	-0.65	-6.38	-0.3	4.65e-10	Myopia (pathological);
LUAD	cis	rs240764	0.717	rs1039032	chr6:101161931	T/C	cg09795085	chr6:101329169	ASCC3	-0.4	-6.97	-0.32	1.21e-11	Neuroticism;
LUAD	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg26384229	chr12:38710491	ALG10B	0.38	6.51	0.3	2.13e-10	Heart rate;
LUAD	trans	rs1493916	0.837	rs2172626	chr18:31410478	C/T	cg27147174	chr7:100797783	AP1S1	-0.62	-10.88	-0.47	1.73e-24	Life satisfaction;
LUAD	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg18190219	chr22:46762943	CELSR1	-0.48	-6.93	-0.32	1.58e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg02782426	chr3:40428986	ENTPD3	-0.36	-7.94	-0.36	1.85e-14	Renal cell carcinoma;
LUAD	cis	rs3125734	0.633	rs10821968	chr10:63993905	C/T	cg19640130	chr10:64028056	RTKN2	0.36	7.8	0.35	4.74e-14	Rheumatoid arthritis;
LUAD	trans	rs1941687	0.505	rs8091920	chr18:31303557	C/G	cg27147174	chr7:100797783	AP1S1	-0.59	-10.02	-0.44	2.47e-21	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.98	0.32	1.18e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-6.37	-0.3	5.02e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.76e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg02782426	chr3:40428986	ENTPD3	0.36	7.89	0.36	2.67e-14	Renal cell carcinoma;
LUAD	cis	rs6060717	0.536	rs11699815	chr20:34543125	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.93	-0.32	1.61e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg25894440	chr7:65020034	NA	-0.63	-6.79	-0.31	3.87e-11	Diabetic kidney disease;
LUAD	trans	rs9348729	1	rs9348729	chr6:26664268	T/C	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.23	-0.33	2.3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs953387	0.956	rs4954572	chr2:136926719	G/T	cg05194412	chr2:137003533	NA	-0.45	-7.27	-0.33	1.7e-12	Arthritis (juvenile idiopathic);
LUAD	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg00745463	chr17:30367425	LRRC37B	0.9	9.8	0.43	1.39e-20	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.91e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs10695717	1	rs10695717	chr22:39558761	A/ATTC	cg18708252	chr22:39545030	CBX7	-0.3	-6.41	-0.3	3.96e-10	Breast cancer;
LUAD	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg03526459	chr1:146549940	NA	-0.37	-7.76	-0.35	6.6e-14	HIV-1 control;
LUAD	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg11663144	chr21:46675770	NA	0.62	12.35	0.51	3.97e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg01475377	chr6:109611718	NA	-0.49	-8.85	-0.4	2.37e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg00745463	chr17:30367425	LRRC37B	-0.79	-9.71	-0.43	2.84e-20	Hip circumference adjusted for BMI;
LUAD	cis	rs367943	0.712	rs13157609	chr5:112683583	G/A	cg12552261	chr5:112820674	MCC	0.46	8.92	0.4	1.38e-17	Type 2 diabetes;
LUAD	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.69	-13.47	-0.55	1.15e-34	Ulcerative colitis;
LUAD	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg00684032	chr4:1343700	KIAA1530	0.41	6.78	0.31	4.04e-11	Obesity-related traits;
LUAD	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-20.46	-0.71	3.39e-65	Height;
LUAD	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg17757837	chr7:157058334	UBE3C	0.47	8.25	0.37	1.96e-15	Body mass index;
LUAD	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg04800585	chr6:26043546	HIST1H2BB	-0.36	-6.37	-0.3	4.83e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg05425664	chr17:57184151	TRIM37	-0.42	-7.62	-0.35	1.65e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg00634984	chr7:65235879	NA	-0.5	-6.58	-0.3	1.39e-10	Aortic root size;
LUAD	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg13770153	chr20:60521292	NA	-0.56	-9.31	-0.41	6.78e-19	Body mass index;
LUAD	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.52	-8.71	-0.39	6.87e-17	Alzheimer's disease (late onset);
LUAD	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg18404041	chr3:52824283	ITIH1	0.43	7.88	0.36	2.81e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11153730	0.503	rs283062	chr6:118621456	A/G	cg21191810	chr6:118973309	C6orf204	-0.49	-9.43	-0.42	2.67e-19	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg07677032	chr17:61819896	STRADA	0.57	10.26	0.45	3.23e-22	Prudent dietary pattern;
LUAD	cis	rs6541297	0.703	rs627702	chr1:230324119	A/G	cg20703242	chr1:230279135	GALNT2	0.43	6.54	0.3	1.76e-10	Coronary artery disease;
LUAD	cis	rs7833986	0.501	rs2953911	chr8:56948009	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	1.01	18.3	0.66	1.63e-55	Height;
LUAD	cis	rs7731657	0.537	rs3962196	chr5:130372512	A/T	cg08523029	chr5:130500466	HINT1	-0.59	-7.65	-0.35	1.38e-13	Fasting plasma glucose;
LUAD	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg21782813	chr7:2030301	MAD1L1	0.47	8.11	0.37	5.43e-15	Schizophrenia;
LUAD	trans	rs7395662	1.000	rs4882136	chr11:48615311	T/A	cg00717180	chr2:96193071	NA	-0.39	-7.27	-0.33	1.72e-12	HDL cholesterol;
LUAD	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg20203395	chr5:56204925	C5orf35	-0.81	-11.49	-0.49	8.58e-27	Initial pursuit acceleration;
LUAD	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg21963583	chr11:68658836	MRPL21	0.65	11.58	0.49	3.95e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg27588902	chr6:42928151	GNMT	-0.36	-9.36	-0.41	4.81e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs953387	1.000	rs6715785	chr2:136910273	C/T	cg05194412	chr2:137003533	NA	-0.39	-6.36	-0.3	5.2400000000000005e-10	Arthritis (juvenile idiopathic);
LUAD	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg18129178	chr5:148520854	ABLIM3	-0.62	-9.5	-0.42	1.64e-19	Breast cancer;
LUAD	cis	rs17092148	0.666	rs62212084	chr20:33458851	A/G	cg16810054	chr20:33298113	TP53INP2	0.4	7.19	0.33	2.96e-12	Neuroticism;
LUAD	cis	rs12122100	0.526	rs12122534	chr1:146504399	A/G	cg02487331	chr1:146550467	NA	0.34	6.48	0.3	2.5e-10	HIV-1 control;
LUAD	cis	rs657075	0.595	rs3749753	chr5:131587131	C/T	cg21138405	chr5:131827807	IRF1	0.47	6.69	0.31	7.02e-11	Rheumatoid arthritis;
LUAD	cis	rs17021463	0.902	rs62320439	chr4:95248721	G/C	cg11021082	chr4:95130006	SMARCAD1	0.42	7.54	0.34	2.8e-13	Testicular germ cell tumor;
LUAD	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.35e-11	Breast cancer;
LUAD	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg10518543	chr12:38710700	ALG10B	-0.43	-7.1	-0.33	5.42e-12	Morning vs. evening chronotype;
LUAD	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg17105886	chr17:28927953	LRRC37B2	0.84	8.11	0.37	5.36e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs220324	0.688	rs9975332	chr21:43559902	C/T	cg08841829	chr21:43638893	ABCG1	0.48	6.55	0.3	1.66e-10	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs9652601	0.959	rs9652582	chr16:11174564	G/A	cg04616529	chr16:11181986	CLEC16A	0.37	6.46	0.3	2.94e-10	Systemic lupus erythematosus;
LUAD	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.86	0.36	3.13e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-9.91	-0.43	5.71e-21	Migraine;Coronary artery disease;
LUAD	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg05182265	chr7:156933206	UBE3C	-0.8	-17.06	-0.64	4.66e-50	Body mass index;
LUAD	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg21433313	chr16:3507492	NAT15	0.76	13.08	0.54	4.7e-33	Tuberculosis;
LUAD	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg25036284	chr2:26402008	FAM59B	-0.58	-8.12	-0.37	5.03e-15	Gut microbiome composition (summer);
LUAD	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg13535736	chr9:111863775	C9orf5	-0.43	-6.53	-0.3	1.86e-10	Menarche (age at onset);
LUAD	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-14.18	-0.57	1.28e-37	Headache;
LUAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg06074448	chr4:187884817	NA	-0.37	-7.3	-0.33	1.47e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11048434	0.736	rs12821842	chr12:9108984	G/A	cg04155231	chr12:9217510	LOC144571	0.39	7.45	0.34	5.24e-13	Sjögren's syndrome;
LUAD	cis	rs12541635	0.966	rs11782609	chr8:106967919	G/A	cg10147462	chr8:107024639	NA	0.47	8.21	0.37	2.68e-15	Age of smoking initiation;
LUAD	cis	rs4588572	0.606	rs4290994	chr5:77742253	C/T	cg11547950	chr5:77652471	NA	-0.62	-10.46	-0.45	6.04e-23	Triglycerides;
LUAD	cis	rs8044868	1.000	rs4238964	chr16:72175156	A/C	cg23815491	chr16:72088622	HP	0.41	7.24	0.33	2.15e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg20587970	chr11:113659929	NA	-1.39	-20.41	-0.7	6.07e-65	Hip circumference adjusted for BMI;
LUAD	cis	rs892961	0.932	rs7216155	chr17:75405155	C/G	cg05865280	chr17:75406074	SEPT9	0.63	18.92	0.68	2.64e-58	Airflow obstruction;
LUAD	cis	rs6547631	0.622	rs10180547	chr2:85926305	G/A	cg21473183	chr2:85925749	GNLY	0.35	7.47	0.34	4.64e-13	Blood protein levels;
LUAD	cis	rs4664304	0.966	rs1397707	chr2:160760972	C/T	cg23995753	chr2:160760732	LY75	-0.47	-8.23	-0.37	2.32e-15	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg07305463	chr2:136567211	LCT	0.37	7.2	0.33	2.71e-12	Mosquito bite size;
LUAD	cis	rs7095607	0.630	rs7069569	chr10:69955140	T/A	cg18986048	chr10:69913749	MYPN	0.41	7.2	0.33	2.82e-12	Lung function (FVC);
LUAD	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	15.06	0.59	2.36e-41	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg02493740	chr2:85810744	VAMP5	-0.46	-8.37	-0.38	8.21e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs4372836	0.543	rs6742291	chr2:29007349	T/C	cg09522027	chr2:28974177	PPP1CB	-0.62	-10.83	-0.47	2.72e-24	Body mass index;
LUAD	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg08514558	chr10:81106712	PPIF	0.49	9.8	0.43	1.39e-20	Height;
LUAD	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg14668632	chr7:2872130	GNA12	-0.7	-12.65	-0.52	2.59e-31	Height;
LUAD	cis	rs1003719	0.667	rs28666643	chr21:38455999	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.45	7.48	0.34	4.22e-13	Eye color traits;
LUAD	cis	rs12541635	0.966	rs62527363	chr8:107024258	A/G	cg10147462	chr8:107024639	NA	0.5	9.11	0.4	3.34e-18	Age of smoking initiation;
LUAD	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg08999081	chr20:33150536	PIGU	-0.58	-12.31	-0.51	5.8e-30	Glomerular filtration rate (creatinine);
LUAD	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg14227996	chr4:17616232	MED28	0.71	7.42	0.34	6.42e-13	Opioid sensitivity;
LUAD	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg15501526	chr10:2543763	NA	0.7	15.87	0.61	7.79e-45	Age-related hearing impairment;
LUAD	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.18	0.37	3.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg10978503	chr1:24200527	CNR2	-0.45	-8.54	-0.38	2.45e-16	Immature fraction of reticulocytes;
LUAD	cis	rs240764	0.817	rs239189	chr6:101128787	C/T	cg09795085	chr6:101329169	ASCC3	0.46	7.97	0.36	1.5e-14	Neuroticism;
LUAD	cis	rs10242455	0.702	rs45448997	chr7:99041598	G/C	cg18809830	chr7:99032528	PTCD1	-0.99	-7.18	-0.33	3.17e-12	Blood metabolite levels;
LUAD	cis	rs62400317	0.859	rs10948221	chr6:45236707	T/G	cg18551225	chr6:44695536	NA	-0.56	-8.7	-0.39	7.44e-17	Total body bone mineral density;
LUAD	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10802521	chr3:52805072	NEK4	-0.54	-9.19	-0.41	1.81e-18	Bipolar disorder;
LUAD	cis	rs9314323	0.767	rs7012604	chr8:26204089	G/A	cg13160058	chr8:26243215	BNIP3L	-0.49	-9.95	-0.44	4.34e-21	Red cell distribution width;
LUAD	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg16680214	chr1:154839983	KCNN3	-0.61	-12.12	-0.51	3.07e-29	Prostate cancer;
LUAD	cis	rs8177876	0.731	rs74882687	chr16:81118920	C/A	cg08591886	chr16:81111003	C16orf46	-0.8	-7.39	-0.34	7.72e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg05084668	chr3:125655381	ALG1L	-0.81	-9.59	-0.42	8.02e-20	Blood pressure (smoking interaction);
LUAD	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg21823605	chr1:152486609	CRCT1	0.29	6.44	0.3	3.22e-10	Hair morphology;
LUAD	cis	rs9486719	0.857	rs13208321	chr6:96860354	C/T	cg06623918	chr6:96969491	KIAA0776	-0.61	-9.4	-0.42	3.58e-19	Migraine;Coronary artery disease;
LUAD	cis	rs9560113	0.573	rs1888304	chr13:112242454	A/G	cg10483660	chr13:112241077	NA	0.47	9.6	0.42	7.18e-20	Menarche (age at onset);
LUAD	cis	rs2425143	1.000	rs11699044	chr20:34312713	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.64	7.84	0.36	3.65e-14	Blood protein levels;
LUAD	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg01475377	chr6:109611718	NA	-0.54	-10.37	-0.45	1.31e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.05	-0.4	5.32e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg14671364	chr1:107599128	PRMT6	0.63	10.8	0.46	3.46e-24	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg18196295	chr10:418757	DIP2C	-0.4	-6.62	-0.31	1.09e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg17757837	chr7:157058334	UBE3C	0.48	8.48	0.38	3.76e-16	Body mass index;
LUAD	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg03433033	chr1:76189801	ACADM	0.93	19.16	0.68	2.33e-59	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg24308560	chr3:49941425	MST1R	0.52	8.65	0.39	1.08e-16	Body mass index;
LUAD	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg08213375	chr14:104286397	PPP1R13B	0.27	7.14	0.33	4.14e-12	Schizophrenia;
LUAD	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg21385522	chr1:16154831	NA	-0.93	-15.3	-0.6	2.18e-42	Dilated cardiomyopathy;
LUAD	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg25344623	chr2:136566232	LCT	-0.34	-6.6	-0.31	1.26e-10	Mosquito bite size;
LUAD	cis	rs72928364	0.929	rs13060849	chr3:100773483	A/C	cg10123952	chr3:100791384	NA	0.76	8.69	0.39	7.85e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7020830	0.931	rs13297576	chr9:37142189	A/C	cg14294708	chr9:37120828	ZCCHC7	0.86	17.32	0.64	3.37e-51	Schizophrenia;
LUAD	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg19729930	chr2:74357872	NA	0.78	11.55	0.49	5.34e-27	Gestational age at birth (maternal effect);
LUAD	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3784262	1.000	rs12910113	chr15:58248373	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.44	-8.94	-0.4	1.25e-17	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.38	1.21e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.559	rs75313693	chr7:106863170	T/C	cg02696742	chr7:106810147	HBP1	-0.78	-10.71	-0.46	7.76e-24	Coronary artery disease;
LUAD	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg06873352	chr17:61820015	STRADA	0.42	7.0	0.32	1e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg08888203	chr3:10149979	C3orf24	0.67	11.23	0.48	8.75e-26	Alzheimer's disease;
LUAD	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg06547715	chr2:218990976	CXCR2	0.28	6.66	0.31	8.68e-11	Colorectal cancer;
LUAD	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg00316803	chr15:76480434	C15orf27	-0.41	-7.59	-0.35	2.03e-13	Blood metabolite levels;
LUAD	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg08742575	chr21:47604166	C21orf56	0.43	7.26	0.33	1.93e-12	Testicular germ cell tumor;
LUAD	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg10544611	chr16:67998164	SLC12A4	-0.64	-7.7	-0.35	1.01e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	9.46	0.42	2.13e-19	Menarche (age at onset);
LUAD	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22857025	chr5:266934	NA	-0.97	-14.63	-0.58	1.67e-39	Breast cancer;
LUAD	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg12927641	chr6:109611667	NA	-0.51	-8.86	-0.4	2.31e-17	Reticulocyte fraction of red cells;
LUAD	trans	rs7591996	0.835	rs7585700	chr2:6504784	A/T	cg09618640	chr6:161258421	NA	-0.37	-6.68	-0.31	7.62e-11	Osteosarcoma;
LUAD	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.86	0.32	2.5e-11	Mood instability;
LUAD	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg21775007	chr8:11205619	TDH	-0.41	-7.2	-0.33	2.78e-12	Retinal vascular caliber;
LUAD	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg19302996	chr17:73780495	UNK	-0.4	-6.74	-0.31	5.31e-11	White matter hyperintensity burden;
LUAD	trans	rs7395662	0.777	rs7114291	chr11:48608251	A/G	cg00717180	chr2:96193071	NA	-0.38	-7.14	-0.33	4e-12	HDL cholesterol;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14385438	chr6:15663468	DTNBP1	-0.38	-6.49	-0.3	2.48e-10	Cancer;
LUAD	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg17644776	chr2:200775616	C2orf69	0.55	7.32	0.34	1.26e-12	Schizophrenia;
LUAD	trans	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.06	-0.32	7.09e-12	Selective IgA deficiency;
LUAD	cis	rs72845660	0.911	rs17707508	chr10:104047836	G/T	cg20641465	chr10:103991465	PITX3	-0.49	-7.0	-0.32	1.02e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg24818145	chr4:99064322	C4orf37	0.48	8.09	0.37	6.3e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg15704280	chr7:45808275	SEPT13	0.68	9.21	0.41	1.51e-18	Axial length;
LUAD	cis	rs8077889	0.672	rs2106764	chr17:41852717	T/A	cg26893861	chr17:41843967	DUSP3	1.13	25.38	0.78	5e-87	Triglycerides;
LUAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg14092988	chr3:52407081	DNAH1	0.41	8.1	0.37	6.13e-15	Electroencephalogram traits;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg02999463	chr8:37707322	BRF2	0.44	7.02	0.32	9.16e-12	Diastolic blood pressure;
LUAD	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg23985595	chr17:80112537	CCDC57	0.5	9.19	0.41	1.8e-18	Life satisfaction;
LUAD	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg05313129	chr8:58192883	C8orf71	-0.58	-8.68	-0.39	8.78e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.86	0.32	2.38e-11	Motion sickness;
LUAD	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg17200465	chr3:40428508	ENTPD3	0.28	6.68	0.31	7.53e-11	Renal cell carcinoma;
LUAD	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg03037974	chr15:76606532	NA	0.48	11.24	0.48	7.72e-26	Blood metabolite levels;
LUAD	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg06547715	chr2:218990976	CXCR2	0.44	10.47	0.45	5.93e-23	Ulcerative colitis;
LUAD	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg19622623	chr12:86230825	RASSF9	-0.55	-9.8	-0.43	1.42e-20	Major depressive disorder;
LUAD	cis	rs12545109	0.642	rs2055984	chr8:57418332	A/G	cg07776626	chr8:57350775	NA	-0.6	-7.74	-0.35	7.64e-14	Obesity-related traits;
LUAD	cis	rs16910800	0.953	rs73481419	chr11:23204953	A/G	cg20040320	chr11:23191996	NA	-0.49	-7.37	-0.34	8.93e-13	Cancer;
LUAD	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg05082376	chr22:42548792	NA	-0.44	-7.69	-0.35	1.04e-13	Schizophrenia;
LUAD	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.44	-6.78	-0.31	3.99e-11	Breast cancer;
LUAD	trans	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg06606381	chr12:133084897	FBRSL1	-0.65	-7.17	-0.33	3.42e-12	Depression;
LUAD	cis	rs887829	0.641	rs10197460	chr2:234589190	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.69	-0.43	3.46e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg12501888	chr15:85177176	SCAND2	-0.43	-6.41	-0.3	3.96e-10	P wave terminal force;
LUAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10150615	chr22:24372951	LOC391322	-0.55	-8.91	-0.4	1.51e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1144713	0.600	rs2683489	chr12:32251181	A/G	cg01321189	chr12:32259338	BICD1	0.36	6.81	0.31	3.44e-11	Obesity-related traits;
LUAD	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.8	0.31	3.49e-11	Rheumatoid arthritis;
LUAD	cis	rs910187	0.605	rs8124918	chr20:45811860	A/G	cg27589058	chr20:45804311	EYA2	-0.33	-7.42	-0.34	6.66e-13	Migraine;
LUAD	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08704250	chr15:31115839	NA	-0.56	-10.0	-0.44	2.94e-21	Huntington's disease progression;
LUAD	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg12564285	chr5:131593104	PDLIM4	0.39	7.14	0.33	3.99e-12	Acylcarnitine levels;
LUAD	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg22676075	chr6:135203613	NA	0.43	7.93	0.36	1.95e-14	Red blood cell count;
LUAD	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg27427491	chr17:78079615	GAA	0.39	7.5	0.34	3.75e-13	Yeast infection;
LUAD	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg11292332	chr7:45801988	SEPT13	-0.3	-6.66	-0.31	8.76e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg09796270	chr17:17721594	SREBF1	0.36	6.78	0.31	3.94e-11	Total body bone mineral density;
LUAD	cis	rs4853036	0.629	rs7577864	chr2:70017435	A/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-6.98	-0.32	1.14e-11	Colorectal or endometrial cancer;
LUAD	cis	rs7851660	0.933	rs12341377	chr9:100610382	C/G	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg00086871	chr4:6988644	TBC1D14	0.74	6.4	0.3	4.13e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs28619038	1	rs28619038	chr15:64642517	C/A	cg08069370	chr15:64387884	SNX1	-0.53	-6.72	-0.31	6e-11	Myeloid white cell count;
LUAD	cis	rs17253792	0.822	rs17746033	chr14:56061837	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg15704280	chr7:45808275	SEPT13	-0.76	-11.65	-0.49	2.19e-27	Height;
LUAD	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg13010199	chr12:38710504	ALG10B	0.41	6.72	0.31	5.75e-11	Bladder cancer;
LUAD	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg18755752	chr8:142205143	DENND3	-0.45	-7.76	-0.35	6.28e-14	Immature fraction of reticulocytes;
LUAD	cis	rs10193935	0.901	rs222483	chr2:42652184	T/G	cg27598129	chr2:42591480	NA	-0.7	-9.06	-0.4	4.99e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg08508325	chr11:3079039	CARS	-0.53	-11.44	-0.49	1.42e-26	Longevity;
LUAD	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg18477163	chr1:228402036	OBSCN	0.44	8.75	0.39	4.99e-17	Diastolic blood pressure;
LUAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg14820908	chr5:178986412	RUFY1	-0.61	-10.46	-0.45	6.27e-23	Lung cancer;
LUAD	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg08761264	chr16:28874980	SH2B1	-0.44	-6.6	-0.31	1.23e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg11822812	chr5:140052017	DND1	0.37	6.54	0.3	1.75e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12530845	0.943	rs55889179	chr7:135331631	C/T	cg23117316	chr7:135346802	PL-5283	-0.51	-8.99	-0.4	8.13e-18	Red blood cell traits;
LUAD	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg20701182	chr2:24300061	SF3B14	0.72	7.92	0.36	2.07e-14	Lymphocyte counts;
LUAD	cis	rs3820068	0.705	rs4646072	chr1:15827711	G/A	cg17385448	chr1:15911702	AGMAT	0.39	6.43	0.3	3.47e-10	Systolic blood pressure;
LUAD	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg23985595	chr17:80112537	CCDC57	-0.5	-9.06	-0.4	4.81e-18	Life satisfaction;
LUAD	cis	rs62400317	0.859	rs62400313	chr6:45256366	A/T	cg18551225	chr6:44695536	NA	-0.53	-8.4	-0.38	7.09e-16	Total body bone mineral density;
LUAD	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg27266060	chr8:22091797	NA	0.45	8.26	0.37	1.84e-15	Hypertriglyceridemia;
LUAD	cis	rs7584330	0.554	rs3751110	chr2:238427142	T/C	cg14458575	chr2:238380390	NA	0.61	9.85	0.43	9.8e-21	Prostate cancer;
LUAD	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.68	-9.05	-0.4	5.07e-18	Iron status biomarkers;
LUAD	cis	rs11756438	0.547	rs2798327	chr6:119005353	C/T	cg21191810	chr6:118973309	C6orf204	0.47	9.13	0.41	2.74e-18	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1965732	0.504	rs10170315	chr2:3715832	G/A	cg00999904	chr2:3704751	ALLC	-0.37	-7.0	-0.32	9.92e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	8.66	0.39	1.02e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs7319311	1.000	rs7320755	chr13:111031092	C/G	cg05272587	chr13:111038400	COL4A2	-0.37	-6.78	-0.31	3.99e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg08859206	chr1:53392774	SCP2	0.57	10.12	0.44	1.1e-21	Monocyte count;
LUAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg13397359	chr6:42928475	GNMT	0.66	13.08	0.54	4.58e-33	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2220004	0.559	rs71490418	chr11:55762060	T/C	cg22937354	chr11:55606216	OR5D16	-0.39	-6.76	-0.31	4.59e-11	Odorant perception (&beta-damascenone);
LUAD	cis	rs7586879	0.521	rs7597332	chr2:25075675	A/G	cg04586622	chr2:25135609	ADCY3	0.37	8.47	0.38	4.06e-16	Body mass index;
LUAD	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg05368731	chr17:41323189	NBR1	0.93	18.96	0.68	1.84e-58	Menopause (age at onset);
LUAD	cis	rs748404	0.697	rs475261	chr15:43546456	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.12	0.37	5.09e-15	Lung cancer;
LUAD	cis	rs6076065	0.723	rs6132607	chr20:23390373	C/G	cg11657817	chr20:23433608	CST11	-0.46	-9.0	-0.4	7.65e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.47	0.3	2.73e-10	Menarche (age at onset);
LUAD	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg25482853	chr8:67687455	SGK3	1.15	17.93	0.66	6.74e-54	Lung disease severity in cystic fibrosis;
LUAD	cis	rs9863	0.828	rs35099862	chr12:124467204	C/A	cg17723958	chr12:124429295	CCDC92	-0.41	-6.71	-0.31	6.15e-11	White blood cell count;
LUAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6756513	0.520	rs6546560	chr2:70173690	A/G	cg02498382	chr2:70120550	SNRNP27	-0.53	-9.84	-0.43	1.04e-20	Breast cancer;Platelet count;
LUAD	cis	rs9447004	0.557	rs2173854	chr6:74426775	T/A	cg23004174	chr6:74404879	CD109	0.47	8.44	0.38	5.11e-16	Blood protein levels;Calcium levels;
LUAD	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10227331	0.846	rs10807647	chr7:157298007	A/G	cg04156418	chr7:157293606	NA	-0.35	-7.5	-0.34	3.85e-13	Inattentive symptoms;
LUAD	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg12311346	chr5:56204834	C5orf35	0.74	11.88	0.5	2.86e-28	Initial pursuit acceleration;
LUAD	trans	rs9951602	0.512	rs56009939	chr18:76644497	T/G	cg02800362	chr5:177631904	HNRNPAB	0.92	14.22	0.57	8.94e-38	Obesity-related traits;
LUAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg15117754	chr3:10150083	C3orf24	0.42	6.83	0.32	2.98e-11	Alzheimer's disease;
LUAD	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg15557168	chr22:42548783	NA	-0.49	-8.87	-0.4	2.01e-17	Schizophrenia;
LUAD	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg06873352	chr17:61820015	STRADA	0.42	6.87	0.32	2.3e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs867371	0.502	rs8025964	chr15:82521770	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.41	-6.87	-0.32	2.31e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LUAD	cis	rs9837602	1.000	rs28714363	chr3:99752068	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.66	9.54	0.42	1.11e-19	Breast cancer;
LUAD	cis	rs55788414	0.932	rs2317122	chr16:81182819	A/G	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.87	-0.36	3.02e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg18402987	chr7:1209562	NA	0.79	9.77	0.43	1.84e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg05966235	chr16:28915196	ATP2A1	0.51	8.08	0.37	6.65e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg02136620	chr5:178986620	RUFY1	0.44	6.74	0.31	5.35e-11	Lung cancer;
LUAD	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg24920358	chr1:40204285	PPIE	0.7	12.5	0.52	9.71e-31	Blood protein levels;
LUAD	cis	rs6906287	0.647	rs7766375	chr6:118918269	G/A	cg18833306	chr6:118973337	C6orf204	0.48	8.38	0.38	7.74e-16	Electrocardiographic conduction measures;
LUAD	trans	rs9733	1.000	rs9733	chr1:150618961	A/C	cg02330719	chr17:25309145	NA	-0.25	-6.44	-0.3	3.24e-10	Tonsillectomy;
LUAD	cis	rs6684514	1.000	rs10908502	chr1:156300082	A/G	cg16558208	chr1:156270281	VHLL	0.53	9.64	0.42	5e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs6993813	0.814	rs1905783	chr8:120014836	C/T	cg01975934	chr8:119970761	NA	-0.37	-7.29	-0.33	1.52e-12	Bone mineral density (hip);
LUAD	cis	rs9487051	0.724	rs13196219	chr6:109635787	A/T	cg21918786	chr6:109611834	NA	-0.43	-6.8	-0.31	3.53e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-6.5	-0.3	2.29e-10	Personality dimensions;
LUAD	cis	rs2421770	0.530	rs3847621	chr11:35364435	G/A	cg13971030	chr11:35366721	SLC1A2	-0.46	-8.03	-0.36	9.6e-15	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs2249625	0.526	rs17725666	chr6:72889711	G/A	cg18830697	chr6:72922368	RIMS1	0.45	8.08	0.37	7.02e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	trans	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	25.61	0.78	5.16e-88	Colorectal cancer;
LUAD	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg18944383	chr4:111397179	ENPEP	0.4	7.96	0.36	1.61e-14	Height;
LUAD	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg24818145	chr4:99064322	C4orf37	0.41	6.89	0.32	2.04e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg00106254	chr7:1943704	MAD1L1	-0.53	-7.99	-0.36	1.33e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg07460842	chr6:66804631	NA	0.96	12.87	0.53	3.14e-32	Exhaled nitric oxide output;
LUAD	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg15467112	chr14:75489610	MLH3	0.35	6.44	0.3	3.24e-10	Height;
LUAD	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg13319975	chr6:146136371	FBXO30	-0.67	-11.65	-0.49	2.13e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg25457927	chr22:38595422	NA	-0.54	-13.59	-0.55	3.65e-35	Cutaneous nevi;
LUAD	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg22823121	chr1:150693482	HORMAD1	0.39	7.59	0.35	2.01e-13	Melanoma;
LUAD	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg07606381	chr6:8435919	SLC35B3	-0.53	-7.42	-0.34	6.46e-13	Motion sickness;
LUAD	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg14416269	chr4:6271139	WFS1	0.63	13.34	0.54	3.88e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.51	0.34	3.56e-13	Hip circumference adjusted for BMI;
LUAD	trans	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.68	-11.82	-0.5	4.65e-28	Mean corpuscular volume;
LUAD	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.43	-0.42	2.82e-19	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs999737	0.694	rs17755925	chr14:69011946	A/G	cg04147497	chr14:69052728	RAD51L1	-0.44	-6.85	-0.32	2.59e-11	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs11640533	0.901	rs2908792	chr16:53412419	A/G	cg04653913	chr16:53407753	NA	0.47	8.5	0.38	3.32e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs10924309	0.855	rs7413150	chr1:245858729	G/A	cg00036263	chr1:245852353	KIF26B	-0.49	-7.75	-0.35	6.66e-14	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg22029157	chr1:209979665	IRF6	0.79	9.47	0.42	2.02e-19	Coronary artery disease;
LUAD	cis	rs8099014	0.911	rs4245269	chr18:56110730	G/A	cg12907477	chr18:56117327	MIR122	0.39	6.71	0.31	6.24e-11	Platelet count;
LUAD	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg15226275	chr6:116381976	FRK	0.22	7.28	0.33	1.67e-12	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg05590025	chr7:65112418	INTS4L2	0.73	7.85	0.36	3.34e-14	Diabetic kidney disease;
LUAD	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg17279839	chr7:150038598	RARRES2	0.47	7.59	0.35	2.11e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs77861329	1.000	rs9882775	chr3:52149649	C/T	cg08692210	chr3:52188851	WDR51A	0.78	6.58	0.3	1.39e-10	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.75	-0.31	4.97e-11	Personality dimensions;
LUAD	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg13606994	chr1:44402422	ARTN	-0.33	-6.7	-0.31	6.68e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1595825	0.891	rs73058867	chr2:198891568	A/G	cg00361562	chr2:198649771	BOLL	-0.47	-6.5	-0.3	2.29e-10	Ulcerative colitis;
LUAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg13560548	chr3:10150139	C3orf24	0.45	7.5	0.34	3.92e-13	Alzheimer's disease;
LUAD	cis	rs7584330	0.704	rs60079197	chr2:238358584	A/T	cg16989719	chr2:238392110	NA	-0.38	-6.61	-0.31	1.16e-10	Prostate cancer;
LUAD	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg05283184	chr6:79620031	NA	-0.61	-12.47	-0.52	1.28e-30	Intelligence (multi-trait analysis);
LUAD	trans	rs225245	0.791	rs6505492	chr17:34026597	C/T	cg19694781	chr19:47549865	TMEM160	-0.47	-7.78	-0.35	5.48e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg08219700	chr8:58056026	NA	0.59	7.91	0.36	2.2e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg16405210	chr4:1374714	KIAA1530	-0.43	-7.34	-0.34	1.12e-12	Obesity-related traits;
LUAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-10.75	-0.46	5.2e-24	Lymphocyte counts;
LUAD	cis	rs7927592	0.513	rs556442	chr11:68192690	G/A	cg02221422	chr11:68192511	LRP5	0.43	7.02	0.32	8.64e-12	Total body bone mineral density;
LUAD	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg11707310	chr1:2537719	MMEL1	-0.37	-7.89	-0.36	2.64e-14	Ulcerative colitis;
LUAD	cis	rs12681287	0.752	rs10435564	chr8:87266239	T/C	cg27223183	chr8:87520930	FAM82B	-0.6	-8.37	-0.38	8.59e-16	Caudate activity during reward;
LUAD	cis	rs6665290	0.669	rs12406714	chr1:227177061	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.12	-30.01	-0.82	7.8e-107	Myeloid white cell count;
LUAD	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg18138036	chr10:133769891	PPP2R2D	0.42	6.83	0.32	3.01e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg05805236	chr11:65401703	PCNXL3	-0.61	-9.8	-0.43	1.47e-20	Acne (severe);
LUAD	cis	rs7536201	0.936	rs6600249	chr1:25305160	T/C	cg23273869	chr1:25296894	NA	-0.37	-7.48	-0.34	4.23e-13	Psoriasis vulgaris;
LUAD	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg05890377	chr2:74357713	NA	0.8	11.32	0.48	3.94e-26	Gestational age at birth (maternal effect);
LUAD	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg01475377	chr6:109611718	NA	-0.51	-9.43	-0.42	2.74e-19	Reticulocyte fraction of red cells;
LUAD	trans	rs75804782	0.521	rs72993073	chr2:239412925	G/A	cg01134436	chr17:81009848	B3GNTL1	0.78	8.45	0.38	4.58e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7737355	0.947	rs31587	chr5:131000711	A/T	cg25547332	chr5:131281432	NA	0.44	6.66	0.31	8.71e-11	Life satisfaction;
LUAD	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg02049041	chr17:27085579	C17orf63	-0.6	-8.13	-0.37	4.76e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg13770153	chr20:60521292	NA	-0.47	-7.82	-0.36	4.29e-14	Body mass index;
LUAD	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.63	0.31	1.04e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.812	rs250888	chr5:131015346	C/T	cg25547332	chr5:131281432	NA	-0.43	-6.96	-0.32	1.33e-11	Life satisfaction;
LUAD	cis	rs6543140	0.964	rs6543136	chr2:103065547	G/A	cg04239558	chr2:103089729	SLC9A4	0.36	7.26	0.33	1.85e-12	Blood protein levels;
LUAD	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg06263672	chr7:65235340	NA	0.49	6.44	0.3	3.32e-10	Aortic root size;
LUAD	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg17644776	chr2:200775616	C2orf69	0.55	7.32	0.34	1.26e-12	Schizophrenia;
LUAD	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.68	-10.38	-0.45	1.22e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg25233709	chr10:116636983	FAM160B1	0.43	8.42	0.38	5.76e-16	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs17092148	1.000	rs6060047	chr20:33367400	G/T	cg16810054	chr20:33298113	TP53INP2	0.51	7.97	0.36	1.46e-14	Neuroticism;
LUAD	trans	rs783540	0.967	rs34186444	chr15:83287500	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.43	-6.79	-0.31	3.86e-11	Schizophrenia;
LUAD	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg06623918	chr6:96969491	KIAA0776	0.88	17.18	0.64	1.44e-50	Headache;
LUAD	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.88	0.4	1.86e-17	Parkinson's disease;
LUAD	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg08219700	chr8:58056026	NA	0.54	7.79	0.35	5.22e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs921968	0.565	rs7595901	chr2:219606931	A/G	cg02176678	chr2:219576539	TTLL4	-0.57	-11.36	-0.48	2.81e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.66	-6.8	-0.31	3.67e-11	Lung cancer in ever smokers;
LUAD	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg12615879	chr12:58013172	SLC26A10	-0.35	-6.71	-0.31	6.33e-11	Celiac disease or Rheumatoid arthritis;
LUAD	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg00147160	chr1:26503991	CNKSR1	0.38	8.84	0.39	2.66e-17	Height;
LUAD	cis	rs57502260	0.680	rs7104806	chr11:68222188	C/T	cg16797656	chr11:68205561	LRP5	0.49	7.56	0.34	2.55e-13	Total body bone mineral density (age 45-60);
LUAD	cis	rs4253772	1.000	rs4253772	chr22:46627603	C/T	cg09491104	chr22:46646882	C22orf40	-0.5	-6.76	-0.31	4.69e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg00933542	chr6:150070202	PCMT1	0.45	10.09	0.44	1.37e-21	Lung cancer;
LUAD	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg00898013	chr13:113819073	PROZ	-0.67	-11.92	-0.5	1.87e-28	Platelet distribution width;
LUAD	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg23815491	chr16:72088622	HP	0.55	9.92	0.43	5.42e-21	Fibrinogen levels;
LUAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00166722	chr3:10149974	C3orf24	0.74	12.66	0.52	2.32e-31	Alzheimer's disease;
LUAD	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg14558114	chr2:88469736	THNSL2	-0.43	-6.8	-0.31	3.54e-11	Response to metformin (IC50);
LUAD	cis	rs6519955	0.860	rs8136098	chr22:46425646	A/G	cg05468064	chr22:46423449	NA	0.51	11.12	0.48	2.34e-25	Dupuytren's disease;
LUAD	cis	rs7779181	0.951	rs6952609	chr7:32343335	A/G	cg27532318	chr7:32358331	NA	0.49	7.85	0.36	3.48e-14	Body mass index;
LUAD	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs654950	0.743	rs115951861	chr1:41992488	C/T	cg06885757	chr1:42089581	HIVEP3	-0.35	-7.36	-0.34	9.93e-13	Airway imaging phenotypes;
LUAD	cis	rs12681287	0.640	rs13251006	chr8:87469105	C/T	cg00550725	chr8:87521180	FAM82B	0.45	6.52	0.3	1.98e-10	Caudate activity during reward;
LUAD	cis	rs6076065	0.802	rs2424527	chr20:23357329	A/C	cg11657817	chr20:23433608	CST11	0.56	11.48	0.49	9.53e-27	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7665090	0.967	rs7690123	chr4:103551759	T/C	cg07973026	chr4:103553119	MANBA	0.48	8.53	0.38	2.63e-16	Primary biliary cholangitis;
LUAD	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg06191203	chr2:152266755	RIF1	-0.63	-10.21	-0.44	4.87e-22	Lung cancer;
LUAD	cis	rs7267979	1.000	rs447722	chr20:25443510	C/T	cg08601574	chr20:25228251	PYGB	0.47	8.7	0.39	7.19e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.23	0.41	1.29e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg06547715	chr2:218990976	CXCR2	0.28	6.57	0.3	1.45e-10	Colorectal cancer;
LUAD	cis	rs10419226	0.541	rs11883401	chr19:18791768	C/G	cg22001208	chr19:18782374	NA	-0.5	-8.46	-0.38	4.43e-16	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs4604732	0.631	rs35046441	chr1:247626812	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg24813613	chr7:1882135	MAD1L1	-0.54	-8.93	-0.4	1.34e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg12179176	chr11:130786555	SNX19	0.74	13.25	0.54	9.43e-34	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg21724239	chr8:58056113	NA	0.81	9.56	0.42	9.92e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7274811	0.711	rs657040	chr20:32001292	A/G	cg14921437	chr20:32255988	NECAB3;C20orf134	0.44	6.75	0.31	4.76e-11	Height;
LUAD	trans	rs2898857	0.524	rs2960172	chr17:47379581	G/A	cg11430096	chr6:110968061	CDK19	0.52	7.68	0.35	1.12e-13	Cancer;
LUAD	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg15017067	chr4:17643749	FAM184B	-0.36	-6.91	-0.32	1.81e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	10.91	0.47	1.34e-24	Hip circumference adjusted for BMI;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg26668828	chr6:292823	DUSP22	-0.79	-13.93	-0.56	1.41e-36	Menopause (age at onset);
LUAD	trans	rs2735413	0.794	rs55951868	chr16:78078804	C/A	cg01028844	chr5:122736986	CEP120	0.43	6.84	0.32	2.84e-11	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg20991723	chr1:152506922	NA	0.34	6.68	0.31	7.5e-11	Plantar warts;
LUAD	cis	rs2294693	0.945	rs932399	chr6:41011266	C/T	cg14769373	chr6:40998127	UNC5CL	-0.49	-7.28	-0.33	1.62e-12	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs2835872	0.759	rs2835900	chr21:39075749	G/T	cg06728970	chr21:39037746	KCNJ6	-0.4	-6.8	-0.31	3.53e-11	Electroencephalographic traits in alcoholism;
LUAD	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg10518543	chr12:38710700	ALG10B	-0.43	-7.04	-0.32	8.01e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg23625390	chr15:77176239	SCAPER	0.37	6.59	0.31	1.33e-10	Blood metabolite levels;
LUAD	cis	rs2275731	0.543	rs10904748	chr10:16520225	A/G	cg04254609	chr10:16479192	PTER	-0.44	-6.86	-0.32	2.47e-11	Bone fracture in osteoporosis;
LUAD	cis	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg02966332	chr20:62369605	LIME1	-0.47	-7.64	-0.35	1.5e-13	Prostate cancer;
LUAD	cis	rs9314323	0.592	rs6981737	chr8:26271100	T/G	cg13160058	chr8:26243215	BNIP3L	-0.36	-7.65	-0.35	1.34e-13	Red cell distribution width;
LUAD	cis	rs1137	1.000	rs205632	chr2:74956316	A/G	cg19285774	chr2:74907978	SEMA4F	-0.39	-7.75	-0.35	7.01e-14	Myopia (pathological);
LUAD	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.64	-8.58	-0.38	1.86e-16	Yeast infection;
LUAD	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.35	-0.41	5.09e-19	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08409687	chr2:201936025	NDUFB3;FAM126B	-0.43	-6.67	-0.31	7.93e-11	Height;
LUAD	cis	rs1965732	0.563	rs13409104	chr2:3718692	C/T	cg10645314	chr2:3704589	ALLC	-0.42	-7.48	-0.34	4.45e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.14	-0.37	4.36e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg11494091	chr17:61959527	GH2	-0.37	-6.48	-0.3	2.57e-10	Height;
LUAD	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg12403142	chr1:92012408	NA	-0.37	-6.81	-0.31	3.37e-11	Breast cancer;
LUAD	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20814179	chr4:940893	TMEM175	0.72	13.31	0.54	5.17e-34	Sjögren's syndrome;
LUAD	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03934478	chr11:495069	RNH1	0.76	8.99	0.4	8.21e-18	Body mass index;
LUAD	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg20628663	chr10:43360327	NA	-0.72	-11.32	-0.48	3.88e-26	Blood protein levels;
LUAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.62	8.68	0.39	8.77e-17	Renal function-related traits (BUN);
LUAD	cis	rs9837602	0.938	rs9828079	chr3:99806645	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-6.86	-0.32	2.5e-11	Breast cancer;
LUAD	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.06	-0.4	4.71e-18	Total body bone mineral density;
LUAD	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	7.86	0.36	3.15e-14	Schizophrenia;
LUAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg10819733	chr22:24237672	NA	-0.38	-7.14	-0.33	4.13e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg03806693	chr22:41940476	POLR3H	0.72	10.0	0.44	2.89e-21	Vitiligo;
LUAD	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	9.44	0.42	2.49e-19	Hip circumference adjusted for BMI;
LUAD	cis	rs7264396	0.561	rs6058387	chr20:34568092	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-6.83	-0.32	2.9e-11	Total cholesterol levels;
LUAD	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg07507251	chr3:52567010	NT5DC2	0.4	7.51	0.34	3.45e-13	Bipolar disorder;
LUAD	cis	rs2797160	0.967	rs80303782	chr6:126004193	C/T	cg05901451	chr6:126070800	HEY2	-0.44	-6.41	-0.3	3.92e-10	Endometrial cancer;
LUAD	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg18932078	chr1:2524107	MMEL1	0.37	6.89	0.32	2e-11	Ulcerative colitis;
LUAD	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.48	-0.34	4.23e-13	Menarche (age at onset);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg13884470	chr9:86595151	HNRNPK;RMI1	-0.39	-6.83	-0.32	3.05e-11	Schizophrenia;
LUAD	cis	rs17092148	0.887	rs6120684	chr20:33179788	A/G	cg16810054	chr20:33298113	TP53INP2	-0.49	-7.49	-0.34	4.06e-13	Neuroticism;
LUAD	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg06640241	chr16:89574553	SPG7	0.67	11.68	0.49	1.62e-27	Multiple myeloma (IgH translocation);
LUAD	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg00634984	chr7:65235879	NA	0.5	6.85	0.32	2.63e-11	Aortic root size;
LUAD	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.59	-0.35	2.07e-13	Monocyte count;
LUAD	cis	rs13315871	1.000	rs4362735	chr3:58429893	C/G	cg12435725	chr3:58293450	RPP14	-0.67	-7.58	-0.35	2.27e-13	Cholesterol, total;
LUAD	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.63	0.31	1.04e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3739034	0.877	rs78877892	chr2:135516504	A/G	cg12500956	chr2:135428796	TMEM163	0.39	6.99	0.32	1.1e-11	Gut microbiome composition (winter);
LUAD	cis	rs6601450	0.579	rs11775625	chr8:10272439	C/T	cg27411982	chr8:10470053	RP1L1	0.34	6.47	0.3	2.66e-10	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7937890	0.559	rs2575830	chr11:14485602	C/A	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.18e-12	Mitochondrial DNA levels;
LUAD	cis	rs9837602	0.938	rs9873709	chr3:99711687	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.58	8.82	0.39	3.09e-17	Breast cancer;
LUAD	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg06608945	chr2:219082296	ARPC2	-0.45	-7.47	-0.34	4.68e-13	Colorectal cancer;
LUAD	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.67	0.39	9.19e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9796	0.866	rs66818965	chr15:41402279	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.38	-7.07	-0.33	6.29e-12	Menopause (age at onset);
LUAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg22535103	chr8:58192502	C8orf71	-0.65	-7.06	-0.32	6.85e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs3784262	0.669	rs4646623	chr15:58257123	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.62	-0.35	1.74e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg17849569	chr6:28058911	ZSCAN12L1	0.31	6.97	0.32	1.24e-11	Parkinson's disease;
LUAD	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	8.06	0.36	7.97e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs3935685	0.874	rs11072662	chr15:77999436	A/G	cg25212270	chr15:78015279	NA	0.33	7.38	0.34	8.35e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs55823223	0.564	rs2034947	chr17:73863929	T/C	cg08125733	chr17:73851984	WBP2	0.57	8.36	0.38	9.02e-16	Psoriasis;
LUAD	cis	rs2629540	0.793	rs10794180	chr10:126449306	T/A	cg08799069	chr10:126477246	METTL10	-0.49	-7.26	-0.33	1.9e-12	Cocaine dependence;
LUAD	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg13012494	chr21:47604986	C21orf56	0.46	7.64	0.35	1.48e-13	Testicular germ cell tumor;
LUAD	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.33	7.07	0.33	6.3e-12	Cardiac Troponin-T levels;
LUAD	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.63	0.42	5.44e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.69	-11.77	-0.5	7.69e-28	Mean corpuscular volume;
LUAD	cis	rs4372836	0.964	rs2293553	chr2:28932284	C/T	cg09522027	chr2:28974177	PPP1CB	0.6	9.03	0.4	6.32e-18	Body mass index;
LUAD	cis	rs76878669	0.561	rs10791872	chr11:66138434	C/G	cg18002602	chr11:66138449	SLC29A2	-0.49	-10.64	-0.46	1.39e-23	Educational attainment (years of education);
LUAD	cis	rs2294693	0.891	rs9369256	chr6:40998344	G/C	cg14769373	chr6:40998127	UNC5CL	-0.54	-8.21	-0.37	2.68e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	trans	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg26043149	chr18:55253948	FECH	-0.48	-8.09	-0.37	6.57e-15	Bone mineral density;
LUAD	cis	rs4845570	0.920	rs10788809	chr1:151760792	A/G	cg07092448	chr1:151763213	TDRKH	0.75	8.56	0.38	2.18e-16	Coronary artery disease;
LUAD	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg10518543	chr12:38710700	ALG10B	-0.43	-7.04	-0.32	7.86e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10193935	0.901	rs17029411	chr2:42479149	G/A	cg27598129	chr2:42591480	NA	-0.73	-9.26	-0.41	1.01e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6554196	0.508	rs3819386	chr4:55527374	T/C	cg18836493	chr4:55524333	KIT	-0.39	-7.31	-0.33	1.35e-12	Monocyte count;
LUAD	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg20307385	chr11:47447363	PSMC3	0.53	7.95	0.36	1.69e-14	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.37	6.38	0.3	4.65e-10	Depression;
LUAD	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg14582100	chr15:45693742	SPATA5L1	0.37	7.46	0.34	4.8e-13	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18876405	chr7:65276391	NA	-0.4	-6.39	-0.3	4.35e-10	Aortic root size;
LUAD	cis	rs1847202	1.000	rs1847202	chr3:72934371	T/C	cg25664220	chr3:72788482	NA	-0.46	-8.2	-0.37	2.82e-15	Motion sickness;
LUAD	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7189233	0.955	rs8044205	chr16:53515093	T/C	cg04059762	chr16:53544020	NA	-0.41	-6.55	-0.3	1.65e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg22852734	chr6:133119734	C6orf192	0.79	9.98	0.44	3.43e-21	Type 2 diabetes nephropathy;
LUAD	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg00383909	chr3:49044727	WDR6	0.99	10.63	0.46	1.45e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11890956	chr21:40555474	PSMG1	-0.68	-11.94	-0.5	1.6e-28	Cognitive function;
LUAD	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg05887092	chr17:76393375	PGS1	0.55	11.08	0.47	3.16e-25	HDL cholesterol levels;
LUAD	cis	rs2992756	0.663	rs2992757	chr1:18807137	T/C	cg24076588	chr1:18808559	KLHDC7A	-0.46	-7.66	-0.35	1.29e-13	Breast cancer;
LUAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.745	rs4997809	chr2:10755542	G/A	cg03983476	chr2:10830698	NOL10	-0.45	-7.82	-0.36	4.17e-14	Prostate cancer;
LUAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg02869364	chr7:1081709	C7orf50	-0.5	-6.55	-0.3	1.65e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.94	0.4	1.25e-17	Childhood ear infection;
LUAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.72	13.99	0.56	7.97e-37	Prudent dietary pattern;
LUAD	cis	rs4144027	0.791	rs67727470	chr14:104361996	A/G	cg12183467	chr14:104352244	NA	0.35	6.74	0.31	5.07e-11	Blood metabolite levels;
LUAD	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg08422745	chr4:174089978	GALNT7	0.95	16.42	0.62	3.14e-47	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	trans	rs1406428	0.573	rs12613632	chr2:51705755	C/G	cg02132458	chr4:57333267	SRP72	0.48	7.0	0.32	9.89e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4148087	1.000	rs1117640	chr21:43625274	T/G	cg08841829	chr21:43638893	ABCG1	-0.58	-7.64	-0.35	1.46e-13	Eating disorder in bipolar disorder;
LUAD	cis	rs6701037	0.522	rs12094153	chr1:175094025	G/A	cg00321850	chr1:175162397	KIAA0040	-0.36	-7.24	-0.33	2.08e-12	Alcohol dependence;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg15383120	chr6:291909	DUSP22	-0.72	-12.02	-0.5	8.1e-29	Menopause (age at onset);
LUAD	trans	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg07817883	chr1:32538562	TMEM39B	1.17	12.18	0.51	1.83e-29	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg05234568	chr11:5960015	NA	-0.57	-10.13	-0.44	1.01e-21	DNA methylation (variation);
LUAD	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2235649	0.833	rs9929264	chr16:1851934	T/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.41	-6.46	-0.3	2.85e-10	Blood metabolite levels;
LUAD	cis	rs8014204	0.804	rs7154845	chr14:75247746	A/G	cg06637938	chr14:75390232	RPS6KL1	0.37	6.82	0.31	3.15e-11	Caffeine consumption;
LUAD	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg07607921	chr17:4047574	ZZEF1;CYB5D2	-0.45	-8.13	-0.37	4.8e-15	Type 2 diabetes;
LUAD	cis	rs9863	0.896	rs77112003	chr12:124487543	C/T	cg17723958	chr12:124429295	CCDC92	-0.42	-6.66	-0.31	8.44e-11	White blood cell count;
LUAD	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg08859206	chr1:53392774	SCP2	-0.58	-10.52	-0.46	3.75e-23	Monocyte count;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg02560808	chr16:70835289	VAC14	0.37	6.44	0.3	3.24e-10	Bipolar disorder;
LUAD	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg01579765	chr21:45077557	HSF2BP	-0.63	-14.67	-0.58	1.09e-39	Mean corpuscular volume;
LUAD	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg20891283	chr12:69753455	YEATS4	0.45	7.28	0.33	1.68e-12	Blood protein levels;
LUAD	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg04703951	chr17:43578652	NA	-0.56	-8.14	-0.37	4.38e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg26566898	chr11:117069891	TAGLN	0.36	6.89	0.32	2.01e-11	Blood protein levels;
LUAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08280861	chr8:58055591	NA	0.63	8.17	0.37	3.53e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs12760731	0.565	rs11583503	chr1:178169663	G/C	cg00404053	chr1:178313656	RASAL2	0.73	9.14	0.41	2.66e-18	Obesity-related traits;
LUAD	cis	rs35883536	1.000	rs2297715	chr1:101092594	A/G	cg06223162	chr1:101003688	GPR88	0.34	6.44	0.3	3.31e-10	Monocyte count;
LUAD	cis	rs17095355	1.000	rs55781439	chr10:111670220	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.71	-9.66	-0.43	4.45e-20	Biliary atresia;
LUAD	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg25985355	chr7:65971099	NA	-0.53	-6.65	-0.31	9.22e-11	Diabetic kidney disease;
LUAD	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg16479474	chr6:28041457	NA	0.35	6.56	0.3	1.53e-10	Cardiac Troponin-T levels;
LUAD	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg15181151	chr6:150070149	PCMT1	0.34	6.66	0.31	8.8e-11	Lung cancer;
LUAD	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg18105134	chr13:113819100	PROZ	-0.8	-14.03	-0.56	5.28e-37	Platelet distribution width;
LUAD	cis	rs9837602	1.000	rs1021103	chr3:99603230	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-7.14	-0.33	4e-12	Breast cancer;
LUAD	trans	rs1728785	1.000	rs1728792	chr16:68596534	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.34	0.45	1.73e-22	Ulcerative colitis;
LUAD	trans	rs9393777	0.920	rs13196692	chr6:27379119	C/T	cg01620082	chr3:125678407	NA	-0.93	-9.34	-0.41	5.4e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs494562	0.892	rs547963	chr6:86118743	T/C	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg18932078	chr1:2524107	MMEL1	0.38	7.06	0.32	6.67e-12	Ulcerative colitis;
LUAD	cis	rs4566648	0.596	rs6841864	chr4:84194038	G/T	cg24939380	chr4:84189574	COQ2	0.4	6.48	0.3	2.53e-10	Monocyte count;
LUAD	cis	rs2282300	0.653	rs12800124	chr11:30239865	A/G	cg06241208	chr11:30344200	C11orf46	-0.59	-7.62	-0.35	1.69e-13	Morning vs. evening chronotype;
LUAD	cis	rs17401966	0.898	rs1396	chr1:10247143	C/A	cg15208524	chr1:10270712	KIF1B	0.53	7.71	0.35	8.81e-14	Hepatocellular carcinoma;
LUAD	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7927592	0.546	rs554734	chr11:68192518	T/G	cg16797656	chr11:68205561	LRP5	0.5	10.18	0.44	6.19e-22	Total body bone mineral density;
LUAD	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg24818145	chr4:99064322	C4orf37	0.43	7.18	0.33	3.22e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg12927641	chr6:109611667	NA	-0.52	-9.3	-0.41	7.77e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-9.04	-0.4	5.67e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7301826	0.571	rs4759788	chr12:131296314	T/C	cg11011512	chr12:131303247	STX2	0.43	7.3	0.33	1.47e-12	Plasma plasminogen activator levels;
LUAD	cis	rs17818399	0.888	rs2346419	chr2:46845069	G/C	cg09399716	chr2:46890238	NA	-0.43	-8.54	-0.38	2.38e-16	Height;
LUAD	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.53e-11	Depression;
LUAD	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg25036284	chr2:26402008	FAM59B	0.84	11.63	0.49	2.59e-27	Gut microbiome composition (summer);
LUAD	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg17410650	chr12:54324560	NA	0.55	11.03	0.47	4.77e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08677398	chr8:58056175	NA	0.43	7.59	0.35	2.03e-13	Developmental language disorder (linguistic errors);
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08811588	chr7:100473311	SRRT	0.51	6.59	0.31	1.29e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg17330251	chr7:94953956	PON1	-0.53	-7.1	-0.33	5.36e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg21204522	chr6:27730016	NA	-0.47	-7.48	-0.34	4.41e-13	Parkinson's disease;
LUAD	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg19163074	chr7:65112434	INTS4L2	0.44	6.66	0.31	8.78e-11	Aortic root size;
LUAD	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg11214544	chr1:2391121	NA	-0.4	-8.34	-0.38	1.07e-15	Schizophrenia;
LUAD	cis	rs11098699	0.821	rs11935129	chr4:124207106	T/A	cg09941581	chr4:124220074	SPATA5	0.5	7.94	0.36	1.83e-14	Mosquito bite size;
LUAD	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	25.68	0.78	2.38e-88	Chronic sinus infection;
LUAD	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg00933542	chr6:150070202	PCMT1	0.45	9.64	0.42	5.2e-20	Lung cancer;
LUAD	cis	rs12216545	0.711	rs2090955	chr7:150235486	A/G	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.55	-0.3	1.69e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg05340658	chr4:99064831	C4orf37	0.53	9.06	0.4	4.81e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4006360	0.610	rs4986661	chr17:39250448	C/G	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.3	0.37	1.43e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg22676075	chr6:135203613	NA	0.5	8.86	0.4	2.21e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg08601574	chr20:25228251	PYGB	0.47	8.89	0.4	1.77e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg15309053	chr8:964076	NA	0.38	8.3	0.37	1.4e-15	Schizophrenia;
LUAD	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	9.58	0.42	8.07e-20	Colorectal cancer;
LUAD	cis	rs9399401	0.667	rs6922607	chr6:142703483	A/G	cg04461802	chr6:142623433	GPR126	0.44	8.48	0.38	3.83e-16	Chronic obstructive pulmonary disease;
LUAD	cis	rs2692947	0.644	rs1168975	chr2:96814075	G/A	cg23100626	chr2:96804247	ASTL	0.38	9.77	0.43	1.82e-20	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	trans	rs7746199	0.611	rs17750747	chr6:27730334	T/C	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.05	-0.44	1.91e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg15790184	chr11:494944	RNH1	0.4	6.64	0.31	9.66e-11	Systemic lupus erythematosus;
LUAD	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.56	8.27	0.37	1.78e-15	Platelet count;
LUAD	cis	rs67981189	0.593	rs4132848	chr14:71459359	A/T	cg15332261	chr14:71375349	PCNX	-0.39	-6.39	-0.3	4.3e-10	Schizophrenia;
LUAD	cis	rs41271951	0.512	rs114222784	chr1:151084781	C/T	cg11822372	chr1:151115635	SEMA6C	-0.82	-6.99	-0.32	1.05e-11	Blood protein levels;
LUAD	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg08027265	chr7:2291960	NA	-0.41	-6.87	-0.32	2.32e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.92	-0.32	1.72e-11	Fear of minor pain;
LUAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.95	-0.4	1.15e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg09455208	chr3:40491958	NA	0.51	10.9	0.47	1.5e-24	Renal cell carcinoma;
LUAD	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg20628663	chr10:43360327	NA	-0.75	-11.53	-0.49	5.96e-27	Blood protein levels;
LUAD	cis	rs758324	0.947	rs1566427	chr5:131191672	G/A	cg06307176	chr5:131281290	NA	0.5	7.95	0.36	1.76e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.22	-0.33	2.39e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.47	7.45	0.34	5.24e-13	Alzheimer's disease (late onset);
LUAD	cis	rs11229555	1.000	rs2275993	chr11:58379987	A/G	cg15696309	chr11:58395628	NA	-0.73	-10.98	-0.47	7.29e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg04398451	chr17:18023971	MYO15A	0.75	13.65	0.55	2.1e-35	Total body bone mineral density;
LUAD	cis	rs2213920	0.516	rs71505548	chr9:118169753	G/A	cg13918206	chr9:118159781	DEC1	-0.57	-6.51	-0.3	2.07e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LUAD	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	6.99	0.32	1.06e-11	Motion sickness;
LUAD	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg09904177	chr6:26538194	HMGN4	0.43	7.21	0.33	2.52e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg19610905	chr11:61596333	FADS2	-0.65	-11.03	-0.47	4.88e-25	Trans fatty acid levels;
LUAD	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg26677194	chr12:130822605	PIWIL1	0.55	8.95	0.4	1.15e-17	Menopause (age at onset);
LUAD	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.83	0.39	2.86e-17	Parkinson's disease;
LUAD	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg23649088	chr2:200775458	C2orf69	0.62	7.77	0.35	6.15e-14	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg25985355	chr7:65971099	NA	-0.51	-6.37	-0.3	4.89e-10	Diabetic kidney disease;
LUAD	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg25985355	chr7:65971099	NA	-0.56	-6.91	-0.32	1.79e-11	Gout;
LUAD	cis	rs2835872	0.758	rs1709835	chr21:39037636	A/G	cg06728970	chr21:39037746	KCNJ6	0.4	7.68	0.35	1.09e-13	Electroencephalographic traits in alcoholism;
LUAD	cis	rs4849845	0.678	rs3896632	chr2:121023496	C/T	cg24070213	chr2:121070622	NA	0.39	7.46	0.34	5.02e-13	Mean platelet volume;
LUAD	cis	rs72928364	1.000	rs62277105	chr3:100601089	T/C	cg10123952	chr3:100791384	NA	0.6	6.7	0.31	6.78e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg02176678	chr2:219576539	TTLL4	0.62	12.15	0.51	2.35e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg07936489	chr17:37558343	FBXL20	-0.52	-7.02	-0.32	8.84e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg06640241	chr16:89574553	SPG7	0.5	8.1	0.37	6.1e-15	Multiple myeloma (IgH translocation);
LUAD	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg05340658	chr4:99064831	C4orf37	0.54	9.15	0.41	2.47e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg07741184	chr6:167504864	NA	0.41	9.5	0.42	1.62e-19	Primary biliary cholangitis;
LUAD	cis	rs4273100	1.000	rs16960499	chr17:19203032	A/G	cg03711562	chr17:18936298	GRAP	-0.42	-8.06	-0.36	8.15e-15	Schizophrenia;
LUAD	trans	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg21659725	chr3:3221576	CRBN	-0.57	-9.17	-0.41	2.14e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg03526776	chr6:41159608	TREML2	0.33	6.85	0.32	2.67e-11	Alzheimer's disease (late onset);
LUAD	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.68	-0.39	8.73e-17	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg17366294	chr4:99064904	C4orf37	0.58	9.97	0.44	3.6e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg26408565	chr15:76604113	ETFA	-0.44	-6.97	-0.32	1.2e-11	Blood metabolite levels;
LUAD	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg17063962	chr7:91808500	NA	0.73	13.2	0.54	1.49e-33	Breast cancer;
LUAD	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg25173405	chr17:45401733	C17orf57	-0.48	-8.21	-0.37	2.72e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs8073060	0.586	rs72829927	chr17:34049992	A/G	cg19694781	chr19:47549865	TMEM160	1.2	18.62	0.67	6e-57	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7828089	0.935	rs896375	chr8:22262098	A/G	cg12081754	chr8:22256438	SLC39A14	0.55	9.66	0.42	4.56e-20	Verbal declarative memory;
LUAD	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg06387496	chr7:2775674	GNA12	-0.39	-6.51	-0.3	2.15e-10	Height;
LUAD	cis	rs7793919	0.764	rs6944865	chr7:4766383	A/T	cg09789173	chr7:4769017	FOXK1	0.77	16.38	0.62	4.71e-47	Mosquito bite size;
LUAD	cis	rs9902453	0.845	rs58575982	chr17:28221776	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.34	0.41	5.55e-19	Coffee consumption (cups per day);
LUAD	cis	rs3733418	0.929	rs7656863	chr4:165883244	T/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.55	-7.16	-0.33	3.69e-12	Obesity-related traits;
LUAD	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg18240062	chr17:79603768	NPLOC4	0.44	7.56	0.34	2.54e-13	Eye color traits;
LUAD	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg03806693	chr22:41940476	POLR3H	0.47	7.15	0.33	3.92e-12	Vitiligo;
LUAD	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg26597838	chr10:835615	NA	0.85	13.28	0.54	7.25e-34	Eosinophil percentage of granulocytes;
LUAD	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg02574844	chr11:5959923	NA	-0.39	-6.68	-0.31	7.4e-11	DNA methylation (variation);
LUAD	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg09904177	chr6:26538194	HMGN4	0.43	7.31	0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10193935	0.901	rs2088281	chr2:42672731	A/G	cg27598129	chr2:42591480	NA	0.74	9.34	0.41	5.73e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg13698153	chr12:118541722	VSIG10	-0.43	-6.55	-0.3	1.72e-10	Vitiligo;
LUAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.54	-8.7	-0.39	7.27e-17	Longevity;Endometriosis;
LUAD	trans	rs9354308	0.868	rs9363456	chr6:66548343	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.87	-0.32	2.3e-11	Metabolite levels;
LUAD	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg14558114	chr2:88469736	THNSL2	0.86	9.25	0.41	1.11e-18	Plasma clusterin levels;
LUAD	cis	rs9807989	0.811	rs11688568	chr2:102969949	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.03e-10	Asthma;
LUAD	cis	rs977987	0.898	rs12918797	chr16:75493810	T/C	cg03315344	chr16:75512273	CHST6	0.66	14.99	0.59	4.83e-41	Dupuytren's disease;
LUAD	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg23954153	chr1:44402353	ARTN	-0.34	-6.73	-0.31	5.62e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7586879	0.828	rs11685125	chr2:25092104	A/G	cg04586622	chr2:25135609	ADCY3	0.35	7.06	0.32	6.74e-12	Body mass index;
LUAD	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg11663144	chr21:46675770	NA	-0.62	-12.47	-0.52	1.34e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg13397359	chr6:42928475	GNMT	0.59	11.2	0.48	1.15e-25	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg24634471	chr8:143751801	JRK	0.48	7.75	0.35	7.1e-14	Schizophrenia;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg26778477	chr19:46295880	DMWD	0.35	6.38	0.3	4.54e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	trans	rs3960554	0.808	rs61303167	chr7:75671175	G/T	cg19862616	chr7:65841803	NCRNA00174	0.82	11.2	0.48	1.15e-25	Eotaxin levels;
LUAD	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.06	-0.32	6.83e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs1595825	0.891	rs7573687	chr2:198893376	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-7.05	-0.32	7.36e-12	Ulcerative colitis;
LUAD	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg19318889	chr4:1322082	MAEA	0.47	7.78	0.35	5.69e-14	Obesity-related traits;
LUAD	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg24558204	chr6:135376177	HBS1L	0.48	8.84	0.39	2.68e-17	Red blood cell count;
LUAD	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg03806693	chr22:41940476	POLR3H	-0.57	-8.4	-0.38	6.62e-16	Vitiligo;
LUAD	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg01191920	chr7:158217561	PTPRN2	0.65	13.74	0.56	8.84e-36	Obesity-related traits;
LUAD	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg15445000	chr17:37608096	MED1	0.44	7.98	0.36	1.38e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs2046867	0.908	rs62251634	chr3:72788705	A/C	cg25664220	chr3:72788482	NA	-0.69	-12.37	-0.52	3.14e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg12588279	chr6:26043732	HIST1H2BB	-0.36	-6.57	-0.3	1.52e-10	Blood metabolite levels;
LUAD	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg21191810	chr6:118973309	C6orf204	-0.53	-8.04	-0.36	9.38e-15	Diastolic blood pressure;
LUAD	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-19.99	-0.7	4.57e-63	Height;
LUAD	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg04034577	chr2:241836375	C2orf54	-0.46	-10.09	-0.44	1.39e-21	Urinary metabolites;
LUAD	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11890956	chr21:40555474	PSMG1	0.78	13.49	0.55	9.29e-35	Cognitive function;
LUAD	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg00277334	chr10:82204260	NA	0.63	10.1	0.44	1.24e-21	Post bronchodilator FEV1;
LUAD	cis	rs6743376	0.556	rs2515394	chr2:113817765	C/T	cg09040174	chr2:113837401	NA	0.52	8.04	0.36	9.12e-15	Inflammatory biomarkers;
LUAD	trans	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05039488	chr6:79577232	IRAK1BP1	0.53	8.71	0.39	6.86e-17	Endometrial cancer;
LUAD	cis	rs9972944	0.702	rs987929	chr17:63765856	A/G	cg07283582	chr17:63770753	CCDC46	-0.5	-11.18	-0.48	1.28e-25	Total body bone mineral density;
LUAD	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	6.77	0.31	4.41e-11	Rheumatoid arthritis;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13521538	chr9:38392470	ALDH1B1	-0.39	-6.5	-0.3	2.23e-10	Cancer;
LUAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.8	14.81	0.58	2.82e-40	Lymphocyte counts;
LUAD	cis	rs9487051	0.768	rs1269172	chr6:109522080	G/C	cg21918786	chr6:109611834	NA	-0.41	-7.23	-0.33	2.33e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs7614311	0.636	rs3821902	chr3:63941697	T/G	cg22134162	chr3:63841271	THOC7	-0.51	-8.47	-0.38	4.21e-16	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.59	-0.3	1.34e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs11771526	0.792	rs17161104	chr7:32298582	C/T	cg27511599	chr7:32358540	NA	0.52	6.68	0.31	7.74e-11	Body mass index;
LUAD	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.55	-0.46	3.01e-23	Schizophrenia;
LUAD	cis	rs9837602	0.576	rs506186	chr3:99442753	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	6.85	0.32	2.56e-11	Breast cancer;
LUAD	cis	rs12760731	0.920	rs12076608	chr1:178487861	C/G	cg00404053	chr1:178313656	RASAL2	0.54	6.46	0.3	2.84e-10	Obesity-related traits;
LUAD	cis	rs2235573	0.517	rs4821727	chr22:38393423	C/A	cg14039649	chr22:38352398	POLR2F	0.35	6.42	0.3	3.74e-10	Glioblastoma;Glioma;
LUAD	cis	rs7586879	1.000	rs6736711	chr2:25116456	C/T	cg04586622	chr2:25135609	ADCY3	0.34	7.37	0.34	9.31e-13	Body mass index;
LUAD	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg21194808	chr1:2205498	SKI	0.4	6.42	0.3	3.77e-10	Height;
LUAD	cis	rs73206853	0.841	rs73191840	chr12:110970457	A/G	cg12870014	chr12:110450643	ANKRD13A	0.6	6.78	0.31	4.14e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02463440	chr8:22132932	PIWIL2	0.57	10.18	0.44	6.38e-22	Hypertriglyceridemia;
LUAD	cis	rs938554	0.955	rs938564	chr4:9922573	T/G	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.37	-0.38	8.57e-16	Blood metabolite levels;
LUAD	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg12193833	chr17:30244370	NA	-0.55	-7.14	-0.33	4.2e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs4072705	0.646	rs7037254	chr9:127245412	C/T	cg13476313	chr9:127244764	NR5A1	-0.37	-9.25	-0.41	1.14e-18	Menarche (age at onset);
LUAD	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg00666640	chr1:248458726	OR2T12	0.32	7.72	0.35	8.74e-14	Common traits (Other);
LUAD	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg21427119	chr20:30132790	HM13	-0.48	-7.64	-0.35	1.43e-13	Mean corpuscular hemoglobin;
LUAD	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg18944383	chr4:111397179	ENPEP	0.39	7.58	0.35	2.28e-13	Height;
LUAD	cis	rs1062746	0.771	rs9308348	chr16:87371941	G/A	cg02258303	chr16:87377426	FBXO31	-0.43	-7.54	-0.34	2.84e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.01	0.32	9.46e-12	Motion sickness;
LUAD	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg03609598	chr5:56110824	MAP3K1	0.5	7.42	0.34	6.53e-13	Initial pursuit acceleration;
LUAD	cis	rs7017914	0.967	rs6991329	chr8:71593425	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.64	-0.31	9.89e-11	Bone mineral density;
LUAD	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg07741184	chr6:167504864	NA	0.31	7.35	0.34	1.04e-12	Crohn's disease;
LUAD	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg05368731	chr17:41323189	NBR1	0.97	20.25	0.7	3.08e-64	Menopause (age at onset);
LUAD	cis	rs10193935	0.901	rs13393459	chr2:42463124	C/T	cg27598129	chr2:42591480	NA	-0.79	-9.56	-0.42	9.55e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6062509	1.000	rs6062509	chr20:62362563	G/T	cg02966332	chr20:62369605	LIME1	-0.48	-7.66	-0.35	1.31e-13	Prostate cancer;
LUAD	trans	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg14917512	chr19:3094685	GNA11	-0.56	-6.66	-0.31	8.45e-11	Diabetic kidney disease;
LUAD	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.74	-0.35	7.24e-14	Body mass index;
LUAD	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.31	0.33	1.35e-12	Tonsillectomy;
LUAD	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg25664220	chr3:72788482	NA	-0.66	-11.58	-0.49	4.12e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg08738300	chr3:44038990	NA	0.42	6.4	0.3	4.23e-10	Coronary artery disease;
LUAD	cis	rs1032833	0.732	rs78804597	chr2:180119259	C/T	cg23883738	chr2:179974586	SESTD1	-0.74	-7.7	-0.35	9.57e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg05616858	chr17:37843591	ERBB2;PGAP3	0.33	7.01	0.32	9.67e-12	Asthma;
LUAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.41	-0.38	6.27e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg20290983	chr6:43655470	MRPS18A	-0.79	-16.07	-0.62	1.01e-45	IgG glycosylation;
LUAD	cis	rs62458065	1.000	rs10250808	chr7:32466153	T/C	cg20159608	chr7:32802032	NA	-0.47	-6.74	-0.31	5.13e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.27	-7.05	-0.32	7.3e-12	Total body bone mineral density;
LUAD	trans	rs4332037	0.523	rs11770148	chr7:1899447	A/G	cg11693508	chr17:37793320	STARD3	0.78	9.78	0.43	1.65e-20	Bipolar disorder;
LUAD	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg20891283	chr12:69753455	YEATS4	0.45	7.41	0.34	6.82e-13	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg26538116	chr2:44223328	LRPPRC	-0.38	-6.58	-0.3	1.41e-10	Subcortical brain region volumes;
LUAD	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg09035930	chr12:129282057	SLC15A4	0.75	17.5	0.65	5.86e-52	Systemic lupus erythematosus;
LUAD	cis	rs6489882	0.671	rs4767025	chr12:113358794	C/T	cg20102336	chr12:113376681	OAS3	-0.54	-8.22	-0.37	2.58e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs5167	0.750	rs3786505	chr19:45490570	A/G	cg09555818	chr19:45449301	APOC2	0.38	7.32	0.34	1.28e-12	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4072705	0.967	rs7020358	chr9:127482471	C/T	cg13476313	chr9:127244764	NR5A1	0.3	7.39	0.34	7.81e-13	Menarche (age at onset);
LUAD	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg08859206	chr1:53392774	SCP2	0.6	11.22	0.48	9.75e-26	Monocyte count;
LUAD	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11644478	chr21:40555479	PSMG1	-0.57	-9.45	-0.42	2.35e-19	Cognitive function;
LUAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg05896524	chr21:47604654	C21orf56	0.76	13.39	0.55	2.58e-34	Testicular germ cell tumor;
LUAD	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg17551891	chr7:1960795	MAD1L1	-0.45	-7.86	-0.36	3.24e-14	Bipolar disorder;
LUAD	cis	rs7000551	0.751	rs896379	chr8:22374200	C/T	cg12081754	chr8:22256438	SLC39A14	0.46	7.75	0.35	6.85e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9341808	1.000	rs1359239	chr6:80956146	G/A	cg08355045	chr6:80787529	NA	0.55	10.29	0.45	2.62e-22	Sitting height ratio;
LUAD	cis	rs317865	0.737	rs73234644	chr4:16190661	T/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.87	8.44	0.38	4.99e-16	Kidney disease (early stage) in type 1 diabetes;
LUAD	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03517284	chr6:25882590	NA	-0.53	-7.54	-0.34	2.9e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs11771526	0.901	rs17161086	chr7:32294254	A/G	cg27532318	chr7:32358331	NA	-0.58	-7.43	-0.34	6.22e-13	Body mass index;
LUAD	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	6.42	0.3	3.69e-10	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg05042697	chr2:10830656	NOL10	-0.37	-6.38	-0.3	4.66e-10	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.67	-10.96	-0.47	9.06e-25	Primary sclerosing cholangitis;
LUAD	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg03714773	chr7:91764589	CYP51A1	0.29	6.75	0.31	4.74e-11	Breast cancer;
LUAD	cis	rs1564271	0.553	rs2489583	chr10:26987698	A/G	cg13837822	chr10:26931731	LOC731789	0.49	10.38	0.45	1.26e-22	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06873352	chr17:61820015	STRADA	0.81	17.88	0.66	1.11e-53	Prudent dietary pattern;
LUAD	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.59	11.24	0.48	8.23e-26	Hemoglobin concentration;
LUAD	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg13393036	chr8:95962371	TP53INP1	0.38	8.19	0.37	3.07e-15	Type 2 diabetes;
LUAD	trans	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg18335740	chr13:41363409	SLC25A15	0.55	9.75	0.43	2.09e-20	Lewy body disease;
LUAD	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg10755058	chr3:40428713	ENTPD3	-0.44	-8.28	-0.37	1.61e-15	Renal cell carcinoma;
LUAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg21280719	chr6:42927975	GNMT	-0.39	-12.28	-0.51	7.71e-30	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1461503	0.868	rs10790543	chr11:122838311	A/C	cg27398637	chr11:122830231	C11orf63	-0.36	-7.01	-0.32	9.34e-12	Menarche (age at onset);
LUAD	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg00933542	chr6:150070202	PCMT1	0.43	9.19	0.41	1.84e-18	Lung cancer;
LUAD	cis	rs34638657	0.732	rs62045963	chr16:82200661	A/G	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.95	-0.32	1.43e-11	Lung adenocarcinoma;
LUAD	trans	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg04995722	chr7:26192034	NFE2L3	0.43	7.49	0.34	4.1e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.25	0.41	1.16e-18	Alzheimer's disease;
LUAD	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg25036284	chr2:26402008	FAM59B	-0.81	-11.7	-0.49	1.37e-27	Gut microbiome composition (summer);
LUAD	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg26818010	chr10:134567672	INPP5A	-0.87	-14.89	-0.59	1.22e-40	Migraine;
LUAD	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg22961513	chr11:14280813	SPON1	0.41	8.36	0.38	9.03e-16	Mitochondrial DNA levels;
LUAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg16606324	chr3:10149918	C3orf24	0.65	10.83	0.47	2.71e-24	Alzheimer's disease;
LUAD	cis	rs35883536	0.588	rs955337	chr1:101108834	A/T	cg06223162	chr1:101003688	GPR88	0.39	7.15	0.33	3.81e-12	Monocyte count;
LUAD	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg05639522	chr1:247681581	NA	0.34	6.44	0.3	3.35e-10	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg00071950	chr4:10020882	SLC2A9	0.73	14.44	0.57	1.04e-38	Bone mineral density;
LUAD	cis	rs4077468	0.927	rs1342063	chr1:205912859	C/T	cg26354017	chr1:205819088	PM20D1	-0.36	-6.51	-0.3	2.17e-10	Cystic fibrosis-related diabetes;
LUAD	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg24399712	chr22:39784796	NA	-0.82	-15.9	-0.61	5.94e-45	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg00634984	chr7:65235879	NA	0.46	7.55	0.34	2.63e-13	Calcium levels;
LUAD	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.02	-0.36	1.06e-14	Menopause (age at onset);
LUAD	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.54	-0.34	2.81e-13	Total cholesterol levels;
LUAD	cis	rs2455601	0.573	rs2653573	chr11:8989874	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-7.58	-0.35	2.18e-13	Schizophrenia;
LUAD	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg16479474	chr6:28041457	NA	0.36	6.39	0.3	4.36e-10	Parkinson's disease;
LUAD	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg15839431	chr19:19639596	YJEFN3	0.53	7.71	0.35	8.98e-14	Bipolar disorder;
LUAD	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg12573674	chr2:1569213	NA	0.63	7.32	0.34	1.23e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg01200585	chr1:228362443	C1orf69	-0.41	-7.62	-0.35	1.67e-13	Diastolic blood pressure;
LUAD	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg15448220	chr1:150897856	SETDB1	0.46	7.99	0.36	1.29e-14	Tonsillectomy;
LUAD	cis	rs4843185	0.731	rs3815795	chr16:85712105	A/G	cg26571870	chr16:85723150	GINS2	0.37	7.44	0.34	5.74e-13	Platelet distribution width;
LUAD	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg24450063	chr1:156163899	SLC25A44	1.14	22.43	0.74	5.55e-74	Testicular germ cell tumor;
LUAD	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg25452165	chr22:42524984	CYP2D6	-0.38	-6.45	-0.3	3.01e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs909341	0.710	rs2297433	chr20:62293460	T/C	cg04115418	chr20:62273971	STMN3	-0.34	-6.36	-0.3	5.32e-10	Atopic dermatitis;
LUAD	cis	rs636291	0.517	rs672606	chr1:10526144	G/A	cg17425144	chr1:10567563	PEX14	0.56	11.08	0.47	3.28e-25	Prostate cancer;
LUAD	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg16049864	chr8:95962084	TP53INP1	-0.56	-12.07	-0.51	4.88e-29	Type 2 diabetes;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg20962211	chr2:183580829	DNAJC10	-0.43	-7.69	-0.35	1.01e-13	Schizophrenia;
LUAD	cis	rs4889855	0.530	rs8080678	chr17:78544003	G/T	cg16591659	chr17:78472290	NA	0.39	6.91	0.32	1.82e-11	Fractional excretion of uric acid;
LUAD	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg18436788	chr1:3704244	LRRC47	0.31	6.39	0.3	4.44e-10	Red cell distribution width;
LUAD	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg05342682	chr7:94953680	PON1	-0.5	-7.01	-0.32	9.28e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7474896	0.583	rs10764144	chr10:37975732	G/C	cg25427524	chr10:38739819	LOC399744	-0.61	-9.03	-0.4	6.3e-18	Obesity (extreme);
LUAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.61	-0.31	1.16e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6500395	1.000	rs12599744	chr16:48716729	G/A	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4523957	0.890	rs6503324	chr17:2100512	C/T	cg16513277	chr17:2031491	SMG6	-0.8	-16.02	-0.61	1.77e-45	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs593982	1.000	rs593982	chr11:65513107	T/C	cg08755490	chr11:65554678	OVOL1	1.34	20.45	0.71	3.77e-65	Atopic dermatitis;
LUAD	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg01657329	chr11:68192670	LRP5	-0.43	-6.77	-0.31	4.29e-11	Total body bone mineral density;
LUAD	cis	rs1003719	0.667	rs8127148	chr21:38481292	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.49	8.29	0.37	1.47e-15	Eye color traits;
LUAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg13560548	chr3:10150139	C3orf24	0.42	6.99	0.32	1.09e-11	Alzheimer's disease;
LUAD	cis	rs922692	0.710	rs1994016	chr15:79080234	C/T	cg22753661	chr15:79092743	ADAMTS7	0.47	7.6	0.35	1.89e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg01528321	chr10:82214614	TSPAN14	0.72	11.18	0.48	1.36e-25	Post bronchodilator FEV1;
LUAD	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg26898376	chr11:64110657	CCDC88B	0.36	6.55	0.3	1.67e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg24818145	chr4:99064322	C4orf37	0.52	7.52	0.34	3.37e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg08888203	chr3:10149979	C3orf24	0.63	10.83	0.47	2.78e-24	Alzheimer's disease;
LUAD	cis	rs11098699	0.821	rs7684799	chr4:124207659	C/T	cg09941581	chr4:124220074	SPATA5	0.5	8.07	0.37	7.58e-15	Mosquito bite size;
LUAD	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg04218760	chr10:45406644	TMEM72	-0.3	-7.81	-0.35	4.68e-14	Mean corpuscular volume;
LUAD	cis	rs8060686	0.516	rs7206792	chr16:68168200	C/G	cg05110241	chr16:68378359	PRMT7	-0.57	-7.23	-0.33	2.32e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1497406	0.744	rs1007887	chr1:16509029	C/T	cg02998240	chr1:16508668	NA	-0.22	-6.44	-0.3	3.24e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg19339811	chr12:50419529	RACGAP1	0.38	6.55	0.3	1.65e-10	Bipolar disorder;
LUAD	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.69	-0.35	1.02e-13	Breast cancer;
LUAD	cis	rs2282802	0.685	rs10077671	chr5:139689505	C/T	cg26211634	chr5:139558579	C5orf32	0.35	6.38	0.3	4.53e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg26338869	chr17:61819248	STRADA	-0.38	-6.37	-0.3	4.96e-10	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg06191203	chr2:152266755	RIF1	-0.52	-8.14	-0.37	4.55e-15	Lung cancer;
LUAD	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg26769984	chr7:1090371	C7orf50	0.6	10.01	0.44	2.6e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg08742575	chr21:47604166	C21orf56	0.45	7.06	0.32	7.04e-12	Testicular germ cell tumor;
LUAD	cis	rs17095355	0.901	rs12569425	chr10:111758177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.26	-0.37	1.95e-15	Biliary atresia;
LUAD	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg13770153	chr20:60521292	NA	-0.48	-8.02	-0.36	1.03e-14	Body mass index;
LUAD	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg01689657	chr7:91764605	CYP51A1	0.3	7.43	0.34	5.99e-13	Breast cancer;
LUAD	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-10.03	-0.44	2.21e-21	Bone mineral density;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02891801	chr12:6472782	SCNN1A	-0.42	-6.63	-0.31	1.02e-10	Height;
LUAD	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg15017067	chr4:17643749	FAM184B	0.36	6.91	0.32	1.75e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg23649088	chr2:200775458	C2orf69	0.67	10.83	0.47	2.63e-24	Schizophrenia;
LUAD	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg04155289	chr7:94953770	PON1	-0.54	-7.31	-0.33	1.36e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg08085267	chr17:45401833	C17orf57	-0.48	-8.04	-0.36	9.38e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg12179176	chr11:130786555	SNX19	0.47	7.59	0.35	2.08e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12681287	0.517	rs13249753	chr8:87513216	A/G	cg27223183	chr8:87520930	FAM82B	-0.72	-10.24	-0.45	3.91e-22	Caudate activity during reward;
LUAD	cis	rs457287	1.000	rs457287	chr9:4834394	A/G	cg14182974	chr9:4791918	RCL1	0.44	6.46	0.3	2.86e-10	Platelet count;
LUAD	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg25324976	chr17:61989376	CSHL1	0.38	7.45	0.34	5.43e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs364477	0.566	rs12236324	chr9:1003634	C/T	cg13952963	chr9:998547	NA	-0.47	-7.18	-0.33	3.17e-12	Major depressive disorder;
LUAD	trans	rs877282	0.838	rs11253373	chr10:774857	A/G	cg22713356	chr15:30763199	NA	1.31	18.46	0.67	3.12e-56	Uric acid levels;
LUAD	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg22676075	chr6:135203613	NA	0.43	7.99	0.36	1.31e-14	Red blood cell count;
LUAD	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.28	-0.51	7.65e-30	Platelet count;
LUAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-7.94	-0.36	1.82e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9905704	0.633	rs2680713	chr17:56523900	G/T	cg19466818	chr17:56409534	MIR142	-0.33	-6.57	-0.3	1.48e-10	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg22535103	chr8:58192502	C8orf71	-0.61	-7.19	-0.33	3.05e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg15704280	chr7:45808275	SEPT13	-0.53	-8.52	-0.38	2.77e-16	Height;
LUAD	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg13685833	chr1:53393034	SCP2	-0.48	-7.79	-0.35	5.17e-14	Monocyte count;
LUAD	cis	rs3018712	0.532	rs10791988	chr11:68416051	A/T	cg16797656	chr11:68205561	LRP5	-0.41	-6.37	-0.3	4.91e-10	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg05340658	chr4:99064831	C4orf37	0.53	8.92	0.4	1.44e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13064411	0.696	rs6769516	chr3:113219905	T/C	cg18753928	chr3:113234510	CCDC52	-0.73	-12.43	-0.52	1.82e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.34	6.45	0.3	3.14e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg24813613	chr7:1882135	MAD1L1	0.43	6.93	0.32	1.55e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg20283391	chr11:68216788	NA	-0.42	-6.56	-0.3	1.56e-10	Total body bone mineral density;
LUAD	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg17757837	chr7:157058334	UBE3C	-0.47	-8.25	-0.37	1.96e-15	Body mass index;
LUAD	cis	rs4846217	0.920	rs17397129	chr1:10345462	C/T	cg17425144	chr1:10567563	PEX14	0.51	7.09	0.33	5.52e-12	Platelet count;
LUAD	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg12923728	chr3:195709715	SDHAP1	0.44	6.72	0.31	6.04e-11	Mean corpuscular volume;
LUAD	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg15133208	chr4:90757351	SNCA	-0.45	-7.12	-0.33	4.76e-12	Neuroticism;
LUAD	trans	rs11700980	0.636	rs2832138	chr21:30284123	G/A	cg14791747	chr16:20752902	THUMPD1	0.59	6.75	0.31	5.01e-11	QRS complex (12-leadsum);
LUAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00166722	chr3:10149974	C3orf24	0.63	10.46	0.45	6.19e-23	Alzheimer's disease;
LUAD	cis	rs73198271	0.710	rs11779561	chr8:8679988	G/C	cg01851573	chr8:8652454	MFHAS1	0.49	8.88	0.4	1.86e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg13012494	chr21:47604986	C21orf56	0.48	7.89	0.36	2.53e-14	Testicular germ cell tumor;
LUAD	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg08859206	chr1:53392774	SCP2	-0.73	-13.88	-0.56	2.25e-36	Monocyte count;
LUAD	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg09455208	chr3:40491958	NA	-0.6	-13.14	-0.54	2.5e-33	Renal cell carcinoma;
LUAD	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg12927641	chr6:109611667	NA	0.5	8.64	0.39	1.14e-16	Reticulocyte fraction of red cells;
LUAD	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.9	-0.36	2.39e-14	Monocyte percentage of white cells;
LUAD	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18876405	chr7:65276391	NA	-0.43	-6.74	-0.31	5.11e-11	Aortic root size;
LUAD	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.35	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.6	-0.35	1.95e-13	Resting heart rate;
LUAD	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg23950597	chr19:37808831	NA	-0.64	-7.68	-0.35	1.11e-13	Coronary artery calcification;
LUAD	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg03948781	chr1:205179583	DSTYK	0.35	6.4	0.3	4.17e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs3820068	0.705	rs6656907	chr1:15896984	A/G	cg24675056	chr1:15929824	NA	0.41	6.54	0.3	1.77e-10	Systolic blood pressure;
LUAD	cis	rs6840360	0.615	rs12641438	chr4:152607586	A/G	cg22705602	chr4:152727874	NA	-0.48	-8.97	-0.4	1e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs2346177	0.519	rs2121698	chr2:46709571	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-7.73	-0.35	7.99e-14	HDL cholesterol;
LUAD	trans	rs877282	0.945	rs71491303	chr10:772884	G/T	cg22713356	chr15:30763199	NA	1.17	16.73	0.63	1.35e-48	Uric acid levels;
LUAD	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg18230493	chr5:56204884	C5orf35	1.07	15.92	0.61	4.74e-45	Initial pursuit acceleration;
LUAD	cis	rs877282	1.000	rs12773872	chr10:771939	T/C	cg06581033	chr10:766294	NA	-0.55	-7.44	-0.34	5.75e-13	Uric acid levels;
LUAD	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg25358565	chr5:93447407	FAM172A	0.62	7.29	0.33	1.53e-12	Diabetic retinopathy;
LUAD	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg13606994	chr1:44402422	ARTN	-0.37	-7.3	-0.33	1.41e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg12011299	chr4:100065546	ADH4	0.73	13.45	0.55	1.43e-34	Alcohol dependence;
LUAD	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.15e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg03806693	chr22:41940476	POLR3H	0.73	9.81	0.43	1.33e-20	Vitiligo;
LUAD	cis	rs12681287	0.604	rs71502657	chr8:87478781	T/A	cg27223183	chr8:87520930	FAM82B	-0.65	-9.19	-0.41	1.72e-18	Caudate activity during reward;
LUAD	cis	rs1032833	0.643	rs77956380	chr2:180111404	T/G	cg23883738	chr2:179974586	SESTD1	-0.72	-8.09	-0.37	6.27e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs12579753	1.000	rs10862374	chr12:82250809	G/C	cg07988820	chr12:82153109	PPFIA2	-0.44	-6.75	-0.31	4.8e-11	Resting heart rate;
LUAD	trans	rs12517041	1.000	rs10473633	chr5:23310565	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg22920501	chr2:26401640	FAM59B	-0.82	-11.57	-0.49	4.27e-27	Gut microbiome composition (summer);
LUAD	cis	rs9462027	0.606	rs12201281	chr6:34681091	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.35	8.72	0.39	6.26e-17	Systemic lupus erythematosus;
LUAD	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg15704280	chr7:45808275	SEPT13	0.64	8.64	0.39	1.14e-16	Axial length;
LUAD	cis	rs889398	0.769	rs12927052	chr16:69857043	A/G	cg00738113	chr16:70207722	CLEC18C	0.33	6.49	0.3	2.42e-10	Body mass index;
LUAD	cis	rs9467160	1.000	rs9461010	chr6:24440206	T/C	cg16211469	chr6:24423932	MRS2	0.43	6.89	0.32	1.98e-11	Liver enzyme levels;
LUAD	cis	rs4280164	0.551	rs12436194	chr14:24804859	C/T	cg22990158	chr14:24802150	ADCY4	0.56	8.52	0.38	2.9e-16	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg13073564	chr4:8508604	NA	0.58	10.51	0.45	4.22e-23	Response to antineoplastic agents;
LUAD	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg14343924	chr8:8086146	FLJ10661	-0.47	-7.38	-0.34	8.23e-13	Mood instability;
LUAD	cis	rs225245	0.817	rs225269	chr17:33967931	G/T	cg05299278	chr17:33885742	SLFN14	0.52	11.98	0.5	1.14e-28	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	trans	rs9784649	1.000	rs55806673	chr5:24957298	A/G	cg08600765	chr20:34638493	LOC647979	-0.56	-7.46	-0.34	4.86e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg04398451	chr17:18023971	MYO15A	-0.63	-11.4	-0.48	2.01e-26	Total body bone mineral density;
LUAD	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg05697835	chr1:2722811	NA	0.31	6.49	0.3	2.46e-10	Ulcerative colitis;
LUAD	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg09033577	chr2:88485744	THNSL2	0.44	7.8	0.35	5.04e-14	Response to metformin (IC50);
LUAD	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg21475434	chr5:93447410	FAM172A	0.8	8.86	0.4	2.21e-17	Diabetic retinopathy;
LUAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg10729496	chr3:10149963	C3orf24	0.58	9.34	0.41	5.58e-19	Alzheimer's disease;
LUAD	cis	rs12545109	0.765	rs2576594	chr8:57412126	T/G	cg21220214	chr8:57350948	NA	-0.63	-8.72	-0.39	6.38e-17	Obesity-related traits;
LUAD	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg14582100	chr15:45693742	SPATA5L1	0.63	12.39	0.52	2.75e-30	Homoarginine levels;
LUAD	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg24642844	chr7:1081250	C7orf50	-0.87	-9.49	-0.42	1.77e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9902453	0.808	rs56216220	chr17:28209182	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.92	0.4	1.41e-17	Coffee consumption (cups per day);
LUAD	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.88	-0.32	2.12e-11	Neuroticism;
LUAD	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg04025307	chr7:1156635	C7orf50	0.58	8.48	0.38	3.82e-16	Bronchopulmonary dysplasia;
LUAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.28	0.37	1.67e-15	Alzheimer's disease;
LUAD	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg25985355	chr7:65971099	NA	-0.55	-6.76	-0.31	4.56e-11	Diabetic kidney disease;
LUAD	cis	rs12549902	0.933	rs17659428	chr8:41513809	T/C	cg17182837	chr8:41585554	ANK1	-0.36	-7.49	-0.34	4.16e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUAD	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg04414720	chr1:150670196	GOLPH3L	0.72	13.36	0.54	3.28e-34	Tonsillectomy;
LUAD	trans	rs11039798	1.000	rs7102865	chr11:48458361	A/C	cg02254774	chr11:50257496	LOC441601	0.53	6.73	0.31	5.38e-11	Axial length;
LUAD	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg25894440	chr7:65020034	NA	0.63	6.89	0.32	2.01e-11	Diabetic kidney disease;
LUAD	cis	rs78456975	1.000	rs72776252	chr2:1525599	G/A	cg01028140	chr2:1542097	TPO	-0.6	-7.64	-0.35	1.48e-13	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs1595825	0.891	rs2164070	chr2:198881730	G/C	cg00361562	chr2:198649771	BOLL	-0.49	-6.83	-0.32	2.94e-11	Ulcerative colitis;
LUAD	trans	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg01620082	chr3:125678407	NA	-0.61	-6.44	-0.3	3.34e-10	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs2797160	0.515	rs9375409	chr6:125972798	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.87	-0.36	2.92e-14	Endometrial cancer;
LUAD	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg04450456	chr4:17643702	FAM184B	0.4	7.95	0.36	1.69e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2882667	0.964	rs2288824	chr5:138298396	C/T	cg04439458	chr5:138467593	SIL1	-0.41	-7.44	-0.34	5.69e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27297192	chr10:134578999	INPP5A	0.38	6.7	0.31	6.64e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg06544989	chr22:39130855	UNC84B	0.42	8.39	0.38	7.23e-16	Menopause (age at onset);
LUAD	cis	rs28830936	1.000	rs12440747	chr15:42036690	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.36	-7.59	-0.35	2.02e-13	Diastolic blood pressure;
LUAD	cis	rs1728785	0.901	rs1645974	chr16:68564774	C/G	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.3100000000000001e-10	Ulcerative colitis;
LUAD	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg00310523	chr12:86230176	RASSF9	0.37	7.32	0.34	1.25e-12	Major depressive disorder;
LUAD	cis	rs6062509	0.929	rs55791529	chr20:62363858	C/T	cg02966332	chr20:62369605	LIME1	-0.46	-7.51	-0.34	3.5e-13	Prostate cancer;
LUAD	cis	rs12210905	0.610	rs72845033	chr6:27546262	C/T	cg08851530	chr6:28072375	NA	0.91	6.79	0.31	3.81e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs9948	0.786	rs62156234	chr2:97436292	C/G	cg20312557	chr2:97357134	FER1L5	-0.63	-7.36	-0.34	9.71e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs4891159	0.548	rs617823	chr18:74120233	A/G	cg24786174	chr18:74118243	ZNF516	0.92	23.75	0.76	7.41e-80	Longevity;
LUAD	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg19767477	chr5:127420684	SLC12A2	-0.41	-6.4	-0.3	4.09e-10	Ileal carcinoids;
LUAD	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.49	0.49	8.53e-27	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg09184832	chr6:79620586	NA	-0.51	-9.25	-0.41	1.11e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00166722	chr3:10149974	C3orf24	0.74	12.65	0.52	2.48e-31	Alzheimer's disease;
LUAD	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	cis	rs4604732	0.631	rs56704806	chr1:247626148	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.86	-0.36	3.32e-14	Diabetic kidney disease;
LUAD	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg00086871	chr4:6988644	TBC1D14	0.74	6.38	0.3	4.58e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs116095464	1.000	rs2721025	chr5:347444	G/C	cg22857025	chr5:266934	NA	-1.02	-8.37	-0.38	8.41e-16	Breast cancer;
LUAD	cis	rs1003719	0.788	rs4816560	chr21:38487561	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.42	0.38	5.92e-16	Eye color traits;
LUAD	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.09	0.37	6.3e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5758511	0.524	rs738257	chr22:42569298	C/A	cg00645731	chr22:42541494	CYP2D7P1	0.67	11.75	0.5	8.74e-28	Birth weight;
LUAD	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg11833968	chr6:79620685	NA	-0.43	-8.02	-0.36	1.05e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.0	-0.36	1.17e-14	Diabetic kidney disease;
LUAD	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg13732083	chr21:47605072	C21orf56	0.44	7.31	0.33	1.33e-12	Testicular germ cell tumor;
LUAD	cis	rs2230307	0.536	rs561119	chr1:100603891	G/A	cg20868668	chr1:100435035	SLC35A3	-0.51	-7.67	-0.35	1.16e-13	Carotid intima media thickness;
LUAD	trans	rs3857536	0.813	rs9360189	chr6:66933424	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.35	-0.3	5.66e-10	Blood trace element (Cu levels);
LUAD	cis	rs4692589	0.606	rs34752946	chr4:170951738	G/T	cg19918862	chr4:170955249	NA	0.33	6.48	0.3	2.52e-10	Anxiety disorder;
LUAD	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06544989	chr22:39130855	UNC84B	0.42	7.76	0.35	6.43e-14	Menopause (age at onset);
LUAD	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg02683114	chr2:24398427	C2orf84	-0.53	-7.8	-0.35	4.83e-14	Asthma;
LUAD	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg00495681	chr13:53174319	NA	0.53	9.97	0.44	3.63e-21	Lewy body disease;
LUAD	cis	rs8177876	0.658	rs16954505	chr16:81074160	T/G	cg08591886	chr16:81111003	C16orf46	-0.79	-7.33	-0.34	1.19e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg08219700	chr8:58056026	NA	0.51	7.44	0.34	5.83e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs9487051	0.768	rs9398188	chr6:109526615	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.09	-0.33	5.7e-12	Reticulocyte fraction of red cells;
LUAD	trans	rs2235573	0.551	rs139895	chr22:38397034	A/G	cg19894588	chr14:64061835	NA	-0.51	-7.86	-0.36	3.11e-14	Glioblastoma;Glioma;
LUAD	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg04568274	chr7:158649319	WDR60	0.42	6.88	0.32	2.13e-11	Height;
LUAD	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg26022315	chr17:47021804	SNF8	0.4	7.28	0.33	1.63e-12	Type 2 diabetes;
LUAD	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg23533926	chr12:111358616	MYL2	-0.43	-7.34	-0.34	1.07e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs12711979	0.765	rs13030772	chr2:3821280	T/C	cg17052675	chr2:3827356	NA	-0.51	-10.53	-0.46	3.52e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg05590025	chr7:65112418	INTS4L2	0.74	8.05	0.36	8.39e-15	Diabetic kidney disease;
LUAD	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg10876282	chr6:28092338	ZSCAN16	0.45	6.91	0.32	1.8e-11	Cardiac Troponin-T levels;
LUAD	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.12	-0.37	5.16e-15	Diabetic kidney disease;
LUAD	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg07741184	chr6:167504864	NA	0.28	6.89	0.32	2.05e-11	Crohn's disease;
LUAD	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg03433033	chr1:76189801	ACADM	0.74	11.22	0.48	9.22e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9863	0.828	rs7135314	chr12:124478566	A/T	cg17723958	chr12:124429295	CCDC92	-0.41	-6.71	-0.31	6.18e-11	White blood cell count;
LUAD	cis	rs2997447	0.744	rs2997442	chr1:26403530	T/G	cg00147160	chr1:26503991	CNKSR1	0.36	6.69	0.31	7.26e-11	QRS complex (12-leadsum);
LUAD	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg02734326	chr4:10020555	SLC2A9	0.56	9.91	0.43	5.81e-21	Bone mineral density;
LUAD	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg13736514	chr6:26305472	NA	-0.69	-13.15	-0.54	2.33e-33	Educational attainment;
LUAD	cis	rs9837602	1.000	rs62285462	chr3:99769834	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	9.19	0.41	1.73e-18	Breast cancer;
LUAD	cis	rs7119	0.635	rs867916	chr15:77882860	A/G	cg27398640	chr15:77910606	LINGO1	0.41	7.92	0.36	2.05e-14	Type 2 diabetes;
LUAD	trans	rs6601327	0.767	rs10109026	chr8:9411986	C/T	cg27411982	chr8:10470053	RP1L1	0.38	7.17	0.33	3.39e-12	Multiple myeloma (hyperdiploidy);
LUAD	trans	rs8002861	0.664	rs9525873	chr13:44482204	T/C	cg12856521	chr11:46389249	DGKZ	0.44	7.5	0.34	3.83e-13	Leprosy;
LUAD	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.49	-0.3	2.47e-10	Total body bone mineral density;
LUAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.28	0.37	1.67e-15	Alzheimer's disease;
LUAD	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg00310523	chr12:86230176	RASSF9	0.41	8.68	0.39	8.6e-17	Major depressive disorder;
LUAD	cis	rs10540	0.584	rs10751658	chr11:437401	C/G	cg03352830	chr11:487213	PTDSS2	-0.49	-7.02	-0.32	8.65e-12	Body mass index;
LUAD	cis	rs1816752	0.776	rs7998843	chr13:25017285	T/C	cg02811702	chr13:24901961	NA	0.46	7.91	0.36	2.32e-14	Obesity-related traits;
LUAD	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg19318889	chr4:1322082	MAEA	0.87	14.62	0.58	1.83e-39	Longevity;
LUAD	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg04414720	chr1:150670196	GOLPH3L	0.67	11.79	0.5	6.3e-28	Melanoma;
LUAD	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	9.01	0.4	7.19e-18	Lung cancer in ever smokers;
LUAD	cis	rs10464059	0.511	rs3805705	chr5:179738237	T/C	cg23248424	chr5:179741104	GFPT2	0.51	6.36	0.3	5.22e-10	Parkinson's disease;
LUAD	cis	rs6594713	0.605	rs11241213	chr5:112851088	T/A	cg12552261	chr5:112820674	MCC	0.53	7.29	0.33	1.51e-12	Brain cytoarchitecture;
LUAD	cis	rs354225	0.544	rs3796018	chr2:54807281	C/T	cg01766943	chr2:54829624	SPTBN1	0.38	7.27	0.33	1.78e-12	Schizophrenia;
LUAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.41	-7.17	-0.33	3.34e-12	Longevity;Endometriosis;
LUAD	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	7.52	0.34	3.37e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg21775007	chr8:11205619	TDH	0.36	6.5	0.3	2.27e-10	Myopia (pathological);
LUAD	cis	rs57920188	0.584	rs12080562	chr1:4089697	C/A	cg10510935	chr1:4059661	NA	0.45	6.99	0.32	1.09e-11	Interleukin-17 levels;
LUAD	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg11663144	chr21:46675770	NA	-0.6	-11.84	-0.5	4.01e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.44	8.85	0.4	2.44e-17	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg17366294	chr4:99064904	C4orf37	0.59	11.03	0.47	4.74e-25	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.11	0.4	3.37e-18	Alzheimer's disease;
LUAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg18765753	chr7:1198926	ZFAND2A	0.49	8.35	0.38	1.02e-15	Longevity;Endometriosis;
LUAD	cis	rs472402	0.623	rs8192130	chr5:6636450	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.4	-6.39	-0.3	4.43e-10	Response to amphetamines;
LUAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg12379764	chr21:47803548	PCNT	-0.38	-6.44	-0.3	3.17e-10	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12612619	0.704	rs6754356	chr2:27315021	G/A	cg00617064	chr2:27272375	NA	-0.38	-7.11	-0.33	5.08e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg26677194	chr12:130822605	PIWIL1	0.56	9.24	0.41	1.24e-18	Menopause (age at onset);
LUAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg17178900	chr1:205818956	PM20D1	-0.45	-7.55	-0.34	2.73e-13	Parkinson's disease;
LUAD	cis	rs3736594	1.000	rs13013484	chr2:27988821	G/A	cg27432699	chr2:27873401	GPN1	-0.44	-6.97	-0.32	1.22e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs17739167	0.550	rs2665213	chr15:42234265	T/G	cg20935245	chr15:42234343	EHD4	-0.44	-7.68	-0.35	1.13e-13	Monocyte count;
LUAD	trans	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	10.46	0.45	6.2e-23	Type 2 diabetes;
LUAD	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg22823121	chr1:150693482	HORMAD1	0.45	8.64	0.39	1.17e-16	Melanoma;
LUAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg00280220	chr17:61926910	NA	0.38	7.22	0.33	2.51e-12	Prudent dietary pattern;
LUAD	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg17971929	chr21:40555470	PSMG1	0.53	8.38	0.38	7.85e-16	Cognitive function;
LUAD	cis	rs61990749	0.544	rs7151211	chr14:78151901	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.49	-6.36	-0.3	5.27e-10	Fibroblast growth factor basic levels;
LUAD	trans	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.34	-0.64	2.91e-51	Exhaled nitric oxide output;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg23435730	chr3:127770634	SEC61A1	0.4	6.6	0.31	1.23e-10	Bilirubin levels;
LUAD	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.86	-0.36	3.12e-14	Diabetic kidney disease;
LUAD	cis	rs2806561	0.894	rs629107	chr1:23537971	C/T	cg19743168	chr1:23544995	NA	0.44	7.98	0.36	1.36e-14	Height;
LUAD	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03934478	chr11:495069	RNH1	0.77	9.23	0.41	1.29e-18	Body mass index;
LUAD	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09263875	chr16:632152	PIGQ	0.82	17.74	0.65	4.77e-53	Height;
LUAD	cis	rs9314323	0.798	rs2019239	chr8:26217354	G/A	cg13160058	chr8:26243215	BNIP3L	-0.48	-9.85	-0.43	9.31e-21	Red cell distribution width;
LUAD	cis	rs59698941	0.527	rs1032764	chr5:132185419	A/C	cg16419906	chr5:132167176	NA	-0.33	-6.5	-0.3	2.2e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs735539	0.521	rs2147347	chr13:21410468	C/T	cg27499820	chr13:21296301	IL17D	0.45	6.85	0.32	2.56e-11	Dental caries;
LUAD	cis	rs57920188	0.535	rs7412438	chr1:4095581	C/G	cg10510935	chr1:4059661	NA	0.44	6.8	0.31	3.6e-11	Interleukin-17 levels;
LUAD	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg08601574	chr20:25228251	PYGB	0.47	8.88	0.4	1.93e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23248424	chr5:179741104	GFPT2	-0.69	-11.76	-0.5	8.11e-28	Height;
LUAD	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg01097406	chr16:89675127	NA	0.46	10.07	0.44	1.66e-21	Vitiligo;
LUAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.56	7.79	0.35	5.14e-14	Renal function-related traits (BUN);
LUAD	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg13010199	chr12:38710504	ALG10B	-0.39	-6.4	-0.3	4.23e-10	Bladder cancer;
LUAD	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-12.11	-0.51	3.48e-29	Mean corpuscular volume;
LUAD	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg13606994	chr1:44402422	ARTN	-0.38	-7.35	-0.34	1.03e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10979	1.000	rs9484769	chr6:143896719	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.22	-0.45	4.58e-22	Hypospadias;
LUAD	cis	rs1535500	0.935	rs34247110	chr6:39282371	G/A	cg06347083	chr6:39282316	KCNK17	-0.36	-7.29	-0.33	1.58e-12	Type 2 diabetes;
LUAD	trans	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.64	0.49	2.27e-27	Mean corpuscular volume;
LUAD	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg19875535	chr5:140030758	IK	0.47	7.71	0.35	8.78e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg22482690	chr17:47019901	SNF8	0.44	8.32	0.38	1.21e-15	Type 2 diabetes;
LUAD	cis	rs9486719	1.000	rs2179126	chr6:96871350	A/G	cg06623918	chr6:96969491	KIAA0776	0.71	10.01	0.44	2.62e-21	Migraine;Coronary artery disease;
LUAD	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.08	-0.33	6.14e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg14917512	chr19:3094685	GNA11	-0.57	-6.8	-0.31	3.63e-11	Diabetic kidney disease;
LUAD	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg03929089	chr4:120376271	NA	-0.99	-20.65	-0.71	4.76e-66	Height;
LUAD	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27286337	chr10:134555280	INPP5A	0.72	9.63	0.42	5.48e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.64	8.56	0.38	2.05e-16	Renal function-related traits (BUN);
LUAD	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg23173402	chr1:227635558	NA	0.69	6.56	0.3	1.57e-10	Major depressive disorder;
LUAD	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg25173405	chr17:45401733	C17orf57	-0.45	-7.63	-0.35	1.54e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9308433	0.529	rs4655336	chr1:214499667	A/C	cg06198575	chr1:214491504	SMYD2	0.45	7.66	0.35	1.29e-13	IgG glycosylation;
LUAD	cis	rs7731657	0.537	rs2419938	chr5:130349567	G/A	cg08523029	chr5:130500466	HINT1	0.58	7.65	0.35	1.33e-13	Fasting plasma glucose;
LUAD	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg22467129	chr15:76604101	ETFA	0.45	7.93	0.36	1.93e-14	Blood metabolite levels;
LUAD	cis	rs9362426	0.943	rs7744338	chr6:88101999	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.4	6.78	0.31	4.01e-11	Depressive episodes in bipolar disorder;
LUAD	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.64	11.2	0.48	1.1e-25	Birth weight;
LUAD	cis	rs55788414	0.651	rs2317121	chr16:81182826	T/G	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.78	-0.35	5.67e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.99	-0.36	1.34e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg20503657	chr10:835505	NA	0.97	14.97	0.59	6.02e-41	Eosinophil percentage of granulocytes;
LUAD	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg03948781	chr1:205179583	DSTYK	0.32	6.39	0.3	4.29e-10	Red blood cell count;
LUAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg11050988	chr7:1952600	MAD1L1	-0.36	-7.06	-0.32	6.98e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.94	0.47	1.05e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg11766577	chr21:47581405	C21orf56	-0.53	-8.69	-0.39	7.85e-17	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg05340658	chr4:99064831	C4orf37	0.53	8.96	0.4	1.04e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg23758822	chr17:41437982	NA	0.99	20.82	0.71	8.69e-67	Menopause (age at onset);
LUAD	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.42	-0.52	2.08e-30	Breast cancer;
LUAD	cis	rs62400317	0.826	rs12203466	chr6:45330263	T/A	cg18551225	chr6:44695536	NA	-0.52	-8.16	-0.37	3.95e-15	Total body bone mineral density;
LUAD	trans	rs7555117	0.794	rs2989476	chr1:61059259	C/G	cg01200289	chr4:77227751	STBD1	-0.4	-6.38	-0.3	4.54e-10	Facial morphology (factor 19);
LUAD	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.33e-13	Menopause (age at onset);
LUAD	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24308560	chr3:49941425	MST1R	-0.46	-7.67	-0.35	1.23e-13	Body mass index;
LUAD	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg12623302	chr6:28058802	ZSCAN12L1	0.35	6.96	0.32	1.31e-11	Depression;
LUAD	cis	rs1816752	0.817	rs7985394	chr13:25012852	C/G	cg02811702	chr13:24901961	NA	0.46	7.96	0.36	1.61e-14	Obesity-related traits;
LUAD	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg12140854	chr5:148520817	ABLIM3	-0.66	-10.65	-0.46	1.23e-23	Breast cancer;
LUAD	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg20991723	chr1:152506922	NA	0.32	6.43	0.3	3.42e-10	Hair morphology;
LUAD	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg00933542	chr6:150070202	PCMT1	0.43	8.88	0.4	1.98e-17	Lung cancer;
LUAD	cis	rs12997796	0.556	rs13004867	chr2:86982504	C/G	cg23743911	chr2:86949715	RMND5A	0.43	6.37	0.3	4.83e-10	Schizophrenia;
LUAD	cis	rs5756813	0.661	rs5995500	chr22:38204640	A/G	cg06521852	chr22:38141419	TRIOBP	0.47	8.62	0.39	1.37e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs7582720	1.000	rs116678869	chr2:203819471	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg05623727	chr3:50126028	RBM5	-0.32	-6.93	-0.32	1.58e-11	Body mass index;
LUAD	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg10589385	chr1:150898437	SETDB1	0.39	7.42	0.34	6.51e-13	Tonsillectomy;
LUAD	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg02574844	chr11:5959923	NA	0.43	7.89	0.36	2.66e-14	DNA methylation (variation);
LUAD	cis	rs657075	0.757	rs35316456	chr5:131643824	G/A	cg21138405	chr5:131827807	IRF1	0.51	6.42	0.3	3.61e-10	Rheumatoid arthritis;
LUAD	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg18306943	chr3:40428807	ENTPD3	0.42	7.04	0.32	7.93e-12	Renal cell carcinoma;
LUAD	cis	rs78761021	0.860	rs79705409	chr17:9776970	T/C	cg26853458	chr17:9805074	RCVRN	0.35	6.77	0.31	4.42e-11	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.46	0.42	2.24e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12517041	1.000	rs4374724	chr5:23309672	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg14289826	chr9:140003911	NA	0.32	6.38	0.3	4.7e-10	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	trans	rs11650494	0.908	rs11656535	chr17:47425588	C/T	cg11430096	chr6:110968061	CDK19	0.86	6.8	0.31	3.58e-11	Prostate cancer;
LUAD	trans	rs8073060	0.586	rs225303	chr17:33922149	A/G	cg19694781	chr19:47549865	TMEM160	1.18	19.09	0.68	4.73e-59	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs9346649	0.630	rs6913441	chr6:168491271	C/T	cg02770688	chr6:168491649	NA	0.51	9.78	0.43	1.72e-20	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs11893307	0.509	rs2109958	chr2:191533114	T/C	cg27211696	chr2:191398769	TMEM194B	-0.43	-6.5	-0.3	2.31e-10	Mean platelet volume;
LUAD	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg02990361	chr1:107599529	PRMT6	-0.51	-8.56	-0.38	2.06e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg00666640	chr1:248458726	OR2T12	0.34	8.17	0.37	3.56e-15	Common traits (Other);
LUAD	cis	rs3784262	1.000	rs3784262	chr15:58253106	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.45	-9.32	-0.41	6.5e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg15962314	chr1:44399869	ARTN	0.3	6.93	0.32	1.61e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg09509183	chr1:209979624	IRF6	0.57	7.81	0.36	4.49e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg05340658	chr4:99064831	C4orf37	-0.56	-9.56	-0.42	9.81e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.74	13.57	0.55	4.45e-35	Axial length;
LUAD	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg05283184	chr6:79620031	NA	-0.45	-7.86	-0.36	3.26e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg18187862	chr3:45730750	SACM1L	0.52	7.98	0.36	1.41e-14	Primary sclerosing cholangitis;
LUAD	cis	rs1044826	0.647	rs4683463	chr3:139196946	T/G	cg00490450	chr3:139108681	COPB2	0.4	6.38	0.3	4.78e-10	Obesity-related traits;
LUAD	cis	rs877282	1.000	rs12775643	chr10:773242	G/A	cg17470449	chr10:769945	NA	0.68	10.62	0.46	1.59e-23	Uric acid levels;
LUAD	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg18446336	chr7:2847575	GNA12	-0.38	-7.08	-0.33	6e-12	Height;
LUAD	cis	rs3087591	1.000	rs2952978	chr17:29474744	A/C	cg24425628	chr17:29625626	OMG;NF1	0.42	6.84	0.32	2.85e-11	Hip circumference;
LUAD	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg09537434	chr19:41945824	ATP5SL	-0.47	-7.37	-0.34	8.93e-13	Height;
LUAD	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03517284	chr6:25882590	NA	0.59	9.89	0.43	6.74e-21	Blood metabolite levels;
LUAD	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg21918786	chr6:109611834	NA	-0.54	-9.49	-0.42	1.66e-19	Reticulocyte fraction of red cells;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg13690588	chr1:28415118	EYA3	-0.41	-6.6	-0.31	1.22e-10	Schizophrenia;
LUAD	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg17279839	chr7:150038598	RARRES2	-0.45	-7.59	-0.35	2.05e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg09184832	chr6:79620586	NA	-0.39	-6.59	-0.31	1.32e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-8.34	-0.38	1.04e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg11965913	chr1:205819406	PM20D1	0.41	6.37	0.3	4.89e-10	Prostate-specific antigen levels;
LUAD	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-7.82	-0.36	4.26e-14	Neutrophil percentage of white cells;
LUAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-7.25	-0.33	2.06e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs447921	0.817	rs11077822	chr17:74455605	G/A	cg17201438	chr17:74438067	UBE2O	-0.46	-6.78	-0.31	3.97e-11	Mitochondrial DNA levels;
LUAD	cis	rs2625529	0.824	rs12916694	chr15:72298140	C/T	cg16672083	chr15:72433130	SENP8	-0.77	-12.82	-0.53	5.37e-32	Red blood cell count;
LUAD	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.63	-8.23	-0.37	2.35e-15	Yeast infection;
LUAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg21724239	chr8:58056113	NA	0.82	9.72	0.43	2.76e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6554196	0.508	rs999020	chr4:55524304	T/C	cg18836493	chr4:55524333	KIT	-0.37	-7.04	-0.32	7.96e-12	Monocyte count;
LUAD	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg12623918	chr2:306882	NA	0.33	6.81	0.31	3.44e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs1232027	0.700	rs844370	chr5:79943002	T/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-7.95	-0.36	1.74e-14	Huntington's disease progression;
LUAD	cis	rs9427116	0.677	rs9426831	chr1:154609657	A/T	cg17218026	chr1:154582156	ADAR	-0.52	-10.09	-0.44	1.34e-21	Blood protein levels;
LUAD	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg00255919	chr5:131827918	IRF1	0.49	11.85	0.5	3.74e-28	Asthma (sex interaction);
LUAD	cis	rs57994353	0.897	rs11999609	chr9:139363539	C/T	cg14019695	chr9:139328340	INPP5E	0.39	6.39	0.3	4.34e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs6545883	0.895	rs2421192	chr2:61643631	T/C	cg15711740	chr2:61764176	XPO1	0.39	6.37	0.3	4.95e-10	Tuberculosis;
LUAD	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg16205897	chr5:131564050	P4HA2	0.36	8.21	0.37	2.73e-15	Blood metabolite levels;
LUAD	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg11663144	chr21:46675770	NA	-0.62	-12.4	-0.52	2.49e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg07636037	chr3:49044803	WDR6	0.62	12.01	0.5	8.32e-29	Parkinson's disease;
LUAD	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg12311346	chr5:56204834	C5orf35	-0.53	-8.45	-0.38	4.68e-16	Coronary artery disease;
LUAD	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-9.74	-0.43	2.36e-20	Gut microbiome composition (summer);
LUAD	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg03733263	chr8:22462867	KIAA1967	0.73	12.13	0.51	2.83e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg22532475	chr10:104410764	TRIM8	-0.42	-7.89	-0.36	2.55e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4849845	0.573	rs33971369	chr2:121024987	A/G	cg24070213	chr2:121070622	NA	0.4	7.58	0.35	2.15e-13	Mean platelet volume;
LUAD	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg27124370	chr19:33622961	WDR88	-0.47	-7.51	-0.34	3.5e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.41	7.9	0.36	2.37e-14	Depressive symptoms;
LUAD	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg25985355	chr7:65971099	NA	-0.55	-6.79	-0.31	3.77e-11	Diabetic kidney disease;
LUAD	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg23625390	chr15:77176239	SCAPER	0.43	7.67	0.35	1.23e-13	Blood metabolite levels;
LUAD	cis	rs13082711	0.522	rs514668	chr3:27330972	A/G	cg02860705	chr3:27208620	NA	0.52	8.56	0.38	2.12e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg01579765	chr21:45077557	HSF2BP	0.53	11.9	0.5	2.23e-28	Mean corpuscular volume;
LUAD	cis	rs12210905	1.000	rs12201774	chr6:27058312	A/G	cg11502198	chr6:26597334	ABT1	-0.78	-6.36	-0.3	5.28e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs8067545	0.717	rs7207625	chr17:20001612	G/A	cg04132472	chr17:19861366	AKAP10	0.31	7.32	0.34	1.25e-12	Schizophrenia;
LUAD	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.54e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26402253	chr7:87849886	SRI	-0.44	-6.79	-0.31	3.81e-11	Height;
LUAD	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg07432352	chr17:45403706	C17orf57	-0.42	-7.88	-0.36	2.83e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg11247378	chr22:39784982	NA	0.75	14.44	0.57	1e-38	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	6.52	0.3	2.07e-10	Lung cancer in ever smokers;
LUAD	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg15921436	chr17:44337874	NA	-0.63	-9.48	-0.42	1.82e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg06641503	chr3:48959341	ARIH2	-0.39	-7.74	-0.35	7.59e-14	Menarche (age at onset);
LUAD	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg08885076	chr2:99613938	TSGA10	0.4	7.56	0.34	2.61e-13	Chronic sinus infection;
LUAD	cis	rs644148	0.836	rs2571112	chr19:45000319	T/A	cg15540054	chr19:45004280	ZNF180	-0.4	-6.41	-0.3	3.88e-10	Personality dimensions;
LUAD	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.51	0.55	8.12e-35	Tonsillectomy;
LUAD	cis	rs3916	0.911	rs12829722	chr12:121155622	C/T	cg27246729	chr12:121163418	ACADS	0.46	7.27	0.33	1.77e-12	Urinary metabolites (H-NMR features);
LUAD	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg20933634	chr6:27740509	NA	0.49	7.84	0.36	3.58e-14	Parkinson's disease;
LUAD	cis	rs7177699	0.557	rs7165902	chr15:79115872	T/G	cg00540400	chr15:79124168	NA	0.44	9.62	0.42	6.23e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.89e-14	Depression;
LUAD	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.95	-0.32	1.39e-11	Height;
LUAD	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-9.25	-0.41	1.08e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg05754148	chr16:3507555	NAT15	0.48	7.04	0.32	7.64e-12	Body mass index (adult);
LUAD	cis	rs6906287	0.647	rs6569015	chr6:118686344	C/T	cg05564266	chr6:118973597	C6orf204	0.34	7.11	0.33	4.99e-12	Electrocardiographic conduction measures;
LUAD	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7659604	0.502	rs4075066	chr4:122684283	T/C	cg06713675	chr4:122721982	EXOSC9	0.42	7.61	0.35	1.83e-13	Type 2 diabetes;
LUAD	cis	rs7799006	1.000	rs7787274	chr7:2275993	G/A	cg02951883	chr7:2050386	MAD1L1	-0.5	-7.98	-0.36	1.35e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg18512352	chr11:47633146	NA	-0.56	-9.99	-0.44	3.17e-21	Subjective well-being;
LUAD	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg25894440	chr7:65020034	NA	-0.69	-7.33	-0.34	1.21e-12	Diabetic kidney disease;
LUAD	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.76	0.39	4.61e-17	Parkinson's disease;
LUAD	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg07617317	chr6:118971624	C6orf204	0.56	8.68	0.39	8.5e-17	Diastolic blood pressure;
LUAD	cis	rs12618769	0.625	rs3769717	chr2:99124817	G/A	cg10123293	chr2:99228465	UNC50	0.46	8.21	0.37	2.77e-15	Bipolar disorder;
LUAD	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg17063962	chr7:91808500	NA	0.68	12.12	0.51	3.04e-29	Breast cancer;
LUAD	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18876405	chr7:65276391	NA	-0.57	-9.66	-0.43	4.25e-20	Aortic root size;
LUAD	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg21471580	chr8:22132874	PIWIL2	0.45	7.95	0.36	1.67e-14	Hypertriglyceridemia;
LUAD	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg19622623	chr12:86230825	RASSF9	-0.56	-9.87	-0.43	8.37e-21	Major depressive disorder;
LUAD	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.43	0.38	5.38e-16	Breast cancer;
LUAD	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg13319975	chr6:146136371	FBXO30	-0.65	-11.16	-0.48	1.55e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.45	-0.52	1.54e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs9914544	0.545	rs35911764	chr17:18782582	C/T	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.49	-0.3	2.45e-10	Educational attainment (years of education);
LUAD	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-6.68	-0.31	7.42e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg17800788	chr1:21766015	NBPF3	0.37	7.22	0.33	2.39e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.25	0.37	2.07e-15	Breast cancer;
LUAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg11062466	chr8:58055876	NA	0.68	9.0	0.4	7.57e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg21918786	chr6:109611834	NA	0.53	9.44	0.42	2.52e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs11971779	0.680	rs4732373	chr7:139086535	T/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg08470875	chr2:26401718	FAM59B	-0.77	-10.38	-0.45	1.18e-22	Gut microbiome composition (summer);
LUAD	trans	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg04775059	chr7:64541387	NA	-0.51	-6.6	-0.31	1.22e-10	Aortic root size;
LUAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00149659	chr3:10157352	C3orf10	0.87	11.52	0.49	6.73e-27	Alzheimer's disease;
LUAD	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.7	0.31	6.74e-11	Depression;
LUAD	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg11189052	chr15:85197271	WDR73	0.67	8.87	0.4	2.05e-17	Schizophrenia;
LUAD	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg25324976	chr17:61989376	CSHL1	0.38	7.37	0.34	9.28e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg11247378	chr22:39784982	NA	-0.7	-12.33	-0.51	4.71e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg25358565	chr5:93447407	FAM172A	0.68	7.69	0.35	1.02e-13	Diabetic retinopathy;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg21508023	chr5:171533930	STK10	0.41	6.43	0.3	3.49e-10	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.94	0.44	4.72e-21	Ulcerative colitis;
LUAD	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg12311346	chr5:56204834	C5orf35	-0.47	-7.71	-0.35	9.36e-14	Coronary artery disease;
LUAD	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg08219700	chr8:58056026	NA	0.6	8.29	0.37	1.49e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg09365446	chr1:150670422	GOLPH3L	0.56	9.71	0.43	3.05e-20	Melanoma;
LUAD	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg07305463	chr2:136567211	LCT	0.38	7.2	0.33	2.69e-12	Mosquito bite size;
LUAD	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg13813247	chr22:41461852	NA	-0.46	-7.55	-0.34	2.63e-13	Neuroticism;
LUAD	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg14202850	chr17:43974869	MAPT;LOC100130148	0.39	6.64	0.31	9.4e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg05665937	chr4:1216051	CTBP1	0.43	7.54	0.34	2.82e-13	Obesity-related traits;
LUAD	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg17031739	chr1:67600172	NA	-0.52	-9.5	-0.42	1.54e-19	Psoriasis;
LUAD	cis	rs2408955	0.522	rs11168408	chr12:48498327	G/A	cg04545296	chr12:48745243	ZNF641	-0.35	-8.8	-0.39	3.54e-17	Glycated hemoglobin levels;
LUAD	cis	rs2464469	0.526	rs11071363	chr15:58333961	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-7.12	-0.33	4.53e-12	Barrett's esophagus  or Esophageal adenocarcinoma;
LUAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg03037974	chr15:76606532	NA	0.38	8.13	0.37	4.74e-15	Blood metabolite levels;
LUAD	cis	rs9486719	1.000	rs11153067	chr6:97039421	A/T	cg06623918	chr6:96969491	KIAA0776	0.69	9.94	0.44	4.65e-21	Migraine;Coronary artery disease;
LUAD	cis	rs11030122	0.702	rs12223176	chr11:3982537	T/G	cg18678763	chr11:4115507	RRM1	-0.44	-7.33	-0.34	1.14e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	6.66	0.31	8.58e-11	Lung function (FEV1/FVC);
LUAD	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg22117172	chr7:91764530	CYP51A1	0.34	7.45	0.34	5.32e-13	Breast cancer;
LUAD	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08704250	chr15:31115839	NA	-0.55	-10.05	-0.44	1.92e-21	Huntington's disease progression;
LUAD	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg06221963	chr1:154839813	KCNN3	-0.85	-19.71	-0.69	8.25e-62	Prostate cancer;
LUAD	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg14552801	chr7:65878734	NA	0.4	6.9	0.32	1.87e-11	Aortic root size;
LUAD	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg11502198	chr6:26597334	ABT1	0.54	9.14	0.41	2.56e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs757110	0.902	rs2074310	chr11:17421886	T/C	cg04705435	chr11:17411270	KCNJ11	0.4	6.36	0.3	5.27e-10	Type 2 diabetes;
LUAD	trans	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg04995722	chr7:26192034	NFE2L3	0.39	6.86	0.32	2.48e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.21	-0.54	1.34e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.73	0.35	8.15e-14	Resting heart rate;
LUAD	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg23625390	chr15:77176239	SCAPER	-0.5	-7.84	-0.36	3.76e-14	Blood metabolite levels;
LUAD	trans	rs55986470	0.646	rs79795396	chr2:239419181	T/C	cg01134436	chr17:81009848	B3GNTL1	0.8	8.18	0.37	3.31e-15	Chronotype;
LUAD	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg03477792	chr4:77819574	ANKRD56	0.48	7.18	0.33	3.23e-12	Emphysema distribution in smoking;
LUAD	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg24558204	chr6:135376177	HBS1L	0.45	8.32	0.38	1.21e-15	Red blood cell count;
LUAD	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg16479474	chr6:28041457	NA	-0.47	-8.13	-0.37	4.77e-15	Depression;
LUAD	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg27539214	chr16:67997921	SLC12A4	-0.66	-8.3	-0.37	1.42e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6499255	0.904	rs9929720	chr16:69557096	C/T	cg00738113	chr16:70207722	CLEC18C	0.39	6.77	0.31	4.31e-11	IgE levels;
LUAD	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg05714579	chr10:131428358	MGMT	0.4	6.53	0.3	1.84e-10	Response to temozolomide;
LUAD	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg02269571	chr22:50332266	NA	-0.61	-9.41	-0.42	3.27e-19	Schizophrenia;
LUAD	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg01251548	chr11:17372745	DKFZp686O24166	-0.4	-7.43	-0.34	6.07e-13	Type 2 diabetes;
LUAD	cis	rs3760982	1.000	rs10421887	chr19:44294849	C/T	cg11993925	chr19:44307056	LYPD5	-0.38	-7.6	-0.35	1.94e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs10865541	0.870	rs6548161	chr2:3424350	A/G	cg22182287	chr2:3452347	TTC15	0.46	7.89	0.36	2.65e-14	Obesity-related traits;
LUAD	cis	rs62400317	0.821	rs72857080	chr6:45198373	G/A	cg18551225	chr6:44695536	NA	-0.55	-8.22	-0.37	2.56e-15	Total body bone mineral density;
LUAD	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg09526685	chr4:187126073	CYP4V2	1.01	10.39	0.45	1.11e-22	Blood protein levels;
LUAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24503407	chr1:205819492	PM20D1	0.91	20.8	0.71	1.03e-66	Menarche (age at onset);
LUAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg21280719	chr6:42927975	GNMT	0.4	12.29	0.51	7.07e-30	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg10862848	chr6:42927986	GNMT	0.32	9.21	0.41	1.49e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.48	-0.3	2.48e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg18171855	chr10:2543474	NA	0.36	7.0	0.32	1.01e-11	Age-related hearing impairment;
LUAD	trans	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg01620082	chr3:125678407	NA	-0.51	-6.92	-0.32	1.71e-11	Depression;
LUAD	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg11663144	chr21:46675770	NA	-0.59	-10.93	-0.47	1.21e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg10053473	chr17:62856997	LRRC37A3	0.78	11.09	0.47	2.96e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.62e-18	Life satisfaction;
LUAD	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg08027265	chr7:2291960	NA	-0.41	-7.15	-0.33	3.87e-12	Schizophrenia;
LUAD	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg10755058	chr3:40428713	ENTPD3	0.46	8.63	0.39	1.25e-16	Renal cell carcinoma;
LUAD	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg25985355	chr7:65971099	NA	-0.56	-6.91	-0.32	1.79e-11	Gout;
LUAD	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg17063962	chr7:91808500	NA	0.71	12.45	0.52	1.53e-30	Breast cancer;
LUAD	cis	rs868036	1.000	rs1026735	chr15:68101700	A/G	cg08079166	chr15:68083412	MAP2K5	0.3	6.49	0.3	2.39e-10	Restless legs syndrome;
LUAD	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg18944383	chr4:111397179	ENPEP	0.34	6.56	0.3	1.6e-10	Height;
LUAD	trans	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg07211511	chr3:129823064	LOC729375	-0.85	-11.93	-0.5	1.76e-28	Blood pressure (smoking interaction);
LUAD	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg09650180	chr20:62225654	GMEB2	-0.47	-6.7	-0.31	6.67e-11	Glioblastoma;
LUAD	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg27427491	chr17:78079615	GAA	-0.38	-6.58	-0.3	1.37e-10	Yeast infection;
LUAD	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg23173402	chr1:227635558	NA	0.71	6.73	0.31	5.44e-11	Major depressive disorder;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg07004357	chr22:18893614	DGCR6	0.42	6.87	0.32	2.35e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg17644776	chr2:200775616	C2orf69	-0.53	-6.66	-0.31	8.36e-11	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg05340658	chr4:99064831	C4orf37	0.56	9.58	0.42	8.67e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg25319279	chr11:5960081	NA	-0.4	-7.03	-0.32	8.44e-12	DNA methylation (variation);
LUAD	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg06558623	chr16:89946397	TCF25	1.15	10.34	0.45	1.72e-22	Skin colour saturation;
LUAD	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg03929089	chr4:120376271	NA	-0.88	-17.17	-0.64	1.66e-50	Height;
LUAD	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg00431813	chr7:1051703	C7orf50	-0.36	-6.45	-0.3	3.06e-10	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.39	0.52	2.65e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg20908204	chr19:46285434	DMPK	-0.43	-9.73	-0.43	2.45e-20	Coronary artery disease;
LUAD	cis	rs2806561	0.695	rs67238799	chr1:23335012	G/A	cg12483005	chr1:23474871	LUZP1	0.43	7.0	0.32	9.95e-12	Height;
LUAD	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.57	-7.36	-0.34	9.77e-13	Body mass index;
LUAD	cis	rs6547631	0.622	rs10180451	chr2:85926238	G/T	cg21473183	chr2:85925749	GNLY	0.35	7.49	0.34	4.02e-13	Blood protein levels;
LUAD	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg12407791	chr17:73824354	UNC13D	-0.32	-6.69	-0.31	6.9e-11	White matter hyperintensity burden;
LUAD	cis	rs11723261	0.664	rs4627799	chr4:132389	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	7.99	0.36	1.26e-14	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs4332037	0.523	rs11770148	chr7:1899447	A/G	cg23422044	chr7:1970798	MAD1L1	-0.53	-6.48	-0.3	2.59e-10	Bipolar disorder;
LUAD	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg25985355	chr7:65971099	NA	0.54	6.64	0.31	9.39e-11	Diabetic kidney disease;
LUAD	cis	rs897984	0.542	rs750952	chr16:31093954	C/T	cg02466173	chr16:30829666	NA	-0.53	-9.24	-0.41	1.19e-18	Dementia with Lewy bodies;
LUAD	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.36e-12	Lung cancer;
LUAD	cis	rs868036	1.000	rs1026732	chr15:68095085	C/T	cg24579218	chr15:68104479	NA	-0.38	-7.14	-0.33	4.16e-12	Restless legs syndrome;
LUAD	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06022373	chr22:39101656	GTPBP1	0.46	7.28	0.33	1.66e-12	Menopause (age at onset);
LUAD	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19717773	chr7:2847554	GNA12	-0.54	-9.21	-0.41	1.48e-18	Height;
LUAD	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg23231163	chr10:75533350	FUT11	-0.51	-9.37	-0.41	4.29e-19	Inflammatory bowel disease;
LUAD	cis	rs9462027	0.628	rs2764211	chr6:34704613	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.35	9.07	0.4	4.49e-18	Systemic lupus erythematosus;
LUAD	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg03161606	chr19:29218774	NA	0.53	6.69	0.31	7.25e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs1868673	1.000	rs1450344	chr3:150185745	G/A	cg04908077	chr3:150187338	NA	-0.32	-6.64	-0.31	9.45e-11	Waist circumference;
LUAD	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg15704280	chr7:45808275	SEPT13	-1.0	-20.25	-0.7	2.94e-64	Coronary artery disease;
LUAD	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg03733263	chr8:22462867	KIAA1967	-0.69	-12.18	-0.51	1.81e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg08048268	chr3:133502702	NA	-0.41	-7.97	-0.36	1.54e-14	Iron status biomarkers;
LUAD	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg12011299	chr4:100065546	ADH4	0.76	15.61	0.6	1e-43	Alcohol dependence;
LUAD	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg10591111	chr5:226296	SDHA	-0.54	-7.26	-0.33	1.86e-12	Breast cancer;
LUAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00149659	chr3:10157352	C3orf10	0.6	8.23	0.37	2.4e-15	Alzheimer's disease;
LUAD	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.63	0.31	1.05e-10	Parkinson's disease;
LUAD	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg08645402	chr16:4508243	NA	0.53	9.8	0.43	1.41e-20	Schizophrenia;
LUAD	cis	rs11971779	0.553	rs10269108	chr7:139106332	G/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.38e-10	Diisocyanate-induced asthma;
LUAD	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg17757837	chr7:157058334	UBE3C	-0.49	-8.63	-0.39	1.29e-16	Body mass index;
LUAD	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg05182265	chr7:156933206	UBE3C	-0.8	-17.24	-0.64	8.1e-51	Body mass index;
LUAD	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.65	-0.35	1.39e-13	Alzheimer's disease (late onset);
LUAD	cis	rs7759001	0.857	rs4305708	chr6:27372303	T/G	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.84e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-9.6	-0.42	7e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg13390004	chr1:15929781	NA	0.48	8.47	0.38	3.95e-16	Systolic blood pressure;
LUAD	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.56	8.17	0.37	3.6e-15	Platelet count;
LUAD	cis	rs60871478	0.645	rs111968669	chr7:856683	C/T	cg00475322	chr7:917719	C7orf20	0.51	7.11	0.33	4.94e-12	Cerebrospinal P-tau181p levels;
LUAD	trans	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.26	-0.37	1.93e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg20528787	chr7:158032352	PTPRN2	0.34	6.49	0.3	2.44e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6028335	0.674	rs66647661	chr20:37671577	C/T	cg27660920	chr20:37554817	FAM83D	0.53	6.67	0.31	7.98e-11	Alcohol and nicotine co-dependence;
LUAD	cis	rs1387259	0.690	rs1601985	chr12:48761914	A/G	cg04545296	chr12:48745243	ZNF641	0.4	10.11	0.44	1.18e-21	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs7927592	0.789	rs2291467	chr11:68216756	C/T	cg20283391	chr11:68216788	NA	-0.47	-7.17	-0.33	3.33e-12	Total body bone mineral density;
LUAD	cis	rs250677	0.559	rs17109198	chr5:148369712	C/T	cg18129178	chr5:148520854	ABLIM3	-0.51	-7.62	-0.35	1.72e-13	Breast cancer;
LUAD	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg22532475	chr10:104410764	TRIM8	-0.48	-9.21	-0.41	1.53e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg17366294	chr4:99064904	C4orf37	0.65	12.39	0.52	2.75e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9796	0.870	rs2412572	chr15:41264426	G/C	cg18705301	chr15:41695430	NDUFAF1	0.37	6.82	0.31	3.06e-11	Menopause (age at onset);
LUAD	cis	rs11771526	1.000	rs17351142	chr7:32339843	T/G	cg27511599	chr7:32358540	NA	0.61	7.15	0.33	3.84e-12	Body mass index;
LUAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.41	-7.34	-0.34	1.09e-12	Longevity;Endometriosis;
LUAD	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg17264618	chr3:40429014	ENTPD3	0.39	8.12	0.37	4.97e-15	Renal cell carcinoma;
LUAD	cis	rs7771547	0.723	rs73423325	chr6:36554289	G/A	cg07856975	chr6:36356162	ETV7	0.45	6.39	0.3	4.41e-10	Platelet distribution width;
LUAD	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg12310025	chr6:25882481	NA	-0.58	-9.61	-0.42	6.79e-20	Blood metabolite levels;
LUAD	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg23029597	chr12:123009494	RSRC2	-0.58	-9.24	-0.41	1.21e-18	Body mass index;
LUAD	cis	rs8044995	0.563	rs7190134	chr16:68381516	A/G	cg09835421	chr16:68378352	PRMT7	1.03	12.01	0.5	8.2e-29	Schizophrenia;
LUAD	cis	rs7617773	0.780	rs7632297	chr3:48348163	A/C	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.91	0.36	2.27e-14	Bladder cancer;
LUAD	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg24578937	chr1:2090814	PRKCZ	0.79	15.79	0.61	1.69e-44	Height;
LUAD	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11644478	chr21:40555479	PSMG1	-0.54	-8.64	-0.39	1.2e-16	Cognitive function;
LUAD	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg06618935	chr21:46677482	NA	0.48	9.42	0.42	2.98e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4812048	0.895	rs236691	chr20:57583536	G/C	cg14073986	chr20:57617431	SLMO2	0.52	6.71	0.31	6.34e-11	Mean platelet volume;
LUAD	cis	rs887829	0.570	rs7563561	chr2:234598991	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.7	-0.43	3.3e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs3760982	0.585	rs8109812	chr19:44298494	C/A	cg12072164	chr19:44306565	LYPD5	0.42	8.53	0.38	2.57e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs9948	0.655	rs17119591	chr2:97435557	G/A	cg20312557	chr2:97357134	FER1L5	-0.75	-8.48	-0.38	3.77e-16	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg11301795	chr4:187892539	NA	-0.72	-14.33	-0.57	3.05e-38	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg19626725	chr5:178986131	RUFY1	0.44	8.01	0.36	1.1e-14	Lung cancer;
LUAD	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.24	0.37	2.17e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg08601574	chr20:25228251	PYGB	-0.44	-8.16	-0.37	3.82e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg16647868	chr5:131706066	SLC22A5	0.39	6.43	0.3	3.43e-10	Blood metabolite levels;
LUAD	trans	rs7246760	0.867	rs8102257	chr19:9830795	C/T	cg02900749	chr2:68251473	NA	-0.56	-6.49	-0.3	2.42e-10	Pursuit maintenance gain;
LUAD	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.35	-6.77	-0.31	4.41e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	trans	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg18335740	chr13:41363409	SLC25A15	0.53	9.17	0.41	2.01e-18	Lewy body disease;
LUAD	cis	rs9786986	0.764	rs10925929	chr1:235696885	C/T	cg08848088	chr1:235714526	GNG4	0.51	6.48	0.3	2.52e-10	Body mass index;
LUAD	cis	rs9462027	0.583	rs2744974	chr6:34579431	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.88	-0.4	1.95e-17	Systemic lupus erythematosus;
LUAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg08888203	chr3:10149979	C3orf24	0.68	10.85	0.47	2.23e-24	Alzheimer's disease;
LUAD	cis	rs146009840	1	rs146009840	chr15:78906177	A/T	cg18825076	chr15:78729989	IREB2	-0.57	-9.12	-0.41	3.16e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs9535307	0.769	rs9535306	chr13:50290817	A/G	cg03658251	chr13:50265850	EBPL	0.5	6.51	0.3	2.15e-10	Obesity-related traits;
LUAD	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-9.68	-0.43	3.91e-20	Gut microbiome composition (summer);
LUAD	cis	rs9796	0.870	rs1001341	chr15:41261491	T/A	cg18705301	chr15:41695430	NDUFAF1	0.4	7.6	0.35	1.91e-13	Menopause (age at onset);
LUAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	7.46	0.34	4.82e-13	Alzheimer's disease;
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg04882175	chr6:131122610	NA	-0.41	-6.37	-0.3	4.85e-10	Height;
LUAD	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg24803719	chr17:45855879	NA	-0.33	-7.53	-0.34	3.13e-13	IgG glycosylation;
LUAD	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg03714773	chr7:91764589	CYP51A1	0.27	6.54	0.3	1.8e-10	Breast cancer;
LUAD	cis	rs7830933	0.780	rs6983481	chr8:23609009	G/T	cg04349084	chr8:23602677	NA	0.48	6.93	0.32	1.58e-11	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
LUAD	cis	rs2235649	0.704	rs1742425	chr16:1904524	G/A	cg08610935	chr16:1836813	NUBP2	-0.48	-7.07	-0.33	6.43e-12	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22691505	chr7:6312217	CYTH3	-0.56	-6.86	-0.32	2.44e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg07930552	chr6:133119739	C6orf192	0.63	7.39	0.34	7.95e-13	Type 2 diabetes nephropathy;
LUAD	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg16414030	chr3:133502952	NA	-0.51	-9.1	-0.4	3.69e-18	Iron status biomarkers;
LUAD	cis	rs1215050	0.791	rs165242	chr4:98686482	A/C	cg17366294	chr4:99064904	C4orf37	-0.4	-6.84	-0.32	2.79e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg07617317	chr6:118971624	C6orf204	0.54	8.01	0.36	1.11e-14	Diastolic blood pressure;
LUAD	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg05991184	chr2:219186017	PNKD	-0.37	-7.21	-0.33	2.64e-12	Colorectal cancer;
LUAD	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg04369109	chr6:150039330	LATS1	-0.45	-7.5	-0.34	3.85e-13	Lung cancer;
LUAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg01448562	chr3:133502909	NA	0.79	16.24	0.62	1.87e-46	Iron status biomarkers;
LUAD	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg08508325	chr11:3079039	CARS	-0.53	-11.09	-0.47	2.9e-25	Longevity;
LUAD	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg00310523	chr12:86230176	RASSF9	0.41	8.08	0.37	6.88e-15	Major depressive disorder;
LUAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg08027265	chr7:2291960	NA	0.41	6.96	0.32	1.28e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg07169764	chr2:136633963	MCM6	0.79	9.3	0.41	7.44e-19	Corneal structure;
LUAD	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg00339695	chr16:24857497	SLC5A11	0.71	10.99	0.47	6.84e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.39	0.42	3.76e-19	Colorectal cancer;
LUAD	cis	rs11249608	0.636	rs6868893	chr5:178449826	C/A	cg01312482	chr5:178451176	ZNF879	-0.44	-6.7	-0.31	6.67e-11	Pubertal anthropometrics;
LUAD	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg19418458	chr7:158789849	NA	-0.55	-9.9	-0.43	6.52e-21	Facial morphology (factor 20);
LUAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg11494091	chr17:61959527	GH2	0.74	18.63	0.67	5.61e-57	Prudent dietary pattern;
LUAD	trans	rs1493916	1.000	rs990882	chr18:31398180	T/G	cg15819921	chr19:927150	ARID3A	-0.45	-7.31	-0.33	1.39e-12	Life satisfaction;
LUAD	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg07636037	chr3:49044803	WDR6	0.63	12.26	0.51	8.57e-30	Parkinson's disease;
LUAD	cis	rs11771526	0.792	rs28394389	chr7:32298509	C/T	cg27532318	chr7:32358331	NA	0.56	7.2	0.33	2.73e-12	Body mass index;
LUAD	cis	rs9487051	0.734	rs56214745	chr6:109536748	G/T	cg21918786	chr6:109611834	NA	-0.43	-7.51	-0.34	3.61e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg21681030	chr2:46777652	RHOQ	0.46	7.83	0.36	4.01e-14	Height;
LUAD	cis	rs977987	0.778	rs2113232	chr16:75391185	T/C	cg03315344	chr16:75512273	CHST6	0.65	14.19	0.57	1.22e-37	Dupuytren's disease;
LUAD	cis	rs8077889	0.917	rs9901676	chr17:41911818	T/C	cg26893861	chr17:41843967	DUSP3	0.91	15.54	0.6	2.09e-43	Triglycerides;
LUAD	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg09796270	chr17:17721594	SREBF1	0.35	6.51	0.3	2.11e-10	Total body bone mineral density;
LUAD	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.35e-11	Breast cancer;
LUAD	cis	rs6460942	1.000	rs7808819	chr7:12297440	C/T	cg06484146	chr7:12443880	VWDE	-0.55	-6.95	-0.32	1.36e-11	Coronary artery disease;
LUAD	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg03983476	chr2:10830698	NOL10	0.48	8.37	0.38	8.2e-16	Prostate cancer;
LUAD	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg12927641	chr6:109611667	NA	-0.53	-9.21	-0.41	1.54e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg06064525	chr11:970664	AP2A2	-0.43	-8.36	-0.38	9.3e-16	Alzheimer's disease (late onset);
LUAD	cis	rs747650	0.859	rs4567413	chr11:47232184	A/G	cg19486271	chr11:47235900	DDB2	-0.45	-7.44	-0.34	5.66e-13	Acne (severe);
LUAD	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg00074818	chr8:8560427	CLDN23	-0.6	-9.55	-0.42	1.09e-19	Obesity-related traits;
LUAD	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg19302996	chr17:73780495	UNK	-0.39	-6.63	-0.31	1.01e-10	White matter hyperintensity burden;
LUAD	cis	rs11169225	1.000	rs11169225	chr12:50345671	T/A	cg09002919	chr12:50339186	NA	0.58	7.08	0.33	6.23e-12	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg12062639	chr20:23401060	NAPB	1.1	11.08	0.47	3.16e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	12.44	0.52	1.8e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6906287	0.573	rs11153732	chr6:118704967	C/T	cg18833306	chr6:118973337	C6orf204	0.46	8.18	0.37	3.47e-15	Electrocardiographic conduction measures;
LUAD	cis	rs4072705	0.646	rs915034	chr9:127244955	G/A	cg13476313	chr9:127244764	NR5A1	0.37	9.34	0.41	5.59e-19	Menarche (age at onset);
LUAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg18402987	chr7:1209562	NA	0.78	9.54	0.42	1.15e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg22906224	chr7:99728672	NA	0.61	10.0	0.44	2.76e-21	Coronary artery disease;
LUAD	cis	rs6546550	0.935	rs13392884	chr2:70036711	A/G	cg02498382	chr2:70120550	SNRNP27	-0.53	-9.78	-0.43	1.67e-20	Prevalent atrial fibrillation;
LUAD	cis	rs9788721	0.934	rs1051730	chr15:78894339	G/A	cg18825076	chr15:78729989	IREB2	-0.57	-9.22	-0.41	1.39e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg23254163	chr1:152506842	NA	0.25	6.8	0.31	3.59e-11	Hair morphology;
LUAD	cis	rs6960043	0.818	rs10258074	chr7:15064216	A/T	cg19272540	chr7:15055459	NA	-0.36	-7.88	-0.36	2.71e-14	Type 2 diabetes;
LUAD	cis	rs7737355	0.812	rs13172003	chr5:131087656	T/C	cg06307176	chr5:131281290	NA	0.46	7.74	0.35	7.32e-14	Life satisfaction;
LUAD	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg00684032	chr4:1343700	KIAA1530	0.39	6.68	0.31	7.55e-11	Obesity-related traits;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg18493069	chr6:108582623	SNX3	-0.51	-7.09	-0.33	5.6e-12	Testicular germ cell tumor;
LUAD	cis	rs8077889	0.763	rs4792913	chr17:41854497	T/C	cg26893861	chr17:41843967	DUSP3	1.13	25.38	0.78	5e-87	Triglycerides;
LUAD	trans	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.16	28.67	0.81	3.25e-101	Colorectal cancer;
LUAD	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg11822812	chr5:140052017	DND1	-0.36	-6.56	-0.3	1.6e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11893307	0.509	rs2109957	chr2:191535311	T/C	cg11845111	chr2:191398756	TMEM194B	-0.48	-6.94	-0.32	1.51e-11	Mean platelet volume;
LUAD	cis	rs2357013	0.725	rs6545317	chr2:53227148	A/T	cg07782112	chr2:53107842	NA	-0.35	-6.88	-0.32	2.13e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg21191810	chr6:118973309	C6orf204	0.5	7.74	0.35	7.18e-14	Diastolic blood pressure;
LUAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg20607798	chr8:58055168	NA	0.68	9.04	0.4	5.65e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs35306767	0.855	rs12770190	chr10:951262	C/T	cg20503657	chr10:835505	NA	0.94	12.86	0.53	3.47e-32	Eosinophil percentage of granulocytes;
LUAD	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12667521	chr19:29218732	NA	0.59	8.42	0.38	6.1e-16	Methadone dose in opioid dependence;
LUAD	cis	rs1395	0.961	rs4665965	chr2:27536380	C/T	cg23587288	chr2:27483067	SLC30A3	0.37	7.03	0.32	8.15e-12	Blood metabolite levels;
LUAD	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg11339718	chr16:89000225	CBFA2T3	-0.34	-6.46	-0.3	2.85e-10	Social autistic-like traits;
LUAD	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg18180107	chr4:99064573	C4orf37	0.42	6.74	0.31	5.2e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.2	16.62	0.63	4.41e-48	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.99	-0.36	1.33e-14	Monocyte percentage of white cells;
LUAD	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg26408565	chr15:76604113	ETFA	-0.49	-7.77	-0.35	5.82e-14	Blood metabolite levels;
LUAD	cis	rs123509	0.687	rs73077220	chr3:42842340	T/C	cg10144569	chr3:42726640	KBTBD5	-0.48	-7.12	-0.33	4.74e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs938554	0.577	rs7683856	chr4:10000947	A/G	cg00071950	chr4:10020882	SLC2A9	0.61	9.48	0.42	1.89e-19	Blood metabolite levels;
LUAD	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg06387496	chr7:2775674	GNA12	-0.4	-6.7	-0.31	6.84e-11	Height;
LUAD	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg17173187	chr15:85201210	NMB	0.47	8.15	0.37	4.17e-15	Schizophrenia;
LUAD	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg14186256	chr22:23484241	RTDR1	0.47	8.05	0.36	8.64e-15	Bone mineral density;
LUAD	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg23583168	chr7:148888333	NA	-0.91	-18.75	-0.67	1.62e-57	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg07636037	chr3:49044803	WDR6	0.35	6.37	0.3	4.8e-10	Resting heart rate;
LUAD	cis	rs6076065	0.548	rs1112819	chr20:23323987	A/G	cg11657817	chr20:23433608	CST11	0.53	11.2	0.48	1.13e-25	Facial morphology (factor 15, philtrum width);
LUAD	trans	rs5756813	1.000	rs5756813	chr22:38175477	A/C	cg19894588	chr14:64061835	NA	-0.57	-9.17	-0.41	2.07e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg05590025	chr7:65112418	INTS4L2	0.74	8.06	0.36	7.95e-15	Diabetic kidney disease;
LUAD	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg00634984	chr7:65235879	NA	0.49	6.86	0.32	2.44e-11	Aortic root size;
LUAD	cis	rs2797160	1.000	rs1578794	chr6:126015469	T/C	cg05901451	chr6:126070800	HEY2	0.45	6.71	0.31	6.22e-11	Endometrial cancer;
LUAD	trans	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg06175025	chr14:78082992	SPTLC2	0.39	6.36	0.3	5.34e-10	Bone mineral density;
LUAD	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg18944383	chr4:111397179	ENPEP	0.38	7.76	0.35	6.25e-14	Height;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg25798026	chr22:32149910	DEPDC5	0.37	6.6	0.31	1.22e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg06028605	chr16:24865363	SLC5A11	0.41	7.19	0.33	3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg13560548	chr3:10150139	C3orf24	0.4	6.56	0.3	1.53e-10	Alzheimer's disease;
LUAD	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg23649088	chr2:200775458	C2orf69	0.62	8.21	0.37	2.77e-15	Schizophrenia;
LUAD	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg18105134	chr13:113819100	PROZ	-1.0	-18.41	-0.67	5.1e-56	Platelet distribution width;
LUAD	cis	rs1215050	0.791	rs548892	chr4:98724701	C/T	cg05340658	chr4:99064831	C4orf37	0.44	7.3	0.33	1.43e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18099408	chr3:52552593	STAB1	-0.46	-8.03	-0.36	9.79e-15	Bipolar disorder;
LUAD	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg19875535	chr5:140030758	IK	0.45	7.42	0.34	6.44e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00166722	chr3:10149974	C3orf24	-0.69	-11.8	-0.5	5.89e-28	Alzheimer's disease;
LUAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg20126647	chr17:40714003	COASY	-0.41	-6.92	-0.32	1.66e-11	Colorectal or endometrial cancer;
LUAD	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg10755058	chr3:40428713	ENTPD3	0.45	8.47	0.38	4.09e-16	Renal cell carcinoma;
LUAD	cis	rs7809950	1.000	rs7782057	chr7:107098877	T/A	cg23024343	chr7:107201750	COG5	-0.73	-12.27	-0.51	8.18e-30	Coronary artery disease;
LUAD	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg08470875	chr2:26401718	FAM59B	-0.77	-10.45	-0.45	7e-23	Gut microbiome composition (summer);
LUAD	trans	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.0	-0.4	7.63e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg03929089	chr4:120376271	NA	-0.94	-17.81	-0.65	2.37e-53	Coronary artery disease;
LUAD	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg10518543	chr12:38710700	ALG10B	0.5	8.19	0.37	3.09e-15	Morning vs. evening chronotype;
LUAD	trans	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg05926928	chr17:57297772	GDPD1	-0.52	-7.51	-0.34	3.66e-13	Schizophrenia;
LUAD	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg03806693	chr22:41940476	POLR3H	-0.78	-11.06	-0.47	3.63e-25	Vitiligo;
LUAD	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg06636551	chr8:101224915	SPAG1	0.36	6.61	0.31	1.16e-10	Atrioventricular conduction;
LUAD	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg13535736	chr9:111863775	C9orf5	-0.43	-6.66	-0.31	8.37e-11	Menarche (age at onset);
LUAD	cis	rs346785	0.692	rs8074821	chr17:74293099	A/G	cg09812376	chr17:74270190	QRICH2	-0.31	-6.45	-0.3	3.01e-10	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs2908197	0.788	rs6465111	chr7:75991378	A/G	cg24580635	chr7:76178542	LOC100133091	-0.42	-6.73	-0.31	5.67e-11	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg02454025	chr1:11042201	C1orf127	1.04	17.71	0.65	6.82e-53	Ewing sarcoma;
LUAD	cis	rs116248771	0.739	rs73156437	chr3:158359284	T/C	cg16708174	chr3:158430962	RARRES1	0.47	6.82	0.31	3.07e-11	diarrhoeal disease at age 2;
LUAD	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg25753631	chr6:25732923	NA	-0.45	-7.98	-0.36	1.37e-14	Iron status biomarkers;
LUAD	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg23803603	chr1:2058230	PRKCZ	0.4	7.23	0.33	2.31e-12	Height;
LUAD	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg25828334	chr19:18545568	ISYNA1	-0.39	-7.82	-0.36	4.17e-14	Breast cancer;
LUAD	cis	rs9796	0.727	rs12101934	chr15:41353079	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.41	-7.5	-0.34	3.85e-13	Menopause (age at onset);
LUAD	cis	rs859767	0.741	rs6759065	chr2:135389197	A/G	cg12500956	chr2:135428796	TMEM163	-0.29	-7.77	-0.35	6.02e-14	Neuroticism;
LUAD	cis	rs4594175	0.926	rs10138269	chr14:51615360	T/C	cg23942311	chr14:51606299	NA	0.64	11.16	0.48	1.61e-25	Cancer;
LUAD	cis	rs863345	0.625	rs12063360	chr1:158499494	A/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg23815491	chr16:72088622	HP	0.52	9.56	0.42	9.44e-20	Fibrinogen levels;
LUAD	cis	rs6494488	0.500	rs72742930	chr15:64870344	A/T	cg08069370	chr15:64387884	SNX1	-0.74	-6.56	-0.3	1.62e-10	Coronary artery disease;
LUAD	cis	rs9535307	0.719	rs1009333	chr13:50383341	T/C	cg04663916	chr13:50265991	EBPL	-0.62	-6.96	-0.32	1.31e-11	Obesity-related traits;
LUAD	cis	rs12472274	0.941	rs12616232	chr2:239080093	C/T	cg17459225	chr2:239074497	NA	0.66	9.09	0.4	3.92e-18	Phospholipid levels (plasma);
LUAD	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg25767906	chr1:53392781	SCP2	0.38	6.97	0.32	1.21e-11	Monocyte count;
LUAD	cis	rs921968	0.565	rs586194	chr2:219610433	A/G	cg02176678	chr2:219576539	TTLL4	-0.55	-10.67	-0.46	1.06e-23	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg03388025	chr16:89894329	SPIRE2	-0.32	-6.99	-0.32	1.08e-11	Vitiligo;
LUAD	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg12311346	chr5:56204834	C5orf35	-0.56	-9.0	-0.4	7.61e-18	Coronary artery disease;
LUAD	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg24818145	chr4:99064322	C4orf37	0.43	7.18	0.33	3.22e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2762353	0.574	rs4409177	chr6:25694491	T/G	cg15691649	chr6:25882328	NA	0.63	9.67	0.43	4.23e-20	Blood metabolite levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09114546	chr16:70099078	PDXDC2	-0.39	-6.75	-0.31	4.8e-11	Cancer;
LUAD	cis	rs7828089	0.819	rs12548353	chr8:22243491	T/C	cg12081754	chr8:22256438	SLC39A14	0.52	9.18	0.41	1.9e-18	Verbal declarative memory;
LUAD	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg06618935	chr21:46677482	NA	-0.42	-8.45	-0.38	4.67e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg09537434	chr19:41945824	ATP5SL	-0.52	-8.22	-0.37	2.55e-15	Height;
LUAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.74	-0.35	7.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg17366294	chr4:99064904	C4orf37	-0.48	-8.35	-0.38	9.53e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg10518543	chr12:38710700	ALG10B	-0.41	-6.43	-0.3	3.48e-10	Bladder cancer;
LUAD	cis	rs11958404	0.932	rs11950881	chr5:157410550	C/T	cg05962755	chr5:157440814	NA	0.46	6.73	0.31	5.52e-11	IgG glycosylation;
LUAD	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg11247378	chr22:39784982	NA	-0.76	-14.27	-0.57	5.33e-38	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg09658497	chr7:2847517	GNA12	-0.56	-9.47	-0.42	1.94e-19	Height;
LUAD	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.18	-0.44	6.5e-22	Platelet count;
LUAD	cis	rs72772090	0.539	rs56213813	chr5:96112284	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-7.36	-0.34	9.41e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1497406	0.744	rs7538966	chr1:16504549	T/C	cg02998240	chr1:16508668	NA	-0.23	-6.75	-0.31	5.02e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg06784218	chr1:46089804	CCDC17	-0.6	-13.34	-0.54	3.85e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2485376	0.546	rs10748816	chr10:103987986	G/A	cg20641465	chr10:103991465	PITX3	0.45	7.93	0.36	1.95e-14	QT interval;
LUAD	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg24558204	chr6:135376177	HBS1L	0.47	8.67	0.39	9.21e-17	Reticulocyte count;High light scatter reticulocyte count;
LUAD	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg11645453	chr3:52864694	ITIH4	0.53	9.3	0.41	7.6e-19	Schizophrenia;
LUAD	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg23172400	chr8:95962367	TP53INP1	-0.37	-8.9	-0.4	1.62e-17	Type 2 diabetes;
LUAD	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg02734326	chr4:10020555	SLC2A9	0.5	8.68	0.39	8.67e-17	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg18827107	chr12:86230957	RASSF9	-0.53	-9.31	-0.41	7.2e-19	Major depressive disorder;
LUAD	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-16.14	-0.62	5.45e-46	Chronic sinus infection;
LUAD	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg27661571	chr11:113659931	NA	-0.55	-6.82	-0.31	3.18e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg27535305	chr1:53392650	SCP2	-0.34	-6.97	-0.32	1.22e-11	Monocyte count;
LUAD	trans	rs8002861	0.905	rs12428350	chr13:44446161	G/A	cg17145862	chr1:211918768	LPGAT1	-0.69	-15.07	-0.59	2.28e-41	Leprosy;
LUAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg01448562	chr3:133502909	NA	-0.78	-15.05	-0.59	2.75e-41	Iron status biomarkers;
LUAD	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg02038168	chr22:39784481	NA	-0.58	-10.2	-0.44	5.49e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs9473147	0.516	rs9395279	chr6:47542864	C/T	cg20196966	chr6:47445060	CD2AP	0.44	7.01	0.32	9.26e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg18827107	chr12:86230957	RASSF9	-0.7	-12.83	-0.53	4.78e-32	Major depressive disorder;
LUAD	cis	rs7180079	1.000	rs7176847	chr15:64552207	C/G	cg08069370	chr15:64387884	SNX1	-0.51	-6.56	-0.3	1.6e-10	Monocyte count;
LUAD	cis	rs6960043	0.782	rs4721401	chr7:15064896	T/G	cg19272540	chr7:15055459	NA	-0.35	-7.72	-0.35	8.5e-14	Type 2 diabetes;
LUAD	cis	rs9393692	0.557	rs56763414	chr6:26286468	T/C	cg00631329	chr6:26305371	NA	-0.52	-8.26	-0.37	1.89e-15	Educational attainment;
LUAD	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg04990556	chr1:26633338	UBXN11	-0.39	-6.46	-0.3	2.93e-10	Obesity-related traits;
LUAD	cis	rs28595532	0.668	rs56410164	chr4:119331625	A/G	cg02775129	chr4:119771670	NA	-0.65	-6.48	-0.3	2.57e-10	Cannabis dependence symptom count;
LUAD	cis	rs6881634	0.501	rs66602879	chr5:77728196	T/C	cg11547950	chr5:77652471	NA	-0.35	-6.35	-0.3	5.51e-10	Hippocampal atrophy;
LUAD	cis	rs7192380	0.965	rs7187634	chr16:69663371	T/C	cg26679644	chr16:69762563	NA	0.5	9.73	0.43	2.49e-20	Sjögren's syndrome;
LUAD	cis	rs11690462	0.926	rs12615704	chr2:26551903	G/C	cg13255216	chr2:26625047	C2orf39	0.37	6.4	0.3	4.1e-10	Coronary artery disease;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg00941745	chr8:109261117	EIF3E	-0.42	-7.13	-0.33	4.51e-12	Subcortical brain region volumes;
LUAD	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.47	0.38	4.01e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg16325326	chr1:53192061	ZYG11B	0.67	13.04	0.54	6.69e-33	Monocyte count;
LUAD	cis	rs2073300	1.000	rs12625804	chr20:23441981	G/A	cg09953122	chr20:23471693	CST8	-0.65	-6.39	-0.3	4.29e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg02176678	chr2:219576539	TTLL4	-0.83	-17.6	-0.65	2.12e-52	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.73	0.31	5.69e-11	Menarche (age at onset);
LUAD	cis	rs1550582	0.547	rs6991998	chr8:135580221	C/A	cg17885191	chr8:135476712	NA	0.63	8.25	0.37	2.08e-15	Educational attainment;
LUAD	cis	rs3806843	0.576	rs246062	chr5:140324580	T/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.61	-0.31	1.19e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg07677032	chr17:61819896	STRADA	0.57	10.23	0.45	4.42e-22	Prudent dietary pattern;
LUAD	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.3	6.53	0.3	1.89e-10	Parkinson's disease;
LUAD	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg03929089	chr4:120376271	NA	-0.98	-20.58	-0.71	1.01e-65	Height;
LUAD	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg00666640	chr1:248458726	OR2T12	0.34	8.27	0.37	1.81e-15	Common traits (Other);
LUAD	cis	rs4372836	0.729	rs4666122	chr2:29092850	G/T	cg09522027	chr2:28974177	PPP1CB	0.65	11.4	0.48	2.02e-26	Body mass index;
LUAD	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg00933542	chr6:150070202	PCMT1	0.42	8.76	0.39	4.75e-17	Lung cancer;
LUAD	cis	rs8025790	0.508	rs28673019	chr15:67809823	T/A	cg24579218	chr15:68104479	NA	-0.49	-8.03	-0.36	9.98e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03264133	chr6:25882463	NA	0.47	7.09	0.33	5.61e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg05110241	chr16:68378359	PRMT7	-0.81	-8.72	-0.39	6.45e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07636037	chr3:49044803	WDR6	0.48	8.39	0.38	7.24e-16	Menarche (age at onset);
LUAD	cis	rs2235649	0.592	rs11647980	chr16:1959753	G/A	cg08610935	chr16:1836813	NUBP2	-0.51	-7.44	-0.34	5.57e-13	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15414828	chr11:71791511	LRTOMT;NUMA1	-0.57	-7.17	-0.33	3.32e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg05665937	chr4:1216051	CTBP1	0.45	7.92	0.36	2.17e-14	Obesity-related traits;
LUAD	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg15557168	chr22:42548783	NA	-0.48	-8.53	-0.38	2.67e-16	Schizophrenia;
LUAD	cis	rs55823223	0.648	rs56901103	chr17:73865667	C/A	cg08125733	chr17:73851984	WBP2	0.58	8.44	0.38	5.19e-16	Psoriasis;
LUAD	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg04398451	chr17:18023971	MYO15A	0.63	11.25	0.48	7.05e-26	Total body bone mineral density;
LUAD	trans	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg07936489	chr17:37558343	FBXL20	-0.45	-7.08	-0.33	6.02e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg03467027	chr4:99064603	C4orf37	0.4	6.46	0.3	2.93e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11048434	0.673	rs1124402	chr12:9062606	C/T	cg13575925	chr12:9217583	LOC144571	0.37	6.86	0.32	2.42e-11	Sjögren's syndrome;
LUAD	cis	rs3857067	0.806	rs11943926	chr4:95136512	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.38	-6.82	-0.31	3.06e-11	QT interval;
LUAD	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	7.95	0.36	1.68e-14	Rheumatoid arthritis;
LUAD	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	7.78	0.35	5.7e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24394865	chr11:66206319	MRPL11	0.43	6.49	0.3	2.4e-10	Gut microbiome composition (summer);
LUAD	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg00857998	chr1:205179979	DSTYK	0.4	6.68	0.31	7.41e-11	Red blood cell count;
LUAD	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	9.43	0.42	2.76e-19	Melanoma;
LUAD	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg17063962	chr7:91808500	NA	-0.68	-12.03	-0.51	6.84e-29	Breast cancer;
LUAD	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg14092988	chr3:52407081	DNAH1	0.44	8.83	0.39	2.75e-17	Bipolar disorder;
LUAD	cis	rs6445967	0.530	rs57925583	chr3:58393153	T/G	cg23715586	chr3:58305044	RPP14	0.41	6.73	0.31	5.52e-11	Platelet count;
LUAD	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg02569458	chr12:86230093	RASSF9	-0.41	-7.6	-0.35	1.95e-13	Major depressive disorder;
LUAD	cis	rs28595532	0.764	rs115916994	chr4:119688758	A/G	cg21605333	chr4:119757512	SEC24D	0.83	7.78	0.35	5.59e-14	Cannabis dependence symptom count;
LUAD	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg07741184	chr6:167504864	NA	0.35	8.01	0.36	1.12e-14	Primary biliary cholangitis;
LUAD	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg18252515	chr7:66147081	NA	-0.63	-6.86	-0.32	2.52e-11	Diabetic kidney disease;
LUAD	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.86	0.32	2.46e-11	Obesity-related traits;
LUAD	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	7.48	0.34	4.2e-13	Schizophrenia;
LUAD	cis	rs9522267	0.502	rs9515450	chr13:112234262	T/C	cg10483660	chr13:112241077	NA	-0.31	-6.62	-0.31	1.09e-10	Hepatitis;
LUAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	8.96	0.4	1.06e-17	Platelet count;
LUAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-9.21	-0.41	1.53e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.35	-0.34	1.06e-12	Resting heart rate;
LUAD	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg01416388	chr22:39784598	NA	-0.52	-8.73	-0.39	6.02e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.58	0.52	4.73e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg17971929	chr21:40555470	PSMG1	0.57	8.98	0.4	9.14e-18	Cognitive function;
LUAD	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg13334819	chr7:99746414	C7orf59	-0.64	-10.24	-0.45	4.04e-22	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21005948	chr18:46065258	KIAA0427	-0.53	-6.46	-0.3	2.87e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7474896	0.526	rs1208716	chr10:38089273	T/A	cg25427524	chr10:38739819	LOC399744	-0.62	-8.77	-0.39	4.42e-17	Obesity (extreme);
LUAD	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg07936489	chr17:37558343	FBXL20	-0.46	-7.26	-0.33	1.82e-12	Glomerular filtration rate (creatinine);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg19262334	chr18:74631861	ZNF236	-0.42	-7.2	-0.33	2.84e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg24818145	chr4:99064322	C4orf37	0.45	7.65	0.35	1.35e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7193541	0.684	rs7191665	chr16:74688948	T/G	cg01733217	chr16:74700730	RFWD3	0.68	13.53	0.55	6.68e-35	Multiple myeloma;
LUAD	trans	rs1997103	0.863	rs6956287	chr7:55415107	T/C	cg20935933	chr6:143382018	AIG1	0.54	7.36	0.34	9.44e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg14343924	chr8:8086146	FLJ10661	-0.46	-7.4	-0.34	7.55e-13	Joint mobility (Beighton score);
LUAD	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg22532475	chr10:104410764	TRIM8	0.34	6.85	0.32	2.57e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg27446573	chr6:127587934	RNF146	0.44	6.62	0.31	1.06e-10	Breast cancer;
LUAD	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg02524346	chr8:600233	NA	0.82	8.38	0.38	7.67e-16	IgG glycosylation;
LUAD	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.33	0.45	1.84e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs41271473	0.526	rs1925720	chr1:228728377	G/C	cg10167378	chr1:228756711	NA	0.68	9.14	0.41	2.59e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs17095355	1.000	rs975442	chr10:111705895	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.71	-9.39	-0.42	3.76e-19	Biliary atresia;
LUAD	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg26513180	chr16:89883248	FANCA	0.82	7.41	0.34	6.77e-13	Skin colour saturation;
LUAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg07217954	chr7:1067459	C7orf50	0.43	6.66	0.31	8.41e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg22138573	chr13:60718665	DIAPH3	-0.39	-6.72	-0.31	5.71e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg07402062	chr16:89894098	SPIRE2	0.45	11.48	0.49	9.4e-27	Vitiligo;
LUAD	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg22823121	chr1:150693482	HORMAD1	0.44	8.91	0.4	1.55e-17	Tonsillectomy;
LUAD	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg08847533	chr14:75593920	NEK9	-0.38	-6.43	-0.3	3.5e-10	Height;
LUAD	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg01765077	chr12:122356316	WDR66	0.6	10.16	0.44	7.78e-22	Mean corpuscular volume;
LUAD	cis	rs2637266	1.000	rs2579761	chr10:78321040	C/T	cg18941641	chr10:78392320	NA	0.32	6.61	0.31	1.13e-10	Pulmonary function;
LUAD	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg09365446	chr1:150670422	GOLPH3L	0.63	10.99	0.47	6.79e-25	Melanoma;
LUAD	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.97	0.36	1.44e-14	Parkinson's disease;
LUAD	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg10523679	chr1:76189770	ACADM	-0.75	-11.72	-0.5	1.14e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg11502198	chr6:26597334	ABT1	0.64	11.09	0.47	2.91e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-7.85	-0.36	3.42e-14	Bipolar disorder;
LUAD	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg05590025	chr7:65112418	INTS4L2	0.74	7.9	0.36	2.39e-14	Diabetic kidney disease;
LUAD	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	9.83	0.43	1.12e-20	Electrocardiographic conduction measures;
LUAD	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg18129178	chr5:148520854	ABLIM3	-0.62	-9.52	-0.42	1.32e-19	Breast cancer;
LUAD	cis	rs10193935	1.000	rs12612527	chr2:42392099	T/C	cg27598129	chr2:42591480	NA	-0.82	-9.67	-0.43	4.22e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6062509	0.965	rs1056441	chr20:62370349	T/C	cg01176363	chr20:62369445	LIME1	-0.5	-7.97	-0.36	1.53e-14	Prostate cancer;
LUAD	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg18230493	chr5:56204884	C5orf35	-0.45	-7.61	-0.35	1.83e-13	Coronary artery disease;
LUAD	cis	rs1018836	0.886	rs4734246	chr8:91569028	A/C	cg16814680	chr8:91681699	NA	-0.71	-12.25	-0.51	9.82e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg03474202	chr17:45855739	NA	-0.38	-8.96	-0.4	1.09e-17	IgG glycosylation;
LUAD	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.26	-6.48	-0.3	2.51e-10	Coronary artery disease;
LUAD	cis	rs2806561	0.964	rs683052	chr1:23514953	T/C	cg12483005	chr1:23474871	LUZP1	0.38	6.64	0.31	9.66e-11	Height;
LUAD	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg24675056	chr1:15929824	NA	0.49	8.58	0.39	1.8e-16	Systolic blood pressure;
LUAD	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg26587870	chr6:27730563	NA	-0.48	-7.99	-0.36	1.31e-14	Parkinson's disease;
LUAD	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg12034118	chr1:209979487	IRF6	0.53	6.4	0.3	4.08e-10	Cleft lip with or without cleft palate;
LUAD	trans	rs7395662	1.000	rs7121992	chr11:48592582	C/T	cg00717180	chr2:96193071	NA	-0.38	-7.16	-0.33	3.55e-12	HDL cholesterol;
LUAD	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg22920501	chr2:26401640	FAM59B	-0.97	-15.56	-0.6	1.66e-43	Gut microbiome composition (summer);
LUAD	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg04450456	chr4:17643702	FAM184B	0.42	8.32	0.38	1.19e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18404041	chr3:52824283	ITIH1	-0.6	-12.07	-0.51	5.17e-29	Bipolar disorder;
LUAD	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.12	-0.33	4.66e-12	Coronary artery disease;
LUAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg27454412	chr7:1067447	C7orf50	0.42	6.71	0.31	6.26e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg17173187	chr15:85201210	NMB	0.51	8.72	0.39	6.27e-17	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	8.45	0.38	4.7e-16	Alzheimer's disease;
LUAD	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg24579218	chr15:68104479	NA	-0.61	-9.82	-0.43	1.19e-20	Restless legs syndrome;
LUAD	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.98	-0.36	1.41e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7107174	0.892	rs3018313	chr11:77989644	C/T	cg02023728	chr11:77925099	USP35	0.47	7.26	0.33	1.89e-12	Testicular germ cell tumor;
LUAD	cis	rs6558530	0.965	rs730379	chr8:1708093	A/C	cg19131313	chr8:1704013	NA	-0.45	-7.21	-0.33	2.56e-12	Systolic blood pressure;
LUAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.55e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg13685833	chr1:53393034	SCP2	-0.5	-8.0	-0.36	1.19e-14	Monocyte count;
LUAD	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg04398451	chr17:18023971	MYO15A	-0.77	-13.41	-0.55	2.1e-34	Total body bone mineral density;
LUAD	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	6.97	0.32	1.24e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg00898013	chr13:113819073	PROZ	-0.7	-12.36	-0.51	3.68e-30	Platelet distribution width;
LUAD	cis	rs2688608	0.698	rs2633313	chr10:75683865	C/T	cg23231163	chr10:75533350	FUT11	-0.37	-6.82	-0.31	3.07e-11	Inflammatory bowel disease;
LUAD	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg09796270	chr17:17721594	SREBF1	0.37	7.38	0.34	8.42e-13	Total body bone mineral density;
LUAD	cis	rs6489882	0.703	rs10850096	chr12:113360786	T/C	cg20102336	chr12:113376681	OAS3	-0.55	-8.35	-0.38	9.81e-16	Chronic lymphocytic leukemia;
LUAD	cis	rs4845570	0.749	rs11576810	chr1:151712201	C/G	cg07092448	chr1:151763213	TDRKH	-0.71	-7.92	-0.36	2.1e-14	Coronary artery disease;
LUAD	cis	rs12893668	0.637	rs4525427	chr14:104072793	C/A	cg01849466	chr14:104193079	ZFYVE21	-0.52	-8.18	-0.37	3.34e-15	Reticulocyte count;
LUAD	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg01475377	chr6:109611718	NA	-0.54	-10.51	-0.45	4.22e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg18306943	chr3:40428807	ENTPD3	-0.36	-6.37	-0.3	4.95e-10	Renal cell carcinoma;
LUAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg02524346	chr8:600233	NA	1.07	10.95	0.47	9.91e-25	IgG glycosylation;
LUAD	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg04772025	chr11:68637568	NA	0.57	9.07	0.4	4.47e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg07677032	chr17:61819896	STRADA	0.56	10.09	0.44	1.41e-21	Prudent dietary pattern;
LUAD	cis	rs11924390	0.749	rs822364	chr3:186452716	A/G	cg12454167	chr3:186435060	KNG1	0.4	8.34	0.38	1.09e-15	Adiponectin levels;
LUAD	cis	rs500891	0.574	rs3798889	chr6:84121512	G/T	cg08257003	chr6:84140564	ME1	0.34	6.53	0.3	1.9e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs7727544	0.582	rs2301579	chr5:131553340	C/A	cg14196790	chr5:131705035	SLC22A5	0.39	6.77	0.31	4.34e-11	Blood metabolite levels;
LUAD	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg25535316	chr11:579198	PHRF1	-0.37	-6.39	-0.3	4.31e-10	Systemic lupus erythematosus;
LUAD	trans	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg04775059	chr7:64541387	NA	0.51	6.76	0.31	4.58e-11	Aortic root size;
LUAD	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg00310523	chr12:86230176	RASSF9	0.39	7.71	0.35	9.02e-14	Major depressive disorder;
LUAD	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18099408	chr3:52552593	STAB1	-0.48	-8.27	-0.37	1.77e-15	Bipolar disorder;
LUAD	cis	rs28595532	0.920	rs56389935	chr4:119683571	G/A	cg14228332	chr4:119757509	SEC24D	0.8	7.57	0.35	2.28e-13	Cannabis dependence symptom count;
LUAD	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg21823605	chr1:152486609	CRCT1	0.28	6.42	0.3	3.66e-10	Hair morphology;
LUAD	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg03929089	chr4:120376271	NA	-0.98	-20.58	-0.71	1.01e-65	Height;
LUAD	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg26587870	chr6:27730563	NA	-0.76	-8.29	-0.37	1.52e-15	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg18833306	chr6:118973337	C6orf204	0.51	7.37	0.34	9.13e-13	Diastolic blood pressure;
LUAD	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg02569458	chr12:86230093	RASSF9	-0.43	-8.04	-0.36	8.94e-15	Major depressive disorder;
LUAD	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg20119798	chr7:94954144	PON1	-0.48	-6.54	-0.3	1.79e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs752010	0.806	rs10890148	chr1:42091517	T/C	cg06885757	chr1:42089581	HIVEP3	0.48	10.86	0.47	2.11e-24	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs7789940	0.951	rs73140055	chr7:75975777	A/T	cg10167463	chr7:75959203	YWHAG	-0.7	-12.76	-0.53	8.88e-32	Multiple sclerosis;
LUAD	cis	rs657075	0.697	rs35373795	chr5:131753824	G/T	cg21138405	chr5:131827807	IRF1	0.55	6.5	0.3	2.26e-10	Rheumatoid arthritis;
LUAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6594713	0.605	rs66540465	chr5:112840706	G/A	cg12552261	chr5:112820674	MCC	0.53	7.33	0.34	1.14e-12	Brain cytoarchitecture;
LUAD	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.77	0.31	4.36e-11	Motion sickness;
LUAD	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg13319975	chr6:146136371	FBXO30	-0.57	-9.44	-0.42	2.44e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9863	0.896	rs4930722	chr12:124423275	C/G	cg17723958	chr12:124429295	CCDC92	-0.44	-6.99	-0.32	1.06e-11	White blood cell count;
LUAD	cis	rs698833	0.886	rs2927433	chr2:44580737	T/A	cg04920474	chr2:44395004	PPM1B	0.44	8.0	0.36	1.21e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03264133	chr6:25882463	NA	-0.73	-10.17	-0.44	7.17e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs75920871	0.925	rs61903426	chr11:116968268	C/T	cg04087571	chr11:116723030	SIK3	-0.32	-6.51	-0.3	2.07e-10	Subjective well-being;
LUAD	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg22431228	chr1:16359049	CLCNKA	-0.65	-13.58	-0.55	4.23e-35	Systolic blood pressure;
LUAD	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg09904177	chr6:26538194	HMGN4	0.45	7.58	0.35	2.19e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9473147	0.543	rs9367279	chr6:47448336	A/G	cg20196966	chr6:47445060	CD2AP	0.41	6.35	0.3	5.55e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg16680214	chr1:154839983	KCNN3	-0.51	-10.24	-0.45	3.85e-22	Prostate cancer;
LUAD	cis	rs8177876	0.749	rs2278025	chr16:81079241	C/T	cg08591886	chr16:81111003	C16orf46	0.67	6.74	0.31	5.07e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs3733418	0.929	rs72697952	chr4:165900928	A/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.55	-7.25	-0.33	2e-12	Obesity-related traits;
LUAD	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg17063962	chr7:91808500	NA	-0.61	-10.13	-0.44	9.55e-22	Breast cancer;
LUAD	cis	rs9296092	0.538	rs9296094	chr6:33520064	A/G	cg13560919	chr6:33536144	NA	-0.87	-15.54	-0.6	2.02e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs12210905	1.000	rs115268625	chr6:26948229	C/G	cg11502198	chr6:26597334	ABT1	-0.81	-6.86	-0.32	2.53e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg27411982	chr8:10470053	RP1L1	0.37	6.38	0.3	4.52e-10	Retinal vascular caliber;
LUAD	cis	rs4930561	0.739	rs12225316	chr11:67976003	T/C	cg04465784	chr11:67976953	SUV420H1	-0.28	-8.28	-0.37	1.59e-15	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs870825	0.616	rs1401358	chr4:185640057	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	14.32	0.57	3.3e-38	Blood protein levels;
LUAD	cis	rs7937890	0.559	rs2575853	chr11:14533963	T/C	cg02251663	chr11:14281053	SPON1	-0.34	-6.49	-0.3	2.42e-10	Mitochondrial DNA levels;
LUAD	cis	rs11657217	1.000	rs11657217	chr17:77709339	C/G	cg06901238	chr17:77706717	ENPP7	0.71	13.18	0.54	1.81e-33	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
LUAD	trans	rs2797160	1.000	rs1739371	chr6:126011291	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.55	8.66	0.39	9.68e-17	Endometrial cancer;
LUAD	trans	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg18335740	chr13:41363409	SLC25A15	-0.58	-10.26	-0.45	3.2e-22	Lewy body disease;
LUAD	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg18351406	chr4:77819688	ANKRD56	0.58	9.24	0.41	1.21e-18	Emphysema distribution in smoking;
LUAD	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg27411982	chr8:10470053	RP1L1	0.4	7.17	0.33	3.33e-12	Retinal vascular caliber;
LUAD	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg13685833	chr1:53393034	SCP2	-0.51	-8.09	-0.37	6.16e-15	Monocyte count;
LUAD	cis	rs1595825	0.786	rs116046984	chr2:198884413	G/A	cg00361562	chr2:198649771	BOLL	-0.46	-6.49	-0.3	2.43e-10	Ulcerative colitis;
LUAD	cis	rs7799006	0.929	rs745566	chr7:2256406	T/C	cg08027265	chr7:2291960	NA	-0.61	-10.73	-0.46	6.54e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg12016809	chr21:47604291	C21orf56	0.65	11.47	0.49	1.03e-26	Testicular germ cell tumor;
LUAD	cis	rs673604	1.000	rs11264120	chr1:35676595	G/A	cg12633102	chr1:35676489	NA	-0.7	-8.93	-0.4	1.34e-17	Endometrial cancer;
LUAD	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.27	-0.33	1.71e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs3862030	0.694	rs2025712	chr10:104230064	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-8.02	-0.36	1.06e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs7665090	1.000	rs2866413	chr4:103557077	G/A	cg07973026	chr4:103553119	MANBA	0.47	8.41	0.38	6.43e-16	Primary biliary cholangitis;
LUAD	trans	rs853679	0.546	rs2232426	chr6:28360659	G/C	cg06606381	chr12:133084897	FBRSL1	-1.23	-10.69	-0.46	9.35e-24	Depression;
LUAD	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg23803603	chr1:2058230	PRKCZ	-0.39	-6.97	-0.32	1.26e-11	Height;
LUAD	trans	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg26043149	chr18:55253948	FECH	-0.42	-6.89	-0.32	2.04e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7759001	0.857	rs4713090	chr6:27350847	C/T	cg18711553	chr6:27366782	ZNF391	0.39	6.39	0.3	4.29e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg08989290	chr16:615782	NHLRC4	0.31	6.72	0.31	5.75e-11	Height;
LUAD	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg21681030	chr2:46777652	RHOQ	0.42	7.04	0.32	7.59e-12	Height;
LUAD	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg13319975	chr6:146136371	FBXO30	0.59	9.84	0.43	1.02e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3981351	0.797	rs61866462	chr10:115464690	C/T	cg24846397	chr10:115438155	CASP7	-0.39	-6.38	-0.3	4.54e-10	Obesity-related traits;
LUAD	cis	rs9914988	1.000	rs6803	chr17:27187789	C/T	cg02049041	chr17:27085579	C17orf63	-0.6	-8.09	-0.37	6.37e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.02	-0.4	6.56e-18	Total body bone mineral density;
LUAD	cis	rs6545883	0.894	rs6545867	chr2:61651027	C/T	cg15711740	chr2:61764176	XPO1	0.41	6.57	0.3	1.52e-10	Tuberculosis;
LUAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.4	0.3	4.24e-10	Hypertriglyceridemia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24875440	chr1:27986375	NA	-0.55	-6.8	-0.31	3.55e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25951811	chr14:96858416	AK7	-0.54	-6.61	-0.31	1.16e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg09359103	chr1:154839909	KCNN3	-0.91	-21.13	-0.72	3.5e-68	Prostate cancer;
LUAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg00106254	chr7:1943704	MAD1L1	-0.64	-9.81	-0.43	1.29e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs2742234	0.541	rs11238481	chr10:43719286	A/G	cg15436174	chr10:43711423	RASGEF1A	0.55	9.02	0.4	6.55e-18	Hirschsprung disease;
LUAD	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.93	0.53	1.89e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.91	0.32	1.78e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12545109	0.879	rs1513317	chr8:57372966	C/G	cg09654669	chr8:57350985	NA	-0.7	-9.92	-0.43	5.4e-21	Obesity-related traits;
LUAD	cis	rs11126435	0.858	rs363673	chr2:74933923	C/T	cg19285774	chr2:74907978	SEMA4F	0.37	6.41	0.3	3.79e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg25894440	chr7:65020034	NA	-0.69	-7.3	-0.33	1.42e-12	Diabetic kidney disease;
LUAD	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg25173405	chr17:45401733	C17orf57	0.45	7.73	0.35	7.82e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7932354	0.528	rs4752957	chr11:47125632	T/G	cg19486271	chr11:47235900	DDB2	-0.44	-7.06	-0.32	6.8e-12	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg09455208	chr3:40491958	NA	0.65	14.24	0.57	6.94e-38	Renal cell carcinoma;
LUAD	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg16205897	chr5:131564050	P4HA2	0.31	6.52	0.3	1.96e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs3760982	0.585	rs67648499	chr19:44294055	G/A	cg12072164	chr19:44306565	LYPD5	0.42	8.48	0.38	3.85e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs2286885	1.000	rs10733678	chr9:129242280	G/A	cg15282417	chr9:129245246	FAM125B	0.42	8.71	0.39	7.11e-17	Intraocular pressure;
LUAD	cis	rs31872	0.521	rs246050	chr5:140326860	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Visceral adipose tissue adjusted for BMI;
LUAD	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg17330251	chr7:94953956	PON1	-0.52	-6.82	-0.31	3.12e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26297968	chr2:211035960	C2orf67	0.41	6.58	0.3	1.37e-10	Height;
LUAD	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg06199346	chr11:14280333	SPON1	-0.32	-6.47	-0.3	2.79e-10	Mitochondrial DNA levels;
LUAD	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg05043794	chr9:111880884	C9orf5	-0.41	-6.56	-0.3	1.54e-10	Menarche (age at onset);
LUAD	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg06671706	chr8:8559999	CLDN23	0.6	10.34	0.45	1.74e-22	Obesity-related traits;
LUAD	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.47	0.34	4.74e-13	Electroencephalogram traits;
LUAD	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg04414720	chr1:150670196	GOLPH3L	0.63	10.93	0.47	1.18e-24	Melanoma;
LUAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.45	-9.02	-0.4	6.69e-18	Longevity;Endometriosis;
LUAD	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.54	-9.03	-0.4	6.2e-18	Electrocardiographic conduction measures;
LUAD	cis	rs10899021	0.920	rs7122710	chr11:74323175	C/T	cg25880958	chr11:74394337	NA	-0.62	-8.46	-0.38	4.49e-16	Response to metformin (IC50);
LUAD	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.26	-0.45	3.42e-22	Menopause (age at onset);
LUAD	cis	rs7903847	0.596	rs11189203	chr10:99159096	C/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.77	-0.35	5.85e-14	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg07570687	chr10:102243282	WNT8B	0.48	7.34	0.34	1.09e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg21171335	chr12:122356390	WDR66	0.77	14.29	0.57	4.39e-38	Mean corpuscular volume;
LUAD	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg00204512	chr16:28754710	NA	0.34	7.28	0.33	1.66e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs79839061	0.520	rs2279187	chr4:875529	C/T	cg07828340	chr4:882639	GAK	0.99	9.62	0.42	6.02e-20	Intelligence (multi-trait analysis);
LUAD	trans	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg26043149	chr18:55253948	FECH	0.5	8.11	0.37	5.55e-15	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg11707310	chr1:2537719	MMEL1	0.37	7.94	0.36	1.81e-14	Ulcerative colitis;
LUAD	cis	rs1816752	1.000	rs7999554	chr13:25009769	C/A	cg02811702	chr13:24901961	NA	0.44	7.29	0.33	1.51e-12	Obesity-related traits;
LUAD	cis	rs3845702	0.736	rs6433816	chr2:180809317	G/C	cg01881094	chr2:180872142	CWC22	-0.8	-8.46	-0.38	4.39e-16	Schizophrenia;
LUAD	cis	rs11811982	0.793	rs76872038	chr1:227375617	G/A	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic disc area;
LUAD	cis	rs494562	0.803	rs727870	chr6:86131156	A/G	cg13315970	chr6:86159197	NT5E	0.65	7.8	0.35	4.99e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg23950597	chr19:37808831	NA	-0.62	-7.32	-0.34	1.23e-12	Coronary artery calcification;
LUAD	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg23992470	chr4:843637	GAK	0.58	6.99	0.32	1.11e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg19418458	chr7:158789849	NA	-0.58	-10.21	-0.44	4.89e-22	Facial morphology (factor 20);
LUAD	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg16680214	chr1:154839983	KCNN3	-0.62	-12.9	-0.53	2.54e-32	Prostate cancer;
LUAD	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg25036284	chr2:26402008	FAM59B	0.81	10.76	0.46	4.83e-24	Gut microbiome composition (summer);
LUAD	cis	rs3125734	0.633	rs6479804	chr10:64048327	T/C	cg19640130	chr10:64028056	RTKN2	-0.35	-7.46	-0.34	4.81e-13	Rheumatoid arthritis;
LUAD	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-24.27	-0.76	3.73e-82	Height;
LUAD	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg23982607	chr1:1823379	GNB1	-0.89	-18.34	-0.67	1.04e-55	Body mass index;
LUAD	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.77	-0.31	4.33e-11	Post bronchodilator FEV1;
LUAD	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg05872129	chr22:39784769	NA	-0.75	-12.15	-0.51	2.48e-29	Post bronchodilator FEV1;
LUAD	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg09365446	chr1:150670422	GOLPH3L	0.55	9.62	0.42	6.27e-20	Melanoma;
LUAD	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg26022315	chr17:47021804	SNF8	0.41	7.38	0.34	8.45e-13	Type 2 diabetes;
LUAD	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg04248312	chr19:17393744	ANKLE1	-0.93	-17.18	-0.64	1.45e-50	Systemic lupus erythematosus;
LUAD	cis	rs17401966	0.838	rs946502	chr1:10309279	G/C	cg15208524	chr1:10270712	KIF1B	0.44	6.77	0.31	4.26e-11	Hepatocellular carcinoma;
LUAD	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg08885076	chr2:99613938	TSGA10	-0.39	-6.97	-0.32	1.24e-11	Chronic sinus infection;
LUAD	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg17911788	chr17:44343683	NA	-0.5	-7.05	-0.32	7.42e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg10560079	chr2:191398806	TMEM194B	0.46	8.17	0.37	3.6e-15	Pulse pressure;
LUAD	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg14671364	chr1:107599128	PRMT6	-0.55	-9.71	-0.43	2.86e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.57	7.96	0.36	1.64e-14	Platelet count;
LUAD	cis	rs2109514	0.840	rs10228178	chr7:116132211	G/A	cg12739419	chr7:116140593	CAV2	-0.33	-6.88	-0.32	2.11e-11	Prevalent atrial fibrillation;
LUAD	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg27432699	chr2:27873401	GPN1	-0.39	-6.6	-0.31	1.23e-10	Total body bone mineral density;
LUAD	cis	rs10744422	1.000	rs3817094	chr12:123332032	T/C	cg16953816	chr12:123349952	VPS37B	0.59	6.64	0.31	9.46e-11	Schizophrenia;
LUAD	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg06740227	chr12:86229804	RASSF9	0.47	8.25	0.37	2.09e-15	Major depressive disorder;
LUAD	trans	rs587242	1.000	rs61786491	chr1:96904651	G/C	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs877282	0.898	rs36064821	chr10:760952	C/T	cg17470449	chr10:769945	NA	0.6	8.62	0.39	1.35e-16	Uric acid levels;
LUAD	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.85	-0.36	3.47e-14	Blood metabolite levels;
LUAD	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg24829409	chr8:58192753	C8orf71	-0.57	-6.67	-0.31	8.05e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg23018236	chr17:30244563	NA	-0.67	-8.16	-0.37	3.88e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg02508848	chr16:68573721	ZFP90	-0.42	-6.57	-0.3	1.44e-10	Ulcerative colitis;
LUAD	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg20848291	chr7:100343083	ZAN	0.37	6.42	0.3	3.57e-10	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs7614311	0.681	rs2241822	chr3:63965304	A/G	cg22134162	chr3:63841271	THOC7	-0.54	-9.12	-0.41	3.08e-18	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs986417	0.901	rs1884094	chr14:61016933	C/G	cg27398547	chr14:60952738	C14orf39	0.59	7.11	0.33	4.95e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg13870426	chr17:30244630	NA	-0.57	-6.63	-0.31	1.05e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs11209185	0.509	rs12142271	chr1:68446837	A/G	cg22082780	chr1:68452167	NA	0.51	10.57	0.46	2.41e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs2764208	0.860	rs205286	chr6:34551334	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.73	-0.39	5.82e-17	Systemic lupus erythematosus;
LUAD	cis	rs13315871	1.000	rs11713214	chr3:58445991	C/T	cg20936604	chr3:58311152	NA	-0.68	-6.96	-0.32	1.3e-11	Cholesterol, total;
LUAD	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg17863274	chr19:49399704	TULP2	-0.64	-9.78	-0.43	1.74e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg20487152	chr13:99095054	FARP1	-0.47	-8.05	-0.36	8.28e-15	Longevity;
LUAD	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.9	0.47	1.49e-24	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9302065	0.529	rs2993582	chr13:95958181	G/T	cg24476569	chr13:95954382	ABCC4	-0.61	-11.16	-0.48	1.61e-25	Blood metabolite levels;
LUAD	cis	rs7584330	0.617	rs28725355	chr2:238372824	T/G	cg16989719	chr2:238392110	NA	-0.36	-7.44	-0.34	5.57e-13	Prostate cancer;
LUAD	cis	rs1594829	0.553	rs1564577	chr8:26164723	G/A	cg13160058	chr8:26243215	BNIP3L	-0.33	-7.36	-0.34	9.35e-13	Height;
LUAD	cis	rs7590720	0.959	rs2372684	chr2:216884764	C/A	cg12620499	chr2:216877984	MREG	0.53	8.45	0.38	4.77e-16	Alcohol dependence;
LUAD	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg04282206	chr17:62833786	PLEKHM1P	-0.42	-7.06	-0.32	6.69e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	7.44	0.34	5.65e-13	Schizophrenia;
LUAD	cis	rs12681287	0.640	rs7460650	chr8:87474085	A/G	cg27223183	chr8:87520930	FAM82B	-0.67	-9.67	-0.43	4.22e-20	Caudate activity during reward;
LUAD	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg22349387	chr12:9600060	DDX12	-0.51	-9.09	-0.4	3.75e-18	Breast size;
LUAD	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg19436804	chr8:8560866	CLDN23	0.42	6.5	0.3	2.21e-10	Obesity-related traits;
LUAD	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.56	0.3	1.58e-10	Cardiac Troponin-T levels;
LUAD	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.31	-7.09	-0.33	5.7e-12	Dupuytren's disease;
LUAD	trans	rs75804782	0.521	rs55988884	chr2:239396930	G/A	cg01134436	chr17:81009848	B3GNTL1	0.78	8.59	0.39	1.74e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs11771526	0.901	rs11764193	chr7:32272200	C/T	cg13207630	chr7:32358064	NA	0.54	7.0	0.32	1.01e-11	Body mass index;
LUAD	cis	rs10203711	0.668	rs7425902	chr2:239524556	C/T	cg03218584	chr2:239511283	NA	0.37	6.94	0.32	1.49e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg22681709	chr2:178499509	PDE11A	-0.54	-9.18	-0.41	1.96e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs684232	0.602	rs2543775	chr17:557123	G/A	cg12384639	chr17:618140	VPS53	0.48	8.22	0.37	2.6e-15	Prostate cancer;
LUAD	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg17595323	chr11:93583763	C11orf90	-0.43	-9.03	-0.4	5.91e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	trans	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17712092	chr4:129076599	LARP1B	0.94	17.76	0.65	3.94e-53	Eosinophil percentage of white cells;
LUAD	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg02696790	chr15:75250997	RPP25	0.39	7.42	0.34	6.67e-13	Breast cancer;
LUAD	trans	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg04775059	chr7:64541387	NA	0.5	6.72	0.31	5.94e-11	Aortic root size;
LUAD	cis	rs9447004	0.584	rs12215671	chr6:74435607	T/C	cg23004174	chr6:74404879	CD109	0.46	8.38	0.38	8.08e-16	Blood protein levels;Calcium levels;
LUAD	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg00310523	chr12:86230176	RASSF9	0.4	7.92	0.36	2.17e-14	Major depressive disorder;
LUAD	cis	rs28374715	0.662	rs1554445	chr15:41503198	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.86	-15.2	-0.59	6.36e-42	Ulcerative colitis;
LUAD	cis	rs654950	0.875	rs4660544	chr1:41996871	T/C	cg06885757	chr1:42089581	HIVEP3	-0.32	-6.62	-0.31	1.08e-10	Airway imaging phenotypes;
LUAD	cis	rs6484504	0.576	rs208103	chr11:31167400	A/G	cg14844989	chr11:31128820	NA	-0.44	-7.99	-0.36	1.28e-14	Red blood cell count;
LUAD	trans	rs8180209	1.000	rs3857061	chr4:90686742	A/G	cg16061777	chr16:76269192	NA	0.41	6.45	0.3	2.99e-10	Parkinson's disease;
LUAD	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg22961513	chr11:14280813	SPON1	0.44	9.04	0.4	5.49e-18	Mitochondrial DNA levels;
LUAD	cis	rs151234	0.741	rs56236750	chr16:28594711	C/T	cg04643524	chr16:28609220	SULT1A2	0.63	8.79	0.39	3.91e-17	Platelet distribution width;
LUAD	cis	rs4481887	0.800	rs28680862	chr1:248515419	T/C	cg13385794	chr1:248469461	NA	0.23	6.41	0.3	3.92e-10	Common traits (Other);
LUAD	cis	rs17401966	0.898	rs12757288	chr1:10323921	T/C	cg19773385	chr1:10388646	KIF1B	-0.39	-6.46	-0.3	2.89e-10	Hepatocellular carcinoma;
LUAD	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg05425664	chr17:57184151	TRIM37	-0.41	-7.34	-0.34	1.13e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg03340356	chr1:67600835	NA	0.44	7.6	0.35	1.91e-13	Psoriasis;
LUAD	cis	rs9811920	0.683	rs793502	chr3:99588417	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.51	9.99	0.44	3.12e-21	Axial length;
LUAD	cis	rs17401966	0.838	rs7553935	chr1:10375179	G/A	cg15208524	chr1:10270712	KIF1B	0.42	6.55	0.3	1.64e-10	Hepatocellular carcinoma;
LUAD	cis	rs7665090	1.000	rs2866414	chr4:103557219	C/T	cg07973026	chr4:103553119	MANBA	0.47	8.41	0.38	6.43e-16	Primary biliary cholangitis;
LUAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg15117754	chr3:10150083	C3orf24	0.4	6.61	0.31	1.13e-10	Alzheimer's disease;
LUAD	cis	rs829883	0.659	rs11109524	chr12:98939172	G/A	cg25150519	chr12:98850993	NA	-0.5	-7.9	-0.36	2.39e-14	Colorectal adenoma (advanced);
LUAD	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg01017244	chr2:74357527	NA	0.9	13.97	0.56	9.63e-37	Gestational age at birth (maternal effect);
LUAD	cis	rs9394841	0.667	rs9357366	chr6:41786976	T/G	cg17623882	chr6:41773611	USP49	-0.47	-6.62	-0.31	1.1e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg04225089	chr17:73874465	TRIM47	-0.4	-7.06	-0.32	6.77e-12	Psoriasis;
LUAD	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg06609049	chr19:2785107	THOP1	1.11	21.8	0.73	3.54e-71	Total cholesterol levels;
LUAD	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg02807482	chr3:125708958	NA	-0.65	-8.39	-0.38	7.15e-16	Blood pressure (smoking interaction);
LUAD	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.44	-8.16	-0.37	3.84e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7119038	0.774	rs11217020	chr11:118639353	G/A	cg19308663	chr11:118741387	NA	0.48	6.69	0.31	7.14e-11	Sjögren's syndrome;
LUAD	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg22823121	chr1:150693482	HORMAD1	-0.38	-7.5	-0.34	3.85e-13	Tonsillectomy;
LUAD	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg23649088	chr2:200775458	C2orf69	-0.57	-6.71	-0.31	6.25e-11	Schizophrenia;
LUAD	cis	rs11030122	0.702	rs7102215	chr11:3943970	C/T	cg18678763	chr11:4115507	RRM1	-0.45	-7.43	-0.34	6.04e-13	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg06199346	chr11:14280333	SPON1	0.36	7.64	0.35	1.43e-13	Mitochondrial DNA levels;
LUAD	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg12311346	chr5:56204834	C5orf35	-0.52	-8.33	-0.38	1.12e-15	Coronary artery disease;
LUAD	trans	rs7781370	1.000	rs7781370	chr7:96133531	A/G	cg18185028	chr3:154042079	DHX36	-0.38	-6.38	-0.3	4.64e-10	Bone mineral density (hip);
LUAD	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg02421172	chr7:1938701	MAD1L1	0.46	6.44	0.3	3.31e-10	Bipolar disorder;
LUAD	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg05283184	chr6:79620031	NA	-0.61	-12.41	-0.52	2.26e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.38	-6.65	-0.31	9.12e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00149659	chr3:10157352	C3orf10	0.6	8.28	0.37	1.64e-15	Alzheimer's disease;
LUAD	trans	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg26043149	chr18:55253948	FECH	-0.42	-6.85	-0.32	2.59e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg04282206	chr17:62833786	PLEKHM1P	-0.52	-8.2	-0.37	2.82e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg03433033	chr1:76189801	ACADM	-0.51	-7.44	-0.34	5.76e-13	Daytime sleep phenotypes;
LUAD	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg27411982	chr8:10470053	RP1L1	0.38	6.96	0.32	1.28e-11	Monocyte count;
LUAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg27588902	chr6:42928151	GNMT	-0.35	-9.41	-0.42	3.24e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs12545109	0.800	rs2118261	chr8:57393286	A/G	cg07776626	chr8:57350775	NA	0.6	8.97	0.4	9.37e-18	Obesity-related traits;
LUAD	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg27432699	chr2:27873401	GPN1	-0.41	-6.92	-0.32	1.73e-11	Total body bone mineral density;
LUAD	cis	rs9283706	0.548	rs10044452	chr5:66302605	C/T	cg11590213	chr5:66331682	MAST4	0.4	6.36	0.3	5.21e-10	Coronary artery disease;
LUAD	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg07776626	chr8:57350775	NA	-0.6	-8.83	-0.39	2.82e-17	Obesity-related traits;
LUAD	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.36	-0.6	1.23e-42	Chronic sinus infection;
LUAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg18538332	chr22:24372958	LOC391322	-0.58	-10.03	-0.44	2.28e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10465746	0.967	rs12120160	chr1:84342835	T/G	cg10977910	chr1:84465055	TTLL7	0.5	8.19	0.37	3.07e-15	Obesity-related traits;
LUAD	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg01299579	chr2:10830716	NOL10	-0.43	-7.68	-0.35	1.09e-13	Prostate cancer;
LUAD	cis	rs1595825	0.945	rs73056883	chr2:198824638	A/G	cg00361562	chr2:198649771	BOLL	-0.47	-6.72	-0.31	5.79e-11	Ulcerative colitis;
LUAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.08	-0.33	6.21e-12	Testicular germ cell tumor;
LUAD	cis	rs6541297	0.703	rs2748117	chr1:230320156	C/T	cg20703242	chr1:230279135	GALNT2	-0.46	-7.0	-0.32	9.88e-12	Coronary artery disease;
LUAD	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg14345882	chr6:26364793	BTN3A2	0.7	7.15	0.33	3.76e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2237234	0.848	rs2237235	chr6:26391395	A/G	cg14345882	chr6:26364793	BTN3A2	0.51	6.89	0.32	1.97e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs739496	0.947	rs2301621	chr12:111895272	C/T	cg10833066	chr12:111807467	FAM109A	0.42	6.78	0.31	4.08e-11	Platelet count;
LUAD	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg10556349	chr10:835070	NA	0.48	6.58	0.3	1.42e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg20848291	chr7:100343083	ZAN	0.39	6.77	0.31	4.45e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs760805	1.000	rs10903115	chr1:25261696	A/G	cg22509179	chr1:25234806	RUNX3	-0.73	-13.2	-0.54	1.5e-33	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2901656	0.502	rs9425601	chr1:172377262	G/A	cg03748243	chr1:172413542	C1orf105;PIGC	-0.42	-7.83	-0.36	3.87e-14	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg11494091	chr17:61959527	GH2	0.74	18.45	0.67	3.54e-56	Prudent dietary pattern;
LUAD	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg26022315	chr17:47021804	SNF8	0.42	7.5	0.34	3.7e-13	Type 2 diabetes;
LUAD	cis	rs73206853	0.764	rs7312469	chr12:110889072	A/G	cg12870014	chr12:110450643	ANKRD13A	0.59	6.4	0.3	4.03e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg01657329	chr11:68192670	LRP5	-0.41	-6.5	-0.3	2.25e-10	Total body bone mineral density;
LUAD	cis	rs346785	0.692	rs7225131	chr17:74290097	T/A	cg09812376	chr17:74270190	QRICH2	-0.3	-6.37	-0.3	4.87e-10	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03517284	chr6:25882590	NA	-0.54	-8.1	-0.37	5.78e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg05966235	chr16:28915196	ATP2A1	0.47	7.61	0.35	1.75e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg15226275	chr6:116381976	FRK	0.23	7.65	0.35	1.41e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg08999081	chr20:33150536	PIGU	-0.63	-14.31	-0.57	3.69e-38	Glomerular filtration rate (creatinine);
LUAD	cis	rs12760731	0.641	rs10047148	chr1:178250266	T/C	cg00404053	chr1:178313656	RASAL2	0.68	8.75	0.39	5.09e-17	Obesity-related traits;
LUAD	cis	rs1595825	0.891	rs74965164	chr2:198499162	C/T	cg00982548	chr2:198649783	BOLL	-0.62	-8.88	-0.4	1.95e-17	Ulcerative colitis;
LUAD	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg26513180	chr16:89883248	FANCA	0.78	6.75	0.31	5.04e-11	Skin colour saturation;
LUAD	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.76	-0.35	6.44e-14	Diabetic kidney disease;
LUAD	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	ch.11.42038R	chr11:967971	AP2A2	0.39	6.88	0.32	2.23e-11	Alzheimer's disease (late onset);
LUAD	cis	rs7089973	0.872	rs41284358	chr10:116622339	A/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.69	0.43	3.5e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg14552801	chr7:65878734	NA	-0.38	-6.37	-0.3	4.96e-10	Aortic root size;
LUAD	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg27535305	chr1:53392650	SCP2	-0.4	-8.17	-0.37	3.7e-15	Monocyte count;
LUAD	trans	rs79911532	0.515	rs75257637	chr7:75712848	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	8.61	0.39	1.47e-16	Mononucleosis;
LUAD	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg18404041	chr3:52824283	ITIH1	0.52	8.99	0.4	8.31e-18	Schizophrenia;
LUAD	trans	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg06606381	chr12:133084897	FBRSL1	-0.8	-6.85	-0.32	2.69e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6684514	1.000	rs11264468	chr1:156274585	C/G	cg16558208	chr1:156270281	VHLL	0.53	9.59	0.42	7.44e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs539096	0.692	rs6686238	chr1:44210253	C/G	cg12908607	chr1:44402522	ARTN	-0.37	-7.21	-0.33	2.62e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg12179176	chr11:130786555	SNX19	0.65	10.78	0.46	4.06e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg24562669	chr7:97807699	LMTK2	0.33	7.98	0.36	1.34e-14	Breast cancer;
LUAD	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg23283495	chr1:209979779	IRF6	0.72	10.65	0.46	1.22e-23	Cleft lip with or without cleft palate;
LUAD	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg03929089	chr4:120376271	NA	-0.51	-8.14	-0.37	4.61e-15	Coronary artery disease;
LUAD	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.74	15.93	0.61	4.36e-45	White blood cell count (basophil);White blood cell count;
LUAD	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg06108461	chr20:60628389	TAF4	-1.11	-20.45	-0.71	4.01e-65	Body mass index;
LUAD	cis	rs9287719	0.774	rs4997811	chr2:10755538	T/C	cg01299579	chr2:10830716	NOL10	-0.41	-7.17	-0.33	3.39e-12	Prostate cancer;
LUAD	cis	rs6840360	1.000	rs1355413	chr4:152633667	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.36	-0.3	5.28e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg25208724	chr1:156163844	SLC25A44	1.01	17.96	0.66	5.19e-54	Testicular germ cell tumor;
LUAD	cis	rs6484504	0.625	rs1535741	chr11:31375072	T/C	cg14844989	chr11:31128820	NA	0.44	8.04	0.36	9.14e-15	Red blood cell count;
LUAD	cis	rs684232	0.644	rs2657613	chr17:623902	T/C	cg15660573	chr17:549704	VPS53	-0.68	-12.73	-0.53	1.14e-31	Prostate cancer;
LUAD	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg03289416	chr15:75166202	SCAMP2	0.39	6.77	0.31	4.44e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs4604732	0.527	rs60444724	chr1:247623164	T/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.42	6.87	0.32	2.36e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.77	-14.69	-0.58	9.17e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs6426558	0.502	rs1929858	chr1:227220175	C/A	cg10327440	chr1:227177885	CDC42BPA	0.56	8.99	0.4	8.25e-18	Neutrophil percentage of white cells;
LUAD	cis	rs10203711	0.932	rs4353597	chr2:239597772	C/G	cg14580085	chr2:239553406	NA	0.41	8.65	0.39	1.07e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg03676636	chr4:99064102	C4orf37	0.33	8.52	0.38	2.91e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg11266682	chr4:10021025	SLC2A9	0.69	15.75	0.61	2.65e-44	Bone mineral density;
LUAD	trans	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17712092	chr4:129076599	LARP1B	0.88	16.44	0.62	2.56e-47	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23583168	chr7:148888333	NA	-0.92	-18.84	-0.68	6.4e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7903847	0.667	rs10882931	chr10:99165794	C/A	cg20016023	chr10:99160130	RRP12	-0.28	-6.78	-0.31	4.08e-11	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs11088226	0.750	rs2833885	chr21:33923161	A/G	cg09050820	chr6:167586206	TCP10L2	0.61	8.89	0.4	1.74e-17	Gastritis;
LUAD	cis	rs7737355	0.812	rs40991	chr5:131000654	C/A	cg25547332	chr5:131281432	NA	0.44	6.66	0.31	8.71e-11	Life satisfaction;
LUAD	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg11292332	chr7:45801988	SEPT13	-0.28	-6.36	-0.3	5.26e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg05340658	chr4:99064831	C4orf37	0.53	9.02	0.4	6.77e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg19862616	chr7:65841803	NCRNA00174	-1.07	-27.41	-0.8	7.69e-96	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9467160	0.651	rs9393557	chr6:24453195	C/G	cg20631270	chr6:24437470	GPLD1	0.41	6.45	0.3	3.01e-10	Liver enzyme levels;
LUAD	cis	rs12971120	0.588	rs12606654	chr18:72126710	C/T	cg25817165	chr18:72167213	CNDP2	-0.59	-6.73	-0.31	5.58e-11	Refractive error;
LUAD	cis	rs2806561	1.000	rs681753	chr1:23515216	T/C	cg12483005	chr1:23474871	LUZP1	0.38	6.64	0.31	9.66e-11	Height;
LUAD	trans	rs9929218	0.871	rs1862748	chr16:68832943	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-12.78	-0.53	7.62e-32	Colorectal cancer;
LUAD	cis	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg14039649	chr22:38352398	POLR2F	0.37	6.66	0.31	8.42e-11	Glioblastoma;Glioma;
LUAD	cis	rs1697139	0.935	rs1625369	chr5:66513022	C/T	cg11553311	chr5:66541588	NA	0.34	6.38	0.3	4.76e-10	Breast cancer;
LUAD	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26314531	chr2:26401878	FAM59B	-0.74	-10.65	-0.46	1.26e-23	Gut microbiome composition (summer);
LUAD	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg13319975	chr6:146136371	FBXO30	-0.65	-11.36	-0.48	2.88e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.16	0.33	3.64e-12	Menopause (age at onset);
LUAD	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg24848339	chr3:12840334	CAND2	0.49	10.43	0.45	7.82e-23	QRS complex (12-leadsum);
LUAD	cis	rs11048434	0.761	rs12827988	chr12:9130287	A/G	cg26114124	chr12:9217669	LOC144571	0.38	6.97	0.32	1.24e-11	Sjögren's syndrome;
LUAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg07677032	chr17:61819896	STRADA	0.55	10.08	0.44	1.52e-21	Prudent dietary pattern;
LUAD	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg09137382	chr11:130731461	NA	0.43	8.02	0.36	1.04e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.55	-0.42	1.04e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg17264618	chr3:40429014	ENTPD3	0.44	9.28	0.41	9.04e-19	Renal cell carcinoma;
LUAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.47e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg08761264	chr16:28874980	SH2B1	-0.44	-6.62	-0.31	1.09e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg24112000	chr20:60950667	NA	-0.76	-10.84	-0.47	2.47e-24	Colorectal cancer;
LUAD	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg17863274	chr19:49399704	TULP2	-0.46	-6.43	-0.3	3.49e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg09873201	chr16:3507582	NAT15	0.56	8.39	0.38	7.35e-16	Tuberculosis;
LUAD	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-8.27	-0.37	1.79e-15	Gut microbiome composition (summer);
LUAD	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg11189052	chr15:85197271	WDR73	0.65	8.8	0.39	3.55e-17	Schizophrenia;
LUAD	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg10909506	chr17:38081995	ORMDL3	0.38	6.56	0.3	1.59e-10	Self-reported allergy;
LUAD	cis	rs6138458	1.000	rs6114980	chr20:24974288	A/G	cg06937882	chr20:24974362	C20orf3	-0.34	-6.81	-0.31	3.26e-11	Blood protein levels;
LUAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg03188948	chr7:1209495	NA	0.81	9.91	0.43	5.78e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22496380	chr5:211416	CCDC127	-0.95	-13.32	-0.54	4.88e-34	Breast cancer;
LUAD	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg08085267	chr17:45401833	C17orf57	0.64	11.77	0.5	7.09e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs75920871	0.702	rs59511712	chr11:116945762	C/T	cg04087571	chr11:116723030	SIK3	-0.32	-7.4	-0.34	7.59e-13	Subjective well-being;
LUAD	cis	rs7582720	1.000	rs72932554	chr2:203845828	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.64	0.42	5.27e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.35	-0.41	4.99e-19	Life satisfaction;
LUAD	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg08470875	chr2:26401718	FAM59B	-0.6	-8.2	-0.37	2.96e-15	Gut microbiome composition (summer);
LUAD	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg01097406	chr16:89675127	NA	0.46	9.79	0.43	1.6e-20	Vitiligo;
LUAD	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg21918786	chr6:109611834	NA	-0.58	-10.61	-0.46	1.8e-23	Reticulocyte fraction of red cells;
LUAD	trans	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg19469189	chr11:128781035	KCNJ5	-0.43	-6.58	-0.3	1.41e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg16989719	chr2:238392110	NA	-0.32	-6.69	-0.31	7.11e-11	Prostate cancer;
LUAD	cis	rs16910800	1.000	rs73479578	chr11:23197173	C/T	cg20040320	chr11:23191996	NA	-0.48	-7.19	-0.33	2.93e-12	Cancer;
LUAD	cis	rs2742234	0.590	rs2435337	chr10:43661836	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.52	-8.88	-0.4	1.97e-17	Hirschsprung disease;
LUAD	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg22920501	chr2:26401640	FAM59B	0.82	11.49	0.49	8.73e-27	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.1	0.33	5.4e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.57	-0.49	4.54e-27	Primary sclerosing cholangitis;
LUAD	cis	rs829883	0.932	rs249840	chr12:98871993	T/C	cg25150519	chr12:98850993	NA	0.67	11.18	0.48	1.3e-25	Colorectal adenoma (advanced);
LUAD	cis	rs750460	0.816	rs4886778	chr15:74225388	C/A	cg23484268	chr15:74220776	LOXL1	0.38	7.51	0.34	3.45e-13	Height;
LUAD	cis	rs8077889	0.672	rs1230400	chr17:41845451	G/A	cg26893861	chr17:41843967	DUSP3	-1.14	-26.41	-0.79	1.6e-91	Triglycerides;
LUAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg04025307	chr7:1156635	C7orf50	0.66	7.49	0.34	3.93e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18876405	chr7:65276391	NA	0.59	10.01	0.44	2.68e-21	Aortic root size;
LUAD	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg12365402	chr11:9010492	NRIP3	-0.46	-8.93	-0.4	1.29e-17	Hemoglobin concentration;
LUAD	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg15445000	chr17:37608096	MED1	0.44	8.21	0.37	2.77e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18099408	chr3:52552593	STAB1	-0.48	-8.42	-0.38	5.98e-16	Bipolar disorder;
LUAD	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg00717180	chr2:96193071	NA	-0.41	-7.55	-0.34	2.76e-13	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg17366294	chr4:99064904	C4orf37	0.66	11.77	0.5	7.45e-28	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg03948781	chr1:205179583	DSTYK	0.33	6.53	0.3	1.85e-10	Red blood cell count;
LUAD	cis	rs1448094	0.617	rs7297449	chr12:86468442	A/C	cg18827107	chr12:86230957	RASSF9	0.48	8.45	0.38	4.67e-16	Major depressive disorder;
LUAD	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg23262073	chr20:60523788	NA	-0.44	-7.62	-0.35	1.69e-13	Body mass index;
LUAD	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg26343298	chr8:95960752	TP53INP1	0.37	7.82	0.36	4.12e-14	Type 2 diabetes;
LUAD	cis	rs612683	0.524	rs11166456	chr1:100925633	C/T	cg06223162	chr1:101003688	GPR88	0.39	7.44	0.34	5.66e-13	Breast cancer;
LUAD	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg23758822	chr17:41437982	NA	-0.9	-18.07	-0.66	1.71e-54	Menopause (age at onset);
LUAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg15242686	chr22:24348715	GSTTP1	-0.42	-7.1	-0.33	5.37e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg04851639	chr8:1020857	NA	-0.36	-8.54	-0.38	2.49e-16	Schizophrenia;
LUAD	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg00898013	chr13:113819073	PROZ	-0.65	-11.21	-0.48	1.04e-25	Platelet distribution width;
LUAD	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg00814883	chr7:100076585	TSC22D4	-0.81	-11.29	-0.48	5.22e-26	Platelet count;
LUAD	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.48	-0.38	3.74e-16	Height;
LUAD	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg02018176	chr4:1364513	KIAA1530	0.37	6.88	0.32	2.23e-11	Obesity-related traits;
LUAD	cis	rs367943	0.634	rs6891281	chr5:112960014	G/A	cg12552261	chr5:112820674	MCC	0.38	6.58	0.3	1.37e-10	Type 2 diabetes;
LUAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.54	-0.3	1.74e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2735413	0.918	rs12925605	chr16:78071715	G/A	cg04733911	chr16:78082701	NA	-0.34	-8.17	-0.37	3.56e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.11	-0.41	3.2e-18	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.14	-0.33	4.17e-12	Dental caries;
LUAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg23283495	chr1:209979779	IRF6	0.72	11.56	0.49	4.61e-27	Cleft lip with or without cleft palate;
LUAD	cis	rs6430585	0.591	rs4585083	chr2:136486342	C/T	cg07169764	chr2:136633963	MCM6	0.7	7.83	0.36	3.92e-14	Corneal structure;
LUAD	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg23533926	chr12:111358616	MYL2	0.4	7.03	0.32	8.18e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg03563238	chr19:33554763	RHPN2	0.34	8.18	0.37	3.29e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9479482	0.967	rs1853664	chr6:150355266	A/G	cg25797454	chr6:150327115	RAET1K	0.33	7.37	0.34	9.11e-13	Alopecia areata;
LUAD	cis	rs17270561	0.609	rs9467572	chr6:25704126	T/G	cg25753631	chr6:25732923	NA	0.4	7.06	0.32	6.85e-12	Iron status biomarkers;
LUAD	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.38	-0.38	7.81e-16	Total body bone mineral density;
LUAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg13126279	chr21:47581558	C21orf56	-0.43	-7.47	-0.34	4.51e-13	Testicular germ cell tumor;
LUAD	cis	rs41271473	0.526	rs12353961	chr1:228738252	G/C	cg16512390	chr1:228756714	NA	0.68	9.07	0.4	4.45e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg19875535	chr5:140030758	IK	0.44	7.41	0.34	6.93e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg20607798	chr8:58055168	NA	0.82	9.86	0.43	9.07e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg24920358	chr1:40204285	PPIE	0.7	12.71	0.53	1.45e-31	Blood protein levels;
LUAD	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg21775007	chr8:11205619	TDH	-0.52	-9.54	-0.42	1.14e-19	Retinal vascular caliber;
LUAD	cis	rs1403694	1.000	rs2304451	chr3:186437661	G/C	cg12454167	chr3:186435060	KNG1	0.43	8.85	0.4	2.34e-17	Blood protein levels;
LUAD	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.46	0.34	5.03e-13	Bipolar disorder;
LUAD	cis	rs4953318	0.619	rs12105417	chr2:46361255	A/C	cg12428440	chr2:46370979	PRKCE	0.42	6.68	0.31	7.51e-11	Red blood cell count;Hematocrit;Red blood cell traits;
LUAD	cis	rs1009647	0.656	rs10147254	chr14:55850315	C/A	cg04306507	chr14:55594613	LGALS3	0.4	7.82	0.36	4.2e-14	Testicular germ cell tumor;
LUAD	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg04414720	chr1:150670196	GOLPH3L	0.6	10.27	0.45	2.97e-22	Melanoma;
LUAD	cis	rs2625529	0.652	rs1481862	chr15:72245648	G/A	cg16672083	chr15:72433130	SENP8	0.6	10.92	0.47	1.22e-24	Red blood cell count;
LUAD	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg14983838	chr19:29218262	NA	0.66	9.72	0.43	2.82e-20	Methadone dose in opioid dependence;
LUAD	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg04450456	chr4:17643702	FAM184B	-0.43	-8.53	-0.38	2.59e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	7.66	0.35	1.31e-13	Tonsillectomy;
LUAD	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg21100191	chr22:23484243	RTDR1	0.71	12.37	0.52	3.16e-30	Bone mineral density;
LUAD	cis	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg04455712	chr21:45112962	RRP1B	0.46	9.09	0.4	3.81e-18	Mean corpuscular volume;
LUAD	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-7.84	-0.36	3.64e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs13082711	0.911	rs13078798	chr3:27445971	A/G	cg02860705	chr3:27208620	NA	-0.55	-8.59	-0.39	1.67e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs427394	0.659	rs419128	chr5:6739791	G/A	cg12316010	chr5:6737918	POLS	0.39	7.43	0.34	5.88e-13	Menopause (age at onset);
LUAD	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.52	-0.3	2.04e-10	Calcium levels;
LUAD	trans	rs11039798	0.688	rs10839007	chr11:48703442	A/C	cg02254774	chr11:50257496	LOC441601	0.53	6.61	0.31	1.19e-10	Axial length;
LUAD	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg12740337	chr6:28058973	ZSCAN12L1	0.35	6.65	0.31	9.19e-11	Lung cancer in ever smokers;
LUAD	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg00981070	chr1:2046702	PRKCZ	0.36	6.97	0.32	1.25e-11	Height;
LUAD	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg09537434	chr19:41945824	ATP5SL	-0.45	-7.24	-0.33	2.18e-12	Height;
LUAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg14789911	chr21:47582049	C21orf56	-0.5	-8.96	-0.4	1.06e-17	Testicular germ cell tumor;
LUAD	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg16989719	chr2:238392110	NA	-0.35	-7.22	-0.33	2.5e-12	Prostate cancer;
LUAD	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg16680214	chr1:154839983	KCNN3	-0.66	-13.59	-0.55	3.78e-35	Prostate cancer;
LUAD	cis	rs75920871	0.800	rs59266239	chr11:116911077	C/T	cg04087571	chr11:116723030	SIK3	-0.32	-6.74	-0.31	5.13e-11	Subjective well-being;
LUAD	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg00933542	chr6:150070202	PCMT1	0.48	10.06	0.44	1.69e-21	Lung cancer;
LUAD	cis	rs2625529	0.652	rs8036307	chr15:72175120	A/G	cg16672083	chr15:72433130	SENP8	0.63	11.71	0.49	1.28e-27	Red blood cell count;
LUAD	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26314531	chr2:26401878	FAM59B	-0.55	-7.66	-0.35	1.26e-13	Gut microbiome composition (summer);
LUAD	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg17366294	chr4:99064904	C4orf37	0.47	8.34	0.38	1.03e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4372836	0.504	rs6730321	chr2:29004299	T/C	cg09522027	chr2:28974177	PPP1CB	-0.61	-10.88	-0.47	1.82e-24	Body mass index;
LUAD	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg23283495	chr1:209979779	IRF6	0.4	7.18	0.33	3.08e-12	Monobrow;
LUAD	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg12034118	chr1:209979487	IRF6	0.54	6.59	0.31	1.33e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.97	0.47	8.47e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg11494091	chr17:61959527	GH2	0.74	18.62	0.67	6.03e-57	Prudent dietary pattern;
LUAD	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.39	6.52	0.3	1.95e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.41	-0.34	7.02e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2224391	0.540	rs1570085	chr6:5253063	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-8.66	-0.39	1.03e-16	Height;
LUAD	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.77	0.31	4.27e-11	Depression;
LUAD	cis	rs6494488	0.500	rs72744764	chr15:65076887	G/A	cg08069370	chr15:64387884	SNX1	-0.72	-6.64	-0.31	9.61e-11	Coronary artery disease;
LUAD	cis	rs12049351	0.774	rs12125978	chr1:229627722	T/C	cg11742688	chr1:229674241	ABCB10	-0.42	-6.4	-0.3	4.04e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs55665837	1.000	rs55665837	chr11:14495049	C/T	cg19336497	chr11:14380999	RRAS2	-0.5	-10.16	-0.44	7.83e-22	Vitamin D levels;
LUAD	cis	rs10992471	0.603	rs7864575	chr9:95304647	G/A	cg14631576	chr9:95140430	CENPP	-0.5	-10.15	-0.44	8.35e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7493	0.950	rs11981299	chr7:95029701	T/A	cg19678392	chr7:94953810	PON1	-0.58	-7.92	-0.36	2.11e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg17644776	chr2:200775616	C2orf69	0.59	10.14	0.44	8.63e-22	Osteoporosis;
LUAD	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg22431228	chr1:16359049	CLCNKA	-0.37	-6.78	-0.31	4.16e-11	Dilated cardiomyopathy;
LUAD	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg26343298	chr8:95960752	TP53INP1	0.36	7.66	0.35	1.3e-13	Type 2 diabetes;
LUAD	cis	rs6460942	0.915	rs72584550	chr7:12304990	G/A	cg06484146	chr7:12443880	VWDE	-0.45	-6.59	-0.31	1.33e-10	Coronary artery disease;
LUAD	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11644478	chr21:40555479	PSMG1	0.7	11.63	0.49	2.48e-27	Cognitive function;
LUAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.41	0.55	2.12e-34	Prudent dietary pattern;
LUAD	cis	rs1595825	0.891	rs79845692	chr2:198523541	T/C	cg11031976	chr2:198649780	BOLL	-0.46	-6.84	-0.32	2.82e-11	Ulcerative colitis;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg14534336	chr10:65028980	JMJD1C	-0.4	-6.89	-0.32	1.99e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg07507251	chr3:52567010	NT5DC2	0.38	7.35	0.34	1e-12	Bipolar disorder;
LUAD	cis	rs151234	0.800	rs231974	chr16:28540322	A/T	cg04643524	chr16:28609220	SULT1A2	0.57	7.56	0.34	2.57e-13	Platelet distribution width;
LUAD	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.9	12.92	0.53	2.11e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg05535760	chr7:792225	HEATR2	0.83	11.11	0.48	2.47e-25	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg13319975	chr6:146136371	FBXO30	0.56	9.52	0.42	1.36e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg10755058	chr3:40428713	ENTPD3	0.38	7.37	0.34	8.91e-13	Renal cell carcinoma;
LUAD	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.18	0.37	3.44e-15	Breast cancer;
LUAD	trans	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.74	11.08	0.47	3.17e-25	Ulcerative colitis;
LUAD	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg20203395	chr5:56204925	C5orf35	-0.84	-12.03	-0.5	7.06e-29	Initial pursuit acceleration;
LUAD	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg05110241	chr16:68378359	PRMT7	-0.83	-9.07	-0.4	4.59e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4711336	1.000	rs3818523	chr6:33660371	G/A	cg13859433	chr6:33739653	LEMD2	-0.3	-7.02	-0.32	8.72e-12	Height;
LUAD	cis	rs12210905	0.688	rs12193557	chr6:27435944	T/C	cg08851530	chr6:28072375	NA	1.03	7.92	0.36	2.19e-14	Hip circumference adjusted for BMI;
LUAD	trans	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.94	-0.36	1.83e-14	Gout;
LUAD	trans	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg06606381	chr12:133084897	FBRSL1	-0.54	-6.53	-0.3	1.89e-10	Depression;
LUAD	cis	rs9796	0.840	rs1009913	chr15:41331050	C/T	cg18705301	chr15:41695430	NDUFAF1	0.38	7.14	0.33	3.99e-12	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9644630	1.000	rs6988743	chr8:19369583	C/A	cg06699216	chr8:19333253	CSGALNACT1	-0.32	-7.47	-0.34	4.49e-13	Oropharynx cancer;
LUAD	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg24848339	chr3:12840334	CAND2	-0.45	-8.97	-0.4	9.57e-18	QRS complex (12-leadsum);
LUAD	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.86	0.4	2.24e-17	Parkinson's disease;
LUAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	9.07	0.4	4.44e-18	Alzheimer's disease;
LUAD	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg05754148	chr16:3507555	NAT15	0.43	6.63	0.31	1.01e-10	Body mass index (adult);
LUAD	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg03609598	chr5:56110824	MAP3K1	-0.65	-9.06	-0.4	4.69e-18	Initial pursuit acceleration;
LUAD	cis	rs62238980	0.614	rs17745543	chr22:32475456	G/A	cg00543991	chr22:32367038	NA	0.92	8.7	0.39	7.27e-17	Childhood ear infection;
LUAD	trans	rs1493916	0.905	rs7239283	chr18:31395397	G/A	cg27147174	chr7:100797783	AP1S1	-0.69	-12.54	-0.52	7.11e-31	Life satisfaction;
LUAD	trans	rs3858145	0.588	rs4142048	chr10:70044031	T/C	cg04882175	chr6:131122610	NA	-0.57	-6.77	-0.31	4.42e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUAD	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg03806693	chr22:41940476	POLR3H	-0.8	-11.43	-0.49	1.5e-26	Vitiligo;
LUAD	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg06108461	chr20:60628389	TAF4	-0.96	-17.44	-0.65	1e-51	Body mass index;
LUAD	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg14671364	chr1:107599128	PRMT6	-0.64	-11.06	-0.47	3.65e-25	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg14895029	chr7:2775587	GNA12	-0.39	-6.36	-0.3	5.26e-10	Height;
LUAD	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg08085267	chr17:45401833	C17orf57	-0.55	-9.67	-0.43	4.05e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs57590327	0.628	rs34439726	chr3:81667241	C/T	cg07356753	chr3:81810745	GBE1	-0.5	-6.69	-0.31	7.17e-11	Extraversion;
LUAD	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg22676075	chr6:135203613	NA	0.42	7.86	0.36	3.3e-14	Red blood cell count;
LUAD	cis	rs7589728	0.844	rs77144652	chr2:88496684	G/A	cg04511125	chr2:88470314	THNSL2	0.79	8.13	0.37	4.96e-15	Plasma clusterin levels;
LUAD	cis	rs9807989	0.507	rs2310300	chr2:103049074	A/G	cg03938978	chr2:103052716	IL18RAP	0.46	10.49	0.45	4.89e-23	Asthma;
LUAD	cis	rs4786125	0.879	rs11640468	chr16:6895945	C/T	cg03623568	chr16:6915990	A2BP1	-0.37	-8.06	-0.36	7.77e-15	Heart rate variability traits (SDNN);
LUAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.49	6.52	0.3	2.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3784262	0.669	rs7178598	chr15:58309016	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.5	-0.34	3.89e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	8.02	0.36	1.01e-14	Breast cancer;
LUAD	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg18944383	chr4:111397179	ENPEP	0.38	7.67	0.35	1.19e-13	Height;
LUAD	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg13606994	chr1:44402422	ARTN	-0.33	-6.75	-0.31	4.99e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg21963583	chr11:68658836	MRPL21	0.67	11.92	0.5	1.94e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9462027	0.606	rs9462024	chr6:34772793	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.71	-0.39	6.76e-17	Systemic lupus erythematosus;
LUAD	trans	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg24644049	chr4:85504048	CDS1	0.86	7.02	0.32	8.92e-12	Skin colour saturation;
LUAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg11062466	chr8:58055876	NA	0.46	6.54	0.3	1.75e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg04369109	chr6:150039330	LATS1	-0.44	-7.5	-0.34	3.75e-13	Lung cancer;
LUAD	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg23262351	chr6:79576851	IRAK1BP1	0.42	6.84	0.32	2.83e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs315934	0.664	rs315921	chr2:113872051	C/T	cg09040174	chr2:113837401	NA	-0.58	-6.74	-0.31	5.32e-11	Dysmenorrheic pain;
LUAD	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg25173405	chr17:45401733	C17orf57	-0.6	-10.46	-0.45	6.36e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03517284	chr6:25882590	NA	0.6	10.02	0.44	2.41e-21	Blood metabolite levels;
LUAD	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg06641503	chr3:48959341	ARIH2	-0.4	-7.85	-0.36	3.49e-14	Parkinson's disease;
LUAD	cis	rs754466	0.874	rs61855849	chr10:79659934	G/A	cg17075019	chr10:79541650	NA	-0.85	-14.09	-0.57	3.07e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg04025307	chr7:1156635	C7orf50	0.58	9.18	0.41	1.99e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg19622623	chr12:86230825	RASSF9	-0.55	-9.75	-0.43	2.11e-20	Major depressive disorder;
LUAD	cis	rs7709909	0.653	rs40139	chr5:80033835	A/G	cg24059623	chr5:79951536	MSH3;DHFR	0.47	8.48	0.38	3.9e-16	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	trans	rs1941687	0.831	rs12958029	chr18:31388680	A/G	cg27147174	chr7:100797783	AP1S1	-0.5	-8.27	-0.37	1.72e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg24818145	chr4:99064322	C4orf37	-0.41	-6.96	-0.32	1.34e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12612619	0.704	rs6742004	chr2:27309659	A/C	cg00617064	chr2:27272375	NA	-0.38	-7.18	-0.33	3.25e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg14019146	chr3:50243930	SLC38A3	-0.55	-10.64	-0.46	1.34e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs2742540	0.503	rs11042121	chr11:8932640	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.57	9.76	0.43	1.93e-20	Hematocrit;
LUAD	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg01065977	chr19:18549689	ISYNA1	-0.39	-7.59	-0.35	2.07e-13	Breast cancer;
LUAD	cis	rs9914988	0.943	rs28847895	chr17:27172520	T/C	cg02049041	chr17:27085579	C17orf63	0.64	8.56	0.38	2.1e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6594713	0.642	rs13169748	chr5:112848999	C/T	cg12552261	chr5:112820674	MCC	0.54	7.43	0.34	6.03e-13	Brain cytoarchitecture;
LUAD	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg26441486	chr22:50317300	CRELD2	0.43	6.45	0.3	3.1e-10	Schizophrenia;
LUAD	cis	rs2797160	0.967	rs1739368	chr6:126011079	C/T	cg05901451	chr6:126070800	HEY2	0.45	6.65	0.31	9e-11	Endometrial cancer;
LUAD	cis	rs9394841	0.692	rs9381094	chr6:41800629	T/C	cg25600774	chr6:41776562	USP49	-0.42	-6.47	-0.3	2.78e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs1395	0.626	rs72817537	chr2:27497549	G/A	cg23587288	chr2:27483067	SLC30A3	-0.41	-7.06	-0.32	6.91e-12	Blood metabolite levels;
LUAD	cis	rs12410462	0.502	rs115241368	chr1:227795465	A/G	cg23173402	chr1:227635558	NA	0.67	6.37	0.3	4.82e-10	Major depressive disorder;
LUAD	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg06781209	chr11:61594997	FADS2	0.42	7.61	0.35	1.86e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-7.95	-0.36	1.78e-14	Total body bone mineral density;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03577601	chr20:47663236	CSE1L	-0.43	-7.13	-0.33	4.24e-12	Cancer;
LUAD	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg09184832	chr6:79620586	NA	-0.53	-9.84	-0.43	1.07e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg02951883	chr7:2050386	MAD1L1	-0.81	-13.6	-0.55	3.22e-35	Bipolar disorder and schizophrenia;
LUAD	cis	rs2235649	0.833	rs9939694	chr16:1852760	C/T	cg08610935	chr16:1836813	NUBP2	-0.49	-7.33	-0.34	1.14e-12	Blood metabolite levels;
LUAD	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg17757837	chr7:157058334	UBE3C	0.47	8.39	0.38	7.42e-16	Body mass index;
LUAD	cis	rs2066819	1.000	rs2291361	chr12:56717805	G/A	cg26714650	chr12:56694279	CS	-0.85	-7.1	-0.33	5.17e-12	Psoriasis vulgaris;
LUAD	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg17366294	chr4:99064904	C4orf37	0.64	12.15	0.51	2.48e-29	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35771425	0.642	rs11586974	chr1:211464115	A/G	cg25617285	chr1:211431773	RCOR3	0.46	8.44	0.38	4.99e-16	Educational attainment (years of education);
LUAD	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg25457927	chr22:38595422	NA	-0.53	-13.87	-0.56	2.48e-36	Cutaneous nevi;
LUAD	trans	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg18187862	chr3:45730750	SACM1L	-0.54	-7.97	-0.36	1.51e-14	Primary sclerosing cholangitis;
LUAD	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07636037	chr3:49044803	WDR6	0.49	8.45	0.38	4.73e-16	Menarche (age at onset);
LUAD	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.89	-0.53	2.66e-32	Chronic sinus infection;
LUAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg14092988	chr3:52407081	DNAH1	0.35	7.06	0.32	6.98e-12	Electroencephalogram traits;
LUAD	cis	rs2262909	0.962	rs439574	chr19:22232024	A/C	cg11619707	chr19:22235551	ZNF257	-0.44	-7.13	-0.33	4.39e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	trans	rs208520	0.690	rs207094	chr6:66799009	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-17.73	-0.65	5.21e-53	Exhaled nitric oxide output;
LUAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg21285383	chr16:89894308	SPIRE2	-0.42	-10.28	-0.45	2.78e-22	Vitiligo;
LUAD	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.51	-0.3	2.17e-10	Depression;
LUAD	cis	rs7072216	0.922	rs942814	chr10:100151305	A/G	cg26618903	chr10:100175079	PYROXD2	-0.33	-7.09	-0.33	5.81e-12	Metabolite levels;
LUAD	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg15467112	chr14:75489610	MLH3	0.35	6.41	0.3	3.86e-10	Height;
LUAD	cis	rs9902453	0.904	rs4598962	chr17:28293948	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	10.24	0.45	4.04e-22	Coffee consumption (cups per day);
LUAD	cis	rs922182	0.569	rs7180050	chr15:64263784	G/A	cg02919090	chr15:64263738	DAPK2	0.42	8.31	0.37	1.34e-15	Blood protein levels;
LUAD	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	8.73	0.39	6.16e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs887829	0.570	rs7608175	chr2:234599089	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.54	9.39	0.42	3.89e-19	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs977987	0.843	rs11649638	chr16:75488285	G/A	cg03315344	chr16:75512273	CHST6	0.65	14.08	0.57	3.24e-37	Dupuytren's disease;
LUAD	cis	rs59104589	0.617	rs16842449	chr2:242354979	C/T	cg08645257	chr2:242211290	HDLBP	0.44	6.9	0.32	1.91e-11	Fibrinogen levels;
LUAD	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg02951883	chr7:2050386	MAD1L1	-0.74	-12.64	-0.52	2.69e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.07e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg20203395	chr5:56204925	C5orf35	-0.49	-7.67	-0.35	1.2e-13	Coronary artery disease;
LUAD	cis	rs7759001	0.857	rs6936356	chr6:27358853	A/C	cg18711553	chr6:27366782	ZNF391	0.4	6.56	0.3	1.56e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg05805236	chr11:65401703	PCNXL3	-0.55	-8.77	-0.39	4.4e-17	Acne (severe);
LUAD	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg00310523	chr12:86230176	RASSF9	-0.37	-7.4	-0.34	7.35e-13	Major depressive disorder;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg10596108	chr19:50169499	BCL2L12;IRF3	-0.66	-6.75	-0.31	4.76e-11	Type 2 diabetes;
LUAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.65	-0.31	9.34e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs8010715	0.636	rs2277482	chr14:24587795	C/T	cg23112188	chr14:24563095	PCK2	-0.35	-6.97	-0.32	1.24e-11	IgG glycosylation;
LUAD	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg25251562	chr2:3704773	ALLC	-0.43	-7.64	-0.35	1.51e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09525994	chr12:48512905	PFKM	-0.46	-7.0	-0.32	9.85e-12	Height;
LUAD	cis	rs12824058	0.737	rs873663	chr12:130816316	C/T	cg24838063	chr12:130822603	PIWIL1	0.63	10.44	0.45	7.53e-23	Menopause (age at onset);
LUAD	cis	rs9462027	0.628	rs2764208	chr6:34714322	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-8.42	-0.38	5.89e-16	Systemic lupus erythematosus;
LUAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg00106254	chr7:1943704	MAD1L1	-0.63	-9.56	-0.42	9.57e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs250585	0.736	rs250583	chr16:23403510	A/G	cg00143387	chr16:23521605	GGA2	-0.58	-8.31	-0.37	1.3e-15	Egg allergy;
LUAD	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg25456477	chr12:86230367	RASSF9	0.37	7.14	0.33	4.14e-12	Major depressive disorder;
LUAD	cis	rs4523957	0.690	rs7213715	chr17:2093511	A/T	cg16513277	chr17:2031491	SMG6	-0.94	-18.22	-0.66	3.72e-55	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg26068271	chr17:76253126	NA	0.45	7.6	0.35	1.94e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg11494091	chr17:61959527	GH2	0.68	16.22	0.62	2.41e-46	Prudent dietary pattern;
LUAD	trans	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg00953403	chr17:74099816	EXOC7	0.43	6.63	0.31	1.01e-10	Psychosis in Alzheimer's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11668638	chr6:42952412	PPP2R5D	-0.42	-6.76	-0.31	4.7e-11	Height;
LUAD	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg16447950	chr5:562315	NA	-0.44	-7.09	-0.33	5.74e-12	Obesity-related traits;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg02514519	chr11:61348922	SYT7	0.42	6.72	0.31	5.91e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26314531	chr2:26401878	FAM59B	0.57	7.88	0.36	2.71e-14	Gut microbiome composition (summer);
LUAD	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg22823121	chr1:150693482	HORMAD1	0.41	7.96	0.36	1.57e-14	Melanoma;
LUAD	cis	rs4774899	1.000	rs2116066	chr15:57254778	A/G	cg14026238	chr15:57616123	NA	0.34	6.54	0.3	1.75e-10	Urinary tract infection frequency;
LUAD	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.9	0.36	2.47e-14	Morning vs. evening chronotype;
LUAD	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	15.23	0.6	4.5e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg25102621	chr11:107328605	CWF19L2	-0.66	-6.38	-0.3	4.74e-10	Type 2 diabetes;
LUAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg11494091	chr17:61959527	GH2	0.74	18.39	0.67	6.14e-56	Prudent dietary pattern;
LUAD	cis	rs3106136	0.546	rs7685121	chr4:95175682	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.09	-0.44	1.4e-21	Capecitabine sensitivity;
LUAD	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.58	0.49	4.12e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs113835537	0.529	rs11227511	chr11:66281244	A/C	cg26679405	chr11:66247800	DPP3	-0.45	-6.47	-0.3	2.71e-10	Airway imaging phenotypes;
LUAD	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-8.5	-0.38	3.3e-16	Reticulocyte count;
LUAD	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg12292205	chr6:26970375	C6orf41	-0.56	-6.8	-0.31	3.55e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg09455208	chr3:40491958	NA	-0.57	-12.7	-0.53	1.63e-31	Renal cell carcinoma;
LUAD	cis	rs735539	0.645	rs9552248	chr13:21159200	G/A	cg27499820	chr13:21296301	IL17D	0.51	8.37	0.38	8.23e-16	Dental caries;
LUAD	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg02493740	chr2:85810744	VAMP5	-0.62	-11.38	-0.48	2.32e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.23	-0.33	2.34e-12	Height;
LUAD	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg09222892	chr1:25734099	RHCE	-0.5	-9.15	-0.41	2.36e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs7119	0.604	rs2271397	chr15:77907775	T/C	cg27398640	chr15:77910606	LINGO1	0.41	8.21	0.37	2.68e-15	Type 2 diabetes;
LUAD	cis	rs4372836	0.729	rs67410623	chr2:29057440	G/A	cg09522027	chr2:28974177	PPP1CB	0.66	11.59	0.49	3.58e-27	Body mass index;
LUAD	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg23602478	chr1:26503979	CNKSR1	0.28	7.01	0.32	9.26e-12	Height;
LUAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg00106254	chr7:1943704	MAD1L1	0.58	8.8	0.39	3.45e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	7.48	0.34	4.19e-13	Menarche (age at onset);
LUAD	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg11833968	chr6:79620685	NA	-0.44	-8.29	-0.37	1.48e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2357013	0.752	rs4672085	chr2:53154899	G/A	cg07782112	chr2:53107842	NA	-0.36	-7.14	-0.33	4.17e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	9.69	0.43	3.6e-20	Total body bone mineral density;
LUAD	trans	rs3219090	1.000	rs3219090	chr1:226564691	A/G	cg27539482	chr13:111589090	NA	-0.4	-6.66	-0.31	8.51e-11	Melanoma;
LUAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg26338869	chr17:61819248	STRADA	-0.38	-6.35	-0.3	5.48e-10	Prudent dietary pattern;
LUAD	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg16205897	chr5:131564050	P4HA2	0.31	6.76	0.31	4.7e-11	Blood metabolite levels;
LUAD	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.04	-0.32	7.58e-12	Neuroticism;
LUAD	cis	rs657075	0.697	rs3805678	chr5:131675207	G/A	cg21138405	chr5:131827807	IRF1	0.5	6.36	0.3	5.25e-10	Rheumatoid arthritis;
LUAD	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.67	0.35	1.16e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.47	6.53	0.3	1.85e-10	Renal function-related traits (BUN);
LUAD	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg25036284	chr2:26402008	FAM59B	0.84	11.61	0.49	3.12e-27	Mean corpuscular hemoglobin;
LUAD	cis	rs9462027	0.628	rs34141614	chr6:34777031	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.76	-0.39	4.66e-17	Systemic lupus erythematosus;
LUAD	cis	rs78456975	0.550	rs10197874	chr2:1545310	A/G	cg01028140	chr2:1542097	TPO	-0.47	-7.66	-0.35	1.32e-13	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg13736514	chr6:26305472	NA	-0.72	-13.66	-0.55	1.96e-35	Educational attainment;
LUAD	cis	rs6761276	0.752	rs12477866	chr2:113835908	C/T	cg10479672	chr2:113810641	IL1F8	-0.38	-7.65	-0.35	1.39e-13	Protein quantitative trait loci;
LUAD	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg18854424	chr1:2615690	NA	0.43	9.36	0.41	4.9e-19	Ulcerative colitis;
LUAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg02951883	chr7:2050386	MAD1L1	-0.7	-10.94	-0.47	1.06e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg27113419	chr16:58533979	NDRG4	-0.72	-6.49	-0.3	2.39e-10	Schizophrenia;
LUAD	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg00316803	chr15:76480434	C15orf27	-0.4	-7.53	-0.34	3.13e-13	Blood metabolite levels;
LUAD	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	trans	rs11088226	0.645	rs2409457	chr21:33929895	T/C	cg09050820	chr6:167586206	TCP10L2	0.91	12.94	0.53	1.67e-32	Gastritis;
LUAD	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg19635926	chr16:89946313	TCF25	0.67	6.42	0.3	3.57e-10	Skin colour saturation;
LUAD	cis	rs62400317	0.859	rs12205860	chr6:45157323	G/A	cg18551225	chr6:44695536	NA	-0.55	-8.44	-0.38	5.14e-16	Total body bone mineral density;
LUAD	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg27433088	chr4:174089019	GALNT7	0.4	7.73	0.35	8e-14	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg15445000	chr17:37608096	MED1	0.43	7.94	0.36	1.87e-14	Glomerular filtration rate (creatinine);
LUAD	trans	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg25482853	chr8:67687455	SGK3	0.68	10.44	0.45	7.68e-23	Obesity-related traits;
LUAD	trans	rs2288327	0.557	rs60488846	chr2:179357842	C/T	cg14011486	chr1:26737247	LIN28	0.56	7.66	0.35	1.26e-13	Atrial fibrillation;
LUAD	cis	rs9341808	0.754	rs9341811	chr6:80982701	G/A	cg08355045	chr6:80787529	NA	0.53	9.51	0.42	1.41e-19	Sitting height ratio;
LUAD	trans	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg20587970	chr11:113659929	NA	-0.69	-10.43	-0.45	8.32e-23	Hip circumference adjusted for BMI;
LUAD	cis	rs62400317	0.762	rs12208605	chr6:44963735	A/C	cg18551225	chr6:44695536	NA	0.57	8.68	0.39	8.6e-17	Total body bone mineral density;
LUAD	cis	rs4148087	0.932	rs2839477	chr21:43611735	C/T	cg08841829	chr21:43638893	ABCG1	-0.54	-7.24	-0.33	2.12e-12	Eating disorder in bipolar disorder;
LUAD	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg07741184	chr6:167504864	NA	0.31	7.06	0.32	6.7e-12	Crohn's disease;
LUAD	cis	rs7493	0.901	rs11767787	chr7:95026753	T/C	cg20119798	chr7:94954144	PON1	-0.5	-7.06	-0.32	7.03e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg18187862	chr3:45730750	SACM1L	0.52	8.06	0.36	8.06e-15	Primary sclerosing cholangitis;
LUAD	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10802521	chr3:52805072	NEK4	-0.61	-11.15	-0.48	1.73e-25	Bipolar disorder;
LUAD	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg22431228	chr1:16359049	CLCNKA	-0.42	-8.28	-0.37	1.64e-15	Systolic blood pressure;
LUAD	cis	rs11828289	0.607	rs78341320	chr11:23188865	C/T	cg20040320	chr11:23191996	NA	-0.7	-8.11	-0.37	5.7e-15	Cancer;
LUAD	cis	rs4631830	0.863	rs10826127	chr10:51530757	G/A	cg20129853	chr10:51489980	NA	-0.34	-6.7	-0.31	6.57e-11	Prostate-specific antigen levels;
LUAD	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-8.31	-0.37	1.34e-15	Personality dimensions;
LUAD	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg25894440	chr7:65020034	NA	-0.68	-7.26	-0.33	1.81e-12	Diabetic kidney disease;
LUAD	cis	rs4631830	0.900	rs10763546	chr10:51536399	C/G	cg20129853	chr10:51489980	NA	-0.35	-7.05	-0.32	7.34e-12	Prostate-specific antigen levels;
LUAD	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.14	-0.51	2.6e-29	Platelet count;
LUAD	cis	rs986417	0.748	rs1956552	chr14:60942685	A/G	cg27398547	chr14:60952738	C14orf39	0.69	8.31	0.37	1.29e-15	Gut microbiota (bacterial taxa);
LUAD	cis	rs12579753	0.917	rs76240969	chr12:82195236	C/A	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.28	-0.33	1.6e-12	Resting heart rate;
LUAD	cis	rs2131877	0.913	rs1874101	chr3:194849057	C/T	cg19760965	chr3:194868843	C3orf21	-0.39	-6.45	-0.3	3.01e-10	Non-small cell lung cancer;
LUAD	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.34	6.8	0.31	3.57e-11	Obesity-related traits;
LUAD	cis	rs8014204	0.905	rs8014289	chr14:75377352	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.41	-7.22	-0.33	2.48e-12	Caffeine consumption;
LUAD	cis	rs2880765	0.835	rs4842886	chr15:86035773	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.47	-0.3	2.77e-10	Coronary artery disease;
LUAD	cis	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg07460842	chr6:66804631	NA	0.92	14.57	0.58	2.83e-39	Exhaled nitric oxide levels;
LUAD	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg09455208	chr3:40491958	NA	0.52	10.93	0.47	1.14e-24	Renal cell carcinoma;
LUAD	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg17264618	chr3:40429014	ENTPD3	0.41	9.07	0.4	4.58e-18	Renal cell carcinoma;
LUAD	trans	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg07923666	chr12:49932857	KCNH3	-0.55	-6.52	-0.3	2.04e-10	Resting heart rate;
LUAD	cis	rs2404602	0.622	rs11632365	chr15:77139080	G/A	cg00316803	chr15:76480434	C15orf27	0.45	6.59	0.31	1.3e-10	Blood metabolite levels;
LUAD	cis	rs10193935	0.901	rs10196091	chr2:42541591	T/C	cg27598129	chr2:42591480	NA	-0.7	-9.28	-0.41	9.21e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg02527881	chr3:46936655	PTH1R	0.45	8.64	0.39	1.19e-16	Colorectal cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14941466	chr18:66382226	CCDC102B;TMX3	-0.42	-6.49	-0.3	2.39e-10	Height;
LUAD	cis	rs2455799	1.000	rs13092817	chr3:15889398	C/G	cg16303742	chr3:15540471	COLQ	-0.39	-6.64	-0.31	9.84e-11	Mean platelet volume;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg16782848	chr15:83479213	WHAMM	0.41	6.36	0.3	5.36e-10	QT interval;
LUAD	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg04450456	chr4:17643702	FAM184B	0.37	6.95	0.32	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21659725	chr3:3221576	CRBN	-0.64	-10.26	-0.45	3.22e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg20774722	chr17:19551893	ALDH3A2	-0.43	-7.16	-0.33	3.59e-12	Schizophrenia;
LUAD	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11644478	chr21:40555479	PSMG1	0.69	11.53	0.49	6.26e-27	Cognitive function;
LUAD	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg21204522	chr6:27730016	NA	-0.44	-6.94	-0.32	1.51e-11	Parkinson's disease;
LUAD	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg02463440	chr8:22132932	PIWIL2	0.56	10.28	0.45	2.9e-22	Hypertriglyceridemia;
LUAD	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg07636037	chr3:49044803	WDR6	0.62	10.66	0.46	1.13e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg21545522	chr1:205238299	TMCC2	0.36	6.89	0.32	2e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs11696501	0.688	rs714595	chr20:44330591	G/A	cg11783356	chr20:44313418	WFDC10B	-0.49	-7.79	-0.35	5.22e-14	Brain structure;
LUAD	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg18132916	chr6:79620363	NA	-0.46	-7.83	-0.36	3.91e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg03467027	chr4:99064603	C4orf37	0.4	6.38	0.3	4.54e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.89	-0.36	2.52e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs75920871	0.764	rs61903394	chr11:116931898	G/A	cg04087571	chr11:116723030	SIK3	-0.32	-6.61	-0.31	1.16e-10	Subjective well-being;
LUAD	cis	rs7737355	0.812	rs244738	chr5:130851170	A/G	cg25547332	chr5:131281432	NA	0.41	6.56	0.3	1.57e-10	Life satisfaction;
LUAD	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg19318889	chr4:1322082	MAEA	0.82	13.79	0.56	5.39e-36	Longevity;
LUAD	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.61	10.46	0.45	6.41e-23	Cognitive ability;
LUAD	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg08859206	chr1:53392774	SCP2	0.6	11.22	0.48	9.75e-26	Monocyte count;
LUAD	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-7.08	-0.33	6e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24308560	chr3:49941425	MST1R	0.54	9.21	0.41	1.57e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg08989290	chr16:615782	NHLRC4	0.31	6.72	0.31	5.75e-11	Height;
LUAD	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.51	-0.34	3.56e-13	Lung cancer;
LUAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg22535103	chr8:58192502	C8orf71	-0.74	-9.2	-0.41	1.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg27494647	chr7:150038898	RARRES2	0.52	9.39	0.42	3.69e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs3198697	0.617	rs11075253	chr16:15148646	C/A	cg27102117	chr16:15229624	NA	0.43	6.54	0.3	1.76e-10	Triglycerides;
LUAD	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg19163074	chr7:65112434	INTS4L2	0.44	6.73	0.31	5.45e-11	Aortic root size;
LUAD	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg04414720	chr1:150670196	GOLPH3L	0.6	10.27	0.45	2.97e-22	Melanoma;
LUAD	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.01	0.32	9.46e-12	Motion sickness;
LUAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg24503407	chr1:205819492	PM20D1	0.74	14.85	0.59	1.85e-40	Menarche (age at onset);
LUAD	cis	rs9914544	0.564	rs12451220	chr17:18778421	C/T	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.49	-0.3	2.45e-10	Educational attainment (years of education);
LUAD	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg10164272	chr16:89456328	ANKRD11	-0.43	-6.89	-0.32	2e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs7177699	0.525	rs56076311	chr15:79115120	A/G	cg00540400	chr15:79124168	NA	-0.46	-9.81	-0.43	1.31e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7084921	0.578	rs7474935	chr10:101875936	G/C	cg19754520	chr10:101825118	CPN1	-0.35	-6.97	-0.32	1.2e-11	Bone mineral density;
LUAD	cis	rs6754311	0.731	rs218174	chr2:136658345	C/T	cg15123519	chr2:136567270	LCT	0.37	6.81	0.31	3.47e-11	Mosquito bite size;
LUAD	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg05340658	chr4:99064831	C4orf37	0.54	8.98	0.4	8.94e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg05368731	chr17:41323189	NBR1	-0.8	-16.27	-0.62	1.39e-46	Menopause (age at onset);
LUAD	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg17063962	chr7:91808500	NA	0.7	12.02	0.5	7.56e-29	Breast cancer;
LUAD	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg06611532	chr13:114900021	NA	0.37	8.35	0.38	1.01e-15	Schizophrenia;
LUAD	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg05084668	chr3:125655381	ALG1L	-0.67	-9.59	-0.42	7.84e-20	Blood pressure (smoking interaction);
LUAD	cis	rs7116495	1.000	rs677279	chr11:71770469	G/A	cg07596299	chr11:71824057	C11orf51	-0.79	-6.69	-0.31	7.12e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.49	0.38	3.41e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg15448220	chr1:150897856	SETDB1	0.46	7.94	0.36	1.86e-14	Tonsillectomy;
LUAD	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg22166914	chr1:53195759	ZYG11B	-0.44	-7.62	-0.35	1.65e-13	Monocyte count;
LUAD	cis	rs8077889	0.750	rs231541	chr17:41941788	C/G	cg26893861	chr17:41843967	DUSP3	-0.87	-10.89	-0.47	1.7e-24	Triglycerides;
LUAD	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg23625390	chr15:77176239	SCAPER	0.35	6.35	0.3	5.5e-10	Blood metabolite levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24720442	chr19:56154855	ZNF581	-0.41	-6.36	-0.3	5.22e-10	Height;
LUAD	cis	rs78761021	0.867	rs7219033	chr17:9787958	G/A	cg26853458	chr17:9805074	RCVRN	0.35	7.16	0.33	3.67e-12	Type 2 diabetes;
LUAD	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg27129171	chr3:47204927	SETD2	0.42	6.91	0.32	1.78e-11	Colorectal cancer;
LUAD	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg12140854	chr5:148520817	ABLIM3	-0.69	-10.03	-0.44	2.23e-21	Breast cancer;
LUAD	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.42	-8.25	-0.37	2.02e-15	Glomerular filtration rate;
LUAD	cis	rs9768139	0.696	rs4909177	chr7:158117047	A/T	cg24154853	chr7:158122151	PTPRN2	0.58	11.46	0.49	1.13e-26	Calcium levels;
LUAD	cis	rs1160297	0.576	rs67939368	chr2:53093152	G/C	cg07782112	chr2:53107842	NA	0.39	8.32	0.38	1.18e-15	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs12122100	0.651	rs12129691	chr1:146554147	C/T	cg03526459	chr1:146549940	NA	-0.37	-6.82	-0.31	3.16e-11	HIV-1 control;
LUAD	cis	rs6564851	0.506	rs72831372	chr16:81250503	C/T	cg00908271	chr16:81254010	PKD1L2	0.32	6.62	0.31	1.1e-10	Carotenoid and tocopherol levels;
LUAD	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.96	-0.32	1.29e-11	Longevity;
LUAD	trans	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.66	-11.43	-0.49	1.46e-26	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs524023	1.000	rs505802	chr11:64357072	T/C	cg19131476	chr11:64387923	NRXN2	0.37	6.95	0.32	1.39e-11	Urate levels in obese individuals;
LUAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.5e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.47	-0.65	7.35e-52	Height;
LUAD	cis	rs16910800	0.953	rs7126961	chr11:23204237	C/T	cg20040320	chr11:23191996	NA	-0.49	-7.37	-0.34	8.93e-13	Cancer;
LUAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg22907277	chr7:1156413	C7orf50	0.68	8.74	0.39	5.41e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg00717180	chr2:96193071	NA	-0.36	-6.48	-0.3	2.51e-10	Coronary artery disease;
LUAD	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg24801067	chr17:62843696	NA	0.53	8.55	0.38	2.31e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs556990	0.574	rs473598	chr13:113801189	C/T	cg00898013	chr13:113819073	PROZ	-0.46	-6.86	-0.32	2.44e-11	Blood protein levels;
LUAD	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.78	-0.39	4.02e-17	Alcohol dependence;
LUAD	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg04414720	chr1:150670196	GOLPH3L	0.73	13.62	0.55	2.78e-35	Tonsillectomy;
LUAD	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg18105134	chr13:113819100	PROZ	-0.87	-15.4	-0.6	8.76e-43	Platelet distribution width;
LUAD	cis	rs2835872	0.733	rs1787393	chr21:39035934	G/A	cg06728970	chr21:39037746	KCNJ6	0.4	7.69	0.35	1.05e-13	Electroencephalographic traits in alcoholism;
LUAD	trans	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg03886242	chr7:26192032	NFE2L3	-0.43	-7.59	-0.35	2.06e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9581857	0.556	rs9581863	chr13:28040171	A/G	cg22138327	chr13:27999177	GTF3A	0.77	11.02	0.47	5.19e-25	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.52	9.01	0.4	7.38e-18	Electrocardiographic conduction measures;
LUAD	cis	rs1950626	0.623	rs2295657	chr14:101430620	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.35	7.09	0.33	5.78e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs12545109	0.959	rs12546307	chr8:57314790	T/A	cg07776626	chr8:57350775	NA	-0.63	-8.95	-0.4	1.1e-17	Obesity-related traits;
LUAD	cis	rs2070677	0.935	rs12245318	chr10:135419483	A/G	cg20169779	chr10:135381914	SYCE1	-0.52	-8.14	-0.37	4.47e-15	Gout;
LUAD	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg05754148	chr16:3507555	NAT15	-0.73	-11.64	-0.49	2.31e-27	Tuberculosis;
LUAD	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg22029157	chr1:209979665	IRF6	0.79	11.58	0.49	3.83e-27	Cleft lip with or without cleft palate;
LUAD	cis	rs7301826	0.627	rs1077317	chr12:131314977	C/T	cg11011512	chr12:131303247	STX2	0.44	7.42	0.34	6.37e-13	Plasma plasminogen activator levels;
LUAD	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg25811766	chr13:21894605	NA	-0.62	-7.54	-0.34	2.91e-13	White matter hyperintensity burden;
LUAD	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg03037974	chr15:76606532	NA	-0.42	-9.56	-0.42	9.72e-20	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06361278	chr17:25783929	NA	-0.57	-6.96	-0.32	1.29e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19717773	chr7:2847554	GNA12	-0.52	-9.54	-0.42	1.16e-19	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg27539214	chr16:67997921	SLC12A4	-0.75	-9.68	-0.43	3.65e-20	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11098699	0.784	rs7674700	chr4:124239023	C/T	cg09941581	chr4:124220074	SPATA5	-0.42	-6.88	-0.32	2.14e-11	Mosquito bite size;
LUAD	cis	rs4321325	0.733	rs78593261	chr2:127947044	G/A	cg11380483	chr2:127933992	NA	0.5	6.49	0.3	2.45e-10	Protein C levels;
LUAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg22907277	chr7:1156413	C7orf50	0.68	7.97	0.36	1.49e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg07917127	chr4:99064746	C4orf37	0.41	6.85	0.32	2.55e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg01689657	chr7:91764605	CYP51A1	0.32	7.95	0.36	1.68e-14	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03900353	chr1:212732456	NA	-0.41	-6.56	-0.3	1.6e-10	Height;
LUAD	cis	rs62238980	0.614	rs79738052	chr22:32455812	G/A	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs7178572	0.568	rs4886850	chr15:77404160	G/C	cg15453836	chr15:77711506	NA	-0.38	-6.57	-0.3	1.49e-10	Type 2 diabetes;
LUAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg25985355	chr7:65971099	NA	-0.54	-6.74	-0.31	5.14e-11	Diabetic kidney disease;
LUAD	cis	rs1018836	0.544	rs2063978	chr8:91459525	C/T	cg16814680	chr8:91681699	NA	-0.54	-8.68	-0.39	8.64e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	8.18	0.37	3.38e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.55	7.83	0.36	3.87e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg08601574	chr20:25228251	PYGB	-0.44	-8.17	-0.37	3.48e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg22535103	chr8:58192502	C8orf71	-0.74	-9.2	-0.41	1.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.46	7.62	0.35	1.63e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6740322	0.748	rs1549723	chr2:43460514	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.81	-11.97	-0.5	1.27e-28	Coronary artery disease;
LUAD	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg08219700	chr8:58056026	NA	0.41	6.39	0.3	4.44e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg18621852	chr3:10150065	C3orf24	0.42	7.42	0.34	6.4e-13	Alzheimer's disease;
LUAD	cis	rs12505328	0.593	rs880961	chr4:174362252	A/T	cg12145043	chr4:174357286	NA	-0.53	-7.84	-0.36	3.68e-14	Chin dimples;
LUAD	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg24818145	chr4:99064322	C4orf37	0.39	6.48	0.3	2.51e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg17173187	chr15:85201210	NMB	0.39	6.55	0.3	1.64e-10	Schizophrenia;
LUAD	cis	rs7737355	0.738	rs40990	chr5:130994429	G/A	cg06307176	chr5:131281290	NA	0.45	7.27	0.33	1.76e-12	Life satisfaction;
LUAD	trans	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg04775059	chr7:64541387	NA	0.5	6.72	0.31	5.94e-11	Aortic root size;
LUAD	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg01312482	chr5:178451176	ZNF879	-0.45	-7.02	-0.32	9.12e-12	Pubertal anthropometrics;
LUAD	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg02423579	chr7:2872169	GNA12	0.73	11.76	0.5	7.9e-28	Height;
LUAD	cis	rs2996428	0.536	rs12126653	chr1:3773815	C/G	cg13057898	chr1:3703894	LRRC47	0.61	10.14	0.44	8.82e-22	Red cell distribution width;
LUAD	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg14668632	chr7:2872130	GNA12	-0.46	-7.98	-0.36	1.38e-14	Height;
LUAD	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.42	-0.34	6.68e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1003719	0.737	rs9974374	chr21:38479885	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.65	0.39	1.06e-16	Eye color traits;
LUAD	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07266350	chr3:49460521	AMT;NICN1	0.37	6.53	0.3	1.84e-10	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg17366294	chr4:99064904	C4orf37	0.66	12.63	0.52	2.96e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11229555	0.874	rs11229519	chr11:58310587	C/T	cg15696309	chr11:58395628	NA	-0.72	-10.28	-0.45	2.93e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27209265	chr16:790912	NARFL	-0.59	-7.19	-0.33	3.02e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg06640241	chr16:89574553	SPG7	0.69	12.02	0.5	7.8e-29	Multiple myeloma (IgH translocation);
LUAD	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg08470875	chr2:26401718	FAM59B	0.7	9.0	0.4	7.74e-18	Gut microbiome composition (summer);
LUAD	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20456258	chr4:962124	DGKQ	0.4	6.82	0.31	3.18e-11	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.86e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs55986470	0.670	rs56313033	chr2:239346202	C/T	cg01134436	chr17:81009848	B3GNTL1	0.82	8.71	0.39	7.01e-17	Chronotype;
LUAD	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg14092988	chr3:52407081	DNAH1	0.45	8.97	0.4	1e-17	Bipolar disorder;
LUAD	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg22532475	chr10:104410764	TRIM8	-0.56	-10.36	-0.45	1.5e-22	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/A	cg13736514	chr6:26305472	NA	-0.51	-8.33	-0.38	1.13e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.85	-0.36	3.57e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg27284194	chr4:1044797	NA	0.52	8.48	0.38	3.79e-16	Recombination rate (males);
LUAD	cis	rs7903847	0.642	rs10882914	chr10:99142057	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-7.12	-0.33	4.78e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	8.14	0.37	4.41e-15	Tonsillectomy;
LUAD	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg23712970	chr14:23540735	ACIN1	0.51	6.38	0.3	4.54e-10	Response to statin therapy;
LUAD	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg04944784	chr2:26401820	FAM59B	0.83	11.35	0.48	3.04e-26	Gut microbiome composition (summer);
LUAD	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-9.24	-0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	trans	rs637571	0.780	rs653914	chr11:65676516	A/G	cg17712092	chr4:129076599	LARP1B	1.06	22.49	0.74	2.95e-74	Eosinophil percentage of white cells;
LUAD	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6489882	0.703	rs10850095	chr12:113360575	T/C	cg20102336	chr12:113376681	OAS3	-0.54	-8.25	-0.37	2.05e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg02880119	chr16:3481970	NA	0.53	8.2	0.37	2.99e-15	Body mass index (adult);
LUAD	cis	rs6541297	0.702	rs4846904	chr1:230279410	G/A	cg20703242	chr1:230279135	GALNT2	0.66	12.24	0.51	1.03e-29	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg19761014	chr17:28927070	LRRC37B2	0.85	7.33	0.34	1.17e-12	Body mass index;
LUAD	trans	rs1864729	1.000	rs2053481	chr8:98278923	C/T	cg08679828	chr8:102218111	ZNF706	-0.82	-8.65	-0.39	1.06e-16	Estradiol plasma levels (breast cancer);
LUAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg06606381	chr12:133084897	FBRSL1	-0.65	-7.74	-0.35	7.22e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg06387496	chr7:2775674	GNA12	-0.4	-6.57	-0.3	1.48e-10	Height;
LUAD	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg07362569	chr17:61921086	SMARCD2	0.39	6.68	0.31	7.59e-11	Prudent dietary pattern;
LUAD	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-10.39	-0.45	1.12e-22	Gut microbiome composition (summer);
LUAD	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	7.44	0.34	5.85e-13	Menarche (age at onset);
LUAD	cis	rs116248771	0.739	rs1051109	chr3:158415344	T/C	cg16708174	chr3:158430962	RARRES1	0.46	6.76	0.31	4.73e-11	diarrhoeal disease at age 2;
LUAD	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18099408	chr3:52552593	STAB1	-0.46	-8.03	-0.36	9.79e-15	Bipolar disorder;
LUAD	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg24324837	chr19:49891574	CCDC155	-0.47	-6.55	-0.3	1.65e-10	Multiple sclerosis;
LUAD	cis	rs12681287	0.752	rs4282548	chr8:87270792	A/T	cg27223183	chr8:87520930	FAM82B	-0.63	-8.7	-0.39	7.21e-17	Caudate activity during reward;
LUAD	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg10589385	chr1:150898437	SETDB1	0.39	6.88	0.32	2.22e-11	Urate levels;
LUAD	cis	rs7665090	1.000	rs4013	chr4:103552813	C/T	cg07973026	chr4:103553119	MANBA	0.48	8.53	0.38	2.69e-16	Primary biliary cholangitis;
LUAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg18538332	chr22:24372958	LOC391322	0.51	8.37	0.38	8.34e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11214589	0.747	rs11214577	chr11:113204266	A/G	cg14159747	chr11:113255604	NA	-0.6	-12.4	-0.52	2.57e-30	Neuroticism;
LUAD	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg19193384	chr17:30244184	NA	-0.52	-6.63	-0.31	1.02e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.42	-8.07	-0.37	7.11e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg13319975	chr6:146136371	FBXO30	0.81	14.17	0.57	1.46e-37	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg18129748	chr3:49941408	MST1R	-0.42	-6.86	-0.32	2.53e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4594175	0.707	rs4606635	chr14:51712092	T/C	cg23942311	chr14:51606299	NA	0.55	9.21	0.41	1.49e-18	Cancer;
LUAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-7.91	-0.36	2.34e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1595825	0.945	rs6756641	chr2:198849672	T/G	cg10547527	chr2:198650123	BOLL	-0.5	-7.14	-0.33	4.1e-12	Ulcerative colitis;
LUAD	trans	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg26043149	chr18:55253948	FECH	0.43	7.03	0.32	8.56e-12	Bone mineral density;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11027325	chr2:239148674	HES6	-0.54	-6.92	-0.32	1.68e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.24	0.37	2.19e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg13565492	chr6:43139072	SRF	-0.74	-10.12	-0.44	1.05e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	7.27	0.33	1.73e-12	Alzheimer's disease;
LUAD	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs68170813	0.559	rs78888729	chr7:106940957	G/C	cg23024343	chr7:107201750	COG5	0.48	7.0	0.32	9.9e-12	Coronary artery disease;
LUAD	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg02251663	chr11:14281053	SPON1	-0.37	-7.11	-0.33	4.82e-12	Mitochondrial DNA levels;
LUAD	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18876405	chr7:65276391	NA	-0.58	-9.75	-0.43	2.07e-20	Aortic root size;
LUAD	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	6.64	0.31	9.39e-11	Schizophrenia;
LUAD	trans	rs4714291	0.855	rs1743971	chr6:40095927	A/C	cg02267698	chr19:7991119	CTXN1	0.43	6.53	0.3	1.9e-10	Strep throat;
LUAD	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg02176678	chr2:219576539	TTLL4	-0.74	-15.09	-0.59	1.74e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1595825	0.838	rs79381203	chr2:198573762	A/G	cg11031976	chr2:198649780	BOLL	-0.47	-7.08	-0.33	5.91e-12	Ulcerative colitis;
LUAD	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.71	-13.05	-0.54	6.14e-33	Menarche (age at onset);
LUAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.41	-6.5	-0.3	2.31e-10	Longevity;Endometriosis;
LUAD	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.57	9.95	0.44	4.36e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs7395662	0.929	rs34584314	chr11:48627686	G/T	cg00717180	chr2:96193071	NA	-0.39	-7.38	-0.34	8.47e-13	HDL cholesterol;
LUAD	cis	rs9560113	1.000	rs9555809	chr13:112181401	T/C	cg14154082	chr13:112174009	NA	0.36	6.64	0.31	9.5e-11	Menarche (age at onset);
LUAD	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg20203395	chr5:56204925	C5orf35	0.63	9.81	0.43	1.33e-20	Initial pursuit acceleration;
LUAD	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23583168	chr7:148888333	NA	-1.06	-26.37	-0.79	2.44e-91	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs829883	0.659	rs10860342	chr12:98941223	C/T	cg25150519	chr12:98850993	NA	0.54	8.46	0.38	4.38e-16	Colorectal adenoma (advanced);
LUAD	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18404041	chr3:52824283	ITIH1	-0.6	-12.5	-0.52	1.03e-30	Bipolar disorder;
LUAD	cis	rs9796	0.717	rs2947494	chr15:41375741	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.43	-7.98	-0.36	1.4e-14	Menopause (age at onset);
LUAD	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg17724175	chr1:150552817	MCL1	-0.38	-9.3	-0.41	7.37e-19	Tonsillectomy;
LUAD	cis	rs7178572	0.568	rs12912050	chr15:77689423	C/T	cg15453836	chr15:77711506	NA	-0.36	-6.42	-0.3	3.59e-10	Type 2 diabetes;
LUAD	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg26752003	chr8:145688521	CYHR1	0.52	9.22	0.41	1.46e-18	Age at first birth;
LUAD	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg18105134	chr13:113819100	PROZ	0.86	15.5	0.6	3.2e-43	Platelet distribution width;
LUAD	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg17063962	chr7:91808500	NA	0.65	11.84	0.5	3.98e-28	Breast cancer;
LUAD	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-8.9	-0.4	1.62e-17	Life satisfaction;
LUAD	cis	rs3820068	0.705	rs72643694	chr1:15860185	C/T	cg13390004	chr1:15929781	NA	0.41	6.7	0.31	6.58e-11	Systolic blood pressure;
LUAD	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg19700328	chr14:106028568	NA	-0.45	-7.69	-0.35	1.03e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg27284194	chr4:1044797	NA	0.69	9.97	0.44	3.76e-21	Recombination rate (females);
LUAD	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18404041	chr3:52824283	ITIH1	-0.6	-11.93	-0.5	1.71e-28	Bipolar disorder;
LUAD	cis	rs1018836	0.923	rs7007102	chr8:91629730	T/A	cg16814680	chr8:91681699	NA	-0.7	-11.77	-0.5	7.35e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.12	-0.37	5.11e-15	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	trans	rs9951602	0.833	rs9953548	chr18:76640601	C/T	cg02800362	chr5:177631904	HNRNPAB	1.0	12.0	0.5	8.95e-29	Obesity-related traits;
LUAD	cis	rs2806561	0.664	rs4620508	chr1:23307438	C/T	cg12483005	chr1:23474871	LUZP1	0.43	7.02	0.32	8.8e-12	Height;
LUAD	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg06191203	chr2:152266755	RIF1	-0.51	-7.78	-0.35	5.63e-14	Lung cancer;
LUAD	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg09904177	chr6:26538194	HMGN4	0.41	6.81	0.31	3.38e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4462272	0.699	rs7893845	chr10:101893296	G/T	cg02250046	chr10:101825185	CPN1	-0.32	-6.38	-0.3	4.67e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg11941060	chr3:133502564	NA	-0.66	-11.93	-0.5	1.8e-28	Iron status biomarkers;
LUAD	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg22906224	chr7:99728672	NA	0.69	11.68	0.49	1.68e-27	Coronary artery disease;
LUAD	cis	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	8.07	0.37	7.51e-15	Lymphocyte counts;Red cell distribution width;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg18017109	chr1:10458942	PGD	-0.74	-7.48	-0.34	4.45e-13	Type 2 diabetes;
LUAD	cis	rs2637266	1.000	rs2637267	chr10:78331803	A/G	cg18941641	chr10:78392320	NA	0.31	6.4	0.3	4.05e-10	Pulmonary function;
LUAD	trans	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg14343924	chr8:8086146	FLJ10661	-0.4	-6.36	-0.3	5.17e-10	Neuroticism;
LUAD	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg11189052	chr15:85197271	WDR73	0.68	9.18	0.41	1.98e-18	Schizophrenia;
LUAD	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg02951883	chr7:2050386	MAD1L1	-0.81	-13.72	-0.56	1.04e-35	Bipolar disorder and schizophrenia;
LUAD	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg17173187	chr15:85201210	NMB	0.47	8.04	0.36	9.37e-15	Schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17664568	chr10:98346460	TM9SF3	-0.41	-6.41	-0.3	3.93e-10	Height;
LUAD	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg08523384	chr5:141488047	NDFIP1	-0.48	-7.3	-0.33	1.42e-12	Crohn's disease;
LUAD	cis	rs9875589	0.509	rs6783645	chr3:14024542	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	6.47	0.3	2.64e-10	Ovarian reserve;
LUAD	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18876405	chr7:65276391	NA	-0.42	-6.64	-0.31	9.59e-11	Aortic root size;
LUAD	cis	rs8014204	0.836	rs12888998	chr14:75292662	G/T	cg03030879	chr14:75389066	RPS6KL1	-0.35	-6.67	-0.31	8.09e-11	Caffeine consumption;
LUAD	cis	rs3087591	0.960	rs4435317	chr17:29436512	G/C	cg24425628	chr17:29625626	OMG;NF1	0.42	6.65	0.31	9.08e-11	Hip circumference;
LUAD	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.51	8.74	0.39	5.56e-17	Alzheimer's disease (late onset);
LUAD	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg00310523	chr12:86230176	RASSF9	0.41	8.58	0.39	1.81e-16	Major depressive disorder;
LUAD	cis	rs11809207	1.000	rs11247865	chr1:26517773	T/C	cg00147160	chr1:26503991	CNKSR1	0.41	8.39	0.38	7.55e-16	Height;
LUAD	cis	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg13789015	chr9:136890014	NCRNA00094	0.82	14.04	0.56	4.94e-37	Platelet distribution width;
LUAD	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.87	-0.36	2.92e-14	Type 2 diabetes;
LUAD	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg02428538	chr16:24856791	SLC5A11	-0.66	-9.41	-0.42	3.12e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.88	0.47	1.73e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.5	-8.99	-0.4	8.19e-18	Lymphocyte counts;
LUAD	cis	rs938554	0.657	rs7679724	chr4:9985376	G/T	cg00071950	chr4:10020882	SLC2A9	0.6	10.23	0.45	4.19e-22	Blood metabolite levels;
LUAD	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg01200585	chr1:228362443	C1orf69	0.42	7.57	0.35	2.41e-13	Diastolic blood pressure;
LUAD	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.46	0.45	6.15e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg01802117	chr1:53393560	SCP2	-0.35	-6.97	-0.32	1.23e-11	Monocyte count;
LUAD	cis	rs7512552	0.839	rs11577843	chr1:150398258	A/G	cg15654264	chr1:150340011	RPRD2	0.58	11.22	0.48	9.82e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg11859384	chr17:80120422	CCDC57	-0.48	-8.61	-0.39	1.42e-16	Life satisfaction;
LUAD	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg09455208	chr3:40491958	NA	0.65	14.35	0.57	2.48e-38	Renal cell carcinoma;
LUAD	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg19163074	chr7:65112434	INTS4L2	-0.45	-6.87	-0.32	2.37e-11	Aortic root size;
LUAD	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26314531	chr2:26401878	FAM59B	-0.7	-9.53	-0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg02487331	chr1:146550467	NA	-0.34	-6.47	-0.3	2.69e-10	HIV-1 control;
LUAD	trans	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg03886242	chr7:26192032	NFE2L3	0.36	6.43	0.3	3.54e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4891159	0.527	rs690593	chr18:74160408	C/G	cg24786174	chr18:74118243	ZNF516	0.87	19.72	0.69	7.08e-62	Longevity;
LUAD	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg23649088	chr2:200775458	C2orf69	0.6	7.94	0.36	1.88e-14	Schizophrenia;
LUAD	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.32e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2425143	0.915	rs2378408	chr20:34367732	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	7.44	0.34	5.54e-13	Blood protein levels;
LUAD	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg02450064	chr17:40260053	DHX58	-0.45	-7.48	-0.34	4.26e-13	Fibrinogen levels;
LUAD	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg00757033	chr12:89920650	WDR51B	-0.67	-11.66	-0.49	1.92e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9649213	0.614	rs4729432	chr7:97947055	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.73	-10.86	-0.47	2.04e-24	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs9393692	0.557	rs2893842	chr6:26338434	T/G	cg13736514	chr6:26305472	NA	-0.49	-7.68	-0.35	1.1e-13	Educational attainment;
LUAD	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg15704280	chr7:45808275	SEPT13	-0.89	-16.25	-0.62	1.76e-46	Height;
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg15383120	chr6:291909	DUSP22	-0.69	-11.63	-0.49	2.66e-27	Menopause (age at onset);
LUAD	cis	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg07460842	chr6:66804631	NA	0.59	9.22	0.41	1.39e-18	Type 2 diabetes;
LUAD	cis	rs12549902	0.966	rs4317621	chr8:41516581	A/G	cg17182837	chr8:41585554	ANK1	-0.31	-6.43	-0.3	3.56e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUAD	cis	rs1006703	0.544	rs35299172	chr17:3834598	C/T	cg09591406	chr17:3833873	ATP2A3	0.52	7.23	0.33	2.27e-12	Glucose homeostasis traits;
LUAD	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg12179176	chr11:130786555	SNX19	0.55	9.27	0.41	9.37e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg15083037	chr5:83017644	HAPLN1	-0.5	-7.4	-0.34	7.45e-13	Prostate cancer;
LUAD	cis	rs2073300	1.000	rs79169006	chr20:23443535	A/T	cg12062639	chr20:23401060	NAPB	0.98	8.35	0.38	9.91e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg07157834	chr1:205819609	PM20D1	0.5	8.09	0.37	6.6e-15	Parkinson's disease;
LUAD	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	7.37	0.34	8.99e-13	Platelet count;
LUAD	cis	rs2882667	0.638	rs6895690	chr5:138465851	C/T	cg04439458	chr5:138467593	SIL1	-0.35	-6.4	-0.3	4.11e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg24955955	chr5:415729	AHRR	0.78	8.87	0.4	2.14e-17	Fat distribution (HIV);
LUAD	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg00757033	chr12:89920650	WDR51B	0.7	12.14	0.51	2.6e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg18099408	chr3:52552593	STAB1	-0.39	-6.83	-0.32	2.9e-11	Bipolar disorder;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26733140	chr11:63993641	NUDT22;TRPT1	-0.54	-6.87	-0.32	2.32e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg03929089	chr4:120376271	NA	-0.6	-9.45	-0.42	2.31e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6684514	1.000	rs10908498	chr1:156278175	T/C	cg16558208	chr1:156270281	VHLL	0.53	9.65	0.42	4.74e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-7.27	-0.33	1.76e-12	Neutrophil percentage of white cells;
LUAD	cis	rs2455799	0.573	rs2455829	chr3:15746937	G/A	cg16303742	chr3:15540471	COLQ	-0.5	-9.35	-0.41	5.1e-19	Mean platelet volume;
LUAD	cis	rs9287719	0.745	rs4997809	chr2:10755542	G/A	cg02196655	chr2:10830764	NOL10	-0.42	-7.5	-0.34	3.7e-13	Prostate cancer;
LUAD	cis	rs4889855	0.556	rs4508465	chr17:78543368	G/A	cg16591659	chr17:78472290	NA	0.44	7.76	0.35	6.28e-14	Fractional excretion of uric acid;
LUAD	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg25811766	chr13:21894605	NA	-0.62	-7.52	-0.34	3.33e-13	White matter hyperintensity burden;
LUAD	cis	rs59104589	0.569	rs4254498	chr2:242363611	G/C	cg08645257	chr2:242211290	HDLBP	0.46	7.44	0.34	5.86e-13	Fibrinogen levels;
LUAD	cis	rs6446731	0.593	rs2530601	chr4:3272378	C/G	cg08886695	chr4:3369023	RGS12	-0.49	-8.22	-0.37	2.48e-15	Mean platelet volume;
LUAD	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	9.4e-15	Tonsillectomy;
LUAD	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg19163074	chr7:65112434	INTS4L2	0.44	6.76	0.31	4.56e-11	Aortic root size;
LUAD	cis	rs4713675	0.584	rs7739505	chr6:33670370	G/A	cg13859433	chr6:33739653	LEMD2	-0.31	-7.28	-0.33	1.65e-12	Plateletcrit;
LUAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg20607798	chr8:58055168	NA	0.6	7.69	0.35	1.07e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg06558623	chr16:89946397	TCF25	1.12	9.76	0.43	2.05e-20	Skin colour saturation;
LUAD	cis	rs735539	0.645	rs9552252	chr13:21192905	C/T	cg27499820	chr13:21296301	IL17D	0.54	8.85	0.4	2.38e-17	Dental caries;
LUAD	cis	rs13315871	0.929	rs11717700	chr3:58250876	T/A	cg12435725	chr3:58293450	RPP14	-0.73	-7.6	-0.35	1.96e-13	Cholesterol, total;
LUAD	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg12935359	chr14:103987150	CKB	0.49	7.68	0.35	1.08e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs13090388	1	rs13090388	chr3:49391082	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-9.51	-0.42	1.48e-19	Intelligence (multi-trait analysis);Educational attainment (years of education);
LUAD	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg12908607	chr1:44402522	ARTN	-0.52	-10.15	-0.44	8.33e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg02527881	chr3:46936655	PTH1R	0.44	8.41	0.38	6.51e-16	Colorectal cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09597530	chr12:48551185	ASB8	-0.43	-6.52	-0.3	1.97e-10	Height;
LUAD	cis	rs9473147	0.516	rs6903331	chr6:47562915	A/G	cg02130027	chr6:47444894	CD2AP	0.35	6.68	0.31	7.35e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7095607	0.521	rs2673792	chr10:69927959	T/A	cg18986048	chr10:69913749	MYPN	0.47	8.13	0.37	4.73e-15	Lung function (FVC);
LUAD	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg17173187	chr15:85201210	NMB	0.49	8.36	0.38	9.26e-16	Schizophrenia;
LUAD	cis	rs10979	1.000	rs9376761	chr6:143887165	G/A	cg25407410	chr6:143891975	LOC285740	-0.63	-9.94	-0.44	4.57e-21	Hypospadias;
LUAD	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg24069376	chr3:38537580	EXOG	-0.41	-10.2	-0.44	5.5e-22	Electrocardiographic conduction measures;
LUAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg10729496	chr3:10149963	C3orf24	-0.51	-8.37	-0.38	8.33e-16	Alzheimer's disease;
LUAD	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.22	-0.54	1.24e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15123200	chr17:38136865	PSMD3	-0.43	-6.62	-0.31	1.06e-10	Height;
LUAD	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg23283495	chr1:209979779	IRF6	0.74	8.98	0.4	9.29e-18	Coronary artery disease;
LUAD	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.17	-0.51	2.08e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2235642	0.601	rs2235647	chr16:1601331	C/A	cg03034668	chr16:1723424	CRAMP1L	-0.44	-7.34	-0.34	1.12e-12	Coronary artery disease;
LUAD	cis	rs1395	0.778	rs2580761	chr2:27426362	G/A	cg23587288	chr2:27483067	SLC30A3	-0.42	-7.88	-0.36	2.84e-14	Blood metabolite levels;
LUAD	cis	rs35883536	0.967	rs1855788	chr1:101118331	A/G	cg06223162	chr1:101003688	GPR88	0.35	6.48	0.3	2.56e-10	Monocyte count;
LUAD	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg09491104	chr22:46646882	C22orf40	-0.52	-7.38	-0.34	8.32e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg11915388	chr22:42470451	FAM109B	-0.4	-7.2	-0.33	2.77e-12	Schizophrenia;
LUAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg26338869	chr17:61819248	STRADA	-0.38	-6.39	-0.3	4.33e-10	Prudent dietary pattern;
LUAD	cis	rs12472274	0.646	rs35468889	chr2:239090959	G/A	cg17459225	chr2:239074497	NA	0.65	7.45	0.34	5.4e-13	Phospholipid levels (plasma);
LUAD	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg19163074	chr7:65112434	INTS4L2	0.45	6.9	0.32	1.85e-11	Aortic root size;
LUAD	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg08885076	chr2:99613938	TSGA10	0.41	7.61	0.35	1.84e-13	Chronic sinus infection;
LUAD	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.43	-7.67	-0.35	1.23e-13	Longevity;Endometriosis;
LUAD	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.54	0.3	1.81e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg18225595	chr11:63971243	STIP1	0.53	9.0	0.4	7.88e-18	Platelet count;
LUAD	trans	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg01620082	chr3:125678407	NA	-0.92	-7.33	-0.34	1.2e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg21252483	chr19:49399788	TULP2	-0.73	-11.68	-0.49	1.67e-27	Red cell distribution width;
LUAD	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.61	-12.19	-0.51	1.64e-29	Homoarginine levels;
LUAD	cis	rs2235649	0.663	rs113908028	chr16:1848915	G/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-6.73	-0.31	5.59e-11	Blood metabolite levels;
LUAD	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg21399703	chr1:247681439	NA	0.43	7.77	0.35	5.82e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10802521	chr3:52805072	NEK4	-0.53	-9.07	-0.4	4.38e-18	Bipolar disorder;
LUAD	cis	rs9354308	0.866	rs2802054	chr6:66544766	G/C	cg07460842	chr6:66804631	NA	0.49	7.47	0.34	4.73e-13	Metabolite levels;
LUAD	cis	rs654384	1.000	rs654384	chr7:4166659	C/T	cg26275264	chr7:4183598	SDK1	0.4	7.41	0.34	7.06e-13	Positive affect;
LUAD	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg08027265	chr7:2291960	NA	-0.4	-6.47	-0.3	2.78e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6993813	0.843	rs28437165	chr8:120030474	T/C	cg01975934	chr8:119970761	NA	-0.37	-7.24	-0.33	2.09e-12	Bone mineral density (hip);
LUAD	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg09399716	chr2:46890238	NA	-0.45	-9.06	-0.4	4.91e-18	Height;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05157318	chr1:29508594	SFRS4	-0.68	-6.71	-0.31	6.25e-11	Type 2 diabetes;
LUAD	cis	rs10193935	0.792	rs222472	chr2:42662911	C/T	cg27598129	chr2:42591480	NA	-0.63	-8.19	-0.37	3.1e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2932538	0.922	rs6658555	chr1:113098534	C/T	cg22162597	chr1:113214053	CAPZA1	0.46	6.72	0.31	5.89e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs733175	0.855	rs6853437	chr4:10005435	A/G	cg00071950	chr4:10020882	SLC2A9	-0.6	-9.38	-0.41	4.06e-19	Psychosis and Alzheimer's disease;
LUAD	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg03609598	chr5:56110824	MAP3K1	-0.58	-7.95	-0.36	1.71e-14	Initial pursuit acceleration;
LUAD	trans	rs11039798	0.841	rs12221667	chr11:48548549	G/T	cg03929089	chr4:120376271	NA	0.65	6.41	0.3	3.78e-10	Axial length;
LUAD	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg14092988	chr3:52407081	DNAH1	0.36	7.16	0.33	3.6e-12	Bipolar disorder;
LUAD	cis	rs8040855	0.599	rs1964724	chr15:85726500	G/C	cg04831495	chr15:85060580	GOLGA6L5	0.45	7.8	0.35	5.05e-14	Bulimia nervosa;
LUAD	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg12035532	chr1:1886765	KIAA1751	0.41	6.94	0.32	1.45e-11	Body mass index;
LUAD	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg09654669	chr8:57350985	NA	-0.67	-10.19	-0.44	5.74e-22	Obesity-related traits;
LUAD	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06022373	chr22:39101656	GTPBP1	0.47	7.37	0.34	9.13e-13	Menopause (age at onset);
LUAD	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.65	-0.35	1.37e-13	Monocyte count;
LUAD	cis	rs7737355	0.947	rs4705894	chr5:131079288	A/G	cg06307176	chr5:131281290	NA	0.5	7.85	0.36	3.37e-14	Life satisfaction;
LUAD	cis	rs12410462	0.502	rs78101727	chr1:227732069	C/T	cg23173402	chr1:227635558	NA	0.72	6.49	0.3	2.41e-10	Major depressive disorder;
LUAD	cis	rs10992471	0.603	rs13301537	chr9:95229047	A/G	cg14631576	chr9:95140430	CENPP	-0.56	-11.52	-0.49	7.08e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg18621852	chr3:10150065	C3orf24	0.47	8.18	0.37	3.35e-15	Alzheimer's disease;
LUAD	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg22681709	chr2:178499509	PDE11A	-0.42	-6.96	-0.32	1.32e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.45	8.41	0.38	6.31e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg15468180	chr1:107600409	PRMT6	-0.45	-7.7	-0.35	9.74e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg07305463	chr2:136567211	LCT	-0.37	-7.12	-0.33	4.64e-12	Mosquito bite size;
LUAD	trans	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg26384229	chr12:38710491	ALG10B	0.45	7.15	0.33	3.94e-12	Morning vs. evening chronotype;
LUAD	cis	rs77741769	0.529	rs10849791	chr12:121235280	T/C	cg02419362	chr12:121203948	SPPL3	0.41	8.42	0.38	5.95e-16	Mean corpuscular volume;
LUAD	cis	rs8112211	0.834	rs4312417	chr19:38797189	A/G	cg14299480	chr19:38876666	GGN	-0.42	-7.52	-0.34	3.39e-13	Blood protein levels;
LUAD	cis	rs7192380	0.737	rs7204433	chr16:69589924	A/G	cg00738113	chr16:70207722	CLEC18C	-0.32	-6.5	-0.3	2.29e-10	Sjögren's syndrome;
LUAD	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg25809561	chr17:30822961	MYO1D	0.46	8.32	0.38	1.21e-15	Schizophrenia;
LUAD	cis	rs7809615	0.892	rs58964157	chr7:99034055	G/A	cg03133378	chr7:99195931	NA	-0.54	-6.53	-0.3	1.92e-10	Blood metabolite ratios;
LUAD	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg18196295	chr10:418757	DIP2C	-0.42	-7.06	-0.32	6.89e-12	Psychosis in Alzheimer's disease;
LUAD	trans	rs208520	0.690	rs207740	chr6:66764132	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	17.11	0.64	3e-50	Exhaled nitric oxide output;
LUAD	cis	rs807669	0.835	rs1780639	chr22:19174603	T/C	cg24911827	chr22:19170109	CLTCL1	0.45	9.27	0.41	9.71e-19	Metabolite levels;
LUAD	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg06074448	chr4:187884817	NA	0.36	7.03	0.32	8.46e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7301016	1.000	rs10877856	chr12:62870536	C/G	cg11441379	chr12:63026424	NA	0.52	6.39	0.3	4.45e-10	IgG glycosylation;
LUAD	trans	rs1941687	0.797	rs6507069	chr18:31393188	C/G	cg27147174	chr7:100797783	AP1S1	-0.5	-8.26	-0.37	1.93e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg01097406	chr16:89675127	NA	0.42	9.17	0.41	2.04e-18	Vitiligo;
LUAD	cis	rs4689388	0.890	rs9993624	chr4:6286528	C/T	cg25554036	chr4:6271136	WFS1	0.71	14.52	0.58	4.66e-39	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg19622623	chr12:86230825	RASSF9	0.42	7.49	0.34	3.93e-13	Major depressive disorder;
LUAD	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	6.82	0.31	3.16e-11	Rheumatoid arthritis;
LUAD	cis	rs9392556	0.829	rs7757606	chr6:4119704	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.43	-7.36	-0.34	9.38e-13	Blood metabolite levels;
LUAD	cis	rs2224391	0.628	rs2753240	chr6:5254124	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.62	-9.31	-0.41	6.81e-19	Height;
LUAD	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.84	-0.32	2.8e-11	Retinal vascular caliber;
LUAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg08860498	chr17:40838861	CNTNAP1	0.37	6.47	0.3	2.65e-10	Colorectal or endometrial cancer;
LUAD	trans	rs7181230	0.845	rs4923852	chr15:40377865	A/G	cg22705835	chr10:65332833	REEP3	0.31	6.42	0.3	3.59e-10	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg10755058	chr3:40428713	ENTPD3	0.46	8.55	0.38	2.33e-16	Renal cell carcinoma;
LUAD	cis	rs754466	0.580	rs10430529	chr10:79582623	C/A	cg17075019	chr10:79541650	NA	-0.9	-18.99	-0.68	1.35e-58	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs56161922	1.000	rs74692669	chr1:207818120	G/C	cg11752769	chr1:207818423	CR1L	-0.65	-6.84	-0.32	2.78e-11	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg08027265	chr7:2291960	NA	-0.43	-7.79	-0.35	5.41e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg15181151	chr6:150070149	PCMT1	0.37	7.11	0.33	4.84e-12	Lung cancer;
LUAD	cis	rs7267979	0.789	rs6083841	chr20:25384564	C/T	cg08601574	chr20:25228251	PYGB	-0.39	-7.19	-0.33	2.94e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg13770153	chr20:60521292	NA	-0.47	-7.78	-0.35	5.61e-14	Body mass index;
LUAD	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-8.82	-0.39	3.13e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2932538	0.922	rs3790612	chr1:113084146	G/A	cg22162597	chr1:113214053	CAPZA1	0.46	6.79	0.31	3.87e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.94e-11	Hepatitis;
LUAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06873352	chr17:61820015	STRADA	0.82	18.34	0.67	1.09e-55	Prudent dietary pattern;
LUAD	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg13859433	chr6:33739653	LEMD2	-0.39	-9.34	-0.41	5.67e-19	Crohn's disease;
LUAD	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg15028436	chr7:37888078	TXNDC3	0.38	7.54	0.34	2.97e-13	Alzheimer's disease (late onset);
LUAD	cis	rs6500395	0.888	rs8057165	chr16:48563467	A/C	cg04672837	chr16:48644449	N4BP1	0.39	6.69	0.31	6.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-10.74	-0.46	5.73e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg15445000	chr17:37608096	MED1	0.45	8.31	0.37	1.36e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs870825	0.616	rs7678900	chr4:185635249	A/G	cg04058563	chr4:185651563	MLF1IP	0.89	14.42	0.57	1.33e-38	Blood protein levels;
LUAD	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg20503657	chr10:835505	NA	0.65	8.4	0.38	6.75e-16	Eosinophil percentage of granulocytes;
LUAD	cis	rs2455799	0.634	rs4685266	chr3:15908766	A/G	cg16303742	chr3:15540471	COLQ	-0.47	-8.62	-0.39	1.39e-16	Mean platelet volume;
LUAD	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg00280220	chr17:61926910	NA	0.36	6.99	0.32	1.08e-11	Prudent dietary pattern;
LUAD	cis	rs910187	0.605	rs8184673	chr20:45806262	C/T	cg27589058	chr20:45804311	EYA2	-0.38	-8.85	-0.4	2.39e-17	Migraine;
LUAD	cis	rs6494488	0.500	rs72744710	chr15:65014078	G/A	cg08069370	chr15:64387884	SNX1	-0.77	-6.84	-0.32	2.85e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg17366294	chr4:99064904	C4orf37	0.6	11.17	0.48	1.4e-25	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.559	rs74906766	chr7:106885236	T/A	cg02696742	chr7:106810147	HBP1	-0.75	-10.44	-0.45	7.23e-23	Coronary artery disease;
LUAD	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg06221963	chr1:154839813	KCNN3	0.81	19.16	0.68	2.26e-59	Prostate cancer;
LUAD	cis	rs7512552	0.809	rs828783	chr1:150376977	C/T	cg15654264	chr1:150340011	RPRD2	0.62	11.77	0.5	7.69e-28	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12292205	chr6:26970375	C6orf41	-0.47	-6.57	-0.3	1.47e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs11249608	0.548	rs7707587	chr5:178462590	G/C	cg01312482	chr5:178451176	ZNF879	-0.46	-7.13	-0.33	4.28e-12	Pubertal anthropometrics;
LUAD	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.0	-0.32	1.02e-11	Height;
LUAD	cis	rs7818345	0.967	rs4549789	chr8:19284015	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.33	7.21	0.33	2.65e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.6	-0.42	7.19e-20	Life satisfaction;
LUAD	trans	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.4	0.42	3.44e-19	Mean corpuscular volume;
LUAD	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg02733842	chr7:1102375	C7orf50	-0.57	-9.05	-0.4	5.14e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.8	-0.35	4.77e-14	Diabetic kidney disease;
LUAD	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.43	-8.43	-0.38	5.44e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg21100191	chr22:23484243	RTDR1	0.71	12.73	0.53	1.21e-31	Bone mineral density;
LUAD	cis	rs10865541	0.902	rs12476309	chr2:3404845	C/T	cg22182287	chr2:3452347	TTC15	0.44	7.63	0.35	1.54e-13	Obesity-related traits;
LUAD	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.61	-0.31	1.18e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.51	0.45	4.29e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg06618935	chr21:46677482	NA	-0.46	-9.4	-0.42	3.41e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3125734	0.516	rs4119	chr10:64033807	C/T	cg09941381	chr10:64027924	RTKN2	-0.36	-7.0	-0.32	1.02e-11	Rheumatoid arthritis;
LUAD	trans	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.68	0.43	3.86e-20	Mean corpuscular volume;
LUAD	cis	rs9644630	0.897	rs13266857	chr8:19364515	C/T	cg06699216	chr8:19333253	CSGALNACT1	0.29	6.58	0.3	1.37e-10	Oropharynx cancer;
LUAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs12517041	0.572	rs3919638	chr5:23303287	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.57	-0.3	1.47e-10	Calcium levels;
LUAD	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg05727186	chr17:43697356	MGC57346	-0.54	-6.8	-0.31	3.68e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs1493916	0.905	rs34910379	chr18:31400047	A/G	cg13755796	chr4:20253514	NA	-0.42	-7.12	-0.33	4.63e-12	Life satisfaction;
LUAD	cis	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg07460842	chr6:66804631	NA	-1.21	-30.92	-0.83	1.26e-110	Exhaled nitric oxide output;
LUAD	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg25036284	chr2:26402008	FAM59B	-0.83	-11.68	-0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19748678	chr4:122722346	EXOSC9	0.42	6.73	0.31	5.42e-11	Type 2 diabetes;
LUAD	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg22676075	chr6:135203613	NA	0.37	6.88	0.32	2.21e-11	Red blood cell count;
LUAD	cis	rs7851660	0.775	rs7034336	chr9:100661100	C/T	cg13688889	chr9:100608707	NA	-0.54	-9.17	-0.41	2.08e-18	Strep throat;
LUAD	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg17724175	chr1:150552817	MCL1	0.39	9.28	0.41	9.17e-19	Tonsillectomy;
LUAD	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg00310523	chr12:86230176	RASSF9	0.4	8.04	0.36	9.14e-15	Major depressive disorder;
LUAD	cis	rs2235642	0.859	rs9927529	chr16:1619488	C/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.27	-6.59	-0.3	1.34e-10	Coronary artery disease;
LUAD	cis	rs79349575	0.715	rs999474	chr17:46987665	G/A	cg22482690	chr17:47019901	SNF8	-0.37	-7.06	-0.32	6.89e-12	Type 2 diabetes;
LUAD	cis	rs240764	0.658	rs4463266	chr6:101223997	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-7.62	-0.35	1.67e-13	Neuroticism;
LUAD	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg12311346	chr5:56204834	C5orf35	-0.51	-8.09	-0.37	6.52e-15	Coronary artery disease;
LUAD	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	7.67	0.35	1.18e-13	Schizophrenia;
LUAD	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg18190219	chr22:46762943	CELSR1	-0.44	-6.53	-0.3	1.88e-10	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg19936585	chr2:139259770	SPOPL	-0.73	-7.29	-0.33	1.49e-12	Type 2 diabetes;
LUAD	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg20991723	chr1:152506922	NA	0.34	6.64	0.31	9.55e-11	Hair morphology;
LUAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.47	6.53	0.3	1.9e-10	Renal function-related traits (BUN);
LUAD	cis	rs889398	0.741	rs2362642	chr16:69931458	G/A	cg00738113	chr16:70207722	CLEC18C	-0.35	-6.95	-0.32	1.43e-11	Body mass index;
LUAD	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg08601574	chr20:25228251	PYGB	0.47	8.88	0.4	1.93e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg14416269	chr4:6271139	WFS1	0.66	14.17	0.57	1.4e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg01528321	chr10:82214614	TSPAN14	0.57	8.98	0.4	8.94e-18	Post bronchodilator FEV1;
LUAD	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg15123519	chr2:136567270	LCT	0.39	7.26	0.33	1.89e-12	Mosquito bite size;
LUAD	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg13319975	chr6:146136371	FBXO30	-0.77	-13.34	-0.54	3.85e-34	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg00898013	chr13:113819073	PROZ	-0.65	-11.66	-0.49	1.97e-27	Platelet distribution width;
LUAD	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-6.81	-0.31	3.41e-11	IgG glycosylation;
LUAD	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg02461776	chr11:598696	PHRF1	0.47	6.87	0.32	2.31e-11	Systemic lupus erythematosus;
LUAD	cis	rs7072216	0.763	rs1061437	chr10:100176154	C/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.57	-0.38	1.91e-16	Metabolite levels;
LUAD	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22455342	chr2:225449267	CUL3	-0.66	-10.28	-0.45	2.79e-22	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg06060754	chr5:176797920	RGS14	0.56	10.72	0.46	6.99e-24	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs3772130	0.923	rs34865234	chr3:121560995	C/T	cg20356878	chr3:121714668	ILDR1	0.53	8.25	0.37	2.09e-15	Cognitive performance;
LUAD	cis	rs3125734	0.572	rs3864794	chr10:64041956	A/C	cg09941381	chr10:64027924	RTKN2	-0.32	-7.45	-0.34	5.15e-13	Rheumatoid arthritis;
LUAD	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg00784671	chr22:46762841	CELSR1	-0.57	-7.73	-0.35	7.8500000000000006e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4372836	0.504	rs7601934	chr2:29032673	A/C	cg09522027	chr2:28974177	PPP1CB	0.58	10.31	0.45	2.12e-22	Body mass index;
LUAD	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg12292205	chr6:26970375	C6orf41	0.58	10.39	0.45	1.12e-22	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg10523679	chr1:76189770	ACADM	0.98	19.68	0.69	1.14e-61	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9473147	0.516	rs4715018	chr6:47441871	T/C	cg02130027	chr6:47444894	CD2AP	0.38	7.09	0.33	5.58e-12	Platelet distribution width;Mean platelet volume;
LUAD	trans	rs853679	0.556	rs34706883	chr6:27805255	A/C	cg01620082	chr3:125678407	NA	-1.04	-10.35	-0.45	1.52e-22	Depression;
LUAD	cis	rs12545109	0.836	rs2196586	chr8:57347126	C/T	cg07776626	chr8:57350775	NA	0.62	8.74	0.39	5.66e-17	Obesity-related traits;
LUAD	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg13354988	chr2:263656	ACP1;SH3YL1	0.3	6.56	0.3	1.53e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs11165623	0.792	rs9437607	chr1:96977788	G/A	cg10631902	chr5:14652156	NA	-0.56	-10.79	-0.46	3.73e-24	Hip circumference;Waist circumference;
LUAD	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.19	-0.41	1.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9287719	0.578	rs7598541	chr2:10700516	G/A	cg02196655	chr2:10830764	NOL10	-0.37	-6.37	-0.3	5.08e-10	Prostate cancer;
LUAD	cis	rs597583	1.000	rs521609	chr11:117407301	C/T	cg27161313	chr11:117392002	DSCAML1	-0.43	-7.31	-0.33	1.37e-12	Putamen volume;
LUAD	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg13126279	chr21:47581558	C21orf56	-0.5	-8.22	-0.37	2.58e-15	Testicular germ cell tumor;
LUAD	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg05283184	chr6:79620031	NA	-0.63	-12.5	-0.52	9.75e-31	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.59	-0.46	2.04e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.13	-0.41	2.85e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.53	-9.93	-0.43	5.16e-21	Longevity;Endometriosis;
LUAD	cis	rs3806843	0.576	rs246003	chr5:140340865	C/G	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.38	-0.3	4.65e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg09222892	chr1:25734099	RHCE	0.5	9.31	0.41	7.25e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.57	-0.35	2.39e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.54	0.42	1.19e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg17063962	chr7:91808500	NA	0.7	12.65	0.52	2.41e-31	Breast cancer;
LUAD	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.35	-0.38	1.02e-15	Breast cancer;
LUAD	cis	rs4629710	0.645	rs35561719	chr6:131551244	G/A	cg12606694	chr6:131520996	AKAP7	0.48	7.04	0.32	7.65e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs3815700	1.000	rs8109885	chr19:33095557	A/G	cg02997394	chr19:33096574	ANKRD27	0.65	8.54	0.38	2.36e-16	Eosinophilic esophagitis;
LUAD	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg22823121	chr1:150693482	HORMAD1	-0.44	-8.98	-0.4	9.13e-18	Tonsillectomy;
LUAD	cis	rs6993813	0.872	rs4273881	chr8:120016355	T/C	cg01975934	chr8:119970761	NA	-0.37	-7.35	-0.34	1.03e-12	Bone mineral density (hip);
LUAD	cis	rs11585357	0.895	rs72633806	chr1:17617943	A/G	cg08277548	chr1:17600880	PADI3	-0.95	-13.79	-0.56	5.47e-36	Hair shape;
LUAD	cis	rs1395	0.778	rs2078616	chr2:27441904	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.47	8.61	0.39	1.44e-16	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12200560	0.505	rs4839848	chr6:97076577	G/A	cg06623918	chr6:96969491	KIAA0776	0.47	7.35	0.34	1.01e-12	Coronary heart disease;
LUAD	trans	rs28735056	0.967	rs11660941	chr18:77630600	G/C	cg05926928	chr17:57297772	GDPD1	-0.47	-6.44	-0.3	3.19e-10	Schizophrenia;
LUAD	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg15147215	chr3:52552868	STAB1	-0.38	-7.06	-0.32	7.06e-12	Bipolar disorder;
LUAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.68	0.31	7.6e-11	Prudent dietary pattern;
LUAD	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	6.8	0.31	3.47e-11	Platelet count;
LUAD	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-6.74	-0.31	5.11e-11	IgG glycosylation;
LUAD	cis	rs7945718	0.967	rs10765989	chr11:12769397	A/G	cg25843174	chr11:12811716	TEAD1	-0.22	-6.77	-0.31	4.26e-11	Educational attainment (years of education);
LUAD	cis	rs13315871	1.000	rs71311871	chr3:58420613	A/G	cg20936604	chr3:58311152	NA	-0.69	-6.83	-0.32	2.88e-11	Cholesterol, total;
LUAD	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg20673091	chr1:2541236	MMEL1	-0.4	-8.57	-0.38	1.97e-16	Ulcerative colitis;
LUAD	cis	rs10865541	0.902	rs33997548	chr2:3419366	A/G	cg22182287	chr2:3452347	TTC15	0.46	8.04	0.36	9.09e-15	Obesity-related traits;
LUAD	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg23172400	chr8:95962367	TP53INP1	-0.31	-7.34	-0.34	1.1e-12	Type 2 diabetes;
LUAD	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg15017067	chr4:17643749	FAM184B	0.34	6.4	0.3	4.02e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs752010	0.695	rs11210508	chr1:42106935	A/G	cg06885757	chr1:42089581	HIVEP3	0.39	8.27	0.37	1.81e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg25251562	chr2:3704773	ALLC	-0.45	-8.06	-0.36	8.12e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg03806693	chr22:41940476	POLR3H	-0.45	-6.82	-0.31	3.06e-11	Neuroticism;
LUAD	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.54	7.39	0.34	7.9e-13	Platelet count;
LUAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.55	-6.74	-0.31	5.31e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs868036	1.000	rs7168156	chr15:68102933	T/C	cg24579218	chr15:68104479	NA	-0.4	-7.45	-0.34	5.44e-13	Restless legs syndrome;
LUAD	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg17173187	chr15:85201210	NMB	0.48	8.53	0.38	2.55e-16	Schizophrenia;
LUAD	cis	rs500891	0.525	rs1170346	chr6:84021751	C/T	cg08257003	chr6:84140564	ME1	0.35	6.45	0.3	3.12e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg09796270	chr17:17721594	SREBF1	-0.37	-6.93	-0.32	1.59e-11	Total body bone mineral density;
LUAD	cis	rs10821973	0.527	rs2393869	chr10:63999263	G/A	cg09941381	chr10:64027924	RTKN2	-0.34	-6.82	-0.31	3.26e-11	Hypothyroidism;
LUAD	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg22852734	chr6:133119734	C6orf192	0.95	7.2	0.33	2.85e-12	Type 2 diabetes nephropathy;
LUAD	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg13319975	chr6:146136371	FBXO30	-0.55	-9.03	-0.4	6.19e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg19825600	chr2:3704501	ALLC	-0.4	-7.5	-0.34	3.83e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg22676075	chr6:135203613	NA	0.56	9.97	0.44	3.64e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg24397884	chr7:158709396	WDR60	0.64	8.79	0.39	3.86e-17	Height;
LUAD	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg18944383	chr4:111397179	ENPEP	0.38	7.62	0.35	1.66e-13	Height;
LUAD	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg10518543	chr12:38710700	ALG10B	-0.44	-7.16	-0.33	3.71e-12	Bladder cancer;
LUAD	trans	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg26043149	chr18:55253948	FECH	0.55	9.21	0.41	1.5e-18	Bone mineral density;
LUAD	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg22920501	chr2:26401640	FAM59B	0.7	10.16	0.44	7.55e-22	Gut microbiome composition (summer);
LUAD	cis	rs35883536	0.647	rs11166485	chr1:101048805	G/C	cg06223162	chr1:101003688	GPR88	-0.49	-9.54	-0.42	1.12e-19	Monocyte count;
LUAD	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg12179176	chr11:130786555	SNX19	0.55	9.3	0.41	7.43e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg11859384	chr17:80120422	CCDC57	0.43	7.7	0.35	9.65e-14	Life satisfaction;
LUAD	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.77	-0.31	4.31e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs3760982	0.585	rs67648499	chr19:44294055	G/A	cg11993925	chr19:44307056	LYPD5	0.54	11.08	0.47	3.12e-25	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.92	-0.43	5.23e-21	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs9462027	0.561	rs3798348	chr6:34771892	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.71	-0.39	7.17e-17	Systemic lupus erythematosus;
LUAD	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18404041	chr3:52824283	ITIH1	-0.62	-12.52	-0.52	7.9e-31	Bipolar disorder;
LUAD	cis	rs4604732	0.588	rs4925551	chr1:247631724	T/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.14	0.33	4.19e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg27411982	chr8:10470053	RP1L1	0.39	6.71	0.31	6.24e-11	Mood instability;
LUAD	cis	rs6993813	0.872	rs9650075	chr8:120017079	A/G	cg01975934	chr8:119970761	NA	-0.37	-7.32	-0.34	1.29e-12	Bone mineral density (hip);
LUAD	cis	rs6484504	0.512	rs2761594	chr11:31318244	A/G	cg14844989	chr11:31128820	NA	0.46	8.4	0.38	6.97e-16	Red blood cell count;
LUAD	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg11766577	chr21:47581405	C21orf56	-0.46	-7.88	-0.36	2.83e-14	Testicular germ cell tumor;
LUAD	cis	rs2404602	0.735	rs2454454	chr15:76823647	A/G	cg23625390	chr15:77176239	SCAPER	-0.46	-7.68	-0.35	1.14e-13	Blood metabolite levels;
LUAD	cis	rs11098699	0.784	rs13123959	chr4:124245086	C/T	cg09941581	chr4:124220074	SPATA5	0.42	6.66	0.31	8.48e-11	Mosquito bite size;
LUAD	cis	rs870825	0.616	rs7667409	chr4:185650941	C/T	cg04058563	chr4:185651563	MLF1IP	-0.89	-14.55	-0.58	3.4e-39	Blood protein levels;
LUAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg07677032	chr17:61819896	STRADA	0.57	10.27	0.45	3.13e-22	Prudent dietary pattern;
LUAD	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg03929089	chr4:120376271	NA	0.5	7.37	0.34	8.93e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg11965913	chr1:205819406	PM20D1	0.81	17.05	0.64	5.34e-50	Menarche (age at onset);
LUAD	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg18252515	chr7:66147081	NA	-0.64	-6.92	-0.32	1.65e-11	Diabetic kidney disease;
LUAD	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg25233709	chr10:116636983	FAM160B1	0.41	8.1	0.37	6e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.44	-0.49	1.35e-26	Type 2 diabetes;
LUAD	cis	rs2688608	0.647	rs2633319	chr10:75691247	A/T	cg23231163	chr10:75533350	FUT11	-0.39	-7.19	-0.33	2.89e-12	Inflammatory bowel disease;
LUAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg08888203	chr3:10149979	C3orf24	0.72	12.87	0.53	3.35e-32	Alzheimer's disease;
LUAD	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg24733560	chr20:60626293	TAF4	0.51	10.26	0.45	3.41e-22	Body mass index;
LUAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg04352962	chr1:209979756	IRF6	0.47	6.38	0.3	4.58e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg23625390	chr15:77176239	SCAPER	-0.38	-6.77	-0.31	4.28e-11	Blood metabolite levels;
LUAD	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.26	-0.33	1.92e-12	Reticulocyte count;
LUAD	cis	rs4853525	0.522	rs7574840	chr2:191584236	C/G	cg11845111	chr2:191398756	TMEM194B	-0.44	-7.11	-0.33	5.06e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	trans	rs853679	0.599	rs149990	chr6:27998258	G/A	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.6	-0.35	1.98e-13	Depression;
LUAD	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.81	-0.31	3.3e-11	Retinal vascular caliber;
LUAD	cis	rs2455799	0.634	rs62243670	chr3:15918990	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-9.01	-0.4	7.35e-18	Mean platelet volume;
LUAD	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg07606381	chr6:8435919	SLC35B3	0.42	6.82	0.31	3.13e-11	Motion sickness;
LUAD	cis	rs1816752	0.789	rs7986037	chr13:25012853	A/G	cg02811702	chr13:24901961	NA	0.46	7.96	0.36	1.61e-14	Obesity-related traits;
LUAD	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.46	-7.51	-0.34	3.58e-13	Lymphocyte percentage of white cells;
LUAD	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg07153921	chr17:41440717	NA	-0.4	-6.83	-0.32	2.95e-11	Menopause (age at onset);
LUAD	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg03929089	chr4:120376271	NA	-0.99	-20.65	-0.71	4.76e-66	Height;
LUAD	cis	rs427394	0.582	rs274661	chr5:6704848	C/T	cg14682080	chr5:6737778	POLS	0.33	7.28	0.33	1.6e-12	Menopause (age at onset);
LUAD	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg02569458	chr12:86230093	RASSF9	0.44	8.05	0.36	8.3e-15	Major depressive disorder;
LUAD	cis	rs490234	0.676	rs4838264	chr9:128225561	T/C	cg14078157	chr9:128172775	NA	-0.46	-8.07	-0.37	7.53e-15	Mean arterial pressure;
LUAD	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg14664628	chr15:75095509	CSK	-0.49	-8.09	-0.37	6.44e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg02269571	chr22:50332266	NA	-0.68	-9.85	-0.43	9.49e-21	Schizophrenia;
LUAD	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg04450456	chr4:17643702	FAM184B	0.36	6.81	0.31	3.3e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13315871	1.000	rs36037390	chr3:58321954	C/T	cg12435725	chr3:58293450	RPP14	-0.71	-7.52	-0.34	3.34e-13	Cholesterol, total;
LUAD	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-7.76	-0.35	6.42e-14	Lung cancer;
LUAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg08132940	chr7:1081526	C7orf50	-0.45	-6.96	-0.32	1.32e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6460942	0.915	rs62448620	chr7:12458170	C/T	cg06484146	chr7:12443880	VWDE	-0.58	-7.32	-0.34	1.28e-12	Coronary artery disease;
LUAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.6	-10.4	-0.45	1.03e-22	Lymphocyte counts;
LUAD	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg03676636	chr4:99064102	C4orf37	0.3	7.23	0.33	2.26e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1160297	0.609	rs10167421	chr2:53096163	G/C	cg07782112	chr2:53107842	NA	0.42	8.91	0.4	1.55e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg15557168	chr22:42548783	NA	-0.57	-11.04	-0.47	4.47e-25	Schizophrenia;
LUAD	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg04455712	chr21:45112962	RRP1B	0.43	8.87	0.4	2.13e-17	Mean corpuscular volume;
LUAD	cis	rs208520	0.909	rs9354411	chr6:67019930	A/G	cg07460842	chr6:66804631	NA	0.85	9.97	0.44	3.63e-21	Exhaled nitric oxide output;
LUAD	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg22467129	chr15:76604101	ETFA	-0.47	-7.92	-0.36	2.09e-14	Blood metabolite levels;
LUAD	trans	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	15.39	0.6	8.83e-43	Exhaled nitric oxide levels;
LUAD	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21385522	chr1:16154831	NA	0.56	8.28	0.37	1.63e-15	Dilated cardiomyopathy;
LUAD	cis	rs7264396	0.836	rs6058276	chr20:34187728	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-6.7	-0.31	6.76e-11	Total cholesterol levels;
LUAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg14820908	chr5:178986412	RUFY1	0.56	8.22	0.37	2.58e-15	Lung cancer;
LUAD	cis	rs1232027	0.616	rs1824839	chr5:79961362	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg16680214	chr1:154839983	KCNN3	-0.63	-13.26	-0.54	8.05e-34	Prostate cancer;
LUAD	cis	rs7771547	0.603	rs72852338	chr6:36554240	A/C	cg07856975	chr6:36356162	ETV7	0.53	7.08	0.33	6.05e-12	Platelet distribution width;
LUAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.47	-8.59	-0.39	1.75e-16	Longevity;Endometriosis;
LUAD	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg15485101	chr11:133734466	NA	0.38	8.27	0.37	1.81e-15	Childhood ear infection;
LUAD	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg05044414	chr3:183734942	ABCC5	0.48	10.03	0.44	2.24e-21	Anterior chamber depth;
LUAD	cis	rs593982	0.925	rs603509	chr11:65507605	C/T	cg08755490	chr11:65554678	OVOL1	-1.2	-19.42	-0.69	1.56e-60	Atopic dermatitis;
LUAD	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg25894440	chr7:65020034	NA	-0.67	-7.19	-0.33	2.98e-12	Diabetic kidney disease;
LUAD	cis	rs208520	0.837	rs208498	chr6:66931560	G/A	cg07460842	chr6:66804631	NA	-0.96	-13.9	-0.56	2e-36	Exhaled nitric oxide output;
LUAD	cis	rs877282	0.947	rs7923867	chr10:768094	G/A	cg17470449	chr10:769945	NA	0.62	8.71	0.39	7.04e-17	Uric acid levels;
LUAD	cis	rs11771526	0.686	rs77847042	chr7:32277207	A/G	cg27532318	chr7:32358331	NA	0.53	7.11	0.33	5.06e-12	Body mass index;
LUAD	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg02038168	chr22:39784481	NA	-0.57	-9.85	-0.43	9.6e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs7524258	0.868	rs6577428	chr1:7314655	C/T	cg07173049	chr1:7289937	CAMTA1	-0.53	-9.84	-0.43	1e-20	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	trans	rs12200782	0.932	rs72844476	chr6:26574150	C/T	cg08851530	chr6:28072375	NA	0.74	6.81	0.31	3.46e-11	Small cell lung carcinoma;
LUAD	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs3087591	1.000	rs2905791	chr17:29472888	T/C	cg24425628	chr17:29625626	OMG;NF1	0.42	6.84	0.32	2.81e-11	Hip circumference;
LUAD	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg14458575	chr2:238380390	NA	0.66	12.84	0.53	4.46e-32	Prostate cancer;
LUAD	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg11502198	chr6:26597334	ABT1	0.85	11.4	0.48	1.91e-26	Small cell lung carcinoma;
LUAD	cis	rs12155623	0.619	rs870397	chr8:49861225	C/T	cg22283653	chr8:49824208	NA	0.41	7.78	0.35	5.72e-14	Sudden cardiac arrest;
LUAD	cis	rs9400271	0.527	rs4945829	chr6:109638828	T/C	cg21918786	chr6:109611834	NA	0.39	6.48	0.3	2.5e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg17971929	chr21:40555470	PSMG1	0.56	8.96	0.4	1.02e-17	Cognitive function;
LUAD	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg13870426	chr17:30244630	NA	-0.55	-6.49	-0.3	2.35e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs10493773	0.618	rs34746573	chr1:86075360	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.47	-7.28	-0.33	1.61e-12	Urate levels in overweight individuals;
LUAD	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg22117172	chr7:91764530	CYP51A1	0.31	6.51	0.3	2.12e-10	Breast cancer;
LUAD	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg21285383	chr16:89894308	SPIRE2	-0.4	-9.58	-0.42	8.19e-20	Vitiligo;
LUAD	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.4	-0.34	7.53e-13	Breast cancer;
LUAD	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg12645284	chr15:79092878	ADAMTS7	0.45	7.17	0.33	3.45e-12	Coronary artery disease or large artery stroke;
LUAD	cis	rs9826463	0.527	rs73238169	chr3:142099367	G/A	cg20824294	chr3:142316082	PLS1	0.43	7.15	0.33	3.75e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.77	-0.31	4.31e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg00933542	chr6:150070202	PCMT1	0.45	9.67	0.43	3.95e-20	Lung cancer;
LUAD	cis	rs1559088	0.895	rs7246562	chr19:33546088	T/G	cg27124370	chr19:33622961	WDR88	0.45	6.82	0.31	3.07e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs55788414	0.860	rs28697180	chr16:81185079	C/T	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.91	-0.36	2.31e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs2455601	0.608	rs11042104	chr11:8890924	C/G	cg09997546	chr11:8931473	C11orf17;ST5	0.42	7.93	0.36	2.01e-14	Schizophrenia;
LUAD	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg11859384	chr17:80120422	CCDC57	0.48	8.72	0.39	6.39e-17	Life satisfaction;
LUAD	trans	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg12568669	chr8:11666485	FDFT1	0.23	6.43	0.3	3.46e-10	Mood instability;
LUAD	cis	rs490234	0.812	rs4838268	chr9:128280315	G/T	cg14078157	chr9:128172775	NA	-0.43	-7.86	-0.36	3.25e-14	Mean arterial pressure;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg21400344	chr1:25870172	LDLRAP1	0.41	6.39	0.3	4.48e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg14844989	chr11:31128820	NA	-0.47	-8.51	-0.38	3.14e-16	Red blood cell count;
LUAD	cis	rs240764	0.746	rs151572	chr6:101110984	C/T	cg09795085	chr6:101329169	ASCC3	0.44	7.51	0.34	3.56e-13	Neuroticism;
LUAD	cis	rs73206853	0.534	rs12302069	chr12:110512359	A/G	cg12870014	chr12:110450643	ANKRD13A	0.8	8.02	0.36	1.03e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg21970626	chr13:21893289	NA	-0.47	-8.22	-0.37	2.44e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs7851660	0.548	rs1156850	chr9:100573164	G/A	cg13688889	chr9:100608707	NA	-0.62	-10.69	-0.46	8.74e-24	Strep throat;
LUAD	cis	rs6484504	0.625	rs796341	chr11:31414151	G/A	cg26647111	chr11:31128758	NA	0.44	7.73	0.35	7.74e-14	Red blood cell count;
LUAD	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.26e-12	Tonsillectomy;
LUAD	trans	rs4650994	0.524	rs1998544	chr1:178605276	T/C	cg05059571	chr16:84539110	KIAA1609	0.68	11.93	0.5	1.75e-28	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg20673091	chr1:2541236	MMEL1	0.37	7.67	0.35	1.16e-13	Ulcerative colitis;
LUAD	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg18187862	chr3:45730750	SACM1L	0.51	7.83	0.36	3.96e-14	Primary sclerosing cholangitis;
LUAD	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg09117114	chr16:67998030	SLC12A4	0.54	6.94	0.32	1.48e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4629710	0.592	rs66533103	chr6:131531016	C/T	cg12606694	chr6:131520996	AKAP7	0.5	7.51	0.34	3.58e-13	Multiple myeloma (IgH translocation);
LUAD	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg19729930	chr2:74357872	NA	-0.91	-13.88	-0.56	2.29e-36	Gestational age at birth (maternal effect);
LUAD	cis	rs354225	0.544	rs11902987	chr2:54805587	C/T	cg01766943	chr2:54829624	SPTBN1	0.38	7.04	0.32	7.75e-12	Schizophrenia;
LUAD	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg13010199	chr12:38710504	ALG10B	0.39	6.48	0.3	2.49e-10	Resting heart rate;
LUAD	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg06558623	chr16:89946397	TCF25	1.14	10.3	0.45	2.39e-22	Skin colour saturation;
LUAD	trans	rs2806561	1.000	rs2776822	chr1:23492782	A/G	cg23182539	chr10:121355708	TIAL1	0.38	6.43	0.3	3.37e-10	Height;
LUAD	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg18477163	chr1:228402036	OBSCN	-0.35	-6.92	-0.32	1.72e-11	Diastolic blood pressure;
LUAD	cis	rs2692947	0.537	rs11164050	chr2:96352451	T/C	cg23100626	chr2:96804247	ASTL	0.31	7.51	0.34	3.43e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg24558204	chr6:135376177	HBS1L	0.46	8.62	0.39	1.35e-16	Red blood cell count;
LUAD	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg12483005	chr1:23474871	LUZP1	0.52	9.14	0.41	2.62e-18	Height;
LUAD	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-7.99	-0.36	1.32e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs208520	0.909	rs9354411	chr6:67019930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	10.94	0.47	1.05e-24	Exhaled nitric oxide output;
LUAD	cis	rs7944584	0.632	rs11039159	chr11:47294021	G/T	cg20307385	chr11:47447363	PSMC3	0.42	6.5	0.3	2.31e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg07617317	chr6:118971624	C6orf204	0.55	8.51	0.38	3.16e-16	Diastolic blood pressure;
LUAD	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg20476274	chr7:133979776	SLC35B4	-0.68	-12.26	-0.51	9.26e-30	Mean platelet volume;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg01596986	chr13:48611463	NUDT15	0.4	7.05	0.32	7.23e-12	Bipolar disorder;
LUAD	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg26384229	chr12:38710491	ALG10B	0.47	7.62	0.35	1.66e-13	Morning vs. evening chronotype;
LUAD	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg20607287	chr7:12443886	VWDE	-0.53	-6.67	-0.31	8.01e-11	Coronary artery disease;
LUAD	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.82	-0.39	3.1e-17	Initial pursuit acceleration;
LUAD	cis	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg20368463	chr18:77673604	PQLC1	0.46	7.32	0.34	1.3e-12	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg17063962	chr7:91808500	NA	0.65	11.68	0.49	1.65e-27	Breast cancer;
LUAD	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg04824913	chr4:887549	GAK	-0.44	-6.45	-0.3	3.04e-10	Systemic sclerosis;
LUAD	cis	rs7975161	0.938	rs10400561	chr12:104640920	A/G	cg25273343	chr12:104657179	TXNRD1	-0.7	-8.54	-0.38	2.53e-16	Toenail selenium levels;
LUAD	trans	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg14917512	chr19:3094685	GNA11	-0.54	-6.52	-0.3	2.03e-10	Diabetic kidney disease;
LUAD	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg23281280	chr6:28129359	ZNF389	0.44	6.37	0.3	4.93e-10	Depression;
LUAD	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg26408565	chr15:76604113	ETFA	-0.44	-7.2	-0.33	2.71e-12	Blood metabolite levels;
LUAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.4	8.31	0.37	1.28e-15	Lymphocyte counts;
LUAD	cis	rs11741688	0.597	rs6880072	chr5:178334480	G/C	cg09339527	chr5:178322752	ZFP2	-0.35	-7.35	-0.34	1.01e-12	Sleep duration;
LUAD	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21659725	chr3:3221576	CRBN	0.86	18.2	0.66	4.47e-55	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg27454412	chr7:1067447	C7orf50	0.4	6.9	0.32	1.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg05564831	chr3:52568323	NT5DC2	-0.36	-6.64	-0.31	9.8e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.86	-0.5	3.36e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg11266682	chr4:10021025	SLC2A9	0.69	15.76	0.61	2.27e-44	Bone mineral density;
LUAD	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg07636037	chr3:49044803	WDR6	0.46	8.07	0.37	7.33e-15	Menarche (age at onset);
LUAD	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg24579218	chr15:68104479	NA	-0.49	-8.3	-0.37	1.43e-15	Obesity;
LUAD	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.34	-0.34	1.1e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg08888203	chr3:10149979	C3orf24	0.71	10.86	0.47	2.14e-24	Alzheimer's disease;
LUAD	cis	rs7737355	0.947	rs6884741	chr5:130894613	A/G	cg06307176	chr5:131281290	NA	0.5	7.85	0.36	3.54e-14	Life satisfaction;
LUAD	cis	rs11811982	0.655	rs75813302	chr1:227572370	A/T	cg24860534	chr1:227506868	CDC42BPA	0.66	7.2	0.33	2.8e-12	Optic disc area;
LUAD	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg06671706	chr8:8559999	CLDN23	-0.6	-10.34	-0.45	1.66e-22	Obesity-related traits;
LUAD	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.38	7.76	0.35	6.46e-14	Hemoglobin concentration;
LUAD	cis	rs796825	0.564	rs11708297	chr3:120099799	G/T	cg21790991	chr3:120137480	FSTL1	-0.4	-6.7	-0.31	6.51e-11	HIV-1 susceptibility;
LUAD	cis	rs9948	0.881	rs3731941	chr2:97476219	A/G	cg20312557	chr2:97357134	FER1L5	-0.63	-7.38	-0.34	8.7e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs2050392	0.858	rs2250569	chr10:30698914	G/C	cg18806716	chr10:30721971	MAP3K8	-0.52	-10.55	-0.46	2.91e-23	Inflammatory bowel disease;
LUAD	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg03233332	chr7:66118400	NA	-0.44	-6.75	-0.31	4.97e-11	Aortic root size;
LUAD	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg04756594	chr16:24857601	SLC5A11	0.54	10.31	0.45	2.18e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs877282	0.945	rs12767287	chr10:787310	A/G	cg06581033	chr10:766294	NA	-0.57	-7.64	-0.35	1.5e-13	Uric acid levels;
LUAD	trans	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg26043149	chr18:55253948	FECH	-0.44	-7.23	-0.33	2.21e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg21724239	chr8:58056113	NA	0.53	7.1	0.33	5.29e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.46	9.48	0.42	1.84e-19	Monocyte percentage of white cells;
LUAD	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.91	12.99	0.53	1.07e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg25358565	chr5:93447407	FAM172A	-0.67	-7.76	-0.35	6.26e-14	Diabetic retinopathy;
LUAD	cis	rs12618769	0.597	rs3754891	chr2:99088018	T/C	cg10123293	chr2:99228465	UNC50	0.43	8.05	0.36	8.67e-15	Bipolar disorder;
LUAD	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24308560	chr3:49941425	MST1R	-0.58	-9.9	-0.43	6.3e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs3106136	0.967	rs11097411	chr4:95222626	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.25	-0.37	2.1e-15	Capecitabine sensitivity;
LUAD	cis	rs7432375	0.580	rs4678441	chr3:136532828	T/C	cg15507776	chr3:136538369	TMEM22	0.39	6.96	0.32	1.3e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17152411	1.000	rs11245432	chr10:126616861	G/A	cg07906193	chr10:126599966	NA	0.55	7.31	0.33	1.36e-12	Height;
LUAD	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg22906224	chr7:99728672	NA	-0.56	-9.73	-0.43	2.45e-20	Coronary artery disease;
LUAD	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg06641503	chr3:48959341	ARIH2	-0.38	-7.03	-0.32	8.17e-12	Menarche (age at onset);
LUAD	cis	rs78456975	0.506	rs10206900	chr2:1552841	T/C	cg12573674	chr2:1569213	NA	-0.59	-8.21	-0.37	2.62e-15	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg08885076	chr2:99613938	TSGA10	-0.4	-7.09	-0.33	5.53e-12	Chronic sinus infection;
LUAD	cis	rs1975974	1.000	rs1985718	chr17:21731656	C/T	cg18423549	chr17:21743878	NA	-0.79	-13.74	-0.56	8.74e-36	Psoriasis;
LUAD	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg03605463	chr16:89740564	NA	0.58	10.48	0.45	5.13e-23	Hemoglobin concentration;
LUAD	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg18230493	chr5:56204884	C5orf35	0.54	8.66	0.39	1.02e-16	Coronary artery disease;
LUAD	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg03929089	chr4:120376271	NA	-0.93	-18.06	-0.66	1.83e-54	Height;
LUAD	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg10018233	chr7:150070692	REPIN1	0.48	7.65	0.35	1.36e-13	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs4799710	0.643	rs10468909	chr18:31293499	G/A	cg27147174	chr7:100797783	AP1S1	-0.46	-7.47	-0.34	4.5e-13	Pulmonary function;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg24797967	chr1:147932055	FLJ39739	-0.43	-6.45	-0.3	3e-10	Blood protein levels;
LUAD	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg11663144	chr21:46675770	NA	-0.58	-11.58	-0.49	3.99e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6543140	0.964	rs918000	chr2:103067862	C/T	cg03938978	chr2:103052716	IL18RAP	0.35	6.8	0.31	3.53e-11	Blood protein levels;
LUAD	cis	rs7771547	0.603	rs6913530	chr6:36598209	A/G	cg04289385	chr6:36355825	ETV7	-0.5	-6.69	-0.31	7.21e-11	Platelet distribution width;
LUAD	cis	rs12478296	0.892	rs60042638	chr2:243038707	G/A	cg06360820	chr2:242988706	NA	-0.84	-9.71	-0.43	3e-20	Obesity-related traits;
LUAD	trans	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg17178900	chr1:205818956	PM20D1	-0.46	-7.17	-0.33	3.28e-12	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg12863693	chr15:85201151	NMB	0.36	6.49	0.3	2.41e-10	Schizophrenia;
LUAD	cis	rs7737355	0.947	rs6895841	chr5:130773534	A/G	cg25547332	chr5:131281432	NA	0.42	6.46	0.3	2.86e-10	Life satisfaction;
LUAD	cis	rs4901869	0.966	rs12878614	chr14:59339477	A/C	cg02291164	chr14:59296302	NA	0.61	14.85	0.59	1.93e-40	Panic disorder;
LUAD	cis	rs9768139	0.708	rs6459858	chr7:158115055	A/G	cg25566285	chr7:158114605	PTPRN2	0.54	11.65	0.49	2.07e-27	Calcium levels;
LUAD	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.41	8.2	0.37	2.9e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21028142	chr17:79581711	NPLOC4	-0.45	-9.79	-0.43	1.54e-20	Eye color traits;
LUAD	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg19622623	chr12:86230825	RASSF9	-0.55	-9.77	-0.43	1.85e-20	Major depressive disorder;
LUAD	cis	rs6840360	0.571	rs4696099	chr4:152501951	C/G	cg22705602	chr4:152727874	NA	-0.41	-7.13	-0.33	4.4e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7945718	0.934	rs3993110	chr11:12794530	A/C	cg25843174	chr11:12811716	TEAD1	0.23	6.82	0.31	3.16e-11	Educational attainment (years of education);
LUAD	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg21427119	chr20:30132790	HM13	-0.59	-8.82	-0.39	2.93e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg07527032	chr15:84868466	LOC388152	0.44	6.62	0.31	1.09e-10	Schizophrenia;
LUAD	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg09184832	chr6:79620586	NA	0.51	8.98	0.4	8.71e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs240764	0.817	rs239247	chr6:101088350	T/C	cg09795085	chr6:101329169	ASCC3	0.43	7.29	0.33	1.51e-12	Neuroticism;
LUAD	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg04414720	chr1:150670196	GOLPH3L	-0.52	-8.74	-0.39	5.43e-17	Tonsillectomy;
LUAD	cis	rs7584330	0.554	rs3751106	chr2:238428418	G/A	cg14458575	chr2:238380390	NA	0.51	8.21	0.37	2.7e-15	Prostate cancer;
LUAD	cis	rs9581857	0.615	rs79553479	chr13:28007862	G/A	cg22138327	chr13:27999177	GTF3A	0.92	10.63	0.46	1.44e-23	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.49	10.35	0.45	1.54e-22	Platelet count;
LUAD	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg03037974	chr15:76606532	NA	0.45	10.47	0.45	6.01e-23	Blood metabolite levels;
LUAD	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.46	-8.0	-0.36	1.2e-14	Breast cancer;
LUAD	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg02269571	chr22:50332266	NA	-0.61	-9.39	-0.42	3.65e-19	Schizophrenia;
LUAD	cis	rs6901250	0.851	rs607372	chr6:117155929	A/G	cg12892004	chr6:117198278	RFX6	-0.34	-7.24	-0.33	2.17e-12	C-reactive protein levels;
LUAD	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg04398451	chr17:18023971	MYO15A	-0.73	-13.05	-0.54	5.91e-33	Total body bone mineral density;
LUAD	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.6	8.57	0.38	1.93e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg17644776	chr2:200775616	C2orf69	-0.58	-9.82	-0.43	1.21e-20	Osteoporosis;
LUAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg11905131	chr22:24372483	LOC391322	-0.57	-9.51	-0.42	1.44e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg16342193	chr10:102329863	NA	-0.39	-6.86	-0.32	2.49e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7517126	0.688	rs7548145	chr1:196935696	T/C	cg07209298	chr1:196795943	CFHR1	0.57	6.43	0.3	3.5e-10	Blood protein levels;
LUAD	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg02782426	chr3:40428986	ENTPD3	0.41	8.83	0.39	2.83e-17	Renal cell carcinoma;
LUAD	cis	rs2131877	0.956	rs2279632	chr3:194869285	G/A	cg19760965	chr3:194868843	C3orf21	0.43	7.12	0.33	4.68e-12	Non-small cell lung cancer;
LUAD	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg04287289	chr16:89883240	FANCA	0.7	6.58	0.3	1.43e-10	Skin colour saturation;
LUAD	cis	rs2997447	0.655	rs12059101	chr1:26384013	A/G	cg19633962	chr1:26362018	EXTL1	-0.56	-6.66	-0.31	8.59e-11	QRS complex (12-leadsum);
LUAD	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7705042	1.000	rs7705042	chr5:141492419	C/A	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.55	-0.3	1.66e-10	Asthma;
LUAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18402987	chr7:1209562	NA	0.46	7.72	0.35	8.52e-14	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08677398	chr8:58056175	NA	0.51	6.56	0.3	1.61e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.44	-0.3	3.28e-10	Breast cancer;
LUAD	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.18	-0.37	3.36e-15	Total body bone mineral density;
LUAD	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg22467129	chr15:76604101	ETFA	0.47	7.8	0.35	4.79e-14	Blood metabolite levels;
LUAD	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg05182265	chr7:156933206	UBE3C	0.81	17.37	0.65	2.13e-51	Body mass index;
LUAD	cis	rs4332037	0.715	rs57234495	chr7:1906466	G/A	cg23422044	chr7:1970798	MAD1L1	-0.53	-6.52	-0.3	1.99e-10	Bipolar disorder;
LUAD	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg18252515	chr7:66147081	NA	0.61	6.69	0.31	6.92e-11	Diabetic kidney disease;
LUAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.48	6.81	0.31	3.4e-11	Renal function-related traits (BUN);
LUAD	cis	rs977987	0.806	rs7199132	chr16:75450039	C/T	cg03315344	chr16:75512273	CHST6	0.64	14.06	0.56	4.12e-37	Dupuytren's disease;
LUAD	cis	rs72772090	0.539	rs3333	chr5:96115111	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.3	-0.33	1.4e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.33	6.58	0.3	1.39e-10	Obesity-related traits;
LUAD	cis	rs7731657	0.575	rs12513465	chr5:130364503	A/G	cg08523029	chr5:130500466	HINT1	-0.58	-7.38	-0.34	8.34e-13	Fasting plasma glucose;
LUAD	cis	rs4795519	0.849	rs11658968	chr17:22144986	G/T	cg22648282	chr17:21454238	C17orf51	-0.38	-6.42	-0.3	3.64e-10	Chronic myeloid leukemia;
LUAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg24813613	chr7:1882135	MAD1L1	-0.53	-8.74	-0.39	5.67e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg21918786	chr6:109611834	NA	-0.58	-10.61	-0.46	1.8e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs2067615	0.524	rs1882543	chr12:107067160	A/G	cg15890332	chr12:107067104	RFX4	-0.41	-8.7	-0.39	7.31e-17	Heart rate;
LUAD	cis	rs6690583	1.000	rs2304641	chr1:85513398	C/T	cg22153463	chr1:85462885	MCOLN2	0.59	7.05	0.32	7.16e-12	Serum sulfate level;
LUAD	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg17366294	chr4:99064904	C4orf37	0.57	9.73	0.43	2.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.67	-0.39	9.2e-17	Endometrial cancer;
LUAD	trans	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg18187862	chr3:45730750	SACM1L	0.55	8.61	0.39	1.5e-16	Primary sclerosing cholangitis;
LUAD	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg11915388	chr22:42470451	FAM109B	-0.41	-7.38	-0.34	8.39e-13	Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19541147	chr11:111957761	TIMM8B;SDHD	-0.39	-6.35	-0.3	5.49e-10	Cancer;
LUAD	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg22598563	chr5:131563921	P4HA2	-0.29	-7.25	-0.33	2.04e-12	Blood metabolite levels;
LUAD	cis	rs77741769	0.529	rs1467283	chr12:121210220	G/C	cg02419362	chr12:121203948	SPPL3	0.41	8.36	0.38	8.89e-16	Mean corpuscular volume;
LUAD	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg22117172	chr7:91764530	CYP51A1	0.33	7.05	0.32	7.2e-12	Breast cancer;
LUAD	cis	rs896543	0.657	rs10179774	chr2:237487588	C/T	cg25295825	chr2:237489920	CXCR7	0.38	6.55	0.3	1.71e-10	Alcohol dependence (age at onset);
LUAD	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.37	-0.41	4.57e-19	Type 2 diabetes;
LUAD	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg01579765	chr21:45077557	HSF2BP	-0.57	-13.4	-0.55	2.23e-34	Mean corpuscular volume;
LUAD	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg24069376	chr3:38537580	EXOG	0.45	11.0	0.47	6.54e-25	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.32	0.37	1.26e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.31	-0.33	1.34e-12	Breast cancer;
LUAD	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg22868518	chr11:507468	RNH1	-0.67	-6.85	-0.32	2.65e-11	Body mass index;
LUAD	trans	rs4942242	0.663	rs34978818	chr13:44214096	T/C	cg19169023	chr15:41853346	TYRO3	-0.65	-11.2	-0.48	1.16e-25	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.9	0.43	6.13e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	cis	rs8170	0.603	rs10259	chr19:17430915	G/A	cg12247222	chr19:17403313	ABHD8	0.44	6.78	0.31	4.09e-11	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUAD	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg12062639	chr20:23401060	NAPB	1.11	11.56	0.49	4.76e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs11209185	0.602	rs12029657	chr1:68432702	G/C	cg22082780	chr1:68452167	NA	-0.38	-7.53	-0.34	3.18e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs7927771	0.524	rs11039431	chr11:47872012	G/T	cg18512352	chr11:47633146	NA	0.36	6.39	0.3	4.37e-10	Subjective well-being;
LUAD	cis	rs73206853	0.563	rs74869743	chr12:111204031	T/C	cg12870014	chr12:110450643	ANKRD13A	0.57	6.55	0.3	1.63e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs3931020	0.657	rs10890142	chr1:75179129	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.48	6.42	0.3	3.65e-10	Resistin levels;
LUAD	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.69	-0.35	1.01e-13	Breast cancer;
LUAD	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg18876405	chr7:65276391	NA	0.64	11.14	0.48	1.88e-25	Aortic root size;
LUAD	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg19729930	chr2:74357872	NA	0.96	15.67	0.61	6.01e-44	Gestational age at birth (maternal effect);
LUAD	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg23533926	chr12:111358616	MYL2	-0.43	-7.34	-0.34	1.07e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg12034118	chr1:209979487	IRF6	0.5	7.16	0.33	3.68e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs7100689	0.622	rs7082093	chr10:82134954	T/G	cg00277334	chr10:82204260	NA	-0.62	-10.06	-0.44	1.66e-21	Post bronchodilator FEV1;
LUAD	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg15704280	chr7:45808275	SEPT13	-1.05	-23.63	-0.75	2.46e-79	Height;
LUAD	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg12573674	chr2:1569213	NA	-0.58	-8.78	-0.39	4.06e-17	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7737355	0.812	rs3776013	chr5:130867404	C/T	cg25547332	chr5:131281432	NA	0.42	6.78	0.31	4.03e-11	Life satisfaction;
LUAD	trans	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17712092	chr4:129076599	LARP1B	0.85	16.28	0.62	1.24e-46	Eosinophil percentage of white cells;
LUAD	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.78	-13.55	-0.55	5.49e-35	Chronic sinus infection;
LUAD	cis	rs7705042	0.865	rs413214	chr5:141530157	G/A	cg23435118	chr5:141488016	NDFIP1	-0.41	-7.01	-0.32	9.48e-12	Asthma;
LUAD	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.16	-0.54	2.23e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg08085267	chr17:45401833	C17orf57	0.53	8.97	0.4	9.55e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21173440	chr5:55008212	SLC38A9	-0.53	-6.48	-0.3	2.59e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs954108	0.584	rs9314922	chr13:29379229	A/G	cg11788234	chr13:29393811	NA	0.47	9.53	0.42	1.29e-19	Obesity-related traits;
LUAD	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg08773314	chr2:239334832	ASB1	0.45	10.29	0.45	2.5e-22	Multiple system atrophy;
LUAD	cis	rs73206853	0.563	rs16940950	chr12:111136459	A/G	cg12870014	chr12:110450643	ANKRD13A	0.61	6.74	0.31	5.25e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.11	-0.44	1.2e-21	Migraine;Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg23018236	chr17:30244563	NA	-0.68	-8.33	-0.38	1.15e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24531977	chr5:56204891	C5orf35	-0.97	-15.11	-0.59	1.48e-41	Initial pursuit acceleration;
LUAD	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg00666640	chr1:248458726	OR2T12	0.32	7.66	0.35	1.25e-13	Common traits (Other);
LUAD	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg21918786	chr6:109611834	NA	-0.6	-11.27	-0.48	5.97e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg15557168	chr22:42548783	NA	-0.49	-8.66	-0.39	1e-16	Schizophrenia;
LUAD	cis	rs813218	0.523	rs497868	chr3:99450187	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.43	-8.1	-0.37	5.98e-15	Orofacial clefts;
LUAD	cis	rs2797160	1.000	rs6933471	chr6:126017029	T/G	cg05901451	chr6:126070800	HEY2	0.44	6.52	0.3	2.03e-10	Endometrial cancer;
LUAD	cis	rs796364	0.715	rs77089299	chr2:201116853	A/G	cg23649088	chr2:200775458	C2orf69	-0.68	-7.02	-0.32	8.68e-12	Schizophrenia;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg17674090	chr5:52083609	ITGA1;PELO	-0.39	-6.67	-0.31	7.91e-11	Subcortical brain region volumes;
LUAD	cis	rs17102423	0.768	rs8005829	chr14:65576165	C/T	cg11161011	chr14:65562177	MAX	0.39	6.5	0.3	2.21e-10	Obesity-related traits;
LUAD	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg25985355	chr7:65971099	NA	-0.51	-6.37	-0.3	4.89e-10	Diabetic kidney disease;
LUAD	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg07169764	chr2:136633963	MCM6	0.66	8.45	0.38	4.64e-16	Corneal structure;
LUAD	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg23254163	chr1:152506842	NA	0.27	7.51	0.34	3.45e-13	Hair morphology;
LUAD	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg04553112	chr3:125709451	NA	-0.54	-7.06	-0.32	6.77e-12	Blood pressure (smoking interaction);
LUAD	cis	rs2235649	0.592	rs7197113	chr16:1969483	G/A	cg07386859	chr16:1872102	HAGH	0.44	6.36	0.3	5.13e-10	Blood metabolite levels;
LUAD	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg15691649	chr6:25882328	NA	-0.7	-11.17	-0.48	1.47e-25	Uric acid levels;
LUAD	cis	rs12681288	0.550	rs73176529	chr8:962283	G/C	cg04851639	chr8:1020857	NA	-0.31	-7.23	-0.33	2.26e-12	Schizophrenia;
LUAD	cis	rs7089973	0.564	rs55671354	chr10:116571281	T/C	cg25233709	chr10:116636983	FAM160B1	0.43	8.61	0.39	1.48e-16	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4888262	0.526	rs12921903	chr16:74625575	C/T	cg01733217	chr16:74700730	RFWD3	0.5	8.52	0.38	2.83e-16	Testicular germ cell tumor;
LUAD	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg18854424	chr1:2615690	NA	0.43	9.44	0.42	2.53e-19	Ulcerative colitis;
LUAD	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.17	-0.33	3.29e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06544989	chr22:39130855	UNC84B	0.46	8.53	0.38	2.63e-16	Menopause (age at onset);
LUAD	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg06558623	chr16:89946397	TCF25	1.23	12.4	0.52	2.47e-30	Skin colour saturation;
LUAD	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg15704280	chr7:45808275	SEPT13	-1.07	-25.01	-0.77	2.01e-85	Height;
LUAD	cis	rs877282	0.797	rs35927768	chr10:753095	T/C	cg17470449	chr10:769945	NA	0.57	7.75	0.35	6.96e-14	Uric acid levels;
LUAD	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg00631329	chr6:26305371	NA	0.45	7.48	0.34	4.37e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg11833968	chr6:79620685	NA	-0.43	-7.96	-0.36	1.57e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg06784218	chr1:46089804	CCDC17	-0.53	-11.48	-0.49	9.64e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.67	-0.31	8.19e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.57	7.77	0.35	5.85e-14	Renal function-related traits (BUN);
LUAD	cis	rs1448094	0.872	rs10863147	chr12:86408441	G/C	cg00310523	chr12:86230176	RASSF9	0.36	7.64	0.35	1.45e-13	Major depressive disorder;
LUAD	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-7.23	-0.33	2.33e-12	Bipolar disorder;
LUAD	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg15226275	chr6:116381976	FRK	0.23	7.64	0.35	1.43e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs34734847	1.000	rs2948149	chr12:121162854	T/G	cg27246729	chr12:121163418	ACADS	0.42	7.93	0.36	1.91e-14	Mean corpuscular volume;
LUAD	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg19436804	chr8:8560866	CLDN23	0.42	6.45	0.3	3.05e-10	Obesity-related traits;
LUAD	cis	rs11025523	0.848	rs10833309	chr11:20378045	A/G	cg02900213	chr11:20385756	HTATIP2	-0.44	-7.09	-0.33	5.77e-12	Obesity-related traits;
LUAD	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.55	8.76	0.39	4.77e-17	Platelet count;
LUAD	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg02782426	chr3:40428986	ENTPD3	-0.38	-8.22	-0.37	2.46e-15	Renal cell carcinoma;
LUAD	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg26408565	chr15:76604113	ETFA	-0.45	-7.36	-0.34	9.45e-13	Blood metabolite levels;
LUAD	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	14.34	0.57	2.63e-38	Smoking behavior;
LUAD	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg14664628	chr15:75095509	CSK	0.6	9.95	0.44	4.34e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs4846217	1.000	rs6679596	chr1:10454502	A/T	cg17425144	chr1:10567563	PEX14	-0.5	-6.63	-0.31	1.03e-10	Platelet count;
LUAD	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg03929089	chr4:120376271	NA	-0.98	-20.23	-0.7	3.63e-64	Height;
LUAD	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg19418458	chr7:158789849	NA	0.64	11.37	0.48	2.46e-26	Facial morphology (factor 20);
LUAD	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.76	0.31	4.55e-11	Depression;
LUAD	cis	rs6546550	0.935	rs11673826	chr2:70041033	G/A	cg02498382	chr2:70120550	SNRNP27	-0.55	-10.71	-0.46	7.45e-24	Prevalent atrial fibrillation;
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01516881	chr6:292596	DUSP22	0.77	13.45	0.55	1.42e-34	Menopause (age at onset);
LUAD	cis	rs2224391	0.518	rs72815613	chr6:5289798	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.63	-7.5	-0.34	3.78e-13	Height;
LUAD	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-8.28	-0.37	1.69e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1595825	1.000	rs56765024	chr2:198876286	G/T	cg10547527	chr2:198650123	BOLL	-0.48	-6.68	-0.31	7.67e-11	Ulcerative colitis;
LUAD	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg11301795	chr4:187892539	NA	-0.81	-17.37	-0.65	2.18e-51	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg12940439	chr1:67600707	NA	0.48	9.12	0.41	2.97e-18	Psoriasis;
LUAD	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg21918786	chr6:109611834	NA	-0.6	-11.35	-0.48	2.98e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.585	rs201004	chr6:27804934	T/C	cg21204522	chr6:27730016	NA	-0.48	-7.25	-0.33	1.96e-12	Depression;
LUAD	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg05865280	chr17:75406074	SEPT9	0.61	19.3	0.68	5.44e-60	Airflow obstruction;
LUAD	cis	rs62238980	0.614	rs117628874	chr22:32452970	T/C	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs35883536	0.626	rs7545966	chr1:101047633	G/A	cg06223162	chr1:101003688	GPR88	-0.48	-9.31	-0.41	7.07e-19	Monocyte count;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg20881074	chr2:45236659	SIX2	-0.4	-6.72	-0.31	5.72e-11	Vertical cup-disc ratio;
LUAD	cis	rs9400271	0.632	rs949882	chr6:109586062	A/G	cg21918786	chr6:109611834	NA	0.39	6.62	0.31	1.09e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs1371614	0.523	rs2891534	chr2:27184446	A/G	cg00617064	chr2:27272375	NA	-0.38	-7.35	-0.34	1.06e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.58	6.81	0.31	3.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-9.93	-0.43	4.81e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg13319975	chr6:146136371	FBXO30	-0.64	-11.11	-0.48	2.51e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13315871	1.000	rs4585221	chr3:58415567	C/T	cg20936604	chr3:58311152	NA	-0.69	-6.92	-0.32	1.68e-11	Cholesterol, total;
LUAD	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg19052272	chr2:3704530	ALLC	-0.43	-7.99	-0.36	1.26e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg20607798	chr8:58055168	NA	0.58	7.31	0.34	1.31e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs2797160	0.967	rs1578793	chr6:126015057	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.58e-17	Endometrial cancer;
LUAD	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg24801067	chr17:62843696	NA	0.54	8.65	0.39	1.11e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg13319975	chr6:146136371	FBXO30	0.58	10.07	0.44	1.55e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	11.59	0.49	3.62e-27	Eosinophil percentage of white cells;
LUAD	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg11915388	chr22:42470451	FAM109B	0.39	6.84	0.32	2.85e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6906287	0.647	rs12192682	chr6:118863594	A/G	cg18833306	chr6:118973337	C6orf204	0.47	8.43	0.38	5.36e-16	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg24818145	chr4:99064322	C4orf37	0.46	7.89	0.36	2.64e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7927771	0.757	rs1057233	chr11:47376448	G/A	cg18512352	chr11:47633146	NA	0.43	7.34	0.34	1.12e-12	Subjective well-being;
LUAD	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg04398451	chr17:18023971	MYO15A	-0.77	-14.13	-0.57	2.19e-37	Total body bone mineral density;
LUAD	trans	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.12	27.12	0.8	1.37e-94	Colorectal cancer;
LUAD	cis	rs1018836	0.923	rs6989123	chr8:91551234	A/T	cg16814680	chr8:91681699	NA	-0.74	-13.37	-0.55	2.84e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs57046232	0.552	rs6133306	chr20:6333294	T/G	cg21095983	chr6:86352623	SYNCRIP	0.41	6.36	0.3	5.14e-10	Colorectal cancer;
LUAD	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg19980929	chr12:42632907	YAF2	-0.34	-6.56	-0.3	1.56e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs6063312	1.000	rs6063313	chr20:47343532	G/A	cg18078177	chr20:47281410	PREX1	0.66	8.31	0.37	1.32e-15	Tonometry;
LUAD	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.52	0.42	1.32e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg14689365	chr7:158441557	NCAPG2	0.39	6.47	0.3	2.78e-10	Height;
LUAD	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg03467027	chr4:99064603	C4orf37	0.41	6.63	0.31	1.02e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg22535103	chr8:58192502	C8orf71	-0.77	-10.84	-0.47	2.43e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs7712671	0.840	rs11241418	chr5:116527405	C/T	cg05257600	chr5:87564880	TMEM161B	0.39	6.36	0.3	5.12e-10	Schizophrenia;
LUAD	cis	rs2637266	1.000	rs1907319	chr10:78337049	A/G	cg18941641	chr10:78392320	NA	-0.33	-6.82	-0.31	3.13e-11	Pulmonary function;
LUAD	cis	rs3823572	0.542	rs2953634	chr7:133640386	C/T	cg03336402	chr7:133662267	EXOC4	0.44	7.96	0.36	1.62e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3791556	0.842	rs55840142	chr2:240106884	G/A	cg03281426	chr2:240109471	HDAC4	0.52	9.59	0.42	7.48e-20	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg00530320	chr1:46809349	NSUN4	0.52	8.04	0.36	9.29e-15	Menopause (age at onset);
LUAD	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg03233332	chr7:66118400	NA	0.43	6.62	0.31	1.12e-10	Aortic root size;
LUAD	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg09184832	chr6:79620586	NA	-0.52	-9.73	-0.43	2.56e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg11494091	chr17:61959527	GH2	0.74	18.32	0.67	1.27e-55	Prudent dietary pattern;
LUAD	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg22875332	chr1:76189707	ACADM	-0.86	-15.69	-0.61	4.63e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg15448220	chr1:150897856	SETDB1	0.53	9.22	0.41	1.44e-18	Melanoma;
LUAD	trans	rs877282	0.853	rs10904545	chr10:757100	G/A	cg22713356	chr15:30763199	NA	1.23	15.56	0.6	1.71e-43	Uric acid levels;
LUAD	cis	rs6987853	0.736	rs6991995	chr8:42436219	A/C	cg09913449	chr8:42400586	C8orf40	0.5	10.07	0.44	1.6e-21	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg00339695	chr16:24857497	SLC5A11	-0.47	-8.9	-0.4	1.69e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg13560548	chr3:10150139	C3orf24	0.43	7.12	0.33	4.52e-12	Alzheimer's disease;
LUAD	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg26384229	chr12:38710491	ALG10B	0.4	6.44	0.3	3.27e-10	Morning vs. evening chronotype;
LUAD	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg12908607	chr1:44402522	ARTN	-0.52	-9.95	-0.44	4.2e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.6	0.31	1.22e-10	Cardiac Troponin-T levels;
LUAD	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.74	-15.62	-0.6	9.08e-44	Lung cancer;
LUAD	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg21028142	chr17:79581711	NPLOC4	0.37	7.56	0.34	2.59e-13	Eye color traits;
LUAD	cis	rs739496	0.947	rs2238154	chr12:111882485	C/A	cg10833066	chr12:111807467	FAM109A	0.46	8.28	0.37	1.6e-15	Platelet count;
LUAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg21724239	chr8:58056113	NA	0.64	8.15	0.37	4.16e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs11958404	0.932	rs72818104	chr5:157437632	T/C	cg05962755	chr5:157440814	NA	0.71	9.95	0.44	4.36e-21	IgG glycosylation;
LUAD	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg21171335	chr12:122356390	WDR66	0.77	14.39	0.57	1.69e-38	Mean corpuscular volume;
LUAD	cis	rs1113500	0.933	rs4590700	chr1:108638344	G/T	cg06207961	chr1:108661230	NA	0.44	8.37	0.38	8.46e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs977987	0.806	rs12933281	chr16:75483064	T/G	cg03315344	chr16:75512273	CHST6	0.64	13.9	0.56	1.9e-36	Dupuytren's disease;
LUAD	cis	rs4588572	0.644	rs1428864	chr5:77780263	C/T	cg11547950	chr5:77652471	NA	-0.61	-10.15	-0.44	8.08e-22	Triglycerides;
LUAD	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg08601574	chr20:25228251	PYGB	0.46	8.51	0.38	3.16e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg19318889	chr4:1322082	MAEA	-0.44	-7.52	-0.34	3.39e-13	Obesity-related traits;
LUAD	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg07169764	chr2:136633963	MCM6	0.62	7.49	0.34	4.15e-13	Corneal structure;
LUAD	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg19442545	chr10:75533431	FUT11	-0.48	-7.94	-0.36	1.78e-14	Inflammatory bowel disease;
LUAD	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21171335	chr12:122356390	WDR66	0.7	12.86	0.53	3.47e-32	Mean corpuscular volume;
LUAD	cis	rs9308433	0.529	rs904321	chr1:214506550	G/C	cg06198575	chr1:214491504	SMYD2	0.44	7.45	0.34	5.45e-13	IgG glycosylation;
LUAD	cis	rs10848704	0.525	rs4765709	chr12:2883637	C/T	cg19995117	chr12:2880862	NA	0.46	9.45	0.42	2.36e-19	Quantitative traits;
LUAD	cis	rs6908034	0.600	rs79733895	chr6:19799541	A/G	cg02682789	chr6:19804855	NA	0.96	9.47	0.42	2.01e-19	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg21775979	chr11:780331	NA	0.41	7.65	0.35	1.38e-13	Breast cancer;
LUAD	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg24397884	chr7:158709396	WDR60	-0.68	-9.42	-0.42	2.94e-19	Height;
LUAD	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg16325326	chr1:53192061	ZYG11B	0.5	8.4	0.38	7.08e-16	Monocyte count;
LUAD	cis	rs600231	0.665	rs1626021	chr11:65226187	A/G	cg21890820	chr11:65308645	LTBP3	0.48	7.58	0.35	2.17e-13	Bone mineral density;
LUAD	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.83	-11.35	-0.48	3.1e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.22	-0.37	2.6e-15	Prostate cancer;
LUAD	cis	rs4776059	0.916	rs2414161	chr15:52883285	T/C	cg24008177	chr15:52972085	KIAA1370	0.25	6.78	0.31	4.14e-11	Schizophrenia;
LUAD	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.82	-0.43	1.24e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg19622623	chr12:86230825	RASSF9	-0.42	-7.49	-0.34	3.94e-13	Major depressive disorder;
LUAD	cis	rs2282300	0.739	rs67670125	chr11:30214914	C/T	cg25418670	chr11:30344373	C11orf46	-0.5	-6.97	-0.32	1.25e-11	Morning vs. evening chronotype;
LUAD	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.17	-0.41	2.16e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-8.14	-0.37	4.41e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg04034577	chr2:241836375	C2orf54	-0.48	-10.46	-0.45	6.47e-23	Urinary metabolites;
LUAD	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.33	-6.43	-0.3	3.55e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs741677	0.893	rs1978963	chr17:483832	T/C	cg06217071	chr17:408420	NA	0.36	7.34	0.34	1.12e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2274273	0.563	rs79163357	chr14:55738449	G/A	cg04306507	chr14:55594613	LGALS3	0.41	7.93	0.36	1.96e-14	Protein biomarker;
LUAD	cis	rs10203711	0.933	rs7591829	chr2:239586185	A/T	cg14580085	chr2:239553406	NA	0.4	8.62	0.39	1.39e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs977987	0.931	rs1834013	chr16:75496163	G/T	cg03315344	chr16:75512273	CHST6	0.66	14.71	0.58	7.17e-40	Dupuytren's disease;
LUAD	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-7.56	-0.34	2.57e-13	Bone mineral density (hip);Bone mineral density (spine);
LUAD	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg18132916	chr6:79620363	NA	-0.47	-8.12	-0.37	5.28e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs55665837	0.519	rs1451677	chr11:14746012	A/C	cg19336497	chr11:14380999	RRAS2	-0.41	-7.91	-0.36	2.3e-14	Vitamin D levels;
LUAD	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26314531	chr2:26401878	FAM59B	-0.58	-8.0	-0.36	1.19e-14	Gut microbiome composition (summer);
LUAD	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.02	0.32	9.05e-12	Motion sickness;
LUAD	cis	rs887829	0.588	rs4663971	chr2:234674252	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-8.31	-0.37	1.31e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg15704280	chr7:45808275	SEPT13	0.64	8.64	0.39	1.14e-16	Axial length;
LUAD	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg12927641	chr6:109611667	NA	-0.54	-9.71	-0.43	3.04e-20	Reticulocyte fraction of red cells;
LUAD	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg04051697	chr2:88470813	THNSL2	0.4	6.41	0.3	3.93e-10	Response to metformin (IC50);
LUAD	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg06623918	chr6:96969491	KIAA0776	0.7	9.31	0.41	6.99e-19	Migraine;Coronary artery disease;
LUAD	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg27170947	chr2:26402098	FAM59B	-0.62	-8.7	-0.39	7.22e-17	Gut microbiome composition (summer);
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg02796970	chr10:39023768	NA	-0.48	-7.78	-0.35	5.74e-14	Menopause (age at onset);
LUAD	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg02886208	chr11:14281011	SPON1	-0.41	-8.18	-0.37	3.26e-15	Mitochondrial DNA levels;
LUAD	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg13918804	chr1:2043761	PRKCZ	0.39	6.5	0.3	2.33e-10	Height;
LUAD	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.46	7.46	0.34	4.93e-13	Lung cancer in ever smokers;
LUAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg11062466	chr8:58055876	NA	0.68	9.01	0.4	7.05e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6894268	0.722	rs6601058	chr5:179032187	A/G	cg26135573	chr5:179059668	NA	0.64	8.66	0.39	1.02e-16	Eating disorders;
LUAD	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg00310523	chr12:86230176	RASSF9	0.37	7.4	0.34	7.64e-13	Major depressive disorder;
LUAD	trans	rs2235573	0.551	rs139897	chr22:38399098	A/G	cg19894588	chr14:64061835	NA	0.52	8.19	0.37	3.05e-15	Glioblastoma;Glioma;
LUAD	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg05665937	chr4:1216051	CTBP1	0.37	6.35	0.3	5.52e-10	Obesity-related traits;
LUAD	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg21775007	chr8:11205619	TDH	-0.38	-6.76	-0.31	4.53e-11	Mood instability;
LUAD	cis	rs68170813	0.559	rs78079372	chr7:106934548	T/G	cg23024343	chr7:107201750	COG5	0.45	6.56	0.3	1.56e-10	Coronary artery disease;
LUAD	cis	rs9534288	0.740	rs7989892	chr13:46630641	C/T	cg15192986	chr13:46630673	CPB2	-0.45	-6.44	-0.3	3.25e-10	Blood protein levels;
LUAD	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg27087555	chr16:88793112	FAM38A	0.82	8.01	0.36	1.11e-14	Plateletcrit;
LUAD	cis	rs921968	0.565	rs1078803	chr2:219606538	A/C	cg02176678	chr2:219576539	TTLL4	0.57	11.5	0.49	7.97e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg16325326	chr1:53192061	ZYG11B	0.62	10.76	0.46	4.77e-24	Monocyte count;
LUAD	cis	rs41271473	0.526	rs10916343	chr1:228727961	C/T	cg16512390	chr1:228756714	NA	0.69	9.2	0.41	1.65e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg04154034	chr17:28927549	LRRC37B2	0.57	6.67	0.31	8.05e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6138458	1.000	rs2387362	chr20:24899906	C/T	cg26195577	chr20:24973756	C20orf3	-0.96	-16.03	-0.61	1.65e-45	Blood protein levels;
LUAD	cis	rs933688	0.532	rs12514092	chr5:90540522	T/G	cg17503389	chr5:90575422	NA	-0.43	-6.92	-0.32	1.65e-11	Smoking behavior;
LUAD	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18404041	chr3:52824283	ITIH1	-0.47	-9.4	-0.42	3.34e-19	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.09	0.37	6.3e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg09455208	chr3:40491958	NA	0.57	12.79	0.53	6.67e-32	Renal cell carcinoma;
LUAD	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg26587870	chr6:27730563	NA	-0.48	-7.9	-0.36	2.45e-14	Parkinson's disease;
LUAD	cis	rs907683	0.533	rs12469789	chr2:220293242	C/T	cg15015639	chr2:220282977	DES	0.48	8.98	0.4	8.84e-18	Resting heart rate;
LUAD	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg11344533	chr11:111475393	SIK2	-0.35	-6.64	-0.31	9.9e-11	Primary sclerosing cholangitis;
LUAD	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg14828511	chr1:107599125	PRMT6	0.59	10.4	0.45	1.04e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg05340658	chr4:99064831	C4orf37	0.47	6.51	0.3	2.08e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11890956	chr21:40555474	PSMG1	0.78	13.17	0.54	2.02e-33	Cognitive function;
LUAD	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg04154034	chr17:28927549	LRRC37B2	0.59	6.81	0.31	3.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2004318	1.000	rs113092603	chr19:55078755	G/A	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.93e-13	Blood protein levels;
LUAD	trans	rs9784649	1.000	rs1493479	chr5:24987768	A/G	cg08600765	chr20:34638493	LOC647979	-0.57	-7.65	-0.35	1.36e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs6490294	0.659	rs642898	chr12:112141233	A/G	cg10833066	chr12:111807467	FAM109A	0.37	6.87	0.32	2.28e-11	Mean platelet volume;
LUAD	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg03806693	chr22:41940476	POLR3H	-0.45	-6.61	-0.31	1.16e-10	Vitiligo;
LUAD	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg18252515	chr7:66147081	NA	-0.6	-6.73	-0.31	5.43e-11	Diabetic kidney disease;
LUAD	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg22963979	chr7:1858916	MAD1L1	-0.47	-8.13	-0.37	4.79e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs4604732	0.631	rs10925044	chr1:247627071	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	ch.7.2185748R	chr7:101827539	CUX1	-0.37	-6.44	-0.3	3.3e-10	Cancer;
LUAD	cis	rs6489882	0.867	rs7305035	chr12:113365803	T/C	cg20102336	chr12:113376681	OAS3	-0.6	-9.31	-0.41	6.92e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg17063962	chr7:91808500	NA	0.68	12.32	0.51	5.26e-30	Breast cancer;
LUAD	cis	rs7593730	1.000	rs4410242	chr2:161192070	A/G	cg22609984	chr2:161126801	NA	0.45	7.27	0.33	1.79e-12	Type 2 diabetes;
LUAD	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg23985595	chr17:80112537	CCDC57	0.53	9.68	0.43	3.62e-20	Life satisfaction;
LUAD	cis	rs11971779	0.680	rs73154134	chr7:139039951	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.5	0.3	2.27e-10	Diisocyanate-induced asthma;
LUAD	cis	rs1950626	0.833	rs12892225	chr14:101415413	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.38	7.31	0.34	1.32e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.35	7.2	0.33	2.79e-12	Depression;
LUAD	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9462027	0.588	rs13215181	chr6:34759881	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-8.9	-0.4	1.69e-17	Systemic lupus erythematosus;
LUAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.7	-0.31	6.78e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg21385522	chr1:16154831	NA	-0.73	-11.36	-0.48	2.77e-26	Dilated cardiomyopathy;
LUAD	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg08807101	chr21:30365312	RNF160	0.39	6.69	0.31	7.09e-11	Dental caries;
LUAD	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg04990556	chr1:26633338	UBXN11	-0.39	-6.51	-0.3	2.08e-10	Obesity-related traits;
LUAD	cis	rs1451375	0.652	rs1470747	chr7:50627009	C/T	cg18232548	chr7:50535776	DDC	0.5	7.2	0.33	2.76e-12	Malaria;
LUAD	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg04944784	chr2:26401820	FAM59B	0.73	10.29	0.45	2.68e-22	Gut microbiome composition (summer);
LUAD	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg21153622	chr11:89784906	NA	-0.34	-6.64	-0.31	9.66e-11	Coronary artery disease;
LUAD	cis	rs494562	0.892	rs575477	chr6:86118064	A/G	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00802000	chr16:706648	WDR90	-0.41	-7.79	-0.35	5.16e-14	Height;
LUAD	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg20673091	chr1:2541236	MMEL1	0.45	9.92	0.43	5.23e-21	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs2239547	0.522	rs9846976	chr3:53007995	T/C	cg11645453	chr3:52864694	ITIH4	0.56	10.57	0.46	2.47e-23	Schizophrenia;
LUAD	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg27411982	chr8:10470053	RP1L1	-0.39	-7.09	-0.33	5.53e-12	Neuroticism;
LUAD	cis	rs4481887	0.676	rs1544177	chr1:248524683	C/G	cg00666640	chr1:248458726	OR2T12	0.27	6.76	0.31	4.72e-11	Common traits (Other);
LUAD	cis	rs7095607	0.560	rs10997955	chr10:69914664	C/T	cg18986048	chr10:69913749	MYPN	0.45	7.69	0.35	1.05e-13	Lung function (FVC);
LUAD	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg15485101	chr11:133734466	NA	0.39	8.69	0.39	7.77e-17	Childhood ear infection;
LUAD	trans	rs10838798	0.563	rs4752894	chr11:48120936	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.51	-0.34	3.44e-13	Height;
LUAD	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.96	-0.32	1.32e-11	Type 2 diabetes;
LUAD	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.57	-0.35	2.36e-13	Blood metabolite levels;
LUAD	cis	rs1395	0.925	rs1659701	chr2:27414877	T/C	cg23587288	chr2:27483067	SLC30A3	0.41	8.39	0.38	7.44e-16	Blood metabolite levels;
LUAD	cis	rs4356932	1.000	rs4241579	chr4:76947284	A/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.49	-0.3	2.36e-10	Blood protein levels;
LUAD	cis	rs7192380	0.895	rs2917670	chr16:69758963	T/C	cg26679644	chr16:69762563	NA	-0.53	-10.12	-0.44	1.05e-21	Sjögren's syndrome;
LUAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg03354898	chr7:1950403	MAD1L1	0.41	7.76	0.35	6.51e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg13535736	chr9:111863775	C9orf5	-0.43	-6.62	-0.31	1.09e-10	Menarche (age at onset);
LUAD	cis	rs3772130	0.583	rs9819530	chr3:121387784	T/G	cg20356878	chr3:121714668	ILDR1	0.6	11.4	0.48	1.96e-26	Cognitive performance;
LUAD	trans	rs2797160	1.000	rs2747717	chr6:126008435	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.85	0.4	2.33e-17	Endometrial cancer;
LUAD	cis	rs1797081	0.646	rs7090256	chr10:16851949	T/G	cg23933602	chr10:16859644	RSU1	0.76	14.35	0.57	2.58e-38	Platelet distribution width;
LUAD	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg07343612	chr16:622815	PIGQ	-0.8	-15.66	-0.61	6.29e-44	Height;
LUAD	cis	rs4588572	0.561	rs12697887	chr5:77804729	A/G	cg11547950	chr5:77652471	NA	-0.61	-9.17	-0.41	2.11e-18	Triglycerides;
LUAD	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.22e-32	Immature fraction of reticulocytes;
LUAD	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-10.62	-0.46	1.61e-23	Gut microbiome composition (summer);
LUAD	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg21385522	chr1:16154831	NA	-1.02	-20.98	-0.71	1.67e-67	Dilated cardiomyopathy;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13896783	chr2:159313876	CCDC148;PKP4	-0.51	-6.38	-0.3	4.71e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1904096	0.506	rs13434570	chr4:95168019	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.1	-0.44	1.24e-21	Type 2 diabetes;
LUAD	cis	rs12900413	0.523	rs11636525	chr15:90300478	A/G	cg24249390	chr15:90295951	MESP1	-0.35	-6.85	-0.32	2.66e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg13012494	chr21:47604986	C21orf56	0.47	7.75	0.35	6.93e-14	Testicular germ cell tumor;
LUAD	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-9.71	-0.43	3.06e-20	Migraine;Coronary artery disease;
LUAD	trans	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg04565464	chr8:145669602	NFKBIL2	0.46	7.0	0.32	9.84e-12	Schizophrenia;
LUAD	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg09936400	chr10:82049201	MAT1A	-0.37	-6.47	-0.3	2.69e-10	Post bronchodilator FEV1;
LUAD	cis	rs7267979	0.844	rs6115188	chr20:25432170	G/T	cg08601574	chr20:25228251	PYGB	0.42	7.85	0.36	3.47e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg06558623	chr16:89946397	TCF25	1.15	10.16	0.44	7.69e-22	Skin colour saturation;
LUAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg00280220	chr17:61926910	NA	0.36	6.98	0.32	1.17e-11	Prudent dietary pattern;
LUAD	cis	rs4604732	0.536	rs12037221	chr1:247631212	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.14	0.33	4.19e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.68	10.63	0.46	1.47e-23	Resting heart rate;
LUAD	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg22676075	chr6:135203613	NA	0.55	9.71	0.43	3.03e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	trans	rs775326	0.849	rs16891858	chr5:62749746	G/T	cg15717719	chr2:24150218	ATAD2B	-0.36	-6.46	-0.3	2.87e-10	Educational attainment (years of education);
LUAD	cis	rs12681287	0.752	rs10435563	chr8:87266060	C/T	cg27223183	chr8:87520930	FAM82B	-0.6	-8.37	-0.38	8.59e-16	Caudate activity during reward;
LUAD	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg00634984	chr7:65235879	NA	0.48	6.56	0.3	1.55e-10	Aortic root size;
LUAD	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg21775007	chr8:11205619	TDH	0.57	10.41	0.45	9.36e-23	Retinal vascular caliber;
LUAD	cis	rs11255291	1.000	rs7080828	chr10:7733770	G/A	cg13340899	chr10:7670827	ITIH5	0.38	6.43	0.3	3.55e-10	Ovarian reserve;
LUAD	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg11062466	chr8:58055876	NA	0.66	8.67	0.39	9.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs34734847	1.000	rs2948149	chr12:121162854	T/G	cg21892295	chr12:121157589	UNC119B	-0.46	-8.53	-0.38	2.69e-16	Mean corpuscular volume;
LUAD	cis	rs9297145	0.565	rs7794690	chr7:98764768	G/A	cg05967295	chr7:98741636	SMURF1	-0.72	-13.11	-0.54	3.3e-33	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.86	-0.32	2.53e-11	Type 2 diabetes;
LUAD	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg27529037	chr20:44575021	PCIF1	0.46	8.07	0.37	7.5e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg27129171	chr3:47204927	SETD2	0.43	6.99	0.32	1.07e-11	Colorectal cancer;
LUAD	cis	rs6011002	0.745	rs1151625	chr20:62369997	C/T	cg21849932	chr20:62369462	LIME1	0.78	6.45	0.3	3.09e-10	Dental caries;
LUAD	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg11292332	chr7:45801988	SEPT13	-0.28	-6.36	-0.3	5.26e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg24818145	chr4:99064322	C4orf37	0.48	8.05	0.36	8.77e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg04995722	chr7:26192034	NFE2L3	-0.44	-7.55	-0.34	2.76e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7851660	0.527	rs7870795	chr9:100574120	A/G	cg13688889	chr9:100608707	NA	-0.58	-10.27	-0.45	2.97e-22	Strep throat;
LUAD	cis	rs7122539	0.646	rs682842	chr11:66568943	A/G	cg24851651	chr11:66362959	CCS	-0.39	-7.12	-0.33	4.75e-12	HIV-1 susceptibility;
LUAD	cis	rs1821002	1	rs1821002	chr8:10640065	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.54	-0.3	1.76e-10	Systolic blood pressure;
LUAD	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg08601574	chr20:25228251	PYGB	-0.44	-8.16	-0.37	3.83e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg26647111	chr11:31128758	NA	-0.47	-8.13	-0.37	4.71e-15	Red blood cell count;
LUAD	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	6.59	0.3	1.35e-10	Cognitive test performance;
LUAD	cis	rs9900062	0.586	rs12600679	chr17:62687327	T/G	cg02598441	chr17:62777298	LOC146880	-0.5	-6.37	-0.3	4.98e-10	QT interval;
LUAD	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg11707310	chr1:2537719	MMEL1	0.38	8.08	0.37	6.86e-15	Ulcerative colitis;
LUAD	cis	rs17532515	0.628	rs1494808	chr4:141483735	A/C	cg09181644	chr4:141490428	UCP1	0.33	7.19	0.33	2.95e-12	Select biomarker traits;
LUAD	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg24579218	chr15:68104479	NA	-0.56	-9.73	-0.43	2.52e-20	Restless legs syndrome;
LUAD	cis	rs7192380	0.964	rs8055756	chr16:69648653	A/G	cg00738113	chr16:70207722	CLEC18C	0.33	6.76	0.31	4.58e-11	Sjögren's syndrome;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11393614	chr10:88282152	WAPAL	-0.4	-6.52	-0.3	1.99e-10	Cancer;
LUAD	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg15691649	chr6:25882328	NA	-0.45	-6.45	-0.3	3e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs11249608	0.548	rs7732719	chr5:178463054	A/G	cg01312482	chr5:178451176	ZNF879	-0.45	-7.07	-0.33	6.32e-12	Pubertal anthropometrics;
LUAD	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg23254163	chr1:152506842	NA	-0.25	-6.79	-0.31	3.89e-11	Hair morphology;
LUAD	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg15704280	chr7:45808275	SEPT13	-0.97	-20.27	-0.7	2.41e-64	Height;
LUAD	cis	rs2479724	0.625	rs9394835	chr6:41818200	A/T	cg17623882	chr6:41773611	USP49	-0.53	-8.47	-0.38	3.95e-16	Menarche (age at onset);
LUAD	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg13770153	chr20:60521292	NA	-0.58	-9.7	-0.43	3.15e-20	Body mass index;
LUAD	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.71	-0.39	7.02e-17	Total body bone mineral density;
LUAD	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg22920501	chr2:26401640	FAM59B	0.97	14.19	0.57	1.17e-37	Gut microbiome composition (summer);
LUAD	cis	rs67366981	1.000	rs67130018	chr14:77703280	C/T	cg22824376	chr14:77648248	TMEM63C	0.6	6.42	0.3	3.59e-10	Obsessive-compulsive symptoms;
LUAD	cis	rs7937890	0.559	rs2597219	chr11:14530866	C/G	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.12e-10	Mitochondrial DNA levels;
LUAD	cis	rs72928364	0.656	rs13096071	chr3:100801643	C/T	cg10123952	chr3:100791384	NA	-0.79	-7.21	-0.33	2.61e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg18180107	chr4:99064573	C4orf37	0.47	6.47	0.3	2.76e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2262909	1.000	rs2359821	chr19:22208314	C/T	cg05197062	chr11:11642011	GALNTL4	-0.54	-8.09	-0.37	6.21e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg18740769	chr5:86564730	RASA1	0.39	6.45	0.3	2.98e-10	Schizophrenia;
LUAD	cis	rs2050392	1.000	rs2489864	chr10:30693744	C/G	cg18806716	chr10:30721971	MAP3K8	-0.54	-10.85	-0.47	2.28e-24	Inflammatory bowel disease;
LUAD	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23158103	chr7:148848205	ZNF398	-0.43	-7.45	-0.34	5.21e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg22467129	chr15:76604101	ETFA	-0.52	-9.06	-0.4	4.87e-18	Blood metabolite levels;
LUAD	cis	rs16910800	0.731	rs1065631	chr11:23186810	T/C	cg20040320	chr11:23191996	NA	-0.75	-10.02	-0.44	2.32e-21	Cancer;
LUAD	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg04539111	chr16:67997858	SLC12A4	-0.58	-7.06	-0.32	6.99e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg18129748	chr3:49941408	MST1R	0.4	6.56	0.3	1.6e-10	Body mass index;
LUAD	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg21854759	chr1:92012499	NA	0.47	6.85	0.32	2.6e-11	Eosinophil percentage of white cells;
LUAD	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-11.6	-0.49	3.49e-27	Coronary artery disease;
LUAD	cis	rs9467160	0.871	rs13191455	chr6:24448459	T/C	cg20631270	chr6:24437470	GPLD1	0.43	6.64	0.31	9.73e-11	Liver enzyme levels;
LUAD	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg11645453	chr3:52864694	ITIH4	-0.34	-6.6	-0.31	1.2e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9878978	0.893	rs13091098	chr3:2463850	A/G	cg21928760	chr3:2462534	CNTN4	-0.33	-6.41	-0.3	3.92e-10	Blood pressure (smoking interaction);
LUAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.49	-7.17	-0.33	3.29e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28374715	0.662	rs28827035	chr15:41492290	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.89	-16.38	-0.62	4.93e-47	Ulcerative colitis;
LUAD	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg27129171	chr3:47204927	SETD2	0.4	6.36	0.3	5.28e-10	Colorectal cancer;
LUAD	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg02569458	chr12:86230093	RASSF9	0.42	7.99	0.36	1.29e-14	Major depressive disorder;
LUAD	cis	rs8040855	0.599	rs6496793	chr15:85725746	T/A	cg04831495	chr15:85060580	GOLGA6L5	0.45	7.8	0.35	5.05e-14	Bulimia nervosa;
LUAD	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg02775129	chr4:119771670	NA	-0.86	-8.15	-0.37	4.09e-15	Cannabis dependence symptom count;
LUAD	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg18230493	chr5:56204884	C5orf35	0.9	12.98	0.53	1.15e-32	Initial pursuit acceleration;
LUAD	cis	rs59104589	0.583	rs28386824	chr2:242349893	A/G	cg08645257	chr2:242211290	HDLBP	0.43	7.04	0.32	7.73e-12	Fibrinogen levels;
LUAD	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg00933542	chr6:150070202	PCMT1	0.47	10.22	0.45	4.57e-22	Lung cancer;
LUAD	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg02158880	chr13:53174818	NA	-0.55	-9.52	-0.42	1.36e-19	Lewy body disease;
LUAD	cis	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg08601574	chr20:25228251	PYGB	-0.44	-8.16	-0.37	4e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg26384229	chr12:38710491	ALG10B	0.45	7.36	0.34	9.52e-13	Bladder cancer;
LUAD	cis	rs6761276	0.780	rs12477867	chr2:113835919	C/A	cg06383401	chr2:113825234	IL1F10	-0.3	-6.41	-0.3	3.97e-10	Protein quantitative trait loci;
LUAD	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11890956	chr21:40555474	PSMG1	-0.56	-9.75	-0.43	2.17e-20	Menarche (age at onset);
LUAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.67	-0.31	8.19e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.26e-12	Tonsillectomy;
LUAD	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg06641503	chr3:48959341	ARIH2	-0.4	-7.97	-0.36	1.46e-14	Parkinson's disease;
LUAD	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg00898013	chr13:113819073	PROZ	-0.67	-11.92	-0.5	1.87e-28	Platelet distribution width;
LUAD	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg05564831	chr3:52568323	NT5DC2	0.38	6.93	0.32	1.61e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.2	-0.37	2.88e-15	Total cholesterol levels;
LUAD	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg23172400	chr8:95962367	TP53INP1	-0.36	-8.54	-0.38	2.47e-16	Type 2 diabetes;
LUAD	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg15147215	chr3:52552868	STAB1	-0.38	-7.08	-0.33	5.93e-12	Bipolar disorder;
LUAD	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.26	-0.37	1.88e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg22907277	chr7:1156413	C7orf50	0.74	11.05	0.47	4.15e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-16.45	-0.62	2.36e-47	Colorectal cancer;
LUAD	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg05665937	chr4:1216051	CTBP1	0.47	7.29	0.33	1.5e-12	Longevity;
LUAD	cis	rs6494488	0.500	rs72741325	chr15:64730384	T/C	cg08069370	chr15:64387884	SNX1	-0.76	-6.76	-0.31	4.65e-11	Coronary artery disease;
LUAD	trans	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	8.38	0.38	8.09e-16	Mean corpuscular volume;
LUAD	cis	rs9392556	0.829	rs853417	chr6:4113123	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.42	-7.28	-0.33	1.59e-12	Blood metabolite levels;
LUAD	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg02160872	chr5:212506	CCDC127	-0.49	-6.37	-0.3	5e-10	Breast cancer;
LUAD	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg18252515	chr7:66147081	NA	-0.64	-6.92	-0.32	1.65e-11	Diabetic kidney disease;
LUAD	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.6	-0.42	7.05e-20	Schizophrenia;
LUAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg21280719	chr6:42927975	GNMT	0.39	11.94	0.5	1.55e-28	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs2797160	0.935	rs12717178	chr6:126016499	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.48e-17	Endometrial cancer;
LUAD	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg07211511	chr3:129823064	LOC729375	-0.8	-11.69	-0.49	1.47e-27	Blood pressure (smoking interaction);
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg23970758	chr19:38893547	FAM98C	0.41	6.81	0.31	3.43e-11	Hepatitis;
LUAD	cis	rs6011002	0.550	rs6010634	chr20:62363838	T/C	cg01176363	chr20:62369445	LIME1	-0.79	-6.63	-0.31	1.05e-10	Dental caries;
LUAD	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg14926445	chr8:58193284	C8orf71	-0.44	-6.49	-0.3	2.34e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs11051970	0.636	rs2733703	chr12:32561794	C/T	cg02745156	chr12:32552066	NA	0.31	6.69	0.31	6.98e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4253772	0.530	rs9615990	chr22:46804154	G/A	cg09491104	chr22:46646882	C22orf40	-0.51	-6.38	-0.3	4.59e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg20503657	chr10:835505	NA	0.93	14.08	0.56	3.38e-37	Eosinophil percentage of granulocytes;
LUAD	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06505273	chr16:24850292	NA	0.5	7.35	0.34	1.05e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg07917127	chr4:99064746	C4orf37	0.43	6.64	0.31	9.57e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs78761021	0.720	rs7221637	chr17:9797209	C/T	cg26853458	chr17:9805074	RCVRN	0.41	7.9	0.36	2.49e-14	Type 2 diabetes;
LUAD	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11644478	chr21:40555479	PSMG1	-0.41	-6.74	-0.31	5.31e-11	Menarche (age at onset);
LUAD	cis	rs36096196	0.891	rs12081179	chr1:2251119	A/G	cg17974515	chr1:2252516	NA	0.41	6.95	0.32	1.41e-11	Coronary artery disease;
LUAD	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg21699342	chr2:239360505	ASB1	0.48	8.88	0.4	1.88e-17	Multiple system atrophy;
LUAD	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.78	0.35	5.55e-14	Bladder cancer;
LUAD	cis	rs7633770	0.786	rs1402148	chr3:46678295	C/T	cg11219411	chr3:46661640	NA	0.55	12.06	0.51	5.34e-29	Coronary artery disease;
LUAD	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg21724239	chr8:58056113	NA	0.77	9.14	0.41	2.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs500891	0.525	rs3778201	chr6:84081405	C/T	cg08257003	chr6:84140564	ME1	0.34	6.68	0.31	7.78e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg11822812	chr5:140052017	DND1	0.37	6.69	0.31	7.17e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.47	0.3	2.64e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8073060	0.518	rs225285	chr17:33931084	G/C	cg19694781	chr19:47549865	TMEM160	-0.88	-13.53	-0.55	6.23e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg00933542	chr6:150070202	PCMT1	0.43	9.16	0.41	2.18e-18	Lung cancer;
LUAD	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg00071950	chr4:10020882	SLC2A9	0.65	10.98	0.47	7.58e-25	Blood metabolite levels;
LUAD	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.46	9.5	0.42	1.56e-19	Monocyte percentage of white cells;
LUAD	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg23262351	chr6:79576851	IRAK1BP1	0.43	7.27	0.33	1.72e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04967530	chr3:99979613	TBC1D23	-0.42	-6.58	-0.3	1.42e-10	Height;
LUAD	cis	rs7779181	1.000	rs7780009	chr7:32341543	G/A	cg13207630	chr7:32358064	NA	0.46	7.19	0.33	2.94e-12	Body mass index;
LUAD	trans	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg03886242	chr7:26192032	NFE2L3	-0.47	-8.41	-0.38	6.49e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7010267	0.687	rs13264791	chr8:120013090	A/G	cg01975934	chr8:119970761	NA	-0.34	-6.67	-0.31	8.09e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg21775007	chr8:11205619	TDH	0.39	6.52	0.3	2.01e-10	Neuroticism;
LUAD	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg09537434	chr19:41945824	ATP5SL	-0.52	-8.13	-0.37	4.67e-15	Height;
LUAD	trans	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-10.18	-0.44	6.24e-22	Obesity-related traits;
LUAD	cis	rs4660214	0.568	rs967530	chr1:39596137	T/A	cg27567593	chr1:39956653	BMP8A	0.33	6.37	0.3	5.02e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1595825	0.891	rs77946222	chr2:198533251	C/T	cg11031976	chr2:198649780	BOLL	-0.48	-7.02	-0.32	8.89e-12	Ulcerative colitis;
LUAD	trans	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg11693508	chr17:37793320	STARD3	0.6	7.64	0.35	1.47e-13	Neuroticism;
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15891076	chr10:65930618	NA	0.42	6.63	0.31	1.05e-10	Hepatitis;
LUAD	cis	rs9392556	0.829	rs584585	chr6:4118789	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.38	-6.9	-0.32	1.91e-11	Blood metabolite levels;
LUAD	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg20991723	chr1:152506922	NA	0.33	6.41	0.3	3.9e-10	Hair morphology;
LUAD	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg04450456	chr4:17643702	FAM184B	0.4	7.96	0.36	1.6e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9462027	0.651	rs4259246	chr6:34803947	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.77	-0.39	4.37e-17	Systemic lupus erythematosus;
LUAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.91e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg11062466	chr8:58055876	NA	0.46	6.52	0.3	1.95e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg05340658	chr4:99064831	C4orf37	0.56	9.44	0.42	2.52e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg26597838	chr10:835615	NA	-0.63	-10.8	-0.47	3.41e-24	Eosinophil percentage of granulocytes;
LUAD	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-11.52	-0.49	7.01e-27	Monocyte percentage of white cells;
LUAD	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg17863274	chr19:49399704	TULP2	-0.65	-9.96	-0.44	3.83e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.74	-13.43	-0.55	1.7e-34	Menarche (age at onset);
LUAD	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg08873628	chr1:175162347	KIAA0040	0.39	6.64	0.31	9.74e-11	Alcohol dependence;
LUAD	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg13334819	chr7:99746414	C7orf59	0.64	10.31	0.45	2.27e-22	Coronary artery disease;
LUAD	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg23950597	chr19:37808831	NA	-0.62	-7.42	-0.34	6.54e-13	Coronary artery calcification;
LUAD	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.35	-7.37	-0.34	9.11e-13	Hemoglobin concentration;
LUAD	cis	rs41311933	0.803	rs62578405	chr9:123709795	C/T	cg13567360	chr9:123745713	C5	-0.83	-7.2	-0.33	2.82e-12	Coronary artery disease;
LUAD	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg02782426	chr3:40428986	ENTPD3	0.35	7.11	0.33	5.13e-12	Renal cell carcinoma;
LUAD	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg00129232	chr17:37814104	STARD3	-0.47	-7.59	-0.35	2.07e-13	Asthma;
LUAD	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg05283184	chr6:79620031	NA	-0.54	-10.39	-0.45	1.12e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs11153730	0.503	rs283066	chr6:118620064	A/G	cg05564266	chr6:118973597	C6orf204	0.3	6.38	0.3	4.78e-10	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs1723838	0.510	rs17132534	chr11:73691774	A/G	cg10064339	chr11:73693792	UCP2	0.91	8.23	0.37	2.42e-15	Obesity-related traits;
LUAD	cis	rs6445967	0.569	rs9986	chr3:58280406	A/G	cg13750441	chr3:58318267	PXK	-0.32	-6.6	-0.31	1.23e-10	Platelet count;
LUAD	cis	rs11077998	0.901	rs3794723	chr17:80529495	G/A	cg10255544	chr17:80519551	FOXK2	0.34	6.65	0.31	8.89e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs501916	0.930	rs687566	chr15:48031281	T/C	cg16110827	chr15:48056943	SEMA6D	0.32	6.39	0.3	4.51e-10	Inflammatory bowel disease;Ulcerative colitis;
LUAD	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.57	-9.66	-0.43	4.45e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.96	-0.32	1.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg18827107	chr12:86230957	RASSF9	-0.49	-8.54	-0.38	2.53e-16	Major depressive disorder;
LUAD	cis	rs7241530	0.717	rs28612511	chr18:75889196	T/G	cg14642773	chr18:75888474	NA	0.32	6.56	0.3	1.55e-10	Educational attainment (years of education);
LUAD	cis	rs2070677	0.935	rs11101887	chr10:135418062	G/A	cg20169779	chr10:135381914	SYCE1	-0.52	-8.14	-0.37	4.47e-15	Gout;
LUAD	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg05283184	chr6:79620031	NA	-0.45	-7.82	-0.36	4.13e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6487679	0.526	rs34362	chr12:9385425	C/T	cg08997352	chr12:9597637	DDX12	0.47	7.21	0.33	2.53e-12	Non-alcoholic fatty liver disease histology (AST);
LUAD	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg03874509	chr1:107600012	PRMT6	0.49	7.86	0.36	3.12e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs10788972	0.933	rs4492560	chr1:54568488	G/A	cg25741118	chr1:54482237	LDLRAD1	-0.24	-6.82	-0.31	3.11e-11	Parkinson disease and lewy body pathology;
LUAD	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-8.38	-0.38	7.67e-16	Alzheimer's disease (late onset);
LUAD	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg18827107	chr12:86230957	RASSF9	-0.62	-11.01	-0.47	5.74e-25	Major depressive disorder;
LUAD	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg14686297	chr22:46650375	NA	-0.38	-6.57	-0.3	1.44e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg22535103	chr8:58192502	C8orf71	-0.59	-7.04	-0.32	7.87e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6484504	0.600	rs10835763	chr11:31345574	G/A	cg14844989	chr11:31128820	NA	0.45	8.26	0.37	1.86e-15	Red blood cell count;
LUAD	cis	rs427941	0.703	rs201457	chr7:101741338	C/A	cg06246474	chr7:101738831	CUX1	0.41	7.29	0.33	1.57e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg24733560	chr20:60626293	TAF4	0.41	8.2	0.37	2.86e-15	Body mass index;
LUAD	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.93	-0.32	1.61e-11	Neuroticism;
LUAD	trans	rs2380220	0.574	rs9374322	chr6:95998994	G/A	cg21865736	chr4:2628771	FAM193A	-0.42	-6.44	-0.3	3.34e-10	Behavioural disinhibition (generation interaction);
LUAD	cis	rs6866614	0.608	rs17132288	chr5:131336105	C/T	cg14196790	chr5:131705035	SLC22A5	0.4	6.94	0.32	1.45e-11	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg14343924	chr8:8086146	FLJ10661	-0.5	-8.15	-0.37	4.05e-15	Mood instability;
LUAD	cis	rs1497406	0.744	rs10907282	chr1:16510139	A/G	cg02998240	chr1:16508668	NA	-0.21	-6.46	-0.3	2.91e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs7395662	1.000	rs10839171	chr11:48923034	C/A	cg00717180	chr2:96193071	NA	0.39	7.43	0.34	6.09e-13	HDL cholesterol;
LUAD	cis	rs9814567	0.712	rs9838621	chr3:134332319	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg00339695	chr16:24857497	SLC5A11	0.52	9.48	0.42	1.86e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg18225595	chr11:63971243	STIP1	0.39	6.93	0.32	1.59e-11	Platelet count;
LUAD	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg17264618	chr3:40429014	ENTPD3	-0.38	-8.48	-0.38	3.82e-16	Renal cell carcinoma;
LUAD	cis	rs897984	0.568	rs56083427	chr16:30881298	C/T	cg02466173	chr16:30829666	NA	-0.66	-10.48	-0.45	5.49e-23	Dementia with Lewy bodies;
LUAD	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg06784218	chr1:46089804	CCDC17	0.51	11.21	0.48	1.05e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg21214613	chr1:16344536	HSPB7	-0.34	-6.37	-0.3	4.86e-10	Systolic blood pressure;
LUAD	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.32	7.14	0.33	4.23e-12	Prostate cancer;
LUAD	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg23533926	chr12:111358616	MYL2	-0.43	-7.34	-0.34	1.07e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg21951975	chr1:209979733	IRF6	0.58	7.08	0.33	6.05e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs67981189	0.529	rs2526858	chr14:71412340	T/C	cg15910301	chr14:71632612	NA	-0.42	-6.55	-0.3	1.68e-10	Schizophrenia;
LUAD	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.54	8.43	0.38	5.49e-16	Platelet count;
LUAD	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.78	0.46	4.29e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.88	-0.32	2.19e-11	Neuroticism;
LUAD	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg17971929	chr21:40555470	PSMG1	0.55	8.62	0.39	1.39e-16	Cognitive function;
LUAD	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg05368731	chr17:41323189	NBR1	0.83	16.33	0.62	8.05e-47	Menopause (age at onset);
LUAD	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg02733842	chr7:1102375	C7orf50	-0.61	-9.44	-0.42	2.63e-19	Bronchopulmonary dysplasia;
LUAD	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg05368731	chr17:41323189	NBR1	0.97	20.9	0.71	3.65e-67	Menopause (age at onset);
LUAD	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg17971929	chr21:40555470	PSMG1	0.56	8.86	0.4	2.22e-17	Cognitive function;
LUAD	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.72	-13.42	-0.55	1.83e-34	Tonsillectomy;
LUAD	trans	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg26043149	chr18:55253948	FECH	-0.42	-6.84	-0.32	2.81e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg21475434	chr5:93447410	FAM172A	0.72	7.7	0.35	9.96e-14	Diabetic retinopathy;
LUAD	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.58	0.35	2.14e-13	Tonsillectomy;
LUAD	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg26597838	chr10:835615	NA	1.03	15.89	0.61	6.22e-45	Eosinophil percentage of granulocytes;
LUAD	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg22823121	chr1:150693482	HORMAD1	0.46	9.1	0.4	3.67e-18	Tonsillectomy;
LUAD	cis	rs9837602	1.000	rs9864437	chr3:99764754	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.97	-0.32	1.25e-11	Breast cancer;
LUAD	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg25358565	chr5:93447407	FAM172A	0.61	7.34	0.34	1.12e-12	Diabetic retinopathy;
LUAD	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs239198	0.602	rs17672397	chr6:101288160	C/T	cg09795085	chr6:101329169	ASCC3	0.41	7.14	0.33	4e-12	Menarche (age at onset);
LUAD	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25427524	chr10:38739819	LOC399744	-0.76	-13.65	-0.55	2.11e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs17401966	0.800	rs2039778	chr1:10354601	A/G	cg15208524	chr1:10270712	KIF1B	0.42	6.52	0.3	1.98e-10	Hepatocellular carcinoma;
LUAD	cis	rs17102423	0.768	rs34459643	chr14:65579414	A/T	cg16583315	chr14:65563665	MAX	0.34	6.38	0.3	4.69e-10	Obesity-related traits;
LUAD	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg23625390	chr15:77176239	SCAPER	0.4	6.91	0.32	1.75e-11	Blood metabolite levels;
LUAD	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg23887609	chr12:130822674	PIWIL1	0.4	6.64	0.31	9.93e-11	Menopause (age at onset);
LUAD	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.18	-0.37	3.43e-15	Personality dimensions;
LUAD	cis	rs2839627	0.638	rs8133179	chr21:44272327	G/A	cg03543861	chr21:44258195	NA	0.63	7.84	0.36	3.6e-14	Information processing speed;
LUAD	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.45	-8.49	-0.38	3.52e-16	Menarche (age at onset);
LUAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg04775059	chr7:64541387	NA	0.51	8.38	0.38	8.14e-16	Calcium levels;
LUAD	trans	rs459571	0.920	rs433402	chr9:136898627	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.66	-9.57	-0.42	8.77e-20	Platelet distribution width;
LUAD	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.4	6.82	0.31	3.19e-11	Total body bone mineral density;
LUAD	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg27572855	chr1:25598939	RHD	-0.53	-11.36	-0.48	2.71e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.04	0.32	7.86e-12	Prostate cancer;
LUAD	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg22431228	chr1:16359049	CLCNKA	0.42	7.06	0.32	6.88e-12	Dilated cardiomyopathy;
LUAD	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg20203395	chr5:56204925	C5orf35	-0.84	-11.94	-0.5	1.55e-28	Initial pursuit acceleration;
LUAD	cis	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-7.17	-0.33	3.26e-12	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg08132940	chr7:1081526	C7orf50	-0.79	-10.66	-0.46	1.14e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7843479	0.562	rs4872191	chr8:21824547	A/G	cg03445287	chr8:21823731	XPO7	-0.49	-9.11	-0.4	3.34e-18	Mean corpuscular volume;
LUAD	trans	rs11650494	0.908	rs11658111	chr17:47383994	C/T	cg11430096	chr6:110968061	CDK19	0.87	6.79	0.31	3.86e-11	Prostate cancer;
LUAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg22907277	chr7:1156413	C7orf50	0.59	9.88	0.43	7.7e-21	Longevity;Endometriosis;
LUAD	trans	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	1.04e-10	Diabetic kidney disease;
LUAD	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg22618164	chr12:122356400	WDR66	-0.74	-13.55	-0.55	5.39e-35	Mean corpuscular volume;
LUAD	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg10909506	chr17:38081995	ORMDL3	0.41	7.19	0.33	3.04e-12	Self-reported allergy;
LUAD	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg13319975	chr6:146136371	FBXO30	-0.62	-10.9	-0.47	1.53e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11167764	1.000	rs13354528	chr5:141476769	C/T	cg23435118	chr5:141488016	NDFIP1	-0.48	-7.22	-0.33	2.36e-12	Crohn's disease;
LUAD	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.43	0.3	3.42e-10	Joint mobility (Beighton score);
LUAD	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg21028142	chr17:79581711	NPLOC4	0.42	8.85	0.4	2.44e-17	Eye color traits;
LUAD	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.9	0.36	2.47e-14	Morning vs. evening chronotype;
LUAD	cis	rs250585	0.736	rs30015	chr16:23413774	T/C	cg00143387	chr16:23521605	GGA2	0.62	8.9	0.4	1.63e-17	Egg allergy;
LUAD	cis	rs1868673	1.000	rs28514580	chr3:150154365	G/T	cg04908077	chr3:150187338	NA	-0.31	-6.35	-0.3	5.53e-10	Waist circumference;
LUAD	cis	rs2857891	1.000	rs2638092	chr11:6961746	G/A	cg04053776	chr11:6947353	ZNF215	0.48	6.74	0.31	5.34e-11	Response to cytadine analogues (cytosine arabinoside);
LUAD	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg09796270	chr17:17721594	SREBF1	0.37	7.13	0.33	4.49e-12	Total body bone mineral density;
LUAD	cis	rs9487051	0.799	rs830553	chr6:109550017	T/G	cg12927641	chr6:109611667	NA	-0.39	-6.58	-0.3	1.37e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs727505	0.909	rs1031957	chr7:124627301	T/C	cg23710748	chr7:124431027	NA	-0.44	-8.56	-0.38	2.16e-16	Lewy body disease;
LUAD	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg07936489	chr17:37558343	FBXL20	0.51	6.98	0.32	1.14e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs9814567	0.712	rs4955545	chr3:134332926	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.94	-0.53	1.62e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs243505	0.528	rs6977453	chr7:148474746	A/G	cg09806900	chr7:148480153	CUL1	0.48	8.14	0.37	4.42e-15	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2239547	0.522	rs2564947	chr3:53046216	C/T	cg11645453	chr3:52864694	ITIH4	-0.53	-10.18	-0.44	6.43e-22	Schizophrenia;
LUAD	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg12034118	chr1:209979487	IRF6	0.53	7.09	0.33	5.74e-12	Cleft lip with or without cleft palate;
LUAD	trans	rs970548	0.606	rs12355888	chr10:45931564	G/T	cg14222797	chr10:16859974	RSU1	-0.68	-7.2	-0.33	2.82e-12	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg09436375	chr6:42928200	GNMT	0.29	8.32	0.37	1.23e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03737984	chr11:33280157	HIPK3	0.42	6.42	0.3	3.74e-10	Gut microbiome composition (summer);
LUAD	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-10.94	-0.47	1.07e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg15557168	chr22:42548783	NA	-0.36	-6.36	-0.3	5.22e-10	Cognitive function;
LUAD	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg04414720	chr1:150670196	GOLPH3L	0.73	13.42	0.55	1.78e-34	Tonsillectomy;
LUAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03452623	chr4:187889614	NA	-0.82	-16.97	-0.64	1.22e-49	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs220324	0.688	rs9637293	chr21:43570977	G/A	cg08841829	chr21:43638893	ABCG1	-0.51	-7.08	-0.33	5.91e-12	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg09184832	chr6:79620586	NA	-0.52	-9.83	-0.43	1.14e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg06623918	chr6:96969491	KIAA0776	0.87	17.08	0.64	3.8300000000000002e-50	Headache;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19763735	chr2:170550826	C2orf77;PHOSPHO2;KLHL23	-0.43	-6.56	-0.3	1.62e-10	Height;
LUAD	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.9	-0.36	2.39e-14	Diabetic kidney disease;
LUAD	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06544989	chr22:39130855	UNC84B	-0.43	-7.84	-0.36	3.7e-14	Menopause (age at onset);
LUAD	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.37	-7.31	-0.33	1.35e-12	Total body bone mineral density;
LUAD	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg03929089	chr4:120376271	NA	-0.91	-17.08	-0.64	3.96e-50	Coronary artery disease;
LUAD	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg10523679	chr1:76189770	ACADM	-0.73	-11.4	-0.48	1.92e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg03605463	chr16:89740564	NA	0.67	11.44	0.49	1.34e-26	Vitiligo;
LUAD	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg03037974	chr15:76606532	NA	0.37	7.93	0.36	2e-14	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.38e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs752010	0.714	rs7515948	chr1:42079046	T/G	cg06885757	chr1:42089581	HIVEP3	0.47	11.03	0.47	4.89e-25	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs7394190	0.748	rs4114992	chr10:75566829	A/G	cg02286717	chr10:75415704	SYNPO2L	-0.36	-6.37	-0.3	4.83e-10	Incident atrial fibrillation;
LUAD	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.91	9.57	0.42	9.15e-20	Initial pursuit acceleration;
LUAD	cis	rs3774830	0.714	rs7657964	chr4:5466327	C/G	cg26943120	chr4:5472116	STK32B	-0.38	-7.79	-0.35	5.3e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg13722127	chr7:150037890	RARRES2	0.45	7.77	0.35	5.9e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4819852	1.000	rs7285377	chr22:19987202	G/T	cg07821417	chr22:19972146	ARVCF	0.43	7.7	0.35	9.63e-14	Pulse pressure;
LUAD	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.66	-0.43	4.31e-20	Bone mineral density;
LUAD	cis	rs2066819	1.000	rs11171803	chr12:56718422	T/C	cg26714650	chr12:56694279	CS	-0.88	-6.79	-0.31	3.89e-11	Psoriasis vulgaris;
LUAD	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg11189052	chr15:85197271	WDR73	0.65	8.44	0.38	5.06e-16	Schizophrenia;
LUAD	cis	rs7616330	0.836	rs73118214	chr3:71047396	A/C	cg20891481	chr3:71115714	FOXP1	0.5	8.18	0.37	3.34e-15	QT interval;
LUAD	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg09517075	chr8:22133004	PIWIL2	0.46	8.54	0.38	2.37e-16	Hypertriglyceridemia;
LUAD	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg06558623	chr16:89946397	TCF25	0.61	6.55	0.3	1.66e-10	Skin colour saturation;
LUAD	cis	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg12292205	chr6:26970375	C6orf41	-0.48	-6.49	-0.3	2.35e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg26343298	chr8:95960752	TP53INP1	0.37	7.82	0.36	4.12e-14	Type 2 diabetes;
LUAD	cis	rs367943	0.698	rs6594746	chr5:112995895	A/C	cg12552261	chr5:112820674	MCC	-0.5	-9.03	-0.4	5.98e-18	Type 2 diabetes;
LUAD	cis	rs68170813	0.559	rs6964966	chr7:106933099	C/G	cg23024343	chr7:107201750	COG5	0.5	7.36	0.34	9.88e-13	Coronary artery disease;
LUAD	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg22482690	chr17:47019901	SNF8	0.44	8.37	0.38	8.71e-16	Type 2 diabetes;
LUAD	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg14186256	chr22:23484241	RTDR1	0.49	8.24	0.37	2.14e-15	Bone mineral density;
LUAD	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg11965913	chr1:205819406	PM20D1	-0.4	-6.52	-0.3	1.98e-10	Prostate-specific antigen levels;
LUAD	trans	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.52	-0.34	3.4e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg18833306	chr6:118973337	C6orf204	-0.49	-7.27	-0.33	1.75e-12	Renal cell carcinoma;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg19354750	chr17:61554413	ACE	-0.37	-6.36	-0.3	5.2e-10	Vertical cup-disc ratio;
LUAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	7.27	0.33	1.73e-12	Alzheimer's disease;
LUAD	cis	rs2777491	1.000	rs11631770	chr15:41737059	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.69	-13.36	-0.54	3.39e-34	Ulcerative colitis;
LUAD	cis	rs9302690	1.000	rs75700677	chr16:57480315	G/A	cg27017172	chr16:57497170	POLR2C	0.97	8.06	0.37	7.7e-15	Blood protein levels;
LUAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs9462027	0.628	rs9469891	chr6:34767396	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.71	-0.39	7.17e-17	Systemic lupus erythematosus;
LUAD	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg02176678	chr2:219576539	TTLL4	0.74	14.81	0.58	2.93e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs11771526	0.792	rs17161105	chr7:32299187	T/C	cg13207630	chr7:32358064	NA	0.57	7.25	0.33	2.03e-12	Body mass index;
LUAD	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg12310025	chr6:25882481	NA	-0.44	-6.71	-0.31	6.32e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2797685	0.898	rs697693	chr1:7886424	C/T	cg04725166	chr1:7887271	PER3	-0.45	-6.96	-0.32	1.32e-11	Crohn's disease;
LUAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.58	0.3	1.42e-10	Prudent dietary pattern;
LUAD	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg00933542	chr6:150070202	PCMT1	0.45	9.2	0.41	1.68e-18	Lung cancer;
LUAD	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg09184832	chr6:79620586	NA	-0.51	-9.53	-0.42	1.28e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg09060608	chr5:178986726	RUFY1	0.63	9.58	0.42	8.3e-20	Lung cancer;
LUAD	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg11645453	chr3:52864694	ITIH4	0.45	9.1	0.4	3.47e-18	Bipolar disorder;
LUAD	cis	rs7107174	0.792	rs2888465	chr11:77945807	T/C	cg02023728	chr11:77925099	USP35	0.45	7.04	0.32	7.77e-12	Testicular germ cell tumor;
LUAD	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-12.07	-0.51	5.07e-29	Bipolar disorder;
LUAD	cis	rs6752107	0.935	rs10929322	chr2:234149702	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.52	-9.22	-0.41	1.37e-18	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs887829	0.570	rs10203266	chr2:234596368	G/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.65	-0.42	4.81e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3772130	0.962	rs9826473	chr3:121556219	C/T	cg20356878	chr3:121714668	ILDR1	0.52	8.57	0.38	1.98e-16	Cognitive performance;
LUAD	trans	rs783540	0.746	rs7165125	chr15:83297936	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.65	-0.31	8.86e-11	Schizophrenia;
LUAD	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg02269571	chr22:50332266	NA	-0.64	-9.75	-0.43	2.15e-20	Schizophrenia;
LUAD	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg11344533	chr11:111475393	SIK2	-0.37	-6.77	-0.31	4.23e-11	Primary sclerosing cholangitis;
LUAD	cis	rs4692589	1.000	rs4692589	chr4:170935245	C/T	cg19918862	chr4:170955249	NA	-0.29	-7.07	-0.33	6.35e-12	Anxiety disorder;
LUAD	cis	rs965604	0.965	rs4299116	chr15:78766194	T/A	cg18825076	chr15:78729989	IREB2	-0.42	-7.19	-0.33	2.95e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	7.49	0.34	4.14e-13	Schizophrenia;
LUAD	cis	rs9644630	0.841	rs6984449	chr8:19327959	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.36	6.87	0.32	2.35e-11	Oropharynx cancer;
LUAD	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-14.51	-0.58	5.23e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.39	-0.3	4.34e-10	Aortic root size;
LUAD	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg13010199	chr12:38710504	ALG10B	0.38	6.37	0.3	5.04e-10	Bladder cancer;
LUAD	cis	rs7187994	0.895	rs12933276	chr16:84770867	C/T	cg07647771	chr16:84786436	USP10	-0.37	-9.08	-0.4	4.25e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg04287289	chr16:89883240	FANCA	0.7	12.74	0.53	1.1e-31	Vitiligo;
LUAD	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg22598563	chr5:131563921	P4HA2	-0.3	-7.44	-0.34	5.78e-13	Blood metabolite levels;
LUAD	trans	rs2797160	1.000	rs1739349	chr6:126014984	G/C	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.58e-17	Endometrial cancer;
LUAD	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg03563238	chr19:33554763	RHPN2	-0.33	-8.02	-0.36	1.02e-14	Colorectal cancer;
LUAD	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.31	0.33	1.36e-12	Morning vs. evening chronotype;
LUAD	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg18944383	chr4:111397179	ENPEP	0.38	7.62	0.35	1.66e-13	Height;
LUAD	cis	rs17155006	0.621	rs436573	chr7:107739906	A/T	cg05962710	chr7:107745446	LAMB4	-0.36	-7.78	-0.35	5.54e-14	Pneumococcal bacteremia;
LUAD	cis	rs7843479	0.930	rs4871903	chr8:21827833	C/T	cg03445287	chr8:21823731	XPO7	0.44	7.97	0.36	1.45e-14	Mean corpuscular volume;
LUAD	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg21475434	chr5:93447410	FAM172A	0.72	8.17	0.37	3.56e-15	Diabetic retinopathy;
LUAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg13560548	chr3:10150139	C3orf24	0.49	7.73	0.35	7.96e-14	Alzheimer's disease;
LUAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg04025307	chr7:1156635	C7orf50	0.6	6.84	0.32	2.78e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08109568	chr15:31115862	NA	-0.79	-13.64	-0.55	2.35e-35	Huntington's disease progression;
LUAD	cis	rs11048434	0.649	rs11613650	chr12:9060396	T/C	cg13575925	chr12:9217583	LOC144571	0.37	6.75	0.31	4.91e-11	Sjögren's syndrome;
LUAD	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.4	-6.44	-0.3	3.33e-10	Longevity;Endometriosis;
LUAD	cis	rs847851	1.000	rs1535001	chr6:34927280	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-7.31	-0.34	1.31e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.35	-7.36	-0.34	9.91e-13	Hemoglobin concentration;
LUAD	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.69	0.31	7.14e-11	Cardiac Troponin-T levels;
LUAD	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg04944784	chr2:26401820	FAM59B	-0.71	-9.96	-0.44	3.85e-21	Gut microbiome composition (summer);
LUAD	cis	rs4074961	0.527	rs10908355	chr1:38035286	G/T	cg12696750	chr1:38022466	DNALI1	0.37	6.47	0.3	2.7e-10	Axial length;
LUAD	cis	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg26958806	chr6:27640298	NA	0.64	6.53	0.3	1.91e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.83	-16.85	-0.63	4.28e-49	Birth weight;
LUAD	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg11901034	chr3:128598214	ACAD9	-0.55	-8.74	-0.39	5.33e-17	IgG glycosylation;
LUAD	cis	rs1232027	0.656	rs1650671	chr5:79960268	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.99	-0.32	1.07e-11	Huntington's disease progression;
LUAD	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg06558623	chr16:89946397	TCF25	1.18	10.49	0.45	4.78e-23	Skin colour saturation;
LUAD	cis	rs73086581	0.687	rs16989002	chr20:3850703	G/C	cg02187196	chr20:3869020	PANK2	0.49	6.8	0.31	3.54e-11	Response to antidepressants in depression;
LUAD	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg21028142	chr17:79581711	NPLOC4	0.38	7.58	0.35	2.26e-13	Eye color traits;
LUAD	trans	rs1493916	0.721	rs4799723	chr18:31367050	T/G	cg15819921	chr19:927150	ARID3A	-0.48	-8.07	-0.37	7.28e-15	Life satisfaction;
LUAD	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg19622623	chr12:86230825	RASSF9	0.43	7.59	0.35	2e-13	Major depressive disorder;
LUAD	cis	rs72766638	0.848	rs11789898	chr9:136925663	A/C	cg13789015	chr9:136890014	NCRNA00094	-0.58	-7.74	-0.35	7.2e-14	Mosquito bite size;
LUAD	cis	rs300774	1.000	rs300793	chr2:108411	A/T	cg21211680	chr2:198530	NA	-0.47	-6.77	-0.31	4.21e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs9399401	0.633	rs1329705	chr6:142753338	G/A	cg03128060	chr6:142623767	GPR126	0.46	8.95	0.4	1.15e-17	Chronic obstructive pulmonary disease;
LUAD	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg05283184	chr6:79620031	NA	-0.6	-12.21	-0.51	1.37e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg22907277	chr7:1156413	C7orf50	0.72	8.55	0.38	2.29e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7432375	0.610	rs7633629	chr3:136517028	T/A	cg15507776	chr3:136538369	TMEM22	0.39	7.01	0.32	9.24e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg02734326	chr4:10020555	SLC2A9	-0.53	-9.14	-0.41	2.7e-18	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg23711669	chr6:146136114	FBXO30	0.39	6.62	0.31	1.11e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.83	0.36	4.09e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg02079420	chr8:82753780	SNX16	-0.43	-8.69	-0.39	7.83e-17	Diastolic blood pressure;
LUAD	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.32	6.84	0.32	2.86e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12541635	0.677	rs7460291	chr8:107057861	A/G	cg10147462	chr8:107024639	NA	0.52	9.28	0.41	9.08e-19	Age of smoking initiation;
LUAD	trans	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg19862616	chr7:65841803	NCRNA00174	1.06	27.31	0.8	2.21e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.38	-9.96	-0.44	3.82e-21	Total body bone mineral density;
LUAD	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.53	7.58	0.35	2.19e-13	Platelet count;
LUAD	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg01788221	chr16:89496183	ANKRD11	-0.37	-7.11	-0.33	4.83e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	14.91	0.59	1.01e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg16479474	chr6:28041457	NA	0.43	7.38	0.34	8.39e-13	Depression;
LUAD	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg16325326	chr1:53192061	ZYG11B	-0.63	-11.72	-0.5	1.12e-27	Monocyte count;
LUAD	cis	rs9902453	0.967	rs9904336	chr17:28357080	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.26	-0.41	1e-18	Coffee consumption (cups per day);
LUAD	cis	rs657075	0.697	rs36108085	chr5:131686479	T/G	cg21138405	chr5:131827807	IRF1	0.53	6.55	0.3	1.66e-10	Rheumatoid arthritis;
LUAD	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.44	8.0	0.36	1.24e-14	Systemic lupus erythematosus;
LUAD	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg13319975	chr6:146136371	FBXO30	-0.6	-10.16	-0.44	7.87e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.11	-0.33	5.14e-12	Coronary artery disease;
LUAD	cis	rs250677	0.522	rs919731	chr5:148352150	T/C	cg12140854	chr5:148520817	ABLIM3	0.57	9.13	0.41	2.82e-18	Breast cancer;
LUAD	cis	rs4789939	0.528	rs2377003	chr17:76878902	T/C	cg19944656	chr17:76876040	TIMP2	-0.61	-7.2	-0.33	2.77e-12	Dupuytren's disease;
LUAD	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg06108461	chr20:60628389	TAF4	-0.82	-13.97	-0.56	9.79e-37	Body mass index;
LUAD	cis	rs4664304	0.772	rs6737904	chr2:160872526	G/C	cg23995753	chr2:160760732	LY75	-0.43	-7.33	-0.34	1.15e-12	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs1973993	0.691	rs4000303	chr1:96913765	A/G	cg10631902	chr5:14652156	NA	0.75	15.84	0.61	1.02e-44	Weight;
LUAD	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg06740227	chr12:86229804	RASSF9	-0.45	-7.86	-0.36	3.22e-14	Major depressive disorder;
LUAD	cis	rs2404602	0.598	rs11855999	chr15:76627333	A/C	cg23625390	chr15:77176239	SCAPER	-0.44	-6.42	-0.3	3.71e-10	Blood metabolite levels;
LUAD	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg22532475	chr10:104410764	TRIM8	-0.43	-8.53	-0.38	2.67e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg15445000	chr17:37608096	MED1	0.43	7.98	0.36	1.35e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg14343924	chr8:8086146	FLJ10661	-0.5	-7.65	-0.35	1.4e-13	Mood instability;
LUAD	cis	rs68170813	0.559	rs80153759	chr7:106944145	C/A	cg23024343	chr7:107201750	COG5	0.5	7.24	0.33	2.07e-12	Coronary artery disease;
LUAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg04025307	chr7:1156635	C7orf50	0.49	8.33	0.38	1.13e-15	Longevity;Endometriosis;
LUAD	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	14.91	0.59	1.08e-40	Smoking behavior;
LUAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	13.0	0.53	9.93e-33	Prudent dietary pattern;
LUAD	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg22815214	chr1:201083145	CACNA1S	-0.47	-8.03	-0.36	9.43e-15	Permanent tooth development;
LUAD	cis	rs12545109	0.765	rs2438063	chr8:57384360	A/G	cg21220214	chr8:57350948	NA	0.63	9.06	0.4	4.86e-18	Obesity-related traits;
LUAD	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	7.55	0.34	2.77e-13	Menopause (age at onset);
LUAD	cis	rs4243830	1.000	rs10158949	chr1:6583701	T/C	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.78	-8.35	-0.38	9.8e-16	Body mass index;
LUAD	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.46e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13082711	0.648	rs13085782	chr3:27404390	C/G	cg02860705	chr3:27208620	NA	0.74	10.93	0.47	1.12e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6840360	0.533	rs4696297	chr4:152725838	T/G	cg22705602	chr4:152727874	NA	0.46	8.74	0.39	5.43e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs11078597	0.708	rs7503952	chr17:1649259	G/C	cg18436246	chr17:1640651	WDR81	0.78	12.27	0.51	8e-30	Serum albumin level;
LUAD	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-6.96	-0.32	1.29e-11	IgG glycosylation;
LUAD	cis	rs4900538	0.963	rs942023	chr14:102972170	T/C	cg18135206	chr14:102964638	TECPR2	1.04	23.07	0.75	7.91e-77	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg15900387	chr1:150738905	CTSS	-0.37	-6.81	-0.31	3.47e-11	Melanoma;
LUAD	cis	rs2992756	0.617	rs3007719	chr1:18811668	C/T	cg24076588	chr1:18808559	KLHDC7A	0.4	6.36	0.3	5.09e-10	Breast cancer;
LUAD	cis	rs12681287	0.888	rs2976201	chr8:87335937	T/C	cg27223183	chr8:87520930	FAM82B	-0.67	-9.55	-0.42	1.1e-19	Caudate activity during reward;
LUAD	cis	rs12612619	0.732	rs1078809	chr2:27288915	C/T	cg00617064	chr2:27272375	NA	-0.38	-7.2	-0.33	2.76e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs6430585	0.591	rs75223002	chr2:136525309	G/T	cg07169764	chr2:136633963	MCM6	0.79	8.99	0.4	8.57e-18	Corneal structure;
LUAD	cis	rs7614311	0.636	rs56165216	chr3:63916620	C/T	cg22134162	chr3:63841271	THOC7	-0.4	-7.11	-0.33	5.03e-12	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg22907277	chr7:1156413	C7orf50	0.49	8.29	0.37	1.55e-15	Longevity;Endometriosis;
LUAD	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg18854424	chr1:2615690	NA	0.34	7.58	0.35	2.15e-13	Multiple sclerosis;
LUAD	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg21100191	chr22:23484243	RTDR1	0.71	12.75	0.53	9.69e-32	Bone mineral density;
LUAD	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg00666640	chr1:248458726	OR2T12	0.3	7.24	0.33	2.14e-12	Common traits (Other);
LUAD	cis	rs6500395	1.000	rs9930199	chr16:48571263	A/G	cg04672837	chr16:48644449	N4BP1	0.37	6.39	0.3	4.51e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg15992532	chr8:142229932	SLC45A4	0.49	8.77	0.39	4.58e-17	Immature fraction of reticulocytes;
LUAD	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg12062639	chr20:23401060	NAPB	1.09	11.23	0.48	8.38e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs877282	0.945	rs877280	chr10:771599	C/T	cg06581033	chr10:766294	NA	-0.57	-7.68	-0.35	1.11e-13	Uric acid levels;
LUAD	cis	rs4523957	0.533	rs170043	chr17:2200434	G/T	cg16513277	chr17:2031491	SMG6	-0.63	-8.81	-0.39	3.34e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7833986	0.501	rs17812659	chr8:56889862	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.92	14.56	0.58	3.18e-39	Height;
LUAD	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg25767906	chr1:53392781	SCP2	-0.4	-7.37	-0.34	8.8e-13	Monocyte count;
LUAD	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg09137382	chr11:130731461	NA	0.4	7.42	0.34	6.48e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2735413	0.958	rs11150034	chr16:78066369	G/A	cg04733911	chr16:78082701	NA	-0.32	-7.44	-0.34	5.67e-13	Systolic blood pressure (alcohol consumption interaction);
LUAD	trans	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg19676328	chr12:49525230	TUBA1B	-0.69	-11.09	-0.47	2.88e-25	Total cholesterol levels;
LUAD	cis	rs427394	0.659	rs274675	chr5:6755319	C/T	cg14682080	chr5:6737778	POLS	0.32	6.95	0.32	1.36e-11	Menopause (age at onset);
LUAD	trans	rs2270927	0.790	rs6874435	chr5:75574855	A/G	cg13563193	chr19:33072644	PDCD5	0.72	8.22	0.37	2.51e-15	Mean corpuscular volume;
LUAD	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.15	0.44	8.6e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg03037974	chr15:76606532	NA	0.4	8.86	0.4	2.3e-17	Blood metabolite levels;
LUAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.41	-8.55	-0.38	2.24e-16	Lymphocyte counts;
LUAD	cis	rs12541635	1.000	rs1896919	chr8:107090357	C/G	cg10147462	chr8:107024639	NA	-0.41	-7.41	-0.34	6.94e-13	Age of smoking initiation;
LUAD	cis	rs6446731	0.517	rs2858087	chr4:3268892	A/T	cg08886695	chr4:3369023	RGS12	0.47	7.81	0.35	4.67e-14	Mean platelet volume;
LUAD	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg01444801	chr10:135216882	MTG1	-0.54	-7.28	-0.33	1.59e-12	Systemic lupus erythematosus;
LUAD	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18876405	chr7:65276391	NA	-0.42	-6.79	-0.31	3.87e-11	Aortic root size;
LUAD	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg14530993	chr4:882597	GAK	0.71	6.78	0.31	3.99e-11	Parkinson's disease;
LUAD	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg15605315	chr1:45957053	TESK2	-0.41	-6.43	-0.3	3.54e-10	High light scatter reticulocyte count;
LUAD	cis	rs34734847	1.000	rs56179458	chr12:121157535	G/A	cg21892295	chr12:121157589	UNC119B	-0.45	-8.21	-0.37	2.77e-15	Mean corpuscular volume;
LUAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg11062466	chr8:58055876	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg01689657	chr7:91764605	CYP51A1	0.3	7.29	0.33	1.56e-12	Breast cancer;
LUAD	cis	rs231513	0.954	rs231506	chr17:41970191	A/G	cg26893861	chr17:41843967	DUSP3	-0.53	-6.35	-0.3	5.43e-10	Cognitive function;
LUAD	cis	rs1595825	1.000	rs6434950	chr2:198869979	A/G	cg00982548	chr2:198649783	BOLL	-0.6	-8.64	-0.39	1.18e-16	Ulcerative colitis;
LUAD	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg03037974	chr15:76606532	NA	0.38	8.19	0.37	3.2e-15	Blood metabolite levels;
LUAD	trans	rs12517041	0.872	rs1896723	chr5:23303194	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.57	-0.3	1.47e-10	Calcium levels;
LUAD	cis	rs6494488	0.500	rs72741385	chr15:64809311	A/T	cg08069370	chr15:64387884	SNX1	-0.75	-6.73	-0.31	5.69e-11	Coronary artery disease;
LUAD	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg13319975	chr6:146136371	FBXO30	-0.63	-10.92	-0.47	1.3e-24	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1997103	1.000	rs7779040	chr7:55412947	T/C	cg20935933	chr6:143382018	AIG1	0.55	7.8	0.35	4.76e-14	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2455826	0.521	rs13062323	chr3:15817502	T/G	cg16303742	chr3:15540471	COLQ	-0.39	-6.48	-0.3	2.54e-10	Inflammatory skin disease;
LUAD	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg03676636	chr4:99064102	C4orf37	0.32	8.21	0.37	2.66e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4853525	0.859	rs11897136	chr2:191711080	C/T	cg27211696	chr2:191398769	TMEM194B	-0.36	-6.41	-0.3	3.93e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.03	0.32	8.26e-12	Menopause (age at onset);
LUAD	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg00666640	chr1:248458726	OR2T12	0.34	8.19	0.37	3.11e-15	Common traits (Other);
LUAD	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg07423050	chr13:99094983	FARP1	-0.54	-9.05	-0.4	5.31e-18	Neuroticism;
LUAD	cis	rs77972916	0.611	rs10495899	chr2:43602304	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-8.22	-0.37	2.53e-15	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs3741798	1.000	rs61922052	chr12:12497620	A/G	cg08615371	chr12:12503544	MANSC1	0.74	6.8	0.31	3.67e-11	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs208520	0.690	rs851468	chr6:66825875	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.18	-0.64	1.47e-50	Exhaled nitric oxide output;
LUAD	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg11833968	chr6:79620685	NA	-0.44	-8.27	-0.37	1.74e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6424115	0.708	rs34570472	chr1:24191720	A/G	cg15997130	chr1:24165203	NA	-0.48	-7.43	-0.34	6.18e-13	Immature fraction of reticulocytes;
LUAD	cis	rs2688608	0.736	rs2227566	chr10:75673731	C/T	cg19442545	chr10:75533431	FUT11	-0.39	-6.58	-0.3	1.38e-10	Inflammatory bowel disease;
LUAD	cis	rs7274811	0.634	rs4911356	chr20:32255034	T/C	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.47	-7.27	-0.33	1.74e-12	Height;
LUAD	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg09509183	chr1:209979624	IRF6	0.37	6.52	0.3	2e-10	Monobrow;
LUAD	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.11e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4594175	0.677	rs7149846	chr14:51739654	A/C	cg23942311	chr14:51606299	NA	0.51	8.82	0.39	3.08e-17	Cancer;
LUAD	cis	rs2075165	0.901	rs1804999	chr1:156219450	A/G	cg20302342	chr1:156215951	PAQR6	0.39	8.85	0.4	2.45e-17	Tonsillectomy;
LUAD	cis	rs12545109	0.879	rs2670015	chr8:57376607	T/A	cg21220214	chr8:57350948	NA	-0.66	-9.13	-0.41	2.89e-18	Obesity-related traits;
LUAD	cis	rs7336332	0.598	rs10220056	chr13:28003781	T/G	cg22138327	chr13:27999177	GTF3A	0.77	9.9	0.43	6.38e-21	Weight;
LUAD	cis	rs4006360	0.575	rs7503162	chr17:39233899	A/G	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.06	0.36	7.88e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg13047869	chr3:10149882	C3orf24	0.53	8.04	0.36	9.37e-15	Alzheimer's disease;
LUAD	cis	rs1018836	0.608	rs1033348	chr8:91464169	C/G	cg16814680	chr8:91681699	NA	-0.53	-8.67	-0.39	9.54e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13082711	0.558	rs640912	chr3:27364092	C/A	cg02860705	chr3:27208620	NA	0.5	8.27	0.37	1.8e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs9972944	0.651	rs12601958	chr17:63820304	A/G	cg07283582	chr17:63770753	CCDC46	-0.45	-9.56	-0.42	1.01e-19	Total body bone mineral density;
LUAD	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.42	-7.84	-0.36	3.64e-14	Systemic lupus erythematosus;
LUAD	cis	rs3018712	0.532	rs948863	chr11:68420974	G/A	cg16797656	chr11:68205561	LRP5	-0.43	-6.62	-0.31	1.11e-10	Total body bone mineral density;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27274463	chr12:110338238	TCHP	-0.53	-6.41	-0.3	3.88e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.4	-7.43	-0.34	5.97e-13	IgG glycosylation;
LUAD	cis	rs6696239	0.513	rs4653514	chr1:227753082	T/C	cg12133451	chr1:227746453	NA	0.37	6.55	0.3	1.68e-10	Height;
LUAD	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	10.95	0.47	9.73e-25	Hip circumference adjusted for BMI;
LUAD	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	12.54	0.52	7.14e-31	Monocyte percentage of white cells;
LUAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg15117754	chr3:10150083	C3orf24	-0.44	-7.1	-0.33	5.25e-12	Alzheimer's disease;
LUAD	cis	rs28595532	0.688	rs116566508	chr4:119619195	G/A	cg21605333	chr4:119757512	SEC24D	0.86	7.91	0.36	2.3e-14	Cannabis dependence symptom count;
LUAD	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg21016266	chr12:122356598	WDR66	0.67	12.05	0.51	6.07e-29	Mean corpuscular volume;
LUAD	cis	rs478304	0.934	rs509206	chr11:65493807	C/T	cg27068330	chr11:65405492	SIPA1	0.55	8.49	0.38	3.63e-16	Acne (severe);
LUAD	cis	rs438465	1.000	rs391468	chr6:169809099	C/T	cg11181693	chr6:169825345	NA	-0.67	-8.61	-0.39	1.46e-16	Corneal astigmatism;
LUAD	cis	rs4774899	0.966	rs2585082	chr15:57257958	A/C	cg14026238	chr15:57616123	NA	0.34	6.47	0.3	2.78e-10	Urinary tract infection frequency;
LUAD	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg23231163	chr10:75533350	FUT11	-0.51	-9.37	-0.41	4.29e-19	Inflammatory bowel disease;
LUAD	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg06092702	chr1:163392909	NA	-0.36	-8.33	-0.38	1.17e-15	Motion sickness;
LUAD	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg16447950	chr5:562315	NA	-0.41	-6.58	-0.3	1.4e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs2797160	0.967	rs6910786	chr6:126017141	A/T	cg05901451	chr6:126070800	HEY2	0.44	6.45	0.3	3.12e-10	Endometrial cancer;
LUAD	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg20469991	chr17:27169893	C17orf63	-0.51	-6.45	-0.3	3.05e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg22963979	chr7:1858916	MAD1L1	-0.69	-12.26	-0.51	8.62e-30	Bipolar disorder and schizophrenia;
LUAD	cis	rs9807989	0.507	rs2110659	chr2:103043867	G/A	cg03938978	chr2:103052716	IL18RAP	0.46	10.49	0.45	4.89e-23	Asthma;
LUAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.91	0.36	2.29e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4711350	1.000	rs4711350	chr6:33741716	A/G	cg18005901	chr6:33739558	LEMD2	-0.52	-7.53	-0.34	3.17e-13	Schizophrenia;
LUAD	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11644478	chr21:40555479	PSMG1	0.67	11.26	0.48	6.75e-26	Cognitive function;
LUAD	cis	rs4786125	0.665	rs1565633	chr16:6919428	G/C	cg03623568	chr16:6915990	A2BP1	-0.48	-10.24	-0.45	3.77e-22	Heart rate variability traits (SDNN);
LUAD	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg19678392	chr7:94953810	PON1	-0.55	-7.24	-0.33	2.15e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-7.38	-0.34	8.3e-13	Alzheimer's disease (late onset);
LUAD	trans	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg01620082	chr3:125678407	NA	-1.1	-10.56	-0.46	2.69e-23	Depression;
LUAD	cis	rs4481887	0.741	rs28468416	chr1:248564451	G/T	cg00666640	chr1:248458726	OR2T12	0.27	6.35	0.3	5.46e-10	Common traits (Other);
LUAD	cis	rs10140922	0.966	rs10135277	chr14:35823231	A/G	cg07166546	chr14:35805898	NA	0.25	6.36	0.3	5.19e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg12419862	chr22:24373484	LOC391322	-0.73	-13.11	-0.54	3.34e-33	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9462027	0.630	rs9469871	chr6:34745007	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.0	-0.4	7.78e-18	Systemic lupus erythematosus;
LUAD	cis	rs3806843	0.547	rs246010	chr5:140336635	A/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs79839061	0.732	rs35177456	chr4:828994	C/T	cg07828340	chr4:882639	GAK	1.02	9.11	0.4	3.34e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs999737	0.922	rs10483812	chr14:69017843	C/G	cg04147497	chr14:69052728	RAD51L1	-0.43	-6.43	-0.3	3.49e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs12900413	0.687	rs8035472	chr15:90313432	T/C	cg24249390	chr15:90295951	MESP1	-0.34	-6.83	-0.32	2.94e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg19073576	chr13:113808243	NA	-0.44	-6.49	-0.3	2.47e-10	Platelet distribution width;
LUAD	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg00666640	chr1:248458726	OR2T12	0.3	7.24	0.33	2.14e-12	Common traits (Other);
LUAD	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg03289416	chr15:75166202	SCAMP2	0.6	10.3	0.45	2.36e-22	Breast cancer;
LUAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg05434287	chr7:2030229	MAD1L1	0.39	6.38	0.3	4.76e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs752010	0.695	rs11210509	chr1:42109311	A/G	cg06885757	chr1:42089581	HIVEP3	0.38	8.15	0.37	4.05e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg01097406	chr16:89675127	NA	-0.31	-6.5	-0.3	2.21e-10	Vitiligo;
LUAD	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg19622623	chr12:86230825	RASSF9	-0.47	-8.09	-0.37	6.58e-15	Major depressive disorder;
LUAD	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg13606994	chr1:44402422	ARTN	-0.33	-6.79	-0.31	3.82e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg08997352	chr12:9597637	DDX12	-0.65	-11.47	-0.49	1.03e-26	Breast size;
LUAD	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg03948781	chr1:205179583	DSTYK	0.33	6.47	0.3	2.7e-10	Red blood cell count;
LUAD	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg05535760	chr7:792225	HEATR2	-0.82	-9.66	-0.43	4.49e-20	Cerebrospinal P-tau181p levels;
LUAD	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg17863274	chr19:49399704	TULP2	-0.57	-9.03	-0.4	6.02e-18	Red cell distribution width;
LUAD	cis	rs17401966	0.800	rs12122029	chr1:10339822	G/A	cg15208524	chr1:10270712	KIF1B	0.43	6.81	0.31	3.43e-11	Hepatocellular carcinoma;
LUAD	cis	rs12155623	0.504	rs10808736	chr8:49873039	C/A	cg22283653	chr8:49824208	NA	0.45	8.97	0.4	9.65e-18	Sudden cardiac arrest;
LUAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg02869364	chr7:1081709	C7orf50	-0.51	-6.56	-0.3	1.53e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6594713	0.837	rs13180516	chr5:112732998	G/A	cg12552261	chr5:112820674	MCC	0.46	6.72	0.31	5.84e-11	Brain cytoarchitecture;
LUAD	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg02176678	chr2:219576539	TTLL4	0.75	15.22	0.59	4.98e-42	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg09650180	chr20:62225654	GMEB2	-0.46	-6.49	-0.3	2.45e-10	Glioblastoma;
LUAD	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg05373962	chr22:49881684	NA	-0.54	-12.62	-0.52	3.26e-31	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.65	0.31	8.95e-11	Schizophrenia;
LUAD	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg00204512	chr16:28754710	NA	0.31	6.36	0.3	5.21e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6750795	0.602	rs1667317	chr2:232412036	T/C	cg19187155	chr2:232395269	NMUR1	0.59	8.76	0.39	4.77e-17	Height;
LUAD	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg12016809	chr21:47604291	C21orf56	0.45	7.51	0.34	3.64e-13	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg01416388	chr22:39784598	NA	-0.5	-8.65	-0.39	1.06e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg01503450	chr10:980765	NA	-0.37	-6.4	-0.3	4.18e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg06138931	chr13:21896616	NA	0.42	7.49	0.34	4.05e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs7178375	0.607	rs34178381	chr15:31222585	G/C	cg15020726	chr15:31196382	MTMR15	0.71	7.42	0.34	6.47e-13	Hypertriglyceridemia;
LUAD	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg01874867	chr7:94954059	PON1	-0.5	-6.95	-0.32	1.42e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06028605	chr16:24865363	SLC5A11	0.55	8.48	0.38	3.88e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg11707310	chr1:2537719	MMEL1	-0.38	-7.91	-0.36	2.28e-14	Ulcerative colitis;
LUAD	cis	rs2046867	0.862	rs9827405	chr3:72827115	C/T	cg25664220	chr3:72788482	NA	-0.62	-10.93	-0.47	1.19e-24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs17155006	0.746	rs366690	chr7:107749880	T/G	cg05962710	chr7:107745446	LAMB4	-0.34	-7.27	-0.33	1.74e-12	Pneumococcal bacteremia;
LUAD	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg19622623	chr12:86230825	RASSF9	-0.35	-6.51	-0.3	2.16e-10	Major depressive disorder;
LUAD	cis	rs7524258	0.868	rs7538921	chr1:7267007	T/C	cg07173049	chr1:7289937	CAMTA1	0.51	9.4	0.42	3.55e-19	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg05373962	chr22:49881684	NA	-0.49	-9.89	-0.43	6.66e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs12545109	0.836	rs2196586	chr8:57347126	C/T	cg21220214	chr8:57350948	NA	0.61	8.51	0.38	3.08e-16	Obesity-related traits;
LUAD	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg14834391	chr1:2537342	MMEL1	-0.31	-6.56	-0.3	1.61e-10	Ulcerative colitis;
LUAD	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg09491104	chr22:46646882	C22orf40	-0.6	-7.85	-0.36	3.38e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg27490568	chr2:178487706	NA	0.4	6.53	0.3	1.86e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg07150166	chr2:30669952	LCLAT1	0.77	7.41	0.34	7.15e-13	Midgestational circulating levels of PBDEs (fetal genetic effect);
LUAD	cis	rs921968	0.565	rs13408427	chr2:219628389	C/T	cg02176678	chr2:219576539	TTLL4	-0.58	-11.44	-0.49	1.32e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs11811982	0.793	rs77783161	chr1:227490374	A/C	cg24860534	chr1:227506868	CDC42BPA	0.64	7.02	0.32	8.81e-12	Optic disc area;
LUAD	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg17724175	chr1:150552817	MCL1	0.37	8.37	0.38	8.58e-16	Melanoma;
LUAD	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg06618935	chr21:46677482	NA	-0.46	-9.3	-0.41	7.53e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg01765077	chr12:122356316	WDR66	0.58	10.13	0.44	9.85e-22	Mean corpuscular volume;
LUAD	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg15691649	chr6:25882328	NA	-0.44	-7.19	-0.33	3.05e-12	Blood metabolite levels;
LUAD	cis	rs2485376	0.813	rs1005044	chr10:104152143	C/A	cg20641465	chr10:103991465	PITX3	-0.53	-9.13	-0.41	2.8e-18	QT interval;
LUAD	cis	rs8062405	0.755	rs4149398	chr16:28608938	C/G	cg00204512	chr16:28754710	NA	0.32	6.79	0.31	3.93e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2455799	0.927	rs2455837	chr3:15759240	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.65	-0.31	8.93e-11	Mean platelet volume;
LUAD	cis	rs7665090	0.714	rs5026475	chr4:103554821	T/C	cg07973026	chr4:103553119	MANBA	0.45	7.5	0.34	3.7e-13	Primary biliary cholangitis;
LUAD	cis	rs6445967	0.569	rs8723	chr3:58280311	A/G	cg13750441	chr3:58318267	PXK	-0.31	-6.58	-0.3	1.36e-10	Platelet count;
LUAD	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg08508325	chr11:3079039	CARS	-0.63	-14.2	-0.57	1.05e-37	Longevity;
LUAD	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs240764	0.817	rs12214151	chr6:101159516	G/T	cg09795085	chr6:101329169	ASCC3	-0.43	-7.44	-0.34	5.68e-13	Neuroticism;
LUAD	cis	rs8027181	1.000	rs4777542	chr15:73082366	C/T	cg25632853	chr15:73088954	NA	-0.37	-8.16	-0.37	3.75e-15	Triglyceride levels;
LUAD	cis	rs7542375	0.507	rs2784270	chr1:221094967	C/T	cg16008148	chr1:221062819	NA	-0.4	-8.01	-0.36	1.13e-14	Obesity-related traits;
LUAD	cis	rs7274811	0.711	rs293713	chr20:31942247	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.5	7.7	0.35	9.95e-14	Height;
LUAD	trans	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg26043149	chr18:55253948	FECH	0.49	8.0	0.36	1.18e-14	Bone mineral density;
LUAD	cis	rs57920188	0.513	rs4290031	chr1:4094701	A/G	cg20703997	chr1:4087676	NA	0.48	8.99	0.4	8.47e-18	Interleukin-17 levels;
LUAD	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg12179176	chr11:130786555	SNX19	0.44	7.32	0.34	1.24e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg20628663	chr10:43360327	NA	0.63	9.98	0.44	3.46e-21	Blood protein levels;
LUAD	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg09537434	chr19:41945824	ATP5SL	-0.47	-7.51	-0.34	3.57e-13	Height;
LUAD	cis	rs909002	0.800	rs3134718	chr1:32089839	C/T	cg13919466	chr1:32135498	COL16A1	-0.34	-7.89	-0.36	2.58e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4604732	0.527	rs79329288	chr1:247626513	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.54	0.3	1.75e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg15017067	chr4:17643749	FAM184B	0.34	6.58	0.3	1.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09574498	chr17:48944758	NA	-0.5	-8.5	-0.38	3.28e-16	Cancer;
LUAD	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.62	-0.42	5.86e-20	Platelet count;
LUAD	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg16205897	chr5:131564050	P4HA2	-0.31	-6.54	-0.3	1.75e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg20701182	chr2:24300061	SF3B14	-0.47	-6.52	-0.3	2.01e-10	Asthma;
LUAD	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg05340658	chr4:99064831	C4orf37	0.54	9.16	0.41	2.27e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10193935	1.000	rs10190326	chr2:42388262	A/C	cg27598129	chr2:42591480	NA	0.68	9.09	0.4	3.76e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs657075	0.697	rs34604423	chr5:131653511	T/C	cg21138405	chr5:131827807	IRF1	0.5	6.42	0.3	3.76e-10	Rheumatoid arthritis;
LUAD	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg14008862	chr17:28927542	LRRC37B2	0.66	6.49	0.3	2.4e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7116495	1.000	rs10736786	chr11:71763274	C/T	cg07596299	chr11:71824057	C11orf51	-0.78	-6.65	-0.31	8.85e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.54	-9.84	-0.43	1.04e-20	Axial length;
LUAD	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg13606994	chr1:44402422	ARTN	-0.32	-6.69	-0.31	7.21e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg10729496	chr3:10149963	C3orf24	0.64	9.56	0.42	9.9e-20	Alzheimer's disease;
LUAD	cis	rs7116495	1.000	rs73539532	chr11:71815684	C/A	cg07596299	chr11:71824057	C11orf51	0.76	6.42	0.3	3.61e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg16031515	chr1:205743344	RAB7L1	-0.34	-6.78	-0.31	4.09e-11	Menarche (age at onset);
LUAD	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.92	0.32	1.71e-11	Rheumatoid arthritis;
LUAD	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg13334819	chr7:99746414	C7orf59	0.64	9.83	0.43	1.14e-20	Coronary artery disease;
LUAD	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg10523679	chr1:76189770	ACADM	0.92	18.4	0.67	5.55e-56	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg11707310	chr1:2537719	MMEL1	0.37	7.79	0.35	5.38e-14	Ulcerative colitis;
LUAD	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24308560	chr3:49941425	MST1R	-0.56	-9.43	-0.42	2.65e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg12034118	chr1:209979487	IRF6	0.58	7.69	0.35	1.04e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs67385638	0.962	rs72872549	chr11:5290053	C/T	cg12559170	chr11:5275217	HBG2	0.32	6.43	0.3	3.45e-10	Hemoglobin levels;
LUAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13012494	chr21:47604986	C21orf56	0.5	8.3	0.37	1.39e-15	Testicular germ cell tumor;
LUAD	cis	rs4072705	0.646	rs915032	chr9:127245682	G/C	cg01786973	chr9:127249749	NR5A1	0.3	6.75	0.31	4.75e-11	Menarche (age at onset);
LUAD	trans	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg01620082	chr3:125678407	NA	-0.81	-8.1	-0.37	6.15e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	13.97	0.56	9.34e-37	Lung cancer in ever smokers;
LUAD	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg02753203	chr1:228287806	NA	0.56	10.18	0.44	6.46e-22	Diastolic blood pressure;
LUAD	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg17264618	chr3:40429014	ENTPD3	-0.39	-8.58	-0.39	1.79e-16	Renal cell carcinoma;
LUAD	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg14725641	chr11:61582763	MIR1908;FADS1	-0.55	-6.84	-0.32	2.77e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs4481887	0.676	rs28684663	chr1:248548325	T/C	cg13385794	chr1:248469461	NA	0.24	6.49	0.3	2.44e-10	Common traits (Other);
LUAD	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg25237894	chr2:233734115	C2orf82	-0.59	-11.1	-0.48	2.57e-25	Coronary artery disease;
LUAD	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg18404041	chr3:52824283	ITIH1	0.41	7.55	0.34	2.65e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg10876282	chr6:28092338	ZSCAN16	0.42	6.85	0.32	2.64e-11	Parkinson's disease;
LUAD	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.44	-6.86	-0.32	2.49e-11	Breast cancer;
LUAD	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg16680214	chr1:154839983	KCNN3	-0.64	-13.27	-0.54	7.29e-34	Prostate cancer;
LUAD	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg07061783	chr6:25882402	NA	0.51	8.02	0.36	1.04e-14	Blood metabolite levels;
LUAD	cis	rs6761276	0.752	rs12477866	chr2:113835908	C/T	cg06383401	chr2:113825234	IL1F10	-0.3	-6.41	-0.3	3.97e-10	Protein quantitative trait loci;
LUAD	trans	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg19862616	chr7:65841803	NCRNA00174	1.06	27.06	0.8	2.41e-94	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7773004	0.905	rs3778279	chr6:26325463	T/C	cg00631329	chr6:26305371	NA	-0.52	-8.92	-0.4	1.45e-17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs11098699	0.784	rs6835971	chr4:124230999	A/G	cg09941581	chr4:124220074	SPATA5	0.43	6.95	0.32	1.36e-11	Mosquito bite size;
LUAD	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-8.33	-0.38	1.16e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs7759001	0.817	rs10080814	chr6:27362874	T/G	cg18711553	chr6:27366782	ZNF391	0.39	6.54	0.3	1.81e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.77	-0.31	4.23e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg08893839	chr5:154027129	NA	0.55	7.27	0.33	1.73e-12	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.35	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg22823121	chr1:150693482	HORMAD1	-0.39	-7.73	-0.35	7.99e-14	Tonsillectomy;
LUAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14893161	chr1:205819251	PM20D1	-0.72	-14.55	-0.58	3.48e-39	Monocyte percentage of white cells;
LUAD	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg06608945	chr2:219082296	ARPC2	-0.42	-6.88	-0.32	2.18e-11	Colorectal cancer;
LUAD	trans	rs75804782	0.630	rs3739070	chr2:239306268	A/C	cg01134436	chr17:81009848	B3GNTL1	0.77	6.82	0.31	3.19e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg21782813	chr7:2030301	MAD1L1	0.54	9.58	0.42	8.64e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs7274811	0.711	rs291697	chr20:31985248	T/C	cg03904042	chr20:32255491	NECAB3;C20orf134	0.49	7.27	0.33	1.79e-12	Height;
LUAD	cis	rs1865721	0.771	rs72975988	chr18:73128289	T/G	cg26385618	chr18:73139727	C18orf62	-0.51	-10.1	-0.44	1.25e-21	Intelligence;
LUAD	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg11317459	chr13:21872234	NA	1.24	21.22	0.72	1.43e-68	White matter hyperintensity burden;
LUAD	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg23954153	chr1:44402353	ARTN	-0.37	-7.1	-0.33	5.37e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg12365402	chr11:9010492	NRIP3	0.48	8.92	0.4	1.37e-17	Hemoglobin concentration;
LUAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg27454412	chr7:1067447	C7orf50	0.48	7.73	0.35	7.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg10755058	chr3:40428713	ENTPD3	0.43	8.34	0.38	1.06e-15	Renal cell carcinoma;
LUAD	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg11645453	chr3:52864694	ITIH4	0.53	9.64	0.42	5.17e-20	Schizophrenia;
LUAD	trans	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg13565492	chr6:43139072	SRF	-0.61	-6.47	-0.3	2.76e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs738322	0.718	rs3761445	chr22:38595411	G/A	cg25457927	chr22:38595422	NA	0.69	20.37	0.7	9.15e-65	Cutaneous nevi;
LUAD	trans	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg07211511	chr3:129823064	LOC729375	-0.48	-6.39	-0.3	4.46e-10	Blood pressure (smoking interaction);
LUAD	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg08601574	chr20:25228251	PYGB	0.48	8.79	0.39	3.81e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg11693508	chr17:37793320	STARD3	0.81	10.23	0.45	4.34e-22	Bipolar disorder;
LUAD	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg04398451	chr17:18023971	MYO15A	-0.65	-11.71	-0.49	1.3e-27	Total body bone mineral density;
LUAD	cis	rs12210905	0.610	rs12204953	chr6:27396737	G/A	cg08851530	chr6:28072375	NA	1.03	7.52	0.34	3.21e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg24562669	chr7:97807699	LMTK2	0.29	6.96	0.32	1.34e-11	Breast cancer;
LUAD	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg17177755	chr1:15930204	NA	0.43	6.94	0.32	1.47e-11	Systolic blood pressure;
LUAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg13560548	chr3:10150139	C3orf24	0.44	6.68	0.31	7.4e-11	Alzheimer's disease;
LUAD	cis	rs6591182	0.967	rs11227229	chr11:65354150	C/T	cg27068330	chr11:65405492	SIPA1	-0.46	-7.34	-0.34	1.11e-12	Non-alcoholic fatty liver disease histology (lobular);
LUAD	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg26408565	chr15:76604113	ETFA	-0.44	-7.02	-0.32	8.8e-12	Blood metabolite levels;
LUAD	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-11.02	-0.47	5.51e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg18833306	chr6:118973337	C6orf204	-0.52	-7.5	-0.34	3.77e-13	Diastolic blood pressure;
LUAD	cis	rs2046867	0.908	rs62251648	chr3:72806083	A/G	cg04365224	chr3:72788183	NA	-0.48	-7.31	-0.33	1.38e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs727505	0.866	rs67132333	chr7:124719801	A/G	cg23710748	chr7:124431027	NA	-0.42	-8.51	-0.38	3.02e-16	Lewy body disease;
LUAD	cis	rs1044826	0.642	rs6799312	chr3:139211932	C/T	cg00490450	chr3:139108681	COPB2	0.41	6.47	0.3	2.64e-10	Obesity-related traits;
LUAD	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg11707310	chr1:2537719	MMEL1	0.4	8.3	0.37	1.39e-15	Ulcerative colitis;
LUAD	cis	rs7274811	0.681	rs293733	chr20:31975976	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.51	7.66	0.35	1.26e-13	Height;
LUAD	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg22598563	chr5:131563921	P4HA2	-0.34	-8.89	-0.4	1.83e-17	Blood metabolite levels;
LUAD	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg19980929	chr12:42632907	YAF2	0.35	6.75	0.31	4.77e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs494562	0.892	rs683218	chr6:86118584	A/G	cg21730993	chr6:86159210	NT5E	0.73	8.2	0.37	2.89e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.56	-0.35	2.5e-13	Bipolar disorder;
LUAD	cis	rs6669919	0.553	rs7527603	chr1:211668090	G/A	cg10512769	chr1:211675356	NA	-0.42	-8.26	-0.37	1.94e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs2235573	0.625	rs713991	chr22:38426043	A/G	cg19894588	chr14:64061835	NA	0.42	6.47	0.3	2.68e-10	Glioblastoma;Glioma;
LUAD	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-10.24	-0.45	3.88e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg07926092	chr13:79233506	RNF219	0.75	10.35	0.45	1.57e-22	Large artery stroke;
LUAD	cis	rs870825	0.616	rs7694899	chr4:185625390	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	13.66	0.55	1.93e-35	Blood protein levels;
LUAD	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg09455208	chr3:40491958	NA	0.63	14.01	0.56	6.45e-37	Renal cell carcinoma;
LUAD	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg11517269	chr6:28058789	ZSCAN12L1	0.39	7.37	0.34	8.95e-13	Lung cancer in ever smokers;
LUAD	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg02176678	chr2:219576539	TTLL4	-0.82	-17.41	-0.65	1.35e-51	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4974559	0.895	rs12646130	chr4:1330530	G/C	cg07757535	chr4:1339547	NA	0.42	6.81	0.31	3.4e-11	Systolic blood pressure;
LUAD	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg18854424	chr1:2615690	NA	0.42	9.1	0.4	3.72e-18	Ulcerative colitis;
LUAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg05434287	chr7:2030229	MAD1L1	0.43	6.82	0.31	3.2e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg26043149	chr18:55253948	FECH	-0.5	-8.14	-0.37	4.55e-15	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1847202	0.787	rs13071878	chr3:72951084	G/A	cg25664220	chr3:72788482	NA	-0.42	-7.28	-0.33	1.67e-12	Motion sickness;
LUAD	trans	rs1973993	0.745	rs6593606	chr1:96968005	C/T	cg10631902	chr5:14652156	NA	-0.46	-7.85	-0.36	3.45e-14	Weight;
LUAD	cis	rs7953508	0.711	rs11107117	chr12:93979419	T/C	cg18151635	chr12:93972918	NA	-0.73	-11.26	-0.48	6.48e-26	Pubertal anthropometrics;
LUAD	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg07423050	chr13:99094983	FARP1	-0.43	-7.32	-0.34	1.27e-12	Longevity;
LUAD	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.76	-0.31	4.59e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4919694	1.000	rs76255497	chr10:104651955	T/C	cg04362960	chr10:104952993	NT5C2	0.74	8.03	0.36	9.68e-15	Arsenic metabolism;
LUAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg00280220	chr17:61926910	NA	0.36	6.9	0.32	1.9e-11	Prudent dietary pattern;
LUAD	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg23982607	chr1:1823379	GNB1	-0.9	-19.18	-0.68	1.93e-59	Body mass index;
LUAD	cis	rs7665090	1.000	rs735403	chr4:103553543	A/G	cg07973026	chr4:103553119	MANBA	-0.48	-8.62	-0.39	1.3e-16	Primary biliary cholangitis;
LUAD	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg09365446	chr1:150670422	GOLPH3L	0.65	12.11	0.51	3.3600000000000003e-29	Tonsillectomy;
LUAD	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg12311346	chr5:56204834	C5orf35	-0.57	-9.07	-0.4	4.51e-18	Coronary artery disease;
LUAD	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg22117172	chr7:91764530	CYP51A1	0.35	7.93	0.36	2.01e-14	Breast cancer;
LUAD	cis	rs9469890	0.604	rs76452512	chr6:34504388	G/C	cg17674042	chr6:34482479	PACSIN1	-0.52	-6.99	-0.32	1.07e-11	Pubertal anthropometrics;Coronary artery disease;
LUAD	trans	rs7395662	0.677	rs10839110	chr11:48839960	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.4	-0.34	7.32e-13	HDL cholesterol;
LUAD	cis	rs4523957	0.890	rs216222	chr17:2155701	T/A	cg16513277	chr17:2031491	SMG6	0.77	14.88	0.59	1.48e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg11833968	chr6:79620685	NA	-0.44	-8.2	-0.37	2.95e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg00814883	chr7:100076585	TSC22D4	-0.86	-13.1	-0.54	3.82e-33	Platelet count;
LUAD	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg16797656	chr11:68205561	LRP5	-0.46	-9.21	-0.41	1.49e-18	Total body bone mineral density;
LUAD	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg02683114	chr2:24398427	C2orf84	-0.54	-8.04	-0.36	9.16e-15	Asthma;
LUAD	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg06608945	chr2:219082296	ARPC2	0.44	7.41	0.34	7.14e-13	Colorectal cancer;
LUAD	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.69	0.31	7.15e-11	Depression;
LUAD	cis	rs4969178	0.622	rs11657987	chr17:76387363	G/T	cg05887092	chr17:76393375	PGS1	0.54	10.64	0.46	1.33e-23	HDL cholesterol levels;
LUAD	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg19875535	chr5:140030758	IK	0.43	7.27	0.33	1.71e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2979489	0.891	rs16877096	chr8:30364388	T/C	cg26383811	chr8:30366931	RBPMS	-0.7	-11.14	-0.48	1.89e-25	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.1	-0.4	3.68e-18	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs1997103	0.822	rs10273426	chr7:55417857	G/A	cg20935933	chr6:143382018	AIG1	0.55	7.6	0.35	1.99e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs738321	0.757	rs12329956	chr22:38535946	G/A	cg17652424	chr22:38574118	PLA2G6	-0.28	-7.47	-0.34	4.54e-13	Breast cancer;
LUAD	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg11833968	chr6:79620685	NA	-0.43	-8.11	-0.37	5.62e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg19034708	chr8:17780168	PCM1	-0.4	-6.61	-0.31	1.14e-10	Subcortical brain region volumes;
LUAD	cis	rs76878669	0.515	rs947978	chr11:66108660	C/T	cg10616300	chr11:66138557	SLC29A2	0.34	7.15	0.33	3.85e-12	Educational attainment (years of education);
LUAD	cis	rs7617773	0.780	rs2541	chr3:48339618	A/G	cg11946769	chr3:48343235	NME6	0.44	6.8	0.31	3.52e-11	Coronary artery disease;
LUAD	cis	rs2072499	0.966	rs887953	chr1:156191149	T/C	cg25208724	chr1:156163844	SLC25A44	1.1	21.52	0.72	6.66e-70	Testicular germ cell tumor;
LUAD	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg22532475	chr10:104410764	TRIM8	0.45	8.56	0.38	2.11e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg15358701	chr1:161410459	NA	-0.68	-6.93	-0.32	1.58e-11	Rheumatoid arthritis;
LUAD	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg17366294	chr4:99064904	C4orf37	0.71	13.31	0.54	5.17e-34	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.31	-0.37	1.31e-15	Breast cancer;
LUAD	cis	rs12681287	0.640	rs72606633	chr8:87476236	T/C	cg27223183	chr8:87520930	FAM82B	-0.67	-9.61	-0.42	6.38e-20	Caudate activity during reward;
LUAD	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg04369109	chr6:150039330	LATS1	-0.44	-7.59	-0.35	2.12e-13	Lung cancer;
LUAD	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg27490568	chr2:178487706	NA	0.41	6.83	0.32	2.89e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	10.85	0.47	2.33e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7617773	0.817	rs13072018	chr3:48320332	G/A	cg11946769	chr3:48343235	NME6	0.43	6.68	0.31	7.65e-11	Coronary artery disease;
LUAD	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg15147215	chr3:52552868	STAB1	-0.41	-7.41	-0.34	7.02e-13	Bipolar disorder;
LUAD	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg21724239	chr8:58056113	NA	0.66	8.71	0.39	6.88e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg17848003	chr1:3704513	LRRC47	0.52	10.59	0.46	2.17e-23	Red cell distribution width;
LUAD	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.88	-0.32	2.15e-11	Total cholesterol levels;
LUAD	cis	rs601339	1.000	rs525215	chr12:123179771	G/A	cg11919336	chr12:123188078	GPR109A	0.47	7.32	0.34	1.23e-12	Adiponectin levels;
LUAD	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23248424	chr5:179741104	GFPT2	-0.7	-11.64	-0.49	2.31e-27	Height;
LUAD	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg05342682	chr7:94953680	PON1	-0.53	-7.19	-0.33	2.94e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg14458575	chr2:238380390	NA	0.97	18.44	0.67	3.66e-56	Prostate cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg17728503	chr2:190526181	ASNSD1	-0.39	-6.66	-0.31	8.73e-11	Schizophrenia;
LUAD	cis	rs2882667	0.858	rs11959851	chr5:138421405	C/G	cg04439458	chr5:138467593	SIL1	-0.51	-9.32	-0.41	6.71e-19	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6546550	0.935	rs2168115	chr2:70034793	A/G	cg02498382	chr2:70120550	SNRNP27	-0.53	-9.75	-0.43	2.2e-20	Prevalent atrial fibrillation;
LUAD	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg04944784	chr2:26401820	FAM59B	-0.77	-10.57	-0.46	2.53e-23	Gut microbiome composition (summer);
LUAD	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.67e-15	Bipolar disorder;
LUAD	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg25769590	chr7:158789503	NA	-0.34	-6.41	-0.3	3.87e-10	Facial morphology (factor 20);
LUAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.84	0.43	1.07e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg18129178	chr5:148520854	ABLIM3	-0.64	-9.72	-0.43	2.73e-20	Breast cancer;
LUAD	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg22455342	chr2:225449267	CUL3	0.48	8.04	0.36	9.19e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg23131131	chr22:24373011	LOC391322	-0.63	-11.04	-0.47	4.37e-25	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs35883536	0.609	rs1855631	chr1:101040010	C/T	cg06223162	chr1:101003688	GPR88	-0.45	-8.6	-0.39	1.62e-16	Monocyte count;
LUAD	cis	rs6714710	0.603	rs11684749	chr2:98420142	G/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.18	0.37	3.37e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.57	-10.32	-0.45	2.05e-22	Schizophrenia;
LUAD	cis	rs3857067	0.806	rs34396894	chr4:95097600	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.38	-6.64	-0.31	9.81e-11	QT interval;
LUAD	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg05340658	chr4:99064831	C4orf37	0.45	6.78	0.31	4.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg01579765	chr21:45077557	HSF2BP	-0.57	-13.0	-0.53	9.37e-33	Mean corpuscular volume;
LUAD	cis	rs7394190	0.748	rs1057410	chr10:75574079	G/A	cg02286717	chr10:75415704	SYNPO2L	-0.37	-6.55	-0.3	1.69e-10	Incident atrial fibrillation;
LUAD	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg04944784	chr2:26401820	FAM59B	0.87	12.16	0.51	2.29e-29	Gut microbiome composition (summer);
LUAD	cis	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-7.01	-0.32	9.64e-12	Neuroticism;
LUAD	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.07	0.37	7.1e-15	Menopause (age at onset);
LUAD	cis	rs2346268	0.605	rs13310832	chr7:133646213	T/G	cg03336402	chr7:133662267	EXOC4	-0.41	-7.6	-0.35	1.9e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7771547	0.519	rs4713973	chr6:36382044	A/G	cg07856975	chr6:36356162	ETV7	0.53	8.0	0.36	1.22e-14	Platelet distribution width;
LUAD	cis	rs28595532	0.546	rs17516389	chr4:119239267	T/C	cg02775129	chr4:119771670	NA	-0.64	-6.9	-0.32	1.86e-11	Cannabis dependence symptom count;
LUAD	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg09137382	chr11:130731461	NA	0.43	7.95	0.36	1.69e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg25237894	chr2:233734115	C2orf82	-0.6	-11.78	-0.5	6.88e-28	Coronary artery disease;
LUAD	cis	rs7512552	0.839	rs11581351	chr1:150440200	G/C	cg15654264	chr1:150340011	RPRD2	0.59	11.49	0.49	8.49e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.42	-0.34	6.46e-13	Electroencephalogram traits;
LUAD	cis	rs11098699	0.784	rs13123501	chr4:124244899	C/A	cg09941581	chr4:124220074	SPATA5	0.42	6.66	0.31	8.48e-11	Mosquito bite size;
LUAD	cis	rs2637266	1.000	rs7082587	chr10:78386328	C/T	cg18941641	chr10:78392320	NA	0.35	7.29	0.33	1.52e-12	Pulmonary function;
LUAD	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg25237894	chr2:233734115	C2orf82	-0.57	-11.14	-0.48	1.96e-25	Coronary artery disease;
LUAD	trans	rs2270927	0.510	rs31244	chr5:75594743	G/A	cg13563193	chr19:33072644	PDCD5	0.97	8.95	0.4	1.16e-17	Mean corpuscular volume;
LUAD	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg05768032	chr16:30646687	NA	0.44	7.78	0.35	5.57e-14	Multiple myeloma;
LUAD	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg25324976	chr17:61989376	CSHL1	0.37	7.22	0.33	2.43e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg27284194	chr4:1044797	NA	0.7	10.13	0.44	9.73e-22	Recombination rate (females);
LUAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg00106254	chr7:1943704	MAD1L1	-0.48	-6.91	-0.32	1.83e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs3849570	0.643	rs6797240	chr3:81971856	T/C	cg07356753	chr3:81810745	GBE1	-0.49	-8.22	-0.37	2.45e-15	Waist circumference;Body mass index;
LUAD	cis	rs6691722	0.503	rs3765428	chr1:24706113	G/A	cg02336364	chr1:24764700	NIPAL3	0.3	6.36	0.3	5.23e-10	Response to interferon beta in multiple sclerosis;
LUAD	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg24920358	chr1:40204285	PPIE	0.7	12.53	0.52	7.23e-31	Blood protein levels;
LUAD	cis	rs9341808	0.683	rs9359409	chr6:80826897	C/G	cg08355045	chr6:80787529	NA	0.56	10.1	0.44	1.26e-21	Sitting height ratio;
LUAD	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg22823121	chr1:150693482	HORMAD1	0.44	8.91	0.4	1.55e-17	Tonsillectomy;
LUAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg10729496	chr3:10149963	C3orf24	0.58	9.34	0.41	5.7e-19	Alzheimer's disease;
LUAD	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.83	-0.58	2.33e-40	Schizophrenia;
LUAD	cis	rs12545109	0.800	rs1440763	chr8:57410481	C/A	cg21220214	chr8:57350948	NA	-0.62	-8.61	-0.39	1.51e-16	Obesity-related traits;
LUAD	cis	rs6782228	0.565	rs12695509	chr3:128417044	A/T	cg16766828	chr3:128327626	NA	-0.39	-7.3	-0.33	1.43e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	7.4	0.34	7.46e-13	Platelet count;
LUAD	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg04896959	chr15:78267971	NA	0.56	10.85	0.47	2.36e-24	Coronary artery disease or large artery stroke;
LUAD	cis	rs4691139	1.000	rs6855591	chr4:165906723	T/A	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.44	-8.74	-0.39	5.52e-17	Ovarian cancer in BRCA1 mutation carriers;
LUAD	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg03929089	chr4:120376271	NA	-0.67	-9.62	-0.42	5.93e-20	Coronary artery disease;
LUAD	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg06740227	chr12:86229804	RASSF9	0.42	7.16	0.33	3.68e-12	Major depressive disorder;
LUAD	cis	rs2070677	0.542	rs7086127	chr10:135393731	T/C	cg20169779	chr10:135381914	SYCE1	-0.52	-8.27	-0.37	1.81e-15	Gout;
LUAD	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg06618935	chr21:46677482	NA	-0.5	-10.01	-0.44	2.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12216545	0.765	rs2140142	chr7:150249068	T/C	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.39	-0.3	4.27e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg26556186	chr7:128431582	CCDC136	-0.49	-6.54	-0.3	1.81e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs2625529	0.526	rs16956623	chr15:72536695	T/C	cg16672083	chr15:72433130	SENP8	0.67	12.42	0.52	2.04e-30	Red blood cell count;
LUAD	cis	rs4774899	0.752	rs1820995	chr15:57332971	A/G	cg14026238	chr15:57616123	NA	-0.42	-7.96	-0.36	1.62e-14	Urinary tract infection frequency;
LUAD	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.06	-15.03	-0.59	3.32e-41	Schizophrenia;
LUAD	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg06191203	chr2:152266755	RIF1	-0.61	-9.25	-0.41	1.13e-18	Lung cancer;
LUAD	cis	rs12801636	0.512	rs12420618	chr11:65412974	C/G	cg16535667	chr11:65410126	SIPA1	-0.48	-6.84	-0.32	2.87e-11	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs2445762	0.559	rs4774585	chr15:51616480	G/A	cg07517944	chr15:51633816	GLDN	0.44	7.54	0.34	2.91e-13	Hormone measurements;
LUAD	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg21028142	chr17:79581711	NPLOC4	0.38	7.62	0.35	1.63e-13	Eye color traits;
LUAD	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg24818145	chr4:99064322	C4orf37	0.45	7.64	0.35	1.49e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg13334819	chr7:99746414	C7orf59	-0.71	-10.82	-0.47	2.99e-24	Coronary artery disease;
LUAD	cis	rs4285028	0.747	rs1127412	chr3:121414061	C/T	cg11130432	chr3:121712080	ILDR1	-0.45	-6.53	-0.3	1.92e-10	Multiple sclerosis;
LUAD	cis	rs2387326	0.680	rs11016097	chr10:129942948	T/C	cg16087940	chr10:129947807	NA	-0.64	-8.82	-0.39	2.95e-17	Select biomarker traits;
LUAD	cis	rs12681287	0.640	rs6992944	chr8:87419308	G/T	cg27223183	chr8:87520930	FAM82B	0.67	9.42	0.42	2.92e-19	Caudate activity during reward;
LUAD	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg14668632	chr7:2872130	GNA12	-0.47	-8.3	-0.37	1.44e-15	Height;
LUAD	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg13319975	chr6:146136371	FBXO30	0.63	10.83	0.47	2.73e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg22681709	chr2:178499509	PDE11A	-0.45	-7.5	-0.34	3.74e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg07432352	chr17:45403706	C17orf57	0.41	7.8	0.35	4.95e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs704	0.605	rs2071379	chr17:26695832	A/G	cg10342447	chr17:26645325	TMEM97	-0.38	-7.7	-0.35	1e-13	Osteoprotegerin levels;
LUAD	trans	rs3857536	0.813	rs9354404	chr6:66948408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg27454412	chr7:1067447	C7orf50	0.48	7.68	0.35	1.09e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg04772025	chr11:68637568	NA	0.59	9.57	0.42	8.73e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.34	-0.34	1.1e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg21017887	chr14:105400489	NA	-0.7	-12.83	-0.53	4.72e-32	Rheumatoid arthritis;
LUAD	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.57	-0.3	1.47e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2901656	0.502	rs9425308	chr1:172383265	A/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.4	7.4	0.34	7.48e-13	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg20283391	chr11:68216788	NA	-0.43	-6.89	-0.32	2.02e-11	Total body bone mineral density;
LUAD	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg24154853	chr7:158122151	PTPRN2	0.48	8.05	0.36	8.38e-15	Response to amphetamines;
LUAD	trans	rs4650994	1.000	rs10798617	chr1:178515806	T/C	cg05059571	chr16:84539110	KIAA1609	-0.61	-10.43	-0.45	7.92e-23	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg18252515	chr7:66147081	NA	-0.61	-6.79	-0.31	3.86e-11	Diabetic kidney disease;
LUAD	trans	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg24644049	chr4:85504048	CDS1	0.89	7.59	0.35	2.05e-13	Skin colour saturation;
LUAD	trans	rs12517041	1.000	rs10064991	chr5:23318464	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.73	-0.31	5.37e-11	Calcium levels;
LUAD	trans	rs7781370	1.000	rs7781370	chr7:96133531	A/G	cg21403089	chr7:108166784	PNPLA8	-0.39	-6.54	-0.3	1.76e-10	Bone mineral density (hip);
LUAD	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg03806693	chr22:41940476	POLR3H	0.63	9.37	0.41	4.28e-19	Vitiligo;
LUAD	cis	rs11785400	0.890	rs13279182	chr8:143720544	A/G	cg24634471	chr8:143751801	JRK	0.46	7.16	0.33	3.5e-12	Schizophrenia;
LUAD	cis	rs7582720	0.943	rs115130739	chr2:203725677	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.12	0.41	3.09e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	9.63	0.42	5.79e-20	Electrocardiographic conduction measures;
LUAD	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg05042697	chr2:10830656	NOL10	0.38	6.63	0.31	9.95e-11	Prostate cancer;
LUAD	cis	rs684232	0.583	rs2543776	chr17:557149	G/A	cg12384639	chr17:618140	VPS53	0.44	7.48	0.34	4.45e-13	Prostate cancer;
LUAD	trans	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.72	10.71	0.46	7.48e-24	Ulcerative colitis;
LUAD	trans	rs350729	0.579	rs1451459	chr2:53088412	G/A	cg14903689	chr21:46875218	COL18A1	0.34	6.35	0.3	5.49e-10	Bronchodilator response in asthma;
LUAD	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg04944784	chr2:26401820	FAM59B	-0.71	-10.02	-0.44	2.37e-21	Gut microbiome composition (summer);
LUAD	cis	rs3862030	0.720	rs11595149	chr10:104235978	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-8.08	-0.37	6.94e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg21226059	chr5:178986404	RUFY1	0.65	9.91	0.43	6.06e-21	Lung cancer;
LUAD	cis	rs8027181	0.839	rs8024986	chr15:73024868	A/G	cg25632853	chr15:73088954	NA	-0.31	-6.63	-0.31	1.04e-10	Triglyceride levels;
LUAD	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg05044414	chr3:183734942	ABCC5	0.48	10.06	0.44	1.79e-21	Anterior chamber depth;
LUAD	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg23281280	chr6:28129359	ZNF389	0.46	6.68	0.31	7.58e-11	Depression;
LUAD	cis	rs1595825	0.891	rs1030796	chr2:198674673	A/G	cg00982548	chr2:198649783	BOLL	-0.65	-9.06	-0.4	4.97e-18	Ulcerative colitis;
LUAD	cis	rs7173743	0.756	rs4539564	chr15:79128499	G/A	cg15571903	chr15:79123663	NA	0.44	8.84	0.39	2.56e-17	Coronary artery disease;
LUAD	cis	rs7177699	0.557	rs62011002	chr15:79120578	C/T	cg15571903	chr15:79123663	NA	0.38	7.58	0.35	2.25e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg22079354	chr11:130786696	SNX19	0.47	8.21	0.37	2.74e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg03806693	chr22:41940476	POLR3H	-0.62	-9.04	-0.4	5.88e-18	Vitiligo;
LUAD	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg18854424	chr1:2615690	NA	0.41	8.95	0.4	1.13e-17	Ulcerative colitis;
LUAD	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.08	-0.4	4.33e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-7.92	-0.36	2.07e-14	Neutrophil percentage of white cells;
LUAD	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg24818145	chr4:99064322	C4orf37	0.47	7.21	0.33	2.58e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7551222	0.752	rs4951407	chr1:204558070	G/T	cg20240347	chr1:204465584	NA	0.32	6.38	0.3	4.72e-10	Schizophrenia;
LUAD	cis	rs17270561	0.583	rs6908713	chr6:25703611	G/A	cg25753631	chr6:25732923	NA	0.4	7.05	0.32	7.29e-12	Iron status biomarkers;
LUAD	cis	rs6484504	0.576	rs208071	chr11:31144996	C/T	cg26647111	chr11:31128758	NA	-0.47	-8.26	-0.37	1.9e-15	Red blood cell count;
LUAD	cis	rs4629710	0.592	rs67399092	chr6:131582936	G/A	cg12606694	chr6:131520996	AKAP7	0.5	7.23	0.33	2.24e-12	Multiple myeloma (IgH translocation);
LUAD	trans	rs11184708	0.509	rs79197702	chr1:106256892	T/C	cg06936704	chr20:37009829	NA	0.64	6.36	0.3	5.38e-10	Waist-to-hip circumference ratio (ever vs never smoking interaction);
LUAD	trans	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.57	-0.3	1.47e-10	Systolic blood pressure;
LUAD	cis	rs13082711	0.554	rs674798	chr3:27332302	G/T	cg02860705	chr3:27208620	NA	0.52	8.57	0.38	1.94e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg03651054	chr13:50194643	NA	0.4	8.03	0.36	9.54e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	trans	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.73	0.35	8.15e-14	Resting heart rate;
LUAD	cis	rs12545109	0.876	rs1992120	chr8:57337112	G/A	cg17761419	chr8:57350749	NA	-0.59	-8.04	-0.36	8.95e-15	Obesity-related traits;
LUAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.37	-0.48	2.61e-26	Bipolar disorder and schizophrenia;
LUAD	cis	rs8064299	0.574	rs1879455	chr17:72774738	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.4	6.46	0.3	2.9e-10	Monocyte count;
LUAD	cis	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg26958806	chr6:27640298	NA	0.64	6.35	0.3	5.45e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg25173405	chr17:45401733	C17orf57	-0.58	-9.34	-0.41	5.54e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.25	-0.33	2.03e-12	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs35264875	0.846	rs72930627	chr11:68867121	C/A	cg02660097	chr11:68866761	NA	0.52	7.27	0.33	1.8e-12	Blond vs. brown hair color;
LUAD	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg18806716	chr10:30721971	MAP3K8	-0.63	-12.78	-0.53	7.71e-32	Inflammatory bowel disease;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg24568646	chr21:30446238	CCT8	0.43	6.93	0.32	1.54e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1997103	1.000	rs6958664	chr7:55404958	T/G	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs16910800	1.000	rs1531808	chr11:23194465	C/A	cg20040320	chr11:23191996	NA	-0.5	-7.4	-0.34	7.26e-13	Cancer;
LUAD	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg26528668	chr16:1614120	IFT140	0.49	8.87	0.4	2.13e-17	Coronary artery disease;
LUAD	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.69	-11.22	-0.48	9.37e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg06271696	chr7:157225062	NA	-0.52	-10.95	-0.47	9.92e-25	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg17724175	chr1:150552817	MCL1	0.33	7.65	0.35	1.4e-13	Tonsillectomy;
LUAD	trans	rs1997103	1.000	rs2331064	chr7:55408610	C/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-7.32	-0.34	1.24e-12	Platelet count;
LUAD	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg15704280	chr7:45808275	SEPT13	0.72	10.91	0.47	1.33e-24	Coronary artery disease;
LUAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg11965913	chr1:205819406	PM20D1	0.96	23.24	0.75	1.37e-77	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.9	0.36	2.44e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1950626	0.833	rs12891189	chr14:101415523	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.38	7.23	0.33	2.32e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg06064525	chr11:970664	AP2A2	-0.54	-11.05	-0.47	3.99e-25	Alzheimer's disease (late onset);
LUAD	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg24399712	chr22:39784796	NA	-0.79	-15.38	-0.6	1.04e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg01579765	chr21:45077557	HSF2BP	-0.57	-13.18	-0.54	1.85e-33	Mean corpuscular volume;
LUAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	12.82	0.53	5.2e-32	Prudent dietary pattern;
LUAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg13047869	chr3:10149882	C3orf24	0.6	10.03	0.44	2.24e-21	Alzheimer's disease;
LUAD	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg11663144	chr21:46675770	NA	-0.48	-9.04	-0.4	5.47e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.5	-8.27	-0.37	1.8e-15	Tonsillectomy;
LUAD	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg27411982	chr8:10470053	RP1L1	-0.39	-7.29	-0.33	1.52e-12	Neuroticism;
LUAD	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg21427119	chr20:30132790	HM13	-0.49	-7.8	-0.35	4.98e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.17	0.37	3.59e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg16647868	chr5:131706066	SLC22A5	-0.51	-8.14	-0.37	4.5e-15	Breast cancer;
LUAD	trans	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-8.51	-0.38	3.08e-16	Endometrial cancer;
LUAD	cis	rs4711350	0.862	rs487835	chr6:33710933	G/A	cg18005901	chr6:33739558	LEMD2	0.5	7.12	0.33	4.54e-12	Schizophrenia;
LUAD	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg06873352	chr17:61820015	STRADA	0.42	6.99	0.32	1.06e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg07870213	chr5:140052090	DND1	0.72	11.09	0.47	3.04e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10916814	0.632	rs6691041	chr1:20898650	A/G	cg24502330	chr1:20914028	CDA	-0.36	-7.18	-0.33	3.14e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg12179176	chr11:130786555	SNX19	0.55	9.27	0.41	9.37e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg09643151	chr2:201981873	CFLAR	-0.35	-6.37	-0.3	5e-10	Schizophrenia;
LUAD	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg11317459	chr13:21872234	NA	-1.09	-14.71	-0.58	7.3e-40	White matter hyperintensity burden;
LUAD	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg03929089	chr4:120376271	NA	-0.44	-6.76	-0.31	4.54e-11	HDL cholesterol;
LUAD	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg09359103	chr1:154839909	KCNN3	-0.88	-19.45	-0.69	1.23e-60	Prostate cancer;
LUAD	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.59	-10.25	-0.45	3.75e-22	Menarche (age at onset);
LUAD	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.24	-6.41	-0.3	3.83e-10	Total body bone mineral density;
LUAD	cis	rs9914988	0.943	rs4794836	chr17:27082710	C/G	cg02049041	chr17:27085579	C17orf63	-0.58	-8.13	-0.37	4.94e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg25753631	chr6:25732923	NA	-0.38	-6.58	-0.3	1.4e-10	Iron status biomarkers;
LUAD	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg24642844	chr7:1081250	C7orf50	-0.88	-9.71	-0.43	3.06e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs807669	0.903	rs807667	chr22:19161327	A/G	cg24911827	chr22:19170109	CLTCL1	-0.44	-9.23	-0.41	1.32e-18	Metabolite levels;
LUAD	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg16479474	chr6:28041457	NA	0.39	6.9	0.32	1.91e-11	Parkinson's disease;
LUAD	cis	rs137699	1.000	rs760742	chr22:39755190	G/T	cg05872129	chr22:39784769	NA	-0.51	-8.45	-0.38	4.86e-16	IgG glycosylation;
LUAD	cis	rs7830933	1.000	rs7830933	chr8:23603324	A/G	cg04349084	chr8:23602677	NA	0.51	7.34	0.34	1.11e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
LUAD	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.56	-0.38	2.16e-16	Total body bone mineral density;
LUAD	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg02886208	chr11:14281011	SPON1	-0.39	-7.92	-0.36	2.18e-14	Mitochondrial DNA levels;
LUAD	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg16647868	chr5:131706066	SLC22A5	0.36	6.4	0.3	4.21e-10	Blood metabolite levels;
LUAD	cis	rs35079168	0.923	rs11103473	chr9:137287629	A/T	cg00753924	chr9:137298813	RXRA	0.38	6.39	0.3	4.5e-10	Intelligence;
LUAD	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg11887960	chr12:57824829	NA	0.59	7.34	0.34	1.1e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg23301539	chr8:142222248	SLC45A4	-0.47	-8.08	-0.37	6.8e-15	Immature fraction of reticulocytes;
LUAD	cis	rs6674176	0.542	rs803679	chr1:44349405	G/A	cg12908607	chr1:44402522	ARTN	-0.4	-7.14	-0.33	4e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg18335740	chr13:41363409	SLC25A15	0.62	11.34	0.48	3.27e-26	Lewy body disease;
LUAD	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg21782813	chr7:2030301	MAD1L1	0.46	8.2	0.37	2.88e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.69	-0.35	1.02e-13	Breast cancer;
LUAD	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg06784218	chr1:46089804	CCDC17	-0.53	-11.59	-0.49	3.71e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.99e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg27494647	chr7:150038898	RARRES2	0.54	9.25	0.41	1.13e-18	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.61	0.31	1.15e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs367943	0.698	rs9326900	chr5:112972859	A/G	cg12552261	chr5:112820674	MCC	0.47	8.41	0.38	6.39e-16	Type 2 diabetes;
LUAD	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.87	0.32	2.36e-11	Motion sickness;
LUAD	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg09835421	chr16:68378352	PRMT7	-0.85	-9.1	-0.4	3.55e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg16205897	chr5:131564050	P4HA2	-0.34	-7.62	-0.35	1.7e-13	Blood metabolite levels;
LUAD	cis	rs7647973	1.000	rs11130189	chr3:49347357	C/A	cg07266350	chr3:49460521	AMT;NICN1	-0.39	-6.93	-0.32	1.54e-11	Menarche (age at onset);
LUAD	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg11814155	chr7:99998594	ZCWPW1	0.42	7.44	0.34	5.75e-13	Platelet count;
LUAD	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22968622	chr17:43663579	NA	1.24	21.73	0.73	7.49e-71	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2840044	1.000	rs225277	chr17:33973311	G/A	cg05299278	chr17:33885742	SLFN14	0.42	8.54	0.38	2.42e-16	Response to radiotherapy in cancer (late toxicity);
LUAD	trans	rs7395662	1.000	rs11039777	chr11:48517049	T/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.64	-0.31	9.84e-11	HDL cholesterol;
LUAD	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg04287289	chr16:89883240	FANCA	0.7	6.38	0.3	4.6e-10	Skin colour saturation;
LUAD	trans	rs6561151	0.681	rs4942249	chr13:44426804	C/A	cg12856521	chr11:46389249	DGKZ	0.84	11.5	0.49	7.93e-27	Crohn's disease;
LUAD	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg25804541	chr17:80189381	SLC16A3	0.32	7.09	0.33	5.63e-12	Life satisfaction;
LUAD	trans	rs7395662	0.786	rs12791074	chr11:49005023	G/A	cg15704280	chr7:45808275	SEPT13	-0.44	-7.04	-0.32	7.71e-12	HDL cholesterol;
LUAD	trans	rs877282	0.853	rs7092652	chr10:756109	G/A	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-9.93	-0.43	5.14e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs2797160	1.000	rs984040	chr6:126021277	A/G	cg05901451	chr6:126070800	HEY2	0.43	6.61	0.31	1.15e-10	Endometrial cancer;
LUAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg22105103	chr4:187893119	NA	0.53	11.42	0.49	1.57e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9503598	0.778	rs1328688	chr6:3468508	G/A	cg00476032	chr6:3446245	SLC22A23	0.36	7.79	0.35	5.32e-14	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs4660214	0.666	rs1775656	chr1:39911001	C/T	cg27567593	chr1:39956653	BMP8A	-0.35	-6.94	-0.32	1.46e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg24848339	chr3:12840334	CAND2	0.43	8.92	0.4	1.45e-17	QRS complex (12-leadsum);
LUAD	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.5	10.48	0.45	5.15e-23	Monocyte percentage of white cells;
LUAD	cis	rs68170813	0.559	rs12536485	chr7:106978005	T/C	cg23024343	chr7:107201750	COG5	0.48	6.85	0.32	2.56e-11	Coronary artery disease;
LUAD	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.77	-0.35	5.82e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg03806693	chr22:41940476	POLR3H	-0.61	-8.73	-0.39	6.08e-17	Vitiligo;
LUAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg22907277	chr7:1156413	C7orf50	0.48	8.03	0.36	9.73e-15	Longevity;Endometriosis;
LUAD	cis	rs4285028	0.747	rs12634032	chr3:121524575	G/A	cg11130432	chr3:121712080	ILDR1	-0.57	-8.03	-0.36	9.72e-15	Multiple sclerosis;
LUAD	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg25324976	chr17:61989376	CSHL1	0.38	7.27	0.33	1.76e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs12618769	0.597	rs3754881	chr2:99132093	G/A	cg10123293	chr2:99228465	UNC50	0.47	8.55	0.38	2.34e-16	Bipolar disorder;
LUAD	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg03609598	chr5:56110824	MAP3K1	-0.64	-8.84	-0.39	2.67e-17	Initial pursuit acceleration;
LUAD	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg18306943	chr3:40428807	ENTPD3	0.41	6.86	0.32	2.46e-11	Renal cell carcinoma;
LUAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg04414720	chr1:150670196	GOLPH3L	0.76	13.65	0.55	2.16e-35	Tonsillectomy;
LUAD	cis	rs1232027	0.622	rs6151633	chr5:79966766	G/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.33	-0.34	1.16e-12	Huntington's disease progression;
LUAD	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg05425664	chr17:57184151	TRIM37	-0.43	-7.61	-0.35	1.84e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.84	-0.32	2.87e-11	Systolic blood pressure;
LUAD	cis	rs868036	1.000	rs1026735	chr15:68101700	A/G	cg24579218	chr15:68104479	NA	-0.4	-7.45	-0.34	5.44e-13	Restless legs syndrome;
LUAD	cis	rs2274273	0.875	rs2075602	chr14:55609774	A/G	cg04306507	chr14:55594613	LGALS3	0.41	8.51	0.38	2.98e-16	Protein biomarker;
LUAD	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg27068330	chr11:65405492	SIPA1	0.56	8.87	0.4	2.11e-17	Acne (severe);
LUAD	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1784581	0.651	rs1784593	chr6:162386096	A/T	cg17173639	chr6:162384350	PARK2	-0.51	-9.09	-0.4	3.82e-18	Itch intensity from mosquito bite;
LUAD	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.37	-6.76	-0.31	4.69e-11	Caffeine consumption;
LUAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg00080972	chr5:178986291	RUFY1	-0.71	-12.74	-0.53	1.04e-31	Lung cancer;
LUAD	cis	rs28595532	0.920	rs17323877	chr4:119671188	A/G	cg21605333	chr4:119757512	SEC24D	0.78	6.5	0.3	2.24e-10	Cannabis dependence symptom count;
LUAD	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.42	0.38	5.75e-16	Platelet count;
LUAD	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg08885076	chr2:99613938	TSGA10	0.37	6.75	0.31	4.83e-11	Chronic sinus infection;
LUAD	cis	rs9604529	0.557	rs74841821	chr13:114742213	G/A	cg24241305	chr13:114826075	RASA3	-0.45	-6.83	-0.32	2.98e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12711979	1.000	rs6542655	chr2:3872434	T/C	cg17052675	chr2:3827356	NA	-0.48	-8.77	-0.39	4.25e-17	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-9.74	-0.43	2.36e-20	Gut microbiome composition (summer);
LUAD	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg17971929	chr21:40555470	PSMG1	0.52	8.27	0.37	1.82e-15	Cognitive function;
LUAD	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg00666640	chr1:248458726	OR2T12	0.32	7.88	0.36	2.86e-14	Common traits (Other);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06620762	chr15:76136437	UBE2Q2	-0.42	-6.64	-0.31	9.43e-11	Height;
LUAD	cis	rs6062509	0.732	rs6062304	chr20:62351539	A/T	cg01176363	chr20:62369445	LIME1	-0.47	-7.66	-0.35	1.27e-13	Prostate cancer;
LUAD	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg10802521	chr3:52805072	NEK4	-0.38	-6.5	-0.3	2.26e-10	Electroencephalogram traits;
LUAD	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg08027265	chr7:2291960	NA	-0.46	-8.23	-0.37	2.42e-15	Schizophrenia;
LUAD	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.47	0.52	1.27e-30	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg26811252	chr16:29126840	RRN3P2	0.6	10.24	0.45	3.99e-22	Menopause (age at onset);
LUAD	cis	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg21775007	chr8:11205619	TDH	0.57	10.08	0.44	1.5e-21	Retinal vascular caliber;
LUAD	cis	rs909002	0.703	rs4949460	chr1:32143138	A/G	cg13919466	chr1:32135498	COL16A1	0.33	7.89	0.36	2.7e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg07570687	chr10:102243282	WNT8B	0.45	6.84	0.32	2.73e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.44	-8.45	-0.38	4.89e-16	Longevity;Endometriosis;
LUAD	cis	rs2224391	0.554	rs114825667	chr6:5242618	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-8.74	-0.39	5.46e-17	Height;
LUAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.18	0.54	1.83e-33	Prudent dietary pattern;
LUAD	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg17545662	chr6:170176663	C6orf70	0.43	7.5	0.34	3.82e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15369054	chr17:80825471	TBCD	-0.43	-7.17	-0.33	3.4e-12	Breast cancer;
LUAD	trans	rs57024841	0.562	rs7862602	chr9:139840471	G/T	cg16658931	chr19:51171061	SHANK1	-0.35	-6.61	-0.31	1.15e-10	Beta-trace protein levels;
LUAD	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg07423050	chr13:99094983	FARP1	-0.54	-9.09	-0.4	3.81e-18	Longevity;
LUAD	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg18404041	chr3:52824283	ITIH1	0.41	7.46	0.34	5e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg27446573	chr6:127587934	RNF146	0.43	6.63	0.31	1.03e-10	Breast cancer;
LUAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg11062466	chr8:58055876	NA	0.84	10.6	0.46	2.01e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg09904177	chr6:26538194	HMGN4	0.42	6.92	0.32	1.68e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg06046430	chr4:77819534	ANKRD56	0.54	8.64	0.39	1.21e-16	Emphysema distribution in smoking;
LUAD	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.16	0.37	3.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg18827107	chr12:86230957	RASSF9	-0.45	-8.22	-0.37	2.47e-15	Major depressive disorder;
LUAD	cis	rs2882667	0.858	rs13174479	chr5:138444170	G/A	cg04439458	chr5:138467593	SIL1	-0.53	-9.53	-0.42	1.27e-19	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg22676075	chr6:135203613	NA	0.4	7.35	0.34	1.02e-12	Red blood cell count;
LUAD	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21659725	chr3:3221576	CRBN	0.86	18.51	0.67	1.87e-56	Intelligence (multi-trait analysis);
LUAD	cis	rs1160297	0.576	rs724860	chr2:53099406	A/G	cg07782112	chr2:53107842	NA	0.43	9.2	0.41	1.61e-18	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg03929089	chr4:120376271	NA	-0.71	-10.63	-0.46	1.47e-23	Coronary artery disease;
LUAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg13047869	chr3:10149882	C3orf24	0.64	10.67	0.46	1.08e-23	Alzheimer's disease;
LUAD	cis	rs6543140	0.929	rs11465700	chr2:103057668	G/A	cg04239558	chr2:103089729	SLC9A4	0.34	6.93	0.32	1.6e-11	Blood protein levels;
LUAD	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg00071950	chr4:10020882	SLC2A9	-0.72	-14.32	-0.57	3.22e-38	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1983170	0.736	rs745731	chr1:92011467	G/T	cg02896835	chr1:92012615	NA	0.57	8.0	0.36	1.17e-14	Eosinophil percentage of white cells;
LUAD	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg18016565	chr1:150552671	MCL1	-0.44	-7.46	-0.34	4.87e-13	Urate levels;
LUAD	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg11833968	chr6:79620685	NA	-0.42	-7.86	-0.36	3.12e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg26536354	chr8:144654954	C8orf73	0.62	6.78	0.31	4.05e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg25457927	chr22:38595422	NA	0.53	13.82	0.56	3.95e-36	Cutaneous nevi;
LUAD	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.41	-6.41	-0.3	3.8e-10	Menarche (age at onset);
LUAD	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg17366294	chr4:99064904	C4orf37	0.66	12.82	0.53	5.17e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg22823121	chr1:150693482	HORMAD1	-0.44	-8.83	-0.39	2.74e-17	Tonsillectomy;
LUAD	trans	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.9	-0.36	2.44e-14	Depression;
LUAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.46	0.55	1.28e-34	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.27e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.938	rs9626814	chr22:46637254	C/T	cg09491104	chr22:46646882	C22orf40	-0.57	-8.94	-0.4	1.25e-17	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs73198271	0.515	rs1589613	chr8:8626940	T/C	cg01851573	chr8:8652454	MFHAS1	0.58	7.8	0.35	4.89e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs11945232	0.929	rs28736552	chr4:88356111	T/C	cg23841344	chr4:88312519	HSD17B11	-0.53	-7.64	-0.35	1.51e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2637266	1.000	rs10219107	chr10:78364369	T/C	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.72e-11	Pulmonary function;
LUAD	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg09904177	chr6:26538194	HMGN4	-0.4	-6.6	-0.31	1.25e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg09455208	chr3:40491958	NA	0.65	14.33	0.57	2.99e-38	Renal cell carcinoma;
LUAD	cis	rs8192282	0.739	rs7539745	chr1:154526414	C/G	cg16683920	chr1:154474344	TDRD10;SHE	-0.46	-7.05	-0.32	7.32e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4285028	0.948	rs7651226	chr3:121670802	G/T	cg20356878	chr3:121714668	ILDR1	-0.51	-6.83	-0.32	3.03e-11	Multiple sclerosis;
LUAD	cis	rs1595825	0.891	rs996427	chr2:198685609	G/A	cg11031976	chr2:198649780	BOLL	-0.46	-6.96	-0.32	1.28e-11	Ulcerative colitis;
LUAD	cis	rs1113500	0.933	rs10881497	chr1:108634515	A/G	cg06207961	chr1:108661230	NA	-0.45	-8.54	-0.38	2.5e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg24675056	chr1:15929824	NA	0.46	7.92	0.36	2.09e-14	Systolic blood pressure;
LUAD	cis	rs2908197	0.699	rs2860469	chr7:75960506	A/C	cg24580635	chr7:76178542	LOC100133091	-0.42	-6.57	-0.3	1.47e-10	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg00310523	chr12:86230176	RASSF9	0.34	7.35	0.34	1.06e-12	Major depressive disorder;
LUAD	cis	rs427394	0.659	rs274674	chr5:6755460	C/T	cg10857441	chr5:6722123	POLS	-0.61	-10.78	-0.46	4.2e-24	Menopause (age at onset);
LUAD	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg21211367	chr2:162094118	NA	0.45	7.97	0.36	1.46e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg05342682	chr7:94953680	PON1	0.51	7.13	0.33	4.27e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2274273	0.905	rs8007620	chr14:55586587	T/C	cg04306507	chr14:55594613	LGALS3	0.38	7.82	0.36	4.18e-14	Protein biomarker;
LUAD	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg13511324	chr14:104056883	C14orf153	0.26	6.49	0.3	2.43e-10	Coronary artery disease;
LUAD	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg12310025	chr6:25882481	NA	-0.97	-17.39	-0.65	1.66e-51	Urate levels;
LUAD	cis	rs10193935	0.892	rs7574609	chr2:42388468	C/A	cg27598129	chr2:42591480	NA	-0.72	-9.44	-0.42	2.59e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4853036	0.638	rs55723319	chr2:70118385	C/T	cg02498382	chr2:70120550	SNRNP27	-0.55	-7.2	-0.33	2.68e-12	Colorectal or endometrial cancer;
LUAD	cis	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg07460842	chr6:66804631	NA	-1.04	-16.27	-0.62	1.46e-46	Exhaled nitric oxide output;
LUAD	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg17761419	chr8:57350749	NA	-0.52	-7.86	-0.36	3.16e-14	Obesity-related traits;
LUAD	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs2688608	0.901	rs2675671	chr10:75632760	C/T	cg19442545	chr10:75533431	FUT11	-0.42	-7.12	-0.33	4.59e-12	Inflammatory bowel disease;
LUAD	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg12432903	chr7:1882776	MAD1L1	-0.5	-8.28	-0.37	1.64e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg00634984	chr7:65235879	NA	-0.47	-6.51	-0.3	2.15e-10	Aortic root size;
LUAD	cis	rs2050392	1.000	rs2183176	chr10:30698544	C/T	cg18806716	chr10:30721971	MAP3K8	0.52	10.38	0.45	1.19e-22	Inflammatory bowel disease;
LUAD	cis	rs2554380	0.628	rs4843158	chr15:84471636	G/C	cg14598478	chr15:84363061	ADAMTSL3	-0.39	-6.76	-0.31	4.62e-11	Height;
LUAD	cis	rs11229555	0.874	rs11605269	chr11:58350872	A/G	cg15696309	chr11:58395628	NA	-0.72	-10.3	-0.45	2.35e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10513696	chr12:27863634	MRPS35	-0.42	-6.42	-0.3	3.6e-10	Height;
LUAD	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg26818010	chr10:134567672	INPP5A	-0.97	-15.56	-0.6	1.65e-43	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs3849570	0.555	rs9968070	chr3:82010368	G/A	cg07356753	chr3:81810745	GBE1	-0.52	-8.68	-0.39	8.94e-17	Waist circumference;Body mass index;
LUAD	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg16479474	chr6:28041457	NA	0.43	7.38	0.34	8.39e-13	Depression;
LUAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.56	-6.99	-0.32	1.09e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg00071950	chr4:10020882	SLC2A9	0.83	17.76	0.65	4.05e-53	Bone mineral density;
LUAD	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg11833968	chr6:79620685	NA	-0.44	-8.17	-0.37	3.56e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs11209185	0.545	rs1926284	chr1:68446291	T/C	cg22082780	chr1:68452167	NA	0.51	10.49	0.45	4.74e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	trans	rs9411298	0.630	rs9411299	chr9:139938793	C/G	cg16658931	chr19:51171061	SHANK1	0.41	6.49	0.3	2.45e-10	Monocyte percentage of white cells;
LUAD	cis	rs3784262	1.000	rs4646586	chr15:58305344	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.47	-9.58	-0.42	8.44e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs4638749	0.677	rs115510885	chr2:108824365	C/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.27	-0.33	1.76e-12	Blood pressure;
LUAD	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg14769373	chr6:40998127	UNC5CL	0.36	6.36	0.3	5.4e-10	Alzheimer's disease (late onset);
LUAD	cis	rs11048434	0.736	rs11048344	chr12:9122609	G/C	cg23795048	chr12:9217529	LOC144571	0.41	7.51	0.34	3.54e-13	Sjögren's syndrome;
LUAD	cis	rs12545109	0.800	rs2118260	chr8:57393481	T/C	cg11919837	chr8:57350735	NA	-0.46	-6.57	-0.3	1.44e-10	Obesity-related traits;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01406341	chr2:220042724	FAM134A;C2orf24	-0.42	-6.87	-0.32	2.24e-11	Cancer;
LUAD	cis	rs7010267	0.740	rs7464496	chr8:119954842	T/C	cg01975934	chr8:119970761	NA	-0.35	-6.61	-0.31	1.17e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg22823121	chr1:150693482	HORMAD1	0.47	9.15	0.41	2.46e-18	Tonsillectomy;
LUAD	cis	rs868036	0.918	rs4776967	chr15:68033922	T/C	cg24579218	chr15:68104479	NA	-0.42	-7.63	-0.35	1.56e-13	Restless legs syndrome;
LUAD	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg17788362	chr6:86352627	SYNCRIP	0.4	6.39	0.3	4.35e-10	Smooth-surface caries;
LUAD	trans	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg01620082	chr3:125678407	NA	0.4	6.36	0.3	5.23e-10	Parkinson's disease;
LUAD	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg18252515	chr7:66147081	NA	0.6	6.68	0.31	7.56e-11	Diabetic kidney disease;
LUAD	cis	rs1595825	0.891	rs58409972	chr2:198897061	A/T	cg00361562	chr2:198649771	BOLL	-0.53	-7.05	-0.32	7.36e-12	Ulcerative colitis;
LUAD	cis	rs9972944	0.756	rs9907969	chr17:63754860	G/T	cg07283582	chr17:63770753	CCDC46	-0.52	-11.77	-0.5	7.57e-28	Total body bone mineral density;
LUAD	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg11663144	chr21:46675770	NA	-0.51	-9.14	-0.41	2.63e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.4	8.66	0.39	1.02e-16	Tonsillectomy;
LUAD	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-20.84	-0.71	6.96e-67	Height;
LUAD	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg23281280	chr6:28129359	ZNF389	0.48	6.71	0.31	6.44e-11	Depression;
LUAD	cis	rs11811982	0.793	rs77071507	chr1:227407469	T/C	cg24860534	chr1:227506868	CDC42BPA	0.64	7.2	0.33	2.79e-12	Optic disc area;
LUAD	cis	rs490234	0.683	rs2841326	chr9:128161768	G/A	cg13590414	chr9:128173245	NA	-0.33	-6.51	-0.3	2.08e-10	Mean arterial pressure;
LUAD	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg27411982	chr8:10470053	RP1L1	0.4	7.05	0.32	7.51e-12	Retinal vascular caliber;
LUAD	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	7.86	0.36	3.27e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg00147160	chr1:26503991	CNKSR1	0.39	9.09	0.4	3.85e-18	Height;
LUAD	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg15445000	chr17:37608096	MED1	0.44	8.14	0.37	4.43e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg01324343	chr3:183735012	ABCC5	0.93	24.93	0.77	4.85e-85	Anterior chamber depth;
LUAD	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg10755058	chr3:40428713	ENTPD3	0.34	6.51	0.3	2.13e-10	Renal cell carcinoma;
LUAD	cis	rs7945718	1.000	rs12269900	chr11:12748518	G/A	cg25843174	chr11:12811716	TEAD1	0.24	7.08	0.33	6.02e-12	Educational attainment (years of education);
LUAD	cis	rs3931020	0.688	rs968358	chr1:75193989	G/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.48	6.36	0.3	5.26e-10	Resistin levels;
LUAD	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg18944383	chr4:111397179	ENPEP	0.38	7.58	0.35	2.18e-13	Height;
LUAD	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg13319975	chr6:146136371	FBXO30	-0.79	-13.58	-0.55	4.1e-35	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg19862616	chr7:65841803	NCRNA00174	1.04	25.7	0.78	2.02e-88	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg02869364	chr7:1081709	C7orf50	-0.51	-6.61	-0.31	1.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.64	-10.06	-0.44	1.74e-21	Lymphocyte percentage of white cells;
LUAD	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg22532475	chr10:104410764	TRIM8	0.36	7.17	0.33	3.27e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.64	0.31	9.42e-11	Depression;
LUAD	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-9.27	-0.41	9.75e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs698833	0.886	rs698824	chr2:44723123	G/T	cg04920474	chr2:44395004	PPM1B	0.36	6.5	0.3	2.29e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs897080	0.552	rs1085442	chr2:44635454	C/A	cg00619915	chr2:44497795	NA	-0.43	-6.69	-0.31	7.22e-11	Height;
LUAD	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg08632164	chr7:65971372	NA	-0.37	-6.39	-0.3	4.41e-10	Aortic root size;
LUAD	cis	rs2268241	0.938	rs9978166	chr21:34770516	A/G	cg14850771	chr21:34775459	IFNGR2	0.64	7.6	0.35	1.96e-13	Obesity-related traits;
LUAD	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg07741184	chr6:167504864	NA	-0.28	-6.77	-0.31	4.37e-11	Primary biliary cholangitis;
LUAD	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.57	-0.35	2.3e-13	Blood metabolite levels;
LUAD	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.57	-0.42	8.77e-20	Schizophrenia;
LUAD	cis	rs12079745	0.793	rs12062884	chr1:169209513	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.1	-8.03	-0.36	9.8e-15	QT interval;
LUAD	cis	rs9487051	0.768	rs9398188	chr6:109526615	G/A	cg01475377	chr6:109611718	NA	-0.38	-6.76	-0.31	4.47e-11	Reticulocyte fraction of red cells;
LUAD	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-24.12	-0.76	1.69e-81	Height;
LUAD	cis	rs9811920	0.809	rs1384062	chr3:99597928	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.61	11.72	0.5	1.15e-27	Axial length;
LUAD	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg09222892	chr1:25734099	RHCE	-0.5	-9.36	-0.41	4.7e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg11494091	chr17:61959527	GH2	0.74	18.63	0.67	5.61e-57	Prudent dietary pattern;
LUAD	cis	rs7020830	0.894	rs28766572	chr9:37093872	G/T	cg14294708	chr9:37120828	ZCCHC7	0.81	15.81	0.61	1.45e-44	Schizophrenia;
LUAD	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg04414720	chr1:150670196	GOLPH3L	0.66	11.71	0.49	1.27e-27	Tonsillectomy;
LUAD	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg27446573	chr6:127587934	RNF146	0.43	6.54	0.3	1.81e-10	Breast cancer;
LUAD	cis	rs62238980	0.614	rs117185558	chr22:32403523	A/G	cg00543991	chr22:32367038	NA	0.96	9.05	0.4	5.32e-18	Childhood ear infection;
LUAD	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg03396347	chr1:1875803	NA	-0.6	-14.85	-0.59	1.91e-40	Body mass index;
LUAD	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg27411982	chr8:10470053	RP1L1	0.38	7.05	0.32	7.24e-12	Retinal vascular caliber;
LUAD	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg14008862	chr17:28927542	LRRC37B2	0.64	6.36	0.3	5.12e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg07507251	chr3:52567010	NT5DC2	0.34	6.59	0.31	1.27e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs738322	0.554	rs6001033	chr22:38557513	T/A	cg25457927	chr22:38595422	NA	-0.54	-12.8	-0.53	6.38e-32	Cutaneous nevi;
LUAD	cis	rs3806843	0.576	rs246074	chr5:140307969	C/G	cg18668511	chr5:140557227	PCDHB8	-0.38	-6.82	-0.31	3.22e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11971779	0.680	rs3924445	chr7:139044172	C/A	cg23387468	chr7:139079360	LUC7L2	0.28	6.49	0.3	2.47e-10	Diisocyanate-induced asthma;
LUAD	cis	rs1941023	0.584	rs7935082	chr11:60155000	T/C	cg08716584	chr11:60157161	MS4A7	-0.48	-9.3	-0.41	7.57e-19	Congenital heart disease (maternal effect);
LUAD	cis	rs12760731	0.641	rs11588490	chr1:178328139	T/A	cg00404053	chr1:178313656	RASAL2	0.66	8.48	0.38	3.81e-16	Obesity-related traits;
LUAD	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg04414720	chr1:150670196	GOLPH3L	0.6	10.26	0.45	3.2800000000000002e-22	Melanoma;
LUAD	cis	rs713477	1.000	rs28604440	chr14:55911324	C/T	cg13175173	chr14:55914753	NA	-0.33	-6.84	-0.32	2.79e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.53	0.34	3.03e-13	Bipolar disorder;
LUAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.75	-0.31	4.76e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2067615	0.524	rs4964187	chr12:107080313	C/A	cg15890332	chr12:107067104	RFX4	0.41	8.66	0.39	9.81e-17	Heart rate;
LUAD	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg03474202	chr17:45855739	NA	0.32	7.11	0.33	4.82e-12	IgG glycosylation;
LUAD	trans	rs116939006	1.000	rs11988587	chr8:14267835	G/T	cg16330849	chr6:10694809	C6orf52;PAK1IP1	-0.69	-6.64	-0.31	9.46e-11	Response to paliperidone in schizophrenia (negative Marder score);
LUAD	cis	rs3790645	0.958	rs2290589	chr1:26880288	C/T	cg23229016	chr1:26872525	RPS6KA1	0.21	6.84	0.32	2.78e-11	Glucose homeostasis traits;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06419771	chr15:42264912	EHD4	-0.43	-6.6	-0.31	1.25e-10	Height;
LUAD	cis	rs829883	0.724	rs1439774	chr12:98907692	C/T	cg25150519	chr12:98850993	NA	-0.53	-8.24	-0.37	2.2e-15	Colorectal adenoma (advanced);
LUAD	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.65	9.65	0.42	4.84e-20	Lymphocyte percentage of white cells;
LUAD	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg09904177	chr6:26538194	HMGN4	0.44	7.39	0.34	7.86e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-7.47	-0.34	4.66e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg25173405	chr17:45401733	C17orf57	-0.49	-8.05	-0.36	8.31e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs240764	0.658	rs4840147	chr6:101182323	T/C	cg09795085	chr6:101329169	ASCC3	-0.48	-8.55	-0.38	2.24e-16	Neuroticism;
LUAD	cis	rs7759001	0.857	rs6934933	chr6:27354862	T/C	cg18711553	chr6:27366782	ZNF391	0.39	6.43	0.3	3.36e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg27432699	chr2:27873401	GPN1	-0.38	-6.44	-0.3	3.21e-10	Total body bone mineral density;
LUAD	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg15691649	chr6:25882328	NA	0.45	7.34	0.34	1.08e-12	Blood metabolite levels;
LUAD	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg19980929	chr12:42632907	YAF2	0.33	6.43	0.3	3.52e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07157834	chr1:205819609	PM20D1	-0.63	-11.6	-0.49	3.21e-27	Monocyte percentage of white cells;
LUAD	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03264133	chr6:25882463	NA	-0.49	-7.41	-0.34	6.85e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03934478	chr11:495069	RNH1	0.76	8.92	0.4	1.44e-17	Body mass index;
LUAD	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg17366294	chr4:99064904	C4orf37	0.47	8.38	0.38	8.17e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs9393777	0.778	rs35741362	chr6:27007687	T/C	cg01620082	chr3:125678407	NA	-0.71	-8.27	-0.37	1.75e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg03713592	chr11:72463424	ARAP1	0.57	7.3	0.33	1.44e-12	Type 2 diabetes;
LUAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.87	17.01	0.64	8.13e-50	Lymphocyte counts;
LUAD	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg00717180	chr2:96193071	NA	-0.41	-7.55	-0.34	2.76e-13	HDL cholesterol;
LUAD	cis	rs2734839	0.964	rs1107162	chr11:113289037	A/G	cg14159747	chr11:113255604	NA	-0.54	-10.24	-0.45	3.99e-22	Information processing speed;
LUAD	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1497406	0.744	rs1007887	chr1:16509029	C/T	cg20430773	chr1:16534157	ARHGEF19	0.37	6.41	0.3	4e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg11833968	chr6:79620685	NA	0.44	7.75	0.35	6.88e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg20203395	chr5:56204925	C5orf35	-0.65	-10.01	-0.44	2.53e-21	Initial pursuit acceleration;
LUAD	cis	rs4460629	0.712	rs11264313	chr1:155076505	A/G	cg23973274	chr1:155060172	NA	-0.37	-6.4	-0.3	4.19e-10	Serum magnesium levels;
LUAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.81	-0.31	3.27e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg20203395	chr5:56204925	C5orf35	0.64	9.82	0.43	1.18e-20	Initial pursuit acceleration;
LUAD	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg21475434	chr5:93447410	FAM172A	-0.58	-7.44	-0.34	5.48e-13	Diabetic retinopathy;
LUAD	trans	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg26043149	chr18:55253948	FECH	0.42	6.95	0.32	1.36e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg10356904	chr22:49881777	NA	-0.41	-7.95	-0.36	1.73e-14	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.44	-0.49	1.38e-26	Primary sclerosing cholangitis;
LUAD	trans	rs1997103	1.000	rs6949222	chr7:55411264	C/T	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1395	0.778	rs56364136	chr2:27451429	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.41	7.72	0.35	8.39e-14	Blood metabolite levels;
LUAD	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg18446336	chr7:2847575	GNA12	-0.36	-6.71	-0.31	6.11e-11	Height;
LUAD	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg10591111	chr5:226296	SDHA	-0.55	-7.13	-0.33	4.26e-12	Breast cancer;
LUAD	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg25894440	chr7:65020034	NA	-0.6	-6.48	-0.3	2.61e-10	Diabetic kidney disease;
LUAD	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg06636551	chr8:101224915	SPAG1	-0.37	-6.76	-0.31	4.62e-11	Atrioventricular conduction;
LUAD	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg18944383	chr4:111397179	ENPEP	-0.39	-7.05	-0.32	7.46e-12	Coronary artery disease;
LUAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg21226059	chr5:178986404	RUFY1	0.59	10.06	0.44	1.71e-21	Lung cancer;
LUAD	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.71	-0.35	9.25e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg18404041	chr3:52824283	ITIH1	0.56	9.3	0.41	7.69e-19	Schizophrenia;
LUAD	cis	rs8060686	0.516	rs9939821	chr16:68167787	T/A	cg05110241	chr16:68378359	PRMT7	-0.58	-7.26	-0.33	1.86e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7707921	1.000	rs4703879	chr5:81553815	C/T	cg15871215	chr5:81402204	ATG10	-0.7	-10.04	-0.44	2.03e-21	Breast cancer;
LUAD	cis	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg09526685	chr4:187126073	CYP4V2	0.88	9.74	0.43	2.27e-20	Blood protein levels;
LUAD	trans	rs75804782	0.521	rs55657931	chr2:239422072	A/G	cg01134436	chr17:81009848	B3GNTL1	0.56	6.51	0.3	2.15e-10	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg26408565	chr15:76604113	ETFA	-0.45	-7.3	-0.33	1.46e-12	Blood metabolite levels;
LUAD	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg26677194	chr12:130822605	PIWIL1	0.55	9.07	0.4	4.52e-18	Menopause (age at onset);
LUAD	cis	rs4006360	0.503	rs1848808	chr17:39249321	T/C	cg16090541	chr17:39240343	KRTAP4-7	-0.36	-6.42	-0.3	3.75e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs220324	0.688	rs2012103	chr21:43561369	A/G	cg08841829	chr21:43638893	ABCG1	-0.48	-6.49	-0.3	2.38e-10	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg12011299	chr4:100065546	ADH4	-0.72	-13.09	-0.54	4.31e-33	Alcohol dependence;
LUAD	cis	rs13082711	0.911	rs2887926	chr3:27494475	T/C	cg02860705	chr3:27208620	NA	0.57	8.74	0.39	5.33e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs990171	0.538	rs11687071	chr2:103111920	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	6.57	0.3	1.52e-10	Lymphocyte counts;
LUAD	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg13010199	chr12:38710504	ALG10B	0.39	6.38	0.3	4.74e-10	Bladder cancer;
LUAD	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-6.41	-0.3	3.97e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg09085632	chr11:111637200	PPP2R1B	0.62	9.35	0.41	4.96e-19	Primary sclerosing cholangitis;
LUAD	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.96	0.4	1.04e-17	Menarche (age at onset);
LUAD	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.85	0.32	2.58e-11	Schizophrenia;
LUAD	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.33	-0.34	1.14e-12	Lung cancer;
LUAD	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg03676636	chr4:99064102	C4orf37	0.29	7.0	0.32	1.02e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7551222	0.752	rs4328119	chr1:204564986	C/T	cg20240347	chr1:204465584	NA	-0.33	-6.43	-0.3	3.35e-10	Schizophrenia;
LUAD	trans	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.08	-0.33	6.23e-12	Dental caries;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg24426209	chr7:92157939	PEX1;C7orf64	-0.65	-6.69	-0.31	7.29e-11	Type 2 diabetes;
LUAD	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg06784218	chr1:46089804	CCDC17	0.54	11.63	0.49	2.67e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg09998033	chr7:158218633	PTPRN2	-0.54	-9.68	-0.43	3.77e-20	Obesity-related traits;
LUAD	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.12e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg21028142	chr17:79581711	NPLOC4	0.36	7.16	0.33	3.7e-12	Eye color traits;
LUAD	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05901451	chr6:126070800	HEY2	-0.81	-15.18	-0.59	7.69e-42	Brugada syndrome;
LUAD	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs9826463	0.818	rs9858204	chr3:142299855	C/T	cg20824294	chr3:142316082	PLS1	0.43	7.8	0.35	4.86e-14	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs617219	0.889	rs4466139	chr5:78430058	T/C	cg25119155	chr5:78426943	BHMT	0.35	6.36	0.3	5.23e-10	Betaine levels in individuals undergoing cardiac evaluation;
LUAD	cis	rs727505	1.000	rs722560	chr7:124488035	T/C	cg23710748	chr7:124431027	NA	-0.49	-9.92	-0.43	5.5e-21	Lewy body disease;
LUAD	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg21862992	chr11:68658383	NA	0.53	10.0	0.44	2.82e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1847202	0.762	rs62249896	chr3:72949857	C/G	cg25664220	chr3:72788482	NA	-0.42	-7.37	-0.34	9.09e-13	Motion sickness;
LUAD	cis	rs11809207	0.501	rs3762460	chr1:26495550	A/G	cg00300879	chr1:26503847	CNKSR1	0.27	7.57	0.35	2.42e-13	Height;
LUAD	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.73	-0.39	5.83e-17	Total body bone mineral density;
LUAD	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg08859206	chr1:53392774	SCP2	-0.5	-9.03	-0.4	6.3e-18	Monocyte count;
LUAD	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg03676636	chr4:99064102	C4orf37	0.32	8.4	0.38	6.98e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62238980	0.614	rs77621610	chr22:32503278	A/G	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs6693567	0.565	rs578353	chr1:150287884	C/G	cg15654264	chr1:150340011	RPRD2	0.37	6.76	0.31	4.63e-11	Migraine;
LUAD	cis	rs7274811	0.711	rs291669	chr20:31945364	C/T	cg14921437	chr20:32255988	NECAB3;C20orf134	0.51	7.92	0.36	2.12e-14	Height;
LUAD	cis	rs77861329	0.920	rs808787	chr3:52203249	G/A	cg08692210	chr3:52188851	WDR51A	0.86	8.27	0.37	1.79e-15	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs250677	0.687	rs250679	chr5:148434952	A/T	cg23229984	chr5:148520753	ABLIM3	-0.41	-6.52	-0.3	1.99e-10	Breast cancer;
LUAD	trans	rs2544390	1.000	rs2673172	chr2:170204800	A/C	cg24201716	chr10:115933917	C10orf118;MIR2110	-0.36	-6.43	-0.3	3.44e-10	Urate levels;
LUAD	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-20.58	-0.71	1.06e-65	Height;
LUAD	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg00271210	chr6:167070053	RPS6KA2	0.34	6.42	0.3	3.75e-10	Crohn's disease;
LUAD	cis	rs7536201	1.000	rs2063112	chr1:25303905	G/A	cg23273869	chr1:25296894	NA	-0.4	-8.07	-0.37	7.41e-15	Psoriasis vulgaris;
LUAD	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.61	-0.35	1.83e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6543140	0.855	rs4851591	chr2:103077423	T/C	cg03938978	chr2:103052716	IL18RAP	0.35	6.8	0.31	3.6e-11	Blood protein levels;
LUAD	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg18833306	chr6:118973337	C6orf204	-0.52	-7.49	-0.34	3.93e-13	Diastolic blood pressure;
LUAD	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg05966235	chr16:28915196	ATP2A1	-0.4	-6.41	-0.3	3.95e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs3087591	0.821	rs12949024	chr17:29445086	A/T	cg24425628	chr17:29625626	OMG;NF1	0.45	6.96	0.32	1.33e-11	Hip circumference;
LUAD	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg04025307	chr7:1156635	C7orf50	0.59	8.94	0.4	1.22e-17	Bronchopulmonary dysplasia;
LUAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg05434287	chr7:2030229	MAD1L1	0.44	7.44	0.34	5.74e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs1595825	0.891	rs77946222	chr2:198533251	C/T	cg00982548	chr2:198649783	BOLL	-0.61	-8.53	-0.38	2.71e-16	Ulcerative colitis;
LUAD	cis	rs7771547	0.508	rs3798471	chr6:36499571	C/T	cg07856975	chr6:36356162	ETV7	0.42	6.47	0.3	2.69e-10	Platelet distribution width;
LUAD	cis	rs938554	0.542	rs7678287	chr4:10000501	A/G	cg02734326	chr4:10020555	SLC2A9	0.47	6.7	0.31	6.79e-11	Blood metabolite levels;
LUAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg03188948	chr7:1209495	NA	0.83	10.1	0.44	1.29e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg19487717	chr11:70263216	CTTN	-0.38	-6.61	-0.31	1.17e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg09117114	chr16:67998030	SLC12A4	-0.47	-6.75	-0.31	4.93e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4900538	0.963	rs8017980	chr14:102961341	C/G	cg18135206	chr14:102964638	TECPR2	1.07	23.72	0.76	1.01e-79	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg01851573	chr8:8652454	MFHAS1	-0.43	-7.62	-0.35	1.63e-13	Mood instability;
LUAD	cis	rs7520050	1.000	rs785473	chr1:46516863	T/C	cg06784218	chr1:46089804	CCDC17	-0.31	-6.58	-0.3	1.4e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs1832871	0.711	rs9459918	chr6:158703604	A/C	cg07165851	chr6:158734300	TULP4	0.71	11.01	0.47	5.8e-25	Height;
LUAD	trans	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.55	9.34	0.41	5.51e-19	Brugada syndrome;
LUAD	cis	rs1030877	0.515	rs1020064	chr2:105897740	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.41	6.63	0.31	1.03e-10	Obesity-related traits;
LUAD	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.04	0.32	7.83e-12	Colorectal cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13236315	chr12:53645720	MFSD5	-0.41	-6.52	-0.3	2.04e-10	Height;
LUAD	cis	rs8130944	0.859	rs11702318	chr21:44112366	C/T	cg16784985	chr21:44105474	PDE9A	-0.39	-6.67	-0.31	8.15e-11	Perceived unattractiveness to mosquitoes;
LUAD	trans	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg03886242	chr7:26192032	NFE2L3	-0.42	-7.51	-0.34	3.59e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg06606381	chr12:133084897	FBRSL1	-0.71	-8.3	-0.37	1.45e-15	Depression;
LUAD	cis	rs2108225	0.872	rs7792139	chr7:107445433	G/A	cg18560240	chr7:107437656	SLC26A3	-0.45	-7.42	-0.34	6.47e-13	Ulcerative colitis;
LUAD	cis	rs10129255	0.500	rs8004923	chr14:107194164	A/G	cg07958169	chr14:107095056	NA	-0.37	-7.35	-0.34	1.05e-12	Kawasaki disease;
LUAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08677398	chr8:58056175	NA	0.52	6.78	0.31	3.94e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.73	-0.35	8.09e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs58804349	0.685	rs11239855	chr10:43483879	A/G	cg15903213	chr10:43522190	NA	0.62	6.53	0.3	1.9e-10	Pediatric bone mineral content (radius);
LUAD	cis	rs17095355	1.000	rs7080576	chr10:111710817	C/T	cg00817464	chr10:111662876	XPNPEP1	0.71	9.84	0.43	1.03e-20	Biliary atresia;
LUAD	cis	rs7107174	1.000	rs10899477	chr11:78052104	A/T	cg02023728	chr11:77925099	USP35	0.46	7.1	0.33	5.37e-12	Testicular germ cell tumor;
LUAD	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.5e-19	Life satisfaction;
LUAD	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg07606381	chr6:8435919	SLC35B3	0.44	7.24	0.33	2.18e-12	Motion sickness;
LUAD	cis	rs1595825	0.838	rs73056856	chr2:198801209	C/G	cg00982548	chr2:198649783	BOLL	-0.63	-8.98	-0.4	8.75e-18	Ulcerative colitis;
LUAD	cis	rs9372498	0.505	rs62422248	chr6:118987610	T/C	cg21191810	chr6:118973309	C6orf204	-0.54	-8.47	-0.38	4e-16	Diastolic blood pressure;
LUAD	cis	rs1953600	0.870	rs2573356	chr10:81949363	C/T	cg04850286	chr10:81895943	PLAC9	0.36	6.48	0.3	2.63e-10	Sarcoidosis;
LUAD	cis	rs708547	0.647	rs6843644	chr4:57891239	G/A	cg00922110	chr4:57842668	C4orf14	-0.42	-7.89	-0.36	2.54e-14	Response to bleomycin (chromatid breaks);
LUAD	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24838063	chr12:130822603	PIWIL1	0.64	10.7	0.46	8.19e-24	Menopause (age at onset);
LUAD	cis	rs1957429	0.808	rs11628910	chr14:65332392	A/G	cg23373153	chr14:65346875	NA	0.6	6.6	0.31	1.2e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg09640425	chr7:158790006	NA	-0.48	-8.05	-0.36	8.33e-15	Facial morphology (factor 20);
LUAD	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg14416269	chr4:6271139	WFS1	0.62	13.16	0.54	2.09e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6446731	0.734	rs10937921	chr4:3276491	C/T	cg08886695	chr4:3369023	RGS12	-0.4	-6.45	-0.3	3.07e-10	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs656900	0.647	rs898436	chr15:80117132	C/T	cg02196730	chr15:80188777	MTHFS	-0.42	-7.13	-0.33	4.41e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4631830	0.863	rs2926494	chr10:51517356	T/C	cg20129853	chr10:51489980	NA	-0.33	-6.48	-0.3	2.59e-10	Prostate-specific antigen levels;
LUAD	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg17749961	chr2:30669863	LCLAT1	0.49	6.38	0.3	4.71e-10	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg24818145	chr4:99064322	C4orf37	0.46	7.61	0.35	1.75e-13	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg20587970	chr11:113659929	NA	-1.44	-20.72	-0.71	2.39e-66	Hip circumference adjusted for BMI;
LUAD	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.73e-16	Neutrophil percentage of white cells;
LUAD	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	7.5	0.34	3.68e-13	Platelet count;
LUAD	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg00999904	chr2:3704751	ALLC	-0.51	-8.73	-0.39	5.93e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07157834	chr1:205819609	PM20D1	0.54	9.59	0.42	7.87e-20	Menarche (age at onset);
LUAD	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg03806693	chr22:41940476	POLR3H	0.64	9.04	0.4	5.76e-18	Vitiligo;
LUAD	cis	rs1595825	0.891	rs16866940	chr2:198509058	C/T	cg00982548	chr2:198649783	BOLL	-0.62	-8.88	-0.4	1.95e-17	Ulcerative colitis;
LUAD	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg04155289	chr7:94953770	PON1	-0.52	-6.89	-0.32	1.99e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9296095	0.519	rs6918046	chr6:33514567	T/A	cg14003231	chr6:33640908	ITPR3	0.38	7.14	0.33	4.2e-12	Platelet count;
LUAD	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11644478	chr21:40555479	PSMG1	-0.57	-9.61	-0.42	6.63e-20	Cognitive function;
LUAD	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.38e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7680126	0.596	rs17418478	chr4:10316851	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-7.1	-0.33	5.26e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg20933634	chr6:27740509	NA	0.46	7.27	0.33	1.77e-12	Parkinson's disease;
LUAD	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg09936400	chr10:82049201	MAT1A	0.36	6.38	0.3	4.55e-10	Post bronchodilator FEV1;
LUAD	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.98	-0.32	1.15e-11	Height;
LUAD	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.22	-0.54	1.24e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg20291162	chr17:40259547	DHX58	-0.69	-10.58	-0.46	2.29e-23	Fibrinogen levels;
LUAD	cis	rs7932354	0.528	rs747650	chr11:47176005	C/T	cg19486271	chr11:47235900	DDB2	0.42	6.7	0.31	6.52e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs7771547	0.573	rs621796	chr6:36472259	A/T	cg07856975	chr6:36356162	ETV7	0.42	6.43	0.3	3.46e-10	Platelet distribution width;
LUAD	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg02696790	chr15:75250997	RPP25	0.34	6.73	0.31	5.51e-11	Caffeine consumption;
LUAD	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg06808227	chr14:105710500	BRF1	-0.42	-6.42	-0.3	3.6e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg08601574	chr20:25228251	PYGB	-0.46	-8.72	-0.39	6.46e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.01	-0.36	1.12e-14	Gout;
LUAD	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg07828340	chr4:882639	GAK	1.07	10.88	0.47	1.74e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18876405	chr7:65276391	NA	-0.53	-9.16	-0.41	2.18e-18	Aortic root size;
LUAD	cis	rs6717918	0.887	rs13020779	chr2:233149600	A/G	ch.2.233013039R	chr2:233304795	NA	0.46	6.76	0.31	4.5e-11	Height;
LUAD	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.63	0.31	1.03e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs75804782	0.641	rs1030786	chr2:239361150	A/G	cg01134436	chr17:81009848	B3GNTL1	0.74	8.34	0.38	1.08e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.17	-0.51	2.08e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7665090	1.000	rs2272696	chr4:103555821	G/A	cg07973026	chr4:103553119	MANBA	0.47	8.43	0.38	5.37e-16	Primary biliary cholangitis;
LUAD	cis	rs494562	0.892	rs520090	chr6:86116635	G/A	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg21248554	chr2:27665150	KRTCAP3	0.3	8.3	0.37	1.39e-15	Total body bone mineral density;
LUAD	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg18306943	chr3:40428807	ENTPD3	0.43	7.21	0.33	2.65e-12	Renal cell carcinoma;
LUAD	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg21658235	chr8:22456391	C8orf58	-0.39	-6.7	-0.31	6.58e-11	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs34172651	0.917	rs11646987	chr16:24832408	G/T	cg04756594	chr16:24857601	SLC5A11	0.52	10.18	0.44	6.67e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.76e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10203711	0.681	rs10202058	chr2:239607772	T/C	cg14580085	chr2:239553406	NA	0.3	6.55	0.3	1.67e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs743757	0.878	rs9867588	chr3:50526880	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.46	6.72	0.31	6.02e-11	Diastolic blood pressure;
LUAD	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg13010199	chr12:38710504	ALG10B	0.39	6.35	0.3	5.4e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg08280861	chr8:58055591	NA	0.57	7.54	0.34	2.91e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs4280164	0.551	rs3212243	chr14:24810370	T/C	cg22990158	chr14:24802150	ADCY4	0.54	8.25	0.37	2.01e-15	Parent of origin effect on language impairment (paternal);
LUAD	trans	rs9906155	1.000	rs8080918	chr17:75738935	A/G	cg21458116	chr22:38004573	GGA1	0.76	6.66	0.31	8.33e-11	Body mass index;
LUAD	trans	rs12200782	1.000	rs12195971	chr6:26460424	G/A	cg08851530	chr6:28072375	NA	0.77	6.9	0.32	1.85e-11	Small cell lung carcinoma;
LUAD	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg14396892	chr9:96623032	NA	-0.44	-8.44	-0.38	5.28e-16	DNA methylation (variation);
LUAD	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg08888203	chr3:10149979	C3orf24	0.72	11.17	0.48	1.48e-25	Alzheimer's disease;
LUAD	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.46	0.3	2.91e-10	Breast cancer;
LUAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg08132940	chr7:1081526	C7orf50	-0.77	-10.29	-0.45	2.49e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs17818399	0.533	rs13420857	chr2:46798005	C/G	cg26688816	chr2:46740690	ATP6V1E2	0.38	6.45	0.3	3.07e-10	Height;
LUAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg18402987	chr7:1209562	NA	0.78	9.39	0.42	3.74e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg01448562	chr3:133502909	NA	-0.69	-12.69	-0.53	1.72e-31	Iron status biomarkers;
LUAD	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg09904177	chr6:26538194	HMGN4	0.43	7.21	0.33	2.52e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg13319975	chr6:146136371	FBXO30	-0.63	-10.78	-0.46	4.35e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.79	0.35	5.21e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6005807	0.719	rs9625524	chr22:29052951	C/T	cg12565055	chr22:29076175	TTC28	0.73	8.75	0.39	5.31e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs2302190	0.882	rs11658998	chr17:56655786	T/G	cg25885038	chr17:56607967	SEPT4	-0.51	-8.12	-0.37	5.11e-15	Vitamin D levels;
LUAD	cis	rs2880765	0.835	rs900573	chr15:86037993	G/T	cg13263323	chr15:86062960	AKAP13	0.47	8.81	0.39	3.18e-17	Coronary artery disease;
LUAD	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg17105886	chr17:28927953	LRRC37B2	0.66	7.32	0.34	1.23e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9393692	0.620	rs9358918	chr6:26286744	C/T	cg00631329	chr6:26305371	NA	-0.56	-9.87	-0.43	8.01e-21	Educational attainment;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07079833	chr8:38239909	WHSC1L1	-0.67	-6.79	-0.31	3.84e-11	Type 2 diabetes;
LUAD	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg14895029	chr7:2775587	GNA12	-0.44	-6.93	-0.32	1.58e-11	Height;
LUAD	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06022373	chr22:39101656	GTPBP1	0.44	6.63	0.31	1.03e-10	Menopause (age at onset);
LUAD	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg00206168	chr11:65308501	LTBP3	1.26	10.13	0.44	1e-21	Height;
LUAD	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg19761014	chr17:28927070	LRRC37B2	0.77	7.73	0.35	7.65e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg07806771	chr7:64541737	NA	-0.44	-7.07	-0.33	6.32e-12	Calcium levels;
LUAD	trans	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg01620082	chr3:125678407	NA	-1.02	-9.23	-0.41	1.3e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg24324837	chr19:49891574	CCDC155	0.57	8.88	0.4	1.9e-17	Multiple sclerosis;
LUAD	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.47	0.34	4.76e-13	Breast cancer;
LUAD	cis	rs2279817	0.820	rs11203440	chr1:18026352	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.56	8.93	0.4	1.34e-17	Neuroticism;
LUAD	cis	rs56104184	0.830	rs73061622	chr19:49358111	C/T	cg21252483	chr19:49399788	TULP2	-0.67	-9.18	-0.41	1.98e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	15.8	0.61	1.55e-44	Bone mineral density;
LUAD	trans	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg07817883	chr1:32538562	TMEM39B	1.11	11.79	0.5	6.44e-28	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7666738	0.688	rs35739409	chr4:98576934	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.62	0.35	1.7e-13	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.64	-0.31	9.77e-11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LUAD	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg15448220	chr1:150897856	SETDB1	-0.45	-7.17	-0.33	3.35e-12	Blood protein levels;
LUAD	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.36e-12	Lung cancer;
LUAD	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg16414030	chr3:133502952	NA	0.39	6.9	0.32	1.91e-11	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg11645453	chr3:52864694	ITIH4	0.39	7.64	0.35	1.42e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg22875332	chr1:76189707	ACADM	0.78	13.06	0.54	5.64e-33	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg21659725	chr3:3221576	CRBN	-0.57	-9.06	-0.4	4.73e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6906287	0.647	rs6936178	chr6:118718242	C/T	cg21191810	chr6:118973309	C6orf204	0.5	9.66	0.43	4.27e-20	Electrocardiographic conduction measures;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg24337881	chr12:102091387	CHPT1	-0.67	-6.51	-0.3	2.13e-10	Type 2 diabetes;
LUAD	cis	rs7246865	0.859	rs11086052	chr19:17169081	G/A	cg19418318	chr19:17219073	MYO9B	0.39	6.41	0.3	3.88e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg00321850	chr1:175162397	KIAA0040	-0.52	-11.13	-0.48	2.05e-25	Alcohol dependence;
LUAD	cis	rs4343996	0.869	rs10266047	chr7:3476501	C/G	cg21248987	chr7:3385318	SDK1	0.35	6.42	0.3	3.63e-10	Motion sickness;
LUAD	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg07570687	chr10:102243282	WNT8B	0.48	7.28	0.33	1.63e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.4	6.63	0.31	1.04e-10	Type 2 diabetes;
LUAD	cis	rs684232	0.602	rs416662	chr17:535699	A/G	cg12384639	chr17:618140	VPS53	0.48	8.21	0.37	2.78e-15	Prostate cancer;
LUAD	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg22875332	chr1:76189707	ACADM	0.86	16.0	0.61	2.1e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg24308560	chr3:49941425	MST1R	0.5	8.29	0.37	1.51e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs12681287	0.605	rs2953509	chr8:87343194	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-9.57	-0.42	8.82e-20	Caudate activity during reward;
LUAD	cis	rs752010	0.808	rs7529858	chr1:42086606	G/C	cg06885757	chr1:42089581	HIVEP3	0.48	11.06	0.47	3.88e-25	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg16647868	chr5:131706066	SLC22A5	0.48	7.74	0.35	7.28e-14	Breast cancer;
LUAD	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg14668632	chr7:2872130	GNA12	-0.57	-10.24	-0.45	4.08e-22	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg12011299	chr4:100065546	ADH4	0.69	12.26	0.51	8.85e-30	Smoking initiation;
LUAD	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg13813247	chr22:41461852	NA	-0.5	-7.94	-0.36	1.78e-14	Neuroticism;
LUAD	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg23254163	chr1:152506842	NA	0.26	7.05	0.32	7.19e-12	Hair morphology;
LUAD	trans	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg07211511	chr3:129823064	LOC729375	-0.87	-9.67	-0.43	4.18e-20	Blood pressure (smoking interaction);
LUAD	cis	rs72928364	1.000	rs41273553	chr3:100617532	T/C	cg10123952	chr3:100791384	NA	0.61	6.97	0.32	1.19e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs17155006	0.664	rs371024	chr7:107741055	A/G	cg05962710	chr7:107745446	LAMB4	-0.35	-7.32	-0.34	1.29e-12	Pneumococcal bacteremia;
LUAD	cis	rs9341808	0.718	rs9443735	chr6:80820474	G/T	cg08355045	chr6:80787529	NA	0.56	10.04	0.44	2.04e-21	Sitting height ratio;
LUAD	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg26769984	chr7:1090371	C7orf50	0.6	9.56	0.42	9.93e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg13902645	chr11:5959945	NA	-0.52	-9.13	-0.41	2.94e-18	DNA methylation (variation);
LUAD	cis	rs7759001	0.857	rs10080558	chr6:27362898	G/A	cg18711553	chr6:27366782	ZNF391	0.39	6.54	0.3	1.81e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.4	8.55	0.38	2.26e-16	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12753518	chr1:28414763	EYA3	-0.4	-6.41	-0.3	3.79e-10	Height;
LUAD	cis	rs4380275	1.000	rs6548253	chr2:773655	A/G	cg21665850	chr2:731073	NA	0.5	8.94	0.4	1.24e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUAD	trans	rs10178094	0.504	rs3772073	chr2:161140870	T/C	cg14706852	chr2:127976351	NA	-0.37	-6.75	-0.31	4.76e-11	White blood cell count;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26260386	chr4:140477698	SETD7	-0.45	-7.02	-0.32	8.73e-12	Height;
LUAD	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-14.52	-0.58	4.8e-39	Chronic sinus infection;
LUAD	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg03714773	chr7:91764589	CYP51A1	0.28	6.72	0.31	5.95e-11	Breast cancer;
LUAD	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg17366294	chr4:99064904	C4orf37	0.66	12.79	0.53	6.94e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7680126	0.597	rs78917351	chr4:10208063	A/C	cg00071950	chr4:10020882	SLC2A9	-0.59	-8.13	-0.37	4.79e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	trans	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.04	-0.32	7.96e-12	Dental caries;
LUAD	cis	rs877426	0.681	rs75632431	chr13:114814916	A/G	cg21461300	chr13:114830702	RASA3	-0.43	-6.37	-0.3	4.89e-10	Facial morphology (factor 14, intercanthal width);
LUAD	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg00383909	chr3:49044727	WDR6	1.01	9.7	0.43	3.31e-20	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	trans	rs3960554	1.000	rs3960554	chr7:75845597	G/T	cg19862616	chr7:65841803	NCRNA00174	0.81	10.6	0.46	1.99e-23	Eotaxin levels;
LUAD	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg27129171	chr3:47204927	SETD2	0.39	6.42	0.3	3.68e-10	Colorectal cancer;
LUAD	trans	rs208520	0.690	rs207114	chr6:66791703	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.74	-0.65	4.89e-53	Exhaled nitric oxide output;
LUAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.65	-8.1	-0.37	6.06e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6430585	0.591	rs12466487	chr2:136407078	C/T	cg07169764	chr2:136633963	MCM6	-0.69	-7.98	-0.36	1.43e-14	Corneal structure;
LUAD	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg13319975	chr6:146136371	FBXO30	-0.57	-9.47	-0.42	2.01e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1953600	0.870	rs2788296	chr10:81937889	G/A	cg00277334	chr10:82204260	NA	0.42	7.09	0.33	5.6e-12	Sarcoidosis;
LUAD	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg16486109	chr11:613632	IRF7	0.49	8.14	0.37	4.35e-15	Systemic lupus erythematosus;
LUAD	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg09658497	chr7:2847517	GNA12	-0.55	-9.27	-0.41	9.95e-19	Height;
LUAD	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg04705435	chr11:17411270	KCNJ11	0.42	7.02	0.32	8.98e-12	Type 2 diabetes;
LUAD	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg03929089	chr4:120376271	NA	0.53	6.85	0.32	2.54e-11	Axial length;
LUAD	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg14582100	chr15:45693742	SPATA5L1	0.64	12.48	0.52	1.23e-30	Homoarginine levels;
LUAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg15147215	chr3:52552868	STAB1	-0.47	-8.81	-0.39	3.35e-17	Electroencephalogram traits;
LUAD	cis	rs7216064	1.000	rs3206817	chr17:65892834	A/G	cg08758996	chr17:66097529	LOC651250	0.45	6.94	0.32	1.51e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs9796	0.558	rs7166905	chr15:41514876	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.44	-7.94	-0.36	1.78e-14	Menopause (age at onset);
LUAD	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg05368731	chr17:41323189	NBR1	0.96	20.2	0.7	5.37e-64	Menopause (age at onset);
LUAD	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg19041857	chr6:27730383	NA	-0.35	-6.39	-0.3	4.46e-10	Parkinson's disease;
LUAD	cis	rs2625529	0.761	rs972028	chr15:72173092	C/T	cg16672083	chr15:72433130	SENP8	-0.65	-11.34	-0.48	3.27e-26	Red blood cell count;
LUAD	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.61	8.25	0.37	2.03e-15	Gut microbiome composition (summer);
LUAD	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06544989	chr22:39130855	UNC84B	-0.43	-8.11	-0.37	5.55e-15	Menopause (age at onset);
LUAD	cis	rs7177699	0.581	rs7165081	chr15:79123396	C/G	cg00540400	chr15:79124168	NA	0.44	9.73	0.43	2.48e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg09455208	chr3:40491958	NA	0.6	12.65	0.52	2.51e-31	Renal cell carcinoma;
LUAD	trans	rs9302065	0.565	rs2993584	chr13:95961678	C/A	cg19955956	chr7:72299837	SBDSP;TYW1B	0.54	9.34	0.41	5.56e-19	Blood metabolite levels;
LUAD	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg05425664	chr17:57184151	TRIM37	0.45	7.95	0.36	1.73e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg21984481	chr17:79567631	NPLOC4	0.53	11.38	0.48	2.28e-26	Eye color traits;
LUAD	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg18252515	chr7:66147081	NA	-0.63	-6.96	-0.32	1.29e-11	Gout;
LUAD	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg01528321	chr10:82214614	TSPAN14	0.55	8.4	0.38	6.92e-16	Post bronchodilator FEV1;
LUAD	cis	rs8060686	0.516	rs8044995	chr16:68189340	G/A	cg09835421	chr16:68378352	PRMT7	-0.55	-6.89	-0.32	2.01e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg26924012	chr15:45694286	SPATA5L1	1.02	18.85	0.68	5.65e-58	Homoarginine levels;
LUAD	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg23625390	chr15:77176239	SCAPER	-0.47	-7.63	-0.35	1.5700000000000001e-13	Blood metabolite levels;
LUAD	cis	rs4148087	0.929	rs4148085	chr21:43620277	T/A	cg08841829	chr21:43638893	ABCG1	-0.55	-7.52	-0.34	3.25e-13	Eating disorder in bipolar disorder;
LUAD	cis	rs6881634	0.508	rs10053035	chr5:77652346	C/T	cg11547950	chr5:77652471	NA	-0.43	-7.84	-0.36	3.62e-14	Hippocampal atrophy;
LUAD	cis	rs2274273	0.901	rs112870553	chr14:55790062	T/G	cg04306507	chr14:55594613	LGALS3	0.41	8.62	0.39	1.35e-16	Protein biomarker;
LUAD	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg12311346	chr5:56204834	C5orf35	-0.59	-9.45	-0.42	2.38e-19	Coronary artery disease;
LUAD	trans	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg14406256	chr12:34175567	ALG10	-0.39	-6.57	-0.3	1.44e-10	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.76	-0.31	4.64e-11	Height;
LUAD	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg02993280	chr1:107599747	PRMT6	0.48	7.37	0.34	8.85e-13	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg11247378	chr22:39784982	NA	-0.72	-13.16	-0.54	2.2e-33	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg12432903	chr7:1882776	MAD1L1	-0.45	-7.04	-0.32	7.84e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg00280220	chr17:61926910	NA	0.36	6.98	0.32	1.17e-11	Prudent dietary pattern;
LUAD	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg22676075	chr6:135203613	NA	-0.39	-7.09	-0.33	5.5e-12	Red blood cell count;
LUAD	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	10.15	0.44	8.49e-22	Electrocardiographic conduction measures;
LUAD	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg23018236	chr17:30244563	NA	-0.69	-8.39	-0.38	7.53e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg15448220	chr1:150897856	SETDB1	-0.41	-7.04	-0.32	7.99e-12	Tonsillectomy;
LUAD	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg23758822	chr17:41437982	NA	0.98	19.68	0.69	1.1e-61	Menopause (age at onset);
LUAD	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg13393036	chr8:95962371	TP53INP1	-0.4	-9.64	-0.42	5.25e-20	Type 2 diabetes;
LUAD	cis	rs727479	0.502	rs28757202	chr15:51503881	T/A	cg19946085	chr15:51559439	CYP19A1	-0.35	-6.42	-0.3	3.56e-10	Estradiol levels;
LUAD	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-11.86	-0.5	3.21e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg21890820	chr11:65308645	LTBP3	1.25	10.3	0.45	2.44e-22	Height;
LUAD	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg03878208	chr11:72483293	STARD10	0.59	7.88	0.36	2.78e-14	Type 2 diabetes;
LUAD	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg19622623	chr12:86230825	RASSF9	-0.47	-8.1	-0.37	6.03e-15	Major depressive disorder;
LUAD	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18876405	chr7:65276391	NA	-0.43	-6.84	-0.32	2.84e-11	Aortic root size;
LUAD	cis	rs910187	0.605	rs6018317	chr20:45803236	A/G	cg27589058	chr20:45804311	EYA2	-0.37	-8.38	-0.38	8.01e-16	Migraine;
LUAD	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg00898013	chr13:113819073	PROZ	-0.69	-12.14	-0.51	2.61e-29	Platelet distribution width;
LUAD	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg23758822	chr17:41437982	NA	0.99	20.56	0.71	1.3e-65	Menopause (age at onset);
LUAD	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg10589385	chr1:150898437	SETDB1	0.45	8.44	0.38	5.11e-16	Melanoma;
LUAD	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-12.0	-0.5	9.42e-29	Bipolar disorder;
LUAD	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.46	-7.59	-0.35	2.02e-13	Longevity;Endometriosis;
LUAD	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg07570687	chr10:102243282	WNT8B	0.45	6.99	0.32	1.07e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg24728912	chr5:14143221	TRIO	-0.53	-6.52	-0.3	1.97e-10	Colorectal cancer;
LUAD	trans	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg01620082	chr3:125678407	NA	-0.8	-8.08	-0.37	6.7e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg18811423	chr2:55921094	PNPT1	0.56	9.48	0.42	1.82e-19	Metabolic syndrome;
LUAD	cis	rs7254114	0.578	rs4804574	chr19:11317482	G/A	cg02815516	chr19:11306319	KANK2	0.31	6.67	0.31	7.85e-11	Immature fraction of reticulocytes;
LUAD	cis	rs7799006	0.964	rs3757440	chr7:2272936	A/G	cg08027265	chr7:2291960	NA	-0.54	-10.47	-0.45	5.75e-23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg15017067	chr4:17643749	FAM184B	0.38	7.42	0.34	6.2800000000000005e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg25985355	chr7:65971099	NA	-0.53	-6.56	-0.3	1.58e-10	Diabetic kidney disease;
LUAD	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11890956	chr21:40555474	PSMG1	-0.59	-9.61	-0.42	6.61e-20	Cognitive function;
LUAD	cis	rs12618769	0.543	rs3769728	chr2:99103001	G/A	cg10123293	chr2:99228465	UNC50	0.46	8.04	0.36	9.19e-15	Bipolar disorder;
LUAD	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-6.88	-0.32	2.13e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-8.53	-0.38	2.62e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs250677	0.522	rs10045726	chr5:148352990	C/T	cg18129178	chr5:148520854	ABLIM3	0.53	8.27	0.37	1.73e-15	Breast cancer;
LUAD	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg17366294	chr4:99064904	C4orf37	0.66	12.59	0.52	4.32e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08109568	chr15:31115862	NA	-0.61	-10.43	-0.45	8.27e-23	Huntington's disease progression;
LUAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs12541635	0.801	rs12155859	chr8:107105384	C/T	cg10147462	chr8:107024639	NA	-0.42	-7.34	-0.34	1.11e-12	Age of smoking initiation;
LUAD	cis	rs933688	0.527	rs10038090	chr5:90582456	C/G	cg00335715	chr5:90575459	NA	-0.63	-8.83	-0.39	2.75e-17	Smoking behavior;
LUAD	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg25358565	chr5:93447407	FAM172A	0.66	7.68	0.35	1.15e-13	Diabetic retinopathy;
LUAD	cis	rs1018836	0.632	rs6988302	chr8:91477660	C/T	cg16814680	chr8:91681699	NA	-0.64	-10.75	-0.46	5.4e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg02551604	chr5:131831745	NA	-0.61	-10.08	-0.44	1.46e-21	Asthma (sex interaction);
LUAD	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg06131755	chr6:160182447	ACAT2	0.43	6.42	0.3	3.77e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg09796270	chr17:17721594	SREBF1	0.37	7.49	0.34	3.97e-13	Total body bone mineral density;
LUAD	cis	rs2487048	0.725	rs2422493	chr9:107690995	G/A	cg14019050	chr9:107690770	ABCA1	-0.39	-7.26	-0.33	1.93e-12	Intraocular pressure;
LUAD	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg25382214	chr1:3105252	PRDM16	-0.33	-6.57	-0.3	1.46e-10	Migraine;
LUAD	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg07936489	chr17:37558343	FBXL20	-0.44	-6.78	-0.31	4.09e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs78487399	0.808	rs13409687	chr2:43701151	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-6.43	-0.3	3.4e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	trans	rs1997103	0.954	rs9649854	chr7:55410213	G/A	cg20935933	chr6:143382018	AIG1	0.54	7.63	0.35	1.58e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs12446554	0.509	rs56100071	chr16:19709751	C/T	cg01578585	chr16:19721878	C16orf88	0.55	7.71	0.35	8.96e-14	Obesity;
LUAD	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg07967210	chr17:47022446	SNF8	0.36	6.4	0.3	4.19e-10	Coronary heart disease;
LUAD	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg08859206	chr1:53392774	SCP2	0.57	10.27	0.45	3.07e-22	Monocyte count;
LUAD	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg21856205	chr7:94953877	PON1	0.47	6.88	0.32	2.12e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg11189052	chr15:85197271	WDR73	0.69	9.2	0.41	1.68e-18	Schizophrenia;
LUAD	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-8.24	-0.37	2.22e-15	Height;
LUAD	cis	rs7107174	1.000	rs2510054	chr11:77959659	A/G	cg02023728	chr11:77925099	USP35	-0.48	-7.51	-0.34	3.66e-13	Testicular germ cell tumor;
LUAD	cis	rs62229266	0.659	rs2255734	chr21:37411909	T/C	cg12218747	chr21:37451666	NA	-0.42	-7.36	-0.34	9.62e-13	Mitral valve prolapse;
LUAD	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg17372223	chr3:52568218	NT5DC2	0.37	6.79	0.31	3.86e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg08399230	chr16:4665037	FAM100A	-0.38	-6.38	-0.3	4.64e-10	Vertical cup-disc ratio;
LUAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg27454412	chr7:1067447	C7orf50	0.44	7.01	0.32	9.38e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg27446573	chr6:127587934	RNF146	0.42	6.45	0.3	3.11e-10	Breast cancer;
LUAD	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg08632164	chr7:65971372	NA	-0.55	-6.41	-0.3	3.8e-10	Diabetic kidney disease;
LUAD	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg15557168	chr22:42548783	NA	0.37	6.85	0.32	2.61e-11	Cognitive function;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg06037631	chr2:74942369	NA	0.39	6.48	0.3	2.55e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs752010	0.543	rs1570355	chr1:42042317	C/T	cg06885757	chr1:42089581	HIVEP3	0.38	8.54	0.38	2.44e-16	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs11811982	0.793	rs79611117	chr1:227339435	A/G	cg24860534	chr1:227506868	CDC42BPA	0.66	7.22	0.33	2.41e-12	Optic disc area;
LUAD	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg04369109	chr6:150039330	LATS1	-0.44	-7.11	-0.33	5.07e-12	Lung cancer;
LUAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03188948	chr7:1209495	NA	0.48	8.06	0.37	7.63e-15	Longevity;Endometriosis;
LUAD	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg02423579	chr7:2872169	GNA12	-0.54	-9.38	-0.41	4.14e-19	Height;
LUAD	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg18252515	chr7:66147081	NA	-0.63	-6.96	-0.32	1.34e-11	Diabetic kidney disease;
LUAD	cis	rs908922	0.676	rs1053590	chr1:152488428	T/C	cg21823605	chr1:152486609	CRCT1	0.29	6.52	0.3	2.06e-10	Hair morphology;
LUAD	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg02176678	chr2:219576539	TTLL4	0.75	15.06	0.59	2.35e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg00074818	chr8:8560427	CLDN23	0.66	10.08	0.44	1.46e-21	Obesity-related traits;
LUAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg12016809	chr21:47604291	C21orf56	0.54	9.07	0.4	4.64e-18	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.91	0.36	2.22e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	1.000	rs1304165	chr2:198877300	G/A	cg00982548	chr2:198649783	BOLL	-0.63	-9.01	-0.4	7.29e-18	Ulcerative colitis;
LUAD	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg08601574	chr20:25228251	PYGB	-0.46	-8.55	-0.38	2.35e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs78049276	0.736	rs6842241	chr4:148400819	C/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.63	-7.75	-0.35	6.96e-14	Pulse pressure;
LUAD	cis	rs7166081	0.738	rs2286664	chr15:67701495	A/G	cg24579218	chr15:68104479	NA	-0.43	-7.46	-0.34	5.05e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs6076065	0.683	rs2424557	chr20:23422159	C/G	cg11657817	chr20:23433608	CST11	-0.52	-10.27	-0.45	3.12e-22	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2274273	0.905	rs8007614	chr14:55586575	A/G	cg04306507	chr14:55594613	LGALS3	0.38	8.01	0.36	1.11e-14	Protein biomarker;
LUAD	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg09184832	chr6:79620586	NA	-0.49	-9.18	-0.41	1.88e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7789940	1.000	rs17149161	chr7:75978229	C/A	cg10167463	chr7:75959203	YWHAG	-0.71	-12.9	-0.53	2.54e-32	Multiple sclerosis;
LUAD	cis	rs57920188	0.535	rs4520388	chr1:4092671	T/G	cg20703997	chr1:4087676	NA	0.48	9.02	0.4	6.84e-18	Interleukin-17 levels;
LUAD	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg11266682	chr4:10021025	SLC2A9	0.67	15.67	0.61	5.48e-44	Bone mineral density;
LUAD	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg13390004	chr1:15929781	NA	0.46	8.11	0.37	5.35e-15	Systolic blood pressure;
LUAD	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg08742575	chr21:47604166	C21orf56	0.43	7.26	0.33	1.93e-12	Testicular germ cell tumor;
LUAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg07217954	chr7:1067459	C7orf50	0.44	7.26	0.33	1.89e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg02880119	chr16:3481970	NA	-0.54	-8.3	-0.37	1.4e-15	Body mass index (adult);
LUAD	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg02012338	chr4:187126139	CYP4V2	-1.08	-10.54	-0.46	3.08e-23	Blood protein levels;
LUAD	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg01516881	chr6:292596	DUSP22	-0.55	-9.04	-0.4	5.72e-18	Menopause (age at onset);
LUAD	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg04703951	chr17:43578652	NA	-0.56	-8.14	-0.37	4.38e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs12681287	0.640	rs12544463	chr8:87481114	A/G	cg27223183	chr8:87520930	FAM82B	-0.67	-9.61	-0.42	6.38e-20	Caudate activity during reward;
LUAD	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg15017067	chr4:17643749	FAM184B	0.35	6.84	0.32	2.75e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg21659725	chr3:3221576	CRBN	0.38	6.4	0.3	4.2e-10	Resting heart rate;
LUAD	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg26597838	chr10:835615	NA	0.84	11.56	0.49	4.78e-27	Eosinophil percentage of granulocytes;
LUAD	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.58e-13	Tonsillectomy;
LUAD	cis	rs2795502	0.564	rs11239840	chr10:43439353	C/T	cg08461752	chr10:43522343	NA	-0.77	-8.18	-0.37	3.44e-15	Blood protein levels;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg17010769	chr15:79165973	MORF4L1	-0.49	-6.5	-0.3	2.25e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg23625390	chr15:77176239	SCAPER	0.38	6.52	0.3	2.03e-10	Blood metabolite levels;
LUAD	cis	rs939658	0.805	rs35230534	chr15:79441093	T/C	cg17916960	chr15:79447300	NA	-0.53	-11.26	-0.48	6.91e-26	Refractive error;
LUAD	cis	rs7680126	0.536	rs3796841	chr4:10007904	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	8.15	0.37	4.24e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08109568	chr15:31115862	NA	0.54	9.46	0.42	2.09e-19	Huntington's disease progression;
LUAD	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg22117172	chr7:91764530	CYP51A1	0.34	7.37	0.34	9.32e-13	Breast cancer;
LUAD	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg03714773	chr7:91764589	CYP51A1	0.27	6.49	0.3	2.48e-10	Breast cancer;
LUAD	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg01765077	chr12:122356316	WDR66	0.47	8.02	0.36	1.02e-14	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg18252515	chr7:66147081	NA	-0.64	-6.9	-0.32	1.87e-11	Diabetic kidney disease;
LUAD	cis	rs9302065	0.565	rs2993585	chr13:95961966	G/A	cg24476569	chr13:95954382	ABCC4	-0.6	-11.02	-0.47	5.53e-25	Blood metabolite levels;
LUAD	trans	rs11039798	0.920	rs8186465	chr11:48796771	T/C	cg02254774	chr11:50257496	LOC441601	0.53	6.68	0.31	7.63e-11	Axial length;
LUAD	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg05966235	chr16:28915196	ATP2A1	0.47	7.56	0.35	2.45e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg10544611	chr16:67998164	SLC12A4	-0.54	-6.87	-0.32	2.38e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg12011299	chr4:100065546	ADH4	0.63	13.02	0.53	7.94e-33	Alcohol dependence;
LUAD	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg18854424	chr1:2615690	NA	-0.42	-9.08	-0.4	4.12e-18	Ulcerative colitis;
LUAD	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.23	-0.41	1.3e-18	Type 2 diabetes;
LUAD	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg14186256	chr22:23484241	RTDR1	0.43	7.41	0.34	6.79e-13	Bone mineral density;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04787786	chr20:34286964	ROMO1;NFS1	0.43	6.58	0.3	1.39e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs300703	0.654	rs300771	chr2:117241	A/G	cg21211680	chr2:198530	NA	-0.63	-8.26	-0.37	1.87e-15	Blood protein levels;
LUAD	cis	rs2286885	1.000	rs7851961	chr9:129249140	G/A	cg15282417	chr9:129245246	FAM125B	0.45	9.21	0.41	1.48e-18	Intraocular pressure;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26632232	chr19:12551472	ZNF443	-0.54	-6.55	-0.3	1.63e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.16	0.37	3.85e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg04455712	chr21:45112962	RRP1B	0.51	10.06	0.44	1.7e-21	Mean corpuscular volume;
LUAD	cis	rs6062509	0.965	rs6062504	chr20:62348907	A/G	cg02966332	chr20:62369605	LIME1	-0.46	-7.6	-0.35	1.87e-13	Prostate cancer;
LUAD	cis	rs6494488	0.500	rs72742989	chr15:64994464	A/G	cg08069370	chr15:64387884	SNX1	-0.76	-6.84	-0.32	2.71e-11	Coronary artery disease;
LUAD	cis	rs28655083	0.879	rs1502444	chr16:77059172	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.41	-6.77	-0.31	4.43e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	11.77	0.5	7.32e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg17372223	chr3:52568218	NT5DC2	0.36	6.79	0.31	3.81e-11	Bipolar disorder;
LUAD	cis	rs10129255	0.500	rs1024350	chr14:107141122	C/T	cg07958169	chr14:107095056	NA	-0.38	-7.57	-0.35	2.35e-13	Kawasaki disease;
LUAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	trans	rs11039798	1.000	rs7131020	chr11:48642132	A/G	cg03929089	chr4:120376271	NA	0.58	6.48	0.3	2.58e-10	Axial length;
LUAD	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.38	0.34	8.49e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7737355	0.738	rs13174592	chr5:130963700	C/T	cg06307176	chr5:131281290	NA	0.39	6.46	0.3	2.88e-10	Life satisfaction;
LUAD	cis	rs754466	0.580	rs17516020	chr10:79538734	C/T	cg17075019	chr10:79541650	NA	-0.84	-14.27	-0.57	5.43e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg19336497	chr11:14380999	RRAS2	-0.66	-14.25	-0.57	6.37e-38	Sense of smell;
LUAD	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg15181151	chr6:150070149	PCMT1	0.39	7.51	0.34	3.43e-13	Lung cancer;
LUAD	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg17724175	chr1:150552817	MCL1	0.36	8.32	0.37	1.26e-15	Melanoma;
LUAD	cis	rs938554	0.784	rs7682751	chr4:9976294	A/G	cg00071950	chr4:10020882	SLC2A9	0.53	8.24	0.37	2.24e-15	Blood metabolite levels;
LUAD	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg09365446	chr1:150670422	GOLPH3L	0.67	12.13	0.51	2.85e-29	Tonsillectomy;
LUAD	cis	rs943466	0.955	rs2281819	chr6:33771673	T/A	cg16010596	chr6:33739607	LEMD2	-0.39	-7.26	-0.33	1.9e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg01200585	chr1:228362443	C1orf69	0.42	7.55	0.34	2.72e-13	Diastolic blood pressure;
LUAD	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg05564831	chr3:52568323	NT5DC2	0.37	6.61	0.31	1.14e-10	Body mass index;
LUAD	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.39	-7.06	-0.32	6.85e-12	Cystic fibrosis severity;
LUAD	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-8.22	-0.37	2.5e-15	Morning vs. evening chronotype;
LUAD	cis	rs11031096	0.502	rs720571	chr11:4001328	G/T	cg18678763	chr11:4115507	RRM1	-0.45	-7.31	-0.34	1.31e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs6840360	0.530	rs62327350	chr4:152641202	G/A	cg22705602	chr4:152727874	NA	-0.45	-7.89	-0.36	2.61e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg04995722	chr7:26192034	NFE2L3	0.44	7.51	0.34	3.55e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg01689657	chr7:91764605	CYP51A1	0.33	8.19	0.37	3.11e-15	Breast cancer;
LUAD	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.6	-9.01	-0.4	7.05e-18	IgG glycosylation;
LUAD	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02475777	chr4:1388615	CRIPAK	0.65	9.13	0.41	2.73e-18	Longevity;
LUAD	cis	rs10129255	0.518	rs10150460	chr14:107133196	C/G	cg23076370	chr14:107095027	NA	0.4	7.87	0.36	3.03e-14	Kawasaki disease;
LUAD	cis	rs8060686	0.623	rs7201591	chr16:68086105	A/G	cg05110241	chr16:68378359	PRMT7	-0.53	-6.97	-0.32	1.23e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1832871	0.672	rs9457363	chr6:158777515	C/T	cg07165851	chr6:158734300	TULP4	0.69	10.7	0.46	8.33e-24	Height;
LUAD	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.55	-0.34	2.73e-13	Resting heart rate;
LUAD	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg24069376	chr3:38537580	EXOG	0.43	10.31	0.45	2.25e-22	Electrocardiographic conduction measures;
LUAD	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg07507251	chr3:52567010	NT5DC2	0.39	7.51	0.34	3.62e-13	Bipolar disorder;
LUAD	cis	rs12711979	0.566	rs6706842	chr2:3853962	G/C	cg17052675	chr2:3827356	NA	-0.41	-7.25	-0.33	1.96e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg11584989	chr19:19387371	SF4	-0.39	-6.76	-0.31	4.51e-11	Tonsillectomy;
LUAD	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg21433313	chr16:3507492	NAT15	0.75	9.43	0.42	2.76e-19	Tuberculosis;
LUAD	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg06092702	chr1:163392909	NA	-0.41	-9.22	-0.41	1.4e-18	Motion sickness;
LUAD	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg03433033	chr1:76189801	ACADM	0.77	12.57	0.52	5.06e-31	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg24829409	chr8:58192753	C8orf71	-0.61	-8.07	-0.37	7.12e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9393692	0.557	rs1883213	chr6:26303178	A/C	cg13736514	chr6:26305472	NA	-0.54	-8.82	-0.39	2.93e-17	Educational attainment;
LUAD	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	1.000	rs7579905	chr2:198868109	T/A	cg00982548	chr2:198649783	BOLL	-0.59	-8.4	-0.38	6.86e-16	Ulcerative colitis;
LUAD	cis	rs7009516	0.745	rs1492414	chr8:24224911	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.35	7.07	0.33	6.39e-12	Hair greying;
LUAD	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg02775129	chr4:119771670	NA	-0.89	-8.03	-0.36	9.85e-15	Cannabis dependence symptom count;
LUAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg07685180	chr8:600429	NA	0.88	8.7	0.39	7.38e-17	IgG glycosylation;
LUAD	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.0	0.32	9.82e-12	Prostate cancer;
LUAD	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg26513180	chr16:89883248	FANCA	-0.52	-9.42	-0.42	3.05e-19	Vitiligo;
LUAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg08888203	chr3:10149979	C3orf24	0.73	11.17	0.48	1.44e-25	Alzheimer's disease;
LUAD	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-6.87	-0.32	2.34e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg17372223	chr3:52568218	NT5DC2	0.44	8.3	0.37	1.38e-15	Electroencephalogram traits;
LUAD	cis	rs6495122	0.662	rs11632414	chr15:75061916	A/G	cg14664628	chr15:75095509	CSK	-0.5	-8.3	-0.37	1.43e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs6542838	0.641	rs6704682	chr2:99499602	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.35	-0.34	1.07e-12	Fear of minor pain;
LUAD	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg08601574	chr20:25228251	PYGB	-0.49	-9.17	-0.41	2.02e-18	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs859767	0.924	rs842349	chr2:135342452	G/T	cg12500956	chr2:135428796	TMEM163	0.32	8.4	0.38	6.68e-16	Neuroticism;
LUAD	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg05110241	chr16:68378359	PRMT7	-0.75	-7.91	-0.36	2.25e-14	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg24644049	chr4:85504048	CDS1	0.9	7.58	0.35	2.22e-13	Skin colour saturation;
LUAD	cis	rs727505	1.000	rs10271646	chr7:124549573	T/C	cg23710748	chr7:124431027	NA	-0.44	-9.4	-0.42	3.59e-19	Lewy body disease;
LUAD	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg26597838	chr10:835615	NA	0.83	11.08	0.47	3.22e-25	Eosinophil percentage of granulocytes;
LUAD	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.3	-7.01	-0.32	9.71e-12	Prostate cancer;
LUAD	cis	rs6432018	1.000	rs6432018	chr2:9721896	C/A	cg12832956	chr2:9616023	IAH1	-0.36	-6.43	-0.3	3.51e-10	Heart rate variability traits;
LUAD	cis	rs9399401	0.626	rs7776356	chr6:142777029	A/G	cg03128060	chr6:142623767	GPR126	0.42	8.05	0.36	8.47e-15	Chronic obstructive pulmonary disease;
LUAD	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg12573674	chr2:1569213	NA	-0.61	-8.8	-0.39	3.43e-17	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg10833826	chr17:76837038	USP36	0.41	6.61	0.31	1.19e-10	Optic cup area;
LUAD	cis	rs17401966	0.838	rs4846206	chr1:10310258	G/C	cg15208524	chr1:10270712	KIF1B	0.44	6.79	0.31	3.75e-11	Hepatocellular carcinoma;
LUAD	cis	rs9807989	0.507	rs6758936	chr2:102991369	A/G	cg03938978	chr2:103052716	IL18RAP	-0.45	-10.23	-0.45	4.18e-22	Asthma;
LUAD	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg17063962	chr7:91808500	NA	0.68	12.37	0.52	3.29e-30	Breast cancer;
LUAD	cis	rs11126435	0.858	rs363669	chr2:74929196	G/A	cg19285774	chr2:74907978	SEMA4F	0.36	6.41	0.3	3.99e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg00530320	chr1:46809349	NSUN4	0.53	8.23	0.37	2.33e-15	Menopause (age at onset);
LUAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg16606324	chr3:10149918	C3orf24	0.69	9.91	0.43	5.81e-21	Alzheimer's disease;
LUAD	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg16797656	chr11:68205561	LRP5	0.45	8.53	0.38	2.59e-16	Total body bone mineral density;
LUAD	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg25237894	chr2:233734115	C2orf82	-0.48	-9.21	-0.41	1.49e-18	Coronary artery disease;
LUAD	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs5756813	0.688	rs2413483	chr22:38127950	C/T	cg06521852	chr22:38141419	TRIOBP	0.5	8.8	0.39	3.63e-17	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg05234568	chr11:5960015	NA	-0.58	-11.12	-0.48	2.24e-25	DNA methylation (variation);
LUAD	cis	rs6894249	0.874	rs11745587	chr5:131796922	A/G	cg21138405	chr5:131827807	IRF1	-0.32	-6.62	-0.31	1.09e-10	Asthma;
LUAD	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg14019146	chr3:50243930	SLC38A3	-0.55	-10.97	-0.47	8.51e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs35740288	0.731	rs11634651	chr15:86093926	A/C	cg13263323	chr15:86062960	AKAP13	-0.45	-7.24	-0.33	2.17e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg10729496	chr3:10149963	C3orf24	0.63	9.66	0.43	4.48e-20	Alzheimer's disease;
LUAD	cis	rs10189230	0.967	rs13026380	chr2:222352715	G/A	cg14652038	chr2:222343519	EPHA4	0.43	8.59	0.39	1.73e-16	Urate levels in lean individuals;
LUAD	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg18932078	chr1:2524107	MMEL1	0.37	6.85	0.32	2.65e-11	Ulcerative colitis;
LUAD	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	7.67	0.35	1.21e-13	Menopause (age at onset);
LUAD	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.32	6.68	0.31	7.65e-11	Obesity-related traits;
LUAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg07217954	chr7:1067459	C7orf50	0.43	6.59	0.3	1.34e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs73206853	0.686	rs7139314	chr12:110923871	G/A	cg12870014	chr12:110450643	ANKRD13A	0.64	7.43	0.34	6.13e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs4988958	0.565	rs1035125	chr2:103033839	C/A	cg03938978	chr2:103052716	IL18RAP	0.44	10.14	0.44	8.64e-22	Asthma (childhood onset);
LUAD	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg21782813	chr7:2030301	MAD1L1	0.42	6.95	0.32	1.43e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg11645453	chr3:52864694	ITIH4	0.54	10.04	0.44	2.08e-21	Schizophrenia;
LUAD	cis	rs12210905	1.000	rs76889265	chr6:27008835	T/C	cg11502198	chr6:26597334	ABT1	-0.79	-6.52	-0.3	2.06e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.5	-0.34	3.89e-13	Coronary artery disease;
LUAD	cis	rs7633770	0.805	rs11130098	chr3:46661926	A/G	cg11219411	chr3:46661640	NA	-0.57	-13.26	-0.54	8.19e-34	Coronary artery disease;
LUAD	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg01689657	chr7:91764605	CYP51A1	0.37	9.18	0.41	1.93e-18	Breast cancer;
LUAD	cis	rs1385374	0.858	rs10847696	chr12:129297153	G/A	cg09035930	chr12:129282057	SLC15A4	-0.74	-8.51	-0.38	3.11e-16	Systemic lupus erythematosus;
LUAD	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg05590025	chr7:65112418	INTS4L2	0.73	7.84	0.36	3.67e-14	Diabetic kidney disease;
LUAD	cis	rs12474201	1.000	rs12474201	chr2:46921285	C/T	cg09399716	chr2:46890238	NA	-0.34	-6.37	-0.3	4.95e-10	Height;
LUAD	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg20556744	chr2:9614537	IAH1	0.66	6.56	0.3	1.55e-10	Opioid sensitivity;
LUAD	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg17063962	chr7:91808500	NA	0.67	11.91	0.5	2.14e-28	Breast cancer;
LUAD	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg06532163	chr17:45867833	NA	-0.48	-8.81	-0.39	3.22e-17	IgG glycosylation;
LUAD	cis	rs612683	0.694	rs6688166	chr1:101000717	G/C	cg09408571	chr1:101003634	GPR88	0.33	6.5	0.3	2.27e-10	Breast cancer;
LUAD	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18876405	chr7:65276391	NA	0.55	9.22	0.41	1.46e-18	Aortic root size;
LUAD	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg14458575	chr2:238380390	NA	0.54	9.98	0.44	3.25e-21	Prostate cancer;
LUAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.49	-8.72	-0.39	6.41e-17	Lymphocyte counts;
LUAD	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg07636037	chr3:49044803	WDR6	0.55	10.18	0.44	6.43e-22	Menarche (age at onset);
LUAD	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.62	0.31	1.08e-10	Cognitive test performance;
LUAD	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg21770322	chr7:97807741	LMTK2	0.35	8.49	0.38	3.57e-16	Breast cancer;
LUAD	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg12927641	chr6:109611667	NA	-0.53	-9.21	-0.41	1.54e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg12311346	chr5:56204834	C5orf35	-0.45	-7.29	-0.33	1.57e-12	Coronary artery disease;
LUAD	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg06618935	chr21:46677482	NA	-0.46	-9.24	-0.41	1.2e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg18451016	chr1:38461880	NA	0.39	7.61	0.35	1.85e-13	Coronary artery disease;
LUAD	cis	rs2281845	0.507	rs11589642	chr1:201100748	A/G	cg06714761	chr1:201096289	NA	-0.35	-7.74	-0.35	7.24e-14	Permanent tooth development;
LUAD	cis	rs2066819	0.892	rs112931321	chr12:56667894	C/T	cg26714650	chr12:56694279	CS	-0.86	-7.24	-0.33	2.09e-12	Psoriasis vulgaris;
LUAD	cis	rs1451375	0.741	rs55738142	chr7:50632326	T/C	cg18232548	chr7:50535776	DDC	0.53	8.59	0.39	1.67e-16	Malaria;
LUAD	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg23758822	chr17:41437982	NA	0.99	20.83	0.71	7.7e-67	Menopause (age at onset);
LUAD	cis	rs1598856	0.932	rs2168803	chr4:103428615	A/T	cg07973026	chr4:103553119	MANBA	0.4	6.44	0.3	3.29e-10	Primary biliary cholangitis;
LUAD	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.43	-0.45	8.35e-23	Monocyte percentage of white cells;
LUAD	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg07741184	chr6:167504864	NA	-0.3	-7.17	-0.33	3.48e-12	Crohn's disease;
LUAD	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg27432699	chr2:27873401	GPN1	-0.64	-11.28	-0.48	5.57e-26	Oral cavity cancer;
LUAD	cis	rs1847202	1.000	rs7634188	chr3:72941289	A/G	cg25664220	chr3:72788482	NA	0.44	8.04	0.36	9.02e-15	Motion sickness;
LUAD	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg18490616	chr2:88469792	THNSL2	0.78	8.37	0.38	8.31e-16	Plasma clusterin levels;
LUAD	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.1	-0.51	3.68e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg08601574	chr20:25228251	PYGB	-0.47	-8.81	-0.39	3.3e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.36	-0.34	9.5e-13	Resting heart rate;
LUAD	cis	rs56307353	0.652	rs4807191	chr19:1990309	C/T	cg17884674	chr19:1967198	CSNK1G2	-0.23	-6.6	-0.31	1.22e-10	Coronary artery disease;
LUAD	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg08885076	chr2:99613938	TSGA10	0.36	6.51	0.3	2.14e-10	Chronic sinus infection;
LUAD	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.12	-0.41	3e-18	Total body bone mineral density;
LUAD	cis	rs9811920	0.516	rs793486	chr3:99493165	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-8.51	-0.38	3.03e-16	Axial length;
LUAD	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg07917127	chr4:99064746	C4orf37	0.42	7.01	0.32	9.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg24920358	chr1:40204285	PPIE	0.7	12.47	0.52	1.29e-30	Blood protein levels;
LUAD	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-8.62	-0.39	1.31e-16	Heart rate;
LUAD	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg09835421	chr16:68378352	PRMT7	-0.73	-8.37	-0.38	8.28e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg08798685	chr6:27730294	NA	-0.44	-7.17	-0.33	3.43e-12	Parkinson's disease;
LUAD	trans	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg26043149	chr18:55253948	FECH	0.5	8.21	0.37	2.65e-15	Bone mineral density;
LUAD	cis	rs13088645	0.532	rs9857134	chr3:134161607	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	8.72	0.39	6.58e-17	Coronary artery disease;
LUAD	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg04539111	chr16:67997858	SLC12A4	-0.52	-6.4	-0.3	4.19e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7264396	0.580	rs6060648	chr20:34456704	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.08	-0.33	6.03e-12	Total cholesterol levels;
LUAD	cis	rs7937890	0.559	rs10766184	chr11:14542577	A/G	cg23387056	chr11:14280742	SPON1	-0.33	-6.4	-0.3	4.11e-10	Mitochondrial DNA levels;
LUAD	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.96	-0.36	1.55e-14	Diabetic kidney disease;
LUAD	cis	rs28595532	1.000	rs11931194	chr4:119631160	C/T	cg14228332	chr4:119757509	SEC24D	0.75	7.03	0.32	8.59e-12	Cannabis dependence symptom count;
LUAD	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg17063962	chr7:91808500	NA	-0.65	-11.14	-0.48	1.9e-25	Breast cancer;
LUAD	cis	rs16958440	0.867	rs10083937	chr18:44695602	A/G	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg05110241	chr16:68378359	PRMT7	-0.7	-7.99	-0.36	1.26e-14	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs7395662	1.000	rs34636547	chr11:48590103	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.12e-12	HDL cholesterol;
LUAD	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg14092988	chr3:52407081	DNAH1	0.45	9.07	0.4	4.35e-18	Bipolar disorder;
LUAD	cis	rs859767	0.741	rs11682346	chr2:135388261	G/A	cg12500956	chr2:135428796	TMEM163	-0.29	-7.64	-0.35	1.48e-13	Neuroticism;
LUAD	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg00495681	chr13:53174319	NA	0.66	13.19	0.54	1.66e-33	Lewy body disease;
LUAD	cis	rs4730250	0.655	rs75243311	chr7:106890791	C/T	cg23024343	chr7:107201750	COG5	0.5	7.3	0.33	1.43e-12	Osteoarthritis;
LUAD	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg26528668	chr16:1614120	IFT140	0.6	10.94	0.47	1.02e-24	Coronary artery disease;
LUAD	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg09085632	chr11:111637200	PPP2R1B	0.68	10.25	0.45	3.47e-22	Primary sclerosing cholangitis;
LUAD	cis	rs2579519	0.547	rs2463560	chr2:96595589	T/C	cg23100626	chr2:96804247	ASTL	0.3	7.72	0.35	8.24e-14	Diastolic blood pressure;
LUAD	cis	rs778371	0.723	rs12105766	chr2:233617647	A/G	cg08000102	chr2:233561755	GIGYF2	0.41	6.57	0.3	1.44e-10	Schizophrenia;
LUAD	cis	rs73198271	0.603	rs557892	chr8:8596048	A/C	cg01851573	chr8:8652454	MFHAS1	0.42	7.56	0.35	2.45e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06873352	chr17:61820015	STRADA	0.82	18.62	0.67	6.01e-57	Prudent dietary pattern;
LUAD	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg24801067	chr17:62843696	NA	0.62	8.94	0.4	1.2e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg21226059	chr5:178986404	RUFY1	0.62	9.97	0.44	3.52e-21	Lung cancer;
LUAD	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg20503657	chr10:835505	NA	0.94	12.86	0.53	3.47e-32	Eosinophil percentage of granulocytes;
LUAD	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.86	-0.53	3.5e-32	Dilated cardiomyopathy;
LUAD	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.41	-0.34	6.72e-13	Schizophrenia;
LUAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg18402987	chr7:1209562	NA	0.85	11.27	0.48	6e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg09242721	chr3:3168535	TRNT1	-0.4	-6.75	-0.31	4.74e-11	Schizophrenia;
LUAD	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.03	0.32	8.57e-12	Motion sickness;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg10445487	chr16:75599896	GABARAPL2	-0.38	-6.48	-0.3	2.49e-10	Subcortical brain region volumes;
LUAD	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg06199346	chr11:14280333	SPON1	-0.31	-6.42	-0.3	3.68e-10	Mitochondrial DNA levels;
LUAD	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg03467027	chr4:99064603	C4orf37	0.4	6.37	0.3	4.96e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.63	-0.31	9.98e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1385374	0.800	rs12321679	chr12:129284791	G/A	cg09035930	chr12:129282057	SLC15A4	-0.65	-6.91	-0.32	1.79e-11	Systemic lupus erythematosus;
LUAD	cis	rs2795502	0.935	rs2744060	chr10:43262616	C/G	cg27426351	chr10:43362370	NA	-0.53	-7.18	-0.33	3.18e-12	Blood protein levels;
LUAD	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg08807101	chr21:30365312	RNF160	-0.48	-7.86	-0.36	3.11e-14	Dental caries;
LUAD	cis	rs17102423	0.755	rs11625045	chr14:65549089	C/T	cg11161011	chr14:65562177	MAX	-0.49	-7.87	-0.36	2.94e-14	Obesity-related traits;
LUAD	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.22	-0.37	2.45e-15	Bipolar disorder;
LUAD	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg23029597	chr12:123009494	RSRC2	-0.57	-9.03	-0.4	6.03e-18	Body mass index;
LUAD	trans	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg01620082	chr3:125678407	NA	-1.04	-10.23	-0.45	4.13e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2637266	0.935	rs2579728	chr10:78395598	A/G	cg18941641	chr10:78392320	NA	0.34	7.1	0.33	5.37e-12	Pulmonary function;
LUAD	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg08632164	chr7:65971372	NA	-0.55	-6.42	-0.3	3.67e-10	Diabetic kidney disease;
LUAD	cis	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg05084668	chr3:125655381	ALG1L	-0.64	-10.48	-0.45	5.13e-23	Blood pressure (smoking interaction);
LUAD	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.75	0.31	4.96e-11	Parkinson's disease;
LUAD	cis	rs3818285	0.959	rs35712139	chr10:111642934	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.43	-0.38	5.58e-16	Superior crus of antihelix expression;
LUAD	trans	rs8002861	0.875	rs11616803	chr13:44457109	A/G	cg17145862	chr1:211918768	LPGAT1	-0.7	-15.23	-0.6	4.4e-42	Leprosy;
LUAD	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg05865280	chr17:75406074	SEPT9	0.61	19.11	0.68	4e-59	Airflow obstruction;
LUAD	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg21016266	chr12:122356598	WDR66	0.66	12.06	0.51	5.31e-29	Mean corpuscular volume;
LUAD	cis	rs500891	0.525	rs7768550	chr6:84075810	T/G	cg08257003	chr6:84140564	ME1	0.35	6.7	0.31	6.49e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg20487152	chr13:99095054	FARP1	-0.48	-8.35	-0.38	1.01e-15	Longevity;
LUAD	cis	rs490234	0.841	rs829314	chr9:128415506	A/T	cg14078157	chr9:128172775	NA	0.41	7.59	0.35	2.07e-13	Mean arterial pressure;
LUAD	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18876405	chr7:65276391	NA	-0.41	-6.45	-0.3	3.13e-10	Aortic root size;
LUAD	trans	rs13219787	0.915	rs13214703	chr6:27941387	A/G	cg01426208	chr6:29720641	NA	0.86	6.82	0.31	3.19e-11	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;
LUAD	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg11062466	chr8:58055876	NA	0.51	7.09	0.33	5.72e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg25985355	chr7:65971099	NA	-0.55	-6.72	-0.31	5.8200000000000003e-11	Diabetic kidney disease;
LUAD	cis	rs7089973	0.872	rs35628210	chr10:116630031	G/A	cg25233709	chr10:116636983	FAM160B1	0.39	7.67	0.35	1.21e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4730250	0.707	rs4730222	chr7:106810293	G/C	cg23024343	chr7:107201750	COG5	0.5	6.78	0.31	4.17e-11	Osteoarthritis;
LUAD	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg14779329	chr11:130786720	SNX19	0.39	6.84	0.32	2.74e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg24644049	chr4:85504048	CDS1	0.89	7.32	0.34	1.3e-12	Skin colour saturation;
LUAD	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.45	0.3	3.06e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg11859384	chr17:80120422	CCDC57	-0.48	-8.61	-0.39	1.41e-16	Life satisfaction;
LUAD	cis	rs1595825	1.000	rs79508374	chr2:198864568	G/A	cg11031976	chr2:198649780	BOLL	-0.42	-6.37	-0.3	4.96e-10	Ulcerative colitis;
LUAD	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06028605	chr16:24865363	SLC5A11	0.57	8.97	0.4	9.72e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg16262614	chr3:133464971	TF	0.43	8.81	0.39	3.31e-17	Iron status biomarkers (transferrin levels);
LUAD	cis	rs7149337	0.805	rs2999354	chr14:51607179	C/G	cg23942311	chr14:51606299	NA	0.88	20.43	0.7	4.83e-65	Cancer;
LUAD	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg21427119	chr20:30132790	HM13	-0.47	-7.63	-0.35	1.56e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg11766577	chr21:47581405	C21orf56	-0.63	-11.33	-0.48	3.77e-26	Testicular germ cell tumor;
LUAD	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs4954585	0.659	rs4072435	chr2:137013901	C/T	cg05194412	chr2:137003533	NA	0.62	11.2	0.48	1.12e-25	Colorectal cancer;
LUAD	cis	rs8060686	0.516	rs2290699	chr16:68289059	C/T	cg05110241	chr16:68378359	PRMT7	-0.59	-7.55	-0.34	2.63e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.04	-0.32	7.69e-12	Joint mobility (Beighton score);
LUAD	trans	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg01620082	chr3:125678407	NA	-0.44	-6.7	-0.31	6.82e-11	Parkinson's disease;
LUAD	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg04865290	chr3:52927548	TMEM110	-0.58	-7.42	-0.34	6.52e-13	Immune reponse to smallpox (secreted IL-2);
LUAD	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg05340658	chr4:99064831	C4orf37	0.54	9.15	0.41	2.34e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg03929089	chr4:120376271	NA	-0.66	-9.27	-0.41	9.29e-19	Coronary artery disease;
LUAD	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg04944784	chr2:26401820	FAM59B	-0.73	-10.27	-0.45	3.15e-22	Gut microbiome composition (summer);
LUAD	cis	rs3125734	0.633	rs4979782	chr10:63998527	C/T	cg19640130	chr10:64028056	RTKN2	-0.34	-7.21	-0.33	2.66e-12	Rheumatoid arthritis;
LUAD	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg08085267	chr17:45401833	C17orf57	0.58	10.41	0.45	9.22e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg03037974	chr15:76606532	NA	0.36	7.54	0.34	2.96e-13	Blood metabolite levels;
LUAD	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg00020340	chr7:910388	UNC84A	0.63	6.93	0.32	1.54e-11	Initial pursuit acceleration;
LUAD	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg21433313	chr16:3507492	NAT15	-0.73	-12.39	-0.52	2.66e-30	Tuberculosis;
LUAD	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg10518543	chr12:38710700	ALG10B	-0.51	-8.41	-0.38	6.57e-16	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937890	0.559	rs2575823	chr11:14521354	C/A	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.15e-12	Mitochondrial DNA levels;
LUAD	trans	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.67	-0.35	1.19e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	7.29	0.33	1.51e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs416603	0.967	rs11640138	chr16:11362729	A/G	cg00044050	chr16:11439710	C16orf75	0.58	9.29	0.41	7.93e-19	Type 1 diabetes;
LUAD	cis	rs4343996	0.719	rs13221852	chr7:3489139	A/C	cg21248987	chr7:3385318	SDK1	0.34	6.55	0.3	1.67e-10	Motion sickness;
LUAD	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg06131755	chr6:160182447	ACAT2	0.43	6.44	0.3	3.3e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.62	-0.31	1.08e-10	Alzheimer's disease (late onset);
LUAD	cis	rs10193935	0.748	rs11124879	chr2:42697576	C/A	cg27598129	chr2:42591480	NA	0.78	9.37	0.41	4.23e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg07570687	chr10:102243282	WNT8B	0.46	7.09	0.33	5.58e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.37	0.38	8.26e-16	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13713052	chr3:122102218	FAM162A;CCDC58	-0.45	-7.11	-0.33	4.82e-12	Height;
LUAD	cis	rs17155006	0.746	rs370495	chr7:107746246	T/C	cg05962710	chr7:107745446	LAMB4	-0.32	-6.9	-0.32	1.95e-11	Pneumococcal bacteremia;
LUAD	cis	rs6546550	0.901	rs6741449	chr2:70156589	A/G	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.1	-0.48	2.58e-25	Prevalent atrial fibrillation;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg05002974	chr5:81574439	RPS23	-0.42	-7.01	-0.32	9.41e-12	Schizophrenia;
LUAD	cis	rs9400271	0.632	rs9374069	chr6:109586334	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.43	-0.3	3.36e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg08085267	chr17:45401833	C17orf57	0.64	11.77	0.5	7.09e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg03030879	chr14:75389066	RPS6KL1	0.36	6.74	0.31	5.16e-11	Caffeine consumption;
LUAD	cis	rs1595825	0.891	rs73056859	chr2:198801720	A/G	cg00982548	chr2:198649783	BOLL	-0.62	-8.74	-0.39	5.39e-17	Ulcerative colitis;
LUAD	cis	rs6881634	0.501	rs13155116	chr5:77724873	A/T	cg11547950	chr5:77652471	NA	-0.36	-6.57	-0.3	1.52e-10	Hippocampal atrophy;
LUAD	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg06453172	chr10:134556979	INPP5A	-0.66	-10.06	-0.44	1.7e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.48	7.77	0.35	5.88e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg08888203	chr3:10149979	C3orf24	-0.74	-12.73	-0.53	1.19e-31	Alzheimer's disease;
LUAD	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.58	-8.12	-0.37	5.21e-15	Gut microbiome composition (summer);
LUAD	cis	rs1882538	0.569	rs11562036	chr7:133076862	T/C	cg10665199	chr7:133106180	EXOC4	0.62	10.46	0.45	6.09e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs16910800	0.731	rs35725172	chr11:23185968	G/A	cg20040320	chr11:23191996	NA	-0.75	-10.01	-0.44	2.66e-21	Cancer;
LUAD	cis	rs7301016	0.901	rs7975109	chr12:62941643	C/T	cg11441379	chr12:63026424	NA	0.62	7.79	0.35	5.16e-14	IgG glycosylation;
LUAD	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg12756686	chr19:29218302	NA	0.52	6.62	0.31	1.07e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.49	0.3	2.38e-10	Cardiac Troponin-T levels;
LUAD	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg09491104	chr22:46646882	C22orf40	-0.68	-12.6	-0.52	4.01e-31	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs3820068	0.705	rs4646075	chr1:15827461	T/C	cg13390004	chr1:15929781	NA	0.4	6.51	0.3	2.15e-10	Systolic blood pressure;
LUAD	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01570182	chr17:44337453	NA	1.09	16.23	0.62	2.07e-46	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.74	9.59	0.42	7.81e-20	Body mass index;
LUAD	cis	rs2554380	0.891	rs2244838	chr15:84298598	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.53	-8.2	-0.37	2.87e-15	Height;
LUAD	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg14458575	chr2:238380390	NA	0.99	20.0	0.7	3.91e-63	Prostate cancer;
LUAD	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg13732083	chr21:47605072	C21orf56	-0.51	-8.45	-0.38	4.8e-16	Testicular germ cell tumor;
LUAD	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg11502198	chr6:26597334	ABT1	0.66	11.38	0.48	2.33e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg27068330	chr11:65405492	SIPA1	0.57	9.02	0.4	6.48e-18	Acne (severe);
LUAD	cis	rs9837602	1.000	rs10049383	chr3:99748548	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-7.04	-0.32	7.84e-12	Breast cancer;
LUAD	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg13319975	chr6:146136371	FBXO30	-0.58	-9.71	-0.43	2.86e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9972944	0.729	rs10512505	chr17:63776696	A/G	cg07283582	chr17:63770753	CCDC46	0.48	10.33	0.45	1.86e-22	Total body bone mineral density;
LUAD	trans	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04565464	chr8:145669602	NFKBIL2	0.45	6.67	0.31	8.25e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg05084668	chr3:125655381	ALG1L	-0.61	-8.95	-0.4	1.16e-17	Blood pressure (smoking interaction);
LUAD	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg00300879	chr1:26503847	CNKSR1	0.29	8.53	0.38	2.57e-16	Height;
LUAD	cis	rs9837602	1.000	rs6802422	chr3:99778655	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	6.8	0.31	3.54e-11	Breast cancer;
LUAD	cis	rs77861329	1.000	rs9843299	chr3:52137469	G/T	cg08692210	chr3:52188851	WDR51A	0.81	6.94	0.32	1.45e-11	Macrophage inflammatory protein 1b levels;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg13284070	chr3:128483832	RAB7A	0.4	6.37	0.3	5e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg18305652	chr10:134549665	INPP5A	0.61	11.81	0.5	4.99e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg08219700	chr8:58056026	NA	0.5	7.23	0.33	2.31e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg07423050	chr13:99094983	FARP1	-0.56	-9.42	-0.42	3.05e-19	Longevity;
LUAD	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg03676636	chr4:99064102	C4orf37	0.37	9.56	0.42	9.75e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg05082376	chr22:42548792	NA	-0.43	-7.63	-0.35	1.61e-13	Schizophrenia;
LUAD	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg19773385	chr1:10388646	KIF1B	-0.43	-6.9	-0.32	1.92e-11	Hepatocellular carcinoma;
LUAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg11494091	chr17:61959527	GH2	0.73	18.01	0.66	2.99e-54	Prudent dietary pattern;
LUAD	trans	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg26818010	chr10:134567672	INPP5A	0.9	15.1	0.59	1.64e-41	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1595825	0.891	rs57340905	chr2:198565823	C/T	cg10547527	chr2:198650123	BOLL	-0.51	-7.1	-0.33	5.19e-12	Ulcerative colitis;
LUAD	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg13180566	chr4:1052158	NA	-0.4	-6.77	-0.31	4.25e-11	Recombination rate (females);
LUAD	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg15691649	chr6:25882328	NA	-0.4	-6.58	-0.3	1.43e-10	Blood metabolite levels;
LUAD	trans	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg01620082	chr3:125678407	NA	-0.83	-8.57	-0.38	1.97e-16	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.18	-0.33	3.08e-12	Dental caries;
LUAD	cis	rs240764	0.697	rs12189562	chr6:101168679	A/G	cg09795085	chr6:101329169	ASCC3	-0.39	-6.57	-0.3	1.47e-10	Neuroticism;
LUAD	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg12437481	chr16:420112	MRPL28	-0.39	-6.73	-0.31	5.58e-11	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs7584330	0.518	rs74003108	chr2:238448000	T/C	cg14458575	chr2:238380390	NA	0.75	10.98	0.47	7.54e-25	Prostate cancer;
LUAD	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.64	9.94	0.44	4.71e-21	Platelet count;
LUAD	cis	rs7614311	0.594	rs3774709	chr3:63882476	A/G	cg22134162	chr3:63841271	THOC7	-0.4	-7.6	-0.35	1.94e-13	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg09998033	chr7:158218633	PTPRN2	0.41	7.17	0.33	3.37e-12	Obesity-related traits;
LUAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18402987	chr7:1209562	NA	0.46	7.52	0.34	3.42e-13	Longevity;Endometriosis;
LUAD	cis	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.98	-0.36	1.43e-14	Retinal vascular caliber;
LUAD	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs1535500	0.756	rs3807042	chr6:39290834	G/T	cg06347083	chr6:39282316	KCNK17	0.34	7.16	0.33	3.58e-12	Type 2 diabetes;
LUAD	trans	rs7395662	1.000	rs12365220	chr11:48555957	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.1e-12	HDL cholesterol;
LUAD	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	6.87	0.32	2.26e-11	Platelet count;
LUAD	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg11663144	chr21:46675770	NA	-0.6	-11.83	-0.5	4.19e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg00101154	chr16:420108	MRPL28	-0.46	-6.77	-0.31	4.38e-11	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs35883536	0.935	rs3904674	chr1:101138932	C/T	cg06223162	chr1:101003688	GPR88	0.35	6.5	0.3	2.2e-10	Monocyte count;
LUAD	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24531977	chr5:56204891	C5orf35	-0.96	-14.82	-0.58	2.48e-40	Initial pursuit acceleration;
LUAD	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg18016565	chr1:150552671	MCL1	-0.47	-8.32	-0.38	1.19e-15	Urate levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg09973416	chr16:85644118	KIAA0182	-0.38	-6.4	-0.3	4.17e-10	Schizophrenia;
LUAD	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg04731861	chr2:219085781	ARPC2	0.23	7.09	0.33	5.61e-12	Colorectal cancer;
LUAD	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.73	0.35	7.86e-14	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs7395662	0.782	rs66468703	chr11:48738773	T/C	cg00717180	chr2:96193071	NA	-0.44	-8.41	-0.38	6.31e-16	HDL cholesterol;
LUAD	cis	rs7619708	1	rs7619708	chr3:195810187	T/C	cg01181863	chr3:195395398	SDHAP2	0.52	6.55	0.3	1.71e-10	Red cell distribution width;
LUAD	cis	rs1371614	0.545	rs3769136	chr2:27168743	C/T	cg00617064	chr2:27272375	NA	-0.35	-6.6	-0.31	1.25e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg03188948	chr7:1209495	NA	0.81	9.78	0.43	1.65e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	5.84e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg10729496	chr3:10149963	C3orf24	0.57	9.51	0.42	1.49e-19	Alzheimer's disease;
LUAD	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg04511125	chr2:88470314	THNSL2	0.98	11.28	0.48	5.76e-26	Plasma clusterin levels;
LUAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.76e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg04775059	chr7:64541387	NA	-0.51	-7.05	-0.32	7.46e-12	Aortic root size;
LUAD	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg02505535	chr3:195703920	SDHAP1	-0.35	-7.49	-0.34	4e-13	Pancreatic cancer;
LUAD	cis	rs72928364	0.929	rs17284842	chr3:100644947	T/C	cg10123952	chr3:100791384	NA	0.64	7.32	0.34	1.26e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1816752	0.755	rs1981277	chr13:24983513	G/A	cg02811702	chr13:24901961	NA	0.42	7.36	0.34	9.42e-13	Obesity-related traits;
LUAD	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg15445000	chr17:37608096	MED1	-0.45	-8.3	-0.37	1.41e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs11971779	0.680	rs1986447	chr7:139082080	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg21775007	chr8:11205619	TDH	-0.53	-9.49	-0.42	1.68e-19	Retinal vascular caliber;
LUAD	cis	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.65	0.31	9.09e-11	Endometrial cancer;
LUAD	cis	rs367943	0.712	rs26966	chr5:112740434	T/C	cg12552261	chr5:112820674	MCC	0.46	8.97	0.4	9.46e-18	Type 2 diabetes;
LUAD	cis	rs1232027	0.700	rs67837398	chr5:79932496	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs73198271	0.740	rs1039911	chr8:8648206	G/A	cg01851573	chr8:8652454	MFHAS1	0.49	8.73	0.39	5.81e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.51	-10.65	-0.46	1.26e-23	Monocyte percentage of white cells;
LUAD	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg22618164	chr12:122356400	WDR66	0.75	13.84	0.56	3.42e-36	Mean corpuscular volume;
LUAD	cis	rs62400317	0.859	rs11967630	chr6:45128524	G/C	cg20913747	chr6:44695427	NA	-0.4	-6.48	-0.3	2.52e-10	Total body bone mineral density;
LUAD	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg27661571	chr11:113659931	NA	-0.56	-6.95	-0.32	1.38e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg15181151	chr6:150070149	PCMT1	0.34	6.59	0.31	1.3e-10	Testicular germ cell tumor;
LUAD	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg06108461	chr20:60628389	TAF4	-0.79	-13.27	-0.54	7.59e-34	Body mass index;
LUAD	cis	rs2236918	0.664	rs1776146	chr1:242040577	A/T	cg21919602	chr1:242011447	EXO1	-0.4	-6.64	-0.31	9.72e-11	Menopause (age at onset);
LUAD	cis	rs1043515	0.748	rs11657530	chr17:36942814	T/C	cg09592244	chr17:37024020	NA	0.39	6.64	0.31	9.56e-11	Height;
LUAD	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg22681709	chr2:178499509	PDE11A	0.44	7.3	0.33	1.41e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg04025307	chr7:1156635	C7orf50	0.53	8.93	0.4	1.33e-17	Longevity;Endometriosis;
LUAD	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg01689657	chr7:91764605	CYP51A1	-0.29	-7.0	-0.32	1.04e-11	Breast cancer;
LUAD	cis	rs11676348	0.935	rs4674250	chr2:218977531	G/A	cg06547715	chr2:218990976	CXCR2	0.38	8.67	0.39	9.19e-17	Ulcerative colitis;
LUAD	cis	rs55665837	1.000	rs10047429	chr11:14439032	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-10.32	-0.45	1.95e-22	Vitamin D levels;
LUAD	cis	rs500891	0.525	rs3778205	chr6:84060477	G/T	cg08257003	chr6:84140564	ME1	0.34	6.68	0.31	7.45e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs7617773	0.780	rs13066044	chr3:48377276	C/T	cg11946769	chr3:48343235	NME6	0.44	6.7	0.31	6.73e-11	Coronary artery disease;
LUAD	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg25457927	chr22:38595422	NA	-0.54	-14.2	-0.57	1.03e-37	Cutaneous nevi;
LUAD	cis	rs7089973	0.836	rs7895551	chr10:116625481	C/T	cg23260525	chr10:116636907	FAM160B1	0.43	9.68	0.43	3.68e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg14227996	chr4:17616232	MED28	0.7	7.16	0.33	3.71e-12	Opioid sensitivity;
LUAD	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.64	-11.06	-0.47	3.91e-25	Urate levels;
LUAD	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg23758822	chr17:41437982	NA	0.99	19.86	0.69	1.64e-62	Menopause (age at onset);
LUAD	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18876405	chr7:65276391	NA	-0.42	-6.68	-0.31	7.32e-11	Aortic root size;
LUAD	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg27279351	chr12:120934652	DYNLL1	-0.43	-6.55	-0.3	1.7e-10	High light scatter reticulocyte count;
LUAD	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg09658497	chr7:2847517	GNA12	-0.55	-9.42	-0.42	2.98e-19	Height;
LUAD	cis	rs4795519	0.602	rs12451024	chr17:22183514	A/G	cg22648282	chr17:21454238	C17orf51	-0.4	-6.63	-0.31	1.01e-10	Chronic myeloid leukemia;
LUAD	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg07423050	chr13:99094983	FARP1	-0.54	-9.15	-0.41	2.37e-18	Longevity;
LUAD	cis	rs7680126	0.633	rs4698014	chr4:10286301	C/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.02	-0.32	8.84e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs35883536	1.000	rs1932351	chr1:101142049	C/T	cg06223162	chr1:101003688	GPR88	0.38	6.96	0.32	1.28e-11	Monocyte count;
LUAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg03188948	chr7:1209495	NA	0.4	6.52	0.3	1.97e-10	Longevity;Endometriosis;
LUAD	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg15997130	chr1:24165203	NA	0.54	9.28	0.41	8.71e-19	Immature fraction of reticulocytes;
LUAD	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-7.43	-0.34	5.97e-13	Neutrophil percentage of white cells;
LUAD	cis	rs2580764	0.566	rs2968794	chr2:55290651	C/G	cg09592903	chr2:55203963	RTN4	-0.41	-9.27	-0.41	9.28e-19	Mean platelet volume;
LUAD	cis	rs10905065	0.895	rs3736462	chr10:5804455	A/G	cg11519256	chr10:5708881	ASB13	0.42	6.9	0.32	1.91e-11	Menopause (age at onset);
LUAD	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg12564285	chr5:131593104	PDLIM4	0.37	6.42	0.3	3.75e-10	Acylcarnitine levels;
LUAD	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg16479474	chr6:28041457	NA	0.37	6.55	0.3	1.68e-10	Cardiac Troponin-T levels;
LUAD	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	8.88e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7712401	0.601	rs246265	chr5:122254950	C/T	cg19077854	chr5:122220652	SNX24	0.34	6.43	0.3	3.53e-10	Mean platelet volume;
LUAD	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg24977338	chr2:113188963	RGPD8;RGPD5	0.61	8.1	0.37	6.11e-15	Yeast infection;
LUAD	cis	rs1868673	1.000	rs4681619	chr3:150160253	G/A	cg04908077	chr3:150187338	NA	-0.32	-6.56	-0.3	1.58e-10	Waist circumference;
LUAD	cis	rs1564271	0.528	rs1980756	chr10:26979371	G/C	cg13837822	chr10:26931731	LOC731789	0.5	10.63	0.46	1.45e-23	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUAD	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg09263875	chr16:632152	PIGQ	0.81	17.39	0.65	1.66e-51	Height;
LUAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.47	-8.48	-0.38	3.73e-16	Longevity;Endometriosis;
LUAD	cis	rs3784262	1.000	rs12903551	chr15:58268372	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.46	-9.42	-0.42	3.05e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg15501526	chr10:2543763	NA	0.7	15.84	0.61	1.01e-44	Age-related hearing impairment;
LUAD	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23158103	chr7:148848205	ZNF398	-0.65	-12.15	-0.51	2.4e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg22681709	chr2:178499509	PDE11A	-0.52	-8.88	-0.4	1.92e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-8.33	-0.38	1.17e-15	Type 2 diabetes;
LUAD	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg11301795	chr4:187892539	NA	-0.76	-15.15	-0.59	9.69e-42	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg00271210	chr6:167070053	RPS6KA2	0.35	6.8	0.31	3.47e-11	Crohn's disease;
LUAD	cis	rs7536201	1.000	rs11249218	chr1:25300256	A/G	cg23273869	chr1:25296894	NA	-0.39	-8.07	-0.37	7.56e-15	Psoriasis vulgaris;
LUAD	cis	rs1030877	0.515	rs920217	chr2:105904662	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.42	-6.78	-0.31	3.98e-11	Obesity-related traits;
LUAD	cis	rs72928364	0.929	rs13059867	chr3:100765548	T/C	cg10123952	chr3:100791384	NA	0.74	8.42	0.38	5.86e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs494562	1.000	rs495472	chr6:86117021	C/T	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	trans	rs3960554	1.000	rs2079477	chr7:75836549	C/G	cg19862616	chr7:65841803	NCRNA00174	0.8	11.2	0.48	1.17e-25	Eotaxin levels;
LUAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.62	8.79	0.39	3.83e-17	Renal function-related traits (BUN);
LUAD	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs921968	0.565	rs608047	chr2:219615910	A/C	cg02176678	chr2:219576539	TTLL4	0.55	10.52	0.46	3.65e-23	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08280861	chr8:58055591	NA	0.62	8.16	0.37	3.9e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg18305652	chr10:134549665	INPP5A	0.58	11.95	0.5	1.45e-28	Migraine;
LUAD	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg25173405	chr17:45401733	C17orf57	-0.46	-7.61	-0.35	1.75e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs76878669	0.561	rs905770	chr11:66156765	A/G	cg10616300	chr11:66138557	SLC29A2	0.37	7.77	0.35	6.14e-14	Educational attainment (years of education);
LUAD	cis	rs12541635	0.677	rs1603357	chr8:107000565	G/C	cg10147462	chr8:107024639	NA	0.54	9.78	0.43	1.7e-20	Age of smoking initiation;
LUAD	cis	rs1816752	0.740	rs6490924	chr13:25007052	G/A	cg02811702	chr13:24901961	NA	-0.38	-6.45	-0.3	3e-10	Obesity-related traits;
LUAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.01	0.53	8.72e-33	Prudent dietary pattern;
LUAD	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22590775	chr19:49891494	CCDC155	0.59	8.55	0.38	2.25e-16	Multiple sclerosis;
LUAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg21724239	chr8:58056113	NA	0.46	6.5	0.3	2.29e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.59	-0.35	2.01e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4253772	0.938	rs75977757	chr22:46641525	G/T	cg09491104	chr22:46646882	C22orf40	-0.51	-6.99	-0.32	1.11e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg27572855	chr1:25598939	RHD	0.53	11.29	0.48	5.29e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.77	-0.31	4.43e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs806794	0.810	rs62396185	chr6:26180634	G/C	cg13736514	chr6:26305472	NA	-0.49	-7.33	-0.34	1.21e-12	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUAD	cis	rs9341808	0.718	rs9352806	chr6:80980057	G/T	cg08355045	chr6:80787529	NA	0.6	11.29	0.48	5.32e-26	Sitting height ratio;
LUAD	cis	rs2976388	0.578	rs4736324	chr8:143830462	G/A	cg20108693	chr8:143823809	SLURP1	0.3	6.98	0.32	1.14e-11	Urinary tract infection frequency;
LUAD	cis	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg27411982	chr8:10470053	RP1L1	-0.39	-6.91	-0.32	1.74e-11	Systolic blood pressure;
LUAD	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg19761014	chr17:28927070	LRRC37B2	0.7	6.61	0.31	1.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg10589385	chr1:150898437	SETDB1	0.44	8.44	0.38	5.11e-16	Melanoma;
LUAD	cis	rs7975161	0.938	rs4964271	chr12:104652441	T/C	cg25273343	chr12:104657179	TXNRD1	-0.68	-8.37	-0.38	8.63e-16	Toenail selenium levels;
LUAD	trans	rs7395662	0.963	rs7951432	chr11:48591280	T/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.65	-0.31	9.09e-11	HDL cholesterol;
LUAD	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg15181151	chr6:150070149	PCMT1	0.38	7.49	0.34	4.02e-13	Lung cancer;
LUAD	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg01689657	chr7:91764605	CYP51A1	0.35	8.77	0.39	4.54e-17	Breast cancer;
LUAD	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg05340658	chr4:99064831	C4orf37	0.55	9.4	0.42	3.54e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg13047869	chr3:10149882	C3orf24	0.64	9.6	0.42	6.98e-20	Alzheimer's disease;
LUAD	cis	rs11771526	0.901	rs28631129	chr7:32305044	G/C	cg27532318	chr7:32358331	NA	0.59	7.51	0.34	3.57e-13	Body mass index;
LUAD	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg06002616	chr8:101225028	SPAG1	-0.41	-8.27	-0.37	1.71e-15	Atrioventricular conduction;
LUAD	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg25985355	chr7:65971099	NA	-0.53	-6.59	-0.31	1.33e-10	Diabetic kidney disease;
LUAD	cis	rs789294	1	rs789294	chr3:154057741	C/G	cg17054900	chr3:154042577	DHX36	0.65	7.12	0.33	4.55e-12	Coronary artery disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04442520	chr7:135195000	CNOT4	-0.38	-6.4	-0.3	4.15e-10	Cancer;
LUAD	cis	rs877282	0.891	rs11599917	chr10:762288	G/A	cg17470449	chr10:769945	NA	0.6	8.55	0.38	2.29e-16	Uric acid levels;
LUAD	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg01689657	chr7:91764605	CYP51A1	0.31	7.85	0.36	3.51e-14	Breast cancer;
LUAD	cis	rs2657888	0.593	rs2638319	chr12:56857057	A/G	cg23002907	chr12:56915593	RBMS2	-0.41	-7.5	-0.34	3.67e-13	Adiponectin levels;
LUAD	cis	rs806795	0.513	rs80292109	chr6:26237068	A/G	cg00631329	chr6:26305371	NA	-0.49	-7.57	-0.35	2.36e-13	Mosquito bite size;
LUAD	cis	rs738321	0.757	rs4820314	chr22:38518538	G/A	cg25457927	chr22:38595422	NA	-0.54	-11.89	-0.5	2.43e-28	Breast cancer;
LUAD	trans	rs10838798	0.584	rs1566732	chr11:48151494	A/C	cg15704280	chr7:45808275	SEPT13	0.48	7.44	0.34	5.82e-13	Height;
LUAD	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg03676636	chr4:99064102	C4orf37	0.32	8.22	0.37	2.47e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg19901468	chr14:105411992	AHNAK2	0.54	10.6	0.46	1.94e-23	Rheumatoid arthritis;
LUAD	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg03354898	chr7:1950403	MAD1L1	-0.45	-8.69	-0.39	7.87e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg08677398	chr8:58056175	NA	0.44	6.71	0.31	6.08e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg21385606	chr21:47601150	C21orf56	-0.36	-6.46	-0.3	2.81e-10	Testicular germ cell tumor;
LUAD	cis	rs4767364	1.000	rs7977534	chr12:112717920	T/C	cg10833066	chr12:111807467	FAM109A	0.35	6.51	0.3	2.09e-10	Oral cavity and pharyngeal cancer;
LUAD	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11644478	chr21:40555479	PSMG1	0.68	11.2	0.48	1.11e-25	Cognitive function;
LUAD	trans	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg24644049	chr4:85504048	CDS1	0.88	7.39	0.34	8.02e-13	Skin colour saturation;
LUAD	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg23933602	chr10:16859644	RSU1	0.54	7.48	0.34	4.45e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs9914544	0.545	rs9914914	chr17:18787780	G/A	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.49	-0.3	2.45e-10	Educational attainment (years of education);
LUAD	cis	rs9394169	0.613	rs4713685	chr6:33774525	C/T	cg16010596	chr6:33739607	LEMD2	0.33	6.53	0.3	1.87e-10	Essential tremor;
LUAD	cis	rs2455799	0.573	rs2470546	chr3:15733897	T/C	cg16303742	chr3:15540471	COLQ	-0.46	-8.4	-0.38	6.72e-16	Mean platelet volume;
LUAD	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg17173187	chr15:85201210	NMB	0.4	6.55	0.3	1.63e-10	Schizophrenia;
LUAD	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg03806693	chr22:41940476	POLR3H	-0.47	-7.22	-0.33	2.36e-12	Neuroticism;
LUAD	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg03983476	chr2:10830698	NOL10	0.4	6.82	0.31	3.2e-11	Prostate cancer;
LUAD	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg10589385	chr1:150898437	SETDB1	0.42	7.87	0.36	3.03e-14	Melanoma;
LUAD	cis	rs459571	1.000	rs467387	chr9:136907005	G/A	cg13789015	chr9:136890014	NCRNA00094	0.87	14.53	0.58	4.51e-39	Platelet distribution width;
LUAD	trans	rs2470578	0.716	rs2733514	chr3:17323931	A/G	cg14819958	chr11:45826606	SLC35C1	-0.39	-6.36	-0.3	5.39e-10	Schizophrenia;
LUAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg02136620	chr5:178986620	RUFY1	0.5	8.4	0.38	6.8e-16	Lung cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg08779779	chr2:200322566	SATB2	-0.39	-6.35	-0.3	5.41e-10	Schizophrenia;
LUAD	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg18721089	chr20:30220636	NA	-0.5	-7.09	-0.33	5.77e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg09035930	chr12:129282057	SLC15A4	-0.74	-17.7	-0.65	7.14e-53	Systemic lupus erythematosus;
LUAD	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg00316803	chr15:76480434	C15orf27	0.4	6.4	0.3	4.21e-10	Blood metabolite levels;
LUAD	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	8.04	0.36	8.97e-15	Tonsillectomy;
LUAD	cis	rs243505	0.660	rs7785022	chr7:148533384	C/T	cg09806900	chr7:148480153	CUL1	0.41	6.41	0.3	3.87e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2882667	0.858	rs2043271	chr5:138459108	A/G	cg04439458	chr5:138467593	SIL1	-0.54	-9.89	-0.43	7.08e-21	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg17366294	chr4:99064904	C4orf37	0.66	12.83	0.53	4.58e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg05044414	chr3:183734942	ABCC5	0.45	9.65	0.42	4.93e-20	Anterior chamber depth;
LUAD	cis	rs9393777	0.513	rs13194053	chr6:27143883	T/C	cg12292205	chr6:26970375	C6orf41	-0.58	-7.01	-0.32	9.66e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg00280220	chr17:61926910	NA	0.37	7.07	0.33	6.3e-12	Prudent dietary pattern;
LUAD	cis	rs68170813	0.559	rs78553765	chr7:106930787	C/T	cg23024343	chr7:107201750	COG5	0.51	7.4	0.34	7.48e-13	Coronary artery disease;
LUAD	trans	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg19676328	chr12:49525230	TUBA1B	-0.73	-11.52	-0.49	6.83e-27	Total cholesterol levels;
LUAD	cis	rs9296092	0.538	rs115770720	chr6:33517032	A/T	cg13560919	chr6:33536144	NA	-0.88	-16.53	-0.63	1e-47	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.59	-0.46	2.04e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg02773041	chr1:40204384	PPIE	-0.52	-8.58	-0.38	1.83e-16	Blood protein levels;
LUAD	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg25985355	chr7:65971099	NA	0.37	6.86	0.32	2.45e-11	Aortic root size;
LUAD	cis	rs847851	0.958	rs847850	chr6:34904968	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-7.3	-0.33	1.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg03929089	chr4:120376271	NA	0.57	7.5	0.34	3.7e-13	Axial length;
LUAD	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg15017067	chr4:17643749	FAM184B	0.34	6.76	0.31	4.61e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg14019146	chr3:50243930	SLC38A3	-0.41	-6.71	-0.31	6.32e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg19717773	chr7:2847554	GNA12	-0.55	-10.3	-0.45	2.36e-22	Height;
LUAD	cis	rs986417	1.000	rs2144114	chr14:61064210	T/C	cg27398547	chr14:60952738	C14orf39	0.64	7.12	0.33	4.64e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg01765077	chr12:122356316	WDR66	0.56	9.49	0.42	1.73e-19	Mean corpuscular volume;
LUAD	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg10327440	chr1:227177885	CDC42BPA	-1.13	-32.21	-0.84	6.98e-116	Myeloid white cell count;
LUAD	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg05805236	chr11:65401703	PCNXL3	-0.55	-8.77	-0.39	4.4e-17	Acne (severe);
LUAD	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg09491104	chr22:46646882	C22orf40	0.63	11.38	0.48	2.3e-26	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg26022315	chr17:47021804	SNF8	0.4	7.27	0.33	1.77e-12	Type 2 diabetes;
LUAD	cis	rs593982	0.920	rs618456	chr11:65475620	C/T	cg08755490	chr11:65554678	OVOL1	1.2	14.53	0.58	4.21e-39	Atopic dermatitis;
LUAD	cis	rs7789940	1.000	rs7789940	chr7:75951230	A/G	cg10167463	chr7:75959203	YWHAG	-0.71	-12.7	-0.53	1.5e-31	Multiple sclerosis;
LUAD	cis	rs7671266	0.668	rs10002562	chr4:10159736	C/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-8.68	-0.39	8.66e-17	Cardiovascular disease risk factors;
LUAD	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.7	0.31	6.81e-11	Schizophrenia;
LUAD	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.39	0.34	7.8e-13	Hypertriglyceridemia;
LUAD	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg24399712	chr22:39784796	NA	-0.79	-15.14	-0.59	1.09e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs300774	0.925	rs300719	chr2:136203	C/T	cg21211680	chr2:198530	NA	-0.45	-7.14	-0.33	3.98e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg21385522	chr1:16154831	NA	-0.73	-11.36	-0.48	2.77e-26	Dilated cardiomyopathy;
LUAD	cis	rs3784262	0.669	rs4646635	chr15:58252277	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.4	-8.0	-0.36	1.2e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg05872129	chr22:39784769	NA	-0.8	-15.0	-0.59	4.31e-41	Intelligence (multi-trait analysis);
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg13789711	chr9:139743225	PHPT1	0.4	6.59	0.31	1.3e-10	Diastolic blood pressure;
LUAD	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg07538946	chr5:131705188	SLC22A5	0.54	8.89	0.4	1.84e-17	Blood metabolite levels;
LUAD	cis	rs6714710	0.603	rs2305143	chr2:98413781	C/T	cg26665480	chr2:98280029	ACTR1B	0.5	8.19	0.37	3.12e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23158103	chr7:148848205	ZNF398	-0.62	-11.38	-0.48	2.29e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg00981070	chr1:2046702	PRKCZ	-0.37	-7.82	-0.36	4.24e-14	Height;
LUAD	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg03929089	chr4:120376271	NA	-0.99	-20.65	-0.71	4.76e-66	Height;
LUAD	cis	rs4481887	0.821	rs7515408	chr1:248425738	C/T	cg00666640	chr1:248458726	OR2T12	0.34	8.08	0.37	7e-15	Common traits (Other);
LUAD	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg08807101	chr21:30365312	RNF160	-0.44	-7.5	-0.34	3.88e-13	Dental caries;
LUAD	cis	rs7107174	1.000	rs10899491	chr11:78106305	T/C	cg02023728	chr11:77925099	USP35	0.47	7.25	0.33	1.95e-12	Testicular germ cell tumor;
LUAD	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.74	-13.41	-0.55	2.09e-34	Axial length;
LUAD	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg04800585	chr6:26043546	HIST1H2BB	0.51	8.63	0.39	1.23e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg08085267	chr17:45401833	C17orf57	0.53	8.9	0.4	1.7e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12541635	1.000	rs2881037	chr8:107090901	C/T	cg10147462	chr8:107024639	NA	-0.42	-7.54	-0.34	2.91e-13	Age of smoking initiation;
LUAD	cis	rs73206853	0.563	rs1107652	chr12:111176213	A/G	cg12870014	chr12:110450643	ANKRD13A	0.61	7.11	0.33	4.93e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg10589385	chr1:150898437	SETDB1	0.39	7.14	0.33	4.1e-12	Melanoma;
LUAD	cis	rs2425143	1.000	rs1118233	chr20:34228349	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.61	-0.35	1.79e-13	Blood protein levels;
LUAD	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs977987	0.645	rs10871311	chr16:75450912	T/A	cg03315344	chr16:75512273	CHST6	0.64	14.0	0.56	7.15e-37	Dupuytren's disease;
LUAD	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg05991184	chr2:219186017	PNKD	0.38	7.52	0.34	3.29e-13	Colorectal cancer;
LUAD	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.56	-7.28	-0.33	1.68e-12	Body mass index;
LUAD	trans	rs629535	0.814	rs614050	chr8:70065642	G/A	cg21567404	chr3:27674614	NA	1.01	18.42	0.67	4.82e-56	Dupuytren's disease;
LUAD	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.39	6.44	0.3	3.26e-10	Type 2 diabetes;
LUAD	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.62	-11.36	-0.48	2.81e-26	Hip circumference adjusted for BMI;
LUAD	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg17509989	chr5:176798049	RGS14	0.59	10.54	0.46	3.13e-23	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-9.7	-0.43	3.09e-20	Gut microbiome composition (summer);
LUAD	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	cis	rs910187	0.678	rs6122562	chr20:45813847	A/G	cg27589058	chr20:45804311	EYA2	-0.33	-7.47	-0.34	4.7e-13	Migraine;
LUAD	cis	rs2617583	0.509	rs62331137	chr5:1459573	A/G	cg13982541	chr5:1466431	LPCAT1	0.59	9.28	0.41	9.12e-19	Breast cancer;
LUAD	cis	rs7149337	0.837	rs10132658	chr14:51677599	C/T	cg23942311	chr14:51606299	NA	0.88	20.05	0.7	2.52e-63	Cancer;
LUAD	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg25894440	chr7:65020034	NA	-0.61	-6.5	-0.3	2.2e-10	Diabetic kidney disease;
LUAD	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg21475434	chr5:93447410	FAM172A	0.74	8.56	0.38	2.15e-16	Diabetic retinopathy;
LUAD	cis	rs10106298	0.904	rs7835270	chr8:103668320	A/G	cg10187029	chr8:103597600	NA	0.48	7.8	0.35	4.82e-14	Schizophrenia;
LUAD	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg25324976	chr17:61989376	CSHL1	0.38	7.39	0.34	7.83e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6840360	0.615	rs12647465	chr4:152607318	C/A	cg22705602	chr4:152727874	NA	-0.47	-8.78	-0.39	3.99e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg18385719	chr4:75023649	MTHFD2L	-0.65	-6.56	-0.3	1.55e-10	Type 2 diabetes;
LUAD	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg17366294	chr4:99064904	C4orf37	0.62	9.83	0.43	1.11e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504073	0.647	rs10435612	chr8:49993696	A/T	cg00325661	chr8:49890786	NA	0.45	10.07	0.44	1.64e-21	Blood metabolite ratios;
LUAD	trans	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg13565492	chr6:43139072	SRF	-0.6	-6.42	-0.3	3.67e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3806843	0.576	rs155360	chr5:140309016	C/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.43	-0.3	3.45e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs57590327	0.555	rs3943556	chr3:81738892	G/C	cg07356753	chr3:81810745	GBE1	-0.61	-9.83	-0.43	1.1e-20	Extraversion;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05210886	chr1:245133216	EFCAB2	-0.48	-8.66	-0.39	1e-16	Cancer;
LUAD	cis	rs4838594	0.590	rs1867579	chr10:49671394	A/G	cg06705548	chr10:49218579	LOC399753	0.31	6.54	0.3	1.76e-10	Daytime sleep phenotypes;
LUAD	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg00316803	chr15:76480434	C15orf27	-0.41	-7.78	-0.35	5.59e-14	Blood metabolite levels;
LUAD	cis	rs7851660	0.809	rs7032086	chr9:100656402	T/G	cg13688889	chr9:100608707	NA	-0.54	-9.17	-0.41	2.01e-18	Strep throat;
LUAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.6	8.45	0.38	4.86e-16	Gut microbiome composition (summer);
LUAD	cis	rs6445967	0.545	rs7632758	chr3:58282897	G/C	cg13750441	chr3:58318267	PXK	-0.32	-6.72	-0.31	5.87e-11	Platelet count;
LUAD	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg19875535	chr5:140030758	IK	0.45	7.45	0.34	5.13e-13	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02410754	chr1:32410520	NA	0.52	6.98	0.32	1.11e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg00450029	chr8:599525	NA	0.83	8.13	0.37	4.73e-15	IgG glycosylation;
LUAD	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06505273	chr16:24850292	NA	0.45	6.49	0.3	2.4e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.623	rs7204208	chr16:68069416	A/G	cg09835421	chr16:68378352	PRMT7	-0.52	-6.6	-0.31	1.24e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1451375	0.959	rs6962356	chr7:50621941	T/C	cg18232548	chr7:50535776	DDC	0.5	8.31	0.37	1.36e-15	Malaria;
LUAD	cis	rs755249	0.508	rs10888688	chr1:39637305	A/G	cg27567593	chr1:39956653	BMP8A	0.36	7.16	0.33	3.51e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg15445000	chr17:37608096	MED1	0.44	8.19	0.37	3.14e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs4713675	0.565	rs9368773	chr6:33682541	C/A	cg13859433	chr6:33739653	LEMD2	-0.3	-7.17	-0.33	3.48e-12	Plateletcrit;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg18845578	chr2:240003174	HDAC4	0.45	7.46	0.34	4.95e-13	Vertical cup-disc ratio;
LUAD	cis	rs7843479	0.601	rs11785043	chr8:21810377	C/T	cg03445287	chr8:21823731	XPO7	-0.5	-9.4	-0.42	3.46e-19	Mean corpuscular volume;
LUAD	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg18944383	chr4:111397179	ENPEP	-0.53	-10.28	-0.45	2.89e-22	Height;
LUAD	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg27170947	chr2:26402098	FAM59B	-0.57	-8.13	-0.37	4.89e-15	Gut microbiome composition (summer);
LUAD	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg04225089	chr17:73874465	TRIM47	-0.4	-7.06	-0.32	6.77e-12	Psoriasis;
LUAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg27170947	chr2:26402098	FAM59B	0.82	11.43	0.49	1.48e-26	Gut microbiome composition (summer);
LUAD	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg08997352	chr12:9597637	DDX12	-0.64	-10.82	-0.47	2.88e-24	Breast size;
LUAD	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg26924012	chr15:45694286	SPATA5L1	1.02	18.89	0.68	3.74e-58	Homoarginine levels;
LUAD	cis	rs2932538	0.922	rs12739994	chr1:113131159	T/C	cg22162597	chr1:113214053	CAPZA1	0.45	6.54	0.3	1.83e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs12291225	0.535	rs16930126	chr11:14404983	C/T	cg19336497	chr11:14380999	RRAS2	0.59	12.93	0.53	1.78e-32	Sense of smell;
LUAD	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg06108461	chr20:60628389	TAF4	-0.93	-16.72	-0.63	1.52e-48	Body mass index;
LUAD	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg26384229	chr12:38710491	ALG10B	0.47	7.68	0.35	1.11e-13	Bladder cancer;
LUAD	cis	rs7833986	1.000	rs34230678	chr8:57083117	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	9.88	0.43	7.49e-21	Height;
LUAD	cis	rs12760731	0.720	rs12048834	chr1:178353998	A/G	cg00404053	chr1:178313656	RASAL2	0.73	9.26	0.41	1.01e-18	Obesity-related traits;
LUAD	trans	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.88	-0.32	2.19e-11	Diabetic kidney disease;
LUAD	cis	rs7107174	1.000	rs2510036	chr11:77966788	G/T	cg02023728	chr11:77925099	USP35	0.53	8.13	0.37	4.64e-15	Testicular germ cell tumor;
LUAD	cis	rs10865541	0.902	rs10206964	chr2:3425948	T/C	cg22182287	chr2:3452347	TTC15	0.46	7.79	0.35	5.15e-14	Obesity-related traits;
LUAD	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg00634984	chr7:65235879	NA	-0.47	-6.45	-0.3	3.11e-10	Aortic root size;
LUAD	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg09835421	chr16:68378352	PRMT7	-0.72	-8.15	-0.37	4.25e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11077998	0.935	rs12185276	chr17:80498997	T/C	cg10255544	chr17:80519551	FOXK2	0.35	7.0	0.32	9.85e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg06608945	chr2:219082296	ARPC2	-0.42	-6.95	-0.32	1.38e-11	Colorectal cancer;
LUAD	cis	rs6545883	0.929	rs7606167	chr2:61742654	C/G	cg15711740	chr2:61764176	XPO1	-0.41	-6.5	-0.3	2.27e-10	Tuberculosis;
LUAD	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg11859384	chr17:80120422	CCDC57	0.5	8.98	0.4	9.07e-18	Life satisfaction;
LUAD	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg07636037	chr3:49044803	WDR6	0.62	12.09	0.51	4.21e-29	Parkinson's disease;
LUAD	cis	rs4481887	0.830	rs4364913	chr1:248515635	C/A	cg00666640	chr1:248458726	OR2T12	0.31	7.57	0.35	2.35e-13	Common traits (Other);
LUAD	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg11189052	chr15:85197271	WDR73	0.65	8.78	0.39	4.13e-17	Schizophrenia;
LUAD	cis	rs225245	0.755	rs7217565	chr17:34024707	C/A	cg05299278	chr17:33885742	SLFN14	0.5	11.24	0.48	7.66e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg18230493	chr5:56204884	C5orf35	-0.44	-7.4	-0.34	7.44e-13	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.73	-0.31	5.51e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg18755752	chr8:142205143	DENND3	-0.46	-8.11	-0.37	5.35e-15	Immature fraction of reticulocytes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg27025088	chr2:27008761	CENPA	-0.4	-6.65	-0.31	8.81e-11	Cancer;
LUAD	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg11266682	chr4:10021025	SLC2A9	0.67	15.77	0.61	2.08e-44	Bone mineral density;
LUAD	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg03188948	chr7:1209495	NA	0.72	7.26	0.33	1.93e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg26384229	chr12:38710491	ALG10B	0.45	7.34	0.34	1.09e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10489202	0.632	rs6659713	chr1:168072249	G/T	cg24449463	chr1:168025552	DCAF6	0.6	9.71	0.43	3.04e-20	Schizophrenia;
LUAD	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg26384229	chr12:38710491	ALG10B	0.42	6.96	0.32	1.32e-11	Morning vs. evening chronotype;
LUAD	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg18827107	chr12:86230957	RASSF9	-0.53	-9.42	-0.42	3.06e-19	Major depressive disorder;
LUAD	cis	rs7017914	0.967	rs1477944	chr8:71615600	C/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.86	-10.17	-0.44	7.3e-22	Lung cancer in ever smokers;
LUAD	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg24069376	chr3:38537580	EXOG	0.3	7.11	0.33	5.1e-12	Electrocardiographic conduction measures;
LUAD	cis	rs6929812	0.588	rs6456788	chr6:27422066	C/T	cg18711553	chr6:27366782	ZNF391	0.4	6.71	0.31	6.13e-11	Neuroticism (multi-trait analysis);
LUAD	cis	rs2070997	0.617	rs7848941	chr9:133744672	G/A	cg01000188	chr9:133769184	QRFP	0.51	6.48	0.3	2.49e-10	Response to amphetamines;
LUAD	cis	rs4711350	0.911	rs9461907	chr6:33726990	A/C	cg18005901	chr6:33739558	LEMD2	-0.44	-6.56	-0.3	1.54e-10	Schizophrenia;
LUAD	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg11766577	chr21:47581405	C21orf56	-0.46	-7.88	-0.36	2.83e-14	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.68e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.8	-0.31	3.64e-11	Personality dimensions;
LUAD	cis	rs8113142	0.550	rs66459748	chr19:29131294	T/G	cg14983838	chr19:29218262	NA	0.41	6.41	0.3	3.79e-10	Femoral neck bone geometry and menarche (age at onset);
LUAD	cis	rs4964805	0.632	rs11111782	chr12:104188476	A/G	cg02344784	chr12:104178138	NT5DC3	-0.46	-9.2	-0.41	1.7e-18	Attention deficit hyperactivity disorder;
LUAD	cis	rs7584330	0.554	rs3751107	chr2:238427251	G/A	cg14458575	chr2:238380390	NA	0.61	9.85	0.43	9.8e-21	Prostate cancer;
LUAD	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg06287003	chr12:125626642	AACS	-0.44	-7.64	-0.35	1.44e-13	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00166722	chr3:10149974	C3orf24	0.74	12.62	0.52	3.33e-31	Alzheimer's disease;
LUAD	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg23933602	chr10:16859644	RSU1	0.58	8.69	0.39	7.82e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.42	-0.34	6.63e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2274471	0.738	rs7865605	chr9:5003093	G/A	cg03390472	chr9:5043263	JAK2	-0.5	-7.7	-0.35	9.57e-14	Crohn's disease;
LUAD	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg12011299	chr4:100065546	ADH4	0.77	17.38	0.65	1.9e-51	Alcohol dependence;
LUAD	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg09873201	chr16:3507582	NAT15	0.55	6.6	0.31	1.25e-10	Tuberculosis;
LUAD	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg23533926	chr12:111358616	MYL2	-0.4	-6.87	-0.32	2.38e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs74417235	0.528	rs9324789	chr5:154074362	C/T	cg07371521	chr5:154026371	NA	-0.39	-6.58	-0.3	1.37e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg13119609	chr19:45449297	APOC2	0.6	12.97	0.53	1.23e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2880765	0.835	rs4344688	chr15:86043007	A/C	cg04831495	chr15:85060580	GOLGA6L5	-0.37	-6.35	-0.3	5.56e-10	Coronary artery disease;
LUAD	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg23422044	chr7:1970798	MAD1L1	-0.58	-7.21	-0.33	2.61e-12	Bipolar disorder;
LUAD	cis	rs11126435	0.858	rs9679458	chr2:74930741	G/A	cg19285774	chr2:74907978	SEMA4F	0.37	6.49	0.3	2.45e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg05805236	chr11:65401703	PCNXL3	0.6	10.1	0.44	1.24e-21	Acne (severe);
LUAD	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg00316803	chr15:76480434	C15orf27	0.43	8.21	0.37	2.8e-15	Blood metabolite levels;
LUAD	cis	rs1018836	0.886	rs10956750	chr8:91621704	G/C	cg16814680	chr8:91681699	NA	-0.7	-11.77	-0.5	7.31e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7107174	1.000	rs10793311	chr11:78104399	G/C	cg02023728	chr11:77925099	USP35	0.47	7.25	0.33	1.95e-12	Testicular germ cell tumor;
LUAD	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg18761221	chr20:60518478	NA	-0.57	-10.15	-0.44	8.58e-22	Obesity-related traits;
LUAD	trans	rs3960554	0.932	rs11975745	chr7:75843524	T/C	cg19862616	chr7:65841803	NCRNA00174	0.81	10.44	0.45	7.66e-23	Eotaxin levels;
LUAD	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg04414720	chr1:150670196	GOLPH3L	0.67	11.79	0.5	6.3e-28	Melanoma;
LUAD	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg11663144	chr21:46675770	NA	-0.62	-12.41	-0.52	2.17e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2882667	0.537	rs6887866	chr5:138437696	T/C	cg04439458	chr5:138467593	SIL1	-0.35	-6.47	-0.3	2.69e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs752010	0.871	rs2038976	chr1:42094498	A/G	cg06885757	chr1:42089581	HIVEP3	0.48	10.83	0.47	2.84e-24	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg22963979	chr7:1858916	MAD1L1	-0.57	-9.54	-0.42	1.14e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs4268898	0.828	rs2702121	chr2:24610392	C/A	cg06627628	chr2:24431161	ITSN2	0.49	8.01	0.36	1.12e-14	Asthma;
LUAD	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.94	-0.32	1.45e-11	Total cholesterol levels;
LUAD	cis	rs1448094	0.872	rs7975457	chr12:86410404	C/T	cg06740227	chr12:86229804	RASSF9	0.39	7.05	0.32	7.41e-12	Major depressive disorder;
LUAD	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.56	-0.38	2.03e-16	Alcohol dependence;
LUAD	cis	rs12049351	0.774	rs10916495	chr1:229635521	A/G	cg11742688	chr1:229674241	ABCB10	-0.42	-6.42	-0.3	3.7e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg12863693	chr15:85201151	NMB	0.43	7.98	0.36	1.41e-14	Schizophrenia;
LUAD	cis	rs7771547	0.573	rs522179	chr6:36391605	G/A	cg07856975	chr6:36356162	ETV7	0.49	7.68	0.35	1.11e-13	Platelet distribution width;
LUAD	cis	rs7737355	1.000	rs27708	chr5:130743541	C/T	cg06307176	chr5:131281290	NA	-0.48	-7.6	-0.35	1.96e-13	Life satisfaction;
LUAD	trans	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg07211511	chr3:129823064	LOC729375	-0.71	-9.93	-0.43	5.08e-21	Blood pressure (smoking interaction);
LUAD	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg04225089	chr17:73874465	TRIM47	-0.38	-6.79	-0.31	3.84e-11	Psoriasis;
LUAD	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg21475434	chr5:93447410	FAM172A	0.76	8.43	0.38	5.66e-16	Diabetic retinopathy;
LUAD	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg01868782	chr6:126071099	HEY2	0.32	6.67	0.31	7.83e-11	Brugada syndrome;
LUAD	cis	rs6500395	1.000	rs12919520	chr16:48705760	G/C	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg26597838	chr10:835615	NA	-0.51	-8.23	-0.37	2.28e-15	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg08807101	chr21:30365312	RNF160	-0.44	-7.58	-0.35	2.28e-13	Dental caries;
LUAD	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg20701182	chr2:24300061	SF3B14	0.47	6.39	0.3	4.5e-10	Asthma;
LUAD	cis	rs3806843	0.517	rs246031	chr5:140333107	G/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg25173405	chr17:45401733	C17orf57	-0.46	-7.57	-0.35	2.29e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg21372672	chr17:16614065	CCDC144A	-0.4	-6.73	-0.31	5.42e-11	Educational attainment (years of education);
LUAD	cis	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg07988820	chr12:82153109	PPFIA2	-0.47	-6.95	-0.32	1.37e-11	Resting heart rate;
LUAD	trans	rs7615952	0.688	rs4422259	chr3:125545831	C/T	cg00769240	chr8:12517080	NA	-0.39	-6.88	-0.32	2.13e-11	Blood pressure (smoking interaction);
LUAD	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18876405	chr7:65276391	NA	-0.45	-7.29	-0.33	1.54e-12	Aortic root size;
LUAD	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg06697600	chr4:7070879	GRPEL1	-0.53	-8.47	-0.38	4.18e-16	Monocyte percentage of white cells;
LUAD	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg11502198	chr6:26597334	ABT1	0.68	11.85	0.5	3.49e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.702	rs72670252	chr4:119337546	A/C	cg21605333	chr4:119757512	SEC24D	0.69	6.75	0.31	4.86e-11	Cannabis dependence symptom count;
LUAD	cis	rs775227	1.000	rs13093350	chr3:112993063	A/G	cg18753928	chr3:113234510	CCDC52	0.41	6.37	0.3	5e-10	Dental caries;
LUAD	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg06671706	chr8:8559999	CLDN23	0.38	6.66	0.31	8.68e-11	Mood instability;
LUAD	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg15704280	chr7:45808275	SEPT13	0.64	8.17	0.37	3.52e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs28595532	0.545	rs17594782	chr4:119250877	G/T	cg02775129	chr4:119771670	NA	-0.58	-6.47	-0.3	2.67e-10	Cannabis dependence symptom count;
LUAD	cis	rs929596	0.785	rs11695484	chr2:234654449	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.75	-12.71	-0.53	1.44e-31	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.22e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg15017067	chr4:17643749	FAM184B	0.34	6.55	0.3	1.66e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08109568	chr15:31115862	NA	0.76	12.74	0.53	1.12e-31	Huntington's disease progression;
LUAD	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg09835421	chr16:68378352	PRMT7	-1.07	-12.3	-0.51	6.4e-30	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg25985355	chr7:65971099	NA	-0.52	-6.47	-0.3	2.66e-10	Diabetic kidney disease;
LUAD	cis	rs6847149	0.929	rs10857002	chr4:110773433	A/C	cg07850274	chr4:110748770	RRH	0.5	7.27	0.33	1.7e-12	Exercise treadmill test traits;
LUAD	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg16989719	chr2:238392110	NA	-0.36	-6.75	-0.31	4.8e-11	Prostate cancer;
LUAD	cis	rs116248771	0.793	rs73156465	chr3:158374535	C/G	cg16708174	chr3:158430962	RARRES1	0.47	6.83	0.32	3.03e-11	diarrhoeal disease at age 2;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05468351	chr5:21459598	LOC728411	-0.45	-6.75	-0.31	5.02e-11	Height;
LUAD	trans	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg05926928	chr17:57297772	GDPD1	1.41	19.47	0.69	9.12e-61	Opioid sensitivity;
LUAD	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg12756686	chr19:29218302	NA	0.63	8.22	0.37	2.49e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	trans	rs877282	0.520	rs12360072	chr10:813082	C/T	cg22713356	chr15:30763199	NA	0.45	6.7	0.31	6.51e-11	Uric acid levels;
LUAD	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg15181151	chr6:150070149	PCMT1	0.4	7.78	0.35	5.5e-14	Lung cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17808901	chr3:39093368	WDR48	-0.44	-7.24	-0.33	2.13e-12	Height;
LUAD	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg00321850	chr1:175162397	KIAA0040	0.53	11.53	0.49	6.25e-27	Alcohol dependence;
LUAD	cis	rs999737	0.853	rs17828907	chr14:69011205	A/T	cg04147497	chr14:69052728	RAD51L1	-0.42	-6.61	-0.31	1.17e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs7408868	1.000	rs7250232	chr19:15277199	C/T	cg14696996	chr19:15285081	NOTCH3	0.68	9.09	0.4	3.94e-18	Pulse pressure;
LUAD	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs3125734	0.633	rs10761616	chr10:64009076	G/A	cg09941381	chr10:64027924	RTKN2	-0.31	-7.28	-0.33	1.69e-12	Rheumatoid arthritis;
LUAD	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg19743168	chr1:23544995	NA	0.37	6.44	0.3	3.27e-10	Height;
LUAD	cis	rs1555895	0.576	rs12413763	chr10:849454	A/G	cg20503657	chr10:835505	NA	0.41	6.4	0.3	4.1e-10	Survival in rectal cancer;
LUAD	cis	rs1232027	0.656	rs966762	chr5:79936799	A/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg12935359	chr14:103987150	CKB	0.52	8.09	0.37	6.33e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg10792982	chr14:105748885	BRF1	-0.43	-9.53	-0.42	1.24e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2046867	0.908	rs11928067	chr3:72796340	T/C	cg04365224	chr3:72788183	NA	-0.48	-7.31	-0.33	1.38e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22857025	chr5:266934	NA	-0.95	-13.91	-0.56	1.67e-36	Breast cancer;
LUAD	cis	rs11048434	0.736	rs1805732	chr12:9090892	A/G	cg23795048	chr12:9217529	LOC144571	-0.43	-7.98	-0.36	1.36e-14	Sjögren's syndrome;
LUAD	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg15181151	chr6:150070149	PCMT1	0.42	8.72	0.39	6.3e-17	Lung cancer;
LUAD	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg26924012	chr15:45694286	SPATA5L1	0.99	18.22	0.66	3.45e-55	Homoarginine levels;
LUAD	cis	rs6688613	1.000	rs7528849	chr1:166954870	A/G	cg07049167	chr1:166818506	POGK	0.41	6.86	0.32	2.42e-11	Refractive astigmatism;
LUAD	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg02421172	chr7:1938701	MAD1L1	0.45	6.53	0.3	1.91e-10	Bipolar disorder;
LUAD	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg12179176	chr11:130786555	SNX19	0.53	8.66	0.39	9.74e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4664304	0.629	rs17239981	chr2:160847667	C/T	cg23995753	chr2:160760732	LY75	-0.39	-6.71	-0.31	6.36e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg18105139	chr6:28058856	ZSCAN12L1	-0.27	-6.44	-0.3	3.24e-10	Depression;
LUAD	cis	rs17532515	0.628	rs3113195	chr4:141475837	A/G	cg09181644	chr4:141490428	UCP1	-0.32	-7.17	-0.33	3.27e-12	Select biomarker traits;
LUAD	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg14779329	chr11:130786720	SNX19	-0.37	-6.54	-0.3	1.8e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg06784218	chr1:46089804	CCDC17	0.5	11.01	0.47	5.95e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.5	-7.67	-0.35	1.21e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg16006841	chr5:176797999	RGS14	-0.76	-13.42	-0.55	1.78e-34	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs41271473	0.898	rs12028277	chr1:228829657	A/G	cg10167378	chr1:228756711	NA	0.49	6.99	0.32	1.06e-11	Chronic lymphocytic leukemia;
LUAD	cis	rs1032833	0.558	rs1838873	chr2:179939457	C/T	cg23883738	chr2:179974586	SESTD1	-0.72	-7.05	-0.32	7.36e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg18129178	chr5:148520854	ABLIM3	-0.63	-9.65	-0.42	4.65e-20	Breast cancer;
LUAD	cis	rs2294693	0.947	rs736793	chr6:40997919	A/T	cg14769373	chr6:40998127	UNC5CL	-0.55	-8.54	-0.38	2.39e-16	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.7	0.46	8.11e-24	Smoking behavior;
LUAD	cis	rs4343996	0.747	rs7791617	chr7:3504800	C/T	cg21248987	chr7:3385318	SDK1	-0.37	-6.71	-0.31	6.27e-11	Motion sickness;
LUAD	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.7	-0.35	9.82e-14	Total body bone mineral density;
LUAD	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg11915388	chr22:42470451	FAM109B	0.41	7.09	0.33	5.8e-12	Schizophrenia;
LUAD	cis	rs8112211	0.637	rs2270093	chr19:38839859	T/C	cg14299480	chr19:38876666	GGN	-0.46	-7.43	-0.34	6.11e-13	Blood protein levels;
LUAD	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg25985355	chr7:65971099	NA	-0.53	-6.6	-0.31	1.22e-10	Diabetic kidney disease;
LUAD	cis	rs8192282	0.739	rs4474240	chr1:154457855	A/C	cg07911225	chr1:154474108	TDRD10;SHE	-0.4	-6.98	-0.32	1.16e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs894734	0.535	rs2366142	chr12:54323148	T/C	cg17410650	chr12:54324560	NA	-0.58	-12.19	-0.51	1.62e-29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUAD	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg02454025	chr1:11042201	C1orf127	1.04	17.71	0.65	6.82e-53	Ewing sarcoma;
LUAD	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg20933634	chr6:27740509	NA	0.53	8.09	0.37	6.34e-15	Parkinson's disease;
LUAD	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.05	-0.36	8.75e-15	Total body bone mineral density;
LUAD	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg05865280	chr17:75406074	SEPT9	0.62	19.67	0.69	1.17e-61	Airflow obstruction;
LUAD	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg26022315	chr17:47021804	SNF8	0.41	7.38	0.34	8.45e-13	Type 2 diabetes;
LUAD	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg04036182	chr15:45458818	NA	-0.41	-7.19	-0.33	3e-12	Glomerular filtration rate;
LUAD	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg06637938	chr14:75390232	RPS6KL1	0.38	6.68	0.31	7.65e-11	Caffeine consumption;
LUAD	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg22676075	chr6:135203613	NA	0.41	7.5	0.34	3.82e-13	Red blood cell count;
LUAD	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg10755058	chr3:40428713	ENTPD3	0.46	8.67	0.39	9.15e-17	Renal cell carcinoma;
LUAD	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	8.42	0.38	5.83e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg00074818	chr8:8560427	CLDN23	0.6	9.28	0.41	8.79e-19	Obesity-related traits;
LUAD	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg00310523	chr12:86230176	RASSF9	0.41	8.22	0.37	2.52e-15	Major depressive disorder;
LUAD	cis	rs1953600	0.870	rs2788295	chr10:81941007	C/G	cg00277334	chr10:82204260	NA	0.42	7.09	0.33	5.6e-12	Sarcoidosis;
LUAD	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg25985355	chr7:65971099	NA	-0.55	-6.75	-0.31	4.77e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11800820	0.536	rs10802409	chr1:246632031	C/T	cg16700716	chr1:246684329	NA	0.39	7.54	0.34	2.9e-13	Obesity-related traits;
LUAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg04025307	chr7:1156635	C7orf50	0.81	15.12	0.59	1.36e-41	Longevity;Endometriosis;
LUAD	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg19761014	chr17:28927070	LRRC37B2	0.86	8.46	0.38	4.36e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg23992470	chr4:843637	GAK	0.52	7.92	0.36	2.12e-14	Parkinson's disease;
LUAD	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg26384229	chr12:38710491	ALG10B	-0.43	-7.3	-0.33	1.41e-12	Morning vs. evening chronotype;
LUAD	cis	rs26868	0.766	rs26867	chr16:2249410	T/C	cg02248941	chr16:2239361	CASKIN1	0.5	9.63	0.42	5.4e-20	Height;
LUAD	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg06873352	chr17:61820015	STRADA	-0.69	-13.05	-0.54	6e-33	Prudent dietary pattern;
LUAD	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg21385522	chr1:16154831	NA	-1.02	-21.02	-0.71	1.12e-67	Dilated cardiomyopathy;
LUAD	cis	rs877282	0.898	rs12356744	chr10:757477	G/C	cg17470449	chr10:769945	NA	0.59	8.02	0.36	1.07e-14	Uric acid levels;
LUAD	trans	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.51	8.16	0.37	3.86e-15	Endometrial cancer;
LUAD	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06022373	chr22:39101656	GTPBP1	0.44	6.75	0.31	5.04e-11	Menopause (age at onset);
LUAD	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg16797656	chr11:68205561	LRP5	0.46	9.76	0.43	2.01e-20	Total body bone mineral density;
LUAD	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg22442454	chr1:209979470	IRF6	0.57	6.37	0.3	5.03e-10	Coronary artery disease;
LUAD	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.57	0.46	2.39e-23	Colorectal cancer;
LUAD	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.68	13.36	0.54	3.2e-34	Cognitive ability;
LUAD	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg25767906	chr1:53392781	SCP2	0.36	6.92	0.32	1.65e-11	Monocyte count;
LUAD	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg23649088	chr2:200775458	C2orf69	-0.62	-7.79	-0.35	5.38e-14	Schizophrenia;
LUAD	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg01065977	chr19:18549689	ISYNA1	-0.41	-7.81	-0.36	4.46e-14	Breast cancer;
LUAD	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg12863693	chr15:85201151	NMB	0.37	6.61	0.31	1.16e-10	Schizophrenia;
LUAD	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg12588279	chr6:26043732	HIST1H2BB	0.38	6.39	0.3	4.3e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg00922110	chr4:57842668	C4orf14	-0.43	-7.31	-0.33	1.34e-12	Response to bleomycin (chromatid breaks);
LUAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.57	7.7	0.35	9.61e-14	Renal function-related traits (BUN);
LUAD	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06022373	chr22:39101656	GTPBP1	0.45	7.14	0.33	4.15e-12	Menopause (age at onset);
LUAD	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg06064525	chr11:970664	AP2A2	-0.55	-11.26	-0.48	6.74e-26	Alzheimer's disease (late onset);
LUAD	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg21951975	chr1:209979733	IRF6	0.55	7.18	0.33	3.11e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg26818010	chr10:134567672	INPP5A	-0.96	-15.49	-0.6	3.29e-43	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg10596483	chr8:143751796	JRK	0.44	7.08	0.33	6.14e-12	Schizophrenia;
LUAD	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24838063	chr12:130822603	PIWIL1	0.64	10.7	0.46	8.19e-24	Menopause (age at onset);
LUAD	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg12436631	chr1:155007014	DCST1;DCST2	0.3	6.96	0.32	1.29e-11	Prostate cancer;
LUAD	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg12119029	chr16:89752879	CDK10	0.32	6.63	0.31	1.06e-10	Vitiligo;
LUAD	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg18132916	chr6:79620363	NA	-0.45	-7.72	-0.35	8.48e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2281636	1.000	rs2231675	chr10:101492241	G/A	cg17885402	chr10:101492224	COX15;CUTC	0.4	6.79	0.31	3.93e-11	Obesity-related traits;
LUAD	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg00310523	chr12:86230176	RASSF9	0.42	8.36	0.38	8.93e-16	Major depressive disorder;
LUAD	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-7.28	-0.33	1.66e-12	Personality dimensions;
LUAD	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg11859384	chr17:80120422	CCDC57	0.49	8.92	0.4	1.44e-17	Life satisfaction;
LUAD	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg22852734	chr6:133119734	C6orf192	0.7	6.89	0.32	2.06e-11	Type 2 diabetes nephropathy;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg26567249	chr8:97247842	UQCRB	0.42	6.81	0.31	3.3e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg14835575	chr10:16859367	RSU1	1.0	15.31	0.6	2.12e-42	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.01e-10	Skin colour saturation;
LUAD	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg15448220	chr1:150897856	SETDB1	0.54	9.04	0.4	5.66e-18	Melanoma;
LUAD	cis	rs6840360	0.571	rs875667	chr4:152525477	G/A	cg22705602	chr4:152727874	NA	-0.44	-7.51	-0.34	3.57e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg00310523	chr12:86230176	RASSF9	0.36	7.37	0.34	9.31e-13	Major depressive disorder;
LUAD	cis	rs1044826	0.642	rs295479	chr3:139223865	C/T	cg00490450	chr3:139108681	COPB2	0.4	6.42	0.3	3.59e-10	Obesity-related traits;
LUAD	cis	rs12620999	0.941	rs10929215	chr2:238037456	G/A	cg23555395	chr2:238036564	NA	-0.6	-9.18	-0.41	1.89e-18	Systemic lupus erythematosus;
LUAD	cis	rs9487051	0.768	rs1269172	chr6:109522080	G/C	cg01475377	chr6:109611718	NA	-0.37	-6.79	-0.31	3.92e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	9.71	0.43	2.94e-20	Total body bone mineral density;
LUAD	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg06387496	chr7:2775674	GNA12	-0.4	-6.7	-0.31	6.72e-11	Height;
LUAD	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg18016565	chr1:150552671	MCL1	-0.46	-8.13	-0.37	4.96e-15	Urate levels;
LUAD	cis	rs7671266	0.571	rs4643800	chr4:10407572	G/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.18	-0.33	3.16e-12	Cardiovascular disease risk factors;
LUAD	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg21475434	chr5:93447410	FAM172A	0.59	7.49	0.34	4.05e-13	Diabetic retinopathy;
LUAD	trans	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg16724585	chr3:197361211	NA	-0.51	-7.58	-0.35	2.15e-13	Pancreatic cancer;
LUAD	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg11915388	chr22:42470451	FAM109B	-0.39	-7.0	-0.32	1.02e-11	Schizophrenia;
LUAD	cis	rs929596	0.755	rs6742078	chr2:234672639	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.72	12.7	0.53	1.56e-31	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs68170813	0.559	rs76299183	chr7:106904859	A/G	cg02696742	chr7:106810147	HBP1	-0.76	-10.71	-0.46	7.32e-24	Coronary artery disease;
LUAD	trans	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17712092	chr4:129076599	LARP1B	1.06	23.33	0.75	5.47e-78	Eosinophil percentage of white cells;
LUAD	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg03909863	chr11:638404	DRD4	-0.49	-6.64	-0.31	9.51e-11	Systemic lupus erythematosus;
LUAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg21733973	chr7:65235735	NA	0.46	7.39	0.34	8.03e-13	Calcium levels;
LUAD	cis	rs6964587	0.758	rs35963176	chr7:91617115	C/T	cg17063962	chr7:91808500	NA	0.52	7.44	0.34	5.71e-13	Breast cancer;
LUAD	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg21475434	chr5:93447410	FAM172A	0.76	8.52	0.38	2.87e-16	Diabetic retinopathy;
LUAD	cis	rs3784262	0.904	rs4646616	chr15:58261349	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.45	-9.3	-0.41	7.3e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.31	-7.88	-0.36	2.82e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs6840360	0.530	rs6839802	chr4:152485834	G/A	cg22705602	chr4:152727874	NA	-0.37	-6.64	-0.31	9.65e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg22153745	chr1:153894579	GATAD2B	-0.53	-7.86	-0.36	3.23e-14	Total cholesterol levels;
LUAD	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg16060761	chr17:80687452	NA	-0.53	-7.24	-0.33	2.2e-12	Glycated hemoglobin levels;
LUAD	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.81	-0.36	4.47e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg04025307	chr7:1156635	C7orf50	0.65	9.19	0.41	1.84e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs656900	0.669	rs7178799	chr15:80119323	T/C	cg02196730	chr15:80188777	MTHFS	0.44	7.2	0.33	2.68e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg00316803	chr15:76480434	C15orf27	-0.39	-7.15	-0.33	3.84e-12	Blood metabolite levels;
LUAD	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs758324	0.947	rs13170693	chr5:131187826	T/C	cg06307176	chr5:131281290	NA	0.5	7.95	0.36	1.76e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg05805236	chr11:65401703	PCNXL3	-0.52	-8.6	-0.39	1.63e-16	Acne (severe);
LUAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.41	0.55	2.09e-34	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.15e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs300774	0.800	rs300732	chr2:166725	A/G	cg21211680	chr2:198530	NA	-0.49	-7.8	-0.35	4.9e-14	Suicide attempts in bipolar disorder;
LUAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg21724239	chr8:58056113	NA	0.65	8.41	0.38	6.32e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg20203395	chr5:56204925	C5orf35	-0.6	-9.27	-0.41	9.59e-19	Coronary artery disease;
LUAD	cis	rs6906287	0.694	rs11968293	chr6:118634698	A/C	cg21191810	chr6:118973309	C6orf204	0.36	6.7	0.31	6.74e-11	Electrocardiographic conduction measures;
LUAD	cis	rs732716	0.853	rs12459922	chr19:4455862	A/G	cg21934504	chr19:4445085	UBXN6	0.47	7.85	0.36	3.56e-14	Mean corpuscular volume;
LUAD	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.43	-8.5	-0.38	3.17e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg11317459	chr13:21872234	NA	1.24	20.96	0.71	2.1e-67	White matter hyperintensity burden;
LUAD	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4730250	0.670	rs9641380	chr7:106868151	C/G	cg02696742	chr7:106810147	HBP1	-0.78	-10.9	-0.47	1.5e-24	Osteoarthritis;
LUAD	cis	rs6445967	0.530	rs55724153	chr3:58391587	T/C	cg13750441	chr3:58318267	PXK	-0.33	-6.73	-0.31	5.46e-11	Platelet count;
LUAD	cis	rs4700695	0.614	rs251618	chr5:65215939	C/T	cg21114390	chr5:65439923	SFRS12	0.62	7.64	0.35	1.43e-13	Facial morphology (factor 19);
LUAD	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg03806693	chr22:41940476	POLR3H	-0.58	-8.43	-0.38	5.33e-16	Vitiligo;
LUAD	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.48e-10	Prostate cancer;
LUAD	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg23096020	chr7:158799433	NA	-0.36	-6.75	-0.31	4.94e-11	Facial morphology (factor 20);
LUAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg19026029	chr1:205785957	NA	0.32	6.54	0.3	1.81e-10	Menarche (age at onset);
LUAD	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg22482690	chr17:47019901	SNF8	0.44	8.37	0.38	8.71e-16	Type 2 diabetes;
LUAD	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	7.65	0.35	1.4e-13	Menopause (age at onset);
LUAD	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.39	-0.34	7.8e-13	Neuroticism;
LUAD	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg13319975	chr6:146136371	FBXO30	0.63	10.92	0.47	1.26e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	3.96e-11	Parkinson's disease;
LUAD	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg05805236	chr11:65401703	PCNXL3	0.57	9.68	0.43	3.88e-20	Systemic lupus erythematosus;
LUAD	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg17177755	chr1:15930204	NA	0.46	7.35	0.34	1e-12	Systolic blood pressure;
LUAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg19130645	chr7:65235666	NA	0.49	8.25	0.37	1.98e-15	Calcium levels;
LUAD	cis	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg27411982	chr8:10470053	RP1L1	-0.46	-8.28	-0.37	1.62e-15	Neuroticism;
LUAD	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg26850624	chr5:429559	AHRR	-0.42	-6.65	-0.31	9.24e-11	Cystic fibrosis severity;
LUAD	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-10.32	-0.45	1.94e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg11822812	chr5:140052017	DND1	-0.44	-7.92	-0.36	2.17e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2046867	0.628	rs7356054	chr3:72912727	A/G	cg25664220	chr3:72788482	NA	-0.56	-10.45	-0.45	6.97e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs9354308	0.933	rs2802062	chr6:66561973	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.53	8.01	0.36	1.12e-14	Metabolite levels;
LUAD	cis	rs897080	0.515	rs2850290	chr2:44636055	A/G	cg00619915	chr2:44497795	NA	-0.44	-6.76	-0.31	4.66e-11	Height;
LUAD	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg16850897	chr7:100343110	ZAN	-0.65	-10.26	-0.45	3.44e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg25024717	chr12:54324583	NA	-0.33	-6.85	-0.32	2.65e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg08000102	chr2:233561755	GIGYF2	0.42	6.48	0.3	2.53e-10	Coronary artery disease;
LUAD	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6908034	0.607	rs12526109	chr6:19820089	C/A	cg02682789	chr6:19804855	NA	0.93	8.5	0.38	3.17e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs1003719	0.788	rs2835578	chr21:38457671	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.34e-16	Eye color traits;
LUAD	cis	rs7665090	0.806	rs404574	chr4:103583208	A/G	cg07973026	chr4:103553119	MANBA	-0.41	-7.1	-0.33	5.2e-12	Primary biliary cholangitis;
LUAD	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg08470875	chr2:26401718	FAM59B	0.75	10.51	0.46	4.13e-23	Gut microbiome composition (summer);
LUAD	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.8	0.43	1.38e-20	Colorectal cancer;
LUAD	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21659725	chr3:3221576	CRBN	0.87	18.73	0.67	1.97e-57	Intelligence (multi-trait analysis);
LUAD	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg25566285	chr7:158114605	PTPRN2	0.52	11.01	0.47	6.02e-25	Calcium levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26823630	chr4:110354443	SEC24B	-0.4	-6.69	-0.31	6.97e-11	Cancer;
LUAD	cis	rs2880765	0.835	rs11856869	chr15:86029097	C/G	cg13263323	chr15:86062960	AKAP13	-0.49	-9.0	-0.4	7.54e-18	Coronary artery disease;
LUAD	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg25358565	chr5:93447407	FAM172A	0.61	7.71	0.35	9.25e-14	Diabetic retinopathy;
LUAD	cis	rs524023	0.914	rs2360873	chr11:64391157	G/C	cg19131476	chr11:64387923	NRXN2	-0.42	-8.32	-0.38	1.18e-15	Urate levels in obese individuals;
LUAD	cis	rs68170813	0.559	rs7798223	chr7:106829223	T/C	cg23024343	chr7:107201750	COG5	0.49	7.09	0.33	5.65e-12	Coronary artery disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04674081	chr11:63742019	COX8A	-0.41	-6.9	-0.32	1.86e-11	Cancer;
LUAD	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	10.66	0.46	1.19e-23	Hip circumference adjusted for BMI;
LUAD	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg01503450	chr10:980765	NA	-0.37	-6.37	-0.3	4.96e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg12292205	chr6:26970375	C6orf41	-0.48	-7.08	-0.33	6.02e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg14668632	chr7:2872130	GNA12	-0.75	-13.26	-0.54	8.42e-34	Height;
LUAD	cis	rs727505	0.908	rs56155943	chr7:124606346	T/G	cg23710748	chr7:124431027	NA	-0.44	-8.64	-0.39	1.14e-16	Lewy body disease;
LUAD	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg17366294	chr4:99064904	C4orf37	0.66	12.86	0.53	3.55e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4820539	1.000	rs1051875	chr22:23466031	G/A	cg21100191	chr22:23484243	RTDR1	0.7	12.56	0.52	5.53e-31	Bone mineral density;
LUAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg20607798	chr8:58055168	NA	0.66	8.74	0.39	5.64e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.52e-35	Alcohol dependence;
LUAD	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg03676636	chr4:99064102	C4orf37	0.35	8.98	0.4	9.25e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg03806693	chr22:41940476	POLR3H	0.63	9.26	0.41	1.06e-18	Vitiligo;
LUAD	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.07	0.37	7.6e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.61	10.38	0.45	1.2e-22	Cognitive ability;
LUAD	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg05182265	chr7:156933206	UBE3C	-0.8	-17.24	-0.64	8.1e-51	Body mass index;
LUAD	cis	rs739496	0.947	rs6490162	chr12:111941120	T/C	cg10833066	chr12:111807467	FAM109A	0.38	6.45	0.3	2.98e-10	Platelet count;
LUAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.45	-7.82	-0.36	4.16e-14	Longevity;Endometriosis;
LUAD	cis	rs9300255	0.722	rs12304248	chr12:123810425	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	6.62	0.31	1.1e-10	Neutrophil percentage of white cells;
LUAD	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg18180107	chr4:99064573	C4orf37	0.43	6.91	0.32	1.75e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.25	0.33	2.06e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs739496	0.793	rs607316	chr12:111969448	C/T	cg10833066	chr12:111807467	FAM109A	0.39	6.61	0.31	1.15e-10	Platelet count;
LUAD	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg17264618	chr3:40429014	ENTPD3	0.42	8.93	0.4	1.35e-17	Renal cell carcinoma;
LUAD	cis	rs453301	0.605	rs7843024	chr8:8799976	G/A	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.06	-0.32	6.66e-12	Joint mobility (Beighton score);
LUAD	cis	rs344364	0.576	rs238677	chr16:1883279	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.37	-6.57	-0.3	1.5e-10	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs11051970	0.611	rs56146365	chr12:32529634	A/G	cg02745156	chr12:32552066	NA	0.31	6.75	0.31	5.02e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00149659	chr3:10157352	C3orf10	0.6	8.65	0.39	1.07e-16	Alzheimer's disease;
LUAD	cis	rs7551222	0.752	rs4951393	chr1:204489557	A/C	cg20240347	chr1:204465584	NA	0.32	6.46	0.3	2.85e-10	Schizophrenia;
LUAD	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg13319975	chr6:146136371	FBXO30	-0.58	-9.67	-0.43	3.99e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2286503	0.780	rs12113458	chr7:22855628	G/T	cg06496272	chr7:22895283	SNORD93	-0.37	-6.38	-0.3	4.67e-10	Fibrinogen;
LUAD	cis	rs9463078	0.665	rs4714816	chr6:44715168	T/C	cg25276700	chr6:44698697	NA	0.37	6.94	0.32	1.44e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUAD	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg23598886	chr18:12777645	NA	0.62	7.86	0.36	3.14e-14	Inflammatory skin disease;
LUAD	cis	rs9811920	0.809	rs766778	chr3:99751480	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	7.52	0.34	3.3e-13	Axial length;
LUAD	trans	rs12200782	1.000	rs12211201	chr6:26461461	A/G	cg08851530	chr6:28072375	NA	0.77	6.9	0.32	1.85e-11	Small cell lung carcinoma;
LUAD	trans	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg18187862	chr3:45730750	SACM1L	0.49	7.75	0.35	6.89e-14	Primary sclerosing cholangitis;
LUAD	cis	rs8064299	0.597	rs9944506	chr17:72782726	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.41	6.69	0.31	7.21e-11	Monocyte count;
LUAD	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg08885076	chr2:99613938	TSGA10	-0.38	-6.69	-0.31	7.28e-11	Chronic sinus infection;
LUAD	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg20291162	chr17:40259547	DHX58	-0.67	-10.64	-0.46	1.33e-23	Fibrinogen levels;
LUAD	cis	rs9322817	0.691	rs9391249	chr6:105343433	T/A	cg02098413	chr6:105308735	HACE1	0.42	8.95	0.4	1.13e-17	Thyroid stimulating hormone;
LUAD	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22857025	chr5:266934	NA	-0.97	-14.47	-0.58	7.55e-39	Breast cancer;
LUAD	cis	rs17155006	0.746	rs429252	chr7:107745554	T/C	cg05962710	chr7:107745446	LAMB4	-0.35	-7.34	-0.34	1.11e-12	Pneumococcal bacteremia;
LUAD	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg16414030	chr3:133502952	NA	-0.44	-7.64	-0.35	1.47e-13	Iron status biomarkers;
LUAD	cis	rs12949688	0.935	rs9893344	chr17:55826114	G/A	cg12582317	chr17:55822272	NA	0.35	7.07	0.33	6.38e-12	Schizophrenia;
LUAD	cis	rs77861329	1.000	rs2304505	chr3:52184760	T/C	cg08692210	chr3:52188851	WDR51A	0.8	7.6	0.35	1.88e-13	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg27490568	chr2:178487706	NA	-0.57	-8.59	-0.39	1.75e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg27144592	chr16:783916	NARFL	0.35	6.47	0.3	2.75e-10	Height;
LUAD	cis	rs977987	0.868	rs10871313	chr16:75507094	C/T	cg03315344	chr16:75512273	CHST6	0.63	13.24	0.54	1.02e-33	Dupuytren's disease;
LUAD	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg08470875	chr2:26401718	FAM59B	-0.77	-10.37	-0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg23887609	chr12:130822674	PIWIL1	0.4	6.66	0.31	8.62e-11	Menopause (age at onset);
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg02796970	chr10:39023768	NA	-0.48	-7.63	-0.35	1.5700000000000001e-13	Menopause (age at onset);
LUAD	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg02569458	chr12:86230093	RASSF9	-0.41	-7.6	-0.35	1.95e-13	Major depressive disorder;
LUAD	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg10560079	chr2:191398806	TMEM194B	-0.39	-7.09	-0.33	5.8e-12	Pulse pressure;
LUAD	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg15704280	chr7:45808275	SEPT13	-1.07	-25.01	-0.77	2.01e-85	Height;
LUAD	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg01689657	chr7:91764605	CYP51A1	0.38	9.33	0.41	6.2e-19	Breast cancer;
LUAD	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.51	-0.3	2.13e-10	Breast cancer;
LUAD	cis	rs7542375	0.683	rs11587049	chr1:221099886	A/G	cg16008148	chr1:221062819	NA	-0.41	-6.74	-0.31	5.29e-11	Obesity-related traits;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg08180934	chr12:16035177	STRAP	-0.38	-6.75	-0.31	4.88e-11	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg05590025	chr7:65112418	INTS4L2	-0.76	-7.97	-0.36	1.5e-14	Diabetic kidney disease;
LUAD	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg12292205	chr6:26970375	C6orf41	-0.58	-7.12	-0.33	4.64e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg23750338	chr8:142222470	SLC45A4	0.61	13.79	0.56	5.71e-36	Immature fraction of reticulocytes;
LUAD	cis	rs2835872	0.828	rs2835839	chr21:38991034	A/G	cg06728970	chr21:39037746	KCNJ6	-0.35	-6.42	-0.3	3.59e-10	Electroencephalographic traits in alcoholism;
LUAD	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg23933602	chr10:16859644	RSU1	0.66	11.46	0.49	1.2e-26	Platelet distribution width;
LUAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07167872	chr1:205819463	PM20D1	-0.72	-14.34	-0.57	2.75e-38	Monocyte percentage of white cells;
LUAD	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg13271783	chr10:134563150	INPP5A	-0.4	-6.81	-0.31	3.39e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg14019146	chr3:50243930	SLC38A3	0.37	7.25	0.33	2.04e-12	Menarche (age at onset);
LUAD	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg03714773	chr7:91764589	CYP51A1	0.3	6.95	0.32	1.39e-11	Breast cancer;
LUAD	cis	rs12928939	0.518	rs12445564	chr16:71943309	C/T	cg03805757	chr16:71968109	PKD1L3	-0.5	-8.04	-0.36	9.18e-15	Post bronchodilator FEV1;
LUAD	cis	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.95	-0.32	1.39e-11	Triglycerides;
LUAD	cis	rs17433780	0.836	rs61798917	chr1:89506093	G/A	cg09516651	chr1:89888402	LOC400759	0.5	9.23	0.41	1.27e-18	Carotid intima media thickness;
LUAD	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg21427119	chr20:30132790	HM13	-0.59	-8.74	-0.39	5.5e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg27454412	chr7:1067447	C7orf50	0.48	7.71	0.35	8.96e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06028605	chr16:24865363	SLC5A11	0.59	8.98	0.4	9.02e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg08999081	chr20:33150536	PIGU	-0.35	-6.88	-0.32	2.18e-11	Glomerular filtration rate (creatinine);
LUAD	trans	rs6540	1.000	rs540078	chr11:254256	C/T	cg01022370	chr8:8749074	MFHAS1	0.71	7.59	0.35	2.1e-13	Endometriosis;
LUAD	cis	rs791888	0.929	rs2755431	chr10:89415104	C/T	cg13926569	chr10:89418898	PAPSS2	-0.48	-8.84	-0.39	2.58e-17	Magnesium levels;
LUAD	cis	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg00071950	chr4:10020882	SLC2A9	0.5	7.23	0.33	2.31e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg18827107	chr12:86230957	RASSF9	-0.71	-13.07	-0.54	4.86e-33	Major depressive disorder;
LUAD	cis	rs2455826	0.544	rs2455832	chr3:15751584	T/C	cg16303742	chr3:15540471	COLQ	-0.4	-6.63	-0.31	1.01e-10	Inflammatory skin disease;
LUAD	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg26924012	chr15:45694286	SPATA5L1	0.84	14.33	0.57	3.05e-38	Homoarginine levels;
LUAD	cis	rs447921	0.813	rs34234366	chr17:74398510	C/A	cg17201438	chr17:74438067	UBE2O	0.67	8.42	0.38	5.74e-16	Mitochondrial DNA levels;
LUAD	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg27219399	chr15:67835830	MAP2K5	0.39	6.45	0.3	3.14e-10	Obesity;
LUAD	cis	rs7094131	0.523	rs10764343	chr10:22882655	G/C	cg19500236	chr10:22911537	PIP4K2A	0.41	7.48	0.34	4.2e-13	Obesity-related traits;
LUAD	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-7.17	-0.33	3.3e-12	Longevity;Endometriosis;
LUAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg22963979	chr7:1858916	MAD1L1	0.49	8.23	0.37	2.42e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs7395662	1.000	rs6485882	chr11:48592435	C/G	cg03929089	chr4:120376271	NA	0.42	7.05	0.32	7.36e-12	HDL cholesterol;
LUAD	cis	rs9644630	0.930	rs7005075	chr8:19367452	G/C	cg06699216	chr8:19333253	CSGALNACT1	0.3	7.06	0.32	6.95e-12	Oropharynx cancer;
LUAD	cis	rs250567	0.609	rs80096684	chr16:23525104	C/A	cg00143387	chr16:23521605	GGA2	-0.66	-7.81	-0.35	4.71e-14	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.03	0.32	8.54e-12	Rheumatoid arthritis;
LUAD	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg04772025	chr11:68637568	NA	0.58	9.16	0.41	2.29e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs9503551	0.710	rs7747259	chr6:3339106	A/G	cg13915676	chr9:139305538	SDCCAG3;PMPCA	-0.47	-6.35	-0.3	5.72e-10	Nicotine dependence;
LUAD	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg22105103	chr4:187893119	NA	-0.53	-11.24	-0.48	8.23e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg26513180	chr16:89883248	FANCA	0.64	6.53	0.3	1.89e-10	Skin colour saturation;
LUAD	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg00530320	chr1:46809349	NSUN4	0.51	7.86	0.36	3.16e-14	Menopause (age at onset);
LUAD	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.46	7.67	0.35	1.2e-13	Squamous cell carcinoma;
LUAD	trans	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.66	-10.98	-0.47	7.8e-25	Mean corpuscular volume;
LUAD	cis	rs117623576	0.590	rs2988084	chr10:32398653	C/T	cg03047570	chr10:32398778	NA	0.52	8.03	0.36	9.73e-15	Anti-saccade response;
LUAD	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg02527881	chr3:46936655	PTH1R	-0.54	-11.14	-0.48	1.92e-25	Colorectal cancer;
LUAD	cis	rs4901869	0.932	rs12878445	chr14:59339361	A/G	cg02291164	chr14:59296302	NA	0.63	15.57	0.6	1.61e-43	Panic disorder;
LUAD	cis	rs7617773	0.743	rs11716371	chr3:48362750	C/T	cg11946769	chr3:48343235	NME6	0.43	6.65	0.31	9.13e-11	Coronary artery disease;
LUAD	cis	rs10193935	0.892	rs12612372	chr2:42414035	A/G	cg27598129	chr2:42591480	NA	-0.78	-10.28	-0.45	2.87e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5167	0.566	rs2075620	chr19:45480037	C/T	cg13119609	chr19:45449297	APOC2	-0.39	-6.91	-0.32	1.81e-11	Blood protein levels;
LUAD	trans	rs9929218	1.000	rs4783570	chr16:68806539	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.93	-0.56	1.47e-36	Colorectal cancer;
LUAD	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg06608945	chr2:219082296	ARPC2	0.52	8.93	0.4	1.35e-17	Colorectal cancer;
LUAD	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg13722127	chr7:150037890	RARRES2	0.45	7.37	0.34	8.77e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs11958404	0.932	rs72816541	chr5:157414686	G/A	cg05962755	chr5:157440814	NA	0.42	6.49	0.3	2.4e-10	IgG glycosylation;
LUAD	cis	rs12545109	0.879	rs2576580	chr8:57365828	G/C	cg07776626	chr8:57350775	NA	-0.66	-9.29	-0.41	8.28e-19	Obesity-related traits;
LUAD	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg20891558	chr2:74357851	NA	0.96	16.97	0.64	1.23e-49	Gestational age at birth (maternal effect);
LUAD	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.46	0.34	5.03e-13	Bipolar disorder;
LUAD	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg15181151	chr6:150070149	PCMT1	0.33	6.56	0.3	1.62e-10	Testicular germ cell tumor;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25303336	chr6:33756862	LEMD2	-0.41	-6.37	-0.3	4.96e-10	Height;
LUAD	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.26	0.37	1.86e-15	Breast cancer;
LUAD	cis	rs2386661	0.704	rs2386650	chr10:5678058	G/A	cg26603656	chr10:5671107	NA	0.42	7.14	0.33	4.13e-12	Breast cancer;
LUAD	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.43	-0.34	5.99e-13	Retinal vascular caliber;
LUAD	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg01884057	chr2:25150051	NA	-0.32	-6.68	-0.31	7.39e-11	Body mass index;
LUAD	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg07741184	chr6:167504864	NA	0.4	9.25	0.41	1.15e-18	Crohn's disease;
LUAD	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.81	-0.31	3.45e-11	Diabetic kidney disease;
LUAD	cis	rs2996428	0.561	rs2275827	chr1:3746585	T/G	cg22529645	chr1:3704559	LRRC47	0.52	9.79	0.43	1.55e-20	Red cell distribution width;
LUAD	cis	rs6761276	0.899	rs6759676	chr2:113836348	A/G	cg06383401	chr2:113825234	IL1F10	0.3	6.53	0.3	1.84e-10	Protein quantitative trait loci;
LUAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg05896524	chr21:47604654	C21orf56	0.54	9.05	0.4	5.32e-18	Testicular germ cell tumor;
LUAD	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg14847009	chr1:175162515	KIAA0040	-0.33	-8.71	-0.39	7.09e-17	Alcohol dependence;
LUAD	cis	rs12620999	0.941	rs1986830	chr2:237978320	C/T	cg23555395	chr2:238036564	NA	0.57	8.95	0.4	1.1e-17	Systemic lupus erythematosus;
LUAD	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.53	-10.82	-0.47	2.9e-24	Monocyte percentage of white cells;
LUAD	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg07636037	chr3:49044803	WDR6	0.47	7.9	0.36	2.37e-14	Menarche (age at onset);
LUAD	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.38	6.38	0.3	4.55e-10	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg06221963	chr1:154839813	KCNN3	-0.85	-20.05	-0.7	2.36e-63	Prostate cancer;
LUAD	cis	rs7267979	0.789	rs4815400	chr20:25292560	T/C	cg08601574	chr20:25228251	PYGB	-0.41	-7.63	-0.35	1.54e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs13064411	0.696	rs36054418	chr3:113204762	G/T	cg10517650	chr3:113235015	CCDC52	-0.56	-9.72	-0.43	2.67e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg05351302	chr7:87563908	ADAM22	-0.46	-6.74	-0.31	5.11e-11	Blood protein levels;
LUAD	cis	rs6499255	0.904	rs9929720	chr16:69557096	C/T	cg15192750	chr16:69999425	NA	-0.48	-7.55	-0.34	2.65e-13	IgE levels;
LUAD	cis	rs6840360	0.837	rs13146981	chr4:152720703	T/C	cg22705602	chr4:152727874	NA	0.32	6.54	0.3	1.76e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg16099169	chr2:106886729	NA	-0.62	-9.57	-0.42	9.12e-20	Facial morphology (factor 23);
LUAD	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg16479474	chr6:28041457	NA	0.45	7.59	0.35	2.08e-13	Depression;
LUAD	cis	rs8017423	0.967	rs7158180	chr14:90729117	C/T	cg14092571	chr14:90743983	NA	-0.48	-8.28	-0.37	1.68e-15	Mortality in heart failure;
LUAD	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg25767906	chr1:53392781	SCP2	0.41	7.43	0.34	5.93e-13	Monocyte count;
LUAD	trans	rs800082	0.690	rs6440260	chr3:144289214	C/A	cg24215973	chr2:240111563	HDAC4	-0.59	-9.46	-0.42	2.21e-19	Smoking behavior;
LUAD	cis	rs3125734	0.633	rs4979773	chr10:63967731	G/C	cg09941381	chr10:64027924	RTKN2	-0.3	-6.86	-0.32	2.48e-11	Rheumatoid arthritis;
LUAD	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg27661571	chr11:113659931	NA	-0.53	-6.71	-0.31	6.25e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs77861329	1.000	rs9809977	chr3:52166147	T/C	cg08692210	chr3:52188851	WDR51A	0.83	7.75	0.35	6.7e-14	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs4908760	0.773	rs301805	chr1:8481016	T/G	cg01447281	chr1:8482689	RERE	-0.39	-7.96	-0.36	1.58e-14	Vitiligo;
LUAD	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg23262073	chr20:60523788	NA	-0.38	-6.86	-0.32	2.52e-11	Body mass index;
LUAD	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg17063962	chr7:91808500	NA	-0.68	-12.07	-0.51	4.93e-29	Breast cancer;
LUAD	cis	rs2224391	0.554	rs2224392	chr6:5261136	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.62	-9.3	-0.41	7.47e-19	Height;
LUAD	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg11645453	chr3:52864694	ITIH4	-0.39	-7.62	-0.35	1.7e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.69	10.7	0.46	8.26e-24	Lymphocyte percentage of white cells;
LUAD	cis	rs6541297	0.757	rs642235	chr1:230325027	C/G	cg20703242	chr1:230279135	GALNT2	-0.44	-6.72	-0.31	5.93e-11	Coronary artery disease;
LUAD	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg00999904	chr2:3704751	ALLC	-0.51	-8.76	-0.39	4.67e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg25894440	chr7:65020034	NA	-0.63	-6.71	-0.31	6.35e-11	Gout;
LUAD	cis	rs1451375	0.669	rs59086818	chr7:50653830	G/A	cg18232548	chr7:50535776	DDC	0.5	8.14	0.37	4.43e-15	Malaria;
LUAD	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1965732	0.504	rs10170315	chr2:3715832	G/A	cg10645314	chr2:3704589	ALLC	-0.41	-7.07	-0.33	6.3e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg06740227	chr12:86229804	RASSF9	0.45	7.95	0.36	1.73e-14	Major depressive disorder;
LUAD	cis	rs7584330	0.554	rs111512641	chr2:238429538	G/A	cg14458575	chr2:238380390	NA	0.65	10.19	0.44	5.99e-22	Prostate cancer;
LUAD	cis	rs35883536	1.000	rs34441740	chr1:101137046	C/G	cg06223162	chr1:101003688	GPR88	0.35	6.5	0.3	2.2e-10	Monocyte count;
LUAD	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg02931644	chr1:25747376	RHCE	0.43	9.2	0.41	1.69e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg06046430	chr4:77819534	ANKRD56	0.53	8.59	0.39	1.66e-16	Emphysema distribution in smoking;
LUAD	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg10356904	chr22:49881777	NA	-0.41	-8.02	-0.36	1.08e-14	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs12048904	0.504	rs67999847	chr1:101295459	C/T	cg14530983	chr3:88190749	ZNF654	0.38	6.42	0.3	3.61e-10	Multiple sclerosis;
LUAD	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg09904177	chr6:26538194	HMGN4	0.44	7.31	0.34	1.31e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2279817	0.818	rs34304724	chr1:17994850	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-6.9	-0.32	1.9e-11	Neuroticism;
LUAD	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg07917127	chr4:99064746	C4orf37	0.45	7.35	0.34	1.03e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg15737290	chr11:93063684	CCDC67	0.53	7.44	0.34	5.64e-13	Pulmonary function decline;
LUAD	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg01620082	chr3:125678407	NA	-0.99	-9.64	-0.42	5.04e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.86	12.37	0.52	3.34e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs72928364	0.872	rs13064121	chr3:100710713	C/T	cg10123952	chr3:100791384	NA	0.62	7.22	0.33	2.41e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs4714291	0.963	rs9369159	chr6:39998853	T/C	cg02267698	chr19:7991119	CTXN1	0.43	6.53	0.3	1.85e-10	Strep throat;
LUAD	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg18512352	chr11:47633146	NA	-0.5	-9.02	-0.4	6.82e-18	Subjective well-being;
LUAD	cis	rs72634258	0.945	rs12757968	chr1:8106201	A/G	cg26816564	chr1:7831052	VAMP3	0.52	6.65	0.31	8.86e-11	Inflammatory bowel disease;
LUAD	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg26958806	chr6:27640298	NA	0.63	6.4	0.3	4.24e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs870825	0.616	rs28497285	chr4:185629169	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs12079745	0.623	rs115415855	chr1:169322993	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.11	-7.53	-0.34	3.06e-13	QT interval;
LUAD	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg00074818	chr8:8560427	CLDN23	0.69	10.53	0.46	3.54e-23	Obesity-related traits;
LUAD	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18404041	chr3:52824283	ITIH1	-0.6	-12.12	-0.51	3.31e-29	Bipolar disorder;
LUAD	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg23815491	chr16:72088622	HP	0.54	9.94	0.44	4.49e-21	Fibrinogen levels;
LUAD	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg12311346	chr5:56204834	C5orf35	1.15	17.41	0.65	1.44e-51	Initial pursuit acceleration;
LUAD	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.31	-0.33	1.38e-12	Lung cancer;
LUAD	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg03611598	chr17:48586076	MYCBPAP	0.76	10.2	0.44	5.55e-22	Visceral fat;
LUAD	trans	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg14917512	chr19:3094685	GNA11	0.56	6.69	0.31	7e-11	Diabetic kidney disease;
LUAD	cis	rs6087990	0.806	rs910084	chr20:31379665	C/T	cg13636640	chr20:31349939	DNMT3B	0.75	13.05	0.54	6.28e-33	Ulcerative colitis;
LUAD	cis	rs870825	0.616	rs57271221	chr4:185627198	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	12.46	0.52	1.43e-30	Blood protein levels;
LUAD	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg14092988	chr3:52407081	DNAH1	0.36	7.16	0.33	3.61e-12	Bipolar disorder;
LUAD	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22496380	chr5:211416	CCDC127	-0.92	-12.52	-0.52	8.03e-31	Breast cancer;
LUAD	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg13902645	chr11:5959945	NA	-0.59	-11.23	-0.48	8.56e-26	DNA methylation (variation);
LUAD	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.37	-6.45	-0.3	3.14e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg04352962	chr1:209979756	IRF6	0.52	6.67	0.31	7.85e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs4409675	0.556	rs2064710	chr1:28231154	G/A	cg23691781	chr1:28212827	C1orf38	0.37	10.63	0.46	1.46e-23	Corneal astigmatism;
LUAD	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.68	-10.45	-0.45	7.08e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg03676636	chr4:99064102	C4orf37	0.32	8.49	0.38	3.56e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg14895029	chr7:2775587	GNA12	-0.44	-7.11	-0.33	4.84e-12	Height;
LUAD	cis	rs2274273	1.000	rs11621351	chr14:55616740	C/A	cg04306507	chr14:55594613	LGALS3	0.38	7.66	0.35	1.32e-13	Protein biomarker;
LUAD	cis	rs2742234	0.955	rs2075910	chr10:43614230	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.45	-8.03	-0.36	1e-14	Hirschsprung disease;
LUAD	cis	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg21775007	chr8:11205619	TDH	0.42	6.97	0.32	1.2e-11	Neuroticism;
LUAD	cis	rs3951016	0.514	rs283067	chr6:118620030	T/A	cg18833306	chr6:118973337	C6orf204	0.49	8.44	0.38	5.06e-16	Resting heart rate;
LUAD	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg16060761	chr17:80687452	NA	0.47	7.03	0.32	8.14e-12	Breast cancer;
LUAD	cis	rs7192380	1.000	rs8049728	chr16:69654790	G/T	cg00738113	chr16:70207722	CLEC18C	-0.34	-6.96	-0.32	1.29e-11	Sjögren's syndrome;
LUAD	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg06623918	chr6:96969491	KIAA0776	0.88	17.35	0.64	2.62e-51	Headache;
LUAD	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg13699009	chr12:122356056	WDR66	0.32	6.97	0.32	1.22e-11	Mean corpuscular volume;
LUAD	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg26536354	chr8:144654954	C8orf73	0.62	6.72	0.31	6.04e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg00280220	chr17:61926910	NA	0.36	6.83	0.32	3e-11	Prudent dietary pattern;
LUAD	cis	rs3219474	0.502	rs41343546	chr1:45908263	A/G	cg06784218	chr1:46089804	CCDC17	0.6	7.94	0.36	1.78e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg08601574	chr20:25228251	PYGB	-0.44	-8.17	-0.37	3.48e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg07570687	chr10:102243282	WNT8B	0.43	6.57	0.3	1.46e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1832871	0.672	rs9457361	chr6:158771750	G/A	cg07165851	chr6:158734300	TULP4	0.73	11.26	0.48	6.59e-26	Height;
LUAD	cis	rs2485376	0.967	rs772026	chr10:104075541	T/G	cg20641465	chr10:103991465	PITX3	-0.57	-10.64	-0.46	1.38e-23	QT interval;
LUAD	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg06108461	chr20:60628389	TAF4	-0.74	-12.35	-0.51	4e-30	Body mass index;
LUAD	cis	rs11098699	0.821	rs11734868	chr4:124211544	A/G	cg09941581	chr4:124220074	SPATA5	0.5	8.11	0.37	5.69e-15	Mosquito bite size;
LUAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg16606324	chr3:10149918	C3orf24	0.69	9.99	0.44	3.03e-21	Alzheimer's disease;
LUAD	cis	rs3820068	0.705	rs11577225	chr1:15864242	T/C	cg24675056	chr1:15929824	NA	0.42	6.73	0.31	5.61e-11	Systolic blood pressure;
LUAD	cis	rs367943	0.666	rs7725589	chr5:112693366	G/A	cg12552261	chr5:112820674	MCC	0.46	9.04	0.4	5.69e-18	Type 2 diabetes;
LUAD	trans	rs800082	0.668	rs9876975	chr3:144292255	G/A	cg24215973	chr2:240111563	HDAC4	-0.6	-9.84	-0.43	1e-20	Smoking behavior;
LUAD	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg00495681	chr13:53174319	NA	0.68	13.14	0.54	2.68e-33	Lewy body disease;
LUAD	cis	rs7474896	0.559	rs2738185	chr10:38247736	G/A	cg25427524	chr10:38739819	LOC399744	0.58	8.35	0.38	9.92e-16	Obesity (extreme);
LUAD	cis	rs599083	0.793	rs314750	chr11:68182028	G/A	cg16797656	chr11:68205561	LRP5	-0.45	-8.79	-0.39	3.87e-17	Bone mineral density (spine);
LUAD	cis	rs7582720	1.000	rs77268589	chr2:203751981	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.42e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2456568	0.802	rs10765640	chr11:93636462	C/T	cg26875233	chr11:93583750	C11orf90	-0.29	-6.39	-0.3	4.36e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg14092988	chr3:52407081	DNAH1	0.41	8.09	0.37	6.37e-15	Electroencephalogram traits;
LUAD	cis	rs6752107	0.935	rs11690131	chr2:234148383	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.53	9.12	0.41	2.96e-18	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg10518543	chr12:38710700	ALG10B	0.47	7.92	0.36	2.09e-14	Morning vs. evening chronotype;
LUAD	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14169450	chr9:139327907	INPP5E	-0.46	-8.61	-0.39	1.42e-16	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg08742575	chr21:47604166	C21orf56	0.61	10.71	0.46	7.44e-24	Testicular germ cell tumor;
LUAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg15117754	chr3:10150083	C3orf24	0.42	6.99	0.32	1.07e-11	Alzheimer's disease;
LUAD	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg18209359	chr17:80159595	CCDC57	-0.4	-6.8	-0.31	3.61e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg00106254	chr7:1943704	MAD1L1	0.63	9.73	0.43	2.58e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs4664308	1.000	rs4665147	chr2:160917062	A/G	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.79	-0.31	3.88e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg26039829	chr8:22132926	PIWIL2	0.55	10.13	0.44	9.46e-22	Hypertriglyceridemia;
LUAD	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.22	-0.33	2.5e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04127825	chr1:167503222	NA	0.43	6.82	0.31	3.11e-11	Monocyte percentage of white cells;
LUAD	cis	rs7301826	0.651	rs4514465	chr12:131313669	T/A	cg11011512	chr12:131303247	STX2	0.43	7.34	0.34	1.1e-12	Plasma plasminogen activator levels;
LUAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08439880	chr3:133502540	NA	-0.46	-9.08	-0.4	4.34e-18	Iron status biomarkers;
LUAD	cis	rs4786125	0.636	rs8062299	chr16:6902722	T/C	cg03623568	chr16:6915990	A2BP1	-0.48	-10.44	-0.45	7.41e-23	Heart rate variability traits (SDNN);
LUAD	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs10838798	0.584	rs4752899	chr11:48141855	T/G	cg00717180	chr2:96193071	NA	-0.38	-7.12	-0.33	4.79e-12	Height;
LUAD	cis	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg08601574	chr20:25228251	PYGB	-0.44	-8.16	-0.37	3.82e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg07507251	chr3:52567010	NT5DC2	0.37	7.32	0.34	1.26e-12	Bipolar disorder;
LUAD	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg11822812	chr5:140052017	DND1	-0.41	-7.48	-0.34	4.24e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23158103	chr7:148848205	ZNF398	-0.65	-12.1	-0.51	3.86e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs13064411	0.696	rs2129434	chr3:113138763	A/C	cg18753928	chr3:113234510	CCDC52	-0.67	-11.29	-0.48	5.18e-26	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg00431813	chr7:1051703	C7orf50	-0.4	-7.0	-0.32	9.99e-12	Longevity;Endometriosis;
LUAD	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg12011299	chr4:100065546	ADH4	0.69	12.49	0.52	1.07e-30	Smoking initiation;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07123227	chr8:30891112	WRN;PURG	-0.52	-6.35	-0.3	5.51e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg20503657	chr10:835505	NA	0.8	10.63	0.46	1.49e-23	Eosinophil percentage of granulocytes;
LUAD	cis	rs240764	0.669	rs846800	chr6:101270498	C/G	cg09795085	chr6:101329169	ASCC3	0.45	7.93	0.36	1.93e-14	Neuroticism;
LUAD	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	6.87	0.32	2.26e-11	Breast cancer;
LUAD	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.89	-0.36	2.67e-14	Personality dimensions;
LUAD	cis	rs17102423	0.594	rs10151162	chr14:65566695	T/C	cg16583315	chr14:65563665	MAX	-0.35	-6.46	-0.3	2.88e-10	Obesity-related traits;
LUAD	cis	rs7975161	0.638	rs7137288	chr12:104591886	C/A	cg25273343	chr12:104657179	TXNRD1	-0.49	-7.28	-0.33	1.69e-12	Toenail selenium levels;
LUAD	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.15	15.04	0.59	3.01e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg19418458	chr7:158789849	NA	0.65	8.71	0.39	6.78e-17	Facial morphology (factor 20);
LUAD	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg01299579	chr2:10830716	NOL10	-0.42	-7.34	-0.34	1.13e-12	Prostate cancer;
LUAD	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg09658497	chr7:2847517	GNA12	-0.49	-9.4	-0.42	3.45e-19	Height;
LUAD	cis	rs752010	0.875	rs11210501	chr1:42091634	T/C	cg06885757	chr1:42089581	HIVEP3	0.4	8.33	0.38	1.16e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg26554054	chr8:600488	NA	-0.73	-7.48	-0.34	4.33e-13	IgG glycosylation;
LUAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2455601	0.882	rs11042106	chr11:8896083	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.51	8.17	0.37	3.61e-15	Schizophrenia;
LUAD	cis	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg27411982	chr8:10470053	RP1L1	-0.38	-7.12	-0.33	4.64e-12	Neuroticism;
LUAD	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg05368731	chr17:41323189	NBR1	0.95	19.46	0.69	1.04e-60	Menopause (age at onset);
LUAD	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg10018233	chr7:150070692	REPIN1	0.47	7.26	0.33	1.86e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg21775007	chr8:11205619	TDH	0.45	7.91	0.36	2.2e-14	Retinal vascular caliber;
LUAD	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.19	-0.37	3.19e-15	Bipolar disorder;
LUAD	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg17644776	chr2:200775616	C2orf69	0.37	6.48	0.3	2.52e-10	Asthma (bronchodilator response);
LUAD	cis	rs16910800	1.000	rs2468647	chr11:23202054	C/T	cg20040320	chr11:23191996	NA	0.48	7.33	0.34	1.21e-12	Cancer;
LUAD	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11644478	chr21:40555479	PSMG1	0.6	9.5	0.42	1.63e-19	Cognitive function;
LUAD	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg08029281	chr1:67600428	NA	0.36	6.83	0.32	2.95e-11	Psoriasis;
LUAD	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11153730	0.503	rs369383	chr6:118618400	T/A	cg18833306	chr6:118973337	C6orf204	0.55	10.24	0.45	3.95e-22	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs977987	0.806	rs4993969	chr16:75411521	A/T	cg03315344	chr16:75512273	CHST6	0.63	13.93	0.56	1.45e-36	Dupuytren's disease;
LUAD	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg06637938	chr14:75390232	RPS6KL1	0.36	6.61	0.31	1.14e-10	Caffeine consumption;
LUAD	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg00071950	chr4:10020882	SLC2A9	-0.62	-12.1	-0.51	3.84e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg08999081	chr20:33150536	PIGU	0.46	8.83	0.39	2.85e-17	Coronary artery disease;
LUAD	cis	rs13064411	0.518	rs7637618	chr3:113176122	G/A	cg18753928	chr3:113234510	CCDC52	-0.48	-8.74	-0.39	5.6e-17	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg10518543	chr12:38710700	ALG10B	0.44	7.52	0.34	3.32e-13	Heart rate;
LUAD	cis	rs7010267	0.596	rs6996754	chr8:120034870	T/C	cg01975934	chr8:119970761	NA	-0.34	-6.44	-0.3	3.3e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs13082711	0.911	rs73046191	chr3:27454398	T/A	cg02860705	chr3:27208620	NA	0.56	8.77	0.39	4.29e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg03609598	chr5:56110824	MAP3K1	-0.66	-9.07	-0.4	4.44e-18	Initial pursuit acceleration;
LUAD	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.13	0.37	4.74e-15	Menopause (age at onset);
LUAD	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg17200465	chr3:40428508	ENTPD3	0.27	6.39	0.3	4.36e-10	Renal cell carcinoma;
LUAD	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.39	0.55	2.41e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.69	-11.89	-0.5	2.44e-28	Menarche (age at onset);
LUAD	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg00255919	chr5:131827918	IRF1	-0.43	-8.66	-0.39	1.02e-16	Asthma (sex interaction);
LUAD	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg07570687	chr10:102243282	WNT8B	0.46	6.96	0.32	1.28e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg17063962	chr7:91808500	NA	0.67	11.95	0.5	1.5e-28	Breast cancer;
LUAD	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg10434728	chr15:90938212	IQGAP1	0.36	7.18	0.33	3.08e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg05084668	chr3:125655381	ALG1L	-0.61	-8.95	-0.4	1.16e-17	Blood pressure (smoking interaction);
LUAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg23958373	chr8:599963	NA	1.14	10.33	0.45	1.79e-22	IgG glycosylation;
LUAD	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.44	-0.42	2.55e-19	Schizophrenia;
LUAD	cis	rs652260	0.663	rs580984	chr19:7881030	C/T	cg26014689	chr19:7917955	EVI5L	-0.43	-7.68	-0.35	1.11e-13	Menarche (age at onset);
LUAD	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg09117114	chr16:67998030	SLC12A4	-0.58	-7.57	-0.35	2.35e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11771526	0.551	rs2392053	chr7:32259056	C/T	cg13207630	chr7:32358064	NA	-0.5	-7.07	-0.33	6.34e-12	Body mass index;
LUAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg16414030	chr3:133502952	NA	-0.72	-14.75	-0.58	5.29e-40	Iron status biomarkers;
LUAD	cis	rs2070433	0.539	rs1008548	chr21:47959692	G/A	cg12379764	chr21:47803548	PCNT	0.48	6.99	0.32	1.05e-11	Lymphocyte counts;
LUAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg04775059	chr7:64541387	NA	0.58	9.44	0.42	2.61e-19	Calcium levels;
LUAD	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg06641503	chr3:48959341	ARIH2	-0.41	-8.02	-0.36	1.08e-14	Parkinson's disease;
LUAD	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg20290983	chr6:43655470	MRPS18A	1.07	26.7	0.79	8.83e-93	IgG glycosylation;
LUAD	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg19622623	chr12:86230825	RASSF9	-0.37	-6.82	-0.31	3.23e-11	Major depressive disorder;
LUAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07167872	chr1:205819463	PM20D1	0.89	20.19	0.7	5.73e-64	Menarche (age at onset);
LUAD	cis	rs11577318	0.853	rs7416513	chr1:26647949	G/C	cg00852783	chr1:26633632	UBXN11	0.44	7.01	0.32	9.55e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6087990	0.863	rs1569686	chr20:31367079	G/T	cg13636640	chr20:31349939	DNMT3B	0.82	15.37	0.6	1.12e-42	Ulcerative colitis;
LUAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.3	-7.02	-0.32	8.98e-12	Lymphocyte counts;
LUAD	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg15790184	chr11:494944	RNH1	0.4	6.64	0.31	9.47e-11	Systemic lupus erythematosus;
LUAD	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg04450456	chr4:17643702	FAM184B	0.42	8.38	0.38	7.95e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21582582	chr3:182698605	DCUN1D1	0.71	14.0	0.56	7.37e-37	Intelligence (multi-trait analysis);
LUAD	trans	rs62103177	0.714	rs28691615	chr18:77612254	C/T	cg05926928	chr17:57297772	GDPD1	0.84	11.94	0.5	1.61e-28	Opioid sensitivity;
LUAD	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg09184832	chr6:79620586	NA	-0.5	-9.11	-0.41	3.27e-18	Intelligence (multi-trait analysis);
LUAD	trans	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg20503657	chr10:835505	NA	0.98	14.43	0.57	1.13e-38	Eosinophil percentage of granulocytes;
LUAD	cis	rs6908034	0.660	rs6918235	chr6:19788427	A/T	cg02682789	chr6:19804855	NA	0.95	9.2	0.41	1.65e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24838063	chr12:130822603	PIWIL1	0.63	10.79	0.46	3.8e-24	Menopause (age at onset);
LUAD	cis	rs240764	0.853	rs12206945	chr6:101018032	C/T	cg09795085	chr6:101329169	ASCC3	0.41	7.12	0.33	4.63e-12	Neuroticism;
LUAD	cis	rs12900413	0.687	rs12911196	chr15:90310734	G/C	cg24249390	chr15:90295951	MESP1	-0.34	-6.62	-0.31	1.08e-10	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.93	-0.36	1.91e-14	Diabetic kidney disease;
LUAD	cis	rs722864	0.665	rs3754747	chr2:173965296	C/T	cg09210666	chr2:173941575	ZAK	0.53	7.18	0.33	3.08e-12	Lung cancer;
LUAD	cis	rs1018836	0.608	rs1033347	chr8:91464137	G/A	cg16814680	chr8:91681699	NA	-0.55	-9.08	-0.4	4.15e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs68170813	0.559	rs7779062	chr7:106880195	T/A	cg02696742	chr7:106810147	HBP1	-0.74	-10.49	-0.45	5e-23	Coronary artery disease;
LUAD	cis	rs10489202	0.909	rs61809580	chr1:168091602	A/C	cg24449463	chr1:168025552	DCAF6	-0.53	-6.39	-0.3	4.29e-10	Schizophrenia;
LUAD	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg07741184	chr6:167504864	NA	0.35	7.96	0.36	1.57e-14	Primary biliary cholangitis;
LUAD	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg20265528	chr2:105853269	NA	-0.37	-6.6	-0.31	1.25e-10	Type 2 diabetes;
LUAD	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg03929089	chr4:120376271	NA	-0.64	-9.57	-0.42	8.9e-20	Coronary artery disease;
LUAD	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.36	7.15	0.33	3.73e-12	Parkinson's disease;
LUAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06873352	chr17:61820015	STRADA	0.83	18.42	0.67	4.62e-56	Prudent dietary pattern;
LUAD	cis	rs7202877	0.610	rs3844219	chr16:75370230	G/T	cg03315344	chr16:75512273	CHST6	0.49	6.9	0.32	1.91e-11	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs4072705	0.617	rs10283445	chr9:127243637	A/G	cg13476313	chr9:127244764	NR5A1	0.35	8.91	0.4	1.55e-17	Menarche (age at onset);
LUAD	cis	rs4638749	0.677	rs6757761	chr2:108834842	T/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.38	-0.34	8.25e-13	Blood pressure;
LUAD	cis	rs524023	0.915	rs531763	chr11:64352063	A/G	cg19131476	chr11:64387923	NRXN2	0.37	7.09	0.33	5.52e-12	Urate levels in obese individuals;
LUAD	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg02176678	chr2:219576539	TTLL4	-0.6	-11.67	-0.49	1.81e-27	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs1904173	1.000	rs12517406	chr5:25384728	T/C	cg08850729	chr1:60036715	FGGY	0.55	6.43	0.3	3.4e-10	IgG glycosylation;
LUAD	cis	rs62400317	0.762	rs12198308	chr6:44911886	C/T	cg18551225	chr6:44695536	NA	-0.6	-9.01	-0.4	7.3e-18	Total body bone mineral density;
LUAD	trans	rs6921919	0.673	rs13201681	chr6:28394680	C/T	cg01620082	chr3:125678407	NA	-1.1	-10.03	-0.44	2.29e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.72	13.32	0.54	4.62e-34	Lymphocyte counts;
LUAD	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg26343298	chr8:95960752	TP53INP1	0.38	8.02	0.36	1.07e-14	Type 2 diabetes;
LUAD	cis	rs1160297	0.576	rs13003962	chr2:53110176	C/T	cg07782112	chr2:53107842	NA	0.38	8.09	0.37	6.34e-15	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg09035930	chr12:129282057	SLC15A4	0.72	16.51	0.63	1.26e-47	Systemic lupus erythematosus;
LUAD	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg03733263	chr8:22462867	KIAA1967	0.65	10.98	0.47	7.88e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs12210905	0.841	rs12206996	chr6:27066415	A/G	cg11502198	chr6:26597334	ABT1	-0.78	-6.36	-0.3	5.28e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.06	0.32	6.95e-12	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs758324	0.812	rs667419	chr5:131282064	A/G	cg25547332	chr5:131281432	NA	0.41	6.72	0.31	5.94e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.85e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8014204	0.804	rs35769520	chr14:75255115	G/A	cg06637938	chr14:75390232	RPS6KL1	0.37	6.8	0.31	3.66e-11	Caffeine consumption;
LUAD	cis	rs1535500	1.000	rs1535500	chr6:39284050	G/T	cg03252829	chr6:39282164	KCNK17	-0.31	-6.63	-0.31	1.03e-10	Type 2 diabetes;
LUAD	cis	rs1232027	0.700	rs1677696	chr5:79935017	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg17366294	chr4:99064904	C4orf37	0.66	12.75	0.53	9.81e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.86	-0.36	3.15e-14	Prostate cancer;
LUAD	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg10518543	chr12:38710700	ALG10B	-0.51	-8.31	-0.37	1.35e-15	Morning vs. evening chronotype;
LUAD	cis	rs7705042	0.865	rs12655465	chr5:141522213	C/T	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.71	-0.31	6.44e-11	Asthma;
LUAD	cis	rs17092148	0.887	rs4911430	chr20:33145404	C/G	cg16810054	chr20:33298113	TP53INP2	-0.48	-7.18	-0.33	3.1e-12	Neuroticism;
LUAD	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg14343924	chr8:8086146	FLJ10661	0.4	6.61	0.31	1.18e-10	Neuroticism;
LUAD	trans	rs7395662	1.000	rs4882130	chr11:48588954	C/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.76e-10	HDL cholesterol;
LUAD	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg16686185	chr17:78078845	GAA	-0.4	-6.59	-0.31	1.3e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.43	0.3	3.35e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg03563238	chr19:33554763	RHPN2	-0.34	-8.07	-0.37	7.47e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs629535	0.725	rs639127	chr8:70073251	A/G	cg21567404	chr3:27674614	NA	1.0	18.27	0.66	2.26e-55	Dupuytren's disease;
LUAD	cis	rs17608059	0.901	rs11078215	chr17:13906934	T/C	cg11395062	chr17:14139857	CDRT15	0.54	8.75	0.39	5.05e-17	Temperament;
LUAD	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg13319975	chr6:146136371	FBXO30	-0.64	-10.92	-0.47	1.25e-24	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9784649	1.000	rs55924805	chr5:24999756	C/T	cg08600765	chr20:34638493	LOC647979	-0.62	-7.69	-0.35	1.02e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg15448220	chr1:150897856	SETDB1	0.58	9.69	0.43	3.44e-20	Melanoma;
LUAD	cis	rs922182	0.556	rs10851734	chr15:64216247	C/T	cg02919090	chr15:64263738	DAPK2	-0.36	-6.84	-0.32	2.85e-11	Blood protein levels;
LUAD	cis	rs12760731	0.565	rs7536856	chr1:178057927	A/G	cg00404053	chr1:178313656	RASAL2	0.67	8.58	0.39	1.81e-16	Obesity-related traits;
LUAD	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg24558204	chr6:135376177	HBS1L	0.42	7.54	0.34	2.94e-13	Red blood cell count;
LUAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.62	-10.89	-0.47	1.67e-24	Lymphocyte counts;
LUAD	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg15445000	chr17:37608096	MED1	-0.43	-7.96	-0.36	1.6e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs427394	0.582	rs274665	chr5:6707981	C/T	cg14682080	chr5:6737778	POLS	0.34	7.33	0.34	1.21e-12	Menopause (age at onset);
LUAD	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg26384229	chr12:38710491	ALG10B	0.4	6.85	0.32	2.63e-11	Morning vs. evening chronotype;
LUAD	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.95	-0.36	1.67e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.9	10.93	0.47	1.19e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6696239	0.513	rs1021553	chr1:227743987	G/T	cg12133451	chr1:227746453	NA	0.37	6.69	0.31	7.07e-11	Height;
LUAD	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg17595323	chr11:93583763	C11orf90	-0.43	-8.97	-0.4	9.9e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg13319975	chr6:146136371	FBXO30	0.61	9.97	0.44	3.64e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11771526	0.892	rs1376282	chr7:32370492	A/G	cg27511599	chr7:32358540	NA	0.61	7.06	0.32	6.68e-12	Body mass index;
LUAD	cis	rs6867032	0.917	rs10474733	chr5:2004160	A/G	cg26168224	chr5:2018326	NA	-0.72	-14.52	-0.58	4.84e-39	Gut microbiome composition (winter);
LUAD	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg17105886	chr17:28927953	LRRC37B2	0.76	7.18	0.33	3.14e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg11098525	chr4:1320231	MAEA	-0.39	-6.49	-0.3	2.34e-10	Obesity-related traits;
LUAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg15242686	chr22:24348715	GSTTP1	0.43	7.46	0.34	5.06e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs79911532	0.515	rs78085898	chr7:75703215	T/C	cg19862616	chr7:65841803	NCRNA00174	0.84	8.61	0.39	1.47e-16	Mononucleosis;
LUAD	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs921968	0.565	rs6436082	chr2:219639430	A/G	cg02176678	chr2:219576539	TTLL4	-0.58	-11.8	-0.5	5.42e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6987853	0.787	rs2974358	chr8:42434403	T/C	cg09913449	chr8:42400586	C8orf40	0.48	9.3	0.41	7.69e-19	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg22166914	chr1:53195759	ZYG11B	0.4	6.66	0.31	8.78e-11	Monocyte count;
LUAD	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg15017067	chr4:17643749	FAM184B	0.37	7.06	0.32	6.69e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg21482837	chr2:85581528	ELMOD3;RETSAT	0.41	6.65	0.31	9.07e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg15448220	chr1:150897856	SETDB1	-0.4	-6.45	-0.3	3.05e-10	Tonsillectomy;
LUAD	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg00074818	chr8:8560427	CLDN23	0.69	10.72	0.46	7.23e-24	Obesity-related traits;
LUAD	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg08645402	chr16:4508243	NA	0.55	9.94	0.44	4.65e-21	Schizophrenia;
LUAD	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg26384229	chr12:38710491	ALG10B	0.47	7.49	0.34	4.18e-13	Bladder cancer;
LUAD	trans	rs9929218	1.000	rs7186084	chr16:68816260	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.75	12.55	0.52	6.06e-31	Colorectal cancer;
LUAD	cis	rs684232	0.666	rs838371	chr17:609275	T/C	cg12384639	chr17:618140	VPS53	0.49	8.67	0.39	9.6e-17	Prostate cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17597374	chr11:61106595	DAK	0.48	6.48	0.3	2.57e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg09491104	chr22:46646882	C22orf40	0.72	13.32	0.54	4.92e-34	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg06606381	chr12:133084897	FBRSL1	-0.9	-8.62	-0.39	1.3e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg14343924	chr8:8086146	FLJ10661	-0.48	-7.73	-0.35	8.13e-14	Mood instability;
LUAD	cis	rs438465	1.000	rs374076	chr6:169819775	C/T	cg11181693	chr6:169825345	NA	-0.64	-7.93	-0.36	1.95e-14	Corneal astigmatism;
LUAD	cis	rs804280	0.662	rs7826055	chr8:11611723	G/C	cg23972785	chr8:11611189	GATA4	-0.39	-6.39	-0.3	4.38e-10	Myopia (pathological);
LUAD	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg17761419	chr8:57350749	NA	-0.52	-7.89	-0.36	2.64e-14	Obesity-related traits;
LUAD	trans	rs8073060	0.586	rs225307	chr17:33918311	A/G	cg19694781	chr19:47549865	TMEM160	1.23	19.6	0.69	2.59e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg09359103	chr1:154839909	KCNN3	-0.93	-21.08	-0.72	6.09e-68	Prostate cancer;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg17424134	chr2:27616206	FTHL3;PPM1G	0.45	7.19	0.33	2.97e-12	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs16858210	0.826	rs35494670	chr3:183606357	T/G	cg01324343	chr3:183735012	ABCC5	0.43	6.79	0.31	3.79e-11	Menopause (age at onset);
LUAD	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg21427119	chr20:30132790	HM13	-0.57	-9.18	-0.41	2e-18	Mean corpuscular hemoglobin;
LUAD	cis	rs35205176	0.644	rs12669616	chr7:51570093	T/C	cg20478239	chr7:51544475	NA	-0.34	-6.49	-0.3	2.46e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg08470875	chr2:26401718	FAM59B	-0.77	-10.45	-0.45	7e-23	Gut microbiome composition (summer);
LUAD	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg02569458	chr12:86230093	RASSF9	-0.42	-7.77	-0.35	5.83e-14	Major depressive disorder;
LUAD	trans	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg19862616	chr7:65841803	NCRNA00174	1.06	27.27	0.8	3.21e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	10.36	0.45	1.39e-22	Electrocardiographic conduction measures;
LUAD	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg08999081	chr20:33150536	PIGU	-0.37	-7.44	-0.34	5.6e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg07741184	chr6:167504864	NA	0.31	7.42	0.34	6.36e-13	Crohn's disease;
LUAD	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.52	-0.38	2.75e-16	Height;
LUAD	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg17644776	chr2:200775616	C2orf69	-0.56	-7.53	-0.34	3.12e-13	Schizophrenia;
LUAD	cis	rs10504073	0.565	rs35282337	chr8:49920994	G/A	cg00325661	chr8:49890786	NA	0.47	10.49	0.45	4.96e-23	Blood metabolite ratios;
LUAD	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg03676636	chr4:99064102	C4orf37	0.37	9.45	0.42	2.41e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg23625390	chr15:77176239	SCAPER	0.37	6.61	0.31	1.13e-10	Blood metabolite levels;
LUAD	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg08645402	chr16:4508243	NA	0.6	11.55	0.49	5.3e-27	Schizophrenia;
LUAD	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg13385794	chr1:248469461	NA	0.27	7.28	0.33	1.63e-12	Common traits (Other);
LUAD	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg25457927	chr22:38595422	NA	-0.55	-14.55	-0.58	3.49e-39	Cutaneous nevi;
LUAD	cis	rs11030122	0.733	rs10835331	chr11:3957365	C/T	cg18678763	chr11:4115507	RRM1	-0.42	-7.07	-0.33	6.51e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg06547715	chr2:218990976	CXCR2	0.37	8.49	0.38	3.53e-16	Ulcerative colitis;
LUAD	trans	rs75804782	0.521	rs56121087	chr2:239435766	A/G	cg01134436	chr17:81009848	B3GNTL1	0.79	8.6	0.39	1.61e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg08470875	chr2:26401718	FAM59B	-0.6	-8.2	-0.37	2.96e-15	Gut microbiome composition (summer);
LUAD	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg00316803	chr15:76480434	C15orf27	0.4	7.61	0.35	1.75e-13	Blood metabolite levels;
LUAD	cis	rs782590	0.607	rs2061032	chr2:55679490	T/C	cg03859395	chr2:55845619	SMEK2	0.57	9.53	0.42	1.21e-19	Metabolic syndrome;
LUAD	cis	rs7116495	1.000	rs73543609	chr11:71816619	G/T	cg07596299	chr11:71824057	C11orf51	0.76	6.42	0.3	3.61e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs877282	0.797	rs35927768	chr10:753095	T/C	cg06581033	chr10:766294	NA	-0.56	-7.24	-0.33	2.07e-12	Uric acid levels;
LUAD	cis	rs9788682	0.747	rs28480606	chr15:78762313	A/G	cg18825076	chr15:78729989	IREB2	0.56	7.72	0.35	8.28e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg19196401	chr6:110721138	DDO	-0.44	-8.32	-0.37	1.24e-15	Platelet distribution width;
LUAD	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg14343924	chr8:8086146	FLJ10661	-0.56	-8.85	-0.4	2.34e-17	Schizophrenia;
LUAD	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg20991723	chr1:152506922	NA	0.34	6.65	0.31	9.11e-11	Hair morphology;
LUAD	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg08027265	chr7:2291960	NA	0.44	8.13	0.37	4.85e-15	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUAD	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg00383909	chr3:49044727	WDR6	0.82	8.88	0.4	1.89e-17	Cognitive function;
LUAD	trans	rs1941687	0.563	rs9953034	chr18:31335294	A/G	cg13755796	chr4:20253514	NA	-0.4	-6.83	-0.32	3.03e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs10203711	0.966	rs7594129	chr2:239600686	G/T	cg14580085	chr2:239553406	NA	0.39	8.5	0.38	3.18e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg15605315	chr1:45957053	TESK2	0.49	7.7	0.35	9.75e-14	High light scatter reticulocyte count;
LUAD	cis	rs8049603	0.812	rs5731	chr16:23197545	C/G	cg09552652	chr16:23197569	SCNN1G	0.36	6.44	0.3	3.17e-10	Multiple sclerosis;
LUAD	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.67	-0.35	1.18e-13	Lung cancer;
LUAD	cis	rs6782228	0.606	rs2712419	chr3:128340896	T/C	cg16766828	chr3:128327626	NA	-0.38	-7.14	-0.33	4.05e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-13.6	-0.55	3.45e-35	Chronic sinus infection;
LUAD	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg23435118	chr5:141488016	NDFIP1	-0.5	-7.62	-0.35	1.72e-13	Crohn's disease;
LUAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg01579765	chr21:45077557	HSF2BP	0.6	14.4	0.57	1.56e-38	Mean corpuscular volume;
LUAD	cis	rs7587476	0.601	rs17489363	chr2:215674341	A/G	cg04004882	chr2:215674386	BARD1	-0.53	-7.11	-0.33	5.05e-12	Neuroblastoma;
LUAD	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg22535103	chr8:58192502	C8orf71	-0.61	-6.66	-0.31	8.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg26513180	chr16:89883248	FANCA	0.76	6.92	0.32	1.64e-11	Skin colour saturation;
LUAD	cis	rs6964587	0.692	rs4729021	chr7:91758422	C/A	cg17063962	chr7:91808500	NA	0.69	12.18	0.51	1.76e-29	Breast cancer;
LUAD	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg02592271	chr2:27665507	KRTCAP3	0.26	6.98	0.32	1.13e-11	Total body bone mineral density;
LUAD	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg16479474	chr6:28041457	NA	0.49	8.23	0.37	2.37e-15	Depression;
LUAD	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.68	12.96	0.53	1.39e-32	Cognitive ability;
LUAD	cis	rs829883	0.659	rs12366950	chr12:98947900	T/C	cg25150519	chr12:98850993	NA	-0.5	-7.74	-0.35	7.59e-14	Colorectal adenoma (advanced);
LUAD	cis	rs10979	1.000	rs12191231	chr6:143891114	A/C	cg25407410	chr6:143891975	LOC285740	-0.64	-10.31	-0.45	2.2e-22	Hypospadias;
LUAD	cis	rs1062746	0.738	rs2303764	chr16:87377455	C/G	cg02258303	chr16:87377426	FBXO31	0.45	7.91	0.36	2.28e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg01579765	chr21:45077557	HSF2BP	-0.66	-15.47	-0.6	4.18e-43	Mean corpuscular volume;
LUAD	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg17264618	chr3:40429014	ENTPD3	-0.3	-6.5	-0.3	2.24e-10	Renal cell carcinoma;
LUAD	cis	rs6426558	0.537	rs12139758	chr1:227260519	A/G	cg10327440	chr1:227177885	CDC42BPA	0.57	9.12	0.41	3.06e-18	Neutrophil percentage of white cells;
LUAD	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg23260525	chr10:116636907	FAM160B1	0.47	10.98	0.47	7.38e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9896933	0.614	rs3785511	chr17:80886316	G/T	cg15369054	chr17:80825471	TBCD	-0.54	-6.38	-0.3	4.74e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg00647820	chr17:40259828	DHX58	-0.44	-7.01	-0.32	9.19e-12	Fibrinogen levels;
LUAD	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.1	-0.4	3.56e-18	Alcohol dependence;
LUAD	cis	rs7927592	0.513	rs556442	chr11:68192690	G/A	cg01657329	chr11:68192670	LRP5	0.55	9.73	0.43	2.43e-20	Total body bone mineral density;
LUAD	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg23860436	chr12:58378763	NA	0.43	7.35	0.34	1.03e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg15691649	chr6:25882328	NA	0.63	9.73	0.43	2.61e-20	Blood metabolite levels;
LUAD	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	8.73	0.39	6.03e-17	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg09835421	chr16:68378352	PRMT7	-0.82	-8.57	-0.38	1.99e-16	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs7246760	0.867	rs67634928	chr19:9802397	C/G	cg02900749	chr2:68251473	NA	-0.59	-6.51	-0.3	2.07e-10	Pursuit maintenance gain;
LUAD	cis	rs2996428	0.709	rs12127399	chr1:3721609	G/A	cg22529645	chr1:3704559	LRRC47	0.56	10.25	0.45	3.55e-22	Red cell distribution width;
LUAD	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg18132916	chr6:79620363	NA	0.45	7.94	0.36	1.87e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs754466	0.580	rs2579178	chr10:79529215	A/G	cg17075019	chr10:79541650	NA	0.91	18.98	0.68	1.41e-58	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg00310523	chr12:86230176	RASSF9	0.37	7.48	0.34	4.42e-13	Major depressive disorder;
LUAD	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg25985355	chr7:65971099	NA	-0.5	-6.45	-0.3	3.1e-10	Diabetic kidney disease;
LUAD	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg17173187	chr15:85201210	NMB	0.39	6.52	0.3	2.03e-10	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg25985355	chr7:65971099	NA	0.53	6.57	0.3	1.49e-10	Diabetic kidney disease;
LUAD	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg27489772	chr12:121021490	NA	0.58	6.99	0.32	1.07e-11	Type 1 diabetes nephropathy;
LUAD	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.63	0.35	1.61e-13	Platelet count;
LUAD	cis	rs16958440	0.867	rs117060920	chr18:44709035	G/A	cg17192377	chr18:44677553	HDHD2	0.86	7.96	0.36	1.56e-14	Sitting height ratio;
LUAD	cis	rs6688613	0.694	rs12062326	chr1:166820186	G/A	cg07049167	chr1:166818506	POGK	0.61	9.85	0.43	9.22e-21	Refractive astigmatism;
LUAD	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.23	0.33	2.25e-12	Blood metabolite levels;
LUAD	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg18240062	chr17:79603768	NPLOC4	-0.46	-8.13	-0.37	4.93e-15	Eye color traits;
LUAD	cis	rs4372836	0.505	rs6710082	chr2:28989977	A/C	cg09522027	chr2:28974177	PPP1CB	-0.63	-11.02	-0.47	5.32e-25	Body mass index;
LUAD	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg01689657	chr7:91764605	CYP51A1	-0.29	-6.81	-0.31	3.37e-11	Breast cancer;
LUAD	cis	rs61990749	0.597	rs11624101	chr14:78138059	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.52	-6.48	-0.3	2.54e-10	Fibroblast growth factor basic levels;
LUAD	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg16325326	chr1:53192061	ZYG11B	0.68	12.49	0.52	1.08e-30	Monocyte count;
LUAD	cis	rs7089973	0.934	rs68085797	chr10:116632130	A/T	cg23260525	chr10:116636907	FAM160B1	0.43	9.11	0.4	3.4e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg25036284	chr2:26402008	FAM59B	-0.58	-8.09	-0.37	6.19e-15	Gut microbiome composition (summer);
LUAD	cis	rs113835537	0.660	rs7116940	chr11:66303895	T/C	cg24851651	chr11:66362959	CCS	0.56	9.57	0.42	9e-20	Airway imaging phenotypes;
LUAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.36	-0.3	5.22e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7208859	0.614	rs216477	chr17:28866744	A/C	cg17105886	chr17:28927953	LRRC37B2	-0.66	-6.78	-0.31	3.97e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg02158880	chr13:53174818	NA	0.63	11.14	0.48	1.91e-25	Lewy body disease;
LUAD	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg23933602	chr10:16859644	RSU1	0.71	12.36	0.52	3.61e-30	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg06028605	chr16:24865363	SLC5A11	0.39	6.7	0.31	6.63e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg20203395	chr5:56204925	C5orf35	-0.82	-11.72	-0.5	1.16e-27	Initial pursuit acceleration;
LUAD	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg21775007	chr8:11205619	TDH	0.49	8.88	0.4	1.92e-17	Retinal vascular caliber;
LUAD	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg03859395	chr2:55845619	SMEK2	0.72	13.31	0.54	5.03e-34	Metabolic syndrome;
LUAD	trans	rs12517041	0.935	rs28493622	chr5:23282147	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.47	-0.3	2.73e-10	Calcium levels;
LUAD	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg16680214	chr1:154839983	KCNN3	0.66	13.9	0.56	1.85e-36	Prostate cancer;
LUAD	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.891	rs892513	chr2:198905874	A/G	cg10547527	chr2:198650123	BOLL	0.52	7.29	0.33	1.57e-12	Ulcerative colitis;
LUAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00149659	chr3:10157352	C3orf10	-0.86	-11.67	-0.49	1.88e-27	Alzheimer's disease;
LUAD	cis	rs13082711	0.911	rs34307140	chr3:27467875	A/C	cg02860705	chr3:27208620	NA	0.58	8.99	0.4	8.15e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs870825	0.860	rs72703526	chr4:185605676	A/T	cg04058563	chr4:185651563	MLF1IP	0.78	10.21	0.44	4.85e-22	Blood protein levels;
LUAD	cis	rs1045714	0.895	rs1107690	chr7:2640595	G/T	cg24848437	chr7:2645542	IQCE	0.69	7.99	0.36	1.27e-14	Urate levels in lean individuals;
LUAD	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg13535736	chr9:111863775	C9orf5	-0.42	-6.52	-0.3	1.98e-10	Menarche (age at onset);
LUAD	trans	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg07211511	chr3:129823064	LOC729375	-0.54	-7.32	-0.34	1.3e-12	Blood pressure (smoking interaction);
LUAD	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg18306943	chr3:40428807	ENTPD3	0.41	6.98	0.32	1.14e-11	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg03467027	chr4:99064603	C4orf37	0.4	6.49	0.3	2.41e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs367943	0.712	rs1120091	chr5:112684229	C/A	cg12552261	chr5:112820674	MCC	0.46	8.94	0.4	1.22e-17	Type 2 diabetes;
LUAD	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	7.5	0.34	3.9e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg18105134	chr13:113819100	PROZ	-1.05	-19.41	-0.69	1.85e-60	Platelet distribution width;
LUAD	cis	rs9462027	0.630	rs7341267	chr6:34727031	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.94	-0.4	1.27e-17	Systemic lupus erythematosus;
LUAD	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg14983838	chr19:29218262	NA	0.51	7.31	0.33	1.34e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg09365446	chr1:150670422	GOLPH3L	0.63	10.96	0.47	9.32e-25	Melanoma;
LUAD	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg25237894	chr2:233734115	C2orf82	0.61	11.63	0.49	2.5e-27	Coronary artery disease;
LUAD	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg22349387	chr12:9600060	DDX12	-0.43	-7.41	-0.34	7.03e-13	Breast size;
LUAD	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg27489772	chr12:121021490	NA	0.56	7.04	0.32	7.9e-12	Type 1 diabetes nephropathy;
LUAD	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg18016565	chr1:150552671	MCL1	-0.4	-6.95	-0.32	1.36e-11	Tonsillectomy;
LUAD	trans	rs62458065	0.850	rs62458099	chr7:32472395	C/T	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.44	-0.34	5.76e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg22681709	chr2:178499509	PDE11A	-0.46	-7.38	-0.34	8.3e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7009516	0.819	rs12542012	chr8:24223031	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.43	8.56	0.38	2.06e-16	Hair greying;
LUAD	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg27532560	chr4:187881888	NA	-0.38	-7.31	-0.34	1.32e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs62238980	0.614	rs74450300	chr22:32403780	C/G	cg00543991	chr22:32367038	NA	0.96	9.05	0.4	5.32e-18	Childhood ear infection;
LUAD	cis	rs10129255	0.500	rs6576230	chr14:107186778	C/A	cg23076370	chr14:107095027	NA	-0.44	-8.74	-0.39	5.5e-17	Kawasaki disease;
LUAD	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg09021430	chr5:549028	NA	-0.68	-13.32	-0.54	4.96e-34	Lung disease severity in cystic fibrosis;
LUAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg05564831	chr3:52568323	NT5DC2	0.48	9.71	0.43	2.91e-20	Electroencephalogram traits;
LUAD	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22968622	chr17:43663579	NA	1.38	24.88	0.77	8.14e-85	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg00383909	chr3:49044727	WDR6	0.9	10.18	0.44	6.57e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-12.4	-0.52	2.54e-30	Chronic sinus infection;
LUAD	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg20307385	chr11:47447363	PSMC3	0.53	7.92	0.36	2.06e-14	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg08754654	chr5:154026448	NA	-0.56	-9.37	-0.41	4.38e-19	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-9.18	-0.41	1.89e-18	Total body bone mineral density;
LUAD	cis	rs4356932	1.000	rs6532105	chr4:76953895	C/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.37	-6.71	-0.31	6.28e-11	Blood protein levels;
LUAD	cis	rs11264213	0.551	rs11263852	chr1:36554442	G/C	cg27506609	chr1:36549197	TEKT2	-0.66	-7.8	-0.35	4.97e-14	Schizophrenia;
LUAD	cis	rs8044868	1.000	rs8052338	chr16:72185674	C/T	cg23815491	chr16:72088622	HP	0.4	7.27	0.33	1.73e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs7107174	0.892	rs2090095	chr11:78034020	G/A	cg19901956	chr11:77921274	USP35	-0.45	-6.41	-0.3	3.84e-10	Testicular germ cell tumor;
LUAD	cis	rs1784581	0.588	rs9458428	chr6:162424579	A/G	cg17173639	chr6:162384350	PARK2	-0.45	-7.98	-0.36	1.41e-14	Itch intensity from mosquito bite;
LUAD	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18099408	chr3:52552593	STAB1	-0.46	-8.12	-0.37	5e-15	Bipolar disorder;
LUAD	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg26513180	chr16:89883248	FANCA	0.58	9.21	0.41	1.53e-18	Vitiligo;
LUAD	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg16099599	chr11:93583650	C11orf90	-0.32	-6.39	-0.3	4.43e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs11756438	0.572	rs2638541	chr6:119003743	A/T	cg21191810	chr6:118973309	C6orf204	0.47	9.14	0.41	2.56e-18	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7267979	0.714	rs1555329	chr20:25231858	G/A	cg08601574	chr20:25228251	PYGB	0.45	8.41	0.38	6.28e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs28830936	0.966	rs62002090	chr15:42092326	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.34	-6.66	-0.31	8.36e-11	Diastolic blood pressure;
LUAD	cis	rs11048434	0.612	rs7299653	chr12:9058993	A/T	cg13575925	chr12:9217583	LOC144571	0.35	6.47	0.3	2.77e-10	Sjögren's syndrome;
LUAD	cis	rs13323323	0.652	rs9825080	chr3:44251270	C/T	cg17279458	chr3:44753948	ZNF502	-0.43	-6.78	-0.31	4.12e-11	IgG glycosylation;
LUAD	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg05896524	chr21:47604654	C21orf56	0.44	6.71	0.31	6.36e-11	Testicular germ cell tumor;
LUAD	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.32	0.34	1.3e-12	Obesity-related traits;
LUAD	trans	rs12517041	1.000	rs35380017	chr5:23310237	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg16606324	chr3:10149918	C3orf24	0.68	11.37	0.48	2.59e-26	Alzheimer's disease;
LUAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg23978390	chr7:1156363	C7orf50	0.43	6.88	0.32	2.17e-11	Longevity;Endometriosis;
LUAD	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg03340356	chr1:67600835	NA	0.43	7.59	0.35	2.06e-13	Psoriasis;
LUAD	cis	rs4243830	1.000	rs12047931	chr1:6587614	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.83	8.46	0.38	4.31e-16	Body mass index;
LUAD	cis	rs9972944	0.756	rs9894010	chr17:63760156	T/G	cg07283582	chr17:63770753	CCDC46	-0.52	-11.72	-0.5	1.12e-27	Total body bone mineral density;
LUAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.71	-14.0	-0.56	7.49e-37	Longevity;Endometriosis;
LUAD	cis	rs11741688	0.557	rs6600994	chr5:178336005	T/A	cg21944022	chr5:178288650	ZNF354B	0.5	9.19	0.41	1.82e-18	Sleep duration;
LUAD	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-13.15	-0.54	2.31e-33	Body mass index;
LUAD	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg12292205	chr6:26970375	C6orf41	-0.57	-9.97	-0.44	3.56e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	cis	rs863345	0.526	rs857724	chr1:158607372	C/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.43	-0.3	3.43e-10	Pneumococcal bacteremia;
LUAD	cis	rs7192380	0.893	rs12924052	chr16:69777246	T/C	cg00738113	chr16:70207722	CLEC18C	0.37	7.4	0.34	7.42e-13	Sjögren's syndrome;
LUAD	cis	rs9811920	0.809	rs793475	chr3:99543764	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.56	-10.65	-0.46	1.24e-23	Axial length;
LUAD	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg11822372	chr1:151115635	SEMA6C	0.62	8.32	0.38	1.18e-15	Blood trace element (Cu levels);
LUAD	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg15790184	chr11:494944	RNH1	0.41	7.08	0.33	5.98e-12	Systemic lupus erythematosus;
LUAD	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg12756686	chr19:29218302	NA	0.65	8.93	0.4	1.29e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg03806693	chr22:41940476	POLR3H	-0.49	-7.22	-0.33	2.45e-12	Vitiligo;
LUAD	cis	rs2425143	1.000	rs7264414	chr20:34446826	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.18	-0.33	3.25e-12	Blood protein levels;
LUAD	cis	rs78761021	0.867	rs62066059	chr17:9784989	T/G	cg26853458	chr17:9805074	RCVRN	0.37	7.36	0.34	9.97e-13	Type 2 diabetes;
LUAD	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg25554036	chr4:6271136	WFS1	0.67	12.25	0.51	9.62e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg25985355	chr7:65971099	NA	0.38	7.15	0.33	3.83e-12	Aortic root size;
LUAD	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg21724239	chr8:58056113	NA	0.52	7.03	0.32	8.51e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg22535103	chr8:58192502	C8orf71	-0.59	-7.04	-0.32	7.87e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs73198271	0.515	rs113056462	chr8:8638568	T/C	cg01851573	chr8:8652454	MFHAS1	0.61	7.99	0.36	1.33e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1371867	0.775	rs3020183	chr8:101233297	A/T	cg20500540	chr8:101228448	SPAG1	-0.38	-6.79	-0.31	3.77e-11	Atrioventricular conduction;
LUAD	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-8.03	-0.36	9.79e-15	Bipolar disorder;
LUAD	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.5	-8.32	-0.37	1.24e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg19773385	chr1:10388646	KIF1B	-0.39	-6.41	-0.3	3.89e-10	Hepatocellular carcinoma;
LUAD	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.87	0.36	2.95e-14	Depression;
LUAD	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	trans	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.23	-0.33	2.27e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg18190219	chr22:46762943	CELSR1	-0.49	-7.11	-0.33	4.92e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.9	-0.36	2.47e-14	Blood metabolite levels;
LUAD	cis	rs4285028	0.948	rs34478505	chr3:121694071	C/T	cg11130432	chr3:121712080	ILDR1	-0.59	-8.46	-0.38	4.37e-16	Multiple sclerosis;
LUAD	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg25894440	chr7:65020034	NA	-0.69	-7.38	-0.34	8.32e-13	Diabetic kidney disease;
LUAD	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.73	0.35	7.84e-14	Breast cancer;
LUAD	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	7.4	0.34	7.46e-13	Platelet count;
LUAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg07362569	chr17:61921086	SMARCD2	-0.37	-6.37	-0.3	4.93e-10	Prudent dietary pattern;
LUAD	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-7.07	-0.33	6.45e-12	Longevity;Endometriosis;
LUAD	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg22442454	chr1:209979470	IRF6	0.54	7.25	0.33	1.95e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs11229555	0.874	rs10896787	chr11:58285494	G/T	cg15696309	chr11:58395628	NA	-0.74	-10.43	-0.45	8.02e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23583168	chr7:148888333	NA	-0.93	-19.37	-0.69	2.73e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.12	-0.37	5.02e-15	Diabetic kidney disease;
LUAD	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg24397884	chr7:158709396	WDR60	0.48	8.08	0.37	6.73e-15	Height;
LUAD	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	7.98	0.36	1.35e-14	Breast cancer;
LUAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.59	0.31	1.32e-10	Prudent dietary pattern;
LUAD	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24531977	chr5:56204891	C5orf35	-1.21	-19.16	-0.68	2.3e-59	Initial pursuit acceleration;
LUAD	cis	rs77972916	0.505	rs11899984	chr2:43578246	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.72	-9.97	-0.44	3.71e-21	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg03188948	chr7:1209495	NA	0.59	8.87	0.4	2.02e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12050794	0.671	rs2052713	chr15:72520392	G/C	cg16672083	chr15:72433130	SENP8	0.64	12.0	0.5	9.17e-29	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs3204270	0.543	rs34034499	chr17:79638568	G/C	cg09655341	chr17:79618100	PDE6G	0.46	6.38	0.3	4.73e-10	Dental caries;
LUAD	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-7.98	-0.36	1.36e-14	Diabetic kidney disease;
LUAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg22907277	chr7:1156413	C7orf50	0.7	8.24	0.37	2.2e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg14343924	chr8:8086146	FLJ10661	0.46	7.24	0.33	2.11e-12	Mood instability;
LUAD	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg12863693	chr15:85201151	NMB	0.36	6.46	0.3	2.88e-10	Schizophrenia;
LUAD	cis	rs9633740	1.000	rs1902660	chr10:82263683	G/C	cg01528321	chr10:82214614	TSPAN14	0.75	9.94	0.44	4.47e-21	Post bronchodilator FEV1;
LUAD	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg18944383	chr4:111397179	ENPEP	0.51	9.25	0.41	1.08e-18	Coronary artery disease;
LUAD	cis	rs62344088	0.590	rs6872820	chr5:178900	G/A	cg22857025	chr5:266934	NA	-0.88	-8.09	-0.37	6.46e-15	Asthma (childhood onset);
LUAD	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg14829155	chr15:31115871	NA	-0.57	-9.65	-0.42	4.87e-20	Huntington's disease progression;
LUAD	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg20019720	chr6:154832845	CNKSR3	0.65	12.84	0.53	4.41e-32	Lipoprotein (a) levels;
LUAD	cis	rs2629540	0.889	rs10901815	chr10:126435598	G/A	cg08799069	chr10:126477246	METTL10	-0.48	-7.11	-0.33	5.1e-12	Cocaine dependence;
LUAD	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.78	10.85	0.47	2.3e-24	Smoking behavior;
LUAD	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg14343924	chr8:8086146	FLJ10661	0.41	6.56	0.3	1.56e-10	Systolic blood pressure;
LUAD	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg05925327	chr15:68127851	NA	-0.44	-6.72	-0.31	5.85e-11	Restless legs syndrome;
LUAD	cis	rs500891	0.553	rs2095447	chr6:84112756	C/G	cg08257003	chr6:84140564	ME1	-0.34	-6.61	-0.31	1.16e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg10518543	chr12:38710700	ALG10B	-0.5	-8.34	-0.38	1.09e-15	Morning vs. evening chronotype;
LUAD	trans	rs2420915	0.841	rs2248051	chr10:122854749	G/T	cg02981078	chr12:88428011	C12orf29	-0.52	-6.53	-0.3	1.85e-10	Fibrinogen levels;
LUAD	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.42	2.49e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg04455712	chr21:45112962	RRP1B	-0.48	-9.43	-0.42	2.78e-19	Mean corpuscular volume;
LUAD	cis	rs427394	0.659	rs274695	chr5:6732252	G/C	cg14682080	chr5:6737778	POLS	0.35	7.56	0.34	2.56e-13	Menopause (age at onset);
LUAD	trans	rs17684571	0.700	rs17684802	chr6:56678652	A/G	cg23842572	chr17:17030253	MPRIP	-0.41	-6.57	-0.3	1.46e-10	Schizophrenia;
LUAD	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg11887960	chr12:57824829	NA	0.59	7.3	0.33	1.46e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs4589502	0.925	rs4259997	chr15:67153310	A/G	cg09911534	chr15:67153556	NA	0.38	6.39	0.3	4.43e-10	Lung cancer (smoking interaction);
LUAD	cis	rs7267979	0.866	rs2424699	chr20:25257462	G/A	cg08601574	chr20:25228251	PYGB	0.47	8.53	0.38	2.63e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg06618935	chr21:46677482	NA	-0.36	-6.88	-0.32	2.16e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg26195577	chr20:24973756	C20orf3	0.98	16.78	0.63	8.38e-49	Blood protein levels;
LUAD	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.33	7.32	0.34	1.3e-12	Parkinson's disease;
LUAD	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg14582100	chr15:45693742	SPATA5L1	0.41	8.23	0.37	2.33e-15	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg25237894	chr2:233734115	C2orf82	0.63	11.93	0.5	1.77e-28	Coronary artery disease;
LUAD	trans	rs4714291	0.802	rs7759622	chr6:40114735	C/T	cg02267698	chr19:7991119	CTXN1	-0.45	-7.02	-0.32	8.82e-12	Strep throat;
LUAD	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg11663144	chr21:46675770	NA	-0.6	-11.83	-0.5	4.19e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg06131755	chr6:160182447	ACAT2	0.44	6.54	0.3	1.81e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.28	-0.33	1.61e-12	Glomerular filtration rate;
LUAD	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg15900387	chr1:150738905	CTSS	-0.37	-6.66	-0.31	8.51e-11	Melanoma;
LUAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.8	-0.31	3.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.48	-0.3	2.5e-10	Alzheimer's disease (late onset);
LUAD	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg11859384	chr17:80120422	CCDC57	-0.49	-8.91	-0.4	1.48e-17	Life satisfaction;
LUAD	cis	rs68170813	1.000	rs68170813	chr7:107259721	T/C	cg02696742	chr7:106810147	HBP1	-0.5	-6.69	-0.31	7.12e-11	Coronary artery disease;
LUAD	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg04703951	chr17:43578652	NA	-0.44	-6.83	-0.32	2.93e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4288356	1	rs4288356	chr8:141055724	G/A	cg05910124	chr8:141057427	TRAPPC9	-0.31	-6.41	-0.3	3.87e-10	Pulse pressure;
LUAD	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg06671706	chr8:8559999	CLDN23	0.67	11.81	0.5	5.2e-28	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg18180107	chr4:99064573	C4orf37	0.4	6.51	0.3	2.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg13560548	chr3:10150139	C3orf24	0.45	7.66	0.35	1.27e-13	Alzheimer's disease;
LUAD	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg14403583	chr14:105418241	AHNAK2	-0.44	-8.31	-0.37	1.31e-15	Rheumatoid arthritis;
LUAD	cis	rs494562	0.892	rs4624841	chr6:86130251	G/A	cg13315970	chr6:86159197	NT5E	0.72	7.94	0.36	1.83e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg07917127	chr4:99064746	C4orf37	0.42	6.88	0.32	2.11e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg09365446	chr1:150670422	GOLPH3L	-0.4	-6.44	-0.3	3.23e-10	Tonsillectomy;
LUAD	cis	rs12681287	0.752	rs7846635	chr8:87304281	G/A	cg27223183	chr8:87520930	FAM82B	-0.63	-8.66	-0.39	9.82e-17	Caudate activity during reward;
LUAD	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg03388025	chr16:89894329	SPIRE2	-0.51	-7.07	-0.32	6.63e-12	Caffeine consumption;
LUAD	cis	rs250585	1.000	rs7203580	chr16:23504248	C/T	cg00143387	chr16:23521605	GGA2	-0.63	-7.73	-0.35	8.1e-14	Egg allergy;
LUAD	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg05340658	chr4:99064831	C4orf37	0.56	9.61	0.42	6.82e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2456568	0.802	rs10765638	chr11:93636171	A/T	cg26875233	chr11:93583750	C11orf90	-0.29	-6.39	-0.3	4.36e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs2274273	0.967	rs10147667	chr14:55570849	C/T	cg04306507	chr14:55594613	LGALS3	-0.37	-7.47	-0.34	4.67e-13	Protein biomarker;
LUAD	cis	rs12545109	0.800	rs2610058	chr8:57409120	G/A	cg17761419	chr8:57350749	NA	-0.53	-7.51	-0.34	3.48e-13	Obesity-related traits;
LUAD	cis	rs4285028	0.898	rs4305455	chr3:121619774	T/C	cg11130432	chr3:121712080	ILDR1	-0.55	-8.05	-0.36	8.57e-15	Multiple sclerosis;
LUAD	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg02569458	chr12:86230093	RASSF9	0.43	8.14	0.37	4.54e-15	Major depressive disorder;
LUAD	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg12140854	chr5:148520817	ABLIM3	-0.68	-10.97	-0.47	8.04e-25	Breast cancer;
LUAD	trans	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg26043149	chr18:55253948	FECH	0.51	8.19	0.37	3.17e-15	Bone mineral density;
LUAD	cis	rs68170813	0.641	rs34084719	chr7:107095227	A/G	cg23024343	chr7:107201750	COG5	0.54	7.06	0.32	6.71e-12	Coronary artery disease;
LUAD	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.0	0.32	9.82e-12	Prostate cancer;
LUAD	cis	rs78487399	0.710	rs7561114	chr2:43701951	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-6.43	-0.3	3.4e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg11901034	chr3:128598214	ACAD9	-0.5	-7.81	-0.36	4.45e-14	IgG glycosylation;
LUAD	cis	rs9473147	0.516	rs7749167	chr6:47493940	G/A	cg12968598	chr6:47444699	CD2AP	0.35	6.35	0.3	5.46e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg11707310	chr1:2537719	MMEL1	-0.38	-8.11	-0.37	5.69e-15	Ulcerative colitis;
LUAD	cis	rs3820068	0.705	rs59502343	chr1:15872617	T/C	cg13390004	chr1:15929781	NA	0.41	6.48	0.3	2.54e-10	Systolic blood pressure;
LUAD	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg02753203	chr1:228287806	NA	0.57	10.68	0.46	9.98e-24	Diastolic blood pressure;
LUAD	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg18527919	chr2:24398170	C2orf84	0.41	6.75	0.31	4.97e-11	Asthma;
LUAD	cis	rs3125734	0.660	rs10733769	chr10:63974255	G/T	cg09941381	chr10:64027924	RTKN2	-0.3	-6.82	-0.31	3.15e-11	Rheumatoid arthritis;
LUAD	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg10434728	chr15:90938212	IQGAP1	-0.36	-6.95	-0.32	1.42e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs35740288	0.770	rs4843081	chr15:86153044	T/C	cg13263323	chr15:86062960	AKAP13	-0.44	-7.02	-0.32	8.78e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg02551604	chr5:131831745	NA	-0.61	-10.02	-0.44	2.39e-21	Asthma (sex interaction);
LUAD	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg26384229	chr12:38710491	ALG10B	0.45	7.01	0.32	9.54e-12	Heart rate;
LUAD	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg20556744	chr2:9614537	IAH1	0.65	6.61	0.31	1.19e-10	Opioid sensitivity;
LUAD	cis	rs9925964	0.935	rs12597511	chr16:31145219	C/T	cg03418659	chr16:31128414	MYST1	0.4	6.58	0.3	1.41e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7527798	0.544	rs11118354	chr1:207856868	A/G	cg09232269	chr1:207846808	CR1L	-0.37	-7.14	-0.33	4.07e-12	Erythrocyte sedimentation rate;
LUAD	cis	rs6500395	1.000	rs1486412	chr16:48651750	A/T	cg04672837	chr16:48644449	N4BP1	0.39	6.7	0.31	6.62e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.71	-13.3	-0.54	5.92e-34	Menarche (age at onset);
LUAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg10295955	chr4:187884368	NA	-1.14	-27.43	-0.8	6.56e-96	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg02018176	chr4:1364513	KIAA1530	0.47	8.61	0.39	1.44e-16	Longevity;
LUAD	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg20203395	chr5:56204925	C5orf35	-0.81	-11.49	-0.49	8.58e-27	Initial pursuit acceleration;
LUAD	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	7.13	0.33	4.46e-12	Schizophrenia;
LUAD	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.55	0.38	2.35e-16	Breast cancer;
LUAD	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg18351406	chr4:77819688	ANKRD56	0.62	9.78	0.43	1.73e-20	Emphysema distribution in smoking;
LUAD	cis	rs727505	0.754	rs56056794	chr7:124783027	C/T	cg23710748	chr7:124431027	NA	-0.39	-7.8	-0.35	4.74e-14	Lewy body disease;
LUAD	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg13699009	chr12:122356056	WDR66	0.3	6.74	0.31	5.32e-11	Mean corpuscular volume;
LUAD	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	6.62	0.31	1.07e-10	Tonsillectomy;
LUAD	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs11651000	0.654	rs12451801	chr17:45820975	T/C	cg03474202	chr17:45855739	NA	-0.35	-7.44	-0.34	5.52e-13	IgG glycosylation;
LUAD	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg06221963	chr1:154839813	KCNN3	-0.85	-20.1	-0.7	1.48e-63	Prostate cancer;
LUAD	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg02696790	chr15:75250997	RPP25	0.37	7.31	0.34	1.32e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21659725	chr3:3221576	CRBN	0.51	8.44	0.38	5.21e-16	Body mass index;
LUAD	cis	rs2455799	0.574	rs2455801	chr3:15701857	C/T	cg16303742	chr3:15540471	COLQ	-0.51	-9.77	-0.43	1.8e-20	Mean platelet volume;
LUAD	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg02493740	chr2:85810744	VAMP5	-0.45	-8.06	-0.37	7.63e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-9.97	-0.44	3.66e-21	Alzheimer's disease;
LUAD	cis	rs8064299	0.597	rs7210318	chr17:72783385	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.42	6.74	0.31	5.34e-11	Monocyte count;
LUAD	cis	rs4722585	0.605	rs10268883	chr7:26200417	C/T	cg07876897	chr7:26191696	NFE2L3	0.46	7.24	0.33	2.08e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg02574844	chr11:5959923	NA	-0.42	-7.32	-0.34	1.23e-12	DNA methylation (variation);
LUAD	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	9.11	0.41	3.26e-18	Total body bone mineral density;
LUAD	cis	rs701145	0.585	rs357494	chr3:153937753	G/A	cg17054900	chr3:154042577	DHX36	0.65	6.99	0.32	1.06e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.9	0.36	2.44e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2445762	0.559	rs4774585	chr15:51616480	G/A	cg00184732	chr15:51633821	GLDN	0.42	7.15	0.33	3.94e-12	Hormone measurements;
LUAD	cis	rs2455799	0.613	rs12491914	chr3:15808672	A/C	cg16303742	chr3:15540471	COLQ	-0.5	-9.31	-0.41	7.27e-19	Mean platelet volume;
LUAD	cis	rs7705042	0.727	rs1062158	chr5:141523000	C/T	cg23435118	chr5:141488016	NDFIP1	-0.41	-7.01	-0.32	9.23e-12	Asthma;
LUAD	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg11062466	chr8:58055876	NA	0.47	6.73	0.31	5.53e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg24088639	chr11:34937564	PDHX;APIP	-0.45	-7.17	-0.33	3.31e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg08999081	chr20:33150536	PIGU	-0.37	-7.45	-0.34	5.48e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg22676075	chr6:135203613	NA	0.38	6.9	0.32	1.88e-11	Red blood cell count;
LUAD	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg22467129	chr15:76604101	ETFA	-0.5	-8.71	-0.39	7.01e-17	Blood metabolite levels;
LUAD	trans	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg26043149	chr18:55253948	FECH	-0.42	-6.99	-0.32	1.11e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2839627	0.638	rs8134227	chr21:44257902	C/T	cg03543861	chr21:44258195	NA	0.64	8.2	0.37	2.92e-15	Information processing speed;
LUAD	trans	rs75804782	0.572	rs72982580	chr2:239447783	A/G	cg01134436	chr17:81009848	B3GNTL1	0.79	8.64	0.39	1.17e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg17063962	chr7:91808500	NA	0.6	9.8	0.43	1.39e-20	Breast cancer;
LUAD	trans	rs9467711	0.591	rs9461219	chr6:25836927	C/G	cg06606381	chr12:133084897	FBRSL1	0.81	7.02	0.32	9.03e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg14829155	chr15:31115871	NA	-0.59	-9.66	-0.43	4.37e-20	Huntington's disease progression;
LUAD	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg09516651	chr1:89888402	LOC400759	0.4	7.72	0.35	8.41e-14	Carotid intima media thickness;
LUAD	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg23231163	chr10:75533350	FUT11	-0.54	-10.33	-0.45	1.91e-22	Inflammatory bowel disease;
LUAD	cis	rs9863	0.861	rs7131882	chr12:124426736	C/T	cg17723958	chr12:124429295	CCDC92	-0.43	-7.01	-0.32	9.6e-12	White blood cell count;
LUAD	cis	rs7945705	0.967	rs7123429	chr11:8866808	C/G	cg12365402	chr11:9010492	NRIP3	-0.43	-7.98	-0.36	1.38e-14	Hemoglobin concentration;
LUAD	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg03929089	chr4:120376271	NA	0.56	6.99	0.32	1.06e-11	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg22681709	chr2:178499509	PDE11A	-0.42	-6.94	-0.32	1.53e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs12579753	0.917	rs2401003	chr12:82215192	G/A	cg07988820	chr12:82153109	PPFIA2	-0.46	-6.99	-0.32	1.06e-11	Resting heart rate;
LUAD	cis	rs829883	0.659	rs11109517	chr12:98921574	A/C	cg25150519	chr12:98850993	NA	0.5	7.85	0.36	3.5e-14	Colorectal adenoma (advanced);
LUAD	cis	rs656900	0.874	rs685487	chr15:80136129	A/G	cg02196730	chr15:80188777	MTHFS	-0.4	-6.56	-0.3	1.54e-10	Cerebrospinal P-tau181p levels;
LUAD	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg05182265	chr7:156933206	UBE3C	0.8	17.11	0.64	2.98e-50	Body mass index;
LUAD	cis	rs60154123	0.614	rs127043	chr1:210459011	T/G	cg22029157	chr1:209979665	IRF6	0.49	6.47	0.3	2.74e-10	Coronary artery disease;
LUAD	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg17971929	chr21:40555470	PSMG1	0.53	8.38	0.38	7.74e-16	Cognitive function;
LUAD	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg13385794	chr1:248469461	NA	0.25	6.94	0.32	1.46e-11	Common traits (Other);
LUAD	cis	rs1344694	0.566	rs4672790	chr2:216892446	C/T	cg12620499	chr2:216877984	MREG	0.43	7.61	0.35	1.78e-13	Alcohol dependence;
LUAD	cis	rs12681287	0.511	rs7839601	chr8:87503839	G/C	cg27223183	chr8:87520930	FAM82B	-0.7	-9.86	-0.43	8.57e-21	Caudate activity during reward;
LUAD	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg07936489	chr17:37558343	FBXL20	0.5	6.75	0.31	5.01e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7818345	1.000	rs4618712	chr8:19302621	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.89	0.32	2e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-7.44	-0.34	5.74e-13	Personality dimensions;
LUAD	cis	rs939584	1.000	rs10190313	chr2:647577	A/G	cg03444855	chr2:621920	NA	-0.39	-6.49	-0.3	2.37e-10	Body mass index;
LUAD	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg06873352	chr17:61820015	STRADA	0.43	7.06	0.32	6.88e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7818345	0.967	rs11204040	chr8:19288525	T/A	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.83	0.32	2.98e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs3845702	1.000	rs3738943	chr2:180846743	G/T	cg01881094	chr2:180872142	CWC22	-0.57	-7.1	-0.33	5.22e-12	Schizophrenia;
LUAD	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg04731861	chr2:219085781	ARPC2	0.23	7.13	0.33	4.34e-12	Colorectal cancer;
LUAD	cis	rs1448094	0.617	rs7297449	chr12:86468442	A/C	cg19622623	chr12:86230825	RASSF9	0.41	7.33	0.34	1.2e-12	Major depressive disorder;
LUAD	cis	rs1799949	0.757	rs9915489	chr17:41173226	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.37	6.47	0.3	2.73e-10	Menopause (age at onset);
LUAD	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg10556349	chr10:835070	NA	0.67	7.86	0.36	3.29e-14	Eosinophil percentage of granulocytes;
LUAD	cis	rs7193541	0.684	rs4888265	chr16:74683737	T/C	cg01733217	chr16:74700730	RFWD3	0.68	13.36	0.54	3.16e-34	Multiple myeloma;
LUAD	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg09509183	chr1:209979624	IRF6	0.59	7.35	0.34	1.04e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg03878208	chr11:72483293	STARD10	0.59	8.58	0.38	1.85e-16	Type 2 diabetes;
LUAD	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg00383909	chr3:49044727	WDR6	0.42	6.49	0.3	2.4e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.43	0.38	5.48e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg04111992	chr7:158790115	NA	-0.5	-8.48	-0.38	3.85e-16	Facial morphology (factor 20);
LUAD	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.82	0.36	4.3e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg24644049	chr4:85504048	CDS1	0.7	6.87	0.32	2.34e-11	Skin colour saturation;
LUAD	cis	rs6424115	0.545	rs11576333	chr1:24065770	C/T	cg10978503	chr1:24200527	CNR2	-0.43	-7.98	-0.36	1.4e-14	Immature fraction of reticulocytes;
LUAD	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg26384229	chr12:38710491	ALG10B	0.47	7.55	0.34	2.64e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	9.12	0.41	3.11e-18	Electrocardiographic conduction measures;
LUAD	trans	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg06606381	chr12:133084897	FBRSL1	-0.81	-6.85	-0.32	2.67e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.57	9.19	0.41	1.79e-18	Cognitive ability;
LUAD	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-15.3	-0.6	2.31e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg18806716	chr10:30721971	MAP3K8	0.61	11.96	0.5	1.4e-28	Inflammatory bowel disease;
LUAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg05313129	chr8:58192883	C8orf71	-0.54	-6.73	-0.31	5.66e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg08508325	chr11:3079039	CARS	0.44	9.14	0.41	2.72e-18	Calcium levels;
LUAD	cis	rs5758659	0.729	rs134866	chr22:42650663	C/T	cg15128208	chr22:42549153	NA	-0.37	-7.56	-0.34	2.55e-13	Cognitive function;
LUAD	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.7	-11.39	-0.48	2.22e-26	Urate levels;
LUAD	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.68	0.31	7.32e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg07461501	chr17:79650226	HGS;ARL16	-0.69	-9.93	-0.43	5.03e-21	Obesity-related traits;
LUAD	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.54	0.3	1.81e-10	Parkinson's disease;
LUAD	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg12863693	chr15:85201151	NMB	0.45	8.38	0.38	7.83e-16	Schizophrenia;
LUAD	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg05590025	chr7:65112418	INTS4L2	-0.67	-7.34	-0.34	1.11e-12	Diabetic kidney disease;
LUAD	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg07636037	chr3:49044803	WDR6	-0.48	-7.76	-0.35	6.57e-14	Menarche (age at onset);
LUAD	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg05665937	chr4:1216051	CTBP1	0.42	7.01	0.32	9.46e-12	Obesity-related traits;
LUAD	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg04539111	chr16:67997858	SLC12A4	-0.52	-6.4	-0.3	4.19e-10	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	9.03	0.4	5.91e-18	Alzheimer's disease;
LUAD	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg17177755	chr1:15930204	NA	0.49	7.74	0.35	7.56e-14	Systolic blood pressure;
LUAD	cis	rs1823874	1.000	rs1823874	chr15:100357435	T/C	cg16400843	chr15:100339927	C15orf51	0.3	6.91	0.32	1.76e-11	IgG glycosylation;
LUAD	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg11189052	chr15:85197271	WDR73	0.6	7.83	0.36	3.96e-14	Schizophrenia;
LUAD	trans	rs2797160	1.000	rs1739363	chr6:126020980	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.53	8.48	0.38	3.77e-16	Endometrial cancer;
LUAD	cis	rs12681287	0.640	rs6992287	chr8:87418960	G/A	cg00550725	chr8:87521180	FAM82B	-0.44	-6.42	-0.3	3.69e-10	Caudate activity during reward;
LUAD	cis	rs7582720	1.000	rs72934737	chr2:203740798	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.45	0.42	2.39e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7017914	0.967	rs6993170	chr8:71693519	A/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.46	-0.3	2.95e-10	Bone mineral density;
LUAD	trans	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg01620082	chr3:125678407	NA	-0.44	-6.7	-0.31	6.82e-11	Depression;
LUAD	trans	rs507080	0.922	rs654792	chr11:118552996	A/C	cg03741566	chr6:64346779	NA	-0.43	-6.43	-0.3	3.36e-10	Serum metabolite levels;
LUAD	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg14664628	chr15:75095509	CSK	-0.53	-8.55	-0.38	2.24e-16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs9302065	0.565	rs2992905	chr13:95958190	C/T	cg24476569	chr13:95954382	ABCC4	-0.61	-11.16	-0.48	1.61e-25	Blood metabolite levels;
LUAD	cis	rs1595825	0.891	rs3851979	chr2:198707638	A/T	cg00361562	chr2:198649771	BOLL	0.49	7.07	0.33	6.25e-12	Ulcerative colitis;
LUAD	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg09021430	chr5:549028	NA	-0.57	-14.14	-0.57	1.99e-37	Obesity-related traits;
LUAD	cis	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg01251360	chr16:68772225	CDH1	-0.29	-9.04	-0.4	5.72e-18	Colorectal cancer;
LUAD	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg00300879	chr1:26503847	CNKSR1	0.29	8.34	0.38	1.04e-15	Height;
LUAD	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg09137382	chr11:130731461	NA	0.42	7.6	0.35	1.97e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4846217	0.920	rs17401588	chr1:10368099	A/G	cg17425144	chr1:10567563	PEX14	-0.54	-6.57	-0.3	1.51e-10	Platelet count;
LUAD	cis	rs9905704	0.633	rs2632523	chr17:56506634	G/A	cg19466818	chr17:56409534	MIR142	-0.34	-6.76	-0.31	4.59e-11	Testicular germ cell tumor;
LUAD	cis	rs250585	1.000	rs250577	chr16:23428058	T/C	cg00143387	chr16:23521605	GGA2	0.61	7.51	0.34	3.45e-13	Egg allergy;
LUAD	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs78761021	0.755	rs75458334	chr17:9795535	C/T	cg26853458	chr17:9805074	RCVRN	0.4	7.68	0.35	1.08e-13	Type 2 diabetes;
LUAD	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg12062639	chr20:23401060	NAPB	1.1	11.43	0.49	1.54e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg08761264	chr16:28874980	SH2B1	-0.44	-6.62	-0.31	1.09e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21659725	chr3:3221576	CRBN	-0.51	-8.27	-0.37	1.71e-15	Body mass index;
LUAD	cis	rs10992471	0.729	rs2181585	chr9:95551830	G/A	cg14631576	chr9:95140430	CENPP	-0.37	-7.44	-0.34	5.75e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs250585	0.764	rs4967958	chr16:23528123	T/C	cg00143387	chr16:23521605	GGA2	-0.61	-7.55	-0.34	2.66e-13	Egg allergy;
LUAD	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg19000871	chr14:103996768	TRMT61A	-0.44	-7.81	-0.36	4.45e-14	Coronary artery disease;
LUAD	cis	rs965604	1.000	rs12903295	chr15:78778972	A/G	cg18825076	chr15:78729989	IREB2	-0.41	-6.98	-0.32	1.16e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg05425664	chr17:57184151	TRIM37	-0.45	-7.83	-0.36	3.98e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18033235	chr19:16989681	SIN3B	0.6	7.34	0.34	1.08e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4774899	0.869	rs2169465	chr15:57422552	T/G	cg14026238	chr15:57616123	NA	-0.4	-7.77	-0.35	5.96e-14	Urinary tract infection frequency;
LUAD	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg22529645	chr1:3704559	LRRC47	0.57	10.64	0.46	1.42e-23	Red cell distribution width;
LUAD	trans	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg01620082	chr3:125678407	NA	-0.43	-6.58	-0.3	1.35e-10	Parkinson's disease;
LUAD	cis	rs4660306	0.961	rs1337902	chr1:45952066	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.5	-7.82	-0.36	4.34e-14	Homocysteine levels;
LUAD	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg25753631	chr6:25732923	NA	-0.45	-7.99	-0.36	1.32e-14	Iron status biomarkers;
LUAD	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg07708487	chr16:89387014	ANKRD11	-0.32	-6.4	-0.3	4.09e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23158103	chr7:148848205	ZNF398	0.66	12.49	0.52	1.08e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs853679	0.546	rs34871267	chr6:28364232	G/A	cg01620082	chr3:125678407	NA	-1.1	-10.07	-0.44	1.57e-21	Depression;
LUAD	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg01206211	chr2:36825736	FEZ2	0.52	9.73	0.43	2.5e-20	Height;
LUAD	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-8.5	-0.38	3.3e-16	Reticulocyte count;
LUAD	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg00316803	chr15:76480434	C15orf27	0.39	6.55	0.3	1.7e-10	Blood metabolite levels;
LUAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg16606324	chr3:10149918	C3orf24	0.68	11.37	0.48	2.59e-26	Alzheimer's disease;
LUAD	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg07061783	chr6:25882402	NA	-0.52	-8.21	-0.37	2.72e-15	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12049351	0.774	rs6661924	chr1:229642740	G/T	cg11742688	chr1:229674241	ABCB10	-0.41	-6.5	-0.3	2.32e-10	Circulating myeloperoxidase levels (plasma);
LUAD	trans	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg01620082	chr3:125678407	NA	-1.05	-10.37	-0.45	1.34e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.32	-7.89	-0.36	2.66e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg05896524	chr21:47604654	C21orf56	0.54	8.87	0.4	2.13e-17	Testicular germ cell tumor;
LUAD	cis	rs17608059	0.611	rs2108591	chr17:13922625	C/A	cg27005118	chr17:13972210	COX10	-0.34	-7.04	-0.32	7.71e-12	Temperament;
LUAD	cis	rs36051895	0.664	rs7851455	chr9:5100501	G/C	cg02405213	chr9:5042618	JAK2	-0.45	-6.71	-0.31	6.08e-11	Pediatric autoimmune diseases;
LUAD	cis	rs7107174	0.892	rs2512519	chr11:77953015	C/T	cg02023728	chr11:77925099	USP35	0.52	7.94	0.36	1.79e-14	Testicular germ cell tumor;
LUAD	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg06131755	chr6:160182447	ACAT2	0.43	6.42	0.3	3.77e-10	Age-related macular degeneration (geographic atrophy);
LUAD	trans	rs11650494	0.908	rs75904857	chr17:47370449	T/G	cg11430096	chr6:110968061	CDK19	0.85	6.5	0.3	2.28e-10	Prostate cancer;
LUAD	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg09365446	chr1:150670422	GOLPH3L	0.66	12.3	0.51	6.1e-30	Tonsillectomy;
LUAD	cis	rs12505328	0.514	rs6836022	chr4:174390724	A/T	cg12145043	chr4:174357286	NA	0.43	7.04	0.32	7.81e-12	Chin dimples;
LUAD	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.05	-0.32	7.33e-12	Height;
LUAD	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg10862848	chr6:42927986	GNMT	-0.32	-9.26	-0.41	1.02e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg24069376	chr3:38537580	EXOG	-0.37	-8.49	-0.38	3.64e-16	Electrocardiographic conduction measures;
LUAD	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	9.78	0.43	1.73e-20	Total body bone mineral density;
LUAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00166722	chr3:10149974	C3orf24	0.71	12.34	0.51	4.35e-30	Alzheimer's disease;
LUAD	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg18305652	chr10:134549665	INPP5A	0.58	11.93	0.5	1.72e-28	Migraine;
LUAD	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg21100191	chr22:23484243	RTDR1	0.71	12.73	0.53	1.21e-31	Bone mineral density;
LUAD	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg21427119	chr20:30132790	HM13	-0.61	-8.97	-0.4	1e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg12310025	chr6:25882481	NA	0.5	8.47	0.38	4.09e-16	Blood metabolite levels;
LUAD	cis	rs9341808	0.935	rs9448894	chr6:80837253	G/T	cg08355045	chr6:80787529	NA	0.46	8.23	0.37	2.42e-15	Sitting height ratio;
LUAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg03188948	chr7:1209495	NA	0.39	6.52	0.3	2.05e-10	Longevity;Endometriosis;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg10463451	chr21:37432625	SETD4	-0.42	-6.84	-0.32	2.72e-11	Schizophrenia;
LUAD	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg16205897	chr5:131564050	P4HA2	-0.36	-8.48	-0.38	3.77e-16	Blood metabolite levels;
LUAD	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg04705435	chr11:17411270	KCNJ11	0.43	7.3	0.33	1.4e-12	Type 2 diabetes;
LUAD	cis	rs986417	1.000	rs1956554	chr14:60963775	C/T	cg27398547	chr14:60952738	C14orf39	-0.64	-7.85	-0.36	3.46e-14	Gut microbiota (bacterial taxa);
LUAD	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-18.87	-0.68	4.49e-58	Height;
LUAD	trans	rs10838798	0.584	rs4752899	chr11:48141855	T/G	cg15704280	chr7:45808275	SEPT13	-0.48	-7.51	-0.34	3.62e-13	Height;
LUAD	cis	rs524023	0.957	rs12365089	chr11:64364735	A/T	cg14139581	chr11:64358342	SLC22A12	-0.31	-6.38	-0.3	4.58e-10	Urate levels in obese individuals;
LUAD	cis	rs427941	0.703	rs201443	chr7:101737688	A/T	cg06246474	chr7:101738831	CUX1	0.41	7.21	0.33	2.67e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs35771425	0.500	rs3738199	chr1:211545344	A/G	cg25617285	chr1:211431773	RCOR3	-0.52	-10.5	-0.45	4.47e-23	Educational attainment (years of education);
LUAD	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg03878208	chr11:72483293	STARD10	0.59	8.46	0.38	4.49e-16	Type 2 diabetes;
LUAD	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg09184832	chr6:79620586	NA	-0.51	-9.55	-0.42	1.1e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs78761021	0.898	rs79871388	chr17:9776839	C/T	cg26853458	chr17:9805074	RCVRN	0.35	6.77	0.31	4.42e-11	Type 2 diabetes;
LUAD	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg26384229	chr12:38710491	ALG10B	-0.4	-6.79	-0.31	3.79e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg05925327	chr15:68127851	NA	-0.43	-6.52	-0.3	2.03e-10	Restless legs syndrome;
LUAD	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.74	-12.43	-0.52	1.91e-30	Primary sclerosing cholangitis;
LUAD	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg25173405	chr17:45401733	C17orf57	0.45	7.31	0.34	1.32e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs300703	0.542	rs300697	chr2:184496	C/T	cg21211680	chr2:198530	NA	-0.52	-7.05	-0.32	7.17e-12	Blood protein levels;
LUAD	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg18854424	chr1:2615690	NA	0.42	9.17	0.41	2.06e-18	Ulcerative colitis;
LUAD	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg06060754	chr5:176797920	RGS14	0.52	9.77	0.43	1.88e-20	Hemoglobin concentration;Hematocrit;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18093693	chr15:72668265	HEXA;C15orf34	-0.41	-6.38	-0.3	4.71e-10	Height;
LUAD	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg13160058	chr8:26243215	BNIP3L	0.47	9.81	0.43	1.29e-20	Red cell distribution width;
LUAD	cis	rs1957429	0.731	rs10144554	chr14:65321514	T/G	cg23373153	chr14:65346875	NA	0.59	6.61	0.31	1.14e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg01119278	chr6:110721349	DDO	-0.46	-8.52	-0.38	2.78e-16	Platelet distribution width;
LUAD	trans	rs6561151	0.681	rs61209988	chr13:44416335	G/C	cg12856521	chr11:46389249	DGKZ	0.84	11.5	0.49	7.93e-27	Crohn's disease;
LUAD	cis	rs929596	0.697	rs17863787	chr2:234611094	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.71	-12.12	-0.51	3.27e-29	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg17177755	chr1:15930204	NA	0.46	7.43	0.34	5.89e-13	Systolic blood pressure;
LUAD	cis	rs796825	0.530	rs2319670	chr3:119996276	T/C	cg21790991	chr3:120137480	FSTL1	-0.47	-8.0	-0.36	1.17e-14	HIV-1 susceptibility;
LUAD	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg17105886	chr17:28927953	LRRC37B2	0.76	7.18	0.33	3.14e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.11	0.37	5.47e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg18755752	chr8:142205143	DENND3	0.41	7.15	0.33	3.9e-12	Immature fraction of reticulocytes;
LUAD	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg06740227	chr12:86229804	RASSF9	-0.43	-7.58	-0.35	2.17e-13	Major depressive disorder;
LUAD	trans	rs8073060	0.544	rs225287	chr17:33929487	G/T	cg19694781	chr19:47549865	TMEM160	-1.23	-19.59	-0.69	2.75e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.66	-0.31	8.6e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1595825	0.678	rs57265854	chr2:198917263	C/A	cg00982548	chr2:198649783	BOLL	-0.64	-8.8	-0.39	3.44e-17	Ulcerative colitis;
LUAD	cis	rs12216545	0.765	rs6980388	chr7:150250709	T/C	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.39	-0.3	4.27e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg24642844	chr7:1081250	C7orf50	-0.88	-14.06	-0.56	4.22e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg13390004	chr1:15929781	NA	0.48	8.5	0.38	3.18e-16	Systolic blood pressure;
LUAD	cis	rs2579500	0.702	rs6576974	chr2:97244385	A/G	cg23100626	chr2:96804247	ASTL	-0.28	-6.97	-0.32	1.21e-11	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg18129748	chr3:49941408	MST1R	-0.4	-6.45	-0.3	3.1e-10	Body mass index;
LUAD	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg14019146	chr3:50243930	SLC38A3	0.35	6.79	0.31	3.81e-11	Menarche (age at onset);
LUAD	cis	rs67397200	0.590	rs12327712	chr19:17424947	T/G	cg12247222	chr19:17403313	ABHD8	0.43	7.31	0.33	1.38e-12	Breast cancer;Breast Cancer in BRCA1 mutation carriers;Breast cancer (estrogen-receptor negative);
LUAD	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg09796270	chr17:17721594	SREBF1	0.4	7.94	0.36	1.78e-14	Total body bone mineral density;
LUAD	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg10523679	chr1:76189770	ACADM	-0.91	-18.3	-0.66	1.52e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7527798	0.592	rs4097398	chr1:207857760	C/T	cg09232269	chr1:207846808	CR1L	-0.37	-7.14	-0.33	4.07e-12	Erythrocyte sedimentation rate;
LUAD	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg07917127	chr4:99064746	C4orf37	0.5	8.13	0.37	4.76e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs60871478	0.636	rs61441144	chr7:897784	C/T	cg05535760	chr7:792225	HEATR2	-0.82	-9.59	-0.42	7.73e-20	Cerebrospinal P-tau181p levels;
LUAD	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	6.92	0.32	1.65e-11	Lung cancer in ever smokers;
LUAD	trans	rs75804782	0.625	rs10929276	chr2:239468585	A/G	cg01134436	chr17:81009848	B3GNTL1	0.71	7.28	0.33	1.64e-12	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.91	0.32	1.77e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17532515	0.652	rs6536976	chr4:141378978	C/T	cg03645522	chr4:141391200	NA	0.4	6.43	0.3	3.46e-10	Select biomarker traits;
LUAD	cis	rs2235649	0.588	rs11863172	chr16:1909083	C/G	cg07386859	chr16:1872102	HAGH	0.51	7.0	0.32	1.03e-11	Blood metabolite levels;
LUAD	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg23649088	chr2:200775458	C2orf69	-0.49	-8.42	-0.38	5.7e-16	QT interval;
LUAD	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	14.28	0.57	5.1e-38	Lung cancer in ever smokers;
LUAD	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg13390004	chr1:15929781	NA	0.48	8.53	0.38	2.63e-16	Systolic blood pressure;
LUAD	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg05340658	chr4:99064831	C4orf37	0.57	9.63	0.42	5.4e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.17	-0.33	3.29e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs76878669	0.561	rs2236679	chr11:66108894	G/C	cg10616300	chr11:66138557	SLC29A2	-0.35	-7.4	-0.34	7.61e-13	Educational attainment (years of education);
LUAD	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg00530320	chr1:46809349	NSUN4	0.51	8.1	0.37	5.84e-15	Menopause (age at onset);
LUAD	cis	rs72634258	0.554	rs13306061	chr1:7913445	C/T	cg26816564	chr1:7831052	VAMP3	0.64	9.03	0.4	6.29e-18	Inflammatory bowel disease;
LUAD	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg08999081	chr20:33150536	PIGU	-0.63	-14.06	-0.56	4.29e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg21918786	chr6:109611834	NA	0.58	11.08	0.47	3.11e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg18404041	chr3:52824283	ITIH1	-0.55	-9.27	-0.41	9.37e-19	Schizophrenia;
LUAD	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg06618935	chr21:46677482	NA	-0.46	-9.36	-0.41	4.85e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9462027	0.583	rs9469862	chr6:34729848	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.81	-0.39	3.26e-17	Systemic lupus erythematosus;
LUAD	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg13770153	chr20:60521292	NA	-0.58	-9.6	-0.42	7.18e-20	Body mass index;
LUAD	cis	rs796364	0.662	rs11688415	chr2:201143409	C/T	cg23649088	chr2:200775458	C2orf69	0.64	6.87	0.32	2.29e-11	Schizophrenia;
LUAD	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.73	-14.12	-0.57	2.34e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg07138768	chr7:917805	C7orf20	0.36	7.2	0.33	2.82e-12	Perceived unattractiveness to mosquitoes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14173624	chr17:72199366	RPL38	-0.45	-6.9	-0.32	1.93e-11	Height;
LUAD	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg26076054	chr5:421317	AHRR	-0.43	-6.38	-0.3	4.66e-10	Cystic fibrosis severity;
LUAD	trans	rs1941687	0.563	rs1586987	chr18:31338661	A/G	cg15819921	chr19:927150	ARID3A	-0.47	-8.05	-0.36	8.26e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs2686555	0.754	rs2461507	chr12:121084269	A/G	cg18477009	chr12:121087777	CABP1	0.37	7.05	0.32	7.33e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg17177755	chr1:15930204	NA	0.43	6.93	0.32	1.57e-11	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg03676636	chr4:99064102	C4orf37	0.32	7.87	0.36	3.1e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg14917512	chr19:3094685	GNA11	-0.57	-6.84	-0.32	2.82e-11	Diabetic kidney disease;
LUAD	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00684032	chr4:1343700	KIAA1530	0.5	8.24	0.37	2.24e-15	Obesity-related traits;
LUAD	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg05887092	chr17:76393375	PGS1	0.41	7.19	0.33	2.96e-12	HDL cholesterol levels;
LUAD	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05665937	chr4:1216051	CTBP1	0.46	7.0	0.32	1.01e-11	Longevity;
LUAD	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg24675056	chr1:15929824	NA	0.5	8.72	0.39	6.23e-17	Systolic blood pressure;
LUAD	cis	rs2795502	0.564	rs72777187	chr10:43432224	C/T	cg20628663	chr10:43360327	NA	0.59	7.0	0.32	1.04e-11	Blood protein levels;
LUAD	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg25985355	chr7:65971099	NA	-0.55	-6.74	-0.31	5.08e-11	Diabetic kidney disease;
LUAD	cis	rs7274811	0.681	rs210074	chr20:31949756	A/T	cg14921437	chr20:32255988	NECAB3;C20orf134	0.5	7.7	0.35	9.44e-14	Height;
LUAD	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	10.41	0.45	9.28e-23	Electrocardiographic conduction measures;
LUAD	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg18944383	chr4:111397179	ENPEP	0.41	7.62	0.35	1.72e-13	Coronary artery disease;
LUAD	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	7.2	0.33	2.79e-12	Rheumatoid arthritis;
LUAD	cis	rs2286503	0.752	rs6461669	chr7:22858066	T/G	cg06496272	chr7:22895283	SNORD93	-0.39	-6.92	-0.32	1.67e-11	Fibrinogen;
LUAD	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	7.22	0.33	2.38e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4786125	0.581	rs1473519	chr16:6921533	G/A	cg03623568	chr16:6915990	A2BP1	-0.47	-10.16	-0.44	7.32e-22	Heart rate variability traits (SDNN);
LUAD	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21582582	chr3:182698605	DCUN1D1	0.61	10.36	0.45	1.39e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs730775	0.505	rs325001	chr6:44270936	A/G	cg21130236	chr6:44246755	TMEM151B	0.36	7.56	0.35	2.47e-13	Monocyte percentage of white cells;Monocyte count;
LUAD	cis	rs7909074	0.714	rs10900129	chr10:45398609	G/C	cg04218760	chr10:45406644	TMEM72	-0.26	-6.58	-0.3	1.41e-10	Mean corpuscular volume;
LUAD	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-6.86	-0.32	2.46e-11	Total body bone mineral density;
LUAD	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg18825076	chr15:78729989	IREB2	0.47	6.36	0.3	5.28e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg25738037	chr1:168025549	DCAF6	0.47	7.06	0.32	6.84e-12	Schizophrenia;
LUAD	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg09085632	chr11:111637200	PPP2R1B	0.63	9.42	0.42	2.87e-19	Primary sclerosing cholangitis;
LUAD	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-7.71	-0.35	8.89e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg13319975	chr6:146136371	FBXO30	-0.67	-11.83	-0.5	4.12e-28	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11971779	0.618	rs13068	chr7:139104141	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	7.16e-11	Diisocyanate-induced asthma;
LUAD	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg18016565	chr1:150552671	MCL1	0.41	7.55	0.34	2.78e-13	Tonsillectomy;
LUAD	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg05966235	chr16:28915196	ATP2A1	0.47	7.71	0.35	8.82e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg16647868	chr5:131706066	SLC22A5	0.4	6.95	0.32	1.36e-11	Blood metabolite levels;
LUAD	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg12310025	chr6:25882481	NA	0.83	13.69	0.55	1.41e-35	Blood metabolite levels;
LUAD	trans	rs7395662	1.000	rs12421879	chr11:48689978	A/T	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	2.03e-12	HDL cholesterol;
LUAD	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg19635926	chr16:89946313	TCF25	0.72	6.4	0.3	4.04e-10	Skin colour saturation;
LUAD	cis	rs8067287	0.749	rs62065426	chr17:16831506	G/C	cg26910001	chr17:16838321	NA	-0.49	-6.8	-0.31	3.6e-11	Diabetic kidney disease;
LUAD	cis	rs497273	0.517	rs510351	chr12:121186737	A/G	cg13914990	chr12:121174878	ACADS	0.34	6.56	0.3	1.56e-10	Systemic lupus erythematosus;
LUAD	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08219700	chr8:58056026	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.49	-0.3	2.38e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg14668632	chr7:2872130	GNA12	-0.72	-12.65	-0.52	2.58e-31	Height;
LUAD	cis	rs738322	0.870	rs5750558	chr22:38582497	G/A	cg17652424	chr22:38574118	PLA2G6	0.29	8.52	0.38	2.79e-16	Cutaneous nevi;
LUAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.54	-0.46	3.12e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg09367891	chr1:107599246	PRMT6	-0.58	-9.66	-0.42	4.56e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg18016565	chr1:150552671	MCL1	0.39	7.1	0.33	5.2e-12	Tonsillectomy;
LUAD	trans	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg26043149	chr18:55253948	FECH	0.45	7.24	0.33	2.16e-12	Bone mineral density;
LUAD	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.42	0.34	6.46e-13	Bipolar disorder;
LUAD	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.71	0.35	9.08e-14	Lung cancer;
LUAD	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg00666640	chr1:248458726	OR2T12	0.34	8.24	0.37	2.13e-15	Common traits (Other);
LUAD	cis	rs250677	1.000	rs190378	chr5:148434275	G/T	cg12140854	chr5:148520817	ABLIM3	-0.59	-9.54	-0.42	1.16e-19	Breast cancer;
LUAD	cis	rs12545109	0.765	rs2576594	chr8:57412126	T/G	cg07776626	chr8:57350775	NA	-0.62	-8.6	-0.39	1.52e-16	Obesity-related traits;
LUAD	cis	rs12976411	0.575	rs7252058	chr19:32827391	G/A	cg18253629	chr19:32836317	ZNF507	0.65	6.8	0.31	3.66e-11	Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs4073416	0.542	rs2183277	chr14:66035429	T/C	cg10998611	chr14:65879393	FUT8;LOC645431	-0.42	-6.37	-0.3	4.97e-10	N-glycan levels;
LUAD	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg05768032	chr16:30646687	NA	0.46	8.29	0.37	1.53e-15	Multiple myeloma;
LUAD	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg00255919	chr5:131827918	IRF1	0.28	6.43	0.3	3.47e-10	Breast cancer;Mosquito bite size;
LUAD	trans	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg14343924	chr8:8086146	FLJ10661	0.44	6.59	0.31	1.35e-10	Neuroticism;
LUAD	cis	rs17155006	0.711	rs377007	chr7:107750446	T/A	cg05962710	chr7:107745446	LAMB4	-0.36	-7.43	-0.34	5.96e-13	Pneumococcal bacteremia;
LUAD	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg10518543	chr12:38710700	ALG10B	-0.43	-7.21	-0.33	2.54e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs11771526	0.901	rs34376799	chr7:32316932	T/C	cg13207630	chr7:32358064	NA	0.58	7.35	0.34	1.06e-12	Body mass index;
LUAD	cis	rs9581857	0.685	rs10467687	chr13:28036516	G/A	cg22138327	chr13:27999177	GTF3A	0.88	10.15	0.44	8.23e-22	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7945718	0.839	rs10831911	chr11:12834858	C/T	cg25843174	chr11:12811716	TEAD1	0.23	6.88	0.32	2.19e-11	Educational attainment (years of education);
LUAD	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-14.52	-0.58	4.96e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg26384229	chr12:38710491	ALG10B	0.46	7.36	0.34	9.42e-13	Bladder cancer;
LUAD	cis	rs12348691	0.503	rs1867279	chr9:100616041	T/C	cg13688889	chr9:100608707	NA	-0.63	-10.31	-0.45	2.22e-22	Alopecia areata;
LUAD	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg00316803	chr15:76480434	C15orf27	-0.4	-6.72	-0.31	5.97e-11	Blood metabolite levels;
LUAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg10729496	chr3:10149963	C3orf24	-0.46	-6.5	-0.3	2.31e-10	Alzheimer's disease;
LUAD	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg05425664	chr17:57184151	TRIM37	0.4	7.14	0.33	4.11e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs76878669	0.561	rs2279862	chr11:66135179	C/T	cg10616300	chr11:66138557	SLC29A2	0.34	7.27	0.33	1.77e-12	Educational attainment (years of education);
LUAD	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg06781209	chr11:61594997	FADS2	-0.43	-7.65	-0.35	1.36e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg00647820	chr17:40259828	DHX58	0.45	7.16	0.33	3.49e-12	Fibrinogen levels;
LUAD	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg02527881	chr3:46936655	PTH1R	-0.57	-11.8	-0.5	5.54e-28	Colorectal cancer;
LUAD	cis	rs6500395	1.000	rs1558815	chr16:48704869	C/A	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg03929089	chr4:120376271	NA	-0.44	-6.76	-0.31	4.55e-11	HDL cholesterol;
LUAD	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg04731861	chr2:219085781	ARPC2	0.27	8.12	0.37	5.18e-15	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg27570636	chr1:214454189	SMYD2	0.4	6.35	0.3	5.64e-10	Monocyte percentage of white cells;
LUAD	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg00701064	chr4:6280414	WFS1	0.63	13.9	0.56	1.98e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg05182265	chr7:156933206	UBE3C	0.67	13.03	0.54	7.08e-33	Body mass index;
LUAD	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg00321850	chr1:175162397	KIAA0040	-0.51	-10.93	-0.47	1.15e-24	Alcohol dependence;
LUAD	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg18854424	chr1:2615690	NA	-0.41	-8.83	-0.39	2.91e-17	Ulcerative colitis;
LUAD	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg18110333	chr6:292329	DUSP22	-0.55	-9.09	-0.4	3.88e-18	Menopause (age at onset);
LUAD	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.77e-11	Depression;
LUAD	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg19336497	chr11:14380999	RRAS2	-0.66	-14.28	-0.57	5.02e-38	Sense of smell;
LUAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg10862848	chr6:42927986	GNMT	-0.32	-9.23	-0.41	1.27e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs2270927	0.510	rs6891108	chr5:75579152	C/A	cg13563193	chr19:33072644	PDCD5	1.07	9.81	0.43	1.31e-20	Mean corpuscular volume;
LUAD	trans	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.12	27.14	0.8	1.16e-94	Colorectal cancer;
LUAD	cis	rs6906287	0.647	rs59671368	chr6:118911430	T/A	cg05564266	chr6:118973597	C6orf204	0.37	7.76	0.35	6.24e-14	Electrocardiographic conduction measures;
LUAD	cis	rs2230307	0.656	rs1395332	chr1:100503993	A/C	cg20868668	chr1:100435035	SLC35A3	0.54	7.85	0.36	3.56e-14	Carotid intima media thickness;
LUAD	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg06713675	chr4:122721982	EXOSC9	-0.83	-17.87	-0.66	1.23e-53	Type 2 diabetes;
LUAD	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg26597838	chr10:835615	NA	-0.53	-8.33	-0.38	1.13e-15	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03934478	chr11:495069	RNH1	-0.77	-9.62	-0.42	5.98e-20	Body mass index;
LUAD	trans	rs9929218	0.529	rs11640736	chr16:68738324	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.05	24.42	0.76	8.18e-83	Colorectal cancer;
LUAD	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg14664628	chr15:75095509	CSK	-0.5	-8.09	-0.37	6.16e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08677398	chr8:58056175	NA	0.48	6.84	0.32	2.83e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs11088226	0.681	rs2833911	chr21:33949629	C/T	cg09050820	chr6:167586206	TCP10L2	-0.91	-13.35	-0.54	3.43e-34	Gastritis;
LUAD	trans	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg14791747	chr16:20752902	THUMPD1	-0.47	-7.24	-0.33	2.11e-12	Dental caries;
LUAD	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.71	8.19	0.37	3.08e-15	Yeast infection;
LUAD	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.93	0.36	1.91e-14	Depression;
LUAD	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.52	0.34	3.42e-13	Tonsillectomy;
LUAD	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	14.93	0.59	8.39e-41	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs868036	0.681	rs28626095	chr15:68066729	T/C	cg24579218	chr15:68104479	NA	-0.56	-9.44	-0.42	2.61e-19	Restless legs syndrome;
LUAD	cis	rs701145	0.640	rs357506	chr3:153932403	A/C	cg17054900	chr3:154042577	DHX36	0.65	6.99	0.32	1.06e-11	Coronary artery disease;
LUAD	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg21918786	chr6:109611834	NA	-0.53	-9.46	-0.42	2.13e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg13606994	chr1:44402422	ARTN	-0.32	-6.45	-0.3	3.11e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg07936489	chr17:37558343	FBXL20	-0.44	-6.88	-0.32	2.14e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.12	-0.33	4.61e-12	Morning vs. evening chronotype;
LUAD	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg11247378	chr22:39784982	NA	-0.75	-14.06	-0.56	4.24e-37	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16931877	chr3:32726605	CNOT10	-0.52	-6.64	-0.31	9.58e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg24069376	chr3:38537580	EXOG	-0.43	-10.33	-0.45	1.84e-22	Electrocardiographic conduction measures;
LUAD	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg10978503	chr1:24200527	CNR2	-0.56	-12.29	-0.51	6.9e-30	Immature fraction of reticulocytes;
LUAD	trans	rs75804782	0.625	rs56411186	chr2:239466753	A/C	cg01134436	chr17:81009848	B3GNTL1	0.76	7.68	0.35	1.12e-13	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.87	17.01	0.64	7.93e-50	Lymphocyte counts;
LUAD	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg12011299	chr4:100065546	ADH4	-0.74	-13.72	-0.56	1.04e-35	Alcohol dependence;
LUAD	trans	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg04775059	chr7:64541387	NA	0.51	6.76	0.31	4.64e-11	Aortic root size;
LUAD	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.5	0.3	2.31e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7072216	0.853	rs6584194	chr10:100160399	T/C	cg26618903	chr10:100175079	PYROXD2	-0.33	-7.18	-0.33	3.09e-12	Metabolite levels;
LUAD	cis	rs11098699	0.821	rs17006775	chr4:124214850	A/G	cg09941581	chr4:124220074	SPATA5	-0.5	-8.34	-0.38	1.03e-15	Mosquito bite size;
LUAD	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.45	-8.16	-0.37	3.78e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.8	0.43	1.38e-20	Colorectal cancer;
LUAD	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg22166914	chr1:53195759	ZYG11B	0.4	6.72	0.31	5.86e-11	Monocyte count;
LUAD	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.98	10.62	0.46	1.57e-23	Initial pursuit acceleration;
LUAD	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg08859206	chr1:53392774	SCP2	-0.59	-10.54	-0.46	3.14e-23	Monocyte count;
LUAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.84	-15.98	-0.61	2.52e-45	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg17366294	chr4:99064904	C4orf37	0.65	12.64	0.52	2.84e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg10792982	chr14:105748885	BRF1	0.46	9.91	0.43	5.74e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg24642844	chr7:1081250	C7orf50	-0.8	-13.09	-0.54	4.15e-33	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg25811766	chr13:21894605	NA	-0.6	-6.95	-0.32	1.43e-11	White matter hyperintensity burden;
LUAD	cis	rs6499255	1.000	rs11644838	chr16:69812705	G/C	cg15192750	chr16:69999425	NA	0.55	8.74	0.39	5.55e-17	IgE levels;
LUAD	cis	rs12711979	0.509	rs10195488	chr2:3824135	T/C	cg17052675	chr2:3827356	NA	-0.84	-19.39	-0.69	2.24e-60	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg19622623	chr12:86230825	RASSF9	-0.52	-9.65	-0.42	4.82e-20	Major depressive disorder;
LUAD	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg11822812	chr5:140052017	DND1	-0.45	-8.1	-0.37	5.95e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg05340658	chr4:99064831	C4orf37	0.46	6.99	0.32	1.05e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg23803603	chr1:2058230	PRKCZ	0.4	6.47	0.3	2.64e-10	Height;
LUAD	cis	rs7827545	1.000	rs7463007	chr8:135567143	C/T	cg17885191	chr8:135476712	NA	0.48	7.7	0.35	9.74e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs3784262	0.669	rs12914455	chr15:58312096	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.33	-0.34	1.18e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1997103	1.000	rs10279035	chr7:55412055	C/T	cg17469321	chr7:55412551	NA	0.67	11.32	0.48	3.95e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.59e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg12379764	chr21:47803548	PCNT	-0.37	-6.4	-0.3	4.11e-10	Testicular germ cell tumor;
LUAD	trans	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg02002194	chr4:3960332	NA	-0.29	-7.19	-0.33	2.87e-12	Mood instability;
LUAD	cis	rs6430585	0.591	rs12476135	chr2:136486340	T/C	cg07169764	chr2:136633963	MCM6	0.7	7.83	0.36	3.92e-14	Corneal structure;
LUAD	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg08280861	chr8:58055591	NA	0.55	7.36	0.34	9.66e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs887829	0.570	rs4261716	chr2:234593117	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.6	-0.42	7.26e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs4343996	0.650	rs10274594	chr7:3463561	T/G	cg21248987	chr7:3385318	SDK1	0.37	6.75	0.31	4.94e-11	Motion sickness;
LUAD	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg03806693	chr22:41940476	POLR3H	0.71	9.81	0.43	1.29e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs4774899	1.000	rs12905900	chr15:57322886	G/A	cg14026238	chr15:57616123	NA	0.34	6.43	0.3	3.51e-10	Urinary tract infection frequency;
LUAD	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.5	0.3	2.24e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg00666640	chr1:248458726	OR2T12	0.32	7.99	0.36	1.25e-14	Common traits (Other);
LUAD	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg21890820	chr11:65308645	LTBP3	0.46	7.25	0.33	2.05e-12	Bone mineral density;
LUAD	cis	rs72928364	1.000	rs7431835	chr3:100642723	T/A	cg10123952	chr3:100791384	NA	0.62	7.33	0.34	1.18e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg21918786	chr6:109611834	NA	-0.6	-11.27	-0.48	5.97e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs4006360	0.514	rs1588393	chr17:39247900	T/C	cg20663846	chr17:39254439	KRTAP4-8	0.4	9.08	0.4	4.09e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs886126	1.000	rs3809286	chr12:111664404	C/T	cg10833066	chr12:111807467	FAM109A	0.58	10.69	0.46	8.76e-24	Coronary heart disease;
LUAD	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-10.08	-0.44	1.46e-21	Hip circumference adjusted for BMI;
LUAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18402987	chr7:1209562	NA	0.48	8.51	0.38	3.05e-16	Longevity;Endometriosis;
LUAD	cis	rs7178572	0.568	rs4886862	chr15:77652368	T/C	cg15453836	chr15:77711506	NA	-0.39	-6.77	-0.31	4.21e-11	Type 2 diabetes;
LUAD	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg00277334	chr10:82204260	NA	0.62	10.37	0.45	1.3e-22	Post bronchodilator FEV1;
LUAD	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg05340658	chr4:99064831	C4orf37	0.53	8.98	0.4	8.92e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg05283184	chr6:79620031	NA	-0.61	-12.24	-0.51	1.05e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg03037974	chr15:76606532	NA	0.38	8.03	0.36	9.49e-15	Blood metabolite levels;
LUAD	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg14779329	chr11:130786720	SNX19	0.41	7.18	0.33	3.23e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg14092988	chr3:52407081	DNAH1	0.64	12.49	0.52	1.11e-30	Bipolar disorder;
LUAD	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg03388025	chr16:89894329	SPIRE2	0.32	6.95	0.32	1.42e-11	Vitiligo;
LUAD	cis	rs1595825	0.891	rs16825181	chr2:198740276	G/T	cg11031976	chr2:198649780	BOLL	-0.5	-6.9	-0.32	1.89e-11	Ulcerative colitis;
LUAD	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05901451	chr6:126070800	HEY2	-0.71	-12.44	-0.52	1.72e-30	Brugada syndrome;
LUAD	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg27411982	chr8:10470053	RP1L1	-0.37	-6.64	-0.31	9.41e-11	Retinal vascular caliber;
LUAD	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg12623302	chr6:28058802	ZSCAN12L1	-0.32	-6.57	-0.3	1.51e-10	Depression;
LUAD	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-6.69	-0.31	7.23e-11	Personality dimensions;
LUAD	trans	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg03467027	chr4:99064603	C4orf37	-0.42	-6.83	-0.32	2.92e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-7.98	-0.36	1.38e-14	Electroencephalogram traits;
LUAD	cis	rs7588746	0.544	rs2163548	chr2:201226862	C/G	cg23649088	chr2:200775458	C2orf69	-0.63	-6.76	-0.31	4.5e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
LUAD	cis	rs2046867	0.661	rs9861834	chr3:72909272	C/T	cg25664220	chr3:72788482	NA	-0.58	-10.51	-0.46	4.04e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs75804782	0.515	rs11897824	chr2:239311445	A/G	cg01134436	chr17:81009848	B3GNTL1	0.71	6.58	0.3	1.43e-10	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs6961069	0.806	rs12706912	chr7:80252295	A/C	cg04458919	chr7:80252533	CD36	-0.37	-6.95	-0.32	1.41e-11	Platelet count;
LUAD	cis	rs7773004	0.936	rs6917995	chr6:26327814	T/C	cg00631329	chr6:26305371	NA	-0.51	-8.81	-0.39	3.24e-17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg07917127	chr4:99064746	C4orf37	0.4	6.52	0.3	2.05e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12681287	0.752	rs34279109	chr8:87247944	G/A	cg00550725	chr8:87521180	FAM82B	0.43	6.35	0.3	5.49e-10	Caudate activity during reward;
LUAD	cis	rs1595825	0.786	rs75619425	chr2:198537281	A/G	cg11031976	chr2:198649780	BOLL	-0.47	-6.98	-0.32	1.16e-11	Ulcerative colitis;
LUAD	cis	rs829661	0.532	rs7602714	chr2:30789607	C/G	cg12454169	chr2:30669597	LCLAT1	-0.44	-6.75	-0.31	5.02e-11	Midgestational circulating levels of PBDEs (fetal genetic effect);
LUAD	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg01200585	chr1:228362443	C1orf69	-0.38	-7.1	-0.33	5.2e-12	Diastolic blood pressure;
LUAD	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg22875332	chr1:76189707	ACADM	0.73	11.3	0.48	4.82e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg11693508	chr17:37793320	STARD3	0.6	8.29	0.37	1.51e-15	Bipolar disorder;
LUAD	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg02569458	chr12:86230093	RASSF9	0.46	8.37	0.38	8.49e-16	Major depressive disorder;
LUAD	cis	rs4853036	0.951	rs10185266	chr2:70152407	C/G	cg02498382	chr2:70120550	SNRNP27	-0.51	-8.3	-0.37	1.42e-15	Colorectal or endometrial cancer;
LUAD	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg05887092	chr17:76393375	PGS1	0.43	7.43	0.34	5.95e-13	HDL cholesterol levels;
LUAD	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg18827107	chr12:86230957	RASSF9	-0.49	-8.71	-0.39	6.99e-17	Major depressive disorder;
LUAD	cis	rs11771526	1.000	rs11771526	chr7:32342618	A/G	cg13207630	chr7:32358064	NA	0.68	7.85	0.36	3.44e-14	Body mass index;
LUAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg13560548	chr3:10150139	C3orf24	0.45	7.33	0.34	1.21e-12	Alzheimer's disease;
LUAD	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg23711669	chr6:146136114	FBXO30	-0.39	-6.43	-0.3	3.55e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg17105886	chr17:28927953	LRRC37B2	0.82	8.05	0.36	8.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg11062466	chr8:58055876	NA	0.56	8.0	0.36	1.21e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs2279817	0.913	rs11203436	chr1:18019016	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.58	9.11	0.41	3.29e-18	Neuroticism;
LUAD	trans	rs800082	1.000	rs9289678	chr3:144307096	C/T	cg24215973	chr2:240111563	HDAC4	0.41	6.38	0.3	4.67e-10	Smoking behavior;
LUAD	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg11901034	chr3:128598214	ACAD9	-0.49	-7.53	-0.34	3.07e-13	IgG glycosylation;
LUAD	cis	rs2573652	0.928	rs2581348	chr15:100514063	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.49	-8.82	-0.39	3.02e-17	Height;
LUAD	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg18833306	chr6:118973337	C6orf204	-0.54	-7.61	-0.35	1.81e-13	Renal cell carcinoma;
LUAD	cis	rs28374715	0.617	rs28626792	chr15:41562218	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-10.87	-0.47	1.95e-24	Ulcerative colitis;
LUAD	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg06484146	chr7:12443880	VWDE	-0.58	-7.31	-0.33	1.36e-12	Coronary artery disease;
LUAD	cis	rs10193935	0.901	rs1496329	chr2:42688797	T/C	cg27598129	chr2:42591480	NA	0.75	9.31	0.41	7e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.41	-0.34	6.72e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs208520	0.690	rs207119	chr6:66786408	C/T	cg07460842	chr6:66804631	NA	-1.06	-16.63	-0.63	3.97e-48	Exhaled nitric oxide output;
LUAD	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.46	-7.21	-0.33	2.63e-12	Longevity;Endometriosis;
LUAD	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg20744362	chr22:50050164	C22orf34	0.33	6.94	0.32	1.45e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7665090	0.934	rs6844332	chr4:103555252	G/A	cg07973026	chr4:103553119	MANBA	0.47	8.3	0.37	1.41e-15	Primary biliary cholangitis;
LUAD	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.08	-0.4	4.31e-18	Total body bone mineral density;
LUAD	cis	rs34734847	0.842	rs7308648	chr12:121144144	C/G	cg13914990	chr12:121174878	ACADS	0.38	7.49	0.34	4.09e-13	Mean corpuscular volume;
LUAD	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg15485101	chr11:133734466	NA	0.38	8.17	0.37	3.63e-15	Childhood ear infection;
LUAD	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg03467027	chr4:99064603	C4orf37	0.4	6.46	0.3	2.93e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg04756594	chr16:24857601	SLC5A11	0.52	10.17	0.44	7.24e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg23625390	chr15:77176239	SCAPER	-0.38	-6.69	-0.31	6.97e-11	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs8038465	0.592	rs1542579	chr15:73935897	A/G	cg15420318	chr15:73925796	NPTN	0.49	8.27	0.37	1.75e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg16060761	chr17:80687452	NA	-0.57	-8.27	-0.37	1.73e-15	Glycated hemoglobin levels;
LUAD	trans	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11651000	0.761	rs11657388	chr17:45820707	C/G	cg03474202	chr17:45855739	NA	-0.35	-7.44	-0.34	5.77e-13	IgG glycosylation;
LUAD	cis	rs490234	0.552	rs3122938	chr9:128157326	A/G	cg14078157	chr9:128172775	NA	0.46	8.28	0.37	1.69e-15	Mean arterial pressure;
LUAD	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.08	-0.37	7.04e-15	Personality dimensions;
LUAD	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg09184832	chr6:79620586	NA	-0.51	-9.74	-0.43	2.34e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.54	-0.34	2.81e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs11039798	0.588	rs584899	chr11:48431408	T/C	cg15704280	chr7:45808275	SEPT13	-0.58	-7.81	-0.36	4.41e-14	Axial length;
LUAD	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7487075	0.578	rs2897951	chr12:46809206	G/A	cg23829395	chr12:46796953	NA	0.32	6.98	0.32	1.16e-11	Itch intensity from mosquito bite;
LUAD	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg09085632	chr11:111637200	PPP2R1B	0.61	9.14	0.41	2.57e-18	Primary sclerosing cholangitis;
LUAD	cis	rs1832871	0.672	rs11751553	chr6:158774750	C/T	cg07165851	chr6:158734300	TULP4	-0.7	-10.73	-0.46	6.26e-24	Height;
LUAD	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg16327482	chr19:10226339	EIF3G	0.32	6.64	0.31	9.4e-11	Narcolepsy;
LUAD	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg17724175	chr1:150552817	MCL1	0.39	9.28	0.41	9.17e-19	Tonsillectomy;
LUAD	cis	rs7737355	0.812	rs11750704	chr5:130911578	C/A	cg06307176	chr5:131281290	NA	0.42	6.73	0.31	5.41e-11	Life satisfaction;
LUAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg07362569	chr17:61921086	SMARCD2	0.39	6.76	0.31	4.46e-11	Prudent dietary pattern;
LUAD	cis	rs1595825	0.891	rs16825181	chr2:198740276	G/T	cg10547527	chr2:198650123	BOLL	-0.56	-7.36	-0.34	9.71e-13	Ulcerative colitis;
LUAD	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg07636037	chr3:49044803	WDR6	0.46	7.62	0.35	1.72e-13	Menarche (age at onset);
LUAD	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	15.41	0.6	7.95e-43	Bone mineral density;
LUAD	cis	rs9323205	0.953	rs7141012	chr14:51600948	C/G	cg23942311	chr14:51606299	NA	-0.62	-9.45	-0.42	2.26e-19	Cancer;
LUAD	cis	rs240764	0.817	rs240145	chr6:101079610	A/C	cg09795085	chr6:101329169	ASCC3	0.43	7.52	0.34	3.23e-13	Neuroticism;
LUAD	trans	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17712092	chr4:129076599	LARP1B	0.79	14.51	0.58	5.25e-39	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs6499255	1.000	rs12596679	chr16:69822680	A/G	cg15192750	chr16:69999425	NA	-0.49	-7.75	-0.35	7.04e-14	IgE levels;
LUAD	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg15962314	chr1:44399869	ARTN	0.29	6.88	0.32	2.23e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg18527919	chr2:24398170	C2orf84	0.43	6.63	0.31	1e-10	Asthma;
LUAD	cis	rs6906287	0.647	rs57813349	chr6:118763858	C/A	cg18833306	chr6:118973337	C6orf204	0.43	7.54	0.34	2.93e-13	Electrocardiographic conduction measures;
LUAD	cis	rs2050392	0.928	rs6481677	chr10:30701816	A/G	cg18806716	chr10:30721971	MAP3K8	-0.52	-10.57	-0.46	2.46e-23	Inflammatory bowel disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05617452	chr16:1877333	HAGH;FAHD1	-0.58	-7.15	-0.33	3.75e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.67	0.39	9.26e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs708547	0.647	rs1718878	chr4:57876955	G/A	cg00922110	chr4:57842668	C4orf14	-0.44	-8.13	-0.37	4.7e-15	Response to bleomycin (chromatid breaks);
LUAD	cis	rs6554196	0.525	rs3819391	chr4:55526702	A/G	cg18836493	chr4:55524333	KIT	-0.37	-7.05	-0.32	7.17e-12	Monocyte count;
LUAD	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.58	-0.3	1.41e-10	Height;
LUAD	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg12863693	chr15:85201151	NMB	0.38	6.49	0.3	2.36e-10	Schizophrenia;
LUAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg18402987	chr7:1209562	NA	0.78	9.77	0.43	1.76e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1728785	1.000	rs1728789	chr16:68595776	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.31	0.45	2.19e-22	Ulcerative colitis;
LUAD	cis	rs7671266	0.668	rs10007416	chr4:10159457	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-7.6	-0.35	1.92e-13	Cardiovascular disease risk factors;
LUAD	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg11645453	chr3:52864694	ITIH4	0.38	7.48	0.34	4.3e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg27129171	chr3:47204927	SETD2	0.41	6.5	0.3	2.32e-10	Colorectal cancer;
LUAD	cis	rs7909074	0.691	rs11239274	chr10:45393219	A/C	cg04218760	chr10:45406644	TMEM72	0.25	6.44	0.3	3.19e-10	Mean corpuscular volume;
LUAD	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg14092988	chr3:52407081	DNAH1	0.45	8.98	0.4	8.87e-18	Bipolar disorder;
LUAD	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.44	-0.34	5.83e-13	Mood instability;
LUAD	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.04	-23.33	-0.75	5.26e-78	Chronic sinus infection;
LUAD	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg22884516	chr22:45809543	SMC1B;RIBC2	-0.62	-6.73	-0.31	5.56e-11	Tonsillectomy;
LUAD	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.03	0.32	8.25e-12	Platelet count;
LUAD	cis	rs77741769	0.529	rs3901854	chr12:121225526	C/T	cg02419362	chr12:121203948	SPPL3	0.41	8.27	0.37	1.72e-15	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg17366294	chr4:99064904	C4orf37	0.65	12.56	0.52	5.93e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg22676075	chr6:135203613	NA	0.56	9.94	0.44	4.6e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg26384229	chr12:38710491	ALG10B	0.44	7.38	0.34	8.33e-13	Morning vs. evening chronotype;
LUAD	cis	rs2735413	0.918	rs36068555	chr16:78077082	G/A	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs990171	0.538	rs2075191	chr2:103118299	G/T	cg03938978	chr2:103052716	IL18RAP	0.33	6.55	0.3	1.71e-10	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg17366294	chr4:99064904	C4orf37	0.65	12.54	0.52	6.58e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg05709478	chr1:6581295	PLEKHG5	-0.57	-7.38	-0.34	8.51e-13	Body mass index;
LUAD	cis	rs17608059	0.545	rs9944522	chr17:13918783	C/T	cg27005118	chr17:13972210	COX10	-0.35	-7.12	-0.33	4.72e-12	Temperament;
LUAD	cis	rs1595825	0.891	rs76308665	chr2:198518062	C/T	cg10547527	chr2:198650123	BOLL	-0.54	-7.66	-0.35	1.26e-13	Ulcerative colitis;
LUAD	cis	rs11696501	0.843	rs6130846	chr20:44115129	A/G	cg11783356	chr20:44313418	WFDC10B	-0.47	-7.2	-0.33	2.84e-12	Brain structure;
LUAD	trans	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg13565492	chr6:43139072	SRF	-0.61	-6.43	-0.3	3.55e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg11292332	chr7:45801988	SEPT13	-0.31	-6.87	-0.32	2.31e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg08125733	chr17:73851984	WBP2	0.57	8.41	0.38	6.47e-16	Psoriasis;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01745873	chr17:28706715	CPD	0.42	6.61	0.31	1.17e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs986417	1.000	rs10144805	chr14:60927652	T/C	cg27398547	chr14:60952738	C14orf39	0.63	7.72	0.35	8.34e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.65	-0.35	1.38e-13	Blood metabolite levels;
LUAD	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg07936489	chr17:37558343	FBXL20	0.43	6.72	0.31	6.02e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.59e-12	Crohn's disease;
LUAD	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.78e-11	Crohn's disease;
LUAD	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01570182	chr17:44337453	NA	1.09	16.23	0.62	2.07e-46	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg00802000	chr16:706648	WDR90	-0.42	-7.71	-0.35	8.9e-14	Height;
LUAD	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg20503657	chr10:835505	NA	-0.48	-7.42	-0.34	6.34e-13	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs12681287	0.547	rs7465511	chr8:87521481	C/T	cg27223183	chr8:87520930	FAM82B	-0.73	-10.26	-0.45	3.31e-22	Caudate activity during reward;
LUAD	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.61e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg00071950	chr4:10020882	SLC2A9	-0.58	-10.93	-0.47	1.15e-24	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg06873352	chr17:61820015	STRADA	-0.41	-6.98	-0.32	1.16e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs709400	0.965	rs861534	chr14:104168701	C/T	cg01849466	chr14:104193079	ZFYVE21	0.46	7.71	0.35	8.94e-14	Body mass index;
LUAD	cis	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg00071950	chr4:10020882	SLC2A9	0.49	7.02	0.32	9.03e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7903847	0.620	rs9787454	chr10:99155561	A/T	cg20016023	chr10:99160130	RRP12	-0.31	-7.42	-0.34	6.64e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9300255	0.664	rs12316131	chr12:123817796	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	6.47	0.3	2.75e-10	Neutrophil percentage of white cells;
LUAD	cis	rs490234	0.729	rs10819050	chr9:128237178	G/T	cg14078157	chr9:128172775	NA	-0.42	-7.79	-0.35	5.33e-14	Mean arterial pressure;
LUAD	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg05754148	chr16:3507555	NAT15	-0.83	-9.13	-0.41	2.94e-18	Tuberculosis;
LUAD	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg24397884	chr7:158709396	WDR60	0.46	8.07	0.37	7.38e-15	Height;
LUAD	cis	rs2267137	0.843	rs570731	chr22:29758817	A/G	cg07256473	chr22:29710276	RASL10A	-0.44	-8.24	-0.37	2.11e-15	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7771547	0.574	rs9349001	chr6:36550681	C/T	cg04289385	chr6:36355825	ETV7	0.48	6.41	0.3	3.79e-10	Platelet distribution width;
LUAD	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg06064525	chr11:970664	AP2A2	-0.55	-11.27	-0.48	5.91e-26	Alzheimer's disease (late onset);
LUAD	cis	rs151234	0.741	rs151229	chr16:28584937	G/A	cg04609801	chr16:28609176	SULT1A2	0.62	8.84	0.39	2.6e-17	Platelet distribution width;
LUAD	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg18252515	chr7:66147081	NA	0.6	6.68	0.31	7.56e-11	Diabetic kidney disease;
LUAD	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg15445000	chr17:37608096	MED1	0.44	8.17	0.37	3.6e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg03983476	chr2:10830698	NOL10	-0.46	-8.21	-0.37	2.74e-15	Prostate cancer;
LUAD	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg07617317	chr6:118971624	C6orf204	0.54	8.46	0.38	4.34e-16	Diastolic blood pressure;
LUAD	cis	rs9811920	0.683	rs793502	chr3:99588417	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-6.99	-0.32	1.07e-11	Axial length;
LUAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg00106254	chr7:1943704	MAD1L1	-0.56	-8.24	-0.37	2.14e-15	Testicular germ cell tumor;
LUAD	cis	rs6906287	0.609	rs11153759	chr6:118920860	T/A	cg05564266	chr6:118973597	C6orf204	0.37	7.75	0.35	6.98e-14	Electrocardiographic conduction measures;
LUAD	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg20203395	chr5:56204925	C5orf35	0.98	13.88	0.56	2.43e-36	Initial pursuit acceleration;
LUAD	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-8.23	-0.37	2.3e-15	Alzheimer's disease (late onset);
LUAD	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg03806693	chr22:41940476	POLR3H	0.7	8.66	0.39	1.04e-16	Vitiligo;
LUAD	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg14895029	chr7:2775587	GNA12	-0.39	-6.35	-0.3	5.51e-10	Height;
LUAD	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	trans	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg14791747	chr16:20752902	THUMPD1	0.48	7.09	0.33	5.8e-12	Pancreatic cancer;
LUAD	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg18105134	chr13:113819100	PROZ	-0.81	-14.41	-0.57	1.46e-38	Platelet distribution width;
LUAD	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg17177755	chr1:15930204	NA	0.46	7.43	0.34	5.89e-13	Systolic blood pressure;
LUAD	cis	rs367943	1.000	rs348955	chr5:112821643	C/T	cg12552261	chr5:112820674	MCC	-0.58	-10.95	-0.47	1.02e-24	Type 2 diabetes;
LUAD	cis	rs7818345	0.935	rs6991212	chr8:19276522	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.3	6.61	0.31	1.15e-10	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg22705602	chr4:152727874	NA	-0.4	-7.07	-0.33	6.3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg14582100	chr15:45693742	SPATA5L1	0.43	8.59	0.39	1.65e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg09060608	chr5:178986726	RUFY1	0.78	13.96	0.56	1.09e-36	Lung cancer;
LUAD	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg02807482	chr3:125708958	NA	-0.67	-9.03	-0.4	6.36e-18	Blood pressure (smoking interaction);
LUAD	cis	rs2357013	0.718	rs2195659	chr2:53238427	C/G	cg07782112	chr2:53107842	NA	-0.34	-6.81	-0.31	3.45e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.68	12.96	0.53	1.39e-32	Cognitive ability;
LUAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13126279	chr21:47581558	C21orf56	0.54	9.15	0.41	2.44e-18	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2732480	1.000	rs2732480	chr12:48736303	A/C	cg00796672	chr12:48596817	OR10AD1	-0.33	-7.14	-0.33	4.09e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs9948	0.655	rs62156228	chr2:97420335	A/G	cg20312557	chr2:97357134	FER1L5	-0.73	-8.22	-0.37	2.53e-15	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs1003719	0.788	rs4817845	chr21:38447132	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.44	0.38	5.28e-16	Eye color traits;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg22126032	chr7:116166529	CAV1	0.4	6.37	0.3	5.08e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg09365446	chr1:150670422	GOLPH3L	0.53	9.54	0.42	1.19e-19	Melanoma;
LUAD	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg17366294	chr4:99064904	C4orf37	0.62	11.5	0.49	8.03e-27	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.69	0.35	1.02e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67366981	0.925	rs41438045	chr14:77692781	A/T	cg22824376	chr14:77648248	TMEM63C	0.6	6.37	0.3	4.83e-10	Obsessive-compulsive symptoms;
LUAD	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	18.34	0.67	1.1e-55	Bone mineral density;
LUAD	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.28	-6.38	-0.3	4.68e-10	Systemic lupus erythematosus;
LUAD	cis	rs12286929	0.556	rs11605461	chr11:115053011	C/T	cg04055981	chr11:115044050	NA	-0.44	-8.23	-0.37	2.4e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg06671706	chr8:8559999	CLDN23	0.67	11.69	0.49	1.45e-27	Obesity-related traits;
LUAD	cis	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg07460842	chr6:66804631	NA	1.06	16.76	0.63	1.03e-48	Exhaled nitric oxide output;
LUAD	cis	rs4917300	0.869	rs13252175	chr8:143095930	C/T	cg25363559	chr8:143086065	NA	-0.34	-6.79	-0.31	3.85e-11	Amyotrophic lateral sclerosis;
LUAD	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18404041	chr3:52824283	ITIH1	-0.59	-11.93	-0.5	1.76e-28	Bipolar disorder;
LUAD	cis	rs6445967	0.530	rs62258074	chr3:58353966	C/G	cg13750441	chr3:58318267	PXK	-0.32	-6.56	-0.3	1.62e-10	Platelet count;
LUAD	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg21984481	chr17:79567631	NPLOC4	0.56	11.78	0.5	6.74e-28	Eye color traits;
LUAD	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg02176678	chr2:219576539	TTLL4	0.74	14.98	0.59	5.28e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg17724175	chr1:150552817	MCL1	0.39	9.37	0.41	4.5e-19	Tonsillectomy;
LUAD	trans	rs877282	0.583	rs11253429	chr10:823234	A/C	cg22713356	chr15:30763199	NA	0.9	10.7	0.46	8.23e-24	Uric acid levels;
LUAD	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg14019695	chr9:139328340	INPP5E	0.49	9.33	0.41	5.97e-19	Monocyte percentage of white cells;
LUAD	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg00376283	chr12:123451042	ABCB9	0.41	6.52	0.3	2.03e-10	Platelet count;
LUAD	trans	rs11039798	1.000	rs12281162	chr11:48650491	T/C	cg15704280	chr7:45808275	SEPT13	0.66	7.67	0.35	1.23e-13	Axial length;
LUAD	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg13390004	chr1:15929781	NA	0.47	8.33	0.38	1.17e-15	Systolic blood pressure;
LUAD	cis	rs9905704	0.589	rs2632509	chr17:56487887	C/T	cg19466818	chr17:56409534	MIR142	0.35	7.07	0.32	6.56e-12	Testicular germ cell tumor;
LUAD	trans	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg20556744	chr2:9614537	IAH1	0.62	6.56	0.3	1.56e-10	Opioid sensitivity;
LUAD	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg15147215	chr3:52552868	STAB1	-0.4	-7.14	-0.33	4.04e-12	Bipolar disorder;
LUAD	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg15448220	chr1:150897856	SETDB1	0.54	9.31	0.41	6.88e-19	Melanoma;
LUAD	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg19761014	chr17:28927070	LRRC37B2	0.7	6.43	0.3	3.37e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg11494091	chr17:61959527	GH2	0.74	18.35	0.67	9.02e-56	Prudent dietary pattern;
LUAD	cis	rs113835537	0.529	rs7950790	chr11:66258053	G/A	cg24851651	chr11:66362959	CCS	0.55	9.84	0.43	1.04e-20	Airway imaging phenotypes;
LUAD	cis	rs2274273	0.624	rs78205412	chr14:55781250	G/A	cg04306507	chr14:55594613	LGALS3	0.42	8.08	0.37	6.71e-15	Protein biomarker;
LUAD	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg07578070	chr6:150326732	RAET1K	0.39	6.7	0.31	6.56e-11	Alopecia areata;
LUAD	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg10876282	chr6:28092338	ZSCAN16	0.44	7.08	0.33	5.87e-12	Parkinson's disease;
LUAD	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.43	-7.4	-0.34	7.37e-13	Glomerular filtration rate in chronic kidney disease;
LUAD	trans	rs9354308	0.868	rs9363460	chr6:66557539	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.51	-0.3	2.12e-10	Metabolite levels;
LUAD	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.67	0.39	9.26e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.54	-9.22	-0.41	1.46e-18	Menarche (age at onset);
LUAD	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.73	-0.31	5.43e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	0.46	8.14	0.37	4.51e-15	Age at first birth;
LUAD	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg00666640	chr1:248458726	OR2T12	0.31	7.6	0.35	1.94e-13	Common traits (Other);
LUAD	cis	rs1882538	0.506	rs7805858	chr7:133126589	G/T	cg10665199	chr7:133106180	EXOC4	0.6	10.47	0.45	5.8e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs71327718	1	rs71327718	chr3:125592857	C/G	cg05084668	chr3:125655381	ALG1L	-0.82	-10.51	-0.45	4.26e-23	Metabolite levels (HVA/5-HIAA ratio);
LUAD	cis	rs870825	0.860	rs34985821	chr4:185599489	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	11.39	0.48	2.05e-26	Blood protein levels;
LUAD	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg16797656	chr11:68205561	LRP5	0.45	8.64	0.39	1.15e-16	Total body bone mineral density;
LUAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg11062466	chr8:58055876	NA	0.65	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg02733842	chr7:1102375	C7orf50	-0.68	-9.8	-0.43	1.45e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.1	0.37	6.02e-15	Menopause (age at onset);
LUAD	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg08847533	chr14:75593920	NEK9	0.4	6.83	0.32	2.94e-11	Height;
LUAD	cis	rs4332037	0.722	rs28705934	chr7:1916116	T/A	cg23422044	chr7:1970798	MAD1L1	-0.5	-7.07	-0.33	6.47e-12	Bipolar disorder;
LUAD	cis	rs6942407	0.592	rs1024457	chr7:86764142	T/G	cg02420886	chr7:86849541	C7orf23	0.64	7.24	0.33	2.07e-12	Food allergy;
LUAD	trans	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.78	-0.31	3.95e-11	Diabetic kidney disease;
LUAD	cis	rs2041840	1.000	rs6730503	chr2:37528478	A/G	cg25727520	chr2:37576821	QPCT	0.34	6.93	0.32	1.54e-11	Chronic lymphocytic leukemia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02847575	chr16:30382517	TBC1D10B	-0.41	-6.4	-0.3	4.19e-10	Height;
LUAD	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg23229984	chr5:148520753	ABLIM3	0.47	7.22	0.33	2.4e-12	Breast cancer;
LUAD	cis	rs6906287	0.573	rs7757943	chr6:118697981	C/G	cg18833306	chr6:118973337	C6orf204	0.45	8.08	0.37	6.85e-15	Electrocardiographic conduction measures;
LUAD	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg09365446	chr1:150670422	GOLPH3L	-0.64	-12.01	-0.5	8.81e-29	Tonsillectomy;
LUAD	cis	rs7799006	0.929	rs745565	chr7:2256689	G/C	cg02951883	chr7:2050386	MAD1L1	-0.5	-7.4	-0.34	7.6e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs559928	0.553	rs1320628	chr11:64175986	C/T	cg05555928	chr11:63887634	MACROD1	-0.46	-7.36	-0.34	9.88e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUAD	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg13813247	chr22:41461852	NA	-0.45	-7.33	-0.34	1.15e-12	Neuroticism;
LUAD	cis	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg27411982	chr8:10470053	RP1L1	0.4	6.82	0.31	3.24e-11	Neuroticism;
LUAD	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.9	0.53	2.54e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937890	0.559	rs2575853	chr11:14533963	T/C	cg02886208	chr11:14281011	SPON1	-0.34	-6.57	-0.3	1.45e-10	Mitochondrial DNA levels;
LUAD	cis	rs4819052	0.704	rs2297283	chr21:46683590	G/A	cg06618935	chr21:46677482	NA	-0.35	-6.76	-0.31	4.5e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg03467027	chr4:99064603	C4orf37	0.41	6.63	0.31	1.03e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg16606324	chr3:10149918	C3orf24	0.59	9.56	0.42	1.01e-19	Alzheimer's disease;
LUAD	cis	rs10821973	0.527	rs4636536	chr10:63979147	C/A	cg09941381	chr10:64027924	RTKN2	-0.34	-6.72	-0.31	5.72e-11	Hypothyroidism;
LUAD	trans	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-8.96	-0.4	1.08e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg21775007	chr8:11205619	TDH	0.56	9.91	0.43	5.88e-21	Retinal vascular caliber;
LUAD	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg13319975	chr6:146136371	FBXO30	-0.6	-10.04	-0.44	2.08e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg24818145	chr4:99064322	C4orf37	0.47	7.81	0.35	4.64e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.07	0.37	7.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg18180107	chr4:99064573	C4orf37	0.47	7.25	0.33	2e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg04369109	chr6:150039330	LATS1	-0.49	-7.52	-0.34	3.22e-13	Lung cancer;
LUAD	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg27661571	chr11:113659931	NA	-0.55	-6.73	-0.31	5.51e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg07460842	chr6:66804631	NA	0.95	15.06	0.59	2.43e-41	Exhaled nitric oxide levels;
LUAD	cis	rs17655565	0.904	rs3809172	chr12:52695198	G/C	cg08257133	chr12:52711352	KRT83	0.42	6.81	0.31	3.4e-11	Plasma amyloid beta peptide concentrations (ABx-42);
LUAD	trans	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg19862616	chr7:65841803	NCRNA00174	1.04	25.17	0.77	4.05e-86	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg11494091	chr17:61959527	GH2	0.43	8.09	0.37	6.17e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs151234	0.676	rs508022	chr16:28573963	C/T	cg04609801	chr16:28609176	SULT1A2	0.62	9.03	0.4	6.14e-18	Platelet distribution width;
LUAD	cis	rs11771526	0.642	rs11762517	chr7:32336793	T/C	cg27532318	chr7:32358331	NA	0.55	7.38	0.34	8.5e-13	Body mass index;
LUAD	cis	rs10992471	0.676	rs13286566	chr9:95473178	C/T	cg14631576	chr9:95140430	CENPP	-0.48	-9.58	-0.42	8.64e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs2204008	0.617	rs11831608	chr12:38210687	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.41	-0.3	3.92e-10	Bladder cancer;
LUAD	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg05234568	chr11:5960015	NA	-0.47	-8.15	-0.37	4.26e-15	DNA methylation (variation);
LUAD	cis	rs6840360	0.593	rs1429559	chr4:152681952	A/G	cg22705602	chr4:152727874	NA	-0.48	-9.27	-0.41	9.87e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.62e-18	Life satisfaction;
LUAD	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg26587870	chr6:27730563	NA	-0.49	-7.25	-0.33	2.05e-12	Depression;
LUAD	cis	rs9399401	1.000	rs9399401	chr6:142668901	T/C	cg03128060	chr6:142623767	GPR126	0.32	7.06	0.32	6.79e-12	Chronic obstructive pulmonary disease;
LUAD	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg01416388	chr22:39784598	NA	-0.52	-8.86	-0.4	2.25e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs4853036	1.000	rs34587942	chr2:70081501	G/A	cg02498382	chr2:70120550	SNRNP27	-0.5	-8.1	-0.37	5.84e-15	Colorectal or endometrial cancer;
LUAD	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg13393036	chr8:95962371	TP53INP1	-0.29	-6.58	-0.3	1.41e-10	Alzheimer's disease (late onset);
LUAD	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg27588902	chr6:42928151	GNMT	0.32	6.59	0.31	1.33e-10	Blood protein levels;
LUAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00166722	chr3:10149974	C3orf24	0.63	10.42	0.45	8.88e-23	Alzheimer's disease;
LUAD	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg08048268	chr3:133502702	NA	-0.41	-8.37	-0.38	8.7e-16	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg00105475	chr2:10696890	NA	0.36	6.58	0.3	1.4e-10	Prostate cancer;
LUAD	cis	rs868036	1.000	rs8037262	chr15:68108572	C/T	cg24579218	chr15:68104479	NA	-0.4	-7.49	-0.34	4.07e-13	Restless legs syndrome;
LUAD	cis	rs2235649	0.592	rs8046208	chr16:1964008	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-7.03	-0.32	8.26e-12	Blood metabolite levels;
LUAD	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg01200585	chr1:228362443	C1orf69	-0.38	-7.18	-0.33	3.07e-12	Diastolic blood pressure;
LUAD	cis	rs12618769	0.543	rs56357378	chr2:99032455	T/G	cg10123293	chr2:99228465	UNC50	0.45	8.17	0.37	3.53e-15	Bipolar disorder;
LUAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg08132940	chr7:1081526	C7orf50	-0.79	-10.67	-0.46	1.04e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg22907277	chr7:1156413	C7orf50	0.68	7.98	0.36	1.35e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg13319975	chr6:146136371	FBXO30	-0.76	-12.84	-0.53	4.35e-32	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9863	0.931	rs2178663	chr12:124433905	C/T	cg17723958	chr12:124429295	CCDC92	-0.42	-6.76	-0.31	4.48e-11	White blood cell count;
LUAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00149659	chr3:10157352	C3orf10	0.63	8.82	0.39	3.02e-17	Alzheimer's disease;
LUAD	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg27490568	chr2:178487706	NA	0.43	7.3	0.33	1.46e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs8040855	0.599	rs6496800	chr15:85728286	G/C	cg04831495	chr15:85060580	GOLGA6L5	0.45	7.76	0.35	6.47e-14	Bulimia nervosa;
LUAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08677398	chr8:58056175	NA	0.46	6.41	0.3	3.88e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg10518543	chr12:38710700	ALG10B	0.49	8.34	0.38	1.04e-15	Morning vs. evening chronotype;
LUAD	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg06784218	chr1:46089804	CCDC17	0.6	13.39	0.55	2.41e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs72781680	1.000	rs17763442	chr2:24255991	C/T	cg06627628	chr2:24431161	ITSN2	-0.57	-6.55	-0.3	1.72e-10	Lymphocyte counts;
LUAD	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg19875535	chr5:140030758	IK	0.44	7.41	0.34	6.93e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.33	0.34	1.18e-12	Menopause (age at onset);
LUAD	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg23719950	chr11:63933701	MACROD1	-0.61	-7.57	-0.35	2.33e-13	Mean platelet volume;
LUAD	cis	rs2535633	0.631	rs2710346	chr3:52974152	C/T	cg18404041	chr3:52824283	ITIH1	0.4	6.86	0.32	2.49e-11	Body mass index;
LUAD	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg05044414	chr3:183734942	ABCC5	0.47	9.9	0.43	6.17e-21	Anterior chamber depth;
LUAD	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg27490568	chr2:178487706	NA	0.39	6.51	0.3	2.09e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7192380	0.964	rs55780735	chr16:69740374	A/G	cg26679644	chr16:69762563	NA	-0.51	-9.9	-0.43	6.34e-21	Sjögren's syndrome;
LUAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.04	-0.4	5.61e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06873352	chr17:61820015	STRADA	0.83	18.28	0.66	1.98e-55	Prudent dietary pattern;
LUAD	trans	rs62458065	1.000	rs979355	chr7:32463933	A/G	cg00845942	chr12:64062724	DPY19L2	0.46	6.62	0.31	1.06e-10	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg20108693	chr8:143823809	SLURP1	0.3	6.97	0.32	1.21e-11	Urinary tract infection frequency;
LUAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.6	-0.31	1.27e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	7.17	0.33	3.42e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs1003719	0.646	rs2835671	chr21:38581125	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.14	-0.37	4.62e-15	Eye color traits;
LUAD	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg15704280	chr7:45808275	SEPT13	-0.62	-9.45	-0.42	2.39e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg19193384	chr17:30244184	NA	-0.51	-6.63	-0.31	1.01e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.83	-0.36	3.97e-14	Diabetic kidney disease;
LUAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg05434287	chr7:2030229	MAD1L1	0.41	6.74	0.31	5.04e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg13319975	chr6:146136371	FBXO30	-0.59	-10.08	-0.44	1.45e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1448094	0.842	rs7301280	chr12:86455752	G/T	cg19622623	chr12:86230825	RASSF9	0.36	6.48	0.3	2.54e-10	Major depressive disorder;
LUAD	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg26446133	chr18:72167187	CNDP2	-0.82	-12.06	-0.51	5.33e-29	Refractive error;
LUAD	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.7	-0.31	6.77e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11030122	0.645	rs11493482	chr11:4034772	A/G	cg18678763	chr11:4115507	RRM1	-0.45	-7.32	-0.34	1.23e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg01324343	chr3:183735012	ABCC5	0.94	24.96	0.77	3.49e-85	Anterior chamber depth;
LUAD	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg06197492	chr11:2016605	H19	0.42	8.44	0.38	5e-16	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg13385794	chr1:248469461	NA	0.26	6.98	0.32	1.13e-11	Common traits (Other);
LUAD	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg05043794	chr9:111880884	C9orf5	-0.41	-6.92	-0.32	1.66e-11	Menarche (age at onset);
LUAD	cis	rs7937890	0.559	rs2575836	chr11:14497864	T/G	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.15e-12	Mitochondrial DNA levels;
LUAD	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06544989	chr22:39130855	UNC84B	0.45	9.07	0.4	4.63e-18	Menopause (age at onset);
LUAD	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg27411982	chr8:10470053	RP1L1	0.4	7.02	0.32	9.09e-12	Mood instability;
LUAD	cis	rs2742417	0.603	rs2742449	chr3:45764544	T/C	cg10512202	chr3:45649293	LIMD1	0.47	8.79	0.39	3.69e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg18404041	chr3:52824283	ITIH1	0.41	7.56	0.34	2.6e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-9.55	-0.42	1.03e-19	Migraine;Coronary artery disease;
LUAD	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg09184832	chr6:79620586	NA	-0.48	-9.11	-0.4	3.33e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg22508957	chr16:3507546	NAT15	0.49	7.13	0.33	4.32e-12	Body mass index (adult);
LUAD	cis	rs1322639	0.668	rs9766666	chr6:169613541	G/T	cg04662567	chr6:169592167	NA	-0.31	-6.69	-0.31	7.27e-11	Pulse pressure;
LUAD	cis	rs2455799	0.553	rs2262664	chr3:15768097	A/T	cg16303742	chr3:15540471	COLQ	-0.5	-9.26	-0.41	1.06e-18	Mean platelet volume;
LUAD	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg08632164	chr7:65971372	NA	0.37	6.53	0.3	1.86e-10	Aortic root size;
LUAD	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg18404041	chr3:52824283	ITIH1	-0.53	-8.94	-0.4	1.22e-17	Schizophrenia;
LUAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg11062466	chr8:58055876	NA	0.65	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7561528	0.501	rs11689089	chr2:127887865	T/C	cg08168897	chr2:127865431	BIN1	-0.43	-6.44	-0.3	3.17e-10	Alzheimer's disease;Alzheimer's disease (late onset);
LUAD	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg09904177	chr6:26538194	HMGN4	0.44	7.36	0.34	9.71e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg26384229	chr12:38710491	ALG10B	0.48	7.78	0.35	5.45e-14	Bladder cancer;
LUAD	trans	rs1337391	0.764	rs10738439	chr9:16612956	A/C	cg08976687	chr2:85515537	TCF7L1	-0.47	-6.53	-0.3	1.9e-10	Heschl's gyrus morphology;
LUAD	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.9	-0.47	1.56e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7072216	0.763	rs942805	chr10:100168372	G/A	cg26618903	chr10:100175079	PYROXD2	-0.36	-7.94	-0.36	1.8e-14	Metabolite levels;
LUAD	cis	rs240764	0.717	rs151640	chr6:101111521	A/C	cg09795085	chr6:101329169	ASCC3	0.4	6.91	0.32	1.78e-11	Neuroticism;
LUAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg07362569	chr17:61921086	SMARCD2	0.39	6.74	0.31	5.29e-11	Prudent dietary pattern;
LUAD	cis	rs6687430	0.526	rs6688558	chr1:10611403	A/G	cg17425144	chr1:10567563	PEX14	0.55	10.72	0.46	6.9e-24	Hand grip strength;
LUAD	cis	rs1113500	0.836	rs2801220	chr1:108584649	A/G	cg06207961	chr1:108661230	NA	-0.4	-7.38	-0.34	8.26e-13	Growth-regulated protein alpha levels;
LUAD	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.67	-0.31	8.08e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg14926445	chr8:58193284	C8orf71	-0.48	-7.0	-0.32	1.03e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs8030485	0.536	rs12595749	chr15:79432359	A/G	cg17916960	chr15:79447300	NA	0.41	7.89	0.36	2.68e-14	Left ventricle wall thickness;
LUAD	cis	rs1448094	0.967	rs2044617	chr12:86324089	T/C	cg02569458	chr12:86230093	RASSF9	0.37	7.07	0.33	6.27e-12	Major depressive disorder;
LUAD	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg05697835	chr1:2722811	NA	0.31	6.41	0.3	3.78e-10	Ulcerative colitis;
LUAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg05434287	chr7:2030229	MAD1L1	0.39	6.46	0.3	2.97e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg02371401	chr5:676784	TPPP	-0.4	-6.85	-0.32	2.65e-11	Obesity-related traits;
LUAD	cis	rs698833	0.828	rs1067341	chr2:44623687	G/A	cg04920474	chr2:44395004	PPM1B	0.36	6.61	0.31	1.14e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg20476274	chr7:133979776	SLC35B4	0.75	13.4	0.55	2.29e-34	Mean platelet volume;
LUAD	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg15704280	chr7:45808275	SEPT13	-1.06	-23.42	-0.75	2.17e-78	Height;
LUAD	cis	rs7584330	0.697	rs1979762	chr2:238436502	T/C	cg14458575	chr2:238380390	NA	0.54	10.0	0.44	2.92e-21	Prostate cancer;
LUAD	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-8.7	-0.39	7.22e-17	Gut microbiome composition (summer);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg27129297	chr1:155293118	RUSC1;C1orf104	-0.39	-6.8	-0.31	3.6e-11	Cancer;
LUAD	cis	rs2041840	1.000	rs10178975	chr2:37514564	T/C	cg25727520	chr2:37576821	QPCT	-0.37	-7.63	-0.35	1.5700000000000001e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg24818145	chr4:99064322	C4orf37	0.47	7.96	0.36	1.57e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg14565881	chr1:76190040	ACADM	0.49	6.36	0.3	5.21e-10	Lung function (FEV1);
LUAD	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg18721089	chr20:30220636	NA	-0.45	-6.76	-0.31	4.71e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg11189052	chr15:85197271	WDR73	-0.77	-13.46	-0.55	1.27e-34	P wave terminal force;
LUAD	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg11859384	chr17:80120422	CCDC57	0.5	8.98	0.4	9.07e-18	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg12863693	chr15:85201151	NMB	0.37	6.49	0.3	2.35e-10	Schizophrenia;
LUAD	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg07138768	chr7:917805	C7orf20	-0.35	-7.17	-0.33	3.33e-12	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs12545109	0.800	rs2582401	chr8:57401656	A/G	cg17761419	chr8:57350749	NA	-0.54	-7.65	-0.35	1.33e-13	Obesity-related traits;
LUAD	cis	rs731174	0.797	rs670692	chr1:38148124	G/A	cg06917450	chr1:38156652	C1orf109	-0.41	-6.42	-0.3	3.71e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg13319975	chr6:146136371	FBXO30	0.82	14.28	0.57	4.93e-38	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4077515	0.874	rs10781505	chr9:139271355	C/T	cg14019695	chr9:139328340	INPP5E	-0.39	-7.26	-0.33	1.81e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg19773385	chr1:10388646	KIF1B	-0.42	-6.87	-0.32	2.37e-11	Hepatocellular carcinoma;
LUAD	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg22681709	chr2:178499509	PDE11A	-0.54	-9.04	-0.4	5.86e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg27411982	chr8:10470053	RP1L1	0.39	6.89	0.32	2.03e-11	Systolic blood pressure;
LUAD	cis	rs6545883	0.931	rs12713438	chr2:61725501	G/A	cg15711740	chr2:61764176	XPO1	-0.4	-6.5	-0.3	2.29e-10	Tuberculosis;
LUAD	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg25237894	chr2:233734115	C2orf82	-0.6	-11.34	-0.48	3.44e-26	Coronary artery disease;
LUAD	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg22961513	chr11:14280813	SPON1	-0.42	-8.63	-0.39	1.26e-16	Mitochondrial DNA levels;
LUAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.45	-8.73	-0.39	5.81e-17	Longevity;Endometriosis;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg07204937	chr10:99609863	GOLGA7B	0.38	6.58	0.3	1.38e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg03929089	chr4:120376271	NA	-0.97	-20.08	-0.7	1.84e-63	Height;
LUAD	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.39	-8.13	-0.37	4.94e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs62400317	0.762	rs72865923	chr6:44878942	T/G	cg20913747	chr6:44695427	NA	-0.44	-6.91	-0.32	1.84e-11	Total body bone mineral density;
LUAD	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg09365446	chr1:150670422	GOLPH3L	0.64	11.28	0.48	5.59e-26	Melanoma;
LUAD	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg14416269	chr4:6271139	WFS1	0.67	14.28	0.57	4.69e-38	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg09222892	chr1:25734099	RHCE	-0.5	-9.36	-0.41	4.93e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg23301539	chr8:142222248	SLC45A4	0.49	8.95	0.4	1.17e-17	Immature fraction of reticulocytes;
LUAD	cis	rs17092148	0.887	rs4911431	chr20:33158318	G/A	cg16810054	chr20:33298113	TP53INP2	-0.53	-7.99	-0.36	1.3e-14	Neuroticism;
LUAD	cis	rs6489785	0.525	rs584001	chr12:121228055	G/T	cg02419362	chr12:121203948	SPPL3	0.34	6.47	0.3	2.76e-10	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg27489772	chr12:121021490	NA	0.55	6.94	0.32	1.48e-11	Type 1 diabetes nephropathy;
LUAD	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg22823121	chr1:150693482	HORMAD1	-0.4	-7.84	-0.36	3.74e-14	Lymphocyte counts;
LUAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-9.76	-0.43	2.03e-20	Lymphocyte counts;
LUAD	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg08761264	chr16:28874980	SH2B1	-0.44	-6.77	-0.31	4.36e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9527	0.518	rs10883802	chr10:104680362	C/T	cg15744005	chr10:104629667	AS3MT	0.48	6.52	0.3	2.06e-10	Arsenic metabolism;
LUAD	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg10591111	chr5:226296	SDHA	-0.56	-7.21	-0.33	2.55e-12	Breast cancer;
LUAD	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg13319975	chr6:146136371	FBXO30	0.66	11.23	0.48	8.78e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.8	-0.39	3.47e-17	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06022373	chr22:39101656	GTPBP1	0.46	7.25	0.33	2.06e-12	Menopause (age at onset);
LUAD	cis	rs909002	0.800	rs6703093	chr1:32093561	C/T	cg13919466	chr1:32135498	COL16A1	-0.35	-8.18	-0.37	3.43e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg25319279	chr11:5960081	NA	-0.38	-7.36	-0.34	9.73e-13	DNA methylation (variation);
LUAD	cis	rs747650	0.892	rs7937101	chr11:47226488	A/G	cg19486271	chr11:47235900	DDB2	-0.48	-7.69	-0.35	1.05e-13	Acne (severe);
LUAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg02951883	chr7:2050386	MAD1L1	-0.64	-10.34	-0.45	1.66e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	10.4	0.45	1.04e-22	Electrocardiographic conduction measures;
LUAD	trans	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-8.7	-0.39	7.45e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs427941	0.667	rs201436	chr7:101733576	T/C	cg06246474	chr7:101738831	CUX1	0.41	7.12	0.33	4.67e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg11976233	chr4:56719715	EXOC1	-0.41	-7.0	-0.32	1.02e-11	Schizophrenia;
LUAD	cis	rs870825	0.616	rs28558715	chr4:185627761	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	trans	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.61	-0.31	1.15e-10	Diabetic kidney disease;
LUAD	cis	rs89107	0.576	rs11967375	chr6:118823975	A/G	cg21191810	chr6:118973309	C6orf204	0.41	7.57	0.35	2.39e-13	Cardiac structure and function;
LUAD	cis	rs12200560	0.505	rs211167	chr6:97069087	T/A	cg06623918	chr6:96969491	KIAA0776	0.45	6.75	0.31	5.02e-11	Coronary heart disease;
LUAD	cis	rs2235649	0.833	rs9929262	chr16:1851928	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.47	-7.76	-0.35	6.56e-14	Blood metabolite levels;
LUAD	cis	rs10992471	0.756	rs7848055	chr9:95115492	A/C	cg14631576	chr9:95140430	CENPP	-0.48	-9.63	-0.42	5.53e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs4243830	0.850	rs1010584	chr1:6579843	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.53	-7.46	-0.34	5.1e-13	Body mass index;
LUAD	cis	rs864537	0.646	rs1723016	chr1:167433056	T/C	cg22356347	chr1:167427500	CD247	-0.46	-9.18	-0.41	1.87e-18	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.43	8.19	0.37	3.04e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.5e-19	Life satisfaction;
LUAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14159672	chr1:205819179	PM20D1	0.78	15.43	0.6	6.52e-43	Menarche (age at onset);
LUAD	cis	rs9487051	0.803	rs410449	chr6:109539853	C/T	cg21918786	chr6:109611834	NA	-0.41	-6.98	-0.32	1.18e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg23587288	chr2:27483067	SLC30A3	-0.4	-7.86	-0.36	3.32e-14	Blood metabolite levels;
LUAD	trans	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg19862616	chr7:65841803	NCRNA00174	1.05	26.66	0.79	1.38e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg05304507	chr6:116381966	FRK	0.2	6.81	0.31	3.37e-11	Cholesterol, total;LDL cholesterol;
LUAD	trans	rs7395662	0.963	rs7952491	chr11:48663295	T/A	cg00717180	chr2:96193071	NA	-0.35	-6.49	-0.3	2.47e-10	HDL cholesterol;
LUAD	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg22823121	chr1:150693482	HORMAD1	0.42	7.99	0.36	1.26e-14	Melanoma;
LUAD	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg24579218	chr15:68104479	NA	-0.53	-9.16	-0.41	2.26e-18	Restless legs syndrome;
LUAD	cis	rs931127	0.719	rs2170082	chr11:65454795	A/G	cg27068330	chr11:65405492	SIPA1	-0.41	-6.65	-0.31	8.97e-11	Systemic lupus erythematosus;
LUAD	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg00666640	chr1:248458726	OR2T12	0.34	8.3	0.37	1.4e-15	Common traits (Other);
LUAD	cis	rs12472274	0.646	rs34465035	chr2:239114093	C/A	cg17459225	chr2:239074497	NA	0.66	7.39	0.34	7.75e-13	Phospholipid levels (plasma);
LUAD	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.23	-0.33	2.33e-12	Lung cancer;
LUAD	trans	rs1997103	1.000	rs4948011	chr7:55403859	A/G	cg20935933	chr6:143382018	AIG1	0.52	7.38	0.34	8.51e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.72	-0.35	8.3e-14	Breast cancer;
LUAD	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs12505328	0.966	rs2877784	chr4:174355494	T/C	cg12145043	chr4:174357286	NA	-0.58	-10.25	-0.45	3.65e-22	Chin dimples;
LUAD	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.36	0.34	9.88e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10848704	1.000	rs10848704	chr12:2882544	A/G	cg19995117	chr12:2880862	NA	-0.65	-13.8	-0.56	5.21e-36	Quantitative traits;
LUAD	cis	rs2387326	1.000	rs2387326	chr10:129933456	C/T	cg16087940	chr10:129947807	NA	-0.51	-7.21	-0.33	2.63e-12	Select biomarker traits;
LUAD	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg11070056	chr1:107600091	PRMT6	0.64	11.14	0.48	1.97e-25	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg12863693	chr15:85201151	NMB	0.4	7.4	0.34	7.52e-13	Schizophrenia;
LUAD	cis	rs7274811	0.652	rs149236	chr20:32023380	C/T	cg13403462	chr20:32256071	NECAB3;C20orf134	0.46	6.97	0.32	1.2e-11	Height;
LUAD	cis	rs7336332	0.600	rs9579083	chr13:28017270	G/C	cg22138327	chr13:27999177	GTF3A	0.72	9.64	0.42	5.05e-20	Weight;
LUAD	trans	rs2270927	0.510	rs246814	chr5:75599208	C/T	cg13563193	chr19:33072644	PDCD5	0.97	8.99	0.4	8.27e-18	Mean corpuscular volume;
LUAD	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.51	-0.42	1.51e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs939658	1.000	rs8031019	chr15:79458512	C/T	cg17916960	chr15:79447300	NA	-0.46	-9.83	-0.43	1.14e-20	Refractive error;
LUAD	cis	rs4460629	0.742	rs7366355	chr1:155076734	C/T	cg23973274	chr1:155060172	NA	-0.37	-6.38	-0.3	4.52e-10	Serum magnesium levels;
LUAD	cis	rs4691139	1.000	rs1914859	chr4:165906141	C/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.44	-8.68	-0.39	8.88e-17	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.39	0.34	7.87e-13	Hypertriglyceridemia;
LUAD	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg08048268	chr3:133502702	NA	-0.41	-7.52	-0.34	3.24e-13	Iron status biomarkers;
LUAD	cis	rs9897596	1	rs9897596	chr17:17593453	T/C	cg04398451	chr17:18023971	MYO15A	0.41	6.91	0.32	1.75e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.31e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.41	-0.3	3.87e-10	Neuroticism;
LUAD	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.97	-0.32	1.24e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.57	-0.49	4.54e-27	Primary sclerosing cholangitis;
LUAD	cis	rs7000551	0.606	rs3802199	chr8:22267385	A/G	cg12081754	chr8:22256438	SLC39A14	0.89	13.68	0.55	1.5e-35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08219700	chr8:58056026	NA	0.62	8.2	0.37	2.88e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.91	-0.32	1.8e-11	Obesity-related traits;
LUAD	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs12681287	0.609	rs13279850	chr8:87477800	C/T	cg27223183	chr8:87520930	FAM82B	-0.65	-9.34	-0.41	5.36e-19	Caudate activity during reward;
LUAD	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.55	7.82	0.36	4.32e-14	Platelet count;
LUAD	cis	rs12541635	0.677	rs61002083	chr8:106982132	A/G	cg10147462	chr8:107024639	NA	0.54	9.83	0.43	1.16e-20	Age of smoking initiation;
LUAD	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg00071950	chr4:10020882	SLC2A9	0.59	11.15	0.48	1.69e-25	Bone mineral density;
LUAD	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.3	-0.33	1.47e-12	Reticulocyte count;
LUAD	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.94e-11	Hepatitis;
LUAD	cis	rs4660214	0.666	rs629093	chr1:39833503	A/G	cg27567593	chr1:39956653	BMP8A	-0.36	-7.31	-0.34	1.31e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg24308560	chr3:49941425	MST1R	-0.5	-8.32	-0.37	1.23e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7945718	0.967	rs7927470	chr11:12748899	A/T	cg25843174	chr11:12811716	TEAD1	0.23	6.85	0.32	2.6e-11	Educational attainment (years of education);
LUAD	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	6.5	0.3	2.29e-10	Schizophrenia;
LUAD	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg27411982	chr8:10470053	RP1L1	-0.39	-7.13	-0.33	4.48e-12	Retinal vascular caliber;
LUAD	trans	rs225245	1.000	rs225245	chr17:33946107	A/G	cg19694781	chr19:47549865	TMEM160	-0.4	-6.51	-0.3	2.17e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.51	0.34	3.54e-13	Tonsillectomy;
LUAD	cis	rs2296342	0.652	rs2296338	chr6:33630816	G/A	cg14003231	chr6:33640908	ITPR3	0.41	8.0	0.36	1.25e-14	Schizophrenia;
LUAD	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg00701064	chr4:6280414	WFS1	0.66	14.3	0.57	4.23e-38	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg24578937	chr1:2090814	PRKCZ	0.57	12.07	0.51	4.97e-29	Height;
LUAD	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.48	-9.97	-0.44	3.68e-21	Total body bone mineral density;
LUAD	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg27129171	chr3:47204927	SETD2	0.41	6.81	0.31	3.33e-11	Colorectal cancer;
LUAD	cis	rs877282	0.945	rs12782447	chr10:771870	C/T	cg06581033	chr10:766294	NA	-0.57	-7.77	-0.35	5.98e-14	Uric acid levels;
LUAD	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg02775129	chr4:119771670	NA	-0.88	-8.19	-0.37	3.21e-15	Cannabis dependence symptom count;
LUAD	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg22029157	chr1:209979665	IRF6	0.7	9.39	0.42	3.84e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg25427524	chr10:38739819	LOC399744	0.81	15.66	0.61	6.06e-44	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6782228	0.606	rs2712417	chr3:128345179	A/G	cg16766828	chr3:128327626	NA	-0.38	-7.14	-0.33	4.05e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg15549821	chr19:49342101	PLEKHA4	-1.18	-18.35	-0.67	9.13e-56	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg11766577	chr21:47581405	C21orf56	-0.49	-8.02	-0.36	1.05e-14	Testicular germ cell tumor;
LUAD	cis	rs6489882	0.902	rs3759376	chr12:113373563	A/G	cg20102336	chr12:113376681	OAS3	-0.6	-9.46	-0.42	2.12e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg20673091	chr1:2541236	MMEL1	0.39	8.42	0.38	5.93e-16	Ulcerative colitis;
LUAD	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg25456477	chr12:86230367	RASSF9	0.35	7.09	0.33	5.61e-12	Major depressive disorder;
LUAD	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg11993925	chr19:44307056	LYPD5	0.61	12.64	0.52	2.69e-31	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg07606381	chr6:8435919	SLC35B3	0.42	6.84	0.32	2.82e-11	Motion sickness;
LUAD	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg26536354	chr8:144654954	C8orf73	0.6	6.68	0.31	7.77e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18876405	chr7:65276391	NA	-0.41	-6.62	-0.31	1.06e-10	Aortic root size;
LUAD	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg08632164	chr7:65971372	NA	-0.55	-6.37	-0.3	4.93e-10	Diabetic kidney disease;
LUAD	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.66	-0.31	8.53e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs7317038	0.643	rs4907625	chr13:114023625	A/G	cg06648835	chr13:114024480	NA	0.34	6.89	0.32	1.98e-11	Mean platelet volume;
LUAD	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg18132916	chr6:79620363	NA	0.44	7.11	0.33	5.1e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg14829155	chr15:31115871	NA	-0.59	-10.02	-0.44	2.46e-21	Huntington's disease progression;
LUAD	cis	rs240764	0.817	rs12216304	chr6:101174161	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-7.54	-0.34	2.93e-13	Neuroticism;
LUAD	cis	rs6906287	0.647	rs3798420	chr6:118786486	T/C	cg05564266	chr6:118973597	C6orf204	0.33	7.06	0.32	7.02e-12	Electrocardiographic conduction measures;
LUAD	cis	rs8017423	0.967	rs55962513	chr14:90729460	C/G	cg14092571	chr14:90743983	NA	-0.48	-8.28	-0.37	1.68e-15	Mortality in heart failure;
LUAD	cis	rs9341808	0.667	rs12209624	chr6:80919133	G/A	cg08355045	chr6:80787529	NA	0.49	8.79	0.39	3.74e-17	Sitting height ratio;
LUAD	cis	rs2230307	0.572	rs11166408	chr1:100641350	A/T	cg20868668	chr1:100435035	SLC35A3	-0.52	-7.29	-0.33	1.5e-12	Carotid intima media thickness;
LUAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.67	-0.31	8.19e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg01620082	chr3:125678407	NA	-0.45	-6.71	-0.31	6.45e-11	Depression;
LUAD	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg23229984	chr5:148520753	ABLIM3	0.49	7.51	0.34	3.65e-13	Breast cancer;
LUAD	cis	rs738322	0.836	rs4821741	chr22:38514745	A/G	cg17652424	chr22:38574118	PLA2G6	-0.28	-8.17	-0.37	3.61e-15	Cutaneous nevi;
LUAD	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg09455208	chr3:40491958	NA	0.57	12.59	0.52	4.26e-31	Renal cell carcinoma;
LUAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg07402062	chr16:89894098	SPIRE2	-0.44	-11.46	-0.49	1.11e-26	Vitiligo;
LUAD	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.6	-0.35	1.86e-13	Total body bone mineral density;
LUAD	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-8.45	-0.38	4.85e-16	Alzheimer's disease (late onset);
LUAD	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14159672	chr1:205819179	PM20D1	-0.57	-10.13	-0.44	1e-21	Menarche (age at onset);
LUAD	cis	rs239198	0.602	rs9377240	chr6:101323752	C/T	cg09795085	chr6:101329169	ASCC3	0.42	7.03	0.32	8.32e-12	Menarche (age at onset);
LUAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg05313129	chr8:58192883	C8orf71	-0.6	-7.46	-0.34	5.08e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg21475434	chr5:93447410	FAM172A	-0.47	-6.36	-0.3	5.1e-10	Diabetic retinopathy;
LUAD	cis	rs208520	0.690	rs864314	chr6:66814830	G/A	cg07460842	chr6:66804631	NA	-1.24	-31.84	-0.84	2.21e-114	Exhaled nitric oxide output;
LUAD	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	3.96e-11	Depression;
LUAD	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg27170947	chr2:26402098	FAM59B	-0.54	-7.78	-0.35	5.69e-14	Gut microbiome composition (summer);
LUAD	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.47	7.54	0.34	2.98e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7527798	0.592	rs960086	chr1:207827069	A/G	cg09232269	chr1:207846808	CR1L	-0.37	-7.07	-0.33	6.44e-12	Erythrocyte sedimentation rate;
LUAD	trans	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg05926928	chr17:57297772	GDPD1	0.5	7.61	0.35	1.75e-13	Schizophrenia;
LUAD	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg10556349	chr10:835070	NA	0.55	6.94	0.32	1.46e-11	Eosinophil percentage of granulocytes;
LUAD	trans	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg24644049	chr4:85504048	CDS1	0.86	7.78	0.35	5.78e-14	Skin colour saturation;
LUAD	cis	rs934734	0.752	rs268136	chr2:65607543	C/T	cg11674355	chr2:65610261	SPRED2	0.36	6.37	0.3	5.01e-10	Rheumatoid arthritis;
LUAD	cis	rs9948	0.521	rs61750875	chr2:97359364	A/G	cg20312557	chr2:97357134	FER1L5	-0.51	-6.46	-0.3	2.93e-10	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg02371401	chr5:676784	TPPP	-0.48	-7.83	-0.36	3.9e-14	Lung disease severity in cystic fibrosis;
LUAD	cis	rs2067615	0.599	rs3759310	chr12:107166122	C/G	cg15890332	chr12:107067104	RFX4	0.38	8.21	0.37	2.7e-15	Heart rate;
LUAD	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg03929089	chr4:120376271	NA	-0.52	-7.64	-0.35	1.45e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs11167764	0.895	rs891986	chr5:141466080	C/G	cg23435118	chr5:141488016	NDFIP1	-0.47	-6.95	-0.32	1.39e-11	Crohn's disease;
LUAD	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg09654669	chr8:57350985	NA	-0.64	-10.0	-0.44	2.8e-21	Obesity-related traits;
LUAD	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg04944784	chr2:26401820	FAM59B	0.88	12.13	0.51	2.99e-29	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg22535103	chr8:58192502	C8orf71	-0.72	-8.81	-0.39	3.25e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg05283184	chr6:79620031	NA	-0.55	-11.04	-0.47	4.6e-25	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-20.31	-0.7	1.58e-64	Height;
LUAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg07677032	chr17:61819896	STRADA	0.58	10.68	0.46	1e-23	Prudent dietary pattern;
LUAD	cis	rs76878669	0.516	rs7104570	chr11:66159098	A/G	cg18002602	chr11:66138449	SLC29A2	0.48	10.42	0.45	9.01e-23	Educational attainment (years of education);
LUAD	cis	rs7241530	0.636	rs11873523	chr18:75897751	G/A	cg14642773	chr18:75888474	NA	0.35	6.35	0.3	5.46e-10	Educational attainment (years of education);
LUAD	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg24848339	chr3:12840334	CAND2	0.42	8.4	0.38	6.63e-16	QRS complex (12-leadsum);
LUAD	trans	rs199950	0.915	rs4651109	chr1:181569891	G/T	cg24508471	chr22:30935971	NA	-0.36	-6.58	-0.3	1.4e-10	Body mass index (change over time);
LUAD	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg26924012	chr15:45694286	SPATA5L1	0.58	9.8	0.43	1.46e-20	Response to fenofibrate (adiponectin levels);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg17597744	chr8:53627099	RB1CC1	-0.72	-6.81	-0.31	3.28e-11	Type 2 diabetes;
LUAD	cis	rs7614311	0.681	rs6796317	chr3:63927739	A/G	cg22134162	chr3:63841271	THOC7	-0.52	-8.65	-0.39	1.05e-16	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs6743376	0.556	rs6733859	chr2:113819382	C/T	cg09040174	chr2:113837401	NA	0.51	7.96	0.36	1.61e-14	Inflammatory biomarkers;
LUAD	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg25173405	chr17:45401733	C17orf57	-0.41	-6.62	-0.31	1.1e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2019216	0.542	rs1850564	chr17:21911794	T/C	cg22648282	chr17:21454238	C17orf51	-0.45	-8.01	-0.36	1.08e-14	Pelvic organ prolapse;
LUAD	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg23435118	chr5:141488016	NDFIP1	-0.5	-7.72	-0.35	8.7e-14	Crohn's disease;
LUAD	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.31	-6.8	-0.31	3.56e-11	Dupuytren's disease;
LUAD	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg02990361	chr1:107599529	PRMT6	-0.64	-10.8	-0.46	3.47e-24	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg24813613	chr7:1882135	MAD1L1	-0.42	-6.85	-0.32	2.68e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs28735056	0.846	rs12958903	chr18:77628996	A/G	cg05926928	chr17:57297772	GDPD1	0.5	7.37	0.34	8.96e-13	Schizophrenia;
LUAD	cis	rs9283706	0.607	rs10471696	chr5:66304823	T/C	cg11590213	chr5:66331682	MAST4	0.42	6.82	0.31	3.16e-11	Coronary artery disease;
LUAD	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg00647820	chr17:40259828	DHX58	-0.45	-7.2	-0.33	2.75e-12	Fibrinogen levels;
LUAD	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg23262073	chr20:60523788	NA	-0.36	-6.4	-0.3	4.04e-10	Body mass index;
LUAD	trans	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg07211511	chr3:129823064	LOC729375	-0.53	-7.49	-0.34	4.08e-13	Blood pressure (smoking interaction);
LUAD	trans	rs11039798	1.000	rs7942042	chr11:48520270	A/G	cg03929089	chr4:120376271	NA	0.57	6.46	0.3	2.88e-10	Axial length;
LUAD	cis	rs6701037	1.000	rs6677097	chr1:175123897	C/G	cg00321850	chr1:175162397	KIAA0040	-0.49	-10.47	-0.45	5.85e-23	Alcohol dependence;
LUAD	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05901451	chr6:126070800	HEY2	-0.79	-14.42	-0.57	1.23e-38	Brugada syndrome;
LUAD	cis	rs7043114	0.507	rs7037075	chr9:95216613	G/A	cg14631576	chr9:95140430	CENPP	-0.42	-8.62	-0.39	1.32e-16	Height;
LUAD	cis	rs1003719	0.788	rs2040341	chr21:38489753	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.47	0.38	4.01e-16	Eye color traits;
LUAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-7.92	-0.36	2.12e-14	Neutrophil percentage of white cells;
LUAD	cis	rs12579753	0.871	rs10862362	chr12:82199383	T/G	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.28	-0.33	1.6e-12	Resting heart rate;
LUAD	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg02018176	chr4:1364513	KIAA1530	0.37	6.45	0.3	3.02e-10	Obesity-related traits;
LUAD	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg25173405	chr17:45401733	C17orf57	0.47	7.91	0.36	2.35e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg04287289	chr16:89883240	FANCA	0.82	7.27	0.33	1.72e-12	Skin colour saturation;
LUAD	cis	rs11051970	0.636	rs1128591	chr12:32569351	T/C	cg24626660	chr12:32551988	NA	0.34	7.17	0.33	3.46e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg15181151	chr6:150070149	PCMT1	0.4	8.23	0.37	2.36e-15	Lung cancer;
LUAD	cis	rs3845702	0.736	rs72960664	chr2:180832672	C/T	cg01881094	chr2:180872142	CWC22	0.78	8.16	0.37	4.01e-15	Schizophrenia;
LUAD	cis	rs6684514	0.961	rs10908501	chr1:156285513	G/T	cg16558208	chr1:156270281	VHLL	0.53	9.78	0.43	1.66e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.43	-6.82	-0.31	3.23e-11	Alzheimer's disease (late onset);
LUAD	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg10544611	chr16:67998164	SLC12A4	-0.69	-8.21	-0.37	2.79e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12016809	chr21:47604291	C21orf56	0.53	7.49	0.34	4.12e-13	Testicular germ cell tumor;
LUAD	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.35	7.01	0.32	9.42e-12	Obesity-related traits;
LUAD	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg18306943	chr3:40428807	ENTPD3	-0.4	-7.09	-0.33	5.61e-12	Renal cell carcinoma;
LUAD	cis	rs899997	0.773	rs11072784	chr15:78966058	T/C	cg04896959	chr15:78267971	NA	0.51	8.05	0.36	8.68e-15	Coronary artery disease or large artery stroke;
LUAD	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg22963979	chr7:1858916	MAD1L1	-0.48	-8.52	-0.38	2.86e-16	Bipolar disorder and schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26270411	chr20:43514327	YWHAB	-0.6	-7.31	-0.33	1.32e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12478296	1.000	rs66612947	chr2:243035962	A/T	cg06360820	chr2:242988706	NA	-0.86	-9.67	-0.43	3.98e-20	Obesity-related traits;
LUAD	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.89	-0.32	2.06e-11	Retinal vascular caliber;
LUAD	cis	rs7937890	0.631	rs7118886	chr11:14427517	T/C	cg02251663	chr11:14281053	SPON1	-0.34	-6.56	-0.3	1.62e-10	Mitochondrial DNA levels;
LUAD	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.35	-7.41	-0.34	6.85e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-15.42	-0.6	6.59e-43	Chronic sinus infection;
LUAD	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg04155289	chr7:94953770	PON1	-0.52	-7.02	-0.32	8.71e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs174601	0.861	rs174584	chr11:61610750	G/A	cg21709803	chr11:61594965	FADS2	-0.35	-6.5	-0.3	2.26e-10	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg08807101	chr21:30365312	RNF160	0.44	7.65	0.35	1.39e-13	Dental caries;
LUAD	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06028808	chr11:68637592	NA	0.43	6.9	0.32	1.96e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.02	0.32	8.93e-12	Motion sickness;
LUAD	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.66	0.31	8.79e-11	Parkinson's disease;
LUAD	trans	rs9951602	0.512	rs9946115	chr18:76654531	A/C	cg02800362	chr5:177631904	HNRNPAB	0.91	14.57	0.58	3.06e-39	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.87	-0.36	3e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg06112835	chr11:68658793	MRPL21	0.47	8.35	0.38	1e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg08601574	chr20:25228251	PYGB	0.49	8.99	0.4	8.08e-18	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2274273	0.682	rs8008134	chr14:55507520	T/C	cg04306507	chr14:55594613	LGALS3	0.33	6.75	0.31	4.92e-11	Protein biomarker;
LUAD	cis	rs4713118	0.619	rs200486	chr6:27779506	C/T	cg08798685	chr6:27730294	NA	-0.44	-6.62	-0.31	1.06e-10	Parkinson's disease;
LUAD	trans	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg03886242	chr7:26192032	NFE2L3	-0.47	-8.17	-0.37	3.62e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg01868782	chr6:126071099	HEY2	0.31	6.47	0.3	2.77e-10	Brugada syndrome;
LUAD	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg04218760	chr10:45406644	TMEM72	-0.32	-8.04	-0.36	9e-15	Mean corpuscular volume;
LUAD	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg18277682	chr1:228362509	C1orf69	-0.39	-6.53	-0.3	1.91e-10	Diastolic blood pressure;
LUAD	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg09658497	chr7:2847517	GNA12	-0.54	-9.15	-0.41	2.42e-18	Height;
LUAD	cis	rs2445762	0.600	rs12148492	chr15:51653193	A/C	cg20344442	chr15:51633704	GLDN	-0.36	-6.37	-0.3	4.93e-10	Hormone measurements;
LUAD	cis	rs7107174	1.000	rs10899457	chr11:78001163	T/A	cg02023728	chr11:77925099	USP35	0.48	7.34	0.34	1.09e-12	Testicular germ cell tumor;
LUAD	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg10755058	chr3:40428713	ENTPD3	0.46	8.54	0.38	2.44e-16	Renal cell carcinoma;
LUAD	trans	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg00953403	chr17:74099816	EXOC7	-0.44	-6.88	-0.32	2.12e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs1113500	0.897	rs4628530	chr1:108638708	T/G	cg06207961	chr1:108661230	NA	0.45	8.42	0.38	5.94e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg00255919	chr5:131827918	IRF1	-0.3	-6.6	-0.31	1.2e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06022373	chr22:39101656	GTPBP1	0.48	7.89	0.36	2.68e-14	Menopause (age at onset);
LUAD	cis	rs7851660	0.844	rs907581	chr9:100622189	A/G	cg13688889	chr9:100608707	NA	-0.5	-8.46	-0.38	4.51e-16	Strep throat;
LUAD	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.82	-0.31	3.17e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg04565464	chr8:145669602	NFKBIL2	0.43	6.37	0.3	5.02e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs11030122	0.702	rs7950153	chr11:3951337	T/C	cg18678763	chr11:4115507	RRM1	-0.42	-7.15	-0.33	3.95e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs8049603	0.812	rs4073931	chr16:23195717	C/T	cg09552652	chr16:23197569	SCNN1G	0.36	6.4	0.3	4.12e-10	Multiple sclerosis;
LUAD	cis	rs9863	0.896	rs12829951	chr12:124425841	A/G	cg17723958	chr12:124429295	CCDC92	-0.44	-7.13	-0.33	4.39e-12	White blood cell count;
LUAD	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg26384229	chr12:38710491	ALG10B	0.44	7.21	0.33	2.66e-12	Bladder cancer;
LUAD	cis	rs713477	0.967	rs6573031	chr14:55913763	C/G	cg13175173	chr14:55914753	NA	-0.35	-7.4	-0.34	7.41e-13	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs513349	0.964	rs210141	chr6:33546825	T/C	cg07679836	chr6:33548423	BAK1	0.47	9.1	0.4	3.56e-18	Platelet count;
LUAD	cis	rs4953076	0.573	rs6726680	chr2:44406686	C/G	cg04920474	chr2:44395004	PPM1B	0.54	8.35	0.38	9.61e-16	Height;
LUAD	cis	rs73206853	0.764	rs7312139	chr12:110985442	C/A	cg12870014	chr12:110450643	ANKRD13A	0.63	7.05	0.32	7.46e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs2816062	0.813	rs2816053	chr1:18895819	A/G	cg18795169	chr1:18902165	NA	-0.92	-21.82	-0.73	2.98e-71	Urate levels in lean individuals;
LUAD	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg16482183	chr6:26056742	HIST1H1C	0.45	6.53	0.3	1.93e-10	Iron status biomarkers;
LUAD	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.01	-0.36	1.14e-14	Diabetic kidney disease;
LUAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg24642844	chr7:1081250	C7orf50	-0.83	-12.64	-0.52	2.82e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs71478720	1.000	rs3882892	chr11:112014986	C/T	cg04929355	chr11:112034997	IL18	0.45	6.88	0.32	2.13e-11	Interleukin-18 levels;
LUAD	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg05717871	chr11:638507	DRD4	-0.4	-6.35	-0.3	5.42e-10	Systemic lupus erythematosus;
LUAD	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg15448220	chr1:150897856	SETDB1	0.53	9.09	0.4	3.9e-18	Melanoma;
LUAD	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg10876282	chr6:28092338	ZSCAN16	0.42	6.42	0.3	3.74e-10	Parkinson's disease;
LUAD	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg18138036	chr10:133769891	PPP2R2D	0.44	6.88	0.32	2.12e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs7731657	0.537	rs4705997	chr5:130356026	C/A	cg08523029	chr5:130500466	HINT1	0.58	7.58	0.35	2.22e-13	Fasting plasma glucose;
LUAD	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-6.72	-0.31	5.8e-11	Bladder cancer;
LUAD	cis	rs739496	0.615	rs7977828	chr12:112094766	A/G	cg10833066	chr12:111807467	FAM109A	0.44	7.14	0.33	4.04e-12	Platelet count;
LUAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg21724239	chr8:58056113	NA	0.7	7.74	0.35	7.49e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg17366294	chr4:99064904	C4orf37	-0.55	-9.34	-0.41	5.38e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4493873	0.869	rs10095065	chr8:92089473	T/C	cg16814680	chr8:91681699	NA	0.41	6.62	0.31	1.12e-10	Migraine - clinic-based;
LUAD	cis	rs12681287	0.640	rs13256765	chr8:87457833	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-9.59	-0.42	7.69e-20	Caudate activity during reward;
LUAD	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg02931644	chr1:25747376	RHCE	0.41	8.46	0.38	4.4e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs71478720	0.953	rs11606049	chr11:112033129	C/T	cg04929355	chr11:112034997	IL18	0.44	6.87	0.32	2.37e-11	Interleukin-18 levels;
LUAD	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg03983476	chr2:10830698	NOL10	-0.47	-8.1	-0.37	5.86e-15	Prostate cancer;
LUAD	cis	rs938554	0.692	rs13125209	chr4:9982044	A/C	cg00071950	chr4:10020882	SLC2A9	0.52	8.17	0.37	3.5e-15	Blood metabolite levels;
LUAD	cis	rs11677370	0.561	rs13015012	chr2:3821252	C/G	cg17052675	chr2:3827356	NA	0.58	9.94	0.44	4.58e-21	Type 2 diabetes;
LUAD	trans	rs2840044	1.000	rs7212704	chr17:33898897	C/T	cg19694781	chr19:47549865	TMEM160	0.64	10.37	0.45	1.29e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	trans	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.32	0.54	4.65e-34	Exhaled nitric oxide output;
LUAD	cis	rs752010	0.714	rs6658500	chr1:42088344	A/G	cg06885757	chr1:42089581	HIVEP3	-0.47	-10.9	-0.47	1.52e-24	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg17264618	chr3:40429014	ENTPD3	-0.4	-8.41	-0.38	6.25e-16	Renal cell carcinoma;
LUAD	cis	rs17092148	0.636	rs17122844	chr20:33452600	C/T	cg16810054	chr20:33298113	TP53INP2	0.38	6.91	0.32	1.79e-11	Neuroticism;
LUAD	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg06002616	chr8:101225028	SPAG1	-0.38	-7.86	-0.36	3.28e-14	Atrioventricular conduction;
LUAD	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg09658497	chr7:2847517	GNA12	-0.55	-9.38	-0.41	4.11e-19	Height;
LUAD	cis	rs1784581	0.721	rs9365356	chr6:162414789	A/G	cg17173639	chr6:162384350	PARK2	0.49	9.07	0.4	4.47e-18	Itch intensity from mosquito bite;
LUAD	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.43	0.52	1.87e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08879724	chr3:156893035	NA	-0.39	-6.61	-0.31	1.19e-10	Cancer;
LUAD	cis	rs11696501	0.688	rs11696685	chr20:44295134	A/G	cg11783356	chr20:44313418	WFDC10B	-0.47	-7.61	-0.35	1.84e-13	Brain structure;
LUAD	cis	rs35883536	0.647	rs10875314	chr1:101043207	G/C	cg06223162	chr1:101003688	GPR88	-0.46	-8.97	-0.4	9.34e-18	Monocyte count;
LUAD	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.04e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg00814883	chr7:100076585	TSC22D4	-0.82	-11.68	-0.49	1.64e-27	Platelet count;
LUAD	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.16	0.33	3.56e-12	Motion sickness;
LUAD	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg19875535	chr5:140030758	IK	0.47	7.99	0.36	1.28e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs2742417	1.000	rs2673065	chr3:45771222	C/T	cg10512202	chr3:45649293	LIMD1	0.36	6.39	0.3	4.39e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg19767477	chr5:127420684	SLC12A2	-0.41	-6.4	-0.3	4.09e-10	Ileal carcinoids;
LUAD	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg04414720	chr1:150670196	GOLPH3L	0.72	13.15	0.54	2.3e-33	Tonsillectomy;
LUAD	cis	rs7043114	0.525	rs8067	chr9:95218829	G/T	cg14631576	chr9:95140430	CENPP	-0.42	-8.62	-0.39	1.32e-16	Height;
LUAD	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.01	0.36	1.11e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs80319144	0.953	rs74504705	chr2:159165286	T/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.65	0.31	9.06e-11	Restless legs syndrome;
LUAD	cis	rs7009516	0.819	rs12682329	chr8:24220798	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.42	-8.47	-0.38	4.11e-16	Hair greying;
LUAD	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg05182265	chr7:156933206	UBE3C	-0.81	-17.42	-0.65	1.26e-51	Body mass index;
LUAD	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg17425144	chr1:10567563	PEX14	-0.6	-12.49	-0.52	1.07e-30	Prostate cancer;
LUAD	cis	rs9443645	0.507	rs9352633	chr6:79462623	C/G	cg11833968	chr6:79620685	NA	-0.39	-7.04	-0.32	8.01e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg01200585	chr1:228362443	C1orf69	0.42	6.82	0.31	3.17e-11	Diastolic blood pressure;
LUAD	cis	rs6665290	0.835	rs7549586	chr1:227214566	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-32.02	-0.84	4.16e-115	Myeloid white cell count;
LUAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.64	8.72	0.39	6.54e-17	Renal function-related traits (BUN);
LUAD	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.64	0.31	9.36e-11	Depression;
LUAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-6.87	-0.32	2.29e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.12	-0.54	3.15e-33	Breast cancer;
LUAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.31e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11958404	0.932	rs72816584	chr5:157433190	G/A	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs7727544	0.584	rs7714191	chr5:131341541	C/G	cg14196790	chr5:131705035	SLC22A5	0.42	7.31	0.34	1.31e-12	Blood metabolite levels;
LUAD	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs6545883	0.831	rs2592356	chr2:61810428	G/C	cg15711740	chr2:61764176	XPO1	-0.41	-6.56	-0.3	1.6e-10	Tuberculosis;
LUAD	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06873352	chr17:61820015	STRADA	0.52	8.44	0.38	5.01e-16	Height;
LUAD	cis	rs208520	0.690	rs207108	chr6:66794096	T/C	cg07460842	chr6:66804631	NA	-1.06	-16.63	-0.63	3.97e-48	Exhaled nitric oxide output;
LUAD	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg18944383	chr4:111397179	ENPEP	-0.37	-7.07	-0.33	6.63e-12	Coronary artery disease;
LUAD	trans	rs9467711	0.591	rs13206501	chr6:26110148	T/C	cg06606381	chr12:133084897	FBRSL1	-0.67	-6.71	-0.31	6.27e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg03806693	chr22:41940476	POLR3H	-0.58	-8.78	-0.39	3.96e-17	Vitiligo;
LUAD	cis	rs3820068	0.705	rs4646110	chr1:15817318	A/T	cg13390004	chr1:15929781	NA	0.43	6.85	0.32	2.63e-11	Systolic blood pressure;
LUAD	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.03	-0.36	9.69e-15	Diabetic kidney disease;
LUAD	trans	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg03929089	chr4:120376271	NA	-0.47	-7.26	-0.33	1.82e-12	HDL cholesterol;
LUAD	cis	rs12545109	0.879	rs893234	chr8:57363885	G/A	cg19413350	chr8:57351067	NA	-0.47	-7.08	-0.33	6.19e-12	Obesity-related traits;
LUAD	cis	rs9788682	0.747	rs2568485	chr15:78752114	C/T	cg18825076	chr15:78729989	IREB2	-0.55	-7.85	-0.36	3.52e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs4891159	0.790	rs17059379	chr18:74160316	A/T	cg24786174	chr18:74118243	ZNF516	0.77	14.39	0.57	1.64e-38	Longevity;
LUAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg16414030	chr3:133502952	NA	-0.73	-14.48	-0.58	7.33e-39	Iron status biomarkers;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg18393173	chr6:34856135	ANKS1A;TAF11	0.41	6.55	0.3	1.67e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6685188	0.843	rs1775139	chr1:205672357	C/G	cg14159672	chr1:205819179	PM20D1	0.41	6.71	0.31	6.16e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs12681288	0.748	rs2701932	chr8:1026946	C/G	cg15309053	chr8:964076	NA	0.39	8.14	0.37	4.34e-15	Schizophrenia;
LUAD	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg15485101	chr11:133734466	NA	0.34	7.69	0.35	1.05e-13	Childhood ear infection;
LUAD	cis	rs1904096	0.506	rs2632412	chr4:95149319	A/C	cg11021082	chr4:95130006	SMARCAD1	0.5	8.73	0.39	5.94e-17	Type 2 diabetes;
LUAD	cis	rs2718058	0.519	rs2722242	chr7:37873610	A/G	cg15028436	chr7:37888078	TXNDC3	-0.34	-7.13	-0.33	4.24e-12	Alzheimer's disease (late onset);
LUAD	cis	rs4253772	0.872	rs14843	chr22:46639462	A/T	cg09491104	chr22:46646882	C22orf40	-0.51	-6.99	-0.32	1.11e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg10295955	chr4:187884368	NA	-1.17	-30.82	-0.83	3.54e-110	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18402987	chr7:1209562	NA	0.43	6.99	0.32	1.09e-11	Longevity;Endometriosis;
LUAD	cis	rs55665837	0.540	rs10766192	chr11:14811686	A/G	cg19336497	chr11:14380999	RRAS2	-0.4	-7.48	-0.34	4.41e-13	Vitamin D levels;
LUAD	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg17173187	chr15:85201210	NMB	0.54	9.5	0.42	1.6e-19	Schizophrenia;
LUAD	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg00255919	chr5:131827918	IRF1	-0.28	-6.51	-0.3	2.12e-10	Blood metabolite levels;
LUAD	cis	rs1034435	0.755	rs6007871	chr22:48894392	C/G	cg05992904	chr22:48892994	FAM19A5	-0.73	-16.03	-0.61	1.65e-45	Late-onset Alzheimer's disease;
LUAD	trans	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg06606381	chr12:133084897	FBRSL1	-0.54	-7.39	-0.34	7.79e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg00717180	chr2:96193071	NA	-0.36	-6.44	-0.3	3.18e-10	Coronary artery disease;
LUAD	cis	rs7680126	0.633	rs28378345	chr4:10209897	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.76	-0.31	4.65e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-7.25	-0.33	2e-12	Bipolar disorder;
LUAD	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg23029597	chr12:123009494	RSRC2	-0.58	-9.01	-0.4	7.37e-18	Body mass index;
LUAD	cis	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg05084668	chr3:125655381	ALG1L	-0.58	-9.25	-0.41	1.15e-18	Blood pressure (smoking interaction);
LUAD	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg15445000	chr17:37608096	MED1	-0.44	-8.21	-0.37	2.73e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg23018236	chr17:30244563	NA	0.59	6.74	0.31	5.29e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg23803603	chr1:2058230	PRKCZ	-0.39	-6.61	-0.31	1.13e-10	Height;
LUAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.67	-12.47	-0.52	1.27e-30	Prudent dietary pattern;
LUAD	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg19610905	chr11:61596333	FADS2	-0.68	-11.07	-0.47	3.46e-25	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg08798685	chr6:27730294	NA	-0.46	-6.68	-0.31	7.61e-11	Depression;
LUAD	cis	rs8060686	0.516	rs7184821	chr16:68270229	T/C	cg05110241	chr16:68378359	PRMT7	-0.61	-7.87	-0.36	3e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg21191810	chr6:118973309	C6orf204	-0.53	-8.04	-0.36	9.13e-15	Diastolic blood pressure;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27090007	chr13:28519388	ATP5EP2	-0.56	-7.16	-0.33	3.53e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg25817165	chr18:72167213	CNDP2	-0.7	-10.0	-0.44	2.79e-21	Refractive error;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg17291625	chr16:236080	NA	-0.39	-6.35	-0.3	5.57e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg24675056	chr1:15929824	NA	0.47	8.21	0.37	2.75e-15	Systolic blood pressure;
LUAD	cis	rs4076764	0.515	rs4657268	chr1:163376507	A/T	cg06092702	chr1:163392909	NA	-0.28	-6.36	-0.3	5.14e-10	Motion sickness;
LUAD	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg14186256	chr22:23484241	RTDR1	0.44	7.49	0.34	3.95e-13	Bone mineral density;
LUAD	cis	rs28374715	0.557	rs11855854	chr15:41434729	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.84	-14.18	-0.57	1.25e-37	Ulcerative colitis;
LUAD	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg20503657	chr10:835505	NA	-0.44	-6.81	-0.31	3.41e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs55788414	0.932	rs9921666	chr16:81181669	T/C	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.9	-0.36	2.46e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg22117172	chr7:91764530	CYP51A1	0.34	7.51	0.34	3.46e-13	Breast cancer;
LUAD	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg01874867	chr7:94954059	PON1	-0.5	-6.92	-0.32	1.69e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg00101154	chr16:420108	MRPL28	-0.43	-6.48	-0.3	2.56e-10	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs7527798	0.571	rs11118237	chr1:207818719	G/A	cg09232269	chr1:207846808	CR1L	-0.35	-6.44	-0.3	3.32e-10	Erythrocyte sedimentation rate;
LUAD	cis	rs9902453	0.765	rs2127001	chr17:28098219	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.61	-0.46	1.8e-23	Coffee consumption (cups per day);
LUAD	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.4	-7.35	-0.34	1.01e-12	IgG glycosylation;
LUAD	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg27535305	chr1:53392650	SCP2	0.46	9.22	0.41	1.39e-18	Monocyte count;
LUAD	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg23939001	chr4:940644	TMEM175	-0.51	-8.02	-0.36	1.03e-14	Parkinson's disease;
LUAD	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.3	-7.64	-0.35	1.44e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs7759001	0.857	rs2393931	chr6:27353114	T/C	cg18711553	chr6:27366782	ZNF391	0.39	6.43	0.3	3.36e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg11339718	chr16:89000225	CBFA2T3	0.35	7.06	0.32	6.66e-12	Social autistic-like traits;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02422812	chr5:154062204	NA	-0.42	-6.76	-0.31	4.56e-11	Height;
LUAD	trans	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg11693508	chr17:37793320	STARD3	0.58	7.23	0.33	2.29e-12	Neuroticism;
LUAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.25	-0.37	2.05e-15	Alzheimer's disease;
LUAD	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg17264618	chr3:40429014	ENTPD3	-0.41	-9.42	-0.42	2.98e-19	Renal cell carcinoma;
LUAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08677398	chr8:58056175	NA	0.49	6.94	0.32	1.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg03233332	chr7:66118400	NA	0.44	6.69	0.31	7.12e-11	Aortic root size;
LUAD	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg03808351	chr9:123631620	PHF19	0.41	6.64	0.31	9.59e-11	Birth weight;
LUAD	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.52	0.42	1.3e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg06611532	chr13:114900021	NA	0.38	8.98	0.4	9.08e-18	Schizophrenia;
LUAD	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg12310025	chr6:25882481	NA	-0.4	-6.54	-0.3	1.76e-10	Height;
LUAD	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg13685833	chr1:53393034	SCP2	-0.4	-6.52	-0.3	2.05e-10	Monocyte count;
LUAD	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg24818145	chr4:99064322	C4orf37	0.47	7.86	0.36	3.31e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2294693	0.634	rs9471470	chr6:41012991	A/T	cg14769373	chr6:40998127	UNC5CL	-0.45	-7.2	-0.33	2.7e-12	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs3760982	0.813	rs8104447	chr19:44293278	T/C	cg12072164	chr19:44306565	LYPD5	-0.41	-8.05	-0.36	8.61e-15	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg05966235	chr16:28915196	ATP2A1	0.47	7.61	0.35	1.75e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg06064525	chr11:970664	AP2A2	-0.53	-10.86	-0.47	2.05e-24	Alzheimer's disease (late onset);
LUAD	trans	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.17	-0.64	1.56e-50	Exhaled nitric oxide output;
LUAD	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.34	-7.28	-0.33	1.67e-12	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs701145	0.585	rs398512	chr3:153909988	T/C	cg14299572	chr10:34021103	NA	-0.4	-6.44	-0.3	3.28e-10	Coronary artery disease;
LUAD	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg12035532	chr1:1886765	KIAA1751	0.38	6.54	0.3	1.81e-10	Body mass index;
LUAD	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.66	0.31	8.31e-11	Depression;
LUAD	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.65	-9.72	-0.43	2.76e-20	IgG glycosylation;
LUAD	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg14582100	chr15:45693742	SPATA5L1	0.64	12.54	0.52	6.88e-31	Homoarginine levels;
LUAD	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21028142	chr17:79581711	NPLOC4	0.45	9.77	0.43	1.78e-20	Eye color traits;
LUAD	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg18180107	chr4:99064573	C4orf37	0.43	6.96	0.32	1.27e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs36051895	0.695	rs11794778	chr9:5023794	G/T	cg02405213	chr9:5042618	JAK2	-0.48	-6.64	-0.31	9.78e-11	Pediatric autoimmune diseases;
LUAD	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-8.4	-0.38	6.6e-16	Alzheimer's disease (late onset);
LUAD	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.67	-10.17	-0.44	7.24e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg00071950	chr4:10020882	SLC2A9	0.64	12.23	0.51	1.18e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg21918786	chr6:109611834	NA	-0.58	-10.91	-0.47	1.4e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs4380275	1.000	rs4359695	chr2:774214	G/C	cg21665850	chr2:731073	NA	0.5	8.94	0.4	1.24e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUAD	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg01874867	chr7:94954059	PON1	-0.52	-6.93	-0.32	1.55e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2386661	0.826	rs7073741	chr10:5671213	G/A	cg26603656	chr10:5671107	NA	0.4	6.98	0.32	1.18e-11	Breast cancer;
LUAD	cis	rs72949976	1.000	rs62186569	chr2:214034151	C/T	cg08319019	chr2:214017104	IKZF2	-0.51	-7.67	-0.35	1.18e-13	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs863345	0.604	rs12123305	chr1:158498955	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg27129171	chr3:47204927	SETD2	0.44	7.11	0.33	5.06e-12	Colorectal cancer;
LUAD	cis	rs41271951	0.512	rs12074309	chr1:151087827	T/C	cg11822372	chr1:151115635	SEMA6C	-0.82	-6.99	-0.32	1.05e-11	Blood protein levels;
LUAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18402987	chr7:1209562	NA	0.39	6.35	0.3	5.43e-10	Longevity;Endometriosis;
LUAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.56	-10.6	-0.46	2.01e-23	Longevity;Endometriosis;
LUAD	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.0	0.32	9.8e-12	Motion sickness;
LUAD	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg18200150	chr17:30822561	MYO1D	0.42	7.88	0.36	2.85e-14	Schizophrenia;
LUAD	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg13722127	chr7:150037890	RARRES2	0.5	8.61	0.39	1.48e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg12698349	chr2:225449008	CUL3	0.64	9.79	0.43	1.53e-20	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg04025307	chr7:1156635	C7orf50	0.69	12.39	0.52	2.65e-30	Longevity;Endometriosis;
LUAD	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.51	0.34	3.53e-13	Bipolar disorder;
LUAD	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg08280861	chr8:58055591	NA	0.64	8.29	0.37	1.49e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg04267008	chr7:1944627	MAD1L1	0.54	8.24	0.37	2.18e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg05368731	chr17:41323189	NBR1	0.97	20.3	0.7	1.77e-64	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9837602	0.683	rs9825882	chr3:99906250	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.56	-7.63	-0.35	1.58e-13	Breast cancer;
LUAD	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg17971929	chr21:40555470	PSMG1	0.53	8.25	0.37	2.07e-15	Cognitive function;
LUAD	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.21	-0.33	2.62e-12	Height;
LUAD	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg24130564	chr14:104152367	KLC1	-0.54	-9.67	-0.43	4.19e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2408955	0.521	rs10875753	chr12:48557141	C/T	cg04545296	chr12:48745243	ZNF641	0.31	8.09	0.37	6.33e-15	Glycated hemoglobin levels;
LUAD	cis	rs7267979	0.789	rs6076347	chr20:25398790	C/T	cg08601574	chr20:25228251	PYGB	-0.37	-7.0	-0.32	1.01e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg12645284	chr15:79092878	ADAMTS7	0.48	7.56	0.35	2.5e-13	Coronary artery disease or large artery stroke;
LUAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg06074448	chr4:187884817	NA	-0.41	-8.39	-0.38	7.45e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg21854759	chr1:92012499	NA	0.46	8.57	0.38	1.92e-16	Breast cancer;
LUAD	cis	rs4713118	1.000	rs13215072	chr6:27677728	A/G	cg26587870	chr6:27730563	NA	-0.4	-6.45	-0.3	2.98e-10	Parkinson's disease;
LUAD	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.53	-9.33	-0.41	6.16e-19	Axial length;
LUAD	cis	rs4481887	0.927	rs6666903	chr1:248465582	T/A	cg00666640	chr1:248458726	OR2T12	0.29	6.86	0.32	2.47e-11	Common traits (Other);
LUAD	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg22189786	chr22:42395067	WBP2NL	0.46	6.61	0.31	1.19e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs1595825	0.627	rs77353793	chr2:198470546	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.68	-0.31	7.63e-11	Ulcerative colitis;
LUAD	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg15181151	chr6:150070149	PCMT1	0.41	8.57	0.38	1.89e-16	Lung cancer;
LUAD	cis	rs11756438	0.572	rs1844964	chr6:119002528	C/T	cg21191810	chr6:118973309	C6orf204	0.48	9.27	0.41	9.58e-19	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg02527881	chr3:46936655	PTH1R	0.44	8.32	0.38	1.19e-15	Colorectal cancer;
LUAD	cis	rs6906287	0.647	rs4946350	chr6:118945433	A/C	cg05564266	chr6:118973597	C6orf204	0.37	7.67	0.35	1.21e-13	Electrocardiographic conduction measures;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16008918	chr4:78740080	CNOT6L	-0.4	-6.59	-0.31	1.32e-10	Cancer;
LUAD	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg01256987	chr12:42539512	GXYLT1	-0.34	-6.5	-0.3	2.32e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg18944383	chr4:111397179	ENPEP	0.37	7.43	0.34	6.25e-13	Height;
LUAD	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23221052	chr5:179740743	GFPT2	-0.67	-10.51	-0.46	4.02e-23	Height;
LUAD	cis	rs10744422	1.000	rs12255	chr12:123350204	C/T	cg16953816	chr12:123349952	VPS37B	0.63	7.07	0.33	6.31e-12	Schizophrenia;
LUAD	cis	rs7189233	1.000	rs7189819	chr16:53536345	C/T	cg04059762	chr16:53544020	NA	-0.43	-6.96	-0.32	1.28e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg25894440	chr7:65020034	NA	0.64	6.92	0.32	1.65e-11	Diabetic kidney disease;
LUAD	cis	rs6500395	1.000	rs12597928	chr16:48714366	G/A	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	8.07	0.37	7.1e-15	Rheumatoid arthritis;
LUAD	cis	rs79839061	0.636	rs73207778	chr4:836762	C/T	cg07828340	chr4:882639	GAK	1.07	9.56	0.42	9.9e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs3931020	0.657	rs277376	chr1:75242246	G/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.5	-6.7	-0.31	6.6e-11	Resistin levels;
LUAD	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg11062466	chr8:58055876	NA	0.55	7.48	0.34	4.32e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs1847202	0.859	rs13075769	chr3:72939295	C/T	cg25664220	chr3:72788482	NA	-0.46	-8.06	-0.36	7.94e-15	Motion sickness;
LUAD	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08048268	chr3:133502702	NA	-0.55	-10.74	-0.46	6e-24	Iron status biomarkers;
LUAD	cis	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg07460842	chr6:66804631	NA	0.62	9.71	0.43	3.03e-20	Type 2 diabetes;
LUAD	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg04944784	chr2:26401820	FAM59B	-0.71	-9.94	-0.43	4.77e-21	Gut microbiome composition (summer);
LUAD	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg24562669	chr7:97807699	LMTK2	0.33	7.9	0.36	2.44e-14	Breast cancer;
LUAD	cis	rs870825	0.932	rs2696059	chr4:185575127	A/T	cg04058563	chr4:185651563	MLF1IP	-0.65	-8.16	-0.37	3.76e-15	Blood protein levels;
LUAD	cis	rs7937890	0.532	rs2256884	chr11:14476402	A/T	cg23387056	chr11:14280742	SPON1	-0.34	-6.46	-0.3	2.88e-10	Mitochondrial DNA levels;
LUAD	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg26384229	chr12:38710491	ALG10B	0.43	7.12	0.33	4.7e-12	Bladder cancer;
LUAD	cis	rs17401966	1.000	rs12755094	chr1:10305711	T/C	cg15208524	chr1:10270712	KIF1B	0.55	8.23	0.37	2.33e-15	Hepatocellular carcinoma;
LUAD	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg09835421	chr16:68378352	PRMT7	-0.82	-8.83	-0.39	2.73e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs72928364	0.858	rs116833538	chr3:100777793	T/A	cg10123952	chr3:100791384	NA	0.46	6.38	0.3	4.62e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg19875535	chr5:140030758	IK	0.44	7.49	0.34	4.1e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.78	-10.1	-0.44	1.26e-21	Body mass index;
LUAD	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	7.6	0.35	1.92e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg03806693	chr22:41940476	POLR3H	0.61	8.92	0.4	1.39e-17	Vitiligo;
LUAD	cis	rs10821973	0.527	rs1432415	chr10:63975339	T/C	cg09941381	chr10:64027924	RTKN2	-0.34	-6.74	-0.31	5.22e-11	Hypothyroidism;
LUAD	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg25767906	chr1:53392781	SCP2	0.45	8.27	0.37	1.81e-15	Monocyte count;
LUAD	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.44	-0.42	2.44e-19	Life satisfaction;
LUAD	cis	rs6496044	0.568	rs2344436	chr15:86074906	C/T	cg13263323	chr15:86062960	AKAP13	-0.57	-10.6	-0.46	1.88e-23	Interstitial lung disease;
LUAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg10729496	chr3:10149963	C3orf24	0.64	9.56	0.42	9.9e-20	Alzheimer's disease;
LUAD	cis	rs15676	0.783	rs6478851	chr9:131561110	G/A	cg00228799	chr9:131580591	ENDOG	-0.47	-7.26	-0.33	1.9e-12	Blood metabolite levels;
LUAD	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg18854424	chr1:2615690	NA	0.43	9.55	0.42	1.05e-19	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs36051895	0.695	rs2183137	chr9:5026293	A/G	cg02405213	chr9:5042618	JAK2	-0.51	-7.08	-0.33	6.01e-12	Pediatric autoimmune diseases;
LUAD	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.33	0.38	1.1e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg22117172	chr7:91764530	CYP51A1	0.33	7.05	0.32	7.33e-12	Breast cancer;
LUAD	cis	rs6993813	0.620	rs6984675	chr8:120045227	T/G	cg01975934	chr8:119970761	NA	-0.34	-6.46	-0.3	2.88e-10	Bone mineral density (hip);
LUAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg14820908	chr5:178986412	RUFY1	0.62	10.77	0.46	4.61e-24	Lung cancer;
LUAD	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23158103	chr7:148848205	ZNF398	-0.61	-11.24	-0.48	8.18e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00475815	chr3:196594767	SENP5	-0.52	-6.37	-0.3	4.81e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10865541	1.000	rs10165099	chr2:3402591	T/C	cg22182287	chr2:3452347	TTC15	0.4	6.8	0.31	3.47e-11	Obesity-related traits;
LUAD	cis	rs13315871	1.000	rs9864824	chr3:58394835	A/G	cg20936604	chr3:58311152	NA	0.67	6.85	0.32	2.69e-11	Cholesterol, total;
LUAD	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg12310025	chr6:25882481	NA	-0.39	-6.37	-0.3	4.99e-10	Height;
LUAD	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg27426351	chr10:43362370	NA	-0.53	-8.12	-0.37	5e-15	Blood protein levels;
LUAD	cis	rs4917300	0.802	rs11167111	chr8:143097622	G/C	cg25363559	chr8:143086065	NA	-0.34	-6.64	-0.31	9.4e-11	Amyotrophic lateral sclerosis;
LUAD	cis	rs5756391	0.523	rs2049908	chr22:37311089	A/G	cg16356956	chr22:37317934	CSF2RB	0.35	7.57	0.35	2.38e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg25173405	chr17:45401733	C17orf57	-0.4	-6.55	-0.3	1.72e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4917300	0.605	rs10108708	chr8:143102886	A/G	cg25363559	chr8:143086065	NA	-0.47	-9.47	-0.42	1.98e-19	Amyotrophic lateral sclerosis;
LUAD	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23158103	chr7:148848205	ZNF398	-0.65	-12.06	-0.51	5.49e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg05340658	chr4:99064831	C4orf37	0.53	9.01	0.4	7.15e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg24578937	chr1:2090814	PRKCZ	-0.5	-9.91	-0.43	6.06e-21	Height;
LUAD	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Colorectal cancer;
LUAD	cis	rs910187	0.605	rs6018320	chr20:45804412	A/G	cg27589058	chr20:45804311	EYA2	-0.35	-7.98	-0.36	1.39e-14	Migraine;
LUAD	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg26022315	chr17:47021804	SNF8	0.42	7.71	0.35	9.28e-14	Type 2 diabetes;
LUAD	cis	rs2455799	0.613	rs4684259	chr3:15791279	G/A	cg16303742	chr3:15540471	COLQ	-0.52	-9.72	-0.43	2.83e-20	Mean platelet volume;
LUAD	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.04e-13	Morning vs. evening chronotype;
LUAD	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.68	-0.31	7.75e-11	Diabetic kidney disease;
LUAD	cis	rs2253017	0.767	rs4770070	chr13:21330776	G/A	cg27499820	chr13:21296301	IL17D	0.52	7.81	0.36	4.4e-14	PR segment;
LUAD	trans	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-15.18	-0.59	7.5e-42	Exhaled nitric oxide output;
LUAD	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.8	0.46	3.55e-24	Smoking behavior;
LUAD	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg24069376	chr3:38537580	EXOG	0.36	8.33	0.38	1.17e-15	Electrocardiographic conduction measures;
LUAD	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg05564831	chr3:52568323	NT5DC2	0.37	7.16	0.33	3.58e-12	Bipolar disorder;
LUAD	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg13319975	chr6:146136371	FBXO30	0.64	11.12	0.48	2.29e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7215564	0.908	rs34084509	chr17:78696577	C/A	cg09596252	chr17:78655493	RPTOR	0.66	6.88	0.32	2.11e-11	Myopia (pathological);
LUAD	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg22532475	chr10:104410764	TRIM8	-0.45	-8.86	-0.4	2.27e-17	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg20361540	chr12:123380447	VPS37B	-0.4	-6.55	-0.3	1.72e-10	Schizophrenia;
LUAD	cis	rs11811982	0.793	rs79235719	chr1:227510167	A/G	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs13315871	0.929	rs71311853	chr3:58319152	C/T	cg12435725	chr3:58293450	RPP14	-0.73	-7.72	-0.35	8.35e-14	Cholesterol, total;
LUAD	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg03433033	chr1:76189801	ACADM	0.8	13.01	0.53	8.83e-33	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6066835	1.000	rs56343427	chr20:47355273	C/T	cg18078177	chr20:47281410	PREX1	0.74	6.67	0.31	8.03e-11	Multiple myeloma;
LUAD	cis	rs1870323	0.527	rs610476	chr11:86184102	G/A	cg01663953	chr11:86133777	CCDC81	0.38	6.83	0.32	2.97e-11	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule);
LUAD	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.65	-0.49	2.13e-27	Bone mineral density;
LUAD	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg01191920	chr7:158217561	PTPRN2	0.57	11.86	0.5	3.29e-28	Obesity-related traits;
LUAD	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg19052272	chr2:3704530	ALLC	-0.42	-7.35	-0.34	1.05e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-7.03	-0.32	8.4e-12	IgG glycosylation;
LUAD	cis	rs78761021	0.867	rs17681738	chr17:9793240	C/T	cg26853458	chr17:9805074	RCVRN	0.35	6.74	0.31	5.12e-11	Type 2 diabetes;
LUAD	cis	rs1784581	0.588	rs7758559	chr6:162438635	G/T	cg17173639	chr6:162384350	PARK2	0.45	8.16	0.37	3.8e-15	Itch intensity from mosquito bite;
LUAD	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg06558623	chr16:89946397	TCF25	0.99	10.23	0.45	4.23e-22	Interleukin-17 levels;
LUAD	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.38	0.38	7.77e-16	Platelet count;
LUAD	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.73	0.31	5.49e-11	Colorectal cancer;
LUAD	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-10.12	-0.44	1.1e-21	Bone mineral density;
LUAD	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg01299579	chr2:10830716	NOL10	-0.43	-7.64	-0.35	1.45e-13	Prostate cancer;
LUAD	trans	rs2262909	0.962	rs439574	chr19:22232024	A/C	cg05197062	chr11:11642011	GALNTL4	-0.49	-7.89	-0.36	2.61e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs877282	0.842	rs35117541	chr10:764683	C/T	cg06581033	chr10:766294	NA	-0.59	-7.98	-0.36	1.39e-14	Uric acid levels;
LUAD	cis	rs1915146	0.656	rs10794201	chr10:126846531	C/T	cg05090351	chr10:126851162	NA	0.52	9.62	0.42	6.25e-20	Menarche (age at onset);
LUAD	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg10518543	chr12:38710700	ALG10B	-0.43	-7.05	-0.32	7.16e-12	Morning vs. evening chronotype;
LUAD	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.45	-0.34	5.33e-13	Electroencephalogram traits;
LUAD	cis	rs7776786	0.870	rs12540224	chr7:18830489	C/T	cg13420273	chr7:18810212	HDAC9	-0.32	-6.75	-0.31	4.96e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10865541	1.000	rs10165099	chr2:3402591	T/C	cg13173536	chr2:3403300	TTC15	-0.34	-6.57	-0.3	1.45e-10	Obesity-related traits;
LUAD	cis	rs62238980	0.614	rs4821023	chr22:32414413	G/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19626725	chr5:178986131	RUFY1	0.62	11.66	0.49	1.93e-27	Lung cancer;
LUAD	trans	rs587242	0.501	rs605401	chr1:97209880	A/T	cg10631902	chr5:14652156	NA	0.39	6.55	0.3	1.64e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg00383909	chr3:49044727	WDR6	0.98	10.41	0.45	9.22e-23	Cognitive function;
LUAD	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg18240062	chr17:79603768	NPLOC4	0.39	6.85	0.32	2.59e-11	Eye color traits;
LUAD	trans	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-10.18	-0.44	6.37e-22	Endometrial cancer;
LUAD	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg07870213	chr5:140052090	DND1	-0.67	-10.12	-0.44	1.03e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.68	12.05	0.51	6.03e-29	Cognitive ability;
LUAD	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg13010199	chr12:38710504	ALG10B	0.41	6.64	0.31	9.86e-11	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.89	0.53	2.7e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg02775129	chr4:119771670	NA	0.89	8.32	0.38	1.18e-15	Cannabis dependence symptom count;
LUAD	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg06046430	chr4:77819534	ANKRD56	0.55	8.91	0.4	1.52e-17	Emphysema distribution in smoking;
LUAD	cis	rs9902453	0.904	rs12936302	chr17:28349476	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.32	-0.45	2.02e-22	Coffee consumption (cups per day);
LUAD	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg08029281	chr1:67600428	NA	0.36	7.15	0.33	3.78e-12	Psoriasis;
LUAD	cis	rs939584	1.000	rs4429506	chr2:652576	C/A	cg03444855	chr2:621920	NA	-0.38	-6.36	-0.3	5.23e-10	Body mass index;
LUAD	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.58	-10.34	-0.45	1.74e-22	Homoarginine levels;
LUAD	cis	rs9372498	0.536	rs62422189	chr6:118907053	C/T	cg07617317	chr6:118971624	C6orf204	0.54	7.81	0.36	4.46e-14	Diastolic blood pressure;
LUAD	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg18232548	chr7:50535776	DDC	-0.73	-14.0	-0.56	7.46e-37	Systemic sclerosis;
LUAD	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.92	-0.5	1.91e-28	Electroencephalogram traits;
LUAD	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg09365446	chr1:150670422	GOLPH3L	0.61	10.91	0.47	1.39e-24	Melanoma;
LUAD	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-11.26	-0.48	6.7e-26	Hemoglobin concentration;
LUAD	cis	rs2625529	0.938	rs2742323	chr15:72116778	A/T	cg16672083	chr15:72433130	SENP8	0.73	12.33	0.51	4.53e-30	Red blood cell count;
LUAD	cis	rs9473147	0.543	rs9473119	chr6:47450618	G/A	cg20196966	chr6:47445060	CD2AP	0.41	6.35	0.3	5.55e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg24450063	chr1:156163899	SLC25A44	1.05	17.16	0.64	1.71e-50	Testicular germ cell tumor;
LUAD	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg03161606	chr19:29218774	NA	0.61	8.75	0.39	5.32e-17	Methadone dose in opioid dependence;
LUAD	cis	rs7072216	0.843	rs4400721	chr10:100147097	C/T	cg26618903	chr10:100175079	PYROXD2	-0.35	-7.2	-0.33	2.76e-12	Metabolite levels;
LUAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg18538332	chr22:24372958	LOC391322	-0.45	-7.31	-0.34	1.32e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg23982607	chr1:1823379	GNB1	-0.89	-18.27	-0.66	2.12e-55	Body mass index;
LUAD	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg09323728	chr8:95962352	TP53INP1	-0.32	-7.68	-0.35	1.09e-13	Type 2 diabetes;
LUAD	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-12.01	-0.5	8.63e-29	Bipolar disorder;
LUAD	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg19163074	chr7:65112434	INTS4L2	-0.45	-6.87	-0.32	2.37e-11	Aortic root size;
LUAD	cis	rs877282	0.898	rs12358513	chr10:757571	A/G	cg06581033	chr10:766294	NA	-0.56	-7.21	-0.33	2.57e-12	Uric acid levels;
LUAD	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.34	0.67	1.09e-55	Prudent dietary pattern;
LUAD	cis	rs2637266	0.935	rs2583049	chr10:78403962	T/C	cg18941641	chr10:78392320	NA	0.34	7.04	0.32	7.75e-12	Pulmonary function;
LUAD	cis	rs7107174	1.000	rs10899453	chr11:77997482	A/C	cg02023728	chr11:77925099	USP35	0.47	7.25	0.33	1.94e-12	Testicular germ cell tumor;
LUAD	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.02	0.32	8.9e-12	Hypertriglyceridemia;
LUAD	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	8.62	0.39	1.31e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs755249	0.501	rs2484133	chr1:39653994	T/C	cg27567593	chr1:39956653	BMP8A	-0.35	-6.57	-0.3	1.52e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg00310523	chr12:86230176	RASSF9	0.38	7.68	0.35	1.1e-13	Major depressive disorder;
LUAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06873352	chr17:61820015	STRADA	0.81	18.0	0.66	3.52e-54	Prudent dietary pattern;
LUAD	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg08601574	chr20:25228251	PYGB	-0.47	-8.89	-0.4	1.74e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg01620082	chr3:125678407	NA	-0.41	-6.43	-0.3	3.4e-10	Parkinson's disease;
LUAD	cis	rs7809950	0.954	rs2520243	chr7:107136973	T/C	cg23024343	chr7:107201750	COG5	-0.73	-12.39	-0.52	2.72e-30	Coronary artery disease;
LUAD	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03934478	chr11:495069	RNH1	0.75	8.97	0.4	1e-17	Body mass index;
LUAD	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.26	-0.54	8.68e-34	Alcohol dependence;
LUAD	cis	rs7493	0.950	rs11981299	chr7:95029701	T/A	cg04155289	chr7:94953770	PON1	-0.53	-7.03	-0.32	8.47e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19346786	chr7:2764209	NA	-0.52	-11.58	-0.49	4.06e-27	Height;
LUAD	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	9.35	0.41	5.01e-19	Melanoma;
LUAD	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg11814155	chr7:99998594	ZCWPW1	0.43	7.37	0.34	9.23e-13	Platelet count;
LUAD	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg06740227	chr12:86229804	RASSF9	0.44	7.67	0.35	1.22e-13	Major depressive disorder;
LUAD	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg08213375	chr14:104286397	PPP1R13B	0.28	7.22	0.33	2.43e-12	Schizophrenia;
LUAD	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg05872129	chr22:39784769	NA	-0.72	-11.76	-0.5	7.85e-28	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg04455712	chr21:45112962	RRP1B	-0.4	-8.07	-0.37	7.23e-15	Mean corpuscular volume;
LUAD	trans	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.02	0.5	7.62e-29	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7523875	0.516	rs6540683	chr1:211516262	G/A	cg25617285	chr1:211431773	RCOR3	-0.44	-7.61	-0.35	1.81e-13	Mean corpuscular volume;
LUAD	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06022373	chr22:39101656	GTPBP1	0.45	7.53	0.34	3.06e-13	Menopause (age at onset);
LUAD	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg27432699	chr2:27873401	GPN1	-0.59	-10.36	-0.45	1.45e-22	Oral cavity cancer;
LUAD	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg11062466	chr8:58055876	NA	0.68	8.79	0.39	3.8e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg15017067	chr4:17643749	FAM184B	0.36	7.04	0.32	7.63e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg02782426	chr3:40428986	ENTPD3	0.44	9.26	0.41	1.03e-18	Renal cell carcinoma;
LUAD	cis	rs3862030	0.720	rs11593971	chr10:104234090	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-8.09	-0.37	6.46e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg10295955	chr4:187884368	NA	-1.17	-30.81	-0.83	3.81e-110	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.61	10.72	0.46	7.05e-24	Birth weight;
LUAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg02869364	chr7:1081709	C7orf50	-0.36	-6.83	-0.32	2.88e-11	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg08085267	chr17:45401833	C17orf57	0.52	8.79	0.39	3.83e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg27411982	chr8:10470053	RP1L1	0.43	7.84	0.36	3.65e-14	Retinal vascular caliber;
LUAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08439880	chr3:133502540	NA	-0.43	-8.72	-0.39	6.52e-17	Iron status biomarkers;
LUAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg13047869	chr3:10149882	C3orf24	0.67	11.48	0.49	9.3e-27	Alzheimer's disease;
LUAD	cis	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg14348967	chr4:10160060	NA	-0.39	-6.48	-0.3	2.51e-10	Gout;Urate levels;Serum uric acid levels;
LUAD	trans	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg04775059	chr7:64541387	NA	0.52	6.79	0.31	3.83e-11	Aortic root size;
LUAD	cis	rs17433780	0.808	rs12125301	chr1:89508501	G/A	cg09516651	chr1:89888402	LOC400759	0.55	10.55	0.46	3e-23	Carotid intima media thickness;
LUAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg00080972	chr5:178986291	RUFY1	0.63	11.03	0.47	5.05e-25	Lung cancer;
LUAD	cis	rs7833986	1.000	rs56699713	chr8:57096670	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.66	9.12	0.41	3.07e-18	Height;
LUAD	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg02931644	chr1:25747376	RHCE	0.48	10.39	0.45	1.17e-22	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg02993280	chr1:107599747	PRMT6	0.53	8.71	0.39	6.93e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.24	-0.33	2.18e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg14343924	chr8:8086146	FLJ10661	-0.5	-7.78	-0.35	5.43e-14	Joint mobility (Beighton score);
LUAD	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18099408	chr3:52552593	STAB1	-0.46	-8.09	-0.37	6.6e-15	Bipolar disorder;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg18287962	chr20:25176437	ENTPD6	0.38	6.37	0.3	4.83e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg21775007	chr8:11205619	TDH	-0.5	-9.0	-0.4	7.51e-18	Retinal vascular caliber;
LUAD	cis	rs2302190	0.882	rs3809709	chr17:56590559	C/T	cg25885038	chr17:56607967	SEPT4	-0.51	-8.24	-0.37	2.14e-15	Vitamin D levels;
LUAD	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg18209359	chr17:80159595	CCDC57	0.4	6.93	0.32	1.61e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg11645453	chr3:52864694	ITIH4	0.36	6.45	0.3	3.14e-10	Bipolar disorder;
LUAD	cis	rs1018836	0.847	rs4735226	chr8:91569238	T/A	cg16814680	chr8:91681699	NA	-0.71	-12.25	-0.51	9.82e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs587242	1.000	rs552032	chr1:96895482	G/C	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	trans	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-8.89	-0.4	1.84e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg21153622	chr11:89784906	NA	-0.33	-6.56	-0.3	1.62e-10	Coronary artery disease;
LUAD	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg27490568	chr2:178487706	NA	0.44	7.52	0.34	3.37e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg12935359	chr14:103987150	CKB	-0.48	-7.93	-0.36	2.02e-14	Body mass index;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17187048	chr2:122407283	CLASP1	-0.49	-7.55	-0.34	2.72e-13	Height;
LUAD	cis	rs113835537	0.529	rs78999944	chr11:66251228	C/G	cg24851651	chr11:66362959	CCS	0.57	10.03	0.44	2.22e-21	Airway imaging phenotypes;
LUAD	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg18305652	chr10:134549665	INPP5A	0.62	11.85	0.5	3.61e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg24803719	chr17:45855879	NA	-0.34	-6.56	-0.3	1.58e-10	IgG glycosylation;
LUAD	cis	rs10193935	0.901	rs13413617	chr2:42537546	A/G	cg27598129	chr2:42591480	NA	-0.62	-8.16	-0.37	3.9e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03760483	chr17:6899297	ALOX12	0.34	6.56	0.3	1.53e-10	Tonsillectomy;
LUAD	cis	rs72772090	0.710	rs113710451	chr5:96060306	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-6.78	-0.31	4.05e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6543140	0.964	rs11886793	chr2:103072220	T/G	cg03938978	chr2:103052716	IL18RAP	0.35	6.8	0.31	3.6e-11	Blood protein levels;
LUAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg20607798	chr8:58055168	NA	0.66	8.66	0.39	1.02e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs13315871	1.000	rs9864325	chr3:58336846	A/C	cg20936604	chr3:58311152	NA	-0.67	-7.38	-0.34	8.28e-13	Cholesterol, total;
LUAD	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg18827107	chr12:86230957	RASSF9	-0.61	-10.51	-0.45	4.17e-23	Major depressive disorder;
LUAD	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07636037	chr3:49044803	WDR6	-0.47	-7.91	-0.36	2.24e-14	Menarche (age at onset);
LUAD	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg18196295	chr10:418757	DIP2C	0.39	6.38	0.3	4.62e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg17063962	chr7:91808500	NA	-0.68	-12.25	-0.51	9.82e-30	Breast cancer;
LUAD	cis	rs7617773	0.780	rs13085251	chr3:48340045	C/T	cg11946769	chr3:48343235	NME6	0.44	6.8	0.31	3.52e-11	Coronary artery disease;
LUAD	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg15448220	chr1:150897856	SETDB1	0.57	9.88	0.43	7.45e-21	Melanoma;
LUAD	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg10591111	chr5:226296	SDHA	-0.55	-7.14	-0.33	4.05e-12	Breast cancer;
LUAD	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02018176	chr4:1364513	KIAA1530	0.69	11.96	0.5	1.37e-28	Longevity;
LUAD	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg12573674	chr2:1569213	NA	-0.58	-6.73	-0.31	5.62e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs1003719	0.523	rs1063949	chr21:38574675	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.2	-0.37	2.89e-15	Eye color traits;
LUAD	cis	rs755249	0.588	rs2275767	chr1:39945297	C/T	cg27567593	chr1:39956653	BMP8A	0.35	7.15	0.33	3.75e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg13319975	chr6:146136371	FBXO30	-0.61	-10.4	-0.45	1.03e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg12205435	chr5:138714322	SLC23A1	-0.39	-6.68	-0.31	7.7e-11	Esophageal squamous cell carcinoma;
LUAD	cis	rs73198271	0.603	rs571130	chr8:8593691	A/G	cg01851573	chr8:8652454	MFHAS1	0.44	8.04	0.36	9.06e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg04154034	chr17:28927549	LRRC37B2	0.71	6.79	0.31	3.74e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10193935	0.901	rs997288	chr2:42525582	C/G	cg27598129	chr2:42591480	NA	-0.7	-8.99	-0.4	8.28e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg25817165	chr18:72167213	CNDP2	-0.73	-10.88	-0.47	1.75e-24	Refractive error;
LUAD	cis	rs3931020	0.657	rs277368	chr1:75230606	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.5	-6.55	-0.3	1.66e-10	Resistin levels;
LUAD	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg11494091	chr17:61959527	GH2	-0.73	-16.75	-0.63	1.12e-48	Prudent dietary pattern;
LUAD	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg23985595	chr17:80112537	CCDC57	-0.5	-9.13	-0.41	2.74e-18	Life satisfaction;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg23835894	chr22:30685664	GATSL3	0.44	6.99	0.32	1.07e-11	Diastolic blood pressure;
LUAD	cis	rs6906287	0.609	rs10457342	chr6:118948033	A/G	cg18833306	chr6:118973337	C6orf204	0.48	8.41	0.38	6.16e-16	Electrocardiographic conduction measures;
LUAD	cis	rs8060686	0.623	rs28700885	chr16:68154544	A/G	cg09835421	chr16:68378352	PRMT7	-0.52	-6.67	-0.31	7.88e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg09998033	chr7:158218633	PTPRN2	-0.44	-7.86	-0.36	3.26e-14	Obesity-related traits;
LUAD	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	7.76	0.35	6.23e-14	Menopause (age at onset);
LUAD	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg21252483	chr19:49399788	TULP2	-0.55	-7.69	-0.35	1.04e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs10465746	0.935	rs12758441	chr1:84352034	A/G	cg10977910	chr1:84465055	TTLL7	0.5	8.19	0.37	3.07e-15	Obesity-related traits;
LUAD	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg12292205	chr6:26970375	C6orf41	0.38	6.83	0.32	3.01e-11	Schizophrenia;
LUAD	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg21724239	chr8:58056113	NA	0.68	8.58	0.38	1.86e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg20203395	chr5:56204925	C5orf35	-0.82	-11.64	-0.49	2.35e-27	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg17366294	chr4:99064904	C4orf37	0.58	9.86	0.43	8.6e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2302190	0.882	rs3744111	chr17:56607959	G/A	cg25885038	chr17:56607967	SEPT4	-0.51	-8.29	-0.37	1.52e-15	Vitamin D levels;
LUAD	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg03714773	chr7:91764589	CYP51A1	0.27	6.46	0.3	2.89e-10	Breast cancer;
LUAD	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg00277334	chr10:82204260	NA	-0.52	-8.58	-0.38	1.85e-16	Post bronchodilator FEV1;
LUAD	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.74	-0.35	7.18e-14	Lung cancer;
LUAD	cis	rs1215050	0.791	rs13114823	chr4:98671119	G/A	cg17366294	chr4:99064904	C4orf37	-0.45	-7.94	-0.36	1.84e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs61884328	0.535	rs4647735	chr11:47253075	T/A	cg13308137	chr11:47528955	CUGBP1	0.43	6.85	0.32	2.66e-11	Total body bone mineral density (age over 60);
LUAD	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg19912559	chr1:40204330	PPIE	0.56	9.66	0.43	4.29e-20	Blood protein levels;
LUAD	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg22676075	chr6:135203613	NA	0.4	7.46	0.34	4.95e-13	Red blood cell count;
LUAD	cis	rs240764	0.658	rs9485410	chr6:101261007	A/G	cg09795085	chr6:101329169	ASCC3	0.45	8.07	0.37	7.48e-15	Neuroticism;
LUAD	cis	rs6500395	0.928	rs4785532	chr16:48695500	G/A	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.07e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg10295955	chr4:187884368	NA	-1.18	-30.7	-0.83	1.05e-109	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10129255	0.500	rs1974468	chr14:107142166	A/G	cg07958169	chr14:107095056	NA	-0.39	-7.73	-0.35	7.83e-14	Kawasaki disease;
LUAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.47	-7.47	-0.34	4.66e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10865541	0.869	rs4971499	chr2:3438749	C/G	cg22182287	chr2:3452347	TTC15	0.46	7.78	0.35	5.44e-14	Obesity-related traits;
LUAD	cis	rs7223966	0.584	rs76957877	chr17:61621330	C/T	cg11494091	chr17:61959527	GH2	0.38	6.52	0.3	1.99e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg22920501	chr2:26401640	FAM59B	0.78	10.21	0.44	5.06e-22	Gut microbiome composition (summer);
LUAD	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg26893861	chr17:41843967	DUSP3	-0.95	-14.77	-0.58	4.28e-40	Triglycerides;
LUAD	cis	rs1728785	0.901	rs11865339	chr16:68565296	C/T	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.3100000000000001e-10	Ulcerative colitis;
LUAD	cis	rs2573652	1.000	rs2573652	chr15:100514614	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.48	-8.4	-0.38	7.03e-16	Height;
LUAD	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg18306943	chr3:40428807	ENTPD3	0.39	6.75	0.31	4.88e-11	Renal cell carcinoma;
LUAD	cis	rs12681287	0.640	rs13252046	chr8:87477751	G/T	cg27223183	chr8:87520930	FAM82B	-0.67	-9.61	-0.42	6.38e-20	Caudate activity during reward;
LUAD	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-7.98	-0.36	1.35e-14	Electroencephalogram traits;
LUAD	cis	rs7665090	0.905	rs2866410	chr4:103554335	T/A	cg07973026	chr4:103553119	MANBA	0.49	8.73	0.39	6e-17	Primary biliary cholangitis;
LUAD	cis	rs754466	0.580	rs11002293	chr10:79537965	C/T	cg17075019	chr10:79541650	NA	-0.92	-19.79	-0.69	3.57e-62	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12348691	0.503	rs10983975	chr9:100614188	A/C	cg13688889	chr9:100608707	NA	-0.63	-10.31	-0.45	2.22e-22	Alopecia areata;
LUAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg18252515	chr7:66147081	NA	-0.62	-6.81	-0.31	3.45e-11	Diabetic kidney disease;
LUAD	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg23758822	chr17:41437982	NA	0.99	20.03	0.7	3.12e-63	Menopause (age at onset);
LUAD	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg23954153	chr1:44402353	ARTN	-0.39	-7.44	-0.34	5.56e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.3	6.44	0.3	3.29e-10	Depression;
LUAD	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg03467027	chr4:99064603	C4orf37	0.41	6.62	0.31	1.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg06108461	chr20:60628389	TAF4	-1.12	-20.51	-0.71	2.18e-65	Body mass index;
LUAD	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg11247378	chr22:39784982	NA	0.7	12.89	0.53	2.57e-32	Intelligence (multi-trait analysis);
LUAD	cis	rs12541635	0.677	rs11781331	chr8:107066936	G/A	cg10147462	chr8:107024639	NA	-0.53	-9.47	-0.42	1.98e-19	Age of smoking initiation;
LUAD	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg16680214	chr1:154839983	KCNN3	-0.62	-12.78	-0.53	7.13e-32	Prostate cancer;
LUAD	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.55	-8.58	-0.38	1.84e-16	IgG glycosylation;
LUAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27297192	chr10:134578999	INPP5A	0.39	6.87	0.32	2.31e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.53	-0.38	2.65e-16	Breast cancer;
LUAD	cis	rs10744422	0.925	rs2880678	chr12:123317099	C/T	cg16953816	chr12:123349952	VPS37B	0.63	7.13	0.33	4.45e-12	Schizophrenia;
LUAD	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg09065629	chr16:1709722	CRAMP1L	0.42	7.28	0.33	1.63e-12	Coronary artery disease;
LUAD	trans	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg06437703	chr8:37914619	EIF4EBP1	-0.68	-12.85	-0.53	3.83e-32	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg15147215	chr3:52552868	STAB1	-0.4	-7.15	-0.33	3.75e-12	Bipolar disorder;
LUAD	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.46	0.34	4.88e-13	Menopause (age at onset);
LUAD	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg21475434	chr5:93447410	FAM172A	0.74	8.33	0.38	1.1e-15	Diabetic retinopathy;
LUAD	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg22920501	chr2:26401640	FAM59B	-0.77	-10.93	-0.47	1.15e-24	Gut microbiome composition (summer);
LUAD	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg24848339	chr3:12840334	CAND2	0.49	10.35	0.45	1.59e-22	QRS complex (12-leadsum);
LUAD	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03517284	chr6:25882590	NA	-0.49	-7.89	-0.36	2.6e-14	Blood metabolite levels;
LUAD	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg02423579	chr7:2872169	GNA12	-0.6	-9.97	-0.44	3.5e-21	Height;
LUAD	cis	rs1032833	0.643	rs116230656	chr2:180107139	G/A	cg23883738	chr2:179974586	SESTD1	-0.72	-8.18	-0.37	3.46e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg08999081	chr20:33150536	PIGU	0.47	8.91	0.4	1.55e-17	Coronary artery disease;
LUAD	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg21862992	chr11:68658383	NA	0.48	8.59	0.39	1.66e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs62458065	0.640	rs4141788	chr7:32519264	T/C	cg20159608	chr7:32802032	NA	-0.57	-7.52	-0.34	3.23e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	trans	rs2262909	0.962	rs55735642	chr19:22241176	C/T	cg17074339	chr11:11642133	GALNTL4	0.47	7.71	0.35	8.79e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg18512352	chr11:47633146	NA	-0.37	-6.8	-0.31	3.49e-11	Subjective well-being;
LUAD	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.02	0.36	1.08e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.65	-0.31	9.31e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg02018176	chr4:1364513	KIAA1530	0.36	6.82	0.31	3.08e-11	Obesity-related traits;
LUAD	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-9.37	-0.41	4.45e-19	Schizophrenia;
LUAD	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg19041857	chr6:27730383	NA	-0.44	-7.61	-0.35	1.82e-13	Parkinson's disease;
LUAD	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg25251562	chr2:3704773	ALLC	-0.43	-7.56	-0.35	2.53e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs926938	0.560	rs360610	chr1:115393915	T/C	cg12756093	chr1:115239321	AMPD1	0.38	6.72	0.31	5.96e-11	Autism;
LUAD	trans	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg24644049	chr4:85504048	CDS1	0.86	7.03	0.32	8.32e-12	Skin colour saturation;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg04000159	chr8:54755598	ATP6V1H	-0.41	-7.03	-0.32	8.37e-12	Schizophrenia;
LUAD	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg08885076	chr2:99613938	TSGA10	0.37	6.84	0.32	2.81e-11	Chronic sinus infection;
LUAD	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.87	-0.32	2.37e-11	Height;
LUAD	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-12.7	-0.53	1.6e-31	Migraine;Coronary artery disease;
LUAD	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg27068330	chr11:65405492	SIPA1	-0.75	-11.29	-0.48	4.96e-26	Acne (severe);
LUAD	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.22	-0.41	1.39e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg15181151	chr6:150070149	PCMT1	0.42	8.39	0.38	7.56e-16	Lung cancer;
LUAD	cis	rs1034435	0.755	rs5768680	chr22:48892919	T/C	cg05992904	chr22:48892994	FAM19A5	-0.75	-16.59	-0.63	5.86e-48	Late-onset Alzheimer's disease;
LUAD	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg14092988	chr3:52407081	DNAH1	0.37	7.46	0.34	5.06e-13	Electroencephalogram traits;
LUAD	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg04225089	chr17:73874465	TRIM47	-0.38	-6.82	-0.31	3.23e-11	Psoriasis;
LUAD	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg05425664	chr17:57184151	TRIM37	0.44	7.87	0.36	3.07e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs438465	0.786	rs430206	chr6:169827066	A/G	cg11181693	chr6:169825345	NA	-0.65	-8.22	-0.37	2.57e-15	Corneal astigmatism;
LUAD	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-13.87	-0.56	2.6e-36	Headache;
LUAD	cis	rs8040855	0.644	rs4635318	chr15:85726737	C/A	cg04831495	chr15:85060580	GOLGA6L5	0.43	6.93	0.32	1.59e-11	Bulimia nervosa;
LUAD	cis	rs4730250	0.802	rs77936580	chr7:106946343	G/A	cg23024343	chr7:107201750	COG5	0.49	6.99	0.32	1.05e-11	Osteoarthritis;
LUAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg04025307	chr7:1156635	C7orf50	0.84	16.24	0.62	1.85e-46	Longevity;Endometriosis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14021555	chr22:43485536	TTLL1	-0.41	-6.36	-0.3	5.32e-10	Height;
LUAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg12432903	chr7:1882776	MAD1L1	-0.4	-6.61	-0.31	1.17e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg02251663	chr11:14281053	SPON1	-0.34	-6.69	-0.31	7.01e-11	Mitochondrial DNA levels;
LUAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	14.92	0.59	9.84e-41	Lung cancer in ever smokers;
LUAD	cis	rs2835872	0.758	rs1709820	chr21:39035971	A/C	cg06728970	chr21:39037746	KCNJ6	0.4	7.66	0.35	1.26e-13	Electroencephalographic traits in alcoholism;
LUAD	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24531977	chr5:56204891	C5orf35	-0.97	-15.03	-0.59	3.34e-41	Initial pursuit acceleration;
LUAD	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.53e-11	Crohn's disease;
LUAD	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03264133	chr6:25882463	NA	-0.57	-9.38	-0.41	4.16e-19	Blood metabolite levels;
LUAD	cis	rs9807989	0.507	rs6543133	chr2:103040177	A/T	cg03938978	chr2:103052716	IL18RAP	0.45	10.37	0.45	1.29e-22	Asthma;
LUAD	cis	rs1950626	0.699	rs12896504	chr14:101467948	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.39	-7.06	-0.32	6.85e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg02782426	chr3:40428986	ENTPD3	-0.4	-8.85	-0.4	2.41e-17	Renal cell carcinoma;
LUAD	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg07741184	chr6:167504864	NA	0.36	8.15	0.37	4.17e-15	Crohn's disease;
LUAD	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg16988262	chr1:15930761	NA	0.42	7.16	0.33	3.64e-12	Systolic blood pressure;
LUAD	cis	rs72928364	1.000	rs73137276	chr3:100613898	G/C	cg10123952	chr3:100791384	NA	0.6	6.58	0.3	1.36e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11756438	0.683	rs4945624	chr6:119017155	G/T	cg21191810	chr6:118973309	C6orf204	0.4	6.96	0.32	1.27e-11	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11890956	chr21:40555474	PSMG1	0.81	14.13	0.57	2.17e-37	Cognitive function;
LUAD	cis	rs6558530	0.692	rs12335115	chr8:1699852	C/G	cg19131313	chr8:1704013	NA	-0.43	-6.44	-0.3	3.22e-10	Systolic blood pressure;
LUAD	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.27	-7.0	-0.32	1e-11	Total body bone mineral density;
LUAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg11050988	chr7:1952600	MAD1L1	-0.38	-7.81	-0.35	4.63e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg15448220	chr1:150897856	SETDB1	0.46	7.98	0.36	1.42e-14	Tonsillectomy;
LUAD	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg00383909	chr3:49044727	WDR6	0.9	10.18	0.44	6.57e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs454510	0.816	rs347904	chr1:120177620	C/T	cg11530693	chr1:120165357	ZNF697	0.58	8.87	0.4	2e-17	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.67	-0.35	1.2e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7932354	0.528	rs10838654	chr11:47095511	G/C	cg19486271	chr11:47235900	DDB2	-0.48	-7.66	-0.35	1.3e-13	Bone mineral density (hip);Bone mineral density;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22777949	chr11:810211	SNORA52;RPLP2	-0.59	-7.06	-0.32	7.03e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18876405	chr7:65276391	NA	0.44	6.94	0.32	1.47e-11	Aortic root size;
LUAD	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg19717773	chr7:2847554	GNA12	-0.45	-7.68	-0.35	1.08e-13	Height;
LUAD	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg05368731	chr17:41323189	NBR1	0.98	21.08	0.72	5.91e-68	Menopause (age at onset);
LUAD	trans	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.71	12.32	0.51	5.06e-30	Mean corpuscular volume;
LUAD	cis	rs113835537	0.529	rs74869459	chr11:66296569	T/C	cg24851651	chr11:66362959	CCS	0.58	10.16	0.44	7.58e-22	Airway imaging phenotypes;
LUAD	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg08798685	chr6:27730294	NA	-0.7	-7.38	-0.34	8.45e-13	Depression;
LUAD	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg00310523	chr12:86230176	RASSF9	0.4	8.23	0.37	2.42e-15	Major depressive disorder;
LUAD	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-8.15	-0.37	4.19e-15	Total cholesterol levels;
LUAD	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.62	-8.15	-0.37	4.22e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7213347	0.780	rs216224	chr17:2156285	T/C	cg02569219	chr17:2266849	SGSM2	0.42	6.75	0.31	4.87e-11	Total body bone mineral density;
LUAD	cis	rs9487051	0.768	rs351729	chr6:109511668	T/C	cg21918786	chr6:109611834	NA	0.41	7.57	0.35	2.33e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg21862992	chr11:68658383	NA	0.55	9.76	0.43	2.01e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg15445000	chr17:37608096	MED1	-0.45	-8.32	-0.37	1.23e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg08989290	chr16:615782	NHLRC4	0.31	6.72	0.31	5.75e-11	Height;
LUAD	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg15448220	chr1:150897856	SETDB1	0.48	8.03	0.36	9.54e-15	Melanoma;
LUAD	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.23	0.33	2.25e-12	Blood metabolite levels;
LUAD	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg07061783	chr6:25882402	NA	-0.6	-9.49	-0.42	1.72e-19	Urate levels;
LUAD	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg05283184	chr6:79620031	NA	-0.55	-10.53	-0.46	3.56e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07092213	chr7:1199455	ZFAND2A	0.41	6.89	0.32	2.06e-11	Longevity;Endometriosis;
LUAD	cis	rs9354308	0.933	rs12194424	chr6:66574007	T/C	cg07460842	chr6:66804631	NA	0.46	6.94	0.32	1.52e-11	Metabolite levels;
LUAD	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg18180107	chr4:99064573	C4orf37	0.42	6.75	0.31	4.94e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.95	-0.36	1.77e-14	Monocyte percentage of white cells;
LUAD	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg23985595	chr17:80112537	CCDC57	0.53	9.74	0.43	2.39e-20	Life satisfaction;
LUAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg08132940	chr7:1081526	C7orf50	-0.77	-10.31	-0.45	2.21e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg09796270	chr17:17721594	SREBF1	-0.4	-8.31	-0.37	1.3e-15	Total body bone mineral density;
LUAD	cis	rs10392	0.543	rs6015981	chr20:37533958	A/G	cg27552599	chr20:37590471	DHX35	0.37	6.39	0.3	4.41e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg14784868	chr12:69753453	YEATS4	0.48	8.0	0.36	1.21e-14	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7536201	1.000	rs4648890	chr1:25293941	C/T	cg23273869	chr1:25296894	NA	-0.33	-6.63	-0.31	1.03e-10	Psoriasis vulgaris;
LUAD	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg14668632	chr7:2872130	GNA12	-0.73	-12.86	-0.53	3.47e-32	Height;
LUAD	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg17747265	chr1:1875780	NA	0.63	14.31	0.57	3.53e-38	Body mass index;
LUAD	trans	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg21775007	chr8:11205619	TDH	0.39	6.68	0.31	7.65e-11	Mood instability;
LUAD	cis	rs2658782	0.906	rs2658791	chr11:93198983	T/C	cg15737290	chr11:93063684	CCDC67	0.5	6.62	0.31	1.11e-10	Pulmonary function decline;
LUAD	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg23029597	chr12:123009494	RSRC2	-0.42	-6.69	-0.31	6.9e-11	Body mass index;
LUAD	cis	rs684232	0.666	rs838373	chr17:567171	T/C	cg12384639	chr17:618140	VPS53	0.49	8.45	0.38	4.62e-16	Prostate cancer;
LUAD	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg12011299	chr4:100065546	ADH4	0.7	12.61	0.52	3.55e-31	Alcohol dependence;
LUAD	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs3733418	0.929	rs4690797	chr4:165908505	G/C	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.52	-6.73	-0.31	5.69e-11	Obesity-related traits;
LUAD	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg18132916	chr6:79620363	NA	-0.47	-8.23	-0.37	2.27e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg22676075	chr6:135203613	NA	0.52	9.05	0.4	5.22e-18	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg13736514	chr6:26305472	NA	-0.72	-13.69	-0.55	1.48e-35	Educational attainment;
LUAD	cis	rs4660214	0.614	rs1537815	chr1:39744618	A/G	cg27567593	chr1:39956653	BMP8A	0.34	6.85	0.32	2.67e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg26587870	chr6:27730563	NA	0.47	7.81	0.36	4.43e-14	Parkinson's disease;
LUAD	trans	rs11650494	0.908	rs78208413	chr17:47398282	G/A	cg11430096	chr6:110968061	CDK19	0.87	6.51	0.3	2.12e-10	Prostate cancer;
LUAD	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03517284	chr6:25882590	NA	-0.69	-10.35	-0.45	1.58e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg02450064	chr17:40260053	DHX58	0.47	7.86	0.36	3.2e-14	Fibrinogen levels;
LUAD	cis	rs7737355	0.836	rs10900800	chr5:130914946	G/A	cg06307176	chr5:131281290	NA	0.42	6.77	0.31	4.37e-11	Life satisfaction;
LUAD	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg27454412	chr7:1067447	C7orf50	-0.44	-7.75	-0.35	6.71e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs7481584	0.847	rs1468102	chr11:3004526	C/G	cg11201177	chr11:2961805	NA	0.39	6.59	0.31	1.33e-10	Calcium levels;
LUAD	cis	rs6500602	0.653	rs4786488	chr16:4442527	C/T	cg08645402	chr16:4508243	NA	0.48	8.26	0.37	1.85e-15	Schizophrenia;
LUAD	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg21204522	chr6:27730016	NA	-0.47	-7.49	-0.34	4.02e-13	Parkinson's disease;
LUAD	cis	rs354225	0.544	rs10169975	chr2:54808159	C/T	cg01766943	chr2:54829624	SPTBN1	0.38	7.21	0.33	2.56e-12	Schizophrenia;
LUAD	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg08773314	chr2:239334832	ASB1	0.45	10.38	0.45	1.24e-22	Multiple system atrophy;
LUAD	cis	rs7937890	0.559	rs2167160	chr11:14507449	C/A	cg23387056	chr11:14280742	SPON1	-0.34	-6.67	-0.31	8.19e-11	Mitochondrial DNA levels;
LUAD	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg19318889	chr4:1322082	MAEA	0.45	7.3	0.33	1.4e-12	Obesity-related traits;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25454755	chr9:102584145	NR4A3	-0.44	-6.92	-0.32	1.71e-11	Height;
LUAD	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.82	-0.39	3.1e-17	Initial pursuit acceleration;
LUAD	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	6.65	0.31	9.31e-11	Tonsillectomy;
LUAD	trans	rs6920965	0.602	rs10872302	chr6:126180631	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-8.32	-0.38	1.21e-15	High light scatter reticulocyte count;
LUAD	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg03433033	chr1:76189801	ACADM	0.68	9.67	0.43	4.07e-20	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6714710	0.580	rs55886305	chr2:98495661	T/G	cg26665480	chr2:98280029	ACTR1B	0.5	8.25	0.37	2.05e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg16647868	chr5:131706066	SLC22A5	0.51	8.0	0.36	1.17e-14	Blood metabolite levels;
LUAD	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg03467027	chr4:99064603	C4orf37	0.44	7.14	0.33	4.07e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21528620	chr1:110753221	KCNC4	-0.53	-6.41	-0.3	3.79e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg26958806	chr6:27640298	NA	0.67	6.64	0.31	9.51e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg25985355	chr7:65971099	NA	0.52	6.58	0.3	1.41e-10	Diabetic kidney disease;
LUAD	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.41	-7.88	-0.36	2.76e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9486719	1.000	rs11152968	chr6:96908653	A/G	cg06623918	chr6:96969491	KIAA0776	0.68	9.71	0.43	2.85e-20	Migraine;Coronary artery disease;
LUAD	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg23262073	chr20:60523788	NA	-0.37	-6.43	-0.3	3.54e-10	Body mass index;
LUAD	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.35	7.16	0.33	3.69e-12	Parkinson's disease;
LUAD	cis	rs4356932	0.967	rs6856958	chr4:76952356	T/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.5	-0.3	2.22e-10	Blood protein levels;
LUAD	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg08807101	chr21:30365312	RNF160	-0.45	-7.84	-0.36	3.59e-14	Dental caries;
LUAD	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg00484396	chr16:3507460	NAT15	-0.76	-8.42	-0.38	6.04e-16	Tuberculosis;
LUAD	cis	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg21775007	chr8:11205619	TDH	0.37	6.41	0.3	3.86e-10	Neuroticism;
LUAD	trans	rs4650994	0.525	rs11806608	chr1:178511375	T/C	cg05059571	chr16:84539110	KIAA1609	-0.76	-13.94	-0.56	1.27e-36	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs7737355	0.504	rs31256	chr5:130828749	T/C	cg25547332	chr5:131281432	NA	0.43	6.6	0.31	1.22e-10	Life satisfaction;
LUAD	cis	rs2274273	0.624	rs7155954	chr14:55750943	G/A	cg04306507	chr14:55594613	LGALS3	0.41	7.86	0.36	3.18e-14	Protein biomarker;
LUAD	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg15181151	chr6:150070149	PCMT1	0.33	6.6	0.31	1.25e-10	Testicular germ cell tumor;
LUAD	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-8.33	-0.38	1.13e-15	Blood metabolite levels;
LUAD	cis	rs1595825	1.000	rs7582715	chr2:198874310	T/G	cg00982548	chr2:198649783	BOLL	-0.6	-8.64	-0.39	1.18e-16	Ulcerative colitis;
LUAD	trans	rs9929218	1.000	rs8056538	chr16:68802282	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-13.27	-0.54	7.83e-34	Colorectal cancer;
LUAD	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg04944784	chr2:26401820	FAM59B	0.91	13.67	0.55	1.81e-35	Gut microbiome composition (summer);
LUAD	cis	rs9467160	1.000	rs6922313	chr6:24438719	C/T	cg16211469	chr6:24423932	MRS2	0.43	6.88	0.32	2.1e-11	Liver enzyme levels;
LUAD	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg17200465	chr3:40428508	ENTPD3	0.27	6.48	0.3	2.51e-10	Renal cell carcinoma;
LUAD	trans	rs1997103	0.911	rs9642575	chr7:55399090	C/T	cg20935933	chr6:143382018	AIG1	0.53	7.46	0.34	4.94e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs7246760	0.867	rs58461110	chr19:9833390	G/A	cg02900749	chr2:68251473	NA	-0.58	-6.58	-0.3	1.37e-10	Pursuit maintenance gain;
LUAD	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg24069376	chr3:38537580	EXOG	-0.45	-10.92	-0.47	1.25e-24	Electrocardiographic conduction measures;
LUAD	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.78	-0.35	5.7e-14	Blood metabolite levels;
LUAD	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg17644776	chr2:200775616	C2orf69	0.53	7.61	0.35	1.76e-13	Schizophrenia;
LUAD	cis	rs9341808	0.754	rs9352817	chr6:81025879	T/G	cg08355045	chr6:80787529	NA	0.55	10.08	0.44	1.46e-21	Sitting height ratio;
LUAD	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.6	-0.52	3.97e-31	Monocyte count;
LUAD	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22455342	chr2:225449267	CUL3	0.71	10.96	0.47	8.69e-25	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg14061069	chr19:46274453	DMPK	-0.48	-10.13	-0.44	9.46e-22	Coronary artery disease;
LUAD	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21659725	chr3:3221576	CRBN	-0.65	-10.47	-0.45	5.95e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.69	11.92	0.5	1.94e-28	Mean corpuscular volume;
LUAD	cis	rs123509	0.731	rs73087348	chr3:42811571	C/T	cg10144569	chr3:42726640	KBTBD5	-0.45	-6.6	-0.31	1.21e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg23283495	chr1:209979779	IRF6	0.41	7.32	0.34	1.24e-12	Monobrow;
LUAD	cis	rs4683142	0.518	rs6441938	chr3:46045619	C/G	cg11211486	chr3:46033800	FYCO1	-0.43	-6.67	-0.31	8.12e-11	Methadone dose in opioid dependence;
LUAD	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg25985355	chr7:65971099	NA	-0.35	-6.5	-0.3	2.29e-10	Aortic root size;
LUAD	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg06740227	chr12:86229804	RASSF9	0.42	7.23	0.33	2.31e-12	Major depressive disorder;
LUAD	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06028808	chr11:68637592	NA	0.5	8.35	0.38	9.53e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg12935359	chr14:103987150	CKB	-0.46	-7.61	-0.35	1.79e-13	Body mass index;
LUAD	cis	rs3812762	0.868	rs7952335	chr11:8754031	A/G	cg03980550	chr11:8754370	ST5	0.37	6.51	0.3	2.18e-10	Hypospadias;
LUAD	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.47e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7680126	0.596	rs17198547	chr4:10141419	A/G	cg11266682	chr4:10021025	SLC2A9	0.46	7.66	0.35	1.31e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	6.82	0.31	3.13e-11	Motion sickness;
LUAD	cis	rs7487075	0.619	rs4768718	chr12:46834336	G/C	cg23829395	chr12:46796953	NA	0.31	6.95	0.32	1.42e-11	Itch intensity from mosquito bite;
LUAD	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg04287289	chr16:89883240	FANCA	-0.4	-6.58	-0.3	1.42e-10	Vitiligo;
LUAD	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg02951883	chr7:2050386	MAD1L1	-0.74	-12.71	-0.53	1.41e-31	Schizophrenia;
LUAD	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg14092988	chr3:52407081	DNAH1	-0.33	-6.59	-0.31	1.32e-10	Electroencephalogram traits;
LUAD	cis	rs9929218	0.539	rs1125557	chr16:68809599	G/A	cg01251360	chr16:68772225	CDH1	-0.26	-8.05	-0.36	8.5e-15	Colorectal cancer;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg14037413	chr11:9482594	ZNF143	0.39	6.49	0.3	2.35e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs738321	0.757	rs4820315	chr22:38518731	C/T	cg17652424	chr22:38574118	PLA2G6	-0.25	-6.43	-0.3	3.5e-10	Breast cancer;
LUAD	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg04990556	chr1:26633338	UBXN11	-0.41	-6.72	-0.31	5.85e-11	Obesity-related traits;
LUAD	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.67	0.31	8.26e-11	Cardiac Troponin-T levels;
LUAD	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-8.49	-0.38	3.55e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg12935359	chr14:103987150	CKB	-0.47	-7.88	-0.36	2.88e-14	Body mass index;
LUAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg20276088	chr3:133502917	NA	-0.42	-7.57	-0.35	2.33e-13	Iron status biomarkers;
LUAD	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	7.9	0.36	2.38e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2302190	0.882	rs9911609	chr17:56673087	T/C	cg25885038	chr17:56607967	SEPT4	-0.51	-8.12	-0.37	5.11e-15	Vitamin D levels;
LUAD	cis	rs854765	0.693	rs4924822	chr17:17748013	A/G	cg09796270	chr17:17721594	SREBF1	-0.41	-8.07	-0.37	7.48e-15	Total body bone mineral density;
LUAD	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg22676075	chr6:135203613	NA	0.39	6.96	0.32	1.33e-11	Red blood cell count;
LUAD	cis	rs6906287	0.561	rs2078079	chr6:118705213	G/A	cg05564266	chr6:118973597	C6orf204	0.38	8.38	0.38	7.87e-16	Electrocardiographic conduction measures;
LUAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg22907277	chr7:1156413	C7orf50	0.68	8.0	0.36	1.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg09796270	chr17:17721594	SREBF1	0.37	7.45	0.34	5.24e-13	Total body bone mineral density;
LUAD	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg17105886	chr17:28927953	LRRC37B2	0.77	7.72	0.35	8.51e-14	Body mass index;
LUAD	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg15448220	chr1:150897856	SETDB1	0.54	9.11	0.41	3.28e-18	Melanoma;
LUAD	trans	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg26043149	chr18:55253948	FECH	-0.42	-6.8	-0.31	3.51e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg16680214	chr1:154839983	KCNN3	0.62	12.92	0.53	2e-32	Prostate cancer;
LUAD	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg01181863	chr3:195395398	SDHAP2	-0.58	-8.5	-0.38	3.28e-16	Pancreatic cancer;
LUAD	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-39.48	-0.89	5.97e-144	Myeloid white cell count;
LUAD	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.57	-0.35	2.39e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg17200465	chr3:40428508	ENTPD3	0.27	6.6	0.31	1.23e-10	Renal cell carcinoma;
LUAD	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg09998033	chr7:158218633	PTPRN2	0.56	10.18	0.44	6.63e-22	Obesity-related traits;
LUAD	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg00933542	chr6:150070202	PCMT1	0.41	8.69	0.39	8.09e-17	Lung cancer;
LUAD	cis	rs12545109	0.879	rs893234	chr8:57363885	G/A	cg09654669	chr8:57350985	NA	-0.7	-9.88	-0.43	7.31e-21	Obesity-related traits;
LUAD	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg00898013	chr13:113819073	PROZ	-0.69	-12.16	-0.51	2.2e-29	Platelet distribution width;
LUAD	cis	rs10129255	0.500	rs10142931	chr14:107190525	A/C	cg07958169	chr14:107095056	NA	-0.36	-7.14	-0.33	4.12e-12	Kawasaki disease;
LUAD	trans	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.06	-26.67	-0.79	1.21e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.56e-12	Crohn's disease;
LUAD	cis	rs56283067	0.773	rs56115627	chr6:44683049	G/A	cg18551225	chr6:44695536	NA	-0.6	-9.98	-0.44	3.4e-21	Total body bone mineral density;
LUAD	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	10.44	0.45	7.36e-23	Electrocardiographic conduction measures;
LUAD	cis	rs2637266	1.000	rs7081214	chr10:78361134	G/A	cg18941641	chr10:78392320	NA	0.33	6.82	0.31	3.21e-11	Pulmonary function;
LUAD	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.61	0.35	1.8e-13	Cannabis dependence symptom count;
LUAD	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg19163074	chr7:65112434	INTS4L2	0.41	6.41	0.3	3.84e-10	Aortic root size;
LUAD	cis	rs6076065	0.723	rs7269627	chr20:23362727	A/T	cg11657817	chr20:23433608	CST11	0.47	8.78	0.39	4.17e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7818345	0.967	rs17479099	chr8:19277144	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.32	6.95	0.32	1.4e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05938683	chr1:85156187	SSX2IP	-0.67	-6.5	-0.3	2.21e-10	Type 2 diabetes;
LUAD	cis	rs1953600	0.837	rs2573352	chr10:81939813	T/C	cg04850286	chr10:81895943	PLAC9	0.36	6.44	0.3	3.25e-10	Sarcoidosis;
LUAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08677398	chr8:58056175	NA	0.46	6.54	0.3	1.76e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4700695	0.614	rs437399	chr5:65208533	A/G	cg21114390	chr5:65439923	SFRS12	0.65	8.04	0.36	9.21e-15	Facial morphology (factor 19);
LUAD	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg07936489	chr17:37558343	FBXL20	-0.46	-7.34	-0.34	1.08e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs8177876	0.822	rs9926174	chr16:81111436	A/G	cg08591886	chr16:81111003	C16orf46	-0.77	-7.13	-0.33	4.34e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs738321	0.757	rs5750546	chr22:38542499	C/T	cg25457927	chr22:38595422	NA	-0.54	-11.99	-0.5	1.06e-28	Breast cancer;
LUAD	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.8	0.39	3.48e-17	Menopause (age at onset);
LUAD	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.39	0.34	7.8e-13	Colorectal cancer;
LUAD	cis	rs8060686	0.623	rs6499163	chr16:68243486	G/T	cg05110241	chr16:68378359	PRMT7	-0.56	-7.23	-0.33	2.29e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg21433313	chr16:3507492	NAT15	-0.73	-8.07	-0.37	7.52e-15	Tuberculosis;
LUAD	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg07549590	chr16:15018862	NA	-0.55	-10.61	-0.46	1.84e-23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg02423579	chr7:2872169	GNA12	-0.56	-9.47	-0.42	2.07e-19	Height;
LUAD	cis	rs12216545	0.765	rs10254007	chr7:150253381	C/T	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.38	-0.3	4.78e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg22823121	chr1:150693482	HORMAD1	-0.38	-7.48	-0.34	4.4e-13	Tonsillectomy;
LUAD	cis	rs4711336	0.809	rs749338	chr6:33653448	A/G	cg13859433	chr6:33739653	LEMD2	0.29	6.65	0.31	9.23e-11	Height;
LUAD	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg09455208	chr3:40491958	NA	0.55	12.19	0.51	1.75e-29	Renal cell carcinoma;
LUAD	cis	rs300703	0.678	rs423643	chr2:199648	A/C	cg21211680	chr2:198530	NA	0.59	7.93	0.36	1.96e-14	Blood protein levels;
LUAD	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.92	-0.47	1.23e-24	Total body bone mineral density;
LUAD	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg05340658	chr4:99064831	C4orf37	0.43	7.25	0.33	2.01e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3733418	0.929	rs13110309	chr4:165889672	T/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.49	-6.39	-0.3	4.34e-10	Obesity-related traits;
LUAD	trans	rs2262909	0.962	rs401424	chr19:22232023	A/G	cg17074339	chr11:11642133	GALNTL4	-0.39	-6.5	-0.3	2.29e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs863345	0.604	rs1578762	chr1:158497440	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.39	-0.3	4.26e-10	Pneumococcal bacteremia;
LUAD	cis	rs3845702	0.736	rs6722147	chr2:180829704	G/A	cg01881094	chr2:180872142	CWC22	-0.82	-8.82	-0.39	3.09e-17	Schizophrenia;
LUAD	cis	rs11718455	0.920	rs34909426	chr3:44000472	G/A	cg08738300	chr3:44038990	NA	0.42	6.48	0.3	2.55e-10	Coronary artery disease;
LUAD	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg05110241	chr16:68378359	PRMT7	-0.84	-9.44	-0.42	2.46e-19	Magnesium levels;
LUAD	trans	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg01620082	chr3:125678407	NA	-0.99	-8.93	-0.4	1.32e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11971779	0.648	rs6946113	chr7:139106126	A/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	7.16e-11	Diisocyanate-induced asthma;
LUAD	cis	rs77972916	0.505	rs6727824	chr2:43528377	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-10.45	-0.45	7.09e-23	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs3806843	0.576	rs246005	chr5:140339884	A/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.52	-0.3	2.03e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19606431	chr6:131949205	MED23	-0.56	-6.98	-0.32	1.14e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1395	1.000	rs1275501	chr2:27419282	A/C	cg23587288	chr2:27483067	SLC30A3	0.38	7.74	0.35	7.41e-14	Blood metabolite levels;
LUAD	trans	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg06606381	chr12:133084897	FBRSL1	-1.12	-10.31	-0.45	2.2e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7520050	0.931	rs785472	chr1:46518288	T/A	cg06784218	chr1:46089804	CCDC17	-0.31	-6.58	-0.3	1.4e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.83	-0.61	1.2e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs12446554	0.509	rs56108048	chr16:19709779	T/C	cg01578585	chr16:19721878	C16orf88	0.52	7.5	0.34	3.86e-13	Obesity;
LUAD	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg17366294	chr4:99064904	C4orf37	0.61	10.32	0.45	2.1e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.68	0.49	1.6e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg27494647	chr7:150038898	RARRES2	0.51	8.67	0.39	9.25e-17	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg18825076	chr15:78729989	IREB2	0.51	6.98	0.32	1.15e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.75	-0.31	5.03e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg25173405	chr17:45401733	C17orf57	0.54	9.05	0.4	5.39e-18	Coronary artery disease;
LUAD	cis	rs11167764	0.945	rs13161849	chr5:141473395	A/G	cg23435118	chr5:141488016	NDFIP1	-0.48	-7.17	-0.33	3.27e-12	Crohn's disease;
LUAD	cis	rs10992471	0.729	rs1022844	chr9:95553464	A/T	cg14631576	chr9:95140430	CENPP	-0.37	-7.37	-0.34	9.02e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg08280861	chr8:58055591	NA	0.75	8.98	0.4	8.72e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg22153463	chr1:85462885	MCOLN2	-0.56	-7.97	-0.36	1.53e-14	Serum sulfate level;
LUAD	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg04772025	chr11:68637568	NA	0.57	9.07	0.4	4.47e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg00278107	chr5:1061253	SLC12A7	-0.51	-9.68	-0.43	3.64e-20	QT interval;
LUAD	cis	rs9393692	0.620	rs9357005	chr6:26336838	C/A	cg13736514	chr6:26305472	NA	-0.49	-8.35	-0.38	9.51e-16	Educational attainment;
LUAD	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg23985595	chr17:80112537	CCDC57	0.53	9.74	0.43	2.39e-20	Life satisfaction;
LUAD	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg22681709	chr2:178499509	PDE11A	-0.45	-7.52	-0.34	3.31e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg25025879	chr12:53359317	NA	-0.73	-12.19	-0.51	1.7e-29	Cancer (pleiotropy);
LUAD	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25427524	chr10:38739819	LOC399744	0.76	13.27	0.54	7.62e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11890956	chr21:40555474	PSMG1	0.82	14.66	0.58	1.25e-39	Cognitive function;
LUAD	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg24733560	chr20:60626293	TAF4	0.41	6.94	0.32	1.49e-11	Body mass index;
LUAD	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg00271210	chr6:167070053	RPS6KA2	0.35	6.65	0.31	9.31e-11	Crohn's disease;
LUAD	cis	rs6684428	1.000	rs12124871	chr1:56372247	C/T	cg11651538	chr1:56320950	NA	-0.4	-6.39	-0.3	4.39e-10	Airflow obstruction;
LUAD	cis	rs4523957	0.788	rs11078865	chr17:2109109	T/A	cg16513277	chr17:2031491	SMG6	-0.76	-14.08	-0.56	3.53e-37	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg12035532	chr1:1886765	KIAA1751	0.4	6.63	0.31	1.03e-10	Body mass index;
LUAD	cis	rs9462027	0.606	rs7768759	chr6:34795685	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.56	-0.38	2.05e-16	Systemic lupus erythematosus;
LUAD	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg04034577	chr2:241836375	C2orf54	-0.47	-10.24	-0.45	3.86e-22	Urinary metabolites;
LUAD	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg11915388	chr22:42470451	FAM109B	0.34	6.4	0.3	4.2e-10	Cognitive function;
LUAD	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg25173405	chr17:45401733	C17orf57	-0.58	-9.86	-0.43	9.04e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4888262	0.545	rs4072450	chr16:74666634	G/C	cg01733217	chr16:74700730	RFWD3	0.52	8.74	0.39	5.6e-17	Testicular germ cell tumor;
LUAD	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg23649088	chr2:200775458	C2orf69	0.61	8.2	0.37	2.87e-15	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9467603	0.547	rs9295661	chr6:25450026	A/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-6.54	-0.3	1.73e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7202877	0.610	rs468079	chr16:75428474	G/A	cg03315344	chr16:75512273	CHST6	-0.49	-6.58	-0.3	1.42e-10	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.29	0.37	1.55e-15	Alzheimer's disease;
LUAD	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg00074818	chr8:8560427	CLDN23	0.67	10.32	0.45	1.97e-22	Obesity-related traits;
LUAD	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	7.25	0.33	2.05e-12	Neuroticism;
LUAD	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03517284	chr6:25882590	NA	-0.85	-14.4	-0.57	1.55e-38	Blood metabolite levels;
LUAD	cis	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg02807482	chr3:125708958	NA	-0.62	-6.46	-0.3	2.95e-10	Blood pressure (smoking interaction);
LUAD	cis	rs28595532	0.920	rs17257945	chr4:119666465	T/A	cg02775129	chr4:119771670	NA	-0.86	-7.93	-0.36	1.99e-14	Cannabis dependence symptom count;
LUAD	cis	rs2882667	0.964	rs67296915	chr5:138301599	C/T	cg04439458	chr5:138467593	SIL1	-0.37	-6.85	-0.32	2.64e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs62238980	0.614	rs17682385	chr22:32387572	C/T	cg00543991	chr22:32367038	NA	0.92	8.15	0.37	4.03e-15	Childhood ear infection;
LUAD	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg14582100	chr15:45693742	SPATA5L1	0.64	12.5	0.52	9.64e-31	Homoarginine levels;
LUAD	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg05182265	chr7:156933206	UBE3C	-0.8	-17.25	-0.64	7.38e-51	Body mass index;
LUAD	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg03806693	chr22:41940476	POLR3H	0.58	8.36	0.38	9.44e-16	Vitiligo;
LUAD	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.46	-7.6	-0.35	1.86e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7851660	1.000	rs7851660	chr9:100610759	C/A	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	cis	rs315934	0.664	rs113723100	chr2:113852748	C/T	cg09040174	chr2:113837401	NA	-0.61	-7.4	-0.34	7.6e-13	Dysmenorrheic pain;
LUAD	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg23254163	chr1:152506842	NA	0.25	7.07	0.33	6.24e-12	Hair morphology;
LUAD	cis	rs490234	0.841	rs477813	chr9:128416874	C/T	cg14078157	chr9:128172775	NA	0.4	7.28	0.33	1.69e-12	Mean arterial pressure;
LUAD	cis	rs7944584	0.563	rs2280231	chr11:47600438	C/T	cg20307385	chr11:47447363	PSMC3	0.51	7.53	0.34	3.09e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00149659	chr3:10157352	C3orf10	0.64	8.83	0.39	2.8e-17	Alzheimer's disease;
LUAD	cis	rs1403694	1.000	rs1624230	chr3:186438935	A/C	cg12454167	chr3:186435060	KNG1	-0.42	-8.87	-0.4	2.03e-17	Blood protein levels;
LUAD	cis	rs123509	0.913	rs123506	chr3:42775976	T/C	cg12982090	chr3:42733453	KBTBD5	0.54	9.64	0.42	5.19e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7274811	0.652	rs293732	chr20:31975090	G/A	cg13403462	chr20:32256071	NECAB3;C20orf134	0.45	6.77	0.31	4.24e-11	Height;
LUAD	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-6.71	-0.31	6.11e-11	Tonsillectomy;
LUAD	cis	rs4925114	0.568	rs9900803	chr17:17650978	C/T	cg09796270	chr17:17721594	SREBF1	-0.36	-7.11	-0.33	5.11e-12	Body mass index;
LUAD	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg05623727	chr3:50126028	RBM5	-0.34	-7.38	-0.34	8.64e-13	Body mass index;
LUAD	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg19875535	chr5:140030758	IK	-0.45	-7.6	-0.35	1.94e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1692580	0.870	rs263532	chr1:2164116	T/C	cg24578937	chr1:2090814	PRKCZ	0.47	9.0	0.4	7.7e-18	Coronary artery disease;
LUAD	cis	rs62400317	0.859	rs2038765	chr6:45076494	A/G	cg18551225	chr6:44695536	NA	-0.54	-8.47	-0.38	4.22e-16	Total body bone mineral density;
LUAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14893161	chr1:205819251	PM20D1	0.79	16.7	0.63	1.8e-48	Menarche (age at onset);
LUAD	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg23018236	chr17:30244563	NA	-0.69	-8.39	-0.38	7.53e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg06784218	chr1:46089804	CCDC17	0.51	11.37	0.48	2.47e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9394152	0.845	rs9394153	chr6:33471630	A/C	cg13560919	chr6:33536144	NA	0.51	8.64	0.39	1.17e-16	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs13082711	1.000	rs73050029	chr3:27514760	C/A	cg02860705	chr3:27208620	NA	0.64	9.34	0.41	5.4e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs62238980	0.614	rs76853252	chr22:32455857	T/C	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18876405	chr7:65276391	NA	0.6	10.14	0.44	8.74e-22	Aortic root size;
LUAD	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg06784218	chr1:46089804	CCDC17	-0.53	-11.84	-0.5	3.99e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg11062466	chr8:58055876	NA	0.46	6.89	0.32	2.03e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg03859395	chr2:55845619	SMEK2	0.67	11.93	0.5	1.72e-28	Metabolic syndrome;
LUAD	cis	rs9329221	0.682	rs11786677	chr8:10264260	A/G	cg21775007	chr8:11205619	TDH	0.37	6.5	0.3	2.25e-10	Neuroticism;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg21092834	chr11:107462721	LOC643923;ELMOD1	-0.34	-6.49	-0.3	2.37e-10	Subcortical brain region volumes;
LUAD	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg22906224	chr7:99728672	NA	-0.55	-9.49	-0.42	1.73e-19	Coronary artery disease;
LUAD	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg17724175	chr1:150552817	MCL1	0.39	9.39	0.42	3.82e-19	Tonsillectomy;
LUAD	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg06784218	chr1:46089804	CCDC17	0.59	13.33	0.54	4.4e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg21823605	chr1:152486609	CRCT1	0.28	6.42	0.3	3.66e-10	Hair morphology;
LUAD	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg09323728	chr8:95962352	TP53INP1	0.29	6.38	0.3	4.55e-10	Type 2 diabetes;
LUAD	trans	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.66	-0.31	8.66e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg06608945	chr2:219082296	ARPC2	0.52	8.86	0.4	2.24e-17	Colorectal cancer;
LUAD	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24531977	chr5:56204891	C5orf35	-1.0	-15.36	-0.6	1.21e-42	Initial pursuit acceleration;
LUAD	cis	rs6761276	0.899	rs11677043	chr2:113835520	A/G	cg06383401	chr2:113825234	IL1F10	-0.29	-6.38	-0.3	4.71e-10	Protein quantitative trait loci;
LUAD	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg10518543	chr12:38710700	ALG10B	-0.42	-6.88	-0.32	2.2e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs11681884	0.892	rs11683132	chr2:113845001	A/G	cg12858261	chr2:113808755	IL1F8	0.51	6.42	0.3	3.6e-10	Stroke;
LUAD	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg11833968	chr6:79620685	NA	-0.44	-8.28	-0.37	1.68e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.617	rs6964395	chr7:107080667	G/C	cg23024343	chr7:107201750	COG5	0.52	6.51	0.3	2.12e-10	Coronary artery disease;
LUAD	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg18209359	chr17:80159595	CCDC57	-0.38	-6.4	-0.3	4.08e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs116248771	0.690	rs73156491	chr3:158416572	A/G	cg16708174	chr3:158430962	RARRES1	0.48	6.97	0.32	1.23e-11	diarrhoeal disease at age 2;
LUAD	cis	rs921968	0.565	rs7603709	chr2:219642601	C/T	cg02176678	chr2:219576539	TTLL4	-0.58	-11.98	-0.5	1.09e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg25535316	chr11:579198	PHRF1	-0.4	-6.48	-0.3	2.59e-10	Systemic lupus erythematosus;
LUAD	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg27454412	chr7:1067447	C7orf50	-0.34	-6.5	-0.3	2.33e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg09997546	chr11:8931473	C11orf17;ST5	0.38	8.03	0.36	9.66e-15	Hemoglobin concentration;
LUAD	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22857025	chr5:266934	NA	-1.04	-13.41	-0.55	2.08e-34	Breast cancer;
LUAD	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.59	-12.31	-0.51	5.38e-30	Monocyte percentage of white cells;
LUAD	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.14	-0.57	1.99e-37	Intelligence (multi-trait analysis);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01598046	chr3:49894152	TRAIP	-0.39	-6.48	-0.3	2.59e-10	Cancer;
LUAD	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23583168	chr7:148888333	NA	-0.91	-18.84	-0.68	6.35e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg12311346	chr5:56204834	C5orf35	-0.43	-7.1	-0.33	5.28e-12	Coronary artery disease;
LUAD	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg12935359	chr14:103987150	CKB	-0.49	-7.85	-0.36	3.52e-14	Body mass index;
LUAD	cis	rs8025790	0.508	rs4776943	chr15:67836069	T/C	cg27219399	chr15:67835830	MAP2K5	0.44	7.58	0.35	2.2e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg08916839	chr5:415575	AHRR	0.85	9.94	0.44	4.68e-21	Fat distribution (HIV);
LUAD	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	9.25	0.41	1.13e-18	Colorectal cancer;
LUAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg08132940	chr7:1081526	C7orf50	-0.77	-10.43	-0.45	8.21e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1595825	0.735	rs2053394	chr2:198946335	C/T	cg10547527	chr2:198650123	BOLL	-0.53	-7.07	-0.33	6.52e-12	Ulcerative colitis;
LUAD	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg10636054	chr15:40330586	SRP14	0.92	10.79	0.46	3.8e-24	Corneal curvature;
LUAD	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg13642260	chr9:130955380	CIZ1	-0.45	-7.66	-0.35	1.24e-13	Attention deficit hyperactivity disorder;
LUAD	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg25985355	chr7:65971099	NA	-0.51	-6.37	-0.3	4.89e-10	Diabetic kidney disease;
LUAD	trans	rs2018683	1.000	rs740252	chr7:28997765	C/G	cg19402173	chr7:128379420	CALU	-0.64	-10.77	-0.46	4.74e-24	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11971779	0.680	rs6960876	chr7:139112176	C/T	cg24109934	chr7:139138155	KLRG2	0.31	6.45	0.3	3.02e-10	Diisocyanate-induced asthma;
LUAD	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21659725	chr3:3221576	CRBN	-0.85	-17.93	-0.66	7.21e-54	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg25036284	chr2:26402008	FAM59B	-0.83	-11.68	-0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg26304593	chr6:42947056	PEX6	-0.46	-7.68	-0.35	1.11e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg04772025	chr11:68637568	NA	0.57	8.99	0.4	8.39e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.55	0.3	1.71e-10	Cognitive test performance;
LUAD	trans	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg13565492	chr6:43139072	SRF	-0.6	-6.35	-0.3	5.49e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.34e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6087990	0.735	rs2424914	chr20:31374520	A/G	cg13636640	chr20:31349939	DNMT3B	0.74	13.33	0.54	4.43e-34	Ulcerative colitis;
LUAD	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg23262073	chr20:60523788	NA	-0.36	-6.39	-0.3	4.27e-10	Body mass index;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg02711849	chr3:126398161	NA	0.41	6.44	0.3	3.16e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs7903847	0.642	rs10882913	chr10:99141845	C/T	cg20016023	chr10:99160130	RRP12	-0.3	-7.12	-0.33	4.78e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg23216685	chr1:86174607	ZNHIT6	-0.45	-8.89	-0.4	1.82e-17	Urate levels in overweight individuals;
LUAD	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg04842962	chr6:43655489	MRPS18A	1.06	26.62	0.79	1.97e-92	IgG glycosylation;
LUAD	cis	rs3774749	0.565	rs2624839	chr3:50202231	T/C	cg14019146	chr3:50243930	SLC38A3	-0.35	-6.75	-0.31	4.86e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03452623	chr4:187889614	NA	-0.81	-16.43	-0.62	2.81e-47	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs262150	0.501	rs1017034	chr7:158820460	A/G	cg09826364	chr7:158789723	NA	-0.4	-7.0	-0.32	1.02e-11	Facial morphology (factor 20);
LUAD	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg06640241	chr16:89574553	SPG7	0.46	7.61	0.35	1.74e-13	Multiple myeloma (IgH translocation);
LUAD	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.46	9.5	0.42	1.63e-19	Monocyte percentage of white cells;
LUAD	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg17264618	chr3:40429014	ENTPD3	0.42	9.17	0.41	2.08e-18	Renal cell carcinoma;
LUAD	cis	rs9462027	0.606	rs205258	chr6:34564243	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.87	-0.4	2.04e-17	Systemic lupus erythematosus;
LUAD	cis	rs870825	0.746	rs1107908	chr4:185620113	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06221963	chr1:154839813	KCNN3	-0.85	-20.74	-0.71	1.96e-66	Prostate cancer;
LUAD	cis	rs4523957	0.583	rs4349181	chr17:2040963	A/G	cg16513277	chr17:2031491	SMG6	-0.99	-20.27	-0.7	2.57e-64	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Parkinson's disease;
LUAD	cis	rs4604732	0.631	rs12080860	chr1:247623053	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.39	6.87	0.32	2.32e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs35995292	0.963	rs10242978	chr7:38898823	A/G	cg19327137	chr7:38886074	VPS41	0.5	8.37	0.38	8.69e-16	Subjective well-being (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg05110241	chr16:68378359	PRMT7	-0.69	-7.9	-0.36	2.52e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg08999081	chr20:33150536	PIGU	-0.63	-14.12	-0.57	2.25e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07256732	chr16:621771	PIGQ	-0.32	-6.63	-0.31	1.02e-10	Height;
LUAD	cis	rs494562	0.773	rs6919207	chr6:86129271	C/T	cg13315970	chr6:86159197	NT5E	0.7	7.8	0.35	4.79e-14	Blood metabolite levels;Metabolic traits;
LUAD	trans	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg11693508	chr17:37793320	STARD3	-0.67	-9.43	-0.42	2.75e-19	Bipolar disorder;
LUAD	cis	rs4713118	1.000	rs4713118	chr6:27676794	A/G	cg20933634	chr6:27740509	NA	0.41	6.37	0.3	4.93e-10	Parkinson's disease;
LUAD	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg23277830	chr1:3704460	LRRC47	0.42	8.48	0.38	3.83e-16	Red cell distribution width;
LUAD	cis	rs939658	0.805	rs1915726	chr15:79420620	C/G	cg17916960	chr15:79447300	NA	-0.52	-11.05	-0.47	4e-25	Refractive error;
LUAD	cis	rs9715521	0.935	rs72634625	chr4:59836434	T/A	cg11281224	chr4:60001000	NA	-0.56	-9.43	-0.42	2.8e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.35	7.19	0.33	2.88e-12	Depression;
LUAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00166722	chr3:10149974	C3orf24	0.64	9.65	0.42	4.75e-20	Alzheimer's disease;
LUAD	cis	rs59698941	0.943	rs67422135	chr5:132222728	T/A	cg14825688	chr5:132208181	LEAP2	-0.47	-6.65	-0.31	8.85e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs3007168	0.951	rs3007078	chr14:51612550	T/A	cg23942311	chr14:51606299	NA	0.54	7.39	0.34	8.02e-13	Cancer;
LUAD	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	0.39	6.47	0.3	2.7e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4845570	1.000	rs4845570	chr1:151759104	C/T	cg07092448	chr1:151763213	TDRKH	0.7	8.34	0.38	1.07e-15	Coronary artery disease;
LUAD	cis	rs1595825	0.891	rs73061069	chr2:198908825	A/G	cg00982548	chr2:198649783	BOLL	-0.67	-9.46	-0.42	2.1e-19	Ulcerative colitis;
LUAD	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg11502198	chr6:26597334	ABT1	0.54	9.14	0.41	2.56e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.49	-0.3	2.38e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg02423579	chr7:2872169	GNA12	-0.79	-13.76	-0.56	7.21e-36	Height;
LUAD	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg07636037	chr3:49044803	WDR6	0.55	10.28	0.45	2.86e-22	Menarche (age at onset);
LUAD	cis	rs12711979	0.509	rs10205540	chr2:3827839	A/G	cg17052675	chr2:3827356	NA	-0.85	-20.56	-0.71	1.25e-65	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs7274811	0.846	rs57668191	chr20:32289763	A/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.48	-6.85	-0.32	2.61e-11	Height;
LUAD	cis	rs2835872	0.758	rs1787399	chr21:39037883	A/G	cg06728970	chr21:39037746	KCNJ6	0.41	7.74	0.35	7.6e-14	Electroencephalographic traits in alcoholism;
LUAD	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06544989	chr22:39130855	UNC84B	0.45	9.2	0.41	1.66e-18	Menopause (age at onset);
LUAD	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg15181151	chr6:150070149	PCMT1	0.34	6.51	0.3	2.1e-10	Lung cancer;
LUAD	cis	rs1044573	0.514	rs2268879	chr20:25177805	C/T	cg08601574	chr20:25228251	PYGB	-0.36	-6.61	-0.31	1.13e-10	Allergic rhinitis;
LUAD	cis	rs4253772	0.872	rs45528736	chr22:46638312	A/G	cg09491104	chr22:46646882	C22orf40	-0.54	-7.83	-0.36	4.09e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg26441486	chr22:50317300	CRELD2	0.44	6.67	0.31	8.26e-11	Schizophrenia;
LUAD	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg07507251	chr3:52567010	NT5DC2	0.36	6.41	0.3	3.98e-10	Bipolar disorder;
LUAD	cis	rs7072216	0.763	rs10883090	chr10:100167236	G/C	cg26618903	chr10:100175079	PYROXD2	-0.36	-7.87	-0.36	3.07e-14	Metabolite levels;
LUAD	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg06618935	chr21:46677482	NA	-0.49	-10.11	-0.44	1.19e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg02018176	chr4:1364513	KIAA1530	0.43	7.57	0.35	2.34e-13	Obesity-related traits;
LUAD	cis	rs9473147	0.543	rs9473126	chr6:47481833	C/G	cg02130027	chr6:47444894	CD2AP	0.38	7.1	0.33	5.44e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg06028605	chr16:24865363	SLC5A11	0.39	6.92	0.32	1.65e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	1.000	rs4882117	chr11:48565468	G/T	cg00717180	chr2:96193071	NA	-0.4	-7.46	-0.34	4.97e-13	HDL cholesterol;
LUAD	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg25233709	chr10:116636983	FAM160B1	0.44	8.87	0.4	2.13e-17	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg13600149	chr9:98079129	FANCC	-0.42	-7.29	-0.33	1.49e-12	Subcortical brain region volumes;
LUAD	cis	rs12976411	0.575	rs55679515	chr19:32823044	G/A	cg18253629	chr19:32836317	ZNF507	0.65	6.84	0.32	2.87e-11	Coronary artery disease;
LUAD	cis	rs13315871	0.929	rs11715290	chr3:58298413	C/T	cg20936604	chr3:58311152	NA	-0.75	-7.61	-0.35	1.82e-13	Cholesterol, total;
LUAD	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs796364	0.616	rs2103094	chr2:200687954	T/C	cg23649088	chr2:200775458	C2orf69	0.52	6.5	0.3	2.33e-10	Schizophrenia;
LUAD	cis	rs6062509	1.000	rs6011066	chr20:62364180	G/A	cg02966332	chr20:62369605	LIME1	-0.47	-7.7	-0.35	9.85e-14	Prostate cancer;
LUAD	cis	rs7216064	0.953	rs12601759	chr17:65955284	A/G	cg08758996	chr17:66097529	LOC651250	0.47	7.11	0.33	4.88e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg22681709	chr2:178499509	PDE11A	-0.51	-8.28	-0.37	1.58e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.69	-0.35	1.07e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12681287	0.752	rs67615966	chr8:87255203	C/A	cg27223183	chr8:87520930	FAM82B	-0.59	-8.05	-0.36	8.64e-15	Caudate activity during reward;
LUAD	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg08807101	chr21:30365312	RNF160	0.44	7.65	0.35	1.36e-13	Dental caries;
LUAD	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg06544989	chr22:39130855	UNC84B	0.43	8.54	0.38	2.52e-16	Menopause (age at onset);
LUAD	cis	rs1143633	0.566	rs12987491	chr2:113691499	G/A	cg12858261	chr2:113808755	IL1F8	-0.39	-7.16	-0.33	3.55e-12	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2239547	0.562	rs2581810	chr3:52960859	C/T	cg11645453	chr3:52864694	ITIH4	-0.54	-10.31	-0.45	2.15e-22	Schizophrenia;
LUAD	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg23018236	chr17:30244563	NA	-0.69	-8.48	-0.38	3.69e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs11811982	0.793	rs115823838	chr1:227303587	C/T	cg24860534	chr1:227506868	CDC42BPA	0.64	6.51	0.3	2.17e-10	Optic disc area;
LUAD	cis	rs9902453	0.934	rs4427857	chr17:28457989	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.85	0.43	9.94e-21	Coffee consumption (cups per day);
LUAD	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.59	-0.39	1.67e-16	Total body bone mineral density;
LUAD	cis	rs10821973	0.527	rs1368158	chr10:64000878	T/G	cg09941381	chr10:64027924	RTKN2	-0.35	-6.85	-0.32	2.64e-11	Hypothyroidism;
LUAD	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg20362242	chr5:692897	TPPP	0.46	6.54	0.3	1.74e-10	Obesity-related traits;
LUAD	trans	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	10.5	0.45	4.57e-23	Type 2 diabetes;
LUAD	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg21028142	chr17:79581711	NPLOC4	0.43	8.83	0.39	2.75e-17	Eye color traits;
LUAD	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg18944383	chr4:111397179	ENPEP	0.5	8.85	0.4	2.44e-17	Coronary artery disease;
LUAD	cis	rs714027	0.837	rs713875	chr22:30592487	C/G	cg00539347	chr22:30592296	NA	-0.29	-6.81	-0.31	3.38e-11	Lymphocyte counts;
LUAD	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg13722127	chr7:150037890	RARRES2	0.52	8.87	0.4	2.12e-17	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg14893161	chr1:205819251	PM20D1	-0.52	-7.9	-0.36	2.51e-14	Menarche (age at onset);
LUAD	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg21699342	chr2:239360505	ASB1	0.56	10.86	0.47	2.06e-24	Multiple system atrophy;
LUAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg20607798	chr8:58055168	NA	0.81	9.75	0.43	2.11e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg05283184	chr6:79620031	NA	-0.6	-11.63	-0.49	2.46e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs4713675	0.584	rs6457739	chr6:33673831	A/G	cg14003231	chr6:33640908	ITPR3	0.49	9.52	0.42	1.33e-19	Plateletcrit;
LUAD	cis	rs62400317	0.826	rs4400216	chr6:45237955	T/G	cg20913747	chr6:44695427	NA	-0.42	-6.69	-0.31	6.92e-11	Total body bone mineral density;
LUAD	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg07169764	chr2:136633963	MCM6	0.82	9.54	0.42	1.13e-19	Corneal structure;
LUAD	trans	rs8073060	0.821	rs11080355	chr17:33872694	T/A	cg19694781	chr19:47549865	TMEM160	0.8	12.83	0.53	4.72e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	trans	rs79976124	1.000	rs79976124	chr6:66618657	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	9.79	0.43	1.55e-20	Type 2 diabetes;
LUAD	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg15181151	chr6:150070149	PCMT1	0.42	8.53	0.38	2.61e-16	Lung cancer;
LUAD	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg18209359	chr17:80159595	CCDC57	-0.38	-6.35	-0.3	5.5e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs62400317	0.859	rs17209678	chr6:45163601	C/T	cg18551225	chr6:44695536	NA	-0.56	-8.56	-0.38	2.1e-16	Total body bone mineral density;
LUAD	cis	rs1595825	0.786	rs74484541	chr2:198894223	T/C	cg00982548	chr2:198649783	BOLL	-0.65	-9.18	-0.41	1.88e-18	Ulcerative colitis;
LUAD	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-8.88	-0.4	1.91e-17	Blood metabolite levels;
LUAD	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg01884057	chr2:25150051	NA	0.4	8.64	0.39	1.18e-16	Body mass index in non-asthmatics;
LUAD	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg27539214	chr16:67997921	SLC12A4	-0.64	-7.86	-0.36	3.28e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg18129748	chr3:49941408	MST1R	0.39	6.44	0.3	3.3e-10	Body mass index;
LUAD	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-11.22	-0.48	9.77e-26	Asthma;
LUAD	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.22	0.37	2.51e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.88	0.53	2.85e-32	Cognitive ability;
LUAD	cis	rs2625529	0.689	rs12161990	chr15:72202440	T/C	cg16672083	chr15:72433130	SENP8	0.67	12.13	0.51	2.99e-29	Red blood cell count;
LUAD	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.72	-0.31	5.98e-11	Total body bone mineral density;
LUAD	cis	rs68170813	0.559	rs5002976	chr7:107050620	C/G	cg02696742	chr7:106810147	HBP1	-0.79	-10.37	-0.45	1.35e-22	Coronary artery disease;
LUAD	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg12179176	chr11:130786555	SNX19	0.55	9.27	0.41	9.37e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs12216545	0.737	rs1916010	chr7:150234051	A/G	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.54	-0.3	1.81e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1816752	0.719	rs11843470	chr13:24997699	A/C	cg02811702	chr13:24901961	NA	0.43	7.54	0.34	2.9e-13	Obesity-related traits;
LUAD	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03517284	chr6:25882590	NA	-0.57	-9.28	-0.41	8.66e-19	Blood metabolite levels;
LUAD	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.93	0.53	1.89e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10089	0.953	rs1432614	chr5:127416919	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	9.91	0.43	5.89e-21	Ileal carcinoids;
LUAD	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18404041	chr3:52824283	ITIH1	-0.61	-12.47	-0.52	1.32e-30	Bipolar disorder;
LUAD	cis	rs57590327	0.503	rs13080520	chr3:81850742	T/C	cg07356753	chr3:81810745	GBE1	-0.54	-8.73	-0.39	6.11e-17	Extraversion;
LUAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-8.87	-0.4	2.01e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-12.07	-0.51	5e-29	Bipolar disorder;
LUAD	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg07402062	chr16:89894098	SPIRE2	0.46	11.8	0.5	5.79e-28	Vitiligo;
LUAD	cis	rs34638657	0.797	rs11645045	chr16:82202137	G/A	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.66	-0.31	8.73e-11	Lung adenocarcinoma;
LUAD	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg05340658	chr4:99064831	C4orf37	0.44	6.81	0.31	3.34e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg05402854	chr6:111408840	SLC16A10	-0.36	-6.38	-0.3	4.68e-10	Vertical cup-disc ratio;
LUAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg02869364	chr7:1081709	C7orf50	-0.51	-6.55	-0.3	1.71e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg18446336	chr7:2847575	GNA12	-0.37	-6.82	-0.31	3.19e-11	Height;
LUAD	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg14668632	chr7:2872130	GNA12	-0.48	-8.45	-0.38	4.76e-16	Height;
LUAD	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.75	-0.35	6.76e-14	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06370812	chr3:195501042	MUC4	0.5	6.36	0.3	5.38e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	7.37	0.34	8.87e-13	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg02524346	chr8:600233	NA	1.07	10.66	0.46	1.18e-23	IgG glycosylation;
LUAD	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg05110241	chr16:68378359	PRMT7	-0.84	-9.16	-0.41	2.2e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs57590327	0.503	rs12638997	chr3:81844912	A/G	cg07356753	chr3:81810745	GBE1	-0.61	-9.96	-0.44	3.99e-21	Extraversion;
LUAD	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg11901034	chr3:128598214	ACAD9	-0.49	-7.61	-0.35	1.8e-13	IgG glycosylation;
LUAD	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.34	-0.34	1.09e-12	Lung cancer;
LUAD	cis	rs59698941	0.527	rs7719428	chr5:132180919	C/G	cg14825688	chr5:132208181	LEAP2	0.53	10.8	0.46	3.5e-24	Apolipoprotein A-IV levels;
LUAD	cis	rs7705042	0.865	rs12656877	chr5:141490091	T/C	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.53	-0.3	1.84e-10	Asthma;
LUAD	cis	rs7851660	0.809	rs1561961	chr9:100667599	C/T	cg13688889	chr9:100608707	NA	-0.54	-9.1	-0.4	3.64e-18	Strep throat;
LUAD	trans	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.53	8.07	0.37	7.09e-15	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg12564285	chr5:131593104	PDLIM4	-0.35	-6.69	-0.31	7.2e-11	Acylcarnitine levels;
LUAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg22907277	chr7:1156413	C7orf50	0.68	8.0	0.36	1.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4664308	0.967	rs7563607	chr2:160910215	C/G	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.75	-0.31	4.93e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-7.76	-0.35	6.65e-14	Tonsillectomy;
LUAD	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg13535736	chr9:111863775	C9orf5	0.44	6.9	0.32	1.93e-11	Menarche (age at onset);
LUAD	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08045932	chr20:61659980	NA	0.51	9.67	0.43	4.09e-20	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg02734326	chr4:10020555	SLC2A9	0.57	10.04	0.44	1.99e-21	Bone mineral density;
LUAD	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.6	-7.19	-0.33	3.02e-12	Body mass index;
LUAD	cis	rs11958404	0.615	rs6884132	chr5:157437035	G/A	cg05962755	chr5:157440814	NA	0.41	7.62	0.35	1.7e-13	IgG glycosylation;
LUAD	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg16006841	chr5:176797999	RGS14	0.54	9.74	0.43	2.25e-20	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs12519773	0.501	rs4321736	chr5:92533363	C/T	cg18783429	chr5:92414398	NA	0.45	7.91	0.36	2.25e-14	Migraine;
LUAD	cis	rs67981189	0.529	rs8181986	chr14:71582244	G/A	cg15910301	chr14:71632612	NA	0.42	6.68	0.31	7.59e-11	Schizophrenia;
LUAD	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg00339695	chr16:24857497	SLC5A11	0.7	11.33	0.48	3.71e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg08601574	chr20:25228251	PYGB	0.49	8.99	0.4	8.08e-18	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7737355	0.898	rs1016068	chr5:131100246	T/C	cg25547332	chr5:131281432	NA	0.45	6.76	0.31	4.47e-11	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg17366294	chr4:99064904	C4orf37	-0.65	-12.49	-0.52	1.0500000000000001e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4683142	0.518	rs7653682	chr3:46029271	A/G	cg11211486	chr3:46033800	FYCO1	-0.4	-6.55	-0.3	1.68e-10	Methadone dose in opioid dependence;
LUAD	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg05665937	chr4:1216051	CTBP1	-0.41	-7.3	-0.33	1.48e-12	Obesity-related traits;
LUAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg18402987	chr7:1209562	NA	0.61	8.76	0.39	4.63e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg07157834	chr1:205819609	PM20D1	0.46	7.68	0.35	1.13e-13	Menarche (age at onset);
LUAD	cis	rs10864907	0.614	rs12711745	chr2:113700355	T/C	cg12858261	chr2:113808755	IL1F8	0.39	7.17	0.33	3.27e-12	Pulmonary function;
LUAD	cis	rs7172809	0.573	rs8035526	chr15:77683247	T/G	cg11865553	chr15:77376250	NA	-0.39	-6.46	-0.3	2.91e-10	Glucose homeostasis traits;
LUAD	cis	rs6500395	1.000	rs12599028	chr16:48713082	C/A	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg26304593	chr6:42947056	PEX6	-0.46	-7.83	-0.36	4e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg11693508	chr17:37793320	STARD3	-0.76	-9.66	-0.43	4.39e-20	Bipolar disorder;
LUAD	cis	rs12431939	0.571	rs7493931	chr14:51736401	T/C	cg23942311	chr14:51606299	NA	0.45	7.0	0.32	1.02e-11	Cancer;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg18342900	chr16:46865048	C16orf87	0.42	6.86	0.32	2.38e-11	Bilirubin levels;
LUAD	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.37	-7.88	-0.36	2.87e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3849570	1.000	rs9826270	chr3:81841869	C/T	cg07356753	chr3:81810745	GBE1	-0.71	-12.54	-0.52	7.02e-31	Waist circumference;Body mass index;
LUAD	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg19622623	chr12:86230825	RASSF9	-0.45	-7.91	-0.36	2.3e-14	Major depressive disorder;
LUAD	trans	rs11039798	0.764	rs11040030	chr11:48800985	C/T	cg02254774	chr11:50257496	LOC441601	0.53	6.68	0.31	7.63e-11	Axial length;
LUAD	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6906287	0.647	rs35730412	chr6:118707343	T/C	cg05564266	chr6:118973597	C6orf204	0.34	7.09	0.33	5.56e-12	Electrocardiographic conduction measures;
LUAD	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg13390004	chr1:15929781	NA	0.49	8.61	0.39	1.49e-16	Systolic blood pressure;
LUAD	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg18240062	chr17:79603768	NPLOC4	0.46	8.08	0.37	6.63e-15	Eye color traits;
LUAD	cis	rs7539409	0.651	rs6576953	chr1:84316946	A/G	cg10977910	chr1:84465055	TTLL7	0.77	8.92	0.4	1.42e-17	Alzheimer's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17003783	chr8:33330584	FUT10	-0.59	-7.25	-0.33	1.98e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg25985355	chr7:65971099	NA	-0.55	-6.67	-0.31	8.05e-11	Diabetic kidney disease;
LUAD	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg20362242	chr5:692897	TPPP	0.55	6.82	0.31	3.22e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs1215050	0.755	rs7696354	chr4:98820330	T/C	cg17366294	chr4:99064904	C4orf37	0.47	8.16	0.37	3.82e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11051970	0.704	rs7312698	chr12:32554695	G/T	cg24626660	chr12:32551988	NA	0.34	7.22	0.33	2.39e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg26597838	chr10:835615	NA	1.04	16.91	0.64	2.28e-49	Eosinophil percentage of granulocytes;
LUAD	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg07776626	chr8:57350775	NA	-0.61	-9.07	-0.4	4.63e-18	Obesity-related traits;
LUAD	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg14458575	chr2:238380390	NA	0.86	12.88	0.53	2.93e-32	Prostate cancer;
LUAD	trans	rs7181230	0.885	rs8026641	chr15:40338861	C/T	cg22705835	chr10:65332833	REEP3	0.35	6.95	0.32	1.37e-11	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs6906287	0.669	rs2184402	chr6:118935341	T/C	cg21191810	chr6:118973309	C6orf204	0.51	9.8	0.43	1.47e-20	Electrocardiographic conduction measures;
LUAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg11062466	chr8:58055876	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg02569823	chr6:5851330	NA	0.4	6.42	0.3	3.69e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.07	-0.33	6.25e-12	Joint mobility (Beighton score);
LUAD	cis	rs6761276	0.837	rs11887823	chr2:113835311	T/A	cg02343335	chr2:113785852	IL1F8	-0.35	-7.01	-0.32	9.26e-12	Protein quantitative trait loci;
LUAD	cis	rs6076065	0.748	rs4815198	chr20:23343491	T/C	cg11657817	chr20:23433608	CST11	0.58	12.15	0.51	2.33e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10802521	chr3:52805072	NEK4	-0.61	-11.14	-0.48	1.83e-25	Electroencephalogram traits;
LUAD	cis	rs11031096	0.502	rs7935824	chr11:4046900	C/G	cg18678763	chr11:4115507	RRM1	-0.47	-7.74	-0.35	7.61e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg14968603	chr10:102046143	BLOC1S2	-0.45	-6.57	-0.3	1.5e-10	Testicular germ cell tumor;
LUAD	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg10556349	chr10:835070	NA	0.53	6.83	0.32	2.97e-11	Eosinophil percentage of granulocytes;
LUAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.63	-9.31	-0.41	7.09e-19	Alzheimer's disease;
LUAD	cis	rs8177876	0.818	rs59177227	chr16:81115129	G/T	cg08591886	chr16:81111003	C16orf46	-0.79	-7.37	-0.34	8.94e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.95	-0.32	1.37e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1829883	1.000	rs1829883	chr5:98781103	C/T	cg08333243	chr5:99726346	NA	-0.37	-7.1	-0.33	5.42e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs240764	0.658	rs6925823	chr6:101179273	C/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.64	-0.39	1.2e-16	Neuroticism;
LUAD	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg11663144	chr21:46675770	NA	-0.6	-11.83	-0.5	4.19e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2579500	0.807	rs4907200	chr2:97320737	T/G	cg23100626	chr2:96804247	ASTL	-0.29	-7.21	-0.33	2.66e-12	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg22079354	chr11:130786696	SNX19	0.37	6.38	0.3	4.76e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs12579753	0.917	rs10778834	chr12:82199742	A/C	cg07988820	chr12:82153109	PPFIA2	-0.45	-7.08	-0.33	6.05e-12	Resting heart rate;
LUAD	cis	rs9796	0.775	rs57393155	chr15:41426251	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.39	-7.12	-0.33	4.81e-12	Menopause (age at onset);
LUAD	trans	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg06606381	chr12:133084897	FBRSL1	-1.21	-10.77	-0.46	4.5e-24	Depression;
LUAD	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg06623918	chr6:96969491	KIAA0776	-0.74	-10.36	-0.45	1.51e-22	Migraine;Coronary artery disease;
LUAD	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg09509183	chr1:209979624	IRF6	0.37	6.52	0.3	1.96e-10	Monobrow;
LUAD	trans	rs2797160	1.000	rs1777225	chr6:126018270	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.55	8.63	0.39	1.29e-16	Endometrial cancer;
LUAD	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg02574844	chr11:5959923	NA	-0.43	-7.41	-0.34	7.04e-13	DNA methylation (variation);
LUAD	trans	rs853679	0.546	rs200981	chr6:27833174	A/G	cg01620082	chr3:125678407	NA	-0.83	-8.99	-0.4	8.47e-18	Depression;
LUAD	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg18404041	chr3:52824283	ITIH1	0.41	7.58	0.35	2.26e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.39	-7.16	-0.33	3.5e-12	Caffeine consumption;
LUAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg21724239	chr8:58056113	NA	-0.73	-9.77	-0.43	1.8899999999999998e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg25251562	chr2:3704773	ALLC	0.4	7.17	0.33	3.35e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg15704280	chr7:45808275	SEPT13	-0.74	-10.88	-0.47	1.83e-24	Coronary artery disease;
LUAD	cis	rs4888262	0.526	rs7193508	chr16:74628630	G/T	cg01733217	chr16:74700730	RFWD3	0.5	8.53	0.38	2.54e-16	Testicular germ cell tumor;
LUAD	cis	rs17095355	0.818	rs7090570	chr10:111772798	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.41	-0.34	7.11e-13	Biliary atresia;
LUAD	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg06544989	chr22:39130855	UNC84B	0.4	7.25	0.33	2.04e-12	Menopause (age at onset);
LUAD	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg18230493	chr5:56204884	C5orf35	0.42	7.2	0.33	2.75e-12	Coronary artery disease;
LUAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg18621852	chr3:10150065	C3orf24	0.46	7.98	0.36	1.39e-14	Alzheimer's disease;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg03000844	chr2:242641386	ING5	-0.55	-6.64	-0.31	9.81e-11	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	trans	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.91	-0.32	1.8e-11	Gout;
LUAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg09060608	chr5:178986726	RUFY1	0.61	10.55	0.46	2.86e-23	Lung cancer;
LUAD	trans	rs9393777	0.920	rs67859638	chr6:27357978	A/G	cg01620082	chr3:125678407	NA	-1.1	-10.13	-0.44	1.01e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs897984	0.568	rs8063565	chr16:30883965	G/C	cg02466173	chr16:30829666	NA	0.64	10.24	0.45	3.99e-22	Dementia with Lewy bodies;
LUAD	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg11317459	chr13:21872234	NA	-1.09	-14.71	-0.58	7.3e-40	White matter hyperintensity burden;
LUAD	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.1	-0.33	5.25e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs1461503	0.809	rs7121955	chr11:122845478	A/T	cg27398637	chr11:122830231	C11orf63	-0.35	-6.65	-0.31	9.35e-11	Menarche (age at onset);
LUAD	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg00316803	chr15:76480434	C15orf27	-0.41	-7.76	-0.35	6.3e-14	Blood metabolite levels;
LUAD	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg26343298	chr8:95960752	TP53INP1	0.38	7.96	0.36	1.64e-14	Type 2 diabetes;
LUAD	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg13319975	chr6:146136371	FBXO30	-0.61	-10.59	-0.46	2.17e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg05535760	chr7:792225	HEATR2	0.83	11.14	0.48	1.81e-25	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4660214	0.724	rs3931300	chr1:39660847	A/G	cg27567593	chr1:39956653	BMP8A	0.36	7.06	0.32	7e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg02584489	chr3:37493436	ITGA9	0.39	6.42	0.3	3.69e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg00666640	chr1:248458726	OR2T12	0.32	7.58	0.35	2.28e-13	Common traits (Other);
LUAD	trans	rs2735413	0.918	rs12918959	chr16:78081719	T/C	cg01028844	chr5:122736986	CEP120	0.41	6.48	0.3	2.6200000000000003e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg21775007	chr8:11205619	TDH	-0.41	-7.35	-0.34	1.05e-12	Systolic blood pressure;
LUAD	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg12863693	chr15:85201151	NMB	0.42	7.61	0.35	1.85e-13	Schizophrenia;
LUAD	cis	rs7737355	1.000	rs6596010	chr5:130625411	G/A	cg06307176	chr5:131281290	NA	0.44	7.1	0.33	5.34e-12	Life satisfaction;
LUAD	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg07936489	chr17:37558343	FBXL20	-0.52	-6.99	-0.32	1.08e-11	Glomerular filtration rate (creatinine);
LUAD	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg27661571	chr11:113659931	NA	-0.56	-6.92	-0.32	1.69e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg15962314	chr1:44399869	ARTN	0.32	6.99	0.32	1.05e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg12714757	chr17:73874637	TRIM47	-0.43	-6.64	-0.31	9.84e-11	Psoriasis;
LUAD	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg15017067	chr4:17643749	FAM184B	0.36	7.17	0.33	3.37e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg17366294	chr4:99064904	C4orf37	0.67	12.57	0.52	5.14e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg22920501	chr2:26401640	FAM59B	-0.96	-14.21	-0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg22532475	chr10:104410764	TRIM8	-0.43	-7.94	-0.36	1.8e-14	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg23803603	chr1:2058230	PRKCZ	0.41	6.67	0.31	7.78e-11	Height;
LUAD	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg09184832	chr6:79620586	NA	0.48	8.83	0.39	2.91e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg25324976	chr17:61989376	CSHL1	0.38	7.39	0.34	7.83e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.51	0.42	1.4e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg04450456	chr4:17643702	FAM184B	0.39	7.85	0.36	3.54e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg11062466	chr8:58055876	NA	0.7	9.28	0.41	8.92e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.45	-7.98	-0.36	1.36e-14	Caffeine consumption;
LUAD	cis	rs7828089	0.582	rs13259873	chr8:22266292	C/T	cg12081754	chr8:22256438	SLC39A14	0.74	12.3	0.51	5.98e-30	Verbal declarative memory;
LUAD	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.6	0.42	7.16e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg10523679	chr1:76189770	ACADM	0.9	16.17	0.62	3.77e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg10523679	chr1:76189770	ACADM	0.87	15.49	0.6	3.36e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg11250194	chr11:61601937	FADS2	-0.63	-8.43	-0.38	5.3e-16	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs2019216	0.521	rs2175657	chr17:21908494	T/G	cg05591447	chr17:21909280	FLJ36000	-0.27	-6.62	-0.31	1.11e-10	Pelvic organ prolapse;
LUAD	cis	rs9314323	0.524	rs7816609	chr8:26202482	A/C	cg13160058	chr8:26243215	BNIP3L	-0.38	-7.87	-0.36	2.99e-14	Red cell distribution width;
LUAD	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.55e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10465746	0.905	rs12738214	chr1:84359050	C/A	cg10977910	chr1:84465055	TTLL7	0.5	7.97	0.36	1.52e-14	Obesity-related traits;
LUAD	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg21138405	chr5:131827807	IRF1	0.3	6.45	0.3	3.02e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg19678392	chr7:94953810	PON1	-0.74	-13.88	-0.56	2.42e-36	Paraoxonase activity;
LUAD	cis	rs10193935	0.901	rs10201586	chr2:42622594	C/G	cg27598129	chr2:42591480	NA	-0.7	-9.14	-0.41	2.54e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg26924012	chr15:45694286	SPATA5L1	1.02	18.92	0.68	2.86e-58	Homoarginine levels;
LUAD	cis	rs1595825	0.838	rs80172713	chr2:198508044	T/C	cg10547527	chr2:198650123	BOLL	-0.54	-7.56	-0.35	2.52e-13	Ulcerative colitis;
LUAD	cis	rs1232027	0.622	rs2897262	chr5:79962676	A/G	cg24059623	chr5:79951536	MSH3;DHFR	0.43	6.93	0.32	1.54e-11	Huntington's disease progression;
LUAD	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg21960279	chr19:17905606	B3GNT3	0.47	9.15	0.41	2.37e-18	Tumor biomarkers;
LUAD	cis	rs7524258	0.868	rs1304712	chr1:7270538	C/T	cg07173049	chr1:7289937	CAMTA1	0.49	9.46	0.42	2.18e-19	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg19773385	chr1:10388646	KIF1B	-0.41	-6.7	-0.31	6.53e-11	Hepatocellular carcinoma;
LUAD	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg11663144	chr21:46675770	NA	-0.61	-12.2	-0.51	1.51e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9796	0.866	rs2176998	chr15:41420807	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.38	-7.06	-0.32	6.87e-12	Menopause (age at onset);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14107975	chr11:96076498	MAML2	-0.56	-6.78	-0.31	4.1e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg03563238	chr19:33554763	RHPN2	-0.38	-8.86	-0.4	2.3e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg01802117	chr1:53393560	SCP2	0.35	6.94	0.32	1.52e-11	Monocyte count;
LUAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg08470875	chr2:26401718	FAM59B	-0.77	-10.37	-0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs2455601	0.608	rs16906256	chr11:8887097	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-8.32	-0.37	1.24e-15	Schizophrenia;
LUAD	cis	rs11649653	0.502	rs4889490	chr16:30823047	A/C	cg02466173	chr16:30829666	NA	-0.54	-9.75	-0.43	2.11e-20	Triglycerides;
LUAD	trans	rs7395662	1.000	rs7479134	chr11:48625409	A/C	cg15704280	chr7:45808275	SEPT13	-0.41	-6.47	-0.3	2.71e-10	HDL cholesterol;
LUAD	cis	rs7089973	0.584	rs4752255	chr10:116576790	C/T	cg23260525	chr10:116636907	FAM160B1	0.47	10.38	0.45	1.23e-22	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs11031096	0.782	rs7130580	chr11:4169301	G/A	cg18678763	chr11:4115507	RRM1	-0.43	-7.52	-0.34	3.39e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg04775059	chr7:64541387	NA	0.58	9.43	0.42	2.66e-19	Calcium levels;
LUAD	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg08859206	chr1:53392774	SCP2	-0.67	-12.65	-0.52	2.42e-31	Monocyte count;
LUAD	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.31	-0.34	1.32e-12	Glomerular filtration rate;
LUAD	cis	rs12681287	0.547	rs10087788	chr8:87544174	G/A	cg27223183	chr8:87520930	FAM82B	0.72	10.23	0.45	4.23e-22	Caudate activity during reward;
LUAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg00280220	chr17:61926910	NA	0.36	6.98	0.32	1.17e-11	Prudent dietary pattern;
LUAD	cis	rs8130944	0.859	rs2300958	chr21:44119561	G/C	cg16784985	chr21:44105474	PDE9A	-0.38	-6.57	-0.3	1.46e-10	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.53	-0.3	1.9e-10	Total body bone mineral density;
LUAD	cis	rs7617773	0.780	rs4479622	chr3:48338173	C/T	cg11946769	chr3:48343235	NME6	0.44	6.8	0.31	3.52e-11	Coronary artery disease;
LUAD	cis	rs3125734	0.571	rs7100401	chr10:64024417	C/G	cg09941381	chr10:64027924	RTKN2	-0.31	-7.22	-0.33	2.41e-12	Rheumatoid arthritis;
LUAD	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg12311346	chr5:56204834	C5orf35	1.14	17.39	0.65	1.71e-51	Initial pursuit acceleration;
LUAD	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18876405	chr7:65276391	NA	-0.42	-6.63	-0.31	1.02e-10	Aortic root size;
LUAD	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg12483005	chr1:23474871	LUZP1	0.52	9.0	0.4	7.99e-18	Height;
LUAD	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg21220214	chr8:57350948	NA	-0.61	-8.96	-0.4	1.08e-17	Obesity-related traits;
LUAD	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23158103	chr7:148848205	ZNF398	-0.63	-11.62	-0.49	2.83e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs10838798	0.523	rs11039543	chr11:48168103	G/A	cg00717180	chr2:96193071	NA	-0.41	-7.43	-0.34	5.97e-13	Height;
LUAD	trans	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg25894440	chr7:65020034	NA	-0.64	-6.82	-0.31	3.21e-11	Gout;
LUAD	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg10876282	chr6:28092338	ZSCAN16	0.44	6.59	0.31	1.28e-10	Parkinson's disease;
LUAD	cis	rs10203711	1.000	rs6713610	chr2:239566874	C/A	cg14580085	chr2:239553406	NA	0.41	8.9	0.4	1.64e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.93	-0.61	4.48e-45	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg05110241	chr16:68378359	PRMT7	-0.7	-7.93	-0.36	1.93e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg22535103	chr8:58192502	C8orf71	-0.74	-10.44	-0.45	7.32e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg09904177	chr6:26538194	HMGN4	0.43	7.26	0.33	1.86e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg22875332	chr1:76189707	ACADM	0.86	15.85	0.61	9.91e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg05896524	chr21:47604654	C21orf56	0.56	9.33	0.41	5.95e-19	Testicular germ cell tumor;
LUAD	cis	rs3862030	0.694	rs41306870	chr10:104229785	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-8.02	-0.36	1.06e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.29	6.73	0.31	5.55e-11	Prostate cancer;
LUAD	cis	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-7.83	-0.36	4.06e-14	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg16006841	chr5:176797999	RGS14	-0.59	-9.33	-0.41	5.81e-19	Urate levels in lean individuals;
LUAD	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg04352962	chr1:209979756	IRF6	0.51	6.53	0.3	1.84e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg04632378	chr13:21900426	NA	0.43	7.52	0.34	3.35e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg06784218	chr1:46089804	CCDC17	-0.53	-11.84	-0.5	3.99e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.19	0.33	2.91e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.78	-0.31	4.13e-11	Diabetic kidney disease;
LUAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg13047869	chr3:10149882	C3orf24	0.69	11.79	0.5	6.4e-28	Alzheimer's disease;
LUAD	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg07700843	chr1:2391317	NA	-0.51	-11.79	-0.5	6.0500000000000004e-28	Schizophrenia;
LUAD	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg17845761	chr1:175162550	KIAA0040	-0.37	-9.63	-0.42	5.64e-20	Alcohol dependence;
LUAD	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg06608945	chr2:219082296	ARPC2	-0.42	-6.98	-0.32	1.12e-11	Colorectal cancer;
LUAD	cis	rs921968	0.565	rs12612395	chr2:219621642	G/C	cg02176678	chr2:219576539	TTLL4	-0.57	-11.35	-0.48	2.94e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg19678392	chr7:94953810	PON1	-0.59	-8.28	-0.37	1.58e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	8.83	0.39	2.84e-17	Mean corpuscular volume;
LUAD	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg11645453	chr3:52864694	ITIH4	0.58	11.0	0.47	6.28e-25	Schizophrenia;
LUAD	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.22	-0.41	1.46e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs78761021	0.867	rs17681708	chr17:9792872	T/C	cg26853458	chr17:9805074	RCVRN	0.36	7.0	0.32	1.03e-11	Type 2 diabetes;
LUAD	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.75	-0.35	6.69e-14	Breast cancer;
LUAD	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23583168	chr7:148888333	NA	1.03	25.16	0.77	4.56e-86	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg23262351	chr6:79576851	IRAK1BP1	0.44	7.49	0.34	4.03e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg11822812	chr5:140052017	DND1	0.38	7.03	0.32	8.08e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg15147215	chr3:52552868	STAB1	-0.4	-7.49	-0.34	3.96e-13	Electroencephalogram traits;
LUAD	cis	rs62238980	0.614	rs75840726	chr22:32425834	A/G	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	trans	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg07393940	chr7:158741817	NA	-0.69	-11.89	-0.5	2.57e-28	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg27129171	chr3:47204927	SETD2	0.43	6.99	0.32	1.1e-11	Colorectal cancer;
LUAD	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg22529645	chr1:3704559	LRRC47	0.56	10.52	0.46	3.7e-23	Red cell distribution width;
LUAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg03188948	chr7:1209495	NA	0.75	9.77	0.43	1.88e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504073	0.647	rs4873312	chr8:49991145	A/G	cg00325661	chr8:49890786	NA	0.45	10.17	0.44	6.95e-22	Blood metabolite ratios;
LUAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08677398	chr8:58056175	NA	0.49	6.41	0.3	3.84e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10211518	chr19:633735	POLRMT	0.44	6.95	0.32	1.42e-11	Gut microbiome composition (summer);
LUAD	cis	rs3812762	0.957	rs6484008	chr11:8754148	A/G	cg03980550	chr11:8754370	ST5	0.37	6.62	0.31	1.08e-10	Hypospadias;
LUAD	cis	rs75920871	0.841	rs7112967	chr11:116831912	C/T	cg04087571	chr11:116723030	SIK3	-0.32	-6.43	-0.3	3.37e-10	Subjective well-being;
LUAD	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg11494091	chr17:61959527	GH2	-0.77	-19.76	-0.69	4.91e-62	Prudent dietary pattern;
LUAD	trans	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg24644049	chr4:85504048	CDS1	0.88	7.19	0.33	2.97e-12	Skin colour saturation;
LUAD	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg23229984	chr5:148520753	ABLIM3	0.49	7.52	0.34	3.37e-13	Breast cancer;
LUAD	cis	rs4900538	0.855	rs12587464	chr14:102886561	G/C	cg18135206	chr14:102964638	TECPR2	-1.02	-20.71	-0.71	2.72e-66	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09263875	chr16:632152	PIGQ	0.83	17.9	0.66	9.32e-54	Height;
LUAD	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg24578937	chr1:2090814	PRKCZ	-0.55	-11.4	-0.48	1.89e-26	Height;
LUAD	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg14530993	chr4:882597	GAK	0.81	7.97	0.36	1.48e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.27	-0.37	1.75e-15	Schizophrenia;
LUAD	cis	rs2447097	0.935	rs2447094	chr17:2294048	A/C	cg27406664	chr17:2294951	MNT	0.65	13.71	0.55	1.14e-35	Autism spectrum disorder;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04804616	chr16:30622014	ZNF689	-0.41	-6.55	-0.3	1.69e-10	Cancer;
LUAD	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.65	-0.31	8.93e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs17826219	0.789	rs4794873	chr17:28748352	C/T	cg19761014	chr17:28927070	LRRC37B2	0.69	6.95	0.32	1.42e-11	Body mass index;
LUAD	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg18806716	chr10:30721971	MAP3K8	-0.78	-16.49	-0.63	1.58e-47	Inflammatory bowel disease;
LUAD	cis	rs7582720	1.000	rs3845800	chr2:203734365	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.66	-8.8	-0.39	3.4e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs11614062	0.761	rs11107115	chr12:93972987	A/G	cg18151635	chr12:93972918	NA	-0.79	-11.82	-0.5	4.53e-28	Height;
LUAD	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg00071950	chr4:10020882	SLC2A9	-0.62	-11.9	-0.5	2.32e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.33	-8.26	-0.37	1.91e-15	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	trans	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.28	0.45	2.82e-22	Mean corpuscular volume;
LUAD	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg18811423	chr2:55921094	PNPT1	0.51	8.34	0.38	1.05e-15	Metabolic syndrome;
LUAD	cis	rs1595825	0.732	rs2340687	chr2:198460040	T/G	cg00982548	chr2:198649783	BOLL	-0.52	-6.91	-0.32	1.84e-11	Ulcerative colitis;
LUAD	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.43	-0.45	7.96e-23	Monocyte percentage of white cells;
LUAD	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg18827107	chr12:86230957	RASSF9	-0.48	-8.67	-0.39	9.58e-17	Major depressive disorder;
LUAD	trans	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg26811252	chr16:29126840	RRN3P2	-0.53	-8.98	-0.4	9.3e-18	Menopause (age at onset);
LUAD	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg21385522	chr1:16154831	NA	0.59	8.7	0.39	7.41e-17	Dilated cardiomyopathy;
LUAD	trans	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg21659725	chr3:3221576	CRBN	0.4	6.71	0.31	6.2e-11	Resting heart rate;
LUAD	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg18209359	chr17:80159595	CCDC57	-0.4	-6.8	-0.31	3.61e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg12458913	chr13:53173898	NA	0.41	7.37	0.34	8.97e-13	Lewy body disease;
LUAD	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-23.72	-0.76	1.02e-79	Height;
LUAD	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27297192	chr10:134578999	INPP5A	0.38	6.7	0.31	6.64e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.42	-0.42	2.89e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg18538332	chr22:24372958	LOC391322	-0.58	-9.88	-0.43	7.65e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3820068	0.580	rs12760698	chr1:16009814	G/A	cg24675056	chr1:15929824	NA	0.47	7.93	0.36	1.93e-14	Systolic blood pressure;
LUAD	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.91	0.36	2.31e-14	Parkinson's disease;
LUAD	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.2	-0.51	1.56e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4862307	0.836	rs11132220	chr4:184997247	A/T	cg06737308	chr4:185021514	ENPP6	-0.59	-10.09	-0.44	1.33e-21	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg03806693	chr22:41940476	POLR3H	0.71	10.22	0.44	4.7e-22	Vitiligo;
LUAD	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg03733263	chr8:22462867	KIAA1967	-0.75	-12.85	-0.53	3.99e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg08645402	chr16:4508243	NA	-0.54	-9.78	-0.43	1.67e-20	Schizophrenia;
LUAD	trans	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg19862616	chr7:65841803	NCRNA00174	1.04	25.75	0.78	1.24e-88	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg19717773	chr7:2847554	GNA12	-0.55	-10.3	-0.45	2.39e-22	Height;
LUAD	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg05340658	chr4:99064831	C4orf37	-0.45	-7.36	-0.34	9.83e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg17330251	chr7:94953956	PON1	-0.55	-7.65	-0.35	1.41e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7589728	0.748	rs35051888	chr2:88482258	G/A	cg14558114	chr2:88469736	THNSL2	0.79	8.2	0.37	2.81e-15	Plasma clusterin levels;
LUAD	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.61	-11.49	-0.49	9.09e-27	Schizophrenia;
LUAD	cis	rs68170813	0.523	rs7777976	chr7:106888594	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.51	-0.46	3.96e-23	Coronary artery disease;
LUAD	cis	rs12410462	0.901	rs2814090	chr1:227658444	C/G	cg23173402	chr1:227635558	NA	-0.64	-7.64	-0.35	1.49e-13	Major depressive disorder;
LUAD	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg25769590	chr7:158789503	NA	-0.38	-7.04	-0.32	7.62e-12	Facial morphology (factor 20);
LUAD	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	8.08	0.37	6.84e-15	Breast cancer;
LUAD	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24531977	chr5:56204891	C5orf35	-0.99	-15.28	-0.6	2.86e-42	Initial pursuit acceleration;
LUAD	cis	rs870825	0.520	rs10022842	chr4:185649459	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs7584330	0.518	rs13420503	chr2:238437623	G/A	cg14458575	chr2:238380390	NA	0.6	9.31	0.41	7.14e-19	Prostate cancer;
LUAD	cis	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg12964065	chr18:77638022	KCNG2	0.55	6.84	0.32	2.85e-11	Opioid sensitivity;
LUAD	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-6.86	-0.32	2.39e-11	Bladder cancer;
LUAD	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg10802521	chr3:52805072	NEK4	-0.44	-6.4	-0.3	4.1e-10	Schizophrenia;
LUAD	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	7.22	0.33	2.51e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7584330	0.554	rs10173100	chr2:238433040	A/G	cg14458575	chr2:238380390	NA	0.6	9.5	0.42	1.5700000000000001e-19	Prostate cancer;
LUAD	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg14689365	chr7:158441557	NCAPG2	0.4	6.8	0.31	3.67e-11	Height;
LUAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.83	0.43	1.14e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1997103	0.954	rs4947505	chr7:55409448	T/C	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg03806693	chr22:41940476	POLR3H	0.55	8.13	0.37	4.65e-15	Vitiligo;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03624415	chr15:64995499	OAZ2	-0.46	-7.11	-0.33	4.87e-12	Height;
LUAD	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg27124370	chr19:33622961	WDR88	0.45	6.88	0.32	2.12e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9487051	0.799	rs351724	chr6:109546577	T/C	cg01475377	chr6:109611718	NA	-0.38	-7.1	-0.33	5.27e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs17095355	0.605	rs3780950	chr10:111641706	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-7.52	-0.34	3.41e-13	Biliary atresia;
LUAD	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg14228332	chr4:119757509	SEC24D	0.81	7.61	0.35	1.8e-13	Cannabis dependence symptom count;
LUAD	cis	rs2932538	0.885	rs6661642	chr1:113090109	T/C	cg22162597	chr1:113214053	CAPZA1	0.46	6.93	0.32	1.62e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg23625390	chr15:77176239	SCAPER	-0.52	-8.31	-0.37	1.36e-15	Blood metabolite levels;
LUAD	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg12310025	chr6:25882481	NA	0.83	13.5	0.55	8.82e-35	Blood metabolite levels;
LUAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg10295955	chr4:187884368	NA	-1.14	-27.53	-0.8	2.48e-96	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg17366294	chr4:99064904	C4orf37	-0.44	-7.32	-0.34	1.25e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg26408565	chr15:76604113	ETFA	-0.45	-7.31	-0.33	1.37e-12	Blood metabolite levels;
LUAD	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg22546130	chr22:19950026	COMT	-0.46	-9.86	-0.43	8.73e-21	Blood metabolite levels;
LUAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg25811766	chr13:21894605	NA	0.6	9.7	0.43	3.19e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.43	-7.69	-0.35	1.06e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19346786	chr7:2764209	NA	-0.54	-11.77	-0.5	7.26e-28	Height;
LUAD	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11890956	chr21:40555474	PSMG1	-0.52	-8.93	-0.4	1.31e-17	Menarche (age at onset);
LUAD	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg17372223	chr3:52568218	NT5DC2	0.33	6.42	0.3	3.65e-10	Bipolar disorder;
LUAD	cis	rs9796	0.870	rs28479904	chr15:41268305	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.37	-7.01	-0.32	9.74e-12	Menopause (age at onset);
LUAD	cis	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg07460842	chr6:66804631	NA	0.96	12.87	0.53	3.14e-32	Exhaled nitric oxide output;
LUAD	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg00316803	chr15:76480434	C15orf27	-0.4	-7.9	-0.36	2.46e-14	Blood metabolite levels;
LUAD	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18876405	chr7:65276391	NA	-0.46	-7.14	-0.33	4.04e-12	Aortic root size;
LUAD	trans	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.81	0.5	5.32e-28	Mean corpuscular volume;
LUAD	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg01884057	chr2:25150051	NA	0.34	7.2	0.33	2.71e-12	Body mass index;
LUAD	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18876405	chr7:65276391	NA	-0.46	-7.26	-0.33	1.85e-12	Aortic root size;
LUAD	trans	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg09872104	chr7:134855509	C7orf49	-0.87	-7.54	-0.34	2.84e-13	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg07741184	chr6:167504864	NA	-0.3	-7.11	-0.33	5.05e-12	Crohn's disease;
LUAD	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.37	-7.88	-0.36	2.87e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs454510	0.816	rs838987	chr1:120176127	A/G	cg16322792	chr1:120165303	ZNF697	0.49	8.89	0.4	1.85e-17	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs220324	0.688	rs11701255	chr21:43577614	C/G	cg08841829	chr21:43638893	ABCG1	-0.51	-6.89	-0.32	2.06e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02767759	chr16:30366751	CD2BP2	-0.41	-6.35	-0.3	5.72e-10	Height;
LUAD	cis	rs9652601	0.959	rs12925642	chr16:11171602	A/G	cg04616529	chr16:11181986	CLEC16A	0.37	6.62	0.31	1.11e-10	Systemic lupus erythematosus;
LUAD	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg22496339	chr2:162101262	NA	0.42	6.72	0.31	5.8e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs3087591	0.960	rs2018634	chr17:29560678	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.65	-0.31	9.21e-11	Hip circumference;
LUAD	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	8.26	0.37	1.91e-15	Breast cancer;
LUAD	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.3	-7.46	-0.34	4.84e-13	Total body bone mineral density;
LUAD	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.83	-0.39	2.89e-17	Total body bone mineral density;
LUAD	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.61	9.65	0.42	4.89e-20	Colorectal cancer;
LUAD	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.54	0.38	2.4e-16	Parkinson's disease;
LUAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00166722	chr3:10149974	C3orf24	0.63	10.42	0.45	8.88e-23	Alzheimer's disease;
LUAD	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg08997352	chr12:9597637	DDX12	-0.64	-11.27	-0.48	5.9e-26	Breast size;
LUAD	cis	rs13082711	0.863	rs66743193	chr3:27471958	G/A	cg02860705	chr3:27208620	NA	0.64	9.56	0.42	1.02e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs10100465	0.961	rs35342556	chr8:118643635	G/T	cg09430518	chr8:118662568	NA	-0.34	-6.7	-0.31	6.61e-11	Leprosy;
LUAD	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg02450064	chr17:40260053	DHX58	-0.45	-7.52	-0.34	3.39e-13	Fibrinogen levels;
LUAD	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg26513180	chr16:89883248	FANCA	0.76	6.92	0.32	1.64e-11	Skin colour saturation;
LUAD	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg19761014	chr17:28927070	LRRC37B2	0.9	8.82	0.39	3.11e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg27170947	chr2:26402098	FAM59B	0.64	8.18	0.37	3.33e-15	Gut microbiome composition (summer);
LUAD	cis	rs1832871	0.672	rs62437399	chr6:158784251	C/A	cg07165851	chr6:158734300	TULP4	0.71	11.07	0.47	3.5e-25	Height;
LUAD	cis	rs600626	0.636	rs10793125	chr11:75452364	C/T	cg24262691	chr11:75473276	NA	-0.45	-6.42	-0.3	3.59e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.08	-0.44	1.44e-21	Migraine;Coronary artery disease;
LUAD	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg07599136	chr5:415885	AHRR	0.77	8.46	0.38	4.39e-16	Fat distribution (HIV);
LUAD	cis	rs16858210	0.874	rs34113436	chr3:183573836	G/A	cg01324343	chr3:183735012	ABCC5	0.42	6.45	0.3	3.05e-10	Menopause (age at onset);
LUAD	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06112835	chr11:68658793	MRPL21	0.51	9.37	0.41	4.35e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs1178968	1.000	rs4717751	chr7:72750627	G/A	cg15428835	chr7:75027521	TRIM73;TRIM74	0.5	6.38	0.3	4.77e-10	Triglyceride levels;
LUAD	cis	rs7744392	0.557	rs7739752	chr6:35339035	C/T	cg03355690	chr6:35265616	DEF6	0.63	6.36	0.3	5.32e-10	Cataracts in type 2 diabetes;
LUAD	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg23815491	chr16:72088622	HP	0.55	10.02	0.44	2.49e-21	Fibrinogen levels;
LUAD	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg24675056	chr1:15929824	NA	0.48	8.35	0.38	9.97e-16	Systolic blood pressure;
LUAD	cis	rs7094131	0.558	rs11013066	chr10:22901754	C/T	cg19500236	chr10:22911537	PIP4K2A	0.4	6.58	0.3	1.36e-10	Obesity-related traits;
LUAD	cis	rs7000551	0.505	rs73227818	chr8:22243325	T/C	cg12081754	chr8:22256438	SLC39A14	0.83	13.32	0.54	4.86e-34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-8.74	-0.39	5.35e-17	Schizophrenia;
LUAD	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg17420585	chr12:42539391	GXYLT1	-0.38	-6.69	-0.31	7.22e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs1143633	0.530	rs4538207	chr2:113701863	G/T	cg12858261	chr2:113808755	IL1F8	0.39	7.17	0.33	3.27e-12	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg12927641	chr6:109611667	NA	-0.51	-8.84	-0.4	2.51e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs7173743	0.756	rs7169511	chr15:79128665	T/C	cg15571903	chr15:79123663	NA	0.44	8.84	0.39	2.56e-17	Coronary artery disease;
LUAD	cis	rs9392556	0.829	rs613260	chr6:4120567	C/G	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.4	-6.89	-0.32	2.08e-11	Blood metabolite levels;
LUAD	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	10.15	0.44	8.34e-22	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2251260	0.685	rs2246700	chr14:62008147	T/A	cg13564459	chr14:62004353	PRKCH	0.42	6.84	0.32	2.75e-11	Yeast infection;
LUAD	cis	rs9972944	0.729	rs1541610	chr17:63773836	C/T	cg07283582	chr17:63770753	CCDC46	0.46	10.03	0.44	2.28e-21	Total body bone mineral density;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03433669	chr11:64956192	CAPN1	0.52	6.71	0.31	6.19e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11048434	0.626	rs1805736	chr12:9084931	A/G	cg13575925	chr12:9217583	LOC144571	-0.38	-7.16	-0.33	3.55e-12	Sjögren's syndrome;
LUAD	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18876405	chr7:65276391	NA	-0.42	-6.72	-0.31	5.87e-11	Aortic root size;
LUAD	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg12623918	chr2:306882	NA	0.36	7.28	0.33	1.69e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg06784218	chr1:46089804	CCDC17	0.5	11.0	0.47	6.34e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg05865280	chr17:75406074	SEPT9	0.61	19.44	0.69	1.28e-60	Airflow obstruction;
LUAD	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg16988262	chr1:15930761	NA	0.43	7.1	0.33	5.25e-12	Systolic blood pressure;
LUAD	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg22676075	chr6:135203613	NA	0.53	9.46	0.42	2.15e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg02743256	chr7:2109353	MAD1L1	0.43	6.36	0.3	5.32e-10	Bipolar disorder;
LUAD	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg00933542	chr6:150070202	PCMT1	0.45	9.86	0.43	8.84e-21	Lung cancer;
LUAD	cis	rs515186	1	rs515186	chr6:36397492	T/G	cg04289385	chr6:36355825	ETV7	0.43	6.61	0.31	1.14e-10	Mean platelet volume;
LUAD	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg05805236	chr11:65401703	PCNXL3	-0.55	-8.76	-0.39	4.78e-17	Acne (severe);
LUAD	trans	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	7.66	0.35	1.27e-13	Resting heart rate;
LUAD	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg25237894	chr2:233734115	C2orf82	-0.62	-11.68	-0.49	1.64e-27	Coronary artery disease;
LUAD	cis	rs7264396	0.836	rs6120995	chr20:34185726	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-6.73	-0.31	5.52e-11	Total cholesterol levels;
LUAD	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg24818145	chr4:99064322	C4orf37	0.41	7.0	0.32	9.96e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.09e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.54	8.71	0.39	6.88e-17	Total body bone mineral density;
LUAD	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.38	6.56	0.3	1.57e-10	Blood metabolite levels;
LUAD	cis	rs9902453	1.000	rs62070312	chr17:28438877	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.2	0.41	1.7e-18	Coffee consumption (cups per day);
LUAD	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg21153622	chr11:89784906	NA	-0.33	-6.62	-0.31	1.08e-10	Coronary artery disease;
LUAD	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg02734326	chr4:10020555	SLC2A9	-0.5	-8.71	-0.39	6.86e-17	Bone mineral density;
LUAD	trans	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg10370574	chr19:1840461	REXO1	-0.64	-10.85	-0.47	2.21e-24	Bipolar disorder;
LUAD	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg27284194	chr4:1044797	NA	0.54	8.96	0.4	1.06e-17	Recombination rate (males);
LUAD	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg24675056	chr1:15929824	NA	0.49	8.48	0.38	3.92e-16	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg05340658	chr4:99064831	C4orf37	0.54	9.17	0.41	2.01e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg12311346	chr5:56204834	C5orf35	-0.53	-8.5	-0.38	3.23e-16	Coronary artery disease;
LUAD	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-11.46	-0.49	1.18e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01570182	chr17:44337453	NA	-0.77	-12.51	-0.52	9.15e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10992471	0.535	rs10117041	chr9:95282331	A/G	cg14631576	chr9:95140430	CENPP	-0.51	-10.22	-0.45	4.58e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg06671706	chr8:8559999	CLDN23	0.64	10.87	0.47	1.98e-24	Obesity-related traits;
LUAD	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	6.05e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg09491104	chr22:46646882	C22orf40	-0.63	-10.99	-0.47	6.71e-25	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2554380	0.943	rs2585052	chr15:84355990	T/A	cg14598478	chr15:84363061	ADAMTSL3	-0.58	-8.8	-0.39	3.5e-17	Height;
LUAD	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg03340356	chr1:67600835	NA	0.42	7.19	0.33	2.93e-12	Psoriasis;
LUAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg12419862	chr22:24373484	LOC391322	-0.68	-11.65	-0.49	2.2e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg12407791	chr17:73824354	UNC13D	-0.32	-6.78	-0.31	4.13e-11	White matter hyperintensity burden;
LUAD	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg11494091	chr17:61959527	GH2	0.45	8.49	0.38	3.43e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.22	-0.54	1.18e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.61	0.39	1.48e-16	Menarche (age at onset);
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg03395511	chr6:291903	DUSP22	-0.76	-12.99	-0.53	1.1e-32	Menopause (age at onset);
LUAD	cis	rs9902453	0.933	rs8080343	chr17:28456758	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	8.77	0.39	4.46e-17	Coffee consumption (cups per day);
LUAD	cis	rs887829	0.508	rs1104892	chr2:234620272	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-8.29	-0.37	1.56e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg03929089	chr4:120376271	NA	-0.93	-17.14	-0.64	2.18e-50	Height;
LUAD	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg22532475	chr10:104410764	TRIM8	-0.44	-8.56	-0.38	2.09e-16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19717773	chr7:2847554	GNA12	0.56	9.7	0.43	3.32e-20	Height;
LUAD	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg02450064	chr17:40260053	DHX58	-0.45	-7.48	-0.34	4.26e-13	Fibrinogen levels;
LUAD	trans	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg07211511	chr3:129823064	LOC729375	-0.55	-7.49	-0.34	4.02e-13	Blood pressure (smoking interaction);
LUAD	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.47	-9.26	-0.41	1.07e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg19862616	chr7:65841803	NCRNA00174	1.04	25.75	0.78	1.24e-88	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.36	-6.77	-0.31	4.39e-11	Longevity;Endometriosis;
LUAD	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg02560186	chr11:3602584	NA	-0.34	-6.6	-0.31	1.24e-10	Blood pressure (smoking interaction);
LUAD	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07343612	chr16:622815	PIGQ	-0.82	-16.42	-0.62	3.28e-47	Height;
LUAD	trans	rs524023	0.914	rs2666559	chr11:64439227	G/T	cg21422400	chr1:1747243	GNB1	0.45	7.28	0.33	1.69e-12	Urate levels in obese individuals;
LUAD	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg19761014	chr17:28927070	LRRC37B2	0.84	8.25	0.37	1.97e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6076065	0.894	rs2243448	chr20:23378345	G/A	cg11657817	chr20:23433608	CST11	0.58	12.12	0.51	3.23e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs9487051	0.702	rs368467	chr6:109519451	T/C	cg01475377	chr6:109611718	NA	-0.39	-7.33	-0.34	1.18e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs7945705	0.875	rs10769955	chr11:8784647	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.47	8.24	0.37	2.18e-15	Hemoglobin concentration;
LUAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg14893161	chr1:205819251	PM20D1	-0.53	-8.33	-0.38	1.1e-15	Parkinson's disease;
LUAD	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg09911534	chr15:67153556	NA	0.36	6.66	0.31	8.46e-11	Lung cancer (smoking interaction);
LUAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs533581	0.866	rs488251	chr16:88972554	G/A	cg05579598	chr16:88989069	CBFA2T3	0.33	6.75	0.31	5.04e-11	Social autistic-like traits;
LUAD	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-10.97	-0.47	8.25e-25	Hemoglobin concentration;
LUAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg06453172	chr10:134556979	INPP5A	-0.79	-11.26	-0.48	6.57e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg03037974	chr15:76606532	NA	0.39	8.47	0.38	4.01e-16	Blood metabolite levels;
LUAD	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg10589385	chr1:150898437	SETDB1	0.45	8.26	0.37	1.91e-15	Melanoma;
LUAD	cis	rs250677	0.522	rs4705301	chr5:148354902	C/G	cg18129178	chr5:148520854	ABLIM3	-0.51	-7.99	-0.36	1.27e-14	Breast cancer;
LUAD	cis	rs6500395	1.000	rs11640463	chr16:48644434	A/T	cg04672837	chr16:48644449	N4BP1	0.39	6.82	0.31	3.1e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	7.53	0.34	3.2e-13	Schizophrenia;
LUAD	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg09904177	chr6:26538194	HMGN4	0.41	6.56	0.3	1.56e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg15445000	chr17:37608096	MED1	0.44	8.19	0.37	3.14e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg22681709	chr2:178499509	PDE11A	-0.42	-6.98	-0.32	1.18e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6835098	1.000	rs10031414	chr4:174084953	A/C	cg08422745	chr4:174089978	GALNT7	-0.96	-18.57	-0.67	9.94e-57	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg22920501	chr2:26401640	FAM59B	-0.96	-14.21	-0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	trans	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg18335740	chr13:41363409	SLC25A15	0.52	9.34	0.41	5.4e-19	Lewy body disease;
LUAD	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg07211511	chr3:129823064	LOC729375	-0.84	-12.28	-0.51	7.3e-30	Blood pressure (smoking interaction);
LUAD	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg06558623	chr16:89946397	TCF25	1.22	12.45	0.52	1.6e-30	Skin colour saturation;
LUAD	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg00277334	chr10:82204260	NA	-0.49	-7.94	-0.36	1.86e-14	Post bronchodilator FEV1;
LUAD	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	7.18	0.33	3.08e-12	Schizophrenia;
LUAD	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-8.08	-0.37	6.66e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg11693508	chr17:37793320	STARD3	0.72	9.21	0.41	1.51e-18	Bipolar disorder;
LUAD	cis	rs4604732	0.631	rs75600450	chr1:247625492	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.53	-7.84	-0.36	3.77e-14	IgG glycosylation;
LUAD	trans	rs11039798	1.000	rs6485848	chr11:48541517	G/T	cg02254774	chr11:50257496	LOC441601	0.53	6.59	0.31	1.3100000000000001e-10	Axial length;
LUAD	cis	rs4642101	0.560	rs4535210	chr3:12839617	T/G	cg24848339	chr3:12840334	CAND2	0.43	8.46	0.38	4.35e-16	QRS complex (12-leadsum);
LUAD	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg09359103	chr1:154839909	KCNN3	-0.91	-21.12	-0.72	3.92e-68	Prostate cancer;
LUAD	cis	rs7180079	1.000	rs56239026	chr15:64566958	C/T	cg08069370	chr15:64387884	SNX1	-0.51	-6.56	-0.3	1.6e-10	Monocyte count;
LUAD	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg03929089	chr4:120376271	NA	-0.92	-17.61	-0.65	1.82e-52	Height;
LUAD	cis	rs59698941	0.943	rs12519955	chr5:132283095	G/A	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs8060686	0.516	rs7206792	chr16:68168200	C/G	cg09835421	chr16:68378352	PRMT7	-0.56	-7.02	-0.32	8.65e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19346786	chr7:2764209	NA	-0.52	-11.38	-0.48	2.32e-26	Height;
LUAD	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg02421172	chr7:1938701	MAD1L1	-0.49	-6.97	-0.32	1.23e-11	Bipolar disorder;
LUAD	trans	rs10937405	0.520	rs1364596	chr3:189260625	A/G	cg21612617	chr4:126813319	NA	-0.33	-6.38	-0.3	4.57e-10	Lung adenocarcinoma;
LUAD	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg22681709	chr2:178499509	PDE11A	-0.38	-6.97	-0.32	1.19e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.28	-0.37	1.59e-15	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg07677032	chr17:61819896	STRADA	-0.48	-8.36	-0.38	9.15e-16	Prudent dietary pattern;
LUAD	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg17410650	chr12:54324560	NA	-0.55	-11.12	-0.48	2.16e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg07917127	chr4:99064746	C4orf37	0.42	7.01	0.32	9.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	1.000	rs115706377	chr4:119628481	G/A	cg14228332	chr4:119757509	SEC24D	0.77	7.07	0.32	6.56e-12	Cannabis dependence symptom count;
LUAD	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg05590025	chr7:65112418	INTS4L2	0.75	8.03	0.36	9.57e-15	Diabetic kidney disease;
LUAD	cis	rs367943	0.966	rs348947	chr5:112822795	C/G	cg12552261	chr5:112820674	MCC	-0.59	-11.17	-0.48	1.49e-25	Type 2 diabetes;
LUAD	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg16322792	chr1:120165303	ZNF697	-0.71	-18.9	-0.68	3.47e-58	Systemic lupus erythematosus;
LUAD	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg07930552	chr6:133119739	C6orf192	0.65	7.91	0.36	2.28e-14	Type 2 diabetes nephropathy;
LUAD	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg22823121	chr1:150693482	HORMAD1	0.45	9.13	0.41	2.95e-18	Tonsillectomy;
LUAD	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg16325326	chr1:53192061	ZYG11B	0.63	12.44	0.52	1.79e-30	Monocyte count;
LUAD	cis	rs1847202	0.859	rs4566476	chr3:72948995	G/C	cg25664220	chr3:72788482	NA	-0.43	-7.6	-0.35	1.93e-13	Motion sickness;
LUAD	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg08493051	chr2:3487164	NA	-0.43	-7.71	-0.35	9.05e-14	Neurofibrillary tangles;
LUAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg11965913	chr1:205819406	PM20D1	-0.5	-8.3	-0.37	1.45e-15	Parkinson's disease;
LUAD	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02463440	chr8:22132932	PIWIL2	0.53	9.66	0.43	4.33e-20	Hypertriglyceridemia;
LUAD	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg25324976	chr17:61989376	CSHL1	0.34	6.76	0.31	4.73e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.32	-0.34	1.27e-12	Total body bone mineral density;
LUAD	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg07386859	chr16:1872102	HAGH	-0.5	-8.02	-0.36	1.02e-14	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs2278491	0.557	rs4876680	chr8:117777914	C/G	cg23513447	chr8:117778558	UTP23	-0.54	-7.65	-0.35	1.32e-13	Body mass index;
LUAD	cis	rs11214589	0.905	rs10891539	chr11:113236492	G/C	cg14159747	chr11:113255604	NA	0.66	14.32	0.57	3.37e-38	Neuroticism;
LUAD	cis	rs796364	0.525	rs10931895	chr2:201143242	C/T	cg17644776	chr2:200775616	C2orf69	0.46	6.77	0.31	4.19e-11	Schizophrenia;
LUAD	cis	rs4594175	0.926	rs12101170	chr14:51611902	T/C	cg23942311	chr14:51606299	NA	0.64	10.99	0.47	6.95e-25	Cancer;
LUAD	cis	rs10929159	0.928	rs9636243	chr2:236925259	C/T	cg14895183	chr2:236924282	AGAP1	0.38	6.52	0.3	1.99e-10	Parkinson's disease;
LUAD	trans	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg26043149	chr18:55253948	FECH	-0.44	-6.97	-0.32	1.24e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg09359103	chr1:154839909	KCNN3	-0.88	-19.41	-0.69	1.72e-60	Prostate cancer;
LUAD	cis	rs3106136	0.843	rs901615	chr4:95228687	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.36	-6.47	-0.3	2.72e-10	Capecitabine sensitivity;
LUAD	cis	rs4150161	0.656	rs2288026	chr16:84220344	C/G	cg10106505	chr16:84220380	TAF1C	0.89	8.65	0.39	1.08e-16	Systolic blood pressure response to hydrochlorothiazide in hypertension;
LUAD	cis	rs977987	0.654	rs8054194	chr16:75497160	G/T	cg03315344	chr16:75512273	CHST6	0.65	14.13	0.57	2.01e-37	Dupuytren's disease;
LUAD	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-8.21	-0.37	2.73e-15	HDL cholesterol;
LUAD	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg02574844	chr11:5959923	NA	-0.39	-6.59	-0.31	1.32e-10	DNA methylation (variation);
LUAD	cis	rs2742234	0.868	rs2505512	chr10:43633596	G/A	cg02780029	chr10:43622663	RET	-0.44	-7.18	-0.33	3.18e-12	Hirschsprung disease;
LUAD	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg27572855	chr1:25598939	RHD	0.59	13.3	0.54	5.56e-34	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg07677032	chr17:61819896	STRADA	-0.52	-9.21	-0.41	1.48e-18	Prudent dietary pattern;
LUAD	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg03563238	chr19:33554763	RHPN2	-0.33	-8.08	-0.37	6.8e-15	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.32	0.37	1.26e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg26750617	chr12:132293702	NA	-0.42	-6.87	-0.32	2.33e-11	Migraine;
LUAD	cis	rs727505	0.607	rs67313231	chr7:124804532	T/A	cg23710748	chr7:124431027	NA	-0.39	-7.91	-0.36	2.32e-14	Lewy body disease;
LUAD	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg11189052	chr15:85197271	WDR73	0.58	7.46	0.34	4.96e-13	Schizophrenia;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg11090826	chr3:69101654	TMF1	0.38	6.72	0.31	5.93e-11	Bipolar disorder;
LUAD	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-6.83	-0.32	2.93e-11	Lung cancer;
LUAD	cis	rs2579500	0.807	rs6576976	chr2:97246667	T/C	cg23100626	chr2:96804247	ASTL	-0.28	-7.11	-0.33	4.89e-12	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs250585	1.000	rs152454	chr16:23583111	C/T	cg00143387	chr16:23521605	GGA2	-0.67	-7.84	-0.36	3.71e-14	Egg allergy;
LUAD	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg04025307	chr7:1156635	C7orf50	0.57	8.12	0.37	5.2e-15	Bronchopulmonary dysplasia;
LUAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg05434287	chr7:2030229	MAD1L1	0.41	6.74	0.31	5.04e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg27129171	chr3:47204927	SETD2	-0.41	-6.67	-0.31	8.23e-11	Colorectal cancer;
LUAD	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg21856205	chr7:94953877	PON1	-0.55	-7.7	-0.35	9.5e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs897984	0.571	rs7184567	chr16:31021078	C/T	cg02466173	chr16:30829666	NA	-0.58	-10.08	-0.44	1.52e-21	Dementia with Lewy bodies;
LUAD	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg08847533	chr14:75593920	NEK9	0.42	7.1	0.33	5.24e-12	Height;
LUAD	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.47	2.75e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2274471	0.645	rs3780376	chr9:5109485	G/T	cg03390472	chr9:5043263	JAK2	-0.55	-7.84	-0.36	3.6e-14	Crohn's disease;
LUAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg11062466	chr8:58055876	NA	0.67	8.87	0.4	2.01e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6594713	0.837	rs6887914	chr5:112711486	C/T	cg12552261	chr5:112820674	MCC	0.46	6.73	0.31	5.5e-11	Brain cytoarchitecture;
LUAD	cis	rs2019216	0.542	rs1850564	chr17:21911794	T/C	cg05591447	chr17:21909280	FLJ36000	-0.27	-6.71	-0.31	6.1e-11	Pelvic organ prolapse;
LUAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg15242686	chr22:24348715	GSTTP1	0.43	7.32	0.34	1.26e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg23505145	chr19:12996616	KLF1	0.61	9.97	0.44	3.56e-21	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg06718696	chr17:78121285	EIF4A3	0.61	8.95	0.4	1.14e-17	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04385818	chr19:49468626	FTL	-0.55	-8.06	-0.36	8.04e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg11941060	chr3:133502564	NA	-0.42	-6.94	-0.32	1.48e-11	Iron status biomarkers;
LUAD	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11890956	chr21:40555474	PSMG1	0.58	10.01	0.44	2.56e-21	Cognitive function;
LUAD	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg16325326	chr1:53192061	ZYG11B	0.57	9.93	0.43	5.21e-21	Monocyte count;
LUAD	cis	rs6993813	0.807	rs4424296	chr8:120013276	C/T	cg01975934	chr8:119970761	NA	-0.34	-6.57	-0.3	1.45e-10	Bone mineral density (hip);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg04900672	chr7:1987197	MAD1L1	-0.43	-7.16	-0.33	3.63e-12	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs1493916	1.000	rs12457802	chr18:31389865	A/G	cg13755796	chr4:20253514	NA	0.41	6.87	0.32	2.31e-11	Life satisfaction;
LUAD	trans	rs9784649	1.000	rs55924805	chr5:24999756	C/T	cg11038491	chr20:34638489	LOC647979	-0.66	-8.14	-0.37	4.51e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg25173405	chr17:45401733	C17orf57	-0.52	-8.76	-0.39	4.61e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12824058	0.707	rs2398509	chr12:130816464	T/C	cg23887609	chr12:130822674	PIWIL1	0.39	6.43	0.3	3.42e-10	Menopause (age at onset);
LUAD	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg21427119	chr20:30132790	HM13	-0.59	-8.82	-0.39	2.93e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.08	-0.37	6.72e-15	Bipolar disorder;
LUAD	cis	rs16910800	0.731	rs59333536	chr11:23191649	G/A	cg20040320	chr11:23191996	NA	-0.73	-9.89	-0.43	7.04e-21	Cancer;
LUAD	trans	rs1959947	0.585	rs8008487	chr14:41534471	A/C	cg19977241	chr2:74692637	MOGS	0.39	6.6	0.31	1.26e-10	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg02574844	chr11:5959923	NA	0.52	9.94	0.44	4.46e-21	DNA methylation (variation);
LUAD	cis	rs4700695	0.764	rs10066817	chr5:65319853	A/G	cg21114390	chr5:65439923	SFRS12	0.64	7.82	0.36	4.17e-14	Facial morphology (factor 19);
LUAD	trans	rs2735413	0.875	rs11649082	chr16:78082256	C/T	cg01028844	chr5:122736986	CEP120	0.41	6.5	0.3	2.24e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.655	rs11587521	chr1:15839206	T/C	cg24675056	chr1:15929824	NA	0.42	6.71	0.31	6.11e-11	Systolic blood pressure;
LUAD	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.7	-0.31	6.57e-11	Total body bone mineral density;
LUAD	cis	rs11971779	0.666	rs6467847	chr7:139079436	T/C	cg23387468	chr7:139079360	LUC7L2	0.3	6.61	0.31	1.13e-10	Diisocyanate-induced asthma;
LUAD	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.59	-0.35	2.05e-13	Tonsillectomy;
LUAD	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg19761014	chr17:28927070	LRRC37B2	0.64	7.44	0.34	5.81e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg08859206	chr1:53392774	SCP2	0.6	11.22	0.48	9.75e-26	Monocyte count;
LUAD	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg03467027	chr4:99064603	C4orf37	0.41	6.64	0.31	9.5e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg19610905	chr11:61596333	FADS2	-0.64	-10.62	-0.46	1.6e-23	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg27539214	chr16:67997921	SLC12A4	-0.68	-8.09	-0.37	6.58e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6688613	1.000	rs17551703	chr1:166957879	T/C	cg07049167	chr1:166818506	POGK	0.41	6.86	0.32	2.43e-11	Refractive astigmatism;
LUAD	cis	rs751837	0.591	rs10138056	chr14:103424854	A/G	cg10087771	chr14:103399429	CDC42BPB	0.64	7.31	0.34	1.32e-12	Large B-cell lymphoma;
LUAD	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg07677032	chr17:61819896	STRADA	0.44	6.58	0.3	1.37e-10	Height;
LUAD	cis	rs1865721	0.761	rs11660256	chr18:73219532	C/T	cg26385618	chr18:73139727	C18orf62	-0.36	-6.7	-0.31	6.59e-11	Intelligence;
LUAD	cis	rs2637266	0.935	rs2579774	chr10:78402253	T/C	cg18941641	chr10:78392320	NA	0.34	7.04	0.32	7.75e-12	Pulmonary function;
LUAD	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-6.91	-0.32	1.78e-11	Retinal vascular caliber;
LUAD	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg04450456	chr4:17643702	FAM184B	0.37	7.2	0.33	2.8e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg15017067	chr4:17643749	FAM184B	0.36	6.91	0.32	1.81e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.41	6.41	0.3	3.78e-10	Multiple sclerosis;
LUAD	cis	rs1232027	0.666	rs1650693	chr5:79952827	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.94	-0.36	1.9e-14	Huntington's disease progression;
LUAD	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg10556349	chr10:835070	NA	0.66	7.71	0.35	9.39e-14	Eosinophil percentage of granulocytes;
LUAD	cis	rs701145	0.585	rs2596629	chr3:153931142	A/C	cg17054900	chr3:154042577	DHX36	0.65	6.99	0.32	1.06e-11	Coronary artery disease;
LUAD	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg06671706	chr8:8559999	CLDN23	0.65	11.27	0.48	5.94e-26	Obesity-related traits;
LUAD	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg05731713	chr7:157510257	PTPRN2	0.43	10.0	0.44	2.72e-21	Bipolar disorder and schizophrenia;
LUAD	trans	rs12517041	1.000	rs1593967	chr5:23313900	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.55	-0.3	1.72e-10	Calcium levels;
LUAD	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	15.35	0.6	1.41e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg13319975	chr6:146136371	FBXO30	0.64	10.88	0.47	1.71e-24	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg18975462	chr8:119123269	EXT1	-0.47	-6.43	-0.3	3.55e-10	Testicular germ cell tumor;
LUAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg17372223	chr3:52568218	NT5DC2	0.4	7.46	0.34	5.07e-13	Electroencephalogram traits;
LUAD	cis	rs12760731	0.720	rs10913553	chr1:178423062	G/C	cg00404053	chr1:178313656	RASAL2	0.64	8.05	0.36	8.64e-15	Obesity-related traits;
LUAD	cis	rs1847202	0.859	rs4274693	chr3:72949375	A/G	cg25664220	chr3:72788482	NA	-0.43	-7.52	-0.34	3.27e-13	Motion sickness;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06193633	chr1:236958574	MTR	-0.58	-7.04	-0.32	7.71e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg15704280	chr7:45808275	SEPT13	0.58	7.84	0.36	3.76e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6445967	1.000	rs34611088	chr3:58312923	G/A	cg23715586	chr3:58305044	RPP14	0.42	7.58	0.35	2.16e-13	Platelet count;
LUAD	cis	rs2386661	0.826	rs4749922	chr10:5680689	A/G	cg26603656	chr10:5671107	NA	0.41	7.09	0.33	5.63e-12	Breast cancer;
LUAD	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg01528321	chr10:82214614	TSPAN14	-0.72	-11.24	-0.48	7.68e-26	Post bronchodilator FEV1;
LUAD	cis	rs12545109	0.800	rs1837620	chr8:57399473	C/A	cg11919837	chr8:57350735	NA	-0.46	-6.73	-0.31	5.5e-11	Obesity-related traits;
LUAD	cis	rs3760982	0.585	rs8109812	chr19:44298494	C/A	cg11993925	chr19:44307056	LYPD5	0.53	11.1	0.48	2.57e-25	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg02527881	chr3:46936655	PTH1R	0.44	8.42	0.38	5.72e-16	Colorectal cancer;
LUAD	cis	rs1045714	0.836	rs73033691	chr7:2636522	T/G	cg20813462	chr7:2646259	IQCE	0.69	7.67	0.35	1.18e-13	Urate levels in lean individuals;
LUAD	cis	rs2882667	0.893	rs10069961	chr5:138294568	A/G	cg04439458	chr5:138467593	SIL1	-0.38	-6.95	-0.32	1.43e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg10518543	chr12:38710700	ALG10B	0.4	6.46	0.3	2.94e-10	Morning vs. evening chronotype;
LUAD	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg13385794	chr1:248469461	NA	0.26	7.03	0.32	8.6e-12	Common traits (Other);
LUAD	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.74	0.43	2.28e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg01884057	chr2:25150051	NA	0.37	8.06	0.36	7.73e-15	Body mass index in non-asthmatics;
LUAD	cis	rs9513627	0.915	rs9582298	chr13:100118707	T/C	cg25919922	chr13:100150906	NA	-0.69	-6.6	-0.31	1.25e-10	Obesity-related traits;
LUAD	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg06640241	chr16:89574553	SPG7	0.47	7.72	0.35	8.51e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs7727544	0.582	rs10075459	chr5:131541363	C/G	cg14196790	chr5:131705035	SLC22A5	0.42	7.33	0.34	1.17e-12	Blood metabolite levels;
LUAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg11494091	chr17:61959527	GH2	0.74	18.58	0.67	9.11e-57	Prudent dietary pattern;
LUAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg22907277	chr7:1156413	C7orf50	0.67	8.37	0.38	8.4e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11681884	1.000	rs17042853	chr2:113848200	T/A	cg12858261	chr2:113808755	IL1F8	0.52	6.56	0.3	1.58e-10	Stroke;
LUAD	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg15181151	chr6:150070149	PCMT1	0.43	8.76	0.39	4.7e-17	Lung cancer;
LUAD	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24531977	chr5:56204891	C5orf35	-0.96	-14.69	-0.58	9.31e-40	Initial pursuit acceleration;
LUAD	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg12884169	chr21:40033163	ERG	0.49	10.58	0.46	2.23e-23	Coronary artery disease;
LUAD	trans	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.62	0.46	1.58e-23	Ulcerative colitis;
LUAD	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.12	0.48	2.22e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs910187	0.605	rs6063080	chr20:45805091	G/A	cg27589058	chr20:45804311	EYA2	-0.37	-8.41	-0.38	6.19e-16	Migraine;
LUAD	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg22482690	chr17:47019901	SNF8	0.45	8.46	0.38	4.31e-16	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.33	0.38	1.13e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-8.32	-0.38	1.19e-15	Hemoglobin concentration;
LUAD	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg24450063	chr1:156163899	SLC25A44	1.18	28.3	0.81	1.25e-99	Testicular germ cell tumor;
LUAD	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg23029597	chr12:123009494	RSRC2	-0.57	-9.15	-0.41	2.38e-18	Body mass index;
LUAD	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg02788857	chr8:22132959	PIWIL2	0.55	10.08	0.44	1.5e-21	Hypertriglyceridemia;
LUAD	cis	rs7100689	0.598	rs35353819	chr10:82135737	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	10.4	0.45	1.01e-22	Post bronchodilator FEV1;
LUAD	trans	rs853679	0.607	rs72846794	chr6:28137499	G/A	cg01620082	chr3:125678407	NA	-1.1	-10.38	-0.45	1.25e-22	Depression;
LUAD	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.06	0.32	6.9e-12	Hypertriglyceridemia;
LUAD	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg16512390	chr1:228756714	NA	-0.45	-7.57	-0.35	2.42e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs4363385	0.507	rs6587710	chr1:152870716	A/G	cg07796016	chr1:152779584	LCE1C	-0.39	-6.58	-0.3	1.39e-10	Inflammatory skin disease;
LUAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.66	0.31	8.54e-11	Prudent dietary pattern;
LUAD	cis	rs7771547	0.519	rs67313027	chr6:36363487	G/C	cg07856975	chr6:36356162	ETV7	0.53	7.95	0.36	1.67e-14	Platelet distribution width;
LUAD	cis	rs1395	0.778	rs2580759	chr2:27432500	G/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.45	-8.27	-0.37	1.7e-15	Blood metabolite levels;
LUAD	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg26924012	chr15:45694286	SPATA5L1	0.65	10.87	0.47	1.94e-24	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs2742234	0.541	rs1879310	chr10:43734775	A/G	cg15436174	chr10:43711423	RASGEF1A	0.53	8.96	0.4	1.08e-17	Hirschsprung disease;
LUAD	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg20701182	chr2:24300061	SF3B14	0.9	13.79	0.56	5.75e-36	Lymphocyte counts;
LUAD	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.21e-19	Life satisfaction;
LUAD	cis	rs2594714	0.515	rs10411270	chr19:13940838	A/T	cg18576835	chr19:13944261	NA	-0.52	-9.45	-0.42	2.4e-19	Breast cancer;
LUAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	10.88	0.47	1.74e-24	Resting heart rate;
LUAD	cis	rs6582630	0.562	rs35080195	chr12:38310866	G/A	cg10518543	chr12:38710700	ALG10B	-0.42	-6.89	-0.32	2.05e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg27124370	chr19:33622961	WDR88	0.46	7.08	0.33	5.86e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.85	-0.36	3.4e-14	Blood metabolite levels;
LUAD	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg18451016	chr1:38461880	NA	-0.41	-7.53	-0.34	3.02e-13	Coronary artery disease;
LUAD	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg13319975	chr6:146136371	FBXO30	-0.64	-11.0	-0.47	6.45e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg19773385	chr1:10388646	KIF1B	-0.43	-6.9	-0.32	1.92e-11	Hepatocellular carcinoma;
LUAD	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4650994	1.000	rs12138541	chr1:178518707	G/A	cg05059571	chr16:84539110	KIAA1609	-0.61	-10.43	-0.45	7.95e-23	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.48	-6.42	-0.3	3.59e-10	Depression;
LUAD	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg05368731	chr17:41323189	NBR1	0.96	20.58	0.71	1.05e-65	Menopause (age at onset);
LUAD	cis	rs4253772	0.591	rs739165	chr22:46684528	C/T	cg09491104	chr22:46646882	C22orf40	-0.59	-7.58	-0.35	2.26e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg21918786	chr6:109611834	NA	-0.6	-11.12	-0.48	2.21e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg27490568	chr2:178487706	NA	0.4	6.78	0.31	4.03e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4481887	0.893	rs11204632	chr1:248479532	G/A	cg13385794	chr1:248469461	NA	0.25	6.74	0.31	5.29e-11	Common traits (Other);
LUAD	cis	rs2996428	0.709	rs6424052	chr1:3713746	A/G	cg18436788	chr1:3704244	LRRC47	0.33	6.74	0.31	5.24e-11	Red cell distribution width;
LUAD	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg04111992	chr7:158790115	NA	0.43	6.73	0.31	5.71e-11	Facial morphology (factor 20);
LUAD	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg20607798	chr8:58055168	NA	0.61	7.85	0.36	3.49e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg14092988	chr3:52407081	DNAH1	0.54	10.97	0.47	8.54e-25	Bipolar disorder;
LUAD	trans	rs8002861	0.664	rs4942246	chr13:44404853	A/G	cg17145862	chr1:211918768	LPGAT1	0.65	13.1	0.54	3.69e-33	Leprosy;
LUAD	cis	rs2456568	0.867	rs7935801	chr11:93658000	G/A	cg26875233	chr11:93583750	C11orf90	-0.29	-6.36	-0.3	5.32e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg01689657	chr7:91764605	CYP51A1	0.35	8.77	0.39	4.54e-17	Breast cancer;
LUAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg18621852	chr3:10150065	C3orf24	0.51	9.11	0.4	3.39e-18	Alzheimer's disease;
LUAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.31	6.41	0.3	3.99e-10	Obesity-related traits;
LUAD	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.6	-0.58	2.09e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg18621852	chr3:10150065	C3orf24	0.48	8.45	0.38	4.89e-16	Alzheimer's disease;
LUAD	cis	rs7937890	0.559	rs2575825	chr11:14472096	T/C	cg06199346	chr11:14280333	SPON1	-0.33	-6.61	-0.31	1.17e-10	Mitochondrial DNA levels;
LUAD	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	7.57	0.35	2.38e-13	Menopause (age at onset);
LUAD	cis	rs62238980	0.614	rs79343805	chr22:32522040	A/C	cg00543991	chr22:32367038	NA	0.88	8.51	0.38	3.06e-16	Childhood ear infection;
LUAD	cis	rs752010	0.967	rs10890153	chr1:42102060	C/A	cg06885757	chr1:42089581	HIVEP3	0.46	9.8	0.43	1.45e-20	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg06641503	chr3:48959341	ARIH2	-0.39	-7.16	-0.33	3.6e-12	Menarche (age at onset);
LUAD	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.22	-0.37	2.45e-15	Bipolar disorder;
LUAD	cis	rs2294693	0.945	rs10947944	chr6:41004657	T/C	cg14769373	chr6:40998127	UNC5CL	-0.51	-7.68	-0.35	1.09e-13	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.05e-19	Life satisfaction;
LUAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	9.7	0.43	3.28e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg01191920	chr7:158217561	PTPRN2	-0.55	-10.89	-0.47	1.66e-24	Obesity-related traits;
LUAD	trans	rs28735056	0.967	rs623546	chr18:77595228	C/T	cg05926928	chr17:57297772	GDPD1	-0.5	-7.08	-0.33	6.06e-12	Schizophrenia;
LUAD	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg15147215	chr3:52552868	STAB1	-0.41	-7.43	-0.34	6.14e-13	Bipolar disorder;
LUAD	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg07741184	chr6:167504864	NA	-0.33	-7.56	-0.34	2.6e-13	Primary biliary cholangitis;
LUAD	cis	rs2651899	0.865	rs2817126	chr1:3083246	T/G	cg22396632	chr1:3079212	PRDM16	-0.37	-8.39	-0.38	7.13e-16	Migraine;
LUAD	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg26690334	chr16:1524521	CLCN7	-0.4	-7.8	-0.35	4.93e-14	Bone mineral density;
LUAD	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg03806693	chr22:41940476	POLR3H	-0.76	-10.04	-0.44	2.07e-21	Vitiligo;
LUAD	trans	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg00769240	chr8:12517080	NA	-0.44	-7.43	-0.34	5.88e-13	Blood pressure (smoking interaction);
LUAD	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.41	-7.83	-0.36	3.89e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6089584	0.546	rs6089308	chr20:60583529	C/T	cg24733560	chr20:60626293	TAF4	0.44	8.75	0.39	5.3e-17	Body mass index;
LUAD	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg03609598	chr5:56110824	MAP3K1	-0.61	-8.2	-0.37	2.92e-15	Initial pursuit acceleration;
LUAD	cis	rs1696756	0.877	rs1663223	chr17:77826509	A/G	cg02876276	chr17:77834299	NA	0.49	7.07	0.33	6.32e-12	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs12765878	0.967	rs7920217	chr10:105668172	C/T	cg11005552	chr10:105648138	OBFC1	0.44	8.34	0.38	1.05e-15	Coronary artery disease;
LUAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg22907277	chr7:1156413	C7orf50	0.46	7.99	0.36	1.3e-14	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs72928364	0.872	rs2576382	chr3:100667829	T/A	cg10123952	chr3:100791384	NA	-0.56	-6.9	-0.32	1.86e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg06611532	chr13:114900021	NA	0.37	8.78	0.39	4.16e-17	Schizophrenia;
LUAD	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg12863693	chr15:85201151	NMB	0.44	8.23	0.37	2.26e-15	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg19636519	chr7:99541626	NA	0.39	7.0	0.32	1.03e-11	Coronary artery disease;
LUAD	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg11502198	chr6:26597334	ABT1	0.49	7.98	0.36	1.43e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg13319975	chr6:146136371	FBXO30	-0.63	-10.81	-0.47	3.32e-24	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg07393940	chr7:158741817	NA	0.66	11.29	0.48	5.31e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs526821	0.553	rs295597	chr11:55470003	T/C	cg04317927	chr11:55418816	OR4S2	0.37	6.7	0.31	6.5e-11	Pediatric bone mineral density (spine);
LUAD	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Hypertriglyceridemia;
LUAD	cis	rs10203711	1.000	rs907111	chr2:239566426	T/C	cg14580085	chr2:239553406	NA	0.41	8.79	0.39	3.82e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12756686	chr19:29218302	NA	0.68	9.85	0.43	9.4e-21	Methadone dose in opioid dependence;
LUAD	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg21204522	chr6:27730016	NA	-0.44	-6.9	-0.32	1.85e-11	Parkinson's disease;
LUAD	cis	rs7737355	0.773	rs3756290	chr5:130951750	A/G	cg06307176	chr5:131281290	NA	0.4	6.48	0.3	2.63e-10	Life satisfaction;
LUAD	cis	rs7010267	0.570	rs7838083	chr8:120016805	A/G	cg01975934	chr8:119970761	NA	-0.34	-6.57	-0.3	1.49e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg02023728	chr11:77925099	USP35	0.4	6.68	0.31	7.41e-11	Testicular germ cell tumor;
LUAD	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.55	-9.41	-0.42	3.1400000000000002e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg15181151	chr6:150070149	PCMT1	0.42	8.73	0.39	6.13e-17	Lung cancer;
LUAD	cis	rs7095607	0.813	rs7895737	chr10:69924146	A/G	cg18986048	chr10:69913749	MYPN	0.38	6.56	0.3	1.54e-10	Lung function (FVC);
LUAD	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg27490568	chr2:178487706	NA	0.39	6.66	0.31	8.74e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.66	-0.43	4.48e-20	Schizophrenia;
LUAD	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg06671706	chr8:8559999	CLDN23	0.65	11.35	0.48	2.99e-26	Obesity-related traits;
LUAD	cis	rs679087	1.000	rs439639	chr12:29917641	A/C	cg14258853	chr12:29935411	TMTC1	-0.6	-10.36	-0.45	1.44e-22	Schizophrenia;
LUAD	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.98	-0.4	8.9e-18	Total body bone mineral density;
LUAD	cis	rs7017914	0.967	rs7000647	chr8:71688408	C/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.46	-0.3	2.82e-10	Bone mineral density;
LUAD	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg21231944	chr12:82153410	PPFIA2	-0.37	-6.69	-0.31	7.14e-11	Resting heart rate;
LUAD	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg05896524	chr21:47604654	C21orf56	-0.46	-7.08	-0.33	6.18e-12	Testicular germ cell tumor;
LUAD	cis	rs11626933	0.589	rs10140761	chr14:90740588	G/C	cg14092571	chr14:90743983	NA	0.65	11.94	0.5	1.62e-28	Gut microbiota (bacterial taxa);
LUAD	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg09323728	chr8:95962352	TP53INP1	-0.33	-7.91	-0.36	2.33e-14	Type 2 diabetes;
LUAD	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg15921436	chr17:44337874	NA	0.89	11.51	0.49	7.26e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.24	-0.37	2.22e-15	Prostate cancer;
LUAD	cis	rs1018836	0.884	rs7823461	chr8:91581075	T/C	cg16814680	chr8:91681699	NA	-0.7	-12.07	-0.51	5.2e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg18446336	chr7:2847575	GNA12	0.35	6.5	0.3	2.22e-10	Height;
LUAD	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg25036284	chr2:26402008	FAM59B	-0.58	-8.09	-0.37	6.31e-15	Gut microbiome composition (summer);
LUAD	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg06108461	chr20:60628389	TAF4	-1.03	-18.5	-0.67	2.06e-56	Body mass index;
LUAD	trans	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg01620082	chr3:125678407	NA	-0.44	-6.56	-0.3	1.61e-10	Depression;
LUAD	cis	rs829880	0.858	rs733180	chr12:98842588	C/T	cg25150519	chr12:98850993	NA	0.64	11.8	0.5	5.66e-28	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg27494647	chr7:150038898	RARRES2	0.54	9.6	0.42	7.12e-20	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg25319279	chr11:5960081	NA	-0.41	-7.63	-0.35	1.55e-13	DNA methylation (variation);
LUAD	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg02551604	chr5:131831745	NA	0.69	11.69	0.49	1.51e-27	Asthma (sex interaction);
LUAD	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg15911859	chr22:45810043	RIBC2;SMC1B	0.85	10.19	0.44	6.12e-22	Tonsillectomy;
LUAD	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg19336497	chr11:14380999	RRAS2	-0.69	-16.22	-0.62	2.24e-46	Sense of smell;
LUAD	cis	rs7172809	0.573	rs3784787	chr15:77681010	T/C	cg11865553	chr15:77376250	NA	-0.39	-6.46	-0.3	2.91e-10	Glucose homeostasis traits;
LUAD	cis	rs1032833	0.643	rs115110396	chr2:180107140	C/T	cg23883738	chr2:179974586	SESTD1	-0.72	-8.19	-0.37	3.17e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs804280	0.662	rs11784693	chr8:11610674	C/T	cg23972785	chr8:11611189	GATA4	-0.42	-7.17	-0.33	3.3e-12	Myopia (pathological);
LUAD	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg03676636	chr4:99064102	C4orf37	0.31	8.05	0.36	8.46e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg05872129	chr22:39784769	NA	-0.71	-9.79	-0.43	1.49e-20	IgG glycosylation;
LUAD	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14169450	chr9:139327907	INPP5E	-0.42	-7.93	-0.36	1.97e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7625357	0.627	rs6763377	chr3:169322958	A/G	cg14572252	chr3:169309425	MECOM	-0.44	-7.61	-0.35	1.74e-13	Childhood and early adolescence aggressive behavior;
LUAD	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg08085267	chr17:45401833	C17orf57	0.62	11.06	0.47	3.81e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	7.1	0.33	5.34e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs4790333	0.562	rs2447104	chr17:2257532	C/T	cg02569219	chr17:2266849	SGSM2	0.52	9.81	0.43	1.37e-20	Proinsulin levels;
LUAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-7.93	-0.36	1.93e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg15128208	chr22:42549153	NA	0.41	6.47	0.3	2.71e-10	Birth weight;
LUAD	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg05717871	chr11:638507	DRD4	-0.45	-6.58	-0.3	1.38e-10	Systemic lupus erythematosus;
LUAD	trans	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6076065	0.692	rs2424549	chr20:23394563	C/A	cg11657817	chr20:23433608	CST11	0.46	8.59	0.39	1.65e-16	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg23625390	chr15:77176239	SCAPER	-0.53	-8.13	-0.37	4.95e-15	Blood metabolite levels;
LUAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.48	-0.3	2.5e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs863345	0.604	rs6674656	chr1:158495431	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.39	-0.3	4.26e-10	Pneumococcal bacteremia;
LUAD	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03934478	chr11:495069	RNH1	0.75	8.9	0.4	1.64e-17	Body mass index;
LUAD	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.13	0.33	4.36e-12	Motion sickness;
LUAD	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg08885076	chr2:99613938	TSGA10	0.36	6.49	0.3	2.45e-10	Chronic sinus infection;
LUAD	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.41	6.64	0.31	9.53e-11	Bipolar disorder;
LUAD	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg10589385	chr1:150898437	SETDB1	0.4	7.49	0.34	4.04e-13	Melanoma;
LUAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22338127	chr1:209979572	IRF6	0.49	6.77	0.31	4.19e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg00339695	chr16:24857497	SLC5A11	0.73	11.63	0.49	2.67e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs790123	0.842	rs796889	chr3:122398461	T/C	cg15604389	chr3:122379662	NA	0.46	7.67	0.35	1.21e-13	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg01416388	chr22:39784598	NA	-0.45	-6.83	-0.32	2.89e-11	Post bronchodilator FEV1;
LUAD	cis	rs12210905	0.688	rs12213533	chr6:27346021	C/T	cg08851530	chr6:28072375	NA	1.09	7.97	0.36	1.45e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs6867032	0.876	rs1552435	chr5:2018378	A/G	cg26168224	chr5:2018326	NA	0.83	19.65	0.69	1.55e-61	Gut microbiome composition (winter);
LUAD	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09263875	chr16:632152	PIGQ	0.82	17.86	0.66	1.48e-53	Height;
LUAD	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg13390004	chr1:15929781	NA	0.48	8.5	0.38	3.18e-16	Systolic blood pressure;
LUAD	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg22920501	chr2:26401640	FAM59B	0.97	14.27	0.57	5.39e-38	Gut microbiome composition (summer);
LUAD	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg12458913	chr13:53173898	NA	0.39	6.96	0.32	1.31e-11	Lewy body disease;
LUAD	cis	rs6665290	0.904	rs1045285	chr1:227179054	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.2	-38.3	-0.88	1.39e-139	Myeloid white cell count;
LUAD	trans	rs9467711	0.745	rs9467714	chr6:26340785	C/T	cg06606381	chr12:133084897	FBRSL1	-0.6	-6.53	-0.3	1.93e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg04155289	chr7:94953770	PON1	-0.71	-12.45	-0.52	1.52e-30	Paraoxonase activity;
LUAD	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-7.29	-0.33	1.53e-12	Morning vs. evening chronotype;
LUAD	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.79	-0.35	5.18e-14	Type 2 diabetes;
LUAD	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11644478	chr21:40555479	PSMG1	0.57	8.87	0.4	2.09e-17	Cognitive function;
LUAD	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14240646	chr10:27532245	ACBD5	-0.89	-12.42	-0.52	2.02e-30	Breast cancer;
LUAD	trans	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs36093924	0.646	rs4822069	chr22:42351481	T/C	cg15128208	chr22:42549153	NA	0.34	6.64	0.31	9.71e-11	Intelligence;
LUAD	cis	rs2637266	0.935	rs7477361	chr10:78393586	G/A	cg18941641	chr10:78392320	NA	0.35	7.23	0.33	2.23e-12	Pulmonary function;
LUAD	cis	rs11771526	0.892	rs62457534	chr7:32357652	G/A	cg27511599	chr7:32358540	NA	0.61	6.94	0.32	1.52e-11	Body mass index;
LUAD	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg24634471	chr8:143751801	JRK	0.48	7.65	0.35	1.4e-13	Schizophrenia;
LUAD	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg04455712	chr21:45112962	RRP1B	0.43	8.71	0.39	6.87e-17	Mean corpuscular volume;
LUAD	cis	rs7264396	0.563	rs2425081	chr20:34299733	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2.04e-15	Total cholesterol levels;
LUAD	cis	rs977987	0.815	rs11149821	chr16:75422817	C/T	cg03315344	chr16:75512273	CHST6	0.64	14.1	0.57	2.7e-37	Dupuytren's disease;
LUAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08439880	chr3:133502540	NA	0.42	8.52	0.38	2.87e-16	Iron status biomarkers;
LUAD	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg01324343	chr3:183735012	ABCC5	0.95	25.02	0.77	1.94e-85	Anterior chamber depth;
LUAD	cis	rs2067615	0.542	rs4964184	chr12:107070425	A/T	cg15890332	chr12:107067104	RFX4	0.39	8.26	0.37	1.94e-15	Heart rate;
LUAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg16606324	chr3:10149918	C3orf24	0.69	11.52	0.49	7.01e-27	Alzheimer's disease;
LUAD	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg21984481	chr17:79567631	NPLOC4	-0.58	-12.06	-0.51	5.63e-29	Eye color traits;
LUAD	cis	rs6546550	0.935	rs1531025	chr2:70055505	G/T	cg02498382	chr2:70120550	SNRNP27	-0.55	-10.33	-0.45	1.9e-22	Prevalent atrial fibrillation;
LUAD	cis	rs11811982	0.793	rs77218109	chr1:227469249	C/G	cg24860534	chr1:227506868	CDC42BPA	0.7	7.57	0.35	2.36e-13	Optic disc area;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg03324837	chr17:61044407	NA	-0.39	-6.5	-0.3	2.22e-10	Subcortical brain region volumes;
LUAD	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg03233332	chr7:66118400	NA	-0.45	-6.63	-0.31	1.02e-10	Aortic root size;
LUAD	cis	rs752010	0.756	rs6600380	chr1:42054814	C/T	cg06885757	chr1:42089581	HIVEP3	-0.39	-8.48	-0.38	3.73e-16	Lupus nephritis in systemic lupus erythematosus;
LUAD	trans	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg19862616	chr7:65841803	NCRNA00174	1.04	25.8	0.78	7.32e-89	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg07256732	chr16:621771	PIGQ	-0.32	-6.5	-0.3	2.31e-10	Height;
LUAD	cis	rs3540	0.921	rs8034050	chr15:91000206	C/T	cg10434728	chr15:90938212	IQGAP1	0.35	6.38	0.3	4.64e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg00666640	chr1:248458726	OR2T12	0.31	7.67	0.35	1.2e-13	Common traits (Other);
LUAD	cis	rs76878669	0.561	rs55998145	chr11:66152586	A/G	cg18002602	chr11:66138449	SLC29A2	0.47	10.18	0.44	6.37e-22	Educational attainment (years of education);
LUAD	cis	rs1595825	0.891	rs4422151	chr2:198544183	A/T	cg10547527	chr2:198650123	BOLL	-0.55	-7.88	-0.36	2.78e-14	Ulcerative colitis;
LUAD	cis	rs1451375	0.617	rs17733244	chr7:50575495	T/C	cg18232548	chr7:50535776	DDC	0.68	8.63	0.39	1.28e-16	Malaria;
LUAD	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg11502198	chr6:26597334	ABT1	0.67	11.64	0.49	2.29e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg15208524	chr1:10270712	KIF1B	0.43	6.49	0.3	2.44e-10	Hepatocellular carcinoma;
LUAD	cis	rs9972944	0.729	rs7209787	chr17:63769896	G/C	cg07283582	chr17:63770753	CCDC46	-0.51	-11.48	-0.49	9.67e-27	Total body bone mineral density;
LUAD	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg25809561	chr17:30822961	MYO1D	0.46	8.38	0.38	8.11e-16	Schizophrenia;
LUAD	cis	rs9463078	0.715	rs1557143	chr6:44756415	T/C	cg25276700	chr6:44698697	NA	0.34	6.39	0.3	4.37e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUAD	trans	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg00953403	chr17:74099816	EXOC7	-0.57	-8.91	-0.4	1.53e-17	Psychosis in Alzheimer's disease;
LUAD	cis	rs4006360	0.506	rs8080177	chr17:39301645	C/T	cg20663846	chr17:39254439	KRTAP4-8	0.35	7.26	0.33	1.86e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg15147215	chr3:52552868	STAB1	-0.38	-7.08	-0.33	5.87e-12	Electroencephalogram traits;
LUAD	cis	rs7737355	0.853	rs6596024	chr5:130769785	A/C	cg25547332	chr5:131281432	NA	0.43	6.96	0.32	1.3e-11	Life satisfaction;
LUAD	cis	rs7144547	0.803	rs8008602	chr14:81890171	T/A	cg02996355	chr14:81879375	NA	-0.77	-11.97	-0.5	1.19e-28	Prudent dietary pattern;
LUAD	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg13319975	chr6:146136371	FBXO30	0.65	10.89	0.47	1.59e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg14552801	chr7:65878734	NA	0.38	6.38	0.3	4.71e-10	Aortic root size;
LUAD	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg05313129	chr8:58192883	C8orf71	-0.49	-7.42	-0.34	6.61e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8040855	0.860	rs7172266	chr15:85716213	C/T	cg04831495	chr15:85060580	GOLGA6L5	0.43	7.04	0.32	7.86e-12	Bulimia nervosa;
LUAD	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.63	0.31	1.02e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12505328	0.932	rs12502428	chr4:174357592	G/A	cg12145043	chr4:174357286	NA	0.57	10.21	0.44	5.17e-22	Chin dimples;
LUAD	cis	rs7789940	0.817	rs6946310	chr7:75936099	T/C	cg10167463	chr7:75959203	YWHAG	-0.55	-9.31	-0.41	7.16e-19	Multiple sclerosis;
LUAD	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.4	-7.15	-0.33	3.74e-12	Tonsillectomy;
LUAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg07217954	chr7:1067459	C7orf50	0.43	6.62	0.31	1.11e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-10.75	-0.46	5.2e-24	Lymphocyte counts;
LUAD	cis	rs684232	0.933	rs866304	chr17:587729	T/C	cg12384639	chr17:618140	VPS53	0.44	7.35	0.34	1.06e-12	Prostate cancer;
LUAD	cis	rs933688	0.532	rs973332	chr5:90555129	C/T	cg00335715	chr5:90575459	NA	-0.44	-6.75	-0.31	4.9e-11	Smoking behavior;
LUAD	cis	rs4343996	0.869	rs10232431	chr7:3511115	G/A	cg21248987	chr7:3385318	SDK1	0.37	6.68	0.31	7.76e-11	Motion sickness;
LUAD	cis	rs2455799	0.573	rs2654648	chr3:15775425	T/C	cg16303742	chr3:15540471	COLQ	-0.52	-9.58	-0.42	8.67e-20	Mean platelet volume;
LUAD	cis	rs9951602	0.703	rs2959407	chr18:76682915	A/G	cg00806245	chr18:76673096	NA	-0.38	-6.95	-0.32	1.4e-11	Obesity-related traits;
LUAD	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg00898013	chr13:113819073	PROZ	-0.67	-11.78	-0.5	6.73e-28	Platelet distribution width;
LUAD	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg08601574	chr20:25228251	PYGB	0.42	7.64	0.35	1.42e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg05896524	chr21:47604654	C21orf56	-0.59	-9.77	-0.43	1.88e-20	Testicular germ cell tumor;
LUAD	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg21138405	chr5:131827807	IRF1	0.6	13.88	0.56	2.35e-36	Asthma (sex interaction);
LUAD	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.37	6.53	0.3	1.88e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg25894440	chr7:65020034	NA	-0.67	-7.17	-0.33	3.4e-12	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05665937	chr4:1216051	CTBP1	0.46	6.92	0.32	1.69e-11	Longevity;
LUAD	cis	rs6541297	0.703	rs607553	chr1:230316444	T/A	cg20703242	chr1:230279135	GALNT2	-0.47	-6.94	-0.32	1.45e-11	Coronary artery disease;
LUAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg20607798	chr8:58055168	NA	0.67	8.77	0.39	4.44e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg23625390	chr15:77176239	SCAPER	0.4	6.99	0.32	1.06e-11	Blood metabolite levels;
LUAD	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-7.45	-0.34	5.28e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg14196790	chr5:131705035	SLC22A5	0.38	6.76	0.31	4.52e-11	Blood metabolite levels;
LUAD	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg06623918	chr6:96969491	KIAA0776	0.88	17.56	0.65	3.16e-52	Headache;
LUAD	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg13813247	chr22:41461852	NA	-0.48	-7.54	-0.34	2.86e-13	Neuroticism;
LUAD	trans	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.92	-0.36	2.09e-14	Breast cancer;
LUAD	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg26384229	chr12:38710491	ALG10B	-0.4	-6.62	-0.31	1.12e-10	Bladder cancer;
LUAD	trans	rs62458065	1.000	rs10250808	chr7:32466153	T/C	cg00845942	chr12:64062724	DPY19L2	-0.46	-6.65	-0.31	9.17e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2625529	0.617	rs13858	chr15:72433144	C/T	cg16672083	chr15:72433130	SENP8	-0.62	-11.95	-0.5	1.43e-28	Red blood cell count;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg02096656	chr7:139025181	C7orf55	0.39	6.37	0.3	4.91e-10	Optic cup area;
LUAD	cis	rs16866061	1.000	rs72974219	chr2:225423784	G/C	cg12698349	chr2:225449008	CUL3	0.77	13.5	0.55	8.79e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg06552810	chr11:31128660	NA	-0.33	-6.4	-0.3	4.08e-10	Red blood cell count;
LUAD	cis	rs300774	0.925	rs6735974	chr2:179581	A/G	cg21211680	chr2:198530	NA	-0.56	-8.56	-0.38	2.08e-16	Suicide attempts in bipolar disorder;
LUAD	cis	rs2230307	0.572	rs17122001	chr1:100628311	A/T	cg20868668	chr1:100435035	SLC35A3	0.54	8.03	0.36	9.79e-15	Carotid intima media thickness;
LUAD	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19346786	chr7:2764209	NA	-0.57	-12.32	-0.51	5.05e-30	Height;
LUAD	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg25324976	chr17:61989376	CSHL1	0.38	7.39	0.34	7.97e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg18404041	chr3:52824283	ITIH1	-0.35	-6.6	-0.31	1.23e-10	Electroencephalogram traits;
LUAD	cis	rs6076065	0.723	rs2424546	chr20:23391751	G/T	cg11657817	chr20:23433608	CST11	0.47	8.92	0.4	1.45e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg24818145	chr4:99064322	C4orf37	0.47	7.94	0.36	1.87e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-10.76	-0.46	5.01e-24	Bone mineral density;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06451949	chr17:48942959	NA	-0.4	-6.36	-0.3	5.26e-10	Height;
LUAD	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	9.38	0.42	3.94e-19	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg11707310	chr1:2537719	MMEL1	0.37	7.85	0.36	3.39e-14	Ulcerative colitis;
LUAD	cis	rs76419734	0.510	rs2193856	chr4:106742958	A/C	cg05309399	chr4:106552544	FLJ20184	0.51	7.12	0.33	4.61e-12	Post bronchodilator FEV1;
LUAD	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg03526776	chr6:41159608	TREML2	0.33	6.83	0.32	2.88e-11	Alzheimer's disease (late onset);
LUAD	cis	rs79839061	0.732	rs11734742	chr4:821565	C/T	cg14530993	chr4:882597	GAK	0.75	6.57	0.3	1.46e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg18446336	chr7:2847575	GNA12	-0.37	-6.84	-0.32	2.77e-11	Height;
LUAD	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg03161606	chr19:29218774	NA	0.59	7.94	0.36	1.88e-14	Methadone dose in opioid dependence;
LUAD	cis	rs10419226	0.555	rs12976113	chr19:18767480	A/G	cg22001208	chr19:18782374	NA	-0.47	-7.8	-0.35	4.89e-14	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg24642844	chr7:1081250	C7orf50	-0.98	-14.82	-0.58	2.67e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg25985355	chr7:65971099	NA	-0.38	-6.89	-0.32	2.02e-11	Aortic root size;
LUAD	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg08439880	chr3:133502540	NA	-0.35	-6.71	-0.31	6.13e-11	Iron status biomarkers;
LUAD	cis	rs4638749	0.677	rs2219082	chr2:108854182	C/A	cg25838818	chr2:108905173	SULT1C2	-0.4	-7.01	-0.32	9.74e-12	Blood pressure;
LUAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg02951883	chr7:2050386	MAD1L1	-0.73	-11.56	-0.49	4.7e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs7851660	0.874	rs10122541	chr9:100628268	G/A	cg13688889	chr9:100608707	NA	-0.48	-8.26	-0.37	1.87e-15	Strep throat;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg07683663	chr4:147096828	LSM6	0.42	6.55	0.3	1.71e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg22618164	chr12:122356400	WDR66	0.73	13.3	0.54	6.02e-34	Mean corpuscular volume;
LUAD	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08439880	chr3:133502540	NA	-0.47	-9.42	-0.42	3.03e-19	Iron status biomarkers;
LUAD	cis	rs7731657	0.537	rs11744408	chr5:130360784	T/C	cg08523029	chr5:130500466	HINT1	0.46	6.42	0.3	3.6e-10	Fasting plasma glucose;
LUAD	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg25251562	chr2:3704773	ALLC	-0.37	-6.78	-0.31	4.18e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg04398451	chr17:18023971	MYO15A	0.78	14.15	0.57	1.76e-37	Total body bone mineral density;
LUAD	cis	rs11893307	0.509	rs17465200	chr2:191549636	C/T	cg11845111	chr2:191398756	TMEM194B	-0.45	-6.68	-0.31	7.41e-11	Mean platelet volume;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24052698	chr1:182584193	NA	-0.51	-6.48	-0.3	2.49e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6500395	1.000	rs4493038	chr16:48683920	A/G	cg04672837	chr16:48644449	N4BP1	0.39	6.81	0.31	3.4e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1448094	0.802	rs11117146	chr12:86382870	C/T	cg00310523	chr12:86230176	RASSF9	-0.35	-7.45	-0.34	5.43e-13	Major depressive disorder;
LUAD	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg00020340	chr7:910388	UNC84A	-0.65	-7.13	-0.33	4.29e-12	Initial pursuit acceleration;
LUAD	cis	rs1524976	1.000	rs62255324	chr3:65505514	C/T	cg16238336	chr3:65465873	MAGI1	-0.69	-7.6	-0.35	1.94e-13	PR interval;
LUAD	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg04414720	chr1:150670196	GOLPH3L	0.71	13.15	0.54	2.43e-33	Tonsillectomy;
LUAD	cis	rs10504073	0.647	rs28685207	chr8:50003484	A/G	cg00325661	chr8:49890786	NA	0.45	10.12	0.44	1.06e-21	Blood metabolite ratios;
LUAD	trans	rs783540	0.934	rs803747	chr15:83258096	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.45	-7.19	-0.33	3.01e-12	Schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12393716	chr11:62495049	TTC9C;HNRNPUL2	-0.41	-6.5	-0.3	2.29e-10	Height;
LUAD	cis	rs4711350	0.765	rs2395446	chr6:33743264	C/T	cg13859433	chr6:33739653	LEMD2	-0.38	-8.09	-0.37	6.17e-15	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs12618769	0.597	rs3769723	chr2:99105988	A/G	cg10123293	chr2:99228465	UNC50	0.46	8.34	0.38	1.03e-15	Bipolar disorder;
LUAD	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg02176678	chr2:219576539	TTLL4	0.61	11.71	0.49	1.27e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg20302342	chr1:156215951	PAQR6	0.39	8.68	0.39	8.92e-17	Tonsillectomy;
LUAD	cis	rs2034088	0.833	rs7219151	chr17:440497	G/A	cg13332499	chr17:408570	NA	0.43	9.69	0.43	3.4e-20	Hip circumference adjusted for BMI;
LUAD	cis	rs1595825	0.891	rs1851779	chr2:198647108	C/T	cg00982548	chr2:198649783	BOLL	-0.66	-9.3	-0.41	7.6e-19	Ulcerative colitis;
LUAD	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg24154853	chr7:158122151	PTPRN2	0.57	11.38	0.48	2.29e-26	Calcium levels;
LUAD	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg16205897	chr5:131564050	P4HA2	-0.35	-7.76	-0.35	6.57e-14	Blood metabolite levels;
LUAD	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg18825076	chr15:78729989	IREB2	0.49	6.75	0.31	5.01e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1953600	0.645	rs2573351	chr10:81931441	A/G	cg00277334	chr10:82204260	NA	-0.41	-7.06	-0.32	6.71e-12	Sarcoidosis;
LUAD	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7589728	0.748	rs3791357	chr2:88478664	C/T	cg04511125	chr2:88470314	THNSL2	0.9	9.23	0.41	1.3e-18	Plasma clusterin levels;
LUAD	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg17366294	chr4:99064904	C4orf37	0.64	12.21	0.51	1.43e-29	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg03609598	chr5:56110824	MAP3K1	-0.61	-8.0	-0.36	1.2e-14	Initial pursuit acceleration;
LUAD	cis	rs4072705	0.616	rs915033	chr9:127245558	C/G	cg01786973	chr9:127249749	NR5A1	0.29	6.58	0.3	1.36e-10	Menarche (age at onset);
LUAD	trans	rs8002861	0.664	rs895266	chr13:44461179	T/C	cg17145862	chr1:211918768	LPGAT1	0.64	12.45	0.52	1.51e-30	Leprosy;
LUAD	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg26022315	chr17:47021804	SNF8	0.4	7.28	0.33	1.63e-12	Type 2 diabetes;
LUAD	cis	rs2762353	0.574	rs4409177	chr6:25694491	T/G	cg03264133	chr6:25882463	NA	0.82	13.65	0.55	2.04e-35	Blood metabolite levels;
LUAD	trans	rs11148252	0.634	rs66849828	chr13:52714837	C/A	cg18335740	chr13:41363409	SLC25A15	0.46	7.68	0.35	1.11e-13	Lewy body disease;
LUAD	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg18252515	chr7:66147081	NA	-0.63	-6.94	-0.32	1.5e-11	Gout;
LUAD	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23583168	chr7:148888333	NA	-1.05	-25.95	-0.78	1.69e-89	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs3820068	0.705	rs2042369	chr1:15843244	A/G	cg24675056	chr1:15929824	NA	-0.4	-6.44	-0.3	3.23e-10	Systolic blood pressure;
LUAD	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg00129232	chr17:37814104	STARD3	-0.47	-7.59	-0.35	2.01e-13	Asthma;
LUAD	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.05	-0.32	7.55e-12	Height;
LUAD	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg04093404	chr1:6614507	TAS1R1;NOL9	0.7	8.34	0.38	1.05e-15	Body mass index;
LUAD	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg18230493	chr5:56204884	C5orf35	-0.62	-9.79	-0.43	1.51e-20	Coronary artery disease;
LUAD	cis	rs4601821	0.823	rs10891546	chr11:113265292	C/T	cg14159747	chr11:113255604	NA	-0.49	-9.81	-0.43	1.36e-20	Alcoholic chronic pancreatitis;
LUAD	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	7.17	0.33	3.32e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10489202	1.000	rs34774552	chr1:168032245	G/A	cg24449463	chr1:168025552	DCAF6	-0.59	-7.37	-0.34	9.34e-13	Schizophrenia;
LUAD	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg12437481	chr16:420112	MRPL28	-0.6	-10.88	-0.47	1.77e-24	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg19442545	chr10:75533431	FUT11	-0.49	-8.27	-0.37	1.71e-15	Inflammatory bowel disease;
LUAD	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg09365446	chr1:150670422	GOLPH3L	0.62	10.91	0.47	1.39e-24	Melanoma;
LUAD	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11890956	chr21:40555474	PSMG1	-0.55	-8.9	-0.4	1.69e-17	Cognitive function;
LUAD	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg04450456	chr4:17643702	FAM184B	0.39	7.55	0.34	2.68e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg03886242	chr7:26192032	NFE2L3	-0.43	-7.4	-0.34	7.23e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9322817	0.691	rs6571207	chr6:105242161	A/C	cg02098413	chr6:105308735	HACE1	-0.43	-9.16	-0.41	2.24e-18	Thyroid stimulating hormone;
LUAD	trans	rs7395662	0.593	rs8188975	chr11:48891877	A/G	cg00717180	chr2:96193071	NA	0.38	7.12	0.33	4.53e-12	HDL cholesterol;
LUAD	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg20933634	chr6:27740509	NA	0.49	7.94	0.36	1.87e-14	Parkinson's disease;
LUAD	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21582582	chr3:182698605	DCUN1D1	0.71	14.0	0.56	7.37e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg11707310	chr1:2537719	MMEL1	-0.41	-8.62	-0.39	1.34e-16	Ulcerative colitis;
LUAD	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg09359103	chr1:154839909	KCNN3	-0.91	-21.51	-0.72	7e-70	Prostate cancer;
LUAD	cis	rs13064411	0.696	rs2087129	chr3:113142769	T/A	cg10517650	chr3:113235015	CCDC52	-0.48	-7.97	-0.36	1.48e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	ch.11.29638519R	chr11:29681943	NA	-0.36	-6.4	-0.3	4.21e-10	Migraine with aura;
LUAD	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.76	0.39	4.58e-17	Cannabis dependence symptom count;
LUAD	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg19041857	chr6:27730383	NA	-0.47	-7.68	-0.35	1.11e-13	Breast cancer;
LUAD	cis	rs10465746	0.780	rs11163862	chr1:84355418	A/T	cg10977910	chr1:84465055	TTLL7	-0.6	-9.88	-0.43	7.75e-21	Obesity-related traits;
LUAD	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg00631329	chr6:26305371	NA	-0.69	-13.57	-0.55	4.45e-35	Educational attainment;
LUAD	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg26566898	chr11:117069891	TAGLN	0.34	6.55	0.3	1.65e-10	Blood protein levels;
LUAD	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.34	-0.41	5.4e-19	Life satisfaction;
LUAD	cis	rs9462027	0.628	rs10947521	chr6:34689377	G/T	cg07306190	chr6:34760872	UHRF1BP1	0.35	9.0	0.4	7.61e-18	Systemic lupus erythematosus;
LUAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-9.43	-0.42	2.83e-19	Alzheimer's disease;
LUAD	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18404041	chr3:52824283	ITIH1	-0.61	-12.22	-0.51	1.32e-29	Bipolar disorder;
LUAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00166722	chr3:10149974	C3orf24	0.73	10.94	0.47	1.1e-24	Alzheimer's disease;
LUAD	cis	rs1215050	0.765	rs1588018	chr4:98756324	G/C	cg05340658	chr4:99064831	C4orf37	0.43	7.24	0.33	2.09e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.76	10.54	0.46	3.33e-23	Smoking behavior;
LUAD	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06022373	chr22:39101656	GTPBP1	-0.5	-8.15	-0.37	4.09e-15	Menopause (age at onset);
LUAD	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg17173187	chr15:85201210	NMB	0.5	8.61	0.39	1.47e-16	Schizophrenia;
LUAD	cis	rs240764	0.782	rs239222	chr6:101112817	T/A	cg09795085	chr6:101329169	ASCC3	0.43	7.36	0.34	9.82e-13	Neuroticism;
LUAD	cis	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg00071950	chr4:10020882	SLC2A9	0.47	6.77	0.31	4.19e-11	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg23503501	chr22:45809793	SMC1B;RIBC2	0.73	7.33	0.34	1.15e-12	Tonsillectomy;
LUAD	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-19.85	-0.69	1.88e-62	Height;
LUAD	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg15556689	chr8:8085844	FLJ10661	0.42	6.76	0.31	4.55e-11	Mood instability;
LUAD	cis	rs12286929	0.661	rs7947402	chr11:115088420	T/C	cg04055981	chr11:115044050	NA	0.42	7.45	0.34	5.31e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs77972916	0.517	rs17406126	chr2:43546632	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-6.96	-0.32	1.27e-11	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs236907	0.859	rs6656852	chr1:171752373	A/G	cg13482142	chr2:234261155	NA	0.49	6.36	0.3	5.09e-10	Mean platelet volume;
LUAD	cis	rs2274273	0.840	rs11626751	chr14:55835227	T/C	cg04306507	chr14:55594613	LGALS3	0.44	9.33	0.41	5.97e-19	Protein biomarker;
LUAD	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg06221963	chr1:154839813	KCNN3	-0.85	-20.06	-0.7	2.11e-63	Prostate cancer;
LUAD	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-7.01	-0.32	9.45e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg23229984	chr5:148520753	ABLIM3	-0.5	-8.0	-0.36	1.17e-14	Breast cancer;
LUAD	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg23262073	chr20:60523788	NA	-0.36	-6.43	-0.3	3.43e-10	Body mass index;
LUAD	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg06640241	chr16:89574553	SPG7	0.49	7.75	0.35	7e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg08280861	chr8:58055591	NA	0.56	7.1	0.33	5.34e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs220324	0.688	rs4450717	chr21:43566297	C/G	cg09727148	chr21:43560719	UMODL1	0.54	8.17	0.37	3.71e-15	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg19761014	chr17:28927070	LRRC37B2	0.83	8.46	0.38	4.42e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg01689657	chr7:91764605	CYP51A1	0.38	9.15	0.41	2.52e-18	Breast cancer;
LUAD	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg01475377	chr6:109611718	NA	-0.51	-9.43	-0.42	2.74e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg00071950	chr4:10020882	SLC2A9	0.85	18.46	0.67	3.04e-56	Bone mineral density;
LUAD	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg20503657	chr10:835505	NA	-0.47	-7.37	-0.34	8.84e-13	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.51	-10.59	-0.46	2.02e-23	Monocyte percentage of white cells;
LUAD	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg17366294	chr4:99064904	C4orf37	0.48	8.38	0.38	8.04e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg14917512	chr19:3094685	GNA11	-0.57	-6.7	-0.31	6.66e-11	Diabetic kidney disease;
LUAD	cis	rs3106136	1.000	rs3106136	chr4:95153349	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.74	-0.35	7.41e-14	Capecitabine sensitivity;
LUAD	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg03806693	chr22:41940476	POLR3H	0.7	9.64	0.42	5.03e-20	Vitiligo;
LUAD	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg09367891	chr1:107599246	PRMT6	0.57	9.04	0.4	5.49e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg12863693	chr15:85201151	NMB	-0.38	-6.73	-0.31	5.45e-11	Schizophrenia;
LUAD	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg20476274	chr7:133979776	SLC35B4	0.7	11.85	0.5	3.51e-28	Mean platelet volume;
LUAD	trans	rs10802346	0.545	rs6662672	chr1:246387611	A/C	cg13514129	chr1:39547527	MACF1	0.61	10.95	0.47	9.39e-25	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg03563238	chr19:33554763	RHPN2	-0.32	-7.87	-0.36	3.06e-14	Bone properties (heel);
LUAD	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg02176678	chr2:219576539	TTLL4	-0.7	-13.73	-0.56	9.37e-36	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.01	0.36	1.11e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05000987	chr1:87379871	SEP15;HS2ST1	-0.42	-6.46	-0.3	2.82e-10	Height;
LUAD	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	6.93	0.32	1.63e-11	Motion sickness;
LUAD	cis	rs17102423	0.755	rs7154852	chr14:65553822	C/A	cg11161011	chr14:65562177	MAX	-0.51	-8.13	-0.37	4.94e-15	Obesity-related traits;
LUAD	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.03	-0.32	8.42e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.83	0.32	2.93e-11	Hypertriglyceridemia;
LUAD	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg01236616	chr12:121019343	POP5	-1.24	-19.05	-0.68	7.19e-59	Type 1 diabetes nephropathy;
LUAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg07685180	chr8:600429	NA	0.87	9.02	0.4	6.48e-18	IgG glycosylation;
LUAD	trans	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg01620082	chr3:125678407	NA	-0.69	-7.95	-0.36	1.73e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg11584989	chr19:19387371	SF4	0.58	9.3	0.41	7.53e-19	Bipolar disorder;
LUAD	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg15445000	chr17:37608096	MED1	-0.45	-8.31	-0.37	1.28e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg07507251	chr3:52567010	NT5DC2	0.37	7.32	0.34	1.26e-12	Bipolar disorder;
LUAD	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.4	-6.4	-0.3	4.14e-10	Glycated hemoglobin levels;
LUAD	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26314531	chr2:26401878	FAM59B	-0.68	-9.13	-0.41	2.77e-18	Gut microbiome composition (summer);
LUAD	cis	rs754466	1.000	rs12220902	chr10:79682918	C/T	cg17075019	chr10:79541650	NA	-0.8	-13.23	-0.54	1.1e-33	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs752010	0.967	rs6703597	chr1:42097904	C/T	cg06885757	chr1:42089581	HIVEP3	0.44	9.22	0.41	1.39e-18	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs1371867	0.810	rs3020182	chr8:101233008	T/C	cg06002616	chr8:101225028	SPAG1	0.44	8.96	0.4	1.02e-17	Atrioventricular conduction;
LUAD	cis	rs62400317	0.821	rs12206568	chr6:45152747	C/T	cg20913747	chr6:44695427	NA	-0.4	-6.48	-0.3	2.59e-10	Total body bone mineral density;
LUAD	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg04727924	chr7:799746	HEATR2	-0.55	-7.51	-0.34	3.58e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg25767906	chr1:53392781	SCP2	-0.46	-8.51	-0.38	3.09e-16	Monocyte count;
LUAD	cis	rs4713675	0.584	rs4713661	chr6:33674174	C/A	cg13859433	chr6:33739653	LEMD2	-0.29	-6.93	-0.32	1.6e-11	Plateletcrit;
LUAD	trans	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg24644049	chr4:85504048	CDS1	0.92	7.94	0.36	1.84e-14	Skin colour saturation;
LUAD	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.96	-0.32	1.28e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs57920188	0.703	rs3813810	chr1:4088339	G/T	cg20703997	chr1:4087676	NA	0.51	9.56	0.42	1.01e-19	Interleukin-17 levels;
LUAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg22907277	chr7:1156413	C7orf50	0.68	7.87	0.36	2.95e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg24147428	chr11:65409760	SIPA1	-0.61	-9.53	-0.42	1.29e-19	Blood pressure (age interaction);
LUAD	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg12623918	chr2:306882	NA	0.35	6.91	0.32	1.74e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg27284194	chr4:1044797	NA	0.54	8.9	0.4	1.67e-17	Recombination rate (males);
LUAD	trans	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.26	-0.37	1.93e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg05342682	chr7:94953680	PON1	-0.51	-7.1	-0.33	5.24e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.4	-0.48	1.96e-26	Type 2 diabetes;
LUAD	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg14343924	chr8:8086146	FLJ10661	0.45	6.82	0.31	3.1e-11	Joint mobility (Beighton score);
LUAD	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.37	0.45	1.35e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs7487075	0.619	rs9971879	chr12:46806773	T/C	cg23829395	chr12:46796953	NA	0.32	6.98	0.32	1.16e-11	Itch intensity from mosquito bite;
LUAD	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg22920501	chr2:26401640	FAM59B	0.73	10.59	0.46	2.0500000000000001e-23	Gut microbiome composition (summer);
LUAD	cis	rs7937890	0.559	rs2597217	chr11:14532883	A/G	cg23387056	chr11:14280742	SPON1	-0.34	-6.67	-0.31	8.19e-11	Mitochondrial DNA levels;
LUAD	cis	rs2274273	0.624	rs10141396	chr14:55816925	A/C	cg04306507	chr14:55594613	LGALS3	0.45	8.42	0.38	5.95e-16	Protein biomarker;
LUAD	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.86	12.37	0.52	3.34e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg21100191	chr22:23484243	RTDR1	0.67	11.56	0.49	4.88e-27	Bone mineral density;
LUAD	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg03433033	chr1:76189801	ACADM	0.73	11.07	0.47	3.54e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9473147	0.503	rs9473123	chr6:47475339	G/A	cg20196966	chr6:47445060	CD2AP	0.45	7.03	0.32	8.2e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg01884057	chr2:25150051	NA	0.33	6.98	0.32	1.11e-11	Body mass index;
LUAD	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg07917127	chr4:99064746	C4orf37	0.42	7.02	0.32	9.05e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs708547	0.647	rs781668	chr4:57825140	C/T	cg00922110	chr4:57842668	C4orf14	0.38	7.13	0.33	4.33e-12	Response to bleomycin (chromatid breaks);
LUAD	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg18932078	chr1:2524107	MMEL1	0.39	7.28	0.33	1.66e-12	Ulcerative colitis;
LUAD	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.4	-0.45	1.06e-22	Total body bone mineral density;
LUAD	trans	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg07817883	chr1:32538562	TMEM39B	-0.52	-7.15	-0.33	3.94e-12	Monocyte percentage of white cells;
LUAD	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03517284	chr6:25882590	NA	0.54	7.97	0.36	1.52e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs10812641	0.875	rs7032942	chr9:2792552	A/C	cg05800723	chr4:79103126	FRAS1	0.38	6.89	0.32	2.09e-11	Blood trace element (Se levels);
LUAD	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03934478	chr11:495069	RNH1	0.66	7.62	0.35	1.65e-13	Body mass index;
LUAD	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg02696790	chr15:75250997	RPP25	-0.35	-6.52	-0.3	1.96e-10	Breast cancer;
LUAD	cis	rs9341808	0.500	rs2223873	chr6:81048288	A/G	cg08355045	chr6:80787529	NA	0.47	8.19	0.37	3.07e-15	Sitting height ratio;
LUAD	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg02421172	chr7:1938701	MAD1L1	0.46	6.74	0.31	5.13e-11	Bipolar disorder;
LUAD	cis	rs9430161	0.579	rs6694011	chr1:11036935	G/A	cg02454025	chr1:11042201	C1orf127	0.98	16.69	0.63	2.13e-48	Ewing sarcoma;
LUAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14159672	chr1:205819179	PM20D1	0.79	15.86	0.61	8.61e-45	Menarche (age at onset);
LUAD	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg17724175	chr1:150552817	MCL1	0.3	6.8	0.31	3.61e-11	Melanoma;
LUAD	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg26384229	chr12:38710491	ALG10B	-0.37	-6.43	-0.3	3.45e-10	Morning vs. evening chronotype;
LUAD	cis	rs932287	0.666	rs10840161	chr11:9053824	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.46	8.45	0.38	4.73e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17152411	1.000	rs7914110	chr10:126599886	C/G	cg07906193	chr10:126599966	NA	0.56	7.79	0.35	5.1e-14	Height;
LUAD	cis	rs6987853	0.966	rs2923428	chr8:42388301	T/C	cg09913449	chr8:42400586	C8orf40	0.43	7.92	0.36	2.14e-14	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.5	0.55	8.62e-35	Exhaled nitric oxide output;
LUAD	cis	rs367943	0.666	rs1850412	chr5:112696768	A/G	cg21806985	chr5:112824646	MCC	0.25	6.4	0.3	4.06e-10	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg11062466	chr8:58055876	NA	0.65	8.63	0.39	1.21e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs73416724	1.000	rs78014492	chr6:43289599	C/T	cg26312998	chr6:43337775	ZNF318	0.55	6.59	0.31	1.32e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg01312482	chr5:178451176	ZNF879	-0.46	-7.06	-0.32	6.85e-12	Pubertal anthropometrics;
LUAD	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	7.58	0.35	2.2e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg02993280	chr1:107599747	PRMT6	-0.55	-8.99	-0.4	8.1e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg18477163	chr1:228402036	OBSCN	0.44	7.79	0.35	5.27e-14	Diastolic blood pressure;
LUAD	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg24818145	chr4:99064322	C4orf37	-0.4	-6.75	-0.31	4.77e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10896135	0.526	rs484262	chr11:66399681	C/T	cg15964523	chr11:66469143	SPTBN2	0.42	6.98	0.32	1.16e-11	Bipolar disorder;
LUAD	cis	rs6906287	0.647	rs6925641	chr6:118821894	C/T	cg18833306	chr6:118973337	C6orf204	0.47	8.35	0.38	1.02e-15	Electrocardiographic conduction measures;
LUAD	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg18252515	chr7:66147081	NA	0.62	6.77	0.31	4.25e-11	Diabetic kidney disease;
LUAD	cis	rs7107174	1.000	rs2450128	chr11:77940075	G/A	cg02023728	chr11:77925099	USP35	0.42	6.99	0.32	1.07e-11	Testicular germ cell tumor;
LUAD	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg11833968	chr6:79620685	NA	-0.43	-7.96	-0.36	1.59e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg11645453	chr3:52864694	ITIH4	-0.36	-6.94	-0.32	1.45e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.01	0.32	9.52e-12	Motion sickness;
LUAD	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.17	0.33	3.34e-12	Motion sickness;
LUAD	cis	rs80319144	1.000	rs113144913	chr2:159290486	G/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.9	0.32	1.88e-11	Restless legs syndrome;
LUAD	cis	rs4631830	0.540	rs2926493	chr10:51492131	G/A	cg20129853	chr10:51489980	NA	-0.43	-8.73	-0.39	5.81e-17	Prostate-specific antigen levels;
LUAD	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.45	7.91	0.36	2.26e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg24642844	chr7:1081250	C7orf50	-0.96	-14.36	-0.57	2.34e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg21782813	chr7:2030301	MAD1L1	-0.5	-8.55	-0.38	2.29e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs1595825	1.000	rs1440090	chr2:198879297	T/G	cg10547527	chr2:198650123	BOLL	-0.47	-6.64	-0.31	9.38e-11	Ulcerative colitis;
LUAD	cis	rs8077889	0.750	rs231539	chr17:41942109	T/C	cg26893861	chr17:41843967	DUSP3	-0.93	-11.58	-0.49	4.09e-27	Triglycerides;
LUAD	cis	rs4523957	0.928	rs441750	chr17:2190767	T/C	cg16513277	chr17:2031491	SMG6	0.77	14.4	0.57	1.52e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05901451	chr6:126070800	HEY2	0.46	6.97	0.32	1.22e-11	Endometrial cancer;
LUAD	cis	rs12681287	0.752	rs12679266	chr8:87258833	T/C	cg27223183	chr8:87520930	FAM82B	-0.61	-8.36	-0.38	8.99e-16	Caudate activity during reward;
LUAD	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-6.63	-0.31	1.04e-10	Tonsillectomy;
LUAD	cis	rs17095355	1.000	rs12570145	chr10:111712913	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.65	-8.1	-0.37	6.01e-15	Biliary atresia;
LUAD	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg15704280	chr7:45808275	SEPT13	-0.91	-17.46	-0.65	8.48e-52	Coronary artery disease;
LUAD	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg06740227	chr12:86229804	RASSF9	0.4	7.01	0.32	9.27e-12	Major depressive disorder;
LUAD	trans	rs1864729	1.000	rs1864729	chr8:98282189	G/A	cg08679828	chr8:102218111	ZNF706	-0.83	-8.79	-0.39	3.88e-17	Estradiol plasma levels (breast cancer);
LUAD	cis	rs1696756	0.877	rs1663223	chr17:77826509	A/G	cg00646381	chr17:77835854	NA	0.47	7.32	0.34	1.28e-12	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs2274471	0.678	rs7867965	chr9:5104574	G/T	cg03390472	chr9:5043263	JAK2	-0.53	-7.62	-0.35	1.73e-13	Crohn's disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06294637	chr8:59465767	SDCBP	-0.6	-6.41	-0.3	3.89e-10	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	trans	rs11039798	0.764	rs7294013	chr11:48762416	G/A	cg15704280	chr7:45808275	SEPT13	0.67	7.84	0.36	3.58e-14	Axial length;
LUAD	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs1983170	0.736	rs13447495	chr1:91974965	A/G	cg25838465	chr1:92012736	NA	0.52	6.71	0.31	6.22e-11	Eosinophil percentage of white cells;
LUAD	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg00074818	chr8:8560427	CLDN23	0.66	10.12	0.44	1.07e-21	Obesity-related traits;
LUAD	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg02569458	chr12:86230093	RASSF9	0.38	6.93	0.32	1.58e-11	Major depressive disorder;
LUAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg07677032	chr17:61819896	STRADA	0.57	10.23	0.45	4.42e-22	Prudent dietary pattern;
LUAD	cis	rs737008	0.960	rs34764020	chr16:11378359	C/T	cg00044050	chr16:11439710	C16orf75	-0.45	-6.53	-0.3	1.89e-10	Obesity-related traits;
LUAD	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg19901468	chr14:105411992	AHNAK2	-0.54	-10.58	-0.46	2.23e-23	Rheumatoid arthritis;
LUAD	cis	rs7953508	0.506	rs768775	chr12:93968197	T/C	cg18151635	chr12:93972918	NA	-0.78	-11.79	-0.5	6.39e-28	Pubertal anthropometrics;
LUAD	cis	rs870825	0.655	rs35397385	chr4:185639095	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.97	0.56	9.31e-37	Blood protein levels;
LUAD	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg03354898	chr7:1950403	MAD1L1	-0.45	-8.59	-0.39	1.72e-16	Bipolar disorder and schizophrenia;
LUAD	trans	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04565464	chr8:145669602	NFKBIL2	0.46	7.08	0.33	6e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4911259	0.552	rs13042651	chr20:31467423	C/T	cg13636640	chr20:31349939	DNMT3B	-0.57	-9.37	-0.41	4.52e-19	Inflammatory bowel disease;
LUAD	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.74	-13.3	-0.54	5.89e-34	Axial length;
LUAD	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.67	0.39	9.26e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3849570	0.643	rs6548779	chr3:81968512	A/G	cg07356753	chr3:81810745	GBE1	-0.48	-7.93	-0.36	1.99e-14	Waist circumference;Body mass index;
LUAD	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg23231163	chr10:75533350	FUT11	-0.52	-9.68	-0.43	3.82e-20	Inflammatory bowel disease;
LUAD	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg07636037	chr3:49044803	WDR6	0.62	11.68	0.49	1.65e-27	Parkinson's disease;
LUAD	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg25894440	chr7:65020034	NA	0.63	6.89	0.32	2.01e-11	Diabetic kidney disease;
LUAD	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg23281280	chr6:28129359	ZNF389	0.48	6.71	0.31	6.44e-11	Depression;
LUAD	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg05234568	chr11:5960015	NA	-0.51	-9.06	-0.4	4.97e-18	DNA methylation (variation);
LUAD	cis	rs738322	0.600	rs6001035	chr22:38562425	A/G	cg17652424	chr22:38574118	PLA2G6	-0.3	-8.33	-0.38	1.1e-15	Cutaneous nevi;
LUAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg25811766	chr13:21894605	NA	0.65	8.39	0.38	7.4e-16	White matter hyperintensity burden;
LUAD	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg15133208	chr4:90757351	SNCA	-0.45	-7.12	-0.33	4.76e-12	Neuroticism;
LUAD	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg08798685	chr6:27730294	NA	-0.39	-6.37	-0.3	4.79e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg07741184	chr6:167504864	NA	0.36	8.11	0.37	5.42e-15	Primary biliary cholangitis;
LUAD	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.7	0.53	1.56e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62025270	0.547	rs8035496	chr15:86134332	T/C	cg13263323	chr15:86062960	AKAP13	0.48	7.41	0.34	6.92e-13	Idiopathic pulmonary fibrosis;
LUAD	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg27661571	chr11:113659931	NA	-0.65	-7.71	-0.35	9.19e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.27	6.57	0.3	1.46e-10	Cardiac Troponin-T levels;
LUAD	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.96	20.72	0.71	2.41e-66	Chronic sinus infection;
LUAD	cis	rs9796	0.689	rs8032195	chr15:41448790	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.44	-8.12	-0.37	5.01e-15	Menopause (age at onset);
LUAD	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg09163369	chr1:210001066	C1orf107	0.5	7.0	0.32	1e-11	Orofacial clefts;
LUAD	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg00802000	chr16:706648	WDR90	-0.39	-7.13	-0.33	4.5e-12	Height;
LUAD	cis	rs10911363	0.570	rs2702204	chr1:183457396	A/G	cg09173681	chr1:183549694	NCF2	0.56	10.22	0.44	4.7e-22	Systemic lupus erythematosus;
LUAD	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg16989719	chr2:238392110	NA	-0.35	-7.23	-0.33	2.2e-12	Prostate cancer;
LUAD	cis	rs2253017	0.723	rs2818989	chr13:21386851	A/C	cg27499820	chr13:21296301	IL17D	0.46	7.76	0.35	6.43e-14	PR segment;
LUAD	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg02421172	chr7:1938701	MAD1L1	0.45	6.54	0.3	1.79e-10	Bipolar disorder;
LUAD	cis	rs2274273	0.805	rs11628437	chr14:55775468	G/A	cg04306507	chr14:55594613	LGALS3	0.42	8.89	0.4	1.8e-17	Protein biomarker;
LUAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg13732083	chr21:47605072	C21orf56	0.42	6.99	0.32	1.11e-11	Testicular germ cell tumor;
LUAD	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg02423579	chr7:2872169	GNA12	0.79	13.77	0.56	6.43e-36	Height;
LUAD	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg21605333	chr4:119757512	SEC24D	0.93	8.74	0.39	5.54e-17	Cannabis dependence symptom count;
LUAD	cis	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg02951883	chr7:2050386	MAD1L1	0.53	7.66	0.35	1.32e-13	Neuroticism;
LUAD	cis	rs4253772	0.530	rs8140573	chr22:46800363	G/C	cg00784671	chr22:46762841	CELSR1	-0.61	-7.28	-0.33	1.63e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg03433033	chr1:76189801	ACADM	-0.49	-7.31	-0.33	1.37e-12	Daytime sleep phenotypes;
LUAD	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg00898013	chr13:113819073	PROZ	-0.83	-15.02	-0.59	3.5e-41	Platelet distribution width;
LUAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg22907277	chr7:1156413	C7orf50	0.68	8.0	0.36	1.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs778371	0.676	rs2293780	chr2:233635213	T/C	cg08000102	chr2:233561755	GIGYF2	0.41	6.68	0.31	7.42e-11	Schizophrenia;
LUAD	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.29	-0.37	1.49e-15	Menopause (age at onset);
LUAD	trans	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.4	0.45	1.04e-22	Mean corpuscular volume;
LUAD	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.51	-0.3	2.08e-10	Breast cancer;
LUAD	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg00316803	chr15:76480434	C15orf27	0.44	6.9	0.32	1.88e-11	Blood metabolite levels;
LUAD	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg12501888	chr15:85177176	SCAND2	0.49	7.38	0.34	8.61e-13	P wave terminal force;
LUAD	cis	rs2204008	0.567	rs2703685	chr12:38081423	G/C	cg26384229	chr12:38710491	ALG10B	0.41	6.83	0.32	3.01e-11	Bladder cancer;
LUAD	cis	rs6761276	0.899	rs11677088	chr2:113835603	A/G	cg02343335	chr2:113785852	IL1F8	-0.35	-7.01	-0.32	9.26e-12	Protein quantitative trait loci;
LUAD	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg16325326	chr1:53192061	ZYG11B	0.62	10.76	0.46	4.77e-24	Monocyte count;
LUAD	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg17173187	chr15:85201210	NMB	0.41	6.65	0.31	9.08e-11	Schizophrenia;
LUAD	cis	rs1018836	0.608	rs2205150	chr8:91483232	G/A	cg16814680	chr8:91681699	NA	-0.52	-8.59	-0.39	1.7e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1950626	0.796	rs7152870	chr14:101389987	T/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.37	-6.97	-0.32	1.23e-11	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	trans	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg27600084	chr12:12264075	NA	0.41	7.58	0.35	2.24e-13	Breast size;
LUAD	trans	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg14917512	chr19:3094685	GNA11	-0.56	-6.55	-0.3	1.72e-10	Diabetic kidney disease;
LUAD	trans	rs7395662	0.736	rs4882036	chr11:48749384	A/G	cg00717180	chr2:96193071	NA	-0.44	-8.42	-0.38	6e-16	HDL cholesterol;
LUAD	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg16950941	chr11:66035639	RAB1B	0.46	7.7	0.35	9.85e-14	Gout;
LUAD	trans	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg08071915	chr8:12219732	FAM66A	-0.43	-7.15	-0.33	3.89e-12	Parkinson's disease;
LUAD	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg07930552	chr6:133119739	C6orf192	0.6	7.41	0.34	7.03e-13	Type 2 diabetes nephropathy;
LUAD	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg08999081	chr20:33150536	PIGU	0.51	10.51	0.45	4.18e-23	Coronary artery disease;
LUAD	cis	rs497273	0.534	rs608394	chr12:121194053	C/T	cg02419362	chr12:121203948	SPPL3	0.37	7.47	0.34	4.66e-13	Systemic lupus erythematosus;
LUAD	cis	rs55665837	1.000	rs11023216	chr11:14437153	G/A	cg19336497	chr11:14380999	RRAS2	-0.5	-10.09	-0.44	1.35e-21	Vitamin D levels;
LUAD	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg27572855	chr1:25598939	RHD	-0.54	-11.73	-0.5	1.01e-27	Erythrocyte sedimentation rate;
LUAD	cis	rs672059	0.513	rs572977	chr1:183164991	C/G	cg05929019	chr1:183155154	LAMC2	-0.36	-7.9	-0.36	2.39e-14	Hypertriglyceridemia;
LUAD	cis	rs8062405	0.573	rs7140	chr16:28995757	C/A	cg05966235	chr16:28915196	ATP2A1	-0.47	-7.06	-0.32	7.05e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7937682	0.562	rs527847	chr11:111369132	A/C	cg09085632	chr11:111637200	PPP2R1B	0.45	7.34	0.34	1.12e-12	Primary sclerosing cholangitis;
LUAD	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-8.47	-0.38	4.18e-16	Menarche (age at onset);
LUAD	trans	rs4650994	0.550	rs10913573	chr1:178530455	G/A	cg05059571	chr16:84539110	KIAA1609	0.42	6.54	0.3	1.82e-10	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs6546550	0.935	rs6747542	chr2:70106832	T/C	cg02498382	chr2:70120550	SNRNP27	-0.55	-10.9	-0.47	1.57e-24	Prevalent atrial fibrillation;
LUAD	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg18932078	chr1:2524107	MMEL1	-0.37	-6.91	-0.32	1.82e-11	Multiple sclerosis;
LUAD	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg05590025	chr7:65112418	INTS4L2	0.75	7.93	0.36	1.95e-14	Diabetic kidney disease;
LUAD	cis	rs2242073	0.935	rs72968201	chr2:208997619	T/C	cg06181187	chr2:209010896	CRYGB	0.36	6.65	0.31	9.34e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg18827107	chr12:86230957	RASSF9	-0.53	-9.34	-0.41	5.41e-19	Major depressive disorder;
LUAD	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg02018176	chr4:1364513	KIAA1530	0.38	7.13	0.33	4.25e-12	Obesity-related traits;
LUAD	cis	rs4594175	0.847	rs17252303	chr14:51632246	C/T	cg23942311	chr14:51606299	NA	0.65	11.29	0.48	5.22e-26	Cancer;
LUAD	trans	rs4650994	1.000	rs4650994	chr1:178515312	A/G	cg05059571	chr16:84539110	KIAA1609	0.62	10.77	0.46	4.6e-24	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.23	-0.37	2.27e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg03467027	chr4:99064603	C4orf37	0.43	6.88	0.32	2.21e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg25482853	chr8:67687455	SGK3	1.18	18.2	0.66	4.58e-55	Lung disease severity in cystic fibrosis;
LUAD	cis	rs367943	0.712	rs1366393	chr5:112729472	A/G	cg12552261	chr5:112820674	MCC	0.47	9.25	0.41	1.09e-18	Type 2 diabetes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05728519	chr12:48551378	ASB8	-0.43	-7.05	-0.32	7.38e-12	Cancer;
LUAD	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.95	0.32	1.37e-11	Parkinson's disease;
LUAD	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg07636037	chr3:49044803	WDR6	0.61	9.93	0.43	5.1e-21	Menarche (age at onset);
LUAD	cis	rs751728	1.000	rs9380378	chr6:33765479	T/C	cg13859433	chr6:33739653	LEMD2	-0.36	-8.34	-0.38	1.06e-15	Crohn's disease;
LUAD	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg25753631	chr6:25732923	NA	-0.42	-7.28	-0.33	1.63e-12	Iron status biomarkers;
LUAD	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg27494647	chr7:150038898	RARRES2	0.51	8.92	0.4	1.4e-17	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.38	-0.41	4.11e-19	Life satisfaction;
LUAD	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06544989	chr22:39130855	UNC84B	0.41	7.64	0.35	1.5e-13	Menopause (age at onset);
LUAD	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg03678062	chr6:149772716	ZC3H12D	-0.31	-6.86	-0.32	2.42e-11	Dupuytren's disease;
LUAD	cis	rs295140	0.605	rs159321	chr2:201184713	C/T	cg23649088	chr2:200775458	C2orf69	-0.44	-7.73	-0.35	8.05e-14	QT interval;
LUAD	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg22467129	chr15:76604101	ETFA	-0.51	-8.84	-0.39	2.55e-17	Blood metabolite levels;
LUAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg05564831	chr3:52568323	NT5DC2	0.36	6.56	0.3	1.55e-10	Electroencephalogram traits;
LUAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg25703541	chr22:24373054	LOC391322	-0.83	-15.29	-0.6	2.51e-42	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26314531	chr2:26401878	FAM59B	-0.64	-8.63	-0.39	1.23e-16	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08219700	chr8:58056026	NA	0.56	7.71	0.35	8.86e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.69	-0.49	1.57e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6908034	0.607	rs73376680	chr6:19808099	G/A	cg02682789	chr6:19804855	NA	0.84	8.71	0.39	6.87e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg03806693	chr22:41940476	POLR3H	-0.74	-9.9	-0.43	6.29e-21	Vitiligo;
LUAD	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg04455712	chr21:45112962	RRP1B	0.49	9.6	0.42	7.21e-20	Mean corpuscular volume;
LUAD	cis	rs3198697	0.663	rs12928099	chr16:15150505	C/A	cg27102117	chr16:15229624	NA	0.45	6.91	0.32	1.8e-11	Triglycerides;
LUAD	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	7.64	0.35	1.45e-13	Menopause (age at onset);
LUAD	cis	rs7771547	0.519	rs6928287	chr6:36375438	G/A	cg07856975	chr6:36356162	ETV7	0.52	7.83	0.36	3.98e-14	Platelet distribution width;
LUAD	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	10.2	0.44	5.52e-22	Lung cancer in ever smokers;
LUAD	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg07538946	chr5:131705188	SLC22A5	0.45	7.33	0.34	1.19e-12	Blood metabolite levels;
LUAD	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg24531977	chr5:56204891	C5orf35	0.6	9.54	0.42	1.15e-19	Type 2 diabetes;
LUAD	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg05896524	chr21:47604654	C21orf56	0.53	8.91	0.4	1.52e-17	Testicular germ cell tumor;
LUAD	cis	rs77861329	1.000	rs352150	chr3:52209995	A/G	cg08692210	chr3:52188851	WDR51A	0.86	8.36	0.38	9.34e-16	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg14196790	chr5:131705035	SLC22A5	-0.46	-8.36	-0.38	9.09e-16	Breast cancer;Mosquito bite size;
LUAD	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg23601416	chr22:19950040	COMT	-0.39	-8.35	-0.38	1.01e-15	Blood metabolite levels;
LUAD	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs4919694	1.000	rs7100592	chr10:104769098	T/G	cg04362960	chr10:104952993	NT5C2	0.72	7.65	0.35	1.41e-13	Arsenic metabolism;
LUAD	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.53	0.3	1.84e-10	Menarche (age at onset);
LUAD	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.51	-8.41	-0.38	6.27e-16	Reticulocyte count;
LUAD	cis	rs2046867	0.818	rs17010184	chr3:72870242	A/T	cg25664220	chr3:72788482	NA	0.64	11.4	0.48	1.98e-26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27286337	chr10:134555280	INPP5A	0.72	9.55	0.42	1.08e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6484504	0.625	rs7940420	chr11:31366700	T/A	cg26647111	chr11:31128758	NA	0.44	7.77	0.35	6.07e-14	Red blood cell count;
LUAD	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg18932078	chr1:2524107	MMEL1	0.35	6.55	0.3	1.7e-10	Ulcerative colitis;
LUAD	cis	rs654950	0.806	rs10749832	chr1:42041806	C/T	cg06885757	chr1:42089581	HIVEP3	0.5	11.48	0.49	9.39e-27	Airway imaging phenotypes;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg21364231	chr7:152161058	LOC100128822	-0.72	-6.72	-0.31	5.71e-11	Type 2 diabetes;
LUAD	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.61	-11.18	-0.48	1.29e-25	Urate levels in overweight individuals;
LUAD	cis	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg02508848	chr16:68573721	ZFP90	-0.42	-6.6	-0.31	1.22e-10	Ulcerative colitis;
LUAD	cis	rs754466	0.561	rs72806025	chr10:79707026	C/T	cg17075019	chr10:79541650	NA	-0.64	-7.84	-0.36	3.6e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7615952	0.611	rs12488771	chr3:125700526	A/G	cg05084668	chr3:125655381	ALG1L	-0.81	-8.9	-0.4	1.71e-17	Blood pressure (smoking interaction);
LUAD	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg23254163	chr1:152506842	NA	0.25	7.07	0.33	6.24e-12	Hair morphology;
LUAD	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05665937	chr4:1216051	CTBP1	-0.45	-7.26	-0.33	1.83e-12	Obesity-related traits;
LUAD	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg06713675	chr4:122721982	EXOSC9	-0.84	-18.2	-0.66	4.47e-55	Type 2 diabetes;
LUAD	cis	rs13315871	0.858	rs4075404	chr3:58411419	C/T	cg20936604	chr3:58311152	NA	-0.69	-7.25	-0.33	1.94e-12	Cholesterol, total;
LUAD	trans	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.39	-0.3	4.45e-10	Aortic root size;
LUAD	cis	rs7274811	0.652	rs158672	chr20:32023286	T/C	cg14921437	chr20:32255988	NECAB3;C20orf134	0.47	7.0	0.32	1.01e-11	Height;
LUAD	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg23815491	chr16:72088622	HP	0.52	9.55	0.42	1.04e-19	Fibrinogen levels;
LUAD	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg18833306	chr6:118973337	C6orf204	-0.49	-7.22	-0.33	2.39e-12	Diastolic blood pressure;
LUAD	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg11941060	chr3:133502564	NA	-0.46	-8.2	-0.37	2.94e-15	Ankle injury;
LUAD	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg21427119	chr20:30132790	HM13	-0.57	-9.05	-0.4	5.39e-18	Mean corpuscular hemoglobin;
LUAD	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.36	-6.91	-0.32	1.75e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.46	-0.34	4.96e-13	Electroencephalogram traits;
LUAD	cis	rs4919694	1.000	rs112809537	chr10:104670346	C/T	cg04362960	chr10:104952993	NT5C2	0.74	7.94	0.36	1.84e-14	Arsenic metabolism;
LUAD	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg25985355	chr7:65971099	NA	-0.55	-6.75	-0.31	4.77e-11	Diabetic kidney disease;
LUAD	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg08439880	chr3:133502540	NA	-0.36	-6.89	-0.32	2.05e-11	Iron status biomarkers;
LUAD	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg00495681	chr13:53174319	NA	0.55	10.25	0.45	3.62e-22	Lewy body disease;
LUAD	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg04511125	chr2:88470314	THNSL2	0.98	11.28	0.48	5.76e-26	Plasma clusterin levels;
LUAD	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg03467027	chr4:99064603	C4orf37	0.39	6.41	0.3	3.86e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg02569458	chr12:86230093	RASSF9	0.37	7.11	0.33	5.11e-12	Major depressive disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20409358	chr4:174255887	HMGB2	-0.41	-6.35	-0.3	5.46e-10	Height;
LUAD	cis	rs7799006	0.582	rs7781284	chr7:2339405	G/T	cg08027265	chr7:2291960	NA	-0.47	-8.66	-0.39	1.01e-16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-10.75	-0.46	5.33e-24	Lymphocyte counts;
LUAD	cis	rs11948739	0.501	rs79115810	chr5:130374516	A/G	cg08523029	chr5:130500466	HINT1	-0.59	-7.65	-0.35	1.4e-13	Pediatric bone mineral content (hip);
LUAD	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg22563815	chr15:78856949	CHRNA5	0.32	6.44	0.3	3.17e-10	Sudden cardiac arrest;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07106325	chr12:120740337	SIRT4	-0.67	-6.39	-0.3	4.3e-10	Type 2 diabetes;
LUAD	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg18446336	chr7:2847575	GNA12	-0.41	-7.59	-0.35	2.13e-13	Height;
LUAD	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg17063962	chr7:91808500	NA	0.67	11.94	0.5	1.6e-28	Breast cancer;
LUAD	cis	rs11741688	0.557	rs2004503	chr5:178337122	C/T	cg09339527	chr5:178322752	ZFP2	-0.33	-6.91	-0.32	1.81e-11	Sleep duration;
LUAD	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.54	-0.42	1.12e-19	Schizophrenia;
LUAD	cis	rs17067123	0.614	rs1036767	chr4:180068417	G/A	cg26610307	chr4:180072759	NA	-0.52	-6.79	-0.31	3.87e-11	Response to hepatitis C treatment;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg06329197	chr16:27214832	JMJD5	-0.39	-6.89	-0.32	2.06e-11	Subcortical brain region volumes;
LUAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.82	9.38	0.42	3.96e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg07460842	chr6:66804631	NA	0.62	9.74	0.43	2.32e-20	Type 2 diabetes;
LUAD	cis	rs9487051	0.834	rs351728	chr6:109549099	T/C	cg21918786	chr6:109611834	NA	-0.4	-6.99	-0.32	1.05e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.48	7.41	0.34	6.94e-13	Schizophrenia;
LUAD	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.61	0.31	1.15e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs4604732	0.631	rs74154672	chr1:247625625	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg03433033	chr1:76189801	ACADM	-0.82	-14.42	-0.57	1.24e-38	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg18621852	chr3:10150065	C3orf24	0.48	8.32	0.38	1.2e-15	Alzheimer's disease;
LUAD	cis	rs4919694	1.000	rs12242000	chr10:104702413	A/C	cg04362960	chr10:104952993	NT5C2	0.74	7.93	0.36	1.98e-14	Arsenic metabolism;
LUAD	cis	rs10129255	0.500	rs10131875	chr14:107201036	T/C	cg23076370	chr14:107095027	NA	-0.42	-8.5	-0.38	3.41e-16	Kawasaki disease;
LUAD	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg11416102	chr8:651193	ERICH1	0.93	9.2	0.41	1.71e-18	IgG glycosylation;
LUAD	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg22532475	chr10:104410764	TRIM8	-0.44	-8.68	-0.39	8.58e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2797160	0.967	rs1777224	chr6:126019527	T/C	cg05901451	chr6:126070800	HEY2	0.45	6.67	0.31	8.11e-11	Endometrial cancer;
LUAD	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg08807101	chr21:30365312	RNF160	0.44	7.58	0.35	2.17e-13	Dental caries;
LUAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00166722	chr3:10149974	C3orf24	0.63	10.46	0.45	6.19e-23	Alzheimer's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25377475	chr1:236030556	LYST	-0.52	-6.38	-0.3	4.69e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg09222892	chr1:25734099	RHCE	-0.47	-8.7	-0.39	7.18e-17	Erythrocyte sedimentation rate;
LUAD	cis	rs887829	0.570	rs11680450	chr2:234597483	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.6	-0.42	7.07e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs9400271	0.632	rs949882	chr6:109586062	A/G	cg01475377	chr6:109611718	NA	0.38	6.7	0.31	6.68e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg03929089	chr4:120376271	NA	-0.83	-15.07	-0.59	2.13e-41	Coronary artery disease;
LUAD	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg01097406	chr16:89675127	NA	0.43	9.24	0.41	1.22e-18	Vitiligo;
LUAD	trans	rs9217	1.000	rs55749333	chr17:7371932	C/T	cg08566640	chr11:64091735	NA	0.42	6.84	0.32	2.86e-11	Height;
LUAD	cis	rs7809950	0.678	rs2395868	chr7:106897500	C/T	cg23024343	chr7:107201750	COG5	0.81	13.98	0.56	8.59e-37	Coronary artery disease;
LUAD	cis	rs7809615	0.901	rs11973801	chr7:99102911	A/G	cg12290671	chr7:99195819	NA	-0.71	-8.1	-0.37	5.85e-15	Blood metabolite ratios;
LUAD	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.56	9.31	0.41	7.23e-19	Menarche (age at onset);
LUAD	cis	rs243505	0.762	rs933436	chr7:148487329	A/C	cg09806900	chr7:148480153	CUL1	-0.45	-8.04	-0.36	9.35e-15	Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs4650994	0.593	rs6700266	chr1:178508930	A/G	cg05059571	chr16:84539110	KIAA1609	-0.47	-7.09	-0.33	5.62e-12	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs3818285	0.556	rs2084607	chr10:111681411	C/T	cg00817464	chr10:111662876	XPNPEP1	0.72	11.39	0.48	2.2e-26	Superior crus of antihelix expression;
LUAD	cis	rs3087591	0.960	rs9303642	chr17:29578360	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.62	-0.31	1.1e-10	Hip circumference;
LUAD	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.5	-8.34	-0.38	1.05e-15	Tonsillectomy;
LUAD	cis	rs733175	0.830	rs6813650	chr4:10061060	T/G	cg00071950	chr4:10020882	SLC2A9	0.47	7.19	0.33	3.05e-12	Psychosis and Alzheimer's disease;
LUAD	cis	rs1018836	0.851	rs2023624	chr8:91618874	T/C	cg16814680	chr8:91681699	NA	-0.69	-11.84	-0.5	3.9e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg18621852	chr3:10150065	C3orf24	0.45	7.82	0.36	4.2e-14	Alzheimer's disease;
LUAD	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05665937	chr4:1216051	CTBP1	0.47	7.0	0.32	1e-11	Longevity;
LUAD	cis	rs6500395	1.000	rs8044519	chr16:48669081	G/T	cg04672837	chr16:48644449	N4BP1	0.38	6.69	0.31	7.06e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs13082711	0.911	rs4973770	chr3:27425815	C/T	cg02860705	chr3:27208620	NA	0.55	8.55	0.38	2.34e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg11941060	chr3:133502564	NA	-0.67	-11.67	-0.49	1.74e-27	Iron status biomarkers;
LUAD	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-20.31	-0.7	1.58e-64	Height;
LUAD	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24531977	chr5:56204891	C5orf35	-0.98	-14.96	-0.59	6.3e-41	Initial pursuit acceleration;
LUAD	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg08885076	chr2:99613938	TSGA10	0.37	6.65	0.31	9.32e-11	Chronic sinus infection;
LUAD	cis	rs2573652	1.000	rs2581345	chr15:100514291	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.5	-8.88	-0.4	1.96e-17	Height;
LUAD	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg11814155	chr7:99998594	ZCWPW1	0.43	7.48	0.34	4.27e-13	Platelet count;
LUAD	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg16205897	chr5:131564050	P4HA2	-0.41	-9.19	-0.41	1.74e-18	Blood metabolite levels;
LUAD	cis	rs6577655	0.517	rs6999469	chr8:135577530	G/A	cg17885191	chr8:135476712	NA	0.64	8.35	0.38	9.85e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.61	-0.31	1.16e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs870825	0.860	rs72703521	chr4:185603080	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	10.21	0.44	4.85e-22	Blood protein levels;
LUAD	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg06532163	chr17:45867833	NA	0.47	8.36	0.38	9.04e-16	IgG glycosylation;
LUAD	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg03929089	chr4:120376271	NA	0.82	15.0	0.59	4.35e-41	Coronary artery disease;
LUAD	cis	rs6840360	0.533	rs1397683	chr4:152715916	T/C	cg22705602	chr4:152727874	NA	0.46	8.91	0.4	1.55e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.63	-10.42	-0.45	9.13e-23	Longevity;Endometriosis;
LUAD	cis	rs12545109	0.959	rs12547974	chr8:57314785	G/T	cg09654669	chr8:57350985	NA	-0.66	-9.5	-0.42	1.61e-19	Obesity-related traits;
LUAD	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg14983838	chr19:29218262	NA	0.57	7.14	0.33	4.11e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg26408565	chr15:76604113	ETFA	-0.43	-6.73	-0.31	5.52e-11	Blood metabolite levels;
LUAD	cis	rs7771547	0.519	rs9654588	chr6:36363923	A/C	cg04289385	chr6:36355825	ETV7	0.55	8.0	0.36	1.19e-14	Platelet distribution width;
LUAD	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg16797656	chr11:68205561	LRP5	0.46	9.74	0.43	2.32e-20	Total body bone mineral density;
LUAD	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg04248312	chr19:17393744	ANKLE1	-1.0	-18.47	-0.67	2.7e-56	Systemic lupus erythematosus;
LUAD	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg25985355	chr7:65971099	NA	-0.55	-6.76	-0.31	4.73e-11	Diabetic kidney disease;
LUAD	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg04000281	chr11:63949212	NA	-0.29	-6.62	-0.31	1.07e-10	Platelet count;
LUAD	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2797160	1.000	rs2797161	chr6:126010789	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.69	0.31	7.03e-11	Endometrial cancer;
LUAD	cis	rs1018836	0.923	rs4735260	chr8:91617157	C/G	cg16814680	chr8:91681699	NA	0.69	11.97	0.5	1.19e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06028808	chr11:68637592	NA	0.47	7.7	0.35	9.5e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg19622623	chr12:86230825	RASSF9	-0.55	-9.95	-0.44	4.23e-21	Major depressive disorder;
LUAD	trans	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg05590025	chr7:65112418	INTS4L2	-0.76	-6.82	-0.31	3.09e-11	Gout;
LUAD	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg25036284	chr2:26402008	FAM59B	0.83	11.53	0.49	6.03e-27	Gut microbiome composition (summer);
LUAD	cis	rs6076065	0.723	rs2424532	chr20:23373877	G/A	cg11657817	chr20:23433608	CST11	0.48	8.95	0.4	1.12e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs208520	0.661	rs207090	chr6:66783963	T/A	cg07460842	chr6:66804631	NA	-1.06	-16.63	-0.63	3.97e-48	Exhaled nitric oxide output;
LUAD	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg17063962	chr7:91808500	NA	-0.66	-11.47	-0.49	1.07e-26	Breast cancer;
LUAD	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg07636037	chr3:49044803	WDR6	0.5	8.46	0.38	4.3e-16	Menarche (age at onset);
LUAD	cis	rs490234	0.841	rs513568	chr9:128411854	G/A	cg14078157	chr9:128172775	NA	-0.4	-7.34	-0.34	1.08e-12	Mean arterial pressure;
LUAD	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg07266350	chr3:49460521	AMT;NICN1	-0.38	-6.75	-0.31	5.01e-11	Menarche (age at onset);
LUAD	cis	rs4343996	0.870	rs4443553	chr7:3378635	T/C	cg21248987	chr7:3385318	SDK1	-0.34	-6.51	-0.3	2.16e-10	Motion sickness;
LUAD	cis	rs4006360	0.525	rs3907875	chr17:39268353	A/G	cg20663846	chr17:39254439	KRTAP4-8	-0.39	-8.53	-0.38	2.57e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	10.82	0.47	2.92e-24	Hip circumference adjusted for BMI;
LUAD	cis	rs6138458	0.962	rs6036976	chr20:24901567	T/G	cg06937882	chr20:24974362	C20orf3	0.33	6.47	0.3	2.72e-10	Blood protein levels;
LUAD	cis	rs11048434	0.736	rs11048190	chr12:9104939	C/T	cg23795048	chr12:9217529	LOC144571	0.41	7.53	0.34	3e-13	Sjögren's syndrome;
LUAD	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg09021430	chr5:549028	NA	-0.49	-12.39	-0.52	2.64e-30	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs12135894	0.648	rs4648423	chr1:3765678	C/T	cg22529645	chr1:3704559	LRRC47	-0.51	-10.35	-0.45	1.6400000000000001e-22	Mean corpuscular volume;
LUAD	cis	rs1941184	0.500	rs56069436	chr18:29031612	C/T	cg03238162	chr18:29027701	DSG3	0.36	6.4	0.3	4.05e-10	Parkinson's disease (age of onset);
LUAD	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg15691649	chr6:25882328	NA	-0.44	-6.38	-0.3	4.65e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs17401966	1.000	rs1049887	chr1:10460485	T/C	cg15208524	chr1:10270712	KIF1B	0.53	7.55	0.34	2.68e-13	Hepatocellular carcinoma;
LUAD	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.82	0.31	3.12e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg25985355	chr7:65971099	NA	-0.55	-6.74	-0.31	5.08e-11	Diabetic kidney disease;
LUAD	cis	rs9811920	0.809	rs4928235	chr3:99706870	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.6	-11.23	-0.48	8.89e-26	Axial length;
LUAD	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.46	7.62	0.35	1.63e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs41311933	0.656	rs113277364	chr9:123836084	G/A	cg13567360	chr9:123745713	C5	-0.72	-8.46	-0.38	4.28e-16	Coronary artery disease;
LUAD	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.13e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg25894440	chr7:65020034	NA	0.64	6.92	0.32	1.65e-11	Diabetic kidney disease;
LUAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.64	8.8	0.39	3.44e-17	Renal function-related traits (BUN);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02099313	chr1:231114956	TTC13;ARV1	-0.46	-7.2	-0.33	2.76e-12	Height;
LUAD	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.91e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs877282	0.945	rs10904554	chr10:786768	T/C	cg17470449	chr10:769945	NA	0.61	8.57	0.38	2.01e-16	Uric acid levels;
LUAD	trans	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg01620082	chr3:125678407	NA	0.67	7.14	0.33	4.22e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.45	0.52	1.55e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4604732	0.631	rs11490198	chr1:247625703	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg09835421	chr16:68378352	PRMT7	-0.93	-10.94	-0.47	1.11e-24	Magnesium levels;
LUAD	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg13319975	chr6:146136371	FBXO30	-0.65	-11.22	-0.48	9.53e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11971779	0.688	rs8137	chr7:139104461	A/C	cg23387468	chr7:139079360	LUC7L2	-0.28	-6.42	-0.3	3.7e-10	Diisocyanate-induced asthma;
LUAD	cis	rs10499694	0.933	rs7778349	chr7:50593157	C/T	cg18232548	chr7:50535776	DDC	-0.44	-7.5	-0.34	3.75e-13	Body mass index;
LUAD	cis	rs11811982	0.793	rs76046364	chr1:227439222	A/G	cg24860534	chr1:227506868	CDC42BPA	0.63	6.86	0.32	2.45e-11	Optic disc area;
LUAD	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs6076065	0.723	rs2281429	chr20:23399544	A/T	cg11657817	chr20:23433608	CST11	0.46	8.51	0.38	3.15e-16	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs36096196	0.891	rs74046969	chr1:2251348	G/A	cg17974515	chr1:2252516	NA	0.42	6.97	0.32	1.26e-11	Coronary artery disease;
LUAD	cis	rs669446	0.533	rs3791042	chr1:44219275	T/C	cg12908607	chr1:44402522	ARTN	-0.37	-7.09	-0.33	5.53e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	trans	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg24644049	chr4:85504048	CDS1	0.89	7.31	0.33	1.37e-12	Skin colour saturation;
LUAD	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.55	-0.3	1.63e-10	Total body bone mineral density;
LUAD	cis	rs117623576	0.941	rs211423	chr10:32398777	A/G	cg03047570	chr10:32398778	NA	0.91	11.54	0.49	5.9e-27	Anti-saccade response;
LUAD	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg14345882	chr6:26364793	BTN3A2	0.7	7.15	0.33	3.76e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs13082711	0.522	rs479302	chr3:27363033	A/G	cg02860705	chr3:27208620	NA	0.52	8.53	0.38	2.72e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6665290	0.904	rs1045286	chr1:227179037	A/C	cg10327440	chr1:227177885	CDC42BPA	1.19	38.15	0.88	5.16e-139	Myeloid white cell count;
LUAD	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg06532163	chr17:45867833	NA	0.46	8.1	0.37	6.08e-15	IgG glycosylation;
LUAD	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg05182265	chr7:156933206	UBE3C	0.81	17.35	0.64	2.66e-51	Body mass index;
LUAD	cis	rs225245	0.817	rs225297	chr17:33924587	G/A	cg05299278	chr17:33885742	SLFN14	0.52	11.95	0.5	1.43e-28	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7671266	0.622	rs11943276	chr4:10403545	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-7.11	-0.33	4.83e-12	Cardiovascular disease risk factors;
LUAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-9.24	-0.41	1.2e-18	Alzheimer's disease;
LUAD	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg05110241	chr16:68378359	PRMT7	-0.75	-7.91	-0.36	2.25e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9300255	0.602	rs2851435	chr12:123712416	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.14	-0.33	3.98e-12	Neutrophil percentage of white cells;
LUAD	cis	rs497273	0.512	rs504403	chr12:121133037	C/G	cg13914990	chr12:121174878	ACADS	-0.35	-6.69	-0.31	7.04e-11	Systemic lupus erythematosus;
LUAD	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27297192	chr10:134578999	INPP5A	0.36	6.47	0.3	2.68e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg00814883	chr7:100076585	TSC22D4	-0.87	-13.14	-0.54	2.52e-33	Platelet count;
LUAD	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg02493740	chr2:85810744	VAMP5	-0.62	-11.33	-0.48	3.74e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg23649088	chr2:200775458	C2orf69	-0.6	-7.17	-0.33	3.44e-12	Schizophrenia;
LUAD	cis	rs8042849	1	rs8042849	chr15:78817929	C/T	cg18825076	chr15:78729989	IREB2	0.55	9.17	0.41	2.09e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Parental lifespan;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg05368731	chr17:41323189	NBR1	0.97	20.42	0.7	5.25e-65	Menopause (age at onset);
LUAD	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg19792802	chr11:65647270	CTSW	-0.41	-6.42	-0.3	3.72e-10	Crohn's disease;
LUAD	cis	rs2580764	0.598	rs7340476	chr2:55227346	G/C	cg09592903	chr2:55203963	RTN4	-0.46	-10.62	-0.46	1.58e-23	Mean platelet volume;
LUAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg15117754	chr3:10150083	C3orf24	0.41	6.64	0.31	9.59e-11	Alzheimer's disease;
LUAD	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg05340658	chr4:99064831	C4orf37	-0.44	-7.29	-0.33	1.49e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs9951602	0.512	rs1599633	chr18:76643526	T/C	cg02800362	chr5:177631904	HNRNPAB	0.92	14.18	0.57	1.25e-37	Obesity-related traits;
LUAD	cis	rs727505	0.954	rs28638102	chr7:124499480	A/C	cg23710748	chr7:124431027	NA	-0.47	-9.56	-0.42	9.77e-20	Lewy body disease;
LUAD	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.37	7.39	0.34	7.72e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg08219700	chr8:58056026	NA	0.69	8.98	0.4	9.17e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg04287289	chr16:89883240	FANCA	0.73	13.66	0.55	1.83e-35	Vitiligo;
LUAD	cis	rs6076065	0.723	rs743024	chr20:23342476	C/T	cg11657817	chr20:23433608	CST11	-0.47	-9.0	-0.4	7.89e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2067615	0.542	rs4346064	chr12:107081599	C/A	cg15890332	chr12:107067104	RFX4	0.4	8.46	0.38	4.37e-16	Heart rate;
LUAD	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.54	7.48	0.34	4.31e-13	Platelet count;
LUAD	cis	rs7107174	1.000	rs11237468	chr11:78072833	A/G	cg19901956	chr11:77921274	USP35	-0.48	-6.85	-0.32	2.62e-11	Testicular germ cell tumor;
LUAD	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	7.49	0.34	4.17e-13	Parkinson's disease;
LUAD	cis	rs954108	0.809	rs1792022	chr13:29367967	A/G	cg11788234	chr13:29393811	NA	-0.33	-6.78	-0.31	4.07e-11	Obesity-related traits;
LUAD	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg03733263	chr8:22462867	KIAA1967	0.73	11.92	0.5	1.86e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	trans	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	cis	rs806795	0.580	rs811041	chr6:26226032	C/G	cg13736514	chr6:26305472	NA	-0.51	-8.17	-0.37	3.67e-15	Mosquito bite size;
LUAD	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08109568	chr15:31115862	NA	-0.59	-10.17	-0.44	6.9e-22	Huntington's disease progression;
LUAD	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg06713675	chr4:122721982	EXOSC9	-0.6	-11.72	-0.5	1.18e-27	Type 2 diabetes;
LUAD	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg00750074	chr16:89608354	SPG7	-0.53	-8.96	-0.4	1.07e-17	Multiple myeloma (IgH translocation);
LUAD	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg23533926	chr12:111358616	MYL2	-0.42	-7.24	-0.33	2.2e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg06112835	chr11:68658793	MRPL21	0.5	8.89	0.4	1.78e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg05340658	chr4:99064831	C4orf37	0.56	9.51	0.42	1.45e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg06627628	chr2:24431161	ITSN2	0.53	8.94	0.4	1.17e-17	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg11584989	chr19:19387371	SF4	0.36	6.46	0.3	2.93e-10	Tonsillectomy;
LUAD	cis	rs2485376	1.000	rs812799	chr10:104036355	C/T	cg20641465	chr10:103991465	PITX3	-0.58	-10.63	-0.46	1.56e-23	QT interval;
LUAD	cis	rs1957429	0.808	rs11158564	chr14:65335082	G/A	cg23373153	chr14:65346875	NA	0.61	6.73	0.31	5.42e-11	Pediatric areal bone mineral density (radius);
LUAD	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg09455208	chr3:40491958	NA	0.63	13.85	0.56	3.24e-36	Renal cell carcinoma;
LUAD	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg04772025	chr11:68637568	NA	0.58	9.02	0.4	6.7e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4664304	0.903	rs72957576	chr2:160754132	A/C	cg23995753	chr2:160760732	LY75	-0.47	-8.38	-0.38	7.91e-16	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs11971779	0.616	rs7784192	chr7:139039649	T/C	cg23387468	chr7:139079360	LUC7L2	0.28	6.49	0.3	2.47e-10	Diisocyanate-induced asthma;
LUAD	cis	rs4280164	0.708	rs78269053	chr14:24794314	A/G	cg22990158	chr14:24802150	ADCY4	0.54	7.65	0.35	1.33e-13	Parent of origin effect on language impairment (paternal);
LUAD	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.73	-14.17	-0.57	1.37e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs35883536	1.000	rs2050472	chr1:101125560	T/C	cg06223162	chr1:101003688	GPR88	0.37	6.94	0.32	1.51e-11	Monocyte count;
LUAD	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg12119029	chr16:89752879	CDK10	-0.33	-7.39	-0.34	8e-13	Hemoglobin concentration;
LUAD	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg10518543	chr12:38710700	ALG10B	0.45	7.41	0.34	6.76e-13	Morning vs. evening chronotype;
LUAD	trans	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.44	7.0	0.32	9.85e-12	Brugada syndrome;
LUAD	cis	rs9473147	0.543	rs9367279	chr6:47448336	A/G	cg02130027	chr6:47444894	CD2AP	0.36	6.76	0.31	4.52e-11	Platelet distribution width;Mean platelet volume;
LUAD	trans	rs11671005	0.568	rs73068325	chr19:59079096	C/T	cg22037779	chr5:139682734	PFDN1	-0.67	-8.71	-0.39	7.05e-17	Mean platelet volume;
LUAD	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg02782426	chr3:40428986	ENTPD3	-0.33	-7.12	-0.33	4.52e-12	Renal cell carcinoma;
LUAD	cis	rs7107174	0.901	rs2450140	chr11:77924388	T/C	cg02023728	chr11:77925099	USP35	0.49	7.6	0.35	1.88e-13	Testicular germ cell tumor;
LUAD	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg01516881	chr6:292596	DUSP22	-0.56	-9.33	-0.41	6.09e-19	Menopause (age at onset);
LUAD	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg22166914	chr1:53195759	ZYG11B	-0.42	-7.17	-0.33	3.4e-12	Monocyte count;
LUAD	cis	rs494562	0.730	rs9450270	chr6:86114766	A/G	cg27297263	chr6:86160468	NT5E	0.53	6.41	0.3	3.89e-10	Blood metabolite levels;Metabolic traits;
LUAD	trans	rs79911532	0.515	rs10235228	chr7:75833282	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	8.83	0.39	2.82e-17	Mononucleosis;
LUAD	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.3	-0.37	1.38e-15	Height;
LUAD	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-9.44	-0.42	2.5e-19	Bipolar disorder;
LUAD	trans	rs62458065	1.000	rs10231294	chr7:32465357	C/T	cg00845942	chr12:64062724	DPY19L2	-0.46	-6.65	-0.31	9.17e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg14396892	chr9:96623032	NA	-0.4	-7.65	-0.35	1.33e-13	DNA methylation (variation);
LUAD	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg15704280	chr7:45808275	SEPT13	-0.69	-11.05	-0.47	4.22e-25	Height;
LUAD	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.79	0.31	3.9e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11048434	0.761	rs2377675	chr12:9124765	C/T	cg23795048	chr12:9217529	LOC144571	0.45	8.22	0.37	2.48e-15	Sjögren's syndrome;
LUAD	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg09359103	chr1:154839909	KCNN3	-0.92	-20.67	-0.71	4.08e-66	Prostate cancer;
LUAD	cis	rs7487075	0.619	rs10748448	chr12:46803338	C/T	cg23829395	chr12:46796953	NA	0.3	6.71	0.31	6.27e-11	Itch intensity from mosquito bite;
LUAD	cis	rs909002	0.849	rs6663012	chr1:32091779	T/G	cg13919466	chr1:32135498	COL16A1	-0.35	-8.2	-0.37	2.84e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7937682	0.793	rs7130440	chr11:111417779	A/G	cg09085632	chr11:111637200	PPP2R1B	0.44	6.79	0.31	3.86e-11	Primary sclerosing cholangitis;
LUAD	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.7	0.39	7.71e-17	Cannabis dependence symptom count;
LUAD	trans	rs8002861	0.754	rs7330760	chr13:44403088	A/T	cg12856521	chr11:46389249	DGKZ	-0.49	-8.47	-0.38	4.09e-16	Leprosy;
LUAD	cis	rs7731657	0.510	rs2569257	chr5:130245468	A/G	cg08523029	chr5:130500466	HINT1	-0.59	-7.55	-0.34	2.75e-13	Fasting plasma glucose;
LUAD	trans	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.4	-0.38	7.05e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7582720	1.000	rs79539678	chr2:203740938	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.45	0.42	2.39e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg12193833	chr17:30244370	NA	-0.57	-6.87	-0.32	2.32e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs7744392	1.000	rs61333739	chr6:35326284	A/G	cg03355690	chr6:35265616	DEF6	0.79	6.47	0.3	2.66e-10	Cataracts in type 2 diabetes;
LUAD	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg27284194	chr4:1044797	NA	0.7	10.2	0.44	5.31e-22	Recombination rate (females);
LUAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg27454412	chr7:1067447	C7orf50	0.45	7.7	0.35	9.91e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7000551	0.505	rs13258195	chr8:22227271	A/G	cg12081754	chr8:22256438	SLC39A14	-0.8	-12.69	-0.53	1.68e-31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg12179176	chr11:130786555	SNX19	0.56	9.15	0.41	2.53e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs17092148	0.636	rs11697978	chr20:33460366	G/C	cg16810054	chr20:33298113	TP53INP2	0.43	7.57	0.35	2.43e-13	Neuroticism;
LUAD	cis	rs7072216	0.555	rs2296432	chr10:100184063	C/G	cg26618903	chr10:100175079	PYROXD2	-0.38	-7.21	-0.33	2.53e-12	Metabolite levels;
LUAD	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg05342682	chr7:94953680	PON1	-0.51	-7.15	-0.33	3.81e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs13082711	0.554	rs1494422	chr3:27375190	T/C	cg02860705	chr3:27208620	NA	-0.67	-10.62	-0.46	1.6e-23	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg14458575	chr2:238380390	NA	0.65	12.6	0.52	4.05e-31	Prostate cancer;
LUAD	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-6.77	-0.31	4.29e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6960043	0.738	rs12538043	chr7:15058998	C/G	cg19272540	chr7:15055459	NA	0.4	9.07	0.4	4.57e-18	Type 2 diabetes;
LUAD	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11890956	chr21:40555474	PSMG1	0.79	13.96	0.56	1.09e-36	Cognitive function;
LUAD	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18876405	chr7:65276391	NA	0.62	10.39	0.45	1.13e-22	Aortic root size;
LUAD	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg19163074	chr7:65112434	INTS4L2	0.45	6.89	0.32	2.05e-11	Aortic root size;
LUAD	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11890956	chr21:40555474	PSMG1	-0.65	-11.2	-0.48	1.12e-25	Cognitive function;
LUAD	cis	rs11078597	0.731	rs62090051	chr17:1640640	C/G	cg18436246	chr17:1640651	WDR81	0.78	12.07	0.51	4.76e-29	Serum albumin level;
LUAD	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg15181151	chr6:150070149	PCMT1	0.37	7.36	0.34	9.79e-13	Lung cancer;
LUAD	cis	rs10979	1.000	rs1416207	chr6:143889275	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.3	-0.45	2.33e-22	Hypospadias;
LUAD	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.66	0.35	1.27e-13	Depression;
LUAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg08888203	chr3:10149979	C3orf24	0.73	11.17	0.48	1.44e-25	Alzheimer's disease;
LUAD	cis	rs1723838	0.826	rs74635683	chr11:73377955	C/T	cg10064339	chr11:73693792	UCP2	0.84	6.58	0.3	1.37e-10	Obesity-related traits;
LUAD	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg27411982	chr8:10470053	RP1L1	0.4	6.99	0.32	1.11e-11	Retinal vascular caliber;
LUAD	cis	rs6906287	0.647	rs12660455	chr6:118717382	C/T	cg21191810	chr6:118973309	C6orf204	0.5	9.69	0.43	3.56e-20	Electrocardiographic conduction measures;
LUAD	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg02423579	chr7:2872169	GNA12	-0.56	-9.75	-0.43	2.2e-20	Height;
LUAD	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg11062466	chr8:58055876	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg09165964	chr15:75287851	SCAMP5	-0.44	-6.59	-0.3	1.34e-10	Blood trace element (Zn levels);
LUAD	trans	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.09	-0.47	3.02e-25	Depression;
LUAD	cis	rs877282	0.898	rs11253339	chr10:759640	C/T	cg17470449	chr10:769945	NA	0.6	8.58	0.38	1.87e-16	Uric acid levels;
LUAD	cis	rs55665837	0.701	rs10160597	chr11:14603992	G/A	cg19336497	chr11:14380999	RRAS2	-0.4	-7.18	-0.33	3.1e-12	Vitamin D levels;
LUAD	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	9.87	0.43	8.47e-21	Electrocardiographic conduction measures;
LUAD	cis	rs4853036	0.672	rs34764641	chr2:70024823	G/T	cg02498382	chr2:70120550	SNRNP27	-0.44	-6.69	-0.31	7.04e-11	Colorectal or endometrial cancer;
LUAD	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg08508325	chr11:3079039	CARS	0.43	8.85	0.4	2.5e-17	Calcium levels;
LUAD	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.18	-11.62	-0.49	2.86e-27	Mean platelet volume;
LUAD	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg15704280	chr7:45808275	SEPT13	-0.73	-12.13	-0.51	2.76e-29	Coronary artery disease;
LUAD	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg04154034	chr17:28927549	LRRC37B2	0.55	6.45	0.3	3.09e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg07460842	chr6:66804631	NA	0.61	9.77	0.43	1.82e-20	Type 2 diabetes;
LUAD	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg24069376	chr3:38537580	EXOG	-0.44	-10.35	-0.45	1.58e-22	Electrocardiographic conduction measures;
LUAD	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg27572855	chr1:25598939	RHD	0.53	11.35	0.48	3.09e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg08470875	chr2:26401718	FAM59B	-0.72	-10.47	-0.45	6.02e-23	Gut microbiome composition (summer);
LUAD	trans	rs7746199	0.736	rs13202295	chr6:27698837	C/T	cg01620082	chr3:125678407	NA	-1.08	-10.25	-0.45	3.48e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2882667	0.964	rs11958050	chr5:138301828	A/G	cg04439458	chr5:138467593	SIL1	-0.38	-7.1	-0.33	5.41e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs4594175	0.926	rs12432356	chr14:51631223	T/G	cg23942311	chr14:51606299	NA	0.65	11.44	0.49	1.42e-26	Cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg14863489	chr8:121457196	MTBP;MRPL13	-0.66	-6.62	-0.31	1.12e-10	Type 2 diabetes;
LUAD	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg21017887	chr14:105400489	NA	-0.74	-14.21	-0.57	9.41e-38	Rheumatoid arthritis;
LUAD	cis	rs9283706	0.593	rs10077634	chr5:66303346	G/A	cg11590213	chr5:66331682	MAST4	0.42	6.53	0.3	1.87e-10	Coronary artery disease;
LUAD	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg19413350	chr8:57351067	NA	-0.42	-6.7	-0.31	6.48e-11	Obesity-related traits;
LUAD	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg15133208	chr4:90757351	SNCA	-0.46	-7.0	-0.32	1.04e-11	Neuroticism;
LUAD	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg04568274	chr7:158649319	WDR60	0.42	6.79	0.31	3.93e-11	Height;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg03031660	chr17:73257791	MRPS7;GGA3	-0.41	-6.99	-0.32	1.06e-11	Subcortical brain region volumes;
LUAD	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg06740227	chr12:86229804	RASSF9	0.37	6.61	0.31	1.15e-10	Major depressive disorder;
LUAD	cis	rs3540	0.554	rs12900987	chr15:91071776	T/C	cg10434728	chr15:90938212	IQGAP1	-0.36	-6.83	-0.32	2.94e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg19318889	chr4:1322082	MAEA	0.85	13.85	0.56	3.23e-36	Longevity;
LUAD	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg01657329	chr11:68192670	LRP5	-0.55	-9.91	-0.43	6.08e-21	Total body bone mineral density;
LUAD	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg22906224	chr7:99728672	NA	0.57	9.34	0.41	5.6e-19	Coronary artery disease;
LUAD	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg25173405	chr17:45401733	C17orf57	-0.54	-9.23	-0.41	1.29e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs250677	0.522	rs998304	chr5:148382365	C/A	cg18129178	chr5:148520854	ABLIM3	-0.51	-7.6	-0.35	1.89e-13	Breast cancer;
LUAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg19862616	chr7:65841803	NCRNA00174	1.06	27.46	0.8	4.59e-96	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4642101	0.737	rs9877165	chr3:12828497	C/T	cg24848339	chr3:12840334	CAND2	0.4	8.01	0.36	1.12e-14	QRS complex (12-leadsum);
LUAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg02136620	chr5:178986620	RUFY1	0.43	6.64	0.31	9.58e-11	Lung cancer;
LUAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.47	-7.57	-0.35	2.38e-13	Renal function-related traits (BUN);
LUAD	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg25828334	chr19:18545568	ISYNA1	0.38	7.68	0.35	1.13e-13	Breast cancer;
LUAD	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg11062466	chr8:58055876	NA	0.66	8.51	0.38	3.1e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg04511125	chr2:88470314	THNSL2	-0.99	-11.17	-0.48	1.4e-25	Plasma clusterin levels;
LUAD	cis	rs4853036	0.672	rs12995760	chr2:70029812	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.36	-0.3	5.14e-10	Colorectal or endometrial cancer;
LUAD	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg12000995	chr2:27665139	KRTCAP3	0.31	7.92	0.36	2.09e-14	Total body bone mineral density;
LUAD	cis	rs11048434	0.736	rs11048344	chr12:9122609	G/C	cg26114124	chr12:9217669	LOC144571	0.35	6.42	0.3	3.71e-10	Sjögren's syndrome;
LUAD	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg04450456	chr4:17643702	FAM184B	0.37	6.95	0.32	1.39e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7177699	0.557	rs62011002	chr15:79120578	C/T	cg00540400	chr15:79124168	NA	0.44	9.6	0.42	6.99e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg13073564	chr4:8508604	NA	0.48	7.84	0.36	3.64e-14	Response to antineoplastic agents;
LUAD	cis	rs494562	0.892	rs640093	chr6:86115866	C/T	cg21730993	chr6:86159210	NT5E	0.6	6.95	0.32	1.35e-11	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg05966235	chr16:28915196	ATP2A1	0.4	6.51	0.3	2.17e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs490234	0.756	rs6478705	chr9:128216326	G/T	cg14078157	chr9:128172775	NA	-0.45	-8.33	-0.38	1.13e-15	Mean arterial pressure;
LUAD	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg25838465	chr1:92012736	NA	-0.69	-14.86	-0.59	1.77e-40	Breast cancer;
LUAD	cis	rs8044868	0.586	rs7201643	chr16:72100780	C/A	cg23815491	chr16:72088622	HP	0.55	10.27	0.45	3.1e-22	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.64	0.31	9.47e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10203711	0.966	rs9287635	chr2:239582267	C/T	cg14580085	chr2:239553406	NA	0.42	9.01	0.4	7.39e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg03433033	chr1:76189801	ACADM	-0.49	-7.12	-0.33	4.71e-12	Daytime sleep phenotypes;
LUAD	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg14582100	chr15:45693742	SPATA5L1	0.63	12.28	0.51	7.24e-30	Homoarginine levels;
LUAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.4	-6.97	-0.32	1.2e-11	Longevity;Endometriosis;
LUAD	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.49e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg15704280	chr7:45808275	SEPT13	-0.78	-12.17	-0.51	1.96e-29	Coronary artery disease;
LUAD	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg00484396	chr16:3507460	NAT15	0.75	9.98	0.44	3.35e-21	Tuberculosis;
LUAD	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.12	-23.78	-0.76	5.78e-80	Ulcerative colitis;
LUAD	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg09455208	chr3:40491958	NA	-0.58	-12.63	-0.52	3.09e-31	Renal cell carcinoma;
LUAD	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.52	-9.72	-0.43	2.75e-20	Homoarginine levels;
LUAD	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.56	-0.35	2.51e-13	Neutrophil percentage of white cells;
LUAD	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.05	-0.44	1.81e-21	Migraine;Coronary artery disease;
LUAD	cis	rs953387	1.000	rs4954392	chr2:136901607	A/G	cg05194412	chr2:137003533	NA	-0.4	-6.59	-0.3	1.34e-10	Arthritis (juvenile idiopathic);
LUAD	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg03806693	chr22:41940476	POLR3H	0.55	8.11	0.37	5.49e-15	Vitiligo;
LUAD	trans	rs75804782	0.641	rs112066551	chr2:239362486	G/A	cg01134436	chr17:81009848	B3GNTL1	0.81	8.84	0.39	2.65e-17	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg17063962	chr7:91808500	NA	0.67	11.85	0.5	3.51e-28	Breast cancer;
LUAD	trans	rs9951602	0.512	rs3859325	chr18:76652175	A/G	cg02800362	chr5:177631904	HNRNPAB	0.91	14.5	0.58	5.82e-39	Obesity-related traits;
LUAD	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg01299579	chr2:10830716	NOL10	-0.45	-7.97	-0.36	1.44e-14	Prostate cancer;
LUAD	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg16797656	chr11:68205561	LRP5	0.5	9.65	0.42	4.69e-20	Total body bone mineral density;
LUAD	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00802000	chr16:706648	WDR90	-0.4	-7.43	-0.34	6.07e-13	Height;
LUAD	cis	rs62238980	0.521	rs117792024	chr22:32379444	G/A	cg02631450	chr22:32366979	NA	0.79	6.46	0.3	2.9e-10	Childhood ear infection;
LUAD	cis	rs3806843	0.607	rs246060	chr5:140324749	T/C	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8060686	0.546	rs8047978	chr16:68143598	T/G	cg05110241	chr16:68378359	PRMT7	-0.56	-7.2	-0.33	2.72e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2625529	0.586	rs7170456	chr15:72469946	G/C	cg16672083	chr15:72433130	SENP8	0.66	12.21	0.51	1.39e-29	Red blood cell count;
LUAD	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18876405	chr7:65276391	NA	0.57	9.45	0.42	2.36e-19	Aortic root size;
LUAD	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg18806716	chr10:30721971	MAP3K8	-0.65	-12.84	-0.53	4.47e-32	Inflammatory bowel disease;
LUAD	trans	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.84	-0.32	2.83e-11	Diabetic kidney disease;
LUAD	trans	rs208520	0.837	rs208488	chr6:66926902	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-14.1	-0.57	2.83e-37	Exhaled nitric oxide output;
LUAD	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-12.87	-0.53	3.15e-32	Axial length;
LUAD	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg04842962	chr6:43655489	MRPS18A	0.79	15.36	0.6	1.19e-42	IgG glycosylation;
LUAD	cis	rs7759001	0.857	rs6912091	chr6:27354852	C/G	cg18711553	chr6:27366782	ZNF391	0.39	6.43	0.3	3.36e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.87	-0.36	3.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14240646	chr10:27532245	ACBD5	-0.86	-11.62	-0.49	2.7e-27	Breast cancer;
LUAD	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg17306686	chr7:157230923	NA	0.46	9.18	0.41	1.99e-18	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.7	-11.65	-0.49	2.17e-27	Blood protein levels;
LUAD	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg05082376	chr22:42548792	NA	-0.42	-7.24	-0.33	2.2e-12	Schizophrenia;
LUAD	trans	rs8073060	0.544	rs225246	chr17:33944773	T/C	cg19694781	chr19:47549865	TMEM160	-1.25	-19.64	-0.69	1.57e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs73198271	0.920	rs11781542	chr8:8617181	G/T	cg01851573	chr8:8652454	MFHAS1	0.51	8.38	0.38	7.96e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs11671005	0.695	rs11673069	chr19:58934918	C/G	cg13877915	chr19:58951672	ZNF132	0.56	7.35	0.34	1.04e-12	Mean platelet volume;
LUAD	cis	rs6494488	0.500	rs72741381	chr15:64806561	G/A	cg08069370	chr15:64387884	SNX1	-0.75	-6.73	-0.31	5.69e-11	Coronary artery disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg14266050	chr4:2845671	ADD1	-0.66	-6.47	-0.3	2.72e-10	Type 2 diabetes;
LUAD	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	12.36	0.52	3.54e-30	Monocyte percentage of white cells;
LUAD	cis	rs7017914	0.934	rs78923624	chr8:71677839	G/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.67e-10	Bone mineral density;
LUAD	cis	rs7671266	0.668	rs10007416	chr4:10159457	T/C	cg00071950	chr4:10020882	SLC2A9	-0.64	-8.79	-0.39	3.74e-17	Cardiovascular disease risk factors;
LUAD	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg03806693	chr22:41940476	POLR3H	0.72	10.07	0.44	1.64e-21	Vitiligo;
LUAD	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg26343298	chr8:95960752	TP53INP1	0.37	7.77	0.35	6.16e-14	Type 2 diabetes;
LUAD	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg25566285	chr7:158114605	PTPRN2	-0.54	-11.89	-0.5	2.63e-28	Calcium levels;
LUAD	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21659725	chr3:3221576	CRBN	-0.63	-10.96	-0.47	9.15e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs72634258	0.945	rs34124834	chr1:8028930	T/G	cg26816564	chr1:7831052	VAMP3	0.55	7.01	0.32	9.28e-12	Inflammatory bowel disease;
LUAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg08742575	chr21:47604166	C21orf56	-0.57	-9.43	-0.42	2.79e-19	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg27432699	chr2:27873401	GPN1	0.57	10.16	0.44	7.81e-22	Oral cavity cancer;
LUAD	cis	rs4523957	0.786	rs59428454	chr17:2114063	T/A	cg16513277	chr17:2031491	SMG6	-0.81	-15.37	-0.6	1.09e-42	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07157834	chr1:205819609	PM20D1	0.74	14.33	0.57	3.01e-38	Menarche (age at onset);
LUAD	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg17845761	chr1:175162550	KIAA0040	0.36	9.44	0.42	2.46e-19	Alcohol dependence;
LUAD	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg19052272	chr2:3704530	ALLC	0.38	6.73	0.31	5.64e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.3	-0.37	1.45e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg17366294	chr4:99064904	C4orf37	-0.48	-8.48	-0.38	3.68e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs459571	0.959	rs455381	chr9:136905577	C/A	cg13789015	chr9:136890014	NCRNA00094	0.86	14.61	0.58	1.99e-39	Platelet distribution width;
LUAD	trans	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.7	-9.6	-0.42	7.05e-20	Obesity-related traits;
LUAD	trans	rs8073060	0.586	rs2011897	chr17:34054408	A/T	cg19694781	chr19:47549865	TMEM160	1.2	19.09	0.68	4.93e-59	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg03874509	chr1:107600012	PRMT6	0.55	9.48	0.42	1.89e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg07979401	chr6:33739406	LEMD2	-0.54	-9.69	-0.43	3.41e-20	Schizophrenia;
LUAD	cis	rs9487051	0.735	rs351754	chr6:109537553	A/G	cg12927641	chr6:109611667	NA	0.37	6.35	0.3	5.52e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg10862848	chr6:42927986	GNMT	-0.32	-9.31	-0.41	6.77e-19	Plasma homocysteine levels (post-methionine load test);
LUAD	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg14343924	chr8:8086146	FLJ10661	0.45	7.22	0.33	2.48e-12	Retinal vascular caliber;
LUAD	cis	rs7809950	0.637	rs2701685	chr7:107299584	A/G	cg23024343	chr7:107201750	COG5	0.69	11.55	0.49	5.35e-27	Coronary artery disease;
LUAD	trans	rs701145	0.537	rs1713842	chr3:153786243	T/A	cg14299572	chr10:34021103	NA	0.37	6.41	0.3	3.78e-10	Coronary artery disease;
LUAD	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg20673091	chr1:2541236	MMEL1	0.44	9.71	0.43	2.93e-20	Ulcerative colitis;
LUAD	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26314531	chr2:26401878	FAM59B	0.75	10.7	0.46	8.33e-24	Gut microbiome composition (summer);
LUAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg06453172	chr10:134556979	INPP5A	-0.79	-11.26	-0.48	6.85e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg24069376	chr3:38537580	EXOG	-0.33	-7.45	-0.34	5.3e-13	Electrocardiographic conduction measures;
LUAD	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg10518543	chr12:38710700	ALG10B	-0.53	-8.61	-0.39	1.47e-16	Morning vs. evening chronotype;
LUAD	cis	rs208520	0.779	rs208451	chr6:66906155	G/A	cg07460842	chr6:66804631	NA	-1.0	-13.92	-0.56	1.58e-36	Exhaled nitric oxide output;
LUAD	cis	rs7709909	0.553	rs32951	chr5:80021168	A/C	cg24059623	chr5:79951536	MSH3;DHFR	0.49	7.44	0.34	5.8e-13	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs1524976	1.000	rs62255276	chr3:65457776	C/A	cg16238336	chr3:65465873	MAGI1	-0.67	-7.6	-0.35	1.86e-13	PR interval;
LUAD	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg27068330	chr11:65405492	SIPA1	0.54	8.53	0.38	2.67e-16	Acne (severe);
LUAD	cis	rs1232027	0.700	rs1643652	chr5:79955079	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.76	-0.35	6.44e-14	Huntington's disease progression;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03902233	chr6:122792987	PKIB;SERINC1	-0.53	-6.38	-0.3	4.59e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg14343924	chr8:8086146	FLJ10661	0.45	7.13	0.33	4.49e-12	Mood instability;
LUAD	cis	rs3784262	0.669	rs12909979	chr15:58241022	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.45	-0.34	5.26e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-10.92	-0.47	1.26e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs17102423	0.654	rs8008095	chr14:65525794	A/G	cg11161011	chr14:65562177	MAX	-0.38	-6.4	-0.3	4.18e-10	Obesity-related traits;
LUAD	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg14458575	chr2:238380390	NA	-0.76	-15.92	-0.61	4.64e-45	Prostate cancer;
LUAD	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg25985355	chr7:65971099	NA	0.39	7.13	0.33	4.48e-12	Aortic root size;
LUAD	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg11070056	chr1:107600091	PRMT6	0.55	9.52	0.42	1.39e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg23815491	chr16:72088622	HP	0.54	9.98	0.44	3.26e-21	Fibrinogen levels;
LUAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.29	0.41	8.04e-19	Alzheimer's disease;
LUAD	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg17264618	chr3:40429014	ENTPD3	0.4	9.0	0.4	7.65e-18	Renal cell carcinoma;
LUAD	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg11050988	chr7:1952600	MAD1L1	0.33	6.86	0.32	2.41e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg04450456	chr4:17643702	FAM184B	0.41	8.21	0.37	2.74e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs775227	0.706	rs808951	chr3:113002150	A/G	cg18753928	chr3:113234510	CCDC52	0.44	7.08	0.33	6.05e-12	Dental caries;
LUAD	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg02375832	chr11:62437615	C11orf48	-0.35	-6.72	-0.31	5.8e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	trans	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg00769240	chr8:12517080	NA	-0.44	-7.43	-0.34	5.88e-13	Blood pressure (smoking interaction);
LUAD	cis	rs3125734	0.719	rs4529854	chr10:64043975	C/T	cg09941381	chr10:64027924	RTKN2	-0.31	-7.11	-0.33	5.03e-12	Rheumatoid arthritis;
LUAD	cis	rs208520	0.586	rs208442	chr6:66900618	T/A	cg07460842	chr6:66804631	NA	-0.68	-10.11	-0.44	1.18e-21	Exhaled nitric oxide output;
LUAD	trans	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.81	-0.36	4.41e-14	Breast cancer;
LUAD	cis	rs10911363	0.571	rs6424897	chr1:183419203	T/C	cg09173681	chr1:183549694	NCF2	-0.53	-9.79	-0.43	1.52e-20	Systemic lupus erythematosus;
LUAD	cis	rs4988958	0.527	rs3771155	chr2:103037826	A/G	cg03938978	chr2:103052716	IL18RAP	0.45	10.33	0.45	1.82e-22	Asthma (childhood onset);
LUAD	cis	rs701145	0.585	rs401162	chr3:153905988	T/A	cg17054900	chr3:154042577	DHX36	0.61	6.71	0.31	6.35e-11	Coronary artery disease;
LUAD	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg26677194	chr12:130822605	PIWIL1	0.58	9.47	0.42	1.97e-19	Menopause (age at onset);
LUAD	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg05340658	chr4:99064831	C4orf37	0.45	6.96	0.32	1.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7020830	0.898	rs7038219	chr9:37182892	C/A	cg14294708	chr9:37120828	ZCCHC7	0.81	15.96	0.61	3.08e-45	Schizophrenia;
LUAD	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg21733973	chr7:65235735	NA	0.43	6.94	0.32	1.51e-11	Aortic root size;
LUAD	cis	rs4378999	0.748	rs2219890	chr3:51383506	G/T	cg12934382	chr3:51741135	GRM2	0.39	6.96	0.32	1.34e-11	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg06453172	chr10:134556979	INPP5A	-0.78	-10.84	-0.47	2.61e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg20933634	chr6:27740509	NA	0.49	7.27	0.33	1.72e-12	Breast cancer;
LUAD	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg25809561	chr17:30822961	MYO1D	0.46	8.32	0.38	1.21e-15	Schizophrenia;
LUAD	cis	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg07460842	chr6:66804631	NA	1.08	17.32	0.64	3.44e-51	Exhaled nitric oxide output;
LUAD	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg15557168	chr22:42548783	NA	0.51	9.41	0.42	3.33e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg17173187	chr15:85201210	NMB	0.49	8.61	0.39	1.43e-16	Schizophrenia;
LUAD	cis	rs868036	0.756	rs2241421	chr15:68082825	G/A	cg08079166	chr15:68083412	MAP2K5	0.3	6.44	0.3	3.27e-10	Restless legs syndrome;
LUAD	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg23985595	chr17:80112537	CCDC57	0.52	9.49	0.42	1.76e-19	Life satisfaction;
LUAD	cis	rs7512552	0.839	rs12042229	chr1:150447398	A/G	cg15654264	chr1:150340011	RPRD2	0.6	11.4	0.48	1.95e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg04775059	chr7:64541387	NA	0.51	6.97	0.32	1.2e-11	Aortic root size;
LUAD	cis	rs6901004	0.596	rs411604	chr6:111565847	A/G	cg15721981	chr6:111408429	SLC16A10	-0.5	-8.17	-0.37	3.57e-15	Blood metabolite levels;
LUAD	cis	rs7680126	0.500	rs4697717	chr4:10149784	C/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.44	-0.34	5.85e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg16325326	chr1:53192061	ZYG11B	-0.63	-11.72	-0.5	1.12e-27	Monocyte count;
LUAD	cis	rs12144309	0.608	rs1217408	chr1:114396280	T/C	cg03325407	chr1:114423726	BCL2L15	0.4	7.04	0.32	7.78e-12	Coronary artery disease;
LUAD	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg13393036	chr8:95962371	TP53INP1	-0.41	-9.96	-0.44	3.93e-21	Type 2 diabetes;
LUAD	trans	rs57046232	0.552	rs1998971	chr20:6334912	G/A	cg21095983	chr6:86352623	SYNCRIP	0.41	6.37	0.3	4.84e-10	Colorectal cancer;
LUAD	cis	rs72772090	0.539	rs11749811	chr5:96115925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.3	-0.33	1.4e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7737355	0.812	rs42256	chr5:130705906	T/C	cg06307176	chr5:131281290	NA	-0.39	-6.6	-0.31	1.22e-10	Life satisfaction;
LUAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.46	-8.27	-0.37	1.75e-15	Longevity;Endometriosis;
LUAD	cis	rs55823223	0.648	rs56901103	chr17:73865667	C/A	cg09253696	chr17:73873529	TRIM47	-0.43	-7.25	-0.33	1.99e-12	Psoriasis;
LUAD	trans	rs264943	0.783	rs7583069	chr2:104231852	C/T	cg11295801	chr6:150039190	LATS1	0.39	6.48	0.3	2.63e-10	HIV-1 viral setpoint;
LUAD	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	17.44	0.65	1.06e-51	Homoarginine levels;
LUAD	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg18196295	chr10:418757	DIP2C	-0.44	-6.73	-0.31	5.71e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg23933602	chr10:16859644	RSU1	0.56	7.64	0.35	1.47e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg22117172	chr7:91764530	CYP51A1	0.37	8.01	0.36	1.13e-14	Breast cancer;
LUAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	9.96	0.44	4.01e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12545109	0.800	rs1595940	chr8:57398309	T/C	cg09654669	chr8:57350985	NA	-0.67	-9.61	-0.42	6.34e-20	Obesity-related traits;
LUAD	cis	rs12505328	0.966	rs2028538	chr4:174356838	T/G	cg12145043	chr4:174357286	NA	-0.57	-9.84	-0.43	1.02e-20	Chin dimples;
LUAD	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	8.75	0.39	5.09e-17	Glomerular filtration rate;
LUAD	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg16647868	chr5:131706066	SLC22A5	0.36	6.47	0.3	2.65e-10	Blood metabolite levels;
LUAD	cis	rs7301826	0.651	rs10773824	chr12:131298851	G/A	cg11011512	chr12:131303247	STX2	0.44	7.55	0.34	2.78e-13	Plasma plasminogen activator levels;
LUAD	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg06713675	chr4:122721982	EXOSC9	-0.74	-15.71	-0.61	4.01e-44	Type 2 diabetes;
LUAD	cis	rs6489882	0.902	rs3759375	chr12:113373588	A/G	cg20102336	chr12:113376681	OAS3	-0.6	-9.46	-0.42	2.12e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.43	-0.3	3.52e-10	Breast cancer;
LUAD	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg12444411	chr7:2802554	GNA12	-0.35	-6.44	-0.3	3.27e-10	Height;
LUAD	cis	rs1865721	1.000	rs7236756	chr18:73175689	T/C	cg26385618	chr18:73139727	C18orf62	-0.43	-7.77	-0.35	6.11e-14	Intelligence;
LUAD	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg03037974	chr15:76606532	NA	0.38	8.03	0.36	9.64e-15	Blood metabolite levels;
LUAD	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg27144592	chr16:783916	NARFL	0.35	6.46	0.3	2.96e-10	Height;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg01777103	chr8:145550585	DGAT1	0.37	6.47	0.3	2.7e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg20607798	chr8:58055168	NA	0.66	8.7	0.39	7.67e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg09085632	chr11:111637200	PPP2R1B	0.64	9.95	0.44	4.24e-21	Primary sclerosing cholangitis;
LUAD	cis	rs4711350	1.000	rs943472	chr6:33738442	T/C	cg07979401	chr6:33739406	LEMD2	-0.52	-8.64	-0.39	1.13e-16	Schizophrenia;
LUAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06873352	chr17:61820015	STRADA	-0.77	-16.45	-0.62	2.26e-47	Prudent dietary pattern;
LUAD	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg01475377	chr6:109611718	NA	0.54	10.34	0.45	1.78e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg20991723	chr1:152506922	NA	0.35	6.85	0.32	2.63e-11	Hair morphology;
LUAD	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.88	0.4	1.86e-17	Parkinson's disease;
LUAD	cis	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg00071950	chr4:10020882	SLC2A9	0.5	7.19	0.33	3.04e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.39	-7.62	-0.35	1.64e-13	Total body bone mineral density;
LUAD	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.48	-0.45	5.41e-23	Total body bone mineral density;
LUAD	cis	rs7851660	0.809	rs7036589	chr9:100657720	A/T	cg13688889	chr9:100608707	NA	0.52	8.84	0.4	2.52e-17	Strep throat;
LUAD	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.6	-0.35	1.98e-13	Blood metabolite levels;
LUAD	cis	rs2445762	0.642	rs72729210	chr15:51633629	G/A	cg07517944	chr15:51633816	GLDN	0.4	6.89	0.32	2.05e-11	Hormone measurements;
LUAD	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs7771547	0.519	rs12190911	chr6:36378487	C/T	cg07856975	chr6:36356162	ETV7	-0.54	-8.06	-0.36	7.71e-15	Platelet distribution width;
LUAD	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg24803719	chr17:45855879	NA	-0.34	-7.51	-0.34	3.57e-13	IgG glycosylation;
LUAD	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg20701182	chr2:24300061	SF3B14	0.61	6.71	0.31	6.32e-11	Lymphocyte counts;
LUAD	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg03609598	chr5:56110824	MAP3K1	-0.66	-9.08	-0.4	4.14e-18	Initial pursuit acceleration;
LUAD	cis	rs34286592	1.000	rs3976455	chr16:29861447	C/T	cg08218971	chr16:29826754	C16orf53;PRRT2	0.4	6.71	0.31	6.21e-11	Multiple sclerosis;
LUAD	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg04287289	chr16:89883240	FANCA	0.8	7.02	0.32	9.05e-12	Skin colour saturation;
LUAD	cis	rs1232027	0.700	rs836822	chr5:79943776	C/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-7.95	-0.36	1.74e-14	Huntington's disease progression;
LUAD	cis	rs7607369	0.648	rs7559490	chr2:219656867	A/T	cg02176678	chr2:219576539	TTLL4	-0.69	-13.74	-0.56	9.1e-36	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg02527881	chr3:46936655	PTH1R	-0.5	-10.12	-0.44	1.08e-21	Colorectal cancer;
LUAD	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25427524	chr10:38739819	LOC399744	-0.76	-13.57	-0.55	4.31e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg17724175	chr1:150552817	MCL1	0.39	9.28	0.41	9.17e-19	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg07917127	chr4:99064746	C4orf37	0.4	6.5	0.3	2.31e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11048434	0.736	rs12423746	chr12:9113002	G/T	cg26114124	chr12:9217669	LOC144571	0.36	6.6	0.31	1.22e-10	Sjögren's syndrome;
LUAD	cis	rs494562	0.892	rs515980	chr6:86119917	C/T	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg07810366	chr2:100720526	AFF3	0.34	6.93	0.32	1.63e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs6445967	0.569	rs9845705	chr3:58281868	T/G	cg23715586	chr3:58305044	RPP14	0.39	6.5	0.3	2.29e-10	Platelet count;
LUAD	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs12545109	0.800	rs1440747	chr8:57417924	G/T	cg07776626	chr8:57350775	NA	0.62	8.69	0.39	7.82e-17	Obesity-related traits;
LUAD	cis	rs7727544	0.557	rs715285	chr5:131485383	A/G	cg14196790	chr5:131705035	SLC22A5	0.42	7.35	0.34	1.05e-12	Blood metabolite levels;
LUAD	cis	rs6906287	0.631	rs2798321	chr6:118991602	G/T	cg21191810	chr6:118973309	C6orf204	0.46	8.64	0.39	1.16e-16	Electrocardiographic conduction measures;
LUAD	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg21433313	chr16:3507492	NAT15	-0.77	-8.46	-0.38	4.37e-16	Tuberculosis;
LUAD	trans	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg22823121	chr1:150693482	HORMAD1	-0.4	-7.78	-0.35	5.58e-14	Urate levels;
LUAD	trans	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg26043149	chr18:55253948	FECH	-0.42	-6.71	-0.31	6.46e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4664304	0.900	rs17231993	chr2:160741415	C/T	cg23995753	chr2:160760732	LY75	-0.44	-7.84	-0.36	3.66e-14	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	12.28	0.51	7.24e-30	Homoarginine levels;
LUAD	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg03609598	chr5:56110824	MAP3K1	-0.69	-9.32	-0.41	6.72e-19	Initial pursuit acceleration;
LUAD	cis	rs62458065	1.000	rs10231294	chr7:32465357	C/T	cg20159608	chr7:32802032	NA	-0.47	-6.74	-0.31	5.13e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg23625390	chr15:77176239	SCAPER	0.42	7.34	0.34	1.07e-12	Blood metabolite levels;
LUAD	cis	rs12760731	0.565	rs57247289	chr1:178090138	G/A	cg00404053	chr1:178313656	RASAL2	0.66	8.7	0.39	7.29e-17	Obesity-related traits;
LUAD	cis	rs11078597	0.614	rs62090057	chr17:1645526	C/T	cg18436246	chr17:1640651	WDR81	0.79	12.45	0.52	1.53e-30	Serum albumin level;
LUAD	cis	rs17539620	0.624	rs111868524	chr6:154839960	G/C	cg20019720	chr6:154832845	CNKSR3	0.65	12.61	0.52	3.61e-31	Lipoprotein (a) levels;
LUAD	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs599083	0.829	rs23691	chr11:68178668	G/A	cg02221422	chr11:68192511	LRP5	0.43	6.78	0.31	4.03e-11	Bone mineral density (spine);
LUAD	cis	rs1595825	1.000	rs73058834	chr2:198873779	T/G	cg00982548	chr2:198649783	BOLL	-0.65	-9.2	-0.41	1.65e-18	Ulcerative colitis;
LUAD	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg13010199	chr12:38710504	ALG10B	0.39	6.46	0.3	2.82e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7771547	0.723	rs10807169	chr6:36556569	A/G	cg07856975	chr6:36356162	ETV7	0.45	6.45	0.3	3.06e-10	Platelet distribution width;
LUAD	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg12927641	chr6:109611667	NA	-0.5	-8.77	-0.39	4.53e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg23815491	chr16:72088622	HP	0.59	11.17	0.48	1.4e-25	Fibrinogen levels;
LUAD	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg22823121	chr1:150693482	HORMAD1	0.48	9.29	0.41	8.36e-19	Melanoma;
LUAD	cis	rs7274811	0.554	rs6120299	chr20:32133491	T/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.51	-7.36	-0.34	9.74e-13	Height;
LUAD	cis	rs6684514	0.845	rs12138564	chr1:156291600	G/T	cg16558208	chr1:156270281	VHLL	0.53	9.78	0.43	1.62e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs116248771	0.739	rs4679833	chr3:158339835	G/A	cg16708174	chr3:158430962	RARRES1	0.5	7.23	0.33	2.23e-12	diarrhoeal disease at age 2;
LUAD	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg03806693	chr22:41940476	POLR3H	-0.46	-6.86	-0.32	2.42e-11	Neuroticism;
LUAD	cis	rs57994353	1.000	rs57994353	chr9:139356987	T/C	cg14364472	chr9:139394549	NOTCH1	-0.41	-6.4	-0.3	4.06e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18099408	chr3:52552593	STAB1	-0.43	-7.7	-0.35	1e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg15181151	chr6:150070149	PCMT1	0.36	7.05	0.32	7.5e-12	Lung cancer;
LUAD	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg03467027	chr4:99064603	C4orf37	0.43	7.06	0.32	7.06e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg21605333	chr4:119757512	SEC24D	0.93	8.74	0.39	5.54e-17	Cannabis dependence symptom count;
LUAD	cis	rs6906287	0.647	rs12206329	chr6:118863789	G/T	cg18833306	chr6:118973337	C6orf204	0.47	8.43	0.38	5.36e-16	Electrocardiographic conduction measures;
LUAD	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg06784218	chr1:46089804	CCDC17	0.5	10.92	0.47	1.22e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs11945232	1.000	rs28406846	chr4:88343468	C/G	cg23841344	chr4:88312519	HSD17B11	-0.56	-8.43	-0.38	5.5e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg00083206	chr6:110721305	DDO	0.46	8.48	0.38	3.73e-16	Platelet distribution width;
LUAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.22	-0.41	1.38e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg21153622	chr11:89784906	NA	-0.33	-6.47	-0.3	2.75e-10	Coronary artery disease;
LUAD	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg02466173	chr16:30829666	NA	-0.69	-12.58	-0.52	4.63e-31	Multiple myeloma;
LUAD	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg08999081	chr20:33150536	PIGU	-0.37	-7.21	-0.33	2.52e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg11871910	chr12:69753446	YEATS4	0.47	7.52	0.34	3.24e-13	Blood protein levels;
LUAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg08888203	chr3:10149979	C3orf24	0.77	13.53	0.55	6.67e-35	Alzheimer's disease;
LUAD	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg27446573	chr6:127587934	RNF146	0.45	6.64	0.31	9.39e-11	Breast cancer;
LUAD	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg01815783	chr4:1047043	NA	0.28	6.44	0.3	3.24e-10	Recombination rate (males);
LUAD	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg07677032	chr17:61819896	STRADA	-0.5	-8.41	-0.38	6.36e-16	Prudent dietary pattern;
LUAD	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg15448220	chr1:150897856	SETDB1	0.54	9.31	0.41	6.88e-19	Melanoma;
LUAD	trans	rs8023401	0.938	rs12592240	chr15:48809080	A/G	cg26807912	chr15:101970241	PCSK6	-0.54	-6.98	-0.32	1.16e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs3087591	0.887	rs1013946	chr17:29530350	A/C	cg24425628	chr17:29625626	OMG;NF1	0.41	6.78	0.31	4.12e-11	Hip circumference;
LUAD	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg00339695	chr16:24857497	SLC5A11	-0.71	-11.47	-0.49	1.07e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.44	-6.79	-0.31	3.9e-11	Longevity;Endometriosis;
LUAD	cis	rs6445967	0.554	rs12494710	chr3:58430207	C/T	cg23715586	chr3:58305044	RPP14	0.39	6.36	0.3	5.38e-10	Platelet count;
LUAD	trans	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.3	0.41	7.51e-19	Mean corpuscular volume;
LUAD	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9399401	0.626	rs3817928	chr6:142750516	A/G	cg03128060	chr6:142623767	GPR126	0.46	8.95	0.4	1.1e-17	Chronic obstructive pulmonary disease;
LUAD	trans	rs1997103	1.000	rs1965556	chr7:55403584	C/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg18190219	chr22:46762943	CELSR1	-0.54	-6.71	-0.31	6.12e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg11502198	chr6:26597334	ABT1	0.56	9.35	0.41	5.23e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs250585	1.000	rs6497672	chr16:23544295	G/A	cg00143387	chr16:23521605	GGA2	-0.68	-7.99	-0.36	1.27e-14	Egg allergy;
LUAD	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg19622623	chr12:86230825	RASSF9	-0.39	-6.94	-0.32	1.48e-11	Major depressive disorder;
LUAD	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg01475377	chr6:109611718	NA	-0.53	-10.17	-0.44	6.99e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg11062466	chr8:58055876	NA	0.45	6.46	0.3	2.84e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg04398451	chr17:18023971	MYO15A	-0.87	-17.16	-0.64	1.85e-50	Total body bone mineral density;
LUAD	cis	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg02508848	chr16:68573721	ZFP90	-0.42	-6.55	-0.3	1.72e-10	Ulcerative colitis;
LUAD	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.51	-6.99	-0.32	1.07e-11	Platelet count;
LUAD	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg12756686	chr19:29218302	NA	0.54	6.88	0.32	2.21e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs2971970	0.519	rs10232278	chr7:133628547	G/A	cg03336402	chr7:133662267	EXOC4	0.39	7.08	0.33	6.15e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg11189052	chr15:85197271	WDR73	-0.72	-12.5	-0.52	9.74e-31	P wave terminal force;
LUAD	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg03690763	chr11:133734501	NA	0.29	6.93	0.32	1.55e-11	Childhood ear infection;
LUAD	cis	rs12541635	0.934	rs4734893	chr8:106990275	T/G	cg10147462	chr8:107024639	NA	0.51	9.12	0.41	3.15e-18	Age of smoking initiation;
LUAD	cis	rs6005807	0.719	rs134547	chr22:28801009	A/G	cg12565055	chr22:29076175	TTC28	0.73	8.67	0.39	9.61e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25427524	chr10:38739819	LOC399744	-0.8	-14.36	-0.57	2.26e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg14530993	chr4:882597	GAK	0.7	6.74	0.31	5.15e-11	Parkinson's disease;
LUAD	cis	rs2455799	0.927	rs2470514	chr3:15750344	A/C	cg16303742	chr3:15540471	COLQ	-0.41	-6.93	-0.32	1.59e-11	Mean platelet volume;
LUAD	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg06623918	chr6:96969491	KIAA0776	-0.68	-9.48	-0.42	1.83e-19	Migraine;Coronary artery disease;
LUAD	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg00383909	chr3:49044727	WDR6	0.99	10.64	0.46	1.41e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg15128208	chr22:42549153	NA	0.4	6.51	0.3	2.17e-10	Birth weight;
LUAD	cis	rs701145	0.938	rs701133	chr3:154070312	A/G	cg17054900	chr3:154042577	DHX36	0.63	7.05	0.32	7.18e-12	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.98	0.53	1.21e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg15445000	chr17:37608096	MED1	-0.45	-8.35	-0.38	9.75e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg10518543	chr12:38710700	ALG10B	0.42	6.47	0.3	2.73e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.8	0.39	3.41e-17	Rheumatoid arthritis;
LUAD	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.82	-0.39	2.94e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7213347	0.780	rs1555568	chr17:2149505	T/C	cg02569219	chr17:2266849	SGSM2	-0.45	-7.11	-0.33	4.89e-12	Total body bone mineral density;
LUAD	cis	rs5758511	0.773	rs11913631	chr22:42347371	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.38	6.48	0.3	2.54e-10	Birth weight;
LUAD	cis	rs2880765	0.835	rs56406982	chr15:86036379	G/A	cg13263323	chr15:86062960	AKAP13	-0.48	-8.84	-0.39	2.56e-17	Coronary artery disease;
LUAD	cis	rs7809950	0.784	rs7803102	chr7:107248929	T/G	cg23024343	chr7:107201750	COG5	0.73	11.97	0.5	1.18e-28	Coronary artery disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16224018	chr12:124069324	TMED2	-0.53	-6.88	-0.32	2.16e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs208520	0.661	rs150263	chr6:66777620	T/C	cg07460842	chr6:66804631	NA	-1.06	-16.47	-0.63	1.82e-47	Exhaled nitric oxide output;
LUAD	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg17178900	chr1:205818956	PM20D1	-0.46	-7.1	-0.33	5.35e-12	Menarche (age at onset);
LUAD	cis	rs6564851	0.506	rs56389890	chr16:81259266	G/T	cg00908271	chr16:81254010	PKD1L2	0.32	6.66	0.31	8.33e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg16850897	chr7:100343110	ZAN	-0.6	-8.14	-0.37	4.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17952111	chr19:54960355	LENG8	-0.55	-6.71	-0.31	6.38e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg10729496	chr3:10149963	C3orf24	0.49	7.88	0.36	2.73e-14	Alzheimer's disease;
LUAD	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg26587870	chr6:27730563	NA	-0.49	-8.18	-0.37	3.36e-15	Parkinson's disease;
LUAD	cis	rs220324	0.688	rs9984377	chr21:43574845	G/A	cg09727148	chr21:43560719	UMODL1	0.57	8.27	0.37	1.75e-15	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7043114	0.525	rs7853859	chr9:95151377	A/G	cg14631576	chr9:95140430	CENPP	-0.42	-8.65	-0.39	1.06e-16	Height;
LUAD	cis	rs76878669	0.561	rs7107191	chr11:66140397	G/A	cg18002602	chr11:66138449	SLC29A2	0.47	10.16	0.44	7.74e-22	Educational attainment (years of education);
LUAD	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg00339695	chr16:24857497	SLC5A11	0.47	8.63	0.39	1.24e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs9905704	0.633	rs72841019	chr17:56496346	G/A	cg19466818	chr17:56409534	MIR142	-0.33	-6.54	-0.3	1.81e-10	Testicular germ cell tumor;
LUAD	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg05590025	chr7:65112418	INTS4L2	-0.72	-7.65	-0.35	1.33e-13	Diabetic kidney disease;
LUAD	cis	rs10193935	0.579	rs62142594	chr2:42524531	G/A	cg27598129	chr2:42591480	NA	-0.77	-7.02	-0.32	8.96e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.947	rs6895841	chr5:130773534	A/G	cg06307176	chr5:131281290	NA	0.49	7.9	0.36	2.38e-14	Life satisfaction;
LUAD	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg00634984	chr7:65235879	NA	0.47	6.44	0.3	3.28e-10	Aortic root size;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00614832	chr16:73092394	ZFHX3	-0.42	-6.6	-0.31	1.25e-10	Height;
LUAD	cis	rs9473147	0.571	rs9395285	chr6:47554177	G/A	cg20196966	chr6:47445060	CD2AP	0.43	6.64	0.31	9.38e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg06784218	chr1:46089804	CCDC17	0.5	11.05	0.47	4.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg22764044	chr5:178986830	RUFY1	0.51	8.6	0.39	1.55e-16	Lung cancer;
LUAD	cis	rs2235649	0.833	rs55684627	chr16:1848817	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-6.72	-0.31	6.01e-11	Blood metabolite levels;
LUAD	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg05368731	chr17:41323189	NBR1	0.82	16.57	0.63	6.75e-48	Menopause (age at onset);
LUAD	cis	rs9302635	0.513	rs3812987	chr16:72158920	C/A	cg23815491	chr16:72088622	HP	0.48	7.6	0.35	1.91e-13	Blood protein levels;
LUAD	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg27219399	chr15:67835830	MAP2K5	0.4	6.6	0.31	1.25e-10	Restless legs syndrome;
LUAD	cis	rs12505328	0.593	rs880960	chr4:174362409	A/G	cg12145043	chr4:174357286	NA	-0.52	-7.76	-0.35	6.45e-14	Chin dimples;
LUAD	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.35	7.02	0.32	9.14e-12	Obesity-related traits;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24047259	chr14:65347275	NA	-0.55	-6.59	-0.31	1.3e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2235642	0.533	rs2076436	chr16:1608082	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.52	-8.15	-0.37	4.14e-15	Coronary artery disease;
LUAD	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg15962314	chr1:44399869	ARTN	0.34	7.67	0.35	1.19e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22496380	chr5:211416	CCDC127	-0.94	-13.27	-0.54	7.85e-34	Breast cancer;
LUAD	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg18755752	chr8:142205143	DENND3	-0.44	-7.67	-0.35	1.19e-13	Immature fraction of reticulocytes;
LUAD	cis	rs7582720	1.000	rs72932789	chr2:203699379	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.39	0.42	3.83e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg02527881	chr3:46936655	PTH1R	0.46	8.87	0.4	2.07e-17	Colorectal cancer;
LUAD	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg16647868	chr5:131706066	SLC22A5	-0.48	-7.72	-0.35	8.7e-14	Breast cancer;
LUAD	cis	rs1595825	0.891	rs17520121	chr2:198898718	T/G	cg00361562	chr2:198649771	BOLL	-0.49	-6.78	-0.31	4.16e-11	Ulcerative colitis;
LUAD	cis	rs3925075	0.966	rs7195945	chr16:31344309	T/C	cg02846316	chr16:31340340	ITGAM	0.32	6.51	0.3	2.17e-10	IgA nephropathy;
LUAD	cis	rs600626	0.541	rs11236528	chr11:75469476	T/C	cg24262691	chr11:75473276	NA	0.59	8.05	0.36	8.44e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg03690763	chr11:133734501	NA	-0.34	-7.94	-0.36	1.89e-14	Childhood ear infection;
LUAD	trans	rs7395662	0.547	rs10769442	chr11:48765027	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.22	-0.33	2.48e-12	HDL cholesterol;
LUAD	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg09117114	chr16:67998030	SLC12A4	-0.62	-8.12	-0.37	5.14e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.07e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.05	0.36	8.46e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg27411982	chr8:10470053	RP1L1	-0.36	-6.46	-0.3	2.95e-10	Triglycerides;
LUAD	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg18016565	chr1:150552671	MCL1	0.41	7.52	0.34	3.34e-13	Tonsillectomy;
LUAD	cis	rs9905704	0.633	rs4793588	chr17:56471051	G/T	cg19466818	chr17:56409534	MIR142	0.34	6.72	0.31	5.76e-11	Testicular germ cell tumor;
LUAD	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	11.5	0.49	8.26e-27	Resting heart rate;
LUAD	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.82	0.36	4.31e-14	Bladder cancer;
LUAD	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00684032	chr4:1343700	KIAA1530	0.49	8.09	0.37	6.22e-15	Obesity-related traits;
LUAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg22907277	chr7:1156413	C7orf50	0.71	8.31	0.37	1.27e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35146811	0.844	rs12705071	chr7:99682026	T/C	cg22906224	chr7:99728672	NA	0.61	9.75	0.43	2.22e-20	Coronary artery disease;
LUAD	cis	rs2692947	0.770	rs2315421	chr2:96497516	G/C	cg23100626	chr2:96804247	ASTL	0.31	7.77	0.35	5.87e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.18	-0.37	3.39e-15	Bipolar disorder;
LUAD	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg18854424	chr1:2615690	NA	-0.42	-9.15	-0.41	2.46e-18	Multiple sclerosis;
LUAD	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg04455712	chr21:45112962	RRP1B	0.48	9.57	0.42	9.33e-20	Mean corpuscular volume;
LUAD	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg27170947	chr2:26402098	FAM59B	0.59	8.39	0.38	7.21e-16	Gut microbiome composition (summer);
LUAD	cis	rs698833	0.819	rs1372078	chr2:44543389	A/T	cg04920474	chr2:44395004	PPM1B	-0.4	-7.24	-0.33	2.08e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs8014204	0.836	rs8021280	chr14:75290018	C/G	cg06637938	chr14:75390232	RPS6KL1	0.39	7.19	0.33	2.88e-12	Caffeine consumption;
LUAD	cis	rs4919694	1.000	rs12257941	chr10:104833161	C/T	cg04362960	chr10:104952993	NT5C2	0.72	7.75	0.35	6.81e-14	Arsenic metabolism;
LUAD	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg02454025	chr1:11042201	C1orf127	1.04	17.71	0.65	6.82e-53	Ewing sarcoma;
LUAD	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg26647111	chr11:31128758	NA	-0.46	-7.95	-0.36	1.69e-14	Red blood cell count;
LUAD	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg12179176	chr11:130786555	SNX19	0.54	9.11	0.4	3.37e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06873352	chr17:61820015	STRADA	0.82	18.29	0.66	1.79e-55	Prudent dietary pattern;
LUAD	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.54	-0.34	2.95e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.4	0.34	7.47e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7937890	0.559	rs2597208	chr11:14472329	A/C	cg23387056	chr11:14280742	SPON1	-0.35	-6.7	-0.31	6.83e-11	Mitochondrial DNA levels;
LUAD	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg15704280	chr7:45808275	SEPT13	-0.53	-8.65	-0.39	1.06e-16	HDL cholesterol;
LUAD	cis	rs12545109	0.800	rs2576591	chr8:57423606	A/G	cg09654669	chr8:57350985	NA	-0.64	-9.22	-0.41	1.44e-18	Obesity-related traits;
LUAD	cis	rs2286503	0.839	rs2270103	chr7:22862722	C/T	cg06496272	chr7:22895283	SNORD93	-0.41	-7.27	-0.33	1.74e-12	Fibrinogen;
LUAD	cis	rs2302190	0.941	rs6503865	chr17:56549672	A/C	cg25885038	chr17:56607967	SEPT4	-0.42	-6.53	-0.3	1.88e-10	Vitamin D levels;
LUAD	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg05590025	chr7:65112418	INTS4L2	-0.77	-8.13	-0.37	4.65e-15	Diabetic kidney disease;
LUAD	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg22920501	chr2:26401640	FAM59B	0.98	15.15	0.59	9.58e-42	Gut microbiome composition (summer);
LUAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg07362569	chr17:61921086	SMARCD2	-0.39	-6.8	-0.31	3.53e-11	Prudent dietary pattern;
LUAD	cis	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg01251360	chr16:68772225	CDH1	-0.28	-8.81	-0.39	3.21e-17	Colorectal cancer;
LUAD	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg08761264	chr16:28874980	SH2B1	-0.43	-6.51	-0.3	2.19e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg16647868	chr5:131706066	SLC22A5	-0.4	-6.91	-0.32	1.84e-11	Blood metabolite levels;
LUAD	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	8.32	0.38	1.19e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg04295297	chr6:135502378	MYB	-0.39	-6.37	-0.3	4.97e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg07741184	chr6:167504864	NA	0.34	7.8	0.35	4.78e-14	Crohn's disease;
LUAD	cis	rs12446554	0.511	rs72769544	chr16:19777237	A/T	cg01578585	chr16:19721878	C16orf88	0.53	7.37	0.34	8.78e-13	Obesity;
LUAD	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg23887609	chr12:130822674	PIWIL1	0.44	7.44	0.34	5.54e-13	Menopause (age at onset);
LUAD	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg13393036	chr8:95962371	TP53INP1	-0.38	-8.05	-0.36	8.4e-15	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.14	0.41	2.7e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg24733560	chr20:60626293	TAF4	0.48	8.42	0.38	5.93e-16	Body mass index;
LUAD	trans	rs62103177	0.608	rs8088089	chr18:77832154	A/G	cg05926928	chr17:57297772	GDPD1	-0.81	-9.98	-0.44	3.29e-21	Opioid sensitivity;
LUAD	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg24690094	chr11:67383802	NA	0.4	7.12	0.33	4.63e-12	Mean corpuscular volume;
LUAD	trans	rs7395662	1.000	rs7481880	chr11:48609347	C/T	cg15704280	chr7:45808275	SEPT13	-0.41	-6.47	-0.3	2.64e-10	HDL cholesterol;
LUAD	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg22906224	chr7:99728672	NA	-0.59	-10.23	-0.45	4.15e-22	Coronary artery disease;
LUAD	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg04414720	chr1:150670196	GOLPH3L	0.74	13.85	0.56	3.17e-36	Tonsillectomy;
LUAD	cis	rs117623576	0.941	rs17230152	chr10:32431969	A/G	cg03047570	chr10:32398778	NA	-0.79	-9.37	-0.41	4.33e-19	Anti-saccade response;
LUAD	cis	rs10203711	0.966	rs907105	chr2:239565052	A/G	cg14580085	chr2:239553406	NA	0.4	8.46	0.38	4.47e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs71478720	0.729	rs12795478	chr11:112068100	A/T	cg04929355	chr11:112034997	IL18	0.39	6.54	0.3	1.83e-10	Interleukin-18 levels;
LUAD	cis	rs8053891	0.502	rs34679758	chr16:71995427	A/G	cg04254540	chr16:71951199	KIAA0174	-0.72	-7.13	-0.33	4.32e-12	Coronary artery disease;
LUAD	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg11344533	chr11:111475393	SIK2	0.35	6.64	0.31	9.44e-11	Primary sclerosing cholangitis;
LUAD	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg20119798	chr7:94954144	PON1	-0.46	-6.39	-0.3	4.35e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20273774	chr5:180671298	GNB2L1;SNORD95	-0.44	-6.81	-0.31	3.35e-11	Height;
LUAD	cis	rs868036	1.000	rs1026731	chr15:68095018	G/A	cg24579218	chr15:68104479	NA	-0.39	-7.29	-0.33	1.53e-12	Restless legs syndrome;
LUAD	trans	rs853679	0.607	rs34878803	chr6:28250179	T/C	cg06606381	chr12:133084897	FBRSL1	-1.19	-11.33	-0.48	3.51e-26	Depression;
LUAD	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	8.34	0.38	1.09e-15	Body mass index;
LUAD	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.35e-11	Breast cancer;
LUAD	cis	rs2797160	1.000	rs1739354	chr6:126017808	G/C	cg05901451	chr6:126070800	HEY2	0.46	6.79	0.31	3.79e-11	Endometrial cancer;
LUAD	trans	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg01620082	chr3:125678407	NA	-0.44	-6.7	-0.31	6.82e-11	Depression;
LUAD	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg14343924	chr8:8086146	FLJ10661	-0.49	-8.0	-0.36	1.23e-14	Mood instability;
LUAD	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg20135002	chr11:47629003	NA	-0.41	-7.19	-0.33	2.88e-12	Subjective well-being;
LUAD	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg00277334	chr10:82204260	NA	-0.68	-10.83	-0.47	2.73e-24	Post bronchodilator FEV1;
LUAD	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06028808	chr11:68637592	NA	0.42	6.82	0.31	3.14e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg12863693	chr15:85201151	NMB	0.38	6.81	0.31	3.35e-11	Schizophrenia;
LUAD	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg27170947	chr2:26402098	FAM59B	0.83	12.4	0.52	2.58e-30	Gut microbiome composition (summer);
LUAD	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.62	0.31	1.09e-10	Depression;
LUAD	cis	rs2387326	0.723	rs67579537	chr10:129940527	G/A	cg16087940	chr10:129947807	NA	-0.62	-8.29	-0.37	1.47e-15	Select biomarker traits;
LUAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg21280719	chr6:42927975	GNMT	-0.4	-12.24	-0.51	1.04e-29	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg08601574	chr20:25228251	PYGB	-0.47	-8.88	-0.4	1.86e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg14779329	chr11:130786720	SNX19	0.39	6.83	0.32	2.93e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg15448220	chr1:150897856	SETDB1	0.51	8.81	0.39	3.2e-17	Melanoma;
LUAD	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg10978503	chr1:24200527	CNR2	0.6	12.83	0.53	4.53e-32	Immature fraction of reticulocytes;
LUAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.01	-0.36	1.11e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg26384229	chr12:38710491	ALG10B	0.44	7.24	0.33	2.15e-12	Bladder cancer;
LUAD	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg09455208	chr3:40491958	NA	0.64	13.72	0.55	1.12e-35	Renal cell carcinoma;
LUAD	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26818010	chr10:134567672	INPP5A	-0.85	-15.07	-0.59	2.08e-41	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg15557168	chr22:42548783	NA	0.51	9.49	0.42	1.7e-19	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21659725	chr3:3221576	CRBN	-0.62	-10.46	-0.45	6.34e-23	Intelligence (multi-trait analysis);
LUAD	trans	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg14917512	chr19:3094685	GNA11	-0.56	-6.71	-0.31	6.33e-11	Diabetic kidney disease;
LUAD	cis	rs7680126	0.632	rs78030862	chr4:10150412	G/A	cg02734326	chr4:10020555	SLC2A9	-0.5	-6.73	-0.31	5.43e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.22	-0.57	8.38e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg25730555	chr22:47059586	GRAMD4	0.39	7.19	0.33	3.03e-12	Urate levels in obese individuals;
LUAD	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg09509183	chr1:209979624	IRF6	0.56	7.66	0.35	1.26e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg15017067	chr4:17643749	FAM184B	0.34	6.59	0.31	1.3e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10465746	0.780	rs7551787	chr1:84419297	A/G	cg10977910	chr1:84465055	TTLL7	0.61	10.04	0.44	2.09e-21	Obesity-related traits;
LUAD	cis	rs7582720	1.000	rs72936856	chr2:203775712	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg27432699	chr2:27873401	GPN1	-0.39	-6.64	-0.31	9.37e-11	Total body bone mineral density;
LUAD	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg08219700	chr8:58056026	NA	0.49	7.17	0.33	3.48e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03934478	chr11:495069	RNH1	0.75	8.87	0.4	2.12e-17	Body mass index;
LUAD	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg17264618	chr3:40429014	ENTPD3	0.42	9.06	0.4	4.85e-18	Renal cell carcinoma;
LUAD	cis	rs11209185	0.602	rs1926300	chr1:68439174	G/A	cg22082780	chr1:68452167	NA	0.38	7.53	0.34	3.18e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs714027	1.000	rs1003342	chr22:30570022	A/G	cg11564601	chr22:30592435	NA	0.38	8.28	0.37	1.64e-15	Lymphocyte counts;
LUAD	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg18944383	chr4:111397179	ENPEP	0.42	8.33	0.38	1.15e-15	Height;
LUAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg03354898	chr7:1950403	MAD1L1	-0.38	-6.94	-0.32	1.5e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg13565492	chr6:43139072	SRF	-0.61	-6.45	-0.3	2.99e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2692947	0.644	rs2969491	chr2:96794982	C/T	cg23100626	chr2:96804247	ASTL	0.38	9.9	0.43	6.59e-21	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs17655565	1.000	rs76413558	chr12:52694156	A/G	cg08257133	chr12:52711352	KRT83	0.42	6.89	0.32	1.97e-11	Plasma amyloid beta peptide concentrations (ABx-42);
LUAD	cis	rs12545109	0.879	rs7845180	chr8:57324431	C/T	cg07776626	chr8:57350775	NA	0.62	8.84	0.39	2.57e-17	Obesity-related traits;
LUAD	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06112835	chr11:68658793	MRPL21	0.52	9.44	0.42	2.62e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7927592	0.546	rs683978	chr11:68192421	T/C	cg16797656	chr11:68205561	LRP5	0.5	10.18	0.44	6.19e-22	Total body bone mineral density;
LUAD	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.19	-0.37	3.08e-15	Total body bone mineral density;
LUAD	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21984481	chr17:79567631	NPLOC4	-0.71	-16.9	-0.63	2.38e-49	Eye color traits;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg13482925	chr10:64028750	RTKN2	0.41	6.58	0.3	1.41e-10	Diastolic blood pressure;
LUAD	trans	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.05	-0.32	7.54e-12	Pancreatic cancer;
LUAD	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs7487075	0.619	rs6582658	chr12:46856095	G/A	cg23829395	chr12:46796953	NA	0.31	6.82	0.31	3.16e-11	Itch intensity from mosquito bite;
LUAD	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg22823121	chr1:150693482	HORMAD1	-0.4	-7.97	-0.36	1.46e-14	Tonsillectomy;
LUAD	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg00933542	chr6:150070202	PCMT1	0.45	9.62	0.42	6.28e-20	Lung cancer;
LUAD	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg17120908	chr11:65337727	SSSCA1	-0.58	-9.0	-0.4	7.74e-18	Bone mineral density;
LUAD	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg04545296	chr12:48745243	ZNF641	0.39	9.98	0.44	3.38e-21	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg00745463	chr17:30367425	LRRC37B	0.66	7.91	0.36	2.3e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs4566648	0.548	rs4693596	chr4:84189869	C/T	cg24939380	chr4:84189574	COQ2	0.46	8.41	0.38	6.33e-16	Monocyte count;
LUAD	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.83	-0.32	2.95e-11	Height;Educational attainment;Head circumference (infant);
LUAD	cis	rs494562	0.892	rs7753711	chr6:86130699	G/T	cg27297263	chr6:86160468	NT5E	-0.6	-6.9	-0.32	1.96e-11	Blood metabolite levels;Metabolic traits;
LUAD	trans	rs66573146	1.000	rs56350643	chr4:7017591	G/A	cg07817883	chr1:32538562	TMEM39B	1.51	12.54	0.52	6.81e-31	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs12530845	1.000	rs12540688	chr7:135329690	T/C	cg23117316	chr7:135346802	PL-5283	-0.5	-9.3	-0.41	7.55e-19	Red blood cell traits;
LUAD	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg18190219	chr22:46762943	CELSR1	-0.46	-6.84	-0.32	2.82e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.67	-0.35	1.23e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6688613	0.759	rs61815132	chr1:166920911	A/G	cg07049167	chr1:166818506	POGK	0.54	8.38	0.38	7.93e-16	Refractive astigmatism;
LUAD	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24531977	chr5:56204891	C5orf35	-0.99	-14.94	-0.59	8.01e-41	Initial pursuit acceleration;
LUAD	cis	rs4764487	0.760	rs4764488	chr12:6332910	A/G	cg08284733	chr12:6341482	CD9	0.37	6.65	0.31	8.95e-11	Mean platelet volume;
LUAD	cis	rs11048434	0.736	rs7302417	chr12:9091116	G/T	cg13575925	chr12:9217583	LOC144571	0.39	7.47	0.34	4.7e-13	Sjögren's syndrome;
LUAD	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg18230493	chr5:56204884	C5orf35	-0.45	-7.56	-0.34	2.59e-13	Coronary artery disease;
LUAD	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg17105886	chr17:28927953	LRRC37B2	0.76	7.18	0.33	3.14e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs5756391	0.568	rs10222232	chr22:37317970	A/G	cg16356956	chr22:37317934	CSF2RB	0.31	6.51	0.3	2.07e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs62400317	0.859	rs17209636	chr6:45142517	T/G	cg18551225	chr6:44695536	NA	-0.53	-8.3	-0.37	1.37e-15	Total body bone mineral density;
LUAD	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-15.17	-0.59	8.32e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg10876282	chr6:28092338	ZSCAN16	0.45	7.28	0.33	1.6e-12	Parkinson's disease;
LUAD	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.39	-0.45	1.16e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.06e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg07917127	chr4:99064746	C4orf37	0.39	6.46	0.3	2.96e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg12310025	chr6:25882481	NA	-0.56	-9.14	-0.41	2.61e-18	Blood metabolite levels;
LUAD	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg01571169	chr16:87367721	FBXO31	-0.4	-6.43	-0.3	3.55e-10	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg03929089	chr4:120376271	NA	-0.84	-15.27	-0.6	2.97e-42	Coronary artery disease;
LUAD	cis	rs2412208	0.727	rs7543531	chr1:7072726	A/G	cg20434152	chr1:7120926	CAMTA1	0.28	6.4	0.3	4.19e-10	Survival in sporadic amyotrophic lateral sclerosis;
LUAD	cis	rs151234	0.741	rs151230	chr16:28583215	G/A	cg04609801	chr16:28609176	SULT1A2	0.63	9.08	0.4	4.31e-18	Platelet distribution width;
LUAD	cis	rs4700695	0.719	rs27046	chr5:65439964	G/C	cg21114390	chr5:65439923	SFRS12	-0.97	-15.27	-0.6	2.9e-42	Facial morphology (factor 19);
LUAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs57590327	0.503	rs9874464	chr3:81505488	C/G	cg07356753	chr3:81810745	GBE1	-0.49	-7.61	-0.35	1.77e-13	Extraversion;
LUAD	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.81	0.35	4.6e-14	Depression;
LUAD	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg08470875	chr2:26401718	FAM59B	0.64	7.97	0.36	1.49e-14	Gut microbiome composition (summer);
LUAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg15117754	chr3:10150083	C3orf24	0.42	6.68	0.31	7.38e-11	Alzheimer's disease;
LUAD	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.3	-6.9	-0.32	1.86e-11	Dupuytren's disease;
LUAD	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg26677194	chr12:130822605	PIWIL1	0.55	9.07	0.4	4.52e-18	Menopause (age at onset);
LUAD	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg25358565	chr5:93447407	FAM172A	0.66	7.53	0.34	3.04e-13	Diabetic retinopathy;
LUAD	cis	rs4954585	0.683	rs13004902	chr2:137027680	A/G	cg05194412	chr2:137003533	NA	0.62	11.24	0.48	8.27e-26	Colorectal cancer;
LUAD	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	7.33	0.34	1.18e-12	Parkinson's disease;
LUAD	cis	rs4604732	0.631	rs11490201	chr1:247626262	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg01475377	chr6:109611718	NA	-0.51	-9.38	-0.41	4.05e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg06713675	chr4:122721982	EXOSC9	-0.75	-15.79	-0.61	1.67e-44	Type 2 diabetes;
LUAD	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.41	-8.94	-0.4	1.23e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9394841	0.667	rs9394831	chr6:41753084	C/T	cg17623882	chr6:41773611	USP49	-0.52	-7.34	-0.34	1.1e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg06092702	chr1:163392909	NA	0.38	8.39	0.38	7.52e-16	Motion sickness;
LUAD	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg05082376	chr22:42548792	NA	-0.42	-7.35	-0.34	1e-12	Schizophrenia;
LUAD	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg06064525	chr11:970664	AP2A2	-0.43	-8.35	-0.38	9.54e-16	Alzheimer's disease (late onset);
LUAD	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.42	0.55	1.78e-34	Tonsillectomy;
LUAD	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg03467027	chr4:99064603	C4orf37	0.4	6.42	0.3	3.65e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg03188948	chr7:1209495	NA	0.82	9.95	0.44	4.28e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs877282	0.947	rs12358875	chr10:757531	T/C	cg17470449	chr10:769945	NA	0.59	8.02	0.36	1.07e-14	Uric acid levels;
LUAD	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg00530320	chr1:46809349	NSUN4	0.53	8.23	0.37	2.33e-15	Menopause (age at onset);
LUAD	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18404041	chr3:52824283	ITIH1	-0.62	-12.62	-0.52	3.4e-31	Bipolar disorder;
LUAD	cis	rs344364	0.602	rs8044343	chr16:1881145	G/C	cg08610935	chr16:1836813	NUBP2	-0.5	-7.65	-0.35	1.33e-13	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg18230493	chr5:56204884	C5orf35	-0.84	-12.37	-0.52	3.12e-30	Initial pursuit acceleration;
LUAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg07677032	chr17:61819896	STRADA	-0.57	-10.48	-0.45	5.18e-23	Prudent dietary pattern;
LUAD	cis	rs8017423	0.647	rs4904677	chr14:90819245	C/T	cg14092571	chr14:90743983	NA	0.39	6.63	0.31	1.01e-10	Mortality in heart failure;
LUAD	cis	rs61990749	0.597	rs7147516	chr14:78153980	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.49	-6.36	-0.3	5.27e-10	Fibroblast growth factor basic levels;
LUAD	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg17652424	chr22:38574118	PLA2G6	-0.32	-9.72	-0.43	2.73e-20	Cutaneous nevi;
LUAD	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg09033577	chr2:88485744	THNSL2	-0.53	-6.63	-0.31	1.02e-10	Plasma clusterin levels;
LUAD	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg24640516	chr1:210004059	C1orf107	0.38	6.67	0.31	8.15e-11	Orofacial clefts;
LUAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg05665937	chr4:1216051	CTBP1	0.39	6.64	0.31	9.6e-11	Obesity-related traits;
LUAD	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg19163074	chr7:65112434	INTS4L2	0.44	6.76	0.31	4.58e-11	Aortic root size;
LUAD	cis	rs12618769	0.625	rs4850878	chr2:99112180	T/A	cg10123293	chr2:99228465	UNC50	0.46	8.12	0.37	5.1e-15	Bipolar disorder;
LUAD	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg11822812	chr5:140052017	DND1	-0.4	-7.43	-0.34	6.17e-13	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21659725	chr3:3221576	CRBN	0.69	11.28	0.48	5.53e-26	Resting heart rate;
LUAD	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-7.94	-0.36	1.87e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg21211367	chr2:162094118	NA	0.45	7.97	0.36	1.49e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.52	7.0	0.32	1.01e-11	Platelet count;
LUAD	cis	rs4343996	0.692	rs10258501	chr7:3460355	A/C	cg21248987	chr7:3385318	SDK1	0.35	6.4	0.3	4.17e-10	Motion sickness;
LUAD	cis	rs34638657	0.732	rs10514532	chr16:82200337	C/T	cg09439754	chr16:82129088	HSD17B2	0.35	6.62	0.31	1.09e-10	Lung adenocarcinoma;
LUAD	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg15704280	chr7:45808275	SEPT13	0.81	14.56	0.58	3.35e-39	Height;
LUAD	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.69	0.31	6.95e-11	Depression;
LUAD	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg12365402	chr11:9010492	NRIP3	0.48	9.14	0.41	2.69e-18	Hemoglobin concentration;
LUAD	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.17	-0.44	6.94e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs3823572	0.542	rs2860599	chr7:133648625	C/T	cg03336402	chr7:133662267	EXOC4	0.42	7.74	0.35	7.17e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs7615952	0.546	rs11718647	chr3:125352022	G/A	cg00769240	chr8:12517080	NA	-0.38	-6.58	-0.3	1.38e-10	Blood pressure (smoking interaction);
LUAD	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg00802000	chr16:706648	WDR90	-0.38	-7.14	-0.33	4.15e-12	Height;
LUAD	cis	rs4865169	0.560	rs1277311	chr4:57902761	C/T	cg00922110	chr4:57842668	C4orf14	-0.35	-6.43	-0.3	3.43e-10	Breast cancer;
LUAD	trans	rs800082	1.000	rs9849975	chr3:144294530	A/G	cg24215973	chr2:240111563	HDAC4	-0.42	-6.56	-0.3	1.56e-10	Smoking behavior;
LUAD	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg09904177	chr6:26538194	HMGN4	0.43	7.31	0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs12472274	0.646	rs11688732	chr2:239096622	G/T	cg17459225	chr2:239074497	NA	0.65	7.31	0.33	1.33e-12	Phospholipid levels (plasma);
LUAD	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg17105886	chr17:28927953	LRRC37B2	0.83	8.1	0.37	5.96e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07157834	chr1:205819609	PM20D1	0.84	17.76	0.65	3.97e-53	Menarche (age at onset);
LUAD	cis	rs10193935	0.901	rs6720837	chr2:42463173	A/T	cg27598129	chr2:42591480	NA	-0.64	-8.1	-0.37	6.15e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.32	-6.9	-0.32	1.89e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg19130645	chr7:65235666	NA	-0.47	-7.93	-0.36	1.97e-14	Calcium levels;
LUAD	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.57	-9.66	-0.43	4.45e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs4523957	0.928	rs8077545	chr17:2184555	A/G	cg16513277	chr17:2031491	SMG6	-0.77	-14.4	-0.57	1.47e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg05665937	chr4:1216051	CTBP1	0.42	6.93	0.32	1.59e-11	Obesity-related traits;
LUAD	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg14847009	chr1:175162515	KIAA0040	-0.33	-8.68	-0.39	8.67e-17	Alcohol dependence;
LUAD	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg17063962	chr7:91808500	NA	0.67	11.91	0.5	2.09e-28	Breast cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	ch.1.1180380F	chr1:37182591	NA	-0.39	-6.56	-0.3	1.61e-10	Cancer;
LUAD	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg23254163	chr1:152506842	NA	0.27	7.35	0.34	1.04e-12	Hair morphology;
LUAD	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg26597838	chr10:835615	NA	1.05	16.71	0.63	1.74e-48	Eosinophil percentage of granulocytes;
LUAD	cis	rs3087591	0.919	rs2072131	chr17:29559588	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.42	-6.87	-0.32	2.29e-11	Hip circumference;
LUAD	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07343612	chr16:622815	PIGQ	-0.83	-17.12	-0.64	2.73e-50	Height;
LUAD	cis	rs67311347	0.544	rs6804545	chr3:40354040	G/C	cg02782426	chr3:40428986	ENTPD3	0.35	7.36	0.34	9.46e-13	Renal cell carcinoma;
LUAD	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg00495681	chr13:53174319	NA	0.81	16.15	0.62	4.99e-46	Lewy body disease;
LUAD	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg08885076	chr2:99613938	TSGA10	-0.4	-7.09	-0.33	5.53e-12	Chronic sinus infection;
LUAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg11301795	chr4:187892539	NA	-0.77	-15.68	-0.61	5.23e-44	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7614311	0.731	rs6445387	chr3:63962678	C/G	cg22134162	chr3:63841271	THOC7	-0.42	-7.73	-0.35	8.1e-14	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg13319975	chr6:146136371	FBXO30	-0.65	-11.08	-0.47	3.17e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg22907277	chr7:1156413	C7orf50	0.59	9.9	0.43	6.5e-21	Longevity;Endometriosis;
LUAD	trans	rs9929218	0.954	rs12919719	chr16:68822341	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-13.21	-0.54	1.29e-33	Colorectal cancer;
LUAD	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg04414720	chr1:150670196	GOLPH3L	0.72	13.36	0.54	3.28e-34	Tonsillectomy;
LUAD	cis	rs10465746	0.967	rs12757632	chr1:84416408	T/C	cg10977910	chr1:84465055	TTLL7	0.49	7.97	0.36	1.5e-14	Obesity-related traits;
LUAD	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg26114124	chr12:9217669	LOC144571	0.4	7.27	0.33	1.74e-12	Sjögren's syndrome;
LUAD	cis	rs7224314	0.895	rs11654663	chr17:65389305	A/C	cg01507342	chr17:65387096	PITPNC1	-0.53	-8.87	-0.4	2e-17	Diisocyanate-induced asthma;
LUAD	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-7.23	-0.33	2.31e-12	Morning vs. evening chronotype;
LUAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.45e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg24634471	chr8:143751801	JRK	0.47	7.63	0.35	1.58e-13	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs13082711	0.911	rs13097178	chr3:27527920	T/C	cg02860705	chr3:27208620	NA	0.6	8.88	0.4	1.88e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.47	-7.97	-0.36	1.51e-14	Longevity;Endometriosis;
LUAD	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11890956	chr21:40555474	PSMG1	-0.55	-9.45	-0.42	2.37e-19	Menarche (age at onset);
LUAD	cis	rs526821	0.574	rs11230156	chr11:55334809	A/G	cg04317927	chr11:55418816	OR4S2	0.41	7.8	0.35	4.93e-14	Pediatric bone mineral density (spine);
LUAD	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg12288994	chr5:1860383	NA	0.27	6.48	0.3	2.6e-10	Cardiovascular disease risk factors;
LUAD	cis	rs7301016	1.000	rs11174495	chr12:62864931	A/G	cg11441379	chr12:63026424	NA	0.54	6.9	0.32	1.96e-11	IgG glycosylation;
LUAD	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg18171855	chr10:2543474	NA	-0.37	-7.43	-0.34	6e-13	Age-related hearing impairment;
LUAD	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02018176	chr4:1364513	KIAA1530	0.69	12.07	0.51	5.02e-29	Longevity;
LUAD	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg18876405	chr7:65276391	NA	-0.6	-10.39	-0.45	1.13e-22	Aortic root size;
LUAD	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg22496339	chr2:162101262	NA	-0.46	-6.63	-0.31	1.05e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LUAD	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg03526776	chr6:41159608	TREML2	-0.33	-6.99	-0.32	1.07e-11	Alzheimer's disease (late onset);
LUAD	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg22676075	chr6:135203613	NA	0.42	7.81	0.35	4.58e-14	Red blood cell count;
LUAD	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg10356904	chr22:49881777	NA	-0.4	-7.59	-0.35	2.08e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2479724	0.636	rs1192238	chr6:41803836	C/T	cg17623882	chr6:41773611	USP49	0.53	7.87	0.36	3.08e-14	Menarche (age at onset);
LUAD	cis	rs10736390	1.000	rs11206402	chr1:55104317	G/C	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.77	-14.76	-0.58	4.73e-40	Survival in pancreatic cancer;
LUAD	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg14668632	chr7:2872130	GNA12	-0.43	-7.49	-0.34	4.13e-13	Height;
LUAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg20849893	chr7:64541193	NA	-0.45	-7.29	-0.33	1.59e-12	Calcium levels;
LUAD	cis	rs68170813	0.652	rs17404067	chr7:107168119	G/T	cg02696742	chr7:106810147	HBP1	-0.78	-9.22	-0.41	1.39e-18	Coronary artery disease;
LUAD	cis	rs137699	1.000	rs5757632	chr22:39756097	A/C	cg05872129	chr22:39784769	NA	-0.53	-8.88	-0.4	1.92e-17	IgG glycosylation;
LUAD	cis	rs7517126	1.000	rs2336505	chr1:196843655	A/G	cg07209298	chr1:196795943	CFHR1	0.47	6.38	0.3	4.79e-10	Blood protein levels;
LUAD	trans	rs11088226	1.000	rs11701091	chr21:33920244	T/A	cg09050820	chr6:167586206	TCP10L2	0.56	7.35	0.34	1.01e-12	Gastritis;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg04205485	chr20:32399084	CHMP4B	-0.66	-6.37	-0.3	5.04e-10	Type 2 diabetes;
LUAD	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg27129171	chr3:47204927	SETD2	0.41	6.8	0.31	3.48e-11	Colorectal cancer;
LUAD	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27286337	chr10:134555280	INPP5A	0.7	9.81	0.43	1.37e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6011002	0.808	rs1291211	chr20:62337622	A/G	cg01176363	chr20:62369445	LIME1	-0.69	-6.39	-0.3	4.32e-10	Dental caries;
LUAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	10.68	0.46	9.45e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4523957	0.583	rs2760744	chr17:2017029	T/C	cg16513277	chr17:2031491	SMG6	-0.94	-18.63	-0.67	5.23e-57	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg00071950	chr4:10020882	SLC2A9	0.86	18.34	0.67	1.01e-55	Bone mineral density;
LUAD	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg02631126	chr6:28058918	ZSCAN12L1	-0.32	-6.79	-0.31	3.89e-11	Depression;
LUAD	trans	rs587242	1.000	rs60507779	chr1:96914875	C/A	cg10631902	chr5:14652156	NA	0.46	7.6	0.35	1.96e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg10589385	chr1:150898437	SETDB1	0.43	7.93	0.36	1.93e-14	Melanoma;
LUAD	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg11673840	chr17:47092156	IGF2BP1	-0.34	-6.92	-0.32	1.64e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713675	0.565	rs4713668	chr6:33690796	C/T	cg14003231	chr6:33640908	ITPR3	0.49	9.54	0.42	1.14e-19	Plateletcrit;
LUAD	cis	rs13394619	0.565	rs12478958	chr2:11748037	A/G	cg07314298	chr2:11723111	GREB1	-0.44	-8.11	-0.37	5.63e-15	Endometriosis;
LUAD	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg15448220	chr1:150897856	SETDB1	-0.41	-6.94	-0.32	1.53e-11	Tonsillectomy;
LUAD	cis	rs68170813	0.641	rs77397573	chr7:107006892	G/A	cg23024343	chr7:107201750	COG5	0.52	7.41	0.34	6.99e-13	Coronary artery disease;
LUAD	cis	rs6430585	0.646	rs12468768	chr2:136494985	C/T	cg07169764	chr2:136633963	MCM6	0.77	8.34	0.38	1.04e-15	Corneal structure;
LUAD	cis	rs12367572	0.965	rs10880696	chr12:45234989	A/G	cg04608330	chr12:45269318	NELL2	0.35	6.51	0.3	2.19e-10	Gut microbiome composition (summer);
LUAD	cis	rs7551222	0.716	rs7541589	chr1:204542521	G/A	cg20240347	chr1:204465584	NA	-0.34	-6.44	-0.3	3.23e-10	Schizophrenia;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg00013441	chr12:123258908	CCDC62	-0.41	-6.37	-0.3	4.93e-10	Vertical cup-disc ratio;
LUAD	cis	rs1451375	0.652	rs7803903	chr7:50625945	C/T	cg18232548	chr7:50535776	DDC	0.5	7.21	0.33	2.56e-12	Malaria;
LUAD	cis	rs654384	0.798	rs12701426	chr7:4176315	A/G	cg26275264	chr7:4183598	SDK1	-0.38	-7.36	-0.34	9.79e-13	Positive affect;
LUAD	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg07606381	chr6:8435919	SLC35B3	0.42	7.03	0.32	8.57e-12	Motion sickness;
LUAD	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg11301795	chr4:187892539	NA	0.73	14.56	0.58	3.34e-39	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7220401	0.789	rs4794859	chr17:27962393	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.43	-6.89	-0.32	2.06e-11	Coronary artery disease;
LUAD	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.66	12.39	0.52	2.62e-30	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs57994353	0.861	rs34302850	chr9:139327064	A/G	cg14169450	chr9:139327907	INPP5E	0.41	7.03	0.32	8.39e-12	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg01874867	chr7:94954059	PON1	-0.5	-6.92	-0.32	1.69e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4356932	1.000	rs3921	chr4:76942943	C/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.35	-6.4	-0.3	4.13e-10	Blood protein levels;
LUAD	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	12.43	0.52	1.87e-30	Monocyte percentage of white cells;
LUAD	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.73	0.31	5.51e-11	Menarche (age at onset);
LUAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg00431813	chr7:1051703	C7orf50	-0.44	-8.34	-0.38	1.06e-15	Longevity;Endometriosis;
LUAD	cis	rs853679	0.607	rs72846794	chr6:28137499	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.56	6.53	0.3	1.91e-10	Depression;
LUAD	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg03684893	chr10:554711	DIP2C	-0.5	-9.46	-0.42	2.18e-19	Psychosis in Alzheimer's disease;
LUAD	cis	rs6906287	0.647	rs973944	chr6:118850956	T/G	cg05564266	chr6:118973597	C6orf204	0.35	7.43	0.34	6.24e-13	Electrocardiographic conduction measures;
LUAD	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg00745463	chr17:30367425	LRRC37B	-0.97	-11.75	-0.5	8.7e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg07423050	chr13:99094983	FARP1	-0.54	-9.06	-0.4	4.8e-18	Longevity;
LUAD	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg12311346	chr5:56204834	C5orf35	-0.92	-13.64	-0.55	2.32e-35	Initial pursuit acceleration;
LUAD	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.57	-8.85	-0.4	2.37e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06022373	chr22:39101656	GTPBP1	0.47	7.3	0.33	1.43e-12	Menopause (age at onset);
LUAD	cis	rs9972944	0.729	rs1895035	chr17:63777711	G/A	cg07283582	chr17:63770753	CCDC46	0.49	10.6	0.46	1.87e-23	Total body bone mineral density;
LUAD	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.27	-7.03	-0.32	8.57e-12	Total body bone mineral density;
LUAD	cis	rs2294693	0.945	rs2073015	chr6:41008747	A/G	cg14769373	chr6:40998127	UNC5CL	-0.5	-7.6	-0.35	1.9e-13	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Depression;
LUAD	trans	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17712092	chr4:129076599	LARP1B	0.85	15.9	0.61	5.89e-45	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs7771547	0.519	rs12206445	chr6:36379628	G/A	cg07856975	chr6:36356162	ETV7	0.56	8.25	0.37	2e-15	Platelet distribution width;
LUAD	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg19052272	chr2:3704530	ALLC	-0.62	-10.57	-0.46	2.5e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.64	-0.42	5.01e-20	Schizophrenia;
LUAD	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg18833306	chr6:118973337	C6orf204	-0.53	-7.55	-0.34	2.68e-13	Diastolic blood pressure;
LUAD	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg03690763	chr11:133734501	NA	-0.28	-6.74	-0.31	5.11e-11	Childhood ear infection;
LUAD	cis	rs3820068	0.705	rs4646022	chr1:15839112	G/A	cg24675056	chr1:15929824	NA	0.42	6.78	0.31	3.98e-11	Systolic blood pressure;
LUAD	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.52	-8.82	-0.39	2.92e-17	Alzheimer's disease (late onset);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg25944898	chr11:64085532	PRDX5;TRMT112	-0.68	-6.46	-0.3	2.8e-10	Type 2 diabetes;
LUAD	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg01065977	chr19:18549689	ISYNA1	0.42	8.03	0.36	1.01e-14	Breast cancer;
LUAD	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg22875332	chr1:76189707	ACADM	0.73	11.32	0.48	3.82e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg01579765	chr21:45077557	HSF2BP	0.55	11.82	0.5	4.65e-28	Mean corpuscular volume;
LUAD	cis	rs490234	0.902	rs12351538	chr9:128281503	A/G	cg14078157	chr9:128172775	NA	-0.37	-6.69	-0.31	7.04e-11	Mean arterial pressure;
LUAD	cis	rs6542838	0.673	rs13005148	chr2:99467538	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.75	-0.31	4.86e-11	Fear of minor pain;
LUAD	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.99	0.32	1.07e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg24634471	chr8:143751801	JRK	0.49	7.89	0.36	2.53e-14	Schizophrenia;
LUAD	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg05425664	chr17:57184151	TRIM37	-0.37	-6.39	-0.3	4.34e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg22535103	chr8:58192502	C8orf71	-0.73	-10.55	-0.46	3.02e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg07917127	chr4:99064746	C4orf37	0.39	6.58	0.3	1.37e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg01579765	chr21:45077557	HSF2BP	-0.61	-13.38	-0.55	2.69e-34	Mean corpuscular volume;
LUAD	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg10523679	chr1:76189770	ACADM	-0.45	-6.41	-0.3	3.83e-10	Daytime sleep phenotypes;
LUAD	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg18944383	chr4:111397179	ENPEP	0.41	8.11	0.37	5.53e-15	Height;
LUAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg22535103	chr8:58192502	C8orf71	-0.55	-7.27	-0.33	1.76e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs420259	0.516	rs2072062	chr16:23540798	C/T	cg00143387	chr16:23521605	GGA2	-0.7	-9.63	-0.42	5.6e-20	Bipolar disorder;
LUAD	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08109568	chr15:31115862	NA	-0.78	-13.94	-0.56	1.35e-36	Huntington's disease progression;
LUAD	cis	rs240764	0.697	rs370757	chr6:101134156	T/C	cg09795085	chr6:101329169	ASCC3	0.4	6.74	0.31	5.14e-11	Neuroticism;
LUAD	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg21862992	chr11:68658383	NA	-0.5	-9.16	-0.41	2.21e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.82	-0.36	4.23e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs78761021	0.720	rs56086072	chr17:9798412	C/T	cg26853458	chr17:9805074	RCVRN	0.42	8.01	0.36	1.09e-14	Type 2 diabetes;
LUAD	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg00300879	chr1:26503847	CNKSR1	0.29	8.53	0.38	2.57e-16	Height;
LUAD	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06028605	chr16:24865363	SLC5A11	-0.52	-7.79	-0.35	5.22e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg00277334	chr10:82204260	NA	-0.56	-9.27	-0.41	9.67e-19	Post bronchodilator FEV1;
LUAD	cis	rs10489202	0.632	rs3767476	chr1:168066940	C/T	cg25738037	chr1:168025549	DCAF6	-0.45	-6.63	-0.31	1.05e-10	Schizophrenia;
LUAD	cis	rs3820068	0.655	rs72645826	chr1:15889741	A/G	cg24675056	chr1:15929824	NA	0.43	6.78	0.31	4.1e-11	Systolic blood pressure;
LUAD	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.99	21.75	0.73	6.07e-71	Chronic sinus infection;
LUAD	cis	rs12545109	0.800	rs1440747	chr8:57417924	G/T	cg21220214	chr8:57350948	NA	0.61	8.49	0.38	3.45e-16	Obesity-related traits;
LUAD	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg17724175	chr1:150552817	MCL1	0.32	7.7	0.35	9.81e-14	Melanoma;
LUAD	cis	rs17532515	0.652	rs56146404	chr4:141381040	C/T	cg03645522	chr4:141391200	NA	0.39	6.41	0.3	3.92e-10	Select biomarker traits;
LUAD	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg21214613	chr1:16344536	HSPB7	0.56	10.18	0.44	6.46e-22	Dilated cardiomyopathy;
LUAD	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	10.66	0.46	1.14e-23	Hip circumference adjusted for BMI;
LUAD	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg01874867	chr7:94954059	PON1	-0.48	-6.47	-0.3	2.74e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg22596557	chr22:38142152	TRIOBP	-0.49	-6.6	-0.31	1.24e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg02990361	chr1:107599529	PRMT6	-0.52	-8.99	-0.4	8.34e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs3791556	1.000	rs2411429	chr2:240113928	A/G	cg03281426	chr2:240109471	HDAC4	0.47	8.1	0.37	5.76e-15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.09e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg04756594	chr16:24857601	SLC5A11	-0.57	-9.7	-0.43	3.18e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs9486719	1.000	rs2472888	chr6:96865501	T/C	cg06623918	chr6:96969491	KIAA0776	0.71	9.98	0.44	3.33e-21	Migraine;Coronary artery disease;
LUAD	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23158103	chr7:148848205	ZNF398	-0.61	-11.02	-0.47	5.36e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg03188948	chr7:1209495	NA	0.66	9.51	0.42	1.41e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7428	0.545	rs7572750	chr2:85552186	C/A	cg24342717	chr2:85555507	TGOLN2	-0.48	-7.8	-0.35	4.93e-14	Ear protrusion;
LUAD	cis	rs4356932	1.000	rs10025102	chr4:76955358	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.54	-0.3	1.78e-10	Blood protein levels;
LUAD	cis	rs938554	0.736	rs4697699	chr4:9945722	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.17	-0.33	3.3e-12	Blood metabolite levels;
LUAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg13397359	chr6:42928475	GNMT	0.72	14.73	0.58	6.34e-40	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs295140	0.605	rs159320	chr2:201187775	A/G	cg23649088	chr2:200775458	C2orf69	0.45	7.79	0.35	5.23e-14	QT interval;
LUAD	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg02158880	chr13:53174818	NA	0.51	8.85	0.4	2.39e-17	Lewy body disease;
LUAD	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.22e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10203711	1.000	rs907100	chr2:239563579	G/C	cg14580085	chr2:239553406	NA	0.4	8.51	0.38	3.07e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg06618935	chr21:46677482	NA	-0.51	-10.01	-0.44	2.7e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg11189052	chr15:85197271	WDR73	-0.78	-13.5	-0.55	8.5e-35	P wave terminal force;
LUAD	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.74	13.57	0.55	4.45e-35	Axial length;
LUAD	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg11663144	chr21:46675770	NA	-0.62	-11.76	-0.5	8.05e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7662987	1.000	rs7683704	chr4:100004226	C/T	cg12011299	chr4:100065546	ADH4	-0.58	-6.51	-0.3	2.09e-10	Smoking initiation;
LUAD	cis	rs6066825	0.590	rs6063307	chr20:47304045	A/G	cg18078177	chr20:47281410	PREX1	0.41	6.92	0.32	1.69e-11	Colorectal cancer;
LUAD	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg12564285	chr5:131593104	PDLIM4	0.37	6.44	0.3	3.2e-10	Breast cancer;
LUAD	cis	rs7116495	0.737	rs7126838	chr11:71826237	A/G	cg07596299	chr11:71824057	C11orf51	0.75	6.51	0.3	2.2e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs2625529	0.556	rs1552134	chr15:72232898	T/A	cg16672083	chr15:72433130	SENP8	0.62	11.47	0.49	1.07e-26	Red blood cell count;
LUAD	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg01475377	chr6:109611718	NA	-0.54	-10.42	-0.45	8.98e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg03806693	chr22:41940476	POLR3H	0.53	7.85	0.36	3.52e-14	Vitiligo;
LUAD	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg02038168	chr22:39784481	NA	0.56	10.0	0.44	2.93e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg18180107	chr4:99064573	C4orf37	0.46	7.22	0.33	2.39e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg08132940	chr7:1081526	C7orf50	-0.73	-9.72	-0.43	2.72e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg01503450	chr10:980765	NA	-0.37	-6.42	-0.3	3.61e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg25753631	chr6:25732923	NA	-0.44	-7.83	-0.36	3.95e-14	Iron status biomarkers;
LUAD	trans	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg06263672	chr7:65235340	NA	0.47	6.56	0.3	1.62e-10	Aortic root size;
LUAD	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg13271783	chr10:134563150	INPP5A	-0.41	-6.68	-0.31	7.32e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08219700	chr8:58056026	NA	0.63	8.88	0.4	1.9e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	10.36	0.45	1.42e-22	Colorectal cancer;
LUAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg11941060	chr3:133502564	NA	0.61	11.0	0.47	6.14e-25	Iron status biomarkers;
LUAD	cis	rs3784262	1.000	rs11855259	chr15:58249377	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.45	-9.25	-0.41	1.14e-18	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg04678565	chr6:33539085	NA	-0.68	-6.89	-0.32	2.09e-11	Type 2 diabetes;
LUAD	cis	rs1003719	0.751	rs56268364	chr21:38542765	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.44	-0.38	5.25e-16	Eye color traits;
LUAD	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg08847533	chr14:75593920	NEK9	0.42	7.2	0.33	2.76e-12	Height;
LUAD	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg07936489	chr17:37558343	FBXL20	-0.47	-7.54	-0.34	2.9e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.54	-9.56	-0.42	1.01e-19	Axial length;
LUAD	cis	rs727505	0.954	rs59379598	chr7:124596903	C/G	cg23710748	chr7:124431027	NA	-0.43	-8.41	-0.38	6.39e-16	Lewy body disease;
LUAD	cis	rs654950	1.000	rs646228	chr1:41986066	A/C	cg06885757	chr1:42089581	HIVEP3	0.44	9.64	0.42	5.09e-20	Airway imaging phenotypes;
LUAD	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	7.88	0.36	2.82e-14	Tonsillectomy;
LUAD	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18099408	chr3:52552593	STAB1	0.4	7.3	0.33	1.45e-12	Bipolar disorder;
LUAD	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg13385794	chr1:248469461	NA	0.27	7.22	0.33	2.4e-12	Common traits (Other);
LUAD	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg11494091	chr17:61959527	GH2	0.42	7.69	0.35	1.01e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs657075	0.697	rs2073645	chr5:131724814	A/G	cg21138405	chr5:131827807	IRF1	0.53	6.47	0.3	2.71e-10	Rheumatoid arthritis;
LUAD	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg06718696	chr17:78121285	EIF4A3	-0.62	-9.16	-0.41	2.3e-18	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg03477792	chr4:77819574	ANKRD56	0.49	7.36	0.34	9.35e-13	Emphysema distribution in smoking;
LUAD	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg00933542	chr6:150070202	PCMT1	0.46	9.97	0.44	3.54e-21	Lung cancer;
LUAD	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg13319975	chr6:146136371	FBXO30	-0.55	-9.16	-0.41	2.33e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg23018236	chr17:30244563	NA	-0.68	-8.23	-0.37	2.28e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22857025	chr5:266934	NA	-0.93	-14.61	-0.58	1.91e-39	Breast cancer;
LUAD	cis	rs367943	0.712	rs6867397	chr5:112725759	C/T	cg12552261	chr5:112820674	MCC	-0.5	-9.65	-0.42	4.97e-20	Type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg13047869	chr3:10149882	C3orf24	0.66	11.16	0.48	1.61e-25	Alzheimer's disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21552867	chr2:84686507	SUCLG1	-0.39	-6.41	-0.3	3.98e-10	Cancer;
LUAD	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg03388025	chr16:89894329	SPIRE2	0.5	13.07	0.54	5.02e-33	Vitiligo;
LUAD	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg17063962	chr7:91808500	NA	0.68	12.31	0.51	5.78e-30	Breast cancer;
LUAD	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg11909912	chr17:43974919	MAPT;LOC100130148	0.4	6.83	0.32	2.96e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7903847	0.642	rs11189191	chr10:99148796	T/C	cg08345082	chr10:99160200	RRP12	-0.35	-6.91	-0.32	1.83e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg09085632	chr11:111637200	PPP2R1B	0.62	9.27	0.41	9.68e-19	Primary sclerosing cholangitis;
LUAD	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.37	-0.41	4.57e-19	Type 2 diabetes;
LUAD	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg22823121	chr1:150693482	HORMAD1	-0.39	-7.76	-0.35	6.47e-14	Tonsillectomy;
LUAD	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg21918786	chr6:109611834	NA	-0.6	-11.05	-0.47	4.09e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg17063962	chr7:91808500	NA	0.67	11.86	0.5	3.21e-28	Breast cancer;
LUAD	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg06064525	chr11:970664	AP2A2	-0.53	-10.86	-0.47	2.05e-24	Alzheimer's disease (late onset);
LUAD	cis	rs2224391	0.737	rs36117780	chr6:5262233	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-9.82	-0.43	1.22e-20	Height;
LUAD	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg22852734	chr6:133119734	C6orf192	0.73	8.4	0.38	6.68e-16	Type 2 diabetes nephropathy;
LUAD	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22496380	chr5:211416	CCDC127	-0.92	-12.49	-0.52	1.08e-30	Breast cancer;
LUAD	cis	rs7017914	0.934	rs35109143	chr8:71577900	C/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.52	-0.3	1.98e-10	Bone mineral density;
LUAD	cis	rs35883536	1.000	rs2491822	chr1:101115839	T/C	cg06223162	chr1:101003688	GPR88	-0.37	-6.92	-0.32	1.72e-11	Monocyte count;
LUAD	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg27219399	chr15:67835830	MAP2K5	0.41	6.52	0.3	1.97e-10	Restless legs syndrome;
LUAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg27588902	chr6:42928151	GNMT	-0.37	-9.72	-0.43	2.66e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs751837	0.591	rs10131775	chr14:103422829	G/A	cg10087771	chr14:103399429	CDC42BPB	0.69	6.87	0.32	2.35e-11	Large B-cell lymphoma;
LUAD	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.2	-0.37	2.92e-15	Total body bone mineral density;
LUAD	cis	rs9486719	0.948	rs2472906	chr6:96875318	G/T	cg06623918	chr6:96969491	KIAA0776	0.71	10.02	0.44	2.32e-21	Migraine;Coronary artery disease;
LUAD	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.76	0.31	4.45e-11	Parkinson's disease;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10519680	chr8:37707506	BRF2	0.42	6.4	0.3	4.05e-10	Monocyte percentage of white cells;
LUAD	cis	rs6723108	0.702	rs55920206	chr2:135432066	C/T	cg12500956	chr2:135428796	TMEM163	-0.28	-7.65	-0.35	1.37e-13	Type 2 diabetes;
LUAD	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg03806693	chr22:41940476	POLR3H	-0.75	-9.98	-0.44	3.39e-21	Vitiligo;
LUAD	cis	rs2882667	0.861	rs10043676	chr5:138389561	C/T	cg04439458	chr5:138467593	SIL1	-0.4	-7.35	-0.34	1.02e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg27170947	chr2:26402098	FAM59B	-0.84	-12.31	-0.51	5.6e-30	Gut microbiome composition (summer);
LUAD	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg19163074	chr7:65112434	INTS4L2	0.44	6.75	0.31	5e-11	Aortic root size;
LUAD	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg20917491	chr3:195578259	NA	0.4	6.4	0.3	4.09e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.4	-7.31	-0.33	1.37e-12	Urate levels in overweight individuals;
LUAD	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg11502198	chr6:26597334	ABT1	0.64	11.17	0.48	1.48e-25	Intelligence (multi-trait analysis);
LUAD	trans	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg06606381	chr12:133084897	FBRSL1	-0.79	-8.12	-0.37	5.1e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10865541	0.934	rs4627605	chr2:3411923	G/A	cg13173536	chr2:3403300	TTC15	-0.34	-6.97	-0.32	1.25e-11	Obesity-related traits;
LUAD	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg04703951	chr17:43578652	NA	0.56	7.69	0.35	1.02e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.01	10.88	0.47	1.81e-24	Initial pursuit acceleration;
LUAD	cis	rs9826463	0.582	rs2291363	chr3:142116151	A/G	cg20824294	chr3:142316082	PLS1	0.38	6.38	0.3	4.62e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	trans	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	17.11	0.64	3e-50	Exhaled nitric oxide output;
LUAD	cis	rs7319311	0.899	rs9521729	chr13:111029970	G/A	cg05272587	chr13:111038400	COL4A2	0.4	6.86	0.32	2.51e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs57590327	0.503	rs12152272	chr3:81911684	G/A	cg07356753	chr3:81810745	GBE1	-0.58	-9.23	-0.41	1.33e-18	Extraversion;
LUAD	trans	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.74	0.46	5.74e-24	Exhaled nitric oxide output;
LUAD	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg26408565	chr15:76604113	ETFA	0.54	9.56	0.42	9.64e-20	Blood metabolite levels;
LUAD	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.19	14.9	0.59	1.18e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs77106637	0.722	rs11605691	chr11:72419514	C/T	cg03878208	chr11:72483293	STARD10	0.57	7.22	0.33	2.38e-12	Type 2 diabetes;
LUAD	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg24069376	chr3:38537580	EXOG	0.34	7.84	0.36	3.81e-14	Electrocardiographic conduction measures;
LUAD	cis	rs2880765	0.835	rs4280192	chr15:86043020	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.37	-6.35	-0.3	5.56e-10	Coronary artery disease;
LUAD	trans	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg18335740	chr13:41363409	SLC25A15	0.6	11.06	0.47	3.87e-25	Lewy body disease;
LUAD	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.78	10.59	0.46	2.14e-23	Smoking behavior;
LUAD	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg00310523	chr12:86230176	RASSF9	-0.34	-7.25	-0.33	1.94e-12	Major depressive disorder;
LUAD	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.45	-0.34	5.34e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg26304593	chr6:42947056	PEX6	-0.46	-7.8	-0.35	4.82e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26251429	chr2:28113398	BRE;RBKS;LOC100302650	-0.54	-6.51	-0.3	2.16e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg17747265	chr1:1875780	NA	-0.74	-17.99	-0.66	3.87e-54	Body mass index;
LUAD	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg17366294	chr4:99064904	C4orf37	-0.48	-8.53	-0.38	2.66e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg03676636	chr4:99064102	C4orf37	0.32	8.24	0.37	2.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.95	13.85	0.56	3.17e-36	Schizophrenia;
LUAD	trans	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg07817883	chr1:32538562	TMEM39B	1.26	12.1	0.51	3.85e-29	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg16205897	chr5:131564050	P4HA2	-0.46	-10.89	-0.47	1.61e-24	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10169971	chr6:83902988	RWDD2A;PGM3	-0.54	-6.56	-0.3	1.6e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03797768	chr13:24040813	NA	0.41	6.83	0.32	2.97e-11	Gut microbiome composition (summer);
LUAD	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.59	8.52	0.38	2.93e-16	Platelet count;
LUAD	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg16342193	chr10:102329863	NA	-0.37	-6.59	-0.31	1.27e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg19318889	chr4:1322082	MAEA	-0.75	-12.81	-0.53	5.77e-32	Obesity-related traits;
LUAD	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg02527881	chr3:46936655	PTH1R	0.45	8.79	0.39	3.82e-17	Colorectal cancer;
LUAD	cis	rs68170813	0.641	rs12532953	chr7:106865920	C/T	cg23024343	chr7:107201750	COG5	0.49	7.03	0.32	8.41e-12	Coronary artery disease;
LUAD	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06544989	chr22:39130855	UNC84B	-0.41	-7.7	-0.35	9.98e-14	Menopause (age at onset);
LUAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.56	-9.91	-0.43	5.85e-21	Longevity;Endometriosis;
LUAD	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg14343924	chr8:8086146	FLJ10661	0.46	7.08	0.33	6.13e-12	Mood instability;
LUAD	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11644478	chr21:40555479	PSMG1	0.69	11.55	0.49	5.09e-27	Cognitive function;
LUAD	cis	rs71191701	1.000	rs71191701	chr9:139322257	G/C	cg14169450	chr9:139327907	INPP5E	0.46	7.9	0.36	2.38e-14	Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LUAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18402987	chr7:1209562	NA	0.46	7.82	0.36	4.33e-14	Longevity;Endometriosis;
LUAD	cis	rs76419734	0.510	rs2544417	chr4:106745405	A/G	cg05309399	chr4:106552544	FLJ20184	0.51	7.06	0.32	6.69e-12	Post bronchodilator FEV1;
LUAD	trans	rs11054731	1.000	rs10845501	chr12:12415697	A/G	cg10577346	chr11:8704225	RPL27A	0.39	6.38	0.3	4.75e-10	Coronary artery calcification;
LUAD	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg26811252	chr16:29126840	RRN3P2	0.67	11.22	0.48	9.73e-26	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg12458913	chr13:53173898	NA	0.35	6.41	0.3	3.93e-10	Lewy body disease;
LUAD	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03452623	chr4:187889614	NA	0.8	16.17	0.62	3.8e-46	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg21095983	chr6:86352623	SYNCRIP	0.46	7.21	0.33	2.6e-12	Smooth-surface caries;
LUAD	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg18944383	chr4:111397179	ENPEP	0.38	7.66	0.35	1.31e-13	Height;
LUAD	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.92	0.32	1.64e-11	Motion sickness;
LUAD	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg10639395	chr11:8710044	RPL27A	-0.33	-6.62	-0.31	1.09e-10	Hemoglobin concentration;
LUAD	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg07617317	chr6:118971624	C6orf204	0.55	8.33	0.38	1.14e-15	Diastolic blood pressure;
LUAD	cis	rs9914988	0.943	rs2043032	chr17:27136692	A/G	cg02049041	chr17:27085579	C17orf63	0.57	7.03	0.32	8.29e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1941023	0.503	rs7944025	chr11:60142538	C/A	cg08716584	chr11:60157161	MS4A7	-0.49	-9.39	-0.42	3.68e-19	Congenital heart disease (maternal effect);
LUAD	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg22442454	chr1:209979470	IRF6	0.54	7.28	0.33	1.67e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg10518543	chr12:38710700	ALG10B	-0.44	-7.15	-0.33	3.73e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs3096299	0.809	rs2911264	chr16:89499272	A/C	cg06640241	chr16:89574553	SPG7	0.51	8.43	0.38	5.31e-16	Multiple myeloma (IgH translocation);
LUAD	cis	rs9560113	1.000	rs9555807	chr13:112179965	C/T	cg14154082	chr13:112174009	NA	0.37	6.87	0.32	2.33e-11	Menarche (age at onset);
LUAD	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg18105134	chr13:113819100	PROZ	-0.85	-15.09	-0.59	1.87e-41	Platelet distribution width;
LUAD	cis	rs908922	0.676	rs578382	chr1:152514054	A/G	cg20991723	chr1:152506922	NA	-0.33	-6.61	-0.31	1.18e-10	Hair morphology;
LUAD	cis	rs7107174	1.000	rs2510051	chr11:77981171	A/C	cg02023728	chr11:77925099	USP35	0.49	7.57	0.35	2.43e-13	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg14664628	chr15:75095509	CSK	-0.49	-8.28	-0.37	1.61e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg26587870	chr6:27730563	NA	-0.76	-8.31	-0.37	1.32e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12681287	0.640	rs7816275	chr8:87373404	A/G	cg27223183	chr8:87520930	FAM82B	0.68	9.54	0.42	1.19e-19	Caudate activity during reward;
LUAD	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg06108461	chr20:60628389	TAF4	-0.94	-16.8	-0.63	6.65e-49	Body mass index;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg24511731	chr8:133787538	PHF20L1	-0.64	-6.64	-0.31	9.61e-11	Type 2 diabetes;
LUAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg09060608	chr5:178986726	RUFY1	0.67	10.09	0.44	1.39e-21	Lung cancer;
LUAD	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg25738037	chr1:168025549	DCAF6	-0.5	-7.49	-0.34	3.98e-13	Schizophrenia;
LUAD	cis	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg02508848	chr16:68573721	ZFP90	-0.42	-6.55	-0.3	1.72e-10	Ulcerative colitis;
LUAD	cis	rs3820068	0.705	rs4646103	chr1:15819827	T/A	cg24675056	chr1:15929824	NA	0.43	6.82	0.31	3.21e-11	Systolic blood pressure;
LUAD	trans	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg26043149	chr18:55253948	FECH	-0.48	-8.21	-0.37	2.64e-15	Bone mineral density;
LUAD	cis	rs2777491	0.574	rs2730056	chr15:41735785	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.11	-23.25	-0.75	1.23e-77	Ulcerative colitis;
LUAD	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.19	-0.33	3.02e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg11062466	chr8:58055876	NA	0.68	8.43	0.38	5.68e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg18854424	chr1:2615690	NA	0.43	9.43	0.42	2.76e-19	Ulcerative colitis;
LUAD	cis	rs1904096	0.506	rs6841121	chr4:95222995	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.52	-9.92	-0.43	5.42e-21	Type 2 diabetes;
LUAD	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.41	-0.55	1.98e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.55	9.07	0.4	4.47e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg06641503	chr3:48959341	ARIH2	-0.41	-7.19	-0.33	3.06e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg02931644	chr1:25747376	RHCE	0.43	9.18	0.41	1.95e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg06640241	chr16:89574553	SPG7	0.46	7.43	0.34	6.07e-13	Multiple myeloma (IgH translocation);
LUAD	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21659725	chr3:3221576	CRBN	-0.64	-10.1	-0.44	1.27e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7192380	1.000	rs8061052	chr16:69656532	G/A	cg26679644	chr16:69762563	NA	0.49	9.51	0.42	1.5e-19	Sjögren's syndrome;
LUAD	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg17264618	chr3:40429014	ENTPD3	0.42	9.16	0.41	2.32e-18	Renal cell carcinoma;
LUAD	cis	rs1832871	0.541	rs62438579	chr6:158873858	T/A	cg07165851	chr6:158734300	TULP4	0.5	7.36	0.34	9.66e-13	Height;
LUAD	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-7.89	-0.36	2.62e-14	Breast cancer;
LUAD	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg24596788	chr1:163392923	NA	-0.37	-8.16	-0.37	3.9e-15	Motion sickness;
LUAD	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg17147758	chr8:6949321	NA	-0.5	-8.91	-0.4	1.56e-17	Blood pressure (smoking interaction);
LUAD	cis	rs7580658	0.545	rs13006847	chr2:127952263	C/T	cg16751203	chr2:127950803	CYP27C1	-0.4	-6.83	-0.32	3.01e-11	Protein C levels;
LUAD	cis	rs9560113	1.000	rs4773384	chr13:112177987	A/G	cg14154082	chr13:112174009	NA	0.37	6.87	0.32	2.32e-11	Menarche (age at onset);
LUAD	cis	rs868036	1.000	rs7168156	chr15:68102933	T/C	cg08079166	chr15:68083412	MAP2K5	0.3	6.49	0.3	2.39e-10	Restless legs syndrome;
LUAD	trans	rs11644601	1	rs11644601	chr16:15172118	T/C	cg04146151	chr16:2155961	PKD1	-0.5	-7.73	-0.35	8.07e-14	Metabolite levels (lipid measures);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01256882	chr5:1271100	TERT	0.49	6.4	0.3	4.08e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs295140	0.565	rs295139	chr2:201159988	T/A	cg23649088	chr2:200775458	C2orf69	0.5	8.56	0.38	2.12e-16	QT interval;
LUAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.59	0.31	1.28e-10	Prudent dietary pattern;
LUAD	cis	rs9868809	0.881	rs13076269	chr3:48675925	T/C	cg00383909	chr3:49044727	WDR6	0.62	6.91	0.32	1.74e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1816752	0.870	rs8000215	chr13:25009786	A/G	cg02811702	chr13:24901961	NA	0.44	7.48	0.34	4.29e-13	Obesity-related traits;
LUAD	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg04455712	chr21:45112962	RRP1B	0.46	9.04	0.4	5.77e-18	Mean corpuscular volume;
LUAD	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-23.52	-0.75	7.74e-79	Height;
LUAD	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg13319975	chr6:146136371	FBXO30	-0.61	-10.54	-0.46	3.21e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg17279839	chr7:150038598	RARRES2	0.47	7.86	0.36	3.31e-14	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02294249	chr13:34392492	RFC3	-0.43	-6.7	-0.31	6.64e-11	Height;
LUAD	cis	rs113835537	0.529	rs3179961	chr11:66244454	A/G	cg24851651	chr11:66362959	CCS	0.57	9.97	0.44	3.7e-21	Airway imaging phenotypes;
LUAD	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg07432352	chr17:45403706	C17orf57	0.35	6.58	0.3	1.36e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7771547	0.723	rs2145048	chr6:36557580	C/A	cg07856975	chr6:36356162	ETV7	0.45	6.39	0.3	4.32e-10	Platelet distribution width;
LUAD	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg06623918	chr6:96969491	KIAA0776	0.89	17.71	0.65	6.38e-53	Headache;
LUAD	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg17063962	chr7:91808500	NA	0.62	10.02	0.44	2.34e-21	Breast cancer;
LUAD	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-7.31	-0.34	1.3e-12	Glaucoma (primary open-angle);
LUAD	trans	rs7395662	1.000	rs4882096	chr11:48534102	T/G	cg15704280	chr7:45808275	SEPT13	-0.41	-6.41	-0.3	3.84e-10	HDL cholesterol;
LUAD	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg16102102	chr5:83017553	HAPLN1	-0.79	-13.13	-0.54	2.9e-33	Prostate cancer;
LUAD	cis	rs9517313	0.554	rs3809366	chr13:99230266	C/T	cg07423050	chr13:99094983	FARP1	-0.56	-9.28	-0.41	8.58e-19	Neuroticism;
LUAD	trans	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg16006296	chr10:38738647	LOC399744	0.35	6.44	0.3	3.25e-10	Diastolic blood pressure;
LUAD	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg16680214	chr1:154839983	KCNN3	-0.67	-14.15	-0.57	1.73e-37	Prostate cancer;
LUAD	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.7	-0.46	8.46e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg04539111	chr16:67997858	SLC12A4	-0.52	-6.51	-0.3	2.14e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg18129748	chr3:49941408	MST1R	-0.4	-6.58	-0.3	1.38e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9768139	0.708	rs36064654	chr7:158116632	C/T	cg25566285	chr7:158114605	PTPRN2	0.53	11.24	0.48	7.86e-26	Calcium levels;
LUAD	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg02228675	chr17:40259724	DHX58	-0.43	-6.82	-0.31	3.2e-11	Fibrinogen levels;
LUAD	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21582582	chr3:182698605	DCUN1D1	0.58	9.74	0.43	2.32e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.47	-0.34	4.65e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs9393692	0.557	rs12660432	chr6:26317384	C/T	cg00631329	chr6:26305371	NA	-0.56	-9.44	-0.42	2.62e-19	Educational attainment;
LUAD	cis	rs7301826	1.000	rs4759793	chr12:131297238	A/G	cg11011512	chr12:131303247	STX2	0.39	6.71	0.31	6.14e-11	Plasma plasminogen activator levels;
LUAD	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg00339695	chr16:24857497	SLC5A11	0.7	11.33	0.48	3.71e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.41	-0.45	9.44e-23	Glomerular filtration rate;
LUAD	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.59	0.31	1.32e-10	Prudent dietary pattern;
LUAD	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg03806693	chr22:41940476	POLR3H	0.74	10.04	0.44	1.97e-21	Vitiligo;
LUAD	cis	rs13064411	0.518	rs2399480	chr3:113228599	T/C	cg10517650	chr3:113235015	CCDC52	-0.45	-8.19	-0.37	3.14e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg16606324	chr3:10149918	C3orf24	0.68	11.12	0.48	2.23e-25	Alzheimer's disease;
LUAD	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg00310523	chr12:86230176	RASSF9	-0.37	-7.39	-0.34	8.14e-13	Major depressive disorder;
LUAD	cis	rs2455601	1.000	rs7104661	chr11:8902501	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.46	-6.56	-0.3	1.55e-10	Schizophrenia;
LUAD	cis	rs7944584	0.611	rs10838696	chr11:47363285	A/G	cg20307385	chr11:47447363	PSMC3	-0.47	-7.38	-0.34	8.22e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs13082711	0.911	rs11717669	chr3:27458484	C/T	cg02860705	chr3:27208620	NA	0.65	9.65	0.42	4.93e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs2859741	0.967	rs494157	chr1:37512995	C/T	cg09363841	chr1:37513479	NA	0.36	9.38	0.41	4.04e-19	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg23018236	chr17:30244563	NA	-0.62	-8.19	-0.37	3.03e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg21214613	chr1:16344536	HSPB7	0.61	11.92	0.5	1.95e-28	Systolic blood pressure;
LUAD	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg08470875	chr2:26401718	FAM59B	-0.73	-10.36	-0.45	1.46e-22	Gut microbiome composition (summer);
LUAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg26554054	chr8:600488	NA	0.87	7.96	0.36	1.59e-14	IgG glycosylation;
LUAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg00106254	chr7:1943704	MAD1L1	-0.63	-9.59	-0.42	7.81e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.83	-0.5	4.14e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs870825	0.860	rs11132253	chr4:185595472	C/T	cg04058563	chr4:185651563	MLF1IP	0.75	10.52	0.46	3.72e-23	Blood protein levels;
LUAD	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg21204522	chr6:27730016	NA	-0.41	-6.67	-0.31	8.23e-11	Parkinson's disease;
LUAD	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.33	-9.1	-0.4	3.46e-18	Total body bone mineral density;
LUAD	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	7.17	0.33	3.29e-12	Parkinson's disease;
LUAD	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-7.25	-0.33	1.99e-12	IgG glycosylation;
LUAD	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg18232548	chr7:50535776	DDC	-0.71	-12.45	-0.52	1.63e-30	Response to zileuton treatment in asthma (FEV1 change interaction);
LUAD	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg18252515	chr7:66147081	NA	-0.61	-6.72	-0.31	5.83e-11	Diabetic kidney disease;
LUAD	trans	rs11671005	0.610	rs3794966	chr19:59068996	C/T	cg22037779	chr5:139682734	PFDN1	-0.67	-8.93	-0.4	1.3e-17	Mean platelet volume;
LUAD	cis	rs10129255	0.500	rs8011115	chr14:107194530	T/C	cg07958169	chr14:107095056	NA	-0.35	-6.86	-0.32	2.5e-11	Kawasaki disease;
LUAD	cis	rs2050392	1.000	rs2050392	chr10:30691503	G/A	cg18806716	chr10:30721971	MAP3K8	-0.55	-10.76	-0.46	5.18e-24	Inflammatory bowel disease;
LUAD	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg08885076	chr2:99613938	TSGA10	0.35	6.45	0.3	3.08e-10	Chronic sinus infection;
LUAD	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg10468373	chr11:64009913	FKBP2	0.5	6.45	0.3	3.11e-10	Mean platelet volume;
LUAD	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg19875535	chr5:140030758	IK	-0.39	-6.61	-0.31	1.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-9.19	-0.41	1.76e-18	Gut microbiome composition (summer);
LUAD	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg23625390	chr15:77176239	SCAPER	-0.55	-8.86	-0.4	2.22e-17	Blood metabolite levels;
LUAD	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-7.78	-0.35	5.52e-14	Total body bone mineral density;
LUAD	cis	rs3125734	0.582	rs7904465	chr10:64002393	G/A	cg19640130	chr10:64028056	RTKN2	-0.35	-7.45	-0.34	5.17e-13	Rheumatoid arthritis;
LUAD	cis	rs2274273	0.805	rs10131926	chr14:55713246	T/C	cg04306507	chr14:55594613	LGALS3	0.42	8.64	0.39	1.14e-16	Protein biomarker;
LUAD	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18876405	chr7:65276391	NA	0.56	9.42	0.42	2.99e-19	Aortic root size;
LUAD	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.12	-0.59	1.27e-41	Chronic sinus infection;
LUAD	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22857025	chr5:266934	NA	-0.96	-14.33	-0.57	2.98e-38	Breast cancer;
LUAD	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.56	-0.42	9.95e-20	Platelet count;
LUAD	cis	rs9595066	0.627	rs4942287	chr13:44734696	C/T	cg04068111	chr13:44716778	NA	0.53	9.31	0.41	6.76e-19	Schizophrenia;
LUAD	cis	rs7017914	0.967	rs13256250	chr8:71596193	G/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.66	-0.31	8.78e-11	Bone mineral density;
LUAD	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg19717773	chr7:2847554	GNA12	-0.47	-8.04	-0.36	8.88e-15	Height;
LUAD	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg25237894	chr2:233734115	C2orf82	0.61	11.61	0.49	3.2e-27	Coronary artery disease;
LUAD	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg05373962	chr22:49881684	NA	-0.48	-9.14	-0.41	2.73e-18	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg03609598	chr5:56110824	MAP3K1	-0.63	-8.53	-0.38	2.6e-16	Initial pursuit acceleration;
LUAD	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg00631329	chr6:26305371	NA	-0.49	-8.91	-0.4	1.58e-17	Educational attainment;
LUAD	cis	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.75	-0.35	6.92e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg01448562	chr3:133502909	NA	-0.48	-8.23	-0.37	2.34e-15	Iron status biomarkers;
LUAD	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg16342193	chr10:102329863	NA	-0.38	-6.68	-0.31	7.63e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs7737355	0.738	rs3776016	chr5:130855352	C/T	cg25547332	chr5:131281432	NA	0.42	6.88	0.32	2.15e-11	Life satisfaction;
LUAD	trans	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg16724585	chr3:197361211	NA	-0.5	-7.63	-0.35	1.62e-13	Pancreatic cancer;
LUAD	cis	rs8077889	0.917	rs60335331	chr17:41907509	A/G	cg26893861	chr17:41843967	DUSP3	0.92	15.52	0.6	2.46e-43	Triglycerides;
LUAD	cis	rs7178572	0.568	rs8037561	chr15:77680462	A/G	cg15453836	chr15:77711506	NA	-0.36	-6.42	-0.3	3.59e-10	Type 2 diabetes;
LUAD	trans	rs783540	0.521	rs28719490	chr15:83389440	A/G	cg18393722	chr15:85113863	UBE2QP1	0.53	7.71	0.35	9e-14	Schizophrenia;
LUAD	trans	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg07211511	chr3:129823064	LOC729375	-0.91	-12.47	-0.52	1.32e-30	Blood pressure (smoking interaction);
LUAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6906287	0.647	rs3734381	chr6:118887303	A/G	cg05564266	chr6:118973597	C6orf204	0.33	6.74	0.31	5.23e-11	Electrocardiographic conduction measures;
LUAD	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg26384229	chr12:38710491	ALG10B	-0.38	-6.53	-0.3	1.91e-10	Bladder cancer;
LUAD	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg00484396	chr16:3507460	NAT15	-0.72	-11.88	-0.5	2.77e-28	Tuberculosis;
LUAD	cis	rs4253772	0.938	rs11704979	chr22:46632994	G/A	cg09491104	chr22:46646882	C22orf40	-0.5	-6.75	-0.31	4.79e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2224391	0.704	rs9504371	chr6:5261608	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-9.76	-0.43	2.05e-20	Height;
LUAD	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg20456258	chr4:962124	DGKQ	0.35	6.43	0.3	3.4e-10	Sjögren's syndrome;
LUAD	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg06221963	chr1:154839813	KCNN3	0.86	20.37	0.7	8.67e-65	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.52	0.42	1.33e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3761218	1.000	rs3761218	chr20:3776175	A/G	cg02737268	chr20:3780182	CDC25B	-0.3	-6.8	-0.31	3.62e-11	Bipolar disorder;
LUAD	cis	rs80319144	1.000	rs112805856	chr2:159266371	G/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.38	6.98	0.32	1.17e-11	Restless legs syndrome;
LUAD	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg08632164	chr7:65971372	NA	0.36	6.38	0.3	4.65e-10	Aortic root size;
LUAD	cis	rs2030746	0.521	rs2311598	chr2:121331102	A/G	cg03661458	chr2:121334411	NA	-0.37	-6.53	-0.3	1.94e-10	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LUAD	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg06453172	chr10:134556979	INPP5A	-0.78	-11.0	-0.47	6.12e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg10729496	chr3:10149963	C3orf24	0.55	9.23	0.41	1.27e-18	Alzheimer's disease;
LUAD	cis	rs6489882	1.000	rs7977345	chr12:113380708	A/T	cg20102336	chr12:113376681	OAS3	-0.55	-8.65	-0.39	1.11e-16	Chronic lymphocytic leukemia;
LUAD	cis	rs12681287	0.640	rs28561640	chr8:87425638	G/A	cg27223183	chr8:87520930	FAM82B	0.68	9.45	0.42	2.34e-19	Caudate activity during reward;
LUAD	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-8.2	-0.37	2.83e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg20307385	chr11:47447363	PSMC3	0.53	7.92	0.36	2.06e-14	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs6062509	0.811	rs6062498	chr20:62339059	C/G	cg01176363	chr20:62369445	LIME1	-0.46	-7.48	-0.34	4.37e-13	Prostate cancer;
LUAD	cis	rs2425143	1.000	rs11699690	chr20:34271774	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.28	-0.33	1.6e-12	Blood protein levels;
LUAD	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg15664640	chr17:80829946	TBCD	-0.82	-15.53	-0.6	2.31e-43	Breast cancer;
LUAD	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.3	6.6	0.31	1.26e-10	Systemic lupus erythematosus;
LUAD	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg16205897	chr5:131564050	P4HA2	-0.33	-7.47	-0.34	4.54e-13	Blood metabolite levels;
LUAD	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg00204512	chr16:28754710	NA	0.33	7.11	0.33	4.84e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.57	-7.11	-0.33	5.01e-12	Body mass index;
LUAD	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01570182	chr17:44337453	NA	1.13	17.2	0.64	1.13e-50	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18404041	chr3:52824283	ITIH1	-0.48	-9.25	-0.41	1.11e-18	Electroencephalogram traits;
LUAD	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg18876405	chr7:65276391	NA	0.41	6.43	0.3	3.43e-10	Aortic root size;
LUAD	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg07570687	chr10:102243282	WNT8B	0.44	6.73	0.31	5.55e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg00316803	chr15:76480434	C15orf27	-0.41	-7.65	-0.35	1.37e-13	Blood metabolite levels;
LUAD	cis	rs68170813	1.000	rs35024078	chr7:107245468	A/G	cg23024343	chr7:107201750	COG5	0.44	6.55	0.3	1.69e-10	Coronary artery disease;
LUAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg21237687	chr17:6899380	ALOX12	-0.36	-6.86	-0.32	2.52e-11	Tonsillectomy;
LUAD	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg16797656	chr11:68205561	LRP5	0.45	8.47	0.38	4.1e-16	Total body bone mineral density;
LUAD	cis	rs6484504	0.576	rs438578	chr11:31222579	A/G	cg26647111	chr11:31128758	NA	0.47	8.41	0.38	6.33e-16	Red blood cell count;
LUAD	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg04154034	chr17:28927549	LRRC37B2	0.7	6.93	0.32	1.53e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.04	0.32	8.06e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1003719	0.708	rs8126491	chr21:38551219	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.4	-0.38	6.71e-16	Eye color traits;
LUAD	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg13319975	chr6:146136371	FBXO30	0.59	9.91	0.43	6.11e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2742417	1.000	rs2742422	chr3:45732820	G/A	cg10512202	chr3:45649293	LIMD1	0.37	6.55	0.3	1.72e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg18200150	chr17:30822561	MYO1D	-0.41	-7.7	-0.35	1e-13	Schizophrenia;
LUAD	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg12365402	chr11:9010492	NRIP3	0.49	9.02	0.4	6.74e-18	Hemoglobin concentration;
LUAD	trans	rs4714291	1.000	rs4714290	chr6:40003502	A/G	cg02267698	chr19:7991119	CTXN1	0.43	6.47	0.3	2.77e-10	Strep throat;
LUAD	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg23262073	chr20:60523788	NA	-0.48	-7.72	-0.35	8.62e-14	Body mass index;
LUAD	cis	rs2742234	0.590	rs2435383	chr10:43675671	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.52	-8.9	-0.4	1.67e-17	Hirschsprung disease;
LUAD	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg23281280	chr6:28129359	ZNF389	0.45	6.54	0.3	1.77e-10	Depression;
LUAD	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.81	-0.36	4.47e-14	Personality dimensions;
LUAD	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg26441486	chr22:50317300	CRELD2	0.44	6.68	0.31	7.35e-11	Schizophrenia;
LUAD	cis	rs7220401	0.542	rs55644350	chr17:27913368	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.42	6.8	0.31	3.55e-11	Coronary artery disease;
LUAD	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg06641503	chr3:48959341	ARIH2	-0.4	-7.78	-0.35	5.65e-14	Parkinson's disease;
LUAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.42	0.3	3.67e-10	Platelet count;
LUAD	cis	rs9899728	0.764	rs7219493	chr17:73044188	T/C	cg27626185	chr17:73056755	KCTD2	-0.56	-6.91	-0.32	1.82e-11	Alzheimer's disease or small vessel stroke;
LUAD	cis	rs11166629	1.000	rs1545240	chr8:135642632	A/C	cg27224718	chr8:135614730	ZFAT	0.59	10.39	0.45	1.15e-22	Smoking quantity;
LUAD	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg16486109	chr11:613632	IRF7	0.49	8.16	0.37	3.97e-15	Systemic lupus erythematosus;
LUAD	cis	rs9287719	0.649	rs58633964	chr2:10736382	T/G	cg01299579	chr2:10830716	NOL10	-0.45	-7.87	-0.36	2.9e-14	Prostate cancer;
LUAD	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg18306943	chr3:40428807	ENTPD3	-0.38	-6.49	-0.3	2.44e-10	Renal cell carcinoma;
LUAD	cis	rs5756391	0.503	rs9607395	chr22:37315742	C/T	cg16356956	chr22:37317934	CSF2RB	0.33	7.24	0.33	2.16e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg08645402	chr16:4508243	NA	0.59	10.89	0.47	1.59e-24	Schizophrenia;
LUAD	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg15962314	chr1:44399869	ARTN	0.27	6.4	0.3	4.21e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg10589385	chr1:150898437	SETDB1	0.39	7.51	0.34	3.57e-13	Tonsillectomy;
LUAD	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg06547715	chr2:218990976	CXCR2	-0.27	-6.45	-0.3	3.01e-10	Colorectal cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26496372	chr5:37379396	WDR70	-0.46	-7.1	-0.33	5.17e-12	Height;
LUAD	cis	rs12545109	0.723	rs2610045	chr8:57413439	A/G	cg09654669	chr8:57350985	NA	0.64	9.83	0.43	1.11e-20	Obesity-related traits;
LUAD	cis	rs6743376	0.556	rs1374286	chr2:113819007	C/G	cg09040174	chr2:113837401	NA	0.52	8.02	0.36	1.02e-14	Inflammatory biomarkers;
LUAD	cis	rs7617773	0.780	rs35411187	chr3:48360017	C/G	cg11946769	chr3:48343235	NME6	0.44	6.79	0.31	3.73e-11	Coronary artery disease;
LUAD	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg06618935	chr21:46677482	NA	-0.5	-10.05	-0.44	1.93e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg07460842	chr6:66804631	NA	0.96	12.78	0.53	7.63e-32	Exhaled nitric oxide output;
LUAD	cis	rs62400317	0.859	rs4479922	chr6:45248371	T/C	cg18551225	chr6:44695536	NA	-0.56	-8.74	-0.39	5.51e-17	Total body bone mineral density;
LUAD	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg14343924	chr8:8086146	FLJ10661	0.51	8.1	0.37	5.84e-15	Mood instability;
LUAD	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg11822812	chr5:140052017	DND1	0.38	6.66	0.31	8.67e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10392	0.543	rs4812336	chr20:37547374	G/A	cg27552599	chr20:37590471	DHX35	0.41	6.82	0.31	3.22e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs3849570	1.000	rs78242412	chr3:81747219	A/G	cg07356753	chr3:81810745	GBE1	-0.69	-12.16	-0.51	2.14e-29	Waist circumference;Body mass index;
LUAD	trans	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg11693508	chr17:37793320	STARD3	0.51	7.44	0.34	5.75e-13	Neuroticism;
LUAD	cis	rs7828089	0.819	rs11136021	chr8:22244672	T/C	cg12081754	chr8:22256438	SLC39A14	0.52	9.16	0.41	2.17e-18	Verbal declarative memory;
LUAD	trans	rs564343	0.966	rs484983	chr11:65880463	G/A	cg26701943	chr11:108369231	KDELC2	-0.45	-7.5	-0.34	3.83e-13	Obesity (early onset extreme);
LUAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg10150615	chr22:24372951	LOC391322	-0.49	-8.12	-0.37	5.23e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs7395662	0.927	rs4882141	chr11:48627525	C/T	cg00717180	chr2:96193071	NA	-0.36	-6.59	-0.31	1.3100000000000001e-10	HDL cholesterol;
LUAD	cis	rs7010267	0.623	rs13254554	chr8:120010805	T/C	cg01975934	chr8:119970761	NA	-0.35	-6.7	-0.31	6.85e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-7.97	-0.36	1.48e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg17074396	chr22:49843754	NA	-0.31	-6.5	-0.3	2.26e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg09658497	chr7:2847517	GNA12	-0.53	-9.29	-0.41	8.37e-19	Height;
LUAD	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg11663144	chr21:46675770	NA	-0.48	-8.23	-0.37	2.35e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs597583	0.951	rs636530	chr11:117421858	C/T	cg27161313	chr11:117392002	DSCAML1	0.39	6.75	0.31	4.88e-11	Putamen volume;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17826168	chr19:6464103	CRB3	-0.44	-6.44	-0.3	3.33e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6831352	0.765	rs35361391	chr4:100069281	A/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.26	-0.54	8.48e-34	Alcohol dependence;
LUAD	cis	rs9287719	0.649	rs6732429	chr2:10758972	C/T	cg03983476	chr2:10830698	NOL10	0.38	6.6	0.31	1.22e-10	Prostate cancer;
LUAD	cis	rs775227	0.574	rs13067967	chr3:113265215	C/G	cg10517650	chr3:113235015	CCDC52	-0.49	-7.09	-0.33	5.76e-12	Dental caries;
LUAD	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg13180566	chr4:1052158	NA	-0.4	-6.78	-0.31	4.04e-11	Recombination rate (females);
LUAD	cis	rs7779181	1.000	rs7780009	chr7:32341543	G/A	cg27532318	chr7:32358331	NA	0.47	7.64	0.35	1.43e-13	Body mass index;
LUAD	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11166629	1.000	rs6577713	chr8:135645592	C/A	cg27224718	chr8:135614730	ZFAT	0.6	10.74	0.46	5.79e-24	Smoking quantity;
LUAD	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg02269571	chr22:50332266	NA	-0.89	-9.63	-0.42	5.74e-20	Mean platelet volume;
LUAD	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg02221750	chr19:17393354	ANKLE1	-0.79	-12.76	-0.53	9.1e-32	Systemic lupus erythematosus;
LUAD	cis	rs732716	0.740	rs62129356	chr19:4400314	C/T	cg21934504	chr19:4445085	UBXN6	0.46	7.69	0.35	1.03e-13	Mean corpuscular volume;
LUAD	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg15744005	chr10:104629667	AS3MT	-0.34	-6.69	-0.31	7.05e-11	Arsenic metabolism;
LUAD	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg06740227	chr12:86229804	RASSF9	0.45	7.88	0.36	2.78e-14	Major depressive disorder;
LUAD	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg24069376	chr3:38537580	EXOG	0.35	8.03	0.36	9.45e-15	Electrocardiographic conduction measures;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16786661	chr2:234160315	ATG16L1	-0.55	-6.66	-0.31	8.43e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg18131467	chr2:239335373	ASB1	0.73	12.68	0.52	1.88e-31	Multiple system atrophy;
LUAD	trans	rs7944735	0.607	rs34895872	chr11:48021778	A/G	cg15704280	chr7:45808275	SEPT13	0.64	9.05	0.4	5.12e-18	Intraocular pressure;
LUAD	trans	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg11693508	chr17:37793320	STARD3	-0.51	-7.15	-0.33	3.77e-12	Bipolar disorder;
LUAD	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg11915388	chr22:42470451	FAM109B	0.4	7.03	0.32	8.23e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg11211951	chr8:145729740	GPT	-0.36	-6.9	-0.32	1.9e-11	Age at first birth;
LUAD	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg19622623	chr12:86230825	RASSF9	-0.55	-9.79	-0.43	1.53e-20	Major depressive disorder;
LUAD	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg26752003	chr8:145688521	CYHR1	0.43	7.33	0.34	1.2e-12	Age at first birth;
LUAD	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg06784218	chr1:46089804	CCDC17	0.56	12.25	0.51	9.58e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2019216	0.542	rs8073228	chr17:21909838	C/G	cg22648282	chr17:21454238	C17orf51	-0.46	-8.1	-0.37	5.76e-15	Pelvic organ prolapse;
LUAD	trans	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg14917512	chr19:3094685	GNA11	0.54	6.4	0.3	4.03e-10	Diabetic kidney disease;
LUAD	cis	rs1595825	0.891	rs77946222	chr2:198533251	C/T	cg10547527	chr2:198650123	BOLL	-0.53	-7.35	-0.34	1.06e-12	Ulcerative colitis;
LUAD	cis	rs7904368	0.754	rs66491181	chr10:16849430	T/C	cg23933602	chr10:16859644	RSU1	0.61	8.38	0.38	8.01e-16	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg22166914	chr1:53195759	ZYG11B	-0.48	-7.9	-0.36	2.51e-14	Monocyte count;
LUAD	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.75	0.31	4.86e-11	Breast cancer;
LUAD	cis	rs748404	0.697	rs492743	chr15:43560945	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.14	0.37	4.58e-15	Lung cancer;
LUAD	cis	rs2816062	0.786	rs2816055	chr1:18898248	A/G	cg18795169	chr1:18902165	NA	-0.92	-22.24	-0.73	3.99e-73	Urate levels in lean individuals;
LUAD	cis	rs6489882	0.671	rs7135577	chr12:113358106	A/G	cg20102336	chr12:113376681	OAS3	-0.54	-8.23	-0.37	2.3e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg12927641	chr6:109611667	NA	-0.46	-8.04	-0.36	9.29e-15	Reticulocyte fraction of red cells;
LUAD	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg10755058	chr3:40428713	ENTPD3	0.44	8.4	0.38	6.83e-16	Renal cell carcinoma;
LUAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg00431813	chr7:1051703	C7orf50	-0.38	-6.96	-0.32	1.27e-11	Longevity;Endometriosis;
LUAD	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg16989719	chr2:238392110	NA	-0.36	-6.85	-0.32	2.62e-11	Prostate cancer;
LUAD	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg21475434	chr5:93447410	FAM172A	0.75	8.4	0.38	6.97e-16	Diabetic retinopathy;
LUAD	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.46	8.04	0.36	9.16e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg17366294	chr4:99064904	C4orf37	0.66	12.8	0.53	5.97e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg14019146	chr3:50243930	SLC38A3	0.37	6.91	0.32	1.77e-11	Body mass index;
LUAD	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.35	-0.34	1e-12	Morning vs. evening chronotype;
LUAD	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg05966235	chr16:28915196	ATP2A1	0.51	8.16	0.37	3.85e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg18200150	chr17:30822561	MYO1D	0.73	15.99	0.61	2.35e-45	Schizophrenia;
LUAD	cis	rs9796	0.558	rs6492993	chr15:41526104	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.46	-8.48	-0.38	3.85e-16	Menopause (age at onset);
LUAD	trans	rs9928842	0.679	rs4888361	chr16:75267676	A/G	cg24077593	chr11:47421745	NA	0.52	6.7	0.31	6.66e-11	Alcoholic chronic pancreatitis;
LUAD	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg26408565	chr15:76604113	ETFA	-0.44	-7.19	-0.33	2.93e-12	Blood metabolite levels;
LUAD	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg19912559	chr1:40204330	PPIE	0.57	9.94	0.44	4.64e-21	Blood protein levels;
LUAD	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.75	0.39	5.06e-17	Lung cancer in ever smokers;
LUAD	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18867708	chr6:26865862	GUSBL1	-0.43	-6.68	-0.31	7.32e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03934478	chr11:495069	RNH1	0.74	8.87	0.4	2.07e-17	Body mass index;
LUAD	trans	rs11039798	1.000	rs9667626	chr11:48485877	T/C	cg03929089	chr4:120376271	NA	0.57	6.58	0.3	1.41e-10	Axial length;
LUAD	cis	rs2625529	0.642	rs2200056	chr15:72302667	T/C	cg16672083	chr15:72433130	SENP8	-0.76	-12.78	-0.53	7.44e-32	Red blood cell count;
LUAD	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg03713592	chr11:72463424	ARAP1	0.62	7.74	0.35	7.52e-14	Type 2 diabetes;
LUAD	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg23283495	chr1:209979779	IRF6	0.68	8.9	0.4	1.6e-17	Cleft lip with or without cleft palate;
LUAD	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg05425664	chr17:57184151	TRIM37	0.42	7.44	0.34	5.5e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	15.52	0.6	2.47e-43	Bone mineral density;
LUAD	cis	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg05084668	chr3:125655381	ALG1L	-0.48	-7.41	-0.34	6.71e-13	Blood pressure (smoking interaction);
LUAD	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg10589385	chr1:150898437	SETDB1	0.45	8.44	0.38	5.11e-16	Melanoma;
LUAD	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg03929089	chr4:120376271	NA	0.82	14.99	0.59	4.81e-41	Coronary artery disease;
LUAD	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg16989719	chr2:238392110	NA	-0.34	-7.38	-0.34	8.35e-13	Prostate cancer;
LUAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg00290607	chr11:67383545	NA	0.55	9.28	0.41	8.79e-19	Mean corpuscular volume;
LUAD	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg18827107	chr12:86230957	RASSF9	-0.53	-9.31	-0.41	7.2e-19	Major depressive disorder;
LUAD	cis	rs7241530	0.585	rs7233393	chr18:75888229	G/A	cg14642773	chr18:75888474	NA	0.36	6.69	0.31	6.99e-11	Educational attainment (years of education);
LUAD	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg02269571	chr22:50332266	NA	-0.67	-9.51	-0.42	1.48e-19	Schizophrenia;
LUAD	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg11189052	chr15:85197271	WDR73	-0.55	-6.84	-0.32	2.82e-11	Schizophrenia;
LUAD	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs6684514	1.000	rs12022194	chr1:156312331	T/A	cg16558208	chr1:156270281	VHLL	0.53	9.58	0.42	8.04e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs4889855	0.556	rs3923514	chr17:78515210	A/G	cg16591659	chr17:78472290	NA	0.45	8.05	0.36	8.45e-15	Fractional excretion of uric acid;
LUAD	cis	rs1448094	0.842	rs7966352	chr12:86438705	A/C	cg00310523	chr12:86230176	RASSF9	0.34	7.24	0.33	2.11e-12	Major depressive disorder;
LUAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg23743428	chr13:21893420	NA	-0.47	-8.91	-0.4	1.56e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs4660214	0.666	rs7414381	chr1:39741520	A/T	cg27567593	chr1:39956653	BMP8A	0.33	6.7	0.31	6.57e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7107174	1.000	rs729354	chr11:77962453	T/A	cg02023728	chr11:77925099	USP35	0.45	7.02	0.32	8.73e-12	Testicular germ cell tumor;
LUAD	cis	rs12478296	1.000	rs55717005	chr2:243041071	T/A	cg06360820	chr2:242988706	NA	-0.84	-9.54	-0.42	1.16e-19	Obesity-related traits;
LUAD	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg09904177	chr6:26538194	HMGN4	0.41	6.56	0.3	1.56e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs12618769	0.652	rs17506535	chr2:99222834	G/C	cg10123293	chr2:99228465	UNC50	0.51	8.79	0.39	3.88e-17	Bipolar disorder;
LUAD	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg05887092	chr17:76393375	PGS1	0.41	7.28	0.33	1.65e-12	HDL cholesterol levels;
LUAD	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg02734326	chr4:10020555	SLC2A9	0.56	9.91	0.43	5.81e-21	Bone mineral density;
LUAD	cis	rs4786125	0.587	rs9938245	chr16:6926744	T/G	cg03623568	chr16:6915990	A2BP1	-0.47	-9.9	-0.43	6.58e-21	Heart rate variability traits (SDNN);
LUAD	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.5	0.3	2.24e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg11062466	chr8:58055876	NA	0.45	6.37	0.3	4.92e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs938554	0.694	rs4697700	chr4:9945792	C/G	cg00071950	chr4:10020882	SLC2A9	0.49	7.86	0.36	3.22e-14	Blood metabolite levels;
LUAD	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	12.33	0.51	4.7e-30	Bone mineral density;
LUAD	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.38e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12200782	0.932	rs12189841	chr6:26544798	A/T	cg08851530	chr6:28072375	NA	0.71	6.63	0.31	1.01e-10	Small cell lung carcinoma;
LUAD	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg16797656	chr11:68205561	LRP5	0.47	9.23	0.41	1.27e-18	Total body bone mineral density;
LUAD	cis	rs6460942	1.000	rs77494477	chr7:12315302	A/T	cg06484146	chr7:12443880	VWDE	-0.54	-6.4	-0.3	4.16e-10	Coronary artery disease;
LUAD	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg02221750	chr19:17393354	ANKLE1	-0.76	-12.13	-0.51	3.02e-29	Systemic lupus erythematosus;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg23260799	chr11:451101	PTDSS2	0.38	6.38	0.3	4.76e-10	Schizophrenia;
LUAD	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg01028140	chr2:1542097	TPO	-0.49	-6.63	-0.31	1.03e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg13319975	chr6:146136371	FBXO30	-0.58	-9.74	-0.43	2.38e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg07362569	chr17:61921086	SMARCD2	0.37	6.42	0.3	3.57e-10	Prudent dietary pattern;
LUAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg27454412	chr7:1067447	C7orf50	0.48	7.73	0.35	7.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg02782426	chr3:40428986	ENTPD3	0.44	9.39	0.42	3.82e-19	Renal cell carcinoma;
LUAD	trans	rs1941687	0.527	rs12608181	chr18:31339351	T/G	cg13755796	chr4:20253514	NA	-0.39	-6.64	-0.31	9.64e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg17178900	chr1:205818956	PM20D1	-0.44	-6.85	-0.32	2.56e-11	Menarche (age at onset);
LUAD	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.59	7.41	0.34	6.73e-13	Inflammatory bowel disease;
LUAD	cis	rs4964805	0.606	rs7312606	chr12:104188385	C/G	cg02344784	chr12:104178138	NT5DC3	0.45	9.15	0.41	2.4e-18	Attention deficit hyperactivity disorder;
LUAD	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg02775129	chr4:119771670	NA	-0.88	-8.19	-0.37	3.21e-15	Cannabis dependence symptom count;
LUAD	trans	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.7	0.43	3.2e-20	Mean corpuscular volume;
LUAD	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg18833306	chr6:118973337	C6orf204	-0.52	-7.46	-0.34	5.03e-13	Diastolic blood pressure;
LUAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08280861	chr8:58055591	NA	0.65	8.58	0.39	1.79e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg15128208	chr22:42549153	NA	0.42	6.66	0.31	8.37e-11	Birth weight;
LUAD	cis	rs4713675	0.546	rs791903	chr6:33702645	G/C	cg14003231	chr6:33640908	ITPR3	-0.41	-7.84	-0.36	3.58e-14	Plateletcrit;
LUAD	cis	rs7191700	0.509	rs416603	chr16:11364079	A/T	cg00044050	chr16:11439710	C16orf75	-0.57	-8.99	-0.4	8.6e-18	Multiple sclerosis;
LUAD	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg24813613	chr7:1882135	MAD1L1	-0.43	-6.66	-0.31	8.34e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg21659725	chr3:3221576	CRBN	0.39	6.55	0.3	1.72e-10	Resting heart rate;
LUAD	cis	rs7582720	1.000	rs72936353	chr2:204070956	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.58	0.42	8.55e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg16414030	chr3:133502952	NA	-0.42	-7.77	-0.35	6.19e-14	Ankle injury;
LUAD	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg23950597	chr19:37808831	NA	-0.6	-7.52	-0.34	3.32e-13	Coronary artery calcification;
LUAD	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg18132916	chr6:79620363	NA	-0.45	-7.78	-0.35	5.43e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.44	-0.3	3.18e-10	Schizophrenia;
LUAD	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.59	-0.35	2.07e-13	Menarche (age at onset);
LUAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg18621852	chr3:10150065	C3orf24	0.51	9.11	0.4	3.39e-18	Alzheimer's disease;
LUAD	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg16099599	chr11:93583650	C11orf90	-0.32	-6.44	-0.3	3.16e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs73198271	0.740	rs10109886	chr8:8680558	G/A	cg01851573	chr8:8652454	MFHAS1	0.49	9.01	0.4	7.14e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23583168	chr7:148888333	NA	-0.9	-18.52	-0.67	1.58e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.78	-0.46	4.08e-24	Obesity-related traits;
LUAD	trans	rs2840044	1.000	rs8073935	chr17:33985849	C/T	cg19694781	chr19:47549865	TMEM160	-0.63	-10.25	-0.45	3.73e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg12698349	chr2:225449008	CUL3	0.68	10.25	0.45	3.67e-22	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.71e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg03929089	chr4:120376271	NA	-0.98	-20.3	-0.7	1.86e-64	Height;
LUAD	cis	rs9972944	0.756	rs6504353	chr17:63768013	T/C	cg07283582	chr17:63770753	CCDC46	-0.51	-11.6	-0.49	3.32e-27	Total body bone mineral density;
LUAD	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg16060761	chr17:80687452	NA	0.69	11.32	0.48	4.03e-26	Glycated hemoglobin levels;
LUAD	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg02450064	chr17:40260053	DHX58	-0.46	-7.85	-0.36	3.35e-14	Fibrinogen levels;
LUAD	cis	rs231513	1.000	rs231518	chr17:41961451	C/T	cg26893861	chr17:41843967	DUSP3	0.58	6.62	0.31	1.09e-10	Cognitive function;
LUAD	cis	rs72928364	1.000	rs79265689	chr3:100621684	C/A	cg10123952	chr3:100791384	NA	0.63	7.24	0.33	2.2e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2908197	0.843	rs2961041	chr7:75945944	C/T	cg24580635	chr7:76178542	LOC100133091	-0.42	-6.49	-0.3	2.36e-10	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs459571	0.916	rs109536	chr9:136889987	G/C	cg13789015	chr9:136890014	NCRNA00094	0.84	14.44	0.57	1.09e-38	Platelet distribution width;
LUAD	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.79	0.35	5.07e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs12545109	0.800	rs1437278	chr8:57357024	T/C	cg09654669	chr8:57350985	NA	-0.71	-9.95	-0.44	4.12e-21	Obesity-related traits;
LUAD	cis	rs2274471	0.645	rs12237834	chr9:5093646	C/T	cg03390472	chr9:5043263	JAK2	-0.61	-8.65	-0.39	1.12e-16	Crohn's disease;
LUAD	trans	rs11088226	0.681	rs11702499	chr21:33938565	C/T	cg09050820	chr6:167586206	TCP10L2	0.91	12.44	0.52	1.65e-30	Gastritis;
LUAD	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg01851573	chr8:8652454	MFHAS1	-0.46	-8.2	-0.37	2.81e-15	Mood instability;
LUAD	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg25319279	chr11:5960081	NA	-0.38	-6.78	-0.31	3.98e-11	DNA methylation (variation);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21679509	chr7:28219613	JAZF1	-0.6	-7.45	-0.34	5.4e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.4	-6.61	-0.31	1.18e-10	Longevity;Endometriosis;
LUAD	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.42	2.49e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs2718058	0.519	rs2722242	chr7:37873610	A/G	cg24998770	chr7:37888106	TXNDC3	-0.29	-6.62	-0.31	1.11e-10	Alzheimer's disease (late onset);
LUAD	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg07211511	chr3:129823064	LOC729375	-0.83	-12.15	-0.51	2.49e-29	Blood pressure (smoking interaction);
LUAD	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg09184832	chr6:79620586	NA	-0.52	-9.69	-0.43	3.39e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg25985355	chr7:65971099	NA	-0.4	-7.38	-0.34	8.44e-13	Aortic root size;
LUAD	cis	rs7216064	0.953	rs10445361	chr17:65962238	G/T	cg08758996	chr17:66097529	LOC651250	-0.43	-6.76	-0.31	4.74e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-6.64	-0.31	9.61e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	7.4	0.34	7.3e-13	Schizophrenia;
LUAD	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.01	-0.32	9.6e-12	Breast cancer;
LUAD	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg23649088	chr2:200775458	C2orf69	0.81	15.08	0.59	2.02e-41	Osteoporosis;
LUAD	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg18854424	chr1:2615690	NA	0.34	7.89	0.36	2.56e-14	Ulcerative colitis;
LUAD	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg22455342	chr2:225449267	CUL3	0.45	7.53	0.34	3.2e-13	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs10129255	0.518	rs8009594	chr14:107185733	G/T	cg23076370	chr14:107095027	NA	-0.44	-8.9	-0.4	1.6e-17	Kawasaki disease;
LUAD	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg26513180	chr16:89883248	FANCA	0.8	7.16	0.33	3.56e-12	Skin colour saturation;
LUAD	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg08601574	chr20:25228251	PYGB	-0.44	-8.17	-0.37	3.65e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg24241305	chr13:114826075	RASA3	-0.44	-7.06	-0.32	6.94e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs1997103	1.000	rs6966183	chr7:55407546	A/C	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs62400317	0.859	rs12193720	chr6:45103362	A/G	cg18551225	chr6:44695536	NA	-0.54	-8.58	-0.39	1.79e-16	Total body bone mineral density;
LUAD	trans	rs9914544	1.000	rs7223231	chr17:18811846	C/T	cg21372672	chr17:16614065	CCDC144A	-0.41	-6.87	-0.32	2.27e-11	Educational attainment (years of education);
LUAD	cis	rs8077889	1.000	rs17674998	chr17:41879544	A/G	cg26893861	chr17:41843967	DUSP3	0.89	14.18	0.57	1.27e-37	Triglycerides;
LUAD	cis	rs7582720	0.945	rs72934601	chr2:204031137	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.44	0.42	2.48e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs250585	1.000	rs6497674	chr16:23562309	A/T	cg00143387	chr16:23521605	GGA2	-0.68	-8.09	-0.37	6.34e-15	Egg allergy;
LUAD	cis	rs7614311	0.731	rs3774727	chr3:63977875	A/G	cg22134162	chr3:63841271	THOC7	-0.54	-9.14	-0.41	2.66e-18	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs6541297	0.703	rs678050	chr1:230313911	T/C	cg20703242	chr1:230279135	GALNT2	-0.48	-7.07	-0.32	6.64e-12	Coronary artery disease;
LUAD	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg12927641	chr6:109611667	NA	-0.52	-9.3	-0.41	7.77e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs240764	0.658	rs846803	chr6:101272801	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.3	-0.37	1.4e-15	Neuroticism;
LUAD	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg23711669	chr6:146136114	FBXO30	0.42	7.26	0.33	1.91e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8017423	0.935	rs11621820	chr14:90727154	C/T	cg14092571	chr14:90743983	NA	-0.48	-8.29	-0.37	1.48e-15	Mortality in heart failure;
LUAD	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.85	0.53	3.87e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs977987	0.806	rs7202596	chr16:75491072	G/T	cg03315344	chr16:75512273	CHST6	0.65	14.42	0.57	1.26e-38	Dupuytren's disease;
LUAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg18621852	chr3:10150065	C3orf24	0.45	7.65	0.35	1.4e-13	Alzheimer's disease;
LUAD	cis	rs4713675	0.565	rs4713671	chr6:33699899	A/G	cg14003231	chr6:33640908	ITPR3	0.45	8.57	0.38	2.01e-16	Plateletcrit;
LUAD	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg22166914	chr1:53195759	ZYG11B	-0.45	-7.7	-0.35	9.43e-14	Monocyte count;
LUAD	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg03929089	chr4:120376271	NA	-0.97	-19.76	-0.69	5e-62	Height;
LUAD	cis	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg21775007	chr8:11205619	TDH	0.37	6.44	0.3	3.16e-10	Neuroticism;
LUAD	cis	rs62238980	0.614	rs79781828	chr22:32413050	C/G	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg21856205	chr7:94953877	PON1	-0.56	-7.96	-0.36	1.63e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg16680214	chr1:154839983	KCNN3	-0.63	-13.26	-0.54	8.05e-34	Prostate cancer;
LUAD	cis	rs11048434	0.666	rs12371786	chr12:9090086	G/A	cg04155231	chr12:9217510	LOC144571	0.41	7.85	0.36	3.46e-14	Sjögren's syndrome;
LUAD	cis	rs354225	0.597	rs4347868	chr2:54830616	G/A	cg01766943	chr2:54829624	SPTBN1	0.4	7.37	0.34	8.77e-13	Schizophrenia;
LUAD	trans	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg02002194	chr4:3960332	NA	-0.26	-6.37	-0.3	4.86e-10	Joint mobility (Beighton score);
LUAD	cis	rs300774	0.925	rs300735	chr2:167739	C/G	cg21211680	chr2:198530	NA	-0.48	-7.53	-0.34	3.09e-13	Suicide attempts in bipolar disorder;
LUAD	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22968622	chr17:43663579	NA	-0.94	-16.5	-0.63	1.42e-47	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.49	-0.34	4.04e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg10523679	chr1:76189770	ACADM	-0.73	-11.09	-0.47	2.8e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01570182	chr17:44337453	NA	1.11	17.74	0.65	4.84e-53	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.66	-12.25	-0.51	9.79e-30	Longevity;Endometriosis;
LUAD	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg00666640	chr1:248458726	OR2T12	0.34	8.27	0.37	1.76e-15	Common traits (Other);
LUAD	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08564027	chr20:61660810	NA	0.88	18.83	0.68	6.9e-58	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg12179176	chr11:130786555	SNX19	0.55	9.29	0.41	8.21e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg03959625	chr15:84868606	LOC388152	0.41	6.55	0.3	1.7e-10	Schizophrenia;
LUAD	cis	rs9462027	0.606	rs7759227	chr6:34728230	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.94	-0.4	1.27e-17	Systemic lupus erythematosus;
LUAD	cis	rs1865721	0.771	rs7231277	chr18:73136724	A/G	cg26385618	chr18:73139727	C18orf62	-0.51	-10.44	-0.45	7.67e-23	Intelligence;
LUAD	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	7.53	0.34	3.2e-13	Schizophrenia;
LUAD	cis	rs2742417	0.967	rs6800556	chr3:45752229	G/T	cg10512202	chr3:45649293	LIMD1	0.36	6.49	0.3	2.39e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	trans	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg21659725	chr3:3221576	CRBN	-0.58	-9.2	-0.41	1.6e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs490234	0.775	rs12341245	chr9:128340941	C/T	cg14078157	chr9:128172775	NA	-0.4	-7.17	-0.33	3.34e-12	Mean arterial pressure;
LUAD	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg00933542	chr6:150070202	PCMT1	0.42	8.56	0.38	2.14e-16	Lung cancer;
LUAD	cis	rs12760731	0.565	rs10913516	chr1:178169493	G/A	cg00404053	chr1:178313656	RASAL2	0.74	9.18	0.41	1.9e-18	Obesity-related traits;
LUAD	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.64	0.39	1.16e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.35	0.34	9.99e-13	Menopause (age at onset);
LUAD	cis	rs1215050	0.791	rs783959	chr4:98893476	C/T	cg17366294	chr4:99064904	C4orf37	-0.49	-8.78	-0.39	4.01e-17	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.08e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	7.85	0.36	3.46e-14	Menopause (age at onset);
LUAD	cis	rs2387326	0.717	rs10829336	chr10:129943532	T/C	cg16087940	chr10:129947807	NA	-0.65	-9.09	-0.4	3.81e-18	Select biomarker traits;
LUAD	trans	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.72	-9.9	-0.43	6.41e-21	Obesity-related traits;
LUAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg21237687	chr17:6899380	ALOX12	0.4	7.29	0.33	1.5e-12	Tonsillectomy;
LUAD	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg15128208	chr22:42549153	NA	0.43	6.65	0.31	8.82e-11	Birth weight;
LUAD	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.0	-0.36	1.19e-14	Total body bone mineral density;
LUAD	cis	rs9462027	0.628	rs9462015	chr6:34739726	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.84	-0.39	2.55e-17	Systemic lupus erythematosus;
LUAD	cis	rs12618769	0.597	rs72820002	chr2:99075259	T/A	cg10123293	chr2:99228465	UNC50	0.47	8.65	0.39	1.11e-16	Bipolar disorder;
LUAD	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg03714773	chr7:91764589	CYP51A1	0.27	6.45	0.3	2.97e-10	Breast cancer;
LUAD	cis	rs684232	0.931	rs410157	chr17:598240	T/C	cg15660573	chr17:549704	VPS53	-0.41	-6.57	-0.3	1.51e-10	Prostate cancer;
LUAD	cis	rs12620999	0.941	rs2078469	chr2:237983273	C/G	cg23555395	chr2:238036564	NA	0.57	8.83	0.39	2.9e-17	Systemic lupus erythematosus;
LUAD	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.44	-6.95	-0.32	1.39e-11	Schizophrenia;
LUAD	cis	rs2455799	1.000	rs12634892	chr3:15879168	A/G	cg16303742	chr3:15540471	COLQ	-0.38	-6.69	-0.31	7.24e-11	Mean platelet volume;
LUAD	cis	rs6908034	0.607	rs73378506	chr6:19819987	T/C	cg26817755	chr6:19812885	NA	0.48	6.67	0.31	8.24e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05901451	chr6:126070800	HEY2	-0.76	-13.62	-0.55	2.65e-35	Brugada syndrome;
LUAD	cis	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg08601574	chr20:25228251	PYGB	0.46	8.61	0.39	1.4e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg16325326	chr1:53192061	ZYG11B	0.61	11.08	0.47	3.11e-25	Monocyte count;
LUAD	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.34	6.5	0.3	2.27e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg01657329	chr11:68192670	LRP5	-0.54	-9.55	-0.42	1.06e-19	Total body bone mineral density;
LUAD	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg27170947	chr2:26402098	FAM59B	-0.83	-12.29	-0.51	6.47e-30	Gut microbiome composition (summer);
LUAD	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg25753631	chr6:25732923	NA	-0.38	-6.45	-0.3	2.99e-10	Iron status biomarkers;
LUAD	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg13319975	chr6:146136371	FBXO30	0.68	11.78	0.5	6.62e-28	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.5	-0.34	3.77e-13	Menarche (age at onset);
LUAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg16590910	chr6:42928470	GNMT	0.35	6.5	0.3	2.2e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7094131	0.523	rs10764342	chr10:22882081	A/G	cg19500236	chr10:22911537	PIP4K2A	0.41	7.53	0.34	3.01e-13	Obesity-related traits;
LUAD	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg19318889	chr4:1322082	MAEA	0.58	9.86	0.43	9.11e-21	Longevity;
LUAD	cis	rs3087591	0.920	rs2905881	chr17:29547862	T/C	cg24425628	chr17:29625626	OMG;NF1	0.42	6.95	0.32	1.4e-11	Hip circumference;
LUAD	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg26513180	chr16:89883248	FANCA	-0.42	-6.86	-0.32	2.4e-11	Vitiligo;
LUAD	cis	rs4372836	1.000	rs4640348	chr2:28965479	T/C	cg09522027	chr2:28974177	PPP1CB	-0.62	-10.04	-0.44	2.05e-21	Body mass index;
LUAD	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg10426581	chr7:100472382	SRRT	0.77	10.2	0.44	5.46e-22	Resting heart rate;
LUAD	cis	rs13064411	0.696	rs7622740	chr3:113206771	G/A	cg10517650	chr3:113235015	CCDC52	-0.56	-9.5	-0.42	1.62e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.14	0.37	4.56e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg10518543	chr12:38710700	ALG10B	-0.49	-8.22	-0.37	2.5e-15	Morning vs. evening chronotype;
LUAD	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg03037974	chr15:76606532	NA	0.32	6.59	0.31	1.3100000000000001e-10	Blood metabolite levels;
LUAD	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg02466173	chr16:30829666	NA	-0.85	-17.47	-0.65	7.37e-52	Dementia with Lewy bodies;
LUAD	cis	rs35146811	0.589	rs1727142	chr7:99816179	T/C	cg22906224	chr7:99728672	NA	-0.62	-10.55	-0.46	3.06e-23	Coronary artery disease;
LUAD	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg24801067	chr17:62843696	NA	0.64	8.73	0.39	5.89e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs17095355	0.818	rs12572438	chr10:111769236	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.58	-6.71	-0.31	6.09e-11	Biliary atresia;
LUAD	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg20587970	chr11:113659929	NA	-1.4	-20.93	-0.71	2.68e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-8.09	-0.37	6.39e-15	Total cholesterol levels;
LUAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg11965913	chr1:205819406	PM20D1	0.47	7.55	0.34	2.71e-13	Parkinson's disease;
LUAD	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg00204512	chr16:28754710	NA	0.33	7.11	0.33	4.84e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7640424	0.819	rs34937412	chr3:107829484	G/C	cg09227934	chr3:107805635	CD47	-0.54	-9.41	-0.42	3.25e-19	Body mass index;
LUAD	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.91	9.59	0.42	7.78e-20	Initial pursuit acceleration;
LUAD	cis	rs2233152	0.572	rs10403040	chr19:41296046	A/T	cg21869046	chr19:41225005	ITPKC	-0.38	-6.98	-0.32	1.13e-11	Kawasaki disease;
LUAD	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg21798802	chr22:38057573	PDXP	0.34	6.98	0.32	1.16e-11	Fat distribution (HIV);
LUAD	cis	rs6028335	0.610	rs16987687	chr20:37566737	T/C	cg27660920	chr20:37554817	FAM83D	0.56	7.22	0.33	2.51e-12	Alcohol and nicotine co-dependence;
LUAD	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg14228332	chr4:119757509	SEC24D	0.69	6.98	0.32	1.12e-11	Cannabis dependence symptom count;
LUAD	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg26408565	chr15:76604113	ETFA	0.47	7.56	0.34	2.6e-13	Blood metabolite levels;
LUAD	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg23109721	chr2:106886537	NA	0.53	7.49	0.34	3.95e-13	Facial morphology (factor 23);
LUAD	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg27170947	chr2:26402098	FAM59B	0.65	8.26	0.37	1.82e-15	Gut microbiome composition (summer);
LUAD	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg08470875	chr2:26401718	FAM59B	-0.57	-7.84	-0.36	3.81e-14	Gut microbiome composition (summer);
LUAD	cis	rs12210905	0.688	rs72841397	chr6:27488423	C/A	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.91	-0.36	2.21e-14	Total body bone mineral density;
LUAD	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg23018236	chr17:30244563	NA	-0.59	-7.46	-0.34	4.93e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs1448094	0.842	rs7978562	chr12:86451478	A/G	cg00310523	chr12:86230176	RASSF9	0.33	6.81	0.31	3.36e-11	Major depressive disorder;
LUAD	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19981660	chr12:132434166	EP400	-0.55	-6.58	-0.3	1.39e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg26043149	chr18:55253948	FECH	0.44	7.11	0.33	5.05e-12	Bone mineral density;
LUAD	trans	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg06606381	chr12:133084897	FBRSL1	-1.11	-10.33	-0.45	1.84e-22	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg21862992	chr11:68658383	NA	0.53	9.73	0.43	2.5e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11696501	0.688	rs2281211	chr20:44312858	C/T	cg11783356	chr20:44313418	WFDC10B	-0.48	-7.79	-0.35	5.38e-14	Brain structure;
LUAD	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg27661571	chr11:113659931	NA	-0.62	-7.99	-0.36	1.26e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg04369109	chr6:150039330	LATS1	-0.42	-6.89	-0.32	1.99e-11	Lung cancer;
LUAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg10819733	chr22:24237672	NA	-0.4	-7.33	-0.34	1.17e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg02931644	chr1:25747376	RHCE	0.43	8.84	0.39	2.58e-17	Erythrocyte sedimentation rate;
LUAD	cis	rs954108	0.966	rs9508155	chr13:29372016	C/T	cg11788234	chr13:29393811	NA	0.37	7.38	0.34	8.33e-13	Obesity-related traits;
LUAD	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg04772025	chr11:68637568	NA	0.53	8.54	0.38	2.43e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6604026	0.740	rs10782946	chr1:93352669	G/A	cg17283838	chr1:93427260	FAM69A	-0.41	-6.51	-0.3	2.1e-10	Multiple sclerosis;
LUAD	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg23229984	chr5:148520753	ABLIM3	0.5	7.7	0.35	9.72e-14	Breast cancer;
LUAD	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg02269571	chr22:50332266	NA	0.59	8.96	0.4	1.05e-17	Schizophrenia;
LUAD	cis	rs67385638	1.000	rs72872548	chr11:5289139	C/A	cg12559170	chr11:5275217	HBG2	0.34	6.93	0.32	1.6e-11	Hemoglobin levels;
LUAD	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21028142	chr17:79581711	NPLOC4	0.45	9.79	0.43	1.54e-20	Eye color traits;
LUAD	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg12564285	chr5:131593104	PDLIM4	-0.39	-6.66	-0.31	8.41e-11	Blood metabolite levels;
LUAD	trans	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs17095355	0.786	rs58096078	chr10:111734286	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.67	-9.08	-0.4	4.09e-18	Biliary atresia;
LUAD	cis	rs7779181	0.808	rs57877670	chr7:32290694	T/C	cg27532318	chr7:32358331	NA	0.39	6.39	0.3	4.38e-10	Body mass index;
LUAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg08132940	chr7:1081526	C7orf50	-0.44	-6.67	-0.31	7.82e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg15117754	chr3:10150083	C3orf24	-0.43	-6.98	-0.32	1.13e-11	Alzheimer's disease;
LUAD	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg14458575	chr2:238380390	NA	0.68	12.82	0.53	5.2e-32	Prostate cancer;
LUAD	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg12193833	chr17:30244370	NA	-0.58	-7.04	-0.32	7.63e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7786877	0.626	rs11983745	chr7:100223678	T/C	cg16850897	chr7:100343110	ZAN	-0.6	-8.09	-0.37	6.33e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6987853	0.933	rs2923434	chr8:42422307	A/G	cg09913449	chr8:42400586	C8orf40	0.42	7.73	0.35	7.87e-14	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs264943	0.967	rs10185399	chr2:104214676	A/T	cg21422400	chr1:1747243	GNB1	0.38	6.52	0.3	1.98e-10	HIV-1 viral setpoint;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06966887	chr5:443603	EXOC3;C5orf55	-0.43	-6.94	-0.32	1.5e-11	Height;
LUAD	cis	rs7809950	0.817	rs2712224	chr7:107181235	C/A	cg23024343	chr7:107201750	COG5	-0.86	-14.34	-0.57	2.88e-38	Coronary artery disease;
LUAD	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg03168497	chr17:48586147	MYCBPAP	-0.52	-6.94	-0.32	1.48e-11	Visceral fat;
LUAD	trans	rs1941687	0.505	rs9956918	chr18:31315878	C/G	cg27147174	chr7:100797783	AP1S1	0.56	9.65	0.42	4.72e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs7737355	0.812	rs26003	chr5:130990384	T/C	cg06307176	chr5:131281290	NA	0.44	7.26	0.33	1.84e-12	Life satisfaction;
LUAD	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg18306943	chr3:40428807	ENTPD3	0.41	7.01	0.32	9.77e-12	Renal cell carcinoma;
LUAD	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs17433780	0.964	rs12146148	chr1:89471892	C/T	cg09516651	chr1:89888402	LOC400759	0.51	9.19	0.41	1.8e-18	Carotid intima media thickness;
LUAD	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.17	0.37	3.65e-15	Breast cancer;
LUAD	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.8	-11.93	-0.5	1.73e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-6.5	-0.3	2.31e-10	Height;
LUAD	cis	rs4148883	0.603	rs6833176	chr4:100131163	G/C	cg12011299	chr4:100065546	ADH4	-0.54	-10.73	-0.46	6.4e-24	Alcohol dependence;
LUAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg22907277	chr7:1156413	C7orf50	0.68	8.0	0.36	1.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg05991184	chr2:219186017	PNKD	-0.36	-7.02	-0.32	8.81e-12	Colorectal cancer;
LUAD	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg21191810	chr6:118973309	C6orf204	-0.47	-7.52	-0.34	3.37e-13	Diastolic blood pressure;
LUAD	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg09455208	chr3:40491958	NA	-0.5	-10.4	-0.45	1.06e-22	Renal cell carcinoma;
LUAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-9.6	-0.42	7.12e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.39	0.38	7.13e-16	Breast cancer;
LUAD	cis	rs7045138	1	rs7045138	chr9:100591463	C/T	cg13688889	chr9:100608707	NA	-0.4	-7.47	-0.34	4.64e-13	Thyroid hormone levels;
LUAD	cis	rs7178572	1.000	rs8034133	chr15:77763712	C/G	cg15453836	chr15:77711506	NA	-0.35	-6.41	-0.3	3.78e-10	Type 2 diabetes;
LUAD	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg25344623	chr2:136566232	LCT	-0.33	-6.49	-0.3	2.39e-10	Mosquito bite size;
LUAD	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.78	-0.39	4.19e-17	Total body bone mineral density;
LUAD	cis	rs1215050	0.791	rs4699318	chr4:98664370	T/G	cg05340658	chr4:99064831	C4orf37	-0.43	-7.01	-0.32	9.19e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg12935359	chr14:103987150	CKB	0.5	7.69	0.35	1.03e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg05697835	chr1:2722811	NA	-0.3	-6.37	-0.3	4.9e-10	Ulcerative colitis;
LUAD	cis	rs2404602	0.552	rs11634428	chr15:77084582	T/C	cg00316803	chr15:76480434	C15orf27	0.45	6.64	0.31	9.91e-11	Blood metabolite levels;
LUAD	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg26384229	chr12:38710491	ALG10B	0.47	7.59	0.35	2.05e-13	Bladder cancer;
LUAD	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.82	-0.39	3.1e-17	Initial pursuit acceleration;
LUAD	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg21220214	chr8:57350948	NA	-0.59	-8.66	-0.39	1.03e-16	Obesity-related traits;
LUAD	cis	rs9522267	0.535	rs9515447	chr13:112222303	C/T	cg10483660	chr13:112241077	NA	-0.32	-6.96	-0.32	1.28e-11	Hepatitis;
LUAD	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.75	0.46	5.2e-24	Smoking behavior;
LUAD	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.7e-32	Immature fraction of reticulocytes;
LUAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg03188948	chr7:1209495	NA	0.87	11.81	0.5	5.24e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs738322	0.600	rs6001035	chr22:38562425	A/G	cg25457927	chr22:38595422	NA	-0.52	-12.23	-0.51	1.18e-29	Cutaneous nevi;
LUAD	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg05283184	chr6:79620031	NA	-0.62	-12.47	-0.52	1.34e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs113835537	0.529	rs11227499	chr11:66272824	A/G	cg24851651	chr11:66362959	CCS	0.49	8.8	0.39	3.41e-17	Airway imaging phenotypes;
LUAD	cis	rs2294693	0.947	rs4714417	chr6:40987782	A/G	cg14769373	chr6:40998127	UNC5CL	-0.53	-8.24	-0.37	2.18e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.73	-13.22	-0.54	1.19e-33	Axial length;
LUAD	cis	rs4774899	0.966	rs62022237	chr15:57513613	C/T	cg14026238	chr15:57616123	NA	0.35	6.58	0.3	1.38e-10	Urinary tract infection frequency;
LUAD	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-8.22	-0.37	2.44e-15	Monocyte percentage of white cells;
LUAD	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25427524	chr10:38739819	LOC399744	-0.75	-13.38	-0.55	2.83e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg08888203	chr3:10149979	C3orf24	0.74	12.98	0.53	1.18e-32	Alzheimer's disease;
LUAD	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg23950597	chr19:37808831	NA	-0.64	-7.68	-0.35	1.11e-13	Coronary artery calcification;
LUAD	cis	rs1595825	0.891	rs16825181	chr2:198740276	G/T	cg00982548	chr2:198649783	BOLL	-0.68	-9.04	-0.4	5.48e-18	Ulcerative colitis;
LUAD	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg02423579	chr7:2872169	GNA12	-0.54	-9.14	-0.41	2.62e-18	Height;
LUAD	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg26587870	chr6:27730563	NA	-0.51	-8.41	-0.38	6.36e-16	Parkinson's disease;
LUAD	cis	rs7922314	0.510	rs9990	chr10:64567938	C/T	cg14943953	chr10:64564468	ADO	-0.56	-6.58	-0.3	1.42e-10	Cutaneous psoriasis;
LUAD	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.61	-10.22	-0.45	4.61e-22	Glomerular filtration rate;
LUAD	trans	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.93	16.22	0.62	2.4e-46	Colorectal cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg20828837	chr20:5731032	C20orf196	-0.44	-7.49	-0.34	4e-13	Cancer;
LUAD	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg14895029	chr7:2775587	GNA12	-0.45	-7.26	-0.33	1.83e-12	Height;
LUAD	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg06263672	chr7:65235340	NA	0.47	6.37	0.3	4.9e-10	Aortic root size;
LUAD	cis	rs12681287	0.640	rs10095498	chr8:87425651	C/T	cg27223183	chr8:87520930	FAM82B	0.68	9.48	0.42	1.91e-19	Caudate activity during reward;
LUAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg20607798	chr8:58055168	NA	0.58	7.31	0.34	1.31e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg06618935	chr21:46677482	NA	-0.49	-10.03	-0.44	2.19e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.73e-16	Neutrophil percentage of white cells;
LUAD	cis	rs950880	0.593	rs887971	chr2:103041167	T/C	cg03938978	chr2:103052716	IL18RAP	-0.33	-6.36	-0.3	5.3e-10	Serum protein levels (sST2);
LUAD	trans	rs4650994	0.623	rs12121188	chr1:178622499	G/A	cg05059571	chr16:84539110	KIAA1609	0.47	7.62	0.35	1.67e-13	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs10421328	0.848	rs867616	chr19:19757682	C/T	cg11584989	chr19:19387371	SF4	0.46	6.58	0.3	1.41e-10	Parental longevity (combined parental age at death);
LUAD	cis	rs2455799	0.573	rs2470520	chr3:15762920	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-9.23	-0.41	1.35e-18	Mean platelet volume;
LUAD	cis	rs7828089	0.715	rs11136029	chr8:22253485	A/G	cg12081754	chr8:22256438	SLC39A14	-0.6	-10.76	-0.46	5.09e-24	Verbal declarative memory;
LUAD	cis	rs7107174	1.000	rs55761949	chr11:77993860	A/G	cg19901956	chr11:77921274	USP35	-0.53	-6.78	-0.31	3.96e-11	Testicular germ cell tumor;
LUAD	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg00074818	chr8:8560427	CLDN23	0.62	9.69	0.43	3.36e-20	Obesity-related traits;
LUAD	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.18	-0.33	3.12e-12	Height;
LUAD	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg05590025	chr7:65112418	INTS4L2	-0.67	-7.34	-0.34	1.11e-12	Diabetic kidney disease;
LUAD	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg22349387	chr12:9600060	DDX12	0.4	6.72	0.31	5.95e-11	Breast size;
LUAD	cis	rs3760982	0.585	rs8109478	chr19:44298256	C/T	cg21496419	chr19:44306685	LYPD5	0.32	7.28	0.33	1.63e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs2880765	0.835	rs4843062	chr15:86040137	A/G	cg13263323	chr15:86062960	AKAP13	-0.49	-9.09	-0.4	3.84e-18	Coronary artery disease;
LUAD	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg26384229	chr12:38710491	ALG10B	0.46	7.48	0.34	4.35e-13	Bladder cancer;
LUAD	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg03433033	chr1:76189801	ACADM	-0.51	-7.5	-0.34	3.7e-13	Daytime sleep phenotypes;
LUAD	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg06623918	chr6:96969491	KIAA0776	0.87	17.04	0.64	5.77e-50	Headache;
LUAD	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg09904177	chr6:26538194	HMGN4	0.43	7.31	0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg17200465	chr3:40428508	ENTPD3	0.27	6.51	0.3	2.11e-10	Renal cell carcinoma;
LUAD	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg04025307	chr7:1156635	C7orf50	-0.67	-12.21	-0.51	1.37e-29	Longevity;Endometriosis;
LUAD	trans	rs800082	1.000	rs28847402	chr3:144316893	C/G	cg24215973	chr2:240111563	HDAC4	-0.41	-6.48	-0.3	2.57e-10	Smoking behavior;
LUAD	cis	rs1448094	0.872	rs7300073	chr12:86393513	A/C	cg19622623	chr12:86230825	RASSF9	-0.4	-7.25	-0.33	2e-12	Major depressive disorder;
LUAD	cis	rs2274273	0.870	rs28716725	chr14:55816610	T/C	cg04306507	chr14:55594613	LGALS3	0.41	8.68	0.39	8.74e-17	Protein biomarker;
LUAD	cis	rs62103177	0.564	rs3930042	chr18:77723843	G/A	cg02751453	chr18:77725136	HSBP1L1	-0.44	-7.51	-0.34	3.5e-13	Opioid sensitivity;
LUAD	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg25173405	chr17:45401733	C17orf57	-0.54	-9.37	-0.41	4.51e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg02775129	chr4:119771670	NA	-0.75	-7.28	-0.33	1.66e-12	Cannabis dependence symptom count;
LUAD	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03713592	chr11:72463424	ARAP1	0.91	11.41	0.49	1.73e-26	Type 2 diabetes;
LUAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg12034118	chr1:209979487	IRF6	0.46	6.71	0.31	6.43e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs752010	0.749	rs10749841	chr1:42112054	G/T	cg06885757	chr1:42089581	HIVEP3	0.36	7.51	0.34	3.64e-13	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg26384229	chr12:38710491	ALG10B	0.44	7.17	0.33	3.31e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9427116	0.502	rs9426830	chr1:154594690	A/G	cg17218026	chr1:154582156	ADAR	0.5	9.91	0.43	5.79e-21	Blood protein levels;
LUAD	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8067545	0.750	rs6587215	chr17:19980779	G/T	cg04132472	chr17:19861366	AKAP10	0.28	6.66	0.31	8.54e-11	Schizophrenia;
LUAD	trans	rs12200782	1.000	rs12208390	chr6:26437106	C/T	cg08851530	chr6:28072375	NA	0.72	6.5	0.3	2.27e-10	Small cell lung carcinoma;
LUAD	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg05043794	chr9:111880884	C9orf5	-0.46	-7.97	-0.36	1.48e-14	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09690373	chr8:29120781	KIF13B	-0.37	-6.5	-0.3	2.29e-10	Cancer;
LUAD	cis	rs7937890	0.505	rs4403769	chr11:14450176	C/T	cg23387056	chr11:14280742	SPON1	-0.35	-6.72	-0.31	5.73e-11	Mitochondrial DNA levels;
LUAD	cis	rs9354308	0.899	rs2814099	chr6:66555130	A/G	cg07460842	chr6:66804631	NA	0.5	7.48	0.34	4.42e-13	Metabolite levels;
LUAD	trans	rs2235573	0.625	rs139901	chr22:38406147	T/C	cg19894588	chr14:64061835	NA	0.42	6.61	0.31	1.18e-10	Glioblastoma;Glioma;
LUAD	cis	rs500891	0.525	rs3757011	chr6:84081069	G/C	cg08257003	chr6:84140564	ME1	0.34	6.68	0.31	7.78e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs11640533	0.901	rs2908790	chr16:53412161	T/C	cg02380802	chr16:53407808	NA	0.4	7.11	0.33	4.9e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06873352	chr17:61820015	STRADA	0.83	18.59	0.67	8.47e-57	Prudent dietary pattern;
LUAD	cis	rs7107174	1.000	rs10501426	chr11:78057122	C/T	cg19901956	chr11:77921274	USP35	-0.49	-6.94	-0.32	1.48e-11	Testicular germ cell tumor;
LUAD	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg21385522	chr1:16154831	NA	0.44	6.65	0.31	9.07e-11	Dilated cardiomyopathy;
LUAD	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg06627628	chr2:24431161	ITSN2	-0.48	-6.66	-0.31	8.49e-11	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	1.01e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg22535103	chr8:58192502	C8orf71	-0.54	-6.46	-0.3	2.86e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.44	0.3	3.31e-10	Parkinson's disease;
LUAD	trans	rs7395662	0.853	rs35255233	chr11:48442870	T/A	cg00717180	chr2:96193071	NA	-0.38	-7.03	-0.32	8.6e-12	HDL cholesterol;
LUAD	cis	rs4889855	0.530	rs8079792	chr17:78609394	A/G	cg16591659	chr17:78472290	NA	-0.42	-7.37	-0.34	8.99e-13	Fractional excretion of uric acid;
LUAD	cis	rs9297145	0.565	rs941001	chr7:98735185	A/T	cg05967295	chr7:98741636	SMURF1	-0.72	-13.35	-0.54	3.55e-34	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg27426351	chr10:43362370	NA	0.48	7.66	0.35	1.24e-13	Blood protein levels;
LUAD	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg04989706	chr14:50066350	PPIL5	-0.49	-7.16	-0.33	3.53e-12	Carotid intima media thickness;
LUAD	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg00933542	chr6:150070202	PCMT1	0.43	9.24	0.41	1.26e-18	Lung cancer;
LUAD	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg02569458	chr12:86230093	RASSF9	0.43	7.87	0.36	2.97e-14	Major depressive disorder;
LUAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.57	-6.99	-0.32	1.09e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg18490616	chr2:88469792	THNSL2	-0.67	-10.55	-0.46	3.07e-23	Response to metformin (IC50);
LUAD	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg03676636	chr4:99064102	C4orf37	-0.3	-7.17	-0.33	3.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1325195	1.000	rs1325195	chr1:179071756	G/A	cg11624085	chr17:8464688	MYH10	-0.45	-7.02	-0.32	9.04e-12	IgE grass sensitization;
LUAD	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg00999904	chr2:3704751	ALLC	-0.38	-7.26	-0.33	1.84e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4604732	0.631	rs12031721	chr1:247623773	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	8.97	0.4	9.41e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs1941687	0.800	rs17753910	chr18:31387643	T/C	cg27147174	chr7:100797783	AP1S1	-0.55	-9.32	-0.41	6.2800000000000005e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs2282300	0.739	rs1765139	chr11:30353725	T/C	cg25418670	chr11:30344373	C11orf46	-0.48	-6.51	-0.3	2.17e-10	Morning vs. evening chronotype;
LUAD	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg12311346	chr5:56204834	C5orf35	-0.92	-13.47	-0.55	1.2e-34	Initial pursuit acceleration;
LUAD	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs427394	0.659	rs274678	chr5:6752385	A/G	cg10857441	chr5:6722123	POLS	0.59	10.4	0.45	1.04e-22	Menopause (age at onset);
LUAD	cis	rs6024905	0.551	rs2425364	chr20:36969340	G/T	cg07053727	chr20:36965646	BPI	0.39	7.56	0.34	2.6e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg05084668	chr3:125655381	ALG1L	-0.49	-7.56	-0.34	2.57e-13	Blood pressure (smoking interaction);
LUAD	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-8.28	-0.37	1.69e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg14668632	chr7:2872130	GNA12	-0.48	-8.45	-0.38	4.76e-16	Height;
LUAD	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg22532475	chr10:104410764	TRIM8	-0.36	-7.28	-0.33	1.61e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg02869364	chr7:1081709	C7orf50	-0.47	-6.66	-0.31	8.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3823572	0.564	rs2971953	chr7:133663576	C/T	cg03336402	chr7:133662267	EXOC4	-0.41	-7.59	-0.35	2.08e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg02734326	chr4:10020555	SLC2A9	0.63	11.27	0.48	5.95e-26	Bone mineral density;
LUAD	cis	rs7927771	0.524	rs10838784	chr11:47882341	G/A	cg18512352	chr11:47633146	NA	0.37	6.68	0.31	7.56e-11	Subjective well-being;
LUAD	cis	rs7010267	0.568	rs2220189	chr8:120007708	C/G	cg01975934	chr8:119970761	NA	-0.36	-6.84	-0.32	2.76e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.8	-0.31	3.48e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7731657	0.537	rs2419934	chr5:130295768	T/C	cg08523029	chr5:130500466	HINT1	-0.58	-7.45	-0.34	5.28e-13	Fasting plasma glucose;
LUAD	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs332507	0.830	rs3772786	chr3:124395250	A/C	cg05980111	chr3:124395277	KALRN	0.47	7.38	0.34	8.21e-13	Plateletcrit;
LUAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg20503657	chr10:835505	NA	-0.48	-7.52	-0.34	3.29e-13	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg14202850	chr17:43974869	MAPT;LOC100130148	0.38	6.39	0.3	4.27e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02463440	chr8:22132932	PIWIL2	0.57	10.26	0.45	3.3e-22	Hypertriglyceridemia;
LUAD	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.4	7.72	0.35	8.53e-14	Lung cancer in ever smokers;
LUAD	cis	rs568617	0.533	rs679147	chr11:65644363	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.46	-7.08	-0.33	6.08e-12	Crohn's disease;
LUAD	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg09222892	chr1:25734099	RHCE	-0.47	-8.71	-0.39	7.17e-17	Erythrocyte sedimentation rate;
LUAD	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22857025	chr5:266934	NA	-0.96	-14.14	-0.57	1.9e-37	Breast cancer;
LUAD	cis	rs2249625	0.874	rs1830335	chr6:72902788	C/T	cg18830697	chr6:72922368	RIMS1	-0.35	-6.69	-0.31	7.23e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg16205897	chr5:131564050	P4HA2	0.31	7.08	0.33	5.89e-12	Breast cancer;
LUAD	cis	rs1595825	0.891	rs16867018	chr2:198521490	C/T	cg10547527	chr2:198650123	BOLL	-0.54	-7.66	-0.35	1.3e-13	Ulcerative colitis;
LUAD	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.69	0.31	7.1e-11	Depression;
LUAD	cis	rs9393692	0.620	rs9393697	chr6:26293841	C/T	cg00631329	chr6:26305371	NA	-0.55	-9.5	-0.42	1.63e-19	Educational attainment;
LUAD	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.33	7.16	0.33	3.7e-12	Cardiac Troponin-T levels;
LUAD	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.33	6.61	0.31	1.13e-10	Menarche (age at onset);
LUAD	cis	rs11051970	0.589	rs325425	chr12:32531212	G/T	cg24626660	chr12:32551988	NA	0.3	6.38	0.3	4.57e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg20587970	chr11:113659929	NA	-1.2	-17.85	-0.66	1.57e-53	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.97	0.32	1.21e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7395662	0.784	rs75694945	chr11:48865463	C/T	cg00717180	chr2:96193071	NA	0.39	7.41	0.34	7.13e-13	HDL cholesterol;
LUAD	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg05791153	chr7:19748676	TWISTNB	-0.73	-7.9	-0.36	2.5e-14	Thyroid stimulating hormone;
LUAD	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg19622623	chr12:86230825	RASSF9	-0.55	-9.8	-0.43	1.46e-20	Major depressive disorder;
LUAD	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg14530993	chr4:882597	GAK	0.73	6.9	0.32	1.89e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg10518543	chr12:38710700	ALG10B	-0.51	-8.33	-0.38	1.11e-15	Morning vs. evening chronotype;
LUAD	trans	rs1997103	1.000	rs4947499	chr7:55407196	T/C	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg05042697	chr2:10830656	NOL10	-0.37	-6.44	-0.3	3.18e-10	Prostate cancer;
LUAD	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg13870426	chr17:30244630	NA	-0.55	-6.49	-0.3	2.35e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg04455712	chr21:45112962	RRP1B	-0.4	-7.9	-0.36	2.41e-14	Mean corpuscular volume;
LUAD	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs4891159	0.527	rs34956524	chr18:74130480	A/G	cg24786174	chr18:74118243	ZNF516	0.9	22.63	0.74	6.83e-75	Longevity;
LUAD	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg22491629	chr6:157744540	C6orf35	-0.8	-8.8	-0.39	3.4e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7945705	0.846	rs4929911	chr11:8816495	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.49	8.67	0.39	9.4e-17	Hemoglobin concentration;
LUAD	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg10018233	chr7:150070692	REPIN1	0.47	7.37	0.34	9.03e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg00271210	chr6:167070053	RPS6KA2	0.34	6.6	0.31	1.27e-10	Crohn's disease;
LUAD	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg06641503	chr3:48959341	ARIH2	-0.4	-7.97	-0.36	1.45e-14	Parkinson's disease;
LUAD	cis	rs6028335	0.610	rs72623594	chr20:37576255	G/A	cg27660920	chr20:37554817	FAM83D	0.56	7.27	0.33	1.71e-12	Alcohol and nicotine co-dependence;
LUAD	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg06096015	chr1:231504339	EGLN1	0.33	6.36	0.3	5.22e-10	Hemoglobin concentration;
LUAD	cis	rs752010	0.714	rs10890144	chr1:42085397	G/T	cg06885757	chr1:42089581	HIVEP3	0.42	9.46	0.42	2.19e-19	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs2573652	1.000	rs2727196	chr15:100513529	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.49	-8.56	-0.38	2.09e-16	Height;
LUAD	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	7.03	0.32	8.08e-12	Cognitive test performance;
LUAD	cis	rs727505	1.000	rs56356267	chr7:124557549	A/G	cg23710748	chr7:124431027	NA	-0.47	-9.56	-0.42	9.86e-20	Lewy body disease;
LUAD	cis	rs3812049	0.532	rs251389	chr5:127541877	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	6.59	0.3	1.34e-10	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs2073300	1.000	rs12625160	chr20:23442008	T/C	cg12062639	chr20:23401060	NAPB	1.0	9.21	0.41	1.47e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.56	-6.75	-0.31	4.92e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11811982	0.793	rs74475302	chr1:227319072	A/G	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic disc area;
LUAD	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg25036284	chr2:26402008	FAM59B	-0.68	-9.24	-0.41	1.2e-18	Gut microbiome composition (summer);
LUAD	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg14983838	chr19:29218262	NA	0.67	9.82	0.43	1.21e-20	Methadone dose in opioid dependence;
LUAD	cis	rs10979	0.965	rs9390111	chr6:143894272	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-10.28	-0.45	2.77e-22	Hypospadias;
LUAD	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg00339695	chr16:24857497	SLC5A11	-0.48	-8.78	-0.39	4.12e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg17264618	chr3:40429014	ENTPD3	0.42	9.13	0.41	2.76e-18	Renal cell carcinoma;
LUAD	cis	rs317865	0.737	rs28516589	chr4:16234111	C/T	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.81	7.35	0.34	1.03e-12	Kidney disease (early stage) in type 1 diabetes;
LUAD	cis	rs10733682	0.633	rs869500	chr9:129465898	G/A	cg00232160	chr9:129468157	NA	0.51	9.28	0.41	8.85e-19	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg09085632	chr11:111637200	PPP2R1B	0.67	11.18	0.48	1.36e-25	Primary sclerosing cholangitis;
LUAD	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.48	-0.3	2.49e-10	Bladder cancer;
LUAD	cis	rs7582720	1.000	rs72934735	chr2:203740010	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.45	0.42	2.39e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs4523957	0.651	rs9894613	chr17:2071058	C/T	cg16513277	chr17:2031491	SMG6	-0.96	-19.08	-0.68	5.52e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg25358565	chr5:93447407	FAM172A	0.63	7.78	0.35	5.58e-14	Diabetic retinopathy;
LUAD	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.48	-0.38	3.77e-16	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-8.58	-0.38	1.85e-16	Alzheimer's disease (late onset);
LUAD	cis	rs1018836	0.828	rs4735236	chr8:91583909	A/G	cg16814680	chr8:91681699	NA	-0.58	-9.74	-0.43	2.26e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg07936489	chr17:37558343	FBXL20	-0.46	-7.22	-0.33	2.48e-12	Glomerular filtration rate (creatinine);
LUAD	trans	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	15.46	0.6	4.8e-43	Exhaled nitric oxide levels;
LUAD	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg13393036	chr8:95962371	TP53INP1	-0.36	-8.61	-0.39	1.45e-16	Type 2 diabetes;
LUAD	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg03209412	chr4:183728196	NA	0.72	10.63	0.46	1.46e-23	Pediatric autoimmune diseases;
LUAD	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg05665937	chr4:1216051	CTBP1	0.42	7.04	0.32	7.61e-12	Obesity-related traits;
LUAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg21782813	chr7:2030301	MAD1L1	0.54	9.38	0.41	4.15e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg19622623	chr12:86230825	RASSF9	-0.36	-6.62	-0.31	1.06e-10	Major depressive disorder;
LUAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg16447950	chr5:562315	NA	-0.41	-6.41	-0.3	3.91e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs1448094	0.872	rs7311150	chr12:86435989	A/T	cg18827107	chr12:86230957	RASSF9	-0.45	-8.15	-0.37	4.16e-15	Major depressive disorder;
LUAD	trans	rs9393777	0.920	rs34953377	chr6:27381660	T/C	cg01620082	chr3:125678407	NA	-0.79	-8.47	-0.38	3.97e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.91	-0.36	2.2e-14	Diabetic kidney disease;
LUAD	cis	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg23422044	chr7:1970798	MAD1L1	-0.58	-7.14	-0.33	4.16e-12	Bipolar disorder;
LUAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg27454412	chr7:1067447	C7orf50	0.48	7.74	0.35	7.28e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg24818145	chr4:99064322	C4orf37	0.48	7.93	0.36	1.97e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.41	6.89	0.32	1.97e-11	Age at first birth;
LUAD	trans	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg26043149	chr18:55253948	FECH	0.44	7.13	0.33	4.43e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	cg22532475	chr10:104410764	TRIM8	-0.32	-6.47	-0.3	2.72e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg03474202	chr17:45855739	NA	-0.36	-8.66	-0.39	9.7e-17	IgG glycosylation;
LUAD	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg03690763	chr11:133734501	NA	-0.28	-6.71	-0.31	6.37e-11	Childhood ear infection;
LUAD	cis	rs4588572	0.643	rs7701154	chr5:77716621	G/A	cg11547950	chr5:77652471	NA	-0.79	-12.91	-0.53	2.29e-32	Triglycerides;
LUAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	cis	rs367615	1.000	rs58931051	chr5:108907732	A/G	cg17395555	chr5:108820864	NA	0.46	7.54	0.34	2.99e-13	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs12541635	0.801	rs28709304	chr8:107106368	T/G	cg10147462	chr8:107024639	NA	-0.42	-7.34	-0.34	1.11e-12	Age of smoking initiation;
LUAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg14926445	chr8:58193284	C8orf71	-0.44	-6.66	-0.31	8.4e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg01475377	chr6:109611718	NA	-0.52	-9.86	-0.43	8.5e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg14092988	chr3:52407081	DNAH1	0.37	7.48	0.34	4.47e-13	Bipolar disorder;
LUAD	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg24578937	chr1:2090814	PRKCZ	0.79	16.49	0.63	1.56e-47	Height;
LUAD	trans	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg24644049	chr4:85504048	CDS1	0.85	7.17	0.33	3.38e-12	Skin colour saturation;
LUAD	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg04772025	chr11:68637568	NA	0.59	9.37	0.41	4.44e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26314531	chr2:26401878	FAM59B	-0.72	-9.81	-0.43	1.33e-20	Gut microbiome composition (summer);
LUAD	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg10518543	chr12:38710700	ALG10B	-0.44	-7.2	-0.33	2.72e-12	Heart rate;
LUAD	cis	rs892961	0.965	rs312856	chr17:75401598	A/G	cg05865280	chr17:75406074	SEPT9	0.63	19.65	0.69	1.54e-61	Airflow obstruction;
LUAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg17372223	chr3:52568218	NT5DC2	0.4	7.46	0.34	4.95e-13	Electroencephalogram traits;
LUAD	cis	rs3936840	0.548	rs1190545	chr14:102904179	G/C	cg18135206	chr14:102964638	TECPR2	-0.44	-6.57	-0.3	1.46e-10	Plateletcrit;
LUAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg08027265	chr7:2291960	NA	-0.45	-7.43	-0.34	6.02e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg17747265	chr1:1875780	NA	-0.75	-18.51	-0.67	1.78e-56	Body mass index;
LUAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg13752114	chr3:195489708	MUC4	-0.67	-7.59	-0.35	2.1e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs13082711	0.911	rs4973772	chr3:27450234	G/T	cg02860705	chr3:27208620	NA	0.59	8.99	0.4	8.62e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg11663144	chr21:46675770	NA	-0.57	-11.23	-0.48	9e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-11.28	-0.48	5.81e-26	Asthma;
LUAD	cis	rs89107	0.583	rs11752626	chr6:118788652	G/T	cg21191810	chr6:118973309	C6orf204	0.4	7.4	0.34	7.39e-13	Cardiac structure and function;
LUAD	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.37	0.34	9.15e-13	Bladder cancer;
LUAD	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.16	-34.23	-0.86	5.7e-124	Myeloid white cell count;
LUAD	cis	rs28493229	0.708	rs10408065	chr19:41161096	T/C	cg21869046	chr19:41225005	ITPKC	0.51	8.76	0.39	4.75e-17	Kawasaki disease;
LUAD	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg00717180	chr2:96193071	NA	-0.41	-7.6	-0.35	1.95e-13	HDL cholesterol;
LUAD	trans	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.6	-0.39	1.55e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs56161922	1.000	rs12567945	chr1:207841934	T/C	cg11752769	chr1:207818423	CR1L	-0.67	-7.0	-0.32	9.84e-12	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg23954153	chr1:44402353	ARTN	-0.37	-6.82	-0.31	3.25e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs62064224	0.553	rs9896320	chr17:30689814	G/A	cg18200150	chr17:30822561	MYO1D	0.42	7.73	0.35	7.9e-14	Schizophrenia;
LUAD	cis	rs9297145	0.724	rs62473013	chr7:98762418	G/T	cg05967295	chr7:98741636	SMURF1	0.97	15.74	0.61	2.99e-44	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	trans	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg06606381	chr12:133084897	FBRSL1	-0.98	-9.56	-0.42	1.01e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg24335600	chr1:241682994	FH	-0.38	-6.78	-0.31	4.04e-11	Schizophrenia;
LUAD	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg11645453	chr3:52864694	ITIH4	0.33	6.43	0.3	3.35e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.16	0.54	2.07e-33	Prudent dietary pattern;
LUAD	cis	rs2274273	0.837	rs59871474	chr14:55779363	T/C	cg04306507	chr14:55594613	LGALS3	0.43	8.98	0.4	9e-18	Protein biomarker;
LUAD	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.63	-0.31	1.04e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25333826	chr2:55276186	RTN4	-0.43	-6.68	-0.31	7.67e-11	Height;
LUAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg02869364	chr7:1081709	C7orf50	-0.47	-6.39	-0.3	4.47e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg00280220	chr17:61926910	NA	0.37	7.16	0.33	3.5e-12	Prudent dietary pattern;
LUAD	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg12927641	chr6:109611667	NA	-0.49	-8.71	-0.39	7.17e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg23758822	chr17:41437982	NA	0.99	20.7	0.71	2.9e-66	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.22e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg24578937	chr1:2090814	PRKCZ	0.79	16.43	0.62	2.88e-47	Height;
LUAD	cis	rs6594713	0.604	rs1922679	chr5:112637754	A/G	cg12552261	chr5:112820674	MCC	-0.45	-6.5	-0.3	2.28e-10	Brain cytoarchitecture;
LUAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg08132940	chr7:1081526	C7orf50	-0.79	-10.72	-0.46	6.96e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1448094	0.872	rs12322940	chr12:86406708	G/C	cg25456477	chr12:86230367	RASSF9	0.32	6.48	0.3	2.51e-10	Major depressive disorder;
LUAD	cis	rs7665090	1.000	rs2903283	chr4:103557753	T/C	cg07973026	chr4:103553119	MANBA	0.47	8.41	0.38	6.43e-16	Primary biliary cholangitis;
LUAD	cis	rs1451375	0.617	rs9942686	chr7:50596381	G/A	cg18232548	chr7:50535776	DDC	0.62	8.51	0.38	3.07e-16	Malaria;
LUAD	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.18	0.37	3.25e-15	Breast cancer;
LUAD	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg16647868	chr5:131706066	SLC22A5	-0.39	-6.64	-0.31	9.75e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg08999081	chr20:33150536	PIGU	0.62	13.92	0.56	1.54e-36	Glomerular filtration rate (creatinine);
LUAD	trans	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg14791747	chr16:20752902	THUMPD1	-0.89	-15.54	-0.6	2.11e-43	Cognitive test performance;
LUAD	cis	rs2806561	1.000	rs654585	chr1:23514714	T/C	cg19743168	chr1:23544995	NA	0.4	7.37	0.34	9.16e-13	Height;
LUAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg14893161	chr1:205819251	PM20D1	0.49	7.94	0.36	1.9e-14	Parkinson's disease;
LUAD	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg09835421	chr16:68378352	PRMT7	-1.07	-12.66	-0.52	2.2e-31	Schizophrenia;
LUAD	cis	rs1595825	0.891	rs73054819	chr2:198625744	G/T	cg11031976	chr2:198649780	BOLL	-0.45	-6.67	-0.31	7.79e-11	Ulcerative colitis;
LUAD	cis	rs755249	0.565	rs722357	chr1:39944768	C/T	cg27567593	chr1:39956653	BMP8A	0.35	7.2	0.33	2.74e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	12.38	0.52	2.96e-30	Monocyte percentage of white cells;
LUAD	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg01475377	chr6:109611718	NA	0.54	10.59	0.46	2.16e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs72827839	0.516	rs72833461	chr17:45938105	T/G	cg23391107	chr17:45924227	SP6	0.43	6.87	0.32	2.27e-11	Ease of getting up in the morning;
LUAD	cis	rs755249	0.501	rs621807	chr1:39842443	G/A	cg27567593	chr1:39956653	BMP8A	-0.34	-6.6	-0.31	1.22e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4664304	0.742	rs67017730	chr2:160732793	T/G	cg06573604	chr2:160760825	LY75	-0.39	-6.41	-0.3	3.92e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs169797	0.748	rs372769	chr20:31938224	A/C	cg14921437	chr20:32255988	NECAB3;C20orf134	0.46	6.76	0.31	4.5e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs9394169	0.613	rs4713685	chr6:33774525	C/T	cg07979401	chr6:33739406	LEMD2	0.4	7.45	0.34	5.27e-13	Essential tremor;
LUAD	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg16479474	chr6:28041457	NA	-0.5	-8.6	-0.39	1.6e-16	Depression;
LUAD	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg05535760	chr7:792225	HEATR2	-0.84	-9.96	-0.44	3.86e-21	Cerebrospinal P-tau181p levels;
LUAD	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg00933542	chr6:150070202	PCMT1	0.46	10.08	0.44	1.5e-21	Lung cancer;
LUAD	cis	rs1018836	0.608	rs11997663	chr8:91474484	A/C	cg16814680	chr8:91681699	NA	-0.52	-8.51	-0.38	2.99e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05901451	chr6:126070800	HEY2	-0.68	-11.74	-0.5	9.47e-28	Brugada syndrome;
LUAD	cis	rs2073300	1.000	rs6048813	chr20:23448221	G/A	cg12062639	chr20:23401060	NAPB	0.75	6.96	0.32	1.28e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4072705	0.562	rs7855918	chr9:127239939	T/C	cg13476313	chr9:127244764	NR5A1	0.36	8.75	0.39	4.95e-17	Menarche (age at onset);
LUAD	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg01324343	chr3:183735012	ABCC5	-0.8	-17.3	-0.64	4.44e-51	Anterior chamber depth;
LUAD	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg15921436	chr17:44337874	NA	-0.59	-8.84	-0.39	2.61e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9308433	0.529	rs4655332	chr1:214490756	G/A	cg06198575	chr1:214491504	SMYD2	0.46	7.79	0.35	5.08e-14	IgG glycosylation;
LUAD	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.58	-0.3	1.41e-10	Height;
LUAD	cis	rs2224391	0.628	rs2753234	chr6:5251050	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-8.78	-0.39	3.97e-17	Height;
LUAD	cis	rs9902453	0.817	rs62068620	chr17:28167674	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.3	0.41	7.7e-19	Coffee consumption (cups per day);
LUAD	cis	rs4072705	0.967	rs10818985	chr9:127450571	C/T	cg13476313	chr9:127244764	NR5A1	0.32	7.66	0.35	1.29e-13	Menarche (age at onset);
LUAD	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg21823605	chr1:152486609	CRCT1	0.29	6.49	0.3	2.38e-10	Hair morphology;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27498675	chr19:41945691	ATP5SL	-0.45	-7.01	-0.32	9.23e-12	Height;
LUAD	cis	rs17597773	0.527	rs2484698	chr1:221086065	A/T	cg16008148	chr1:221062819	NA	-0.43	-8.51	-0.38	3.15e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg05187965	chr10:45406764	TMEM72	-0.44	-8.91	-0.4	1.54e-17	Mean corpuscular volume;
LUAD	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg21827317	chr3:136751795	NA	0.52	10.43	0.45	8.25e-23	Schizophrenia;
LUAD	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg05896524	chr21:47604654	C21orf56	0.54	9.05	0.4	5.18e-18	Testicular germ cell tumor;
LUAD	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg09796270	chr17:17721594	SREBF1	0.37	7.45	0.34	5.24e-13	Total body bone mineral density;
LUAD	trans	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.92	0.4	1.46e-17	Endometrial cancer;
LUAD	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25427524	chr10:38739819	LOC399744	-0.69	-12.63	-0.52	3.05e-31	Extrinsic epigenetic age acceleration;
LUAD	cis	rs11958404	0.932	rs72816574	chr5:157429882	T/C	cg05962755	chr5:157440814	NA	0.69	9.52	0.42	1.31e-19	IgG glycosylation;
LUAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg02136620	chr5:178986620	RUFY1	0.56	9.23	0.41	1.33e-18	Lung cancer;
LUAD	cis	rs1595825	0.786	rs75415672	chr2:198535679	G/A	cg11031976	chr2:198649780	BOLL	-0.48	-7.09	-0.33	5.82e-12	Ulcerative colitis;
LUAD	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.9	-0.32	1.92e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs13082711	0.554	rs10514679	chr3:27412591	A/G	cg02860705	chr3:27208620	NA	0.69	10.43	0.45	8.17e-23	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs11585357	0.557	rs17378462	chr1:17595702	C/T	cg08277548	chr1:17600880	PADI3	-0.67	-8.68	-0.39	8.98e-17	Hair shape;
LUAD	cis	rs6445967	0.530	rs4420888	chr3:58392817	C/T	cg23715586	chr3:58305044	RPP14	0.41	6.73	0.31	5.52e-11	Platelet count;
LUAD	cis	rs151234	0.676	rs151320	chr16:28568678	A/G	cg04609801	chr16:28609176	SULT1A2	-0.61	-8.85	-0.4	2.38e-17	Platelet distribution width;
LUAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.37	7.81	0.36	4.49e-14	Hemoglobin concentration;
LUAD	cis	rs11229555	0.645	rs7946522	chr11:58197905	G/C	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7851660	0.844	rs993501	chr9:100623377	A/G	cg13688889	chr9:100608707	NA	0.51	8.72	0.39	6.46e-17	Strep throat;
LUAD	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg21963583	chr11:68658836	MRPL21	0.64	11.32	0.48	3.91e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg13385794	chr1:248469461	NA	0.25	6.95	0.32	1.35e-11	Common traits (Other);
LUAD	cis	rs4243830	0.850	rs11122043	chr1:6580429	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.54	-6.85	-0.32	2.63e-11	Body mass index;
LUAD	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg09365446	chr1:150670422	GOLPH3L	0.62	10.71	0.46	7.9e-24	Melanoma;
LUAD	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg24733560	chr20:60626293	TAF4	0.41	8.01	0.36	1.09e-14	Body mass index;
LUAD	cis	rs9462027	0.628	rs4601124	chr6:34776910	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.76	-0.39	4.66e-17	Systemic lupus erythematosus;
LUAD	trans	rs9354308	0.899	rs2802058	chr6:66550787	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.54	8.19	0.37	3.23e-15	Metabolite levels;
LUAD	cis	rs7084921	0.533	rs12765091	chr10:101855231	G/C	cg02250046	chr10:101825185	CPN1	-0.35	-6.6	-0.31	1.24e-10	Bone mineral density;
LUAD	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg02527881	chr3:46936655	PTH1R	-0.47	-8.96	-0.4	1.03e-17	Colorectal cancer;
LUAD	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg01097406	chr16:89675127	NA	0.43	9.47	0.42	1.92e-19	Vitiligo;
LUAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08048268	chr3:133502702	NA	-0.54	-10.99	-0.47	7.15e-25	Iron status biomarkers;
LUAD	cis	rs2580764	0.678	rs2580765	chr2:55204028	A/C	cg09592903	chr2:55203963	RTN4	0.47	10.87	0.47	1.9e-24	Mean platelet volume;
LUAD	cis	rs41271473	0.526	rs28593014	chr1:228743576	G/A	cg16512390	chr1:228756714	NA	0.68	9.06	0.4	4.72e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-7.47	-0.34	4.58e-13	Total cholesterol levels;
LUAD	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg26513180	chr16:89883248	FANCA	0.78	7.15	0.33	3.9e-12	Skin colour saturation;
LUAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg10150615	chr22:24372951	LOC391322	-0.54	-8.72	-0.39	6.57e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg22535103	chr8:58192502	C8orf71	-0.61	-6.74	-0.31	5.19e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9341808	0.718	rs12208016	chr6:80823563	G/A	cg08355045	chr6:80787529	NA	0.56	10.1	0.44	1.26e-21	Sitting height ratio;
LUAD	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg17366294	chr4:99064904	C4orf37	0.61	11.36	0.48	2.73e-26	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg16486109	chr11:613632	IRF7	0.49	8.17	0.37	3.65e-15	Systemic lupus erythematosus;
LUAD	cis	rs12410462	0.792	rs994666	chr1:227651454	C/T	cg04117972	chr1:227635322	NA	-0.57	-6.4	-0.3	4.05e-10	Major depressive disorder;
LUAD	cis	rs2742234	0.590	rs2503848	chr10:43672785	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.52	-8.9	-0.4	1.67e-17	Hirschsprung disease;
LUAD	cis	rs7843479	0.601	rs2306646	chr8:21846586	C/G	cg03445287	chr8:21823731	XPO7	-0.48	-8.9	-0.4	1.6e-17	Mean corpuscular volume;
LUAD	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg14019146	chr3:50243930	SLC38A3	0.55	11.16	0.48	1.6e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg26818010	chr10:134567672	INPP5A	-0.86	-14.88	-0.59	1.38e-40	Migraine;
LUAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg00450029	chr8:599525	NA	0.86	7.81	0.36	4.55e-14	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.74	0.31	5.2e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.773	rs421790	chr6:109543428	T/A	cg21918786	chr6:109611834	NA	-0.41	-6.92	-0.32	1.67e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs7009516	0.783	rs4872228	chr8:24219671	G/C	cg01759110	chr8:24241694	ADAMDEC1	-0.38	-7.57	-0.35	2.37e-13	Hair greying;
LUAD	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg23625390	chr15:77176239	SCAPER	-0.55	-8.94	-0.4	1.22e-17	Blood metabolite levels;
LUAD	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.59	9.91	0.43	6.12e-21	Electrocardiographic conduction measures;
LUAD	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg03714773	chr7:91764589	CYP51A1	0.28	6.69	0.31	6.9e-11	Breast cancer;
LUAD	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg04398451	chr17:18023971	MYO15A	-0.91	-17.96	-0.66	5.05e-54	Total body bone mineral density;
LUAD	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg15017067	chr4:17643749	FAM184B	-0.35	-6.7	-0.31	6.87e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs17532515	0.505	rs1472269	chr4:141493004	A/G	cg09181644	chr4:141490428	UCP1	0.35	7.16	0.33	3.52e-12	Select biomarker traits;
LUAD	cis	rs2652834	0.851	rs4238370	chr15:63347363	T/G	cg25406657	chr15:63342033	TPM1	-0.4	-6.52	-0.3	2.05e-10	HDL cholesterol;
LUAD	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg21204522	chr6:27730016	NA	-0.65	-6.74	-0.31	5.19e-11	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs59698941	0.943	rs67074969	chr5:132251063	T/A	cg14825688	chr5:132208181	LEAP2	-0.47	-6.41	-0.3	3.91e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.48e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg03806693	chr22:41940476	POLR3H	0.73	9.89	0.43	6.67e-21	Vitiligo;
LUAD	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg03885332	chr11:832357	CD151	-0.42	-7.91	-0.36	2.3e-14	Mean platelet volume;
LUAD	cis	rs714515	0.934	rs2227200	chr1:172333448	A/G	cg14508705	chr1:172360182	DNM3	-0.37	-6.48	-0.3	2.63e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs7520050	0.902	rs9429088	chr1:46497500	T/A	cg06784218	chr1:46089804	CCDC17	-0.3	-6.39	-0.3	4.45e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs2688608	0.868	rs2688625	chr10:75631548	T/C	cg23231163	chr10:75533350	FUT11	-0.44	-8.02	-0.36	1.02e-14	Inflammatory bowel disease;
LUAD	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg23649088	chr2:200775458	C2orf69	-0.49	-8.61	-0.39	1.47e-16	QT interval;
LUAD	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg26384229	chr12:38710491	ALG10B	-0.41	-6.96	-0.32	1.34e-11	Heart rate;
LUAD	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg03526776	chr6:41159608	TREML2	0.54	10.69	0.46	9.15e-24	Alzheimer's disease (late onset);
LUAD	trans	rs853679	0.607	rs56075693	chr6:28290328	T/G	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.18	-0.48	1.34e-25	Depression;
LUAD	trans	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.75	12.54	0.52	6.69e-31	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs12976411	0.702	rs35465982	chr19:32819413	A/G	cg02282382	chr19:32836354	ZNF507	0.76	6.76	0.31	4.69e-11	Coronary artery disease;
LUAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg14092988	chr3:52407081	DNAH1	0.4	7.95	0.36	1.7e-14	Bipolar disorder;
LUAD	cis	rs7017914	0.935	rs7826483	chr8:71702893	T/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.44	-0.3	3.17e-10	Bone mineral density;
LUAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg18402987	chr7:1209562	NA	0.78	9.56	0.42	9.57e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg21252483	chr19:49399788	TULP2	-0.61	-10.08	-0.44	1.52e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs57590327	0.503	rs13075250	chr3:81907952	T/C	cg07356753	chr3:81810745	GBE1	-0.58	-9.19	-0.41	1.77e-18	Extraversion;
LUAD	trans	rs877282	0.891	rs12357999	chr10:796468	A/C	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg15744005	chr10:104629667	AS3MT	-0.33	-6.57	-0.3	1.48e-10	Immature fraction of reticulocytes;Schizophrenia;
LUAD	trans	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg18187862	chr3:45730750	SACM1L	0.54	8.3	0.37	1.43e-15	Primary sclerosing cholangitis;
LUAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.51	-9.05	-0.4	5.34e-18	Lymphocyte counts;
LUAD	cis	rs738322	0.775	rs13056506	chr22:38580917	G/T	cg17652424	chr22:38574118	PLA2G6	0.25	7.04	0.32	7.9e-12	Cutaneous nevi;
LUAD	cis	rs3789045	0.826	rs12040520	chr1:204564762	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.39	-6.81	-0.31	3.45e-11	Educational attainment (college completion);
LUAD	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg23301539	chr8:142222248	SLC45A4	-0.48	-8.57	-0.38	2.02e-16	Immature fraction of reticulocytes;
LUAD	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg06636551	chr8:101224915	SPAG1	0.36	6.67	0.31	8.26e-11	Atrioventricular conduction;
LUAD	cis	rs11229555	0.609	rs4598685	chr11:58216864	A/G	cg15696309	chr11:58395628	NA	-0.74	-10.33	-0.45	1.92e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.5	0.42	1.62e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-7.38	-0.34	8.22e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs12368653	0.701	rs238517	chr12:58117737	T/G	cg12615879	chr12:58013172	SLC26A10	0.51	10.75	0.46	5.65e-24	Multiple sclerosis;
LUAD	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg05887092	chr17:76393375	PGS1	0.55	11.2	0.48	1.13e-25	HDL cholesterol levels;
LUAD	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.55	7.78	0.35	5.54e-14	Platelet count;
LUAD	trans	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg27411982	chr8:10470053	RP1L1	-0.4	-7.15	-0.33	3.96e-12	Mood instability;
LUAD	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg25358565	chr5:93447407	FAM172A	0.59	6.79	0.31	3.88e-11	Diabetic retinopathy;
LUAD	cis	rs3812111	0.510	rs1931892	chr6:116594511	A/C	cg18828861	chr6:116576566	TSPYL4	0.37	7.15	0.33	3.81e-12	Age-related macular degeneration;
LUAD	cis	rs2357013	0.752	rs35254490	chr2:53152835	G/A	cg07782112	chr2:53107842	NA	-0.38	-7.47	-0.34	4.5e-13	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg23533926	chr12:111358616	MYL2	0.4	6.84	0.32	2.77e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs738322	0.804	rs4821742	chr22:38514839	T/C	cg25457927	chr22:38595422	NA	-0.46	-10.77	-0.46	4.47e-24	Cutaneous nevi;
LUAD	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg11266682	chr4:10021025	SLC2A9	0.67	15.46	0.6	4.49e-43	Bone mineral density;
LUAD	cis	rs61897795	0.628	rs174585	chr11:61611694	G/A	cg21709803	chr11:61594965	FADS2	-0.45	-6.95	-0.32	1.43e-11	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs72772090	0.539	rs11747896	chr5:96113397	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.59	6.88	0.32	2.16e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg14092988	chr3:52407081	DNAH1	0.37	7.53	0.34	3.09e-13	Bipolar disorder;
LUAD	cis	rs2070997	0.586	rs7851994	chr9:133749848	C/T	cg13397898	chr9:133768931	QRFP	0.45	6.53	0.3	1.92e-10	Response to amphetamines;
LUAD	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg17425144	chr1:10567563	PEX14	0.53	10.68	0.46	1.01e-23	Prostate cancer;
LUAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	cis	rs7289126	0.868	rs2267377	chr22:38629519	T/C	cg17652424	chr22:38574118	PLA2G6	-0.23	-6.53	-0.3	1.93e-10	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7851660	0.839	rs10113884	chr9:100624622	C/T	cg13688889	chr9:100608707	NA	-0.5	-8.38	-0.38	7.66e-16	Strep throat;
LUAD	cis	rs2019216	1.000	rs2019216	chr17:21909650	C/T	cg05591447	chr17:21909280	FLJ36000	-0.29	-7.84	-0.36	3.6e-14	Pelvic organ prolapse;
LUAD	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.47	-7.65	-0.35	1.36e-13	Total body bone mineral density;
LUAD	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg12458913	chr13:53173898	NA	0.36	6.46	0.3	2.82e-10	Lewy body disease;
LUAD	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.89e-14	Depression;
LUAD	cis	rs34734847	0.898	rs696339	chr12:121169436	A/T	cg13914990	chr12:121174878	ACADS	0.4	7.88	0.36	2.79e-14	Mean corpuscular volume;
LUAD	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg07395648	chr5:131743802	NA	-0.38	-6.65	-0.31	9.23e-11	Breast cancer;
LUAD	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.88	0.4	1.86e-17	Parkinson's disease;
LUAD	cis	rs7119	0.604	rs2682927	chr15:77859168	C/T	cg27398640	chr15:77910606	LINGO1	0.39	7.13	0.33	4.32e-12	Type 2 diabetes;
LUAD	cis	rs89107	1.000	rs9489327	chr6:118561889	T/C	cg18833306	chr6:118973337	C6orf204	0.44	7.9	0.36	2.42e-14	Cardiac structure and function;
LUAD	cis	rs6429082	0.521	rs291390	chr1:235649678	T/C	cg26050004	chr1:235667680	B3GALNT2	0.39	6.57	0.3	1.49e-10	Adiposity;
LUAD	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg21204522	chr6:27730016	NA	-0.47	-7.47	-0.34	4.75e-13	Parkinson's disease;
LUAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg24813613	chr7:1882135	MAD1L1	-0.58	-9.33	-0.41	6.18e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg14584255	chr6:163149320	PACRG;PARK2	-0.33	-6.39	-0.3	4.44e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26314531	chr2:26401878	FAM59B	-0.72	-9.64	-0.42	5.26e-20	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9308433	0.798	rs10157166	chr1:214484950	C/T	cg06198575	chr1:214491504	SMYD2	0.38	6.59	0.31	1.33e-10	IgG glycosylation;
LUAD	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg20283391	chr11:68216788	NA	-0.42	-6.56	-0.3	1.56e-10	Total body bone mineral density;
LUAD	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg21153622	chr11:89784906	NA	-0.33	-6.45	-0.3	3.12e-10	Coronary artery disease;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg11383374	chr1:181074738	NA	-0.52	-7.2	-0.33	2.78e-12	Blood protein levels;
LUAD	cis	rs6543140	0.929	rs6742530	chr2:103082280	G/A	cg04239558	chr2:103089729	SLC9A4	0.36	7.33	0.34	1.15e-12	Blood protein levels;
LUAD	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg02018176	chr4:1364513	KIAA1530	-0.37	-6.81	-0.31	3.36e-11	Obesity-related traits;
LUAD	cis	rs80319144	1.000	rs78219577	chr2:159207367	C/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.77	0.31	4.19e-11	Restless legs syndrome;
LUAD	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg06558623	chr16:89946397	TCF25	1.21	12.18	0.51	1.83e-29	Skin colour saturation;
LUAD	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg12365402	chr11:9010492	NRIP3	-0.43	-8.19	-0.37	3.03e-15	Hemoglobin concentration;
LUAD	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.57	0.42	9.21e-20	Cognitive ability;
LUAD	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg02631126	chr6:28058918	ZSCAN12L1	-0.38	-7.7	-0.35	1e-13	Depression;
LUAD	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg05368731	chr17:41323189	NBR1	0.97	20.51	0.71	2.03e-65	Menopause (age at onset);
LUAD	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg00666640	chr1:248458726	OR2T12	0.3	7.22	0.33	2.5e-12	Common traits (Other);
LUAD	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.57	-0.3	1.49e-10	Morning vs. evening chronotype;
LUAD	trans	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.68	-11.62	-0.49	2.79e-27	Mean corpuscular volume;
LUAD	cis	rs8018808	0.935	rs11159261	chr14:77921120	A/G	cg20045696	chr14:77926864	AHSA1	0.35	6.37	0.3	5.03e-10	Myeloid white cell count;
LUAD	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg18944383	chr4:111397179	ENPEP	0.39	7.89	0.36	2.56e-14	Height;
LUAD	cis	rs8017423	0.647	rs11626821	chr14:90824945	A/G	cg14092571	chr14:90743983	NA	0.38	6.43	0.3	3.42e-10	Mortality in heart failure;
LUAD	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg06740227	chr12:86229804	RASSF9	0.41	7.66	0.35	1.29e-13	Major depressive disorder;
LUAD	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.81	-0.31	3.38e-11	Diabetic kidney disease;
LUAD	cis	rs877282	0.786	rs11253392	chr10:788768	G/A	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg21854759	chr1:92012499	NA	-0.49	-9.13	-0.41	2.95e-18	Breast cancer;
LUAD	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.89	-0.5	2.61e-28	Mean corpuscular volume;
LUAD	cis	rs354225	0.544	rs10208219	chr2:54806047	G/A	cg26097391	chr2:54893211	SPTBN1	0.42	6.43	0.3	3.48e-10	Schizophrenia;
LUAD	trans	rs7395662	0.963	rs10769389	chr11:48618011	C/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.48	-0.3	2.57e-10	HDL cholesterol;
LUAD	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	8.3	0.37	1.38e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg16606324	chr3:10149918	C3orf24	0.68	11.12	0.48	2.23e-25	Alzheimer's disease;
LUAD	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg06618935	chr21:46677482	NA	-0.43	-8.48	-0.38	3.88e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-11.68	-0.49	1.6e-27	Bipolar disorder;
LUAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.61	0.31	1.19e-10	Prudent dietary pattern;
LUAD	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.54	-0.34	2.9e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1953600	0.729	rs2819872	chr10:81906269	A/G	cg04850286	chr10:81895943	PLAC9	0.36	6.73	0.31	5.49e-11	Sarcoidosis;
LUAD	cis	rs3821902	0.606	rs73119095	chr3:64018177	G/T	cg22134162	chr3:63841271	THOC7	-0.42	-6.86	-0.32	2.48e-11	Breast cancer;
LUAD	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.82e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg23954153	chr1:44402353	ARTN	0.35	6.72	0.31	6.07e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7107174	1.000	rs4945268	chr11:78037936	T/C	cg02023728	chr11:77925099	USP35	0.44	6.73	0.31	5.63e-11	Testicular germ cell tumor;
LUAD	trans	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg03929089	chr4:120376271	NA	0.59	6.78	0.31	3.94e-11	Axial length;
LUAD	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg05966235	chr16:28915196	ATP2A1	0.49	7.87	0.36	3.09e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs11971779	0.618	rs6943788	chr7:139087697	C/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg24879335	chr3:133465180	TF	0.4	8.37	0.38	8.61e-16	Iron status biomarkers (transferrin levels);
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg17643699	chr12:27091484	FGFR1OP2;C12orf11	0.38	6.66	0.31	8.62e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg11494091	chr17:61959527	GH2	0.73	18.25	0.66	2.62e-55	Prudent dietary pattern;
LUAD	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.43	6.9	0.32	1.89e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9900062	0.546	rs2428352	chr17:62694738	C/T	cg02598441	chr17:62777298	LOC146880	0.53	6.88	0.32	2.1e-11	QT interval;
LUAD	cis	rs2294693	0.945	rs9349175	chr6:40982401	T/C	cg14769373	chr6:40998127	UNC5CL	-0.54	-8.32	-0.38	1.22e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg15247329	chr7:2764246	NA	-0.36	-6.63	-0.31	1.05e-10	Height;
LUAD	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg09796270	chr17:17721594	SREBF1	0.37	7.38	0.34	8.72e-13	Total body bone mineral density;
LUAD	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.62	9.17	0.41	2.06e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12681288	0.782	rs2600499	chr8:1026619	C/T	cg15309053	chr8:964076	NA	0.4	8.16	0.37	3.77e-15	Schizophrenia;
LUAD	cis	rs6545883	0.929	rs1186707	chr2:61673520	C/A	cg15711740	chr2:61764176	XPO1	-0.4	-6.45	-0.3	2.99e-10	Tuberculosis;
LUAD	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.27	-0.37	1.75e-15	Total body bone mineral density;
LUAD	cis	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg24851651	chr11:66362959	CCS	-0.54	-8.9	-0.4	1.71e-17	Airway imaging phenotypes;
LUAD	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	6.2e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg15247329	chr7:2764246	NA	-0.36	-6.54	-0.3	1.83e-10	Height;
LUAD	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg12458913	chr13:53173898	NA	0.45	8.04	0.36	8.96e-15	Lewy body disease;
LUAD	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg10755058	chr3:40428713	ENTPD3	0.38	7.4	0.34	7.31e-13	Renal cell carcinoma;
LUAD	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg13402656	chr8:1511478	DLGAP2	-0.73	-14.79	-0.58	3.43e-40	Lung cancer;
LUAD	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.34	6.8	0.31	3.54e-11	Obesity-related traits;
LUAD	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg23758822	chr17:41437982	NA	1.0	21.23	0.72	1.23e-68	Menopause (age at onset);
LUAD	cis	rs4144027	0.818	rs881057	chr14:104354258	T/G	cg12183467	chr14:104352244	NA	-0.36	-6.94	-0.32	1.49e-11	Blood metabolite levels;
LUAD	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg17757837	chr7:157058334	UBE3C	-0.47	-8.31	-0.37	1.36e-15	Body mass index;
LUAD	cis	rs13064411	0.696	rs9860549	chr3:113148368	G/A	cg10517650	chr3:113235015	CCDC52	-0.49	-8.25	-0.37	2.09e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg12011299	chr4:100065546	ADH4	0.72	13.38	0.55	2.81e-34	Alcohol dependence;
LUAD	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg02527881	chr3:46936655	PTH1R	0.46	8.85	0.4	2.48e-17	Colorectal cancer;
LUAD	cis	rs6087990	0.669	rs2424929	chr20:31389518	A/G	cg13636640	chr20:31349939	DNMT3B	0.74	13.18	0.54	1.75e-33	Ulcerative colitis;
LUAD	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg22963979	chr7:1858916	MAD1L1	-0.57	-9.62	-0.42	6.07e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.78	-0.53	7.26e-32	Breast cancer;
LUAD	cis	rs701145	0.938	rs701144	chr3:154059576	C/T	cg17054900	chr3:154042577	DHX36	0.65	7.15	0.33	3.78e-12	Coronary artery disease;
LUAD	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg05665937	chr4:1216051	CTBP1	-0.45	-8.22	-0.37	2.52e-15	Obesity-related traits;
LUAD	cis	rs3784262	0.904	rs4646620	chr15:58258241	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.44	-9.01	-0.4	6.95e-18	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg00280220	chr17:61926910	NA	0.36	6.9	0.32	1.9e-11	Prudent dietary pattern;
LUAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg00280220	chr17:61926910	NA	0.36	6.96	0.32	1.28e-11	Prudent dietary pattern;
LUAD	cis	rs367943	0.712	rs26968	chr5:112742429	A/G	cg12552261	chr5:112820674	MCC	0.48	9.22	0.41	1.39e-18	Type 2 diabetes;
LUAD	cis	rs6594713	1.000	rs6594713	chr5:112715374	A/C	cg12552261	chr5:112820674	MCC	0.53	8.57	0.38	1.98e-16	Brain cytoarchitecture;
LUAD	cis	rs6484504	0.576	rs208090	chr11:31190992	T/C	cg26647111	chr11:31128758	NA	-0.47	-8.31	-0.37	1.33e-15	Red blood cell count;
LUAD	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.55	-9.83	-0.43	1.15e-20	Eosinophil percentage of white cells;
LUAD	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg23625390	chr15:77176239	SCAPER	-0.46	-7.07	-0.33	6.47e-12	Blood metabolite levels;
LUAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08677398	chr8:58056175	NA	0.48	6.81	0.31	3.36e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.16	-0.41	2.31e-18	Total body bone mineral density;
LUAD	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg21385522	chr1:16154831	NA	-0.69	-10.86	-0.47	2.14e-24	Dilated cardiomyopathy;
LUAD	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg01097406	chr16:89675127	NA	0.46	9.85	0.43	9.91e-21	Vitiligo;
LUAD	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg12623918	chr2:306882	NA	0.34	6.88	0.32	2.23e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg02951883	chr7:2050386	MAD1L1	-0.74	-12.74	-0.53	1.13e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs7680126	0.596	rs10489070	chr4:10276352	C/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-7.65	-0.35	1.35e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg14552801	chr7:65878734	NA	0.37	6.38	0.3	4.71e-10	Aortic root size;
LUAD	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg08132940	chr7:1081526	C7orf50	-0.44	-7.07	-0.33	6.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-15.51	-0.6	2.94e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9297145	0.715	rs62473008	chr7:98751541	A/G	cg05967295	chr7:98741636	SMURF1	0.99	15.69	0.61	4.53e-44	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs10465746	0.967	rs1570690	chr1:84377515	G/T	cg10977910	chr1:84465055	TTLL7	0.49	7.85	0.36	3.39e-14	Obesity-related traits;
LUAD	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21659725	chr3:3221576	CRBN	0.51	8.44	0.38	5.22e-16	Body mass index;
LUAD	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg05805236	chr11:65401703	PCNXL3	-0.55	-8.77	-0.39	4.4e-17	Acne (severe);
LUAD	cis	rs7759001	0.857	rs1022518	chr6:27364886	A/G	cg18711553	chr6:27366782	ZNF391	0.39	6.55	0.3	1.69e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.3	6.35	0.3	5.54e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg06547715	chr2:218990976	CXCR2	0.44	10.39	0.45	1.09e-22	Ulcerative colitis;
LUAD	cis	rs1832871	0.683	rs6908487	chr6:158713047	G/T	cg07165851	chr6:158734300	TULP4	0.71	11.16	0.48	1.62e-25	Height;
LUAD	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10802521	chr3:52805072	NEK4	-0.59	-10.08	-0.44	1.44e-21	Bipolar disorder;
LUAD	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.63	8.55	0.38	2.27e-16	Gut microbiome composition (summer);
LUAD	cis	rs7727544	0.582	rs7703009	chr5:131552385	C/G	cg14196790	chr5:131705035	SLC22A5	0.42	7.15	0.33	3.79e-12	Blood metabolite levels;
LUAD	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.73	0.39	5.78e-17	Lung cancer in ever smokers;
LUAD	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.54	-0.58	3.78e-39	Schizophrenia;
LUAD	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.49	8.51	0.38	3.13e-16	Intelligence (multi-trait analysis);
LUAD	trans	rs3219090	0.861	rs1858550	chr1:226608104	C/A	cg27539482	chr13:111589090	NA	0.41	6.71	0.31	6.39e-11	Melanoma;
LUAD	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg26384229	chr12:38710491	ALG10B	0.45	7.45	0.34	5.46e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg11189052	chr15:85197271	WDR73	0.66	8.88	0.4	1.99e-17	Schizophrenia;
LUAD	cis	rs73206853	0.563	rs73194051	chr12:111204186	T/C	cg12870014	chr12:110450643	ANKRD13A	0.56	6.42	0.3	3.73e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg26384229	chr12:38710491	ALG10B	0.49	7.89	0.36	2.54e-14	Bladder cancer;
LUAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08280861	chr8:58055591	NA	0.62	8.04	0.36	9.1e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg21918786	chr6:109611834	NA	-0.57	-10.72	-0.46	7.19e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.55	0.3	1.67e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24786176	chr4:113153431	AP1AR	-0.45	-7.11	-0.33	5.09e-12	Height;
LUAD	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg03037974	chr15:76606532	NA	0.39	8.25	0.37	2.02e-15	Blood metabolite levels;
LUAD	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.14	-16.45	-0.62	2.43e-47	Schizophrenia;
LUAD	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10802521	chr3:52805072	NEK4	-0.52	-8.72	-0.39	6.37e-17	Bipolar disorder;
LUAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08219700	chr8:58056026	NA	-0.56	-7.82	-0.36	4.26e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg06623918	chr6:96969491	KIAA0776	0.7	10.38	0.45	1.18e-22	Migraine;Coronary artery disease;
LUAD	cis	rs9650657	0.771	rs4240670	chr8:10665848	T/A	cg27411982	chr8:10470053	RP1L1	-0.37	-6.4	-0.3	4.08e-10	Neuroticism;
LUAD	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-13.55	-0.55	5.43e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11644478	chr21:40555479	PSMG1	-0.55	-9.13	-0.41	2.78e-18	Cognitive function;
LUAD	cis	rs3106136	0.967	rs61004493	chr4:95163317	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.44	-0.34	5.56e-13	Capecitabine sensitivity;
LUAD	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.18e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1497828	0.956	rs1007736	chr1:217547852	C/T	cg04411442	chr1:217543379	NA	0.36	6.59	0.31	1.32e-10	Dialysis-related mortality;
LUAD	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg24768116	chr2:27665128	KRTCAP3	0.39	10.43	0.45	8.29e-23	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.65	0.42	4.89e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg04362960	chr10:104952993	NT5C2	-0.69	-7.73	-0.35	7.86e-14	Arsenic metabolism;
LUAD	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg26384229	chr12:38710491	ALG10B	-0.4	-6.63	-0.31	1.01e-10	Morning vs. evening chronotype;
LUAD	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg04511125	chr2:88470314	THNSL2	-0.75	-12.75	-0.53	9.99e-32	Response to metformin (IC50);
LUAD	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg05110241	chr16:68378359	PRMT7	-0.85	-8.98	-0.4	8.79e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-10.29	-0.45	2.68e-22	Chronic sinus infection;
LUAD	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.95	-0.4	1.09e-17	Gut microbiome composition (summer);
LUAD	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg12179176	chr11:130786555	SNX19	0.54	8.93	0.4	1.34e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.46	0.52	1.4e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg00933542	chr6:150070202	PCMT1	0.45	9.85	0.43	9.89e-21	Lung cancer;
LUAD	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.6	-0.71	8.12e-66	Height;
LUAD	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg14416269	chr4:6271139	WFS1	0.62	13.36	0.54	3.25e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg21659725	chr3:3221576	CRBN	0.39	6.51	0.3	2.1e-10	Resting heart rate;
LUAD	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg04106633	chr4:1044584	NA	0.56	9.98	0.44	3.28e-21	Recombination rate (males);
LUAD	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.55	-0.34	2.75e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs4790333	0.529	rs3101409	chr17:2258147	C/T	cg02569219	chr17:2266849	SGSM2	0.52	9.87	0.43	8.29e-21	Proinsulin levels;
LUAD	trans	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg21051086	chr3:73046214	PPP4R2	-0.45	-7.35	-0.34	1.05e-12	Pancreatic cancer;
LUAD	cis	rs1045714	0.895	rs73043182	chr7:2646005	C/T	cg20813462	chr7:2646259	IQCE	0.64	7.19	0.33	2.98e-12	Urate levels in lean individuals;
LUAD	cis	rs7809950	1.000	rs10276604	chr7:107216738	C/T	cg23024343	chr7:107201750	COG5	0.73	11.83	0.5	4.17e-28	Coronary artery disease;
LUAD	trans	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg04775059	chr7:64541387	NA	0.5	6.72	0.31	5.94e-11	Aortic root size;
LUAD	cis	rs1451375	0.959	rs1451373	chr7:50622606	A/G	cg18232548	chr7:50535776	DDC	0.58	9.5	0.42	1.6e-19	Malaria;
LUAD	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg18129178	chr5:148520854	ABLIM3	-0.54	-8.54	-0.38	2.38e-16	Breast cancer;
LUAD	cis	rs12545109	0.917	rs10098993	chr8:57323116	T/C	cg17761419	chr8:57350749	NA	-0.56	-7.9	-0.36	2.39e-14	Obesity-related traits;
LUAD	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.78	11.06	0.47	3.84e-25	Smoking behavior;
LUAD	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03452623	chr4:187889614	NA	-0.84	-18.07	-0.66	1.58e-54	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2227564	0.761	rs2227552	chr10:75669319	C/T	cg23231163	chr10:75533350	FUT11	-0.44	-6.84	-0.32	2.72e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg24879335	chr3:133465180	TF	0.39	8.15	0.37	4.08e-15	Iron status biomarkers (transferrin levels);
LUAD	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg02951883	chr7:2050386	MAD1L1	-0.75	-12.72	-0.53	1.32e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg08888203	chr3:10149979	C3orf24	0.72	12.89	0.53	2.61e-32	Alzheimer's disease;
LUAD	trans	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg12575136	chr18:32820987	ZNF397	0.44	6.87	0.32	2.31e-11	White blood cell count;
LUAD	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg18755752	chr8:142205143	DENND3	-0.73	-14.82	-0.58	2.68e-40	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.72	-9.45	-0.42	2.26e-19	Body mass index;
LUAD	cis	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.91	-0.36	2.21e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.02e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34311866	0.808	rs17783233	chr4:976598	T/C	cg07828340	chr4:882639	GAK	0.91	9.38	0.42	3.92e-19	Parkinson's disease;
LUAD	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg06387496	chr7:2775674	GNA12	-0.39	-6.43	-0.3	3.39e-10	Height;
LUAD	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg09365446	chr1:150670422	GOLPH3L	-0.44	-7.5	-0.34	3.66e-13	Tonsillectomy;
LUAD	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg20701182	chr2:24300061	SF3B14	0.56	6.65	0.31	8.93e-11	Lymphocyte counts;
LUAD	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	7.06	0.32	6.94e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg14202850	chr17:43974869	MAPT;LOC100130148	0.4	6.73	0.31	5.38e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg12483005	chr1:23474871	LUZP1	0.52	9.0	0.4	7.99e-18	Height;
LUAD	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg10556349	chr10:835070	NA	0.58	7.26	0.33	1.82e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg06623918	chr6:96969491	KIAA0776	-0.7	-9.59	-0.42	7.63e-20	Migraine;Coronary artery disease;
LUAD	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg14558114	chr2:88469736	THNSL2	0.65	7.25	0.33	2e-12	Plasma clusterin levels;
LUAD	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03647317	chr4:187891568	NA	-0.37	-7.16	-0.33	3.63e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2625529	0.617	rs7175373	chr15:72203517	G/T	cg16672083	chr15:72433130	SENP8	0.6	11.24	0.48	8.28e-26	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.46	7.55	0.34	2.75e-13	Alzheimer's disease (late onset);
LUAD	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg00701064	chr4:6280414	WFS1	0.65	13.98	0.56	9.1e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg06263672	chr7:65235340	NA	-0.48	-6.46	-0.3	2.82e-10	Aortic root size;
LUAD	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg09835421	chr16:68378352	PRMT7	-0.91	-9.74	-0.43	2.41e-20	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg25985355	chr7:65971099	NA	-0.56	-6.91	-0.32	1.79e-11	Gout;
LUAD	cis	rs6908034	0.660	rs111509549	chr6:19798370	A/G	cg02682789	chr6:19804855	NA	0.96	9.47	0.42	2.01e-19	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs1696756	0.638	rs1290396	chr17:77830767	C/T	cg00646381	chr17:77835854	NA	0.52	9.05	0.4	5.15e-18	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs9811920	0.732	rs7613864	chr3:99602470	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.61	11.72	0.5	1.15e-27	Axial length;
LUAD	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.05	0.36	8.77e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg00484396	chr16:3507460	NAT15	0.72	13.37	0.54	3.1e-34	Tuberculosis;
LUAD	cis	rs1816752	0.819	rs7316961	chr13:24985177	C/T	cg02811702	chr13:24901961	NA	0.43	7.48	0.34	4.4e-13	Obesity-related traits;
LUAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg11645453	chr3:52864694	ITIH4	0.38	7.82	0.36	4.38e-14	Bipolar disorder;
LUAD	trans	rs7939886	0.764	rs11227350	chr11:55912289	T/C	cg15704280	chr7:45808275	SEPT13	0.66	6.38	0.3	4.79e-10	Myopia (pathological);
LUAD	cis	rs2274273	1.000	rs66871576	chr14:55629050	C/T	cg04306507	chr14:55594613	LGALS3	0.38	7.61	0.35	1.81e-13	Protein biomarker;
LUAD	cis	rs7100689	0.725	rs10749574	chr10:82136856	T/C	cg01528321	chr10:82214614	TSPAN14	0.66	10.02	0.44	2.45e-21	Post bronchodilator FEV1;
LUAD	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg23533926	chr12:111358616	MYL2	-0.4	-6.77	-0.31	4.23e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg26587870	chr6:27730563	NA	-0.48	-7.9	-0.36	2.45e-14	Parkinson's disease;
LUAD	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg05340658	chr4:99064831	C4orf37	0.54	9.21	0.41	1.57e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26314531	chr2:26401878	FAM59B	-0.55	-7.71	-0.35	9.38e-14	Gut microbiome composition (summer);
LUAD	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg10755058	chr3:40428713	ENTPD3	0.39	7.41	0.34	7.07e-13	Renal cell carcinoma;
LUAD	cis	rs986417	1.000	rs1116853	chr14:60917476	A/G	cg27398547	chr14:60952738	C14orf39	0.64	7.64	0.35	1.46e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg09455208	chr3:40491958	NA	0.56	12.45	0.52	1.52e-30	Renal cell carcinoma;
LUAD	cis	rs17095355	0.642	rs7918758	chr10:111919866	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.64	-8.59	-0.39	1.67e-16	Biliary atresia;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17940234	chr6:150070697	PCMT1	-0.48	-6.66	-0.31	8.36e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs3806843	0.576	rs246007	chr5:140338748	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.52	-0.3	2.03e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs75804782	0.641	rs11904390	chr2:239344663	T/A	cg01134436	chr17:81009848	B3GNTL1	0.74	8.18	0.37	3.29e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs494562	0.892	rs490079	chr6:86117599	T/C	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs4268898	0.636	rs72803210	chr2:24615710	A/G	cg02683114	chr2:24398427	C2orf84	-0.52	-7.41	-0.34	6.9e-13	Asthma;
LUAD	cis	rs7582720	1.000	rs72932561	chr2:203848402	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.64	0.42	5.27e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.3	-0.41	7.71e-19	Type 2 diabetes;
LUAD	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.57	-7.7	-0.35	9.54e-14	Body mass index;
LUAD	cis	rs6835098	0.692	rs6822683	chr4:174063974	G/A	cg27433088	chr4:174089019	GALNT7	0.36	6.89	0.32	1.98e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs11771526	0.681	rs11767011	chr7:32420648	G/A	cg27532318	chr7:32358331	NA	0.7	7.53	0.34	3.08e-13	Body mass index;
LUAD	cis	rs28595532	0.748	rs72670248	chr4:119335536	A/C	cg21605333	chr4:119757512	SEC24D	0.69	6.74	0.31	5.21e-11	Cannabis dependence symptom count;
LUAD	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg12940439	chr1:67600707	NA	0.49	9.31	0.41	7.08e-19	Psoriasis;
LUAD	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg15485101	chr11:133734466	NA	0.37	7.92	0.36	2.15e-14	Childhood ear infection;
LUAD	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.91	-0.32	1.78e-11	Height;
LUAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg19026029	chr1:205785957	NA	0.31	6.35	0.3	5.48e-10	Menarche (age at onset);
LUAD	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg23803603	chr1:2058230	PRKCZ	-0.4	-7.19	-0.33	2.98e-12	Height;
LUAD	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg25894440	chr7:65020034	NA	-0.64	-7.0	-0.32	1.02e-11	Diabetic kidney disease;
LUAD	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.36	0.3	5.36e-10	Obesity-related traits;
LUAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08280861	chr8:58055591	NA	0.63	8.28	0.37	1.69e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg11909912	chr17:43974919	MAPT;LOC100130148	0.37	6.68	0.31	7.56e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs16854884	0.632	rs1910691	chr3:143656905	G/A	cg01302019	chr3:143689584	C3orf58	-0.4	-6.88	-0.32	2.22e-11	Economic and political preferences (feminism/equality);
LUAD	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08280861	chr8:58055591	NA	0.69	8.59	0.39	1.63e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.47	7.53	0.34	3.03e-13	Total body bone mineral density;
LUAD	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg22920501	chr2:26401640	FAM59B	-0.76	-10.97	-0.47	8.37e-25	Gut microbiome composition (summer);
LUAD	cis	rs6785206	0.892	rs6793907	chr3:128391626	A/G	cg16766828	chr3:128327626	NA	0.84	9.02	0.4	6.7e-18	Lymphocyte percentage of white cells;
LUAD	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg00750074	chr16:89608354	SPG7	-0.58	-9.98	-0.44	3.39e-21	Multiple myeloma (IgH translocation);
LUAD	cis	rs2067615	0.579	rs11113119	chr12:107200056	C/A	cg15890332	chr12:107067104	RFX4	0.39	8.42	0.38	5.99e-16	Heart rate;
LUAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg02869364	chr7:1081709	C7orf50	-0.5	-6.43	-0.3	3.45e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg23950597	chr19:37808831	NA	-0.62	-7.59	-0.35	2.09e-13	Coronary artery calcification;
LUAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg13047869	chr3:10149882	C3orf24	0.66	11.19	0.48	1.27e-25	Alzheimer's disease;
LUAD	cis	rs6484504	0.600	rs208063	chr11:31159777	C/T	cg26647111	chr11:31128758	NA	-0.47	-8.22	-0.37	2.48e-15	Red blood cell count;
LUAD	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-12.15	-0.51	2.49e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg26668828	chr6:292823	DUSP22	-0.8	-14.17	-0.57	1.46e-37	Menopause (age at onset);
LUAD	cis	rs2554380	0.843	rs1426160	chr15:84408634	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.48	-7.74	-0.35	7.3e-14	Height;
LUAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg03188948	chr7:1209495	NA	0.42	6.66	0.31	8.77e-11	Longevity;Endometriosis;
LUAD	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg00495681	chr13:53174319	NA	0.7	13.82	0.56	4.14e-36	Lewy body disease;
LUAD	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg15704280	chr7:45808275	SEPT13	0.9	17.52	0.65	4.7e-52	Coronary artery disease;
LUAD	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg18721089	chr20:30220636	NA	-0.41	-6.36	-0.3	5.28e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg00495681	chr13:53174319	NA	-0.48	-8.9	-0.4	1.68e-17	Lewy body disease;
LUAD	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-13.84	-0.56	3.42e-36	Headache;
LUAD	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4812048	0.649	rs6070702	chr20:57621562	G/C	cg14073986	chr20:57617431	SLMO2	0.81	9.71	0.43	3.01e-20	Mean platelet volume;
LUAD	cis	rs6696239	0.513	rs10495276	chr1:227736946	C/T	cg12133451	chr1:227746453	NA	0.38	6.93	0.32	1.6e-11	Height;
LUAD	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.4	6.4	0.3	4.22e-10	Coronary artery disease;
LUAD	cis	rs12545109	0.800	rs1595940	chr8:57398309	T/C	cg07776626	chr8:57350775	NA	-0.63	-8.99	-0.4	8.05e-18	Obesity-related traits;
LUAD	cis	rs34734847	0.842	rs7308648	chr12:121144144	C/G	cg21892295	chr12:121157589	UNC119B	-0.39	-6.99	-0.32	1.07e-11	Mean corpuscular volume;
LUAD	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg23281280	chr6:28129359	ZNF389	0.44	6.44	0.3	3.22e-10	Depression;
LUAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg00450029	chr8:599525	NA	0.81	8.03	0.36	1.01e-14	IgG glycosylation;
LUAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg05313129	chr8:58192883	C8orf71	-0.54	-7.04	-0.32	7.65e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4786125	0.636	rs7192853	chr16:6918241	G/C	cg03623568	chr16:6915990	A2BP1	-0.48	-10.41	-0.45	9.34e-23	Heart rate variability traits (SDNN);
LUAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg11062466	chr8:58055876	NA	0.74	13.17	0.54	1.92e-33	Developmental language disorder (linguistic errors);
LUAD	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg14784868	chr12:69753453	YEATS4	0.44	7.18	0.33	3.26e-12	Blood protein levels;
LUAD	cis	rs4638749	1.000	rs2198463	chr2:108875093	T/A	cg06795125	chr2:108905320	SULT1C2	-0.42	-6.58	-0.3	1.36e-10	Blood pressure;
LUAD	cis	rs16921914	0.559	rs2985140	chr11:31315886	C/T	cg14844989	chr11:31128820	NA	0.46	8.44	0.38	5.22e-16	Bone mineral density (spine);
LUAD	cis	rs62238980	0.614	rs1475997	chr22:32465025	G/A	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg25237894	chr2:233734115	C2orf82	0.64	12.02	0.5	7.78e-29	Coronary artery disease;
LUAD	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18876405	chr7:65276391	NA	-0.42	-6.68	-0.31	7.75e-11	Aortic root size;
LUAD	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg24324837	chr19:49891574	CCDC155	0.54	7.55	0.34	2.74e-13	Multiple sclerosis;
LUAD	cis	rs7178375	0.607	rs12903674	chr15:31194552	G/C	cg03767031	chr15:31195708	MTMR15	0.8	8.04	0.36	9.04e-15	Hypertriglyceridemia;
LUAD	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg07570687	chr10:102243282	WNT8B	0.48	7.34	0.34	1.09e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7000551	0.527	rs11783730	chr8:22244897	C/T	cg12081754	chr8:22256438	SLC39A14	0.88	14.26	0.57	6.14e-38	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21659725	chr3:3221576	CRBN	0.51	8.37	0.38	8.26e-16	Body mass index;
LUAD	cis	rs13315871	1.000	rs28489489	chr3:58443755	C/A	cg12435725	chr3:58293450	RPP14	-0.67	-7.45	-0.34	5.31e-13	Cholesterol, total;
LUAD	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg27144592	chr16:783916	NARFL	0.35	6.47	0.3	2.75e-10	Height;
LUAD	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.47e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4691139	0.903	rs6835415	chr4:165920084	G/A	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.43	-8.2	-0.37	2.9e-15	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs11229555	0.874	rs10896794	chr11:58339124	T/C	cg15696309	chr11:58395628	NA	-0.71	-10.19	-0.44	5.95e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg01579765	chr21:45077557	HSF2BP	-0.6	-13.37	-0.54	3.06e-34	Mean corpuscular volume;
LUAD	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg18129178	chr5:148520854	ABLIM3	0.6	9.1	0.4	3.67e-18	Breast cancer;
LUAD	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg11266682	chr4:10021025	SLC2A9	0.68	15.8	0.61	1.55e-44	Bone mineral density;
LUAD	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg18811423	chr2:55921094	PNPT1	0.52	8.63	0.39	1.23e-16	Metabolic syndrome;
LUAD	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg18230493	chr5:56204884	C5orf35	-0.59	-9.51	-0.42	1.42e-19	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08219700	chr8:58056026	NA	0.61	8.59	0.39	1.64e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg16647868	chr5:131706066	SLC22A5	0.5	7.93	0.36	1.97e-14	Breast cancer;
LUAD	cis	rs4631830	0.832	rs2337711	chr10:51504604	C/T	cg20129853	chr10:51489980	NA	0.33	6.46	0.3	2.81e-10	Prostate-specific antigen levels;
LUAD	cis	rs13040088	1.000	rs6090155	chr20:61527378	G/A	cg23096297	chr20:61557774	DIDO1	0.74	10.4	0.45	1.08e-22	Menopause (age at onset);
LUAD	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	8.23	0.37	2.39e-15	Parkinson's disease;
LUAD	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.91	0.36	2.31e-14	Parkinson's disease;
LUAD	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.48	0.34	4.47e-13	Bipolar disorder;
LUAD	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.33	6.42	0.3	3.57e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-7.45	-0.34	5.2e-13	Alzheimer's disease (late onset);
LUAD	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg09117114	chr16:67998030	SLC12A4	-0.47	-6.75	-0.31	4.8e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg03714773	chr7:91764589	CYP51A1	0.29	6.96	0.32	1.28e-11	Breast cancer;
LUAD	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.39	-7.73	-0.35	7.72e-14	Glomerular filtration rate;
LUAD	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.65	0.31	9.11e-11	Depression;
LUAD	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg26343298	chr8:95960752	TP53INP1	0.37	7.91	0.36	2.23e-14	Type 2 diabetes;
LUAD	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg22166914	chr1:53195759	ZYG11B	0.39	6.59	0.31	1.28e-10	Monocyte count;
LUAD	cis	rs4845570	0.920	rs6694952	chr1:151760131	T/C	cg07092448	chr1:151763213	TDRKH	0.74	8.45	0.38	4.84e-16	Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg18811423	chr2:55921094	PNPT1	0.51	8.39	0.38	7.15e-16	Metabolic syndrome;
LUAD	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg12645284	chr15:79092878	ADAMTS7	0.48	7.56	0.35	2.5e-13	Coronary artery disease or large artery stroke;
LUAD	cis	rs7274811	0.744	rs6119395	chr20:32244711	G/T	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.46	-6.78	-0.31	4.06e-11	Height;
LUAD	cis	rs1691799	0.899	rs4762091	chr12:66747863	A/G	cg16791601	chr12:66731901	HELB	-0.36	-6.49	-0.3	2.39e-10	White blood cell count (basophil);
LUAD	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.98	0.32	1.18e-11	Colorectal cancer;
LUAD	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg27211696	chr2:191398769	TMEM194B	0.68	9.17	0.41	2.11e-18	Diastolic blood pressure;
LUAD	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg09455208	chr3:40491958	NA	0.55	12.08	0.51	4.64e-29	Renal cell carcinoma;
LUAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg05457628	chr5:178986728	RUFY1	-0.56	-9.46	-0.42	2.19e-19	Lung cancer;
LUAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-10.14	-0.44	9.08e-22	Longevity;Endometriosis;
LUAD	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg03806693	chr22:41940476	POLR3H	0.73	9.89	0.43	7.14e-21	Vitiligo;
LUAD	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.22	-0.37	2.6e-15	Total body bone mineral density;
LUAD	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg19346786	chr7:2764209	NA	-0.31	-6.71	-0.31	6.36e-11	Height;
LUAD	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg02221422	chr11:68192511	LRP5	0.42	6.38	0.3	4.66e-10	Bone mineral density (spine);
LUAD	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-9.61	-0.42	6.52e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6988985	0.765	rs10096393	chr8:143984315	T/C	cg10324643	chr8:143916377	GML	0.31	6.43	0.3	3.37e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs1113500	0.541	rs9803640	chr1:108576267	A/C	cg06207961	chr1:108661230	NA	-0.41	-6.56	-0.3	1.62e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs2282300	0.739	rs1222215	chr11:30347596	C/T	cg06241208	chr11:30344200	C11orf46	-0.55	-6.99	-0.32	1.07e-11	Morning vs. evening chronotype;
LUAD	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.03	-0.36	9.69e-15	Diabetic kidney disease;
LUAD	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg05805236	chr11:65401703	PCNXL3	-0.61	-9.83	-0.43	1.17e-20	Acne (severe);
LUAD	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	8.44	0.38	5.11e-16	Breast cancer;
LUAD	cis	rs78761021	0.867	rs17676097	chr17:9791549	A/G	cg26853458	chr17:9805074	RCVRN	0.36	7.02	0.32	9.06e-12	Type 2 diabetes;
LUAD	trans	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg14791747	chr16:20752902	THUMPD1	0.74	10.02	0.44	2.33e-21	Cognitive test performance;
LUAD	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg07606381	chr6:8435919	SLC35B3	0.41	6.76	0.31	4.6e-11	Motion sickness;
LUAD	cis	rs17095355	1.000	rs17126890	chr10:111699169	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.71	-9.75	-0.43	2.1e-20	Biliary atresia;
LUAD	cis	rs4638749	0.677	rs7570544	chr2:108848137	C/T	cg25838818	chr2:108905173	SULT1C2	-0.37	-6.64	-0.31	9.76e-11	Blood pressure;
LUAD	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.58	-0.35	2.26e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12893597	0.715	rs71429953	chr14:76819480	C/T	cg20290672	chr14:76816747	NA	-0.46	-7.54	-0.34	2.9e-13	Maximal oxygen uptake response;
LUAD	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg02423579	chr7:2872169	GNA12	-0.87	-14.8	-0.58	3.23e-40	Height;
LUAD	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.82	-0.43	1.23e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg07952391	chr2:88470173	THNSL2	0.78	8.39	0.38	7.58e-16	Plasma clusterin levels;
LUAD	cis	rs9581857	0.547	rs9579096	chr13:28084069	T/C	cg22138327	chr13:27999177	GTF3A	0.86	9.06	0.4	4.74e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg25358565	chr5:93447407	FAM172A	0.61	7.71	0.35	8.98e-14	Diabetic retinopathy;
LUAD	trans	rs9354308	0.899	rs2802055	chr6:66545756	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.53	8.12	0.37	5.28e-15	Metabolite levels;
LUAD	cis	rs9399401	0.633	rs262118	chr6:142843054	C/A	cg03128060	chr6:142623767	GPR126	0.45	8.08	0.37	6.74e-15	Chronic obstructive pulmonary disease;
LUAD	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg07917127	chr4:99064746	C4orf37	0.38	6.35	0.3	5.44e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.36	-0.45	1.43e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs4730250	0.554	rs112665932	chr7:106916121	A/G	cg23024343	chr7:107201750	COG5	0.49	6.51	0.3	2.12e-10	Osteoarthritis;
LUAD	trans	rs877282	0.898	rs12358966	chr10:758703	A/G	cg22713356	chr15:30763199	NA	1.2	15.94	0.61	3.96e-45	Uric acid levels;
LUAD	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg21775007	chr8:11205619	TDH	0.47	8.15	0.37	4.29e-15	Retinal vascular caliber;
LUAD	cis	rs220324	0.738	rs9984147	chr21:43590428	A/T	cg08841829	chr21:43638893	ABCG1	-0.47	-6.53	-0.3	1.84e-10	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs11247915	0.583	rs34058882	chr1:26659794	C/T	cg15628303	chr1:26608928	UBXN11	0.48	8.71	0.39	6.85e-17	Obesity-related traits;
LUAD	cis	rs4493873	0.869	rs57987672	chr8:92119197	T/A	cg16814680	chr8:91681699	NA	0.43	6.8	0.31	3.48e-11	Migraine - clinic-based;
LUAD	cis	rs12422267	0.536	rs7976530	chr12:132609140	C/T	cg09764611	chr12:132620959	NA	-0.64	-11.03	-0.47	5.06e-25	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18404041	chr3:52824283	ITIH1	-0.6	-12.15	-0.51	2.4e-29	Bipolar disorder;
LUAD	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg06618935	chr21:46677482	NA	-0.5	-10.01	-0.44	2.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06022373	chr22:39101656	GTPBP1	0.49	8.15	0.37	4.2e-15	Menopause (age at onset);
LUAD	cis	rs1847202	0.517	rs13062803	chr3:72951840	T/A	cg25664220	chr3:72788482	NA	-0.41	-7.23	-0.33	2.29e-12	Motion sickness;
LUAD	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21582582	chr3:182698605	DCUN1D1	0.6	9.74	0.43	2.35e-20	Resting heart rate;
LUAD	cis	rs7264396	0.563	rs2425130	chr20:34335059	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.07	-0.37	7.53e-15	Total cholesterol levels;
LUAD	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg05340658	chr4:99064831	C4orf37	0.53	9.06	0.4	4.81e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2594714	0.538	rs895819	chr19:13947292	A/G	cg18576835	chr19:13944261	NA	-0.48	-8.73	-0.39	6.05e-17	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17539315	chr12:50794919	LARP4	-0.5	-7.72	-0.35	8.63e-14	Height;
LUAD	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.31	-0.33	1.37e-12	Lung cancer;
LUAD	cis	rs7799006	0.862	rs3757439	chr7:2272122	C/T	cg02951883	chr7:2050386	MAD1L1	-0.53	-8.37	-0.38	8.22e-16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs9479482	0.967	rs1853664	chr6:150355266	A/G	cg08316699	chr6:150357289	NA	0.33	6.94	0.32	1.47e-11	Alopecia areata;
LUAD	trans	rs524023	0.914	rs2666559	chr11:64439227	G/T	cg16714605	chr19:10765132	ILF3;LOC147727	-0.41	-6.64	-0.31	9.88e-11	Urate levels in obese individuals;
LUAD	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.94	0.44	4.76e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg18404041	chr3:52824283	ITIH1	0.53	8.8	0.39	3.64e-17	Schizophrenia;
LUAD	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg21827317	chr3:136751795	NA	0.36	6.58	0.3	1.37e-10	Neuroticism;
LUAD	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.13	0.33	4.45e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs921968	0.565	rs4674328	chr2:219593203	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-11.3	-0.48	4.73e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg07305463	chr2:136567211	LCT	0.38	6.83	0.32	2.9100000000000002e-11	Mosquito bite size;
LUAD	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1215050	0.818	rs165238	chr4:98712138	G/T	cg17366294	chr4:99064904	C4orf37	0.46	8.13	0.37	4.74e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg13047869	chr3:10149882	C3orf24	0.59	9.99	0.44	2.95e-21	Alzheimer's disease;
LUAD	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg00277334	chr10:82204260	NA	-0.61	-10.31	-0.45	2.22e-22	Post bronchodilator FEV1;
LUAD	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg06618935	chr21:46677482	NA	-0.41	-8.13	-0.37	4.88e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4853036	0.586	rs7558899	chr2:70010351	T/C	cg02498382	chr2:70120550	SNRNP27	-0.46	-6.44	-0.3	3.28e-10	Colorectal or endometrial cancer;
LUAD	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg05991184	chr2:219186017	PNKD	-0.36	-7.16	-0.33	3.49e-12	Colorectal cancer;
LUAD	cis	rs9560113	1.000	rs9560106	chr13:112179605	A/G	cg14154082	chr13:112174009	NA	0.36	6.82	0.31	3.24e-11	Menarche (age at onset);
LUAD	trans	rs2840044	0.534	rs321596	chr17:33885736	C/T	cg19694781	chr19:47549865	TMEM160	0.44	7.37	0.34	9.23e-13	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs2932538	0.922	rs12750023	chr1:113118329	G/A	cg22162597	chr1:113214053	CAPZA1	0.46	6.88	0.32	2.1e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs977987	0.806	rs12599361	chr16:75434973	A/T	cg03315344	chr16:75512273	CHST6	0.64	14.15	0.57	1.69e-37	Dupuytren's disease;
LUAD	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	9.52	0.42	1.39e-19	Axial length;
LUAD	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg16325326	chr1:53192061	ZYG11B	0.63	12.38	0.52	3.09e-30	Monocyte count;
LUAD	cis	rs3736594	0.765	rs12994085	chr2:27952406	C/T	cg27432699	chr2:27873401	GPN1	-0.43	-6.74	-0.31	5.27e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	trans	rs3219090	1.000	rs2048424	chr1:226583007	G/C	cg27539482	chr13:111589090	NA	0.4	6.73	0.31	5.51e-11	Melanoma;
LUAD	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.71	-10.54	-0.46	3.21e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg10909506	chr17:38081995	ORMDL3	0.37	6.49	0.3	2.44e-10	Self-reported allergy;
LUAD	trans	rs11039798	0.925	rs10769373	chr11:48531980	T/A	cg02254774	chr11:50257496	LOC441601	0.52	6.49	0.3	2.39e-10	Axial length;
LUAD	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08859206	chr1:53392774	SCP2	-0.7	-13.32	-0.54	4.99e-34	Monocyte count;
LUAD	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg23587288	chr2:27483067	SLC30A3	-0.43	-8.45	-0.38	4.69e-16	Blood metabolite levels;
LUAD	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19524238	chr7:2802976	GNA12	-0.31	-6.39	-0.3	4.44e-10	Height;
LUAD	trans	rs258892	0.842	rs34956	chr5:72203696	T/C	cg14879065	chr14:104662468	NA	-0.35	-6.44	-0.3	3.2e-10	Small cell lung carcinoma;
LUAD	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg07936489	chr17:37558343	FBXL20	0.44	6.89	0.32	2.03e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg10518543	chr12:38710700	ALG10B	0.49	8.05	0.36	8.65e-15	Morning vs. evening chronotype;
LUAD	cis	rs3087591	0.960	rs2905878	chr17:29511199	T/C	cg24425628	chr17:29625626	OMG;NF1	0.42	6.82	0.31	3.18e-11	Hip circumference;
LUAD	cis	rs7119	0.717	rs12904348	chr15:77815738	G/C	cg27398640	chr15:77910606	LINGO1	-0.34	-6.55	-0.3	1.63e-10	Type 2 diabetes;
LUAD	cis	rs4604732	0.588	rs7552443	chr1:247628583	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.18	0.33	3.06e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.65	-7.21	-0.33	2.54e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-7.63	-0.35	1.53e-13	Total body bone mineral density;
LUAD	cis	rs7177699	0.525	rs7166770	chr15:79113568	A/G	cg00540400	chr15:79124168	NA	0.44	9.5	0.42	1.61e-19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs72634258	0.945	rs12730860	chr1:8132462	T/C	cg26816564	chr1:7831052	VAMP3	0.56	7.47	0.34	4.68e-13	Inflammatory bowel disease;
LUAD	cis	rs3784262	0.565	rs4646606	chr15:58287526	A/G	cg12031962	chr15:58353849	ALDH1A2	0.34	6.46	0.3	2.85e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.35	7.29	0.33	1.49e-12	Parkinson's disease;
LUAD	cis	rs3849570	0.961	rs11710970	chr3:81693489	T/C	cg07356753	chr3:81810745	GBE1	-0.68	-11.78	-0.5	6.65e-28	Waist circumference;Body mass index;
LUAD	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg24531977	chr5:56204891	C5orf35	0.53	8.56	0.38	2.12e-16	Coronary artery disease;
LUAD	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18099408	chr3:52552593	STAB1	-0.42	-7.13	-0.33	4.42e-12	Bipolar disorder;
LUAD	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg17849569	chr6:28058911	ZSCAN12L1	-0.32	-6.69	-0.31	6.92e-11	Depression;
LUAD	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.38	0.38	7.67e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg06618935	chr21:46677482	NA	-0.52	-10.34	-0.45	1.72e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg17971929	chr21:40555470	PSMG1	0.48	7.11	0.33	4.97e-12	Cognitive function;
LUAD	cis	rs2651899	0.867	rs2742675	chr1:3079905	A/G	cg22396632	chr1:3079212	PRDM16	-0.38	-8.51	-0.38	3.15e-16	Migraine;
LUAD	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg24818145	chr4:99064322	C4orf37	0.46	7.83	0.36	4.07e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs62103177	0.535	rs62101568	chr18:77934671	G/A	cg05926928	chr17:57297772	GDPD1	0.59	6.76	0.31	4.56e-11	Opioid sensitivity;
LUAD	cis	rs738321	0.725	rs5756926	chr22:38542613	T/C	cg25457927	chr22:38595422	NA	-0.54	-12.04	-0.51	6.36e-29	Breast cancer;
LUAD	cis	rs57920188	0.584	rs12080516	chr1:4089613	C/T	cg20703997	chr1:4087676	NA	0.48	8.97	0.4	9.48e-18	Interleukin-17 levels;
LUAD	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg15628303	chr1:26608928	UBXN11	-0.36	-6.36	-0.3	5.39e-10	Height;
LUAD	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg22916017	chr11:64110731	CCDC88B	0.36	6.53	0.3	1.93e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg15017067	chr4:17643749	FAM184B	0.37	7.04	0.32	7.83e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg02466173	chr16:30829666	NA	-0.7	-12.26	-0.51	8.82e-30	Multiple myeloma;
LUAD	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.93	-0.36	2.04e-14	Total body bone mineral density;
LUAD	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg08085267	chr17:45401833	C17orf57	-0.64	-11.32	-0.48	3.9e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.91	0.76	1.47e-80	Chronic sinus infection;
LUAD	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg07432352	chr17:45403706	C17orf57	-0.4	-7.68	-0.35	1.15e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg02782426	chr3:40428986	ENTPD3	-0.41	-8.99	-0.4	8.29e-18	Renal cell carcinoma;
LUAD	cis	rs68170813	0.559	rs12534676	chr7:106943640	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-10.68	-0.46	9.67e-24	Coronary artery disease;
LUAD	cis	rs17197710	0.673	rs3736101	chr11:47306628	G/A	cg13308137	chr11:47528955	CUGBP1	0.46	7.18	0.33	3.11e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg13263323	chr15:86062960	AKAP13	0.46	7.72	0.35	8.55e-14	Coronary artery disease;
LUAD	trans	rs225245	0.817	rs225273	chr17:33970935	A/T	cg19694781	chr19:47549865	TMEM160	-0.45	-7.33	-0.34	1.16e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg19622623	chr12:86230825	RASSF9	-0.39	-6.88	-0.32	2.18e-11	Major depressive disorder;
LUAD	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-8.71	-0.39	6.99e-17	Schizophrenia;
LUAD	cis	rs57502260	0.704	rs55975204	chr11:68249124	C/T	cg16797656	chr11:68205561	LRP5	0.46	6.85	0.32	2.65e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg04287289	chr16:89883240	FANCA	0.78	6.95	0.32	1.37e-11	Skin colour saturation;
LUAD	cis	rs427941	0.668	rs201461	chr7:101741625	T/C	cg06246474	chr7:101738831	CUX1	0.41	7.29	0.33	1.57e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.32e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg05283184	chr6:79620031	NA	-0.55	-11.03	-0.47	4.8e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23583168	chr7:148888333	NA	-0.89	-17.93	-0.66	6.9e-54	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.79	-0.43	1.59e-20	Alzheimer's disease;
LUAD	cis	rs494562	0.730	rs313204	chr6:86114296	C/A	cg13315970	chr6:86159197	NT5E	0.59	6.91	0.32	1.8e-11	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7236492	0.572	rs78124041	chr18:77181489	G/A	cg15644404	chr18:77186268	NFATC1	-0.77	-7.12	-0.33	4.81e-12	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg09021430	chr5:549028	NA	-0.69	-13.88	-0.56	2.24e-36	Lung disease severity in cystic fibrosis;
LUAD	cis	rs62238980	0.614	rs2413063	chr22:32458252	A/C	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg00634984	chr7:65235879	NA	-0.47	-6.46	-0.3	2.81e-10	Aortic root size;
LUAD	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg00310523	chr12:86230176	RASSF9	0.41	8.1	0.37	6.07e-15	Major depressive disorder;
LUAD	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg14835575	chr10:16859367	RSU1	1.01	15.09	0.59	1.88e-41	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs10499694	0.933	rs998850	chr7:50607388	G/C	cg18232548	chr7:50535776	DDC	-0.47	-7.96	-0.36	1.61e-14	Body mass index;
LUAD	trans	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg26811252	chr16:29126840	RRN3P2	0.59	10.13	0.44	9.52e-22	Menopause (age at onset);
LUAD	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg05340658	chr4:99064831	C4orf37	-0.46	-7.54	-0.34	2.82e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06873352	chr17:61820015	STRADA	-0.52	-8.42	-0.38	5.91e-16	Height;
LUAD	cis	rs2233152	0.610	rs10405596	chr19:41314720	C/T	cg21869046	chr19:41225005	ITPKC	0.46	8.28	0.37	1.62e-15	Kawasaki disease;
LUAD	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg18761221	chr20:60518478	NA	-0.58	-10.23	-0.45	4.24e-22	Obesity-related traits;
LUAD	cis	rs7107174	1.000	rs10899468	chr11:78016650	C/T	cg02023728	chr11:77925099	USP35	0.52	7.77	0.35	6.01e-14	Testicular germ cell tumor;
LUAD	cis	rs9287719	0.649	rs6722126	chr2:10721642	A/G	cg03983476	chr2:10830698	NOL10	-0.38	-6.41	-0.3	3.88e-10	Prostate cancer;
LUAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg27454412	chr7:1067447	C7orf50	0.44	7.07	0.33	6.35e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.84	-0.36	3.69e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg00750074	chr16:89608354	SPG7	-0.54	-9.1	-0.4	3.57e-18	Multiple myeloma (IgH translocation);
LUAD	cis	rs8017423	0.967	rs2277514	chr14:90723059	T/C	cg14092571	chr14:90743983	NA	-0.49	-8.68	-0.39	8.85e-17	Mortality in heart failure;
LUAD	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg00666640	chr1:248458726	OR2T12	0.27	6.35	0.3	5.46e-10	Common traits (Other);
LUAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.21e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg26338869	chr17:61819248	STRADA	-0.38	-6.38	-0.3	4.65e-10	Prudent dietary pattern;
LUAD	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.41	-7.35	-0.34	1.05e-12	Alzheimer's disease (late onset);
LUAD	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs12210905	1.000	rs12203728	chr6:27051750	G/C	cg11502198	chr6:26597334	ABT1	-0.78	-6.46	-0.3	2.86e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.88	-0.32	2.1e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.22	-0.41	1.41e-18	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg18180107	chr4:99064573	C4orf37	0.42	6.86	0.32	2.39e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg22117172	chr7:91764530	CYP51A1	0.35	7.64	0.35	1.45e-13	Breast cancer;
LUAD	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg17644776	chr2:200775616	C2orf69	0.44	7.03	0.32	8.31e-12	Osteoporosis;
LUAD	trans	rs12310956	0.510	rs10844690	chr12:33854752	C/A	cg10518543	chr12:38710700	ALG10B	0.4	6.37	0.3	5.05e-10	Morning vs. evening chronotype;
LUAD	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22496380	chr5:211416	CCDC127	-0.92	-12.42	-0.52	1.97e-30	Breast cancer;
LUAD	cis	rs7474896	0.537	rs2749586	chr10:38270214	G/C	cg25427524	chr10:38739819	LOC399744	0.59	8.47	0.38	4.17e-16	Obesity (extreme);
LUAD	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg27284194	chr4:1044797	NA	0.65	9.25	0.41	1.13e-18	Recombination rate (females);
LUAD	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg03948781	chr1:205179583	DSTYK	0.35	6.36	0.3	5.17e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg26384229	chr12:38710491	ALG10B	0.48	7.88	0.36	2.86e-14	Bladder cancer;
LUAD	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg18932078	chr1:2524107	MMEL1	0.35	6.63	0.31	1.04e-10	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg08601574	chr20:25228251	PYGB	0.47	8.81	0.39	3.14e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg00933542	chr6:150070202	PCMT1	0.31	6.48	0.3	2.6200000000000003e-10	Testicular germ cell tumor;
LUAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg05434287	chr7:2030229	MAD1L1	0.41	6.74	0.31	5.04e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs4853036	0.539	rs10205368	chr2:69996154	A/G	cg02498382	chr2:70120550	SNRNP27	-0.47	-6.78	-0.31	4.1e-11	Colorectal or endometrial cancer;
LUAD	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg21918786	chr6:109611834	NA	-0.53	-9.57	-0.42	9.07e-20	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
LUAD	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg10518543	chr12:38710700	ALG10B	-0.43	-7.17	-0.33	3.29e-12	Bladder cancer;
LUAD	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg17366294	chr4:99064904	C4orf37	0.47	8.34	0.38	1.03e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs698833	0.852	rs698774	chr2:44584314	C/T	cg04920474	chr2:44395004	PPM1B	0.36	6.59	0.31	1.3100000000000001e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03934478	chr11:495069	RNH1	0.75	9.12	0.41	3.11e-18	Body mass index;
LUAD	cis	rs2041840	1.000	rs2041837	chr2:37468564	G/T	cg25727520	chr2:37576821	QPCT	-0.34	-7.04	-0.32	7.8e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg05590025	chr7:65112418	INTS4L2	-0.73	-6.64	-0.31	9.79e-11	Diabetic kidney disease;
LUAD	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12756686	chr19:29218302	NA	0.68	9.85	0.43	9.4e-21	Methadone dose in opioid dependence;
LUAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08219700	chr8:58056026	NA	0.6	7.91	0.36	2.21e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1595825	0.945	rs73056880	chr2:198822292	G/A	cg00982548	chr2:198649783	BOLL	-0.63	-8.93	-0.4	1.34e-17	Ulcerative colitis;
LUAD	cis	rs8044868	0.530	rs4788464	chr16:72223899	T/C	cg23815491	chr16:72088622	HP	0.46	8.61	0.39	1.45e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg17063962	chr7:91808500	NA	0.64	10.65	0.46	1.24e-23	Breast cancer;
LUAD	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06022373	chr22:39101656	GTPBP1	0.46	7.3	0.33	1.43e-12	Menopause (age at onset);
LUAD	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg19717773	chr7:2847554	GNA12	-0.52	-8.7	-0.39	7.2e-17	Height;
LUAD	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg15448220	chr1:150897856	SETDB1	-0.46	-8.15	-0.37	4.18e-15	Tonsillectomy;
LUAD	cis	rs2116941	0.523	rs17000211	chr19:10369086	C/T	cg01850179	chr19:10340795	S1PR2	0.62	10.04	0.44	2.1e-21	Pulse pressure;
LUAD	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.78	-0.43	1.63e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs9826463	0.582	rs73238143	chr3:142054935	A/G	cg20824294	chr3:142316082	PLS1	0.42	6.97	0.32	1.21e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1816752	0.811	rs9507337	chr13:24984945	A/T	cg02811702	chr13:24901961	NA	0.42	7.36	0.34	9.42e-13	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9473147	0.543	rs9473126	chr6:47481833	C/G	cg12968598	chr6:47444699	CD2AP	0.36	6.46	0.3	2.81e-10	Platelet distribution width;Mean platelet volume;
LUAD	trans	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg06606381	chr12:133084897	FBRSL1	-0.68	-7.09	-0.33	5.76e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs77972916	0.536	rs11679731	chr2:43589064	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-7.02	-0.32	9.13e-12	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg07393940	chr7:158741817	NA	-0.67	-11.45	-0.49	1.29e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs12079745	0.793	rs57776592	chr1:169268023	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-1.11	-8.07	-0.37	7.41e-15	QT interval;
LUAD	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg18105134	chr13:113819100	PROZ	-0.88	-15.28	-0.6	2.79e-42	Platelet distribution width;
LUAD	cis	rs1045714	0.943	rs1045711	chr7:2653571	C/T	cg20813462	chr7:2646259	IQCE	0.67	7.16	0.33	3.57e-12	Urate levels in lean individuals;
LUAD	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.81	-0.43	1.33e-20	Gut microbiome composition (summer);
LUAD	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg02551604	chr5:131831745	NA	0.63	10.28	0.45	2.73e-22	Asthma (sex interaction);
LUAD	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg08470875	chr2:26401718	FAM59B	0.79	11.21	0.48	1.02e-25	Gut microbiome composition (summer);
LUAD	cis	rs4523957	0.614	rs1563966	chr17:2095954	A/G	cg16513277	chr17:2031491	SMG6	0.7	12.78	0.53	7.2e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11890956	chr21:40555474	PSMG1	0.82	14.66	0.58	1.25e-39	Cognitive function;
LUAD	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.76	0.31	4.64e-11	Obesity-related traits;
LUAD	cis	rs9364220	0.794	rs9346650	chr6:168492963	C/T	cg02770688	chr6:168491649	NA	-0.36	-6.55	-0.3	1.72e-10	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
LUAD	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg16482183	chr6:26056742	HIST1H1C	0.54	7.51	0.34	3.47e-13	Iron status biomarkers;
LUAD	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg07157834	chr1:205819609	PM20D1	-0.47	-6.9	-0.32	1.96e-11	Menarche (age at onset);
LUAD	cis	rs6961069	0.743	rs1358337	chr7:80288385	C/T	cg04458919	chr7:80252533	CD36	-0.36	-6.89	-0.32	2.03e-11	Platelet count;
LUAD	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg23649088	chr2:200775458	C2orf69	0.62	8.14	0.37	4.44e-15	Schizophrenia;
LUAD	cis	rs2425143	0.818	rs11700299	chr20:34548865	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-6.76	-0.31	4.46e-11	Blood protein levels;
LUAD	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg03983476	chr2:10830698	NOL10	0.4	6.8	0.31	3.68e-11	Prostate cancer;
LUAD	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg08999081	chr20:33150536	PIGU	-0.62	-13.74	-0.56	8.78e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs7258465	1.000	rs8111708	chr19:18558876	A/G	cg25828334	chr19:18545568	ISYNA1	-0.4	-7.97	-0.36	1.49e-14	Breast cancer;
LUAD	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.19	-0.37	3.16e-15	Cannabis dependence symptom count;
LUAD	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg04546413	chr19:29218101	NA	0.57	8.13	0.37	4.88e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.55	7.61	0.35	1.84e-13	Platelet count;
LUAD	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg13770153	chr20:60521292	NA	-0.44	-7.12	-0.33	4.68e-12	Body mass index;
LUAD	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.88	0.53	2.99e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg02018176	chr4:1364513	KIAA1530	0.36	6.37	0.3	5.04e-10	Obesity-related traits;
LUAD	cis	rs4493873	0.869	rs7815938	chr8:92109673	A/T	cg16814680	chr8:91681699	NA	0.42	6.8	0.31	3.59e-11	Migraine - clinic-based;
LUAD	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg00495681	chr13:53174319	NA	0.5	9.1	0.4	3.6e-18	Lewy body disease;
LUAD	cis	rs174601	0.615	rs174534	chr11:61549458	C/T	cg19610905	chr11:61596333	FADS2	0.54	8.86	0.4	2.23e-17	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs10129255	0.500	rs988134	chr14:107184937	A/G	cg23076370	chr14:107095027	NA	-0.44	-8.74	-0.39	5.5e-17	Kawasaki disease;
LUAD	trans	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg03929089	chr4:120376271	NA	0.55	6.4	0.3	4.22e-10	Intraocular pressure;
LUAD	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.4e-15	Prostate cancer;
LUAD	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg18138036	chr10:133769891	PPP2R2D	0.41	6.65	0.31	9.17e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.9	-0.32	1.87e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg24450063	chr1:156163899	SLC25A44	1.14	26.77	0.79	4.47e-93	Testicular germ cell tumor;
LUAD	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg14186256	chr22:23484241	RTDR1	0.47	8.13	0.37	4.63e-15	Bone mineral density;
LUAD	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg13319975	chr6:146136371	FBXO30	-0.58	-9.78	-0.43	1.74e-20	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02729269	chr16:127772	MPG	-0.53	-6.53	-0.3	1.95e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg17173187	chr15:85201210	NMB	0.43	6.65	0.31	8.85e-11	Schizophrenia;
LUAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg10729496	chr3:10149963	C3orf24	0.49	7.88	0.36	2.73e-14	Alzheimer's disease;
LUAD	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg00204512	chr16:28754710	NA	-0.32	-6.92	-0.32	1.64e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg02196655	chr2:10830764	NOL10	-0.43	-7.75	-0.35	6.8e-14	Prostate cancer;
LUAD	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.9	-0.36	2.45e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.4	0.3	4.19e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg05872129	chr22:39784769	NA	-0.8	-14.97	-0.59	5.6e-41	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	0.782	rs4882064	chr11:48455757	C/T	cg00717180	chr2:96193071	NA	0.36	6.75	0.31	4.83e-11	HDL cholesterol;
LUAD	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg08470875	chr2:26401718	FAM59B	0.76	9.57	0.42	9.06e-20	Gut microbiome composition (summer);
LUAD	cis	rs7107174	1.000	rs2511185	chr11:77982496	C/A	cg02023728	chr11:77925099	USP35	0.41	7.01	0.32	9.57e-12	Testicular germ cell tumor;
LUAD	cis	rs7944584	0.551	rs12224672	chr11:47500400	C/T	cg20307385	chr11:47447363	PSMC3	0.51	7.62	0.35	1.7e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs6445967	0.554	rs6779083	chr3:58438135	T/C	cg13750441	chr3:58318267	PXK	-0.31	-6.4	-0.3	4.1e-10	Platelet count;
LUAD	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06544989	chr22:39130855	UNC84B	0.42	7.73	0.35	8.09e-14	Menopause (age at onset);
LUAD	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg11766577	chr21:47581405	C21orf56	-0.49	-7.99	-0.36	1.32e-14	Testicular germ cell tumor;
LUAD	cis	rs13315871	1.000	rs36037390	chr3:58321954	C/T	cg20936604	chr3:58311152	NA	-0.71	-7.11	-0.33	4.95e-12	Cholesterol, total;
LUAD	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.37	-6.46	-0.3	2.81e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg21770322	chr7:97807741	LMTK2	0.35	8.35	0.38	9.91e-16	Breast cancer;
LUAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg25811766	chr13:21894605	NA	0.56	8.46	0.38	4.54e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg24558204	chr6:135376177	HBS1L	0.49	8.98	0.4	9.03e-18	Red blood cell count;
LUAD	cis	rs7481584	0.961	rs12797969	chr11:3019216	C/T	cg11201177	chr11:2961805	NA	0.4	6.63	0.31	1e-10	Calcium levels;
LUAD	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg19767477	chr5:127420684	SLC12A2	-0.44	-6.73	-0.31	5.38e-11	Ileal carcinoids;
LUAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13732083	chr21:47605072	C21orf56	-0.62	-10.54	-0.46	3.24e-23	Testicular germ cell tumor;
LUAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg10729496	chr3:10149963	C3orf24	0.53	8.44	0.38	5.25e-16	Alzheimer's disease;
LUAD	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg11494091	chr17:61959527	GH2	0.43	8.38	0.38	8.14e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs931812	0.825	rs6993937	chr8:101898707	A/G	cg20993868	chr7:22813445	NA	0.64	13.14	0.54	2.63e-33	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs2235649	0.798	rs9932875	chr16:1848012	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.5	-8.4	-0.38	6.8e-16	Blood metabolite levels;
LUAD	cis	rs4285028	0.747	rs1128163	chr3:121350573	A/G	cg11130432	chr3:121712080	ILDR1	-0.44	-6.37	-0.3	4.98e-10	Multiple sclerosis;
LUAD	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-11.18	-0.48	1.29e-25	Monocyte percentage of white cells;
LUAD	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg15704280	chr7:45808275	SEPT13	0.64	8.19	0.37	3.01e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08677398	chr8:58056175	NA	0.48	6.77	0.31	4.3e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg16235748	chr6:149772707	ZC3H12D	-0.31	-6.98	-0.32	1.14e-11	Dupuytren's disease;
LUAD	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg13393036	chr8:95962371	TP53INP1	-0.41	-9.76	-0.43	1.99e-20	Type 2 diabetes;
LUAD	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg16479474	chr6:28041457	NA	0.45	7.88	0.36	2.81e-14	Depression;
LUAD	cis	rs9584850	0.874	rs4584	chr13:99101869	G/C	cg17380943	chr13:99100506	FARP1	-0.36	-6.92	-0.32	1.73e-11	Neuroticism;
LUAD	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.87	-0.32	2.27e-11	Total cholesterol levels;
LUAD	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg02527881	chr3:46936655	PTH1R	0.44	8.63	0.39	1.3e-16	Colorectal cancer;
LUAD	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg14092988	chr3:52407081	DNAH1	0.46	9.2	0.41	1.62e-18	Bipolar disorder;
LUAD	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg19980929	chr12:42632907	YAF2	0.33	6.36	0.3	5.18e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg25237894	chr2:233734115	C2orf82	0.63	11.98	0.5	1.16e-28	Coronary artery disease;
LUAD	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg14773178	chr5:1868261	NA	0.33	6.52	0.3	2e-10	Cardiovascular disease risk factors;
LUAD	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.74	0.31	5.06e-11	Rheumatoid arthritis;
LUAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg13397359	chr6:42928475	GNMT	-0.49	-9.17	-0.41	2.15e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg15369054	chr17:80825471	TBCD	0.65	10.91	0.47	1.33e-24	Breast cancer;
LUAD	cis	rs1865721	0.728	rs7232269	chr18:73219023	G/A	cg26385618	chr18:73139727	C18orf62	-0.36	-6.7	-0.31	6.59e-11	Intelligence;
LUAD	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg16797656	chr11:68205561	LRP5	0.45	8.67	0.39	9.5e-17	Total body bone mineral density;
LUAD	trans	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg04775059	chr7:64541387	NA	0.52	6.79	0.31	3.72e-11	Aortic root size;
LUAD	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg12573674	chr2:1569213	NA	-0.56	-8.3	-0.37	1.39e-15	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg02466173	chr16:30829666	NA	-0.7	-12.58	-0.52	4.61e-31	Multiple myeloma;
LUAD	trans	rs1904173	0.599	rs35469063	chr5:25063806	G/A	cg04802221	chr16:67223955	EXOC3L	0.49	6.64	0.31	9.39e-11	IgG glycosylation;
LUAD	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg03713592	chr11:72463424	ARAP1	-0.6	-7.92	-0.36	2.16e-14	Type 2 diabetes;
LUAD	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg26384229	chr12:38710491	ALG10B	0.46	7.47	0.34	4.66e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg05368731	chr17:41323189	NBR1	0.96	20.32	0.7	1.44e-64	Menopause (age at onset);
LUAD	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg07305463	chr2:136567211	LCT	0.39	7.37	0.34	9.17e-13	Mosquito bite size;
LUAD	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg06640241	chr16:89574553	SPG7	0.45	7.21	0.33	2.53e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg17200465	chr3:40428508	ENTPD3	0.28	6.69	0.31	6.93e-11	Renal cell carcinoma;
LUAD	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg11189052	chr15:85197271	WDR73	0.67	8.87	0.4	2.02e-17	Schizophrenia;
LUAD	cis	rs9584850	0.874	rs3742137	chr13:99102449	C/T	cg17380943	chr13:99100506	FARP1	-0.35	-6.56	-0.3	1.59e-10	Neuroticism;
LUAD	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.16	0.37	3.75e-15	Breast cancer;
LUAD	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg23803603	chr1:2058230	PRKCZ	-0.42	-7.28	-0.33	1.69e-12	Height;
LUAD	trans	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.54	8.68	0.39	8.79e-17	Endometrial cancer;
LUAD	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg06640241	chr16:89574553	SPG7	0.48	7.9	0.36	2.36e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg23301539	chr8:142222248	SLC45A4	-0.47	-8.14	-0.37	4.51e-15	Immature fraction of reticulocytes;
LUAD	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg23533926	chr12:111358616	MYL2	-0.43	-7.39	-0.34	8.09e-13	Extrinsic epigenetic age acceleration;
LUAD	trans	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.72	-9.85	-0.43	9.36e-21	Obesity-related traits;
LUAD	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg22920501	chr2:26401640	FAM59B	-0.7	-10.4	-0.45	1.03e-22	Gut microbiome composition (summer);
LUAD	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08045932	chr20:61659980	NA	0.51	9.68	0.43	3.75e-20	Prostate cancer (SNP x SNP interaction);
LUAD	trans	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg01620082	chr3:125678407	NA	-0.8	-8.1	-0.37	5.9e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg06740227	chr12:86229804	RASSF9	-0.41	-7.23	-0.33	2.27e-12	Major depressive disorder;
LUAD	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg00750074	chr16:89608354	SPG7	-0.57	-9.65	-0.42	4.73e-20	Multiple myeloma (IgH translocation);
LUAD	cis	rs9473147	0.543	rs9296558	chr6:47451883	C/T	cg02130027	chr6:47444894	CD2AP	0.37	7.06	0.32	6.88e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg21427119	chr20:30132790	HM13	0.47	7.41	0.34	7.09e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs933688	0.532	rs2973477	chr5:90553722	C/T	cg00335715	chr5:90575459	NA	-0.44	-6.75	-0.31	4.9e-11	Smoking behavior;
LUAD	cis	rs231513	0.906	rs179586	chr17:41999094	T/C	cg26893861	chr17:41843967	DUSP3	-0.69	-7.66	-0.35	1.28e-13	Cognitive function;
LUAD	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.34	6.36	0.3	5.16e-10	Lung cancer in ever smokers;
LUAD	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg23260525	chr10:116636907	FAM160B1	0.47	11.0	0.47	6.26e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg11301795	chr4:187892539	NA	0.49	9.15	0.41	2.52e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6761276	0.649	rs10184259	chr2:113838628	T/C	cg09040174	chr2:113837401	NA	0.71	12.77	0.53	8.52e-32	Protein quantitative trait loci;
LUAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06873352	chr17:61820015	STRADA	0.82	18.11	0.66	1.08e-54	Prudent dietary pattern;
LUAD	cis	rs7493	0.851	rs11770903	chr7:95026327	A/G	cg01874867	chr7:94954059	PON1	-0.52	-7.25	-0.33	2.03e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19312935	chr22:42017417	PPPDE2;XRCC6	0.48	6.38	0.3	4.67e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6500395	1.000	rs1120276	chr16:48598517	C/G	cg04672837	chr16:48644449	N4BP1	0.37	6.45	0.3	3.15e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg22029157	chr1:209979665	IRF6	-0.55	-10.73	-0.46	6.59e-24	Monobrow;
LUAD	cis	rs7737355	0.947	rs6882552	chr5:130841493	A/G	cg25547332	chr5:131281432	NA	0.42	6.36	0.3	5.27e-10	Life satisfaction;
LUAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg27141850	chr2:20869434	GDF7	-0.42	-10.11	-0.44	1.19e-21	Abdominal aortic aneurysm;
LUAD	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg04414720	chr1:150670196	GOLPH3L	0.72	13.36	0.54	3.28e-34	Tonsillectomy;
LUAD	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg24562669	chr7:97807699	LMTK2	-0.29	-6.51	-0.3	2.13e-10	Breast cancer;
LUAD	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.85	0.4	2.46e-17	Menopause (age at onset);
LUAD	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg10589385	chr1:150898437	SETDB1	0.41	7.79	0.35	5.06e-14	Melanoma;
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01585723	chr16:33734837	NA	-0.35	-6.61	-0.31	1.18e-10	Menopause (age at onset);
LUAD	cis	rs262150	0.625	rs55882200	chr7:158769280	G/C	cg19418458	chr7:158789849	NA	0.68	8.62	0.39	1.32e-16	Facial morphology (factor 20);
LUAD	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg07389463	chr12:132296394	NA	0.57	11.08	0.47	3.31e-25	Migraine;
LUAD	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.26e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg08807101	chr21:30365312	RNF160	0.52	8.89	0.4	1.83e-17	Dental caries;
LUAD	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg11189052	chr15:85197271	WDR73	0.6	7.78	0.35	5.57e-14	Schizophrenia;
LUAD	cis	rs669446	0.533	rs2158956	chr1:44211697	T/C	cg12908607	chr1:44402522	ARTN	-0.37	-7.16	-0.33	3.71e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg18833306	chr6:118973337	C6orf204	-0.53	-7.67	-0.35	1.23e-13	Diastolic blood pressure;
LUAD	trans	rs12200782	1.000	rs12201802	chr6:26398664	G/A	cg08851530	chr6:28072375	NA	0.74	6.65	0.31	9.31e-11	Small cell lung carcinoma;
LUAD	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg02683114	chr2:24398427	C2orf84	-0.54	-8.0	-0.36	1.19e-14	Asthma;
LUAD	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15664640	chr17:80829946	TBCD	0.72	14.57	0.58	2.88e-39	Breast cancer;
LUAD	cis	rs68170813	0.559	rs74387778	chr7:106963213	T/C	cg23024343	chr7:107201750	COG5	0.49	6.95	0.32	1.38e-11	Coronary artery disease;
LUAD	cis	rs6489882	0.867	rs4766676	chr12:113365581	A/G	cg20102336	chr12:113376681	OAS3	0.55	8.36	0.38	9.46e-16	Chronic lymphocytic leukemia;
LUAD	cis	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.41	-0.34	7e-13	Resting heart rate;
LUAD	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.58	-0.35	2.25e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg24848339	chr3:12840334	CAND2	0.44	9.11	0.4	3.39e-18	QRS complex (12-leadsum);
LUAD	cis	rs7551222	0.691	rs11240760	chr1:204547268	A/G	cg20240347	chr1:204465584	NA	-0.33	-6.45	-0.3	3.03e-10	Schizophrenia;
LUAD	cis	rs57920188	0.640	rs10915600	chr1:4082105	T/G	cg20703997	chr1:4087676	NA	0.47	8.56	0.38	2.05e-16	Interleukin-17 levels;
LUAD	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg11707310	chr1:2537719	MMEL1	0.38	7.93	0.36	1.99e-14	Ulcerative colitis;
LUAD	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg13319975	chr6:146136371	FBXO30	-0.65	-11.3	-0.48	4.69e-26	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07080049	chr9:96214194	FAM120A;FAM120AOS	-0.41	-6.47	-0.3	2.75e-10	Height;
LUAD	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg02951883	chr7:2050386	MAD1L1	0.78	13.98	0.56	9.02e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.64	-11.74	-0.5	9.64e-28	Lymphocyte counts;
LUAD	trans	rs1997103	1.000	rs4947503	chr7:55409427	G/T	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs8067287	0.546	rs62065425	chr17:16828711	C/T	cg26910001	chr17:16838321	NA	-0.49	-6.8	-0.31	3.6e-11	Diabetic kidney disease;
LUAD	cis	rs743757	0.878	rs1467914	chr3:50523668	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	7.22	0.33	2.39e-12	Diastolic blood pressure;
LUAD	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg27490568	chr2:178487706	NA	0.51	8.28	0.37	1.62e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg11915388	chr22:42470451	FAM109B	-0.42	-7.59	-0.35	2.06e-13	Schizophrenia;
LUAD	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg06002616	chr8:101225028	SPAG1	0.37	7.51	0.34	3.47e-13	Atrioventricular conduction;
LUAD	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6541297	0.703	rs671682	chr1:230313651	C/G	cg20703242	chr1:230279135	GALNT2	-0.48	-7.11	-0.33	4.9e-12	Coronary artery disease;
LUAD	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg23758822	chr17:41437982	NA	1.0	20.88	0.71	4.81e-67	Menopause (age at onset);
LUAD	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.65	-9.74	-0.43	2.35e-20	IgG glycosylation;
LUAD	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg14895029	chr7:2775587	GNA12	-0.4	-6.49	-0.3	2.46e-10	Height;
LUAD	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg22532475	chr10:104410764	TRIM8	0.44	8.46	0.38	4.3e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.9	-0.36	2.47e-14	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg17366294	chr4:99064904	C4orf37	0.67	12.8	0.53	6.15e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg08999081	chr20:33150536	PIGU	0.46	8.41	0.38	6.53e-16	Coronary artery disease;
LUAD	trans	rs12210905	1.000	rs7759955	chr6:26709424	G/A	cg08851530	chr6:28072375	NA	0.72	6.58	0.3	1.36e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	7.68	0.35	1.12e-13	Tonsillectomy;
LUAD	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg06766960	chr11:133703094	NA	-0.45	-8.41	-0.38	6.53e-16	Childhood ear infection;
LUAD	cis	rs7937890	0.631	rs7118886	chr11:14427517	T/C	cg23387056	chr11:14280742	SPON1	-0.37	-7.45	-0.34	5.4e-13	Mitochondrial DNA levels;
LUAD	cis	rs11901793	0.505	rs11688053	chr2:237494289	A/T	cg25295825	chr2:237489920	CXCR7	0.5	7.03	0.32	8.13e-12	Total mean fractional anisotropy measurement in first episode schizophrenia;
LUAD	cis	rs9462027	0.628	rs1125340	chr6:34786408	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-8.82	-0.39	2.94e-17	Systemic lupus erythematosus;
LUAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg22442454	chr1:209979470	IRF6	0.48	7.06	0.32	6.79e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg09796270	chr17:17721594	SREBF1	-0.36	-6.61	-0.31	1.16e-10	Total body bone mineral density;
LUAD	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg10792982	chr14:105748885	BRF1	0.45	9.34	0.41	5.59e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg24803719	chr17:45855879	NA	-0.33	-7.27	-0.33	1.76e-12	IgG glycosylation;
LUAD	cis	rs2230307	0.536	rs496798	chr1:100507990	G/A	cg20868668	chr1:100435035	SLC35A3	0.54	7.87	0.36	3.02e-14	Carotid intima media thickness;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10177591	chr6:43027482	KLC4;MRPL2	-0.41	-6.63	-0.31	1.04e-10	Height;
LUAD	cis	rs77741769	0.571	rs73415720	chr12:121344515	T/C	cg02419362	chr12:121203948	SPPL3	0.43	8.78	0.39	4.11e-17	Mean corpuscular volume;
LUAD	cis	rs6076065	0.510	rs6137899	chr20:23320137	C/T	cg11657817	chr20:23433608	CST11	0.49	8.91	0.4	1.59e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg04025307	chr7:1156635	C7orf50	0.7	12.73	0.53	1.24e-31	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg18876405	chr7:65276391	NA	0.63	10.86	0.47	2.1e-24	Calcium levels;
LUAD	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg26408565	chr15:76604113	ETFA	-0.45	-7.57	-0.35	2.32e-13	Blood metabolite levels;
LUAD	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg25358565	chr5:93447407	FAM172A	0.62	7.62	0.35	1.64e-13	Diabetic retinopathy;
LUAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg24813613	chr7:1882135	MAD1L1	-0.54	-9.01	-0.4	7.33e-18	Bipolar disorder and schizophrenia;
LUAD	trans	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg18187862	chr3:45730750	SACM1L	-0.47	-6.72	-0.31	5.94e-11	Primary sclerosing cholangitis;
LUAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg10295955	chr4:187884368	NA	-1.17	-30.82	-0.83	3.54e-110	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg22963979	chr7:1858916	MAD1L1	-0.65	-11.65	-0.49	2.2e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03647317	chr4:187891568	NA	0.37	7.02	0.32	9e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.54	14.31	0.57	3.55e-38	Schizophrenia;
LUAD	cis	rs12986413	0.651	rs2238610	chr19:2146852	T/C	cg09261902	chr19:2140048	AP3D1	0.34	6.78	0.31	4.16e-11	Height;
LUAD	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.14	-0.33	4.05e-12	Breast cancer;
LUAD	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.44	0.3	3.23e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2455799	0.613	rs1345157	chr3:15895581	C/G	cg16303742	chr3:15540471	COLQ	-0.52	-9.55	-0.42	1.06e-19	Mean platelet volume;
LUAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	11.37	0.48	2.54e-26	Prudent dietary pattern;
LUAD	cis	rs377457	0.857	rs11644122	chr16:85740750	C/T	cg02758499	chr16:85682440	KIAA0182	0.39	7.0	0.32	9.85e-12	Type 2 diabetes;
LUAD	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.78	-0.31	4.07e-11	Retinal vascular caliber;
LUAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg08132940	chr7:1081526	C7orf50	-0.76	-10.23	-0.45	4.21e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11811982	0.793	rs79578285	chr1:227573505	T/C	cg24860534	chr1:227506868	CDC42BPA	0.66	7.2	0.33	2.8e-12	Optic disc area;
LUAD	cis	rs3772130	0.885	rs9816844	chr3:121496324	C/T	cg20356878	chr3:121714668	ILDR1	0.51	8.1	0.37	5.81e-15	Cognitive performance;
LUAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.57	-10.67	-0.46	1.07e-23	Longevity;Endometriosis;
LUAD	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg10018233	chr7:150070692	REPIN1	0.5	7.8	0.35	4.95e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs909002	0.889	rs1061392	chr1:32118160	C/A	cg13919466	chr1:32135498	COL16A1	-0.37	-8.37	-0.38	8.38e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.84	0.32	2.8e-11	Depression;
LUAD	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg20380214	chr12:9217688	LOC144571	0.34	6.42	0.3	3.59e-10	Sjögren's syndrome;
LUAD	cis	rs2732480	0.500	rs1387257	chr12:48636666	C/A	cg04545296	chr12:48745243	ZNF641	0.39	10.09	0.44	1.32e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg03859395	chr2:55845619	SMEK2	-0.45	-6.66	-0.31	8.36e-11	Metabolic syndrome;
LUAD	cis	rs250677	0.522	rs12523526	chr5:148349107	A/C	cg18129178	chr5:148520854	ABLIM3	0.51	7.57	0.35	2.39e-13	Breast cancer;
LUAD	cis	rs7089973	0.966	rs12772800	chr10:116630962	A/G	cg25233709	chr10:116636983	FAM160B1	0.36	6.78	0.31	4.05e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg21475434	chr5:93447410	FAM172A	-0.79	-9.24	-0.41	1.26e-18	Diabetic retinopathy;
LUAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg07806771	chr7:64541737	NA	0.47	7.55	0.34	2.74e-13	Calcium levels;
LUAD	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg15445000	chr17:37608096	MED1	-0.45	-8.38	-0.38	7.9e-16	Glomerular filtration rate (creatinine);
LUAD	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg15704280	chr7:45808275	SEPT13	0.8	14.13	0.57	2.03e-37	Coronary artery disease;
LUAD	cis	rs9826463	0.759	rs73228782	chr3:142341896	G/A	cg20824294	chr3:142316082	PLS1	0.47	6.65	0.31	8.95e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg22508957	chr16:3507546	NAT15	0.82	10.83	0.47	2.75e-24	Tuberculosis;
LUAD	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg15704280	chr7:45808275	SEPT13	-0.52	-8.26	-0.37	1.9e-15	HDL cholesterol;
LUAD	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg10755058	chr3:40428713	ENTPD3	0.34	6.47	0.3	2.65e-10	Renal cell carcinoma;
LUAD	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg12311346	chr5:56204834	C5orf35	0.72	11.48	0.49	9.47e-27	Initial pursuit acceleration;
LUAD	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg10589385	chr1:150898437	SETDB1	-0.35	-6.43	-0.3	3.42e-10	Urate levels;
LUAD	cis	rs6087990	0.735	rs1855350	chr20:31387525	C/T	cg13636640	chr20:31349939	DNMT3B	0.74	13.21	0.54	1.36e-33	Ulcerative colitis;
LUAD	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg08280861	chr8:58055591	NA	0.72	8.58	0.38	1.85e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs57590327	0.503	rs13066091	chr3:81589912	T/C	cg07356753	chr3:81810745	GBE1	-0.52	-7.89	-0.36	2.57e-14	Extraversion;
LUAD	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.47	0.38	4.01e-16	Platelet count;
LUAD	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg07541023	chr7:19748670	TWISTNB	0.54	7.48	0.34	4.19e-13	Night sleep phenotypes;
LUAD	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22496380	chr5:211416	CCDC127	-0.92	-12.49	-0.52	1.08e-30	Breast cancer;
LUAD	cis	rs240764	0.604	rs9377234	chr6:101263035	C/T	cg09795085	chr6:101329169	ASCC3	0.41	7.09	0.33	5.56e-12	Neuroticism;
LUAD	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg21252483	chr19:49399788	TULP2	-0.88	-14.31	-0.57	3.61e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs16910800	0.731	rs16910754	chr11:23192015	A/G	cg20040320	chr11:23191996	NA	0.69	9.18	0.41	1.95e-18	Cancer;
LUAD	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg18190219	chr22:46762943	CELSR1	-0.58	-6.44	-0.3	3.23e-10	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg18944383	chr4:111397179	ENPEP	0.39	7.81	0.36	4.43e-14	Height;
LUAD	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg08798685	chr6:27730294	NA	-0.47	-7.13	-0.33	4.27e-12	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
LUAD	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.61	-11.34	-0.48	3.39e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg00757033	chr12:89920650	WDR51B	0.69	11.41	0.49	1.76e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.31	6.41	0.3	3.92e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	7.4	0.34	7.56e-13	Tonsillectomy;
LUAD	trans	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.42	-7.09	-0.33	5.74e-12	Body mass index;
LUAD	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg15181151	chr6:150070149	PCMT1	0.39	7.78	0.35	5.72e-14	Lung cancer;
LUAD	cis	rs1595825	0.945	rs7426250	chr2:198837358	G/A	cg00982548	chr2:198649783	BOLL	-0.63	-8.93	-0.4	1.31e-17	Ulcerative colitis;
LUAD	cis	rs6500395	0.963	rs6500405	chr16:48690486	C/T	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.07e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg06108461	chr20:60628389	TAF4	-1.08	-19.49	-0.69	7.75e-61	Body mass index;
LUAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg10862848	chr6:42927986	GNMT	-0.31	-9.07	-0.4	4.67e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.88	-0.32	2.12e-11	Gout;
LUAD	cis	rs9467160	1.000	rs9467158	chr6:24441215	G/A	cg16211469	chr6:24423932	MRS2	0.44	6.88	0.32	2.2e-11	Liver enzyme levels;
LUAD	trans	rs853679	1.000	rs853676	chr6:28299687	C/T	cg06606381	chr12:133084897	FBRSL1	-0.57	-6.78	-0.31	4.01e-11	Depression;
LUAD	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg05044414	chr3:183734942	ABCC5	0.38	7.71	0.35	9.12e-14	Anterior chamber depth;
LUAD	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg24578937	chr1:2090814	PRKCZ	-0.59	-11.51	-0.49	7.45e-27	Height;
LUAD	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.17	-0.33	3.48e-12	Breast cancer;
LUAD	cis	rs116248771	0.690	rs73156492	chr3:158416799	G/C	cg16708174	chr3:158430962	RARRES1	0.48	6.97	0.32	1.23e-11	diarrhoeal disease at age 2;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01585723	chr16:33734837	NA	0.36	6.64	0.31	9.61e-11	Menopause (age at onset);
LUAD	cis	rs10896135	0.526	rs624561	chr11:66414915	C/T	cg24851651	chr11:66362959	CCS	-0.5	-7.95	-0.36	1.74e-14	Bipolar disorder;
LUAD	cis	rs4713675	0.565	rs4713668	chr6:33690796	C/T	cg13859433	chr6:33739653	LEMD2	-0.3	-7.11	-0.33	4.85e-12	Plateletcrit;
LUAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg13560548	chr3:10150139	C3orf24	0.42	6.79	0.31	3.93e-11	Alzheimer's disease;
LUAD	cis	rs62238980	0.614	rs75386630	chr22:32380975	G/C	cg02631450	chr22:32366979	NA	0.79	6.46	0.3	2.9e-10	Childhood ear infection;
LUAD	cis	rs910187	0.678	rs6122564	chr20:45814745	A/C	cg27589058	chr20:45804311	EYA2	-0.31	-7.1	-0.33	5.34e-12	Migraine;
LUAD	cis	rs4077515	0.935	rs3812565	chr9:139272502	T/C	cg14169450	chr9:139327907	INPP5E	0.37	6.47	0.3	2.7e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6901250	0.851	rs339360	chr6:117160872	G/T	cg12892004	chr6:117198278	RFX6	-0.34	-7.24	-0.33	2.18e-12	C-reactive protein levels;
LUAD	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg18180107	chr4:99064573	C4orf37	0.43	6.89	0.32	2.08e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg07538946	chr5:131705188	SLC22A5	0.47	7.77	0.35	5.92e-14	Blood metabolite levels;
LUAD	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg23533926	chr12:111358616	MYL2	-0.42	-7.31	-0.33	1.39e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs422249	0.720	rs174455	chr11:61656117	A/G	cg01500311	chr11:61656094	FADS3	-0.37	-7.02	-0.32	8.82e-12	Trans fatty acid levels;
LUAD	cis	rs6087990	0.899	rs4911107	chr20:31374991	G/A	cg13636640	chr20:31349939	DNMT3B	0.78	14.81	0.58	2.88e-40	Ulcerative colitis;
LUAD	cis	rs7737355	0.898	rs3775998	chr5:130979332	A/G	cg06307176	chr5:131281290	NA	0.53	8.24	0.37	2.24e-15	Life satisfaction;
LUAD	cis	rs68170813	0.605	rs75659533	chr7:107134987	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-10.38	-0.45	1.2e-22	Coronary artery disease;
LUAD	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.21	0.44	5.05e-22	Ileal carcinoids;
LUAD	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.21	-0.33	2.61e-12	Bipolar disorder;
LUAD	trans	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg26043149	chr18:55253948	FECH	-0.45	-7.75	-0.35	7.04e-14	Bone mineral density;
LUAD	cis	rs9837602	0.938	rs1017968	chr3:99787011	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-6.68	-0.31	7.39e-11	Breast cancer;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg06988368	chr1:147142773	ACP6	0.41	7.08	0.33	5.9e-12	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00166722	chr3:10149974	C3orf24	0.74	12.65	0.52	2.48e-31	Alzheimer's disease;
LUAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg19318889	chr4:1322082	MAEA	0.46	7.63	0.35	1.61e-13	Obesity-related traits;
LUAD	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg24675056	chr1:15929824	NA	0.49	8.46	0.38	4.35e-16	Systolic blood pressure;
LUAD	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg02269571	chr22:50332266	NA	-0.57	-8.64	-0.39	1.16e-16	Schizophrenia;
LUAD	cis	rs367615	0.704	rs72804385	chr5:108848143	T/C	cg17395555	chr5:108820864	NA	0.67	14.41	0.57	1.44e-38	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs6750795	0.870	rs6754952	chr2:232381245	G/T	cg19187155	chr2:232395269	NMUR1	-0.57	-11.08	-0.47	3.05e-25	Height;
LUAD	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg03806693	chr22:41940476	POLR3H	-0.66	-9.62	-0.42	6.11e-20	Vitiligo;
LUAD	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg07362569	chr17:61921086	SMARCD2	0.4	6.92	0.32	1.72e-11	Prudent dietary pattern;
LUAD	cis	rs12210905	1.000	rs7759955	chr6:26709424	G/A	cg11502198	chr6:26597334	ABT1	-0.78	-6.73	-0.31	5.51e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg21775007	chr8:11205619	TDH	-0.5	-9.0	-0.4	7.68e-18	Retinal vascular caliber;
LUAD	cis	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg01251360	chr16:68772225	CDH1	-0.28	-8.85	-0.4	2.43e-17	Colorectal cancer;
LUAD	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.53	-9.16	-0.41	2.2e-18	Breast cancer;
LUAD	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.44	-0.42	2.57e-19	Schizophrenia;
LUAD	cis	rs6964587	0.758	rs7798233	chr7:91500083	G/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-6.9	-0.32	1.88e-11	Breast cancer;
LUAD	cis	rs4290604	0.679	rs4663700	chr2:238036764	T/C	cg23555395	chr2:238036564	NA	-0.52	-7.01	-0.32	9.39e-12	Asthma;
LUAD	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg26446133	chr18:72167187	CNDP2	-0.92	-16.16	-0.62	4.19e-46	Refractive error;
LUAD	cis	rs1018836	0.564	rs7821994	chr8:91700916	C/T	cg16814680	chr8:91681699	NA	-1.02	-22.68	-0.74	4.3e-75	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg14092988	chr3:52407081	DNAH1	0.4	7.95	0.36	1.73e-14	Electroencephalogram traits;
LUAD	cis	rs8044868	0.586	rs7200854	chr16:72083318	G/A	cg23815491	chr16:72088622	HP	0.53	9.68	0.43	3.7799999999999997e-20	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg03929089	chr4:120376271	NA	-0.91	-17.23	-0.64	8.69e-51	Coronary artery disease;
LUAD	cis	rs7100689	0.580	rs2168721	chr10:82208192	A/G	cg01528321	chr10:82214614	TSPAN14	0.62	9.79	0.43	1.58e-20	Post bronchodilator FEV1;
LUAD	cis	rs231513	0.954	rs231512	chr17:41965831	G/A	cg26893861	chr17:41843967	DUSP3	-0.66	-7.53	-0.34	3.15e-13	Cognitive function;
LUAD	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg12310025	chr6:25882481	NA	0.89	14.63	0.58	1.58e-39	Blood metabolite levels;
LUAD	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg01200585	chr1:228362443	C1orf69	0.42	7.6	0.35	1.94e-13	Diastolic blood pressure;
LUAD	cis	rs2742417	0.609	rs2673066	chr3:45771200	C/T	cg10512202	chr3:45649293	LIMD1	0.48	8.92	0.4	1.42e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg16205897	chr5:131564050	P4HA2	-0.33	-7.37	-0.34	9.02e-13	Blood metabolite levels;
LUAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg09436375	chr6:42928200	GNMT	-0.29	-8.36	-0.38	9.34e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs78487399	0.808	rs6544668	chr2:43732488	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.52	-0.3	1.98e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	6.88	0.32	2.17e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-8.4	-0.38	6.6e-16	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg21280719	chr6:42927975	GNMT	-0.4	-12.2	-0.51	1.54e-29	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs17067123	0.614	rs56749262	chr4:180067592	C/A	cg26610307	chr4:180072759	NA	-0.52	-6.74	-0.31	5.21e-11	Response to hepatitis C treatment;
LUAD	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg22753661	chr15:79092743	ADAMTS7	0.52	8.07	0.37	7.37e-15	Coronary artery disease or large artery stroke;
LUAD	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg25427524	chr10:38739819	LOC399744	0.57	10.07	0.44	1.66e-21	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg19077165	chr18:44547161	KATNAL2	0.45	7.79	0.35	5.4e-14	Personality dimensions;
LUAD	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg01324343	chr3:183735012	ABCC5	0.92	24.74	0.77	3.11e-84	Anterior chamber depth;
LUAD	cis	rs13095912	0.962	rs1568664	chr3:185312231	T/C	cg11274856	chr3:185301563	NA	0.37	7.46	0.34	5.05e-13	Systolic blood pressure;
LUAD	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg08847533	chr14:75593920	NEK9	0.41	6.98	0.32	1.18e-11	Height;
LUAD	cis	rs13315871	1.000	rs13078787	chr3:58430487	C/T	cg12435725	chr3:58293450	RPP14	-0.67	-7.44	-0.34	5.6e-13	Cholesterol, total;
LUAD	cis	rs4774899	0.752	rs2733170	chr15:57320664	C/T	cg14026238	chr15:57616123	NA	-0.38	-7.19	-0.33	2.93e-12	Urinary tract infection frequency;
LUAD	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg22920501	chr2:26401640	FAM59B	0.97	13.31	0.54	5.02e-34	Gut microbiome composition (summer);
LUAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg10819733	chr22:24237672	NA	-0.39	-7.51	-0.34	3.62e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9925964	0.967	rs1549293	chr16:31141993	C/T	cg03418659	chr16:31128414	MYST1	0.4	6.62	0.31	1.09e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg09835421	chr16:68378352	PRMT7	-0.82	-8.83	-0.39	2.73e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg10589385	chr1:150898437	SETDB1	0.39	7.2	0.33	2.71e-12	Melanoma;
LUAD	cis	rs68170813	0.617	rs7797791	chr7:107197222	T/C	cg02696742	chr7:106810147	HBP1	-0.72	-8.03	-0.36	9.8e-15	Coronary artery disease;
LUAD	cis	rs1127311	1.000	rs1127311	chr1:154556663	G/A	cg17218026	chr1:154582156	ADAR	0.5	9.67	0.43	3.98e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	9.21	0.41	1.58e-18	Melanoma;
LUAD	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg04800585	chr6:26043546	HIST1H2BB	-0.4	-7.36	-0.34	9.94e-13	Blood metabolite levels;
LUAD	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg26513180	chr16:89883248	FANCA	0.7	13.05	0.54	6.2e-33	Vitiligo;
LUAD	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg24450063	chr1:156163899	SLC25A44	1.22	29.42	0.82	2.26e-104	Testicular germ cell tumor;
LUAD	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg05340658	chr4:99064831	C4orf37	0.45	7.39	0.34	8.14e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg26818010	chr10:134567672	INPP5A	-0.96	-15.8	-0.61	1.63e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg22166914	chr1:53195759	ZYG11B	0.44	7.58	0.35	2.21e-13	Monocyte count;
LUAD	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg13385794	chr1:248469461	NA	0.25	6.94	0.32	1.52e-11	Common traits (Other);
LUAD	cis	rs3096299	0.838	rs3096319	chr16:89402634	C/G	cg07708487	chr16:89387014	ANKRD11	-0.34	-6.74	-0.31	5.33e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg15242686	chr22:24348715	GSTTP1	0.47	8.13	0.37	4.92e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10193935	0.786	rs13399052	chr2:42385151	G/A	cg27598129	chr2:42591480	NA	-0.66	-8.76	-0.39	4.78e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg21995068	chr20:25989032	LOC100134868	-0.45	-7.3	-0.33	1.41e-12	Colorectal or endometrial cancer;
LUAD	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg27170947	chr2:26402098	FAM59B	-0.63	-8.92	-0.4	1.46e-17	Gut microbiome composition (summer);
LUAD	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.59	11.26	0.48	6.59e-26	Hemoglobin concentration;
LUAD	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.47	8.49	0.38	3.6e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.79	-0.43	1.52e-20	Gut microbiome composition (summer);
LUAD	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg07402062	chr16:89894098	SPIRE2	0.43	10.78	0.46	4.22e-24	Vitiligo;
LUAD	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg03433033	chr1:76189801	ACADM	0.67	9.71	0.43	2.98e-20	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg06618935	chr21:46677482	NA	0.42	7.75	0.35	6.84e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1018836	0.923	rs7812970	chr8:91541229	G/A	cg16814680	chr8:91681699	NA	-0.77	-13.52	-0.55	7.17e-35	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg08027265	chr7:2291960	NA	-0.49	-8.45	-0.38	4.85e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2742234	0.541	rs10793422	chr10:43703874	G/A	cg15436174	chr10:43711423	RASGEF1A	0.52	8.75	0.39	5.22e-17	Hirschsprung disease;
LUAD	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg07936489	chr17:37558343	FBXL20	0.49	6.7	0.31	6.71e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.94	-0.36	1.78e-14	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.6	-7.12	-0.33	4.77e-12	Body mass index;
LUAD	cis	rs231513	0.871	rs231522	chr17:41954602	A/G	cg26893861	chr17:41843967	DUSP3	-0.66	-7.49	-0.34	4.13e-13	Cognitive function;
LUAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.89	-0.32	2.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.8	0.35	4.77e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs57590327	0.555	rs2053805	chr3:81738414	T/C	cg07356753	chr3:81810745	GBE1	-0.61	-9.83	-0.43	1.1e-20	Extraversion;
LUAD	trans	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.3	0.45	2.36e-22	Mean corpuscular volume;
LUAD	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg21709803	chr11:61594965	FADS2	0.41	7.24	0.33	2.1e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18876405	chr7:65276391	NA	-0.41	-6.48	-0.3	2.59e-10	Aortic root size;
LUAD	trans	rs1493916	0.748	rs1389535	chr18:31310416	A/G	cg27147174	chr7:100797783	AP1S1	0.61	10.63	0.46	1.44e-23	Life satisfaction;
LUAD	cis	rs9462027	0.628	rs2814969	chr6:34713399	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.18	-0.41	1.93e-18	Systemic lupus erythematosus;
LUAD	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg14926445	chr8:58193284	C8orf71	-0.44	-6.38	-0.3	4.75e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9972944	0.676	rs8067129	chr17:63762984	C/T	cg07283582	chr17:63770753	CCDC46	-0.51	-11.18	-0.48	1.31e-25	Total body bone mineral density;
LUAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg02869364	chr7:1081709	C7orf50	-0.51	-6.67	-0.31	7.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.51	-9.11	-0.4	3.38e-18	Lymphocyte counts;
LUAD	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs9487051	0.768	rs458185	chr6:109524074	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.8	-0.31	3.58e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg02782426	chr3:40428986	ENTPD3	0.43	9.23	0.41	1.31e-18	Renal cell carcinoma;
LUAD	cis	rs727505	0.954	rs66526112	chr7:124504074	C/A	cg23710748	chr7:124431027	NA	-0.47	-9.56	-0.42	9.77e-20	Lewy body disease;
LUAD	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg14668632	chr7:2872130	GNA12	-0.47	-8.3	-0.37	1.41e-15	Height;
LUAD	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg04568274	chr7:158649319	WDR60	0.42	6.86	0.32	2.38e-11	Height;
LUAD	cis	rs6714710	0.603	rs35505530	chr2:98506910	T/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.25	0.37	2.07e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs4790333	0.539	rs67887169	chr17:2256828	G/A	cg02569219	chr17:2266849	SGSM2	0.53	10.0	0.44	2.94e-21	Proinsulin levels;
LUAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg15117754	chr3:10150083	C3orf24	0.42	7.0	0.32	1.03e-11	Alzheimer's disease;
LUAD	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg14552801	chr7:65878734	NA	0.38	6.5	0.3	2.27e-10	Aortic root size;
LUAD	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg03037974	chr15:76606532	NA	0.37	7.74	0.35	7.19e-14	Blood metabolite levels;
LUAD	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.79	-0.31	3.78e-11	Crohn's disease;
LUAD	cis	rs2235649	0.833	rs9929185	chr16:1852070	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.41	-6.46	-0.3	2.85e-10	Blood metabolite levels;
LUAD	cis	rs4588572	0.643	rs10474554	chr5:77799158	C/T	cg11547950	chr5:77652471	NA	-0.77	-11.77	-0.5	7.63e-28	Triglycerides;
LUAD	cis	rs76419734	0.614	rs17035951	chr4:106527613	A/G	cg05309399	chr4:106552544	FLJ20184	-0.55	-6.75	-0.31	4.9e-11	Post bronchodilator FEV1;
LUAD	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg26597838	chr10:835615	NA	1.09	17.13	0.64	2.42e-50	Eosinophil percentage of granulocytes;
LUAD	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24308560	chr3:49941425	MST1R	-0.57	-9.45	-0.42	2.32e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg15485101	chr11:133734466	NA	0.39	8.37	0.38	8.23e-16	Childhood ear infection;
LUAD	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg05082376	chr22:42548792	NA	-0.42	-7.02	-0.32	8.89e-12	Schizophrenia;
LUAD	cis	rs7202877	0.656	rs4888394	chr16:75413709	T/C	cg03315344	chr16:75512273	CHST6	0.48	6.52	0.3	2.04e-10	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg02733842	chr7:1102375	C7orf50	-0.58	-9.02	-0.4	6.56e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs13095912	0.785	rs4686682	chr3:185307402	C/T	cg11274856	chr3:185301563	NA	0.49	9.12	0.41	2.98e-18	Systolic blood pressure;
LUAD	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg26043149	chr18:55253948	FECH	0.51	8.31	0.37	1.34e-15	Bone mineral density;
LUAD	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.15e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg21051086	chr3:73046214	PPP4R2	-0.46	-7.37	-0.34	8.76e-13	Pancreatic cancer;
LUAD	cis	rs4664308	0.967	rs56293836	chr2:160910958	T/C	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.67	-0.31	8.17e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs12617721	0.756	rs3754889	chr2:99088633	T/G	cg10123293	chr2:99228465	UNC50	0.47	8.34	0.38	1.05e-15	Bipolar disorder with mood-incongruent psychosis;
LUAD	cis	rs806795	0.513	rs10946808	chr6:26233387	A/G	cg13736514	chr6:26305472	NA	-0.51	-7.7	-0.35	9.98e-14	Mosquito bite size;
LUAD	cis	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg07460842	chr6:66804631	NA	0.61	9.7	0.43	3.31e-20	Type 2 diabetes;
LUAD	trans	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg01620082	chr3:125678407	NA	0.67	7.31	0.33	1.31e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26314531	chr2:26401878	FAM59B	-0.73	-10.74	-0.46	5.84e-24	Gut microbiome composition (summer);
LUAD	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.69	0.35	1.01e-13	Bladder cancer;
LUAD	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.11	-24.49	-0.77	4.14e-83	Ulcerative colitis;
LUAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg13560548	chr3:10150139	C3orf24	0.42	6.93	0.32	1.54e-11	Alzheimer's disease;
LUAD	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg12379764	chr21:47803548	PCNT	-0.45	-7.34	-0.34	1.14e-12	Testicular germ cell tumor;
LUAD	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg03732007	chr1:2071316	PRKCZ	0.34	6.75	0.31	4.76e-11	Height;
LUAD	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg01416388	chr22:39784598	NA	-0.51	-8.57	-0.38	1.94e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg12373951	chr3:133503437	NA	0.35	6.82	0.31	3.1e-11	Iron status biomarkers;
LUAD	cis	rs4006360	0.546	rs1848812	chr17:39235917	C/T	cg16090541	chr17:39240343	KRTAP4-7	-0.37	-6.57	-0.3	1.44e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.77	0.39	4.32e-17	Lung cancer in ever smokers;
LUAD	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-9.09	-0.4	3.85e-18	Total body bone mineral density;
LUAD	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg03264133	chr6:25882463	NA	0.47	7.65	0.35	1.36e-13	Blood metabolite levels;
LUAD	cis	rs7737355	0.853	rs26004	chr5:130988955	G/T	cg25547332	chr5:131281432	NA	0.42	6.9	0.32	1.93e-11	Life satisfaction;
LUAD	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg15445000	chr17:37608096	MED1	0.44	8.18	0.37	3.38e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs9399401	0.667	rs7757571	chr6:142702589	A/C	cg03128060	chr6:142623767	GPR126	0.51	10.3	0.45	2.37e-22	Chronic obstructive pulmonary disease;
LUAD	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg08999081	chr20:33150536	PIGU	-0.37	-7.32	-0.34	1.23e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg00071950	chr4:10020882	SLC2A9	0.66	12.91	0.53	2.32e-32	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg27144592	chr16:783916	NARFL	0.37	6.78	0.31	4.06e-11	Height;
LUAD	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg23260525	chr10:116636907	FAM160B1	0.53	12.67	0.52	2e-31	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10197940	0.578	rs6718653	chr2:152346118	C/A	cg06191203	chr2:152266755	RIF1	-0.47	-7.32	-0.34	1.26e-12	Lung cancer;
LUAD	cis	rs7524258	0.867	rs916392	chr1:7271930	T/C	cg07173049	chr1:7289937	CAMTA1	0.51	9.43	0.42	2.72e-19	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs11048434	0.649	rs11613650	chr12:9060396	T/C	cg26114124	chr12:9217669	LOC144571	0.36	6.46	0.3	2.88e-10	Sjögren's syndrome;
LUAD	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg22823121	chr1:150693482	HORMAD1	0.45	9.13	0.41	2.95e-18	Tonsillectomy;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16561543	chr14:105714843	BRF1;BTBD6	-0.53	-6.41	-0.3	3.87e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3806843	0.547	rs246010	chr5:140336635	A/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg22823121	chr1:150693482	HORMAD1	0.43	8.79	0.39	3.66e-17	Tonsillectomy;
LUAD	trans	rs2840044	1.000	rs9900378	chr17:33911302	C/T	cg19694781	chr19:47549865	TMEM160	0.64	10.25	0.45	3.59e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06544989	chr22:39130855	UNC84B	0.42	7.49	0.34	4.12e-13	Menopause (age at onset);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24972377	chr12:122326574	PSMD9	-0.54	-6.47	-0.3	2.64e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7116495	1.000	rs4944232	chr11:71642258	A/G	cg18441811	chr11:71824068	C11orf51	0.71	6.47	0.3	2.71e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24308560	chr3:49941425	MST1R	-0.57	-9.61	-0.42	6.34e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.14	-0.33	4.12e-12	Menopause (age at onset);
LUAD	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg11266682	chr4:10021025	SLC2A9	0.5	10.99	0.47	7.15e-25	Bone mineral density;
LUAD	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg15123519	chr2:136567270	LCT	0.39	7.15	0.33	3.88e-12	Mosquito bite size;
LUAD	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg11871910	chr12:69753446	YEATS4	0.7	12.04	0.51	6.75e-29	Blood protein levels;
LUAD	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg22029157	chr1:209979665	IRF6	0.45	7.98	0.36	1.36e-14	Monobrow;
LUAD	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg26727032	chr16:67993705	SLC12A4	-0.49	-8.06	-0.36	7.92e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.51	-0.38	3.12e-16	Gut microbiome composition (summer);
LUAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg23283495	chr1:209979779	IRF6	0.71	11.18	0.48	1.35e-25	Cleft lip with or without cleft palate;
LUAD	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg21427119	chr20:30132790	HM13	-0.62	-9.46	-0.42	2.24e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs7737355	0.812	rs26010	chr5:131013815	G/A	cg25547332	chr5:131281432	NA	0.43	7.02	0.32	8.82e-12	Life satisfaction;
LUAD	cis	rs72766638	1.000	rs72766638	chr9:136931778	C/A	cg13789015	chr9:136890014	NCRNA00094	0.62	7.86	0.36	3.14e-14	Mosquito bite size;
LUAD	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg22117172	chr7:91764530	CYP51A1	0.31	6.75	0.31	5.03e-11	Breast cancer;
LUAD	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg24558204	chr6:135376177	HBS1L	0.49	9.15	0.41	2.41e-18	Red blood cell count;
LUAD	cis	rs7809950	0.678	rs79902674	chr7:106866498	A/C	cg23024343	chr7:107201750	COG5	-0.81	-13.07	-0.54	5.1e-33	Coronary artery disease;
LUAD	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg05872129	chr22:39784769	NA	-0.77	-14.88	-0.59	1.47e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg10802521	chr3:52805072	NEK4	-0.53	-9.37	-0.41	4.46e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg00898013	chr13:113819073	PROZ	-0.64	-11.53	-0.49	6.29e-27	Platelet distribution width;
LUAD	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg22431228	chr1:16359049	CLCNKA	0.43	7.54	0.34	2.82e-13	Dilated cardiomyopathy;
LUAD	cis	rs7027203	1.000	rs7027203	chr9:96562563	A/C	cg14598338	chr9:96623480	NA	0.38	7.58	0.35	2.15e-13	DNA methylation (variation);
LUAD	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg10518543	chr12:38710700	ALG10B	-0.48	-7.81	-0.36	4.5e-14	Morning vs. evening chronotype;
LUAD	cis	rs2795502	0.564	rs11239842	chr10:43444882	A/G	cg08461752	chr10:43522343	NA	-0.77	-8.18	-0.37	3.44e-15	Blood protein levels;
LUAD	cis	rs36051895	0.632	rs10815164	chr9:5131312	T/A	cg02405213	chr9:5042618	JAK2	-0.47	-6.44	-0.3	3.27e-10	Pediatric autoimmune diseases;
LUAD	cis	rs6604026	0.630	rs10874753	chr1:93429087	A/C	cg17283838	chr1:93427260	FAM69A	-0.43	-6.47	-0.3	2.71e-10	Multiple sclerosis;
LUAD	cis	rs1032833	0.732	rs2028906	chr2:180028772	C/T	cg23883738	chr2:179974586	SESTD1	-0.65	-7.31	-0.34	1.32e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg08601574	chr20:25228251	PYGB	-0.44	-8.16	-0.37	3.83e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs68170813	0.559	rs12532967	chr7:106937418	T/C	cg23024343	chr7:107201750	COG5	0.5	7.13	0.33	4.27e-12	Coronary artery disease;
LUAD	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg03188948	chr7:1209495	NA	0.62	6.41	0.3	3.87e-10	Longevity;Endometriosis;
LUAD	cis	rs4285028	0.948	rs12637351	chr3:121694412	A/G	cg20356878	chr3:121714668	ILDR1	0.47	6.41	0.3	3.89e-10	Multiple sclerosis;
LUAD	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg22676075	chr6:135203613	NA	0.4	7.34	0.34	1.08e-12	Red blood cell count;
LUAD	cis	rs73110464	0.505	rs2682296	chr12:53308265	G/A	cg14581129	chr12:53358946	NA	-0.41	-6.72	-0.31	5.98e-11	Cancer (pleiotropy);
LUAD	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg13390004	chr1:15929781	NA	0.48	8.54	0.38	2.51e-16	Systolic blood pressure;
LUAD	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg07537917	chr2:241836409	C2orf54	0.28	7.64	0.35	1.45e-13	Urinary metabolites;
LUAD	cis	rs7786808	0.530	rs6459875	chr7:158186141	C/T	cg09998033	chr7:158218633	PTPRN2	0.46	8.13	0.37	4.77e-15	Obesity-related traits;
LUAD	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg22875332	chr1:76189707	ACADM	-0.86	-15.85	-0.61	9.66e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6005807	0.843	rs73430186	chr22:29004821	G/A	cg12565055	chr22:29076175	TTC28	0.67	6.63	0.31	1.02e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg11693508	chr17:37793320	STARD3	0.72	9.46	0.42	2.14e-19	Bipolar disorder;
LUAD	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg16680214	chr1:154839983	KCNN3	-0.63	-13.26	-0.54	8.05e-34	Prostate cancer;
LUAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg07362569	chr17:61921086	SMARCD2	0.39	6.68	0.31	7.43e-11	Prudent dietary pattern;
LUAD	cis	rs57590327	0.555	rs13088603	chr3:81791167	A/G	cg07356753	chr3:81810745	GBE1	-0.63	-10.09	-0.44	1.3e-21	Extraversion;
LUAD	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg21475434	chr5:93447410	FAM172A	0.77	8.65	0.39	1.08e-16	Diabetic retinopathy;
LUAD	cis	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg23950597	chr19:37808831	NA	-0.64	-7.57	-0.35	2.43e-13	Coronary artery calcification;
LUAD	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.626	rs9615960	chr22:46752307	G/A	cg00784671	chr22:46762841	CELSR1	-0.69	-7.84	-0.36	3.82e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2573652	1.000	rs2581358	chr15:100513725	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.51	-8.95	-0.4	1.13e-17	Height;
LUAD	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg18240062	chr17:79603768	NPLOC4	0.36	6.35	0.3	5.42e-10	Eye color traits;
LUAD	cis	rs863345	0.604	rs10908666	chr1:158500098	G/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.49	-0.3	2.34e-10	Pneumococcal bacteremia;
LUAD	cis	rs7709909	0.967	rs32952	chr5:80021445	A/C	cg24059623	chr5:79951536	MSH3;DHFR	0.39	6.58	0.3	1.43e-10	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg15242686	chr22:24348715	GSTTP1	0.41	6.75	0.31	4.91e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2901656	0.691	rs10798005	chr1:172382965	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	-0.45	-8.78	-0.39	4.04e-17	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs4523957	0.651	rs1994883	chr17:2083881	T/A	cg16513277	chr17:2031491	SMG6	-0.95	-18.95	-0.68	2.08e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs36051895	0.664	rs884132	chr9:5114522	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-6.49	-0.3	2.38e-10	Pediatric autoimmune diseases;
LUAD	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg23625390	chr15:77176239	SCAPER	0.39	7.01	0.32	9.27e-12	Blood metabolite levels;
LUAD	cis	rs1816752	0.905	rs8002215	chr13:24990367	A/G	cg02811702	chr13:24901961	NA	0.41	7.1	0.33	5.35e-12	Obesity-related traits;
LUAD	cis	rs12519773	0.967	rs4242239	chr5:92482226	A/G	cg18783429	chr5:92414398	NA	0.37	6.43	0.3	3.48e-10	Migraine;
LUAD	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	9.4e-15	Tonsillectomy;
LUAD	cis	rs910187	0.678	rs3818008	chr20:45816488	C/T	cg27589058	chr20:45804311	EYA2	-0.3	-6.94	-0.32	1.5e-11	Migraine;
LUAD	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-8.49	-0.38	3.65e-16	Glomerular filtration rate;
LUAD	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.74	-12.43	-0.52	1.81e-30	Primary sclerosing cholangitis;
LUAD	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg11247378	chr22:39784982	NA	-0.7	-12.33	-0.51	4.71e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg01579765	chr21:45077557	HSF2BP	-0.6	-13.4	-0.55	2.24e-34	Mean corpuscular volume;
LUAD	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg18240062	chr17:79603768	NPLOC4	0.36	6.35	0.3	5.42e-10	Eye color traits;
LUAD	cis	rs10748180	0.502	rs1043781	chr12:72097418	C/G	cg10168894	chr12:72148281	RAB21	-0.43	-6.52	-0.3	2.05e-10	Economic and political preferences (time);
LUAD	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg20476274	chr7:133979776	SLC35B4	0.84	16.33	0.62	8.09e-47	Mean platelet volume;
LUAD	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg19193384	chr17:30244184	NA	-0.52	-6.63	-0.31	1.02e-10	Hip circumference adjusted for BMI;
LUAD	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg26384229	chr12:38710491	ALG10B	0.44	7.36	0.34	9.38e-13	Morning vs. evening chronotype;
LUAD	cis	rs12545109	0.765	rs2576594	chr8:57412126	T/G	cg09654669	chr8:57350985	NA	-0.65	-9.14	-0.41	2.67e-18	Obesity-related traits;
LUAD	trans	rs11039798	1.000	rs10769370	chr11:48515430	A/G	cg02254774	chr11:50257496	LOC441601	0.52	6.65	0.31	9.17e-11	Axial length;
LUAD	cis	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg23442198	chr4:187126114	CYP4V2	0.93	9.85	0.43	9.56e-21	Blood protein levels;
LUAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg03886242	chr7:26192032	NFE2L3	0.36	6.42	0.3	3.57e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-7.56	-0.35	2.52e-13	Height;Educational attainment;Head circumference (infant);
LUAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08280861	chr8:58055591	NA	0.55	7.04	0.32	8.03e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21659725	chr3:3221576	CRBN	0.52	8.4	0.38	7.03e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-7.35	-0.34	1.02e-12	Longevity;Endometriosis;
LUAD	cis	rs490234	0.702	rs4838277	chr9:128367886	C/T	cg14078157	chr9:128172775	NA	-0.46	-8.14	-0.37	4.43e-15	Mean arterial pressure;
LUAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg07021052	chr2:20871279	NA	-0.43	-7.5	-0.34	3.89e-13	Abdominal aortic aneurysm;
LUAD	cis	rs3806843	0.576	rs246028	chr5:140333513	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg09060608	chr5:178986726	RUFY1	0.7	12.01	0.5	8.71e-29	Lung cancer;
LUAD	cis	rs9287719	0.614	rs6432105	chr2:10697599	G/A	cg02196655	chr2:10830764	NOL10	-0.38	-6.46	-0.3	2.95e-10	Prostate cancer;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17774305	chr12:50505649	C12orf62	0.42	6.6	0.31	1.22e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs2997447	0.846	rs3008225	chr1:26390181	T/A	cg00147160	chr1:26503991	CNKSR1	0.36	6.83	0.32	2.94e-11	QRS complex (12-leadsum);
LUAD	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg07570687	chr10:102243282	WNT8B	0.45	6.99	0.32	1.1e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg19636519	chr7:99541626	NA	0.41	7.35	0.34	1.05e-12	Coronary artery disease;
LUAD	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg13535736	chr9:111863775	C9orf5	-0.43	-6.67	-0.31	7.96e-11	Menarche (age at onset);
LUAD	cis	rs34734847	1.000	rs3021338	chr12:121162989	A/G	cg27246729	chr12:121163418	ACADS	0.4	7.55	0.34	2.69e-13	Mean corpuscular volume;
LUAD	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg27572855	chr1:25598939	RHD	0.53	11.36	0.48	2.78e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs7267979	0.586	rs6037057	chr20:25182089	T/C	cg08601574	chr20:25228251	PYGB	0.36	6.61	0.31	1.14e-10	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg15181151	chr6:150070149	PCMT1	0.42	8.59	0.39	1.74e-16	Lung cancer;
LUAD	cis	rs17608059	0.545	rs736261	chr17:13936404	A/G	cg11395062	chr17:14139857	CDRT15	0.45	7.15	0.33	3.76e-12	Temperament;
LUAD	cis	rs17433780	0.836	rs17434342	chr1:89505742	C/G	cg09516651	chr1:89888402	LOC400759	-0.46	-8.71	-0.39	6.76e-17	Carotid intima media thickness;
LUAD	cis	rs2387326	0.767	rs11016096	chr10:129942734	G/A	cg16087940	chr10:129947807	NA	-0.64	-8.59	-0.39	1.7e-16	Select biomarker traits;
LUAD	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg04450456	chr4:17643702	FAM184B	0.4	7.8	0.35	4.9e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12545109	0.842	rs2582379	chr8:57395243	C/T	cg09654669	chr8:57350985	NA	0.65	8.93	0.4	1.32e-17	Obesity-related traits;
LUAD	trans	rs941408	1.000	rs941406	chr19:2803623	A/G	cg19676328	chr12:49525230	TUBA1B	-0.69	-10.97	-0.47	8.11e-25	Total cholesterol levels;
LUAD	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg20556744	chr2:9614537	IAH1	0.64	6.72	0.31	5.98e-11	Opioid sensitivity;
LUAD	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.66	-11.4	-0.48	1.95e-26	Axial length;
LUAD	cis	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg21775007	chr8:11205619	TDH	0.37	6.39	0.3	4.27e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg17177755	chr1:15930204	NA	0.43	7.12	0.33	4.77e-12	Systolic blood pressure;
LUAD	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg16405210	chr4:1374714	KIAA1530	-0.61	-9.32	-0.41	6.41e-19	Longevity;
LUAD	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg09365446	chr1:150670422	GOLPH3L	0.66	12.3	0.51	6.1e-30	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.61	0.31	1.16e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4942242	1.000	rs1105856	chr13:44227067	G/T	cg19169023	chr15:41853346	TYRO3	0.53	9.08	0.4	4.14e-18	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.48	0.3	2.53e-10	Breast cancer;
LUAD	cis	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg27411982	chr8:10470053	RP1L1	0.38	6.9	0.32	1.93e-11	Neuroticism;
LUAD	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg18512352	chr11:47633146	NA	-0.42	-7.31	-0.33	1.36e-12	Subjective well-being;
LUAD	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg02931644	chr1:25747376	RHCE	-0.41	-8.51	-0.38	3.14e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs897984	0.542	rs3751855	chr16:31091209	T/C	cg02466173	chr16:30829666	NA	-0.56	-9.74	-0.43	2.25e-20	Dementia with Lewy bodies;
LUAD	cis	rs4409675	0.576	rs6700473	chr1:28236682	C/T	cg23691781	chr1:28212827	C1orf38	0.35	9.05	0.4	5.29e-18	Corneal astigmatism;
LUAD	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.59	-0.49	3.54e-27	Primary sclerosing cholangitis;
LUAD	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg16486109	chr11:613632	IRF7	0.54	9.03	0.4	6.3e-18	Systemic lupus erythematosus;
LUAD	cis	rs60154123	0.772	rs614167	chr1:210425895	T/C	cg22029157	chr1:209979665	IRF6	0.63	7.01	0.32	9.34e-12	Coronary artery disease;
LUAD	cis	rs9837602	1.000	rs62285478	chr3:99822135	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-6.85	-0.32	2.63e-11	Breast cancer;
LUAD	cis	rs5769707	0.632	rs135872	chr22:50009300	T/C	cg20744362	chr22:50050164	C22orf34	0.37	7.08	0.33	5.87e-12	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.25	-0.51	9.53e-30	Platelet count;
LUAD	trans	rs3857536	0.730	rs7761295	chr6:66932532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.35	-0.3	5.66e-10	Blood trace element (Cu levels);
LUAD	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg13813247	chr22:41461852	NA	-0.46	-7.51	-0.34	3.55e-13	Neuroticism;
LUAD	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg25767906	chr1:53392781	SCP2	-0.35	-6.6	-0.31	1.21e-10	Monocyte count;
LUAD	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg12656391	chr1:43425156	SLC2A1	-0.61	-9.71	-0.43	3.07e-20	Monocyte count;
LUAD	cis	rs11214589	1.000	rs11214589	chr11:113245048	C/T	cg14159747	chr11:113255604	NA	0.65	13.8	0.56	5.21e-36	Neuroticism;
LUAD	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg26384229	chr12:38710491	ALG10B	0.44	6.91	0.32	1.81e-11	Heart rate;
LUAD	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg16479474	chr6:28041457	NA	0.37	6.97	0.32	1.25e-11	Parkinson's disease;
LUAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-7.38	-0.34	8.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2387326	1.000	rs10764751	chr10:129926420	A/C	cg16087940	chr10:129947807	NA	-0.49	-6.49	-0.3	2.43e-10	Select biomarker traits;
LUAD	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg12564285	chr5:131593104	PDLIM4	0.39	7.32	0.34	1.24e-12	Acylcarnitine levels;
LUAD	cis	rs2242073	0.627	rs4276012	chr2:208999891	C/T	cg06181187	chr2:209010896	CRYGB	-0.34	-6.77	-0.31	4.37e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	6.39	0.3	4.47e-10	Bipolar disorder;
LUAD	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg05872129	chr22:39784769	NA	-0.83	-15.85	-0.61	9.34e-45	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-10.82	-0.47	2.97e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7192380	0.624	rs11075730	chr16:69650522	C/T	cg26679644	chr16:69762563	NA	0.42	6.8	0.31	3.58e-11	Sjögren's syndrome;
LUAD	cis	rs3806843	0.607	rs246044	chr5:140330656	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.33	-6.79	-0.31	3.8e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg23231163	chr10:75533350	FUT11	-0.53	-9.65	-0.42	4.81e-20	Inflammatory bowel disease;
LUAD	cis	rs35740288	0.770	rs11631018	chr15:86140534	G/A	cg13263323	chr15:86062960	AKAP13	-0.42	-6.66	-0.31	8.78e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg05110241	chr16:68378359	PRMT7	-0.8	-8.88	-0.4	1.91e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11626933	1.000	rs6575122	chr14:90753556	A/G	cg14092571	chr14:90743983	NA	-0.96	-18.18	-0.66	5.52e-55	Gut microbiota (bacterial taxa);
LUAD	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg27170947	chr2:26402098	FAM59B	-0.81	-11.51	-0.49	7.14e-27	Gut microbiome composition (summer);
LUAD	cis	rs10489202	0.865	rs744168	chr1:168094079	G/T	cg24449463	chr1:168025552	DCAF6	-0.54	-6.5	-0.3	2.2e-10	Schizophrenia;
LUAD	cis	rs9462027	0.628	rs7774697	chr6:34791027	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.34	8.64	0.39	1.19e-16	Systemic lupus erythematosus;
LUAD	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg15704280	chr7:45808275	SEPT13	-0.59	-9.85	-0.43	9.28e-21	Coronary artery disease;
LUAD	cis	rs12145833	0.596	rs12043646	chr1:243281992	G/A	cg02356786	chr1:243265016	LOC731275	0.74	8.13	0.37	4.91e-15	Obesity (early onset extreme);
LUAD	cis	rs240764	0.579	rs9386233	chr6:101149540	C/T	cg09795085	chr6:101329169	ASCC3	0.39	6.47	0.3	2.79e-10	Neuroticism;
LUAD	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg06060754	chr5:176797920	RGS14	0.54	8.65	0.39	1.04e-16	Urate levels in lean individuals;
LUAD	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.32e-15	Prostate cancer;
LUAD	cis	rs3820068	0.705	rs72645808	chr1:15870118	G/C	cg13390004	chr1:15929781	NA	0.43	6.61	0.31	1.17e-10	Systolic blood pressure;
LUAD	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg27068330	chr11:65405492	SIPA1	0.57	9.02	0.4	6.48e-18	Acne (severe);
LUAD	cis	rs986417	0.748	rs10150234	chr14:61031284	C/G	cg27398547	chr14:60952738	C14orf39	-0.53	-6.71	-0.31	6.41e-11	Gut microbiota (bacterial taxa);
LUAD	cis	rs7975161	0.520	rs4502051	chr12:104695569	A/T	cg25273343	chr12:104657179	TXNRD1	-0.62	-6.47	-0.3	2.71e-10	Toenail selenium levels;
LUAD	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg18944383	chr4:111397179	ENPEP	0.4	8.16	0.37	3.75e-15	Height;
LUAD	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg23260525	chr10:116636907	FAM160B1	0.48	11.07	0.47	3.37e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10865541	0.934	rs4627605	chr2:3411923	G/A	cg22182287	chr2:3452347	TTC15	0.42	7.36	0.34	9.78e-13	Obesity-related traits;
LUAD	cis	rs17608059	0.611	rs62052300	chr17:13916799	G/A	cg11395062	chr17:14139857	CDRT15	0.48	7.72	0.35	8.52e-14	Temperament;
LUAD	cis	rs807669	0.505	rs28651174	chr22:19236489	C/T	cg02655711	chr22:19163373	SLC25A1	0.57	10.79	0.46	3.85e-24	Metabolite levels;
LUAD	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg14092988	chr3:52407081	DNAH1	0.35	6.79	0.31	3.69e-11	Bipolar disorder;
LUAD	cis	rs1950626	0.750	rs35683125	chr14:101454750	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.42	7.71	0.35	8.98e-14	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.8	-0.31	3.53e-11	Mood instability;
LUAD	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg23649088	chr2:200775458	C2orf69	0.52	8.29	0.37	1.53e-15	Osteoporosis;
LUAD	cis	rs6426558	0.502	rs2813965	chr1:227445733	A/G	cg10327440	chr1:227177885	CDC42BPA	0.59	9.47	0.42	1.97e-19	Neutrophil percentage of white cells;
LUAD	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg14092988	chr3:52407081	DNAH1	0.46	9.1	0.4	3.61e-18	Bipolar disorder;
LUAD	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg07423050	chr13:99094983	FARP1	-0.52	-8.67	-0.39	9.12e-17	Longevity;
LUAD	cis	rs3916	1.000	rs34708625	chr12:121180019	T/C	cg27246729	chr12:121163418	ACADS	0.47	7.25	0.33	1.95e-12	Urinary metabolites (H-NMR features);
LUAD	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg15128208	chr22:42549153	NA	0.45	7.25	0.33	2.02e-12	Birth weight;
LUAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-10.0	-0.44	2.92e-21	Lymphocyte counts;
LUAD	cis	rs977987	0.872	rs4887816	chr16:75319716	T/C	cg03315344	chr16:75512273	CHST6	0.63	13.8	0.56	5.06e-36	Dupuytren's disease;
LUAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg26516362	chr5:178986906	RUFY1	0.61	10.96	0.47	9.33e-25	Lung cancer;
LUAD	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg18252515	chr7:66147081	NA	-0.61	-6.6	-0.31	1.2e-10	Diabetic kidney disease;
LUAD	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.47	-8.16	-0.37	3.94e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg11833968	chr6:79620685	NA	0.43	8.16	0.37	3.9e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2455799	0.573	rs2174172	chr3:15768579	C/A	cg16303742	chr3:15540471	COLQ	-0.52	-9.6	-0.42	7.28e-20	Mean platelet volume;
LUAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.71e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg26043149	chr18:55253948	FECH	0.61	10.06	0.44	1.8e-21	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs863345	0.604	rs1578763	chr1:158497414	C/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.39	-0.3	4.26e-10	Pneumococcal bacteremia;
LUAD	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg11645453	chr3:52864694	ITIH4	0.52	10.14	0.44	8.82e-22	Bipolar disorder;
LUAD	trans	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg24644049	chr4:85504048	CDS1	0.93	7.81	0.36	4.5e-14	Skin colour saturation;
LUAD	cis	rs76419734	0.558	rs11730082	chr4:106521866	C/T	cg05309399	chr4:106552544	FLJ20184	-0.56	-6.9	-0.32	1.88e-11	Post bronchodilator FEV1;
LUAD	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.99	-0.36	1.28e-14	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg08859206	chr1:53392774	SCP2	-0.53	-9.51	-0.42	1.44e-19	Monocyte count;
LUAD	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg08029281	chr1:67600428	NA	0.36	7.03	0.32	8.18e-12	Psoriasis;
LUAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-11.02	-0.47	5.4e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg16797656	chr11:68205561	LRP5	0.45	8.39	0.38	7.4e-16	Total body bone mineral density;
LUAD	cis	rs1018836	0.923	rs4734269	chr8:91635474	G/C	cg16814680	chr8:91681699	NA	-0.65	-10.92	-0.47	1.32e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg23229984	chr5:148520753	ABLIM3	0.49	7.07	0.33	6.37e-12	Breast cancer;
LUAD	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg24733560	chr20:60626293	TAF4	-0.43	-7.13	-0.33	4.47e-12	Body mass index;
LUAD	cis	rs10392	0.543	rs6028197	chr20:37534193	C/T	cg27552599	chr20:37590471	DHX35	0.38	6.43	0.3	3.41e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg06623918	chr6:96969491	KIAA0776	-0.87	-16.91	-0.64	2.2e-49	Headache;
LUAD	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg00409905	chr10:38381863	ZNF37A	-0.4	-6.47	-0.3	2.66e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg08601574	chr20:25228251	PYGB	0.45	8.36	0.38	9.03e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg15448220	chr1:150897856	SETDB1	0.53	9.32	0.41	6.74e-19	Tonsillectomy;
LUAD	cis	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg21775007	chr8:11205619	TDH	0.38	6.7	0.31	6.83e-11	Neuroticism;
LUAD	cis	rs7680126	0.626	rs11721501	chr4:10189135	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-7.45	-0.34	5.27e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg03806693	chr22:41940476	POLR3H	-0.75	-9.95	-0.44	4.29e-21	Vitiligo;
LUAD	trans	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	15.69	0.61	4.92e-44	Exhaled nitric oxide levels;
LUAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg21782813	chr7:2030301	MAD1L1	0.6	10.51	0.46	4e-23	Bipolar disorder and schizophrenia;
LUAD	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21582582	chr3:182698605	DCUN1D1	0.56	9.6	0.42	7.03e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs3815148	chr7:106938420	G/T	cg02696742	chr7:106810147	HBP1	0.74	10.91	0.47	1.35e-24	Coronary artery disease;
LUAD	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-7.62	-0.35	1.63e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg12011299	chr4:100065546	ADH4	0.61	12.78	0.53	7.39e-32	Alcohol dependence;
LUAD	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg02574844	chr11:5959923	NA	0.4	6.72	0.31	5.79e-11	DNA methylation (variation);
LUAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06873352	chr17:61820015	STRADA	0.81	18.3	0.66	1.61e-55	Prudent dietary pattern;
LUAD	cis	rs2274273	0.837	rs8008119	chr14:55831228	T/C	cg04306507	chr14:55594613	LGALS3	0.43	8.93	0.4	1.35e-17	Protein biomarker;
LUAD	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.69	0.31	7.15e-11	Depression;
LUAD	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg13010344	chr12:123464640	ARL6IP4	0.39	6.8	0.31	3.58e-11	Platelet count;
LUAD	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs2835872	1.000	rs2835872	chr21:39027272	G/A	cg06728970	chr21:39037746	KCNJ6	-0.4	-7.27	-0.33	1.8e-12	Electroencephalographic traits in alcoholism;
LUAD	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg13385794	chr1:248469461	NA	0.24	6.61	0.31	1.13e-10	Common traits (Other);
LUAD	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg10589385	chr1:150898437	SETDB1	-0.4	-7.69	-0.35	1.03e-13	Tonsillectomy;
LUAD	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg23625390	chr15:77176239	SCAPER	0.4	7.03	0.32	8.44e-12	Blood metabolite levels;
LUAD	cis	rs758324	0.947	rs4493667	chr5:131247218	G/T	cg06307176	chr5:131281290	NA	-0.53	-8.44	-0.38	4.99e-16	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg12573674	chr2:1569213	NA	-0.59	-8.85	-0.4	2.45e-17	IgG glycosylation;
LUAD	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25427524	chr10:38739819	LOC399744	-0.76	-13.56	-0.55	4.99e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg27426351	chr10:43362370	NA	-0.53	-8.12	-0.37	5e-15	Blood protein levels;
LUAD	cis	rs4730250	0.670	rs9641380	chr7:106868151	C/G	cg23024343	chr7:107201750	COG5	0.5	7.33	0.34	1.18e-12	Osteoarthritis;
LUAD	cis	rs208520	0.955	rs208538	chr6:66964492	C/G	cg07460842	chr6:66804631	NA	-0.94	-13.01	-0.53	8.7e-33	Exhaled nitric oxide output;
LUAD	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.39	6.81	0.31	3.42e-11	Insulin-like growth factors;
LUAD	cis	rs7731657	0.537	rs10478953	chr5:130185380	A/C	cg08523029	chr5:130500466	HINT1	0.59	7.73	0.35	7.87e-14	Fasting plasma glucose;
LUAD	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg27539214	chr16:67997921	SLC12A4	-0.65	-8.19	-0.37	3.02e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg01802117	chr1:53393560	SCP2	-0.35	-7.0	-0.32	1.01e-11	Monocyte count;
LUAD	cis	rs7191700	0.511	rs8058983	chr16:11360849	A/G	cg00044050	chr16:11439710	C16orf75	-0.63	-9.9	-0.43	6.14e-21	Multiple sclerosis;
LUAD	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg12193833	chr17:30244370	NA	-0.58	-6.95	-0.32	1.35e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs17021463	0.902	rs34465979	chr4:95257554	C/A	cg11021082	chr4:95130006	SMARCAD1	0.46	8.39	0.38	7.53e-16	Testicular germ cell tumor;
LUAD	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg08885076	chr2:99613938	TSGA10	-0.41	-7.21	-0.33	2.63e-12	Chronic sinus infection;
LUAD	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg09455208	chr3:40491958	NA	0.65	14.05	0.56	4.49e-37	Renal cell carcinoma;
LUAD	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg17724175	chr1:150552817	MCL1	-0.27	-6.37	-0.3	4.84e-10	Tonsillectomy;
LUAD	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg01200585	chr1:228362443	C1orf69	-0.4	-7.23	-0.33	2.23e-12	Diastolic blood pressure;
LUAD	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg06640241	chr16:89574553	SPG7	0.49	8.06	0.36	8.01e-15	Multiple myeloma (IgH translocation);
LUAD	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg06784218	chr1:46089804	CCDC17	0.59	13.28	0.54	6.8e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs12600053	0.687	rs11149686	chr16:84847247	A/G	cg09249803	chr16:84846936	NA	0.39	6.79	0.31	3.72e-11	Asthma (childhood onset);
LUAD	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg19729930	chr2:74357872	NA	1.05	17.43	0.65	1.13e-51	Gestational age at birth (maternal effect);
LUAD	cis	rs7149337	0.717	rs4309324	chr14:51606336	A/T	cg23942311	chr14:51606299	NA	-0.87	-20.58	-0.71	1.03e-65	Cancer;
LUAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg21856205	chr7:94953877	PON1	-0.68	-12.23	-0.51	1.15e-29	Paraoxonase activity;
LUAD	cis	rs4481887	0.617	rs7511986	chr1:248527810	G/A	cg00666640	chr1:248458726	OR2T12	0.27	6.73	0.31	5.38e-11	Common traits (Other);
LUAD	cis	rs7709909	0.720	rs6868774	chr5:79985963	T/C	cg24059623	chr5:79951536	MSH3;DHFR	0.46	8.6	0.39	1.55e-16	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	trans	rs12517041	1.000	rs4547895	chr5:23323269	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.49	-6.85	-0.32	2.55e-11	Calcium levels;
LUAD	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg15147215	chr3:52552868	STAB1	-0.42	-7.57	-0.35	2.34e-13	Bipolar disorder;
LUAD	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg22868518	chr11:507468	RNH1	-0.66	-6.65	-0.31	8.81e-11	Body mass index;
LUAD	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg15997130	chr1:24165203	NA	-0.54	-9.53	-0.42	1.23e-19	Immature fraction of reticulocytes;
LUAD	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg12623918	chr2:306882	NA	0.34	6.88	0.32	2.23e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg25173405	chr17:45401733	C17orf57	0.45	7.83	0.36	4.03e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs73086581	1.000	rs6107386	chr20:3972756	A/C	cg02187196	chr20:3869020	PANK2	0.45	6.51	0.3	2.13e-10	Response to antidepressants in depression;
LUAD	cis	rs4699052	0.963	rs2085978	chr4:104193614	A/G	cg16532752	chr4:104119610	CENPE	-0.49	-7.57	-0.35	2.38e-13	Testicular germ cell tumor;
LUAD	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg13722127	chr7:150037890	RARRES2	0.49	7.96	0.36	1.59e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg17366294	chr4:99064904	C4orf37	0.47	8.22	0.37	2.53e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg22532475	chr10:104410764	TRIM8	-0.49	-9.0	-0.4	7.76e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs7395662	1.000	rs7482528	chr11:48640052	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	2.02e-12	HDL cholesterol;
LUAD	cis	rs9314323	0.964	rs3808579	chr8:26250682	C/T	cg13160058	chr8:26243215	BNIP3L	-0.47	-9.84	-0.43	1.03e-20	Red cell distribution width;
LUAD	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.78	-0.31	4.07e-11	Post bronchodilator FEV1;
LUAD	cis	rs62238980	0.614	rs73391051	chr22:32475878	G/C	cg00543991	chr22:32367038	NA	0.92	8.7	0.39	7.27e-17	Childhood ear infection;
LUAD	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.5	0.34	3.72e-13	Tonsillectomy;
LUAD	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.58e-12	Breast cancer;
LUAD	trans	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg03886242	chr7:26192032	NFE2L3	-0.48	-8.47	-0.38	4e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs77861329	1.000	rs114209632	chr3:52188361	C/T	cg08692210	chr3:52188851	WDR51A	0.78	6.58	0.3	1.39e-10	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg20203395	chr5:56204925	C5orf35	-0.82	-11.64	-0.49	2.35e-27	Initial pursuit acceleration;
LUAD	cis	rs8044868	0.586	rs7199261	chr16:72082788	A/G	cg23815491	chr16:72088622	HP	0.53	9.68	0.43	3.7799999999999997e-20	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg05425664	chr17:57184151	TRIM37	0.43	7.84	0.36	3.8e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9788682	0.668	rs2036529	chr15:78726272	A/T	cg18825076	chr15:78729989	IREB2	-0.52	-7.21	-0.33	2.64e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs2996428	0.709	rs12127399	chr1:3721609	G/A	cg17443473	chr1:3703550	LRRC47	0.46	7.69	0.35	1.06e-13	Red cell distribution width;
LUAD	cis	rs1707322	0.638	rs1707302	chr1:46600917	A/G	cg06784218	chr1:46089804	CCDC17	-0.44	-9.64	-0.42	4.99e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs11039798	1.000	rs7924372	chr11:48556319	T/A	cg03929089	chr4:120376271	NA	0.65	6.41	0.3	3.78e-10	Axial length;
LUAD	cis	rs500891	0.547	rs1170480	chr6:84036345	A/G	cg08257003	chr6:84140564	ME1	0.34	6.38	0.3	4.57e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg05340658	chr4:99064831	C4orf37	-0.46	-7.64	-0.35	1.42e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	cis	rs9584850	0.834	rs8481	chr13:99105395	G/A	cg20750642	chr13:99100586	FARP1	-0.32	-6.69	-0.31	7.28e-11	Neuroticism;
LUAD	cis	rs6484504	0.532	rs11031342	chr11:31309818	G/A	cg14844989	chr11:31128820	NA	-0.46	-8.4	-0.38	6.97e-16	Red blood cell count;
LUAD	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg24690094	chr11:67383802	NA	0.4	7.12	0.33	4.56e-12	Mean corpuscular volume;
LUAD	cis	rs6500395	1.000	rs3848322	chr16:48620964	C/A	cg04672837	chr16:48644449	N4BP1	0.38	6.61	0.31	1.15e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs909002	0.800	rs1056526	chr1:32084904	C/T	cg13919466	chr1:32135498	COL16A1	-0.34	-7.91	-0.36	2.31e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg24675056	chr1:15929824	NA	0.47	8.21	0.37	2.75e-15	Systolic blood pressure;
LUAD	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg06092702	chr1:163392909	NA	-0.35	-7.75	-0.35	6.68e-14	Motion sickness;
LUAD	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg00647820	chr17:40259828	DHX58	-0.44	-6.9	-0.32	1.94e-11	Fibrinogen levels;
LUAD	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg17644776	chr2:200775616	C2orf69	0.55	7.32	0.34	1.3e-12	Schizophrenia;
LUAD	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg25457927	chr22:38595422	NA	-0.53	-13.78	-0.56	5.99e-36	Cutaneous nevi;
LUAD	cis	rs62400317	0.859	rs12209161	chr6:45104321	G/A	cg18551225	chr6:44695536	NA	-0.54	-8.48	-0.38	3.77e-16	Total body bone mineral density;
LUAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.77	-9.43	-0.42	2.82e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg06618935	chr21:46677482	NA	-0.49	-9.71	-0.43	3.02e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7010267	0.902	rs4242592	chr8:119968975	T/G	cg01975934	chr8:119970761	NA	-0.41	-7.74	-0.35	7.43e-14	Total body bone mineral density (age 45-60);
LUAD	cis	rs738322	0.511	rs2267370	chr22:38576826	G/A	cg25457927	chr22:38595422	NA	-0.49	-10.75	-0.46	5.54e-24	Cutaneous nevi;
LUAD	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg24503407	chr1:205819492	PM20D1	0.52	7.93	0.36	1.97e-14	Menarche (age at onset);
LUAD	trans	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-17.17	-0.64	1.56e-50	Exhaled nitric oxide output;
LUAD	cis	rs7326068	0.610	rs2772169	chr13:21314725	T/C	cg27499820	chr13:21296301	IL17D	0.53	7.91	0.36	2.3e-14	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.91	-0.36	2.2e-14	Diabetic kidney disease;
LUAD	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg15247329	chr7:2764246	NA	-0.36	-6.44	-0.3	3.16e-10	Height;
LUAD	cis	rs2029213	0.523	rs3773745	chr3:53270424	A/G	cg16894138	chr3:53270350	TKT	-0.34	-7.72	-0.35	8.68e-14	Heart rate;
LUAD	cis	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg07460842	chr6:66804631	NA	0.9	12.14	0.51	2.56e-29	Exhaled nitric oxide output;
LUAD	cis	rs755249	0.588	rs6665948	chr1:39944180	A/G	cg27567593	chr1:39956653	BMP8A	0.35	7.18	0.33	3.08e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.86	-0.36	3.19e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.33	-0.51	4.82e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg18825076	chr15:78729989	IREB2	0.5	6.96	0.32	1.34e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg23958373	chr8:599963	NA	1.1	10.66	0.46	1.2e-23	IgG glycosylation;
LUAD	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg09365446	chr1:150670422	GOLPH3L	0.62	10.73	0.46	6.25e-24	Melanoma;
LUAD	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg22618164	chr12:122356400	WDR66	0.76	13.94	0.56	1.27e-36	Mean corpuscular volume;
LUAD	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg16797656	chr11:68205561	LRP5	-0.46	-9.75	-0.43	2.11e-20	Total body bone mineral density;
LUAD	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.43	-0.34	5.95e-13	Type 2 diabetes;
LUAD	cis	rs4853036	1.000	rs6718012	chr2:70078258	T/C	cg02498382	chr2:70120550	SNRNP27	-0.5	-8.11	-0.37	5.37e-15	Colorectal or endometrial cancer;
LUAD	cis	rs829883	0.659	rs11109528	chr12:98951362	G/A	cg25150519	chr12:98850993	NA	-0.5	-7.69	-0.35	1.02e-13	Colorectal adenoma (advanced);
LUAD	cis	rs7149242	0.500	rs10144381	chr14:101173297	C/T	cg10189261	chr14:101176105	NA	-0.41	-7.45	-0.34	5.34e-13	Platelet count;
LUAD	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.96e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.945	rs7426250	chr2:198837358	G/A	cg11031976	chr2:198649780	BOLL	-0.47	-6.95	-0.32	1.41e-11	Ulcerative colitis;
LUAD	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.79	-0.35	5.27e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg10589385	chr1:150898437	SETDB1	-0.39	-6.96	-0.32	1.3e-11	Blood protein levels;
LUAD	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg17971929	chr21:40555470	PSMG1	0.57	9.02	0.4	6.62e-18	Cognitive function;
LUAD	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg04545296	chr12:48745243	ZNF641	0.39	9.84	0.43	1.02e-20	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg27494647	chr7:150038898	RARRES2	0.43	7.04	0.32	7.95e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg12927641	chr6:109611667	NA	-0.52	-9.05	-0.4	5.21e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.51	-6.46	-0.3	2.93e-10	Iron status biomarkers;
LUAD	trans	rs28735056	0.904	rs62103174	chr18:77621048	A/G	cg05926928	chr17:57297772	GDPD1	0.51	7.67	0.35	1.16e-13	Schizophrenia;
LUAD	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg14893161	chr1:205819251	PM20D1	-0.52	-7.93	-0.36	1.92e-14	Menarche (age at onset);
LUAD	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26314531	chr2:26401878	FAM59B	-0.61	-8.38	-0.38	7.78e-16	Gut microbiome composition (summer);
LUAD	cis	rs6840360	0.593	rs2175409	chr4:152701656	A/G	cg22705602	chr4:152727874	NA	-0.46	-8.89	-0.4	1.75e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7274811	0.744	rs2071054	chr20:32265839	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.5	-7.46	-0.34	5.04e-13	Height;
LUAD	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.43	-0.52	1.89e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs8060686	0.546	rs8047343	chr16:68143745	G/A	cg09835421	chr16:68378352	PRMT7	-0.54	-6.87	-0.32	2.3e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg13685833	chr1:53393034	SCP2	0.49	7.62	0.35	1.7e-13	Monocyte count;
LUAD	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.41	0.38	6.2e-16	Platelet count;
LUAD	trans	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.4	-0.38	7.05e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg03563238	chr19:33554763	RHPN2	-0.37	-8.67	-0.39	9.33e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg19610905	chr11:61596333	FADS2	0.57	9.89	0.43	7.18e-21	Trans fatty acid levels;
LUAD	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg20203395	chr5:56204925	C5orf35	-0.83	-11.78	-0.5	6.48e-28	Type 2 diabetes;
LUAD	cis	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg21775007	chr8:11205619	TDH	-0.39	-6.6	-0.31	1.25e-10	Neuroticism;
LUAD	cis	rs2060793	0.506	rs10741658	chr11:14924736	T/C	cg19336497	chr11:14380999	RRAS2	-0.32	-6.37	-0.3	4.84e-10	Vitamin D levels;
LUAD	cis	rs2806561	0.734	rs2235548	chr1:23394062	G/A	cg12483005	chr1:23474871	LUZP1	0.43	7.02	0.32	9.13e-12	Height;
LUAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg07677032	chr17:61819896	STRADA	0.55	10.09	0.44	1.41e-21	Prudent dietary pattern;
LUAD	cis	rs8027181	0.839	rs9460	chr15:73044575	C/T	cg25632853	chr15:73088954	NA	0.3	6.57	0.3	1.51e-10	Triglyceride levels;
LUAD	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg01689657	chr7:91764605	CYP51A1	0.3	7.2	0.33	2.86e-12	Breast cancer;
LUAD	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg07917127	chr4:99064746	C4orf37	0.4	6.62	0.31	1.07e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.63	-0.42	5.56e-20	Life satisfaction;
LUAD	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg15556689	chr8:8085844	FLJ10661	0.44	6.85	0.32	2.67e-11	Mood instability;
LUAD	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg04705435	chr11:17411270	KCNJ11	0.46	8.06	0.37	7.63e-15	Type 2 diabetes;
LUAD	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	18.34	0.67	1.1e-55	Bone mineral density;
LUAD	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg09367891	chr1:107599246	PRMT6	-0.57	-9.54	-0.42	1.19e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs739496	0.843	rs598711	chr12:111973140	A/G	cg10833066	chr12:111807467	FAM109A	0.43	6.67	0.31	8.22e-11	Platelet count;
LUAD	cis	rs7665090	1.000	rs9996834	chr4:103557529	T/G	cg07973026	chr4:103553119	MANBA	0.47	8.41	0.38	6.43e-16	Primary biliary cholangitis;
LUAD	trans	rs3960554	0.529	rs7800970	chr7:75880198	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.52	-7.97	-0.36	1.45e-14	Eotaxin levels;
LUAD	cis	rs863345	0.625	rs4575081	chr1:158504837	C/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs8067545	0.641	rs397969	chr17:19804247	T/C	cg04132472	chr17:19861366	AKAP10	0.39	9.13	0.41	2.76e-18	Schizophrenia;
LUAD	trans	rs6822892	0.727	rs1593357	chr4:157742691	C/T	cg02470959	chr12:132196036	SFRS8	0.49	7.67	0.35	1.23e-13	HDL cholesterol levels;
LUAD	trans	rs11039798	0.920	rs11040015	chr11:48783130	G/T	cg03929089	chr4:120376271	NA	0.59	6.87	0.32	2.24e-11	Axial length;
LUAD	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg18944383	chr4:111397179	ENPEP	0.38	7.69	0.35	1.05e-13	Height;
LUAD	cis	rs1210638	0.575	rs11703200	chr22:18959169	G/A	cg12798833	chr22:18958832	DGCR5	0.51	7.81	0.36	4.53e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs2455799	0.613	rs6789076	chr3:15807725	A/T	cg16303742	chr3:15540471	COLQ	0.49	9.13	0.41	2.74e-18	Mean platelet volume;
LUAD	cis	rs3820068	0.656	rs72645829	chr1:15889748	A/G	cg24675056	chr1:15929824	NA	0.43	6.78	0.31	4.1e-11	Systolic blood pressure;
LUAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg26338869	chr17:61819248	STRADA	-0.39	-6.58	-0.3	1.37e-10	Prudent dietary pattern;
LUAD	cis	rs2274273	0.901	rs17674563	chr14:55831125	G/A	cg04306507	chr14:55594613	LGALS3	0.43	9.07	0.4	4.66e-18	Protein biomarker;
LUAD	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg21427119	chr20:30132790	HM13	-0.49	-7.88	-0.36	2.77e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg18132916	chr6:79620363	NA	-0.44	-7.56	-0.34	2.59e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs938554	0.657	rs7679724	chr4:9985376	G/T	cg11266682	chr4:10021025	SLC2A9	0.42	7.76	0.35	6.29e-14	Blood metabolite levels;
LUAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg16606324	chr3:10149918	C3orf24	0.59	9.65	0.42	4.73e-20	Alzheimer's disease;
LUAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.33	-6.58	-0.3	1.39e-10	Longevity;Endometriosis;
LUAD	cis	rs10129255	0.556	rs9324093	chr14:107139910	C/T	cg07958169	chr14:107095056	NA	-0.34	-6.8	-0.31	3.54e-11	Kawasaki disease;
LUAD	cis	rs2581828	0.656	rs2163167	chr3:53131772	T/C	cg24530246	chr3:53118167	NA	0.31	6.56	0.3	1.54e-10	Crohn's disease;
LUAD	cis	rs9372498	0.536	rs62422189	chr6:118907053	C/T	cg21191810	chr6:118973309	C6orf204	-0.53	-7.98	-0.36	1.38e-14	Diastolic blood pressure;
LUAD	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg22681709	chr2:178499509	PDE11A	-0.42	-7.21	-0.33	2.54e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10821973	0.527	rs4979762	chr10:64008308	C/T	cg09941381	chr10:64027924	RTKN2	-0.35	-6.83	-0.32	2.97e-11	Hypothyroidism;
LUAD	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg06740227	chr12:86229804	RASSF9	0.39	6.97	0.32	1.19e-11	Major depressive disorder;
LUAD	cis	rs4891159	0.790	rs4891018	chr18:74127082	A/T	cg24786174	chr18:74118243	ZNF516	-0.79	-15.45	-0.6	5.01e-43	Longevity;
LUAD	cis	rs6961069	0.745	rs11770358	chr7:80271330	A/T	cg04458919	chr7:80252533	CD36	0.37	7.16	0.33	3.6e-12	Platelet count;
LUAD	cis	rs9905704	0.628	rs2531735	chr17:56551139	A/G	cg19466818	chr17:56409534	MIR142	0.33	6.58	0.3	1.38e-10	Testicular germ cell tumor;
LUAD	cis	rs7665090	1.000	rs12644381	chr4:103552430	A/G	cg07973026	chr4:103553119	MANBA	0.48	8.53	0.38	2.63e-16	Primary biliary cholangitis;
LUAD	cis	rs7582720	1.000	rs72932572	chr2:203859391	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.64	0.42	5.27e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03264133	chr6:25882463	NA	-0.52	-7.71	-0.35	8.96e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	9.65	0.42	4.77e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1595825	0.891	rs73056877	chr2:198816724	A/C	cg11031976	chr2:198649780	BOLL	-0.47	-6.94	-0.32	1.5e-11	Ulcerative colitis;
LUAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg18538332	chr22:24372958	LOC391322	-0.51	-8.34	-0.38	1.08e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg01256987	chr12:42539512	GXYLT1	-0.5	-10.33	-0.45	1.91e-22	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.98	-0.36	1.35e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2455601	0.679	rs2653559	chr11:8900394	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-6.72	-0.31	5.8e-11	Schizophrenia;
LUAD	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg23758822	chr17:41437982	NA	1.01	21.18	0.72	2.19e-68	Menopause (age at onset);
LUAD	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg09491104	chr22:46646882	C22orf40	-0.64	-11.32	-0.48	3.94e-26	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg12193833	chr17:30244370	NA	-0.52	-6.54	-0.3	1.81e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg17480646	chr11:65405466	SIPA1	-0.46	-6.84	-0.32	2.8e-11	Acne (severe);
LUAD	cis	rs4629710	0.592	rs4424112	chr6:131563788	C/T	cg12606694	chr6:131520996	AKAP7	0.5	7.33	0.34	1.2e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs2908197	0.737	rs6465096	chr7:75972872	T/G	cg24580635	chr7:76178542	LOC100133091	-0.42	-6.71	-0.31	6.35e-11	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg00684032	chr4:1343700	KIAA1530	0.42	6.93	0.32	1.55e-11	Obesity-related traits;
LUAD	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg14583973	chr4:3374767	RGS12	0.31	7.97	0.36	1.54e-14	Serum sulfate level;
LUAD	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	9.4e-15	Tonsillectomy;
LUAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg12016809	chr21:47604291	C21orf56	-0.66	-11.65	-0.49	2.2e-27	Testicular germ cell tumor;
LUAD	cis	rs2455799	0.613	rs11712323	chr3:15891360	T/C	cg16303742	chr3:15540471	COLQ	-0.52	-9.64	-0.42	5.03e-20	Mean platelet volume;
LUAD	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg13722127	chr7:150037890	RARRES2	0.47	8.34	0.38	1.03e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs524023	0.629	rs480617	chr11:64478320	C/T	cg19131476	chr11:64387923	NRXN2	-0.35	-6.52	-0.3	2.01e-10	Urate levels in obese individuals;
LUAD	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg08008072	chr16:1524255	CLCN7	0.74	19.04	0.68	7.66e-59	Bone mineral density;
LUAD	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3825199	0.515	rs2072593	chr12:93970026	T/C	cg18151635	chr12:93972918	NA	-0.78	-11.79	-0.5	6.39e-28	Height;
LUAD	trans	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg21659725	chr3:3221576	CRBN	-0.49	-8.29	-0.37	1.5e-15	Body mass index;
LUAD	cis	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg02240030	chr7:2089880	MAD1L1	0.32	6.4	0.3	4.08e-10	Neuroticism;
LUAD	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg01874867	chr7:94954059	PON1	-0.53	-7.26	-0.33	1.85e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg12573674	chr2:1569213	NA	-0.57	-8.22	-0.37	2.51e-15	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg27494647	chr7:150038898	RARRES2	0.38	6.85	0.32	2.54e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7149337	0.805	rs71422017	chr14:51612417	A/T	cg23942311	chr14:51606299	NA	0.88	20.43	0.7	4.83e-65	Cancer;
LUAD	cis	rs2806561	0.929	rs2746556	chr1:23524541	G/A	cg12483005	chr1:23474871	LUZP1	0.39	6.69	0.31	7.21e-11	Height;
LUAD	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg12623302	chr6:28058802	ZSCAN12L1	-0.34	-6.77	-0.31	4.2e-11	Depression;
LUAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.35	0.54	3.74e-34	Prudent dietary pattern;
LUAD	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg05665937	chr4:1216051	CTBP1	0.43	7.27	0.33	1.78e-12	Obesity-related traits;
LUAD	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg18138036	chr10:133769891	PPP2R2D	0.42	6.86	0.32	2.43e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08109568	chr15:31115862	NA	-0.73	-12.4	-0.52	2.55e-30	Huntington's disease progression;
LUAD	cis	rs68170813	0.559	rs17427158	chr7:106824259	G/T	cg02696742	chr7:106810147	HBP1	-0.79	-11.09	-0.47	3.01e-25	Coronary artery disease;
LUAD	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	9.32	0.41	6.62e-19	Total body bone mineral density;
LUAD	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07266350	chr3:49460521	AMT;NICN1	0.37	6.46	0.3	2.85e-10	Menarche (age at onset);
LUAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg08027265	chr7:2291960	NA	-0.42	-6.72	-0.31	6.05e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg03929089	chr4:120376271	NA	-0.68	-10.33	-0.45	1.86e-22	Coronary artery disease;
LUAD	cis	rs2816062	0.786	rs2745320	chr1:18893592	G/A	cg18795169	chr1:18902165	NA	-0.94	-22.53	-0.74	1.96e-74	Urate levels in lean individuals;
LUAD	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg02993280	chr1:107599747	PRMT6	0.53	8.71	0.39	6.93e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg05340658	chr4:99064831	C4orf37	-0.56	-9.55	-0.42	1.09e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg22166914	chr1:53195759	ZYG11B	0.51	8.64	0.39	1.13e-16	Monocyte count;
LUAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17748167	chr1:31769917	ZCCHC17;SNRNP40	-0.62	-7.57	-0.35	2.3e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg15782153	chr7:917662	C7orf20	0.47	6.89	0.32	2e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg20503657	chr10:835505	NA	1.22	17.94	0.66	6.16e-54	Eosinophil percentage of granulocytes;
LUAD	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg27490568	chr2:178487706	NA	0.74	10.79	0.46	3.88e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs54211	0.572	rs137626	chr22:39716271	A/G	cg24399712	chr22:39784796	NA	-0.55	-6.92	-0.32	1.69e-11	Sudden cardiac arrest;
LUAD	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.88	0.4	1.92e-17	Cognitive ability;
LUAD	cis	rs7561273	0.586	rs11902756	chr2:24300932	A/G	cg20701182	chr2:24300061	SF3B14	0.51	8.19	0.37	3.16e-15	Quantitative traits;
LUAD	cis	rs4743820	0.651	rs10114465	chr9:93936592	C/T	cg14446406	chr9:93919335	NA	0.47	7.73	0.35	8.17e-14	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg15309053	chr8:964076	NA	0.36	7.99	0.36	1.28e-14	Schizophrenia;
LUAD	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg00495681	chr13:53174319	NA	0.56	10.36	0.45	1.45e-22	Lewy body disease;
LUAD	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg17063962	chr7:91808500	NA	-0.68	-12.07	-0.51	4.76e-29	Breast cancer;
LUAD	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg17971929	chr21:40555470	PSMG1	0.56	8.77	0.39	4.58e-17	Cognitive function;
LUAD	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23583168	chr7:148888333	NA	-0.91	-18.84	-0.68	6.36e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg03806693	chr22:41940476	POLR3H	-0.75	-9.98	-0.44	3.39e-21	Vitiligo;
LUAD	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.49	7.52	0.34	3.26e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs4650994	0.967	rs6681043	chr1:178525957	A/G	cg05059571	chr16:84539110	KIAA1609	-0.59	-10.11	-0.44	1.19e-21	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs9494145	0.838	rs9483788	chr6:135435501	T/C	cg22676075	chr6:135203613	NA	0.49	6.97	0.32	1.19e-11	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUAD	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.69	11.3	0.48	4.65e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs79057730	0.599	rs78347394	chr7:831817	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.9	9.28	0.41	9.02e-19	Initial pursuit acceleration;
LUAD	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.47	-0.34	4.62e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	trans	rs2018683	0.834	rs2012754	chr7:29026257	G/A	cg19402173	chr7:128379420	CALU	-0.63	-10.53	-0.46	3.51e-23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-7.79	-0.35	5.28e-14	Breast cancer;
LUAD	cis	rs2992756	0.663	rs1360916	chr1:18801697	G/A	cg24076588	chr1:18808559	KLHDC7A	-0.46	-7.41	-0.34	6.85e-13	Breast cancer;
LUAD	cis	rs12545109	0.571	rs1370306	chr8:57299137	C/G	cg17761419	chr8:57350749	NA	-0.53	-7.49	-0.34	4.05e-13	Obesity-related traits;
LUAD	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg02773041	chr1:40204384	PPIE	0.52	8.48	0.38	3.9e-16	Blood protein levels;
LUAD	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg13607699	chr17:42295918	UBTF	0.56	9.21	0.41	1.49e-18	Total body bone mineral density;
LUAD	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg08885076	chr2:99613938	TSGA10	-0.37	-6.49	-0.3	2.36e-10	Chronic sinus infection;
LUAD	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg24558204	chr6:135376177	HBS1L	0.47	8.71	0.39	6.82e-17	Red blood cell count;
LUAD	cis	rs300774	0.748	rs409657	chr2:129009	C/T	cg21211680	chr2:198530	NA	-0.46	-7.33	-0.34	1.16e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg04369109	chr6:150039330	LATS1	-0.44	-7.44	-0.34	5.61e-13	Lung cancer;
LUAD	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg13073564	chr4:8508604	NA	-0.5	-9.09	-0.4	3.95e-18	Response to antineoplastic agents;
LUAD	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg13073564	chr4:8508604	NA	-0.55	-10.08	-0.44	1.44e-21	Response to antineoplastic agents;
LUAD	trans	rs11039798	0.688	rs12277029	chr11:48852833	G/T	cg15704280	chr7:45808275	SEPT13	0.67	7.83	0.36	3.98e-14	Axial length;
LUAD	cis	rs4629710	0.592	rs9492868	chr6:131542238	A/C	cg12606694	chr6:131520996	AKAP7	0.47	6.92	0.32	1.65e-11	Multiple myeloma (IgH translocation);
LUAD	trans	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg07061783	chr6:25882402	NA	0.38	6.48	0.3	2.63e-10	Blood metabolite levels;
LUAD	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg19302996	chr17:73780495	UNK	-0.47	-7.78	-0.35	5.72e-14	White matter hyperintensity burden;
LUAD	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg04369109	chr6:150039330	LATS1	-0.46	-7.52	-0.34	3.38e-13	Lung cancer;
LUAD	cis	rs1595825	0.891	rs73054819	chr2:198625744	G/T	cg00361562	chr2:198649771	BOLL	-0.46	-6.53	-0.3	1.93e-10	Ulcerative colitis;
LUAD	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg09455208	chr3:40491958	NA	0.56	12.36	0.52	3.57e-30	Renal cell carcinoma;
LUAD	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg12311346	chr5:56204834	C5orf35	-0.44	-7.21	-0.33	2.59e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs56346965	0.751	rs1155061	chr2:191566381	G/A	cg27211696	chr2:191398769	TMEM194B	0.43	7.55	0.34	2.74e-13	Bone mineral density (Ward's triangle area);
LUAD	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg26727032	chr16:67993705	SLC12A4	-0.5	-8.2	-0.37	3.01e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg25452165	chr22:42524984	CYP2D6	0.39	6.37	0.3	5.02e-10	Schizophrenia;
LUAD	cis	rs758324	0.947	rs11948962	chr5:131113830	C/T	cg06307176	chr5:131281290	NA	0.51	8.07	0.37	7.09e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6445967	0.545	rs62259789	chr3:58435822	C/T	cg23715586	chr3:58305044	RPP14	0.39	6.41	0.3	3.88e-10	Platelet count;
LUAD	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-15.13	-0.59	1.16e-41	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg04703951	chr17:43578652	NA	-0.43	-7.03	-0.32	8.28e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg24818145	chr4:99064322	C4orf37	0.52	7.57	0.35	2.32e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg02221750	chr19:17393354	ANKLE1	-0.78	-12.65	-0.52	2.51e-31	Systemic lupus erythematosus;
LUAD	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg05110241	chr16:68378359	PRMT7	-0.82	-8.89	-0.4	1.79e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	trans	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg26043149	chr18:55253948	FECH	-0.39	-6.51	-0.3	2.07e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3813948	0.543	rs2808466	chr1:207273751	T/C	cg22332276	chr1:207277018	C4BPA	-0.64	-8.51	-0.38	3.16e-16	C4b binding protein levels;
LUAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg13385794	chr1:248469461	NA	0.27	7.27	0.33	1.71e-12	Common traits (Other);
LUAD	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg00852783	chr1:26633632	UBXN11	0.42	7.45	0.34	5.18e-13	Obesity-related traits;
LUAD	cis	rs2554380	1.000	rs2554380	chr15:84315884	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.59	-9.06	-0.4	4.88e-18	Height;
LUAD	cis	rs8017423	0.904	rs11848894	chr14:90723660	C/A	cg14092571	chr14:90743983	NA	-0.5	-8.87	-0.4	2.08e-17	Mortality in heart failure;
LUAD	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg21204522	chr6:27730016	NA	-0.48	-7.59	-0.35	2.08e-13	Parkinson's disease;
LUAD	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg17105886	chr17:28927953	LRRC37B2	0.83	8.0	0.36	1.18e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.43	9.01	0.4	7.27e-18	Total body bone mineral density;
LUAD	cis	rs714027	1.000	rs4823074	chr22:30512478	G/A	cg11564601	chr22:30592435	NA	-0.39	-8.38	-0.38	8.04e-16	Lymphocyte counts;
LUAD	cis	rs7843479	0.965	rs13278159	chr8:21799737	C/A	cg03445287	chr8:21823731	XPO7	-0.47	-8.54	-0.38	2.51e-16	Mean corpuscular volume;
LUAD	cis	rs12618769	0.570	rs17444095	chr2:99075817	C/G	cg10123293	chr2:99228465	UNC50	0.45	7.9	0.36	2.42e-14	Bipolar disorder;
LUAD	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg10523679	chr1:76189770	ACADM	-0.47	-6.56	-0.3	1.54e-10	Daytime sleep phenotypes;
LUAD	trans	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg14917512	chr19:3094685	GNA11	-0.58	-6.85	-0.32	2.54e-11	Diabetic kidney disease;
LUAD	cis	rs10979	0.597	rs9403516	chr6:143908139	A/T	cg25407410	chr6:143891975	LOC285740	0.5	7.04	0.32	8.04e-12	Hypospadias;
LUAD	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2455799	0.519	rs2062821	chr3:15697644	A/T	cg16303742	chr3:15540471	COLQ	-0.57	-10.43	-0.45	7.83e-23	Mean platelet volume;
LUAD	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg22823121	chr1:150693482	HORMAD1	0.41	7.83	0.36	3.99e-14	Melanoma;
LUAD	cis	rs599083	0.829	rs23691	chr11:68178668	G/A	cg01657329	chr11:68192670	LRP5	0.49	8.03	0.36	9.59e-15	Bone mineral density (spine);
LUAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg16606324	chr3:10149918	C3orf24	0.68	11.41	0.49	1.78e-26	Alzheimer's disease;
LUAD	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06544989	chr22:39130855	UNC84B	0.43	8.03	0.36	9.95e-15	Menopause (age at onset);
LUAD	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg03948781	chr1:205179583	DSTYK	0.33	6.47	0.3	2.68e-10	Red blood cell count;
LUAD	cis	rs73416724	1.000	rs80193186	chr6:43362324	G/T	cg26312998	chr6:43337775	ZNF318	0.53	6.41	0.3	3.83e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7705042	0.865	rs4391200	chr5:141509537	A/G	cg08523384	chr5:141488047	NDFIP1	-0.38	-6.49	-0.3	2.41e-10	Asthma;
LUAD	trans	rs11673344	0.931	rs7256746	chr19:37665975	A/G	cg22500585	chr3:52739706	GLT8D1;SPCS1	-0.37	-6.43	-0.3	3.47e-10	Obesity-related traits;
LUAD	cis	rs11771526	0.901	rs17161086	chr7:32294254	A/G	cg13207630	chr7:32358064	NA	-0.61	-7.54	-0.34	2.82e-13	Body mass index;
LUAD	cis	rs7552167	0.925	rs78312791	chr1:24513613	C/A	cg01960748	chr1:24522592	NA	0.83	10.68	0.46	1.01e-23	Psoriasis vulgaris;
LUAD	cis	rs68170813	0.641	rs6979368	chr7:107089009	C/G	cg02696742	chr7:106810147	HBP1	-0.79	-10.51	-0.45	4.19e-23	Coronary artery disease;
LUAD	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg17147758	chr8:6949321	NA	-0.5	-8.97	-0.4	9.59e-18	Blood pressure (smoking interaction);
LUAD	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg00277334	chr10:82204260	NA	-0.62	-10.01	-0.44	2.69e-21	Post bronchodilator FEV1;
LUAD	cis	rs657075	0.697	rs3761659	chr5:131657784	G/C	cg21138405	chr5:131827807	IRF1	0.5	6.42	0.3	3.76e-10	Rheumatoid arthritis;
LUAD	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg04111992	chr7:158790115	NA	-0.44	-7.58	-0.35	2.14e-13	Facial morphology (factor 20);
LUAD	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg05425664	chr17:57184151	TRIM37	-0.38	-6.66	-0.31	8.45e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg27490568	chr2:178487706	NA	0.42	7.08	0.33	6.13e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	10.08	0.44	1.45e-21	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	7.6	0.35	1.93e-13	Mood instability;
LUAD	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11644478	chr21:40555479	PSMG1	-0.58	-9.75	-0.43	2.08e-20	Cognitive function;
LUAD	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg26408565	chr15:76604113	ETFA	-0.44	-7.2	-0.33	2.71e-12	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.53e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11893307	0.509	rs2356126	chr2:191542514	C/T	cg11845111	chr2:191398756	TMEM194B	-0.46	-6.93	-0.32	1.57e-11	Mean platelet volume;
LUAD	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg20607798	chr8:58055168	NA	0.79	9.59	0.42	7.66e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2637266	0.967	rs12244619	chr10:78352502	C/T	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs977987	0.806	rs8056236	chr16:75448273	C/T	cg03315344	chr16:75512273	CHST6	0.64	14.06	0.56	4.3e-37	Dupuytren's disease;
LUAD	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18876405	chr7:65276391	NA	-0.43	-6.82	-0.31	3.18e-11	Aortic root size;
LUAD	cis	rs10207060	0.771	rs4852124	chr2:240680022	C/T	cg07506560	chr2:240697449	NA	0.46	9.45	0.42	2.27e-19	Obesity-related traits;
LUAD	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	11.35	0.48	3.03e-26	Eosinophil percentage of white cells;
LUAD	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg25566285	chr7:158114605	PTPRN2	0.53	11.55	0.49	5.2e-27	Calcium levels;
LUAD	cis	rs6076065	0.723	rs6083100	chr20:23358651	G/A	cg11657817	chr20:23433608	CST11	0.47	8.78	0.39	4.17e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs28374715	0.578	rs17730888	chr15:41637547	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.08	-23.28	-0.75	9.6e-78	Ulcerative colitis;
LUAD	cis	rs4919694	1.000	rs75219158	chr10:104747594	C/T	cg04362960	chr10:104952993	NT5C2	0.8	8.11	0.37	5.6e-15	Arsenic metabolism;
LUAD	cis	rs778371	0.915	rs938569	chr2:233759695	C/G	cg08000102	chr2:233561755	GIGYF2	0.43	6.46	0.3	2.95e-10	Schizophrenia;
LUAD	cis	rs59104589	0.617	rs57696929	chr2:242380382	T/C	cg08645257	chr2:242211290	HDLBP	0.41	6.81	0.31	3.28e-11	Fibrinogen levels;
LUAD	cis	rs2274471	0.699	rs10815160	chr9:5116616	A/C	cg03390472	chr9:5043263	JAK2	-0.53	-8.22	-0.37	2.45e-15	Crohn's disease;
LUAD	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg11618577	chr2:27665543	KRTCAP3	-0.26	-6.84	-0.32	2.72e-11	Total body bone mineral density;
LUAD	cis	rs9354308	0.840	rs17508021	chr6:66569748	G/A	cg07460842	chr6:66804631	NA	0.49	7.28	0.33	1.66e-12	Metabolite levels;
LUAD	cis	rs8058578	0.633	rs113448632	chr16:30898219	C/T	cg02466173	chr16:30829666	NA	-0.68	-10.58	-0.46	2.26e-23	Multiple myeloma;
LUAD	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.59	7.81	0.35	4.68e-14	Gut microbiome composition (summer);
LUAD	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg10468373	chr11:64009913	FKBP2	0.55	6.89	0.32	1.98e-11	Mean platelet volume;
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg11235426	chr6:292522	DUSP22	0.79	13.75	0.56	8.1e-36	Menopause (age at onset);
LUAD	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-10.53	-0.46	3.39e-23	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.27	0.37	1.73e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs494562	1.000	rs7763191	chr6:86118317	A/T	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs68170813	0.652	rs6947674	chr7:107193504	T/C	cg02696742	chr7:106810147	HBP1	-0.76	-9.04	-0.4	5.57e-18	Coronary artery disease;
LUAD	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22857025	chr5:266934	NA	-0.97	-14.68	-0.58	1.01e-39	Breast cancer;
LUAD	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg24733560	chr20:60626293	TAF4	0.48	9.37	0.41	4.39e-19	Body mass index;
LUAD	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg14893161	chr1:205819251	PM20D1	-0.45	-7.16	-0.33	3.61e-12	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs2274273	0.837	rs7142857	chr14:55704128	C/T	cg04306507	chr14:55594613	LGALS3	0.42	8.65	0.39	1.09e-16	Protein biomarker;
LUAD	cis	rs11811982	0.793	rs11806633	chr1:227308416	C/T	cg24860534	chr1:227506868	CDC42BPA	-0.58	-6.58	-0.3	1.42e-10	Optic disc area;
LUAD	cis	rs7975161	0.608	rs10861169	chr12:104610640	C/T	cg25282972	chr12:104565846	NA	-0.33	-6.54	-0.3	1.73e-10	Toenail selenium levels;
LUAD	cis	rs4711350	1.000	rs751727	chr6:33764158	A/G	cg18005901	chr6:33739558	LEMD2	-0.51	-7.49	-0.34	4.1e-13	Schizophrenia;
LUAD	cis	rs34734847	0.750	rs3829290	chr12:121126438	T/C	cg21892295	chr12:121157589	UNC119B	-0.37	-6.64	-0.31	9.58e-11	Mean corpuscular volume;
LUAD	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg17757837	chr7:157058334	UBE3C	0.49	8.72	0.39	6.4e-17	Body mass index;
LUAD	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg03929089	chr4:120376271	NA	-0.82	-14.56	-0.58	3.26e-39	Height;
LUAD	trans	rs2797160	1.000	rs1739377	chr6:126012236	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.53	8.61	0.39	1.46e-16	Endometrial cancer;
LUAD	cis	rs2652834	0.718	rs2729831	chr15:63396039	A/T	cg25406657	chr15:63342033	TPM1	-0.38	-6.51	-0.3	2.18e-10	HDL cholesterol;
LUAD	cis	rs7274811	0.625	rs293707	chr20:31937048	T/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.48	6.8	0.31	3.59e-11	Height;
LUAD	cis	rs11741688	0.631	rs4444956	chr5:178325515	A/G	cg09339527	chr5:178322752	ZFP2	-0.34	-7.01	-0.32	9.6e-12	Sleep duration;
LUAD	trans	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg07211511	chr3:129823064	LOC729375	-0.56	-7.24	-0.33	2.08e-12	Blood pressure (smoking interaction);
LUAD	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg00898013	chr13:113819073	PROZ	0.73	13.16	0.54	2.16e-33	Platelet distribution width;
LUAD	cis	rs6500395	1.000	rs1558816	chr16:48704868	T/A	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs13082711	0.554	rs34066402	chr3:27387987	G/A	cg02860705	chr3:27208620	NA	0.72	10.83	0.47	2.78e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg09137382	chr11:130731461	NA	0.4	7.32	0.34	1.25e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2066819	1.000	rs79436528	chr12:56686997	C/T	cg26714650	chr12:56694279	CS	-0.86	-7.23	-0.33	2.25e-12	Psoriasis vulgaris;
LUAD	cis	rs8060686	0.858	rs7198357	chr16:67884619	A/G	cg26727032	chr16:67993705	SLC12A4	0.48	8.03	0.36	1e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg14820908	chr5:178986412	RUFY1	0.48	8.03	0.36	9.76e-15	Lung cancer;
LUAD	cis	rs9811920	0.666	rs793456	chr3:99525631	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	6.69	0.31	7.27e-11	Axial length;
LUAD	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg08859206	chr1:53392774	SCP2	0.63	11.41	0.49	1.85e-26	Monocyte count;
LUAD	cis	rs10821973	0.527	rs4979764	chr10:64012925	G/A	cg09941381	chr10:64027924	RTKN2	-0.36	-7.15	-0.33	3.85e-12	Hypothyroidism;
LUAD	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.75	-0.31	5.03e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg21605333	chr4:119757512	SEC24D	0.93	8.74	0.39	5.54e-17	Cannabis dependence symptom count;
LUAD	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg18230493	chr5:56204884	C5orf35	-0.84	-12.18	-0.51	1.92e-29	Initial pursuit acceleration;
LUAD	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg17252645	chr8:143867129	LY6D	-0.36	-6.68	-0.31	7.34e-11	Urinary tract infection frequency;
LUAD	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.81	0.36	4.47e-14	Bladder cancer;
LUAD	cis	rs7759001	0.817	rs9461379	chr6:27360366	A/T	cg18711553	chr6:27366782	ZNF391	0.4	6.55	0.3	1.64e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs4072705	0.646	rs2416933	chr9:127245529	C/T	cg13476313	chr9:127244764	NR5A1	-0.33	-8.4	-0.38	6.65e-16	Menarche (age at onset);
LUAD	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg13319975	chr6:146136371	FBXO30	-0.61	-10.37	-0.45	1.28e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg18132916	chr6:79620363	NA	-0.45	-7.81	-0.36	4.47e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4691139	0.903	rs6812591	chr4:165920175	T/A	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.44	-8.48	-0.38	3.85e-16	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg03806693	chr22:41940476	POLR3H	-0.71	-10.13	-0.44	9.63e-22	Vitiligo;
LUAD	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-20.27	-0.7	2.41e-64	Height;
LUAD	cis	rs7503807	1.000	rs901064	chr17:78596040	C/T	cg09596252	chr17:78655493	RPTOR	-0.41	-7.89	-0.36	2.58e-14	Obesity;
LUAD	cis	rs2066819	1.000	rs75754909	chr12:56726349	A/G	cg26714650	chr12:56694279	CS	-0.85	-7.1	-0.33	5.17e-12	Psoriasis vulgaris;
LUAD	cis	rs2233152	0.656	rs10405633	chr19:41291703	G/A	cg21869046	chr19:41225005	ITPKC	0.42	7.59	0.35	2.09e-13	Kawasaki disease;
LUAD	cis	rs240764	0.567	rs12528607	chr6:101260131	A/G	cg09795085	chr6:101329169	ASCC3	0.4	7.02	0.32	8.89e-12	Neuroticism;
LUAD	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.75	0.46	5.2e-24	Smoking behavior;
LUAD	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg08085267	chr17:45401833	C17orf57	0.59	10.61	0.46	1.83e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4771122	0.500	rs1049302	chr13:27998769	T/C	cg27031448	chr13:27998168	GTF3A	-0.36	-6.64	-0.31	9.38e-11	Body mass index;
LUAD	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18876405	chr7:65276391	NA	0.56	9.42	0.42	3.01e-19	Aortic root size;
LUAD	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg22117172	chr7:91764530	CYP51A1	0.34	7.27	0.33	1.73e-12	Breast cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07511459	chr21:40684751	BRWD1	-0.41	-6.57	-0.3	1.52e-10	Cancer;
LUAD	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg15704280	chr7:45808275	SEPT13	0.97	18.96	0.68	1.82e-58	Height;
LUAD	cis	rs7202877	0.706	rs8046184	chr16:75411725	T/C	cg03315344	chr16:75512273	CHST6	0.47	6.41	0.3	3.95e-10	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07157834	chr1:205819609	PM20D1	0.72	14.07	0.56	3.58e-37	Menarche (age at onset);
LUAD	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.68	0.31	7.44e-11	Parkinson's disease;
LUAD	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.91	-0.36	2.34e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.21e-19	Life satisfaction;
LUAD	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg24308560	chr3:49941425	MST1R	0.54	8.98	0.4	9.31e-18	Body mass index;
LUAD	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg07212818	chr11:638076	DRD4	-0.47	-6.66	-0.31	8.69e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs870825	0.655	rs1527870	chr4:185616631	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.09	0.57	3.19e-37	Blood protein levels;
LUAD	cis	rs10489202	1.000	rs2272911	chr1:167936302	C/T	cg24449463	chr1:168025552	DCAF6	-0.56	-7.25	-0.33	1.98e-12	Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06456389	chr10:99052468	ARHGAP19	-0.41	-6.96	-0.32	1.31e-11	Cancer;
LUAD	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg17971929	chr21:40555470	PSMG1	0.53	8.35	0.38	9.6e-16	Cognitive function;
LUAD	cis	rs7707921	0.881	rs74906189	chr5:81261923	A/G	cg15871215	chr5:81402204	ATG10	-0.7	-9.63	-0.42	5.6e-20	Breast cancer;
LUAD	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg11266682	chr4:10021025	SLC2A9	0.66	14.87	0.59	1.56e-40	Bone mineral density;
LUAD	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg09904177	chr6:26538194	HMGN4	0.42	6.96	0.32	1.34e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg00106254	chr7:1943704	MAD1L1	-0.54	-7.77	-0.35	6.04e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg16049864	chr8:95962084	TP53INP1	-0.51	-10.95	-0.47	9.84e-25	Type 2 diabetes;
LUAD	cis	rs15676	0.783	rs7858732	chr9:131563540	A/G	cg00228799	chr9:131580591	ENDOG	-0.45	-6.97	-0.32	1.23e-11	Blood metabolite levels;
LUAD	cis	rs11229555	0.574	rs11603800	chr11:58202085	A/G	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6066825	0.644	rs761271	chr20:47315637	A/G	cg18078177	chr20:47281410	PREX1	0.42	7.01	0.32	9.54e-12	Colorectal cancer;
LUAD	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-7.68	-0.35	1.09e-13	Total body bone mineral density;
LUAD	cis	rs9486719	0.843	rs976357	chr6:96849679	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	9.62	0.42	5.97e-20	Migraine;Coronary artery disease;
LUAD	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg10057126	chr4:77819792	ANKRD56	0.52	8.78	0.39	3.94e-17	Emphysema distribution in smoking;
LUAD	trans	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg21659725	chr3:3221576	CRBN	-0.49	-8.45	-0.38	4.88e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.24	-0.33	2.08e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs68170813	0.559	rs76307631	chr7:107058018	A/G	cg02696742	chr7:106810147	HBP1	-0.8	-10.68	-0.46	9.46e-24	Coronary artery disease;
LUAD	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg15704280	chr7:45808275	SEPT13	0.63	8.33	0.38	1.11e-15	Axial length;
LUAD	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg26893861	chr17:41843967	DUSP3	0.91	14.92	0.59	9.92e-41	Triglycerides;
LUAD	cis	rs17102423	0.602	rs1270073	chr14:65566257	C/A	cg16583315	chr14:65563665	MAX	-0.35	-6.47	-0.3	2.72e-10	Obesity-related traits;
LUAD	cis	rs9393692	0.620	rs6930616	chr6:26331969	A/G	cg13736514	chr6:26305472	NA	-0.49	-8.35	-0.38	9.51e-16	Educational attainment;
LUAD	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.55	-6.93	-0.32	1.6e-11	Body mass index;
LUAD	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.46	7.2	0.33	2.81e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg06641503	chr3:48959341	ARIH2	-0.34	-6.44	-0.3	3.33e-10	Parkinson's disease;
LUAD	cis	rs11971779	0.648	rs6974099	chr7:139098566	A/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08280861	chr8:58055591	NA	0.63	8.31	0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs752010	0.905	rs2038977	chr1:42094659	A/G	cg06885757	chr1:42089581	HIVEP3	0.48	10.92	0.47	1.21e-24	Lupus nephritis in systemic lupus erythematosus;
LUAD	trans	rs1997103	0.798	rs12154964	chr7:55414041	G/A	cg20935933	chr6:143382018	AIG1	0.55	7.83	0.36	4.02e-14	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs13315871	1.000	rs71311857	chr3:58323377	A/G	cg20936604	chr3:58311152	NA	-0.72	-7.22	-0.33	2.51e-12	Cholesterol, total;
LUAD	cis	rs73198271	0.960	rs11778970	chr8:8609334	G/C	cg01851573	chr8:8652454	MFHAS1	0.53	8.52	0.38	2.87e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg05665937	chr4:1216051	CTBP1	0.39	6.64	0.31	9.6e-11	Obesity-related traits;
LUAD	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg16479474	chr6:28041457	NA	-0.44	-7.74	-0.35	7.39e-14	Depression;
LUAD	trans	rs79911532	0.515	rs77381667	chr7:75663126	C/T	cg19862616	chr7:65841803	NCRNA00174	0.82	8.5	0.38	3.28e-16	Mononucleosis;
LUAD	cis	rs7582720	1.000	rs72926772	chr2:203804289	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg01802117	chr1:53393560	SCP2	0.44	8.23	0.37	2.34e-15	Monocyte count;
LUAD	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg05555928	chr11:63887634	MACROD1	0.5	10.31	0.45	2.27e-22	Platelet count;
LUAD	cis	rs4660214	0.666	rs11205696	chr1:39621552	C/T	cg27567593	chr1:39956653	BMP8A	0.33	6.44	0.3	3.32e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg04025307	chr7:1156635	C7orf50	0.6	6.75	0.31	4.88e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62458065	1.000	rs979355	chr7:32463933	A/G	cg20159608	chr7:32802032	NA	0.47	6.77	0.31	4.39e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7149337	1.000	rs8006432	chr14:51731306	A/T	cg23942311	chr14:51606299	NA	0.79	16.49	0.63	1.6e-47	Cancer;
LUAD	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.47	-6.48	-0.3	2.56e-10	Gut microbiome composition (summer);
LUAD	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg25237894	chr2:233734115	C2orf82	0.61	11.22	0.48	9.06e-26	Coronary artery disease;
LUAD	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg22618164	chr12:122356400	WDR66	0.72	12.97	0.53	1.22e-32	Mean corpuscular volume;
LUAD	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.34	6.5	0.3	2.27e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg16203607	chr17:62500946	DDX5	0.4	6.43	0.3	3.56e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg21951975	chr1:209979733	IRF6	0.55	7.13	0.33	4.48e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs1018836	0.668	rs9297857	chr8:91480964	A/C	cg16814680	chr8:91681699	NA	-0.65	-10.85	-0.47	2.34e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs300774	0.925	rs300722	chr2:134249	A/C	cg21211680	chr2:198530	NA	-0.46	-7.29	-0.33	1.51e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg27631724	chr1:11040367	C1orf127	0.53	8.98	0.4	8.82e-18	Ewing sarcoma;
LUAD	cis	rs4853525	0.859	rs1894775	chr2:191716706	T/C	cg27211696	chr2:191398769	TMEM194B	-0.37	-6.62	-0.31	1.08e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs13082711	0.554	rs35840701	chr3:27334231	A/C	cg02860705	chr3:27208620	NA	0.78	12.13	0.51	2.84e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs58749629	1.000	rs58749629	chr20:44571317	G/A	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.57	-7.1	-0.33	5.33e-12	Abdominal aortic aneurysm;
LUAD	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg21138405	chr5:131827807	IRF1	0.56	12.0	0.5	9.67e-29	Asthma (sex interaction);
LUAD	cis	rs16882447	0.607	rs2783	chr5:53489874	C/T	cg06461071	chr5:53490839	ARL15	-0.41	-7.4	-0.34	7.29e-13	Systolic blood pressure (dietary potassium intake interaction);
LUAD	cis	rs868036	0.881	rs12708496	chr15:68054098	T/C	cg24579218	chr15:68104479	NA	0.36	6.72	0.31	5.78e-11	Restless legs syndrome;
LUAD	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg21827317	chr3:136751795	NA	0.35	6.38	0.3	4.74e-10	Neuroticism;
LUAD	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg09184832	chr6:79620586	NA	-0.4	-6.56	-0.3	1.61e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg27446573	chr6:127587934	RNF146	0.44	6.62	0.31	1.06e-10	Breast cancer;
LUAD	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg01097406	chr16:89675127	NA	0.45	9.79	0.43	1.59e-20	Vitiligo;
LUAD	cis	rs9300255	0.722	rs28592876	chr12:123866429	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.39	6.62	0.31	1.1e-10	Neutrophil percentage of white cells;
LUAD	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg17264618	chr3:40429014	ENTPD3	0.38	8.38	0.38	8.14e-16	Renal cell carcinoma;
LUAD	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.28	0.33	1.59e-12	Parkinson's disease;
LUAD	cis	rs11051970	0.661	rs188979	chr12:32569684	G/T	cg24626660	chr12:32551988	NA	0.34	7.14	0.33	4.15e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.47	6.68	0.31	7.32e-11	Platelet count;
LUAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08048268	chr3:133502702	NA	-0.53	-10.63	-0.46	1.47e-23	Iron status biomarkers;
LUAD	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg22467129	chr15:76604101	ETFA	-0.47	-7.85	-0.36	3.45e-14	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6484504	0.576	rs208067	chr11:31153578	C/T	cg26647111	chr11:31128758	NA	-0.47	-8.26	-0.37	1.9e-15	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg03467027	chr4:99064603	C4orf37	-0.43	-7.02	-0.32	8.91e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg09365446	chr1:150670422	GOLPH3L	0.62	11.11	0.48	2.49e-25	Melanoma;
LUAD	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg10978503	chr1:24200527	CNR2	0.55	11.82	0.5	4.51e-28	Immature fraction of reticulocytes;
LUAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.52	-9.02	-0.4	6.42e-18	Longevity;Endometriosis;
LUAD	trans	rs11885103	0.519	rs2685263	chr2:549873	C/G	cg12228919	chr15:44955936	SPG11	0.41	6.41	0.3	4.01e-10	Heschl's gyrus morphology;
LUAD	cis	rs679087	0.932	rs721617	chr12:29934586	C/T	cg14258853	chr12:29935411	TMTC1	0.66	12.14	0.51	2.66e-29	Schizophrenia;
LUAD	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg26408565	chr15:76604113	ETFA	-0.43	-6.96	-0.32	1.31e-11	Blood metabolite levels;
LUAD	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg17063962	chr7:91808500	NA	0.68	12.02	0.5	7.99e-29	Breast cancer;
LUAD	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.42	0.34	6.33e-13	Bipolar disorder;
LUAD	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.62	10.11	0.44	1.15e-21	Cognitive ability;
LUAD	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.7	0.31	6.49e-11	Breast cancer;
LUAD	cis	rs2066819	1.000	rs77131854	chr12:56664231	C/T	cg26714650	chr12:56694279	CS	-0.84	-7.01	-0.32	9.24e-12	Psoriasis vulgaris;
LUAD	trans	rs7246760	0.867	rs2336089	chr19:9849972	C/T	cg02900749	chr2:68251473	NA	-0.67	-7.07	-0.33	6.36e-12	Pursuit maintenance gain;
LUAD	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg07828340	chr4:882639	GAK	0.98	10.05	0.44	1.9e-21	Parkinson's disease;
LUAD	trans	rs11054731	1.000	rs10845501	chr12:12415697	A/G	cg23246901	chr12:113772827	SLC24A6	0.41	6.43	0.3	3.51e-10	Coronary artery calcification;
LUAD	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg27539214	chr16:67997921	SLC12A4	-0.72	-9.1	-0.4	3.45e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg18105134	chr13:113819100	PROZ	-1.0	-18.57	-0.67	9.74e-57	Platelet distribution width;
LUAD	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg25894440	chr7:65020034	NA	0.64	6.8	0.31	3.54e-11	Diabetic kidney disease;
LUAD	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg21191810	chr6:118973309	C6orf204	-0.47	-7.52	-0.34	3.37e-13	Diastolic blood pressure;
LUAD	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.7	-0.31	6.49e-11	Neuroticism;
LUAD	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg00717180	chr2:96193071	NA	-0.44	-8.48	-0.38	3.83e-16	HDL cholesterol;
LUAD	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg13126279	chr21:47581558	C21orf56	-0.44	-7.64	-0.35	1.48e-13	Testicular germ cell tumor;
LUAD	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg20587970	chr11:113659929	NA	-1.38	-20.36	-0.7	1.01e-64	Hip circumference adjusted for BMI;
LUAD	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg06618935	chr21:46677482	NA	-0.51	-10.02	-0.44	2.45e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg09033577	chr2:88485744	THNSL2	-0.54	-6.5	-0.3	2.22e-10	Plasma clusterin levels;
LUAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg11062466	chr8:58055876	NA	0.68	9.02	0.4	6.48e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15369054	chr17:80825471	TBCD	0.66	11.03	0.47	4.95e-25	Breast cancer;
LUAD	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	13.97	0.56	9.34e-37	Lung cancer in ever smokers;
LUAD	cis	rs1461503	0.934	rs7121840	chr11:122845360	A/G	cg27398637	chr11:122830231	C11orf63	-0.36	-6.81	-0.31	3.43e-11	Menarche (age at onset);
LUAD	cis	rs1595825	0.891	rs73056811	chr2:198766642	T/C	cg11031976	chr2:198649780	BOLL	-0.48	-7.19	-0.33	2.89e-12	Ulcerative colitis;
LUAD	cis	rs9796	0.804	rs28688742	chr15:41403638	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.42	-7.74	-0.35	7.16e-14	Menopause (age at onset);
LUAD	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.56	-0.3	1.57e-10	Bladder cancer;
LUAD	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11890956	chr21:40555474	PSMG1	0.79	13.56	0.55	5.07e-35	Cognitive function;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14797243	chr11:68671428	IGHMBP2;MRPL21	0.42	6.74	0.31	5.35e-11	Gut microbiome composition (summer);
LUAD	cis	rs56283067	0.847	rs10456535	chr6:44692758	G/A	cg18551225	chr6:44695536	NA	-0.61	-10.15	-0.44	8.03e-22	Total body bone mineral density;
LUAD	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg15962314	chr1:44399869	ARTN	-0.32	-6.43	-0.3	3.46e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg27539214	chr16:67997921	SLC12A4	0.66	8.31	0.37	1.34e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg03609598	chr5:56110824	MAP3K1	-0.66	-9.07	-0.4	4.48e-18	Initial pursuit acceleration;
LUAD	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg11663144	chr21:46675770	NA	-0.59	-11.7	-0.49	1.34e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg06671706	chr8:8559999	CLDN23	0.65	11.36	0.48	2.84e-26	Obesity-related traits;
LUAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg22907277	chr7:1156413	C7orf50	0.6	10.2	0.44	5.49e-22	Longevity;Endometriosis;
LUAD	cis	rs1444418	1.000	rs9971363	chr10:64563702	A/G	cg14943953	chr10:64564468	ADO	-0.55	-6.82	-0.31	3.07e-11	Atopic dermatitis;
LUAD	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.46	0.34	5.06e-13	Electroencephalogram traits;
LUAD	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg27490568	chr2:178487706	NA	0.43	7.08	0.33	6.08e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs875971	0.528	rs801213	chr7:66014918	C/T	cg04775059	chr7:64541387	NA	-0.5	-6.72	-0.31	5.89e-11	Aortic root size;
LUAD	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.17	0.37	3.53e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg02753203	chr1:228287806	NA	-0.47	-8.63	-0.39	1.26e-16	Diastolic blood pressure;
LUAD	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2688608	0.698	rs2633323	chr10:75694826	G/A	cg23231163	chr10:75533350	FUT11	-0.37	-6.83	-0.32	3e-11	Inflammatory bowel disease;
LUAD	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg05368731	chr17:41323189	NBR1	0.96	19.61	0.69	2.37e-61	Menopause (age at onset);
LUAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg16414030	chr3:133502952	NA	-0.63	-12.46	-0.52	1.46e-30	Iron status biomarkers;
LUAD	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.39	-0.38	7.53e-16	Breast cancer;
LUAD	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.45	0.3	3.02e-10	Depression;
LUAD	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.78	14.58	0.58	2.54e-39	Lymphocyte counts;
LUAD	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.91	0.4	1.48e-17	Cognitive ability;
LUAD	cis	rs4776059	1.000	rs62023352	chr15:52889448	T/C	cg24008177	chr15:52972085	KIAA1370	0.25	6.86	0.32	2.45e-11	Schizophrenia;
LUAD	trans	rs551517	0.541	rs496475	chr9:113638236	G/T	cg13103209	chr11:118966133	H2AFX	0.36	6.7	0.31	6.76e-11	Post bronchodilator FEV1 in COPD;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg01446614	chr12:114404317	RBM19	0.4	6.37	0.3	5.01e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg02160872	chr5:212506	CCDC127	-0.51	-6.61	-0.31	1.16e-10	Breast cancer;
LUAD	cis	rs6484504	0.652	rs494464	chr11:31386150	C/T	cg14844989	chr11:31128820	NA	0.43	7.94	0.36	1.79e-14	Red blood cell count;
LUAD	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg17063962	chr7:91808500	NA	0.7	12.68	0.52	1.94e-31	Breast cancer;
LUAD	cis	rs7254827	0.784	rs8108205	chr19:17220341	G/A	cg19418318	chr19:17219073	MYO9B	-0.56	-6.55	-0.3	1.7e-10	Mean platelet volume;
LUAD	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg21191810	chr6:118973309	C6orf204	-0.52	-8.14	-0.37	4.53e-15	Diastolic blood pressure;
LUAD	cis	rs4343996	0.902	rs4521670	chr7:3383603	C/T	cg21248987	chr7:3385318	SDK1	0.34	6.44	0.3	3.26e-10	Motion sickness;
LUAD	trans	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.74	11.15	0.48	1.79e-25	Ulcerative colitis;
LUAD	cis	rs7107174	0.892	rs10899487	chr11:78085474	G/A	cg02023728	chr11:77925099	USP35	0.43	6.83	0.32	2.98e-11	Testicular germ cell tumor;
LUAD	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg06627628	chr2:24431161	ITSN2	-0.69	-10.98	-0.47	7.52e-25	Asthma;
LUAD	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21582582	chr3:182698605	DCUN1D1	0.55	9.36	0.41	4.94e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs5756813	0.782	rs3171656	chr22:38172213	G/A	cg19894588	chr14:64061835	NA	-0.45	-6.37	-0.3	4.91e-10	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg13560548	chr3:10150139	C3orf24	0.42	6.99	0.32	1.09e-11	Alzheimer's disease;
LUAD	cis	rs807669	0.903	rs807666	chr22:19160549	C/T	cg24911827	chr22:19170109	CLTCL1	0.46	9.53	0.42	1.2e-19	Metabolite levels;
LUAD	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg15445000	chr17:37608096	MED1	-0.44	-8.1	-0.37	6.1e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs17095355	0.818	rs4275548	chr10:111910971	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.27	-0.37	1.7e-15	Biliary atresia;
LUAD	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg26597838	chr10:835615	NA	1.05	16.88	0.63	3.02e-49	Eosinophil percentage of granulocytes;
LUAD	cis	rs6601327	0.575	rs7001832	chr8:9607235	C/G	cg27411982	chr8:10470053	RP1L1	-0.35	-6.38	-0.3	4.64e-10	Multiple myeloma (hyperdiploidy);
LUAD	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg27432699	chr2:27873401	GPN1	0.57	10.08	0.44	1.49e-21	Oral cavity cancer;
LUAD	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg18232548	chr7:50535776	DDC	-0.64	-11.67	-0.49	1.83e-27	Systemic sclerosis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00723019	chr19:48867290	TMEM143;SYNGR4	-0.53	-6.39	-0.3	4.38e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11229555	0.645	rs12294062	chr11:58175603	G/T	cg15696309	chr11:58395628	NA	-0.73	-10.3	-0.45	2.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.36	-0.6	1.23e-42	Chronic sinus infection;
LUAD	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg06028605	chr16:24865363	SLC5A11	-0.44	-6.69	-0.31	7.11e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	7.04	0.32	7.8e-12	Depression;
LUAD	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg20135002	chr11:47629003	NA	-0.42	-7.34	-0.34	1.08e-12	Subjective well-being;
LUAD	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.57	10.55	0.46	3.01e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs834811	1.000	rs834811	chr7:135884571	A/G	cg01726295	chr7:135938950	NA	0.26	6.57	0.3	1.5e-10	Post-traumatic stress disorder;
LUAD	trans	rs617791	0.508	rs747526	chr11:65776071	C/A	cg17712092	chr4:129076599	LARP1B	-0.77	-11.87	-0.5	3.04e-28	Breast cancer;
LUAD	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.56	0.3	1.56e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg21475434	chr5:93447410	FAM172A	-0.62	-7.7	-0.35	9.98e-14	Diabetic retinopathy;
LUAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.28	0.54	7.04e-34	Prudent dietary pattern;
LUAD	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg21475434	chr5:93447410	FAM172A	-0.6	-7.71	-0.35	9.05e-14	Diabetic retinopathy;
LUAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-6.78	-0.31	4e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg05283184	chr6:79620031	NA	-0.62	-12.33	-0.51	4.59e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg22467129	chr15:76604101	ETFA	-0.6	-10.98	-0.47	7.42e-25	Blood metabolite levels;
LUAD	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg16647868	chr5:131706066	SLC22A5	0.5	8.06	0.37	7.67e-15	Acylcarnitine levels;
LUAD	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.52	0.46	3.66e-23	Colorectal cancer;
LUAD	cis	rs12208915	0.731	rs9443630	chr6:79661777	G/T	cg09184832	chr6:79620586	NA	0.52	7.32	0.34	1.26e-12	Left atrial antero-posterior diameter;
LUAD	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.99	-0.32	1.1e-11	Neuroticism;
LUAD	cis	rs2742417	1.000	rs2742418	chr3:45731920	C/T	cg10512202	chr3:45649293	LIMD1	0.36	6.41	0.3	3.92e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg26597838	chr10:835615	NA	1.31	20.91	0.71	3.5e-67	Eosinophil percentage of granulocytes;
LUAD	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg17644776	chr2:200775616	C2orf69	-0.53	-7.35	-0.34	1.05e-12	Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04704382	chr3:129611754	TMCC1	-0.4	-6.48	-0.3	2.52e-10	Cancer;
LUAD	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg24675056	chr1:15929824	NA	0.49	8.5	0.38	3.39e-16	Systolic blood pressure;
LUAD	cis	rs9611519	1.000	rs5758267	chr22:41619350	A/T	cg13813247	chr22:41461852	NA	0.38	6.46	0.3	2.9e-10	Neuroticism;
LUAD	cis	rs10911363	0.659	rs6669960	chr1:183436577	C/G	cg09173681	chr1:183549694	NCF2	-0.57	-10.29	-0.45	2.53e-22	Systemic lupus erythematosus;
LUAD	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg23625390	chr15:77176239	SCAPER	-0.52	-8.07	-0.37	7.11e-15	Blood metabolite levels;
LUAD	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg10468373	chr11:64009913	FKBP2	0.54	6.8	0.31	3.62e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg03609598	chr5:56110824	MAP3K1	0.48	7.09	0.33	5.82e-12	Initial pursuit acceleration;
LUAD	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg01689657	chr7:91764605	CYP51A1	0.35	8.5	0.38	3.27e-16	Breast cancer;
LUAD	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg17366294	chr4:99064904	C4orf37	0.68	13.11	0.54	3.3e-33	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg14343924	chr8:8086146	FLJ10661	0.44	7.05	0.32	7.23e-12	Mood instability;
LUAD	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg25173405	chr17:45401733	C17orf57	-0.46	-7.52	-0.34	3.33e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg05090351	chr10:126851162	NA	-0.53	-10.38	-0.45	1.27e-22	Menarche (age at onset);
LUAD	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg06108461	chr20:60628389	TAF4	-0.81	-14.02	-0.56	6.21e-37	Body mass index;
LUAD	trans	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg24644049	chr4:85504048	CDS1	0.87	7.47	0.34	4.56e-13	Skin colour saturation;
LUAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg18538332	chr22:24372958	LOC391322	-0.46	-7.97	-0.36	1.54e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg14202850	chr17:43974869	MAPT;LOC100130148	0.4	6.76	0.31	4.63e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg14196790	chr5:131705035	SLC22A5	0.37	6.47	0.3	2.67e-10	Breast cancer;
LUAD	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.15	-0.41	2.5e-18	Bipolar disorder;
LUAD	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg17480646	chr11:65405466	SIPA1	0.44	6.66	0.31	8.79e-11	Acne (severe);
LUAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07157834	chr1:205819609	PM20D1	0.72	13.71	0.55	1.23e-35	Menarche (age at onset);
LUAD	cis	rs7592578	0.508	rs10931451	chr2:191270888	G/A	cg27211696	chr2:191398769	TMEM194B	-0.47	-6.43	-0.3	3.49e-10	Diastolic blood pressure;
LUAD	cis	rs57994353	0.802	rs12002854	chr9:139377499	G/A	cg13856295	chr9:139396418	NOTCH1	-0.42	-6.62	-0.31	1.08e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg24879335	chr3:133465180	TF	0.38	7.79	0.35	5.21e-14	Iron status biomarkers (transferrin levels);
LUAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03452623	chr4:187889614	NA	-0.81	-16.55	-0.63	8.13e-48	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7215564	0.908	rs4969246	chr17:78740579	G/A	cg09596252	chr17:78655493	RPTOR	-0.5	-6.38	-0.3	4.66e-10	Myopia (pathological);
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg15383120	chr6:291909	DUSP22	0.67	11.39	0.48	2.12e-26	Menopause (age at onset);
LUAD	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg08470875	chr2:26401718	FAM59B	-0.67	-9.07	-0.4	4.67e-18	Gut microbiome composition (summer);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25587535	chr5:153857846	HAND1	-0.44	-6.48	-0.3	2.52e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.46	9.0	0.4	7.68e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg01579765	chr21:45077557	HSF2BP	-0.57	-13.34	-0.54	3.97e-34	Mean corpuscular volume;
LUAD	cis	rs6500602	0.592	rs28789232	chr16:4447552	C/A	cg08645402	chr16:4508243	NA	0.5	7.82	0.36	4.22e-14	Schizophrenia;
LUAD	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg14416269	chr4:6271139	WFS1	0.62	13.36	0.54	3.27e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg02524346	chr8:600233	NA	1.08	10.71	0.46	7.41e-24	IgG glycosylation;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22655561	chr5:176883211	PRR7	-0.38	-6.52	-0.3	2.06e-10	Cancer;
LUAD	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg01200585	chr1:228362443	C1orf69	0.43	7.4	0.34	7.31e-13	Diastolic blood pressure;
LUAD	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg15704280	chr7:45808275	SEPT13	0.9	17.49	0.65	6.15e-52	Coronary artery disease;
LUAD	cis	rs4523957	0.553	rs2641440	chr17:2027182	G/C	cg16513277	chr17:2031491	SMG6	-0.96	-19.29	-0.68	6.04e-60	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs367615	0.704	rs72802966	chr5:108846754	T/G	cg17395555	chr5:108820864	NA	0.66	14.27	0.57	5.25e-38	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.19	0.33	2.91e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg12645284	chr15:79092878	ADAMTS7	0.47	7.63	0.35	1.58e-13	Coronary artery disease or large artery stroke;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06583108	chr12:85430029	TSPAN19;LRRIQ1	-0.63	-6.38	-0.3	4.75e-10	Type 2 diabetes;
LUAD	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg11663144	chr21:46675770	NA	-0.6	-11.61	-0.49	3.08e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg15017067	chr4:17643749	FAM184B	0.36	7.03	0.32	8.22e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs28595532	0.702	rs72670252	chr4:119337546	A/C	cg02775129	chr4:119771670	NA	-0.66	-6.5	-0.3	2.2e-10	Cannabis dependence symptom count;
LUAD	cis	rs12530845	0.887	rs61360007	chr7:135316879	G/A	cg23117316	chr7:135346802	PL-5283	-0.5	-8.71	-0.39	6.71e-17	Red blood cell traits;
LUAD	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg18876405	chr7:65276391	NA	0.61	10.43	0.45	7.87e-23	Aortic root size;
LUAD	cis	rs4766566	0.694	rs1362006	chr12:111742222	A/G	cg10833066	chr12:111807467	FAM109A	0.66	13.74	0.56	8.5000000000000007e-36	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUAD	cis	rs7582720	1.000	rs72934505	chr2:203916487	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.24	0.41	1.23e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2109514	0.902	rs6980387	chr7:116126882	A/G	cg12739419	chr7:116140593	CAV2	-0.32	-6.74	-0.31	5.1e-11	Prevalent atrial fibrillation;
LUAD	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg18016565	chr1:150552671	MCL1	0.41	7.52	0.34	3.34e-13	Tonsillectomy;
LUAD	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg16325326	chr1:53192061	ZYG11B	0.47	7.64	0.35	1.44e-13	Monocyte count;
LUAD	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.19	0.33	2.91e-12	Rheumatoid arthritis;
LUAD	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg17644776	chr2:200775616	C2orf69	0.52	6.53	0.3	1.9e-10	Schizophrenia;
LUAD	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg08859206	chr1:53392774	SCP2	0.59	10.98	0.47	7.87e-25	Monocyte count;
LUAD	cis	rs1865721	0.771	rs727893	chr18:73136931	G/A	cg26385618	chr18:73139727	C18orf62	-0.51	-10.33	-0.45	1.85e-22	Intelligence;
LUAD	cis	rs6500395	0.708	rs28449353	chr16:48555134	T/A	cg04672837	chr16:48644449	N4BP1	0.38	6.52	0.3	2.01e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg20933634	chr6:27740509	NA	0.45	7.12	0.33	4.68e-12	Parkinson's disease;
LUAD	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg07305463	chr2:136567211	LCT	0.38	6.97	0.32	1.23e-11	Mosquito bite size;
LUAD	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.18	0.44	6.42e-22	Ileal carcinoids;
LUAD	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg06131755	chr6:160182447	ACAT2	0.43	6.48	0.3	2.57e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg22338127	chr1:209979572	IRF6	0.51	6.5	0.3	2.3e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs877282	0.898	rs12354872	chr10:763362	G/A	cg06581033	chr10:766294	NA	-0.59	-7.98	-0.36	1.39e-14	Uric acid levels;
LUAD	cis	rs6424115	0.618	rs10917420	chr1:24062987	C/T	cg10978503	chr1:24200527	CNR2	0.41	8.23	0.37	2.29e-15	Immature fraction of reticulocytes;
LUAD	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg14186256	chr22:23484241	RTDR1	0.46	7.99	0.36	1.28e-14	Bone mineral density;
LUAD	trans	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg25894440	chr7:65020034	NA	-0.73	-6.68	-0.31	7.41e-11	Gout;
LUAD	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg11822812	chr5:140052017	DND1	-0.44	-8.19	-0.37	3.07e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7084921	0.521	rs12772820	chr10:101873824	A/G	cg19754520	chr10:101825118	CPN1	-0.32	-6.74	-0.31	5.19e-11	Bone mineral density;
LUAD	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.61	0.55	3.06e-35	Tonsillectomy;
LUAD	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg00255919	chr5:131827918	IRF1	0.5	11.83	0.5	4.33e-28	Asthma (sex interaction);
LUAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg10729496	chr3:10149963	C3orf24	0.5	8.03	0.36	9.6e-15	Alzheimer's disease;
LUAD	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg05805236	chr11:65401703	PCNXL3	0.39	6.53	0.3	1.87e-10	Acne (severe);
LUAD	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.07	-0.32	6.59e-12	Lung cancer;
LUAD	cis	rs7617773	0.780	rs36121690	chr3:48345511	C/T	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg27124370	chr19:33622961	WDR88	0.43	6.66	0.31	8.47e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10992471	0.603	rs12341817	chr9:95252152	C/T	cg14631576	chr9:95140430	CENPP	-0.56	-11.47	-0.49	1.09e-26	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.42	-0.34	6.4e-13	Glomerular filtration rate;
LUAD	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg02493740	chr2:85810744	VAMP5	-0.4	-7.18	-0.33	3.08e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26376749	chr17:30677620	ZNF207	-0.46	-7.36	-0.34	9.44e-13	Height;
LUAD	cis	rs8067545	0.750	rs4925081	chr17:19991993	A/G	cg04132472	chr17:19861366	AKAP10	-0.29	-7.02	-0.32	9.11e-12	Schizophrenia;
LUAD	cis	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg05084668	chr3:125655381	ALG1L	-0.63	-10.09	-0.44	1.37e-21	Blood pressure (smoking interaction);
LUAD	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg21433313	chr16:3507492	NAT15	-0.74	-12.7	-0.53	1.6e-31	Tuberculosis;
LUAD	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.23	0.37	2.29e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs1267303	0.637	rs1745371	chr1:46985192	C/T	cg16387850	chr1:46982889	NA	-0.46	-7.97	-0.36	1.51e-14	Monobrow;
LUAD	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg04455712	chr21:45112962	RRP1B	0.47	9.19	0.41	1.84e-18	Mean corpuscular volume;
LUAD	cis	rs2637266	0.703	rs2583062	chr10:78558472	T/C	cg18941641	chr10:78392320	NA	0.31	6.41	0.3	3.94e-10	Pulmonary function;
LUAD	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg16102102	chr5:83017553	HAPLN1	-0.79	-13.33	-0.54	4.25e-34	Prostate cancer;
LUAD	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg08048268	chr3:133502702	NA	-0.39	-7.41	-0.34	6.88e-13	Iron status biomarkers;
LUAD	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg17366294	chr4:99064904	C4orf37	0.66	12.7	0.53	1.56e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg10589385	chr1:150898437	SETDB1	0.39	7.42	0.34	6.51e-13	Tonsillectomy;
LUAD	cis	rs7851660	0.874	rs7860144	chr9:100626884	A/G	cg13688889	chr9:100608707	NA	-0.48	-8.26	-0.37	1.87e-15	Strep throat;
LUAD	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg04414720	chr1:150670196	GOLPH3L	0.73	13.64	0.55	2.2e-35	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg18180107	chr4:99064573	C4orf37	0.42	6.84	0.32	2.74e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.62	8.67	0.39	9.47e-17	Renal function-related traits (BUN);
LUAD	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg07741184	chr6:167504864	NA	0.35	8.06	0.36	7.85e-15	Crohn's disease;
LUAD	cis	rs10193935	0.901	rs222464	chr2:42643889	C/T	cg27598129	chr2:42591480	NA	-0.77	-9.99	-0.44	3.07e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg06547715	chr2:218990976	CXCR2	0.28	6.57	0.3	1.45e-10	Colorectal cancer;
LUAD	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.31	6.97	0.32	1.24e-11	Parkinson's disease;
LUAD	cis	rs751728	1.000	rs747695	chr6:33736672	G/A	cg13859433	chr6:33739653	LEMD2	-0.38	-8.79	-0.39	3.7e-17	Crohn's disease;
LUAD	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg26384229	chr12:38710491	ALG10B	0.47	7.53	0.34	3.06e-13	Heart rate;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg19596790	chr3:9691124	MTMR14	0.41	7.03	0.32	8.39e-12	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg18827107	chr12:86230957	RASSF9	0.67	12.7	0.53	1.6e-31	Major depressive disorder;
LUAD	cis	rs68170813	0.523	rs12154285	chr7:106993573	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-10.31	-0.45	2.24e-22	Coronary artery disease;
LUAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.87	16.74	0.63	1.25e-48	Lymphocyte counts;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21157115	chr9:33001303	APTX	-0.38	-6.47	-0.3	2.64e-10	Cancer;
LUAD	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg10518543	chr12:38710700	ALG10B	0.43	7.18	0.33	3.11e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg25173405	chr17:45401733	C17orf57	-0.55	-9.27	-0.41	9.88e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7289126	0.966	rs2267380	chr22:38631768	T/C	cg25457927	chr22:38595422	NA	-0.44	-10.42	-0.45	8.71e-23	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.69	-0.31	7.21e-11	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs1493916	0.744	rs7504560	chr18:31312148	A/G	cg27147174	chr7:100797783	AP1S1	-0.6	-10.41	-0.45	9.84e-23	Life satisfaction;
LUAD	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.83	0.32	2.98e-11	Motion sickness;
LUAD	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg06074448	chr4:187884817	NA	-0.36	-7.05	-0.32	7.53e-12	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg04703951	chr17:43578652	NA	-0.58	-8.24	-0.37	2.13e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs877282	0.898	rs11253348	chr10:765852	C/T	cg22713356	chr15:30763199	NA	1.28	17.23	0.64	8.53e-51	Uric acid levels;
LUAD	trans	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg11693508	chr17:37793320	STARD3	0.77	10.05	0.44	1.84e-21	Bipolar disorder;
LUAD	cis	rs59104589	0.583	rs73002176	chr2:242332438	T/C	cg08645257	chr2:242211290	HDLBP	0.46	7.43	0.34	6.21e-13	Fibrinogen levels;
LUAD	cis	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg07460842	chr6:66804631	NA	-0.64	-9.25	-0.41	1.1e-18	Blood trace element (Cu levels);
LUAD	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg05082376	chr22:42548792	NA	-0.39	-6.96	-0.32	1.33e-11	Cognitive function;
LUAD	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg16989719	chr2:238392110	NA	-0.35	-7.37	-0.34	9.16e-13	Prostate cancer;
LUAD	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.47e-10	Depression;
LUAD	trans	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg07817883	chr1:32538562	TMEM39B	1.27	12.17	0.51	1.94e-29	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9462027	0.540	rs9366863	chr6:34688946	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.35	9.0	0.4	7.61e-18	Systemic lupus erythematosus;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg06310300	chr7:100076089	TSC22D4	0.38	6.65	0.31	9.21e-11	Bilirubin levels;
LUAD	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg01324343	chr3:183735012	ABCC5	0.9	24.09	0.76	2.3e-81	Anterior chamber depth;
LUAD	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg01448562	chr3:133502909	NA	-0.52	-9.09	-0.4	4.01e-18	Iron status biomarkers;
LUAD	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg24397884	chr7:158709396	WDR60	-0.69	-9.59	-0.42	7.57e-20	Height;
LUAD	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg00933542	chr6:150070202	PCMT1	0.44	9.68	0.43	3.86e-20	Lung cancer;
LUAD	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg00129232	chr17:37814104	STARD3	-0.46	-7.86	-0.36	3.12e-14	Asthma;
LUAD	cis	rs9650657	0.707	rs2005309	chr8:10652170	T/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.42	-0.3	3.75e-10	Neuroticism;
LUAD	cis	rs3821902	0.646	rs10510901	chr3:64013062	A/G	cg22134162	chr3:63841271	THOC7	-0.37	-6.37	-0.3	4.86e-10	Breast cancer;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg18088712	chr1:16810147	CROCCL2	-0.43	-6.89	-0.32	1.99e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg16606324	chr3:10149918	C3orf24	0.68	11.37	0.48	2.59e-26	Alzheimer's disease;
LUAD	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03934478	chr11:495069	RNH1	0.75	8.96	0.4	1.03e-17	Body mass index;
LUAD	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg23992470	chr4:843637	GAK	0.69	7.49	0.34	4.18e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg07936489	chr17:37558343	FBXL20	0.47	7.5	0.34	3.91e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg15128208	chr22:42549153	NA	-0.43	-8.87	-0.4	2.14e-17	Cognitive function;
LUAD	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg22823121	chr1:150693482	HORMAD1	0.41	7.96	0.36	1.57e-14	Melanoma;
LUAD	cis	rs12049351	0.774	rs767303	chr1:229698931	A/C	cg11742688	chr1:229674241	ABCB10	-0.41	-6.77	-0.31	4.4e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg11062466	chr8:58055876	NA	0.57	7.59	0.35	2.02e-13	Developmental language disorder (linguistic errors);
LUAD	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg04703951	chr17:43578652	NA	0.6	8.4	0.38	6.72e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg18132916	chr6:79620363	NA	0.44	7.44	0.34	5.57e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9394841	0.692	rs9394834	chr6:41806793	G/A	cg25600774	chr6:41776562	USP49	-0.42	-6.47	-0.3	2.78e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg18944383	chr4:111397179	ENPEP	0.5	9.94	0.44	4.68e-21	Coronary artery disease;
LUAD	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg17063962	chr7:91808500	NA	0.68	12.43	0.52	1.8e-30	Breast cancer;
LUAD	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg15557168	chr22:42548783	NA	-0.44	-8.31	-0.37	1.3e-15	Cognitive function;
LUAD	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg18477163	chr1:228402036	OBSCN	-0.37	-7.31	-0.33	1.37e-12	Diastolic blood pressure;
LUAD	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.59e-12	Crohn's disease;
LUAD	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg06002616	chr8:101225028	SPAG1	-0.4	-8.0	-0.36	1.17e-14	Atrioventricular conduction;
LUAD	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg18827107	chr12:86230957	RASSF9	-0.71	-13.05	-0.54	6.13e-33	Major depressive disorder;
LUAD	cis	rs7465272	1.000	rs7465272	chr8:143691838	A/T	cg10104451	chr8:143696006	ARC	-0.64	-8.6	-0.39	1.55e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs494562	1.000	rs7763191	chr6:86118317	A/T	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg16988262	chr1:15930761	NA	0.41	6.84	0.32	2.85e-11	Systolic blood pressure;
LUAD	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg11965913	chr1:205819406	PM20D1	-0.58	-10.42	-0.45	8.52e-23	Menarche (age at onset);
LUAD	cis	rs6545883	0.929	rs7563678	chr2:61741811	C/T	cg15711740	chr2:61764176	XPO1	0.41	6.71	0.31	6.2e-11	Tuberculosis;
LUAD	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-7.03	-0.32	8.51e-12	Lung cancer;
LUAD	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg14784868	chr12:69753453	YEATS4	0.43	6.81	0.31	3.45e-11	Blood protein levels;
LUAD	trans	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.16	27.98	0.81	2.76e-98	Exhaled nitric oxide output;
LUAD	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg21823605	chr1:152486609	CRCT1	0.28	6.52	0.3	2.01e-10	Hair morphology;
LUAD	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.18	-0.37	3.36e-15	Total body bone mineral density;
LUAD	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.73	-14.12	-0.57	2.21e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg25985355	chr7:65971099	NA	0.53	6.6	0.31	1.22e-10	Diabetic kidney disease;
LUAD	cis	rs6076065	0.676	rs4813490	chr20:23325150	A/G	cg11657817	chr20:23433608	CST11	0.48	9.09	0.4	3.82e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg06060754	chr5:176797920	RGS14	0.56	10.88	0.47	1.84e-24	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs7149337	0.837	rs4296182	chr14:51662167	A/C	cg23942311	chr14:51606299	NA	0.86	19.22	0.68	1.27e-59	Cancer;
LUAD	cis	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05901451	chr6:126070800	HEY2	0.44	6.6	0.31	1.24e-10	Endometrial cancer;
LUAD	trans	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg01620082	chr3:125678407	NA	-0.71	-7.15	-0.33	3.79e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg02782426	chr3:40428986	ENTPD3	0.44	9.29	0.41	8.2e-19	Renal cell carcinoma;
LUAD	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg07936489	chr17:37558343	FBXL20	-0.48	-7.45	-0.34	5.38e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg08085267	chr17:45401833	C17orf57	0.64	11.66	0.49	2.01e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1816752	0.905	rs4770680	chr13:25015248	T/C	cg02811702	chr13:24901961	NA	0.45	7.9	0.36	2.5e-14	Obesity-related traits;
LUAD	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg25173405	chr17:45401733	C17orf57	-0.41	-6.55	-0.3	1.64e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg04772025	chr11:68637568	NA	0.54	8.42	0.38	6e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1997103	1.000	rs1965556	chr7:55403584	C/G	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg08601574	chr20:25228251	PYGB	0.46	8.71	0.39	6.82e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs929596	0.563	rs1105879	chr2:234602202	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.63	-10.66	-0.46	1.12e-23	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.59	-6.87	-0.32	2.33e-11	Lung cancer in ever smokers;
LUAD	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg06784218	chr1:46089804	CCDC17	0.52	11.47	0.49	1.08e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.23	-0.37	2.38e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg18335740	chr13:41363409	SLC25A15	0.51	9.18	0.41	1.94e-18	Lewy body disease;
LUAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18404041	chr3:52824283	ITIH1	-0.52	-10.21	-0.44	4.89e-22	Electroencephalogram traits;
LUAD	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg01528321	chr10:82214614	TSPAN14	0.64	10.16	0.44	7.33e-22	Post bronchodilator FEV1;
LUAD	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg27279351	chr12:120934652	DYNLL1	0.44	6.67	0.31	7.91e-11	High light scatter reticulocyte count;
LUAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg03354898	chr7:1950403	MAD1L1	-0.39	-7.12	-0.33	4.69e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs72928364	1.000	rs1036467	chr3:100642804	C/T	cg10123952	chr3:100791384	NA	0.64	7.32	0.34	1.26e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14159672	chr1:205819179	PM20D1	0.91	20.5	0.71	2.43e-65	Menarche (age at onset);
LUAD	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg03651054	chr13:50194643	NA	0.39	7.98	0.36	1.36e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg00745463	chr17:30367425	LRRC37B	-0.88	-11.32	-0.48	3.95e-26	Hip circumference adjusted for BMI;
LUAD	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg23018236	chr17:30244563	NA	-0.68	-8.33	-0.38	1.14e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg09658497	chr7:2847517	GNA12	-0.47	-8.62	-0.39	1.31e-16	Height;
LUAD	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg18252515	chr7:66147081	NA	-0.62	-6.88	-0.32	2.23e-11	Diabetic kidney disease;
LUAD	cis	rs7107174	1.000	rs2512544	chr11:77986371	A/T	cg02023728	chr11:77925099	USP35	0.47	7.35	0.34	1.04e-12	Testicular germ cell tumor;
LUAD	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	13.68	0.55	1.51e-35	Lung cancer in ever smokers;
LUAD	cis	rs12210905	0.800	rs12209651	chr6:26660925	A/C	cg11502198	chr6:26597334	ABT1	-0.76	-6.54	-0.3	1.77e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg21385522	chr1:16154831	NA	0.44	6.66	0.31	8.42e-11	Dilated cardiomyopathy;
LUAD	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	11.84	0.5	3.95e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs7119	0.717	rs12916682	chr15:77807937	A/T	cg27398640	chr15:77910606	LINGO1	-0.35	-6.63	-0.31	1e-10	Type 2 diabetes;
LUAD	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.32	-6.68	-0.31	7.53e-11	Hemoglobin concentration;
LUAD	cis	rs8048589	1.000	rs13336687	chr16:12187065	C/T	cg03816625	chr16:12192430	SNX29	0.55	8.06	0.36	8.08e-15	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs9322817	0.607	rs7772567	chr6:105155782	C/A	cg02098413	chr6:105308735	HACE1	-0.4	-8.25	-0.37	2.04e-15	Thyroid stimulating hormone;
LUAD	cis	rs1448094	0.802	rs7487591	chr12:86434112	T/C	cg00310523	chr12:86230176	RASSF9	0.35	7.33	0.34	1.16e-12	Major depressive disorder;
LUAD	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg00484396	chr16:3507460	NAT15	0.75	9.95	0.44	4.15e-21	Tuberculosis;
LUAD	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.36e-12	Lung cancer;
LUAD	cis	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-7.03	-0.32	8.35e-12	Morning vs. evening chronotype;
LUAD	cis	rs2235649	0.828	rs9938694	chr16:1849872	T/C	cg08610935	chr16:1836813	NUBP2	-0.48	-7.49	-0.34	4.18e-13	Blood metabolite levels;
LUAD	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg18512352	chr11:47633146	NA	-0.47	-8.28	-0.37	1.58e-15	Subjective well-being;
LUAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	7.92	0.36	2.14e-14	Menarche (age at onset);
LUAD	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg15133208	chr4:90757351	SNCA	-0.46	-6.81	-0.31	3.26e-11	Neuroticism;
LUAD	cis	rs4713118	0.505	rs156740	chr6:27960435	G/A	cg16479474	chr6:28041457	NA	0.33	6.46	0.3	2.88e-10	Parkinson's disease;
LUAD	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg06387496	chr7:2775674	GNA12	-0.39	-6.57	-0.3	1.51e-10	Height;
LUAD	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.35	-18.07	-0.66	1.71e-54	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg08027265	chr7:2291960	NA	0.47	8.29	0.37	1.54e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg10819733	chr22:24237672	NA	-0.45	-8.64	-0.39	1.17e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg06519183	chr17:74387073	UBE2O	0.4	6.72	0.31	5.93e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9549367	0.673	rs3024735	chr13:113819513	G/A	cg18105134	chr13:113819100	PROZ	-1.01	-18.42	-0.67	4.85e-56	Platelet distribution width;
LUAD	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.69	0.39	7.74e-17	Menopause (age at onset);
LUAD	cis	rs4604732	0.631	rs60311891	chr1:247623127	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.43	6.99	0.32	1.1e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs7555117	0.794	rs2989476	chr1:61059259	C/G	cg07074473	chr2:70121414	SNRNP27	-0.4	-6.46	-0.3	2.85e-10	Facial morphology (factor 19);
LUAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg10729496	chr3:10149963	C3orf24	0.58	9.45	0.42	2.41e-19	Alzheimer's disease;
LUAD	cis	rs3806843	0.548	rs246056	chr5:140325600	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.33	-6.79	-0.31	3.8e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs875971	1.000	rs778710	chr7:65854834	T/C	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg04036182	chr15:45458818	NA	-0.41	-7.08	-0.33	6.06e-12	Glomerular filtration rate;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg04286729	chr1:1407183	ATAD3B	-0.65	-6.65	-0.31	9.31e-11	Type 2 diabetes;
LUAD	cis	rs739496	0.843	rs10774629	chr12:112020214	G/C	cg10833066	chr12:111807467	FAM109A	-0.42	-6.59	-0.31	1.3e-10	Platelet count;
LUAD	cis	rs7187994	0.848	rs8048680	chr16:84762708	A/G	cg07647771	chr16:84786436	USP10	-0.37	-9.54	-0.42	1.18e-19	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg08999081	chr20:33150536	PIGU	0.6	13.35	0.54	3.67e-34	Glomerular filtration rate (creatinine);
LUAD	cis	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg07460842	chr6:66804631	NA	-0.97	-14.22	-0.57	8.57e-38	Exhaled nitric oxide output;
LUAD	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.54	-0.38	2.4e-16	Total body bone mineral density;
LUAD	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.66e-15	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs558133	1.000	rs558133	chr5:78425188	G/T	cg25119155	chr5:78426943	BHMT	0.49	8.88	0.4	2e-17	Blood and toenail selenium levels;
LUAD	cis	rs684232	0.623	rs391002	chr17:535441	T/G	cg12384639	chr17:618140	VPS53	0.48	8.21	0.37	2.78e-15	Prostate cancer;
LUAD	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg08807101	chr21:30365312	RNF160	0.51	8.84	0.39	2.55e-17	Dental caries;
LUAD	cis	rs10423674	0.526	rs12462498	chr19:18832950	A/G	cg14292368	chr19:18793705	CRTC1	0.44	7.85	0.36	3.34e-14	Menarche (age at onset);
LUAD	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg08645402	chr16:4508243	NA	0.5	8.09	0.37	6.3e-15	Schizophrenia;
LUAD	cis	rs208520	0.661	rs704519	chr6:66801136	T/C	cg07460842	chr6:66804631	NA	-1.08	-16.74	-0.63	1.25e-48	Exhaled nitric oxide output;
LUAD	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg15445000	chr17:37608096	MED1	0.45	8.24	0.37	2.2e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs4786125	0.587	rs12709158	chr16:6925056	A/G	cg03623568	chr16:6915990	A2BP1	-0.49	-10.43	-0.45	8.21e-23	Heart rate variability traits (SDNN);
LUAD	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg26408565	chr15:76604113	ETFA	-0.44	-7.21	-0.33	2.58e-12	Blood metabolite levels;
LUAD	cis	rs11626933	1.000	rs3825661	chr14:90767607	C/T	cg14092571	chr14:90743983	NA	0.88	16.91	0.64	2.33e-49	Gut microbiota (bacterial taxa);
LUAD	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg03452623	chr4:187889614	NA	-0.8	-16.59	-0.63	5.75e-48	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.25	-0.33	2.06e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01570182	chr17:44337453	NA	1.15	17.76	0.65	4.01e-53	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs250585	1.000	rs6497671	chr16:23536684	T/C	cg00143387	chr16:23521605	GGA2	-0.63	-7.49	-0.34	4.01e-13	Egg allergy;
LUAD	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg17264618	chr3:40429014	ENTPD3	0.37	7.81	0.36	4.47e-14	Renal cell carcinoma;
LUAD	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg06092702	chr1:163392909	NA	-0.37	-8.47	-0.38	4.11e-16	Motion sickness;
LUAD	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.14	-0.44	9.11e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg13390004	chr1:15929781	NA	0.48	8.51	0.38	3.05e-16	Systolic blood pressure;
LUAD	cis	rs4077515	0.967	rs10781500	chr9:139269338	A/G	cg14019695	chr9:139328340	INPP5E	-0.37	-7.18	-0.33	3.12e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg20673091	chr1:2541236	MMEL1	0.4	8.51	0.38	3.16e-16	Ulcerative colitis;
LUAD	cis	rs7727544	0.625	rs4705916	chr5:131407493	C/A	cg14196790	chr5:131705035	SLC22A5	0.48	8.28	0.37	1.61e-15	Blood metabolite levels;
LUAD	cis	rs4853525	0.818	rs4853520	chr2:191719498	A/G	cg27211696	chr2:191398769	TMEM194B	-0.38	-6.66	-0.31	8.73e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg13047869	chr3:10149882	C3orf24	0.52	7.79	0.35	5.4e-14	Alzheimer's disease;
LUAD	cis	rs68170813	0.559	rs1018946	chr7:106851754	T/C	cg02696742	chr7:106810147	HBP1	-0.78	-10.71	-0.46	7.76e-24	Coronary artery disease;
LUAD	cis	rs4233802	1.000	rs4425094	chr2:151139891	C/T	cg25300694	chr2:151184358	NA	0.86	7.34	0.34	1.14e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg26384229	chr12:38710491	ALG10B	0.4	6.87	0.32	2.3e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg10862848	chr6:42927986	GNMT	-0.32	-9.23	-0.41	1.34e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7539409	0.651	rs7521788	chr1:84309320	G/T	cg10977910	chr1:84465055	TTLL7	0.77	8.86	0.4	2.29e-17	Alzheimer's disease;
LUAD	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg23992470	chr4:843637	GAK	0.68	7.13	0.33	4.41e-12	Parkinson's disease;
LUAD	cis	rs3812111	0.510	rs4946151	chr6:116595289	G/C	cg18828861	chr6:116576566	TSPYL4	0.37	7.11	0.33	5.01e-12	Age-related macular degeneration;
LUAD	cis	rs12505328	0.514	rs10029046	chr4:174381905	G/T	cg12145043	chr4:174357286	NA	-0.47	-7.16	-0.33	3.5e-12	Chin dimples;
LUAD	cis	rs7177699	0.557	rs8027833	chr15:79112837	T/C	cg00540400	chr15:79124168	NA	0.44	9.42	0.42	2.88e-19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.64	0.55	2.2e-35	Tonsillectomy;
LUAD	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	9.32	0.41	6.7e-19	Melanoma;
LUAD	cis	rs7493	0.901	rs13226149	chr7:95025600	G/A	cg20119798	chr7:94954144	PON1	-0.48	-6.79	-0.31	3.82e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg22920501	chr2:26401640	FAM59B	-0.82	-11.51	-0.49	7.66e-27	Gut microbiome composition (summer);
LUAD	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg09127314	chr1:152161683	NA	0.4	6.55	0.3	1.66e-10	Inflammatory skin disease;
LUAD	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg16647868	chr5:131706066	SLC22A5	0.38	6.62	0.31	1.09e-10	Blood metabolite levels;
LUAD	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg22852734	chr6:133119734	C6orf192	0.79	9.78	0.43	1.67e-20	Type 2 diabetes nephropathy;
LUAD	trans	rs1493916	0.748	rs7230463	chr18:31309133	G/C	cg15819921	chr19:927150	ARID3A	-0.39	-6.44	-0.3	3.21e-10	Life satisfaction;
LUAD	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.36	-7.74	-0.35	7.36e-14	Hemoglobin concentration;
LUAD	cis	rs11048434	0.626	rs1805736	chr12:9084931	A/G	cg04155231	chr12:9217510	LOC144571	-0.38	-7.24	-0.33	2.17e-12	Sjögren's syndrome;
LUAD	cis	rs62238980	0.614	rs17683310	chr22:32477445	A/G	cg00543991	chr22:32367038	NA	-0.82	-8.32	-0.37	1.24e-15	Childhood ear infection;
LUAD	trans	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg18187862	chr3:45730750	SACM1L	0.48	7.57	0.35	2.41e-13	Primary sclerosing cholangitis;
LUAD	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg12927641	chr6:109611667	NA	-0.51	-8.82	-0.39	2.96e-17	Reticulocyte fraction of red cells;
LUAD	trans	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg24644049	chr4:85504048	CDS1	0.89	7.6	0.35	1.89e-13	Skin colour saturation;
LUAD	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg17178900	chr1:205818956	PM20D1	-0.47	-7.48	-0.34	4.37e-13	Parkinson's disease;
LUAD	cis	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg21775007	chr8:11205619	TDH	-0.43	-7.38	-0.34	8.41e-13	Retinal vascular caliber;
LUAD	cis	rs494562	0.892	rs1322403	chr6:86127162	A/G	cg21730993	chr6:86159210	NT5E	0.71	7.75	0.35	6.84e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg09367891	chr1:107599246	PRMT6	0.51	8.61	0.39	1.47e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg15309053	chr8:964076	NA	0.34	7.42	0.34	6.51e-13	Schizophrenia;
LUAD	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg05340658	chr4:99064831	C4orf37	0.47	6.62	0.31	1.1e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg24846343	chr22:24311635	DDTL	0.84	20.82	0.71	8.86e-67	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12474201	0.619	rs17821827	chr2:46918682	C/T	cg09399716	chr2:46890238	NA	-0.56	-10.33	-0.45	1.81e-22	Height;
LUAD	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg20701182	chr2:24300061	SF3B14	0.63	7.12	0.33	4.52e-12	Lymphocyte counts;
LUAD	cis	rs1461503	0.868	rs7126785	chr11:122839564	C/A	cg27398637	chr11:122830231	C11orf63	-0.36	-7.01	-0.32	9.34e-12	Menarche (age at onset);
LUAD	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.41	-0.42	3.26e-19	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-10.06	-0.44	1.8e-21	Brugada syndrome;
LUAD	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg04398451	chr17:18023971	MYO15A	-0.88	-16.63	-0.63	3.77e-48	Total body bone mineral density;
LUAD	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg12292205	chr6:26970375	C6orf41	-0.53	-9.26	-0.41	1.01e-18	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg12908607	chr1:44402522	ARTN	-0.52	-10.31	-0.45	2.21e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs13394619	0.935	rs6746291	chr2:11728381	T/C	cg07314298	chr2:11723111	GREB1	-0.55	-10.49	-0.45	4.82e-23	Endometriosis;
LUAD	cis	rs684232	0.602	rs2160955	chr17:560604	T/C	cg15660573	chr17:549704	VPS53	-0.89	-17.98	-0.66	4.26e-54	Prostate cancer;
LUAD	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg18944383	chr4:111397179	ENPEP	-0.51	-9.22	-0.41	1.47e-18	Coronary artery disease;
LUAD	cis	rs7737355	0.947	rs10067982	chr5:130835940	C/G	cg06307176	chr5:131281290	NA	0.48	7.61	0.35	1.74e-13	Life satisfaction;
LUAD	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg14835575	chr10:16859367	RSU1	0.51	7.89	0.36	2.66e-14	Platelet distribution width;
LUAD	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.24	-0.37	2.16e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.44	-6.86	-0.32	2.49e-11	Breast cancer;
LUAD	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg17425144	chr1:10567563	PEX14	0.59	12.2	0.51	1.51e-29	Prostate cancer;
LUAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg18621852	chr3:10150065	C3orf24	0.48	8.3	0.37	1.44e-15	Alzheimer's disease;
LUAD	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg07636037	chr3:49044803	WDR6	0.64	12.52	0.52	8.46e-31	Parkinson's disease;
LUAD	cis	rs9479482	0.967	rs9479478	chr6:150354608	T/G	cg25797454	chr6:150327115	RAET1K	0.34	7.49	0.34	3.98e-13	Alopecia areata;
LUAD	cis	rs2235649	0.798	rs78540053	chr16:1853275	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.43	-6.86	-0.32	2.38e-11	Blood metabolite levels;
LUAD	cis	rs684232	0.583	rs17677436	chr17:520314	T/C	cg12384639	chr17:618140	VPS53	0.49	8.24	0.37	2.17e-15	Prostate cancer;
LUAD	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg12573674	chr2:1569213	NA	-0.61	-7.2	-0.33	2.74e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs727505	0.754	rs55859595	chr7:124783083	G/T	cg23710748	chr7:124431027	NA	-0.38	-7.8	-0.35	4.88e-14	Lewy body disease;
LUAD	cis	rs2262909	0.962	rs408687	chr19:22231123	T/C	cg11619707	chr19:22235551	ZNF257	-0.48	-7.48	-0.34	4.22e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg18833306	chr6:118973337	C6orf204	0.5	7.21	0.33	2.53e-12	Diastolic blood pressure;
LUAD	trans	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.96	0.44	3.77e-21	Ulcerative colitis;
LUAD	cis	rs9560113	0.509	rs4773390	chr13:112208904	G/A	cg10483660	chr13:112241077	NA	0.47	9.39	0.42	3.65e-19	Menarche (age at onset);
LUAD	cis	rs34734847	1.000	rs10431385	chr12:121128882	T/C	cg21892295	chr12:121157589	UNC119B	-0.46	-8.62	-0.39	1.34e-16	Mean corpuscular volume;
LUAD	cis	rs2275731	0.526	rs10904749	chr10:16522338	A/G	cg04254609	chr10:16479192	PTER	-0.46	-7.43	-0.34	5.93e-13	Bone fracture in osteoporosis;
LUAD	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.7	-0.58	8.21e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25621096	chr1:151032116	CDC42SE1;MLLT11	-0.62	-7.57	-0.35	2.41e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs727505	0.607	rs59635547	chr7:124796371	A/C	cg23710748	chr7:124431027	NA	-0.38	-7.6	-0.35	1.9e-13	Lewy body disease;
LUAD	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg17105886	chr17:28927953	LRRC37B2	0.78	7.73	0.35	7.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7107174	1.000	rs2510041	chr11:77945284	G/A	cg02023728	chr11:77925099	USP35	0.4	6.76	0.31	4.65e-11	Testicular germ cell tumor;
LUAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg21782813	chr7:2030301	MAD1L1	0.44	7.12	0.33	4.79e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.57	11.0	0.47	6.1e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg25233709	chr10:116636983	FAM160B1	0.41	8.26	0.37	1.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.05	0.44	1.94e-21	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	10.59	0.46	2.04e-23	Ulcerative colitis;
LUAD	trans	rs3857536	0.813	rs7757647	chr6:66947207	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	cis	rs3849570	0.555	rs6790351	chr3:82008988	C/T	cg07356753	chr3:81810745	GBE1	-0.52	-8.7	-0.39	7.45e-17	Waist circumference;Body mass index;
LUAD	cis	rs877282	0.898	rs10904546	chr10:757222	A/G	cg17470449	chr10:769945	NA	0.58	7.89	0.36	2.63e-14	Uric acid levels;
LUAD	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg08514558	chr10:81106712	PPIF	0.51	9.8	0.43	1.48e-20	Height;
LUAD	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg13685833	chr1:53393034	SCP2	-0.5	-8.25	-0.37	2.08e-15	Monocyte count;
LUAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10150615	chr22:24372951	LOC391322	-0.56	-9.25	-0.41	1.08e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11112613	0.609	rs6539218	chr12:105934875	C/T	cg03607813	chr12:105948248	NA	0.68	9.69	0.43	3.49e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg18402987	chr7:1209562	NA	0.63	9.2	0.41	1.63e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs2066819	1.000	rs78121408	chr12:56684798	C/T	cg26714650	chr12:56694279	CS	-0.86	-7.23	-0.33	2.25e-12	Psoriasis vulgaris;
LUAD	cis	rs12681287	0.640	rs7832493	chr8:87371533	A/C	cg27223183	chr8:87520930	FAM82B	0.68	9.54	0.42	1.19e-19	Caudate activity during reward;
LUAD	cis	rs113835537	0.529	rs57634456	chr11:66250838	A/C	cg26679405	chr11:66247800	DPP3	-0.44	-6.49	-0.3	2.46e-10	Airway imaging phenotypes;
LUAD	cis	rs733175	0.830	rs714873	chr4:10059618	G/A	cg00071950	chr4:10020882	SLC2A9	0.46	7.14	0.33	4.19e-12	Psychosis and Alzheimer's disease;
LUAD	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg15664640	chr17:80829946	TBCD	0.6	11.58	0.49	4e-27	Breast cancer;
LUAD	cis	rs2019216	0.500	rs4325621	chr17:21926257	T/G	cg22648282	chr17:21454238	C17orf51	-0.47	-7.94	-0.36	1.89e-14	Pelvic organ prolapse;
LUAD	cis	rs76878669	0.561	rs10750784	chr11:66110666	A/G	cg18002602	chr11:66138449	SLC29A2	-0.49	-10.59	-0.46	2.0500000000000001e-23	Educational attainment (years of education);
LUAD	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg13918804	chr1:2043761	PRKCZ	0.41	6.94	0.32	1.44e-11	Height;
LUAD	cis	rs754466	1.000	rs12220311	chr10:79681507	C/T	cg17075019	chr10:79541650	NA	-0.83	-13.74	-0.56	8.56e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10484885	0.878	rs17763820	chr6:90569634	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.63	-6.59	-0.31	1.3100000000000001e-10	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs4268898	1.000	rs6746005	chr2:24434345	G/A	cg02683114	chr2:24398427	C2orf84	0.42	6.99	0.32	1.08e-11	Asthma;
LUAD	trans	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg21659725	chr3:3221576	CRBN	0.38	6.4	0.3	4.15e-10	Resting heart rate;
LUAD	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg06387496	chr7:2775674	GNA12	0.38	6.5	0.3	2.32e-10	Height;
LUAD	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.33	0.34	1.2e-12	Blood metabolite levels;
LUAD	cis	rs2625529	0.530	rs2959930	chr15:72598614	A/G	cg16672083	chr15:72433130	SENP8	-0.63	-10.72	-0.46	6.73e-24	Red blood cell count;
LUAD	cis	rs62400317	0.826	rs12205468	chr6:45310285	G/A	cg20913747	chr6:44695427	NA	-0.41	-6.66	-0.31	8.48e-11	Total body bone mineral density;
LUAD	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg24596788	chr1:163392923	NA	0.36	7.98	0.36	1.44e-14	Motion sickness;
LUAD	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg02160872	chr5:212506	CCDC127	-0.49	-6.41	-0.3	3.96e-10	Breast cancer;
LUAD	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg18180107	chr4:99064573	C4orf37	0.4	6.48	0.3	2.54e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg00383909	chr3:49044727	WDR6	0.97	10.36	0.45	1.44e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs4664304	1.000	rs3806603	chr2:160761808	T/C	cg06573604	chr2:160760825	LY75	-0.39	-6.58	-0.3	1.36e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs112990264	0.656	rs6540756	chr1:212878828	C/T	cg01785514	chr1:212988523	TATDN3	0.96	8.92	0.4	1.41e-17	Itch intensity from mosquito bite;
LUAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.53	-8.51	-0.38	3.13e-16	Longevity;Endometriosis;
LUAD	cis	rs9560113	0.960	rs9560101	chr13:112173798	G/A	cg14154082	chr13:112174009	NA	0.36	6.66	0.31	8.28e-11	Menarche (age at onset);
LUAD	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg19346786	chr7:2764209	NA	-0.52	-11.29	-0.48	5.34e-26	Height;
LUAD	cis	rs4711350	0.954	rs943464	chr6:33731469	A/G	cg07979401	chr6:33739406	LEMD2	0.47	8.08	0.37	6.69e-15	Schizophrenia;
LUAD	trans	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg14917512	chr19:3094685	GNA11	-0.56	-6.66	-0.31	8.45e-11	Diabetic kidney disease;
LUAD	cis	rs9902453	0.726	rs3110494	chr17:27976597	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.78	0.43	1.72e-20	Coffee consumption (cups per day);
LUAD	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg12698349	chr2:225449008	CUL3	0.69	10.26	0.45	3.35e-22	IgE levels in asthmatics (D.p. specific);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	ch.2.195648145F	chr2:195939902	NA	-0.36	-6.57	-0.3	1.46e-10	Subcortical brain region volumes;
LUAD	cis	rs758324	0.648	rs31473	chr5:131404446	A/T	cg06307176	chr5:131281290	NA	-0.39	-6.67	-0.31	8.06e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg21475434	chr5:93447410	FAM172A	-0.48	-6.55	-0.3	1.63e-10	Diabetic retinopathy;
LUAD	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.66	0.39	1.01e-16	Menopause (age at onset);
LUAD	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg03233332	chr7:66118400	NA	-0.46	-6.88	-0.32	2.22e-11	Aortic root size;
LUAD	cis	rs9807989	0.811	rs11688559	chr2:102969913	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.03e-10	Asthma;
LUAD	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg02734326	chr4:10020555	SLC2A9	0.64	11.35	0.48	3.04e-26	Bone mineral density;
LUAD	cis	rs7809950	1.000	rs3801954	chr7:107117048	C/T	cg23024343	chr7:107201750	COG5	-0.73	-12.37	-0.52	3.32e-30	Coronary artery disease;
LUAD	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg12292205	chr6:26970375	C6orf41	-0.55	-6.75	-0.31	4.92e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs938554	0.868	rs734553	chr4:9923004	G/T	cg11266682	chr4:10021025	SLC2A9	0.42	7.52	0.34	3.4e-13	Blood metabolite levels;
LUAD	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg13679303	chr9:96623674	NA	-0.37	-7.38	-0.34	8.43e-13	DNA methylation (variation);
LUAD	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10802521	chr3:52805072	NEK4	0.55	9.34	0.41	5.51e-19	Bipolar disorder;
LUAD	cis	rs9715521	0.589	rs11726451	chr4:59852381	A/C	cg11281224	chr4:60001000	NA	-0.5	-8.26	-0.37	1.92e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg00310523	chr12:86230176	RASSF9	0.35	7.34	0.34	1.12e-12	Major depressive disorder;
LUAD	cis	rs9902453	0.765	rs2628167	chr17:28064498	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.54	-0.46	3.24e-23	Coffee consumption (cups per day);
LUAD	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg13327785	chr12:132219529	SFRS8	-0.4	-7.09	-0.33	5.75e-12	Migraine;
LUAD	cis	rs68170813	0.559	rs79978998	chr7:106845482	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-10.82	-0.47	2.96e-24	Coronary artery disease;
LUAD	cis	rs4713675	0.546	rs10947435	chr6:33718075	G/A	cg13859433	chr6:33739653	LEMD2	-0.31	-7.46	-0.34	4.83e-13	Plateletcrit;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11217840	chr2:214016358	IKZF2	-0.39	-6.65	-0.31	8.83e-11	Cancer;
LUAD	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg12193833	chr17:30244370	NA	-0.51	-6.74	-0.31	5.11e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg08222618	chr4:941054	TMEM175	0.64	10.07	0.44	1.56e-21	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.7	13.01	0.53	8.37e-33	Cognitive ability;
LUAD	cis	rs7107174	1.000	rs2450122	chr11:77930345	T/C	cg19901956	chr11:77921274	USP35	-0.53	-6.56	-0.3	1.61e-10	Testicular germ cell tumor;
LUAD	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg23985595	chr17:80112537	CCDC57	0.53	9.74	0.43	2.39e-20	Life satisfaction;
LUAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg11965913	chr1:205819406	PM20D1	0.83	17.34	0.64	2.85e-51	Menarche (age at onset);
LUAD	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg24818145	chr4:99064322	C4orf37	0.45	6.98	0.32	1.14e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	5.84e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4460629	0.680	rs10796938	chr1:155072055	C/A	cg23973274	chr1:155060172	NA	-0.37	-6.36	-0.3	5.17e-10	Serum magnesium levels;
LUAD	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg03714773	chr7:91764589	CYP51A1	-0.31	-7.25	-0.33	1.94e-12	Breast cancer;
LUAD	cis	rs116095464	1.000	rs62331560	chr5:346785	G/C	cg22496380	chr5:211416	CCDC127	-1.0	-7.76	-0.35	6.23e-14	Breast cancer;
LUAD	trans	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.43	0.45	8.36e-23	Mean corpuscular volume;
LUAD	cis	rs1639906	1.000	rs1637759	chr7:2220053	C/T	cg18044113	chr7:2236405	MAD1L1	-0.39	-7.49	-0.34	4.12e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg11062466	chr8:58055876	NA	0.8	10.1	0.44	1.27e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg04545296	chr12:48745243	ZNF641	0.38	9.59	0.42	7.76e-20	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs2731664	0.792	rs2630765	chr5:176876825	T/C	cg23176889	chr5:176863531	GRK6	-0.69	-13.06	-0.54	5.49e-33	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg20607798	chr8:58055168	NA	0.61	7.67	0.35	1.16e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg00280220	chr17:61926910	NA	0.36	7.0	0.32	9.86e-12	Prudent dietary pattern;
LUAD	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.93	-0.5	1.76e-28	Bipolar disorder;
LUAD	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg05182265	chr7:156933206	UBE3C	-0.8	-17.05	-0.64	5.49e-50	Body mass index;
LUAD	cis	rs2235649	0.746	rs35104579	chr16:1848657	A/T	cg08610935	chr16:1836813	NUBP2	-0.5	-7.64	-0.35	1.49e-13	Blood metabolite levels;
LUAD	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg20607798	chr8:58055168	NA	0.78	9.54	0.42	1.16e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.71	-13.61	-0.55	2.98e-35	Ulcerative colitis;
LUAD	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg26384229	chr12:38710491	ALG10B	0.47	7.68	0.35	1.14e-13	Morning vs. evening chronotype;
LUAD	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg03037974	chr15:76606532	NA	0.38	8.04	0.36	9.03e-15	Blood metabolite levels;
LUAD	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg18944383	chr4:111397179	ENPEP	0.37	6.78	0.31	3.95e-11	Coronary artery disease;
LUAD	cis	rs6445967	0.530	rs72624863	chr3:58365300	A/G	cg23715586	chr3:58305044	RPP14	0.41	6.69	0.31	7.23e-11	Platelet count;
LUAD	cis	rs9914544	0.564	rs7223173	chr17:18805887	A/G	cg25390199	chr17:18761479	PRPSAP2	-0.39	-6.57	-0.3	1.45e-10	Educational attainment (years of education);
LUAD	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg01528321	chr10:82214614	TSPAN14	0.75	11.31	0.48	4.36e-26	Post bronchodilator FEV1;
LUAD	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg21138405	chr5:131827807	IRF1	0.56	12.03	0.51	6.92e-29	Asthma (sex interaction);
LUAD	cis	rs6754311	0.517	rs1469995	chr2:136542559	G/A	cg07169764	chr2:136633963	MCM6	0.64	8.2	0.37	2.84e-15	Mosquito bite size;
LUAD	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg11663144	chr21:46675770	NA	-0.6	-11.83	-0.5	4.19e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.47e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg03806693	chr22:41940476	POLR3H	0.73	10.09	0.44	1.35e-21	Vitiligo;
LUAD	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg02527881	chr3:46936655	PTH1R	-0.57	-11.8	-0.5	5.54e-28	Colorectal cancer;
LUAD	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg20607798	chr8:58055168	NA	0.81	9.81	0.43	1.36e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.4	-0.34	7.51e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs12976411	0.575	rs35798291	chr19:32826264	T/C	cg18253629	chr19:32836317	ZNF507	0.65	6.86	0.32	2.38e-11	Coronary artery disease;
LUAD	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg04398451	chr17:18023971	MYO15A	-0.88	-16.63	-0.63	3.77e-48	Total body bone mineral density;
LUAD	cis	rs758324	0.947	rs6596040	chr5:131198777	C/T	cg25547332	chr5:131281432	NA	0.44	6.7	0.31	6.68e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	6.45	0.3	3.14e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg11707310	chr1:2537719	MMEL1	-0.4	-8.78	-0.39	4.03e-17	Ulcerative colitis;
LUAD	trans	rs701145	0.938	rs355768	chr3:154045001	A/G	cg14299572	chr10:34021103	NA	-0.39	-6.45	-0.3	3.12e-10	Coronary artery disease;
LUAD	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.57	9.84	0.43	1.06e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs10838798	0.504	rs11039530	chr11:48145746	C/T	cg21153622	chr11:89784906	NA	-0.35	-7.0	-0.32	9.99e-12	Height;
LUAD	cis	rs490234	0.719	rs13287525	chr9:128219180	T/C	cg14078157	chr9:128172775	NA	-0.49	-9.09	-0.4	3.74e-18	Mean arterial pressure;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24149930	chr19:33182641	NUDT19	-0.6	-7.25	-0.33	2e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7224314	1.000	rs62084078	chr17:65386886	T/C	cg01507342	chr17:65387096	PITPNC1	-0.55	-9.2	-0.41	1.66e-18	Diisocyanate-induced asthma;
LUAD	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg27068330	chr11:65405492	SIPA1	-0.76	-11.64	-0.49	2.4200000000000002e-27	Acne (severe);
LUAD	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg15744005	chr10:104629667	AS3MT	-0.35	-6.88	-0.32	2.1e-11	Arsenic metabolism;
LUAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03452623	chr4:187889614	NA	-0.83	-17.3	-0.64	4.07e-51	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg15605315	chr1:45957053	TESK2	0.44	6.79	0.31	3.74e-11	High light scatter reticulocyte count;
LUAD	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg03929089	chr4:120376271	NA	-0.46	-7.11	-0.33	4.93e-12	Height;
LUAD	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg08085267	chr17:45401833	C17orf57	-0.69	-13.07	-0.54	4.96e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7759001	0.817	rs9461380	chr6:27363557	G/T	cg18711553	chr6:27366782	ZNF391	0.39	6.52	0.3	2.05e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg04539111	chr16:67997858	SLC12A4	-0.52	-6.59	-0.31	1.29e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg13565492	chr6:43139072	SRF	-0.75	-9.99	-0.44	3.04e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg14228332	chr4:119757509	SEC24D	0.86	7.55	0.34	2.73e-13	Cannabis dependence symptom count;
LUAD	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg25324976	chr17:61989376	CSHL1	-0.38	-7.29	-0.33	1.52e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2274273	0.588	rs2880103	chr14:55737832	A/C	cg04306507	chr14:55594613	LGALS3	0.42	8.01	0.36	1.1e-14	Protein biomarker;
LUAD	cis	rs9341808	0.667	rs10943698	chr6:80934301	C/T	cg08355045	chr6:80787529	NA	0.48	8.53	0.38	2.55e-16	Sitting height ratio;
LUAD	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg23711669	chr6:146136114	FBXO30	0.38	6.52	0.3	2.01e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg15128208	chr22:42549153	NA	-0.43	-8.94	-0.4	1.23e-17	Cognitive function;
LUAD	cis	rs2554380	0.657	rs4530091	chr15:84482778	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.39	-6.52	-0.3	1.95e-10	Height;
LUAD	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg06002616	chr8:101225028	SPAG1	-0.4	-8.19	-0.37	3.15e-15	Atrioventricular conduction;
LUAD	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg26384229	chr12:38710491	ALG10B	-0.43	-7.35	-0.34	1.04e-12	Morning vs. evening chronotype;
LUAD	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg12935359	chr14:103987150	CKB	-0.46	-7.41	-0.34	6.86e-13	Body mass index;
LUAD	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg03676636	chr4:99064102	C4orf37	0.3	7.32	0.34	1.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg06074448	chr4:187884817	NA	0.39	7.94	0.36	1.81e-14	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6496044	0.611	rs8026938	chr15:86069118	G/T	cg13263323	chr15:86062960	AKAP13	0.59	11.25	0.48	7.34e-26	Interstitial lung disease;
LUAD	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg09796270	chr17:17721594	SREBF1	0.37	7.08	0.33	6.11e-12	Total body bone mineral density;
LUAD	cis	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.79	-0.35	5.25e-14	Neuroticism;
LUAD	cis	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg21775007	chr8:11205619	TDH	0.54	9.81	0.43	1.29e-20	Retinal vascular caliber;
LUAD	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg16325326	chr1:53192061	ZYG11B	0.72	13.81	0.56	4.42e-36	Monocyte count;
LUAD	cis	rs7945718	0.805	rs6486059	chr11:12824581	A/G	cg25843174	chr11:12811716	TEAD1	-0.22	-6.69	-0.31	7.09e-11	Educational attainment (years of education);
LUAD	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.48	-0.34	4.3e-13	Menarche (age at onset);
LUAD	cis	rs938554	0.513	rs3733588	chr4:9997303	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.47	-0.34	4.5e-13	Blood metabolite levels;
LUAD	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg06873352	chr17:61820015	STRADA	0.43	7.13	0.33	4.34e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.32e-11	Breast cancer;
LUAD	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	8.88e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs755249	0.508	rs624971	chr1:39858947	C/T	cg27567593	chr1:39956653	BMP8A	-0.36	-7.29	-0.33	1.49e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2279817	1.000	rs35148872	chr1:18020184	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.54	-8.23	-0.37	2.35e-15	Neuroticism;
LUAD	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.56	-0.3	1.54e-10	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.85	0.43	9.44e-21	Ulcerative colitis;
LUAD	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg26408565	chr15:76604113	ETFA	-0.47	-7.87	-0.36	3.07e-14	Blood metabolite levels;
LUAD	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg15147215	chr3:52552868	STAB1	-0.37	-7.1	-0.33	5.36e-12	Bipolar disorder;
LUAD	cis	rs9427116	0.502	rs3766922	chr1:154577055	A/C	cg17218026	chr1:154582156	ADAR	0.47	9.37	0.41	4.31e-19	Blood protein levels;
LUAD	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11890956	chr21:40555474	PSMG1	0.75	12.87	0.53	3.39e-32	Cognitive function;
LUAD	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg14343924	chr8:8086146	FLJ10661	-0.39	-6.35	-0.3	5.47e-10	Triglycerides;
LUAD	cis	rs354225	0.584	rs7586311	chr2:54810762	A/G	cg26097391	chr2:54893211	SPTBN1	0.42	6.49	0.3	2.47e-10	Schizophrenia;
LUAD	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.14	-0.33	4.18e-12	Schizophrenia;
LUAD	cis	rs733592	1.000	rs1859440	chr12:48427329	T/C	cg24011408	chr12:48396354	COL2A1	-0.35	-7.31	-0.33	1.34e-12	Plateletcrit;
LUAD	cis	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg11143507	chr3:125485238	NA	-0.44	-7.28	-0.33	1.64e-12	Blood pressure (smoking interaction);
LUAD	cis	rs7582720	1.000	rs72926783	chr2:203815740	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg24818145	chr4:99064322	C4orf37	0.48	8.14	0.37	4.61e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9788682	0.747	rs2656073	chr15:78742276	G/T	cg18825076	chr15:78729989	IREB2	0.54	7.56	0.34	2.57e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg00898013	chr13:113819073	PROZ	-0.81	-14.94	-0.59	7.74e-41	Platelet distribution width;
LUAD	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg07741184	chr6:167504864	NA	0.36	8.12	0.37	5.12e-15	Primary biliary cholangitis;
LUAD	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg18198730	chr1:247681584	NA	0.43	7.66	0.35	1.25e-13	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09542690	chr3:44519182	ZNF445	-0.67	-6.48	-0.3	2.6e-10	Type 2 diabetes;
LUAD	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg17757837	chr7:157058334	UBE3C	0.48	8.54	0.38	2.4e-16	Body mass index;
LUAD	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg15448220	chr1:150897856	SETDB1	0.49	8.25	0.37	1.99e-15	Melanoma;
LUAD	trans	rs1941687	0.563	rs1565784	chr18:31358491	G/T	cg13755796	chr4:20253514	NA	0.39	6.69	0.31	7.15e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01570182	chr17:44337453	NA	1.07	15.77	0.61	2.11e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.51	-0.3	2.17e-10	Depression;
LUAD	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.25	-0.33	2.06e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs989128	0.600	rs73338243	chr17:48631324	T/C	cg24438145	chr17:48624694	SPATA20	0.38	6.58	0.3	1.37e-10	Type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg08888203	chr3:10149979	C3orf24	0.7	12.44	0.52	1.79e-30	Alzheimer's disease;
LUAD	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.57	10.03	0.44	2.2e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg15900387	chr1:150738905	CTSS	-0.37	-6.77	-0.31	4.18e-11	Urate levels;
LUAD	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	11.18	0.48	1.31e-25	Bone mineral density;
LUAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg11941060	chr3:133502564	NA	-0.65	-11.5	-0.49	7.76e-27	Iron status biomarkers;
LUAD	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg25173405	chr17:45401733	C17orf57	-0.49	-8.09	-0.37	6.37e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9811920	0.809	rs793443	chr3:99573547	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.6	-11.6	-0.49	3.24e-27	Axial length;
LUAD	cis	rs926938	0.563	rs360586	chr1:115467489	A/G	cg12756093	chr1:115239321	AMPD1	0.38	6.5	0.3	2.26e-10	Autism;
LUAD	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg27446573	chr6:127587934	RNF146	0.43	6.47	0.3	2.72e-10	Breast cancer;
LUAD	trans	rs208520	0.690	rs207118	chr6:66788948	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.32	-0.64	3.48e-51	Exhaled nitric oxide output;
LUAD	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-9.05	-0.4	5.16e-18	Life satisfaction;
LUAD	cis	rs1045714	0.895	rs4719594	chr7:2639790	G/A	cg20813462	chr7:2646259	IQCE	0.67	7.51	0.34	3.51e-13	Urate levels in lean individuals;
LUAD	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg26513180	chr16:89883248	FANCA	0.69	6.51	0.3	2.18e-10	Skin colour saturation;
LUAD	cis	rs7172809	0.599	rs10519158	chr15:77412457	G/C	cg11865553	chr15:77376250	NA	-0.39	-6.46	-0.3	2.87e-10	Glucose homeostasis traits;
LUAD	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg21220214	chr8:57350948	NA	-0.59	-8.64	-0.39	1.14e-16	Obesity-related traits;
LUAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg18402987	chr7:1209562	NA	-0.4	-6.41	-0.3	3.97e-10	Longevity;Endometriosis;
LUAD	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg25894440	chr7:65020034	NA	0.63	6.64	0.31	9.86e-11	Diabetic kidney disease;
LUAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13126279	chr21:47581558	C21orf56	0.62	11.4	0.48	1.91e-26	Testicular germ cell tumor;
LUAD	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg22681709	chr2:178499509	PDE11A	-0.5	-6.65	-0.31	9.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9341808	0.935	rs2322633	chr6:80845989	C/T	cg08355045	chr6:80787529	NA	-0.48	-8.87	-0.4	2.03e-17	Sitting height ratio;
LUAD	cis	rs3857067	0.806	rs2865343	chr4:95103005	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.38	-6.63	-0.31	1.01e-10	QT interval;
LUAD	trans	rs11650494	0.908	rs73324323	chr17:47420054	G/T	cg11430096	chr6:110968061	CDK19	0.86	6.8	0.31	3.58e-11	Prostate cancer;
LUAD	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg03929089	chr4:120376271	NA	-0.81	-14.3	-0.57	4.14e-38	Height;
LUAD	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg15017067	chr4:17643749	FAM184B	0.34	6.55	0.3	1.66e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15541040	chr2:3486749	NA	-0.43	-7.43	-0.34	6.1e-13	Neurofibrillary tangles;
LUAD	cis	rs2286885	1.000	rs10819169	chr9:129249625	C/T	cg15282417	chr9:129245246	FAM125B	0.45	9.14	0.41	2.73e-18	Intraocular pressure;
LUAD	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.53	-0.34	3.02e-13	Total cholesterol levels;
LUAD	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18876405	chr7:65276391	NA	-0.41	-6.47	-0.3	2.72e-10	Aortic root size;
LUAD	cis	rs9560113	0.960	rs4773378	chr13:112174154	G/A	cg14154082	chr13:112174009	NA	0.36	6.66	0.31	8.28e-11	Menarche (age at onset);
LUAD	cis	rs2046867	0.862	rs62251656	chr3:72827393	T/C	cg25664220	chr3:72788482	NA	-0.66	-11.55	-0.49	5.04e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.11	-0.33	4.84e-12	Blood metabolite levels;
LUAD	cis	rs73416724	1.000	rs78567061	chr6:43293446	G/A	cg26312998	chr6:43337775	ZNF318	0.57	6.83	0.32	2.97e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10193935	0.901	rs222471	chr2:42638057	C/T	cg27598129	chr2:42591480	NA	0.71	9.4	0.42	3.42e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73195822	0.506	rs55948838	chr12:111142793	C/T	cg12870014	chr12:110450643	ANKRD13A	0.62	7.09	0.33	5.55e-12	Itch intensity from mosquito bite;
LUAD	trans	rs1493916	1.000	rs990882	chr18:31398180	T/G	cg27147174	chr7:100797783	AP1S1	-0.67	-11.71	-0.49	1.26e-27	Life satisfaction;
LUAD	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg12373951	chr3:133503437	NA	0.37	7.16	0.33	3.54e-12	Iron status biomarkers;
LUAD	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.52	-0.3	2.03e-10	Breast cancer;
LUAD	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg07570687	chr10:102243282	WNT8B	0.42	6.36	0.3	5.14e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg17264618	chr3:40429014	ENTPD3	0.42	8.87	0.4	2.11e-17	Renal cell carcinoma;
LUAD	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-10.37	-0.45	1.33e-22	Gut microbiome composition (summer);
LUAD	cis	rs2806561	0.929	rs627304	chr1:23537555	A/G	cg12483005	chr1:23474871	LUZP1	0.39	6.56	0.3	1.6e-10	Height;
LUAD	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs2742234	1.000	rs1864395	chr10:43655697	G/A	cg02780029	chr10:43622663	RET	-0.43	-7.11	-0.33	5.14e-12	Hirschsprung disease;
LUAD	cis	rs4730250	0.707	rs80095766	chr7:106901394	G/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.58	-0.46	2.2e-23	Osteoarthritis;
LUAD	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg04546413	chr19:29218101	NA	0.59	7.58	0.35	2.25e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs68170813	0.617	rs76923959	chr7:107182915	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-9.09	-0.4	3.86e-18	Coronary artery disease;
LUAD	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg14779329	chr11:130786720	SNX19	0.39	6.83	0.32	2.93e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs9393777	0.778	rs13212921	chr6:27205422	C/T	cg01620082	chr3:125678407	NA	-0.83	-9.01	-0.4	7.39e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg15790184	chr11:494944	RNH1	0.54	6.66	0.31	8.28e-11	Body mass index;
LUAD	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg02683114	chr2:24398427	C2orf84	-0.52	-7.75	-0.35	7.03e-14	Asthma;
LUAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-8.7	-0.39	7.63e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7737355	0.947	rs32115	chr5:131051328	A/G	cg25547332	chr5:131281432	NA	0.45	7.03	0.32	8.42e-12	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.24	0.37	2.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8010715	0.520	rs12435994	chr14:24589461	A/C	cg23112188	chr14:24563095	PCK2	-0.32	-6.45	-0.3	3.01e-10	IgG glycosylation;
LUAD	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg12179176	chr11:130786555	SNX19	0.54	9.09	0.4	3.73e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg11814155	chr7:99998594	ZCWPW1	0.45	7.82	0.36	4.35e-14	Platelet count;
LUAD	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg18512352	chr11:47633146	NA	-0.56	-10.04	-0.44	2.02e-21	Subjective well-being;
LUAD	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg11859384	chr17:80120422	CCDC57	0.47	8.23	0.37	2.34e-15	Life satisfaction;
LUAD	cis	rs516243	0.703	rs284262	chr1:10743363	T/C	cg02903756	chr1:10750680	CASZ1	-0.49	-9.22	-0.41	1.45e-18	Migraine - clinic-based;
LUAD	cis	rs4774899	0.966	rs12917093	chr15:57522301	G/T	cg14026238	chr15:57616123	NA	0.35	6.64	0.31	9.63e-11	Urinary tract infection frequency;
LUAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg15117754	chr3:10150083	C3orf24	0.42	6.68	0.31	7.38e-11	Alzheimer's disease;
LUAD	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg19980929	chr12:42632907	YAF2	0.34	6.56	0.3	1.61e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.41	7.07	0.33	6.31e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	8.16	0.37	3.87e-15	Tonsillectomy;
LUAD	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg17279839	chr7:150038598	RARRES2	0.45	7.45	0.34	5.2e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg18180107	chr4:99064573	C4orf37	0.43	6.9	0.32	1.93e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.59	0.31	1.32e-10	Prudent dietary pattern;
LUAD	cis	rs6754311	0.517	rs1865452	chr2:136539330	C/T	cg07169764	chr2:136633963	MCM6	0.64	8.29	0.37	1.52e-15	Mosquito bite size;
LUAD	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg06112835	chr11:68658793	MRPL21	0.5	8.86	0.4	2.27e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg06547715	chr2:218990976	CXCR2	0.28	6.83	0.32	3.03e-11	Colorectal cancer;
LUAD	trans	rs1493916	1.000	rs9964702	chr18:31390427	A/C	cg27147174	chr7:100797783	AP1S1	-0.67	-11.83	-0.5	4.24e-28	Life satisfaction;
LUAD	cis	rs1595825	0.891	rs73054867	chr2:198700417	C/G	cg10547527	chr2:198650123	BOLL	-0.55	-7.93	-0.36	2.03e-14	Ulcerative colitis;
LUAD	cis	rs1451375	1.000	rs921451	chr7:50623285	A/G	cg18232548	chr7:50535776	DDC	0.58	9.63	0.42	5.65e-20	Malaria;
LUAD	cis	rs9581857	0.547	rs9579094	chr13:28081495	G/A	cg22138327	chr13:27999177	GTF3A	0.85	9.02	0.4	6.56e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18876405	chr7:65276391	NA	-0.56	-9.45	-0.42	2.41e-19	Aortic root size;
LUAD	cis	rs6942407	0.546	rs2373387	chr7:86745948	T/G	cg02420886	chr7:86849541	C7orf23	0.56	6.67	0.31	7.9e-11	Food allergy;
LUAD	cis	rs3862030	0.720	rs1056744	chr10:104236687	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-8.23	-0.37	2.26e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg02985366	chr16:32360428	NA	-0.42	-7.35	-0.34	1.06e-12	Menopause (age at onset);
LUAD	trans	rs55780018	0.645	rs12998817	chr2:208500945	A/G	cg16143763	chr17:41116517	AARSD1	0.38	6.59	0.31	1.3e-10	Systolic blood pressure;
LUAD	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-10.31	-0.45	2.22e-22	Electroencephalogram traits;
LUAD	cis	rs17401966	1.000	rs12130220	chr1:10359944	T/G	cg15208524	chr1:10270712	KIF1B	0.55	8.29	0.37	1.56e-15	Hepatocellular carcinoma;
LUAD	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	6.4	0.3	4.06e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg24308560	chr3:49941425	MST1R	-0.53	-8.6	-0.39	1.52e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.59	0.31	1.28e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	10.13	0.44	9.75e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg06627628	chr2:24431161	ITSN2	-0.5	-8.26	-0.37	1.85e-15	Asthma;
LUAD	cis	rs7193541	0.684	rs4887783	chr16:74700743	G/C	cg01733217	chr16:74700730	RFWD3	0.69	13.39	0.55	2.53e-34	Multiple myeloma;
LUAD	cis	rs4660214	0.666	rs11205698	chr1:39624380	C/T	cg27567593	chr1:39956653	BMP8A	0.32	6.36	0.3	5.35e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg27446573	chr6:127587934	RNF146	0.45	6.61	0.31	1.18e-10	Breast cancer;
LUAD	cis	rs8027181	1.000	rs8027181	chr15:73088869	A/T	cg25632853	chr15:73088954	NA	0.37	8.24	0.37	2.19e-15	Triglyceride levels;
LUAD	cis	rs2019216	0.500	rs908696	chr17:21940987	T/G	cg22648282	chr17:21454238	C17orf51	-0.43	-6.67	-0.31	7.97e-11	Pelvic organ prolapse;
LUAD	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg25319279	chr11:5960081	NA	-0.38	-6.72	-0.31	5.97e-11	DNA methylation (variation);
LUAD	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg16414030	chr3:133502952	NA	-0.52	-9.46	-0.42	2.18e-19	Iron status biomarkers;
LUAD	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg20578329	chr17:80767326	TBCD	0.64	8.25	0.37	1.98e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg25382214	chr1:3105252	PRDM16	-0.33	-6.67	-0.31	7.92e-11	Migraine;
LUAD	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.54	-9.55	-0.42	1.05e-19	Axial length;
LUAD	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.39	-0.38	7.54e-16	Neutrophil percentage of white cells;
LUAD	trans	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg19862616	chr7:65841803	NCRNA00174	1.05	26.51	0.79	5.76e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7809615	0.901	rs6947941	chr7:99156446	G/T	cg12290671	chr7:99195819	NA	-0.72	-8.05	-0.36	8.6e-15	Blood metabolite ratios;
LUAD	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg00603274	chr11:61596626	FADS2	-0.38	-6.8	-0.31	3.68e-11	Trans fatty acid levels;
LUAD	trans	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg18834416	chr8:37888184	EIF4EBP1	0.4	6.6	0.31	1.2e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2249625	0.874	rs2463733	chr6:72882996	T/C	cg18830697	chr6:72922368	RIMS1	-0.36	-6.78	-0.31	4.01e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg06784218	chr1:46089804	CCDC17	0.5	10.92	0.47	1.22e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg12573674	chr2:1569213	NA	-0.59	-6.98	-0.32	1.13e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg18477163	chr1:228402036	OBSCN	-0.38	-7.61	-0.35	1.86e-13	Diastolic blood pressure;
LUAD	cis	rs4356932	0.967	rs4859591	chr4:76948578	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.49	-0.3	2.36e-10	Blood protein levels;
LUAD	cis	rs17401966	0.838	rs55676616	chr1:10290126	T/C	cg15208524	chr1:10270712	KIF1B	0.44	6.69	0.31	6.96e-11	Hepatocellular carcinoma;
LUAD	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg21856205	chr7:94953877	PON1	-0.56	-7.98	-0.36	1.39e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg26924012	chr15:45694286	SPATA5L1	1.02	18.85	0.68	5.65e-58	Homoarginine levels;
LUAD	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	7.99	0.36	1.26e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.37	0.34	9.06e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg06873684	chr19:4472059	HDGF2	-0.41	-7.05	-0.32	7.34e-12	Subcortical brain region volumes;
LUAD	cis	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	7.78	0.35	5.42e-14	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs77741769	0.571	rs4766979	chr12:121281748	G/A	cg02419362	chr12:121203948	SPPL3	0.43	8.76	0.39	4.59e-17	Mean corpuscular volume;
LUAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg18402987	chr7:1209562	NA	0.74	9.98	0.44	3.45e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19717773	chr7:2847554	GNA12	-0.55	-9.42	-0.42	2.94e-19	Height;
LUAD	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.5	-0.3	2.29e-10	Coronary artery disease;
LUAD	cis	rs55665837	1.000	rs34980103	chr11:14512885	C/T	cg19336497	chr11:14380999	RRAS2	-0.5	-9.97	-0.44	3.71e-21	Vitamin D levels;
LUAD	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs10927875	0.691	rs2017583	chr1:16350028	A/G	cg21214613	chr1:16344536	HSPB7	0.58	10.25	0.45	3.67e-22	Dilated cardiomyopathy;
LUAD	cis	rs4662945	0.603	rs2406981	chr2:130305487	A/G	cg05962382	chr2:130345044	NA	-0.39	-7.26	-0.33	1.81e-12	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs7937890	0.559	rs2575836	chr11:14497864	T/G	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.25e-11	Mitochondrial DNA levels;
LUAD	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg11766577	chr21:47581405	C21orf56	0.51	8.36	0.38	8.94e-16	Testicular germ cell tumor;
LUAD	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12379764	chr21:47803548	PCNT	0.53	8.13	0.37	4.87e-15	Testicular germ cell tumor;
LUAD	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg15997130	chr1:24165203	NA	0.56	9.98	0.44	3.26e-21	Immature fraction of reticulocytes;
LUAD	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg05754148	chr16:3507555	NAT15	-0.71	-10.37	-0.45	1.36e-22	Tuberculosis;
LUAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg08219700	chr8:58056026	NA	0.42	6.4	0.3	4.12e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg02569458	chr12:86230093	RASSF9	0.46	8.34	0.38	1.06e-15	Major depressive disorder;
LUAD	cis	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg12623302	chr6:28058802	ZSCAN12L1	0.53	6.52	0.3	1.99e-10	Depression;
LUAD	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg01884057	chr2:25150051	NA	0.33	7.13	0.33	4.49e-12	Body mass index;
LUAD	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg17279839	chr7:150038598	RARRES2	0.46	7.72	0.35	8.28e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg13126279	chr21:47581558	C21orf56	-0.44	-7.56	-0.35	2.46e-13	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.95e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg22676075	chr6:135203613	NA	0.39	7.17	0.33	3.44e-12	Red blood cell count;
LUAD	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.94	0.32	1.47e-11	Blood metabolite levels;
LUAD	trans	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg11693508	chr17:37793320	STARD3	0.6	7.65	0.35	1.35e-13	Neuroticism;
LUAD	cis	rs684232	0.602	rs331010	chr17:547124	G/A	cg15660573	chr17:549704	VPS53	-0.88	-18.37	-0.67	7.54e-56	Prostate cancer;
LUAD	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg20291162	chr17:40259547	DHX58	0.72	11.19	0.48	1.24e-25	Fibrinogen levels;
LUAD	cis	rs9469890	0.604	rs76452512	chr6:34504388	G/C	cg14254433	chr6:34482411	PACSIN1	-0.61	-8.55	-0.38	2.25e-16	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg17105886	chr17:28927953	LRRC37B2	0.68	7.76	0.35	6.28e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg04995722	chr7:26192034	NFE2L3	0.44	7.61	0.35	1.77e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11112613	0.713	rs12316204	chr12:105944244	G/A	cg03607813	chr12:105948248	NA	0.83	14.01	0.56	6.86e-37	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg16405210	chr4:1374714	KIAA1530	-0.63	-9.67	-0.43	4.03e-20	Longevity;
LUAD	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg05368731	chr17:41323189	NBR1	0.95	19.41	0.69	1.72e-60	Menopause (age at onset);
LUAD	cis	rs9283706	0.608	rs13171572	chr5:66334552	T/A	cg11590213	chr5:66331682	MAST4	0.41	6.64	0.31	9.84e-11	Coronary artery disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14906687	chr6:157099894	ARID1B	-0.43	-6.71	-0.31	6.43e-11	Height;
LUAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg21724239	chr8:58056113	NA	0.72	8.74	0.39	5.32e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg22823121	chr1:150693482	HORMAD1	0.48	9.38	0.41	4.07e-19	Melanoma;
LUAD	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.34	0.34	1.13e-12	Bipolar disorder;
LUAD	cis	rs76878669	0.561	rs7105015	chr11:66159390	A/G	cg18002602	chr11:66138449	SLC29A2	0.49	10.37	0.45	1.39e-22	Educational attainment (years of education);
LUAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg10295955	chr4:187884368	NA	-1.14	-27.96	-0.81	3.52e-98	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg21775007	chr8:11205619	TDH	0.55	9.87	0.43	8.03e-21	Retinal vascular caliber;
LUAD	trans	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg11693508	chr17:37793320	STARD3	0.75	10.15	0.44	8.17e-22	Bipolar disorder;
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg21548813	chr6:291882	DUSP22	0.76	13.06	0.54	5.43e-33	Menopause (age at onset);
LUAD	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-8.18	-0.37	3.24e-15	Type 2 diabetes;
LUAD	cis	rs12760731	0.920	rs74226628	chr1:178484594	T/C	cg00404053	chr1:178313656	RASAL2	0.6	6.73	0.31	5.59e-11	Obesity-related traits;
LUAD	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg14582100	chr15:45693742	SPATA5L1	0.55	10.41	0.45	9.61e-23	Homoarginine levels;
LUAD	cis	rs2046867	0.862	rs6788139	chr3:72835630	A/G	cg25664220	chr3:72788482	NA	0.63	11.15	0.48	1.76e-25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs17401966	0.838	rs4846209	chr1:10322054	G/A	cg15208524	chr1:10270712	KIF1B	0.43	6.7	0.31	6.87e-11	Hepatocellular carcinoma;
LUAD	cis	rs2230307	0.536	rs11166384	chr1:100439890	C/T	cg20868668	chr1:100435035	SLC35A3	0.55	7.82	0.36	4.36e-14	Carotid intima media thickness;
LUAD	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg02569458	chr12:86230093	RASSF9	0.44	8.09	0.37	6.59e-15	Major depressive disorder;
LUAD	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg10518543	chr12:38710700	ALG10B	0.41	6.35	0.3	5.54e-10	Heart rate;
LUAD	cis	rs863345	0.535	rs12064570	chr1:158499631	T/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.52	-0.3	2.01e-10	Pneumococcal bacteremia;
LUAD	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg07636037	chr3:49044803	WDR6	-0.5	-8.3	-0.37	1.43e-15	Menarche (age at onset);
LUAD	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg24829409	chr8:58192753	C8orf71	-0.59	-6.99	-0.32	1.07e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs8192282	0.739	rs7513603	chr1:154481158	T/C	cg07911225	chr1:154474108	TDRD10;SHE	-0.44	-7.38	-0.34	8.43e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg27661571	chr11:113659931	NA	-0.53	-6.55	-0.3	1.64e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg13685833	chr1:53393034	SCP2	-0.4	-6.71	-0.31	6.39e-11	Monocyte count;
LUAD	cis	rs1843834	1.000	rs1565072	chr2:225545245	C/T	cg22455342	chr2:225449267	CUL3	-0.46	-6.61	-0.31	1.13e-10	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs4888262	0.526	rs7191754	chr16:74610850	G/T	cg01733217	chr16:74700730	RFWD3	0.51	8.62	0.39	1.35e-16	Testicular germ cell tumor;
LUAD	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-23.61	-0.75	3.15e-79	Height;
LUAD	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg10909506	chr17:38081995	ORMDL3	0.37	6.52	0.3	1.96e-10	Self-reported allergy;
LUAD	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg12119029	chr16:89752879	CDK10	0.31	6.63	0.31	1.03e-10	Hemoglobin concentration;
LUAD	cis	rs240764	0.645	rs240111	chr6:101059499	C/A	cg09795085	chr6:101329169	ASCC3	0.39	6.79	0.31	3.7e-11	Neuroticism;
LUAD	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg22906224	chr7:99728672	NA	0.55	9.5	0.42	1.5700000000000001e-19	Coronary artery disease;
LUAD	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg16479474	chr6:28041457	NA	0.38	6.57	0.3	1.51e-10	Parkinson's disease;
LUAD	trans	rs875971	0.964	rs778723	chr7:65829497	T/C	cg14917512	chr19:3094685	GNA11	-0.38	-6.61	-0.31	1.18e-10	Aortic root size;
LUAD	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg13319975	chr6:146136371	FBXO30	-0.61	-10.46	-0.45	6.22e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg21963583	chr11:68658836	MRPL21	0.66	11.7	0.49	1.4e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg26587870	chr6:27730563	NA	-0.5	-8.27	-0.37	1.78e-15	Parkinson's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11544721	chr5:89705346	CETN3	-0.49	-7.68	-0.35	1.09e-13	Height;
LUAD	trans	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg17712092	chr4:129076599	LARP1B	1.06	22.37	0.74	1.07e-73	Eosinophil percentage of white cells;
LUAD	cis	rs887829	0.570	rs13015720	chr2:234600999	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.69	-0.43	3.53e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.46e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.89	-0.53	2.75e-32	Breast cancer;
LUAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg04025307	chr7:1156635	C7orf50	0.6	6.74	0.31	5.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg26513180	chr16:89883248	FANCA	-0.48	-7.92	-0.36	2.18e-14	Vitiligo;
LUAD	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg10556349	chr10:835070	NA	0.68	7.97	0.36	1.45e-14	Eosinophil percentage of granulocytes;
LUAD	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	6.83	0.32	2.89e-11	Menarche (age at onset);
LUAD	trans	rs79911532	0.515	rs113244522	chr7:75715307	G/A	cg19862616	chr7:65841803	NCRNA00174	0.82	8.47	0.38	4e-16	Mononucleosis;
LUAD	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23158103	chr7:148848205	ZNF398	-0.67	-12.48	-0.52	1.17e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg12373951	chr3:133503437	NA	-0.41	-8.23	-0.37	2.26e-15	Iron status biomarkers;
LUAD	cis	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg21775007	chr8:11205619	TDH	0.57	10.13	0.44	9.47e-22	Retinal vascular caliber;
LUAD	cis	rs2224391	0.628	rs2773316	chr6:5254448	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-8.76	-0.39	4.7e-17	Height;
LUAD	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg05991184	chr2:219186017	PNKD	0.35	6.7	0.31	6.6e-11	Colorectal cancer;
LUAD	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-11.1	-0.47	2.75e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs870825	0.616	rs7700216	chr4:185648510	G/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg02176678	chr2:219576539	TTLL4	0.7	13.95	0.56	1.23e-36	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg20607798	chr8:58055168	NA	0.57	7.67	0.35	1.16e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07636037	chr3:49044803	WDR6	0.49	8.38	0.38	7.85e-16	Menarche (age at onset);
LUAD	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg08916839	chr5:415575	AHRR	0.82	9.47	0.42	2.03e-19	Fat distribution (HIV);
LUAD	trans	rs1941687	0.672	rs1026257	chr18:31418131	C/T	cg27147174	chr7:100797783	AP1S1	0.53	9.5	0.42	1.52e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.83	-0.36	4.04e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg07570687	chr10:102243282	WNT8B	0.48	7.21	0.33	2.57e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs11809207	0.855	rs17257155	chr1:26526439	C/T	cg00300879	chr1:26503847	CNKSR1	-0.28	-6.77	-0.31	4.45e-11	Height;
LUAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg11494091	chr17:61959527	GH2	0.74	18.52	0.67	1.62e-56	Prudent dietary pattern;
LUAD	trans	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg11693508	chr17:37793320	STARD3	0.69	9.36	0.41	4.67e-19	Bipolar disorder;
LUAD	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg15557168	chr22:42548783	NA	-0.36	-6.41	-0.3	3.96e-10	Cognitive function;
LUAD	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg04546413	chr19:29218101	NA	0.7	10.44	0.45	7.46e-23	Methadone dose in opioid dependence;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05052335	chr5:130970657	RAPGEF6	-0.42	-6.38	-0.3	4.74e-10	Height;
LUAD	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.37	-0.34	8.99e-13	Menarche (age at onset);
LUAD	cis	rs2742234	0.541	rs11528481	chr10:43737767	C/A	cg15436174	chr10:43711423	RASGEF1A	0.53	8.88	0.4	1.86e-17	Hirschsprung disease;
LUAD	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.94	-0.32	1.49e-11	Bipolar disorder;
LUAD	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg12311346	chr5:56204834	C5orf35	-0.41	-6.48	-0.3	2.49e-10	Coronary artery disease;
LUAD	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.09	-0.57	3.18e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg18180107	chr4:99064573	C4orf37	0.43	6.93	0.32	1.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9462027	0.628	rs2814942	chr6:34644261	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-8.44	-0.38	4.95e-16	Systemic lupus erythematosus;
LUAD	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg07741184	chr6:167504864	NA	-0.3	-7.11	-0.33	5.05e-12	Crohn's disease;
LUAD	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg27535305	chr1:53392650	SCP2	-0.36	-7.47	-0.34	4.53e-13	Monocyte count;
LUAD	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-13.33	-0.54	4.25e-34	Extrinsic epigenetic age acceleration;
LUAD	trans	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg18187862	chr3:45730750	SACM1L	0.5	7.85	0.36	3.51e-14	Primary sclerosing cholangitis;
LUAD	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg09796270	chr17:17721594	SREBF1	0.38	7.79	0.35	5.3e-14	Total body bone mineral density;
LUAD	cis	rs8017423	0.522	rs12887028	chr14:90819605	A/G	cg14092571	chr14:90743983	NA	0.39	6.63	0.31	1.04e-10	Mortality in heart failure;
LUAD	cis	rs367943	0.966	rs444322	chr5:112815399	C/T	cg12552261	chr5:112820674	MCC	-0.58	-11.04	-0.47	4.66e-25	Type 2 diabetes;
LUAD	cis	rs877282	0.945	rs35342920	chr10:790484	T/C	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	trans	rs7246760	0.609	rs57889827	chr19:9777459	T/C	cg02900749	chr2:68251473	NA	-0.59	-6.43	-0.3	3.44e-10	Pursuit maintenance gain;
LUAD	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg03684893	chr10:554711	DIP2C	-0.37	-6.6	-0.31	1.23e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg11663144	chr21:46675770	NA	-0.48	-9.27	-0.41	9.57e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4660214	0.666	rs2275186	chr1:39766055	C/T	cg27567593	chr1:39956653	BMP8A	0.35	7.16	0.33	3.67e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	0.6	6.94	0.32	1.46e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg16447950	chr5:562315	NA	-0.41	-6.41	-0.3	3.91e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs10979	0.557	rs9285501	chr6:143915121	G/C	cg25407410	chr6:143891975	LOC285740	-0.55	-7.69	-0.35	1.01e-13	Hypospadias;
LUAD	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg11494091	chr17:61959527	GH2	0.44	8.23	0.37	2.37e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg27494647	chr7:150038898	RARRES2	0.55	9.35	0.41	5.01e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg00495681	chr13:53174319	NA	-0.5	-8.99	-0.4	8.06e-18	Lewy body disease;
LUAD	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg17063962	chr7:91808500	NA	0.68	12.03	0.5	6.94e-29	Breast cancer;
LUAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg00166722	chr3:10149974	C3orf24	0.62	9.36	0.41	4.58e-19	Alzheimer's disease;
LUAD	cis	rs11671005	0.735	rs34188294	chr19:58919557	G/A	cg13877915	chr19:58951672	ZNF132	0.52	6.74	0.31	5.25e-11	Mean platelet volume;
LUAD	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg04450456	chr4:17643702	FAM184B	0.42	8.34	0.38	1.09e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg25019722	chr6:37503610	NA	-0.32	-7.1	-0.33	5.17e-12	Cognitive performance;
LUAD	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.36	-0.6	1.23e-42	Chronic sinus infection;
LUAD	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.48	-0.3	2.61e-10	Bladder cancer;
LUAD	cis	rs999737	0.778	rs11624333	chr14:68979835	A/G	cg04147497	chr14:69052728	RAD51L1	-0.44	-6.78	-0.31	4.09e-11	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg07617317	chr6:118971624	C6orf204	0.54	8.29	0.37	1.5e-15	Renal cell carcinoma;
LUAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg07217954	chr7:1067459	C7orf50	0.43	6.63	0.31	1.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg20607287	chr7:12443886	VWDE	-0.54	-6.83	-0.32	2.97e-11	Coronary artery disease;
LUAD	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25427524	chr10:38739819	LOC399744	0.77	13.85	0.56	3.07e-36	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg06873352	chr17:61820015	STRADA	0.41	6.9	0.32	1.96e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg08601574	chr20:25228251	PYGB	0.46	8.74	0.39	5.37e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg08601574	chr20:25228251	PYGB	-0.47	-8.82	-0.39	2.94e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.78	-13.35	-0.54	3.65e-34	Chronic sinus infection;
LUAD	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg05304507	chr6:116381966	FRK	0.2	6.93	0.32	1.6e-11	Cholesterol, total;LDL cholesterol;
LUAD	trans	rs7762018	0.760	rs28660085	chr6:170101996	C/G	cg06875740	chr19:51307921	C19orf48	-0.48	-6.54	-0.3	1.75e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18876405	chr7:65276391	NA	-0.42	-6.71	-0.31	6.1e-11	Aortic root size;
LUAD	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-7.44	-0.34	5.71e-13	Morning vs. evening chronotype;
LUAD	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg04851639	chr8:1020857	NA	-0.46	-11.24	-0.48	8.27e-26	Schizophrenia;
LUAD	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.64	-0.31	9.82e-11	Prostate cancer;
LUAD	cis	rs2637266	0.783	rs846647	chr10:78515508	C/G	cg18941641	chr10:78392320	NA	0.31	6.38	0.3	4.77e-10	Pulmonary function;
LUAD	cis	rs6993813	0.843	rs17176952	chr8:120042383	C/A	cg01975934	chr8:119970761	NA	-0.37	-7.2	-0.33	2.83e-12	Bone mineral density (hip);
LUAD	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg05340658	chr4:99064831	C4orf37	0.51	8.47	0.38	4.13e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17152411	1.000	rs7086447	chr10:126593553	C/A	cg07906193	chr10:126599966	NA	0.53	7.6	0.35	1.95e-13	Height;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg06591456	chr7:4814952	KIAA0415	-0.39	-6.52	-0.3	1.96e-10	Subcortical brain region volumes;
LUAD	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg13271783	chr10:134563150	INPP5A	-0.4	-6.57	-0.3	1.46e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg08610935	chr16:1836813	NUBP2	0.46	7.21	0.33	2.53e-12	Insulin-like growth factors;
LUAD	cis	rs2235649	0.833	rs9939766	chr16:1852808	C/A	cg08610935	chr16:1836813	NUBP2	-0.49	-7.33	-0.34	1.14e-12	Blood metabolite levels;
LUAD	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg09222892	chr1:25734099	RHCE	-0.5	-9.39	-0.42	3.73e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.67	-10.35	-0.45	1.62e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg22920501	chr2:26401640	FAM59B	-0.96	-14.2	-0.57	1.07e-37	Gut microbiome composition (summer);
LUAD	trans	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.67	-9.72	-0.43	2.66e-20	Blood trace element (Cu levels);
LUAD	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18099408	chr3:52552593	STAB1	-0.46	-8.07	-0.37	7.46e-15	Bipolar disorder;
LUAD	cis	rs4984778	0.717	rs2738892	chr16:1268758	A/G	cg07748719	chr16:1272498	TPSG1	0.73	12.78	0.53	7.23e-32	Blood protein levels;
LUAD	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg12292205	chr6:26970375	C6orf41	-0.57	-6.95	-0.32	1.35e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg04450456	chr4:17643702	FAM184B	0.42	8.45	0.38	4.59e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4700695	0.719	rs27086	chr5:65453185	A/G	cg21114390	chr5:65439923	SFRS12	-0.93	-14.49	-0.58	6.17e-39	Facial morphology (factor 19);
LUAD	trans	rs7395662	0.818	rs34486360	chr11:48782472	G/T	cg00717180	chr2:96193071	NA	-0.38	-7.17	-0.33	3.33e-12	HDL cholesterol;
LUAD	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.43	-7.24	-0.33	2.17e-12	Hypertriglyceridemia;
LUAD	cis	rs977987	0.872	rs1559339	chr16:75318646	A/G	cg03315344	chr16:75512273	CHST6	0.62	13.47	0.55	1.12e-34	Dupuytren's disease;
LUAD	trans	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg01620082	chr3:125678407	NA	-0.46	-6.98	-0.32	1.12e-11	Depression;
LUAD	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs7289126	1.000	rs5756986	chr22:38640841	A/G	cg17652424	chr22:38574118	PLA2G6	-0.23	-6.63	-0.31	1.04e-10	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs2882667	0.556	rs6873733	chr5:138403317	G/T	cg04439458	chr5:138467593	SIL1	-0.36	-6.76	-0.31	4.5e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-17.1	-0.64	3.11e-50	Exhaled nitric oxide output;
LUAD	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg03929089	chr4:120376271	NA	-0.78	-13.09	-0.54	4.29e-33	Height;
LUAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg05564831	chr3:52568323	NT5DC2	0.4	7.37	0.34	9.12e-13	Electroencephalogram traits;
LUAD	cis	rs67981189	0.821	rs2286310	chr14:71523605	C/T	cg15816911	chr14:71606274	NA	0.36	6.38	0.3	4.63e-10	Schizophrenia;
LUAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.54	-7.07	-0.32	6.62e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg12935359	chr14:103987150	CKB	0.5	7.76	0.35	6.56e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg21918786	chr6:109611834	NA	-0.6	-11.11	-0.48	2.44e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs12760731	0.720	rs10913552	chr1:178411543	G/A	cg00404053	chr1:178313656	RASAL2	0.49	6.81	0.31	3.37e-11	Obesity-related traits;
LUAD	cis	rs11771526	0.901	rs11761481	chr7:32293994	C/T	cg27532318	chr7:32358331	NA	0.53	7.08	0.33	6.11e-12	Body mass index;
LUAD	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00684032	chr4:1343700	KIAA1530	0.49	8.1	0.37	5.77e-15	Obesity-related traits;
LUAD	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg15017067	chr4:17643749	FAM184B	0.33	6.48	0.3	2.53e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8014204	0.804	rs34956813	chr14:75254167	G/A	cg06637938	chr14:75390232	RPS6KL1	0.37	6.8	0.31	3.66e-11	Caffeine consumption;
LUAD	cis	rs12681287	0.640	rs6471309	chr8:87387760	C/T	cg00550725	chr8:87521180	FAM82B	0.45	6.52	0.3	2e-10	Caudate activity during reward;
LUAD	cis	rs4604732	0.631	rs4411161	chr1:247632374	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.03	0.32	8.3e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs113835537	0.529	rs116867234	chr11:66209024	C/T	cg26679405	chr11:66247800	DPP3	-0.46	-6.45	-0.3	3.02e-10	Airway imaging phenotypes;
LUAD	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.85	-0.32	2.69e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs36051895	0.695	rs12347727	chr9:5000811	A/G	cg02405213	chr9:5042618	JAK2	-0.49	-6.86	-0.32	2.41e-11	Pediatric autoimmune diseases;
LUAD	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22496380	chr5:211416	CCDC127	-1.2	-13.57	-0.55	4.56e-35	Breast cancer;
LUAD	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg25767906	chr1:53392781	SCP2	0.46	8.54	0.38	2.41e-16	Monocyte count;
LUAD	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg26924012	chr15:45694286	SPATA5L1	0.64	11.01	0.47	5.78e-25	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg07617317	chr6:118971624	C6orf204	0.54	8.16	0.37	3.78e-15	Diastolic blood pressure;
LUAD	trans	rs6561151	0.645	rs61959960	chr13:44439265	T/G	cg17145862	chr1:211918768	LPGAT1	0.56	7.61	0.35	1.79e-13	Crohn's disease;
LUAD	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg04450456	chr4:17643702	FAM184B	0.4	7.8	0.35	5.03e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9902453	1.000	rs4581755	chr17:28427898	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	9.18	0.41	1.89e-18	Coffee consumption (cups per day);
LUAD	cis	rs7394190	0.748	rs11000775	chr10:75539010	T/C	cg02286717	chr10:75415704	SYNPO2L	-0.37	-6.67	-0.31	7.95e-11	Incident atrial fibrillation;
LUAD	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg02527881	chr3:46936655	PTH1R	0.39	7.61	0.35	1.75e-13	Colorectal cancer;
LUAD	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg10876282	chr6:28092338	ZSCAN16	0.45	7.14	0.33	3.99e-12	Cardiac Troponin-T levels;
LUAD	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg05991184	chr2:219186017	PNKD	-0.38	-7.43	-0.34	5.97e-13	Colorectal cancer;
LUAD	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg12908607	chr1:44402522	ARTN	-0.52	-10.3	-0.45	2.37e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg25344623	chr2:136566232	LCT	-0.34	-6.58	-0.3	1.43e-10	Mosquito bite size;
LUAD	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg10556349	chr10:835070	NA	0.56	7.03	0.32	8.22e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.46	6.73	0.31	5.64e-11	Resistin levels;
LUAD	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.1	0.37	5.93e-15	Menopause (age at onset);
LUAD	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg00316803	chr15:76480434	C15orf27	-0.4	-7.53	-0.34	3.08e-13	Blood metabolite levels;
LUAD	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg06740227	chr12:86229804	RASSF9	0.43	7.21	0.33	2.56e-12	Major depressive disorder;
LUAD	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg22598563	chr5:131563921	P4HA2	0.27	6.63	0.31	1.01e-10	Blood metabolite levels;
LUAD	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg05768032	chr16:30646687	NA	0.48	8.59	0.39	1.7e-16	Multiple myeloma;
LUAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg00431813	chr7:1051703	C7orf50	-0.44	-8.36	-0.38	9.26e-16	Longevity;Endometriosis;
LUAD	cis	rs2286885	0.965	rs10819167	chr9:129241716	T/A	cg15282417	chr9:129245246	FAM125B	0.43	8.7	0.39	7.42e-17	Intraocular pressure;
LUAD	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg06484146	chr7:12443880	VWDE	-0.61	-8.06	-0.36	8.07e-15	Coronary artery disease;
LUAD	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-8.19	-0.37	3.09e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg21724239	chr8:58056113	NA	0.64	8.16	0.37	3.84e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1113500	1.000	rs1113500	chr1:108595442	G/T	cg06207961	chr1:108661230	NA	-0.44	-8.33	-0.38	1.11e-15	Growth-regulated protein alpha levels;
LUAD	cis	rs1997103	0.911	rs17777	chr7:55380765	T/C	cg17469321	chr7:55412551	NA	0.67	11.43	0.49	1.52e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.52	0.3	2.05e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.2	-0.51	1.59e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg03806693	chr22:41940476	POLR3H	0.63	9.45	0.42	2.35e-19	Cannabis dependence symptom count;
LUAD	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg23649088	chr2:200775458	C2orf69	0.56	9.76	0.43	1.98e-20	Systolic blood pressure;
LUAD	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg12573674	chr2:1569213	NA	-0.57	-8.26	-0.37	1.83e-15	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg01324343	chr3:183735012	ABCC5	0.77	17.1	0.64	3.41e-50	Anterior chamber depth;
LUAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg12432903	chr7:1882776	MAD1L1	-0.53	-8.65	-0.39	1.04e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23583168	chr7:148888333	NA	-0.93	-19.37	-0.69	2.73e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg03929089	chr4:120376271	NA	-0.97	-19.76	-0.69	5e-62	Height;
LUAD	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.41	-0.34	7.02e-13	Bipolar disorder;
LUAD	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg10544611	chr16:67998164	SLC12A4	0.63	7.35	0.34	1.02e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg10755058	chr3:40428713	ENTPD3	0.37	7.22	0.33	2.49e-12	Renal cell carcinoma;
LUAD	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg11663144	chr21:46675770	NA	-0.41	-6.69	-0.31	7.11e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12681287	0.570	rs10956830	chr8:87430483	T/A	cg27223183	chr8:87520930	FAM82B	0.67	9.58	0.42	8.35e-20	Caudate activity during reward;
LUAD	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg26818010	chr10:134567672	INPP5A	-0.87	-14.88	-0.59	1.48e-40	Migraine;
LUAD	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21582582	chr3:182698605	DCUN1D1	0.61	9.69	0.43	3.56e-20	Resting heart rate;
LUAD	cis	rs2839186	0.584	rs2032111	chr21:47904569	G/A	cg11766577	chr21:47581405	C21orf56	-0.48	-7.68	-0.35	1.1e-13	Testicular germ cell tumor;
LUAD	cis	rs4601821	0.895	rs2282511	chr11:113244177	A/C	cg14159747	chr11:113255604	NA	0.47	8.72	0.39	6.63e-17	Alcoholic chronic pancreatitis;
LUAD	cis	rs1371614	0.611	rs4665920	chr2:27128834	G/A	cg00617064	chr2:27272375	NA	0.35	6.69	0.31	6.99e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	7.09	0.33	5.67e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg01171360	chr6:293285	DUSP22	-0.51	-8.64	-0.39	1.15e-16	Menopause (age at onset);
LUAD	cis	rs2742417	1.000	rs2742397	chr3:45758946	C/G	cg10512202	chr3:45649293	LIMD1	-0.38	-6.61	-0.31	1.19e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg07917127	chr4:99064746	C4orf37	0.41	6.72	0.31	6.05e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8025790	0.508	rs12905371	chr15:67845930	C/T	cg27219399	chr15:67835830	MAP2K5	0.41	7.24	0.33	2.2e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg00316803	chr15:76480434	C15orf27	-0.41	-7.91	-0.36	2.31e-14	Blood metabolite levels;
LUAD	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg05754148	chr16:3507555	NAT15	0.66	11.32	0.48	3.86e-26	Tuberculosis;
LUAD	cis	rs7809950	0.773	rs2237668	chr7:107050209	A/G	cg23024343	chr7:107201750	COG5	-0.87	-14.75	-0.58	4.93e-40	Coronary artery disease;
LUAD	cis	rs4853036	0.680	rs35413900	chr2:70113900	C/G	cg02498382	chr2:70120550	SNRNP27	-0.53	-7.57	-0.35	2.41e-13	Colorectal or endometrial cancer;
LUAD	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-13.98	-0.56	9.07e-37	Chronic sinus infection;
LUAD	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg03806693	chr22:41940476	POLR3H	-0.68	-9.18	-0.41	1.93e-18	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg22535103	chr8:58192502	C8orf71	-0.75	-10.62	-0.46	1.68e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg02683114	chr2:24398427	C2orf84	-0.4	-6.38	-0.3	4.52e-10	Asthma;
LUAD	trans	rs4650994	0.935	rs2811289	chr1:178572693	G/A	cg05059571	chr16:84539110	KIAA1609	0.54	9.04	0.4	5.74e-18	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.8	0.35	5e-14	Lung cancer;
LUAD	cis	rs12545109	0.700	rs2670045	chr8:57393695	A/G	cg07080864	chr8:57359956	PENK	-0.37	-6.56	-0.3	1.57e-10	Obesity-related traits;
LUAD	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg05991184	chr2:219186017	PNKD	-0.35	-6.68	-0.31	7.7e-11	Colorectal cancer;
LUAD	cis	rs7582720	0.836	rs72938315	chr2:204121063	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.66	8.74	0.39	5.49e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2992756	0.663	rs3007718	chr1:18808465	T/A	cg24076588	chr1:18808559	KLHDC7A	-0.46	-7.59	-0.35	2.04e-13	Breast cancer;
LUAD	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg07570687	chr10:102243282	WNT8B	0.48	7.39	0.34	8.08e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg27572855	chr1:25598939	RHD	0.53	11.39	0.48	2.15e-26	Erythrocyte sedimentation rate;
LUAD	trans	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.26	-0.37	1.93e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs262150	0.659	rs73167293	chr7:158772638	C/T	cg12257156	chr7:158823799	VIPR2	0.43	6.42	0.3	3.65e-10	Facial morphology (factor 20);
LUAD	trans	rs2797160	1.000	rs1739374	chr6:126011825	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.53	8.61	0.39	1.44e-16	Endometrial cancer;
LUAD	cis	rs7208859	0.614	rs4794874	chr17:28841318	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.66	-6.94	-0.32	1.53e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7095607	0.560	rs2087344	chr10:69922735	A/G	cg18986048	chr10:69913749	MYPN	-0.46	-7.94	-0.36	1.79e-14	Lung function (FVC);
LUAD	cis	rs2840044	1.000	rs2840044	chr17:33892068	A/G	cg05299278	chr17:33885742	SLFN14	-0.44	-9.05	-0.4	5.24e-18	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.09	0.33	5.82e-12	Depression;
LUAD	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg15448220	chr1:150897856	SETDB1	0.46	7.97	0.36	1.47e-14	Tonsillectomy;
LUAD	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg05966235	chr16:28915196	ATP2A1	0.46	7.48	0.34	4.21e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7809799	0.571	rs111251485	chr7:98958230	G/A	cg12290671	chr7:99195819	NA	-0.75	-6.44	-0.3	3.16e-10	Ulcerative colitis;
LUAD	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.48	6.83	0.32	2.93e-11	Platelet count;
LUAD	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg07606381	chr6:8435919	SLC35B3	0.4	6.82	0.31	3.1e-11	Motion sickness;
LUAD	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg04450456	chr4:17643702	FAM184B	0.4	7.8	0.35	4.9e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg18306943	chr3:40428807	ENTPD3	0.36	6.36	0.3	5.26e-10	Renal cell carcinoma;
LUAD	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg15448220	chr1:150897856	SETDB1	0.46	7.98	0.36	1.44e-14	Tonsillectomy;
LUAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg24642844	chr7:1081250	C7orf50	-0.88	-13.74	-0.56	8.68e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1941023	0.606	rs3825020	chr11:60184191	G/A	cg08716584	chr11:60157161	MS4A7	-0.35	-6.49	-0.3	2.34e-10	Congenital heart disease (maternal effect);
LUAD	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg18131467	chr2:239335373	ASB1	0.73	12.8	0.53	6.11e-32	Multiple system atrophy;
LUAD	cis	rs4774899	0.752	rs2920267	chr15:57351029	C/T	cg14026238	chr15:57616123	NA	0.43	8.35	0.38	1.01e-15	Urinary tract infection frequency;
LUAD	cis	rs4523957	0.820	rs9908972	chr17:2103810	A/C	cg16513277	chr17:2031491	SMG6	-0.8	-15.43	-0.6	6.36e-43	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg15744005	chr10:104629667	AS3MT	-0.38	-7.41	-0.34	7.11e-13	Arsenic metabolism;
LUAD	cis	rs1712517	1.000	rs3123794	chr10:105033742	A/G	cg05636881	chr10:105038444	INA	0.32	6.45	0.3	3.02e-10	Migraine;
LUAD	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg17105886	chr17:28927953	LRRC37B2	0.81	7.85	0.36	3.4e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.4	6.91	0.32	1.82e-11	Age at first birth;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23108125	chr5:176882586	PRR7	-0.54	-6.56	-0.3	1.59e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7707921	0.541	rs10066167	chr5:81495445	C/T	cg15871215	chr5:81402204	ATG10	0.65	11.4	0.48	1.89e-26	Breast cancer;
LUAD	cis	rs10097731	0.901	rs10464890	chr8:82042727	A/G	cg25230327	chr8:82042993	NA	-0.66	-11.44	-0.49	1.36e-26	Serum total protein level;
LUAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.9	0.43	6.13e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.62	-0.31	1.09e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9462027	0.606	rs1201874	chr6:34549810	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.73	-0.39	5.82e-17	Systemic lupus erythematosus;
LUAD	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg17863274	chr19:49399704	TULP2	-0.66	-10.01	-0.44	2.58e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs367615	0.661	rs9326773	chr5:108833523	C/T	cg17395555	chr5:108820864	NA	0.68	14.62	0.58	1.76e-39	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs11696845	0.604	rs1980577	chr20:43382112	A/G	cg09357268	chr20:43379437	KCNK15	0.38	6.52	0.3	2.01e-10	Obesity-related traits;
LUAD	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg27129171	chr3:47204927	SETD2	0.42	6.74	0.31	5.2e-11	Colorectal cancer;
LUAD	cis	rs11153730	0.503	rs188181	chr6:118620094	C/T	cg18833306	chr6:118973337	C6orf204	0.55	10.17	0.44	7.18e-22	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	trans	rs2018683	0.649	rs221171	chr7:29006139	C/G	cg19402173	chr7:128379420	CALU	0.52	8.23	0.37	2.34e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-8.05	-0.36	8.48e-15	Fear of minor pain;
LUAD	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg18252515	chr7:66147081	NA	-0.62	-6.68	-0.31	7.75e-11	Diabetic kidney disease;
LUAD	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg20790798	chr5:1857306	NA	-0.45	-7.68	-0.35	1.13e-13	Cardiovascular disease risk factors;
LUAD	cis	rs8049603	0.773	rs12924086	chr16:23184357	G/A	cg09552652	chr16:23197569	SCNN1G	0.37	6.46	0.3	2.92e-10	Multiple sclerosis;
LUAD	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg26513180	chr16:89883248	FANCA	0.72	6.9	0.32	1.86e-11	Skin colour saturation;
LUAD	trans	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg21659725	chr3:3221576	CRBN	-0.48	-8.1	-0.37	6e-15	Body mass index;
LUAD	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-7.55	-0.34	2.62e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg18016565	chr1:150552671	MCL1	-0.41	-7.23	-0.33	2.22e-12	Tonsillectomy;
LUAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00166722	chr3:10149974	C3orf24	0.74	12.68	0.52	1.89e-31	Alzheimer's disease;
LUAD	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.59	-0.31	1.29e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.37	-6.51	-0.3	2.13e-10	Coronary artery disease;
LUAD	cis	rs6060717	0.536	rs6060666	chr20:34478954	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.06	-0.32	7.08e-12	Hip circumference adjusted for BMI;
LUAD	trans	rs587242	0.868	rs12040479	chr1:97042980	C/G	cg10631902	chr5:14652156	NA	0.4	6.51	0.3	2.18e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06028808	chr11:68637592	NA	0.45	7.43	0.34	6.03e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1403694	0.695	rs5029975	chr3:186436918	A/G	cg12454167	chr3:186435060	KNG1	-0.5	-10.55	-0.46	3.03e-23	Blood protein levels;
LUAD	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.57	-0.35	2.38e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs5758659	0.819	rs134871	chr22:42652716	A/G	cg15128208	chr22:42549153	NA	-0.36	-7.35	-0.34	1.05e-12	Cognitive function;
LUAD	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg23954153	chr1:44402353	ARTN	-0.33	-6.6	-0.31	1.24e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4242434	0.927	rs3735894	chr8:22454826	A/G	cg03733263	chr8:22462867	KIAA1967	0.72	12.27	0.51	8.01e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg03433033	chr1:76189801	ACADM	0.93	19.16	0.68	2.43e-59	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03264133	chr6:25882463	NA	-0.54	-7.9	-0.36	2.46e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7712401	0.601	rs27976	chr5:122206460	C/T	cg19077854	chr5:122220652	SNX24	-0.36	-6.97	-0.32	1.23e-11	Mean platelet volume;
LUAD	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.22	0.33	2.39e-12	Parkinson's disease;
LUAD	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg14780466	chr2:20870812	GDF7	-0.44	-8.13	-0.37	4.66e-15	Abdominal aortic aneurysm;
LUAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg07806771	chr7:64541737	NA	0.48	7.72	0.35	8.66e-14	Calcium levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16159717	chr5:60628008	ZSWIM6	-0.39	-6.47	-0.3	2.71e-10	Cancer;
LUAD	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg15704280	chr7:45808275	SEPT13	0.63	8.6	0.39	1.59e-16	Axial length;
LUAD	cis	rs4711336	0.712	rs942641	chr6:33687007	G/A	cg14003231	chr6:33640908	ITPR3	0.46	9.27	0.41	9.93e-19	Height;
LUAD	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg09365446	chr1:150670422	GOLPH3L	0.55	9.64	0.42	5.37e-20	Melanoma;
LUAD	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.56	-0.38	2.15e-16	Alzheimer's disease (late onset);
LUAD	cis	rs7843479	0.965	rs17581910	chr8:21799626	A/G	cg03445287	chr8:21823731	XPO7	-0.47	-8.54	-0.38	2.51e-16	Mean corpuscular volume;
LUAD	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg05564831	chr3:52568323	NT5DC2	0.34	6.63	0.31	1.05e-10	Bipolar disorder;
LUAD	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.78	-12.61	-0.52	3.73e-31	Primary sclerosing cholangitis;
LUAD	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg06108461	chr20:60628389	TAF4	-0.76	-13.15	-0.54	2.31e-33	Body mass index;
LUAD	cis	rs10392	0.543	rs4300896	chr20:37580130	A/C	cg27552599	chr20:37590471	DHX35	0.42	7.2	0.33	2.72e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.49	-7.98	-0.36	1.41e-14	Lymphocyte percentage of white cells;
LUAD	trans	rs87938	0.863	rs108606	chr3:41155615	G/A	cg11224624	chr8:145049280	PLEC1	-0.41	-6.73	-0.31	5.64e-11	Bone mineral density (hip);
LUAD	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg16479474	chr6:28041457	NA	0.35	6.59	0.31	1.29e-10	Parkinson's disease;
LUAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg18621852	chr3:10150065	C3orf24	0.5	9.06	0.4	5.05e-18	Alzheimer's disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02204578	chr7:132766399	CHCHD3	-0.38	-6.57	-0.3	1.5e-10	Cancer;
LUAD	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg14061069	chr19:46274453	DMPK	-0.47	-9.9	-0.43	6.39e-21	Coronary artery disease;
LUAD	trans	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg18335740	chr13:41363409	SLC25A15	0.48	8.59	0.39	1.7e-16	Lewy body disease;
LUAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg14159672	chr1:205819179	PM20D1	0.5	7.62	0.35	1.64e-13	Parkinson's disease;
LUAD	trans	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg14917512	chr19:3094685	GNA11	0.36	6.48	0.3	2.55e-10	Aortic root size;
LUAD	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg14196790	chr5:131705035	SLC22A5	0.38	6.71	0.31	6.43e-11	Breast cancer;
LUAD	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg14584255	chr6:163149320	PACRG;PARK2	-0.38	-7.12	-0.33	4.68e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09553402	chr5:180229753	MGAT1	-0.67	-6.86	-0.32	2.41e-11	Type 2 diabetes;
LUAD	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg11822812	chr5:140052017	DND1	0.38	6.9	0.32	1.97e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs741677	0.963	rs441821	chr17:474394	A/G	cg13332499	chr17:408570	NA	0.35	6.87	0.32	2.35e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs992157	0.764	rs4552182	chr2:219184872	G/T	cg05991184	chr2:219186017	PNKD	-0.41	-7.73	-0.35	8.08e-14	Colorectal cancer;
LUAD	cis	rs9715521	0.677	rs6822690	chr4:59853530	A/G	cg11281224	chr4:60001000	NA	-0.59	-10.73	-0.46	6.38e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.17	0.33	3.34e-12	Motion sickness;
LUAD	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg12310025	chr6:25882481	NA	-0.53	-7.75	-0.35	6.93e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg18016565	chr1:150552671	MCL1	0.41	7.49	0.34	4.14e-13	Tonsillectomy;
LUAD	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg16647868	chr5:131706066	SLC22A5	-0.47	-7.61	-0.35	1.81e-13	Breast cancer;
LUAD	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg08470875	chr2:26401718	FAM59B	-0.6	-8.1	-0.37	5.81e-15	Gut microbiome composition (summer);
LUAD	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	8.36	0.38	8.83e-16	Rheumatoid arthritis;
LUAD	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg05966235	chr16:28915196	ATP2A1	0.42	6.89	0.32	2.02e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg07371521	chr5:154026371	NA	-0.6	-9.69	-0.43	3.56e-20	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-7.52	-0.34	3.35e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg22907277	chr7:1156413	C7orf50	0.68	7.98	0.36	1.35e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs315934	0.664	rs67213447	chr2:113857964	C/T	cg09040174	chr2:113837401	NA	-0.61	-7.4	-0.34	7.6e-13	Dysmenorrheic pain;
LUAD	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg25554036	chr4:6271136	WFS1	-0.65	-12.86	-0.53	3.55e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg09021430	chr5:549028	NA	-0.49	-12.23	-0.51	1.2e-29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.41	-7.97	-0.36	1.5e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs757081	0.608	rs214938	chr11:17188516	C/T	cg15432903	chr11:17409602	KCNJ11	-0.4	-6.38	-0.3	4.57e-10	Systolic blood pressure;
LUAD	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg20933634	chr6:27740509	NA	0.53	8.03	0.36	9.56e-15	Parkinson's disease;
LUAD	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg06671706	chr8:8559999	CLDN23	0.66	11.33	0.48	3.46e-26	Obesity-related traits;
LUAD	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg16647868	chr5:131706066	SLC22A5	-0.5	-7.8	-0.35	4.99e-14	Blood metabolite levels;
LUAD	cis	rs7731657	0.537	rs1120621	chr5:130340853	T/C	cg08523029	chr5:130500466	HINT1	0.58	7.73	0.35	7.73e-14	Fasting plasma glucose;
LUAD	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg18306943	chr3:40428807	ENTPD3	0.36	6.35	0.3	5.46e-10	Renal cell carcinoma;
LUAD	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg17063962	chr7:91808500	NA	0.6	9.81	0.43	1.27e-20	Breast cancer;
LUAD	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.43	-0.45	7.96e-23	Monocyte percentage of white cells;
LUAD	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg18477163	chr1:228402036	OBSCN	-0.37	-7.42	-0.34	6.4e-13	Diastolic blood pressure;
LUAD	cis	rs7582720	1.000	rs6435169	chr2:203753016	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg22875332	chr1:76189707	ACADM	-0.86	-16.44	-0.62	2.49e-47	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg08885076	chr2:99613938	TSGA10	0.36	6.65	0.31	9.14e-11	Chronic sinus infection;
LUAD	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg17757837	chr7:157058334	UBE3C	-0.43	-7.07	-0.33	6.24e-12	Body mass index;
LUAD	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg05665937	chr4:1216051	CTBP1	0.44	7.45	0.34	5.17e-13	Obesity-related traits;
LUAD	cis	rs6908034	0.607	rs77753186	chr6:19812980	G/C	cg02682789	chr6:19804855	NA	0.91	9.09	0.4	3.9e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	7.61	0.35	1.83e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs597583	0.806	rs11605509	chr11:117396433	T/C	cg27161313	chr11:117392002	DSCAML1	-0.49	-8.16	-0.37	3.93e-15	Putamen volume;
LUAD	cis	rs4660214	0.666	rs587404	chr1:39908506	G/A	cg27567593	chr1:39956653	BMP8A	-0.34	-6.75	-0.31	4.94e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs35264875	0.851	rs72930631	chr11:68867835	T/C	cg02660097	chr11:68866761	NA	0.51	7.81	0.36	4.41e-14	Blond vs. brown hair color;
LUAD	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.76	-0.31	4.59e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg15128208	chr22:42549153	NA	-0.38	-7.6	-0.35	1.96e-13	Cognitive function;
LUAD	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg22029157	chr1:209979665	IRF6	0.75	9.81	0.43	1.3e-20	Cleft lip with or without cleft palate;
LUAD	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg08470875	chr2:26401718	FAM59B	-0.58	-7.93	-0.36	1.93e-14	Gut microbiome composition (summer);
LUAD	trans	rs853679	1.000	rs11965538	chr6:28239915	G/A	cg06606381	chr12:133084897	FBRSL1	-0.59	-7.45	-0.34	5.22e-13	Depression;
LUAD	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg24675056	chr1:15929824	NA	0.49	8.63	0.39	1.3e-16	Systolic blood pressure;
LUAD	cis	rs4243830	0.737	rs925745	chr1:6615690	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.53	-6.49	-0.3	2.37e-10	Body mass index;
LUAD	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.54	-0.46	3.33e-23	Monocyte percentage of white cells;
LUAD	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	10.07	0.44	1.66e-21	Resting heart rate;
LUAD	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.79	0.35	5.14e-14	Depression;
LUAD	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg02038168	chr22:39784481	NA	-0.6	-10.66	-0.46	1.21e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs10170310	0.872	rs62161711	chr2:139259222	A/G	cg03782584	chr2:139258740	SPOPL	0.32	6.68	0.31	7.54e-11	Response to antipsychotic treatment;
LUAD	cis	rs4889855	0.556	rs56873925	chr17:78536611	C/T	cg16591659	chr17:78472290	NA	0.45	7.88	0.36	2.86e-14	Fractional excretion of uric acid;
LUAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	cis	rs2239547	0.562	rs2581810	chr3:52960859	C/T	cg18404041	chr3:52824283	ITIH1	0.53	9.13	0.41	2.81e-18	Schizophrenia;
LUAD	cis	rs7903847	0.596	rs9787426	chr10:99155327	A/G	cg20016023	chr10:99160130	RRP12	-0.31	-7.42	-0.34	6.64e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg11941060	chr3:133502564	NA	-0.46	-7.71	-0.35	9.23e-14	Iron status biomarkers;
LUAD	cis	rs12541635	0.966	rs2132471	chr8:107000963	G/A	cg10147462	chr8:107024639	NA	0.5	9.05	0.4	5.38e-18	Age of smoking initiation;
LUAD	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg00310523	chr12:86230176	RASSF9	0.38	7.6	0.35	1.9e-13	Major depressive disorder;
LUAD	cis	rs8013055	0.699	rs66798104	chr14:105987782	C/G	cg19700328	chr14:106028568	NA	-0.41	-6.92	-0.32	1.72e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg00898013	chr13:113819073	PROZ	0.57	10.46	0.45	6.15e-23	Platelet distribution width;
LUAD	cis	rs6445967	0.530	rs12495722	chr3:58401595	C/T	cg23715586	chr3:58305044	RPP14	0.41	6.84	0.32	2.76e-11	Platelet count;
LUAD	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg06784218	chr1:46089804	CCDC17	0.6	13.33	0.54	4.38e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11890956	chr21:40555474	PSMG1	-0.64	-10.91	-0.47	1.33e-24	Cognitive function;
LUAD	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.4	0.3	4.14e-10	Parkinson's disease;
LUAD	cis	rs2882667	0.754	rs11746434	chr5:138435303	A/G	cg04439458	chr5:138467593	SIL1	-0.54	-9.48	-0.42	1.81e-19	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6490294	0.583	rs7314282	chr12:112502438	A/G	cg10833066	chr12:111807467	FAM109A	0.35	6.62	0.31	1.12e-10	Mean platelet volume;
LUAD	trans	rs1422110	0.616	rs6452689	chr5:85445059	A/T	cg01787110	chr1:109008453	NBPF6	0.62	10.48	0.45	5.51e-23	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg24069376	chr3:38537580	EXOG	0.32	6.78	0.31	4.15e-11	Electrocardiographic conduction measures;
LUAD	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg00300879	chr1:26503847	CNKSR1	0.29	8.4	0.38	7.06e-16	Height;
LUAD	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg21285383	chr16:89894308	SPIRE2	0.41	9.98	0.44	3.31e-21	Vitiligo;
LUAD	cis	rs853679	0.607	rs35098436	chr6:28134221	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.56	6.53	0.3	1.91e-10	Depression;
LUAD	cis	rs2224391	0.628	rs2773307	chr6:5244290	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.62	-9.64	-0.42	5.02e-20	Height;
LUAD	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.34	6.82	0.31	3.16e-11	Obesity-related traits;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19092999	chr3:113415735	KIAA2018	-0.4	-6.6	-0.31	1.22e-10	Cancer;
LUAD	trans	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg11693508	chr17:37793320	STARD3	0.71	9.05	0.4	5.19e-18	Neuroticism;
LUAD	trans	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.6	-10.54	-0.46	3.16e-23	Mean corpuscular volume;
LUAD	cis	rs6906287	0.631	rs9320663	chr6:118986172	A/G	cg05564266	chr6:118973597	C6orf204	0.36	7.65	0.35	1.37e-13	Electrocardiographic conduction measures;
LUAD	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg02993280	chr1:107599747	PRMT6	-0.55	-8.99	-0.4	8.44e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs999737	0.887	rs17828955	chr14:69016645	T/C	cg04147497	chr14:69052728	RAD51L1	-0.45	-6.92	-0.32	1.7e-11	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.42	0.34	6.41e-13	Menopause (age at onset);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg04207741	chr12:57482553	NAB2	-0.41	-6.8	-0.31	3.67e-11	Schizophrenia;
LUAD	cis	rs7923837	0.687	rs10882102	chr10:94466495	G/C	cg25093409	chr10:94429542	NA	0.37	6.54	0.3	1.83e-10	Body mass index;Multiple sclerosis;
LUAD	cis	rs4862307	0.762	rs28584149	chr4:184996482	C/T	cg06737308	chr4:185021514	ENPP6	0.57	9.51	0.42	1.5e-19	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg08601574	chr20:25228251	PYGB	0.47	8.59	0.39	1.65e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg13276752	chr17:57970287	TUBD1;RPS6KB1	-0.41	-7.16	-0.33	3.54e-12	Subcortical brain region volumes;
LUAD	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg03732007	chr1:2071316	PRKCZ	-0.34	-6.87	-0.32	2.34e-11	Height;
LUAD	cis	rs3813948	0.908	rs11120211	chr1:207276379	A/G	cg11153969	chr1:207277031	C4BPA	0.68	7.14	0.33	4.08e-12	C4b binding protein levels;
LUAD	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg17031739	chr1:67600172	NA	0.47	8.39	0.38	7.52e-16	Psoriasis;
LUAD	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg27286337	chr10:134555280	INPP5A	-0.95	-18.95	-0.68	2.07e-58	Migraine;
LUAD	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06028605	chr16:24865363	SLC5A11	0.55	8.48	0.38	3.88e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs490234	0.676	rs13293034	chr9:128256951	C/T	cg14078157	chr9:128172775	NA	-0.46	-8.13	-0.37	4.75e-15	Mean arterial pressure;
LUAD	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18876405	chr7:65276391	NA	0.45	7.19	0.33	2.9e-12	Aortic root size;
LUAD	cis	rs1011018	0.554	rs56124209	chr7:139463275	C/G	cg26515926	chr7:139453581	HIPK2	-0.49	-6.38	-0.3	4.56e-10	Systolic blood pressure;
LUAD	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg01849466	chr14:104193079	ZFYVE21	0.51	8.31	0.37	1.36e-15	Body mass index;
LUAD	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg23985595	chr17:80112537	CCDC57	0.54	9.86	0.43	8.73e-21	Life satisfaction;
LUAD	trans	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg06606381	chr12:133084897	FBRSL1	-0.65	-7.17	-0.33	3.42e-12	Depression;
LUAD	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg01236616	chr12:121019343	POP5	1.24	19.45	0.69	1.21e-60	Type 1 diabetes nephropathy;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06138422	chr12:133338013	ANKLE2	-0.58	-6.97	-0.32	1.18e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.52	-0.34	3.33e-13	Lung cancer;
LUAD	cis	rs9837602	1.000	rs2291495	chr3:99782227	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	9.04	0.4	5.82e-18	Breast cancer;
LUAD	trans	rs629535	0.547	rs72654095	chr8:70120770	A/G	cg21567404	chr3:27674614	NA	-0.97	-15.85	-0.61	9.9e-45	Dupuytren's disease;
LUAD	cis	rs7264396	0.563	rs3827029	chr20:34332784	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.59	7.81	0.36	4.5e-14	Total cholesterol levels;
LUAD	trans	rs11039798	0.920	rs11039848	chr11:48598243	C/T	cg15704280	chr7:45808275	SEPT13	0.74	7.62	0.35	1.63e-13	Axial length;
LUAD	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg00745463	chr17:30367425	LRRC37B	0.81	9.48	0.42	1.85e-19	Hip circumference adjusted for BMI;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21790971	chr4:54244117	FIP1L1	-0.42	-6.68	-0.31	7.75e-11	Height;
LUAD	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03264133	chr6:25882463	NA	-0.5	-7.32	-0.34	1.28e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg02685945	chr6:22570146	HDGFL1	-0.41	-6.36	-0.3	5.31e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg09945482	chr18:12777974	NA	0.53	6.64	0.31	9.65e-11	Inflammatory skin disease;
LUAD	cis	rs2235642	0.505	rs56359342	chr16:1654948	G/A	cg03034668	chr16:1723424	CRAMP1L	-0.47	-8.14	-0.37	4.48e-15	Coronary artery disease;
LUAD	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23583168	chr7:148888333	NA	-1.04	-24.81	-0.77	1.61e-84	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg05340658	chr4:99064831	C4orf37	0.53	8.98	0.4	9.13e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs757110	0.933	rs7124355	chr11:17412960	C/T	cg15432903	chr11:17409602	KCNJ11	-0.43	-7.28	-0.33	1.64e-12	Type 2 diabetes;
LUAD	trans	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg24644049	chr4:85504048	CDS1	0.92	7.92	0.36	2.16e-14	Skin colour saturation;
LUAD	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg09165964	chr15:75287851	SCAMP5	-0.47	-7.12	-0.33	4.53e-12	Blood trace element (Zn levels);
LUAD	cis	rs7680126	0.596	rs74778870	chr4:10298583	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.63	-0.31	1.02e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs4930561	0.765	rs1894204	chr11:67929671	C/T	cg04465784	chr11:67976953	SUV420H1	-0.27	-8.06	-0.36	8.08e-15	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg01324343	chr3:183735012	ABCC5	0.94	24.66	0.77	6.97e-84	Anterior chamber depth;
LUAD	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg11235426	chr6:292522	DUSP22	-0.56	-9.12	-0.41	3.14e-18	Menopause (age at onset);
LUAD	cis	rs7737355	0.947	rs28720007	chr5:131077709	C/T	cg25547332	chr5:131281432	NA	0.44	6.74	0.31	5.19e-11	Life satisfaction;
LUAD	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg06937882	chr20:24974362	C20orf3	-0.35	-6.92	-0.32	1.73e-11	Blood protein levels;
LUAD	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.25	0.33	2.06e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2735413	0.874	rs12917942	chr16:78064220	T/G	cg04733911	chr16:78082701	NA	-0.34	-7.9	-0.36	2.4e-14	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg15128208	chr22:42549153	NA	0.39	7.76	0.35	6.63e-14	Cognitive function;
LUAD	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg05234568	chr11:5960015	NA	0.55	10.74	0.46	6.15e-24	DNA methylation (variation);
LUAD	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.56	8.11	0.37	5.72e-15	Platelet count;
LUAD	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg13770153	chr20:60521292	NA	-0.59	-9.1	-0.4	3.56e-18	Body mass index;
LUAD	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg03676636	chr4:99064102	C4orf37	0.3	7.45	0.34	5.4e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg10729496	chr3:10149963	C3orf24	0.59	9.52	0.42	1.32e-19	Alzheimer's disease;
LUAD	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg27102117	chr16:15229624	NA	0.54	9.8	0.43	1.49e-20	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg05313129	chr8:58192883	C8orf71	-0.54	-6.95	-0.32	1.38e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg06618935	chr21:46677482	NA	-0.41	-8.22	-0.37	2.57e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg14791747	chr16:20752902	THUMPD1	0.46	7.05	0.32	7.42e-12	Dental caries;
LUAD	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg02176678	chr2:219576539	TTLL4	0.68	13.36	0.54	3.29e-34	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.7	-0.46	8.37e-24	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg10356904	chr22:49881777	NA	-0.37	-7.23	-0.33	2.34e-12	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-6.53	-0.3	1.91e-10	Immature fraction of reticulocytes;Schizophrenia;
LUAD	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg15605315	chr1:45957053	TESK2	0.49	7.72	0.35	8.41e-14	High light scatter reticulocyte count;
LUAD	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg07917127	chr4:99064746	C4orf37	0.41	6.81	0.31	3.28e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10129255	0.500	rs8014529	chr14:107192302	G/A	cg23076370	chr14:107095027	NA	-0.44	-8.72	-0.39	6.58e-17	Kawasaki disease;
LUAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg07677032	chr17:61819896	STRADA	0.56	10.14	0.44	9.26e-22	Prudent dietary pattern;
LUAD	cis	rs2735413	0.918	rs4888725	chr16:78076761	C/T	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs17135859	0.909	rs10055496	chr5:113001797	C/T	cg12552261	chr5:112820674	MCC	0.48	6.58	0.3	1.38e-10	F-cell distribution;
LUAD	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg05368731	chr17:41323189	NBR1	0.83	16.6	0.63	5e-48	Menopause (age at onset);
LUAD	cis	rs494562	0.892	rs632163	chr6:86122062	C/T	cg13315970	chr6:86159197	NT5E	0.67	7.9	0.36	2.49e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs701145	0.938	rs701135	chr3:154065455	C/G	cg17054900	chr3:154042577	DHX36	0.63	7.05	0.32	7.4e-12	Coronary artery disease;
LUAD	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg12623918	chr2:306882	NA	0.34	6.79	0.31	3.76e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9948	0.521	rs62156206	chr2:97357108	G/A	cg20312557	chr2:97357134	FER1L5	-0.65	-7.35	-0.34	1e-12	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg00383909	chr3:49044727	WDR6	0.42	6.49	0.3	2.4e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg06618935	chr21:46677482	NA	-0.5	-10.0	-0.44	2.88e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-7.69	-0.35	1.06e-13	Height;Educational attainment;Head circumference (infant);
LUAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg21237687	chr17:6899380	ALOX12	-0.42	-7.73	-0.35	8.04e-14	Tonsillectomy;
LUAD	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg02734326	chr4:10020555	SLC2A9	-0.41	-7.06	-0.32	6.9e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg05043794	chr9:111880884	C9orf5	0.42	7.23	0.33	2.33e-12	Menarche (age at onset);
LUAD	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg07169764	chr2:136633963	MCM6	0.68	8.32	0.37	1.23e-15	Corneal structure;
LUAD	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.52	-0.34	3.41e-13	Bipolar disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00419759	chr1:114301964	PHTF1	-0.45	-6.97	-0.32	1.23e-11	Height;
LUAD	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg13385794	chr1:248469461	NA	0.26	7.14	0.33	4.14e-12	Common traits (Other);
LUAD	trans	rs3942852	0.910	rs11603850	chr11:48140900	G/A	cg03929089	chr4:120376271	NA	-0.54	-7.22	-0.33	2.36e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg21191810	chr6:118973309	C6orf204	-0.48	-7.66	-0.35	1.28e-13	Diastolic blood pressure;
LUAD	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg08742575	chr21:47604166	C21orf56	0.44	7.28	0.33	1.64e-12	Testicular germ cell tumor;
LUAD	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg06608945	chr2:219082296	ARPC2	0.52	8.93	0.4	1.32e-17	Colorectal cancer;
LUAD	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg19318889	chr4:1322082	MAEA	0.46	8.04	0.36	9.22e-15	Obesity-related traits;
LUAD	trans	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg07211511	chr3:129823064	LOC729375	-0.54	-6.98	-0.32	1.14e-11	Blood pressure (smoking interaction);
LUAD	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg16205897	chr5:131564050	P4HA2	-0.34	-8.01	-0.36	1.09e-14	Blood metabolite levels;
LUAD	cis	rs7084921	0.578	rs11592631	chr10:101878219	G/A	cg19754520	chr10:101825118	CPN1	-0.35	-7.03	-0.32	8.18e-12	Bone mineral density;
LUAD	cis	rs10992471	0.528	rs4744135	chr9:95251874	A/C	cg14631576	chr9:95140430	CENPP	0.5	10.26	0.45	3.31e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg14092988	chr3:52407081	DNAH1	0.45	8.98	0.4	9.3e-18	Bipolar disorder;
LUAD	cis	rs2692947	0.727	rs749457	chr2:96795944	A/G	cg23100626	chr2:96804247	ASTL	0.34	9.1	0.4	3.48e-18	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs6543140	0.964	rs6748390	chr2:103062175	A/G	cg04239558	chr2:103089729	SLC9A4	0.34	6.9	0.32	1.93e-11	Blood protein levels;
LUAD	cis	rs7927771	0.524	rs9633830	chr11:47849470	T/G	cg18512352	chr11:47633146	NA	0.36	6.41	0.3	3.97e-10	Subjective well-being;
LUAD	cis	rs10419226	0.577	rs886443	chr19:18783785	A/G	cg22001208	chr19:18782374	NA	-0.5	-8.49	-0.38	3.48e-16	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	trans	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.45	-0.34	5.45e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg18827107	chr12:86230957	RASSF9	-0.49	-8.8	-0.39	3.63e-17	Major depressive disorder;
LUAD	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg03929089	chr4:120376271	NA	-0.6	-9.38	-0.41	3.95e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg02228675	chr17:40259724	DHX58	-0.44	-7.09	-0.33	5.79e-12	Fibrinogen levels;
LUAD	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs9296092	0.538	rs62405941	chr6:33517297	G/A	cg13560919	chr6:33536144	NA	-0.87	-15.31	-0.6	2.12e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg03733263	chr8:22462867	KIAA1967	-0.59	-9.99	-0.44	3.12e-21	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs8192282	0.739	rs6427720	chr1:154501756	G/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.46	-7.08	-0.33	6.18e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg26513180	chr16:89883248	FANCA	0.46	7.58	0.35	2.28e-13	Vitiligo;
LUAD	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11644478	chr21:40555479	PSMG1	-0.55	-9.06	-0.4	5.05e-18	Cognitive function;
LUAD	cis	rs4711350	0.862	rs530614	chr6:33714781	G/A	cg18005901	chr6:33739558	LEMD2	0.48	6.81	0.31	3.42e-11	Schizophrenia;
LUAD	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg00106254	chr7:1943704	MAD1L1	-0.44	-6.55	-0.3	1.71e-10	Schizophrenia;
LUAD	cis	rs2070488	0.730	rs2268759	chr3:38514327	G/A	cg24069376	chr3:38537580	EXOG	0.36	8.2	0.37	2.98e-15	Electrocardiographic conduction measures;
LUAD	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg22117172	chr7:91764530	CYP51A1	0.38	8.2	0.37	2.81e-15	Breast cancer;
LUAD	trans	rs867371	0.502	rs7176926	chr15:82538094	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.41	-6.91	-0.32	1.85e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LUAD	cis	rs9394841	0.692	rs9394834	chr6:41806793	G/A	cg17623882	chr6:41773611	USP49	-0.49	-6.86	-0.32	2.45e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21028142	chr17:79581711	NPLOC4	0.45	9.79	0.43	1.54e-20	Eye color traits;
LUAD	trans	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-10.35	-0.45	1.6e-22	Obesity-related traits;
LUAD	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg20607287	chr7:12443886	VWDE	-0.53	-6.67	-0.31	8.01e-11	Coronary artery disease;
LUAD	trans	rs1864729	1.000	rs2853318	chr8:98283509	A/T	cg08679828	chr8:102218111	ZNF706	-0.82	-8.58	-0.39	1.85e-16	Estradiol plasma levels (breast cancer);
LUAD	cis	rs9888739	0.800	rs7193268	chr16:31340997	A/G	cg15817542	chr16:31343056	ITGAM	0.41	7.07	0.33	6.35e-12	Systemic lupus erythematosus;
LUAD	cis	rs454510	1.000	rs422647	chr1:120195840	T/C	cg11530693	chr1:120165357	ZNF697	0.55	8.2	0.37	2.97e-15	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg02421172	chr7:1938701	MAD1L1	0.4	6.36	0.3	5.21e-10	Bipolar disorder;
LUAD	cis	rs11811982	0.793	rs7530155	chr1:227410186	C/A	cg24860534	chr1:227506868	CDC42BPA	0.71	7.67	0.35	1.22e-13	Optic disc area;
LUAD	cis	rs2996428	0.629	rs12135894	chr1:3728061	C/T	cg17848003	chr1:3704513	LRRC47	0.53	10.6	0.46	1.92e-23	Red cell distribution width;
LUAD	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg05768032	chr16:30646687	NA	0.43	7.64	0.35	1.47e-13	Multiple myeloma;
LUAD	cis	rs11677416	1.000	rs1878319	chr2:113544826	G/A	cg27083787	chr2:113543245	IL1A	0.38	6.63	0.31	1.01e-10	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg22676075	chr6:135203613	NA	0.4	7.46	0.34	4.95e-13	Red blood cell count;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg21400344	chr1:25870172	LDLRAP1	-0.41	-6.56	-0.3	1.55e-10	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.43	0.38	5.55e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg02176678	chr2:219576539	TTLL4	0.74	14.98	0.59	5.28e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg13560548	chr3:10150139	C3orf24	0.41	6.73	0.31	5.48e-11	Alzheimer's disease;
LUAD	cis	rs3803170	0.513	rs4766572	chr12:111830765	G/A	cg10833066	chr12:111807467	FAM109A	0.47	8.71	0.39	6.67e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs250677	0.524	rs250665	chr5:148454394	A/C	cg12140854	chr5:148520817	ABLIM3	-0.53	-8.88	-0.4	1.97e-17	Breast cancer;
LUAD	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg25894440	chr7:65020034	NA	-0.62	-6.57	-0.3	1.49e-10	Diabetic kidney disease;
LUAD	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-7.26	-0.33	1.84e-12	Personality dimensions;
LUAD	cis	rs8192282	0.739	rs4585969	chr1:154498957	C/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.46	-7.08	-0.33	6.18e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs15676	0.838	rs2280841	chr9:131600111	T/C	cg00228799	chr9:131580591	ENDOG	0.48	7.37	0.34	9.09e-13	Blood metabolite levels;
LUAD	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg20587970	chr11:113659929	NA	-1.2	-18.26	-0.66	2.43e-55	Hip circumference adjusted for BMI;
LUAD	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg22920501	chr2:26401640	FAM59B	-0.96	-14.21	-0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6546550	0.901	rs12232914	chr2:70117176	C/T	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.07	-0.47	3.33e-25	Prevalent atrial fibrillation;
LUAD	cis	rs7503807	0.905	rs9909449	chr17:78614393	A/G	cg09596252	chr17:78655493	RPTOR	0.4	7.82	0.36	4.21e-14	Obesity;
LUAD	cis	rs17401966	0.838	rs1538557	chr1:10297230	T/C	cg15208524	chr1:10270712	KIF1B	0.42	6.45	0.3	3.05e-10	Hepatocellular carcinoma;
LUAD	trans	rs1351696	1	rs1351696	chr11:48382471	A/G	cg03929089	chr4:120376271	NA	-0.55	-6.42	-0.3	3.62e-10	D-dimer levels;
LUAD	cis	rs58799304	0.618	rs35997354	chr1:156071806	G/A	cg24450063	chr1:156163899	SLC25A44	0.52	6.56	0.3	1.55e-10	Ischemic stroke;
LUAD	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg26446133	chr18:72167187	CNDP2	-0.92	-16.19	-0.62	3.3e-46	Refractive error;
LUAD	cis	rs2233152	0.519	rs11083567	chr19:41318306	C/T	cg21869046	chr19:41225005	ITPKC	0.37	7.02	0.32	8.77e-12	Kawasaki disease;
LUAD	trans	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg26043149	chr18:55253948	FECH	-0.42	-6.89	-0.32	2.04e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg05234568	chr11:5960015	NA	0.52	9.88	0.43	7.82e-21	DNA methylation (variation);
LUAD	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg26597838	chr10:835615	NA	1.3	20.16	0.7	7.85e-64	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg26727032	chr16:67993705	SLC12A4	-0.47	-6.62	-0.31	1.07e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs57994353	0.897	rs11999609	chr9:139363539	C/T	cg13856295	chr9:139396418	NOTCH1	-0.43	-6.82	-0.31	3.08e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	6.94	0.32	1.45e-11	Schizophrenia;
LUAD	trans	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-7.39	-0.34	8.01e-13	Blood trace element (Cu levels);
LUAD	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg19413350	chr8:57351067	NA	-0.41	-6.57	-0.3	1.44e-10	Obesity-related traits;
LUAD	cis	rs4852324	0.536	rs17009553	chr2:74220035	A/G	cg05890377	chr2:74357713	NA	-0.81	-7.23	-0.33	2.33e-12	Systemic lupus erythematosus;
LUAD	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg15017067	chr4:17643749	FAM184B	0.37	7.45	0.34	5.31e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg02951883	chr7:2050386	MAD1L1	-0.75	-12.74	-0.53	1.13e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.42	6.98	0.32	1.12e-11	Resistin levels;
LUAD	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg07061783	chr6:25882402	NA	-0.39	-6.62	-0.31	1.07e-10	Blood metabolite levels;
LUAD	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg10802521	chr3:52805072	NEK4	-0.44	-6.36	-0.3	5.19e-10	Schizophrenia;
LUAD	cis	rs10208940	0.502	rs10203846	chr2:68670921	G/A	cg12452813	chr2:68675892	NA	-0.54	-8.69	-0.39	8.03e-17	Urate levels in lean individuals;
LUAD	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg17200465	chr3:40428508	ENTPD3	-0.27	-6.87	-0.32	2.25e-11	Renal cell carcinoma;
LUAD	cis	rs3820068	0.655	rs59605679	chr1:15863796	T/G	cg24675056	chr1:15929824	NA	0.43	6.73	0.31	5.37e-11	Systolic blood pressure;
LUAD	cis	rs7180079	1.000	rs7177457	chr15:64530839	C/T	cg08069370	chr15:64387884	SNX1	-0.51	-6.56	-0.3	1.6e-10	Monocyte count;
LUAD	cis	rs8099014	1.000	rs12608175	chr18:56129976	T/C	cg12907477	chr18:56117327	MIR122	0.38	6.42	0.3	3.76e-10	Platelet count;
LUAD	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg18200150	chr17:30822561	MYO1D	0.73	15.63	0.61	8.19e-44	Schizophrenia;
LUAD	cis	rs3803170	0.513	rs4572196	chr12:111831993	A/G	cg10833066	chr12:111807467	FAM109A	0.49	9.09	0.4	3.79e-18	Mean corpuscular hemoglobin;
LUAD	cis	rs7677751	0.806	rs7698425	chr4:55090656	C/T	cg17187183	chr4:55093834	PDGFRA	0.52	8.77	0.39	4.57e-17	Corneal astigmatism;
LUAD	trans	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.94	0.44	4.58e-21	Ulcerative colitis;
LUAD	cis	rs6456156	0.819	rs7765739	chr6:167518472	C/T	cg07741184	chr6:167504864	NA	0.31	7.29	0.33	1.51e-12	Primary biliary cholangitis;
LUAD	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg23649088	chr2:200775458	C2orf69	-0.57	-7.08	-0.33	5.97e-12	Schizophrenia;
LUAD	cis	rs1475911	0.947	rs67055914	chr21:43510427	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.69	10.11	0.44	1.16e-21	IgG glycosylation;
LUAD	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.47	-9.79	-0.43	1.58e-20	Total body bone mineral density;
LUAD	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs477692	0.544	rs7923750	chr10:131446895	G/C	cg05714579	chr10:131428358	MGMT	-0.45	-7.05	-0.32	7.29e-12	Response to temozolomide;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg00960509	chr1:21671908	ECE1	-0.73	-6.88	-0.32	2.1e-11	Type 2 diabetes;
LUAD	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg08742575	chr21:47604166	C21orf56	0.43	7.26	0.33	1.93e-12	Testicular germ cell tumor;
LUAD	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg13385794	chr1:248469461	NA	0.25	6.81	0.31	3.26e-11	Common traits (Other);
LUAD	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg06263672	chr7:65235340	NA	0.47	6.41	0.3	3.8e-10	Aortic root size;
LUAD	cis	rs9462027	0.628	rs10947532	chr6:34780315	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.76	-0.39	4.66e-17	Systemic lupus erythematosus;
LUAD	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg19678392	chr7:94953810	PON1	-0.57	-7.92	-0.36	2.06e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9341808	0.718	rs3812121	chr6:80968727	A/G	cg08355045	chr6:80787529	NA	0.57	10.32	0.45	2.09e-22	Sitting height ratio;
LUAD	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg07917127	chr4:99064746	C4orf37	0.45	7.2	0.33	2.77e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.891	rs73054827	chr2:198649905	G/A	cg00982548	chr2:198649783	BOLL	-0.65	-9.19	-0.41	1.73e-18	Ulcerative colitis;
LUAD	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg05110241	chr16:68378359	PRMT7	-0.82	-8.9	-0.4	1.7e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg11189052	chr15:85197271	WDR73	0.59	7.61	0.35	1.84e-13	Schizophrenia;
LUAD	cis	rs8099014	0.861	rs4245270	chr18:56112854	A/G	cg12907477	chr18:56117327	MIR122	0.51	8.36	0.38	9.22e-16	Platelet count;
LUAD	trans	rs75804782	0.641	rs11902599	chr2:239348400	C/T	cg01134436	chr17:81009848	B3GNTL1	0.73	8.02	0.36	1.02e-14	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24531977	chr5:56204891	C5orf35	-0.96	-11.43	-0.49	1.51e-26	Type 2 diabetes;
LUAD	cis	rs6445967	0.554	rs7230	chr3:58413662	G/A	cg23715586	chr3:58305044	RPP14	0.4	6.61	0.31	1.17e-10	Platelet count;
LUAD	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.33e-13	Depression;
LUAD	cis	rs3772130	0.926	rs66653099	chr3:121393089	T/G	cg20356878	chr3:121714668	ILDR1	0.45	6.9	0.32	1.91e-11	Cognitive performance;
LUAD	trans	rs264943	0.967	rs10185399	chr2:104214676	A/T	cg18845578	chr2:240003174	HDAC4	0.41	7.2	0.33	2.69e-12	HIV-1 viral setpoint;
LUAD	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg18404041	chr3:52824283	ITIH1	-0.53	-9.82	-0.43	1.23e-20	Bipolar disorder;
LUAD	cis	rs877282	0.898	rs12358513	chr10:757571	A/G	cg17470449	chr10:769945	NA	0.59	8.02	0.36	1.07e-14	Uric acid levels;
LUAD	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08109568	chr15:31115862	NA	-0.59	-9.68	-0.43	3.74e-20	Huntington's disease progression;
LUAD	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg25324976	chr17:61989376	CSHL1	0.38	7.52	0.34	3.31e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg00071950	chr4:10020882	SLC2A9	-0.59	-10.33	-0.45	1.81e-22	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12760731	0.720	rs3791023	chr1:178398092	A/C	cg00404053	chr1:178313656	RASAL2	0.62	7.95	0.36	1.68e-14	Obesity-related traits;
LUAD	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg07776626	chr8:57350775	NA	-0.6	-9.01	-0.4	7.35e-18	Obesity-related traits;
LUAD	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg16006841	chr5:176797999	RGS14	0.55	9.96	0.44	3.9e-21	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg05313129	chr8:58192883	C8orf71	-0.53	-7.99	-0.36	1.3e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs56283067	0.887	rs10948171	chr6:44761028	C/T	cg18551225	chr6:44695536	NA	-0.6	-9.14	-0.41	2.7e-18	Total body bone mineral density;
LUAD	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg08316699	chr6:150357289	NA	0.32	6.74	0.31	5.07e-11	Alopecia areata;
LUAD	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.43	7.59	0.35	2.12e-13	Lung cancer in ever smokers;
LUAD	cis	rs754466	0.874	rs55910200	chr10:79665173	T/C	cg17075019	chr10:79541650	NA	-0.84	-13.79	-0.56	5.46e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9905704	0.633	rs2021733	chr17:56489168	C/T	cg19466818	chr17:56409534	MIR142	0.35	6.79	0.31	3.73e-11	Testicular germ cell tumor;
LUAD	cis	rs10746514	1.000	rs11122416	chr1:232249928	A/G	cg09506761	chr1:232265262	NA	0.37	6.8	0.31	3.54e-11	Response to statin therapy;
LUAD	cis	rs11676348	0.710	rs11894169	chr2:219046846	T/C	cg06547715	chr2:218990976	CXCR2	-0.29	-6.6	-0.31	1.22e-10	Ulcerative colitis;
LUAD	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.32	-0.34	1.22e-12	Blood metabolite levels;
LUAD	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg07930552	chr6:133119739	C6orf192	0.6	7.41	0.34	7.03e-13	Type 2 diabetes nephropathy;
LUAD	trans	rs747782	0.528	rs624348	chr11:48400795	G/A	cg03929089	chr4:120376271	NA	-0.55	-6.4	-0.3	4.22e-10	Intraocular pressure;
LUAD	cis	rs7202877	0.611	rs4888395	chr16:75413715	T/G	cg03315344	chr16:75512273	CHST6	0.48	6.52	0.3	2.04e-10	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg25358565	chr5:93447407	FAM172A	0.6	6.59	0.31	1.28e-10	Diabetic retinopathy;
LUAD	cis	rs2840044	1.000	rs9891800	chr17:33895015	G/C	cg05299278	chr17:33885742	SLFN14	-0.44	-8.94	-0.4	1.26e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg05043794	chr9:111880884	C9orf5	0.45	7.87	0.36	3e-14	Menarche (age at onset);
LUAD	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg04545296	chr12:48745243	ZNF641	0.4	10.09	0.44	1.34e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs12216545	0.737	rs7808866	chr7:150223982	A/T	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.67	-0.31	8.21e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg09085632	chr11:111637200	PPP2R1B	0.75	11.78	0.5	6.62e-28	Primary sclerosing cholangitis;
LUAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10819733	chr22:24237672	NA	-0.39	-7.18	-0.33	3.2e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg00086871	chr4:6988644	TBC1D14	0.74	6.37	0.3	4.98e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs4664304	1.000	rs6735923	chr2:160769588	A/G	cg06573604	chr2:160760825	LY75	-0.4	-6.67	-0.31	8.18e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs6761276	0.899	rs11678375	chr2:113835691	T/C	cg06383401	chr2:113825234	IL1F10	-0.3	-6.41	-0.3	3.97e-10	Protein quantitative trait loci;
LUAD	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg09324608	chr17:30823087	MYO1D	0.48	8.91	0.4	1.57e-17	Schizophrenia;
LUAD	cis	rs775227	0.636	rs3773697	chr3:113023509	C/T	cg18753928	chr3:113234510	CCDC52	-0.61	-7.93	-0.36	1.95e-14	Dental caries;
LUAD	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg03874509	chr1:107600012	PRMT6	-0.48	-8.81	-0.39	3.36e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs783540	0.934	rs10400906	chr15:83297138	A/G	cg18393722	chr15:85113863	UBE2QP1	0.42	6.91	0.32	1.78e-11	Schizophrenia;
LUAD	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-7.16	-0.33	3.67e-12	Longevity;Endometriosis;
LUAD	cis	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg01251360	chr16:68772225	CDH1	-0.29	-9.15	-0.41	2.46e-18	Colorectal cancer;
LUAD	cis	rs7250872	0.568	rs749109	chr19:1819736	G/A	cg10370574	chr19:1840461	REXO1	-0.64	-10.67	-0.46	1.05e-23	Bipolar disorder;
LUAD	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.41	8.2	0.37	2.9e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs629535	1.000	rs629535	chr8:70007938	C/T	cg21567404	chr3:27674614	NA	-0.99	-17.15	-0.64	2.04e-50	Dupuytren's disease;
LUAD	trans	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.46	-7.55	-0.34	2.63e-13	Body mass index;
LUAD	cis	rs4891159	0.790	rs72975925	chr18:74143902	G/A	cg24786174	chr18:74118243	ZNF516	-0.8	-14.59	-0.58	2.47e-39	Longevity;
LUAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg26338869	chr17:61819248	STRADA	-0.39	-6.59	-0.31	1.3e-10	Prudent dietary pattern;
LUAD	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg14983838	chr19:29218262	NA	0.56	7.24	0.33	2.1e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11644478	chr21:40555479	PSMG1	0.71	11.91	0.5	2.17e-28	Cognitive function;
LUAD	cis	rs62229266	0.557	rs4817761	chr21:37395556	C/T	cg08632701	chr21:37451849	NA	-0.41	-6.51	-0.3	2.14e-10	Mitral valve prolapse;
LUAD	trans	rs11039798	1.000	rs12281162	chr11:48650491	T/C	cg02254774	chr11:50257496	LOC441601	0.54	6.77	0.31	4.29e-11	Axial length;
LUAD	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg22683308	chr4:1340831	KIAA1530	-0.5	-8.27	-0.37	1.7e-15	Longevity;
LUAD	cis	rs1595825	0.891	rs77032596	chr2:198603185	T/G	cg00982548	chr2:198649783	BOLL	-0.67	-9.02	-0.4	6.44e-18	Ulcerative colitis;
LUAD	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg15911859	chr22:45810043	RIBC2;SMC1B	0.89	10.23	0.45	4.4e-22	Tonsillectomy;
LUAD	cis	rs367943	1.000	rs348958	chr5:112821137	G/A	cg12552261	chr5:112820674	MCC	-0.59	-11.13	-0.48	2.02e-25	Type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05018671	chr8:27146760	TRIM35	0.58	7.25	0.33	1.95e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg25894440	chr7:65020034	NA	-0.7	-7.45	-0.34	5.26e-13	Diabetic kidney disease;
LUAD	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.2	0.33	2.69e-12	Motion sickness;
LUAD	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg02782426	chr3:40428986	ENTPD3	0.41	8.91	0.4	1.5e-17	Renal cell carcinoma;
LUAD	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg26924012	chr15:45694286	SPATA5L1	1.02	19.16	0.68	2.32e-59	Homoarginine levels;
LUAD	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg18180107	chr4:99064573	C4orf37	0.42	6.76	0.31	4.64e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11249608	0.750	rs6891216	chr5:178447026	G/C	cg01312482	chr5:178451176	ZNF879	-0.42	-6.49	-0.3	2.4e-10	Pubertal anthropometrics;
LUAD	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg01528321	chr10:82214614	TSPAN14	0.52	8.21	0.37	2.76e-15	Post bronchodilator FEV1;
LUAD	cis	rs4389656	0.857	rs274680	chr5:6749085	T/G	cg10857441	chr5:6722123	POLS	-0.43	-7.46	-0.34	5.1e-13	Coronary artery disease;
LUAD	cis	rs2692947	0.832	rs2579550	chr2:96741944	G/A	cg23100626	chr2:96804247	ASTL	0.36	8.86	0.4	2.29e-17	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	trans	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.19	29.98	0.82	1.07e-106	Exhaled nitric oxide output;
LUAD	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg02269571	chr22:50332266	NA	-0.67	-9.57	-0.42	9.14e-20	Schizophrenia;
LUAD	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg27661571	chr11:113659931	NA	-0.73	-8.63	-0.39	1.28e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11644478	chr21:40555479	PSMG1	0.7	11.78	0.5	6.5e-28	Cognitive function;
LUAD	cis	rs31872	0.521	rs246050	chr5:140326860	T/G	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Visceral adipose tissue adjusted for BMI;
LUAD	cis	rs10499694	0.933	rs11575352	chr7:50594982	A/G	cg18232548	chr7:50535776	DDC	-0.44	-7.54	-0.34	2.97e-13	Body mass index;
LUAD	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg00277334	chr10:82204260	NA	0.49	8.06	0.36	8.02e-15	Post bronchodilator FEV1;
LUAD	cis	rs3784262	0.692	rs1822205	chr15:58284657	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.56	-0.35	2.45e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	trans	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg24644049	chr4:85504048	CDS1	0.8	7.22	0.33	2.49e-12	Skin colour saturation;
LUAD	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg11057378	chr10:81107060	PPIF	0.37	6.85	0.32	2.6e-11	Height;
LUAD	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg23281280	chr6:28129359	ZNF389	0.48	6.71	0.31	6.44e-11	Depression;
LUAD	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg15744005	chr10:104629667	AS3MT	-0.34	-6.82	-0.31	3.21e-11	Immature fraction of reticulocytes;Schizophrenia;
LUAD	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg26354017	chr1:205819088	PM20D1	-0.57	-10.34	-0.45	1.73e-22	Menarche (age at onset);
LUAD	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg08859206	chr1:53392774	SCP2	-0.58	-10.64	-0.46	1.43e-23	Monocyte count;
LUAD	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.22	-0.54	1.24e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg06263672	chr7:65235340	NA	-0.47	-6.4	-0.3	4.15e-10	Aortic root size;
LUAD	cis	rs986417	0.901	rs6573314	chr14:60972045	C/T	cg27398547	chr14:60952738	C14orf39	0.67	8.03	0.36	9.45e-15	Gut microbiota (bacterial taxa);
LUAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg08132940	chr7:1081526	C7orf50	-0.74	-10.05	-0.44	1.92e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg12564285	chr5:131593104	PDLIM4	-0.38	-6.62	-0.31	1.08e-10	Breast cancer;
LUAD	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg08645402	chr16:4508243	NA	-0.51	-8.94	-0.4	1.21e-17	Schizophrenia;
LUAD	cis	rs75920871	0.925	rs61903421	chr11:116961802	A/T	cg04087571	chr11:116723030	SIK3	-0.33	-6.69	-0.31	7.14e-11	Subjective well-being;
LUAD	cis	rs13315871	0.929	rs7635697	chr3:58313706	G/A	cg20936604	chr3:58311152	NA	-0.73	-7.37	-0.34	8.92e-13	Cholesterol, total;
LUAD	cis	rs796825	0.530	rs34829073	chr3:119943371	C/T	cg21790991	chr3:120137480	FSTL1	-0.42	-7.26	-0.33	1.88e-12	HIV-1 susceptibility;
LUAD	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg20701182	chr2:24300061	SF3B14	-0.89	-13.41	-0.55	1.99e-34	Lymphocyte counts;
LUAD	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg02734326	chr4:10020555	SLC2A9	-0.39	-6.38	-0.3	4.74e-10	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs4604732	0.631	rs10925044	chr1:247627071	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg04398451	chr17:18023971	MYO15A	-0.76	-13.86	-0.56	2.75e-36	Total body bone mineral density;
LUAD	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.18	-0.44	6.2e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg09704166	chr2:114031854	PAX8;LOC440839	-0.43	-6.51	-0.3	2.17e-10	Renal function-related traits (BUN);
LUAD	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg07741184	chr6:167504864	NA	0.36	8.24	0.37	2.11e-15	Primary biliary cholangitis;
LUAD	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg21191810	chr6:118973309	C6orf204	-0.48	-7.66	-0.35	1.28e-13	Diastolic blood pressure;
LUAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg25243455	chr2:114033360	PAX8;LOC440839	-0.36	-7.9	-0.36	2.4e-14	Lymphocyte counts;
LUAD	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg05872129	chr22:39784769	NA	-0.81	-15.17	-0.59	7.9e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs2456568	0.503	rs4254038	chr11:93666978	T/C	cg26875233	chr11:93583750	C11orf90	-0.41	-8.71	-0.39	6.81e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs2797160	1.000	rs4897152	chr6:126002400	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.6	-0.31	1.23e-10	Endometrial cancer;
LUAD	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg07936489	chr17:37558343	FBXL20	-0.47	-7.35	-0.34	1.04e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs9811920	0.965	rs6767441	chr3:99863183	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.38	-6.86	-0.32	2.47e-11	Axial length;
LUAD	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg14092988	chr3:52407081	DNAH1	0.45	9.15	0.41	2.51e-18	Bipolar disorder;
LUAD	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg17366294	chr4:99064904	C4orf37	0.51	9.15	0.41	2.45e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.37	-0.41	4.45e-19	Schizophrenia;
LUAD	cis	rs67072384	0.748	rs6592484	chr11:72464470	C/T	cg04827223	chr11:72435913	ARAP1	-0.57	-7.0	-0.32	9.99e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg22189786	chr22:42395067	WBP2NL	0.46	6.54	0.3	1.78e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs367943	1.000	rs348944	chr5:112822925	C/T	cg12552261	chr5:112820674	MCC	-0.59	-11.17	-0.48	1.49e-25	Type 2 diabetes;
LUAD	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg16447950	chr5:562315	NA	-0.41	-6.41	-0.3	3.89e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs1692580	0.846	rs377599	chr1:2164699	C/T	cg24578937	chr1:2090814	PRKCZ	0.56	10.77	0.46	4.55e-24	Coronary artery disease;
LUAD	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg15017067	chr4:17643749	FAM184B	0.33	6.41	0.3	3.85e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg27446573	chr6:127587934	RNF146	0.43	6.47	0.3	2.7e-10	Breast cancer;
LUAD	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-11.89	-0.5	2.58e-28	Mean corpuscular volume;
LUAD	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg21153622	chr11:89784906	NA	-0.33	-6.38	-0.3	4.54e-10	Coronary artery disease;
LUAD	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg06740227	chr12:86229804	RASSF9	0.45	7.88	0.36	2.75e-14	Major depressive disorder;
LUAD	cis	rs11209185	0.509	rs9436791	chr1:68452857	A/C	cg22082780	chr1:68452167	NA	0.54	11.54	0.49	5.74e-27	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg00495681	chr13:53174319	NA	-0.43	-7.31	-0.33	1.35e-12	Lewy body disease;
LUAD	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg03929089	chr4:120376271	NA	0.82	15.09	0.59	1.79e-41	Coronary artery disease;
LUAD	cis	rs427941	0.632	rs201490	chr7:101751910	C/T	cg06246474	chr7:101738831	CUX1	0.38	6.51	0.3	2.14e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7665090	0.517	rs1585214	chr4:103444533	T/C	cg07973026	chr4:103553119	MANBA	0.4	6.42	0.3	3.71e-10	Primary biliary cholangitis;
LUAD	cis	rs10489202	0.632	rs275137	chr1:168051266	A/C	cg25738037	chr1:168025549	DCAF6	0.54	7.99	0.36	1.27e-14	Schizophrenia;
LUAD	cis	rs2346177	0.806	rs56048837	chr2:46656647	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.4	-6.35	-0.3	5.54e-10	HDL cholesterol;
LUAD	cis	rs3733418	0.929	rs13149738	chr4:165905697	T/C	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-6.71	-0.31	6.29e-11	Obesity-related traits;
LUAD	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg02423579	chr7:2872169	GNA12	-0.84	-14.42	-0.57	1.28e-38	Height;
LUAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg04234412	chr22:24373322	LOC391322	-0.79	-14.16	-0.57	1.54e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg22963979	chr7:1858916	MAD1L1	-0.52	-8.96	-0.4	1.05e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg14728415	chr7:32535168	LSM5;AVL9	-0.57	-9.27	-0.41	9.74e-19	Cognitive ability;
LUAD	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg05425664	chr17:57184151	TRIM37	0.43	7.5	0.34	3.88e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08950929	chr16:58768327	GOT2	-0.41	-6.48	-0.3	2.61e-10	Height;
LUAD	cis	rs1160297	0.576	rs1451460	chr2:53088148	C/T	cg07782112	chr2:53107842	NA	0.4	8.57	0.38	1.91e-16	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.78e-11	Crohn's disease;
LUAD	cis	rs477692	0.604	rs1008982	chr10:131445731	T/C	cg05714579	chr10:131428358	MGMT	-0.41	-6.82	-0.31	3.23e-11	Response to temozolomide;
LUAD	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg19346786	chr7:2764209	NA	-0.57	-12.21	-0.51	1.43e-29	Height;
LUAD	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg15181151	chr6:150070149	PCMT1	0.41	8.51	0.38	3.04e-16	Lung cancer;
LUAD	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg06641503	chr3:48959341	ARIH2	-0.4	-7.91	-0.36	2.32e-14	Parkinson's disease;
LUAD	cis	rs877282	0.898	rs11253338	chr10:759559	C/T	cg06581033	chr10:766294	NA	-0.48	-6.55	-0.3	1.69e-10	Uric acid levels;
LUAD	cis	rs3784262	0.669	rs3784259	chr15:58257847	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.4	-8.08	-0.37	6.69e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.45	-0.34	5.31e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18876405	chr7:65276391	NA	0.41	6.53	0.3	1.88e-10	Aortic root size;
LUAD	cis	rs11771526	0.681	rs79578813	chr7:32308867	G/T	cg27532318	chr7:32358331	NA	0.59	7.63	0.35	1.61e-13	Body mass index;
LUAD	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	7.25	0.33	2.02e-12	Menarche (age at onset);
LUAD	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg15691649	chr6:25882328	NA	-0.78	-12.23	-0.51	1.13e-29	Urate levels;
LUAD	cis	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg07460842	chr6:66804631	NA	-1.04	-16.24	-0.62	1.97e-46	Exhaled nitric oxide output;
LUAD	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27286337	chr10:134555280	INPP5A	0.69	9.74	0.43	2.34e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg27572855	chr1:25598939	RHD	0.59	13.17	0.54	1.93e-33	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg13770153	chr20:60521292	NA	-0.56	-9.31	-0.41	6.78e-19	Body mass index;
LUAD	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg12311346	chr5:56204834	C5orf35	-0.47	-7.71	-0.35	9.3e-14	Coronary artery disease;
LUAD	cis	rs7301016	1.000	rs10877857	chr12:62872211	C/T	cg11441379	chr12:63026424	NA	0.52	6.39	0.3	4.45e-10	IgG glycosylation;
LUAD	cis	rs71636778	0.543	rs75305560	chr1:27242521	T/G	cg12203394	chr1:27248618	NUDC	0.52	6.59	0.31	1.33e-10	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.37	-0.34	8.82e-13	Retinal vascular caliber;
LUAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg07157834	chr1:205819609	PM20D1	0.47	7.19	0.33	2.95e-12	Parkinson's disease;
LUAD	cis	rs3815700	1.000	rs2287670	chr19:33095057	G/A	cg02997394	chr19:33096574	ANKRD27	0.66	8.64	0.39	1.15e-16	Eosinophilic esophagitis;
LUAD	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg08523384	chr5:141488047	NDFIP1	-0.49	-7.41	-0.34	6.85e-13	Crohn's disease;
LUAD	cis	rs6499255	1.000	rs4497676	chr16:69814950	G/A	cg15192750	chr16:69999425	NA	0.51	8.13	0.37	4.7e-15	IgE levels;
LUAD	cis	rs558133	1.000	rs622087	chr5:78418346	T/G	cg25119155	chr5:78426943	BHMT	0.53	9.24	0.41	1.17e-18	Blood and toenail selenium levels;
LUAD	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg18477163	chr1:228402036	OBSCN	0.44	7.75	0.35	7.12e-14	Diastolic blood pressure;
LUAD	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.81e-12	Hypertriglyceridemia;
LUAD	cis	rs2932538	0.922	rs112363416	chr1:113107543	T/C	cg22162597	chr1:113214053	CAPZA1	0.45	6.7	0.31	6.77e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg14196790	chr5:131705035	SLC22A5	0.46	8.39	0.38	7.23e-16	Blood metabolite levels;
LUAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg00280220	chr17:61926910	NA	0.36	6.83	0.32	3e-11	Prudent dietary pattern;
LUAD	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg23166289	chr1:210001082	C1orf107	0.49	6.93	0.32	1.56e-11	Orofacial clefts;
LUAD	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.39	6.39	0.3	4.42e-10	Type 2 diabetes;
LUAD	cis	rs2882667	0.931	rs12719518	chr5:138340976	T/C	cg04439458	chr5:138467593	SIL1	-0.39	-7.14	-0.33	4.04e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg00933542	chr6:150070202	PCMT1	0.44	9.72	0.43	2.82e-20	Lung cancer;
LUAD	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg07930552	chr6:133119739	C6orf192	0.6	7.41	0.34	7.03e-13	Type 2 diabetes nephropathy;
LUAD	cis	rs4711336	0.967	rs4711338	chr6:33660188	T/C	cg14003231	chr6:33640908	ITPR3	0.5	9.54	0.42	1.13e-19	Height;
LUAD	cis	rs3806843	0.521	rs246061	chr5:140324656	C/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg18761221	chr20:60518478	NA	-0.56	-9.24	-0.41	1.22e-18	Obesity-related traits;
LUAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06873352	chr17:61820015	STRADA	0.81	18.02	0.66	2.74e-54	Prudent dietary pattern;
LUAD	cis	rs6445967	0.518	rs62259820	chr3:58438900	C/T	cg13750441	chr3:58318267	PXK	-0.32	-6.57	-0.3	1.45e-10	Platelet count;
LUAD	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-7.45	-0.34	5.41e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg09509183	chr1:209979624	IRF6	0.62	7.27	0.33	1.76e-12	Cleft lip with or without cleft palate;
LUAD	trans	rs7395662	0.857	rs11040074	chr11:48856726	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.26	-0.33	1.88e-12	HDL cholesterol;
LUAD	cis	rs4589502	1.000	rs75502100	chr15:67131417	T/C	cg09911534	chr15:67153556	NA	-0.49	-6.53	-0.3	1.88e-10	Lung cancer (smoking interaction);
LUAD	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg10909506	chr17:38081995	ORMDL3	0.38	6.6	0.31	1.23e-10	Self-reported allergy;
LUAD	cis	rs8077889	0.672	rs1230397	chr17:41844689	A/G	cg26893861	chr17:41843967	DUSP3	1.2	29.11	0.82	4.42e-103	Triglycerides;
LUAD	cis	rs6076065	0.755	rs3746734	chr20:23349765	C/T	cg11657817	chr20:23433608	CST11	0.47	9.05	0.4	5.23e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7009516	0.766	rs13279289	chr8:24232368	A/G	cg01759110	chr8:24241694	ADAMDEC1	-0.44	-8.83	-0.39	2.82e-17	Hair greying;
LUAD	trans	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg04775059	chr7:64541387	NA	0.51	6.88	0.32	2.17e-11	Aortic root size;
LUAD	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs34734847	0.787	rs658521	chr12:121162414	G/T	cg21892295	chr12:121157589	UNC119B	-0.36	-6.4	-0.3	4.09e-10	Mean corpuscular volume;
LUAD	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg23815491	chr16:72088622	HP	0.52	9.56	0.42	9.44e-20	Fibrinogen levels;
LUAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg23978390	chr7:1156363	C7orf50	0.55	8.71	0.39	7.11e-17	Longevity;Endometriosis;
LUAD	cis	rs7264396	0.563	rs2425094	chr20:34306974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2.04e-15	Total cholesterol levels;
LUAD	cis	rs55788414	0.932	rs8043592	chr16:81182537	A/G	cg06400318	chr16:81190750	PKD1L2	-0.61	-8.05	-0.36	8.26e-15	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs59698941	0.527	rs1557852	chr5:132181800	G/A	cg14825688	chr5:132208181	LEAP2	-0.52	-10.56	-0.46	2.76e-23	Apolipoprotein A-IV levels;
LUAD	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.52	-8.41	-0.38	6.49e-16	Total body bone mineral density;
LUAD	cis	rs7809615	0.901	rs13243267	chr7:99053314	C/G	cg12290671	chr7:99195819	NA	0.67	8.05	0.36	8.18e-15	Blood metabolite ratios;
LUAD	trans	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg01620082	chr3:125678407	NA	0.62	7.62	0.35	1.67e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg12310025	chr6:25882481	NA	-0.58	-9.55	-0.42	1.1e-19	Blood metabolite levels;
LUAD	cis	rs11247915	0.540	rs11582416	chr1:26677721	A/G	cg15628303	chr1:26608928	UBXN11	-0.48	-8.73	-0.39	5.98e-17	Obesity-related traits;
LUAD	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg02782426	chr3:40428986	ENTPD3	0.43	9.21	0.41	1.59e-18	Renal cell carcinoma;
LUAD	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg02775129	chr4:119771670	NA	-0.93	-8.23	-0.37	2.35e-15	Cannabis dependence symptom count;
LUAD	trans	rs11039798	0.920	rs116109043	chr11:48976940	C/T	cg15704280	chr7:45808275	SEPT13	0.67	7.8	0.35	4.95e-14	Axial length;
LUAD	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg09359103	chr1:154839909	KCNN3	-0.81	-16.27	-0.62	1.37e-46	Prostate cancer;
LUAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08219700	chr8:58056026	NA	0.62	8.73	0.39	5.98e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg02508848	chr16:68573721	ZFP90	-0.42	-6.55	-0.3	1.72e-10	Ulcerative colitis;
LUAD	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg11502198	chr6:26597334	ABT1	0.66	10.7	0.46	8.1e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg04155289	chr7:94953770	PON1	-0.51	-6.55	-0.3	1.66e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.35e-11	Breast cancer;
LUAD	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg11833968	chr6:79620685	NA	-0.43	-8.03	-0.36	9.98e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg07570687	chr10:102243282	WNT8B	-0.44	-6.7	-0.31	6.61e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs2235573	0.653	rs6519095	chr22:38431917	G/A	cg19894588	chr14:64061835	NA	0.44	6.86	0.32	2.5e-11	Glioblastoma;Glioma;
LUAD	cis	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg14634687	chr17:47094252	IGF2BP1	0.27	6.66	0.31	8.41e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	trans	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.72	12.44	0.52	1.74e-30	Mean corpuscular volume;
LUAD	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg06784218	chr1:46089804	CCDC17	-0.52	-11.35	-0.48	3.16e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg12140854	chr5:148520817	ABLIM3	-0.62	-9.75	-0.43	2.17e-20	Breast cancer;
LUAD	cis	rs9473147	0.543	rs9349407	chr6:47453378	C/G	cg02130027	chr6:47444894	CD2AP	0.33	6.49	0.3	2.46e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg11494091	chr17:61959527	GH2	0.75	18.49	0.67	2.26e-56	Prudent dietary pattern;
LUAD	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06544989	chr22:39130855	UNC84B	0.42	7.81	0.35	4.61e-14	Menopause (age at onset);
LUAD	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg22961513	chr11:14280813	SPON1	-0.4	-8.3	-0.37	1.4e-15	Mitochondrial DNA levels;
LUAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08677398	chr8:58056175	NA	0.48	6.69	0.31	7.1e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg18755752	chr8:142205143	DENND3	-0.79	-16.19	-0.62	3.28e-46	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	trans	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg11693508	chr17:37793320	STARD3	0.49	7.12	0.33	4.62e-12	Bipolar disorder;
LUAD	trans	rs2262909	0.925	rs56073035	chr19:22276298	C/G	cg17074339	chr11:11642133	GALNTL4	0.48	7.84	0.36	3.71e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg18969171	chr14:35591572	PPP2R3C;KIAA0391	-0.42	-7.46	-0.34	4.9e-13	Subcortical brain region volumes;
LUAD	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg02527881	chr3:46936655	PTH1R	0.45	8.88	0.4	1.94e-17	Colorectal cancer;
LUAD	trans	rs1864729	1.000	rs2853320	chr8:98283523	C/G	cg08679828	chr8:102218111	ZNF706	-0.82	-8.58	-0.39	1.85e-16	Estradiol plasma levels (breast cancer);
LUAD	cis	rs12545109	0.800	rs1996105	chr8:57413123	A/G	cg19413350	chr8:57351067	NA	-0.44	-6.66	-0.31	8.75e-11	Obesity-related traits;
LUAD	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-9.81	-0.43	1.37e-20	Platelet count;
LUAD	cis	rs5756391	0.546	rs5756405	chr22:37310954	A/G	cg16356956	chr22:37317934	CSF2RB	0.34	7.56	0.34	2.6e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	11.75	0.5	8.47e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg17031739	chr1:67600172	NA	0.51	9.08	0.4	4.26e-18	Psoriasis;
LUAD	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg02574844	chr11:5959923	NA	-0.4	-6.77	-0.31	4.31e-11	DNA methylation (variation);
LUAD	cis	rs2625529	0.652	rs28650442	chr15:72155445	A/T	cg16672083	chr15:72433130	SENP8	-0.64	-12.22	-0.51	1.3e-29	Red blood cell count;
LUAD	cis	rs5756813	0.661	rs6000898	chr22:38202399	T/C	cg06521852	chr22:38141419	TRIOBP	0.47	8.51	0.38	2.96e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-6.94	-0.32	1.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.96	12.03	0.5	7.2e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg18876405	chr7:65276391	NA	0.63	10.93	0.47	1.13e-24	Aortic root size;
LUAD	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.86	-0.4	2.24e-17	Total body bone mineral density;
LUAD	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg25233709	chr10:116636983	FAM160B1	-0.39	-7.36	-0.34	9.77e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg00071950	chr4:10020882	SLC2A9	-0.59	-10.81	-0.47	3.12e-24	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg21214613	chr1:16344536	HSPB7	0.35	6.51	0.3	2.17e-10	Systolic blood pressure;
LUAD	cis	rs2688608	1.000	rs2688608	chr10:75658349	G/T	cg19442545	chr10:75533431	FUT11	-0.4	-6.78	-0.31	4.06e-11	Inflammatory bowel disease;
LUAD	cis	rs2637266	0.967	rs2395407	chr10:78380573	T/A	cg18941641	chr10:78392320	NA	0.34	7.12	0.33	4.79e-12	Pulmonary function;
LUAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.55	-10.68	-0.46	9.94e-24	Longevity;Endometriosis;
LUAD	cis	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg22705602	chr4:152727874	NA	-0.37	-6.48	-0.3	2.52e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg07930552	chr6:133119739	C6orf192	0.68	8.28	0.37	1.64e-15	Type 2 diabetes nephropathy;
LUAD	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg21724239	chr8:58056113	NA	0.63	7.99	0.36	1.33e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg00129232	chr17:37814104	STARD3	-0.47	-7.96	-0.36	1.65e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs9972944	0.631	rs6504345	chr17:63757052	T/G	cg07283582	chr17:63770753	CCDC46	-0.5	-11.44	-0.49	1.33e-26	Total body bone mineral density;
LUAD	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg14552801	chr7:65878734	NA	-0.38	-6.51	-0.3	2.16e-10	Aortic root size;
LUAD	cis	rs11722228	0.522	rs12503195	chr4:10082772	T/C	cg25629930	chr4:10089839	WDR1	-0.55	-8.73	-0.39	5.98e-17	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs68170813	0.652	rs6957186	chr7:107200592	T/C	cg23024343	chr7:107201750	COG5	0.54	6.78	0.31	4.03e-11	Coronary artery disease;
LUAD	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg09537434	chr19:41945824	ATP5SL	0.55	8.6	0.39	1.53e-16	Height;
LUAD	cis	rs4964805	0.954	rs11111786	chr12:104189057	T/C	cg02344784	chr12:104178138	NT5DC3	0.37	6.4	0.3	4.15e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs11971779	0.648	rs6946113	chr7:139106126	A/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.38e-10	Diisocyanate-induced asthma;
LUAD	cis	rs7095607	0.693	rs7896727	chr10:69952376	C/T	cg18986048	chr10:69913749	MYPN	0.42	7.42	0.34	6.49e-13	Lung function (FVC);
LUAD	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.0	-0.36	1.17e-14	Diabetic kidney disease;
LUAD	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg06263672	chr7:65235340	NA	0.47	6.41	0.3	3.8e-10	Aortic root size;
LUAD	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg03806693	chr22:41940476	POLR3H	0.64	8.93	0.4	1.27e-17	Vitiligo;
LUAD	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg25767906	chr1:53392781	SCP2	-0.47	-8.81	-0.39	3.37e-17	Monocyte count;
LUAD	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg17063962	chr7:91808500	NA	0.67	11.87	0.5	3.15e-28	Breast cancer;
LUAD	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.63	0.31	9.95e-11	Parkinson's disease;
LUAD	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg09796270	chr17:17721594	SREBF1	0.36	6.67	0.31	8.08e-11	Total body bone mineral density;
LUAD	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg06074448	chr4:187884817	NA	-0.36	-6.81	-0.31	3.43e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs877282	1.000	rs11253367	chr10:773389	G/A	cg06581033	chr10:766294	NA	-0.48	-6.83	-0.32	2.9100000000000002e-11	Uric acid levels;
LUAD	cis	rs1232027	0.656	rs1677623	chr5:79959103	A/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.0	-0.32	1.04e-11	Huntington's disease progression;
LUAD	trans	rs3219090	0.861	rs2695240	chr1:226607336	T/C	cg27539482	chr13:111589090	NA	0.41	6.77	0.31	4.3e-11	Melanoma;
LUAD	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.59	0.3	1.35e-10	Cardiac Troponin-T levels;
LUAD	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg19761014	chr17:28927070	LRRC37B2	0.77	9.16	0.41	2.22e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4321325	0.733	rs4284778	chr2:127946326	A/G	cg11380483	chr2:127933992	NA	0.47	6.5	0.3	2.3e-10	Protein C levels;
LUAD	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg09184832	chr6:79620586	NA	-0.4	-6.63	-0.31	1.04e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.83	0.32	3.01e-11	Cardiac Troponin-T levels;
LUAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg14789911	chr21:47582049	C21orf56	-0.45	-8.05	-0.36	8.63e-15	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg20607798	chr8:58055168	NA	0.6	8.16	0.37	3.76e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg14784868	chr12:69753453	YEATS4	0.46	7.59	0.35	2.02e-13	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg08616760	chr5:178157801	ZNF354A	-0.37	-6.59	-0.31	1.3100000000000001e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
LUAD	cis	rs4631830	0.863	rs10826125	chr10:51530505	G/A	cg20129853	chr10:51489980	NA	-0.32	-6.39	-0.3	4.35e-10	Prostate-specific antigen levels;
LUAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg26354017	chr1:205819088	PM20D1	0.81	17.06	0.64	5.12e-50	Menarche (age at onset);
LUAD	cis	rs7773004	0.905	rs994379	chr6:26305407	C/G	cg00631329	chr6:26305371	NA	0.53	9.22	0.41	1.4e-18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22857025	chr5:266934	NA	-0.97	-14.68	-0.58	1.01e-39	Breast cancer;
LUAD	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg22823121	chr1:150693482	HORMAD1	0.48	9.37	0.41	4.49e-19	Urate levels;
LUAD	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg20362242	chr5:692897	TPPP	0.57	6.98	0.32	1.15e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs6754311	0.544	rs11693502	chr2:136808949	C/T	cg07305463	chr2:136567211	LCT	0.33	6.51	0.3	2.16e-10	Mosquito bite size;
LUAD	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg21890820	chr11:65308645	LTBP3	0.48	7.67	0.35	1.21e-13	Bone mineral density;
LUAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	cis	rs2386661	0.826	rs1317516	chr10:5672720	A/G	cg26603656	chr10:5671107	NA	-0.42	-7.11	-0.33	4.94e-12	Breast cancer;
LUAD	cis	rs6541297	1.000	rs7543050	chr1:230278291	C/G	cg20703242	chr1:230279135	GALNT2	0.65	11.85	0.5	3.59e-28	Coronary artery disease;
LUAD	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg22681709	chr2:178499509	PDE11A	-0.53	-9.29	-0.41	8e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg09184832	chr6:79620586	NA	-0.49	-9.02	-0.4	6.61e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg26076054	chr5:421317	AHRR	-0.43	-6.38	-0.3	4.66e-10	Cystic fibrosis severity;
LUAD	trans	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg07817883	chr1:32538562	TMEM39B	1.5	12.94	0.53	1.61e-32	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg21775007	chr8:11205619	TDH	-0.5	-9.01	-0.4	7.16e-18	Retinal vascular caliber;
LUAD	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.86e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg08807101	chr21:30365312	RNF160	-0.44	-7.67	-0.35	1.22e-13	Dental caries;
LUAD	cis	rs6942407	0.546	rs7780698	chr7:86835731	T/G	cg02420886	chr7:86849541	C7orf23	0.7	7.58	0.35	2.18e-13	Food allergy;
LUAD	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg08798685	chr6:27730294	NA	-0.44	-7.09	-0.33	5.49e-12	Parkinson's disease;
LUAD	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg15448220	chr1:150897856	SETDB1	0.51	8.97	0.4	9.77e-18	Melanoma;
LUAD	cis	rs524023	0.957	rs893006	chr11:64365796	C/A	cg19131476	chr11:64387923	NRXN2	-0.38	-7.2	-0.33	2.86e-12	Urate levels in obese individuals;
LUAD	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg22676075	chr6:135203613	NA	0.55	9.83	0.43	1.13e-20	Red blood cell count;
LUAD	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22307029	chr19:49891270	CCDC155	0.67	9.65	0.42	4.78e-20	Multiple sclerosis;
LUAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg22764044	chr5:178986830	RUFY1	-0.7	-12.55	-0.52	6.11e-31	Lung cancer;
LUAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg02782426	chr3:40428986	ENTPD3	0.42	9.34	0.41	5.7e-19	Renal cell carcinoma;
LUAD	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.79	0.31	3.71e-11	Hypertriglyceridemia;
LUAD	cis	rs55728055	0.661	rs56411340	chr22:31984476	G/T	cg01338084	chr22:32026380	PISD	0.89	6.89	0.32	1.98e-11	Age-related hearing impairment;
LUAD	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg12667521	chr19:29218732	NA	0.51	7.18	0.33	3.26e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg22029157	chr1:209979665	IRF6	0.7	9.39	0.42	3.84e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg24675658	chr1:53192096	ZYG11B	-0.4	-6.79	-0.31	3.78e-11	Monocyte count;
LUAD	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg02423579	chr7:2872169	GNA12	-0.58	-9.89	-0.43	7.03e-21	Height;
LUAD	cis	rs1784581	0.588	rs9346893	chr6:162417511	C/G	cg17173639	chr6:162384350	PARK2	0.45	8.03	0.36	9.58e-15	Itch intensity from mosquito bite;
LUAD	cis	rs367615	0.552	rs2963023	chr5:108730070	C/T	cg17395555	chr5:108820864	NA	-0.5	-9.45	-0.42	2.33e-19	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg08601574	chr20:25228251	PYGB	0.46	8.77	0.39	4.37e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg11859384	chr17:80120422	CCDC57	-0.48	-8.59	-0.39	1.67e-16	Life satisfaction;
LUAD	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22857025	chr5:266934	NA	-0.99	-14.44	-0.57	1.05e-38	Breast cancer;
LUAD	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4889855	0.556	rs74003969	chr17:78526212	C/T	cg16591659	chr17:78472290	NA	0.44	7.65	0.35	1.38e-13	Fractional excretion of uric acid;
LUAD	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg15445000	chr17:37608096	MED1	-0.45	-8.37	-0.38	8.22e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs12760731	0.565	rs11585355	chr1:178181219	T/G	cg00404053	chr1:178313656	RASAL2	0.74	9.36	0.41	4.73e-19	Obesity-related traits;
LUAD	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg03605463	chr16:89740564	NA	0.65	11.78	0.5	6.69e-28	Vitiligo;
LUAD	cis	rs6740322	0.895	rs6744746	chr2:43555805	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.78	11.85	0.5	3.68e-28	Coronary artery disease;
LUAD	cis	rs10193935	0.901	rs13426988	chr2:42604081	G/A	cg27598129	chr2:42591480	NA	-0.76	-8.65	-0.39	1.07e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.967	rs17825877	chr17:28515188	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	8.34	0.38	1.02e-15	Coffee consumption (cups per day);
LUAD	trans	rs9784649	0.891	rs57762467	chr5:25025700	C/T	cg11038491	chr20:34638489	LOC647979	-0.73	-8.47	-0.38	4.07e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6678622	0.831	rs12401738	chr1:78446761	G/A	cg21968580	chr1:78470640	DNAJB4	0.41	6.51	0.3	2.12e-10	Hip circumference;
LUAD	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg09137382	chr11:130731461	NA	0.4	7.39	0.34	8.09e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg00784671	chr22:46762841	CELSR1	-0.6	-7.46	-0.34	4.99e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	8.75e-12	Aortic root size;
LUAD	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg06808227	chr14:105710500	BRF1	-0.41	-6.45	-0.3	3.03e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg21856205	chr7:94953877	PON1	-0.54	-7.59	-0.35	2.13e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg09835421	chr16:68378352	PRMT7	-0.81	-8.86	-0.4	2.2e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg19610905	chr11:61596333	FADS2	-0.66	-11.2	-0.48	1.17e-25	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs713477	0.935	rs4901564	chr14:55912409	G/T	cg13175173	chr14:55914753	NA	-0.35	-7.2	-0.33	2.78e-12	Pediatric bone mineral content (femoral neck);
LUAD	trans	rs7487075	0.786	rs7980775	chr12:46674873	A/G	cg17341174	chr7:97923834	BAIAP2L1	-0.34	-6.44	-0.3	3.32e-10	Itch intensity from mosquito bite;
LUAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg23978390	chr7:1156363	C7orf50	0.52	7.05	0.32	7.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08280861	chr8:58055591	NA	0.77	9.68	0.43	3.81e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg17063962	chr7:91808500	NA	-0.61	-10.49	-0.45	4.95e-23	Breast cancer;
LUAD	cis	rs10056811	0.556	rs55810502	chr5:74380959	A/G	cg19683494	chr5:74908142	NA	0.48	6.71	0.31	6.31e-11	Coronary artery disease;
LUAD	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg27539214	chr16:67997921	SLC12A4	-0.66	-8.33	-0.38	1.13e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs72928364	1.000	rs35517882	chr3:100697174	T/C	cg10123952	chr3:100791384	NA	0.64	7.47	0.34	4.74e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs10411161	0.752	rs10402107	chr19:52384600	A/G	cg22319618	chr22:45562946	NUP50	-0.59	-8.35	-0.38	9.98e-16	Breast cancer;
LUAD	cis	rs936229	0.511	rs12591513	chr15:75102714	G/A	cg14664628	chr15:75095509	CSK	-0.49	-8.08	-0.37	6.8e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs13315871	1.000	rs35792042	chr3:58409668	C/T	cg20936604	chr3:58311152	NA	-0.7	-7.15	-0.33	3.72e-12	Cholesterol, total;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg20826792	chr1:29425	WASH5P	-0.41	-6.46	-0.3	2.89e-10	Vertical cup-disc ratio;
LUAD	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg26647111	chr11:31128758	NA	-0.46	-8.2	-0.37	2.88e-15	Red blood cell count;
LUAD	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21659725	chr3:3221576	CRBN	-0.51	-8.4	-0.38	7e-16	Body mass index;
LUAD	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg08999081	chr20:33150536	PIGU	-0.6	-13.36	-0.54	3.16e-34	Glomerular filtration rate (creatinine);
LUAD	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg07708487	chr16:89387014	ANKRD11	-0.33	-6.75	-0.31	4.78e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg15123519	chr2:136567270	LCT	0.4	7.36	0.34	9.95e-13	Mosquito bite size;
LUAD	cis	rs4077468	1.000	rs4077468	chr1:205914757	A/G	cg07167872	chr1:205819463	PM20D1	-0.37	-6.64	-0.31	9.48e-11	Cystic fibrosis-related diabetes;
LUAD	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg01097406	chr16:89675127	NA	-0.33	-6.61	-0.31	1.17e-10	Vitiligo;
LUAD	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.38	-6.48	-0.3	2.53e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs243505	0.691	rs243480	chr7:148452905	G/T	cg09806900	chr7:148480153	CUL1	-0.44	-6.58	-0.3	1.4e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg04703951	chr17:43578652	NA	0.59	8.17	0.37	3.5e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs13201294	1	rs13201294	chr6:27556141	A/T	cg01620082	chr3:125678407	NA	-0.77	-8.53	-0.38	2.57e-16	Squamous cell lung carcinoma;
LUAD	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg15962314	chr1:44399869	ARTN	0.32	6.9	0.32	1.94e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	11.87	0.5	3.08e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10203711	0.933	rs7584327	chr2:239584203	A/T	cg14580085	chr2:239553406	NA	0.4	8.62	0.39	1.38e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.01	0.32	9.31e-12	Renal cell carcinoma;
LUAD	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg12935359	chr14:103987150	CKB	0.52	8.08	0.37	6.69e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	7.54	0.34	2.97e-13	Alzheimer's disease;
LUAD	cis	rs7799006	0.929	rs7781856	chr7:2257199	C/T	cg02951883	chr7:2050386	MAD1L1	-0.49	-7.76	-0.35	6.32e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg05373962	chr22:49881684	NA	-0.48	-9.87	-0.43	7.85e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg22676075	chr6:135203613	NA	0.4	7.32	0.34	1.25e-12	Red blood cell count;
LUAD	trans	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.5	0.45	4.54e-23	Mean corpuscular volume;
LUAD	cis	rs7731657	0.509	rs2250348	chr5:130243531	T/A	cg08523029	chr5:130500466	HINT1	-0.59	-7.55	-0.34	2.75e-13	Fasting plasma glucose;
LUAD	cis	rs3087591	0.960	rs6505232	chr17:29611411	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.57	-0.3	1.53e-10	Hip circumference;
LUAD	cis	rs6738485	0.588	rs12712247	chr2:106849382	C/T	cg16099169	chr2:106886729	NA	-0.37	-6.4	-0.3	4.18e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs73206853	0.841	rs78843188	chr12:110827923	G/C	cg12870014	chr12:110450643	ANKRD13A	0.61	6.73	0.31	5.38e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs3806843	0.576	rs246002	chr5:140341104	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.53	-0.3	1.88e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg03030879	chr14:75389066	RPS6KL1	0.36	6.73	0.31	5.52e-11	Caffeine consumption;
LUAD	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.49	-7.74	-0.35	7.18e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg06781209	chr11:61594997	FADS2	-0.64	-9.54	-0.42	1.16e-19	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	trans	rs875971	1.000	rs778722	chr7:65844828	T/C	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg22618164	chr12:122356400	WDR66	0.68	12.16	0.51	2.11e-29	Mean corpuscular volume;
LUAD	cis	rs12519773	0.550	rs4242242	chr5:92519387	G/A	cg18783429	chr5:92414398	NA	0.47	8.22	0.37	2.51e-15	Migraine;
LUAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg01448562	chr3:133502909	NA	0.66	12.17	0.51	1.97e-29	Iron status biomarkers;
LUAD	cis	rs6674176	0.569	rs11210935	chr1:44369444	G/A	cg15962314	chr1:44399869	ARTN	0.3	6.46	0.3	2.84e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs62238980	0.614	rs117338422	chr22:32399226	C/G	cg00543991	chr22:32367038	NA	0.95	8.87	0.4	2.05e-17	Childhood ear infection;
LUAD	cis	rs300774	0.925	rs384286	chr2:128345	C/T	cg21211680	chr2:198530	NA	-0.46	-7.33	-0.34	1.16e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg17757837	chr7:157058334	UBE3C	0.48	8.55	0.38	2.34e-16	Body mass index;
LUAD	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg23803603	chr1:2058230	PRKCZ	0.4	6.41	0.3	3.95e-10	Height;
LUAD	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg06532163	chr17:45867833	NA	0.49	8.71	0.39	6.72e-17	IgG glycosylation;
LUAD	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.52	-0.34	3.32e-13	Total body bone mineral density;
LUAD	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg02176678	chr2:219576539	TTLL4	0.68	13.49	0.55	9.42e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs68170813	0.559	rs79026644	chr7:107031803	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-10.68	-0.46	9.71e-24	Coronary artery disease;
LUAD	cis	rs6908034	0.556	rs79028848	chr6:19783153	G/A	cg02682789	chr6:19804855	NA	0.97	9.13	0.41	2.81e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg00745463	chr17:30367425	LRRC37B	-0.79	-9.71	-0.43	2.84e-20	Hip circumference adjusted for BMI;
LUAD	cis	rs1065656	0.553	rs344357	chr16:1836255	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.55	-8.19	-0.37	3.11e-15	Insulin-like growth factors;
LUAD	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.57	-0.35	2.38e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-11.92	-0.5	1.94e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg10591111	chr5:226296	SDHA	-0.54	-7.02	-0.32	9.16e-12	Breast cancer;
LUAD	cis	rs7020830	0.931	rs13288178	chr9:37107799	A/G	cg14294708	chr9:37120828	ZCCHC7	0.83	16.11	0.62	7.14e-46	Schizophrenia;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22564551	chr10:89115108	NA	0.46	6.7	0.31	6.51e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs35771425	1.000	rs11579557	chr1:211619703	A/G	cg10512769	chr1:211675356	NA	0.38	6.48	0.3	2.53e-10	Educational attainment (years of education);
LUAD	cis	rs367943	0.712	rs9326887	chr5:112728581	T/A	cg12552261	chr5:112820674	MCC	0.48	9.34	0.41	5.49e-19	Type 2 diabetes;
LUAD	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-7.03	-0.32	8.47e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg07988820	chr12:82153109	PPFIA2	-0.49	-7.47	-0.34	4.79e-13	Resting heart rate;
LUAD	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg25811766	chr13:21894605	NA	-0.62	-7.54	-0.34	2.91e-13	White matter hyperintensity burden;
LUAD	cis	rs739496	0.947	rs55851737	chr12:111936838	T/C	cg10833066	chr12:111807467	FAM109A	0.41	6.64	0.31	9.95e-11	Platelet count;
LUAD	cis	rs6484504	0.625	rs1535741	chr11:31375072	T/C	cg26647111	chr11:31128758	NA	0.43	7.57	0.35	2.36e-13	Red blood cell count;
LUAD	cis	rs4481887	0.512	rs1538702	chr1:248519665	A/G	cg00666640	chr1:248458726	OR2T12	0.3	6.36	0.3	5.37e-10	Common traits (Other);
LUAD	cis	rs7584330	0.554	rs729388	chr2:238425004	G/C	cg14458575	chr2:238380390	NA	0.53	8.71	0.39	7.11e-17	Prostate cancer;
LUAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.59	-7.34	-0.34	1.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg21724239	chr8:58056113	NA	0.72	9.55	0.42	1.07e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.2	-0.33	2.83e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs3772130	0.583	rs28497949	chr3:121448675	T/A	cg20356878	chr3:121714668	ILDR1	0.6	11.26	0.48	6.49e-26	Cognitive performance;
LUAD	cis	rs7809950	1.000	rs28714607	chr7:107106253	T/C	cg23024343	chr7:107201750	COG5	-0.74	-12.66	-0.52	2.3e-31	Coronary artery disease;
LUAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg12016809	chr21:47604291	C21orf56	0.51	8.43	0.38	5.42e-16	Testicular germ cell tumor;
LUAD	cis	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg14019146	chr3:50243930	SLC38A3	-0.47	-9.38	-0.41	4.08e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg20891283	chr12:69753455	YEATS4	0.45	7.35	0.34	1.06e-12	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs877282	0.682	rs2265092	chr10:780293	C/T	cg17470449	chr10:769945	NA	-0.44	-7.1	-0.33	5.15e-12	Uric acid levels;
LUAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg11965913	chr1:205819406	PM20D1	0.82	16.63	0.63	3.86e-48	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg05340658	chr4:99064831	C4orf37	0.54	9.17	0.41	2.05e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7177699	0.557	rs4389113	chr15:79121739	G/A	cg15571903	chr15:79123663	NA	-0.39	-7.79	-0.35	5.21e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs73206853	0.698	rs1018133	chr12:111121302	G/C	cg12870014	chr12:110450643	ANKRD13A	0.6	6.81	0.31	3.36e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs1448094	0.872	rs4919777	chr12:86358491	C/T	cg02569458	chr12:86230093	RASSF9	0.37	7.09	0.33	5.79e-12	Major depressive disorder;
LUAD	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.81	-0.31	3.44e-11	Personality dimensions;
LUAD	cis	rs2067615	0.579	rs4964492	chr12:107222774	C/T	cg15890332	chr12:107067104	RFX4	0.38	8.24	0.37	2.18e-15	Heart rate;
LUAD	cis	rs240764	0.594	rs7356804	chr6:101078438	A/G	cg09795085	chr6:101329169	ASCC3	0.39	6.52	0.3	2.05e-10	Neuroticism;
LUAD	cis	rs89107	0.641	rs431115	chr6:118612615	C/T	cg18833306	chr6:118973337	C6orf204	0.55	10.27	0.45	3.1e-22	Cardiac structure and function;
LUAD	cis	rs597539	0.690	rs7104351	chr11:68617886	A/G	cg06028808	chr11:68637592	NA	0.5	8.19	0.37	3.22e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg06608945	chr2:219082296	ARPC2	-0.43	-6.63	-0.31	1.02e-10	Ulcerative colitis;
LUAD	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.67	-0.35	1.2e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs6087990	0.899	rs6058893	chr20:31392777	C/T	cg13636640	chr20:31349939	DNMT3B	0.79	14.85	0.59	1.89e-40	Ulcerative colitis;
LUAD	cis	rs12286929	0.736	rs11215397	chr11:115044076	G/A	cg04055981	chr11:115044050	NA	0.48	8.77	0.39	4.55e-17	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg16099599	chr11:93583650	C11orf90	-0.32	-6.36	-0.3	5.33e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg00933542	chr6:150070202	PCMT1	0.36	7.39	0.34	7.97e-13	Testicular germ cell tumor;
LUAD	cis	rs2249625	0.508	rs60020363	chr6:72844706	C/T	cg18830697	chr6:72922368	RIMS1	0.47	8.5	0.38	3.2e-16	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg04117972	chr1:227635322	NA	0.65	6.6	0.31	1.24e-10	Major depressive disorder;
LUAD	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg00933542	chr6:150070202	PCMT1	0.43	9.19	0.41	1.84e-18	Lung cancer;
LUAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg20276088	chr3:133502917	NA	0.41	7.09	0.33	5.54e-12	Iron status biomarkers;
LUAD	cis	rs1232027	0.700	rs1677688	chr5:79938007	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg02018176	chr4:1364513	KIAA1530	0.69	11.73	0.5	1.02e-27	Longevity;
LUAD	cis	rs758324	0.812	rs4280859	chr5:131246941	A/T	cg06307176	chr5:131281290	NA	-0.46	-7.64	-0.35	1.42e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.5	0.3	2.24e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	8.02	0.36	1.07e-14	Parkinson's disease;
LUAD	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg04772025	chr11:68637568	NA	0.54	8.69	0.39	8.3e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3784262	0.565	rs2899613	chr15:58347260	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.58	-0.35	2.24e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg13073564	chr4:8508604	NA	0.48	7.76	0.35	6.48e-14	Response to antineoplastic agents;
LUAD	trans	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg18834416	chr8:37888184	EIF4EBP1	0.46	7.78	0.35	5.59e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7267979	0.844	rs4815413	chr20:25359229	G/T	cg08601574	chr20:25228251	PYGB	-0.41	-7.69	-0.35	1.03e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4073416	0.542	rs8010726	chr14:65932597	C/T	cg10998611	chr14:65879393	FUT8;LOC645431	-0.42	-6.38	-0.3	4.61e-10	N-glycan levels;
LUAD	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.6	11.48	0.49	9.95e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6960043	0.743	rs1002061	chr7:15039499	A/T	cg19272540	chr7:15055459	NA	-0.34	-7.35	-0.34	1.03e-12	Type 2 diabetes;
LUAD	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg24955955	chr5:415729	AHRR	0.79	8.91	0.4	1.53e-17	Fat distribution (HIV);
LUAD	trans	rs11039798	0.541	rs12283728	chr11:48796407	G/A	cg03929089	chr4:120376271	NA	0.59	6.8	0.31	3.56e-11	Axial length;
LUAD	cis	rs6484504	0.600	rs366758	chr11:31222499	A/C	cg26647111	chr11:31128758	NA	-0.46	-8.24	-0.37	2.13e-15	Red blood cell count;
LUAD	cis	rs4268898	1.000	rs2303294	chr2:24432620	A/G	cg06627628	chr2:24431161	ITSN2	0.46	7.89	0.36	2.63e-14	Asthma;
LUAD	cis	rs8014204	0.836	rs12588415	chr14:75278211	G/A	cg06637938	chr14:75390232	RPS6KL1	0.39	7.19	0.33	2.9e-12	Caffeine consumption;
LUAD	cis	rs67072384	0.818	rs6592483	chr11:72463974	A/G	cg04827223	chr11:72435913	ARAP1	-0.6	-6.53	-0.3	1.85e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs9443645	0.527	rs12527806	chr6:79507667	A/T	cg23262351	chr6:79576851	IRAK1BP1	-0.41	-6.48	-0.3	2.6200000000000003e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg17279839	chr7:150038598	RARRES2	0.44	7.25	0.33	1.96e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg13180566	chr4:1052158	NA	-0.39	-6.61	-0.31	1.19e-10	Recombination rate (females);
LUAD	trans	rs28489187	0.558	rs2474123	chr1:85827452	C/T	cg06295548	chr4:146296778	NA	-0.4	-6.55	-0.3	1.69e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg18932078	chr1:2524107	MMEL1	-0.35	-6.5	-0.3	2.3e-10	Ulcerative colitis;
LUAD	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg06636551	chr8:101224915	SPAG1	-0.38	-6.87	-0.32	2.28e-11	Atrioventricular conduction;
LUAD	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.13	-0.37	4.66e-15	Total body bone mineral density;
LUAD	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg23283495	chr1:209979779	IRF6	0.41	7.32	0.34	1.24e-12	Monobrow;
LUAD	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	7.58	0.35	2.15e-13	Tonsillectomy;
LUAD	cis	rs113835537	0.877	rs2229455	chr11:66328055	A/G	cg24851651	chr11:66362959	CCS	0.55	7.99	0.36	1.29e-14	Airway imaging phenotypes;
LUAD	cis	rs7771547	0.607	rs584196	chr6:36456243	G/C	cg07856975	chr6:36356162	ETV7	0.42	6.47	0.3	2.66e-10	Platelet distribution width;
LUAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00149659	chr3:10157352	C3orf10	0.6	7.94	0.36	1.88e-14	Alzheimer's disease;
LUAD	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg16797656	chr11:68205561	LRP5	0.46	8.89	0.4	1.78e-17	Total body bone mineral density;
LUAD	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg12193833	chr17:30244370	NA	-0.59	-7.14	-0.33	4.18e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg00750074	chr16:89608354	SPG7	-0.65	-11.57	-0.49	4.18e-27	Multiple myeloma (IgH translocation);
LUAD	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.17	0.37	3.65e-15	Rheumatoid arthritis;
LUAD	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg16205897	chr5:131564050	P4HA2	-0.3	-6.38	-0.3	4.74e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg21823605	chr1:152486609	CRCT1	0.29	6.66	0.31	8.42e-11	Hair morphology;
LUAD	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg06028808	chr11:68637592	NA	-0.4	-6.61	-0.31	1.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03452623	chr4:187889614	NA	-0.82	-16.67	-0.63	2.58e-48	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11890956	chr21:40555474	PSMG1	0.7	11.5	0.49	8.26e-27	Cognitive function;
LUAD	cis	rs6993813	0.843	rs78317345	chr8:120046243	A/C	cg01975934	chr8:119970761	NA	-0.38	-7.33	-0.34	1.19e-12	Bone mineral density (hip);
LUAD	cis	rs11676348	0.772	rs10932745	chr2:218942976	T/C	cg06547715	chr2:218990976	CXCR2	0.31	7.02	0.32	8.97e-12	Ulcerative colitis;
LUAD	cis	rs7903847	0.642	rs11189196	chr10:99155079	A/G	cg20016023	chr10:99160130	RRP12	-0.31	-7.42	-0.34	6.64e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg18252515	chr7:66147081	NA	0.61	6.7	0.31	6.5500000000000006e-11	Diabetic kidney disease;
LUAD	trans	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg16006296	chr10:38738647	LOC399744	0.37	6.67	0.31	7.89e-11	Diastolic blood pressure;
LUAD	cis	rs8067545	0.750	rs3862152	chr17:19959693	C/T	cg04132472	chr17:19861366	AKAP10	0.28	6.58	0.3	1.38e-10	Schizophrenia;
LUAD	trans	rs1864729	1.000	rs2451113	chr8:98273448	G/A	cg08679828	chr8:102218111	ZNF706	-0.79	-7.99	-0.36	1.31e-14	Estradiol plasma levels (breast cancer);
LUAD	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg23758822	chr17:41437982	NA	0.91	18.19	0.66	5.03e-55	Menopause (age at onset);
LUAD	cis	rs10465746	0.935	rs35946036	chr1:84438991	A/G	cg10977910	chr1:84465055	TTLL7	0.51	8.21	0.37	2.71e-15	Obesity-related traits;
LUAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.94	0.56	1.3e-36	Prudent dietary pattern;
LUAD	cis	rs754466	0.580	rs1866437	chr10:79526766	A/G	cg17075019	chr10:79541650	NA	-0.91	-18.67	-0.67	3.47e-57	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg16342193	chr10:102329863	NA	-0.38	-6.59	-0.31	1.29e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs469568	0.901	rs338874	chr5:178668964	G/C	cg08999896	chr5:178685787	ADAMTS2	0.35	7.36	0.34	9.42e-13	Stroke (pediatric);
LUAD	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.14	0.33	4.05e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17253792	0.822	rs10143002	chr14:56074278	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	trans	rs75804782	0.625	rs72984528	chr2:239469373	T/C	cg01134436	chr17:81009848	B3GNTL1	0.71	7.28	0.33	1.64e-12	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs490234	0.812	rs13300639	chr9:128407298	A/G	cg14078157	chr9:128172775	NA	-0.42	-7.39	-0.34	7.92e-13	Mean arterial pressure;
LUAD	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg03929089	chr4:120376271	NA	0.57	7.13	0.33	4.42e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg01448562	chr3:133502909	NA	-0.71	-13.39	-0.55	2.41e-34	Iron status biomarkers;
LUAD	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.62	0.31	1.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg24818145	chr4:99064322	C4orf37	0.49	7.87	0.36	3.03e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg05368731	chr17:41323189	NBR1	0.98	21.09	0.72	5.32e-68	Menopause (age at onset);
LUAD	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg26384229	chr12:38710491	ALG10B	-0.43	-7.18	-0.33	3.11e-12	Bladder cancer;
LUAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg06753367	chr22:24256600	NA	-0.45	-8.03	-0.36	9.73e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg09835421	chr16:68378352	PRMT7	-0.8	-8.75	-0.39	5.03e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13082711	0.554	rs73055750	chr3:27401505	C/G	cg02860705	chr3:27208620	NA	0.7	10.64	0.46	1.35e-23	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.44	-0.55	1.49e-34	Alcohol dependence;
LUAD	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg22963979	chr7:1858916	MAD1L1	-0.48	-8.12	-0.37	5.3e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.02	-0.36	1.05e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg08601574	chr20:25228251	PYGB	0.44	8.12	0.37	5.33e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10802521	chr3:52805072	NEK4	-0.55	-9.18	-0.41	1.91e-18	Bipolar disorder;
LUAD	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03352830	chr11:487213	PTDSS2	0.78	10.48	0.45	5.14e-23	Body mass index;
LUAD	cis	rs9807989	0.507	rs2287033	chr2:103011237	C/T	cg03938978	chr2:103052716	IL18RAP	-0.43	-9.89	-0.43	6.97e-21	Asthma;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02453779	chr11:105948520	AASDHPPT;KBTBD3	-0.58	-7.0	-0.32	1.02e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg08999081	chr20:33150536	PIGU	-0.6	-13.35	-0.54	3.75e-34	Glomerular filtration rate (creatinine);
LUAD	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg21427119	chr20:30132790	HM13	-0.56	-8.42	-0.38	5.92e-16	Mean corpuscular hemoglobin;
LUAD	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg20203395	chr5:56204925	C5orf35	-0.57	-8.92	-0.4	1.4e-17	Coronary artery disease;
LUAD	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg01475377	chr6:109611718	NA	-0.5	-9.4	-0.42	3.39e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs6960043	0.782	rs1558317	chr7:15065564	T/A	cg19272540	chr7:15055459	NA	-0.36	-7.8	-0.35	4.85e-14	Type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21944557	chr1:179923876	CEP350	-0.54	-6.49	-0.3	2.38e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1950626	0.833	rs1951025	chr14:101406022	T/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.38	7.23	0.33	2.32e-12	Pelvic organ prolapse (moderate/severe);
LUAD	trans	rs2018683	0.624	rs2286220	chr7:28998699	G/C	cg19402173	chr7:128379420	CALU	-0.5	-8.1	-0.37	5.81e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9473147	0.516	rs9296564	chr6:47494759	A/G	cg20196966	chr6:47445060	CD2AP	0.45	7.11	0.33	5.09e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg15485101	chr11:133734466	NA	0.34	7.69	0.35	1.05e-13	Childhood ear infection;
LUAD	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg02423579	chr7:2872169	GNA12	-0.82	-13.8	-0.56	5.05e-36	Height;
LUAD	cis	rs12368653	0.789	rs2270777	chr12:58145156	C/T	cg12615879	chr12:58013172	SLC26A10	0.46	9.59	0.42	7.83e-20	Multiple sclerosis;
LUAD	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg21475434	chr5:93447410	FAM172A	0.77	8.6	0.39	1.57e-16	Diabetic retinopathy;
LUAD	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg13556452	chr1:2391241	NA	-0.38	-7.1	-0.33	5.26e-12	Non-obstructive azoospermia;
LUAD	cis	rs1448094	0.842	rs10863155	chr12:86446416	T/C	cg06740227	chr12:86229804	RASSF9	-0.35	-6.47	-0.3	2.65e-10	Major depressive disorder;
LUAD	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.6	8.81	0.39	3.21e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs1493916	0.837	rs2172626	chr18:31410478	C/T	cg15819921	chr19:927150	ARID3A	-0.42	-6.86	-0.32	2.44e-11	Life satisfaction;
LUAD	cis	rs4343996	0.837	rs7802250	chr7:3475820	G/C	cg21248987	chr7:3385318	SDK1	0.35	6.42	0.3	3.63e-10	Motion sickness;
LUAD	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg14092988	chr3:52407081	DNAH1	0.44	8.87	0.4	2.04e-17	Bipolar disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02628353	chr7:26241504	HNRNPA2B1;CBX3	-0.43	-6.78	-0.31	4.18e-11	Height;
LUAD	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg14343924	chr8:8086146	FLJ10661	0.46	6.96	0.32	1.27e-11	Joint mobility (Beighton score);
LUAD	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg07538946	chr5:131705188	SLC22A5	-0.48	-8.07	-0.37	7.49e-15	Blood metabolite levels;
LUAD	cis	rs3790645	1.000	rs282175	chr1:26895802	A/G	cg23229016	chr1:26872525	RPS6KA1	0.2	6.8	0.31	3.56e-11	Glucose homeostasis traits;
LUAD	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.96	-0.5	1.32e-28	Bipolar disorder;
LUAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	cis	rs7336332	0.598	rs1885989	chr13:28010117	G/A	cg22138327	chr13:27999177	GTF3A	0.78	10.14	0.44	9.18e-22	Weight;
LUAD	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg15557168	chr22:42548783	NA	0.37	6.61	0.31	1.15e-10	Cognitive function;
LUAD	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg06558623	chr16:89946397	TCF25	1.17	10.78	0.46	4.32e-24	Skin colour saturation;
LUAD	cis	rs17155006	0.638	rs2074747	chr7:107744735	G/A	cg05962710	chr7:107745446	LAMB4	-0.34	-7.2	-0.33	2.86e-12	Pneumococcal bacteremia;
LUAD	cis	rs870825	0.616	rs35533356	chr4:185639134	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.65	0.55	2.1e-35	Blood protein levels;
LUAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg12419862	chr22:24373484	LOC391322	-0.8	-14.8	-0.58	3.25e-40	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg05665937	chr4:1216051	CTBP1	0.45	7.94	0.36	1.78e-14	Obesity-related traits;
LUAD	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21659725	chr3:3221576	CRBN	-0.87	-18.51	-0.67	1.91e-56	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg11494091	chr17:61959527	GH2	0.75	18.46	0.67	3.14e-56	Prudent dietary pattern;
LUAD	trans	rs78049276	0.688	rs17612693	chr4:148365339	T/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.63	-7.36	-0.34	9.98e-13	Pulse pressure;
LUAD	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg04155793	chr16:89752847	CDK10	0.32	6.81	0.31	3.36e-11	Hemoglobin concentration;
LUAD	cis	rs877282	0.853	rs7092652	chr10:756109	G/A	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.53	-9.33	-0.41	6.16e-19	Axial length;
LUAD	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	8.11	0.37	5.38e-15	Breast cancer;
LUAD	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.49	-0.49	8.8e-27	Bipolar disorder;
LUAD	cis	rs2224391	0.590	rs2753235	chr6:5252182	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.55	8.33	0.38	1.14e-15	Height;
LUAD	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg24977027	chr2:88469347	THNSL2	-0.37	-6.76	-0.31	4.73e-11	Response to metformin (IC50);
LUAD	cis	rs4460629	0.742	rs4625273	chr1:155076043	C/T	cg23973274	chr1:155060172	NA	-0.37	-6.38	-0.3	4.52e-10	Serum magnesium levels;
LUAD	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	9.41	0.42	3.21e-19	Multiple sclerosis;
LUAD	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.29	0.51	6.53e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs74181299	0.964	rs1009358	chr2:65276452	C/T	cg05010058	chr2:65284262	CEP68	-0.29	-6.44	-0.3	3.17e-10	Pulse pressure;
LUAD	cis	rs922692	0.744	rs12903203	chr15:79084933	T/C	cg22753661	chr15:79092743	ADAMTS7	0.49	8.26	0.37	1.83e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06873352	chr17:61820015	STRADA	0.82	18.4	0.67	5.43e-56	Prudent dietary pattern;
LUAD	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg12573674	chr2:1569213	NA	-0.63	-7.28	-0.33	1.67e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9837602	1.000	rs13069311	chr3:99801628	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-6.95	-0.32	1.41e-11	Breast cancer;
LUAD	cis	rs9341808	0.667	rs2490241	chr6:80846342	T/C	cg08355045	chr6:80787529	NA	0.45	7.94	0.36	1.8e-14	Sitting height ratio;
LUAD	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg26384229	chr12:38710491	ALG10B	0.48	7.97	0.36	1.47e-14	Bladder cancer;
LUAD	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.46	7.2	0.33	2.81e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2979489	0.945	rs17627903	chr8:30351812	T/C	cg26383811	chr8:30366931	RBPMS	-0.68	-10.45	-0.45	6.83e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs4604732	0.578	rs12036417	chr1:247624805	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.45	7.26	0.33	1.85e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs790123	0.692	rs790129	chr3:122385170	C/T	cg15604389	chr3:122379662	NA	-0.46	-7.64	-0.35	1.47e-13	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg11301795	chr4:187892539	NA	-0.76	-15.26	-0.6	3.3e-42	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs490234	0.746	rs1266009	chr9:128192316	A/G	cg14078157	chr9:128172775	NA	-0.44	-8.0	-0.36	1.23e-14	Mean arterial pressure;
LUAD	cis	rs7202877	0.561	rs9933956	chr16:75362813	T/C	cg03315344	chr16:75512273	CHST6	0.47	6.68	0.31	7.47e-11	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs775227	0.574	rs36108475	chr3:113038406	C/T	cg18753928	chr3:113234510	CCDC52	-0.67	-8.64	-0.39	1.16e-16	Dental caries;
LUAD	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	8.82	0.39	2.91e-17	Ileal carcinoids;
LUAD	cis	rs6138458	0.626	rs6050259	chr20:25011423	A/G	cg26195577	chr20:24973756	C20orf3	0.71	12.15	0.51	2.4e-29	Blood protein levels;
LUAD	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.54	0.3	1.76e-10	Lung cancer in ever smokers;
LUAD	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg21926612	chr6:163149169	PACRG;PARK2	1.2	16.12	0.62	6.43e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4774899	0.698	rs2951903	chr15:57366404	C/T	cg14026238	chr15:57616123	NA	0.42	8.07	0.37	7.61e-15	Urinary tract infection frequency;
LUAD	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg22681709	chr2:178499509	PDE11A	-0.44	-7.29	-0.33	1.53e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg09060608	chr5:178986726	RUFY1	-0.75	-13.83	-0.56	3.66e-36	Lung cancer;
LUAD	cis	rs4588572	0.643	rs1529499	chr5:77721431	T/C	cg11547950	chr5:77652471	NA	-0.77	-12.5	-0.52	9.98e-31	Triglycerides;
LUAD	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg21100191	chr22:23484243	RTDR1	0.68	11.81	0.5	5.08e-28	Bone mineral density;
LUAD	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.15	0.33	3.96e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg00316803	chr15:76480434	C15orf27	0.4	6.45	0.3	3.06e-10	Blood metabolite levels;
LUAD	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg08027265	chr7:2291960	NA	-0.47	-8.22	-0.37	2.61e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg24562669	chr7:97807699	LMTK2	0.3	7.03	0.32	8.37e-12	Breast cancer;
LUAD	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg21214613	chr1:16344536	HSPB7	-0.45	-7.77	-0.35	5.81e-14	Dilated cardiomyopathy;
LUAD	cis	rs7737355	0.947	rs244733	chr5:130822778	T/C	cg06307176	chr5:131281290	NA	0.51	8.1	0.37	6e-15	Life satisfaction;
LUAD	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg14228332	chr4:119757509	SEC24D	-0.85	-8.03	-0.36	1e-14	Cannabis dependence symptom count;
LUAD	cis	rs6690583	0.623	rs61768853	chr1:85455707	T/C	cg22153463	chr1:85462885	MCOLN2	0.55	6.37	0.3	4.97e-10	Serum sulfate level;
LUAD	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg23172400	chr8:95962367	TP53INP1	-0.35	-8.31	-0.37	1.35e-15	Type 2 diabetes;
LUAD	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg04703951	chr17:43578652	NA	-0.56	-8.08	-0.37	6.96e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-9.58	-0.42	8.12e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg09873201	chr16:3507582	NAT15	0.5	7.89	0.36	2.68e-14	Tuberculosis;
LUAD	cis	rs7258465	0.896	rs8103660	chr19:18566395	T/C	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.71	-0.31	6.22e-11	Breast cancer;
LUAD	cis	rs10916814	1.000	rs4654863	chr1:20902244	G/A	cg24502330	chr1:20914028	CDA	-0.38	-7.1	-0.33	5.31e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg24011408	chr12:48396354	COL2A1	-0.43	-9.44	-0.42	2.63e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg25208724	chr1:156163844	SLC25A44	1.12	25.22	0.78	2.45e-86	Testicular germ cell tumor;
LUAD	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg08645402	chr16:4508243	NA	0.57	10.67	0.46	1.1e-23	Schizophrenia;
LUAD	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg03474202	chr17:45855739	NA	-0.38	-8.91	-0.4	1.56e-17	IgG glycosylation;
LUAD	cis	rs9715521	0.900	rs6551646	chr4:59824827	A/G	cg11281224	chr4:60001000	NA	-0.57	-9.57	-0.42	9.14e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg05373962	chr22:49881684	NA	-0.56	-13.47	-0.55	1.14e-34	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg06558623	chr16:89946397	TCF25	1.16	9.84	0.43	1.01e-20	Skin colour saturation;
LUAD	cis	rs931127	0.505	rs746429	chr11:65417434	G/A	cg27068330	chr11:65405492	SIPA1	-0.79	-12.22	-0.51	1.3e-29	Systemic lupus erythematosus;
LUAD	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg02221422	chr11:68192511	LRP5	-0.41	-6.65	-0.31	9.09e-11	Total body bone mineral density;
LUAD	cis	rs593982	0.843	rs565267	chr11:65473597	T/C	cg08755490	chr11:65554678	OVOL1	1.21	13.7	0.55	1.24e-35	Atopic dermatitis;
LUAD	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg14458575	chr2:238380390	NA	0.65	12.23	0.51	1.13e-29	Prostate cancer;
LUAD	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.43	-8.5	-0.38	3.17e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4243830	0.850	rs11122043	chr1:6580429	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.58	-8.02	-0.36	1.08e-14	Body mass index;
LUAD	cis	rs1595825	0.891	rs58409972	chr2:198897061	A/T	cg00982548	chr2:198649783	BOLL	-0.71	-9.43	-0.42	2.82e-19	Ulcerative colitis;
LUAD	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs62229266	0.835	rs998384	chr21:37445526	G/C	cg08632701	chr21:37451849	NA	-0.47	-7.82	-0.36	4.32e-14	Mitral valve prolapse;
LUAD	cis	rs9399401	0.626	rs12664563	chr6:142785201	A/G	cg03128060	chr6:142623767	GPR126	0.43	8.18	0.37	3.31e-15	Chronic obstructive pulmonary disease;
LUAD	trans	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg27411982	chr8:10470053	RP1L1	0.38	6.64	0.31	9.77e-11	Mood instability;
LUAD	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg03929089	chr4:120376271	NA	-0.56	-8.34	-0.38	1.05e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7264396	0.836	rs6058275	chr20:34186331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-6.78	-0.31	4.08e-11	Total cholesterol levels;
LUAD	cis	rs9837602	1.000	rs28714363	chr3:99752068	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.97	-0.32	1.24e-11	Breast cancer;
LUAD	cis	rs2657888	0.598	rs2657909	chr12:56895503	T/C	cg23002907	chr12:56915593	RBMS2	0.42	7.55	0.34	2.69e-13	Adiponectin levels;
LUAD	cis	rs420259	0.516	rs7405145	chr16:23537772	A/G	cg00143387	chr16:23521605	GGA2	-0.7	-9.58	-0.42	8.54e-20	Bipolar disorder;
LUAD	cis	rs11696501	0.637	rs2093090	chr20:44205464	C/T	cg11783356	chr20:44313418	WFDC10B	-0.46	-7.1	-0.33	5.4e-12	Brain structure;
LUAD	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg02775129	chr4:119771670	NA	-0.86	-8.15	-0.37	4.09e-15	Cannabis dependence symptom count;
LUAD	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg02176678	chr2:219576539	TTLL4	0.68	13.71	0.55	1.17e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg08798685	chr6:27730294	NA	0.37	6.48	0.3	2.59e-10	Parkinson's disease;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg10867947	chr8:95835263	INTS8	0.41	6.37	0.3	4.93e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg08632164	chr7:65971372	NA	-0.54	-6.38	-0.3	4.62e-10	Diabetic kidney disease;
LUAD	cis	rs3820068	0.705	rs74054769	chr1:15860147	A/C	cg24675056	chr1:15929824	NA	0.42	6.71	0.31	6.37e-11	Systolic blood pressure;
LUAD	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg00666640	chr1:248458726	OR2T12	0.27	6.42	0.3	3.75e-10	Common traits (Other);
LUAD	trans	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg18335740	chr13:41363409	SLC25A15	-0.5	-8.48	-0.38	3.85e-16	Lewy body disease;
LUAD	cis	rs225245	0.817	rs225299	chr17:33922742	T/C	cg05299278	chr17:33885742	SLFN14	0.51	11.64	0.49	2.45e-27	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg02951883	chr7:2050386	MAD1L1	0.53	7.12	0.33	4.59e-12	Neuroticism;
LUAD	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg17971929	chr21:40555470	PSMG1	0.49	7.36	0.34	9.77e-13	Cognitive function;
LUAD	cis	rs2046867	0.774	rs1393585	chr3:72886722	A/G	cg04365224	chr3:72788183	NA	-0.44	-6.55	-0.3	1.66e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs738322	0.646	rs132972	chr22:38562056	T/C	cg17652424	chr22:38574118	PLA2G6	-0.25	-7.0	-0.32	9.99e-12	Cutaneous nevi;
LUAD	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg08219700	chr8:58056026	NA	0.54	7.7	0.35	9.64e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg03433033	chr1:76189801	ACADM	0.86	17.44	0.65	1.08e-51	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs3849570	0.925	rs6765917	chr3:81891116	C/T	cg07356753	chr3:81810745	GBE1	-0.62	-10.96	-0.47	8.91e-25	Waist circumference;Body mass index;
LUAD	cis	rs1997103	1.000	rs6954474	chr7:55404847	A/G	cg17469321	chr7:55412551	NA	0.66	11.27	0.48	5.89e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg17279839	chr7:150038598	RARRES2	0.46	7.8	0.35	4.85e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg21214613	chr1:16344536	HSPB7	-0.41	-6.58	-0.3	1.38e-10	Dilated cardiomyopathy;
LUAD	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg24768116	chr2:27665128	KRTCAP3	0.26	6.38	0.3	4.62e-10	Oral cavity cancer;
LUAD	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg18305652	chr10:134549665	INPP5A	0.57	11.83	0.5	4.36e-28	Migraine;
LUAD	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg13390004	chr1:15929781	NA	0.46	8.13	0.37	4.71e-15	Systolic blood pressure;
LUAD	cis	rs1712517	0.771	rs11191666	chr10:105127278	A/G	cg05636881	chr10:105038444	INA	0.32	6.39	0.3	4.5e-10	Migraine;
LUAD	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg17480646	chr11:65405466	SIPA1	-0.45	-6.79	-0.31	3.93e-11	Acne (severe);
LUAD	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg15017067	chr4:17643749	FAM184B	0.38	7.42	0.34	6.2800000000000005e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg12034118	chr1:209979487	IRF6	0.55	7.33	0.34	1.16e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg07362569	chr17:61921086	SMARCD2	0.39	6.76	0.31	4.55e-11	Prudent dietary pattern;
LUAD	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06028808	chr11:68637592	NA	0.49	8.0	0.36	1.23e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg00106254	chr7:1943704	MAD1L1	-0.56	-8.71	-0.39	7.14e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs3087591	1.000	rs7220268	chr17:29451910	T/C	cg24425628	chr17:29625626	OMG;NF1	0.4	6.36	0.3	5.29e-10	Hip circumference;
LUAD	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg24675056	chr1:15929824	NA	0.49	8.48	0.38	3.92e-16	Systolic blood pressure;
LUAD	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.82	-0.31	3.07e-11	Personality dimensions;
LUAD	cis	rs7089973	0.872	rs17092542	chr10:116630289	G/A	cg25233709	chr10:116636983	FAM160B1	0.39	7.6	0.35	1.98e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06028605	chr16:24865363	SLC5A11	-0.52	-7.79	-0.35	5.22e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg05110241	chr16:68378359	PRMT7	-0.93	-10.14	-0.44	8.99e-22	Schizophrenia;
LUAD	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.39	0.42	3.82e-19	Urate levels;
LUAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg10819733	chr22:24237672	NA	-0.4	-7.33	-0.34	1.16e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.24	0.37	2.19e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.62	-0.31	1.1e-10	Neuroticism;
LUAD	cis	rs17401966	0.838	rs10492971	chr1:10342975	G/A	cg15208524	chr1:10270712	KIF1B	0.43	6.81	0.31	3.43e-11	Hepatocellular carcinoma;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06401449	chr12:64798028	XPOT	-0.45	-7.01	-0.32	9.26e-12	Height;
LUAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg10729496	chr3:10149963	C3orf24	-0.59	-9.89	-0.43	6.68e-21	Alzheimer's disease;
LUAD	cis	rs11771526	0.901	rs10252755	chr7:32304676	G/A	cg27532318	chr7:32358331	NA	0.59	7.4	0.34	7.31e-13	Body mass index;
LUAD	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg04025307	chr7:1156635	C7orf50	0.6	9.43	0.42	2.69e-19	Bronchopulmonary dysplasia;
LUAD	cis	rs1535500	1.000	rs3734618	chr6:39284184	A/G	cg06347083	chr6:39282316	KCNK17	-0.36	-7.54	-0.34	2.87e-13	Type 2 diabetes;
LUAD	trans	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg27411982	chr8:10470053	RP1L1	0.42	7.59	0.35	2.09e-13	Mood instability;
LUAD	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	6.48	0.3	2.54e-10	Tonsillectomy;
LUAD	cis	rs17401966	1.000	rs17396382	chr1:10290268	T/C	cg15208524	chr1:10270712	KIF1B	0.57	8.03	0.36	1.01e-14	Hepatocellular carcinoma;
LUAD	cis	rs9863	0.794	rs12310367	chr12:124486678	A/G	cg17723958	chr12:124429295	CCDC92	-0.4	-6.52	-0.3	1.97e-10	White blood cell count;
LUAD	cis	rs889398	0.802	rs12925700	chr16:69793463	C/A	cg00738113	chr16:70207722	CLEC18C	0.34	6.82	0.31	3.1e-11	Body mass index;
LUAD	cis	rs2485376	1.000	rs1796765	chr10:104060529	C/T	cg20641465	chr10:103991465	PITX3	-0.56	-10.35	-0.45	1.56e-22	QT interval;
LUAD	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg01528321	chr10:82214614	TSPAN14	-0.64	-10.42	-0.45	9.03e-23	Post bronchodilator FEV1;
LUAD	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg03713592	chr11:72463424	ARAP1	0.64	7.95	0.36	1.78e-14	Type 2 diabetes;
LUAD	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg01028140	chr2:1542097	TPO	-0.56	-7.43	-0.34	6.25e-13	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.91	-0.4	1.55e-17	Alcohol dependence;
LUAD	cis	rs7326068	0.557	rs4331211	chr13:21125299	T/C	cg27499820	chr13:21296301	IL17D	0.51	8.39	0.38	7.26e-16	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg06636551	chr8:101224915	SPAG1	-0.38	-6.92	-0.32	1.64e-11	Atrioventricular conduction;
LUAD	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.39	-7.56	-0.35	2.5e-13	Total body bone mineral density;
LUAD	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg27432699	chr2:27873401	GPN1	-0.41	-6.71	-0.31	6.19e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg22681709	chr2:178499509	PDE11A	0.5	8.44	0.38	5.01e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2625529	0.762	rs1384007	chr15:72229534	T/C	cg16672083	chr15:72433130	SENP8	-0.76	-12.46	-0.52	1.44e-30	Red blood cell count;
LUAD	cis	rs3785574	0.650	rs3815358	chr17:62010270	A/G	cg11494091	chr17:61959527	GH2	-0.4	-7.13	-0.33	4.43e-12	Height;
LUAD	cis	rs4588572	0.686	rs34262593	chr5:77666427	T/C	cg11547950	chr5:77652471	NA	0.78	11.85	0.5	3.56e-28	Triglycerides;
LUAD	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.55	-9.32	-0.41	6.64e-19	Colorectal cancer;
LUAD	cis	rs7119	0.604	rs2667781	chr15:77858619	A/C	cg27398640	chr15:77910606	LINGO1	0.39	7.21	0.33	2.56e-12	Type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg14926445	chr8:58193284	C8orf71	-0.48	-7.0	-0.32	9.85e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs68170813	0.559	rs1548524	chr7:106944563	G/T	cg02696742	chr7:106810147	HBP1	0.77	10.85	0.47	2.39e-24	Coronary artery disease;
LUAD	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg02931644	chr1:25747376	RHCE	0.49	10.41	0.45	9.29e-23	Erythrocyte sedimentation rate;
LUAD	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg20701182	chr2:24300061	SF3B14	0.63	7.08	0.33	5.93e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.73	0.31	5.4e-11	Aortic root size;
LUAD	cis	rs9888739	0.844	rs41476751	chr16:31335906	T/C	cg15817542	chr16:31343056	ITGAM	-0.37	-6.41	-0.3	3.93e-10	Systemic lupus erythematosus;
LUAD	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg22676075	chr6:135203613	NA	0.51	8.98	0.4	8.93e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs752010	0.841	rs6661784	chr1:42080312	A/T	cg06885757	chr1:42089581	HIVEP3	0.42	9.21	0.41	1.58e-18	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg01475377	chr6:109611718	NA	-0.54	-10.51	-0.45	4.22e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg21285383	chr16:89894308	SPIRE2	-0.41	-9.84	-0.43	1.01e-20	Vitiligo;
LUAD	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg07606381	chr6:8435919	SLC35B3	0.42	6.87	0.32	2.31e-11	Motion sickness;
LUAD	cis	rs427941	0.703	rs201452	chr7:101739663	C/T	cg06246474	chr7:101738831	CUX1	0.41	7.25	0.33	1.98e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7072216	0.763	rs4475861	chr10:100164989	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-8.29	-0.37	1.57e-15	Metabolite levels;
LUAD	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12016809	chr21:47604291	C21orf56	-0.54	-8.71	-0.39	7.02e-17	Testicular germ cell tumor;
LUAD	cis	rs3820068	0.705	rs57238793	chr1:15890029	A/G	cg13390004	chr1:15929781	NA	0.45	6.92	0.32	1.69e-11	Systolic blood pressure;
LUAD	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg01788221	chr16:89496183	ANKRD11	-0.33	-6.35	-0.3	5.44e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg26769984	chr7:1090371	C7orf50	0.45	7.07	0.33	6.36e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg10544611	chr16:67998164	SLC12A4	-0.7	-8.35	-0.38	9.81e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs16867335	0.652	rs1528439	chr2:181462035	C/T	cg23363182	chr2:181467187	NA	-0.4	-6.61	-0.31	1.17e-10	Survival in rectal cancer;
LUAD	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.43	0.55	1.69e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg09359103	chr1:154839909	KCNN3	-0.88	-19.46	-0.69	1.05e-60	Prostate cancer;
LUAD	cis	rs7903847	0.642	rs11189192	chr10:99149403	G/A	cg20016023	chr10:99160130	RRP12	-0.29	-6.96	-0.32	1.33e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg22508957	chr16:3507546	NAT15	0.37	6.46	0.3	2.83e-10	Body mass index (adult);
LUAD	cis	rs6684428	1.000	rs12141666	chr1:56370556	T/C	cg11651538	chr1:56320950	NA	-0.4	-6.39	-0.3	4.39e-10	Airflow obstruction;
LUAD	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg20487152	chr13:99095054	FARP1	-0.48	-8.11	-0.37	5.71e-15	Longevity;
LUAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.39	-0.38	7.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs807669	0.903	rs1018764	chr22:19172006	T/C	cg24911827	chr22:19170109	CLTCL1	0.45	9.49	0.42	1.73e-19	Metabolite levels;
LUAD	cis	rs7020830	0.931	rs13295115	chr9:37157964	T/G	cg14294708	chr9:37120828	ZCCHC7	0.85	16.3	0.62	1.04e-46	Schizophrenia;
LUAD	cis	rs9796	0.621	rs1659228	chr15:41471978	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.49	-0.38	3.46e-16	Menopause (age at onset);
LUAD	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg11707310	chr1:2537719	MMEL1	0.38	8.11	0.37	5.69e-15	Ulcerative colitis;
LUAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02359409	chr6:42947317	PEX6	-0.37	-6.38	-0.3	4.75e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4853036	1.000	rs35002543	chr2:70091299	A/G	cg02498382	chr2:70120550	SNRNP27	-0.5	-8.1	-0.37	5.96e-15	Colorectal or endometrial cancer;
LUAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.9	0.47	1.51e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg04455712	chr21:45112962	RRP1B	0.47	9.32	0.41	6.43e-19	Mean corpuscular volume;
LUAD	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg20933634	chr6:27740509	NA	0.46	7.27	0.33	1.77e-12	Parkinson's disease;
LUAD	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.84	-0.36	3.71e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1160297	0.576	rs1376567	chr2:53098515	C/G	cg07782112	chr2:53107842	NA	0.37	8.22	0.37	2.58e-15	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg20790798	chr5:1857306	NA	-0.46	-7.83	-0.36	4.02e-14	Cardiovascular disease risk factors;
LUAD	cis	rs11809207	0.501	rs3762460	chr1:26495550	A/G	cg00147160	chr1:26503991	CNKSR1	0.4	9.29	0.41	8.27e-19	Height;
LUAD	cis	rs3849570	0.533	rs4440144	chr3:81988359	A/G	cg07356753	chr3:81810745	GBE1	-0.51	-8.55	-0.38	2.3e-16	Waist circumference;Body mass index;
LUAD	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg14895029	chr7:2775587	GNA12	-0.43	-6.84	-0.32	2.74e-11	Height;
LUAD	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg02176678	chr2:219576539	TTLL4	0.68	13.54	0.55	6.08e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs62238980	0.614	rs76222062	chr22:32457049	T/G	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg17366294	chr4:99064904	C4orf37	0.48	8.43	0.38	5.47e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.46	0.34	4.82e-13	Hypertriglyceridemia;
LUAD	cis	rs9948	0.786	rs62156227	chr2:97417942	C/A	cg20312557	chr2:97357134	FER1L5	-0.62	-7.3	-0.33	1.44e-12	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs2421770	0.530	rs3901811	chr11:35365675	C/T	cg13971030	chr11:35366721	SLC1A2	-0.46	-8.01	-0.36	1.1e-14	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs7771547	0.603	rs72852338	chr6:36554240	A/C	cg04289385	chr6:36355825	ETV7	0.5	6.62	0.31	1.09e-10	Platelet distribution width;
LUAD	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21582582	chr3:182698605	DCUN1D1	-0.73	-14.12	-0.57	2.39e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs73206853	0.841	rs55634798	chr12:110833748	G/T	cg12870014	chr12:110450643	ANKRD13A	0.63	6.91	0.32	1.84e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.2	-0.33	2.83e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10129255	0.518	rs8009612	chr14:107185749	G/T	cg07958169	chr14:107095056	NA	-0.37	-7.43	-0.34	5.89e-13	Kawasaki disease;
LUAD	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	8.32	0.38	1.22e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs17102423	0.731	rs10143198	chr14:65555471	C/T	cg11161011	chr14:65562177	MAX	-0.4	-6.82	-0.31	3.1e-11	Obesity-related traits;
LUAD	cis	rs2637266	1.000	rs11001829	chr10:78343387	A/T	cg18941641	chr10:78392320	NA	0.33	6.87	0.32	2.37e-11	Pulmonary function;
LUAD	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-8.31	-0.37	1.33e-15	Monocyte percentage of white cells;
LUAD	cis	rs7192380	1.000	rs11640319	chr16:69633515	G/A	cg26679644	chr16:69762563	NA	0.49	9.47	0.42	1.99e-19	Sjögren's syndrome;
LUAD	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg27102117	chr16:15229624	NA	0.57	10.34	0.45	1.66e-22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg00898013	chr13:113819073	PROZ	-0.78	-14.14	-0.57	1.86e-37	Platelet distribution width;
LUAD	cis	rs3823572	0.564	rs2971983	chr7:133652537	A/G	cg03336402	chr7:133662267	EXOC4	-0.41	-7.62	-0.35	1.64e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7193541	0.662	rs8052367	chr16:74658867	G/A	cg01733217	chr16:74700730	RFWD3	0.69	13.38	0.55	2.62e-34	Multiple myeloma;
LUAD	cis	rs9902453	0.691	rs140701	chr17:28538532	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.41	6.9	0.32	1.94e-11	Coffee consumption (cups per day);
LUAD	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.08	13.93	0.56	1.4e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg13012494	chr21:47604986	C21orf56	0.47	7.75	0.35	6.93e-14	Testicular germ cell tumor;
LUAD	cis	rs1784581	0.651	rs1784590	chr6:162389462	C/A	cg17173639	chr6:162384350	PARK2	-0.51	-9.32	-0.41	6.7e-19	Itch intensity from mosquito bite;
LUAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg22535103	chr8:58192502	C8orf71	-0.75	-9.19	-0.41	1.85e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs698833	0.886	rs2304770	chr2:44569328	T/A	cg04920474	chr2:44395004	PPM1B	0.41	7.38	0.34	8.42e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.49	7.84	0.36	3.72e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4006360	0.604	rs3843964	chr17:39227984	C/T	cg20663846	chr17:39254439	KRTAP4-8	-0.39	-8.78	-0.39	4.12e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg26513180	chr16:89883248	FANCA	0.47	7.37	0.34	9.19e-13	Vitiligo;
LUAD	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg09359103	chr1:154839909	KCNN3	-0.91	-21.11	-0.72	4.36e-68	Prostate cancer;
LUAD	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg00280220	chr17:61926910	NA	0.37	7.13	0.33	4.26e-12	Prudent dietary pattern;
LUAD	cis	rs1395	0.922	rs13404446	chr2:27519254	C/T	cg23587288	chr2:27483067	SLC30A3	-0.39	-7.49	-0.34	4.06e-13	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.46e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.4	0.3	4.06e-10	Depression;
LUAD	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg05234568	chr11:5960015	NA	-0.51	-9.14	-0.41	2.58e-18	DNA methylation (variation);
LUAD	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg07741184	chr6:167504864	NA	-0.34	-7.96	-0.36	1.6e-14	Crohn's disease;
LUAD	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg03929089	chr4:120376271	NA	-0.51	-6.72	-0.31	5.75e-11	Axial length;
LUAD	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg13679303	chr9:96623674	NA	-0.36	-7.11	-0.33	4.97e-12	DNA methylation (variation);
LUAD	cis	rs6426558	0.515	rs7543579	chr1:227377699	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.56	-8.92	-0.4	1.46e-17	Neutrophil percentage of white cells;
LUAD	cis	rs7107174	0.901	rs2511159	chr11:77974193	G/T	cg19901956	chr11:77921274	USP35	0.46	6.5	0.3	2.29e-10	Testicular germ cell tumor;
LUAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg07677032	chr17:61819896	STRADA	0.57	10.29	0.45	2.7e-22	Prudent dietary pattern;
LUAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.35	-0.41	4.99e-19	Life satisfaction;
LUAD	cis	rs250677	0.524	rs40521	chr5:148439639	C/T	cg18129178	chr5:148520854	ABLIM3	0.49	7.94	0.36	1.89e-14	Breast cancer;
LUAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg13047869	chr3:10149882	C3orf24	0.53	8.04	0.36	9.37e-15	Alzheimer's disease;
LUAD	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg08773314	chr2:239334832	ASB1	0.46	10.5	0.45	4.5e-23	Multiple system atrophy;
LUAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.57	7.87	0.36	3e-14	Renal function-related traits (BUN);
LUAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg08132940	chr7:1081526	C7orf50	-0.76	-10.27	-0.45	3.19e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg27170947	chr2:26402098	FAM59B	-0.63	-8.92	-0.4	1.46e-17	Gut microbiome composition (summer);
LUAD	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.35	-0.3	5.42e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg06873352	chr17:61820015	STRADA	0.43	7.01	0.32	9.25e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg24642844	chr7:1081250	C7orf50	-0.88	-9.71	-0.43	2.96e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2579500	0.844	rs2708975	chr2:97184160	G/A	cg23100626	chr2:96804247	ASTL	0.27	6.55	0.3	1.67e-10	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.54	-8.95	-0.4	1.12e-17	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.09	-0.33	5.65e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10781543	0.763	rs10781539	chr9:139320965	G/A	cg14169450	chr9:139327907	INPP5E	0.45	8.14	0.37	4.43e-15	Monocyte percentage of white cells;
LUAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13126279	chr21:47581558	C21orf56	-0.62	-11.4	-0.48	1.9e-26	Testicular germ cell tumor;
LUAD	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg21138405	chr5:131827807	IRF1	-0.56	-12.3	-0.51	6.01e-30	Asthma (sex interaction);
LUAD	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg02269571	chr22:50332266	NA	-0.67	-9.63	-0.42	5.61e-20	Schizophrenia;
LUAD	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.34	7.18	0.33	3.07e-12	Cardiac Troponin-T levels;
LUAD	cis	rs7301016	0.948	rs11614822	chr12:62931690	T/G	cg11441379	chr12:63026424	NA	0.59	7.31	0.34	1.32e-12	IgG glycosylation;
LUAD	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-7.21	-0.33	2.59e-12	Personality dimensions;
LUAD	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.86	-0.5	3.36e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4523957	0.583	rs923864	chr17:2031507	C/T	cg16513277	chr17:2031491	SMG6	-0.98	-20.08	-0.7	1.79e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11644478	chr21:40555479	PSMG1	0.59	9.36	0.41	4.69e-19	Cognitive function;
LUAD	cis	rs12760731	0.565	rs12037925	chr1:178160268	C/T	cg00404053	chr1:178313656	RASAL2	0.73	9.11	0.41	3.27e-18	Obesity-related traits;
LUAD	cis	rs954108	0.522	rs7983818	chr13:29383182	A/C	cg11788234	chr13:29393811	NA	-0.44	-9.38	-0.41	4.17e-19	Obesity-related traits;
LUAD	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg05991184	chr2:219186017	PNKD	0.35	6.77	0.31	4.28e-11	Colorectal cancer;
LUAD	cis	rs2274273	0.588	rs7154831	chr14:55823965	A/C	cg04306507	chr14:55594613	LGALS3	0.41	8.0	0.36	1.24e-14	Protein biomarker;
LUAD	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02463440	chr8:22132932	PIWIL2	0.54	9.91	0.43	5.94e-21	Hypertriglyceridemia;
LUAD	cis	rs9467160	0.953	rs13205577	chr6:24448648	A/T	cg16211469	chr6:24423932	MRS2	0.43	6.71	0.31	6.12e-11	Liver enzyme levels;
LUAD	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg09998033	chr7:158218633	PTPRN2	-0.41	-7.11	-0.33	5.08e-12	Obesity-related traits;
LUAD	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg15128208	chr22:42549153	NA	-0.42	-8.53	-0.38	2.61e-16	Cognitive function;
LUAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06873352	chr17:61820015	STRADA	0.82	18.21	0.66	3.8e-55	Prudent dietary pattern;
LUAD	cis	rs727505	0.954	rs28728448	chr7:124532938	T/A	cg23710748	chr7:124431027	NA	-0.46	-9.45	-0.42	2.41e-19	Lewy body disease;
LUAD	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg13813247	chr22:41461852	NA	-0.49	-7.88	-0.36	2.9e-14	Neuroticism;
LUAD	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg12863693	chr15:85201151	NMB	0.38	6.78	0.31	4.04e-11	Schizophrenia;
LUAD	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg02569458	chr12:86230093	RASSF9	0.38	7.39	0.34	7.92e-13	Major depressive disorder;
LUAD	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg02931644	chr1:25747376	RHCE	0.49	10.59	0.46	2.17e-23	Erythrocyte sedimentation rate;
LUAD	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.67	0.39	9.26e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg05283184	chr6:79620031	NA	-0.46	-7.91	-0.36	2.32e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9392556	0.829	rs689308	chr6:4127730	A/C	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.42	-7.2	-0.33	2.82e-12	Blood metabolite levels;
LUAD	trans	rs7395662	0.963	rs61930968	chr11:48581649	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.14e-12	HDL cholesterol;
LUAD	cis	rs4006360	0.646	rs4890158	chr17:39295805	A/T	cg20663846	chr17:39254439	KRTAP4-8	0.36	7.86	0.36	3.32e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs7432375	0.610	rs4420814	chr3:136513282	T/C	cg15507776	chr3:136538369	TMEM22	0.39	6.92	0.32	1.7e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg24642844	chr7:1081250	C7orf50	-0.97	-14.71	-0.58	7.38e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg01200585	chr1:228362443	C1orf69	0.45	7.4	0.34	7.52e-13	Diastolic blood pressure;
LUAD	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg18827107	chr12:86230957	RASSF9	0.54	9.74	0.43	2.24e-20	Major depressive disorder;
LUAD	cis	rs72901758	0.768	rs72901762	chr17:76244926	A/G	cg26068271	chr17:76253126	NA	0.45	7.59	0.35	2.12e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs34734847	0.871	rs2239760	chr12:121163518	C/A	cg27246729	chr12:121163418	ACADS	0.41	7.77	0.35	5.92e-14	Mean corpuscular volume;
LUAD	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.39	-7.65	-0.35	1.36e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg23803603	chr1:2058230	PRKCZ	0.44	7.0	0.32	1.02e-11	Height;
LUAD	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.66	-10.79	-0.46	3.73e-24	IgG glycosylation;
LUAD	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.53	-0.3	1.94e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg20933634	chr6:27740509	NA	0.51	8.0	0.36	1.18e-14	Parkinson's disease;
LUAD	cis	rs2227564	0.620	rs3812637	chr10:75568846	C/T	cg23231163	chr10:75533350	FUT11	-0.43	-6.78	-0.31	4.12e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9814567	0.712	rs9838467	chr3:134332222	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg11663144	chr21:46675770	NA	-0.48	-8.98	-0.4	8.84e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg21699342	chr2:239360505	ASB1	0.54	10.56	0.46	2.75e-23	Multiple system atrophy;
LUAD	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg10057126	chr4:77819792	ANKRD56	0.53	9.05	0.4	5.24e-18	Emphysema distribution in smoking;
LUAD	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.4	-0.45	1.06e-22	Total body bone mineral density;
LUAD	trans	rs9929218	0.954	rs9928796	chr16:68820718	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.47	-0.55	1.15e-34	Colorectal cancer;
LUAD	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg15445000	chr17:37608096	MED1	0.46	8.38	0.38	8e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg17105886	chr17:28927953	LRRC37B2	0.66	7.6	0.35	1.92e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg18811423	chr2:55921094	PNPT1	0.51	8.26	0.37	1.92e-15	Metabolic syndrome;
LUAD	cis	rs12995491	0.843	rs1878809	chr2:88518315	C/T	cg04511125	chr2:88470314	THNSL2	-0.4	-6.97	-0.32	1.24e-11	Response to metformin (IC50);
LUAD	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg03929089	chr4:120376271	NA	0.75	12.95	0.53	1.56e-32	Height;
LUAD	cis	rs7267979	1.000	rs422844	chr20:25445591	T/C	cg08601574	chr20:25228251	PYGB	0.47	8.7	0.39	7.19e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9902453	0.817	rs9909128	chr17:28161482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	10.72	0.46	6.95e-24	Coffee consumption (cups per day);
LUAD	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg04944784	chr2:26401820	FAM59B	-0.76	-10.41	-0.45	9.53e-23	Gut microbiome composition (summer);
LUAD	cis	rs9473147	0.516	rs6931478	chr6:47461913	C/A	cg02130027	chr6:47444894	CD2AP	0.36	6.87	0.32	2.33e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg02018176	chr4:1364513	KIAA1530	0.56	10.57	0.46	2.49e-23	Longevity;
LUAD	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg06108461	chr20:60628389	TAF4	-1.13	-20.72	-0.71	2.45e-66	Body mass index;
LUAD	trans	rs1728785	1.000	rs1645979	chr16:68603660	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.74	10.95	0.47	9.65e-25	Ulcerative colitis;
LUAD	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.17e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1697139	0.583	rs11739727	chr5:66540940	G/A	cg11553311	chr5:66541588	NA	0.43	8.13	0.37	4.94e-15	Breast cancer;
LUAD	trans	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg18335740	chr13:41363409	SLC25A15	0.52	8.62	0.39	1.39e-16	Lewy body disease;
LUAD	cis	rs1232027	0.666	rs1677685	chr5:79938941	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.32	6.67	0.31	8.15e-11	Menopause (age at onset);
LUAD	cis	rs7107174	1.000	rs2511180	chr11:77937255	A/G	cg02023728	chr11:77925099	USP35	0.54	8.24	0.37	2.16e-15	Testicular germ cell tumor;
LUAD	cis	rs2412459	1.000	rs2412459	chr15:40295959	C/T	cg10636054	chr15:40330586	SRP14	0.75	8.5	0.38	3.33e-16	Response to haloperidol in psychosis;
LUAD	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg26354017	chr1:205819088	PM20D1	0.48	7.96	0.36	1.56e-14	Parkinson's disease;
LUAD	cis	rs71478720	0.953	rs5744249	chr11:112025306	A/C	cg26534425	chr11:112034925	IL18	0.5	7.51	0.34	3.56e-13	Interleukin-18 levels;
LUAD	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg03563238	chr19:33554763	RHPN2	0.33	8.01	0.36	1.09e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	8.51	0.38	3.02e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg11871910	chr12:69753446	YEATS4	0.55	8.46	0.38	4.55e-16	Blood protein levels;
LUAD	trans	rs7395662	0.963	rs11039772	chr11:48513892	T/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.51	-0.3	2.08e-10	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg08601574	chr20:25228251	PYGB	0.43	7.95	0.36	1.72e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.5	0.34	3.82e-13	Breast cancer;
LUAD	cis	rs6594713	0.921	rs7731231	chr5:112717546	C/A	cg12552261	chr5:112820674	MCC	0.54	8.53	0.38	2.68e-16	Brain cytoarchitecture;
LUAD	cis	rs977987	0.806	rs12051136	chr16:75435731	G/T	cg03315344	chr16:75512273	CHST6	0.64	14.14	0.57	1.96e-37	Dupuytren's disease;
LUAD	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24838063	chr12:130822603	PIWIL1	0.64	10.79	0.46	3.97e-24	Menopause (age at onset);
LUAD	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg14583973	chr4:3374767	RGS12	0.29	7.51	0.34	3.53e-13	Serum sulfate level;
LUAD	cis	rs1595825	0.891	rs16825188	chr2:198741134	G/C	cg00982548	chr2:198649783	BOLL	-0.67	-9.19	-0.41	1.75e-18	Ulcerative colitis;
LUAD	cis	rs9462027	0.628	rs998278	chr6:34765584	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.63	-0.39	1.22e-16	Systemic lupus erythematosus;
LUAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	3.98e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs713477	0.967	rs4898865	chr14:55910998	G/A	cg13175173	chr14:55914753	NA	-0.33	-6.95	-0.32	1.41e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg06641503	chr3:48959341	ARIH2	-0.41	-8.19	-0.37	3.09e-15	Parkinson's disease;
LUAD	trans	rs28735056	0.563	rs12968139	chr18:77685520	A/G	cg05926928	chr17:57297772	GDPD1	-0.5	-7.58	-0.35	2.25e-13	Schizophrenia;
LUAD	cis	rs9487051	0.773	rs351749	chr6:109533353	A/T	cg21918786	chr6:109611834	NA	-0.42	-7.25	-0.33	1.95e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.59	0.31	1.3e-10	Depression;
LUAD	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.56	7.83	0.36	3.97e-14	Platelet count;
LUAD	cis	rs295140	0.803	rs4233994	chr2:201129211	G/C	cg23649088	chr2:200775458	C2orf69	-0.39	-6.42	-0.3	3.63e-10	QT interval;
LUAD	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg04117972	chr1:227635322	NA	0.67	6.74	0.31	5.34e-11	Major depressive disorder;
LUAD	cis	rs2637266	0.935	rs12259550	chr10:78352843	A/G	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg00316803	chr15:76480434	C15orf27	-0.42	-8.07	-0.37	7.17e-15	Blood metabolite levels;
LUAD	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs55823223	0.648	rs72860389	chr17:73866071	C/T	cg12714757	chr17:73874637	TRIM47	-0.47	-7.28	-0.33	1.63e-12	Psoriasis;
LUAD	trans	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg14917512	chr19:3094685	GNA11	0.57	6.73	0.31	5.52e-11	Diabetic kidney disease;
LUAD	cis	rs315934	0.664	rs1623119	chr2:113862058	A/T	cg09040174	chr2:113837401	NA	-0.61	-7.4	-0.34	7.6e-13	Dysmenorrheic pain;
LUAD	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg03388025	chr16:89894329	SPIRE2	-0.5	-13.21	-0.54	1.41e-33	Vitiligo;
LUAD	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg14689365	chr7:158441557	NCAPG2	0.4	6.68	0.31	7.53e-11	Height;
LUAD	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg07157834	chr1:205819609	PM20D1	-0.43	-6.62	-0.31	1.06e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs35995292	0.534	rs917322	chr7:38943165	A/T	cg19327137	chr7:38886074	VPS41	-0.73	-15.53	-0.6	2.29e-43	Subjective well-being (multi-trait analysis);
LUAD	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg18512352	chr11:47633146	NA	0.42	7.28	0.33	1.67e-12	Subjective well-being;
LUAD	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg25767906	chr1:53392781	SCP2	-0.42	-7.68	-0.35	1.1e-13	Monocyte count;
LUAD	cis	rs6009527	0.752	rs7286232	chr22:49568490	A/G	cg12746016	chr22:49560550	NA	0.52	10.15	0.44	8.18e-22	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUAD	cis	rs12681287	0.640	rs7816629	chr8:87350788	A/T	cg00550725	chr8:87521180	FAM82B	0.47	6.74	0.31	5.32e-11	Caudate activity during reward;
LUAD	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-11.68	-0.49	1.6e-27	Bipolar disorder;
LUAD	cis	rs4343996	0.869	rs4544975	chr7:3385384	G/T	cg21248987	chr7:3385318	SDK1	-0.36	-6.64	-0.31	9.78e-11	Motion sickness;
LUAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.85	16.26	0.62	1.65e-46	Lymphocyte counts;
LUAD	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-11.36	-0.48	2.81e-26	Gut microbiome composition (summer);
LUAD	cis	rs73198271	0.515	rs75660006	chr8:8619594	C/T	cg01851573	chr8:8652454	MFHAS1	0.59	7.44	0.34	5.82e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7707921	0.505	rs12516434	chr5:81428072	T/A	cg15871215	chr5:81402204	ATG10	0.63	10.16	0.44	7.69e-22	Breast cancer;
LUAD	cis	rs1847202	0.793	rs11918132	chr3:72952144	C/T	cg25664220	chr3:72788482	NA	-0.41	-7.2	-0.33	2.8e-12	Motion sickness;
LUAD	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg27490568	chr2:178487706	NA	0.4	6.76	0.31	4.71e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg06740227	chr12:86229804	RASSF9	0.47	8.2	0.37	2.91e-15	Major depressive disorder;
LUAD	cis	rs7000551	0.675	rs2469758	chr8:22363032	C/T	cg12081754	chr8:22256438	SLC39A14	0.44	7.36	0.34	9.94e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg18016565	chr1:150552671	MCL1	-0.39	-6.75	-0.31	5.01e-11	Tonsillectomy;
LUAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg18621852	chr3:10150065	C3orf24	0.48	8.45	0.38	4.89e-16	Alzheimer's disease;
LUAD	trans	rs12517041	1.000	rs2356716	chr5:23308496	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs2625529	0.590	rs713048	chr15:72543084	G/A	cg16672083	chr15:72433130	SENP8	-0.77	-13.46	-0.55	1.32e-34	Red blood cell count;
LUAD	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.21	15.86	0.61	9.06e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg13045639	chr21:40555880	PSMG1	0.42	7.65	0.35	1.39e-13	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg26513180	chr16:89883248	FANCA	0.66	12.16	0.51	2.11e-29	Vitiligo;
LUAD	cis	rs6087990	0.965	rs2424899	chr20:31343543	A/C	cg13636640	chr20:31349939	DNMT3B	0.85	16.14	0.62	5.5e-46	Ulcerative colitis;
LUAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg08219700	chr8:58056026	NA	0.48	6.61	0.31	1.13e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg01528321	chr10:82214614	TSPAN14	0.66	10.13	0.44	9.44e-22	Post bronchodilator FEV1;
LUAD	cis	rs490234	0.932	rs506874	chr9:128319066	G/A	cg14078157	chr9:128172775	NA	0.37	6.89	0.32	1.99e-11	Mean arterial pressure;
LUAD	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg03929089	chr4:120376271	NA	-0.45	-6.96	-0.32	1.27e-11	HDL cholesterol;
LUAD	trans	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg01620082	chr3:125678407	NA	-0.45	-6.71	-0.31	6.45e-11	Depression;
LUAD	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22496380	chr5:211416	CCDC127	-0.93	-13.12	-0.54	3.15e-33	Breast cancer;
LUAD	cis	rs11249608	0.548	rs2047354	chr5:178455247	T/C	cg01312482	chr5:178451176	ZNF879	-0.43	-6.75	-0.31	5.03e-11	Pubertal anthropometrics;
LUAD	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg17372223	chr3:52568218	NT5DC2	-0.39	-7.07	-0.33	6.44e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg04455712	chr21:45112962	RRP1B	0.4	7.81	0.35	4.64e-14	Mean corpuscular volume;
LUAD	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg16414030	chr3:133502952	NA	0.39	6.87	0.32	2.29e-11	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg08761264	chr16:28874980	SH2B1	-0.45	-6.9	-0.32	1.88e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	10.4	0.45	1e-22	Electrocardiographic conduction measures;
LUAD	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg19622623	chr12:86230825	RASSF9	0.42	7.49	0.34	3.93e-13	Major depressive disorder;
LUAD	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11644478	chr21:40555479	PSMG1	0.69	11.54	0.49	5.83e-27	Cognitive function;
LUAD	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg26384229	chr12:38710491	ALG10B	-0.4	-6.84	-0.32	2.86e-11	Heart rate;
LUAD	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.59	-0.52	4.41e-31	Monocyte count;
LUAD	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg24154853	chr7:158122151	PTPRN2	0.54	11.01	0.47	5.67e-25	Calcium levels;
LUAD	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg17346650	chr17:80929145	B3GNTL1	0.41	7.62	0.35	1.68e-13	Glycated hemoglobin levels;
LUAD	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg11663144	chr21:46675770	NA	-0.55	-10.82	-0.47	2.99e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs8051149	0.948	rs28609922	chr16:87876631	C/A	cg01412419	chr16:87856264	NA	0.41	6.77	0.31	4.31e-11	Blood metabolite levels;
LUAD	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg22815214	chr1:201083145	CACNA1S	0.55	9.34	0.41	5.64e-19	Permanent tooth development;
LUAD	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg00784671	chr22:46762841	CELSR1	-0.61	-7.56	-0.35	2.46e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs208520	0.661	rs207099	chr6:66796373	A/C	cg07460842	chr6:66804631	NA	-1.08	-16.76	-0.63	1.03e-48	Exhaled nitric oxide output;
LUAD	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg17063962	chr7:91808500	NA	0.68	11.45	0.49	1.21e-26	Breast cancer;
LUAD	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg15485101	chr11:133734466	NA	0.33	7.19	0.33	2.87e-12	Childhood ear infection;
LUAD	cis	rs4148087	1.000	rs9977571	chr21:43624157	G/A	cg08841829	chr21:43638893	ABCG1	-0.58	-7.64	-0.35	1.46e-13	Eating disorder in bipolar disorder;
LUAD	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg11189052	chr15:85197271	WDR73	0.68	8.96	0.4	1.06e-17	Schizophrenia;
LUAD	cis	rs7771547	0.574	rs9368943	chr6:36566575	C/T	cg07856975	chr6:36356162	ETV7	0.53	7.09	0.33	5.76e-12	Platelet distribution width;
LUAD	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg03806693	chr22:41940476	POLR3H	-0.83	-11.76	-0.5	8.38e-28	Vitiligo;
LUAD	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg20290983	chr6:43655470	MRPS18A	1.06	26.95	0.79	7.9e-94	IgG glycosylation;
LUAD	trans	rs6921919	1.000	rs6922111	chr6:28325308	C/T	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.46	-0.3	2.87e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7680126	0.632	rs11731464	chr4:10148376	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-7.47	-0.34	4.56e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg15128208	chr22:42549153	NA	0.43	6.72	0.31	5.96e-11	Birth weight;
LUAD	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.32	-0.34	1.28e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg09021430	chr5:549028	NA	-0.67	-13.14	-0.54	2.54e-33	Obesity-related traits;
LUAD	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06544989	chr22:39130855	UNC84B	0.44	8.35	0.38	9.51e-16	Menopause (age at onset);
LUAD	cis	rs791888	0.929	rs791887	chr10:89411554	A/G	cg13926569	chr10:89418898	PAPSS2	-0.47	-8.75	-0.39	5.04e-17	Magnesium levels;
LUAD	cis	rs10129255	0.500	rs988133	chr14:107184963	A/G	cg23076370	chr14:107095027	NA	-0.44	-8.74	-0.39	5.5e-17	Kawasaki disease;
LUAD	cis	rs516243	0.703	rs544722	chr1:10743042	T/C	cg02903756	chr1:10750680	CASZ1	-0.49	-9.22	-0.41	1.39e-18	Migraine - clinic-based;
LUAD	cis	rs11030122	0.702	rs10835312	chr11:3950253	G/A	cg18678763	chr11:4115507	RRM1	-0.44	-7.24	-0.33	2.15e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00166722	chr3:10149974	C3orf24	0.7	12.15	0.51	2.46e-29	Alzheimer's disease;
LUAD	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg21280719	chr6:42927975	GNMT	0.3	6.91	0.32	1.75e-11	Blood protein levels;
LUAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg00450029	chr8:599525	NA	0.83	7.99	0.36	1.26e-14	IgG glycosylation;
LUAD	trans	rs11039798	1.000	rs11039904	chr11:48682597	T/A	cg15704280	chr7:45808275	SEPT13	0.68	7.89	0.36	2.55e-14	Axial length;
LUAD	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg26022315	chr17:47021804	SNF8	0.41	7.3	0.33	1.47e-12	Type 2 diabetes;
LUAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg11494091	chr17:61959527	GH2	0.74	18.45	0.67	3.25e-56	Prudent dietary pattern;
LUAD	cis	rs12618769	0.597	rs72821908	chr2:99085359	A/G	cg10123293	chr2:99228465	UNC50	0.47	8.6	0.39	1.52e-16	Bipolar disorder;
LUAD	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg00310523	chr12:86230176	RASSF9	0.39	7.76	0.35	6.55e-14	Major depressive disorder;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg22232616	chr8:144898139	SCRIB	-0.64	-6.38	-0.3	4.64e-10	Type 2 diabetes;
LUAD	cis	rs7809950	0.817	rs62483725	chr7:107201575	G/A	cg23024343	chr7:107201750	COG5	-0.87	-14.97	-0.59	5.65e-41	Coronary artery disease;
LUAD	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg07404485	chr7:94953653	PON1	0.5	7.24	0.33	2.15e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.56	0.3	1.55e-10	Menarche (age at onset);
LUAD	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg03526776	chr6:41159608	TREML2	0.32	6.68	0.31	7.51e-11	Alzheimer's disease (late onset);
LUAD	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg09904177	chr6:26538194	HMGN4	0.42	6.93	0.32	1.58e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg18876405	chr7:65276391	NA	-0.63	-10.97	-0.47	7.98e-25	Calcium levels;
LUAD	cis	rs533581	0.866	rs4995274	chr16:88970040	T/C	cg16701003	chr16:89028210	CBFA2T3	0.51	10.4	0.45	1.07e-22	Social autistic-like traits;
LUAD	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	7.95	0.36	1.77e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs9560113	1.000	rs4773383	chr13:112177764	C/T	cg14154082	chr13:112174009	NA	0.37	6.87	0.32	2.32e-11	Menarche (age at onset);
LUAD	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg07636037	chr3:49044803	WDR6	0.6	11.34	0.48	3.29e-26	Parkinson's disease;
LUAD	cis	rs356992	0.915	rs168562	chr2:60747192	T/C	cg08426369	chr2:60753602	BCL11A	0.46	7.7	0.35	9.88e-14	Educational attainment (years of education);
LUAD	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg03467027	chr4:99064603	C4orf37	0.4	6.47	0.3	2.77e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9393692	0.557	rs2893820	chr6:26295686	G/A	cg13736514	chr6:26305472	NA	-0.54	-8.81	-0.39	3.24e-17	Educational attainment;
LUAD	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg23758822	chr17:41437982	NA	0.89	18.32	0.67	1.23e-55	Menopause (age at onset);
LUAD	cis	rs7746199	0.611	rs17750747	chr6:27730334	T/C	cg26958806	chr6:27640298	NA	0.63	6.43	0.3	3.43e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg19077165	chr18:44547161	KATNAL2	0.47	8.17	0.37	3.69e-15	Personality dimensions;
LUAD	cis	rs2479724	0.901	rs1051130	chr6:41903782	A/C	cg17623882	chr6:41773611	USP49	-0.57	-9.99	-0.44	3.08e-21	Menarche (age at onset);
LUAD	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	7.59	0.35	2.01e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7945718	0.875	rs9888181	chr11:12782781	G/A	cg25843174	chr11:12811716	TEAD1	0.27	7.84	0.36	3.61e-14	Educational attainment (years of education);
LUAD	trans	rs783540	0.500	rs783541	chr15:83255061	T/C	cg16105309	chr15:79090380	ADAMTS7	0.41	7.07	0.33	6.32e-12	Schizophrenia;
LUAD	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg11494091	chr17:61959527	GH2	0.38	6.93	0.32	1.57e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4604732	0.631	rs34443739	chr1:247626913	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.16	0.33	3.56e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs68092024	0.731	rs792841	chr3:99471308	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.5	-9.36	-0.41	4.92e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs6714710	0.603	rs13020776	chr2:98402753	T/A	cg26665480	chr2:98280029	ACTR1B	0.5	8.17	0.37	3.49e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs6594713	0.807	rs10477490	chr5:112687408	G/A	cg12552261	chr5:112820674	MCC	0.52	7.95	0.36	1.7e-14	Brain cytoarchitecture;
LUAD	cis	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg00071950	chr4:10020882	SLC2A9	0.48	6.91	0.32	1.83e-11	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg03859395	chr2:55845619	SMEK2	0.76	14.22	0.57	9.21e-38	Metabolic syndrome;
LUAD	cis	rs1215050	0.791	rs783969	chr4:98906504	C/T	cg17366294	chr4:99064904	C4orf37	0.48	8.43	0.38	5.5e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.43	-0.42	2.72e-19	Life satisfaction;
LUAD	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg00634984	chr7:65235879	NA	-0.51	-6.91	-0.32	1.77e-11	Aortic root size;
LUAD	cis	rs11229555	0.645	rs11229463	chr11:58210147	A/G	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg27124370	chr19:33622961	WDR88	0.43	6.66	0.31	8.47e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg04365224	chr3:72788183	NA	-0.47	-6.91	-0.32	1.83e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg04944784	chr2:26401820	FAM59B	0.88	12.13	0.51	2.99e-29	Gut microbiome composition (summer);
LUAD	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg04369109	chr6:150039330	LATS1	-0.44	-7.26	-0.33	1.88e-12	Lung cancer;
LUAD	cis	rs17197710	0.608	rs4647736	chr11:47253137	C/T	cg13308137	chr11:47528955	CUGBP1	0.48	7.07	0.33	6.4e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12620999	0.838	rs13007071	chr2:238038755	A/G	cg23555395	chr2:238036564	NA	-0.6	-9.2	-0.41	1.66e-18	Systemic lupus erythematosus;
LUAD	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2274273	0.837	rs8011329	chr14:55677255	G/A	cg04306507	chr14:55594613	LGALS3	0.39	8.19	0.37	3.15e-15	Protein biomarker;
LUAD	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.22	-0.33	2.4e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7707921	0.958	rs4703870	chr5:81492643	G/A	cg15871215	chr5:81402204	ATG10	0.7	10.03	0.44	2.23e-21	Breast cancer;
LUAD	cis	rs9875589	0.509	rs12330714	chr3:14040342	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	7.23	0.33	2.3e-12	Ovarian reserve;
LUAD	cis	rs6831352	0.505	rs11722561	chr4:100088737	T/A	cg12011299	chr4:100065546	ADH4	0.44	8.3	0.37	1.44e-15	Alcohol dependence;
LUAD	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg05340658	chr4:99064831	C4orf37	0.46	7.04	0.32	7.69e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10979	1.000	rs9285500	chr6:143897614	G/C	cg25407410	chr6:143891975	LOC285740	-0.64	-10.28	-0.45	2.77e-22	Hypospadias;
LUAD	cis	rs6546550	0.904	rs3771537	chr2:70038792	A/C	cg02498382	chr2:70120550	SNRNP27	-0.54	-10.58	-0.46	2.38e-23	Prevalent atrial fibrillation;
LUAD	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-8.52	-0.38	2.92e-16	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg01620082	chr3:125678407	NA	-0.46	-6.76	-0.31	4.61e-11	Depression;
LUAD	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg21475434	chr5:93447410	FAM172A	0.74	8.46	0.38	4.31e-16	Diabetic retinopathy;
LUAD	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg18512352	chr11:47633146	NA	-0.39	-6.86	-0.32	2.46e-11	Subjective well-being;
LUAD	cis	rs1232027	0.700	rs1650709	chr5:79937174	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg04414720	chr1:150670196	GOLPH3L	0.72	12.54	0.52	6.78e-31	Melanoma;
LUAD	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg11250194	chr11:61601937	FADS2	-0.43	-6.62	-0.31	1.07e-10	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg24410064	chr7:7222050	C1GALT1	-0.48	-6.58	-0.3	1.35e-10	Testicular germ cell tumor;
LUAD	trans	rs4714291	0.963	rs761801	chr6:39997176	G/A	cg02267698	chr19:7991119	CTXN1	0.44	6.64	0.31	9.86e-11	Strep throat;
LUAD	trans	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.91	-0.36	2.34e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg03188948	chr7:1209495	NA	0.65	9.34	0.41	5.58e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg27661571	chr11:113659931	NA	-0.7	-8.14	-0.37	4.58e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs6674176	0.542	rs2906468	chr1:44319007	A/G	cg13606994	chr1:44402422	ARTN	-0.33	-6.6	-0.31	1.25e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg00280220	chr17:61926910	NA	0.36	6.95	0.32	1.41e-11	Prudent dietary pattern;
LUAD	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg24818145	chr4:99064322	C4orf37	0.47	7.95	0.36	1.71e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg06074448	chr4:187884817	NA	-0.38	-7.49	-0.34	4.11e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg15556689	chr8:8085844	FLJ10661	0.43	6.74	0.31	5.05e-11	Mood instability;
LUAD	cis	rs1971762	0.583	rs3852561	chr12:54085842	C/T	cg23533419	chr12:54090519	NA	-0.34	-6.43	-0.3	3.41e-10	Height;
LUAD	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg01528321	chr10:82214614	TSPAN14	0.54	8.64	0.39	1.16e-16	Post bronchodilator FEV1;
LUAD	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.52	-9.1	-0.4	3.61e-18	Melanoma;
LUAD	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg22868518	chr11:507468	RNH1	-0.65	-6.55	-0.3	1.62e-10	Body mass index;
LUAD	trans	rs2797160	1.000	rs1739378	chr6:126012262	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.9	0.4	1.6e-17	Endometrial cancer;
LUAD	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg24578937	chr1:2090814	PRKCZ	0.56	11.87	0.5	3.03e-28	Height;
LUAD	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24308560	chr3:49941425	MST1R	0.55	9.33	0.41	5.97e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg19875535	chr5:140030758	IK	-0.45	-7.64	-0.35	1.43e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg06002616	chr8:101225028	SPAG1	0.37	7.65	0.35	1.35e-13	Atrioventricular conduction;
LUAD	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.5	-9.37	-0.41	4.56e-19	Longevity;Endometriosis;
LUAD	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg11901034	chr3:128598214	ACAD9	-0.48	-7.49	-0.34	4.03e-13	IgG glycosylation;
LUAD	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.15e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg07211511	chr3:129823064	LOC729375	-0.44	-6.51	-0.3	2.14e-10	Blood pressure (smoking interaction);
LUAD	cis	rs7223966	0.729	rs7921	chr17:62006259	G/A	cg11494091	chr17:61959527	GH2	0.45	7.77	0.35	5.88e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2046867	0.818	rs17010133	chr3:72827987	T/C	cg25664220	chr3:72788482	NA	-0.7	-12.22	-0.51	1.29e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg01884057	chr2:25150051	NA	0.34	7.2	0.33	2.71e-12	Body mass index;
LUAD	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.891	rs76308665	chr2:198518062	C/T	cg11031976	chr2:198649780	BOLL	-0.46	-6.78	-0.31	3.99e-11	Ulcerative colitis;
LUAD	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6906287	0.669	rs2356491	chr6:118806564	A/G	cg18833306	chr6:118973337	C6orf204	0.45	8.06	0.36	7.72e-15	Electrocardiographic conduction measures;
LUAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg06074448	chr4:187884817	NA	-0.37	-7.31	-0.33	1.38e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg09365446	chr1:150670422	GOLPH3L	0.65	12.11	0.51	3.3600000000000003e-29	Melanoma;
LUAD	trans	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg07393940	chr7:158741817	NA	-0.67	-11.48	-0.49	9.27e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs405460	0.517	rs392030	chr14:59298856	C/T	cg02291164	chr14:59296302	NA	-0.43	-8.16	-0.37	3.86e-15	Obesity-related traits;
LUAD	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg22753661	chr15:79092743	ADAMTS7	0.52	7.91	0.36	2.22e-14	Coronary artery disease or large artery stroke;
LUAD	cis	rs986417	1.000	rs1313243	chr14:60876398	C/T	cg27398547	chr14:60952738	C14orf39	-0.64	-7.76	-0.35	6.32e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg21862992	chr11:68658383	NA	0.53	9.62	0.42	6.22e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg20119798	chr7:94954144	PON1	-0.48	-6.53	-0.3	1.94e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg20503657	chr10:835505	NA	-0.46	-7.02	-0.32	8.64e-12	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-9.1	-0.4	3.66e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg07402062	chr16:89894098	SPIRE2	0.43	10.81	0.47	3.26e-24	Vitiligo;
LUAD	trans	rs3960554	0.569	rs11973658	chr7:75882026	A/C	cg19862616	chr7:65841803	NCRNA00174	0.6	9.41	0.42	3.21e-19	Eotaxin levels;
LUAD	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22590775	chr19:49891494	CCDC155	0.72	11.58	0.49	4.03e-27	Multiple sclerosis;
LUAD	cis	rs2455799	0.891	rs4685261	chr3:15851906	T/C	cg16303742	chr3:15540471	COLQ	-0.38	-6.6	-0.31	1.27e-10	Mean platelet volume;
LUAD	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18099408	chr3:52552593	STAB1	-0.42	-7.53	-0.34	3.04e-13	Bipolar disorder;
LUAD	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06028808	chr11:68637592	NA	-0.44	-7.38	-0.34	8.41e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-8.03	-0.36	9.89e-15	Platelet count;
LUAD	cis	rs11051970	0.679	rs2931554	chr12:32556162	G/A	cg24626660	chr12:32551988	NA	0.34	7.31	0.33	1.34e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg16988262	chr1:15930761	NA	0.41	6.87	0.32	2.34e-11	Systolic blood pressure;
LUAD	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg18132916	chr6:79620363	NA	-0.46	-7.95	-0.36	1.68e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05535760	chr7:792225	HEATR2	-1.01	-12.57	-0.52	5.11e-31	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg17366294	chr4:99064904	C4orf37	-0.67	-13.06	-0.54	5.42e-33	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg04398451	chr17:18023971	MYO15A	-0.65	-11.71	-0.49	1.3e-27	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08280861	chr8:58055591	NA	0.63	8.3	0.37	1.42e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.61	12.73	0.53	1.19e-31	Monocyte percentage of white cells;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg20718083	chr11:65554410	OVOL1	-0.4	-6.54	-0.3	1.76e-10	Subcortical brain region volumes;
LUAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg23131131	chr22:24373011	LOC391322	-0.59	-9.86	-0.43	9.15e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg21280719	chr6:42927975	GNMT	-0.39	-11.88	-0.5	2.64e-28	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs629535	0.767	rs62513418	chr8:70114376	G/T	cg21567404	chr3:27674614	NA	-0.95	-17.02	-0.64	7.15e-50	Dupuytren's disease;
LUAD	cis	rs13315871	0.929	rs9818581	chr3:58293101	A/G	cg12435725	chr3:58293450	RPP14	-0.74	-7.88	-0.36	2.86e-14	Cholesterol, total;
LUAD	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.71e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg25985355	chr7:65971099	NA	-0.51	-6.51	-0.3	2.16e-10	Diabetic kidney disease;
LUAD	cis	rs7932354	0.528	rs11039097	chr11:47131881	C/T	cg19486271	chr11:47235900	DDB2	-0.43	-6.69	-0.31	7.14e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg04673462	chr1:38461896	NA	0.41	8.36	0.38	9.31e-16	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.78	-0.31	3.98e-11	Schizophrenia;
LUAD	cis	rs11974702	1	rs11974702	chr7:99163951	A/G	cg03133378	chr7:99195931	NA	-0.59	-6.79	-0.31	3.74e-11	Blood metabolite levels;
LUAD	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg22467129	chr15:76604101	ETFA	-0.49	-7.91	-0.36	2.25e-14	Blood metabolite levels;
LUAD	cis	rs1448094	1.000	rs4919776	chr12:86353763	T/C	cg00310523	chr12:86230176	RASSF9	0.33	7.01	0.32	9.76e-12	Major depressive disorder;
LUAD	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.69	-0.35	1.01e-13	Bipolar disorder;
LUAD	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg22920501	chr2:26401640	FAM59B	0.97	14.94	0.59	7.76e-41	Gut microbiome composition (summer);
LUAD	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg02569458	chr12:86230093	RASSF9	0.41	7.47	0.34	4.76e-13	Major depressive disorder;
LUAD	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg14343924	chr8:8086146	FLJ10661	0.46	7.09	0.33	5.83e-12	Mood instability;
LUAD	cis	rs829883	1.000	rs2908843	chr12:98889332	C/G	cg25150519	chr12:98850993	NA	-0.66	-11.16	-0.48	1.56e-25	Colorectal adenoma (advanced);
LUAD	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg18827107	chr12:86230957	RASSF9	-0.67	-12.32	-0.51	5.37e-30	Major depressive disorder;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg23666278	chr2:171785822	GORASP2	-0.42	-7.15	-0.33	3.77e-12	Schizophrenia;
LUAD	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg25828334	chr19:18545568	ISYNA1	-0.38	-7.61	-0.35	1.82e-13	Breast cancer;
LUAD	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05890377	chr2:74357713	NA	0.85	12.13	0.51	2.99e-29	Gestational age at birth (maternal effect);
LUAD	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.16	0.37	3.86e-15	Rheumatoid arthritis;
LUAD	cis	rs7771547	0.521	rs2180929	chr6:36394087	G/A	cg07856975	chr6:36356162	ETV7	0.51	7.53	0.34	3.16e-13	Platelet distribution width;
LUAD	trans	rs75804782	0.625	rs61178898	chr2:239461810	C/T	cg01134436	chr17:81009848	B3GNTL1	0.76	7.67	0.35	1.16e-13	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2067615	0.507	rs10746063	chr12:107086240	G/T	cg15890332	chr12:107067104	RFX4	0.41	8.59	0.39	1.63e-16	Heart rate;
LUAD	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg15017067	chr4:17643749	FAM184B	-0.38	-7.27	-0.33	1.81e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg18138036	chr10:133769891	PPP2R2D	0.41	6.65	0.31	9.3e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	trans	rs1728785	0.901	rs1170438	chr16:68608256	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.71	0.46	7.71e-24	Ulcerative colitis;
LUAD	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg17757837	chr7:157058334	UBE3C	0.46	8.31	0.37	1.29e-15	Body mass index;
LUAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg08888203	chr3:10149979	C3orf24	0.72	12.89	0.53	2.62e-32	Alzheimer's disease;
LUAD	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg03929089	chr4:120376271	NA	-0.47	-7.52	-0.34	3.41e-13	HDL cholesterol;
LUAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08439880	chr3:133502540	NA	0.44	8.67	0.39	9.2e-17	Iron status biomarkers;
LUAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14893161	chr1:205819251	PM20D1	0.51	8.23	0.37	2.37e-15	Parkinson's disease;
LUAD	cis	rs6430585	0.583	rs2839740	chr2:136648883	G/T	cg07169764	chr2:136633963	MCM6	0.79	9.18	0.41	1.92e-18	Corneal structure;
LUAD	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg06092702	chr1:163392909	NA	0.36	8.33	0.38	1.11e-15	Motion sickness;
LUAD	cis	rs2439831	0.850	rs67541383	chr15:44172548	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	9.39	0.42	3.86e-19	Lung cancer in ever smokers;
LUAD	cis	rs9450351	0.744	rs6902904	chr6:86202703	C/T	cg13315970	chr6:86159197	NT5E	0.72	6.6	0.31	1.26e-10	Interferon gamma-induced protein 10 levels;
LUAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.52	-0.46	3.84e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg05304507	chr6:116381966	FRK	0.2	6.7	0.31	6.57e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs1595825	0.891	rs16824376	chr2:198684342	C/T	cg11031976	chr2:198649780	BOLL	-0.48	-7.13	-0.33	4.23e-12	Ulcerative colitis;
LUAD	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.8	-0.35	4.77e-14	Diabetic kidney disease;
LUAD	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03517284	chr6:25882590	NA	0.6	9.98	0.44	3.25e-21	Blood metabolite levels;
LUAD	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg25566285	chr7:158114605	PTPRN2	-0.53	-11.5	-0.49	7.82e-27	Calcium levels;
LUAD	cis	rs727505	0.564	rs56068095	chr7:124831906	A/T	cg23710748	chr7:124431027	NA	-0.36	-7.23	-0.33	2.22e-12	Lewy body disease;
LUAD	cis	rs2292884	0.505	rs78063959	chr2:238428961	G/A	cg14458575	chr2:238380390	NA	0.72	11.37	0.48	2.54e-26	Prostate cancer;
LUAD	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg06627628	chr2:24431161	ITSN2	-0.64	-10.08	-0.44	1.5e-21	Asthma;
LUAD	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg00277334	chr10:82204260	NA	-0.67	-12.18	-0.51	1.8e-29	Post bronchodilator FEV1;
LUAD	cis	rs7580658	0.545	rs13001179	chr2:127952193	A/C	cg16751203	chr2:127950803	CYP27C1	0.4	6.73	0.31	5.63e-11	Protein C levels;
LUAD	cis	rs67366981	1.000	rs56357623	chr14:77697393	C/A	cg22824376	chr14:77648248	TMEM63C	0.75	8.03	0.36	9.72e-15	Obsessive-compulsive symptoms;
LUAD	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg17264618	chr3:40429014	ENTPD3	0.38	8.51	0.38	3.08e-16	Renal cell carcinoma;
LUAD	cis	rs55665837	0.540	rs12290926	chr11:14695046	A/G	cg19336497	chr11:14380999	RRAS2	-0.41	-7.83	-0.36	3.9e-14	Vitamin D levels;
LUAD	cis	rs2485376	1.000	rs3758551	chr10:104002409	A/G	cg20641465	chr10:103991465	PITX3	0.57	10.42	0.45	8.85e-23	QT interval;
LUAD	cis	rs3806933	0.522	rs12521169	chr5:110448313	G/A	cg17157872	chr5:110408788	TSLP	0.35	6.71	0.31	6.15e-11	Eosinophilic esophagitis;
LUAD	cis	rs11677416	1.000	rs1800587	chr2:113542960	C/T	cg27083787	chr2:113543245	IL1A	0.38	6.64	0.31	9.84e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg27454412	chr7:1067447	C7orf50	-0.35	-6.91	-0.32	1.76e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg17177755	chr1:15930204	NA	0.44	7.13	0.33	4.43e-12	Systolic blood pressure;
LUAD	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg03806693	chr22:41940476	POLR3H	0.52	7.69	0.35	1.07e-13	Vitiligo;
LUAD	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg12311346	chr5:56204834	C5orf35	-0.43	-7.09	-0.33	5.77e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg22535103	chr8:58192502	C8orf71	-0.72	-8.94	-0.4	1.24e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg22532475	chr10:104410764	TRIM8	-0.64	-11.91	-0.5	2.04e-28	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7937890	0.559	rs2597221	chr11:14527075	C/T	cg06199346	chr11:14280333	SPON1	-0.32	-6.42	-0.3	3.58e-10	Mitochondrial DNA levels;
LUAD	cis	rs4888378	0.600	rs729109	chr16:75316074	A/G	cg03315344	chr16:75512273	CHST6	-0.45	-7.65	-0.35	1.38e-13	Coronary artery disease;
LUAD	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.57	-0.49	4.54e-27	Primary sclerosing cholangitis;
LUAD	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg00757033	chr12:89920650	WDR51B	0.67	11.55	0.49	5.43e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs4462272	0.557	rs17729876	chr10:101999746	G/A	cg19754520	chr10:101825118	CPN1	-0.3	-6.38	-0.3	4.67e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg07606381	chr6:8435919	SLC35B3	0.4	6.83	0.31	3.05e-11	Motion sickness;
LUAD	cis	rs7932354	0.528	rs7103581	chr11:47072805	G/T	cg19486271	chr11:47235900	DDB2	-0.46	-7.28	-0.33	1.6e-12	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg25894440	chr7:65020034	NA	-0.66	-7.12	-0.33	4.54e-12	Diabetic kidney disease;
LUAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg08742575	chr21:47604166	C21orf56	0.42	7.09	0.33	5.59e-12	Testicular germ cell tumor;
LUAD	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg02269571	chr22:50332266	NA	-0.61	-9.37	-0.41	4.51e-19	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg17063962	chr7:91808500	NA	0.67	11.94	0.5	1.55e-28	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05744073	chr17:1953268	MIR132	-0.45	-7.06	-0.32	7.1e-12	Height;
LUAD	cis	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg02421172	chr7:1938701	MAD1L1	0.43	6.51	0.3	2.16e-10	Bipolar disorder;
LUAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg03188948	chr7:1209495	NA	0.41	6.56	0.3	1.57e-10	Longevity;Endometriosis;
LUAD	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.64	0.39	1.17e-16	Parkinson's disease;
LUAD	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg27113419	chr16:58533979	NDRG4	-0.72	-6.49	-0.3	2.41e-10	Schizophrenia;
LUAD	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg00310523	chr12:86230176	RASSF9	0.37	7.5	0.34	3.82e-13	Major depressive disorder;
LUAD	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg13870426	chr17:30244630	NA	-0.55	-6.47	-0.3	2.65e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs7107174	1.000	rs10899460	chr11:78010080	A/G	cg02023728	chr11:77925099	USP35	0.49	7.35	0.34	1.02e-12	Testicular germ cell tumor;
LUAD	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11644478	chr21:40555479	PSMG1	0.69	11.54	0.49	5.68e-27	Cognitive function;
LUAD	cis	rs34172651	0.917	rs11646987	chr16:24832408	G/T	cg00339695	chr16:24857497	SLC5A11	0.48	8.87	0.4	2.11e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg11266682	chr4:10021025	SLC2A9	0.67	15.23	0.6	4.5e-42	Bone mineral density;
LUAD	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg00339695	chr16:24857497	SLC5A11	0.53	9.71	0.43	2.97e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg05043794	chr9:111880884	C9orf5	-0.45	-7.77	-0.35	5.87e-14	Menarche (age at onset);
LUAD	cis	rs240764	0.554	rs6570970	chr6:101233082	C/A	cg09795085	chr6:101329169	ASCC3	0.41	7.17	0.33	3.39e-12	Neuroticism;
LUAD	cis	rs807669	0.548	rs762522	chr22:19180575	C/T	cg02655711	chr22:19163373	SLC25A1	0.7	14.15	0.57	1.7e-37	Metabolite levels;
LUAD	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg15557168	chr22:42548783	NA	-0.45	-8.36	-0.38	8.92e-16	Cognitive function;
LUAD	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg17724175	chr1:150552817	MCL1	0.4	9.7	0.43	3.13e-20	Melanoma;
LUAD	cis	rs11229555	0.645	rs11229443	chr11:58197188	G/C	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg12310025	chr6:25882481	NA	-0.62	-9.23	-0.41	1.33e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs4072705	0.617	rs10283445	chr9:127243637	A/G	cg14219918	chr9:127249562	NR5A1	0.28	6.46	0.3	2.92e-10	Menarche (age at onset);
LUAD	cis	rs7166081	0.738	rs28399271	chr15:67710011	G/A	cg27219399	chr15:67835830	MAP2K5	0.43	7.51	0.34	3.57e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.72	-9.81	-0.43	1.36e-20	Menarche (age at onset);
LUAD	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11890956	chr21:40555474	PSMG1	0.83	14.92	0.59	9.48e-41	Cognitive function;
LUAD	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg08470875	chr2:26401718	FAM59B	0.76	10.22	0.45	4.49e-22	Gut microbiome composition (summer);
LUAD	cis	rs9469578	0.636	rs16869463	chr6:33714983	A/G	cg18708504	chr6:33715942	IP6K3	-0.58	-7.06	-0.32	6.69e-12	Phosphorus levels;
LUAD	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg10589385	chr1:150898437	SETDB1	0.45	8.44	0.38	5.11e-16	Melanoma;
LUAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-9.43	-0.42	2.83e-19	Alzheimer's disease;
LUAD	cis	rs10916814	0.704	rs4655221	chr1:20899265	C/A	cg24502330	chr1:20914028	CDA	-0.36	-7.18	-0.33	3.14e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1865721	0.771	rs72975985	chr18:73127648	C/T	cg26385618	chr18:73139727	C18orf62	-0.51	-10.13	-0.44	9.43e-22	Intelligence;
LUAD	cis	rs3125734	0.608	rs7094950	chr10:64019744	T/C	cg19640130	chr10:64028056	RTKN2	-0.35	-7.38	-0.34	8.57e-13	Rheumatoid arthritis;
LUAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg22105103	chr4:187893119	NA	0.57	12.27	0.51	8.17e-30	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg14773178	chr5:1868261	NA	0.33	6.48	0.3	2.6e-10	Cardiovascular disease risk factors;
LUAD	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg14266287	chr2:239334506	ASB1	-0.29	-6.35	-0.3	5.44e-10	Multiple system atrophy;
LUAD	cis	rs1691799	0.867	rs1168344	chr12:66758213	G/A	cg16791601	chr12:66731901	HELB	-0.37	-6.68	-0.31	7.4e-11	White blood cell count (basophil);
LUAD	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg00321850	chr1:175162397	KIAA0040	-0.51	-11.12	-0.48	2.3e-25	Alcohol dependence;
LUAD	trans	rs9951602	0.512	rs4799247	chr18:76653449	G/A	cg02800362	chr5:177631904	HNRNPAB	0.91	14.55	0.58	3.71e-39	Obesity-related traits;
LUAD	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg24818145	chr4:99064322	C4orf37	0.47	7.84	0.36	3.71e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12208915	0.731	rs9448581	chr6:79553378	A/G	cg05283184	chr6:79620031	NA	-0.45	-6.5	-0.3	2.27e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs2688608	0.905	rs2633300	chr10:75656647	A/C	cg23231163	chr10:75533350	FUT11	-0.38	-7.16	-0.33	3.71e-12	Inflammatory bowel disease;
LUAD	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06544989	chr22:39130855	UNC84B	-0.47	-9.26	-0.41	1e-18	Menopause (age at onset);
LUAD	cis	rs7119038	0.818	rs17122453	chr11:118683564	G/A	cg19308663	chr11:118741387	NA	0.43	6.41	0.3	3.97e-10	Sjögren's syndrome;
LUAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg00684032	chr4:1343700	KIAA1530	0.39	6.51	0.3	2.14e-10	Obesity-related traits;
LUAD	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg24069376	chr3:38537580	EXOG	-0.33	-7.75	-0.35	6.7e-14	Electrocardiographic conduction measures;
LUAD	cis	rs62229266	0.626	rs7280896	chr21:37460906	G/A	cg12218747	chr21:37451666	NA	-0.65	-12.14	-0.51	2.74e-29	Mitral valve prolapse;
LUAD	trans	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg18335740	chr13:41363409	SLC25A15	0.62	11.38	0.48	2.36e-26	Lewy body disease;
LUAD	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg18305652	chr10:134549665	INPP5A	0.6	11.03	0.47	4.89e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg07423050	chr13:99094983	FARP1	-0.52	-8.75	-0.39	5.26e-17	Longevity;
LUAD	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2282300	0.739	rs1222215	chr11:30347596	C/T	cg25418670	chr11:30344373	C11orf46	-0.52	-6.94	-0.32	1.5e-11	Morning vs. evening chronotype;
LUAD	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg20503657	chr10:835505	NA	1.24	18.49	0.67	2.18e-56	Eosinophil percentage of granulocytes;
LUAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.62	0.55	2.7e-35	Prudent dietary pattern;
LUAD	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.99	-0.36	1.33e-14	Diabetic kidney disease;
LUAD	cis	rs10419226	0.555	rs3764627	chr19:18747696	C/T	cg22001208	chr19:18782374	NA	-0.5	-8.6	-0.39	1.53e-16	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs6076065	0.707	rs12349	chr20:23352480	A/G	cg11657817	chr20:23433608	CST11	0.58	12.2	0.51	1.57e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs427394	0.659	rs274695	chr5:6732252	G/C	cg10857441	chr5:6722123	POLS	-0.62	-11.05	-0.47	4.18e-25	Menopause (age at onset);
LUAD	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg03433033	chr1:76189801	ACADM	0.75	11.44	0.49	1.37e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7809615	0.901	rs10226310	chr7:99118320	G/A	cg12290671	chr7:99195819	NA	-0.68	-7.99	-0.36	1.25e-14	Blood metabolite ratios;
LUAD	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg01802117	chr1:53393560	SCP2	-0.38	-7.28	-0.33	1.6e-12	Monocyte count;
LUAD	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.02	0.36	1.02e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4692589	0.965	rs2291167	chr4:170950887	G/A	cg19918862	chr4:170955249	NA	0.3	7.07	0.33	6.29e-12	Anxiety disorder;
LUAD	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg15181151	chr6:150070149	PCMT1	0.4	8.12	0.37	5e-15	Lung cancer;
LUAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.79	-0.39	3.86e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs1371614	0.611	rs7557229	chr2:27130891	T/C	cg00617064	chr2:27272375	NA	0.34	6.61	0.31	1.16e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg21471580	chr8:22132874	PIWIL2	0.44	7.78	0.35	5.45e-14	Hypertriglyceridemia;
LUAD	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.7e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg13870426	chr17:30244630	NA	-0.55	-6.51	-0.3	2.17e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg09835421	chr16:68378352	PRMT7	-0.75	-8.61	-0.39	1.43e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07157834	chr1:205819609	PM20D1	-0.59	-10.99	-0.47	7.03e-25	Monocyte percentage of white cells;
LUAD	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg04034577	chr2:241836375	C2orf54	0.46	9.99	0.44	3.07e-21	Urinary metabolites;
LUAD	cis	rs12545109	0.800	rs2609978	chr8:57394467	T/C	cg09654669	chr8:57350985	NA	-0.7	-9.94	-0.44	4.63e-21	Obesity-related traits;
LUAD	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg15226275	chr6:116381976	FRK	0.23	7.65	0.35	1.41e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg12311346	chr5:56204834	C5orf35	-0.9	-13.44	-0.55	1.58e-34	Initial pursuit acceleration;
LUAD	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg15017067	chr4:17643749	FAM184B	0.33	6.5	0.3	2.25e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg23978390	chr7:1156363	C7orf50	0.53	6.62	0.31	1.1e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs68170813	0.523	rs10253172	chr7:106786474	C/T	cg02696742	chr7:106810147	HBP1	0.82	10.9	0.47	1.49e-24	Coronary artery disease;
LUAD	cis	rs11209185	0.509	rs2419044	chr1:68421087	C/T	cg22082780	chr1:68452167	NA	0.48	9.92	0.43	5.21e-21	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs1003719	0.680	rs2154537	chr21:38502012	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.53	-8.91	-0.4	1.54e-17	Eye color traits;
LUAD	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21016266	chr12:122356598	WDR66	0.65	11.87	0.5	3.13e-28	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg05665937	chr4:1216051	CTBP1	0.48	7.15	0.33	3.73e-12	Longevity;
LUAD	trans	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg07393940	chr7:158741817	NA	-0.66	-11.41	-0.49	1.79e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08703553	chr2:111436428	BUB1	-0.44	-6.73	-0.31	5.37e-11	Height;
LUAD	trans	rs17685	0.740	rs2286821	chr7:75611355	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.95	-20.21	-0.7	4.43e-64	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs561341	0.609	rs739800	chr17:30190083	T/A	cg20587970	chr11:113659929	NA	0.87	11.45	0.49	1.3e-26	Hip circumference adjusted for BMI;
LUAD	cis	rs7582720	1.000	rs72926802	chr2:203830228	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg17299007	chr1:248814626	OR2T27	0.29	6.52	0.3	2.06e-10	Common traits (Other);
LUAD	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg20307385	chr11:47447363	PSMC3	0.53	7.94	0.36	1.87e-14	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg26384229	chr12:38710491	ALG10B	0.4	6.93	0.32	1.63e-11	Heart rate;
LUAD	trans	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg26043149	chr18:55253948	FECH	-0.42	-6.91	-0.32	1.78e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6960043	0.584	rs10244143	chr7:15042959	C/T	cg19272540	chr7:15055459	NA	0.31	6.82	0.31	3.16e-11	Type 2 diabetes;
LUAD	cis	rs4900538	0.819	rs72700604	chr14:102882307	G/A	cg18135206	chr14:102964638	TECPR2	-1.01	-21.02	-0.71	1.08e-67	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06022373	chr22:39101656	GTPBP1	0.45	7.51	0.34	3.66e-13	Menopause (age at onset);
LUAD	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg17063962	chr7:91808500	NA	-0.64	-11.16	-0.48	1.64e-25	Breast cancer;
LUAD	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg05340658	chr4:99064831	C4orf37	0.51	8.52	0.38	2.85e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg01475377	chr6:109611718	NA	-0.53	-10.12	-0.44	1.1e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg27489772	chr12:121021490	NA	0.5	6.56	0.3	1.61e-10	Type 1 diabetes nephropathy;
LUAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg12432903	chr7:1882776	MAD1L1	-0.53	-8.66	-0.39	1.01e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg00277334	chr10:82204260	NA	-0.57	-9.47	-0.42	2.07e-19	Post bronchodilator FEV1;
LUAD	cis	rs61021925	1	rs61021925	chr12:122863659	T/C	cg23029597	chr12:123009494	RSRC2	0.41	6.69	0.31	7.21e-11	Schizophrenia;
LUAD	cis	rs10979	0.928	rs6924967	chr6:143906235	C/T	cg25407410	chr6:143891975	LOC285740	-0.63	-9.88	-0.43	7.61e-21	Hypospadias;
LUAD	cis	rs1232027	0.622	rs1650656	chr5:79964800	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.45	-7.39	-0.34	7.89e-13	Huntington's disease progression;
LUAD	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.34	7.18	0.33	3.07e-12	Parkinson's disease;
LUAD	cis	rs853679	0.760	rs9295768	chr6:28209102	G/A	cg16479474	chr6:28041457	NA	0.41	6.68	0.31	7.73e-11	Depression;
LUAD	cis	rs6906287	0.647	rs6902812	chr6:118936294	A/G	cg18833306	chr6:118973337	C6orf204	0.49	8.62	0.39	1.37e-16	Electrocardiographic conduction measures;
LUAD	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg13732083	chr21:47605072	C21orf56	0.42	6.95	0.32	1.39e-11	Testicular germ cell tumor;
LUAD	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg23954153	chr1:44402353	ARTN	-0.37	-7.16	-0.33	3.62e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs17135859	1.000	rs13435951	chr5:112994003	C/G	cg12552261	chr5:112820674	MCC	-0.54	-7.55	-0.34	2.67e-13	F-cell distribution;
LUAD	cis	rs367943	1.000	rs348931	chr5:112812864	G/C	cg12552261	chr5:112820674	MCC	-0.58	-11.04	-0.47	4.66e-25	Type 2 diabetes;
LUAD	cis	rs12545109	0.765	rs2576594	chr8:57412126	T/G	cg17761419	chr8:57350749	NA	-0.54	-7.65	-0.35	1.39e-13	Obesity-related traits;
LUAD	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg02423579	chr7:2872169	GNA12	-0.91	-16.7	-0.63	1.79e-48	Height;
LUAD	cis	rs9948	0.786	rs111237064	chr2:97456578	T/C	cg20312557	chr2:97357134	FER1L5	-0.64	-7.55	-0.34	2.62e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg07828340	chr4:882639	GAK	1.04	11.44	0.49	1.38e-26	Intelligence (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg10069734	chr2:120124354	DBI;C2orf76	-0.68	-6.48	-0.3	2.6e-10	Type 2 diabetes;
LUAD	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg18944383	chr4:111397179	ENPEP	0.54	10.47	0.45	6e-23	Height;
LUAD	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg13073564	chr4:8508604	NA	0.48	7.79	0.35	5.34e-14	Response to antineoplastic agents;
LUAD	cis	rs17826219	0.585	rs8064302	chr17:28724938	G/A	cg19761014	chr17:28927070	LRRC37B2	-0.69	-6.91	-0.32	1.83e-11	Body mass index;
LUAD	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg06640241	chr16:89574553	SPG7	0.48	7.92	0.36	2.13e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs4795519	0.808	rs11650291	chr17:22153109	A/T	cg22648282	chr17:21454238	C17orf51	-0.39	-6.45	-0.3	3.02e-10	Chronic myeloid leukemia;
LUAD	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg06671706	chr8:8559999	CLDN23	0.64	10.97	0.47	8.09e-25	Obesity-related traits;
LUAD	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.95	0.47	9.51e-25	Smoking behavior;
LUAD	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg18230493	chr5:56204884	C5orf35	0.71	11.18	0.48	1.35e-25	Initial pursuit acceleration;
LUAD	cis	rs9581857	0.547	rs9581869	chr13:28082498	G/A	cg22138327	chr13:27999177	GTF3A	0.89	9.73	0.43	2.62e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs2979489	0.945	rs12548554	chr8:30346544	G/A	cg26383811	chr8:30366931	RBPMS	-0.68	-10.45	-0.45	6.83e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.04	0.32	7.99e-12	Menopause (age at onset);
LUAD	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg20283391	chr11:68216788	NA	-0.4	-6.45	-0.3	3.09e-10	Total body bone mineral density;
LUAD	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg10596483	chr8:143751796	JRK	0.46	7.34	0.34	1.08e-12	Schizophrenia;
LUAD	trans	rs853679	1.000	rs11965538	chr6:28239915	G/A	cg01620082	chr3:125678407	NA	-0.5	-6.74	-0.31	5.08e-11	Depression;
LUAD	cis	rs12824058	0.707	rs2398509	chr12:130816464	T/C	cg26677194	chr12:130822605	PIWIL1	0.55	8.9	0.4	1.65e-17	Menopause (age at onset);
LUAD	cis	rs7301016	1.000	rs10877859	chr12:62873873	G/A	cg11441379	chr12:63026424	NA	0.52	6.39	0.3	4.45e-10	IgG glycosylation;
LUAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.31e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg25358565	chr5:93447407	FAM172A	0.61	7.24	0.33	2.15e-12	Diabetic retinopathy;
LUAD	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg22491629	chr6:157744540	C6orf35	-0.78	-8.99	-0.4	8.53e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18876405	chr7:65276391	NA	0.47	7.4	0.34	7.17e-13	Aortic root size;
LUAD	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg23533926	chr12:111358616	MYL2	-0.43	-7.39	-0.34	8.09e-13	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg01765077	chr12:122356316	WDR66	0.51	8.63	0.39	1.24e-16	Mean corpuscular volume;
LUAD	cis	rs1595825	1.000	rs1595825	chr2:198875464	G/A	cg00982548	chr2:198649783	BOLL	-0.6	-8.68	-0.39	8.65e-17	Ulcerative colitis;
LUAD	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.7e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6920965	0.545	rs614031	chr6:126165720	A/C	cg05901451	chr6:126070800	HEY2	-0.43	-7.11	-0.33	5.03e-12	High light scatter reticulocyte count;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15730116	chr12:76953768	OSBPL8	-0.54	-6.45	-0.3	2.98e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg17063962	chr7:91808500	NA	-0.63	-10.7	-0.46	8.27e-24	Breast cancer;
LUAD	cis	rs2734839	0.964	rs2734838	chr11:113286501	A/G	cg14159747	chr11:113255604	NA	0.54	10.2	0.44	5.52e-22	Information processing speed;
LUAD	cis	rs7582720	0.943	rs72932559	chr2:203847382	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.64	0.42	5.27e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-8.03	-0.36	1.01e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg26043149	chr18:55253948	FECH	0.4	6.48	0.3	2.5e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs738321	0.762	rs4820321	chr22:38579569	T/A	cg17652424	chr22:38574118	PLA2G6	-0.3	-7.96	-0.36	1.64e-14	Breast cancer;
LUAD	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg23435118	chr5:141488016	NDFIP1	-0.49	-7.44	-0.34	5.69e-13	Crohn's disease;
LUAD	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg21775007	chr8:11205619	TDH	-0.4	-6.98	-0.32	1.13e-11	Retinal vascular caliber;
LUAD	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg05890377	chr2:74357713	NA	0.82	12.17	0.51	1.94e-29	Gestational age at birth (maternal effect);
LUAD	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs490234	0.841	rs626667	chr9:128428404	A/G	cg14078157	chr9:128172775	NA	0.42	7.54	0.34	2.96e-13	Mean arterial pressure;
LUAD	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg25767906	chr1:53392781	SCP2	-0.44	-8.13	-0.37	4.76e-15	Monocyte count;
LUAD	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg09365446	chr1:150670422	GOLPH3L	0.66	12.57	0.52	5.38e-31	Tonsillectomy;
LUAD	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg09796270	chr17:17721594	SREBF1	0.4	8.12	0.37	5.18e-15	Total body bone mineral density;
LUAD	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg08885076	chr2:99613938	TSGA10	0.37	6.77	0.31	4.38e-11	Chronic sinus infection;
LUAD	cis	rs494562	0.892	rs567686	chr6:86124164	A/T	cg21730993	chr6:86159210	NT5E	0.72	7.99	0.36	1.31e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg18621852	chr3:10150065	C3orf24	0.48	8.35	0.38	1.02e-15	Alzheimer's disease;
LUAD	cis	rs13082711	0.595	rs17681498	chr3:27331258	T/C	cg02860705	chr3:27208620	NA	0.78	12.05	0.51	6.14e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs17054265	1.000	rs17054265	chr9:91260562	C/T	cg14112041	chr9:91262358	LOC286238	0.34	6.4	0.3	4.16e-10	Obesity-related traits;
LUAD	cis	rs34734847	0.703	rs3794215	chr12:121168083	T/C	cg21892295	chr12:121157589	UNC119B	-0.37	-6.45	-0.3	3.11e-10	Mean corpuscular volume;
LUAD	trans	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.3e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6906287	0.561	rs2078079	chr6:118705213	G/A	cg18833306	chr6:118973337	C6orf204	0.55	10.41	0.45	9.64e-23	Electrocardiographic conduction measures;
LUAD	cis	rs28735056	0.967	rs498541	chr18:77589655	G/A	cg20368463	chr18:77673604	PQLC1	-0.41	-6.43	-0.3	3.43e-10	Schizophrenia;
LUAD	cis	rs701145	0.938	rs355769	chr3:154042550	T/C	cg17054900	chr3:154042577	DHX36	0.66	7.32	0.34	1.29e-12	Coronary artery disease;
LUAD	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg04414720	chr1:150670196	GOLPH3L	0.73	12.68	0.52	1.86e-31	Melanoma;
LUAD	trans	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg01620082	chr3:125678407	NA	-0.72	-7.91	-0.36	2.34e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.49	-0.3	2.38e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7567389	0.568	rs7568070	chr2:127953054	A/C	cg11380483	chr2:127933992	NA	0.41	7.45	0.34	5.29e-13	Self-rated health;
LUAD	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg06808227	chr14:105710500	BRF1	-0.4	-6.39	-0.3	4.37e-10	Platelet count;
LUAD	cis	rs2274273	0.624	rs7140628	chr14:55760681	A/C	cg04306507	chr14:55594613	LGALS3	0.4	7.85	0.36	3.43e-14	Protein biomarker;
LUAD	cis	rs2249625	0.564	rs2496489	chr6:72877338	G/A	cg18830697	chr6:72922368	RIMS1	-0.45	-8.12	-0.37	5.21e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.73	-8.62	-0.39	1.39e-16	Body mass index;
LUAD	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.68	-0.39	8.66e-17	Alzheimer's disease (late onset);
LUAD	cis	rs4660214	0.590	rs11205885	chr1:39772305	C/T	cg27567593	chr1:39956653	BMP8A	0.36	7.14	0.33	4.08e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6005807	0.719	rs134524	chr22:28773804	G/A	cg12565055	chr22:29076175	TTC28	-0.79	-8.91	-0.4	1.51e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg18230493	chr5:56204884	C5orf35	0.71	11.33	0.48	3.55e-26	Initial pursuit acceleration;
LUAD	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg02734326	chr4:10020555	SLC2A9	0.53	9.28	0.41	8.8e-19	Bone mineral density;
LUAD	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24531977	chr5:56204891	C5orf35	0.96	15.01	0.59	3.88e-41	Initial pursuit acceleration;
LUAD	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg06618935	chr21:46677482	NA	0.51	10.23	0.45	4.33e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg17173187	chr15:85201210	NMB	0.54	9.45	0.42	2.29e-19	Schizophrenia;
LUAD	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg06636551	chr8:101224915	SPAG1	0.37	6.8	0.31	3.52e-11	Atrioventricular conduction;
LUAD	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg04414720	chr1:150670196	GOLPH3L	0.72	12.76	0.53	9.4e-32	Melanoma;
LUAD	cis	rs3916	0.662	rs2138249	chr12:121124142	A/C	cg27246729	chr12:121163418	ACADS	0.38	6.88	0.32	2.2e-11	Urinary metabolites (H-NMR features);
LUAD	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg06547715	chr2:218990976	CXCR2	-0.28	-6.76	-0.31	4.53e-11	Colorectal cancer;
LUAD	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg00745463	chr17:30367425	LRRC37B	0.68	8.15	0.37	4.23e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.95e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22857025	chr5:266934	NA	-0.98	-13.86	-0.56	2.77e-36	Breast cancer;
LUAD	cis	rs13064411	0.696	rs9836396	chr3:113184282	T/C	cg10517650	chr3:113235015	CCDC52	-0.51	-8.97	-0.4	9.88e-18	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs12464483	0.556	rs2609934	chr2:30895979	G/A	cg12454169	chr2:30669597	LCLAT1	0.58	7.84	0.36	3.8e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.83	0.32	2.88e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg16479474	chr6:28041457	NA	0.41	6.98	0.32	1.16e-11	Parkinson's disease;
LUAD	cis	rs2286503	0.839	rs2270107	chr7:22862183	G/A	cg06496272	chr7:22895283	SNORD93	-0.41	-7.27	-0.33	1.74e-12	Fibrinogen;
LUAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.63	-0.46	1.47e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg18477163	chr1:228402036	OBSCN	-0.35	-7.03	-0.32	8.53e-12	Diastolic blood pressure;
LUAD	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg02428538	chr16:24856791	SLC5A11	-0.56	-7.82	-0.36	4.37e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg18129748	chr3:49941408	MST1R	-0.4	-6.64	-0.31	9.51e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs12474201	0.928	rs12998762	chr2:46938393	A/C	cg09399716	chr2:46890238	NA	-0.36	-6.62	-0.31	1.09e-10	Height;
LUAD	trans	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg14791747	chr16:20752902	THUMPD1	0.51	7.6	0.35	1.98e-13	Pancreatic cancer;
LUAD	trans	rs7395662	0.890	rs11039806	chr11:48547716	T/A	cg15704280	chr7:45808275	SEPT13	-0.41	-6.37	-0.3	4.81e-10	HDL cholesterol;
LUAD	cis	rs7107174	1.000	rs10899483	chr11:78061057	G/C	cg19901956	chr11:77921274	USP35	-0.51	-7.02	-0.32	9.04e-12	Testicular germ cell tumor;
LUAD	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg20203395	chr5:56204925	C5orf35	-0.83	-12.03	-0.5	6.92e-29	Initial pursuit acceleration;
LUAD	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24531977	chr5:56204891	C5orf35	-0.97	-14.57	-0.58	2.85e-39	Initial pursuit acceleration;
LUAD	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg19678392	chr7:94953810	PON1	-0.6	-7.94	-0.36	1.81e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2233152	0.519	rs10423139	chr19:41320459	C/G	cg21869046	chr19:41225005	ITPKC	0.35	6.51	0.3	2.19e-10	Kawasaki disease;
LUAD	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg08859206	chr1:53392774	SCP2	-0.75	-14.53	-0.58	4.16e-39	Monocyte count;
LUAD	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg26516362	chr5:178986906	RUFY1	0.57	8.73	0.39	6.17e-17	Lung cancer;
LUAD	cis	rs1784581	0.674	rs1789989	chr6:162408138	C/T	cg17173639	chr6:162384350	PARK2	0.45	8.18	0.37	3.46e-15	Itch intensity from mosquito bite;
LUAD	cis	rs9372498	0.536	rs62422236	chr6:118972633	G/T	cg07617317	chr6:118971624	C6orf204	0.53	7.62	0.35	1.7e-13	Diastolic blood pressure;
LUAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg04025307	chr7:1156635	C7orf50	0.61	6.84	0.32	2.78e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg02880119	chr16:3481970	NA	0.54	8.05	0.36	8.29e-15	Body mass index (adult);
LUAD	cis	rs73198271	0.751	rs617813	chr8:8635888	A/G	cg01851573	chr8:8652454	MFHAS1	0.4	7.24	0.33	2.12e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg07507251	chr3:52567010	NT5DC2	-0.37	-7.26	-0.33	1.82e-12	Bipolar disorder;
LUAD	cis	rs9768139	0.683	rs7779781	chr7:158115071	T/C	cg24154853	chr7:158122151	PTPRN2	0.57	11.26	0.48	6.52e-26	Calcium levels;
LUAD	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg17063962	chr7:91808500	NA	0.7	12.6	0.52	3.84e-31	Breast cancer;
LUAD	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg11098525	chr4:1320231	MAEA	-0.39	-6.48	-0.3	2.6200000000000003e-10	Obesity-related traits;
LUAD	cis	rs500891	0.525	rs1145898	chr6:84039566	T/C	cg08257003	chr6:84140564	ME1	0.33	6.4	0.3	4.18e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs12200782	1.000	rs6456741	chr6:26617058	C/T	cg11502198	chr6:26597334	ABT1	-0.79	-6.82	-0.31	3.11e-11	Small cell lung carcinoma;
LUAD	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg06671706	chr8:8559999	CLDN23	0.66	11.39	0.48	2.2e-26	Obesity-related traits;
LUAD	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg01884057	chr2:25150051	NA	0.35	7.45	0.34	5.23e-13	Body mass index;
LUAD	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	7.41	0.34	7.1e-13	Menopause (age at onset);
LUAD	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.28	-0.33	1.62e-12	Total body bone mineral density;
LUAD	cis	rs9372498	0.505	rs62422247	chr6:118987559	G/T	cg07617317	chr6:118971624	C6orf204	0.56	8.4	0.38	6.94e-16	Diastolic blood pressure;
LUAD	cis	rs9462027	0.628	rs6899938	chr6:34749113	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.91	-0.4	1.57e-17	Systemic lupus erythematosus;
LUAD	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg06484146	chr7:12443880	VWDE	-0.58	-7.33	-0.34	1.17e-12	Coronary artery disease;
LUAD	cis	rs68170813	0.559	rs12537733	chr7:106965447	A/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.63	-0.46	1.46e-23	Coronary artery disease;
LUAD	cis	rs1595825	0.891	rs16825786	chr2:198794681	G/T	cg11031976	chr2:198649780	BOLL	-0.47	-7.03	-0.32	8.13e-12	Ulcerative colitis;
LUAD	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg00933542	chr6:150070202	PCMT1	0.45	9.52	0.42	1.34e-19	Lung cancer;
LUAD	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg10978503	chr1:24200527	CNR2	-0.43	-7.96	-0.36	1.58e-14	Immature fraction of reticulocytes;
LUAD	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.5	-0.3	2.29e-10	Coronary artery disease;
LUAD	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg22508957	chr16:3507546	NAT15	0.83	8.69	0.39	7.97e-17	Tuberculosis;
LUAD	trans	rs68151129	0.613	rs9524449	chr13:94994934	T/C	cg10907866	chr3:42190778	TRAK1	0.54	6.35	0.3	5.49e-10	Lower facial height;
LUAD	cis	rs56161922	0.908	rs78159416	chr1:207820375	C/A	cg11752769	chr1:207818423	CR1L	-0.65	-6.84	-0.32	2.76e-11	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs16910800	1.000	rs2449439	chr11:23200798	C/T	cg20040320	chr11:23191996	NA	0.46	6.99	0.32	1.11e-11	Cancer;
LUAD	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg03732007	chr1:2071316	PRKCZ	-0.36	-7.25	-0.33	1.98e-12	Height;
LUAD	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg06627628	chr2:24431161	ITSN2	0.42	7.07	0.33	6.34e-12	Asthma;
LUAD	trans	rs2262909	0.962	rs1526884	chr19:22303651	A/G	cg17074339	chr11:11642133	GALNTL4	0.46	7.4	0.34	7.2e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg15448220	chr1:150897856	SETDB1	0.47	8.09	0.37	6.35e-15	Tonsillectomy;
LUAD	cis	rs2425143	0.818	rs11167280	chr20:34560526	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-6.76	-0.31	4.54e-11	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.8	0.35	4.77e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg03733263	chr8:22462867	KIAA1967	0.61	10.17	0.44	7.11e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs3007168	0.557	rs12586836	chr14:51735194	C/T	cg23942311	chr14:51606299	NA	0.49	6.63	0.31	1.03e-10	Cancer;
LUAD	cis	rs6495122	0.594	rs11072507	chr15:75054866	G/C	cg14664628	chr15:75095509	CSK	-0.5	-8.26	-0.37	1.85e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg04842962	chr6:43655489	MRPS18A	1.05	26.45	0.79	1.09e-91	IgG glycosylation;
LUAD	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg18512352	chr11:47633146	NA	-0.42	-7.31	-0.33	1.36e-12	Subjective well-being;
LUAD	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2131877	0.956	rs12639008	chr3:194871007	C/G	cg19760965	chr3:194868843	C3orf21	0.39	6.56	0.3	1.56e-10	Non-small cell lung cancer;
LUAD	cis	rs10465746	0.967	rs11576870	chr1:84333301	G/A	cg10977910	chr1:84465055	TTLL7	0.5	8.19	0.37	3.05e-15	Obesity-related traits;
LUAD	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-10.47	-0.45	5.55e-23	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	7.47	0.34	4.64e-13	Renal cell carcinoma;
LUAD	cis	rs17213078	0.602	rs4851113	chr2:106747009	G/C	cg16099169	chr2:106886729	NA	0.38	6.44	0.3	3.21e-10	Facial morphology (factor 23);
LUAD	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg23649088	chr2:200775458	C2orf69	0.59	8.57	0.38	1.91e-16	Schizophrenia;
LUAD	cis	rs4006360	0.551	rs11868548	chr17:39237132	C/G	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.37	0.38	8.48e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg03959625	chr15:84868606	LOC388152	0.42	6.74	0.31	5.29e-11	Schizophrenia;
LUAD	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg22508957	chr16:3507546	NAT15	-0.45	-7.41	-0.34	6.75e-13	Body mass index (adult);
LUAD	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg23954153	chr1:44402353	ARTN	-0.33	-6.4	-0.3	4.11e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg18335740	chr13:41363409	SLC25A15	0.72	13.88	0.56	2.22e-36	Lewy body disease;
LUAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg21724239	chr8:58056113	NA	0.58	8.17	0.37	3.51e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4006360	0.511	rs7503699	chr17:39258027	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.39	8.61	0.39	1.41e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs4664304	0.708	rs7564243	chr2:160726868	G/A	cg23995753	chr2:160760732	LY75	-0.41	-6.88	-0.32	2.2e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg06784218	chr1:46089804	CCDC17	0.55	11.84	0.5	4.01e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg12140854	chr5:148520817	ABLIM3	-0.6	-9.97	-0.44	3.7e-21	Breast cancer;
LUAD	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.51	8.54	0.38	2.49e-16	Lymphocyte percentage of white cells;
LUAD	trans	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.87	-0.36	2.99e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg15467112	chr14:75489610	MLH3	-0.38	-7.02	-0.32	8.76e-12	Height;
LUAD	cis	rs9326248	0.559	rs4938334	chr11:116931042	G/C	cg20608306	chr11:116969690	SIK3	0.31	6.84	0.32	2.87e-11	Blood protein levels;
LUAD	cis	rs12997796	0.556	rs34933869	chr2:86922397	T/C	cg23743911	chr2:86949715	RMND5A	0.44	6.49	0.3	2.36e-10	Schizophrenia;
LUAD	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg16479474	chr6:28041457	NA	0.44	7.94	0.36	1.85e-14	Depression;
LUAD	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg17279839	chr7:150038598	RARRES2	0.44	7.63	0.35	1.62e-13	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs7395662	0.963	rs10769382	chr11:48590415	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.12e-12	HDL cholesterol;
LUAD	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg20503657	chr10:835505	NA	0.99	14.89	0.59	1.34e-40	Eosinophil percentage of granulocytes;
LUAD	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.36	0.34	9.98e-13	Tonsillectomy;
LUAD	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg17971929	chr21:40555470	PSMG1	0.56	8.96	0.4	1.02e-17	Cognitive function;
LUAD	trans	rs2262909	0.962	rs425781	chr19:22229306	A/G	cg17074339	chr11:11642133	GALNTL4	-0.46	-7.51	-0.34	3.63e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00166722	chr3:10149974	C3orf24	0.74	12.65	0.52	2.48e-31	Alzheimer's disease;
LUAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg14789911	chr21:47582049	C21orf56	-0.43	-7.87	-0.36	3.08e-14	Testicular germ cell tumor;
LUAD	cis	rs9393692	0.557	rs56763414	chr6:26286468	T/C	cg13736514	chr6:26305472	NA	-0.51	-7.91	-0.36	2.23e-14	Educational attainment;
LUAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg13560548	chr3:10150139	C3orf24	0.4	6.56	0.3	1.53e-10	Alzheimer's disease;
LUAD	trans	rs6678622	0.831	rs12401738	chr1:78446761	G/A	cg20826526	chr3:156266748	SSR3	-0.47	-7.03	-0.32	8.39e-12	Hip circumference;
LUAD	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg21963583	chr11:68658836	MRPL21	0.64	11.34	0.48	3.27e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs72928364	0.860	rs16843229	chr3:100802220	G/A	cg10123952	chr3:100791384	NA	0.57	6.84	0.32	2.86e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9447004	0.584	rs7747167	chr6:74430673	T/G	cg23004174	chr6:74404879	CD109	0.47	8.53	0.38	2.67e-16	Blood protein levels;Calcium levels;
LUAD	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	8.1	0.37	5.92e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg13918804	chr1:2043761	PRKCZ	0.4	6.74	0.31	5.15e-11	Height;
LUAD	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg18252515	chr7:66147081	NA	-0.62	-6.68	-0.31	7.75e-11	Diabetic kidney disease;
LUAD	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02475777	chr4:1388615	CRIPAK	0.69	10.01	0.44	2.56e-21	Longevity;
LUAD	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg11663144	chr21:46675770	NA	-0.61	-12.03	-0.5	7.13e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg03433033	chr1:76189801	ACADM	-0.46	-6.73	-0.31	5.61e-11	Daytime sleep phenotypes;
LUAD	cis	rs3784262	0.669	rs4646602	chr15:58294757	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.4	-7.87	-0.36	3.04e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18876405	chr7:65276391	NA	-0.56	-9.36	-0.41	4.88e-19	Aortic root size;
LUAD	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.41	0.49	1.77e-26	Hip circumference adjusted for BMI;
LUAD	cis	rs17155006	0.746	rs401066	chr7:107747937	G/A	cg05962710	chr7:107745446	LAMB4	-0.34	-7.31	-0.33	1.37e-12	Pneumococcal bacteremia;
LUAD	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	24.46	0.77	5.54e-83	Chronic sinus infection;
LUAD	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg09253696	chr17:73873529	TRIM47	-0.47	-7.76	-0.35	6.41e-14	Psoriasis;
LUAD	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.88	-0.36	2.74e-14	Reticulocyte count;
LUAD	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg06558623	chr16:89946397	TCF25	1.15	10.14	0.44	9.29e-22	Skin colour saturation;
LUAD	cis	rs68170813	0.559	rs114221457	chr7:107019913	C/G	cg23024343	chr7:107201750	COG5	0.51	7.17	0.33	3.48e-12	Coronary artery disease;
LUAD	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg10518543	chr12:38710700	ALG10B	-0.42	-6.83	-0.32	2.95e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg06092702	chr1:163392909	NA	-0.34	-7.43	-0.34	6e-13	Motion sickness;
LUAD	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg03477792	chr4:77819574	ANKRD56	0.48	7.29	0.33	1.53e-12	Emphysema distribution in smoking;
LUAD	trans	rs9929218	1.000	rs2113201	chr16:68815000	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.63	-0.55	2.64e-35	Colorectal cancer;
LUAD	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg11247378	chr22:39784982	NA	-0.66	-10.45	-0.45	6.59e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg15133208	chr4:90757351	SNCA	-0.47	-7.08	-0.33	6e-12	Neuroticism;
LUAD	trans	rs853679	0.607	rs66868086	chr6:27865902	A/T	cg01620082	chr3:125678407	NA	-1.1	-10.16	-0.44	7.59e-22	Depression;
LUAD	cis	rs2387326	0.717	rs12252256	chr10:129944616	C/T	cg16087940	chr10:129947807	NA	-0.63	-9.02	-0.4	6.75e-18	Select biomarker traits;
LUAD	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	trans	rs17685	0.849	rs3815455	chr7:75611756	C/T	cg19862616	chr7:65841803	NCRNA00174	0.82	14.78	0.58	3.84e-40	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg09222892	chr1:25734099	RHCE	-0.47	-8.71	-0.39	7.15e-17	Erythrocyte sedimentation rate;
LUAD	cis	rs7267979	0.740	rs2259961	chr20:25282626	T/G	cg08601574	chr20:25228251	PYGB	0.41	7.63	0.35	1.54e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs11671005	0.735	rs11881000	chr19:58932788	C/T	cg13877915	chr19:58951672	ZNF132	0.56	7.35	0.34	1.04e-12	Mean platelet volume;
LUAD	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.78	12.95	0.53	1.51e-32	Menarche (age at onset);
LUAD	cis	rs1595825	0.838	rs7603283	chr2:198517592	A/G	cg00982548	chr2:198649783	BOLL	-0.62	-8.82	-0.39	3.14e-17	Ulcerative colitis;
LUAD	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg21918786	chr6:109611834	NA	-0.58	-11.03	-0.47	4.88e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs8192282	0.739	rs10908846	chr1:154501364	C/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.42	-7.15	-0.33	3.86e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg11871910	chr12:69753446	YEATS4	0.71	12.02	0.5	7.72e-29	Blood protein levels;
LUAD	trans	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg08071915	chr8:12219732	FAM66A	-0.41	-6.77	-0.31	4.43e-11	Mood instability;
LUAD	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.48	-8.46	-0.38	4.4e-16	Alzheimer's disease (late onset);
LUAD	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg13385794	chr1:248469461	NA	0.26	6.79	0.31	3.92e-11	Common traits (Other);
LUAD	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg14092988	chr3:52407081	DNAH1	0.45	9.04	0.4	5.62e-18	Bipolar disorder;
LUAD	cis	rs6740322	0.895	rs6544643	chr2:43560072	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.76	-11.14	-0.48	1.9e-25	Coronary artery disease;
LUAD	cis	rs9900062	0.546	rs2676289	chr17:62705738	A/G	cg02097616	chr17:62675921	NA	-0.69	-11.84	-0.5	4.04e-28	QT interval;
LUAD	cis	rs6076065	0.723	rs2424537	chr20:23382026	T/C	cg11657817	chr20:23433608	CST11	0.46	8.7	0.39	7.26e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg21724239	chr8:58056113	NA	0.8	9.72	0.43	2.8e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs1232027	0.666	rs1650700	chr5:79944432	G/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-7.99	-0.36	1.31e-14	Huntington's disease progression;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12560154	chr19:11925149	ZNF440	-0.45	-6.82	-0.31	3.11e-11	Height;
LUAD	cis	rs1476679	0.962	rs34995835	chr7:99990364	T/G	cg22906224	chr7:99728672	NA	-0.44	-6.96	-0.32	1.29e-11	Alzheimer's disease (late onset);
LUAD	cis	rs17067123	0.614	rs11727059	chr4:180065225	G/A	cg26610307	chr4:180072759	NA	-0.52	-6.75	-0.31	4.86e-11	Response to hepatitis C treatment;
LUAD	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg18944383	chr4:111397179	ENPEP	0.38	7.71	0.35	8.85e-14	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18548362	chr4:1857197	LETM1	-0.58	-7.08	-0.33	6.2e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs41311933	0.803	rs62578417	chr9:123727440	A/T	cg13567360	chr9:123745713	C5	-0.82	-7.15	-0.33	3.91e-12	Coronary artery disease;
LUAD	cis	rs1965732	0.563	rs13409104	chr2:3718692	C/T	cg00999904	chr2:3704751	ALLC	-0.38	-7.42	-0.34	6.41e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08048268	chr3:133502702	NA	-0.55	-10.78	-0.46	4.36e-24	Iron status biomarkers;
LUAD	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	7.48	0.34	4.2e-13	Schizophrenia;
LUAD	cis	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg07460842	chr6:66804631	NA	-0.98	-14.69	-0.58	8.84e-40	Exhaled nitric oxide output;
LUAD	cis	rs9837602	1.000	rs7616988	chr3:99701134	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.49	7.68	0.35	1.08e-13	Breast cancer;
LUAD	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.49	0.3	2.36e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.06	24.31	0.76	2.55e-82	Chronic sinus infection;
LUAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg06784218	chr1:46089804	CCDC17	0.6	13.34	0.54	4.09e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg08859206	chr1:53392774	SCP2	-0.65	-11.77	-0.5	7.1e-28	Monocyte count;
LUAD	cis	rs4691139	0.903	rs13127378	chr4:165918637	G/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.46	-8.83	-0.39	2.71e-17	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.9	0.36	2.43e-14	Breast cancer;
LUAD	cis	rs2840044	1.000	rs11653310	chr17:33893378	C/G	cg05299278	chr17:33885742	SLFN14	0.43	8.67	0.39	9.67e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18099408	chr3:52552593	STAB1	-0.4	-7.44	-0.34	5.71e-13	Bipolar disorder;
LUAD	cis	rs9486719	1.000	rs2263192	chr6:96873037	C/G	cg06623918	chr6:96969491	KIAA0776	0.72	9.99	0.44	2.95e-21	Migraine;Coronary artery disease;
LUAD	cis	rs1595825	0.891	rs78835808	chr2:198669110	G/A	cg10547527	chr2:198650123	BOLL	-0.53	-7.05	-0.32	7.15e-12	Ulcerative colitis;
LUAD	cis	rs921968	0.528	rs35695178	chr2:219589164	C/T	cg02176678	chr2:219576539	TTLL4	-0.59	-12.08	-0.51	4.68e-29	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg18944383	chr4:111397179	ENPEP	0.41	7.73	0.35	7.81e-14	Coronary artery disease;
LUAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg21724239	chr8:58056113	NA	0.67	8.55	0.38	2.33e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg02733842	chr7:1102375	C7orf50	-0.47	-7.97	-0.36	1.52e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.87	0.36	2.95e-14	Depression;
LUAD	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg06713675	chr4:122721982	EXOSC9	-0.86	-18.31	-0.67	1.36e-55	Type 2 diabetes;
LUAD	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.44	-0.49	1.38e-26	Primary sclerosing cholangitis;
LUAD	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06022373	chr22:39101656	GTPBP1	0.47	7.38	0.34	8.23e-13	Menopause (age at onset);
LUAD	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg21475434	chr5:93447410	FAM172A	-0.49	-6.51	-0.3	2.08e-10	Diabetic retinopathy;
LUAD	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg21153622	chr11:89784906	NA	-0.32	-6.35	-0.3	5.51e-10	Coronary artery disease;
LUAD	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg05665937	chr4:1216051	CTBP1	0.42	7.01	0.32	9.29e-12	Obesity-related traits;
LUAD	cis	rs829883	0.872	rs1641641	chr12:98896018	A/C	cg25150519	chr12:98850993	NA	0.67	11.08	0.47	3.26e-25	Colorectal adenoma (advanced);
LUAD	trans	rs9951602	0.512	rs8089108	chr18:76651361	C/T	cg02800362	chr5:177631904	HNRNPAB	0.92	14.03	0.56	5.64e-37	Obesity-related traits;
LUAD	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg16486109	chr11:613632	IRF7	0.49	7.3	0.33	1.4e-12	Systemic lupus erythematosus;
LUAD	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.78	0.39	4.07e-17	Menopause (age at onset);
LUAD	trans	rs1493916	0.777	rs1941685	chr18:31304318	G/T	cg15819921	chr19:927150	ARID3A	-0.42	-6.86	-0.32	2.4e-11	Life satisfaction;
LUAD	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg14092988	chr3:52407081	DNAH1	-0.41	-8.3	-0.37	1.38e-15	Bipolar disorder;
LUAD	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14829155	chr15:31115871	NA	-0.79	-13.45	-0.55	1.38e-34	Huntington's disease progression;
LUAD	trans	rs9467711	0.651	rs34197618	chr6:26083519	T/C	cg06606381	chr12:133084897	FBRSL1	-1.16	-8.64	-0.39	1.13e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg00784671	chr22:46762841	CELSR1	-0.63	-7.67	-0.35	1.22e-13	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03223185	chr6:15246159	JARID2	-0.45	-6.95	-0.32	1.37e-11	Height;
LUAD	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg25358565	chr5:93447407	FAM172A	0.62	7.6	0.35	1.88e-13	Diabetic retinopathy;
LUAD	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22857025	chr5:266934	NA	-0.97	-14.64	-0.58	1.49e-39	Breast cancer;
LUAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.53	0.52	7.54e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-9.01	-0.4	7.25e-18	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg04944784	chr2:26401820	FAM59B	-0.76	-10.52	-0.46	3.75e-23	Gut microbiome composition (summer);
LUAD	cis	rs752010	0.902	rs28635337	chr1:42101391	G/A	cg06885757	chr1:42089581	HIVEP3	0.43	9.07	0.4	4.42e-18	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs3087591	0.960	rs4559963	chr17:29438558	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	6.75	0.31	4.78e-11	Hip circumference;
LUAD	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.46	7.29	0.33	1.49e-12	Alzheimer's disease (late onset);
LUAD	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg14541582	chr5:601475	NA	-0.36	-7.58	-0.35	2.19e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg09455208	chr3:40491958	NA	0.57	12.68	0.52	1.8e-31	Renal cell carcinoma;
LUAD	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg24733560	chr20:60626293	TAF4	0.46	8.17	0.37	3.72e-15	Body mass index;
LUAD	cis	rs11597390	0.777	rs7900372	chr10:101840052	T/C	cg19754520	chr10:101825118	CPN1	-0.35	-7.46	-0.34	5.04e-13	Liver enzyme levels;
LUAD	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.53	-8.95	-0.4	1.12e-17	Tonsillectomy;
LUAD	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.57	-8.95	-0.4	1.12e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15664640	chr17:80829946	TBCD	0.79	15.77	0.61	2.18e-44	Breast cancer;
LUAD	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg01200585	chr1:228362443	C1orf69	-0.38	-7.08	-0.33	6.11e-12	Diastolic blood pressure;
LUAD	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg21775007	chr8:11205619	TDH	-0.5	-9.08	-0.4	4.26e-18	Retinal vascular caliber;
LUAD	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg05313129	chr8:58192883	C8orf71	-0.5	-7.83	-0.36	3.89e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg15448220	chr1:150897856	SETDB1	0.41	6.79	0.31	3.86e-11	Tonsillectomy;
LUAD	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg20673091	chr1:2541236	MMEL1	0.38	8.05	0.36	8.41e-15	Ulcerative colitis;
LUAD	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.15	0.37	4.06e-15	Menopause (age at onset);
LUAD	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg11584989	chr19:19387371	SF4	-0.35	-6.42	-0.3	3.6e-10	Tonsillectomy;
LUAD	cis	rs62238980	0.521	rs78578916	chr22:32456881	G/A	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	7.19	0.33	3.03e-12	Hypertriglyceridemia;
LUAD	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg27129171	chr3:47204927	SETD2	0.42	6.9	0.32	1.97e-11	Colorectal cancer;
LUAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-10.39	-0.45	1.09e-22	Longevity;Endometriosis;
LUAD	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg11494091	chr17:61959527	GH2	0.43	8.09	0.37	6.17e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs3806843	0.576	rs251370	chr5:140246287	C/T	cg09052108	chr5:140557253	PCDHB8	0.36	6.48	0.3	2.54e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.76	-0.31	4.59e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg08382946	chr5:1082689	SLC12A7	0.39	6.37	0.3	4.9e-10	QT interval;
LUAD	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg26384229	chr12:38710491	ALG10B	0.49	8.0	0.36	1.24e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg13010199	chr12:38710504	ALG10B	0.38	6.35	0.3	5.5e-10	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.68	-0.31	7.32e-11	Neuroticism;
LUAD	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg16797656	chr11:68205561	LRP5	-0.46	-8.73	-0.39	5.93e-17	Total body bone mineral density;
LUAD	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg07061783	chr6:25882402	NA	0.53	8.4	0.38	6.94e-16	Blood metabolite levels;
LUAD	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.8	-0.5	5.61e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg01689657	chr7:91764605	CYP51A1	0.36	8.67	0.39	9.56e-17	Breast cancer;
LUAD	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg00021532	chr16:4324280	TFAP4	0.75	15.78	0.61	1.93e-44	Prostate-specific antigen levels;
LUAD	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg19678392	chr7:94953810	PON1	-0.57	-7.73	-0.35	7.93e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg11915388	chr22:42470451	FAM109B	0.39	6.92	0.32	1.63e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1003719	0.715	rs2835639	chr21:38537016	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.42	-0.38	5.97e-16	Eye color traits;
LUAD	cis	rs12464483	0.524	rs4952173	chr2:30888346	G/T	cg17749961	chr2:30669863	LCLAT1	0.47	6.36	0.3	5.2e-10	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs6714710	0.603	rs17489984	chr2:98421364	A/G	cg26665480	chr2:98280029	ACTR1B	0.5	8.15	0.37	4.23e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24308560	chr3:49941425	MST1R	-0.59	-9.99	-0.44	3.07e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs34734847	0.898	rs696339	chr12:121169436	A/T	cg27246729	chr12:121163418	ACADS	0.37	6.93	0.32	1.57e-11	Mean corpuscular volume;
LUAD	cis	rs2455826	0.521	rs2455845	chr3:15768293	T/C	cg16303742	chr3:15540471	COLQ	-0.38	-6.39	-0.3	4.43e-10	Inflammatory skin disease;
LUAD	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21582582	chr3:182698605	DCUN1D1	0.69	12.99	0.53	1.02e-32	Intelligence (multi-trait analysis);
LUAD	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg18854424	chr1:2615690	NA	0.33	7.76	0.35	6.23e-14	Ulcerative colitis;
LUAD	cis	rs9948	0.786	rs56797569	chr2:97413555	G/T	cg20312557	chr2:97357134	FER1L5	-0.62	-7.3	-0.33	1.44e-12	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg04398451	chr17:18023971	MYO15A	0.69	12.33	0.51	4.8e-30	Total body bone mineral density;
LUAD	trans	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg18335740	chr13:41363409	SLC25A15	0.51	8.99	0.4	8.49e-18	Lewy body disease;
LUAD	trans	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.39	-0.3	4.45e-10	Aortic root size;
LUAD	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg04369109	chr6:150039330	LATS1	-0.44	-7.44	-0.34	5.8e-13	Lung cancer;
LUAD	cis	rs4774899	0.966	rs12914418	chr15:57506355	C/G	cg14026238	chr15:57616123	NA	0.36	6.76	0.31	4.72e-11	Urinary tract infection frequency;
LUAD	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg04000281	chr11:63949212	NA	-0.29	-6.62	-0.31	1.07e-10	Platelet count;
LUAD	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg11887960	chr12:57824829	NA	0.59	7.34	0.34	1.1e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg02733842	chr7:1102375	C7orf50	-0.41	-6.7	-0.31	6.72e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06112835	chr11:68658793	MRPL21	0.53	9.49	0.42	1.72e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.61	-7.24	-0.33	2.1e-12	Body mass index;
LUAD	cis	rs7593730	0.636	rs7583157	chr2:161114552	A/G	cg22609984	chr2:161126801	NA	0.57	10.43	0.45	8.36e-23	Type 2 diabetes;
LUAD	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg03037974	chr15:76606532	NA	0.33	6.82	0.31	3.17e-11	Blood metabolite levels;
LUAD	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg07810366	chr2:100720526	AFF3	0.37	7.83	0.36	4.03e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs78487399	0.808	rs17030925	chr2:43713808	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-6.71	-0.31	6.27e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12379764	chr21:47803548	PCNT	-0.56	-8.43	-0.38	5.64e-16	Testicular germ cell tumor;
LUAD	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg15017067	chr4:17643749	FAM184B	0.34	6.63	0.31	1.03e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1595825	0.891	rs78835808	chr2:198669110	G/A	cg11031976	chr2:198649780	BOLL	-0.49	-6.89	-0.32	2.05e-11	Ulcerative colitis;
LUAD	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg00898013	chr13:113819073	PROZ	0.74	13.33	0.54	4.52e-34	Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.19	0.41	1.83e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12142240	0.959	rs12137934	chr1:46728913	A/G	cg00530320	chr1:46809349	NSUN4	0.44	6.83	0.32	2.95e-11	Menopause (age at onset);
LUAD	cis	rs9902453	0.845	rs3115099	chr17:28019293	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.25	0.41	1.14e-18	Coffee consumption (cups per day);
LUAD	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg25985355	chr7:65971099	NA	-0.56	-6.85	-0.32	2.56e-11	Diabetic kidney disease;
LUAD	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.36	-6.69	-0.31	7.31e-11	Caffeine consumption;
LUAD	cis	rs11811982	0.793	rs116805426	chr1:227394024	T/C	cg24860534	chr1:227506868	CDC42BPA	0.6	6.96	0.32	1.34e-11	Optic disc area;
LUAD	cis	rs2302190	0.769	rs6503864	chr17:56549671	C/A	cg25885038	chr17:56607967	SEPT4	-0.54	-7.92	-0.36	2.15e-14	Vitamin D levels;
LUAD	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.48	7.11	0.33	4.87e-12	Gut microbiome composition (summer);
LUAD	cis	rs2835872	0.733	rs1709822	chr21:39035485	A/G	cg06728970	chr21:39037746	KCNJ6	0.4	7.7	0.35	9.57e-14	Electroencephalographic traits in alcoholism;
LUAD	cis	rs921968	0.565	rs35594672	chr2:219589280	T/A	cg02176678	chr2:219576539	TTLL4	-0.59	-11.99	-0.5	1.06e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg02569458	chr12:86230093	RASSF9	0.42	7.88	0.36	2.87e-14	Major depressive disorder;
LUAD	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg17366294	chr4:99064904	C4orf37	0.51	9.16	0.41	2.2e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs1493916	0.967	rs9953765	chr18:31399464	A/G	cg13755796	chr4:20253514	NA	-0.41	-6.85	-0.32	2.7e-11	Life satisfaction;
LUAD	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg23985595	chr17:80112537	CCDC57	-0.53	-9.66	-0.43	4.38e-20	Life satisfaction;
LUAD	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg18867708	chr6:26865862	GUSBL1	-0.42	-6.68	-0.31	7.72e-11	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23647530	chr1:155036154	EFNA4	-0.38	-6.38	-0.3	4.71e-10	Cancer;
LUAD	cis	rs870825	0.616	rs745656	chr4:185637523	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	14.04	0.56	4.87e-37	Blood protein levels;
LUAD	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg06636551	chr8:101224915	SPAG1	-0.36	-6.56	-0.3	1.54e-10	Atrioventricular conduction;
LUAD	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg13319975	chr6:146136371	FBXO30	-0.64	-10.92	-0.47	1.23e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg21171335	chr12:122356390	WDR66	0.77	14.32	0.57	3.44e-38	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg05340658	chr4:99064831	C4orf37	0.54	9.18	0.41	1.91e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.47	6.89	0.32	1.98e-11	Schizophrenia;
LUAD	cis	rs806215	0.950	rs3735644	chr7:127222157	G/A	cg25922125	chr7:127225783	GCC1	-0.49	-6.71	-0.31	6.23e-11	Type 2 diabetes;
LUAD	cis	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg19875535	chr5:140030758	IK	-0.4	-6.65	-0.31	8.89e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg00814883	chr7:100076585	TSC22D4	-0.48	-6.35	-0.3	5.4e-10	Lung function (FEV1/FVC);
LUAD	cis	rs12618769	0.543	rs72819980	chr2:99040522	A/G	cg10123293	chr2:99228465	UNC50	0.46	8.28	0.37	1.63e-15	Bipolar disorder;
LUAD	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.65e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs354225	0.546	rs10170646	chr2:54799606	T/C	cg26097391	chr2:54893211	SPTBN1	0.47	8.17	0.37	3.51e-15	Schizophrenia;
LUAD	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.63	0.39	1.29e-16	Menarche (age at onset);
LUAD	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg00431813	chr7:1051703	C7orf50	-0.53	-10.47	-0.45	5.88e-23	Longevity;Endometriosis;
LUAD	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg22105103	chr4:187893119	NA	0.52	11.22	0.48	9.04e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9462027	0.628	rs2764206	chr6:34712900	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.12	-0.41	3.03e-18	Systemic lupus erythematosus;
LUAD	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg04756594	chr16:24857601	SLC5A11	0.54	10.3	0.45	2.45e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.46	-0.34	4.98e-13	Breast cancer;
LUAD	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.69	-0.35	1.05e-13	Bipolar disorder;
LUAD	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg24733560	chr20:60626293	TAF4	0.47	9.41	0.42	3.22e-19	Body mass index;
LUAD	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg05368731	chr17:41323189	NBR1	0.97	20.31	0.7	1.74e-64	Menopause (age at onset);
LUAD	cis	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg05084668	chr3:125655381	ALG1L	0.75	9.82	0.43	1.21e-20	Blood pressure (smoking interaction);
LUAD	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg08085267	chr17:45401833	C17orf57	0.65	11.9	0.5	2.27e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07266350	chr3:49460521	AMT;NICN1	-0.36	-6.48	-0.3	2.59e-10	Menarche (age at onset);
LUAD	cis	rs929596	0.674	rs2602374	chr2:234568964	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-7.06	-0.32	6.69e-12	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.55	-9.33	-0.41	6.17e-19	Glomerular filtration rate;
LUAD	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35740288	0.731	rs12913556	chr15:86102196	C/T	cg13263323	chr15:86062960	AKAP13	-0.44	-7.04	-0.32	8.05e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg16797656	chr11:68205561	LRP5	0.45	8.47	0.38	4.1e-16	Total body bone mineral density;
LUAD	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg23625390	chr15:77176239	SCAPER	0.37	6.43	0.3	3.37e-10	Blood metabolite levels;
LUAD	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg12756686	chr19:29218302	NA	0.68	8.75	0.39	5.27e-17	Methadone dose in opioid dependence;
LUAD	cis	rs2012796	0.785	rs61986597	chr14:81853107	T/C	cg02996355	chr14:81879375	NA	0.54	8.26	0.37	1.85e-15	Night sleep phenotypes;
LUAD	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg22823121	chr1:150693482	HORMAD1	0.44	8.91	0.4	1.55e-17	Tonsillectomy;
LUAD	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg05283184	chr6:79620031	NA	-0.61	-12.41	-0.52	2.26e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs208520	0.690	rs207096	chr6:66797287	T/C	cg07460842	chr6:66804631	NA	-1.09	-17.03	-0.64	6.56e-50	Exhaled nitric oxide output;
LUAD	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg05564831	chr3:52568323	NT5DC2	-0.36	-6.59	-0.31	1.3e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs59698941	0.943	rs66500331	chr5:132261693	G/A	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg23602478	chr1:26503979	CNKSR1	0.27	6.43	0.3	3.44e-10	Height;
LUAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.78	-9.44	-0.42	2.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg20135002	chr11:47629003	NA	-0.41	-7.16	-0.33	3.54e-12	Subjective well-being;
LUAD	cis	rs7731657	0.537	rs4706002	chr5:130373830	C/T	cg08523029	chr5:130500466	HINT1	-0.59	-7.61	-0.35	1.77e-13	Fasting plasma glucose;
LUAD	cis	rs2046867	0.818	rs6786469	chr3:72873809	A/G	cg25664220	chr3:72788482	NA	-0.66	-11.58	-0.49	3.89e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11644478	chr21:40555479	PSMG1	0.69	11.45	0.49	1.23e-26	Cognitive function;
LUAD	cis	rs11229555	0.645	rs11229462	chr11:58209931	A/T	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7465272	1.000	rs13258638	chr8:143683582	C/T	cg10104451	chr8:143696006	ARC	-0.58	-7.91	-0.36	2.3e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08677398	chr8:58056175	NA	0.52	6.78	0.31	3.94e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7737355	0.812	rs6881486	chr5:130793836	C/T	cg25547332	chr5:131281432	NA	-0.43	-7.0	-0.32	9.85e-12	Life satisfaction;
LUAD	cis	rs10504073	0.647	rs1511359	chr8:50006448	T/A	cg00325661	chr8:49890786	NA	0.46	10.3	0.45	2.41e-22	Blood metabolite ratios;
LUAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg22907277	chr7:1156413	C7orf50	0.57	9.38	0.41	4.05e-19	Longevity;Endometriosis;
LUAD	cis	rs870825	0.616	rs28636679	chr4:185627481	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.99	0.56	8.3e-37	Blood protein levels;
LUAD	cis	rs17739794	0.517	rs6982473	chr8:773986	G/T	cg01971667	chr8:817044	NA	-0.33	-6.67	-0.31	8.09e-11	Clozapine-induced cytotoxicity;
LUAD	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.51e-15	Bipolar disorder;
LUAD	cis	rs4950928	0.823	rs10920579	chr1:203158972	A/G	cg17014757	chr1:203156097	CHI3L1	-0.62	-8.87	-0.4	2.14e-17	YKL-40 levels;
LUAD	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg11057378	chr10:81107060	PPIF	0.36	6.82	0.31	3.21e-11	Height;
LUAD	cis	rs1444418	1.000	rs7090365	chr10:64564428	A/C	cg14943953	chr10:64564468	ADO	-0.55	-6.8	-0.31	3.61e-11	Atopic dermatitis;
LUAD	cis	rs11734570	0.581	rs55958238	chr4:38604331	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.45	6.38	0.3	4.75e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg03676636	chr4:99064102	C4orf37	0.32	8.34	0.38	1.06e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-8.35	-0.38	1e-15	Monocyte percentage of white cells;
LUAD	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg26727032	chr16:67993705	SLC12A4	-0.55	-7.4	-0.34	7.62e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs891088	0.622	rs11670932	chr19:7206790	A/G	cg09779027	chr19:7224513	INSR	-0.46	-6.88	-0.32	2.22e-11	Hip circumference adjusted for BMI;Height;
LUAD	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg15128208	chr22:42549153	NA	-0.4	-8.14	-0.37	4.48e-15	Cognitive function;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg25109026	chr1:33004971	ZBTB8A	-0.39	-6.79	-0.31	3.84e-11	Cancer;
LUAD	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23583168	chr7:148888333	NA	-0.9	-18.16	-0.66	6.95e-55	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg11062466	chr8:58055876	NA	0.64	8.38	0.38	7.84e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg12160578	chr15:63334699	TPM1	-0.36	-6.65	-0.31	9.04e-11	Platelet count;
LUAD	trans	rs587242	1.000	rs7543590	chr1:96892216	T/C	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs12532878	0.652	rs62482223	chr7:100198878	C/A	cg20848291	chr7:100343083	ZAN	-0.49	-7.24	-0.33	2.08e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg04545296	chr12:48745243	ZNF641	-0.42	-10.66	-0.46	1.19e-23	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs6494488	0.500	rs72744788	chr15:65095235	C/T	cg08069370	chr15:64387884	SNX1	-0.74	-6.64	-0.31	9.68e-11	Coronary artery disease;
LUAD	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg00504896	chr12:9437009	LOC642846	-0.48	-8.0	-0.36	1.21e-14	Breast size;
LUAD	trans	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg03886242	chr7:26192032	NFE2L3	-0.43	-7.45	-0.34	5.18e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg23172400	chr8:95962367	TP53INP1	-0.37	-8.69	-0.39	8.27e-17	Type 2 diabetes;
LUAD	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.47	7.13	0.33	4.47e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg05110241	chr16:68378359	PRMT7	-0.83	-9.03	-0.4	6.05e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg17063962	chr7:91808500	NA	0.73	13.24	0.54	9.97e-34	Breast cancer;
LUAD	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg21798802	chr22:38057573	PDXP	0.48	9.6	0.42	7.23e-20	Fat distribution (HIV);
LUAD	cis	rs908922	0.676	rs498184	chr1:152501423	G/C	cg21823605	chr1:152486609	CRCT1	0.29	6.66	0.31	8.54e-11	Hair morphology;
LUAD	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg22875332	chr1:76189707	ACADM	0.86	15.95	0.61	3.44e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg00530320	chr1:46809349	NSUN4	0.51	7.79	0.35	5.09e-14	Menopause (age at onset);
LUAD	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg21775007	chr8:11205619	TDH	0.48	8.59	0.39	1.73e-16	Retinal vascular caliber;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg08376864	chr3:192958726	MGC2889;HRASLS	-0.39	-6.7	-0.31	6.57e-11	Subcortical brain region volumes;
LUAD	cis	rs17095355	1.000	rs11194924	chr10:111695773	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.72	-9.68	-0.43	3.77e-20	Biliary atresia;
LUAD	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg00504896	chr12:9437009	LOC642846	-0.42	-6.62	-0.31	1.11e-10	Breast size;
LUAD	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	9.96	0.44	3.98e-21	Ileal carcinoids;
LUAD	cis	rs447921	0.813	rs4419085	chr17:74443683	C/T	cg17201438	chr17:74438067	UBE2O	-0.63	-8.55	-0.38	2.28e-16	Mitochondrial DNA levels;
LUAD	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg07917127	chr4:99064746	C4orf37	0.38	6.4	0.3	4.21e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg20701182	chr2:24300061	SF3B14	0.56	6.7	0.31	6.83e-11	Lymphocyte counts;
LUAD	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg11189052	chr15:85197271	WDR73	-0.62	-7.91	-0.36	2.3e-14	Schizophrenia;
LUAD	cis	rs68170813	0.559	rs17349904	chr7:106897237	A/C	cg23024343	chr7:107201750	COG5	0.46	6.56	0.3	1.61e-10	Coronary artery disease;
LUAD	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg00310523	chr12:86230176	RASSF9	0.46	9.25	0.41	1.1e-18	Major depressive disorder;
LUAD	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg23301539	chr8:142222248	SLC45A4	-0.47	-8.62	-0.39	1.34e-16	Immature fraction of reticulocytes;
LUAD	cis	rs2625529	0.701	rs62025574	chr15:72236075	C/T	cg16672083	chr15:72433130	SENP8	-0.76	-12.46	-0.52	1.44e-30	Red blood cell count;
LUAD	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.3	-6.44	-0.3	3.34e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg19761014	chr17:28927070	LRRC37B2	0.8	8.07	0.37	7.18e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg17644776	chr2:200775616	C2orf69	0.59	10.16	0.44	7.92e-22	Osteoporosis;
LUAD	cis	rs7107174	1.000	rs2450131	chr11:77944568	A/C	cg02023728	chr11:77925099	USP35	0.5	7.61	0.35	1.79e-13	Testicular germ cell tumor;
LUAD	cis	rs36051895	0.632	rs10815171	chr9:5172567	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-6.71	-0.31	6.15e-11	Pediatric autoimmune diseases;
LUAD	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg22676075	chr6:135203613	NA	0.37	6.88	0.32	2.16e-11	Red blood cell count;
LUAD	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-8.02	-0.36	1.06e-14	Monocyte percentage of white cells;
LUAD	cis	rs7116495	0.881	rs673478	chr11:71799104	G/A	cg07596299	chr11:71824057	C11orf51	-0.78	-6.78	-0.31	4.09e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.69	0.35	1.01e-13	Bladder cancer;
LUAD	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg20701182	chr2:24300061	SF3B14	0.63	7.16	0.33	3.64e-12	Lymphocyte counts;
LUAD	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg06740227	chr12:86229804	RASSF9	0.47	8.09	0.37	6.55e-15	Major depressive disorder;
LUAD	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg00717180	chr2:96193071	NA	-0.36	-6.51	-0.3	2.17e-10	Coronary artery disease;
LUAD	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg14583973	chr4:3374767	RGS12	0.3	7.64	0.35	1.45e-13	Serum sulfate level;
LUAD	cis	rs4700695	0.925	rs6878011	chr5:65392465	G/A	cg21114390	chr5:65439923	SFRS12	-0.57	-6.53	-0.3	1.84e-10	Facial morphology (factor 19);
LUAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08677398	chr8:58056175	NA	0.48	6.78	0.31	4.13e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15133313	chr6:53213956	ELOVL5	-0.54	-6.57	-0.3	1.51e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03352830	chr11:487213	PTDSS2	0.82	10.79	0.46	3.87e-24	Body mass index;
LUAD	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg04450456	chr4:17643702	FAM184B	0.4	7.94	0.36	1.83e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg22117172	chr7:91764530	CYP51A1	0.32	7.08	0.33	5.97e-12	Breast cancer;
LUAD	cis	rs6460942	0.555	rs7803268	chr7:12306793	G/A	cg06484146	chr7:12443880	VWDE	-0.54	-6.8	-0.31	3.5e-11	Coronary artery disease;
LUAD	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg03433033	chr1:76189801	ACADM	-0.86	-14.84	-0.59	2.1e-40	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg21214613	chr1:16344536	HSPB7	-0.41	-7.36	-0.34	9.36e-13	Systolic blood pressure;
LUAD	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18404041	chr3:52824283	ITIH1	-0.57	-11.87	-0.5	2.94e-28	Bipolar disorder;
LUAD	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg22618164	chr12:122356400	WDR66	0.64	11.46	0.49	1.11e-26	Mean corpuscular volume;
LUAD	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg00852783	chr1:26633632	UBXN11	0.44	7.68	0.35	1.13e-13	Obesity-related traits;
LUAD	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg08027265	chr7:2291960	NA	-0.47	-8.49	-0.38	3.59e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs2479724	0.846	rs2251084	chr6:41838119	T/C	cg17623882	chr6:41773611	USP49	-0.62	-11.57	-0.49	4.36e-27	Menarche (age at onset);
LUAD	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.29	0.54	6.06e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs7939886	0.920	rs77391761	chr11:55814896	G/C	cg15704280	chr7:45808275	SEPT13	0.67	6.54	0.3	1.83e-10	Myopia (pathological);
LUAD	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.03e-19	Life satisfaction;
LUAD	cis	rs16958440	0.867	rs77615793	chr18:44684464	C/G	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg01251360	chr16:68772225	CDH1	-0.3	-9.5	-0.42	1.55e-19	Colorectal cancer;
LUAD	cis	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg27411982	chr8:10470053	RP1L1	-0.39	-6.98	-0.32	1.13e-11	Systolic blood pressure;
LUAD	trans	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg13565492	chr6:43139072	SRF	-0.58	-6.57	-0.3	1.51e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg04282206	chr17:62833786	PLEKHM1P	-0.54	-8.23	-0.37	2.32e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg06606381	chr12:133084897	FBRSL1	-1.17	-10.03	-0.44	2.16e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs10100465	0.961	rs1508555	chr8:118638344	T/C	cg09430518	chr8:118662568	NA	-0.34	-6.79	-0.31	3.93e-11	Leprosy;
LUAD	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg05434287	chr7:2030229	MAD1L1	0.41	6.66	0.31	8.72e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs11098699	0.821	rs7665722	chr4:124201501	A/G	cg09941581	chr4:124220074	SPATA5	0.48	7.86	0.36	3.25e-14	Mosquito bite size;
LUAD	trans	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg14917512	chr19:3094685	GNA11	-0.58	-6.86	-0.32	2.47e-11	Diabetic kidney disease;
LUAD	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.21	-0.41	1.51e-18	Bipolar disorder;
LUAD	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg21220214	chr8:57350948	NA	-0.6	-8.69	-0.39	8.27e-17	Obesity-related traits;
LUAD	cis	rs2835872	0.759	rs2835898	chr21:39071781	T/C	cg06728970	chr21:39037746	KCNJ6	-0.39	-6.72	-0.31	5.97e-11	Electroencephalographic traits in alcoholism;
LUAD	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg18306943	chr3:40428807	ENTPD3	0.38	6.71	0.31	6.46e-11	Renal cell carcinoma;
LUAD	cis	rs7000551	0.715	rs2469745	chr8:22343464	C/T	cg12081754	chr8:22256438	SLC39A14	0.48	7.83	0.36	4e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9948	0.655	rs2314399	chr2:97442390	G/A	cg20312557	chr2:97357134	FER1L5	-0.74	-8.29	-0.37	1.53e-15	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg04756594	chr16:24857601	SLC5A11	0.53	10.22	0.45	4.52e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22857025	chr5:266934	NA	-0.97	-14.47	-0.58	7.55e-39	Breast cancer;
LUAD	cis	rs7215564	0.908	rs35884143	chr17:78656043	A/G	cg09596252	chr17:78655493	RPTOR	0.56	6.87	0.32	2.26e-11	Myopia (pathological);
LUAD	cis	rs16910800	0.953	rs7122949	chr11:23203530	C/T	cg20040320	chr11:23191996	NA	0.49	7.32	0.34	1.3e-12	Cancer;
LUAD	cis	rs561341	0.689	rs578635	chr17:30289897	A/C	cg00745463	chr17:30367425	LRRC37B	-0.53	-7.25	-0.33	2.03e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs3820068	0.580	rs12760698	chr1:16009814	G/A	cg16988262	chr1:15930761	NA	0.42	6.7	0.31	6.49e-11	Systolic blood pressure;
LUAD	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg09137382	chr11:130731461	NA	-0.39	-7.06	-0.32	7.09e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2554380	0.800	rs2562768	chr15:84382953	C/T	cg14598478	chr15:84363061	ADAMTSL3	0.46	7.23	0.33	2.25e-12	Height;
LUAD	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.03	0.36	9.9e-15	Rheumatoid arthritis;
LUAD	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.45	-0.42	2.38e-19	Life satisfaction;
LUAD	cis	rs4664304	0.629	rs56122507	chr2:160847353	T/C	cg23995753	chr2:160760732	LY75	-0.39	-6.66	-0.31	8.33e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg25985355	chr7:65971099	NA	-0.54	-6.73	-0.31	5.41e-11	Diabetic kidney disease;
LUAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06873352	chr17:61820015	STRADA	0.82	18.13	0.66	9.04e-55	Prudent dietary pattern;
LUAD	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12756686	chr19:29218302	NA	0.64	10.05	0.44	1.88e-21	Methadone dose in opioid dependence;
LUAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg12419862	chr22:24373484	LOC391322	-0.74	-13.15	-0.54	2.37e-33	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg02158880	chr13:53174818	NA	0.39	6.39	0.3	4.35e-10	Lewy body disease;
LUAD	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.27	0.33	1.77e-12	Breast cancer;
LUAD	cis	rs16958440	0.867	rs59217333	chr18:44694844	A/C	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs4072705	0.904	rs721863	chr9:127536267	A/T	cg13476313	chr9:127244764	NR5A1	0.31	7.37	0.34	8.75e-13	Menarche (age at onset);
LUAD	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg07080864	chr8:57359956	PENK	-0.37	-6.58	-0.3	1.43e-10	Obesity-related traits;
LUAD	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg03605463	chr16:89740564	NA	0.67	11.61	0.49	3.15e-27	Vitiligo;
LUAD	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.79	-0.35	5.16e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg25985355	chr7:65971099	NA	0.53	6.72	0.31	6e-11	Diabetic kidney disease;
LUAD	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg27490568	chr2:178487706	NA	0.38	6.42	0.3	3.59e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.94e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg04414720	chr1:150670196	GOLPH3L	-0.54	-9.13	-0.41	2.74e-18	Lymphocyte counts;
LUAD	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg06547715	chr2:218990976	CXCR2	0.44	10.63	0.46	1.46e-23	Ulcerative colitis;
LUAD	cis	rs897984	0.806	rs12924903	chr16:30928970	C/T	cg02466173	chr16:30829666	NA	-0.6	-10.73	-0.46	6.27e-24	Dementia with Lewy bodies;
LUAD	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.3	0.37	1.4e-15	Platelet count;
LUAD	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg05564831	chr3:52568323	NT5DC2	-0.37	-6.72	-0.31	5.86e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg04731861	chr2:219085781	ARPC2	0.27	8.41	0.38	6.33e-16	Colorectal cancer;
LUAD	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-38.42	-0.88	5.23e-140	Myeloid white cell count;
LUAD	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg25554036	chr4:6271136	WFS1	0.69	13.73	0.56	9.79e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg17105886	chr17:28927953	LRRC37B2	0.62	7.12	0.33	4.74e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg25894440	chr7:65020034	NA	0.68	7.32	0.34	1.3e-12	Diabetic kidney disease;
LUAD	trans	rs11165623	0.564	rs6593611	chr1:97001996	T/C	cg10631902	chr5:14652156	NA	-0.41	-7.38	-0.34	8.3e-13	Hip circumference;Waist circumference;
LUAD	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.9	-0.32	1.96e-11	Diabetic kidney disease;
LUAD	cis	rs4790333	0.539	rs67887169	chr17:2256828	G/A	cg27406664	chr17:2294951	MNT	0.4	8.04	0.36	9.32e-15	Proinsulin levels;
LUAD	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg03733263	chr8:22462867	KIAA1967	0.74	12.93	0.53	1.79e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg13047869	chr3:10149882	C3orf24	0.64	11.08	0.47	3.12e-25	Alzheimer's disease;
LUAD	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg06641503	chr3:48959341	ARIH2	-0.37	-7.24	-0.33	2.13e-12	Menarche (age at onset);
LUAD	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-7.47	-0.34	4.69e-13	Major depressive disorder;
LUAD	trans	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg01620082	chr3:125678407	NA	-1.1	-10.56	-0.46	2.69e-23	Depression;
LUAD	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg09796270	chr17:17721594	SREBF1	-0.4	-8.06	-0.36	7.77e-15	Total body bone mineral density;
LUAD	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg15704280	chr7:45808275	SEPT13	-0.78	-12.25	-0.51	1e-29	Height;
LUAD	cis	rs7975161	1.000	rs4964728	chr12:104649733	G/A	cg25273343	chr12:104657179	TXNRD1	-0.65	-8.47	-0.38	4.22e-16	Toenail selenium levels;
LUAD	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg08645402	chr16:4508243	NA	0.57	9.94	0.44	4.76e-21	Schizophrenia;
LUAD	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	10.15	0.44	8.49e-22	Electrocardiographic conduction measures;
LUAD	trans	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.39	-6.45	-0.3	3.06e-10	Menarche (age at onset);
LUAD	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg24069376	chr3:38537580	EXOG	0.36	8.26	0.37	1.94e-15	Electrocardiographic conduction measures;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19622574	chr2:234160013	ATG16L1	-0.39	-6.46	-0.3	2.95e-10	Cancer;
LUAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08280861	chr8:58055591	NA	0.63	8.31	0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.31	7.01	0.32	9.47e-12	Parkinson's disease;
LUAD	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg09658497	chr7:2847517	GNA12	-0.51	-8.56	-0.38	2.13e-16	Height;
LUAD	cis	rs10916814	0.632	rs7524492	chr1:20902750	G/A	cg24502330	chr1:20914028	CDA	-0.36	-7.15	-0.33	3.88e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg21545522	chr1:205238299	TMCC2	0.38	6.94	0.32	1.51e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg11941060	chr3:133502564	NA	0.4	6.67	0.31	7.9e-11	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs231513	0.911	rs124720	chr17:41960141	A/G	cg26893861	chr17:41843967	DUSP3	-0.66	-7.49	-0.34	4.19e-13	Cognitive function;
LUAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg23131131	chr22:24373011	LOC391322	-0.53	-8.72	-0.39	6.46e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg14644787	chr7:87849494	SRI	-0.49	-6.84	-0.32	2.74e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg11247378	chr22:39784982	NA	-0.7	-12.33	-0.51	4.71e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs9364220	0.684	rs9355053	chr6:168493061	G/C	cg02770688	chr6:168491649	NA	-0.35	-6.81	-0.31	3.34e-11	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
LUAD	trans	rs9467711	0.591	rs41266779	chr6:26021872	C/T	cg06606381	chr12:133084897	FBRSL1	-1.16	-8.64	-0.39	1.13e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7252981	0.632	rs880090	chr19:19740729	C/G	cg11584989	chr19:19387371	SF4	0.44	7.55	0.34	2.78e-13	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg12458913	chr13:53173898	NA	0.38	6.88	0.32	2.17e-11	Lewy body disease;
LUAD	cis	rs9549328	0.670	rs2993344	chr13:113617022	C/T	cg17524180	chr13:113633600	MCF2L	0.3	6.46	0.3	2.9e-10	Systolic blood pressure;
LUAD	cis	rs7107174	1.000	rs10793300	chr11:78019582	T/A	cg19901956	chr11:77921274	USP35	-0.53	-6.45	-0.3	3.15e-10	Testicular germ cell tumor;
LUAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07167872	chr1:205819463	PM20D1	0.77	15.32	0.6	1.83e-42	Menarche (age at onset);
LUAD	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg11965913	chr1:205819406	PM20D1	-0.54	-8.25	-0.37	2e-15	Menarche (age at onset);
LUAD	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.56	0.3	1.56e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg21153622	chr11:89784906	NA	-0.35	-6.86	-0.32	2.53e-11	HDL cholesterol;
LUAD	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg18306943	chr3:40428807	ENTPD3	0.41	7.17	0.33	3.34e-12	Renal cell carcinoma;
LUAD	cis	rs78761021	0.867	rs77902029	chr17:9791780	T/A	cg26853458	chr17:9805074	RCVRN	0.36	6.95	0.32	1.37e-11	Type 2 diabetes;
LUAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.81	-0.31	3.33e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg00083206	chr6:110721305	DDO	-0.41	-7.65	-0.35	1.4e-13	Platelet distribution width;
LUAD	cis	rs877282	0.945	rs17293517	chr10:778770	C/T	cg17470449	chr10:769945	NA	0.66	9.62	0.42	6e-20	Uric acid levels;
LUAD	cis	rs17401966	0.931	rs12408430	chr1:10323339	T/A	cg15208524	chr1:10270712	KIF1B	0.48	7.42	0.34	6.55e-13	Hepatocellular carcinoma;
LUAD	trans	rs8073060	0.586	rs226089	chr17:34016935	C/T	cg19694781	chr19:47549865	TMEM160	-1.22	-19.42	-0.69	1.67e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.61	0.31	1.15e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg04586622	chr2:25135609	ADCY3	0.37	8.54	0.38	2.45e-16	Body mass index;
LUAD	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg05673287	chr15:77411982	SGK269	-0.43	-7.36	-0.34	9.78e-13	Type 2 diabetes;
LUAD	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06544989	chr22:39130855	UNC84B	0.47	9.31	0.41	7.01e-19	Menopause (age at onset);
LUAD	cis	rs6445967	0.530	rs6804567	chr3:58365912	T/A	cg13750441	chr3:58318267	PXK	-0.32	-6.63	-0.31	1.03e-10	Platelet count;
LUAD	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg06608945	chr2:219082296	ARPC2	-0.47	-7.95	-0.36	1.76e-14	Colorectal cancer;
LUAD	cis	rs367943	0.698	rs10046061	chr5:112976533	A/G	cg12552261	chr5:112820674	MCC	0.47	8.41	0.38	6.39e-16	Type 2 diabetes;
LUAD	cis	rs10089	0.953	rs13358455	chr5:127365786	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	9.79	0.43	1.52e-20	Ileal carcinoids;
LUAD	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg01884057	chr2:25150051	NA	0.34	7.29	0.33	1.57e-12	Body mass index in non-asthmatics;
LUAD	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg13736514	chr6:26305472	NA	-0.67	-12.81	-0.53	5.57e-32	Educational attainment;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16265552	chr3:113667068	ZDHHC23	-0.41	-6.45	-0.3	3.13e-10	Height;
LUAD	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.45	0.3	3.02e-10	Parkinson's disease;
LUAD	cis	rs35771425	0.642	rs11586974	chr1:211464115	A/G	cg26515805	chr1:211431828	RCOR3	0.39	7.19	0.33	3e-12	Educational attainment (years of education);
LUAD	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	7.21	0.33	2.58e-12	Hypertriglyceridemia;
LUAD	trans	rs877282	0.898	rs11253350	chr10:765968	G/A	cg22713356	chr15:30763199	NA	1.28	17.3	0.64	4.19e-51	Uric acid levels;
LUAD	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg15704280	chr7:45808275	SEPT13	-0.68	-11.07	-0.47	3.55e-25	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.77	-0.31	4.37e-11	Post bronchodilator FEV1;
LUAD	cis	rs600231	0.571	rs10896000	chr11:65218018	A/G	cg17120908	chr11:65337727	SSSCA1	-0.59	-8.98	-0.4	8.87e-18	Bone mineral density;
LUAD	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg18305652	chr10:134549665	INPP5A	0.6	11.08	0.47	3.14e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7043114	0.507	rs10820971	chr9:95161740	G/C	cg14631576	chr9:95140430	CENPP	-0.39	-7.91	-0.36	2.35e-14	Height;
LUAD	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.34e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10203711	0.933	rs11883643	chr2:239586885	A/G	cg14580085	chr2:239553406	NA	0.39	8.22	0.37	2.43e-15	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg00784671	chr22:46762841	CELSR1	-0.57	-7.68	-0.35	1.11e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs55665837	1.000	rs4412729	chr11:14439000	A/G	cg19336497	chr11:14380999	RRAS2	-0.47	-9.12	-0.41	3.1e-18	Vitamin D levels;
LUAD	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg27426351	chr10:43362370	NA	-0.53	-8.12	-0.37	5e-15	Blood protein levels;
LUAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg16606324	chr3:10149918	C3orf24	0.67	11.16	0.48	1.57e-25	Alzheimer's disease;
LUAD	cis	rs807669	0.548	rs885978	chr22:19198226	A/G	cg02655711	chr22:19163373	SLC25A1	0.68	13.8	0.56	4.82e-36	Metabolite levels;
LUAD	trans	rs984440	0.922	rs7008947	chr8:139075668	G/A	cg03334052	chr1:168888044	NA	-0.47	-6.69	-0.31	7.05e-11	Obesity-related traits;
LUAD	cis	rs2274273	0.662	rs2147970	chr14:55660217	C/T	cg04306507	chr14:55594613	LGALS3	0.42	7.82	0.36	4.39e-14	Protein biomarker;
LUAD	trans	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg12400702	chr3:12838781	CAND2	0.31	6.38	0.3	4.61e-10	Parkinson's disease;
LUAD	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg05368731	chr17:41323189	NBR1	0.96	20.2	0.7	5.37e-64	Menopause (age at onset);
LUAD	cis	rs7937890	0.559	rs2597217	chr11:14532883	A/G	cg22961513	chr11:14280813	SPON1	-0.37	-7.06	-0.32	6.82e-12	Mitochondrial DNA levels;
LUAD	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg27411982	chr8:10470053	RP1L1	0.46	8.29	0.37	1.57e-15	Neuroticism;
LUAD	cis	rs2275731	0.625	rs7904333	chr10:16476271	C/T	cg04254609	chr10:16479192	PTER	-0.5	-8.38	-0.38	8.04e-16	Bone fracture in osteoporosis;
LUAD	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg12011299	chr4:100065546	ADH4	0.68	12.19	0.51	1.62e-29	Smoking initiation;
LUAD	cis	rs10465746	0.967	rs10493744	chr1:84444752	C/T	cg10977910	chr1:84465055	TTLL7	-0.49	-8.09	-0.37	6.56e-15	Obesity-related traits;
LUAD	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg00898013	chr13:113819073	PROZ	-0.83	-14.99	-0.59	4.74e-41	Platelet distribution width;
LUAD	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg25566285	chr7:158114605	PTPRN2	0.52	11.01	0.47	6.02e-25	Calcium levels;
LUAD	trans	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg26043149	chr18:55253948	FECH	0.39	6.51	0.3	2.18e-10	Bone mineral density;
LUAD	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg06547715	chr2:218990976	CXCR2	0.29	6.72	0.31	5.79e-11	Colorectal cancer;
LUAD	cis	rs1232027	0.656	rs1677643	chr5:79963940	C/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.15	-0.33	3.76e-12	Huntington's disease progression;
LUAD	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-7.89	-0.36	2.7e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg16479474	chr6:28041457	NA	0.45	7.73	0.35	7.89e-14	Parkinson's disease;
LUAD	cis	rs9549328	0.670	rs2873372	chr13:113613383	A/G	cg17524180	chr13:113633600	MCF2L	-0.33	-6.69	-0.31	7.22e-11	Systolic blood pressure;
LUAD	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.82	-0.36	4.14e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.84	0.43	1.07e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg26818010	chr10:134567672	INPP5A	-0.93	-15.41	-0.6	7.68e-43	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg21285383	chr16:89894308	SPIRE2	0.42	10.11	0.44	1.11e-21	Vitiligo;
LUAD	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg26528668	chr16:1614120	IFT140	-0.5	-9.02	-0.4	6.83e-18	Coronary artery disease;
LUAD	cis	rs57920188	0.658	rs7548273	chr1:4078945	G/C	cg10510935	chr1:4059661	NA	0.48	7.35	0.34	1.05e-12	Interleukin-17 levels;
LUAD	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg25036284	chr2:26402008	FAM59B	0.84	11.84	0.5	3.81e-28	Gut microbiome composition (summer);
LUAD	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg11663144	chr21:46675770	NA	-0.59	-11.76	-0.5	7.73e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg05603938	chr12:6960421	USP5;CDCA3	-0.41	-6.72	-0.31	5.94e-11	Subcortical brain region volumes;
LUAD	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg02269571	chr22:50332266	NA	-0.61	-9.26	-0.41	1e-18	Schizophrenia;
LUAD	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg00677455	chr12:58241039	CTDSP2	0.43	7.19	0.33	2.89e-12	Multiple sclerosis;
LUAD	cis	rs1595825	1.000	rs1440087	chr2:198871476	G/C	cg00361562	chr2:198649771	BOLL	-0.46	-6.42	-0.3	3.58e-10	Ulcerative colitis;
LUAD	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg06808227	chr14:105710500	BRF1	-0.42	-6.85	-0.32	2.69e-11	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs908922	0.676	rs477621	chr1:152486252	T/C	cg23254163	chr1:152506842	NA	0.26	7.13	0.33	4.25e-12	Hair morphology;
LUAD	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg07636037	chr3:49044803	WDR6	0.53	10.06	0.44	1.69e-21	Menarche (age at onset);
LUAD	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg13390004	chr1:15929781	NA	0.49	8.4	0.38	6.59e-16	Systolic blood pressure;
LUAD	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg19413350	chr8:57351067	NA	-0.41	-6.49	-0.3	2.43e-10	Obesity-related traits;
LUAD	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg01741372	chr11:783889	NA	-0.47	-10.13	-0.44	9.68e-22	Breast cancer;
LUAD	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg17105886	chr17:28927953	LRRC37B2	0.76	7.6	0.35	1.97e-13	Body mass index;
LUAD	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg17724175	chr1:150552817	MCL1	0.39	9.43	0.42	2.64e-19	Tonsillectomy;
LUAD	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg22117172	chr7:91764530	CYP51A1	0.34	7.31	0.33	1.34e-12	Breast cancer;
LUAD	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg26566898	chr11:117069891	TAGLN	-0.35	-6.97	-0.32	1.22e-11	Blood protein levels;
LUAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg00431813	chr7:1051703	C7orf50	-0.46	-8.83	-0.39	2.81e-17	Longevity;Endometriosis;
LUAD	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.68	-11.4	-0.48	2e-26	Primary sclerosing cholangitis;
LUAD	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg22166914	chr1:53195759	ZYG11B	0.46	8.06	0.37	7.64e-15	Monocyte count;
LUAD	cis	rs9837602	0.872	rs34996634	chr3:99738219	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	8.5	0.38	3.23e-16	Breast cancer;
LUAD	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg16205897	chr5:131564050	P4HA2	-0.42	-9.38	-0.41	4.13e-19	Blood metabolite levels;
LUAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.6	0.31	1.2e-10	Prudent dietary pattern;
LUAD	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg24308560	chr3:49941425	MST1R	-0.5	-8.12	-0.37	5.08e-15	Body mass index;
LUAD	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg23598886	chr18:12777645	NA	0.64	8.0	0.36	1.22e-14	Inflammatory skin disease;
LUAD	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg06532163	chr17:45867833	NA	0.47	8.52	0.38	2.87e-16	IgG glycosylation;
LUAD	cis	rs2455799	0.553	rs12495958	chr3:15941439	G/T	cg16303742	chr3:15540471	COLQ	-0.46	-8.34	-0.38	1.02e-15	Mean platelet volume;
LUAD	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg25251562	chr2:3704773	ALLC	0.56	9.29	0.41	8.53e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.63	0.31	1.05e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg07504864	chr6:88412167	NCRNA00120;AKIRIN2	-0.42	-7.3	-0.33	1.43e-12	Subcortical brain region volumes;
LUAD	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.67	11.03	0.47	4.92e-25	Height;
LUAD	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg14458575	chr2:238380390	NA	0.79	14.65	0.58	1.31e-39	Prostate cancer;
LUAD	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg15921436	chr17:44337874	NA	-0.72	-9.5	-0.42	1.61e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1448094	0.967	rs7313443	chr12:86332940	G/A	cg02569458	chr12:86230093	RASSF9	0.37	7.07	0.33	6.27e-12	Major depressive disorder;
LUAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg22663859	chr13:21900854	NA	0.48	8.11	0.37	5.69e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg14458575	chr2:238380390	NA	0.77	11.46	0.49	1.14e-26	Prostate cancer;
LUAD	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg23260525	chr10:116636907	FAM160B1	0.47	10.87	0.47	1.93e-24	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg03467027	chr4:99064603	C4orf37	0.46	7.18	0.33	3.26e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg02734326	chr4:10020555	SLC2A9	0.45	8.16	0.37	3.97e-15	Bone mineral density;
LUAD	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-6.98	-0.32	1.12e-11	Lung cancer;
LUAD	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.67	-0.43	3.94e-20	Bone mineral density;
LUAD	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg02221422	chr11:68192511	LRP5	-0.41	-6.55	-0.3	1.63e-10	Total body bone mineral density;
LUAD	cis	rs72634258	0.945	rs12736494	chr1:8136016	G/A	cg26816564	chr1:7831052	VAMP3	0.56	7.16	0.33	3.57e-12	Inflammatory bowel disease;
LUAD	cis	rs7771547	0.519	rs4713972	chr6:36371316	C/A	cg07856975	chr6:36356162	ETV7	0.54	8.03	0.36	1.01e-14	Platelet distribution width;
LUAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg01448562	chr3:133502909	NA	-0.67	-12.74	-0.53	1.12e-31	Iron status biomarkers;
LUAD	cis	rs12210905	0.688	rs75968505	chr6:27476996	T/C	cg08851530	chr6:28072375	NA	1.03	7.92	0.36	2.19e-14	Hip circumference adjusted for BMI;
LUAD	trans	rs3857536	0.813	rs2040591	chr6:66945915	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	8.99	0.4	8.53e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg00530320	chr1:46809349	NSUN4	0.5	7.6	0.35	1.9e-13	Menopause (age at onset);
LUAD	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg03859395	chr2:55845619	SMEK2	0.7	12.48	0.52	1.17e-30	Metabolic syndrome;
LUAD	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg00666640	chr1:248458726	OR2T12	0.32	7.65	0.35	1.34e-13	Common traits (Other);
LUAD	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg10589385	chr1:150898437	SETDB1	-0.37	-6.41	-0.3	3.88e-10	Urate levels;
LUAD	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg18477163	chr1:228402036	OBSCN	0.37	6.95	0.32	1.37e-11	Diastolic blood pressure;
LUAD	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg07570687	chr10:102243282	WNT8B	0.48	7.28	0.33	1.6e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7336332	0.598	rs9581850	chr13:28012265	A/G	cg22138327	chr13:27999177	GTF3A	0.77	9.95	0.44	4.34e-21	Weight;
LUAD	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.4	0.3	4.19e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg03188948	chr7:1209495	NA	0.8	9.76	0.43	2.04e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs11650494	0.908	rs77338752	chr17:47372328	A/C	cg11430096	chr6:110968061	CDK19	0.88	6.67	0.31	8.14e-11	Prostate cancer;
LUAD	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg17644776	chr2:200775616	C2orf69	-0.57	-7.41	-0.34	6.71e-13	Schizophrenia;
LUAD	cis	rs7707921	0.957	rs226205	chr5:81593654	C/T	cg15871215	chr5:81402204	ATG10	0.66	9.32	0.41	6.64e-19	Breast cancer;
LUAD	cis	rs7665090	0.967	rs6821133	chr4:103555253	T/C	cg07973026	chr4:103553119	MANBA	0.47	8.3	0.37	1.41e-15	Primary biliary cholangitis;
LUAD	cis	rs7705042	0.828	rs10875596	chr5:141495715	T/C	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.53	-0.3	1.85e-10	Asthma;
LUAD	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg09065629	chr16:1709722	CRAMP1L	0.43	7.36	0.34	9.61e-13	Coronary artery disease;
LUAD	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg17971929	chr21:40555470	PSMG1	0.56	8.86	0.4	2.22e-17	Cognitive function;
LUAD	cis	rs938554	0.612	rs4385059	chr4:9989233	A/G	cg00071950	chr4:10020882	SLC2A9	-0.6	-8.93	-0.4	1.36e-17	Blood metabolite levels;
LUAD	cis	rs887829	0.570	rs6724485	chr2:234592816	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.6	-0.42	7.26e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs7215564	0.908	rs2340772	chr17:78752017	C/A	cg09596252	chr17:78655493	RPTOR	-0.51	-6.47	-0.3	2.78e-10	Myopia (pathological);
LUAD	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg14664628	chr15:75095509	CSK	-0.6	-9.49	-0.42	1.7e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg04414720	chr1:150670196	GOLPH3L	-0.47	-7.37	-0.34	8.8e-13	Tonsillectomy;
LUAD	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg09835421	chr16:68378352	PRMT7	-0.55	-6.89	-0.32	2e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg27539214	chr16:67997921	SLC12A4	-0.62	-8.75	-0.39	5.29e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg07414643	chr4:187882934	NA	0.32	6.57	0.3	1.5e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg11859384	chr17:80120422	CCDC57	0.44	7.79	0.35	5.1e-14	Life satisfaction;
LUAD	cis	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05901451	chr6:126070800	HEY2	0.59	9.33	0.41	6.17e-19	Endometrial cancer;
LUAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg08742575	chr21:47604166	C21orf56	-0.62	-11.07	-0.47	3.6e-25	Testicular germ cell tumor;
LUAD	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg12310025	chr6:25882481	NA	-0.56	-9.04	-0.4	5.83e-18	Blood metabolite levels;
LUAD	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.68e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs28595532	0.748	rs72670248	chr4:119335536	A/C	cg02775129	chr4:119771670	NA	-0.66	-6.5	-0.3	2.25e-10	Cannabis dependence symptom count;
LUAD	cis	rs4692589	1.000	rs1871683	chr4:170937348	T/C	cg19918862	chr4:170955249	NA	0.29	6.95	0.32	1.36e-11	Anxiety disorder;
LUAD	cis	rs1448094	0.785	rs7955173	chr12:86447214	G/A	cg06740227	chr12:86229804	RASSF9	-0.35	-6.42	-0.3	3.77e-10	Major depressive disorder;
LUAD	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg17652424	chr22:38574118	PLA2G6	-0.33	-9.95	-0.44	4.4e-21	Cutaneous nevi;
LUAD	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg25753631	chr6:25732923	NA	-0.37	-6.43	-0.3	3.49e-10	Iron status biomarkers;
LUAD	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.23	0.37	2.35e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg24818145	chr4:99064322	C4orf37	0.4	6.61	0.31	1.18e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg00310523	chr12:86230176	RASSF9	0.42	8.95	0.4	1.12e-17	Major depressive disorder;
LUAD	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg00631329	chr6:26305371	NA	0.46	7.6	0.35	1.92e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg03929089	chr4:120376271	NA	0.68	9.83	0.43	1.14e-20	Coronary artery disease;
LUAD	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg20701182	chr2:24300061	SF3B14	0.54	6.68	0.31	7.34e-11	Lymphocyte counts;
LUAD	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24531977	chr5:56204891	C5orf35	-0.95	-14.31	-0.57	3.71e-38	Initial pursuit acceleration;
LUAD	cis	rs72928364	1.000	rs34565718	chr3:100652890	A/G	cg10123952	chr3:100791384	NA	0.65	7.37	0.34	8.86e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg10518543	chr12:38710700	ALG10B	-0.42	-6.88	-0.32	2.16e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.83	0.31	3.04e-11	Cognitive test performance;
LUAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg04025307	chr7:1156635	C7orf50	0.6	6.77	0.31	4.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg00280220	chr17:61926910	NA	0.36	6.94	0.32	1.44e-11	Prudent dietary pattern;
LUAD	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg14458575	chr2:238380390	NA	0.78	15.93	0.61	4.31e-45	Prostate cancer;
LUAD	cis	rs8067287	0.762	rs11651352	chr17:16824909	A/G	cg26910001	chr17:16838321	NA	0.47	6.68	0.31	7.54e-11	Diabetic kidney disease;
LUAD	cis	rs904251	0.523	rs2797794	chr6:37480604	T/C	cg25019722	chr6:37503610	NA	-0.33	-7.54	-0.34	2.95e-13	Cognitive performance;
LUAD	cis	rs12050794	0.636	rs4506844	chr15:72509138	C/T	cg16672083	chr15:72433130	SENP8	0.63	11.61	0.49	3.12e-27	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg00666640	chr1:248458726	OR2T12	0.33	7.91	0.36	2.23e-14	Common traits (Other);
LUAD	cis	rs2979489	0.891	rs17626867	chr8:30311177	G/T	cg26383811	chr8:30366931	RBPMS	-0.65	-10.17	-0.44	6.78e-22	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22857025	chr5:266934	NA	-0.97	-13.23	-0.54	1.14e-33	Breast cancer;
LUAD	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg02269571	chr22:50332266	NA	-0.62	-9.49	-0.42	1.67e-19	Schizophrenia;
LUAD	trans	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg04995722	chr7:26192034	NFE2L3	-0.41	-6.79	-0.31	3.69e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9863	0.896	rs34854841	chr12:124451504	A/G	cg17723958	chr12:124429295	CCDC92	-0.41	-6.61	-0.31	1.15e-10	White blood cell count;
LUAD	cis	rs977987	0.736	rs11865296	chr16:75473693	C/T	cg03315344	chr16:75512273	CHST6	0.65	14.13	0.57	2.07e-37	Dupuytren's disease;
LUAD	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg13180566	chr4:1052158	NA	-0.4	-6.78	-0.31	4.04e-11	Recombination rate (females);
LUAD	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg08439880	chr3:133502540	NA	-0.41	-7.46	-0.34	4.87e-13	Iron status biomarkers;
LUAD	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg16681516	chr19:46297285	DMWD	0.46	9.12	0.41	2.97e-18	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs344364	0.602	rs7188401	chr16:1876949	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.44	-7.53	-0.34	3.15e-13	Glomerular filtration rate in chronic kidney disease;
LUAD	trans	rs12517041	1.000	rs6887969	chr5:23304261	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.57	-0.3	1.47e-10	Calcium levels;
LUAD	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg07332563	chr6:291687	DUSP22	-0.69	-11.89	-0.5	2.41e-28	Menopause (age at onset);
LUAD	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg12940439	chr1:67600707	NA	0.49	9.24	0.41	1.18e-18	Psoriasis;
LUAD	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg23262073	chr20:60523788	NA	-0.45	-7.7	-0.35	9.48e-14	Body mass index;
LUAD	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	7.77	0.35	6.06e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg11502198	chr6:26597334	ABT1	0.56	9.35	0.41	5.14e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-9.49	-0.42	1.68e-19	Longevity;Endometriosis;
LUAD	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg20701182	chr2:24300061	SF3B14	0.53	6.4	0.3	4.03e-10	Lymphocyte counts;
LUAD	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg11645453	chr3:52864694	ITIH4	0.6	11.29	0.48	5.14e-26	Schizophrenia;
LUAD	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg06671706	chr8:8559999	CLDN23	0.65	11.34	0.48	3.39e-26	Obesity-related traits;
LUAD	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg25767906	chr1:53392781	SCP2	0.4	7.3	0.33	1.44e-12	Monocyte count;
LUAD	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22496380	chr5:211416	CCDC127	-1.01	-13.64	-0.55	2.4e-35	Breast cancer;
LUAD	cis	rs62400317	0.859	rs12214749	chr6:45307906	A/G	cg18551225	chr6:44695536	NA	-0.56	-8.79	-0.39	3.7e-17	Total body bone mineral density;
LUAD	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	8.59	0.39	1.7e-16	Eosinophil percentage of white cells;
LUAD	cis	rs6840360	0.615	rs4696267	chr4:152464500	A/G	cg22705602	chr4:152727874	NA	-0.37	-6.71	-0.31	6.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg05313129	chr8:58192883	C8orf71	0.54	7.37	0.34	9.05e-13	Developmental language disorder (linguistic errors);
LUAD	trans	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg08071915	chr8:12219732	FAM66A	0.41	6.5	0.3	2.22e-10	Recombination measurement;
LUAD	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg03806693	chr22:41940476	POLR3H	0.74	9.95	0.44	4.33e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg27432699	chr2:27873401	GPN1	-0.38	-6.35	-0.3	5.56e-10	Total body bone mineral density;
LUAD	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg24558204	chr6:135376177	HBS1L	0.48	7.98	0.36	1.38e-14	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.39	0.34	7.8e-13	Hypertriglyceridemia;
LUAD	cis	rs2073300	1.000	rs2207988	chr20:23446000	C/A	cg12062639	chr20:23401060	NAPB	0.7	6.62	0.31	1.12e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.03	0.36	9.87e-15	Menopause (age at onset);
LUAD	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21582582	chr3:182698605	DCUN1D1	0.61	9.83	0.43	1.1e-20	Resting heart rate;
LUAD	cis	rs7107174	0.901	rs2450138	chr11:77924870	C/T	cg19901956	chr11:77921274	USP35	-0.5	-6.38	-0.3	4.7e-10	Testicular germ cell tumor;
LUAD	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg20476274	chr7:133979776	SLC35B4	0.58	9.5	0.42	1.53e-19	Mean platelet volume;
LUAD	cis	rs11958404	0.932	rs72818108	chr5:157437883	A/T	cg05962755	chr5:157440814	NA	0.71	9.95	0.44	4.36e-21	IgG glycosylation;
LUAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.78	14.59	0.58	2.44e-39	Lymphocyte counts;
LUAD	cis	rs6761276	0.899	rs12466799	chr2:113835999	T/C	cg02343335	chr2:113785852	IL1F8	-0.35	-7.01	-0.32	9.26e-12	Protein quantitative trait loci;
LUAD	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.5	-7.86	-0.36	3.32e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg21204522	chr6:27730016	NA	-0.48	-7.59	-0.35	2.08e-13	Parkinson's disease;
LUAD	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg21100191	chr22:23484243	RTDR1	0.71	12.6	0.52	3.86e-31	Bone mineral density;
LUAD	cis	rs3106136	0.967	rs282448	chr4:95141411	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.6	-0.35	1.89e-13	Capecitabine sensitivity;
LUAD	cis	rs6740322	0.895	rs10210125	chr2:43556433	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.78	-11.57	-0.49	4.5e-27	Coronary artery disease;
LUAD	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg02773041	chr1:40204384	PPIE	0.53	8.81	0.39	3.29e-17	Blood protein levels;
LUAD	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.97	20.88	0.71	4.9e-67	Chronic sinus infection;
LUAD	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.44	-0.42	2.51e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs990171	0.538	rs4851014	chr2:103116276	C/T	cg03938978	chr2:103052716	IL18RAP	0.34	6.7	0.31	6.72e-11	Lymphocyte counts;
LUAD	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg18827107	chr12:86230957	RASSF9	-0.53	-9.57	-0.42	8.82e-20	Major depressive disorder;
LUAD	cis	rs13064411	0.518	rs6769604	chr3:113185064	A/G	cg18753928	chr3:113234510	CCDC52	-0.46	-8.5	-0.38	3.23e-16	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg17264618	chr3:40429014	ENTPD3	0.42	9.03	0.4	6.08e-18	Renal cell carcinoma;
LUAD	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg18129748	chr3:49941408	MST1R	0.4	6.51	0.3	2.18e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs7781370	1.000	rs7781370	chr7:96133531	A/G	cg20826792	chr1:29425	WASH5P	-0.4	-6.56	-0.3	1.58e-10	Bone mineral density (hip);
LUAD	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03264133	chr6:25882463	NA	-0.49	-7.2	-0.33	2.69e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4072705	0.967	rs4838200	chr9:127451057	A/G	cg13476313	chr9:127244764	NR5A1	-0.33	-7.81	-0.36	4.44e-14	Menarche (age at onset);
LUAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.67	0.31	7.95e-11	Prudent dietary pattern;
LUAD	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg17264618	chr3:40429014	ENTPD3	0.39	8.83	0.39	2.74e-17	Renal cell carcinoma;
LUAD	cis	rs6011002	0.745	rs1151625	chr20:62369997	C/T	cg01176363	chr20:62369445	LIME1	0.79	6.63	0.31	1.05e-10	Dental caries;
LUAD	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg25767906	chr1:53392781	SCP2	-0.48	-8.94	-0.4	1.22e-17	Monocyte count;
LUAD	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg08645402	chr16:4508243	NA	-0.58	-11.14	-0.48	1.85e-25	Schizophrenia;
LUAD	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.91	-0.36	2.24e-14	Monocyte percentage of white cells;
LUAD	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.28	-0.33	1.62e-12	Total body bone mineral density;
LUAD	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.46	7.51	0.34	3.54e-13	Electrocardiographic conduction measures;
LUAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08439880	chr3:133502540	NA	-0.49	-10.23	-0.45	4.12e-22	Iron status biomarkers;
LUAD	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.35	-6.78	-0.31	4.18e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg15017067	chr4:17643749	FAM184B	-0.35	-6.9	-0.32	1.95e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg13560548	chr3:10150139	C3orf24	0.46	7.03	0.32	8.6e-12	Alzheimer's disease;
LUAD	cis	rs240764	0.853	rs12190903	chr6:100983505	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-7.27	-0.33	1.77e-12	Neuroticism;
LUAD	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg03563238	chr19:33554763	RHPN2	-0.37	-8.64	-0.39	1.21e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.13	-0.33	4.26e-12	Breast cancer;
LUAD	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg01475377	chr6:109611718	NA	-0.51	-9.53	-0.42	1.27e-19	Reticulocyte fraction of red cells;
LUAD	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg15383120	chr6:291909	DUSP22	-0.5	-8.37	-0.38	8.69e-16	Menopause (age at onset);
LUAD	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.57	-0.42	8.91e-20	Schizophrenia;
LUAD	cis	rs6445967	0.530	rs12634132	chr3:58409082	A/G	cg23715586	chr3:58305044	RPP14	0.41	6.75	0.31	4.8e-11	Platelet count;
LUAD	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg24112000	chr20:60950667	NA	-0.68	-9.84	-0.43	1.08e-20	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.46	0.45	6.18e-23	Colorectal cancer;
LUAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg12419862	chr22:24373484	LOC391322	-0.82	-15.84	-0.61	1.1e-44	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg12573674	chr2:1569213	NA	-0.57	-6.96	-0.32	1.3e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg25985355	chr7:65971099	NA	-0.55	-6.83	-0.32	2.94e-11	Diabetic kidney disease;
LUAD	cis	rs11676348	0.776	rs11690316	chr2:219017462	A/G	cg06547715	chr2:218990976	CXCR2	0.42	10.15	0.44	8.01e-22	Ulcerative colitis;
LUAD	cis	rs2230307	0.536	rs482466	chr1:100488177	C/T	cg20868668	chr1:100435035	SLC35A3	0.51	7.7	0.35	9.55e-14	Carotid intima media thickness;
LUAD	cis	rs2629540	0.824	rs1552345	chr10:126477406	A/G	cg08799069	chr10:126477246	METTL10	-0.48	-7.34	-0.34	1.14e-12	Cocaine dependence;
LUAD	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22857025	chr5:266934	NA	-1.01	-12.74	-0.53	1.08e-31	Breast cancer;
LUAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	8.24	0.37	2.13e-15	Alzheimer's disease;
LUAD	cis	rs7680126	0.633	rs17389602	chr4:10206926	T/A	cg02734326	chr4:10020555	SLC2A9	-0.54	-6.89	-0.32	2.09e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg22676075	chr6:135203613	NA	0.41	7.6	0.35	1.96e-13	Red blood cell count;
LUAD	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.08	0.33	6.09e-12	Depression;
LUAD	trans	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg02002194	chr4:3960332	NA	-0.28	-6.78	-0.31	4.13e-11	Systolic blood pressure;
LUAD	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg07527032	chr15:84868466	LOC388152	0.44	6.63	0.31	1.04e-10	Schizophrenia;
LUAD	trans	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg21659725	chr3:3221576	CRBN	-0.58	-9.2	-0.41	1.6e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs12545109	0.571	rs4237014	chr8:57284479	C/A	cg19413350	chr8:57351067	NA	-0.44	-6.39	-0.3	4.48e-10	Obesity-related traits;
LUAD	cis	rs9486719	1.000	rs11752584	chr6:96884952	C/A	cg06623918	chr6:96969491	KIAA0776	-0.71	-10.02	-0.44	2.32e-21	Migraine;Coronary artery disease;
LUAD	cis	rs7737355	0.947	rs6864173	chr5:130871822	T/C	cg06307176	chr5:131281290	NA	0.52	8.1	0.37	5.77e-15	Life satisfaction;
LUAD	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg25173405	chr17:45401733	C17orf57	0.46	7.86	0.36	3.22e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg07211511	chr3:129823064	LOC729375	-0.44	-6.38	-0.3	4.66e-10	Blood pressure (smoking interaction);
LUAD	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg11901034	chr3:128598214	ACAD9	-0.55	-8.7	-0.39	7.41e-17	IgG glycosylation;
LUAD	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg26769984	chr7:1090371	C7orf50	0.56	9.44	0.42	2.62e-19	Bronchopulmonary dysplasia;
LUAD	cis	rs3106136	0.967	rs2632399	chr4:95153741	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.56	-0.34	2.55e-13	Capecitabine sensitivity;
LUAD	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg25817165	chr18:72167213	CNDP2	-0.7	-10.57	-0.46	2.57e-23	Refractive error;
LUAD	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg18806716	chr10:30721971	MAP3K8	-0.65	-12.96	-0.53	1.4e-32	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.65	-0.42	4.97e-20	Alzheimer's disease;
LUAD	cis	rs4523957	0.890	rs12941836	chr17:2194874	C/G	cg16513277	chr17:2031491	SMG6	0.75	13.69	0.55	1.47e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2795502	0.872	rs2744062	chr10:43254789	T/A	cg27426351	chr10:43362370	NA	-0.53	-6.91	-0.32	1.79e-11	Blood protein levels;
LUAD	cis	rs2735413	0.875	rs4888736	chr16:78083784	T/C	cg04733911	chr16:78082701	NA	-0.34	-8.17	-0.37	3.53e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg17264618	chr3:40429014	ENTPD3	0.38	8.54	0.38	2.42e-16	Renal cell carcinoma;
LUAD	cis	rs2734839	0.964	rs1800498	chr11:113291588	G/A	cg14159747	chr11:113255604	NA	0.54	10.4	0.45	1e-22	Information processing speed;
LUAD	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg09359103	chr1:154839909	KCNN3	0.89	20.36	0.7	1.04e-64	Prostate cancer;
LUAD	cis	rs10979	1.000	rs9376760	chr6:143886969	C/T	cg25407410	chr6:143891975	LOC285740	-0.59	-9.28	-0.41	8.83e-19	Hypospadias;
LUAD	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg00666640	chr1:248458726	OR2T12	0.3	7.26	0.33	1.87e-12	Common traits (Other);
LUAD	trans	rs11246602	1	rs11246602	chr11:51512090	T/C	cg15704280	chr7:45808275	SEPT13	0.67	6.86	0.32	2.47e-11	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg02524346	chr8:600233	NA	1.13	10.32	0.45	2.09e-22	IgG glycosylation;
LUAD	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg17120908	chr11:65337727	SSSCA1	-0.6	-9.51	-0.42	1.48e-19	Bone mineral density;
LUAD	cis	rs28374715	0.662	rs28554139	chr15:41531084	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.9	-17.33	-0.64	3.25e-51	Ulcerative colitis;
LUAD	cis	rs56283067	0.887	rs62437973	chr6:44761978	G/A	cg18551225	chr6:44695536	NA	-0.6	-9.14	-0.41	2.7e-18	Total body bone mineral density;
LUAD	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.72	0.39	6.32e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg11344533	chr11:111475393	SIK2	-0.37	-6.8	-0.31	3.52e-11	Primary sclerosing cholangitis;
LUAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27297192	chr10:134578999	INPP5A	0.38	6.7	0.31	6.64e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg14582100	chr15:45693742	SPATA5L1	0.64	12.48	0.52	1.23e-30	Homoarginine levels;
LUAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00149659	chr3:10157352	C3orf10	0.86	11.7	0.49	1.4e-27	Alzheimer's disease;
LUAD	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.03	0.32	8.12e-12	Menopause (age at onset);
LUAD	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg09796270	chr17:17721594	SREBF1	0.39	7.55	0.34	2.74e-13	Total body bone mineral density;
LUAD	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg18180107	chr4:99064573	C4orf37	0.42	6.72	0.31	5.92e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg09365446	chr1:150670422	GOLPH3L	0.66	12.57	0.52	5.15e-31	Tonsillectomy;
LUAD	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg01884057	chr2:25150051	NA	0.32	6.75	0.31	5.01e-11	Body mass index;
LUAD	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.45	6.78	0.31	4.17e-11	Schizophrenia;
LUAD	cis	rs6908034	0.660	rs74795718	chr6:19782299	G/A	cg02682789	chr6:19804855	NA	0.99	9.09	0.4	3.94e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg22117172	chr7:91764530	CYP51A1	0.38	8.23	0.37	2.38e-15	Breast cancer;
LUAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.46	6.38	0.3	4.68e-10	Renal function-related traits (BUN);
LUAD	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg26587870	chr6:27730563	NA	-0.68	-7.21	-0.33	2.63e-12	Depression;
LUAD	cis	rs7208859	0.614	rs4794874	chr17:28841318	C/T	cg17105886	chr17:28927953	LRRC37B2	-0.67	-7.03	-0.32	8.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg00277334	chr10:82204260	NA	-0.94	-21.51	-0.72	6.97e-70	Post bronchodilator FEV1;
LUAD	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg11189052	chr15:85197271	WDR73	0.68	9.1	0.4	3.69e-18	Schizophrenia;
LUAD	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg00701064	chr4:6280414	WFS1	0.58	10.78	0.46	4.09e-24	Cisplatin-induced ototoxicity;
LUAD	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg17366294	chr4:99064904	C4orf37	0.66	12.78	0.53	7.72e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs427941	0.703	rs201449	chr7:101739054	A/G	cg06246474	chr7:101738831	CUX1	0.4	7.14	0.33	4.11e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg03030879	chr14:75389066	RPS6KL1	0.36	6.79	0.31	3.82e-11	Caffeine consumption;
LUAD	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg04511125	chr2:88470314	THNSL2	0.87	9.57	0.42	8.78e-20	Plasma clusterin levels;
LUAD	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg05165339	chr4:1420672	NA	-0.29	-6.54	-0.3	1.83e-10	Longevity;
LUAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg00450029	chr8:599525	NA	-0.76	-7.8	-0.35	4.85e-14	IgG glycosylation;
LUAD	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg16680214	chr1:154839983	KCNN3	-0.61	-12.62	-0.52	3.43e-31	Prostate cancer;
LUAD	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg27284194	chr4:1044797	NA	0.69	10.11	0.44	1.17e-21	Recombination rate (females);
LUAD	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg24733560	chr20:60626293	TAF4	0.42	8.5	0.38	3.24e-16	Body mass index;
LUAD	cis	rs10484885	0.752	rs72921948	chr6:90582560	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.7	-10.0	-0.44	2.9e-21	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg26043149	chr18:55253948	FECH	0.43	7.12	0.33	4.65e-12	Bone mineral density;
LUAD	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.87	-0.4	2.11e-17	Menopause (age at onset);
LUAD	cis	rs7633770	0.735	rs4683271	chr3:46684823	A/G	cg11219411	chr3:46661640	NA	-0.49	-10.49	-0.45	4.82e-23	Coronary artery disease;
LUAD	trans	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg26384229	chr12:38710491	ALG10B	0.38	6.37	0.3	5.01e-10	Morning vs. evening chronotype;
LUAD	cis	rs4662945	0.525	rs28625431	chr2:130303333	A/G	cg05962382	chr2:130345044	NA	-0.36	-6.79	-0.31	3.73e-11	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg24399712	chr22:39784796	NA	-0.75	-12.99	-0.53	1.07e-32	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg05805236	chr11:65401703	PCNXL3	0.42	7.28	0.33	1.66e-12	Acne (severe);
LUAD	cis	rs2004318	1.000	rs75132967	chr19:55077987	T/C	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.93e-13	Blood protein levels;
LUAD	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg11266682	chr4:10021025	SLC2A9	0.65	15.38	0.6	1.05e-42	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7107174	1.000	rs1006441	chr11:77932126	G/C	cg02023728	chr11:77925099	USP35	0.52	7.94	0.36	1.89e-14	Testicular germ cell tumor;
LUAD	cis	rs2445762	0.642	rs72729210	chr15:51633629	G/A	cg00184732	chr15:51633821	GLDN	0.38	6.74	0.31	5.21e-11	Hormone measurements;
LUAD	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-10.84	-0.47	2.43e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18876405	chr7:65276391	NA	-0.62	-10.28	-0.45	2.72e-22	Aortic root size;
LUAD	cis	rs3772130	0.923	rs4298081	chr3:121526037	T/G	cg20356878	chr3:121714668	ILDR1	0.53	8.55	0.38	2.27e-16	Cognitive performance;
LUAD	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg16850897	chr7:100343110	ZAN	0.43	7.63	0.35	1.55e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.84	12.21	0.51	1.38e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg20607798	chr8:58055168	NA	0.74	9.02	0.4	6.74e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04633058	chr17:48474099	LRRC59	0.42	6.6	0.31	1.21e-10	Gut microbiome composition (summer);
LUAD	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg13319975	chr6:146136371	FBXO30	-0.59	-9.74	-0.43	2.35e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg07570687	chr10:102243282	WNT8B	0.48	7.37	0.34	9.16e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg18854424	chr1:2615690	NA	0.43	9.54	0.42	1.14e-19	Ulcerative colitis;
LUAD	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg17366294	chr4:99064904	C4orf37	0.54	9.9	0.43	6.44e-21	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg27411982	chr8:10470053	RP1L1	0.45	8.03	0.36	9.59e-15	Mood instability;
LUAD	cis	rs11811982	0.793	rs74896174	chr1:227512973	G/A	cg24860534	chr1:227506868	CDC42BPA	0.71	7.41	0.34	6.93e-13	Optic disc area;
LUAD	cis	rs4698790	0.593	rs7356506	chr4:110683454	G/A	cg07850274	chr4:110748770	RRH	0.42	6.78	0.31	3.98e-11	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUAD	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg02753203	chr1:228287806	NA	-0.48	-8.7	-0.39	7.24e-17	Diastolic blood pressure;
LUAD	cis	rs13190036	0.551	rs11955537	chr5:176574088	A/G	cg06733329	chr5:176740039	MXD3	0.46	6.7	0.31	6.56e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	cis	rs56161922	1.000	rs4562622	chr1:207876577	A/C	cg11752769	chr1:207818423	CR1L	0.62	6.62	0.31	1.06e-10	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg20933634	chr6:27740509	NA	0.49	7.92	0.36	2.18e-14	Parkinson's disease;
LUAD	cis	rs68149176	0.772	rs61527026	chr16:87878783	C/G	cg03553613	chr16:87879502	SLC7A5	-0.63	-9.11	-0.4	3.39e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg06781209	chr11:61594997	FADS2	-0.39	-7.44	-0.34	5.71e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg02527881	chr3:46936655	PTH1R	-0.47	-9.15	-0.41	2.45e-18	Colorectal cancer;
LUAD	cis	rs3772130	0.961	rs11716984	chr3:121362407	A/T	cg20356878	chr3:121714668	ILDR1	0.48	7.4	0.34	7.27e-13	Cognitive performance;
LUAD	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg03929089	chr4:120376271	NA	-0.51	-8.18	-0.37	3.3e-15	HDL cholesterol;
LUAD	cis	rs1832871	0.711	rs9459829	chr6:158680799	C/T	cg07165851	chr6:158734300	TULP4	0.71	11.06	0.47	3.81e-25	Height;
LUAD	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg10523679	chr1:76189770	ACADM	0.77	11.22	0.48	9.24e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2625529	0.824	rs4777480	chr15:72328997	A/C	cg16672083	chr15:72433130	SENP8	-0.76	-12.99	-0.53	1.02e-32	Red blood cell count;
LUAD	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Colorectal cancer;
LUAD	cis	rs593982	0.843	rs552312	chr11:65477349	C/T	cg08755490	chr11:65554678	OVOL1	1.24	14.87	0.59	1.55e-40	Atopic dermatitis;
LUAD	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg12011299	chr4:100065546	ADH4	0.74	13.77	0.56	6.49e-36	Alcohol dependence;
LUAD	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-7.09	-0.33	5.78e-12	Personality dimensions;
LUAD	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg10560079	chr2:191398806	TMEM194B	-0.41	-7.31	-0.34	1.32e-12	Pulse pressure;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02690648	chr8:10683044	PINX1;MIR1322	0.4	6.49	0.3	2.43e-10	Gut microbiome composition (summer);
LUAD	cis	rs3784262	0.528	rs4646588	chr15:58304313	A/G	cg12031962	chr15:58353849	ALDH1A2	0.37	7.05	0.32	7.19e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg05865280	chr17:75406074	SEPT9	0.61	19.3	0.68	5.44e-60	Airflow obstruction;
LUAD	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg06784218	chr1:46089804	CCDC17	0.6	13.37	0.55	2.89e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg10356904	chr22:49881777	NA	-0.41	-8.08	-0.37	6.61e-15	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs11048434	0.736	rs11048195	chr12:9105923	A/G	cg04155231	chr12:9217510	LOC144571	0.39	7.43	0.34	6.07e-13	Sjögren's syndrome;
LUAD	cis	rs2677744	0.626	rs12915155	chr15:91490894	G/T	cg23684204	chr15:91497937	RCCD1	0.43	6.96	0.32	1.27e-11	Attention deficit hyperactivity disorder;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg20089077	chr19:37569736	ZNF420	-0.38	-6.7	-0.31	6.5e-11	Subcortical brain region volumes;
LUAD	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg00717180	chr2:96193071	NA	-0.4	-7.56	-0.35	2.54e-13	HDL cholesterol;
LUAD	cis	rs35883536	0.967	rs4908085	chr1:101087901	C/G	cg06223162	chr1:101003688	GPR88	0.36	6.55	0.3	1.64e-10	Monocyte count;
LUAD	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg27170947	chr2:26402098	FAM59B	-0.81	-11.51	-0.49	7.14e-27	Gut microbiome composition (summer);
LUAD	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26314531	chr2:26401878	FAM59B	-0.58	-7.96	-0.36	1.56e-14	Gut microbiome composition (summer);
LUAD	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg07828340	chr4:882639	GAK	1.07	11.0	0.47	6.1e-25	Intelligence (multi-trait analysis);
LUAD	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg21095983	chr6:86352623	SYNCRIP	0.44	7.17	0.33	3.33e-12	Smooth-surface caries;
LUAD	cis	rs8063761	0.689	rs4785763	chr16:90066936	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.42	-6.65	-0.31	9.33e-11	Squamous cell carcinoma;
LUAD	cis	rs2979489	0.891	rs17552243	chr8:30362627	T/C	cg26383811	chr8:30366931	RBPMS	-0.71	-10.79	-0.46	3.94e-24	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg16797656	chr11:68205561	LRP5	0.47	9.15	0.41	2.36e-18	Total body bone mineral density;
LUAD	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg01802117	chr1:53393560	SCP2	0.33	6.62	0.31	1.12e-10	Monocyte count;
LUAD	cis	rs2281636	0.894	rs1332103	chr10:101375896	A/G	cg17885402	chr10:101492224	COX15;CUTC	-0.39	-6.7	-0.31	6.76e-11	Obesity-related traits;
LUAD	cis	rs240764	0.853	rs12206182	chr6:101033379	A/C	cg09795085	chr6:101329169	ASCC3	-0.42	-7.09	-0.33	5.84e-12	Neuroticism;
LUAD	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg09491104	chr22:46646882	C22orf40	-0.67	-11.94	-0.5	1.67e-28	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.56	-10.07	-0.44	1.61e-21	Lymphocyte counts;
LUAD	cis	rs72945132	0.638	rs627079	chr11:70165505	G/T	cg05964544	chr11:70165517	PPFIA1	-0.54	-7.18	-0.33	3.13e-12	Coronary artery disease;
LUAD	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg10018233	chr7:150070692	REPIN1	0.52	8.13	0.37	4.74e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg27490568	chr2:178487706	NA	0.57	8.46	0.38	4.33e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg19678392	chr7:94953810	PON1	-0.57	-7.73	-0.35	7.93e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs78707713	0.560	rs35060419	chr10:71229539	A/G	cg12610070	chr10:71211762	TSPAN15	-0.38	-9.42	-0.42	2.95e-19	Venous thromboembolism;
LUAD	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg08773314	chr2:239334832	ASB1	0.41	9.35	0.41	5.22e-19	Multiple system atrophy;
LUAD	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg01448562	chr3:133502909	NA	-0.48	-8.23	-0.37	2.34e-15	Iron status biomarkers;
LUAD	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg19041857	chr6:27730383	NA	-0.39	-6.69	-0.31	6.95e-11	Parkinson's disease;
LUAD	cis	rs7107174	0.901	rs2450136	chr11:77925273	T/G	cg02023728	chr11:77925099	USP35	0.49	7.76	0.35	6.47e-14	Testicular germ cell tumor;
LUAD	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg21775007	chr8:11205619	TDH	0.38	6.66	0.31	8.53e-11	Retinal vascular caliber;
LUAD	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg11871910	chr12:69753446	YEATS4	0.52	8.13	0.37	4.69e-15	Blood protein levels;
LUAD	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg05865280	chr17:75406074	SEPT9	0.61	19.3	0.68	5.44e-60	Airflow obstruction;
LUAD	cis	rs3812762	0.957	rs7120004	chr11:8769097	A/G	cg03980550	chr11:8754370	ST5	0.37	6.43	0.3	3.54e-10	Hypospadias;
LUAD	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg13722127	chr7:150037890	RARRES2	-0.48	-8.57	-0.38	2.02e-16	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg03929089	chr4:120376271	NA	-0.92	-17.83	-0.66	2.01e-53	Height;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08713116	chr13:41885295	NAA16	-0.63	-6.55	-0.3	1.69e-10	Type 2 diabetes;
LUAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg11965913	chr1:205819406	PM20D1	0.46	7.43	0.34	6.22e-13	Parkinson's disease;
LUAD	cis	rs74181299	1.000	rs74181299	chr2:65283972	T/C	cg05010058	chr2:65284262	CEP68	0.31	6.81	0.31	3.31e-11	Pulse pressure;
LUAD	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg25208724	chr1:156163844	SLC25A44	0.86	8.7	0.39	7.19e-17	Paclitaxel disposition in epithelial ovarian cancer;
LUAD	cis	rs7945705	0.776	rs2316865	chr11:8815470	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.33	6.55	0.3	1.64e-10	Hemoglobin concentration;
LUAD	cis	rs7274811	0.744	rs6141962	chr20:32110312	T/C	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.46	-6.84	-0.32	2.73e-11	Height;
LUAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg18621852	chr3:10150065	C3orf24	0.49	8.83	0.39	2.72e-17	Alzheimer's disease;
LUAD	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg22815214	chr1:201083145	CACNA1S	0.54	9.55	0.42	1.03e-19	Permanent tooth development;
LUAD	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs2992756	0.663	rs2992753	chr1:18808292	A/C	cg24076588	chr1:18808559	KLHDC7A	0.46	7.67	0.35	1.18e-13	Breast cancer;
LUAD	cis	rs68170813	0.559	rs1121312	chr7:106927820	C/T	cg23024343	chr7:107201750	COG5	0.5	7.2	0.33	2.85e-12	Coronary artery disease;
LUAD	trans	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg21284400	chr1:149981654	OTUD7B	-0.39	-6.61	-0.31	1.16e-10	Longevity;Endometriosis;
LUAD	cis	rs790123	1.000	rs2650950	chr3:122382048	C/T	cg24850323	chr3:122379709	NA	0.37	6.58	0.3	1.39e-10	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-9.46	-0.42	2.14e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs870825	0.587	rs35377170	chr4:185639728	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.12	0.57	2.26e-37	Blood protein levels;
LUAD	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg07936489	chr17:37558343	FBXL20	0.45	7.09	0.33	5.62e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs250585	1.000	rs1468138	chr16:23535680	A/C	cg00143387	chr16:23521605	GGA2	-0.63	-7.49	-0.34	4.01e-13	Egg allergy;
LUAD	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.51	-0.34	3.51e-13	Coronary artery disease;
LUAD	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg00383909	chr3:49044727	WDR6	0.95	9.56	0.42	9.76e-20	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	trans	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.5	-0.3	2.28e-10	Aortic root size;
LUAD	cis	rs7814319	0.933	rs13260865	chr8:97238472	A/T	cg20787634	chr8:97240163	UQCRB	-0.38	-7.52	-0.34	3.35e-13	Lung function (FVC);
LUAD	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg02158880	chr13:53174818	NA	0.44	6.89	0.32	2.02e-11	Lewy body disease;
LUAD	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg04414720	chr1:150670196	GOLPH3L	0.72	12.86	0.53	3.46e-32	Melanoma;
LUAD	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg03714773	chr7:91764589	CYP51A1	-0.27	-6.54	-0.3	1.82e-10	Breast cancer;
LUAD	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg03806693	chr22:41940476	POLR3H	-0.53	-7.94	-0.36	1.81e-14	Vitiligo;
LUAD	cis	rs11249608	0.548	rs6867208	chr5:178455575	G/A	cg01312482	chr5:178451176	ZNF879	-0.46	-7.07	-0.33	6.52e-12	Pubertal anthropometrics;
LUAD	cis	rs6446731	0.593	rs7674472	chr4:3273538	C/G	cg08886695	chr4:3369023	RGS12	-0.5	-8.49	-0.38	3.46e-16	Mean platelet volume;
LUAD	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg23815491	chr16:72088622	HP	0.6	11.35	0.48	3.06e-26	Fibrinogen levels;
LUAD	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg04058563	chr4:185651563	MLF1IP	0.42	7.44	0.34	5.51e-13	Kawasaki disease;
LUAD	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg23018236	chr17:30244563	NA	-0.69	-8.47	-0.38	3.96e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg12458913	chr13:53173898	NA	0.46	8.13	0.37	4.63e-15	Lewy body disease;
LUAD	cis	rs2992756	0.625	rs2992752	chr1:18808526	A/C	cg14356550	chr1:18808102	KLHDC7A	-0.56	-9.85	-0.43	9.67e-21	Breast cancer;
LUAD	cis	rs9462027	0.628	rs7752060	chr6:34760325	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.0	-0.4	7.78e-18	Systemic lupus erythematosus;
LUAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14893161	chr1:205819251	PM20D1	0.82	17.23	0.64	8.85e-51	Menarche (age at onset);
LUAD	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg22482690	chr17:47019901	SNF8	0.46	8.94	0.4	1.21e-17	Type 2 diabetes;
LUAD	cis	rs2455799	0.634	rs13085226	chr3:15923750	C/T	cg16303742	chr3:15540471	COLQ	-0.47	-8.78	-0.39	4.22e-17	Mean platelet volume;
LUAD	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.32	-7.47	-0.34	4.54e-13	Lung cancer;
LUAD	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73206853	0.764	rs76142162	chr12:110884307	C/G	cg12870014	chr12:110450643	ANKRD13A	0.61	6.86	0.32	2.51e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg02030672	chr11:45687055	CHST1	-0.36	-6.37	-0.3	4.95e-10	Obesity-related traits;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03634887	chr16:66730948	CMTM4	-0.46	-7.42	-0.34	6.57e-13	Height;
LUAD	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	6.52	0.3	2.07e-10	Lung cancer in ever smokers;
LUAD	cis	rs727505	0.954	rs2170352	chr7:124605584	G/A	cg23710748	chr7:124431027	NA	-0.42	-8.38	-0.38	7.73e-16	Lewy body disease;
LUAD	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg00255919	chr5:131827918	IRF1	-0.47	-10.89	-0.47	1.67e-24	Asthma (sex interaction);
LUAD	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg18306943	chr3:40428807	ENTPD3	-0.38	-6.49	-0.3	2.47e-10	Renal cell carcinoma;
LUAD	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg26384229	chr12:38710491	ALG10B	0.52	8.6	0.39	1.55e-16	Heart rate;
LUAD	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg09085632	chr11:111637200	PPP2R1B	0.65	9.86	0.43	9.06e-21	Primary sclerosing cholangitis;
LUAD	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg22906224	chr7:99728672	NA	0.57	9.34	0.41	5.6e-19	Coronary artery disease;
LUAD	cis	rs2932538	0.885	rs3762335	chr1:113100548	C/T	cg22162597	chr1:113214053	CAPZA1	0.45	6.82	0.31	3.12e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.48	7.73	0.35	7.88e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg11584989	chr19:19387371	SF4	0.36	6.46	0.3	2.95e-10	Tonsillectomy;
LUAD	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg27661571	chr11:113659931	NA	-0.65	-7.63	-0.35	1.5700000000000001e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs11771526	0.786	rs11768955	chr7:32378706	T/C	cg27511599	chr7:32358540	NA	0.64	6.84	0.32	2.74e-11	Body mass index;
LUAD	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg23281280	chr6:28129359	ZNF389	0.48	6.68	0.31	7.61e-11	Depression;
LUAD	cis	rs10916814	1.000	rs12145310	chr1:20901064	C/A	cg24502330	chr1:20914028	CDA	-0.38	-7.12	-0.33	4.7e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	7.65	0.35	1.4e-13	Menopause (age at onset);
LUAD	cis	rs2302190	1.000	rs8065388	chr17:56562132	C/T	cg25885038	chr17:56607967	SEPT4	-0.42	-7.0	-0.32	9.84e-12	Vitamin D levels;
LUAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03647317	chr4:187891568	NA	-0.35	-6.47	-0.3	2.75e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1973993	0.745	rs6593602	chr1:96951281	G/A	cg10631902	chr5:14652156	NA	-0.46	-7.92	-0.36	2.14e-14	Weight;
LUAD	cis	rs713587	0.525	rs1541984	chr2:25082414	G/A	cg04586622	chr2:25135609	ADCY3	0.38	8.82	0.39	3.1e-17	Body mass index in non-asthmatics;
LUAD	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22496380	chr5:211416	CCDC127	0.95	13.29	0.54	6.5e-34	Breast cancer;
LUAD	cis	rs1395	0.778	rs2580761	chr2:27426362	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.5	8.87	0.4	2.02e-17	Blood metabolite levels;
LUAD	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg06784218	chr1:46089804	CCDC17	0.54	11.66	0.49	2.02e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21659725	chr3:3221576	CRBN	0.7	11.42	0.49	1.61e-26	Resting heart rate;
LUAD	trans	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.72	-9.76	-0.43	2e-20	Obesity-related traits;
LUAD	cis	rs12541635	0.967	rs13256474	chr8:107086419	T/C	cg10147462	chr8:107024639	NA	-0.42	-7.58	-0.35	2.24e-13	Age of smoking initiation;
LUAD	cis	rs12545109	0.879	rs1975285	chr8:57358682	G/C	cg17761419	chr8:57350749	NA	-0.58	-8.11	-0.37	5.59e-15	Obesity-related traits;
LUAD	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg11301795	chr4:187892539	NA	-0.78	-16.6	-0.63	5.3e-48	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg07606381	chr6:8435919	SLC35B3	0.41	6.83	0.32	2.98e-11	Motion sickness;
LUAD	cis	rs17092148	0.836	rs4564863	chr20:33179367	T/C	cg16810054	chr20:33298113	TP53INP2	-0.49	-7.57	-0.35	2.33e-13	Neuroticism;
LUAD	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg09033577	chr2:88485744	THNSL2	-0.6	-6.95	-0.32	1.36e-11	Plasma clusterin levels;
LUAD	trans	rs683250	0.931	rs671321	chr11:83292373	G/T	cg21475434	chr5:93447410	FAM172A	0.38	6.38	0.3	4.53e-10	Subcortical brain region volumes;
LUAD	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg01579765	chr21:45077557	HSF2BP	-0.61	-13.61	-0.55	2.94e-35	Mean corpuscular volume;
LUAD	cis	rs2235649	0.843	rs9932890	chr16:1847868	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.5	8.37	0.38	8.2e-16	Blood metabolite levels;
LUAD	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg04398451	chr17:18023971	MYO15A	-0.86	-15.65	-0.61	6.69e-44	Total body bone mineral density;
LUAD	cis	rs6701037	0.875	rs1057301	chr1:175126524	T/C	cg00321850	chr1:175162397	KIAA0040	-0.51	-10.81	-0.47	3.11e-24	Alcohol dependence;
LUAD	cis	rs11833313	1	rs11833313	chr12:110510470	A/G	cg12870014	chr12:110450643	ANKRD13A	0.8	8.02	0.36	1.03e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg16647868	chr5:131706066	SLC22A5	0.49	7.66	0.35	1.25e-13	Breast cancer;
LUAD	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg07917127	chr4:99064746	C4orf37	0.4	6.65	0.31	8.98e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg11663144	chr21:46675770	NA	-0.59	-11.23	-0.48	8.87e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg00310523	chr12:86230176	RASSF9	0.41	8.71	0.39	6.76e-17	Major depressive disorder;
LUAD	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg11859384	chr17:80120422	CCDC57	0.49	8.88	0.4	1.9e-17	Life satisfaction;
LUAD	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg17279839	chr7:150038598	RARRES2	0.47	7.86	0.36	3.31e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7107174	1.000	rs729354	chr11:77962453	T/A	cg19901956	chr11:77921274	USP35	-0.53	-6.81	-0.31	3.3e-11	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs57920188	0.703	rs3813810	chr1:4088339	G/T	cg10510935	chr1:4059661	NA	0.43	6.59	0.31	1.29e-10	Interleukin-17 levels;
LUAD	cis	rs7264396	0.563	rs2425090	chr20:34304783	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2.04e-15	Total cholesterol levels;
LUAD	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg12908607	chr1:44402522	ARTN	-0.46	-9.07	-0.4	4.61e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg27539214	chr16:67997921	SLC12A4	-0.65	-8.19	-0.37	3.02e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg18230493	chr5:56204884	C5orf35	-0.85	-12.49	-0.52	1.09e-30	Initial pursuit acceleration;
LUAD	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg15181151	chr6:150070149	PCMT1	0.36	7.14	0.33	4.13e-12	Lung cancer;
LUAD	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg16680214	chr1:154839983	KCNN3	-0.63	-13.3	-0.54	5.68e-34	Prostate cancer;
LUAD	trans	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.51	-0.38	3.11e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg02683114	chr2:24398427	C2orf84	-0.53	-7.82	-0.36	4.33e-14	Asthma;
LUAD	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg11062466	chr8:58055876	NA	0.55	7.48	0.34	4.27e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs9902453	0.654	rs3794809	chr17:28531258	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	8.79	0.39	3.79e-17	Coffee consumption (cups per day);
LUAD	cis	rs12949688	0.967	rs7220397	chr17:55823522	C/G	cg12582317	chr17:55822272	NA	0.37	7.35	0.34	1.06e-12	Schizophrenia;
LUAD	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg13073564	chr4:8508604	NA	-0.63	-11.39	-0.48	2.09e-26	Response to antineoplastic agents;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg07608032	chr19:21579862	ZNF493	0.4	6.67	0.31	8.1e-11	Anger;
LUAD	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg09365446	chr1:150670422	GOLPH3L	-0.49	-8.59	-0.39	1.72e-16	Tonsillectomy;
LUAD	cis	rs12545109	0.679	rs1973628	chr8:57429360	T/C	cg07776626	chr8:57350775	NA	-0.67	-7.94	-0.36	1.81e-14	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg23985595	chr17:80112537	CCDC57	0.45	8.02	0.36	1.05e-14	Life satisfaction;
LUAD	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	7.07	0.33	6.45e-12	Tonsillectomy;
LUAD	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg04586622	chr2:25135609	ADCY3	-0.36	-8.26	-0.37	1.94e-15	Body mass index;
LUAD	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs12545109	0.879	rs1975285	chr8:57358682	G/C	cg09654669	chr8:57350985	NA	-0.71	-9.89	-0.43	6.95e-21	Obesity-related traits;
LUAD	trans	rs9914544	0.545	rs3803835	chr17:18793061	C/T	cg21372672	chr17:16614065	CCDC144A	-0.36	-6.45	-0.3	3.04e-10	Educational attainment (years of education);
LUAD	trans	rs9929218	0.954	rs34097984	chr16:68824148	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.72	-0.53	1.32e-31	Colorectal cancer;
LUAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	12.53	0.52	7.29e-31	Lymphocyte counts;
LUAD	cis	rs7671266	0.668	rs10002562	chr4:10159736	C/G	cg02734326	chr4:10020555	SLC2A9	-0.51	-6.69	-0.31	7.31e-11	Cardiovascular disease risk factors;
LUAD	cis	rs4006360	0.560	rs3861283	chr17:39243940	C/G	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.27	0.37	1.75e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.75	-0.35	6.72e-14	Prostate cancer;
LUAD	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.53	9.04	0.4	5.59e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.54	0.3	1.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg04989706	chr14:50066350	PPIL5	-0.53	-7.72	-0.35	8.46e-14	Carotid intima media thickness;
LUAD	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg22139774	chr2:100720529	AFF3	-0.36	-7.0	-0.32	1.04e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg07460842	chr6:66804631	NA	-0.67	-11.76	-0.5	7.89e-28	Initial pursuit acceleration in psychotic disorders;
LUAD	trans	rs8073060	0.516	rs2376177	chr17:33938089	T/G	cg19694781	chr19:47549865	TMEM160	-1.26	-20.33	-0.7	1.31e-64	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs6543140	0.865	rs6760275	chr2:103079607	C/T	cg04239558	chr2:103089729	SLC9A4	0.36	7.3	0.33	1.47e-12	Blood protein levels;
LUAD	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg08632164	chr7:65971372	NA	0.37	6.41	0.3	3.96e-10	Aortic root size;
LUAD	cis	rs2882667	0.824	rs12173085	chr5:138480025	A/G	cg04439458	chr5:138467593	SIL1	-0.56	-10.02	-0.44	2.32e-21	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg19622623	chr12:86230825	RASSF9	-0.38	-6.76	-0.31	4.59e-11	Major depressive disorder;
LUAD	cis	rs1524976	0.698	rs9864728	chr3:65486793	A/C	cg16238336	chr3:65465873	MAGI1	0.64	7.37	0.34	9.02e-13	PR interval;
LUAD	cis	rs55788414	0.527	rs2873368	chr16:81184208	C/G	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.91	-0.36	2.31e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg21399703	chr1:247681439	NA	-0.43	-8.23	-0.37	2.41e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4389656	0.625	rs7712516	chr5:6745571	A/T	cg10857441	chr5:6722123	POLS	-0.44	-7.41	-0.34	7.05e-13	Coronary artery disease;
LUAD	cis	rs12545109	0.613	rs10958480	chr8:57278717	A/T	cg21220214	chr8:57350948	NA	-0.64	-8.71	-0.39	7.12e-17	Obesity-related traits;
LUAD	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg12062639	chr20:23401060	NAPB	1.08	11.0	0.47	6.14e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6460942	0.732	rs73677576	chr7:12286535	G/A	cg06484146	chr7:12443880	VWDE	-0.5	-6.41	-0.3	3.95e-10	Coronary artery disease;
LUAD	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg15467112	chr14:75489610	MLH3	0.35	6.36	0.3	5.33e-10	Height;
LUAD	cis	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg27411982	chr8:10470053	RP1L1	0.36	6.35	0.3	5.49e-10	Systolic blood pressure;
LUAD	trans	rs2797160	1.000	rs1612249	chr6:126014916	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.58e-17	Endometrial cancer;
LUAD	trans	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.06	-27.02	-0.8	3.65e-94	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg06740227	chr12:86229804	RASSF9	-0.41	-7.36	-0.34	9.88e-13	Major depressive disorder;
LUAD	cis	rs7536201	1.000	rs7555518	chr1:25299404	T/A	cg23273869	chr1:25296894	NA	-0.39	-8.07	-0.37	7.56e-15	Psoriasis vulgaris;
LUAD	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg14668632	chr7:2872130	GNA12	-0.48	-8.48	-0.38	3.89e-16	Height;
LUAD	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg18404041	chr3:52824283	ITIH1	-0.41	-7.55	-0.34	2.65e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg01416388	chr22:39784598	NA	-0.52	-8.64	-0.39	1.17e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs2242073	0.935	rs12468692	chr2:209002111	T/A	cg06181187	chr2:209010896	CRYGB	0.36	6.37	0.3	4.96e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.29	-7.0	-0.32	9.85e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg11871910	chr12:69753446	YEATS4	0.7	12.21	0.51	1.35e-29	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg04995722	chr7:26192034	NFE2L3	-0.41	-7.06	-0.32	6.93e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg18446336	chr7:2847575	GNA12	-0.34	-6.4	-0.3	4.17e-10	Height;
LUAD	cis	rs1595825	0.891	rs73054817	chr2:198623751	A/G	cg00982548	chr2:198649783	BOLL	-0.65	-9.06	-0.4	4.77e-18	Ulcerative colitis;
LUAD	cis	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg07460842	chr6:66804631	NA	1.08	16.84	0.63	4.38e-49	Exhaled nitric oxide output;
LUAD	cis	rs1997103	0.911	rs9642575	chr7:55399090	C/T	cg17469321	chr7:55412551	NA	0.67	11.41	0.49	1.73e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg18512352	chr11:47633146	NA	-0.38	-6.71	-0.31	6.39e-11	Subjective well-being;
LUAD	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg07343612	chr16:622815	PIGQ	-0.8	-15.98	-0.61	2.62e-45	Height;
LUAD	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg26022315	chr17:47021804	SNF8	0.41	7.37	0.34	9.33e-13	Type 2 diabetes;
LUAD	cis	rs55665837	0.540	rs10832299	chr11:14769392	G/A	cg19336497	chr11:14380999	RRAS2	-0.4	-7.51	-0.34	3.58e-13	Vitamin D levels;
LUAD	trans	rs7395662	1.000	rs115224187	chr11:48757499	G/A	cg15704280	chr7:45808275	SEPT13	0.45	6.87	0.32	2.25e-11	HDL cholesterol;
LUAD	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg00784671	chr22:46762841	CELSR1	-0.62	-7.71	-0.35	8.92e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs41271473	0.898	rs12028277	chr1:228829657	A/G	cg16512390	chr1:228756714	NA	0.56	8.08	0.37	6.63e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg05340658	chr4:99064831	C4orf37	0.53	9.05	0.4	5.17e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.86	-0.32	2.48e-11	Fear of minor pain;
LUAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg11693508	chr17:37793320	STARD3	0.77	10.05	0.44	1.84e-21	Bipolar disorder;
LUAD	cis	rs7084921	0.526	rs11594323	chr10:101880479	G/A	cg19754520	chr10:101825118	CPN1	-0.31	-6.44	-0.3	3.2e-10	Bone mineral density;
LUAD	cis	rs2735413	0.958	rs7192416	chr16:78063143	C/T	cg04733911	chr16:78082701	NA	-0.35	-8.22	-0.37	2.55e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02743136	chr17:75398583	SEPT9	0.46	6.49	0.3	2.37e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9522267	0.502	rs9522281	chr13:112222389	G/A	cg10483660	chr13:112241077	NA	-0.32	-6.96	-0.32	1.28e-11	Hepatitis;
LUAD	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs637571	0.607	rs574586	chr11:65697083	G/A	cg17712092	chr4:129076599	LARP1B	1.0	20.35	0.7	1.05e-64	Eosinophil percentage of white cells;
LUAD	cis	rs3791556	0.501	rs3791533	chr2:240100616	G/A	cg03281426	chr2:240109471	HDAC4	0.46	8.66	0.39	9.95e-17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg13271783	chr10:134563150	INPP5A	-0.41	-6.43	-0.3	3.37e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg18867708	chr6:26865862	GUSBL1	0.42	6.65	0.31	9.29e-11	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10932289	chr17:55038442	COIL	-0.53	-6.36	-0.3	5.25e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg01448562	chr3:133502909	NA	-0.59	-11.32	-0.48	3.98e-26	Ankle injury;
LUAD	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg17200465	chr3:40428508	ENTPD3	0.27	6.56	0.3	1.54e-10	Renal cell carcinoma;
LUAD	cis	rs7953508	0.506	rs930316	chr12:93967035	A/G	cg18151635	chr12:93972918	NA	-0.79	-11.91	-0.5	2.05e-28	Pubertal anthropometrics;
LUAD	cis	rs12681287	0.640	rs12679811	chr8:87465370	T/C	cg27223183	chr8:87520930	FAM82B	-0.68	-9.59	-0.42	7.69e-20	Caudate activity during reward;
LUAD	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg11663144	chr21:46675770	NA	-0.61	-12.24	-0.51	1.11e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg01448562	chr3:133502909	NA	-0.48	-8.25	-0.37	2.01e-15	Iron status biomarkers;
LUAD	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg02753203	chr1:228287806	NA	-0.46	-8.33	-0.38	1.13e-15	Diastolic blood pressure;
LUAD	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg25554036	chr4:6271136	WFS1	0.66	12.65	0.52	2.55e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg05665937	chr4:1216051	CTBP1	0.44	7.51	0.34	3.64e-13	Obesity-related traits;
LUAD	cis	rs863345	0.526	rs857723	chr1:158604000	C/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.47	-0.3	2.73e-10	Pneumococcal bacteremia;
LUAD	cis	rs77741769	0.571	rs3861797	chr12:121255334	T/C	cg02419362	chr12:121203948	SPPL3	0.41	8.39	0.38	7.24e-16	Mean corpuscular volume;
LUAD	cis	rs12681287	0.517	rs34367154	chr8:87508749	A/T	cg27223183	chr8:87520930	FAM82B	-0.71	-10.12	-0.44	1.07e-21	Caudate activity during reward;
LUAD	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg08085267	chr17:45401833	C17orf57	0.59	10.64	0.46	1.43e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg24642844	chr7:1081250	C7orf50	-0.98	-14.87	-0.59	1.54e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg06002616	chr8:101225028	SPAG1	0.37	7.51	0.34	3.47e-13	Atrioventricular conduction;
LUAD	trans	rs7944735	0.507	rs7114598	chr11:48101766	C/T	cg03929089	chr4:120376271	NA	0.63	8.98	0.4	8.71e-18	Intraocular pressure;
LUAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg07404485	chr7:94953653	PON1	-0.49	-9.27	-0.41	9.89e-19	Paraoxonase activity;
LUAD	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.52	-8.23	-0.37	2.35e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs240764	0.619	rs9399652	chr6:101120006	C/T	cg09795085	chr6:101329169	ASCC3	-0.38	-6.35	-0.3	5.53e-10	Neuroticism;
LUAD	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.3	-0.33	1.44e-12	Bipolar disorder;
LUAD	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg15448220	chr1:150897856	SETDB1	-0.57	-10.03	-0.44	2.15e-21	Melanoma;
LUAD	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg26343298	chr8:95960752	TP53INP1	0.4	8.5	0.38	3.22e-16	Type 2 diabetes;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg24132989	chr6:88050339	C6orf162	0.38	6.35	0.3	5.53e-10	Schizophrenia;
LUAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.5	-9.46	-0.42	2.1e-19	Lymphocyte counts;
LUAD	cis	rs497273	0.517	rs580240	chr12:121199903	T/G	cg02419362	chr12:121203948	SPPL3	0.38	7.61	0.35	1.77e-13	Systemic lupus erythematosus;
LUAD	cis	rs870825	0.860	rs28696121	chr4:185598743	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	12.48	0.52	1.22e-30	Blood protein levels;
LUAD	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg15147215	chr3:52552868	STAB1	-0.39	-7.19	-0.33	2.99e-12	Electroencephalogram traits;
LUAD	trans	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg21659725	chr3:3221576	CRBN	-0.59	-9.5	-0.42	1.61e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg12365402	chr11:9010492	NRIP3	0.48	8.82	0.39	2.95e-17	Hemoglobin concentration;
LUAD	cis	rs4601821	0.583	rs1893696	chr11:113206275	G/A	cg14159747	chr11:113255604	NA	0.36	6.65	0.31	9.18e-11	Alcoholic chronic pancreatitis;
LUAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.87	16.46	0.62	2.16e-47	Lymphocyte counts;
LUAD	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg13393036	chr8:95962371	TP53INP1	-0.31	-6.49	-0.3	2.43e-10	Type 2 diabetes;
LUAD	cis	rs669446	0.533	rs11210913	chr1:44222597	G/A	cg12908607	chr1:44402522	ARTN	-0.37	-7.15	-0.33	3.96e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs10979	0.964	rs35826562	chr6:143898672	G/A	cg25407410	chr6:143891975	LOC285740	-0.65	-10.29	-0.45	2.7e-22	Hypospadias;
LUAD	cis	rs2625529	0.617	rs2128112	chr15:72186286	A/T	cg16672083	chr15:72433130	SENP8	0.62	11.84	0.5	3.81e-28	Red blood cell count;
LUAD	cis	rs73086581	1.000	rs73086544	chr20:3950928	C/A	cg02187196	chr20:3869020	PANK2	0.46	6.49	0.3	2.34e-10	Response to antidepressants in depression;
LUAD	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg14847009	chr1:175162515	KIAA0040	-0.33	-8.68	-0.39	8.67e-17	Alcohol dependence;
LUAD	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs853679	0.607	rs13217984	chr6:28139710	A/T	cg01620082	chr3:125678407	NA	-1.1	-10.38	-0.45	1.25e-22	Depression;
LUAD	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg18854424	chr1:2615690	NA	0.43	9.44	0.42	2.53e-19	Ulcerative colitis;
LUAD	cis	rs7582720	0.832	rs115194657	chr2:203829284	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.49	0.45	4.78e-23	Colorectal cancer;
LUAD	cis	rs6835098	1.000	rs28477433	chr4:174085820	T/C	cg27433088	chr4:174089019	GALNT7	0.39	7.5	0.34	3.85e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg17971929	chr21:40555470	PSMG1	0.53	8.38	0.38	8.1e-16	Cognitive function;
LUAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14159672	chr1:205819179	PM20D1	-0.5	-8.18	-0.37	3.39e-15	Parkinson's disease;
LUAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.31e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg16049864	chr8:95962084	TP53INP1	0.39	7.48	0.34	4.44e-13	Type 2 diabetes;
LUAD	cis	rs2046867	0.819	rs34132129	chr3:72829100	A/G	cg25664220	chr3:72788482	NA	-0.71	-12.58	-0.52	4.58e-31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9633740	0.773	rs1870148	chr10:82271341	G/A	cg01528321	chr10:82214614	TSPAN14	0.75	9.6	0.42	7.4e-20	Post bronchodilator FEV1;
LUAD	cis	rs755249	0.564	rs6691194	chr1:39948741	G/A	cg27567593	chr1:39956653	BMP8A	0.35	7.18	0.33	3.13e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg11965913	chr1:205819406	PM20D1	0.96	23.24	0.75	1.37e-77	Menarche (age at onset);
LUAD	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg13180566	chr4:1052158	NA	-0.38	-6.52	-0.3	1.96e-10	Recombination rate (females);
LUAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg04025307	chr7:1156635	C7orf50	0.6	6.77	0.31	4.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg24069376	chr3:38537580	EXOG	0.37	8.39	0.38	7.29e-16	Electrocardiographic conduction measures;
LUAD	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg01324343	chr3:183735012	ABCC5	0.94	25.48	0.78	1.85e-87	Anterior chamber depth;
LUAD	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg20503657	chr10:835505	NA	0.96	14.64	0.58	1.52e-39	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.16	0.37	3.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14893161	chr1:205819251	PM20D1	0.61	11.51	0.49	7.39e-27	Menarche (age at onset);
LUAD	cis	rs859767	0.540	rs6739706	chr2:135407409	A/C	cg12500956	chr2:135428796	TMEM163	-0.28	-7.56	-0.34	2.55e-13	Neuroticism;
LUAD	cis	rs2625529	0.590	rs12904652	chr15:72548765	T/C	cg16672083	chr15:72433130	SENP8	-0.66	-11.72	-0.5	1.15e-27	Red blood cell count;
LUAD	cis	rs11676348	0.729	rs13013361	chr2:218947515	A/T	cg06547715	chr2:218990976	CXCR2	0.41	9.8	0.43	1.43e-20	Ulcerative colitis;
LUAD	cis	rs6754311	0.684	rs11681248	chr2:136820076	C/T	cg07305463	chr2:136567211	LCT	0.34	6.53	0.3	1.87e-10	Mosquito bite size;
LUAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.49	-0.3	2.38e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg18755752	chr8:142205143	DENND3	-0.46	-8.11	-0.37	5.35e-15	Immature fraction of reticulocytes;
LUAD	cis	rs6062509	1.000	rs6011066	chr20:62364180	G/A	cg01176363	chr20:62369445	LIME1	-0.48	-7.65	-0.35	1.35e-13	Prostate cancer;
LUAD	cis	rs12155623	0.578	rs13277226	chr8:49883029	G/T	cg22283653	chr8:49824208	NA	-0.38	-7.74	-0.35	7.22e-14	Sudden cardiac arrest;
LUAD	cis	rs7586879	1.000	rs12713419	chr2:25121853	G/A	cg04586622	chr2:25135609	ADCY3	0.33	6.86	0.32	2.51e-11	Body mass index;
LUAD	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.65	0.31	9.11e-11	Depression;
LUAD	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg04287289	chr16:89883240	FANCA	0.8	7.02	0.32	9.05e-12	Skin colour saturation;
LUAD	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg06552810	chr11:31128660	NA	-0.34	-6.71	-0.31	6.14e-11	Red blood cell count;
LUAD	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.43	-6.88	-0.32	2.17e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs250677	0.798	rs11168080	chr5:148409821	C/T	cg18129178	chr5:148520854	ABLIM3	-0.6	-8.54	-0.38	2.5e-16	Breast cancer;
LUAD	cis	rs752010	0.841	rs7519983	chr1:42083369	C/T	cg06885757	chr1:42089581	HIVEP3	0.42	9.3	0.41	7.54e-19	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs2692947	0.644	rs3821051	chr2:96912787	A/G	cg23100626	chr2:96804247	ASTL	-0.34	-8.76	-0.39	4.78e-17	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11890956	chr21:40555474	PSMG1	0.82	14.64	0.58	1.49e-39	Cognitive function;
LUAD	cis	rs123509	0.687	rs73075301	chr3:42832650	C/T	cg12982090	chr3:42733453	KBTBD5	-0.53	-9.02	-0.4	6.41e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg20701182	chr2:24300061	SF3B14	0.89	13.35	0.54	3.48e-34	Lymphocyte counts;
LUAD	cis	rs11640533	0.901	rs2908792	chr16:53412419	A/G	cg10144400	chr16:53407678	NA	0.4	6.94	0.32	1.51e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg05110241	chr16:68378359	PRMT7	-0.97	-10.7	-0.46	8.21e-24	Schizophrenia;
LUAD	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg22875332	chr1:76189707	ACADM	0.96	22.66	0.74	5.02e-75	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg00933542	chr6:150070202	PCMT1	0.35	7.41	0.34	7.13e-13	Testicular germ cell tumor;
LUAD	cis	rs886126	0.761	rs10774615	chr12:111659096	T/C	cg10833066	chr12:111807467	FAM109A	0.55	10.4	0.45	1.02e-22	Coronary heart disease;
LUAD	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.35	-7.58	-0.35	2.21e-13	Hemoglobin concentration;
LUAD	trans	rs10411161	0.702	rs11879336	chr19:52389627	C/T	cg22319618	chr22:45562946	NUP50	-0.63	-8.37	-0.38	8.38e-16	Breast cancer;
LUAD	trans	rs2235573	0.625	rs139905	chr22:38409596	C/T	cg19894588	chr14:64061835	NA	-0.41	-6.47	-0.3	2.67e-10	Glioblastoma;Glioma;
LUAD	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg24558204	chr6:135376177	HBS1L	0.46	8.58	0.38	1.87e-16	Red blood cell count;
LUAD	cis	rs11214589	0.935	rs2186800	chr11:113242860	G/A	cg14159747	chr11:113255604	NA	0.68	14.52	0.58	4.59e-39	Neuroticism;
LUAD	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.64	-0.31	9.37e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7799006	0.929	rs745565	chr7:2256689	G/C	cg08027265	chr7:2291960	NA	-0.61	-10.73	-0.46	6.54e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs427941	0.703	rs201453	chr7:101739788	T/C	cg06246474	chr7:101738831	CUX1	0.41	7.25	0.33	1.98e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg25894440	chr7:65020034	NA	0.61	6.58	0.3	1.37e-10	Diabetic kidney disease;
LUAD	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg00290607	chr11:67383545	NA	0.4	6.58	0.3	1.36e-10	Mean corpuscular volume;
LUAD	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg12311346	chr5:56204834	C5orf35	-0.92	-13.47	-0.55	1.2e-34	Initial pursuit acceleration;
LUAD	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg13390004	chr1:15929781	NA	0.47	8.34	0.38	1.06e-15	Systolic blood pressure;
LUAD	cis	rs1692580	0.777	rs10910037	chr1:2184280	T/C	cg24578937	chr1:2090814	PRKCZ	0.56	10.87	0.47	2e-24	Coronary artery disease;
LUAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-10.88	-0.47	1.84e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs2625529	0.652	rs2957728	chr15:72236432	G/T	cg16672083	chr15:72433130	SENP8	0.63	11.85	0.5	3.72e-28	Red blood cell count;
LUAD	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg07708487	chr16:89387014	ANKRD11	-0.34	-6.79	-0.31	3.86e-11	Multiple myeloma (IgH translocation);
LUAD	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	8.79	0.39	3.68e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg26043149	chr18:55253948	FECH	0.51	8.31	0.37	1.35e-15	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7584330	0.697	rs7574337	chr2:238439503	A/G	cg14458575	chr2:238380390	NA	0.55	10.09	0.44	1.32e-21	Prostate cancer;
LUAD	cis	rs758324	0.812	rs12653237	chr5:131241778	C/T	cg25547332	chr5:131281432	NA	0.42	6.9	0.32	1.9e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg19046167	chr17:80928561	B3GNTL1	0.42	6.39	0.3	4.31e-10	Glycated hemoglobin levels;
LUAD	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg12292205	chr6:26970375	C6orf41	0.38	6.61	0.31	1.15e-10	Schizophrenia;
LUAD	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.55	-0.34	2.69e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg21130718	chr4:1044621	NA	0.47	8.15	0.37	4.04e-15	Recombination rate (males);
LUAD	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg00484396	chr16:3507460	NAT15	-0.69	-11.71	-0.49	1.2100000000000001e-27	Tuberculosis;
LUAD	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg03609598	chr5:56110824	MAP3K1	0.41	6.54	0.3	1.75e-10	Coronary artery disease;
LUAD	trans	rs853679	0.607	rs35001169	chr6:28187632	T/G	cg01620082	chr3:125678407	NA	-1.1	-10.34	-0.45	1.67e-22	Depression;
LUAD	cis	rs7975161	0.608	rs10861169	chr12:104610640	C/T	cg25273343	chr12:104657179	TXNRD1	-0.52	-7.93	-0.36	1.91e-14	Toenail selenium levels;
LUAD	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg00933542	chr6:150070202	PCMT1	0.43	8.84	0.4	2.51e-17	Lung cancer;
LUAD	trans	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg19862616	chr7:65841803	NCRNA00174	1.04	25.7	0.78	2.02e-88	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg08999081	chr20:33150536	PIGU	0.62	13.92	0.56	1.54e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg23985595	chr17:80112537	CCDC57	0.52	9.54	0.42	1.11e-19	Life satisfaction;
LUAD	cis	rs1595825	0.891	rs73054825	chr2:198636355	G/C	cg00982548	chr2:198649783	BOLL	-0.66	-9.5	-0.42	1.54e-19	Ulcerative colitis;
LUAD	cis	rs7625357	0.599	rs9831902	chr3:169322313	A/G	cg14572252	chr3:169309425	MECOM	-0.47	-7.88	-0.36	2.89e-14	Childhood and early adolescence aggressive behavior;
LUAD	cis	rs367943	1.000	rs348929	chr5:112814883	T/A	cg12552261	chr5:112820674	MCC	-0.58	-11.04	-0.47	4.66e-25	Type 2 diabetes;
LUAD	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg02896835	chr1:92012615	NA	0.54	8.25	0.37	2.07e-15	Eosinophil percentage of white cells;
LUAD	trans	rs8002861	0.934	rs9533685	chr13:44468331	A/G	cg17145862	chr1:211918768	LPGAT1	0.77	18.34	0.67	1.04e-55	Leprosy;
LUAD	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg03647317	chr4:187891568	NA	-0.34	-6.36	-0.3	5.32e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9427116	0.967	rs7547072	chr1:154639255	A/G	cg17218026	chr1:154582156	ADAR	-0.39	-7.58	-0.35	2.14e-13	Blood protein levels;
LUAD	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg25985355	chr7:65971099	NA	-0.53	-6.55	-0.3	1.66e-10	Diabetic kidney disease;
LUAD	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.75	-0.31	4.78e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg22823121	chr1:150693482	HORMAD1	0.45	9.17	0.41	2.15e-18	Tonsillectomy;
LUAD	cis	rs77972916	0.536	rs7589361	chr2:43589328	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-7.68	-0.35	1.08e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7178572	0.568	rs3743478	chr15:77400388	T/C	cg15453836	chr15:77711506	NA	-0.37	-6.43	-0.3	3.55e-10	Type 2 diabetes;
LUAD	cis	rs9473147	0.516	rs4715018	chr6:47441871	T/C	cg20196966	chr6:47445060	CD2AP	0.43	6.54	0.3	1.83e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg03433033	chr1:76189801	ACADM	0.88	16.54	0.63	9.52e-48	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg12698349	chr2:225449008	CUL3	0.67	10.12	0.44	1.04e-21	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs2387326	1.000	rs2387328	chr10:129925986	C/T	cg16087940	chr10:129947807	NA	-0.49	-6.5	-0.3	2.32e-10	Select biomarker traits;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05147328	chr17:79849438	ANAPC11;THOC4	0.46	7.35	0.34	1.03e-12	Monocyte percentage of white cells;
LUAD	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12379764	chr21:47803548	PCNT	0.67	11.42	0.49	1.62e-26	Testicular germ cell tumor;
LUAD	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg07757535	chr4:1339547	NA	0.29	6.38	0.3	4.76e-10	Longevity;
LUAD	cis	rs62229266	0.771	rs7277791	chr21:37383227	C/A	cg08632701	chr21:37451849	NA	-0.46	-7.61	-0.35	1.75e-13	Mitral valve prolapse;
LUAD	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg06453172	chr10:134556979	INPP5A	0.43	6.93	0.32	1.59e-11	Migraine;
LUAD	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg03864215	chr11:17408437	KCNJ11	-0.32	-6.44	-0.3	3.2e-10	Type 2 diabetes;
LUAD	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.56	-0.3	1.54e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg08048268	chr3:133502702	NA	-0.46	-8.47	-0.38	4.16e-16	Iron status biomarkers;
LUAD	cis	rs3733418	0.929	rs13134940	chr4:165889612	G/A	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-6.98	-0.32	1.12e-11	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6740322	0.948	rs6715072	chr2:43562230	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-10.77	-0.46	4.5e-24	Coronary artery disease;
LUAD	cis	rs7945718	0.967	rs1440286	chr11:12809152	G/A	cg25843174	chr11:12811716	TEAD1	0.25	7.57	0.35	2.31e-13	Educational attainment (years of education);
LUAD	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg25985355	chr7:65971099	NA	0.37	6.83	0.31	3.05e-11	Aortic root size;
LUAD	cis	rs7937890	0.559	rs2597197	chr11:14489832	G/A	cg06199346	chr11:14280333	SPON1	-0.33	-6.53	-0.3	1.94e-10	Mitochondrial DNA levels;
LUAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7799006	0.634	rs34502289	chr7:2311266	G/A	cg08027265	chr7:2291960	NA	-0.71	-13.85	-0.56	3.07e-36	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11771526	0.901	rs62457467	chr7:32301101	T/A	cg13207630	chr7:32358064	NA	0.58	7.23	0.33	2.21e-12	Body mass index;
LUAD	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg21862992	chr11:68658383	NA	-0.51	-9.42	-0.42	3.06e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg12935359	chr14:103987150	CKB	-0.44	-7.02	-0.32	8.99e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg01028140	chr2:1542097	TPO	-0.43	-7.1	-0.33	5.14e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg07936489	chr17:37558343	FBXL20	0.45	7.06	0.32	6.82e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg18827107	chr12:86230957	RASSF9	0.7	13.05	0.54	5.84e-33	Major depressive disorder;
LUAD	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	-0.73	-8.37	-0.38	8.34e-16	Yeast infection;
LUAD	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg11502198	chr6:26597334	ABT1	0.67	11.69	0.49	1.56e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg21963583	chr11:68658836	MRPL21	0.64	11.64	0.49	2.44e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs783540	0.632	rs17356528	chr15:83305550	A/G	cg16105309	chr15:79090380	ADAMTS7	0.42	7.54	0.34	2.83e-13	Schizophrenia;
LUAD	cis	rs2235649	0.561	rs12599786	chr16:1965257	T/G	cg08610935	chr16:1836813	NUBP2	-0.49	-7.25	-0.33	1.98e-12	Blood metabolite levels;
LUAD	cis	rs2019216	0.542	rs7405615	chr17:21935430	C/G	cg22648282	chr17:21454238	C17orf51	-0.48	-8.2	-0.37	3.01e-15	Pelvic organ prolapse;
LUAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg23958373	chr8:599963	NA	1.0	9.69	0.43	3.59e-20	IgG glycosylation;
LUAD	cis	rs9427116	0.502	rs9427100	chr1:154583762	G/A	cg17218026	chr1:154582156	ADAR	0.5	9.91	0.43	5.69e-21	Blood protein levels;
LUAD	cis	rs909002	1.000	rs2292993	chr1:32140733	C/T	cg13919466	chr1:32135498	COL16A1	-0.43	-10.6	-0.46	1.91e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs6500395	1.000	rs11859909	chr16:48668441	T/C	cg04672837	chr16:48644449	N4BP1	0.38	6.69	0.31	7.06e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs11811982	0.793	rs75714085	chr1:227325816	C/A	cg24860534	chr1:227506868	CDC42BPA	0.66	7.22	0.33	2.41e-12	Optic disc area;
LUAD	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg16989719	chr2:238392110	NA	-0.38	-7.99	-0.36	1.25e-14	Prostate cancer;
LUAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg02951883	chr7:2050386	MAD1L1	-0.82	-13.8	-0.56	5.08e-36	Bipolar disorder and schizophrenia;
LUAD	trans	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg18187862	chr3:45730750	SACM1L	0.49	7.75	0.35	6.89e-14	Primary sclerosing cholangitis;
LUAD	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.31	6.41	0.3	3.79e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	7.49	0.34	4.01e-13	Menarche (age at onset);
LUAD	cis	rs847851	0.917	rs6912327	chr6:34764922	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-7.55	-0.34	2.73e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1561198	0.523	rs2040349	chr2:85889525	A/C	cg02493740	chr2:85810744	VAMP5	-0.44	-7.58	-0.35	2.27e-13	Coronary artery disease;
LUAD	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg02782426	chr3:40428986	ENTPD3	0.31	6.61	0.31	1.15e-10	Renal cell carcinoma;
LUAD	cis	rs2262909	0.962	rs11669110	chr19:22296485	A/G	cg11619707	chr19:22235551	ZNF257	0.49	7.5	0.34	3.84e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2625529	0.586	rs2306489	chr15:72227471	G/A	cg16672083	chr15:72433130	SENP8	0.63	11.71	0.49	1.2100000000000001e-27	Red blood cell count;
LUAD	cis	rs7707921	1.000	rs79616997	chr5:81504600	G/T	cg15871215	chr5:81402204	ATG10	-0.71	-10.18	-0.44	6.5600000000000005e-22	Breast cancer;
LUAD	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg05110241	chr16:68378359	PRMT7	-0.94	-10.59	-0.46	2.15e-23	Magnesium levels;
LUAD	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg04414720	chr1:150670196	GOLPH3L	0.72	12.71	0.53	1.49e-31	Melanoma;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg03039399	chr16:3930658	CREBBP	0.45	6.82	0.31	3.24e-11	QT interval;
LUAD	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	7.94	0.36	1.81e-14	Tonsillectomy;
LUAD	cis	rs10979	1.000	rs6570566	chr6:143899534	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.2	-0.44	5.25e-22	Hypospadias;
LUAD	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg25173405	chr17:45401733	C17orf57	-0.41	-6.54	-0.3	1.77e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.91	0.32	1.82e-11	Hypertriglyceridemia;
LUAD	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.5	0.34	3.72e-13	Tonsillectomy;
LUAD	cis	rs12049351	0.774	rs4925455	chr1:229623665	T/A	cg11742688	chr1:229674241	ABCB10	-0.41	-6.56	-0.3	1.59e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs11622475	1.000	rs2368984	chr14:104372055	A/C	cg12183467	chr14:104352244	NA	-0.42	-7.61	-0.35	1.75e-13	Bipolar disorder;
LUAD	cis	rs155346	1.000	rs265159	chr5:139390752	A/G	cg01090482	chr5:139365336	NRG2	-0.33	-6.53	-0.3	1.9e-10	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUAD	cis	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.72	-0.35	8.21e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg19610905	chr11:61596333	FADS2	-0.67	-10.81	-0.47	3.33e-24	Bipolar disorder;
LUAD	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg22875332	chr1:76189707	ACADM	-0.65	-10.35	-0.45	1.58e-22	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg17366294	chr4:99064904	C4orf37	0.48	8.48	0.38	3.84e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7614311	0.636	rs73117041	chr3:63896266	A/T	cg22134162	chr3:63841271	THOC7	-0.52	-8.58	-0.39	1.78e-16	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs8014204	0.806	rs11159105	chr14:75298052	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.35	-6.68	-0.31	7.32e-11	Caffeine consumption;
LUAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08280861	chr8:58055591	NA	0.54	6.74	0.31	5.21e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11676348	0.808	rs4674261	chr2:219005009	G/C	cg06547715	chr2:218990976	CXCR2	0.33	7.49	0.34	4.19e-13	Ulcerative colitis;
LUAD	cis	rs1728785	1.000	rs4783653	chr16:68562815	C/T	cg02508848	chr16:68573721	ZFP90	-0.41	-6.55	-0.3	1.66e-10	Ulcerative colitis;
LUAD	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg07636037	chr3:49044803	WDR6	0.35	6.48	0.3	2.61e-10	Resting heart rate;
LUAD	cis	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg12800200	chr2:69260302	ANTXR1	0.37	6.37	0.3	4.94e-10	Breast cancer;
LUAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg05665937	chr4:1216051	CTBP1	0.44	7.51	0.34	3.6e-13	Obesity-related traits;
LUAD	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.8	-0.35	4.75e-14	Neutrophil percentage of white cells;
LUAD	cis	rs10465746	0.935	rs12410617	chr1:84379461	G/C	cg10977910	chr1:84465055	TTLL7	0.5	8.05	0.36	8.43e-15	Obesity-related traits;
LUAD	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg14416269	chr4:6271139	WFS1	0.59	12.2	0.51	1.5e-29	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs11640533	0.901	rs2908792	chr16:53412419	A/G	cg08681685	chr16:53407594	NA	0.43	7.39	0.34	7.91e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7851660	0.844	rs13287360	chr9:100637681	A/G	cg13688889	chr9:100608707	NA	-0.52	-8.69	-0.39	7.94e-17	Strep throat;
LUAD	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.81	0.35	4.6e-14	Parkinson's disease;
LUAD	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg00647820	chr17:40259828	DHX58	-0.45	-7.2	-0.33	2.75e-12	Fibrinogen levels;
LUAD	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.94	14.47	0.58	7.63e-39	Schizophrenia;
LUAD	cis	rs4664304	1.000	rs4664304	chr2:160794008	A/G	cg23995753	chr2:160760732	LY75	-0.48	-8.39	-0.38	7.25e-16	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	12.15	0.51	2.52e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs886126	0.950	rs6490025	chr12:111691081	T/C	cg10833066	chr12:111807467	FAM109A	0.55	9.97	0.44	3.61e-21	Coronary heart disease;
LUAD	trans	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-8.65	-0.39	1.11e-16	Brugada syndrome;
LUAD	cis	rs11048434	0.736	rs35870866	chr12:9129091	C/A	cg04155231	chr12:9217510	LOC144571	0.42	7.9	0.36	2.36e-14	Sjögren's syndrome;
LUAD	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg19318889	chr4:1322082	MAEA	0.45	7.28	0.33	1.61e-12	Obesity-related traits;
LUAD	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg24818145	chr4:99064322	C4orf37	0.49	8.11	0.37	5.73e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg03929089	chr4:120376271	NA	-0.45	-6.91	-0.32	1.78e-11	HDL cholesterol;
LUAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg04267008	chr7:1944627	MAD1L1	0.62	9.25	0.41	1.09e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg15704280	chr7:45808275	SEPT13	0.77	12.58	0.52	4.62e-31	Coronary artery disease;
LUAD	trans	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg26384229	chr12:38710491	ALG10B	0.39	6.43	0.3	3.45e-10	Morning vs. evening chronotype;
LUAD	cis	rs62238980	0.522	rs117390331	chr22:32461489	T/C	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg00074818	chr8:8560427	CLDN23	-0.59	-9.22	-0.41	1.43e-18	Obesity-related traits;
LUAD	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg18016565	chr1:150552671	MCL1	-0.41	-7.23	-0.33	2.22e-12	Tonsillectomy;
LUAD	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg16479474	chr6:28041457	NA	0.44	7.45	0.34	5.43e-13	Depression;
LUAD	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg21724239	chr8:58056113	NA	0.69	8.75	0.39	5.21e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.55	-0.89	3.42e-144	Myeloid white cell count;
LUAD	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.69	-6.77	-0.31	4.35e-11	Body mass index;
LUAD	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg18512352	chr11:47633146	NA	-0.4	-6.92	-0.32	1.64e-11	Subjective well-being;
LUAD	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg23533926	chr12:111358616	MYL2	-0.42	-7.05	-0.32	7.23e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg24733560	chr20:60626293	TAF4	0.43	7.31	0.34	1.3e-12	Body mass index;
LUAD	cis	rs3761847	0.622	rs10435888	chr9:123819603	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	6.49	0.3	2.38e-10	Rheumatoid arthritis;
LUAD	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg06191203	chr2:152266755	RIF1	-0.49	-7.2	-0.33	2.84e-12	Lung cancer;
LUAD	cis	rs490234	0.616	rs2648318	chr9:128163447	T/C	cg14078157	chr9:128172775	NA	-0.49	-9.32	-0.41	6.33e-19	Mean arterial pressure;
LUAD	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg07507251	chr3:52567010	NT5DC2	0.37	7.34	0.34	1.09e-12	Bipolar disorder;
LUAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00149659	chr3:10157352	C3orf10	0.61	8.68	0.39	8.54e-17	Alzheimer's disease;
LUAD	cis	rs300703	0.719	rs423314	chr2:195372	A/G	cg21211680	chr2:198530	NA	0.64	8.73	0.39	5.9e-17	Blood protein levels;
LUAD	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg03806693	chr22:41940476	POLR3H	-0.44	-6.77	-0.31	4.33e-11	Neuroticism;
LUAD	cis	rs7301016	1.000	rs11174494	chr12:62864877	A/T	cg11441379	chr12:63026424	NA	0.54	6.9	0.32	1.96e-11	IgG glycosylation;
LUAD	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg17724175	chr1:150552817	MCL1	0.39	9.39	0.42	3.82e-19	Tonsillectomy;
LUAD	cis	rs7937890	0.559	rs2575825	chr11:14472096	T/C	cg22961513	chr11:14280813	SPON1	-0.37	-7.02	-0.32	8.67e-12	Mitochondrial DNA levels;
LUAD	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg06808227	chr14:105710500	BRF1	-0.43	-6.71	-0.31	6.41e-11	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs8062405	0.756	rs151182	chr16:28495752	C/T	cg00204512	chr16:28754710	NA	0.33	6.87	0.32	2.24e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs853679	0.607	rs66886492	chr6:28089731	C/T	cg01620082	chr3:125678407	NA	-1.09	-10.25	-0.45	3.5e-22	Depression;
LUAD	trans	rs7395662	0.929	rs10838934	chr11:48547072	G/A	cg00717180	chr2:96193071	NA	-0.4	-7.45	-0.34	5.38e-13	HDL cholesterol;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23061114	chr2:95540265	TEKT4	-0.47	-6.91	-0.32	1.8e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg21963583	chr11:68658836	MRPL21	0.64	11.16	0.48	1.53e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs11039798	1.000	rs10160423	chr11:48457227	G/T	cg03929089	chr4:120376271	NA	0.57	6.61	0.31	1.18e-10	Axial length;
LUAD	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg26384229	chr12:38710491	ALG10B	0.49	7.97	0.36	1.46e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06873352	chr17:61820015	STRADA	0.83	18.35	0.67	9.13e-56	Prudent dietary pattern;
LUAD	cis	rs7177699	0.557	rs4389113	chr15:79121739	G/A	cg00540400	chr15:79124168	NA	-0.46	-9.77	-0.43	1.78e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg26022315	chr17:47021804	SNF8	0.41	7.38	0.34	8.45e-13	Type 2 diabetes;
LUAD	cis	rs713587	0.521	rs35177510	chr2:25089594	C/A	cg01884057	chr2:25150051	NA	0.33	6.97	0.32	1.23e-11	Body mass index in non-asthmatics;
LUAD	cis	rs4903214	1.000	rs2024244	chr14:74710864	C/A	cg11132536	chr14:74711944	VSX2	-0.41	-6.4	-0.3	4.14e-10	Inflammatory bowel disease;
LUAD	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.77e-11	Depression;
LUAD	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg17644776	chr2:200775616	C2orf69	0.56	7.41	0.34	6.87e-13	Schizophrenia;
LUAD	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.63	0.31	1.05e-10	Parkinson's disease;
LUAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg26818010	chr10:134567672	INPP5A	-0.98	-16.24	-0.62	1.94e-46	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs859767	0.741	rs35599954	chr2:135392481	T/C	cg12500956	chr2:135428796	TMEM163	-0.31	-8.09	-0.37	6.56e-15	Neuroticism;
LUAD	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg19875535	chr5:140030758	IK	-0.4	-6.67	-0.31	8.15e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg05564831	chr3:52568323	NT5DC2	-0.36	-6.54	-0.3	1.82e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs3960554	0.932	rs4728597	chr7:75821062	C/T	cg19862616	chr7:65841803	NCRNA00174	0.82	10.79	0.46	3.72e-24	Eotaxin levels;
LUAD	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg03929089	chr4:120376271	NA	0.55	7.15	0.33	3.93e-12	Axial length;
LUAD	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26314531	chr2:26401878	FAM59B	-0.76	-10.76	-0.46	4.88e-24	Gut microbiome composition (summer);
LUAD	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.12	0.33	4.64e-12	Tonsillectomy;
LUAD	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg19622623	chr12:86230825	RASSF9	-0.47	-8.04	-0.36	9.08e-15	Major depressive disorder;
LUAD	trans	rs6684428	0.536	rs4573554	chr1:56398037	C/T	cg23598080	chr1:180204499	LHX4	0.31	6.39	0.3	4.32e-10	Airflow obstruction;
LUAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08677398	chr8:58056175	NA	0.47	6.58	0.3	1.37e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg15110403	chr19:17392923	ANKLE1	-0.46	-7.44	-0.34	5.65e-13	Systemic lupus erythematosus;
LUAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg21605333	chr4:119757512	SEC24D	0.93	8.76	0.39	4.9e-17	Cannabis dependence symptom count;
LUAD	cis	rs9796	0.689	rs72737758	chr15:41449778	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.46	-8.41	-0.38	6.2e-16	Menopause (age at onset);
LUAD	cis	rs11809207	1.000	rs11809207	chr1:26521140	G/A	cg00300879	chr1:26503847	CNKSR1	0.29	7.04	0.32	7.9e-12	Height;
LUAD	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg01689657	chr7:91764605	CYP51A1	0.35	8.74	0.39	5.52e-17	Breast cancer;
LUAD	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg11766577	chr21:47581405	C21orf56	-0.44	-7.62	-0.35	1.73e-13	Testicular germ cell tumor;
LUAD	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg21252483	chr19:49399788	TULP2	-0.88	-14.3	-0.57	3.88e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg04111992	chr7:158790115	NA	-0.42	-7.18	-0.33	3.1e-12	Facial morphology (factor 20);
LUAD	cis	rs2033908	0.619	rs10765994	chr11:12850819	A/G	cg25843174	chr11:12811716	TEAD1	0.21	6.46	0.3	2.93e-10	Sitting height ratio;
LUAD	cis	rs9796	0.689	rs9888710	chr15:41446153	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.45	-8.34	-0.38	1.08e-15	Menopause (age at onset);
LUAD	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.35	-0.38	9.63e-16	Prostate cancer;
LUAD	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg19346786	chr7:2764209	NA	-0.52	-11.25	-0.48	7.47e-26	Height;
LUAD	cis	rs12612619	0.732	rs2289360	chr2:27302165	T/C	cg00617064	chr2:27272375	NA	-0.37	-7.0	-0.32	1.03e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs2797160	1.000	rs1777222	chr6:126021030	C/T	cg05901451	chr6:126070800	HEY2	0.43	6.51	0.3	2.13e-10	Endometrial cancer;
LUAD	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg12292205	chr6:26970375	C6orf41	0.37	6.58	0.3	1.36e-10	Schizophrenia;
LUAD	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg06618935	chr21:46677482	NA	-0.5	-10.0	-0.44	2.83e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6494488	0.500	rs72741332	chr15:64744790	T/C	cg08069370	chr15:64387884	SNX1	-0.76	-6.75	-0.31	4.76e-11	Coronary artery disease;
LUAD	cis	rs9900062	0.546	rs2428352	chr17:62694738	C/T	cg02097616	chr17:62675921	NA	-0.74	-12.64	-0.52	2.71e-31	QT interval;
LUAD	cis	rs2731664	0.792	rs2630763	chr5:176901005	T/A	cg23176889	chr5:176863531	GRK6	-0.71	-13.45	-0.55	1.45e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg22907277	chr7:1156413	C7orf50	0.49	8.21	0.37	2.62e-15	Longevity;Endometriosis;
LUAD	cis	rs3790645	0.874	rs9438508	chr1:26893069	T/C	cg23229016	chr1:26872525	RPS6KA1	0.21	6.96	0.32	1.31e-11	Glucose homeostasis traits;
LUAD	cis	rs1476679	1.000	rs34919929	chr7:100012334	G/A	cg19116668	chr7:99932089	PMS2L1	0.32	6.73	0.31	5.63e-11	Alzheimer's disease (late onset);
LUAD	cis	rs7737355	0.773	rs28852	chr5:131027842	A/C	cg25547332	chr5:131281432	NA	0.44	7.11	0.33	5.12e-12	Life satisfaction;
LUAD	cis	rs3803170	0.513	rs7299142	chr12:111829513	G/A	cg10833066	chr12:111807467	FAM109A	0.47	8.71	0.39	6.67e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.6	10.36	0.45	1.41e-22	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.59	0.31	1.33e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg05754148	chr16:3507555	NAT15	-0.43	-6.62	-0.31	1.07e-10	Body mass index (adult);
LUAD	cis	rs6062509	0.732	rs6062304	chr20:62351539	A/T	cg21849932	chr20:62369462	LIME1	-0.46	-7.28	-0.33	1.6e-12	Prostate cancer;
LUAD	cis	rs4889855	0.556	rs11547301	chr17:78518780	C/T	cg16591659	chr17:78472290	NA	0.43	7.45	0.34	5.18e-13	Fractional excretion of uric acid;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12361356	chr1:200708503	CAMSAP1L1	-0.38	-6.42	-0.3	3.6e-10	Cancer;
LUAD	cis	rs56309584	0.523	rs3027172	chr17:8055723	A/G	cg08322244	chr17:8066669	VAMP2	-0.47	-6.37	-0.3	5.02e-10	Initial pursuit acceleration;
LUAD	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg23166289	chr1:210001082	C1orf107	0.49	6.87	0.32	2.26e-11	Orofacial clefts;
LUAD	cis	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.41	7.88	0.36	2.87e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4929949	0.545	rs11042032	chr11:8696872	A/T	cg10639395	chr11:8710044	RPL27A	0.38	7.03	0.32	8.54e-12	Body mass index;
LUAD	cis	rs10089	1.000	rs59484271	chr5:127503781	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.58	8.46	0.38	4.36e-16	Ileal carcinoids;
LUAD	cis	rs4812048	0.793	rs62205397	chr20:57597011	C/T	cg14073986	chr20:57617431	SLMO2	0.62	7.64	0.35	1.5e-13	Mean platelet volume;
LUAD	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg14092988	chr3:52407081	DNAH1	0.45	8.88	0.4	1.87e-17	Bipolar disorder;
LUAD	cis	rs938554	0.737	rs10939637	chr4:9977577	A/G	cg11266682	chr4:10021025	SLC2A9	0.43	7.58	0.35	2.17e-13	Blood metabolite levels;
LUAD	cis	rs754466	1.000	rs12220328	chr10:79681482	G/C	cg17075019	chr10:79541650	NA	-0.8	-13.28	-0.54	6.89e-34	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.44	-0.3	3.35e-10	Triglycerides;
LUAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg08219700	chr8:58056026	NA	0.43	6.52	0.3	2.06e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.29	6.51	0.3	2.18e-10	Parkinson's disease;
LUAD	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.33	-6.99	-0.32	1.09e-11	Schizophrenia;
LUAD	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg27279351	chr12:120934652	DYNLL1	0.43	6.49	0.3	2.34e-10	High light scatter reticulocyte count;
LUAD	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg16988262	chr1:15930761	NA	0.43	7.27	0.33	1.74e-12	Systolic blood pressure;
LUAD	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.09	0.37	6.38e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.42	6.93	0.32	1.59e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs904251	0.523	rs2776920	chr6:37480605	G/A	cg25019722	chr6:37503610	NA	-0.33	-7.54	-0.34	2.95e-13	Cognitive performance;
LUAD	cis	rs11811982	0.793	rs75330309	chr1:227509115	T/C	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs4481887	0.861	rs4486480	chr1:248449714	C/T	cg00666640	chr1:248458726	OR2T12	0.34	8.08	0.37	6.97e-15	Common traits (Other);
LUAD	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg18129748	chr3:49941408	MST1R	-0.4	-6.55	-0.3	1.7e-10	Body mass index;
LUAD	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg07432352	chr17:45403706	C17orf57	-0.4	-7.87	-0.36	3.05e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21582582	chr3:182698605	DCUN1D1	0.46	7.58	0.35	2.17e-13	Body mass index;
LUAD	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.57	-8.86	-0.4	2.24e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.46	0.34	5.03e-13	Bipolar disorder;
LUAD	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg05082376	chr22:42548792	NA	0.45	7.8	0.35	4.73e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7665090	1.000	rs7665854	chr4:103551909	C/A	cg07973026	chr4:103553119	MANBA	0.48	8.53	0.38	2.63e-16	Primary biliary cholangitis;
LUAD	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg07636037	chr3:49044803	WDR6	0.48	8.0	0.36	1.2e-14	Menarche (age at onset);
LUAD	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.94	-0.32	1.52e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg07460842	chr6:66804631	NA	-1.06	-16.65	-0.63	3.15e-48	Exhaled nitric oxide output;
LUAD	trans	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg14791747	chr16:20752902	THUMPD1	0.51	7.59	0.35	2.08e-13	Pancreatic cancer;
LUAD	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.78	0.39	4.18e-17	Menopause (age at onset);
LUAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg13047869	chr3:10149882	C3orf24	0.64	11.02	0.47	5.16e-25	Alzheimer's disease;
LUAD	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg23096020	chr7:158799433	NA	-0.36	-6.56	-0.3	1.53e-10	Facial morphology (factor 20);
LUAD	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg06221963	chr1:154839813	KCNN3	-0.84	-19.74	-0.69	5.89e-62	Prostate cancer;
LUAD	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg10523679	chr1:76189770	ACADM	-0.72	-11.18	-0.48	1.31e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg21496419	chr19:44306685	LYPD5	0.41	9.24	0.41	1.24e-18	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg27490568	chr2:178487706	NA	0.63	9.16	0.41	2.26e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9658691	0.607	rs12412701	chr10:90782323	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.58	-7.21	-0.33	2.64e-12	Mosquito bite size;
LUAD	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg01475377	chr6:109611718	NA	-0.54	-10.46	-0.45	6.18e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs2239547	0.603	rs7644973	chr3:53082937	C/T	cg11645453	chr3:52864694	ITIH4	0.54	9.9	0.43	6.49e-21	Schizophrenia;
LUAD	trans	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg21659725	chr3:3221576	CRBN	-0.39	-6.57	-0.3	1.45e-10	Resting heart rate;
LUAD	cis	rs4845570	0.920	rs11810571	chr1:151762308	C/G	cg07092448	chr1:151763213	TDRKH	0.73	9.37	0.41	4.28e-19	Coronary artery disease;
LUAD	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg18351406	chr4:77819688	ANKRD56	0.62	10.01	0.44	2.71e-21	Emphysema distribution in smoking;
LUAD	cis	rs9329289	0.510	rs1155447	chr10:2553240	C/T	cg15501526	chr10:2543763	NA	0.52	11.25	0.48	7.09e-26	Age-related hearing impairment;
LUAD	cis	rs9394841	0.667	rs1891453	chr6:41765265	T/C	cg25600774	chr6:41776562	USP49	-0.44	-6.7	-0.31	6.63e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs9427116	0.875	rs11264233	chr1:154625632	C/T	cg17218026	chr1:154582156	ADAR	0.43	8.39	0.38	7.18e-16	Blood protein levels;
LUAD	cis	rs4604732	0.527	rs60444724	chr1:247623164	T/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.39	6.75	0.31	4.92e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg14019146	chr3:50243930	SLC38A3	-0.42	-6.78	-0.31	4.02e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7943953	0.714	rs1453533	chr11:59200069	A/C	cg00706994	chr11:59190310	OR5A2	0.34	6.37	0.3	4.95e-10	Odorant perception (&beta-ionone);
LUAD	cis	rs17401966	1.000	rs12402052	chr1:10318652	C/G	cg15208524	chr1:10270712	KIF1B	0.56	8.21	0.37	2.64e-15	Hepatocellular carcinoma;
LUAD	cis	rs494562	0.892	rs490079	chr6:86117599	T/C	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs250677	0.522	rs10477400	chr5:148359598	T/C	cg12140854	chr5:148520817	ABLIM3	0.55	8.44	0.38	5.11e-16	Breast cancer;
LUAD	cis	rs10489202	0.608	rs10800334	chr1:168075613	T/C	cg25738037	chr1:168025549	DCAF6	-0.45	-6.55	-0.3	1.64e-10	Schizophrenia;
LUAD	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg05714579	chr10:131428358	MGMT	0.4	6.54	0.3	1.77e-10	Response to temozolomide;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg15555402	chr12:19593456	AEBP2	-0.5	-8.66	-0.39	1.02e-16	Schizophrenia;
LUAD	cis	rs4919694	0.901	rs12251035	chr10:104671459	A/C	cg04362960	chr10:104952993	NT5C2	0.74	7.94	0.36	1.84e-14	Arsenic metabolism;
LUAD	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg00814883	chr7:100076585	TSC22D4	-0.87	-13.12	-0.54	3.02e-33	Platelet count;
LUAD	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg22029157	chr1:209979665	IRF6	0.47	8.43	0.38	5.57e-16	Monobrow;
LUAD	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg07741184	chr6:167504864	NA	0.31	7.26	0.33	1.93e-12	Crohn's disease;
LUAD	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg20108693	chr8:143823809	SLURP1	0.31	7.2	0.33	2.8e-12	Urinary tract infection frequency;
LUAD	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg16680214	chr1:154839983	KCNN3	-0.62	-11.98	-0.5	1.14e-28	Prostate cancer;
LUAD	cis	rs2354432	0.714	rs7531962	chr1:146746023	G/A	cg25205988	chr1:146714368	CHD1L	-0.66	-7.05	-0.32	7.3e-12	Mitochondrial DNA levels;
LUAD	cis	rs10916814	0.959	rs12037522	chr1:20900184	A/T	cg24502330	chr1:20914028	CDA	-0.38	-7.12	-0.33	4.7e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2742417	1.000	rs2742447	chr3:45763977	C/T	cg10512202	chr3:45649293	LIMD1	0.39	6.97	0.32	1.23e-11	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg25233709	chr10:116636983	FAM160B1	0.41	8.26	0.37	1.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6987853	0.686	rs55837592	chr8:42359974	T/C	cg09913449	chr8:42400586	C8orf40	-0.43	-8.12	-0.37	4.98e-15	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs877282	0.853	rs11595507	chr10:756703	C/T	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg24112000	chr20:60950667	NA	-0.74	-10.57	-0.46	2.55e-23	Colorectal cancer;
LUAD	cis	rs758324	0.947	rs1875177	chr5:131202625	T/C	cg25547332	chr5:131281432	NA	0.44	6.75	0.31	5e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg03806693	chr22:41940476	POLR3H	-0.58	-8.78	-0.39	3.96e-17	Vitiligo;
LUAD	cis	rs7017914	0.967	rs13271442	chr8:71585169	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.58	-0.3	1.43e-10	Bone mineral density;
LUAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg26554054	chr8:600488	NA	-0.79	-6.78	-0.31	4.06e-11	IgG glycosylation;
LUAD	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg05590025	chr7:65112418	INTS4L2	0.75	7.92	0.36	2.07e-14	Diabetic kidney disease;
LUAD	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg10589385	chr1:150898437	SETDB1	0.41	7.75	0.35	7.13e-14	Melanoma;
LUAD	cis	rs2294693	0.891	rs4714420	chr6:40992799	T/C	cg14769373	chr6:40998127	UNC5CL	-0.52	-7.96	-0.36	1.58e-14	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg13319975	chr6:146136371	FBXO30	-0.64	-11.02	-0.47	5.35e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8017423	0.967	rs8015510	chr14:90729984	C/T	cg14092571	chr14:90743983	NA	-0.47	-8.26	-0.37	1.88e-15	Mortality in heart failure;
LUAD	cis	rs1371614	0.611	rs540490	chr2:27132822	A/T	cg00617064	chr2:27272375	NA	0.36	6.88	0.32	2.21e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg09137382	chr11:130731461	NA	-0.41	-7.54	-0.34	2.97e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg21775007	chr8:11205619	TDH	0.36	6.4	0.3	4.07e-10	Neuroticism;
LUAD	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg18721089	chr20:30220636	NA	-0.47	-6.78	-0.31	3.96e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg06766960	chr11:133703094	NA	0.43	8.22	0.37	2.43e-15	Childhood ear infection;
LUAD	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.23	0.54	1.09e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs13315871	0.790	rs28502788	chr3:58296208	A/T	cg12435725	chr3:58293450	RPP14	-0.75	-8.52	-0.38	2.81e-16	Cholesterol, total;
LUAD	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.82	0.43	1.24e-20	Menarche (age at onset);
LUAD	trans	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg24644049	chr4:85504048	CDS1	0.89	7.32	0.34	1.22e-12	Skin colour saturation;
LUAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.38	-0.38	7.93e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg18876405	chr7:65276391	NA	-0.42	-7.13	-0.33	4.24e-12	Calcium levels;
LUAD	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg24848339	chr3:12840334	CAND2	0.48	9.95	0.44	4.18e-21	QRS complex (12-leadsum);
LUAD	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg09065629	chr16:1709722	CRAMP1L	0.4	6.99	0.32	1.04e-11	Coronary artery disease;
LUAD	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.37	-6.79	-0.31	3.88e-11	Caffeine consumption;
LUAD	cis	rs17433780	0.897	rs12120863	chr1:89501522	T/C	cg09516651	chr1:89888402	LOC400759	0.52	9.21	0.41	1.54e-18	Carotid intima media thickness;
LUAD	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg25985355	chr7:65971099	NA	0.55	6.6	0.31	1.23e-10	Diabetic kidney disease;
LUAD	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg13944838	chr5:179740914	GFPT2	-0.78	-13.73	-0.56	9.75e-36	Height;
LUAD	cis	rs6688613	0.685	rs11579987	chr1:166889364	C/G	cg07049167	chr1:166818506	POGK	-0.51	-7.62	-0.35	1.66e-13	Refractive astigmatism;
LUAD	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg22683308	chr4:1340831	KIAA1530	-0.48	-7.8	-0.35	4.8e-14	Longevity;
LUAD	cis	rs4072705	0.615	rs4838189	chr9:127248926	C/A	cg13476313	chr9:127244764	NR5A1	0.36	8.83	0.39	2.83e-17	Menarche (age at onset);
LUAD	cis	rs62400317	0.859	rs6919873	chr6:45159336	A/G	cg18551225	chr6:44695536	NA	-0.56	-8.65	-0.39	1.05e-16	Total body bone mineral density;
LUAD	cis	rs877282	0.945	rs71491311	chr10:791747	G/A	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	cis	rs6076065	0.723	rs2424554	chr20:23415867	T/C	cg11657817	chr20:23433608	CST11	0.48	8.75	0.39	5.05e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg08132940	chr7:1081526	C7orf50	-0.44	-6.55	-0.3	1.66e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg23352942	chr3:46931381	PTH1R	-0.38	-7.71	-0.35	9.07e-14	Birth weight;
LUAD	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg15017067	chr4:17643749	FAM184B	-0.37	-7.12	-0.33	4.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11126435	0.858	rs12995909	chr2:74933615	C/A	cg19285774	chr2:74907978	SEMA4F	0.36	6.4	0.3	4.14e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.42	2.48e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs9388451	0.505	rs9372828	chr6:126175185	A/T	cg05901451	chr6:126070800	HEY2	-0.59	-9.58	-0.42	8.22e-20	Brugada syndrome;
LUAD	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg06131755	chr6:160182447	ACAT2	0.45	6.92	0.32	1.66e-11	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg04414720	chr1:150670196	GOLPH3L	0.67	11.78	0.5	6.79e-28	Melanoma;
LUAD	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg12310025	chr6:25882481	NA	-0.82	-13.73	-0.56	9.29e-36	Blood metabolite levels;
LUAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg03188948	chr7:1209495	NA	0.84	11.23	0.48	8.58e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg20712883	chr12:51590929	POU6F1	0.48	7.56	0.35	2.49e-13	Cisplatin-induced ototoxicity;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg09529323	chr19:56041778	SBK2	-0.39	-6.5	-0.3	2.33e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg10589385	chr1:150898437	SETDB1	0.39	7.41	0.34	6.98e-13	Tonsillectomy;
LUAD	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg23018236	chr17:30244563	NA	-0.69	-8.34	-0.38	1.02e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg03605463	chr16:89740564	NA	-0.67	-12.59	-0.52	4.33e-31	Vitiligo;
LUAD	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg20891558	chr2:74357851	NA	1.0	15.47	0.6	4.36e-43	Gestational age at birth (maternal effect);
LUAD	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg03233332	chr7:66118400	NA	0.44	6.73	0.31	5.38e-11	Aortic root size;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg16529440	chr12:93323219	EEA1	-0.42	-6.93	-0.32	1.63e-11	Schizophrenia;
LUAD	trans	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg26043149	chr18:55253948	FECH	-0.41	-6.57	-0.3	1.49e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08219700	chr8:58056026	NA	0.64	8.59	0.39	1.75e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg02527881	chr3:46936655	PTH1R	-0.54	-11.14	-0.48	1.92e-25	Colorectal cancer;
LUAD	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg13575925	chr12:9217583	LOC144571	0.39	7.33	0.34	1.2e-12	Sjögren's syndrome;
LUAD	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.61	10.35	0.45	1.55e-22	Cognitive ability;
LUAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13012494	chr21:47604986	C21orf56	0.65	11.3	0.48	4.73e-26	Testicular germ cell tumor;
LUAD	cis	rs3106136	0.527	rs2632410	chr4:95149507	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.24	-0.45	3.92e-22	Capecitabine sensitivity;
LUAD	cis	rs4601821	0.635	rs7114433	chr11:113208098	C/T	cg14159747	chr11:113255604	NA	0.39	7.34	0.34	1.08e-12	Alcoholic chronic pancreatitis;
LUAD	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg01065977	chr19:18549689	ISYNA1	-0.39	-7.55	-0.34	2.63e-13	Breast cancer;
LUAD	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg04450456	chr4:17643702	FAM184B	0.4	7.89	0.36	2.59e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg15704280	chr7:45808275	SEPT13	-0.87	-15.96	-0.61	3.14e-45	Coronary artery disease;
LUAD	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg09509183	chr1:209979624	IRF6	0.52	7.79	0.35	5.15e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg26408565	chr15:76604113	ETFA	-0.42	-6.51	-0.3	2.12e-10	Blood metabolite levels;
LUAD	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg11833968	chr6:79620685	NA	-0.42	-7.87	-0.36	2.92e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg20673091	chr1:2541236	MMEL1	-0.4	-8.57	-0.38	1.97e-16	Ulcerative colitis;
LUAD	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg17344932	chr17:38183730	MED24;SNORD124	0.71	14.55	0.58	3.57e-39	Myeloid white cell count;
LUAD	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg15704280	chr7:45808275	SEPT13	-0.92	-17.9	-0.66	9.54e-54	Coronary artery disease;
LUAD	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg11645453	chr3:52864694	ITIH4	0.33	6.43	0.3	3.45e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg01689657	chr7:91764605	CYP51A1	0.33	8.35	0.38	9.91e-16	Breast cancer;
LUAD	cis	rs354225	0.553	rs7564719	chr2:54829731	A/C	cg01766943	chr2:54829624	SPTBN1	0.4	7.42	0.34	6.6e-13	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.68	-0.35	1.1e-13	Diabetic kidney disease;
LUAD	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg21709803	chr11:61594965	FADS2	-0.41	-7.24	-0.33	2.19e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg00310523	chr12:86230176	RASSF9	0.4	8.01	0.36	1.13e-14	Major depressive disorder;
LUAD	cis	rs7264396	0.563	rs2425079	chr20:34298191	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2.04e-15	Total cholesterol levels;
LUAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg00776166	chr8:613548	NA	0.54	6.83	0.32	2.92e-11	IgG glycosylation;
LUAD	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg10518543	chr12:38710700	ALG10B	-0.43	-7.1	-0.33	5.2e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg05872129	chr22:39784769	NA	-0.81	-15.73	-0.61	3.17e-44	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.49	-0.42	1.7e-19	Life satisfaction;
LUAD	cis	rs1232027	0.656	rs1650658	chr5:79963651	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.15	-0.33	3.76e-12	Huntington's disease progression;
LUAD	cis	rs73086581	0.741	rs17212649	chr20:3853093	A/G	cg02187196	chr20:3869020	PANK2	0.49	6.76	0.31	4.52e-11	Response to antidepressants in depression;
LUAD	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg16988262	chr1:15930761	NA	0.41	6.92	0.32	1.65e-11	Systolic blood pressure;
LUAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	8.31	0.37	1.27e-15	Alzheimer's disease;
LUAD	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg02807482	chr3:125708958	NA	-0.57	-7.95	-0.36	1.69e-14	Blood pressure (smoking interaction);
LUAD	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg08601574	chr20:25228251	PYGB	0.44	8.12	0.37	5.33e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs11039798	1.000	rs10838942	chr11:48557163	C/G	cg15704280	chr7:45808275	SEPT13	0.63	7.23	0.33	2.25e-12	Axial length;
LUAD	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg05665937	chr4:1216051	CTBP1	0.39	6.64	0.31	9.6e-11	Obesity-related traits;
LUAD	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg07538946	chr5:131705188	SLC22A5	0.53	8.67	0.39	9.58e-17	Blood metabolite levels;
LUAD	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg18171855	chr10:2543474	NA	0.35	6.89	0.32	1.98e-11	Age-related hearing impairment;
LUAD	cis	rs9811920	0.515	rs792836	chr3:99476384	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.76	-0.39	4.64e-17	Axial length;
LUAD	cis	rs7107174	0.892	rs2512548	chr11:77962116	A/G	cg02023728	chr11:77925099	USP35	0.45	7.02	0.32	8.84e-12	Testicular germ cell tumor;
LUAD	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg00316803	chr15:76480434	C15orf27	-0.43	-8.51	-0.38	2.98e-16	Blood metabolite levels;
LUAD	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg11494091	chr17:61959527	GH2	0.42	7.92	0.36	2.12e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	13.29	0.54	6.29e-34	Lymphocyte counts;
LUAD	cis	rs8044868	0.512	rs4788461	chr16:72156000	C/A	cg23815491	chr16:72088622	HP	0.5	9.28	0.41	9.08e-19	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs9814567	0.679	rs1880379	chr3:134330612	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	9.84	0.43	1.06e-20	Ileal carcinoids;
LUAD	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.71	-0.35	9.01e-14	Resting heart rate;
LUAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08219700	chr8:58056026	NA	0.57	8.08	0.37	6.8e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg03676636	chr4:99064102	C4orf37	0.29	7.47	0.34	4.5e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3931020	0.548	rs2134836	chr1:75271646	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.46	7.38	0.34	8.27e-13	Resistin levels;
LUAD	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg11859384	chr17:80120422	CCDC57	0.43	7.7	0.35	9.88e-14	Life satisfaction;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08222081	chr3:150264537	SERP1;EIF2A	-0.66	-6.68	-0.31	7.7e-11	Type 2 diabetes;
LUAD	cis	rs17362650	0.653	rs13020173	chr2:9548651	T/G	cg12832956	chr2:9616023	IAH1	-0.49	-8.34	-0.38	1.06e-15	Alcohol dependence (age at onset);
LUAD	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg09137382	chr11:130731461	NA	-0.37	-6.48	-0.3	2.6e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3087591	0.920	rs11080150	chr17:29629326	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.42	-6.76	-0.31	4.65e-11	Hip circumference;
LUAD	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg27539214	chr16:67997921	SLC12A4	-0.66	-8.31	-0.37	1.32e-15	Schizophrenia;
LUAD	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg15921436	chr17:44337874	NA	0.6	7.99	0.36	1.26e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg27170947	chr2:26402098	FAM59B	-0.68	-9.38	-0.41	4.21e-19	Gut microbiome composition (summer);
LUAD	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg13736514	chr6:26305472	NA	0.51	8.64	0.39	1.17e-16	Educational attainment;
LUAD	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg06784218	chr1:46089804	CCDC17	0.51	11.26	0.48	6.76e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg02018176	chr4:1364513	KIAA1530	0.48	8.81	0.39	3.21e-17	Longevity;
LUAD	cis	rs12681287	0.571	rs13254675	chr8:87353594	C/T	cg27223183	chr8:87520930	FAM82B	-0.69	-9.66	-0.43	4.38e-20	Caudate activity during reward;
LUAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11905131	chr22:24372483	LOC391322	-0.55	-9.44	-0.42	2.55e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2004318	1.000	rs2555685	chr19:55067465	C/T	cg03320607	chr19:54800032	LILRA3	0.58	7.3	0.33	1.47e-12	Blood protein levels;
LUAD	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg16342193	chr10:102329863	NA	-0.34	-6.37	-0.3	4.96e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs4891159	0.548	rs10782013	chr18:74128348	C/T	cg24786174	chr18:74118243	ZNF516	0.9	22.59	0.74	1.05e-74	Longevity;
LUAD	cis	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-7.05	-0.32	7.39e-12	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-7.52	-0.34	3.42e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg08885076	chr2:99613938	TSGA10	0.35	6.45	0.3	3.08e-10	Chronic sinus infection;
LUAD	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg05340658	chr4:99064831	C4orf37	0.44	6.69	0.31	7.23e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg17264618	chr3:40429014	ENTPD3	0.37	8.13	0.37	4.71e-15	Renal cell carcinoma;
LUAD	cis	rs7707921	0.881	rs324910	chr5:81400264	A/C	cg15871215	chr5:81402204	ATG10	-0.68	-9.6	-0.42	7.1e-20	Breast cancer;
LUAD	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg07570687	chr10:102243282	WNT8B	-0.44	-6.72	-0.31	5.73e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs4663969	0.839	rs7572563	chr2:234617236	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.36	-0.38	9.41e-16	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.48	6.83	0.32	2.88e-11	Platelet count;
LUAD	cis	rs11828289	0.607	rs79308902	chr11:23163835	G/A	cg20040320	chr11:23191996	NA	-0.66	-7.16	-0.33	3.64e-12	Cancer;
LUAD	cis	rs11971779	0.680	rs6946393	chr7:139106169	C/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	7.16e-11	Diisocyanate-induced asthma;
LUAD	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00166722	chr3:10149974	C3orf24	0.64	9.76	0.43	1.92e-20	Alzheimer's disease;
LUAD	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg21028142	chr17:79581711	NPLOC4	-0.38	-7.72	-0.35	8.23e-14	Eye color traits;
LUAD	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.52	0.3	2e-10	Menarche (age at onset);
LUAD	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18099408	chr3:52552593	STAB1	0.47	8.04	0.36	9.36e-15	Bipolar disorder;
LUAD	cis	rs752010	0.695	rs10789407	chr1:42106538	G/T	cg06885757	chr1:42089581	HIVEP3	0.38	8.11	0.37	5.64e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg24818145	chr4:99064322	C4orf37	0.46	7.19	0.33	2.95e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg07936489	chr17:37558343	FBXL20	0.45	7.09	0.33	5.8e-12	Glomerular filtration rate (creatinine);
LUAD	trans	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg19862616	chr7:65841803	NCRNA00174	1.04	25.06	0.77	1.23e-85	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg16641818	chr10:45869619	ALOX5	0.37	6.55	0.3	1.72e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg25233709	chr10:116636983	FAM160B1	0.41	8.26	0.37	1.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1395	0.778	rs12465084	chr2:27414203	G/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.51	8.9	0.4	1.64e-17	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06758649	chr12:107381105	MTERFD3	-0.57	-6.99	-0.32	1.07e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9287719	0.615	rs12613769	chr2:10742290	C/T	cg02196655	chr2:10830764	NOL10	-0.38	-6.55	-0.3	1.63e-10	Prostate cancer;
LUAD	cis	rs2996428	0.593	rs7513053	chr1:3709487	A/G	cg22529645	chr1:3704559	LRRC47	0.51	9.42	0.42	2.91e-19	Red cell distribution width;
LUAD	cis	rs76419734	0.558	rs4326019	chr4:106527381	A/G	cg05309399	chr4:106552544	FLJ20184	-0.54	-6.72	-0.31	6.04e-11	Post bronchodilator FEV1;
LUAD	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg15691649	chr6:25882328	NA	-0.66	-9.98	-0.44	3.44e-21	Blood metabolite levels;
LUAD	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg22963979	chr7:1858916	MAD1L1	-0.4	-6.47	-0.3	2.67e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs11098699	0.718	rs4833896	chr4:124242583	G/C	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg14008862	chr17:28927542	LRRC37B2	-0.54	-6.4	-0.3	4.16e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs57994353	0.897	rs66477686	chr9:139372224	T/C	cg14364472	chr9:139394549	NOTCH1	-0.45	-6.76	-0.31	4.48e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs943466	1.000	rs61662306	chr6:33746697	G/A	cg16010596	chr6:33739607	LEMD2	-0.4	-7.57	-0.35	2.33e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg05182265	chr7:156933206	UBE3C	-0.8	-17.24	-0.64	8.1e-51	Body mass index;
LUAD	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg24578937	chr1:2090814	PRKCZ	0.79	16.05	0.62	1.28e-45	Height;
LUAD	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg22920501	chr2:26401640	FAM59B	0.95	13.92	0.56	1.51e-36	Gut microbiome composition (summer);
LUAD	cis	rs9354308	0.867	rs2802051	chr6:66536403	C/T	cg07460842	chr6:66804631	NA	0.49	7.5	0.34	3.88e-13	Metabolite levels;
LUAD	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg11814155	chr7:99998594	ZCWPW1	0.45	7.75	0.35	7.02e-14	Platelet count;
LUAD	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg05304507	chr6:116381966	FRK	0.2	6.81	0.31	3.37e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs9972944	0.756	rs7221131	chr17:63764848	G/A	cg07283582	chr17:63770753	CCDC46	-0.5	-11.19	-0.48	1.25e-25	Total body bone mineral density;
LUAD	cis	rs863345	0.535	rs12068285	chr1:158499632	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.52	-0.3	2.01e-10	Pneumococcal bacteremia;
LUAD	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08677398	chr8:58056175	NA	0.51	6.57	0.3	1.5e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg13271783	chr10:134563150	INPP5A	-0.43	-7.47	-0.34	4.57e-13	Migraine;
LUAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg24846343	chr22:24311635	DDTL	0.78	17.36	0.64	2.42e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.49	10.07	0.44	1.64e-21	Monocyte percentage of white cells;
LUAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg24101359	chr6:42928495	GNMT	0.45	8.32	0.37	1.25e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg26384229	chr12:38710491	ALG10B	0.51	8.38	0.38	7.67e-16	Heart rate;
LUAD	cis	rs78761021	0.755	rs79379978	chr17:9794488	G/A	cg26853458	chr17:9805074	RCVRN	0.38	7.02	0.32	9.07e-12	Type 2 diabetes;
LUAD	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg19761014	chr17:28927070	LRRC37B2	0.86	8.36	0.38	9.21e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.09	-0.51	4.03e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.9	-0.32	1.96e-11	Bipolar disorder;
LUAD	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg21153622	chr11:89784906	NA	-0.32	-6.35	-0.3	5.54e-10	Coronary artery disease;
LUAD	cis	rs868943	0.714	rs13193683	chr6:116356235	A/T	cg15226275	chr6:116381976	FRK	0.23	6.41	0.3	3.94e-10	Total cholesterol levels;
LUAD	cis	rs6906287	0.625	rs9489355	chr6:118685314	A/G	cg05564266	chr6:118973597	C6orf204	0.36	7.76	0.35	6.5e-14	Electrocardiographic conduction measures;
LUAD	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg27539214	chr16:67997921	SLC12A4	-0.69	-8.76	-0.39	4.71e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg04455712	chr21:45112962	RRP1B	0.49	9.85	0.43	9.66e-21	Mean corpuscular volume;
LUAD	cis	rs11893307	0.509	rs6726273	chr2:191529696	T/C	cg27211696	chr2:191398769	TMEM194B	-0.43	-6.5	-0.3	2.31e-10	Mean platelet volume;
LUAD	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg22676075	chr6:135203613	NA	0.4	7.27	0.33	1.76e-12	Red blood cell count;
LUAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg13271783	chr10:134563150	INPP5A	-0.42	-6.69	-0.31	6.98e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg15412446	chr2:106886593	NA	-0.85	-16.39	-0.62	4.08e-47	Facial morphology (factor 23);
LUAD	cis	rs77741769	0.571	rs11065282	chr12:121264415	G/T	cg02419362	chr12:121203948	SPPL3	0.43	8.78	0.39	4.17e-17	Mean corpuscular volume;
LUAD	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg02782426	chr3:40428986	ENTPD3	0.36	7.86	0.36	3.16e-14	Renal cell carcinoma;
LUAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg05434287	chr7:2030229	MAD1L1	0.42	6.78	0.31	4.06e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg15468180	chr1:107600409	PRMT6	0.42	7.23	0.33	2.28e-12	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg05313129	chr8:58192883	C8orf71	-0.54	-6.95	-0.32	1.38e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg26408565	chr15:76604113	ETFA	-0.44	-7.17	-0.33	3.32e-12	Blood metabolite levels;
LUAD	cis	rs367943	1.000	rs168366	chr5:112818587	C/T	cg12552261	chr5:112820674	MCC	0.58	11.08	0.47	3.15e-25	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg22535103	chr8:58192502	C8orf71	0.6	6.57	0.3	1.47e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg04398451	chr17:18023971	MYO15A	-0.65	-11.71	-0.49	1.3e-27	Total body bone mineral density;
LUAD	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03517284	chr6:25882590	NA	0.56	9.06	0.4	5.05e-18	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.16e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35883536	0.647	rs7535762	chr1:101047534	A/G	cg06223162	chr1:101003688	GPR88	-0.48	-9.32	-0.41	6.26e-19	Monocyte count;
LUAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg03388025	chr16:89894329	SPIRE2	0.49	12.87	0.53	3.27e-32	Vitiligo;
LUAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg09033563	chr22:24373618	LOC391322	-0.55	-8.9	-0.4	1.62e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	9.12	0.41	3.15e-18	Platelet count;
LUAD	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg26513180	chr16:89883248	FANCA	0.69	13.1	0.54	3.61e-33	Vitiligo;
LUAD	cis	rs1232027	0.656	rs1650661	chr5:79963363	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.15	-0.33	3.76e-12	Huntington's disease progression;
LUAD	cis	rs67072384	1.000	rs72964181	chr11:72440124	C/G	cg04827223	chr11:72435913	ARAP1	-0.63	-6.84	-0.32	2.76e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg20476274	chr7:133979776	SLC35B4	0.84	17.14	0.64	2.21e-50	Mean platelet volume;
LUAD	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg23283495	chr1:209979779	IRF6	0.4	6.89	0.32	2.07e-11	Monobrow;
LUAD	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg05187965	chr10:45406764	TMEM72	-0.48	-9.54	-0.42	1.12e-19	Mean corpuscular volume;
LUAD	trans	rs8073060	0.586	rs225292	chr17:33926383	G/A	cg19694781	chr19:47549865	TMEM160	-0.95	-14.78	-0.58	3.87e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg04450456	chr4:17643702	FAM184B	0.42	8.33	0.38	1.15e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17076921	chr10:75634595	CAMK2G	-0.4	-6.41	-0.3	3.93e-10	Height;
LUAD	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06022373	chr22:39101656	GTPBP1	0.45	7.4	0.34	7.29e-13	Menopause (age at onset);
LUAD	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.06e-19	Life satisfaction;
LUAD	cis	rs76878669	0.561	rs10896111	chr11:66115690	T/C	cg10616300	chr11:66138557	SLC29A2	-0.36	-7.46	-0.34	5.11e-13	Educational attainment (years of education);
LUAD	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg11915388	chr22:42470451	FAM109B	0.39	6.84	0.32	2.85e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg02696790	chr15:75250997	RPP25	0.41	7.97	0.36	1.51e-14	Caffeine consumption;
LUAD	cis	rs7593730	0.537	rs4664013	chr2:161184164	C/G	cg22609984	chr2:161126801	NA	-0.5	-9.34	-0.41	5.46e-19	Type 2 diabetes;
LUAD	cis	rs3820068	0.705	rs4646110	chr1:15817318	A/T	cg24675056	chr1:15929824	NA	0.44	6.91	0.32	1.81e-11	Systolic blood pressure;
LUAD	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg08859206	chr1:53392774	SCP2	0.63	11.57	0.49	4.24e-27	Monocyte count;
LUAD	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg27432699	chr2:27873401	GPN1	0.39	6.57	0.3	1.51e-10	Total body bone mineral density;
LUAD	cis	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg05901451	chr6:126070800	HEY2	0.45	6.71	0.31	6.22e-11	Endometrial cancer;
LUAD	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg09835421	chr16:68378352	PRMT7	-0.82	-8.78	-0.39	4.06e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6674176	0.542	rs3011225	chr1:44319373	G/A	cg12908607	chr1:44402522	ARTN	-0.44	-8.42	-0.38	6.06e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg20362242	chr5:692897	TPPP	0.63	7.93	0.36	2e-14	Obesity-related traits;
LUAD	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.01	-0.32	9.29e-12	Height;
LUAD	cis	rs12711979	0.509	rs10187740	chr2:3823965	A/G	cg17052675	chr2:3827356	NA	0.83	19.07	0.68	5.56e-59	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs791888	0.698	rs7893652	chr10:89431060	A/G	cg13926569	chr10:89418898	PAPSS2	-0.47	-8.53	-0.38	2.63e-16	Magnesium levels;
LUAD	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.6	-10.98	-0.47	7.62e-25	Homoarginine levels;
LUAD	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.6	-0.42	7.19e-20	Life satisfaction;
LUAD	cis	rs1127311	1.000	rs10908419	chr1:154567699	G/A	cg17218026	chr1:154582156	ADAR	0.49	9.55	0.42	1.1e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg00310523	chr12:86230176	RASSF9	0.36	7.27	0.33	1.73e-12	Major depressive disorder;
LUAD	cis	rs9814567	0.752	rs1534029	chr3:134330213	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.95	-0.53	1.52e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.22	-0.33	2.38e-12	Resting heart rate;
LUAD	cis	rs375066	0.592	rs349045	chr19:44299892	A/G	cg12072164	chr19:44306565	LYPD5	-0.37	-7.79	-0.35	5.37e-14	Breast cancer;
LUAD	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg16325326	chr1:53192061	ZYG11B	0.65	12.75	0.53	9.93e-32	Monocyte count;
LUAD	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg01849466	chr14:104193079	ZFYVE21	0.48	7.38	0.34	8.47e-13	Reticulocyte count;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg09820084	chr6:18387507	RNF144B	0.4	6.37	0.3	4.99e-10	Diastolic blood pressure;
LUAD	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg24579218	chr15:68104479	NA	-0.52	-9.0	-0.4	8e-18	Restless legs syndrome;
LUAD	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg06784218	chr1:46089804	CCDC17	0.52	11.43	0.49	1.47e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs3125734	0.633	rs3902162	chr10:64041817	C/T	cg09941381	chr10:64027924	RTKN2	-0.32	-7.51	-0.34	3.54e-13	Rheumatoid arthritis;
LUAD	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-18.67	-0.67	3.65e-57	Coronary artery disease;
LUAD	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.36	0.34	9.58e-13	Tonsillectomy;
LUAD	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs9878978	0.554	rs1354241	chr3:2462577	C/G	cg21928760	chr3:2462534	CNTN4	-0.38	-7.83	-0.36	3.83e-14	Blood pressure (smoking interaction);
LUAD	cis	rs7677751	0.747	rs1800809	chr4:55093914	A/G	cg17187183	chr4:55093834	PDGFRA	0.51	8.63	0.39	1.23e-16	Corneal astigmatism;
LUAD	cis	rs2479724	1.000	rs2254479	chr6:41831143	G/A	cg17623882	chr6:41773611	USP49	-0.61	-11.05	-0.47	4.27e-25	Menarche (age at onset);
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg26668828	chr6:292823	DUSP22	0.77	13.85	0.56	3.13e-36	Menopause (age at onset);
LUAD	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.39	6.36	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7953508	0.750	rs7310389	chr12:93976636	A/G	cg18151635	chr12:93972918	NA	-0.61	-9.67	-0.43	3.99e-20	Pubertal anthropometrics;
LUAD	cis	rs9473147	0.543	rs9296558	chr6:47451883	C/T	cg12968598	chr6:47444699	CD2AP	0.37	6.7	0.31	6.56e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg22676075	chr6:135203613	NA	0.41	7.66	0.35	1.26e-13	Red blood cell count;
LUAD	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg19875535	chr5:140030758	IK	0.44	7.41	0.34	6.93e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg21427119	chr20:30132790	HM13	-0.36	-6.54	-0.3	1.77e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg11663144	chr21:46675770	NA	-0.51	-9.71	-0.43	2.94e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2455799	0.613	rs2345736	chr3:15824860	T/G	cg16303742	chr3:15540471	COLQ	-0.49	-9.11	-0.41	3.21e-18	Mean platelet volume;
LUAD	cis	rs727505	1.000	rs56387611	chr7:124479180	G/A	cg23710748	chr7:124431027	NA	-0.49	-9.77	-0.43	1.84e-20	Lewy body disease;
LUAD	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08048268	chr3:133502702	NA	0.51	10.45	0.45	6.79e-23	Iron status biomarkers;
LUAD	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.51	8.04	0.36	9.12e-15	Platelet count;
LUAD	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg06784218	chr1:46089804	CCDC17	-0.52	-11.47	-0.49	1.06e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg21204522	chr6:27730016	NA	-0.45	-7.17	-0.33	3.36e-12	Parkinson's disease;
LUAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg26338869	chr17:61819248	STRADA	-0.38	-6.43	-0.3	3.45e-10	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2270927	0.510	rs6453214	chr5:75584423	A/G	cg13563193	chr19:33072644	PDCD5	1.02	9.39	0.42	3.68e-19	Mean corpuscular volume;
LUAD	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg00647820	chr17:40259828	DHX58	-0.44	-6.9	-0.32	1.94e-11	Fibrinogen levels;
LUAD	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg18446336	chr7:2847575	GNA12	-0.38	-7.1	-0.33	5.19e-12	Height;
LUAD	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg21427119	chr20:30132790	HM13	-0.46	-7.42	-0.34	6.63e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs68170813	0.559	rs11769861	chr7:106979559	T/C	cg23024343	chr7:107201750	COG5	0.48	6.85	0.32	2.56e-11	Coronary artery disease;
LUAD	cis	rs6063312	0.667	rs9679994	chr20:47281853	T/C	cg18078177	chr20:47281410	PREX1	0.65	10.86	0.47	2.18e-24	Tonometry;
LUAD	cis	rs72772090	0.539	rs11746534	chr5:96124807	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-7.02	-0.32	8.82e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg06558623	chr16:89946397	TCF25	1.17	10.79	0.46	3.79e-24	Skin colour saturation;
LUAD	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	11.88	0.5	2.75e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.5	-0.45	4.41e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs738321	0.757	rs9622732	chr22:38524149	G/C	cg25457927	chr22:38595422	NA	-0.49	-10.79	-0.46	3.71e-24	Breast cancer;
LUAD	cis	rs6484504	0.576	rs9971609	chr11:31434104	C/T	cg26647111	chr11:31128758	NA	0.47	8.14	0.37	4.47e-15	Red blood cell count;
LUAD	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02018176	chr4:1364513	KIAA1530	0.67	11.86	0.5	3.17e-28	Longevity;
LUAD	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg23985595	chr17:80112537	CCDC57	0.42	7.72	0.35	8.53e-14	Life satisfaction;
LUAD	cis	rs2657888	1.000	rs2657901	chr12:56933416	A/G	cg23002907	chr12:56915593	RBMS2	0.35	6.52	0.3	1.95e-10	Adiponectin levels;
LUAD	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg20933634	chr6:27740509	NA	0.49	7.87	0.36	2.98e-14	Parkinson's disease;
LUAD	cis	rs727505	0.954	rs68102397	chr7:124685315	C/T	cg23710748	chr7:124431027	NA	-0.44	-8.83	-0.39	2.9e-17	Lewy body disease;
LUAD	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg24578937	chr1:2090814	PRKCZ	0.79	16.34	0.62	6.72e-47	Height;
LUAD	cis	rs977987	0.806	rs17696696	chr16:75393352	G/T	cg03315344	chr16:75512273	CHST6	-0.63	-13.65	-0.55	2.04e-35	Dupuytren's disease;
LUAD	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.38	-0.3	4.64e-10	Neutrophil percentage of white cells;
LUAD	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg05234568	chr11:5960015	NA	0.65	13.3	0.54	5.69e-34	DNA methylation (variation);
LUAD	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg24690094	chr11:67383802	NA	0.4	7.12	0.33	4.63e-12	Mean corpuscular volume;
LUAD	cis	rs9487051	0.735	rs1341272	chr6:109507533	C/T	cg21918786	chr6:109611834	NA	0.42	7.68	0.35	1.14e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg00666640	chr1:248458726	OR2T12	0.32	7.99	0.36	1.25e-14	Common traits (Other);
LUAD	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg09455208	chr3:40491958	NA	0.52	11.01	0.47	5.87e-25	Renal cell carcinoma;
LUAD	cis	rs11771526	0.901	rs62457502	chr7:32330797	C/T	cg27532318	chr7:32358331	NA	0.59	7.62	0.35	1.71e-13	Body mass index;
LUAD	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg16486109	chr11:613632	IRF7	0.52	7.83	0.36	3.99e-14	Systemic lupus erythematosus;
LUAD	cis	rs7707921	0.752	rs6882565	chr5:81356421	G/A	cg15871215	chr5:81402204	ATG10	-0.65	-10.3	-0.45	2.46e-22	Breast cancer;
LUAD	cis	rs2357013	0.718	rs1446432	chr2:53230750	C/T	cg07782112	chr2:53107842	NA	-0.36	-7.12	-0.33	4.78e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs3087591	1.000	rs2525578	chr17:29711411	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.4	-6.48	-0.3	2.61e-10	Hip circumference;
LUAD	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg09537434	chr19:41945824	ATP5SL	-0.53	-8.38	-0.38	7.95e-16	Height;
LUAD	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg17807903	chr1:86174739	ZNHIT6	0.61	10.83	0.47	2.71e-24	Urate levels in overweight individuals;
LUAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg22105103	chr4:187893119	NA	0.53	11.36	0.48	2.86e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg06784218	chr1:46089804	CCDC17	0.51	11.23	0.48	8.7e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg21475434	chr5:93447410	FAM172A	0.75	8.37	0.38	8.61e-16	Diabetic retinopathy;
LUAD	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg10755058	chr3:40428713	ENTPD3	0.39	7.45	0.34	5.16e-13	Renal cell carcinoma;
LUAD	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.13	-32.33	-0.84	2.27e-116	Myeloid white cell count;
LUAD	trans	rs17604090	0.529	rs2392128	chr7:29711139	A/G	cg27349345	chr7:35225932	NA	0.44	6.44	0.3	3.16e-10	Facial emotion recognition;Facial emotion recognition (sad faces);
LUAD	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg02049041	chr17:27085579	C17orf63	0.63	8.48	0.38	3.93e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs11650175	0.634	rs1833348	chr17:63774619	T/G	cg07283582	chr17:63770753	CCDC46	0.32	6.45	0.3	3.1e-10	Chin dimples;
LUAD	cis	rs367943	0.712	rs6594709	chr5:112700714	T/C	cg12552261	chr5:112820674	MCC	0.47	9.39	0.42	3.87e-19	Type 2 diabetes;
LUAD	cis	rs12765878	0.967	rs10883948	chr10:105667552	G/T	cg11005552	chr10:105648138	OBFC1	0.44	8.34	0.38	1.04e-15	Coronary artery disease;
LUAD	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg01874867	chr7:94954059	PON1	-0.51	-6.99	-0.32	1.07e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6782228	0.606	rs7650156	chr3:128361555	T/A	cg16766828	chr3:128327626	NA	-0.38	-7.21	-0.33	2.57e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs870825	0.616	rs6834156	chr4:185639903	G/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.12	0.57	2.26e-37	Blood protein levels;
LUAD	trans	rs877282	0.853	rs7079299	chr10:756455	A/G	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	cis	rs4629710	0.592	rs9492864	chr6:131531306	A/T	cg12606694	chr6:131520996	AKAP7	0.5	7.51	0.34	3.58e-13	Multiple myeloma (IgH translocation);
LUAD	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg12935359	chr14:103987150	CKB	0.47	7.92	0.36	2.17e-14	Body mass index;
LUAD	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.62	12.21	0.51	1.38e-29	Hemoglobin concentration;
LUAD	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg03676636	chr4:99064102	C4orf37	0.37	9.49	0.42	1.73e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg17971929	chr21:40555470	PSMG1	0.43	6.92	0.32	1.72e-11	Cognitive function;
LUAD	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg01251548	chr11:17372745	DKFZp686O24166	-0.35	-6.39	-0.3	4.31e-10	Type 2 diabetes;
LUAD	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg03808351	chr9:123631620	PHF19	-0.44	-6.56	-0.3	1.58e-10	Birth weight;
LUAD	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg03477792	chr4:77819574	ANKRD56	0.48	7.6	0.35	1.88e-13	Emphysema distribution in smoking;
LUAD	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg22166914	chr1:53195759	ZYG11B	0.46	7.52	0.34	3.3e-13	Monocyte count;
LUAD	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg20933634	chr6:27740509	NA	0.51	7.86	0.36	3.12e-14	Parkinson's disease;
LUAD	trans	rs11039798	0.841	rs7294179	chr11:48765408	G/A	cg03929089	chr4:120376271	NA	0.68	6.78	0.31	4.11e-11	Axial length;
LUAD	cis	rs7107174	1.000	rs2511186	chr11:77984306	C/G	cg02023728	chr11:77925099	USP35	0.49	7.56	0.35	2.45e-13	Testicular germ cell tumor;
LUAD	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg18404041	chr3:52824283	ITIH1	-0.64	-12.6	-0.52	4.04e-31	Bipolar disorder;
LUAD	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg17443473	chr1:3703550	LRRC47	0.47	7.87	0.36	3.09e-14	Red cell distribution width;
LUAD	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg06608945	chr2:219082296	ARPC2	-0.45	-7.43	-0.34	6.25e-13	Colorectal cancer;
LUAD	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	8.16	0.37	3.87e-15	Tonsillectomy;
LUAD	cis	rs35883536	0.566	rs12566440	chr1:101095202	A/G	cg06223162	chr1:101003688	GPR88	0.4	7.38	0.34	8.44e-13	Monocyte count;
LUAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg18538332	chr22:24372958	LOC391322	-0.5	-8.09	-0.37	6.56e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg00933542	chr6:150070202	PCMT1	0.43	9.18	0.41	1.91e-18	Lung cancer;
LUAD	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.19	0.48	1.23e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs12541635	0.934	rs2115703	chr8:107045935	C/G	cg10147462	chr8:107024639	NA	0.48	8.5	0.38	3.2e-16	Age of smoking initiation;
LUAD	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	7.25	0.33	2.05e-12	Iron status biomarkers;
LUAD	trans	rs7181230	0.885	rs4497657	chr15:40359433	A/T	cg22705835	chr10:65332833	REEP3	-0.36	-6.78	-0.31	4.12e-11	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.55	-0.89	3.42e-144	Myeloid white cell count;
LUAD	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg17633681	chr16:88106987	BANP	0.4	6.92	0.32	1.65e-11	Menopause (age at onset);
LUAD	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg18131467	chr2:239335373	ASB1	0.69	11.85	0.5	3.69e-28	Multiple system atrophy;
LUAD	cis	rs300774	0.925	rs424939	chr2:128894	C/T	cg21211680	chr2:198530	NA	-0.46	-7.33	-0.34	1.16e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg07217954	chr7:1067459	C7orf50	-0.36	-6.58	-0.3	1.36e-10	Bronchopulmonary dysplasia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06811360	chr17:8089327	NA	-0.44	-6.74	-0.31	5.2e-11	Height;
LUAD	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.58	-9.96	-0.44	3.83e-21	Menarche (age at onset);
LUAD	cis	rs4947962	0.618	rs12538489	chr7:55099836	C/T	cg23757825	chr7:55092271	EGFR	-0.55	-7.72	-0.35	8.31e-14	Subjective response to lithium treatment;
LUAD	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg18944383	chr4:111397179	ENPEP	0.41	7.67	0.35	1.22e-13	Coronary artery disease;
LUAD	cis	rs4849845	0.637	rs4849851	chr2:121055910	A/C	cg24070213	chr2:121070622	NA	0.4	7.51	0.34	3.49e-13	Mean platelet volume;
LUAD	cis	rs3818285	0.959	rs492943	chr10:111629030	A/T	cg00817464	chr10:111662876	XPNPEP1	0.62	9.09	0.4	3.74e-18	Superior crus of antihelix expression;
LUAD	cis	rs6908034	0.607	rs74559916	chr6:19818717	G/T	cg02682789	chr6:19804855	NA	0.94	8.83	0.39	2.74e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs7731657	0.537	rs9791114	chr5:130361608	A/G	cg08523029	chr5:130500466	HINT1	0.52	7.08	0.33	6.07e-12	Fasting plasma glucose;
LUAD	cis	rs9633740	1.000	rs7896832	chr10:82257570	T/C	cg01528321	chr10:82214614	TSPAN14	0.75	9.96	0.44	3.85e-21	Post bronchodilator FEV1;
LUAD	trans	rs4799710	0.791	rs9964810	chr18:31226058	T/C	cg27147174	chr7:100797783	AP1S1	-0.43	-6.72	-0.31	6.01e-11	Pulmonary function;
LUAD	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg26597838	chr10:835615	NA	0.96	14.92	0.59	9.44e-41	Eosinophil percentage of granulocytes;
LUAD	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg19875535	chr5:140030758	IK	0.45	7.54	0.34	2.92e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2554380	0.843	rs1365198	chr15:84398903	T/G	cg14598478	chr15:84363061	ADAMTSL3	-0.49	-7.59	-0.35	2.09e-13	Height;
LUAD	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg01251548	chr11:17372745	DKFZp686O24166	-0.36	-6.64	-0.31	9.78e-11	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00149659	chr3:10157352	C3orf10	0.55	7.57	0.35	2.41e-13	Alzheimer's disease;
LUAD	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg17200465	chr3:40428508	ENTPD3	0.27	6.97	0.32	1.25e-11	Renal cell carcinoma;
LUAD	cis	rs9715521	0.677	rs62301200	chr4:59855179	G/A	cg11281224	chr4:60001000	NA	-0.59	-10.73	-0.46	6.38e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs17401966	0.931	rs34225619	chr1:10371987	C/T	cg15208524	chr1:10270712	KIF1B	0.55	8.35	0.38	9.71e-16	Hepatocellular carcinoma;
LUAD	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg09491104	chr22:46646882	C22orf40	-0.64	-11.68	-0.49	1.68e-27	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg04025307	chr7:1156635	C7orf50	0.59	6.86	0.32	2.41e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.8	14.9	0.59	1.19e-40	Lymphocyte counts;
LUAD	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg07741184	chr6:167504864	NA	-0.3	-7.12	-0.33	4.53e-12	Crohn's disease;
LUAD	cis	rs12681287	0.640	rs10098356	chr8:87442667	A/G	cg27223183	chr8:87520930	FAM82B	0.67	9.58	0.42	8.35e-20	Caudate activity during reward;
LUAD	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg01689657	chr7:91764605	CYP51A1	0.38	9.17	0.41	2.11e-18	Breast cancer;
LUAD	cis	rs4889855	0.556	rs4890039	chr17:78517883	C/T	cg16591659	chr17:78472290	NA	0.44	7.6	0.35	1.91e-13	Fractional excretion of uric acid;
LUAD	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg22705602	chr4:152727874	NA	-0.4	-6.95	-0.32	1.38e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.35	0.45	1.59e-22	Ileal carcinoids;
LUAD	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg02527881	chr3:46936655	PTH1R	-0.46	-8.94	-0.4	1.19e-17	Colorectal cancer;
LUAD	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg20991723	chr1:152506922	NA	0.33	6.47	0.3	2.78e-10	Hair morphology;
LUAD	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg13319975	chr6:146136371	FBXO30	0.59	10.04	0.44	1.99e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.51	7.01	0.32	9.38e-12	Renal function-related traits (BUN);
LUAD	cis	rs11626933	1.000	rs45463097	chr14:90744188	G/A	cg14092571	chr14:90743983	NA	-0.94	-17.77	-0.65	3.62e-53	Gut microbiota (bacterial taxa);
LUAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.68	0.31	7.44e-11	Prudent dietary pattern;
LUAD	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg21823605	chr1:152486609	CRCT1	0.28	6.59	0.31	1.3e-10	Hair morphology;
LUAD	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg21153622	chr11:89784906	NA	-0.32	-6.46	-0.3	2.95e-10	Height;
LUAD	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg23281280	chr6:28129359	ZNF389	0.46	6.48	0.3	2.5e-10	Depression;
LUAD	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg09537434	chr19:41945824	ATP5SL	-0.42	-6.76	-0.31	4.5e-11	Height;
LUAD	cis	rs1403694	0.695	rs5029969	chr3:186434405	G/T	cg12454167	chr3:186435060	KNG1	0.51	10.59	0.46	2.1e-23	Blood protein levels;
LUAD	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg15467112	chr14:75489610	MLH3	0.35	6.36	0.3	5.33e-10	Height;
LUAD	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg22166914	chr1:53195759	ZYG11B	0.4	6.39	0.3	4.41e-10	Monocyte count;
LUAD	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg05373962	chr22:49881684	NA	-0.5	-10.08	-0.44	1.41e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9788682	0.706	rs2656055	chr15:78720194	C/A	cg18825076	chr15:78729989	IREB2	-0.53	-7.11	-0.33	4.95e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs2262909	0.849	rs10420483	chr19:22190378	A/G	cg11619707	chr19:22235551	ZNF257	-0.44	-6.63	-0.31	1.01e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.73e-16	Neutrophil percentage of white cells;
LUAD	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg09658497	chr7:2847517	GNA12	-0.46	-8.44	-0.38	5.22e-16	Height;
LUAD	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg11859384	chr17:80120422	CCDC57	-0.52	-9.36	-0.41	4.69e-19	Life satisfaction;
LUAD	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg06552810	chr11:31128660	NA	-0.34	-6.63	-0.31	1.05e-10	Red blood cell count;
LUAD	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg10755058	chr3:40428713	ENTPD3	0.39	7.46	0.34	5.02e-13	Renal cell carcinoma;
LUAD	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.66	10.78	0.46	4.12e-24	Height;
LUAD	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg03396347	chr1:1875803	NA	-0.62	-16.03	-0.61	1.59e-45	Body mass index;
LUAD	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg04282206	chr17:62833786	PLEKHM1P	-0.52	-8.03	-0.36	9.69e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg25427524	chr10:38739819	LOC399744	0.62	9.72	0.43	2.63e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg05110241	chr16:68378359	PRMT7	-0.93	-10.61	-0.46	1.75e-23	Schizophrenia;
LUAD	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg14343924	chr8:8086146	FLJ10661	-0.51	-8.18	-0.37	3.32e-15	Mood instability;
LUAD	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg26384229	chr12:38710491	ALG10B	0.48	7.74	0.35	7.17e-14	Bladder cancer;
LUAD	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg24733560	chr20:60626293	TAF4	0.47	8.39	0.38	7.18e-16	Body mass index;
LUAD	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg16479474	chr6:28041457	NA	0.44	7.75	0.35	7.11e-14	Depression;
LUAD	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.51	0.38	3.08e-16	Platelet count;
LUAD	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg14008862	chr17:28927542	LRRC37B2	0.55	6.36	0.3	5.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7737355	1.000	rs2158428	chr5:130751481	T/A	cg06307176	chr5:131281290	NA	-0.49	-7.66	-0.35	1.31e-13	Life satisfaction;
LUAD	cis	rs1160297	0.544	rs10173886	chr2:53094788	T/C	cg07782112	chr2:53107842	NA	0.37	7.81	0.36	4.54e-14	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.45	-0.52	1.54e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs12801636	0.512	rs11227247	chr11:65422853	A/C	cg24147428	chr11:65409760	SIPA1	-0.53	-7.93	-0.36	1.98e-14	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs6906287	0.647	rs13220480	chr6:118916627	G/A	cg05564266	chr6:118973597	C6orf204	0.37	7.76	0.35	6.24e-14	Electrocardiographic conduction measures;
LUAD	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg00922110	chr4:57842668	C4orf14	-0.45	-8.65	-0.39	1.1e-16	Response to bleomycin (chromatid breaks);
LUAD	trans	rs6678622	0.863	rs12741347	chr1:78152792	C/G	cg20826526	chr3:156266748	SSR3	-0.44	-7.2	-0.33	2.85e-12	Hip circumference;
LUAD	cis	rs7512552	0.839	rs6703652	chr1:150465953	T/G	cg15654264	chr1:150340011	RPRD2	0.59	11.31	0.48	4.2e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2686555	0.649	rs1151874	chr12:121092555	T/C	cg18477009	chr12:121087777	CABP1	0.47	8.16	0.37	3.92e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg00086871	chr4:6988644	TBC1D14	0.74	6.35	0.3	5.45e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg07402062	chr16:89894098	SPIRE2	0.44	11.02	0.47	5.49e-25	Vitiligo;
LUAD	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-6.87	-0.32	2.35e-11	Total body bone mineral density;
LUAD	cis	rs938554	0.513	rs3733588	chr4:9997303	A/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-9.65	-0.42	4.76e-20	Blood metabolite levels;
LUAD	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.53	14.39	0.57	1.69e-38	Schizophrenia;
LUAD	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.61	0.31	1.15e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs4774899	0.932	rs12912353	chr15:57516037	A/G	cg14026238	chr15:57616123	NA	0.35	6.71	0.31	6.18e-11	Urinary tract infection frequency;
LUAD	cis	rs870825	0.860	rs72689277	chr4:185593699	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	11.23	0.48	8.44e-26	Blood protein levels;
LUAD	cis	rs7737355	0.947	rs251014	chr5:131029463	A/G	cg25547332	chr5:131281432	NA	0.45	6.68	0.31	7.56e-11	Life satisfaction;
LUAD	cis	rs7589342	0.801	rs13031068	chr2:106455021	A/G	cg16077055	chr2:106428750	NCK2	0.36	6.48	0.3	2.58e-10	Addiction;
LUAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg02493798	chr17:6899577	ALOX12	-0.39	-7.36	-0.34	9.49e-13	Tonsillectomy;
LUAD	cis	rs6445967	0.545	rs67148387	chr3:58281224	A/G	cg23715586	chr3:58305044	RPP14	0.39	6.5	0.3	2.29e-10	Platelet count;
LUAD	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg18180107	chr4:99064573	C4orf37	0.42	6.75	0.31	4.94e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08045932	chr20:61659980	NA	0.5	9.62	0.42	5.9e-20	Prostate cancer (SNP x SNP interaction);
LUAD	trans	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg06606381	chr12:133084897	FBRSL1	-1.13	-10.53	-0.46	3.64e-23	Depression;
LUAD	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg23840854	chr1:161414152	NA	-0.82	-10.73	-0.46	6.68e-24	Rheumatoid arthritis;
LUAD	cis	rs7100689	0.890	rs4934169	chr10:82203663	A/G	cg00277334	chr10:82204260	NA	-0.8	-12.39	-0.52	2.62e-30	Post bronchodilator FEV1;
LUAD	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg17105886	chr17:28927953	LRRC37B2	-0.75	-7.45	-0.34	5.26e-13	Body mass index;
LUAD	cis	rs593982	0.777	rs534414	chr11:65475515	A/G	cg08755490	chr11:65554678	OVOL1	1.24	14.71	0.58	7.44e-40	Atopic dermatitis;
LUAD	cis	rs7927771	0.524	rs2290851	chr11:47753370	C/T	cg18512352	chr11:47633146	NA	-0.37	-6.63	-0.31	1.05e-10	Subjective well-being;
LUAD	cis	rs12711979	0.509	rs13005405	chr2:3826324	C/T	cg17052675	chr2:3827356	NA	-0.83	-19.5	-0.69	6.97e-61	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg24578937	chr1:2090814	PRKCZ	-0.51	-10.06	-0.44	1.67e-21	Height;
LUAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00149659	chr3:10157352	C3orf10	0.65	9.1	0.4	3.64e-18	Alzheimer's disease;
LUAD	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.43	6.75	0.31	4.98e-11	Lung function (FEV1/FVC);
LUAD	trans	rs7395662	1.000	rs12806328	chr11:48647971	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.26	-0.33	1.82e-12	HDL cholesterol;
LUAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg13047869	chr3:10149882	C3orf24	0.66	11.18	0.48	1.38e-25	Alzheimer's disease;
LUAD	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg09222892	chr1:25734099	RHCE	-0.49	-9.17	-0.41	2.16e-18	Erythrocyte sedimentation rate;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04360557	chr1:33282743	S100PBP;YARS	-0.39	-6.41	-0.3	4e-10	Cancer;
LUAD	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg13319975	chr6:146136371	FBXO30	-0.6	-10.13	-0.44	9.54e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-7.05	-0.32	7.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg05865280	chr17:75406074	SEPT9	0.61	19.15	0.68	2.7e-59	Airflow obstruction;
LUAD	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg19773385	chr1:10388646	KIF1B	-0.42	-6.82	-0.31	3.24e-11	Hepatocellular carcinoma;
LUAD	cis	rs684232	0.666	rs1227028	chr17:573298	G/A	cg12384639	chr17:618140	VPS53	0.5	8.51	0.38	2.95e-16	Prostate cancer;
LUAD	cis	rs89107	0.967	rs6912208	chr6:118566516	A/G	cg18833306	chr6:118973337	C6orf204	-0.48	-8.67	-0.39	9.29e-17	Cardiac structure and function;
LUAD	cis	rs7100689	0.560	rs10887891	chr10:82207717	A/C	cg00277334	chr10:82204260	NA	-0.82	-15.37	-0.6	1.13e-42	Post bronchodilator FEV1;
LUAD	cis	rs3812111	0.510	rs1569825	chr6:116590807	T/G	cg18828861	chr6:116576566	TSPYL4	0.37	7.14	0.33	4.11e-12	Age-related macular degeneration;
LUAD	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg14343924	chr8:8086146	FLJ10661	-0.45	-6.77	-0.31	4.32e-11	Joint mobility (Beighton score);
LUAD	trans	rs264943	0.967	rs10185399	chr2:104214676	A/T	cg02784696	chr2:24270586	C2orf44	-0.46	-7.76	-0.35	6.34e-14	HIV-1 viral setpoint;
LUAD	cis	rs4285028	0.848	rs4118376	chr3:121636450	G/A	cg11130432	chr3:121712080	ILDR1	-0.58	-7.93	-0.36	2.01e-14	Multiple sclerosis;
LUAD	cis	rs953387	0.910	rs16833335	chr2:136949744	C/T	cg05194412	chr2:137003533	NA	-0.4	-6.39	-0.3	4.49e-10	Arthritis (juvenile idiopathic);
LUAD	cis	rs7582720	1.000	rs72932590	chr2:203884308	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.27	0.41	9.95e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6076065	0.723	rs2424548	chr20:23394456	A/C	cg11657817	chr20:23433608	CST11	0.47	8.66	0.39	9.76e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg08989290	chr16:615782	NHLRC4	0.31	6.8	0.31	3.6e-11	Height;
LUAD	cis	rs738322	0.511	rs2267371	chr22:38577119	T/G	cg25457927	chr22:38595422	NA	-0.5	-11.09	-0.47	2.81e-25	Cutaneous nevi;
LUAD	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg18854424	chr1:2615690	NA	0.42	9.13	0.41	2.83e-18	Ulcerative colitis;
LUAD	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg21100191	chr22:23484243	RTDR1	0.66	11.55	0.49	5.1e-27	Bone mineral density;
LUAD	cis	rs751728	1.000	rs1359781	chr6:33762104	T/C	cg13859433	chr6:33739653	LEMD2	-0.38	-8.83	-0.39	2.73e-17	Crohn's disease;
LUAD	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg03983476	chr2:10830698	NOL10	-0.46	-7.87	-0.36	3e-14	Prostate cancer;
LUAD	cis	rs76878669	0.561	rs7105015	chr11:66159390	A/G	cg10616300	chr11:66138557	SLC29A2	0.37	7.67	0.35	1.16e-13	Educational attainment (years of education);
LUAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg24846343	chr22:24311635	DDTL	0.8	17.88	0.66	1.19e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg17366294	chr4:99064904	C4orf37	-0.66	-12.53	-0.52	7.17e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg17757837	chr7:157058334	UBE3C	0.47	8.39	0.38	7.32e-16	Body mass index;
LUAD	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg20469991	chr17:27169893	C17orf63	-0.52	-6.51	-0.3	2.08e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg08470875	chr2:26401718	FAM59B	-0.73	-9.32	-0.41	6.61e-19	Gut microbiome composition (summer);
LUAD	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg24558204	chr6:135376177	HBS1L	0.44	8.04	0.36	9.4e-15	Red blood cell count;
LUAD	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg07936489	chr17:37558343	FBXL20	-0.44	-7.0	-0.32	1.03e-11	Glomerular filtration rate (creatinine);
LUAD	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg21214613	chr1:16344536	HSPB7	0.6	11.59	0.49	3.61e-27	Dilated cardiomyopathy;
LUAD	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg00933542	chr6:150070202	PCMT1	0.46	10.0	0.44	2.73e-21	Lung cancer;
LUAD	cis	rs7945718	0.934	rs10831905	chr11:12776467	C/T	cg25843174	chr11:12811716	TEAD1	-0.24	-7.27	-0.33	1.75e-12	Educational attainment (years of education);
LUAD	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18099408	chr3:52552593	STAB1	-0.45	-7.98	-0.36	1.39e-14	Electroencephalogram traits;
LUAD	trans	rs9929218	0.953	rs9939049	chr16:68812301	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.89	-0.56	2.03e-36	Colorectal cancer;
LUAD	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg15117754	chr3:10150083	C3orf24	0.4	6.66	0.31	8.79e-11	Alzheimer's disease;
LUAD	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg21475434	chr5:93447410	FAM172A	0.71	8.14	0.37	4.32e-15	Diabetic retinopathy;
LUAD	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg11833968	chr6:79620685	NA	-0.44	-8.32	-0.38	1.22e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6541297	1.000	rs6686680	chr1:230280522	T/C	cg20703242	chr1:230279135	GALNT2	0.66	11.7	0.49	1.34e-27	Coronary artery disease;
LUAD	trans	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg14917512	chr19:3094685	GNA11	-0.55	-6.5	-0.3	2.29e-10	Diabetic kidney disease;
LUAD	cis	rs2797160	1.000	rs6933302	chr6:126016951	T/C	cg05901451	chr6:126070800	HEY2	0.44	6.52	0.3	2.03e-10	Endometrial cancer;
LUAD	cis	rs3820068	0.705	rs1800616	chr1:15832229	G/A	cg13390004	chr1:15929781	NA	0.41	6.74	0.31	5.16e-11	Systolic blood pressure;
LUAD	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.52	0.3	2.02e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.12e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.54e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7187994	0.672	rs35594082	chr16:84796864	A/C	cg07647771	chr16:84786436	USP10	-0.31	-8.16	-0.37	3.91e-15	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.6	0.31	1.26e-10	Prudent dietary pattern;
LUAD	trans	rs11039798	1.000	rs10769370	chr11:48515430	A/G	cg15704280	chr7:45808275	SEPT13	0.65	7.73	0.35	7.7e-14	Axial length;
LUAD	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg07936489	chr17:37558343	FBXL20	-0.48	-7.57	-0.35	2.4e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg13393036	chr8:95962371	TP53INP1	0.37	8.08	0.37	6.63e-15	Type 2 diabetes;
LUAD	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg00204512	chr16:28754710	NA	0.31	6.64	0.31	9.77e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10504073	0.584	rs11786103	chr8:49904077	A/G	cg00325661	chr8:49890786	NA	0.45	10.29	0.45	2.58e-22	Blood metabolite ratios;
LUAD	trans	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg17712092	chr4:129076599	LARP1B	-0.77	-11.77	-0.5	7.11e-28	Breast cancer;
LUAD	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg02527881	chr3:46936655	PTH1R	0.44	8.49	0.38	3.58e-16	Colorectal cancer;
LUAD	cis	rs1200821	0.559	rs9418267	chr10:37819951	A/G	cg25427524	chr10:38739819	LOC399744	0.49	8.17	0.37	3.52e-15	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs593982	1.000	rs576663	chr11:65498942	G/T	cg08755490	chr11:65554678	OVOL1	1.32	20.4	0.7	6.24e-65	Atopic dermatitis;
LUAD	cis	rs4372836	0.729	rs55785599	chr2:29087814	C/A	cg09522027	chr2:28974177	PPP1CB	0.66	11.54	0.49	5.69e-27	Body mass index;
LUAD	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg25358565	chr5:93447407	FAM172A	0.61	7.71	0.35	8.98e-14	Diabetic retinopathy;
LUAD	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg10876282	chr6:28092338	ZSCAN16	0.42	6.42	0.3	3.74e-10	Parkinson's disease;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03428813	chr2:62115351	CCT4	0.43	6.52	0.3	2.01e-10	Gut microbiome composition (summer);
LUAD	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.4	-6.6	-0.31	1.21e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs56104184	0.830	rs73061622	chr19:49358111	C/T	cg17863274	chr19:49399704	TULP2	-0.53	-7.11	-0.33	5.03e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs208520	1.000	rs208520	chr6:66952828	G/T	cg07460842	chr6:66804631	NA	-0.94	-13.01	-0.53	8.7e-33	Exhaled nitric oxide output;
LUAD	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.51e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.56	-0.42	9.95e-20	Platelet count;
LUAD	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10802521	chr3:52805072	NEK4	-0.6	-10.55	-0.46	3.07e-23	Bipolar disorder;
LUAD	cis	rs6669119	0.668	rs17352385	chr1:19087695	A/G	cg19637330	chr1:19110922	NA	0.63	7.3	0.33	1.47e-12	Percentage gas trapping;
LUAD	cis	rs10992471	0.603	rs4744137	chr9:95288352	G/A	cg14631576	chr9:95140430	CENPP	-0.51	-10.22	-0.45	4.58e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg12432903	chr7:1882776	MAD1L1	-0.43	-6.84	-0.32	2.7e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.4	7.13	0.33	4.23e-12	Menarche (age at onset);
LUAD	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg03433033	chr1:76189801	ACADM	-0.68	-10.87	-0.47	1.92e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4285028	0.948	rs2091664	chr3:121684749	T/A	cg20356878	chr3:121714668	ILDR1	-0.5	-6.76	-0.31	4.51e-11	Multiple sclerosis;
LUAD	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg18252515	chr7:66147081	NA	-0.61	-6.69	-0.31	7.01e-11	Diabetic kidney disease;
LUAD	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg14664628	chr15:75095509	CSK	-0.53	-8.6	-0.39	1.62e-16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.78	-0.5	6.71e-28	Mean corpuscular volume;
LUAD	cis	rs57590327	0.508	rs7621968	chr3:81951460	A/G	cg07356753	chr3:81810745	GBE1	-0.54	-9.0	-0.4	7.87e-18	Extraversion;
LUAD	cis	rs10761482	0.813	rs12776510	chr10:62167928	C/T	cg18175470	chr10:62150864	ANK3	-0.39	-6.54	-0.3	1.77e-10	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.8	0.35	4.93e-14	Breast cancer;
LUAD	cis	rs7833986	0.501	rs2667981	chr8:56894303	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.92	14.71	0.58	7.66e-40	Height;
LUAD	cis	rs887829	0.570	rs6736508	chr2:234595747	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-9.32	-0.41	6.4e-19	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.49	8.57	0.38	2.02e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7843479	0.524	rs1031884	chr8:21788984	C/T	cg03445287	chr8:21823731	XPO7	-0.49	-9.06	-0.4	4.92e-18	Mean corpuscular volume;
LUAD	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg24397884	chr7:158709396	WDR60	0.65	8.85	0.4	2.47e-17	Height;
LUAD	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg26924012	chr15:45694286	SPATA5L1	0.61	10.31	0.45	2.19e-22	Response to fenofibrate (adiponectin levels);
LUAD	trans	rs7395662	1.000	rs4882134	chr11:48598795	A/C	cg00717180	chr2:96193071	NA	-0.39	-7.33	-0.34	1.14e-12	HDL cholesterol;
LUAD	cis	rs4888262	0.604	rs12935075	chr16:74676033	A/T	cg01733217	chr16:74700730	RFWD3	0.52	8.69	0.39	7.94e-17	Testicular germ cell tumor;
LUAD	trans	rs747782	0.528	rs11039674	chr11:48336116	C/T	cg03929089	chr4:120376271	NA	0.56	6.48	0.3	2.6e-10	Intraocular pressure;
LUAD	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.48	7.52	0.34	3.4e-13	Schizophrenia;
LUAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06873352	chr17:61820015	STRADA	0.81	18.02	0.66	2.74e-54	Prudent dietary pattern;
LUAD	trans	rs12517041	0.935	rs1428628	chr5:23311925	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.49	-6.92	-0.32	1.73e-11	Calcium levels;
LUAD	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg03037974	chr15:76606532	NA	0.39	8.54	0.38	2.52e-16	Blood metabolite levels;
LUAD	trans	rs9354308	0.838	rs9363453	chr6:66544051	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.87	-0.32	2.3e-11	Metabolite levels;
LUAD	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg21918786	chr6:109611834	NA	-0.51	-9.38	-0.41	4.14e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg08704250	chr15:31115839	NA	-0.61	-10.23	-0.45	4.44e-22	Huntington's disease progression;
LUAD	trans	rs877282	0.583	rs112372193	chr10:826602	A/G	cg22713356	chr15:30763199	NA	0.88	10.87	0.47	1.92e-24	Uric acid levels;
LUAD	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.15e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg15704280	chr7:45808275	SEPT13	-0.91	-16.76	-0.63	1e-48	Height;
LUAD	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg04025307	chr7:1156635	C7orf50	0.65	12.01	0.5	8.29e-29	Longevity;Endometriosis;
LUAD	cis	rs1003719	0.715	rs6517405	chr21:38560334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-8.17	-0.37	3.54e-15	Eye color traits;
LUAD	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg03388025	chr16:89894329	SPIRE2	-0.51	-13.21	-0.54	1.33e-33	Vitiligo;
LUAD	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg08773314	chr2:239334832	ASB1	0.44	9.56	0.42	9.51e-20	Multiple system atrophy;
LUAD	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg21475434	chr5:93447410	FAM172A	0.77	8.63	0.39	1.23e-16	Diabetic retinopathy;
LUAD	cis	rs7017914	0.967	rs17760497	chr8:71617045	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg09873201	chr16:3507582	NAT15	0.5	7.54	0.34	2.89e-13	Tuberculosis;
LUAD	cis	rs12681288	0.523	rs73176528	chr8:961962	G/A	cg15309053	chr8:964076	NA	0.5	11.27	0.48	6.19e-26	Schizophrenia;
LUAD	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg12140854	chr5:148520817	ABLIM3	0.68	10.87	0.47	1.95e-24	Breast cancer;
LUAD	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg00316803	chr15:76480434	C15orf27	0.44	6.88	0.32	2.11e-11	Blood metabolite levels;
LUAD	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg17173187	chr15:85201210	NMB	0.5	8.85	0.4	2.35e-17	Schizophrenia;
LUAD	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg10589385	chr1:150898437	SETDB1	0.44	7.98	0.36	1.36e-14	Melanoma;
LUAD	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg12436631	chr1:155007014	DCST1;DCST2	0.3	6.96	0.32	1.32e-11	Prostate cancer;
LUAD	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg00666640	chr1:248458726	OR2T12	0.29	6.79	0.31	3.81e-11	Common traits (Other);
LUAD	cis	rs11811982	0.793	rs11808210	chr1:227515049	G/A	cg24860534	chr1:227506868	CDC42BPA	0.67	7.32	0.34	1.25e-12	Optic disc area;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg21460053	chr1:110198853	GSTM4	-0.66	-6.55	-0.3	1.64e-10	Type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs1215050	0.791	rs684210	chr4:98678740	G/C	cg17366294	chr4:99064904	C4orf37	0.45	7.94	0.36	1.86e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg22029157	chr1:209979665	IRF6	0.71	8.78	0.39	3.98e-17	Coronary artery disease;
LUAD	cis	rs7680126	0.597	rs78917351	chr4:10208063	A/C	cg11266682	chr4:10021025	SLC2A9	-0.48	-7.32	-0.34	1.27e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg13770153	chr20:60521292	NA	-0.56	-9.28	-0.41	8.69e-19	Body mass index;
LUAD	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg20673091	chr1:2541236	MMEL1	-0.38	-8.04	-0.36	9.18e-15	Ulcerative colitis;
LUAD	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg19163074	chr7:65112434	INTS4L2	-0.45	-6.87	-0.32	2.37e-11	Aortic root size;
LUAD	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	5e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.39	-7.52	-0.34	3.24e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg02869364	chr7:1081709	C7orf50	-0.5	-6.46	-0.3	2.85e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg10518543	chr12:38710700	ALG10B	-0.48	-8.0	-0.36	1.23e-14	Morning vs. evening chronotype;
LUAD	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg22117172	chr7:91764530	CYP51A1	0.3	6.63	0.31	1.03e-10	Breast cancer;
LUAD	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg16647868	chr5:131706066	SLC22A5	0.5	7.95	0.36	1.66e-14	Breast cancer;
LUAD	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg22431228	chr1:16359049	CLCNKA	-0.64	-13.17	-0.54	2.02e-33	Systolic blood pressure;
LUAD	trans	rs2735413	0.837	rs4888734	chr16:78083685	C/G	cg01028844	chr5:122736986	CEP120	0.41	6.46	0.3	2.87e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg06609049	chr19:2785107	THOP1	0.72	11.68	0.49	1.62e-27	Total cholesterol levels;
LUAD	cis	rs7786877	1.000	rs7786877	chr7:100214015	A/G	cg20848291	chr7:100343083	ZAN	-0.54	-7.6	-0.35	1.99e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg01868782	chr6:126071099	HEY2	0.31	6.35	0.3	5.51e-10	Brugada syndrome;
LUAD	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.01e-10	Skin colour saturation;
LUAD	cis	rs7552167	0.925	rs11249021	chr1:24512881	G/T	cg01960748	chr1:24522592	NA	-0.74	-9.97	-0.44	3.47e-21	Psoriasis vulgaris;
LUAD	cis	rs8077889	1.000	rs4793035	chr17:41887753	C/T	cg26893861	chr17:41843967	DUSP3	0.95	14.58	0.58	2.55e-39	Triglycerides;
LUAD	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg13319975	chr6:146136371	FBXO30	-0.75	-12.66	-0.52	2.33e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg03168497	chr17:48586147	MYCBPAP	0.51	6.66	0.31	8.35e-11	Visceral fat;
LUAD	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg22117172	chr7:91764530	CYP51A1	0.35	7.9	0.36	2.43e-14	Breast cancer;
LUAD	cis	rs2880765	0.835	rs730372	chr15:86038193	G/T	cg13263323	chr15:86062960	AKAP13	0.48	9.02	0.4	6.59e-18	Coronary artery disease;
LUAD	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg13722127	chr7:150037890	RARRES2	0.45	7.82	0.36	4.25e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6908034	0.607	rs112824001	chr6:19804691	C/T	cg02682789	chr6:19804855	NA	0.96	9.47	0.42	2.01e-19	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs2692947	0.644	rs1168976	chr2:96813480	G/A	cg23100626	chr2:96804247	ASTL	0.38	9.82	0.43	1.2e-20	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs62400317	0.762	rs12211922	chr6:44847210	A/G	cg18551225	chr6:44695536	NA	-0.59	-8.88	-0.4	1.98e-17	Total body bone mineral density;
LUAD	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg00933542	chr6:150070202	PCMT1	0.45	8.87	0.4	2.09e-17	Lung cancer;
LUAD	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.37	0.38	8.27e-16	Platelet count;
LUAD	cis	rs752010	0.545	rs6600379	chr1:42053497	T/C	cg06885757	chr1:42089581	HIVEP3	0.37	7.87	0.36	2.92e-14	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg18854424	chr1:2615690	NA	-0.42	-9.07	-0.4	4.56e-18	Ulcerative colitis;
LUAD	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-8.82	-0.39	2.95e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg11941060	chr3:133502564	NA	0.37	6.4	0.3	4.13e-10	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs933688	0.532	rs13165085	chr5:90538448	G/C	cg17503389	chr5:90575422	NA	-0.42	-6.6	-0.31	1.2e-10	Smoking behavior;
LUAD	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg11166453	chr1:247681781	NA	0.38	8.03	0.36	9.52e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs3789045	0.774	rs898388	chr1:204500257	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.43	-7.13	-0.33	4.26e-12	Educational attainment (college completion);
LUAD	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg08470875	chr2:26401718	FAM59B	-0.6	-8.13	-0.37	4.82e-15	Gut microbiome composition (summer);
LUAD	cis	rs6906287	0.647	rs12203006	chr6:118917086	C/T	cg21191810	chr6:118973309	C6orf204	0.5	9.56	0.42	9.46e-20	Electrocardiographic conduction measures;
LUAD	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg23173402	chr1:227635558	NA	0.72	7.74	0.35	7.61e-14	Major depressive disorder;
LUAD	cis	rs9300255	0.722	rs34997336	chr12:123829116	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.4	6.87	0.32	2.33e-11	Neutrophil percentage of white cells;
LUAD	cis	rs938554	0.956	rs13115469	chr4:9925145	T/C	cg00071950	chr4:10020882	SLC2A9	0.55	8.57	0.38	1.97e-16	Blood metabolite levels;
LUAD	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg22467129	chr15:76604101	ETFA	0.46	7.84	0.36	3.72e-14	Blood metabolite levels;
LUAD	cis	rs2073300	1.000	rs6114101	chr20:23446322	C/T	cg12062639	chr20:23401060	NAPB	0.91	8.31	0.37	1.31e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs11153730	0.503	rs369383	chr6:118618400	T/A	cg21191810	chr6:118973309	C6orf204	0.53	10.63	0.46	1.47e-23	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.53	8.18	0.37	3.41e-15	Platelet count;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08732623	chr10:127408269	C10orf137	-0.52	-6.38	-0.3	4.56e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg25036284	chr2:26402008	FAM59B	-0.56	-7.93	-0.36	2e-14	Gut microbiome composition (summer);
LUAD	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.75	0.39	5.3e-17	Menarche (age at onset);
LUAD	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg02551604	chr5:131831745	NA	-0.61	-10.02	-0.44	2.39e-21	Asthma (sex interaction);
LUAD	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg25809561	chr17:30822961	MYO1D	0.77	16.17	0.62	3.97e-46	Schizophrenia;
LUAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	cis	rs4700695	0.511	rs29443	chr5:65504927	G/A	cg21114390	chr5:65439923	SFRS12	-0.78	-12.34	-0.51	4.47e-30	Facial morphology (factor 19);
LUAD	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg18132916	chr6:79620363	NA	-0.44	-7.49	-0.34	3.97e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4523957	0.690	rs28505924	chr17:2088838	G/C	cg16513277	chr17:2031491	SMG6	-0.96	-18.75	-0.67	1.62e-57	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9807989	0.811	rs7608638	chr2:102970289	A/G	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.05e-10	Asthma;
LUAD	trans	rs7615952	0.546	rs111812401	chr3:125361495	G/A	cg00769240	chr8:12517080	NA	-0.38	-6.57	-0.3	1.45e-10	Blood pressure (smoking interaction);
LUAD	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg15557168	chr22:42548783	NA	-0.5	-8.91	-0.4	1.55e-17	Schizophrenia;
LUAD	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.57	-9.86	-0.43	8.5e-21	Prudent dietary pattern;
LUAD	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg23958373	chr8:599963	NA	0.79	8.06	0.36	7.93e-15	IgG glycosylation;
LUAD	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg21890820	chr11:65308645	LTBP3	0.46	7.38	0.34	8.22e-13	Bone mineral density;
LUAD	cis	rs986417	0.901	rs9743622	chr14:61037163	A/T	cg27398547	chr14:60952738	C14orf39	0.62	7.64	0.35	1.48e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs7086627	0.507	rs7077907	chr10:82017082	A/G	cg01528321	chr10:82214614	TSPAN14	0.41	6.61	0.31	1.17e-10	Post bronchodilator FEV1;
LUAD	cis	rs1832871	0.711	rs76962726	chr6:158674041	C/T	cg07165851	chr6:158734300	TULP4	0.72	11.1	0.48	2.6e-25	Height;
LUAD	cis	rs11048434	0.736	rs11048344	chr12:9122609	G/C	cg13575925	chr12:9217583	LOC144571	0.36	6.72	0.31	5.83e-11	Sjögren's syndrome;
LUAD	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg23158103	chr7:148848205	ZNF398	-0.6	-9.97	-0.44	3.72e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-10.85	-0.47	2.38e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	2.95e-12	Motion sickness;
LUAD	cis	rs9972944	0.756	rs9899781	chr17:63769384	C/T	cg07283582	chr17:63770753	CCDC46	-0.51	-11.6	-0.49	3.32e-27	Total body bone mineral density;
LUAD	cis	rs11048434	0.698	rs1805745	chr12:9065226	A/T	cg23795048	chr12:9217529	LOC144571	0.41	7.25	0.33	2.03e-12	Sjögren's syndrome;
LUAD	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg20701182	chr2:24300061	SF3B14	0.57	6.92	0.32	1.71e-11	Lymphocyte counts;
LUAD	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg10518543	chr12:38710700	ALG10B	0.42	6.4	0.3	4.17e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg15181151	chr6:150070149	PCMT1	0.42	8.63	0.39	1.27e-16	Lung cancer;
LUAD	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	ch.11.42038R	chr11:967971	AP2A2	0.39	6.88	0.32	2.19e-11	Alzheimer's disease (late onset);
LUAD	cis	rs36051895	0.659	rs62541538	chr9:5038164	G/A	cg02405213	chr9:5042618	JAK2	-0.48	-6.58	-0.3	1.37e-10	Pediatric autoimmune diseases;
LUAD	cis	rs4853036	0.953	rs3771539	chr2:70033711	G/C	cg02498382	chr2:70120550	SNRNP27	-0.46	-7.4	-0.34	7.19e-13	Colorectal or endometrial cancer;
LUAD	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg00634984	chr7:65235879	NA	0.52	7.38	0.34	8.44e-13	Aortic root size;
LUAD	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg00383909	chr3:49044727	WDR6	0.67	8.49	0.38	3.58e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg02269571	chr22:50332266	NA	-0.67	-9.76	-0.43	2.01e-20	Schizophrenia;
LUAD	cis	rs6992820	0.967	rs4737418	chr8:56711267	A/G	cg06880721	chr8:56792545	LYN	-0.45	-7.4	-0.34	7.3e-13	Mean platelet volume;
LUAD	trans	rs7395662	0.929	rs12363679	chr11:48556023	G/C	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.1e-12	HDL cholesterol;
LUAD	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg15462221	chr8:8086144	FLJ10661	0.42	6.53	0.3	1.9e-10	Mood instability;
LUAD	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.11	0.33	5.13e-12	Menopause (age at onset);
LUAD	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg14582100	chr15:45693742	SPATA5L1	0.43	8.6	0.39	1.58e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs738322	0.804	rs4821742	chr22:38514839	T/C	cg17652424	chr22:38574118	PLA2G6	-0.28	-8.16	-0.37	3.89e-15	Cutaneous nevi;
LUAD	cis	rs4285028	0.948	rs79103597	chr3:121667629	C/T	cg20356878	chr3:121714668	ILDR1	-0.5	-6.73	-0.31	5.44e-11	Multiple sclerosis;
LUAD	cis	rs13394619	1.000	rs13394619	chr2:11727507	A/G	cg07314298	chr2:11723111	GREB1	0.5	9.35	0.41	5.27e-19	Endometriosis;
LUAD	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg17366294	chr4:99064904	C4orf37	-0.56	-9.49	-0.42	1.73e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2797160	0.967	rs1739355	chr6:126018114	A/G	cg05901451	chr6:126070800	HEY2	0.46	6.79	0.31	3.79e-11	Endometrial cancer;
LUAD	cis	rs76878669	0.606	rs1785639	chr11:66100430	G/A	cg18002602	chr11:66138449	SLC29A2	0.46	9.74	0.43	2.32e-20	Educational attainment (years of education);
LUAD	cis	rs9323205	0.731	rs56024569	chr14:51697655	A/G	cg23942311	chr14:51606299	NA	-0.6	-8.7	-0.39	7.39e-17	Cancer;
LUAD	cis	rs1595825	0.891	rs75946628	chr2:198546239	C/T	cg00982548	chr2:198649783	BOLL	-0.65	-8.98	-0.4	9.29e-18	Ulcerative colitis;
LUAD	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-8.81	-0.39	3.37e-17	Multiple sclerosis;Ankylosing spondylitis;
LUAD	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg20487152	chr13:99095054	FARP1	-0.49	-8.21	-0.37	2.76e-15	Longevity;
LUAD	trans	rs2018683	0.523	rs886834	chr7:29021336	G/A	cg19402173	chr7:128379420	CALU	-0.44	-6.94	-0.32	1.52e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.55	0.46	2.83e-23	Colorectal cancer;
LUAD	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg18512352	chr11:47633146	NA	-0.54	-9.49	-0.42	1.69e-19	Subjective well-being;
LUAD	cis	rs10916814	0.588	rs10799640	chr1:20896411	T/C	cg24502330	chr1:20914028	CDA	-0.36	-7.2	-0.33	2.86e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2004318	1.000	rs7258275	chr19:55080756	T/C	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.96e-13	Blood protein levels;
LUAD	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26314531	chr2:26401878	FAM59B	-0.55	-7.71	-0.35	9.38e-14	Gut microbiome composition (summer);
LUAD	cis	rs870825	0.616	rs7678616	chr4:185648714	T/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.55	0.3	1.71e-10	Lung cancer in ever smokers;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg18503387	chr17:55927006	MRPS23	-0.41	-7.06	-0.32	6.72e-12	Subcortical brain region volumes;
LUAD	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg17177755	chr1:15930204	NA	0.44	7.11	0.33	5.08e-12	Systolic blood pressure;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09920427	chr19:12777674	MORG1;MAN2B1	-0.45	-7.36	-0.34	9.75e-13	Height;
LUAD	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg22906224	chr7:99728672	NA	0.55	9.55	0.42	1.07e-19	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg05340658	chr4:99064831	C4orf37	-0.55	-9.46	-0.42	2.21e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-7.72	-0.35	8.65e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4711350	1.000	rs943472	chr6:33738442	T/C	cg16010596	chr6:33739607	LEMD2	-0.38	-6.45	-0.3	3.15e-10	Schizophrenia;
LUAD	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.79	0.31	3.84e-11	Parkinson's disease;
LUAD	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg27432699	chr2:27873401	GPN1	0.43	7.41	0.34	7.11e-13	Total body bone mineral density;
LUAD	cis	rs7809615	0.901	rs10230784	chr7:99113672	G/A	cg12290671	chr7:99195819	NA	-0.69	-8.08	-0.37	6.97e-15	Blood metabolite ratios;
LUAD	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg05368731	chr17:41323189	NBR1	0.86	16.87	0.63	3.38e-49	Menopause (age at onset);
LUAD	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.4	7.04	0.32	7.7e-12	Menarche (age at onset);
LUAD	cis	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg21775007	chr8:11205619	TDH	0.37	6.39	0.3	4.27e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg04218760	chr10:45406644	TMEM72	-0.32	-8.06	-0.36	7.99e-15	Mean corpuscular volume;
LUAD	cis	rs7575217	0.767	rs796064	chr2:101729682	G/A	cg23907051	chr2:101730305	TBC1D8	-0.29	-6.68	-0.31	7.72e-11	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs7107174	1.000	rs7107174	chr11:77997936	C/T	cg19901956	chr11:77921274	USP35	-0.52	-6.46	-0.3	2.92e-10	Testicular germ cell tumor;
LUAD	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg04450456	chr4:17643702	FAM184B	0.37	6.9	0.32	1.93e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.58	-7.45	-0.34	5.42e-13	Alzheimer's disease;
LUAD	cis	rs6138458	1.000	rs11905625	chr20:24977065	A/C	cg26195577	chr20:24973756	C20orf3	0.98	17.44	0.65	9.94e-52	Blood protein levels;
LUAD	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg02389323	chr16:88786976	FAM38A	1.03	10.19	0.44	5.88e-22	Plateletcrit;
LUAD	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg10018233	chr7:150070692	REPIN1	0.48	7.54	0.34	2.9e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1904096	0.506	rs7697827	chr4:95184748	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.48	-8.8	-0.39	3.52e-17	Type 2 diabetes;
LUAD	cis	rs4006360	0.522	rs11871050	chr17:39236997	A/T	cg16090541	chr17:39240343	KRTAP4-7	-0.36	-6.39	-0.3	4.39e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg08885076	chr2:99613938	TSGA10	-0.4	-7.18	-0.33	3.2e-12	Chronic sinus infection;
LUAD	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg22338127	chr1:209979572	IRF6	0.5	6.36	0.3	5.36e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg14820908	chr5:178986412	RUFY1	0.7	12.07	0.51	4.79e-29	Lung cancer;
LUAD	cis	rs11209185	0.509	rs9326078	chr1:68452388	A/G	cg22082780	chr1:68452167	NA	0.51	11.19	0.48	1.19e-25	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg04117972	chr1:227635322	NA	0.64	6.52	0.3	2.01e-10	Major depressive disorder;
LUAD	cis	rs56161922	1.000	rs55821028	chr1:207843000	G/A	cg11752769	chr1:207818423	CR1L	-0.67	-7.0	-0.32	9.84e-12	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg27490568	chr2:178487706	NA	0.58	8.48	0.38	3.89e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01122672	chr16:47178067	NETO2	-0.62	-6.42	-0.3	3.66e-10	Type 2 diabetes;
LUAD	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg26587870	chr6:27730563	NA	-0.49	-7.99	-0.36	1.29e-14	Parkinson's disease;
LUAD	cis	rs6076065	0.676	rs1419005	chr20:23336432	G/T	cg11657817	chr20:23433608	CST11	-0.49	-9.4	-0.42	3.46e-19	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs9287719	0.625	rs7567304	chr2:10790029	T/C	cg01299579	chr2:10830716	NOL10	0.39	6.65	0.31	9.17e-11	Prostate cancer;
LUAD	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg24069376	chr3:38537580	EXOG	0.43	10.42	0.45	9.12e-23	Electrocardiographic conduction measures;
LUAD	trans	rs75804782	0.625	rs10929281	chr2:239468938	G/A	cg01134436	chr17:81009848	B3GNTL1	0.71	7.28	0.33	1.64e-12	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7903847	0.642	rs11189178	chr10:99143272	T/G	cg20016023	chr10:99160130	RRP12	-0.3	-7.12	-0.33	4.78e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg07167872	chr1:205819463	PM20D1	-0.53	-8.02	-0.36	1.03e-14	Menarche (age at onset);
LUAD	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg18230493	chr5:56204884	C5orf35	-0.81	-11.59	-0.49	3.64e-27	Initial pursuit acceleration;
LUAD	cis	rs1971762	0.583	rs1527068	chr12:54088688	A/G	cg23533419	chr12:54090519	NA	-0.34	-6.4	-0.3	4.17e-10	Height;
LUAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg06453172	chr10:134556979	INPP5A	-0.76	-10.99	-0.47	7.11e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9473147	0.516	rs9349413	chr6:47511491	A/G	cg02130027	chr6:47444894	CD2AP	0.36	6.57	0.3	1.49e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs909002	0.849	rs10914458	chr1:32096746	T/C	cg13919466	chr1:32135498	COL16A1	-0.36	-8.38	-0.38	8.16e-16	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg00717180	chr2:96193071	NA	-0.4	-7.39	-0.34	7.77e-13	HDL cholesterol;
LUAD	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.13	-0.37	4.77e-15	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2742234	0.518	rs1254967	chr10:43690391	G/A	cg15436174	chr10:43711423	RASGEF1A	0.53	8.93	0.4	1.32e-17	Hirschsprung disease;
LUAD	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg05887092	chr17:76393375	PGS1	0.42	7.41	0.34	7.1e-13	HDL cholesterol levels;
LUAD	cis	rs3823572	0.542	rs62470448	chr7:133635618	T/A	cg03336402	chr7:133662267	EXOC4	0.44	7.82	0.36	4.27e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs300774	1.000	rs300781	chr2:110385	G/A	cg21211680	chr2:198530	NA	-0.47	-6.78	-0.31	4.02e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg26304593	chr6:42947056	PEX6	-0.46	-7.68	-0.35	1.11e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.5	-8.99	-0.4	8.19e-18	Lymphocyte counts;
LUAD	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg20476274	chr7:133979776	SLC35B4	0.84	16.9	0.63	2.51e-49	Mean platelet volume;
LUAD	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg27494647	chr7:150038898	RARRES2	0.38	6.85	0.32	2.54e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg01689657	chr7:91764605	CYP51A1	-0.39	-9.8	-0.43	1.38e-20	Breast cancer;
LUAD	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.62	-0.35	1.63e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9462027	0.628	rs9357181	chr6:34673833	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.34	8.65	0.39	1.09e-16	Systemic lupus erythematosus;
LUAD	cis	rs35883536	0.647	rs10875317	chr1:101045438	G/T	cg06223162	chr1:101003688	GPR88	-0.45	-8.85	-0.4	2.38e-17	Monocyte count;
LUAD	cis	rs12940923	1.000	rs2856857	chr17:56357833	G/A	cg19466818	chr17:56409534	MIR142	-0.37	-6.38	-0.3	4.7e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.8	-0.31	3.48e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg04414720	chr1:150670196	GOLPH3L	0.62	10.51	0.45	4.26e-23	Melanoma;
LUAD	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg11062466	chr8:58055876	NA	0.44	6.36	0.3	5.4e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.26e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg12011299	chr4:100065546	ADH4	0.68	12.05	0.51	6.24e-29	Smoking initiation;
LUAD	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-9.28	-0.41	9.04e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7640424	0.721	rs162064	chr3:107824061	G/T	cg09227934	chr3:107805635	CD47	-0.38	-6.91	-0.32	1.8e-11	Body mass index;
LUAD	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg21153622	chr11:89784906	NA	-0.33	-6.55	-0.3	1.7e-10	Coronary artery disease;
LUAD	cis	rs300774	0.925	rs300726	chr2:132490	C/G	cg21211680	chr2:198530	NA	-0.47	-7.34	-0.34	1.1e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs7020830	0.505	rs12553878	chr9:37095705	C/T	cg14294708	chr9:37120828	ZCCHC7	0.59	10.47	0.45	5.58e-23	Schizophrenia;
LUAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.68	0.31	7.6e-11	Prudent dietary pattern;
LUAD	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg12379764	chr21:47803548	PCNT	-0.38	-6.42	-0.3	3.75e-10	Testicular germ cell tumor;
LUAD	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg09455208	chr3:40491958	NA	0.64	14.23	0.57	8.13e-38	Renal cell carcinoma;
LUAD	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg16006841	chr5:176797999	RGS14	0.56	10.14	0.44	8.67e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs315934	0.664	rs315922	chr2:113862647	C/T	cg09040174	chr2:113837401	NA	-0.6	-7.1	-0.33	5.34e-12	Dysmenorrheic pain;
LUAD	cis	rs1949733	0.848	rs2255501	chr4:8475014	G/A	cg13073564	chr4:8508604	NA	0.5	8.84	0.39	2.61e-17	Response to antineoplastic agents;
LUAD	trans	rs564343	0.563	rs1642958	chr11:65821973	G/C	cg26701943	chr11:108369231	KDELC2	-0.49	-8.09	-0.37	6.43e-15	Obesity (early onset extreme);
LUAD	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg21153622	chr11:89784906	NA	-0.32	-6.46	-0.3	2.95e-10	Height;
LUAD	trans	rs225245	0.755	rs7217565	chr17:34024707	C/A	cg19694781	chr19:47549865	TMEM160	-0.48	-7.93	-0.36	1.99e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.5	7.8	0.35	4.93e-14	Total body bone mineral density;
LUAD	cis	rs868036	1.000	rs4776377	chr15:68103387	T/C	cg08079166	chr15:68083412	MAP2K5	0.3	6.49	0.3	2.39e-10	Restless legs syndrome;
LUAD	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	7.22	0.33	2.49e-12	Cognitive test performance;
LUAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg15117754	chr3:10150083	C3orf24	0.45	7.24	0.33	2.11e-12	Alzheimer's disease;
LUAD	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg02807482	chr3:125708958	NA	-0.64	-8.35	-0.38	1e-15	Blood pressure (smoking interaction);
LUAD	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg03909863	chr11:638404	DRD4	-0.46	-6.42	-0.3	3.58e-10	Systemic lupus erythematosus;
LUAD	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg08798685	chr6:27730294	NA	-0.43	-6.89	-0.32	2.07e-11	Parkinson's disease;
LUAD	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg13859433	chr6:33739653	LEMD2	-0.34	-7.03	-0.32	8.49e-12	Schizophrenia;
LUAD	cis	rs11958404	0.932	rs59246968	chr5:157418180	T/C	cg05962755	chr5:157440814	NA	0.42	6.57	0.3	1.46e-10	IgG glycosylation;
LUAD	cis	rs17539620	0.624	rs74551216	chr6:154840524	T/C	cg20019720	chr6:154832845	CNKSR3	0.64	12.23	0.51	1.14e-29	Lipoprotein (a) levels;
LUAD	trans	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg18335740	chr13:41363409	SLC25A15	-0.53	-8.9	-0.4	1.65e-17	Lewy body disease;
LUAD	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-8.86	-0.4	2.3e-17	Hemoglobin concentration;
LUAD	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-7.0	-0.32	1.04e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg15445000	chr17:37608096	MED1	0.44	8.17	0.37	3.48e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs2242073	0.733	rs6750890	chr2:209011014	A/C	cg06181187	chr2:209010896	CRYGB	-0.46	-7.49	-0.34	4.14e-13	Attention deficit hyperactivity disorder;
LUAD	cis	rs11048434	0.736	rs12424026	chr12:9110993	T/C	cg13575925	chr12:9217583	LOC144571	0.36	6.83	0.32	2.92e-11	Sjögren's syndrome;
LUAD	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.23	-0.37	2.38e-15	Bipolar disorder;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09090048	chr11:134093731	VPS26B;NCAPD3	-0.55	-6.48	-0.3	2.51e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg11266682	chr4:10021025	SLC2A9	0.6	13.7	0.55	1.28e-35	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs739496	0.843	rs848132	chr12:111989979	C/A	cg10833066	chr12:111807467	FAM109A	0.42	6.58	0.3	1.39e-10	Platelet count;
LUAD	cis	rs80319144	0.855	rs115894713	chr2:159291278	G/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.9	0.32	1.88e-11	Restless legs syndrome;
LUAD	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg09455208	chr3:40491958	NA	0.54	11.18	0.48	1.3e-25	Renal cell carcinoma;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg14664575	chr19:40476624	PSMC4	-0.4	-6.78	-0.31	4.17e-11	Subcortical brain region volumes;
LUAD	cis	rs4662945	0.525	rs10174479	chr2:130296287	A/C	cg05903289	chr2:130345205	NA	-0.31	-6.73	-0.31	5.61e-11	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs9326248	0.510	rs4938332	chr11:116930798	A/G	cg20608306	chr11:116969690	SIK3	0.31	6.84	0.32	2.87e-11	Blood protein levels;
LUAD	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg26384229	chr12:38710491	ALG10B	0.47	7.62	0.35	1.66e-13	Morning vs. evening chronotype;
LUAD	cis	rs775227	0.574	rs60131925	chr3:113034768	T/C	cg18753928	chr3:113234510	CCDC52	-0.62	-7.99	-0.36	1.28e-14	Dental caries;
LUAD	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg03609598	chr5:56110824	MAP3K1	-0.61	-8.2	-0.37	2.92e-15	Initial pursuit acceleration;
LUAD	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg16060761	chr17:80687452	NA	-0.44	-6.78	-0.31	4.17e-11	Breast cancer;
LUAD	cis	rs9309473	0.718	rs6546829	chr2:73613789	C/G	cg20560298	chr2:73613845	ALMS1	-0.45	-7.04	-0.32	7.57e-12	Metabolite levels;
LUAD	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg26587870	chr6:27730563	NA	-0.48	-7.79	-0.35	5.1e-14	Parkinson's disease;
LUAD	cis	rs10823500	0.674	rs7089860	chr10:71992848	C/G	cg02100629	chr10:71892760	AIFM2	-0.35	-7.06	-0.32	7e-12	Blood protein levels;
LUAD	cis	rs1550582	1.000	rs4909827	chr8:135517576	C/T	cg17885191	chr8:135476712	NA	0.72	10.29	0.45	2.57e-22	Educational attainment;
LUAD	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg09537434	chr19:41945824	ATP5SL	-0.49	-7.95	-0.36	1.69e-14	Height;
LUAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.55	-9.71	-0.43	3.05e-20	Lymphocyte counts;
LUAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	trans	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg22823121	chr1:150693482	HORMAD1	-0.39	-7.6	-0.35	1.98e-13	Melanoma;
LUAD	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg26408565	chr15:76604113	ETFA	-0.56	-9.78	-0.43	1.75e-20	Blood metabolite levels;
LUAD	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-9.0	-0.4	7.89e-18	Bipolar disorder;
LUAD	cis	rs5758511	0.773	rs73165164	chr22:42355549	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.38	6.43	0.3	3.47e-10	Birth weight;
LUAD	cis	rs4919694	1.000	rs4919694	chr10:104698978	T/C	cg04362960	chr10:104952993	NT5C2	0.7	7.57	0.35	2.35e-13	Arsenic metabolism;
LUAD	cis	rs755249	0.501	rs2455648	chr1:39643712	C/T	cg27567593	chr1:39956653	BMP8A	-0.35	-6.54	-0.3	1.83e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2016266	0.859	rs7953656	chr12:53738433	G/T	cg26875137	chr12:53738046	NA	0.34	7.02	0.32	8.9e-12	Bone mineral density (spine);Bone mineral density;
LUAD	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg18944383	chr4:111397179	ENPEP	0.37	7.68	0.35	1.12e-13	Height;
LUAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9354308	0.933	rs2802062	chr6:66561973	C/G	cg07460842	chr6:66804631	NA	0.51	7.59	0.35	2.06e-13	Metabolite levels;
LUAD	cis	rs73206853	0.841	rs73206882	chr12:110840515	G/A	cg12870014	chr12:110450643	ANKRD13A	0.61	6.73	0.31	5.38e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg17178900	chr1:205818956	PM20D1	0.74	15.16	0.59	8.61e-42	Menarche (age at onset);
LUAD	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.9	-0.36	2.41e-14	Diabetic kidney disease;
LUAD	cis	rs2456568	0.503	rs4254038	chr11:93666978	T/C	cg17595323	chr11:93583763	C11orf90	-0.44	-8.8	-0.39	3.49e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs17095355	1.000	rs12242642	chr10:111724213	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.69	-9.35	-0.41	5.32e-19	Biliary atresia;
LUAD	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	0.5	6.87	0.32	2.26e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.49	-0.34	4.1e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg12373934	chr17:7590932	WRAP53;TP53	-0.4	-6.44	-0.3	3.2e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1371614	0.501	rs4992933	chr2:27178972	C/A	cg00617064	chr2:27272375	NA	-0.38	-7.31	-0.33	1.36e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs2602836	0.600	rs6858148	chr4:100065917	T/C	cg12011299	chr4:100065546	ADH4	-0.85	-19.2	-0.68	1.5e-59	HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg13319975	chr6:146136371	FBXO30	-0.64	-10.89	-0.47	1.68e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg13319975	chr6:146136371	FBXO30	-0.55	-9.42	-0.42	2.9e-19	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs877282	0.945	rs10904554	chr10:786768	T/C	cg22713356	chr15:30763199	NA	1.34	18.73	0.67	1.85e-57	Uric acid levels;
LUAD	cis	rs76878669	0.561	rs10750784	chr11:66110666	A/G	cg10616300	chr11:66138557	SLC29A2	-0.35	-7.45	-0.34	5.29e-13	Educational attainment (years of education);
LUAD	cis	rs7301016	0.793	rs11174557	chr12:62979216	C/T	cg11441379	chr12:63026424	NA	0.59	7.76	0.35	6.44e-14	IgG glycosylation;
LUAD	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg11189052	chr15:85197271	WDR73	0.59	7.05	0.32	7.55e-12	Schizophrenia;
LUAD	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg14779329	chr11:130786720	SNX19	0.38	6.59	0.3	1.35e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7809950	0.798	rs2701687	chr7:107304628	C/T	cg23024343	chr7:107201750	COG5	0.51	8.5	0.38	3.18e-16	Coronary artery disease;
LUAD	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg09904177	chr6:26538194	HMGN4	0.43	7.03	0.32	8.23e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs617219	0.892	rs1717566	chr5:78432608	T/C	cg25119155	chr5:78426943	BHMT	0.36	6.4	0.3	4.16e-10	Betaine levels in individuals undergoing cardiac evaluation;
LUAD	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg14664628	chr15:75095509	CSK	-0.42	-6.41	-0.3	3.97e-10	Breast cancer;
LUAD	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg10523679	chr1:76189770	ACADM	-0.73	-11.38	-0.48	2.38e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg15133208	chr4:90757351	SNCA	-0.47	-7.54	-0.34	2.98e-13	Neuroticism;
LUAD	cis	rs4523957	0.928	rs9905529	chr17:2177732	T/C	cg16513277	chr17:2031491	SMG6	-0.77	-14.53	-0.58	4.36e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg25767906	chr1:53392781	SCP2	0.41	7.54	0.34	2.94e-13	Monocyte count;
LUAD	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg17644776	chr2:200775616	C2orf69	0.53	7.58	0.35	2.27e-13	Schizophrenia;
LUAD	cis	rs9644630	0.841	rs7018210	chr8:19327643	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.36	6.65	0.31	8.98e-11	Oropharynx cancer;
LUAD	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg00933542	chr6:150070202	PCMT1	0.45	9.85	0.43	9.89e-21	Lung cancer;
LUAD	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg26587870	chr6:27730563	NA	-0.49	-8.18	-0.37	3.36e-15	Parkinson's disease;
LUAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03452623	chr4:187889614	NA	-0.81	-16.62	-0.63	4.13e-48	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg09509183	chr1:209979624	IRF6	0.37	6.52	0.3	2e-10	Monobrow;
LUAD	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg13385794	chr1:248469461	NA	-0.26	-7.15	-0.33	3.73e-12	Common traits (Other);
LUAD	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.38	-6.53	-0.3	1.83e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg08601574	chr20:25228251	PYGB	-0.46	-8.77	-0.39	4.37e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg02734326	chr4:10020555	SLC2A9	0.65	11.46	0.49	1.2e-26	Bone mineral density;
LUAD	cis	rs3784262	0.692	rs4646581	chr15:58307898	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.52	-0.34	3.39e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg25036284	chr2:26402008	FAM59B	-0.83	-11.9	-0.5	2.3e-28	Gut microbiome composition (summer);
LUAD	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg02251663	chr11:14281053	SPON1	-0.39	-7.57	-0.35	2.32e-13	Mitochondrial DNA levels;
LUAD	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg04568274	chr7:158649319	WDR60	0.41	6.59	0.31	1.32e-10	Height;
LUAD	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24351916	chr3:39452635	SNORA62;RPSA	0.57	7.14	0.33	3.99e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	9.34	0.41	5.46e-19	Melanoma;
LUAD	cis	rs1448094	0.617	rs1393612	chr12:86474576	T/C	cg19622623	chr12:86230825	RASSF9	0.41	7.39	0.34	8.03e-13	Major depressive disorder;
LUAD	cis	rs62400317	0.826	rs62438867	chr6:45049787	G/A	cg18551225	chr6:44695536	NA	-0.56	-8.65	-0.39	1.06e-16	Total body bone mineral density;
LUAD	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.53	0.3	1.88e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg04564737	chr14:89029224	ZC3H14	-0.39	-6.35	-0.3	5.5e-10	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs12347191	0.500	rs973473	chr9:100620730	T/G	cg13688889	chr9:100608707	NA	-0.63	-10.21	-0.44	4.95e-22	Orofacial clefts;
LUAD	cis	rs34734847	1.000	rs10431385	chr12:121128882	T/C	cg27246729	chr12:121163418	ACADS	0.39	7.55	0.34	2.77e-13	Mean corpuscular volume;
LUAD	cis	rs11112613	0.713	rs10507192	chr12:105948247	A/G	cg03607813	chr12:105948248	NA	0.82	14.83	0.58	2.31e-40	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg09365446	chr1:150670422	GOLPH3L	0.55	9.62	0.42	6.27e-20	Melanoma;
LUAD	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11644478	chr21:40555479	PSMG1	0.67	11.04	0.47	4.58e-25	Cognitive function;
LUAD	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg15181151	chr6:150070149	PCMT1	0.34	6.75	0.31	4.92e-11	Lung cancer;
LUAD	cis	rs10899021	1.000	rs61900635	chr11:74359010	C/G	cg25880958	chr11:74394337	NA	-0.6	-7.97	-0.36	1.47e-14	Response to metformin (IC50);
LUAD	cis	rs7904368	0.806	rs7899923	chr10:16857394	G/A	cg14835575	chr10:16859367	RSU1	0.96	13.76	0.56	7.59e-36	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg15790184	chr11:494944	RNH1	0.56	6.83	0.32	2.9e-11	Body mass index;
LUAD	cis	rs7937890	0.559	rs2575829	chr11:14485021	C/T	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.18e-12	Mitochondrial DNA levels;
LUAD	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.75	0.31	5.03e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.71e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.7	0.31	6.57e-11	Obesity-related traits;
LUAD	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.34	-0.51	4.3e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	7.95	0.36	1.71e-14	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg08085267	chr17:45401833	C17orf57	-0.67	-12.16	-0.51	2.21e-29	Glaucoma (primary open-angle);
LUAD	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg11502198	chr6:26597334	ABT1	0.73	12.5	0.52	1.02e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00149659	chr3:10157352	C3orf10	0.61	8.49	0.38	3.41e-16	Alzheimer's disease;
LUAD	cis	rs7843479	0.601	rs727693	chr8:21850116	A/G	cg03445287	chr8:21823731	XPO7	-0.48	-8.98	-0.4	9.11e-18	Mean corpuscular volume;
LUAD	cis	rs8051149	0.652	rs9926829	chr16:87883089	A/G	cg01412419	chr16:87856264	NA	-0.41	-6.72	-0.31	5.93e-11	Blood metabolite levels;
LUAD	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg02269571	chr22:50332266	NA	-0.55	-8.19	-0.37	3.19e-15	Schizophrenia;
LUAD	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg08761264	chr16:28874980	SH2B1	-0.45	-6.86	-0.32	2.53e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg07343612	chr16:622815	PIGQ	-0.8	-15.66	-0.61	6.37e-44	Height;
LUAD	cis	rs1816752	0.905	rs7339140	chr13:25011902	A/G	cg02811702	chr13:24901961	NA	0.46	7.93	0.36	2.03e-14	Obesity-related traits;
LUAD	cis	rs3106136	1.000	rs2632401	chr4:95147055	C/G	cg11021082	chr4:95130006	SMARCAD1	0.41	7.76	0.35	6.62e-14	Capecitabine sensitivity;
LUAD	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg19761014	chr17:28927070	LRRC37B2	0.94	8.9	0.4	1.71e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg02018176	chr4:1364513	KIAA1530	0.45	8.19	0.37	3.18e-15	Longevity;
LUAD	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.28	-0.33	1.69e-12	Blood metabolite levels;
LUAD	cis	rs9807989	0.524	rs6759479	chr2:103040047	A/C	cg03938978	chr2:103052716	IL18RAP	0.45	10.37	0.45	1.29e-22	Asthma;
LUAD	cis	rs35883536	1.000	rs4907921	chr1:101128249	C/T	cg06223162	chr1:101003688	GPR88	0.36	6.67	0.31	8.27e-11	Monocyte count;
LUAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg07362569	chr17:61921086	SMARCD2	0.39	6.8	0.31	3.61e-11	Prudent dietary pattern;
LUAD	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.79	-0.5	5.98e-28	Bipolar disorder;
LUAD	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.39	-6.39	-0.3	4.52e-10	Tonsillectomy;
LUAD	cis	rs10992471	0.603	rs12336884	chr9:95234183	A/C	cg14631576	chr9:95140430	CENPP	-0.56	-11.52	-0.49	7.08e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg07570687	chr10:102243282	WNT8B	0.48	7.34	0.34	1.09e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg02228675	chr17:40259724	DHX58	-0.44	-7.09	-0.33	5.79e-12	Fibrinogen levels;
LUAD	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg25767906	chr1:53392781	SCP2	-0.56	-10.58	-0.46	2.36e-23	Monocyte count;
LUAD	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg02423579	chr7:2872169	GNA12	-0.55	-9.37	-0.41	4.28e-19	Height;
LUAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg27454412	chr7:1067447	C7orf50	0.48	7.63	0.35	1.55e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg11062466	chr8:58055876	NA	0.7	9.22	0.41	1.38e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	15.8	0.61	1.58e-44	Exhaled nitric oxide levels;
LUAD	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg18827107	chr12:86230957	RASSF9	-0.7	-12.79	-0.53	6.85e-32	Major depressive disorder;
LUAD	cis	rs6484504	0.532	rs2616799	chr11:31319044	T/C	cg14844989	chr11:31128820	NA	0.46	8.4	0.38	6.97e-16	Red blood cell count;
LUAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg22907277	chr7:1156413	C7orf50	0.7	8.23	0.37	2.4e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.73	0.31	5.59e-11	Cognitive test performance;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg09123773	chr16:48419537	SIAH1	0.45	6.67	0.31	8.13e-11	QT interval;
LUAD	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg15448220	chr1:150897856	SETDB1	0.47	8.09	0.37	6.35e-15	Tonsillectomy;
LUAD	cis	rs4786125	1.000	rs4786125	chr16:6900547	G/A	cg03623568	chr16:6915990	A2BP1	-0.42	-8.47	-0.38	4.1e-16	Heart rate variability traits (SDNN);
LUAD	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg03477792	chr4:77819574	ANKRD56	0.49	7.53	0.34	3.15e-13	Emphysema distribution in smoking;
LUAD	cis	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.42	8.11	0.37	5.36e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg26384229	chr12:38710491	ALG10B	0.42	7.11	0.33	4.88e-12	Morning vs. evening chronotype;
LUAD	cis	rs6840360	0.530	rs12645029	chr4:152650032	T/C	cg22705602	chr4:152727874	NA	-0.46	-8.04	-0.36	8.78e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg26513180	chr16:89883248	FANCA	0.78	7.05	0.32	7.12e-12	Skin colour saturation;
LUAD	trans	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.82	-0.36	4.29e-14	Depression;
LUAD	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.17	-0.33	3.31e-12	Bipolar disorder;
LUAD	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg15557168	chr22:42548783	NA	-0.51	-9.54	-0.42	1.17e-19	Schizophrenia;
LUAD	trans	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg06606381	chr12:133084897	FBRSL1	-0.68	-7.09	-0.33	5.49e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs4650994	1.000	rs10913571	chr1:178526648	A/T	cg05059571	chr16:84539110	KIAA1609	-0.59	-10.06	-0.44	1.71e-21	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg00684032	chr4:1343700	KIAA1530	0.39	6.45	0.3	3.05e-10	Obesity-related traits;
LUAD	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg00933542	chr6:150070202	PCMT1	0.44	9.58	0.42	8.17e-20	Lung cancer;
LUAD	cis	rs4604732	0.631	rs74154675	chr1:247625836	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg21862992	chr11:68658383	NA	0.52	9.56	0.42	9.98e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg17063962	chr7:91808500	NA	0.67	11.67	0.49	1.77e-27	Breast cancer;
LUAD	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg10523679	chr1:76189770	ACADM	0.7	9.84	0.43	1.07e-20	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7759001	0.857	rs1022517	chr6:27365009	G/C	cg18711553	chr6:27366782	ZNF391	0.39	6.55	0.3	1.69e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs9522267	0.535	rs12583489	chr13:112233455	G/A	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.93e-11	Hepatitis;
LUAD	cis	rs4795519	0.922	rs1515750	chr17:22196513	A/T	cg22648282	chr17:21454238	C17orf51	-0.37	-6.37	-0.3	4.89e-10	Chronic myeloid leukemia;
LUAD	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.9	0.36	2.43e-14	Breast cancer;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg02083989	chr12:65153459	GNS	-0.4	-6.87	-0.32	2.26e-11	Subcortical brain region volumes;
LUAD	cis	rs75920871	1.000	rs1473325	chr11:116822034	C/T	cg04087571	chr11:116723030	SIK3	-0.32	-6.5	-0.3	2.33e-10	Subjective well-being;
LUAD	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg26343298	chr8:95960752	TP53INP1	0.37	7.77	0.35	6.16e-14	Type 2 diabetes;
LUAD	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg03161606	chr19:29218774	NA	0.6	8.65	0.39	1.05e-16	Methadone dose in opioid dependence;
LUAD	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.65	-10.97	-0.47	7.91e-25	Glomerular filtration rate;
LUAD	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg21856205	chr7:94953877	PON1	-0.53	-7.14	-0.33	4.08e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs629535	0.814	rs78813708	chr8:70073977	A/G	cg21567404	chr3:27674614	NA	1.0	18.27	0.66	2.26e-55	Dupuytren's disease;
LUAD	cis	rs12900413	0.687	rs12908489	chr15:90304269	A/G	cg24249390	chr15:90295951	MESP1	-0.34	-6.77	-0.31	4.38e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.52	-8.71	-0.39	6.87e-17	Alzheimer's disease (late onset);
LUAD	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02398342	chr17:80708632	TBCD;FN3K	-0.57	-9.87	-0.43	8.05e-21	Glycated hemoglobin levels;
LUAD	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg18196295	chr10:418757	DIP2C	0.47	7.83	0.36	3.91e-14	Psychosis in Alzheimer's disease;
LUAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg05313129	chr8:58192883	C8orf71	-0.53	-8.07	-0.37	7.48e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs13315871	0.929	rs13322000	chr3:58286929	G/A	cg12435725	chr3:58293450	RPP14	-0.74	-7.88	-0.36	2.86e-14	Cholesterol, total;
LUAD	trans	rs747782	0.528	rs624348	chr11:48400795	G/A	cg15704280	chr7:45808275	SEPT13	-0.63	-7.5	-0.34	3.88e-13	Intraocular pressure;
LUAD	cis	rs11229555	0.645	rs11229549	chr11:58395914	T/C	cg15696309	chr11:58395628	NA	-0.62	-7.24	-0.33	2.17e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs58799304	0.531	rs74965833	chr1:156054119	C/T	cg15685922	chr1:156045208	MEX3A	-0.42	-7.34	-0.34	1.07e-12	Ischemic stroke;
LUAD	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg23649088	chr2:200775458	C2orf69	0.8	14.54	0.58	3.82e-39	Osteoporosis;
LUAD	cis	rs7922314	0.510	rs10995312	chr10:64566572	A/G	cg14943953	chr10:64564468	ADO	-0.57	-7.04	-0.32	7.75e-12	Cutaneous psoriasis;
LUAD	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg02240030	chr7:2089880	MAD1L1	0.36	6.65	0.31	9.01e-11	Neuroticism;
LUAD	cis	rs9972944	0.756	rs9907996	chr17:63754889	C/T	cg07283582	chr17:63770753	CCDC46	-0.53	-11.9	-0.5	2.28e-28	Total body bone mineral density;
LUAD	cis	rs3857067	0.806	rs4693374	chr4:95086164	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.36	-6.38	-0.3	4.7e-10	QT interval;
LUAD	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg06640241	chr16:89574553	SPG7	0.71	12.39	0.52	2.78e-30	Multiple myeloma (IgH translocation);
LUAD	cis	rs12950390	0.548	rs62076098	chr17:45860584	C/T	cg03474202	chr17:45855739	NA	-0.3	-7.16	-0.33	3.56e-12	IgG glycosylation;
LUAD	cis	rs10821973	0.550	rs4979765	chr10:64029863	G/C	cg09941381	chr10:64027924	RTKN2	-0.35	-6.91	-0.32	1.74e-11	Hypothyroidism;
LUAD	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg21963583	chr11:68658836	MRPL21	0.62	10.79	0.46	3.88e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg19346786	chr7:2764209	NA	-0.56	-12.16	-0.51	2.17e-29	Height;
LUAD	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg03859395	chr2:55845619	SMEK2	0.75	13.89	0.56	2.02e-36	Metabolic syndrome;
LUAD	cis	rs10489202	0.632	rs202268	chr1:167927339	T/C	cg24449463	chr1:168025552	DCAF6	-0.73	-11.98	-0.5	1.12e-28	Schizophrenia;
LUAD	cis	rs2224391	0.590	rs2773298	chr6:5242067	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-7.86	-0.36	3.11e-14	Height;
LUAD	cis	rs7216064	1.000	rs62084238	chr17:65856573	T/A	cg08758996	chr17:66097529	LOC651250	0.47	7.12	0.33	4.58e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg04876069	chr12:132293656	NA	0.38	6.75	0.31	5.04e-11	Migraine;
LUAD	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-8.38	-0.38	8.11e-16	Blood metabolite levels;
LUAD	cis	rs4776059	1.000	rs4776058	chr15:52880263	A/G	cg24008177	chr15:52972085	KIAA1370	0.24	6.54	0.3	1.79e-10	Schizophrenia;
LUAD	cis	rs4638749	1.000	rs2219078	chr2:108875198	C/T	cg25838818	chr2:108905173	SULT1C2	-0.5	-8.03	-0.36	9.91e-15	Blood pressure;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12813709	chr11:576467	PHRF1;LOC143666	-0.42	-6.4	-0.3	4.23e-10	Height;
LUAD	cis	rs7116495	1.000	rs1573502	chr11:71747428	C/T	cg07596299	chr11:71824057	C11orf51	-0.77	-6.62	-0.31	1.08e-10	Severe influenza A (H1N1) infection;
LUAD	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-20.46	-0.71	3.39e-65	Height;
LUAD	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg09455208	chr3:40491958	NA	-0.54	-11.46	-0.49	1.1e-26	Renal cell carcinoma;
LUAD	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg26597838	chr10:835615	NA	1.28	19.87	0.69	1.55e-62	Eosinophil percentage of granulocytes;
LUAD	trans	rs2235573	0.625	rs8142174	chr22:38427963	C/T	cg19894588	chr14:64061835	NA	0.41	6.39	0.3	4.35e-10	Glioblastoma;Glioma;
LUAD	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg23231163	chr10:75533350	FUT11	-0.52	-9.65	-0.42	4.83e-20	Inflammatory bowel disease;
LUAD	cis	rs1595825	0.891	rs17520121	chr2:198898718	T/G	cg11031976	chr2:198649780	BOLL	-0.45	-6.43	-0.3	3.5e-10	Ulcerative colitis;
LUAD	cis	rs3806843	0.576	rs155361	chr5:140307284	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.64	-0.31	9.4e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg08085267	chr17:45401833	C17orf57	0.65	11.84	0.5	3.92e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg08564027	chr20:61660810	NA	0.81	16.59	0.63	5.81e-48	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs6594713	0.679	rs66572866	chr5:112761470	G/A	cg12552261	chr5:112820674	MCC	0.54	7.52	0.34	3.36e-13	Brain cytoarchitecture;
LUAD	cis	rs7089973	0.836	rs7895551	chr10:116625481	C/T	cg25233709	chr10:116636983	FAM160B1	0.39	7.56	0.35	2.48e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg17757837	chr7:157058334	UBE3C	0.48	8.47	0.38	4.2e-16	Body mass index;
LUAD	cis	rs7264396	0.512	rs2425072	chr20:34293686	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.1	-0.37	5.8e-15	Total cholesterol levels;
LUAD	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg22676075	chr6:135203613	NA	0.52	9.44	0.42	2.47e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27297192	chr10:134578999	INPP5A	0.38	6.7	0.31	6.82e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	trans	rs1493916	0.744	rs7504560	chr18:31312148	A/G	cg15819921	chr19:927150	ARID3A	-0.41	-6.72	-0.31	5.9e-11	Life satisfaction;
LUAD	cis	rs35740288	0.770	rs17570529	chr15:86125607	A/T	cg13263323	chr15:86062960	AKAP13	-0.42	-6.58	-0.3	1.38e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.98	0.53	1.11e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg18190219	chr22:46762943	CELSR1	-0.54	-6.78	-0.31	4.07e-11	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg26043149	chr18:55253948	FECH	0.53	8.81	0.39	3.19e-17	Bone mineral density;
LUAD	cis	rs6545883	0.868	rs7608483	chr2:61836235	A/C	cg15711740	chr2:61764176	XPO1	-0.43	-6.64	-0.31	9.9e-11	Tuberculosis;
LUAD	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg04944784	chr2:26401820	FAM59B	-0.76	-10.46	-0.45	6.36e-23	Gut microbiome composition (summer);
LUAD	cis	rs3813948	0.543	rs11120218	chr1:207278451	C/T	cg11153969	chr1:207277031	C4BPA	-0.68	-8.92	-0.4	1.4e-17	C4b binding protein levels;
LUAD	cis	rs2692947	0.794	rs2692949	chr2:96673525	G/A	cg23100626	chr2:96804247	ASTL	0.3	7.48	0.34	4.4e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg27489772	chr12:121021490	NA	-0.57	-7.18	-0.33	3.25e-12	Type 1 diabetes nephropathy;
LUAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08219700	chr8:58056026	NA	0.71	9.44	0.42	2.57e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7000551	0.675	rs2443503	chr8:22381850	A/G	cg12081754	chr8:22256438	SLC39A14	0.44	7.2	0.33	2.8e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg09033563	chr22:24373618	LOC391322	-0.56	-8.95	-0.4	1.09e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg08847533	chr14:75593920	NEK9	0.4	6.83	0.31	3.05e-11	Height;
LUAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg00431813	chr7:1051703	C7orf50	-0.41	-7.91	-0.36	2.23e-14	Longevity;Endometriosis;
LUAD	cis	rs9486719	0.948	rs2472904	chr6:96874962	T/G	cg06623918	chr6:96969491	KIAA0776	0.71	9.89	0.43	6.83e-21	Migraine;Coronary artery disease;
LUAD	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg12432903	chr7:1882776	MAD1L1	-0.44	-7.05	-0.32	7.56e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2294693	0.853	rs9296350	chr6:40977623	G/A	cg14769373	chr6:40998127	UNC5CL	-0.49	-7.69	-0.35	1.04e-13	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-9.98	-0.44	3.45e-21	Lymphocyte counts;
LUAD	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg25358565	chr5:93447407	FAM172A	0.63	7.37	0.34	8.86e-13	Diabetic retinopathy;
LUAD	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.66	0.31	8.31e-11	Depression;
LUAD	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg11645453	chr3:52864694	ITIH4	0.37	7.05	0.32	7.35e-12	Body mass index;
LUAD	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.15	0.33	3.89e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg08885076	chr2:99613938	TSGA10	0.37	6.51	0.3	2.15e-10	Chronic sinus infection;
LUAD	trans	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg11693508	chr17:37793320	STARD3	0.47	6.93	0.32	1.58e-11	Neuroticism;
LUAD	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg24838063	chr12:130822603	PIWIL1	0.62	10.47	0.45	5.94e-23	Menopause (age at onset);
LUAD	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.9	-0.32	1.93e-11	Height;
LUAD	cis	rs7267979	0.745	rs6132845	chr20:25547767	A/G	cg08601574	chr20:25228251	PYGB	0.34	6.39	0.3	4.4e-10	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6499255	0.951	rs7196943	chr16:69592449	T/A	cg15192750	chr16:69999425	NA	0.54	8.36	0.38	8.83e-16	IgE levels;
LUAD	trans	rs1997103	1.000	rs2009441	chr7:55405989	A/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.13e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg05342682	chr7:94953680	PON1	-0.5	-6.94	-0.32	1.53e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9322817	0.691	rs4460239	chr6:105325562	C/T	cg02098413	chr6:105308735	HACE1	0.4	8.58	0.39	1.8e-16	Thyroid stimulating hormone;
LUAD	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg18135555	chr8:22132992	PIWIL2	0.4	7.12	0.33	4.58e-12	Hypertriglyceridemia;
LUAD	cis	rs13064411	0.735	rs6438157	chr3:113207316	G/T	cg10517650	chr3:113235015	CCDC52	-0.56	-9.63	-0.42	5.58e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs909002	0.745	rs4949458	chr1:32142332	G/T	cg13919466	chr1:32135498	COL16A1	0.35	8.23	0.37	2.29e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg23985595	chr17:80112537	CCDC57	0.42	7.52	0.34	3.37e-13	Life satisfaction;
LUAD	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.7	-7.18	-0.33	3.2e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	6.68	0.31	7.75e-11	Obesity-related traits;
LUAD	cis	rs10242455	0.702	rs73403247	chr7:99088730	G/A	cg18809830	chr7:99032528	PTCD1	-1.0	-7.35	-0.34	1.04e-12	Blood metabolite levels;
LUAD	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg01657329	chr11:68192670	LRP5	-0.43	-6.86	-0.32	2.39e-11	Total body bone mineral density;
LUAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg06263672	chr7:65235340	NA	0.49	7.98	0.36	1.35e-14	Calcium levels;
LUAD	cis	rs4588572	0.644	rs10061149	chr5:77744201	G/A	cg11547950	chr5:77652471	NA	-0.63	-10.57	-0.46	2.39e-23	Triglycerides;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20877507	chr13:50464614	LOC220429	0.53	6.51	0.3	2.08e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg01028140	chr2:1542097	TPO	-0.43	-7.16	-0.33	3.56e-12	IgG glycosylation;
LUAD	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg15704280	chr7:45808275	SEPT13	-1.07	-25.01	-0.77	2.01e-85	Height;
LUAD	cis	rs6701037	0.875	rs1057301	chr1:175126524	T/C	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.9	-0.4	1.6e-17	Alcohol dependence;
LUAD	cis	rs684232	0.931	rs410157	chr17:598240	T/C	cg12384639	chr17:618140	VPS53	0.41	6.63	0.31	1.03e-10	Prostate cancer;
LUAD	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs193541	0.632	rs173481	chr5:122254552	G/A	cg19077854	chr5:122220652	SNX24	0.37	6.35	0.3	5.47e-10	Glucose homeostasis traits;
LUAD	cis	rs1160297	0.643	rs13031599	chr2:53075902	T/C	cg07782112	chr2:53107842	NA	0.4	8.36	0.38	9.42e-16	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-7.07	-0.32	6.65e-12	Triglycerides;
LUAD	cis	rs7428	0.527	rs7607284	chr2:85547376	C/G	cg24342717	chr2:85555507	TGOLN2	-0.48	-7.81	-0.36	4.42e-14	Ear protrusion;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00579200	chr11:133705235	NA	0.41	6.71	0.31	6.33e-11	Gut microbiome composition (summer);
LUAD	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg09065629	chr16:1709722	CRAMP1L	0.42	7.35	0.34	1.01e-12	Coronary artery disease;
LUAD	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg23262073	chr20:60523788	NA	-0.44	-7.58	-0.35	2.14e-13	Body mass index;
LUAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg00280220	chr17:61926910	NA	0.36	6.99	0.32	1.08e-11	Prudent dietary pattern;
LUAD	cis	rs73206853	0.544	rs55752061	chr12:111126096	G/C	cg12870014	chr12:110450643	ANKRD13A	0.61	6.36	0.3	5.33e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg22823121	chr1:150693482	HORMAD1	0.42	8.24	0.37	2.19e-15	Tonsillectomy;
LUAD	trans	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg06606381	chr12:133084897	FBRSL1	-0.64	-7.75	-0.35	7.07e-14	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs9354308	0.677	rs9363462	chr6:66557612	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.55	-0.3	1.64e-10	Metabolite levels;
LUAD	cis	rs4462272	0.675	rs10883446	chr10:101894606	C/G	cg02250046	chr10:101825185	CPN1	-0.32	-6.37	-0.3	4.87e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg19761014	chr17:28927070	LRRC37B2	0.79	9.48	0.42	1.79e-19	Body mass index;
LUAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.05	0.32	7.2e-12	Menopause (age at onset);
LUAD	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg07936489	chr17:37558343	FBXL20	0.45	7.09	0.33	5.71e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-6.37	-0.3	4.82e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs12208915	0.848	rs12209635	chr6:79532215	C/T	cg05283184	chr6:79620031	NA	0.5	6.58	0.3	1.4e-10	Left atrial antero-posterior diameter;
LUAD	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg03929089	chr4:120376271	NA	-0.85	-15.06	-0.59	2.33e-41	Height;
LUAD	cis	rs300703	0.515	rs300693	chr2:181748	C/A	cg24565620	chr2:194026	NA	0.38	6.67	0.31	8.11e-11	Blood protein levels;
LUAD	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg19442545	chr10:75533431	FUT11	-0.5	-8.34	-0.38	1.05e-15	Inflammatory bowel disease;
LUAD	cis	rs2625529	0.526	rs11634622	chr15:72562327	G/A	cg16672083	chr15:72433130	SENP8	0.63	11.69	0.49	1.51e-27	Red blood cell count;
LUAD	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg27124370	chr19:33622961	WDR88	0.46	7.17	0.33	3.32e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs11209002	0.614	rs10736406	chr1:67573238	A/T	cg21115004	chr1:67520352	SLC35D1	0.41	6.85	0.32	2.6e-11	Crohn's disease;
LUAD	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.53	0.34	3.03e-13	Bipolar disorder;
LUAD	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg18129178	chr5:148520854	ABLIM3	-0.57	-8.59	-0.39	1.69e-16	Breast cancer;
LUAD	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06112835	chr11:68658793	MRPL21	0.54	9.67	0.43	4.1e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg18252515	chr7:66147081	NA	-0.62	-6.77	-0.31	4.27e-11	Diabetic kidney disease;
LUAD	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg16988262	chr1:15930761	NA	0.42	7.0	0.32	1.03e-11	Systolic blood pressure;
LUAD	cis	rs7301016	0.846	rs7296573	chr12:63033041	A/C	cg11441379	chr12:63026424	NA	0.64	7.76	0.35	6.45e-14	IgG glycosylation;
LUAD	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg06697600	chr4:7070879	GRPEL1	-0.6	-9.46	-0.42	2.15e-19	Monocyte percentage of white cells;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08328266	chr11:118992044	HINFP	-0.43	-7.0	-0.32	1.04e-11	Cancer;
LUAD	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg08470875	chr2:26401718	FAM59B	-0.74	-10.22	-0.44	4.78e-22	Gut microbiome composition (summer);
LUAD	cis	rs6598955	0.640	rs6667826	chr1:26531408	T/C	cg00852783	chr1:26633632	UBXN11	0.43	7.56	0.34	2.56e-13	Obesity-related traits;
LUAD	cis	rs2275731	0.525	rs7922050	chr10:16479007	C/G	cg04254609	chr10:16479192	PTER	-0.57	-9.52	-0.42	1.3e-19	Bone fracture in osteoporosis;
LUAD	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg15704280	chr7:45808275	SEPT13	-0.93	-18.2	-0.66	4.29e-55	Coronary artery disease;
LUAD	cis	rs2573652	1.000	rs2581362	chr15:100513524	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.49	-8.56	-0.38	2.09e-16	Height;
LUAD	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg17747265	chr1:1875780	NA	0.66	15.29	0.6	2.61e-42	Body mass index;
LUAD	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg00784671	chr22:46762841	CELSR1	-0.58	-7.22	-0.33	2.47e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg05665937	chr4:1216051	CTBP1	-0.47	-7.66	-0.35	1.27e-13	Obesity-related traits;
LUAD	cis	rs41311933	0.803	rs41313597	chr9:123723050	C/T	cg13567360	chr9:123745713	C5	-0.79	-6.91	-0.32	1.75e-11	Coronary artery disease;
LUAD	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	13.06	0.54	5.6e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg17366294	chr4:99064904	C4orf37	0.65	12.39	0.52	2.75e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg07917127	chr4:99064746	C4orf37	0.42	6.97	0.32	1.24e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-9.07	-0.4	4.44e-18	Life satisfaction;
LUAD	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-7.25	-0.33	1.95e-12	Morning vs. evening chronotype;
LUAD	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.42	-8.09	-0.37	6.29e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1451375	0.652	rs7803440	chr7:50625632	C/T	cg18232548	chr7:50535776	DDC	0.5	7.21	0.33	2.56e-12	Malaria;
LUAD	cis	rs4786125	0.665	rs8060329	chr16:6908864	G/A	cg03623568	chr16:6915990	A2BP1	-0.49	-10.72	-0.46	7.17e-24	Heart rate variability traits (SDNN);
LUAD	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg07092213	chr7:1199455	ZFAND2A	0.41	7.12	0.33	4.6e-12	Longevity;Endometriosis;
LUAD	cis	rs758324	0.947	rs10478989	chr5:131116055	A/G	cg25547332	chr5:131281432	NA	0.45	6.76	0.31	4.47e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4243830	0.737	rs11122088	chr1:6603677	T/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.73	-8.68	-0.39	8.49e-17	Body mass index;
LUAD	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg00933542	chr6:150070202	PCMT1	0.43	9.18	0.41	1.91e-18	Lung cancer;
LUAD	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg07636037	chr3:49044803	WDR6	0.64	12.56	0.52	5.59e-31	Parkinson's disease;
LUAD	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg07080864	chr8:57359956	PENK	-0.37	-6.61	-0.31	1.14e-10	Obesity-related traits;
LUAD	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg10792982	chr14:105748885	BRF1	0.41	9.19	0.41	1.76e-18	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs8067545	0.750	rs35003563	chr17:19989218	G/A	cg04132472	chr17:19861366	AKAP10	0.3	7.12	0.33	4.67e-12	Schizophrenia;
LUAD	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg09065629	chr16:1709722	CRAMP1L	0.43	7.41	0.34	7.13e-13	Coronary artery disease;
LUAD	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg27068330	chr11:65405492	SIPA1	-0.8	-12.73	-0.53	1.18e-31	Acne (severe);
LUAD	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.13	-0.37	4.83e-15	Resting heart rate;
LUAD	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	8.33	0.38	1.16e-15	Breast cancer;
LUAD	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg22442454	chr1:209979470	IRF6	0.54	7.14	0.33	4.04e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg03714773	chr7:91764589	CYP51A1	0.31	7.19	0.33	3.05e-12	Breast cancer;
LUAD	trans	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg14791747	chr16:20752902	THUMPD1	0.52	7.33	0.34	1.16e-12	Selective IgA deficiency;
LUAD	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg17443473	chr1:3703550	LRRC47	0.46	7.77	0.35	6.08e-14	Red cell distribution width;
LUAD	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg05991184	chr2:219186017	PNKD	-0.36	-6.92	-0.32	1.64e-11	Colorectal cancer;
LUAD	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg18209359	chr17:80159595	CCDC57	-0.4	-6.89	-0.32	2e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs4650994	0.544	rs10798613	chr1:178500022	C/T	cg05059571	chr16:84539110	KIAA1609	-0.76	-13.54	-0.55	6.11e-35	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.61	10.72	0.46	7.22e-24	Birth weight;
LUAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg18402987	chr7:1209562	NA	0.65	8.64	0.39	1.2e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.52	0.52	8.25e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg27454412	chr7:1067447	C7orf50	0.44	7.01	0.32	9.47e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg03467027	chr4:99064603	C4orf37	0.42	6.91	0.32	1.78e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg07636037	chr3:49044803	WDR6	0.64	12.22	0.51	1.24e-29	Parkinson's disease;
LUAD	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg26924012	chr15:45694286	SPATA5L1	0.64	11.01	0.47	5.78e-25	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg12310025	chr6:25882481	NA	-0.51	-7.67	-0.35	1.21e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.32	0.37	1.26e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00166722	chr3:10149974	C3orf24	0.64	9.68	0.43	3.82e-20	Alzheimer's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06866400	chr6:143771904	ADAT2;PEX3	-0.54	-6.41	-0.3	3.92e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.14e-14	Prostate cancer;
LUAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg16606324	chr3:10149918	C3orf24	0.67	11.16	0.48	1.57e-25	Alzheimer's disease;
LUAD	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.51	-0.38	3.12e-16	Gut microbiome composition (summer);
LUAD	cis	rs733592	1.000	rs733592	chr12:48429776	C/T	cg24011408	chr12:48396354	COL2A1	-0.35	-7.3	-0.33	1.4e-12	Plateletcrit;
LUAD	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg02421172	chr7:1938701	MAD1L1	0.46	6.67	0.31	7.89e-11	Bipolar disorder;
LUAD	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.06e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg13319975	chr6:146136371	FBXO30	-0.62	-10.62	-0.46	1.67e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23158103	chr7:148848205	ZNF398	-0.66	-12.52	-0.52	8.6e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.87e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4900538	0.855	rs1190537	chr14:102887816	C/T	cg18135206	chr14:102964638	TECPR2	-1.01	-21.09	-0.72	5.56e-68	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg04450456	chr4:17643702	FAM184B	0.41	7.84	0.36	3.6e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.61	0.31	1.15e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.39	7.67	0.35	1.16e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg18187862	chr3:45730750	SACM1L	0.49	7.74	0.35	7.53e-14	Primary sclerosing cholangitis;
LUAD	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-6.55	-0.3	1.69e-10	Personality dimensions;
LUAD	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg07599136	chr5:415885	AHRR	0.77	8.53	0.38	2.71e-16	Fat distribution (HIV);
LUAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.57	-9.41	-0.42	3.16e-19	Renal function-related traits (BUN);
LUAD	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg21475434	chr5:93447410	FAM172A	0.57	7.25	0.33	1.97e-12	Diabetic retinopathy;
LUAD	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg15744005	chr10:104629667	AS3MT	-0.41	-7.19	-0.33	3e-12	Arsenic metabolism;
LUAD	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg18252515	chr7:66147081	NA	-0.61	-6.69	-0.31	7.07e-11	Diabetic kidney disease;
LUAD	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.15	0.44	8.6e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg04025307	chr7:1156635	C7orf50	0.66	7.55	0.34	2.66e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg09872104	chr7:134855509	C7orf49	-0.84	-7.3	-0.33	1.46e-12	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs877282	1.000	rs11253366	chr10:773386	C/T	cg06581033	chr10:766294	NA	-0.48	-6.8	-0.31	3.62e-11	Uric acid levels;
LUAD	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.61	0.42	6.48e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2018683	0.707	rs917219	chr7:28975343	A/G	cg19402173	chr7:128379420	CALU	-0.53	-8.6	-0.39	1.55e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg18755752	chr8:142205143	DENND3	0.46	8.08	0.37	7.01e-15	Immature fraction of reticulocytes;
LUAD	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg13768953	chr17:7114967	DLG4	-0.46	-8.24	-0.37	2.18e-15	Adiponectin levels;
LUAD	trans	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg14791747	chr16:20752902	THUMPD1	-0.66	-9.25	-0.41	1.15e-18	Cognitive test performance;
LUAD	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs35771425	1.000	rs35332498	chr1:211559243	A/C	cg25617285	chr1:211431773	RCOR3	-0.44	-6.38	-0.3	4.58e-10	Educational attainment (years of education);
LUAD	trans	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg18834416	chr8:37888184	EIF4EBP1	0.41	6.83	0.32	2.89e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg13319975	chr6:146136371	FBXO30	-0.61	-10.4	-0.45	1e-22	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21128539	chr18:74116273	ZNF516	0.54	6.95	0.32	1.35e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg06108461	chr20:60628389	TAF4	-1.12	-20.51	-0.71	2.1e-65	Body mass index;
LUAD	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.4	7.04	0.32	7.62e-12	Menarche (age at onset);
LUAD	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-14.32	-0.57	3.5e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs13315871	0.929	rs1554124	chr3:58268968	C/G	cg20936604	chr3:58311152	NA	-0.59	-6.67	-0.31	8.25e-11	Cholesterol, total;
LUAD	cis	rs3784262	0.740	rs4646596	chr15:58300895	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.41	-8.03	-0.36	9.52e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg21260072	chr20:39766506	PLCG1	-0.64	-6.79	-0.31	3.83e-11	Type 2 diabetes;
LUAD	trans	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.21	-0.41	1.52e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg19980929	chr12:42632907	YAF2	-0.34	-6.54	-0.3	1.76e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg08742575	chr21:47604166	C21orf56	0.64	11.34	0.48	3.39e-26	Testicular germ cell tumor;
LUAD	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.37	-7.05	-0.32	7.22e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1816752	0.905	rs4769352	chr13:25000375	G/A	cg02811702	chr13:24901961	NA	0.39	6.73	0.31	5.45e-11	Obesity-related traits;
LUAD	cis	rs2806561	0.894	rs1738475	chr1:23536891	C/G	cg19743168	chr1:23544995	NA	0.46	8.49	0.38	3.49e-16	Height;
LUAD	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg14668632	chr7:2872130	GNA12	-0.73	-13.23	-0.54	1.07e-33	Height;
LUAD	cis	rs7927771	0.524	rs7107792	chr11:47669249	A/C	cg18512352	chr11:47633146	NA	0.37	6.61	0.31	1.15e-10	Subjective well-being;
LUAD	cis	rs4285028	0.747	rs1920299	chr3:121593769	A/G	cg11130432	chr3:121712080	ILDR1	0.57	8.14	0.37	4.35e-15	Multiple sclerosis;
LUAD	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.58	-0.52	4.94e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.58	-0.52	4.94e-31	Hip circumference adjusted for BMI;
LUAD	trans	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg27600084	chr12:12264075	NA	0.37	6.79	0.31	3.89e-11	Breast size;
LUAD	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg03806693	chr22:41940476	POLR3H	0.69	9.83	0.43	1.09e-20	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.49	-0.3	2.38e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg02527881	chr3:46936655	PTH1R	0.41	7.91	0.36	2.35e-14	Colorectal cancer;
LUAD	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg21475434	chr5:93447410	FAM172A	0.74	8.33	0.38	1.1e-15	Diabetic retinopathy;
LUAD	cis	rs5756813	0.661	rs2071910	chr22:38204259	C/T	cg06521852	chr22:38141419	TRIOBP	0.47	8.44	0.38	5.21e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs7089973	0.932	rs17794346	chr10:116643095	C/T	cg23260525	chr10:116636907	FAM160B1	-0.41	-8.72	-0.39	6.43e-17	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9581857	0.685	rs9319373	chr13:28042835	A/G	cg22138327	chr13:27999177	GTF3A	0.86	9.67	0.43	4.09e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg25237894	chr2:233734115	C2orf82	-0.6	-11.31	-0.48	4.25e-26	Coronary artery disease;
LUAD	trans	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg02030672	chr11:45687055	CHST1	0.44	7.84	0.36	3.62e-14	Obesity-related traits;
LUAD	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg06558623	chr16:89946397	TCF25	1.15	10.41	0.45	9.62e-23	Skin colour saturation;
LUAD	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg05110241	chr16:68378359	PRMT7	-0.93	-10.42	-0.45	8.89e-23	Schizophrenia;
LUAD	cis	rs17818399	0.926	rs13033177	chr2:46831062	C/A	cg21681030	chr2:46777652	RHOQ	0.4	7.21	0.33	2.58e-12	Height;
LUAD	cis	rs11671005	0.735	rs11666303	chr19:58922502	T/G	cg13877915	chr19:58951672	ZNF132	0.55	7.27	0.33	1.75e-12	Mean platelet volume;
LUAD	trans	rs412658	0.504	rs369128	chr19:22107866	A/T	cg17074339	chr11:11642133	GALNTL4	-0.38	-7.07	-0.33	6.64e-12	Telomere length;
LUAD	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.44	0.57	1.08e-38	Schizophrenia;
LUAD	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-7.82	-0.36	4.32e-14	Morning vs. evening chronotype;
LUAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg26384229	chr12:38710491	ALG10B	-0.44	-7.37	-0.34	9.28e-13	Morning vs. evening chronotype;
LUAD	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg19635926	chr16:89946313	TCF25	0.75	6.74	0.31	5.25e-11	Skin colour saturation;
LUAD	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.62	0.35	1.73e-13	Platelet count;
LUAD	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-18.24	-0.66	2.98e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg12193833	chr17:30244370	NA	0.54	7.01	0.32	9.66e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg20283391	chr11:68216788	NA	-0.42	-6.66	-0.31	8.76e-11	Total body bone mineral density;
LUAD	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg22868518	chr11:507468	RNH1	-0.68	-6.75	-0.31	4.95e-11	Body mass index;
LUAD	cis	rs6062509	0.868	rs3761123	chr20:62342468	G/A	cg02966332	chr20:62369605	LIME1	-0.47	-7.63	-0.35	1.56e-13	Prostate cancer;
LUAD	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg18404041	chr3:52824283	ITIH1	-0.71	-14.56	-0.58	3.11e-39	Bipolar disorder;
LUAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg22535103	chr8:58192502	C8orf71	-0.75	-10.63	-0.46	1.47e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.18	16.1	0.62	8.23e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10465746	0.725	rs12070578	chr1:84349607	A/G	cg10977910	chr1:84465055	TTLL7	0.61	9.82	0.43	1.24e-20	Obesity-related traits;
LUAD	trans	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg05926928	chr17:57297772	GDPD1	-0.5	-7.69	-0.35	1.07e-13	Schizophrenia;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg15846643	chr11:94964345	SESN3	0.4	7.0	0.32	9.78e-12	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg20503657	chr10:835505	NA	1.25	18.38	0.67	7.13e-56	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg05340658	chr4:99064831	C4orf37	0.53	8.98	0.4	8.92e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7089973	0.872	rs7923295	chr10:116625159	C/G	cg23260525	chr10:116636907	FAM160B1	-0.43	-9.68	-0.43	3.81e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-12.15	-0.51	2.5e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.48	-0.3	2.55e-10	Parkinson's disease;
LUAD	trans	rs9929218	0.953	rs17772411	chr16:68810923	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.93	-0.56	1.44e-36	Colorectal cancer;
LUAD	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg13180566	chr4:1052158	NA	-0.39	-6.69	-0.31	7.15e-11	Recombination rate (females);
LUAD	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg07570687	chr10:102243282	WNT8B	0.45	6.95	0.32	1.36e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg09323728	chr8:95962352	TP53INP1	-0.32	-7.69	-0.35	1.07e-13	Type 2 diabetes;
LUAD	trans	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg18335740	chr13:41363409	SLC25A15	0.73	14.06	0.56	4.18e-37	Lewy body disease;
LUAD	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg14668632	chr7:2872130	GNA12	-0.48	-8.67	-0.39	9.02e-17	Height;
LUAD	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg23752985	chr2:85803571	VAMP8	0.33	6.42	0.3	3.75e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00149659	chr3:10157352	C3orf10	0.64	8.98	0.4	9.19e-18	Alzheimer's disease;
LUAD	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg05623727	chr3:50126028	RBM5	0.31	6.74	0.31	5.1e-11	Body mass index;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05309454	chr17:79791505	FAM195B;DYSFIP1	-0.56	-6.85	-0.32	2.61e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg07527032	chr15:84868466	LOC388152	0.44	6.63	0.31	1.04e-10	Schizophrenia;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg07719772	chr16:32360419	NA	-0.5	-7.8	-0.35	4.82e-14	Menopause (age at onset);
LUAD	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg04455712	chr21:45112962	RRP1B	0.43	8.77	0.39	4.55e-17	Mean corpuscular volume;
LUAD	cis	rs6840360	0.550	rs7683134	chr4:152503362	A/C	cg22705602	chr4:152727874	NA	-0.4	-7.01	-0.32	9.72e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg11062466	chr8:58055876	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6432018	0.964	rs7565646	chr2:9728879	A/G	cg12832956	chr2:9616023	IAH1	-0.36	-6.47	-0.3	2.71e-10	Heart rate variability traits;
LUAD	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg04775059	chr7:64541387	NA	0.5	6.82	0.31	3.24e-11	Aortic root size;
LUAD	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11890956	chr21:40555474	PSMG1	0.64	11.1	0.47	2.65e-25	Cognitive function;
LUAD	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.63	-11.03	-0.47	5.11e-25	Hip circumference adjusted for BMI;
LUAD	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.4e-12	Lung cancer;
LUAD	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg06784218	chr1:46089804	CCDC17	0.5	10.92	0.47	1.22e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg26597838	chr10:835615	NA	0.82	12.75	0.53	9.98e-32	Eosinophil percentage of granulocytes;
LUAD	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg19318889	chr4:1322082	MAEA	0.44	7.0	0.32	1.04e-11	Obesity-related traits;
LUAD	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg03289416	chr15:75166202	SCAMP2	0.43	7.52	0.34	3.4e-13	Breast cancer;
LUAD	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg11871910	chr12:69753446	YEATS4	0.7	12.08	0.51	4.35e-29	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg06064525	chr11:970664	AP2A2	-0.55	-11.15	-0.48	1.72e-25	Alzheimer's disease (late onset);
LUAD	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg09904177	chr6:26538194	HMGN4	-0.42	-7.02	-0.32	9.07e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg25457927	chr22:38595422	NA	0.52	13.35	0.54	3.54e-34	Cutaneous nevi;
LUAD	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg20673091	chr1:2541236	MMEL1	-0.4	-8.59	-0.39	1.72e-16	Ulcerative colitis;
LUAD	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg03929089	chr4:120376271	NA	-0.44	-6.79	-0.31	3.77e-11	Height;
LUAD	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg06028605	chr16:24865363	SLC5A11	0.36	6.37	0.3	5.07e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-10.02	-0.44	2.37e-21	Gut microbiome composition (summer);
LUAD	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg13390004	chr1:15929781	NA	0.46	8.13	0.37	4.71e-15	Systolic blood pressure;
LUAD	trans	rs2268363	1.000	rs11693287	chr2:49200929	C/T	cg04222582	chr15:45405103	DUOX2;DUOXA2	0.35	6.44	0.3	3.18e-10	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.86	-0.36	3.12e-14	Diabetic kidney disease;
LUAD	cis	rs17102423	0.826	rs10873180	chr14:65604361	A/G	cg11161011	chr14:65562177	MAX	0.46	7.41	0.34	6.94e-13	Obesity-related traits;
LUAD	cis	rs11030122	0.702	rs1013351	chr11:3952303	A/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.2	-0.33	2.7e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.6	-0.35	1.92e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg13854012	chr2:162103682	NA	-0.46	-9.09	-0.4	3.94e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	cis	rs10193935	1.000	rs10171023	chr2:42407093	G/C	cg27598129	chr2:42591480	NA	-0.75	-9.83	-0.43	1.14e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs295140	0.546	rs295119	chr2:201117944	C/T	cg17644776	chr2:200775616	C2orf69	0.38	6.47	0.3	2.71e-10	QT interval;
LUAD	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg06713675	chr4:122721982	EXOSC9	-0.83	-17.79	-0.65	2.98e-53	Type 2 diabetes;
LUAD	trans	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-10.76	-0.46	5.01e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg13813247	chr22:41461852	NA	-0.5	-7.87	-0.36	2.98e-14	Neuroticism;
LUAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08280861	chr8:58055591	NA	0.76	9.08	0.4	4.14e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08219700	chr8:58056026	NA	0.58	8.03	0.36	9.71e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9314323	0.767	rs10866848	chr8:26208209	G/C	cg13160058	chr8:26243215	BNIP3L	-0.48	-9.89	-0.43	6.65e-21	Red cell distribution width;
LUAD	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg19163074	chr7:65112434	INTS4L2	0.44	6.62	0.31	1.1e-10	Aortic root size;
LUAD	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-10.82	-0.47	2.98e-24	Hemoglobin concentration;
LUAD	cis	rs3760982	1.000	rs11665924	chr19:44286982	G/A	cg12072164	chr19:44306565	LYPD5	0.38	7.63	0.35	1.58e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs4006360	0.632	rs4986668	chr17:39250408	T/G	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.3	0.37	1.43e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg05283184	chr6:79620031	NA	0.61	12.18	0.51	1.79e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	7.0	0.32	9.91e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs62400317	0.859	rs56337964	chr6:45039786	G/A	cg18551225	chr6:44695536	NA	-0.57	-8.73	-0.39	6.02e-17	Total body bone mineral density;
LUAD	cis	rs73198271	0.562	rs55657655	chr8:8675491	G/A	cg01851573	chr8:8652454	MFHAS1	0.68	10.11	0.44	1.18e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs644148	0.836	rs2686776	chr19:45000366	T/C	cg15540054	chr19:45004280	ZNF180	-0.4	-6.4	-0.3	4.18e-10	Personality dimensions;
LUAD	cis	rs2692947	0.673	rs3111873	chr2:96781986	G/C	cg23100626	chr2:96804247	ASTL	-0.38	-10.07	-0.44	1.57e-21	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-8.04	-0.36	9.04e-15	Neutrophil percentage of white cells;
LUAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.39	-8.14	-0.37	4.43e-15	Lymphocyte counts;
LUAD	cis	rs2274273	0.870	rs10149420	chr14:55854257	T/C	cg04306507	chr14:55594613	LGALS3	0.42	8.76	0.39	4.91e-17	Protein biomarker;
LUAD	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg16405210	chr4:1374714	KIAA1530	-0.61	-9.37	-0.41	4.47e-19	Longevity;
LUAD	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg10518543	chr12:38710700	ALG10B	-0.43	-7.01	-0.32	9.31e-12	Heart rate;
LUAD	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.81	-0.31	3.36e-11	Retinal vascular caliber;
LUAD	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.78	-13.56	-0.55	4.76e-35	Chronic sinus infection;
LUAD	cis	rs7927771	0.542	rs7102205	chr11:47745374	C/T	cg18512352	chr11:47633146	NA	0.37	6.42	0.3	3.63e-10	Subjective well-being;
LUAD	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg18761221	chr20:60518478	NA	0.39	6.79	0.31	3.87e-11	Body mass index;
LUAD	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg01579765	chr21:45077557	HSF2BP	-0.59	-13.77	-0.56	6.63e-36	Mean corpuscular volume;
LUAD	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg02775129	chr4:119771670	NA	-0.86	-8.15	-0.37	4.09e-15	Cannabis dependence symptom count;
LUAD	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg00603274	chr11:61596626	FADS2	0.36	6.53	0.3	1.91e-10	Trans fatty acid levels;
LUAD	cis	rs4285028	0.699	rs6771068	chr3:121478745	A/T	cg11130432	chr3:121712080	ILDR1	0.54	7.89	0.36	2.69e-14	Multiple sclerosis;
LUAD	trans	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.69	-0.31	7.09e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg14019146	chr3:50243930	SLC38A3	0.55	11.16	0.48	1.65e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg06740227	chr12:86229804	RASSF9	0.4	6.98	0.32	1.14e-11	Major depressive disorder;
LUAD	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg15128208	chr22:42549153	NA	0.43	6.72	0.31	5.77e-11	Birth weight;
LUAD	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.76	0.31	4.48e-11	Platelet count;
LUAD	cis	rs7107174	1.000	rs4492844	chr11:78026516	A/G	cg02023728	chr11:77925099	USP35	0.5	7.7	0.35	9.5e-14	Testicular germ cell tumor;
LUAD	cis	rs6499255	0.904	rs9929720	chr16:69557096	C/T	cg26679644	chr16:69762563	NA	-0.42	-6.51	-0.3	2.08e-10	IgE levels;
LUAD	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg23172400	chr8:95962367	TP53INP1	-0.37	-8.69	-0.39	8.27e-17	Type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs977987	0.872	rs7206665	chr16:75475287	A/C	cg03315344	chr16:75512273	CHST6	0.64	13.92	0.56	1.52e-36	Dupuytren's disease;
LUAD	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08564027	chr20:61660810	NA	0.82	16.96	0.64	1.38e-49	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg18180107	chr4:99064573	C4orf37	0.46	7.22	0.33	2.39e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg23442477	chr15:85258977	SEC11A	-0.41	-6.99	-0.32	1.1e-11	Subcortical brain region volumes;
LUAD	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg17372223	chr3:52568218	NT5DC2	-0.41	-7.4	-0.34	7.23e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg14552801	chr7:65878734	NA	0.37	6.37	0.3	4.92e-10	Aortic root size;
LUAD	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg22906224	chr7:99728672	NA	0.63	10.81	0.47	3.22e-24	Coronary artery disease;
LUAD	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg21918786	chr6:109611834	NA	-0.57	-10.58	-0.46	2.38e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs2267137	0.835	rs2267133	chr22:29765382	A/T	cg07256473	chr22:29710276	RASL10A	0.43	8.43	0.38	5.43e-16	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-7.46	-0.34	4.95e-13	Total body bone mineral density;
LUAD	cis	rs2070677	0.935	rs12255182	chr10:135404096	G/A	cg20169779	chr10:135381914	SYCE1	-0.51	-8.17	-0.37	3.55e-15	Gout;
LUAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg13560548	chr3:10150139	C3orf24	0.4	6.56	0.3	1.53e-10	Alzheimer's disease;
LUAD	cis	rs741677	0.963	rs441821	chr17:474394	A/G	cg06217071	chr17:408420	NA	0.32	6.37	0.3	5.08e-10	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg22166914	chr1:53195759	ZYG11B	0.45	7.4	0.34	7.3e-13	Monocyte count;
LUAD	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg02993280	chr1:107599747	PRMT6	0.55	8.91	0.4	1.55e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg20302342	chr1:156215951	PAQR6	0.39	8.77	0.39	4.42e-17	Tonsillectomy;
LUAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00149659	chr3:10157352	C3orf10	0.63	8.82	0.39	2.97e-17	Alzheimer's disease;
LUAD	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg23649088	chr2:200775458	C2orf69	-0.62	-7.77	-0.35	6.15e-14	Schizophrenia;
LUAD	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	9.33	0.41	5.81e-19	Monocyte percentage of white cells;
LUAD	cis	rs9372498	0.505	rs62422247	chr6:118987559	G/T	cg18833306	chr6:118973337	C6orf204	-0.54	-7.72	-0.35	8.34e-14	Diastolic blood pressure;
LUAD	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.89	-0.36	2.53e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs89107	0.603	rs387945	chr6:118613313	G/A	cg18833306	chr6:118973337	C6orf204	0.55	10.15	0.44	8.22e-22	Cardiac structure and function;
LUAD	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg03806693	chr22:41940476	POLR3H	-0.45	-6.42	-0.3	3.57e-10	Neuroticism;
LUAD	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-6.76	-0.31	4.57e-11	IgG glycosylation;
LUAD	cis	rs10736390	0.640	rs10888858	chr1:55108978	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.86	-17.59	-0.65	2.28e-52	Survival in pancreatic cancer;
LUAD	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg02371401	chr5:676784	TPPP	-0.41	-7.13	-0.33	4.44e-12	Obesity-related traits;
LUAD	cis	rs59698941	0.550	rs11739194	chr5:132201230	T/C	cg14825688	chr5:132208181	LEAP2	-0.53	-10.79	-0.46	3.76e-24	Apolipoprotein A-IV levels;
LUAD	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.16	-0.41	2.32e-18	Alcohol dependence;
LUAD	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg05872129	chr22:39784769	NA	-0.8	-14.92	-0.59	1e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00166722	chr3:10149974	C3orf24	0.73	12.65	0.52	2.57e-31	Alzheimer's disease;
LUAD	cis	rs12760731	0.720	rs7524556	chr1:178446659	C/T	cg00404053	chr1:178313656	RASAL2	0.57	7.79	0.35	5.19e-14	Obesity-related traits;
LUAD	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.49	0.3	2.45e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg17366294	chr4:99064904	C4orf37	-0.48	-8.51	-0.38	3.16e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg25767906	chr1:53392781	SCP2	-0.42	-7.78	-0.35	5.75e-14	Monocyte count;
LUAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.73	-0.35	7.65e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg04476341	chr5:669733	TPPP	-0.42	-8.27	-0.37	1.78e-15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg24069376	chr3:38537580	EXOG	-0.3	-6.75	-0.31	4.94e-11	Electrocardiographic conduction measures;
LUAD	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg02782426	chr3:40428986	ENTPD3	0.45	9.22	0.41	1.43e-18	Renal cell carcinoma;
LUAD	cis	rs2637266	0.783	rs1797500	chr10:78510400	G/A	cg18941641	chr10:78392320	NA	0.31	6.39	0.3	4.29e-10	Pulmonary function;
LUAD	cis	rs6688613	0.840	rs6699294	chr1:166955174	G/A	cg07049167	chr1:166818506	POGK	0.45	6.66	0.31	8.3e-11	Refractive astigmatism;
LUAD	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.86	0.32	2.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.947	rs31257	chr5:130828715	C/G	cg25547332	chr5:131281432	NA	0.43	6.64	0.31	9.7e-11	Life satisfaction;
LUAD	cis	rs748404	0.723	rs565658	chr15:43556307	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.06	0.36	7.77e-15	Lung cancer;
LUAD	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg14202850	chr17:43974869	MAPT;LOC100130148	0.38	6.36	0.3	5.18e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2882667	0.929	rs34846849	chr5:138360578	T/C	cg04439458	chr5:138467593	SIL1	-0.5	-9.15	-0.41	2.51e-18	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs28595532	0.546	rs13102483	chr4:119246396	G/A	cg02775129	chr4:119771670	NA	-0.75	-6.99	-0.32	1.09e-11	Cannabis dependence symptom count;
LUAD	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg09509183	chr1:209979624	IRF6	0.38	6.65	0.31	9.34e-11	Monobrow;
LUAD	trans	rs1997103	1.000	rs2331067	chr7:55408232	A/T	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2548003	0.518	rs2014316	chr5:28723711	T/C	cg22863700	chr5:28928346	NA	0.47	6.93	0.32	1.53e-11	Hip geometry;
LUAD	cis	rs739496	0.947	rs34368158	chr12:111846028	C/T	cg10833066	chr12:111807467	FAM109A	0.42	6.48	0.3	2.48e-10	Platelet count;
LUAD	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg09184832	chr6:79620586	NA	-0.52	-9.69	-0.43	3.52e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs3087591	0.922	rs2341348	chr17:29534867	C/T	cg24425628	chr17:29625626	OMG;NF1	0.42	6.7	0.31	6.59e-11	Hip circumference;
LUAD	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg06636551	chr8:101224915	SPAG1	0.36	6.67	0.31	8.24e-11	Atrioventricular conduction;
LUAD	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	8.64	0.39	1.2e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg24558204	chr6:135376177	HBS1L	0.45	8.36	0.38	9.01e-16	Red blood cell count;
LUAD	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg10589385	chr1:150898437	SETDB1	0.44	8.12	0.37	5.14e-15	Melanoma;
LUAD	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.89	-9.54	-0.42	1.18e-19	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg03676636	chr4:99064102	C4orf37	0.3	7.29	0.33	1.54e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.89	0.53	2.69e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg02569458	chr12:86230093	RASSF9	-0.41	-7.63	-0.35	1.55e-13	Major depressive disorder;
LUAD	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.73	0.31	5.7e-11	Rheumatoid arthritis;
LUAD	cis	rs1298908	0.897	rs2573326	chr10:82013146	T/C	cg01528321	chr10:82214614	TSPAN14	0.42	6.58	0.3	1.36e-10	Diabetic kidney disease;
LUAD	cis	rs12545109	0.879	rs2576580	chr8:57365828	G/C	cg21220214	chr8:57350948	NA	-0.66	-9.13	-0.41	2.8e-18	Obesity-related traits;
LUAD	cis	rs12049351	0.774	rs34232465	chr1:229631112	C/T	cg11742688	chr1:229674241	ABCB10	-0.42	-6.75	-0.31	4.82e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg10434728	chr15:90938212	IQGAP1	0.37	7.24	0.33	2.16e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg18761221	chr20:60518478	NA	0.39	6.85	0.32	2.54e-11	Body mass index;
LUAD	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg18854424	chr1:2615690	NA	0.41	8.99	0.4	8.25e-18	Ulcerative colitis;
LUAD	cis	rs757081	0.634	rs17472942	chr11:17094702	A/G	cg15432903	chr11:17409602	KCNJ11	-0.41	-6.65	-0.31	8.93e-11	Systolic blood pressure;
LUAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22338127	chr1:209979572	IRF6	0.49	6.73	0.31	5.5e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs17818399	0.926	rs13032670	chr2:46830794	C/T	cg21681030	chr2:46777652	RHOQ	0.4	7.21	0.33	2.58e-12	Height;
LUAD	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg13012494	chr21:47604986	C21orf56	0.47	7.76	0.35	6.64e-14	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg03289416	chr15:75166202	SCAMP2	-0.51	-8.76	-0.39	4.8e-17	Breast cancer;
LUAD	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg04455712	chr21:45112962	RRP1B	0.38	7.56	0.34	2.61e-13	Mean corpuscular volume;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg16261398	chr11:1410750	BRSK2	-0.42	-6.95	-0.32	1.39e-11	Schizophrenia;
LUAD	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg18761221	chr20:60518478	NA	0.39	6.8	0.31	3.64e-11	Body mass index;
LUAD	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg13535736	chr9:111863775	C9orf5	-0.41	-6.46	-0.3	2.93e-10	Menarche (age at onset);
LUAD	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.56	9.13	0.41	2.78e-18	Multiple sclerosis;
LUAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs16910800	0.689	rs7128636	chr11:23164689	C/T	cg20040320	chr11:23191996	NA	-0.65	-7.98	-0.36	1.36e-14	Cancer;
LUAD	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-7.03	-0.32	8.55e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg20380214	chr12:9217688	LOC144571	0.34	6.42	0.3	3.59e-10	Sjögren's syndrome;
LUAD	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg15704280	chr7:45808275	SEPT13	-1.07	-24.81	-0.77	1.63e-84	Height;
LUAD	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg10370574	chr19:1840461	REXO1	0.65	11.21	0.48	1e-25	Bipolar disorder;
LUAD	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg14784868	chr12:69753453	YEATS4	0.45	7.35	0.34	1.06e-12	Blood protein levels;
LUAD	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg23750338	chr8:142222470	SLC45A4	0.62	14.34	0.57	2.73e-38	Immature fraction of reticulocytes;
LUAD	cis	rs17102423	0.573	rs7144259	chr14:65537559	T/A	cg11161011	chr14:65562177	MAX	-0.46	-7.06	-0.32	6.66e-12	Obesity-related traits;
LUAD	cis	rs6484504	0.625	rs10835766	chr11:31374329	C/A	cg14844989	chr11:31128820	NA	0.44	8.04	0.36	9.12e-15	Red blood cell count;
LUAD	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg05110241	chr16:68378359	PRMT7	-0.94	-10.59	-0.46	2.07e-23	Magnesium levels;
LUAD	cis	rs877282	0.786	rs11253392	chr10:788768	G/A	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	cis	rs3774830	0.869	rs11737487	chr4:5446673	G/A	cg26943120	chr4:5472116	STK32B	0.32	6.41	0.3	3.79e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2455601	0.882	rs11042106	chr11:8896083	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.52	7.13	0.33	4.38e-12	Schizophrenia;
LUAD	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.57	0.3	1.45e-10	Cardiac Troponin-T levels;
LUAD	cis	rs10992471	0.528	rs10992347	chr9:95220633	C/A	cg14631576	chr9:95140430	CENPP	-0.49	-10.11	-0.44	1.14e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs2224391	0.628	rs2753239	chr6:5252826	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-8.79	-0.39	3.78e-17	Height;
LUAD	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg01689657	chr7:91764605	CYP51A1	0.33	8.1	0.37	6.03e-15	Breast cancer;
LUAD	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.91	0.4	1.48e-17	Cognitive ability;
LUAD	cis	rs6782228	0.527	rs7426806	chr3:128412930	G/A	cg16766828	chr3:128327626	NA	-0.39	-7.27	-0.33	1.76e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs9393692	0.557	rs17608582	chr6:26318799	C/A	cg13736514	chr6:26305472	NA	-0.53	-8.63	-0.39	1.23e-16	Educational attainment;
LUAD	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg00603274	chr11:61596626	FADS2	0.36	6.36	0.3	5.31e-10	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg04025307	chr7:1156635	C7orf50	0.51	8.11	0.37	5.55e-15	Bronchopulmonary dysplasia;
LUAD	cis	rs6460942	1.000	rs117657017	chr7:12318891	T/C	cg06484146	chr7:12443880	VWDE	-0.55	-6.55	-0.3	1.69e-10	Coronary artery disease;
LUAD	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11644478	chr21:40555479	PSMG1	0.68	10.85	0.47	2.35e-24	Cognitive function;
LUAD	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg15997130	chr1:24165203	NA	0.42	6.89	0.32	1.98e-11	Immature fraction of reticulocytes;
LUAD	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg24675056	chr1:15929824	NA	0.46	8.11	0.37	5.52e-15	Systolic blood pressure;
LUAD	cis	rs10791323	0.521	rs10894756	chr11:133745852	G/A	cg15485101	chr11:133734466	NA	0.31	6.72	0.31	5.77e-11	Childhood ear infection;
LUAD	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.14	-0.37	4.47e-15	Personality dimensions;
LUAD	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg03929089	chr4:120376271	NA	-0.83	-15.1	-0.59	1.55e-41	Coronary artery disease;
LUAD	cis	rs10821973	0.527	rs7076565	chr10:64026793	A/G	cg09941381	chr10:64027924	RTKN2	-0.36	-6.91	-0.32	1.79e-11	Hypothyroidism;
LUAD	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg17177755	chr1:15930204	NA	0.44	7.09	0.33	5.71e-12	Systolic blood pressure;
LUAD	trans	rs75804782	0.521	rs72994970	chr2:239426992	G/A	cg01134436	chr17:81009848	B3GNTL1	0.75	8.03	0.36	1e-14	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03264133	chr6:25882463	NA	-0.55	-7.98	-0.36	1.42e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg01620082	chr3:125678407	NA	-0.69	-7.63	-0.35	1.56e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs673604	0.536	rs72657986	chr1:35683263	A/T	cg12633102	chr1:35676489	NA	-0.74	-7.29	-0.33	1.53e-12	Endometrial cancer;
LUAD	cis	rs2581828	0.656	rs2581800	chr3:53109352	A/G	cg24530246	chr3:53118167	NA	0.3	6.48	0.3	2.53e-10	Crohn's disease;
LUAD	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg26597838	chr10:835615	NA	0.81	12.71	0.53	1.37e-31	Eosinophil percentage of granulocytes;
LUAD	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg00071950	chr4:10020882	SLC2A9	0.82	17.35	0.64	2.59e-51	Bone mineral density;
LUAD	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07266350	chr3:49460521	AMT;NICN1	0.37	6.66	0.31	8.8e-11	Menarche (age at onset);
LUAD	cis	rs28595532	1.000	rs56225646	chr4:119651217	T/C	cg21605333	chr4:119757512	SEC24D	0.87	8.02	0.36	1.02e-14	Cannabis dependence symptom count;
LUAD	trans	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.9	-0.36	2.42e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg21733973	chr7:65235735	NA	0.47	7.7	0.35	9.5e-14	Calcium levels;
LUAD	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10802521	chr3:52805072	NEK4	-0.61	-10.84	-0.47	2.5300000000000002e-24	Bipolar disorder;
LUAD	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg03161606	chr19:29218774	NA	0.59	8.8	0.39	3.4e-17	Methadone dose in opioid dependence;
LUAD	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg04287289	chr16:89883240	FANCA	0.74	7.46	0.34	4.87e-13	Skin colour saturation;
LUAD	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg23985595	chr17:80112537	CCDC57	0.53	9.68	0.43	3.62e-20	Life satisfaction;
LUAD	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	trans	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg18187862	chr3:45730750	SACM1L	-0.55	-8.08	-0.37	6.89e-15	Primary sclerosing cholangitis;
LUAD	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.29	0.33	1.56e-12	Tonsillectomy;
LUAD	cis	rs9581857	0.547	rs78273785	chr13:28052884	T/C	cg22138327	chr13:27999177	GTF3A	0.85	9.25	0.41	1.09e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs220324	0.688	rs715744	chr21:43565503	G/C	cg09727148	chr21:43560719	UMODL1	0.57	8.53	0.38	2.63e-16	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs11671005	0.735	rs3826683	chr19:58918733	T/C	cg13877915	chr19:58951672	ZNF132	0.54	7.14	0.33	4.22e-12	Mean platelet volume;
LUAD	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg13073564	chr4:8508604	NA	-0.61	-11.11	-0.48	2.46e-25	Response to antineoplastic agents;
LUAD	cis	rs9837602	0.935	rs17392948	chr3:99754498	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.62	8.6	0.39	1.57e-16	Breast cancer;
LUAD	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg07936489	chr17:37558343	FBXL20	0.44	6.81	0.31	3.47e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg02734326	chr4:10020555	SLC2A9	-0.42	-7.4	-0.34	7.24e-13	Bone mineral density;
LUAD	cis	rs2688608	0.868	rs2688625	chr10:75631548	T/C	cg19442545	chr10:75533431	FUT11	-0.42	-6.97	-0.32	1.21e-11	Inflammatory bowel disease;
LUAD	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg18944383	chr4:111397179	ENPEP	0.41	8.2	0.37	2.89e-15	Height;
LUAD	cis	rs7814319	1.000	rs7814319	chr8:97263418	C/T	cg20787634	chr8:97240163	UQCRB	-0.35	-6.59	-0.3	1.35e-10	Lung function (FVC);
LUAD	cis	rs7072216	0.763	rs7923729	chr10:100169465	C/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.68	-0.39	8.56e-17	Metabolite levels;
LUAD	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg18190219	chr22:46762943	CELSR1	-0.54	-6.79	-0.31	3.91e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg14664628	chr15:75095509	CSK	-0.42	-6.68	-0.31	7.44e-11	Breast cancer;
LUAD	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg23587288	chr2:27483067	SLC30A3	-0.4	-7.23	-0.33	2.22e-12	Blood metabolite levels;
LUAD	cis	rs7178572	0.568	rs1493700	chr15:77629060	T/C	cg15453836	chr15:77711506	NA	-0.37	-6.53	-0.3	1.92e-10	Type 2 diabetes;
LUAD	cis	rs9297145	0.678	rs62473048	chr7:98775511	T/C	cg05967295	chr7:98741636	SMURF1	0.97	15.71	0.61	3.99e-44	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	trans	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.62	-0.31	1.06e-10	Diabetic kidney disease;
LUAD	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg10556349	chr10:835070	NA	0.62	8.11	0.37	5.41e-15	Eosinophil percentage of granulocytes;
LUAD	trans	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg10208301	chr11:6592745	DNHD1	0.5	6.43	0.3	3.53e-10	Coronary artery calcification;
LUAD	cis	rs9863	0.828	rs11057413	chr12:124489162	A/G	cg17723958	chr12:124429295	CCDC92	-0.41	-6.8	-0.31	3.47e-11	White blood cell count;
LUAD	cis	rs2658782	0.789	rs2259633	chr11:93141580	C/A	cg15737290	chr11:93063684	CCDC67	0.48	6.97	0.32	1.25e-11	Pulmonary function decline;
LUAD	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.62	0.31	1.09e-10	Depression;
LUAD	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-6.86	-0.32	2.43e-11	Alzheimer's disease (late onset);
LUAD	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg18252515	chr7:66147081	NA	-0.63	-6.96	-0.32	1.28e-11	Gout;
LUAD	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg05535760	chr7:792225	HEATR2	0.85	11.45	0.49	1.29e-26	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg06074448	chr4:187884817	NA	-0.38	-7.71	-0.35	8.84e-14	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.64	-0.35	1.49e-13	Personality dimensions;
LUAD	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg11517269	chr6:28058789	ZSCAN12L1	0.25	6.44	0.3	3.34e-10	Cardiac Troponin-T levels;
LUAD	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg14784868	chr12:69753453	YEATS4	0.41	6.58	0.3	1.42e-10	Blood protein levels;
LUAD	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.4	7.29	0.33	1.49e-12	Depression;
LUAD	trans	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	17.21	0.64	1.1e-50	Exhaled nitric oxide output;
LUAD	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg23803603	chr1:2058230	PRKCZ	-0.41	-6.67	-0.31	8.06e-11	Height;
LUAD	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.78	-0.35	5.45e-14	Blood trace element (Zn levels);
LUAD	trans	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg01620082	chr3:125678407	NA	-0.73	-7.53	-0.34	3.04e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg15921436	chr17:44337874	NA	0.83	10.66	0.46	1.13e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg21153622	chr11:89784906	NA	0.33	6.54	0.3	1.82e-10	Coronary artery disease;
LUAD	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg23283495	chr1:209979779	IRF6	0.67	9.19	0.41	1.84e-18	Cleft lip with or without cleft palate;
LUAD	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.8	0.43	1.38e-20	Colorectal cancer;
LUAD	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03647317	chr4:187891568	NA	-0.38	-7.26	-0.33	1.87e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg10876282	chr6:28092338	ZSCAN16	0.44	7.08	0.33	5.87e-12	Parkinson's disease;
LUAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg08888203	chr3:10149979	C3orf24	-0.74	-12.92	-0.53	2.13e-32	Alzheimer's disease;
LUAD	cis	rs12760731	0.641	rs11590951	chr1:178322757	C/T	cg00404053	chr1:178313656	RASAL2	0.65	8.49	0.38	3.47e-16	Obesity-related traits;
LUAD	cis	rs4889855	0.505	rs8076974	chr17:78621817	G/A	cg16591659	chr17:78472290	NA	-0.42	-7.23	-0.33	2.31e-12	Fractional excretion of uric acid;
LUAD	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs758324	0.947	rs6596039	chr5:131198652	C/A	cg25547332	chr5:131281432	NA	0.44	6.7	0.31	6.68e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7680126	0.596	rs917826	chr4:10295595	C/G	cg02734326	chr4:10020555	SLC2A9	-0.48	-6.41	-0.3	3.96e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-7.95	-0.36	1.71e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs250677	0.916	rs17109279	chr5:148416581	A/G	cg12140854	chr5:148520817	ABLIM3	-0.62	-9.74	-0.43	2.3e-20	Breast cancer;
LUAD	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg27454412	chr7:1067447	C7orf50	-0.42	-7.78	-0.35	5.46e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs4713675	0.565	rs6904816	chr6:33676156	G/A	cg13859433	chr6:33739653	LEMD2	-0.3	-7.07	-0.33	6.5e-12	Plateletcrit;
LUAD	cis	rs240764	0.782	rs239223	chr6:101112345	A/G	cg09795085	chr6:101329169	ASCC3	0.44	7.51	0.34	3.56e-13	Neuroticism;
LUAD	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg03929089	chr4:120376271	NA	-0.46	-7.11	-0.33	5.06e-12	HDL cholesterol;
LUAD	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.62	-0.31	1.08e-10	Neuroticism;
LUAD	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-8.65	-0.39	1.1e-16	Cognitive function;
LUAD	cis	rs2425143	0.908	rs58448091	chr20:34325470	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.42	-0.34	6.64e-13	Blood protein levels;
LUAD	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	6.71	0.31	6.22e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg18451016	chr1:38461880	NA	0.39	7.61	0.35	1.85e-13	Coronary artery disease;
LUAD	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg07386859	chr16:1872102	HAGH	-0.5	-7.95	-0.36	1.66e-14	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg16083429	chr3:49237500	CCDC36	-0.34	-6.47	-0.3	2.75e-10	Menarche (age at onset);
LUAD	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-8.22	-0.37	2.51e-15	Bipolar disorder;
LUAD	cis	rs7408868	0.831	rs1548555	chr19:15278057	A/G	cg14696996	chr19:15285081	NOTCH3	0.82	10.59	0.46	2.07e-23	Pulse pressure;
LUAD	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26314531	chr2:26401878	FAM59B	0.65	7.93	0.36	2.01e-14	Gut microbiome composition (summer);
LUAD	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg23260525	chr10:116636907	FAM160B1	-0.43	-9.26	-0.41	1.05e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg13385794	chr1:248469461	NA	0.26	6.88	0.32	2.12e-11	Common traits (Other);
LUAD	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg10591111	chr5:226296	SDHA	-0.55	-7.1	-0.33	5.36e-12	Breast cancer;
LUAD	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05890377	chr2:74357713	NA	0.85	12.08	0.51	4.58e-29	Gestational age at birth (maternal effect);
LUAD	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg17264618	chr3:40429014	ENTPD3	0.38	8.4	0.38	7.03e-16	Renal cell carcinoma;
LUAD	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg08508325	chr11:3079039	CARS	0.44	9.12	0.41	3.03e-18	Calcium levels;
LUAD	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.65e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11811982	0.793	rs116045808	chr1:227420480	G/A	cg24860534	chr1:227506868	CDC42BPA	0.7	7.58	0.35	2.27e-13	Optic disc area;
LUAD	cis	rs62238980	0.614	rs117432936	chr22:32382309	G/T	cg02631450	chr22:32366979	NA	0.81	6.56	0.3	1.61e-10	Childhood ear infection;
LUAD	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg03563238	chr19:33554763	RHPN2	-0.33	-7.9	-0.36	2.48e-14	Bone properties (heel);
LUAD	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg10518543	chr12:38710700	ALG10B	-0.43	-7.11	-0.33	4.89e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1559088	1.000	rs12985438	chr19:33559368	G/A	cg27124370	chr19:33622961	WDR88	0.44	6.72	0.31	5.73e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.58	0.35	2.26e-13	Tonsillectomy;
LUAD	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg26408565	chr15:76604113	ETFA	-0.43	-7.02	-0.32	8.95e-12	Blood metabolite levels;
LUAD	cis	rs4629710	0.592	rs35017713	chr6:131581212	G/A	cg12606694	chr6:131520996	AKAP7	0.51	7.36	0.34	9.68e-13	Multiple myeloma (IgH translocation);
LUAD	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg15704280	chr7:45808275	SEPT13	-1.0	-20.27	-0.7	2.52e-64	Height;
LUAD	cis	rs6546550	0.901	rs10496174	chr2:70153436	T/G	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.16	-0.48	1.61e-25	Prevalent atrial fibrillation;
LUAD	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg26384229	chr12:38710491	ALG10B	0.44	7.37	0.34	9.17e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs3806843	0.520	rs246051	chr5:140326464	G/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs791888	1.000	rs2762521	chr10:89414923	T/A	cg13926569	chr10:89418898	PAPSS2	-0.45	-8.45	-0.38	4.74e-16	Magnesium levels;
LUAD	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg02428538	chr16:24856791	SLC5A11	0.49	6.77	0.31	4.42e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg13560548	chr3:10150139	C3orf24	0.44	7.44	0.34	5.51e-13	Alzheimer's disease;
LUAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg22535103	chr8:58192502	C8orf71	-0.75	-8.88	-0.4	2e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg14343924	chr8:8086146	FLJ10661	0.44	6.96	0.32	1.34e-11	Systolic blood pressure;
LUAD	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg12599982	chr1:44399894	ARTN	0.33	6.56	0.3	1.57e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg15691649	chr6:25882328	NA	-0.57	-7.66	-0.35	1.3e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7727544	0.625	rs4705916	chr5:131407493	C/A	cg16205897	chr5:131564050	P4HA2	-0.35	-7.61	-0.35	1.77e-13	Blood metabolite levels;
LUAD	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.37	7.33	0.34	1.14e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6782228	0.606	rs2712405	chr3:128332082	T/C	cg16766828	chr3:128327626	NA	-0.37	-6.87	-0.32	2.37e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs7589728	0.858	rs1914734	chr2:88529509	T/C	cg04511125	chr2:88470314	THNSL2	0.66	7.78	0.35	5.67e-14	Plasma clusterin levels;
LUAD	trans	rs783540	1.000	rs783540	chr15:83254708	C/T	cg18393722	chr15:85113863	UBE2QP1	0.45	7.51	0.34	3.63e-13	Schizophrenia;
LUAD	trans	rs9784649	0.641	rs72755823	chr5:25075537	T/C	cg08600765	chr20:34638493	LOC647979	-0.91	-11.4	-0.48	1.9e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs12681287	0.673	rs4464946	chr8:87326259	G/A	cg00550725	chr8:87521180	FAM82B	0.45	6.4	0.3	4.25e-10	Caudate activity during reward;
LUAD	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg10518543	chr12:38710700	ALG10B	-0.41	-6.79	-0.31	3.8e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg23587288	chr2:27483067	SLC30A3	-0.4	-7.82	-0.36	4.21e-14	Blood metabolite levels;
LUAD	cis	rs912057	0.526	rs746453	chr6:6734221	C/A	cg06612196	chr6:6737390	NA	0.65	16.09	0.62	8.93e-46	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg20891283	chr12:69753455	YEATS4	0.46	7.32	0.34	1.25e-12	Blood protein levels;
LUAD	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg16680214	chr1:154839983	KCNN3	-0.6	-12.3	-0.51	5.92e-30	Prostate cancer;
LUAD	cis	rs243505	0.762	rs1019218	chr7:148488964	C/T	cg09806900	chr7:148480153	CUL1	0.47	8.08	0.37	7.06e-15	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.12	0.41	3.18e-18	Alzheimer's disease;
LUAD	cis	rs8017423	0.967	rs4904663	chr14:90729565	G/T	cg14092571	chr14:90743983	NA	-0.48	-8.28	-0.37	1.68e-15	Mortality in heart failure;
LUAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg10729496	chr3:10149963	C3orf24	0.6	10.05	0.44	1.82e-21	Alzheimer's disease;
LUAD	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg06138931	chr13:21896616	NA	0.45	6.56	0.3	1.62e-10	White matter hyperintensity burden;
LUAD	cis	rs7737355	0.947	rs10054733	chr5:130989426	C/T	cg25547332	chr5:131281432	NA	0.44	6.61	0.31	1.15e-10	Life satisfaction;
LUAD	trans	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg02030672	chr11:45687055	CHST1	0.41	7.42	0.34	6.33e-13	Obesity-related traits;
LUAD	trans	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg14791747	chr16:20752902	THUMPD1	0.48	7.59	0.35	2.05e-13	Dental caries;
LUAD	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.91	0.32	1.76e-11	Parkinson's disease;
LUAD	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg06740227	chr12:86229804	RASSF9	-0.41	-7.22	-0.33	2.47e-12	Major depressive disorder;
LUAD	cis	rs1509123	0.609	rs11867707	chr17:6714774	G/C	cg12642237	chr17:6703447	TEKT1	-0.48	-6.88	-0.32	2.15e-11	Blood metabolite levels;
LUAD	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg13319975	chr6:146136371	FBXO30	0.61	10.71	0.46	7.36e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg05768032	chr16:30646687	NA	0.49	8.69	0.39	8.1e-17	Multiple myeloma;
LUAD	trans	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg15704280	chr7:45808275	SEPT13	0.64	7.29	0.33	1.58e-12	Axial length;
LUAD	cis	rs754466	0.958	rs58916802	chr10:79695870	G/A	cg17075019	chr10:79541650	NA	-0.81	-13.07	-0.54	5.22e-33	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg18944383	chr4:111397179	ENPEP	0.38	7.81	0.36	4.53e-14	Height;
LUAD	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg03609598	chr5:56110824	MAP3K1	-0.67	-9.11	-0.4	3.38e-18	Initial pursuit acceleration;
LUAD	trans	rs1493916	0.748	rs34501189	chr18:31314196	A/G	cg27147174	chr7:100797783	AP1S1	-0.58	-10.01	-0.44	2.54e-21	Life satisfaction;
LUAD	cis	rs9925964	0.622	rs8046707	chr16:30916233	G/A	cg02466173	chr16:30829666	NA	0.44	7.49	0.34	3.93e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.55	-0.6	1.9e-43	Chronic sinus infection;
LUAD	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.36e-12	Lung cancer;
LUAD	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg06784218	chr1:46089804	CCDC17	0.58	12.98	0.53	1.14e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg10556349	chr10:835070	NA	0.58	7.31	0.34	1.3e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg18306943	chr3:40428807	ENTPD3	0.38	6.55	0.3	1.63e-10	Renal cell carcinoma;
LUAD	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.48	0.3	2.56e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.56	7.49	0.34	4.07e-13	Renal function-related traits (BUN);
LUAD	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg27489772	chr12:121021490	NA	0.53	6.78	0.31	3.95e-11	Type 1 diabetes nephropathy;
LUAD	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg00321850	chr1:175162397	KIAA0040	0.55	11.85	0.5	3.63e-28	Alcohol dependence;
LUAD	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs4728302	0.559	rs12707093	chr7:133200817	C/T	cg10665199	chr7:133106180	EXOC4	0.62	10.47	0.45	5.72e-23	Intelligence;Intelligence (multi-trait analysis);
LUAD	cis	rs6500596	0.570	rs758045	chr16:4434198	A/G	cg08645402	chr16:4508243	NA	0.49	9.01	0.4	6.92e-18	Schizophrenia;
LUAD	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg06784218	chr1:46089804	CCDC17	0.35	7.61	0.35	1.78e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg04545296	chr12:48745243	ZNF641	0.42	10.59	0.46	2.06e-23	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs9837602	1.000	rs923470	chr3:99757792	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.65	9.49	0.42	1.65e-19	Breast cancer;
LUAD	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.64	-0.35	1.5e-13	Personality dimensions;
LUAD	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg21963583	chr11:68658836	MRPL21	0.65	11.58	0.49	3.95e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg05283184	chr6:79620031	NA	-0.61	-12.11	-0.51	3.57e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs7827545	1.000	rs1372662	chr8:135567046	C/G	cg17885191	chr8:135476712	NA	0.49	7.78	0.35	5.56e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg22907277	chr7:1156413	C7orf50	0.68	8.01	0.36	1.12e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12989701	0.877	rs71414738	chr2:127876242	C/T	cg08168897	chr2:127865431	BIN1	0.46	7.17	0.33	3.41e-12	Alzheimer's disease (late onset);
LUAD	cis	rs2016266	0.787	rs4520636	chr12:53752133	G/T	cg26875137	chr12:53738046	NA	0.33	6.81	0.31	3.28e-11	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg23950597	chr19:37808831	NA	-0.61	-7.49	-0.34	4.11e-13	Coronary artery calcification;
LUAD	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg13319975	chr6:146136371	FBXO30	-0.64	-10.92	-0.47	1.25e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs897984	0.542	rs7199949	chr16:31096164	G/C	cg02466173	chr16:30829666	NA	-0.56	-9.64	-0.42	5.39e-20	Dementia with Lewy bodies;
LUAD	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg21471580	chr8:22132874	PIWIL2	0.43	7.71	0.35	9.25e-14	Hypertriglyceridemia;
LUAD	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg01657329	chr11:68192670	LRP5	-0.47	-8.21	-0.37	2.72e-15	Total body bone mineral density;
LUAD	cis	rs6854137	0.967	rs10033898	chr4:169734457	A/G	cg20607169	chr4:169750834	PALLD	-0.51	-9.74	-0.43	2.35e-20	Vein graft stenosis in coronary artery bypass grafting;
LUAD	cis	rs2625529	0.526	rs8031386	chr15:72508799	C/A	cg16672083	chr15:72433130	SENP8	-0.66	-11.8	-0.5	5.76e-28	Red blood cell count;
LUAD	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg09904177	chr6:26538194	HMGN4	-0.42	-6.9	-0.32	1.96e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg21475434	chr5:93447410	FAM172A	0.6	7.73	0.35	7.88e-14	Diabetic retinopathy;
LUAD	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg17200465	chr3:40428508	ENTPD3	0.29	7.27	0.33	1.76e-12	Renal cell carcinoma;
LUAD	cis	rs13315871	1.000	rs75828026	chr3:58346736	C/T	cg12435725	chr3:58293450	RPP14	-0.71	-7.8	-0.35	4.9e-14	Cholesterol, total;
LUAD	cis	rs889398	0.802	rs12919094	chr16:69843357	A/G	cg00738113	chr16:70207722	CLEC18C	0.35	7.03	0.32	8.22e-12	Body mass index;
LUAD	cis	rs9462027	0.628	rs2814957	chr6:34702689	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-9.0	-0.4	7.74e-18	Systemic lupus erythematosus;
LUAD	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg22963979	chr7:1858916	MAD1L1	0.49	8.44	0.38	5.08e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg24069376	chr3:38537580	EXOG	0.44	10.63	0.46	1.56e-23	Electrocardiographic conduction measures;
LUAD	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs13315871	1.000	rs9864325	chr3:58336846	A/C	cg12435725	chr3:58293450	RPP14	-0.64	-7.34	-0.34	1.11e-12	Cholesterol, total;
LUAD	cis	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.36	-0.34	9.4e-13	Resting heart rate;
LUAD	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg24579218	chr15:68104479	NA	-0.56	-9.8	-0.43	1.46e-20	Restless legs syndrome;
LUAD	cis	rs2797160	1.000	rs1739362	chr6:126020703	A/T	cg05901451	chr6:126070800	HEY2	0.46	6.76	0.31	4.49e-11	Endometrial cancer;
LUAD	trans	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg19862616	chr7:65841803	NCRNA00174	1.04	25.02	0.77	1.94e-85	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	7.5	0.34	3.78e-13	Menopause (age at onset);
LUAD	cis	rs7213347	0.707	rs9898390	chr17:2177484	C/G	cg16513277	chr17:2031491	SMG6	-0.44	-6.76	-0.31	4.57e-11	Total body bone mineral density;
LUAD	cis	rs12431939	1.000	rs66680859	chr14:51656399	A/G	cg23942311	chr14:51606299	NA	-0.47	-6.75	-0.31	4.89e-11	Cancer;
LUAD	cis	rs12216545	0.737	rs1522595	chr7:150235835	G/C	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.41	-0.3	3.93e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.09	0.33	5.6e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	7.24	0.33	2.16e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg01620082	chr3:125678407	NA	-1.04	-10.23	-0.45	4.13e-22	Breast cancer;
LUAD	cis	rs4722585	0.605	rs3753098	chr7:26198040	C/T	cg07876897	chr7:26191696	NFE2L3	-0.44	-7.08	-0.33	5.89e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg02158880	chr13:53174818	NA	0.66	11.67	0.49	1.72e-27	Lewy body disease;
LUAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.44	8.64	0.39	1.18e-16	Neutrophil percentage of white cells;
LUAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg02782426	chr3:40428986	ENTPD3	-0.39	-8.55	-0.38	2.28e-16	Renal cell carcinoma;
LUAD	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg17724175	chr1:150552817	MCL1	-0.28	-6.41	-0.3	4e-10	Tonsillectomy;
LUAD	cis	rs17818399	0.815	rs17819022	chr2:46850571	G/A	cg21681030	chr2:46777652	RHOQ	0.4	6.86	0.32	2.45e-11	Height;
LUAD	cis	rs2274273	0.837	rs10141552	chr14:55746091	C/T	cg04306507	chr14:55594613	LGALS3	-0.43	-9.03	-0.4	6.37e-18	Protein biomarker;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg04128307	chr16:75018930	WDR59	-0.4	-6.56	-0.3	1.53e-10	Vertical cup-disc ratio;
LUAD	cis	rs599083	0.793	rs471966	chr11:68173861	C/T	cg16797656	chr11:68205561	LRP5	-0.5	-10.03	-0.44	2.16e-21	Bone mineral density (spine);
LUAD	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg00631329	chr6:26305371	NA	-0.7	-13.48	-0.55	1.01e-34	Educational attainment;
LUAD	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25427524	chr10:38739819	LOC399744	-0.71	-12.86	-0.53	3.39e-32	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg03733263	chr8:22462867	KIAA1967	0.72	11.73	0.5	1.01e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs6543140	0.964	rs6736135	chr2:103064924	A/G	cg04239558	chr2:103089729	SLC9A4	0.35	7.03	0.32	8.36e-12	Blood protein levels;
LUAD	cis	rs6964587	0.621	rs38798	chr7:92044539	C/A	cg17063962	chr7:91808500	NA	-0.59	-9.77	-0.43	1.76e-20	Breast cancer;
LUAD	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg00383909	chr3:49044727	WDR6	0.7	7.06	0.32	6.9e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg11871910	chr12:69753446	YEATS4	0.71	12.32	0.51	4.95e-30	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg20476274	chr7:133979776	SLC35B4	0.83	16.66	0.63	2.87e-48	Mean platelet volume;
LUAD	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg06641503	chr3:48959341	ARIH2	-0.37	-7.42	-0.34	6.39e-13	Menarche (age at onset);
LUAD	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg00603274	chr11:61596626	FADS2	-0.37	-6.52	-0.3	2.06e-10	LDL cholesterol;
LUAD	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg05234568	chr11:5960015	NA	-0.57	-10.16	-0.44	7.57e-22	DNA methylation (variation);
LUAD	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg15557168	chr22:42548783	NA	-0.49	-9.01	-0.4	7.42e-18	Schizophrenia;
LUAD	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg24920358	chr1:40204285	PPIE	0.71	12.65	0.52	2.56e-31	Blood protein levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19345149	chr11:116658875	ZNF259	-0.54	-6.64	-0.31	9.76e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg18305652	chr10:134549665	INPP5A	0.58	11.1	0.47	2.65e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg02228675	chr17:40259724	DHX58	-0.43	-7.1	-0.33	5.16e-12	Fibrinogen levels;
LUAD	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg23985595	chr17:80112537	CCDC57	0.53	9.73	0.43	2.45e-20	Life satisfaction;
LUAD	cis	rs7493	0.950	rs11977702	chr7:95029767	C/T	cg04155289	chr7:94953770	PON1	-0.51	-6.75	-0.31	5.01e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg21475434	chr5:93447410	FAM172A	0.57	7.22	0.33	2.41e-12	Diabetic retinopathy;
LUAD	cis	rs12618769	0.597	rs72819972	chr2:99035113	A/C	cg10123293	chr2:99228465	UNC50	0.46	8.29	0.37	1.52e-15	Bipolar disorder;
LUAD	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-10.55	-0.46	2.96e-23	Gut microbiome composition (summer);
LUAD	cis	rs2882667	1.000	rs10515505	chr5:138313146	A/G	cg04439458	chr5:138467593	SIL1	-0.38	-7.02	-0.32	8.78e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs559928	0.502	rs11601686	chr11:64189110	C/T	cg05555928	chr11:63887634	MACROD1	-0.46	-7.26	-0.33	1.89e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg03188948	chr7:1209495	NA	0.83	10.11	0.44	1.13e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2885135	0.559	rs1148455	chr1:13914230	A/G	cg04886857	chr1:13914270	PDPN	0.33	6.4	0.3	4.11e-10	Response to cytadine analogues (cytosine arabinoside);
LUAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg11494091	chr17:61959527	GH2	-0.74	-18.85	-0.68	5.41e-58	Prudent dietary pattern;
LUAD	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg26958806	chr6:27640298	NA	0.58	6.39	0.3	4.46e-10	Depression;
LUAD	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg26752003	chr8:145688521	CYHR1	0.46	8.13	0.37	4.68e-15	Age at first birth;
LUAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-9.85	-0.43	9.46e-21	Renal function-related traits (BUN);
LUAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	8.74	0.39	5.35e-17	Alzheimer's disease;
LUAD	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg07636037	chr3:49044803	WDR6	0.63	12.4	0.52	2.49e-30	Parkinson's disease;
LUAD	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	6.81	0.31	3.42e-11	Platelet count;
LUAD	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg11707310	chr1:2537719	MMEL1	0.37	7.76	0.35	6.37e-14	Ulcerative colitis;
LUAD	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg03714773	chr7:91764589	CYP51A1	-0.32	-7.61	-0.35	1.79e-13	Breast cancer;
LUAD	cis	rs7107174	0.901	rs7941639	chr11:78116959	A/G	cg19901956	chr11:77921274	USP35	0.51	6.47	0.3	2.67e-10	Testicular germ cell tumor;
LUAD	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg09184832	chr6:79620586	NA	-0.51	-9.51	-0.42	1.47e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg21385522	chr1:16154831	NA	-0.58	-9.7	-0.43	3.15e-20	Systolic blood pressure;
LUAD	cis	rs13064411	0.696	rs6773497	chr3:113186514	T/C	cg10517650	chr3:113235015	CCDC52	-0.53	-9.23	-0.41	1.29e-18	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg23887609	chr12:130822674	PIWIL1	0.4	6.76	0.31	4.48e-11	Menopause (age at onset);
LUAD	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg26587870	chr6:27730563	NA	-0.64	-6.92	-0.32	1.68e-11	Breast cancer;
LUAD	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg13870426	chr17:30244630	NA	-0.56	-6.62	-0.31	1.12e-10	Hip circumference adjusted for BMI;
LUAD	trans	rs11088226	0.538	rs4816436	chr21:33880251	A/G	cg09050820	chr6:167586206	TCP10L2	0.46	7.78	0.35	5.8e-14	Gastritis;
LUAD	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg26818010	chr10:134567672	INPP5A	-0.85	-14.73	-0.58	5.89e-40	Migraine;
LUAD	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.43	-0.38	5.47e-16	Initial pursuit acceleration;
LUAD	cis	rs11051970	0.918	rs325417	chr12:32574217	A/G	cg24626660	chr12:32551988	NA	0.33	6.64	0.31	9.69e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs11971779	0.680	rs9683	chr7:139107739	T/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.38e-10	Diisocyanate-induced asthma;
LUAD	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg12179176	chr11:130786555	SNX19	0.66	11.06	0.47	3.85e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs12545109	0.959	rs12547974	chr8:57314785	G/T	cg17761419	chr8:57350749	NA	-0.58	-8.53	-0.38	2.67e-16	Obesity-related traits;
LUAD	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg08997352	chr12:9597637	DDX12	-0.69	-12.34	-0.51	4.43e-30	Breast size;
LUAD	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg08873628	chr1:175162347	KIAA0040	0.39	6.49	0.3	2.39e-10	Alcohol dependence;
LUAD	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg14343924	chr8:8086146	FLJ10661	-0.39	-6.38	-0.3	4.62e-10	Joint mobility (Beighton score);
LUAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08280861	chr8:58055591	NA	0.65	8.55	0.38	2.28e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.74	-0.46	5.92e-24	Obesity-related traits;
LUAD	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg10356904	chr22:49881777	NA	-0.39	-8.3	-0.37	1.41e-15	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg00684032	chr4:1343700	KIAA1530	0.42	6.96	0.32	1.34e-11	Obesity-related traits;
LUAD	cis	rs9902453	1.000	rs57411618	chr17:28273052	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.22	0.41	1.37e-18	Coffee consumption (cups per day);
LUAD	cis	rs2019216	0.500	rs12450390	chr17:21910636	G/T	cg22648282	chr17:21454238	C17orf51	-0.45	-7.88	-0.36	2.86e-14	Pelvic organ prolapse;
LUAD	cis	rs9392556	0.509	rs588158	chr6:4079592	G/C	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.49	-8.87	-0.4	2.06e-17	Blood metabolite levels;
LUAD	cis	rs2637266	0.716	rs2579734	chr10:78441306	A/G	cg18941641	chr10:78392320	NA	0.33	6.72	0.31	5.79e-11	Pulmonary function;
LUAD	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg26384229	chr12:38710491	ALG10B	0.46	7.47	0.34	4.76e-13	Bladder cancer;
LUAD	cis	rs4523957	0.553	rs2172593	chr17:2025544	G/C	cg16513277	chr17:2031491	SMG6	-0.98	-19.85	-0.69	1.83e-62	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs57920188	0.584	rs12062024	chr1:4089259	A/T	cg20703997	chr1:4087676	NA	-0.46	-8.74	-0.39	5.39e-17	Interleukin-17 levels;
LUAD	cis	rs11640533	0.901	rs11862250	chr16:53415038	C/A	cg27158636	chr16:53407423	NA	0.38	6.35	0.3	5.45e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.34e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg25452165	chr22:42524984	CYP2D6	0.38	6.44	0.3	3.33e-10	Schizophrenia;
LUAD	trans	rs701145	0.640	rs1657621	chr3:153929795	T/C	cg14299572	chr10:34021103	NA	-0.4	-6.65	-0.31	8.87e-11	Coronary artery disease;
LUAD	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg27535305	chr1:53392650	SCP2	-0.39	-7.96	-0.36	1.59e-14	Monocyte count;
LUAD	cis	rs3845702	0.935	rs6433822	chr2:180840422	G/C	cg01881094	chr2:180872142	CWC22	-0.57	-7.01	-0.32	9.76e-12	Schizophrenia;
LUAD	cis	rs6992820	0.967	rs7816281	chr8:56696726	G/A	cg06880721	chr8:56792545	LYN	-0.45	-7.48	-0.34	4.38e-13	Mean platelet volume;
LUAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg07677032	chr17:61819896	STRADA	0.58	10.58	0.46	2.32e-23	Prudent dietary pattern;
LUAD	cis	rs4356932	0.967	rs7659236	chr4:76953611	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.47	-0.3	2.72e-10	Blood protein levels;
LUAD	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-11.17	-0.48	1.47e-25	Hemoglobin concentration;
LUAD	trans	rs4714291	0.802	rs1923465	chr6:39971376	A/T	cg02267698	chr19:7991119	CTXN1	-0.45	-7.09	-0.33	5.85e-12	Strep throat;
LUAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg26338869	chr17:61819248	STRADA	-0.38	-6.44	-0.3	3.27e-10	Prudent dietary pattern;
LUAD	cis	rs1595825	0.735	rs6752454	chr2:198938959	T/G	cg11031976	chr2:198649780	BOLL	-0.45	-6.5	-0.3	2.22e-10	Ulcerative colitis;
LUAD	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg18252515	chr7:66147081	NA	-0.59	-6.54	-0.3	1.83e-10	Diabetic kidney disease;
LUAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg11941060	chr3:133502564	NA	0.66	12.01	0.5	8.43e-29	Iron status biomarkers;
LUAD	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg10518543	chr12:38710700	ALG10B	0.41	6.43	0.3	3.41e-10	Bladder cancer;
LUAD	cis	rs1003719	0.788	rs2835593	chr21:38465873	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.31e-16	Eye color traits;
LUAD	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg17177755	chr1:15930204	NA	0.46	7.38	0.34	8.38e-13	Systolic blood pressure;
LUAD	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27286337	chr10:134555280	INPP5A	0.66	9.53	0.42	1.2e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg05368731	chr17:41323189	NBR1	0.95	19.19	0.68	1.76e-59	Menopause (age at onset);
LUAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg16606324	chr3:10149918	C3orf24	0.59	9.65	0.42	4.73e-20	Alzheimer's disease;
LUAD	cis	rs4774899	0.752	rs28514688	chr15:57399988	C/G	cg14026238	chr15:57616123	NA	-0.43	-8.1	-0.37	5.93e-15	Urinary tract infection frequency;
LUAD	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg09065629	chr16:1709722	CRAMP1L	-0.42	-7.43	-0.34	6.18e-13	Coronary artery disease;
LUAD	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg18944383	chr4:111397179	ENPEP	0.38	7.66	0.35	1.24e-13	Height;
LUAD	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.51	0.3	2.07e-10	Schizophrenia;
LUAD	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg21856205	chr7:94953877	PON1	-0.54	-7.51	-0.34	3.44e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg22482690	chr17:47019901	SNF8	0.45	8.58	0.38	1.86e-16	Type 2 diabetes;
LUAD	cis	rs67981189	0.529	rs2526857	chr14:71412626	A/G	cg15910301	chr14:71632612	NA	-0.42	-6.55	-0.3	1.68e-10	Schizophrenia;
LUAD	cis	rs684232	0.623	rs365118	chr17:580543	G/A	cg12384639	chr17:618140	VPS53	0.47	7.89	0.36	2.67e-14	Prostate cancer;
LUAD	cis	rs877282	0.755	rs11253399	chr10:790030	T/A	cg17470449	chr10:769945	NA	0.48	7.27	0.33	1.75e-12	Uric acid levels;
LUAD	cis	rs701145	0.938	rs2971446	chr3:154073445	G/C	cg17054900	chr3:154042577	DHX36	0.64	7.19	0.33	2.9e-12	Coronary artery disease;
LUAD	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg10792982	chr14:105748885	BRF1	0.45	9.74	0.43	2.28e-20	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9811920	0.928	rs2130369	chr3:99873317	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.54	9.99	0.44	3.14e-21	Axial length;
LUAD	cis	rs3820068	0.705	rs4646083	chr1:15825564	G/A	cg24675056	chr1:15929824	NA	0.41	6.49	0.3	2.45e-10	Systolic blood pressure;
LUAD	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg26597838	chr10:835615	NA	0.8	11.01	0.47	5.87e-25	Eosinophil percentage of granulocytes;
LUAD	trans	rs8002861	0.870	rs4942254	chr13:44451820	C/T	cg17145862	chr1:211918768	LPGAT1	0.71	16.57	0.63	7.02e-48	Leprosy;
LUAD	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-9.92	-0.43	5.51e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2996428	0.709	rs6424052	chr1:3713746	A/G	cg23277830	chr1:3704460	LRRC47	0.47	9.85	0.43	9.87e-21	Red cell distribution width;
LUAD	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg06618935	chr21:46677482	NA	-0.37	-6.99	-0.32	1.06e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg24505687	chr6:33548425	BAK1	0.6	10.36	0.45	1.45e-22	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
LUAD	cis	rs12545109	0.571	rs4314648	chr8:57276937	G/A	cg17761419	chr8:57350749	NA	-0.59	-7.99	-0.36	1.33e-14	Obesity-related traits;
LUAD	cis	rs62238980	0.614	rs79924624	chr22:32497245	A/G	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg16647868	chr5:131706066	SLC22A5	-0.41	-7.05	-0.32	7.49e-12	Blood metabolite levels;
LUAD	cis	rs2239547	0.522	rs9311485	chr3:52987645	T/G	cg11645453	chr3:52864694	ITIH4	-0.54	-10.02	-0.44	2.44e-21	Schizophrenia;
LUAD	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-15.27	-0.6	2.95e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg03188948	chr7:1209495	NA	0.81	9.85	0.43	9.72e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg21724239	chr8:58056113	NA	0.78	9.33	0.41	6.04e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2274273	0.934	rs17740741	chr14:55762712	G/C	cg04306507	chr14:55594613	LGALS3	0.42	8.69	0.39	7.98e-17	Protein biomarker;
LUAD	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg03526776	chr6:41159608	TREML2	0.33	6.95	0.32	1.4e-11	Alzheimer's disease (late onset);
LUAD	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg11050988	chr7:1952600	MAD1L1	-0.39	-8.04	-0.36	9.16e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg15358701	chr1:161410459	NA	-0.68	-6.93	-0.32	1.58e-11	Rheumatoid arthritis;
LUAD	cis	rs9522267	0.535	rs56330641	chr13:112233538	C/T	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.93e-11	Hepatitis;
LUAD	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg08213375	chr14:104286397	PPP1R13B	0.26	6.94	0.32	1.48e-11	Schizophrenia;
LUAD	cis	rs13082711	0.911	rs6777272	chr3:27488310	T/G	cg02860705	chr3:27208620	NA	0.63	9.46	0.42	2.14e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25427524	chr10:38739819	LOC399744	-0.76	-13.79	-0.56	5.41e-36	Extrinsic epigenetic age acceleration;
LUAD	cis	rs912057	0.833	rs1294421	chr6:6743149	A/C	cg06612196	chr6:6737390	NA	0.54	12.33	0.51	4.71e-30	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg08085267	chr17:45401833	C17orf57	-0.68	-11.36	-0.48	2.9e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1941023	0.503	rs4939350	chr11:60136243	C/G	cg08716584	chr11:60157161	MS4A7	-0.49	-9.48	-0.42	1.9e-19	Congenital heart disease (maternal effect);
LUAD	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06873352	chr17:61820015	STRADA	0.56	9.08	0.4	4.04e-18	Height;
LUAD	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-7.42	-0.34	6.34e-13	Alzheimer's disease (late onset);
LUAD	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg26513180	chr16:89883248	FANCA	-0.43	-7.25	-0.33	1.97e-12	Vitiligo;
LUAD	cis	rs7937890	0.869	rs2915404	chr11:14404825	A/G	cg02886208	chr11:14281011	SPON1	-0.37	-7.47	-0.34	4.65e-13	Mitochondrial DNA levels;
LUAD	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg13319975	chr6:146136371	FBXO30	-0.55	-8.65	-0.39	1.09e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg18402987	chr7:1209562	NA	0.8	9.85	0.43	9.51e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.18	-0.37	3.46e-15	Total body bone mineral density;
LUAD	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg17644776	chr2:200775616	C2orf69	0.52	6.53	0.3	1.9e-10	Schizophrenia;
LUAD	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg10518543	chr12:38710700	ALG10B	0.47	7.93	0.36	1.93e-14	Morning vs. evening chronotype;
LUAD	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg09455208	chr3:40491958	NA	0.6	12.65	0.52	2.51e-31	Renal cell carcinoma;
LUAD	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23158103	chr7:148848205	ZNF398	-0.48	-8.49	-0.38	3.51e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg09658497	chr7:2847517	GNA12	-0.43	-7.86	-0.36	3.2e-14	Height;
LUAD	trans	rs12517041	0.935	rs2099089	chr5:23287372	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.51	-0.3	2.11e-10	Calcium levels;
LUAD	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg18944383	chr4:111397179	ENPEP	-0.39	-7.33	-0.34	1.15e-12	Coronary artery disease;
LUAD	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg25344623	chr2:136566232	LCT	-0.35	-6.7	-0.31	6.54e-11	Mosquito bite size;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg03874568	chr17:74667923	NA	0.41	6.66	0.31	8.39e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg00071950	chr4:10020882	SLC2A9	0.79	16.23	0.62	2.14e-46	Bone mineral density;
LUAD	trans	rs11165623	0.585	rs6698447	chr1:96999473	C/T	cg10631902	chr5:14652156	NA	-0.41	-7.48	-0.34	4.48e-13	Hip circumference;Waist circumference;
LUAD	cis	rs3789045	1.000	rs12046747	chr1:204593696	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.39	-6.64	-0.31	9.81e-11	Educational attainment (college completion);
LUAD	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg26384229	chr12:38710491	ALG10B	-0.5	-8.05	-0.36	8.6e-15	Heart rate;
LUAD	cis	rs36051895	0.664	rs17425819	chr9:5114773	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-6.58	-0.3	1.37e-10	Pediatric autoimmune diseases;
LUAD	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg06781209	chr11:61594997	FADS2	-0.4	-7.49	-0.34	4.14e-13	Trans fatty acid levels;
LUAD	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg20307385	chr11:47447363	PSMC3	0.68	11.54	0.49	5.65e-27	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg10556349	chr10:835070	NA	0.68	8.09	0.37	6.37e-15	Eosinophil percentage of granulocytes;
LUAD	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg05754148	chr16:3507555	NAT15	0.65	10.98	0.47	7.51e-25	Tuberculosis;
LUAD	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg14092988	chr3:52407081	DNAH1	0.37	7.48	0.34	4.47e-13	Bipolar disorder;
LUAD	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.48	0.34	4.31e-13	Tonsillectomy;
LUAD	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg12573674	chr2:1569213	NA	-0.56	-8.38	-0.38	7.67e-16	IgG glycosylation;
LUAD	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg12011299	chr4:100065546	ADH4	0.71	12.93	0.53	1.8e-32	Alcohol dependence;
LUAD	cis	rs2475553	0.520	rs62437129	chr6:158655757	T/G	cg07165851	chr6:158734300	TULP4	0.66	9.23	0.41	1.35e-18	Lipoprotein (a) - cholesterol levels;
LUAD	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg20487152	chr13:99095054	FARP1	0.49	8.19	0.37	3.18e-15	Longevity;
LUAD	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg00757033	chr12:89920650	WDR51B	0.67	11.64	0.49	2.35e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg11517269	chr6:28058789	ZSCAN12L1	0.26	6.66	0.31	8.78e-11	Cardiac Troponin-T levels;
LUAD	cis	rs10821973	0.527	rs7072893	chr10:64034178	T/C	cg09941381	chr10:64027924	RTKN2	-0.36	-7.0	-0.32	1.02e-11	Hypothyroidism;
LUAD	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg08847533	chr14:75593920	NEK9	0.42	7.2	0.33	2.81e-12	Height;
LUAD	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg09658497	chr7:2847517	GNA12	-0.51	-8.52	-0.38	2.82e-16	Height;
LUAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg11062466	chr8:58055876	NA	0.57	8.14	0.37	4.57e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs9302065	0.565	rs2992905	chr13:95958190	C/T	cg19955956	chr7:72299837	SBDSP;TYW1B	0.55	9.36	0.41	4.58e-19	Blood metabolite levels;
LUAD	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06544989	chr22:39130855	UNC84B	0.46	9.3	0.41	7.7e-19	Menopause (age at onset);
LUAD	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg17264618	chr3:40429014	ENTPD3	0.43	9.14	0.41	2.64e-18	Renal cell carcinoma;
LUAD	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg26384229	chr12:38710491	ALG10B	0.46	7.58	0.35	2.24e-13	Bladder cancer;
LUAD	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg13180566	chr4:1052158	NA	-0.38	-6.5	-0.3	2.32e-10	Recombination rate (females);
LUAD	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg05110241	chr16:68378359	PRMT7	-0.87	-9.29	-0.41	7.97e-19	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs701145	0.938	rs165275	chr3:153991875	T/C	cg17054900	chr3:154042577	DHX36	0.64	7.1	0.33	5.16e-12	Coronary artery disease;
LUAD	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg05896524	chr21:47604654	C21orf56	-0.46	-7.07	-0.33	6.47e-12	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg07538946	chr5:131705188	SLC22A5	0.51	8.09	0.37	6.23e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05901451	chr6:126070800	HEY2	-0.84	-16.25	-0.62	1.68e-46	Brugada syndrome;
LUAD	cis	rs73206853	0.841	rs56184938	chr12:110817193	T/C	cg12870014	chr12:110450643	ANKRD13A	0.61	6.72	0.31	6.02e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg24069376	chr3:38537580	EXOG	-0.46	-11.05	-0.47	4.07e-25	Electrocardiographic conduction measures;
LUAD	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg21963583	chr11:68658836	MRPL21	0.65	11.57	0.49	4.43e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg11584989	chr19:19387371	SF4	0.37	6.51	0.3	2.19e-10	Tonsillectomy;
LUAD	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.79	-0.35	5.08e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg15117754	chr3:10150083	C3orf24	0.43	7.11	0.33	5.09e-12	Alzheimer's disease;
LUAD	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.52	-0.34	3.42e-13	Schizophrenia;
LUAD	cis	rs73086581	0.838	rs73088426	chr20:4003283	A/T	cg02187196	chr20:3869020	PANK2	0.46	6.36	0.3	5.13e-10	Response to antidepressants in depression;
LUAD	trans	rs7746199	0.736	rs35848276	chr6:27521096	C/T	cg01620082	chr3:125678407	NA	-1.07	-10.2	-0.44	5.26e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1018836	0.892	rs7819519	chr8:91565504	C/T	cg16814680	chr8:91681699	NA	-0.57	-9.54	-0.42	1.12e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7192380	0.630	rs2965749	chr16:69771914	C/T	cg00738113	chr16:70207722	CLEC18C	0.39	7.98	0.36	1.4e-14	Sjögren's syndrome;
LUAD	cis	rs7215564	0.908	rs34914062	chr17:78655909	C/T	cg16980736	chr17:78789706	RPTOR	-0.59	-6.45	-0.3	3.13e-10	Myopia (pathological);
LUAD	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg17200465	chr3:40428508	ENTPD3	0.27	6.76	0.31	4.47e-11	Renal cell carcinoma;
LUAD	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg06784218	chr1:46089804	CCDC17	0.6	13.39	0.55	2.55e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs877282	0.945	rs11253397	chr10:789774	A/G	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg00666640	chr1:248458726	OR2T12	0.32	7.65	0.35	1.4e-13	Common traits (Other);
LUAD	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg24069376	chr3:38537580	EXOG	0.37	8.39	0.38	7.29e-16	Electrocardiographic conduction measures;
LUAD	cis	rs877282	0.898	rs12359731	chr10:759497	A/G	cg17470449	chr10:769945	NA	0.62	9.37	0.41	4.41e-19	Uric acid levels;
LUAD	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg19635926	chr16:89946313	TCF25	0.64	6.57	0.3	1.48e-10	Skin colour saturation;
LUAD	cis	rs494562	0.892	rs521005	chr6:86116542	A/G	cg21730993	chr6:86159210	NT5E	0.72	8.03	0.36	9.62e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1595825	0.891	rs76450397	chr2:198786112	T/C	cg00361562	chr2:198649771	BOLL	-0.47	-6.73	-0.31	5.53e-11	Ulcerative colitis;
LUAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.9	10.85	0.47	2.36e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg24675056	chr1:15929824	NA	0.48	8.35	0.38	9.85e-16	Systolic blood pressure;
LUAD	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.38	0.41	4.09e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.42	-7.5	-0.34	3.73e-13	Longevity;Endometriosis;
LUAD	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.47	-7.09	-0.33	5.56e-12	Gut microbiome composition (summer);
LUAD	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23583168	chr7:148888333	NA	-0.91	-18.66	-0.67	3.98e-57	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs1464500	0.584	rs939855	chr12:24403751	C/T	cg10556349	chr10:835070	NA	-0.46	-6.4	-0.3	4.08e-10	Juvenile osteochondritis dissecans;Response to antipsychotic treatment;
LUAD	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg18351406	chr4:77819688	ANKRD56	-0.59	-9.67	-0.43	4.05e-20	Emphysema distribution in smoking;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg17074213	chr1:92351695	TGFBR3	-0.41	-6.8	-0.31	3.57e-11	Schizophrenia;
LUAD	cis	rs9878978	1.000	rs1542901	chr3:2474012	A/G	cg21928760	chr3:2462534	CNTN4	-0.35	-6.87	-0.32	2.28e-11	Blood pressure (smoking interaction);
LUAD	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg02807482	chr3:125708958	NA	-0.66	-8.76	-0.39	4.84e-17	Blood pressure (smoking interaction);
LUAD	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg26769984	chr7:1090371	C7orf50	-0.57	-9.68	-0.43	3.63e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs11811982	0.793	rs79892036	chr1:227404012	T/C	cg24860534	chr1:227506868	CDC42BPA	0.71	7.66	0.35	1.26e-13	Optic disc area;
LUAD	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.56e-12	Crohn's disease;
LUAD	cis	rs6499255	1.000	rs55863174	chr16:69819996	G/C	cg15192750	chr16:69999425	NA	0.56	8.87	0.4	2.07e-17	IgE levels;
LUAD	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg03161606	chr19:29218774	NA	0.6	8.66	0.39	1.04e-16	Methadone dose in opioid dependence;
LUAD	cis	rs2455799	0.573	rs2455831	chr3:15751583	T/A	cg16303742	chr3:15540471	COLQ	-0.49	-9.08	-0.4	4.07e-18	Mean platelet volume;
LUAD	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.46	8.23	0.37	2.41e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03352830	chr11:487213	PTDSS2	0.81	10.34	0.45	1.78e-22	Body mass index;
LUAD	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg05368731	chr17:41323189	NBR1	0.98	20.4	0.7	6.3e-65	Menopause (age at onset);
LUAD	cis	rs62400317	0.793	rs12190367	chr6:45208938	A/G	cg18551225	chr6:44695536	NA	-0.57	-8.64	-0.39	1.2e-16	Total body bone mineral density;
LUAD	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg27446573	chr6:127587934	RNF146	0.44	6.57	0.3	1.49e-10	Breast cancer;
LUAD	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-23.63	-0.75	2.46e-79	Height;
LUAD	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12681287	0.547	rs7461366	chr8:87511685	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-10.12	-0.44	1.07e-21	Caudate activity during reward;
LUAD	cis	rs11048434	0.636	rs7306161	chr12:9059075	T/A	cg26114124	chr12:9217669	LOC144571	0.36	6.59	0.3	1.34e-10	Sjögren's syndrome;
LUAD	cis	rs2230307	0.536	rs564938	chr1:100592901	T/C	cg20868668	chr1:100435035	SLC35A3	-0.54	-7.76	-0.35	6.44e-14	Carotid intima media thickness;
LUAD	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg09365446	chr1:150670422	GOLPH3L	0.55	9.83	0.43	1.17e-20	Melanoma;
LUAD	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg11645453	chr3:52864694	ITIH4	0.52	10.03	0.44	2.13e-21	Schizophrenia;
LUAD	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg22823121	chr1:150693482	HORMAD1	0.45	9.1	0.4	3.58e-18	Tonsillectomy;
LUAD	cis	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg05084668	chr3:125655381	ALG1L	-0.88	-11.83	-0.5	4.17e-28	Blood pressure (smoking interaction);
LUAD	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.49	-0.34	4.1e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs500891	0.525	rs10943930	chr6:84060858	A/T	cg08257003	chr6:84140564	ME1	0.34	7.04	0.32	7.82e-12	Platelet-derived growth factor BB levels;
LUAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	12.56	0.52	5.69e-31	Lymphocyte counts;
LUAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg17178900	chr1:205818956	PM20D1	0.4	6.5	0.3	2.31e-10	Parkinson's disease;
LUAD	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	8.63	0.39	1.23e-16	Ileal carcinoids;
LUAD	cis	rs11048434	0.736	rs12424026	chr12:9110993	T/C	cg26114124	chr12:9217669	LOC144571	0.36	6.57	0.3	1.45e-10	Sjögren's syndrome;
LUAD	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg00666640	chr1:248458726	OR2T12	0.32	7.93	0.36	2.03e-14	Common traits (Other);
LUAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg08888203	chr3:10149979	C3orf24	0.74	12.88	0.53	2.92e-32	Alzheimer's disease;
LUAD	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg17747265	chr1:1875780	NA	-0.76	-19.19	-0.68	1.73e-59	Body mass index;
LUAD	cis	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg01251360	chr16:68772225	CDH1	-0.29	-9.33	-0.41	5.8e-19	Colorectal cancer;
LUAD	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-7.44	-0.34	5.79e-13	Hemoglobin concentration;
LUAD	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg02428538	chr16:24856791	SLC5A11	0.49	7.07	0.33	6.52e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs3818285	0.679	rs552419	chr10:111630883	G/T	cg00817464	chr10:111662876	XPNPEP1	0.82	15.78	0.61	1.84e-44	Superior crus of antihelix expression;
LUAD	cis	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg01868782	chr6:126071099	HEY2	0.32	6.39	0.3	4.47e-10	Brugada syndrome;
LUAD	cis	rs4774899	0.869	rs8037901	chr15:57421355	C/T	cg14026238	chr15:57616123	NA	0.41	7.88	0.36	2.73e-14	Urinary tract infection frequency;
LUAD	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.06	-0.54	5.73e-33	Breast cancer;
LUAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg22963979	chr7:1858916	MAD1L1	-0.57	-10.0	-0.44	2.72e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg08885076	chr2:99613938	TSGA10	-0.4	-7.08	-0.33	5.91e-12	Chronic sinus infection;
LUAD	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.21	0.33	2.6e-12	Obesity-related traits;
LUAD	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg15017067	chr4:17643749	FAM184B	0.34	6.69	0.31	7.18e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg26769984	chr7:1090371	C7orf50	0.5	7.96	0.36	1.57e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg04287289	chr16:89883240	FANCA	0.72	13.26	0.54	8.77e-34	Vitiligo;
LUAD	cis	rs2485376	1.000	rs4919620	chr10:103998258	A/G	cg20641465	chr10:103991465	PITX3	0.56	10.13	0.44	9.77e-22	QT interval;
LUAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg07677032	chr17:61819896	STRADA	0.58	10.68	0.46	1e-23	Prudent dietary pattern;
LUAD	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg27068330	chr11:65405492	SIPA1	-0.76	-11.67	-0.49	1.86e-27	Acne (severe);
LUAD	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg17971929	chr21:40555470	PSMG1	0.49	7.37	0.34	9.01e-13	Cognitive function;
LUAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg04025307	chr7:1156635	C7orf50	0.6	6.77	0.31	4.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6087990	0.966	rs2377667	chr20:31346925	A/G	cg13636640	chr20:31349939	DNMT3B	0.84	16.03	0.61	1.65e-45	Ulcerative colitis;
LUAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.57	-9.87	-0.43	8.07e-21	Lymphocyte counts;
LUAD	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg27572855	chr1:25598939	RHD	0.55	12.18	0.51	1.91e-29	Erythrocyte sedimentation rate;
LUAD	trans	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg06606381	chr12:133084897	FBRSL1	-0.63	-7.49	-0.34	4.01e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg22496339	chr2:162101262	NA	0.52	8.41	0.38	6.16e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.9	0.32	1.92e-11	Schizophrenia;
LUAD	cis	rs12545109	0.800	rs1530218	chr8:57407864	C/G	cg09654669	chr8:57350985	NA	-0.65	-9.2	-0.41	1.69e-18	Obesity-related traits;
LUAD	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg15485101	chr11:133734466	NA	0.34	7.79	0.35	5.1e-14	Childhood ear infection;
LUAD	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg06627628	chr2:24431161	ITSN2	0.42	7.21	0.33	2.64e-12	Asthma;
LUAD	cis	rs68170813	0.523	rs11766131	chr7:107071138	T/C	cg23024343	chr7:107201750	COG5	0.52	7.2	0.33	2.84e-12	Coronary artery disease;
LUAD	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.13	-0.37	4.66e-15	Total body bone mineral density;
LUAD	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg08916839	chr5:415575	AHRR	0.85	9.94	0.44	4.71e-21	Fat distribution (HIV);
LUAD	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06544989	chr22:39130855	UNC84B	0.45	8.37	0.38	8.58e-16	Menopause (age at onset);
LUAD	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg18132916	chr6:79620363	NA	-0.46	-7.77	-0.35	5.84e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.28	-0.57	5.01e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2387326	0.671	rs12268728	chr10:129945897	G/A	cg16087940	chr10:129947807	NA	-0.63	-9.01	-0.4	6.94e-18	Select biomarker traits;
LUAD	cis	rs6734238	0.834	rs13409371	chr2:113838145	A/G	cg09040174	chr2:113837401	NA	-0.38	-6.39	-0.3	4.35e-10	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
LUAD	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg22681709	chr2:178499509	PDE11A	-0.43	-7.03	-0.32	8.08e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg15448220	chr1:150897856	SETDB1	0.46	7.41	0.34	7.03e-13	Urate levels;
LUAD	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg26195577	chr20:24973756	C20orf3	0.96	16.54	0.63	9.08e-48	Blood protein levels;
LUAD	cis	rs4631830	0.737	rs7071471	chr10:51503335	C/T	cg20129853	chr10:51489980	NA	0.33	6.45	0.3	3.08e-10	Prostate-specific antigen levels;
LUAD	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.65	0.31	8.98e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs59104589	0.617	rs60178325	chr2:242300651	A/T	cg08645257	chr2:242211290	HDLBP	0.47	7.47	0.34	4.59e-13	Fibrinogen levels;
LUAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.54	-9.79	-0.43	1.53e-20	Longevity;Endometriosis;
LUAD	trans	rs7395662	1.000	rs7395662	chr11:48518893	C/T	cg15704280	chr7:45808275	SEPT13	0.41	6.48	0.3	2.6200000000000003e-10	HDL cholesterol;
LUAD	cis	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg07460842	chr6:66804631	NA	-0.88	-14.13	-0.57	2.02e-37	Exhaled nitric oxide output;
LUAD	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg10755058	chr3:40428713	ENTPD3	0.39	7.57	0.35	2.33e-13	Renal cell carcinoma;
LUAD	cis	rs11811982	0.793	rs11801282	chr1:227402910	G/C	cg24860534	chr1:227506868	CDC42BPA	0.71	7.66	0.35	1.26e-13	Optic disc area;
LUAD	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg19318889	chr4:1322082	MAEA	0.49	8.13	0.37	4.94e-15	Longevity;
LUAD	cis	rs7584330	0.518	rs11888077	chr2:238424763	G/A	cg14458575	chr2:238380390	NA	0.85	13.27	0.54	7.59e-34	Prostate cancer;
LUAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg08219700	chr8:58056026	NA	0.42	6.4	0.3	4.22e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs61897795	0.628	rs174585	chr11:61611694	G/A	cg19610905	chr11:61596333	FADS2	-0.7	-9.88	-0.43	7.3e-21	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.39	-6.99	-0.32	1.06e-11	Cystic fibrosis severity;
LUAD	cis	rs909002	0.962	rs1474181	chr1:32136610	C/G	cg13919466	chr1:32135498	COL16A1	-0.43	-10.52	-0.46	3.77e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg26408565	chr15:76604113	ETFA	-0.45	-7.3	-0.33	1.46e-12	Blood metabolite levels;
LUAD	cis	rs6960043	0.738	rs6461153	chr7:15059796	G/C	cg19272540	chr7:15055459	NA	-0.38	-8.57	-0.38	1.95e-16	Type 2 diabetes;
LUAD	cis	rs77972916	0.611	rs61552842	chr2:43584036	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-8.34	-0.38	1.03e-15	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs7181230	0.885	rs28444847	chr15:40356604	C/T	cg22705835	chr10:65332833	REEP3	-0.36	-6.73	-0.31	5.41e-11	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg01579765	chr21:45077557	HSF2BP	-0.57	-12.63	-0.52	2.94e-31	Mean corpuscular volume;
LUAD	cis	rs870825	0.616	rs6843185	chr4:185649878	A/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.18	0.57	1.32e-37	Blood protein levels;
LUAD	cis	rs7072216	0.555	rs2296433	chr10:100184062	C/A	cg26618903	chr10:100175079	PYROXD2	-0.38	-7.21	-0.33	2.53e-12	Metabolite levels;
LUAD	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg23750338	chr8:142222470	SLC45A4	-0.59	-13.39	-0.55	2.52e-34	Immature fraction of reticulocytes;
LUAD	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg03929089	chr4:120376271	NA	0.52	7.65	0.35	1.34e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6545883	0.826	rs1186697	chr2:61661417	G/A	cg15711740	chr2:61764176	XPO1	-0.41	-6.42	-0.3	3.76e-10	Tuberculosis;
LUAD	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg02782426	chr3:40428986	ENTPD3	-0.41	-8.96	-0.4	1.06e-17	Renal cell carcinoma;
LUAD	cis	rs977987	0.806	rs1549306	chr16:75415341	A/G	cg03315344	chr16:75512273	CHST6	0.64	14.19	0.57	1.14e-37	Dupuytren's disease;
LUAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg10729496	chr3:10149963	C3orf24	-0.65	-9.68	-0.43	3.83e-20	Alzheimer's disease;
LUAD	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg09873201	chr16:3507582	NAT15	0.53	8.46	0.38	4.41e-16	Tuberculosis;
LUAD	trans	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg06606381	chr12:133084897	FBRSL1	-0.54	-6.53	-0.3	1.89e-10	Depression;
LUAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.51	6.86	0.32	2.42e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.91	-0.32	1.84e-11	Diabetic kidney disease;
LUAD	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg23544223	chr18:12777786	NA	0.67	8.51	0.38	3e-16	Inflammatory skin disease;
LUAD	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg20503657	chr10:835505	NA	0.82	11.16	0.48	1.6e-25	Eosinophil percentage of granulocytes;
LUAD	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg00603274	chr11:61596626	FADS2	-0.42	-7.04	-0.32	7.85e-12	Trans fatty acid levels;
LUAD	cis	rs73206853	0.534	rs13313219	chr12:110509461	G/A	cg12870014	chr12:110450643	ANKRD13A	0.8	8.02	0.36	1.03e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg05340658	chr4:99064831	C4orf37	0.45	7.34	0.34	1.12e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg04398451	chr17:18023971	MYO15A	0.91	18.31	0.66	1.46e-55	Total body bone mineral density;
LUAD	trans	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg15704280	chr7:45808275	SEPT13	-0.64	-7.5	-0.34	3.76e-13	Intraocular pressure;
LUAD	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg02734326	chr4:10020555	SLC2A9	0.49	7.48	0.34	4.26e-13	Blood metabolite levels;
LUAD	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-7.72	-0.35	8.49e-14	Blood metabolite levels;
LUAD	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.56	0.38	2.18e-16	Parkinson's disease;
LUAD	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg03806693	chr22:41940476	POLR3H	0.76	10.14	0.44	9.01e-22	Vitiligo;
LUAD	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14240646	chr10:27532245	ACBD5	-0.65	-9.74	-0.43	2.25e-20	Breast cancer;
LUAD	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg13319975	chr6:146136371	FBXO30	0.61	10.2	0.44	5.6e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg25036284	chr2:26402008	FAM59B	-0.6	-8.36	-0.38	9.18e-16	Gut microbiome composition (summer);
LUAD	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg02493740	chr2:85810744	VAMP5	-0.47	-8.58	-0.39	1.81e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs6076065	0.609	rs3746736	chr20:23424613	T/C	cg11657817	chr20:23433608	CST11	0.63	13.26	0.54	8.63e-34	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg21775007	chr8:11205619	TDH	0.37	6.47	0.3	2.75e-10	Myopia (pathological);
LUAD	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg23000734	chr10:126850823	CTBP2	-0.52	-10.5	-0.45	4.47e-23	Menarche (age at onset);
LUAD	trans	rs8002861	0.664	rs1808097	chr13:44424766	A/G	cg12856521	chr11:46389249	DGKZ	0.48	8.05	0.36	8.44e-15	Leprosy;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00653609	chr6:39082964	C6orf64	-0.42	-6.63	-0.31	1e-10	Height;
LUAD	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg04450456	chr4:17643702	FAM184B	-0.42	-8.28	-0.37	1.64e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg25985355	chr7:65971099	NA	0.53	6.59	0.31	1.33e-10	Diabetic kidney disease;
LUAD	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg05425664	chr17:57184151	TRIM37	0.38	6.77	0.31	4.4e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg18569988	chr3:195679450	NA	0.43	6.51	0.3	2.1e-10	Pancreatic cancer;
LUAD	cis	rs8038465	0.622	rs17185525	chr15:73885539	T/C	cg15420318	chr15:73925796	NPTN	0.46	7.53	0.34	3.02e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.64	11.2	0.48	1.13e-25	Birth weight;
LUAD	cis	rs7843479	0.601	rs11781959	chr8:21841863	C/G	cg03445287	chr8:21823731	XPO7	-0.48	-8.99	-0.4	8.07e-18	Mean corpuscular volume;
LUAD	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg13736514	chr6:26305472	NA	-0.67	-12.81	-0.53	5.57e-32	Educational attainment;
LUAD	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg24308560	chr3:49941425	MST1R	-0.52	-8.59	-0.39	1.74e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg22431228	chr1:16359049	CLCNKA	-0.53	-9.61	-0.42	6.7e-20	Dilated cardiomyopathy;
LUAD	cis	rs1975974	0.511	rs56047890	chr17:21733405	G/A	cg18423549	chr17:21743878	NA	-0.84	-14.99	-0.59	4.97e-41	Psoriasis;
LUAD	trans	rs2262909	0.962	rs55735642	chr19:22241176	C/T	cg05197062	chr11:11642011	GALNTL4	0.59	9.15	0.41	2.43e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg18932078	chr1:2524107	MMEL1	0.37	6.96	0.32	1.33e-11	Ulcerative colitis;
LUAD	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg13319975	chr6:146136371	FBXO30	0.59	9.69	0.43	3.37e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs727505	1.000	rs6952721	chr7:124480075	T/C	cg23710748	chr7:124431027	NA	-0.43	-9.23	-0.41	1.28e-18	Lewy body disease;
LUAD	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg11645453	chr3:52864694	ITIH4	-0.37	-7.26	-0.33	1.81e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs7591996	0.835	rs7585700	chr2:6504784	A/T	cg01747036	chr13:113140125	TUBGCP3	-0.39	-6.56	-0.3	1.56e-10	Osteosarcoma;
LUAD	cis	rs2485376	0.546	rs10748817	chr10:103988053	C/G	cg20641465	chr10:103991465	PITX3	0.45	7.92	0.36	2.1e-14	QT interval;
LUAD	cis	rs754466	0.580	rs12356063	chr10:79558131	G/C	cg17075019	chr10:79541650	NA	-0.93	-20.57	-0.71	1.19e-65	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg14917512	chr19:3094685	GNA11	0.56	6.72	0.31	6.04e-11	Diabetic kidney disease;
LUAD	cis	rs6024905	0.595	rs2022499	chr20:36966531	G/T	cg07053727	chr20:36965646	BPI	0.39	7.55	0.34	2.74e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs741677	1.000	rs741677	chr17:463843	C/T	cg13332499	chr17:408570	NA	-0.33	-6.55	-0.3	1.67e-10	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg25894440	chr7:65020034	NA	-0.69	-7.33	-0.34	1.21e-12	Diabetic kidney disease;
LUAD	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg10589385	chr1:150898437	SETDB1	0.41	7.67	0.35	1.21e-13	Melanoma;
LUAD	cis	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.03	-0.36	1.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg26043149	chr18:55253948	FECH	0.42	7.06	0.32	7.04e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg13319975	chr6:146136371	FBXO30	-0.59	-10.07	-0.44	1.55e-21	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs11039798	0.688	rs10839007	chr11:48703442	A/C	cg03929089	chr4:120376271	NA	0.59	6.8	0.31	3.49e-11	Axial length;
LUAD	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg10876282	chr6:28092338	ZSCAN16	0.46	7.16	0.33	3.67e-12	Cardiac Troponin-T levels;
LUAD	cis	rs1816752	0.819	rs6490917	chr13:24997257	G/T	cg02811702	chr13:24901961	NA	0.44	7.62	0.35	1.7e-13	Obesity-related traits;
LUAD	cis	rs9875589	0.509	rs7636901	chr3:14030958	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.38	7.09	0.33	5.79e-12	Ovarian reserve;
LUAD	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg21984481	chr17:79567631	NPLOC4	-0.55	-11.48	-0.49	1.01e-26	Eye color traits;
LUAD	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg25894440	chr7:65020034	NA	0.63	6.85	0.32	2.58e-11	Diabetic kidney disease;
LUAD	cis	rs938554	0.692	rs4428284	chr4:9996392	A/T	cg02734326	chr4:10020555	SLC2A9	0.47	6.45	0.3	3.07e-10	Blood metabolite levels;
LUAD	trans	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.88	0.43	7.76e-21	Mean corpuscular volume;
LUAD	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.57	0.52	5.15e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg17757837	chr7:157058334	UBE3C	0.48	8.53	0.38	2.61e-16	Body mass index;
LUAD	cis	rs12681287	0.577	rs10481197	chr8:87546551	A/T	cg27223183	chr8:87520930	FAM82B	0.74	10.36	0.45	1.49e-22	Caudate activity during reward;
LUAD	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg12524338	chr4:183729343	NA	0.62	7.5	0.34	3.83e-13	Pediatric autoimmune diseases;
LUAD	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg21427119	chr20:30132790	HM13	-0.61	-8.97	-0.4	1e-17	Mean corpuscular hemoglobin;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg24689585	chr15:22957012	CYFIP1	-0.5	-8.32	-0.38	1.25e-15	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg27490568	chr2:178487706	NA	0.44	7.46	0.34	4.99e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg04455712	chr21:45112962	RRP1B	0.5	10.11	0.44	1.2e-21	Mean corpuscular volume;
LUAD	cis	rs684232	0.644	rs2543781	chr17:602469	C/G	cg15660573	chr17:549704	VPS53	-0.75	-14.72	-0.58	7.1e-40	Prostate cancer;
LUAD	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg20307385	chr11:47447363	PSMC3	0.52	7.47	0.34	4.5e-13	Diastolic blood pressure;Systolic blood pressure;
LUAD	trans	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg18187862	chr3:45730750	SACM1L	0.53	8.19	0.37	3.22e-15	Primary sclerosing cholangitis;
LUAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg11494091	chr17:61959527	GH2	0.73	18.35	0.67	9.39e-56	Prudent dietary pattern;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg15663678	chr22:22307197	PPM1F	-0.69	-6.6	-0.31	1.26e-10	Type 2 diabetes;
LUAD	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg26384229	chr12:38710491	ALG10B	0.51	8.04	0.36	8.78e-15	Bladder cancer;
LUAD	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg06784218	chr1:46089804	CCDC17	0.59	13.35	0.54	3.53e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7814319	0.901	rs13253635	chr8:97240847	A/G	cg20787634	chr8:97240163	UQCRB	-0.39	-7.6	-0.35	1.9e-13	Lung function (FVC);
LUAD	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg00933542	chr6:150070202	PCMT1	0.43	9.24	0.41	1.26e-18	Lung cancer;
LUAD	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.83	0.36	3.99e-14	Depression;
LUAD	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg13319975	chr6:146136371	FBXO30	-0.61	-10.41	-0.45	9.87e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11229555	0.645	rs35279927	chr11:58212129	G/T	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg18105139	chr6:28058856	ZSCAN12L1	0.27	6.64	0.31	9.51e-11	Cardiac Troponin-T levels;
LUAD	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.3	-0.37	1.43e-15	Total body bone mineral density;
LUAD	cis	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg11143507	chr3:125485238	NA	-0.46	-7.72	-0.35	8.77e-14	Blood pressure (smoking interaction);
LUAD	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg18240062	chr17:79603768	NPLOC4	-0.46	-8.21	-0.37	2.64e-15	Eye color traits;
LUAD	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg00316803	chr15:76480434	C15orf27	-0.39	-7.15	-0.33	3.84e-12	Blood metabolite levels;
LUAD	cis	rs17532515	0.505	rs1800592	chr4:141493961	T/C	cg09181644	chr4:141490428	UCP1	0.36	7.35	0.34	1.04e-12	Select biomarker traits;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg00747290	chr2:42721154	KCNG3	-0.49	-6.56	-0.3	1.6e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg21545522	chr1:205238299	TMCC2	0.36	6.59	0.3	1.34e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg18129748	chr3:49941408	MST1R	0.42	6.99	0.32	1.11e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg08027265	chr7:2291960	NA	0.42	6.86	0.32	2.52e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg11266682	chr4:10021025	SLC2A9	0.65	15.38	0.6	1.05e-42	Bone mineral density;
LUAD	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg16405210	chr4:1374714	KIAA1530	-0.61	-9.69	-0.43	3.49e-20	Longevity;
LUAD	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg09796270	chr17:17721594	SREBF1	-0.4	-7.82	-0.36	4.14e-14	Total body bone mineral density;
LUAD	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg05425664	chr17:57184151	TRIM37	0.42	6.45	0.3	3e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7301826	0.627	rs4325342	chr12:131312482	G/A	cg11011512	chr12:131303247	STX2	0.43	7.28	0.33	1.69e-12	Plasma plasminogen activator levels;
LUAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg24813613	chr7:1882135	MAD1L1	-0.4	-6.5	-0.3	2.27e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg23625390	chr15:77176239	SCAPER	-0.46	-7.27	-0.33	1.7e-12	Blood metabolite levels;
LUAD	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg24397884	chr7:158709396	WDR60	0.57	10.03	0.44	2.16e-21	Height;
LUAD	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg22029157	chr1:209979665	IRF6	-0.75	-9.85	-0.43	9.37e-21	Cleft lip with or without cleft palate;
LUAD	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg03983476	chr2:10830698	NOL10	-0.47	-8.19	-0.37	3.04e-15	Prostate cancer;
LUAD	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg26384229	chr12:38710491	ALG10B	0.52	8.6	0.39	1.55e-16	Heart rate;
LUAD	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg07741184	chr6:167504864	NA	0.36	8.17	0.37	3.66e-15	Primary biliary cholangitis;
LUAD	cis	rs3820068	0.603	rs6429753	chr1:15900537	A/G	cg13390004	chr1:15929781	NA	0.43	6.68	0.31	7.51e-11	Systolic blood pressure;
LUAD	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg11822812	chr5:140052017	DND1	0.38	6.84	0.32	2.76e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg09060608	chr5:178986726	RUFY1	0.48	8.24	0.37	2.24e-15	Lung cancer;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg08263361	chr15:77713262	HMG20A	-0.4	-6.64	-0.31	9.65e-11	Subcortical brain region volumes;
LUAD	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.59	-0.35	2.05e-13	Fear of minor pain;
LUAD	cis	rs9796	0.636	rs1983400	chr15:41373029	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.43	-7.98	-0.36	1.4e-14	Menopause (age at onset);
LUAD	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg18876405	chr7:65276391	NA	0.67	11.53	0.49	6.15e-27	Calcium levels;
LUAD	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg25985355	chr7:65971099	NA	-0.56	-6.85	-0.32	2.68e-11	Diabetic kidney disease;
LUAD	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg14634687	chr17:47094252	IGF2BP1	0.28	6.9	0.32	1.86e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.6	0.31	1.25e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg18132916	chr6:79620363	NA	-0.44	-7.46	-0.34	5.09e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.04	-0.44	1.99e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg04800585	chr6:26043546	HIST1H2BB	0.5	8.47	0.38	4.22e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg15181151	chr6:150070149	PCMT1	0.39	7.91	0.36	2.31e-14	Lung cancer;
LUAD	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg14983838	chr19:29218262	NA	0.67	9.82	0.43	1.21e-20	Methadone dose in opioid dependence;
LUAD	cis	rs113835537	0.529	rs117112180	chr11:66293273	A/G	cg24851651	chr11:66362959	CCS	0.58	9.98	0.44	3.43e-21	Airway imaging phenotypes;
LUAD	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg02461776	chr11:598696	PHRF1	0.49	6.91	0.32	1.8e-11	Systemic lupus erythematosus;
LUAD	cis	rs1595825	0.891	rs79745588	chr2:198516835	G/A	cg10547527	chr2:198650123	BOLL	-0.53	-7.48	-0.34	4.2e-13	Ulcerative colitis;
LUAD	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg12927641	chr6:109611667	NA	-0.51	-8.71	-0.39	6.67e-17	Reticulocyte fraction of red cells;
LUAD	trans	rs783540	0.967	rs7494860	chr15:83334419	A/G	cg18393722	chr15:85113863	UBE2QP1	0.45	7.28	0.33	1.64e-12	Schizophrenia;
LUAD	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg22681709	chr2:178499509	PDE11A	-0.45	-7.37	-0.34	9.28e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.48	0.38	3.71e-16	Platelet count;
LUAD	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg18351406	chr4:77819688	ANKRD56	0.63	10.07	0.44	1.6e-21	Emphysema distribution in smoking;
LUAD	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg12667521	chr19:29218732	NA	0.6	8.14	0.37	4.42e-15	Methadone dose in opioid dependence;
LUAD	cis	rs10865541	0.806	rs10187625	chr2:3421168	A/G	cg22182287	chr2:3452347	TTC15	0.45	7.43	0.34	6.18e-13	Obesity-related traits;
LUAD	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg23262073	chr20:60523788	NA	-0.46	-7.41	-0.34	6.72e-13	Body mass index;
LUAD	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg03929089	chr4:120376271	NA	-0.91	-17.08	-0.64	3.84e-50	Coronary artery disease;
LUAD	cis	rs13064411	0.696	rs9860549	chr3:113148368	G/A	cg18753928	chr3:113234510	CCDC52	-0.67	-11.18	-0.48	1.29e-25	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs2070488	0.804	rs1870914	chr3:38494220	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.54	9.32	0.41	6.72e-19	Electrocardiographic conduction measures;
LUAD	cis	rs2797160	0.935	rs12717178	chr6:126016499	G/A	cg05901451	chr6:126070800	HEY2	0.44	6.52	0.3	2.03e-10	Endometrial cancer;
LUAD	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg00277334	chr10:82204260	NA	-0.6	-10.26	-0.45	3.23e-22	Post bronchodilator FEV1;
LUAD	cis	rs2554380	0.843	rs2562779	chr15:84390975	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.49	-7.59	-0.35	2.09e-13	Height;
LUAD	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	7.89	0.36	2.57e-14	Menarche (age at onset);
LUAD	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg22875332	chr1:76189707	ACADM	0.75	11.84	0.5	3.83e-28	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg05373962	chr22:49881684	NA	-0.5	-10.09	-0.44	1.38e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.34	-6.44	-0.3	3.29e-10	Crohn's disease;
LUAD	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg11494091	chr17:61959527	GH2	0.38	6.78	0.31	3.93e-11	Height;
LUAD	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg17971929	chr21:40555470	PSMG1	0.55	8.41	0.38	6.26e-16	Cognitive function;
LUAD	cis	rs113835537	0.529	rs11227514	chr11:66286627	G/A	cg24851651	chr11:66362959	CCS	0.57	10.22	0.44	4.71e-22	Airway imaging phenotypes;
LUAD	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg12016809	chr21:47604291	C21orf56	0.44	7.36	0.34	9.74e-13	Testicular germ cell tumor;
LUAD	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg02017074	chr12:117425053	FBXW8	0.64	8.56	0.38	2.04e-16	Subcortical brain region volumes;Hippocampal volume;
LUAD	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg07606381	chr6:8435919	SLC35B3	0.41	6.88	0.32	2.13e-11	Motion sickness;
LUAD	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg06636001	chr8:8085503	FLJ10661	0.44	7.11	0.33	4.84e-12	Mood instability;
LUAD	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg12501888	chr15:85177176	SCAND2	-0.44	-6.66	-0.31	8.49e-11	P wave terminal force;
LUAD	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg04025307	chr7:1156635	C7orf50	0.67	7.83	0.36	3.9e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13082711	0.911	rs7644466	chr3:27515271	C/G	cg02860705	chr3:27208620	NA	0.57	8.84	0.39	2.61e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-11.2	-0.48	1.14e-25	Longevity;Endometriosis;
LUAD	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg01528321	chr10:82214614	TSPAN14	0.68	10.35	0.45	1.6e-22	Post bronchodilator FEV1;
LUAD	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg04398451	chr17:18023971	MYO15A	-0.78	-14.23	-0.57	8.07e-38	Total body bone mineral density;
LUAD	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg01416388	chr22:39784598	NA	-0.52	-8.73	-0.39	6.06e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9584850	0.874	rs4584	chr13:99101869	G/C	cg20750642	chr13:99100586	FARP1	-0.34	-7.19	-0.33	3.04e-12	Neuroticism;
LUAD	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg21214613	chr1:16344536	HSPB7	0.35	6.46	0.3	2.87e-10	Systolic blood pressure;
LUAD	cis	rs6782228	0.675	rs4857918	chr3:128383960	T/C	cg16766828	chr3:128327626	NA	-0.38	-6.92	-0.32	1.65e-11	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg08773314	chr2:239334832	ASB1	-0.45	-10.47	-0.45	5.63e-23	Multiple system atrophy;
LUAD	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg23625390	chr15:77176239	SCAPER	0.4	7.19	0.33	2.89e-12	Blood metabolite levels;
LUAD	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg22431228	chr1:16359049	CLCNKA	-0.63	-12.7	-0.53	1.62e-31	Dilated cardiomyopathy;
LUAD	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg22823121	chr1:150693482	HORMAD1	0.42	8.37	0.38	8.43e-16	Tonsillectomy;
LUAD	cis	rs17092148	0.887	rs6059919	chr20:33151545	G/T	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.01	-0.36	1.15e-14	Neuroticism;
LUAD	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.65	0.31	8.98e-11	Menarche (age at onset);
LUAD	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg14343924	chr8:8086146	FLJ10661	0.43	6.62	0.31	1.12e-10	Neuroticism;
LUAD	cis	rs1609391	0.561	rs6439675	chr3:136625436	G/A	cg15507776	chr3:136538369	TMEM22	0.5	8.91	0.4	1.55e-17	Neuroticism;
LUAD	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.52	0.3	1.95e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg05926928	chr17:57297772	GDPD1	1.12	13.73	0.56	1e-35	Opioid sensitivity;
LUAD	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg26354017	chr1:205819088	PM20D1	-0.44	-7.13	-0.33	4.48e-12	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg22532475	chr10:104410764	TRIM8	-0.44	-8.72	-0.39	6.46e-17	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg03676636	chr4:99064102	C4orf37	0.3	7.26	0.33	1.9e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.25	-0.41	1.13e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg11871910	chr12:69753446	YEATS4	0.72	12.7	0.53	1.57e-31	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg07217954	chr7:1067459	C7orf50	0.39	6.38	0.3	4.75e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs240764	0.619	rs6903665	chr6:101148234	T/C	cg09795085	chr6:101329169	ASCC3	0.39	6.47	0.3	2.79e-10	Neuroticism;
LUAD	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg02038168	chr22:39784481	NA	-0.57	-9.91	-0.43	5.66e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg27433088	chr4:174089019	GALNT7	-0.37	-6.8	-0.31	3.55e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs7116495	1.000	rs947932	chr11:71656705	A/G	cg07596299	chr11:71824057	C11orf51	-0.76	-6.69	-0.31	6.89e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs870825	0.616	rs28563856	chr4:185635581	G/A	cg04058563	chr4:185651563	MLF1IP	0.89	14.3	0.57	3.91e-38	Blood protein levels;
LUAD	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg21733927	chr17:75283979	SEPT9	-0.49	-6.37	-0.3	4.96e-10	Cognitive performance;
LUAD	cis	rs739496	0.947	rs7973120	chr12:111856738	T/A	cg10833066	chr12:111807467	FAM109A	0.42	6.76	0.31	4.51e-11	Platelet count;
LUAD	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg20607798	chr8:58055168	NA	-0.54	-7.04	-0.32	8.05e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg18446336	chr7:2847575	GNA12	-0.38	-7.34	-0.34	1.08e-12	Height;
LUAD	trans	rs9929218	0.911	rs1075959	chr16:68832750	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-12.57	-0.52	5.05e-31	Colorectal cancer;
LUAD	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg15128208	chr22:42549153	NA	0.42	6.69	0.31	6.98e-11	Birth weight;
LUAD	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg18721089	chr20:30220636	NA	-0.5	-7.11	-0.33	5.07e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs4523957	0.614	rs2641439	chr17:2017561	C/G	cg16513277	chr17:2031491	SMG6	-0.95	-19.21	-0.68	1.41e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg19041857	chr6:27730383	NA	-0.44	-7.61	-0.35	1.82e-13	Parkinson's disease;
LUAD	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg17480646	chr11:65405466	SIPA1	-0.46	-6.6	-0.31	1.21e-10	Acne (severe);
LUAD	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg18512352	chr11:47633146	NA	0.4	7.14	0.33	4.15e-12	Subjective well-being;
LUAD	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg06558623	chr16:89946397	TCF25	1.14	10.58	0.46	2.2e-23	Skin colour saturation;
LUAD	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.26e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6546550	0.901	rs897120	chr2:70160982	C/T	cg02498382	chr2:70120550	SNRNP27	0.58	11.03	0.47	4.73e-25	Prevalent atrial fibrillation;
LUAD	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg27572855	chr1:25598939	RHD	0.59	13.16	0.54	2.24e-33	Erythrocyte sedimentation rate;
LUAD	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-7.34	-0.34	1.07e-12	Retinal vascular caliber;
LUAD	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg10483660	chr13:112241077	NA	-0.32	-6.86	-0.32	2.41e-11	Hepatitis;
LUAD	cis	rs62400317	0.859	rs72858511	chr6:45218119	A/G	cg20913747	chr6:44695427	NA	-0.42	-6.75	-0.31	4.95e-11	Total body bone mineral density;
LUAD	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg10518543	chr12:38710700	ALG10B	-0.43	-7.01	-0.32	9.31e-12	Heart rate;
LUAD	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg00757033	chr12:89920650	WDR51B	0.7	12.2	0.51	1.47e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg11292332	chr7:45801988	SEPT13	-0.28	-6.36	-0.3	5.26e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg18252515	chr7:66147081	NA	0.6	6.68	0.31	7.56e-11	Diabetic kidney disease;
LUAD	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs7833986	1.000	rs34608229	chr8:57097017	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.76	10.2	0.44	5.57e-22	Height;
LUAD	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg27572855	chr1:25598939	RHD	0.55	12.06	0.51	5.63e-29	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg11901034	chr3:128598214	ACAD9	-0.55	-8.8	-0.39	3.54e-17	IgG glycosylation;
LUAD	cis	rs1003719	0.788	rs2156076	chr21:38452634	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.55	0.38	2.32e-16	Eye color traits;
LUAD	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06544989	chr22:39130855	UNC84B	0.44	8.11	0.37	5.69e-15	Menopause (age at onset);
LUAD	cis	rs735539	0.521	rs716480	chr13:21418094	T/G	cg27499820	chr13:21296301	IL17D	0.45	7.4	0.34	7.43e-13	Dental caries;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg17309464	chr19:36705192	ZNF565;ZNF146	0.4	6.72	0.31	5.86e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg22906224	chr7:99728672	NA	-0.64	-11.13	-0.48	2e-25	Coronary artery disease;
LUAD	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg10589385	chr1:150898437	SETDB1	0.39	7.42	0.34	6.51e-13	Tonsillectomy;
LUAD	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg21214613	chr1:16344536	HSPB7	0.59	11.13	0.48	2.01e-25	Dilated cardiomyopathy;
LUAD	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg03733263	chr8:22462867	KIAA1967	0.71	12.03	0.51	6.84e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs4713118	0.581	rs200504	chr6:27785820	T/C	cg26587870	chr6:27730563	NA	-0.51	-7.96	-0.36	1.64e-14	Parkinson's disease;
LUAD	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg21231944	chr12:82153410	PPFIA2	-0.36	-6.58	-0.3	1.37e-10	Resting heart rate;
LUAD	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg00277334	chr10:82204260	NA	-0.51	-7.94	-0.36	1.89e-14	Post bronchodilator FEV1;
LUAD	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg01200585	chr1:228362443	C1orf69	-0.39	-7.18	-0.33	3.06e-12	Diastolic blood pressure;
LUAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-6.64	-0.31	9.38e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.86	0.32	2.49e-11	Depression;
LUAD	cis	rs9796	0.870	rs7169375	chr15:41311046	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.37	-7.0	-0.32	1.01e-11	Menopause (age at onset);
LUAD	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg06808227	chr14:105710500	BRF1	-0.42	-6.46	-0.3	2.83e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg17724175	chr1:150552817	MCL1	0.4	9.67	0.43	3.96e-20	Tonsillectomy;
LUAD	cis	rs2131877	0.956	rs60143196	chr3:194871710	A/G	cg19760965	chr3:194868843	C3orf21	0.39	6.54	0.3	1.73e-10	Non-small cell lung cancer;
LUAD	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.76	-0.35	6.34e-14	Personality dimensions;
LUAD	trans	rs629535	0.814	rs62513378	chr8:70095788	G/C	cg21567404	chr3:27674614	NA	-0.97	-17.16	-0.64	1.78e-50	Dupuytren's disease;
LUAD	cis	rs12545109	0.765	rs1960727	chr8:57411368	G/A	cg09654669	chr8:57350985	NA	-0.65	-9.32	-0.41	6.71e-19	Obesity-related traits;
LUAD	cis	rs68170813	0.522	rs12531187	chr7:106963650	C/G	cg23024343	chr7:107201750	COG5	0.49	6.95	0.32	1.38e-11	Coronary artery disease;
LUAD	cis	rs4889855	0.545	rs61171555	chr17:78465975	T/G	cg16591659	chr17:78472290	NA	-0.54	-8.81	-0.39	3.23e-17	Fractional excretion of uric acid;
LUAD	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg10596483	chr8:143751796	JRK	0.45	7.24	0.33	2.14e-12	Schizophrenia;
LUAD	cis	rs10992471	0.580	rs7030920	chr9:95122952	A/G	cg14631576	chr9:95140430	CENPP	-0.56	-11.5	-0.49	8.46e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg17252645	chr8:143867129	LY6D	-0.36	-6.8	-0.31	3.62e-11	Urinary tract infection frequency;
LUAD	cis	rs6489882	0.867	rs6489866	chr12:113363408	A/G	cg20102336	chr12:113376681	OAS3	-0.6	-9.4	-0.42	3.45e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26314531	chr2:26401878	FAM59B	-0.72	-9.81	-0.43	1.33e-20	Gut microbiome composition (summer);
LUAD	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg21204522	chr6:27730016	NA	-0.48	-7.59	-0.35	2.08e-13	Parkinson's disease;
LUAD	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg05623727	chr3:50126028	RBM5	-0.31	-6.79	-0.31	3.8e-11	Body mass index;
LUAD	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg17177755	chr1:15930204	NA	0.45	7.29	0.33	1.51e-12	Systolic blood pressure;
LUAD	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg06547715	chr2:218990976	CXCR2	-0.27	-6.49	-0.3	2.44e-10	Colorectal cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg24841124	chr19:16607009	C19orf44;CALR3	-0.65	-6.51	-0.3	2.11e-10	Type 2 diabetes;
LUAD	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg10518543	chr12:38710700	ALG10B	0.52	8.68	0.39	8.61e-17	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.21	-0.33	2.66e-12	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs732716	0.785	rs55660045	chr19:4425305	T/G	cg21934504	chr19:4445085	UBXN6	0.44	7.31	0.33	1.39e-12	Mean corpuscular volume;
LUAD	cis	rs11771526	0.901	rs62457468	chr7:32301341	C/T	cg27532318	chr7:32358331	NA	0.56	7.21	0.33	2.54e-12	Body mass index;
LUAD	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg00852783	chr1:26633632	UBXN11	0.43	7.59	0.35	2.05e-13	Obesity-related traits;
LUAD	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg21775007	chr8:11205619	TDH	-0.53	-9.52	-0.42	1.34e-19	Retinal vascular caliber;
LUAD	cis	rs17270561	0.636	rs11794	chr6:25701718	G/A	cg25753631	chr6:25732923	NA	-0.41	-7.01	-0.32	9.78e-12	Iron status biomarkers;
LUAD	cis	rs7584330	0.504	rs11884519	chr2:238425283	T/C	cg14458575	chr2:238380390	NA	0.52	8.65	0.39	1.05e-16	Prostate cancer;
LUAD	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg04287289	chr16:89883240	FANCA	0.62	6.53	0.3	1.87e-10	Skin colour saturation;
LUAD	cis	rs67517081	1	rs67517081	chr16:30987380	GT/G	cg02466173	chr16:30829666	NA	0.61	10.99	0.47	6.66e-25	Mean corpuscular hemoglobin;
LUAD	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg00071950	chr4:10020882	SLC2A9	0.79	15.96	0.61	3.17e-45	Bone mineral density;
LUAD	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg08125733	chr17:73851984	WBP2	0.52	7.67	0.35	1.24e-13	Psoriasis;
LUAD	cis	rs754466	0.510	rs10824579	chr10:79590685	C/T	cg17075019	chr10:79541650	NA	-0.75	-15.28	-0.6	2.64e-42	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg08807101	chr21:30365312	RNF160	-0.49	-8.18	-0.37	3.36e-15	Dental caries;
LUAD	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg23625390	chr15:77176239	SCAPER	-0.55	-8.86	-0.4	2.22e-17	Blood metabolite levels;
LUAD	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg18944383	chr4:111397179	ENPEP	0.42	8.25	0.37	2.09e-15	Height;
LUAD	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg03929089	chr4:120376271	NA	-0.93	-17.14	-0.64	2.18e-50	Height;
LUAD	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg26408565	chr15:76604113	ETFA	-0.41	-6.39	-0.3	4.38e-10	Blood metabolite levels;
LUAD	cis	rs6489882	0.867	rs6489869	chr12:113363922	A/C	cg20102336	chr12:113376681	OAS3	-0.6	-9.34	-0.41	5.52e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.52	-9.66	-0.43	4.27e-20	Longevity;Endometriosis;
LUAD	cis	rs59698941	0.527	rs1910075	chr5:132180089	A/T	cg14825688	chr5:132208181	LEAP2	-0.52	-10.69	-0.46	8.79e-24	Apolipoprotein A-IV levels;
LUAD	cis	rs89107	0.531	rs1690662	chr6:118612354	A/G	cg18833306	chr6:118973337	C6orf204	0.54	10.18	0.44	6.68e-22	Cardiac structure and function;
LUAD	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg16950941	chr11:66035639	RAB1B	0.43	7.25	0.33	2e-12	Gout;
LUAD	cis	rs6665290	0.669	rs3795445	chr1:227180947	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.12	-30.2	-0.83	1.28e-107	Myeloid white cell count;
LUAD	trans	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg12143784	chr7:64541923	NA	0.42	6.73	0.31	5.38e-11	Aortic root size;
LUAD	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08859206	chr1:53392774	SCP2	-0.72	-13.58	-0.55	4.12e-35	Monocyte count;
LUAD	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg10523679	chr1:76189770	ACADM	-0.9	-15.87	-0.61	8.05e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4974559	0.947	rs12639938	chr4:1343135	G/C	cg07757535	chr4:1339547	NA	0.39	6.36	0.3	5.14e-10	Systolic blood pressure;
LUAD	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg04944784	chr2:26401820	FAM59B	-0.76	-10.52	-0.46	3.75e-23	Gut microbiome composition (summer);
LUAD	cis	rs6594713	0.533	rs12189067	chr5:112981528	C/A	cg12552261	chr5:112820674	MCC	0.52	6.66	0.31	8.69e-11	Brain cytoarchitecture;
LUAD	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg01200585	chr1:228362443	C1orf69	0.46	7.93	0.36	1.98e-14	Diastolic blood pressure;
LUAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg13047869	chr3:10149882	C3orf24	0.66	11.19	0.48	1.19e-25	Alzheimer's disease;
LUAD	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg01579765	chr21:45077557	HSF2BP	-0.57	-13.31	-0.54	5.46e-34	Mean corpuscular volume;
LUAD	cis	rs4722404	0.560	rs6975818	chr7:3115520	C/G	cg19214707	chr7:3157722	NA	-0.42	-6.83	-0.32	2.9e-11	Atopic dermatitis;
LUAD	cis	rs7909074	0.509	rs2026427	chr10:45389704	T/C	cg05187965	chr10:45406764	TMEM72	-0.41	-7.41	-0.34	7.08e-13	Mean corpuscular volume;
LUAD	cis	rs1079204	0.826	rs6743642	chr2:219122466	C/T	cg05728596	chr2:219128475	GPBAR1	-1.23	-13.85	-0.56	2.97e-36	Smooth-surface caries;
LUAD	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg10468373	chr11:64009913	FKBP2	0.51	6.38	0.3	4.71e-10	Mean platelet volume;
LUAD	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg01017244	chr2:74357527	NA	0.86	14.09	0.57	3.11e-37	Gestational age at birth (maternal effect);
LUAD	cis	rs12135894	0.562	rs6688969	chr1:3743391	C/T	cg22529645	chr1:3704559	LRRC47	0.5	10.12	0.44	1.1e-21	Mean corpuscular volume;
LUAD	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg25894440	chr7:65020034	NA	-0.63	-6.7	-0.31	6.86e-11	Diabetic kidney disease;
LUAD	cis	rs910187	0.678	rs1046661	chr20:45817149	G/A	cg27589058	chr20:45804311	EYA2	-0.3	-6.92	-0.32	1.66e-11	Migraine;
LUAD	cis	rs17253792	0.822	rs10150498	chr14:56064124	G/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg13047869	chr3:10149882	C3orf24	0.65	9.64	0.42	5.37e-20	Alzheimer's disease;
LUAD	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg12927641	chr6:109611667	NA	-0.53	-9.46	-0.42	2.15e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs4660214	0.666	rs636083	chr1:39821681	A/G	cg27567593	chr1:39956653	BMP8A	-0.35	-6.83	-0.32	3.02e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.04	0.47	4.43e-25	Height;
LUAD	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg07617317	chr6:118971624	C6orf204	0.55	8.57	0.38	2e-16	Diastolic blood pressure;
LUAD	cis	rs7731657	0.537	rs4705850	chr5:130220358	A/G	cg08523029	chr5:130500466	HINT1	-0.57	-7.41	-0.34	7.15e-13	Fasting plasma glucose;
LUAD	cis	rs12575480	0.744	rs73398059	chr11:2082990	C/T	cg15541987	chr11:2077307	NA	-0.42	-6.48	-0.3	2.58e-10	Pursuit maintenance gain;
LUAD	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg06618935	chr21:46677482	NA	-0.51	-10.15	-0.44	8.23e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg24813613	chr7:1882135	MAD1L1	-0.44	-6.97	-0.32	1.21e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg14343924	chr8:8086146	FLJ10661	0.48	7.77	0.35	5.85e-14	Mood instability;
LUAD	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg08779649	chr13:50194554	NA	0.41	8.24	0.37	2.17e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs427394	0.659	rs187295	chr5:6734326	C/T	cg12316010	chr5:6737918	POLS	0.39	7.44	0.34	5.69e-13	Menopause (age at onset);
LUAD	cis	rs4917385	1	rs4917385	chr10:105003721	T/G	cg04362960	chr10:104952993	NT5C2	0.43	6.48	0.3	2.63e-10	Systemic lupus erythematosus;
LUAD	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg14779329	chr11:130786720	SNX19	0.39	6.84	0.32	2.74e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg22875332	chr1:76189707	ACADM	0.85	15.94	0.61	3.73e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg04287289	chr16:89883240	FANCA	0.77	6.9	0.32	1.87e-11	Skin colour saturation;
LUAD	cis	rs6987853	0.787	rs1343874	chr8:42424746	C/T	cg09913449	chr8:42400586	C8orf40	0.48	9.29	0.41	8.02e-19	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs713587	0.935	rs4430895	chr2:25161386	C/T	cg04586622	chr2:25135609	ADCY3	0.3	6.66	0.31	8.31e-11	Body mass index in non-asthmatics;
LUAD	cis	rs240764	0.604	rs4840153	chr6:101213723	C/T	cg09795085	chr6:101329169	ASCC3	-0.4	-6.92	-0.32	1.71e-11	Neuroticism;
LUAD	cis	rs806215	1.000	rs698406	chr7:127255285	C/G	cg25922125	chr7:127225783	GCC1	0.47	6.86	0.32	2.48e-11	Type 2 diabetes;
LUAD	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs938554	0.612	rs13113918	chr4:9998493	A/G	cg11266682	chr4:10021025	SLC2A9	0.52	9.11	0.4	3.35e-18	Blood metabolite levels;
LUAD	cis	rs7000551	0.689	rs10110254	chr8:22309551	G/T	cg12081754	chr8:22256438	SLC39A14	0.49	8.21	0.37	2.74e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.8	0.31	3.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg03188948	chr7:1209495	NA	0.41	7.04	0.32	7.84e-12	Longevity;Endometriosis;
LUAD	trans	rs9951602	0.512	rs8089247	chr18:76651467	C/A	cg02800362	chr5:177631904	HNRNPAB	0.92	14.03	0.56	5.64e-37	Obesity-related traits;
LUAD	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.5	-10.19	-0.44	5.94e-22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs739496	0.793	rs73199895	chr12:111866087	G/A	cg10833066	chr12:111807467	FAM109A	0.42	6.73	0.31	5.6e-11	Platelet count;
LUAD	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg18129748	chr3:49941408	MST1R	-0.41	-6.58	-0.3	1.39e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1062746	0.544	rs17770933	chr16:87325729	C/T	cg08490791	chr16:87312433	NA	-0.32	-6.52	-0.3	1.99e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.55	-0.58	3.67e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg05865280	chr17:75406074	SEPT9	0.62	19.98	0.7	5.2e-63	Airflow obstruction;
LUAD	cis	rs7017914	0.811	rs4272413	chr8:71636187	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg07404485	chr7:94953653	PON1	-0.49	-7.08	-0.33	6.01e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg14640386	chr17:5185735	RABEP1	-0.7	-6.61	-0.31	1.16e-10	Type 2 diabetes;
LUAD	trans	rs9354308	0.834	rs9354307	chr6:66552953	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.79	-0.31	3.84e-11	Metabolite levels;
LUAD	cis	rs9372498	0.536	rs1319987	chr6:118782236	A/G	cg21191810	chr6:118973309	C6orf204	-0.48	-7.71	-0.35	9.23e-14	Diastolic blood pressure;
LUAD	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg24813613	chr7:1882135	MAD1L1	-0.43	-6.96	-0.32	1.31e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18867708	chr6:26865862	GUSBL1	-0.41	-6.47	-0.3	2.73e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2404618	0.624	rs4338133	chr8:1477507	T/C	cg13402656	chr8:1511478	DLGAP2	-0.71	-14.04	-0.56	5.06e-37	Lung cancer;
LUAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg08888203	chr3:10149979	C3orf24	0.72	12.87	0.53	3.25e-32	Alzheimer's disease;
LUAD	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg04455712	chr21:45112962	RRP1B	0.42	8.41	0.38	6.56e-16	Mean corpuscular volume;
LUAD	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg19318889	chr4:1322082	MAEA	-0.91	-15.86	-0.61	8.81e-45	Longevity;
LUAD	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.6	11.48	0.49	9.94e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg00204512	chr16:28754710	NA	0.31	6.77	0.31	4.44e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs11048434	0.736	rs2041624	chr12:9111855	C/G	cg13575925	chr12:9217583	LOC144571	0.36	6.83	0.32	2.92e-11	Sjögren's syndrome;
LUAD	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg00898013	chr13:113819073	PROZ	-0.67	-12.0	-0.5	9.27e-29	Platelet distribution width;
LUAD	cis	rs2932538	0.922	rs6537745	chr1:113154080	T/C	cg22162597	chr1:113214053	CAPZA1	0.43	6.57	0.3	1.52e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04655372	chr17:46126232	NFE2L1	-0.4	-6.48	-0.3	2.55e-10	Cancer;
LUAD	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg01689657	chr7:91764605	CYP51A1	-0.38	-9.51	-0.42	1.44e-19	Breast cancer;
LUAD	cis	rs6460942	0.915	rs62448620	chr7:12458170	C/T	cg20607287	chr7:12443886	VWDE	-0.54	-6.78	-0.31	3.96e-11	Coronary artery disease;
LUAD	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg12751644	chr20:60527061	NA	-0.41	-6.35	-0.3	5.49e-10	Obesity-related traits;
LUAD	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22857025	chr5:266934	NA	-0.96	-14.38	-0.57	1.9e-38	Breast cancer;
LUAD	cis	rs1847202	0.793	rs13088835	chr3:72949861	A/T	cg25664220	chr3:72788482	NA	-0.45	-7.84	-0.36	3.61e-14	Motion sickness;
LUAD	cis	rs11229555	0.645	rs61903159	chr11:58184475	G/A	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9297145	0.585	rs13235218	chr7:98785080	C/T	cg05967295	chr7:98741636	SMURF1	-0.71	-12.75	-0.53	9.58e-32	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs2625529	0.713	rs12903980	chr15:72165549	C/T	cg16672083	chr15:72433130	SENP8	-0.77	-12.96	-0.53	1.33e-32	Red blood cell count;
LUAD	cis	rs367943	0.799	rs10478135	chr5:112976905	C/A	cg12552261	chr5:112820674	MCC	0.53	9.16	0.41	2.34e-18	Type 2 diabetes;
LUAD	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg23625390	chr15:77176239	SCAPER	0.37	6.71	0.31	6.4e-11	Blood metabolite levels;
LUAD	cis	rs654950	0.783	rs640688	chr1:42001831	A/G	cg06885757	chr1:42089581	HIVEP3	-0.36	-7.89	-0.36	2.57e-14	Airway imaging phenotypes;
LUAD	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg12179176	chr11:130786555	SNX19	0.46	7.7	0.35	9.55e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.28	-0.57	4.94e-38	Intelligence (multi-trait analysis);
LUAD	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.22	-0.54	1.24e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs3820068	0.705	rs57440988	chr1:15879034	T/C	cg13390004	chr1:15929781	NA	0.43	6.86	0.32	2.45e-11	Systolic blood pressure;
LUAD	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg10802521	chr3:52805072	NEK4	-0.38	-6.35	-0.3	5.55e-10	Electroencephalogram traits;
LUAD	cis	rs7274811	0.625	rs211041	chr20:31932068	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.46	6.71	0.31	6.38e-11	Height;
LUAD	cis	rs7923837	0.713	rs10882099	chr10:94460650	T/C	cg25093409	chr10:94429542	NA	0.37	6.78	0.31	4.13e-11	Body mass index;Multiple sclerosis;
LUAD	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.61	8.85	0.4	2.39e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg06558623	chr16:89946397	TCF25	1.15	9.92	0.43	5.28e-21	Skin colour saturation;
LUAD	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg14552801	chr7:65878734	NA	-0.37	-6.35	-0.3	5.43e-10	Aortic root size;
LUAD	cis	rs735539	1.000	rs6490605	chr13:21285009	C/T	cg04906043	chr13:21280425	IL17D	-0.37	-6.85	-0.32	2.62e-11	Dental caries;
LUAD	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05890377	chr2:74357713	NA	0.87	12.26	0.51	8.78e-30	Gestational age at birth (maternal effect);
LUAD	cis	rs1865721	0.728	rs67357037	chr18:73219024	G/T	cg26385618	chr18:73139727	C18orf62	-0.36	-6.7	-0.31	6.59e-11	Intelligence;
LUAD	cis	rs7191700	0.511	rs12923756	chr16:11359675	C/T	cg00044050	chr16:11439710	C16orf75	-0.62	-9.96	-0.44	3.76e-21	Multiple sclerosis;
LUAD	cis	rs4950928	0.823	rs4950882	chr1:203164848	A/G	cg17014757	chr1:203156097	CHI3L1	-0.61	-8.72	-0.39	6.44e-17	YKL-40 levels;
LUAD	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg10356904	chr22:49881777	NA	-0.42	-9.16	-0.41	2.18e-18	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.62	-10.8	-0.46	3.55e-24	Lymphocyte counts;
LUAD	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.25	6.42	0.3	3.61e-10	Parkinson's disease;
LUAD	trans	rs8002861	0.870	rs12865116	chr13:44440441	C/G	cg17145862	chr1:211918768	LPGAT1	-0.69	-15.16	-0.59	8.77e-42	Leprosy;
LUAD	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg05313129	chr8:58192883	C8orf71	-0.52	-7.79	-0.35	5.21e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg22009923	chr11:832065	CD151	-0.33	-6.36	-0.3	5.32e-10	Mean platelet volume;
LUAD	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.63	-0.42	5.56e-20	Life satisfaction;
LUAD	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg17971929	chr21:40555470	PSMG1	0.5	7.32	0.34	1.29e-12	Cognitive function;
LUAD	cis	rs2816062	0.813	rs2816051	chr1:18895460	A/G	cg18795169	chr1:18902165	NA	-0.94	-22.53	-0.74	2.07e-74	Urate levels in lean individuals;
LUAD	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg06623918	chr6:96969491	KIAA0776	0.8	14.71	0.58	7.16e-40	Headache;
LUAD	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg22676075	chr6:135203613	NA	0.53	9.54	0.42	1.11e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg24531977	chr5:56204891	C5orf35	-0.44	-7.26	-0.33	1.93e-12	Coronary artery disease;
LUAD	cis	rs10465746	0.570	rs12402130	chr1:84479838	G/A	cg10977910	chr1:84465055	TTLL7	0.47	7.03	0.32	8.39e-12	Obesity-related traits;
LUAD	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08704250	chr15:31115839	NA	0.46	8.47	0.38	3.98e-16	Huntington's disease progression;
LUAD	cis	rs8044868	0.530	rs9924964	chr16:72085561	T/A	cg23815491	chr16:72088622	HP	0.47	8.44	0.38	4.96e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg24642844	chr7:1081250	C7orf50	-0.58	-9.33	-0.41	6.06e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg24955955	chr5:415729	AHRR	0.71	7.94	0.36	1.87e-14	Fat distribution (HIV);
LUAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.53	-9.1	-0.4	3.61e-18	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg17366294	chr4:99064904	C4orf37	0.51	9.15	0.41	2.46e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9652601	0.779	rs12708716	chr16:11179873	C/T	cg04616529	chr16:11181986	CLEC16A	-0.38	-6.85	-0.32	2.61e-11	Systemic lupus erythematosus;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg09747578	chr1:46769076	LRRC41;UQCRH	0.41	6.49	0.3	2.39e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.19	-0.41	1.77e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg09517075	chr8:22133004	PIWIL2	-0.49	-9.1	-0.4	3.64e-18	Hypertriglyceridemia;
LUAD	cis	rs9486719	1.000	rs11152951	chr6:96894135	C/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.11	-0.44	1.18e-21	Migraine;Coronary artery disease;
LUAD	cis	rs113835537	0.877	rs2275998	chr11:66326581	T/C	cg24851651	chr11:66362959	CCS	0.52	7.83	0.36	3.83e-14	Airway imaging phenotypes;
LUAD	trans	rs1493916	0.837	rs2123333	chr18:31410730	G/A	cg27147174	chr7:100797783	AP1S1	-0.62	-10.88	-0.47	1.73e-24	Life satisfaction;
LUAD	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg27170947	chr2:26402098	FAM59B	-0.69	-9.45	-0.42	2.26e-19	Gut microbiome composition (summer);
LUAD	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg00898013	chr13:113819073	PROZ	0.73	13.17	0.54	1.92e-33	Platelet distribution width;
LUAD	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg25985355	chr7:65971099	NA	-0.51	-6.53	-0.3	1.86e-10	Diabetic kidney disease;
LUAD	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg20476274	chr7:133979776	SLC35B4	0.65	11.42	0.49	1.6e-26	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.81	0.31	3.32e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg17747265	chr1:1875780	NA	-0.71	-17.62	-0.65	1.58e-52	Body mass index;
LUAD	cis	rs62400317	0.859	rs62438864	chr6:45041787	G/A	cg18551225	chr6:44695536	NA	-0.57	-8.73	-0.39	6.02e-17	Total body bone mineral density;
LUAD	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.45	-6.71	-0.31	6.3e-11	Diastolic blood pressure;
LUAD	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg07936489	chr17:37558343	FBXL20	0.5	6.84	0.32	2.77e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs757647	1.000	rs17171818	chr5:137725003	C/T	cg10676309	chr5:137685565	NA	0.37	6.95	0.32	1.37e-11	Menarche (age at onset);
LUAD	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg22676075	chr6:135203613	NA	0.44	8.15	0.37	4.23e-15	Red blood cell count;
LUAD	cis	rs6752107	0.500	rs11893210	chr2:234204672	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.42	6.99	0.32	1.07e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg03354898	chr7:1950403	MAD1L1	0.34	6.46	0.3	2.87e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg22117172	chr7:91764530	CYP51A1	-0.34	-7.2	-0.33	2.76e-12	Breast cancer;
LUAD	cis	rs2573652	0.723	rs2727201	chr15:100515311	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.64	-11.86	-0.5	3.26e-28	Height;
LUAD	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.56	7.94	0.36	1.84e-14	Platelet count;
LUAD	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg18811423	chr2:55921094	PNPT1	0.47	7.59	0.35	2.08e-13	Metabolic syndrome;
LUAD	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg21963583	chr11:68658836	MRPL21	0.68	12.12	0.51	3.24e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs16958440	0.867	rs57744138	chr18:44700482	A/C	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg26924012	chr15:45694286	SPATA5L1	0.57	9.12	0.41	3.01e-18	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg03467027	chr4:99064603	C4orf37	0.43	7.09	0.33	5.69e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05901451	chr6:126070800	HEY2	0.62	10.17	0.44	6.83e-22	Brugada syndrome;
LUAD	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg27490568	chr2:178487706	NA	0.38	6.54	0.3	1.81e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1215050	1.000	rs1215050	chr4:98849826	A/G	cg05340658	chr4:99064831	C4orf37	-0.42	-6.76	-0.31	4.68e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg21153622	chr11:89784906	NA	-0.35	-6.86	-0.32	2.53e-11	HDL cholesterol;
LUAD	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg10523679	chr1:76189770	ACADM	-0.92	-15.6	-0.6	1.16e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg18721089	chr20:30220636	NA	-0.49	-7.06	-0.32	6.99e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg17366294	chr4:99064904	C4orf37	0.47	8.38	0.38	8.17e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.65	0.31	9.11e-11	Depression;
LUAD	cis	rs62238980	0.614	rs80217052	chr22:32413767	T/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.28	-6.8	-0.31	3.5e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	6.65	0.31	8.86e-11	Lung cancer in ever smokers;
LUAD	cis	rs6432018	1.000	rs1111976	chr2:9739555	T/G	cg12832956	chr2:9616023	IAH1	-0.37	-6.65	-0.31	9.04e-11	Heart rate variability traits;
LUAD	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg10356904	chr22:49881777	NA	-0.37	-6.69	-0.31	7.19e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7520050	0.933	rs12565042	chr1:46299110	C/A	cg06784218	chr1:46089804	CCDC17	-0.3	-6.39	-0.3	4.43e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.47e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3857536	0.785	rs2157964	chr6:66938419	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs6500395	0.963	rs2041921	chr16:48714002	T/C	cg04672837	chr16:48644449	N4BP1	-0.38	-6.51	-0.3	2.17e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs7177699	0.581	rs7165081	chr15:79123396	C/G	cg15571903	chr15:79123663	NA	0.42	8.82	0.39	3e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg02002194	chr4:3960332	NA	-0.29	-6.78	-0.31	4.04e-11	Mood instability;
LUAD	trans	rs3857536	0.813	rs6455084	chr6:66935658	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs7274811	0.711	rs291697	chr20:31985248	T/C	cg14921437	chr20:32255988	NECAB3;C20orf134	0.45	6.87	0.32	2.36e-11	Height;
LUAD	cis	rs7737355	0.812	rs244735	chr5:130818061	C/T	cg06307176	chr5:131281290	NA	0.42	6.94	0.32	1.53e-11	Life satisfaction;
LUAD	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg06618935	chr21:46677482	NA	-0.48	-9.74	-0.43	2.24e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.75	0.39	5.22e-17	Menopause (age at onset);
LUAD	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg19774624	chr17:42201019	HDAC5	0.41	7.25	0.33	2.03e-12	Total body bone mineral density;
LUAD	cis	rs62400317	0.826	rs12213735	chr6:45152848	C/T	cg18551225	chr6:44695536	NA	0.51	8.05	0.36	8.38e-15	Total body bone mineral density;
LUAD	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg18944383	chr4:111397179	ENPEP	0.37	7.68	0.35	1.12e-13	Height;
LUAD	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg03929089	chr4:120376271	NA	0.82	14.99	0.59	4.81e-41	Coronary artery disease;
LUAD	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.58	8.08	0.37	6.68e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2227631	0.505	rs12530730	chr7:100758591	T/A	cg18465962	chr7:100767262	NA	0.4	6.8	0.31	3.69e-11	Plasminogen activator inhibitor type 1 levels (PAI-1);
LUAD	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg00802000	chr16:706648	WDR90	-0.37	-6.86	-0.32	2.45e-11	Height;
LUAD	cis	rs9902453	0.817	rs2729449	chr17:28089751	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-9.61	-0.42	6.33e-20	Coffee consumption (cups per day);
LUAD	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.44	-0.42	2.53e-19	Life satisfaction;
LUAD	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	6.81	0.31	3.28e-11	Tonsillectomy;
LUAD	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.58	0.35	2.21e-13	Menopause (age at onset);
LUAD	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg21984481	chr17:79567631	NPLOC4	-0.71	-16.84	-0.63	4.62e-49	Eye color traits;
LUAD	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg25838465	chr1:92012736	NA	-0.76	-16.88	-0.63	3.04e-49	Breast cancer;
LUAD	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06873352	chr17:61820015	STRADA	0.83	18.44	0.67	3.61e-56	Prudent dietary pattern;
LUAD	trans	rs8073060	0.586	rs7213804	chr17:34010931	T/G	cg19694781	chr19:47549865	TMEM160	-1.22	-19.42	-0.69	1.67e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16777910	chr14:90204692	NA	-0.52	-6.79	-0.31	3.71e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs10465746	0.967	rs11163868	chr1:84397013	T/G	cg10977910	chr1:84465055	TTLL7	0.5	8.09	0.37	6.43e-15	Obesity-related traits;
LUAD	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg03037974	chr15:76606532	NA	0.37	7.9	0.36	2.45e-14	Blood metabolite levels;
LUAD	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg00857998	chr1:205179979	DSTYK	0.41	6.72	0.31	5.98e-11	Red blood cell count;
LUAD	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02475777	chr4:1388615	CRIPAK	0.7	10.02	0.44	2.32e-21	Longevity;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15677368	chr1:245133209	EFCAB2	-0.45	-7.11	-0.33	4.94e-12	Height;
LUAD	cis	rs62229266	0.659	rs62230814	chr21:37403546	G/A	cg08632701	chr21:37451849	NA	-0.4	-6.6	-0.31	1.23e-10	Mitral valve prolapse;
LUAD	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg02450064	chr17:40260053	DHX58	-0.45	-7.48	-0.34	4.26e-13	Fibrinogen levels;
LUAD	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.92	-0.43	5.23e-21	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.51	-8.35	-0.38	9.98e-16	Menarche (age at onset);
LUAD	cis	rs57920188	0.584	rs57277002	chr1:4092054	T/G	cg20703997	chr1:4087676	NA	0.48	8.96	0.4	1.08e-17	Interleukin-17 levels;
LUAD	cis	rs490234	0.812	rs7875713	chr9:128268903	G/T	cg14078157	chr9:128172775	NA	-0.43	-7.87	-0.36	2.99e-14	Mean arterial pressure;
LUAD	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg02527881	chr3:46936655	PTH1R	-0.46	-8.89	-0.4	1.78e-17	Colorectal cancer;
LUAD	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg07936489	chr17:37558343	FBXL20	-0.42	-6.53	-0.3	1.85e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg22442454	chr1:209979470	IRF6	0.58	6.51	0.3	2.11e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs6011002	0.564	rs2260045	chr20:62343013	T/C	cg01176363	chr20:62369445	LIME1	-0.79	-6.63	-0.31	1.05e-10	Dental caries;
LUAD	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg09359103	chr1:154839909	KCNN3	-0.94	-22.2	-0.73	5.98e-73	Prostate cancer;
LUAD	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18876405	chr7:65276391	NA	0.41	6.47	0.3	2.68e-10	Aortic root size;
LUAD	trans	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg01620082	chr3:125678407	NA	-0.5	-6.83	-0.32	3e-11	Depression;
LUAD	trans	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg21659725	chr3:3221576	CRBN	0.51	8.29	0.37	1.5e-15	Body mass index;
LUAD	cis	rs3818285	0.959	rs3740137	chr10:111630917	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.59	-8.1	-0.37	5.88e-15	Superior crus of antihelix expression;
LUAD	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg19875535	chr5:140030758	IK	0.46	7.78	0.35	5.77e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg05295671	chr13:79234353	RNF219	0.48	7.07	0.33	6.49e-12	Large artery stroke;
LUAD	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg15445000	chr17:37608096	MED1	0.44	7.78	0.35	5.45e-14	Glomerular filtration rate (creatinine);
LUAD	trans	rs877282	0.947	rs4133015	chr10:774131	T/C	cg22713356	chr15:30763199	NA	1.17	16.83	0.63	4.79e-49	Uric acid levels;
LUAD	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25427524	chr10:38739819	LOC399744	-0.74	-12.99	-0.53	1.06e-32	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6993813	0.872	rs6469795	chr8:120016469	C/T	cg01975934	chr8:119970761	NA	-0.39	-7.6	-0.35	1.89e-13	Bone mineral density (hip);
LUAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg24642844	chr7:1081250	C7orf50	-0.92	-13.9	-0.56	1.97e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg22823121	chr1:150693482	HORMAD1	0.41	7.97	0.36	1.48e-14	Melanoma;
LUAD	cis	rs758324	0.947	rs1846650	chr5:131158767	C/T	cg06307176	chr5:131281290	NA	0.49	7.77	0.35	5.88e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg17200465	chr3:40428508	ENTPD3	-0.27	-6.81	-0.31	3.46e-11	Renal cell carcinoma;
LUAD	cis	rs72928364	1.000	rs35530876	chr3:100680492	T/C	cg10123952	chr3:100791384	NA	0.63	7.31	0.33	1.39e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg10755058	chr3:40428713	ENTPD3	0.38	7.36	0.34	9.79e-13	Renal cell carcinoma;
LUAD	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.59	-0.52	4.41e-31	Monocyte count;
LUAD	trans	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.8	-0.35	4.9e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg09367891	chr1:107599246	PRMT6	0.57	9.43	0.42	2.73e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg04851639	chr8:1020857	NA	-0.38	-9.36	-0.41	4.93e-19	Schizophrenia;
LUAD	cis	rs1595825	0.945	rs76877032	chr2:198840000	G/A	cg00982548	chr2:198649783	BOLL	-0.63	-8.93	-0.4	1.31e-17	Ulcerative colitis;
LUAD	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2637266	0.935	rs7393727	chr10:78365977	T/A	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	cis	rs7786808	0.552	rs4909207	chr7:158187136	G/A	cg01191920	chr7:158217561	PTPRN2	-0.63	-12.98	-0.53	1.11e-32	Obesity-related traits;
LUAD	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg11822812	chr5:140052017	DND1	0.38	6.67	0.31	8.1e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg27102117	chr16:15229624	NA	0.7	12.77	0.53	7.88e-32	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	trans	rs9393777	0.764	rs35565446	chr6:27145341	C/T	cg06606381	chr12:133084897	FBRSL1	-1.16	-10.02	-0.44	2.49e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	0.62	8.14	0.37	4.36e-15	Yeast infection;
LUAD	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg06618935	chr21:46677482	NA	-0.51	-10.2	-0.44	5.31e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg15691649	chr6:25882328	NA	0.63	9.64	0.42	5.31e-20	Blood metabolite levels;
LUAD	cis	rs10901296	0.588	rs12003046	chr9:133741626	T/C	cg03924115	chr9:133768966	QRFP	0.52	6.41	0.3	3.96e-10	Bilirubin levels;
LUAD	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg07493874	chr5:1342172	CLPTM1L	-0.31	-6.6	-0.31	1.24e-10	Lung cancer;
LUAD	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg08000102	chr2:233561755	GIGYF2	0.43	6.51	0.3	2.15e-10	Coronary artery disease;
LUAD	cis	rs17067123	0.614	rs72712853	chr4:180066431	A/G	cg26610307	chr4:180072759	NA	-0.52	-6.75	-0.31	4.86e-11	Response to hepatitis C treatment;
LUAD	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg25358565	chr5:93447407	FAM172A	0.6	7.0	0.32	1.03e-11	Diabetic retinopathy;
LUAD	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.38	-6.8	-0.31	3.56e-11	Tonsillectomy;
LUAD	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg05044414	chr3:183734942	ABCC5	0.48	10.02	0.44	2.31e-21	Anterior chamber depth;
LUAD	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg13010344	chr12:123464640	ARL6IP4	-0.39	-6.72	-0.31	6.02e-11	Platelet count;
LUAD	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg03676636	chr4:99064102	C4orf37	0.29	7.46	0.34	4.87e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg08085267	chr17:45401833	C17orf57	-0.69	-12.42	-0.52	2.11e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg20476274	chr7:133979776	SLC35B4	0.56	9.86	0.43	8.81e-21	Mean platelet volume;
LUAD	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg22875332	chr1:76189707	ACADM	-0.64	-9.95	-0.44	4.21e-21	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9341808	0.519	rs607130	chr6:80999233	T/C	cg08355045	chr6:80787529	NA	-0.4	-6.9	-0.32	1.87e-11	Sitting height ratio;
LUAD	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg26384229	chr12:38710491	ALG10B	0.49	7.93	0.36	1.93e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg22189786	chr22:42395067	WBP2NL	0.45	6.49	0.3	2.42e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg02375832	chr11:62437615	C11orf48	0.34	6.72	0.31	5.95e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg25427524	chr10:38739819	LOC399744	0.6	8.53	0.38	2.72e-16	Obesity (extreme);
LUAD	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.8	-0.35	4.79e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg02683114	chr2:24398427	C2orf84	0.52	7.68	0.35	1.13e-13	Asthma;
LUAD	cis	rs6537837	0.701	rs2304355	chr1:110155524	T/C	cg05049280	chr1:110155535	GNAT2	0.57	6.95	0.32	1.43e-11	Major depressive disorder;
LUAD	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	7.12	0.33	4.53e-12	Tonsillectomy;
LUAD	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	9.78	0.43	1.63e-20	Axial length;
LUAD	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg26384229	chr12:38710491	ALG10B	-0.4	-6.7	-0.31	6.73e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg07460842	chr6:66804631	NA	0.96	12.99	0.53	1.09e-32	Exhaled nitric oxide output;
LUAD	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg21475434	chr5:93447410	FAM172A	0.74	8.23	0.37	2.29e-15	Diabetic retinopathy;
LUAD	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg07538946	chr5:131705188	SLC22A5	0.49	8.09	0.37	6.44e-15	Blood metabolite levels;
LUAD	cis	rs490234	0.902	rs7853181	chr9:128223024	C/T	cg14078157	chr9:128172775	NA	0.4	7.23	0.33	2.25e-12	Mean arterial pressure;
LUAD	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg15226275	chr6:116381976	FRK	0.24	7.7	0.35	9.56e-14	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs4372836	0.964	rs34627117	chr2:28930476	C/G	cg09522027	chr2:28974177	PPP1CB	0.59	8.87	0.4	2.03e-17	Body mass index;
LUAD	trans	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg01620082	chr3:125678407	NA	-1.1	-10.22	-0.45	4.5e-22	Depression;
LUAD	cis	rs11048434	0.661	rs34791180	chr12:9110919	T/C	cg26114124	chr12:9217669	LOC144571	0.36	6.51	0.3	2.09e-10	Sjögren's syndrome;
LUAD	cis	rs757647	0.723	rs2269950	chr5:137730062	A/G	cg10676309	chr5:137685565	NA	0.41	7.14	0.33	4.13e-12	Menarche (age at onset);
LUAD	cis	rs1997103	1.000	rs2177803	chr7:55410773	A/G	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9486719	1.000	rs2472886	chr6:96864876	C/T	cg06623918	chr6:96969491	KIAA0776	0.71	9.96	0.44	3.8e-21	Migraine;Coronary artery disease;
LUAD	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.1	-15.65	-0.61	6.8e-44	Schizophrenia;
LUAD	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.95	-0.4	1.09e-17	Gut microbiome composition (summer);
LUAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg17178900	chr1:205818956	PM20D1	0.45	7.28	0.33	1.61e-12	Parkinson's disease;
LUAD	trans	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg18335740	chr13:41363409	SLC25A15	0.57	10.07	0.44	1.63e-21	Lewy body disease;
LUAD	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg23283495	chr1:209979779	IRF6	0.73	10.61	0.46	1.85e-23	Cleft lip with or without cleft palate;
LUAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg27454412	chr7:1067447	C7orf50	0.4	6.71	0.31	6.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg05991184	chr2:219186017	PNKD	0.37	7.01	0.32	9.56e-12	Colorectal cancer;
LUAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg08085267	chr17:45401833	C17orf57	-0.49	-8.1	-0.37	6.14e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg00001245	chr3:15106710	MRPS25	-0.38	-6.58	-0.3	1.43e-10	Schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25420085	chr6:2766194	WRNIP1	-0.58	-7.14	-0.33	4.05e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs73198271	0.960	rs12155530	chr8:8610964	C/T	cg01851573	chr8:8652454	MFHAS1	0.52	8.43	0.38	5.62e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs7395662	0.794	rs11511967	chr11:48820453	C/T	cg15704280	chr7:45808275	SEPT13	-0.41	-6.39	-0.3	4.37e-10	HDL cholesterol;
LUAD	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg19875535	chr5:140030758	IK	0.45	7.42	0.34	6.44e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.61	9.78	0.43	1.73e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6537837	0.642	rs6658641	chr1:110153198	G/A	cg05049280	chr1:110155535	GNAT2	0.57	7.03	0.32	8.34e-12	Major depressive disorder;
LUAD	trans	rs7395662	1.000	rs11039859	chr11:48611988	G/T	cg00717180	chr2:96193071	NA	-0.4	-7.41	-0.34	7.11e-13	HDL cholesterol;
LUAD	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7107174	1.000	rs4944195	chr11:78003499	T/C	cg19901956	chr11:77921274	USP35	-0.56	-6.86	-0.32	2.53e-11	Testicular germ cell tumor;
LUAD	cis	rs7189233	0.955	rs72801853	chr16:53516824	A/G	cg04059762	chr16:53544020	NA	-0.4	-6.39	-0.3	4.51e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg26574964	chr11:117049906	SIDT2	-0.58	-6.87	-0.32	2.31e-11	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg26384229	chr12:38710491	ALG10B	0.43	7.17	0.33	3.47e-12	Bladder cancer;
LUAD	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg03806693	chr22:41940476	POLR3H	0.72	9.69	0.43	3.55e-20	Vitiligo;
LUAD	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg20290983	chr6:43655470	MRPS18A	1.06	26.88	0.79	1.46e-93	IgG glycosylation;
LUAD	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-11.16	-0.48	1.64e-25	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4072705	0.615	rs6478666	chr9:127249343	C/G	cg01786973	chr9:127249749	NR5A1	-0.3	-6.52	-0.3	2.01e-10	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg06606381	chr12:133084897	FBRSL1	-1.16	-9.97	-0.44	3.51e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg16606324	chr3:10149918	C3orf24	0.65	10.84	0.47	2.49e-24	Alzheimer's disease;
LUAD	cis	rs73206853	0.841	rs17619763	chr12:110645829	C/T	cg12870014	chr12:110450643	ANKRD13A	0.62	6.6	0.31	1.22e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg04995722	chr7:26192034	NFE2L3	-0.44	-7.52	-0.34	3.27e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg07606381	chr6:8435919	SLC35B3	0.44	7.22	0.33	2.48e-12	Motion sickness;
LUAD	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19748678	chr4:122722346	EXOSC9	0.43	6.86	0.32	2.5e-11	Type 2 diabetes;
LUAD	cis	rs13040088	1.000	rs12480117	chr20:61558274	G/A	cg23096297	chr20:61557774	DIDO1	0.77	10.52	0.46	3.8e-23	Menopause (age at onset);
LUAD	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg13010199	chr12:38710504	ALG10B	0.39	6.38	0.3	4.74e-10	Bladder cancer;
LUAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg21782813	chr7:2030301	MAD1L1	0.57	10.08	0.44	1.42e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.71	-12.15	-0.51	2.36e-29	Menarche (age at onset);
LUAD	cis	rs7216064	0.765	rs6504550	chr17:65894542	A/G	cg08758996	chr17:66097529	LOC651250	0.39	6.46	0.3	2.8e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs12210905	0.688	rs72839474	chr6:27324757	T/C	cg08851530	chr6:28072375	NA	1.09	7.97	0.36	1.45e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg15181151	chr6:150070149	PCMT1	0.39	7.52	0.34	3.33e-13	Lung cancer;
LUAD	trans	rs8002861	0.905	rs12430629	chr13:44415919	T/A	cg17145862	chr1:211918768	LPGAT1	-0.67	-14.58	-0.58	2.71e-39	Leprosy;
LUAD	cis	rs367615	0.704	rs4320313	chr5:108828687	A/G	cg17395555	chr5:108820864	NA	0.68	14.84	0.59	2.17e-40	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg07460842	chr6:66804631	NA	0.96	12.93	0.53	1.93e-32	Exhaled nitric oxide output;
LUAD	trans	rs853679	0.546	rs200996	chr6:27811828	G/A	cg01620082	chr3:125678407	NA	-0.8	-8.61	-0.39	1.45e-16	Depression;
LUAD	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg02951883	chr7:2050386	MAD1L1	-0.63	-9.93	-0.43	4.92e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs9296092	0.500	rs9469504	chr6:33527243	G/A	cg13560919	chr6:33536144	NA	-0.9	-16.72	-0.63	1.49e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg07460842	chr6:66804631	NA	0.96	12.89	0.53	2.69e-32	Exhaled nitric oxide output;
LUAD	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg00339695	chr16:24857497	SLC5A11	0.66	10.56	0.46	2.62e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10802521	chr3:52805072	NEK4	-0.61	-10.93	-0.47	1.21e-24	Bipolar disorder;
LUAD	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg25811766	chr13:21894605	NA	0.67	8.99	0.4	8.51e-18	White matter hyperintensity burden;
LUAD	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg07967210	chr17:47022446	SNF8	0.35	6.38	0.3	4.54e-10	Type 2 diabetes;
LUAD	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg23229984	chr5:148520753	ABLIM3	0.48	6.92	0.32	1.64e-11	Breast cancer;
LUAD	cis	rs7132746	0.553	rs56135828	chr12:86191269	T/C	cg18827107	chr12:86230957	RASSF9	-0.47	-6.72	-0.31	6.01e-11	Lewy body disease;
LUAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00149659	chr3:10157352	C3orf10	0.56	7.63	0.35	1.55e-13	Alzheimer's disease;
LUAD	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg13722127	chr7:150037890	RARRES2	0.45	7.76	0.35	6.31e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg02390115	chr1:21767211	NBPF3	0.41	6.97	0.32	1.22e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs250585	0.736	rs499812	chr16:23410419	T/C	cg00143387	chr16:23521605	GGA2	0.58	8.32	0.38	1.19e-15	Egg allergy;
LUAD	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.34	-7.01	-0.32	9.22e-12	Blood metabolite levels;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg24592846	chr11:129873229	NCRNA00167;PRDM10	-0.55	-7.01	-0.32	9.62e-12	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs35883536	0.967	rs4991930	chr1:101122755	T/C	cg06223162	chr1:101003688	GPR88	0.35	6.51	0.3	2.08e-10	Monocyte count;
LUAD	cis	rs7677751	0.806	rs7678144	chr4:55102425	T/C	cg17187183	chr4:55093834	PDGFRA	0.51	8.58	0.38	1.88e-16	Corneal astigmatism;
LUAD	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg20607798	chr8:58055168	NA	0.65	8.6	0.39	1.56e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs7843479	0.870	rs1809498	chr8:21836384	C/G	cg03445287	chr8:21823731	XPO7	0.43	7.73	0.35	8.04e-14	Mean corpuscular volume;
LUAD	trans	rs8002861	0.846	rs56408817	chr13:44471983	A/G	cg12856521	chr11:46389249	DGKZ	-0.38	-6.43	-0.3	3.43e-10	Leprosy;
LUAD	cis	rs870825	0.581	rs28602720	chr4:185630598	T/C	cg04058563	chr4:185651563	MLF1IP	0.9	14.37	0.57	2.08e-38	Blood protein levels;
LUAD	cis	rs7737355	0.947	rs28720007	chr5:131077709	C/T	cg06307176	chr5:131281290	NA	0.52	8.16	0.37	3.77e-15	Life satisfaction;
LUAD	cis	rs7911264	1.000	rs7911264	chr10:94436851	C/T	cg25093409	chr10:94429542	NA	-0.36	-6.98	-0.32	1.12e-11	Inflammatory bowel disease;
LUAD	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg15017067	chr4:17643749	FAM184B	0.37	7.3	0.33	1.45e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg11833968	chr6:79620685	NA	-0.43	-7.91	-0.36	2.3e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-7.48	-0.34	4.24e-13	Monocyte percentage of white cells;
LUAD	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg27170947	chr2:26402098	FAM59B	0.83	10.89	0.47	1.59e-24	Gut microbiome composition (summer);
LUAD	trans	rs9393777	0.844	rs28360634	chr6:27332891	T/C	cg01620082	chr3:125678407	NA	-0.8	-8.59	-0.39	1.68e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-15.43	-0.6	6.2e-43	Chronic sinus infection;
LUAD	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.74	13.57	0.55	4.45e-35	Axial length;
LUAD	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg06640241	chr16:89574553	SPG7	0.66	11.49	0.49	8.62e-27	Multiple myeloma (IgH translocation);
LUAD	cis	rs9487051	0.702	rs670414	chr6:109529912	A/G	cg21918786	chr6:109611834	NA	0.45	8.07	0.37	7.46e-15	Reticulocyte fraction of red cells;
LUAD	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg12623918	chr2:306882	NA	0.34	6.86	0.32	2.4e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg14092571	chr14:90743983	NA	-0.52	-9.37	-0.41	4.4e-19	Mortality in heart failure;
LUAD	cis	rs2425143	1.000	rs28685274	chr20:34358527	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.6	-0.35	1.96e-13	Blood protein levels;
LUAD	cis	rs6541297	0.703	rs652108	chr1:230312704	C/T	cg20703242	chr1:230279135	GALNT2	-0.49	-7.17	-0.33	3.31e-12	Coronary artery disease;
LUAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg00280220	chr17:61926910	NA	0.35	6.68	0.31	7.52e-11	Prudent dietary pattern;
LUAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.37	-6.86	-0.32	2.51e-11	Longevity;Endometriosis;
LUAD	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg06547715	chr2:218990976	CXCR2	0.43	10.22	0.45	4.49e-22	Ulcerative colitis;
LUAD	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg21153622	chr11:89784906	NA	-0.34	-6.84	-0.32	2.72e-11	Height;
LUAD	cis	rs11771526	1.000	rs17351142	chr7:32339843	T/G	cg13207630	chr7:32358064	NA	0.69	7.92	0.36	2.08e-14	Body mass index;
LUAD	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg10523679	chr1:76189770	ACADM	0.9	15.76	0.61	2.35e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg02176678	chr2:219576539	TTLL4	0.75	15.1	0.59	1.64e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg03233332	chr7:66118400	NA	0.44	6.73	0.31	5.44e-11	Aortic root size;
LUAD	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg26818010	chr10:134567672	INPP5A	-0.95	-15.79	-0.61	1.81e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7659604	0.540	rs9995322	chr4:122675642	G/A	cg06713675	chr4:122721982	EXOSC9	0.42	7.68	0.35	1.11e-13	Type 2 diabetes;
LUAD	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg25753631	chr6:25732923	NA	-0.46	-7.97	-0.36	1.49e-14	Iron status biomarkers;
LUAD	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg05082376	chr22:42548792	NA	0.45	7.85	0.36	3.38e-14	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg25482853	chr8:67687455	SGK3	1.18	18.2	0.66	4.58e-55	Lung disease severity in cystic fibrosis;
LUAD	trans	rs5756813	0.754	rs4821711	chr22:38181115	C/T	cg19894588	chr14:64061835	NA	-0.46	-6.53	-0.3	1.89e-10	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg13334819	chr7:99746414	C7orf59	-0.66	-9.89	-0.43	7.1e-21	Coronary artery disease;
LUAD	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg18196295	chr10:418757	DIP2C	0.4	6.77	0.31	4.19e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg15017067	chr4:17643749	FAM184B	0.36	6.89	0.32	2.08e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs397969	0.646	rs1638528	chr17:19837929	A/G	cg04132472	chr17:19861366	AKAP10	0.34	7.38	0.34	8.7e-13	Platelet count;
LUAD	cis	rs7771547	0.574	rs9349001	chr6:36550681	C/T	cg07856975	chr6:36356162	ETV7	0.52	7.0	0.32	1.04e-11	Platelet distribution width;
LUAD	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg11901034	chr3:128598214	ACAD9	-0.5	-7.82	-0.36	4.36e-14	IgG glycosylation;
LUAD	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg00074818	chr8:8560427	CLDN23	0.61	9.37	0.41	4.49e-19	Obesity-related traits;
LUAD	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg13722127	chr7:150037890	RARRES2	0.45	7.77	0.35	5.9e-14	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg16425577	chr8:142139654	DENND3	-0.41	-7.24	-0.33	2.17e-12	Subcortical brain region volumes;
LUAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg07217954	chr7:1067459	C7orf50	0.46	7.16	0.33	3.55e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	6.98	0.32	1.16e-11	Motion sickness;
LUAD	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg08847533	chr14:75593920	NEK9	-0.41	-6.79	-0.31	3.89e-11	Height;
LUAD	cis	rs2882667	0.867	rs11749045	chr5:138420960	C/T	cg04439458	chr5:138467593	SIL1	-0.39	-7.18	-0.33	3.12e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg06808227	chr14:105710500	BRF1	-0.43	-6.45	-0.3	3.03e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg22683308	chr4:1340831	KIAA1530	-0.42	-6.8	-0.31	3.61e-11	Longevity;
LUAD	trans	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	2.89e-11	Diabetic kidney disease;
LUAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg03188948	chr7:1209495	NA	0.83	10.1	0.44	1.29e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg23283495	chr1:209979779	IRF6	-0.62	-9.5	-0.42	1.52e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg22442454	chr1:209979470	IRF6	0.53	6.39	0.3	4.28e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg10909506	chr17:38081995	ORMDL3	-0.37	-6.44	-0.3	3.28e-10	Self-reported allergy;
LUAD	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10802521	chr3:52805072	NEK4	-0.6	-10.55	-0.46	3.04e-23	Bipolar disorder;
LUAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.63	8.64	0.39	1.17e-16	Renal function-related traits (BUN);
LUAD	cis	rs1497406	0.744	rs12562207	chr1:16508059	G/A	cg02998240	chr1:16508668	NA	-0.22	-6.42	-0.3	3.64e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs315934	0.621	rs2121326	chr2:113846975	C/G	cg09040174	chr2:113837401	NA	0.61	7.24	0.33	2.14e-12	Dysmenorrheic pain;
LUAD	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.49	-0.38	3.42e-16	Breast cancer;
LUAD	cis	rs4253772	0.872	rs4253776	chr22:46629479	C/T	cg09491104	chr22:46646882	C22orf40	0.55	8.94	0.4	1.2e-17	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg27170947	chr2:26402098	FAM59B	0.82	11.31	0.48	4.18e-26	Gut microbiome composition (summer);
LUAD	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg07507251	chr3:52567010	NT5DC2	0.35	6.63	0.31	1.02e-10	Bipolar disorder;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg20227212	chr21:18984006	BTG3	-0.39	-6.49	-0.3	2.45e-10	Subcortical brain region volumes;
LUAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg10729496	chr3:10149963	C3orf24	0.57	9.51	0.42	1.49e-19	Alzheimer's disease;
LUAD	cis	rs7089973	1.000	rs7089973	chr10:116569565	A/C	cg23260525	chr10:116636907	FAM160B1	-0.43	-9.44	-0.42	2.5e-19	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs57046232	0.552	rs932828	chr20:6340080	G/A	cg21095983	chr6:86352623	SYNCRIP	0.42	6.64	0.31	9.6e-11	Colorectal cancer;
LUAD	cis	rs977987	0.836	rs34673655	chr16:75323559	T/C	cg03315344	chr16:75512273	CHST6	0.64	13.71	0.55	1.18e-35	Dupuytren's disease;
LUAD	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg01579765	chr21:45077557	HSF2BP	-0.64	-15.25	-0.6	3.8e-42	Mean corpuscular volume;
LUAD	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg03563238	chr19:33554763	RHPN2	-0.38	-8.86	-0.4	2.3e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	14.51	0.58	5.31e-39	Smoking behavior;
LUAD	cis	rs2073300	0.609	rs6137913	chr20:23357725	C/T	cg12062639	chr20:23401060	NAPB	0.92	9.41	0.42	3.27e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg09323728	chr8:95962352	TP53INP1	-0.34	-7.45	-0.34	5.33e-13	Type 2 diabetes;
LUAD	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.96	0.53	1.4e-32	Cognitive ability;
LUAD	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg04287289	chr16:89883240	FANCA	-0.65	-11.24	-0.48	7.72e-26	Vitiligo;
LUAD	cis	rs4243830	0.737	rs4908923	chr1:6614535	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.56	-6.83	-0.32	2.92e-11	Body mass index;
LUAD	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg15448220	chr1:150897856	SETDB1	-0.42	-7.08	-0.33	6.08e-12	Tonsillectomy;
LUAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6752107	0.967	rs36001488	chr2:234185267	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.57	9.95	0.44	4.36e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg15790184	chr11:494944	RNH1	-0.52	-6.67	-0.31	8.06e-11	Body mass index;
LUAD	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg03037974	chr15:76606532	NA	0.39	8.56	0.38	2.09e-16	Blood metabolite levels;
LUAD	cis	rs2971970	0.519	rs6955700	chr7:133633345	T/C	cg03336402	chr7:133662267	EXOC4	0.39	7.13	0.33	4.39e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23248424	chr5:179741104	GFPT2	-0.72	-11.9	-0.5	2.41e-28	Height;
LUAD	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg22571038	chr17:48585470	MYCBPAP	0.49	6.78	0.31	3.96e-11	Visceral fat;
LUAD	cis	rs2220004	0.533	rs11231522	chr11:55678167	T/C	cg22937354	chr11:55606216	OR5D16	-0.39	-7.26	-0.33	1.87e-12	Odorant perception (&beta-damascenone);
LUAD	cis	rs7937890	0.681	rs4756784	chr11:14270904	G/A	cg23387056	chr11:14280742	SPON1	0.38	7.57	0.35	2.41e-13	Mitochondrial DNA levels;
LUAD	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg14983838	chr19:29218262	NA	0.59	9.19	0.41	1.8e-18	Methadone dose in opioid dependence;
LUAD	trans	rs459571	0.959	rs467379	chr9:136905474	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-10.4	-0.45	1.05e-22	Platelet distribution width;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24099023	chr17:56770189	TEX14;RAD51C	-0.51	-6.36	-0.3	5.32e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21466042	chr6:17707449	NUP153	-0.37	-6.48	-0.3	2.54e-10	Cancer;
LUAD	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	10.07	0.44	1.66e-21	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs117623576	0.715	rs11008755	chr10:32360053	C/T	cg03047570	chr10:32398778	NA	0.61	7.58	0.35	2.24e-13	Anti-saccade response;
LUAD	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg23598886	chr18:12777645	NA	0.63	7.93	0.36	2.03e-14	Inflammatory skin disease;
LUAD	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg18180107	chr4:99064573	C4orf37	0.42	6.81	0.31	3.47e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10911363	0.549	rs2794619	chr1:183459670	G/A	cg09173681	chr1:183549694	NCF2	0.56	10.22	0.44	4.7e-22	Systemic lupus erythematosus;
LUAD	cis	rs11971779	0.715	rs10085527	chr7:139064360	G/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.51	-0.3	2.15e-10	Diisocyanate-induced asthma;
LUAD	cis	rs7809615	0.901	rs17161761	chr7:99156934	C/T	cg12290671	chr7:99195819	NA	-0.72	-8.05	-0.36	8.6e-15	Blood metabolite ratios;
LUAD	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs2735413	0.881	rs12921945	chr16:78080133	G/T	cg04733911	chr16:78082701	NA	-0.35	-8.3	-0.37	1.37e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs3789045	0.707	rs61421373	chr1:204560440	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.37	-6.62	-0.31	1.12e-10	Educational attainment (college completion);
LUAD	cis	rs72634258	0.554	rs4908704	chr1:7918904	A/G	cg26816564	chr1:7831052	VAMP3	0.6	8.21	0.37	2.71e-15	Inflammatory bowel disease;
LUAD	cis	rs1032833	0.732	rs17454150	chr2:179994361	C/T	cg23883738	chr2:179974586	SESTD1	-0.7	-7.73	-0.35	8.12e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg07741184	chr6:167504864	NA	0.3	6.84	0.32	2.7e-11	Crohn's disease;
LUAD	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg11707310	chr1:2537719	MMEL1	-0.4	-8.61	-0.39	1.45e-16	Ulcerative colitis;
LUAD	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg21862992	chr11:68658383	NA	0.52	9.44	0.42	2.49e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg26408565	chr15:76604113	ETFA	-0.44	-7.21	-0.33	2.58e-12	Blood metabolite levels;
LUAD	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.4	-7.61	-0.35	1.75e-13	Glomerular filtration rate;
LUAD	cis	rs4845570	0.831	rs11588634	chr1:151780686	T/A	cg07092448	chr1:151763213	TDRKH	-0.74	-7.93	-0.36	2.01e-14	Coronary artery disease;
LUAD	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg07138768	chr7:917805	C7orf20	0.35	6.99	0.32	1.07e-11	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg14583973	chr4:3374767	RGS12	0.29	7.28	0.33	1.68e-12	Serum sulfate level;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03361557	chr19:19774500	ATP13A1	-0.63	-7.64	-0.35	1.47e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7394190	0.688	rs3812629	chr10:75407290	G/A	cg02286717	chr10:75415704	SYNPO2L	-0.38	-6.84	-0.32	2.83e-11	Incident atrial fibrillation;
LUAD	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg27432699	chr2:27873401	GPN1	-0.38	-6.44	-0.3	3.21e-10	Total body bone mineral density;
LUAD	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg00106254	chr7:1943704	MAD1L1	-0.54	-7.95	-0.36	1.68e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-9.62	-0.42	5.85e-20	Gut microbiome composition (summer);
LUAD	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg21427119	chr20:30132790	HM13	-0.47	-7.43	-0.34	6.14e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg09324608	chr17:30823087	MYO1D	-0.38	-6.85	-0.32	2.59e-11	Schizophrenia;
LUAD	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg18105134	chr13:113819100	PROZ	1.06	19.65	0.69	1.44e-61	Platelet distribution width;
LUAD	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.55e-11	Crohn's disease;
LUAD	cis	rs716316	0.532	rs410996	chr20:14905951	A/T	cg04470754	chr20:14904432	MACROD2	0.51	6.9	0.32	1.92e-11	Advanced glycation end-product levels;
LUAD	trans	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg04775059	chr7:64541387	NA	0.5	6.91	0.32	1.76e-11	Aortic root size;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg15572692	chr19:14016919	C19orf57;CC2D1A	-0.67	-6.65	-0.31	8.95e-11	Type 2 diabetes;
LUAD	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg24531977	chr5:56204891	C5orf35	-0.48	-7.92	-0.36	2.09e-14	Coronary artery disease;
LUAD	cis	rs295137	0.799	rs4145969	chr2:201139961	C/T	cg17644776	chr2:200775616	C2orf69	-0.39	-6.65	-0.31	9.26e-11	Asthma (bronchodilator response);
LUAD	cis	rs10992471	0.528	rs3739606	chr9:95237222	G/T	cg14631576	chr9:95140430	CENPP	-0.49	-10.11	-0.44	1.12e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13012494	chr21:47604986	C21orf56	-0.7	-12.04	-0.51	6.46e-29	Testicular germ cell tumor;
LUAD	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.9	0.32	1.9e-11	Blood metabolite levels;
LUAD	cis	rs12612619	0.761	rs34732613	chr2:27254796	T/C	cg00617064	chr2:27272375	NA	-0.38	-7.15	-0.33	3.95e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs7705042	0.865	rs2338821	chr5:141509433	A/G	cg08523384	chr5:141488047	NDFIP1	-0.38	-6.49	-0.3	2.41e-10	Asthma;
LUAD	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg09650180	chr20:62225654	GMEB2	-0.48	-6.93	-0.32	1.55e-11	Glioblastoma;
LUAD	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg06784218	chr1:46089804	CCDC17	0.56	12.25	0.51	9.71e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2041840	0.961	rs2372888	chr2:37460234	C/T	cg25727520	chr2:37576821	QPCT	0.32	6.58	0.3	1.36e-10	Chronic lymphocytic leukemia;
LUAD	cis	rs7680126	0.596	rs4698009	chr4:10284993	A/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-7.16	-0.33	3.66e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs938554	0.876	rs737267	chr4:9934744	G/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.52	-0.34	3.42e-13	Blood metabolite levels;
LUAD	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg14202850	chr17:43974869	MAPT;LOC100130148	0.39	6.6	0.31	1.21e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg18305652	chr10:134549665	INPP5A	0.6	11.35	0.48	2.91e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg09021430	chr5:549028	NA	-0.66	-14.73	-0.58	5.92e-40	Ulcerative colitis;
LUAD	cis	rs3789045	0.774	rs12028476	chr1:204476361	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.43	-7.21	-0.33	2.55e-12	Educational attainment (college completion);
LUAD	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg08439880	chr3:133502540	NA	-0.37	-7.16	-0.33	3.58e-12	Iron status biomarkers;
LUAD	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg22868518	chr11:507468	RNH1	-0.66	-6.65	-0.31	8.81e-11	Body mass index;
LUAD	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs713477	0.967	rs12431542	chr14:55913078	T/C	cg13175173	chr14:55914753	NA	-0.35	-7.34	-0.34	1.09e-12	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-8.88	-0.4	2e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg20607287	chr7:12443886	VWDE	-0.54	-6.78	-0.31	3.96e-11	Coronary artery disease;
LUAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg12432903	chr7:1882776	MAD1L1	-0.4	-6.49	-0.3	2.38e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs315934	0.664	rs10199363	chr2:113840791	A/G	cg09040174	chr2:113837401	NA	-0.61	-7.38	-0.34	8.35e-13	Dysmenorrheic pain;
LUAD	cis	rs4356932	1.000	rs9884374	chr4:76946718	A/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.49	-0.3	2.36e-10	Blood protein levels;
LUAD	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.82	0.36	4.31e-14	Bladder cancer;
LUAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg08888203	chr3:10149979	C3orf24	0.75	13.27	0.54	7.38e-34	Alzheimer's disease;
LUAD	cis	rs2425143	1.000	rs10485510	chr20:34445164	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.17	-0.33	3.32e-12	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs986417	1.000	rs1950904	chr14:60964954	G/C	cg27398547	chr14:60952738	C14orf39	0.66	7.89	0.36	2.59e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg25985355	chr7:65971099	NA	0.54	6.8	0.31	3.56e-11	Diabetic kidney disease;
LUAD	cis	rs17102423	0.623	rs2093989	chr14:65553939	C/T	cg11161011	chr14:65562177	MAX	-0.48	-8.0	-0.36	1.19e-14	Obesity-related traits;
LUAD	cis	rs6542838	0.641	rs11123756	chr2:99508012	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.43	6.74	0.31	5.16e-11	Fear of minor pain;
LUAD	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg26384229	chr12:38710491	ALG10B	0.45	7.39	0.34	8.05e-13	Morning vs. evening chronotype;
LUAD	cis	rs68149176	0.772	rs997762	chr16:87879562	C/A	cg03553613	chr16:87879502	SLC7A5	-0.61	-8.81	-0.39	3.15e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg19901468	chr14:105411992	AHNAK2	-0.52	-10.16	-0.44	7.46e-22	Rheumatoid arthritis;
LUAD	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.61	8.2	0.37	2.91e-15	Gut microbiome composition (summer);
LUAD	cis	rs28595532	0.668	rs56410164	chr4:119331625	A/G	cg21605333	chr4:119757512	SEC24D	0.68	6.74	0.31	5.21e-11	Cannabis dependence symptom count;
LUAD	cis	rs1232027	0.656	rs1650680	chr5:79958366	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.03	-0.32	8.4e-12	Huntington's disease progression;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg19879479	chr6:80246572	LCA5	0.44	7.41	0.34	6.83e-13	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs11771526	0.792	rs62457499	chr7:32319197	T/C	cg27532318	chr7:32358331	NA	0.61	7.64	0.35	1.48e-13	Body mass index;
LUAD	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg22166914	chr1:53195759	ZYG11B	0.4	6.72	0.31	5.8200000000000003e-11	Monocyte count;
LUAD	cis	rs2742234	0.590	rs2742237	chr10:43621323	C/G	cg15436174	chr10:43711423	RASGEF1A	-0.52	-8.66	-0.39	1.03e-16	Hirschsprung disease;
LUAD	cis	rs758324	0.812	rs6893957	chr5:131198780	T/C	cg25547332	chr5:131281432	NA	0.42	6.78	0.31	3.96e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4786125	0.879	rs11645781	chr16:6896128	C/T	cg03623568	chr16:6915990	A2BP1	0.38	8.06	0.37	7.66e-15	Heart rate variability traits (SDNN);
LUAD	cis	rs1113500	0.933	rs11185259	chr1:108635062	A/G	cg06207961	chr1:108661230	NA	-0.44	-8.27	-0.37	1.81e-15	Growth-regulated protein alpha levels;
LUAD	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.29	0.37	1.53e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.62e-12	Crohn's disease;
LUAD	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.32	6.48	0.3	2.63e-10	Parkinson's disease;
LUAD	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg14345882	chr6:26364793	BTN3A2	0.7	7.1	0.33	5.18e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg20487152	chr13:99095054	FARP1	-0.47	-8.02	-0.36	1.05e-14	Longevity;
LUAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg03188948	chr7:1209495	NA	0.43	7.04	0.32	7.87e-12	Longevity;Endometriosis;
LUAD	cis	rs4308124	0.708	rs6716091	chr2:111991133	C/T	cg04571233	chr2:111982156	NA	-0.45	-6.44	-0.3	3.28e-10	Vitiligo;
LUAD	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.56	-9.45	-0.42	2.41e-19	Glomerular filtration rate;
LUAD	cis	rs9427116	0.740	rs11264230	chr1:154608418	G/T	cg17218026	chr1:154582156	ADAR	0.51	9.88	0.43	7.53e-21	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg27284194	chr4:1044797	NA	0.71	10.35	0.45	1.54e-22	Recombination rate (females);
LUAD	cis	rs2625529	0.526	rs8040828	chr15:72492779	C/A	cg16672083	chr15:72433130	SENP8	0.67	12.47	0.52	1.25e-30	Red blood cell count;
LUAD	cis	rs240764	0.658	rs9404053	chr6:101254456	G/A	cg09795085	chr6:101329169	ASCC3	-0.43	-7.59	-0.35	2.04e-13	Neuroticism;
LUAD	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg19875535	chr5:140030758	IK	-0.49	-8.13	-0.37	4.76e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-6.5	-0.3	2.31e-10	Height;
LUAD	cis	rs1816752	1.000	rs7988810	chr13:25019096	T/C	cg02811702	chr13:24901961	NA	0.46	7.59	0.35	2.02e-13	Obesity-related traits;
LUAD	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	7.07	0.33	6.44e-12	Breast cancer;
LUAD	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg09835421	chr16:68378352	PRMT7	-0.81	-8.82	-0.39	2.93e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg08888203	chr3:10149979	C3orf24	0.72	12.89	0.53	2.61e-32	Alzheimer's disease;
LUAD	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg04944784	chr2:26401820	FAM59B	0.89	11.21	0.48	9.96e-26	Gut microbiome composition (summer);
LUAD	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg10755058	chr3:40428713	ENTPD3	0.45	8.44	0.38	5.03e-16	Renal cell carcinoma;
LUAD	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg06873352	chr17:61820015	STRADA	0.42	7.01	0.32	9.4e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1865721	0.804	rs7229401	chr18:73148127	T/G	cg26385618	chr18:73139727	C18orf62	-0.52	-10.03	-0.44	2.19e-21	Intelligence;
LUAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg05896524	chr21:47604654	C21orf56	0.73	12.84	0.53	4.08e-32	Testicular germ cell tumor;
LUAD	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.49	0.3	2.47e-10	Breast cancer;
LUAD	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.41	6.6	0.31	1.26e-10	Total body bone mineral density;
LUAD	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	7.37	0.34	9.33e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	15.15	0.59	9.51e-42	Bone mineral density;
LUAD	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06544989	chr22:39130855	UNC84B	0.38	7.8	0.35	4.94e-14	Menopause (age at onset);
LUAD	cis	rs733175	0.904	rs3775944	chr4:10019974	G/T	cg00071950	chr4:10020882	SLC2A9	0.61	9.14	0.41	2.61e-18	Psychosis and Alzheimer's disease;
LUAD	cis	rs9354308	0.899	rs2814153	chr6:66557611	T/A	cg07460842	chr6:66804631	NA	0.5	7.5	0.34	3.68e-13	Metabolite levels;
LUAD	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg27661571	chr11:113659931	NA	-0.68	-7.9	-0.36	2.4e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg14186256	chr22:23484241	RTDR1	0.42	7.1	0.33	5.17e-12	Bone mineral density;
LUAD	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg05304507	chr6:116381966	FRK	0.2	6.91	0.32	1.81e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg11494091	chr17:61959527	GH2	0.74	18.31	0.66	1.47e-55	Prudent dietary pattern;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg14490972	chr6:43484812	POLR1C;YIPF3	-0.4	-6.73	-0.31	5.44e-11	Subcortical brain region volumes;
LUAD	cis	rs9399401	0.677	rs11155241	chr6:142664439	T/A	cg04461802	chr6:142623433	GPR126	0.43	7.85	0.36	3.54e-14	Chronic obstructive pulmonary disease;
LUAD	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg08798685	chr6:27730294	NA	-0.43	-6.92	-0.32	1.67e-11	Parkinson's disease;
LUAD	cis	rs116248771	0.739	rs16829122	chr3:158312667	T/C	cg16708174	chr3:158430962	RARRES1	0.52	7.36	0.34	9.79e-13	diarrhoeal disease at age 2;
LUAD	cis	rs9479482	0.967	rs9479478	chr6:150354608	T/G	cg08316699	chr6:150357289	NA	0.34	7.16	0.33	3.62e-12	Alopecia areata;
LUAD	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg24308560	chr3:49941425	MST1R	-0.52	-8.56	-0.38	2.1e-16	Body mass index;
LUAD	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg20891283	chr12:69753455	YEATS4	0.44	7.13	0.33	4.26e-12	Blood protein levels;
LUAD	cis	rs968567	0.689	rs61897795	chr11:61618169	A/G	cg21709803	chr11:61594965	FADS2	-0.58	-7.69	-0.35	1.03e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg15485101	chr11:133734466	NA	0.39	8.27	0.37	1.79e-15	Childhood ear infection;
LUAD	cis	rs10857712	0.904	rs7918164	chr10:135223323	G/A	cg01444801	chr10:135216882	MTG1	-0.54	-7.29	-0.33	1.49e-12	Systemic lupus erythematosus;
LUAD	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-9.24	-0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-10.98	-0.47	7.56e-25	Bone mineral density;
LUAD	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg25173405	chr17:45401733	C17orf57	-0.41	-7.01	-0.32	9.67e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7000551	0.751	rs2443505	chr8:22375341	G/A	cg12081754	chr8:22256438	SLC39A14	0.48	7.86	0.36	3.19e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27286337	chr10:134555280	INPP5A	0.66	9.88	0.43	7.59e-21	Migraine;
LUAD	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg20673091	chr1:2541236	MMEL1	0.4	8.54	0.38	2.44e-16	Ulcerative colitis;
LUAD	cis	rs910187	0.605	rs6066224	chr20:45806632	T/A	cg27589058	chr20:45804311	EYA2	-0.37	-8.61	-0.39	1.49e-16	Migraine;
LUAD	trans	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg18187862	chr3:45730750	SACM1L	0.5	7.88	0.36	2.86e-14	Primary sclerosing cholangitis;
LUAD	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg25173405	chr17:45401733	C17orf57	0.45	7.64	0.35	1.43e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10916814	0.632	rs10916818	chr1:20897425	C/T	cg24502330	chr1:20914028	CDA	-0.36	-7.13	-0.33	4.43e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.47	-0.34	4.65e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg26587870	chr6:27730563	NA	-0.69	-7.36	-0.34	9.54e-13	Depression;
LUAD	cis	rs7107174	1.000	rs1017908	chr11:77948095	A/G	cg02023728	chr11:77925099	USP35	0.5	7.55	0.34	2.68e-13	Testicular germ cell tumor;
LUAD	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg07741184	chr6:167504864	NA	0.35	8.14	0.37	4.46e-15	Primary biliary cholangitis;
LUAD	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02475777	chr4:1388615	CRIPAK	0.67	9.49	0.42	1.75e-19	Longevity;
LUAD	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg03806693	chr22:41940476	POLR3H	-0.74	-9.85	-0.43	9.8e-21	Vitiligo;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06082745	chr10:133795139	BNIP3	-0.65	-6.36	-0.3	5.18e-10	Type 2 diabetes;
LUAD	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg13319975	chr6:146136371	FBXO30	-0.55	-9.27	-0.41	9.58e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9462027	0.651	rs13220394	chr6:34810172	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.84	-0.39	2.61e-17	Systemic lupus erythematosus;
LUAD	cis	rs727505	1.000	rs59294613	chr7:124554267	C/A	cg23710748	chr7:124431027	NA	-0.44	-9.35	-0.41	5.31e-19	Lewy body disease;
LUAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg21970626	chr13:21893289	NA	-0.54	-9.11	-0.4	3.45e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg13263323	chr15:86062960	AKAP13	-0.45	-7.36	-0.34	9.88e-13	Coronary artery disease;
LUAD	cis	rs684232	0.688	rs2657633	chr17:600502	C/T	cg15660573	chr17:549704	VPS53	-0.76	-14.71	-0.58	7.82e-40	Prostate cancer;
LUAD	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	11.8	0.5	5.74e-28	Smoking behavior;
LUAD	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg00504896	chr12:9437009	LOC642846	0.44	7.05	0.32	7.33e-12	Breast size;
LUAD	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.51	0.34	3.46e-13	Breast cancer;
LUAD	cis	rs28595532	0.841	rs115233595	chr4:119744214	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg05872129	chr22:39784769	NA	-0.77	-13.86	-0.56	2.74e-36	Intelligence (multi-trait analysis);
LUAD	cis	rs2160860	0.965	rs2543044	chr8:39819087	C/T	cg25981315	chr8:39806701	IDO2	0.35	6.5	0.3	2.21e-10	Blood metabolite levels;
LUAD	cis	rs6432018	0.927	rs11674777	chr2:9734350	T/A	cg12832956	chr2:9616023	IAH1	-0.36	-6.5	-0.3	2.33e-10	Heart rate variability traits;
LUAD	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg18446336	chr7:2847575	GNA12	-0.37	-7.25	-0.33	1.97e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.49	-8.66	-0.39	9.73e-17	Tonsillectomy;
LUAD	cis	rs2835872	0.861	rs67739865	chr21:39049101	G/A	cg06728970	chr21:39037746	KCNJ6	-0.36	-6.44	-0.3	3.27e-10	Electroencephalographic traits in alcoholism;
LUAD	trans	rs87938	1.000	rs406589	chr3:41125313	A/C	cg11224624	chr8:145049280	PLEC1	0.4	6.85	0.32	2.54e-11	Bone mineral density (hip);
LUAD	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.08	-0.4	4.31e-18	Total body bone mineral density;
LUAD	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.26	0.37	1.91e-15	Breast cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21140054	chr3:42632404	SS18L2	-0.56	-6.74	-0.31	5.2e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4006360	0.600	rs1828327	chr17:39249464	T/C	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.3	0.37	1.46e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs943466	0.955	rs2894342	chr6:33774394	C/A	cg16010596	chr6:33739607	LEMD2	-0.38	-7.22	-0.33	2.39e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg00717180	chr2:96193071	NA	0.36	6.68	0.31	7.64e-11	Coronary artery disease;
LUAD	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg18512352	chr11:47633146	NA	-0.57	-10.14	-0.44	8.64e-22	Body mass index;
LUAD	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg00310523	chr12:86230176	RASSF9	0.39	7.92	0.36	2.09e-14	Major depressive disorder;
LUAD	trans	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-7.6	-0.35	1.97e-13	Mood instability;
LUAD	cis	rs4638749	0.677	rs6755078	chr2:108818270	T/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.26	-0.33	1.85e-12	Blood pressure;
LUAD	cis	rs1003719	0.680	rs2835620	chr21:38505581	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-9.06	-0.4	4.8e-18	Eye color traits;
LUAD	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-19.81	-0.69	2.99e-62	Height;
LUAD	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg21385522	chr1:16154831	NA	-0.59	-9.88	-0.43	7.49e-21	Systolic blood pressure;
LUAD	trans	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg01620082	chr3:125678407	NA	-1.1	-10.38	-0.45	1.18e-22	Depression;
LUAD	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.74	0.35	7.46e-14	Breast cancer;
LUAD	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg26039829	chr8:22132926	PIWIL2	0.59	10.85	0.47	2.29e-24	Hypertriglyceridemia;
LUAD	cis	rs2235649	0.704	rs1742425	chr16:1904524	G/A	cg07386859	chr16:1872102	HAGH	0.5	7.25	0.33	1.99e-12	Blood metabolite levels;
LUAD	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg17757837	chr7:157058334	UBE3C	0.47	8.37	0.38	8.56e-16	Body mass index;
LUAD	cis	rs7149242	0.500	rs10144381	chr14:101173297	C/T	cg08175591	chr14:101176152	NA	-0.4	-6.9	-0.32	1.93e-11	Platelet count;
LUAD	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg22681709	chr2:178499509	PDE11A	-0.43	-6.86	-0.32	2.44e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg03188948	chr7:1209495	NA	0.78	10.28	0.45	2.77e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg19875535	chr5:140030758	IK	-0.41	-6.92	-0.32	1.64e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg10434728	chr15:90938212	IQGAP1	0.39	7.84	0.36	3.7e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs6500395	1.000	rs7202551	chr16:48728984	A/G	cg04672837	chr16:48644449	N4BP1	-0.37	-6.43	-0.3	3.46e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg08645402	chr16:4508243	NA	-0.52	-9.75	-0.43	2.11e-20	Schizophrenia;
LUAD	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg02569458	chr12:86230093	RASSF9	0.46	8.37	0.38	8.6e-16	Major depressive disorder;
LUAD	cis	rs7737355	0.853	rs6596024	chr5:130769785	A/C	cg06307176	chr5:131281290	NA	0.43	7.17	0.33	3.32e-12	Life satisfaction;
LUAD	cis	rs240764	0.658	rs11155635	chr6:101199367	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-8.22	-0.37	2.54e-15	Neuroticism;
LUAD	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg25985355	chr7:65971099	NA	0.54	6.67	0.31	8.07e-11	Diabetic kidney disease;
LUAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg13271783	chr10:134563150	INPP5A	-0.41	-6.6	-0.31	1.24e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2455601	0.638	rs2248245	chr11:8988350	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-7.28	-0.33	1.61e-12	Schizophrenia;
LUAD	cis	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg27411982	chr8:10470053	RP1L1	0.39	7.04	0.32	7.64e-12	Systolic blood pressure;
LUAD	cis	rs1595825	0.679	rs7590697	chr2:198378546	A/G	cg00982548	chr2:198649783	BOLL	-0.5	-6.57	-0.3	1.51e-10	Ulcerative colitis;
LUAD	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.52	8.28	0.37	1.58e-15	Total body bone mineral density;
LUAD	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg27631724	chr1:11040367	C1orf127	0.53	8.98	0.4	9.09e-18	Ewing sarcoma;
LUAD	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg18016565	chr1:150552671	MCL1	0.4	7.17	0.33	3.47e-12	Tonsillectomy;
LUAD	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg24399712	chr22:39784796	NA	-0.84	-16.68	-0.63	2.41e-48	Intelligence (multi-trait analysis);
LUAD	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg25358565	chr5:93447407	FAM172A	0.64	7.31	0.33	1.36e-12	Diabetic retinopathy;
LUAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg08888203	chr3:10149979	C3orf24	-0.7	-12.21	-0.51	1.46e-29	Alzheimer's disease;
LUAD	cis	rs7828089	0.934	rs12544427	chr8:22263115	C/T	cg12081754	chr8:22256438	SLC39A14	-0.56	-9.78	-0.43	1.74e-20	Verbal declarative memory;
LUAD	cis	rs9473147	0.543	rs4715025	chr6:47483653	C/G	cg12968598	chr6:47444699	CD2AP	0.36	6.46	0.3	2.81e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg27087555	chr16:88793112	FAM38A	-1.36	-14.22	-0.57	9.02e-38	Plateletcrit;
LUAD	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg05082376	chr22:42548792	NA	0.45	7.85	0.36	3.38e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7187994	0.515	rs9936719	chr16:84730830	C/T	cg07647771	chr16:84786436	USP10	0.26	6.99	0.32	1.08e-11	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg09658497	chr7:2847517	GNA12	-0.46	-7.76	-0.35	6.3e-14	Height;
LUAD	trans	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg24644049	chr4:85504048	CDS1	0.88	7.61	0.35	1.79e-13	Skin colour saturation;
LUAD	trans	rs2018683	0.691	rs4722881	chr7:29001560	A/G	cg19402173	chr7:128379420	CALU	0.52	8.74	0.39	5.34e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg22166914	chr1:53195759	ZYG11B	0.4	6.66	0.31	8.55e-11	Monocyte count;
LUAD	cis	rs4804416	1.000	rs4804414	chr19:7223785	C/T	cg00428638	chr19:7224713	INSR	0.47	9.33	0.41	5.91e-19	Thyroid hormone levels;Hypothyroidism;
LUAD	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg03388025	chr16:89894329	SPIRE2	-0.33	-7.53	-0.34	3.18e-13	Vitiligo;
LUAD	cis	rs7503807	0.935	rs7215534	chr17:78612119	C/T	cg09596252	chr17:78655493	RPTOR	0.41	7.83	0.36	4.05e-14	Obesity;
LUAD	trans	rs12310956	0.532	rs2087270	chr12:33850109	C/T	cg10518543	chr12:38710700	ALG10B	0.42	6.78	0.31	4.01e-11	Morning vs. evening chronotype;
LUAD	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg08219700	chr8:58056026	NA	0.6	8.22	0.37	2.5e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg13679303	chr9:96623674	NA	-0.37	-7.47	-0.34	4.76e-13	DNA methylation (variation);
LUAD	cis	rs11025523	0.904	rs10833311	chr11:20379638	C/T	cg02900213	chr11:20385756	HTATIP2	0.42	6.64	0.31	9.73e-11	Obesity-related traits;
LUAD	cis	rs758324	0.704	rs40401	chr5:131396478	C/T	cg06307176	chr5:131281290	NA	-0.39	-6.71	-0.31	6.35e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg25828334	chr19:18545568	ISYNA1	-0.36	-7.22	-0.33	2.35e-12	Breast cancer;
LUAD	cis	rs4711350	0.954	rs11751943	chr6:33729718	G/C	cg13859433	chr6:33739653	LEMD2	-0.35	-6.58	-0.3	1.37e-10	Schizophrenia;
LUAD	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.45	-0.89	7.93e-144	Myeloid white cell count;
LUAD	cis	rs679087	0.686	rs10843500	chr12:29918582	C/G	cg14258853	chr12:29935411	TMTC1	0.55	9.98	0.44	3.42e-21	Schizophrenia;
LUAD	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.45	-0.34	5.22e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	7.11	0.33	4.99e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7680126	0.633	rs4698040	chr4:10352550	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-7.77	-0.35	6.09e-14	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg21204522	chr6:27730016	NA	-0.45	-7.11	-0.33	4.84e-12	Parkinson's disease;
LUAD	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.25	-0.33	2.06e-12	Total cholesterol levels;
LUAD	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg16989719	chr2:238392110	NA	0.36	6.92	0.32	1.69e-11	Prostate cancer;
LUAD	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg24550644	chr17:30846204	MYO1D	0.5	9.7	0.43	3.32e-20	Schizophrenia;
LUAD	cis	rs9341808	0.587	rs3805859	chr6:81048946	C/A	cg08355045	chr6:80787529	NA	0.47	8.19	0.37	3.06e-15	Sitting height ratio;
LUAD	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg03188948	chr7:1209495	NA	0.61	6.49	0.3	2.46e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	14.32	0.57	3.22e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg13453750	chr1:205783389	SLC41A1	-0.41	-7.22	-0.33	2.45e-12	Menarche (age at onset);
LUAD	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg15181151	chr6:150070149	PCMT1	0.42	8.83	0.39	2.84e-17	Lung cancer;
LUAD	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg07606381	chr6:8435919	SLC35B3	0.41	6.68	0.31	7.42e-11	Motion sickness;
LUAD	cis	rs7274811	0.744	rs6120316	chr20:32177079	T/C	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.5	-7.22	-0.33	2.42e-12	Height;
LUAD	trans	rs2270927	0.510	rs35930860	chr5:75579946	T/C	cg13563193	chr19:33072644	PDCD5	1.02	9.42	0.42	3.02e-19	Mean corpuscular volume;
LUAD	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg26343298	chr8:95960752	TP53INP1	0.33	6.44	0.3	3.17e-10	Type 2 diabetes;
LUAD	cis	rs4730250	0.707	rs3729877	chr7:106787065	T/G	cg23024343	chr7:107201750	COG5	-0.49	-6.76	-0.31	4.68e-11	Osteoarthritis;
LUAD	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg08508325	chr11:3079039	CARS	0.43	8.91	0.4	1.53e-17	Calcium levels;
LUAD	trans	rs701145	0.585	rs447429	chr3:153909946	T/C	cg14299572	chr10:34021103	NA	-0.4	-6.44	-0.3	3.28e-10	Coronary artery disease;
LUAD	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg11909912	chr17:43974919	MAPT;LOC100130148	0.38	6.49	0.3	2.37e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg07404485	chr7:94953653	PON1	-0.49	-7.07	-0.33	6.26e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.61	10.54	0.46	3.2e-23	Cognitive ability;
LUAD	cis	rs2579500	0.848	rs2438712	chr2:97219710	C/T	cg23100626	chr2:96804247	ASTL	0.27	6.52	0.3	1.96e-10	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg17105886	chr17:28927953	LRRC37B2	0.83	8.13	0.37	4.71e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg16606324	chr3:10149918	C3orf24	-0.69	-10.15	-0.44	8.45e-22	Alzheimer's disease;
LUAD	trans	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg04995722	chr7:26192034	NFE2L3	-0.44	-7.57	-0.35	2.28e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4888262	0.508	rs4888258	chr16:74634198	G/T	cg01733217	chr16:74700730	RFWD3	0.51	8.56	0.38	2.04e-16	Testicular germ cell tumor;
LUAD	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg02569458	chr12:86230093	RASSF9	0.39	7.16	0.33	3.57e-12	Major depressive disorder;
LUAD	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg15445000	chr17:37608096	MED1	0.45	8.28	0.37	1.62e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	7.77	0.35	5.96e-14	Tonsillectomy;
LUAD	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25427524	chr10:38739819	LOC399744	-0.76	-13.56	-0.55	4.99e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg10523679	chr1:76189770	ACADM	0.89	15.49	0.6	3.3400000000000002e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg25985355	chr7:65971099	NA	-0.52	-6.47	-0.3	2.66e-10	Diabetic kidney disease;
LUAD	cis	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg07460842	chr6:66804631	NA	0.9	12.21	0.51	1.44e-29	Exhaled nitric oxide output;
LUAD	trans	rs7395662	0.677	rs10839110	chr11:48839960	T/C	cg15704280	chr7:45808275	SEPT13	-0.41	-6.45	-0.3	3.14e-10	HDL cholesterol;
LUAD	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.35	-6.62	-0.31	1.09e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg03396347	chr1:1875803	NA	-0.56	-14.59	-0.58	2.43e-39	Body mass index;
LUAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg21724239	chr8:58056113	NA	0.63	7.57	0.35	2.32e-13	Developmental language disorder (linguistic errors);
LUAD	trans	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg27411982	chr8:10470053	RP1L1	0.41	7.32	0.34	1.22e-12	Mood instability;
LUAD	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-19.14	-0.68	2.78e-59	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7224314	1.000	rs62084076	chr17:65383102	G/A	cg01507342	chr17:65387096	PITPNC1	-0.54	-9.05	-0.4	5.21e-18	Diisocyanate-induced asthma;
LUAD	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg18132916	chr6:79620363	NA	-0.44	-7.64	-0.35	1.43e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	7.56	0.35	2.51e-13	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg07570687	chr10:102243282	WNT8B	0.42	6.44	0.3	3.3e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs754466	0.606	rs7084705	chr10:79596675	A/G	cg17075019	chr10:79541650	NA	-0.84	-17.21	-0.64	1.11e-50	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6906287	0.669	rs12208253	chr6:118925097	G/C	cg18833306	chr6:118973337	C6orf204	0.48	8.29	0.37	1.48e-15	Electrocardiographic conduction measures;
LUAD	cis	rs868036	1.000	rs868037	chr15:68054996	A/G	cg24579218	chr15:68104479	NA	0.36	6.65	0.31	8.99e-11	Restless legs syndrome;
LUAD	cis	rs11771526	0.901	rs62457471	chr7:32306737	A/C	cg27532318	chr7:32358331	NA	0.6	7.69	0.35	1.07e-13	Body mass index;
LUAD	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg25237894	chr2:233734115	C2orf82	0.57	10.88	0.47	1.8e-24	Coronary artery disease;
LUAD	cis	rs754466	0.580	rs10430530	chr10:79582812	T/C	cg17075019	chr10:79541650	NA	-0.91	-19.2	-0.68	1.47e-59	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6542838	0.703	rs7593332	chr2:99467991	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-7.33	-0.34	1.18e-12	Fear of minor pain;
LUAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11905131	chr22:24372483	LOC391322	-0.55	-9.52	-0.42	1.34e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs367943	0.666	rs7703503	chr5:112962334	A/C	cg12552261	chr5:112820674	MCC	0.44	7.98	0.36	1.37e-14	Type 2 diabetes;
LUAD	cis	rs1003719	0.715	rs2051398	chr21:38550258	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.53	0.38	2.67e-16	Eye color traits;
LUAD	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg18306943	chr3:40428807	ENTPD3	0.42	7.12	0.33	4.56e-12	Renal cell carcinoma;
LUAD	cis	rs4660214	0.666	rs683135	chr1:39895460	G/A	cg27567593	chr1:39956653	BMP8A	-0.37	-7.31	-0.33	1.39e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7799006	0.606	rs7792045	chr7:2316852	C/T	cg08027265	chr7:2291960	NA	-0.72	-14.78	-0.58	3.65e-40	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg11502198	chr6:26597334	ABT1	0.55	9.09	0.4	3.73e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs10129255	0.589	rs78599641	chr14:107093581	G/C	cg23076370	chr14:107095027	NA	-0.4	-6.93	-0.32	1.59e-11	Kawasaki disease;
LUAD	cis	rs7771547	0.547	rs1076931	chr6:36562021	G/C	cg02952361	chr6:36355661	ETV7	0.47	6.42	0.3	3.63e-10	Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.43	7.19	0.33	2.88e-12	Insulin-like growth factors;
LUAD	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	11.42	0.49	1.68e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg05342682	chr7:94953680	PON1	-0.5	-6.94	-0.32	1.53e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23583168	chr7:148888333	NA	-0.92	-18.98	-0.68	1.41e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs800082	0.501	rs9844730	chr3:144216886	T/G	cg24215973	chr2:240111563	HDAC4	0.53	8.52	0.38	2.88e-16	Smoking behavior;
LUAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-10.71	-0.46	7.6e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs6554196	0.508	rs999021	chr4:55524533	C/G	cg18836493	chr4:55524333	KIT	-0.37	-6.92	-0.32	1.73e-11	Monocyte count;
LUAD	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg00071950	chr4:10020882	SLC2A9	0.86	18.37	0.67	7.73e-56	Bone mineral density;
LUAD	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg21100191	chr22:23484243	RTDR1	-0.66	-11.73	-0.5	1.03e-27	Bone mineral density;
LUAD	cis	rs4930561	0.739	rs7118045	chr11:67978734	C/G	cg04465784	chr11:67976953	SUV420H1	-0.34	-10.5	-0.45	4.54e-23	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs829883	1.000	rs1347956	chr12:98889564	A/G	cg25150519	chr12:98850993	NA	0.65	10.86	0.47	2.19e-24	Colorectal adenoma (advanced);
LUAD	trans	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg18187862	chr3:45730750	SACM1L	0.5	7.81	0.36	4.58e-14	Primary sclerosing cholangitis;
LUAD	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg23625390	chr15:77176239	SCAPER	-0.45	-7.24	-0.33	2.17e-12	Blood metabolite levels;
LUAD	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2730260	0.537	rs55683317	chr7:158878599	C/T	cg13710308	chr7:158854763	VIPR2	-0.5	-6.37	-0.3	4.92e-10	Myopia (pathological);
LUAD	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg18132916	chr6:79620363	NA	-0.44	-7.56	-0.34	2.59e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.7	0.31	6.76e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg03874509	chr1:107600012	PRMT6	-0.52	-9.06	-0.4	4.84e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg25754956	chr12:51612065	POU6F1	0.54	7.35	0.34	1.04e-12	Cisplatin-induced ototoxicity;
LUAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg05896524	chr21:47604654	C21orf56	0.73	12.76	0.53	9.06e-32	Testicular germ cell tumor;
LUAD	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.05	-0.36	8.53e-15	Cystic fibrosis severity;
LUAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	cis	rs739496	0.947	rs10849949	chr12:111893537	C/T	cg10833066	chr12:111807467	FAM109A	-0.45	-8.15	-0.37	4.04e-15	Platelet count;
LUAD	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg27432699	chr2:27873401	GPN1	0.57	10.09	0.44	1.4e-21	Oral cavity cancer;
LUAD	cis	rs8060686	0.516	rs1975802	chr16:68285847	A/G	cg09835421	chr16:68378352	PRMT7	-0.55	-6.93	-0.32	1.54e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3818285	0.504	rs1973972	chr10:111651133	A/T	cg00817464	chr10:111662876	XPNPEP1	0.66	10.19	0.44	5.97e-22	Superior crus of antihelix expression;
LUAD	cis	rs1451375	0.583	rs3807555	chr7:50610569	A/G	cg18232548	chr7:50535776	DDC	0.59	8.4	0.38	6.82e-16	Malaria;
LUAD	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.24	0.37	2.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg25985355	chr7:65971099	NA	-0.53	-6.55	-0.3	1.66e-10	Diabetic kidney disease;
LUAD	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg27211696	chr2:191398769	TMEM194B	-0.65	-8.33	-0.38	1.12e-15	Diastolic blood pressure;
LUAD	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg08999081	chr20:33150536	PIGU	0.63	14.54	0.58	3.89e-39	Coronary artery disease;
LUAD	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg00981070	chr1:2046702	PRKCZ	-0.36	-6.97	-0.32	1.22e-11	Height;
LUAD	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06544989	chr22:39130855	UNC84B	0.41	7.59	0.35	2.11e-13	Menopause (age at onset);
LUAD	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg04398451	chr17:18023971	MYO15A	-0.67	-12.1	-0.51	3.64e-29	Total body bone mineral density;
LUAD	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg09455208	chr3:40491958	NA	0.65	14.01	0.56	6.97e-37	Renal cell carcinoma;
LUAD	trans	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg24644049	chr4:85504048	CDS1	0.9	7.35	0.34	1.04e-12	Skin colour saturation;
LUAD	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg02569458	chr12:86230093	RASSF9	0.37	7.21	0.33	2.54e-12	Major depressive disorder;
LUAD	cis	rs6964587	0.621	rs38799	chr7:92045139	C/T	cg17063962	chr7:91808500	NA	-0.57	-9.4	-0.42	3.44e-19	Breast cancer;
LUAD	cis	rs9296095	0.950	rs5745587	chr6:33545125	A/G	cg14003231	chr6:33640908	ITPR3	0.52	9.43	0.42	2.79e-19	Platelet count;
LUAD	cis	rs12617721	0.874	rs3754890	chr2:99088624	C/T	cg10123293	chr2:99228465	UNC50	0.47	8.34	0.38	1.05e-15	Bipolar disorder with mood-incongruent psychosis;
LUAD	trans	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg03886242	chr7:26192032	NFE2L3	-0.44	-7.63	-0.35	1.52e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9513627	1.000	rs7338537	chr13:100119581	C/A	cg25919922	chr13:100150906	NA	-0.69	-6.6	-0.31	1.25e-10	Obesity-related traits;
LUAD	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg06697600	chr4:7070879	GRPEL1	-0.51	-8.46	-0.38	4.55e-16	Monocyte percentage of white cells;
LUAD	cis	rs7617773	0.780	rs34749846	chr3:48347168	T/G	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg21951975	chr1:209979733	IRF6	-0.53	-6.59	-0.31	1.28e-10	Coronary artery disease;
LUAD	cis	rs2242073	0.660	rs4375849	chr2:209000170	G/T	cg06181187	chr2:209010896	CRYGB	-0.34	-6.66	-0.31	8.42e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs8048589	0.578	rs11075049	chr16:12173539	C/T	cg03816625	chr16:12192430	SNX29	0.44	6.61	0.31	1.13e-10	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs6748734	0.948	rs6752657	chr2:241840541	G/C	cg04034577	chr2:241836375	C2orf54	-0.49	-10.48	-0.45	5.09e-23	Urinary metabolites;
LUAD	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg06937882	chr20:24974362	C20orf3	-0.35	-6.98	-0.32	1.15e-11	Blood protein levels;
LUAD	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg06609049	chr19:2785107	THOP1	0.72	12.02	0.5	7.74e-29	Total cholesterol levels;
LUAD	cis	rs12681287	0.546	rs12546802	chr8:87499335	T/A	cg27223183	chr8:87520930	FAM82B	-0.71	-10.15	-0.44	8.15e-22	Caudate activity during reward;
LUAD	cis	rs7493	0.950	rs11981299	chr7:95029701	T/A	cg07404485	chr7:94953653	PON1	-0.5	-7.15	-0.33	3.8e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg17177755	chr1:15930204	NA	0.45	7.26	0.33	1.82e-12	Systolic blood pressure;
LUAD	cis	rs3125734	0.633	rs6479792	chr10:63983264	T/G	cg19640130	chr10:64028056	RTKN2	-0.34	-7.15	-0.33	3.73e-12	Rheumatoid arthritis;
LUAD	trans	rs75804782	0.572	rs11900963	chr2:239308049	A/T	cg01134436	chr17:81009848	B3GNTL1	0.7	6.51	0.3	2.08e-10	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs3204270	0.530	rs57707013	chr17:79635281	C/T	cg09655341	chr17:79618100	PDE6G	0.47	6.39	0.3	4.52e-10	Dental caries;
LUAD	cis	rs7197653	0.667	rs12599876	chr16:68393405	C/T	cg05110241	chr16:68378359	PRMT7	-0.96	-10.42	-0.45	8.65e-23	Magnesium levels;
LUAD	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg07538946	chr5:131705188	SLC22A5	0.41	6.72	0.31	5.98e-11	Blood metabolite levels;
LUAD	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg27489772	chr12:121021490	NA	-0.56	-7.12	-0.33	4.65e-12	Type 1 diabetes nephropathy;
LUAD	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg21862992	chr11:68658383	NA	0.52	9.62	0.42	5.96e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs62238980	0.614	rs77112134	chr22:32394449	C/T	cg00543991	chr22:32367038	NA	0.92	8.16	0.37	3.95e-15	Childhood ear infection;
LUAD	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-14.86	-0.59	1.7e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg16988262	chr1:15930761	NA	0.42	6.96	0.32	1.29e-11	Systolic blood pressure;
LUAD	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg04234412	chr22:24373322	LOC391322	-0.91	-17.95	-0.66	5.91e-54	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7586879	0.789	rs67221599	chr2:25131948	T/C	cg04586622	chr2:25135609	ADCY3	0.36	7.26	0.33	1.85e-12	Body mass index;
LUAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.77	-0.35	6.05e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg07741184	chr6:167504864	NA	0.35	8.06	0.36	7.9e-15	Primary biliary cholangitis;
LUAD	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg22823121	chr1:150693482	HORMAD1	0.41	7.96	0.36	1.57e-14	Melanoma;
LUAD	cis	rs4888262	0.545	rs7184754	chr16:74667864	C/T	cg01733217	chr16:74700730	RFWD3	0.52	8.74	0.39	5.6e-17	Testicular germ cell tumor;
LUAD	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg11707310	chr1:2537719	MMEL1	0.37	7.89	0.36	2.52e-14	Ulcerative colitis;
LUAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg04025307	chr7:1156635	C7orf50	0.68	11.92	0.5	1.98e-28	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08677398	chr8:58056175	NA	0.48	6.75	0.31	4.86e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7536201	1.000	rs7529070	chr1:25295580	C/T	cg23273869	chr1:25296894	NA	-0.35	-7.02	-0.32	8.92e-12	Psoriasis vulgaris;
LUAD	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg21475434	chr5:93447410	FAM172A	0.74	8.33	0.38	1.1e-15	Diabetic retinopathy;
LUAD	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg17443473	chr1:3703550	LRRC47	0.47	7.84	0.36	3.77e-14	Red cell distribution width;
LUAD	cis	rs4588572	0.643	rs1864172	chr5:77690945	T/C	cg11547950	chr5:77652471	NA	0.77	12.22	0.51	1.23e-29	Triglycerides;
LUAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs7939886	0.920	rs11231794	chr11:55765776	T/C	cg15704280	chr7:45808275	SEPT13	0.68	6.76	0.31	4.67e-11	Myopia (pathological);
LUAD	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg02389323	chr16:88786976	FAM38A	1.26	11.98	0.5	1.14e-28	Plateletcrit;
LUAD	cis	rs4662945	0.504	rs35568023	chr2:130251812	A/T	cg05962382	chr2:130345044	NA	-0.37	-6.92	-0.32	1.67e-11	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg16325326	chr1:53192061	ZYG11B	0.59	10.6	0.46	1.96e-23	Monocyte count;
LUAD	cis	rs11971779	0.555	rs4728466	chr7:139096365	T/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06022373	chr22:39101656	GTPBP1	0.44	6.94	0.32	1.51e-11	Menopause (age at onset);
LUAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg22535103	chr8:58192502	C8orf71	-0.72	-8.94	-0.4	1.24e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	-0.39	-6.62	-0.31	1.12e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg26304593	chr6:42947056	PEX6	-0.45	-7.44	-0.34	5.53e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg04398451	chr17:18023971	MYO15A	-0.61	-11.19	-0.48	1.2e-25	Total body bone mineral density;
LUAD	cis	rs11030122	0.661	rs963998	chr11:4062803	A/G	cg18678763	chr11:4115507	RRM1	-0.43	-7.11	-0.33	4.91e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs80319144	1.000	rs77150481	chr2:159213758	G/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.36	6.72	0.31	6.08e-11	Restless legs syndrome;
LUAD	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg04545296	chr12:48745243	ZNF641	0.41	10.27	0.45	3.04e-22	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.6	0.31	1.2e-10	Prudent dietary pattern;
LUAD	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.32	-0.34	1.23e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs7582720	0.945	rs72936875	chr2:203791912	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6445967	0.530	rs2090238	chr3:58350770	C/T	cg13750441	chr3:58318267	PXK	-0.32	-6.4	-0.3	4.23e-10	Platelet count;
LUAD	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	12.71	0.53	1.45e-31	Exhaled nitric oxide output;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25332325	chr10:71906362	TYSND1	-0.58	-7.01	-0.32	9.71e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg11247378	chr22:39784982	NA	-0.68	-11.1	-0.47	2.77e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg19767477	chr5:127420684	SLC12A2	-0.41	-6.4	-0.3	4.09e-10	Ileal carcinoids;
LUAD	cis	rs9560113	0.556	rs9560128	chr13:112221924	A/G	cg10483660	chr13:112241077	NA	0.48	9.85	0.43	9.37e-21	Menarche (age at onset);
LUAD	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg10792982	chr14:105748885	BRF1	0.46	9.93	0.43	5.21e-21	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg18187862	chr3:45730750	SACM1L	0.5	7.81	0.36	4.58e-14	Primary sclerosing cholangitis;
LUAD	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg20587970	chr11:113659929	NA	1.08	15.21	0.59	5.49e-42	Hip circumference adjusted for BMI;
LUAD	trans	rs4650994	0.571	rs35758545	chr1:178511924	C/T	cg05059571	chr16:84539110	KIAA1609	0.46	6.95	0.32	1.37e-11	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs457287	0.772	rs412457	chr9:4825277	C/G	cg14182974	chr9:4791918	RCL1	-0.47	-6.36	-0.3	5.28e-10	Platelet count;
LUAD	cis	rs494562	0.892	rs683218	chr6:86118584	A/G	cg17966619	chr6:86160162	NT5E	0.66	7.89	0.36	2.59e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg09060608	chr5:178986726	RUFY1	-0.73	-12.59	-0.52	4.25e-31	Lung cancer;
LUAD	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg14343924	chr8:8086146	FLJ10661	0.43	6.47	0.3	2.76e-10	Mood instability;
LUAD	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg03433033	chr1:76189801	ACADM	0.86	17.43	0.65	1.19e-51	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg21231944	chr12:82153410	PPFIA2	-0.36	-6.56	-0.3	1.62e-10	Resting heart rate;
LUAD	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06022373	chr22:39101656	GTPBP1	0.46	7.21	0.33	2.59e-12	Menopause (age at onset);
LUAD	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg04450456	chr4:17643702	FAM184B	0.37	6.95	0.32	1.39e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12369179	1.000	rs12369179	chr12:122963550	C/T	cg18578876	chr12:123200353	GPR109B	-1.08	-9.92	-0.43	5.54e-21	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
LUAD	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.84e-26	Alzheimer's disease (late onset);
LUAD	cis	rs6960043	0.818	rs10950550	chr7:15063923	T/G	cg19272540	chr7:15055459	NA	0.38	8.28	0.37	1.58e-15	Type 2 diabetes;
LUAD	cis	rs55665837	1.000	rs2305306	chr11:14534999	T/A	cg19336497	chr11:14380999	RRAS2	-0.49	-9.58	-0.42	8.35e-20	Vitamin D levels;
LUAD	trans	rs8073060	0.586	rs226090	chr17:34034059	C/T	cg19694781	chr19:47549865	TMEM160	-1.22	-18.88	-0.68	3.96e-58	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	trans	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg16724585	chr3:197361211	NA	-0.47	-7.19	-0.33	2.94e-12	Pancreatic cancer;
LUAD	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg05373962	chr22:49881684	NA	-0.5	-10.6	-0.46	1.87e-23	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg18196295	chr10:418757	DIP2C	0.47	7.71	0.35	9.3e-14	Psychosis in Alzheimer's disease;
LUAD	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg11871910	chr12:69753446	YEATS4	0.7	12.08	0.51	4.52e-29	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs17152411	1.000	rs17152381	chr10:126592903	T/G	cg07906193	chr10:126599966	NA	0.53	7.6	0.35	1.95e-13	Height;
LUAD	trans	rs9929218	0.953	rs12930910	chr16:68762520	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-15.36	-0.6	1.25e-42	Colorectal cancer;
LUAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg22764044	chr5:178986830	RUFY1	-0.6	-10.76	-0.46	5e-24	Lung cancer;
LUAD	cis	rs367943	1.000	rs348961	chr5:112819944	A/C	cg12552261	chr5:112820674	MCC	-0.62	-9.99	-0.44	3.06e-21	Type 2 diabetes;
LUAD	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg00666640	chr1:248458726	OR2T12	0.3	7.21	0.33	2.67e-12	Common traits (Other);
LUAD	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg11266682	chr4:10021025	SLC2A9	0.67	15.52	0.6	2.67e-43	Bone mineral density;
LUAD	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg11833968	chr6:79620685	NA	-0.44	-8.1	-0.37	5.88e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7119038	0.818	rs11217042	chr11:118682528	G/A	cg19308663	chr11:118741387	NA	0.43	6.41	0.3	3.97e-10	Sjögren's syndrome;
LUAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg22963979	chr7:1858916	MAD1L1	0.71	12.65	0.52	2.54e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs10823500	0.604	rs10740329	chr10:71941253	A/T	cg02100629	chr10:71892760	AIFM2	0.34	7.19	0.33	3.05e-12	Blood protein levels;
LUAD	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg22105103	chr4:187893119	NA	0.53	11.55	0.49	5.35e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11078597	0.731	rs12946666	chr17:1651304	C/G	cg18436246	chr17:1640651	WDR81	0.78	12.63	0.52	3e-31	Serum albumin level;
LUAD	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg24558204	chr6:135376177	HBS1L	0.46	8.56	0.38	2.11e-16	Red blood cell count;
LUAD	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg20607287	chr7:12443886	VWDE	-0.52	-6.67	-0.31	8.13e-11	Coronary artery disease;
LUAD	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg03714773	chr7:91764589	CYP51A1	0.27	6.46	0.3	2.89e-10	Breast cancer;
LUAD	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18876405	chr7:65276391	NA	-0.46	-7.44	-0.34	5.78e-13	Aortic root size;
LUAD	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg08859206	chr1:53392774	SCP2	0.59	10.66	0.46	1.19e-23	Monocyte count;
LUAD	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7107174	1.000	rs11237438	chr11:77998488	T/C	cg19901956	chr11:77921274	USP35	-0.53	-6.86	-0.32	2.5e-11	Testicular germ cell tumor;
LUAD	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg00701064	chr4:6280414	WFS1	0.64	14.06	0.56	3.93e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg21475434	chr5:93447410	FAM172A	0.76	8.62	0.39	1.35e-16	Diabetic retinopathy;
LUAD	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg12311346	chr5:56204834	C5orf35	-0.91	-13.39	-0.55	2.46e-34	Initial pursuit acceleration;
LUAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.14	-0.37	4.61e-15	Alzheimer's disease;
LUAD	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg09491104	chr22:46646882	C22orf40	-0.57	-11.09	-0.47	2.85e-25	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11769966	chr7:140396384	LOC100134713;NDUFB2	-0.41	-6.43	-0.3	3.51e-10	Height;
LUAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-6.98	-0.32	1.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs8002861	0.664	rs9567292	chr13:44444816	A/G	cg17145862	chr1:211918768	LPGAT1	0.65	13.15	0.54	2.33e-33	Leprosy;
LUAD	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg04352962	chr1:209979756	IRF6	0.49	6.37	0.3	4.98e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs295140	0.546	rs295137	chr2:201150040	C/T	cg23649088	chr2:200775458	C2orf69	0.46	7.89	0.36	2.53e-14	QT interval;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg01162436	chr10:15902292	FAM188A	-0.39	-6.58	-0.3	1.4e-10	Subcortical brain region volumes;
LUAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.77	-0.43	1.88e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg08470875	chr2:26401718	FAM59B	-0.57	-8.07	-0.37	7.48e-15	Gut microbiome composition (summer);
LUAD	cis	rs12620999	0.838	rs7589198	chr2:237967615	C/T	cg23555395	chr2:238036564	NA	0.5	7.82	0.36	4.12e-14	Systemic lupus erythematosus;
LUAD	cis	rs877282	0.786	rs10904558	chr10:797509	C/T	cg06581033	chr10:766294	NA	-0.52	-7.37	-0.34	9.33e-13	Uric acid levels;
LUAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.9	0.43	6.13e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg00495681	chr13:53174319	NA	0.5	9.11	0.4	3.4e-18	Lewy body disease;
LUAD	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg00784671	chr22:46762841	CELSR1	-0.63	-7.87	-0.36	3.04e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg01620082	chr3:125678407	NA	-0.61	-7.28	-0.33	1.65e-12	Depression;
LUAD	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg17366294	chr4:99064904	C4orf37	0.47	8.32	0.38	1.19e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg04455712	chr21:45112962	RRP1B	0.43	8.65	0.39	1.11e-16	Mean corpuscular volume;
LUAD	cis	rs3106136	0.900	rs13142645	chr4:95208714	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.14	-0.37	4.32e-15	Capecitabine sensitivity;
LUAD	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg11266682	chr4:10021025	SLC2A9	0.55	11.79	0.5	6.33e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg18512352	chr11:47633146	NA	-0.5	-8.89	-0.4	1.76e-17	Subjective well-being;
LUAD	cis	rs3784262	0.739	rs1550574	chr15:58213368	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.42	-8.44	-0.38	5.1e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg24675056	chr1:15929824	NA	0.49	8.5	0.38	3.32e-16	Systolic blood pressure;
LUAD	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg18402987	chr7:1209562	NA	0.66	6.65	0.31	8.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	12.39	0.52	2.73e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9796	0.621	rs2899013	chr15:41492283	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.44	-8.01	-0.36	1.15e-14	Menopause (age at onset);
LUAD	trans	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.22	-0.37	2.59e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06873352	chr17:61820015	STRADA	0.83	18.64	0.67	4.83e-57	Prudent dietary pattern;
LUAD	cis	rs36051895	0.664	rs7857081	chr9:5096728	G/A	cg02405213	chr9:5042618	JAK2	-0.43	-6.49	-0.3	2.4e-10	Pediatric autoimmune diseases;
LUAD	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg04842962	chr6:43655489	MRPS18A	1.06	26.88	0.79	1.57e-93	IgG glycosylation;
LUAD	trans	rs9951602	0.541	rs56882694	chr18:76647010	C/T	cg02800362	chr5:177631904	HNRNPAB	0.93	14.47	0.58	7.44e-39	Obesity-related traits;
LUAD	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg16325326	chr1:53192061	ZYG11B	-0.51	-8.12	-0.37	5.03e-15	Monocyte count;
LUAD	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg13319975	chr6:146136371	FBXO30	-0.8	-13.53	-0.55	6.67e-35	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs921968	0.565	rs6761437	chr2:219598092	G/A	cg02176678	chr2:219576539	TTLL4	-0.59	-11.89	-0.5	2.42e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg01689657	chr7:91764605	CYP51A1	-0.29	-6.8	-0.31	3.58e-11	Breast cancer;
LUAD	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg13073564	chr4:8508604	NA	-0.54	-10.08	-0.44	1.45e-21	Response to antineoplastic agents;
LUAD	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.31	-6.97	-0.32	1.2e-11	Dupuytren's disease;
LUAD	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg27489772	chr12:121021490	NA	-0.54	-6.7	-0.31	6.58e-11	Type 1 diabetes nephropathy;
LUAD	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg17366294	chr4:99064904	C4orf37	0.6	10.2	0.44	5.25e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg25319279	chr11:5960081	NA	0.36	6.74	0.31	5.11e-11	DNA methylation (variation);
LUAD	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg16797656	chr11:68205561	LRP5	0.46	8.73	0.39	6.16e-17	Total body bone mineral density;
LUAD	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg08798685	chr6:27730294	NA	0.45	7.2	0.33	2.75e-12	Parkinson's disease;
LUAD	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg18129748	chr3:49941408	MST1R	-0.39	-6.37	-0.3	5.03e-10	Body mass index;
LUAD	trans	rs1997103	0.954	rs7811098	chr7:55413012	A/G	cg20935933	chr6:143382018	AIG1	0.55	7.8	0.35	4.76e-14	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs4660214	0.666	rs4617393	chr1:39940223	C/T	cg27567593	chr1:39956653	BMP8A	0.33	6.68	0.31	7.4e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg18180107	chr4:99064573	C4orf37	0.49	7.6	0.35	1.95e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1497406	0.744	rs7538966	chr1:16504549	T/C	cg20430773	chr1:16534157	ARHGEF19	0.4	6.79	0.31	3.81e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10979	0.965	rs9403508	chr6:143887857	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.29	-0.45	2.66e-22	Hypospadias;
LUAD	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg10434728	chr15:90938212	IQGAP1	-0.36	-6.94	-0.32	1.44e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg15448220	chr1:150897856	SETDB1	0.49	8.39	0.38	7.5e-16	Melanoma;
LUAD	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg23985595	chr17:80112537	CCDC57	-0.53	-9.65	-0.42	4.69e-20	Life satisfaction;
LUAD	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs6921919	0.848	rs6903823	chr6:28322296	A/G	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.46	-0.3	2.92e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.08	0.33	6.23e-12	Platelet count;
LUAD	cis	rs7851660	0.809	rs7022148	chr9:100660824	T/C	cg13688889	chr9:100608707	NA	-0.54	-9.17	-0.41	2.08e-18	Strep throat;
LUAD	cis	rs10992471	0.528	rs1924243	chr9:95224847	C/T	cg14631576	chr9:95140430	CENPP	-0.5	-10.18	-0.44	6.28e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs4638749	0.677	rs10189396	chr2:108829637	A/G	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.3	-0.33	1.48e-12	Blood pressure;
LUAD	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.27e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg21475434	chr5:93447410	FAM172A	0.73	8.37	0.38	8.53e-16	Diabetic retinopathy;
LUAD	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg20290983	chr6:43655470	MRPS18A	1.07	27.12	0.8	1.44e-94	IgG glycosylation;
LUAD	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06022373	chr22:39101656	GTPBP1	0.4	6.78	0.31	4.16e-11	Menopause (age at onset);
LUAD	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.49	-0.42	1.69e-19	Life satisfaction;
LUAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg24813613	chr7:1882135	MAD1L1	-0.45	-7.22	-0.33	2.36e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2050392	1.000	rs2265185	chr10:30691777	A/C	cg18806716	chr10:30721971	MAP3K8	-0.54	-10.66	-0.46	1.18e-23	Inflammatory bowel disease;
LUAD	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg00255919	chr5:131827918	IRF1	0.5	11.92	0.5	1.97e-28	Asthma (sex interaction);
LUAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.67e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg15704280	chr7:45808275	SEPT13	0.67	7.82	0.36	4.29e-14	Axial length;
LUAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg24642844	chr7:1081250	C7orf50	-0.98	-14.74	-0.58	5.83e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg20701182	chr2:24300061	SF3B14	0.93	13.9	0.56	1.97e-36	Lymphocyte counts;
LUAD	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg01874867	chr7:94954059	PON1	-0.48	-6.41	-0.3	3.81e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg02734326	chr4:10020555	SLC2A9	-0.5	-8.94	-0.4	1.19e-17	Bone mineral density;
LUAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02353165	chr6:42928485	GNMT	0.39	7.07	0.32	6.59e-12	Plasma homocysteine levels (post-methionine load test);
LUAD	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg21171335	chr12:122356390	WDR66	0.74	13.6	0.55	3.47e-35	Mean corpuscular volume;
LUAD	cis	rs2637266	0.714	rs7895605	chr10:78454207	G/A	cg18941641	chr10:78392320	NA	0.33	6.76	0.31	4.72e-11	Pulmonary function;
LUAD	trans	rs877282	0.853	rs7092805	chr10:756246	G/A	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg02869364	chr7:1081709	C7orf50	-0.5	-6.43	-0.3	3.45e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6987853	0.736	rs35295075	chr8:42428852	A/G	cg09913449	chr8:42400586	C8orf40	0.5	9.98	0.44	3.42e-21	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6138458	1.000	rs227629	chr20:24913551	G/T	cg26195577	chr20:24973756	C20orf3	0.96	16.3	0.62	1.07e-46	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7633770	0.786	rs950190	chr3:46683377	C/T	cg11219411	chr3:46661640	NA	0.58	12.86	0.53	3.49e-32	Coronary artery disease;
LUAD	cis	rs6901250	1.000	rs6901250	chr6:117114025	A/G	cg12892004	chr6:117198278	RFX6	-0.34	-7.06	-0.32	6.86e-12	C-reactive protein levels;
LUAD	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.44	-0.42	2.57e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6494488	0.500	rs72741327	chr15:64730822	G/C	cg08069370	chr15:64387884	SNX1	-0.76	-6.76	-0.31	4.65e-11	Coronary artery disease;
LUAD	cis	rs3091242	0.933	rs9645452	chr1:25668326	C/T	cg27572855	chr1:25598939	RHD	-0.54	-11.75	-0.5	8.98e-28	Erythrocyte sedimentation rate;
LUAD	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg18240062	chr17:79603768	NPLOC4	0.46	8.18	0.37	3.4e-15	Eye color traits;
LUAD	cis	rs2294693	0.634	rs728477	chr6:41015167	T/C	cg14769373	chr6:40998127	UNC5CL	-0.47	-7.44	-0.34	5.5e-13	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs7274811	0.681	rs158676	chr20:31974395	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.51	7.62	0.35	1.69e-13	Height;
LUAD	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg06544989	chr22:39130855	UNC84B	0.43	8.65	0.39	1.1e-16	Menopause (age at onset);
LUAD	trans	rs783540	0.934	rs1594511	chr15:83307063	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.44	-7.13	-0.33	4.42e-12	Schizophrenia;
LUAD	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg23277830	chr1:3704460	LRRC47	0.45	9.01	0.4	7e-18	Red cell distribution width;
LUAD	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg03806693	chr22:41940476	POLR3H	-0.78	-10.96	-0.47	8.67e-25	Vitiligo;
LUAD	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg25456477	chr12:86230367	RASSF9	0.32	6.47	0.3	2.75e-10	Major depressive disorder;
LUAD	cis	rs1045714	1.000	rs1045713	chr7:2653579	G/A	cg24848437	chr7:2645542	IQCE	0.76	8.6	0.39	1.56e-16	Urate levels in lean individuals;
LUAD	cis	rs1865721	0.804	rs4510115	chr18:73209635	G/A	cg26385618	chr18:73139727	C18orf62	-0.38	-6.99	-0.32	1.05e-11	Intelligence;
LUAD	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg25456477	chr12:86230367	RASSF9	0.33	6.68	0.31	7.71e-11	Major depressive disorder;
LUAD	cis	rs28595532	0.688	rs116173135	chr4:119721949	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.41	0.38	6.23e-16	Cannabis dependence symptom count;
LUAD	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg02269571	chr22:50332266	NA	-0.6	-9.09	-0.4	3.85e-18	Schizophrenia;
LUAD	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.82	-0.36	4.36e-14	Total body bone mineral density;
LUAD	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg17063962	chr7:91808500	NA	0.66	11.29	0.48	5.18e-26	Breast cancer;
LUAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg03188948	chr7:1209495	NA	0.81	9.85	0.43	9.21e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg00074818	chr8:8560427	CLDN23	0.64	9.74	0.43	2.36e-20	Obesity-related traits;
LUAD	cis	rs1018836	0.632	rs7002775	chr8:91476765	C/T	cg16814680	chr8:91681699	NA	0.63	10.48	0.45	5.37e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg18016565	chr1:150552671	MCL1	0.4	7.34	0.34	1.09e-12	Tonsillectomy;
LUAD	trans	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg18876405	chr7:65276391	NA	0.48	7.69	0.35	1.04e-13	Corneal structure;
LUAD	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg02038168	chr22:39784481	NA	0.58	9.59	0.42	7.8500000000000006e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.12	-30.11	-0.83	2.87e-107	Myeloid white cell count;
LUAD	cis	rs2455799	0.929	rs2044574	chr3:15849825	C/G	cg16303742	chr3:15540471	COLQ	-0.38	-6.58	-0.3	1.36e-10	Mean platelet volume;
LUAD	cis	rs7216064	1.000	rs56393562	chr17:65933918	C/T	cg08758996	chr17:66097529	LOC651250	0.46	7.08	0.33	6.15e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs2625529	0.730	rs982752	chr15:72145937	C/T	cg16672083	chr15:72433130	SENP8	-0.66	-12.01	-0.5	8.5e-29	Red blood cell count;
LUAD	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg21862992	chr11:68658383	NA	0.54	9.78	0.43	1.64e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg18402987	chr7:1209562	NA	0.81	9.95	0.44	4.29e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-6.99	-0.32	1.06e-11	Blood metabolite levels;
LUAD	cis	rs7975161	0.671	rs7313063	chr12:104602208	G/A	cg25273343	chr12:104657179	TXNRD1	-0.51	-7.59	-0.35	2.03e-13	Toenail selenium levels;
LUAD	cis	rs7677751	0.767	rs7676985	chr4:55064573	G/A	cg17187183	chr4:55093834	PDGFRA	0.43	6.82	0.31	3.17e-11	Corneal astigmatism;
LUAD	trans	rs9784649	0.760	rs17403440	chr5:25054004	C/T	cg08600765	chr20:34638493	LOC647979	-0.72	-10.39	-0.45	1.14e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11890956	chr21:40555474	PSMG1	-0.51	-8.71	-0.39	7.03e-17	Menarche (age at onset);
LUAD	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.99	0.47	6.87e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg13319975	chr6:146136371	FBXO30	0.64	11.0	0.47	6.18e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.52	-8.21	-0.37	2.71e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg27490568	chr2:178487706	NA	0.38	6.44	0.3	3.27e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.09	-0.33	5.78e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg25208724	chr1:156163844	SLC25A44	0.84	8.6	0.39	1.59e-16	Paclitaxel disposition in epithelial ovarian cancer;
LUAD	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg00757033	chr12:89920650	WDR51B	0.69	12.15	0.51	2.5e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg05043794	chr9:111880884	C9orf5	-0.44	-7.64	-0.35	1.47e-13	Menarche (age at onset);
LUAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg04025307	chr7:1156635	C7orf50	0.66	12.13	0.51	2.9e-29	Longevity;Endometriosis;
LUAD	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.41	-0.34	7.07e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg24578937	chr1:2090814	PRKCZ	0.78	16.37	0.62	5.48e-47	Height;
LUAD	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.57	-0.38	1.96e-16	Menopause (age at onset);
LUAD	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg27124370	chr19:33622961	WDR88	0.43	6.66	0.31	8.47e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs12936587	0.535	rs6502615	chr17:17612023	C/T	cg04398451	chr17:18023971	MYO15A	0.41	6.67	0.31	8e-11	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LUAD	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg10909506	chr17:38081995	ORMDL3	0.4	7.28	0.33	1.69e-12	Self-reported allergy;
LUAD	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg07967210	chr17:47022446	SNF8	0.35	6.4	0.3	4.22e-10	Type 2 diabetes;
LUAD	cis	rs9811920	0.535	rs704577	chr3:99487375	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.45	-8.52	-0.38	2.9e-16	Axial length;
LUAD	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.68	-0.39	8.5e-17	Alzheimer's disease (late onset);
LUAD	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg05340658	chr4:99064831	C4orf37	-0.45	-7.37	-0.34	8.8e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.49	7.77	0.35	6.06e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg24578937	chr1:2090814	PRKCZ	-0.51	-10.27	-0.45	3e-22	Height;
LUAD	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg07432352	chr17:45403706	C17orf57	0.44	8.45	0.38	4.57e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs34546498	1	rs34546498	chr6:26961280	C/T	cg06606381	chr12:133084897	FBRSL1	-1.18	-9.91	-0.43	5.99e-21	Breast cancer;
LUAD	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg14668632	chr7:2872130	GNA12	-0.75	-13.56	-0.55	4.86e-35	Height;
LUAD	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg11941060	chr3:133502564	NA	-0.42	-6.94	-0.32	1.48e-11	Iron status biomarkers;
LUAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg03647317	chr4:187891568	NA	-0.35	-6.56	-0.3	1.56e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg22166914	chr1:53195759	ZYG11B	-0.44	-7.62	-0.35	1.73e-13	Monocyte count;
LUAD	cis	rs7827545	1.000	rs6578232	chr8:135565690	G/A	cg17885191	chr8:135476712	NA	0.5	7.95	0.36	1.72e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs78487399	0.808	rs6708735	chr2:43731354	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.52	-0.3	1.98e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs500891	0.525	rs1170339	chr6:84031251	T/C	cg08257003	chr6:84140564	ME1	0.34	6.38	0.3	4.57e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.4	0.42	3.56e-19	Tonsillectomy;
LUAD	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.24	-0.51	1.08e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs243505	0.559	rs10215159	chr7:148479071	G/C	cg09806900	chr7:148480153	CUL1	0.52	8.93	0.4	1.32e-17	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.53	-9.33	-0.41	6.16e-19	Axial length;
LUAD	cis	rs13315871	1.000	rs13076951	chr3:58436703	C/T	cg20936604	chr3:58311152	NA	-0.67	-7.07	-0.33	6.51e-12	Cholesterol, total;
LUAD	cis	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-8.03	-0.36	9.45e-15	Neuroticism;
LUAD	cis	rs1595825	0.891	rs77029420	chr2:198651492	G/A	cg00982548	chr2:198649783	BOLL	-0.68	-8.9	-0.4	1.64e-17	Ulcerative colitis;
LUAD	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg20476274	chr7:133979776	SLC35B4	0.79	14.48	0.58	7.37e-39	Mean platelet volume;
LUAD	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg18833306	chr6:118973337	C6orf204	-0.52	-7.52	-0.34	3.27e-13	Diastolic blood pressure;
LUAD	trans	rs1493916	0.905	rs4799727	chr18:31393095	T/G	cg13755796	chr4:20253514	NA	-0.44	-7.51	-0.34	3.57e-13	Life satisfaction;
LUAD	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg07061783	chr6:25882402	NA	0.51	8.02	0.36	1.04e-14	Blood metabolite levels;
LUAD	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.39	7.48	0.34	4.44e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg27489772	chr12:121021490	NA	0.56	7.04	0.32	7.9e-12	Type 1 diabetes nephropathy;
LUAD	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1232027	0.656	rs836798	chr5:79985907	A/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.41	-6.5	-0.3	2.3e-10	Huntington's disease progression;
LUAD	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg07599136	chr5:415885	AHRR	0.77	8.69	0.39	8.04e-17	Fat distribution (HIV);
LUAD	cis	rs7771547	0.519	rs12190911	chr6:36378487	C/T	cg04289385	chr6:36355825	ETV7	-0.52	-7.61	-0.35	1.84e-13	Platelet distribution width;
LUAD	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg09509183	chr1:209979624	IRF6	0.52	6.63	0.31	1.04e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg21775007	chr8:11205619	TDH	0.49	8.68	0.39	8.37e-17	Retinal vascular caliber;
LUAD	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.07	-0.32	6.63e-12	Blood metabolite levels;
LUAD	cis	rs12348691	0.503	rs4743138	chr9:100614296	C/T	cg13688889	chr9:100608707	NA	0.63	10.29	0.45	2.58e-22	Alopecia areata;
LUAD	cis	rs17270561	0.609	rs4711093	chr6:25687895	T/C	cg25753631	chr6:25732923	NA	-0.39	-6.92	-0.32	1.66e-11	Iron status biomarkers;
LUAD	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	12.43	0.52	1.91e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs933688	0.527	rs10038090	chr5:90582456	C/G	cg17503389	chr5:90575422	NA	-0.59	-7.95	-0.36	1.7e-14	Smoking behavior;
LUAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg20607798	chr8:58055168	NA	0.58	7.41	0.34	6.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs11756438	0.547	rs2798327	chr6:119005353	C/T	cg18833306	chr6:118973337	C6orf204	0.5	9.03	0.4	6.35e-18	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.58	0.38	1.83e-16	Parkinson's disease;
LUAD	trans	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg06606381	chr12:133084897	FBRSL1	-0.89	-9.05	-0.4	5.25e-18	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg06740227	chr12:86229804	RASSF9	-0.41	-7.33	-0.34	1.19e-12	Major depressive disorder;
LUAD	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg20135002	chr11:47629003	NA	-0.41	-7.19	-0.33	3.02e-12	Subjective well-being;
LUAD	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg08219700	chr8:58056026	NA	0.5	7.19	0.33	2.94e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs3820068	0.655	rs72645826	chr1:15889741	A/G	cg13390004	chr1:15929781	NA	0.43	6.86	0.32	2.45e-11	Systolic blood pressure;
LUAD	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg23758822	chr17:41437982	NA	1.02	20.97	0.71	1.89e-67	Menopause (age at onset);
LUAD	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg07967210	chr17:47022446	SNF8	0.36	6.45	0.3	3.11e-10	Type 2 diabetes;
LUAD	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg07167872	chr1:205819463	PM20D1	0.52	9.49	0.42	1.71e-19	Menarche (age at onset);
LUAD	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg11057378	chr10:81107060	PPIF	0.39	7.1	0.33	5.3e-12	Height;
LUAD	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg18230493	chr5:56204884	C5orf35	0.98	14.08	0.57	3.26e-37	Initial pursuit acceleration;
LUAD	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg16680214	chr1:154839983	KCNN3	-0.63	-13.15	-0.54	2.3e-33	Prostate cancer;
LUAD	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.45	-8.04	-0.36	9.41e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg09658497	chr7:2847517	GNA12	-0.48	-8.86	-0.4	2.25e-17	Height;
LUAD	cis	rs4692589	0.581	rs12646523	chr4:170944698	C/T	cg19918862	chr4:170955249	NA	0.33	6.72	0.31	5.92e-11	Anxiety disorder;
LUAD	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg12483005	chr1:23474871	LUZP1	0.52	9.12	0.41	2.97e-18	Height;
LUAD	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg24801067	chr17:62843696	NA	-0.49	-7.42	-0.34	6.48e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.39	6.41	0.3	3.91e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg06453172	chr10:134556979	INPP5A	-0.78	-11.16	-0.48	1.66e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs999737	0.821	rs71423314	chr14:68988664	C/G	cg04147497	chr14:69052728	RAD51L1	-0.49	-7.45	-0.34	5.33e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.53	-0.34	3.18e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg23281280	chr6:28129359	ZNF389	0.46	6.58	0.3	1.39e-10	Parkinson's disease;
LUAD	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg05368731	chr17:41323189	NBR1	0.96	20.39	0.7	7.37e-65	Menopause (age at onset);
LUAD	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg09945482	chr18:12777974	NA	0.54	6.8	0.31	3.53e-11	Inflammatory skin disease;
LUAD	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg18105134	chr13:113819100	PROZ	-0.81	-14.44	-0.57	1.02e-38	Platelet distribution width;
LUAD	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.45	-8.93	-0.4	1.3e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11622475	1.000	rs11622475	chr14:104509076	C/T	cg12183467	chr14:104352244	NA	-0.37	-6.37	-0.3	4.84e-10	Bipolar disorder;
LUAD	cis	rs10760279	0.584	rs10760280	chr9:126112812	A/G	cg14503395	chr9:126128745	CRB2	0.44	7.2	0.33	2.83e-12	Body mass index;
LUAD	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg03354898	chr7:1950403	MAD1L1	0.34	6.46	0.3	2.87e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg22875332	chr1:76189707	ACADM	0.88	16.55	0.63	8.9e-48	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg05896524	chr21:47604654	C21orf56	0.55	9.07	0.4	4.53e-18	Testicular germ cell tumor;
LUAD	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.33	-7.13	-0.33	4.48e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs494562	0.892	rs522129	chr6:86116381	A/G	cg21730993	chr6:86159210	NT5E	0.73	8.25	0.37	2.06e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg04827223	chr11:72435913	ARAP1	-0.57	-8.48	-0.38	3.81e-16	Type 2 diabetes;
LUAD	cis	rs1865721	1.000	rs8091890	chr18:73197242	T/C	cg26385618	chr18:73139727	C18orf62	-0.41	-7.41	-0.34	7e-13	Intelligence;
LUAD	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg19792802	chr11:65647270	CTSW	-0.42	-6.58	-0.3	1.36e-10	Crohn's disease;
LUAD	cis	rs35123781	0.696	rs7703195	chr5:139071632	G/A	cg10513866	chr5:139070639	NA	0.54	8.82	0.39	3.01e-17	Schizophrenia;
LUAD	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg07936489	chr17:37558343	FBXL20	-0.46	-7.34	-0.34	1.08e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.0	-0.36	1.2e-14	Diabetic kidney disease;
LUAD	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06022373	chr22:39101656	GTPBP1	0.45	7.59	0.35	2.09e-13	Menopause (age at onset);
LUAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg20607798	chr8:58055168	NA	0.52	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.21	0.33	2.67e-12	Motion sickness;
LUAD	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18876405	chr7:65276391	NA	0.55	9.26	0.41	1.03e-18	Aortic root size;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg16755220	chr16:12070685	RUNDC2A	-0.41	-6.47	-0.3	2.66e-10	Vertical cup-disc ratio;
LUAD	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.76	9.66	0.43	4.5e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg00321850	chr1:175162397	KIAA0040	0.55	11.9	0.5	2.32e-28	Alcohol dependence;
LUAD	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg26513180	chr16:89883248	FANCA	0.78	7.17	0.33	3.47e-12	Skin colour saturation;
LUAD	cis	rs62238980	0.614	rs17683448	chr22:32487744	C/T	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.79	-0.43	1.59e-20	Alzheimer's disease;
LUAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs870825	0.616	rs6552805	chr4:185637894	C/A	cg04058563	chr4:185651563	MLF1IP	0.88	14.04	0.56	4.87e-37	Blood protein levels;
LUAD	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg10909506	chr17:38081995	ORMDL3	0.38	6.59	0.31	1.32e-10	Self-reported allergy;
LUAD	cis	rs56283067	0.847	rs10456535	chr6:44692758	G/A	cg20913747	chr6:44695427	NA	-0.44	-7.45	-0.34	5.16e-13	Total body bone mineral density;
LUAD	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.73	-0.31	5.58e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg05425664	chr17:57184151	TRIM37	-0.43	-7.72	-0.35	8.77e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg13565492	chr6:43139072	SRF	-0.72	-9.31	-0.41	6.88e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs4714291	0.674	rs3008837	chr6:40046725	C/T	cg02267698	chr19:7991119	CTXN1	-0.47	-7.37	-0.34	9.15e-13	Strep throat;
LUAD	cis	rs3862260	1.000	rs3862260	chr1:120160789	G/A	cg16322792	chr1:120165303	ZNF697	0.61	15.06	0.59	2.54e-41	Systemic lupus erythematosus;
LUAD	cis	rs986417	0.681	rs1254329	chr14:60912870	G/A	cg27398547	chr14:60952738	C14orf39	-0.61	-7.56	-0.34	2.6e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs7536201	1.000	rs2135755	chr1:25302495	G/A	cg23273869	chr1:25296894	NA	-0.38	-7.83	-0.36	3.94e-14	Psoriasis vulgaris;
LUAD	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg06552810	chr11:31128660	NA	-0.34	-6.59	-0.31	1.33e-10	Red blood cell count;
LUAD	cis	rs892085	0.681	rs7246673	chr19:10876841	T/G	cg17710535	chr19:10819994	QTRT1	0.37	6.76	0.31	4.47e-11	Psoriasis vulgaris;Psoriasis;
LUAD	cis	rs9807989	0.507	rs1592458	chr2:103031749	A/T	cg03938978	chr2:103052716	IL18RAP	0.44	10.14	0.44	8.64e-22	Asthma;
LUAD	cis	rs1535500	1.000	rs35099099	chr6:39284857	G/A	cg03252829	chr6:39282164	KCNK17	-0.31	-6.35	-0.3	5.48e-10	Type 2 diabetes;
LUAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg15242686	chr22:24348715	GSTTP1	0.41	7.06	0.32	6.82e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg11344533	chr11:111475393	SIK2	0.36	6.47	0.3	2.69e-10	Primary sclerosing cholangitis;
LUAD	cis	rs3204270	0.714	rs7503307	chr17:79674929	C/G	cg18367735	chr17:79674897	NA	0.54	6.83	0.31	3.05e-11	Dental caries;
LUAD	cis	rs7216064	0.953	rs11868959	chr17:65840810	T/C	cg08758996	chr17:66097529	LOC651250	0.45	6.87	0.32	2.31e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg03676636	chr4:99064102	C4orf37	0.31	8.27	0.37	1.73e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11650494	0.710	rs11654557	chr17:47390136	A/G	cg11430096	chr6:110968061	CDK19	0.87	6.51	0.3	2.12e-10	Prostate cancer;
LUAD	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg18876405	chr7:65276391	NA	0.4	6.36	0.3	5.4e-10	Aortic root size;
LUAD	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg27572855	chr1:25598939	RHD	-0.53	-11.34	-0.48	3.4e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg25894440	chr7:65020034	NA	-0.63	-6.7	-0.31	6.86e-11	Diabetic kidney disease;
LUAD	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg23172400	chr8:95962367	TP53INP1	-0.38	-9.02	-0.4	6.69e-18	Type 2 diabetes;
LUAD	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg09509183	chr1:209979624	IRF6	0.59	8.06	0.36	8.04e-15	Cleft lip with or without cleft palate;
LUAD	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg04703951	chr17:43578652	NA	-0.43	-7.03	-0.32	8.59e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4889855	0.614	rs6565694	chr17:78501101	T/C	cg16591659	chr17:78472290	NA	-0.53	-8.09	-0.37	6.38e-15	Fractional excretion of uric acid;
LUAD	cis	rs910873	0.505	rs6059969	chr20:33245284	T/C	cg16810054	chr20:33298113	TP53INP2	-0.52	-7.63	-0.35	1.53e-13	Melanoma;
LUAD	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg17264618	chr3:40429014	ENTPD3	-0.4	-8.77	-0.39	4.3e-17	Renal cell carcinoma;
LUAD	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg07741184	chr6:167504864	NA	0.29	6.83	0.32	2.96e-11	Crohn's disease;
LUAD	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg05187965	chr10:45406764	TMEM72	-0.48	-9.68	-0.43	3.66e-20	Mean corpuscular volume;
LUAD	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18876405	chr7:65276391	NA	0.57	9.38	0.42	3.98e-19	Aortic root size;
LUAD	cis	rs72681920	0.881	rs28914770	chr4:100233892	C/T	cg12011299	chr4:100065546	ADH4	-0.6	-6.37	-0.3	4.81e-10	Alcohol dependence;
LUAD	cis	rs9462027	0.540	rs9469867	chr6:34742449	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.69	-0.39	8e-17	Systemic lupus erythematosus;
LUAD	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.39	-6.55	-0.3	1.72e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08677398	chr8:58056175	NA	0.47	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg03216991	chr17:2415620	METT10D	-0.69	-6.52	-0.3	1.96e-10	Type 2 diabetes;
LUAD	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg25324976	chr17:61989376	CSHL1	0.36	6.99	0.32	1.06e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	9.89	0.43	6.91e-21	Ileal carcinoids;
LUAD	cis	rs7572644	0.640	rs4665392	chr2:28029649	A/G	cg27432699	chr2:27873401	GPN1	0.42	6.37	0.3	4.89e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUAD	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg15468180	chr1:107600409	PRMT6	0.37	6.46	0.3	2.88e-10	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg03563238	chr19:33554763	RHPN2	-0.39	-9.06	-0.4	4.91e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg14092988	chr3:52407081	DNAH1	0.37	7.49	0.34	4.02e-13	Bipolar disorder;
LUAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg22907277	chr7:1156413	C7orf50	0.7	8.93	0.4	1.27e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11756438	0.572	rs1857312	chr6:119001526	A/C	cg21191810	chr6:118973309	C6orf204	0.49	9.38	0.42	3.9e-19	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2455799	0.613	rs7642876	chr3:15883094	A/G	cg16303742	chr3:15540471	COLQ	-0.52	-9.64	-0.42	5.03e-20	Mean platelet volume;
LUAD	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg11766577	chr21:47581405	C21orf56	-0.46	-7.88	-0.36	2.83e-14	Testicular germ cell tumor;
LUAD	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg25344623	chr2:136566232	LCT	0.34	6.69	0.31	7.3e-11	Mosquito bite size;
LUAD	cis	rs9914988	0.887	rs11080072	chr17:27081160	G/T	cg02049041	chr17:27085579	C17orf63	0.59	8.03	0.36	9.42e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg00383909	chr3:49044727	WDR6	0.88	10.24	0.45	4.01e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	trans	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg06606381	chr12:133084897	FBRSL1	-1.11	-10.33	-0.45	1.84e-22	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7520050	0.966	rs61102033	chr1:46382441	G/T	cg06784218	chr1:46089804	CCDC17	-0.3	-6.35	-0.3	5.43e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs4588572	0.644	rs11742212	chr5:77779033	G/A	cg11547950	chr5:77652471	NA	-0.62	-10.18	-0.44	6.31e-22	Triglycerides;
LUAD	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.08	14.83	0.58	2.31e-40	Lung cancer in ever smokers;
LUAD	cis	rs7582720	0.943	rs72934734	chr2:203739970	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.45	0.42	2.39e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9467160	1.000	rs10946700	chr6:24442158	G/T	cg16211469	chr6:24423932	MRS2	0.43	7.02	0.32	9.15e-12	Liver enzyme levels;
LUAD	trans	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg24644049	chr4:85504048	CDS1	0.89	7.43	0.34	6.14e-13	Skin colour saturation;
LUAD	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg23985595	chr17:80112537	CCDC57	0.52	9.54	0.42	1.11e-19	Life satisfaction;
LUAD	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-8.22	-0.37	2.47e-15	Major depressive disorder;
LUAD	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.58	-9.6	-0.42	6.88e-20	Glomerular filtration rate;
LUAD	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg15412446	chr2:106886593	NA	-0.85	-16.8	-0.63	7.01e-49	Facial morphology (factor 23);
LUAD	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.28	-0.33	1.68e-12	Reticulocyte count;
LUAD	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg23803603	chr1:2058230	PRKCZ	-0.43	-7.38	-0.34	8.69e-13	Height;
LUAD	cis	rs77861329	0.748	rs735768	chr3:52174970	A/C	cg08692210	chr3:52188851	WDR51A	0.54	7.01	0.32	9.58e-12	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg11645453	chr3:52864694	ITIH4	0.39	7.64	0.35	1.42e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg18451016	chr1:38461880	NA	0.45	8.63	0.39	1.28e-16	Coronary artery disease;
LUAD	cis	rs7487075	0.619	rs4076247	chr12:46833450	A/C	cg23829395	chr12:46796953	NA	0.32	7.01	0.32	9.45e-12	Itch intensity from mosquito bite;
LUAD	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23583168	chr7:148888333	NA	1.03	25.42	0.78	3.34e-87	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg17063962	chr7:91808500	NA	0.68	12.19	0.51	1.64e-29	Breast cancer;
LUAD	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg17372223	chr3:52568218	NT5DC2	-0.39	-7.14	-0.33	4.1e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9427116	0.502	rs7531982	chr1:154596122	A/T	cg17218026	chr1:154582156	ADAR	0.48	9.21	0.41	1.53e-18	Blood protein levels;
LUAD	cis	rs938554	0.784	rs11722229	chr4:9980697	C/A	cg00071950	chr4:10020882	SLC2A9	0.53	8.36	0.38	9e-16	Blood metabolite levels;
LUAD	cis	rs12210905	0.688	rs114157955	chr6:27329878	C/T	cg08851530	chr6:28072375	NA	1.09	7.97	0.36	1.45e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg20628663	chr10:43360327	NA	-0.72	-11.0	-0.47	6.12e-25	Blood protein levels;
LUAD	cis	rs12208915	0.945	rs12214796	chr6:79561068	T/C	cg11833968	chr6:79620685	NA	0.51	6.37	0.3	4.89e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs877282	0.853	rs11593836	chr10:756715	G/A	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg15309053	chr8:964076	NA	0.42	8.76	0.39	4.63e-17	Schizophrenia;
LUAD	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg16049864	chr8:95962084	TP53INP1	-0.41	-7.83	-0.36	3.96e-14	Type 2 diabetes;
LUAD	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg17644776	chr2:200775616	C2orf69	0.47	8.04	0.36	9.27e-15	Systolic blood pressure;
LUAD	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg12193833	chr17:30244370	NA	-0.58	-6.95	-0.32	1.35e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs17532515	0.628	rs6840266	chr4:141479999	T/C	cg09181644	chr4:141490428	UCP1	0.33	7.25	0.33	2.03e-12	Select biomarker traits;
LUAD	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.48	-0.38	3.74e-16	Height;
LUAD	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-7.02	-0.32	9e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs1561288	0.559	rs13428823	chr2:25373298	G/A	cg10045137	chr2:25383940	POMC	0.36	7.19	0.33	2.93e-12	Body mass index;
LUAD	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg20628663	chr10:43360327	NA	-0.74	-11.25	-0.48	7.59e-26	Blood protein levels;
LUAD	trans	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg19894588	chr14:64061835	NA	0.5	7.8	0.35	4.85e-14	Glioblastoma;Glioma;
LUAD	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.82	0.31	3.12e-11	Depression;
LUAD	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg00958927	chr1:175162553	KIAA0040	0.25	6.35	0.3	5.54e-10	Alcohol dependence;
LUAD	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg27661571	chr11:113659931	NA	-0.68	-8.08	-0.37	6.72e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg02423579	chr7:2872169	GNA12	-0.76	-12.91	-0.53	2.2e-32	Height;
LUAD	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg22705602	chr4:152727874	NA	-0.42	-7.26	-0.33	1.88e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg27266060	chr8:22091797	NA	0.47	8.6	0.39	1.62e-16	Hypertriglyceridemia;
LUAD	trans	rs225245	0.817	rs225255	chr17:33955243	A/G	cg19694781	chr19:47549865	TMEM160	0.44	7.32	0.34	1.24e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs4629710	0.538	rs11754401	chr6:131582197	G/A	cg12606694	chr6:131520996	AKAP7	0.48	7.0	0.32	9.84e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg06074448	chr4:187884817	NA	-0.42	-8.59	-0.39	1.64e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.79	-0.31	3.79e-11	Diabetic kidney disease;
LUAD	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg24558204	chr6:135376177	HBS1L	0.46	7.91	0.36	2.22e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.52	0.46	3.87e-23	Lung cancer in ever smokers;
LUAD	cis	rs938554	0.571	rs4144	chr4:10016322	T/C	cg00071950	chr4:10020882	SLC2A9	0.61	10.17	0.44	7.2e-22	Blood metabolite levels;
LUAD	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg18190219	chr22:46762943	CELSR1	-0.46	-6.63	-0.31	1.04e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs11677416	1.000	rs1878321	chr2:113544434	A/G	cg27083787	chr2:113543245	IL1A	0.38	6.61	0.31	1.15e-10	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	8.23	0.37	2.4e-15	Breast cancer;
LUAD	cis	rs4006360	0.524	rs7219230	chr17:39286180	T/C	cg20663846	chr17:39254439	KRTAP4-8	0.39	8.62	0.39	1.37e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs9302635	0.513	rs13334151	chr16:72189727	A/C	cg23815491	chr16:72088622	HP	0.5	8.0	0.36	1.19e-14	Blood protein levels;
LUAD	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.47	-0.34	4.68e-13	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6426558	0.537	rs2102634	chr1:227324308	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.55	-8.94	-0.4	1.24e-17	Neutrophil percentage of white cells;
LUAD	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg06713675	chr4:122721982	EXOSC9	-0.81	-16.77	-0.63	9.24e-49	Type 2 diabetes;
LUAD	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg18138036	chr10:133769891	PPP2R2D	0.41	6.69	0.31	7.2e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg17200465	chr3:40428508	ENTPD3	0.27	6.71	0.31	6.31e-11	Renal cell carcinoma;
LUAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.51	-6.92	-0.32	1.63e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg20476274	chr7:133979776	SLC35B4	0.84	16.46	0.62	2.18e-47	Mean platelet volume;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16313264	chr11:57103491	SSRP1	-0.42	-6.55	-0.3	1.63e-10	Height;
LUAD	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg14664628	chr15:75095509	CSK	-0.46	-7.57	-0.35	2.41e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-7.72	-0.35	8.48e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg02269571	chr22:50332266	NA	-0.92	-9.79	-0.43	1.58e-20	Schizophrenia;
LUAD	cis	rs11048434	0.736	rs11048190	chr12:9104939	C/T	cg26114124	chr12:9217669	LOC144571	0.36	6.61	0.31	1.19e-10	Sjögren's syndrome;
LUAD	cis	rs7707921	0.587	rs55885053	chr5:81676162	G/A	cg15871215	chr5:81402204	ATG10	-0.51	-6.96	-0.32	1.29e-11	Breast cancer;
LUAD	cis	rs12912251	0.947	rs7177621	chr15:38999394	C/G	cg01338139	chr15:38987640	C15orf53	-0.55	-8.56	-0.38	2.07e-16	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg20790798	chr5:1857306	NA	-0.47	-7.97	-0.36	1.51e-14	Cardiovascular disease risk factors;
LUAD	cis	rs11167764	0.895	rs891986	chr5:141466080	C/G	cg08523384	chr5:141488047	NDFIP1	-0.46	-6.74	-0.31	5.23e-11	Crohn's disease;
LUAD	cis	rs9393692	0.620	rs9393697	chr6:26293841	C/T	cg13736514	chr6:26305472	NA	-0.53	-9.02	-0.4	6.77e-18	Educational attainment;
LUAD	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg04450456	chr4:17643702	FAM184B	0.4	7.98	0.36	1.38e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7677751	0.806	rs4864859	chr4:55090015	A/G	cg17187183	chr4:55093834	PDGFRA	0.51	8.63	0.39	1.23e-16	Corneal astigmatism;
LUAD	cis	rs7527798	0.592	rs6671969	chr1:207839667	C/T	cg09232269	chr1:207846808	CR1L	-0.35	-6.82	-0.31	3.11e-11	Erythrocyte sedimentation rate;
LUAD	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.4	-8.57	-0.38	2.03e-16	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs9302635	0.513	rs35460163	chr16:72177060	C/T	cg23815491	chr16:72088622	HP	0.47	7.51	0.34	3.48e-13	Blood protein levels;
LUAD	cis	rs7107174	1.000	rs6592772	chr11:78015563	A/C	cg02023728	chr11:77925099	USP35	0.52	7.74	0.35	7.53e-14	Testicular germ cell tumor;
LUAD	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg17063962	chr7:91808500	NA	0.69	12.37	0.52	3.38e-30	Breast cancer;
LUAD	cis	rs36715	1.000	rs36705	chr5:127554486	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.46	6.5	0.3	2.29e-10	Breast cancer;
LUAD	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg27432699	chr2:27873401	GPN1	-0.4	-6.88	-0.32	2.17e-11	Total body bone mineral density;
LUAD	cis	rs6563943	0.857	rs1833965	chr16:83636801	A/C	cg01935413	chr16:83636749	CDH13	-0.38	-7.13	-0.33	4.28e-12	Height;
LUAD	cis	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-7.58	-0.35	2.24e-13	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs7625357	1.000	rs7625357	chr3:169347832	C/T	cg14572252	chr3:169309425	MECOM	-0.37	-6.55	-0.3	1.63e-10	Childhood and early adolescence aggressive behavior;
LUAD	cis	rs7301016	0.948	rs12369985	chr12:62918780	A/G	cg11441379	chr12:63026424	NA	0.56	7.0	0.32	1.01e-11	IgG glycosylation;
LUAD	trans	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg26043149	chr18:55253948	FECH	-0.44	-7.17	-0.33	3.35e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg20673091	chr1:2541236	MMEL1	-0.4	-8.43	-0.38	5.56e-16	Ulcerative colitis;
LUAD	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg26924012	chr15:45694286	SPATA5L1	1.02	19.06	0.68	6.2e-59	Homoarginine levels;
LUAD	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg24848339	chr3:12840334	CAND2	0.49	10.3	0.45	2.39e-22	QRS complex (12-leadsum);
LUAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg16606324	chr3:10149918	C3orf24	0.71	11.72	0.5	1.16e-27	Alzheimer's disease;
LUAD	cis	rs757647	0.723	rs12653150	chr5:137770833	A/G	cg10676309	chr5:137685565	NA	0.42	7.49	0.34	3.97e-13	Menarche (age at onset);
LUAD	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg05425664	chr17:57184151	TRIM37	-0.42	-7.43	-0.34	6.09e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07157834	chr1:205819609	PM20D1	0.7	13.6	0.55	3.25e-35	Menarche (age at onset);
LUAD	trans	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg17712092	chr4:129076599	LARP1B	-0.75	-12.7	-0.53	1.56e-31	Eosinophil percentage of white cells;
LUAD	cis	rs7523050	0.730	rs77425121	chr1:109417677	C/A	cg08274380	chr1:109419600	GPSM2	0.74	6.82	0.31	3.13e-11	Fat distribution (HIV);
LUAD	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg04944784	chr2:26401820	FAM59B	-0.71	-9.92	-0.43	5.28e-21	Gut microbiome composition (summer);
LUAD	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg15485101	chr11:133734466	NA	-0.36	-7.96	-0.36	1.61e-14	Childhood ear infection;
LUAD	cis	rs1298062	0.605	rs10409679	chr19:50983930	C/T	cg11430371	chr19:50961752	MYBPC2	0.37	8.1	0.37	6.09e-15	Age of smoking initiation;
LUAD	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18876405	chr7:65276391	NA	-0.56	-9.44	-0.42	2.48e-19	Aortic root size;
LUAD	cis	rs6558530	0.587	rs6986102	chr8:1700640	C/G	cg19131313	chr8:1704013	NA	-0.42	-6.39	-0.3	4.31e-10	Systolic blood pressure;
LUAD	cis	rs2070488	0.662	rs7373930	chr3:38454931	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.52	7.84	0.36	3.72e-14	Electrocardiographic conduction measures;
LUAD	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg19318889	chr4:1322082	MAEA	0.46	7.51	0.34	3.5e-13	Obesity-related traits;
LUAD	cis	rs7107174	0.892	rs2512529	chr11:77977351	C/T	cg02023728	chr11:77925099	USP35	0.52	7.86	0.36	3.2e-14	Testicular germ cell tumor;
LUAD	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.84	-0.32	2.81e-11	Bipolar disorder;
LUAD	cis	rs4786125	0.519	rs1388805	chr16:6929947	C/T	cg03623568	chr16:6915990	A2BP1	-0.46	-9.39	-0.42	3.67e-19	Heart rate variability traits (SDNN);
LUAD	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg23982607	chr1:1823379	GNB1	0.45	7.68	0.35	1.11e-13	Body mass index;
LUAD	cis	rs9900062	0.560	rs11656678	chr17:62681505	G/A	cg02097616	chr17:62675921	NA	0.58	9.71	0.43	2.95e-20	QT interval;
LUAD	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg15704280	chr7:45808275	SEPT13	-0.54	-8.5	-0.38	3.29e-16	Height;
LUAD	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg18180107	chr4:99064573	C4orf37	0.43	6.99	0.32	1.08e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg05590025	chr7:65112418	INTS4L2	0.74	8.06	0.36	7.95e-15	Diabetic kidney disease;
LUAD	trans	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg18335740	chr13:41363409	SLC25A15	0.63	11.55	0.49	5.07e-27	Lewy body disease;
LUAD	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg08989290	chr16:615782	NHLRC4	0.31	6.72	0.31	5.75e-11	Height;
LUAD	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.25	0.33	2.06e-12	Menopause (age at onset);
LUAD	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg18016565	chr1:150552671	MCL1	-0.41	-7.16	-0.33	3.51e-12	Tonsillectomy;
LUAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg08742575	chr21:47604166	C21orf56	0.56	9.44	0.42	2.47e-19	Testicular germ cell tumor;
LUAD	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg15181151	chr6:150070149	PCMT1	0.44	8.95	0.4	1.12e-17	Lung cancer;
LUAD	cis	rs2281845	0.791	rs1325313	chr1:201076167	C/T	cg17810781	chr1:201082982	CACNA1S	0.36	6.42	0.3	3.67e-10	Permanent tooth development;
LUAD	trans	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg15147215	chr3:52552868	STAB1	-0.4	-7.18	-0.33	3.24e-12	Bipolar disorder;
LUAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg11814155	chr7:99998594	ZCWPW1	0.4	6.8	0.31	3.64e-11	Platelet count;
LUAD	cis	rs9462027	0.628	rs7742652	chr6:34667075	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.34	8.67	0.39	9.5e-17	Systemic lupus erythematosus;
LUAD	trans	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg14917512	chr19:3094685	GNA11	-0.37	-6.44	-0.3	3.29e-10	Aortic root size;
LUAD	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg00857998	chr1:205179979	DSTYK	0.4	6.48	0.3	2.57e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs926938	0.765	rs1884296	chr1:115235716	A/C	cg12756093	chr1:115239321	AMPD1	-0.41	-7.24	-0.33	2.2e-12	Autism;
LUAD	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	7.47	0.34	4.71e-13	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg24818145	chr4:99064322	C4orf37	0.44	7.01	0.32	9.3e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg21775007	chr8:11205619	TDH	0.37	6.37	0.3	4.98e-10	Neuroticism;
LUAD	cis	rs2625529	0.824	rs7170754	chr15:72218594	G/A	cg16672083	chr15:72433130	SENP8	-0.74	-12.37	-0.52	3.32e-30	Red blood cell count;
LUAD	cis	rs7274811	0.744	rs6141411	chr20:32157934	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.49	-7.63	-0.35	1.54e-13	Height;
LUAD	cis	rs9487051	0.735	rs351745	chr6:109529169	C/T	cg01475377	chr6:109611718	NA	0.42	7.88	0.36	2.74e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.17	0.33	3.47e-12	Lung cancer;
LUAD	cis	rs184065563	1	rs184065563	chr6:45144224	G/A	cg18551225	chr6:44695536	NA	-0.53	-8.39	-0.38	7.22e-16	Total body bone mineral density (age over 60);Total body bone mineral density;
LUAD	cis	rs12200560	0.505	rs211173	chr6:97070804	C/T	cg06623918	chr6:96969491	KIAA0776	0.46	7.05	0.32	7.27e-12	Coronary heart disease;
LUAD	cis	rs9902453	0.904	rs9905638	chr17:28261022	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.5	0.45	4.43e-23	Coffee consumption (cups per day);
LUAD	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg12935359	chr14:103987150	CKB	0.49	7.6	0.35	1.88e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.802	rs12369634	chr12:86406792	C/G	cg18827107	chr12:86230957	RASSF9	-0.46	-8.24	-0.37	2.13e-15	Major depressive disorder;
LUAD	cis	rs8044868	0.512	rs10048144	chr16:72052891	C/G	cg23815491	chr16:72088622	HP	0.49	8.6	0.39	1.62e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs8038465	0.622	rs17185294	chr15:73858415	C/T	cg15420318	chr15:73925796	NPTN	-0.44	-7.46	-0.34	4.87e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2455826	0.520	rs2455838	chr3:15760340	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.65	-0.31	8.93e-11	Inflammatory skin disease;
LUAD	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-7.43	-0.34	6.02e-13	Personality dimensions;
LUAD	cis	rs3772130	1.000	rs11721318	chr3:121429485	G/A	cg20356878	chr3:121714668	ILDR1	0.5	7.82	0.36	4.36e-14	Cognitive performance;
LUAD	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg18016565	chr1:150552671	MCL1	0.41	7.55	0.34	2.78e-13	Tonsillectomy;
LUAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00166722	chr3:10149974	C3orf24	0.72	11.23	0.48	8.98e-26	Alzheimer's disease;
LUAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg02524346	chr8:600233	NA	1.04	10.11	0.44	1.14e-21	IgG glycosylation;
LUAD	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg10523679	chr1:76189770	ACADM	0.9	15.75	0.61	2.67e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg20701182	chr2:24300061	SF3B14	0.53	6.42	0.3	3.66e-10	Lymphocyte counts;
LUAD	cis	rs427941	0.703	rs201442	chr7:101737627	C/T	cg06246474	chr7:101738831	CUX1	-0.41	-7.29	-0.33	1.53e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg17911788	chr17:44343683	NA	-0.52	-7.26	-0.33	1.87e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs863345	0.504	rs2022386	chr1:158563076	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.5	-0.3	2.25e-10	Pneumococcal bacteremia;
LUAD	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg18490616	chr2:88469792	THNSL2	0.8	8.36	0.38	9.13e-16	Plasma clusterin levels;
LUAD	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg03433033	chr1:76189801	ACADM	0.77	12.42	0.52	2.05e-30	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.55	-0.3	1.66e-10	Breast cancer;
LUAD	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg21918786	chr6:109611834	NA	-0.58	-10.87	-0.47	2.02e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs68170813	0.559	rs6967638	chr7:106929356	T/G	cg23024343	chr7:107201750	COG5	0.5	7.26	0.33	1.86e-12	Coronary artery disease;
LUAD	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg10755058	chr3:40428713	ENTPD3	0.46	8.43	0.38	5.51e-16	Renal cell carcinoma;
LUAD	cis	rs7587476	0.906	rs17487827	chr2:215644335	C/G	cg04004882	chr2:215674386	BARD1	0.52	6.38	0.3	4.79e-10	Neuroblastoma;
LUAD	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8010715	0.596	rs12435995	chr14:24589464	A/C	cg23112188	chr14:24563095	PCK2	-0.32	-6.45	-0.3	3.01e-10	IgG glycosylation;
LUAD	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.51	0.3	2.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg02527881	chr3:46936655	PTH1R	0.5	10.15	0.44	8.6e-22	Colorectal cancer;
LUAD	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.65	9.01	0.4	7.11e-18	Gut microbiome composition (summer);
LUAD	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	3.96e-11	Parkinson's disease;
LUAD	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg14558114	chr2:88469736	THNSL2	-0.44	-7.04	-0.32	7.81e-12	Response to metformin (IC50);
LUAD	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-7.62	-0.35	1.67e-13	Lung cancer;
LUAD	cis	rs6087990	0.814	rs2424895	chr20:31335978	C/T	cg13636640	chr20:31349939	DNMT3B	-0.76	-14.04	-0.56	4.93e-37	Ulcerative colitis;
LUAD	cis	rs12210905	0.688	rs12215878	chr6:27336844	G/C	cg08851530	chr6:28072375	NA	1.1	7.92	0.36	2.15e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs1478898	0.526	rs1478897	chr8:11395232	A/T	cg27411982	chr8:10470053	RP1L1	0.37	6.74	0.31	5.31e-11	Morning vs. evening chronotype;
LUAD	cis	rs7116495	1.000	rs1939245	chr11:71742532	C/T	cg07596299	chr11:71824057	C11orf51	-0.78	-6.59	-0.3	1.34e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg10755058	chr3:40428713	ENTPD3	-0.35	-6.5	-0.3	2.31e-10	Renal cell carcinoma;
LUAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.6	-0.31	1.22e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg27211696	chr2:191398769	TMEM194B	-0.58	-7.94	-0.36	1.88e-14	Diastolic blood pressure;
LUAD	cis	rs41271951	0.512	rs116666233	chr1:151056058	C/T	cg11822372	chr1:151115635	SEMA6C	-0.82	-6.97	-0.32	1.24e-11	Blood protein levels;
LUAD	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg09359103	chr1:154839909	KCNN3	-0.87	-17.29	-0.64	4.73e-51	Prostate cancer;
LUAD	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg09035930	chr12:129282057	SLC15A4	0.69	15.22	0.59	4.91e-42	Systemic lupus erythematosus;
LUAD	cis	rs9902453	0.899	rs1979572	chr17:28511978	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.64	0.39	1.15e-16	Coffee consumption (cups per day);
LUAD	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg00316803	chr15:76480434	C15orf27	0.4	7.61	0.35	1.78e-13	Blood metabolite levels;
LUAD	cis	rs7561273	0.609	rs10200844	chr2:24293363	A/C	cg20701182	chr2:24300061	SF3B14	0.41	6.85	0.32	2.59e-11	Quantitative traits;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg02842104	chr19:12251201	ZNF20	0.4	6.85	0.32	2.54e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs1497828	0.956	rs2810782	chr1:217544443	C/G	cg04411442	chr1:217543379	NA	0.38	6.9	0.32	1.91e-11	Dialysis-related mortality;
LUAD	cis	rs7937890	0.559	rs2034480	chr11:14466923	G/A	cg06199346	chr11:14280333	SPON1	-0.33	-6.53	-0.3	1.88e-10	Mitochondrial DNA levels;
LUAD	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.54	-9.19	-0.41	1.83e-18	Glomerular filtration rate;
LUAD	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg00717180	chr2:96193071	NA	-0.38	-7.01	-0.32	9.57e-12	Height;
LUAD	trans	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg24644049	chr4:85504048	CDS1	0.93	7.84	0.36	3.58e-14	Skin colour saturation;
LUAD	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-8.37	-0.38	8.28e-16	Monocyte percentage of white cells;
LUAD	cis	rs7254827	0.826	rs12978850	chr19:17222753	C/T	cg19418318	chr19:17219073	MYO9B	-0.56	-6.45	-0.3	3.12e-10	Mean platelet volume;
LUAD	cis	rs9902453	1.000	rs9891871	chr17:28370191	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.28	-0.41	8.99e-19	Coffee consumption (cups per day);
LUAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg03188948	chr7:1209495	NA	0.87	11.48	0.49	9.6800000000000007e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg17757837	chr7:157058334	UBE3C	0.47	8.43	0.38	5.65e-16	Body mass index;
LUAD	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg11057378	chr10:81107060	PPIF	0.36	6.82	0.31	3.21e-11	Height;
LUAD	cis	rs4604732	0.588	rs7549955	chr1:247628321	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.05	0.32	7.27e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg08132940	chr7:1081526	C7orf50	-0.77	-10.56	-0.46	2.79e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.3	-7.96	-0.36	1.56e-14	Total body bone mineral density;
LUAD	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg14343924	chr8:8086146	FLJ10661	0.43	6.63	0.31	1.05e-10	Joint mobility (Beighton score);
LUAD	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.62	0.31	1.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.45	-7.25	-0.33	2.05e-12	Resting heart rate;
LUAD	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg18827107	chr12:86230957	RASSF9	-0.53	-9.29	-0.41	8.42e-19	Major depressive disorder;
LUAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg22907277	chr7:1156413	C7orf50	0.68	7.94	0.36	1.78e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg00784671	chr22:46762841	CELSR1	-0.68	-8.19	-0.37	3.16e-15	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg24829409	chr8:58192753	C8orf71	-0.61	-9.22	-0.41	1.37e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg15133208	chr4:90757351	SNCA	0.44	6.81	0.31	3.44e-11	Neuroticism;
LUAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg04267008	chr7:1944627	MAD1L1	0.49	7.57	0.35	2.29e-13	Schizophrenia;
LUAD	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg26513180	chr16:89883248	FANCA	0.46	7.41	0.34	6.71e-13	Vitiligo;
LUAD	cis	rs1832871	0.672	rs13437296	chr6:158762819	A/C	cg07165851	chr6:158734300	TULP4	0.72	11.04	0.47	4.69e-25	Height;
LUAD	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.11	11.19	0.48	1.21e-25	Lung cancer in ever smokers;
LUAD	cis	rs912057	1.000	rs1294414	chr6:6740366	A/G	cg06612196	chr6:6737390	NA	0.56	12.69	0.53	1.73e-31	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs62238980	0.614	rs17683430	chr22:32487700	G/A	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg04896959	chr15:78267971	NA	0.6	11.54	0.49	5.72e-27	Coronary artery disease or large artery stroke;
LUAD	trans	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg03213289	chr20:61660250	NA	0.69	14.76	0.58	4.6e-40	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg05457628	chr5:178986728	RUFY1	0.68	11.56	0.49	4.91e-27	Lung cancer;
LUAD	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg00071950	chr4:10020882	SLC2A9	0.59	10.71	0.46	7.6e-24	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg19862616	chr7:65841803	NCRNA00174	1.05	26.15	0.79	2.14e-90	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs58106596	0.950	rs11695646	chr2:232584807	C/T	cg26500773	chr2:232646331	PDE6D	0.46	6.8	0.31	3.57e-11	White blood cell count;Lymphocyte counts;
LUAD	cis	rs4664304	0.629	rs62175466	chr2:160852308	C/T	cg23995753	chr2:160760732	LY75	-0.4	-6.87	-0.32	2.31e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.14	-0.33	4.05e-12	Breast cancer;
LUAD	cis	rs4713675	0.565	rs4713665	chr6:33674419	T/G	cg14003231	chr6:33640908	ITPR3	0.49	9.54	0.42	1.17e-19	Plateletcrit;
LUAD	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg11502198	chr6:26597334	ABT1	0.55	9.09	0.4	3.73e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg13854012	chr2:162103682	NA	-0.46	-9.02	-0.4	6.38e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	cis	rs7524258	0.934	rs6689453	chr1:7288384	C/T	cg07173049	chr1:7289937	CAMTA1	0.37	6.86	0.32	2.45e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs6489882	0.703	rs2285934	chr12:113351520	A/C	cg20102336	chr12:113376681	OAS3	-0.45	-7.08	-0.33	5.94e-12	Chronic lymphocytic leukemia;
LUAD	trans	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg18335740	chr13:41363409	SLC25A15	-0.57	-10.07	-0.44	1.58e-21	Lewy body disease;
LUAD	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg21709803	chr11:61594965	FADS2	-0.39	-7.07	-0.32	6.61e-12	Trans fatty acid levels;
LUAD	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg20701182	chr2:24300061	SF3B14	0.64	7.24	0.33	2.19e-12	Lymphocyte counts;
LUAD	cis	rs9614461	0.702	rs2294202	chr22:45738327	A/T	cg15911859	chr22:45810043	RIBC2;SMC1B	0.82	9.54	0.42	1.12e-19	Tonsillectomy;
LUAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg09033563	chr22:24373618	LOC391322	0.5	8.45	0.38	4.91e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg12483005	chr1:23474871	LUZP1	-0.51	-8.95	-0.4	1.15e-17	Height;
LUAD	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg10589385	chr1:150898437	SETDB1	0.45	8.3	0.37	1.41e-15	Melanoma;
LUAD	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg23950597	chr19:37808831	NA	0.56	6.82	0.31	3.07e-11	Coronary artery calcification;
LUAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg24642844	chr7:1081250	C7orf50	-0.95	-14.18	-0.57	1.28e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg02733842	chr7:1102375	C7orf50	-0.67	-10.07	-0.44	1.66e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs26868	0.740	rs26869	chr16:2248786	T/C	cg07587117	chr16:2239488	CASKIN1	0.39	7.3	0.33	1.4e-12	Height;
LUAD	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.78	0.35	5.55e-14	Bladder cancer;
LUAD	cis	rs7289126	1.000	rs7289126	chr22:38628306	A/C	cg25457927	chr22:38595422	NA	0.42	9.89	0.43	6.92e-21	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs10493773	1.000	rs10493774	chr1:86137963	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.51	-8.58	-0.39	1.81e-16	Urate levels in overweight individuals;
LUAD	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg25985355	chr7:65971099	NA	-0.35	-6.5	-0.3	2.29e-10	Aortic root size;
LUAD	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg06641503	chr3:48959341	ARIH2	0.36	6.41	0.3	3.78e-10	Menarche (age at onset);
LUAD	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	ch.11.42038R	chr11:967971	AP2A2	0.4	7.09	0.33	5.5e-12	Alzheimer's disease (late onset);
LUAD	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg00666640	chr1:248458726	OR2T12	0.32	7.71	0.35	9.24e-14	Common traits (Other);
LUAD	cis	rs1018836	0.828	rs7008172	chr8:91551613	C/T	cg16814680	chr8:91681699	NA	-0.57	-9.59	-0.42	7.72e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs62458065	1.000	rs79538247	chr7:32467792	A/G	cg20159608	chr7:32802032	NA	-0.47	-6.67	-0.31	7.95e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg15017067	chr4:17643749	FAM184B	-0.37	-7.1	-0.33	5.42e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg17366294	chr4:99064904	C4orf37	-0.51	-9.13	-0.41	2.88e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6076065	0.748	rs2236023	chr20:23373043	A/C	cg11657817	chr20:23433608	CST11	0.57	11.88	0.5	2.72e-28	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs11048434	0.612	rs7299653	chr12:9058993	A/T	cg04155231	chr12:9217510	LOC144571	0.35	6.46	0.3	2.92e-10	Sjögren's syndrome;
LUAD	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21659725	chr3:3221576	CRBN	-0.84	-17.61	-0.65	1.82e-52	Intelligence (multi-trait analysis);
LUAD	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg05082376	chr22:42548792	NA	-0.49	-8.89	-0.4	1.73e-17	Schizophrenia;
LUAD	cis	rs2637266	1.000	rs12262400	chr10:78386862	T/C	cg18941641	chr10:78392320	NA	0.35	7.29	0.33	1.52e-12	Pulmonary function;
LUAD	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg18490616	chr2:88469792	THNSL2	-0.43	-6.84	-0.32	2.76e-11	Response to metformin (IC50);
LUAD	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg01579765	chr21:45077557	HSF2BP	-0.63	-14.7	-0.58	8.47e-40	Mean corpuscular volume;
LUAD	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg11502198	chr6:26597334	ABT1	0.55	9.17	0.41	2.12e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg25324976	chr17:61989376	CSHL1	0.38	7.33	0.34	1.16e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg21427119	chr20:30132790	HM13	-0.35	-6.4	-0.3	4.06e-10	Mean corpuscular hemoglobin;
LUAD	trans	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg18187862	chr3:45730750	SACM1L	0.5	7.95	0.36	1.68e-14	Primary sclerosing cholangitis;
LUAD	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.68	-10.38	-0.45	1.22e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.58	-0.42	8.57e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg26384229	chr12:38710491	ALG10B	0.44	7.12	0.33	4.77e-12	Morning vs. evening chronotype;
LUAD	cis	rs4356932	1.000	rs4859588	chr4:76943677	C/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.48	-0.3	2.54e-10	Blood protein levels;
LUAD	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg06784218	chr1:46089804	CCDC17	0.52	11.42	0.49	1.69e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2735413	0.875	rs11649082	chr16:78082256	C/T	cg04733911	chr16:78082701	NA	-0.35	-8.21	-0.37	2.74e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg03929089	chr4:120376271	NA	-0.52	-7.67	-0.35	1.2e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6987853	0.787	rs2974346	chr8:42401205	T/C	cg09913449	chr8:42400586	C8orf40	0.53	10.68	0.46	9.84e-24	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg16325326	chr1:53192061	ZYG11B	0.68	13.18	0.54	1.8e-33	Monocyte count;
LUAD	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg24069376	chr3:38537580	EXOG	0.37	8.42	0.38	5.87e-16	Electrocardiographic conduction measures;
LUAD	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.91	0.4	1.5e-17	Cognitive ability;
LUAD	cis	rs2235642	0.621	rs2667665	chr16:1569524	A/C	cg26528668	chr16:1614120	IFT140	0.4	6.59	0.31	1.28e-10	Coronary artery disease;
LUAD	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg17644776	chr2:200775616	C2orf69	-0.53	-7.28	-0.33	1.66e-12	Schizophrenia;
LUAD	cis	rs76878669	0.538	rs73489638	chr11:66127639	C/T	cg18002602	chr11:66138449	SLC29A2	-0.49	-10.64	-0.46	1.39e-23	Educational attainment (years of education);
LUAD	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.51	8.61	0.39	1.51e-16	Electrocardiographic conduction measures;
LUAD	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg05342682	chr7:94953680	PON1	-0.53	-7.44	-0.34	5.58e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg09796270	chr17:17721594	SREBF1	-0.37	-6.95	-0.32	1.35e-11	Total body bone mineral density;
LUAD	cis	rs6500395	1.000	rs9938633	chr16:48682093	G/C	cg04672837	chr16:48644449	N4BP1	0.39	6.77	0.31	4.19e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2274273	0.840	rs3742569	chr14:55818706	T/C	cg04306507	chr14:55594613	LGALS3	0.43	8.92	0.4	1.45e-17	Protein biomarker;
LUAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg08888203	chr3:10149979	C3orf24	0.67	11.62	0.49	2.73e-27	Alzheimer's disease;
LUAD	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg03563238	chr19:33554763	RHPN2	-0.39	-9.17	-0.41	2.14e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.44	-6.39	-0.3	4.45e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2455601	0.671	rs10840135	chr11:8879794	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-8.42	-0.38	5.85e-16	Schizophrenia;
LUAD	cis	rs6835098	1.000	rs1054496	chr4:174089080	A/G	cg08422745	chr4:174089978	GALNT7	-0.96	-17.97	-0.66	4.63e-54	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg26022315	chr17:47021804	SNF8	0.41	7.3	0.33	1.47e-12	Type 2 diabetes;
LUAD	cis	rs1113500	0.787	rs10881502	chr1:108641819	C/T	cg06207961	chr1:108661230	NA	-0.35	-6.59	-0.31	1.3100000000000001e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs1670533	1.000	rs3816474	chr4:1050653	G/A	cg27284194	chr4:1044797	NA	0.69	9.42	0.42	2.9e-19	Recombination rate (females);
LUAD	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg26597838	chr10:835615	NA	0.96	14.92	0.59	9.44e-41	Eosinophil percentage of granulocytes;
LUAD	trans	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg26043149	chr18:55253948	FECH	-0.42	-6.87	-0.32	2.35e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg16486109	chr11:613632	IRF7	0.49	8.15	0.37	4.04e-15	Systemic lupus erythematosus;
LUAD	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.79	0.61	1.71e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2458413	0.563	rs2458419	chr8:105337141	G/C	cg04554929	chr8:105342491	NA	-0.46	-9.09	-0.4	3.78e-18	Paget's disease;
LUAD	cis	rs7707921	1.000	rs6888977	chr5:81533735	C/T	cg15871215	chr5:81402204	ATG10	0.69	10.2	0.44	5.46e-22	Breast cancer;
LUAD	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg18404041	chr3:52824283	ITIH1	-0.56	-10.4	-0.45	1.07e-22	Bipolar disorder;
LUAD	cis	rs10489202	0.608	rs7556350	chr1:168077797	C/T	cg24449463	chr1:168025552	DCAF6	-0.61	-9.41	-0.42	3.25e-19	Schizophrenia;
LUAD	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg15704280	chr7:45808275	SEPT13	0.64	8.64	0.39	1.14e-16	Axial length;
LUAD	cis	rs7202877	0.706	rs2059257	chr16:75396376	G/A	cg03315344	chr16:75512273	CHST6	0.5	7.0	0.32	1e-11	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg22963979	chr7:1858916	MAD1L1	-0.51	-9.02	-0.4	6.38e-18	Schizophrenia;
LUAD	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg11645453	chr3:52864694	ITIH4	-0.54	-10.05	-0.44	1.89e-21	Schizophrenia;
LUAD	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg07212818	chr11:638076	DRD4	-0.45	-6.73	-0.31	5.64e-11	Systemic lupus erythematosus;
LUAD	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg02228675	chr17:40259724	DHX58	-0.45	-7.07	-0.32	6.59e-12	Fibrinogen levels;
LUAD	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg14159672	chr1:205819179	PM20D1	-0.53	-7.89	-0.36	2.7e-14	Menarche (age at onset);
LUAD	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg21171335	chr12:122356390	WDR66	0.74	13.4	0.55	2.2e-34	Mean corpuscular volume;
LUAD	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg21862992	chr11:68658383	NA	0.56	10.16	0.44	7.88e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg14917512	chr19:3094685	GNA11	-0.52	-6.35	-0.3	5.65e-10	Diabetic kidney disease;
LUAD	cis	rs7089973	0.872	rs7072356	chr10:116634651	T/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.65	0.42	4.91e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18867708	chr6:26865862	GUSBL1	0.41	6.52	0.3	2e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.87e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg07936489	chr17:37558343	FBXL20	0.5	6.7	0.31	6.65e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg10792982	chr14:105748885	BRF1	0.45	9.49	0.42	1.68e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs62064224	0.614	rs4794921	chr17:30742310	C/T	cg18200150	chr17:30822561	MYO1D	0.4	7.44	0.34	5.81e-13	Schizophrenia;
LUAD	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg18240062	chr17:79603768	NPLOC4	-0.36	-6.35	-0.3	5.42e-10	Eye color traits;
LUAD	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg23758822	chr17:41437982	NA	0.99	20.01	0.7	3.66e-63	Menopause (age at onset);
LUAD	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg24558204	chr6:135376177	HBS1L	0.47	8.71	0.39	7e-17	Red blood cell count;
LUAD	cis	rs4604732	0.578	rs12038656	chr1:247623816	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	8.9	0.4	1.61e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs17401966	0.838	rs9332414	chr1:10326963	C/T	cg15208524	chr1:10270712	KIF1B	0.44	6.79	0.31	3.85e-11	Hepatocellular carcinoma;
LUAD	cis	rs9297145	0.585	rs17147666	chr7:98781457	A/C	cg05967295	chr7:98741636	SMURF1	-0.76	-13.66	-0.55	1.82e-35	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs4730250	0.707	rs4730222	chr7:106810293	G/C	cg02696742	chr7:106810147	HBP1	-0.89	-11.76	-0.5	7.79e-28	Osteoarthritis;
LUAD	cis	rs3803170	0.513	rs10849943	chr12:111819589	A/G	cg10833066	chr12:111807467	FAM109A	-0.44	-8.29	-0.37	1.53e-15	Mean corpuscular hemoglobin;
LUAD	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg13385794	chr1:248469461	NA	0.24	6.4	0.3	4.07e-10	Common traits (Other);
LUAD	cis	rs28595532	0.546	rs36058627	chr4:119233201	G/T	cg02775129	chr4:119771670	NA	-0.64	-6.9	-0.32	1.86e-11	Cannabis dependence symptom count;
LUAD	cis	rs1595825	0.945	rs76510735	chr2:198823095	G/A	cg00361562	chr2:198649771	BOLL	-0.47	-6.72	-0.31	5.79e-11	Ulcerative colitis;
LUAD	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg13334819	chr7:99746414	C7orf59	0.63	9.9	0.43	6.48e-21	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7582720	1.000	rs72934714	chr2:203711581	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	8.97	0.4	9.37e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs17253792	0.822	rs28392709	chr14:56093685	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	7.57	0.35	2.32e-13	Tonsillectomy;
LUAD	cis	rs7665090	1.000	rs1054037	chr4:103552709	C/T	cg07973026	chr4:103553119	MANBA	0.48	8.53	0.38	2.63e-16	Primary biliary cholangitis;
LUAD	cis	rs9826463	0.582	rs73238159	chr3:142078759	C/T	cg20824294	chr3:142316082	PLS1	0.41	6.62	0.31	1.07e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4389656	0.775	rs274668	chr5:6711630	C/T	cg10857441	chr5:6722123	POLS	-0.46	-7.45	-0.34	5.36e-13	Coronary artery disease;
LUAD	cis	rs8017423	0.647	rs1958345	chr14:90823770	T/C	cg14092571	chr14:90743983	NA	0.39	6.54	0.3	1.81e-10	Mortality in heart failure;
LUAD	trans	rs12517041	1.000	rs1428621	chr5:23283431	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.47	-0.3	2.73e-10	Calcium levels;
LUAD	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg11062466	chr8:58055876	NA	0.78	9.56	0.42	9.57e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15506890	chr2:3487001	NA	0.47	8.16	0.37	3.84e-15	Neurofibrillary tangles;
LUAD	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg01528321	chr10:82214614	TSPAN14	0.68	10.39	0.45	1.1e-22	Post bronchodilator FEV1;
LUAD	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg23229984	chr5:148520753	ABLIM3	-0.5	-7.73	-0.35	7.68e-14	Breast cancer;
LUAD	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg15448220	chr1:150897856	SETDB1	0.54	9.26	0.41	1.03e-18	Melanoma;
LUAD	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg01958934	chr19:45449099	APOC2	0.36	7.05	0.32	7.1e-12	Blood protein levels;
LUAD	cis	rs3760982	0.967	rs3760984	chr19:44286762	C/T	cg12072164	chr19:44306565	LYPD5	0.39	7.82	0.36	4.28e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg01324343	chr3:183735012	ABCC5	-0.87	-17.62	-0.65	1.72e-52	Anterior chamber depth;
LUAD	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg14092988	chr3:52407081	DNAH1	0.37	7.47	0.34	4.74e-13	Bipolar disorder;
LUAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg09060608	chr5:178986726	RUFY1	-0.71	-12.12	-0.51	3.25e-29	Lung cancer;
LUAD	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg12927641	chr6:109611667	NA	-0.5	-8.78	-0.39	4.02e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs13315871	0.929	rs77825960	chr3:58318677	A/G	cg12435725	chr3:58293450	RPP14	-0.75	-8.34	-0.38	1.04e-15	Cholesterol, total;
LUAD	cis	rs57920188	0.535	rs10915659	chr1:4092949	G/A	cg20703997	chr1:4087676	NA	0.48	9.01	0.4	7.04e-18	Interleukin-17 levels;
LUAD	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg00277334	chr10:82204260	NA	-0.57	-9.47	-0.42	2.07e-19	Post bronchodilator FEV1;
LUAD	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg10589385	chr1:150898437	SETDB1	0.42	7.67	0.35	1.17e-13	Melanoma;
LUAD	cis	rs713587	0.713	rs11125884	chr2:25239264	C/T	cg01884057	chr2:25150051	NA	0.31	6.48	0.3	2.51e-10	Body mass index in non-asthmatics;
LUAD	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg08508325	chr11:3079039	CARS	-0.61	-13.35	-0.54	3.58e-34	Longevity;
LUAD	cis	rs7264396	0.563	rs2425111	chr20:34319765	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.26	-0.37	1.9e-15	Total cholesterol levels;
LUAD	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg11645453	chr3:52864694	ITIH4	-0.55	-9.86	-0.43	8.65e-21	Schizophrenia;
LUAD	cis	rs6076065	0.723	rs6137922	chr20:23363773	G/A	cg11657817	chr20:23433608	CST11	0.47	8.85	0.4	2.34e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs9837602	0.938	rs10511177	chr3:99724873	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.49	7.66	0.35	1.32e-13	Breast cancer;
LUAD	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg08847533	chr14:75593920	NEK9	0.41	7.05	0.32	7.21e-12	Height;
LUAD	cis	rs4604732	0.588	rs7549495	chr1:247627806	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.1	0.33	5.32e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs4954585	0.659	rs13018756	chr2:137008235	C/T	cg05194412	chr2:137003533	NA	0.61	11.09	0.47	2.82e-25	Colorectal cancer;
LUAD	cis	rs7149242	0.849	rs10146962	chr14:101170540	A/G	cg18089426	chr14:101175970	NA	0.39	7.1	0.33	5.3e-12	Platelet count;
LUAD	trans	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg26043149	chr18:55253948	FECH	0.43	7.03	0.32	8.56e-12	Bone mineral density;
LUAD	cis	rs2425143	1.000	rs11167275	chr20:34340275	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.85	-0.32	2.58e-11	Blood protein levels;
LUAD	cis	rs7258465	0.931	rs34053595	chr19:18556749	T/C	cg01065977	chr19:18549689	ISYNA1	-0.35	-6.46	-0.3	2.83e-10	Breast cancer;
LUAD	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg02158880	chr13:53174818	NA	0.63	11.5	0.49	8.38e-27	Lewy body disease;
LUAD	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	7.8	0.35	5.04e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs7177699	0.557	rs7403593	chr15:79111962	A/G	cg00540400	chr15:79124168	NA	-0.46	-9.7	-0.43	3.23e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg21890820	chr11:65308645	LTBP3	-0.46	-7.36	-0.34	9.74e-13	Bone mineral density;
LUAD	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.55	-0.3	1.66e-10	Bladder cancer;
LUAD	trans	rs236907	0.859	rs56365362	chr1:171752193	G/A	cg13482142	chr2:234261155	NA	0.49	6.37	0.3	5.07e-10	Mean platelet volume;
LUAD	cis	rs295140	0.506	rs4673855	chr2:201136143	A/G	cg17644776	chr2:200775616	C2orf69	-0.39	-6.65	-0.31	8.96e-11	QT interval;
LUAD	cis	rs427394	0.659	rs274674	chr5:6755460	C/T	cg12316010	chr5:6737918	POLS	0.38	7.19	0.33	3.04e-12	Menopause (age at onset);
LUAD	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg02049041	chr17:27085579	C17orf63	0.64	8.52	0.38	2.81e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09856797	chr16:67980139	SLC12A4	0.46	6.4	0.3	4.12e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1728785	0.688	rs698718	chr16:68560185	A/G	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.3100000000000001e-10	Ulcerative colitis;
LUAD	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg09491104	chr22:46646882	C22orf40	-0.59	-7.49	-0.34	4.07e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4891159	0.756	rs3892540	chr18:74118058	C/T	cg24786174	chr18:74118243	ZNF516	-0.83	-15.49	-0.6	3.33e-43	Longevity;
LUAD	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg05373962	chr22:49881684	NA	-0.48	-11.13	-0.48	2.14e-25	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg21918786	chr6:109611834	NA	-0.58	-10.6	-0.46	1.95e-23	Reticulocyte fraction of red cells;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg03284175	chr1:146643471	PRKAB2	-0.39	-6.46	-0.3	2.93e-10	Subcortical brain region volumes;
LUAD	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg21285383	chr16:89894308	SPIRE2	0.41	10.0	0.44	2.9e-21	Vitiligo;
LUAD	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21171335	chr12:122356390	WDR66	0.67	12.16	0.51	2.15e-29	Mean corpuscular volume;
LUAD	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg05791153	chr7:19748676	TWISTNB	0.85	12.19	0.51	1.69e-29	Night sleep phenotypes;
LUAD	cis	rs10924309	0.855	rs1807291	chr1:245860210	G/A	cg00036263	chr1:245852353	KIF26B	-0.48	-7.42	-0.34	6.68e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs72949976	0.864	rs10176806	chr2:214022596	T/G	cg08319019	chr2:214017104	IKZF2	-0.55	-8.5	-0.38	3.17e-16	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.59e-12	Crohn's disease;
LUAD	cis	rs7818345	0.967	rs12679671	chr8:19270831	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.87	0.32	2.31e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs4006360	0.600	rs6503595	chr17:39257008	C/G	cg20663846	chr17:39254439	KRTAP4-8	0.42	9.35	0.41	4.95e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg16988262	chr1:15930761	NA	0.42	6.96	0.32	1.34e-11	Systolic blood pressure;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg02235289	chr2:27852069	GPN1;CCDC121	0.37	6.35	0.3	5.47e-10	Bipolar disorder;
LUAD	cis	rs4660214	0.724	rs2484751	chr1:39748539	C/A	cg27567593	chr1:39956653	BMP8A	0.33	6.39	0.3	4.26e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs11722228	0.893	rs6449144	chr4:9944650	T/G	cg26043149	chr18:55253948	FECH	-0.72	-11.78	-0.5	6.97e-28	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.31	6.53	0.3	1.91e-10	Hemoglobin concentration;
LUAD	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg13073564	chr4:8508604	NA	-0.54	-10.06	-0.44	1.78e-21	Response to antineoplastic agents;
LUAD	cis	rs7625357	0.651	rs13060556	chr3:169317870	G/A	cg14572252	chr3:169309425	MECOM	-0.47	-8.02	-0.36	1.02e-14	Childhood and early adolescence aggressive behavior;
LUAD	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11644478	chr21:40555479	PSMG1	-0.53	-8.5	-0.38	3.32e-16	Cognitive function;
LUAD	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg07606381	chr6:8435919	SLC35B3	0.42	7.01	0.32	9.52e-12	Motion sickness;
LUAD	cis	rs7017914	0.934	rs6987313	chr8:71570989	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.52	-0.3	1.98e-10	Bone mineral density;
LUAD	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.58e-13	Tonsillectomy;
LUAD	cis	rs8064100	0.526	rs4482278	chr16:56726874	A/T	cg03551406	chr16:56715756	MT1X	0.36	7.0	0.32	1.02e-11	Gambling;
LUAD	cis	rs1018836	0.923	rs6999898	chr8:91650549	G/A	cg16814680	chr8:91681699	NA	-0.7	-11.91	-0.5	2.05e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4853036	0.672	rs6759494	chr2:70030905	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-6.48	-0.3	2.54e-10	Colorectal or endometrial cancer;
LUAD	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg15900387	chr1:150738905	CTSS	-0.36	-6.57	-0.3	1.44e-10	Melanoma;
LUAD	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg17252645	chr8:143867129	LY6D	0.36	6.66	0.31	8.38e-11	Urinary tract infection frequency;
LUAD	cis	rs4356932	1.000	rs4859584	chr4:76943137	C/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.56	-0.3	1.61e-10	Blood protein levels;
LUAD	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19717773	chr7:2847554	GNA12	0.58	10.01	0.44	2.67e-21	Height;
LUAD	cis	rs7630877	0.719	rs73057366	chr3:179672470	C/G	cg18765712	chr3:179670323	PEX5L	0.57	9.53	0.42	1.28e-19	Type 2 diabetes;
LUAD	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg21171335	chr12:122356390	WDR66	-0.73	-13.72	-0.55	1.11e-35	Mean corpuscular volume;
LUAD	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg09835421	chr16:68378352	PRMT7	-0.55	-6.87	-0.32	2.26e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2742417	1.000	rs2673051	chr3:45732409	G/T	cg10512202	chr3:45649293	LIMD1	0.37	6.55	0.3	1.72e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg14779329	chr11:130786720	SNX19	0.37	6.49	0.3	2.38e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2742417	0.935	rs2742393	chr3:45757417	T/A	cg10512202	chr3:45649293	LIMD1	0.36	6.45	0.3	3.03e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg23649088	chr2:200775458	C2orf69	0.63	8.38	0.38	8.07e-16	Schizophrenia;
LUAD	cis	rs3772130	0.962	rs9878086	chr3:121488353	G/A	cg20356878	chr3:121714668	ILDR1	0.51	8.12	0.37	5.26e-15	Cognitive performance;
LUAD	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg22753661	chr15:79092743	ADAMTS7	0.52	8.07	0.37	7.37e-15	Coronary artery disease or large artery stroke;
LUAD	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg00981070	chr1:2046702	PRKCZ	-0.36	-7.62	-0.35	1.66e-13	Height;
LUAD	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	8.53	0.38	2.68e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg03467027	chr4:99064603	C4orf37	0.41	6.7	0.31	6.77e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg03037974	chr15:76606532	NA	0.37	7.8	0.35	4.96e-14	Blood metabolite levels;
LUAD	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.52	0.34	3.2e-13	Breast cancer;
LUAD	cis	rs11771526	0.901	rs62456036	chr7:32266182	C/T	cg13207630	chr7:32358064	NA	0.53	6.95	0.32	1.37e-11	Body mass index;
LUAD	cis	rs6594713	0.921	rs6870401	chr5:112738364	C/G	cg12552261	chr5:112820674	MCC	0.55	8.88	0.4	1.88e-17	Brain cytoarchitecture;
LUAD	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg13902645	chr11:5959945	NA	-0.57	-10.46	-0.45	6.38e-23	DNA methylation (variation);
LUAD	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg17971929	chr21:40555470	PSMG1	0.56	8.78	0.39	4.19e-17	Cognitive function;
LUAD	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg20673091	chr1:2541236	MMEL1	-0.4	-8.59	-0.39	1.72e-16	Ulcerative colitis;
LUAD	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.12	0.33	4.7e-12	Motion sickness;
LUAD	cis	rs59104589	0.583	rs62186399	chr2:242225325	G/C	cg08645257	chr2:242211290	HDLBP	0.5	7.93	0.36	1.97e-14	Fibrinogen levels;
LUAD	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11890956	chr21:40555474	PSMG1	0.56	9.76	0.43	1.91e-20	Cognitive function;
LUAD	cis	rs9462027	0.651	rs7748203	chr6:34812054	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.89	-0.4	1.84e-17	Systemic lupus erythematosus;
LUAD	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg14092988	chr3:52407081	DNAH1	0.37	7.47	0.34	4.74e-13	Bipolar disorder;
LUAD	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg06740227	chr12:86229804	RASSF9	0.39	6.8	0.31	3.66e-11	Major depressive disorder;
LUAD	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg10560079	chr2:191398806	TMEM194B	-0.54	-7.11	-0.33	5.08e-12	Diastolic blood pressure;
LUAD	cis	rs9309473	0.687	rs6710659	chr2:73607510	A/G	cg20560298	chr2:73613845	ALMS1	-0.43	-6.62	-0.31	1.06e-10	Metabolite levels;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg03768106	chr11:111957237	TIMM8B;SDHD	-0.4	-6.58	-0.3	1.39e-10	Subcortical brain region volumes;
LUAD	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg12034118	chr1:209979487	IRF6	0.55	6.5	0.3	2.24e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg10729496	chr3:10149963	C3orf24	-0.56	-9.36	-0.41	4.89e-19	Alzheimer's disease;
LUAD	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg02743256	chr7:2109353	MAD1L1	-0.46	-6.5	-0.3	2.32e-10	Bipolar disorder;
LUAD	cis	rs9462027	0.583	rs9462022	chr6:34761684	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.91	-0.4	1.53e-17	Systemic lupus erythematosus;
LUAD	cis	rs921968	0.565	rs12694439	chr2:219590871	A/G	cg02176678	chr2:219576539	TTLL4	-0.59	-11.99	-0.5	1.06e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg05340658	chr4:99064831	C4orf37	0.45	7.33	0.34	1.19e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg00277334	chr10:82204260	NA	-0.96	-21.36	-0.72	3.2e-69	Post bronchodilator FEV1;
LUAD	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg27494647	chr7:150038898	RARRES2	0.52	9.39	0.42	3.69e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs10080237	0.564	rs2490232	chr6:80814802	C/T	cg08355045	chr6:80787529	NA	-0.6	-11.15	-0.48	1.69e-25	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUAD	cis	rs7493	0.901	rs11767787	chr7:95026753	T/C	cg07404485	chr7:94953653	PON1	-0.53	-7.92	-0.36	2.16e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg08219700	chr8:58056026	NA	0.48	7.04	0.32	7.94e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg07432352	chr17:45403706	C17orf57	-0.41	-7.9	-0.36	2.41e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg24011408	chr12:48396354	COL2A1	0.43	9.61	0.42	6.32e-20	Plateletcrit;
LUAD	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg14343924	chr8:8086146	FLJ10661	0.43	6.67	0.31	7.78e-11	Joint mobility (Beighton score);
LUAD	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg08470875	chr2:26401718	FAM59B	-0.68	-8.99	-0.4	8.36e-18	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1018836	0.786	rs7016220	chr8:91606848	A/G	cg16814680	chr8:91681699	NA	-0.6	-10.01	-0.44	2.53e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg18252515	chr7:66147081	NA	-0.61	-6.6	-0.31	1.2e-10	Diabetic kidney disease;
LUAD	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg21782813	chr7:2030301	MAD1L1	0.53	8.75	0.39	4.98e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg17372223	chr3:52568218	NT5DC2	0.37	6.67	0.31	7.97e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg19318889	chr4:1322082	MAEA	0.46	7.45	0.34	5.27e-13	Obesity-related traits;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg04449512	chr2:70352318	LOC100133985	-0.47	-6.78	-0.31	4.06e-11	Blood protein levels;
LUAD	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.82	-0.36	4.28e-14	Neutrophil percentage of white cells;
LUAD	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06873352	chr17:61820015	STRADA	0.55	8.92	0.4	1.42e-17	Height;
LUAD	trans	rs11039798	1.000	rs7104642	chr11:48588534	C/T	cg02254774	chr11:50257496	LOC441601	0.51	6.48	0.3	2.63e-10	Axial length;
LUAD	trans	rs853679	0.607	rs35345226	chr6:28091580	A/G	cg06606381	chr12:133084897	FBRSL1	-1.21	-10.65	-0.46	1.27e-23	Depression;
LUAD	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.35	-6.78	-0.31	4.01e-11	Multiple sclerosis;Ankylosing spondylitis;
LUAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.01	0.32	9.68e-12	Motion sickness;
LUAD	cis	rs754466	0.510	rs55893027	chr10:79588209	C/T	cg17075019	chr10:79541650	NA	-0.76	-15.27	-0.6	2.98e-42	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10499694	0.868	rs1470749	chr7:50578023	G/T	cg18232548	chr7:50535776	DDC	-0.47	-7.82	-0.36	4.29e-14	Body mass index;
LUAD	cis	rs8077889	0.917	rs6503479	chr17:41917003	A/G	cg26893861	chr17:41843967	DUSP3	0.91	15.45	0.6	5.04e-43	Triglycerides;
LUAD	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg23018236	chr17:30244563	NA	-0.69	-8.39	-0.38	7.53e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-13.33	-0.54	4.25e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs35096708	1.000	rs35096708	chr16:89887249	G/A	cg07402062	chr16:89894098	SPIRE2	-0.4	-7.84	-0.36	3.74e-14	Skin aging (microtopography measurement);
LUAD	cis	rs1497406	0.744	rs12057175	chr1:16508375	A/G	cg02998240	chr1:16508668	NA	-0.24	-7.14	-0.33	4.01e-12	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg06609049	chr19:2785107	THOP1	0.76	13.05	0.54	6.26e-33	Total cholesterol levels;
LUAD	cis	rs55788414	0.932	rs2317119	chr16:81182854	T/C	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.87	-0.36	3.02e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg25173405	chr17:45401733	C17orf57	0.45	7.42	0.34	6.56e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg18402987	chr7:1209562	NA	0.78	9.54	0.42	1.19e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9653442	0.712	rs6749757	chr2:100730111	A/C	cg07810366	chr2:100720526	AFF3	0.33	6.68	0.31	7.52e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg03806693	chr22:41940476	POLR3H	0.52	7.66	0.35	1.24e-13	Vitiligo;
LUAD	trans	rs9951602	0.512	rs7241419	chr18:76640778	C/G	cg02800362	chr5:177631904	HNRNPAB	0.92	14.19	0.57	1.12e-37	Obesity-related traits;
LUAD	cis	rs123509	0.913	rs123506	chr3:42775976	T/C	cg10144569	chr3:42726640	KBTBD5	0.49	7.59	0.35	2e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg15017067	chr4:17643749	FAM184B	-0.38	-7.48	-0.34	4.45e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs79349575	0.655	rs62078384	chr17:47044463	C/T	cg22482690	chr17:47019901	SNF8	0.46	8.65	0.39	1.09e-16	Type 2 diabetes;
LUAD	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg03929089	chr4:120376271	NA	0.5	7.33	0.34	1.21e-12	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21582582	chr3:182698605	DCUN1D1	0.71	13.39	0.55	2.53e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg17063962	chr7:91808500	NA	0.67	11.92	0.5	1.89e-28	Breast cancer;
LUAD	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14829155	chr15:31115871	NA	0.78	13.25	0.54	9.5e-34	Huntington's disease progression;
LUAD	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-14.73	-0.58	6.19e-40	Schizophrenia;
LUAD	cis	rs2839627	0.561	rs9977774	chr21:44342476	G/C	cg03543861	chr21:44258195	NA	0.63	8.64	0.39	1.14e-16	Information processing speed;
LUAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg02951883	chr7:2050386	MAD1L1	-0.67	-11.0	-0.47	6.11e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg15448220	chr1:150897856	SETDB1	0.58	9.8	0.43	1.46e-20	Melanoma;
LUAD	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg09455208	chr3:40491958	NA	-0.55	-11.97	-0.5	1.17e-28	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6028335	0.674	rs59096774	chr20:37603529	A/G	cg27660920	chr20:37554817	FAM83D	0.51	6.47	0.3	2.69e-10	Alcohol and nicotine co-dependence;
LUAD	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.19	-0.51	1.65e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg27432699	chr2:27873401	GPN1	-0.4	-6.65	-0.31	8.98e-11	Total body bone mineral density;
LUAD	cis	rs55665837	0.524	rs61884009	chr11:14426462	C/T	cg19336497	chr11:14380999	RRAS2	-0.61	-12.61	-0.52	3.69e-31	Vitamin D levels;
LUAD	cis	rs11771526	0.901	rs10267589	chr7:32280156	T/C	cg13207630	chr7:32358064	NA	0.54	7.05	0.32	7.41e-12	Body mass index;
LUAD	cis	rs28374715	0.662	rs691906	chr15:41474636	T/A	cg18705301	chr15:41695430	NDUFAF1	0.86	15.72	0.61	3.57e-44	Ulcerative colitis;
LUAD	cis	rs17401966	0.838	rs7553228	chr1:10350438	G/C	cg15208524	chr1:10270712	KIF1B	0.42	6.57	0.3	1.49e-10	Hepatocellular carcinoma;
LUAD	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg08761264	chr16:28874980	SH2B1	-0.45	-6.91	-0.32	1.8e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg21475434	chr5:93447410	FAM172A	0.73	8.38	0.38	7.71e-16	Diabetic retinopathy;
LUAD	cis	rs7072216	0.587	rs3814141	chr10:100171028	G/A	cg26618903	chr10:100175079	PYROXD2	-0.41	-8.36	-0.38	9.35e-16	Metabolite levels;
LUAD	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg21427119	chr20:30132790	HM13	-0.47	-7.62	-0.35	1.66e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs2224391	0.613	rs11757924	chr6:5282516	G/A	cg26704043	chr6:5282702	FARS2	0.4	6.81	0.31	3.35e-11	Height;
LUAD	cis	rs8112211	0.681	rs59898212	chr19:38826656	G/C	cg14299480	chr19:38876666	GGN	-0.45	-7.73	-0.35	7.8e-14	Blood protein levels;
LUAD	cis	rs4631830	0.540	rs2926493	chr10:51492131	G/A	cg16070123	chr10:51489643	NA	-0.38	-6.73	-0.31	5.66e-11	Prostate-specific antigen levels;
LUAD	cis	rs9644630	0.696	rs35736969	chr8:19319620	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.39	7.31	0.34	1.3e-12	Oropharynx cancer;
LUAD	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg14196790	chr5:131705035	SLC22A5	0.48	8.4	0.38	6.97e-16	Breast cancer;Mosquito bite size;
LUAD	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19748678	chr4:122722346	EXOSC9	0.43	6.93	0.32	1.62e-11	Type 2 diabetes;
LUAD	cis	rs71636778	0.543	rs71636796	chr1:27243095	T/C	cg12203394	chr1:27248618	NUDC	0.52	6.59	0.31	1.33e-10	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.9	-0.32	1.97e-11	Mood instability;
LUAD	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg12407791	chr17:73824354	UNC13D	-0.33	-6.78	-0.31	4.03e-11	White matter hyperintensity burden;
LUAD	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg19717773	chr7:2847554	GNA12	-0.53	-10.25	-0.45	3.57e-22	Height;
LUAD	cis	rs7707921	0.881	rs73134739	chr5:81370760	T/C	cg15871215	chr5:81402204	ATG10	-0.7	-9.91	-0.43	5.94e-21	Breast cancer;
LUAD	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg17644776	chr2:200775616	C2orf69	-0.55	-7.58	-0.35	2.17e-13	Schizophrenia;
LUAD	cis	rs1853665	0.580	rs6557201	chr6:150272567	T/C	cg16301758	chr6:150275521	NA	-0.52	-7.51	-0.34	3.63e-13	Radiation response;
LUAD	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.45	0.34	5.34e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs7107174	0.681	rs4340079	chr11:78007920	C/T	cg19901956	chr11:77921274	USP35	-0.48	-6.48	-0.3	2.5e-10	Testicular germ cell tumor;
LUAD	cis	rs7737355	0.773	rs27450	chr5:131006082	A/G	cg06307176	chr5:131281290	NA	0.44	7.21	0.33	2.53e-12	Life satisfaction;
LUAD	trans	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg06606381	chr12:133084897	FBRSL1	-0.88	-7.17	-0.33	3.47e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg13319975	chr6:146136371	FBXO30	0.6	10.08	0.44	1.44e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg04450456	chr4:17643702	FAM184B	-0.39	-7.7	-0.35	9.89e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg12935359	chr14:103987150	CKB	-0.49	-7.75	-0.35	7.08e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg03714773	chr7:91764589	CYP51A1	0.29	6.82	0.31	3.12e-11	Breast cancer;
LUAD	cis	rs2734839	0.929	rs11608185	chr11:113294976	T/C	cg14159747	chr11:113255604	NA	0.53	10.29	0.45	2.63e-22	Information processing speed;
LUAD	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg03983476	chr2:10830698	NOL10	0.46	8.16	0.37	3.85e-15	Prostate cancer;
LUAD	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg25208724	chr1:156163844	SLC25A44	1.05	20.79	0.71	1.12e-66	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg24818145	chr4:99064322	C4orf37	0.44	7.35	0.34	1.01e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.26e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg27494647	chr7:150038898	RARRES2	0.52	9.3	0.41	7.89e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg10729496	chr3:10149963	C3orf24	0.57	9.51	0.42	1.49e-19	Alzheimer's disease;
LUAD	cis	rs9902453	0.874	rs7213517	chr17:28401740	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-9.88	-0.43	7.68e-21	Coffee consumption (cups per day);
LUAD	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg26384229	chr12:38710491	ALG10B	0.48	7.74	0.35	7.17e-14	Bladder cancer;
LUAD	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-7.51	-0.34	3.56e-13	Lung cancer;
LUAD	cis	rs6076065	0.748	rs2281431	chr20:23399304	C/G	cg11657817	chr20:23433608	CST11	0.57	12.13	0.51	3.02e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs3017493	0.786	rs12295625	chr11:70671860	A/G	cg11479156	chr11:70672388	SHANK2	0.54	6.5	0.3	2.29e-10	Renal transplant outcome;
LUAD	cis	rs79057730	0.684	rs6955004	chr7:790792	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.84	9.31	0.41	7.17e-19	Initial pursuit acceleration;
LUAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00149659	chr3:10157352	C3orf10	0.64	9.2	0.41	1.64e-18	Alzheimer's disease;
LUAD	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	10.4	0.45	1.03e-22	Electrocardiographic conduction measures;
LUAD	cis	rs11811982	0.793	rs11800777	chr1:227535532	C/A	cg24860534	chr1:227506868	CDC42BPA	0.71	7.52	0.34	3.35e-13	Optic disc area;
LUAD	cis	rs7937890	0.559	rs2575823	chr11:14521354	C/A	cg06199346	chr11:14280333	SPON1	-0.32	-6.42	-0.3	3.58e-10	Mitochondrial DNA levels;
LUAD	cis	rs300703	0.654	rs435733	chr2:121222	A/G	cg24565620	chr2:194026	NA	0.45	6.81	0.31	3.35e-11	Blood protein levels;
LUAD	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg21724239	chr8:58056113	NA	0.57	7.6	0.35	1.9e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg00071950	chr4:10020882	SLC2A9	0.86	18.34	0.67	1.01e-55	Bone mineral density;
LUAD	cis	rs59698941	0.943	rs67162224	chr5:132289372	T/C	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg09137382	chr11:130731461	NA	-0.4	-7.42	-0.34	6.33e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg04450456	chr4:17643702	FAM184B	0.4	7.85	0.36	3.5e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg06608945	chr2:219082296	ARPC2	-0.46	-8.1	-0.37	6.13e-15	Colorectal cancer;
LUAD	cis	rs727505	0.721	rs17327715	chr7:124760611	G/C	cg23710748	chr7:124431027	NA	-0.38	-7.59	-0.35	2.12e-13	Lewy body disease;
LUAD	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.1	0.37	5.93e-15	Menopause (age at onset);
LUAD	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg18512352	chr11:47633146	NA	0.4	7.02	0.32	8.99e-12	Subjective well-being;
LUAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08280861	chr8:58055591	NA	-0.51	-6.43	-0.3	3.54e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg20469991	chr17:27169893	C17orf63	-0.52	-6.6	-0.31	1.24e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs733175	0.855	rs10022499	chr4:10006537	C/A	cg02734326	chr4:10020555	SLC2A9	0.44	6.37	0.3	5.02e-10	Psychosis and Alzheimer's disease;
LUAD	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg00701064	chr4:6280414	WFS1	0.64	13.7	0.55	1.3e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg12419862	chr22:24373484	LOC391322	-0.68	-11.68	-0.49	1.62e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg13397359	chr6:42928475	GNMT	0.66	12.88	0.53	2.93e-32	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg19041857	chr6:27730383	NA	-0.43	-7.22	-0.33	2.35e-12	Parkinson's disease;
LUAD	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg12927641	chr6:109611667	NA	-0.54	-9.42	-0.42	3.02e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs8051149	0.688	rs12444670	chr16:87870312	C/T	cg01412419	chr16:87856264	NA	0.46	8.33	0.38	1.16e-15	Blood metabolite levels;
LUAD	trans	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg25835954	chr13:50160062	RCBTB1	0.51	8.35	0.38	9.96e-16	Cortisol levels (saliva);
LUAD	cis	rs3849570	0.643	rs10779987	chr3:81970856	C/T	cg07356753	chr3:81810745	GBE1	-0.49	-8.22	-0.37	2.45e-15	Waist circumference;Body mass index;
LUAD	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg21951975	chr1:209979733	IRF6	0.56	8.17	0.37	3.69e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs13064411	0.696	rs6768979	chr3:113204149	G/A	cg18753928	chr3:113234510	CCDC52	-0.73	-12.47	-0.52	1.34e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs494562	0.892	rs567686	chr6:86124164	A/T	cg27297263	chr6:86160468	NT5E	0.59	6.44	0.3	3.3e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.08	0.33	6.19e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg19729930	chr2:74357872	NA	0.99	16.33	0.62	8.11e-47	Gestational age at birth (maternal effect);
LUAD	cis	rs12431939	0.947	rs68180359	chr14:51672027	G/A	cg23942311	chr14:51606299	NA	-0.62	-8.49	-0.38	3.52e-16	Cancer;
LUAD	cis	rs2070488	0.804	rs7372452	chr3:38444298	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	9.16	0.41	2.24e-18	Electrocardiographic conduction measures;
LUAD	cis	rs3784262	0.740	rs4646598	chr15:58300328	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.41	-8.0	-0.36	1.18e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg05340658	chr4:99064831	C4orf37	0.54	9.21	0.41	1.55e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg14092988	chr3:52407081	DNAH1	0.45	9.04	0.4	5.62e-18	Bipolar disorder;
LUAD	cis	rs7588746	0.621	rs4672726	chr2:201149413	C/T	cg23649088	chr2:200775458	C2orf69	-0.48	-7.42	-0.34	6.56e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
LUAD	trans	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg01620082	chr3:125678407	NA	-1.04	-10.35	-0.45	1.52e-22	Depression;
LUAD	cis	rs7582720	1.000	rs72934715	chr2:203713280	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.71	8.91	0.4	1.53e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	trans	rs4942242	0.626	rs7986998	chr13:44209916	G/A	cg19169023	chr15:41853346	TYRO3	0.66	11.73	0.5	1.04e-27	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11644478	chr21:40555479	PSMG1	-0.58	-9.75	-0.43	2.08e-20	Cognitive function;
LUAD	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg27489772	chr12:121021490	NA	0.57	6.9	0.32	1.97e-11	Type 1 diabetes nephropathy;
LUAD	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg15181151	chr6:150070149	PCMT1	0.39	7.8	0.35	5e-14	Lung cancer;
LUAD	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.87	0.32	2.34e-11	Cardiac Troponin-T levels;
LUAD	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06544989	chr22:39130855	UNC84B	0.46	8.63	0.39	1.28e-16	Menopause (age at onset);
LUAD	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg09365446	chr1:150670422	GOLPH3L	0.55	9.74	0.43	2.32e-20	Melanoma;
LUAD	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg10295955	chr4:187884368	NA	-1.18	-31.5	-0.84	5.35e-113	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	13.7	0.55	1.3e-35	Lung cancer in ever smokers;
LUAD	cis	rs7539409	0.604	rs910183	chr1:84297285	A/G	cg10977910	chr1:84465055	TTLL7	0.71	8.33	0.38	1.17e-15	Alzheimer's disease;
LUAD	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg21017887	chr14:105400489	NA	-0.7	-12.26	-0.51	9.15e-30	Rheumatoid arthritis;
LUAD	cis	rs4638749	1.000	rs1466211	chr2:108856412	G/A	cg25838818	chr2:108905173	SULT1C2	-0.53	-8.46	-0.38	4.29e-16	Blood pressure;
LUAD	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg25237894	chr2:233734115	C2orf82	-0.58	-11.4	-0.48	1.94e-26	Coronary artery disease;
LUAD	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg08085267	chr17:45401833	C17orf57	-0.63	-11.23	-0.48	8.91e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg14375799	chr9:139685616	TMEM141	-0.69	-6.65	-0.31	8.98e-11	Type 2 diabetes;
LUAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg22963979	chr7:1858916	MAD1L1	0.45	7.58	0.35	2.14e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg20362242	chr5:692897	TPPP	0.52	6.43	0.3	3.42e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg16405210	chr4:1374714	KIAA1530	-0.62	-9.52	-0.42	1.31e-19	Longevity;
LUAD	trans	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.93	0.43	4.88e-21	Ulcerative colitis;
LUAD	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11890956	chr21:40555474	PSMG1	-0.55	-9.66	-0.43	4.3e-20	Menarche (age at onset);
LUAD	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg25828334	chr19:18545568	ISYNA1	-0.38	-7.75	-0.35	7.14e-14	Breast cancer;
LUAD	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg08999081	chr20:33150536	PIGU	-0.63	-14.12	-0.57	2.25e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg00080972	chr5:178986291	RUFY1	0.45	7.96	0.36	1.6e-14	Lung cancer;
LUAD	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg23985595	chr17:80112537	CCDC57	-0.53	-9.51	-0.42	1.41e-19	Life satisfaction;
LUAD	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg21827317	chr3:136751795	NA	0.36	6.58	0.3	1.37e-10	Neuroticism;
LUAD	cis	rs4481887	0.676	rs1538704	chr1:248523554	C/T	cg00666640	chr1:248458726	OR2T12	0.26	6.68	0.31	7.72e-11	Common traits (Other);
LUAD	cis	rs1788820	0.917	rs4800489	chr18:21125942	A/G	cg14672496	chr18:21087552	C18orf8	0.36	6.83	0.32	3.01e-11	Body mass index;
LUAD	cis	rs1950626	0.671	rs34675695	chr14:101447913	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.42	7.74	0.35	7.54e-14	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg20673091	chr1:2541236	MMEL1	0.29	6.44	0.3	3.25e-10	Ulcerative colitis;
LUAD	cis	rs80319144	1.000	rs76714700	chr2:159265263	T/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.9	0.32	1.92e-11	Restless legs syndrome;
LUAD	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg22676075	chr6:135203613	NA	0.4	7.51	0.34	3.49e-13	Red blood cell count;
LUAD	cis	rs76419734	0.510	rs2544402	chr4:106687733	A/G	cg05309399	chr4:106552544	FLJ20184	0.51	6.84	0.32	2.72e-11	Post bronchodilator FEV1;
LUAD	cis	rs1564271	0.553	rs9334138	chr10:26978929	G/A	cg13837822	chr10:26931731	LOC731789	0.5	10.74	0.46	6.04e-24	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUAD	trans	rs4714291	0.832	rs9471244	chr6:40092331	A/G	cg02267698	chr19:7991119	CTXN1	0.45	7.14	0.33	4.03e-12	Strep throat;
LUAD	cis	rs1371614	0.635	rs4665923	chr2:27138911	C/T	cg00617064	chr2:27272375	NA	-0.34	-6.45	-0.3	3.04e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg24101359	chr6:42928495	GNMT	0.5	9.18	0.41	1.9e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg22508957	chr16:3507546	NAT15	-0.49	-8.08	-0.37	6.88e-15	Body mass index (adult);
LUAD	cis	rs7089973	0.872	rs7918388	chr10:116614563	T/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.8	0.43	1.46e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4790333	0.845	rs7210932	chr17:2272024	A/G	cg27406664	chr17:2294951	MNT	-0.43	-8.61	-0.39	1.46e-16	Proinsulin levels;
LUAD	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg02527881	chr3:46936655	PTH1R	-0.38	-6.99	-0.32	1.06e-11	QT interval;
LUAD	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg21427119	chr20:30132790	HM13	-0.5	-8.02	-0.36	1.04e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg03030879	chr14:75389066	RPS6KL1	0.36	6.75	0.31	4.82e-11	Caffeine consumption;
LUAD	cis	rs9535307	1.000	rs9535307	chr13:50291842	A/C	cg04663916	chr13:50265991	EBPL	0.58	6.82	0.31	3.1e-11	Obesity-related traits;
LUAD	trans	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg26043149	chr18:55253948	FECH	0.51	8.31	0.37	1.35e-15	Bone mineral density;
LUAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.49	6.84	0.32	2.78e-11	Renal function-related traits (BUN);
LUAD	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg01119278	chr6:110721349	DDO	-0.5	-9.32	-0.41	6.59e-19	Platelet distribution width;
LUAD	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg05890377	chr2:74357713	NA	0.84	13.03	0.54	7.58e-33	Gestational age at birth (maternal effect);
LUAD	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg13390004	chr1:15929781	NA	0.48	8.38	0.38	8.18e-16	Systolic blood pressure;
LUAD	cis	rs4604732	0.631	rs74154673	chr1:247625629	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg13870426	chr17:30244630	NA	-0.58	-6.86	-0.32	2.39e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.41	-7.01	-0.32	9.24e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17092148	0.636	rs66535774	chr20:33448560	T/C	cg16810054	chr20:33298113	TP53INP2	0.4	7.56	0.34	2.55e-13	Neuroticism;
LUAD	cis	rs62229266	0.626	rs2835268	chr21:37449136	C/G	cg12218747	chr21:37451666	NA	-0.68	-12.7	-0.53	1.54e-31	Mitral valve prolapse;
LUAD	cis	rs11945232	1.000	rs6854710	chr4:88334640	A/G	cg23841344	chr4:88312519	HSD17B11	-0.58	-8.89	-0.4	1.83e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg11502198	chr6:26597334	ABT1	0.5	8.02	0.36	1.02e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4880487	0.554	rs4880785	chr10:1237920	A/G	cg23624713	chr10:1226645	NA	-0.37	-7.13	-0.33	4.42e-12	Migraine;
LUAD	cis	rs17655565	1.000	rs60696802	chr12:52693176	C/T	cg08257133	chr12:52711352	KRT83	0.43	7.28	0.33	1.67e-12	Plasma amyloid beta peptide concentrations (ABx-42);
LUAD	trans	rs4714291	0.832	rs1404002	chr6:40064600	C/T	cg02267698	chr19:7991119	CTXN1	-0.43	-6.88	-0.32	2.15e-11	Strep throat;
LUAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg23283495	chr1:209979779	IRF6	0.68	11.21	0.48	1.03e-25	Cleft lip with or without cleft palate;
LUAD	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg18190219	chr22:46762943	CELSR1	0.45	6.72	0.31	6.03e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.23	0.54	1.09e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7737355	0.704	rs11749484	chr5:131061607	T/C	cg25547332	chr5:131281432	NA	0.43	7.06	0.32	6.78e-12	Life satisfaction;
LUAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg18621852	chr3:10150065	C3orf24	0.49	8.92	0.4	1.47e-17	Alzheimer's disease;
LUAD	cis	rs8177876	0.749	rs12927239	chr16:81087488	G/A	cg08591886	chr16:81111003	C16orf46	-0.69	-7.09	-0.33	5.71e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg08798685	chr6:27730294	NA	-0.44	-6.99	-0.32	1.05e-11	Parkinson's disease;
LUAD	cis	rs4700695	0.764	rs27701	chr5:65377526	G/C	cg21114390	chr5:65439923	SFRS12	-0.61	-8.01	-0.36	1.1e-14	Facial morphology (factor 19);
LUAD	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.39	6.63	0.31	1.04e-10	Type 2 diabetes;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg11568364	chr10:126432734	FAM53B	-0.62	-6.42	-0.3	3.58e-10	Type 2 diabetes;
LUAD	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg15704280	chr7:45808275	SEPT13	-0.58	-9.53	-0.42	1.27e-19	HDL cholesterol;
LUAD	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg03929089	chr4:120376271	NA	-0.98	-20.96	-0.71	1.99e-67	Height;
LUAD	cis	rs11622475	1.000	rs2273610	chr14:104387642	G/C	cg12183467	chr14:104352244	NA	-0.43	-7.75	-0.35	6.96e-14	Bipolar disorder;
LUAD	cis	rs12900413	0.687	rs35562959	chr15:90310537	C/T	cg24249390	chr15:90295951	MESP1	-0.34	-6.62	-0.31	1.08e-10	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg14343924	chr8:8086146	FLJ10661	0.47	7.23	0.33	2.34e-12	Mood instability;
LUAD	cis	rs9900062	0.586	rs6504250	chr17:62680553	T/C	cg02097616	chr17:62675921	NA	0.74	12.25	0.51	9.36e-30	QT interval;
LUAD	cis	rs6484504	0.576	rs158140	chr11:31212971	T/C	cg26647111	chr11:31128758	NA	-0.46	-8.24	-0.37	2.13e-15	Red blood cell count;
LUAD	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg09491104	chr22:46646882	C22orf40	-0.59	-7.87	-0.36	3.01e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs10193935	0.901	rs72800020	chr2:42655615	A/G	cg27598129	chr2:42591480	NA	-0.75	-9.87	-0.43	8.24e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7147624	1.000	rs61987807	chr14:66207050	G/T	cg03016385	chr14:66212404	NA	-0.58	-6.96	-0.32	1.31e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11644478	chr21:40555479	PSMG1	0.71	11.91	0.5	2.17e-28	Cognitive function;
LUAD	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg13319975	chr6:146136371	FBXO30	-0.59	-10.0	-0.44	2.92e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs757110	0.868	rs5219	chr11:17409572	T/C	cg04705435	chr11:17411270	KCNJ11	0.47	7.78	0.35	5.53e-14	Type 2 diabetes;
LUAD	cis	rs601339	1.000	rs35683065	chr12:123164062	G/C	cg11919336	chr12:123188078	GPR109A	0.44	6.67	0.31	7.78e-11	Adiponectin levels;
LUAD	cis	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg24803719	chr17:45855879	NA	-0.35	-6.82	-0.31	3.07e-11	IgG glycosylation;
LUAD	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-7.53	-0.34	3.15e-13	Neutrophil percentage of white cells;
LUAD	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg12310025	chr6:25882481	NA	-0.58	-9.52	-0.42	1.31e-19	Blood metabolite levels;
LUAD	cis	rs7705042	0.865	rs12653866	chr5:141489921	C/T	cg23435118	chr5:141488016	NDFIP1	-0.38	-6.49	-0.3	2.4e-10	Asthma;
LUAD	trans	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg02002194	chr4:3960332	NA	-0.29	-7.19	-0.33	2.96e-12	Mood instability;
LUAD	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-8.33	-0.38	1.17e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg02782426	chr3:40428986	ENTPD3	-0.33	-6.87	-0.32	2.33e-11	Renal cell carcinoma;
LUAD	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg07153921	chr17:41440717	NA	-0.38	-6.36	-0.3	5.16e-10	Menopause (age at onset);
LUAD	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg15921436	chr17:44337874	NA	0.88	11.69	0.49	1.48e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.09	-0.44	1.38e-21	Migraine;Coronary artery disease;
LUAD	cis	rs12545109	0.800	rs1595940	chr8:57398309	T/C	cg21220214	chr8:57350948	NA	-0.64	-9.06	-0.4	4.89e-18	Obesity-related traits;
LUAD	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg24112000	chr20:60950667	NA	0.73	12.16	0.51	2.13e-29	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg10183150	chr4:120222239	C4orf3	-0.31	-6.41	-0.3	3.83e-10	Corneal astigmatism;
LUAD	cis	rs11048434	0.736	rs2041625	chr12:9112005	C/T	cg23795048	chr12:9217529	LOC144571	0.43	7.91	0.36	2.3e-14	Sjögren's syndrome;
LUAD	cis	rs4790333	0.562	rs2447108	chr17:2257993	C/T	cg02569219	chr17:2266849	SGSM2	0.52	9.87	0.43	8.29e-21	Proinsulin levels;
LUAD	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg22482690	chr17:47019901	SNF8	0.47	9.1	0.4	3.6e-18	Type 2 diabetes;
LUAD	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.47	8.37	0.38	8.27e-16	Type 2 diabetes;
LUAD	cis	rs6835098	0.608	rs2332668	chr4:174163360	A/G	cg27433088	chr4:174089019	GALNT7	0.4	7.84	0.36	3.73e-14	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg06108461	chr20:60628389	TAF4	-0.82	-14.15	-0.57	1.78e-37	Body mass index;
LUAD	trans	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg19862616	chr7:65841803	NCRNA00174	1.04	25.09	0.77	9.05e-86	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg05283184	chr6:79620031	NA	-0.54	-10.38	-0.45	1.24e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-16.17	-0.62	3.79e-46	Schizophrenia;
LUAD	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg04369109	chr6:150039330	LATS1	-0.44	-7.36	-0.34	9.65e-13	Lung cancer;
LUAD	cis	rs11723261	0.621	rs3829	chr4:134851	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.39	6.36	0.3	5.31e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2625529	0.818	rs16956241	chr15:72111688	G/T	cg16672083	chr15:72433130	SENP8	-0.73	-11.96	-0.5	1.33e-28	Red blood cell count;
LUAD	cis	rs9905704	0.633	rs2680687	chr17:56491966	T/C	cg19466818	chr17:56409534	MIR142	-0.35	-6.86	-0.32	2.44e-11	Testicular germ cell tumor;
LUAD	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg07570687	chr10:102243282	WNT8B	0.48	7.39	0.34	8.08e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg07211511	chr3:129823064	LOC729375	-0.55	-7.08	-0.33	5.92e-12	Blood pressure (smoking interaction);
LUAD	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg10589385	chr1:150898437	SETDB1	0.4	7.42	0.34	6.66e-13	Melanoma;
LUAD	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg15628303	chr1:26608928	UBXN11	-0.36	-6.38	-0.3	4.61e-10	Height;
LUAD	cis	rs3750965	0.920	rs4930644	chr11:68819097	C/T	cg06818126	chr11:68850279	TPCN2	-0.46	-6.5	-0.3	2.2e-10	Hair color;
LUAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg13560548	chr3:10150139	C3orf24	0.4	6.56	0.3	1.53e-10	Alzheimer's disease;
LUAD	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg27661571	chr11:113659931	NA	-0.71	-8.32	-0.38	1.21e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.74	0.31	5.13e-11	Parkinson's disease;
LUAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg04025307	chr7:1156635	C7orf50	0.65	7.41	0.34	7.09e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg24596788	chr1:163392923	NA	-0.34	-7.31	-0.33	1.37e-12	Motion sickness;
LUAD	cis	rs7089973	0.966	rs749649	chr10:116641999	G/A	cg23260525	chr10:116636907	FAM160B1	0.42	9.05	0.4	5.17e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg03609598	chr5:56110824	MAP3K1	-0.67	-9.12	-0.41	3.06e-18	Initial pursuit acceleration;
LUAD	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg00277334	chr10:82204260	NA	-0.6	-9.97	-0.44	3.48e-21	Post bronchodilator FEV1;
LUAD	cis	rs1564271	0.632	rs2368183	chr10:26998739	G/C	cg13837822	chr10:26931731	LOC731789	0.46	9.57	0.42	8.8e-20	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUAD	cis	rs471144	0.881	rs12089980	chr1:152431931	C/T	cg13498757	chr1:152161927	NA	0.76	7.91	0.36	2.27e-14	Inflammatory skin disease;
LUAD	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11644478	chr21:40555479	PSMG1	0.68	11.24	0.48	7.82e-26	Cognitive function;
LUAD	cis	rs2249625	0.545	rs10498880	chr6:72882183	G/T	cg18830697	chr6:72922368	RIMS1	0.46	8.23	0.37	2.41e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg09537434	chr19:41945824	ATP5SL	-0.42	-6.62	-0.31	1.12e-10	Height;
LUAD	cis	rs34734847	0.787	rs695949	chr12:121149736	A/G	cg27246729	chr12:121163418	ACADS	0.35	6.51	0.3	2.18e-10	Mean corpuscular volume;
LUAD	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg18755752	chr8:142205143	DENND3	-0.73	-14.47	-0.58	8.02e-39	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg04703951	chr17:43578652	NA	0.61	8.32	0.38	1.22e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.53	-0.3	1.87e-10	Total body bone mineral density;
LUAD	cis	rs11811982	0.793	rs115576012	chr1:227476031	G/A	cg24860534	chr1:227506868	CDC42BPA	0.71	7.5	0.34	3.79e-13	Optic disc area;
LUAD	cis	rs2657888	0.529	rs12316930	chr12:56885816	C/G	cg23002907	chr12:56915593	RBMS2	-0.4	-6.98	-0.32	1.17e-11	Adiponectin levels;
LUAD	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg12908607	chr1:44402522	ARTN	-0.45	-8.95	-0.4	1.1e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21582582	chr3:182698605	DCUN1D1	0.61	9.23	0.41	1.29e-18	Resting heart rate;
LUAD	cis	rs3018712	0.532	rs28551086	chr11:68400739	G/A	cg16797656	chr11:68205561	LRP5	0.44	6.54	0.3	1.73e-10	Total body bone mineral density;
LUAD	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg09222892	chr1:25734099	RHCE	-0.5	-9.31	-0.41	7.19e-19	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg01802117	chr1:53393560	SCP2	-0.4	-7.56	-0.34	2.59e-13	Monocyte count;
LUAD	cis	rs2637266	0.934	rs2395408	chr10:78380929	G/A	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.06e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg05340658	chr4:99064831	C4orf37	0.45	6.91	0.32	1.76e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg08280861	chr8:58055591	NA	0.57	7.41	0.34	6.98e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg18825076	chr15:78729989	IREB2	0.48	6.64	0.31	9.68e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs1018836	0.608	rs2142146	chr8:91464808	T/C	cg16814680	chr8:91681699	NA	-0.56	-9.37	-0.41	4.28e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2235642	0.533	rs2667679	chr16:1654946	G/A	cg26528668	chr16:1614120	IFT140	0.46	7.86	0.36	3.23e-14	Coronary artery disease;
LUAD	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg00666640	chr1:248458726	OR2T12	0.33	7.97	0.36	1.46e-14	Common traits (Other);
LUAD	cis	rs7289126	1.000	rs7290309	chr22:38630287	C/T	cg25457927	chr22:38595422	NA	-0.41	-9.48	-0.42	1.86e-19	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg08027265	chr7:2291960	NA	-0.41	-6.62	-0.31	1.08e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs117623576	0.941	rs17230172	chr10:32438490	G/T	cg03047570	chr10:32398778	NA	-0.8	-9.24	-0.41	1.24e-18	Anti-saccade response;
LUAD	trans	rs1941687	0.673	rs4427879	chr18:31404751	A/G	cg27147174	chr7:100797783	AP1S1	-0.54	-9.35	-0.41	5.05e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg03433033	chr1:76189801	ACADM	-0.49	-7.01	-0.32	9.49e-12	Daytime sleep phenotypes;
LUAD	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	10.33	0.45	1.82e-22	Lung cancer in ever smokers;
LUAD	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg24450063	chr1:156163899	SLC25A44	1.15	26.6	0.79	2.57e-92	Testicular germ cell tumor;
LUAD	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg12179176	chr11:130786555	SNX19	0.4	6.49	0.3	2.35e-10	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.54	-0.3	1.83e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18876405	chr7:65276391	NA	0.42	6.7	0.31	6.8e-11	Aortic root size;
LUAD	cis	rs17401966	0.838	rs12139981	chr1:10390696	T/C	cg19773385	chr1:10388646	KIF1B	-0.41	-6.81	-0.31	3.4e-11	Hepatocellular carcinoma;
LUAD	cis	rs9394841	0.585	rs9381096	chr6:41821137	C/T	cg17623882	chr6:41773611	USP49	-0.53	-7.09	-0.33	5.76e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg08280861	chr8:58055591	NA	0.55	7.52	0.34	3.22e-13	Developmental language disorder (linguistic errors);
LUAD	trans	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg13565492	chr6:43139072	SRF	-0.61	-6.45	-0.3	2.99e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6541297	0.645	rs2296065	chr1:230301776	G/A	cg20703242	chr1:230279135	GALNT2	0.54	7.82	0.36	4.37e-14	Coronary artery disease;
LUAD	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg09184832	chr6:79620586	NA	-0.51	-9.74	-0.43	2.34e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg02158880	chr13:53174818	NA	-0.42	-7.22	-0.33	2.44e-12	Lewy body disease;
LUAD	trans	rs4714291	0.963	rs847777	chr6:40055754	C/T	cg02267698	chr19:7991119	CTXN1	0.44	6.81	0.31	3.43e-11	Strep throat;
LUAD	cis	rs7818345	1.000	rs7011602	chr8:19308915	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.33	7.37	0.34	9.32e-13	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.31	6.45	0.3	3.01e-10	Obesity-related traits;
LUAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	13.22	0.54	1.23e-33	Lymphocyte counts;
LUAD	cis	rs9287719	0.745	rs4997809	chr2:10755542	G/A	cg01299579	chr2:10830716	NOL10	-0.41	-7.17	-0.33	3.39e-12	Prostate cancer;
LUAD	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg14769373	chr6:40998127	UNC5CL	-0.35	-6.54	-0.3	1.73e-10	Alzheimer's disease (late onset);
LUAD	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg04450456	chr4:17643702	FAM184B	-0.42	-8.04	-0.36	9.11e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.39	-6.54	-0.3	1.75e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs4730229	chr7:106925353	A/G	cg02696742	chr7:106810147	HBP1	-0.78	-10.68	-0.46	9.7e-24	Coronary artery disease;
LUAD	cis	rs8077889	0.917	rs4793038	chr17:41916761	A/T	cg26893861	chr17:41843967	DUSP3	0.89	15.08	0.59	1.93e-41	Triglycerides;
LUAD	cis	rs6847149	0.929	rs4698798	chr4:110792629	C/T	cg07850274	chr4:110748770	RRH	-0.46	-7.09	-0.33	5.67e-12	Exercise treadmill test traits;
LUAD	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13315871	1.000	rs9844128	chr3:58391127	C/T	cg12435725	chr3:58293450	RPP14	-0.67	-7.06	-0.32	6.9e-12	Cholesterol, total;
LUAD	cis	rs7224737	0.789	rs8071235	chr17:40300126	C/A	cg02450064	chr17:40260053	DHX58	-0.44	-7.17	-0.33	3.32e-12	Fibrinogen levels;
LUAD	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg04850017	chr11:63683019	RCOR2	0.54	13.09	0.54	3.96e-33	Pulse pressure;
LUAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg13560548	chr3:10150139	C3orf24	0.45	7.66	0.35	1.27e-13	Alzheimer's disease;
LUAD	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg01181863	chr3:195395398	SDHAP2	-0.58	-8.83	-0.39	2.75e-17	Pancreatic cancer;
LUAD	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg14196790	chr5:131705035	SLC22A5	0.38	6.71	0.31	6.25e-11	Blood metabolite levels;
LUAD	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg11871910	chr12:69753446	YEATS4	0.7	12.04	0.51	6.75e-29	Blood protein levels;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg20705469	chr1:233121957	PCNXL2	-0.39	-6.48	-0.3	2.54e-10	Diastolic blood pressure;
LUAD	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg07507251	chr3:52567010	NT5DC2	0.38	7.42	0.34	6.69e-13	Bipolar disorder;
LUAD	cis	rs3760982	1.000	rs10405457	chr19:44296582	G/T	cg11993925	chr19:44307056	LYPD5	0.42	8.39	0.38	7.23e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg04282206	chr17:62833786	PLEKHM1P	-0.54	-8.22	-0.37	2.51e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg24829409	chr8:58192753	C8orf71	-0.57	-6.9	-0.32	1.85e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.38	6.46	0.3	2.96e-10	Rheumatoid arthritis;
LUAD	cis	rs2625529	0.824	rs12592364	chr15:72284647	C/A	cg16672083	chr15:72433130	SENP8	-0.76	-12.67	-0.52	1.99e-31	Red blood cell count;
LUAD	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.27	0.33	1.73e-12	Breast cancer;
LUAD	cis	rs4853036	1.000	rs13020991	chr2:70068642	A/G	cg02498382	chr2:70120550	SNRNP27	-0.5	-8.1	-0.37	5.8e-15	Colorectal or endometrial cancer;
LUAD	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg16989719	chr2:238392110	NA	-0.38	-8.01	-0.36	1.15e-14	Prostate cancer;
LUAD	cis	rs67981189	0.558	rs56043821	chr14:71570552	T/C	cg15910301	chr14:71632612	NA	0.41	6.52	0.3	2.04e-10	Schizophrenia;
LUAD	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg01849466	chr14:104193079	ZFYVE21	0.5	8.37	0.38	8.33e-16	Body mass index;
LUAD	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg05872129	chr22:39784769	NA	-0.82	-15.38	-0.6	1.04e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18402987	chr7:1209562	NA	0.47	8.34	0.38	1.1e-15	Longevity;Endometriosis;
LUAD	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.86	-0.36	3.31e-14	Monocyte percentage of white cells;
LUAD	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.53	-0.52	7.36e-31	Monocyte count;
LUAD	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg04287289	chr16:89883240	FANCA	0.46	7.27	0.33	1.79e-12	Vitiligo;
LUAD	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg27284194	chr4:1044797	NA	0.7	10.13	0.44	9.73e-22	Recombination rate (females);
LUAD	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-9.62	-0.42	5.91e-20	Life satisfaction;
LUAD	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg11663144	chr21:46675770	NA	-0.59	-11.76	-0.5	7.73e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg07195577	chr17:27052828	TLCD1	0.46	6.5	0.3	2.33e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9549328	0.589	rs34144481	chr13:113617322	T/G	cg17524180	chr13:113633600	MCF2L	0.3	6.46	0.3	2.81e-10	Systolic blood pressure;
LUAD	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg21709803	chr11:61594965	FADS2	-0.41	-7.15	-0.33	3.84e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	trans	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg26043149	chr18:55253948	FECH	1.05	17.66	0.65	1.05e-52	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs10089	0.909	rs7732599	chr5:127370421	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	9.79	0.43	1.52e-20	Ileal carcinoids;
LUAD	cis	rs243505	1.000	rs243502	chr7:148437205	C/T	cg09806900	chr7:148480153	CUL1	-0.43	-7.2	-0.33	2.86e-12	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg00784671	chr22:46762841	CELSR1	-0.41	-6.35	-0.3	5.42e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs41311933	1.000	rs41311867	chr9:123753600	G/T	cg13567360	chr9:123745713	C5	-0.83	-9.33	-0.41	6.24e-19	Coronary artery disease;
LUAD	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.93	0.32	1.54e-11	Rheumatoid arthritis;
LUAD	trans	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg27411982	chr8:10470053	RP1L1	-0.4	-7.32	-0.34	1.26e-12	Joint mobility (Beighton score);
LUAD	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.52	10.79	0.46	4e-24	Monocyte percentage of white cells;
LUAD	cis	rs8077889	0.750	rs231535	chr17:41944865	T/G	cg26893861	chr17:41843967	DUSP3	-0.85	-10.92	-0.47	1.32e-24	Triglycerides;
LUAD	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18099408	chr3:52552593	STAB1	-0.43	-7.7	-0.35	1e-13	Bipolar disorder;
LUAD	cis	rs447921	0.813	rs435892	chr17:74398505	A/T	cg17201438	chr17:74438067	UBE2O	-0.62	-8.23	-0.37	2.34e-15	Mitochondrial DNA levels;
LUAD	cis	rs35995292	0.534	rs2392607	chr7:38930380	G/A	cg19327137	chr7:38886074	VPS41	0.73	15.42	0.6	6.82e-43	Subjective well-being (multi-trait analysis);
LUAD	cis	rs1003719	0.688	rs2000416	chr21:38540089	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-7.48	-0.34	4.47e-13	Eye color traits;
LUAD	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg22875332	chr1:76189707	ACADM	0.76	12.25	0.51	9.55e-30	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg11050988	chr7:1952600	MAD1L1	-0.38	-7.77	-0.35	6.01e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs12431939	0.947	rs56156789	chr14:51633899	C/G	cg23942311	chr14:51606299	NA	-0.64	-8.75	-0.39	5.3e-17	Cancer;
LUAD	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.94	-0.36	1.8e-14	Reticulocyte count;
LUAD	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.75	-0.31	5.03e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg24829409	chr8:58192753	C8orf71	-0.61	-9.24	-0.41	1.25e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg24596788	chr1:163392923	NA	-0.34	-7.31	-0.33	1.38e-12	Motion sickness;
LUAD	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.62	10.11	0.44	1.15e-21	Cognitive ability;
LUAD	cis	rs151349	1.000	rs108727	chr20:57584890	C/T	cg23907860	chr20:57583709	CTSZ	0.55	10.49	0.45	4.89e-23	Platelet distribution width;
LUAD	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg00852783	chr1:26633632	UBXN11	0.46	7.61	0.35	1.83e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg20607798	chr8:58055168	NA	0.83	10.02	0.44	2.39e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg22920501	chr2:26401640	FAM59B	-0.8	-11.35	-0.48	2.97e-26	Gut microbiome composition (summer);
LUAD	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.1	-0.33	5.35e-12	Reticulocyte count;
LUAD	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg06740227	chr12:86229804	RASSF9	0.4	6.96	0.32	1.3e-11	Major depressive disorder;
LUAD	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs6546550	0.526	rs6546561	chr2:70174691	C/T	cg02498382	chr2:70120550	SNRNP27	-0.53	-9.64	-0.42	5.33e-20	Prevalent atrial fibrillation;
LUAD	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg03929089	chr4:120376271	NA	-0.98	-20.58	-0.71	1.01e-65	Height;
LUAD	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg23887609	chr12:130822674	PIWIL1	0.4	6.76	0.31	4.49e-11	Menopause (age at onset);
LUAD	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Parkinson's disease;
LUAD	cis	rs2637266	1.000	rs7477433	chr10:78358116	C/T	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs2274273	0.870	rs8018110	chr14:55641714	C/T	cg04306507	chr14:55594613	LGALS3	0.41	8.37	0.38	8.46e-16	Protein biomarker;
LUAD	cis	rs490234	0.702	rs35237975	chr9:128313867	A/G	cg14078157	chr9:128172775	NA	-0.47	-8.43	-0.38	5.48e-16	Mean arterial pressure;
LUAD	cis	rs8060686	0.623	rs12599178	chr16:68128104	A/G	cg26727032	chr16:67993705	SLC12A4	-0.47	-7.78	-0.35	5.76e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg12623302	chr6:28058802	ZSCAN12L1	-0.33	-6.69	-0.31	7.21e-11	Depression;
LUAD	cis	rs4776059	1.000	rs12915981	chr15:52901433	C/T	cg24008177	chr15:52972085	KIAA1370	0.23	6.4	0.3	4.17e-10	Schizophrenia;
LUAD	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg05564831	chr3:52568323	NT5DC2	0.36	6.68	0.31	7.6e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7180079	1.000	rs2306974	chr15:64486527	A/G	cg08069370	chr15:64387884	SNX1	-0.5	-6.37	-0.3	4.86e-10	Monocyte count;
LUAD	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg11502198	chr6:26597334	ABT1	-0.55	-9.13	-0.41	2.85e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs6494488	0.500	rs72742982	chr15:64977055	C/T	cg08069370	chr15:64387884	SNX1	-0.73	-6.48	-0.3	2.51e-10	Coronary artery disease;
LUAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.65	-0.31	9.22e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	12.55	0.52	6.31e-31	Lymphocyte counts;
LUAD	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg24818145	chr4:99064322	C4orf37	0.49	8.44	0.38	4.98e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1832871	0.672	rs12525675	chr6:158708749	A/T	cg07165851	chr6:158734300	TULP4	0.7	11.17	0.48	1.45e-25	Height;
LUAD	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg06074448	chr4:187884817	NA	-0.38	-7.49	-0.34	4.11e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7508679	1.000	rs7508679	chr19:7222832	A/G	cg09779027	chr19:7224513	INSR	0.74	15.86	0.61	9.02e-45	Hypothyroidism;
LUAD	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg27494647	chr7:150038898	RARRES2	0.51	8.94	0.4	1.18e-17	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.37	7.52	0.34	3.4e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg20476274	chr7:133979776	SLC35B4	0.84	16.28	0.62	1.29e-46	Mean platelet volume;
LUAD	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg12623302	chr6:28058802	ZSCAN12L1	-0.33	-6.73	-0.31	5.66e-11	Parkinson's disease;
LUAD	cis	rs7584330	0.554	rs74832280	chr2:238426625	G/A	cg14458575	chr2:238380390	NA	0.61	9.85	0.43	9.8e-21	Prostate cancer;
LUAD	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg02743256	chr7:2109353	MAD1L1	-0.48	-6.62	-0.31	1.12e-10	Bipolar disorder;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg08800530	chr5:175788722	KIAA1191	-0.37	-6.53	-0.3	1.88e-10	Subcortical brain region volumes;
LUAD	cis	rs497273	0.517	rs509152	chr12:121186549	C/G	cg13914990	chr12:121174878	ACADS	-0.34	-6.55	-0.3	1.72e-10	Systemic lupus erythematosus;
LUAD	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.64	-0.35	1.48e-13	Personality dimensions;
LUAD	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11890956	chr21:40555474	PSMG1	-0.56	-9.74	-0.43	2.24e-20	Menarche (age at onset);
LUAD	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg00933542	chr6:150070202	PCMT1	0.44	9.68	0.43	3.86e-20	Lung cancer;
LUAD	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1232027	0.656	rs1650681	chr5:79958258	A/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.02	-0.32	8.67e-12	Huntington's disease progression;
LUAD	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg00933542	chr6:150070202	PCMT1	0.35	7.23	0.33	2.21e-12	Lung cancer;
LUAD	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg20135002	chr11:47629003	NA	-0.4	-7.05	-0.32	7.23e-12	Subjective well-being;
LUAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08048268	chr3:133502702	NA	-0.55	-10.79	-0.46	3.73e-24	Iron status biomarkers;
LUAD	cis	rs3784262	0.869	rs12903792	chr15:58261280	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.45	-9.31	-0.41	6.89e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7680126	0.596	rs17198547	chr4:10141419	A/G	cg02734326	chr4:10020555	SLC2A9	0.48	6.76	0.31	4.46e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9796	0.621	rs12324159	chr15:41462468	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.67	-0.39	9.26e-17	Menopause (age at onset);
LUAD	trans	rs1973993	0.689	rs67544133	chr1:96971241	G/A	cg10631902	chr5:14652156	NA	-0.47	-8.05	-0.36	8.63e-15	Weight;
LUAD	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg07432352	chr17:45403706	C17orf57	-0.4	-7.69	-0.35	1.02e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg21782813	chr7:2030301	MAD1L1	0.51	8.6	0.39	1.62e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg12179176	chr11:130786555	SNX19	0.45	7.28	0.33	1.63e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs6540	1.000	rs548551	chr11:255048	A/T	cg01022370	chr8:8749074	MFHAS1	0.69	7.21	0.33	2.53e-12	Endometriosis;
LUAD	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg04545296	chr12:48745243	ZNF641	0.39	10.01	0.44	2.5e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg04455712	chr21:45112962	RRP1B	0.43	8.67	0.39	9.27e-17	Mean corpuscular volume;
LUAD	cis	rs4953076	0.573	rs6738023	chr2:44405931	T/C	cg04920474	chr2:44395004	PPM1B	0.57	8.76	0.39	4.65e-17	Height;
LUAD	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.51	8.45	0.38	4.62e-16	Electrocardiographic conduction measures;
LUAD	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg14835575	chr10:16859367	RSU1	0.5	7.61	0.35	1.74e-13	Platelet distribution width;
LUAD	cis	rs77106637	0.860	rs7129793	chr11:72455885	C/T	cg03878208	chr11:72483293	STARD10	0.62	8.09	0.37	6.22e-15	Type 2 diabetes;
LUAD	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-9.57	-0.42	9.34e-20	Gut microbiome composition (summer);
LUAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg22764044	chr5:178986830	RUFY1	-0.57	-9.67	-0.43	4.21e-20	Lung cancer;
LUAD	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg08999081	chr20:33150536	PIGU	0.48	9.28	0.41	9.02e-19	Coronary artery disease;
LUAD	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23583168	chr7:148888333	NA	0.92	19.32	0.68	4.29e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg18490616	chr2:88469792	THNSL2	0.8	8.0	0.36	1.17e-14	Plasma clusterin levels;
LUAD	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	7.78	0.35	5.56e-14	Menopause (age at onset);
LUAD	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg17971929	chr21:40555470	PSMG1	0.52	8.15	0.37	4.06e-15	Cognitive function;
LUAD	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg02475777	chr4:1388615	CRIPAK	0.57	8.47	0.38	4.15e-16	Longevity;
LUAD	cis	rs939658	0.805	rs2010524	chr15:79435825	G/T	cg17916960	chr15:79447300	NA	-0.51	-10.63	-0.46	1.53e-23	Refractive error;
LUAD	cis	rs7107174	0.688	rs10899501	chr11:78131408	C/T	cg02023728	chr11:77925099	USP35	0.42	6.4	0.3	4.22e-10	Testicular germ cell tumor;
LUAD	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg00383909	chr3:49044727	WDR6	-0.49	-6.55	-0.3	1.66e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg00074818	chr8:8560427	CLDN23	0.66	10.19	0.44	6.13e-22	Obesity-related traits;
LUAD	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg05182265	chr7:156933206	UBE3C	0.67	13.02	0.53	8.03e-33	Body mass index;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg18000306	chr6:288505	NA	0.42	7.91	0.36	2.28e-14	Menopause (age at onset);
LUAD	cis	rs9296092	0.517	rs78978280	chr6:33520747	T/A	cg13560919	chr6:33536144	NA	-0.87	-15.54	-0.6	2.02e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.76	-0.31	4.72e-11	Height;
LUAD	trans	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg14917512	chr19:3094685	GNA11	-0.38	-6.61	-0.31	1.18e-10	Aortic root size;
LUAD	trans	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg09872104	chr7:134855509	C7orf49	-0.88	-7.63	-0.35	1.6e-13	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs12530845	0.945	rs76298187	chr7:135334534	A/G	cg23117316	chr7:135346802	PL-5283	-0.49	-9.11	-0.41	3.24e-18	Red blood cell traits;
LUAD	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg10556349	chr10:835070	NA	0.47	6.46	0.3	2.96e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg15117754	chr3:10150083	C3orf24	0.43	7.04	0.32	7.93e-12	Alzheimer's disease;
LUAD	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg05966235	chr16:28915196	ATP2A1	0.46	7.44	0.34	5.86e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs56979318	1	rs56979318	chr17:80522718	A/T	cg10255544	chr17:80519551	FOXK2	0.34	6.69	0.31	7.18e-11	Reticulocyte count;
LUAD	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg03806693	chr22:41940476	POLR3H	-0.5	-7.49	-0.34	4.13e-13	Vitiligo;
LUAD	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.47	0.38	3.95e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.83	0.43	1.16e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg13560548	chr3:10150139	C3orf24	0.45	6.99	0.32	1.11e-11	Alzheimer's disease;
LUAD	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.35	7.31	0.33	1.38e-12	Depression;
LUAD	cis	rs853679	0.585	rs201000	chr6:27809159	C/T	cg08798685	chr6:27730294	NA	-0.45	-6.79	-0.31	3.83e-11	Depression;
LUAD	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg18129748	chr3:49941408	MST1R	-0.44	-7.24	-0.33	2.12e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg24112000	chr20:60950667	NA	-0.75	-9.07	-0.4	4.49e-18	Colorectal cancer;
LUAD	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg05725404	chr16:58534157	NDRG4	-0.71	-7.49	-0.34	4.02e-13	Schizophrenia;
LUAD	cis	rs12545109	0.842	rs10958482	chr8:57389331	G/T	cg07776626	chr8:57350775	NA	-0.62	-8.94	-0.4	1.26e-17	Obesity-related traits;
LUAD	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg02527881	chr3:46936655	PTH1R	-0.49	-9.42	-0.42	2.99e-19	Colorectal cancer;
LUAD	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg21100191	chr22:23484243	RTDR1	-0.71	-12.75	-0.53	9.43e-32	Bone mineral density;
LUAD	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.77	-10.15	-0.44	8.59e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg00106254	chr7:1943704	MAD1L1	-0.54	-7.91	-0.36	2.19e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18876405	chr7:65276391	NA	0.44	6.94	0.32	1.47e-11	Aortic root size;
LUAD	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg15790184	chr11:494944	RNH1	0.39	6.38	0.3	4.66e-10	Systemic lupus erythematosus;
LUAD	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg02951883	chr7:2050386	MAD1L1	-0.59	-10.13	-0.44	9.82e-22	Schizophrenia;
LUAD	cis	rs6500395	1.000	rs2111243	chr16:48724897	C/T	cg04672837	chr16:48644449	N4BP1	-0.39	-6.75	-0.31	4.99e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg05368731	chr17:41323189	NBR1	0.98	20.49	0.71	2.59e-65	Menopause (age at onset);
LUAD	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.33	6.45	0.3	3e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg23172400	chr8:95962367	TP53INP1	-0.37	-8.89	-0.4	1.77e-17	Type 2 diabetes;
LUAD	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg00933542	chr6:150070202	PCMT1	0.47	9.96	0.44	3.77e-21	Lung cancer;
LUAD	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg06092702	chr1:163392909	NA	-0.39	-8.71	-0.39	6.8e-17	Motion sickness;
LUAD	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg03929089	chr4:120376271	NA	0.55	7.29	0.33	1.53e-12	Axial length;
LUAD	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg11502198	chr6:26597334	ABT1	0.5	8.07	0.37	7.47e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg09936400	chr10:82049201	MAT1A	-0.38	-6.74	-0.31	5.18e-11	Post bronchodilator FEV1;
LUAD	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg18230493	chr5:56204884	C5orf35	-0.47	-7.96	-0.36	1.63e-14	Coronary artery disease;
LUAD	cis	rs1595825	0.891	rs60582020	chr2:198520555	A/C	cg11031976	chr2:198649780	BOLL	-0.46	-6.83	-0.32	2.93e-11	Ulcerative colitis;
LUAD	cis	rs9902453	0.612	rs2617868	chr17:28073247	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.5	-0.45	4.52e-23	Coffee consumption (cups per day);
LUAD	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.21	-0.41	1.59e-18	Life satisfaction;
LUAD	cis	rs11048434	0.736	rs11048338	chr12:9121362	C/G	cg23795048	chr12:9217529	LOC144571	0.44	8.15	0.37	4.11e-15	Sjögren's syndrome;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17017335	chr3:97540665	NA	-0.41	-6.45	-0.3	2.99e-10	Height;
LUAD	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-9.55	-0.42	1.07e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6906287	0.647	rs3752581	chr6:118869730	G/A	cg05564266	chr6:118973597	C6orf204	0.35	7.44	0.34	5.61e-13	Electrocardiographic conduction measures;
LUAD	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	8.11	0.37	5.71e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs36051895	0.623	rs76960049	chr9:5064548	G/A	cg02405213	chr9:5042618	JAK2	-0.46	-6.59	-0.31	1.32e-10	Pediatric autoimmune diseases;
LUAD	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-9.75	-0.43	2.08e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.58	11.36	0.48	2.89e-26	Hemoglobin concentration;
LUAD	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg05535760	chr7:792225	HEATR2	-0.83	-9.87	-0.43	8.17e-21	Cerebrospinal P-tau181p levels;
LUAD	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg25251562	chr2:3704773	ALLC	0.6	10.04	0.44	2.08e-21	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg24803719	chr17:45855879	NA	-0.34	-7.52	-0.34	3.27e-13	IgG glycosylation;
LUAD	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg02240030	chr7:2089880	MAD1L1	0.37	6.37	0.3	5.07e-10	Neuroticism;
LUAD	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	12.82	0.53	5.16e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9462027	0.628	rs9462026	chr6:34797033	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.49	-0.38	3.49e-16	Systemic lupus erythematosus;
LUAD	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg20503657	chr10:835505	NA	1.25	18.38	0.67	7.13e-56	Eosinophil percentage of granulocytes;
LUAD	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg23376191	chr3:42055737	NA	-0.4	-6.47	-0.3	2.71e-10	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg02038168	chr22:39784481	NA	-0.51	-7.9	-0.36	2.45e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs4006360	1.000	rs4006360	chr17:39250639	A/G	cg20663846	chr17:39254439	KRTAP4-8	-0.36	-8.05	-0.36	8.44e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7737355	0.773	rs4706027	chr5:130932972	T/C	cg25547332	chr5:131281432	NA	0.4	6.44	0.3	3.31e-10	Life satisfaction;
LUAD	cis	rs1873147	0.569	rs8034365	chr15:63309203	C/T	cg12160578	chr15:63334699	TPM1	0.52	7.9	0.36	2.5e-14	Orofacial clefts;
LUAD	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg04352962	chr1:209979756	IRF6	0.5	6.46	0.3	2.86e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg03806693	chr22:41940476	POLR3H	-0.62	-8.78	-0.39	4.09e-17	Vitiligo;
LUAD	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg00204512	chr16:28754710	NA	0.31	6.46	0.3	2.92e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg21100191	chr22:23484243	RTDR1	0.71	12.3	0.51	6.29e-30	Bone mineral density;
LUAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg23978390	chr7:1156363	C7orf50	0.55	8.7	0.39	7.34e-17	Longevity;Endometriosis;
LUAD	cis	rs7582720	1.000	rs116382857	chr2:203751932	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.38	0.41	4.03e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-8.12	-0.37	5.24e-15	Alzheimer's disease;
LUAD	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg03709012	chr19:19516395	GATAD2A	0.53	6.9	0.32	1.92e-11	Nonalcoholic fatty liver disease;
LUAD	cis	rs6906287	0.647	rs2077162	chr6:118687469	G/A	cg18833306	chr6:118973337	C6orf204	0.44	7.71	0.35	8.94e-14	Electrocardiographic conduction measures;
LUAD	cis	rs2224391	0.628	rs2773310	chr6:5250828	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-8.78	-0.39	3.97e-17	Height;
LUAD	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg17366294	chr4:99064904	C4orf37	0.47	8.36	0.38	9.2e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs17532515	0.628	rs7693034	chr4:141478679	C/G	cg09181644	chr4:141490428	UCP1	-0.32	-7.02	-0.32	8.84e-12	Select biomarker traits;
LUAD	cis	rs71478720	0.953	rs7121554	chr11:112048051	C/T	cg04929355	chr11:112034997	IL18	0.45	7.15	0.33	3.81e-12	Interleukin-18 levels;
LUAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03647317	chr4:187891568	NA	-0.36	-6.71	-0.31	6.39e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg27211696	chr2:191398769	TMEM194B	0.61	7.91	0.36	2.22e-14	Diastolic blood pressure;
LUAD	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg23950597	chr19:37808831	NA	-0.6	-7.46	-0.34	4.88e-13	Coronary artery calcification;
LUAD	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg11502198	chr6:26597334	ABT1	0.68	11.91	0.5	2.06e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.55	0.46	2.83e-23	Colorectal cancer;
LUAD	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg23803603	chr1:2058230	PRKCZ	0.39	7.18	0.33	3.06e-12	Height;
LUAD	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.7	0.39	7.71e-17	Menopause (age at onset);
LUAD	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg20991723	chr1:152506922	NA	0.33	6.53	0.3	1.87e-10	Hair morphology;
LUAD	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg19041857	chr6:27730383	NA	-0.37	-6.4	-0.3	4.11e-10	Parkinson's disease;
LUAD	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg06784218	chr1:46089804	CCDC17	-0.49	-10.79	-0.46	3.99e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7737355	0.812	rs7731773	chr5:130973943	A/G	cg06307176	chr5:131281290	NA	0.44	7.16	0.33	3.6e-12	Life satisfaction;
LUAD	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-10.17	-0.44	7.15e-22	Electrocardiographic conduction measures;
LUAD	cis	rs977987	0.778	rs4888413	chr16:75443223	C/A	cg03315344	chr16:75512273	CHST6	0.64	14.07	0.56	3.87e-37	Dupuytren's disease;
LUAD	cis	rs4889855	0.556	rs4890040	chr17:78518408	G/A	cg16591659	chr17:78472290	NA	0.39	6.85	0.32	2.58e-11	Fractional excretion of uric acid;
LUAD	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg13393036	chr8:95962371	TP53INP1	-0.4	-9.56	-0.42	9.47e-20	Type 2 diabetes;
LUAD	cis	rs17102423	0.588	rs7150646	chr14:65540463	G/T	cg11161011	chr14:65562177	MAX	-0.44	-7.22	-0.33	2.46e-12	Obesity-related traits;
LUAD	cis	rs35883536	0.626	rs7536054	chr1:101047849	A/G	cg06223162	chr1:101003688	GPR88	-0.48	-9.31	-0.41	7.07e-19	Monocyte count;
LUAD	cis	rs4253772	0.575	rs9615979	chr22:46789021	G/T	cg18190219	chr22:46762943	CELSR1	-0.6	-6.53	-0.3	1.83e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg25566285	chr7:158114605	PTPRN2	-0.56	-12.47	-0.52	1.35e-30	Calcium levels;
LUAD	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg24578937	chr1:2090814	PRKCZ	0.78	16.28	0.62	1.3e-46	Height;
LUAD	cis	rs10193935	0.901	rs9789740	chr2:42486799	A/G	cg27598129	chr2:42591480	NA	-0.79	-9.73	-0.43	2.57e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg13606994	chr1:44402422	ARTN	-0.33	-6.79	-0.31	3.82e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg09253696	chr17:73873529	TRIM47	-0.41	-7.19	-0.33	3.04e-12	Psoriasis;
LUAD	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg22823121	chr1:150693482	HORMAD1	0.47	9.26	0.41	1.05e-18	Melanoma;
LUAD	cis	rs6684514	1.000	rs12130361	chr1:156260301	C/T	cg16558208	chr1:156270281	VHLL	0.53	9.53	0.42	1.29e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg22442454	chr1:209979470	IRF6	0.53	7.67	0.35	1.23e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg18404041	chr3:52824283	ITIH1	0.62	12.87	0.53	3.11e-32	Bipolar disorder;
LUAD	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg24163568	chr5:669837	TPPP	-0.35	-6.71	-0.31	6.45e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg12365402	chr11:9010492	NRIP3	0.44	8.02	0.36	1.07e-14	Hemoglobin concentration;
LUAD	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.56	0.38	2.12e-16	Rheumatoid arthritis;
LUAD	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg07157834	chr1:205819609	PM20D1	0.49	8.74	0.39	5.55e-17	Menarche (age at onset);
LUAD	trans	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	10.66	0.46	1.12e-23	Type 2 diabetes;
LUAD	cis	rs743757	1.000	rs734767	chr3:50431410	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.43	7.12	0.33	4.56e-12	Diastolic blood pressure;
LUAD	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg12292205	chr6:26970375	C6orf41	0.4	7.13	0.33	4.51e-12	Schizophrenia;
LUAD	cis	rs7100689	0.622	rs10749595	chr10:82172975	C/T	cg00277334	chr10:82204260	NA	-0.63	-9.92	-0.43	5.29e-21	Post bronchodilator FEV1;
LUAD	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg00204512	chr16:28754710	NA	0.31	6.36	0.3	5.21e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.75	16.38	0.62	4.52e-47	White blood cell count;
LUAD	cis	rs25645	0.502	rs8065126	chr17:38099035	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.45	8.37	0.38	8.69e-16	Myeloid white cell count;
LUAD	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg19052272	chr2:3704530	ALLC	-0.42	-7.34	-0.34	1.07e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs6484504	0.532	rs7121949	chr11:31288160	G/T	cg14844989	chr11:31128820	NA	-0.45	-8.36	-0.38	9.37e-16	Red blood cell count;
LUAD	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.53	-9.33	-0.41	6.16e-19	Axial length;
LUAD	cis	rs4698790	0.555	rs4404543	chr4:110686959	G/C	cg07850274	chr4:110748770	RRH	0.41	6.71	0.31	6.1e-11	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUAD	cis	rs4308124	0.708	rs61358692	chr2:111965159	T/C	cg04571233	chr2:111982156	NA	-0.45	-6.42	-0.3	3.76e-10	Vitiligo;
LUAD	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	15.71	0.61	3.73e-44	Smoking behavior;
LUAD	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.76	10.42	0.45	8.82e-23	Smoking behavior;
LUAD	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg13319975	chr6:146136371	FBXO30	0.64	10.98	0.47	7.57e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	4.04e-11	Depression;
LUAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg02951883	chr7:2050386	MAD1L1	-0.97	-18.67	-0.67	3.53e-57	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9972944	0.702	rs987930	chr17:63765862	C/T	cg07283582	chr17:63770753	CCDC46	-0.5	-11.18	-0.48	1.28e-25	Total body bone mineral density;
LUAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.76e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg22431228	chr1:16359049	CLCNKA	-0.53	-9.54	-0.42	1.17e-19	Dilated cardiomyopathy;
LUAD	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.38	6.68	0.31	7.4e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg03526776	chr6:41159608	TREML2	0.33	6.83	0.32	2.88e-11	Alzheimer's disease (late onset);
LUAD	cis	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg02751453	chr18:77725136	HSBP1L1	0.37	7.18	0.33	3.24e-12	Opioid sensitivity;
LUAD	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg10295955	chr4:187884368	NA	-1.15	-28.4	-0.81	4.61e-100	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4077515	0.839	rs3812563	chr9:139271106	A/G	cg14169450	chr9:139327907	INPP5E	0.4	7.27	0.33	1.71e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs62400317	0.793	rs12190367	chr6:45208938	A/G	cg20913747	chr6:44695427	NA	-0.44	-6.84	-0.32	2.78e-11	Total body bone mineral density;
LUAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg18538332	chr22:24372958	LOC391322	-0.47	-7.89	-0.36	2.57e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg08742575	chr21:47604166	C21orf56	0.64	11.34	0.48	3.39e-26	Testicular germ cell tumor;
LUAD	cis	rs7084921	0.608	rs12761969	chr10:101832036	G/C	cg19754520	chr10:101825118	CPN1	-0.35	-7.12	-0.33	4.61e-12	Bone mineral density;
LUAD	cis	rs2686555	0.502	rs693074	chr12:121077728	A/C	cg13504434	chr12:121088311	CABP1	0.39	6.55	0.3	1.63e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg04248312	chr19:17393744	ANKLE1	-1.02	-18.8	-0.67	9.15e-58	Systemic lupus erythematosus;
LUAD	cis	rs3916	0.955	rs12828810	chr12:121152017	T/G	cg27246729	chr12:121163418	ACADS	0.46	7.51	0.34	3.49e-13	Urinary metabolites (H-NMR features);
LUAD	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg05616858	chr17:37843591	ERBB2;PGAP3	0.33	6.69	0.31	7.2e-11	Asthma;
LUAD	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.39	0.38	7.55e-16	Breast cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg17076397	chr5:10353763	MARCH6	-0.69	-6.67	-0.31	8.15e-11	Type 2 diabetes;
LUAD	cis	rs17095355	1.000	rs17126883	chr10:111694696	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.68	-8.97	-0.4	9.83e-18	Biliary atresia;
LUAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08280861	chr8:58055591	NA	0.67	8.72	0.39	6.27e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs786425	0.682	rs7399224	chr12:124195856	G/T	cg02460419	chr12:124198876	ATP6V0A2	0.33	6.52	0.3	1.97e-10	Pubertal anthropometrics;
LUAD	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.76	0.31	4.49e-11	Platelet count;
LUAD	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg03233332	chr7:66118400	NA	0.47	7.06	0.32	6.79e-12	Aortic root size;
LUAD	cis	rs11696501	0.739	rs6073822	chr20:44251880	A/G	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.16	-0.37	3.85e-15	Brain structure;
LUAD	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.36	7.51	0.34	3.51e-13	Parkinson's disease;
LUAD	cis	rs7584330	0.554	rs13411613	chr2:238437560	T/C	cg14458575	chr2:238380390	NA	0.6	9.2	0.41	1.61e-18	Prostate cancer;
LUAD	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg15181151	chr6:150070149	PCMT1	0.35	6.83	0.32	2.9e-11	Lung cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg16645584	chr1:59247487	JUN	-0.47	-7.69	-0.35	1.01e-13	Schizophrenia;
LUAD	cis	rs12286929	0.589	rs4938190	chr11:115087750	C/T	cg04055981	chr11:115044050	NA	0.39	7.02	0.32	8.77e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05787890	chr3:183165321	NA	-0.69	-6.77	-0.31	4.24e-11	Type 2 diabetes;
LUAD	cis	rs11771526	0.901	rs62457473	chr7:32306990	G/A	cg27532318	chr7:32358331	NA	0.58	7.52	0.34	3.42e-13	Body mass index;
LUAD	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg05373962	chr22:49881684	NA	-0.49	-9.64	-0.42	5.15e-20	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg02782426	chr3:40428986	ENTPD3	-0.42	-9.17	-0.41	2.07e-18	Renal cell carcinoma;
LUAD	cis	rs9287719	0.639	rs2357649	chr2:10696788	C/T	cg00105475	chr2:10696890	NA	-0.41	-7.21	-0.33	2.61e-12	Prostate cancer;
LUAD	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg25358565	chr5:93447407	FAM172A	0.65	7.68	0.35	1.11e-13	Diabetic retinopathy;
LUAD	cis	rs2486012	1.000	rs2428954	chr1:44442930	A/G	cg12908607	chr1:44402522	ARTN	0.5	6.49	0.3	2.47e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs7200543	1.000	rs2740	chr16:15132108	A/G	cg24683922	chr1:11983373	KIAA2013	-0.48	-7.99	-0.36	1.28e-14	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg03929089	chr4:120376271	NA	-0.86	-15.74	-0.61	2.96e-44	Coronary artery disease;
LUAD	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg25036284	chr2:26402008	FAM59B	-0.81	-11.67	-0.49	1.82e-27	Gut microbiome composition (summer);
LUAD	cis	rs990171	0.520	rs4851605	chr2:103120868	A/G	cg03938978	chr2:103052716	IL18RAP	0.33	6.54	0.3	1.83e-10	Lymphocyte counts;
LUAD	cis	rs6445967	1.000	rs62258069	chr3:58315263	A/T	cg23715586	chr3:58305044	RPP14	0.46	8.2	0.37	2.85e-15	Platelet count;
LUAD	cis	rs2692947	0.537	rs11688045	chr2:96243805	A/T	cg23100626	chr2:96804247	ASTL	0.34	7.71	0.35	8.89e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg12419862	chr22:24373484	LOC391322	-0.69	-11.7	-0.49	1.43e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg22029157	chr1:209979665	IRF6	0.47	8.39	0.38	7.36e-16	Monobrow;
LUAD	cis	rs220324	0.688	rs8133222	chr21:43568683	A/G	cg08841829	chr21:43638893	ABCG1	-0.47	-6.8	-0.31	3.57e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.57	8.33	0.38	1.17e-15	Platelet count;
LUAD	cis	rs11951515	1.000	rs11951515	chr5:43382858	T/C	cg01983248	chr5:43482804	C5orf28	-0.31	-6.36	-0.3	5.14e-10	Metabolite levels  (X-11787);
LUAD	cis	rs1595825	0.891	rs16826895	chr2:198901642	A/G	cg00982548	chr2:198649783	BOLL	-0.68	-9.45	-0.42	2.37e-19	Ulcerative colitis;
LUAD	cis	rs17155006	0.655	rs389486	chr7:107727804	C/G	cg05962710	chr7:107745446	LAMB4	-0.3	-6.47	-0.3	2.66e-10	Pneumococcal bacteremia;
LUAD	cis	rs11048434	0.736	rs11048337	chr12:9121330	C/A	cg26114124	chr12:9217669	LOC144571	0.35	6.55	0.3	1.64e-10	Sjögren's syndrome;
LUAD	trans	rs877282	0.853	rs11593836	chr10:756715	G/A	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	cis	rs7771547	0.574	rs9368943	chr6:36566575	C/T	cg02952361	chr6:36355661	ETV7	0.49	6.7	0.31	6.78e-11	Platelet distribution width;
LUAD	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg02990361	chr1:107599529	PRMT6	0.6	9.91	0.43	6.12e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs10242455	0.571	rs80045298	chr7:99307453	T/A	cg18809830	chr7:99032528	PTCD1	-0.9	-7.29	-0.33	1.53e-12	Blood metabolite levels;
LUAD	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg26384229	chr12:38710491	ALG10B	-0.46	-7.71	-0.35	8.95e-14	Bladder cancer;
LUAD	cis	rs34638657	0.732	rs12595971	chr16:82200309	T/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.84	-0.32	2.83e-11	Lung adenocarcinoma;
LUAD	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg26384229	chr12:38710491	ALG10B	0.51	8.39	0.38	7.54e-16	Heart rate;
LUAD	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg01028140	chr2:1542097	TPO	-0.41	-6.89	-0.32	2.09e-11	IgG glycosylation;
LUAD	trans	rs9329221	0.712	rs1962073	chr8:10260553	A/G	cg14343924	chr8:8086146	FLJ10661	-0.4	-6.39	-0.3	4.35e-10	Neuroticism;
LUAD	trans	rs4131805	0.619	rs4800306	chr18:26055555	G/A	cg26154937	chr10:49674883	ARHGAP22	0.3	6.41	0.3	3.82e-10	Hip geometry;
LUAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg07414643	chr4:187882934	NA	0.33	6.72	0.31	5.77e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg06532163	chr17:45867833	NA	0.43	7.05	0.32	7.19e-12	IgG glycosylation;
LUAD	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg00757033	chr12:89920650	WDR51B	0.7	12.21	0.51	1.44e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9902453	0.817	rs55974138	chr17:28215546	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.33	0.41	5.88e-19	Coffee consumption (cups per day);
LUAD	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg05373962	chr22:49881684	NA	-0.54	-12.76	-0.53	8.7e-32	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4774899	0.752	rs2962990	chr15:57350965	C/T	cg14026238	chr15:57616123	NA	0.45	8.71	0.39	6.78e-17	Urinary tract infection frequency;
LUAD	cis	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.22	-0.33	2.44e-12	Resting heart rate;
LUAD	cis	rs7739264	0.564	rs2223361	chr6:19790809	C/T	cg02404759	chr6:19790362	NA	-0.35	-6.69	-0.31	6.9e-11	Endometriosis;
LUAD	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg09222892	chr1:25734099	RHCE	-0.5	-9.11	-0.41	3.3e-18	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs701145	0.938	rs355778	chr3:154030349	C/T	cg17054900	chr3:154042577	DHX36	0.66	7.32	0.34	1.29e-12	Coronary artery disease;
LUAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg20607798	chr8:58055168	NA	0.56	6.88	0.32	2.17e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs2735413	0.918	rs11643649	chr16:78081199	T/C	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs9811920	0.809	rs793476	chr3:99541747	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	7.28	0.33	1.67e-12	Axial length;
LUAD	cis	rs2885056	0.800	rs8105074	chr19:10708692	A/G	cg04833646	chr19:10679720	CDKN2D	0.74	10.47	0.45	5.93e-23	Red cell distribution width;
LUAD	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.74	-0.31	5.28e-11	Breast cancer;
LUAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg03188948	chr7:1209495	NA	0.47	7.61	0.35	1.78e-13	Longevity;Endometriosis;
LUAD	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg19622623	chr12:86230825	RASSF9	-0.47	-8.11	-0.37	5.34e-15	Major depressive disorder;
LUAD	cis	rs11696501	0.694	rs6124722	chr20:44263264	G/A	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.12	-0.37	5.07e-15	Brain structure;
LUAD	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.51	8.43	0.38	5.65e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg00321850	chr1:175162397	KIAA0040	-0.51	-10.94	-0.47	1.05e-24	Alcohol dependence;
LUAD	cis	rs89107	0.576	rs114951787	chr6:118839081	C/G	cg21191810	chr6:118973309	C6orf204	0.41	7.7	0.35	9.95e-14	Cardiac structure and function;
LUAD	cis	rs7100689	0.826	rs7098414	chr10:82214586	A/C	cg00277334	chr10:82204260	NA	-0.8	-12.51	-0.52	9.42e-31	Post bronchodilator FEV1;
LUAD	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg17971929	chr21:40555470	PSMG1	0.52	7.92	0.36	2.09e-14	Cognitive function;
LUAD	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg00290607	chr11:67383545	NA	0.39	6.53	0.3	1.84e-10	Mean corpuscular volume;
LUAD	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg01181863	chr3:195395398	SDHAP2	-0.57	-8.74	-0.39	5.33e-17	Pancreatic cancer;
LUAD	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.66	-0.71	4.32e-66	Coronary artery disease;
LUAD	cis	rs4523957	0.748	rs12603592	chr17:2119818	A/T	cg16513277	chr17:2031491	SMG6	-0.8	-15.39	-0.6	9.55e-43	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs853679	0.546	rs13213986	chr6:28358009	T/A	cg01620082	chr3:125678407	NA	-1.1	-10.07	-0.44	1.57e-21	Depression;
LUAD	cis	rs9297145	0.724	rs6958790	chr7:98774738	C/T	cg05967295	chr7:98741636	SMURF1	-0.93	-15.27	-0.6	3.17e-42	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.88	-0.5	2.87e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7851660	0.967	rs3758249	chr9:100614140	T/C	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg15358701	chr1:161410459	NA	0.62	6.47	0.3	2.72e-10	Rheumatoid arthritis;
LUAD	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg23985595	chr17:80112537	CCDC57	0.52	9.54	0.42	1.11e-19	Life satisfaction;
LUAD	cis	rs2239547	0.562	rs35380116	chr3:52979178	A/G	cg11645453	chr3:52864694	ITIH4	-0.56	-10.64	-0.46	1.37e-23	Schizophrenia;
LUAD	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg22535103	chr8:58192502	C8orf71	-0.65	-9.26	-0.41	1.06e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg21709803	chr11:61594965	FADS2	-0.37	-6.72	-0.31	5.76e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg17971929	chr21:40555470	PSMG1	0.54	8.14	0.37	4.44e-15	Cognitive function;
LUAD	cis	rs6499255	0.951	rs60099379	chr16:69582104	A/G	cg15192750	chr16:69999425	NA	0.55	8.5	0.38	3.28e-16	IgE levels;
LUAD	trans	rs75804782	0.641	rs72987327	chr2:239359833	T/G	cg01134436	chr17:81009848	B3GNTL1	0.75	8.47	0.38	3.97e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg02951883	chr7:2050386	MAD1L1	0.53	7.95	0.36	1.71e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs12545109	0.800	rs2576602	chr8:57394495	C/T	cg21220214	chr8:57350948	NA	-0.65	-9.26	-0.41	1.02e-18	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg06636001	chr8:8085503	FLJ10661	0.46	7.26	0.33	1.88e-12	Neuroticism;
LUAD	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.44	0.3	3.28e-10	Depression;
LUAD	cis	rs1018836	0.545	rs4236827	chr8:91688943	A/T	cg16814680	chr8:91681699	NA	-0.95	-21.35	-0.72	3.58e-69	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg04772025	chr11:68637568	NA	-0.57	-9.37	-0.41	4.33e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6738485	0.930	rs4567955	chr2:106790116	A/G	cg15412446	chr2:106886593	NA	0.38	6.45	0.3	3.12e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-7.32	-0.34	1.26e-12	Coronary artery disease;
LUAD	cis	rs2235649	0.552	rs7203361	chr16:1963085	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-7.06	-0.32	6.89e-12	Blood metabolite levels;
LUAD	cis	rs12122100	1.000	rs12122100	chr1:146508934	C/T	cg03526459	chr1:146549940	NA	-0.38	-7.14	-0.33	4.09e-12	HIV-1 control;
LUAD	cis	rs7527798	0.592	rs960088	chr1:207827067	A/C	cg09232269	chr1:207846808	CR1L	-0.37	-7.07	-0.33	6.44e-12	Erythrocyte sedimentation rate;
LUAD	trans	rs2797160	0.508	rs9375404	chr6:125927895	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.47	-7.62	-0.35	1.71e-13	Endometrial cancer;
LUAD	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg25237894	chr2:233734115	C2orf82	-0.61	-11.63	-0.49	2.47e-27	Coronary artery disease;
LUAD	cis	rs17826219	0.562	rs719600	chr17:28731262	G/A	cg19761014	chr17:28927070	LRRC37B2	-0.69	-6.92	-0.32	1.71e-11	Body mass index;
LUAD	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05012983	chr16:28835558	ATXN2L	-0.46	-7.2	-0.33	2.68e-12	Height;
LUAD	cis	rs111547017	1	rs111547017	chr6:43341689	A/G	cg26312998	chr6:43337775	ZNF318	0.55	6.69	0.31	7.22e-11	Schizophrenia;
LUAD	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg01516881	chr6:292596	DUSP22	-0.54	-8.91	-0.4	1.57e-17	Menopause (age at onset);
LUAD	cis	rs7586879	0.789	rs13398155	chr2:25128550	C/T	cg04586622	chr2:25135609	ADCY3	0.36	7.26	0.33	1.92e-12	Body mass index;
LUAD	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	8.75e-12	Aortic root size;
LUAD	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg15605315	chr1:45957053	TESK2	0.49	7.76	0.35	6.57e-14	High light scatter reticulocyte count;
LUAD	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg16262614	chr3:133464971	TF	0.37	7.48	0.34	4.19e-13	Iron status biomarkers (transferrin levels);
LUAD	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg15911859	chr22:45810043	RIBC2;SMC1B	-0.83	-9.84	-0.43	1.04e-20	Tonsillectomy;
LUAD	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg19761014	chr17:28927070	LRRC37B2	0.83	8.13	0.37	4.82e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs8073060	0.586	rs8077826	chr17:34001139	G/A	cg19694781	chr19:47549865	TMEM160	-1.22	-19.51	-0.69	6.52e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg14820908	chr5:178986412	RUFY1	0.55	9.36	0.41	4.59e-19	Lung cancer;
LUAD	cis	rs7692976	0.503	rs9999824	chr4:110935774	A/C	cg06981781	chr4:110842888	EGF	-0.4	-6.71	-0.31	6.27e-11	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg20476274	chr7:133979776	SLC35B4	0.68	11.63	0.49	2.65e-27	Mean platelet volume;
LUAD	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg08219700	chr8:58056026	NA	0.42	6.53	0.3	1.84e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg10295955	chr4:187884368	NA	-1.18	-30.85	-0.83	2.61e-110	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs62458065	0.850	rs7804998	chr7:32461197	T/C	cg00845942	chr12:64062724	DPY19L2	-0.51	-6.76	-0.31	4.59e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2455826	0.874	rs2455853	chr3:15690025	C/T	cg16303742	chr3:15540471	COLQ	-0.42	-6.91	-0.32	1.82e-11	Inflammatory skin disease;
LUAD	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg20487152	chr13:99095054	FARP1	-0.46	-7.9	-0.36	2.42e-14	Longevity;
LUAD	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg00750074	chr16:89608354	SPG7	-0.4	-6.58	-0.3	1.42e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg08989290	chr16:615782	NHLRC4	0.32	6.8	0.31	3.65e-11	Height;
LUAD	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg14584255	chr6:163149320	PACRG;PARK2	-0.36	-6.93	-0.32	1.58e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg21699342	chr2:239360505	ASB1	0.59	11.39	0.48	2.1e-26	Multiple system atrophy;
LUAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg11965913	chr1:205819406	PM20D1	0.96	23.6	0.75	3.53e-79	Menarche (age at onset);
LUAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg08888203	chr3:10149979	C3orf24	0.63	10.73	0.46	6.56e-24	Alzheimer's disease;
LUAD	cis	rs7705042	0.865	rs6874308	chr5:141506911	C/T	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.92	-0.32	1.66e-11	Asthma;
LUAD	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg20673091	chr1:2541236	MMEL1	0.39	8.2	0.37	2.84e-15	Ulcerative colitis;
LUAD	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.23	-0.41	1.35e-18	Total body bone mineral density;
LUAD	cis	rs7588746	0.621	rs2060122	chr2:201153177	A/G	cg23649088	chr2:200775458	C2orf69	-0.47	-7.29	-0.33	1.59e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
LUAD	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.45	6.83	0.32	2.9e-11	Schizophrenia;
LUAD	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11644478	chr21:40555479	PSMG1	0.66	10.96	0.47	8.91e-25	Cognitive function;
LUAD	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg09654669	chr8:57350985	NA	-0.66	-10.09	-0.44	1.37e-21	Obesity-related traits;
LUAD	cis	rs6490294	0.659	rs601663	chr12:112123284	A/G	cg10833066	chr12:111807467	FAM109A	0.35	6.51	0.3	2.17e-10	Mean platelet volume;
LUAD	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	10.4	0.45	1.03e-22	Electrocardiographic conduction measures;
LUAD	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.51	0.3	2.07e-10	Schizophrenia;
LUAD	cis	rs9902453	0.967	rs61240589	chr17:28449035	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.53	0.38	2.62e-16	Coffee consumption (cups per day);
LUAD	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg09263875	chr16:632152	PIGQ	0.8	17.18	0.64	1.51e-50	Height;
LUAD	cis	rs1461503	0.966	rs10790547	chr11:122842110	T/A	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs1816752	0.870	rs9581025	chr13:24997825	T/C	cg02811702	chr13:24901961	NA	0.41	7.23	0.33	2.24e-12	Obesity-related traits;
LUAD	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg19442545	chr10:75533431	FUT11	-0.46	-7.64	-0.35	1.52e-13	Inflammatory bowel disease;
LUAD	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg11833968	chr6:79620685	NA	-0.43	-8.01	-0.36	1.1e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg05368731	chr17:41323189	NBR1	0.96	20.46	0.71	3.7e-65	Menopause (age at onset);
LUAD	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg08645402	chr16:4508243	NA	0.54	9.7	0.43	3.24e-20	Schizophrenia;
LUAD	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg08773314	chr2:239334832	ASB1	0.47	10.64	0.46	1.43e-23	Multiple system atrophy;
LUAD	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg00603274	chr11:61596626	FADS2	-0.49	-8.39	-0.38	7.18e-16	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-10.62	-0.46	1.68e-23	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg06671706	chr8:8559999	CLDN23	0.64	10.95	0.47	9.59e-25	Obesity-related traits;
LUAD	cis	rs74417235	0.610	rs13178134	chr5:154063032	A/T	cg07371521	chr5:154026371	NA	-0.48	-7.9	-0.36	2.39e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg03609598	chr5:56110824	MAP3K1	-0.66	-9.07	-0.4	4.48e-18	Initial pursuit acceleration;
LUAD	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg00071950	chr4:10020882	SLC2A9	0.85	18.61	0.67	6.8e-57	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg24503407	chr1:205819492	PM20D1	0.45	7.1	0.33	5.16e-12	Parkinson's disease;
LUAD	cis	rs7481584	0.962	rs756692	chr11:2973244	G/A	cg11201177	chr11:2961805	NA	0.4	6.69	0.31	6.95e-11	Calcium levels;
LUAD	cis	rs7173743	0.967	rs28580532	chr15:79134724	C/T	cg15571903	chr15:79123663	NA	-0.37	-6.98	-0.32	1.16e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.38e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	1.000	rs4575590	chr17:28361969	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.26	-0.41	1e-18	Coffee consumption (cups per day);
LUAD	cis	rs2985684	0.901	rs57119148	chr14:50097226	T/C	cg04989706	chr14:50066350	PPIL5	-0.5	-7.22	-0.33	2.5e-12	Carotid intima media thickness;
LUAD	trans	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg26043149	chr18:55253948	FECH	-0.42	-6.91	-0.32	1.75e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg24644049	chr4:85504048	CDS1	0.92	7.71	0.35	9.22e-14	Skin colour saturation;
LUAD	cis	rs8060686	0.623	rs6499157	chr16:68105474	A/C	cg26727032	chr16:67993705	SLC12A4	-0.46	-7.73	-0.35	7.78e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg03676636	chr4:99064102	C4orf37	0.34	8.95	0.4	1.17e-17	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg01620082	chr3:125678407	NA	-0.46	-6.76	-0.31	4.68e-11	Depression;
LUAD	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg09085632	chr11:111637200	PPP2R1B	0.66	10.91	0.47	1.35e-24	Primary sclerosing cholangitis;
LUAD	cis	rs59698941	0.882	rs56353702	chr5:132248575	A/G	cg14825688	chr5:132208181	LEAP2	-0.47	-6.41	-0.3	3.91e-10	Apolipoprotein A-IV levels;
LUAD	trans	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg15704280	chr7:45808275	SEPT13	-0.68	-10.35	-0.45	1.54e-22	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2579500	0.807	rs6741277	chr2:97294903	C/T	cg23100626	chr2:96804247	ASTL	-0.29	-7.18	-0.33	3.11e-12	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	7.53	0.34	3.13e-13	Hip circumference adjusted for BMI;
LUAD	trans	rs7246760	0.867	rs8112764	chr19:9748907	G/A	cg02900749	chr2:68251473	NA	-0.59	-6.42	-0.3	3.63e-10	Pursuit maintenance gain;
LUAD	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg26169700	chr22:42538906	CYP2D7P1	-0.6	-7.52	-0.34	3.42e-13	Birth weight;
LUAD	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10802521	chr3:52805072	NEK4	-0.61	-11.16	-0.48	1.56e-25	Bipolar disorder;
LUAD	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg22532475	chr10:104410764	TRIM8	-0.43	-8.01	-0.36	1.12e-14	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg09365446	chr1:150670422	GOLPH3L	-0.42	-7.1	-0.33	5.48e-12	Tonsillectomy;
LUAD	cis	rs8067545	0.750	rs7208025	chr17:19997870	T/C	cg04132472	chr17:19861366	AKAP10	0.29	6.81	0.31	3.43e-11	Schizophrenia;
LUAD	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg27411982	chr8:10470053	RP1L1	0.4	7.0	0.32	1.01e-11	Mood instability;
LUAD	cis	rs10465746	0.905	rs1324484	chr1:84382844	T/C	cg10977910	chr1:84465055	TTLL7	0.49	7.92	0.36	2.13e-14	Obesity-related traits;
LUAD	cis	rs1816752	0.837	rs57052031	chr13:24983868	T/A	cg02811702	chr13:24901961	NA	0.42	7.38	0.34	8.7e-13	Obesity-related traits;
LUAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg24829409	chr8:58192753	C8orf71	-0.61	-9.22	-0.41	1.37e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7671266	0.518	rs16895984	chr4:10284727	C/T	cg00071950	chr4:10020882	SLC2A9	0.49	8.32	0.37	1.23e-15	Cardiovascular disease risk factors;
LUAD	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg22878388	chr2:105853796	NA	-0.44	-7.76	-0.35	6.24e-14	Type 2 diabetes;
LUAD	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.45	-8.05	-0.36	8.72e-15	Longevity;Endometriosis;
LUAD	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg04267008	chr7:1944627	MAD1L1	-0.68	-10.34	-0.45	1.74e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg24399712	chr22:39784796	NA	-0.81	-15.89	-0.61	6.34e-45	Intelligence (multi-trait analysis);
LUAD	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg08439880	chr3:133502540	NA	-0.4	-7.31	-0.33	1.33e-12	Iron status biomarkers;
LUAD	trans	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.79	-0.31	3.73e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg07507251	chr3:52567010	NT5DC2	0.34	6.71	0.31	6.3e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27286337	chr10:134555280	INPP5A	0.73	9.71	0.43	2.92e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25427524	chr10:38739819	LOC399744	-0.75	-13.37	-0.54	3.01e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg26022315	chr17:47021804	SNF8	0.4	7.3	0.33	1.45e-12	Type 2 diabetes;
LUAD	cis	rs2227564	0.830	rs2675667	chr10:75683832	G/A	cg23231163	chr10:75533350	FUT11	-0.42	-6.41	-0.3	3.87e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.0	-0.32	9.9e-12	Height;
LUAD	cis	rs6840360	0.615	rs28659854	chr4:152607442	T/C	cg22705602	chr4:152727874	NA	-0.46	-8.56	-0.38	2.09e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs4660306	1.000	rs10736426	chr1:45984353	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.39	6.5	0.3	2.2e-10	Homocysteine levels;
LUAD	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg01416388	chr22:39784598	NA	-0.47	-7.75	-0.35	6.79e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7394190	0.630	rs78845904	chr10:75517249	C/A	cg02286717	chr10:75415704	SYNPO2L	-0.37	-6.45	-0.3	3.15e-10	Incident atrial fibrillation;
LUAD	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg09835421	chr16:68378352	PRMT7	-0.74	-8.48	-0.38	3.69e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	12.57	0.52	5.18e-31	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4409675	0.913	rs4072744	chr1:28271039	A/T	cg23691781	chr1:28212827	C1orf38	-0.25	-6.42	-0.3	3.59e-10	Corneal astigmatism;
LUAD	cis	rs7043114	0.525	rs10761153	chr9:95130769	A/G	cg14631576	chr9:95140430	CENPP	-0.4	-8.08	-0.37	6.62e-15	Height;
LUAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1595825	1.000	rs73058821	chr2:198864597	A/G	cg11031976	chr2:198649780	BOLL	-0.46	-6.75	-0.31	4.94e-11	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg07757535	chr4:1339547	NA	0.31	7.02	0.32	8.7e-12	Longevity;
LUAD	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg26513180	chr16:89883248	FANCA	0.75	6.76	0.31	4.55e-11	Skin colour saturation;
LUAD	cis	rs12765878	1.000	rs61277100	chr10:105643352	A/G	cg11005552	chr10:105648138	OBFC1	0.44	8.26	0.37	1.91e-15	Coronary artery disease;
LUAD	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg00204512	chr16:28754710	NA	0.33	7.12	0.33	4.52e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.62	-0.35	1.65e-13	Lung cancer;
LUAD	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg02527881	chr3:46936655	PTH1R	-0.48	-9.33	-0.41	5.81e-19	Colorectal cancer;
LUAD	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg02782426	chr3:40428986	ENTPD3	0.42	8.95	0.4	1.15e-17	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg07917127	chr4:99064746	C4orf37	0.42	7.01	0.32	9.44e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10150615	chr22:24372951	LOC391322	-0.55	-8.93	-0.4	1.36e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg13390004	chr1:15929781	NA	0.49	8.61	0.39	1.49e-16	Systolic blood pressure;
LUAD	trans	rs7395662	0.819	rs1473579	chr11:48901553	A/G	cg15704280	chr7:45808275	SEPT13	-0.44	-7.07	-0.33	6.33e-12	HDL cholesterol;
LUAD	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg02389323	chr16:88786976	FAM38A	1.19	11.28	0.48	5.39e-26	Plateletcrit;
LUAD	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg23625390	chr15:77176239	SCAPER	-0.54	-8.23	-0.37	2.36e-15	Blood metabolite levels;
LUAD	cis	rs9875589	0.509	rs1488375	chr3:14061563	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	7.23	0.33	2.3e-12	Ovarian reserve;
LUAD	cis	rs2050392	0.965	rs2265370	chr10:30690581	C/T	cg18806716	chr10:30721971	MAP3K8	-0.56	-10.79	-0.46	3.75e-24	Inflammatory bowel disease;
LUAD	cis	rs713587	0.713	rs11682135	chr2:25205377	G/A	cg01884057	chr2:25150051	NA	-0.33	-6.86	-0.32	2.48e-11	Body mass index in non-asthmatics;
LUAD	trans	rs877282	1.000	rs71494928	chr10:769134	A/G	cg22713356	chr15:30763199	NA	1.34	18.63	0.67	5.57e-57	Uric acid levels;
LUAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg08888203	chr3:10149979	C3orf24	-0.73	-12.85	-0.53	3.73e-32	Alzheimer's disease;
LUAD	trans	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.94	0.44	4.58e-21	Ulcerative colitis;
LUAD	trans	rs10805346	1.000	rs10805346	chr4:9920347	T/C	cg26043149	chr18:55253948	FECH	-0.44	-7.19	-0.33	2.94e-12	Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg16325326	chr1:53192061	ZYG11B	-0.55	-9.21	-0.41	1.48e-18	Monocyte count;
LUAD	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.47	7.61	0.35	1.79e-13	Tonsillectomy;
LUAD	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.31	6.44	0.3	3.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18402987	chr7:1209562	NA	0.38	6.58	0.3	1.37e-10	Longevity;Endometriosis;
LUAD	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg21427119	chr20:30132790	HM13	-0.48	-7.63	-0.35	1.59e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg20108693	chr8:143823809	SLURP1	0.31	7.13	0.33	4.33e-12	Urinary tract infection frequency;
LUAD	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg02275930	chr1:2372054	NA	-0.3	-6.78	-0.31	4.18e-11	Schizophrenia;
LUAD	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.41	-6.71	-0.31	6.32e-11	Tonsillectomy;
LUAD	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg02990361	chr1:107599529	PRMT6	-0.57	-9.25	-0.41	1.17e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg04414720	chr1:150670196	GOLPH3L	0.72	13.36	0.54	3.28e-34	Tonsillectomy;
LUAD	trans	rs208520	0.837	rs208489	chr6:66927584	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-14.06	-0.56	4.08e-37	Exhaled nitric oxide output;
LUAD	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.3	-6.92	-0.32	1.73e-11	Dupuytren's disease;
LUAD	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.56e-12	Crohn's disease;
LUAD	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs727505	0.607	rs67673811	chr7:124802694	C/G	cg23710748	chr7:124431027	NA	-0.39	-7.86	-0.36	3.25e-14	Lewy body disease;
LUAD	cis	rs1712517	0.566	rs1163073	chr10:105022934	C/T	cg04362960	chr10:104952993	NT5C2	0.42	6.55	0.3	1.65e-10	Migraine;
LUAD	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs420259	0.516	rs7190131	chr16:23502149	C/T	cg00143387	chr16:23521605	GGA2	-0.73	-10.1	-0.44	1.24e-21	Bipolar disorder;
LUAD	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg12292205	chr6:26970375	C6orf41	-0.41	-7.06	-0.32	6.84e-12	Schizophrenia;
LUAD	cis	rs1816752	0.870	rs9581029	chr13:24999285	C/A	cg02811702	chr13:24901961	NA	0.42	7.3	0.33	1.47e-12	Obesity-related traits;
LUAD	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg23985595	chr17:80112537	CCDC57	0.53	9.73	0.43	2.6e-20	Life satisfaction;
LUAD	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg06002616	chr8:101225028	SPAG1	-0.38	-7.83	-0.36	3.97e-14	Atrioventricular conduction;
LUAD	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg06453172	chr10:134556979	INPP5A	-0.66	-9.72	-0.43	2.83e-20	Migraine;
LUAD	cis	rs6489882	0.867	rs4988618	chr12:113363178	G/A	cg20102336	chr12:113376681	OAS3	-0.6	-9.34	-0.41	5.6e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.27	-0.33	1.73e-12	Breast cancer;
LUAD	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg15468180	chr1:107600409	PRMT6	0.43	7.35	0.34	1.05e-12	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs11893307	0.507	rs1465304	chr2:191585398	A/G	cg11845111	chr2:191398756	TMEM194B	-0.44	-7.13	-0.33	4.32e-12	Mean platelet volume;
LUAD	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg04450456	chr4:17643702	FAM184B	0.43	8.49	0.38	3.45e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.2	0.33	2.83e-12	Motion sickness;
LUAD	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg13798912	chr7:905769	UNC84A	0.64	7.75	0.35	6.96e-14	Cerebrospinal P-tau181p levels;
LUAD	cis	rs68170813	0.652	rs17482494	chr7:107168487	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-9.09	-0.4	3.86e-18	Coronary artery disease;
LUAD	cis	rs68170813	0.605	rs74632724	chr7:107136759	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-10.48	-0.45	5.28e-23	Coronary artery disease;
LUAD	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg01579765	chr21:45077557	HSF2BP	0.61	13.38	0.55	2.64e-34	Mean corpuscular volume;
LUAD	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg11266682	chr4:10021025	SLC2A9	0.6	12.99	0.53	1.02e-32	Bone mineral density;
LUAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2294693	0.581	rs4714426	chr6:41017596	C/G	cg14769373	chr6:40998127	UNC5CL	-0.46	-7.24	-0.33	2.15e-12	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg08885076	chr2:99613938	TSGA10	0.4	7.37	0.34	8.94e-13	Chronic sinus infection;
LUAD	cis	rs2067615	0.579	rs7486905	chr12:107160169	G/A	cg15890332	chr12:107067104	RFX4	0.39	8.32	0.38	1.22e-15	Heart rate;
LUAD	cis	rs6906287	0.647	rs3752581	chr6:118869730	G/A	cg18833306	chr6:118973337	C6orf204	0.48	8.54	0.38	2.36e-16	Electrocardiographic conduction measures;
LUAD	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg03477792	chr4:77819574	ANKRD56	0.49	7.53	0.34	3.15e-13	Emphysema distribution in smoking;
LUAD	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg00277334	chr10:82204260	NA	-0.96	-22.01	-0.73	4.33e-72	Post bronchodilator FEV1;
LUAD	cis	rs113835537	0.735	rs519380	chr11:66409409	G/A	cg24851651	chr11:66362959	CCS	0.57	9.29	0.41	8.25e-19	Airway imaging phenotypes;
LUAD	cis	rs1983170	1.000	rs10874785	chr1:92015243	G/A	cg25838465	chr1:92012736	NA	0.44	6.84	0.32	2.84e-11	Eosinophil percentage of white cells;
LUAD	cis	rs3774830	0.658	rs171846	chr4:5428077	G/A	cg26943120	chr4:5472116	STK32B	-0.32	-6.41	-0.3	3.87e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.25	0.37	1.97e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg20476274	chr7:133979776	SLC35B4	0.86	17.51	0.65	5.16e-52	Mean platelet volume;
LUAD	cis	rs12530845	1.000	rs12531468	chr7:135336264	T/G	cg23117316	chr7:135346802	PL-5283	-0.47	-8.78	-0.39	4.18e-17	Red blood cell traits;
LUAD	cis	rs7107174	1.000	rs2511171	chr11:77930935	G/A	cg02023728	chr11:77925099	USP35	0.54	8.05	0.36	8.22e-15	Testicular germ cell tumor;
LUAD	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg18446336	chr7:2847575	GNA12	-0.36	-7.5	-0.34	3.9e-13	Height;
LUAD	cis	rs4660214	0.614	rs6688708	chr1:39758993	C/G	cg27567593	chr1:39956653	BMP8A	0.35	6.93	0.32	1.56e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs17095355	0.892	rs7085888	chr10:111713930	A/G	cg00817464	chr10:111662876	XPNPEP1	0.63	8.31	0.37	1.36e-15	Biliary atresia;
LUAD	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg19980929	chr12:42632907	YAF2	-0.34	-6.58	-0.3	1.43e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs17102423	0.594	rs1124751	chr14:65567601	C/A	cg11161011	chr14:65562177	MAX	-0.46	-7.83	-0.36	3.86e-14	Obesity-related traits;
LUAD	trans	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-10.29	-0.45	2.6e-22	Obesity-related traits;
LUAD	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg03859395	chr2:55845619	SMEK2	0.77	14.36	0.57	2.22e-38	Metabolic syndrome;
LUAD	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.87	-0.36	2.99e-14	Diabetic kidney disease;
LUAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg27532560	chr4:187881888	NA	0.34	6.5	0.3	2.2e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-16.81	-0.63	6.03e-49	Exhaled nitric oxide output;
LUAD	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg00634984	chr7:65235879	NA	0.48	6.57	0.3	1.44e-10	Aortic root size;
LUAD	cis	rs1137	0.904	rs205636	chr2:74951336	A/G	cg19285774	chr2:74907978	SEMA4F	0.35	6.61	0.31	1.13e-10	Myopia (pathological);
LUAD	cis	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg05914723	chr15:78953907	NA	0.58	7.87	0.36	3.02e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg22029157	chr1:209979665	IRF6	0.44	7.52	0.34	3.23e-13	Monobrow;
LUAD	cis	rs7737355	0.812	rs10054168	chr5:130788698	C/T	cg25547332	chr5:131281432	NA	-0.41	-6.65	-0.31	9.31e-11	Life satisfaction;
LUAD	cis	rs4919694	0.901	rs10509763	chr10:104776391	G/A	cg04362960	chr10:104952993	NT5C2	0.75	7.94	0.36	1.86e-14	Arsenic metabolism;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05022673	chr6:56819429	DST;BEND6	-0.64	-6.65	-0.31	8.81e-11	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.95	-0.32	1.35e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg00717180	chr2:96193071	NA	-0.4	-7.52	-0.34	3.28e-13	HDL cholesterol;
LUAD	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg22676075	chr6:135203613	NA	0.52	9.23	0.41	1.35e-18	High light scatter reticulocyte percentage of red cells;
LUAD	trans	rs9393777	0.777	rs56114371	chr6:27274834	C/T	cg06606381	chr12:133084897	FBRSL1	-1.04	-9.34	-0.41	5.56e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg19610905	chr11:61596333	FADS2	-0.63	-10.81	-0.47	3.2e-24	Trans fatty acid levels;
LUAD	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg00204512	chr16:28754710	NA	0.35	7.67	0.35	1.17e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs59698941	0.943	rs739863	chr5:132232315	C/T	cg14825688	chr5:132208181	LEAP2	-0.45	-6.55	-0.3	1.72e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg21475434	chr5:93447410	FAM172A	0.77	8.48	0.38	3.85e-16	Diabetic retinopathy;
LUAD	cis	rs7593730	1.000	rs4335904	chr2:161171842	C/A	cg22609984	chr2:161126801	NA	0.45	7.35	0.34	1.04e-12	Type 2 diabetes;
LUAD	trans	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg27411982	chr8:10470053	RP1L1	0.42	7.59	0.35	2.13e-13	Mood instability;
LUAD	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg16988262	chr1:15930761	NA	0.41	6.85	0.32	2.61e-11	Systolic blood pressure;
LUAD	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.54	-0.6	2.1e-43	Chronic sinus infection;
LUAD	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg26587870	chr6:27730563	NA	-0.5	-8.32	-0.38	1.2e-15	Parkinson's disease;
LUAD	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg05896524	chr21:47604654	C21orf56	0.55	8.54	0.38	2.43e-16	Testicular germ cell tumor;
LUAD	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-8.43	-0.38	5.33e-16	Gut microbiome composition (summer);
LUAD	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg18132916	chr6:79620363	NA	-0.47	-8.1	-0.37	6.04e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg14668632	chr7:2872130	GNA12	-0.47	-8.36	-0.38	8.82e-16	Height;
LUAD	trans	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg18187862	chr3:45730750	SACM1L	0.5	7.89	0.36	2.55e-14	Primary sclerosing cholangitis;
LUAD	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.78	-13.43	-0.55	1.74e-34	Chronic sinus infection;
LUAD	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg11833968	chr6:79620685	NA	-0.44	-8.3	-0.37	1.45e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg09537434	chr19:41945824	ATP5SL	-0.49	-7.7	-0.35	9.57e-14	Height;
LUAD	cis	rs2658782	0.526	rs3020062	chr11:93061159	T/C	cg15737290	chr11:93063684	CCDC67	0.58	9.78	0.43	1.73e-20	Pulmonary function decline;
LUAD	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg20135002	chr11:47629003	NA	-0.4	-6.9	-0.32	1.95e-11	Subjective well-being;
LUAD	cis	rs11671005	0.693	rs34023391	chr19:58913368	G/A	cg13877915	chr19:58951672	ZNF132	0.55	7.01	0.32	9.51e-12	Mean platelet volume;
LUAD	cis	rs1018836	0.923	rs13259842	chr8:91550819	A/G	cg16814680	chr8:91681699	NA	-0.74	-13.38	-0.55	2.77e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg16988262	chr1:15930761	NA	0.43	7.15	0.33	3.81e-12	Systolic blood pressure;
LUAD	cis	rs17401966	0.838	rs12125535	chr1:10350849	T/A	cg15208524	chr1:10270712	KIF1B	0.42	6.57	0.3	1.49e-10	Hepatocellular carcinoma;
LUAD	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg04450456	chr4:17643702	FAM184B	0.38	7.41	0.34	6.81e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg25767906	chr1:53392781	SCP2	-0.35	-6.61	-0.31	1.19e-10	Monocyte count;
LUAD	cis	rs863345	0.604	rs12118446	chr1:158496235	T/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.48	-0.3	2.52e-10	Pneumococcal bacteremia;
LUAD	cis	rs701145	0.938	rs1086106	chr3:154084032	C/T	cg17054900	chr3:154042577	DHX36	0.64	7.17	0.33	3.39e-12	Coronary artery disease;
LUAD	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg00666640	chr1:248458726	OR2T12	0.31	7.62	0.35	1.64e-13	Common traits (Other);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26499878	chr11:448138	NA	-0.42	-6.96	-0.32	1.26e-11	Cancer;
LUAD	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg02176678	chr2:219576539	TTLL4	-0.67	-13.13	-0.54	2.85e-33	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10821973	0.527	rs3852407	chr10:64016783	C/T	cg09941381	chr10:64027924	RTKN2	-0.36	-7.15	-0.33	3.85e-12	Hypothyroidism;
LUAD	cis	rs6993813	0.505	rs35533151	chr8:120023725	T/G	cg01975934	chr8:119970761	NA	-0.34	-6.5	-0.3	2.26e-10	Bone mineral density (hip);
LUAD	cis	rs76878669	0.561	rs6591215	chr11:66170611	A/C	cg18002602	chr11:66138449	SLC29A2	-0.47	-10.05	-0.44	1.81e-21	Educational attainment (years of education);
LUAD	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.45	-0.38	4.87e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg22117172	chr7:91764530	CYP51A1	0.36	7.89	0.36	2.64e-14	Breast cancer;
LUAD	cis	rs11229555	1.000	rs11229543	chr11:58370698	G/A	cg15696309	chr11:58395628	NA	-0.73	-10.98	-0.47	7.29e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2637266	1.000	rs7073355	chr10:78354419	G/A	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg21427119	chr20:30132790	HM13	-0.5	-7.98	-0.36	1.41e-14	Mean corpuscular volume;
LUAD	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg07741184	chr6:167504864	NA	0.31	7.47	0.34	4.74e-13	Crohn's disease;
LUAD	trans	rs877282	0.945	rs10904555	chr10:787740	C/A	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	cis	rs9341808	0.591	rs6454147	chr6:80916328	G/A	cg08355045	chr6:80787529	NA	0.53	9.51	0.42	1.41e-19	Sitting height ratio;
LUAD	cis	rs7216064	1.000	rs7216064	chr17:65898809	G/A	cg08758996	chr17:66097529	LOC651250	0.45	7.0	0.32	1.04e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg16988262	chr1:15930761	NA	0.42	6.96	0.32	1.29e-11	Systolic blood pressure;
LUAD	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg17264618	chr3:40429014	ENTPD3	0.4	9.02	0.4	6.49e-18	Renal cell carcinoma;
LUAD	cis	rs1497406	0.773	rs7538833	chr1:16504381	T/C	cg20430773	chr1:16534157	ARHGEF19	0.4	6.86	0.32	2.39e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg02773889	chr13:42615649	NA	-0.38	-6.53	-0.3	1.84e-10	Subcortical brain region volumes;
LUAD	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.96	-0.36	1.62e-14	Prostate cancer;
LUAD	cis	rs7095607	0.813	rs7894981	chr10:69927518	T/C	cg18986048	chr10:69913749	MYPN	0.37	6.4	0.3	4.08e-10	Lung function (FVC);
LUAD	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26314531	chr2:26401878	FAM59B	-0.65	-8.74	-0.39	5.54e-17	Gut microbiome composition (summer);
LUAD	cis	rs7640424	0.929	rs327139	chr3:107822481	G/C	cg09227934	chr3:107805635	CD47	0.52	9.27	0.41	9.26e-19	Body mass index;
LUAD	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg19077165	chr18:44547161	KATNAL2	0.42	7.44	0.34	5.72e-13	Personality dimensions;
LUAD	cis	rs2996428	0.643	rs6424056	chr1:3722486	G/A	cg13057898	chr1:3703894	LRRC47	0.62	10.93	0.47	1.19e-24	Red cell distribution width;
LUAD	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27286337	chr10:134555280	INPP5A	0.71	9.34	0.41	5.74e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.82	0.53	5.17e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg04287289	chr16:89883240	FANCA	0.75	6.37	0.3	5.01e-10	Skin colour saturation;
LUAD	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg12927641	chr6:109611667	NA	-0.53	-9.29	-0.41	8.16e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs243505	1.000	rs243520	chr7:148423560	C/T	cg09806900	chr7:148480153	CUL1	-0.44	-7.46	-0.34	4.83e-13	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23158103	chr7:148848205	ZNF398	-0.67	-12.48	-0.52	1.17e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg16205897	chr5:131564050	P4HA2	-0.34	-7.58	-0.35	2.18e-13	Blood metabolite levels;
LUAD	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg27432699	chr2:27873401	GPN1	-0.57	-10.05	-0.44	1.88e-21	Oral cavity cancer;
LUAD	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg20712883	chr12:51590929	POU6F1	0.48	7.56	0.34	2.6e-13	Cisplatin-induced ototoxicity;
LUAD	cis	rs4961252	0.545	rs1107258	chr8:142104071	G/A	cg09914555	chr8:142094789	NA	-0.43	-6.92	-0.32	1.66e-11	Isovolumetric relaxation time;Response to interferon beta therapy;
LUAD	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg23649088	chr2:200775458	C2orf69	0.73	11.42	0.49	1.65e-26	LDL cholesterol to HDL cholesterol ratio;
LUAD	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg12756686	chr19:29218302	NA	0.71	9.9	0.43	6.29e-21	Methadone dose in opioid dependence;
LUAD	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.11	-0.37	5.51e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg08601574	chr20:25228251	PYGB	-0.45	-8.2	-0.37	2.96e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg07460842	chr6:66804631	NA	1.07	16.98	0.64	1.12e-49	Exhaled nitric oxide output;
LUAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg08280861	chr8:58055591	NA	0.53	7.59	0.35	2.13e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2455799	0.613	rs2246960	chr3:15717693	G/A	cg16303742	chr3:15540471	COLQ	-0.5	-9.19	-0.41	1.81e-18	Mean platelet volume;
LUAD	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	6.56	0.3	1.55e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9807989	0.507	rs6745614	chr2:102991213	A/G	cg03938978	chr2:103052716	IL18RAP	0.44	10.1	0.44	1.25e-21	Asthma;
LUAD	cis	rs17362650	0.960	rs12469362	chr2:9618957	T/C	cg12832956	chr2:9616023	IAH1	-0.49	-7.69	-0.35	1.06e-13	Alcohol dependence (age at onset);
LUAD	cis	rs17102423	0.692	rs762810	chr14:65544367	C/A	cg11161011	chr14:65562177	MAX	-0.45	-7.21	-0.33	2.58e-12	Obesity-related traits;
LUAD	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg26528668	chr16:1614120	IFT140	0.51	9.11	0.41	3.23e-18	Coronary artery disease;
LUAD	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg13385794	chr1:248469461	NA	0.26	7.07	0.32	6.56e-12	Common traits (Other);
LUAD	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.74	13.57	0.55	4.45e-35	Axial length;
LUAD	cis	rs2230307	0.536	rs631977	chr1:100544564	C/G	cg20868668	chr1:100435035	SLC35A3	0.51	7.53	0.34	3.06e-13	Carotid intima media thickness;
LUAD	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg18252515	chr7:66147081	NA	-0.62	-6.88	-0.32	2.23e-11	Diabetic kidney disease;
LUAD	cis	rs3741798	1.000	rs3741798	chr12:12496086	C/T	cg08615371	chr12:12503544	MANSC1	0.74	6.73	0.31	5.55e-11	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg17644776	chr2:200775616	C2orf69	0.46	7.27	0.33	1.78e-12	Osteoporosis;
LUAD	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg07527032	chr15:84868466	LOC388152	0.44	6.63	0.31	1.04e-10	Schizophrenia;
LUAD	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg01689657	chr7:91764605	CYP51A1	0.38	9.08	0.4	4.14e-18	Breast cancer;
LUAD	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.49	0.34	4.04e-13	Bladder cancer;
LUAD	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg21605333	chr4:119757512	SEC24D	0.91	8.75	0.39	5.21e-17	Cannabis dependence symptom count;
LUAD	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs737337	0.623	rs4804155	chr19:11334295	C/G	cg00586551	chr19:11347513	LOC55908;DOCK6	0.52	6.71	0.31	6.34e-11	HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs11771526	0.901	rs10223907	chr7:32297813	G/C	cg13207630	chr7:32358064	NA	0.57	7.11	0.33	5.07e-12	Body mass index;
LUAD	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03517284	chr6:25882590	NA	-0.59	-9.68	-0.43	3.67e-20	Blood metabolite levels;
LUAD	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg24324837	chr19:49891574	CCDC155	0.58	9.08	0.4	4.34e-18	Multiple sclerosis;
LUAD	cis	rs4372836	1.000	rs6710959	chr2:28958603	C/T	cg09522027	chr2:28974177	PPP1CB	-0.62	-10.04	-0.44	2.05e-21	Body mass index;
LUAD	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.7	0.39	7.59e-17	Menarche (age at onset);
LUAD	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg10523679	chr1:76189770	ACADM	0.88	15.48	0.6	3.87e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg03806693	chr22:41940476	POLR3H	-0.54	-8.15	-0.37	4.12e-15	Vitiligo;
LUAD	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg00316803	chr15:76480434	C15orf27	-0.41	-7.62	-0.35	1.65e-13	Blood metabolite levels;
LUAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg10729496	chr3:10149963	C3orf24	0.64	9.56	0.42	9.9e-20	Alzheimer's disease;
LUAD	cis	rs7274811	0.652	rs149236	chr20:32023380	C/T	cg14921437	chr20:32255988	NECAB3;C20orf134	0.48	7.33	0.34	1.2e-12	Height;
LUAD	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg24289452	chr6:170231220	NA	-0.49	-8.74	-0.39	5.33e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs2075165	0.901	rs10908492	chr1:156224795	C/T	cg20302342	chr1:156215951	PAQR6	0.38	8.69	0.39	8.18e-17	Tonsillectomy;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26038708	chr20:30160787	NA	-0.38	-6.71	-0.31	6.29e-11	Cancer;
LUAD	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg19717773	chr7:2847554	GNA12	-0.54	-10.16	-0.44	7.75e-22	Height;
LUAD	cis	rs11650494	0.908	rs75904857	chr17:47370449	T/G	cg08112188	chr17:47440006	ZNF652	0.92	7.75	0.35	6.75e-14	Prostate cancer;
LUAD	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg00255919	chr5:131827918	IRF1	0.47	10.6	0.46	2e-23	Asthma (sex interaction);
LUAD	cis	rs77861329	1.000	rs9843852	chr3:52132029	C/G	cg08692210	chr3:52188851	WDR51A	0.83	7.98	0.36	1.35e-14	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg05754148	chr16:3507555	NAT15	0.46	7.73	0.35	8.07e-14	Body mass index (adult);
LUAD	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.8	0.35	4.98e-14	Bladder cancer;
LUAD	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg06784218	chr1:46089804	CCDC17	0.56	12.73	0.53	1.17e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg14725641	chr11:61582763	MIR1908;FADS1	-0.43	-6.74	-0.31	5.19e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-9.92	-0.43	5.5e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs2742234	0.541	rs10899786	chr10:43744583	G/A	cg15436174	chr10:43711423	RASGEF1A	0.52	8.66	0.39	1.03e-16	Hirschsprung disease;
LUAD	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg19773385	chr1:10388646	KIF1B	-0.41	-6.62	-0.31	1.12e-10	Hepatocellular carcinoma;
LUAD	cis	rs7551222	0.749	rs2887429	chr1:204565012	G/T	cg20240347	chr1:204465584	NA	-0.33	-6.43	-0.3	3.35e-10	Schizophrenia;
LUAD	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.09	0.33	5.7e-12	Menopause (age at onset);
LUAD	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg26924012	chr15:45694286	SPATA5L1	1.02	18.94	0.68	2.31e-58	Homoarginine levels;
LUAD	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg20362242	chr5:692897	TPPP	0.56	6.89	0.32	2.02e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg05340658	chr4:99064831	C4orf37	0.53	8.96	0.4	1.04e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2029213	0.523	rs4687715	chr3:53269904	G/A	cg16894138	chr3:53270350	TKT	0.34	7.78	0.35	5.62e-14	Heart rate;
LUAD	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg07741184	chr6:167504864	NA	0.3	7.19	0.33	2.96e-12	Crohn's disease;
LUAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-7.07	-0.33	6.38e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.85	-0.36	3.4e-14	Blood metabolite levels;
LUAD	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.94	-0.4	1.26e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg08000102	chr2:233561755	GIGYF2	0.41	6.44	0.3	3.18e-10	Coronary artery disease;
LUAD	cis	rs7731657	0.509	rs6595985	chr5:130339400	A/C	cg08523029	chr5:130500466	HINT1	0.57	7.41	0.34	6.76e-13	Fasting plasma glucose;
LUAD	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg09365446	chr1:150670422	GOLPH3L	0.6	10.97	0.47	8.56e-25	Melanoma;
LUAD	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg14828511	chr1:107599125	PRMT6	-0.59	-10.44	-0.45	7.72e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg03806693	chr22:41940476	POLR3H	0.74	9.96	0.44	3.89e-21	Vitiligo;
LUAD	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03352830	chr11:487213	PTDSS2	0.82	10.59	0.46	2.07e-23	Body mass index;
LUAD	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.38	-6.6	-0.31	1.23e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1018836	0.812	rs10808619	chr8:91622916	A/T	cg16814680	chr8:91681699	NA	-0.67	-11.67	-0.49	1.72e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs798766	1.000	rs7682402	chr4:1743343	G/A	cg05874882	chr4:1763078	NA	-0.38	-6.75	-0.31	4.83e-11	Bladder cancer;Urinary bladder cancer;
LUAD	trans	rs1178968	1.000	rs2353062	chr7:72740048	C/T	cg15428835	chr7:75027521	TRIM73;TRIM74	0.5	6.38	0.3	4.77e-10	Triglyceride levels;
LUAD	cis	rs9487051	0.766	rs351748	chr6:109532296	C/T	cg12927641	chr6:109611667	NA	0.37	6.42	0.3	3.69e-10	Reticulocyte fraction of red cells;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg17076397	chr5:10353763	MARCH6	0.4	7.03	0.32	8.49e-12	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs897984	0.762	rs2054213	chr16:30971810	A/G	cg02466173	chr16:30829666	NA	0.65	12.19	0.51	1.75e-29	Dementia with Lewy bodies;
LUAD	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg11645453	chr3:52864694	ITIH4	0.6	11.29	0.48	5.14e-26	Schizophrenia;
LUAD	cis	rs225245	0.782	rs321617	chr17:33915246	A/G	cg05299278	chr17:33885742	SLFN14	0.51	11.64	0.49	2.45e-27	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7945705	0.875	rs11042059	chr11:8795080	G/A	cg12365402	chr11:9010492	NRIP3	0.37	6.54	0.3	1.79e-10	Hemoglobin concentration;
LUAD	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg09455208	chr3:40491958	NA	0.65	14.19	0.57	1.14e-37	Renal cell carcinoma;
LUAD	cis	rs1395	1.000	rs3769143	chr2:27450724	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.39	-7.33	-0.34	1.15e-12	Blood metabolite levels;
LUAD	cis	rs3862030	0.533	rs715440	chr10:104258095	A/T	cg22532475	chr10:104410764	TRIM8	0.34	6.83	0.32	2.94e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg03615207	chr18:12702659	CEP76;PSMG2	-0.41	-6.8	-0.31	3.55e-11	Schizophrenia;
LUAD	trans	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.17	-0.64	1.64e-50	Exhaled nitric oxide output;
LUAD	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg08742575	chr21:47604166	C21orf56	-0.39	-6.71	-0.31	6.3e-11	Testicular germ cell tumor;
LUAD	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg10978503	chr1:24200527	CNR2	0.54	11.74	0.5	9.32e-28	Immature fraction of reticulocytes;
LUAD	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg24675056	chr1:15929824	NA	0.49	8.5	0.38	3.32e-16	Systolic blood pressure;
LUAD	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg03714773	chr7:91764589	CYP51A1	0.28	6.77	0.31	4.19e-11	Breast cancer;
LUAD	cis	rs6546550	0.935	rs2305523	chr2:70039677	G/T	cg02498382	chr2:70120550	SNRNP27	0.54	10.31	0.45	2.22e-22	Prevalent atrial fibrillation;
LUAD	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg11189052	chr15:85197271	WDR73	0.66	8.93	0.4	1.34e-17	Schizophrenia;
LUAD	cis	rs16866061	0.962	rs3845840	chr2:225359100	G/A	cg12698349	chr2:225449008	CUL3	0.74	12.77	0.53	7.91e-32	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg20503657	chr10:835505	NA	0.97	14.97	0.59	6.02e-41	Eosinophil percentage of granulocytes;
LUAD	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10802521	chr3:52805072	NEK4	-0.54	-9.19	-0.41	1.81e-18	Bipolar disorder;
LUAD	cis	rs3733418	0.929	rs1401401	chr4:165927956	G/A	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-6.92	-0.32	1.64e-11	Obesity-related traits;
LUAD	cis	rs7043114	0.563	rs10820990	chr9:95323297	C/T	cg14631576	chr9:95140430	CENPP	0.39	8.22	0.37	2.51e-15	Height;
LUAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg13047869	chr3:10149882	C3orf24	0.65	11.04	0.47	4.37e-25	Alzheimer's disease;
LUAD	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg15790184	chr11:494944	RNH1	0.38	6.53	0.3	1.88e-10	Systemic lupus erythematosus;
LUAD	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg07570687	chr10:102243282	WNT8B	0.46	6.7	0.31	6.48e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs8062405	0.931	rs12928404	chr16:28847246	T/C	cg00204512	chr16:28754710	NA	0.32	6.84	0.32	2.74e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg12573674	chr2:1569213	NA	-0.58	-6.69	-0.31	7.18e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg00666640	chr1:248458726	OR2T12	0.3	7.22	0.33	2.5e-12	Common traits (Other);
LUAD	cis	rs4280164	0.945	rs11158635	chr14:24776769	G/T	cg22990158	chr14:24802150	ADCY4	0.45	6.48	0.3	2.48e-10	Parent of origin effect on language impairment (paternal);
LUAD	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.73	-0.31	5.46e-11	Height;
LUAD	cis	rs4589502	0.800	rs4776855	chr15:67202075	T/C	cg09911534	chr15:67153556	NA	0.4	7.17	0.33	3.31e-12	Lung cancer (smoking interaction);
LUAD	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg03929089	chr4:120376271	NA	0.54	7.2	0.33	2.86e-12	Axial length;
LUAD	cis	rs1403694	0.695	rs3774291	chr3:186433471	C/T	cg12454167	chr3:186435060	KNG1	0.51	10.6	0.46	1.96e-23	Blood protein levels;
LUAD	cis	rs9535307	0.719	rs1201716	chr13:50378425	T/G	cg04663916	chr13:50265991	EBPL	-0.62	-6.98	-0.32	1.17e-11	Obesity-related traits;
LUAD	cis	rs9863	0.828	rs1187415	chr12:124491529	C/G	cg17723958	chr12:124429295	CCDC92	0.4	6.74	0.31	5.24e-11	White blood cell count;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg24278218	chr17:62207299	ERN1	-0.68	-6.68	-0.31	7.61e-11	Type 2 diabetes;
LUAD	cis	rs12620999	0.941	rs10929213	chr2:238020637	A/G	cg23555395	chr2:238036564	NA	-0.61	-9.36	-0.41	4.83e-19	Systemic lupus erythematosus;
LUAD	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg25036284	chr2:26402008	FAM59B	-0.8	-11.81	-0.5	4.99e-28	Gut microbiome composition (summer);
LUAD	cis	rs3935685	0.874	rs56370262	chr15:77996708	G/C	cg25212270	chr15:78015279	NA	0.33	7.21	0.33	2.55e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg18621852	chr3:10150065	C3orf24	0.42	7.41	0.34	7.04e-13	Alzheimer's disease;
LUAD	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	10.07	0.44	1.55e-21	Electrocardiographic conduction measures;
LUAD	trans	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	8.81	0.39	3.29e-17	Coronary artery disease;
LUAD	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg10208301	chr11:6592745	DNHD1	0.5	6.43	0.3	3.53e-10	Coronary artery calcification;
LUAD	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg20814179	chr4:940893	TMEM175	-0.45	-6.92	-0.32	1.7e-11	Parkinson's disease;
LUAD	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg11247378	chr22:39784982	NA	-0.73	-13.11	-0.54	3.48e-33	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.73	-0.35	8.09e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg24101359	chr6:42928495	GNMT	0.46	8.64	0.39	1.15e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg14791747	chr16:20752902	THUMPD1	0.73	9.97	0.44	3.5e-21	Cognitive test performance;
LUAD	cis	rs11741688	0.557	rs6898923	chr5:178330559	C/T	cg21944022	chr5:178288650	ZNF354B	0.5	9.28	0.41	8.92e-19	Sleep duration;
LUAD	cis	rs6987853	1.000	rs6987853	chr8:42457450	T/C	cg09913449	chr8:42400586	C8orf40	0.4	7.02	0.32	8.9e-12	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg05313129	chr8:58192883	C8orf71	-0.58	-8.66	-0.39	9.74e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs7395662	0.963	rs115181013	chr11:48575801	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.36	-0.34	9.81e-13	HDL cholesterol;
LUAD	trans	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg26043149	chr18:55253948	FECH	1.07	18.3	0.66	1.6e-55	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14829155	chr15:31115871	NA	-0.79	-13.45	-0.55	1.38e-34	Huntington's disease progression;
LUAD	cis	rs6908034	0.607	rs76245225	chr6:19813188	T/G	cg02682789	chr6:19804855	NA	0.93	9.06	0.4	4.98e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs929596	0.563	rs1105880	chr2:234601965	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-10.17	-0.44	6.84e-22	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg24397884	chr7:158709396	WDR60	-0.74	-13.67	-0.55	1.73e-35	Height;
LUAD	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg15704280	chr7:45808275	SEPT13	-0.68	-11.07	-0.47	3.55e-25	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs16858210	0.874	rs10937153	chr3:183562925	A/G	cg01324343	chr3:183735012	ABCC5	-0.41	-6.41	-0.3	3.88e-10	Menopause (age at onset);
LUAD	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg21823605	chr1:152486609	CRCT1	0.28	6.43	0.3	3.5e-10	Hair morphology;
LUAD	trans	rs10411161	0.810	rs17778661	chr19:52383288	C/G	cg22319618	chr22:45562946	NUP50	-0.65	-7.45	-0.34	5.14e-13	Breast cancer;
LUAD	cis	rs4523957	0.523	rs2760746	chr17:2034806	G/C	cg16513277	chr17:2031491	SMG6	-0.98	-19.94	-0.7	7.73e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.34	6.95	0.32	1.36e-11	Parkinson's disease;
LUAD	cis	rs12208915	0.731	rs9443630	chr6:79661777	G/T	cg11833968	chr6:79620685	NA	0.51	7.29	0.33	1.53e-12	Left atrial antero-posterior diameter;
LUAD	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg15448220	chr1:150897856	SETDB1	0.53	8.96	0.4	1.02e-17	Tonsillectomy;
LUAD	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg06740227	chr12:86229804	RASSF9	0.46	8.06	0.37	7.67e-15	Major depressive disorder;
LUAD	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg14008862	chr17:28927542	LRRC37B2	0.7	6.8	0.31	3.51e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg05304507	chr6:116381966	FRK	0.19	6.55	0.3	1.64e-10	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg18404041	chr3:52824283	ITIH1	-0.59	-11.07	-0.47	3.37e-25	Bipolar disorder;
LUAD	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg05304507	chr6:116381966	FRK	0.2	6.68	0.31	7.65e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs13190036	0.792	rs6874206	chr5:176650971	G/T	cg06733329	chr5:176740039	MXD3	0.51	7.03	0.32	8.22e-12	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	cis	rs300774	0.925	rs300715	chr2:137962	A/G	cg21211680	chr2:198530	NA	-0.46	-7.33	-0.34	1.16e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs887829	0.694	rs869283	chr2:234626287	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-10.13	-0.44	9.76e-22	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs6076065	0.925	rs6083106	chr20:23368809	A/C	cg11657817	chr20:23433608	CST11	0.47	9.53	0.42	1.22e-19	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs3815700	1.000	rs10406750	chr19:33097144	C/T	cg02997394	chr19:33096574	ANKRD27	0.64	8.64	0.39	1.2e-16	Eosinophilic esophagitis;
LUAD	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg05890377	chr2:74357713	NA	0.74	11.99	0.5	1.02e-28	Gestational age at birth (maternal effect);
LUAD	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18404041	chr3:52824283	ITIH1	-0.48	-9.7	-0.43	3.28e-20	Bipolar disorder;
LUAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg12432903	chr7:1882776	MAD1L1	-0.52	-8.59	-0.39	1.75e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs68170813	0.523	rs4730241	chr7:107057361	G/A	cg23024343	chr7:107201750	COG5	0.51	7.21	0.33	2.65e-12	Coronary artery disease;
LUAD	cis	rs375066	0.620	rs349049	chr19:44301400	T/C	cg11993925	chr19:44307056	LYPD5	-0.38	-7.52	-0.34	3.33e-13	Breast cancer;
LUAD	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg25457927	chr22:38595422	NA	-0.54	-13.56	-0.55	4.79e-35	Cutaneous nevi;
LUAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg02951883	chr7:2050386	MAD1L1	-0.91	-16.37	-0.62	5.29e-47	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.54e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12431939	1.000	rs60818073	chr14:51696649	T/C	cg23942311	chr14:51606299	NA	-0.58	-7.62	-0.35	1.69e-13	Cancer;
LUAD	cis	rs6445967	0.569	rs3773012	chr3:58303069	C/T	cg23715586	chr3:58305044	RPP14	0.41	6.72	0.31	6e-11	Platelet count;
LUAD	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg26384229	chr12:38710491	ALG10B	0.42	7.1	0.33	5.33e-12	Morning vs. evening chronotype;
LUAD	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.4	0.3	4.15e-10	Hypertriglyceridemia;
LUAD	cis	rs10193935	1.000	rs12622910	chr2:42398918	C/A	cg27598129	chr2:42591480	NA	-0.78	-10.32	-0.45	1.95e-22	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg16724585	chr3:197361211	NA	0.5	7.67	0.35	1.23e-13	Pancreatic cancer;
LUAD	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg11871910	chr12:69753446	YEATS4	0.52	8.14	0.37	4.38e-15	Blood protein levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10761372	chr8:143398763	TSNARE1	0.51	6.99	0.32	1.1e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4006360	0.540	rs9915780	chr17:39301074	T/C	cg20663846	chr17:39254439	KRTAP4-8	0.39	9.1	0.4	3.57e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs3823572	0.542	rs2953636	chr7:133637904	A/G	cg03336402	chr7:133662267	EXOC4	0.42	7.71	0.35	9.14e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2274273	0.745	rs56262555	chr14:55561962	C/T	cg04306507	chr14:55594613	LGALS3	0.32	6.45	0.3	3.12e-10	Protein biomarker;
LUAD	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg05872129	chr22:39784769	NA	-0.82	-15.85	-0.61	9.91e-45	Intelligence (multi-trait analysis);
LUAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg14092988	chr3:52407081	DNAH1	0.4	8.09	0.37	6.37e-15	Electroencephalogram traits;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg08965527	chr16:84178213	HSDL1;LRRC50	0.38	6.35	0.3	5.71e-10	Anger;
LUAD	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.41	-7.66	-0.35	1.3e-13	Menopause (age at onset);
LUAD	cis	rs16866061	0.890	rs72972401	chr2:225404668	T/C	cg12698349	chr2:225449008	CUL3	0.78	13.55	0.55	5.38e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.83	0.31	3.04e-11	Cognitive test performance;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01420589	chr4:119757735	SEC24D	-0.39	-6.6	-0.31	1.24e-10	Cancer;
LUAD	cis	rs3806843	0.551	rs246018	chr5:140335043	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-6.61	-0.31	1.14e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg15358701	chr1:161410459	NA	-0.71	-7.22	-0.33	2.48e-12	Rheumatoid arthritis;
LUAD	cis	rs870825	0.616	rs6419939	chr4:185642869	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.03	0.56	5.61e-37	Blood protein levels;
LUAD	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg00784671	chr22:46762841	CELSR1	-0.54	-6.76	-0.31	4.69e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg24818145	chr4:99064322	C4orf37	0.46	7.8	0.35	4.86e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs208520	0.690	rs851464	chr6:66839802	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-17.37	-0.65	2.04e-51	Exhaled nitric oxide output;
LUAD	cis	rs11771526	0.579	rs77818421	chr7:32375129	G/T	cg27511599	chr7:32358540	NA	0.64	6.84	0.32	2.74e-11	Body mass index;
LUAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.52	6.8	0.31	3.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs657075	0.697	rs35497612	chr5:131673106	C/T	cg21138405	chr5:131827807	IRF1	0.52	6.49	0.3	2.41e-10	Rheumatoid arthritis;
LUAD	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs939658	0.805	rs36068099	chr15:79438598	G/C	cg17916960	chr15:79447300	NA	-0.53	-11.28	-0.48	5.58e-26	Refractive error;
LUAD	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-10.95	-0.47	9.68e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17095355	0.818	rs7086057	chr10:111867076	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.67	-9.53	-0.42	1.21e-19	Biliary atresia;
LUAD	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg27490568	chr2:178487706	NA	0.41	6.67	0.31	7.93e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg16850897	chr7:100343110	ZAN	-0.62	-10.4	-0.45	1.03e-22	Other erythrocyte phenotypes;
LUAD	cis	rs41271951	0.512	rs11204765	chr1:151016757	G/A	cg11822372	chr1:151115635	SEMA6C	-0.8	-6.51	-0.3	2.12e-10	Blood protein levels;
LUAD	trans	rs13128441	1.000	rs13128441	chr4:5162389	C/T	cg26099876	chr8:141644609	EIF2C2	-0.47	-6.61	-0.31	1.17e-10	Celiac disease;
LUAD	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22968622	chr17:43663579	NA	0.97	16.87	0.63	3.49e-49	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg14668632	chr7:2872130	GNA12	-0.37	-6.5	-0.3	2.26e-10	Height;
LUAD	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.51	-10.65	-0.46	1.3e-23	Monocyte percentage of white cells;
LUAD	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg27170947	chr2:26402098	FAM59B	0.71	10.51	0.46	4.1000000000000003e-23	Gut microbiome composition (summer);
LUAD	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg00933542	chr6:150070202	PCMT1	0.44	9.76	0.43	1.99e-20	Lung cancer;
LUAD	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg12615879	chr12:58013172	SLC26A10	0.57	12.63	0.52	2.96e-31	Multiple sclerosis;
LUAD	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg14779329	chr11:130786720	SNX19	0.37	6.52	0.3	2e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs877282	0.945	rs11253391	chr10:788752	G/A	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	cis	rs606458	0.920	rs10400348	chr11:64407385	C/A	cg27243166	chr11:64479496	NRXN2	0.52	6.47	0.3	2.72e-10	Urate levels;
LUAD	cis	rs3772130	0.886	rs9825248	chr3:121568711	A/G	cg20356878	chr3:121714668	ILDR1	0.52	8.3	0.37	1.39e-15	Cognitive performance;
LUAD	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg03806693	chr22:41940476	POLR3H	-0.45	-6.55	-0.3	1.68e-10	Vitiligo;
LUAD	cis	rs870825	0.616	rs9631783	chr4:185626511	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.52	-0.38	2.9e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs710865	0.527	rs2275403	chr1:19557713	C/G	cg13387374	chr1:19411106	UBR4	-0.55	-9.49	-0.42	1.7e-19	Brain structure;
LUAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg09509183	chr1:209979624	IRF6	0.56	8.27	0.37	1.7e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg04025307	chr7:1156635	C7orf50	0.6	6.84	0.32	2.78e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7809950	1.000	rs10258385	chr7:107243350	T/C	cg23024343	chr7:107201750	COG5	0.78	12.72	0.53	1.3e-31	Coronary artery disease;
LUAD	cis	rs8044995	0.636	rs12447119	chr16:68297928	G/A	cg09835421	chr16:68378352	PRMT7	-0.95	-9.6	-0.42	7.09e-20	Schizophrenia;
LUAD	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg13385794	chr1:248469461	NA	0.26	7.0	0.32	1.01e-11	Common traits (Other);
LUAD	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.5	-0.3	2.31e-10	Breast cancer;
LUAD	cis	rs6484504	0.576	rs158136	chr11:31220712	C/T	cg14844989	chr11:31128820	NA	-0.44	-8.2	-0.37	2.96e-15	Red blood cell count;
LUAD	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg24562669	chr7:97807699	LMTK2	0.3	7.03	0.32	8.17e-12	Breast cancer;
LUAD	cis	rs28655083	0.552	rs76055145	chr16:77124905	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.5	-7.3	-0.33	1.42e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9487051	0.768	rs2483913	chr6:109521042	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.23	-0.33	2.33e-12	Reticulocyte fraction of red cells;
LUAD	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg18944383	chr4:111397179	ENPEP	0.4	7.96	0.36	1.56e-14	Height;
LUAD	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg10518543	chr12:38710700	ALG10B	-0.5	-8.28	-0.37	1.59e-15	Morning vs. evening chronotype;
LUAD	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg26408565	chr15:76604113	ETFA	-0.44	-7.43	-0.34	5.91e-13	Blood metabolite levels;
LUAD	cis	rs1784581	0.894	rs1626020	chr6:162383379	G/A	cg17173639	chr6:162384350	PARK2	-0.58	-10.73	-0.46	6.3e-24	Itch intensity from mosquito bite;
LUAD	cis	rs4891159	0.756	rs55763305	chr18:74161249	G/C	cg24786174	chr18:74118243	ZNF516	-0.72	-12.83	-0.53	4.75e-32	Longevity;
LUAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg11062466	chr8:58055876	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4711350	0.862	rs487835	chr6:33710933	G/A	cg07979401	chr6:33739406	LEMD2	0.49	7.88	0.36	2.83e-14	Schizophrenia;
LUAD	cis	rs35146811	0.700	rs866500	chr7:99840461	A/G	cg13334819	chr7:99746414	C7orf59	0.59	8.32	0.37	1.26e-15	Coronary artery disease;
LUAD	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg15448220	chr1:150897856	SETDB1	-0.55	-9.56	-0.42	9.99e-20	Melanoma;
LUAD	cis	rs1031391	0.716	rs10772416	chr12:11170087	T/A	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.55	-7.58	-0.35	2.27e-13	Bitter taste perception;
LUAD	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg12458913	chr13:53173898	NA	0.38	7.0	0.32	9.8e-12	Lewy body disease;
LUAD	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.78	-13.39	-0.55	2.5e-34	Chronic sinus infection;
LUAD	cis	rs2274273	0.870	rs10145203	chr14:55784458	A/C	cg04306507	chr14:55594613	LGALS3	0.43	8.8	0.39	3.53e-17	Protein biomarker;
LUAD	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7822232	1.000	rs7822232	chr8:145145687	A/C	cg06239191	chr8:145163136	KIAA1875	-0.62	-6.51	-0.3	2.2e-10	Blood metabolite levels;
LUAD	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg12179176	chr11:130786555	SNX19	0.43	7.03	0.32	8.54e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs250677	0.522	rs6872172	chr5:148359529	G/C	cg18129178	chr5:148520854	ABLIM3	0.51	7.62	0.35	1.65e-13	Breast cancer;
LUAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.39	-0.3	4.26e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.64	-0.39	1.21e-16	Total body bone mineral density;
LUAD	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg24069376	chr3:38537580	EXOG	0.44	10.68	0.46	1.02e-23	Electrocardiographic conduction measures;
LUAD	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg26597838	chr10:835615	NA	-0.51	-8.01	-0.36	1.12e-14	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-20.55	-0.71	1.47e-65	Height;
LUAD	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg25358565	chr5:93447407	FAM172A	0.6	7.63	0.35	1.54e-13	Diabetic retinopathy;
LUAD	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg27129171	chr3:47204927	SETD2	0.42	6.85	0.32	2.63e-11	Colorectal cancer;
LUAD	cis	rs7712401	0.601	rs246269	chr5:122256741	T/C	cg19077854	chr5:122220652	SNX24	0.33	6.38	0.3	4.72e-10	Mean platelet volume;
LUAD	cis	rs9902453	0.808	rs4595850	chr17:28206326	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.61	0.42	6.76e-20	Coffee consumption (cups per day);
LUAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs262150	0.545	rs73167302	chr7:158789762	G/A	cg19418458	chr7:158789849	NA	0.63	8.41	0.38	6.31e-16	Facial morphology (factor 20);
LUAD	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg08508325	chr11:3079039	CARS	-0.62	-13.98	-0.56	8.7e-37	Longevity;
LUAD	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg16647868	chr5:131706066	SLC22A5	0.41	7.15	0.33	3.72e-12	Blood metabolite levels;
LUAD	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg25894440	chr7:65020034	NA	0.64	6.92	0.32	1.65e-11	Diabetic kidney disease;
LUAD	cis	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg12292205	chr6:26970375	C6orf41	-0.57	-7.09	-0.33	5.82e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs7960581	0.585	rs79232389	chr12:99171092	A/T	cg21474062	chr3:141087363	ZBTB38	0.37	6.42	0.3	3.69e-10	Angiotensin-converting enzyme inhibitor intolerance;
LUAD	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg09117114	chr16:67998030	SLC12A4	-0.47	-6.62	-0.31	1.12e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2066819	1.000	rs2306694	chr12:56680636	C/T	cg26714650	chr12:56694279	CS	0.85	7.41	0.34	7.15e-13	Psoriasis vulgaris;
LUAD	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg22705602	chr4:152727874	NA	-0.4	-7.07	-0.33	6.3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg10544611	chr16:67998164	SLC12A4	0.62	7.27	0.33	1.78e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg23711669	chr6:146136114	FBXO30	0.37	6.37	0.3	4.9e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg17063962	chr7:91808500	NA	0.68	12.19	0.51	1.65e-29	Breast cancer;
LUAD	cis	rs3820068	0.705	rs41486146	chr1:15900517	A/G	cg13390004	chr1:15929781	NA	-0.42	-6.52	-0.3	1.98e-10	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.5	0.3	2.24e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11771526	0.901	rs10252755	chr7:32304676	G/A	cg13207630	chr7:32358064	NA	0.6	7.34	0.34	1.07e-12	Body mass index;
LUAD	cis	rs295140	0.506	rs4673855	chr2:201136143	A/G	cg23649088	chr2:200775458	C2orf69	-0.48	-8.31	-0.37	1.33e-15	QT interval;
LUAD	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg23815491	chr16:72088622	HP	0.52	9.61	0.42	6.81e-20	Fibrinogen levels;
LUAD	cis	rs13082711	0.554	rs6804440	chr3:27398150	C/T	cg02860705	chr3:27208620	NA	0.71	10.71	0.46	7.31e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	7.48	0.34	4.2e-13	Iron status biomarkers;
LUAD	trans	rs7395662	0.963	rs9666932	chr11:48726240	G/A	cg00717180	chr2:96193071	NA	0.39	7.23	0.33	2.27e-12	HDL cholesterol;
LUAD	cis	rs41311933	0.710	rs62578382	chr9:123685461	G/C	cg13567360	chr9:123745713	C5	-0.83	-7.22	-0.33	2.36e-12	Coronary artery disease;
LUAD	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg05368731	chr17:41323189	NBR1	0.95	19.46	0.69	1.02e-60	Menopause (age at onset);
LUAD	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg27532560	chr4:187881888	NA	0.34	6.41	0.3	3.87e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs909002	0.800	rs7549590	chr1:32109849	G/A	cg13919466	chr1:32135498	COL16A1	-0.39	-9.02	-0.4	6.8e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs35771425	1.000	rs35513231	chr1:211619503	T/C	cg25617285	chr1:211431773	RCOR3	-0.45	-6.7	-0.31	6.84e-11	Educational attainment (years of education);
LUAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00166722	chr3:10149974	C3orf24	0.68	11.62	0.49	2.75e-27	Alzheimer's disease;
LUAD	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg00684032	chr4:1343700	KIAA1530	0.42	6.93	0.32	1.6e-11	Obesity-related traits;
LUAD	cis	rs11771526	0.786	rs11768955	chr7:32378706	T/C	cg27532318	chr7:32358331	NA	0.72	7.78	0.35	5.8e-14	Body mass index;
LUAD	cis	rs17818399	0.926	rs35350086	chr2:46834036	C/G	cg09399716	chr2:46890238	NA	-0.41	-7.71	-0.35	9.36e-14	Height;
LUAD	cis	rs59698941	0.943	rs67656232	chr5:132254426	T/C	cg14825688	chr5:132208181	LEAP2	-0.47	-6.41	-0.3	3.91e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs2224391	0.628	rs11752747	chr6:5272671	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-8.47	-0.38	3.98e-16	Height;
LUAD	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg00898013	chr13:113819073	PROZ	-0.83	-13.5	-0.55	8.8e-35	Platelet distribution width;
LUAD	cis	rs7818345	1.000	rs7835461	chr8:19307051	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.33	7.31	0.33	1.38e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg05187965	chr10:45406764	TMEM72	-0.49	-9.88	-0.43	7.57e-21	Mean corpuscular volume;
LUAD	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg26384229	chr12:38710491	ALG10B	0.45	7.42	0.34	6.44e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg00757033	chr12:89920650	WDR51B	0.64	10.67	0.46	1.06e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg17077180	chr1:38461687	NA	0.42	8.77	0.39	4.43e-17	Coronary artery disease;
LUAD	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg10755058	chr3:40428713	ENTPD3	-0.37	-6.95	-0.32	1.39e-11	Renal cell carcinoma;
LUAD	cis	rs10791323	0.517	rs1120246	chr11:133745212	G/A	cg15485101	chr11:133734466	NA	0.32	7.13	0.33	4.47e-12	Childhood ear infection;
LUAD	cis	rs6121246	0.909	rs1887732	chr20:30413469	C/T	cg21427119	chr20:30132790	HM13	-0.5	-7.63	-0.35	1.59e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs6545883	0.868	rs2427885	chr2:61816777	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-6.61	-0.31	1.13e-10	Tuberculosis;
LUAD	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-7.45	-0.34	5.16e-13	Lung cancer;
LUAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10802521	chr3:52805072	NEK4	-0.48	-8.13	-0.37	4.67e-15	Electroencephalogram traits;
LUAD	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs778371	0.723	rs1973675	chr2:233636450	C/T	cg08000102	chr2:233561755	GIGYF2	-0.41	-6.68	-0.31	7.38e-11	Schizophrenia;
LUAD	trans	rs2235573	0.594	rs11912649	chr22:38415542	C/T	cg19894588	chr14:64061835	NA	0.43	6.75	0.31	4.77e-11	Glioblastoma;Glioma;
LUAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00166722	chr3:10149974	C3orf24	0.63	10.42	0.45	8.88e-23	Alzheimer's disease;
LUAD	cis	rs6484504	0.576	rs208071	chr11:31144996	C/T	cg14844989	chr11:31128820	NA	-0.44	-8.12	-0.37	5.12e-15	Red blood cell count;
LUAD	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.35	6.65	0.31	9.19e-11	Lung cancer in ever smokers;
LUAD	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11890956	chr21:40555474	PSMG1	-0.59	-10.3	-0.45	2.44e-22	Menarche (age at onset);
LUAD	cis	rs2282300	0.739	rs1222208	chr11:30361377	A/C	cg25418670	chr11:30344373	C11orf46	-0.51	-6.95	-0.32	1.39e-11	Morning vs. evening chronotype;
LUAD	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg03859395	chr2:55845619	SMEK2	0.75	14.1	0.57	2.92e-37	Metabolic syndrome;
LUAD	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	6.57	0.3	1.47e-10	Obesity-related traits;
LUAD	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg21214613	chr1:16344536	HSPB7	0.34	6.43	0.3	3.47e-10	Systolic blood pressure;
LUAD	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg11645453	chr3:52864694	ITIH4	0.6	11.29	0.48	5.14e-26	Schizophrenia;
LUAD	cis	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg06521852	chr22:38141419	TRIOBP	0.49	9.24	0.41	1.2e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.19	0.37	3.13e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs1509123	0.609	rs12103615	chr17:6721182	A/G	cg12642237	chr17:6703447	TEKT1	0.44	6.7	0.31	6.5e-11	Blood metabolite levels;
LUAD	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.28	-0.57	5.01e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1595825	0.891	rs6751690	chr2:198574523	G/A	cg00982548	chr2:198649783	BOLL	-0.6	-8.43	-0.38	5.68e-16	Ulcerative colitis;
LUAD	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg19761014	chr17:28927070	LRRC37B2	0.93	9.19	0.41	1.83e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4853525	0.923	rs2204859	chr2:191736873	C/A	cg11845111	chr2:191398756	TMEM194B	-0.4	-6.36	-0.3	5.28e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg11494091	chr17:61959527	GH2	0.43	8.38	0.38	8.14e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg23533926	chr12:111358616	MYL2	-0.43	-7.34	-0.34	1.07e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2274273	0.934	rs10137307	chr14:55845185	T/C	cg04306507	chr14:55594613	LGALS3	0.42	8.62	0.39	1.35e-16	Protein biomarker;
LUAD	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg17800788	chr1:21766015	NBPF3	0.37	7.28	0.33	1.62e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg21475434	chr5:93447410	FAM172A	0.74	8.58	0.39	1.8e-16	Diabetic retinopathy;
LUAD	cis	rs904251	0.523	rs1776454	chr6:37482099	C/T	cg25019722	chr6:37503610	NA	-0.32	-7.53	-0.34	3.15e-13	Cognitive performance;
LUAD	cis	rs12681287	0.640	rs7461413	chr8:87470978	C/G	cg27223183	chr8:87520930	FAM82B	-0.67	-9.54	-0.42	1.12e-19	Caudate activity during reward;
LUAD	cis	rs79839061	0.667	rs73207777	chr4:836046	A/G	cg07828340	chr4:882639	GAK	1.04	9.38	0.41	4.14e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg08601574	chr20:25228251	PYGB	0.45	8.43	0.38	5.56e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.29	0.41	8.47e-19	Alzheimer's disease;
LUAD	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg10057126	chr4:77819792	ANKRD56	0.53	9.11	0.4	3.35e-18	Emphysema distribution in smoking;
LUAD	cis	rs2625529	0.730	rs2957373	chr15:72340929	T/C	cg16672083	chr15:72433130	SENP8	0.67	12.14	0.51	2.74e-29	Red blood cell count;
LUAD	cis	rs910187	0.605	rs6122559	chr20:45810617	T/G	cg27589058	chr20:45804311	EYA2	-0.34	-7.5	-0.34	3.75e-13	Migraine;
LUAD	cis	rs28595532	0.925	rs116785973	chr4:119611350	G/A	cg21605333	chr4:119757512	SEC24D	0.85	7.86	0.36	3.21e-14	Cannabis dependence symptom count;
LUAD	cis	rs62238980	0.614	rs734091	chr22:32461891	A/T	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs7173743	0.756	rs8030937	chr15:79129587	G/T	cg00540400	chr15:79124168	NA	0.38	7.84	0.36	3.75e-14	Coronary artery disease;
LUAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg09436375	chr6:42928200	GNMT	-0.29	-8.3	-0.37	1.42e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.73	-14.94	-0.59	8.25e-41	Lung cancer;
LUAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.12	0.41	3.07e-18	Alzheimer's disease;
LUAD	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg00852783	chr1:26633632	UBXN11	0.41	7.15	0.33	3.95e-12	Obesity-related traits;
LUAD	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg08470875	chr2:26401718	FAM59B	-0.67	-8.95	-0.4	1.1e-17	Gut microbiome composition (summer);
LUAD	cis	rs12541635	0.701	rs2029878	chr8:107025283	A/G	cg10147462	chr8:107024639	NA	0.48	8.47	0.38	3.95e-16	Age of smoking initiation;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00320243	chr19:18314691	RAB3A	-0.4	-6.48	-0.3	2.58e-10	Cancer;
LUAD	cis	rs13082711	0.911	rs17682751	chr3:27497027	C/T	cg02860705	chr3:27208620	NA	-0.61	-9.54	-0.42	1.11e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg04896959	chr15:78267971	NA	-0.5	-8.83	-0.39	2.79e-17	Coronary artery disease or large artery stroke;
LUAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg04234412	chr22:24373322	LOC391322	-0.8	-14.16	-0.57	1.54e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg09491104	chr22:46646882	C22orf40	-0.58	-11.33	-0.48	3.77e-26	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.63	-0.39	1.26e-16	Height;
LUAD	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg05805236	chr11:65401703	PCNXL3	-0.5	-8.34	-0.38	1.04e-15	Non-alcoholic fatty liver disease histology (lobular);
LUAD	cis	rs6500395	0.963	rs4785248	chr16:48687947	A/G	cg04672837	chr16:48644449	N4BP1	-0.4	-7.07	-0.33	6.4e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg23533926	chr12:111358616	MYL2	-0.43	-7.36	-0.34	9.48e-13	Extrinsic epigenetic age acceleration;
LUAD	trans	rs7591996	0.835	rs7585700	chr2:6504784	A/T	cg22829908	chr10:21814466	C10orf140	-0.38	-6.4	-0.3	4.06e-10	Osteosarcoma;
LUAD	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg27170947	chr2:26402098	FAM59B	0.83	12.12	0.51	3.09e-29	Gut microbiome composition (summer);
LUAD	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg10645314	chr2:3704589	ALLC	-0.6	-9.24	-0.41	1.23e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs6489882	0.932	rs4767045	chr12:113409413	C/T	cg20102336	chr12:113376681	OAS3	-0.46	-6.54	-0.3	1.78e-10	Chronic lymphocytic leukemia;
LUAD	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.96	0.32	1.3e-11	Parkinson's disease;
LUAD	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.14	-0.41	2.57e-18	Life satisfaction;
LUAD	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.61	-0.31	1.19e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.52	-0.3	2.06e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs61774743	0.754	rs11581271	chr1:41835061	C/G	cg08462924	chr1:41848221	NA	0.36	6.42	0.3	3.57e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg10518543	chr12:38710700	ALG10B	-0.47	-7.47	-0.34	4.73e-13	Morning vs. evening chronotype;
LUAD	cis	rs990171	0.538	rs2075188	chr2:103120232	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	6.49	0.3	2.35e-10	Lymphocyte counts;
LUAD	trans	rs9354308	0.809	rs9363461	chr6:66557574	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.64	-0.31	9.78e-11	Metabolite levels;
LUAD	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg18827107	chr12:86230957	RASSF9	-0.56	-9.89	-0.43	6.65e-21	Major depressive disorder;
LUAD	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg05283184	chr6:79620031	NA	-0.6	-12.2	-0.51	1.51e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs923109	0.573	rs1060286	chr1:207250300	G/A	cg24040043	chr1:207224982	YOD1	-0.39	-9.39	-0.42	3.62e-19	Left atrial antero-posterior diameter;
LUAD	cis	rs1190552	0.846	rs3783381	chr14:102965435	A/G	cg18135206	chr14:102964638	TECPR2	0.47	6.63	0.31	1.05e-10	Blood protein levels;
LUAD	cis	rs9341808	0.754	rs10806185	chr6:80954511	G/A	cg08355045	chr6:80787529	NA	0.59	10.71	0.46	7.57e-24	Sitting height ratio;
LUAD	trans	rs9929218	0.731	rs72785179	chr16:68767912	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-15.42	-0.6	6.87e-43	Colorectal cancer;
LUAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.74	-0.35	7.21e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg23283495	chr1:209979779	IRF6	0.7	11.41	0.49	1.82e-26	Cleft lip with or without cleft palate;
LUAD	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-11.47	-0.49	1.09e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs490234	0.756	rs10986849	chr9:128469683	A/G	cg14078157	chr9:128172775	NA	-0.46	-8.36	-0.38	9.27e-16	Mean arterial pressure;
LUAD	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg04944784	chr2:26401820	FAM59B	0.88	12.5	0.52	1.03e-30	Gut microbiome composition (summer);
LUAD	trans	rs10411161	0.702	rs75647161	chr19:52398984	T/C	cg22319618	chr22:45562946	NUP50	-0.66	-9.44	-0.42	2.52e-19	Breast cancer;
LUAD	cis	rs7044106	0.578	rs4837788	chr9:123396801	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.73	0.31	5.62e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg01765077	chr12:122356316	WDR66	0.58	10.16	0.44	7.5e-22	Mean corpuscular volume;
LUAD	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg24578937	chr1:2090814	PRKCZ	0.77	15.45	0.6	4.99e-43	Height;
LUAD	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg07570687	chr10:102243282	WNT8B	0.48	7.28	0.33	1.66e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.44	8.02	0.36	1.03e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.73	-0.35	7.96e-14	Diabetic kidney disease;
LUAD	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg18225595	chr11:63971243	STIP1	0.4	6.99	0.32	1.05e-11	Platelet count;
LUAD	cis	rs7688540	0.800	rs6857106	chr4:249430	A/C	cg12746427	chr4:53362	ZNF718;ZNF595	-0.31	-6.43	-0.3	3.49e-10	Facial morphology (factor 6, height of vermillion lower lip);
LUAD	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.88	0.4	1.91e-17	Menopause (age at onset);
LUAD	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	9.24	0.41	1.21e-18	Hip circumference adjusted for BMI;
LUAD	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg02221750	chr19:17393354	ANKLE1	-0.75	-12.08	-0.51	4.51e-29	Systemic lupus erythematosus;
LUAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg10150615	chr22:24372951	LOC391322	0.5	7.92	0.36	2.11e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9900062	0.535	rs753917	chr17:62673136	C/T	cg02097616	chr17:62675921	NA	0.72	12.1	0.51	3.86e-29	QT interval;
LUAD	cis	rs243505	0.667	rs10249029	chr7:148576042	C/T	cg09806900	chr7:148480153	CUL1	0.4	6.83	0.32	3.03e-11	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs11072805	1	rs11072805	chr15:79078518	T/C	cg22753661	chr15:79092743	ADAMTS7	0.5	8.09	0.37	6.33e-15	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg08645402	chr16:4508243	NA	0.52	9.32	0.41	6.47e-19	Schizophrenia;
LUAD	trans	rs459571	0.959	rs461462	chr9:136911272	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.62	-9.06	-0.4	5.05e-18	Platelet distribution width;
LUAD	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg22117172	chr7:91764530	CYP51A1	0.33	7.28	0.33	1.64e-12	Breast cancer;
LUAD	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.17	-0.33	3.36e-12	Lung cancer;
LUAD	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg21214613	chr1:16344536	HSPB7	-0.43	-7.48	-0.34	4.22e-13	Dilated cardiomyopathy;
LUAD	cis	rs12545109	0.800	rs1530218	chr8:57407864	C/G	cg07776626	chr8:57350775	NA	-0.61	-8.52	-0.38	2.94e-16	Obesity-related traits;
LUAD	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg17863274	chr19:49399704	TULP2	-0.56	-8.71	-0.39	7.12e-17	Red cell distribution width;
LUAD	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg16010596	chr6:33739607	LEMD2	-0.42	-7.74	-0.35	7.27e-14	Schizophrenia;
LUAD	cis	rs3818285	0.610	rs642938	chr10:111633025	A/C	cg00817464	chr10:111662876	XPNPEP1	0.82	15.64	0.61	7.77e-44	Superior crus of antihelix expression;
LUAD	cis	rs7737355	0.812	rs3756289	chr5:130982194	A/G	cg06307176	chr5:131281290	NA	0.44	7.27	0.33	1.75e-12	Life satisfaction;
LUAD	trans	rs9784649	1.000	rs7702197	chr5:24975778	A/G	cg08600765	chr20:34638493	LOC647979	0.55	7.37	0.34	8.8e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4285028	0.699	rs1344279	chr3:121615679	G/A	cg11130432	chr3:121712080	ILDR1	-0.57	-7.93	-0.36	2.03e-14	Multiple sclerosis;
LUAD	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg03289416	chr15:75166202	SCAMP2	0.55	9.36	0.41	4.82e-19	Breast cancer;
LUAD	cis	rs6785206	0.772	rs6439134	chr3:128323504	C/T	cg16766828	chr3:128327626	NA	-0.87	-9.67	-0.43	4.14e-20	Lymphocyte percentage of white cells;
LUAD	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg16479474	chr6:28041457	NA	-0.44	-7.88	-0.36	2.74e-14	Parkinson's disease;
LUAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg14820908	chr5:178986412	RUFY1	0.47	7.85	0.36	3.45e-14	Lung cancer;
LUAD	cis	rs7617773	0.817	rs17786132	chr3:48249420	C/G	cg11946769	chr3:48343235	NME6	0.42	6.49	0.3	2.43e-10	Coronary artery disease;
LUAD	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg16262614	chr3:133464971	TF	0.38	7.56	0.34	2.55e-13	Iron status biomarkers (transferrin levels);
LUAD	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.27	0.33	1.74e-12	Menopause (age at onset);
LUAD	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg16325326	chr1:53192061	ZYG11B	-0.51	-8.12	-0.37	5.03e-15	Monocyte count;
LUAD	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg01657329	chr11:68192670	LRP5	-0.54	-9.62	-0.42	6.04e-20	Total body bone mineral density;
LUAD	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg26039829	chr8:22132926	PIWIL2	0.56	10.35	0.45	1.6e-22	Hypertriglyceridemia;
LUAD	cis	rs1595825	0.945	rs7426250	chr2:198837358	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-7.11	-0.33	5.06e-12	Ulcerative colitis;
LUAD	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-7.92	-0.36	2.07e-14	Neutrophil percentage of white cells;
LUAD	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg26408565	chr15:76604113	ETFA	-0.43	-6.98	-0.32	1.12e-11	Blood metabolite levels;
LUAD	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg16049864	chr8:95962084	TP53INP1	0.39	7.12	0.33	4.7e-12	Type 2 diabetes;
LUAD	cis	rs877282	0.945	rs11253388	chr10:787852	A/G	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg13990141	chr9:96213504	FAM120AOS;FAM120A	-0.67	-6.59	-0.31	1.33e-10	Type 2 diabetes;
LUAD	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg26587870	chr6:27730563	NA	-0.43	-7.05	-0.32	7.2e-12	Parkinson's disease;
LUAD	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.6	-0.6	1.19e-43	Eye color traits;
LUAD	cis	rs4730250	0.711	rs117026964	chr7:107063656	C/A	cg02696742	chr7:106810147	HBP1	-0.71	-8.52	-0.38	2.79e-16	Osteoarthritis;
LUAD	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg15557168	chr22:42548783	NA	-0.49	-9.7	-0.43	3.27e-20	Schizophrenia;
LUAD	cis	rs12541635	0.934	rs11776139	chr8:106983966	A/G	cg10147462	chr8:107024639	NA	0.46	8.07	0.37	7.47e-15	Age of smoking initiation;
LUAD	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg15448220	chr1:150897856	SETDB1	0.55	9.35	0.41	5.02e-19	Melanoma;
LUAD	cis	rs6076065	0.723	rs6137908	chr20:23344590	G/A	cg11657817	chr20:23433608	CST11	0.5	9.14	0.41	2.6e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg00255919	chr5:131827918	IRF1	0.5	11.9	0.5	2.21e-28	Asthma (sex interaction);
LUAD	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg13334819	chr7:99746414	C7orf59	-0.58	-8.65	-0.39	1.1e-16	Coronary artery disease;
LUAD	trans	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.67	-0.35	1.19e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg26384229	chr12:38710491	ALG10B	-0.38	-6.49	-0.3	2.38e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg12179176	chr11:130786555	SNX19	0.54	9.1	0.4	3.69e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg00277334	chr10:82204260	NA	-0.96	-22.11	-0.73	1.46e-72	Post bronchodilator FEV1;
LUAD	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg01689657	chr7:91764605	CYP51A1	0.37	9.06	0.4	4.92e-18	Breast cancer;
LUAD	cis	rs1832871	0.643	rs7750656	chr6:158725907	C/T	cg07165851	chr6:158734300	TULP4	0.7	10.98	0.47	7.79e-25	Height;
LUAD	trans	rs4650994	0.544	rs2476560	chr1:178594919	A/G	cg05059571	chr16:84539110	KIAA1609	0.68	11.92	0.5	1.88e-28	HDL cholesterol levels;HDL cholesterol;
LUAD	trans	rs629535	0.862	rs2472141	chr8:70054216	T/C	cg21567404	chr3:27674614	NA	1.02	18.49	0.67	2.24e-56	Dupuytren's disease;
LUAD	cis	rs4285028	0.731	rs2877561	chr3:121712051	A/C	cg11130432	chr3:121712080	ILDR1	0.56	8.45	0.38	4.87e-16	Multiple sclerosis;
LUAD	cis	rs7241530	0.636	rs28491529	chr18:75889301	A/G	cg14642773	chr18:75888474	NA	0.32	6.53	0.3	1.94e-10	Educational attainment (years of education);
LUAD	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.71	-12.13	-0.51	2.84e-29	Blood protein levels;
LUAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg20283391	chr11:68216788	NA	-0.4	-6.53	-0.3	1.94e-10	Total body bone mineral density;
LUAD	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.65	0.39	1.08e-16	Menarche (age at onset);
LUAD	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-9.41	-0.42	3.19e-19	Type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.81e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs73416724	1.000	rs113163694	chr6:43283410	C/T	cg26312998	chr6:43337775	ZNF318	0.55	6.58	0.3	1.36e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg18132916	chr6:79620363	NA	-0.42	-7.4	-0.34	7.35e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg21427119	chr20:30132790	HM13	-0.61	-8.97	-0.4	1e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs11811982	0.793	rs79146151	chr1:227539055	G/A	cg24860534	chr1:227506868	CDC42BPA	0.71	7.52	0.34	3.35e-13	Optic disc area;
LUAD	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.04	-0.44	2.04e-21	Total body bone mineral density;
LUAD	cis	rs11958404	0.932	rs6870420	chr5:157437166	T/C	cg05962755	chr5:157440814	NA	0.71	9.95	0.44	4.36e-21	IgG glycosylation;
LUAD	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg15017067	chr4:17643749	FAM184B	0.38	7.42	0.34	6.2800000000000005e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7779181	0.808	rs10241729	chr7:32289879	A/G	cg13207630	chr7:32358064	NA	0.4	6.37	0.3	5e-10	Body mass index;
LUAD	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.62	-0.31	1.09e-10	Breast cancer;
LUAD	cis	rs7953508	0.741	rs12312736	chr12:93997264	C/G	cg18151635	chr12:93972918	NA	-0.5	-7.99	-0.36	1.33e-14	Pubertal anthropometrics;
LUAD	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg01819759	chr13:79234251	RNF219	0.58	8.19	0.37	3.18e-15	Large artery stroke;
LUAD	cis	rs244899	0.967	rs244898	chr5:167918926	T/C	cg06604206	chr5:167912465	RARS	-0.41	-7.24	-0.33	2.16e-12	Response to platinum-based chemotherapy (carboplatin);
LUAD	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9399401	0.626	rs4304190	chr6:142778912	A/G	cg04461802	chr6:142623433	GPR126	0.39	7.11	0.33	4.83e-12	Chronic obstructive pulmonary disease;
LUAD	cis	rs796825	0.649	rs4378995	chr3:119996055	G/A	cg21790991	chr3:120137480	FSTL1	-0.4	-6.91	-0.32	1.79e-11	HIV-1 susceptibility;
LUAD	cis	rs921968	0.591	rs6717107	chr2:219588697	A/G	cg02176678	chr2:219576539	TTLL4	-0.59	-11.99	-0.5	1.06e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4604732	0.588	rs12045675	chr1:247623915	C/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.1	0.33	5.19e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg27634071	chr22:45809740	RIBC2;SMC1B	0.6	6.58	0.3	1.41e-10	Tonsillectomy;
LUAD	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg22117172	chr7:91764530	CYP51A1	0.33	7.13	0.33	4.47e-12	Breast cancer;
LUAD	cis	rs7043114	0.525	rs1133908	chr9:95068046	C/T	cg14631576	chr9:95140430	CENPP	-0.41	-8.39	-0.38	7.2e-16	Height;
LUAD	cis	rs8017423	1.000	rs8017423	chr14:90679910	A/G	cg14092571	chr14:90743983	NA	-0.48	-8.55	-0.38	2.19e-16	Mortality in heart failure;
LUAD	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.49	0.38	3.47e-16	Menopause (age at onset);
LUAD	cis	rs12681287	0.511	rs9297923	chr8:87548989	T/C	cg27223183	chr8:87520930	FAM82B	0.73	10.39	0.45	1.11e-22	Caudate activity during reward;
LUAD	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.27	-0.45	3.01e-22	Menopause (age at onset);
LUAD	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg12119029	chr16:89752879	CDK10	0.35	7.34	0.34	1.11e-12	Vitiligo;
LUAD	trans	rs11165623	0.792	rs12123543	chr1:96964549	T/C	cg10631902	chr5:14652156	NA	-0.58	-11.0	-0.47	6.11e-25	Hip circumference;Waist circumference;
LUAD	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26314531	chr2:26401878	FAM59B	-0.7	-9.53	-0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23260255	chr3:187871479	LPP	0.42	6.97	0.32	1.24e-11	Monocyte percentage of white cells;
LUAD	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg16479474	chr6:28041457	NA	0.44	7.46	0.34	4.87e-13	Depression;
LUAD	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.22	0.41	1.43e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg11062466	chr8:58055876	NA	0.66	8.67	0.39	9.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg05368731	chr17:41323189	NBR1	0.98	21.09	0.72	5.32e-68	Menopause (age at onset);
LUAD	cis	rs1232027	0.622	rs2618369	chr5:79978458	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.42	-6.5	-0.3	2.27e-10	Huntington's disease progression;
LUAD	cis	rs1692580	0.807	rs12138597	chr1:2189477	T/C	cg21194808	chr1:2205498	SKI	0.4	6.8	0.31	3.63e-11	Coronary artery disease;
LUAD	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.55	-0.34	2.63e-13	Lung cancer;
LUAD	cis	rs61897795	0.657	rs174590	chr11:61616977	G/C	cg06781209	chr11:61594997	FADS2	-0.43	-7.05	-0.32	7.47e-12	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs9925964	0.967	rs749767	chr16:31124407	C/T	cg03418659	chr16:31128414	MYST1	-0.44	-7.74	-0.35	7.53e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.56	-8.76	-0.39	4.85e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg01851573	chr8:8652454	MFHAS1	-0.44	-8.02	-0.36	1.06e-14	Mood instability;
LUAD	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg11915388	chr22:42470451	FAM109B	0.38	6.92	0.32	1.63e-11	Schizophrenia;
LUAD	cis	rs9430161	0.579	rs6694011	chr1:11036935	G/A	cg27631724	chr1:11040367	C1orf127	0.55	9.6	0.42	7.01e-20	Ewing sarcoma;
LUAD	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg27661571	chr11:113659931	NA	-0.67	-7.76	-0.35	6.22e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs986417	0.818	rs8005621	chr14:61106699	G/A	cg27398547	chr14:60952738	C14orf39	0.54	6.56	0.3	1.59e-10	Gut microbiota (bacterial taxa);
LUAD	cis	rs3764563	0.935	rs1654592	chr19:15690296	T/A	cg20725493	chr19:15740067	CYP4F8	0.61	6.53	0.3	1.92e-10	Inflammatory biomarkers;
LUAD	cis	rs2742234	0.910	rs2505505	chr10:43648221	G/T	cg02780029	chr10:43622663	RET	-0.42	-6.89	-0.32	2.06e-11	Hirschsprung disease;
LUAD	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg20933634	chr6:27740509	NA	0.48	7.68	0.35	1.09e-13	Parkinson's disease;
LUAD	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.4	-7.98	-0.36	1.37e-14	Glomerular filtration rate;
LUAD	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg19743168	chr1:23544995	NA	0.39	6.86	0.32	2.52e-11	Height;
LUAD	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg05665937	chr4:1216051	CTBP1	0.47	6.99	0.32	1.1e-11	Longevity;
LUAD	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg08847533	chr14:75593920	NEK9	0.41	7.06	0.32	7.07e-12	Height;
LUAD	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.12e-17	Cannabis dependence symptom count;
LUAD	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg09222892	chr1:25734099	RHCE	-0.5	-9.38	-0.41	4.2e-19	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs11048434	0.736	rs1049925	chr12:9086898	A/G	cg13575925	chr12:9217583	LOC144571	0.39	7.25	0.33	2.02e-12	Sjögren's syndrome;
LUAD	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg21475434	chr5:93447410	FAM172A	0.76	8.53	0.38	2.58e-16	Diabetic retinopathy;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg14787155	chr3:108308533	DZIP3;KIAA1524	-0.42	-7.21	-0.33	2.52e-12	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.78	0.35	5.76e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2235642	0.507	rs2235645	chr16:1597924	C/T	cg26528668	chr16:1614120	IFT140	0.45	6.84	0.32	2.81e-11	Coronary artery disease;
LUAD	trans	rs7395662	1.000	rs11039800	chr11:48542579	C/T	cg00717180	chr2:96193071	NA	0.4	7.52	0.34	3.35e-13	HDL cholesterol;
LUAD	trans	rs853679	0.607	rs13217619	chr6:28306671	T/C	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.0	-0.47	6.28e-25	Depression;
LUAD	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.62	0.35	1.67e-13	Breast cancer;
LUAD	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg25566285	chr7:158114605	PTPRN2	0.53	11.45	0.49	1.3e-26	Calcium levels;
LUAD	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.62e-13	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg03806693	chr22:41940476	POLR3H	0.73	9.76	0.43	1.93e-20	Vitiligo;
LUAD	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg05590025	chr7:65112418	INTS4L2	-0.77	-8.16	-0.37	3.81e-15	Diabetic kidney disease;
LUAD	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg15737290	chr11:93063684	CCDC67	-0.5	-7.18	-0.33	3.16e-12	Pulmonary function decline;
LUAD	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg10802521	chr3:52805072	NEK4	-0.38	-6.37	-0.3	4.91e-10	Electroencephalogram traits;
LUAD	cis	rs7193541	0.684	rs4888262	chr16:74670458	C/T	cg01733217	chr16:74700730	RFWD3	0.69	13.54	0.55	6.05e-35	Multiple myeloma;
LUAD	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg04398451	chr17:18023971	MYO15A	-0.63	-11.52	-0.49	6.7399999999999993e-27	Total body bone mineral density;
LUAD	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg14725641	chr11:61582763	MIR1908;FADS1	-0.4	-6.37	-0.3	4.82e-10	Trans fatty acid levels;
LUAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	12.62	0.52	3.25e-31	Prudent dietary pattern;
LUAD	cis	rs2730245	0.527	rs2788470	chr7:158649801	G/T	cg24397884	chr7:158709396	WDR60	0.66	8.85	0.4	2.49e-17	Height;
LUAD	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg13770153	chr20:60521292	NA	-0.48	-8.08	-0.37	6.98e-15	Body mass index;
LUAD	trans	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg26043149	chr18:55253948	FECH	-0.4	-6.45	-0.3	3.15e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10500953	chr16:346518	AXIN1	0.55	6.79	0.31	3.71e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1448094	0.842	rs7978562	chr12:86451478	A/G	cg18827107	chr12:86230957	RASSF9	-0.44	-7.95	-0.36	1.67e-14	Major depressive disorder;
LUAD	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.29	6.5	0.3	2.32e-10	Cardiac Troponin-T levels;
LUAD	cis	rs727505	0.865	rs17325193	chr7:124648385	A/G	cg23710748	chr7:124431027	NA	-0.42	-8.32	-0.38	1.2e-15	Lewy body disease;
LUAD	cis	rs9858542	0.537	rs115753735	chr3:49355005	T/C	cg00383909	chr3:49044727	WDR6	0.58	7.6	0.35	1.91e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.48	-8.53	-0.38	2.72e-16	Alzheimer's disease (late onset);
LUAD	cis	rs7551222	0.752	rs6681905	chr1:204535789	T/G	cg20240347	chr1:204465584	NA	-0.33	-6.38	-0.3	4.6e-10	Schizophrenia;
LUAD	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg04539111	chr16:67997858	SLC12A4	-0.52	-6.4	-0.3	4.19e-10	Schizophrenia;
LUAD	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18099408	chr3:52552593	STAB1	-0.45	-7.98	-0.36	1.35e-14	Electroencephalogram traits;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg18110333	chr6:292329	DUSP22	-0.78	-13.01	-0.53	8.49e-33	Menopause (age at onset);
LUAD	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg24450063	chr1:156163899	SLC25A44	0.94	16.21	0.62	2.68e-46	Testicular germ cell tumor;
LUAD	cis	rs11771526	0.901	rs11771230	chr7:32315546	C/T	cg27511599	chr7:32358540	NA	-0.54	-6.66	-0.31	8.73e-11	Body mass index;
LUAD	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	12.18	0.51	1.77e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs1493916	0.870	rs7235698	chr18:31382486	A/G	cg13755796	chr4:20253514	NA	-0.4	-6.76	-0.31	4.69e-11	Life satisfaction;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03182158	chr8:125487804	RNF139	-0.54	-6.54	-0.3	1.78e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.93	0.4	1.35e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.64	0.35	1.42e-13	Depression;
LUAD	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg00814883	chr7:100076585	TSC22D4	0.84	12.52	0.52	8.5e-31	Platelet count;
LUAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg24101359	chr6:42928495	GNMT	0.45	8.4	0.38	6.68e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg11021810	chr14:89720620	FOXN3	-0.59	-9.93	-0.43	5.03e-21	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs28595532	1.000	rs114682099	chr4:119702004	C/T	cg14228332	chr4:119757509	SEC24D	0.8	7.57	0.35	2.28e-13	Cannabis dependence symptom count;
LUAD	cis	rs752010	0.695	rs10789408	chr1:42106579	T/C	cg06885757	chr1:42089581	HIVEP3	0.38	8.11	0.37	5.64e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg22683308	chr4:1340831	KIAA1530	-0.41	-6.73	-0.31	5.54e-11	Longevity;
LUAD	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg01851573	chr8:8652454	MFHAS1	0.41	7.51	0.34	3.53e-13	Mood instability;
LUAD	cis	rs3806843	0.576	rs246063	chr5:140324492	T/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg03030879	chr14:75389066	RPS6KL1	0.35	6.43	0.3	3.46e-10	Caffeine consumption;
LUAD	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg00277334	chr10:82204260	NA	-0.67	-12.06	-0.51	5.53e-29	Post bronchodilator FEV1;
LUAD	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg09085632	chr11:111637200	PPP2R1B	0.63	9.59	0.42	7.44e-20	Primary sclerosing cholangitis;
LUAD	trans	rs11039798	0.536	rs112223280	chr11:48145077	C/G	cg15704280	chr7:45808275	SEPT13	0.8	6.78	0.31	4.03e-11	Axial length;
LUAD	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg01475377	chr6:109611718	NA	-0.53	-9.93	-0.43	4.93e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg14458575	chr2:238380390	NA	0.97	18.7	0.67	2.7e-57	Prostate cancer;
LUAD	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg12311346	chr5:56204834	C5orf35	-0.74	-11.81	-0.5	5.05e-28	Initial pursuit acceleration;
LUAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.55	-10.15	-0.44	8.57e-22	Longevity;Endometriosis;
LUAD	cis	rs2050392	1.000	rs7077496	chr10:30692028	G/A	cg18806716	chr10:30721971	MAP3K8	0.52	10.32	0.45	1.97e-22	Inflammatory bowel disease;
LUAD	cis	rs9951698	0.577	rs2509751	chr18:13085129	G/A	cg12848697	chr18:13133368	NA	0.36	6.9	0.32	1.97e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg00310523	chr12:86230176	RASSF9	0.38	7.56	0.35	2.47e-13	Major depressive disorder;
LUAD	cis	rs6430585	0.583	rs76097170	chr2:136593498	C/T	cg07169764	chr2:136633963	MCM6	0.8	9.21	0.41	1.53e-18	Corneal structure;
LUAD	cis	rs2979489	0.786	rs2915595	chr8:30402817	A/G	cg26383811	chr8:30366931	RBPMS	0.66	10.39	0.45	1.11e-22	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs2425143	1.000	rs56904633	chr20:34400757	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.99	-0.32	1.07e-11	Blood protein levels;
LUAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18404041	chr3:52824283	ITIH1	-0.43	-8.22	-0.37	2.52e-15	Electroencephalogram traits;
LUAD	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg05714579	chr10:131428358	MGMT	0.4	6.57	0.3	1.52e-10	Response to temozolomide;
LUAD	cis	rs597583	0.806	rs2276339	chr11:117395481	G/A	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.55	-0.38	2.21e-16	Putamen volume;
LUAD	cis	rs36051895	0.695	rs62541534	chr9:5028921	C/G	cg02405213	chr9:5042618	JAK2	-0.48	-6.55	-0.3	1.65e-10	Pediatric autoimmune diseases;
LUAD	cis	rs7107174	0.786	rs4945262	chr11:77990831	T/C	cg02023728	chr11:77925099	USP35	0.47	7.18	0.33	3.19e-12	Testicular germ cell tumor;
LUAD	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg09323728	chr8:95962352	TP53INP1	0.28	6.39	0.3	4.26e-10	Type 2 diabetes;
LUAD	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg27661571	chr11:113659931	NA	-0.68	-7.88	-0.36	2.74e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs34286592	0.929	rs11864180	chr16:29830829	T/C	cg08218971	chr16:29826754	C16orf53;PRRT2	0.4	6.44	0.3	3.26e-10	Multiple sclerosis;
LUAD	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg03733263	chr8:22462867	KIAA1967	0.68	11.17	0.48	1.5e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg05283184	chr6:79620031	NA	-0.53	-10.28	-0.45	2.72e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg02743256	chr7:2109353	MAD1L1	-0.47	-6.6	-0.31	1.2e-10	Bipolar disorder;
LUAD	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg05110241	chr16:68378359	PRMT7	-0.69	-7.81	-0.35	4.7e-14	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	6.07e-11	Depression;
LUAD	cis	rs1696756	0.759	rs1298563	chr17:77834703	G/A	cg02876276	chr17:77834299	NA	0.43	6.63	0.31	1e-10	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03517284	chr6:25882590	NA	0.6	9.88	0.43	7.21e-21	Blood metabolite levels;
LUAD	cis	rs12431939	0.947	rs115193312	chr14:51592571	C/A	cg23942311	chr14:51606299	NA	-0.63	-8.37	-0.38	8.28e-16	Cancer;
LUAD	cis	rs9341808	0.556	rs2223875	chr6:81045452	C/T	cg08355045	chr6:80787529	NA	0.47	8.19	0.37	3.07e-15	Sitting height ratio;
LUAD	cis	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg00495681	chr13:53174319	NA	-0.43	-7.32	-0.34	1.23e-12	Lewy body disease;
LUAD	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg01621132	chr19:10221146	PPAN-P2RY11;P2RY11;PPAN	0.34	7.91	0.36	2.31e-14	Narcolepsy;
LUAD	cis	rs7572644	0.699	rs10194283	chr2:28159079	G/A	cg27432699	chr2:27873401	GPN1	-0.42	-6.49	-0.3	2.39e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUAD	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg07217954	chr7:1067459	C7orf50	-0.37	-6.58	-0.3	1.43e-10	Bronchopulmonary dysplasia;
LUAD	trans	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg06606381	chr12:133084897	FBRSL1	-0.94	-9.13	-0.41	2.75e-18	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1023500	0.551	rs4822076	chr22:42364057	C/T	cg15557168	chr22:42548783	NA	-0.46	-7.65	-0.35	1.41e-13	Schizophrenia;
LUAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg08219700	chr8:58056026	NA	0.43	6.65	0.31	9.31e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs1973993	0.689	rs17131755	chr1:96886167	G/A	cg10631902	chr5:14652156	NA	-0.47	-8.01	-0.36	1.13e-14	Weight;
LUAD	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg03690763	chr11:133734501	NA	0.35	7.88	0.36	2.83e-14	Childhood ear infection;
LUAD	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg21385522	chr1:16154831	NA	-0.65	-9.93	-0.43	5.03e-21	Dilated cardiomyopathy;
LUAD	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg00071950	chr4:10020882	SLC2A9	0.85	18.58	0.67	8.8700000000000006e-57	Bone mineral density;
LUAD	cis	rs7582720	1.000	rs6725887	chr2:203745885	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.69	-8.96	-0.4	1.07e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg06713675	chr4:122721982	EXOSC9	0.45	8.34	0.38	1.02e-15	Type 2 diabetes;
LUAD	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg21918786	chr6:109611834	NA	-0.61	-11.38	-0.48	2.4e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8044995	0.563	rs7190134	chr16:68381516	A/G	cg05110241	chr16:68378359	PRMT7	0.93	10.6	0.46	1.88e-23	Schizophrenia;
LUAD	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg06784218	chr1:46089804	CCDC17	0.6	13.43	0.55	1.76e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05901451	chr6:126070800	HEY2	-0.66	-11.14	-0.48	1.91e-25	Brugada syndrome;
LUAD	cis	rs12079745	0.793	rs12063056	chr1:169264107	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.11	-8.07	-0.37	7.41e-15	QT interval;
LUAD	cis	rs7917772	0.604	rs11191358	chr10:104399250	C/T	cg22532475	chr10:104410764	TRIM8	0.4	8.17	0.37	3.65e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18876405	chr7:65276391	NA	0.6	10.14	0.44	8.74e-22	Aortic root size;
LUAD	cis	rs1448094	0.874	rs10779219	chr12:86322643	T/G	cg02569458	chr12:86230093	RASSF9	0.37	7.07	0.33	6.27e-12	Major depressive disorder;
LUAD	cis	rs1832871	0.672	rs56326208	chr6:158762944	C/T	cg07165851	chr6:158734300	TULP4	0.72	11.04	0.47	4.69e-25	Height;
LUAD	cis	rs1691799	0.867	rs1168342	chr12:66758734	A/T	cg16791601	chr12:66731901	HELB	-0.37	-6.78	-0.31	3.98e-11	White blood cell count (basophil);
LUAD	cis	rs12545109	0.800	rs1440763	chr8:57410481	C/A	cg19413350	chr8:57351067	NA	-0.44	-6.64	-0.31	9.91e-11	Obesity-related traits;
LUAD	cis	rs3820068	0.705	rs11589076	chr1:15827027	C/T	cg17385448	chr1:15911702	AGMAT	0.39	6.43	0.3	3.47e-10	Systolic blood pressure;
LUAD	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06112835	chr11:68658793	MRPL21	0.52	9.35	0.41	4.95e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg07305463	chr2:136567211	LCT	-0.35	-6.74	-0.31	5.26e-11	Mosquito bite size;
LUAD	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg09035930	chr12:129282057	SLC15A4	0.75	17.65	0.65	1.21e-52	Systemic lupus erythematosus;
LUAD	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	6.93	0.32	1.62e-11	Schizophrenia;
LUAD	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg06221963	chr1:154839813	KCNN3	-0.85	-20.1	-0.7	1.48e-63	Prostate cancer;
LUAD	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg24596788	chr1:163392923	NA	-0.33	-7.5	-0.34	3.7e-13	Motion sickness;
LUAD	cis	rs7072216	0.770	rs1739	chr10:100176339	A/G	cg26618903	chr10:100175079	PYROXD2	-0.34	-7.68	-0.35	1.13e-13	Metabolite levels;
LUAD	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg06360820	chr2:242988706	NA	-1.07	-10.74	-0.46	5.82e-24	Obesity-related traits;
LUAD	cis	rs7707921	0.723	rs226197	chr5:81574925	G/A	cg15871215	chr5:81402204	ATG10	0.65	10.27	0.45	3.01e-22	Breast cancer;
LUAD	cis	rs7927592	0.546	rs554734	chr11:68192518	T/G	cg01657329	chr11:68192670	LRP5	-0.54	-9.28	-0.41	8.66e-19	Total body bone mineral density;
LUAD	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg00074818	chr8:8560427	CLDN23	0.66	10.12	0.44	1.07e-21	Obesity-related traits;
LUAD	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg05187965	chr10:45406764	TMEM72	-0.47	-9.61	-0.42	6.72e-20	Mean corpuscular volume;
LUAD	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.27	0.37	1.77e-15	Body mass index;
LUAD	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg06641503	chr3:48959341	ARIH2	-0.38	-7.46	-0.34	4.89e-13	Parkinson's disease;
LUAD	cis	rs11229555	0.645	rs11530830	chr11:58252992	C/G	cg15696309	chr11:58395628	NA	0.78	10.67	0.46	1.04e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg25173405	chr17:45401733	C17orf57	0.46	7.53	0.34	3e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg05132306	chr1:1846340	CALML6	-0.36	-7.79	-0.35	5.37e-14	Body mass index;
LUAD	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg04731861	chr2:219085781	ARPC2	0.23	7.14	0.33	4.21e-12	Colorectal cancer;
LUAD	cis	rs968567	0.705	rs174575	chr11:61602003	C/G	cg21709803	chr11:61594965	FADS2	-0.48	-8.81	-0.39	3.35e-17	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs9487051	0.773	rs351749	chr6:109533353	A/T	cg01475377	chr6:109611718	NA	-0.38	-6.92	-0.32	1.64e-11	Reticulocyte fraction of red cells;
LUAD	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg00769240	chr8:12517080	NA	-0.39	-6.49	-0.3	2.45e-10	Blood pressure (smoking interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16978871	chr7:139026114	C7orf55	-0.42	-6.43	-0.3	3.45e-10	Height;
LUAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg10553204	chr2:20871195	GDF7	-0.42	-7.22	-0.33	2.37e-12	Abdominal aortic aneurysm;
LUAD	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg26102564	chr10:131424627	MGMT	0.34	6.48	0.3	2.57e-10	Response to temozolomide;
LUAD	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg07371521	chr5:154026371	NA	0.49	7.87	0.36	3.07e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg05234568	chr11:5960015	NA	-0.58	-10.31	-0.45	2.16e-22	DNA methylation (variation);
LUAD	cis	rs7737355	0.738	rs7379696	chr5:130627460	G/A	cg06307176	chr5:131281290	NA	0.39	6.59	0.31	1.33e-10	Life satisfaction;
LUAD	trans	rs11039798	0.844	rs11040177	chr11:48976211	G/C	cg02254774	chr11:50257496	LOC441601	0.52	6.56	0.3	1.62e-10	Axial length;
LUAD	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.41	-0.34	7.04e-13	Blood metabolite levels;
LUAD	cis	rs807669	0.565	rs5746682	chr22:19185526	C/T	cg02655711	chr22:19163373	SLC25A1	0.72	14.96	0.59	6.76e-41	Metabolite levels;
LUAD	cis	rs731174	0.797	rs679742	chr1:38156190	C/G	cg06917450	chr1:38156652	C1orf109	-0.42	-6.55	-0.3	1.64e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.34	6.5	0.3	2.27e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs1215050	0.791	rs783959	chr4:98893476	C/T	cg24818145	chr4:99064322	C4orf37	-0.4	-6.65	-0.31	9.07e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg26554054	chr8:600488	NA	0.61	6.58	0.3	1.39e-10	IgG glycosylation;
LUAD	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg07537917	chr2:241836409	C2orf54	-0.32	-9.26	-0.41	1.06e-18	Urinary metabolites;
LUAD	cis	rs11677370	0.561	rs11687254	chr2:3830906	C/T	cg17052675	chr2:3827356	NA	-0.65	-11.27	-0.48	6.17e-26	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg07917127	chr4:99064746	C4orf37	-0.43	-7.1	-0.33	5.18e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg21782813	chr7:2030301	MAD1L1	0.4	6.62	0.31	1.07e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs4700695	0.841	rs251304	chr5:65249700	A/G	cg21114390	chr5:65439923	SFRS12	0.62	7.49	0.34	4.12e-13	Facial morphology (factor 19);
LUAD	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg11707310	chr1:2537719	MMEL1	0.38	7.89	0.36	2.57e-14	Ulcerative colitis;
LUAD	cis	rs28595532	1.000	rs115706377	chr4:119628481	G/A	cg21605333	chr4:119757512	SEC24D	0.86	7.91	0.36	2.3e-14	Cannabis dependence symptom count;
LUAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg03188948	chr7:1209495	NA	0.9	11.99	0.5	1.04e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6496044	0.568	rs6496040	chr15:86064129	C/G	cg13263323	chr15:86062960	AKAP13	-0.58	-10.85	-0.47	2.29e-24	Interstitial lung disease;
LUAD	cis	rs2742234	0.868	rs2505512	chr10:43633596	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.46	-8.38	-0.38	7.66e-16	Hirschsprung disease;
LUAD	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg25838465	chr1:92012736	NA	-0.49	-7.33	-0.34	1.2e-12	Eosinophil percentage of white cells;
LUAD	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.5	-10.21	-0.44	5.14e-22	Monocyte percentage of white cells;
LUAD	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg07169764	chr2:136633963	MCM6	0.83	9.44	0.42	2.52e-19	Corneal structure;
LUAD	cis	rs225245	0.817	rs1049379	chr17:33998802	G/C	cg05299278	chr17:33885742	SLFN14	0.5	11.35	0.48	3.09e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg17724175	chr1:150552817	MCL1	0.29	6.66	0.31	8.44e-11	Melanoma;
LUAD	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg24450063	chr1:156163899	SLC25A44	1.15	22.7	0.74	3.44e-75	Testicular germ cell tumor;
LUAD	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg23803603	chr1:2058230	PRKCZ	0.41	6.6	0.31	1.22e-10	Height;
LUAD	cis	rs6714710	0.603	rs4311104	chr2:98424802	A/G	cg26665480	chr2:98280029	ACTR1B	0.5	8.19	0.37	3.04e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg02696790	chr15:75250997	RPP25	-0.35	-6.87	-0.32	2.29e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg16797656	chr11:68205561	LRP5	-0.38	-7.11	-0.33	4.84e-12	Bone mineral density (spine);
LUAD	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23583168	chr7:148888333	NA	-0.92	-18.99	-0.68	1.34e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg04586622	chr2:25135609	ADCY3	0.38	8.55	0.38	2.34e-16	Body mass index;
LUAD	trans	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg26043149	chr18:55253948	FECH	1.06	17.84	0.66	1.68e-53	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg11905131	chr22:24372483	LOC391322	0.48	7.25	0.33	1.97e-12	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs78761021	0.867	rs17810412	chr17:9788279	C/T	cg26853458	chr17:9805074	RCVRN	0.37	7.2	0.33	2.78e-12	Type 2 diabetes;
LUAD	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg20307385	chr11:47447363	PSMC3	0.5	7.36	0.34	9.83e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg18932078	chr1:2524107	MMEL1	-0.35	-6.61	-0.31	1.19e-10	Ulcerative colitis;
LUAD	cis	rs17826219	0.585	rs8064302	chr17:28724938	G/A	cg17105886	chr17:28927953	LRRC37B2	-0.69	-6.85	-0.32	2.58e-11	Body mass index;
LUAD	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg11822812	chr5:140052017	DND1	0.43	7.72	0.35	8.56e-14	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs783540	1.000	rs1267657	chr15:83215251	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.43	-6.79	-0.31	3.81e-11	Schizophrenia;
LUAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg19318889	chr4:1322082	MAEA	0.46	7.63	0.35	1.61e-13	Obesity-related traits;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg14067770	chr11:615950	IRF7	-0.41	-6.67	-0.31	7.84e-11	Schizophrenia;
LUAD	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg04842962	chr6:43655489	MRPS18A	1.06	26.84	0.79	2.34e-93	IgG glycosylation;
LUAD	cis	rs75229567	0.618	rs11495622	chr12:70161286	G/A	cg10114359	chr12:70132523	RAB3IP	0.87	7.23	0.33	2.23e-12	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg21028142	chr17:79581711	NPLOC4	0.34	6.96	0.32	1.28e-11	Eye color traits;
LUAD	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg00603274	chr11:61596626	FADS2	-0.41	-7.0	-0.32	1.03e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg22467129	chr15:76604101	ETFA	-0.48	-7.81	-0.36	4.44e-14	Blood metabolite levels;
LUAD	cis	rs8130944	0.859	rs35729571	chr21:44110493	T/C	cg16784985	chr21:44105474	PDE9A	-0.39	-6.66	-0.31	8.3e-11	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs7589728	0.516	rs79815126	chr2:88488270	G/A	cg04511125	chr2:88470314	THNSL2	0.91	8.28	0.37	1.66e-15	Plasma clusterin levels;
LUAD	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg26924012	chr15:45694286	SPATA5L1	1.02	19.15	0.68	2.64e-59	Homoarginine levels;
LUAD	cis	rs7301016	0.846	rs73126024	chr12:63027764	C/T	cg11441379	chr12:63026424	NA	0.62	7.41	0.34	7.04e-13	IgG glycosylation;
LUAD	cis	rs4889911	0.544	rs1285273	chr17:77830885	A/G	cg01306824	chr17:77834118	NA	0.42	6.71	0.31	6.42e-11	Electroencephalogram traits;
LUAD	cis	rs7107174	1.000	rs11237438	chr11:77998488	T/C	cg02023728	chr11:77925099	USP35	0.46	7.22	0.33	2.46e-12	Testicular germ cell tumor;
LUAD	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg22491629	chr6:157744540	C6orf35	-0.78	-8.89	-0.4	1.78e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg12311346	chr5:56204834	C5orf35	1.14	17.4	0.65	1.59e-51	Initial pursuit acceleration;
LUAD	cis	rs7580658	0.545	rs885276	chr2:127950904	A/T	cg16751203	chr2:127950803	CYP27C1	0.39	6.49	0.3	2.36e-10	Protein C levels;
LUAD	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-20.31	-0.7	1.58e-64	Height;
LUAD	cis	rs375066	0.539	rs11878787	chr19:44330240	G/A	cg12072164	chr19:44306565	LYPD5	-0.34	-6.54	-0.3	1.78e-10	Breast cancer;
LUAD	cis	rs8060686	0.516	rs7193701	chr16:68185160	A/G	cg26727032	chr16:67993705	SLC12A4	0.42	7.15	0.33	3.73e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg05182265	chr7:156933206	UBE3C	0.65	12.73	0.53	1.18e-31	Body mass index;
LUAD	cis	rs9788721	0.868	rs17486278	chr15:78867482	A/C	cg18825076	chr15:78729989	IREB2	-0.53	-8.82	-0.39	2.96e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	trans	rs3198697	0.617	rs11075253	chr16:15148646	C/A	cg04492929	chr16:2155436	PKD1	-0.42	-6.65	-0.31	8.81e-11	Triglycerides;
LUAD	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg06608945	chr2:219082296	ARPC2	0.42	6.97	0.32	1.25e-11	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg21782813	chr7:2030301	MAD1L1	0.43	7.44	0.34	5.71e-13	Schizophrenia;
LUAD	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg00701064	chr4:6280414	WFS1	0.6	11.79	0.5	6.35e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg24450063	chr1:156163899	SLC25A44	0.99	18.05	0.66	2.15e-54	Testicular germ cell tumor;
LUAD	cis	rs7705042	0.865	rs249641	chr5:141525305	A/G	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.67	-0.31	8.2e-11	Asthma;
LUAD	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-7.45	-0.34	5.35e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs4774899	0.966	rs12903115	chr15:57495151	T/G	cg14026238	chr15:57616123	NA	0.37	6.85	0.32	2.55e-11	Urinary tract infection frequency;
LUAD	cis	rs10992471	0.603	rs10114932	chr9:95307901	C/A	cg14631576	chr9:95140430	CENPP	-0.5	-10.16	-0.44	7.78e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg22676075	chr6:135203613	NA	0.52	9.26	0.41	1.03e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs9462027	0.583	rs2814947	chr6:34653268	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-8.58	-0.38	1.86e-16	Systemic lupus erythematosus;
LUAD	cis	rs859767	0.812	rs842355	chr2:135344881	G/C	cg12500956	chr2:135428796	TMEM163	0.3	7.74	0.35	7.5e-14	Neuroticism;
LUAD	trans	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	trans	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg26043149	chr18:55253948	FECH	0.49	7.86	0.36	3.15e-14	Bone mineral density;
LUAD	cis	rs62238980	0.614	rs4821037	chr22:32484201	C/T	cg00543991	chr22:32367038	NA	-0.89	-8.53	-0.38	2.73e-16	Childhood ear infection;
LUAD	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg17911788	chr17:44343683	NA	-0.51	-7.27	-0.33	1.76e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs11247915	0.600	rs12059495	chr1:26655614	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.41	-6.85	-0.32	2.63e-11	Obesity-related traits;
LUAD	cis	rs977987	0.966	rs8055490	chr16:75497135	C/T	cg03315344	chr16:75512273	CHST6	0.66	14.55	0.58	3.6e-39	Dupuytren's disease;
LUAD	cis	rs7119	0.651	rs17394732	chr15:77835657	A/G	cg27398640	chr15:77910606	LINGO1	0.35	6.58	0.3	1.39e-10	Type 2 diabetes;
LUAD	cis	rs7607369	0.536	rs11892469	chr2:219669488	A/T	cg02176678	chr2:219576539	TTLL4	-0.53	-10.22	-0.44	4.74e-22	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg21724239	chr8:58056113	NA	0.65	8.41	0.38	6.32e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg21775007	chr8:11205619	TDH	0.57	10.41	0.45	9.36e-23	Retinal vascular caliber;
LUAD	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg15110403	chr19:17392923	ANKLE1	-0.44	-7.0	-0.32	1.01e-11	Systemic lupus erythematosus;
LUAD	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.58	-9.9	-0.43	6.36e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg10909506	chr17:38081995	ORMDL3	0.38	6.62	0.31	1.11e-10	Self-reported allergy;
LUAD	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg18230493	chr5:56204884	C5orf35	-0.57	-9.31	-0.41	6.77e-19	Coronary artery disease;
LUAD	cis	rs240764	0.578	rs9322216	chr6:101251720	A/C	cg09795085	chr6:101329169	ASCC3	-0.39	-6.66	-0.31	8.34e-11	Neuroticism;
LUAD	cis	rs7017914	0.967	rs13254908	chr8:71626098	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg19678392	chr7:94953810	PON1	0.52	7.61	0.35	1.75e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg18016565	chr1:150552671	MCL1	-0.41	-7.11	-0.33	5.09e-12	Tonsillectomy;
LUAD	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.67	0.31	8.13e-11	Menarche (age at onset);
LUAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg21724239	chr8:58056113	NA	0.81	9.56	0.42	9.92e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg20578329	chr17:80767326	TBCD	0.63	7.63	0.35	1.52e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.81	-12.38	-0.52	2.93e-30	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg13789015	chr9:136890014	NCRNA00094	0.87	14.55	0.58	3.47e-39	Platelet distribution width;
LUAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg26304593	chr6:42947056	PEX6	-0.47	-8.01	-0.36	1.13e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.67	-11.78	-0.5	6.98e-28	Cognitive ability;
LUAD	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg16414030	chr3:133502952	NA	0.66	12.95	0.53	1.48e-32	Iron status biomarkers;
LUAD	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg00933542	chr6:150070202	PCMT1	0.33	6.95	0.32	1.37e-11	Lung cancer;
LUAD	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.57	-0.42	9.08e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg23533926	chr12:111358616	MYL2	-0.42	-7.31	-0.33	1.39e-12	Extrinsic epigenetic age acceleration;
LUAD	trans	rs587242	0.528	rs273878	chr1:97215760	G/C	cg10631902	chr5:14652156	NA	0.39	6.65	0.31	9.33e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg05621596	chr22:47072043	GRAMD4	-0.54	-9.79	-0.43	1.61e-20	Urate levels in obese individuals;
LUAD	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg12623302	chr6:28058802	ZSCAN12L1	-0.32	-6.55	-0.3	1.67e-10	Depression;
LUAD	cis	rs2573652	1.000	rs2573625	chr15:100513158	A/G	cg09918751	chr15:100517450	ADAMTS17	0.44	8.03	0.36	9.74e-15	Height;
LUAD	cis	rs9323205	1.000	rs7149022	chr14:51613980	A/C	cg23942311	chr14:51606299	NA	-0.6	-9.79	-0.43	1.6e-20	Cancer;
LUAD	cis	rs2294693	0.530	rs13205065	chr6:41059610	A/G	cg14769373	chr6:40998127	UNC5CL	-0.59	-8.33	-0.38	1.14e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs6445967	0.530	rs7615468	chr3:58339148	C/T	cg13750441	chr3:58318267	PXK	-0.32	-6.39	-0.3	4.28e-10	Platelet count;
LUAD	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg27124370	chr19:33622961	WDR88	0.44	7.05	0.32	7.19e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg18105134	chr13:113819100	PROZ	-0.81	-14.44	-0.57	1.02e-38	Platelet distribution width;
LUAD	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06544989	chr22:39130855	UNC84B	0.39	7.09	0.33	5.56e-12	Menopause (age at onset);
LUAD	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg00074818	chr8:8560427	CLDN23	0.62	9.35	0.41	4.94e-19	Obesity-related traits;
LUAD	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg15448220	chr1:150897856	SETDB1	0.46	7.91	0.36	2.35e-14	Tonsillectomy;
LUAD	trans	rs629535	0.767	rs72654070	chr8:70079369	G/A	cg21567404	chr3:27674614	NA	-0.99	-18.14	-0.66	8.52e-55	Dupuytren's disease;
LUAD	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg13180566	chr4:1052158	NA	0.38	6.56	0.3	1.59e-10	Recombination rate (females);
LUAD	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg05340658	chr4:99064831	C4orf37	0.53	9.02	0.4	6.77e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1215050	0.791	rs11729826	chr4:98657190	G/T	cg05340658	chr4:99064831	C4orf37	-0.43	-7.01	-0.32	9.19e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7799006	0.723	rs12673108	chr7:2286487	C/A	cg02951883	chr7:2050386	MAD1L1	-0.43	-6.61	-0.31	1.14e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs62229266	0.654	rs62230787	chr21:37376480	A/G	cg12218747	chr21:37451666	NA	-0.44	-7.07	-0.33	6.47e-12	Mitral valve prolapse;
LUAD	cis	rs1784581	0.802	rs6455787	chr6:162411378	G/A	cg17173639	chr6:162384350	PARK2	0.49	9.04	0.4	5.76e-18	Itch intensity from mosquito bite;
LUAD	cis	rs9652601	0.779	rs12935413	chr16:11210447	C/T	cg04616529	chr16:11181986	CLEC16A	0.38	6.76	0.31	4.72e-11	Systemic lupus erythematosus;
LUAD	cis	rs10203711	1.000	rs12692240	chr2:239558688	A/G	cg14580085	chr2:239553406	NA	0.4	8.43	0.38	5.42e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4604732	0.631	rs80319072	chr1:247626835	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.7	-0.46	8.37e-24	Breast cancer;
LUAD	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg02696790	chr15:75250997	RPP25	-0.34	-6.83	-0.32	3.02e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs9394841	0.667	rs12661667	chr6:41792545	C/T	cg25600774	chr6:41776562	USP49	-0.44	-6.76	-0.31	4.51e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.5	-0.3	2.26e-10	Aortic root size;
LUAD	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg07266350	chr3:49460521	AMT;NICN1	-0.38	-6.72	-0.31	5.94e-11	Menarche (age at onset);
LUAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg13560548	chr3:10150139	C3orf24	0.44	7.14	0.33	4.09e-12	Alzheimer's disease;
LUAD	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05890377	chr2:74357713	NA	0.81	12.57	0.52	5e-31	Gestational age at birth (maternal effect);
LUAD	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs11608355	0.521	rs4766469	chr12:109836890	C/G	cg19025524	chr12:109796872	NA	0.36	6.73	0.31	5.4e-11	Neuroticism;
LUAD	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.68	-0.31	7.73e-11	Type 2 diabetes;
LUAD	cis	rs8192282	0.739	rs6670375	chr1:154494947	G/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.45	-6.92	-0.32	1.67e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg11663144	chr21:46675770	NA	-0.59	-11.54	-0.49	5.48e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg18305652	chr10:134549665	INPP5A	0.61	11.82	0.5	4.88e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs68170813	0.522	rs12531187	chr7:106963650	C/G	cg02696742	chr7:106810147	HBP1	-0.77	-10.36	-0.45	1.49e-22	Coronary artery disease;
LUAD	cis	rs790123	0.553	rs1106346	chr3:122354037	A/G	cg15604389	chr3:122379662	NA	0.4	6.9	0.32	1.93e-11	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg18855356	chr1:16957483	CROCCL1	0.52	6.36	0.3	5.34e-10	Colorectal cancer;
LUAD	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg12311346	chr5:56204834	C5orf35	-0.91	-10.7	-0.46	8.38e-24	Type 2 diabetes;
LUAD	cis	rs1816752	0.905	rs9511260	chr13:25011176	T/C	cg02811702	chr13:24901961	NA	0.44	7.62	0.35	1.71e-13	Obesity-related traits;
LUAD	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24113505	chr7:92861286	CCDC132	0.4	6.37	0.3	4.8e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs12541635	0.966	rs2029881	chr8:107002226	A/G	cg10147462	chr8:107024639	NA	0.5	9.05	0.4	5.19e-18	Age of smoking initiation;
LUAD	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg07741184	chr6:167504864	NA	0.29	7.03	0.32	8.51e-12	Crohn's disease;
LUAD	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.47	0.38	4.11e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2840044	1.000	rs225262	chr17:33959697	A/G	cg05299278	chr17:33885742	SLFN14	0.43	8.7	0.39	7.7e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.61	-10.22	-0.45	4.61e-22	Glomerular filtration rate;
LUAD	cis	rs3806933	0.500	rs10491423	chr5:110453977	C/A	cg17157872	chr5:110408788	TSLP	0.34	6.37	0.3	4.8e-10	Eosinophilic esophagitis;
LUAD	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg06618935	chr21:46677482	NA	-0.44	-8.13	-0.37	4.77e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg26597838	chr10:835615	NA	0.81	11.18	0.48	1.28e-25	Eosinophil percentage of granulocytes;
LUAD	cis	rs58804349	1.000	rs58804349	chr10:43355640	G/A	cg08461752	chr10:43522343	NA	-0.51	-6.43	-0.3	3.53e-10	Pediatric bone mineral content (radius);
LUAD	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg07266350	chr3:49460521	AMT;NICN1	0.36	6.39	0.3	4.5e-10	Menarche (age at onset);
LUAD	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.17	-0.41	2.16e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg15445000	chr17:37608096	MED1	0.44	7.99	0.36	1.28e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs524023	0.957	rs10792443	chr11:64395252	G/C	cg19131476	chr11:64387923	NRXN2	-0.43	-8.47	-0.38	4.22e-16	Urate levels in obese individuals;
LUAD	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg04756594	chr16:24857601	SLC5A11	0.53	10.23	0.45	4.24e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg02569458	chr12:86230093	RASSF9	0.44	8.02	0.36	1.06e-14	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.89	0.36	2.61e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg08027265	chr7:2291960	NA	-0.42	-6.8	-0.31	3.65e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg20283391	chr11:68216788	NA	-0.42	-6.6	-0.31	1.23e-10	Total body bone mineral density;
LUAD	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg18351406	chr4:77819688	ANKRD56	0.62	10.04	0.44	2.06e-21	Emphysema distribution in smoking;
LUAD	cis	rs7009516	0.625	rs6997507	chr8:24254123	G/A	cg01759110	chr8:24241694	ADAMDEC1	-0.43	-8.58	-0.38	1.82e-16	Hair greying;
LUAD	cis	rs116248771	0.739	rs73156451	chr3:158365449	T/C	cg16708174	chr3:158430962	RARRES1	0.46	6.8	0.31	3.58e-11	diarrhoeal disease at age 2;
LUAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg18402987	chr7:1209562	NA	0.62	9.05	0.4	5.12e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg18806716	chr10:30721971	MAP3K8	-0.62	-12.31	-0.51	5.51e-30	Inflammatory bowel disease;
LUAD	cis	rs7705042	0.861	rs6860138	chr5:141509985	G/A	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.79	-0.31	3.89e-11	Asthma;
LUAD	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg20933634	chr6:27740509	NA	0.45	7.05	0.32	7.5e-12	Parkinson's disease;
LUAD	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg24069376	chr3:38537580	EXOG	0.46	11.15	0.48	1.8e-25	Electrocardiographic conduction measures;
LUAD	cis	rs9469890	0.604	rs11758420	chr6:34503279	A/C	cg17674042	chr6:34482479	PACSIN1	-0.52	-7.26	-0.33	1.93e-12	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg02038168	chr22:39784481	NA	0.54	9.8	0.43	1.49e-20	IgG glycosylation;
LUAD	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg06558623	chr16:89946397	TCF25	1.22	12.45	0.52	1.6e-30	Skin colour saturation;
LUAD	cis	rs6693567	0.565	rs834243	chr1:150339290	C/A	cg15654264	chr1:150340011	RPRD2	0.36	6.4	0.3	4.24e-10	Migraine;
LUAD	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg06547715	chr2:218990976	CXCR2	0.28	6.57	0.3	1.45e-10	Colorectal cancer;
LUAD	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg19761014	chr17:28927070	LRRC37B2	0.77	7.77	0.35	5.87e-14	Body mass index;
LUAD	cis	rs2882667	0.861	rs10075541	chr5:138390318	C/T	cg04439458	chr5:138467593	SIL1	-0.4	-7.36	-0.34	9.67e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7536201	1.000	rs4265380	chr1:25293356	C/T	cg23273869	chr1:25296894	NA	-0.34	-6.83	-0.31	3.04e-11	Psoriasis vulgaris;
LUAD	cis	rs240764	0.541	rs9390693	chr6:101239935	T/C	cg09795085	chr6:101329169	ASCC3	0.41	7.17	0.33	3.39e-12	Neuroticism;
LUAD	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.61	-0.35	1.79e-13	Blood metabolite levels;
LUAD	trans	rs7395662	1.000	rs11039890	chr11:48653468	C/G	cg00717180	chr2:96193071	NA	-0.39	-7.21	-0.33	2.52e-12	HDL cholesterol;
LUAD	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg22153463	chr1:85462885	MCOLN2	-0.62	-9.02	-0.4	6.74e-18	Serum sulfate level;
LUAD	cis	rs9486719	1.000	rs13208422	chr6:96892119	C/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.04	-0.44	2.05e-21	Migraine;Coronary artery disease;
LUAD	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg22906224	chr7:99728672	NA	0.63	10.79	0.46	3.98e-24	Coronary artery disease;
LUAD	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg16205897	chr5:131564050	P4HA2	-0.34	-7.54	-0.34	2.95e-13	Blood metabolite levels;
LUAD	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	7.94e-19	Tonsillectomy;
LUAD	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg17279839	chr7:150038598	RARRES2	0.43	7.49	0.34	4.1e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg08085267	chr17:45401833	C17orf57	-0.7	-12.44	-0.52	1.77e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg27284194	chr4:1044797	NA	0.7	10.18	0.44	6.52e-22	Recombination rate (females);
LUAD	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg01324343	chr3:183735012	ABCC5	0.92	23.76	0.76	6.73e-80	Anterior chamber depth;
LUAD	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg22166914	chr1:53195759	ZYG11B	0.39	6.5	0.3	2.23e-10	Monocyte count;
LUAD	cis	rs10193935	0.901	rs6727657	chr2:42632117	A/G	cg27598129	chr2:42591480	NA	-0.63	-8.06	-0.36	7.99e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	0.521	rs246061	chr5:140324656	C/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7945718	0.967	rs7930077	chr11:12778769	C/T	cg25843174	chr11:12811716	TEAD1	0.23	6.65	0.31	9.01e-11	Educational attainment (years of education);
LUAD	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.92	-0.32	1.66e-11	Type 2 diabetes;
LUAD	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	4.04e-11	Depression;
LUAD	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.2	0.33	2.71e-12	Tonsillectomy;
LUAD	cis	rs4604732	0.631	rs34924545	chr1:247626892	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.16	0.33	3.56e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg24412501	chr11:13690194	FAR1	-0.67	-6.59	-0.31	1.3e-10	Type 2 diabetes;
LUAD	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg19875535	chr5:140030758	IK	0.45	7.47	0.34	4.69e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg25894440	chr7:65020034	NA	-0.62	-6.69	-0.31	6.99e-11	Diabetic kidney disease;
LUAD	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.42	0.34	6.39e-13	Bipolar disorder;
LUAD	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.04	0.32	7.98e-12	Colorectal cancer;
LUAD	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.42	-0.38	5.82e-16	Breast cancer;
LUAD	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg05835009	chr4:710272	PCGF3	0.59	8.61	0.39	1.45e-16	White blood cell count;
LUAD	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg10560079	chr2:191398806	TMEM194B	0.45	8.1	0.37	6.11e-15	Pulse pressure;
LUAD	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg12379764	chr21:47803548	PCNT	-0.38	-6.45	-0.3	2.99e-10	Testicular germ cell tumor;
LUAD	cis	rs907683	0.584	rs2070927	chr2:220282955	C/T	cg15015639	chr2:220282977	DES	0.46	8.44	0.38	5.18e-16	Resting heart rate;
LUAD	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg26384229	chr12:38710491	ALG10B	-0.46	-7.81	-0.35	4.66e-14	Bladder cancer;
LUAD	cis	rs612683	0.826	rs7556246	chr1:100828914	A/G	cg06223162	chr1:101003688	GPR88	0.41	7.73	0.35	7.97e-14	Breast cancer;
LUAD	cis	rs1451375	0.617	rs1807066	chr7:50543683	T/C	cg18232548	chr7:50535776	DDC	-0.64	-9.01	-0.4	7.21e-18	Malaria;
LUAD	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg07828340	chr4:882639	GAK	0.84	9.88	0.43	7.55e-21	Intelligence (multi-trait analysis);
LUAD	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg01171360	chr6:293285	DUSP22	-0.53	-8.91	-0.4	1.5e-17	Menopause (age at onset);
LUAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg27454412	chr7:1067447	C7orf50	0.44	6.98	0.32	1.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07636037	chr3:49044803	WDR6	-0.48	-8.03	-0.36	1e-14	Menarche (age at onset);
LUAD	cis	rs1448094	0.935	rs11117120	chr12:86336447	G/A	cg00310523	chr12:86230176	RASSF9	0.36	7.73	0.35	7.93e-14	Major depressive disorder;
LUAD	cis	rs55788414	0.932	rs28514797	chr16:81185070	G/A	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.91	-0.36	2.31e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs68170813	0.559	rs79778437	chr7:107004972	T/A	cg02696742	chr7:106810147	HBP1	-0.74	-10.41	-0.45	9.67e-23	Coronary artery disease;
LUAD	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg01391022	chr12:122360665	WDR66	0.39	6.46	0.3	2.91e-10	Mean corpuscular volume;
LUAD	cis	rs500891	0.525	rs2096223	chr6:84077446	T/G	cg08257003	chr6:84140564	ME1	0.35	6.7	0.31	6.63e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg16850897	chr7:100343110	ZAN	0.47	7.92	0.36	2.14e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg00149659	chr3:10157352	C3orf10	0.54	6.81	0.31	3.44e-11	Alzheimer's disease;
LUAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06873352	chr17:61820015	STRADA	0.81	18.02	0.66	2.74e-54	Prudent dietary pattern;
LUAD	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg22029157	chr1:209979665	IRF6	0.81	11.84	0.5	3.98e-28	Cleft lip with or without cleft palate;
LUAD	cis	rs4700695	0.668	rs253212	chr5:65497553	C/T	cg21114390	chr5:65439923	SFRS12	-0.91	-13.98	-0.56	8.87e-37	Facial morphology (factor 19);
LUAD	cis	rs2625529	0.824	rs16953769	chr15:72463325	G/A	cg16672083	chr15:72433130	SENP8	-0.78	-13.15	-0.54	2.43e-33	Red blood cell count;
LUAD	trans	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg21284400	chr1:149981654	OTUD7B	-0.38	-6.54	-0.3	1.73e-10	Longevity;Endometriosis;
LUAD	cis	rs10788264	0.569	rs7089468	chr10:124019052	T/C	cg09507567	chr10:124027408	NA	0.5	11.27	0.48	5.93e-26	Total body bone mineral density;
LUAD	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg17633681	chr16:88106987	BANP	0.39	6.9	0.32	1.9e-11	Menopause (age at onset);
LUAD	cis	rs8099014	0.861	rs4940394	chr18:56134096	T/C	cg12907477	chr18:56117327	MIR122	0.52	8.24	0.37	2.11e-15	Platelet count;
LUAD	cis	rs3820068	0.705	rs72643701	chr1:15866219	G/A	cg13390004	chr1:15929781	NA	0.41	6.58	0.3	1.36e-10	Systolic blood pressure;
LUAD	cis	rs68170813	0.559	rs6971774	chr7:106834139	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.64	-0.46	1.34e-23	Coronary artery disease;
LUAD	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg16647868	chr5:131706066	SLC22A5	0.39	6.75	0.31	4.75e-11	Blood metabolite levels;
LUAD	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg22532475	chr10:104410764	TRIM8	0.57	11.13	0.48	2.13e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4073416	0.568	rs7158153	chr14:66034586	C/A	cg10998611	chr14:65879393	FUT8;LOC645431	-0.43	-6.46	-0.3	2.9e-10	N-glycan levels;
LUAD	cis	rs6500395	1.000	rs1115758	chr16:48599609	T/C	cg04672837	chr16:48644449	N4BP1	0.38	6.49	0.3	2.41e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs612683	0.735	rs3754131	chr1:100931073	A/C	cg09408571	chr1:101003634	GPR88	0.32	6.39	0.3	4.31e-10	Breast cancer;
LUAD	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg11915388	chr22:42470451	FAM109B	-0.4	-7.04	-0.32	8.06e-12	Schizophrenia;
LUAD	cis	rs2625529	0.529	rs7183055	chr15:72377048	C/T	cg16672083	chr15:72433130	SENP8	0.65	12.07	0.51	4.95e-29	Red blood cell count;
LUAD	cis	rs9394841	0.667	rs3747750	chr6:41760372	C/G	cg17623882	chr6:41773611	USP49	-0.52	-7.34	-0.34	1.1e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg14343924	chr8:8086146	FLJ10661	0.43	6.5	0.3	2.28e-10	Joint mobility (Beighton score);
LUAD	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	7.1	0.33	5.29e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.76	0.53	9e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7945705	0.967	rs7123429	chr11:8866808	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-11.43	-0.49	1.55e-26	Hemoglobin concentration;
LUAD	cis	rs427394	0.659	rs175594	chr5:6729885	T/G	cg14682080	chr5:6737778	POLS	0.34	7.48	0.34	4.36e-13	Menopause (age at onset);
LUAD	trans	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg11693508	chr17:37793320	STARD3	0.76	9.95	0.44	4.42e-21	Bipolar disorder;
LUAD	trans	rs11989744	1.000	rs11989744	chr8:23567463	A/G	cg03492747	chr16:86543808	FOXF1	-0.41	-6.88	-0.32	2.14e-11	Waist-hip ratio;
LUAD	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg15448220	chr1:150897856	SETDB1	0.56	9.56	0.42	9.56e-20	Melanoma;
LUAD	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg18180107	chr4:99064573	C4orf37	0.43	6.94	0.32	1.47e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9462027	0.628	rs2477508	chr6:34703695	A/G	cg07306190	chr6:34760872	UHRF1BP1	0.33	8.14	0.37	4.58e-15	Systemic lupus erythematosus;
LUAD	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg06623918	chr6:96969491	KIAA0776	0.72	11.09	0.47	3e-25	Migraine;Coronary artery disease;
LUAD	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-6.84	-0.32	2.83e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg18316386	chr12:58335867	XRCC6BP1	0.41	6.86	0.32	2.4e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3772130	0.564	rs35178434	chr3:121595936	G/A	cg20356878	chr3:121714668	ILDR1	0.69	14.03	0.56	5.45e-37	Cognitive performance;
LUAD	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg17747265	chr1:1875780	NA	-0.75	-17.97	-0.66	4.84e-54	Body mass index;
LUAD	cis	rs7072216	0.763	rs942803	chr10:100168631	G/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-8.32	-0.38	1.22e-15	Metabolite levels;
LUAD	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg11859384	chr17:80120422	CCDC57	-0.49	-8.73	-0.39	6.02e-17	Life satisfaction;
LUAD	cis	rs8027181	0.682	rs890354	chr15:73100924	C/G	cg25632853	chr15:73088954	NA	0.31	6.76	0.31	4.68e-11	Triglyceride levels;
LUAD	cis	rs2455799	1.000	rs2455802	chr3:15702296	T/C	cg16303742	chr3:15540471	COLQ	-0.39	-6.78	-0.31	4.13e-11	Mean platelet volume;
LUAD	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg04455712	chr21:45112962	RRP1B	0.46	9.15	0.41	2.42e-18	Mean corpuscular volume;
LUAD	trans	rs6810798	0.520	rs61435515	chr4:148329369	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.49	-7.47	-0.34	4.77e-13	Coronary artery disease;
LUAD	cis	rs778371	0.723	rs12619195	chr2:233678326	G/A	cg08000102	chr2:233561755	GIGYF2	-0.41	-6.62	-0.31	1.06e-10	Schizophrenia;
LUAD	cis	rs36051895	0.632	rs10974979	chr9:5131731	C/A	cg02405213	chr9:5042618	JAK2	-0.47	-6.36	-0.3	5.16e-10	Pediatric autoimmune diseases;
LUAD	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg00277334	chr10:82204260	NA	-0.55	-8.71	-0.39	7.11e-17	Post bronchodilator FEV1;
LUAD	trans	rs875971	0.545	rs313830	chr7:65551931	T/C	cg04775059	chr7:64541387	NA	-0.52	-6.82	-0.31	3.18e-11	Aortic root size;
LUAD	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg08999081	chr20:33150536	PIGU	-0.34	-6.74	-0.31	5.17e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg00383909	chr3:49044727	WDR6	0.87	10.1	0.44	1.23e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.51	-0.49	7.32e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg19875535	chr5:140030758	IK	-0.45	-7.64	-0.35	1.46e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg02158880	chr13:53174818	NA	0.74	13.17	0.54	1.91e-33	Lewy body disease;
LUAD	cis	rs684232	0.644	rs1227030	chr17:619882	C/T	cg15660573	chr17:549704	VPS53	-0.68	-12.63	-0.52	2.98e-31	Prostate cancer;
LUAD	cis	rs1816752	0.905	rs7991450	chr13:25000036	T/G	cg02811702	chr13:24901961	NA	0.39	6.72	0.31	5.98e-11	Obesity-related traits;
LUAD	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg27661571	chr11:113659931	NA	-0.56	-6.92	-0.32	1.69e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg17366294	chr4:99064904	C4orf37	-0.48	-8.35	-0.38	9.53e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11771526	0.901	rs17161123	chr7:32305426	G/A	cg27511599	chr7:32358540	NA	0.51	6.45	0.3	3.08e-10	Body mass index;
LUAD	cis	rs2853333	0.622	rs2853332	chr19:35746706	A/G	cg08833636	chr19:35715976	FAM187B	0.34	6.4	0.3	4.12e-10	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.13e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06022373	chr22:39101656	GTPBP1	0.45	7.51	0.34	3.62e-13	Menopause (age at onset);
LUAD	cis	rs67180937	0.504	rs3008625	chr1:222820022	A/G	cg09820183	chr1:222886073	C1orf58;AIDA	0.52	6.91	0.32	1.8e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LUAD	trans	rs17685	0.535	rs41296542	chr7:75600008	A/G	cg19862616	chr7:65841803	NCRNA00174	0.65	11.59	0.49	3.74e-27	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs117623576	0.941	rs72784865	chr10:32443875	A/C	cg03047570	chr10:32398778	NA	-0.79	-9.31	-0.41	6.85e-19	Anti-saccade response;
LUAD	cis	rs6906287	0.647	rs12194555	chr6:118819212	C/A	cg18833306	chr6:118973337	C6orf204	0.45	7.98	0.36	1.37e-14	Electrocardiographic conduction measures;
LUAD	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg10802521	chr3:52805072	NEK4	-0.47	-8.1	-0.37	6.04e-15	Bipolar disorder;
LUAD	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg05673287	chr15:77411982	SGK269	-0.42	-7.25	-0.33	1.97e-12	Type 2 diabetes;
LUAD	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg04455712	chr21:45112962	RRP1B	0.44	9.02	0.4	6.53e-18	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg25703541	chr22:24373054	LOC391322	-0.87	-16.63	-0.63	3.86e-48	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg24818145	chr4:99064322	C4orf37	0.46	7.73	0.35	8.18e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg05665937	chr4:1216051	CTBP1	-0.47	-7.66	-0.35	1.27e-13	Obesity-related traits;
LUAD	cis	rs7830933	0.955	rs1550279	chr8:23600854	C/G	cg04349084	chr8:23602677	NA	0.48	6.64	0.31	9.74e-11	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
LUAD	trans	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg18187862	chr3:45730750	SACM1L	0.5	7.89	0.36	2.55e-14	Primary sclerosing cholangitis;
LUAD	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg18404041	chr3:52824283	ITIH1	-0.48	-8.24	-0.37	2.23e-15	Schizophrenia;
LUAD	cis	rs3750965	0.959	rs4930264	chr11:68852181	C/T	cg06818126	chr11:68850279	TPCN2	-0.47	-6.96	-0.32	1.27e-11	Hair color;
LUAD	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.59e-12	Crohn's disease;
LUAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg24813613	chr7:1882135	MAD1L1	-0.55	-8.96	-0.4	1.07e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs3942852	0.955	rs1503190	chr11:48117873	A/G	cg03929089	chr4:120376271	NA	-0.53	-7.07	-0.33	6.36e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67366981	0.841	rs55903932	chr14:77706389	T/C	cg22824376	chr14:77648248	TMEM63C	0.74	7.58	0.35	2.17e-13	Obsessive-compulsive symptoms;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02947993	chr11:27528506	LIN7C;BDNFOS	-0.43	-6.65	-0.31	8.83e-11	Height;
LUAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs7200543	1.000	rs6498540	chr16:15130594	A/G	cg24683922	chr1:11983373	KIAA2013	-0.47	-7.87	-0.36	2.9e-14	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.32	-0.34	1.27e-12	Total body bone mineral density;
LUAD	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	8.77	0.39	4.5e-17	Colorectal cancer;
LUAD	cis	rs4853036	0.951	rs13393656	chr2:70119255	C/A	cg02498382	chr2:70120550	SNRNP27	-0.5	-8.13	-0.37	4.67e-15	Colorectal or endometrial cancer;
LUAD	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.16	-0.33	3.59e-12	Glomerular filtration rate;
LUAD	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg22920501	chr2:26401640	FAM59B	0.98	12.84	0.53	4.32e-32	Gut microbiome composition (summer);
LUAD	cis	rs11112613	0.609	rs4388999	chr12:106047758	G/T	cg03607813	chr12:105948248	NA	0.51	6.81	0.31	3.36e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs4253772	0.786	rs4253765	chr22:46622888	C/T	cg09491104	chr22:46646882	C22orf40	-0.6	-11.58	-0.49	4.04e-27	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg24818145	chr4:99064322	C4orf37	-0.41	-6.75	-0.31	4.99e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg11317459	chr13:21872234	NA	1.25	21.34	0.72	4.16e-69	White matter hyperintensity burden;
LUAD	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.81	-0.36	4.47e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg17652424	chr22:38574118	PLA2G6	-0.33	-10.13	-0.44	9.75e-22	Cutaneous nevi;
LUAD	cis	rs9487051	1.000	rs6568571	chr6:109613252	A/T	cg12927641	chr6:109611667	NA	-0.48	-7.79	-0.35	5.21e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg04731861	chr2:219085781	ARPC2	0.23	7.14	0.33	4.01e-12	Colorectal cancer;
LUAD	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg04851639	chr8:1020857	NA	0.38	8.82	0.39	3.04e-17	Schizophrenia;
LUAD	cis	rs7851660	0.809	rs10984230	chr9:100660284	C/T	cg13688889	chr9:100608707	NA	-0.54	-9.07	-0.4	4.42e-18	Strep throat;
LUAD	cis	rs9715521	0.868	rs62301181	chr4:59834246	A/G	cg11281224	chr4:60001000	NA	-0.55	-9.34	-0.41	5.67e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs79911532	0.515	rs79663210	chr7:75684326	G/A	cg19862616	chr7:65841803	NCRNA00174	0.82	8.57	0.38	1.97e-16	Mononucleosis;
LUAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-9.67	-0.43	4.19e-20	Lymphocyte counts;
LUAD	cis	rs2179367	0.613	rs12207047	chr6:149744632	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.35	-0.3	5.44e-10	Dupuytren's disease;
LUAD	trans	rs2797160	1.000	rs1777183	chr6:126011995	A/C	cg05039488	chr6:79577232	IRAK1BP1	0.53	8.61	0.39	1.44e-16	Endometrial cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03511402	chr16:30583225	ZNF688	-0.43	-7.16	-0.33	3.54e-12	Cancer;
LUAD	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg10468373	chr11:64009913	FKBP2	0.55	6.73	0.31	5.66e-11	Mean platelet volume;
LUAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg24642844	chr7:1081250	C7orf50	-0.46	-7.42	-0.34	6.57e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg10483660	chr13:112241077	NA	-0.32	-7.0	-0.32	9.9e-12	Hepatitis;
LUAD	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg08422745	chr4:174089978	GALNT7	-0.94	-18.14	-0.66	8.38e-55	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg14343924	chr8:8086146	FLJ10661	0.51	7.91	0.36	2.33e-14	Mood instability;
LUAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg11416102	chr8:651193	ERICH1	-0.99	-8.14	-0.37	4.34e-15	IgG glycosylation;
LUAD	cis	rs9863	0.828	rs7311969	chr12:124470333	C/T	cg17723958	chr12:124429295	CCDC92	0.39	6.51	0.3	2.08e-10	White blood cell count;
LUAD	trans	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04565464	chr8:145669602	NFKBIL2	0.44	6.61	0.31	1.16e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg09537434	chr19:41945824	ATP5SL	-0.52	-8.19	-0.37	3.16e-15	Height;
LUAD	trans	rs4714291	0.802	rs1474870	chr6:39980359	C/T	cg02267698	chr19:7991119	CTXN1	0.46	7.35	0.34	1.01e-12	Strep throat;
LUAD	cis	rs752010	0.905	rs4525030	chr1:42091307	G/C	cg06885757	chr1:42089581	HIVEP3	0.4	8.33	0.38	1.16e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs7200543	0.583	rs4985149	chr16:15147338	A/T	cg24683922	chr1:11983373	KIAA2013	-0.45	-7.35	-0.34	1.01e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs9644630	0.932	rs6991941	chr8:19352377	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.3	-7.08	-0.33	6.02e-12	Oropharynx cancer;
LUAD	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.69	-0.31	7.12e-11	Longevity;
LUAD	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg04944784	chr2:26401820	FAM59B	-0.89	-12.57	-0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs11771526	0.901	rs28631129	chr7:32305044	G/C	cg27511599	chr7:32358540	NA	0.51	6.45	0.3	3.08e-10	Body mass index;
LUAD	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg27366882	chr3:133540807	NA	-0.41	-7.36	-0.34	9.67e-13	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.81	-0.36	4.46e-14	Blood metabolite levels;
LUAD	cis	rs6433857	0.536	rs1971135	chr2:181351508	G/A	cg23363182	chr2:181467187	NA	-0.4	-6.56	-0.3	1.57e-10	Body mass index;
LUAD	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg10596483	chr8:143751796	JRK	0.44	7.02	0.32	8.85e-12	Schizophrenia;
LUAD	cis	rs7215564	0.908	rs2315923	chr17:78693678	A/G	cg09596252	chr17:78655493	RPTOR	0.57	6.95	0.32	1.35e-11	Myopia (pathological);
LUAD	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	trans	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg26043149	chr18:55253948	FECH	0.48	7.77	0.35	5.94e-14	Bone mineral density;
LUAD	trans	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	17.47	0.65	7.39e-52	Exhaled nitric oxide output;
LUAD	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg03161606	chr19:29218774	NA	0.6	8.63	0.39	1.23e-16	Methadone dose in opioid dependence;
LUAD	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.03	0.32	8.57e-12	Motion sickness;
LUAD	cis	rs476633	0.691	rs6492997	chr15:41541171	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.49	-8.88	-0.4	1.89e-17	Glomerular filtration rate (creatinine);
LUAD	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg06873352	chr17:61820015	STRADA	0.41	6.94	0.32	1.45e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-9.89	-0.43	6.75e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.96	0.32	1.31e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg08027265	chr7:2291960	NA	-0.43	-7.07	-0.33	6.5e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.63	0.31	1.01e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs7833986	0.534	rs72653928	chr8:56907735	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.93	15.08	0.59	1.99e-41	Height;
LUAD	cis	rs12210905	0.687	rs12191649	chr6:27421208	A/T	cg08851530	chr6:28072375	NA	1.02	7.77	0.35	6.04e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg24846343	chr22:24311635	DDTL	0.7	15.38	0.6	9.8e-43	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg10729496	chr3:10149963	C3orf24	0.57	9.52	0.42	1.35e-19	Alzheimer's disease;
LUAD	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg25173405	chr17:45401733	C17orf57	0.51	8.8	0.39	3.54e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg15704280	chr7:45808275	SEPT13	-1.07	-24.81	-0.77	1.63e-84	Height;
LUAD	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg03690763	chr11:133734501	NA	-0.36	-8.45	-0.38	4.65e-16	Childhood ear infection;
LUAD	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg19500851	chr17:37840957	PGAP3	-0.33	-6.46	-0.3	2.88e-10	Asthma;
LUAD	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.11	0.48	2.48e-25	Height;
LUAD	cis	rs909002	0.830	rs10914461	chr1:32113217	G/A	cg13919466	chr1:32135498	COL16A1	-0.38	-8.85	-0.4	2.44e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg09399716	chr2:46890238	NA	-0.41	-7.27	-0.33	1.79e-12	Height;
LUAD	cis	rs10197940	0.578	rs2045025	chr2:152317531	T/C	cg06191203	chr2:152266755	RIF1	-0.46	-7.15	-0.33	3.91e-12	Lung cancer;
LUAD	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.45	7.44	0.34	5.72e-13	Resistin levels;
LUAD	cis	rs4356932	1.000	rs6532111	chr4:76955914	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.54	-0.3	1.78e-10	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.4	0.42	3.5e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6992820	0.967	rs7013663	chr8:56654839	C/T	cg06880721	chr8:56792545	LYN	-0.44	-7.29	-0.33	1.57e-12	Mean platelet volume;
LUAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg08888203	chr3:10149979	C3orf24	0.74	12.88	0.53	2.92e-32	Alzheimer's disease;
LUAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg07677032	chr17:61819896	STRADA	0.56	10.28	0.45	2.7e-22	Prudent dietary pattern;
LUAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.62	-0.39	1.4e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg18196295	chr10:418757	DIP2C	0.48	7.83	0.36	3.97e-14	Psychosis in Alzheimer's disease;
LUAD	trans	rs4650994	0.544	rs2811311	chr1:178617337	A/G	cg05059571	chr16:84539110	KIAA1609	0.65	11.24	0.48	8.24e-26	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg09455208	chr3:40491958	NA	0.51	10.62	0.46	1.66e-23	Renal cell carcinoma;
LUAD	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg22529645	chr1:3704559	LRRC47	0.56	10.13	0.44	9.4e-22	Red cell distribution width;
LUAD	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.52	-0.34	3.27e-13	Breast cancer;
LUAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00166722	chr3:10149974	C3orf24	0.71	12.14	0.51	2.67e-29	Alzheimer's disease;
LUAD	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg24818145	chr4:99064322	C4orf37	0.43	7.15	0.33	3.9e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs2797160	0.905	rs1418641	chr6:125999854	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.79	-0.39	3.9e-17	Endometrial cancer;
LUAD	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg14196790	chr5:131705035	SLC22A5	0.38	6.57	0.3	1.5e-10	Blood metabolite levels;
LUAD	cis	rs7274811	0.779	rs34145153	chr20:32159067	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.5	-7.3	-0.33	1.44e-12	Height;
LUAD	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg13679303	chr9:96623674	NA	-0.37	-7.4	-0.34	7.22e-13	DNA methylation (variation);
LUAD	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.1	-0.4	3.7e-18	Alcohol dependence;
LUAD	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg11301795	chr4:187892539	NA	-0.76	-15.17	-0.59	8.39e-42	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg06608945	chr2:219082296	ARPC2	-0.42	-6.87	-0.32	2.27e-11	Colorectal cancer;
LUAD	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg02423579	chr7:2872169	GNA12	-0.54	-9.28	-0.41	9.04e-19	Height;
LUAD	cis	rs4664304	0.966	rs925411	chr2:160745785	G/T	cg06573604	chr2:160760825	LY75	-0.4	-6.68	-0.31	7.59e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15541040	chr2:3486749	NA	0.44	7.55	0.34	2.73e-13	Neurofibrillary tangles;
LUAD	cis	rs17739167	0.569	rs11638621	chr15:42228226	C/T	cg20935245	chr15:42234343	EHD4	0.43	7.44	0.34	5.72e-13	Monocyte count;
LUAD	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg03806693	chr22:41940476	POLR3H	-0.64	-9.04	-0.4	5.66e-18	Vitiligo;
LUAD	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg00530320	chr1:46809349	NSUN4	0.51	7.93	0.36	1.92e-14	Menopause (age at onset);
LUAD	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19346786	chr7:2764209	NA	-0.52	-11.41	-0.49	1.74e-26	Height;
LUAD	cis	rs9393692	0.620	rs9358916	chr6:26283185	G/A	cg00631329	chr6:26305371	NA	-0.55	-9.7	-0.43	3.11e-20	Educational attainment;
LUAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg21280719	chr6:42927975	GNMT	-0.39	-11.83	-0.5	4.48e-28	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7246865	0.859	rs1379281	chr19:17189786	A/G	cg19418318	chr19:17219073	MYO9B	-0.45	-7.59	-0.35	2e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg24558204	chr6:135376177	HBS1L	0.48	7.98	0.36	1.38e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg19875535	chr5:140030758	IK	-0.46	-7.55	-0.34	2.75e-13	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs208520	0.837	rs208498	chr6:66931560	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-14.37	-0.57	2.14e-38	Exhaled nitric oxide output;
LUAD	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg17105886	chr17:28927953	LRRC37B2	0.58	6.64	0.31	9.86e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg09365446	chr1:150670422	GOLPH3L	-0.48	-8.29	-0.37	1.55e-15	Tonsillectomy;
LUAD	cis	rs9814567	0.752	rs13098546	chr3:134333161	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	13.54	0.55	5.92e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07970400	chr15:40650285	DISP2	-0.53	-6.4	-0.3	4.1e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg07617317	chr6:118971624	C6orf204	0.55	8.09	0.37	6.19e-15	Diastolic blood pressure;
LUAD	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg00071950	chr4:10020882	SLC2A9	0.61	10.34	0.45	1.66e-22	Blood metabolite levels;
LUAD	cis	rs1448094	0.842	rs7966352	chr12:86438705	A/C	cg02569458	chr12:86230093	RASSF9	0.35	6.87	0.32	2.33e-11	Major depressive disorder;
LUAD	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg18351406	chr4:77819688	ANKRD56	0.61	9.89	0.43	6.98e-21	Emphysema distribution in smoking;
LUAD	cis	rs2882667	0.858	rs6882112	chr5:138413735	C/T	cg04439458	chr5:138467593	SIL1	0.5	9.44	0.42	2.53e-19	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg18351406	chr4:77819688	ANKRD56	0.61	9.68	0.43	3.87e-20	Emphysema distribution in smoking;
LUAD	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.62	0.39	1.34e-16	Menopause (age at onset);
LUAD	cis	rs116095464	1.000	rs10475185	chr5:306981	C/T	cg22857025	chr5:266934	NA	-1.07	-8.59	-0.39	1.73e-16	Breast cancer;
LUAD	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg09904177	chr6:26538194	HMGN4	0.43	7.21	0.33	2.51e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.546	rs35883476	chr6:28368508	G/C	cg12623302	chr6:28058802	ZSCAN12L1	0.6	6.85	0.32	2.57e-11	Depression;
LUAD	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.14	-0.64	2.18e-50	Height;
LUAD	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg09021430	chr5:549028	NA	0.45	11.42	0.49	1.69e-26	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs6445967	0.545	rs67915154	chr3:58281264	C/T	cg13750441	chr3:58318267	PXK	-0.31	-6.59	-0.31	1.32e-10	Platelet count;
LUAD	cis	rs57590327	0.516	rs66665538	chr3:81796391	T/A	cg07356753	chr3:81810745	GBE1	-0.6	-7.88	-0.36	2.77e-14	Extraversion;
LUAD	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg27535305	chr1:53392650	SCP2	0.31	6.5	0.3	2.22e-10	Monocyte count;
LUAD	cis	rs9614461	0.702	rs2294202	chr22:45738327	A/T	cg01808030	chr22:45809952	RIBC2;SMC1B	0.77	8.74	0.39	5.62e-17	Tonsillectomy;
LUAD	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg02018176	chr4:1364513	KIAA1530	0.46	8.53	0.38	2.64e-16	Longevity;
LUAD	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.86	0.76	2.45e-80	Chronic sinus infection;
LUAD	trans	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg18187862	chr3:45730750	SACM1L	0.55	8.35	0.38	1.02e-15	Primary sclerosing cholangitis;
LUAD	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg02733842	chr7:1102375	C7orf50	-0.55	-8.7	-0.39	7.66e-17	Bronchopulmonary dysplasia;
LUAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg22535103	chr8:58192502	C8orf71	-0.65	-6.99	-0.32	1.11e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.44	7.38	0.34	8.32e-13	Body mass index (adult);
LUAD	cis	rs863345	0.526	rs857718	chr1:158595142	T/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.64	-0.31	9.42e-11	Pneumococcal bacteremia;
LUAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg21724239	chr8:58056113	NA	0.65	8.41	0.38	6.32e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25427524	chr10:38739819	LOC399744	0.77	14.9	0.59	1.18e-40	Extrinsic epigenetic age acceleration;
LUAD	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg22532475	chr10:104410764	TRIM8	-0.42	-8.31	-0.37	1.32e-15	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg21862992	chr11:68658383	NA	0.55	9.9	0.43	6.46e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06219592	chr1:28845213	SNHG3-RCC1;RCC1	-0.68	-7.0	-0.32	9.8e-12	Type 2 diabetes;
LUAD	trans	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg25894440	chr7:65020034	NA	-0.63	-6.67	-0.31	8.15e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg09491104	chr22:46646882	C22orf40	-0.55	-7.06	-0.32	6.85e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg10167378	chr1:228756711	NA	0.44	7.32	0.34	1.29e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg21775007	chr8:11205619	TDH	-0.39	-6.68	-0.31	7.53e-11	Retinal vascular caliber;
LUAD	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg06028808	chr11:68637592	NA	0.46	7.46	0.34	4.95e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.62	8.23	0.37	2.29e-15	Renal function-related traits (BUN);
LUAD	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg17366294	chr4:99064904	C4orf37	0.71	13.37	0.55	2.86e-34	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.44	0.3	3.28e-10	Depression;
LUAD	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11890956	chr21:40555474	PSMG1	0.82	14.76	0.58	4.67e-40	Cognitive function;
LUAD	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg08885076	chr2:99613938	TSGA10	-0.39	-6.97	-0.32	1.24e-11	Chronic sinus infection;
LUAD	cis	rs870825	0.587	rs28454955	chr4:185632701	C/T	cg04058563	chr4:185651563	MLF1IP	0.9	14.41	0.57	1.39e-38	Blood protein levels;
LUAD	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg01849466	chr14:104193079	ZFYVE21	0.53	9.6	0.42	7.01e-20	Schizophrenia;
LUAD	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.72	0.31	6e-11	Prudent dietary pattern;
LUAD	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg08677398	chr8:58056175	NA	0.46	6.58	0.3	1.36e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg14773178	chr5:1868261	NA	0.34	6.6	0.31	1.27e-10	Cardiovascular disease risk factors;
LUAD	cis	rs9672608	0.687	rs5019044	chr15:78796282	T/A	cg18825076	chr15:78729989	IREB2	0.56	7.69	0.35	1.05e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs6901250	0.807	rs339303	chr6:117176691	C/T	cg12892004	chr6:117198278	RFX6	-0.34	-7.09	-0.33	5.52e-12	C-reactive protein levels;
LUAD	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg14668632	chr7:2872130	GNA12	0.71	13.05	0.54	5.78e-33	Height;
LUAD	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg01475377	chr6:109611718	NA	-0.53	-9.98	-0.44	3.24e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg22676075	chr6:135203613	NA	-0.61	-11.72	-0.5	1.18e-27	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs758324	0.947	rs11948962	chr5:131113830	C/T	cg25547332	chr5:131281432	NA	0.45	6.76	0.31	4.47e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs34734847	0.965	rs2005455	chr12:121128699	A/G	cg27246729	chr12:121163418	ACADS	0.39	7.36	0.34	9.43e-13	Mean corpuscular volume;
LUAD	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs12142240	0.920	rs6697623	chr1:46757542	G/A	cg00530320	chr1:46809349	NSUN4	0.44	6.85	0.32	2.55e-11	Menopause (age at onset);
LUAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.97	0.47	8.47e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg04450456	chr4:17643702	FAM184B	0.43	8.5	0.38	3.4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg04546413	chr19:29218101	NA	0.58	7.44	0.34	5.82e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg12927641	chr6:109611667	NA	-0.49	-8.72	-0.39	6.37e-17	Reticulocyte fraction of red cells;
LUAD	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg18944383	chr4:111397179	ENPEP	0.39	7.63	0.35	1.55e-13	Height;
LUAD	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.25	-0.51	9.53e-30	Platelet count;
LUAD	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06028808	chr11:68637592	NA	-0.5	-8.53	-0.38	2.55e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg15782153	chr7:917662	C7orf20	0.54	10.12	0.44	1.04e-21	Perceived unattractiveness to mosquitoes;
LUAD	trans	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg26043149	chr18:55253948	FECH	1.01	16.75	0.63	1.15e-48	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7100689	0.646	rs11202725	chr10:82136276	A/G	cg00277334	chr10:82204260	NA	-0.63	-10.54	-0.46	3.26e-23	Post bronchodilator FEV1;
LUAD	trans	rs4657015	1.000	rs4657015	chr1:161272441	A/G	cg18430411	chr8:144873183	SCRIB	-0.65	-13.41	-0.55	2.1e-34	Visceral adipose tissue adjusted for BMI;
LUAD	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg13057898	chr1:3703894	LRRC47	0.56	9.59	0.42	7.96e-20	Red cell distribution width;
LUAD	cis	rs9378688	0.546	rs2505673	chr6:2356229	A/G	cg12303981	chr6:2244766	GMDS	-0.37	-6.41	-0.3	3.84e-10	Caudate nucleus volume;
LUAD	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg16060761	chr17:80687452	NA	0.44	6.66	0.31	8.56e-11	Breast cancer;
LUAD	cis	rs7771547	0.603	rs10947614	chr6:36573822	G/C	cg04289385	chr6:36355825	ETV7	0.49	6.45	0.3	3.13e-10	Platelet distribution width;
LUAD	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg11494091	chr17:61959527	GH2	0.4	7.04	0.32	7.84e-12	Height;
LUAD	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg04450456	chr4:17643702	FAM184B	-0.4	-7.88	-0.36	2.83e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg05425664	chr17:57184151	TRIM37	-0.37	-6.4	-0.3	4.24e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.28	-0.41	9.11e-19	Life satisfaction;
LUAD	trans	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.94	0.4	1.2e-17	Endometrial cancer;
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg02477175	chr16:68345009	PRMT7;SLC7A6OS	-0.37	-6.35	-0.3	5.56e-10	Migraine with aura;
LUAD	trans	rs587242	0.528	rs2101876	chr1:97204575	T/A	cg10631902	chr5:14652156	NA	0.39	6.65	0.31	9.33e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02359409	chr6:42947317	PEX6	-0.38	-6.79	-0.31	3.69e-11	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg02807482	chr3:125708958	NA	-0.65	-8.39	-0.38	7.15e-16	Blood pressure (smoking interaction);
LUAD	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg19610905	chr11:61596333	FADS2	-0.66	-11.28	-0.48	5.78e-26	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs76878669	0.561	rs6591217	chr11:66174653	G/A	cg10616300	chr11:66138557	SLC29A2	-0.35	-7.35	-0.34	1.05e-12	Educational attainment (years of education);
LUAD	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg04414720	chr1:150670196	GOLPH3L	0.67	11.79	0.5	6.3e-28	Melanoma;
LUAD	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg27572855	chr1:25598939	RHD	0.52	11.2	0.48	1.13e-25	Erythrocyte sedimentation rate;
LUAD	cis	rs9902453	1.000	rs9890205	chr17:28382704	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.33	-0.41	6.06e-19	Coffee consumption (cups per day);
LUAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-8.07	-0.37	7.12e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9875589	0.509	rs6770928	chr3:14077189	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	6.52	0.3	1.98e-10	Ovarian reserve;
LUAD	trans	rs9929218	0.906	rs9933844	chr16:68747001	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.92	-16.34	-0.62	7.3e-47	Colorectal cancer;
LUAD	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.66	-0.35	1.26e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg07306088	chr12:46777190	NA	0.45	6.54	0.3	1.8e-10	QT interval;
LUAD	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg03983476	chr2:10830698	NOL10	-0.45	-7.79	-0.35	5.06e-14	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg07423050	chr13:99094983	FARP1	0.57	9.46	0.42	2.12e-19	Longevity;
LUAD	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21659725	chr3:3221576	CRBN	-0.65	-10.34	-0.45	1.74e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg13813247	chr22:41461852	NA	-0.45	-7.35	-0.34	1.05e-12	Neuroticism;
LUAD	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg02807482	chr3:125708958	NA	-0.65	-8.56	-0.38	2.07e-16	Blood pressure (smoking interaction);
LUAD	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg25985355	chr7:65971099	NA	-0.56	-6.85	-0.32	2.68e-11	Diabetic kidney disease;
LUAD	cis	rs75804782	0.557	rs3769118	chr2:239342542	C/G	cg08773314	chr2:239334832	ASB1	-0.43	-6.72	-0.31	5.74e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.3	-0.51	6.25e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg13902645	chr11:5959945	NA	-0.57	-9.99	-0.44	2.95e-21	DNA methylation (variation);
LUAD	cis	rs347685	0.913	rs6440060	chr3:141762853	A/T	cg02222454	chr3:141762828	NA	0.46	6.57	0.3	1.47e-10	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine);
LUAD	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg07537917	chr2:241836409	C2orf54	-0.31	-8.95	-0.4	1.16e-17	Urinary metabolites;
LUAD	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg12623918	chr2:306882	NA	0.36	7.2	0.33	2.78e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7192380	0.651	rs72783115	chr16:69702839	G/A	cg26679644	chr16:69762563	NA	0.44	7.17	0.33	3.41e-12	Sjögren's syndrome;
LUAD	cis	rs7851660	0.874	rs10120412	chr9:100628238	T/C	cg13688889	chr9:100608707	NA	-0.48	-8.22	-0.37	2.53e-15	Strep throat;
LUAD	cis	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg21775007	chr8:11205619	TDH	0.37	6.49	0.3	2.46e-10	Neuroticism;
LUAD	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.78	0.31	4.11e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg04756594	chr16:24857601	SLC5A11	-0.52	-10.26	-0.45	3.43e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs4713675	0.565	rs1555965	chr6:33677400	A/G	cg14003231	chr6:33640908	ITPR3	0.49	9.46	0.42	2.17e-19	Plateletcrit;
LUAD	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg00647820	chr17:40259828	DHX58	-0.44	-7.14	-0.33	4.01e-12	Fibrinogen levels;
LUAD	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18099408	chr3:52552593	STAB1	-0.46	-8.17	-0.37	3.58e-15	Bipolar disorder;
LUAD	cis	rs7712401	0.623	rs26372	chr5:122206447	C/T	cg19077854	chr5:122220652	SNX24	-0.33	-6.4	-0.3	4.24e-10	Mean platelet volume;
LUAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg00634984	chr7:65235879	NA	0.44	7.01	0.32	9.44e-12	Calcium levels;
LUAD	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg18230493	chr5:56204884	C5orf35	0.83	12.48	0.52	1.15e-30	Initial pursuit acceleration;
LUAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg23131131	chr22:24373011	LOC391322	-0.59	-9.78	-0.43	1.71e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14829155	chr15:31115871	NA	-0.72	-12.02	-0.5	8.06e-29	Huntington's disease progression;
LUAD	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.44	-0.34	5.79e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs1973993	0.717	rs55650017	chr1:96952142	G/A	cg10631902	chr5:14652156	NA	-0.46	-7.92	-0.36	2.14e-14	Weight;
LUAD	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg07537917	chr2:241836409	C2orf54	-0.31	-8.71	-0.39	6.96e-17	Urinary metabolites;
LUAD	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-8.14	-0.37	4.44e-15	Blood metabolite levels;
LUAD	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg08601574	chr20:25228251	PYGB	0.46	8.69	0.39	7.91e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg06002616	chr8:101225028	SPAG1	-0.38	-7.83	-0.36	3.97e-14	Atrioventricular conduction;
LUAD	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg00383909	chr3:49044727	WDR6	0.86	9.73	0.43	2.49e-20	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg21724239	chr8:58056113	NA	0.65	7.79	0.35	5.06e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg14186256	chr22:23484241	RTDR1	0.46	7.8	0.35	4.73e-14	Bone mineral density;
LUAD	cis	rs7705042	0.826	rs6883827	chr5:141504991	A/G	cg08523384	chr5:141488047	NDFIP1	-0.38	-6.55	-0.3	1.64e-10	Asthma;
LUAD	cis	rs6594713	0.879	rs13189910	chr5:112740153	G/A	cg12552261	chr5:112820674	MCC	0.55	8.81	0.39	3.15e-17	Brain cytoarchitecture;
LUAD	cis	rs12620999	0.941	rs58678188	chr2:237971036	C/A	cg23555395	chr2:238036564	NA	0.6	9.28	0.41	8.77e-19	Systemic lupus erythematosus;
LUAD	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg11707310	chr1:2537719	MMEL1	0.39	8.18	0.37	3.33e-15	Ulcerative colitis;
LUAD	trans	rs10802346	0.545	rs10802347	chr1:246374268	G/A	cg13514129	chr1:39547527	MACF1	0.63	11.06	0.47	3.76e-25	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs4372836	0.964	rs55721532	chr2:28938968	A/G	cg09522027	chr2:28974177	PPP1CB	0.58	9.04	0.4	5.67e-18	Body mass index;
LUAD	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.04	0.32	7.63e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.62	-0.35	1.72e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg14092571	chr14:90743983	NA	-0.52	-9.23	-0.41	1.28e-18	Mortality in heart failure;
LUAD	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg05187965	chr10:45406764	TMEM72	-0.42	-8.21	-0.37	2.67e-15	Mean corpuscular volume;
LUAD	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg05665937	chr4:1216051	CTBP1	0.42	7.01	0.32	9.46e-12	Obesity-related traits;
LUAD	trans	rs9354308	0.901	rs2814096	chr6:66566131	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.5	7.57	0.35	2.34e-13	Metabolite levels;
LUAD	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg10468373	chr11:64009913	FKBP2	0.52	6.68	0.31	7.64e-11	Mean platelet volume;
LUAD	cis	rs367943	0.712	rs6594707	chr5:112700503	C/T	cg12552261	chr5:112820674	MCC	0.48	9.45	0.42	2.33e-19	Type 2 diabetes;
LUAD	trans	rs1459104	0.636	rs559362	chr11:55275456	T/G	cg03929089	chr4:120376271	NA	0.58	6.59	0.31	1.34e-10	Body mass index;
LUAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08677398	chr8:58056175	NA	0.49	6.94	0.32	1.5e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.42	-6.99	-0.32	1.04e-11	Body mass index;
LUAD	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18876405	chr7:65276391	NA	0.4	6.47	0.3	2.67e-10	Aortic root size;
LUAD	cis	rs1003719	0.591	rs1053984	chr21:38574018	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.44	-7.19	-0.33	2.99e-12	Eye color traits;
LUAD	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg15664640	chr17:80829946	TBCD	0.5	9.46	0.42	2.22e-19	Breast cancer;
LUAD	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg07936489	chr17:37558343	FBXL20	-0.46	-7.34	-0.34	1.07e-12	Glomerular filtration rate (creatinine);
LUAD	trans	rs7395662	1.000	rs11039854	chr11:48607688	G/A	cg15704280	chr7:45808275	SEPT13	-0.41	-6.47	-0.3	2.64e-10	HDL cholesterol;
LUAD	cis	rs7149242	0.697	rs12882815	chr14:101183142	C/G	cg10189261	chr14:101176105	NA	0.39	7.33	0.34	1.19e-12	Platelet count;
LUAD	cis	rs12620999	0.938	rs4575672	chr2:238070572	T/C	cg23555395	chr2:238036564	NA	-0.57	-8.63	-0.39	1.28e-16	Systemic lupus erythematosus;
LUAD	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-8.08	-0.37	7.05e-15	Major depressive disorder;
LUAD	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg27490568	chr2:178487706	NA	0.58	8.68	0.39	8.67e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg12501888	chr15:85177176	SCAND2	-0.45	-6.76	-0.31	4.46e-11	P wave terminal force;
LUAD	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg15147215	chr3:52552868	STAB1	-0.37	-6.75	-0.31	4.98e-11	Electroencephalogram traits;
LUAD	cis	rs7172809	0.643	rs61483316	chr15:77834147	C/T	cg11865553	chr15:77376250	NA	-0.39	-6.73	-0.31	5.46e-11	Glucose homeostasis traits;
LUAD	cis	rs7124681	0.584	rs4752792	chr11:47815702	G/A	cg18512352	chr11:47633146	NA	-0.37	-6.66	-0.31	8.61e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg08601574	chr20:25228251	PYGB	0.43	8.12	0.37	5.32e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg04154034	chr17:28927549	LRRC37B2	0.71	6.79	0.31	3.74e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg08847533	chr14:75593920	NEK9	-0.38	-6.37	-0.3	4.82e-10	Height;
LUAD	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg15549821	chr19:49342101	PLEKHA4	-0.87	-12.67	-0.52	2.07e-31	Red cell distribution width;
LUAD	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg14582100	chr15:45693742	SPATA5L1	0.64	12.48	0.52	1.23e-30	Homoarginine levels;
LUAD	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg11062466	chr8:58055876	NA	0.58	7.29	0.33	1.49e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1595825	0.836	rs79748557	chr2:198567912	G/T	cg00982548	chr2:198649783	BOLL	-0.61	-8.72	-0.39	6.25e-17	Ulcerative colitis;
LUAD	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg08999081	chr20:33150536	PIGU	-0.63	-14.31	-0.57	3.69e-38	Glomerular filtration rate (creatinine);
LUAD	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg15900387	chr1:150738905	CTSS	-0.35	-6.42	-0.3	3.67e-10	Melanoma;
LUAD	cis	rs28374715	0.681	rs28712264	chr15:41588797	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.07	-21.01	-0.71	1.22e-67	Ulcerative colitis;
LUAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-8.9	-0.4	1.64e-17	Longevity;Endometriosis;
LUAD	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg18944383	chr4:111397179	ENPEP	0.39	7.76	0.35	6.24e-14	Height;
LUAD	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.51	0.45	4.29e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg09796270	chr17:17721594	SREBF1	-0.37	-7.14	-0.33	4.02e-12	Total body bone mineral density;
LUAD	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18404041	chr3:52824283	ITIH1	0.71	15.88	0.61	7.41e-45	Bipolar disorder;
LUAD	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg01475377	chr6:109611718	NA	-0.52	-10.05	-0.44	1.87e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg12311346	chr5:56204834	C5orf35	-0.92	-13.77	-0.56	6.83e-36	Initial pursuit acceleration;
LUAD	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg08601574	chr20:25228251	PYGB	-0.47	-8.83	-0.39	2.87e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg19767477	chr5:127420684	SLC12A2	-0.41	-6.45	-0.3	3.04e-10	Ileal carcinoids;
LUAD	cis	rs4523957	0.583	rs2760740	chr17:2020989	A/G	cg16513277	chr17:2031491	SMG6	-0.94	-19.75	-0.69	5.1e-62	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg02696790	chr15:75250997	RPP25	0.36	6.77	0.31	4.34e-11	Breast cancer;
LUAD	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14829155	chr15:31115871	NA	0.71	12.93	0.53	1.92e-32	Huntington's disease progression;
LUAD	cis	rs9346649	0.616	rs1873337	chr6:168492160	T/G	cg02770688	chr6:168491649	NA	0.54	10.3	0.45	2.45e-22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs1595825	0.730	rs1902248	chr2:198492598	C/T	cg11031976	chr2:198649780	BOLL	-0.42	-6.38	-0.3	4.53e-10	Ulcerative colitis;
LUAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg12016809	chr21:47604291	C21orf56	0.57	9.6	0.42	6.86e-20	Testicular germ cell tumor;
LUAD	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg19318889	chr4:1322082	MAEA	0.75	12.89	0.53	2.59e-32	Longevity;
LUAD	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg19761014	chr17:28927070	LRRC37B2	0.86	8.36	0.38	9.21e-16	Body mass index;
LUAD	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg10591111	chr5:226296	SDHA	-0.55	-7.07	-0.33	6.41e-12	Breast cancer;
LUAD	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.48	0.3	2.5e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4700695	0.925	rs1845481	chr5:65397527	A/C	cg21114390	chr5:65439923	SFRS12	-0.64	-8.86	-0.4	2.24e-17	Facial morphology (factor 19);
LUAD	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg21770322	chr7:97807741	LMTK2	0.33	7.72	0.35	8.24e-14	Breast cancer;
LUAD	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.28	-0.45	2.81e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg00316803	chr15:76480434	C15orf27	0.41	6.43	0.3	3.48e-10	Blood metabolite levels;
LUAD	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.76	0.31	4.64e-11	Depression;
LUAD	cis	rs6847149	0.929	rs6839680	chr4:110765496	A/G	cg07850274	chr4:110748770	RRH	-0.54	-8.41	-0.38	6.26e-16	Exercise treadmill test traits;
LUAD	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg24399712	chr22:39784796	NA	-0.8	-15.01	-0.59	4.1e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs7216064	1.000	rs8082512	chr17:65837059	T/C	cg08758996	chr17:66097529	LOC651250	0.46	7.02	0.32	8.67e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs9644630	0.504	rs62496181	chr8:19318989	A/T	cg06562184	chr8:19319451	CSGALNACT1	0.37	6.83	0.32	2.97e-11	Oropharynx cancer;
LUAD	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg06641503	chr3:48959341	ARIH2	-0.4	-7.78	-0.35	5.8e-14	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg07570687	chr10:102243282	WNT8B	0.48	7.28	0.33	1.6e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs4964805	0.657	rs1866293	chr12:104186655	C/T	cg02344784	chr12:104178138	NT5DC3	0.45	9.23	0.41	1.34e-18	Attention deficit hyperactivity disorder;
LUAD	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg06108461	chr20:60628389	TAF4	-1.12	-20.51	-0.71	2.18e-65	Body mass index;
LUAD	cis	rs10489202	0.632	rs202259	chr1:167962072	G/A	cg24449463	chr1:168025552	DCAF6	-0.74	-12.22	-0.51	1.31e-29	Schizophrenia;
LUAD	cis	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg11822812	chr5:140052017	DND1	-0.4	-7.4	-0.34	7.51e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs897984	0.806	rs9319588	chr16:30930983	C/T	cg02466173	chr16:30829666	NA	0.67	12.53	0.52	7.66e-31	Dementia with Lewy bodies;
LUAD	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	7.77e-16	Body mass index;
LUAD	cis	rs9487051	0.735	rs1146246	chr6:109519741	C/T	cg21918786	chr6:109611834	NA	-0.41	-7.55	-0.34	2.75e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.45	6.75	0.31	4.79e-11	Schizophrenia;
LUAD	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24531977	chr5:56204891	C5orf35	-0.99	-15.17	-0.59	8.56e-42	Initial pursuit acceleration;
LUAD	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg26384229	chr12:38710491	ALG10B	0.5	8.08	0.37	6.86e-15	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs943466	1.000	rs7755323	chr6:33761159	A/G	cg16010596	chr6:33739607	LEMD2	-0.4	-7.8	-0.35	4.75e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs17641971	0.684	rs7011891	chr8:49983538	A/C	cg00325661	chr8:49890786	NA	0.29	6.6	0.31	1.22e-10	Blood metabolite levels;
LUAD	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.76	-9.77	-0.43	1.77e-20	Body mass index;
LUAD	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08045932	chr20:61659980	NA	0.55	10.82	0.47	2.91e-24	Prostate cancer (SNP x SNP interaction);
LUAD	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg03929089	chr4:120376271	NA	0.67	9.62	0.42	5.93e-20	Height;
LUAD	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.63	8.67	0.39	9.09e-17	Renal function-related traits (BUN);
LUAD	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg12011299	chr4:100065546	ADH4	0.63	11.46	0.49	1.14e-26	Alcohol dependence;
LUAD	cis	rs13082711	0.596	rs479404	chr3:27363064	T/C	cg02860705	chr3:27208620	NA	0.54	8.84	0.39	2.63e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg19318889	chr4:1322082	MAEA	0.44	7.0	0.32	1.01e-11	Obesity-related traits;
LUAD	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg19000871	chr14:103996768	TRMT61A	0.43	7.55	0.34	2.7e-13	Coronary artery disease;
LUAD	cis	rs2019216	0.500	rs2880292	chr17:21869537	A/G	cg22648282	chr17:21454238	C17orf51	-0.46	-7.74	-0.35	7.61e-14	Pelvic organ prolapse;
LUAD	trans	rs3942852	1.000	rs3942852	chr11:48115089	C/T	cg15704280	chr7:45808275	SEPT13	-0.61	-8.38	-0.38	8.2e-16	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	7.27	0.33	1.73e-12	Alzheimer's disease;
LUAD	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.66	-0.58	1.17e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg26587870	chr6:27730563	NA	-0.66	-7.01	-0.32	9.66e-12	Breast cancer;
LUAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg16606324	chr3:10149918	C3orf24	-0.7	-11.72	-0.5	1.12e-27	Alzheimer's disease;
LUAD	trans	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg01620082	chr3:125678407	NA	-0.44	-6.7	-0.31	6.82e-11	Depression;
LUAD	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg04034577	chr2:241836375	C2orf54	-0.51	-11.33	-0.48	3.53e-26	Urinary metabolites;
LUAD	cis	rs2046867	0.908	rs62251601	chr3:72786768	C/G	cg25664220	chr3:72788482	NA	-0.7	-12.59	-0.52	4.44e-31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg25482853	chr8:67687455	SGK3	1.13	17.37	0.65	2.16e-51	Lung disease severity in cystic fibrosis;
LUAD	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg21385522	chr1:16154831	NA	0.58	9.22	0.41	1.43e-18	Systolic blood pressure;
LUAD	cis	rs2421770	0.530	rs3858470	chr11:35365444	T/C	cg13971030	chr11:35366721	SLC1A2	-0.46	-8.01	-0.36	1.1e-14	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs12620999	0.887	rs10929214	chr2:238037436	C/G	cg23555395	chr2:238036564	NA	-0.62	-9.52	-0.42	1.31e-19	Systemic lupus erythematosus;
LUAD	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.65	0.31	8.98e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs7851660	0.967	rs12348304	chr9:100611233	T/C	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.39	-6.51	-0.3	2.16e-10	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg08558340	chr7:100472263	SRRT	0.51	6.41	0.3	3.79e-10	Resting heart rate;
LUAD	cis	rs1953600	0.870	rs2573370	chr10:81951366	C/T	cg00277334	chr10:82204260	NA	0.42	7.18	0.33	3.19e-12	Sarcoidosis;
LUAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06028808	chr11:68637592	NA	0.45	7.43	0.34	6.03e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg18335740	chr13:41363409	SLC25A15	-0.56	-9.94	-0.44	4.76e-21	Lewy body disease;
LUAD	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	8.77	0.39	4.54e-17	Breast cancer;
LUAD	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg21475434	chr5:93447410	FAM172A	-0.62	-7.66	-0.35	1.32e-13	Diabetic retinopathy;
LUAD	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg06740227	chr12:86229804	RASSF9	0.35	6.48	0.3	2.63e-10	Major depressive disorder;
LUAD	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg22482690	chr17:47019901	SNF8	0.44	8.37	0.38	8.71e-16	Type 2 diabetes;
LUAD	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg18404041	chr3:52824283	ITIH1	-0.48	-9.49	-0.42	1.72e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg18944383	chr4:111397179	ENPEP	0.4	7.96	0.36	1.61e-14	Height;
LUAD	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg05043794	chr9:111880884	C9orf5	-0.44	-7.56	-0.34	2.6e-13	Menarche (age at onset);
LUAD	cis	rs8044995	0.636	rs9888986	chr16:68297228	G/A	cg09835421	chr16:68378352	PRMT7	-0.86	-9.15	-0.41	2.46e-18	Schizophrenia;
LUAD	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg19875535	chr5:140030758	IK	0.44	7.41	0.34	6.93e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg09033563	chr22:24373618	LOC391322	-0.49	-7.53	-0.34	3.18e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg01324343	chr3:183735012	ABCC5	0.94	25.24	0.78	2.14e-86	Anterior chamber depth;
LUAD	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg11502198	chr6:26597334	ABT1	0.56	9.32	0.41	6.74e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs1003719	0.762	rs3787786	chr21:38463436	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.31e-16	Eye color traits;
LUAD	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg05564831	chr3:52568323	NT5DC2	-0.36	-6.58	-0.3	1.42e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7267979	0.844	rs2257649	chr20:25263457	T/G	cg08601574	chr20:25228251	PYGB	0.41	7.77	0.35	5.91e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg19622623	chr12:86230825	RASSF9	-0.44	-7.77	-0.35	5.91e-14	Major depressive disorder;
LUAD	cis	rs2404602	0.735	rs283789	chr15:76777577	G/A	cg23625390	chr15:77176239	SCAPER	0.44	7.1	0.33	5.33e-12	Blood metabolite levels;
LUAD	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.7e-32	Immature fraction of reticulocytes;
LUAD	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg09555818	chr19:45449301	APOC2	0.58	12.72	0.53	1.31e-31	Blood protein levels;
LUAD	cis	rs9556958	0.635	rs4529985	chr13:99167120	G/C	cg07423050	chr13:99094983	FARP1	-0.4	-7.05	-0.32	7.47e-12	Educational attainment (years of education);
LUAD	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg07741184	chr6:167504864	NA	0.28	6.72	0.31	6.03e-11	Crohn's disease;
LUAD	cis	rs34172651	0.545	rs8056132	chr16:24716348	A/G	cg00339695	chr16:24857497	SLC5A11	0.42	7.61	0.35	1.84e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6138458	1.000	rs227630	chr20:24913584	A/G	cg26195577	chr20:24973756	C20orf3	0.96	16.3	0.62	1.07e-46	Blood protein levels;
LUAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08048268	chr3:133502702	NA	-0.53	-10.48	-0.45	5.21e-23	Iron status biomarkers;
LUAD	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.42e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg02696790	chr15:75250997	RPP25	0.4	7.55	0.34	2.74e-13	Breast cancer;
LUAD	trans	rs9408928	0.778	rs9409230	chr9:123967760	A/T	cg10964887	chr6:84937691	KIAA1009	0.64	6.51	0.3	2.16e-10	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs71478720	1.000	rs71478720	chr11:112009605	C/T	cg09122223	chr11:112035175	IL18	0.41	6.36	0.3	5.4e-10	Interleukin-18 levels;
LUAD	cis	rs6685188	0.843	rs1775139	chr1:205672357	C/G	cg11965913	chr1:205819406	PM20D1	0.42	6.93	0.32	1.62e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg27446573	chr6:127587934	RNF146	0.44	6.7	0.31	6.65e-11	Breast cancer;
LUAD	cis	rs12541635	0.934	rs1353450	chr8:107035120	A/G	cg10147462	chr8:107024639	NA	-0.53	-9.94	-0.44	4.43e-21	Age of smoking initiation;
LUAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08219700	chr8:58056026	NA	0.61	8.73	0.39	5.83e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg02447287	chr2:238707023	RBM44	-0.41	-7.13	-0.33	4.46e-12	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.85	-0.32	2.66e-11	Height;
LUAD	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg00310523	chr12:86230176	RASSF9	-0.35	-6.97	-0.32	1.22e-11	Major depressive disorder;
LUAD	cis	rs7918232	0.567	rs4749215	chr10:27312005	T/C	cg14240646	chr10:27532245	ACBD5	-0.62	-9.45	-0.42	2.26e-19	Breast cancer;
LUAD	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg21214613	chr1:16344536	HSPB7	0.6	11.6	0.49	3.35e-27	Dilated cardiomyopathy;
LUAD	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg04546413	chr19:29218101	NA	0.67	8.51	0.38	3.13e-16	Methadone dose in opioid dependence;
LUAD	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg00933542	chr6:150070202	PCMT1	0.45	8.7	0.39	7.64e-17	Lung cancer;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg04924415	chr12:100661456	SCYL2;DEPDC4	-0.48	-6.55	-0.3	1.64e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs7178572	0.568	rs1446312	chr15:77412189	G/C	cg15453836	chr15:77711506	NA	-0.37	-6.39	-0.3	4.36e-10	Type 2 diabetes;
LUAD	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.92	-0.53	2.07e-32	Dilated cardiomyopathy;
LUAD	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg15147215	chr3:52552868	STAB1	0.37	7.06	0.32	6.93e-12	Electroencephalogram traits;
LUAD	cis	rs853679	0.585	rs201000	chr6:27809159	C/T	cg21204522	chr6:27730016	NA	-0.48	-7.25	-0.33	1.96e-12	Depression;
LUAD	cis	rs16866061	1.000	rs72974205	chr2:225408468	C/T	cg12698349	chr2:225449008	CUL3	0.77	13.51	0.55	7.85e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg19413350	chr8:57351067	NA	-0.42	-6.66	-0.31	8.42e-11	Obesity-related traits;
LUAD	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg18490616	chr2:88469792	THNSL2	-0.78	-8.02	-0.36	1.04e-14	Plasma clusterin levels;
LUAD	cis	rs2692947	0.683	rs1813381	chr2:96422939	C/T	cg23100626	chr2:96804247	ASTL	-0.34	-7.95	-0.36	1.67e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7512552	0.809	rs9436112	chr1:150406449	A/C	cg15654264	chr1:150340011	RPRD2	0.58	11.25	0.48	7.53e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg11502198	chr6:26597334	ABT1	0.56	9.32	0.41	6.74e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg12454169	chr2:30669597	LCLAT1	1.03	10.2	0.44	5.31e-22	Midgestational circulating levels of PBDEs (fetal genetic effect);
LUAD	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg02782426	chr3:40428986	ENTPD3	-0.37	-7.76	-0.35	6.22e-14	Renal cell carcinoma;
LUAD	cis	rs904251	0.861	rs2776875	chr6:37486796	G/C	cg25019722	chr6:37503610	NA	-0.3	-6.6	-0.31	1.2e-10	Cognitive performance;
LUAD	trans	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg27411982	chr8:10470053	RP1L1	0.44	7.86	0.36	3.19e-14	Mood instability;
LUAD	cis	rs9826463	0.757	rs73240316	chr3:142266061	A/G	cg20824294	chr3:142316082	PLS1	0.42	7.53	0.34	3.12e-13	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2742417	0.603	rs1468542	chr3:45779136	A/T	cg10512202	chr3:45649293	LIMD1	-0.47	-8.89	-0.4	1.77e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg07507251	chr3:52567010	NT5DC2	0.39	7.65	0.35	1.35e-13	Electroencephalogram traits;
LUAD	cis	rs7524258	0.900	rs6670323	chr1:7301947	C/A	cg07173049	chr1:7289937	CAMTA1	0.42	7.84	0.36	3.74e-14	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	trans	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg09872104	chr7:134855509	C7orf49	-0.8	-6.83	-0.32	2.9e-11	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12292205	chr6:26970375	C6orf41	-0.47	-6.57	-0.3	1.47e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.44	-0.49	1.38e-26	Primary sclerosing cholangitis;
LUAD	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-9.68	-0.43	3.66e-20	Platelet count;
LUAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.82	-18.4	-0.67	5.7e-56	Longevity;Endometriosis;
LUAD	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg22117172	chr7:91764530	CYP51A1	0.36	7.81	0.36	4.5e-14	Breast cancer;
LUAD	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg21028142	chr17:79581711	NPLOC4	0.38	7.49	0.34	4.15e-13	Eye color traits;
LUAD	cis	rs9900062	1.000	rs9900062	chr17:62739574	G/A	cg02598441	chr17:62777298	LOC146880	-0.57	-6.58	-0.3	1.42e-10	QT interval;
LUAD	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24308560	chr3:49941425	MST1R	0.53	8.93	0.4	1.32e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg06060754	chr5:176797920	RGS14	0.57	9.09	0.4	3.74e-18	Urate levels in lean individuals;
LUAD	cis	rs12210905	1.000	rs72843644	chr6:27211601	A/C	cg11502198	chr6:26597334	ABT1	-0.8	-6.54	-0.3	1.81e-10	Hip circumference adjusted for BMI;
LUAD	trans	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg07393940	chr7:158741817	NA	-0.68	-11.59	-0.49	3.51e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7937890	0.531	rs2575828	chr11:14484192	T/C	cg02251663	chr11:14281053	SPON1	-0.34	-6.35	-0.3	5.46e-10	Mitochondrial DNA levels;
LUAD	cis	rs62005083	0.541	rs61059815	chr14:74536465	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.58	7.78	0.35	5.73e-14	Mean corpuscular volume;
LUAD	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06544989	chr22:39130855	UNC84B	0.46	9.26	0.41	1.03e-18	Menopause (age at onset);
LUAD	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.62	7.49	0.34	4.18e-13	Body mass index;
LUAD	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg20290983	chr6:43655470	MRPS18A	0.85	16.96	0.64	1.35e-49	IgG glycosylation;
LUAD	cis	rs3820068	0.705	rs4645992	chr1:15849742	G/T	cg13390004	chr1:15929781	NA	0.44	6.91	0.32	1.78e-11	Systolic blood pressure;
LUAD	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg01312482	chr5:178451176	ZNF879	-0.45	-6.96	-0.32	1.29e-11	Pubertal anthropometrics;
LUAD	trans	rs9329221	0.655	rs4292737	chr8:10259115	A/G	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.72	-0.31	5.8e-11	Neuroticism;
LUAD	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg13319975	chr6:146136371	FBXO30	-0.55	-9.42	-0.42	2.9e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7177699	0.525	rs7402376	chr15:79113570	A/G	cg15571903	chr15:79123663	NA	-0.38	-7.61	-0.35	1.83e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	trans	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.6	-0.35	1.9e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4728302	0.534	rs6976069	chr7:133152898	T/C	cg10665199	chr7:133106180	EXOC4	0.62	11.22	0.48	9.23e-26	Intelligence;Intelligence (multi-trait analysis);
LUAD	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11644478	chr21:40555479	PSMG1	-0.42	-6.94	-0.32	1.47e-11	Menarche (age at onset);
LUAD	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg04154034	chr17:28927549	LRRC37B2	0.66	6.45	0.3	3.01e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg15147215	chr3:52552868	STAB1	-0.38	-7.06	-0.32	7.06e-12	Electroencephalogram traits;
LUAD	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg00310523	chr12:86230176	RASSF9	-0.35	-7.37	-0.34	9.18e-13	Major depressive disorder;
LUAD	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg27144592	chr16:783916	NARFL	0.35	6.36	0.3	5.19e-10	Height;
LUAD	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg13535736	chr9:111863775	C9orf5	-0.43	-6.7	-0.31	6.57e-11	Menarche (age at onset);
LUAD	cis	rs9902453	0.904	rs12939344	chr17:28328819	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.45	-0.45	6.67e-23	Coffee consumption (cups per day);
LUAD	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg08085267	chr17:45401833	C17orf57	-0.65	-11.62	-0.49	2.7e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg08807101	chr21:30365312	RNF160	-0.43	-7.4	-0.34	7.32e-13	Dental caries;
LUAD	cis	rs12801636	0.512	rs12420618	chr11:65412974	C/G	cg24147428	chr11:65409760	SIPA1	-0.54	-7.91	-0.36	2.29e-14	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg20135002	chr11:47629003	NA	-0.42	-7.33	-0.34	1.21e-12	Subjective well-being;
LUAD	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.33	-7.17	-0.33	3.28e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs758324	0.891	rs924435	chr5:131143324	T/A	cg25547332	chr5:131281432	NA	0.5	6.41	0.3	3.87e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs76167968	1	rs76167968	chr1:35681738	T/C	cg12633102	chr1:35676489	NA	-0.69	-9.65	-0.42	4.95e-20	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.66	-0.39	9.95e-17	Total body bone mineral density;
LUAD	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.49	7.42	0.34	6.5e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg17782706	chr4:184580436	C4orf41;RWDD4A	0.46	7.41	0.34	6.73e-13	Monocyte percentage of white cells;
LUAD	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg14458575	chr2:238380390	NA	0.66	12.88	0.53	2.85e-32	Prostate cancer;
LUAD	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg11266682	chr4:10021025	SLC2A9	0.57	12.02	0.5	7.57e-29	Bone mineral density;
LUAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg10729496	chr3:10149963	C3orf24	0.6	10.05	0.44	1.82e-21	Alzheimer's disease;
LUAD	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg21214613	chr1:16344536	HSPB7	-0.4	-6.47	-0.3	2.71e-10	Dilated cardiomyopathy;
LUAD	cis	rs7943203	0.850	rs751343	chr11:108366449	A/C	cg04873221	chr11:107992290	ACAT1	-0.4	-6.39	-0.3	4.47e-10	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs2882667	0.931	rs10044736	chr5:138320809	A/G	cg04439458	chr5:138467593	SIL1	0.38	7.01	0.32	9.2e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg07169764	chr2:136633963	MCM6	0.66	8.1	0.37	5.88e-15	Corneal structure;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg03008269	chr11:13485254	BTBD10	0.4	6.91	0.32	1.74e-11	Bipolar disorder;
LUAD	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg22467129	chr15:76604101	ETFA	0.5	8.52	0.38	2.85e-16	Blood metabolite levels;
LUAD	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg23018236	chr17:30244563	NA	-0.68	-7.9	-0.36	2.35e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs6906287	0.609	rs767139	chr6:118884799	A/G	cg18833306	chr6:118973337	C6orf204	0.49	8.73	0.39	6.07e-17	Electrocardiographic conduction measures;
LUAD	cis	rs6087990	0.735	rs2065576	chr20:31389009	C/T	cg13636640	chr20:31349939	DNMT3B	0.74	13.18	0.54	1.75e-33	Ulcerative colitis;
LUAD	cis	rs1232027	0.656	rs1650685	chr5:79957117	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.09	-0.33	5.53e-12	Huntington's disease progression;
LUAD	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg20991723	chr1:152506922	NA	0.35	6.99	0.32	1.11e-11	Hair morphology;
LUAD	cis	rs739496	0.527	rs3752632	chr12:112376297	C/T	cg10833066	chr12:111807467	FAM109A	0.42	6.87	0.32	2.33e-11	Platelet count;
LUAD	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.48	-8.73	-0.39	5.74e-17	Longevity;Endometriosis;
LUAD	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg23625390	chr15:77176239	SCAPER	0.38	6.61	0.31	1.16e-10	Blood metabolite levels;
LUAD	cis	rs4786125	0.587	rs6500861	chr16:6923966	A/G	cg03623568	chr16:6915990	A2BP1	-0.49	-10.38	-0.45	1.23e-22	Heart rate variability traits (SDNN);
LUAD	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg11189052	chr15:85197271	WDR73	0.58	7.61	0.35	1.77e-13	Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06475972	chr17:34842357	ZNHIT3	-0.39	-6.52	-0.3	1.95e-10	Cancer;
LUAD	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-15.58	-0.6	1.45e-43	Schizophrenia;
LUAD	trans	rs877282	0.945	rs11599043	chr10:777972	C/T	cg22713356	chr15:30763199	NA	1.32	19.37	0.69	2.73e-60	Uric acid levels;
LUAD	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg23625390	chr15:77176239	SCAPER	-0.48	-7.74	-0.35	7.41e-14	Blood metabolite levels;
LUAD	cis	rs9341808	0.644	rs76102095	chr6:80942026	G/C	cg08355045	chr6:80787529	NA	-0.48	-8.49	-0.38	3.64e-16	Sitting height ratio;
LUAD	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg09658497	chr7:2847517	GNA12	-0.56	-9.36	-0.41	4.67e-19	Height;
LUAD	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg03340356	chr1:67600835	NA	-0.45	-7.87	-0.36	3.06e-14	Psoriasis;
LUAD	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22590775	chr19:49891494	CCDC155	0.69	10.37	0.45	1.28e-22	Multiple sclerosis;
LUAD	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.6	-0.42	7.05e-20	Life satisfaction;
LUAD	trans	rs877282	0.898	rs10904546	chr10:757222	A/G	cg22713356	chr15:30763199	NA	1.22	15.42	0.6	6.73e-43	Uric acid levels;
LUAD	cis	rs1595825	0.891	rs73054827	chr2:198649905	G/A	cg00361562	chr2:198649771	BOLL	-0.48	-6.74	-0.31	5.2e-11	Ulcerative colitis;
LUAD	cis	rs986417	0.901	rs1884098	chr14:61038944	A/T	cg27398547	chr14:60952738	C14orf39	0.61	7.71	0.35	9.11e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg11189052	chr15:85197271	WDR73	0.65	8.35	0.38	9.8e-16	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg11062466	chr8:58055876	NA	0.64	8.37	0.38	8.67e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg13393036	chr8:95962371	TP53INP1	-0.41	-9.8	-0.43	1.48e-20	Type 2 diabetes;
LUAD	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg25319279	chr11:5960081	NA	-0.4	-6.96	-0.32	1.27e-11	DNA methylation (variation);
LUAD	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	10.24	0.45	4e-22	Electrocardiographic conduction measures;
LUAD	cis	rs2274273	0.638	rs11622636	chr14:55647840	C/T	cg04306507	chr14:55594613	LGALS3	0.42	7.67	0.35	1.23e-13	Protein biomarker;
LUAD	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg09491104	chr22:46646882	C22orf40	0.63	10.57	0.46	2.52e-23	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg18512352	chr11:47633146	NA	-0.37	-6.74	-0.31	5.18e-11	Subjective well-being;
LUAD	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg15997130	chr1:24165203	NA	0.55	9.5	0.42	1.54e-19	Immature fraction of reticulocytes;
LUAD	cis	rs10899021	0.920	rs12287097	chr11:74332664	A/G	cg25880958	chr11:74394337	NA	-0.62	-8.5	-0.38	3.36e-16	Response to metformin (IC50);
LUAD	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08564027	chr20:61660810	NA	0.81	16.77	0.63	9.1e-49	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg03806693	chr22:41940476	POLR3H	0.69	9.84	0.43	1.08e-20	Vitiligo;
LUAD	trans	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg24644049	chr4:85504048	CDS1	0.86	7.78	0.35	5.78e-14	Skin colour saturation;
LUAD	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.55	0.34	2.62e-13	Platelet count;
LUAD	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.82	-0.36	4.23e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg13047869	chr3:10149882	C3orf24	0.66	11.15	0.48	1.8e-25	Alzheimer's disease;
LUAD	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg13606994	chr1:44402422	ARTN	-0.37	-7.24	-0.33	2.09e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.0	-0.32	1.02e-11	Height;
LUAD	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg22029157	chr1:209979665	IRF6	0.79	9.47	0.42	2.02e-19	Coronary artery disease;
LUAD	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10802521	chr3:52805072	NEK4	-0.54	-8.98	-0.4	8.77e-18	Bipolar disorder;
LUAD	cis	rs6665290	0.904	rs11578103	chr1:227189642	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.45	-0.89	7.93e-144	Myeloid white cell count;
LUAD	cis	rs494562	0.892	rs575477	chr6:86118064	A/G	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg17366294	chr4:99064904	C4orf37	-0.48	-8.42	-0.38	6.07e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	7.94e-19	Tonsillectomy;
LUAD	cis	rs35146811	0.586	rs34213597	chr7:99591021	C/T	cg13334819	chr7:99746414	C7orf59	-0.59	-8.25	-0.37	2.01e-15	Coronary artery disease;
LUAD	trans	rs11088226	0.581	rs1967870	chr21:33882858	A/G	cg09050820	chr6:167586206	TCP10L2	0.45	7.44	0.34	5.48e-13	Gastritis;
LUAD	trans	rs4714291	0.925	rs847750	chr6:40074250	G/A	cg02267698	chr19:7991119	CTXN1	0.43	6.46	0.3	2.94e-10	Strep throat;
LUAD	trans	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg01620082	chr3:125678407	NA	-0.42	-6.47	-0.3	2.68e-10	Depression;
LUAD	cis	rs2224391	0.617	rs67307669	chr6:5293095	C/G	cg26704043	chr6:5282702	FARS2	0.39	6.38	0.3	4.71e-10	Height;
LUAD	cis	rs7614311	0.954	rs2291533	chr3:63817430	C/G	cg22134162	chr3:63841271	THOC7	0.43	8.03	0.36	9.59e-15	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs7937890	0.504	rs2575822	chr11:14519851	C/A	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.12e-10	Mitochondrial DNA levels;
LUAD	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26314531	chr2:26401878	FAM59B	0.52	7.32	0.34	1.23e-12	Gut microbiome composition (summer);
LUAD	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg06784218	chr1:46089804	CCDC17	0.5	11.05	0.47	4.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs5756391	0.546	rs9607396	chr22:37315912	C/A	cg16356956	chr22:37317934	CSF2RB	0.33	7.21	0.33	2.52e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	trans	rs8002861	0.515	rs9525846	chr13:44390857	A/G	cg17145862	chr1:211918768	LPGAT1	-0.57	-11.59	-0.49	3.73e-27	Leprosy;
LUAD	trans	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg06606381	chr12:133084897	FBRSL1	-0.9	-8.49	-0.38	3.45e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2227564	0.620	rs11000765	chr10:75512452	G/C	cg23231163	chr10:75533350	FUT11	-0.41	-6.46	-0.3	2.93e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18099408	chr3:52552593	STAB1	-0.42	-7.44	-0.34	5.5e-13	Bipolar disorder;
LUAD	cis	rs11153730	0.503	rs445099	chr6:118618252	T/C	cg05564266	chr6:118973597	C6orf204	0.3	6.37	0.3	4.82e-10	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs9399401	0.667	rs7757571	chr6:142702589	A/C	cg04461802	chr6:142623433	GPR126	0.46	8.77	0.39	4.46e-17	Chronic obstructive pulmonary disease;
LUAD	trans	rs4650994	0.571	rs6700047	chr1:178508742	G/A	cg05059571	chr16:84539110	KIAA1609	0.46	6.92	0.32	1.67e-11	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg08219700	chr8:58056026	NA	0.66	8.47	0.38	4.12e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg21028142	chr17:79581711	NPLOC4	0.45	9.74	0.43	2.39e-20	Eye color traits;
LUAD	cis	rs7833986	0.501	rs72653948	chr8:56955689	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	16.03	0.61	1.57e-45	Height;
LUAD	trans	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.86	0.36	3.25e-14	Resting heart rate;
LUAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08219700	chr8:58056026	NA	0.68	8.62	0.39	1.37e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg11317459	chr13:21872234	NA	-1.09	-14.71	-0.58	7.3e-40	White matter hyperintensity burden;
LUAD	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg16988262	chr1:15930761	NA	0.42	7.01	0.32	9.42e-12	Systolic blood pressure;
LUAD	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg12908607	chr1:44402522	ARTN	-0.45	-8.95	-0.4	1.1e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06544989	chr22:39130855	UNC84B	0.49	9.7	0.43	3.27e-20	Menopause (age at onset);
LUAD	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23158103	chr7:148848205	ZNF398	-0.64	-11.65	-0.49	2.22e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg07917127	chr4:99064746	C4orf37	0.42	7.02	0.32	9.15e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2224391	0.628	rs2773319	chr6:5258941	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.58	8.92	0.4	1.45e-17	Height;
LUAD	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg19635926	chr16:89946313	TCF25	0.73	6.44	0.3	3.23e-10	Skin colour saturation;
LUAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg11494091	chr17:61959527	GH2	0.74	18.45	0.67	3.27e-56	Prudent dietary pattern;
LUAD	cis	rs939658	1.000	rs8027411	chr15:79461029	G/T	cg17916960	chr15:79447300	NA	0.44	9.19	0.41	1.72e-18	Refractive error;
LUAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg00106254	chr7:1943704	MAD1L1	-0.53	-8.03	-0.36	9.83e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs2455799	0.613	rs4684261	chr3:15796505	G/A	cg16303742	chr3:15540471	COLQ	-0.52	-9.72	-0.43	2.83e-20	Mean platelet volume;
LUAD	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03517284	chr6:25882590	NA	0.9	15.04	0.59	2.94e-41	Blood metabolite levels;
LUAD	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23158103	chr7:148848205	ZNF398	-0.65	-12.35	-0.51	3.78e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg09537434	chr19:41945824	ATP5SL	-0.42	-6.59	-0.31	1.27e-10	Height;
LUAD	cis	rs9807989	0.811	rs4485584	chr2:102970750	T/C	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.05e-10	Asthma;
LUAD	trans	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg18187862	chr3:45730750	SACM1L	0.51	8.05	0.36	8.38e-15	Primary sclerosing cholangitis;
LUAD	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg18827107	chr12:86230957	RASSF9	-0.65	-11.63	-0.49	2.65e-27	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg19875535	chr5:140030758	IK	-0.48	-8.08	-0.37	6.91e-15	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs12517041	1.000	rs4701362	chr5:23300849	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.49	-0.3	2.4e-10	Calcium levels;
LUAD	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.55	0.6	1.85e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg08027265	chr7:2291960	NA	-0.41	-7.26	-0.33	1.91e-12	Schizophrenia;
LUAD	cis	rs2425143	0.915	rs74355238	chr20:34441541	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.12	-0.33	4.74e-12	Blood protein levels;
LUAD	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg02880119	chr16:3481970	NA	-0.55	-8.37	-0.38	8.73e-16	Body mass index (adult);
LUAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-9.35	-0.41	5.18e-19	Alzheimer's disease;
LUAD	cis	rs62238980	0.522	rs117086479	chr22:32389342	A/G	cg00543991	chr22:32367038	NA	0.92	8.14	0.37	4.32e-15	Childhood ear infection;
LUAD	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.81	-14.07	-0.56	3.58e-37	Chronic sinus infection;
LUAD	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg04511125	chr2:88470314	THNSL2	-0.5	-8.38	-0.38	7.98e-16	Response to metformin (IC50);
LUAD	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21659725	chr3:3221576	CRBN	-0.87	-18.36	-0.67	8.22e-56	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg03929089	chr4:120376271	NA	-0.52	-8.18	-0.37	3.35e-15	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4660306	0.848	rs1088099	chr1:45946654	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.51	7.96	0.36	1.55e-14	Homocysteine levels;
LUAD	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs921968	0.565	rs7605055	chr2:219627050	G/C	cg02176678	chr2:219576539	TTLL4	-0.59	-12.09	-0.51	4.13e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg14789911	chr21:47582049	C21orf56	0.49	8.75	0.39	4.98e-17	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-11.08	-0.47	3.15e-25	Developmental language disorder (linguistic errors);
LUAD	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.58	-0.3	1.39e-10	Neuroticism;
LUAD	cis	rs1018836	0.828	rs12548806	chr8:91564256	C/T	cg16814680	chr8:91681699	NA	-0.58	-9.65	-0.42	4.6e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg21782813	chr7:2030301	MAD1L1	-0.47	-8.03	-0.36	9.99e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs10078	0.615	rs2720997	chr5:433654	A/G	cg08916839	chr5:415575	AHRR	0.82	9.48	0.42	1.81e-19	Fat distribution (HIV);
LUAD	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.07	0.33	6.49e-12	Rheumatoid arthritis;
LUAD	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg05373962	chr22:49881684	NA	-0.48	-9.99	-0.44	3.08e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg00117651	chr22:45809523	SMC1B;RIBC2	-0.58	-6.48	-0.3	2.53e-10	Tonsillectomy;
LUAD	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg09654669	chr8:57350985	NA	-0.65	-9.96	-0.44	3.92e-21	Obesity-related traits;
LUAD	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06112835	chr11:68658793	MRPL21	0.51	9.25	0.41	1.1e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg20283391	chr11:68216788	NA	-0.42	-6.6	-0.31	1.23e-10	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs459571	0.920	rs455073	chr9:136909141	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-10.1	-0.44	1.22e-21	Platelet distribution width;
LUAD	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.86	0.53	3.6e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg14530993	chr4:882597	GAK	0.73	6.9	0.32	1.89e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg11963883	chr10:70715832	DDX21	0.43	6.76	0.31	4.57e-11	Diastolic blood pressure;
LUAD	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.52	0.34	3.34e-13	Urate levels;
LUAD	cis	rs1509123	0.609	rs111898934	chr17:6718193	C/A	cg12642237	chr17:6703447	TEKT1	-0.45	-6.4	-0.3	4.24e-10	Blood metabolite levels;
LUAD	cis	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg11143507	chr3:125485238	NA	-0.46	-7.74	-0.35	7.64e-14	Blood pressure (smoking interaction);
LUAD	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg20476274	chr7:133979776	SLC35B4	0.79	14.75	0.58	5.06e-40	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg18305652	chr10:134549665	INPP5A	-0.61	-11.85	-0.5	3.72e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg27068330	chr11:65405492	SIPA1	0.52	6.59	0.31	1.3e-10	Glomerular filtration rate (creatinine);Chronic kidney disease;
LUAD	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg02683114	chr2:24398427	C2orf84	0.43	7.07	0.33	6.3e-12	Asthma;
LUAD	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg13319975	chr6:146136371	FBXO30	0.54	8.88	0.4	1.95e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs868036	0.958	rs3784709	chr15:68072275	C/T	cg24579218	chr15:68104479	NA	-0.35	-6.44	-0.3	3.33e-10	Restless legs syndrome;
LUAD	cis	rs13191362	0.573	rs1877769	chr6:163252315	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.7	9.95	0.44	4.31e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2387326	0.672	rs10829347	chr10:129947386	T/C	cg16087940	chr10:129947807	NA	-0.66	-9.3	-0.41	7.64e-19	Select biomarker traits;
LUAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-7.01	-0.32	9.46e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs921968	0.608	rs658378	chr2:219483881	T/A	cg02176678	chr2:219576539	TTLL4	0.58	10.89	0.47	1.65e-24	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg22906224	chr7:99728672	NA	0.55	9.46	0.42	2.09e-19	Coronary artery disease;
LUAD	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg17063962	chr7:91808500	NA	0.68	12.28	0.51	7.3e-30	Breast cancer;
LUAD	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs35146811	0.589	rs1727142	chr7:99816179	T/C	cg13334819	chr7:99746414	C7orf59	0.64	9.74	0.43	2.37e-20	Coronary artery disease;
LUAD	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg11919837	chr8:57350735	NA	-0.45	-6.82	-0.31	3.23e-11	Obesity-related traits;
LUAD	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg04703221	chr16:69967063	WWP2;MIR140	-0.53	-8.69	-0.39	8.13e-17	Menarche (age at onset);
LUAD	trans	rs62103177	0.608	rs551643	chr18:77838970	C/G	cg05926928	chr17:57297772	GDPD1	-0.81	-10.01	-0.44	2.61e-21	Opioid sensitivity;
LUAD	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg19761014	chr17:28927070	LRRC37B2	0.64	7.4	0.34	7.25e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1372520	0.564	rs356186	chr4:90705364	A/G	cg15133208	chr4:90757351	SNCA	-0.47	-6.82	-0.31	3.18e-11	Neuroticism;
LUAD	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.38	0.3	4.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.01	0.32	9.71e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg20673091	chr1:2541236	MMEL1	0.44	9.52	0.42	1.32e-19	Ulcerative colitis;
LUAD	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg04756594	chr16:24857601	SLC5A11	0.56	9.43	0.42	2.74e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg20203395	chr5:56204925	C5orf35	-0.81	-11.49	-0.49	8.58e-27	Initial pursuit acceleration;
LUAD	cis	rs999943	0.774	rs12212284	chr6:33640874	T/A	cg14003231	chr6:33640908	ITPR3	0.98	19.61	0.69	2.17e-61	Obesity (extreme);
LUAD	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg22920501	chr2:26401640	FAM59B	-0.96	-13.93	-0.56	1.49e-36	Gut microbiome composition (summer);
LUAD	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-8.03	-0.36	9.57e-15	Blood metabolite levels;
LUAD	cis	rs4891159	0.548	rs690423	chr18:74117984	G/A	cg24786174	chr18:74118243	ZNF516	0.91	23.16	0.75	3.2e-77	Longevity;
LUAD	cis	rs757647	0.723	rs757649	chr5:137705468	G/T	cg10676309	chr5:137685565	NA	0.43	7.61	0.35	1.85e-13	Menarche (age at onset);
LUAD	trans	rs9784649	1.000	rs55806673	chr5:24957298	A/G	cg11038491	chr20:34638489	LOC647979	-0.6	-7.87	-0.36	3e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs123509	0.687	rs17238972	chr3:42819975	C/G	cg10144569	chr3:42726640	KBTBD5	-0.47	-6.94	-0.32	1.52e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs76878669	0.561	rs4930178	chr11:66129442	C/G	cg10616300	chr11:66138557	SLC29A2	0.35	7.3	0.33	1.49e-12	Educational attainment (years of education);
LUAD	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg04034577	chr2:241836375	C2orf54	-0.5	-11.34	-0.48	3.4e-26	Urinary metabolites;
LUAD	cis	rs7737355	1.000	rs27873	chr5:130731151	T/C	cg06307176	chr5:131281290	NA	-0.45	-7.33	-0.34	1.2e-12	Life satisfaction;
LUAD	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg12193833	chr17:30244370	NA	-0.58	-7.0	-0.32	1.02e-11	Hip circumference adjusted for BMI;
LUAD	trans	rs7395662	1.000	rs11039871	chr11:48626620	C/T	cg00717180	chr2:96193071	NA	0.37	6.92	0.32	1.7e-11	HDL cholesterol;
LUAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg13047869	chr3:10149882	C3orf24	0.59	9.99	0.44	2.95e-21	Alzheimer's disease;
LUAD	cis	rs7923452	0.938	rs67812762	chr10:30759479	G/T	cg18806716	chr10:30721971	MAP3K8	0.58	7.87	0.36	3.01e-14	Itch intensity from mosquito bite;
LUAD	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg17105886	chr17:28927953	LRRC37B2	0.74	7.36	0.34	9.51e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg10831504	chr12:69005104	RAP1B	-0.36	-6.35	-0.3	5.68e-10	Subcortical brain region volumes;
LUAD	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg07432352	chr17:45403706	C17orf57	0.38	6.98	0.32	1.17e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg08508325	chr11:3079039	CARS	0.42	8.77	0.39	4.43e-17	Calcium levels;
LUAD	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	9.86	0.43	8.79e-21	Lung cancer in ever smokers;
LUAD	cis	rs9283706	0.594	rs1428405	chr5:66327193	A/T	cg11590213	chr5:66331682	MAST4	0.4	6.41	0.3	3.87e-10	Coronary artery disease;
LUAD	cis	rs11696501	0.739	rs6073815	chr20:44234615	A/T	cg11783356	chr20:44313418	WFDC10B	-0.49	-7.76	-0.35	6.41e-14	Brain structure;
LUAD	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg00814883	chr7:100076585	TSC22D4	-0.85	-12.59	-0.52	4.22e-31	Platelet count;
LUAD	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg14530993	chr4:882597	GAK	0.78	7.9	0.36	2.41e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg14196790	chr5:131705035	SLC22A5	0.38	6.6	0.31	1.21e-10	Breast cancer;
LUAD	cis	rs3820068	0.705	rs4646092	chr1:15821673	C/T	cg24675056	chr1:15929824	NA	0.41	6.58	0.3	1.39e-10	Systolic blood pressure;
LUAD	cis	rs11771526	0.892	rs62457504	chr7:32336097	G/A	cg27532318	chr7:32358331	NA	0.7	8.3	0.37	1.42e-15	Body mass index;
LUAD	trans	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.62	10.21	0.44	4.92e-22	Endometrial cancer;
LUAD	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03934478	chr11:495069	RNH1	0.77	9.27	0.41	9.77e-19	Body mass index;
LUAD	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg06641503	chr3:48959341	ARIH2	-0.37	-7.08	-0.33	5.85e-12	Parkinson's disease;
LUAD	cis	rs796825	0.530	rs13060094	chr3:120014311	G/T	cg21790991	chr3:120137480	FSTL1	-0.45	-7.61	-0.35	1.77e-13	HIV-1 susceptibility;
LUAD	cis	rs612683	0.735	rs10493923	chr1:100930254	A/G	cg06223162	chr1:101003688	GPR88	-0.47	-9.08	-0.4	4.08e-18	Breast cancer;
LUAD	cis	rs2505998	0.833	rs2505535	chr10:43593043	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.34	-6.45	-0.3	3.01e-10	Hirschsprung disease;
LUAD	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg17063962	chr7:91808500	NA	0.64	10.74	0.46	6.04e-24	Breast cancer;
LUAD	cis	rs929596	0.785	rs6747843	chr2:234664354	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.76	-13.01	-0.53	8.76e-33	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.94	-0.4	1.22e-17	Initial pursuit acceleration;
LUAD	cis	rs68170813	0.559	rs12537342	chr7:106943563	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.37	-0.45	1.38e-22	Coronary artery disease;
LUAD	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.6	-10.04	-0.44	2.12e-21	Menarche (age at onset);
LUAD	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg04287289	chr16:89883240	FANCA	0.46	7.42	0.34	6.55e-13	Vitiligo;
LUAD	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg19717773	chr7:2847554	GNA12	-0.48	-8.13	-0.37	4.67e-15	Height;
LUAD	cis	rs684232	0.666	rs366151	chr17:598311	A/C	cg15660573	chr17:549704	VPS53	-0.78	-15.2	-0.59	5.91e-42	Prostate cancer;
LUAD	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg26513180	chr16:89883248	FANCA	0.45	7.52	0.34	3.39e-13	Vitiligo;
LUAD	cis	rs2019216	0.500	rs7359613	chr17:21944028	T/C	cg22648282	chr17:21454238	C17orf51	-0.41	-6.38	-0.3	4.65e-10	Pelvic organ prolapse;
LUAD	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg22166914	chr1:53195759	ZYG11B	0.45	7.86	0.36	3.24e-14	Monocyte count;
LUAD	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg03474202	chr17:45855739	NA	-0.4	-8.55	-0.38	2.33e-16	IgG glycosylation;
LUAD	cis	rs7737355	0.673	rs26006	chr5:130982768	A/G	cg25547332	chr5:131281432	NA	0.43	6.98	0.32	1.12e-11	Life satisfaction;
LUAD	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.06e-11	Depression;
LUAD	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg07870213	chr5:140052090	DND1	0.73	11.14	0.48	1.93e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg20587970	chr11:113659929	NA	-1.39	-20.55	-0.71	1.35e-65	Hip circumference adjusted for BMI;
LUAD	cis	rs10493773	0.502	rs12061951	chr1:86081453	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.47	-7.55	-0.34	2.74e-13	Urate levels in overweight individuals;
LUAD	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg22532475	chr10:104410764	TRIM8	-0.43	-8.42	-0.38	6.02e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg27129171	chr3:47204927	SETD2	0.41	6.79	0.31	3.7e-11	Colorectal cancer;
LUAD	cis	rs7851660	0.809	rs12004762	chr9:100652755	A/G	cg13688889	chr9:100608707	NA	-0.54	-9.08	-0.4	4.17e-18	Strep throat;
LUAD	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg18105134	chr13:113819100	PROZ	-1.04	-19.43	-0.69	1.51e-60	Platelet distribution width;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg17077776	chr5:110074606	SLC25A46	-0.38	-6.39	-0.3	4.26e-10	Subcortical brain region volumes;
LUAD	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.93	13.25	0.54	8.81e-34	Smoking behavior;
LUAD	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg19318889	chr4:1322082	MAEA	0.44	7.07	0.33	6.32e-12	Obesity-related traits;
LUAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg08888203	chr3:10149979	C3orf24	0.63	10.73	0.46	6.56e-24	Alzheimer's disease;
LUAD	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg17366294	chr4:99064904	C4orf37	0.48	8.42	0.38	5.92e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07256732	chr16:621771	PIGQ	-0.33	-6.91	-0.32	1.77e-11	Height;
LUAD	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg12365402	chr11:9010492	NRIP3	0.47	8.83	0.39	2.7e-17	Hemoglobin concentration;
LUAD	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg08222618	chr4:941054	TMEM175	0.6	8.47	0.38	3.97e-16	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-7.6	-0.35	1.91e-13	Neutrophil percentage of white cells;
LUAD	cis	rs9473147	0.543	rs7738044	chr6:47469273	A/G	cg02130027	chr6:47444894	CD2AP	0.36	6.94	0.32	1.45e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg01579765	chr21:45077557	HSF2BP	-0.57	-13.11	-0.54	3.35e-33	Mean corpuscular volume;
LUAD	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg19773385	chr1:10388646	KIF1B	0.41	6.84	0.32	2.81e-11	Hepatocellular carcinoma;
LUAD	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg01579765	chr21:45077557	HSF2BP	-0.59	-13.29	-0.54	6.1e-34	Mean corpuscular volume;
LUAD	cis	rs6696239	0.513	rs3010192	chr1:227803051	G/A	cg12133451	chr1:227746453	NA	-0.36	-6.38	-0.3	4.78e-10	Height;
LUAD	cis	rs11958404	0.932	rs72816580	chr5:157432221	A/T	cg05962755	chr5:157440814	NA	0.7	9.77	0.43	1.87e-20	IgG glycosylation;
LUAD	cis	rs6840360	0.571	rs11944139	chr4:152505291	T/C	cg22705602	chr4:152727874	NA	-0.45	-7.7	-0.35	9.52e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1509123	0.609	rs74628192	chr17:6721847	C/A	cg12642237	chr17:6703447	TEKT1	-0.44	-6.42	-0.3	3.59e-10	Blood metabolite levels;
LUAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.53	-8.85	-0.4	2.42e-17	Renal function-related traits (BUN);
LUAD	cis	rs743757	1.000	rs2236954	chr3:50425177	C/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	7.15	0.33	3.83e-12	Diastolic blood pressure;
LUAD	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg21782813	chr7:2030301	MAD1L1	-0.48	-8.3	-0.37	1.38e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16223510	chr6:136610388	BCLAF1	-0.39	-6.37	-0.3	4.83e-10	Cancer;
LUAD	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg17105886	chr17:28927953	LRRC37B2	0.57	6.6	0.31	1.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.38	-6.6	-0.31	1.26e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17641971	0.684	rs4873095	chr8:49990166	A/T	cg00325661	chr8:49890786	NA	0.3	6.8	0.31	3.68e-11	Blood metabolite levels;
LUAD	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg00666640	chr1:248458726	OR2T12	0.32	7.85	0.36	3.43e-14	Common traits (Other);
LUAD	cis	rs1448094	0.842	rs7978562	chr12:86451478	A/G	cg02569458	chr12:86230093	RASSF9	0.35	6.63	0.31	1e-10	Major depressive disorder;
LUAD	trans	rs79911532	0.515	rs116006876	chr7:75775918	G/C	cg19862616	chr7:65841803	NCRNA00174	0.84	8.66	0.39	1.01e-16	Mononucleosis;
LUAD	trans	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg21659725	chr3:3221576	CRBN	-0.59	-9.58	-0.42	8.49e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg01620082	chr3:125678407	NA	-0.44	-6.65	-0.31	8.91e-11	Parkinson's disease;
LUAD	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.78	-0.43	1.63e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.46	0.42	2.24e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg23029597	chr12:123009494	RSRC2	-0.59	-9.78	-0.43	1.67e-20	Body mass index;
LUAD	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg04450456	chr4:17643702	FAM184B	-0.41	-7.95	-0.36	1.7e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7213347	0.780	rs170041	chr17:2170216	C/T	cg02569219	chr17:2266849	SGSM2	0.44	7.08	0.33	5.89e-12	Total body bone mineral density;
LUAD	cis	rs6543140	0.964	rs6543142	chr2:103082006	T/C	cg04239558	chr2:103089729	SLC9A4	0.36	7.33	0.34	1.15e-12	Blood protein levels;
LUAD	cis	rs1941023	0.584	rs2197236	chr11:60168859	T/C	cg08716584	chr11:60157161	MS4A7	-0.45	-8.55	-0.38	2.29e-16	Congenital heart disease (maternal effect);
LUAD	cis	rs4853036	0.597	rs1048165	chr2:70131964	A/C	cg02498382	chr2:70120550	SNRNP27	-0.55	-8.85	-0.4	2.44e-17	Colorectal or endometrial cancer;
LUAD	cis	rs947211	0.752	rs1572931	chr1:205744218	C/T	cg26354017	chr1:205819088	PM20D1	-0.52	-6.43	-0.3	3.46e-10	Parkinson's disease;
LUAD	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26314531	chr2:26401878	FAM59B	-0.58	-8.0	-0.36	1.19e-14	Gut microbiome composition (summer);
LUAD	cis	rs2357013	0.752	rs2048310	chr2:53225842	G/T	cg07782112	chr2:53107842	NA	-0.36	-7.14	-0.33	4.23e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg08132940	chr7:1081526	C7orf50	-0.64	-9.28	-0.41	8.72e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9658691	0.607	rs12416581	chr10:90780440	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.57	-7.54	-0.34	2.85e-13	Mosquito bite size;
LUAD	cis	rs57590327	0.503	rs13062741	chr3:81887124	C/T	cg07356753	chr3:81810745	GBE1	-0.55	-8.9	-0.4	1.61e-17	Extraversion;
LUAD	cis	rs6543140	0.964	rs10193485	chr2:103089573	T/C	cg04239558	chr2:103089729	SLC9A4	0.36	7.19	0.33	2.93e-12	Blood protein levels;
LUAD	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg03929089	chr4:120376271	NA	-0.82	-14.75	-0.58	5.08e-40	Coronary artery disease;
LUAD	cis	rs300774	1.000	rs167282	chr2:117174	A/G	cg21211680	chr2:198530	NA	-0.45	-6.63	-0.31	1.02e-10	Suicide attempts in bipolar disorder;
LUAD	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg11189052	chr15:85197271	WDR73	-0.6	-7.45	-0.34	5.37e-13	Schizophrenia;
LUAD	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg17105886	chr17:28927953	LRRC37B2	0.73	6.64	0.31	9.66e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg17724175	chr1:150552817	MCL1	0.38	8.64	0.39	1.19e-16	Melanoma;
LUAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg05342682	chr7:94953680	PON1	-0.51	-9.38	-0.42	3.92e-19	Paraoxonase activity;
LUAD	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22496380	chr5:211416	CCDC127	-1.22	-15.59	-0.6	1.29e-43	Breast cancer;
LUAD	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	11.26	0.48	6.61e-26	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg21724239	chr8:58056113	NA	0.66	8.95	0.4	1.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs17154702	0.506	rs78790499	chr8:8628827	T/C	cg01851573	chr8:8652454	MFHAS1	0.58	7.75	0.35	6.73e-14	Neurocognitive impairment in HIV-1 infection (continuous);
LUAD	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg01299579	chr2:10830716	NOL10	0.42	7.41	0.34	6.79e-13	Prostate cancer;
LUAD	cis	rs10392	0.543	rs57569873	chr20:37558293	T/C	cg27552599	chr20:37590471	DHX35	0.41	6.89	0.32	1.98e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg26769984	chr7:1090371	C7orf50	-0.71	-11.71	-0.49	1.29e-27	Bronchopulmonary dysplasia;
LUAD	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.57	-0.38	1.96e-16	Alzheimer's disease (late onset);
LUAD	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg00204512	chr16:28754710	NA	0.33	7.12	0.33	4.52e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9837602	0.935	rs9875640	chr3:99729091	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-7.31	-0.33	1.33e-12	Breast cancer;
LUAD	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.95	0.36	1.71e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg21709803	chr11:61594965	FADS2	-0.62	-8.99	-0.4	8.64e-18	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs7809799	0.571	rs11978345	chr7:98930036	G/T	cg12290671	chr7:99195819	NA	-0.79	-6.91	-0.32	1.85e-11	Ulcerative colitis;
LUAD	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg22482690	chr17:47019901	SNF8	0.46	8.98	0.4	9.04e-18	Type 2 diabetes;
LUAD	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03264133	chr6:25882463	NA	-0.44	-6.75	-0.31	4.77e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg02399570	chr3:156877196	CCNL1	0.45	7.44	0.34	5.76e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg02423579	chr7:2872169	GNA12	-0.87	-14.98	-0.59	5.31e-41	Height;
LUAD	cis	rs12530845	0.943	rs58577912	chr7:135329269	T/G	cg23117316	chr7:135346802	PL-5283	-0.51	-8.99	-0.4	8.13e-18	Red blood cell traits;
LUAD	cis	rs11771526	0.901	rs7791914	chr7:32296754	A/G	cg27532318	chr7:32358331	NA	0.56	7.14	0.33	4.18e-12	Body mass index;
LUAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg06074448	chr4:187884817	NA	-0.36	-7.25	-0.33	2.02e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs600231	0.508	rs17146964	chr11:65249145	C/T	cg17120908	chr11:65337727	SSSCA1	0.65	8.51	0.38	3.15e-16	Bone mineral density;
LUAD	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.73	0.35	7.65e-14	Breast cancer;
LUAD	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg10523679	chr1:76189770	ACADM	0.88	15.62	0.6	9.65e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2637266	0.846	rs2583045	chr10:78412385	C/G	cg18941641	chr10:78392320	NA	-0.33	-6.94	-0.32	1.44e-11	Pulmonary function;
LUAD	trans	rs7944735	0.517	rs12274550	chr11:48196752	C/A	cg03929089	chr4:120376271	NA	0.59	6.68	0.31	7.34e-11	Intraocular pressure;
LUAD	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg21918786	chr6:109611834	NA	0.57	11.11	0.48	2.43e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg18230493	chr5:56204884	C5orf35	-0.52	-8.46	-0.38	4.44e-16	Coronary artery disease;
LUAD	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg09796270	chr17:17721594	SREBF1	0.37	7.01	0.32	9.76e-12	Total body bone mineral density;
LUAD	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg04414720	chr1:150670196	GOLPH3L	-0.47	-7.39	-0.34	7.9e-13	Tonsillectomy;
LUAD	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-8.01	-0.36	1.14e-14	Height;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08555112	chr17:48942811	TOB1	0.41	6.4	0.3	4.03e-10	Gut microbiome composition (summer);
LUAD	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg23978390	chr7:1156363	C7orf50	0.51	6.58	0.3	1.37e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg03563238	chr19:33554763	RHPN2	-0.37	-8.56	-0.38	2.12e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9837602	1.000	rs62285461	chr3:99767642	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	9.22	0.41	1.46e-18	Breast cancer;
LUAD	trans	rs1997103	0.911	rs6949931	chr7:55391081	T/C	cg20935933	chr6:143382018	AIG1	0.54	7.6	0.35	1.99e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.83	-0.36	4.01e-14	Neutrophil percentage of white cells;
LUAD	trans	rs7395662	1.000	rs4882129	chr11:48588774	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.12e-12	HDL cholesterol;
LUAD	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg08885076	chr2:99613938	TSGA10	0.41	7.62	0.35	1.67e-13	Chronic sinus infection;
LUAD	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg08470875	chr2:26401718	FAM59B	-0.77	-10.37	-0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs1003719	0.680	rs2835668	chr21:38580151	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.14	-0.37	4.54e-15	Eye color traits;
LUAD	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg22823121	chr1:150693482	HORMAD1	-0.35	-6.58	-0.3	1.42e-10	Tonsillectomy;
LUAD	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg18232548	chr7:50535776	DDC	-0.71	-13.18	-0.54	1.82e-33	Systemic sclerosis;
LUAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg21782813	chr7:2030301	MAD1L1	0.42	6.98	0.32	1.16e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg26384229	chr12:38710491	ALG10B	0.46	7.57	0.35	2.37e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg17177755	chr1:15930204	NA	0.44	7.17	0.33	3.32e-12	Systolic blood pressure;
LUAD	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg13319975	chr6:146136371	FBXO30	-0.59	-9.94	-0.44	4.57e-21	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs75804782	0.625	rs72984530	chr2:239469431	C/T	cg01134436	chr17:81009848	B3GNTL1	0.76	7.68	0.35	1.12e-13	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.62	0.35	1.73e-13	Platelet count;
LUAD	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg01851573	chr8:8652454	MFHAS1	-0.46	-8.4	-0.38	6.89e-16	Mood instability;
LUAD	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg26384229	chr12:38710491	ALG10B	0.47	7.68	0.35	1.11e-13	Bladder cancer;
LUAD	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg10556349	chr10:835070	NA	0.56	7.03	0.32	8.22e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs1267303	0.710	rs1535739	chr1:46957719	A/C	cg16387850	chr1:46982889	NA	0.41	6.95	0.32	1.36e-11	Monobrow;
LUAD	cis	rs9462027	0.651	rs9469885	chr6:34758716	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.0	-0.4	7.78e-18	Systemic lupus erythematosus;
LUAD	cis	rs7584330	0.740	rs10184904	chr2:238428186	G/C	cg14458575	chr2:238380390	NA	0.57	10.79	0.46	3.75e-24	Prostate cancer;
LUAD	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg01324343	chr3:183735012	ABCC5	0.64	12.65	0.52	2.52e-31	Anterior chamber depth;
LUAD	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg16205897	chr5:131564050	P4HA2	-0.41	-9.33	-0.41	5.83e-19	Blood metabolite levels;
LUAD	trans	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg26043149	chr18:55253948	FECH	-0.49	-8.11	-0.37	5.64e-15	Bone mineral density;
LUAD	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg06387496	chr7:2775674	GNA12	-0.38	-6.36	-0.3	5.2400000000000005e-10	Height;
LUAD	cis	rs7020830	0.898	rs13290794	chr9:37183628	C/T	cg14294708	chr9:37120828	ZCCHC7	0.86	17.0	0.64	8.87e-50	Schizophrenia;
LUAD	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg24733560	chr20:60626293	TAF4	0.39	7.66	0.35	1.28e-13	Body mass index;
LUAD	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg19767477	chr5:127420684	SLC12A2	-0.44	-6.75	-0.31	4.94e-11	Ileal carcinoids;
LUAD	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg10755058	chr3:40428713	ENTPD3	0.43	8.39	0.38	7.32e-16	Renal cell carcinoma;
LUAD	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.88	0.4	1.99e-17	Lung cancer in ever smokers;
LUAD	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg20933634	chr6:27740509	NA	0.47	7.4	0.34	7.31e-13	Parkinson's disease;
LUAD	cis	rs494562	0.892	rs498289	chr6:86116721	A/G	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs8060686	0.623	rs56303487	chr16:68029739	C/T	cg05110241	chr16:68378359	PRMT7	-0.54	-6.6	-0.31	1.21e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg10556349	chr10:835070	NA	0.6	7.64	0.35	1.48e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs427941	0.659	rs2529373	chr7:101739618	A/G	cg06246474	chr7:101738831	CUX1	0.41	7.28	0.33	1.6e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg13393036	chr8:95962371	TP53INP1	-0.4	-9.57	-0.42	9.2e-20	Type 2 diabetes;
LUAD	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg11494091	chr17:61959527	GH2	0.45	8.57	0.38	2.03e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9467773	1.000	rs1001687	chr6:26573218	C/G	cg11502198	chr6:26597334	ABT1	0.61	10.06	0.44	1.76e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs12618769	0.597	rs55934321	chr2:99099417	G/A	cg10123293	chr2:99228465	UNC50	0.46	8.04	0.36	9.19e-15	Bipolar disorder;
LUAD	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg07741184	chr6:167504864	NA	0.4	9.25	0.41	1.15e-18	Crohn's disease;
LUAD	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg02782426	chr3:40428986	ENTPD3	0.43	8.77	0.39	4.36e-17	Renal cell carcinoma;
LUAD	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg06287003	chr12:125626642	AACS	-0.4	-6.47	-0.3	2.65e-10	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg10544611	chr16:67998164	SLC12A4	-0.55	-6.85	-0.32	2.66e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.35	-0.38	9.81e-16	Gut microbiome composition (summer);
LUAD	cis	rs12760731	0.668	rs10913548	chr1:178372286	G/A	cg00404053	chr1:178313656	RASAL2	0.73	9.24	0.41	1.19e-18	Obesity-related traits;
LUAD	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg10755058	chr3:40428713	ENTPD3	-0.42	-8.11	-0.37	5.37e-15	Renal cell carcinoma;
LUAD	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg02931644	chr1:25747376	RHCE	0.44	9.17	0.41	2.03e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.47	-0.45	5.54e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg10434728	chr15:90938212	IQGAP1	-0.36	-7.13	-0.33	4.37e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-10.23	-0.45	4.43e-22	Electrocardiographic conduction measures;
LUAD	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	8.02	0.36	1.04e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg07917127	chr4:99064746	C4orf37	0.4	6.62	0.31	1.09e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1728785	1.000	rs1728773	chr16:68563644	A/C	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.3100000000000001e-10	Ulcerative colitis;
LUAD	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg05665937	chr4:1216051	CTBP1	0.41	7.03	0.32	8.5e-12	Obesity-related traits;
LUAD	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.33	0.45	1.84e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg01017244	chr2:74357527	NA	0.9	14.57	0.58	2.93e-39	Gestational age at birth (maternal effect);
LUAD	cis	rs600231	0.706	rs1111934	chr11:65329392	A/G	cg21890820	chr11:65308645	LTBP3	0.59	9.34	0.41	5.51e-19	Bone mineral density;
LUAD	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg03714773	chr7:91764589	CYP51A1	0.31	7.08	0.33	6.02e-12	Breast cancer;
LUAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg08132940	chr7:1081526	C7orf50	-0.47	-6.67	-0.31	8.22e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62238980	0.614	rs116862462	chr22:32470463	C/T	cg00543991	chr22:32367038	NA	0.92	8.7	0.39	7.27e-17	Childhood ear infection;
LUAD	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg13010199	chr12:38710504	ALG10B	0.39	6.62	0.31	1.12e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg23950597	chr19:37808831	NA	-0.65	-7.58	-0.35	2.2e-13	Coronary artery calcification;
LUAD	trans	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.85	0.43	9.44e-21	Ulcerative colitis;
LUAD	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg19622623	chr12:86230825	RASSF9	-0.53	-9.43	-0.42	2.71e-19	Major depressive disorder;
LUAD	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg06028808	chr11:68637592	NA	0.45	7.45	0.34	5.39e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs28830936	0.934	rs3959569	chr15:42115747	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.34	-6.65	-0.31	9.04e-11	Diastolic blood pressure;
LUAD	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg03947459	chr4:1685442	FAM53A	-0.46	-6.36	-0.3	5.3e-10	Bladder cancer;Urinary bladder cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09431544	chr19:14629187	DNAJB1	-0.56	-7.15	-0.33	3.85e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7975161	0.572	rs7132418	chr12:104603591	C/A	cg25273343	chr12:104657179	TXNRD1	-0.66	-7.34	-0.34	1.12e-12	Toenail selenium levels;
LUAD	cis	rs28595532	0.582	rs71608361	chr4:119224081	T/C	cg02775129	chr4:119771670	NA	-0.63	-6.81	-0.31	3.36e-11	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.36e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7809950	0.768	rs62482493	chr7:106951579	T/C	cg23024343	chr7:107201750	COG5	-0.79	-12.65	-0.52	2.56e-31	Coronary artery disease;
LUAD	cis	rs7827545	1.000	rs7008158	chr8:135565982	T/C	cg17885191	chr8:135476712	NA	0.5	7.95	0.36	1.72e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg06784218	chr1:46089804	CCDC17	0.6	13.37	0.55	2.89e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7191439	0.789	rs4433802	chr16:88784964	A/G	cg02389323	chr16:88786976	FAM38A	1.32	11.83	0.5	4.2e-28	Plateletcrit;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg02796970	chr10:39023768	NA	-0.48	-7.63	-0.35	1.58e-13	Menopause (age at onset);
LUAD	cis	rs1843834	0.823	rs2129610	chr2:225505345	G/A	cg22455342	chr2:225449267	CUL3	0.45	6.66	0.31	8.35e-11	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs11229555	0.574	rs12271501	chr11:58214969	T/C	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.46	-7.84	-0.36	3.76e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10916814	0.632	rs10799645	chr1:20903784	T/C	cg24502330	chr1:20914028	CDA	-0.36	-7.09	-0.33	5.68e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg00316803	chr15:76480434	C15orf27	-0.39	-7.41	-0.34	6.7e-13	Blood metabolite levels;
LUAD	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg27433088	chr4:174089019	GALNT7	0.41	7.61	0.35	1.75e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg06623918	chr6:96969491	KIAA0776	0.88	17.24	0.64	7.83e-51	Headache;
LUAD	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg21252483	chr19:49399788	TULP2	-0.64	-8.7	-0.39	7.48e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg09085632	chr11:111637200	PPP2R1B	0.8	13.01	0.53	8.62e-33	Primary sclerosing cholangitis;
LUAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg02951883	chr7:2050386	MAD1L1	-0.94	-16.97	-0.64	1.21e-49	Bipolar disorder and schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12296079	chr11:61849674	NA	-0.47	-7.68	-0.35	1.09e-13	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09455096	chr2:61765470	XPO1	-0.44	-6.85	-0.32	2.67e-11	Height;
LUAD	cis	rs4631830	0.720	rs4935573	chr10:51504385	A/G	cg20129853	chr10:51489980	NA	0.34	6.86	0.32	2.4e-11	Prostate-specific antigen levels;
LUAD	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg23231163	chr10:75533350	FUT11	0.53	10.11	0.44	1.15e-21	Inflammatory bowel disease;
LUAD	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg21385522	chr1:16154831	NA	0.44	6.53	0.3	1.92e-10	Dilated cardiomyopathy;
LUAD	cis	rs11771526	0.901	rs62457473	chr7:32306990	G/A	cg27511599	chr7:32358540	NA	0.5	6.36	0.3	5.2400000000000005e-10	Body mass index;
LUAD	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg17105886	chr17:28927953	LRRC37B2	0.74	6.82	0.31	3.17e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg19678392	chr7:94953810	PON1	0.54	7.32	0.34	1.27e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg15691649	chr6:25882328	NA	0.69	10.46	0.45	6.29e-23	Blood metabolite levels;
LUAD	cis	rs68092024	0.731	rs793480	chr3:99488364	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	7.87	0.36	2.99e-14	Cleft lip with or without cleft palate;
LUAD	trans	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.54	9.22	0.41	1.4e-18	Brugada syndrome;
LUAD	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06028808	chr11:68637592	NA	0.47	7.78	0.35	5.78e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3803170	0.513	rs10849944	chr12:111825389	C/T	cg10833066	chr12:111807467	FAM109A	-0.46	-8.65	-0.39	1.09e-16	Mean corpuscular hemoglobin;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06128509	chr10:91461539	KIF20B	-0.44	-6.85	-0.32	2.67e-11	Height;
LUAD	cis	rs11030122	0.673	rs10835508	chr11:4045360	A/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.46	-0.34	4.81e-13	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06873352	chr17:61820015	STRADA	0.83	18.44	0.67	3.61e-56	Prudent dietary pattern;
LUAD	trans	rs7395662	0.674	rs7124275	chr11:48162305	C/T	cg00717180	chr2:96193071	NA	-0.36	-6.58	-0.3	1.4e-10	HDL cholesterol;
LUAD	cis	rs62400317	0.859	rs72858511	chr6:45218119	A/G	cg18551225	chr6:44695536	NA	-0.55	-8.42	-0.38	5.71e-16	Total body bone mineral density;
LUAD	cis	rs7274811	0.711	rs291698	chr20:31982250	A/T	cg14921437	chr20:32255988	NECAB3;C20orf134	0.45	6.95	0.32	1.4e-11	Height;
LUAD	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg14092988	chr3:52407081	DNAH1	0.37	7.35	0.34	1.02e-12	Electroencephalogram traits;
LUAD	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg06608945	chr2:219082296	ARPC2	-0.42	-6.83	-0.32	2.93e-11	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs7809950	0.678	rs2237659	chr7:106847492	G/T	cg23024343	chr7:107201750	COG5	0.78	12.44	0.52	1.66e-30	Coronary artery disease;
LUAD	cis	rs11077998	0.967	rs12185229	chr17:80499065	G/C	cg10255544	chr17:80519551	FOXK2	0.35	7.0	0.32	9.85e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg17724175	chr1:150552817	MCL1	0.34	7.87	0.36	3.01e-14	Melanoma;
LUAD	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg06484146	chr7:12443880	VWDE	-0.59	-7.55	-0.34	2.73e-13	Coronary artery disease;
LUAD	cis	rs1957429	0.901	rs3813422	chr14:65347404	G/A	cg23373153	chr14:65346875	NA	0.55	6.45	0.3	2.99e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs3820068	0.705	rs4646087	chr1:15822404	A/G	cg24675056	chr1:15929824	NA	0.41	6.49	0.3	2.45e-10	Systolic blood pressure;
LUAD	cis	rs7536201	0.967	rs6600248	chr1:25305157	A/G	cg23273869	chr1:25296894	NA	-0.37	-7.48	-0.34	4.23e-13	Psoriasis vulgaris;
LUAD	cis	rs4786125	0.879	rs7187208	chr16:6894716	T/C	cg03623568	chr16:6915990	A2BP1	-0.41	-8.2	-0.37	2.93e-15	Heart rate variability traits (SDNN);
LUAD	trans	rs2262909	0.962	rs409835	chr19:22230671	T/C	cg05197062	chr11:11642011	GALNTL4	-0.57	-8.81	-0.39	3.18e-17	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg17724175	chr1:150552817	MCL1	0.4	9.73	0.43	2.52e-20	Tonsillectomy;
LUAD	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg04455712	chr21:45112962	RRP1B	0.48	9.69	0.43	3.35e-20	Mean corpuscular volume;
LUAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg14926445	chr8:58193284	C8orf71	-0.5	-7.2	-0.33	2.74e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2932538	0.922	rs999923	chr1:113110548	T/C	cg22162597	chr1:113214053	CAPZA1	0.46	6.88	0.32	2.1e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs3789045	0.560	rs1002779	chr1:204405098	T/A	cg17419461	chr1:204415978	PIK3C2B	-0.57	-9.29	-0.41	8.46e-19	Educational attainment (college completion);
LUAD	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.45	-0.89	7.93e-144	Myeloid white cell count;
LUAD	cis	rs500891	0.525	rs1170484	chr6:84038522	A/G	cg08257003	chr6:84140564	ME1	0.34	6.35	0.3	5.54e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs7640424	0.754	rs182736	chr3:107838891	C/A	cg09227934	chr3:107805635	CD47	0.49	8.62	0.39	1.36e-16	Body mass index;
LUAD	cis	rs354225	0.544	rs12713267	chr2:54805607	T/C	cg01766943	chr2:54829624	SPTBN1	0.4	7.5	0.34	3.76e-13	Schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17766062	chr2:75062663	HK2	-0.42	-6.5	-0.3	2.27e-10	Height;
LUAD	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg17366294	chr4:99064904	C4orf37	-0.51	-9.03	-0.4	5.97e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11890956	chr21:40555474	PSMG1	0.7	11.5	0.49	8.26e-27	Cognitive function;
LUAD	cis	rs4280164	0.551	rs8008406	chr14:24811159	C/T	cg22990158	chr14:24802150	ADCY4	-0.56	-8.84	-0.39	2.6e-17	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg00074818	chr8:8560427	CLDN23	0.69	10.56	0.46	2.75e-23	Obesity-related traits;
LUAD	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	7.29	0.33	1.54e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg25894440	chr7:65020034	NA	-0.61	-6.56	-0.3	1.55e-10	Diabetic kidney disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg10573763	chr19:19030094	COPE;DDX49	-0.42	-7.08	-0.33	6.05e-12	Cancer;
LUAD	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg27087555	chr16:88793112	FAM38A	-1.16	-10.51	-0.46	3.98e-23	Plateletcrit;
LUAD	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg25358565	chr5:93447407	FAM172A	0.64	7.62	0.35	1.63e-13	Diabetic retinopathy;
LUAD	cis	rs416603	0.967	rs7191538	chr16:11363389	C/G	cg00044050	chr16:11439710	C16orf75	-0.59	-9.29	-0.41	8.27e-19	Type 1 diabetes;
LUAD	cis	rs9902453	0.967	rs60176674	chr17:28479854	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.46	0.38	4.47e-16	Coffee consumption (cups per day);
LUAD	trans	rs11885103	0.543	rs2685245	chr2:554536	C/G	cg12228919	chr15:44955936	SPG11	-0.44	-6.8	-0.31	3.6e-11	Heschl's gyrus morphology;
LUAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg24642844	chr7:1081250	C7orf50	-0.92	-13.94	-0.56	1.24e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs208520	1.000	rs208529	chr6:66957549	T/C	cg07460842	chr6:66804631	NA	-0.94	-13.01	-0.53	8.7e-33	Exhaled nitric oxide output;
LUAD	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-7.9	-0.36	2.45e-14	Total body bone mineral density;
LUAD	cis	rs17095355	1.000	rs59804002	chr10:111692043	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.64	-8.17	-0.37	3.66e-15	Biliary atresia;
LUAD	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg20701182	chr2:24300061	SF3B14	0.57	6.85	0.32	2.66e-11	Lymphocyte counts;
LUAD	cis	rs35740288	0.770	rs4843082	chr15:86153390	A/G	cg13263323	chr15:86062960	AKAP13	-0.44	-7.02	-0.32	8.78e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs13315871	0.929	rs11130628	chr3:58315835	T/C	cg20936604	chr3:58311152	NA	-0.78	-8.44	-0.38	5.22e-16	Cholesterol, total;
LUAD	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg27446573	chr6:127587934	RNF146	0.45	6.61	0.31	1.18e-10	Breast cancer;
LUAD	cis	rs859767	0.741	rs4954156	chr2:135395863	T/C	cg12500956	chr2:135428796	TMEM163	-0.31	-8.03	-0.36	9.44e-15	Neuroticism;
LUAD	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg24154853	chr7:158122151	PTPRN2	0.56	11.17	0.48	1.4e-25	Calcium levels;
LUAD	trans	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-10.37	-0.45	1.37e-22	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6430585	0.527	rs7592050	chr2:136459227	C/T	cg07169764	chr2:136633963	MCM6	-0.6	-7.13	-0.33	4.35e-12	Corneal structure;
LUAD	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-6.8	-0.31	3.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg01884057	chr2:25150051	NA	0.33	7.05	0.32	7.51e-12	Body mass index;
LUAD	cis	rs12530845	0.623	rs77454235	chr7:135341862	T/C	cg23117316	chr7:135346802	PL-5283	-0.58	-8.86	-0.4	2.17e-17	Red blood cell traits;
LUAD	cis	rs2455601	1.000	rs11042114	chr11:8919889	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-7.27	-0.33	1.73e-12	Schizophrenia;
LUAD	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.78	-0.43	1.63e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg13319975	chr6:146136371	FBXO30	0.57	9.58	0.42	8.47e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg01017244	chr2:74357527	NA	0.85	12.47	0.52	1.31e-30	Gestational age at birth (maternal effect);
LUAD	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg02734326	chr4:10020555	SLC2A9	0.5	8.83	0.39	2.85e-17	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg20476274	chr7:133979776	SLC35B4	0.55	9.02	0.4	6.8e-18	Mean platelet volume;
LUAD	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg23283495	chr1:209979779	IRF6	0.41	7.32	0.34	1.24e-12	Monobrow;
LUAD	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg12935359	chr14:103987150	CKB	0.51	7.9	0.36	2.47e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.96	0.36	1.58e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs656900	0.874	rs642697	chr15:80121160	C/T	cg02196730	chr15:80188777	MTHFS	-0.43	-6.89	-0.32	2.06e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs34311866	0.808	rs748483	chr4:952409	A/G	cg07828340	chr4:882639	GAK	1.01	10.28	0.45	2.74e-22	Parkinson's disease;
LUAD	cis	rs9323205	0.677	rs12586581	chr14:51722938	G/A	cg23942311	chr14:51606299	NA	-0.56	-8.55	-0.38	2.33e-16	Cancer;
LUAD	cis	rs7851660	0.967	rs4743134	chr9:100598568	C/A	cg13688889	chr9:100608707	NA	-0.52	-9.61	-0.42	6.33e-20	Strep throat;
LUAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07157834	chr1:205819609	PM20D1	0.73	14.11	0.57	2.44e-37	Menarche (age at onset);
LUAD	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.58	-0.52	4.6e-31	Platelet count;
LUAD	cis	rs9309473	0.607	rs6740173	chr2:73602266	C/G	cg20560298	chr2:73613845	ALMS1	-0.44	-6.83	-0.32	2.89e-11	Metabolite levels;
LUAD	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg23840854	chr1:161414152	NA	-0.91	-12.16	-0.51	2.15e-29	Rheumatoid arthritis;
LUAD	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg20476274	chr7:133979776	SLC35B4	0.84	16.84	0.63	4.66e-49	Mean platelet volume;
LUAD	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg00106254	chr7:1943704	MAD1L1	-0.45	-6.97	-0.32	1.25e-11	Schizophrenia;
LUAD	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg01802117	chr1:53393560	SCP2	-0.4	-7.59	-0.35	2.12e-13	Monocyte count;
LUAD	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.32	6.69	0.31	7.09e-11	Obesity-related traits;
LUAD	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg11742103	chr11:62369870	EML3;MTA2	0.58	11.28	0.48	5.46e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs829883	0.664	rs249833	chr12:98832189	T/C	cg25150519	chr12:98850993	NA	0.71	13.23	0.54	1.1e-33	Colorectal adenoma (advanced);
LUAD	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.91	-0.4	1.55e-17	Alcohol dependence;
LUAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03647317	chr4:187891568	NA	-0.36	-6.61	-0.31	1.16e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg13010199	chr12:38710504	ALG10B	0.39	6.49	0.3	2.47e-10	Bladder cancer;
LUAD	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg16102102	chr5:83017553	HAPLN1	-0.74	-12.43	-0.52	1.9e-30	Prostate cancer;
LUAD	cis	rs34172651	0.545	rs9302428	chr16:24717600	C/G	cg00339695	chr16:24857497	SLC5A11	-0.41	-7.35	-0.34	1.04e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7589728	0.516	rs79815126	chr2:88488270	G/A	cg14558114	chr2:88469736	THNSL2	0.81	7.07	0.33	6.3e-12	Plasma clusterin levels;
LUAD	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg11645453	chr3:52864694	ITIH4	-0.55	-10.12	-0.44	1.1e-21	Schizophrenia;
LUAD	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg11645453	chr3:52864694	ITIH4	-0.34	-6.47	-0.3	2.79e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs79996792	1.000	rs79996792	chr2:162443934	A/C	cg22496339	chr2:162101262	NA	0.53	6.85	0.32	2.66e-11	Neuroticism;
LUAD	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05776053	chr2:74358815	NA	0.45	7.18	0.33	3.08e-12	Gestational age at birth (maternal effect);
LUAD	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs9826463	0.582	rs73238185	chr3:142141177	T/C	cg20824294	chr3:142316082	PLS1	0.39	6.7	0.31	6.53e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg05283184	chr6:79620031	NA	-0.61	-12.24	-0.51	1.05e-29	Intelligence (multi-trait analysis);
LUAD	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.35	-18.12	-0.66	9.73e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.43	7.74	0.35	7.27e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.55	-0.3	1.66e-10	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs743757	0.938	rs2236959	chr3:50441627	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	7.26	0.33	1.92e-12	Diastolic blood pressure;
LUAD	cis	rs1950626	0.833	rs35151884	chr14:101394196	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.37	7.09	0.33	5.77e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg20135002	chr11:47629003	NA	-0.42	-7.38	-0.34	8.73e-13	Subjective well-being;
LUAD	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14159672	chr1:205819179	PM20D1	0.51	8.67	0.39	9.44e-17	Menarche (age at onset);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07007080	chr20:44718510	NCOA5	-0.68	-6.65	-0.31	9.33e-11	Type 2 diabetes;
LUAD	cis	rs11098699	0.821	rs13109534	chr4:124211262	T/C	cg09941581	chr4:124220074	SPATA5	0.49	7.96	0.36	1.55e-14	Mosquito bite size;
LUAD	cis	rs1160297	0.576	rs724859	chr2:53099305	C/T	cg07782112	chr2:53107842	NA	0.42	9.14	0.41	2.62e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg06784218	chr1:46089804	CCDC17	0.35	7.61	0.35	1.78e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.59	-12.55	-0.52	6.51e-31	Monocyte percentage of white cells;
LUAD	cis	rs490234	0.841	rs7856366	chr9:128442229	A/G	cg14078157	chr9:128172775	NA	-0.4	-7.17	-0.33	3.37e-12	Mean arterial pressure;
LUAD	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg18306943	chr3:40428807	ENTPD3	-0.37	-6.49	-0.3	2.42e-10	Renal cell carcinoma;
LUAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg02951883	chr7:2050386	MAD1L1	-0.71	-11.76	-0.5	7.89e-28	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg24642844	chr7:1081250	C7orf50	-0.96	-14.39	-0.57	1.62e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg03929089	chr4:120376271	NA	-0.93	-17.48	-0.65	6.84e-52	Height;
LUAD	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg05342682	chr7:94953680	PON1	-0.52	-7.4	-0.34	7.2e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	10.54	0.46	3.29e-23	Type 2 diabetes;
LUAD	cis	rs7264396	0.563	rs78084033	chr20:34219990	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-7.25	-0.33	2e-12	Total cholesterol levels;
LUAD	cis	rs7487075	0.619	rs4768724	chr12:46848416	C/T	cg23829395	chr12:46796953	NA	0.32	7.01	0.32	9.7e-12	Itch intensity from mosquito bite;
LUAD	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg02683114	chr2:24398427	C2orf84	-0.44	-7.07	-0.33	6.37e-12	Asthma;
LUAD	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg13180566	chr4:1052158	NA	0.39	6.62	0.31	1.08e-10	Recombination rate (females);
LUAD	cis	rs4851254	0.660	rs35869550	chr2:100684578	T/A	cg04109781	chr2:100722022	AFF3	0.36	6.38	0.3	4.67e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21659725	chr3:3221576	CRBN	0.5	8.29	0.37	1.49e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.08	-0.33	6e-12	Total body bone mineral density;
LUAD	cis	rs220324	0.688	rs9637293	chr21:43570977	G/A	cg09727148	chr21:43560719	UMODL1	0.52	7.94	0.36	1.84e-14	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg13870426	chr17:30244630	NA	-0.55	-6.45	-0.3	3.15e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg23231163	chr10:75533350	FUT11	-0.51	-9.37	-0.41	4.29e-19	Inflammatory bowel disease;
LUAD	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg00530320	chr1:46809349	NSUN4	0.52	8.14	0.37	4.49e-15	Menopause (age at onset);
LUAD	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg22676075	chr6:135203613	NA	0.55	9.78	0.43	1.64e-20	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg21724239	chr8:58056113	NA	0.8	9.74	0.43	2.34e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16577540	chr5:139682757	PFDN1	-0.52	-6.45	-0.3	3.13e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2971970	0.539	rs2971972	chr7:133644200	A/G	cg03336402	chr7:133662267	EXOC4	-0.41	-7.54	-0.34	2.89e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.78	-0.5	6.8e-28	Mean corpuscular volume;
LUAD	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg25985355	chr7:65971099	NA	-0.54	-6.71	-0.31	6.19e-11	Diabetic kidney disease;
LUAD	cis	rs2882667	0.931	rs10069528	chr5:138354027	A/G	cg04439458	chr5:138467593	SIL1	-0.39	-7.03	-0.32	8.24e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs2834485	1.000	rs2834484	chr21:35816941	G/T	cg07474852	chr4:123073612	NA	-0.54	-8.31	-0.37	1.32e-15	Cancer;
LUAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg15242686	chr22:24348715	GSTTP1	0.4	6.72	0.31	5.74e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg21963583	chr11:68658836	MRPL21	0.68	11.82	0.5	4.83e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg04756594	chr16:24857601	SLC5A11	-0.52	-10.0	-0.44	2.8e-21	Intelligence (multi-trait analysis);
LUAD	trans	rs2797160	1.000	rs4897152	chr6:126002400	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.65	-0.39	1.08e-16	Endometrial cancer;
LUAD	cis	rs60780116	1	rs60780116	chr4:185708807	T/C	cg04058563	chr4:185651563	MLF1IP	0.54	7.6	0.35	1.91e-13	Type 2 diabetes;
LUAD	cis	rs708547	0.647	rs12621	chr4:57897570	G/T	cg00922110	chr4:57842668	C4orf14	-0.42	-7.87	-0.36	2.95e-14	Response to bleomycin (chromatid breaks);
LUAD	trans	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-31.26	-0.84	5.19e-112	Exhaled nitric oxide output;
LUAD	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs7123876	0.553	rs12099027	chr11:72433920	A/G	cg04827223	chr11:72435913	ARAP1	-0.54	-10.38	-0.45	1.25e-22	Body mass index;
LUAD	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg03929089	chr4:120376271	NA	0.83	15.23	0.6	4.6e-42	Coronary artery disease;
LUAD	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg20587970	chr11:113659929	NA	-1.38	-20.91	-0.71	3.54e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg16060761	chr17:80687452	NA	0.49	7.4	0.34	7.57e-13	Breast cancer;
LUAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.58	-7.29	-0.33	1.52e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.72	-13.3	-0.54	5.59e-34	Menarche (age at onset);
LUAD	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg18305652	chr10:134549665	INPP5A	0.61	12.9	0.53	2.47e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	18.01	0.66	3.11e-54	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3087591	0.919	rs2285892	chr17:29553485	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.4	-6.54	-0.3	1.82e-10	Hip circumference;
LUAD	cis	rs1062177	0.855	rs6892117	chr5:151264985	C/T	cg14319409	chr5:151304409	GLRA1	-0.32	-6.7	-0.31	6.51e-11	Preschool internalizing problems;
LUAD	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg21724239	chr8:58056113	NA	0.66	8.13	0.37	4.93e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6840360	0.509	rs62327273	chr4:152547594	A/G	cg22705602	chr4:152727874	NA	-0.41	-7.11	-0.33	5.05e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg19761014	chr17:28927070	LRRC37B2	0.86	8.32	0.38	1.22e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs9951602	0.512	rs6506868	chr18:76642559	C/G	cg02800362	chr5:177631904	HNRNPAB	0.92	14.18	0.57	1.25e-37	Obesity-related traits;
LUAD	cis	rs11811982	0.793	rs77291093	chr1:227498752	G/T	cg24860534	chr1:227506868	CDC42BPA	0.71	7.5	0.34	3.79e-13	Optic disc area;
LUAD	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10802521	chr3:52805072	NEK4	-0.54	-9.0	-0.4	7.68e-18	Bipolar disorder;
LUAD	cis	rs2282300	0.739	rs34044331	chr11:30264486	T/C	cg25418670	chr11:30344373	C11orf46	-0.54	-7.46	-0.34	5.03e-13	Morning vs. evening chronotype;
LUAD	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg24069376	chr3:38537580	EXOG	-0.32	-7.36	-0.34	9.45e-13	Electrocardiographic conduction measures;
LUAD	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg09021430	chr5:549028	NA	-0.69	-14.49	-0.58	6.3e-39	Obesity-related traits;
LUAD	cis	rs13064411	0.627	rs9825827	chr3:113182231	T/C	cg18753928	chr3:113234510	CCDC52	-0.67	-11.61	-0.49	3.15e-27	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs62229266	0.659	rs2255734	chr21:37411909	T/C	cg08632701	chr21:37451849	NA	-0.38	-6.44	-0.3	3.3e-10	Mitral valve prolapse;
LUAD	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg24112000	chr20:60950667	NA	0.72	12.06	0.51	5.23e-29	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7202877	0.706	rs37602	chr16:75505046	C/T	cg03315344	chr16:75512273	CHST6	-0.5	-6.92	-0.32	1.69e-11	Type 2 diabetes;Type 1 diabetes;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg02985366	chr16:32360428	NA	-0.4	-7.01	-0.32	9.47e-12	Menopause (age at onset);
LUAD	cis	rs4853036	0.672	rs35293234	chr2:70025165	C/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-6.69	-0.31	7.04e-11	Colorectal or endometrial cancer;
LUAD	cis	rs2046867	0.862	rs67961837	chr3:72840877	T/G	cg25664220	chr3:72788482	NA	-0.69	-12.37	-0.52	3.17e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-9.63	-0.42	5.71e-20	Brugada syndrome;
LUAD	cis	rs225245	0.791	rs7216391	chr17:34024706	G/A	cg05299278	chr17:33885742	SLFN14	0.5	11.24	0.48	7.66e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg00802000	chr16:706648	WDR90	-0.44	-8.08	-0.37	6.9e-15	Height;
LUAD	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg26384229	chr12:38710491	ALG10B	0.44	7.28	0.33	1.68e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg10057126	chr4:77819792	ANKRD56	0.54	9.31	0.41	6.89e-19	Emphysema distribution in smoking;
LUAD	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.37	0.3	5e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg08132940	chr7:1081526	C7orf50	-0.77	-10.29	-0.45	2.49e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35995292	0.500	rs28369620	chr7:38921872	C/T	cg19327137	chr7:38886074	VPS41	0.72	14.58	0.58	2.61e-39	Subjective well-being (multi-trait analysis);
LUAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg11062466	chr8:58055876	NA	0.68	8.94	0.4	1.25e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10050877	chr8:130952333	FAM49B	-0.42	-6.57	-0.3	1.52e-10	Height;
LUAD	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg14779329	chr11:130786720	SNX19	0.37	6.5	0.3	2.28e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs9348739	1	rs9348739	chr6:26923099	G/C	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.05	-0.32	7.45e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg18944383	chr4:111397179	ENPEP	0.38	7.82	0.36	4.3e-14	Height;
LUAD	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg04398451	chr17:18023971	MYO15A	-0.65	-11.71	-0.49	1.3e-27	Total body bone mineral density;
LUAD	cis	rs907683	0.545	rs3755054	chr2:220280974	C/T	cg15015639	chr2:220282977	DES	0.5	9.2	0.41	1.66e-18	Resting heart rate;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16276070	chr19:58070951	NA	-0.39	-6.82	-0.31	3.14e-11	Cancer;
LUAD	cis	rs1485394	0.778	rs2280448	chr12:53896984	G/A	cg20730629	chr12:53886622	MAP3K12	-0.51	-7.43	-0.34	5.87e-13	Electroencephalogram traits;
LUAD	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg21194808	chr1:2205498	SKI	-0.4	-6.62	-0.31	1.12e-10	Height;
LUAD	cis	rs59698941	0.943	rs10491277	chr5:132236361	G/C	cg14825688	chr5:132208181	LEAP2	-0.47	-6.7	-0.31	6.52e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs7173743	0.756	rs12903668	chr15:79129320	A/G	cg15571903	chr15:79123663	NA	0.4	7.85	0.36	3.55e-14	Coronary artery disease;
LUAD	cis	rs5771069	0.931	rs5771222	chr22:50445704	C/T	cg27467552	chr22:50353597	PIM3	0.46	8.52	0.38	2.8e-16	Ulcerative colitis;
LUAD	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg23625390	chr15:77176239	SCAPER	0.4	6.87	0.32	2.24e-11	Blood metabolite levels;
LUAD	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg23587288	chr2:27483067	SLC30A3	-0.4	-7.23	-0.33	2.22e-12	Blood metabolite levels;
LUAD	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg25985355	chr7:65971099	NA	0.54	6.74	0.31	5.2e-11	Diabetic kidney disease;
LUAD	cis	rs11893307	0.566	rs7558832	chr2:191560589	T/C	cg27211696	chr2:191398769	TMEM194B	-0.43	-6.71	-0.31	6.31e-11	Mean platelet volume;
LUAD	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg27433088	chr4:174089019	GALNT7	0.39	7.58	0.35	2.22e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs7084921	0.548	rs12776483	chr10:101828600	C/A	cg19754520	chr10:101825118	CPN1	-0.35	-7.1	-0.33	5.34e-12	Bone mineral density;
LUAD	cis	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg21775007	chr8:11205619	TDH	0.4	6.72	0.31	5.99e-11	Neuroticism;
LUAD	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg15448220	chr1:150897856	SETDB1	0.49	8.48	0.38	3.87e-16	Tonsillectomy;
LUAD	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg02696790	chr15:75250997	RPP25	0.35	6.96	0.32	1.28e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs57590327	0.555	rs6767749	chr3:81725513	G/A	cg07356753	chr3:81810745	GBE1	-0.61	-9.79	-0.43	1.57e-20	Extraversion;
LUAD	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25427524	chr10:38739819	LOC399744	-0.78	-14.0	-0.56	7.04e-37	Extrinsic epigenetic age acceleration;
LUAD	cis	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg06360820	chr2:242988706	NA	-0.98	-9.8	-0.43	1.45e-20	Obesity-related traits;
LUAD	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg23758822	chr17:41437982	NA	0.99	20.41	0.7	5.72e-65	Menopause (age at onset);
LUAD	cis	rs1030877	0.515	rs2576741	chr2:105897964	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.41	6.63	0.31	1.03e-10	Obesity-related traits;
LUAD	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg06640241	chr16:89574553	SPG7	0.64	10.67	0.46	1.09e-23	Multiple myeloma (IgH translocation);
LUAD	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg03929089	chr4:120376271	NA	-0.88	-17.1	-0.64	3.36e-50	Height;
LUAD	cis	rs240764	0.658	rs9399685	chr6:101204318	C/G	cg09795085	chr6:101329169	ASCC3	-0.42	-7.38	-0.34	8.74e-13	Neuroticism;
LUAD	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.54	7.57	0.35	2.36e-13	Schizophrenia;
LUAD	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.48	0.42	1.89e-19	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg07217954	chr7:1067459	C7orf50	0.43	6.61	0.31	1.14e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg05754148	chr16:3507555	NAT15	0.46	7.21	0.33	2.62e-12	Body mass index (adult);
LUAD	trans	rs9408928	0.778	rs9409230	chr9:123967760	A/T	cg13390975	chr5:34915890	BRIX1;RAD1	0.65	6.55	0.3	1.69e-10	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg22105103	chr4:187893119	NA	0.57	12.61	0.52	3.6e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.61	0.35	1.75e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg25767906	chr1:53392781	SCP2	0.41	7.53	0.34	3e-13	Monocyte count;
LUAD	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg05283184	chr6:79620031	NA	-0.44	-7.68	-0.35	1.08e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg04775059	chr7:64541387	NA	0.51	6.71	0.31	6.44e-11	Aortic root size;
LUAD	cis	rs7843479	0.965	rs11135742	chr8:21802910	A/T	cg03445287	chr8:21823731	XPO7	-0.47	-8.61	-0.39	1.5e-16	Mean corpuscular volume;
LUAD	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.63	0.31	1.03e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg06740227	chr12:86229804	RASSF9	0.44	7.57	0.35	2.34e-13	Major depressive disorder;
LUAD	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg21709803	chr11:61594965	FADS2	-0.64	-9.19	-0.41	1.8e-18	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg03929089	chr4:120376271	NA	0.57	7.18	0.33	3.21e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9921222	0.509	rs2301522	chr16:359953	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.41	-6.64	-0.31	9.84e-11	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg24642844	chr7:1081250	C7orf50	-0.98	-14.73	-0.58	5.99e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9467773	1.000	rs12665431	chr6:26577308	T/A	cg11502198	chr6:26597334	ABT1	0.6	9.93	0.43	4.95e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg13560548	chr3:10150139	C3orf24	0.45	7.49	0.34	4.18e-13	Alzheimer's disease;
LUAD	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg21427119	chr20:30132790	HM13	-0.62	-9.41	-0.42	3.2e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.15	-0.37	4.24e-15	Cannabis dependence symptom count;
LUAD	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg20991723	chr1:152506922	NA	0.32	6.36	0.3	5.2400000000000005e-10	Hair morphology;
LUAD	cis	rs599083	0.829	rs23691	chr11:68178668	G/A	cg16797656	chr11:68205561	LRP5	-0.46	-9.05	-0.4	5.08e-18	Bone mineral density (spine);
LUAD	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg20503657	chr10:835505	NA	0.83	12.83	0.53	4.77e-32	Eosinophil percentage of granulocytes;
LUAD	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg00898013	chr13:113819073	PROZ	-0.81	-14.92	-0.59	9.16e-41	Platelet distribution width;
LUAD	cis	rs220324	0.688	rs9979344	chr21:43559926	C/T	cg09727148	chr21:43560719	UMODL1	0.58	8.83	0.39	2.72e-17	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7107174	0.792	rs10899488	chr11:78088754	A/G	cg02023728	chr11:77925099	USP35	0.44	6.89	0.32	1.97e-11	Testicular germ cell tumor;
LUAD	cis	rs4481887	0.732	rs4526647	chr1:248423788	C/G	cg00666640	chr1:248458726	OR2T12	0.32	7.66	0.35	1.27e-13	Common traits (Other);
LUAD	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg18811423	chr2:55921094	PNPT1	0.51	8.5	0.38	3.24e-16	Metabolic syndrome;
LUAD	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.49	-9.52	-0.42	1.38e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03452623	chr4:187889614	NA	-0.81	-16.44	-0.62	2.5e-47	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03934478	chr11:495069	RNH1	0.78	9.87	0.43	8.47e-21	Body mass index;
LUAD	cis	rs7107174	0.748	rs11237458	chr11:78050849	A/T	cg19901956	chr11:77921274	USP35	-0.5	-7.15	-0.33	3.93e-12	Testicular germ cell tumor;
LUAD	trans	rs1973993	0.544	rs2800427	chr1:97002766	A/C	cg10631902	chr5:14652156	NA	0.61	11.68	0.49	1.69e-27	Weight;
LUAD	cis	rs10203711	0.932	rs4502365	chr2:239597792	G/A	cg14580085	chr2:239553406	NA	0.41	8.67	0.39	9.05e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg08999081	chr20:33150536	PIGU	0.48	9.16	0.41	2.2e-18	Coronary artery disease;
LUAD	trans	rs2735413	0.875	rs4888736	chr16:78083784	T/C	cg01028844	chr5:122736986	CEP120	0.41	6.46	0.3	2.87e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	trans	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg01620082	chr3:125678407	NA	-0.46	-6.69	-0.31	7.12e-11	Depression;
LUAD	cis	rs790123	1.000	rs790116	chr3:122380923	G/C	cg15604389	chr3:122379662	NA	0.48	8.39	0.38	7.59e-16	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7937890	0.559	rs1116739	chr11:14489182	G/C	cg23387056	chr11:14280742	SPON1	-0.35	-6.9	-0.32	1.87e-11	Mitochondrial DNA levels;
LUAD	trans	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg18335740	chr13:41363409	SLC25A15	-0.6	-11.26	-0.48	6.54e-26	Lewy body disease;
LUAD	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg15309053	chr8:964076	NA	0.33	7.26	0.33	1.9e-12	Schizophrenia;
LUAD	cis	rs17826219	0.733	rs7221691	chr17:28723619	C/T	cg17105886	chr17:28927953	LRRC37B2	-0.68	-6.71	-0.31	6.31e-11	Body mass index;
LUAD	cis	rs4947962	0.590	rs759171	chr7:55086212	A/C	cg23757825	chr7:55092271	EGFR	0.52	6.92	0.32	1.71e-11	Subjective response to lithium treatment;
LUAD	cis	rs2657888	1.000	rs7310284	chr12:56935652	A/G	cg23002907	chr12:56915593	RBMS2	0.35	6.45	0.3	2.99e-10	Adiponectin levels;
LUAD	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg00277334	chr10:82204260	NA	-0.57	-9.47	-0.42	2.07e-19	Post bronchodilator FEV1;
LUAD	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg02551604	chr5:131831745	NA	-0.46	-7.7	-0.35	1e-13	Breast cancer;Mosquito bite size;
LUAD	trans	rs2018683	0.707	rs10279610	chr7:28975696	C/G	cg19402173	chr7:128379420	CALU	0.51	8.38	0.38	8.11e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg04414720	chr1:150670196	GOLPH3L	0.71	12.26	0.51	8.51e-30	Melanoma;
LUAD	cis	rs2073300	1.000	rs12625160	chr20:23442008	T/C	cg09953122	chr20:23471693	CST8	-0.65	-6.39	-0.3	4.29e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs3812762	0.957	rs10160684	chr11:8775419	G/A	cg03980550	chr11:8754370	ST5	0.38	6.59	0.31	1.33e-10	Hypospadias;
LUAD	trans	rs10802346	0.514	rs5024440	chr1:246372608	G/C	cg22732515	chr19:44031385	ETHE1	0.58	9.39	0.42	3.7e-19	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg15556689	chr8:8085844	FLJ10661	0.4	6.37	0.3	5e-10	Neuroticism;
LUAD	cis	rs9462027	0.628	rs2764198	chr6:34706128	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.02	-0.4	6.62e-18	Systemic lupus erythematosus;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg05064044	chr6:292385	DUSP22	-0.8	-13.54	-0.55	5.68e-35	Menopause (age at onset);
LUAD	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.46	0.3	2.84e-10	Cardiac Troponin-T levels;
LUAD	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg25324976	chr17:61989376	CSHL1	0.36	7.04	0.32	7.72e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg25894440	chr7:65020034	NA	-0.63	-6.7	-0.31	6.72e-11	Diabetic kidney disease;
LUAD	cis	rs4888262	0.508	rs7189123	chr16:74540097	C/A	cg01733217	chr16:74700730	RFWD3	0.49	8.25	0.37	2.09e-15	Testicular germ cell tumor;
LUAD	cis	rs68170813	0.559	rs17429118	chr7:106964052	C/T	cg23024343	chr7:107201750	COG5	0.49	6.91	0.32	1.8e-11	Coronary artery disease;
LUAD	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg05082376	chr22:42548792	NA	0.43	7.63	0.35	1.61e-13	Schizophrenia;
LUAD	cis	rs7737355	0.812	rs31241	chr5:130808198	T/C	cg06307176	chr5:131281290	NA	0.42	6.98	0.32	1.13e-11	Life satisfaction;
LUAD	cis	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg11266682	chr4:10021025	SLC2A9	0.4	6.57	0.3	1.48e-10	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.79	0.39	3.74e-17	Menopause (age at onset);
LUAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg12016809	chr21:47604291	C21orf56	0.6	10.27	0.45	2.96e-22	Testicular germ cell tumor;
LUAD	cis	rs12135894	0.648	rs4648423	chr1:3765678	C/T	cg18436788	chr1:3704244	LRRC47	-0.3	-6.93	-0.32	1.54e-11	Mean corpuscular volume;
LUAD	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg18138036	chr10:133769891	PPP2R2D	0.42	6.86	0.32	2.43e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.53	-0.52	7.37e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs3820068	0.608	rs11544523	chr1:15904318	C/T	cg24675056	chr1:15929824	NA	0.42	6.7	0.31	6.67e-11	Systolic blood pressure;
LUAD	cis	rs4653767	1.000	rs708773	chr1:226920730	T/C	cg05049329	chr1:226924846	ITPKB	0.45	7.95	0.36	1.73e-14	Parkinson's disease;
LUAD	cis	rs12208915	0.708	rs9361481	chr6:79726750	T/A	cg09184832	chr6:79620586	NA	0.53	7.55	0.34	2.77e-13	Left atrial antero-posterior diameter;
LUAD	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.96	-0.36	1.63e-14	Neutrophil percentage of white cells;
LUAD	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg12923728	chr3:195709715	SDHAP1	0.45	6.83	0.32	2.99e-11	Mean corpuscular volume;
LUAD	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg00316803	chr15:76480434	C15orf27	-0.39	-7.3	-0.33	1.48e-12	Blood metabolite levels;
LUAD	cis	rs790123	0.933	rs1092556	chr3:122387354	T/G	cg22896480	chr3:122379438	NA	0.46	7.83	0.36	3.95e-14	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg09997546	chr11:8931473	C11orf17;ST5	0.37	7.6	0.35	1.95e-13	Hemoglobin concentration;
LUAD	cis	rs7680126	0.500	rs4697935	chr4:10149593	C/T	cg02734326	chr4:10020555	SLC2A9	-0.47	-6.35	-0.3	5.43e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg06002616	chr8:101225028	SPAG1	0.36	7.31	0.34	1.31e-12	Atrioventricular conduction;
LUAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg22907277	chr7:1156413	C7orf50	0.58	10.54	0.46	3.14e-23	Longevity;Endometriosis;
LUAD	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg00318621	chr2:106887213	NA	-0.42	-6.6	-0.31	1.2e-10	Facial morphology (factor 23);
LUAD	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg00431813	chr7:1051703	C7orf50	-0.4	-7.6	-0.35	1.94e-13	Longevity;Endometriosis;
LUAD	cis	rs2455601	0.608	rs1368017	chr11:8867070	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-8.1	-0.37	5.93e-15	Schizophrenia;
LUAD	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg16479474	chr6:28041457	NA	0.38	6.57	0.3	1.51e-10	Parkinson's disease;
LUAD	cis	rs9951698	0.518	rs475438	chr18:13073641	C/T	cg12848697	chr18:13133368	NA	0.35	6.71	0.31	6.43e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22968622	chr17:43663579	NA	-1.18	-19.73	-0.69	6.31e-62	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6138458	1.000	rs227631	chr20:24913653	A/G	cg06937882	chr20:24974362	C20orf3	-0.32	-6.35	-0.3	5.42e-10	Blood protein levels;
LUAD	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg20307385	chr11:47447363	PSMC3	0.7	11.65	0.49	2.06e-27	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs733592	0.504	rs2261608	chr12:48721634	A/T	cg24011408	chr12:48396354	COL2A1	0.34	7.15	0.33	3.86e-12	Plateletcrit;
LUAD	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg07917127	chr4:99064746	C4orf37	0.42	6.97	0.32	1.24e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.853	rs31586	chr5:131000696	A/G	cg06307176	chr5:131281290	NA	0.45	7.42	0.34	6.58e-13	Life satisfaction;
LUAD	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg09835421	chr16:68378352	PRMT7	-0.83	-8.99	-0.4	8.54e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg18105134	chr13:113819100	PROZ	-0.8	-14.09	-0.57	3.1e-37	Platelet distribution width;
LUAD	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg05665937	chr4:1216051	CTBP1	0.47	7.08	0.33	6.03e-12	Longevity;
LUAD	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg18404041	chr3:52824283	ITIH1	-0.67	-14.77	-0.58	4.15e-40	Bipolar disorder;
LUAD	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.1	-0.37	5.89e-15	Diabetic kidney disease;
LUAD	cis	rs7746199	0.736	rs13193480	chr6:27702561	A/G	cg26958806	chr6:27640298	NA	0.64	6.53	0.3	1.91e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs757110	0.526	rs757081	chr11:17351683	C/G	cg15432903	chr11:17409602	KCNJ11	-0.46	-8.08	-0.37	7.03e-15	Type 2 diabetes;
LUAD	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg15921436	chr17:44337874	NA	0.79	10.09	0.44	1.35e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs55823223	0.648	rs66584478	chr17:73870203	G/A	cg04225089	chr17:73874465	TRIM47	-0.38	-6.57	-0.3	1.5e-10	Psoriasis;
LUAD	trans	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg13565492	chr6:43139072	SRF	-0.74	-10.12	-0.44	1.05e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9914988	0.673	rs12325788	chr17:27080049	G/A	cg20469991	chr17:27169893	C17orf63	-0.49	-6.46	-0.3	2.94e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg00634984	chr7:65235879	NA	0.47	6.49	0.3	2.39e-10	Aortic root size;
LUAD	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.51	-0.38	3e-16	Height;
LUAD	cis	rs10899021	0.790	rs12296094	chr11:74321700	C/T	cg25880958	chr11:74394337	NA	-0.6	-8.13	-0.37	4.75e-15	Response to metformin (IC50);
LUAD	trans	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg26043149	chr18:55253948	FECH	1.04	17.62	0.65	1.68e-52	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7731657	0.537	rs10520092	chr5:130202197	C/T	cg08523029	chr5:130500466	HINT1	0.54	6.99	0.32	1.07e-11	Fasting plasma glucose;
LUAD	cis	rs240764	0.604	rs9404016	chr6:101177728	G/A	cg09795085	chr6:101329169	ASCC3	0.44	7.9	0.36	2.46e-14	Neuroticism;
LUAD	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.55	0.58	3.73e-39	Schizophrenia;
LUAD	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg05340658	chr4:99064831	C4orf37	0.47	7.07	0.33	6.42e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.641	rs79434636	chr7:107105656	A/C	cg02696742	chr7:106810147	HBP1	-0.79	-10.58	-0.46	2.33e-23	Coronary artery disease;
LUAD	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg06640241	chr16:89574553	SPG7	0.53	8.79	0.39	3.71e-17	Multiple myeloma (IgH translocation);
LUAD	trans	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg26043149	chr18:55253948	FECH	0.49	7.88	0.36	2.85e-14	Bone mineral density;
LUAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg23958373	chr8:599963	NA	1.06	10.47	0.45	5.85e-23	IgG glycosylation;
LUAD	trans	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg01620082	chr3:125678407	NA	-0.88	-8.81	-0.39	3.38e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg10518543	chr12:38710700	ALG10B	-0.44	-7.24	-0.33	2.11e-12	Bladder cancer;
LUAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.91	-0.36	2.34e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs7395662	1.000	rs4882111	chr11:48558447	G/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.75e-10	HDL cholesterol;
LUAD	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg06784218	chr1:46089804	CCDC17	0.59	13.35	0.54	3.53e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.55	7.84	0.36	3.77e-14	Platelet count;
LUAD	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg02549819	chr16:58548995	SETD6	0.79	6.48	0.3	2.59e-10	Schizophrenia;
LUAD	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg10876282	chr6:28092338	ZSCAN16	0.46	7.15	0.33	3.89e-12	Cardiac Troponin-T levels;
LUAD	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg18854424	chr1:2615690	NA	0.42	9.16	0.41	2.21e-18	Ulcerative colitis;
LUAD	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19346786	chr7:2764209	NA	0.56	12.32	0.51	5.04e-30	Height;
LUAD	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg00339695	chr16:24857497	SLC5A11	-0.65	-10.36	-0.45	1.42e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg06558623	chr16:89946397	TCF25	1.15	10.6	0.46	1.96e-23	Skin colour saturation;
LUAD	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.67	0.39	9.26e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.91	-0.36	2.34e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.527	rs10943588	chr6:79510994	A/C	cg05283184	chr6:79620031	NA	-0.42	-7.43	-0.34	6.04e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs10746514	0.813	rs9724918	chr1:232248087	C/T	cg09506761	chr1:232265262	NA	0.41	7.78	0.35	5.56e-14	Response to statin therapy;
LUAD	cis	rs9837602	1.000	rs35844878	chr3:99796626	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.45	-6.68	-0.31	7.39e-11	Breast cancer;
LUAD	cis	rs921968	0.643	rs1344645	chr2:219538019	A/C	cg02176678	chr2:219576539	TTLL4	0.59	11.49	0.49	8.77e-27	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg03115547	chr19:32836416	ZNF507	-0.39	-6.42	-0.3	3.69e-10	Subcortical brain region volumes;
LUAD	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10821973	0.527	rs4381270	chr10:63995658	G/A	cg09941381	chr10:64027924	RTKN2	-0.34	-6.77	-0.31	4.23e-11	Hypothyroidism;
LUAD	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg06784218	chr1:46089804	CCDC17	0.6	13.37	0.54	3.03e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg27129171	chr3:47204927	SETD2	0.45	7.27	0.33	1.71e-12	Colorectal cancer;
LUAD	cis	rs986417	0.901	rs1950312	chr14:60989784	A/G	cg27398547	chr14:60952738	C14orf39	-0.67	-8.32	-0.38	1.2e-15	Gut microbiota (bacterial taxa);
LUAD	cis	rs62238980	0.614	rs117002438	chr22:32371395	G/A	cg00543991	chr22:32367038	NA	0.91	8.21	0.37	2.8e-15	Childhood ear infection;
LUAD	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg21427119	chr20:30132790	HM13	-0.47	-7.62	-0.35	1.63e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg24154853	chr7:158122151	PTPRN2	0.49	8.09	0.37	6.54e-15	Response to amphetamines;
LUAD	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg02269571	chr22:50332266	NA	-0.68	-9.85	-0.43	9.49e-21	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.47	0.3	2.73e-10	Breast cancer;
LUAD	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg21475434	chr5:93447410	FAM172A	0.75	8.4	0.38	6.97e-16	Diabetic retinopathy;
LUAD	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg07570687	chr10:102243282	WNT8B	0.46	7.06	0.32	6.77e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs2580764	0.573	rs13387751	chr2:55227375	C/G	cg09592903	chr2:55203963	RTN4	-0.46	-10.61	-0.46	1.71e-23	Mean platelet volume;
LUAD	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg26384229	chr12:38710491	ALG10B	-0.48	-8.0	-0.36	1.23e-14	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg03467027	chr4:99064603	C4orf37	0.39	6.45	0.3	3.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1232027	0.666	rs1643634	chr5:79927899	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.82	-0.36	4.32e-14	Huntington's disease progression;
LUAD	cis	rs7737355	1.000	rs6596010	chr5:130625411	G/A	cg25547332	chr5:131281432	NA	0.41	6.44	0.3	3.22e-10	Life satisfaction;
LUAD	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg00852783	chr1:26633632	UBXN11	0.43	7.58	0.35	2.16e-13	Obesity-related traits;
LUAD	cis	rs938554	0.784	rs13131257	chr4:9981889	T/C	cg00071950	chr4:10020882	SLC2A9	0.53	8.24	0.37	2.21e-15	Blood metabolite levels;
LUAD	cis	rs7945705	0.846	rs11042055	chr11:8756856	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.49	8.73	0.39	5.88e-17	Hemoglobin concentration;
LUAD	cis	rs11098699	0.821	rs13141181	chr4:124212126	G/A	cg09941581	chr4:124220074	SPATA5	0.49	7.92	0.36	2.14e-14	Mosquito bite size;
LUAD	cis	rs72928364	0.860	rs34281790	chr3:100790767	G/A	cg10123952	chr3:100791384	NA	0.73	7.96	0.36	1.6e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7617773	0.817	rs11707606	chr3:48237087	A/C	cg11946769	chr3:48343235	NME6	0.41	6.41	0.3	3.78e-10	Coronary artery disease;
LUAD	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg08885076	chr2:99613938	TSGA10	0.37	6.61	0.31	1.13e-10	Chronic sinus infection;
LUAD	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg22676075	chr6:135203613	NA	0.53	9.56	0.42	1e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs6445967	0.545	rs62259319	chr3:58290358	T/C	cg13750441	chr3:58318267	PXK	-0.3	-6.37	-0.3	4.84e-10	Platelet count;
LUAD	cis	rs12541635	0.639	rs6469030	chr8:107030321	C/T	cg10147462	chr8:107024639	NA	0.55	9.74	0.43	2.35e-20	Age of smoking initiation;
LUAD	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg25324976	chr17:61989376	CSHL1	0.42	7.9	0.36	2.41e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11890956	chr21:40555474	PSMG1	0.75	12.56	0.52	5.54e-31	Cognitive function;
LUAD	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.75e-11	Crohn's disease;
LUAD	cis	rs910187	0.678	rs1046667	chr20:45817255	A/C	cg27589058	chr20:45804311	EYA2	-0.3	-6.92	-0.32	1.66e-11	Migraine;
LUAD	cis	rs6785206	1.000	rs2712370	chr3:128425204	C/G	cg16766828	chr3:128327626	NA	-0.79	-8.56	-0.38	2.17e-16	Lymphocyte percentage of white cells;
LUAD	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg18827107	chr12:86230957	RASSF9	-0.69	-12.69	-0.53	1.71e-31	Major depressive disorder;
LUAD	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	21.6	0.72	2.81e-70	Chronic sinus infection;
LUAD	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.7	-11.8	-0.5	5.59e-28	Primary sclerosing cholangitis;
LUAD	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg27494647	chr7:150038898	RARRES2	0.41	6.64	0.31	9.5e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7680126	0.633	rs4698040	chr4:10352550	C/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-7.43	-0.34	6.21e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11674184	0.743	rs12470971	chr2:11725241	A/G	cg07314298	chr2:11723111	GREB1	0.81	17.34	0.64	2.78e-51	Endometriosis;
LUAD	cis	rs1018836	0.923	rs2023626	chr8:91619264	G/T	cg16814680	chr8:91681699	NA	0.66	10.94	0.47	1.07e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs9393777	0.844	rs72839477	chr6:27327000	C/T	cg06606381	chr12:133084897	FBRSL1	-1.1	-9.63	-0.42	5.82e-20	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07556730	chr11:679706	DEAF1	0.52	6.6	0.31	1.26e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs886126	0.853	rs4766558	chr12:111664061	T/G	cg10833066	chr12:111807467	FAM109A	0.58	10.69	0.46	8.76e-24	Coronary heart disease;
LUAD	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg07917127	chr4:99064746	C4orf37	0.4	6.5	0.3	2.22e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.817	rs2617881	chr17:28063275	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.57	-0.42	9.4e-20	Coffee consumption (cups per day);
LUAD	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24308560	chr3:49941425	MST1R	-0.56	-9.43	-0.42	2.65e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs593982	0.920	rs1151501	chr11:65484883	A/G	cg08755490	chr11:65554678	OVOL1	1.26	14.86	0.59	1.78e-40	Atopic dermatitis;
LUAD	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg01475377	chr6:109611718	NA	-0.5	-9.41	-0.42	3.19e-19	Reticulocyte fraction of red cells;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23167218	chr5:138609385	MATR3;SNHG4	-0.53	-6.54	-0.3	1.73e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg05340658	chr4:99064831	C4orf37	0.52	8.79	0.39	3.82e-17	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.69	12.02	0.5	8.08e-29	Mean corpuscular volume;
LUAD	cis	rs68170813	0.559	rs80307895	chr7:106907781	T/A	cg23024343	chr7:107201750	COG5	0.5	7.25	0.33	1.98e-12	Coronary artery disease;
LUAD	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2652834	0.904	rs2729826	chr15:63360446	C/G	cg25406657	chr15:63342033	TPM1	0.4	6.66	0.31	8.42e-11	HDL cholesterol;
LUAD	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg07917127	chr4:99064746	C4orf37	0.41	6.41	0.3	3.92e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg22920501	chr2:26401640	FAM59B	0.97	14.82	0.58	2.59e-40	Gut microbiome composition (summer);
LUAD	cis	rs2294693	0.945	rs68031000	chr6:41008841	G/T	cg14769373	chr6:40998127	UNC5CL	-0.5	-7.6	-0.35	1.9e-13	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.33	7.33	0.34	1.14e-12	Parkinson's disease;
LUAD	cis	rs524023	0.874	rs504915	chr11:64464085	T/A	cg19131476	chr11:64387923	NRXN2	-0.44	-8.43	-0.38	5.48e-16	Urate levels in obese individuals;
LUAD	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg03433033	chr1:76189801	ACADM	0.86	15.55	0.6	1.9e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg00431813	chr7:1051703	C7orf50	-0.37	-6.72	-0.31	5.94e-11	Longevity;Endometriosis;
LUAD	cis	rs240764	0.853	rs12191199	chr6:101008093	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-7.14	-0.33	4.02e-12	Neuroticism;
LUAD	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.56	-0.3	1.56e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg27624424	chr6:160112604	SOD2	-0.44	-6.63	-0.31	1.01e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs2479724	0.935	rs2254936	chr6:41846569	A/G	cg17623882	chr6:41773611	USP49	-0.66	-12.43	-0.52	1.85e-30	Menarche (age at onset);
LUAD	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg17063962	chr7:91808500	NA	0.7	12.44	0.52	1.65e-30	Breast cancer;
LUAD	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg01689657	chr7:91764605	CYP51A1	0.36	8.68	0.39	8.81e-17	Breast cancer;
LUAD	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg11822812	chr5:140052017	DND1	0.38	6.84	0.32	2.78e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.56	-8.94	-0.4	1.19e-17	Longevity;Endometriosis;
LUAD	cis	rs17152411	0.793	rs7085829	chr10:126587142	A/G	cg07906193	chr10:126599966	NA	0.53	7.47	0.34	4.69e-13	Height;
LUAD	cis	rs7584330	0.554	rs7573177	chr2:238444467	C/T	cg14458575	chr2:238380390	NA	-0.58	-9.43	-0.42	2.83e-19	Prostate cancer;
LUAD	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03517284	chr6:25882590	NA	0.84	14.06	0.56	4.12e-37	Blood metabolite levels;
LUAD	cis	rs7793919	0.652	rs10228886	chr7:4783224	C/T	cg00064840	chr7:4784485	FOXK1	-0.33	-6.37	-0.3	4.93e-10	Mosquito bite size;
LUAD	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg19196401	chr6:110721138	DDO	-0.42	-7.89	-0.36	2.53e-14	Platelet distribution width;
LUAD	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg11707310	chr1:2537719	MMEL1	0.37	7.9	0.36	2.39e-14	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg07636037	chr3:49044803	WDR6	-0.53	-10.3	-0.45	2.31e-22	Menarche (age at onset);
LUAD	cis	rs910187	0.641	rs3818011	chr20:45816566	A/G	cg27589058	chr20:45804311	EYA2	-0.31	-7.07	-0.33	6.44e-12	Migraine;
LUAD	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	7.85	0.36	3.42e-14	Breast cancer;
LUAD	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg21399703	chr1:247681439	NA	0.43	8.35	0.38	1.01e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg11494091	chr17:61959527	GH2	0.41	7.19	0.33	3.01e-12	Height;
LUAD	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg13385794	chr1:248469461	NA	0.25	6.76	0.31	4.69e-11	Common traits (Other);
LUAD	cis	rs4766566	0.501	rs3742004	chr12:111798553	A/G	cg10833066	chr12:111807467	FAM109A	0.7	14.03	0.56	5.51e-37	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUAD	cis	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg27411982	chr8:10470053	RP1L1	0.42	8.05	0.36	8.51e-15	Neuroticism;
LUAD	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg16486109	chr11:613632	IRF7	0.5	8.22	0.37	2.58e-15	Systemic lupus erythematosus;
LUAD	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg06740227	chr12:86229804	RASSF9	0.47	8.13	0.37	4.78e-15	Major depressive disorder;
LUAD	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg05590025	chr7:65112418	INTS4L2	-0.55	-6.4	-0.3	4.02e-10	Diabetic kidney disease;
LUAD	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg18135555	chr8:22132992	PIWIL2	0.43	7.78	0.35	5.68e-14	Hypertriglyceridemia;
LUAD	cis	rs11249608	0.600	rs13359570	chr5:178449249	T/G	cg01312482	chr5:178451176	ZNF879	-0.45	-6.98	-0.32	1.14e-11	Pubertal anthropometrics;
LUAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg22535103	chr8:58192502	C8orf71	-0.74	-9.2	-0.41	1.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg24579218	chr15:68104479	NA	0.48	8.02	0.36	1.07e-14	Motion sickness;
LUAD	cis	rs7814319	0.674	rs2643339	chr8:97246978	C/A	cg20787634	chr8:97240163	UQCRB	-0.34	-6.49	-0.3	2.47e-10	Lung function (FVC);
LUAD	cis	rs7680126	0.596	rs35782983	chr4:10117728	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-7.35	-0.34	1.06e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs1395	1.000	rs1659685	chr2:27420690	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.42	-7.96	-0.36	1.62e-14	Blood metabolite levels;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01516881	chr6:292596	DUSP22	-0.78	-13.43	-0.55	1.75e-34	Menopause (age at onset);
LUAD	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg21775007	chr8:11205619	TDH	-0.49	-9.0	-0.4	7.85e-18	Retinal vascular caliber;
LUAD	cis	rs748404	0.650	rs556851	chr15:43571219	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.39	0.34	8.05e-13	Lung cancer;
LUAD	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg17264618	chr3:40429014	ENTPD3	0.4	8.32	0.37	1.26e-15	Renal cell carcinoma;
LUAD	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.53	0.52	7.6e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.95	13.05	0.54	6.31e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg26304593	chr6:42947056	PEX6	-0.47	-7.98	-0.36	1.39e-14	Plasma homocysteine levels (post-methionine load test);
LUAD	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg04398451	chr17:18023971	MYO15A	-0.91	-18.44	-0.67	3.88e-56	Total body bone mineral density;
LUAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg22963979	chr7:1858916	MAD1L1	-0.7	-12.34	-0.51	4.29e-30	Bipolar disorder and schizophrenia;
LUAD	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg21194808	chr1:2205498	SKI	0.4	6.42	0.3	3.77e-10	Height;
LUAD	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg07570687	chr10:102243282	WNT8B	0.45	7.04	0.32	7.59e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs56283067	0.847	rs56172130	chr6:44696262	G/A	cg18551225	chr6:44695536	NA	-0.59	-10.05	-0.44	1.8e-21	Total body bone mineral density;
LUAD	cis	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg07460842	chr6:66804631	NA	1.08	17.32	0.64	3.55e-51	Exhaled nitric oxide output;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06110578	chr6:43597079	MAD2L1BP;GTPBP2	-0.41	-6.41	-0.3	3.88e-10	Height;
LUAD	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg21016266	chr12:122356598	WDR66	0.7	13.0	0.53	9.64e-33	Mean corpuscular volume;
LUAD	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg11494091	chr17:61959527	GH2	0.39	6.72	0.31	5.98e-11	Height;
LUAD	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg03929089	chr4:120376271	NA	-0.52	-6.77	-0.31	4.26e-11	Axial length;
LUAD	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg07741184	chr6:167504864	NA	0.3	7.2	0.33	2.8e-12	Crohn's disease;
LUAD	cis	rs10065203	0.527	rs181927	chr5:14351946	G/T	cg26595256	chr5:14380529	TRIO	-0.41	-7.45	-0.34	5.46e-13	Paclitaxel-induced neuropathy;
LUAD	cis	rs6445967	0.569	rs6794330	chr3:58314756	G/A	cg13750441	chr3:58318267	PXK	-0.32	-6.51	-0.3	2.19e-10	Platelet count;
LUAD	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06544989	chr22:39130855	UNC84B	0.48	9.57	0.42	8.73e-20	Menopause (age at onset);
LUAD	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg03929089	chr4:120376271	NA	0.56	7.31	0.33	1.36e-12	Axial length;
LUAD	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg26384229	chr12:38710491	ALG10B	0.46	7.52	0.34	3.32e-13	Bladder cancer;
LUAD	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg02493740	chr2:85810744	VAMP5	-0.62	-11.41	-0.48	1.86e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg24675056	chr1:15929824	NA	0.48	8.35	0.38	9.99e-16	Systolic blood pressure;
LUAD	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg25251562	chr2:3704773	ALLC	-0.37	-6.91	-0.32	1.77e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg21827317	chr3:136751795	NA	0.36	6.53	0.3	1.94e-10	Neuroticism;
LUAD	trans	rs7395662	1.000	rs11039868	chr11:48622146	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.27	-0.33	1.72e-12	HDL cholesterol;
LUAD	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg05805236	chr11:65401703	PCNXL3	-0.38	-6.43	-0.3	3.37e-10	Acne (severe);
LUAD	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg11494091	chr17:61959527	GH2	0.45	8.76	0.39	4.64e-17	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs986417	0.711	rs761556	chr14:61061034	T/G	cg27398547	chr14:60952738	C14orf39	0.64	7.12	0.33	4.64e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs9902453	0.740	rs1382391	chr17:28111986	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.56	-0.46	2.61e-23	Coffee consumption (cups per day);
LUAD	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg23229984	chr5:148520753	ABLIM3	0.5	7.83	0.36	3.84e-14	Breast cancer;
LUAD	cis	rs7394190	0.748	rs34163229	chr10:75406912	G/T	cg02286717	chr10:75415704	SYNPO2L	-0.38	-6.88	-0.32	2.21e-11	Incident atrial fibrillation;
LUAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg20607798	chr8:58055168	NA	0.68	8.99	0.4	8.34e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.42	0.34	6.46e-13	Bipolar disorder;
LUAD	cis	rs9811920	0.715	rs6810262	chr3:99906342	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.49	9.11	0.4	3.38e-18	Axial length;
LUAD	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.51e-15	Bipolar disorder;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg13892647	chr9:37485877	POLR1E	-0.67	-6.55	-0.3	1.68e-10	Type 2 diabetes;
LUAD	cis	rs10504073	0.647	rs341807	chr8:50032676	C/T	cg00325661	chr8:49890786	NA	0.4	9.02	0.4	6.66e-18	Blood metabolite ratios;
LUAD	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.91	0.4	1.48e-17	Cognitive ability;
LUAD	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg06387496	chr7:2775674	GNA12	-0.39	-6.41	-0.3	3.8e-10	Height;
LUAD	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg06784218	chr1:46089804	CCDC17	-0.51	-11.31	-0.48	4.16e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7617773	0.780	rs35297395	chr3:48342882	C/T	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.06	23.83	0.76	3.27e-80	Chronic sinus infection;
LUAD	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-9.16	-0.41	2.32e-18	Total body bone mineral density;
LUAD	cis	rs748404	0.697	rs531910	chr15:43560607	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.14	0.37	4.58e-15	Lung cancer;
LUAD	trans	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.73	11.66	0.49	1.91e-27	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg10591111	chr5:226296	SDHA	-0.56	-7.27	-0.33	1.81e-12	Breast cancer;
LUAD	cis	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.83	-0.36	3.84e-14	Neuroticism;
LUAD	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.62	0.31	1.12e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	7.57	0.35	2.34e-13	Schizophrenia;
LUAD	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg08999081	chr20:33150536	PIGU	0.63	14.03	0.56	5.5e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs8044868	0.530	rs7186155	chr16:72178196	A/G	cg23815491	chr16:72088622	HP	0.5	9.28	0.41	8.56e-19	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg09085632	chr11:111637200	PPP2R1B	0.75	11.73	0.5	1.06e-27	Primary sclerosing cholangitis;
LUAD	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg23231163	chr10:75533350	FUT11	-0.5	-9.54	-0.42	1.17e-19	Inflammatory bowel disease;
LUAD	trans	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg26043149	chr18:55253948	FECH	-0.48	-7.94	-0.36	1.82e-14	Bone mineral density;
LUAD	cis	rs9581857	0.685	rs9319372	chr13:28042796	C/T	cg22138327	chr13:27999177	GTF3A	-0.85	-9.6	-0.42	7.17e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7402982	0.934	rs8028620	chr15:99202875	C/T	cg03437748	chr15:99193247	IGF1R	0.47	8.31	0.37	1.31e-15	Birth weight;
LUAD	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg10755058	chr3:40428713	ENTPD3	0.39	7.03	0.32	8.11e-12	Renal cell carcinoma;
LUAD	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg09365446	chr1:150670422	GOLPH3L	0.55	9.72	0.43	2.78e-20	Melanoma;
LUAD	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.37	7.17	0.33	3.45e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg16362983	chr14:50335243	NA	-0.37	-6.49	-0.3	2.42e-10	Subcortical brain region volumes;
LUAD	trans	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg21659725	chr3:3221576	CRBN	-0.58	-9.2	-0.41	1.6e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.65	-0.35	1.37e-13	Monocyte count;
LUAD	cis	rs3784262	0.771	rs4775005	chr15:58208165	C/T	cg12031962	chr15:58353849	ALDH1A2	0.41	8.1	0.37	6.14e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.74	0.35	7.22e-14	Breast cancer;
LUAD	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg15017067	chr4:17643749	FAM184B	0.33	6.54	0.3	1.78e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10489202	0.513	rs4657731	chr1:168081255	C/T	cg24449463	chr1:168025552	DCAF6	-0.62	-9.73	-0.43	2.43e-20	Schizophrenia;
LUAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg21724239	chr8:58056113	NA	0.65	8.41	0.38	6.32e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs12545109	0.879	rs1975285	chr8:57358682	G/C	cg11919837	chr8:57350735	NA	-0.48	-6.63	-0.31	1.03e-10	Obesity-related traits;
LUAD	cis	rs10504073	0.647	rs4873314	chr8:50011656	A/C	cg00325661	chr8:49890786	NA	0.46	10.19	0.44	6.11e-22	Blood metabolite ratios;
LUAD	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg12615879	chr12:58013172	SLC26A10	-0.35	-6.9	-0.32	1.95e-11	Multiple sclerosis;
LUAD	cis	rs1160297	0.603	rs10209194	chr2:53024383	C/T	cg07782112	chr2:53107842	NA	0.37	7.38	0.34	8.71e-13	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs13315871	0.929	rs73835170	chr3:58318448	A/G	cg12435725	chr3:58293450	RPP14	-0.75	-8.27	-0.37	1.77e-15	Cholesterol, total;
LUAD	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg14664628	chr15:75095509	CSK	0.55	8.67	0.39	9.64e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg06781209	chr11:61594997	FADS2	-0.4	-7.37	-0.34	8.89e-13	Trans fatty acid levels;
LUAD	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.59	10.03	0.44	2.16e-21	Electrocardiographic conduction measures;
LUAD	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg26343298	chr8:95960752	TP53INP1	0.37	7.85	0.36	3.5e-14	Type 2 diabetes;
LUAD	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.35	-0.3	5.4e-10	Neuroticism;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19545348	chr1:211434133	RCOR3	0.43	6.75	0.31	4.75e-11	Monocyte percentage of white cells;
LUAD	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg18230493	chr5:56204884	C5orf35	-0.53	-8.46	-0.38	4.48e-16	Coronary artery disease;
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg14668821	chr17:77704760	ENPP7	0.33	6.71	0.31	6.22e-11	Menopause (age at onset);
LUAD	trans	rs2262909	0.962	rs411020	chr19:22231102	G/A	cg05197062	chr11:11642011	GALNTL4	-0.58	-9.0	-0.4	7.43e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg13770153	chr20:60521292	NA	-0.58	-8.97	-0.4	9.83e-18	Body mass index;
LUAD	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.77	14.75	0.58	4.99e-40	Intelligence (multi-trait analysis);
LUAD	trans	rs2018683	0.707	rs10279870	chr7:28968935	A/G	cg19402173	chr7:128379420	CALU	-0.52	-8.43	-0.38	5.59e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs775227	0.574	rs13068107	chr3:113029530	A/C	cg18753928	chr3:113234510	CCDC52	-0.62	-8.0	-0.36	1.19e-14	Dental caries;
LUAD	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg18305652	chr10:134549665	INPP5A	0.64	12.21	0.51	1.34e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	10.32	0.45	2.1e-22	Lung cancer in ever smokers;
LUAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg13047869	chr3:10149882	C3orf24	-0.67	-10.08	-0.44	1.5e-21	Alzheimer's disease;
LUAD	cis	rs2985684	0.895	rs3007033	chr14:50103816	T/C	cg04989706	chr14:50066350	PPIL5	-0.47	-6.87	-0.32	2.32e-11	Carotid intima media thickness;
LUAD	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg08916839	chr5:415575	AHRR	0.85	9.94	0.44	4.68e-21	Fat distribution (HIV);
LUAD	cis	rs7173743	0.518	rs12899452	chr15:79112550	T/A	cg00540400	chr15:79124168	NA	0.44	9.28	0.41	8.77e-19	Coronary artery disease;
LUAD	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg02158880	chr13:53174818	NA	0.61	11.02	0.47	5.48e-25	Lewy body disease;
LUAD	cis	rs2224391	0.784	rs59548069	chr6:5276595	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-9.0	-0.4	7.97e-18	Height;
LUAD	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg14343924	chr8:8086146	FLJ10661	0.43	6.81	0.31	3.47e-11	Mood instability;
LUAD	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg02569458	chr12:86230093	RASSF9	0.41	7.73	0.35	7.87e-14	Major depressive disorder;
LUAD	cis	rs4692589	0.581	rs62344678	chr4:170961308	G/A	cg19918862	chr4:170955249	NA	0.32	6.35	0.3	5.42e-10	Anxiety disorder;
LUAD	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg11494091	chr17:61959527	GH2	-0.68	-15.93	-0.61	4.36e-45	Prudent dietary pattern;
LUAD	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.61e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg15704280	chr7:45808275	SEPT13	-0.77	-11.89	-0.5	2.5e-28	Coronary artery disease;
LUAD	cis	rs10097731	0.901	rs10464932	chr8:82042901	T/G	cg25230327	chr8:82042993	NA	-0.66	-11.5	-0.49	7.85e-27	Serum total protein level;
LUAD	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-8.4	-0.38	6.74e-16	Reticulocyte count;
LUAD	cis	rs4662945	0.525	rs4662951	chr2:130256272	C/T	cg05962382	chr2:130345044	NA	-0.36	-6.75	-0.31	4.82e-11	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg06740227	chr12:86229804	RASSF9	-0.43	-7.53	-0.34	3.08e-13	Major depressive disorder;
LUAD	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg07936489	chr17:37558343	FBXL20	0.44	6.94	0.32	1.45e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg24818145	chr4:99064322	C4orf37	0.45	7.62	0.35	1.65e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6577655	0.517	rs62525562	chr8:135587076	C/T	cg17885191	chr8:135476712	NA	0.63	8.31	0.37	1.35e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7551222	0.716	rs11240751	chr1:204462050	A/G	cg20240347	chr1:204465584	NA	-0.34	-6.53	-0.3	1.95e-10	Schizophrenia;
LUAD	cis	rs910187	0.597	rs2073172	chr20:45809176	A/G	cg27589058	chr20:45804311	EYA2	-0.31	-7.01	-0.32	9.42e-12	Migraine;
LUAD	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg20673091	chr1:2541236	MMEL1	-0.38	-8.08	-0.37	7.03e-15	Multiple sclerosis;
LUAD	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg22681709	chr2:178499509	PDE11A	-0.45	-7.48	-0.34	4.37e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7394190	0.748	rs11000777	chr10:75545063	G/C	cg02286717	chr10:75415704	SYNPO2L	-0.36	-6.36	-0.3	5.22e-10	Incident atrial fibrillation;
LUAD	cis	rs7512552	0.839	rs1498308	chr1:150295131	G/T	cg15654264	chr1:150340011	RPRD2	0.57	11.27	0.48	6.2e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9394841	0.692	rs34073739	chr6:41829970	A/G	cg25600774	chr6:41776562	USP49	-0.43	-6.47	-0.3	2.74e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21659725	chr3:3221576	CRBN	-0.7	-11.68	-0.49	1.58e-27	Resting heart rate;
LUAD	trans	rs7246760	1.000	rs67359088	chr19:9863668	C/T	cg02900749	chr2:68251473	NA	-0.64	-7.04	-0.32	7.78e-12	Pursuit maintenance gain;
LUAD	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg25173405	chr17:45401733	C17orf57	-0.54	-9.44	-0.42	2.49e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.62	-0.42	6.01e-20	Life satisfaction;
LUAD	cis	rs12210905	0.688	rs12213471	chr6:27406063	C/G	cg08851530	chr6:28072375	NA	1.03	7.52	0.34	3.3e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs897984	0.721	rs2305884	chr16:30970741	G/A	cg02466173	chr16:30829666	NA	0.65	12.11	0.51	3.63e-29	Dementia with Lewy bodies;
LUAD	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs76878669	1.000	rs76878669	chr11:66092567	C/G	cg18002602	chr11:66138449	SLC29A2	-0.36	-6.35	-0.3	5.46e-10	Educational attainment (years of education);
LUAD	cis	rs9372498	0.536	rs62422221	chr6:118925581	T/C	cg07617317	chr6:118971624	C6orf204	0.55	8.09	0.37	6.35e-15	Diastolic blood pressure;
LUAD	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg02158880	chr13:53174818	NA	0.68	11.91	0.5	2.13e-28	Lewy body disease;
LUAD	cis	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg05299278	chr17:33885742	SLFN14	0.5	11.32	0.48	4.05e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	trans	rs587242	1.000	rs12030271	chr1:96892099	A/G	cg10631902	chr5:14652156	NA	0.44	7.26	0.33	1.86e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg02018176	chr4:1364513	KIAA1530	0.36	6.37	0.3	5.04e-10	Obesity-related traits;
LUAD	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg06641503	chr3:48959341	ARIH2	-0.42	-8.06	-0.36	7.85e-15	Parkinson's disease;
LUAD	cis	rs3916	0.794	rs10431384	chr12:121127347	C/T	cg21892295	chr12:121157589	UNC119B	0.41	7.29	0.33	1.59e-12	Urinary metabolites (H-NMR features);
LUAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg07507251	chr3:52567010	NT5DC2	0.4	7.93	0.36	2e-14	Electroencephalogram traits;
LUAD	cis	rs8060686	1.000	rs8060686	chr16:67911517	T/C	cg26727032	chr16:67993705	SLC12A4	-0.52	-8.8	-0.39	3.54e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2777491	0.574	rs11635906	chr15:41779260	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.08	-22.31	-0.74	1.95e-73	Ulcerative colitis;
LUAD	cis	rs12791968	0.765	rs11038250	chr11:45009114	A/G	cg11846598	chr11:44996168	LOC221122	-0.68	-10.26	-0.45	3.29e-22	Inhibitory control;
LUAD	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg04414720	chr1:150670196	GOLPH3L	0.67	11.52	0.49	6.71e-27	Melanoma;
LUAD	cis	rs9300255	0.770	rs7980687	chr12:123822711	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	6.54	0.3	1.78e-10	Neutrophil percentage of white cells;
LUAD	cis	rs758324	0.773	rs40819	chr5:131305384	G/T	cg06307176	chr5:131281290	NA	-0.44	-7.29	-0.33	1.53e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg06636001	chr8:8085503	FLJ10661	0.44	7.08	0.33	5.99e-12	Mood instability;
LUAD	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg04703951	chr17:43578652	NA	-0.56	-8.08	-0.37	6.65e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs67981189	0.501	rs3829954	chr14:71455540	A/G	cg15910301	chr14:71632612	NA	0.41	6.46	0.3	2.89e-10	Schizophrenia;
LUAD	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	7.75	0.35	6.92e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg05616858	chr17:37843591	ERBB2;PGAP3	0.32	6.63	0.31	1.02e-10	Asthma;
LUAD	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg15992532	chr8:142229932	SLC45A4	0.49	8.77	0.39	4.58e-17	Immature fraction of reticulocytes;
LUAD	cis	rs8044868	1.000	rs8052408	chr16:72158077	C/T	cg23815491	chr16:72088622	HP	0.39	7.27	0.33	1.76e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs7851660	0.967	rs4743135	chr9:100599493	C/T	cg13688889	chr9:100608707	NA	-0.52	-9.61	-0.42	6.33e-20	Strep throat;
LUAD	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg17177755	chr1:15930204	NA	0.44	7.13	0.33	4.38e-12	Systolic blood pressure;
LUAD	cis	rs7187994	0.848	rs12920732	chr16:84780613	C/T	cg07647771	chr16:84786436	USP10	-0.37	-9.42	-0.42	3.06e-19	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg01528321	chr10:82214614	TSPAN14	0.68	11.25	0.48	7.03e-26	Post bronchodilator FEV1;
LUAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.34	0.45	1.77e-22	Prudent dietary pattern;
LUAD	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.04	-0.32	7.82e-12	Coronary artery disease;
LUAD	cis	rs4372836	0.729	rs6547874	chr2:28982030	A/G	cg09522027	chr2:28974177	PPP1CB	-0.7	-12.72	-0.53	1.25e-31	Body mass index;
LUAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.69	-13.44	-0.55	1.48e-34	Longevity;Endometriosis;
LUAD	cis	rs524023	0.874	rs519090	chr11:64456240	G/C	cg19131476	chr11:64387923	NRXN2	-0.43	-8.23	-0.37	2.32e-15	Urate levels in obese individuals;
LUAD	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.05	-0.36	8.29e-15	Personality dimensions;
LUAD	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg20916646	chr4:852691	GAK	0.49	6.66	0.31	8.68e-11	Sjögren's syndrome;
LUAD	cis	rs7274811	0.516	rs3213141	chr20:32274380	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.5	-6.72	-0.31	5.78e-11	Height;
LUAD	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	7.19	0.33	2.98e-12	Platelet count;
LUAD	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg06074448	chr4:187884817	NA	-0.43	-8.98	-0.4	8.93e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg25894440	chr7:65020034	NA	-0.61	-6.5	-0.3	2.26e-10	Diabetic kidney disease;
LUAD	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	8.77	0.39	4.48e-17	Lung cancer in ever smokers;
LUAD	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg19875535	chr5:140030758	IK	0.45	7.45	0.34	5.38e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.46	7.74	0.35	7.17e-14	Lung cancer in ever smokers;
LUAD	cis	rs4660306	0.961	rs4660867	chr1:45986484	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.5	-7.98	-0.36	1.36e-14	Homocysteine levels;
LUAD	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg24579218	chr15:68104479	NA	-0.59	-9.16	-0.41	2.32e-18	Restless legs syndrome;
LUAD	cis	rs7759001	0.857	rs10807020	chr6:27356902	A/G	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.83e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs7187994	0.848	rs12934432	chr16:84770913	T/A	cg07647771	chr16:84786436	USP10	-0.37	-9.08	-0.4	4.25e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08859206	chr1:53392774	SCP2	0.83	15.64	0.61	7.89e-44	Monocyte count;
LUAD	cis	rs13315871	0.929	rs28659863	chr3:58328072	C/T	cg12435725	chr3:58293450	RPP14	-0.74	-8.13	-0.37	4.97e-15	Cholesterol, total;
LUAD	cis	rs490234	0.627	rs4838276	chr9:128364901	A/G	cg14078157	chr9:128172775	NA	0.44	7.96	0.36	1.56e-14	Mean arterial pressure;
LUAD	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg19622623	chr12:86230825	RASSF9	-0.4	-7.11	-0.33	4.93e-12	Major depressive disorder;
LUAD	cis	rs9863	0.827	rs6488913	chr12:124445569	C/G	cg17723958	chr12:124429295	CCDC92	0.4	6.69	0.31	7.22e-11	White blood cell count;
LUAD	trans	rs7395662	1.000	rs7931984	chr11:48580835	T/A	cg00717180	chr2:96193071	NA	-0.39	-7.39	-0.34	8.17e-13	HDL cholesterol;
LUAD	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-15.6	-0.6	1.11e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg07917127	chr4:99064746	C4orf37	0.42	6.89	0.32	2e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.3	7.63	0.35	1.59e-13	Schizophrenia;
LUAD	cis	rs7773004	0.875	rs6456713	chr6:26325843	A/G	cg00631329	chr6:26305371	NA	-0.52	-8.92	-0.4	1.45e-17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs11048434	0.736	rs12833375	chr12:9112018	A/T	cg23795048	chr12:9217529	LOC144571	0.42	7.87	0.36	3.04e-14	Sjögren's syndrome;
LUAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.54	-8.88	-0.4	1.88e-17	Renal function-related traits (BUN);
LUAD	cis	rs4713675	0.584	rs7770465	chr6:33674156	G/C	cg14003231	chr6:33640908	ITPR3	0.5	9.54	0.42	1.18e-19	Plateletcrit;
LUAD	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg15181151	chr6:150070149	PCMT1	0.34	6.66	0.31	8.8e-11	Lung cancer;
LUAD	cis	rs35771425	0.619	rs7529900	chr1:211442661	C/T	cg25617285	chr1:211431773	RCOR3	-0.46	-8.35	-0.38	1e-15	Educational attainment (years of education);
LUAD	cis	rs2932538	0.922	rs7535636	chr1:113101799	C/T	cg22162597	chr1:113214053	CAPZA1	-0.46	-6.9	-0.32	1.94e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs3736594	0.513	rs6547735	chr2:27831607	T/C	cg27432699	chr2:27873401	GPN1	0.46	6.61	0.31	1.17e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs13315871	1.000	rs35621601	chr3:58323174	A/G	cg20936604	chr3:58311152	NA	-0.72	-7.22	-0.33	2.51e-12	Cholesterol, total;
LUAD	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9948	0.529	rs62156222	chr2:97410988	C/A	cg20312557	chr2:97357134	FER1L5	-0.73	-8.19	-0.37	3.13e-15	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs72928364	1.000	rs4928096	chr3:100619760	A/G	cg10123952	chr3:100791384	NA	0.52	6.73	0.31	5.65e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs710865	0.519	rs3748759	chr1:19487656	C/T	cg13387374	chr1:19411106	UBR4	-0.49	-8.58	-0.38	1.85e-16	Brain structure;
LUAD	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg15691649	chr6:25882328	NA	-0.45	-6.45	-0.3	2.99e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19346786	chr7:2764209	NA	-0.55	-11.95	-0.5	1.42e-28	Height;
LUAD	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg05887092	chr17:76393375	PGS1	0.41	7.28	0.33	1.65e-12	HDL cholesterol levels;
LUAD	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg10876282	chr6:28092338	ZSCAN16	0.45	7.29	0.33	1.53e-12	Parkinson's disease;
LUAD	cis	rs7107174	1.000	rs11237462	chr11:78058812	C/A	cg02023728	chr11:77925099	USP35	0.45	7.11	0.33	4.82e-12	Testicular germ cell tumor;
LUAD	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg22166914	chr1:53195759	ZYG11B	0.45	7.32	0.34	1.24e-12	Monocyte count;
LUAD	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg26043149	chr18:55253948	FECH	-0.42	-6.99	-0.32	1.11e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs977987	0.751	rs56004344	chr16:75474189	T/C	cg03315344	chr16:75512273	CHST6	0.65	14.22	0.57	9.13e-38	Dupuytren's disease;
LUAD	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg22920501	chr2:26401640	FAM59B	-0.93	-14.55	-0.58	3.69e-39	Gut microbiome composition (summer);
LUAD	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	9.84	0.43	1.06e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg17173187	chr15:85201210	NMB	0.4	6.4	0.3	4.02e-10	Schizophrenia;
LUAD	cis	rs438034	1.000	rs388355	chr1:214829091	A/G	cg16144317	chr1:214725524	PTPN14	-0.34	-6.37	-0.3	5.04e-10	Response to antineoplastic agents;
LUAD	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg04944784	chr2:26401820	FAM59B	0.88	12.13	0.51	2.99e-29	Gut microbiome composition (summer);
LUAD	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg02734326	chr4:10020555	SLC2A9	0.44	7.69	0.35	1.03e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg07211511	chr3:129823064	LOC729375	-0.57	-7.5	-0.34	3.73e-13	Blood pressure (smoking interaction);
LUAD	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	14.03	0.56	5.74e-37	Smoking behavior;
LUAD	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg15704280	chr7:45808275	SEPT13	-0.93	-18.2	-0.66	4.29e-55	Coronary artery disease;
LUAD	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg21856205	chr7:94953877	PON1	0.55	7.86	0.36	3.13e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg02880119	chr16:3481970	NA	0.57	8.3	0.37	1.37e-15	Body mass index (adult);
LUAD	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg00933542	chr6:150070202	PCMT1	0.45	9.71	0.43	3.01e-20	Lung cancer;
LUAD	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg00684032	chr4:1343700	KIAA1530	-0.37	-6.36	-0.3	5.2400000000000005e-10	Obesity-related traits;
LUAD	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg26898376	chr11:64110657	CCDC88B	0.37	6.86	0.32	2.52e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs7264396	0.561	rs6142470	chr20:34570579	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-6.48	-0.3	2.55e-10	Total cholesterol levels;
LUAD	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg19046167	chr17:80928561	B3GNTL1	0.47	7.13	0.33	4.48e-12	Glycated hemoglobin levels;
LUAD	cis	rs3806843	0.576	rs246032	chr5:140332547	C/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2742234	0.955	rs2503865	chr10:43659536	C/T	cg02780029	chr10:43622663	RET	-0.43	-7.05	-0.32	7.48e-12	Hirschsprung disease;
LUAD	cis	rs1788820	0.957	rs1652340	chr18:21099831	A/C	cg14672496	chr18:21087552	C18orf8	0.35	6.65	0.31	9.3e-11	Body mass index;
LUAD	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg09021430	chr5:549028	NA	-0.58	-13.14	-0.54	2.53e-33	Obesity-related traits;
LUAD	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	ch.11.42038R	chr11:967971	AP2A2	0.4	6.95	0.32	1.36e-11	Alzheimer's disease (late onset);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg19472303	chr3:25705836	TOP2B	-0.42	-7.03	-0.32	8.59e-12	Schizophrenia;
LUAD	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg05340658	chr4:99064831	C4orf37	0.54	8.87	0.4	2.08e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg08470875	chr2:26401718	FAM59B	-0.66	-9.31	-0.41	7.13e-19	Gut microbiome composition (summer);
LUAD	trans	rs8002861	0.905	rs12875768	chr13:44428305	C/T	cg17145862	chr1:211918768	LPGAT1	-0.67	-14.71	-0.58	7.23e-40	Leprosy;
LUAD	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg02733842	chr7:1102375	C7orf50	0.68	10.49	0.45	4.97e-23	Bronchopulmonary dysplasia;
LUAD	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg16647868	chr5:131706066	SLC22A5	0.41	7.17	0.33	3.47e-12	Blood metabolite levels;
LUAD	cis	rs2046867	0.862	rs62251646	chr3:72805787	T/C	cg04365224	chr3:72788183	NA	-0.46	-6.95	-0.32	1.43e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.95	0.47	9.51e-25	Smoking behavior;
LUAD	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg16325326	chr1:53192061	ZYG11B	-0.67	-12.38	-0.52	3e-30	Monocyte count;
LUAD	cis	rs9513627	1.000	rs7338761	chr13:100119731	A/G	cg25919922	chr13:100150906	NA	-0.68	-6.42	-0.3	3.61e-10	Obesity-related traits;
LUAD	cis	rs6545883	0.868	rs6748003	chr2:61806700	T/G	cg15711740	chr2:61764176	XPO1	-0.42	-6.6	-0.31	1.23e-10	Tuberculosis;
LUAD	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg14668632	chr7:2872130	GNA12	-0.49	-8.82	-0.39	3.08e-17	Height;
LUAD	cis	rs2840044	1.000	rs7212704	chr17:33898897	C/T	cg05299278	chr17:33885742	SLFN14	-0.44	-8.91	-0.4	1.49e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg02423579	chr7:2872169	GNA12	-0.52	-8.57	-0.38	1.92e-16	Height;
LUAD	cis	rs9972944	0.902	rs10512504	chr17:63772091	C/T	cg07283582	chr17:63770753	CCDC46	0.52	11.7	0.49	1.39e-27	Total body bone mineral density;
LUAD	trans	rs6601327	0.670	rs12545250	chr8:9420566	T/C	cg27411982	chr8:10470053	RP1L1	0.39	7.32	0.34	1.27e-12	Multiple myeloma (hyperdiploidy);
LUAD	trans	rs7395662	0.895	rs1121000	chr11:48711790	A/T	cg15704280	chr7:45808275	SEPT13	-0.41	-6.35	-0.3	5.44e-10	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.06	0.32	7.06e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg17063962	chr7:91808500	NA	0.72	12.9	0.53	2.35e-32	Breast cancer;
LUAD	cis	rs4523957	0.570	rs2126202	chr17:2095712	G/T	cg16513277	chr17:2031491	SMG6	0.55	10.19	0.44	6.07e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg23719950	chr11:63933701	MACROD1	-0.63	-7.28	-0.33	1.68e-12	Mean platelet volume;
LUAD	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg20587970	chr11:113659929	NA	-1.29	-18.39	-0.67	6.53e-56	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg05340658	chr4:99064831	C4orf37	0.45	6.87	0.32	2.28e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.947	rs3776030	chr5:130776738	A/G	cg25547332	chr5:131281432	NA	-0.44	-6.72	-0.31	5.94e-11	Life satisfaction;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06494227	chr22:30752758	CCDC157;SF3A1	-0.55	-6.66	-0.31	8.55e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg13319975	chr6:146136371	FBXO30	-0.58	-9.74	-0.43	2.4e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg04731861	chr2:219085781	ARPC2	-0.24	-7.46	-0.34	5.05e-13	Colorectal cancer;
LUAD	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg21984481	chr17:79567631	NPLOC4	-0.66	-15.59	-0.6	1.31e-43	Eye color traits;
LUAD	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg22906224	chr7:99728672	NA	-0.56	-9.68	-0.43	3.82e-20	Coronary artery disease;
LUAD	trans	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.23e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs62238980	0.614	rs117827593	chr22:32501199	G/A	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	trans	rs75804782	0.581	rs3191996	chr2:239344412	A/G	cg01134436	chr17:81009848	B3GNTL1	-0.77	-8.61	-0.39	1.43e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg00086871	chr4:6988644	TBC1D14	0.74	6.4	0.3	4.13e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs13394619	1.000	rs4669752	chr2:11727988	G/C	cg07314298	chr2:11723111	GREB1	-0.5	-9.27	-0.41	9.81e-19	Endometriosis;
LUAD	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01570182	chr17:44337453	NA	-0.77	-12.53	-0.52	7.3e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg17077180	chr1:38461687	NA	0.53	11.33	0.48	3.6e-26	Coronary artery disease;
LUAD	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg09085632	chr11:111637200	PPP2R1B	0.63	9.58	0.42	8.24e-20	Primary sclerosing cholangitis;
LUAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg14789911	chr21:47582049	C21orf56	-0.47	-8.39	-0.38	7.33e-16	Testicular germ cell tumor;
LUAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg04025307	chr7:1156635	C7orf50	0.6	6.78	0.31	4.07e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg13180566	chr4:1052158	NA	-0.39	-6.7	-0.31	6.65e-11	Recombination rate (females);
LUAD	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg05110241	chr16:68378359	PRMT7	-0.84	-9.31	-0.41	6.87e-19	Magnesium levels;
LUAD	cis	rs7107174	1.000	rs4627115	chr11:78007873	T/G	cg19901956	chr11:77921274	USP35	-0.56	-6.86	-0.32	2.53e-11	Testicular germ cell tumor;
LUAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg07157834	chr1:205819609	PM20D1	0.41	6.53	0.3	1.88e-10	Parkinson's disease;
LUAD	cis	rs9595066	1.000	rs4942282	chr13:44708416	G/A	cg04068111	chr13:44716778	NA	-0.67	-11.64	-0.49	2.25e-27	Schizophrenia;
LUAD	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg15110403	chr19:17392923	ANKLE1	-0.41	-6.73	-0.31	5.59e-11	Systemic lupus erythematosus;
LUAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-8.13	-0.37	4.68e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.58	-9.93	-0.43	5.17e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs7147624	1.000	rs2411821	chr14:65896914	G/T	cg03016385	chr14:66212404	NA	-0.59	-7.03	-0.32	8.49e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg00603274	chr11:61596626	FADS2	-0.41	-6.91	-0.32	1.77e-11	Bipolar disorder;
LUAD	trans	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg21659725	chr3:3221576	CRBN	0.38	6.36	0.3	5.35e-10	Resting heart rate;
LUAD	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg24324837	chr19:49891574	CCDC155	0.57	8.35	0.38	9.7e-16	Multiple sclerosis;
LUAD	cis	rs7923452	0.938	rs34930615	chr10:30761051	G/A	cg18806716	chr10:30721971	MAP3K8	0.56	7.81	0.35	4.58e-14	Itch intensity from mosquito bite;
LUAD	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.68	10.84	0.47	2.59e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg19875535	chr5:140030758	IK	0.44	7.41	0.34	7.01e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs17608059	0.566	rs17676459	chr17:13910515	A/G	cg27005118	chr17:13972210	COX10	-0.32	-6.59	-0.31	1.33e-10	Temperament;
LUAD	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.49	-9.13	-0.41	2.78e-18	Schizophrenia;
LUAD	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg10518543	chr12:38710700	ALG10B	0.47	7.85	0.36	3.5e-14	Morning vs. evening chronotype;
LUAD	cis	rs735539	0.521	rs693489	chr13:21423005	A/G	cg27499820	chr13:21296301	IL17D	0.44	7.29	0.33	1.55e-12	Dental caries;
LUAD	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.79	8.66	0.39	9.68e-17	Initial pursuit acceleration;
LUAD	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg23758822	chr17:41437982	NA	1.0	20.41	0.7	5.84e-65	Menopause (age at onset);
LUAD	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg22467129	chr15:76604101	ETFA	-0.47	-7.79	-0.35	5.15e-14	Blood metabolite levels;
LUAD	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg02082929	chr2:109068933	GCC2	0.54	13.01	0.53	8.93e-33	Mean platelet volume;
LUAD	trans	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg01620082	chr3:125678407	NA	-0.44	-6.54	-0.3	1.8e-10	Depression;
LUAD	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03264133	chr6:25882463	NA	-0.55	-9.24	-0.41	1.23e-18	Blood metabolite levels;
LUAD	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg02569458	chr12:86230093	RASSF9	-0.43	-7.8	-0.35	4.8e-14	Major depressive disorder;
LUAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg07217954	chr7:1067459	C7orf50	0.4	6.83	0.32	2.96e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg00259882	chr11:70049130	FADD	-0.43	-7.37	-0.34	9.28e-13	Schizophrenia;
LUAD	cis	rs9581857	0.512	rs9581874	chr13:28086956	A/G	cg22138327	chr13:27999177	GTF3A	0.82	8.75	0.39	5.22e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	trans	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg14917512	chr19:3094685	GNA11	-0.57	-6.86	-0.32	2.49e-11	Diabetic kidney disease;
LUAD	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg04287289	chr16:89883240	FANCA	0.78	6.91	0.32	1.74e-11	Skin colour saturation;
LUAD	cis	rs6433857	0.536	rs4625864	chr2:181353942	G/C	cg23363182	chr2:181467187	NA	-0.39	-6.38	-0.3	4.78e-10	Body mass index;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg08376864	chr3:192958726	MGC2889;HRASLS	0.42	6.74	0.31	5.33e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.52	-0.38	2.93e-16	Total body bone mineral density;
LUAD	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg27170947	chr2:26402098	FAM59B	-0.61	-8.5	-0.38	3.17e-16	Gut microbiome composition (summer);
LUAD	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.96	20.72	0.71	2.41e-66	Chronic sinus infection;
LUAD	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1385374	0.841	rs11059929	chr12:129296893	G/A	cg09035930	chr12:129282057	SLC15A4	-0.64	-6.78	-0.31	4.12e-11	Systemic lupus erythematosus;
LUAD	cis	rs738322	0.805	rs2235344	chr22:38518083	G/A	cg25457927	chr22:38595422	NA	-0.48	-11.64	-0.49	2.27e-27	Cutaneous nevi;
LUAD	cis	rs7677751	0.708	rs2052699	chr4:55063994	C/T	cg17187183	chr4:55093834	PDGFRA	0.42	6.89	0.32	2.08e-11	Corneal astigmatism;
LUAD	cis	rs17621444	0.522	rs4752372	chr10:121808896	T/C	cg02041677	chr10:121771263	NA	-0.31	-6.36	-0.3	5.31e-10	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.38e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg15704280	chr7:45808275	SEPT13	-0.65	-9.97	-0.44	3.52e-21	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg08213375	chr14:104286397	PPP1R13B	0.28	7.22	0.33	2.4e-12	Schizophrenia;
LUAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg23978390	chr7:1156363	C7orf50	0.46	7.18	0.33	3.17e-12	Longevity;Endometriosis;
LUAD	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg02527881	chr3:46936655	PTH1R	-0.43	-8.43	-0.38	5.42e-16	Colorectal cancer;
LUAD	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06022373	chr22:39101656	GTPBP1	0.48	8.0	0.36	1.23e-14	Menopause (age at onset);
LUAD	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg19163074	chr7:65112434	INTS4L2	0.43	6.45	0.3	2.98e-10	Aortic root size;
LUAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg16606324	chr3:10149918	C3orf24	0.68	11.12	0.48	2.21e-25	Alzheimer's disease;
LUAD	cis	rs72634258	0.519	rs35197830	chr1:7930983	A/G	cg26816564	chr1:7831052	VAMP3	0.51	7.28	0.33	1.68e-12	Inflammatory bowel disease;
LUAD	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg18876405	chr7:65276391	NA	-0.46	-7.33	-0.34	1.15e-12	Aortic root size;
LUAD	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.39	-6.54	-0.3	1.79e-10	Platelet count;
LUAD	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.54	0.34	2.94e-13	Menopause (age at onset);
LUAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.63	-10.15	-0.44	8.01e-22	Renal function-related traits (BUN);
LUAD	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg04398451	chr17:18023971	MYO15A	-0.77	-14.1	-0.57	2.74e-37	Total body bone mineral density;
LUAD	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.49	0.34	4.02e-13	Bipolar disorder;
LUAD	cis	rs35123781	0.502	rs261532	chr5:138949362	A/C	cg12205435	chr5:138714322	SLC23A1	0.44	7.52	0.34	3.35e-13	Schizophrenia;
LUAD	cis	rs4700695	0.719	rs27588	chr5:65459360	C/A	cg21114390	chr5:65439923	SFRS12	-0.91	-14.3	-0.57	4.13e-38	Facial morphology (factor 19);
LUAD	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg03433033	chr1:76189801	ACADM	0.74	10.92	0.47	1.32e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9902453	0.765	rs2729440	chr17:28106874	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.62	-0.46	1.61e-23	Coffee consumption (cups per day);
LUAD	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	9.55	0.42	1.08e-19	Axial length;
LUAD	cis	rs4006360	0.600	rs6503595	chr17:39257008	C/G	cg12981595	chr17:39254427	KRTAP4-8	0.33	6.5	0.3	2.27e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg24768116	chr2:27665128	KRTCAP3	0.28	6.93	0.32	1.56e-11	Oral cavity cancer;
LUAD	cis	rs600626	0.891	rs695110	chr11:75456581	T/C	cg24262691	chr11:75473276	NA	0.43	7.02	0.32	9.16e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg08885076	chr2:99613938	TSGA10	0.41	7.59	0.35	1.99e-13	Chronic sinus infection;
LUAD	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg21890820	chr11:65308645	LTBP3	0.47	7.55	0.34	2.73e-13	Bone mineral density;
LUAD	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.16	0.33	3.67e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.83	-0.32	2.95e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs9784649	0.771	rs72755810	chr5:25039139	A/C	cg08600765	chr20:34638493	LOC647979	-0.77	-10.45	-0.45	7.07e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg20587970	chr11:113659929	NA	-1.36	-19.95	-0.7	6.99e-63	Hip circumference adjusted for BMI;
LUAD	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg10755058	chr3:40428713	ENTPD3	0.39	7.13	0.33	4.37e-12	Renal cell carcinoma;
LUAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.45	0.3	2.98e-10	Depression;
LUAD	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg04756594	chr16:24857601	SLC5A11	-0.61	-11.81	-0.5	4.98e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg06641503	chr3:48959341	ARIH2	-0.36	-6.46	-0.3	2.86e-10	Menarche (age at onset);
LUAD	trans	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.78	-0.35	5.49e-14	Brugada syndrome;
LUAD	trans	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg18834416	chr8:37888184	EIF4EBP1	0.49	8.24	0.37	2.25e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg06740227	chr12:86229804	RASSF9	0.36	6.36	0.3	5.27e-10	Major depressive disorder;
LUAD	cis	rs7737355	0.773	rs32112	chr5:131048122	G/A	cg25547332	chr5:131281432	NA	0.43	6.94	0.32	1.5e-11	Life satisfaction;
LUAD	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg19622623	chr12:86230825	RASSF9	-0.55	-9.8	-0.43	1.42e-20	Major depressive disorder;
LUAD	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg13918804	chr1:2043761	PRKCZ	0.4	6.77	0.31	4.21e-11	Height;
LUAD	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg05623727	chr3:50126028	RBM5	0.31	6.55	0.3	1.69e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg18806716	chr10:30721971	MAP3K8	-0.64	-12.78	-0.53	7.4e-32	Inflammatory bowel disease;
LUAD	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.56	-8.92	-0.4	1.37e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10657806	chr12:117348826	FBXW8	-0.52	-6.36	-0.3	5.14e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1160297	0.609	rs12622966	chr2:53078420	G/C	cg07782112	chr2:53107842	NA	0.4	8.54	0.38	2.47e-16	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs10484885	0.715	rs2585013	chr6:90553402	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.69	-9.8	-0.43	1.48e-20	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg11663144	chr21:46675770	NA	-0.51	-9.13	-0.41	2.84e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.51	6.93	0.32	1.53e-11	Renal function-related traits (BUN);
LUAD	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.68	-11.4	-0.48	2e-26	Primary sclerosing cholangitis;
LUAD	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.91	-0.5	2.11e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg22681709	chr2:178499509	PDE11A	-0.49	-8.07	-0.37	7.12e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1448094	0.872	rs7311150	chr12:86435989	A/T	cg02569458	chr12:86230093	RASSF9	0.36	6.93	0.32	1.62e-11	Major depressive disorder;
LUAD	cis	rs11048434	0.723	rs2080117	chr12:9138341	C/T	cg23795048	chr12:9217529	LOC144571	0.43	7.92	0.36	2.14e-14	Sjögren's syndrome;
LUAD	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4948275	0.773	rs2256597	chr10:63263294	A/C	cg03237606	chr10:63212265	TMEM26	0.31	6.36	0.3	5.12e-10	Night sleep phenotypes;
LUAD	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.45	-0.3	3.06e-10	Breast cancer;
LUAD	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg07636037	chr3:49044803	WDR6	0.35	6.38	0.3	4.61e-10	Resting heart rate;
LUAD	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg26354017	chr1:205819088	PM20D1	-0.58	-10.64	-0.46	1.42e-23	Menarche (age at onset);
LUAD	cis	rs1865721	1.000	rs62089509	chr18:73194519	G/A	cg26385618	chr18:73139727	C18orf62	-0.41	-7.55	-0.34	2.75e-13	Intelligence;
LUAD	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg11965913	chr1:205819406	PM20D1	0.55	10.09	0.44	1.35e-21	Menarche (age at onset);
LUAD	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg00603274	chr11:61596626	FADS2	-0.38	-6.66	-0.31	8.62e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs13315871	1.000	rs71311870	chr3:58399283	T/C	cg20936604	chr3:58311152	NA	-0.69	-6.9	-0.32	1.86e-11	Cholesterol, total;
LUAD	cis	rs12478296	0.681	rs55802421	chr2:243033962	C/T	cg06360820	chr2:242988706	NA	-0.8	-9.06	-0.4	4.7e-18	Obesity-related traits;
LUAD	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg01802117	chr1:53393560	SCP2	0.33	6.46	0.3	2.82e-10	Monocyte count;
LUAD	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg14784868	chr12:69753453	YEATS4	0.44	7.17	0.33	3.41e-12	Blood protein levels;
LUAD	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg13736514	chr6:26305472	NA	-0.72	-13.53	-0.55	6.41e-35	Educational attainment;
LUAD	cis	rs13223928	0.631	rs12531881	chr7:3156842	C/T	cg19214707	chr7:3157722	NA	-0.52	-9.03	-0.4	6.01e-18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg07936489	chr17:37558343	FBXL20	0.51	6.98	0.32	1.14e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.41	-0.45	9.51e-23	Monocyte percentage of white cells;
LUAD	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg18230493	chr5:56204884	C5orf35	-0.44	-7.4	-0.34	7.44e-13	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs67311347	0.544	rs60329764	chr3:40334621	C/T	cg09455208	chr3:40491958	NA	-0.48	-10.37	-0.45	1.36e-22	Renal cell carcinoma;
LUAD	cis	rs2235649	0.583	rs3760038	chr16:1874717	C/T	cg07386859	chr16:1872102	HAGH	0.5	6.7	0.31	6.72e-11	Blood metabolite levels;
LUAD	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg19729930	chr2:74357872	NA	0.98	16.23	0.62	2.07e-46	Gestational age at birth (maternal effect);
LUAD	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.62	-0.35	1.7e-13	Blood metabolite levels;
LUAD	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg14186256	chr22:23484241	RTDR1	0.48	8.11	0.37	5.65e-15	Bone mineral density;
LUAD	cis	rs9896933	0.615	rs2379354	chr17:80704385	G/A	cg16060761	chr17:80687452	NA	0.56	6.4	0.3	4.08e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg02569458	chr12:86230093	RASSF9	-0.36	-7.03	-0.32	8.19e-12	Major depressive disorder;
LUAD	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21659725	chr3:3221576	CRBN	-0.65	-11.2	-0.48	1.09e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs17255340	0.530	rs6923627	chr6:84064858	G/A	cg08257003	chr6:84140564	ME1	0.34	6.72	0.31	5.9e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg11344533	chr11:111475393	SIK2	-0.35	-6.4	-0.3	4.19e-10	Primary sclerosing cholangitis;
LUAD	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.31	-8.08	-0.37	6.71e-15	Menopause (age at onset);
LUAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14893161	chr1:205819251	PM20D1	0.8	16.81	0.63	6.44e-49	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg17366294	chr4:99064904	C4orf37	0.64	11.9	0.5	2.37e-28	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13082711	0.911	rs13089870	chr3:27447626	C/T	cg02860705	chr3:27208620	NA	0.57	8.76	0.39	4.73e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00149659	chr3:10157352	C3orf10	0.87	10.45	0.45	7.01e-23	Alzheimer's disease;
LUAD	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg27490568	chr2:178487706	NA	0.49	6.56	0.3	1.53e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg18854424	chr1:2615690	NA	0.4	8.63	0.39	1.28e-16	Ulcerative colitis;
LUAD	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2806561	0.828	rs944509	chr1:23542242	C/T	cg12483005	chr1:23474871	LUZP1	-0.38	-6.44	-0.3	3.21e-10	Height;
LUAD	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-7.3	-0.33	1.44e-12	Platelet count;
LUAD	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg21171335	chr12:122356390	WDR66	0.74	13.91	0.56	1.68e-36	Mean corpuscular volume;
LUAD	cis	rs17608059	0.545	rs9915045	chr17:13902636	G/T	cg11395062	chr17:14139857	CDRT15	0.45	7.06	0.32	6.82e-12	Temperament;
LUAD	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg03474202	chr17:45855739	NA	-0.37	-8.69	-0.39	7.77e-17	IgG glycosylation;
LUAD	cis	rs7119	0.667	rs4886889	chr15:77902347	T/C	cg27398640	chr15:77910606	LINGO1	0.39	7.5	0.34	3.73e-13	Type 2 diabetes;
LUAD	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg27572855	chr1:25598939	RHD	0.62	14.18	0.57	1.32e-37	Erythrocyte sedimentation rate;
LUAD	cis	rs6028335	0.610	rs12626028	chr20:37553900	G/C	cg27660920	chr20:37554817	FAM83D	0.57	7.47	0.34	4.63e-13	Alcohol and nicotine co-dependence;
LUAD	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	10.06	0.44	1.76e-21	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03264133	chr6:25882463	NA	-0.91	-16.18	-0.62	3.39e-46	Uric acid levels;
LUAD	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-8.16	-0.37	3.85e-15	Axial length;
LUAD	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg09184832	chr6:79620586	NA	-0.52	-9.85	-0.43	9.48e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	1.000	rs115965820	chr4:119586485	G/A	cg02775129	chr4:119771670	NA	-0.84	-7.82	-0.36	4.27e-14	Cannabis dependence symptom count;
LUAD	cis	rs7737355	0.738	rs3776016	chr5:130855352	C/T	cg06307176	chr5:131281290	NA	0.44	7.27	0.33	1.81e-12	Life satisfaction;
LUAD	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg25358565	chr5:93447407	FAM172A	0.62	7.21	0.33	2.67e-12	Diabetic retinopathy;
LUAD	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg24818145	chr4:99064322	C4orf37	-0.45	-6.95	-0.32	1.41e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17155006	0.691	rs413412	chr7:107745399	A/G	cg05962710	chr7:107745446	LAMB4	-0.34	-7.35	-0.34	1.05e-12	Pneumococcal bacteremia;
LUAD	cis	rs2274273	0.624	rs7152390	chr14:55811701	C/T	cg04306507	chr14:55594613	LGALS3	0.41	7.84	0.36	3.7e-14	Protein biomarker;
LUAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg18305652	chr10:134549665	INPP5A	0.61	11.82	0.5	4.88e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg08355456	chr11:67383691	NA	-0.47	-8.45	-0.38	4.92e-16	Mean corpuscular volume;
LUAD	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg08798685	chr6:27730294	NA	-0.69	-7.3	-0.33	1.47e-12	Depression;
LUAD	trans	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.48	-0.34	4.34e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg04041942	chr8:28747613	INTS9;HMBOX1	-0.4	-6.74	-0.31	5.09e-11	Subcortical brain region volumes;
LUAD	cis	rs2224391	0.628	rs2753245	chr6:5258092	G/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.62	-9.41	-0.42	3.3e-19	Height;
LUAD	cis	rs10193935	0.901	rs7594010	chr2:42534896	C/T	cg27598129	chr2:42591480	NA	-0.79	-9.8	-0.43	1.39e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg13813247	chr22:41461852	NA	-0.5	-7.87	-0.36	3.07e-14	Neuroticism;
LUAD	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg25985355	chr7:65971099	NA	-0.38	-6.93	-0.32	1.62e-11	Aortic root size;
LUAD	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg26446133	chr18:72167187	CNDP2	-0.76	-10.45	-0.45	6.59e-23	Refractive error;
LUAD	cis	rs3806843	0.548	rs246038	chr5:140331699	A/G	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.41	-0.3	3.86e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11890956	chr21:40555474	PSMG1	-0.45	-7.27	-0.33	1.8e-12	Cognitive function;
LUAD	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg01689657	chr7:91764605	CYP51A1	0.3	7.37	0.34	8.88e-13	Breast cancer;
LUAD	cis	rs7737355	0.853	rs10051003	chr5:131072410	C/T	cg25547332	chr5:131281432	NA	0.43	7.02	0.32	8.89e-12	Life satisfaction;
LUAD	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg10523679	chr1:76189770	ACADM	0.95	18.58	0.67	9.41e-57	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4930103	0.711	rs217710	chr11:2007244	C/T	cg06197492	chr11:2016605	H19	0.35	7.03	0.32	8.52e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.66	-10.32	-0.45	2.01e-22	IgG glycosylation;
LUAD	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg01475377	chr6:109611718	NA	-0.5	-9.41	-0.42	3.19e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg26958806	chr6:27640298	NA	0.65	6.57	0.3	1.51e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg21605333	chr4:119757512	SEC24D	0.81	7.78	0.35	5.59e-14	Cannabis dependence symptom count;
LUAD	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg03690763	chr11:133734501	NA	-0.34	-7.79	-0.35	5.16e-14	Childhood ear infection;
LUAD	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.9	0.32	1.92e-11	Schizophrenia;
LUAD	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-7.22	-0.33	2.46e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs12612619	0.690	rs6754371	chr2:27315064	G/A	cg00617064	chr2:27272375	NA	-0.37	-7.03	-0.32	8.3e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs11811982	0.793	rs115332333	chr1:227329006	G/A	cg24860534	chr1:227506868	CDC42BPA	0.66	7.22	0.33	2.41e-12	Optic disc area;
LUAD	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg24818145	chr4:99064322	C4orf37	0.54	7.92	0.36	2.19e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg10164272	chr16:89456328	ANKRD11	-0.4	-6.37	-0.3	5.04e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg04398451	chr17:18023971	MYO15A	0.78	14.16	0.57	1.57e-37	Total body bone mineral density;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg03067574	chr19:47767875	CCDC9	-0.42	-7.07	-0.33	6.42e-12	Diastolic blood pressure;
LUAD	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg16479474	chr6:28041457	NA	0.4	6.95	0.32	1.4e-11	Parkinson's disease;
LUAD	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg12573674	chr2:1569213	NA	-0.57	-6.82	-0.31	3.22e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg05342682	chr7:94953680	PON1	-0.5	-6.97	-0.32	1.2e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg21475434	chr5:93447410	FAM172A	0.75	8.28	0.37	1.67e-15	Diabetic retinopathy;
LUAD	cis	rs7177699	0.550	rs7182716	chr15:79123753	T/C	cg00540400	chr15:79124168	NA	0.44	9.73	0.43	2.48e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg03388025	chr16:89894329	SPIRE2	0.31	6.87	0.32	2.26e-11	Vitiligo;
LUAD	cis	rs3849570	0.643	rs1851928	chr3:81975395	C/T	cg07356753	chr3:81810745	GBE1	-0.49	-8.27	-0.37	1.76e-15	Waist circumference;Body mass index;
LUAD	cis	rs9902453	0.933	rs7216487	chr17:28502642	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	8.75	0.39	5.11e-17	Coffee consumption (cups per day);
LUAD	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg06627628	chr2:24431161	ITSN2	-0.62	-10.1	-0.44	1.25e-21	Asthma;
LUAD	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg05966235	chr16:28915196	ATP2A1	0.46	7.48	0.34	4.21e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg24069376	chr3:38537580	EXOG	0.34	7.78	0.35	5.56e-14	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.83	0.53	4.51e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg20490199	chr8:104033148	ATP6V1C1	-0.41	-6.63	-0.31	1.06e-10	Cancer;
LUAD	cis	rs7107174	1.000	rs10899479	chr11:78052539	A/G	cg02023728	chr11:77925099	USP35	0.45	7.11	0.33	4.82e-12	Testicular germ cell tumor;
LUAD	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.46	0.34	5.03e-13	Bipolar disorder;
LUAD	cis	rs1232027	0.656	rs1650667	chr5:79962226	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	12.41	0.52	2.2e-30	Prudent dietary pattern;
LUAD	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg03037974	chr15:76606532	NA	0.38	7.91	0.36	2.34e-14	Blood metabolite levels;
LUAD	cis	rs736801	0.704	rs56399423	chr5:131672657	T/C	cg14196790	chr5:131705035	SLC22A5	0.51	8.85	0.4	2.47e-17	Breast cancer;Mosquito bite size;
LUAD	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg25894440	chr7:65020034	NA	-0.7	-7.45	-0.34	5.26e-13	Diabetic kidney disease;
LUAD	cis	rs3784262	0.669	rs4646579	chr15:58329528	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.5	-0.34	3.82e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs780096	0.967	rs1260333	chr2:27748624	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.27	-6.89	-0.32	2.02e-11	Total body bone mineral density;
LUAD	cis	rs7107174	0.892	rs10899482	chr11:78060081	A/C	cg19901956	chr11:77921274	USP35	-0.51	-7.17	-0.33	3.29e-12	Testicular germ cell tumor;
LUAD	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg25358565	chr5:93447407	FAM172A	0.62	7.58	0.35	2.2e-13	Diabetic retinopathy;
LUAD	cis	rs73416724	1.000	rs70953670	chr6:43264895	C/A	cg26312998	chr6:43337775	ZNF318	0.56	6.64	0.31	9.91e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg05368731	chr17:41323189	NBR1	0.95	19.61	0.69	2.3e-61	Menopause (age at onset);
LUAD	cis	rs2734839	0.929	rs2734835	chr11:113291343	T/G	cg14159747	chr11:113255604	NA	0.55	10.52	0.46	3.74e-23	Information processing speed;
LUAD	cis	rs12681288	0.550	rs60530879	chr8:958381	G/C	cg04851639	chr8:1020857	NA	-0.34	-7.89	-0.36	2.53e-14	Schizophrenia;
LUAD	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.36	-0.38	8.83e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg05805236	chr11:65401703	PCNXL3	-0.61	-10.13	-0.44	9.42e-22	Acne (severe);
LUAD	trans	rs10411161	1.000	rs3764540	chr19:52380681	T/A	cg22319618	chr22:45562946	NUP50	-0.58	-7.36	-0.34	9.67e-13	Breast cancer;
LUAD	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.85	-0.5	3.72e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg12940439	chr1:67600707	NA	-0.48	-8.93	-0.4	1.27e-17	Psoriasis;
LUAD	cis	rs13082711	0.522	rs820617	chr3:27335510	T/C	cg02860705	chr3:27208620	NA	0.51	8.46	0.38	4.46e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs2554380	0.628	rs890311	chr15:84440952	A/T	cg14598478	chr15:84363061	ADAMTSL3	-0.39	-6.92	-0.32	1.68e-11	Height;
LUAD	trans	rs6011368	0.840	rs6062361	chr20:62904542	C/T	cg13869341	chr1:15865	WASH5P	-0.45	-8.06	-0.36	7.94e-15	Clozapine-induced cytotoxicity;
LUAD	cis	rs4845570	1.000	rs11585294	chr1:151769887	A/C	cg07092448	chr1:151763213	TDRKH	-0.77	-8.84	-0.39	2.67e-17	Coronary artery disease;
LUAD	cis	rs67478160	0.506	rs6575998	chr14:104250417	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.62	-11.57	-0.49	4.45e-27	Schizophrenia;
LUAD	cis	rs7116495	1.000	rs73543633	chr11:71828844	T/C	cg07596299	chr11:71824057	C11orf51	0.75	6.51	0.3	2.2e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg07757535	chr4:1339547	NA	0.31	6.85	0.32	2.7e-11	Longevity;
LUAD	cis	rs2224391	0.518	rs116670419	chr6:5261263	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.62	-9.13	-0.41	2.76e-18	Height;
LUAD	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg11833968	chr6:79620685	NA	-0.44	-8.1	-0.37	6.1e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23158103	chr7:148848205	ZNF398	-0.52	-9.3	-0.41	7.86e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg25828334	chr19:18545568	ISYNA1	-0.35	-6.92	-0.32	1.73e-11	Breast cancer;
LUAD	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg25208724	chr1:156163844	SLC25A44	1.0	15.63	0.6	8.9e-44	Testicular germ cell tumor;
LUAD	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.51	10.59	0.46	2.03e-23	Monocyte percentage of white cells;
LUAD	cis	rs73206853	0.764	rs7311376	chr12:110605559	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	8.03	0.36	9.64e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg03676636	chr4:99064102	C4orf37	0.3	8.04	0.36	9.34e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	7.11	0.33	5.1e-12	Lung cancer;
LUAD	cis	rs2996428	0.667	rs2368534	chr1:3740640	C/T	cg13057898	chr1:3703894	LRRC47	0.64	10.68	0.46	9.54e-24	Red cell distribution width;
LUAD	cis	rs10465746	0.573	rs12121175	chr1:84468961	T/G	cg10977910	chr1:84465055	TTLL7	0.49	7.44	0.34	5.83e-13	Obesity-related traits;
LUAD	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg13390004	chr1:15929781	NA	0.49	8.6	0.39	1.6e-16	Systolic blood pressure;
LUAD	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg01849466	chr14:104193079	ZFYVE21	0.46	7.69	0.35	1.04e-13	Body mass index;
LUAD	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg25324976	chr17:61989376	CSHL1	0.37	7.3	0.33	1.44e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs79839061	0.732	rs7657330	chr4:825156	C/T	cg14530993	chr4:882597	GAK	0.76	6.68	0.31	7.76e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7771547	0.542	rs597153	chr6:36395997	C/T	cg04289385	chr6:36355825	ETV7	0.43	6.61	0.31	1.14e-10	Platelet distribution width;
LUAD	cis	rs870825	0.860	rs10015194	chr4:185598925	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	12.48	0.52	1.22e-30	Blood protein levels;
LUAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg00280220	chr17:61926910	NA	0.37	7.02	0.32	8.68e-12	Prudent dietary pattern;
LUAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg13047869	chr3:10149882	C3orf24	0.68	11.61	0.49	3.09e-27	Alzheimer's disease;
LUAD	cis	rs939658	0.805	rs35602654	chr15:79417527	T/A	cg17916960	chr15:79447300	NA	-0.53	-11.22	-0.48	9.27e-26	Refractive error;
LUAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg14789911	chr21:47582049	C21orf56	0.49	8.83	0.39	2.82e-17	Testicular germ cell tumor;
LUAD	trans	rs9914544	0.689	rs11078421	chr17:18804385	A/G	cg21372672	chr17:16614065	CCDC144A	-0.46	-8.25	-0.37	2.06e-15	Educational attainment (years of education);
LUAD	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg03477792	chr4:77819574	ANKRD56	0.48	7.23	0.33	2.23e-12	Emphysema distribution in smoking;
LUAD	cis	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg24289452	chr6:170231220	NA	-0.58	-6.37	-0.3	4.83e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10457504	chr17:19281708	MAPK7	0.42	6.59	0.31	1.29e-10	Gut microbiome composition (summer);
LUAD	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg07527032	chr15:84868466	LOC388152	0.44	6.65	0.31	9.36e-11	Schizophrenia;
LUAD	cis	rs7737355	0.947	rs3776005	chr5:130879003	T/C	cg25547332	chr5:131281432	NA	0.44	6.83	0.32	2.93e-11	Life satisfaction;
LUAD	trans	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg20587970	chr11:113659929	NA	-1.1	-11.91	-0.5	2.08e-28	Height;
LUAD	cis	rs9297145	1.000	rs9297145	chr7:98759117	A/C	cg05967295	chr7:98741636	SMURF1	0.89	16.18	0.62	3.43e-46	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg00204512	chr16:28754710	NA	0.35	7.65	0.35	1.39e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg11871910	chr12:69753446	YEATS4	0.52	8.13	0.37	4.81e-15	Blood protein levels;
LUAD	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08704250	chr15:31115839	NA	-0.55	-9.97	-0.44	3.75e-21	Huntington's disease progression;
LUAD	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg05340658	chr4:99064831	C4orf37	-0.56	-9.56	-0.42	1.01e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.57	-0.35	2.34e-13	Resting heart rate;
LUAD	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg25036284	chr2:26402008	FAM59B	0.58	8.08	0.37	6.93e-15	Gut microbiome composition (summer);
LUAD	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg08885076	chr2:99613938	TSGA10	-0.39	-6.85	-0.32	2.58e-11	Chronic sinus infection;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg24657604	chr20:328670	NRSN2	0.41	6.44	0.3	3.35e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs55665837	1.000	rs12364959	chr11:14507435	T/C	cg19336497	chr11:14380999	RRAS2	-0.5	-9.97	-0.44	3.71e-21	Vitamin D levels;
LUAD	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg16479474	chr6:28041457	NA	0.34	6.37	0.3	4.84e-10	Parkinson's disease;
LUAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg03188948	chr7:1209495	NA	0.8	9.53	0.42	1.25e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg13047869	chr3:10149882	C3orf24	0.64	11.07	0.47	3.5e-25	Alzheimer's disease;
LUAD	cis	rs3764563	1.000	rs2031061	chr19:15721961	T/C	cg20725493	chr19:15740067	CYP4F8	-0.68	-7.72	-0.35	8.45e-14	Inflammatory biomarkers;
LUAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg24829409	chr8:58192753	C8orf71	-0.61	-7.11	-0.33	4.82e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg09021430	chr5:549028	NA	-0.69	-13.3	-0.54	5.59e-34	Lung disease severity in cystic fibrosis;
LUAD	trans	rs9784649	0.891	rs57355285	chr5:25016384	C/G	cg08600765	chr20:34638493	LOC647979	-0.62	-7.78	-0.35	5.64e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1032833	0.732	rs17453976	chr2:179970978	C/G	cg23883738	chr2:179974586	SESTD1	-0.7	-8.42	-0.38	6.08e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs9323205	0.723	rs61985121	chr14:51705925	A/G	cg23942311	chr14:51606299	NA	-0.59	-8.52	-0.38	2.75e-16	Cancer;
LUAD	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg06808227	chr14:105710500	BRF1	0.41	6.49	0.3	2.36e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs240764	0.746	rs240156	chr6:101063149	C/G	cg09795085	chr6:101329169	ASCC3	0.43	7.26	0.33	1.87e-12	Neuroticism;
LUAD	cis	rs7192380	1.000	rs8061052	chr16:69656532	G/A	cg00738113	chr16:70207722	CLEC18C	-0.34	-6.96	-0.32	1.29e-11	Sjögren's syndrome;
LUAD	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg09491104	chr22:46646882	C22orf40	-0.74	-13.44	-0.55	1.6e-34	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2996428	0.629	rs12135894	chr1:3728061	C/T	cg23277830	chr1:3704460	LRRC47	0.46	9.63	0.42	5.5e-20	Red cell distribution width;
LUAD	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg18252515	chr7:66147081	NA	-0.63	-6.84	-0.32	2.86e-11	Diabetic kidney disease;
LUAD	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg15147215	chr3:52552868	STAB1	-0.43	-7.88	-0.36	2.79e-14	Bipolar disorder;
LUAD	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg23283495	chr1:209979779	IRF6	0.74	8.91	0.4	1.51e-17	Coronary artery disease;
LUAD	cis	rs925255	0.901	rs906805	chr2:28604879	A/G	cg01273330	chr2:28605224	NA	-0.43	-9.74	-0.43	2.36e-20	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs708547	0.647	rs1718831	chr4:57886946	T/G	cg00922110	chr4:57842668	C4orf14	-0.44	-8.13	-0.37	4.7e-15	Response to bleomycin (chromatid breaks);
LUAD	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg01475377	chr6:109611718	NA	0.53	10.41	0.45	9.19e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs8017423	0.647	rs12587362	chr14:90821227	G/T	cg14092571	chr14:90743983	NA	0.39	6.63	0.31	1.02e-10	Mortality in heart failure;
LUAD	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg13319975	chr6:146136371	FBXO30	0.68	11.78	0.5	6.62e-28	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs701145	0.938	rs189588	chr3:153995855	T/G	cg17054900	chr3:154042577	DHX36	0.64	7.1	0.33	5.16e-12	Coronary artery disease;
LUAD	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg04772025	chr11:68637568	NA	0.56	8.96	0.4	1.03e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs67981189	0.634	rs221891	chr14:71611627	C/T	cg15816911	chr14:71606274	NA	-0.37	-6.89	-0.32	2.08e-11	Schizophrenia;
LUAD	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.41	-6.62	-0.31	1.08e-10	Schizophrenia;
LUAD	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg26384229	chr12:38710491	ALG10B	-0.38	-6.51	-0.3	2.14e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg02869364	chr7:1081709	C7orf50	-0.51	-6.61	-0.31	1.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg05535760	chr7:792225	HEATR2	0.86	11.52	0.49	6.55e-27	Cerebrospinal P-tau181p levels;
LUAD	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg14847009	chr1:175162515	KIAA0040	-0.33	-8.61	-0.39	1.5e-16	Alcohol dependence;
LUAD	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.45	-0.34	5.2e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504073	0.669	rs341802	chr8:50039313	C/T	cg00325661	chr8:49890786	NA	0.41	9.2	0.41	1.63e-18	Blood metabolite ratios;
LUAD	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.54	7.74	0.35	7.35e-14	Platelet count;
LUAD	cis	rs62229266	0.804	rs2835231	chr21:37390598	C/T	cg12218747	chr21:37451666	NA	-0.47	-8.1	-0.37	5.91e-15	Mitral valve prolapse;
LUAD	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg16797656	chr11:68205561	LRP5	0.48	9.66	0.43	4.44e-20	Total body bone mineral density;
LUAD	cis	rs2997447	0.706	rs2783713	chr1:26429351	C/A	cg00147160	chr1:26503991	CNKSR1	0.35	6.43	0.3	3.37e-10	QRS complex (12-leadsum);
LUAD	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg06108461	chr20:60628389	TAF4	-0.74	-12.4	-0.52	2.52e-30	Body mass index;
LUAD	cis	rs67981189	0.593	rs221906	chr14:71597393	C/G	cg15816911	chr14:71606274	NA	0.33	6.38	0.3	4.59e-10	Schizophrenia;
LUAD	cis	rs7617773	0.817	rs17647717	chr3:48305456	C/T	cg11946769	chr3:48343235	NME6	0.43	6.55	0.3	1.63e-10	Coronary artery disease;
LUAD	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg10518543	chr12:38710700	ALG10B	-0.48	-7.9	-0.36	2.38e-14	Morning vs. evening chronotype;
LUAD	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg07741184	chr6:167504864	NA	0.36	8.11	0.37	5.42e-15	Primary biliary cholangitis;
LUAD	cis	rs8017423	0.935	rs59179255	chr14:90691773	A/C	cg14092571	chr14:90743983	NA	-0.49	-8.54	-0.38	2.43e-16	Mortality in heart failure;
LUAD	cis	rs11948739	0.610	rs1363695	chr5:130378027	C/T	cg08523029	chr5:130500466	HINT1	-0.58	-7.34	-0.34	1.14e-12	Pediatric bone mineral content (hip);
LUAD	cis	rs12681287	0.604	rs28378899	chr8:87434500	G/C	cg00550725	chr8:87521180	FAM82B	-0.45	-6.63	-0.31	1.02e-10	Caudate activity during reward;
LUAD	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg21214613	chr1:16344536	HSPB7	-0.4	-6.42	-0.3	3.73e-10	Dilated cardiomyopathy;
LUAD	cis	rs7731657	0.537	rs10051429	chr5:130257549	C/T	cg08523029	chr5:130500466	HINT1	0.58	7.49	0.34	4.01e-13	Fasting plasma glucose;
LUAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg26354017	chr1:205819088	PM20D1	0.85	19.43	0.69	1.38e-60	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11169225	0.756	rs3759124	chr12:50343166	G/A	cg04450003	chr12:50355995	AQP5	0.7	9.86	0.43	8.48e-21	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg11062466	chr8:58055876	NA	0.65	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg08761264	chr16:28874980	SH2B1	-0.45	-6.87	-0.32	2.34e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.79	-0.35	5.18e-14	Type 2 diabetes;
LUAD	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg22920501	chr2:26401640	FAM59B	-0.98	-15.3	-0.6	2.34e-42	Gut microbiome composition (summer);
LUAD	trans	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.82	0.43	1.22e-20	Mean corpuscular volume;
LUAD	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg19717773	chr7:2847554	GNA12	-0.51	-9.56	-0.42	9.65e-20	Height;
LUAD	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg17031739	chr1:67600172	NA	0.52	9.23	0.41	1.33e-18	Psoriasis;
LUAD	trans	rs853679	0.607	rs13197176	chr6:28129232	C/T	cg01620082	chr3:125678407	NA	-1.1	-10.38	-0.45	1.25e-22	Depression;
LUAD	cis	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg23422044	chr7:1970798	MAD1L1	-0.5	-7.07	-0.33	6.47e-12	Bipolar disorder;
LUAD	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.74	-0.31	5.17e-11	Joint mobility (Beighton score);
LUAD	cis	rs684232	0.688	rs2657633	chr17:600502	C/T	cg12384639	chr17:618140	VPS53	0.49	8.52	0.38	2.77e-16	Prostate cancer;
LUAD	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg17845761	chr1:175162550	KIAA0040	0.37	10.06	0.44	1.75e-21	Alcohol dependence;
LUAD	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg12599982	chr1:44399894	ARTN	0.34	6.74	0.31	5.36e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg12501888	chr15:85177176	SCAND2	-0.43	-6.41	-0.3	3.96e-10	P wave terminal force;
LUAD	cis	rs68092024	0.731	rs793480	chr3:99488364	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-9.36	-0.41	4.74e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	7.84	0.36	3.69e-14	Menopause (age at onset);
LUAD	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.87	17.36	0.64	2.34e-51	Chronic sinus infection;
LUAD	cis	rs11723261	0.527	rs11731581	chr4:87932	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.51	9.7	0.43	3.09e-20	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.71e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7180079	1.000	rs8032196	chr15:64515822	A/C	cg08069370	chr15:64387884	SNX1	-0.52	-6.58	-0.3	1.38e-10	Monocyte count;
LUAD	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg10544611	chr16:67998164	SLC12A4	-0.55	-6.94	-0.32	1.44e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg24558204	chr6:135376177	HBS1L	0.47	8.6	0.39	1.62e-16	Red blood cell count;
LUAD	cis	rs7072216	0.727	rs7915108	chr10:100164441	T/C	cg26618903	chr10:100175079	PYROXD2	-0.36	-7.64	-0.35	1.49e-13	Metabolite levels;
LUAD	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg23985595	chr17:80112537	CCDC57	-0.53	-9.51	-0.42	1.43e-19	Life satisfaction;
LUAD	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg26373071	chr5:1325741	CLPTM1L	0.36	7.71	0.35	8.93e-14	Lung cancer;
LUAD	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg06808227	chr14:105710500	BRF1	-0.41	-6.39	-0.3	4.34e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03264133	chr6:25882463	NA	-0.46	-6.93	-0.32	1.54e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg18180107	chr4:99064573	C4orf37	0.43	7.01	0.32	9.5e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg13511324	chr14:104056883	C14orf153	0.26	6.48	0.3	2.63e-10	Coronary artery disease;
LUAD	cis	rs4691139	0.658	rs4691141	chr4:165926222	G/A	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.41	-7.73	-0.35	7.73e-14	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg07936489	chr17:37558343	FBXL20	0.5	6.72	0.31	5.74e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg00504896	chr12:9437009	LOC642846	-0.48	-8.04	-0.36	9.11e-15	Breast size;
LUAD	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.41	7.22	0.33	2.37e-12	Menarche (age at onset);
LUAD	cis	rs28595532	0.623	rs34958556	chr4:119222074	C/T	cg02775129	chr4:119771670	NA	-0.63	-6.81	-0.31	3.36e-11	Cannabis dependence symptom count;
LUAD	cis	rs2677744	0.534	rs6496739	chr15:91494430	C/T	cg23684204	chr15:91497937	RCCD1	0.4	6.54	0.3	1.74e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg04731861	chr2:219085781	ARPC2	-0.24	-7.28	-0.33	1.61e-12	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg04025307	chr7:1156635	C7orf50	0.65	7.41	0.34	7.09e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13012494	chr21:47604986	C21orf56	0.66	11.71	0.49	1.25e-27	Testicular germ cell tumor;
LUAD	cis	rs6752107	0.936	rs10195395	chr2:234206504	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	9.36	0.41	4.79e-19	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2073300	1.000	rs6114126	chr20:23452127	A/T	cg12062639	chr20:23401060	NAPB	0.75	6.96	0.32	1.28e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg24154853	chr7:158122151	PTPRN2	0.57	11.38	0.48	2.29e-26	Calcium levels;
LUAD	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg08859206	chr1:53392774	SCP2	0.59	11.08	0.47	3.27e-25	Monocyte count;
LUAD	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg18132916	chr6:79620363	NA	-0.45	-7.72	-0.35	8.48e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	9.33	0.41	6.19e-19	Menarche (age at onset);
LUAD	cis	rs438465	1.000	rs12055542	chr6:169860981	T/G	cg11181693	chr6:169825345	NA	0.63	7.89	0.36	2.62e-14	Corneal astigmatism;
LUAD	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg10755058	chr3:40428713	ENTPD3	0.45	8.51	0.38	3.01e-16	Renal cell carcinoma;
LUAD	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg20476274	chr7:133979776	SLC35B4	0.86	17.45	0.65	9.39e-52	Mean platelet volume;
LUAD	cis	rs62238980	0.614	rs76222062	chr22:32457049	T/G	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs77861329	1.000	rs352149	chr3:52209530	C/A	cg08692210	chr3:52188851	WDR51A	0.86	8.23	0.37	2.42e-15	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs2840044	0.534	rs2124246	chr17:33885431	G/A	cg05299278	chr17:33885742	SLFN14	0.55	12.9	0.53	2.51e-32	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg21782813	chr7:2030301	MAD1L1	-0.5	-8.54	-0.38	2.5e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23583168	chr7:148888333	NA	-0.93	-19.08	-0.68	5.31e-59	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9487051	0.768	rs463916	chr6:109520538	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.81	-0.31	3.27e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg10523679	chr1:76189770	ACADM	-0.75	-11.95	-0.5	1.5e-28	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.32	-0.45	2.09e-22	Total body bone mineral density;
LUAD	cis	rs367943	0.608	rs4705564	chr5:112980196	G/C	cg12552261	chr5:112820674	MCC	0.45	8.23	0.37	2.42e-15	Type 2 diabetes;
LUAD	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg02176678	chr2:219576539	TTLL4	0.68	13.73	0.56	1.02e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg13606994	chr1:44402422	ARTN	0.37	7.44	0.34	5.74e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg02527881	chr3:46936655	PTH1R	-0.5	-10.29	-0.45	2.7e-22	Colorectal cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14660007	chr13:78271894	SLAIN1	-0.5	-6.38	-0.3	4.7e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg04398451	chr17:18023971	MYO15A	-0.64	-11.67	-0.49	1.82e-27	Total body bone mineral density;
LUAD	trans	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg01620082	chr3:125678407	NA	-0.77	-8.29	-0.37	1.54e-15	Breast cancer;
LUAD	cis	rs1832871	0.672	rs62437361	chr6:158728759	C/T	cg07165851	chr6:158734300	TULP4	0.7	10.59	0.46	2.09e-23	Height;
LUAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg07685180	chr8:600429	NA	0.69	7.21	0.33	2.55e-12	IgG glycosylation;
LUAD	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00290607	chr11:67383545	NA	-0.54	-9.31	-0.41	7.12e-19	Mean corpuscular volume;
LUAD	cis	rs7267979	0.657	rs6107073	chr20:25716363	T/C	cg08601574	chr20:25228251	PYGB	0.38	7.18	0.33	3.14e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg25324976	chr17:61989376	CSHL1	0.38	7.47	0.34	4.66e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.76	-0.35	6.28e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg00339695	chr16:24857497	SLC5A11	-0.48	-8.94	-0.4	1.25e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs4766566	0.694	rs3843673	chr12:111746499	A/G	cg10833066	chr12:111807467	FAM109A	0.68	13.91	0.56	1.77e-36	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUAD	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg14668632	chr7:2872130	GNA12	-0.72	-12.52	-0.52	7.91e-31	Height;
LUAD	cis	rs727505	0.564	rs57841320	chr7:124847732	T/A	cg23710748	chr7:124431027	NA	-0.37	-7.39	-0.34	7.77e-13	Lewy body disease;
LUAD	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg25358565	chr5:93447407	FAM172A	0.62	7.21	0.33	2.67e-12	Diabetic retinopathy;
LUAD	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg17173187	chr15:85201210	NMB	0.4	6.4	0.3	4.02e-10	Schizophrenia;
LUAD	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg03878208	chr11:72483293	STARD10	-0.47	-6.91	-0.32	1.78e-11	Type 2 diabetes;
LUAD	trans	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	17.91	0.66	8.54e-54	Exhaled nitric oxide output;
LUAD	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg05665937	chr4:1216051	CTBP1	0.38	6.41	0.3	3.8e-10	Obesity-related traits;
LUAD	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg13722127	chr7:150037890	RARRES2	0.49	8.01	0.36	1.09e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg11062466	chr8:58055876	NA	0.76	9.31	0.41	6.82e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9560113	1.000	rs9560107	chr13:112180146	G/A	cg14154082	chr13:112174009	NA	0.36	6.75	0.31	4.77e-11	Menarche (age at onset);
LUAD	cis	rs6424115	0.594	rs10799802	chr1:24009544	C/T	cg10978503	chr1:24200527	CNR2	0.35	6.77	0.31	4.44e-11	Immature fraction of reticulocytes;
LUAD	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.64	-0.31	9.82e-11	Prostate cancer;
LUAD	cis	rs2997447	0.723	rs2802336	chr1:26473758	A/C	cg00147160	chr1:26503991	CNKSR1	0.34	6.38	0.3	4.53e-10	QRS complex (12-leadsum);
LUAD	cis	rs78761021	0.867	rs62066058	chr17:9784528	A/G	cg26853458	chr17:9805074	RCVRN	0.33	6.68	0.31	7.4e-11	Type 2 diabetes;
LUAD	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg20578329	chr17:80767326	TBCD	-0.65	-7.5	-0.34	3.77e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg05966235	chr16:28915196	ATP2A1	0.46	7.47	0.34	4.56e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9814567	0.752	rs13075117	chr3:134329535	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	13.93	0.56	1.38e-36	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4906332	0.966	rs4906331	chr14:103971374	C/T	cg13511324	chr14:104056883	C14orf153	0.26	6.46	0.3	2.85e-10	Coronary artery disease;
LUAD	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg21475434	chr5:93447410	FAM172A	-0.66	-7.48	-0.34	4.47e-13	Diabetic retinopathy;
LUAD	trans	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg21372672	chr17:16614065	CCDC144A	0.4	6.9	0.32	1.94e-11	Educational attainment (years of education);
LUAD	cis	rs6542838	0.641	rs6760065	chr2:99486318	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.99	-0.32	1.1e-11	Fear of minor pain;
LUAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.8	-0.31	3.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg14847009	chr1:175162515	KIAA0040	0.3	7.75	0.35	6.78e-14	Alcohol dependence;
LUAD	trans	rs208520	0.955	rs208538	chr6:66964492	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-13.49	-0.55	9.7e-35	Exhaled nitric oxide output;
LUAD	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg22532475	chr10:104410764	TRIM8	-0.44	-8.72	-0.39	6.46e-17	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg04586622	chr2:25135609	ADCY3	0.37	8.38	0.38	8.01e-16	Body mass index;
LUAD	cis	rs4268898	0.965	rs4665673	chr2:24459737	A/T	cg02683114	chr2:24398427	C2orf84	0.42	7.04	0.32	7.93e-12	Asthma;
LUAD	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg06618935	chr21:46677482	NA	-0.49	-9.99	-0.44	3.09e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	1.04e-10	Diabetic kidney disease;
LUAD	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg07217954	chr7:1067459	C7orf50	-0.38	-6.85	-0.32	2.55e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg12311346	chr5:56204834	C5orf35	0.73	11.6	0.49	3.39e-27	Initial pursuit acceleration;
LUAD	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg24558204	chr6:135376177	HBS1L	0.43	7.5	0.34	3.69e-13	Red blood cell count;
LUAD	trans	rs853679	0.607	rs56189111	chr6:28271973	C/A	cg01620082	chr3:125678407	NA	-1.1	-10.51	-0.46	4.29e-23	Depression;
LUAD	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-8.25	-0.37	2e-15	Blood metabolite levels;
LUAD	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg25985355	chr7:65971099	NA	0.53	6.72	0.31	6e-11	Diabetic kidney disease;
LUAD	cis	rs9535307	0.929	rs9316474	chr13:50313345	C/A	cg04663916	chr13:50265991	EBPL	0.58	6.89	0.32	2.03e-11	Obesity-related traits;
LUAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg00280220	chr17:61926910	NA	0.37	7.03	0.32	8.08e-12	Prudent dietary pattern;
LUAD	cis	rs35740288	0.770	rs11634177	chr15:86148390	A/G	cg13263323	chr15:86062960	AKAP13	0.46	7.22	0.33	2.46e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg05535760	chr7:792225	HEATR2	0.99	12.71	0.53	1.42e-31	Cerebrospinal P-tau181p levels;
LUAD	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-7.08	-0.33	6.16e-12	Lung cancer;
LUAD	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.64	-11.12	-0.48	2.31e-25	Melanoma;
LUAD	cis	rs11229555	0.645	rs10466659	chr11:58190112	A/G	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs859767	0.672	rs10203582	chr2:135362839	C/A	cg12500956	chr2:135428796	TMEM163	-0.3	-8.13	-0.37	4.88e-15	Neuroticism;
LUAD	cis	rs7584330	0.554	rs75918156	chr2:238426287	G/A	cg14458575	chr2:238380390	NA	0.61	9.85	0.43	9.8e-21	Prostate cancer;
LUAD	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg05966235	chr16:28915196	ATP2A1	0.47	7.65	0.35	1.38e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7932354	0.528	rs7108902	chr11:47091571	C/T	cg19486271	chr11:47235900	DDB2	-0.44	-6.99	-0.32	1.06e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04267008	chr7:1944627	MAD1L1	-0.71	-10.96	-0.47	8.85e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.94	-0.36	1.83e-14	Total body bone mineral density;
LUAD	cis	rs4964805	0.657	rs4964814	chr12:104189384	A/C	cg02344784	chr12:104178138	NT5DC3	-0.45	-9.13	-0.41	2.91e-18	Attention deficit hyperactivity disorder;
LUAD	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg22546130	chr22:19950026	COMT	0.41	8.43	0.38	5.48e-16	Blood metabolite levels;
LUAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.53	-0.46	3.38e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg22875332	chr1:76189707	ACADM	-0.69	-11.11	-0.48	2.42e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1018836	0.892	rs10103198	chr8:91579436	A/T	cg16814680	chr8:91681699	NA	-0.59	-9.7	-0.43	3.16e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg22676075	chr6:135203613	NA	0.4	7.35	0.34	1.02e-12	Red blood cell count;
LUAD	cis	rs12545109	0.800	rs1837617	chr8:57417592	C/T	cg09654669	chr8:57350985	NA	-0.65	-9.43	-0.42	2.75e-19	Obesity-related traits;
LUAD	cis	rs6738485	0.507	rs72819611	chr2:106845912	G/A	cg15412446	chr2:106886593	NA	-0.8	-11.47	-0.49	1.04e-26	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	trans	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg06606381	chr12:133084897	FBRSL1	-0.48	-6.55	-0.3	1.7e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg11734862	chr6:26538671	HMGN4	-0.67	-6.39	-0.3	4.38e-10	Type 2 diabetes;
LUAD	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.73	0.31	5.7e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.06	-14.23	-0.57	7.76e-38	Schizophrenia;
LUAD	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg00071950	chr4:10020882	SLC2A9	0.7	14.27	0.57	5.46e-38	Bone mineral density;
LUAD	cis	rs7177699	0.526	rs7182529	chr15:79123631	T/C	cg15571903	chr15:79123663	NA	0.42	8.82	0.39	3e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg08997352	chr12:9597637	DDX12	-0.64	-10.82	-0.47	2.88e-24	Breast size;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg18185028	chr3:154042079	DHX36	-0.41	-6.71	-0.31	6.27e-11	Vertical cup-disc ratio;
LUAD	trans	rs931812	0.895	rs13251731	chr8:101902528	C/G	cg20993868	chr7:22813445	NA	0.64	13.58	0.55	4.04e-35	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs2274471	0.699	rs10974985	chr9:5156061	C/T	cg03390472	chr9:5043263	JAK2	0.51	7.35	0.34	1.01e-12	Crohn's disease;
LUAD	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg02725872	chr8:58115012	NA	-0.33	-6.46	-0.3	2.9e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg05340658	chr4:99064831	C4orf37	0.45	7.36	0.34	9.65e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.37	20.03	0.7	2.95e-63	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg00666640	chr1:248458726	OR2T12	0.33	7.83	0.36	3.92e-14	Common traits (Other);
LUAD	trans	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg01620082	chr3:125678407	NA	-0.77	-8.49	-0.38	3.62e-16	Breast cancer;
LUAD	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4285028	0.948	rs1920290	chr3:121672305	A/G	cg11130432	chr3:121712080	ILDR1	-0.59	-8.35	-0.38	9.95e-16	Multiple sclerosis;
LUAD	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg21204522	chr6:27730016	NA	-0.47	-7.61	-0.35	1.77e-13	Parkinson's disease;
LUAD	cis	rs68170813	0.559	rs74925723	chr7:106954536	G/C	cg02696742	chr7:106810147	HBP1	-0.76	-10.41	-0.45	9.42e-23	Coronary artery disease;
LUAD	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg13535736	chr9:111863775	C9orf5	-0.42	-6.6	-0.31	1.21e-10	Menarche (age at onset);
LUAD	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg10053473	chr17:62856997	LRRC37A3	0.7	11.34	0.48	3.45e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2294693	0.945	rs742494	chr6:41007835	A/T	cg14769373	chr6:40998127	UNC5CL	-0.51	-7.59	-0.35	2.09e-13	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03452623	chr4:187889614	NA	-0.81	-16.76	-0.63	1.05e-48	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg14583973	chr4:3374767	RGS12	0.3	7.79	0.35	5.07e-14	Serum sulfate level;
LUAD	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg15309053	chr8:964076	NA	0.45	10.05	0.44	1.91e-21	Schizophrenia;
LUAD	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg08999081	chr20:33150536	PIGU	-0.63	-14.1	-0.57	2.92e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08859206	chr1:53392774	SCP2	0.74	13.71	0.55	1.12e-35	Monocyte count;
LUAD	cis	rs17155006	0.746	rs419031	chr7:107750157	G/A	cg05962710	chr7:107745446	LAMB4	-0.34	-7.27	-0.33	1.74e-12	Pneumococcal bacteremia;
LUAD	cis	rs714027	1.000	rs5997579	chr22:30537526	A/G	cg11564601	chr22:30592435	NA	-0.38	-8.09	-0.37	6.2e-15	Lymphocyte counts;
LUAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.4	-8.54	-0.38	2.42e-16	Lymphocyte counts;
LUAD	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg26343298	chr8:95960752	TP53INP1	0.35	7.33	0.34	1.14e-12	Type 2 diabetes;
LUAD	cis	rs6906287	0.647	rs4946350	chr6:118945433	A/C	cg18833306	chr6:118973337	C6orf204	0.49	8.57	0.38	2e-16	Electrocardiographic conduction measures;
LUAD	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg07741184	chr6:167504864	NA	0.39	8.97	0.4	9.39e-18	Crohn's disease;
LUAD	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	8.08	0.37	6.74e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg15448220	chr1:150897856	SETDB1	0.58	9.88	0.43	7.78e-21	Melanoma;
LUAD	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg01657329	chr11:68192670	LRP5	0.46	8.4	0.38	6.99e-16	Total body bone mineral density;
LUAD	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg14558114	chr2:88469736	THNSL2	0.87	9.0	0.4	7.98e-18	Plasma clusterin levels;
LUAD	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg16988262	chr1:15930761	NA	0.41	6.9	0.32	1.97e-11	Systolic blood pressure;
LUAD	trans	rs7395662	0.927	rs12793888	chr11:48488056	A/G	cg15704280	chr7:45808275	SEPT13	-0.41	-6.39	-0.3	4.31e-10	HDL cholesterol;
LUAD	cis	rs4144027	0.967	rs10133399	chr14:104361843	A/T	cg12183467	chr14:104352244	NA	0.38	7.37	0.34	9.04e-13	Blood metabolite levels;
LUAD	cis	rs7512552	0.839	rs834236	chr1:150362968	C/T	cg15654264	chr1:150340011	RPRD2	0.58	11.08	0.47	3.24e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.56	0.35	2.45e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg18876405	chr7:65276391	NA	0.47	7.57	0.35	2.4e-13	Aortic root size;
LUAD	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.41	0.38	6.44e-16	Body mass index;
LUAD	cis	rs9354308	0.933	rs2802064	chr6:66564352	C/T	cg07460842	chr6:66804631	NA	0.51	7.59	0.35	2.06e-13	Metabolite levels;
LUAD	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg00922110	chr4:57842668	C4orf14	-0.44	-8.51	-0.38	3.03e-16	Response to bleomycin (chromatid breaks);
LUAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg11062466	chr8:58055876	NA	0.71	8.95	0.4	1.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7107174	1.000	rs2450129	chr11:77940385	T/C	cg19901956	chr11:77921274	USP35	-0.54	-6.74	-0.31	5.35e-11	Testicular germ cell tumor;
LUAD	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg08422745	chr4:174089978	GALNT7	-0.94	-16.54	-0.63	9.34e-48	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg10819733	chr22:24237672	NA	-0.42	-7.98	-0.36	1.36e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg18099408	chr3:52552593	STAB1	-0.46	-7.22	-0.33	2.51e-12	Bipolar disorder;
LUAD	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg05110241	chr16:68378359	PRMT7	-0.92	-10.24	-0.45	4.05e-22	Schizophrenia;
LUAD	cis	rs17539620	0.565	rs61225515	chr6:154841625	A/G	cg20019720	chr6:154832845	CNKSR3	0.63	11.46	0.49	1.17e-26	Lipoprotein (a) levels;
LUAD	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11696501	0.688	rs6073850	chr20:44301084	C/T	cg11783356	chr20:44313418	WFDC10B	-0.47	-7.39	-0.34	7.76e-13	Brain structure;
LUAD	cis	rs2742234	0.910	rs2503866	chr10:43646261	T/A	cg15436174	chr10:43711423	RASGEF1A	-0.44	-8.03	-0.36	9.53e-15	Hirschsprung disease;
LUAD	trans	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg26043149	chr18:55253948	FECH	0.5	7.99	0.36	1.31e-14	Bone mineral density;
LUAD	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg20587970	chr11:113659929	NA	-1.29	-18.36	-0.67	8.95e-56	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.34e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg21220214	chr8:57350948	NA	-0.59	-8.73	-0.39	6.17e-17	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.37	-0.38	8.48e-16	Cannabis dependence symptom count;
LUAD	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg01200585	chr1:228362443	C1orf69	-0.38	-7.08	-0.33	6.19e-12	Diastolic blood pressure;
LUAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	trans	rs1904173	0.599	rs34839390	chr5:25073949	A/G	cg04802221	chr16:67223955	EXOC3L	0.5	6.99	0.32	1.07e-11	IgG glycosylation;
LUAD	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg09491104	chr22:46646882	C22orf40	0.66	11.96	0.5	1.39e-28	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg19130645	chr7:65235666	NA	0.39	6.47	0.3	2.75e-10	Aortic root size;
LUAD	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg22153463	chr1:85462885	MCOLN2	-0.57	-8.08	-0.37	6.78e-15	Serum sulfate level;
LUAD	cis	rs71478720	0.953	rs1834481	chr11:112023827	C/G	cg09122223	chr11:112035175	IL18	-0.43	-6.84	-0.32	2.73e-11	Interleukin-18 levels;
LUAD	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg00383909	chr3:49044727	WDR6	0.88	9.86	0.43	8.81e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs9487051	0.768	rs442405	chr6:109526980	T/G	cg01475377	chr6:109611718	NA	-0.38	-6.77	-0.31	4.22e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs11671005	0.735	rs3764532	chr19:58929222	G/A	cg13877915	chr19:58951672	ZNF132	0.56	7.42	0.34	6.67e-13	Mean platelet volume;
LUAD	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg02160872	chr5:212506	CCDC127	-0.52	-6.73	-0.31	5.59e-11	Breast cancer;
LUAD	cis	rs6987853	0.736	rs2923446	chr8:42404177	G/A	cg09913449	chr8:42400586	C8orf40	0.52	10.61	0.46	1.78e-23	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg03713592	chr11:72463424	ARAP1	0.59	7.55	0.34	2.75e-13	Type 2 diabetes;
LUAD	cis	rs7582720	1.000	rs72934537	chr2:203969504	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.63	0.42	5.52e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg22906224	chr7:99728672	NA	0.55	9.5	0.42	1.5700000000000001e-19	Coronary artery disease;
LUAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg09033563	chr22:24373618	LOC391322	0.68	11.67	0.49	1.84e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs1337391	0.649	rs6475062	chr9:16563037	G/C	cg08976687	chr2:85515537	TCF7L1	0.43	6.45	0.3	3.08e-10	Heschl's gyrus morphology;
LUAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg08888203	chr3:10149979	C3orf24	0.72	12.74	0.53	1.06e-31	Alzheimer's disease;
LUAD	cis	rs8072100	0.807	rs4561509	chr17:45781799	G/A	cg08085267	chr17:45401833	C17orf57	-0.64	-11.3	-0.48	4.5e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg06641503	chr3:48959341	ARIH2	-0.4	-7.99	-0.36	1.33e-14	Parkinson's disease;
LUAD	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg11822812	chr5:140052017	DND1	-0.44	-8.14	-0.37	4.36e-15	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg20592378	chr7:92861504	CCDC132	0.45	6.69	0.31	7.12e-11	QT interval;
LUAD	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg15445000	chr17:37608096	MED1	-0.44	-8.12	-0.37	5.31e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg26446133	chr18:72167187	CNDP2	-0.84	-13.41	-0.55	2e-34	Refractive error;
LUAD	cis	rs7771547	0.519	rs58153398	chr6:36370394	A/C	cg04289385	chr6:36355825	ETV7	0.49	7.18	0.33	3.09e-12	Platelet distribution width;
LUAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg26338869	chr17:61819248	STRADA	-0.38	-6.38	-0.3	4.73e-10	Prudent dietary pattern;
LUAD	cis	rs7659604	0.521	rs6822155	chr4:122673274	C/A	cg06713675	chr4:122721982	EXOSC9	0.42	7.63	0.35	1.5700000000000001e-13	Type 2 diabetes;
LUAD	cis	rs494562	0.892	rs7767626	chr6:86124394	G/A	cg17966619	chr6:86160162	NT5E	0.65	7.73	0.35	7.8e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7192380	0.893	rs12921782	chr16:69780022	C/T	cg00738113	chr16:70207722	CLEC18C	0.38	7.48	0.34	4.2e-13	Sjögren's syndrome;
LUAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg26354017	chr1:205819088	PM20D1	0.5	8.18	0.37	3.47e-15	Parkinson's disease;
LUAD	cis	rs2455601	0.786	rs3763913	chr11:8951230	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.54	-9.0	-0.4	7.64e-18	Schizophrenia;
LUAD	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg17849569	chr6:28058911	ZSCAN12L1	-0.32	-6.81	-0.31	3.41e-11	Depression;
LUAD	cis	rs62400317	0.762	rs62436369	chr6:44867539	C/G	cg18551225	chr6:44695536	NA	-0.56	-8.47	-0.38	4.04e-16	Total body bone mineral density;
LUAD	cis	rs68170813	0.559	rs12536603	chr7:107002573	T/C	cg23024343	chr7:107201750	COG5	0.52	7.37	0.34	9.29e-13	Coronary artery disease;
LUAD	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.92	-0.4	1.46e-17	Initial pursuit acceleration;
LUAD	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg04155289	chr7:94953770	PON1	-0.52	-6.94	-0.32	1.51e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.47	6.44	0.3	3.31e-10	Renal function-related traits (BUN);
LUAD	cis	rs738322	0.600	rs4821751	chr22:38564457	T/C	cg25457927	chr22:38595422	NA	-0.54	-12.57	-0.52	5.11e-31	Cutaneous nevi;
LUAD	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg13390004	chr1:15929781	NA	0.43	6.83	0.32	2.93e-11	Systolic blood pressure;
LUAD	cis	rs4812048	0.793	rs6070693	chr20:57589516	C/T	cg14073986	chr20:57617431	SLMO2	0.62	7.39	0.34	8.03e-13	Mean platelet volume;
LUAD	cis	rs1707322	0.638	rs9429095	chr1:46603348	A/C	cg06784218	chr1:46089804	CCDC17	-0.37	-7.91	-0.36	2.21e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs2554380	0.783	rs2554385	chr15:84406587	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.48	-7.36	-0.34	9.47e-13	Height;
LUAD	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg12062639	chr20:23401060	NAPB	1.1	11.43	0.49	1.54e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-11.59	-0.49	3.81e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg04450456	chr4:17643702	FAM184B	-0.41	-8.14	-0.37	4.47e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3845702	1.000	rs262279	chr2:180869145	G/A	cg01881094	chr2:180872142	CWC22	0.58	7.51	0.34	3.5e-13	Schizophrenia;
LUAD	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg18944383	chr4:111397179	ENPEP	0.41	8.26	0.37	1.87e-15	Height;
LUAD	cis	rs1105228	0.759	rs581335	chr6:165709371	C/T	cg12582777	chr6:165658423	NA	-0.32	-6.56	-0.3	1.59e-10	Number of pregnancies;Number of children;
LUAD	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg00383909	chr3:49044727	WDR6	0.75	8.6	0.39	1.52e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2041840	1.000	rs11124575	chr2:37500435	G/C	cg25727520	chr2:37576821	QPCT	-0.32	-6.48	-0.3	2.61e-10	Chronic lymphocytic leukemia;
LUAD	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg03806693	chr22:41940476	POLR3H	0.58	8.79	0.39	3.84e-17	Vitiligo;
LUAD	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg18305652	chr10:134549665	INPP5A	0.6	12.14	0.51	2.55e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.65	0.31	8.95e-11	Prudent dietary pattern;
LUAD	cis	rs727505	1.000	rs1541418	chr7:124448672	A/G	cg23710748	chr7:124431027	NA	-0.47	-9.53	-0.42	1.21e-19	Lewy body disease;
LUAD	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Body mass index;
LUAD	cis	rs2625529	0.652	rs2929532	chr15:72345110	C/T	cg16672083	chr15:72433130	SENP8	0.65	12.26	0.51	8.93e-30	Red blood cell count;
LUAD	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg00310523	chr12:86230176	RASSF9	0.38	7.65	0.35	1.4e-13	Major depressive disorder;
LUAD	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.84	-11.95	-0.5	1.49e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg06558623	chr16:89946397	TCF25	1.2	11.02	0.47	5.38e-25	Skin colour saturation;
LUAD	cis	rs4285028	0.747	rs77790376	chr3:121492211	C/T	cg11130432	chr3:121712080	ILDR1	-0.57	-8.0	-0.36	1.24e-14	Multiple sclerosis;
LUAD	trans	rs78049276	0.736	rs73855814	chr4:148397751	G/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.62	-7.15	-0.33	3.74e-12	Pulse pressure;
LUAD	cis	rs747650	0.884	rs7128325	chr11:47046554	G/A	cg19486271	chr11:47235900	DDB2	-0.42	-6.68	-0.31	7.55e-11	Acne (severe);
LUAD	cis	rs7737355	0.898	rs4706024	chr5:130904163	G/A	cg25547332	chr5:131281432	NA	0.44	6.65	0.31	9.33e-11	Life satisfaction;
LUAD	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg04896959	chr15:78267971	NA	-0.63	-10.61	-0.46	1.76e-23	Coronary artery disease or large artery stroke;
LUAD	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg17063962	chr7:91808500	NA	-0.61	-10.48	-0.45	5.12e-23	Breast cancer;
LUAD	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.79	14.86	0.59	1.75e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6541297	0.757	rs600845	chr1:230322708	C/T	cg20703242	chr1:230279135	GALNT2	0.47	7.4	0.34	7.6e-13	Coronary artery disease;
LUAD	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg04414720	chr1:150670196	GOLPH3L	0.66	11.49	0.49	9.16e-27	Melanoma;
LUAD	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg17366294	chr4:99064904	C4orf37	0.65	12.52	0.52	8.25e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg20607798	chr8:58055168	NA	0.67	8.79	0.39	3.8e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg25809561	chr17:30822961	MYO1D	0.46	8.49	0.38	3.48e-16	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg01689657	chr7:91764605	CYP51A1	0.35	8.65	0.39	1.08e-16	Breast cancer;
LUAD	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg16325326	chr1:53192061	ZYG11B	0.58	10.24	0.45	3.85e-22	Monocyte count;
LUAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg12419862	chr22:24373484	LOC391322	0.82	15.83	0.61	1.13e-44	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg21475434	chr5:93447410	FAM172A	0.76	8.5	0.38	3.41e-16	Diabetic retinopathy;
LUAD	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21659725	chr3:3221576	CRBN	-0.64	-11.23	-0.48	8.51e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs4953404	0.613	rs930853	chr2:46898849	A/G	cg09399716	chr2:46890238	NA	-0.34	-6.64	-0.31	9.82e-11	Pulse pressure (alcohol consumption interaction);
LUAD	cis	rs72949976	0.646	rs1441170	chr2:214033563	A/G	cg08319019	chr2:214017104	IKZF2	-0.55	-8.27	-0.37	1.76e-15	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs62229266	0.804	rs62230822	chr21:37429945	T/C	cg08632701	chr21:37451849	NA	-0.44	-7.37	-0.34	8.99e-13	Mitral valve prolapse;
LUAD	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg06641503	chr3:48959341	ARIH2	-0.38	-6.73	-0.31	5.5e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg23978390	chr7:1156363	C7orf50	0.62	9.96	0.44	3.93e-21	Longevity;Endometriosis;
LUAD	cis	rs62238980	0.614	rs77324143	chr22:32401957	C/T	cg00543991	chr22:32367038	NA	0.96	8.92	0.4	1.39e-17	Childhood ear infection;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg25621096	chr1:151032116	CDC42SE1;MLLT11	0.42	6.65	0.31	9.25e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg11189052	chr15:85197271	WDR73	0.66	8.97	0.4	9.39e-18	Schizophrenia;
LUAD	cis	rs9560113	1.000	rs9560104	chr13:112174389	A/G	cg14154082	chr13:112174009	NA	0.35	6.45	0.3	3e-10	Menarche (age at onset);
LUAD	cis	rs2274273	0.662	rs67215571	chr14:55673723	G/A	cg04306507	chr14:55594613	LGALS3	0.43	8.01	0.36	1.14e-14	Protein biomarker;
LUAD	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg26924012	chr15:45694286	SPATA5L1	0.6	10.09	0.44	1.4e-21	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00149659	chr3:10157352	C3orf10	0.64	9.2	0.41	1.64e-18	Alzheimer's disease;
LUAD	cis	rs17401966	1.000	rs58053556	chr1:10442903	A/G	cg15208524	chr1:10270712	KIF1B	0.53	7.69	0.35	1.08e-13	Hepatocellular carcinoma;
LUAD	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.71	0.39	7.03e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg00750074	chr16:89608354	SPG7	-0.57	-9.81	-0.43	1.35e-20	Multiple myeloma (IgH translocation);
LUAD	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg13319975	chr6:146136371	FBXO30	-0.58	-9.7	-0.43	3.19e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg08859206	chr1:53392774	SCP2	-0.81	-15.5	-0.6	3.04e-43	Monocyte count;
LUAD	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg06740227	chr12:86229804	RASSF9	0.43	7.21	0.33	2.56e-12	Major depressive disorder;
LUAD	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg22491629	chr6:157744540	C6orf35	-0.78	-9.06	-0.4	5.03e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg02951883	chr7:2050386	MAD1L1	-0.91	-16.56	-0.63	7.75e-48	Bipolar disorder and schizophrenia;
LUAD	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg12193833	chr17:30244370	NA	-0.58	-7.04	-0.32	7.63e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08219700	chr8:58056026	NA	0.61	8.5	0.38	3.23e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg12011299	chr4:100065546	ADH4	0.69	12.46	0.52	1.49e-30	Alcohol dependence;
LUAD	cis	rs240764	0.658	rs9386257	chr6:101252069	A/T	cg09795085	chr6:101329169	ASCC3	0.42	7.35	0.34	1.05e-12	Neuroticism;
LUAD	cis	rs877282	0.898	rs11253343	chr10:765117	C/T	cg06581033	chr10:766294	NA	-0.58	-7.95	-0.36	1.74e-14	Uric acid levels;
LUAD	cis	rs7737355	0.773	rs31589	chr5:131004646	G/A	cg25547332	chr5:131281432	NA	0.43	6.9	0.32	1.86e-11	Life satisfaction;
LUAD	cis	rs17155006	0.691	rs403731	chr7:107744217	C/T	cg05962710	chr7:107745446	LAMB4	0.34	7.25	0.33	2.02e-12	Pneumococcal bacteremia;
LUAD	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.51	-8.98	-0.4	8.8e-18	Alzheimer's disease (late onset);
LUAD	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.45	-0.3	3.03e-10	Mood instability;
LUAD	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg05665937	chr4:1216051	CTBP1	-0.41	-7.23	-0.33	2.31e-12	Obesity-related traits;
LUAD	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg12193833	chr17:30244370	NA	-0.55	-7.06	-0.32	6.87e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs4700695	0.841	rs27569	chr5:65373419	C/T	cg21114390	chr5:65439923	SFRS12	-0.61	-8.06	-0.36	8.17e-15	Facial morphology (factor 19);
LUAD	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg22508957	chr16:3507546	NAT15	-0.8	-9.31	-0.41	6.94e-19	Tuberculosis;
LUAD	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg26528668	chr16:1614120	IFT140	0.57	10.39	0.45	1.13e-22	Coronary artery disease;
LUAD	cis	rs7937890	0.504	rs2575847	chr11:14471172	C/T	cg23387056	chr11:14280742	SPON1	-0.34	-6.57	-0.3	1.5e-10	Mitochondrial DNA levels;
LUAD	cis	rs11800820	0.536	rs10924739	chr1:246632947	A/G	cg16700716	chr1:246684329	NA	-0.39	-7.29	-0.33	1.52e-12	Obesity-related traits;
LUAD	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg11057378	chr10:81107060	PPIF	0.39	7.08	0.33	5.94e-12	Height;
LUAD	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg27661571	chr11:113659931	NA	-0.68	-7.9	-0.36	2.5e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs4795519	0.784	rs8079151	chr17:22164221	A/C	cg22648282	chr17:21454238	C17orf51	-0.38	-6.62	-0.31	1.08e-10	Chronic myeloid leukemia;
LUAD	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg00647820	chr17:40259828	DHX58	-0.42	-6.72	-0.31	6.03e-11	Fibrinogen levels;
LUAD	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.47	0.34	4.79e-13	Bipolar disorder;
LUAD	cis	rs240764	0.817	rs239190	chr6:101129067	C/T	cg09795085	chr6:101329169	ASCC3	0.46	7.97	0.36	1.5e-14	Neuroticism;
LUAD	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg03467027	chr4:99064603	C4orf37	-0.45	-6.98	-0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg24801067	chr17:62843696	NA	0.65	8.88	0.4	1.87e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg19875535	chr5:140030758	IK	-0.49	-8.13	-0.37	4.63e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1595825	0.838	rs60079260	chr2:198673636	G/A	cg11031976	chr2:198649780	BOLL	-0.49	-6.89	-0.32	2.05e-11	Ulcerative colitis;
LUAD	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg03289416	chr15:75166202	SCAMP2	0.55	9.29	0.41	8.54e-19	Breast cancer;
LUAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07157834	chr1:205819609	PM20D1	0.73	13.99	0.56	7.89e-37	Menarche (age at onset);
LUAD	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg15017067	chr4:17643749	FAM184B	0.33	6.41	0.3	3.84e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg00339695	chr16:24857497	SLC5A11	-0.54	-9.89	-0.43	7.07e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs2227564	0.729	rs2227551	chr10:75669190	G/T	cg23231163	chr10:75533350	FUT11	-0.4	-6.57	-0.3	1.47e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg06640241	chr16:89574553	SPG7	0.48	7.95	0.36	1.74e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs1387259	0.899	rs7307566	chr12:48604682	A/G	cg04545296	chr12:48745243	ZNF641	0.39	9.97	0.44	3.7e-21	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg14983838	chr19:29218262	NA	0.63	7.9	0.36	2.38e-14	Methadone dose in opioid dependence;
LUAD	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-12.04	-0.51	6.52e-29	Breast cancer;
LUAD	cis	rs6500395	1.000	rs8052073	chr16:48682696	T/C	cg04672837	chr16:48644449	N4BP1	0.39	6.77	0.31	4.19e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs59698941	0.882	rs4705977	chr5:132245114	C/A	cg14825688	chr5:132208181	LEAP2	-0.47	-6.41	-0.3	3.91e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg22920501	chr2:26401640	FAM59B	-0.96	-14.2	-0.57	1.07e-37	Gut microbiome composition (summer);
LUAD	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg18180107	chr4:99064573	C4orf37	0.42	6.63	0.31	1.05e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg11871910	chr12:69753446	YEATS4	0.46	7.51	0.34	3.54e-13	Blood protein levels;
LUAD	cis	rs7326068	0.524	rs9506531	chr13:21232983	C/T	cg27499820	chr13:21296301	IL17D	-0.44	-7.96	-0.36	1.62e-14	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs4936323	0.504	rs10891812	chr11:115096431	T/C	cg04055981	chr11:115044050	NA	0.4	7.21	0.33	2.53e-12	Response to cytadine analogues (cytosine arabinoside);
LUAD	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs950027	0.967	rs2643718	chr15:45794662	T/C	cg26924012	chr15:45694286	SPATA5L1	0.48	8.16	0.37	3.89e-15	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.33	6.55	0.3	1.65e-10	Obesity-related traits;
LUAD	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg01689657	chr7:91764605	CYP51A1	0.33	8.26	0.37	1.91e-15	Breast cancer;
LUAD	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg21699342	chr2:239360505	ASB1	0.58	11.39	0.48	2.1e-26	Multiple system atrophy;
LUAD	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg11584989	chr19:19387371	SF4	-0.39	-6.7	-0.31	6.59e-11	Tonsillectomy;
LUAD	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg10518543	chr12:38710700	ALG10B	0.41	6.37	0.3	5.03e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg20129853	chr10:51489980	NA	0.34	6.87	0.32	2.37e-11	Prostate-specific antigen levels;
LUAD	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg26408565	chr15:76604113	ETFA	-0.42	-6.51	-0.3	2.08e-10	Blood metabolite levels;
LUAD	cis	rs2629540	0.889	rs7090422	chr10:126439361	T/A	cg08799069	chr10:126477246	METTL10	-0.49	-7.26	-0.33	1.9e-12	Cocaine dependence;
LUAD	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg05234568	chr11:5960015	NA	-0.54	-9.22	-0.41	1.45e-18	DNA methylation (variation);
LUAD	cis	rs7536201	1.000	rs7547501	chr1:25301653	T/C	cg23273869	chr1:25296894	NA	-0.38	-7.83	-0.36	3.95e-14	Psoriasis vulgaris;
LUAD	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg10755058	chr3:40428713	ENTPD3	0.39	7.53	0.34	3.02e-13	Renal cell carcinoma;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg26316544	chr3:52188418	WDR51A	-0.38	-6.61	-0.31	1.19e-10	Schizophrenia;
LUAD	trans	rs4650994	0.524	rs2761465	chr1:178579404	G/T	cg05059571	chr16:84539110	KIAA1609	0.69	12.05	0.51	5.97e-29	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg21862992	chr11:68658383	NA	0.54	9.79	0.43	1.51e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg14582100	chr15:45693742	SPATA5L1	0.61	11.71	0.49	1.24e-27	Homoarginine levels;
LUAD	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg21138405	chr5:131827807	IRF1	-0.56	-12.48	-0.52	1.19e-30	Asthma (sex interaction);
LUAD	cis	rs62400317	0.826	rs62400335	chr6:45347782	G/A	cg20913747	chr6:44695427	NA	-0.39	-6.35	-0.3	5.48e-10	Total body bone mineral density;
LUAD	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.24	-0.41	1.2e-18	Life satisfaction;
LUAD	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22455342	chr2:225449267	CUL3	0.71	11.02	0.47	5.47e-25	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg14983838	chr19:29218262	NA	0.67	9.86	0.43	9.13e-21	Methadone dose in opioid dependence;
LUAD	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.14	0.33	4.09e-12	Tonsillectomy;
LUAD	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.6	0.31	1.23e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg13319975	chr6:146136371	FBXO30	-0.58	-9.73	-0.43	2.48e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg20673091	chr1:2541236	MMEL1	0.41	8.78	0.39	4.05e-17	Ulcerative colitis;
LUAD	cis	rs7665090	1.000	rs12498722	chr4:103554522	C/T	cg07973026	chr4:103553119	MANBA	0.47	8.43	0.38	5.43e-16	Primary biliary cholangitis;
LUAD	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.06	0.32	7.06e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg07362569	chr17:61921086	SMARCD2	0.39	6.73	0.31	5.59e-11	Prudent dietary pattern;
LUAD	cis	rs9372498	0.505	rs9489462	chr6:118927855	C/T	cg21191810	chr6:118973309	C6orf204	-0.53	-8.22	-0.37	2.44e-15	Diastolic blood pressure;
LUAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.64	-0.42	4.99e-20	Alzheimer's disease;
LUAD	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-9.51	-0.42	1.43e-19	Life satisfaction;
LUAD	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg16482183	chr6:26056742	HIST1H1C	0.37	6.39	0.3	4.38e-10	Height;
LUAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.69	-0.43	3.4e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs7508679	1.000	rs7248104	chr19:7224431	A/G	cg09779027	chr19:7224513	INSR	0.81	18.4	0.67	5.73e-56	Hypothyroidism;
LUAD	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg12483005	chr1:23474871	LUZP1	0.53	9.17	0.41	2.01e-18	Height;
LUAD	cis	rs17092148	0.836	rs6059910	chr20:33142107	T/C	cg16810054	chr20:33298113	TP53INP2	-0.49	-7.26	-0.33	1.89e-12	Neuroticism;
LUAD	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg04756594	chr16:24857601	SLC5A11	-0.52	-10.31	-0.45	2.14e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg13073564	chr4:8508604	NA	-0.59	-10.64	-0.46	1.38e-23	Response to antineoplastic agents;
LUAD	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Colorectal cancer;
LUAD	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.47	0.38	4.01e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1950626	0.750	rs34061904	chr14:101435974	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.57	0.35	2.35e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg18232548	chr7:50535776	DDC	-0.72	-12.68	-0.52	1.91e-31	Response to zileuton treatment in asthma (FEV1 change interaction);
LUAD	cis	rs6541297	0.555	rs910502	chr1:230294185	A/T	cg20703242	chr1:230279135	GALNT2	0.58	8.28	0.37	1.61e-15	Coronary artery disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15527401	chr19:59071099	UBE2M;LOC100131691	-0.41	-6.45	-0.3	3.12e-10	Height;
LUAD	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg00071950	chr4:10020882	SLC2A9	0.63	12.0	0.5	9.33e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg02176678	chr2:219576539	TTLL4	0.68	13.83	0.56	3.66e-36	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg12011299	chr4:100065546	ADH4	0.63	13.07	0.54	4.8e-33	Alcohol dependence;
LUAD	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg02753203	chr1:228287806	NA	0.8	14.46	0.58	8.62e-39	Diastolic blood pressure;
LUAD	cis	rs796364	0.616	rs2140486	chr2:200690102	C/T	cg23649088	chr2:200775458	C2orf69	0.52	6.49	0.3	2.4e-10	Schizophrenia;
LUAD	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.57	10.03	0.44	2.2e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.78e-11	Crohn's disease;
LUAD	cis	rs77741769	0.571	rs3883901	chr12:121256520	A/G	cg02419362	chr12:121203948	SPPL3	0.41	8.42	0.38	5.77e-16	Mean corpuscular volume;
LUAD	cis	rs2795502	0.564	rs11239844	chr10:43453365	G/A	cg20628663	chr10:43360327	NA	0.58	6.7	0.31	6.62e-11	Blood protein levels;
LUAD	cis	rs1595825	0.636	rs111540926	chr2:198885578	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-6.99	-0.32	1.09e-11	Ulcerative colitis;
LUAD	cis	rs10979	0.965	rs9390109	chr6:143892806	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-10.26	-0.45	3.37e-22	Hypospadias;
LUAD	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg13175981	chr1:150552382	MCL1	0.4	6.54	0.3	1.76e-10	Tonsillectomy;
LUAD	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg08085267	chr17:45401833	C17orf57	-0.51	-8.54	-0.38	2.42e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.16	0.33	3.63e-12	Prostate cancer;
LUAD	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg04414720	chr1:150670196	GOLPH3L	0.73	12.57	0.52	5.05e-31	Melanoma;
LUAD	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg21153622	chr11:89784906	NA	-0.34	-6.7	-0.31	6.69e-11	Coronary artery disease;
LUAD	trans	rs800082	0.698	rs800074	chr3:144347638	A/G	cg24215973	chr2:240111563	HDAC4	-0.68	-10.9	-0.47	1.54e-24	Smoking behavior;
LUAD	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06544989	chr22:39130855	UNC84B	0.44	8.81	0.39	3.3e-17	Menopause (age at onset);
LUAD	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11890956	chr21:40555474	PSMG1	0.79	13.96	0.56	1.09e-36	Cognitive function;
LUAD	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg01028140	chr2:1542097	TPO	-0.48	-6.65	-0.31	8.87e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03188948	chr7:1209495	NA	0.48	8.0	0.36	1.22e-14	Longevity;Endometriosis;
LUAD	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg08601574	chr20:25228251	PYGB	0.46	8.51	0.38	3.16e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg11845111	chr2:191398756	TMEM194B	0.68	12.56	0.52	5.88e-31	Pulse pressure;
LUAD	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg13732083	chr21:47605072	C21orf56	0.41	6.79	0.31	3.77e-11	Testicular germ cell tumor;
LUAD	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg24449463	chr1:168025552	DCAF6	0.72	11.88	0.5	2.83e-28	Schizophrenia;
LUAD	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg24768116	chr2:27665128	KRTCAP3	0.38	9.71	0.43	2.97e-20	Total body bone mineral density;
LUAD	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-6.93	-0.32	1.62e-11	Alzheimer's disease (late onset);
LUAD	cis	rs13418410	0.539	rs35866672	chr2:33842174	G/A	cg04131969	chr2:33951647	MYADML	-0.65	-10.42	-0.45	8.56e-23	Non-response to antidepressants and depression;
LUAD	cis	rs3806843	0.576	rs246008	chr5:140338485	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.52	-0.3	2.03e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-23.59	-0.75	3.79e-79	Height;
LUAD	cis	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.72	-0.35	8.36e-14	Neuroticism;
LUAD	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	22.57	0.74	1.34e-74	Chronic sinus infection;
LUAD	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg04568274	chr7:158649319	WDR60	-0.43	-6.68	-0.31	7.75e-11	Height;
LUAD	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg24596788	chr1:163392923	NA	-0.34	-7.31	-0.33	1.38e-12	Motion sickness;
LUAD	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg00074818	chr8:8560427	CLDN23	0.69	10.55	0.46	3.07e-23	Obesity-related traits;
LUAD	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg21856205	chr7:94953877	PON1	-0.56	-7.96	-0.36	1.61e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg06360820	chr2:242988706	NA	-0.91	-10.1	-0.44	1.28e-21	Obesity-related traits;
LUAD	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg06197492	chr11:2016605	H19	0.4	7.99	0.36	1.29e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg05896524	chr21:47604654	C21orf56	-0.78	-13.61	-0.55	3.1e-35	Testicular germ cell tumor;
LUAD	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg23018236	chr17:30244563	NA	-0.68	-8.24	-0.37	2.19e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg21963583	chr11:68658836	MRPL21	0.64	11.31	0.48	4.39e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs1997103	0.954	rs2177809	chr7:55378125	T/C	cg20935933	chr6:143382018	AIG1	0.54	7.49	0.34	4.11e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg12310025	chr6:25882481	NA	0.41	6.6	0.31	1.23e-10	Height;
LUAD	cis	rs76878669	0.519	rs10791869	chr11:66117113	C/T	cg10616300	chr11:66138557	SLC29A2	-0.36	-7.46	-0.34	5.11e-13	Educational attainment (years of education);
LUAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.39	-0.42	3.83e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs612683	0.524	rs479269	chr1:100887616	A/G	cg06223162	chr1:101003688	GPR88	0.37	6.77	0.31	4.31e-11	Breast cancer;
LUAD	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg03684893	chr10:554711	DIP2C	-0.36	-6.35	-0.3	5.46e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.1	13.62	0.55	2.91e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg24813613	chr7:1882135	MAD1L1	-0.45	-7.2	-0.33	2.81e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7572644	0.699	rs2016616	chr2:28134037	A/G	cg27432699	chr2:27873401	GPN1	-0.41	-6.38	-0.3	4.56e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUAD	trans	rs9217	1.000	rs11658168	chr17:7406134	C/T	cg08566640	chr11:64091735	NA	-0.42	-6.86	-0.32	2.41e-11	Height;
LUAD	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg22681709	chr2:178499509	PDE11A	-0.43	-7.1	-0.33	5.28e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg14917512	chr19:3094685	GNA11	-0.54	-6.4	-0.3	4.17e-10	Diabetic kidney disease;
LUAD	trans	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04565464	chr8:145669602	NFKBIL2	-0.43	-6.6	-0.31	1.21e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg06640241	chr16:89574553	SPG7	0.67	11.73	0.5	1.06e-27	Multiple myeloma (IgH translocation);
LUAD	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg09796270	chr17:17721594	SREBF1	0.38	7.56	0.34	2.61e-13	Total body bone mineral density;
LUAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg21724239	chr8:58056113	NA	0.72	9.38	0.41	4.07e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg10523679	chr1:76189770	ACADM	0.78	11.65	0.49	2.12e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs11078597	0.671	rs1310	chr17:1641715	G/T	cg18436246	chr17:1640651	WDR81	0.78	12.09	0.51	3.99e-29	Serum albumin level;
LUAD	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg26384229	chr12:38710491	ALG10B	0.44	7.21	0.33	2.66e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg06002616	chr8:101225028	SPAG1	-0.39	-7.91	-0.36	2.23e-14	Atrioventricular conduction;
LUAD	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg24154853	chr7:158122151	PTPRN2	0.57	11.44	0.49	1.33e-26	Calcium levels;
LUAD	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg06558623	chr16:89946397	TCF25	1.15	10.71	0.46	7.62e-24	Skin colour saturation;
LUAD	cis	rs2573652	1.000	rs2581343	chr15:100514418	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.54	-9.98	-0.44	3.2e-21	Height;
LUAD	trans	rs9302065	0.565	rs2992910	chr13:95962216	T/A	cg19955956	chr7:72299837	SBDSP;TYW1B	0.54	9.27	0.41	9.27e-19	Blood metabolite levels;
LUAD	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg02753203	chr1:228287806	NA	0.81	15.05	0.59	2.76e-41	Diastolic blood pressure;
LUAD	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg02176678	chr2:219576539	TTLL4	0.74	14.81	0.58	2.68e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg09904177	chr6:26538194	HMGN4	0.41	6.57	0.3	1.49e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg04476341	chr5:669733	TPPP	0.41	7.93	0.36	1.94e-14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg05182265	chr7:156933206	UBE3C	-0.8	-17.12	-0.64	2.55e-50	Body mass index;
LUAD	trans	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.75	12.47	0.52	1.32e-30	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg11901034	chr3:128598214	ACAD9	-0.5	-7.6	-0.35	1.98e-13	IgG glycosylation;
LUAD	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.19	0.33	2.94e-12	Breast cancer;
LUAD	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.69	13.09	0.54	4.2e-33	Cognitive ability;
LUAD	cis	rs12912251	0.894	rs7183893	chr15:38996981	A/C	cg01338139	chr15:38987640	C15orf53	-0.59	-9.18	-0.41	1.93e-18	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg03550219	chr3:25705846	TOP2B	-0.65	-6.92	-0.32	1.66e-11	Type 2 diabetes;
LUAD	cis	rs17445774	0.857	rs6435043	chr2:200900974	C/G	cg17644776	chr2:200775616	C2orf69	0.54	8.01	0.36	1.1e-14	LDL cholesterol to HDL cholesterol ratio;
LUAD	cis	rs9633740	0.945	rs6586030	chr10:82254047	C/T	cg00277334	chr10:82204260	NA	0.61	7.45	0.34	5.33e-13	Post bronchodilator FEV1;
LUAD	cis	rs6494488	0.500	rs55990268	chr15:64854304	A/G	cg08069370	chr15:64387884	SNX1	-0.76	-6.77	-0.31	4.45e-11	Coronary artery disease;
LUAD	cis	rs2979489	0.891	rs2979504	chr8:30386641	C/T	cg26383811	chr8:30366931	RBPMS	-0.7	-11.04	-0.47	4.64e-25	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs155346	1.000	rs265153	chr5:139380832	C/A	cg01090482	chr5:139365336	NRG2	-0.35	-6.65	-0.31	9.17e-11	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUAD	cis	rs7633770	0.664	rs11130101	chr3:46685895	T/A	cg11219411	chr3:46661640	NA	-0.44	-8.84	-0.39	2.65e-17	Coronary artery disease;
LUAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13126279	chr21:47581558	C21orf56	-0.61	-10.91	-0.47	1.43e-24	Testicular germ cell tumor;
LUAD	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg02807482	chr3:125708958	NA	0.66	8.75	0.39	4.99e-17	Blood pressure (smoking interaction);
LUAD	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg24818145	chr4:99064322	C4orf37	0.41	6.89	0.32	2.04e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg24801067	chr17:62843696	NA	-0.49	-6.82	-0.31	3.09e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg16797656	chr11:68205561	LRP5	0.46	8.99	0.4	8.09e-18	Total body bone mineral density;
LUAD	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg23533926	chr12:111358616	MYL2	-0.4	-6.85	-0.32	2.66e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.14	0.33	4.2e-12	Parkinson's disease;
LUAD	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg24154853	chr7:158122151	PTPRN2	-0.56	-11.34	-0.48	3.24e-26	Calcium levels;
LUAD	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg13319975	chr6:146136371	FBXO30	0.66	11.42	0.49	1.58e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12545109	0.879	rs2670015	chr8:57376607	T/A	cg17761419	chr8:57350749	NA	-0.59	-8.28	-0.37	1.66e-15	Obesity-related traits;
LUAD	cis	rs35883536	0.846	rs964905	chr1:101087131	T/C	cg06223162	chr1:101003688	GPR88	-0.38	-6.95	-0.32	1.42e-11	Monocyte count;
LUAD	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg15921436	chr17:44337874	NA	0.83	11.2	0.48	1.08e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.67	-0.31	8.19e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg03886242	chr7:26192032	NFE2L3	-0.47	-8.4	-0.38	6.81e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.09	-0.33	5.77e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg00933542	chr6:150070202	PCMT1	0.44	9.6	0.42	6.92e-20	Lung cancer;
LUAD	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg00745463	chr17:30367425	LRRC37B	-1.07	-12.33	-0.51	4.69e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.68	-12.18	-0.51	1.85e-29	Diastolic blood pressure;
LUAD	cis	rs12681287	0.673	rs2976178	chr8:87332552	C/G	cg27223183	chr8:87520930	FAM82B	-0.66	-8.89	-0.4	1.81e-17	Caudate activity during reward;
LUAD	cis	rs2294693	0.945	rs11756893	chr6:41010058	A/C	cg14769373	chr6:40998127	UNC5CL	-0.5	-7.65	-0.35	1.34e-13	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs4774899	1.000	rs11631228	chr15:57256390	A/G	cg14026238	chr15:57616123	NA	0.35	6.67	0.31	8.17e-11	Urinary tract infection frequency;
LUAD	cis	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg27411982	chr8:10470053	RP1L1	0.37	6.35	0.3	5.52e-10	Neuroticism;
LUAD	cis	rs7681423	1.000	rs2066865	chr4:155525276	G/A	cg20735720	chr4:155535218	FGG	-0.52	-7.54	-0.34	2.89e-13	Fibrinogen;
LUAD	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg06781209	chr11:61594997	FADS2	-0.41	-7.62	-0.35	1.73e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg04287289	chr16:89883240	FANCA	0.78	6.92	0.32	1.73e-11	Skin colour saturation;
LUAD	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	8.05	0.36	8.33e-15	Breast cancer;
LUAD	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg07195577	chr17:27052828	TLCD1	0.48	6.71	0.31	6.29e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg07507251	chr3:52567010	NT5DC2	0.41	8.21	0.37	2.8e-15	Electroencephalogram traits;
LUAD	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg05697835	chr1:2722811	NA	0.31	6.35	0.3	5.54e-10	Ulcerative colitis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07281959	chr15:91421381	FURIN	0.46	6.39	0.3	4.47e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs61008539	1.000	rs61008539	chr7:858506	C/G	cg00475322	chr7:917719	C7orf20	0.59	10.47	0.45	5.78e-23	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg04369109	chr6:150039330	LATS1	-0.42	-6.89	-0.32	1.99e-11	Lung cancer;
LUAD	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg11494091	chr17:61959527	GH2	0.43	8.03	0.36	9.51e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg20156080	chr11:68703600	IGHMBP2	-0.43	-6.89	-0.32	2.09e-11	Diastolic blood pressure;
LUAD	cis	rs9972944	0.756	rs8076925	chr17:63764616	A/C	cg07283582	chr17:63770753	CCDC46	-0.43	-9.65	-0.42	4.72e-20	Total body bone mineral density;
LUAD	cis	rs7607369	0.536	rs4674345	chr2:219671598	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-10.34	-0.45	1.77e-22	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg12365402	chr11:9010492	NRIP3	-0.49	-9.83	-0.43	1.16e-20	Hemoglobin concentration;
LUAD	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg09359103	chr1:154839909	KCNN3	-0.87	-17.29	-0.64	4.73e-51	Prostate cancer;
LUAD	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg09137382	chr11:130731461	NA	0.4	7.43	0.34	6.19e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	9.35	0.41	5.3e-19	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg09184467	chr10:14995699	DCLRE1C	-0.42	-7.12	-0.33	4.53e-12	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00166722	chr3:10149974	C3orf24	0.74	12.65	0.52	2.48e-31	Alzheimer's disease;
LUAD	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg07423050	chr13:99094983	FARP1	-0.53	-8.92	-0.4	1.46e-17	Longevity;
LUAD	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg03806693	chr22:41940476	POLR3H	-0.77	-10.29	-0.45	2.64e-22	Vitiligo;
LUAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.62	8.44	0.38	5.21e-16	Renal function-related traits (BUN);
LUAD	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg07157834	chr1:205819609	PM20D1	0.48	7.21	0.33	2.56e-12	Menarche (age at onset);
LUAD	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg25036284	chr2:26402008	FAM59B	-0.58	-8.17	-0.37	3.48e-15	Gut microbiome composition (summer);
LUAD	cis	rs877282	0.945	rs34367686	chr10:791868	G/C	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	trans	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg08071915	chr8:12219732	FAM66A	-0.43	-7.34	-0.34	1.1e-12	Joint mobility (Beighton score);
LUAD	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg12310025	chr6:25882481	NA	-0.56	-9.15	-0.41	2.53e-18	Blood metabolite levels;
LUAD	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg15557168	chr22:42548783	NA	-0.5	-9.17	-0.41	2.14e-18	Schizophrenia;
LUAD	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.2	-0.33	2.71e-12	Total body bone mineral density;
LUAD	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg13057898	chr1:3703894	LRRC47	0.62	10.65	0.46	1.25e-23	Red cell distribution width;
LUAD	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	11.95	0.5	1.46e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg02269571	chr22:50332266	NA	-0.59	-8.88	-0.4	1.86e-17	Schizophrenia;
LUAD	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg14396892	chr9:96623032	NA	-0.45	-8.63	-0.39	1.23e-16	DNA methylation (variation);
LUAD	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg08508325	chr11:3079039	CARS	0.42	8.73	0.39	5.89e-17	Calcium levels;
LUAD	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.08	-0.44	1.42e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs7539409	0.651	rs969724	chr1:84300712	T/G	cg10977910	chr1:84465055	TTLL7	0.77	8.74	0.39	5.47e-17	Alzheimer's disease;
LUAD	cis	rs2985684	1.000	rs17121651	chr14:50097172	T/C	cg04989706	chr14:50066350	PPIL5	-0.46	-6.73	-0.31	5.65e-11	Carotid intima media thickness;
LUAD	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg04117972	chr1:227635322	NA	0.66	6.71	0.31	6.36e-11	Major depressive disorder;
LUAD	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg00750074	chr16:89608354	SPG7	-0.4	-6.71	-0.31	6.12e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs78761021	0.720	rs874174	chr17:9798619	C/T	cg26853458	chr17:9805074	RCVRN	-0.38	-7.51	-0.34	3.45e-13	Type 2 diabetes;
LUAD	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg27170947	chr2:26402098	FAM59B	-0.6	-8.51	-0.38	3.04e-16	Gut microbiome composition (summer);
LUAD	cis	rs6076065	0.723	rs4813493	chr20:23367373	G/C	cg11657817	chr20:23433608	CST11	0.48	8.94	0.4	1.23e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg14008862	chr17:28927542	LRRC37B2	-0.65	-6.45	-0.3	3e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg19163074	chr7:65112434	INTS4L2	0.42	6.4	0.3	4.14e-10	Aortic root size;
LUAD	cis	rs73198271	0.562	rs17631022	chr8:8662197	G/A	cg01851573	chr8:8652454	MFHAS1	0.7	10.53	0.46	3.51e-23	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9715521	0.867	rs7437815	chr4:59826005	T/C	cg11281224	chr4:60001000	NA	-0.57	-9.58	-0.42	8.15e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg13047869	chr3:10149882	C3orf24	0.53	8.01	0.36	1.15e-14	Alzheimer's disease;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg24334803	chr1:249132834	ZNF672	0.43	6.97	0.32	1.22e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs11048434	0.736	rs2377674	chr12:9112761	A/G	cg04155231	chr12:9217510	LOC144571	0.39	7.57	0.35	2.43e-13	Sjögren's syndrome;
LUAD	cis	rs1832871	0.711	rs9459954	chr6:158709345	G/T	cg07165851	chr6:158734300	TULP4	0.69	10.94	0.47	1.03e-24	Height;
LUAD	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3219090	0.962	rs1805414	chr1:226573364	A/G	cg27539482	chr13:111589090	NA	0.41	6.71	0.31	6.09e-11	Melanoma;
LUAD	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg19622623	chr12:86230825	RASSF9	-0.39	-6.9	-0.32	1.92e-11	Major depressive disorder;
LUAD	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg04851639	chr8:1020857	NA	-0.45	-11.38	-0.48	2.29e-26	Schizophrenia;
LUAD	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg20265528	chr2:105853269	NA	-0.38	-6.72	-0.31	5.76e-11	Type 2 diabetes;
LUAD	cis	rs738321	0.757	rs2284062	chr22:38544221	A/G	cg25457927	chr22:38595422	NA	-0.56	-12.61	-0.52	3.7e-31	Breast cancer;
LUAD	cis	rs889398	0.771	rs1566454	chr16:69900083	C/T	cg00738113	chr16:70207722	CLEC18C	-0.35	-7.01	-0.32	9.74e-12	Body mass index;
LUAD	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg23758822	chr17:41437982	NA	0.98	20.28	0.7	2.31e-64	Menopause (age at onset);
LUAD	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg00666640	chr1:248458726	OR2T12	0.32	7.93	0.36	2e-14	Common traits (Other);
LUAD	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.02	0.32	8.87e-12	Hypertriglyceridemia;
LUAD	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg20891283	chr12:69753455	YEATS4	0.46	7.32	0.34	1.25e-12	Blood protein levels;
LUAD	cis	rs2075165	0.901	rs7522860	chr1:156275281	C/T	cg20302342	chr1:156215951	PAQR6	0.35	8.12	0.37	5.21e-15	Tonsillectomy;
LUAD	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg06618935	chr21:46677482	NA	-0.45	-8.56	-0.38	2.11e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10193935	0.901	rs10175378	chr2:42456267	A/C	cg27598129	chr2:42591480	NA	-0.8	-9.58	-0.42	8.49e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7680126	0.644	rs4697703	chr4:10107431	A/G	cg00071950	chr4:10020882	SLC2A9	-0.59	-8.59	-0.39	1.63e-16	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg24324837	chr19:49891574	CCDC155	0.46	6.96	0.32	1.28e-11	Multiple sclerosis;
LUAD	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg14196790	chr5:131705035	SLC22A5	0.47	8.59	0.39	1.72e-16	Blood metabolite levels;
LUAD	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-6.36	-0.3	5.2e-10	Lung cancer;
LUAD	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.76	10.57	0.46	2.52e-23	Smoking behavior;
LUAD	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg23262073	chr20:60523788	NA	-0.46	-7.94	-0.36	1.81e-14	Body mass index;
LUAD	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg03859395	chr2:55845619	SMEK2	0.68	12.46	0.52	1.39e-30	Metabolic syndrome;
LUAD	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg19318889	chr4:1322082	MAEA	0.47	7.87	0.36	3e-14	Obesity-related traits;
LUAD	cis	rs208520	0.754	rs851593	chr6:66875783	C/T	cg07460842	chr6:66804631	NA	1.0	14.79	0.58	3.56e-40	Exhaled nitric oxide output;
LUAD	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.52	6.85	0.32	2.69e-11	Platelet count;
LUAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13012494	chr21:47604986	C21orf56	0.61	10.51	0.45	4.29e-23	Testicular germ cell tumor;
LUAD	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg17551891	chr7:1960795	MAD1L1	-0.39	-6.44	-0.3	3.32e-10	Neuroticism;
LUAD	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72772090	0.539	rs17481759	chr5:96114695	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-7.38	-0.34	8.53e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22496380	chr5:211416	CCDC127	-1.21	-15.83	-0.61	1.19e-44	Breast cancer;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg18683143	chr3:184429764	MAGEF1	-0.43	-6.8	-0.31	3.62e-11	Vertical cup-disc ratio;
LUAD	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg18867708	chr6:26865862	GUSBL1	0.42	6.72	0.31	5.74e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg04450456	chr4:17643702	FAM184B	0.42	8.33	0.38	1.15e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-15.18	-0.59	7.5e-42	Exhaled nitric oxide output;
LUAD	cis	rs7712401	0.601	rs30045	chr5:122271619	C/T	cg19077854	chr5:122220652	SNX24	0.32	6.45	0.3	3.15e-10	Mean platelet volume;
LUAD	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg19761014	chr17:28927070	LRRC37B2	0.67	7.55	0.34	2.62e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg15839431	chr19:19639596	YJEFN3	-0.51	-8.19	-0.37	3.14e-15	Bipolar disorder;
LUAD	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg02788857	chr8:22132959	PIWIL2	0.55	10.27	0.45	2.98e-22	Hypertriglyceridemia;
LUAD	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg22467129	chr15:76604101	ETFA	-0.48	-8.01	-0.36	1.13e-14	Blood metabolite levels;
LUAD	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.48	-8.05	-0.36	8.66e-15	Body mass index;
LUAD	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg13870426	chr17:30244630	NA	-0.55	-6.48	-0.3	2.49e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.86	0.4	2.24e-17	Parkinson's disease;
LUAD	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.32	-0.34	1.28e-12	Lung cancer;
LUAD	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg06740227	chr12:86229804	RASSF9	0.4	6.98	0.32	1.14e-11	Major depressive disorder;
LUAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs220324	0.688	rs9974977	chr21:43563496	G/A	cg09727148	chr21:43560719	UMODL1	0.57	8.61	0.39	1.42e-16	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg02569458	chr12:86230093	RASSF9	0.42	7.9	0.36	2.43e-14	Major depressive disorder;
LUAD	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg21475434	chr5:93447410	FAM172A	0.73	8.29	0.37	1.55e-15	Diabetic retinopathy;
LUAD	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg04455712	chr21:45112962	RRP1B	0.44	9.08	0.4	4.3e-18	Mean corpuscular volume;
LUAD	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg10523679	chr1:76189770	ACADM	0.76	11.31	0.48	4.37e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg01657329	chr11:68192670	LRP5	-0.41	-6.36	-0.3	5.18e-10	Total body bone mineral density;
LUAD	cis	rs1461503	0.934	rs11605693	chr11:122837037	T/C	cg27398637	chr11:122830231	C11orf63	-0.33	-6.35	-0.3	5.41e-10	Menarche (age at onset);
LUAD	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg22105103	chr4:187893119	NA	0.53	11.38	0.48	2.28e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg23750338	chr8:142222470	SLC45A4	-0.6	-13.1	-0.54	3.75e-33	Immature fraction of reticulocytes;
LUAD	cis	rs17095355	0.901	rs28365866	chr10:111767214	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.12	-0.33	4.66e-12	Biliary atresia;
LUAD	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg24675658	chr1:53192096	ZYG11B	-0.39	-6.56	-0.3	1.56e-10	Monocyte count;
LUAD	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg21153622	chr11:89784906	NA	0.33	6.66	0.31	8.48e-11	Coronary artery disease;
LUAD	cis	rs6489882	0.867	rs4766665	chr12:113363109	T/C	cg20102336	chr12:113376681	OAS3	-0.6	-9.34	-0.41	5.6e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs6835098	0.828	rs28612521	chr4:174085294	G/A	cg08422745	chr4:174089978	GALNT7	-0.96	-18.57	-0.67	9.94e-57	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs9902453	0.845	rs2617875	chr17:28090024	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.75	0.43	2.16e-20	Coffee consumption (cups per day);
LUAD	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.63	11.07	0.47	3.48e-25	Birth weight;
LUAD	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg03929089	chr4:120376271	NA	0.84	15.24	0.6	4.11e-42	Coronary artery disease;
LUAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08677398	chr8:58056175	NA	0.45	6.45	0.3	3.07e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg18827107	chr12:86230957	RASSF9	-0.68	-12.35	-0.51	4.01e-30	Major depressive disorder;
LUAD	cis	rs1595825	0.891	rs73054817	chr2:198623751	A/G	cg00361562	chr2:198649771	BOLL	-0.48	-6.69	-0.31	7.15e-11	Ulcerative colitis;
LUAD	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg08085267	chr17:45401833	C17orf57	0.65	11.93	0.5	1.81e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg14396892	chr9:96623032	NA	-0.44	-8.51	-0.38	3.07e-16	DNA methylation (variation);
LUAD	cis	rs4713675	0.546	rs9348925	chr6:33710696	C/T	cg13859433	chr6:33739653	LEMD2	-0.29	-7.03	-0.32	8.4e-12	Plateletcrit;
LUAD	trans	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg27411982	chr8:10470053	RP1L1	0.44	7.84	0.36	3.8e-14	Mood instability;
LUAD	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg02421172	chr7:1938701	MAD1L1	0.44	6.38	0.3	4.67e-10	Neuroticism;
LUAD	cis	rs2996428	0.504	rs3765780	chr1:3767696	C/T	cg17443473	chr1:3703550	LRRC47	-0.37	-6.82	-0.31	3.09e-11	Red cell distribution width;
LUAD	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.85	0.32	2.54e-11	Iron status biomarkers;
LUAD	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg13385794	chr1:248469461	NA	0.26	7.07	0.33	6.48e-12	Common traits (Other);
LUAD	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg05804949	chr7:23719620	C7orf46	0.39	6.67	0.31	8.11e-11	Schizophrenia;
LUAD	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg03433033	chr1:76189801	ACADM	0.85	15.13	0.59	1.24e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00166722	chr3:10149974	C3orf24	0.71	12.36	0.52	3.47e-30	Alzheimer's disease;
LUAD	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.5	0.3	2.25e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg24768116	chr2:27665128	KRTCAP3	0.26	6.43	0.3	3.52e-10	Oral cavity cancer;
LUAD	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg16205897	chr5:131564050	P4HA2	-0.31	-7.03	-0.32	8.13e-12	Breast cancer;
LUAD	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg06532163	chr17:45867833	NA	0.47	8.36	0.38	9.04e-16	IgG glycosylation;
LUAD	cis	rs3733418	0.929	rs13110309	chr4:165889672	T/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-6.98	-0.32	1.12e-11	Obesity-related traits;
LUAD	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg06623918	chr6:96969491	KIAA0776	-0.71	-9.93	-0.43	4.94e-21	Migraine;Coronary artery disease;
LUAD	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.86	0.4	2.32e-17	Parkinson's disease;
LUAD	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1535500	0.935	rs11753141	chr6:39283083	G/A	cg03252829	chr6:39282164	KCNK17	-0.31	-6.64	-0.31	9.76e-11	Type 2 diabetes;
LUAD	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.15	0.48	1.76e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.12	0.41	3.18e-18	Alzheimer's disease;
LUAD	trans	rs2018683	0.707	rs4722878	chr7:28973031	C/T	cg19402173	chr7:128379420	CALU	-0.52	-8.38	-0.38	7.7e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7727544	0.545	rs10074490	chr5:131340032	C/T	cg16205897	chr5:131564050	P4HA2	-0.34	-7.5	-0.34	3.87e-13	Blood metabolite levels;
LUAD	cis	rs2386661	0.826	rs10905519	chr10:5672483	C/A	cg26603656	chr10:5671107	NA	0.41	7.09	0.33	5.76e-12	Breast cancer;
LUAD	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.59	0.42	7.97e-20	Cognitive ability;
LUAD	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116248771	0.739	rs6801874	chr3:158347396	C/G	cg16708174	chr3:158430962	RARRES1	0.47	6.88	0.32	2.22e-11	diarrhoeal disease at age 2;
LUAD	trans	rs11671005	0.610	rs3816329	chr19:59058693	G/A	cg22037779	chr5:139682734	PFDN1	-0.65	-8.55	-0.38	2.2e-16	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg20290983	chr6:43655470	MRPS18A	-1.06	-27.31	-0.8	2.12e-95	IgG glycosylation;
LUAD	trans	rs2735413	0.918	rs4888725	chr16:78076761	C/T	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7937890	0.810	rs10734224	chr11:14424124	G/T	cg06199346	chr11:14280333	SPON1	-0.33	-6.78	-0.31	4.18e-11	Mitochondrial DNA levels;
LUAD	cis	rs12912251	1.000	rs35024396	chr15:38989770	G/A	cg01338139	chr15:38987640	C15orf53	-0.59	-9.29	-0.41	8.34e-19	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs10916814	0.546	rs10799643	chr1:20903181	G/C	cg24502330	chr1:20914028	CDA	-0.36	-7.02	-0.32	8.98e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.65	-0.35	1.4e-13	Blood metabolite levels;
LUAD	trans	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg19676328	chr12:49525230	TUBA1B	0.55	8.05	0.36	8.27e-15	Total cholesterol levels;
LUAD	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg12403142	chr1:92012408	NA	-0.37	-6.81	-0.31	3.37e-11	Breast cancer;
LUAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	12.56	0.52	5.78e-31	Lymphocyte counts;
LUAD	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg03467027	chr4:99064603	C4orf37	0.42	6.38	0.3	4.75e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs829883	0.902	rs1620317	chr12:98890566	T/C	cg25150519	chr12:98850993	NA	0.66	11.0	0.47	6.59e-25	Colorectal adenoma (advanced);
LUAD	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.55	-9.36	-0.41	4.66e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg17178900	chr1:205818956	PM20D1	0.79	17.53	0.65	4.07e-52	Menarche (age at onset);
LUAD	trans	rs786425	0.682	rs12829893	chr12:124166978	A/C	cg11026330	chr4:18023101	LCORL	-0.4	-6.47	-0.3	2.7e-10	Pubertal anthropometrics;
LUAD	cis	rs300774	0.925	rs437409	chr2:142137	G/A	cg21211680	chr2:198530	NA	-0.47	-7.38	-0.34	8.31e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg24920358	chr1:40204285	PPIE	0.7	12.56	0.52	5.79e-31	Blood protein levels;
LUAD	trans	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg06606381	chr12:133084897	FBRSL1	-0.67	-7.27	-0.33	1.73e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3806843	0.576	rs246020	chr5:140334771	G/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg18190219	chr22:46762943	CELSR1	-0.57	-6.85	-0.32	2.69e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg12119029	chr16:89752879	CDK10	0.35	7.26	0.33	1.89e-12	Vitiligo;
LUAD	cis	rs73198271	0.515	rs77703937	chr8:8629129	G/A	cg01851573	chr8:8652454	MFHAS1	0.6	7.97	0.36	1.44e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg07404485	chr7:94953653	PON1	-0.5	-7.42	-0.34	6.3e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs13088645	0.532	rs12695612	chr3:134161824	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	8.73	0.39	5.94e-17	Coronary artery disease;
LUAD	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg23262073	chr20:60523788	NA	-0.47	-7.61	-0.35	1.77e-13	Body mass index;
LUAD	trans	rs9951602	0.573	rs8098953	chr18:76648734	A/G	cg02800362	chr5:177631904	HNRNPAB	0.91	13.98	0.56	9.26e-37	Obesity-related traits;
LUAD	cis	rs62238980	0.614	rs4821024	chr22:32414501	C/T	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg01416388	chr22:39784598	NA	-0.53	-8.87	-0.4	2.06e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg08213375	chr14:104286397	PPP1R13B	0.26	6.64	0.31	9.66e-11	Schizophrenia;
LUAD	cis	rs4713675	0.565	rs4713670	chr6:33699882	C/T	cg14003231	chr6:33640908	ITPR3	-0.45	-8.44	-0.38	5.04e-16	Plateletcrit;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg23127064	chr11:842615	TSPAN4;POLR2L	-0.44	-7.15	-0.33	3.9e-12	Schizophrenia;
LUAD	cis	rs7394190	0.810	rs7394152	chr10:75421446	C/T	cg02286717	chr10:75415704	SYNPO2L	-0.35	-6.37	-0.3	5.06e-10	Incident atrial fibrillation;
LUAD	cis	rs8177876	0.822	rs8177939	chr16:81119196	A/G	cg08591886	chr16:81111003	C16orf46	-0.8	-7.39	-0.34	7.72e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg13271783	chr10:134563150	INPP5A	-0.41	-7.1	-0.33	5.32e-12	Migraine;
LUAD	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg02696790	chr15:75250997	RPP25	0.41	7.91	0.36	2.31e-14	Caffeine consumption;
LUAD	cis	rs6840360	0.615	rs1962910	chr4:152479392	T/A	cg22705602	chr4:152727874	NA	-0.37	-6.71	-0.31	6.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg00933542	chr6:150070202	PCMT1	0.43	9.19	0.41	1.84e-18	Lung cancer;
LUAD	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg01689657	chr7:91764605	CYP51A1	0.31	7.45	0.34	5.16e-13	Breast cancer;
LUAD	cis	rs6993813	0.678	rs2062376	chr8:120010009	C/G	cg01975934	chr8:119970761	NA	-0.36	-6.88	-0.32	2.21e-11	Bone mineral density (hip);
LUAD	cis	rs713587	0.525	rs1541984	chr2:25082414	G/A	cg01884057	chr2:25150051	NA	0.33	7.07	0.32	6.64e-12	Body mass index in non-asthmatics;
LUAD	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg15133208	chr4:90757351	SNCA	-0.47	-7.0	-0.32	1.01e-11	Neuroticism;
LUAD	cis	rs954108	0.809	rs1792023	chr13:29368502	G/A	cg11788234	chr13:29393811	NA	-0.33	-6.78	-0.31	4.07e-11	Obesity-related traits;
LUAD	cis	rs7107174	0.901	rs901105	chr11:77924607	A/C	cg02023728	chr11:77925099	USP35	0.53	8.07	0.37	7.43e-15	Testicular germ cell tumor;
LUAD	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg00074818	chr8:8560427	CLDN23	-0.67	-10.41	-0.45	9.39e-23	Obesity-related traits;
LUAD	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg08645402	chr16:4508243	NA	0.57	9.94	0.44	4.44e-21	Schizophrenia;
LUAD	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg13010199	chr12:38710504	ALG10B	0.39	6.55	0.3	1.68e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg17264618	chr3:40429014	ENTPD3	0.42	8.99	0.4	8.15e-18	Renal cell carcinoma;
LUAD	cis	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg02508848	chr16:68573721	ZFP90	-0.42	-6.6	-0.31	1.22e-10	Ulcerative colitis;
LUAD	cis	rs8192282	0.691	rs4845640	chr1:154497802	C/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.45	-6.98	-0.32	1.16e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs13082711	0.911	rs7640929	chr3:27513944	C/A	cg02860705	chr3:27208620	NA	0.58	8.8	0.39	3.52e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	trans	rs12200782	1.000	rs12204145	chr6:26600156	C/T	cg08851530	chr6:28072375	NA	0.71	6.63	0.31	1.01e-10	Small cell lung carcinoma;
LUAD	cis	rs4774899	1.000	rs11858471	chr15:57262769	T/A	cg14026238	chr15:57616123	NA	0.33	6.44	0.3	3.19e-10	Urinary tract infection frequency;
LUAD	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-8.34	-0.38	1.09e-15	Total cholesterol levels;
LUAD	cis	rs11811982	0.793	rs11801012	chr1:227350198	T/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic disc area;
LUAD	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-7.56	-0.35	2.51e-13	Major depressive disorder;
LUAD	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg19193384	chr17:30244184	NA	-0.53	-6.36	-0.3	5.37e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg14828511	chr1:107599125	PRMT6	-0.6	-10.58	-0.46	2.25e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg14228332	chr4:119757509	SEC24D	0.74	7.65	0.35	1.41e-13	Cannabis dependence symptom count;
LUAD	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	8.96	0.4	1.08e-17	Colorectal cancer;
LUAD	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.61	-0.31	1.13e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg08027265	chr7:2291960	NA	-0.42	-6.8	-0.31	3.65e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.68	-12.39	-0.52	2.76e-30	Axial length;
LUAD	trans	rs11088226	0.681	rs11700671	chr21:33938621	T/A	cg09050820	chr6:167586206	TCP10L2	0.91	12.44	0.52	1.65e-30	Gastritis;
LUAD	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.39	-6.67	-0.31	8.23e-11	Colorectal cancer;
LUAD	cis	rs7173743	0.756	rs6495339	chr15:79128272	T/C	cg15571903	chr15:79123663	NA	0.44	8.84	0.39	2.56e-17	Coronary artery disease;
LUAD	cis	rs9633740	0.773	rs7080009	chr10:82269461	T/C	cg00277334	chr10:82204260	NA	-0.62	-8.31	-0.37	1.27e-15	Post bronchodilator FEV1;
LUAD	cis	rs8060686	0.546	rs7188350	chr16:68149316	T/C	cg05110241	chr16:68378359	PRMT7	-0.54	-7.0	-0.32	1.01e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.48	7.25	0.33	1.98e-12	Total cholesterol levels;
LUAD	trans	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.02	-0.4	6.78e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg11693508	chr17:37793320	STARD3	-0.7	-9.7	-0.43	3.33e-20	Bipolar disorder;
LUAD	cis	rs9283706	0.608	rs10060497	chr5:66332406	A/G	cg11590213	chr5:66331682	MAST4	0.41	6.83	0.32	2.9100000000000002e-11	Coronary artery disease;
LUAD	cis	rs1344694	0.566	rs13029765	chr2:216894976	A/T	cg12620499	chr2:216877984	MREG	0.41	7.07	0.32	6.65e-12	Alcohol dependence;
LUAD	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg09835421	chr16:68378352	PRMT7	-0.82	-8.75	-0.39	5.13e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg15117754	chr3:10150083	C3orf24	0.44	7.09	0.33	5.76e-12	Alzheimer's disease;
LUAD	cis	rs669446	0.591	rs607062	chr1:44133016	A/G	cg12908607	chr1:44402522	ARTN	-0.35	-6.59	-0.31	1.3100000000000001e-10	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs17067123	0.614	rs6850226	chr4:180052577	T/G	cg26610307	chr4:180072759	NA	-0.51	-6.69	-0.31	6.91e-11	Response to hepatitis C treatment;
LUAD	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg15147215	chr3:52552868	STAB1	-0.38	-7.04	-0.32	7.85e-12	Bipolar disorder;
LUAD	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03517284	chr6:25882590	NA	0.85	14.41	0.57	1.36e-38	Blood metabolite levels;
LUAD	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg15704280	chr7:45808275	SEPT13	-0.52	-8.1	-0.37	5.97e-15	HDL cholesterol;
LUAD	cis	rs9807989	0.811	rs11688573	chr2:102969971	C/A	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.03e-10	Asthma;
LUAD	trans	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg14917512	chr19:3094685	GNA11	0.53	6.38	0.3	4.53e-10	Diabetic kidney disease;
LUAD	cis	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg12884169	chr21:40033163	ERG	-0.35	-7.43	-0.34	5.94e-13	Coronary artery disease;
LUAD	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg10589385	chr1:150898437	SETDB1	0.4	7.89	0.36	2.65e-14	Tonsillectomy;
LUAD	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg23950597	chr19:37808831	NA	-0.64	-7.68	-0.35	1.11e-13	Coronary artery calcification;
LUAD	trans	rs587242	0.528	rs12566237	chr1:97186182	A/G	cg10631902	chr5:14652156	NA	0.38	6.39	0.3	4.35e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg02569458	chr12:86230093	RASSF9	0.45	8.24	0.37	2.12e-15	Major depressive disorder;
LUAD	trans	rs11039798	1.000	rs7125913	chr11:48984318	G/A	cg02254774	chr11:50257496	LOC441601	0.52	6.48	0.3	2.56e-10	Axial length;
LUAD	cis	rs7903847	0.642	rs7903562	chr10:99154782	T/C	cg20016023	chr10:99160130	RRP12	-0.31	-7.43	-0.34	6.13e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6433857	0.536	rs1542035	chr2:181351114	T/C	cg23363182	chr2:181467187	NA	-0.4	-6.56	-0.3	1.57e-10	Body mass index;
LUAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18099408	chr3:52552593	STAB1	-0.53	-9.61	-0.42	6.56e-20	Electroencephalogram traits;
LUAD	cis	rs10465746	0.570	rs11163885	chr1:84472956	A/G	cg10977910	chr1:84465055	TTLL7	0.49	7.46	0.34	4.97e-13	Obesity-related traits;
LUAD	cis	rs9837602	1.000	rs9837602	chr3:99824685	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.45	-6.62	-0.31	1.1e-10	Breast cancer;
LUAD	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg10523679	chr1:76189770	ACADM	0.93	17.16	0.64	1.79e-50	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4356932	1.000	rs4583787	chr4:76955069	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.54	-0.3	1.78e-10	Blood protein levels;
LUAD	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.78	0.31	4.09e-11	Parkinson's disease;
LUAD	cis	rs62238980	0.614	rs77661466	chr22:32520016	A/G	cg00543991	chr22:32367038	NA	0.88	8.51	0.38	3.06e-16	Childhood ear infection;
LUAD	cis	rs9595066	1.000	rs66786230	chr13:44711625	T/C	cg04068111	chr13:44716778	NA	-0.64	-11.12	-0.48	2.3e-25	Schizophrenia;
LUAD	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg19875535	chr5:140030758	IK	-0.41	-6.96	-0.32	1.33e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	14.44	0.57	1.02e-38	Lung cancer in ever smokers;
LUAD	cis	rs13315871	1.000	rs13063504	chr3:58409854	A/G	cg20936604	chr3:58311152	NA	-0.69	-7.25	-0.33	1.94e-12	Cholesterol, total;
LUAD	cis	rs6906287	0.647	rs6569013	chr6:118681328	G/T	cg05564266	chr6:118973597	C6orf204	-0.36	-7.62	-0.35	1.65e-13	Electrocardiographic conduction measures;
LUAD	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg00933542	chr6:150070202	PCMT1	0.45	9.98	0.44	3.28e-21	Lung cancer;
LUAD	cis	rs8017423	0.967	rs2151748	chr14:90694897	G/C	cg14092571	chr14:90743983	NA	-0.48	-8.27	-0.37	1.82e-15	Mortality in heart failure;
LUAD	trans	rs208520	0.690	rs207082	chr6:66773796	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-17.44	-0.65	1.04e-51	Exhaled nitric oxide output;
LUAD	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg18240062	chr17:79603768	NPLOC4	0.36	6.42	0.3	3.73e-10	Eye color traits;
LUAD	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg21100191	chr22:23484243	RTDR1	0.71	12.65	0.52	2.44e-31	Bone mineral density;
LUAD	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg25251562	chr2:3704773	ALLC	-0.42	-7.5	-0.34	3.83e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg19678392	chr7:94953810	PON1	-0.55	-7.3	-0.33	1.4e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg21775007	chr8:11205619	TDH	0.38	6.62	0.31	1.12e-10	Mood instability;
LUAD	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg07332563	chr6:291687	DUSP22	-0.45	-7.5	-0.34	3.91e-13	Menopause (age at onset);
LUAD	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg04450456	chr4:17643702	FAM184B	0.4	7.87	0.36	3.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18876405	chr7:65276391	NA	-0.43	-7.04	-0.32	7.76e-12	Aortic root size;
LUAD	cis	rs16958440	0.867	rs79078752	chr18:44667462	A/G	cg17192377	chr18:44677553	HDHD2	0.84	7.85	0.36	3.48e-14	Sitting height ratio;
LUAD	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg23711669	chr6:146136114	FBXO30	0.38	6.4	0.3	4.18e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs735539	0.645	rs6490600	chr13:21208189	G/T	cg27499820	chr13:21296301	IL17D	0.51	8.53	0.38	2.62e-16	Dental caries;
LUAD	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.54	0.3	1.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7705042	0.865	rs4391200	chr5:141509537	A/G	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.78	-0.31	4.1e-11	Asthma;
LUAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg22963979	chr7:1858916	MAD1L1	-0.46	-7.57	-0.35	2.43e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg08079166	chr15:68083412	MAP2K5	-0.3	-6.36	-0.3	5.38e-10	Restless legs syndrome;
LUAD	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg04455712	chr21:45112962	RRP1B	0.4	8.3	0.37	1.38e-15	Mean corpuscular volume;
LUAD	cis	rs778371	0.723	rs283470	chr2:233656918	G/A	cg08000102	chr2:233561755	GIGYF2	0.41	6.69	0.31	7.08e-11	Schizophrenia;
LUAD	cis	rs3845702	0.736	rs56401468	chr2:180857757	C/T	cg01881094	chr2:180872142	CWC22	0.81	8.92	0.4	1.46e-17	Schizophrenia;
LUAD	cis	rs367943	0.637	rs6859521	chr5:113007423	C/T	cg12552261	chr5:112820674	MCC	0.47	8.06	0.36	8.14e-15	Type 2 diabetes;
LUAD	trans	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs300774	0.925	rs300734	chr2:167167	T/G	cg21211680	chr2:198530	NA	-0.49	-7.83	-0.36	4.07e-14	Suicide attempts in bipolar disorder;
LUAD	cis	rs35883536	0.514	rs4908062	chr1:101013211	T/C	cg06223162	chr1:101003688	GPR88	0.54	11.05	0.47	4.23e-25	Monocyte count;
LUAD	cis	rs11249608	0.590	rs36051170	chr5:178447971	T/C	cg01312482	chr5:178451176	ZNF879	-0.44	-6.78	-0.31	4.08e-11	Pubertal anthropometrics;
LUAD	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg27432699	chr2:27873401	GPN1	0.55	9.85	0.43	9.59e-21	Oral cavity cancer;
LUAD	cis	rs798766	0.909	rs28521716	chr4:1745751	A/G	cg05874882	chr4:1763078	NA	-0.37	-6.55	-0.3	1.68e-10	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs2224391	0.784	rs35048711	chr6:5262235	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-9.82	-0.43	1.22e-20	Height;
LUAD	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg15017067	chr4:17643749	FAM184B	0.39	7.53	0.34	3.1e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs75804782	0.566	rs56314406	chr2:239280377	A/G	cg01134436	chr17:81009848	B3GNTL1	0.72	6.35	0.3	5.68e-10	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs9837602	1.000	rs1688772	chr3:99503366	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.53	0.34	3.07e-13	Breast cancer;
LUAD	cis	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.58	-0.3	1.43e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs28374715	0.662	rs522063	chr15:41476209	A/G	cg18705301	chr15:41695430	NDUFAF1	0.8	14.59	0.58	2.49e-39	Ulcerative colitis;
LUAD	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg02423579	chr7:2872169	GNA12	-0.81	-14.14	-0.57	1.84e-37	Height;
LUAD	cis	rs7428	0.545	rs17026212	chr2:85551696	T/G	cg24342717	chr2:85555507	TGOLN2	-0.47	-7.74	-0.35	7.22e-14	Ear protrusion;
LUAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs420259	0.516	rs6497664	chr16:23485353	G/C	cg00143387	chr16:23521605	GGA2	-0.7	-10.06	-0.44	1.7e-21	Bipolar disorder;
LUAD	cis	rs6445967	0.569	rs3773012	chr3:58303069	C/T	cg13750441	chr3:58318267	PXK	-0.31	-6.42	-0.3	3.64e-10	Platelet count;
LUAD	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg26384229	chr12:38710491	ALG10B	0.45	7.44	0.34	5.56e-13	Bladder cancer;
LUAD	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03647317	chr4:187891568	NA	-0.36	-6.7	-0.31	6.78e-11	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs11989744	0.597	rs2033788	chr8:23574847	G/T	cg03492747	chr16:86543808	FOXF1	-0.5	-10.5	-0.45	4.33e-23	Waist-hip ratio;
LUAD	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg11663144	chr21:46675770	NA	-0.59	-11.56	-0.49	4.65e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11625487	0.609	rs74063206	chr14:77981045	C/T	cg20045696	chr14:77926864	AHSA1	-0.59	-6.85	-0.32	2.54e-11	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUAD	cis	rs4006360	0.537	rs12602811	chr17:39245273	C/T	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.27	0.37	1.75e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.49	0.6	3.38e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg01802117	chr1:53393560	SCP2	0.37	7.24	0.33	2.11e-12	Monocyte count;
LUAD	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg18240062	chr17:79603768	NPLOC4	-0.46	-8.02	-0.36	1.08e-14	Eye color traits;
LUAD	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg22508957	chr16:3507546	NAT15	-0.81	-13.44	-0.55	1.54e-34	Tuberculosis;
LUAD	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg12179176	chr11:130786555	SNX19	0.46	7.35	0.34	1.02e-12	Schizophrenia;
LUAD	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg10518543	chr12:38710700	ALG10B	0.42	6.42	0.3	3.68e-10	Bladder cancer;
LUAD	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	10.66	0.46	1.19e-23	Hip circumference adjusted for BMI;
LUAD	cis	rs9487051	0.768	rs461487	chr6:109525504	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.19	-0.33	2.88e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg12179176	chr11:130786555	SNX19	0.66	11.01	0.47	5.88e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.67	-11.19	-0.48	1.19e-25	Primary sclerosing cholangitis;
LUAD	cis	rs13394619	0.744	rs10929759	chr2:11722012	C/G	cg07314298	chr2:11723111	GREB1	0.54	10.28	0.45	2.72e-22	Endometriosis;
LUAD	cis	rs6426558	0.537	rs6699828	chr1:227274591	T/C	cg10327440	chr1:227177885	CDC42BPA	0.57	9.3	0.41	7.48e-19	Neutrophil percentage of white cells;
LUAD	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg15557168	chr22:42548783	NA	-0.5	-8.82	-0.39	2.99e-17	Schizophrenia;
LUAD	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10802521	chr3:52805072	NEK4	-0.62	-11.07	-0.47	3.45e-25	Bipolar disorder;
LUAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.9	10.68	0.46	9.45e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg15247329	chr7:2764246	NA	-0.36	-6.45	-0.3	2.99e-10	Height;
LUAD	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.61	0.31	1.14e-10	Fuchs's corneal dystrophy;
LUAD	trans	rs1493916	0.870	rs7239173	chr18:31395534	A/T	cg13755796	chr4:20253514	NA	-0.43	-7.27	-0.33	1.74e-12	Life satisfaction;
LUAD	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg23711669	chr6:146136114	FBXO30	0.38	6.38	0.3	4.56e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg22535103	chr8:58192502	C8orf71	-0.75	-10.25	-0.45	3.59e-22	Developmental language disorder (linguistic errors);
LUAD	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-15.6	-0.6	1.11e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs7809615	0.901	rs11761528	chr7:99118801	C/T	cg12290671	chr7:99195819	NA	-0.69	-7.84	-0.36	3.67e-14	Blood metabolite ratios;
LUAD	cis	rs9393692	0.557	rs7755741	chr6:26337264	G/A	cg13736514	chr6:26305472	NA	-0.49	-7.7	-0.35	9.8e-14	Educational attainment;
LUAD	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.59	-0.52	4.41e-31	Monocyte count;
LUAD	cis	rs447921	0.736	rs28715905	chr17:74448063	A/C	cg17201438	chr17:74438067	UBE2O	-0.63	-8.54	-0.38	2.5e-16	Mitochondrial DNA levels;
LUAD	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg09796270	chr17:17721594	SREBF1	0.38	7.79	0.35	5.08e-14	Total body bone mineral density;
LUAD	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11890956	chr21:40555474	PSMG1	0.65	8.29	0.37	1.47e-15	Cognitive function;
LUAD	cis	rs9902453	0.904	rs7219456	chr17:28374112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.53	-0.46	3.46e-23	Coffee consumption (cups per day);
LUAD	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg12292205	chr6:26970375	C6orf41	-0.47	-6.56	-0.3	1.6e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg07570687	chr10:102243282	WNT8B	0.42	6.53	0.3	1.87e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs2070488	0.662	rs6599203	chr3:38487802	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.51	8.0	0.36	1.17e-14	Electrocardiographic conduction measures;
LUAD	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg11062466	chr8:58055876	NA	0.6	7.92	0.36	2.08e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg15997130	chr1:24165203	NA	0.54	9.43	0.42	2.81e-19	Immature fraction of reticulocytes;
LUAD	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg17366294	chr4:99064904	C4orf37	0.72	13.47	0.55	1.17e-34	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg01849466	chr14:104193079	ZFYVE21	0.45	7.47	0.34	4.57e-13	Body mass index;
LUAD	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg05313129	chr8:58192883	C8orf71	-0.57	-8.56	-0.38	2.05e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg18527919	chr2:24398170	C2orf84	0.41	6.76	0.31	4.45e-11	Asthma;
LUAD	cis	rs9341808	0.530	rs3805876	chr6:81031539	C/A	cg08355045	chr6:80787529	NA	0.5	8.63	0.39	1.22e-16	Sitting height ratio;
LUAD	cis	rs11971779	0.648	rs10230407	chr7:139103893	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	6.96e-11	Diisocyanate-induced asthma;
LUAD	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-8.35	-0.38	9.75e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.42	-0.3	3.76e-10	Breast cancer;
LUAD	cis	rs4285028	0.948	rs1920309	chr3:121665479	G/A	cg20356878	chr3:121714668	ILDR1	-0.5	-6.73	-0.31	5.44e-11	Multiple sclerosis;
LUAD	cis	rs7584330	0.740	rs12471291	chr2:238441751	T/G	cg14458575	chr2:238380390	NA	0.61	11.47	0.49	1.08e-26	Prostate cancer;
LUAD	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.74	0.43	2.28e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg09835421	chr16:68378352	PRMT7	-0.91	-9.74	-0.43	2.41e-20	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg26855724	chr1:75198818	TYW3;CRYZ	0.42	6.84	0.32	2.79e-11	Resistin levels;
LUAD	cis	rs1816752	0.590	rs61947036	chr13:25017682	T/C	cg02811702	chr13:24901961	NA	0.46	7.89	0.36	2.6e-14	Obesity-related traits;
LUAD	cis	rs1997103	0.954	rs6593222	chr7:55372932	A/C	cg17469321	chr7:55412551	NA	0.67	11.28	0.48	5.71e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs10979	1.000	rs9403505	chr6:143885841	A/G	cg25407410	chr6:143891975	LOC285740	-0.62	-10.17	-0.44	7.22e-22	Hypospadias;
LUAD	cis	rs9341808	0.718	rs3805922	chr6:80891989	A/G	cg08355045	chr6:80787529	NA	0.58	10.49	0.45	4.9e-23	Sitting height ratio;
LUAD	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg15992532	chr8:142229932	SLC45A4	0.48	8.44	0.38	5.27e-16	Immature fraction of reticulocytes;
LUAD	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg00495681	chr13:53174319	NA	0.86	17.67	0.65	9.5e-53	Lewy body disease;
LUAD	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8072100	0.720	rs4794057	chr17:45786452	C/T	cg07432352	chr17:45403706	C17orf57	0.36	6.74	0.31	5.27e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17401966	0.898	rs12117635	chr1:10317445	C/T	cg15208524	chr1:10270712	KIF1B	0.42	6.57	0.3	1.44e-10	Hepatocellular carcinoma;
LUAD	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg05304507	chr6:116381966	FRK	0.19	6.45	0.3	2.99e-10	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs240764	0.658	rs1336251	chr6:101247698	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-7.56	-0.34	2.53e-13	Neuroticism;
LUAD	cis	rs9399401	0.626	rs4304190	chr6:142778912	A/G	cg03128060	chr6:142623767	GPR126	0.44	8.4	0.38	6.59e-16	Chronic obstructive pulmonary disease;
LUAD	trans	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.64	9.54	0.42	1.16e-19	Platelet distribution width;
LUAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.38	-7.13	-0.33	4.27e-12	Longevity;Endometriosis;
LUAD	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-6.66	-0.31	8.64e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg19346786	chr7:2764209	NA	-0.58	-12.47	-0.52	1.25e-30	Height;
LUAD	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg26384229	chr12:38710491	ALG10B	-0.41	-6.91	-0.32	1.84e-11	Morning vs. evening chronotype;
LUAD	cis	rs12478296	1.000	rs56102931	chr2:243039936	A/G	cg06360820	chr2:242988706	NA	-0.84	-9.69	-0.43	3.39e-20	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6908034	0.607	rs79162793	chr6:19813065	A/G	cg02682789	chr6:19804855	NA	0.91	9.09	0.4	3.9e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs7737355	0.704	rs984616	chr5:130891101	C/T	cg06307176	chr5:131281290	NA	0.42	7.01	0.32	9.25e-12	Life satisfaction;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23506944	chr17:28257236	EFCAB5;SSH2	-0.56	-6.8	-0.31	3.6e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9948	0.786	rs62152775	chr2:97448474	G/T	cg20312557	chr2:97357134	FER1L5	-0.63	-7.36	-0.34	9.71e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.26	-0.54	8.48e-34	Chronic sinus infection;
LUAD	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg07636037	chr3:49044803	WDR6	0.36	6.5	0.3	2.31e-10	Resting heart rate;
LUAD	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg09658497	chr7:2847517	GNA12	-0.45	-7.62	-0.35	1.63e-13	Height;
LUAD	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg13334819	chr7:99746414	C7orf59	0.66	10.62	0.46	1.68e-23	Coronary artery disease;
LUAD	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg24069376	chr3:38537580	EXOG	0.43	10.44	0.45	7.57e-23	Electrocardiographic conduction measures;
LUAD	cis	rs11112613	0.713	rs11112590	chr12:105951376	C/G	cg03607813	chr12:105948248	NA	-0.7	-11.32	-0.48	4.11e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.64	-7.14	-0.33	4.15e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs2073300	0.609	rs6132615	chr20:23413200	T/C	cg12062639	chr20:23401060	NAPB	1.11	11.58	0.49	3.94e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10899021	0.790	rs10899019	chr11:74335162	A/G	cg25880958	chr11:74394337	NA	-0.53	-7.17	-0.33	3.36e-12	Response to metformin (IC50);
LUAD	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg00280220	chr17:61926910	NA	0.37	7.17	0.33	3.47e-12	Prudent dietary pattern;
LUAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg10729496	chr3:10149963	C3orf24	0.52	7.81	0.35	4.66e-14	Alzheimer's disease;
LUAD	cis	rs877282	0.838	rs11253408	chr10:796374	T/C	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	cis	rs4713675	0.584	rs9380375	chr6:33682391	G/A	cg14003231	chr6:33640908	ITPR3	0.49	9.49	0.42	1.65e-19	Plateletcrit;
LUAD	cis	rs7737355	1.000	rs6876350	chr5:130604109	G/T	cg06307176	chr5:131281290	NA	0.43	6.92	0.32	1.72e-11	Life satisfaction;
LUAD	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg24879335	chr3:133465180	TF	0.37	7.6	0.35	1.95e-13	Iron status biomarkers (transferrin levels);
LUAD	cis	rs75920871	0.702	rs7946869	chr11:116963312	C/T	cg04087571	chr11:116723030	SIK3	-0.32	-7.36	-0.34	9.89e-13	Subjective well-being;
LUAD	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg13607699	chr17:42295918	UBTF	0.56	9.15	0.41	2.48e-18	Total body bone mineral density;
LUAD	cis	rs500891	0.525	rs2023241	chr6:84051460	G/A	cg08257003	chr6:84140564	ME1	0.34	6.65	0.31	9.02e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs2242663	0.531	rs2511225	chr11:66248431	A/C	cg18002602	chr11:66138449	SLC29A2	-0.33	-7.0	-0.32	9.82e-12	Bipolar disorder;
LUAD	cis	rs11671005	0.735	rs56290606	chr19:58919320	A/G	cg13877915	chr19:58951672	ZNF132	0.55	7.27	0.33	1.75e-12	Mean platelet volume;
LUAD	cis	rs752010	0.871	rs10890149	chr1:42092791	T/A	cg06885757	chr1:42089581	HIVEP3	0.39	8.17	0.37	3.7e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs9715521	0.935	rs56025348	chr4:59836741	T/G	cg11281224	chr4:60001000	NA	-0.56	-9.44	-0.42	2.62e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2046867	0.862	rs6778168	chr3:72840206	T/A	cg25664220	chr3:72788482	NA	-0.61	-11.37	-0.48	2.66e-26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.43	7.74	0.35	7.27e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg02423579	chr7:2872169	GNA12	0.86	15.05	0.59	2.66e-41	Height;
LUAD	cis	rs6754311	0.593	rs11679508	chr2:136474098	A/T	cg07305463	chr2:136567211	LCT	0.34	6.45	0.3	3.11e-10	Mosquito bite size;
LUAD	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.85	-0.47	2.3e-24	Total body bone mineral density;
LUAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg11062466	chr8:58055876	NA	0.66	8.64	0.39	1.2e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg00933542	chr6:150070202	PCMT1	0.44	9.24	0.41	1.21e-18	Lung cancer;
LUAD	cis	rs6684514	0.506	rs3762281	chr1:156304782	A/G	cg20302342	chr1:156215951	PAQR6	0.35	8.19	0.37	3.17e-15	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg08847533	chr14:75593920	NEK9	0.43	7.36	0.34	9.37e-13	Height;
LUAD	cis	rs17102423	0.594	rs7159443	chr14:65550816	T/A	cg16583315	chr14:65563665	MAX	-0.35	-6.58	-0.3	1.36e-10	Obesity-related traits;
LUAD	cis	rs2637266	1.000	rs12774835	chr10:78352226	C/G	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.7	-11.49	-0.49	8.66e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg02569458	chr12:86230093	RASSF9	-0.41	-7.6	-0.35	1.95e-13	Major depressive disorder;
LUAD	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg06618935	chr21:46677482	NA	-0.5	-9.84	-0.43	1.01e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg27544375	chr7:42971887	MRPL32;PSMA2	0.41	6.46	0.3	2.92e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg24399712	chr22:39784796	NA	-0.8	-14.53	-0.58	4.18e-39	Intelligence (multi-trait analysis);
LUAD	cis	rs738321	0.790	rs4820317	chr22:38543287	T/C	cg17652424	chr22:38574118	PLA2G6	-0.29	-7.78	-0.35	5.63e-14	Breast cancer;
LUAD	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg13319975	chr6:146136371	FBXO30	0.66	11.42	0.49	1.58e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs877282	0.945	rs11253396	chr10:789754	C/T	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	trans	rs57046232	0.552	rs2009127	chr20:6341680	C/T	cg21095983	chr6:86352623	SYNCRIP	0.42	6.43	0.3	3.5e-10	Colorectal cancer;
LUAD	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg03929089	chr4:120376271	NA	-0.46	-7.12	-0.33	4.79e-12	Height;
LUAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04267008	chr7:1944627	MAD1L1	-0.69	-10.82	-0.47	2.97e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14159672	chr1:205819179	PM20D1	-0.7	-13.7	-0.55	1.33e-35	Monocyte percentage of white cells;
LUAD	cis	rs12545109	0.671	rs35500854	chr8:57424303	G/A	cg21220214	chr8:57350948	NA	-0.63	-8.65	-0.39	1.06e-16	Obesity-related traits;
LUAD	cis	rs28595532	1.000	rs56225646	chr4:119651217	T/C	cg02775129	chr4:119771670	NA	-0.82	-7.62	-0.35	1.7e-13	Cannabis dependence symptom count;
LUAD	trans	rs2018683	1.000	rs4719963	chr7:29011064	A/G	cg19402173	chr7:128379420	CALU	0.63	10.55	0.46	2.95e-23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg05434287	chr7:2030229	MAD1L1	0.39	6.48	0.3	2.6200000000000003e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg06618935	chr21:46677482	NA	-0.45	-9.22	-0.41	1.38e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3849570	1.000	rs9817181	chr3:81827765	A/C	cg07356753	chr3:81810745	GBE1	-0.71	-12.74	-0.53	1.11e-31	Waist circumference;Body mass index;
LUAD	cis	rs146671954	1	rs146671954	chr9:136934203	G/A	cg13789015	chr9:136890014	NCRNA00094	0.61	7.89	0.36	2.57e-14	Red cell distribution width;
LUAD	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg08999081	chr20:33150536	PIGU	-0.6	-13.35	-0.54	3.75e-34	Glomerular filtration rate (creatinine);
LUAD	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.36	7.05	0.32	7.27e-12	Obesity-related traits;
LUAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.51	6.9	0.32	1.95e-11	Renal function-related traits (BUN);
LUAD	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-15.58	-0.6	1.45e-43	Schizophrenia;
LUAD	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg15704280	chr7:45808275	SEPT13	-1.06	-24.55	-0.77	2.3e-83	Height;
LUAD	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg12292205	chr6:26970375	C6orf41	-0.55	-6.72	-0.31	5.78e-11	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.79	0.35	5.19e-14	Resting heart rate;
LUAD	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.84	-0.32	2.82e-11	Longevity;
LUAD	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg06271696	chr7:157225062	NA	0.36	6.78	0.31	4.11e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs67072384	1.000	rs2365441	chr11:72450226	T/C	cg04827223	chr11:72435913	ARAP1	-0.61	-7.31	-0.33	1.38e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs300703	0.719	rs400040	chr2:199422	G/T	cg21211680	chr2:198530	NA	0.59	7.92	0.36	2.09e-14	Blood protein levels;
LUAD	cis	rs2404618	0.624	rs28439223	chr8:1476901	C/G	cg13402656	chr8:1511478	DLGAP2	-0.71	-14.04	-0.56	4.88e-37	Lung cancer;
LUAD	cis	rs2734839	0.927	rs2734837	chr11:113286829	C/T	cg14159747	chr11:113255604	NA	0.53	9.88	0.43	7.27e-21	Information processing speed;
LUAD	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.62	0.31	1.12e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.22	0.37	2.59e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg24558204	chr6:135376177	HBS1L	0.45	8.0	0.36	1.24e-14	Red blood cell count;
LUAD	cis	rs57994353	0.897	rs72775778	chr9:139381128	G/A	cg13856295	chr9:139396418	NOTCH1	-0.43	-6.75	-0.31	4.91e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs597539	0.690	rs7104351	chr11:68617886	A/G	cg06112835	chr11:68658793	MRPL21	0.5	8.82	0.39	2.94e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.44	-0.34	5.5e-13	Bipolar disorder;
LUAD	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.33	-7.45	-0.34	5.14e-13	Lung cancer;
LUAD	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg00933542	chr6:150070202	PCMT1	0.46	9.89	0.43	6.95e-21	Lung cancer;
LUAD	cis	rs34638657	0.702	rs62044258	chr16:82199461	C/T	cg09439754	chr16:82129088	HSD17B2	-0.37	-7.07	-0.33	6.52e-12	Lung adenocarcinoma;
LUAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg24813613	chr7:1882135	MAD1L1	-0.54	-8.92	-0.4	1.38e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9902453	0.765	rs2628185	chr17:28070107	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.5	-0.45	4.52e-23	Coffee consumption (cups per day);
LUAD	cis	rs9843304	0.528	rs1317213	chr3:149191150	C/T	cg08667024	chr3:149219783	TM4SF4	0.37	6.76	0.31	4.6e-11	Gallstone disease;
LUAD	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.7	-0.31	6.84e-11	Height;
LUAD	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg03929089	chr4:120376271	NA	0.65	10.63	0.46	1.54e-23	Coronary artery disease;
LUAD	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.18	0.37	3.45e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs300703	0.719	rs389621	chr2:206636	C/T	cg21211680	chr2:198530	NA	-0.53	-6.91	-0.32	1.85e-11	Blood protein levels;
LUAD	trans	rs10411161	0.702	rs8113768	chr19:52383938	C/T	cg22319618	chr22:45562946	NUP50	-0.59	-8.24	-0.37	2.13e-15	Breast cancer;
LUAD	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg19041857	chr6:27730383	NA	0.36	6.59	0.3	1.34e-10	Parkinson's disease;
LUAD	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg07757535	chr4:1339547	NA	0.32	6.35	0.3	5.48e-10	Longevity;
LUAD	cis	rs9283706	0.673	rs2006323	chr5:66305992	T/C	cg11590213	chr5:66331682	MAST4	0.41	6.62	0.31	1.08e-10	Coronary artery disease;
LUAD	cis	rs1595825	0.891	rs7587716	chr2:198630667	G/T	cg10547527	chr2:198650123	BOLL	-0.53	-7.37	-0.34	8.82e-13	Ulcerative colitis;
LUAD	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg11189052	chr15:85197271	WDR73	0.58	7.5	0.34	3.83e-13	Schizophrenia;
LUAD	trans	rs2262909	1.000	rs765527	chr19:22129555	A/G	cg17074339	chr11:11642133	GALNTL4	0.42	7.05	0.32	7.28e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10489202	0.608	rs10918827	chr1:168077044	A/G	cg25738037	chr1:168025549	DCAF6	0.45	6.76	0.31	4.51e-11	Schizophrenia;
LUAD	cis	rs2274471	0.660	rs10974948	chr9:5075255	C/T	cg03390472	chr9:5043263	JAK2	-0.57	-8.12	-0.37	5.08e-15	Crohn's disease;
LUAD	cis	rs7192380	0.964	rs11075729	chr16:69620278	G/A	cg00738113	chr16:70207722	CLEC18C	-0.34	-6.92	-0.32	1.67e-11	Sjögren's syndrome;
LUAD	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg12623918	chr2:306882	NA	0.35	7.04	0.32	7.93e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-8.33	-0.38	1.14e-15	Endometrial cancer;
LUAD	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg15181151	chr6:150070149	PCMT1	0.43	8.57	0.38	1.96e-16	Lung cancer;
LUAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg20607798	chr8:58055168	NA	0.72	9.43	0.42	2.64e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7681423	1.000	rs12644950	chr4:155537321	G/A	cg20735720	chr4:155535218	FGG	-0.49	-7.02	-0.32	8.83e-12	Fibrinogen;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15804432	chr15:64454965	PPIB	-0.54	-6.41	-0.3	3.95e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg15123519	chr2:136567270	LCT	0.36	6.36	0.3	5.29e-10	Mosquito bite size;
LUAD	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.91	0.36	2.27e-14	Bladder cancer;
LUAD	cis	rs6496044	0.634	rs4843066	chr15:86062911	C/T	cg13263323	chr15:86062960	AKAP13	-0.59	-10.88	-0.47	1.76e-24	Interstitial lung disease;
LUAD	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg00495681	chr13:53174319	NA	0.6	11.39	0.48	2.19e-26	Lewy body disease;
LUAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg07362569	chr17:61921086	SMARCD2	0.39	6.73	0.31	5.37e-11	Prudent dietary pattern;
LUAD	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg25173405	chr17:45401733	C17orf57	-0.46	-7.62	-0.35	1.72e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9462027	0.628	rs9368832	chr6:34679587	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.35	8.72	0.39	6.45e-17	Systemic lupus erythematosus;
LUAD	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg17757837	chr7:157058334	UBE3C	0.48	8.47	0.38	3.98e-16	Body mass index;
LUAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg00280220	chr17:61926910	NA	0.34	6.54	0.3	1.82e-10	Prudent dietary pattern;
LUAD	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg25828334	chr19:18545568	ISYNA1	-0.39	-7.91	-0.36	2.22e-14	Breast cancer;
LUAD	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06028605	chr16:24865363	SLC5A11	-0.54	-8.34	-0.38	1.09e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.91	0.36	2.29e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12618769	0.597	rs3769724	chr2:99105981	C/T	cg10123293	chr2:99228465	UNC50	0.46	8.08	0.37	6.88e-15	Bipolar disorder;
LUAD	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg21475434	chr5:93447410	FAM172A	0.71	8.44	0.38	4.95e-16	Diabetic retinopathy;
LUAD	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08109568	chr15:31115862	NA	0.77	13.38	0.55	2.64e-34	Huntington's disease progression;
LUAD	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg02743256	chr7:2109353	MAD1L1	-0.4	-6.35	-0.3	5.49e-10	Neuroticism;
LUAD	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg13770153	chr20:60521292	NA	0.97	16.74	0.63	1.31e-48	Obesity-related traits;
LUAD	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	6.84	0.32	2.79e-11	Lung cancer in ever smokers;
LUAD	cis	rs1451375	1.000	rs10247443	chr7:50620586	G/A	cg18232548	chr7:50535776	DDC	0.6	9.88	0.43	7.73e-21	Malaria;
LUAD	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg18854424	chr1:2615690	NA	0.41	9.11	0.4	3.36e-18	Multiple sclerosis;
LUAD	cis	rs61897795	0.628	rs174585	chr11:61611694	G/A	cg06781209	chr11:61594997	FADS2	-0.46	-7.32	-0.34	1.3e-12	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs12431939	1.000	rs34063246	chr14:51663719	G/C	cg23942311	chr14:51606299	NA	-0.6	-7.91	-0.36	2.29e-14	Cancer;
LUAD	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-7.98	-0.36	1.38e-14	Electroencephalogram traits;
LUAD	cis	rs10489202	0.608	rs6657019	chr1:168079669	T/C	cg24449463	chr1:168025552	DCAF6	-0.62	-9.88	-0.43	7.61e-21	Schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11412766	chr2:55276306	RTN4	-0.58	-6.86	-0.32	2.52e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.48	-0.34	4.23e-13	Menarche (age at onset);
LUAD	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg04155289	chr7:94953770	PON1	-0.57	-7.39	-0.34	7.67e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg07460842	chr6:66804631	NA	0.95	15.06	0.59	2.43e-41	Exhaled nitric oxide levels;
LUAD	cis	rs2019216	0.542	rs8073228	chr17:21909838	C/G	cg05591447	chr17:21909280	FLJ36000	-0.28	-6.96	-0.32	1.33e-11	Pelvic organ prolapse;
LUAD	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg06453172	chr10:134556979	INPP5A	0.43	7.04	0.32	7.57e-12	Migraine;
LUAD	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg04287289	chr16:89883240	FANCA	0.79	7.06	0.32	6.75e-12	Skin colour saturation;
LUAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10150615	chr22:24372951	LOC391322	0.57	9.29	0.41	8.45e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg03806693	chr22:41940476	POLR3H	0.72	9.2	0.41	1.6e-18	Cannabis dependence symptom count;
LUAD	cis	rs1595825	0.891	rs60129872	chr2:198653192	A/G	cg10547527	chr2:198650123	BOLL	-0.57	-8.09	-0.37	6.38e-15	Ulcerative colitis;
LUAD	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg11871910	chr12:69753446	YEATS4	0.7	12.2	0.51	1.58e-29	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg06552810	chr11:31128660	NA	-0.33	-6.54	-0.3	1.8e-10	Red blood cell count;
LUAD	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg11814155	chr7:99998594	ZCWPW1	0.45	7.6	0.35	1.9e-13	Platelet count;
LUAD	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg04511125	chr2:88470314	THNSL2	-0.5	-8.63	-0.39	1.28e-16	Response to metformin (IC50);
LUAD	cis	rs741677	0.927	rs2586117	chr17:483887	G/A	cg13332499	chr17:408570	NA	0.35	6.88	0.32	2.1e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs11209185	0.509	rs1926279	chr1:68450681	A/G	cg22082780	chr1:68452167	NA	0.5	10.84	0.47	2.42e-24	Itch intensity from mosquito bite adjusted by bite size;
LUAD	trans	rs11638815	0.603	rs7171180	chr15:83309108	C/T	cg18393722	chr15:85113863	UBE2QP1	0.47	7.28	0.33	1.59e-12	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.91e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg00769240	chr8:12517080	NA	-0.42	-8.06	-0.36	7.75e-15	Blood pressure (smoking interaction);
LUAD	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg05697835	chr1:2722811	NA	-0.3	-6.35	-0.3	5.55e-10	Ulcerative colitis;
LUAD	trans	rs8073060	0.544	rs9912939	chr17:34005264	T/G	cg19694781	chr19:47549865	TMEM160	-1.22	-19.34	-0.69	3.54e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg08645402	chr16:4508243	NA	0.59	10.3	0.45	2.48e-22	Schizophrenia;
LUAD	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg13385794	chr1:248469461	NA	0.26	6.99	0.32	1.08e-11	Common traits (Other);
LUAD	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg24829409	chr8:58192753	C8orf71	-0.62	-9.55	-0.42	1.07e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7589728	1.000	rs6722069	chr2:88533151	C/T	cg04511125	chr2:88470314	THNSL2	0.75	8.27	0.37	1.71e-15	Plasma clusterin levels;
LUAD	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg13319975	chr6:146136371	FBXO30	0.62	10.56	0.46	2.67e-23	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.65	-11.18	-0.48	1.33e-25	Mean corpuscular volume;
LUAD	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg24818145	chr4:99064322	C4orf37	0.49	8.11	0.37	5.73e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg25753631	chr6:25732923	NA	-0.44	-7.76	-0.35	6.26e-14	Iron status biomarkers;
LUAD	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg22906224	chr7:99728672	NA	-0.64	-11.13	-0.48	2e-25	Coronary artery disease;
LUAD	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg15123519	chr2:136567270	LCT	-0.38	-6.99	-0.32	1.09e-11	Mosquito bite size;
LUAD	cis	rs17401966	1.000	rs4846208	chr1:10313839	T/C	cg15208524	chr1:10270712	KIF1B	0.56	8.21	0.37	2.64e-15	Hepatocellular carcinoma;
LUAD	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg14092988	chr3:52407081	DNAH1	0.4	6.49	0.3	2.34e-10	Schizophrenia;
LUAD	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg20302342	chr1:156215951	PAQR6	0.38	8.64	0.39	1.13e-16	Tonsillectomy;
LUAD	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	9.14	0.41	2.57e-18	Menarche (age at onset);
LUAD	cis	rs12541635	0.677	rs10086055	chr8:107024129	C/T	cg10147462	chr8:107024639	NA	0.56	10.14	0.44	8.69e-22	Age of smoking initiation;
LUAD	cis	rs8014204	0.869	rs2070599	chr14:75361177	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.38	-6.75	-0.31	4.84e-11	Caffeine consumption;
LUAD	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.75	7.7	0.35	9.48e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2249625	0.526	rs17781511	chr6:72845455	C/T	cg18830697	chr6:72922368	RIMS1	0.47	8.5	0.38	3.2e-16	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs732716	0.889	rs62129355	chr19:4397034	T/C	cg21934504	chr19:4445085	UBXN6	0.46	8.08	0.37	6.9e-15	Mean corpuscular volume;
LUAD	cis	rs2762353	0.574	rs4419666	chr6:25693274	C/T	cg03264133	chr6:25882463	NA	0.87	14.17	0.57	1.44e-37	Blood metabolite levels;
LUAD	trans	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg26043149	chr18:55253948	FECH	-0.45	-7.16	-0.33	3.69e-12	Bone mineral density;
LUAD	cis	rs896543	0.515	rs62189825	chr2:237494954	C/T	cg25295825	chr2:237489920	CXCR7	0.49	7.0	0.32	1.02e-11	Alcohol dependence (age at onset);
LUAD	cis	rs62238980	0.614	rs77132907	chr22:32501006	T/C	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs10203711	0.966	rs10184252	chr2:239598164	A/G	cg14580085	chr2:239553406	NA	0.41	8.73	0.39	5.94e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs939658	1.000	rs12439908	chr15:79456381	T/C	cg17916960	chr15:79447300	NA	0.45	9.22	0.41	1.45e-18	Refractive error;
LUAD	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.46	-0.34	5.02e-13	Breast cancer;
LUAD	trans	rs78049276	0.688	rs80157433	chr4:148370548	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.62	-7.19	-0.33	3.04e-12	Pulse pressure;
LUAD	cis	rs3733418	0.858	rs11100583	chr4:165877645	C/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.57	-7.23	-0.33	2.35e-12	Obesity-related traits;
LUAD	cis	rs454510	0.726	rs838989	chr1:120182906	G/A	cg11530693	chr1:120165357	ZNF697	0.49	7.65	0.35	1.33e-13	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg18306943	chr3:40428807	ENTPD3	0.42	7.01	0.32	9.58e-12	Renal cell carcinoma;
LUAD	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg09654669	chr8:57350985	NA	-0.66	-9.85	-0.43	9.84e-21	Obesity-related traits;
LUAD	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg03929089	chr4:120376271	NA	0.57	7.41	0.34	6.91e-13	Axial length;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11156286	chr12:133338210	ANKLE2	-0.44	-6.83	-0.32	2.99e-11	Height;
LUAD	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg17105886	chr17:28927953	LRRC37B2	0.66	7.53	0.34	3.01e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg00106254	chr7:1943704	MAD1L1	0.53	8.02	0.36	1.04e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08280861	chr8:58055591	NA	0.76	9.08	0.4	4.14e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg26343298	chr8:95960752	TP53INP1	0.37	7.79	0.35	5.12e-14	Type 2 diabetes;
LUAD	cis	rs367615	0.918	rs10051855	chr5:108859958	G/A	cg17395555	chr5:108820864	NA	0.56	9.32	0.41	6.37e-19	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg00277334	chr10:82204260	NA	-0.48	-7.73	-0.35	7.83e-14	Post bronchodilator FEV1;
LUAD	trans	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg07923666	chr12:49932857	KCNH3	-0.51	-6.37	-0.3	4.81e-10	Resting heart rate;
LUAD	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.08	0.33	6.14e-12	Rheumatoid arthritis;
LUAD	cis	rs6445967	1.000	rs11712758	chr3:58306579	T/C	cg23715586	chr3:58305044	RPP14	0.42	7.64	0.35	1.46e-13	Platelet count;
LUAD	cis	rs9902453	1.000	rs9906340	chr17:28398977	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-9.03	-0.4	6.21e-18	Coffee consumption (cups per day);
LUAD	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.17	-0.33	3.4e-12	Total body bone mineral density;
LUAD	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	9.39	0.42	3.72e-19	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2235649	0.828	rs9925354	chr16:1849866	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.47	-7.73	-0.35	7.72e-14	Blood metabolite levels;
LUAD	cis	rs4743820	0.651	rs2457716	chr9:93937806	A/C	cg14446406	chr9:93919335	NA	-0.47	-7.42	-0.34	6.3e-13	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs2882667	0.861	rs11242445	chr5:138417054	G/T	cg04439458	chr5:138467593	SIL1	-0.4	-7.24	-0.33	2.12e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg24644049	chr4:85504048	CDS1	0.92	7.92	0.36	2.16e-14	Skin colour saturation;
LUAD	trans	rs11039798	0.764	rs11040030	chr11:48800985	C/T	cg03929089	chr4:120376271	NA	0.59	6.8	0.31	3.56e-11	Axial length;
LUAD	trans	rs6921919	0.887	rs7766356	chr6:28400538	T/C	cg06606381	chr12:133084897	FBRSL1	-0.57	-6.97	-0.32	1.22e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg17524180	chr13:113633600	MCF2L	-0.37	-7.52	-0.34	3.4e-13	Systolic blood pressure;
LUAD	trans	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg07817883	chr1:32538562	TMEM39B	1.26	12.1	0.51	3.85e-29	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg06611532	chr13:114900021	NA	0.38	8.88	0.4	1.96e-17	Schizophrenia;
LUAD	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg05304507	chr6:116381966	FRK	0.2	6.79	0.31	3.75e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.6	-0.39	1.55e-16	Alzheimer's disease (late onset);
LUAD	cis	rs6474412	1.000	rs13273442	chr8:42544017	A/G	cg25026480	chr8:42547641	NA	0.36	6.39	0.3	4.48e-10	Smoking behavior;
LUAD	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg02371401	chr5:676784	TPPP	-0.4	-6.85	-0.32	2.65e-11	Obesity-related traits;
LUAD	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-12.89	-0.53	2.75e-32	Breast cancer;
LUAD	cis	rs7072216	0.763	rs2274244	chr10:100175218	A/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.67	-0.39	9.52e-17	Metabolite levels;
LUAD	cis	rs7779181	0.855	rs215610	chr7:32339594	G/A	cg13207630	chr7:32358064	NA	-0.45	-7.13	-0.33	4.29e-12	Body mass index;
LUAD	cis	rs2688608	0.672	rs4065	chr10:75676464	C/T	cg23231163	chr10:75533350	FUT11	-0.37	-6.83	-0.32	2.96e-11	Inflammatory bowel disease;
LUAD	cis	rs12791968	0.917	rs11038239	chr11:45002012	A/G	cg11846598	chr11:44996168	LOC221122	-0.78	-14.01	-0.56	6.94e-37	Inhibitory control;
LUAD	trans	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg07393940	chr7:158741817	NA	0.67	11.58	0.49	3.85e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs11048434	0.723	rs2080116	chr12:9138183	A/G	cg26114124	chr12:9217669	LOC144571	0.38	6.9	0.32	1.89e-11	Sjögren's syndrome;
LUAD	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg14092988	chr3:52407081	DNAH1	0.44	8.97	0.4	9.48e-18	Bipolar disorder;
LUAD	cis	rs12612619	0.732	rs11677841	chr2:27239949	G/T	cg00617064	chr2:27272375	NA	-0.37	-7.0	-0.32	9.95e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	trans	rs11039798	0.764	rs11039929	chr11:48703289	A/G	cg15704280	chr7:45808275	SEPT13	0.67	7.84	0.36	3.58e-14	Axial length;
LUAD	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg19318889	chr4:1322082	MAEA	-0.4	-6.75	-0.31	4.99e-11	Obesity-related traits;
LUAD	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg26513180	chr16:89883248	FANCA	0.65	6.67	0.31	7.99e-11	Skin colour saturation;
LUAD	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.13	-0.33	4.26e-12	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21097640	chr13:28195548	POLR1D;LNX2	-0.42	-6.43	-0.3	3.47e-10	Height;
LUAD	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg27631724	chr1:11040367	C1orf127	0.56	9.99	0.44	3.19e-21	Ewing sarcoma;
LUAD	cis	rs12286929	0.639	rs4938181	chr11:115041163	A/G	cg04055981	chr11:115044050	NA	0.47	8.3	0.37	1.44e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg19700328	chr14:106028568	NA	-0.44	-7.45	-0.34	5.33e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg24069376	chr3:38537580	EXOG	0.45	10.92	0.47	1.29e-24	Electrocardiographic conduction measures;
LUAD	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg23625390	chr15:77176239	SCAPER	-0.52	-7.87	-0.36	2.98e-14	Blood metabolite levels;
LUAD	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03264133	chr6:25882463	NA	-0.58	-9.57	-0.42	9.04e-20	Blood metabolite levels;
LUAD	cis	rs17095355	1.000	rs12570820	chr10:111732507	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.69	-9.35	-0.41	5.32e-19	Biliary atresia;
LUAD	cis	rs11771526	0.901	rs62457468	chr7:32301341	C/T	cg13207630	chr7:32358064	NA	0.58	7.23	0.33	2.21e-12	Body mass index;
LUAD	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg13319975	chr6:146136371	FBXO30	-0.64	-10.92	-0.47	1.25e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg21823605	chr1:152486609	CRCT1	0.29	6.42	0.3	3.64e-10	Hair morphology;
LUAD	cis	rs1595825	0.891	rs73058867	chr2:198891568	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-6.99	-0.32	1.09e-11	Ulcerative colitis;
LUAD	cis	rs870825	0.616	rs2696037	chr4:185610940	C/T	cg04058563	chr4:185651563	MLF1IP	-0.74	-10.76	-0.46	4.89e-24	Blood protein levels;
LUAD	cis	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg07460842	chr6:66804631	NA	-1.09	-24.88	-0.77	7.97e-85	Exhaled nitric oxide output;
LUAD	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg14343924	chr8:8086146	FLJ10661	0.39	6.52	0.3	1.97e-10	Mood instability;
LUAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.84	0.43	1.07e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg11502198	chr6:26597334	ABT1	-0.64	-11.06	-0.47	3.95e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg07460842	chr6:66804631	NA	1.08	17.29	0.64	4.62e-51	Exhaled nitric oxide output;
LUAD	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg23815491	chr16:72088622	HP	0.47	8.41	0.38	6.26e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg11645453	chr3:52864694	ITIH4	0.56	10.6	0.46	1.87e-23	Schizophrenia;
LUAD	cis	rs6494488	0.500	rs111793398	chr15:65079354	C/T	cg08069370	chr15:64387884	SNX1	-0.74	-6.64	-0.31	9.68e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg03676636	chr4:99064102	C4orf37	0.32	8.33	0.38	1.13e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg23029597	chr12:123009494	RSRC2	-0.49	-7.59	-0.35	2.09e-13	Body mass index;
LUAD	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.66	-0.39	1e-16	Total body bone mineral density;
LUAD	cis	rs12681288	0.550	rs76893867	chr8:962618	G/C	cg15309053	chr8:964076	NA	0.5	11.28	0.48	5.66e-26	Schizophrenia;
LUAD	cis	rs4285028	0.747	rs11923248	chr3:121566498	G/T	cg11130432	chr3:121712080	ILDR1	-0.53	-7.29	-0.33	1.51e-12	Multiple sclerosis;
LUAD	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg24801067	chr17:62843696	NA	-0.51	-7.24	-0.33	2.11e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.41	-0.34	7.13e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg09658497	chr7:2847517	GNA12	-0.49	-9.22	-0.41	1.4e-18	Plateletcrit;
LUAD	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.72	-0.35	8.21e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.44	-0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg25767906	chr1:53392781	SCP2	-0.41	-7.16	-0.33	3.67e-12	Monocyte count;
LUAD	cis	rs13064411	0.735	rs10511326	chr3:113216325	T/C	cg18753928	chr3:113234510	CCDC52	-0.73	-12.43	-0.52	1.82e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg24503407	chr1:205819492	PM20D1	0.78	15.79	0.61	1.68e-44	Menarche (age at onset);
LUAD	cis	rs7809615	0.748	rs35183025	chr7:99030782	A/T	cg12290671	chr7:99195819	NA	-0.68	-7.93	-0.36	2.03e-14	Blood metabolite ratios;
LUAD	cis	rs4604732	0.631	rs11490200	chr1:247625915	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2455601	0.882	rs11042115	chr11:8926679	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-7.32	-0.34	1.28e-12	Schizophrenia;
LUAD	trans	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg06606381	chr12:133084897	FBRSL1	-0.53	-6.58	-0.3	1.38e-10	Depression;
LUAD	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.34	-0.34	1.11e-12	Coronary artery disease;
LUAD	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg22139774	chr2:100720529	AFF3	-0.37	-7.34	-0.34	1.11e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	7.49	0.34	3.99e-13	Cognitive test performance;
LUAD	trans	rs629535	0.814	rs72654071	chr8:70079484	A/G	cg21567404	chr3:27674614	NA	-0.99	-18.07	-0.66	1.74e-54	Dupuytren's disease;
LUAD	cis	rs4964805	1.000	rs4964805	chr12:104192824	C/G	cg02344784	chr12:104178138	NT5DC3	0.37	6.45	0.3	3.06e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg22681709	chr2:178499509	PDE11A	-0.44	-7.51	-0.34	3.66e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.65	0.31	9.11e-11	Depression;
LUAD	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg15133208	chr4:90757351	SNCA	-0.46	-6.99	-0.32	1.1e-11	Neuroticism;
LUAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg15147215	chr3:52552868	STAB1	-0.49	-9.62	-0.42	6.07e-20	Electroencephalogram traits;
LUAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.62	-7.89	-0.36	2.63e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs497273	0.552	rs1179939	chr12:121326876	G/C	cg02419362	chr12:121203948	SPPL3	-0.37	-7.43	-0.34	6.23e-13	Systemic lupus erythematosus;
LUAD	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg23982607	chr1:1823379	GNB1	0.6	10.61	0.46	1.8e-23	Body mass index;
LUAD	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg21427119	chr20:30132790	HM13	-0.5	-7.97	-0.36	1.47e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs7944584	0.632	rs7116451	chr11:47322327	G/A	cg20307385	chr11:47447363	PSMC3	0.43	6.75	0.31	4.96e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.22e-12	Tonsillectomy;
LUAD	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg23231163	chr10:75533350	FUT11	-0.51	-9.37	-0.41	4.29e-19	Inflammatory bowel disease;
LUAD	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11644478	chr21:40555479	PSMG1	-0.42	-7.0	-0.32	1.01e-11	Menarche (age at onset);
LUAD	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg04455712	chr21:45112962	RRP1B	0.43	8.9	0.4	1.7e-17	Mean corpuscular volume;
LUAD	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.25	-0.51	9.47e-30	Primary sclerosing cholangitis;
LUAD	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg11663144	chr21:46675770	NA	-0.6	-11.84	-0.5	4.01e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2554380	0.628	rs7175491	chr15:84474939	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.38	-6.77	-0.31	4.2e-11	Height;
LUAD	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Colorectal cancer;
LUAD	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.27	-0.37	1.72e-15	Height;
LUAD	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg07493874	chr5:1342172	CLPTM1L	0.34	7.38	0.34	8.29e-13	Lung cancer;
LUAD	cis	rs938554	0.784	rs4481233	chr4:9956079	A/G	cg11266682	chr4:10021025	SLC2A9	0.5	8.27	0.37	1.7e-15	Blood metabolite levels;
LUAD	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg14541582	chr5:601475	NA	-0.35	-7.55	-0.34	2.71e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.22	-0.33	2.49e-12	Schizophrenia;
LUAD	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg09491104	chr22:46646882	C22orf40	-0.57	-8.37	-0.38	8.25e-16	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12073537	chr12:49658926	TUBA1C	-0.37	-6.41	-0.3	3.83e-10	Cancer;
LUAD	cis	rs4889911	0.544	rs2650254	chr17:77833655	A/G	cg00646381	chr17:77835854	NA	0.51	8.15	0.37	4.13e-15	Electroencephalogram traits;
LUAD	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.47	0.3	2.64e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs17818399	0.926	rs1824050	chr2:46839477	T/C	cg21681030	chr2:46777652	RHOQ	0.42	7.44	0.34	5.74e-13	Height;
LUAD	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg12935359	chr14:103987150	CKB	0.47	7.88	0.36	2.77e-14	Body mass index;
LUAD	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg09455208	chr3:40491958	NA	0.55	12.06	0.51	5.29e-29	Renal cell carcinoma;
LUAD	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg27411982	chr8:10470053	RP1L1	-0.39	-7.19	-0.33	3.01e-12	Neuroticism;
LUAD	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg04025307	chr7:1156635	C7orf50	0.54	9.07	0.4	4.37e-18	Longevity;Endometriosis;
LUAD	cis	rs7107174	1.000	rs12277648	chr11:78054336	C/T	cg19901956	chr11:77921274	USP35	-0.48	-6.9	-0.32	1.94e-11	Testicular germ cell tumor;
LUAD	trans	rs7555117	0.794	rs2989476	chr1:61059259	C/G	cg11062677	chr19:13976917	NA	-0.37	-6.35	-0.3	5.57e-10	Facial morphology (factor 19);
LUAD	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg14092988	chr3:52407081	DNAH1	0.44	8.96	0.4	1.02e-17	Bipolar disorder;
LUAD	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.54	0.55	6.07e-35	Tonsillectomy;
LUAD	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs7903847	0.596	rs869967	chr10:99147975	T/C	cg20016023	chr10:99160130	RRP12	-0.3	-7.16	-0.33	3.5e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs72772090	0.520	rs56325109	chr5:96112295	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-7.36	-0.34	9.41e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2637266	0.791	rs2395392	chr10:78359933	C/A	cg18941641	chr10:78392320	NA	0.32	6.62	0.31	1.1e-10	Pulmonary function;
LUAD	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg21775007	chr8:11205619	TDH	0.47	8.1	0.37	5.98e-15	Retinal vascular caliber;
LUAD	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06112835	chr11:68658793	MRPL21	0.52	9.35	0.41	4.95e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg11070056	chr1:107600091	PRMT6	0.53	9.1	0.4	3.52e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg22598563	chr5:131563921	P4HA2	-0.31	-7.72	-0.35	8.44e-14	Blood metabolite levels;
LUAD	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.48	-0.3	2.48e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7903847	0.642	rs11189183	chr10:99144321	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-7.15	-0.33	3.85e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs36051895	0.626	rs10283564	chr9:5075628	C/G	cg02405213	chr9:5042618	JAK2	-0.48	-6.39	-0.3	4.26e-10	Pediatric autoimmune diseases;
LUAD	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-8.65	-0.39	1.12e-16	Blood metabolite levels;
LUAD	cis	rs2455601	0.638	rs2742478	chr11:8996099	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.49	-8.77	-0.39	4.29e-17	Schizophrenia;
LUAD	cis	rs7617773	0.780	rs4511915	chr3:48343858	G/A	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg24675056	chr1:15929824	NA	0.46	8.1	0.37	5.99e-15	Systolic blood pressure;
LUAD	cis	rs4631830	0.900	rs10763588	chr10:51539762	G/T	cg20129853	chr10:51489980	NA	-0.34	-6.77	-0.31	4.4e-11	Prostate-specific antigen levels;
LUAD	cis	rs877282	0.891	rs10904557	chr10:797490	C/T	cg06581033	chr10:766294	NA	0.52	7.77	0.35	6.02e-14	Uric acid levels;
LUAD	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg04034577	chr2:241836375	C2orf54	-0.48	-10.34	-0.45	1.66e-22	Urinary metabolites;
LUAD	cis	rs5167	0.583	rs7252480	chr19:45458925	C/T	cg13119609	chr19:45449297	APOC2	0.38	6.75	0.31	5.01e-11	Blood protein levels;
LUAD	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.6	8.33	0.38	1.16e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.08	-0.33	6.23e-12	Joint mobility (Beighton score);
LUAD	cis	rs752010	0.631	rs1073197	chr1:42059822	C/T	cg06885757	chr1:42089581	HIVEP3	-0.61	-14.13	-0.57	2.1e-37	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs2806561	0.754	rs10917344	chr1:23342193	C/G	cg19743168	chr1:23544995	NA	-0.35	-6.36	-0.3	5.14e-10	Height;
LUAD	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg12365402	chr11:9010492	NRIP3	-0.52	-10.51	-0.46	4.02e-23	Hemoglobin concentration;
LUAD	cis	rs829883	0.659	rs11109510	chr12:98911382	A/G	cg25150519	chr12:98850993	NA	-0.52	-8.16	-0.37	3.88e-15	Colorectal adenoma (advanced);
LUAD	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg26528668	chr16:1614120	IFT140	0.6	11.08	0.47	3.08e-25	Coronary artery disease;
LUAD	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg00074818	chr8:8560427	CLDN23	0.69	10.55	0.46	3.07e-23	Obesity-related traits;
LUAD	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg23985595	chr17:80112537	CCDC57	0.5	8.99	0.4	8.46e-18	Life satisfaction;
LUAD	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.97	0.32	1.2e-11	Lung cancer;
LUAD	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg17328964	chr8:145687451	CYHR1	-0.72	-13.17	-0.54	1.97e-33	Age at first birth;
LUAD	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg27432699	chr2:27873401	GPN1	-0.4	-6.75	-0.31	4.93e-11	Menopause (age at onset);
LUAD	cis	rs778371	0.624	rs6733495	chr2:233616709	A/G	cg08000102	chr2:233561755	GIGYF2	0.41	6.62	0.31	1.07e-10	Schizophrenia;
LUAD	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.94	-0.32	1.46e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg21640038	chr17:65362901	PSMD12	0.39	6.5	0.3	2.24e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg00684032	chr4:1343700	KIAA1530	0.42	7.04	0.32	7.89e-12	Obesity-related traits;
LUAD	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg20503657	chr10:835505	NA	0.93	14.08	0.56	3.38e-37	Eosinophil percentage of granulocytes;
LUAD	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.58	-0.35	2.22e-13	Lung cancer;
LUAD	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg22467129	chr15:76604101	ETFA	-0.6	-10.98	-0.47	7.5e-25	Blood metabolite levels;
LUAD	cis	rs7737355	0.773	rs32111	chr5:131046708	T/C	cg25547332	chr5:131281432	NA	0.43	6.96	0.32	1.3e-11	Life satisfaction;
LUAD	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.5	-0.3	2.33e-10	Prostate cancer;
LUAD	cis	rs9878978	1.000	rs11716221	chr3:2464738	G/A	cg21928760	chr3:2462534	CNTN4	-0.34	-6.61	-0.31	1.13e-10	Blood pressure (smoking interaction);
LUAD	cis	rs12478296	0.534	rs67092377	chr2:243002171	T/G	cg06360820	chr2:242988706	NA	-0.7	-9.92	-0.43	5.6e-21	Obesity-related traits;
LUAD	cis	rs743757	0.878	rs9867588	chr3:50526880	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.48	7.73	0.35	7.72e-14	Diastolic blood pressure;
LUAD	cis	rs4891159	0.790	rs72975930	chr18:74144645	G/A	cg24786174	chr18:74118243	ZNF516	-0.8	-14.76	-0.58	4.61e-40	Longevity;
LUAD	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg15181151	chr6:150070149	PCMT1	0.44	8.89	0.4	1.78e-17	Lung cancer;
LUAD	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg23649088	chr2:200775458	C2orf69	0.6	8.07	0.37	7.42e-15	Schizophrenia;
LUAD	trans	rs1493916	0.721	rs4471760	chr18:31374233	G/A	cg27147174	chr7:100797783	AP1S1	-0.71	-12.83	-0.53	4.5e-32	Life satisfaction;
LUAD	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg22482690	chr17:47019901	SNF8	0.45	8.77	0.39	4.31e-17	Type 2 diabetes;
LUAD	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg13511324	chr14:104056883	C14orf153	0.27	6.56	0.3	1.59e-10	Reticulocyte count;
LUAD	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg25233709	chr10:116636983	FAM160B1	0.44	8.81	0.39	3.14e-17	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg08000102	chr2:233561755	GIGYF2	-0.42	-6.4	-0.3	4.11e-10	Schizophrenia;
LUAD	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg14895029	chr7:2775587	GNA12	-0.45	-7.16	-0.33	3.62e-12	Height;
LUAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00166722	chr3:10149974	C3orf24	0.73	11.16	0.48	1.62e-25	Alzheimer's disease;
LUAD	cis	rs8099014	1.000	rs4940711	chr18:56135592	C/T	cg12907477	chr18:56117327	MIR122	0.39	6.53	0.3	1.84e-10	Platelet count;
LUAD	cis	rs3812762	0.879	rs10743088	chr11:8787620	A/C	cg03980550	chr11:8754370	ST5	0.38	6.56	0.3	1.55e-10	Hypospadias;
LUAD	trans	rs75804782	0.572	rs56330821	chr2:239273949	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	6.73	0.31	5.44e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg06623918	chr6:96969491	KIAA0776	-0.83	-15.55	-0.6	1.84e-43	Headache;
LUAD	cis	rs13082711	0.911	rs13086867	chr3:27529937	G/A	cg02860705	chr3:27208620	NA	0.61	8.84	0.4	2.53e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg22920501	chr2:26401640	FAM59B	-0.96	-14.61	-0.58	1.89e-39	Gut microbiome composition (summer);
LUAD	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg09491104	chr22:46646882	C22orf40	-0.63	-11.48	-0.49	9.63e-27	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs877282	0.755	rs2486579	chr10:785647	G/A	cg22713356	chr15:30763199	NA	1.06	15.5	0.6	3.11e-43	Uric acid levels;
LUAD	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.06	-0.47	3.76e-25	Type 2 diabetes;
LUAD	cis	rs1881797	0.527	rs1852908	chr1:247678260	C/T	cg21399703	chr1:247681439	NA	0.5	6.72	0.31	5.99e-11	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2050392	0.630	rs303428	chr10:30739058	C/T	cg18806716	chr10:30721971	MAP3K8	0.55	10.39	0.45	1.12e-22	Inflammatory bowel disease;
LUAD	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg20587970	chr11:113659929	NA	-1.14	-15.73	-0.61	3.28e-44	Hip circumference adjusted for BMI;
LUAD	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	8.7	0.39	7.42e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs4660306	0.961	rs4660871	chr1:45995232	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-6.57	-0.3	1.52e-10	Homocysteine levels;
LUAD	cis	rs4273100	1.000	rs12602286	chr17:19236954	G/T	cg19949948	chr17:19361230	NA	0.43	6.37	0.3	5.05e-10	Schizophrenia;
LUAD	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg21204522	chr6:27730016	NA	-0.51	-7.74	-0.35	7.51e-14	Breast cancer;
LUAD	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-12.05	-0.51	6.17e-29	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg08807101	chr21:30365312	RNF160	0.49	8.57	0.38	1.97e-16	Dental caries;
LUAD	cis	rs1003719	0.688	rs2000413	chr21:38539718	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.46	-7.58	-0.35	2.24e-13	Eye color traits;
LUAD	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg02753203	chr1:228287806	NA	-0.46	-8.57	-0.38	2e-16	Diastolic blood pressure;
LUAD	cis	rs1595825	0.786	rs77218291	chr2:198565011	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-7.14	-0.33	4.23e-12	Ulcerative colitis;
LUAD	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg00933542	chr6:150070202	PCMT1	0.4	8.25	0.37	2.07e-15	Lung cancer;
LUAD	cis	rs773506	0.655	rs4744037	chr9:93932488	C/G	cg14446406	chr9:93919335	NA	-0.37	-6.73	-0.31	5.53e-11	Type 2 diabetes nephropathy;
LUAD	cis	rs6076065	0.723	rs2144381	chr20:23369940	C/T	cg11657817	chr20:23433608	CST11	0.46	8.69	0.39	7.85e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7588746	0.621	rs11691757	chr2:201148951	C/T	cg23649088	chr2:200775458	C2orf69	-0.47	-7.29	-0.33	1.57e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
LUAD	cis	rs7020830	0.898	rs2047010	chr9:37077947	A/G	cg14294708	chr9:37120828	ZCCHC7	0.85	16.58	0.63	6.36e-48	Schizophrenia;
LUAD	cis	rs1941023	0.568	rs1373064	chr11:60168200	C/T	cg08716584	chr11:60157161	MS4A7	-0.45	-8.55	-0.38	2.29e-16	Congenital heart disease (maternal effect);
LUAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg22907277	chr7:1156413	C7orf50	0.56	9.5	0.42	1.62e-19	Longevity;Endometriosis;
LUAD	cis	rs12765878	1.000	rs11191843	chr10:105648651	G/C	cg11005552	chr10:105648138	OBFC1	0.44	8.25	0.37	2.06e-15	Coronary artery disease;
LUAD	cis	rs790123	0.553	rs1106346	chr3:122354037	A/G	cg17380795	chr3:122379686	NA	0.44	7.46	0.34	5.03e-13	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs12618769	0.625	rs4850877	chr2:99112154	C/T	cg10123293	chr2:99228465	UNC50	0.46	8.12	0.37	5.1e-15	Bipolar disorder;
LUAD	trans	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg03886242	chr7:26192032	NFE2L3	0.37	6.6	0.31	1.26e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12612619	0.732	rs2053385	chr2:27231145	G/A	cg00617064	chr2:27272375	NA	-0.38	-7.28	-0.33	1.62e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg11062466	chr8:58055876	NA	0.67	8.7	0.39	7.43e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs3806843	0.576	rs246027	chr5:140333601	A/G	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg04181038	chr4:183730758	NA	0.72	10.7	0.46	8.4e-24	Pediatric autoimmune diseases;
LUAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg18621852	chr3:10150065	C3orf24	0.45	7.08	0.33	5.94e-12	Alzheimer's disease;
LUAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-8.93	-0.4	1.32e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg23711669	chr6:146136114	FBXO30	0.39	6.63	0.31	1.01e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg20790798	chr5:1857306	NA	-0.46	-7.66	-0.35	1.32e-13	Cardiovascular disease risk factors;
LUAD	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg22705602	chr4:152727874	NA	-0.42	-7.23	-0.33	2.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg07917127	chr4:99064746	C4orf37	0.44	7.22	0.33	2.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg22482690	chr17:47019901	SNF8	0.47	9.09	0.4	4.01e-18	Type 2 diabetes;
LUAD	cis	rs1692580	0.777	rs12136830	chr1:2189196	A/T	cg21194808	chr1:2205498	SKI	0.4	6.8	0.31	3.63e-11	Coronary artery disease;
LUAD	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg02734326	chr4:10020555	SLC2A9	0.63	11.28	0.48	5.66e-26	Bone mineral density;
LUAD	cis	rs55665837	1.000	rs11023224	chr11:14457739	G/A	cg19336497	chr11:14380999	RRAS2	-0.5	-10.1	-0.44	1.27e-21	Vitamin D levels;
LUAD	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg02734326	chr4:10020555	SLC2A9	0.6	10.64	0.46	1.33e-23	Bone mineral density;
LUAD	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg22117172	chr7:91764530	CYP51A1	0.33	7.34	0.34	1.11e-12	Breast cancer;
LUAD	trans	rs9784649	1.000	rs3933895	chr5:25004929	A/T	cg08600765	chr20:34638493	LOC647979	-0.64	-8.02	-0.36	1.06e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs12517041	1.000	rs1820748	chr5:23323355	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.57	-0.3	1.52e-10	Calcium levels;
LUAD	cis	rs9902453	0.817	rs7217961	chr17:28403112	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-9.88	-0.43	7.68e-21	Coffee consumption (cups per day);
LUAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg02796970	chr10:39023768	NA	0.48	7.76	0.35	6.22e-14	Menopause (age at onset);
LUAD	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg20587970	chr11:113659929	NA	-1.18	-18.04	-0.66	2.34e-54	Hip circumference adjusted for BMI;
LUAD	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg19678392	chr7:94953810	PON1	-0.57	-7.84	-0.36	3.58e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3733418	0.929	rs13120990	chr4:165905118	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.49	-6.98	-0.32	1.16e-11	Obesity-related traits;
LUAD	trans	rs853679	1.000	rs853679	chr6:28296863	C/A	cg06606381	chr12:133084897	FBRSL1	-0.58	-7.17	-0.33	3.29e-12	Depression;
LUAD	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg08999081	chr20:33150536	PIGU	-0.62	-13.96	-0.56	1.08e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	6.44	0.3	3.2e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg11822812	chr5:140052017	DND1	0.39	7.01	0.32	9.72e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs73206853	0.841	rs3026483	chr12:110780905	A/G	cg12870014	chr12:110450643	ANKRD13A	0.6	6.54	0.3	1.82e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg10518543	chr12:38710700	ALG10B	0.42	6.42	0.3	3.68e-10	Bladder cancer;
LUAD	cis	rs9487051	0.698	rs4301336	chr6:109650140	A/T	cg21918786	chr6:109611834	NA	0.4	6.43	0.3	3.39e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.11	-0.33	4.94e-12	Lung cancer;
LUAD	cis	rs2274273	0.837	rs7146748	chr14:55747086	G/A	cg04306507	chr14:55594613	LGALS3	0.42	8.87	0.4	2.1e-17	Protein biomarker;
LUAD	cis	rs76419734	0.558	rs11730825	chr4:106527568	C/T	cg05309399	chr4:106552544	FLJ20184	-0.55	-6.75	-0.31	4.9e-11	Post bronchodilator FEV1;
LUAD	cis	rs2625529	0.526	rs1035744	chr15:72566615	C/T	cg16672083	chr15:72433130	SENP8	0.62	11.33	0.48	3.61e-26	Red blood cell count;
LUAD	trans	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg24644049	chr4:85504048	CDS1	0.89	7.23	0.33	2.21e-12	Skin colour saturation;
LUAD	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg27446573	chr6:127587934	RNF146	0.45	6.59	0.31	1.3100000000000001e-10	Breast cancer;
LUAD	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg06627628	chr2:24431161	ITSN2	-0.46	-6.57	-0.3	1.47e-10	Lymphocyte counts;
LUAD	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg10802521	chr3:52805072	NEK4	-0.49	-8.5	-0.38	3.18e-16	Bipolar disorder;
LUAD	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.7	-0.31	6.52e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11771526	0.901	rs17161137	chr7:32323799	G/T	cg27532318	chr7:32358331	NA	0.62	7.77	0.35	6.21e-14	Body mass index;
LUAD	cis	rs939658	0.776	rs11631411	chr15:79445816	C/T	cg17916960	chr15:79447300	NA	-0.52	-11.04	-0.47	4.67e-25	Refractive error;
LUAD	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg18252515	chr7:66147081	NA	-0.61	-6.79	-0.31	3.86e-11	Diabetic kidney disease;
LUAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-9.73	-0.43	2.54e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6591341	0.515	rs599301	chr11:68189945	G/C	cg01657329	chr11:68192670	LRP5	-0.55	-9.51	-0.42	1.43e-19	Lean body mass;
LUAD	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg05368731	chr17:41323189	NBR1	0.95	20.31	0.7	1.73e-64	Menopause (age at onset);
LUAD	cis	rs6005807	0.777	rs9620809	chr22:29024691	A/G	cg12565055	chr22:29076175	TTC28	0.72	7.44	0.34	5.51e-13	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs7177699	0.550	rs7182716	chr15:79123753	T/C	cg15571903	chr15:79123663	NA	0.42	8.82	0.39	3e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	12.08	0.51	4.43e-29	Hip circumference adjusted for BMI;
LUAD	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg25233709	chr10:116636983	FAM160B1	0.45	8.99	0.4	8.2e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg14668632	chr7:2872130	GNA12	-0.39	-6.84	-0.32	2.73e-11	Height;
LUAD	cis	rs4713675	0.584	rs7759668	chr6:33670406	C/T	cg14003231	chr6:33640908	ITPR3	-0.48	-9.41	-0.42	3.28e-19	Plateletcrit;
LUAD	cis	rs6840360	0.533	rs13139327	chr4:152728590	A/C	cg22705602	chr4:152727874	NA	-0.46	-9.18	-0.41	1.97e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	9.87	0.43	7.88e-21	Total body bone mineral density;
LUAD	cis	rs2840044	1.000	rs225304	chr17:33921857	G/T	cg05299278	chr17:33885742	SLFN14	0.44	8.85	0.4	2.34e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs73198271	0.628	rs11777908	chr8:8590437	C/T	cg01851573	chr8:8652454	MFHAS1	0.47	6.8	0.31	3.6e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs17362650	0.960	rs13011033	chr2:9657312	G/C	cg12832956	chr2:9616023	IAH1	-0.47	-7.43	-0.34	6.16e-13	Alcohol dependence (age at onset);
LUAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.86	16.55	0.63	8.92e-48	Lymphocyte counts;
LUAD	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg22442454	chr1:209979470	IRF6	-0.55	-6.52	-0.3	2.06e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg01324343	chr3:183735012	ABCC5	0.92	24.73	0.77	3.38e-84	Anterior chamber depth;
LUAD	cis	rs3815700	1.000	rs8108840	chr19:33094452	A/C	cg02997394	chr19:33096574	ANKRD27	0.63	8.23	0.37	2.29e-15	Eosinophilic esophagitis;
LUAD	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg13535736	chr9:111863775	C9orf5	-0.44	-6.93	-0.32	1.62e-11	Menarche (age at onset);
LUAD	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg17724175	chr1:150552817	MCL1	0.38	9.18	0.41	1.87e-18	Urate levels;
LUAD	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg20701182	chr2:24300061	SF3B14	0.63	7.12	0.33	4.52e-12	Lymphocyte counts;
LUAD	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	7.42	0.34	6.2800000000000005e-13	Multiple sclerosis;
LUAD	trans	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg14791747	chr16:20752902	THUMPD1	-0.44	-6.8	-0.31	3.69e-11	Dental caries;
LUAD	trans	rs12517041	0.935	rs16892409	chr5:23324350	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.46	-0.3	2.88e-10	Calcium levels;
LUAD	trans	rs7395662	1.000	rs10769390	chr11:48618222	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.27	-0.33	1.72e-12	HDL cholesterol;
LUAD	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.9	0.4	1.71e-17	Parkinson's disease;
LUAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg02951883	chr7:2050386	MAD1L1	-0.86	-14.87	-0.59	1.5e-40	Bipolar disorder and schizophrenia;
LUAD	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18876405	chr7:65276391	NA	-0.6	-10.1	-0.44	1.25e-21	Aortic root size;
LUAD	cis	rs7707921	0.522	rs4703537	chr5:81480371	C/T	cg15871215	chr5:81402204	ATG10	0.65	11.23	0.48	8.31e-26	Breast cancer;
LUAD	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg14345882	chr6:26364793	BTN3A2	0.62	6.75	0.31	4.87e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6545883	0.931	rs11125885	chr2:61755728	G/C	cg15711740	chr2:61764176	XPO1	-0.42	-6.71	-0.31	6.44e-11	Tuberculosis;
LUAD	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg22920501	chr2:26401640	FAM59B	-0.93	-12.87	-0.53	3.39e-32	Gut microbiome composition (summer);
LUAD	trans	rs10802346	0.524	rs10802356	chr1:246385857	T/C	cg13514129	chr1:39547527	MACF1	0.62	11.04	0.47	4.67e-25	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs367943	1.000	rs168365	chr5:112817984	G/A	cg12552261	chr5:112820674	MCC	-0.58	-11.04	-0.47	4.66e-25	Type 2 diabetes;
LUAD	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg02733842	chr7:1102375	C7orf50	-0.59	-9.23	-0.41	1.36e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg17410650	chr12:54324560	NA	-0.54	-10.87	-0.47	1.87e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg12365402	chr11:9010492	NRIP3	0.48	8.97	0.4	9.79e-18	Hemoglobin concentration;
LUAD	cis	rs7561273	0.609	rs3795953	chr2:24345707	C/G	cg20701182	chr2:24300061	SF3B14	0.47	7.63	0.35	1.61e-13	Quantitative traits;
LUAD	cis	rs12949688	1.000	rs886926	chr17:55817413	A/G	cg12582317	chr17:55822272	NA	-0.36	-7.13	-0.33	4.41e-12	Schizophrenia;
LUAD	cis	rs9650315	0.530	rs68005065	chr8:57090308	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	8.1	0.37	5.8e-15	Height;
LUAD	cis	rs10465746	0.725	rs4907185	chr1:84336047	T/C	cg10977910	chr1:84465055	TTLL7	0.61	9.95	0.44	4.37e-21	Obesity-related traits;
LUAD	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.52	8.05	0.36	8.57e-15	Platelet count;
LUAD	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg07917127	chr4:99064746	C4orf37	0.42	7.01	0.32	9.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg08885076	chr2:99613938	TSGA10	-0.37	-6.45	-0.3	3.05e-10	Chronic sinus infection;
LUAD	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg04287289	chr16:89883240	FANCA	0.75	6.37	0.3	5.01e-10	Skin colour saturation;
LUAD	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg04287289	chr16:89883240	FANCA	0.78	6.99	0.32	1.1e-11	Skin colour saturation;
LUAD	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.62	-0.31	1.11e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11890956	chr21:40555474	PSMG1	0.82	14.66	0.58	1.25e-39	Cognitive function;
LUAD	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg02734326	chr4:10020555	SLC2A9	0.63	11.28	0.48	5.66e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg08738300	chr3:44038990	NA	0.43	6.46	0.3	2.87e-10	Coronary artery disease;
LUAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg21782813	chr7:2030301	MAD1L1	0.6	10.51	0.46	4e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg15432903	chr11:17409602	KCNJ11	0.54	10.27	0.45	3.05e-22	Type 2 diabetes;
LUAD	cis	rs2806561	1.000	rs2473851	chr1:23489869	A/G	cg19743168	chr1:23544995	NA	0.39	7.3	0.33	1.41e-12	Height;
LUAD	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg08859206	chr1:53392774	SCP2	-0.48	-8.77	-0.39	4.43e-17	Monocyte count;
LUAD	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.41	-6.59	-0.3	1.35e-10	Schizophrenia;
LUAD	cis	rs8077889	0.672	rs2074143	chr17:41856622	A/G	cg26893861	chr17:41843967	DUSP3	1.13	25.18	0.77	3.87e-86	Triglycerides;
LUAD	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg05835009	chr4:710272	PCGF3	0.57	8.45	0.38	4.64e-16	White blood cell count;
LUAD	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg00071950	chr4:10020882	SLC2A9	0.74	14.9	0.59	1.18e-40	Bone mineral density;
LUAD	cis	rs892961	0.932	rs7223768	chr17:75410521	G/A	cg05865280	chr17:75406074	SEPT9	0.64	19.45	0.69	1.22e-60	Airflow obstruction;
LUAD	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg23750338	chr8:142222470	SLC45A4	0.61	13.93	0.56	1.39e-36	Immature fraction of reticulocytes;
LUAD	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg11062466	chr8:58055876	NA	0.66	8.67	0.39	9.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg23281280	chr6:28129359	ZNF389	0.45	6.56	0.3	1.62e-10	Depression;
LUAD	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg02196655	chr2:10830764	NOL10	0.44	8.08	0.37	6.96e-15	Prostate cancer;
LUAD	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg01236616	chr12:121019343	POP5	-1.17	-16.86	-0.63	3.59e-49	Type 1 diabetes nephropathy;
LUAD	cis	rs7241530	0.689	rs6506735	chr18:75888482	C/T	cg14642773	chr18:75888474	NA	-0.31	-6.53	-0.3	1.92e-10	Educational attainment (years of education);
LUAD	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg27454412	chr7:1067447	C7orf50	-0.34	-6.55	-0.3	1.68e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg19875535	chr5:140030758	IK	0.44	7.41	0.34	7.01e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs750460	0.844	rs8027022	chr15:74226138	G/A	cg23484268	chr15:74220776	LOXL1	0.38	7.52	0.34	3.42e-13	Height;
LUAD	cis	rs9467160	1.000	rs9467162	chr6:24442047	T/C	cg16211469	chr6:24423932	MRS2	0.44	7.03	0.32	8.12e-12	Liver enzyme levels;
LUAD	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg15557168	chr22:42548783	NA	-0.46	-8.65	-0.39	1.05e-16	Cognitive function;
LUAD	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg22529645	chr1:3704559	LRRC47	0.57	10.55	0.46	2.94e-23	Red cell distribution width;
LUAD	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg16049864	chr8:95962084	TP53INP1	-0.56	-12.1	-0.51	3.82e-29	Type 2 diabetes;
LUAD	cis	rs250677	0.687	rs250679	chr5:148434952	A/T	cg18129178	chr5:148520854	ABLIM3	0.47	7.08	0.33	6.17e-12	Breast cancer;
LUAD	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12667521	chr19:29218732	NA	0.54	8.21	0.37	2.75e-15	Methadone dose in opioid dependence;
LUAD	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.74	0.39	5.38e-17	Menopause (age at onset);
LUAD	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg22508957	chr16:3507546	NAT15	-0.49	-8.09	-0.37	6.27e-15	Body mass index (adult);
LUAD	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg10523679	chr1:76189770	ACADM	-0.75	-11.61	-0.49	3.03e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs58106596	0.660	rs62197212	chr2:232562727	G/A	cg01370599	chr3:116745421	NA	0.76	9.73	0.43	2.46e-20	White blood cell count;Lymphocyte counts;
LUAD	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.56	-0.3	1.54e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg00717180	chr2:96193071	NA	-0.4	-7.4	-0.34	7.24e-13	HDL cholesterol;
LUAD	cis	rs2735413	0.914	rs11150035	chr16:78066449	G/C	cg04733911	chr16:78082701	NA	-0.33	-7.56	-0.35	2.51e-13	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs4812048	0.503	rs41314904	chr20:57564489	G/A	cg14073986	chr20:57617431	SLMO2	0.54	6.38	0.3	4.62e-10	Mean platelet volume;
LUAD	cis	rs600626	0.588	rs72997616	chr11:75474195	C/A	cg24262691	chr11:75473276	NA	0.58	7.64	0.35	1.49e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg27411982	chr8:10470053	RP1L1	-0.46	-8.59	-0.39	1.71e-16	Neuroticism;
LUAD	cis	rs727505	0.564	rs4731236	chr7:124827236	G/T	cg23710748	chr7:124431027	NA	-0.34	-6.94	-0.32	1.45e-11	Lewy body disease;
LUAD	cis	rs11696501	0.637	rs3746596	chr20:44312028	C/T	cg11783356	chr20:44313418	WFDC10B	-0.49	-7.66	-0.35	1.3e-13	Brain structure;
LUAD	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.34	-0.34	1.1e-12	Bipolar disorder;
LUAD	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg07936489	chr17:37558343	FBXL20	0.45	7.17	0.33	3.43e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs8030485	0.536	rs4778918	chr15:79434040	T/C	cg17916960	chr15:79447300	NA	0.4	7.87	0.36	3.03e-14	Left ventricle wall thickness;
LUAD	trans	rs2018683	0.707	rs917216	chr7:28971472	A/G	cg19402173	chr7:128379420	CALU	-0.51	-8.11	-0.37	5.5e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg16647868	chr5:131706066	SLC22A5	-0.49	-7.55	-0.34	2.78e-13	Breast cancer;
LUAD	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg01335087	chr22:19950166	COMT	-0.25	-6.91	-0.32	1.8e-11	Blood metabolite levels;
LUAD	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg08422745	chr4:174089978	GALNT7	-0.96	-18.13	-0.66	8.85e-55	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs2070997	0.517	rs9762	chr9:133762553	A/G	cg03924115	chr9:133768966	QRFP	0.45	6.99	0.32	1.09e-11	Response to amphetamines;
LUAD	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.59	-10.11	-0.44	1.19e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs4774899	0.752	rs2585112	chr15:57358428	C/T	cg14026238	chr15:57616123	NA	0.44	8.27	0.37	1.71e-15	Urinary tract infection frequency;
LUAD	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg14779329	chr11:130786720	SNX19	0.43	7.35	0.34	1.02e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6066835	1.000	rs6066830	chr20:47353897	C/T	cg18078177	chr20:47281410	PREX1	0.69	6.41	0.3	3.84e-10	Multiple myeloma;
LUAD	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26314531	chr2:26401878	FAM59B	-0.63	-8.62	-0.39	1.4e-16	Gut microbiome composition (summer);
LUAD	trans	rs853679	0.546	rs13213986	chr6:28358009	T/A	cg06606381	chr12:133084897	FBRSL1	-1.24	-10.7	-0.46	8.18e-24	Depression;
LUAD	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21659725	chr3:3221576	CRBN	-0.65	-11.34	-0.48	3.22e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs490234	0.966	rs545900	chr9:128341278	C/T	cg14078157	chr9:128172775	NA	0.38	7.18	0.33	3.11e-12	Mean arterial pressure;
LUAD	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.19	-0.33	3.02e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs8068544	0.818	rs7209012	chr17:40161323	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.2	-12.25	-0.51	9.73e-30	Reticulocyte fraction of red cells;Reticulocyte count;
LUAD	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg05042697	chr2:10830656	NOL10	-0.37	-6.38	-0.3	4.66e-10	Prostate cancer;
LUAD	trans	rs853679	0.546	rs483143	chr6:27846744	G/C	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.3	-0.37	1.46e-15	Depression;
LUAD	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs829883	0.872	rs1641637	chr12:98890564	G/A	cg25150519	chr12:98850993	NA	0.66	11.0	0.47	6.59e-25	Colorectal adenoma (advanced);
LUAD	cis	rs59698941	0.882	rs67414627	chr5:132258165	A/G	cg14825688	chr5:132208181	LEAP2	-0.47	-6.41	-0.3	3.91e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs4523957	0.583	rs9907384	chr17:2045375	A/C	cg16513277	chr17:2031491	SMG6	-0.98	-19.9	-0.7	1.16e-62	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7246865	0.954	rs55957788	chr19:17207851	G/A	cg19418318	chr19:17219073	MYO9B	0.46	7.94	0.36	1.9e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg26102564	chr10:131424627	MGMT	-0.36	-6.92	-0.32	1.66e-11	Response to temozolomide;
LUAD	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg16680214	chr1:154839983	KCNN3	-0.61	-12.56	-0.52	5.73e-31	Prostate cancer;
LUAD	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg10755058	chr3:40428713	ENTPD3	0.37	7.13	0.33	4.4e-12	Renal cell carcinoma;
LUAD	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg16049864	chr8:95962084	TP53INP1	-0.44	-8.72	-0.39	6.22e-17	Type 2 diabetes;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg24931592	chr11:105948506	AASDHPPT;KBTBD3	0.41	6.42	0.3	3.71e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg23978390	chr7:1156363	C7orf50	0.5	6.46	0.3	2.87e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg00129232	chr17:37814104	STARD3	-0.46	-7.81	-0.36	4.44e-14	Asthma;
LUAD	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg08439880	chr3:133502540	NA	-0.37	-6.83	-0.32	2.94e-11	Iron status biomarkers;
LUAD	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg12373951	chr3:133503437	NA	0.37	7.27	0.33	1.73e-12	Iron status biomarkers;
LUAD	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06544989	chr22:39130855	UNC84B	0.42	7.81	0.35	4.61e-14	Menopause (age at onset);
LUAD	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.75	-0.31	4.96e-11	Morning vs. evening chronotype;
LUAD	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg01689657	chr7:91764605	CYP51A1	0.36	8.79	0.39	3.88e-17	Breast cancer;
LUAD	cis	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-7.59	-0.35	2.01e-13	Resting heart rate;
LUAD	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg18132916	chr6:79620363	NA	-0.45	-7.76	-0.35	6.61e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg22532475	chr10:104410764	TRIM8	-0.45	-8.83	-0.39	2.7e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg02569458	chr12:86230093	RASSF9	0.44	7.81	0.36	4.49e-14	Major depressive disorder;
LUAD	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg17264618	chr3:40429014	ENTPD3	0.4	8.97	0.4	9.61e-18	Renal cell carcinoma;
LUAD	cis	rs807669	0.557	rs712958	chr22:19167409	T/C	cg02655711	chr22:19163373	SLC25A1	0.7	13.68	0.55	1.51e-35	Metabolite levels;
LUAD	cis	rs870825	0.929	rs55635512	chr4:185589982	G/T	cg04058563	chr4:185651563	MLF1IP	0.74	9.42	0.42	2.91e-19	Blood protein levels;
LUAD	cis	rs1595825	0.891	rs73056859	chr2:198801720	A/G	cg00361562	chr2:198649771	BOLL	-0.47	-6.59	-0.31	1.3e-10	Ulcerative colitis;
LUAD	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.3	-0.37	1.38e-15	Height;
LUAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08677398	chr8:58056175	NA	0.42	7.28	0.33	1.67e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6445967	0.569	rs10687	chr3:58305235	A/C	cg23715586	chr3:58305044	RPP14	-0.4	-6.59	-0.3	1.35e-10	Platelet count;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg08741578	chr4:4250464	TMEM128	0.43	6.62	0.31	1.06e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg09658497	chr7:2847517	GNA12	-0.44	-7.86	-0.36	3.12e-14	Height;
LUAD	cis	rs8112211	0.731	rs4386247	chr19:38821474	A/G	cg01275006	chr19:38876250	GGN	-0.49	-6.42	-0.3	3.61e-10	Blood protein levels;
LUAD	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg08742575	chr21:47604166	C21orf56	0.43	6.98	0.32	1.15e-11	Testicular germ cell tumor;
LUAD	trans	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg18187862	chr3:45730750	SACM1L	0.53	8.19	0.37	3.21e-15	Primary sclerosing cholangitis;
LUAD	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg04842962	chr6:43655489	MRPS18A	0.92	17.41	0.65	1.41e-51	IgG glycosylation;
LUAD	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg25535316	chr11:579198	PHRF1	-0.38	-6.69	-0.31	6.88e-11	Systemic lupus erythematosus;
LUAD	cis	rs60154123	0.772	rs815358	chr1:210430437	A/G	cg22029157	chr1:209979665	IRF6	0.62	6.92	0.32	1.66e-11	Coronary artery disease;
LUAD	cis	rs11048434	0.736	rs11048345	chr12:9123056	T/G	cg26114124	chr12:9217669	LOC144571	0.35	6.42	0.3	3.61e-10	Sjögren's syndrome;
LUAD	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg05340658	chr4:99064831	C4orf37	0.45	6.94	0.32	1.45e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg25237894	chr2:233734115	C2orf82	0.61	11.71	0.49	1.28e-27	Coronary artery disease;
LUAD	cis	rs4077515	0.935	rs3088081	chr9:139270149	A/G	cg14169450	chr9:139327907	INPP5E	0.39	7.15	0.33	3.73e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2115536	0.692	rs6495450	chr15:80162499	C/A	cg11839771	chr15:80205821	ST20	-0.37	-6.63	-0.31	1e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.85	-0.32	2.7e-11	Diabetic kidney disease;
LUAD	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.57	-0.49	4.54e-27	Primary sclerosing cholangitis;
LUAD	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg12292205	chr6:26970375	C6orf41	-0.58	-9.98	-0.44	3.22e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg24596788	chr1:163392923	NA	-0.37	-8.15	-0.37	4.12e-15	Motion sickness;
LUAD	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg10351095	chr21:47802916	PCNT	0.5	8.14	0.37	4.59e-15	Testicular germ cell tumor;
LUAD	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg05754148	chr16:3507555	NAT15	0.44	6.44	0.3	3.29e-10	Body mass index (adult);
LUAD	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg04398451	chr17:18023971	MYO15A	-0.63	-11.39	-0.48	2.08e-26	Total body bone mineral density;
LUAD	cis	rs870825	0.932	rs13136635	chr4:185574807	C/T	cg04058563	chr4:185651563	MLF1IP	-0.65	-8.1	-0.37	5.73e-15	Blood protein levels;
LUAD	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg19635926	chr16:89946313	TCF25	0.75	6.76	0.31	4.56e-11	Skin colour saturation;
LUAD	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg00383909	chr3:49044727	WDR6	0.98	10.38	0.45	1.25e-22	Cognitive function;
LUAD	cis	rs2835872	0.758	rs1709832	chr21:39038167	A/C	cg06728970	chr21:39037746	KCNJ6	0.4	7.55	0.34	2.73e-13	Electroencephalographic traits in alcoholism;
LUAD	cis	rs11974702	1	rs11974702	chr7:99163951	A/G	cg12290671	chr7:99195819	NA	-0.7	-7.97	-0.36	1.54e-14	Blood metabolite levels;
LUAD	cis	rs2386661	0.956	rs10905489	chr10:5670541	G/C	cg26603656	chr10:5671107	NA	-0.36	-6.5	-0.3	2.2e-10	Breast cancer;
LUAD	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg09640425	chr7:158790006	NA	-0.45	-7.68	-0.35	1.14e-13	Facial morphology (factor 20);
LUAD	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg04586622	chr2:25135609	ADCY3	0.37	8.46	0.38	4.56e-16	Body mass index;
LUAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg06453172	chr10:134556979	INPP5A	-0.77	-10.93	-0.47	1.16e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg26408565	chr15:76604113	ETFA	-0.44	-7.15	-0.33	3.81e-12	Blood metabolite levels;
LUAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg25243455	chr2:114033360	PAX8;LOC440839	-0.38	-8.49	-0.38	3.64e-16	Lymphocyte counts;
LUAD	cis	rs9304742	0.611	rs10415443	chr19:53464864	C/G	cg09915433	chr19:53449742	NA	-0.48	-8.22	-0.37	2.54e-15	Psoriasis;
LUAD	cis	rs7020830	0.823	rs7019699	chr9:37125081	C/A	cg14294708	chr9:37120828	ZCCHC7	0.85	16.86	0.63	3.59e-49	Schizophrenia;
LUAD	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg07217954	chr7:1067459	C7orf50	-0.44	-7.61	-0.35	1.77e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg02782426	chr3:40428986	ENTPD3	0.35	7.61	0.35	1.85e-13	Renal cell carcinoma;
LUAD	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg19041857	chr6:27730383	NA	-0.46	-7.36	-0.34	9.43e-13	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
LUAD	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg22676075	chr6:135203613	NA	0.41	7.66	0.35	1.26e-13	Red blood cell count;
LUAD	cis	rs7107174	0.901	rs10899497	chr11:78124534	T/C	cg02023728	chr11:77925099	USP35	0.43	6.63	0.31	1.02e-10	Testicular germ cell tumor;
LUAD	cis	rs1113500	0.614	rs1343192	chr1:108613888	C/T	cg06207961	chr1:108661230	NA	0.42	6.9	0.32	1.95e-11	Growth-regulated protein alpha levels;
LUAD	trans	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg24644049	chr4:85504048	CDS1	0.69	6.62	0.31	1.06e-10	Skin colour saturation;
LUAD	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg20673091	chr1:2541236	MMEL1	-0.4	-8.57	-0.38	1.97e-16	Ulcerative colitis;
LUAD	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg14092571	chr14:90743983	NA	-0.93	-17.75	-0.65	4.33e-53	Gut microbiota (bacterial taxa);
LUAD	trans	rs61931739	0.513	rs7956626	chr12:33901640	C/T	cg10518543	chr12:38710700	ALG10B	0.41	6.55	0.3	1.69e-10	Morning vs. evening chronotype;
LUAD	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg24069376	chr3:38537580	EXOG	0.43	10.33	0.45	1.92e-22	Electrocardiographic conduction measures;
LUAD	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg21475434	chr5:93447410	FAM172A	0.75	8.4	0.38	6.97e-16	Diabetic retinopathy;
LUAD	cis	rs7843479	0.965	rs878872	chr8:21834567	A/G	cg03445287	chr8:21823731	XPO7	-0.45	-8.18	-0.37	3.31e-15	Mean corpuscular volume;
LUAD	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg01689657	chr7:91764605	CYP51A1	0.38	9.24	0.41	1.19e-18	Breast cancer;
LUAD	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg14159672	chr1:205819179	PM20D1	0.46	7.35	0.34	1.01e-12	Parkinson's disease;
LUAD	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-8.36	-0.38	8.98e-16	Reticulocyte count;
LUAD	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs367943	0.635	rs2222144	chr5:112712208	G/T	cg12552261	chr5:112820674	MCC	0.47	9.15	0.41	2.36e-18	Type 2 diabetes;
LUAD	cis	rs6545883	0.868	rs2518932	chr2:61801277	T/A	cg15711740	chr2:61764176	XPO1	-0.43	-6.77	-0.31	4.4e-11	Tuberculosis;
LUAD	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22857025	chr5:266934	NA	-0.97	-14.71	-0.58	7.29e-40	Breast cancer;
LUAD	cis	rs2346177	0.542	rs718849	chr2:46698116	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-7.58	-0.35	2.19e-13	HDL cholesterol;
LUAD	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg12310025	chr6:25882481	NA	0.89	14.85	0.59	1.9e-40	Blood metabolite levels;
LUAD	cis	rs57994353	0.897	rs11999609	chr9:139363539	C/T	cg14364472	chr9:139394549	NOTCH1	-0.45	-6.79	-0.31	3.8e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	10.08	0.44	1.48e-21	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg03806693	chr22:41940476	POLR3H	0.69	9.6	0.42	7.05e-20	Vitiligo;
LUAD	cis	rs67981189	0.529	rs8014273	chr14:71509830	A/G	cg15910301	chr14:71632612	NA	0.41	6.43	0.3	3.44e-10	Schizophrenia;
LUAD	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg23950597	chr19:37808831	NA	-0.63	-7.58	-0.35	2.24e-13	Coronary artery calcification;
LUAD	cis	rs7000551	0.505	rs4872499	chr8:22293306	A/G	cg12081754	chr8:22256438	SLC39A14	-0.72	-10.24	-0.45	3.87e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7640424	0.649	rs13091474	chr3:107877134	A/T	cg09227934	chr3:107805635	CD47	-0.5	-8.97	-0.4	9.84e-18	Body mass index;
LUAD	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg06808227	chr14:105710500	BRF1	-0.42	-6.39	-0.3	4.46e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg18404041	chr3:52824283	ITIH1	-0.72	-15.64	-0.61	7.79e-44	Bipolar disorder;
LUAD	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg21214613	chr1:16344536	HSPB7	0.6	11.59	0.49	3.61e-27	Systolic blood pressure;
LUAD	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg26384229	chr12:38710491	ALG10B	0.49	7.88	0.36	2.71e-14	Bladder cancer;
LUAD	cis	rs12049351	0.719	rs4925493	chr1:229623137	T/C	cg11742688	chr1:229674241	ABCB10	-0.4	-6.66	-0.31	8.51e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg17849569	chr6:28058911	ZSCAN12L1	0.31	6.91	0.32	1.81e-11	Parkinson's disease;
LUAD	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg18827107	chr12:86230957	RASSF9	-0.49	-8.59	-0.39	1.73e-16	Major depressive disorder;
LUAD	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.93	0.47	1.12e-24	Colorectal cancer;
LUAD	cis	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg24308560	chr3:49941425	MST1R	-0.53	-8.6	-0.39	1.52e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.9	-0.32	1.86e-11	Retinal vascular caliber;
LUAD	cis	rs6138458	0.717	rs2179732	chr20:25000446	A/T	cg26195577	chr20:24973756	C20orf3	0.75	12.95	0.53	1.53e-32	Blood protein levels;
LUAD	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg15556689	chr8:8085844	FLJ10661	0.4	6.45	0.3	2.98e-10	Mood instability;
LUAD	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg15181151	chr6:150070149	PCMT1	0.43	8.71	0.39	6.74e-17	Lung cancer;
LUAD	cis	rs4713675	0.525	rs622917	chr6:33702869	C/T	cg14003231	chr6:33640908	ITPR3	-0.37	-6.81	-0.31	3.42e-11	Plateletcrit;
LUAD	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	7.59	0.35	2.12e-13	Personality dimensions;
LUAD	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg06618935	chr21:46677482	NA	-0.51	-10.35	-0.45	1.6e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	trans	rs4650994	0.524	rs2209170	chr1:178607388	C/A	cg05059571	chr16:84539110	KIAA1609	0.68	11.81	0.5	4.96e-28	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg08048268	chr3:133502702	NA	-0.35	-6.85	-0.32	2.7e-11	Iron status biomarkers;
LUAD	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-8.9	-0.4	1.67e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg12623302	chr6:28058802	ZSCAN12L1	0.33	7.08	0.33	6.12e-12	Parkinson's disease;
LUAD	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg23029597	chr12:123009494	RSRC2	-0.54	-8.2	-0.37	2.98e-15	Body mass index;
LUAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg25703541	chr22:24373054	LOC391322	-0.86	-16.13	-0.62	5.6e-46	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg18944383	chr4:111397179	ENPEP	-0.5	-9.08	-0.4	4.21e-18	Coronary artery disease;
LUAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg18402987	chr7:1209562	NA	0.81	9.91	0.43	6.12e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2996428	0.561	rs72640913	chr1:3747023	C/G	cg23277830	chr1:3704460	LRRC47	0.41	8.71	0.39	7.16e-17	Red cell distribution width;
LUAD	cis	rs6496044	0.568	rs12708554	chr15:86074297	C/G	cg13263323	chr15:86062960	AKAP13	-0.56	-10.2	-0.44	5.56e-22	Interstitial lung disease;
LUAD	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg02733842	chr7:1102375	C7orf50	-0.59	-9.13	-0.41	2.8e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg26750617	chr12:132293702	NA	-0.39	-6.62	-0.31	1.07e-10	Migraine;
LUAD	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg09904177	chr6:26538194	HMGN4	0.41	6.82	0.31	3.24e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg12062639	chr20:23401060	NAPB	1.1	11.43	0.49	1.54e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.68	-0.35	1.14e-13	Triglycerides;
LUAD	cis	rs4072705	1.000	rs6478671	chr9:127373995	T/A	cg13476313	chr9:127244764	NR5A1	0.3	7.23	0.33	2.28e-12	Menarche (age at onset);
LUAD	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg04155231	chr12:9217510	LOC144571	0.43	8.05	0.36	8.45e-15	Sjögren's syndrome;
LUAD	cis	rs2408955	0.521	rs1476607	chr12:48524804	A/G	cg04545296	chr12:48745243	ZNF641	-0.34	-8.73	-0.39	6.13e-17	Glycated hemoglobin levels;
LUAD	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg17173187	chr15:85201210	NMB	0.47	8.29	0.37	1.47e-15	Schizophrenia;
LUAD	cis	rs4680	1.000	rs4680	chr22:19951271	C/T	cg22546130	chr22:19950026	COMT	0.37	7.98	0.36	1.41e-14	Blood metabolite levels;
LUAD	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11644478	chr21:40555479	PSMG1	0.61	9.56	0.42	9.81e-20	Cognitive function;
LUAD	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7095607	0.813	rs10997963	chr10:69921903	A/G	cg18986048	chr10:69913749	MYPN	-0.37	-6.42	-0.3	3.77e-10	Lung function (FVC);
LUAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.45e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg03651054	chr13:50194643	NA	0.36	7.38	0.34	8.33e-13	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs12936587	0.564	rs7208561	chr17:17615528	C/T	cg01246520	chr17:17644344	RAI1	-0.41	-6.78	-0.31	4.14e-11	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LUAD	cis	rs7779181	1.000	rs7779180	chr7:32347202	A/G	cg13207630	chr7:32358064	NA	0.43	6.61	0.31	1.14e-10	Body mass index;
LUAD	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg03948781	chr1:205179583	DSTYK	0.35	6.43	0.3	3.44e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg04731861	chr2:219085781	ARPC2	0.23	6.97	0.32	1.2e-11	Colorectal cancer;
LUAD	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg15448220	chr1:150897856	SETDB1	-0.48	-8.11	-0.37	5.52e-15	Tonsillectomy;
LUAD	trans	rs1493916	1.000	rs7238717	chr18:31395186	C/T	cg15819921	chr19:927150	ARID3A	-0.45	-7.38	-0.34	8.28e-13	Life satisfaction;
LUAD	trans	rs10838798	0.607	rs11039537	chr11:48154603	A/G	cg00717180	chr2:96193071	NA	-0.38	-6.91	-0.32	1.81e-11	Height;
LUAD	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg03467027	chr4:99064603	C4orf37	0.41	6.73	0.31	5.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9462027	0.628	rs2492860	chr6:34705530	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.02	-0.4	6.62e-18	Systemic lupus erythematosus;
LUAD	cis	rs7731657	0.537	rs987024	chr5:130337029	T/G	cg08523029	chr5:130500466	HINT1	-0.6	-7.72	-0.35	8.44e-14	Fasting plasma glucose;
LUAD	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.74	0.31	5.29e-11	Depression;
LUAD	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg25664220	chr3:72788482	NA	-0.66	-11.58	-0.49	4.12e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg23173402	chr1:227635558	NA	0.74	8.07	0.37	7.58e-15	Major depressive disorder;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03946899	chr15:98503444	ARRDC4	-0.54	-6.54	-0.3	1.73e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg15704280	chr7:45808275	SEPT13	-0.97	-20.27	-0.7	2.41e-64	Height;
LUAD	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg22467129	chr15:76604101	ETFA	-0.47	-7.79	-0.35	5.24e-14	Blood metabolite levels;
LUAD	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg18196295	chr10:418757	DIP2C	0.49	8.27	0.37	1.81e-15	Psychosis in Alzheimer's disease;
LUAD	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg22166914	chr1:53195759	ZYG11B	0.51	8.87	0.4	2.07e-17	Monocyte count;
LUAD	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.66	-10.56	-0.46	2.6e-23	Height;
LUAD	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg10523679	chr1:76189770	ACADM	-0.75	-11.93	-0.5	1.75e-28	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7546094	0.509	rs7415988	chr1:113159730	G/T	cg22162597	chr1:113214053	CAPZA1	-0.46	-6.62	-0.31	1.11e-10	Platelet distribution width;
LUAD	cis	rs7714584	1.000	rs73282209	chr5:150174959	G/A	cg22134413	chr5:150180641	NA	0.63	6.89	0.32	2.04e-11	Crohn's disease;
LUAD	cis	rs250677	1.000	rs36069	chr5:148417253	G/C	cg23229984	chr5:148520753	ABLIM3	0.41	6.61	0.31	1.14e-10	Breast cancer;
LUAD	cis	rs829883	1.000	rs829883	chr12:98879606	G/A	cg25150519	chr12:98850993	NA	0.66	10.96	0.47	8.67e-25	Colorectal adenoma (advanced);
LUAD	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg00784671	chr22:46762841	CELSR1	-0.43	-6.42	-0.3	3.7e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs829661	0.532	rs11678346	chr2:30767508	C/T	cg12454169	chr2:30669597	LCLAT1	-0.43	-6.51	-0.3	2.2e-10	Midgestational circulating levels of PBDEs (fetal genetic effect);
LUAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.51	0.55	8.15e-35	Prudent dietary pattern;
LUAD	cis	rs4662945	0.525	rs28625431	chr2:130303333	A/G	cg05903289	chr2:130345205	NA	-0.31	-6.66	-0.31	8.37e-11	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg17063962	chr7:91808500	NA	0.73	13.26	0.54	8.27e-34	Breast cancer;
LUAD	cis	rs713587	0.646	rs2384061	chr2:25135620	C/T	cg01884057	chr2:25150051	NA	0.35	7.42	0.34	6.59e-13	Body mass index in non-asthmatics;
LUAD	cis	rs8048589	0.898	rs11648235	chr16:12181079	C/T	cg03816625	chr16:12192430	SNX29	0.56	8.23	0.37	2.32e-15	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs738321	0.794	rs5756940	chr22:38558842	C/T	cg25457927	chr22:38595422	NA	-0.56	-12.49	-0.52	1.07e-30	Breast cancer;
LUAD	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg05313129	chr8:58192883	C8orf71	-0.53	-7.75	-0.35	6.77e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9902453	1.000	rs4533340	chr17:28277951	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.29	0.41	7.95e-19	Coffee consumption (cups per day);
LUAD	trans	rs11039798	1.000	rs7104642	chr11:48588534	C/T	cg03929089	chr4:120376271	NA	0.56	6.54	0.3	1.78e-10	Axial length;
LUAD	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg00898013	chr13:113819073	PROZ	0.65	11.49	0.49	8.69e-27	Platelet distribution width;
LUAD	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg04756594	chr16:24857601	SLC5A11	-0.54	-10.27	-0.45	3.06e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	12.15	0.51	2.44e-29	Hip circumference adjusted for BMI;
LUAD	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg07402062	chr16:89894098	SPIRE2	0.44	11.24	0.48	7.65e-26	Vitiligo;
LUAD	cis	rs300774	0.925	rs300739	chr2:161605	A/G	cg21211680	chr2:198530	NA	-0.48	-7.54	-0.34	2.99e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg03433033	chr1:76189801	ACADM	0.83	14.56	0.58	3.23e-39	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg08742575	chr21:47604166	C21orf56	0.51	8.61	0.39	1.41e-16	Testicular germ cell tumor;
LUAD	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg24531977	chr5:56204891	C5orf35	0.41	6.86	0.32	2.42e-11	Coronary artery disease;
LUAD	cis	rs12579753	0.917	rs11115029	chr12:82202219	C/G	cg07988820	chr12:82153109	PPFIA2	-0.45	-7.06	-0.32	6.8e-12	Resting heart rate;
LUAD	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg11707310	chr1:2537719	MMEL1	-0.37	-7.92	-0.36	2.04e-14	Ulcerative colitis;
LUAD	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg26893861	chr17:41843967	DUSP3	0.87	14.28	0.57	4.92e-38	Triglycerides;
LUAD	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-9.24	-0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg15704280	chr7:45808275	SEPT13	0.64	8.17	0.37	3.52e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg25344623	chr2:136566232	LCT	-0.33	-6.52	-0.3	2.03e-10	Mosquito bite size;
LUAD	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg14686297	chr22:46650375	NA	-0.38	-6.57	-0.3	1.44e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4285028	0.747	rs7610298	chr3:121419100	T/A	cg11130432	chr3:121712080	ILDR1	-0.47	-6.82	-0.31	3.11e-11	Multiple sclerosis;
LUAD	cis	rs72901758	0.661	rs56683270	chr17:76247827	T/C	cg26068271	chr17:76253126	NA	0.4	6.9	0.32	1.86e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	trans	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-14.9	-0.59	1.17e-40	Exhaled nitric oxide output;
LUAD	trans	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg18187862	chr3:45730750	SACM1L	-0.48	-7.68	-0.35	1.08e-13	Primary sclerosing cholangitis;
LUAD	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg14895029	chr7:2775587	GNA12	-0.43	-7.05	-0.32	7.38e-12	Height;
LUAD	cis	rs6546550	0.933	rs6546554	chr2:70135706	G/A	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.97	-0.47	8.24e-25	Prevalent atrial fibrillation;
LUAD	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg11663144	chr21:46675770	NA	-0.52	-9.62	-0.42	5.92e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg01475377	chr6:109611718	NA	-0.5	-9.41	-0.42	3.19e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg25344623	chr2:136566232	LCT	0.35	6.8	0.31	3.64e-11	Mosquito bite size;
LUAD	cis	rs77741769	0.571	rs3897746	chr12:121324727	A/G	cg02419362	chr12:121203948	SPPL3	0.4	8.16	0.37	3.87e-15	Mean corpuscular volume;
LUAD	trans	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg03929089	chr4:120376271	NA	0.55	6.4	0.3	4.22e-10	Axial length;
LUAD	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.69	0.31	6.95e-11	Depression;
LUAD	cis	rs89107	0.576	rs72952771	chr6:118883817	C/T	cg21191810	chr6:118973309	C6orf204	0.41	7.52	0.34	3.37e-13	Cardiac structure and function;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09192942	chr16:75682004	KARS;TERF2IP	-0.61	-7.39	-0.34	7.68e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10129255	0.500	rs4774008	chr14:107137290	A/T	cg23076370	chr14:107095027	NA	-0.45	-8.93	-0.4	1.36e-17	Kawasaki disease;
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg05064044	chr6:292385	DUSP22	0.79	13.67	0.55	1.8e-35	Menopause (age at onset);
LUAD	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg05043794	chr9:111880884	C9orf5	-0.41	-7.24	-0.33	2.18e-12	Menarche (age at onset);
LUAD	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg04025307	chr7:1156635	C7orf50	0.57	8.01	0.36	1.13e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg17509989	chr5:176798049	RGS14	0.6	10.54	0.46	3.31e-23	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs73206853	0.764	rs73194012	chr12:111100627	T/C	cg12870014	chr12:110450643	ANKRD13A	0.6	6.79	0.31	3.87e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg17178900	chr1:205818956	PM20D1	-0.53	-9.66	-0.43	4.36e-20	Menarche (age at onset);
LUAD	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg14828511	chr1:107599125	PRMT6	-0.51	-9.34	-0.41	5.38e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg12740337	chr6:28058973	ZSCAN12L1	0.28	6.46	0.3	2.81e-10	Parkinson's disease;
LUAD	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg05368731	chr17:41323189	NBR1	0.96	20.32	0.7	1.44e-64	Menopause (age at onset);
LUAD	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.72	-0.35	8.52e-14	Alzheimer's disease (late onset);
LUAD	cis	rs9372498	0.536	rs62422221	chr6:118925581	T/C	cg18833306	chr6:118973337	C6orf204	-0.55	-7.69	-0.35	1.02e-13	Diastolic blood pressure;
LUAD	cis	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg07460842	chr6:66804631	NA	1.07	16.98	0.64	1.12e-49	Exhaled nitric oxide output;
LUAD	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg09365446	chr1:150670422	GOLPH3L	0.66	12.57	0.52	5.38e-31	Tonsillectomy;
LUAD	cis	rs752010	0.695	rs10890155	chr1:42107843	C/T	cg06885757	chr1:42089581	HIVEP3	0.39	8.26	0.37	1.82e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs4930561	0.714	rs6591335	chr11:67976812	T/C	cg04465784	chr11:67976953	SUV420H1	-0.35	-11.02	-0.47	5.51e-25	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	trans	rs2840044	1.000	rs2840044	chr17:33892068	A/G	cg19694781	chr19:47549865	TMEM160	0.61	9.8	0.43	1.42e-20	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg23131131	chr22:24373011	LOC391322	0.57	9.64	0.42	5.13e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg16606324	chr3:10149918	C3orf24	0.71	11.67	0.49	1.87e-27	Alzheimer's disease;
LUAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.12	0.41	3.18e-18	Alzheimer's disease;
LUAD	cis	rs684232	0.563	rs12939528	chr17:524391	C/T	cg15660573	chr17:549704	VPS53	-0.87	-18.11	-0.66	1.05e-54	Prostate cancer;
LUAD	cis	rs1595825	0.891	rs78198610	chr2:198522769	T/C	cg10547527	chr2:198650123	BOLL	-0.54	-7.66	-0.35	1.3e-13	Ulcerative colitis;
LUAD	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg16680214	chr1:154839983	KCNN3	0.64	13.47	0.55	1.13e-34	Prostate cancer;
LUAD	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg17747265	chr1:1875780	NA	-0.75	-18.16	-0.66	6.5e-55	Body mass index;
LUAD	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg22029157	chr1:209979665	IRF6	0.77	10.1	0.44	1.21e-21	Cleft lip with or without cleft palate;
LUAD	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg26022315	chr17:47021804	SNF8	0.4	7.29	0.33	1.5e-12	Type 2 diabetes;
LUAD	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg18129178	chr5:148520854	ABLIM3	-0.55	-8.71	-0.39	7.12e-17	Breast cancer;
LUAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.87	0.32	2.27e-11	Obesity-related traits;
LUAD	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg03684893	chr10:554711	DIP2C	0.4	6.92	0.32	1.69e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg11859384	chr17:80120422	CCDC57	0.49	8.88	0.4	1.9e-17	Life satisfaction;
LUAD	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg00255919	chr5:131827918	IRF1	0.3	6.68	0.31	7.56e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg26384229	chr12:38710491	ALG10B	-0.46	-7.58	-0.35	2.22e-13	Bladder cancer;
LUAD	trans	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg18335740	chr13:41363409	SLC25A15	-0.51	-9.24	-0.41	1.21e-18	Lewy body disease;
LUAD	cis	rs6993813	0.590	rs10955919	chr8:120020918	C/G	cg01975934	chr8:119970761	NA	-0.34	-6.5	-0.3	2.22e-10	Bone mineral density (hip);
LUAD	cis	rs11677370	0.603	rs1454242	chr2:3848532	G/A	cg17052675	chr2:3827356	NA	-0.61	-10.36	-0.45	1.47e-22	Type 2 diabetes;
LUAD	cis	rs908922	0.651	rs11205035	chr1:152532832	A/G	cg23254163	chr1:152506842	NA	0.25	6.76	0.31	4.47e-11	Hair morphology;
LUAD	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg03929089	chr4:120376271	NA	-0.97	-19.79	-0.69	3.54e-62	Height;
LUAD	cis	rs8017423	0.569	rs10141476	chr14:90823351	C/T	cg14092571	chr14:90743983	NA	0.39	6.54	0.3	1.81e-10	Mortality in heart failure;
LUAD	cis	rs4588572	0.643	rs6453396	chr5:77785387	T/C	cg11547950	chr5:77652471	NA	-0.77	-12.26	-0.51	9.09e-30	Triglycerides;
LUAD	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg14343924	chr8:8086146	FLJ10661	0.45	7.08	0.33	6.02e-12	Systolic blood pressure;
LUAD	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.36	0.41	4.9e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg10869069	chr6:101329502	ASCC3	0.42	6.75	0.31	4.98e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs11958404	0.615	rs10061079	chr5:157449968	G/C	cg05962755	chr5:157440814	NA	0.44	8.46	0.38	4.4e-16	IgG glycosylation;
LUAD	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.81	-14.15	-0.57	1.66e-37	Chronic sinus infection;
LUAD	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg25985355	chr7:65971099	NA	-0.54	-6.59	-0.31	1.3100000000000001e-10	Diabetic kidney disease;
LUAD	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg25894440	chr7:65020034	NA	-0.68	-7.36	-0.34	9.49e-13	Diabetic kidney disease;
LUAD	cis	rs208520	0.754	rs851594	chr6:66876695	A/G	cg07460842	chr6:66804631	NA	-1.03	-15.43	-0.6	6.08e-43	Exhaled nitric oxide output;
LUAD	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.18	0.37	3.45e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs17092148	0.887	rs932542	chr20:33171368	G/C	cg16810054	chr20:33298113	TP53INP2	-0.53	-7.99	-0.36	1.26e-14	Neuroticism;
LUAD	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg04727924	chr7:799746	HEATR2	-0.59	-7.46	-0.34	4.9e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg05887092	chr17:76393375	PGS1	0.56	11.4	0.48	2e-26	HDL cholesterol levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10582045	chr15:43477796	CCNDBP1	-0.57	-6.95	-0.32	1.43e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg25566285	chr7:158114605	PTPRN2	0.54	11.57	0.49	4.46e-27	Calcium levels;
LUAD	cis	rs2835872	0.930	rs2835880	chr21:39032477	A/G	cg06728970	chr21:39037746	KCNJ6	-0.4	-7.3	-0.33	1.41e-12	Electroencephalographic traits in alcoholism;
LUAD	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg11859384	chr17:80120422	CCDC57	0.51	9.23	0.41	1.27e-18	Life satisfaction;
LUAD	cis	rs6445967	0.530	rs12638005	chr3:58287070	T/A	cg23715586	chr3:58305044	RPP14	0.4	6.62	0.31	1.07e-10	Platelet count;
LUAD	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.13	-0.37	4.63e-15	Total body bone mineral density;
LUAD	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg27394845	chr17:28928406	LRRC37B2	0.49	6.37	0.3	4.81e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg05564831	chr3:52568323	NT5DC2	0.38	6.88	0.32	2.16e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg24818145	chr4:99064322	C4orf37	0.43	7.18	0.33	3.22e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg02569458	chr12:86230093	RASSF9	0.38	6.93	0.32	1.58e-11	Major depressive disorder;
LUAD	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	trans	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg15655154	chr3:113604241	GRAMD1C	0.7	13.07	0.54	5.23e-33	Diastolic blood pressure;
LUAD	cis	rs6011002	0.636	rs1758199	chr20:62352827	T/C	cg21849932	chr20:62369462	LIME1	-0.78	-6.47	-0.3	2.78e-10	Dental caries;
LUAD	cis	rs870825	0.616	rs7660939	chr4:185640792	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.17	0.57	1.49e-37	Blood protein levels;
LUAD	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg01579765	chr21:45077557	HSF2BP	-0.57	-11.78	-0.5	6.8e-28	Mean corpuscular volume;
LUAD	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg26384229	chr12:38710491	ALG10B	0.45	7.24	0.33	2.07e-12	Bladder cancer;
LUAD	cis	rs1712517	0.771	rs61871160	chr10:105144288	C/T	cg05636881	chr10:105038444	INA	0.33	6.5	0.3	2.28e-10	Migraine;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg00311307	chr1:24829359	RCAN3	-0.67	-6.37	-0.3	4.85e-10	Type 2 diabetes;
LUAD	cis	rs2464469	0.618	rs8024164	chr15:58205900	A/G	cg12031962	chr15:58353849	ALDH1A2	0.34	6.52	0.3	1.97e-10	Barrett's esophagus  or Esophageal adenocarcinoma;
LUAD	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg07305463	chr2:136567211	LCT	0.38	7.31	0.33	1.33e-12	Mosquito bite size;
LUAD	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14240646	chr10:27532245	ACBD5	-0.89	-12.01	-0.5	8.41e-29	Breast cancer;
LUAD	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg26022315	chr17:47021804	SNF8	0.4	7.21	0.33	2.55e-12	Type 2 diabetes;
LUAD	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg10589385	chr1:150898437	SETDB1	-0.43	-8.17	-0.37	3.65e-15	Melanoma;
LUAD	cis	rs11167764	0.945	rs6878397	chr5:141474012	A/G	cg23435118	chr5:141488016	NDFIP1	-0.48	-7.17	-0.33	3.27e-12	Crohn's disease;
LUAD	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg26898376	chr11:64110657	CCDC88B	0.39	7.18	0.33	3.09e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.02	-0.36	1.05e-14	Diabetic kidney disease;
LUAD	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11644478	chr21:40555479	PSMG1	-0.53	-8.53	-0.38	2.64e-16	Cognitive function;
LUAD	cis	rs7843479	0.582	rs7009693	chr8:21775314	C/T	cg03445287	chr8:21823731	XPO7	-0.45	-8.43	-0.38	5.49e-16	Mean corpuscular volume;
LUAD	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg10018233	chr7:150070692	REPIN1	0.48	7.58	0.35	2.15e-13	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs6076960	0.652	rs3852946	chr20:6255311	C/T	cg17788362	chr6:86352627	SYNCRIP	0.4	6.53	0.3	1.86e-10	Smooth-surface caries;
LUAD	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13126279	chr21:47581558	C21orf56	-0.59	-10.59	-0.46	2.16e-23	Testicular germ cell tumor;
LUAD	cis	rs909002	0.962	rs7537646	chr1:32135495	G/A	cg13919466	chr1:32135498	COL16A1	-0.43	-10.49	-0.45	4.86e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs123509	0.913	rs339685	chr3:42782952	C/G	cg12982090	chr3:42733453	KBTBD5	0.56	9.89	0.43	7.01e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg19622623	chr12:86230825	RASSF9	-0.35	-6.45	-0.3	3.08e-10	Major depressive disorder;
LUAD	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg08949735	chr16:89699720	DPEP1	0.29	6.69	0.31	7.28e-11	Vitiligo;
LUAD	cis	rs2797160	1.000	rs4895798	chr6:126000162	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.73	-0.31	5.6e-11	Endometrial cancer;
LUAD	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.28	-0.51	7.17e-30	Primary sclerosing cholangitis;
LUAD	cis	rs9039	0.959	rs4985101	chr16:9194963	T/C	cg08831531	chr16:9218945	NA	-0.39	-6.98	-0.32	1.14e-11	Menopause (age at onset);
LUAD	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg17074396	chr22:49843754	NA	-0.31	-6.5	-0.3	2.26e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg07570687	chr10:102243282	WNT8B	0.48	7.21	0.33	2.58e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1509123	0.609	rs55944060	chr17:6718878	G/A	cg12642237	chr17:6703447	TEKT1	-0.45	-6.4	-0.3	4.24e-10	Blood metabolite levels;
LUAD	cis	rs4722585	0.533	rs2158359	chr7:26193309	A/C	cg07876897	chr7:26191696	NFE2L3	-0.46	-7.64	-0.35	1.5e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs13095912	1.000	rs13072759	chr3:185326391	G/A	cg11274856	chr3:185301563	NA	0.39	7.84	0.36	3.8e-14	Systolic blood pressure;
LUAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg04455712	chr21:45112962	RRP1B	0.47	9.46	0.42	2.17e-19	Mean corpuscular volume;
LUAD	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20814179	chr4:940893	TMEM175	0.69	11.58	0.49	4.05e-27	Sjögren's syndrome;
LUAD	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg06064525	chr11:970664	AP2A2	-0.42	-8.29	-0.37	1.48e-15	Alzheimer's disease (late onset);
LUAD	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.23	0.48	8.73e-26	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7833986	0.501	rs17814658	chr8:56989130	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	1.02	17.92	0.66	7.34e-54	Height;
LUAD	cis	rs7527798	0.571	rs7531923	chr1:207833336	T/G	cg09232269	chr1:207846808	CR1L	-0.36	-6.99	-0.32	1.09e-11	Erythrocyte sedimentation rate;
LUAD	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg15501526	chr10:2543763	NA	0.7	16.07	0.62	1.06e-45	Age-related hearing impairment;
LUAD	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Depression;
LUAD	cis	rs11734570	0.581	rs73811716	chr4:38590773	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.44	6.36	0.3	5.27e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg09537434	chr19:41945824	ATP5SL	-0.53	-8.31	-0.37	1.32e-15	Height;
LUAD	cis	rs904251	0.600	rs9380673	chr6:37415125	T/C	cg25019722	chr6:37503610	NA	-0.29	-6.42	-0.3	3.59e-10	Cognitive performance;
LUAD	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg26384229	chr12:38710491	ALG10B	0.44	7.29	0.33	1.54e-12	Morning vs. evening chronotype;
LUAD	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg17105886	chr17:28927953	LRRC37B2	0.83	7.92	0.36	2.14e-14	Body mass index;
LUAD	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	10.3	0.45	2.32e-22	Electrocardiographic conduction measures;
LUAD	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg00310523	chr12:86230176	RASSF9	0.4	8.01	0.36	1.13e-14	Major depressive disorder;
LUAD	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg20476274	chr7:133979776	SLC35B4	0.75	13.07	0.54	4.81e-33	Mean platelet volume;
LUAD	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg21427119	chr20:30132790	HM13	-0.5	-7.98	-0.36	1.4e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg15462221	chr8:8086144	FLJ10661	0.41	6.67	0.31	7.89e-11	Neuroticism;
LUAD	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg17401720	chr7:158221031	PTPRN2	0.32	6.55	0.3	1.67e-10	Obesity-related traits;
LUAD	cis	rs12802200	0.561	rs7940600	chr11:572105	A/G	cg16486109	chr11:613632	IRF7	0.54	8.88	0.4	1.9e-17	Systemic lupus erythematosus;
LUAD	cis	rs977987	0.872	rs1542864	chr16:75471378	G/A	cg03315344	chr16:75512273	CHST6	0.64	13.84	0.56	3.37e-36	Dupuytren's disease;
LUAD	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg25358565	chr5:93447407	FAM172A	0.65	7.63	0.35	1.5700000000000001e-13	Diabetic retinopathy;
LUAD	cis	rs977987	0.843	rs4146810	chr16:75415831	A/G	cg03315344	chr16:75512273	CHST6	0.66	14.4	0.57	1.59e-38	Dupuytren's disease;
LUAD	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg15445000	chr17:37608096	MED1	0.44	8.23	0.37	2.26e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg06784218	chr1:46089804	CCDC17	0.54	11.64	0.49	2.33e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg02569458	chr12:86230093	RASSF9	0.44	8.02	0.36	1.06e-14	Major depressive disorder;
LUAD	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg23649088	chr2:200775458	C2orf69	-0.61	-7.88	-0.36	2.71e-14	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg22535103	chr8:58192502	C8orf71	-0.56	-6.73	-0.31	5.55e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12292205	chr6:26970375	C6orf41	-0.47	-6.57	-0.3	1.47e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7709909	0.967	rs3776967	chr5:80002350	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.42	-7.21	-0.33	2.57e-12	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg10802521	chr3:52805072	NEK4	-0.4	-6.66	-0.31	8.45e-11	Hemoglobin concentration;
LUAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg25703541	chr22:24373054	LOC391322	-0.84	-16.05	-0.62	1.23e-45	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2485376	1.000	rs4331020	chr10:104102331	G/A	cg20641465	chr10:103991465	PITX3	-0.57	-10.64	-0.46	1.38e-23	QT interval;
LUAD	cis	rs11178918	0.505	rs74961099	chr12:72154153	A/T	cg10168894	chr12:72148281	RAB21	-0.53	-6.58	-0.3	1.39e-10	Economic and political preferences (time);
LUAD	cis	rs4711350	0.734	rs9380379	chr6:33766131	A/G	cg16010596	chr6:33739607	LEMD2	-0.38	-7.03	-0.32	8.23e-12	Schizophrenia;
LUAD	cis	rs6433857	0.627	rs6741769	chr2:181500545	G/A	cg23363182	chr2:181467187	NA	-0.43	-7.22	-0.33	2.47e-12	Body mass index;
LUAD	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg20302342	chr1:156215951	PAQR6	0.39	8.7	0.39	7.29e-17	Tonsillectomy;
LUAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg20587970	chr11:113659929	NA	-1.38	-20.5	-0.71	2.42e-65	Hip circumference adjusted for BMI;
LUAD	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg04036182	chr15:45458818	NA	-0.41	-7.15	-0.33	3.84e-12	Glomerular filtration rate;
LUAD	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg03806693	chr22:41940476	POLR3H	0.63	9.24	0.41	1.19e-18	Vitiligo;
LUAD	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.92	0.32	1.67e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72928364	0.858	rs66512629	chr3:100719557	T/A	cg10123952	chr3:100791384	NA	0.63	7.31	0.33	1.34e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg10792982	chr14:105748885	BRF1	0.42	9.23	0.41	1.28e-18	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg07636037	chr3:49044803	WDR6	0.63	12.13	0.51	2.93e-29	Parkinson's disease;
LUAD	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.91	-12.39	-0.52	2.67e-30	Lung cancer in ever smokers;
LUAD	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg16988262	chr1:15930761	NA	0.41	6.88	0.32	2.12e-11	Systolic blood pressure;
LUAD	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg23758822	chr17:41437982	NA	1.0	20.98	0.71	1.68e-67	Menopause (age at onset);
LUAD	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg19875535	chr5:140030758	IK	0.45	7.42	0.34	6.44e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg07636037	chr3:49044803	WDR6	0.52	9.98	0.44	3.29e-21	Menarche (age at onset);
LUAD	cis	rs2230307	0.656	rs12146139	chr1:100458417	G/A	cg20868668	chr1:100435035	SLC35A3	0.63	7.58	0.35	2.21e-13	Carotid intima media thickness;
LUAD	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg13870426	chr17:30244630	NA	-0.55	-6.49	-0.3	2.35e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg05044414	chr3:183734942	ABCC5	-0.42	-8.8	-0.39	3.48e-17	Anterior chamber depth;
LUAD	cis	rs1395	1.000	rs1141313	chr2:27460968	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	7.85	0.36	3.4e-14	Blood metabolite levels;
LUAD	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06028605	chr16:24865363	SLC5A11	0.53	8.01	0.36	1.15e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg11301795	chr4:187892539	NA	-0.77	-15.68	-0.61	5.23e-44	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg07828024	chr6:149772892	ZC3H12D	-0.31	-6.83	-0.32	2.94e-11	Dupuytren's disease;
LUAD	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14829155	chr15:31115871	NA	-0.78	-13.63	-0.55	2.62e-35	Huntington's disease progression;
LUAD	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg14092988	chr3:52407081	DNAH1	0.45	9.04	0.4	5.73e-18	Bipolar disorder;
LUAD	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg09184832	chr6:79620586	NA	-0.52	-9.9	-0.43	6.41e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs300703	0.542	rs67993758	chr2:179594	C/T	cg21211680	chr2:198530	NA	-0.53	-7.88	-0.36	2.86e-14	Blood protein levels;
LUAD	cis	rs1385374	0.858	rs11059923	chr12:129293057	G/A	cg09035930	chr12:129282057	SLC15A4	-0.65	-6.91	-0.32	1.79e-11	Systemic lupus erythematosus;
LUAD	cis	rs3806843	0.576	rs265316	chr5:140290843	T/C	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.46	-0.3	2.9e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg01620082	chr3:125678407	NA	-0.69	-7.67	-0.35	1.21e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg15448220	chr1:150897856	SETDB1	0.57	9.72	0.43	2.65e-20	Melanoma;
LUAD	cis	rs11771526	0.901	rs62457503	chr7:32330980	A/C	cg27511599	chr7:32358540	NA	0.57	7.05	0.32	7.52e-12	Body mass index;
LUAD	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg10589385	chr1:150898437	SETDB1	0.42	8.11	0.37	5.39e-15	Melanoma;
LUAD	cis	rs7267979	0.816	rs409853	chr20:25506067	T/C	cg08601574	chr20:25228251	PYGB	0.4	7.44	0.34	5.58e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg05234568	chr11:5960015	NA	-0.56	-10.07	-0.44	1.61e-21	DNA methylation (variation);
LUAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg11301795	chr4:187892539	NA	0.74	15.01	0.59	4.05e-41	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.6	9.73	0.43	2.6e-20	Cognitive ability;
LUAD	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg03690763	chr11:133734501	NA	-0.34	-8.0	-0.36	1.22e-14	Childhood ear infection;
LUAD	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg17644776	chr2:200775616	C2orf69	0.52	7.57	0.35	2.28e-13	Schizophrenia;
LUAD	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg25233709	chr10:116636983	FAM160B1	0.41	8.26	0.37	1.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	9.1	0.4	3.54e-18	Platelet count;
LUAD	cis	rs2505675	1.000	rs2479013	chr6:2356979	C/T	cg12303981	chr6:2244766	GMDS	-0.31	-6.44	-0.3	3.33e-10	Tuberculosis;
LUAD	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg15962314	chr1:44399869	ARTN	0.33	7.52	0.34	3.38e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs977987	0.806	rs2903033	chr16:75389606	T/A	cg03315344	chr16:75512273	CHST6	0.65	14.14	0.57	1.92e-37	Dupuytren's disease;
LUAD	trans	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg21659725	chr3:3221576	CRBN	0.38	6.4	0.3	4.15e-10	Resting heart rate;
LUAD	cis	rs1775715	0.707	rs2808073	chr10:32179275	A/G	cg04359828	chr10:32216031	ARHGAP12	0.31	6.46	0.3	2.82e-10	Bipolar disorder with mood-incongruent psychosis;
LUAD	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.53	-9.39	-0.42	3.89e-19	Axial length;
LUAD	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg15448220	chr1:150897856	SETDB1	0.53	8.92	0.4	1.43e-17	Melanoma;
LUAD	cis	rs4786125	0.626	rs11077095	chr16:6916451	C/T	cg03623568	chr16:6915990	A2BP1	0.47	10.55	0.46	2.93e-23	Heart rate variability traits (SDNN);
LUAD	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg18827107	chr12:86230957	RASSF9	-0.7	-12.92	-0.53	2.12e-32	Major depressive disorder;
LUAD	cis	rs315934	0.664	rs1665188	chr2:113852789	C/G	cg09040174	chr2:113837401	NA	-0.6	-7.42	-0.34	6.69e-13	Dysmenorrheic pain;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09820084	chr6:18387507	RNF144B	-0.42	-6.59	-0.31	1.3e-10	Height;
LUAD	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg15445000	chr17:37608096	MED1	-0.45	-8.38	-0.38	8.1e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg17330251	chr7:94953956	PON1	0.54	7.39	0.34	8.1e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg24642844	chr7:1081250	C7orf50	-0.98	-14.8	-0.58	2.97e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg14092988	chr3:52407081	DNAH1	0.45	9.15	0.41	2.44e-18	Bipolar disorder;
LUAD	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.26e-12	Tonsillectomy;
LUAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.14	-0.37	4.44e-15	Alzheimer's disease;
LUAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg23978390	chr7:1156363	C7orf50	0.66	10.83	0.47	2.84e-24	Longevity;Endometriosis;
LUAD	cis	rs7172809	0.573	rs75180243	chr15:77649707	G/A	cg11865553	chr15:77376250	NA	-0.4	-6.73	-0.31	5.69e-11	Glucose homeostasis traits;
LUAD	cis	rs354225	0.544	rs13423873	chr2:54786677	A/G	cg01766943	chr2:54829624	SPTBN1	0.36	6.46	0.3	2.95e-10	Schizophrenia;
LUAD	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg18404041	chr3:52824283	ITIH1	-0.4	-7.25	-0.33	2.01e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7177699	0.557	rs6495335	chr15:79117133	G/T	cg00540400	chr15:79124168	NA	0.44	9.62	0.42	6.23e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs478304	0.593	rs12576766	chr11:65488556	C/T	cg27068330	chr11:65405492	SIPA1	-0.74	-11.74	-0.5	9.5e-28	Acne (severe);
LUAD	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg08029281	chr1:67600428	NA	-0.36	-6.91	-0.32	1.77e-11	Psoriasis;
LUAD	trans	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg13698153	chr12:118541722	VSIG10	-0.42	-6.54	-0.3	1.82e-10	Vitiligo;
LUAD	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg09365446	chr1:150670422	GOLPH3L	-0.41	-6.71	-0.31	6.28e-11	Tonsillectomy;
LUAD	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg05368731	chr17:41323189	NBR1	0.97	20.73	0.71	2.24e-66	Menopause (age at onset);
LUAD	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.93	13.29	0.54	6.52e-34	Smoking behavior;
LUAD	trans	rs587242	0.528	rs12087010	chr1:97182039	G/A	cg10631902	chr5:14652156	NA	0.38	6.38	0.3	4.63e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs1032833	0.732	rs61179885	chr2:180033590	T/C	cg23883738	chr2:179974586	SESTD1	-0.65	-7.32	-0.34	1.28e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg24558204	chr6:135376177	HBS1L	0.44	7.95	0.36	1.73e-14	Red blood cell count;
LUAD	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg07606381	chr6:8435919	SLC35B3	0.41	6.88	0.32	2.13e-11	Motion sickness;
LUAD	cis	rs7799006	1.000	rs7799006	chr7:2278226	C/T	cg12745145	chr7:2261452	MAD1L1	-0.37	-7.13	-0.33	4.43e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg12573674	chr2:1569213	NA	-0.6	-8.67	-0.39	9e-17	IgG glycosylation;
LUAD	cis	rs12210905	0.688	rs9393814	chr6:27372978	C/T	cg08851530	chr6:28072375	NA	1.09	7.94	0.36	1.88e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs62238980	0.614	rs79667666	chr22:32396346	T/G	cg00543991	chr22:32367038	NA	0.8	7.39	0.34	8.02e-13	Childhood ear infection;
LUAD	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg02569458	chr12:86230093	RASSF9	0.43	7.68	0.35	1.15e-13	Major depressive disorder;
LUAD	cis	rs2505675	0.961	rs2450300	chr6:2322454	C/T	cg12303981	chr6:2244766	GMDS	-0.32	-6.49	-0.3	2.45e-10	Tuberculosis;
LUAD	cis	rs2637266	1.000	rs7098790	chr10:78361077	T/A	cg18941641	chr10:78392320	NA	0.33	6.84	0.32	2.74e-11	Pulmonary function;
LUAD	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg11766577	chr21:47581405	C21orf56	-0.46	-7.88	-0.36	2.83e-14	Testicular germ cell tumor;
LUAD	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg21385522	chr1:16154831	NA	-1.02	-20.98	-0.71	1.67e-67	Dilated cardiomyopathy;
LUAD	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg26022315	chr17:47021804	SNF8	0.4	7.21	0.33	2.53e-12	Type 2 diabetes;
LUAD	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg08999081	chr20:33150536	PIGU	-0.53	-10.84	-0.47	2.47e-24	Coronary artery disease;
LUAD	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg05425664	chr17:57184151	TRIM37	-0.45	-7.96	-0.36	1.61e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs13064411	0.696	rs6768648	chr3:113234141	C/G	cg10517650	chr3:113235015	CCDC52	-0.56	-9.68	-0.43	3.74e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg07460842	chr6:66804631	NA	0.94	14.88	0.59	1.4e-40	Exhaled nitric oxide levels;
LUAD	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg00981070	chr1:2046702	PRKCZ	0.33	6.85	0.32	2.54e-11	Height;
LUAD	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.94	-0.32	1.45e-11	Schizophrenia;
LUAD	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg21724239	chr8:58056113	NA	0.66	8.32	0.38	1.22e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg18305652	chr10:134549665	INPP5A	0.54	11.52	0.49	7.05e-27	Migraine;
LUAD	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.9	0.36	2.43e-14	Breast cancer;
LUAD	cis	rs6445967	0.966	rs9857570	chr3:58280690	A/G	cg23715586	chr3:58305044	RPP14	0.44	8.37	0.38	8.26e-16	Platelet count;
LUAD	trans	rs8073060	0.586	rs9303690	chr17:34005513	C/T	cg19694781	chr19:47549865	TMEM160	-1.23	-20.16	-0.7	7.79e-64	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg18306943	chr3:40428807	ENTPD3	0.41	7.02	0.32	9.06e-12	Renal cell carcinoma;
LUAD	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.54	-0.34	2.94e-13	Personality dimensions;
LUAD	cis	rs10751667	0.600	rs7395387	chr11:1008664	G/C	cg06064525	chr11:970664	AP2A2	-0.35	-6.72	-0.31	5.72e-11	Alzheimer's disease (late onset);
LUAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg07217954	chr7:1067459	C7orf50	0.43	6.62	0.31	1.06e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504073	0.647	rs4873098	chr8:50021041	T/C	cg00325661	chr8:49890786	NA	0.43	9.89	0.43	6.95e-21	Blood metabolite ratios;
LUAD	cis	rs7512552	0.768	rs7517441	chr1:150283643	A/T	cg15654264	chr1:150340011	RPRD2	-0.6	-11.31	-0.48	4.41e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg12311346	chr5:56204834	C5orf35	-0.48	-8.07	-0.37	7.37e-15	Coronary artery disease;
LUAD	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.39	0.42	3.65e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg12432903	chr7:1882776	MAD1L1	-0.44	-7.05	-0.32	7.56e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg04539111	chr16:67997858	SLC12A4	-0.48	-6.41	-0.3	3.94e-10	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs7939886	0.920	rs11227372	chr11:55919682	C/A	cg15704280	chr7:45808275	SEPT13	0.66	6.39	0.3	4.39e-10	Myopia (pathological);
LUAD	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	0.46	7.4	0.34	7.57e-13	Alzheimer's disease (late onset);
LUAD	cis	rs12618769	0.597	rs72821907	chr2:99085296	A/G	cg10123293	chr2:99228465	UNC50	0.47	8.3	0.37	1.43e-15	Bipolar disorder;
LUAD	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg11833968	chr6:79620685	NA	-0.42	-7.86	-0.36	3.12e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7833986	0.501	rs17815934	chr8:57038395	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.97	17.01	0.64	8.45e-50	Height;
LUAD	cis	rs7107174	1.000	rs4627115	chr11:78007873	T/G	cg02023728	chr11:77925099	USP35	0.49	7.24	0.33	2.14e-12	Testicular germ cell tumor;
LUAD	cis	rs10744422	1.000	rs3852537	chr12:123361501	T/C	cg16953816	chr12:123349952	VPS37B	0.63	7.32	0.34	1.26e-12	Schizophrenia;
LUAD	cis	rs6732160	0.932	rs768851	chr2:73378241	G/A	cg01422370	chr2:73384389	NA	0.34	6.65	0.31	8.83e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg11941060	chr3:133502564	NA	-0.65	-11.45	-0.49	1.24e-26	Iron status biomarkers;
LUAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg22907277	chr7:1156413	C7orf50	0.7	8.29	0.37	1.54e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg23950597	chr19:37808831	NA	-0.6	-7.52	-0.34	3.32e-13	Coronary artery calcification;
LUAD	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg27446573	chr6:127587934	RNF146	0.44	6.7	0.31	6.65e-11	Breast cancer;
LUAD	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg08470875	chr2:26401718	FAM59B	-0.6	-8.14	-0.37	4.54e-15	Gut microbiome composition (summer);
LUAD	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.44	6.8	0.31	3.48e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg10755058	chr3:40428713	ENTPD3	0.35	6.62	0.31	1.07e-10	Renal cell carcinoma;
LUAD	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg06108461	chr20:60628389	TAF4	-1.11	-20.23	-0.7	3.67e-64	Body mass index;
LUAD	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24308560	chr3:49941425	MST1R	0.55	9.33	0.41	5.97e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg07217954	chr7:1067459	C7orf50	0.46	7.16	0.33	3.55e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs10802346	0.545	rs10924568	chr1:246385482	C/A	cg13514129	chr1:39547527	MACF1	0.62	11.04	0.47	4.67e-25	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg23260525	chr10:116636907	FAM160B1	0.47	10.79	0.46	3.99e-24	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs16854884	0.739	rs1075113	chr3:143760535	C/T	cg01302019	chr3:143689584	C3orf58	-0.41	-6.93	-0.32	1.59e-11	Economic and political preferences (feminism/equality);
LUAD	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg11663144	chr21:46675770	NA	-0.59	-11.76	-0.5	7.73e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg22467129	chr15:76604101	ETFA	-0.51	-8.95	-0.4	1.17e-17	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg02782426	chr3:40428986	ENTPD3	-0.37	-7.89	-0.36	2.53e-14	Renal cell carcinoma;
LUAD	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg20476274	chr7:133979776	SLC35B4	0.86	17.56	0.65	3.17e-52	Mean platelet volume;
LUAD	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg25894440	chr7:65020034	NA	0.61	6.59	0.31	1.29e-10	Diabetic kidney disease;
LUAD	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg02527881	chr3:46936655	PTH1R	-0.58	-11.89	-0.5	2.42e-28	Colorectal cancer;
LUAD	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg06740227	chr12:86229804	RASSF9	0.45	7.88	0.36	2.78e-14	Major depressive disorder;
LUAD	cis	rs8038465	0.622	rs60696711	chr15:73873005	C/A	cg15420318	chr15:73925796	NPTN	0.45	7.36	0.34	9.99e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1904096	0.506	rs4693378	chr4:95168552	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.1	-0.44	1.24e-21	Type 2 diabetes;
LUAD	cis	rs7173743	0.756	rs4539564	chr15:79128499	G/A	cg00540400	chr15:79124168	NA	0.42	8.56	0.38	2.04e-16	Coronary artery disease;
LUAD	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg18827107	chr12:86230957	RASSF9	0.53	9.45	0.42	2.29e-19	Major depressive disorder;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg16866038	chr11:118443240	ARCN1	-0.6	-6.35	-0.3	5.57e-10	Type 2 diabetes;
LUAD	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.55	-0.3	1.72e-10	Aortic root size;
LUAD	cis	rs11809207	0.903	rs17257148	chr1:26526348	G/C	cg00147160	chr1:26503991	CNKSR1	0.43	8.42	0.38	6.1e-16	Height;
LUAD	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg00204512	chr16:28754710	NA	0.35	7.65	0.35	1.39e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.47	-0.34	4.65e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg07607921	chr17:4047574	ZZEF1;CYB5D2	-0.45	-8.1	-0.37	5.78e-15	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg24829409	chr8:58192753	C8orf71	-0.53	-6.88	-0.32	2.2e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.785	rs7955173	chr12:86447214	G/A	cg18827107	chr12:86230957	RASSF9	0.45	8.14	0.37	4.43e-15	Major depressive disorder;
LUAD	cis	rs8017423	0.967	rs60548738	chr14:90724399	G/A	cg14092571	chr14:90743983	NA	-0.5	-8.87	-0.4	2.15e-17	Mortality in heart failure;
LUAD	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg16647868	chr5:131706066	SLC22A5	0.49	7.85	0.36	3.44e-14	Breast cancer;
LUAD	trans	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	6.07e-11	Depression;
LUAD	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg06608945	chr2:219082296	ARPC2	-0.42	-6.82	-0.31	3.06e-11	Colorectal cancer;
LUAD	trans	rs208520	0.802	rs851600	chr6:66893754	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-14.77	-0.58	4.19e-40	Exhaled nitric oxide output;
LUAD	cis	rs397969	0.621	rs203449	chr17:19824621	C/T	cg04132472	chr17:19861366	AKAP10	0.33	6.91	0.32	1.83e-11	Platelet count;
LUAD	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg06640241	chr16:89574553	SPG7	0.75	13.57	0.55	4.66e-35	Multiple myeloma (IgH translocation);
LUAD	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.38	0.3	4.69e-10	Cardiac Troponin-T levels;
LUAD	cis	rs11811982	0.793	rs79025417	chr1:227579428	G/A	cg24860534	chr1:227506868	CDC42BPA	0.66	7.23	0.33	2.24e-12	Optic disc area;
LUAD	cis	rs909002	0.772	rs10798876	chr1:32074514	C/G	cg13919466	chr1:32135498	COL16A1	-0.38	-8.75	-0.39	5.24e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg22823121	chr1:150693482	HORMAD1	0.38	7.4	0.34	7.34e-13	Melanoma;
LUAD	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg12863693	chr15:85201151	NMB	0.39	7.31	0.33	1.33e-12	Schizophrenia;
LUAD	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg08773314	chr2:239334832	ASB1	0.46	10.58	0.46	2.3e-23	Multiple system atrophy;
LUAD	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg14584255	chr6:163149320	PACRG;PARK2	-0.4	-7.46	-0.34	4.96e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9788682	0.747	rs11072766	chr15:78771546	C/T	cg18825076	chr15:78729989	IREB2	0.53	7.48	0.34	4.46e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg19875535	chr5:140030758	IK	0.45	7.45	0.34	5.38e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg20129853	chr10:51489980	NA	-0.35	-7.12	-0.33	4.78e-12	Prostate-specific antigen levels;
LUAD	cis	rs494562	1.000	rs527670	chr6:86115779	T/C	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.78	-9.58	-0.42	8.29e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1847202	0.963	rs34317383	chr3:72946652	A/C	cg25664220	chr3:72788482	NA	-0.44	-8.09	-0.37	6.6e-15	Motion sickness;
LUAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg12432903	chr7:1882776	MAD1L1	-0.53	-8.87	-0.4	2.01e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-6.87	-0.32	2.35e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg04398451	chr17:18023971	MYO15A	0.66	11.86	0.5	3.34e-28	Total body bone mineral density;
LUAD	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.34	0.34	1.1e-12	Bipolar disorder;
LUAD	cis	rs7172809	0.573	rs13379686	chr15:77436191	T/C	cg11865553	chr15:77376250	NA	-0.39	-6.43	-0.3	3.49e-10	Glucose homeostasis traits;
LUAD	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg19163074	chr7:65112434	INTS4L2	-0.41	-6.36	-0.3	5.21e-10	Aortic root size;
LUAD	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg18446336	chr7:2847575	GNA12	-0.36	-6.91	-0.32	1.75e-11	Height;
LUAD	cis	rs10504073	0.669	rs11779189	chr8:50030592	C/G	cg00325661	chr8:49890786	NA	-0.4	-9.1	-0.4	3.49e-18	Blood metabolite ratios;
LUAD	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg12034118	chr1:209979487	IRF6	0.55	7.24	0.33	2.17e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg22676075	chr6:135203613	NA	0.56	9.95	0.44	4.34e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08219700	chr8:58056026	NA	0.68	8.98	0.4	8.96e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs10193935	0.901	rs222478	chr2:42656919	G/T	cg27598129	chr2:42591480	NA	-0.65	-8.72	-0.39	6.21e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12976411	0.575	rs59552401	chr19:32827401	A/C	cg18253629	chr19:32836317	ZNF507	0.77	7.08	0.33	6.13e-12	Coronary artery disease;
LUAD	cis	rs11971779	0.680	rs10265718	chr7:139100068	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs1950626	0.787	rs34857222	chr14:101391354	G/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.37	7.07	0.33	6.26e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg12310025	chr6:25882481	NA	-0.49	-7.16	-0.33	3.51e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs73206853	0.698	rs73191806	chr12:110899913	A/G	cg12870014	chr12:110450643	ANKRD13A	0.61	6.86	0.32	2.51e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs6076065	0.748	rs2253834	chr20:23387816	C/T	cg11657817	chr20:23433608	CST11	-0.56	-11.72	-0.5	1.14e-27	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7680126	0.626	rs11723388	chr4:10195802	G/A	cg02734326	chr4:10020555	SLC2A9	-0.52	-6.6	-0.31	1.23e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs240764	0.658	rs11155673	chr6:101243283	A/T	cg09795085	chr6:101329169	ASCC3	-0.43	-7.65	-0.35	1.35e-13	Neuroticism;
LUAD	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.62	0.52	3.18e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg06671706	chr8:8559999	CLDN23	0.55	9.63	0.42	5.45e-20	Obesity-related traits;
LUAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg18402987	chr7:1209562	NA	0.87	11.56	0.49	4.82e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg15017067	chr4:17643749	FAM184B	0.36	7.03	0.32	8.13e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg15448220	chr1:150897856	SETDB1	0.56	9.56	0.42	9.56e-20	Melanoma;
LUAD	cis	rs4594175	0.926	rs114230179	chr14:51601974	C/T	cg23942311	chr14:51606299	NA	0.64	11.09	0.47	3e-25	Cancer;
LUAD	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg19635926	chr16:89946313	TCF25	0.78	6.85	0.32	2.58e-11	Skin colour saturation;
LUAD	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg00634984	chr7:65235879	NA	0.49	6.58	0.3	1.41e-10	Aortic root size;
LUAD	cis	rs7937890	0.531	rs2575828	chr11:14484192	T/C	cg23387056	chr11:14280742	SPON1	-0.35	-6.73	-0.31	5.62e-11	Mitochondrial DNA levels;
LUAD	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	9.41	0.42	3.29e-19	Colorectal cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01718711	chr8:8860266	ERI1	-0.45	-7.41	-0.34	7.07e-13	Cancer;
LUAD	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15369054	chr17:80825471	TBCD	-0.62	-10.46	-0.45	6.13e-23	Breast cancer;
LUAD	cis	rs11229555	0.645	rs36002376	chr11:58204809	C/G	cg15696309	chr11:58395628	NA	-0.79	-10.64	-0.46	1.33e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs58804349	0.685	rs9422448	chr10:43288816	A/G	cg20628663	chr10:43360327	NA	0.62	6.46	0.3	2.86e-10	Pediatric bone mineral content (radius);
LUAD	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg24578937	chr1:2090814	PRKCZ	0.78	15.7	0.61	4.43e-44	Height;
LUAD	cis	rs684232	0.666	rs838372	chr17:566428	C/T	cg15660573	chr17:549704	VPS53	-0.8	-15.63	-0.61	8.72e-44	Prostate cancer;
LUAD	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg19997662	chr15:101784653	CHSY1	-0.54	-9.9	-0.43	6.61e-21	Corneal structure;
LUAD	trans	rs17685	0.961	rs41301394	chr7:75612803	C/T	cg19862616	chr7:65841803	NCRNA00174	0.86	15.63	0.61	8.27e-44	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg15445000	chr17:37608096	MED1	0.45	8.31	0.37	1.36e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1832871	0.541	rs11755760	chr6:158886742	A/G	cg07165851	chr6:158734300	TULP4	0.51	7.53	0.34	3e-13	Height;
LUAD	cis	rs6500395	1.000	rs3826174	chr16:48591012	T/C	cg04672837	chr16:48644449	N4BP1	0.38	6.49	0.3	2.41e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13126279	chr21:47581558	C21orf56	-0.61	-11.08	-0.47	3.2e-25	Testicular germ cell tumor;
LUAD	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg07936489	chr17:37558343	FBXL20	-0.46	-7.23	-0.33	2.3e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg23262073	chr20:60523788	NA	0.47	7.26	0.33	1.84e-12	Body mass index;
LUAD	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg01657329	chr11:68192670	LRP5	-0.41	-6.48	-0.3	2.59e-10	Total body bone mineral density;
LUAD	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg08645402	chr16:4508243	NA	0.62	11.21	0.48	1.06e-25	Schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg17754171	chr2:200324668	SATB2	-0.64	-6.37	-0.3	4.96e-10	Type 2 diabetes;
LUAD	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.99e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	15.1	0.59	1.66e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg07606381	chr6:8435919	SLC35B3	-0.42	-7.13	-0.33	4.25e-12	Motion sickness;
LUAD	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg17063962	chr7:91808500	NA	-0.66	-11.23	-0.48	8.86e-26	Breast cancer;
LUAD	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg19041857	chr6:27730383	NA	-0.36	-6.58	-0.3	1.36e-10	Parkinson's disease;
LUAD	cis	rs6542838	0.611	rs17758170	chr2:99531842	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-7.43	-0.34	6.2e-13	Fear of minor pain;
LUAD	cis	rs9787249	0.533	rs1883648	chr1:40246535	T/G	cg19912559	chr1:40204330	PPIE	0.47	8.1	0.37	6.1e-15	Blood protein levels;
LUAD	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg09491104	chr22:46646882	C22orf40	-0.7	-12.91	-0.53	2.13e-32	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6494488	0.500	rs55881719	chr15:64714903	T/G	cg08069370	chr15:64387884	SNX1	-0.75	-6.64	-0.31	9.44e-11	Coronary artery disease;
LUAD	cis	rs6743376	0.556	rs2515397	chr2:113819258	T/C	cg09040174	chr2:113837401	NA	0.5	7.74	0.35	7.49e-14	Inflammatory biomarkers;
LUAD	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21028142	chr17:79581711	NPLOC4	0.45	9.79	0.43	1.5e-20	Eye color traits;
LUAD	cis	rs4819052	0.704	rs2297283	chr21:46683590	G/A	cg11663144	chr21:46675770	NA	-0.39	-7.14	-0.33	4.05e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6445967	0.554	rs12634453	chr3:58434593	A/G	cg13750441	chr3:58318267	PXK	-0.32	-6.59	-0.31	1.3e-10	Platelet count;
LUAD	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg03929089	chr4:120376271	NA	-0.95	-17.59	-0.65	2.2e-52	Height;
LUAD	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg11494091	chr17:61959527	GH2	0.42	8.0	0.36	1.17e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg24818145	chr4:99064322	C4orf37	0.45	7.7	0.35	9.53e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1941023	0.503	rs10750936	chr11:60144180	G/A	cg08716584	chr11:60157161	MS4A7	-0.49	-9.39	-0.42	3.68e-19	Congenital heart disease (maternal effect);
LUAD	trans	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg04565464	chr8:145669602	NFKBIL2	0.48	7.37	0.34	9.23e-13	Schizophrenia;
LUAD	cis	rs743757	1.000	rs2236965	chr3:50453456	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.43	6.81	0.31	3.34e-11	Diastolic blood pressure;
LUAD	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg06784218	chr1:46089804	CCDC17	0.59	13.22	0.54	1.28e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg03714773	chr7:91764589	CYP51A1	0.28	6.75	0.31	5.03e-11	Breast cancer;
LUAD	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg22683308	chr4:1340831	KIAA1530	-0.5	-8.27	-0.37	1.77e-15	Longevity;
LUAD	cis	rs6594713	0.603	rs6879257	chr5:112845803	C/T	cg12552261	chr5:112820674	MCC	0.53	7.36	0.34	9.45e-13	Brain cytoarchitecture;
LUAD	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg13722127	chr7:150037890	RARRES2	0.45	8.11	0.37	5.71e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg07169764	chr2:136633963	MCM6	0.82	9.6	0.42	7.17e-20	Corneal structure;
LUAD	cis	rs9581857	0.615	rs61622854	chr13:28023194	T/A	cg22138327	chr13:27999177	GTF3A	0.83	9.81	0.43	1.33e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.39	-7.24	-0.33	2.17e-12	Longevity;Endometriosis;
LUAD	trans	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg03886242	chr7:26192032	NFE2L3	-0.43	-7.47	-0.34	4.78e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2302190	0.882	rs12939703	chr17:56611090	G/C	cg25885038	chr17:56607967	SEPT4	-0.52	-8.36	-0.38	9.1e-16	Vitamin D levels;
LUAD	cis	rs7937890	0.504	rs2575847	chr11:14471172	C/T	cg22961513	chr11:14280813	SPON1	-0.37	-7.02	-0.32	8.67e-12	Mitochondrial DNA levels;
LUAD	cis	rs7665090	1.000	rs2272697	chr4:103555992	A/G	cg07973026	chr4:103553119	MANBA	0.47	8.43	0.38	5.37e-16	Primary biliary cholangitis;
LUAD	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.96	0.53	1.4e-32	Cognitive ability;
LUAD	trans	rs7395662	0.864	rs7482764	chr11:48625858	T/A	cg00717180	chr2:96193071	NA	-0.39	-7.39	-0.34	8.14e-13	HDL cholesterol;
LUAD	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg04756594	chr16:24857601	SLC5A11	0.51	10.37	0.45	1.29e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg10518543	chr12:38710700	ALG10B	-0.43	-7.0	-0.32	1.01e-11	Bladder cancer;
LUAD	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg26384229	chr12:38710491	ALG10B	0.48	7.97	0.36	1.47e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg07507251	chr3:52567010	NT5DC2	0.32	6.39	0.3	4.38e-10	Bipolar disorder;
LUAD	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg16988262	chr1:15930761	NA	0.41	6.94	0.32	1.51e-11	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.88	0.53	2.99e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2731664	0.792	rs2630767	chr5:176870700	T/C	cg23176889	chr5:176863531	GRK6	-0.68	-12.77	-0.53	8.06e-32	Intelligence (multi-trait analysis);
LUAD	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg17761419	chr8:57350749	NA	-0.51	-7.67	-0.35	1.17e-13	Obesity-related traits;
LUAD	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg02527881	chr3:46936655	PTH1R	0.41	7.84	0.36	3.6e-14	Colorectal cancer;
LUAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.2	0.54	1.51e-33	Prudent dietary pattern;
LUAD	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.64	-11.24	-0.48	7.64e-26	Lymphocyte counts;
LUAD	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24531977	chr5:56204891	C5orf35	-0.79	-12.87	-0.53	3.32e-32	Initial pursuit acceleration;
LUAD	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.01	-0.5	8.8e-29	Primary sclerosing cholangitis;
LUAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.65	-0.39	1.11e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs3125734	0.633	rs4979772	chr10:63967600	C/T	cg09941381	chr10:64027924	RTKN2	0.3	6.88	0.32	2.2e-11	Rheumatoid arthritis;
LUAD	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-14.51	-0.58	5.23e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7927771	0.524	rs7939420	chr11:47723938	A/G	cg18512352	chr11:47633146	NA	-0.36	-6.56	-0.3	1.54e-10	Subjective well-being;
LUAD	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg02734326	chr4:10020555	SLC2A9	0.49	8.83	0.39	2.84e-17	Bone mineral density;
LUAD	cis	rs3540	0.960	rs4031435	chr15:91015566	G/C	cg10434728	chr15:90938212	IQGAP1	0.37	6.81	0.31	3.35e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs977987	0.806	rs8057203	chr16:75404974	T/C	cg03315344	chr16:75512273	CHST6	0.65	14.14	0.57	1.91e-37	Dupuytren's disease;
LUAD	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	cis	rs2279817	0.863	rs2270976	chr1:18023690	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.6	9.6	0.42	6.97e-20	Neuroticism;
LUAD	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg00106254	chr7:1943704	MAD1L1	-0.64	-9.83	-0.43	1.13e-20	Bipolar disorder and schizophrenia;
LUAD	trans	rs12266096	0.680	rs1416923	chr10:86910986	A/T	cg11357369	chr6:164506268	NA	0.35	6.57	0.3	1.44e-10	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LUAD	cis	rs6906287	0.647	rs6569013	chr6:118681328	G/T	cg21191810	chr6:118973309	C6orf204	-0.55	-10.82	-0.47	3.05e-24	Electrocardiographic conduction measures;
LUAD	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg15017067	chr4:17643749	FAM184B	-0.37	-6.93	-0.32	1.57e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13064411	0.591	rs7628945	chr3:113201754	A/T	cg10517650	chr3:113235015	CCDC52	-0.45	-8.31	-0.37	1.28e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg00339695	chr16:24857497	SLC5A11	-0.53	-9.55	-0.42	1.08e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg23254163	chr1:152506842	NA	0.26	7.05	0.32	7.19e-12	Hair morphology;
LUAD	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg07606381	chr6:8435919	SLC35B3	0.42	6.91	0.32	1.77e-11	Motion sickness;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26185531	chr11:75479825	DGAT2	-0.56	-6.85	-0.32	2.6e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1395	1.000	rs1275530	chr2:27432547	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.43	-8.04	-0.36	9.2e-15	Blood metabolite levels;
LUAD	cis	rs739496	0.843	rs7398705	chr12:112016016	A/C	cg10833066	chr12:111807467	FAM109A	-0.39	-6.57	-0.3	1.48e-10	Platelet count;
LUAD	cis	rs10465746	0.714	rs12141272	chr1:84434517	C/T	cg10977910	chr1:84465055	TTLL7	0.59	9.78	0.43	1.67e-20	Obesity-related traits;
LUAD	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg24818145	chr4:99064322	C4orf37	0.4	6.64	0.31	9.52e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9863	0.861	rs34878139	chr12:124446253	T/C	cg17723958	chr12:124429295	CCDC92	-0.4	-6.64	-0.31	9.48e-11	White blood cell count;
LUAD	cis	rs4372836	1.000	rs2276547	chr2:28975107	G/C	cg09522027	chr2:28974177	PPP1CB	-0.63	-9.89	-0.43	6.74e-21	Body mass index;
LUAD	cis	rs11249608	0.636	rs62393070	chr5:178447943	A/G	cg01312482	chr5:178451176	ZNF879	-0.47	-7.2	-0.33	2.73e-12	Pubertal anthropometrics;
LUAD	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-9.91	-0.43	5.71e-21	Migraine;Coronary artery disease;
LUAD	cis	rs1894633	0.574	rs56259646	chr1:172330739	A/G	cg13446689	chr1:172328377	DNM3	0.42	6.79	0.31	3.84e-11	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1113500	1.000	rs1777483	chr1:108609408	A/C	cg06207961	chr1:108661230	NA	-0.42	-7.96	-0.36	1.59e-14	Growth-regulated protein alpha levels;
LUAD	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg25319279	chr11:5960081	NA	-0.4	-7.51	-0.34	3.53e-13	DNA methylation (variation);
LUAD	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg02569458	chr12:86230093	RASSF9	0.44	7.97	0.36	1.53e-14	Major depressive disorder;
LUAD	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg13073564	chr4:8508604	NA	0.48	7.93	0.36	2.02e-14	Response to antineoplastic agents;
LUAD	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg15445000	chr17:37608096	MED1	0.44	8.09	0.37	6.59e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-14.54	-0.58	3.93e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg25753631	chr6:25732923	NA	-0.42	-7.52	-0.34	3.27e-13	Iron status biomarkers;
LUAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00166722	chr3:10149974	C3orf24	0.74	12.6	0.52	3.78e-31	Alzheimer's disease;
LUAD	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg07936489	chr17:37558343	FBXL20	-0.42	-6.78	-0.31	4.09e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.76	-9.68	-0.43	3.83e-20	Body mass index;
LUAD	cis	rs2979489	0.891	rs4285443	chr8:30327317	A/G	cg26383811	chr8:30366931	RBPMS	-0.67	-10.63	-0.46	1.48e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg11151820	chr5:10250162	CCT5;FAM173B	-0.38	-6.37	-0.3	4.95e-10	Subcortical brain region volumes;
LUAD	cis	rs6445967	0.530	rs6804567	chr3:58365912	T/A	cg23715586	chr3:58305044	RPP14	0.41	6.69	0.31	7.23e-11	Platelet count;
LUAD	cis	rs11031096	0.782	rs4910889	chr11:4153231	T/C	cg18678763	chr11:4115507	RRM1	-0.43	-7.47	-0.34	4.68e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.35	-6.87	-0.32	2.32e-11	Glomerular filtration rate;
LUAD	cis	rs9902453	1.000	rs4075623	chr17:28386526	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.26	-0.41	1e-18	Coffee consumption (cups per day);
LUAD	cis	rs4730250	0.707	rs257386	chr7:106807783	C/G	cg23024343	chr7:107201750	COG5	0.51	6.81	0.31	3.38e-11	Osteoarthritis;
LUAD	cis	rs11893307	0.507	rs1465303	chr2:191585440	A/C	cg11845111	chr2:191398756	TMEM194B	-0.44	-7.13	-0.33	4.28e-12	Mean platelet volume;
LUAD	cis	rs7727544	0.582	rs10478998	chr5:131516531	G/A	cg14196790	chr5:131705035	SLC22A5	0.42	7.38	0.34	8.71e-13	Blood metabolite levels;
LUAD	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg11494091	chr17:61959527	GH2	0.45	8.68	0.39	8.42e-17	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg09455208	chr3:40491958	NA	-0.59	-12.84	-0.53	4.41e-32	Renal cell carcinoma;
LUAD	cis	rs4588572	0.601	rs6867673	chr5:77779125	A/G	cg11547950	chr5:77652471	NA	-0.77	-12.28	-0.51	7.19e-30	Triglycerides;
LUAD	cis	rs12530845	1.000	rs4291211	chr7:135335373	C/T	cg23117316	chr7:135346802	PL-5283	-0.49	-9.2	-0.41	1.62e-18	Red blood cell traits;
LUAD	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg08885076	chr2:99613938	TSGA10	0.35	6.45	0.3	3.08e-10	Chronic sinus infection;
LUAD	cis	rs977987	0.778	rs12445726	chr16:75465575	C/T	cg03315344	chr16:75512273	CHST6	0.64	13.99	0.56	7.87e-37	Dupuytren's disease;
LUAD	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-12.15	-0.51	2.49e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.45	7.77	0.35	6.12e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg13393036	chr8:95962371	TP53INP1	-0.4	-9.72	-0.43	2.76e-20	Type 2 diabetes;
LUAD	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg04546413	chr19:29218101	NA	0.76	11.95	0.5	1.44e-28	Methadone dose in opioid dependence;
LUAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg22907277	chr7:1156413	C7orf50	0.76	11.19	0.48	1.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg26043149	chr18:55253948	FECH	-0.46	-7.56	-0.35	2.59e-13	Bone mineral density;
LUAD	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg02931644	chr1:25747376	RHCE	0.48	10.39	0.45	1.17e-22	Erythrocyte sedimentation rate;
LUAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08219700	chr8:58056026	NA	0.63	8.91	0.4	1.49e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg02176678	chr2:219576539	TTLL4	0.61	11.81	0.5	5.15e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.91	-0.36	2.34e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg21231944	chr12:82153410	PPFIA2	-0.37	-6.79	-0.31	3.85e-11	Resting heart rate;
LUAD	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg07936489	chr17:37558343	FBXL20	-0.46	-7.34	-0.34	1.08e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs12620999	1.000	rs4558538	chr2:238055975	C/T	cg23555395	chr2:238036564	NA	-0.61	-9.36	-0.41	4.67e-19	Systemic lupus erythematosus;
LUAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg14789911	chr21:47582049	C21orf56	0.5	9.04	0.4	5.63e-18	Testicular germ cell tumor;
LUAD	cis	rs698833	0.852	rs2582918	chr2:44582275	G/C	cg04920474	chr2:44395004	PPM1B	0.38	6.81	0.31	3.36e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs11030122	0.702	rs10835402	chr11:3990914	T/C	cg18678763	chr11:4115507	RRM1	-0.43	-7.14	-0.33	4.17e-12	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs360929	0.608	rs360903	chr4:152858111	C/T	cg27462160	chr16:89768630	SPATA2L	-0.56	-6.38	-0.3	4.7e-10	Volumetric brain MRI;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg00241218	chr6:31325000	HLA-B	-0.39	-6.57	-0.3	1.47e-10	Schizophrenia;
LUAD	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg26516362	chr5:178986906	RUFY1	0.54	8.47	0.38	3.95e-16	Lung cancer;
LUAD	cis	rs11756438	0.607	rs1688631	chr6:119019064	A/T	cg21191810	chr6:118973309	C6orf204	0.39	7.21	0.33	2.54e-12	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4266144	0.592	rs1545854	chr3:156840138	A/G	cg14969094	chr3:156848003	NA	0.41	6.59	0.31	1.32e-10	Coronary artery disease;
LUAD	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg06640241	chr16:89574553	SPG7	0.52	8.31	0.37	1.31e-15	Multiple myeloma (IgH translocation);
LUAD	cis	rs1395	0.778	rs34618115	chr2:27418289	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.51	9.03	0.4	6.01e-18	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg08999081	chr20:33150536	PIGU	0.63	14.36	0.57	2.27e-38	Coronary artery disease;
LUAD	trans	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Parkinson's disease;
LUAD	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg00255919	chr5:131827918	IRF1	0.5	11.92	0.5	1.97e-28	Asthma (sex interaction);
LUAD	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg11663144	chr21:46675770	NA	-0.5	-8.72	-0.39	6.46e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6961069	0.716	rs11771152	chr7:80271327	T/C	cg04458919	chr7:80252533	CD36	0.37	7.16	0.33	3.6e-12	Platelet count;
LUAD	cis	rs28595532	0.623	rs10016452	chr4:119277490	A/G	cg02775129	chr4:119771670	NA	-0.61	-6.63	-0.31	1.03e-10	Cannabis dependence symptom count;
LUAD	cis	rs9652601	0.959	rs12928537	chr16:11191400	G/A	cg04616529	chr16:11181986	CLEC16A	0.37	6.37	0.3	4.93e-10	Systemic lupus erythematosus;
LUAD	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.51	-0.3	2.1e-10	Aortic root size;
LUAD	cis	rs6992820	1.000	rs6983444	chr8:56759565	G/A	cg06880721	chr8:56792545	LYN	-0.49	-8.14	-0.37	4.34e-15	Mean platelet volume;
LUAD	cis	rs798554	0.591	rs1636248	chr7:2882030	T/C	cg02423579	chr7:2872169	GNA12	-0.57	-9.61	-0.42	6.54e-20	Height;
LUAD	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg17410650	chr12:54324560	NA	-0.57	-12.16	-0.51	2.25e-29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUAD	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg04450456	chr4:17643702	FAM184B	0.36	6.86	0.32	2.53e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg05340658	chr4:99064831	C4orf37	0.53	9.04	0.4	5.48e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7289126	0.966	rs2284072	chr22:38633666	A/C	cg25457927	chr22:38595422	NA	-0.43	-10.3	-0.45	2.4e-22	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.88	0.32	2.13e-11	Motion sickness;
LUAD	cis	rs12912251	1.000	rs12912251	chr15:38986368	G/T	cg01338139	chr15:38987640	C15orf53	-0.6	-9.58	-0.42	8.64e-20	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg13180566	chr4:1052158	NA	-0.39	-6.65	-0.31	9.22e-11	Recombination rate (females);
LUAD	cis	rs870825	0.616	rs28618216	chr4:185648998	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	trans	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg06606381	chr12:133084897	FBRSL1	-0.8	-6.73	-0.31	5.41e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg17724175	chr1:150552817	MCL1	0.36	8.22	0.37	2.44e-15	Melanoma;
LUAD	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg17330251	chr7:94953956	PON1	-0.52	-6.87	-0.32	2.23e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs7395662	1.000	rs4929903	chr11:48913332	T/G	cg15704280	chr7:45808275	SEPT13	-0.44	-7.03	-0.32	8.27e-12	HDL cholesterol;
LUAD	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg22117172	chr7:91764530	CYP51A1	0.3	6.44	0.3	3.21e-10	Breast cancer;
LUAD	cis	rs4268898	1.000	rs4268898	chr2:24490413	C/T	cg02683114	chr2:24398427	C2orf84	0.42	6.98	0.32	1.15e-11	Asthma;
LUAD	cis	rs6546550	0.901	rs11902198	chr2:70144596	C/A	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.97	-0.47	8.24e-25	Prevalent atrial fibrillation;
LUAD	cis	rs9487051	0.724	rs13200047	chr6:109633244	T/C	cg21918786	chr6:109611834	NA	-0.44	-7.07	-0.33	6.3e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg24558204	chr6:135376177	HBS1L	0.44	7.88	0.36	2.76e-14	Red blood cell count;
LUAD	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg06608945	chr2:219082296	ARPC2	-0.43	-7.17	-0.33	3.27e-12	Colorectal cancer;
LUAD	trans	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg01620082	chr3:125678407	NA	-0.44	-6.57	-0.3	1.44e-10	Depression;
LUAD	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg06808227	chr14:105710500	BRF1	-0.41	-6.38	-0.3	4.56e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg20933634	chr6:27740509	NA	0.38	6.54	0.3	1.82e-10	Parkinson's disease;
LUAD	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg14844989	chr11:31128820	NA	-0.44	-8.1	-0.37	5.98e-15	Red blood cell count;
LUAD	cis	rs7818345	0.935	rs7016592	chr8:19277735	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.32	6.99	0.32	1.1e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs11585357	0.843	rs12095095	chr1:17625832	C/G	cg08277548	chr1:17600880	PADI3	-0.83	-12.83	-0.53	4.48e-32	Hair shape;
LUAD	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-12.03	-0.51	6.88e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg09365446	chr1:150670422	GOLPH3L	0.63	10.99	0.47	6.79e-25	Melanoma;
LUAD	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs12765878	1.000	rs9325507	chr10:105645622	C/T	cg11005552	chr10:105648138	OBFC1	0.44	8.26	0.37	1.91e-15	Coronary artery disease;
LUAD	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-6.93	-0.32	1.58e-11	Heart rate;
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg17461271	chr1:172717683	NA	-0.43	-6.46	-0.3	2.88e-10	Height;
LUAD	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18099408	chr3:52552593	STAB1	-0.45	-7.97	-0.36	1.45e-14	Bipolar disorder;
LUAD	cis	rs59698941	0.943	rs57550938	chr5:132248104	G/A	cg14825688	chr5:132208181	LEAP2	-0.47	-6.41	-0.3	3.91e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs1595825	0.891	rs60129872	chr2:198653192	A/G	cg00361562	chr2:198649771	BOLL	-0.45	-6.44	-0.3	3.32e-10	Ulcerative colitis;
LUAD	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg25828334	chr19:18545568	ISYNA1	-0.38	-7.59	-0.35	2.02e-13	Breast cancer;
LUAD	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg04450456	chr4:17643702	FAM184B	-0.37	-7.38	-0.34	8.53e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6906287	0.625	rs7757892	chr6:118844221	G/A	cg05564266	chr6:118973597	C6orf204	0.34	7.15	0.33	3.88e-12	Electrocardiographic conduction measures;
LUAD	cis	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg07460842	chr6:66804631	NA	-1.09	-17.05	-0.64	5.42e-50	Exhaled nitric oxide output;
LUAD	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg21138405	chr5:131827807	IRF1	0.6	13.88	0.56	2.35e-36	Asthma (sex interaction);
LUAD	cis	rs977987	0.806	rs4888411	chr16:75443183	T/A	cg03315344	chr16:75512273	CHST6	0.64	14.08	0.56	3.49e-37	Dupuytren's disease;
LUAD	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg11822812	chr5:140052017	DND1	-0.44	-7.9	-0.36	2.49e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg21427119	chr20:30132790	HM13	-0.62	-9.46	-0.42	2.24e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.76	0.53	9e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7010267	0.805	rs6992497	chr8:119980069	A/G	cg01975934	chr8:119970761	NA	-0.41	-7.79	-0.35	5.24e-14	Total body bone mineral density (age 45-60);
LUAD	cis	rs2408955	0.561	rs9971924	chr12:48479832	C/G	cg04545296	chr12:48745243	ZNF641	-0.34	-8.98	-0.4	9.27e-18	Glycated hemoglobin levels;
LUAD	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg09835421	chr16:68378352	PRMT7	-1.06	-11.82	-0.5	4.56e-28	Schizophrenia;
LUAD	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.42	-7.17	-0.33	3.44e-12	Tonsillectomy;
LUAD	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg15105011	chr4:940614	TMEM175	0.58	9.74	0.43	2.38e-20	Sjögren's syndrome;
LUAD	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.87	-0.32	2.31e-11	Crohn's disease;
LUAD	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.68	13.05	0.54	6e-33	Cognitive ability;
LUAD	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.56	0.34	2.59e-13	Cannabis dependence symptom count;
LUAD	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg21475434	chr5:93447410	FAM172A	-0.65	-7.67	-0.35	1.2e-13	Diabetic retinopathy;
LUAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg03188948	chr7:1209495	NA	0.47	7.71	0.35	9.15e-14	Longevity;Endometriosis;
LUAD	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg23954153	chr1:44402353	ARTN	-0.36	-6.4	-0.3	4.21e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg27446573	chr6:127587934	RNF146	0.45	6.69	0.31	6.92e-11	Breast cancer;
LUAD	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg26597838	chr10:835615	NA	0.77	10.32	0.45	2e-22	Eosinophil percentage of granulocytes;
LUAD	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg10356904	chr22:49881777	NA	-0.33	-6.89	-0.32	2.08e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs12286929	0.607	rs10891808	chr11:115071301	T/C	cg04055981	chr11:115044050	NA	-0.48	-8.91	-0.4	1.56e-17	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	7.55	0.34	2.77e-13	Menopause (age at onset);
LUAD	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg14458575	chr2:238380390	NA	0.68	13.36	0.54	3.26e-34	Prostate cancer;
LUAD	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.55	7.86	0.36	3.13e-14	Platelet count;
LUAD	trans	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg07817883	chr1:32538562	TMEM39B	1.44	11.82	0.5	4.7e-28	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg22105103	chr4:187893119	NA	-0.57	-12.61	-0.52	3.73e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg07677032	chr17:61819896	STRADA	0.57	10.41	0.45	9.16e-23	Prudent dietary pattern;
LUAD	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg06641503	chr3:48959341	ARIH2	-0.36	-6.59	-0.31	1.29e-10	Menarche (age at onset);
LUAD	trans	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg01620082	chr3:125678407	NA	-0.98	-9.65	-0.42	4.92e-20	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.89	-0.5	2.62e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7737355	1.000	rs12654593	chr5:130756867	C/T	cg06307176	chr5:131281290	NA	-0.51	-7.86	-0.36	3.16e-14	Life satisfaction;
LUAD	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg06713675	chr4:122721982	EXOSC9	-0.84	-18.31	-0.66	1.39e-55	Type 2 diabetes;
LUAD	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg25036284	chr2:26402008	FAM59B	-0.58	-7.97	-0.36	1.49e-14	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	6.15e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg08470875	chr2:26401718	FAM59B	-0.63	-8.57	-0.38	1.94e-16	Gut microbiome composition (summer);
LUAD	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg13944838	chr5:179740914	GFPT2	-0.78	-13.29	-0.54	6.29e-34	Height;
LUAD	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg18252515	chr7:66147081	NA	0.59	6.37	0.3	4.95e-10	Diabetic kidney disease;
LUAD	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg15445000	chr17:37608096	MED1	-0.44	-7.9	-0.36	2.42e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg19773385	chr1:10388646	KIF1B	-0.41	-6.7	-0.31	6.53e-11	Hepatocellular carcinoma;
LUAD	cis	rs7737355	0.947	rs11750739	chr5:130911743	C/T	cg06307176	chr5:131281290	NA	0.42	6.73	0.31	5.41e-11	Life satisfaction;
LUAD	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg06740227	chr12:86229804	RASSF9	0.45	7.92	0.36	2.05e-14	Major depressive disorder;
LUAD	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg12863693	chr15:85201151	NMB	0.42	7.59	0.35	2.09e-13	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00166722	chr3:10149974	C3orf24	-0.73	-12.17	-0.51	1.95e-29	Alzheimer's disease;
LUAD	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg04154034	chr17:28927549	LRRC37B2	0.69	6.97	0.32	1.22e-11	Body mass index;
LUAD	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg03929089	chr4:120376271	NA	-0.52	-8.18	-0.37	3.3e-15	HDL cholesterol;
LUAD	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23158103	chr7:148848205	ZNF398	-0.66	-12.48	-0.52	1.17e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg10729496	chr3:10149963	C3orf24	0.57	9.38	0.42	3.97e-19	Alzheimer's disease;
LUAD	cis	rs7274811	0.744	rs209665	chr20:32128889	T/G	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.47	-7.28	-0.33	1.69e-12	Height;
LUAD	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg09365446	chr1:150670422	GOLPH3L	0.62	10.86	0.47	2.12e-24	Melanoma;
LUAD	cis	rs10129255	0.518	rs2006284	chr14:107132201	G/A	cg07958169	chr14:107095056	NA	-0.35	-6.82	-0.31	3.24e-11	Kawasaki disease;
LUAD	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg06112835	chr11:68658793	MRPL21	0.48	8.59	0.39	1.71e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg14092988	chr3:52407081	DNAH1	0.38	7.45	0.34	5.33e-13	Bipolar disorder;
LUAD	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg27171569	chr16:83987465	OSGIN1	-0.56	-10.85	-0.47	2.29e-24	Pursuit maintenance gain;
LUAD	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-9.03	-0.4	6.31e-18	Life satisfaction;
LUAD	cis	rs12200560	0.505	rs9400167	chr6:97077192	G/T	cg06623918	chr6:96969491	KIAA0776	0.47	7.35	0.34	1.01e-12	Coronary heart disease;
LUAD	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg05373962	chr22:49881684	NA	-0.55	-13.1	-0.54	3.62e-33	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg01528321	chr10:82214614	TSPAN14	0.64	10.08	0.44	1.48e-21	Post bronchodilator FEV1;
LUAD	cis	rs9972944	0.589	rs11870559	chr17:63772633	G/A	cg07283582	chr17:63770753	CCDC46	0.5	10.69	0.46	9.03e-24	Total body bone mineral density;
LUAD	cis	rs7818345	0.624	rs12682196	chr8:19332963	A/C	cg06699216	chr8:19333253	CSGALNACT1	0.28	6.52	0.3	2.04e-10	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg25985355	chr7:65971099	NA	-0.51	-6.35	-0.3	5.48e-10	Diabetic kidney disease;
LUAD	cis	rs240764	0.578	rs723743	chr6:101237504	T/C	cg09795085	chr6:101329169	ASCC3	0.41	7.17	0.33	3.39e-12	Neuroticism;
LUAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07677032	chr17:61819896	STRADA	-0.57	-10.56	-0.46	2.6e-23	Prudent dietary pattern;
LUAD	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg24818145	chr4:99064322	C4orf37	-0.42	-6.95	-0.32	1.43e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10465746	0.747	rs10493741	chr1:84388118	G/C	cg10977910	chr1:84465055	TTLL7	0.6	9.86	0.43	8.48e-21	Obesity-related traits;
LUAD	cis	rs1385374	1.000	rs12311303	chr12:129301592	C/T	cg09035930	chr12:129282057	SLC15A4	-0.68	-7.83	-0.36	3.97e-14	Systemic lupus erythematosus;
LUAD	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	7.7	0.35	9.93e-14	Menarche (age at onset);
LUAD	cis	rs12545109	0.800	rs2582401	chr8:57401656	A/G	cg09654669	chr8:57350985	NA	-0.66	-9.32	-0.41	6.51e-19	Obesity-related traits;
LUAD	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg23281280	chr6:28129359	ZNF389	0.46	6.58	0.3	1.39e-10	Parkinson's disease;
LUAD	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg14092988	chr3:52407081	DNAH1	0.34	6.51	0.3	2.15e-10	Bipolar disorder;
LUAD	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.76	-0.31	4.72e-11	Post bronchodilator FEV1;
LUAD	cis	rs9434723	1.000	rs9434723	chr1:9292282	C/T	cg04199779	chr1:9294473	H6PD	0.63	7.18	0.33	3.26e-12	Height;
LUAD	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.88	0.36	2.87e-14	Breast cancer;
LUAD	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	8.86	0.4	2.3e-17	Ileal carcinoids;
LUAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg22906224	chr7:99728672	NA	0.67	11.74	0.5	9.86e-28	Coronary artery disease;
LUAD	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg04455712	chr21:45112962	RRP1B	0.43	8.77	0.39	4.5e-17	Mean corpuscular volume;
LUAD	cis	rs9522267	0.535	rs7323829	chr13:112232308	C/G	cg10483660	chr13:112241077	NA	-0.32	-6.84	-0.32	2.79e-11	Hepatitis;
LUAD	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg24154853	chr7:158122151	PTPRN2	0.58	11.6	0.49	3.48e-27	Calcium levels;
LUAD	cis	rs68170813	0.559	rs10953536	chr7:107021691	G/A	cg23024343	chr7:107201750	COG5	0.53	7.45	0.34	5.46e-13	Coronary artery disease;
LUAD	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg16205897	chr5:131564050	P4HA2	-0.31	-6.69	-0.31	7e-11	Acylcarnitine levels;
LUAD	cis	rs89107	0.576	rs35029749	chr6:118892120	A/C	cg21191810	chr6:118973309	C6orf204	0.39	7.1	0.33	5.38e-12	Cardiac structure and function;
LUAD	cis	rs7586879	1.000	rs10175064	chr2:25117537	T/C	cg04586622	chr2:25135609	ADCY3	0.34	7.38	0.34	8.71e-13	Body mass index;
LUAD	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg27490568	chr2:178487706	NA	0.4	6.82	0.31	3.1e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs68170813	0.559	rs4730232	chr7:106942382	G/C	cg23024343	chr7:107201750	COG5	0.48	7.0	0.32	9.9e-12	Coronary artery disease;
LUAD	cis	rs80319144	0.951	rs79560306	chr2:159244427	T/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.83	0.32	2.95e-11	Restless legs syndrome;
LUAD	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-7.59	-0.35	2.05e-13	Tonsillectomy;
LUAD	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg16479474	chr6:28041457	NA	0.42	7.27	0.33	1.73e-12	Depression;
LUAD	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg12927641	chr6:109611667	NA	-0.5	-8.78	-0.39	4.02e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs28595532	0.925	rs116785973	chr4:119611350	G/A	cg14228332	chr4:119757509	SEC24D	0.77	7.09	0.33	5.82e-12	Cannabis dependence symptom count;
LUAD	cis	rs886126	0.627	rs4766561	chr12:111673244	C/T	cg10833066	chr12:111807467	FAM109A	0.52	7.59	0.35	2.08e-13	Coronary heart disease;
LUAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg00280220	chr17:61926910	NA	0.35	6.59	0.31	1.3e-10	Prudent dietary pattern;
LUAD	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg00981070	chr1:2046702	PRKCZ	-0.35	-6.98	-0.32	1.12e-11	Height;
LUAD	cis	rs2224391	0.518	rs11757927	chr6:5282573	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	0.58	7.25	0.33	1.94e-12	Height;
LUAD	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg22676075	chr6:135203613	NA	0.73	14.45	0.57	9.55e-39	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg18016565	chr1:150552671	MCL1	0.41	7.67	0.35	1.17e-13	Tonsillectomy;
LUAD	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg07741184	chr6:167504864	NA	0.29	7.0	0.32	9.82e-12	Crohn's disease;
LUAD	trans	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.7	-9.52	-0.42	1.34e-19	Obesity-related traits;
LUAD	trans	rs853679	0.607	rs34505829	chr6:28133239	A/T	cg06606381	chr12:133084897	FBRSL1	-1.22	-10.86	-0.47	2.15e-24	Depression;
LUAD	cis	rs79057730	0.599	rs78347394	chr7:831817	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.0	10.7	0.46	8.02e-24	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73198271	0.632	rs570396	chr8:8593652	A/G	cg01851573	chr8:8652454	MFHAS1	0.44	8.04	0.36	9.06e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.41	-6.86	-0.32	2.43e-11	Longevity;Endometriosis;
LUAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg10150615	chr22:24372951	LOC391322	-0.54	-8.74	-0.39	5.7e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.48	-8.05	-0.36	8.66e-15	Body mass index;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg24335600	chr1:241682994	FH	-0.71	-7.47	-0.34	4.74e-13	Type 2 diabetes;
LUAD	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	6.55	0.3	1.67e-10	Hip circumference adjusted for BMI;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10387458	chr1:93645817	TMED5;CCDC18	-0.53	-6.42	-0.3	3.73e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.41	0.55	2.12e-34	Prudent dietary pattern;
LUAD	cis	rs9341808	0.718	rs1324123	chr6:80932894	G/A	cg08355045	chr6:80787529	NA	0.58	10.47	0.45	5.61e-23	Sitting height ratio;
LUAD	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg21204522	chr6:27730016	NA	-0.43	-6.83	-0.32	2.9100000000000002e-11	Parkinson's disease;
LUAD	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg20503657	chr10:835505	NA	0.96	14.69	0.58	9.27e-40	Eosinophil percentage of granulocytes;
LUAD	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg12373951	chr3:133503437	NA	0.36	7.24	0.33	2.17e-12	Iron status biomarkers;
LUAD	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs9900062	0.546	rs2676289	chr17:62705738	A/G	cg02598441	chr17:62777298	LOC146880	0.49	6.46	0.3	2.9e-10	QT interval;
LUAD	cis	rs2974760	0.606	rs2858918	chr16:201183	T/C	cg08400316	chr16:204221	HBZ	0.51	7.85	0.36	3.43e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs977987	0.835	rs7200616	chr16:75366089	G/A	cg03315344	chr16:75512273	CHST6	0.64	14.04	0.56	4.85e-37	Dupuytren's disease;
LUAD	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg18833306	chr6:118973337	C6orf204	-0.52	-7.58	-0.35	2.14e-13	Diastolic blood pressure;
LUAD	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.96	-0.4	1.05e-17	Gut microbiome composition (summer);
LUAD	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs28830936	1.000	rs28830936	chr15:41906408	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.71	-0.31	6.34e-11	Diastolic blood pressure;
LUAD	trans	rs9929218	0.817	rs3118228	chr16:68710737	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.95	-16.87	-0.63	3.46e-49	Colorectal cancer;
LUAD	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg19622623	chr12:86230825	RASSF9	-0.36	-6.63	-0.31	1.01e-10	Major depressive disorder;
LUAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-11.34	-0.48	3.35e-26	Asthma;
LUAD	cis	rs4523957	0.854	rs404392	chr17:2191000	G/A	cg16513277	chr17:2031491	SMG6	0.77	14.4	0.57	1.6e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs11630290	1.000	rs72750981	chr15:63983737	A/T	cg12036633	chr15:63758958	NA	-0.52	-6.92	-0.32	1.65e-11	Iris characteristics;
LUAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg12419862	chr22:24373484	LOC391322	-0.61	-10.18	-0.44	6.35e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3803170	0.513	rs4766573	chr12:111830809	C/A	cg10833066	chr12:111807467	FAM109A	0.47	8.71	0.39	6.67e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg07636037	chr3:49044803	WDR6	0.62	11.98	0.5	1.15e-28	Parkinson's disease;
LUAD	cis	rs8177876	0.749	rs12927828	chr16:81090624	C/G	cg08591886	chr16:81111003	C16orf46	-0.62	-6.71	-0.31	6.12e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs11030122	0.673	rs66596383	chr11:3979745	C/T	cg18678763	chr11:4115507	RRM1	-0.43	-7.24	-0.33	2.14e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg01299579	chr2:10830716	NOL10	-0.41	-7.16	-0.33	3.51e-12	Prostate cancer;
LUAD	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.13	-0.51	2.84e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06873352	chr17:61820015	STRADA	0.55	8.94	0.4	1.23e-17	Height;
LUAD	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg27284194	chr4:1044797	NA	0.7	10.1	0.44	1.2e-21	Recombination rate (females);
LUAD	trans	rs1493916	0.870	rs8097667	chr18:31387003	C/T	cg13755796	chr4:20253514	NA	-0.42	-7.11	-0.33	5.1e-12	Life satisfaction;
LUAD	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.12	-0.33	4.66e-12	Coronary artery disease;
LUAD	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18876405	chr7:65276391	NA	0.41	6.35	0.3	5.53e-10	Aortic root size;
LUAD	cis	rs12049351	0.774	rs11805194	chr1:229631734	T/C	cg11742688	chr1:229674241	ABCB10	-0.42	-6.66	-0.31	8.7e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg23758822	chr17:41437982	NA	0.99	19.86	0.69	1.72e-62	Menopause (age at onset);
LUAD	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg01851573	chr8:8652454	MFHAS1	0.42	7.76	0.35	6.52e-14	Mood instability;
LUAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg07217954	chr7:1067459	C7orf50	0.41	6.89	0.32	2.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg10523679	chr1:76189770	ACADM	0.87	15.47	0.6	4.32e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg18477163	chr1:228402036	OBSCN	0.37	6.95	0.32	1.37e-11	Diastolic blood pressure;
LUAD	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg26597838	chr10:835615	NA	0.96	15.02	0.59	3.51e-41	Eosinophil percentage of granulocytes;
LUAD	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg05425664	chr17:57184151	TRIM37	-0.42	-7.45	-0.34	5.3e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18099408	chr3:52552593	STAB1	-0.55	-9.9	-0.43	6.4e-21	Electroencephalogram traits;
LUAD	cis	rs9323205	0.723	rs12587352	chr14:51739441	T/C	cg23942311	chr14:51606299	NA	-0.56	-8.07	-0.37	7.31e-15	Cancer;
LUAD	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-7.57	-0.35	2.36e-13	Blood metabolite levels;
LUAD	cis	rs6906287	0.647	rs10457330	chr6:118731468	A/T	cg05564266	chr6:118973597	C6orf204	0.33	7.12	0.33	4.72e-12	Electrocardiographic conduction measures;
LUAD	cis	rs62229266	0.839	rs11088335	chr21:37470335	C/T	cg08632701	chr21:37451849	NA	-0.45	-7.67	-0.35	1.22e-13	Mitral valve prolapse;
LUAD	cis	rs4409675	0.576	rs3766396	chr1:28221554	C/T	cg23691781	chr1:28212827	C1orf38	-0.39	-11.18	-0.48	1.39e-25	Corneal astigmatism;
LUAD	cis	rs7223966	0.729	rs9902761	chr17:62010627	A/G	cg06873352	chr17:61820015	STRADA	0.41	6.44	0.3	3.28e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.89	-7.51	-0.34	3.44e-13	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs427941	0.610	rs201489	chr7:101749901	C/T	cg06246474	chr7:101738831	CUX1	0.38	6.51	0.3	2.14e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-8.03	-0.36	1.01e-14	Total body bone mineral density;
LUAD	cis	rs9875589	0.509	rs4685062	chr3:14066409	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	6.61	0.31	1.17e-10	Ovarian reserve;
LUAD	cis	rs2274273	1.000	rs7140872	chr14:55612744	C/T	cg04306507	chr14:55594613	LGALS3	0.37	7.49	0.34	4.04e-13	Protein biomarker;
LUAD	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg07636037	chr3:49044803	WDR6	-0.48	-8.03	-0.36	9.96e-15	Menarche (age at onset);
LUAD	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg03808351	chr9:123631620	PHF19	0.41	6.66	0.31	8.63e-11	Birth weight;
LUAD	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg09509183	chr1:209979624	IRF6	0.57	7.77	0.35	6.04e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs17095355	1.000	rs12263915	chr10:111744664	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.69	-9.27	-0.41	9.35e-19	Biliary atresia;
LUAD	cis	rs17401966	0.964	rs34215045	chr1:10361679	G/A	cg15208524	chr1:10270712	KIF1B	0.55	8.06	0.36	8.15e-15	Hepatocellular carcinoma;
LUAD	cis	rs155346	1.000	rs7728075	chr5:139382353	G/A	cg01090482	chr5:139365336	NRG2	-0.35	-6.65	-0.31	8.86e-11	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUAD	trans	rs9650657	0.769	rs6601527	chr8:10665444	C/A	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.51	-0.3	2.16e-10	Neuroticism;
LUAD	cis	rs677665	0.537	rs12121476	chr1:9335327	C/G	cg25755851	chr1:9335794	NA	0.8	13.83	0.56	3.7e-36	Eosinophil percentage of white cells;
LUAD	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg05110241	chr16:68378359	PRMT7	-0.76	-8.1	-0.37	6.1e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg06697600	chr4:7070879	GRPEL1	-0.51	-8.46	-0.38	4.45e-16	Monocyte percentage of white cells;
LUAD	cis	rs733175	0.830	rs714871	chr4:10059631	G/A	cg00071950	chr4:10020882	SLC2A9	0.46	7.14	0.33	4.19e-12	Psychosis and Alzheimer's disease;
LUAD	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg08779649	chr13:50194554	NA	0.42	8.37	0.38	8.21e-16	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.0	-0.32	9.82e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.38	-6.36	-0.3	5.39e-10	Longevity;Endometriosis;
LUAD	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg04398451	chr17:18023971	MYO15A	-0.88	-16.96	-0.64	1.42e-49	Total body bone mineral density;
LUAD	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	9.65	0.42	4.93e-20	Lung cancer in ever smokers;
LUAD	cis	rs8044868	0.530	rs2241411	chr16:72144493	T/C	cg23815491	chr16:72088622	HP	0.5	9.31	0.41	6.96e-19	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs11112613	0.762	rs66754070	chr12:105949779	G/A	cg03607813	chr12:105948248	NA	0.82	13.9	0.56	1.92e-36	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.51	-0.38	3.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7584330	0.628	rs73098849	chr2:238389739	G/A	cg14458575	chr2:238380390	NA	0.74	11.22	0.48	9.5e-26	Prostate cancer;
LUAD	cis	rs2795502	0.873	rs2795527	chr10:43270240	T/C	cg27426351	chr10:43362370	NA	-0.53	-7.21	-0.33	2.62e-12	Blood protein levels;
LUAD	trans	rs3219090	0.886	rs2377013	chr1:226600665	C/A	cg27539482	chr13:111589090	NA	0.43	7.2	0.33	2.79e-12	Melanoma;
LUAD	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg22508957	chr16:3507546	NAT15	-0.77	-13.23	-0.54	1.12e-33	Tuberculosis;
LUAD	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg24813613	chr7:1882135	MAD1L1	-0.42	-6.74	-0.31	5.22e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08109568	chr15:31115862	NA	0.52	9.05	0.4	5.3e-18	Huntington's disease progression;
LUAD	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg12011299	chr4:100065546	ADH4	-0.72	-13.31	-0.54	5.24e-34	Alcohol dependence;
LUAD	cis	rs28595532	0.623	rs17516540	chr4:119278443	A/G	cg02775129	chr4:119771670	NA	-0.61	-6.63	-0.31	1.03e-10	Cannabis dependence symptom count;
LUAD	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg12310025	chr6:25882481	NA	0.58	9.61	0.42	6.73e-20	Blood metabolite levels;
LUAD	cis	rs1461503	0.900	rs1057704	chr11:122830274	T/C	cg27398637	chr11:122830231	C11orf63	-0.33	-6.37	-0.3	4.97e-10	Menarche (age at onset);
LUAD	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-24.38	-0.76	1.25e-82	Height;
LUAD	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg12927641	chr6:109611667	NA	0.51	8.95	0.4	1.14e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs12548874	0.607	rs12543492	chr8:95891843	C/A	cg16049864	chr8:95962084	TP53INP1	-0.44	-8.48	-0.38	3.85e-16	Hemoglobin concentration;
LUAD	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg09509183	chr1:209979624	IRF6	0.37	6.52	0.3	2e-10	Monobrow;
LUAD	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg00074818	chr8:8560427	CLDN23	0.6	9.39	0.42	3.63e-19	Obesity-related traits;
LUAD	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg02527881	chr3:46936655	PTH1R	0.47	9.33	0.41	5.94e-19	Colorectal cancer;
LUAD	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg25767906	chr1:53392781	SCP2	0.4	7.17	0.33	3.36e-12	Monocyte count;
LUAD	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.93	13.11	0.54	3.37e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.42	6.77	0.31	4.31e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1298062	0.763	rs2387112	chr19:50984853	A/G	cg11430371	chr19:50961752	MYBPC2	0.32	6.48	0.3	2.6e-10	Age of smoking initiation;
LUAD	cis	rs7851660	0.874	rs7847010	chr9:100630439	T/C	cg13688889	chr9:100608707	NA	-0.48	-8.2	-0.37	2.85e-15	Strep throat;
LUAD	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg18854424	chr1:2615690	NA	-0.41	-9.15	-0.41	2.43e-18	Ulcerative colitis;
LUAD	trans	rs1816537	0.935	rs1369819	chr11:112986191	C/T	cg01289020	chr16:71323706	FTSJD1	-0.37	-6.35	-0.3	5.51e-10	Body mass index;
LUAD	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg10518543	chr12:38710700	ALG10B	-0.43	-7.18	-0.33	3.13e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg22920501	chr2:26401640	FAM59B	-0.96	-14.72	-0.58	6.8100000000000004e-40	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.53	0.34	3.08e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.19	-0.44	5.7e-22	Total body bone mineral density;
LUAD	cis	rs938554	0.910	rs10010582	chr4:9937085	C/T	cg00071950	chr4:10020882	SLC2A9	-0.49	-7.76	-0.35	6.61e-14	Blood metabolite levels;
LUAD	cis	rs12618769	0.597	rs4851131	chr2:99036802	A/C	cg10123293	chr2:99228465	UNC50	0.44	7.96	0.36	1.6e-14	Bipolar disorder;
LUAD	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.81	11.54	0.49	5.71e-27	Smoking behavior;
LUAD	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg01324343	chr3:183735012	ABCC5	0.94	25.15	0.77	5.22e-86	Anterior chamber depth;
LUAD	cis	rs2731664	0.792	rs2630764	chr5:176880085	C/T	cg23176889	chr5:176863531	GRK6	-0.68	-12.72	-0.53	1.31e-31	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-7.15	-0.33	3.81e-12	Blood metabolite levels;
LUAD	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.67	-0.35	1.23e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg07741184	chr6:167504864	NA	0.31	7.11	0.33	5.13e-12	Crohn's disease;
LUAD	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08219700	chr8:58056026	NA	0.61	8.59	0.39	1.64e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7945705	0.806	rs12224436	chr11:8815825	C/A	cg12365402	chr11:9010492	NRIP3	0.37	6.47	0.3	2.75e-10	Hemoglobin concentration;
LUAD	cis	rs6430585	1.000	rs6732236	chr2:136501509	T/G	cg07169764	chr2:136633963	MCM6	0.64	8.05	0.36	8.31e-15	Corneal structure;
LUAD	cis	rs701145	0.938	rs1086056	chr3:154088411	T/G	cg17054900	chr3:154042577	DHX36	0.62	6.83	0.32	3e-11	Coronary artery disease;
LUAD	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg07636037	chr3:49044803	WDR6	0.62	11.52	0.49	6.51e-27	Parkinson's disease;
LUAD	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg19773385	chr1:10388646	KIF1B	-0.42	-6.46	-0.3	2.97e-10	Hepatocellular carcinoma;
LUAD	trans	rs9951602	0.512	rs8097996	chr18:76648035	A/G	cg02800362	chr5:177631904	HNRNPAB	0.92	14.21	0.57	9.84e-38	Obesity-related traits;
LUAD	cis	rs4660214	0.666	rs625384	chr1:39893093	C/T	cg27567593	chr1:39956653	BMP8A	-0.34	-6.79	-0.31	3.81e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.42	-6.66	-0.31	8.29e-11	Menarche (age at onset);
LUAD	cis	rs12949688	0.967	rs8064970	chr17:55824687	T/C	cg12582317	chr17:55822272	NA	0.36	7.18	0.33	3.13e-12	Schizophrenia;
LUAD	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg07636037	chr3:49044803	WDR6	0.63	12.17	0.51	1.99e-29	Parkinson's disease;
LUAD	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg06671706	chr8:8559999	CLDN23	0.66	11.4	0.48	1.9e-26	Obesity-related traits;
LUAD	trans	rs1997103	0.911	rs17777	chr7:55380765	T/C	cg20935933	chr6:143382018	AIG1	0.54	7.57	0.35	2.31e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1160297	0.609	rs10208858	chr2:53094982	G/A	cg07782112	chr2:53107842	NA	0.36	7.8	0.35	4.98e-14	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg05896524	chr21:47604654	C21orf56	0.69	12.19	0.51	1.72e-29	Testicular germ cell tumor;
LUAD	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg23281280	chr6:28129359	ZNF389	0.48	6.65	0.31	8.88e-11	Depression;
LUAD	cis	rs4713675	0.565	rs3818524	chr6:33660695	G/C	cg13859433	chr6:33739653	LEMD2	-0.3	-7.0	-0.32	1.02e-11	Plateletcrit;
LUAD	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg18198730	chr1:247681584	NA	0.44	7.62	0.35	1.71e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6782228	0.606	rs10048945	chr3:128409680	C/T	cg16766828	chr3:128327626	NA	-0.4	-7.6	-0.35	1.93e-13	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs4356932	1.000	rs6852075	chr4:76952280	T/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.5	-0.3	2.22e-10	Blood protein levels;
LUAD	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg14552801	chr7:65878734	NA	0.38	6.48	0.3	2.48e-10	Aortic root size;
LUAD	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg20108693	chr8:143823809	SLURP1	0.32	7.29	0.33	1.5e-12	Urinary tract infection frequency;
LUAD	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.49	-8.0	-0.36	1.24e-14	Body mass index;
LUAD	cis	rs11671005	0.735	rs3088284	chr19:58929427	G/A	cg13877915	chr19:58951672	ZNF132	0.56	7.42	0.34	6.67e-13	Mean platelet volume;
LUAD	cis	rs13082711	0.522	rs3103745	chr3:27342927	T/C	cg02860705	chr3:27208620	NA	0.51	8.49	0.38	3.63e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg04352962	chr1:209979756	IRF6	0.51	7.3	0.33	1.48e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg14668632	chr7:2872130	GNA12	-0.69	-12.18	-0.51	1.89e-29	Height;
LUAD	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg17761419	chr8:57350749	NA	-0.52	-7.76	-0.35	6.56e-14	Obesity-related traits;
LUAD	cis	rs4767364	0.614	rs610303	chr12:112145100	C/A	cg10833066	chr12:111807467	FAM109A	0.35	6.65	0.31	9.23e-11	Oral cavity and pharyngeal cancer;
LUAD	cis	rs6906287	0.647	rs57813349	chr6:118763858	C/A	cg21191810	chr6:118973309	C6orf204	0.45	8.72	0.39	6.41e-17	Electrocardiographic conduction measures;
LUAD	cis	rs315934	0.664	rs1688072	chr2:113869347	A/G	cg09040174	chr2:113837401	NA	-0.63	-7.39	-0.34	7.77e-13	Dysmenorrheic pain;
LUAD	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.38	-6.43	-0.3	3.49e-10	Platelet count;
LUAD	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg23992470	chr4:843637	GAK	0.67	7.09	0.33	5.62e-12	Parkinson's disease;
LUAD	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg00310523	chr12:86230176	RASSF9	0.37	7.48	0.34	4.42e-13	Major depressive disorder;
LUAD	cis	rs12765878	1.000	rs11191865	chr10:105672842	G/A	cg11005552	chr10:105648138	OBFC1	0.43	8.17	0.37	3.65e-15	Coronary artery disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19273467	chr1:32110819	PEF1	-0.44	-6.6	-0.31	1.2e-10	Height;
LUAD	cis	rs11671005	0.693	rs11084542	chr19:58932099	T/A	cg13877915	chr19:58951672	ZNF132	0.55	7.3	0.33	1.47e-12	Mean platelet volume;
LUAD	trans	rs4799710	0.537	rs7237757	chr18:31289841	C/T	cg27147174	chr7:100797783	AP1S1	-0.44	-7.03	-0.32	8.55e-12	Pulmonary function;
LUAD	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.44	-0.42	2.51e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11644478	chr21:40555479	PSMG1	-0.58	-9.89	-0.43	6.96e-21	Cognitive function;
LUAD	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.66	-0.31	8.51e-11	Crohn's disease;
LUAD	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg18446336	chr7:2847575	GNA12	-0.32	-6.42	-0.3	3.64e-10	Height;
LUAD	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg14725641	chr11:61582763	MIR1908;FADS1	-0.42	-6.54	-0.3	1.82e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs3087591	0.801	rs2012535	chr17:29561391	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.63	-0.31	1.01e-10	Hip circumference;
LUAD	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg04800585	chr6:26043546	HIST1H2BB	0.44	7.82	0.36	4.39e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs11971779	0.680	rs10085902	chr7:139109105	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	7.16e-11	Diisocyanate-induced asthma;
LUAD	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg22963979	chr7:1858916	MAD1L1	-0.57	-9.56	-0.42	1e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs9300255	0.770	rs12299125	chr12:123862447	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.39	6.71	0.31	6.36e-11	Neutrophil percentage of white cells;
LUAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg08888203	chr3:10149979	C3orf24	0.63	9.79	0.43	1.6e-20	Alzheimer's disease;
LUAD	cis	rs11209185	0.545	rs12030775	chr1:68421189	A/T	cg22082780	chr1:68452167	NA	0.44	9.45	0.42	2.35e-19	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs10504073	0.669	rs62507253	chr8:50028836	C/T	cg00325661	chr8:49890786	NA	0.43	9.42	0.42	3.06e-19	Blood metabolite ratios;
LUAD	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg00504896	chr12:9437009	LOC642846	-0.42	-6.84	-0.32	2.87e-11	Breast size;
LUAD	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg07677032	chr17:61819896	STRADA	0.55	9.93	0.43	4.99e-21	Prudent dietary pattern;
LUAD	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-7.95	-0.36	1.78e-14	Total body bone mineral density;
LUAD	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg25358565	chr5:93447407	FAM172A	0.56	6.65	0.31	8.92e-11	Diabetic retinopathy;
LUAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08677398	chr8:58056175	NA	0.48	6.79	0.31	3.7e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4974559	0.947	rs28540746	chr4:1352954	G/A	cg07757535	chr4:1339547	NA	0.39	6.47	0.3	2.68e-10	Systolic blood pressure;
LUAD	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.55e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2179367	0.613	rs62426122	chr6:149748585	C/G	cg04369109	chr6:150039330	LATS1	-0.43	-6.51	-0.3	2.08e-10	Dupuytren's disease;
LUAD	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg04731861	chr2:219085781	ARPC2	-0.25	-7.58	-0.35	2.16e-13	Colorectal cancer;
LUAD	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-11.52	-0.49	7.08e-27	Hemoglobin concentration;
LUAD	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg07570687	chr10:102243282	WNT8B	0.48	7.31	0.33	1.33e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg21724239	chr8:58056113	NA	0.65	8.02	0.36	1.07e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg21385522	chr1:16154831	NA	0.58	8.61	0.39	1.43e-16	Dilated cardiomyopathy;
LUAD	cis	rs10193935	0.901	rs92303	chr2:42656337	A/G	cg27598129	chr2:42591480	NA	0.68	8.93	0.4	1.29e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg08219700	chr8:58056026	NA	0.5	7.19	0.33	2.94e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg17911788	chr17:44343683	NA	-0.52	-7.28	-0.33	1.6e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7291412	1.000	rs7291412	chr22:46459132	G/T	cg23691090	chr22:46449981	C22orf26;LOC150381	0.37	6.63	0.31	1.01e-10	Dupuytren's disease;Subjective well-being;
LUAD	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg03037974	chr15:76606532	NA	0.38	7.97	0.36	1.44e-14	Blood metabolite levels;
LUAD	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg20701182	chr2:24300061	SF3B14	0.89	13.3	0.54	5.5e-34	Lymphocyte counts;
LUAD	cis	rs41271951	0.512	rs34761930	chr1:151089523	T/C	cg11822372	chr1:151115635	SEMA6C	-0.84	-7.1	-0.33	5.16e-12	Blood protein levels;
LUAD	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg04369109	chr6:150039330	LATS1	-0.42	-6.93	-0.32	1.57e-11	Lung cancer;
LUAD	cis	rs7177699	0.557	rs7164479	chr15:79123054	C/T	cg15571903	chr15:79123663	NA	0.42	8.82	0.39	3e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg24675056	chr1:15929824	NA	0.49	8.39	0.38	7.1e-16	Systolic blood pressure;
LUAD	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg19729930	chr2:74357872	NA	0.99	18.37	0.67	7.85e-56	Gestational age at birth (maternal effect);
LUAD	trans	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg11693508	chr17:37793320	STARD3	0.6	7.7	0.35	1e-13	Neuroticism;
LUAD	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg17063962	chr7:91808500	NA	0.68	12.31	0.51	5.78e-30	Breast cancer;
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg07719772	chr16:32360419	NA	-0.48	-7.6	-0.35	1.98e-13	Menopause (age at onset);
LUAD	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg11584989	chr19:19387371	SF4	-0.39	-6.64	-0.31	9.5e-11	Tonsillectomy;
LUAD	trans	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.42	0.42	3.03e-19	Mean corpuscular volume;
LUAD	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.41	-7.14	-0.33	4.06e-12	Platelet count;
LUAD	cis	rs3007168	1.000	rs2999360	chr14:51605429	G/A	cg23942311	chr14:51606299	NA	0.53	7.31	0.33	1.35e-12	Cancer;
LUAD	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg21724239	chr8:58056113	NA	0.81	9.79	0.43	1.53e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs9302635	0.513	rs9923575	chr16:72230112	C/T	cg23815491	chr16:72088622	HP	0.5	7.69	0.35	1.06e-13	Blood protein levels;
LUAD	cis	rs3087591	0.960	rs4795587	chr17:29587917	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.43	-6.91	-0.32	1.77e-11	Hip circumference;
LUAD	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.44	-0.38	5.08e-16	Prostate cancer;
LUAD	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.91	-0.32	1.81e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg04267008	chr7:1944627	MAD1L1	-0.65	-9.89	-0.43	6.75e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.69	10.6	0.46	1.95e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.16	0.48	1.61e-25	Height;
LUAD	cis	rs1045714	0.895	rs73043180	chr7:2645972	C/T	cg20813462	chr7:2646259	IQCE	0.64	7.15	0.33	3.89e-12	Urate levels in lean individuals;
LUAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg10862848	chr6:42927986	GNMT	-0.34	-9.65	-0.42	4.84e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg05313129	chr8:58192883	C8orf71	-0.61	-7.53	-0.34	3.15e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2446066	0.659	rs11170566	chr12:53907067	C/T	cg20730629	chr12:53886622	MAP3K12	-0.5	-7.4	-0.34	7.64e-13	Red blood cell count;
LUAD	trans	rs57046232	0.552	rs6054184	chr20:6354592	A/G	cg21095983	chr6:86352623	SYNCRIP	0.43	6.64	0.31	9.49e-11	Colorectal cancer;
LUAD	cis	rs67366981	0.720	rs4447349	chr14:77685381	G/A	cg22824376	chr14:77648248	TMEM63C	0.84	9.9	0.43	6.32e-21	Obsessive-compulsive symptoms;
LUAD	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg14671364	chr1:107599128	PRMT6	-0.62	-10.67	-0.46	1.05e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6752107	0.967	rs55835501	chr2:234157733	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.53	9.01	0.4	6.97e-18	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg00339695	chr16:24857497	SLC5A11	-0.55	-9.84	-0.43	1.07e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.41	0.34	6.91e-13	Tonsillectomy;
LUAD	cis	rs868036	1.000	rs4633663	chr15:68106378	G/C	cg24579218	chr15:68104479	NA	-0.4	-7.51	-0.34	3.54e-13	Restless legs syndrome;
LUAD	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg24818145	chr4:99064322	C4orf37	0.47	8.02	0.36	1.06e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23583168	chr7:148888333	NA	-0.91	-18.84	-0.68	6.36e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-8.96	-0.4	1.08e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg21475434	chr5:93447410	FAM172A	0.71	8.45	0.38	4.6e-16	Diabetic retinopathy;
LUAD	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-8.17	-0.37	3.6e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7809950	1.000	rs987391	chr7:107100794	C/G	cg23024343	chr7:107201750	COG5	-0.71	-11.99	-0.5	1.05e-28	Coronary artery disease;
LUAD	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg17063962	chr7:91808500	NA	0.71	12.57	0.52	5.43e-31	Breast cancer;
LUAD	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg16472389	chr18:74514291	NA	0.65	10.46	0.45	6.54e-23	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LUAD	cis	rs2806561	0.769	rs2235547	chr1:23406485	C/G	cg19743168	chr1:23544995	NA	-0.37	-6.65	-0.31	8.9e-11	Height;
LUAD	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg26647111	chr11:31128758	NA	-0.46	-7.98	-0.36	1.42e-14	Red blood cell count;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg25820224	chr2:95787551	MRPS5	-0.37	-6.66	-0.31	8.75e-11	Schizophrenia;
LUAD	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg00933542	chr6:150070202	PCMT1	0.35	7.41	0.34	7.13e-13	Testicular germ cell tumor;
LUAD	cis	rs6594713	0.566	rs35093510	chr5:112925555	A/G	cg12552261	chr5:112820674	MCC	0.52	6.95	0.32	1.37e-11	Brain cytoarchitecture;
LUAD	trans	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg18335740	chr13:41363409	SLC25A15	0.66	12.06	0.51	5.22e-29	Lewy body disease;
LUAD	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg08798685	chr6:27730294	NA	-0.66	-7.61	-0.35	1.84e-13	Depression;
LUAD	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg03929089	chr4:120376271	NA	-0.98	-20.51	-0.71	2.14e-65	Height;
LUAD	cis	rs7267979	0.932	rs6138588	chr20:25487523	C/T	cg08601574	chr20:25228251	PYGB	0.42	7.61	0.35	1.8e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg03037974	chr15:76606532	NA	0.38	7.97	0.36	1.5e-14	Blood metabolite levels;
LUAD	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg03983476	chr2:10830698	NOL10	-0.46	-8.0	-0.36	1.18e-14	Prostate cancer;
LUAD	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.0	0.32	9.9e-12	Motion sickness;
LUAD	cis	rs8002180	0.959	rs8001475	chr13:95922407	T/C	cg24476569	chr13:95954382	ABCC4	0.39	6.36	0.3	5.12e-10	Blood metabolite levels;
LUAD	cis	rs7561273	0.586	rs7580772	chr2:24357657	T/C	cg20701182	chr2:24300061	SF3B14	0.46	7.52	0.34	3.31e-13	Quantitative traits;
LUAD	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg18252515	chr7:66147081	NA	0.6	6.66	0.31	8.3e-11	Diabetic kidney disease;
LUAD	cis	rs478304	0.593	rs75162774	chr11:65492483	G/A	cg05805236	chr11:65401703	PCNXL3	-0.55	-8.92	-0.4	1.45e-17	Acne (severe);
LUAD	cis	rs8192282	0.739	rs6687112	chr1:154497146	C/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.45	-6.93	-0.32	1.63e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.88	-0.5	2.72e-28	Electroencephalogram traits;
LUAD	cis	rs1728785	0.901	rs8050289	chr16:68566976	T/A	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.3100000000000001e-10	Ulcerative colitis;
LUAD	cis	rs7119	0.667	rs907392	chr15:77903393	T/C	cg27398640	chr15:77910606	LINGO1	0.39	7.48	0.34	4.28e-13	Type 2 diabetes;
LUAD	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg24848339	chr3:12840334	CAND2	0.43	8.63	0.39	1.3e-16	QRS complex (12-leadsum);
LUAD	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg06766960	chr11:133703094	NA	-0.46	-8.66	-0.39	1.01e-16	Childhood ear infection;
LUAD	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.27	-7.08	-0.33	6e-12	Total body bone mineral density;
LUAD	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg13319975	chr6:146136371	FBXO30	0.62	10.42	0.45	8.91e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2108225	0.934	rs2190392	chr7:107452685	T/C	cg18560240	chr7:107437656	SLC26A3	-0.41	-6.74	-0.31	5.25e-11	Ulcerative colitis;
LUAD	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg06199346	chr11:14280333	SPON1	0.37	7.94	0.36	1.85e-14	Mitochondrial DNA levels;
LUAD	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg13685833	chr1:53393034	SCP2	-0.5	-7.95	-0.36	1.7e-14	Monocyte count;
LUAD	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg27266060	chr8:22091797	NA	-0.48	-8.68	-0.39	8.53e-17	Hypertriglyceridemia;
LUAD	cis	rs73195822	0.614	rs1123852	chr12:111221408	C/G	cg12870014	chr12:110450643	ANKRD13A	0.61	6.74	0.31	5.22e-11	Itch intensity from mosquito bite;
LUAD	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19717773	chr7:2847554	GNA12	-0.56	-9.68	-0.43	3.74e-20	Height;
LUAD	cis	rs17092148	1.000	rs11699062	chr20:33400379	A/T	cg16810054	chr20:33298113	TP53INP2	0.53	8.2	0.37	2.81e-15	Neuroticism;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg21930229	chr1:32758033	HDAC1	-0.41	-6.73	-0.31	5.7e-11	Subcortical brain region volumes;
LUAD	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg27170947	chr2:26402098	FAM59B	-0.61	-8.63	-0.39	1.23e-16	Gut microbiome composition (summer);
LUAD	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg23254163	chr1:152506842	NA	0.26	7.18	0.33	3.21e-12	Hair morphology;
LUAD	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg07936489	chr17:37558343	FBXL20	0.56	7.53	0.34	3.16e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg27588902	chr6:42928151	GNMT	0.33	8.95	0.4	1.14e-17	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg12863693	chr15:85201151	NMB	-0.29	-6.37	-0.3	5.02e-10	P wave terminal force;
LUAD	trans	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg19862616	chr7:65841803	NCRNA00174	1.07	27.87	0.8	8.31e-98	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg19318889	chr4:1322082	MAEA	-0.73	-12.56	-0.52	5.44e-31	Obesity-related traits;
LUAD	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22857025	chr5:266934	NA	-0.96	-14.42	-0.57	1.32e-38	Breast cancer;
LUAD	cis	rs4588572	0.537	rs7705718	chr5:77730349	T/C	cg11547950	chr5:77652471	NA	-0.62	-10.65	-0.46	1.3e-23	Triglycerides;
LUAD	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg00933542	chr6:150070202	PCMT1	0.45	9.92	0.43	5.41e-21	Lung cancer;
LUAD	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg03474202	chr17:45855739	NA	-0.38	-9.33	-0.41	6.2e-19	IgG glycosylation;
LUAD	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg25985355	chr7:65971099	NA	-0.4	-7.38	-0.34	8.44e-13	Aortic root size;
LUAD	cis	rs7580658	0.534	rs2089109	chr2:127951458	G/A	cg16751203	chr2:127950803	CYP27C1	0.4	6.76	0.31	4.47e-11	Protein C levels;
LUAD	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03517284	chr6:25882590	NA	-0.42	-6.78	-0.31	4.14e-11	Height;
LUAD	cis	rs35883536	0.588	rs10465764	chr1:101105030	A/G	cg06223162	chr1:101003688	GPR88	0.39	7.25	0.33	2.06e-12	Monocyte count;
LUAD	cis	rs113835537	0.529	rs3816492	chr11:66297363	C/T	cg24851651	chr11:66362959	CCS	0.58	9.81	0.43	1.28e-20	Airway imaging phenotypes;
LUAD	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg11502198	chr6:26597334	ABT1	0.85	11.5	0.49	7.82e-27	Small cell lung carcinoma;
LUAD	cis	rs6669072	0.647	rs2954561	chr1:91240853	G/A	cg08895590	chr1:91227319	NA	-0.32	-6.64	-0.31	9.82e-11	Cognitive function;
LUAD	cis	rs4790333	0.529	rs3101409	chr17:2258147	C/T	cg27406664	chr17:2294951	MNT	0.4	8.09	0.37	6.2e-15	Proinsulin levels;
LUAD	cis	rs7851660	0.844	rs10119760	chr9:100624602	G/C	cg13688889	chr9:100608707	NA	-0.5	-8.51	-0.38	3.05e-16	Strep throat;
LUAD	cis	rs3204270	0.639	rs6565620	chr17:79658100	C/T	cg18367735	chr17:79674897	NA	0.52	6.81	0.31	3.29e-11	Dental caries;
LUAD	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg04398451	chr17:18023971	MYO15A	0.66	11.83	0.5	4.22e-28	Total body bone mineral density;
LUAD	cis	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg23950597	chr19:37808831	NA	-0.61	-7.51	-0.34	3.54e-13	Coronary artery calcification;
LUAD	trans	rs375092	0.543	rs6461708	chr7:23415317	A/C	cg00661347	chr10:71661228	COL13A1	0.34	6.63	0.31	1.03e-10	Personality dimensions;
LUAD	trans	rs114934997	1.000	rs56054640	chr5:40385142	T/C	cg19995539	chr12:120539137	RAB35	-0.62	-6.59	-0.31	1.32e-10	Psoriasis;
LUAD	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg22117172	chr7:91764530	CYP51A1	-0.34	-7.41	-0.34	6.72e-13	Breast cancer;
LUAD	cis	rs1595825	0.891	rs16826895	chr2:198901642	A/G	cg11031976	chr2:198649780	BOLL	-0.46	-6.61	-0.31	1.14e-10	Ulcerative colitis;
LUAD	cis	rs11809207	0.501	rs2232654	chr1:26496870	A/G	cg00300879	chr1:26503847	CNKSR1	0.28	7.73	0.35	8.16e-14	Height;
LUAD	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.71	0.35	8.88e-14	Platelet count;
LUAD	cis	rs12618769	0.652	rs3769698	chr2:99233894	T/C	cg10123293	chr2:99228465	UNC50	0.5	8.9	0.4	1.67e-17	Bipolar disorder;
LUAD	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg09117114	chr16:67998030	SLC12A4	-0.62	-8.12	-0.37	5.14e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.43	-8.03	-0.36	9.85e-15	IgG glycosylation;
LUAD	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg04731861	chr2:219085781	ARPC2	-0.23	-7.09	-0.33	5.71e-12	Colorectal cancer;
LUAD	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg06784218	chr1:46089804	CCDC17	-0.6	-13.55	-0.55	5.61e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs807669	0.807	rs712948	chr22:19206499	A/G	cg24911827	chr22:19170109	CLTCL1	0.43	8.57	0.38	1.92e-16	Metabolite levels;
LUAD	cis	rs72949976	0.584	rs12471471	chr2:214023052	C/T	cg08319019	chr2:214017104	IKZF2	-0.59	-9.14	-0.41	2.56e-18	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs10504073	0.647	rs4873317	chr8:50021111	C/T	cg00325661	chr8:49890786	NA	0.44	9.89	0.43	7.09e-21	Blood metabolite ratios;
LUAD	cis	rs9522267	0.707	rs9522282	chr13:112222410	T/C	cg10483660	chr13:112241077	NA	-0.32	-6.6	-0.31	1.25e-10	Hepatitis;
LUAD	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg25753631	chr6:25732923	NA	-0.37	-6.48	-0.3	2.5e-10	Iron status biomarkers;
LUAD	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg03859395	chr2:55845619	SMEK2	0.74	13.8	0.56	5.19e-36	Metabolic syndrome;
LUAD	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.68	0.31	7.58e-11	Depression;
LUAD	trans	rs7944735	0.702	rs60515486	chr11:47682725	A/T	cg15704280	chr7:45808275	SEPT13	0.55	7.31	0.33	1.35e-12	Intraocular pressure;
LUAD	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg08885076	chr2:99613938	TSGA10	-0.41	-7.0	-0.32	9.96e-12	Chronic sinus infection;
LUAD	cis	rs231513	0.954	rs231510	chr17:41966470	T/C	cg26893861	chr17:41843967	DUSP3	-0.54	-6.55	-0.3	1.65e-10	Cognitive function;
LUAD	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg25237894	chr2:233734115	C2orf82	0.62	11.84	0.5	3.84e-28	Coronary artery disease;
LUAD	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg21475434	chr5:93447410	FAM172A	0.74	8.54	0.38	2.41e-16	Diabetic retinopathy;
LUAD	cis	rs6499255	0.951	rs12595878	chr16:69628217	C/T	cg15192750	chr16:69999425	NA	0.53	8.39	0.38	7.44e-16	IgE levels;
LUAD	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-15.21	-0.59	5.52e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg08632164	chr7:65971372	NA	-0.54	-6.42	-0.3	3.69e-10	Diabetic kidney disease;
LUAD	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg04565464	chr8:145669602	NFKBIL2	0.43	6.57	0.3	1.49e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2857078	0.654	rs9896789	chr17:42314567	C/T	cg13607699	chr17:42295918	UBTF	0.58	9.48	0.42	1.81e-19	Red cell distribution width;Reticulocyte count;
LUAD	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg05991184	chr2:219186017	PNKD	-0.35	-6.77	-0.31	4.37e-11	Colorectal cancer;
LUAD	trans	rs1816537	0.904	rs4492854	chr11:112983534	C/T	cg01289020	chr16:71323706	FTSJD1	-0.38	-6.48	-0.3	2.51e-10	Body mass index;
LUAD	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03517284	chr6:25882590	NA	-0.58	-9.56	-0.42	9.84e-20	Blood metabolite levels;
LUAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg13047869	chr3:10149882	C3orf24	0.6	10.1	0.44	1.27e-21	Alzheimer's disease;
LUAD	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg09904177	chr6:26538194	HMGN4	0.44	7.36	0.34	9.71e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs8067287	0.708	rs56408153	chr17:16841034	G/C	cg26910001	chr17:16838321	NA	-0.47	-6.67	-0.31	7.97e-11	Diabetic kidney disease;
LUAD	cis	rs6669919	0.530	rs11587621	chr1:211668400	C/T	cg10512769	chr1:211675356	NA	0.4	8.11	0.37	5.35e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs877282	0.853	rs11595510	chr10:756757	C/G	cg06581033	chr10:766294	NA	-0.56	-7.65	-0.35	1.41e-13	Uric acid levels;
LUAD	cis	rs11098699	0.784	rs7693178	chr4:124247394	T/G	cg09941581	chr4:124220074	SPATA5	0.43	6.83	0.32	2.93e-11	Mosquito bite size;
LUAD	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg18105134	chr13:113819100	PROZ	-1.05	-19.34	-0.68	3.82e-60	Platelet distribution width;
LUAD	cis	rs62238980	0.614	rs77099614	chr22:32452759	A/G	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs8112211	0.834	rs3843754	chr19:38807184	G/A	cg14299480	chr19:38876666	GGN	-0.39	-6.83	-0.31	3.04e-11	Blood protein levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21985132	chr20:42086626	SFRS6	-0.45	-7.23	-0.33	2.26e-12	Height;
LUAD	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-7.52	-0.34	3.35e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs17095355	1.000	rs72828232	chr10:111725298	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.65	-7.98	-0.36	1.4e-14	Biliary atresia;
LUAD	trans	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg01620082	chr3:125678407	NA	-0.71	-7.12	-0.33	4.55e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.3	0.51	6.42e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg01689657	chr7:91764605	CYP51A1	-0.31	-7.53	-0.34	3.17e-13	Breast cancer;
LUAD	cis	rs6906287	0.647	rs3951042	chr6:118722495	C/T	cg21191810	chr6:118973309	C6orf204	0.5	9.64	0.42	5.35e-20	Electrocardiographic conduction measures;
LUAD	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg20673091	chr1:2541236	MMEL1	0.41	8.62	0.39	1.35e-16	Ulcerative colitis;
LUAD	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg23649088	chr2:200775458	C2orf69	0.64	8.42	0.38	6.03e-16	Schizophrenia;
LUAD	trans	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	9.53	0.42	1.21e-19	Mean corpuscular volume;
LUAD	cis	rs7122539	0.734	rs4930391	chr11:66645254	A/G	cg24851651	chr11:66362959	CCS	-0.37	-6.69	-0.31	7.29e-11	HIV-1 susceptibility;
LUAD	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.7	-13.68	-0.55	1.58e-35	Ulcerative colitis;
LUAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg18402987	chr7:1209562	NA	0.7	8.92	0.4	1.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg16988262	chr1:15930761	NA	0.42	6.95	0.32	1.37e-11	Systolic blood pressure;
LUAD	cis	rs2880765	0.743	rs6416598	chr15:86011848	G/A	cg13263323	chr15:86062960	AKAP13	-0.48	-8.64	-0.39	1.14e-16	Coronary artery disease;
LUAD	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-8.37	-0.38	8.2e-16	Gut microbiome composition (summer);
LUAD	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg17366294	chr4:99064904	C4orf37	0.48	8.4	0.38	7.08e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg14834391	chr1:2537342	MMEL1	-0.31	-6.53	-0.3	1.83e-10	Ulcerative colitis;
LUAD	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg13073564	chr4:8508604	NA	0.45	7.68	0.35	1.09e-13	Response to antineoplastic agents;
LUAD	cis	rs701145	0.938	rs701147	chr3:154048295	C/T	cg17054900	chr3:154042577	DHX36	0.65	7.15	0.33	3.84e-12	Coronary artery disease;
LUAD	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg19318889	chr4:1322082	MAEA	0.46	7.45	0.34	5.27e-13	Obesity-related traits;
LUAD	cis	rs8067545	0.641	rs850623	chr17:19837130	C/T	cg04132472	chr17:19861366	AKAP10	0.39	9.25	0.41	1.13e-18	Schizophrenia;
LUAD	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg00666640	chr1:248458726	OR2T12	0.3	7.22	0.33	2.5e-12	Common traits (Other);
LUAD	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg04398451	chr17:18023971	MYO15A	0.64	11.41	0.49	1.72e-26	Total body bone mineral density;
LUAD	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.61	-10.26	-0.45	3.34e-22	Glomerular filtration rate;
LUAD	cis	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.81	-0.31	3.46e-11	Neuroticism;
LUAD	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg05044414	chr3:183734942	ABCC5	0.33	6.36	0.3	5.19e-10	Anterior chamber depth;
LUAD	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06022373	chr22:39101656	GTPBP1	0.45	7.56	0.35	2.51e-13	Menopause (age at onset);
LUAD	cis	rs7680126	0.596	rs10805364	chr4:10275518	A/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.49	-0.3	2.37e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.26	0.54	8.7e-34	Tonsillectomy;
LUAD	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.68	0.49	1.59e-27	Colorectal cancer;
LUAD	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg00857998	chr1:205179979	DSTYK	0.4	6.59	0.31	1.33e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs7481584	0.624	rs1077335	chr11:3030524	A/G	cg08508325	chr11:3079039	CARS	0.45	9.12	0.41	3.17e-18	Calcium levels;
LUAD	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg21475434	chr5:93447410	FAM172A	-0.72	-8.5	-0.38	3.25e-16	Diabetic retinopathy;
LUAD	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg27432699	chr2:27873401	GPN1	-0.4	-6.86	-0.32	2.41e-11	Total body bone mineral density;
LUAD	cis	rs7681423	1.000	rs7681423	chr4:155542248	C/T	cg20735720	chr4:155535218	FGG	-0.5	-7.17	-0.33	3.42e-12	Fibrinogen;
LUAD	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.09	0.33	5.8e-12	Rheumatoid arthritis;
LUAD	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg22920501	chr2:26401640	FAM59B	0.96	13.88	0.56	2.24e-36	Gut microbiome composition (summer);
LUAD	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg01689657	chr7:91764605	CYP51A1	0.37	9.01	0.4	7.36e-18	Breast cancer;
LUAD	cis	rs59698941	0.943	rs66685494	chr5:132291056	A/G	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs240764	0.604	rs9322173	chr6:101203889	G/A	cg09795085	chr6:101329169	ASCC3	0.4	6.85	0.32	2.56e-11	Neuroticism;
LUAD	cis	rs4764487	0.735	rs3181291	chr12:6341499	C/T	cg08284733	chr12:6341482	CD9	0.4	7.36	0.34	9.45e-13	Mean platelet volume;
LUAD	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg24069376	chr3:38537580	EXOG	-0.44	-10.84	-0.47	2.5e-24	Electrocardiographic conduction measures;
LUAD	trans	rs208520	0.690	rs851467	chr6:66802721	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-17.73	-0.65	5.21e-53	Exhaled nitric oxide output;
LUAD	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-6.45	-0.3	3.1e-10	Personality dimensions;
LUAD	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg15017067	chr4:17643749	FAM184B	0.37	7.19	0.33	2.93e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4889855	0.505	rs12952775	chr17:78607820	A/G	cg16591659	chr17:78472290	NA	-0.43	-7.48	-0.34	4.25e-13	Fractional excretion of uric acid;
LUAD	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg25894440	chr7:65020034	NA	0.66	7.03	0.32	8.44e-12	Diabetic kidney disease;
LUAD	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg25208724	chr1:156163844	SLC25A44	1.09	20.99	0.71	1.47e-67	Testicular germ cell tumor;
LUAD	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.56	-0.35	2.48e-13	Lung cancer;
LUAD	cis	rs7617773	0.780	rs11710257	chr3:48373214	T/G	cg11946769	chr3:48343235	NME6	0.44	6.68	0.31	7.32e-11	Coronary artery disease;
LUAD	cis	rs10821973	0.527	rs10740065	chr10:63976415	A/C	cg09941381	chr10:64027924	RTKN2	-0.34	-6.74	-0.31	5.22e-11	Hypothyroidism;
LUAD	cis	rs6545883	1.000	rs778763	chr2:61785639	C/G	cg15711740	chr2:61764176	XPO1	-0.43	-6.93	-0.32	1.57e-11	Tuberculosis;
LUAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-9.2	-0.41	1.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs13082711	0.522	rs653076	chr3:27343691	T/C	cg02860705	chr3:27208620	NA	0.49	8.33	0.38	1.12e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg17182837	chr8:41585554	ANK1	-0.35	-7.1	-0.33	5.27e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUAD	cis	rs41311933	0.656	rs72760205	chr9:123835704	G/A	cg13567360	chr9:123745713	C5	-0.72	-8.46	-0.38	4.28e-16	Coronary artery disease;
LUAD	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg09835421	chr16:68378352	PRMT7	-0.72	-9.32	-0.41	6.59e-19	Schizophrenia;
LUAD	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg08439880	chr3:133502540	NA	-0.36	-6.89	-0.32	2.05e-11	Iron status biomarkers;
LUAD	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg12863693	chr15:85201151	NMB	0.43	7.96	0.36	1.63e-14	Schizophrenia;
LUAD	cis	rs72634258	0.554	rs12745962	chr1:7919825	C/T	cg26816564	chr1:7831052	VAMP3	0.59	8.09	0.37	6.29e-15	Inflammatory bowel disease;
LUAD	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg16205897	chr5:131564050	P4HA2	0.35	7.31	0.33	1.38e-12	Acylcarnitine levels;
LUAD	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg19622623	chr12:86230825	RASSF9	0.44	7.8	0.35	4.93e-14	Major depressive disorder;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg27120934	chr6:129480619	LAMA2	0.42	6.68	0.31	7.68e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs7191439	0.583	rs9935872	chr16:88788477	A/G	cg27087555	chr16:88793112	FAM38A	-1.03	-10.62	-0.46	1.57e-23	Plateletcrit;
LUAD	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg13770153	chr20:60521292	NA	-0.57	-9.52	-0.42	1.33e-19	Body mass index;
LUAD	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg17747265	chr1:1875780	NA	-0.75	-18.11	-0.66	1.11e-54	Body mass index;
LUAD	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.54	-0.3	1.76e-10	Breast cancer;
LUAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg14789911	chr21:47582049	C21orf56	0.42	7.13	0.33	4.51e-12	Testicular germ cell tumor;
LUAD	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg12311346	chr5:56204834	C5orf35	-0.92	-13.47	-0.55	1.2e-34	Initial pursuit acceleration;
LUAD	cis	rs1232027	0.632	rs60244599	chr5:79926427	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg07256732	chr16:621771	PIGQ	-0.33	-6.7	-0.31	6.85e-11	Height;
LUAD	cis	rs17102423	0.685	rs4899161	chr14:65540901	G/A	cg11161011	chr14:65562177	MAX	-0.46	-7.7	-0.35	9.78e-14	Obesity-related traits;
LUAD	cis	rs17270561	0.541	rs17586946	chr6:25939053	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.62	-7.93	-0.36	1.99e-14	Iron status biomarkers;
LUAD	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg16797656	chr11:68205561	LRP5	0.46	9.03	0.4	5.97e-18	Total body bone mineral density;
LUAD	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg13180566	chr4:1052158	NA	-0.4	-6.92	-0.32	1.73e-11	Recombination rate (females);
LUAD	cis	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.86	-0.32	2.44e-11	Endometrial cancer;
LUAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg18305652	chr10:134549665	INPP5A	0.62	12.11	0.51	3.6e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	trans	rs6495785	0.678	rs12906493	chr15:35933286	T/C	cg04307083	chr4:57521138	HOPX	-0.36	-6.87	-0.32	2.27e-11	Menopause (age at onset);
LUAD	cis	rs4917300	0.669	rs4917294	chr8:143119767	C/A	cg25363559	chr8:143086065	NA	-0.4	-8.1	-0.37	5.85e-15	Amyotrophic lateral sclerosis;
LUAD	trans	rs208520	0.706	rs851601	chr6:66893853	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-14.77	-0.58	4.19e-40	Exhaled nitric oxide output;
LUAD	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg13902645	chr11:5959945	NA	-0.56	-10.81	-0.47	3.23e-24	DNA methylation (variation);
LUAD	cis	rs10979	0.557	rs9390116	chr6:143907577	A/G	cg25407410	chr6:143891975	LOC285740	-0.55	-7.69	-0.35	1.05e-13	Hypospadias;
LUAD	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg03948781	chr1:205179583	DSTYK	0.35	6.43	0.3	3.44e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs4604732	0.588	rs6677477	chr1:247629411	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.23	0.33	2.26e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs68170813	0.559	rs17350182	chr7:106909637	T/A	cg02696742	chr7:106810147	HBP1	-0.79	-10.81	-0.47	3.21e-24	Coronary artery disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06474646	chr7:128864675	AHCYL2	-0.57	-7.0	-0.32	1.01e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg25753631	chr6:25732923	NA	0.43	7.7	0.35	9.49e-14	Iron status biomarkers;
LUAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg00080972	chr5:178986291	RUFY1	-0.62	-11.04	-0.47	4.55e-25	Lung cancer;
LUAD	cis	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-7.05	-0.32	7.21e-12	Bipolar disorder;
LUAD	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	9.4e-15	Tonsillectomy;
LUAD	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg06558623	chr16:89946397	TCF25	-0.65	-7.42	-0.34	6.64e-13	Skin colour saturation;
LUAD	cis	rs2239547	0.603	rs7644973	chr3:53082937	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-8.79	-0.39	3.69e-17	Schizophrenia;
LUAD	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg17173187	chr15:85201210	NMB	0.53	9.42	0.42	2.89e-19	Schizophrenia;
LUAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.5e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg27535305	chr1:53392650	SCP2	-0.33	-6.79	-0.31	3.74e-11	Monocyte count;
LUAD	cis	rs89107	0.675	rs283080	chr6:118606000	C/A	cg18833306	chr6:118973337	C6orf204	0.51	9.19	0.41	1.79e-18	Cardiac structure and function;
LUAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg11062466	chr8:58055876	NA	0.66	8.51	0.38	3.1e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6691722	0.506	rs11587667	chr1:24715435	C/G	cg18323236	chr1:24743029	NIPAL3	0.45	7.68	0.35	1.15e-13	Response to interferon beta in multiple sclerosis;
LUAD	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg20503657	chr10:835505	NA	0.7	8.74	0.39	5.69e-17	Eosinophil percentage of granulocytes;
LUAD	cis	rs877282	0.945	rs10904555	chr10:787740	C/A	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24531977	chr5:56204891	C5orf35	-0.85	-12.84	-0.53	4.08e-32	Initial pursuit acceleration;
LUAD	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg12935359	chr14:103987150	CKB	-0.48	-7.77	-0.35	6.09e-14	Body mass index;
LUAD	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.55	-0.34	2.79e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg05110241	chr16:68378359	PRMT7	-0.81	-8.62	-0.39	1.31e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg04267008	chr7:1944627	MAD1L1	-0.75	-12.25	-0.51	9.53e-30	Bipolar disorder and schizophrenia;
LUAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10150615	chr22:24372951	LOC391322	0.53	8.6	0.39	1.62e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg25894440	chr7:65020034	NA	0.67	7.18	0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.47	-8.84	-0.39	2.62e-17	Lymphocyte counts;
LUAD	cis	rs3820068	0.871	rs11585808	chr1:15805662	C/T	cg24675056	chr1:15929824	NA	0.44	6.62	0.31	1.12e-10	Systolic blood pressure;
LUAD	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-6.99	-0.32	1.05e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg05373962	chr22:49881684	NA	-0.53	-12.76	-0.53	8.78e-32	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs12286929	0.609	rs12791813	chr11:115091510	G/A	cg04055981	chr11:115044050	NA	0.41	7.14	0.33	4.05e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg16414030	chr3:133502952	NA	-0.72	-14.61	-0.58	1.95e-39	Iron status biomarkers;
LUAD	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.08	-0.33	6.05e-12	Blood metabolite levels;
LUAD	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg15704280	chr7:45808275	SEPT13	-1.0	-20.27	-0.7	2.52e-64	Height;
LUAD	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.33	0.38	1.13e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11696501	0.895	rs6065823	chr20:44114873	C/T	cg11783356	chr20:44313418	WFDC10B	0.46	7.2	0.33	2.74e-12	Brain structure;
LUAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06873352	chr17:61820015	STRADA	0.83	18.58	0.67	9.19e-57	Prudent dietary pattern;
LUAD	cis	rs4888262	0.526	rs13330282	chr16:74572373	C/T	cg01733217	chr16:74700730	RFWD3	0.48	8.12	0.37	5.28e-15	Testicular germ cell tumor;
LUAD	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg25554036	chr4:6271136	WFS1	0.66	13.28	0.54	6.65e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg13180566	chr4:1052158	NA	-0.4	-6.77	-0.31	4.25e-11	Recombination rate (females);
LUAD	cis	rs9814567	0.502	rs12634127	chr3:134256159	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-8.86	-0.4	2.31e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg04450456	chr4:17643702	FAM184B	-0.42	-8.24	-0.37	2.17e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg04450456	chr4:17643702	FAM184B	0.38	7.37	0.34	8.86e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg06046430	chr4:77819534	ANKRD56	0.54	8.62	0.39	1.31e-16	Emphysema distribution in smoking;
LUAD	cis	rs4462272	0.557	rs3904036	chr10:101998414	T/C	cg19754520	chr10:101825118	CPN1	-0.3	-6.39	-0.3	4.37e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6541297	0.703	rs57992758	chr1:230314396	A/G	cg20703242	chr1:230279135	GALNT2	-0.48	-7.07	-0.32	6.64e-12	Coronary artery disease;
LUAD	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06873352	chr17:61820015	STRADA	0.54	8.85	0.4	2.33e-17	Height;
LUAD	cis	rs2235649	0.663	rs113908028	chr16:1848915	G/C	cg08610935	chr16:1836813	NUBP2	-0.5	-7.71	-0.35	8.96e-14	Blood metabolite levels;
LUAD	cis	rs6987853	0.787	rs2923442	chr8:42435493	T/C	cg09913449	chr8:42400586	C8orf40	0.51	10.24	0.45	4.04e-22	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7187994	0.732	rs3764281	chr16:84767152	A/G	cg07647771	chr16:84786436	USP10	-0.37	-9.21	-0.41	1.58e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	trans	rs4942242	0.617	rs9590778	chr13:44199007	C/G	cg19169023	chr15:41853346	TYRO3	-0.68	-11.87	-0.5	3.07e-28	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs783540	0.609	rs803686	chr15:83219340	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.54	-7.99	-0.36	1.32e-14	Schizophrenia;
LUAD	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14414819	chr6:37225644	TMEM217;TBC1D22B	-0.42	-6.51	-0.3	2.14e-10	Height;
LUAD	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.77	13.24	0.54	1.03e-33	Chronic sinus infection;
LUAD	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg12034118	chr1:209979487	IRF6	0.55	7.25	0.33	2.01e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs4144027	0.869	rs55924227	chr14:104361350	G/C	cg12183467	chr14:104352244	NA	0.37	7.03	0.32	8.07e-12	Blood metabolite levels;
LUAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.52	-9.29	-0.41	8.16e-19	Lymphocyte counts;
LUAD	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg02423579	chr7:2872169	GNA12	-0.9	-16.12	-0.62	6.45e-46	Height;
LUAD	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg13319975	chr6:146136371	FBXO30	-0.58	-9.77	-0.43	1.88e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs806215	1.000	rs712697	chr7:127247132	T/A	cg25922125	chr7:127225783	GCC1	0.49	7.1	0.33	5.47e-12	Type 2 diabetes;
LUAD	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	8.13	0.37	4.65e-15	Blood metabolite levels;
LUAD	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg05535760	chr7:792225	HEATR2	0.83	11.14	0.48	1.81e-25	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg05340658	chr4:99064831	C4orf37	0.56	9.46	0.42	2.13e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4728302	0.608	rs10254118	chr7:133158353	T/A	cg10665199	chr7:133106180	EXOC4	0.67	11.75	0.5	8.81e-28	Intelligence;Intelligence (multi-trait analysis);
LUAD	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg19901468	chr14:105411992	AHNAK2	-0.54	-10.42	-0.45	8.48e-23	Rheumatoid arthritis;
LUAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg11062466	chr8:58055876	NA	0.81	9.84	0.43	1.05e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg12016809	chr21:47604291	C21orf56	0.44	7.36	0.34	9.74e-13	Testicular germ cell tumor;
LUAD	trans	rs783540	0.632	rs17356528	chr15:83305550	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.55	-8.5	-0.38	3.31e-16	Schizophrenia;
LUAD	cis	rs6460942	0.915	rs7803056	chr7:12306913	A/C	cg20607287	chr7:12443886	VWDE	-0.44	-6.41	-0.3	3.94e-10	Coronary artery disease;
LUAD	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg00255919	chr5:131827918	IRF1	0.5	11.9	0.5	2.21e-28	Asthma (sex interaction);
LUAD	cis	rs73416724	0.925	rs112053368	chr6:43382960	C/A	cg26312998	chr6:43337775	ZNF318	0.56	6.83	0.31	3.04e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.76	0.35	6.6e-14	Cannabis dependence symptom count;
LUAD	cis	rs7172809	0.548	rs17385352	chr15:77651305	A/G	cg11865553	chr15:77376250	NA	-0.4	-6.73	-0.31	5.69e-11	Glucose homeostasis traits;
LUAD	trans	rs3779273	0.776	rs1969441	chr7:77835255	G/T	cg05596911	chr5:118502651	DMXL1	-0.4	-7.0	-0.32	9.83e-12	Body mass index;
LUAD	cis	rs11229555	0.574	rs12272096	chr11:58186118	A/G	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg26597838	chr10:835615	NA	0.62	8.66	0.39	9.71e-17	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg05805236	chr11:65401703	PCNXL3	-0.61	-9.78	-0.43	1.63e-20	Acne (severe);
LUAD	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08109568	chr15:31115862	NA	-0.58	-9.72	-0.43	2.82e-20	Huntington's disease progression;
LUAD	cis	rs6688613	0.694	rs1476347	chr1:166815587	G/T	cg07049167	chr1:166818506	POGK	0.65	10.05	0.44	1.8e-21	Refractive astigmatism;
LUAD	cis	rs6426558	0.502	rs2813970	chr1:227410637	C/T	cg10327440	chr1:227177885	CDC42BPA	0.57	9.19	0.41	1.74e-18	Neutrophil percentage of white cells;
LUAD	cis	rs7523050	0.730	rs12734623	chr1:109442654	A/G	cg08274380	chr1:109419600	GPSM2	0.71	6.56	0.3	1.55e-10	Fat distribution (HIV);
LUAD	cis	rs600231	0.508	rs34582634	chr11:65220206	G/A	cg17120908	chr11:65337727	SSSCA1	-0.65	-8.34	-0.38	1.07e-15	Bone mineral density;
LUAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.49	-0.3	2.38e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg02017074	chr12:117425053	FBXW8	0.66	8.68	0.39	8.51e-17	Subcortical brain region volumes;Hippocampal volume;
LUAD	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg27446573	chr6:127587934	RNF146	0.41	6.36	0.3	5.2e-10	Breast cancer;
LUAD	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18876405	chr7:65276391	NA	0.43	6.75	0.31	4.89e-11	Aortic root size;
LUAD	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg25894440	chr7:65020034	NA	-0.62	-6.63	-0.31	1.05e-10	Diabetic kidney disease;
LUAD	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg11645453	chr3:52864694	ITIH4	-0.34	-6.53	-0.3	1.84e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg18402987	chr7:1209562	NA	0.42	6.95	0.32	1.37e-11	Longevity;Endometriosis;
LUAD	cis	rs13315871	1.000	rs71311873	chr3:58447106	C/A	cg20936604	chr3:58311152	NA	-0.68	-6.96	-0.32	1.3e-11	Cholesterol, total;
LUAD	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg21028142	chr17:79581711	NPLOC4	-0.36	-7.26	-0.33	1.86e-12	Eye color traits;
LUAD	cis	rs2651899	0.934	rs10909887	chr1:3087373	A/T	cg22674798	chr1:3096360	PRDM16	-0.39	-9.96	-0.44	3.92e-21	Migraine;
LUAD	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg27394845	chr17:28928406	LRRC37B2	0.53	6.87	0.32	2.37e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	7.4	0.34	7.24e-13	Cognitive test performance;
LUAD	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg02527881	chr3:46936655	PTH1R	0.44	8.38	0.38	7.83e-16	Colorectal cancer;
LUAD	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg18705301	chr15:41695430	NDUFAF1	1.08	24.22	0.76	5.98e-82	Ulcerative colitis;
LUAD	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg09263875	chr16:632152	PIGQ	0.81	17.39	0.65	1.66e-51	Height;
LUAD	cis	rs6558530	0.931	rs4639549	chr8:1708044	A/G	cg19131313	chr8:1704013	NA	-0.46	-7.33	-0.34	1.18e-12	Systolic blood pressure;
LUAD	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg22508957	chr16:3507546	NAT15	0.82	10.8	0.46	3.6e-24	Tuberculosis;
LUAD	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg03929089	chr4:120376271	NA	-0.56	-8.27	-0.37	1.78e-15	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg22230395	chr5:153418202	FAM114A2;MFAP3	0.42	6.76	0.31	4.73e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06521597	chr19:2783551	SGTA	-0.53	-6.47	-0.3	2.74e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7582720	1.000	rs72926793	chr2:203826396	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg27631724	chr1:11040367	C1orf127	0.55	9.67	0.43	4.01e-20	Ewing sarcoma;
LUAD	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.48	-7.78	-0.35	5.73e-14	Alzheimer's disease (late onset);
LUAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg20607798	chr8:58055168	NA	0.72	9.47	0.42	1.93e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.56	-0.3	1.56e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs870825	0.655	rs2017101	chr4:185637381	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	14.04	0.56	4.87e-37	Blood protein levels;
LUAD	cis	rs6066825	0.568	rs6095245	chr20:47320770	G/C	cg18078177	chr20:47281410	PREX1	0.4	6.67	0.31	8.06e-11	Colorectal cancer;
LUAD	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg25894440	chr7:65020034	NA	0.63	6.83	0.32	2.92e-11	Diabetic kidney disease;
LUAD	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg07936489	chr17:37558343	FBXL20	0.51	6.95	0.32	1.37e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.42	-6.91	-0.32	1.81e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg01176363	chr20:62369445	LIME1	-0.5	-8.1	-0.37	5.85e-15	Prostate cancer;
LUAD	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg22029157	chr1:209979665	IRF6	0.8	9.65	0.42	4.64e-20	Cleft lip with or without cleft palate;
LUAD	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg05340658	chr4:99064831	C4orf37	0.42	7.02	0.32	8.95e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2262909	0.962	rs55728714	chr19:22262899	A/G	cg11619707	chr19:22235551	ZNF257	0.49	7.5	0.34	3.89e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs684232	0.666	rs838371	chr17:609275	T/C	cg15660573	chr17:549704	VPS53	-0.77	-15.22	-0.59	5.17e-42	Prostate cancer;
LUAD	cis	rs679087	0.606	rs167318	chr12:29943124	T/C	cg14258853	chr12:29935411	TMTC1	-0.5	-7.16	-0.33	3.54e-12	Schizophrenia;
LUAD	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg05313129	chr8:58192883	C8orf71	-0.5	-7.57	-0.35	2.42e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg25233709	chr10:116636983	FAM160B1	0.41	8.22	0.37	2.54e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs12530845	0.623	rs73721677	chr7:135354238	C/A	cg23117316	chr7:135346802	PL-5283	-0.6	-9.13	-0.41	2.88e-18	Red blood cell traits;
LUAD	cis	rs12549902	1.000	rs12549902	chr8:41509259	C/T	cg17182837	chr8:41585554	ANK1	-0.36	-7.49	-0.34	4.04e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUAD	cis	rs2797160	1.000	rs1739380	chr6:126012858	T/C	cg05901451	chr6:126070800	HEY2	0.47	7.15	0.33	3.77e-12	Endometrial cancer;
LUAD	cis	rs11971779	0.680	rs10229358	chr7:139052545	C/T	cg24109934	chr7:139138155	KLRG2	0.31	6.44	0.3	3.26e-10	Diisocyanate-induced asthma;
LUAD	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg22857025	chr5:266934	NA	-0.88	-9.55	-0.42	1.07e-19	Breast cancer;
LUAD	trans	rs2797160	1.000	rs1739375	chr6:126012013	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.53	8.61	0.39	1.44e-16	Endometrial cancer;
LUAD	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	7.94e-19	Tonsillectomy;
LUAD	cis	rs760805	0.965	rs4648883	chr1:25261203	T/C	cg22509179	chr1:25234806	RUNX3	-0.74	-13.5	-0.55	8.85e-35	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg23254163	chr1:152506842	NA	0.26	7.33	0.34	1.16e-12	Hair morphology;
LUAD	cis	rs62238980	0.614	rs111301871	chr22:32540006	A/C	cg00543991	chr22:32367038	NA	0.93	8.08	0.37	7.04e-15	Childhood ear infection;
LUAD	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg03676636	chr4:99064102	C4orf37	0.3	7.86	0.36	3.16e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg21427119	chr20:30132790	HM13	-0.48	-7.76	-0.35	6.5e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs13088645	0.541	rs9842113	chr3:134192338	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.52	-8.59	-0.39	1.65e-16	Coronary artery disease;
LUAD	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg00717180	chr2:96193071	NA	-0.48	-9.17	-0.41	2.16e-18	Coronary artery disease;
LUAD	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg18827107	chr12:86230957	RASSF9	-0.46	-8.33	-0.38	1.18e-15	Major depressive disorder;
LUAD	cis	rs12765878	1.000	rs3850671	chr10:105659387	T/C	cg11005552	chr10:105648138	OBFC1	0.43	8.16	0.37	3.81e-15	Coronary artery disease;
LUAD	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg09455208	chr3:40491958	NA	-0.51	-10.97	-0.47	7.91e-25	Renal cell carcinoma;
LUAD	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg18512352	chr11:47633146	NA	-0.36	-6.43	-0.3	3.36e-10	Subjective well-being;
LUAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19626725	chr5:178986131	RUFY1	0.59	11.37	0.48	2.45e-26	Lung cancer;
LUAD	cis	rs432925	0.600	rs214247	chr16:349221	A/G	cg06233593	chr16:337645	AXIN1	0.3	6.58	0.3	1.4e-10	Morning vs. evening chronotype;
LUAD	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg11822812	chr5:140052017	DND1	0.38	6.84	0.32	2.78e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.45	-20.25	-0.7	3.24e-64	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs4150161	0.591	rs3759977	chr16:84221170	T/A	cg10106505	chr16:84220380	TAF1C	-1.06	-10.22	-0.45	4.51e-22	Systolic blood pressure response to hydrochlorothiazide in hypertension;
LUAD	cis	rs11098699	0.821	rs904712	chr4:124225337	T/C	cg09941581	chr4:124220074	SPATA5	0.49	7.9	0.36	2.4e-14	Mosquito bite size;
LUAD	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg03609598	chr5:56110824	MAP3K1	-0.46	-6.75	-0.31	4.92e-11	Initial pursuit acceleration;
LUAD	cis	rs7593730	1.000	rs12476804	chr2:161194255	C/T	cg22609984	chr2:161126801	NA	0.44	7.17	0.33	3.3e-12	Type 2 diabetes;
LUAD	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg06484146	chr7:12443880	VWDE	-0.59	-7.55	-0.34	2.73e-13	Coronary artery disease;
LUAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg00280220	chr17:61926910	NA	0.34	6.45	0.3	3.15e-10	Prudent dietary pattern;
LUAD	cis	rs2445762	0.642	rs72729210	chr15:51633629	G/A	cg20344442	chr15:51633704	GLDN	0.5	8.8	0.39	3.59e-17	Hormone measurements;
LUAD	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-7.54	-0.34	2.87e-13	Personality dimensions;
LUAD	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg07305463	chr2:136567211	LCT	0.37	7.2	0.33	2.71e-12	Mosquito bite size;
LUAD	cis	rs1595825	0.891	rs17520121	chr2:198898718	T/G	cg00982548	chr2:198649783	BOLL	-0.68	-9.41	-0.42	3.29e-19	Ulcerative colitis;
LUAD	cis	rs1232027	0.656	rs1677639	chr5:79962548	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs10504073	0.626	rs6472220	chr8:50008477	C/A	cg00325661	chr8:49890786	NA	0.46	10.34	0.45	1.75e-22	Blood metabolite ratios;
LUAD	cis	rs11249608	0.548	rs34881171	chr5:178451932	C/T	cg01312482	chr5:178451176	ZNF879	-0.43	-6.53	-0.3	1.88e-10	Pubertal anthropometrics;
LUAD	cis	rs3806843	0.576	rs246021	chr5:140334504	C/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.84	0.39	2.58e-17	Menopause (age at onset);
LUAD	cis	rs1712517	1.000	rs1163084	chr10:105039048	T/C	cg05636881	chr10:105038444	INA	0.31	6.35	0.3	5.56e-10	Migraine;
LUAD	trans	rs9784649	0.760	rs17403440	chr5:25054004	C/T	cg11038491	chr20:34638489	LOC647979	-0.75	-10.63	-0.46	1.45e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg23887609	chr12:130822674	PIWIL1	-0.41	-6.87	-0.32	2.26e-11	Menopause (age at onset);
LUAD	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg23625390	chr15:77176239	SCAPER	0.41	7.33	0.34	1.14e-12	Blood metabolite levels;
LUAD	cis	rs3204270	0.684	rs62080212	chr17:79642500	G/A	cg18367735	chr17:79674897	NA	0.55	6.87	0.32	2.34e-11	Dental caries;
LUAD	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg08213375	chr14:104286397	PPP1R13B	0.28	7.22	0.33	2.41e-12	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1385374	0.563	rs12299194	chr12:129264838	A/G	cg09035930	chr12:129282057	SLC15A4	-0.66	-7.58	-0.35	2.28e-13	Systemic lupus erythematosus;
LUAD	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg25173405	chr17:45401733	C17orf57	-0.4	-6.5	-0.3	2.21e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3772130	0.962	rs9841595	chr3:121483326	A/G	cg20356878	chr3:121714668	ILDR1	0.52	8.17	0.37	3.58e-15	Cognitive performance;
LUAD	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg07917127	chr4:99064746	C4orf37	0.42	6.96	0.32	1.34e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.7	-13.61	-0.55	3.03e-35	Ulcerative colitis;
LUAD	cis	rs11828289	0.660	rs76379912	chr11:23182498	A/G	cg20040320	chr11:23191996	NA	-0.7	-8.11	-0.37	5.7e-15	Cancer;
LUAD	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06022373	chr22:39101656	GTPBP1	0.47	7.62	0.35	1.69e-13	Menopause (age at onset);
LUAD	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg00255919	chr5:131827918	IRF1	0.39	9.11	0.4	3.43e-18	Breast cancer;Mosquito bite size;
LUAD	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg02931644	chr1:25747376	RHCE	-0.44	-9.06	-0.4	5.01e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	7.39	0.34	8.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg02734326	chr4:10020555	SLC2A9	-0.39	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg22823121	chr1:150693482	HORMAD1	0.42	8.25	0.37	2.06e-15	Melanoma;
LUAD	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg05313129	chr8:58192883	C8orf71	-0.57	-7.86	-0.36	3.27e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg22705602	chr4:152727874	NA	-0.4	-6.95	-0.32	1.38e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg06263672	chr7:65235340	NA	0.51	6.89	0.32	2.05e-11	Aortic root size;
LUAD	cis	rs870825	0.616	rs7683537	chr4:185631998	T/C	cg04058563	chr4:185651563	MLF1IP	0.9	14.41	0.57	1.39e-38	Blood protein levels;
LUAD	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg00071950	chr4:10020882	SLC2A9	0.85	18.61	0.67	6.84e-57	Bone mineral density;
LUAD	cis	rs67311347	0.594	rs12629111	chr3:40285351	T/C	cg10755058	chr3:40428713	ENTPD3	0.35	6.57	0.3	1.48e-10	Renal cell carcinoma;
LUAD	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	7.04	0.32	7.8e-12	Depression;
LUAD	cis	rs8056893	0.686	rs4783558	chr16:68403966	A/G	cg02226672	chr16:68398533	SMPD3	0.39	6.36	0.3	5.18e-10	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUAD	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg13319975	chr6:146136371	FBXO30	-0.64	-11.11	-0.48	2.53e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2404602	0.735	rs2461870	chr15:76813920	T/G	cg23625390	chr15:77176239	SCAPER	-0.46	-7.53	-0.34	3.02e-13	Blood metabolite levels;
LUAD	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.55	0.6	1.85e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7589342	0.831	rs11124062	chr2:106455967	G/A	cg16077055	chr2:106428750	NCK2	0.36	6.43	0.3	3.49e-10	Addiction;
LUAD	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg12564285	chr5:131593104	PDLIM4	-0.4	-6.7	-0.31	6.52e-11	Breast cancer;
LUAD	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg11822812	chr5:140052017	DND1	-0.44	-7.89	-0.36	2.55e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg22875332	chr1:76189707	ACADM	0.87	16.09	0.62	8.93e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg11317459	chr13:21872234	NA	1.23	20.74	0.71	1.9e-66	White matter hyperintensity burden;
LUAD	trans	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg24644049	chr4:85504048	CDS1	0.91	7.79	0.35	5.11e-14	Skin colour saturation;
LUAD	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg03433033	chr1:76189801	ACADM	-0.49	-6.92	-0.32	1.72e-11	Daytime sleep phenotypes;
LUAD	cis	rs220324	0.688	rs8134009	chr21:43568648	T/C	cg08841829	chr21:43638893	ABCG1	-0.47	-6.8	-0.31	3.57e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg07599136	chr5:415885	AHRR	0.76	8.47	0.38	4.17e-16	Fat distribution (HIV);
LUAD	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg07741184	chr6:167504864	NA	0.31	7.44	0.34	5.6e-13	Crohn's disease;
LUAD	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg22529645	chr1:3704559	LRRC47	0.57	10.5	0.45	4.65e-23	Red cell distribution width;
LUAD	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg12011299	chr4:100065546	ADH4	0.65	11.92	0.5	1.86e-28	Alcohol dependence;
LUAD	cis	rs6500395	1.000	rs1909765	chr16:48597358	A/G	cg04672837	chr16:48644449	N4BP1	0.38	6.52	0.3	2.01e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	12.42	0.52	2.06e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg10556349	chr10:835070	NA	0.49	6.51	0.3	2.07e-10	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.01e-10	Skin colour saturation;
LUAD	cis	rs17490626	0.568	rs12413523	chr10:71211664	C/G	cg12610070	chr10:71211762	TSPAN15	-0.41	-10.97	-0.47	8.59e-25	Thrombosis;
LUAD	trans	rs2018683	0.707	rs1874974	chr7:28967647	G/C	cg19402173	chr7:128379420	CALU	-0.51	-8.12	-0.37	5.02e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12541635	0.934	rs62527361	chr8:107021574	T/A	cg10147462	chr8:107024639	NA	0.51	9.27	0.41	9.41e-19	Age of smoking initiation;
LUAD	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11644478	chr21:40555479	PSMG1	0.69	11.45	0.49	1.23e-26	Cognitive function;
LUAD	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18404041	chr3:52824283	ITIH1	-0.58	-11.78	-0.5	6.48e-28	Bipolar disorder;
LUAD	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg21918786	chr6:109611834	NA	-0.6	-11.35	-0.48	3.11e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs55665837	0.502	rs4757269	chr11:14836192	A/C	cg19336497	chr11:14380999	RRAS2	-0.38	-7.0	-0.32	9.93e-12	Vitamin D levels;
LUAD	trans	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg01620082	chr3:125678407	NA	-0.76	-8.29	-0.37	1.49e-15	Breast cancer;
LUAD	cis	rs2274273	0.837	rs7148171	chr14:55770744	G/C	cg04306507	chr14:55594613	LGALS3	0.41	8.44	0.38	5.07e-16	Protein biomarker;
LUAD	cis	rs7633770	0.664	rs7373994	chr3:46701114	C/G	cg11219411	chr3:46661640	NA	-0.48	-10.07	-0.44	1.61e-21	Coronary artery disease;
LUAD	cis	rs2274273	0.638	rs67416413	chr14:55702263	A/G	cg04306507	chr14:55594613	LGALS3	0.44	8.17	0.37	3.56e-15	Protein biomarker;
LUAD	cis	rs17433780	0.928	rs12127787	chr1:89458761	T/C	cg09516651	chr1:89888402	LOC400759	0.49	8.76	0.39	4.89e-17	Carotid intima media thickness;
LUAD	cis	rs56283067	0.847	rs1418432	chr6:44691372	T/C	cg20913747	chr6:44695427	NA	-0.44	-7.46	-0.34	4.9e-13	Total body bone mineral density;
LUAD	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs7833986	0.501	rs72653957	chr8:56990048	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	1.02	17.92	0.66	7.34e-54	Height;
LUAD	cis	rs11031096	0.899	rs11030907	chr11:4109650	C/A	cg18678763	chr11:4115507	RRM1	0.37	6.43	0.3	3.56e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-7.27	-0.33	1.79e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08219700	chr8:58056026	NA	0.68	8.98	0.4	8.96e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7851660	0.874	rs7037175	chr9:100631662	G/C	cg13688889	chr9:100608707	NA	-0.48	-8.27	-0.37	1.72e-15	Strep throat;
LUAD	cis	rs11948739	0.539	rs10045319	chr5:130250710	G/A	cg08523029	chr5:130500466	HINT1	0.59	7.63	0.35	1.52e-13	Pediatric bone mineral content (hip);
LUAD	cis	rs7937890	0.532	rs2256884	chr11:14476402	A/T	cg22961513	chr11:14280813	SPON1	-0.36	-6.9	-0.32	1.87e-11	Mitochondrial DNA levels;
LUAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg03188948	chr7:1209495	NA	0.65	9.52	0.42	1.35e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs16866061	1.000	rs11681451	chr2:225334104	T/C	cg12698349	chr2:225449008	CUL3	0.75	12.86	0.53	3.53e-32	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.36	7.47	0.34	4.55e-13	Parkinson's disease;
LUAD	cis	rs6459804	0.503	rs2159470	chr7:157506540	G/A	cg05731713	chr7:157510257	PTPRN2	0.39	8.02	0.36	1.06e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7903847	0.642	rs11189174	chr10:99139600	C/G	cg20016023	chr10:99160130	RRP12	-0.3	-7.19	-0.33	2.97e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2070488	0.662	rs6599203	chr3:38487802	G/A	cg24069376	chr3:38537580	EXOG	0.32	6.75	0.31	4.84e-11	Electrocardiographic conduction measures;
LUAD	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg12288994	chr5:1860383	NA	0.27	6.54	0.3	1.82e-10	Cardiovascular disease risk factors;
LUAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg00280220	chr17:61926910	NA	0.36	6.94	0.32	1.44e-11	Prudent dietary pattern;
LUAD	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.42	-0.34	6.44e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg22467129	chr15:76604101	ETFA	0.46	7.63	0.35	1.53e-13	Blood metabolite levels;
LUAD	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg23758822	chr17:41437982	NA	1.01	21.51	0.72	7.05e-70	Menopause (age at onset);
LUAD	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg15744005	chr10:104629667	AS3MT	-0.37	-7.1	-0.33	5.39e-12	Arsenic metabolism;
LUAD	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06028808	chr11:68637592	NA	0.43	6.93	0.32	1.53e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg02951883	chr7:2050386	MAD1L1	-0.58	-9.09	-0.4	3.81e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs7927592	0.546	rs497261	chr11:68192244	T/C	cg02221422	chr11:68192511	LRP5	-0.46	-7.29	-0.33	1.56e-12	Total body bone mineral density;
LUAD	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg25566285	chr7:158114605	PTPRN2	-0.53	-11.42	-0.49	1.6e-26	Calcium levels;
LUAD	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.4	6.72	0.31	6.04e-11	Total body bone mineral density;
LUAD	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	8.04	0.36	9.38e-15	Tonsillectomy;
LUAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg03188948	chr7:1209495	NA	0.46	7.41	0.34	6.82e-13	Longevity;Endometriosis;
LUAD	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.15	0.48	1.73e-25	Height;
LUAD	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg24634471	chr8:143751801	JRK	0.48	7.74	0.35	7.6e-14	Schizophrenia;
LUAD	trans	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg13565492	chr6:43139072	SRF	-0.6	-6.4	-0.3	4.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg08888203	chr3:10149979	C3orf24	0.74	12.97	0.53	1.25e-32	Alzheimer's disease;
LUAD	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.85	10.01	0.44	2.65e-21	Yeast infection;
LUAD	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg14413466	chr17:79170920	AZI1	-0.42	-8.87	-0.4	2.01e-17	Frontotemporal dementia;
LUAD	cis	rs10748180	0.502	rs10506640	chr12:72090078	T/C	cg10168894	chr12:72148281	RAB21	-0.45	-7.04	-0.32	8.03e-12	Economic and political preferences (time);
LUAD	cis	rs2625529	0.824	rs55854204	chr15:72433182	C/T	cg16672083	chr15:72433130	SENP8	-0.79	-13.44	-0.55	1.56e-34	Red blood cell count;
LUAD	cis	rs28655083	0.956	rs8060627	chr16:77077065	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-7.07	-0.33	6.42e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.5	0.42	1.62e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg05373962	chr22:49881684	NA	-0.52	-10.69	-0.46	8.82e-24	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg14458575	chr2:238380390	NA	0.75	14.42	0.57	1.26e-38	Prostate cancer;
LUAD	trans	rs75804782	0.691	rs55886641	chr2:239319185	T/C	cg01134436	chr17:81009848	B3GNTL1	0.8	8.62	0.39	1.33e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg18180107	chr4:99064573	C4orf37	0.42	6.75	0.31	4.94e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	8.63	0.39	1.23e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg07217954	chr7:1067459	C7orf50	0.4	6.58	0.3	1.37e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg00106254	chr7:1943704	MAD1L1	-0.6	-8.92	-0.4	1.41e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs62238980	0.522	rs78117433	chr22:32421224	G/A	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg01689657	chr7:91764605	CYP51A1	0.37	8.88	0.4	1.98e-17	Breast cancer;
LUAD	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.47	8.38	0.38	7.82e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg07157834	chr1:205819609	PM20D1	0.41	6.37	0.3	4.98e-10	Parkinson's disease;
LUAD	trans	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg26043149	chr18:55253948	FECH	0.44	6.8	0.31	3.69e-11	Bone mineral density;
LUAD	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg03467027	chr4:99064603	C4orf37	0.42	6.79	0.31	3.9e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7523050	0.730	rs35100394	chr1:109433989	C/G	cg08274380	chr1:109419600	GPSM2	0.71	6.57	0.3	1.49e-10	Fat distribution (HIV);
LUAD	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg18944383	chr4:111397179	ENPEP	0.42	8.14	0.37	4.52e-15	Height;
LUAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg24813613	chr7:1882135	MAD1L1	-0.53	-8.74	-0.39	5.67e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg18187862	chr3:45730750	SACM1L	0.52	8.08	0.37	6.62e-15	Primary sclerosing cholangitis;
LUAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg12034118	chr1:209979487	IRF6	0.46	6.63	0.31	1.04e-10	Cleft lip with or without cleft palate;
LUAD	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.63	-0.31	1.01e-10	Systolic blood pressure;
LUAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg15117754	chr3:10150083	C3orf24	0.42	6.68	0.31	7.38e-11	Alzheimer's disease;
LUAD	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg11502198	chr6:26597334	ABT1	0.55	9.17	0.41	2.12e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg01689657	chr7:91764605	CYP51A1	0.31	7.58	0.35	2.27e-13	Breast cancer;
LUAD	trans	rs7615952	0.575	rs35949599	chr3:125544202	G/A	cg00769240	chr8:12517080	NA	-0.44	-7.43	-0.34	5.88e-13	Blood pressure (smoking interaction);
LUAD	cis	rs7040024	0.754	rs10122680	chr9:852557	A/T	cg14021170	chr9:826657	NA	-0.45	-7.38	-0.34	8.32e-13	Testicular germ cell tumor;Testicular cancer;
LUAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg21724239	chr8:58056113	NA	0.79	9.7	0.43	3.26e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs3774830	0.534	rs7687596	chr4:5472092	C/T	cg26943120	chr4:5472116	STK32B	-0.43	-9.16	-0.41	2.23e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg03563238	chr19:33554763	RHPN2	0.36	8.48	0.38	3.72e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14893161	chr1:205819251	PM20D1	-0.77	-16.49	-0.63	1.59e-47	Menarche (age at onset);
LUAD	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.6	0.31	1.25e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg14835575	chr10:16859367	RSU1	0.95	13.86	0.56	2.81e-36	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	trans	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg26043149	chr18:55253948	FECH	-0.44	-7.28	-0.33	1.69e-12	Bone mineral density;
LUAD	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg11266682	chr4:10021025	SLC2A9	0.62	13.61	0.55	3.07e-35	Bone mineral density;
LUAD	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg09998033	chr7:158218633	PTPRN2	-0.52	-9.43	-0.42	2.76e-19	Obesity-related traits;
LUAD	cis	rs6668534	1.000	rs6668534	chr1:161671995	C/T	cg26156167	chr1:161582651	NA	0.44	6.53	0.3	1.86e-10	Blood protein levels;
LUAD	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.55	-0.34	2.63e-13	Lung cancer;
LUAD	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg03878208	chr11:72483293	STARD10	0.58	8.29	0.37	1.54e-15	Type 2 diabetes;
LUAD	cis	rs4964805	0.526	rs934845	chr12:104185257	T/G	cg02344784	chr12:104178138	NT5DC3	0.5	10.35	0.45	1.52e-22	Attention deficit hyperactivity disorder;
LUAD	cis	rs6785206	0.614	rs2712430	chr3:128337438	A/C	cg16766828	chr3:128327626	NA	-0.84	-9.53	-0.42	1.25e-19	Lymphocyte percentage of white cells;
LUAD	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.57	-9.43	-0.42	2.81e-19	Multiple sclerosis;
LUAD	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg08999081	chr20:33150536	PIGU	0.63	14.53	0.58	4.13e-39	Coronary artery disease;
LUAD	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg22676075	chr6:135203613	NA	0.45	8.39	0.38	7.41e-16	Red blood cell count;
LUAD	cis	rs6546550	0.901	rs6729760	chr2:70161032	C/T	cg02498382	chr2:70120550	SNRNP27	-0.59	-11.46	-0.49	1.18e-26	Prevalent atrial fibrillation;
LUAD	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg15704280	chr7:45808275	SEPT13	0.92	17.93	0.66	7.09e-54	Coronary artery disease;
LUAD	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg22681709	chr2:178499509	PDE11A	-0.53	-8.91	-0.4	1.52e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4743820	0.651	rs73494920	chr9:93923153	G/C	cg14446406	chr9:93919335	NA	0.5	8.35	0.38	9.92e-16	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg06271696	chr7:157225062	NA	-0.52	-11.01	-0.47	5.74e-25	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg15445000	chr17:37608096	MED1	0.44	8.18	0.37	3.44e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg22117172	chr7:91764530	CYP51A1	-0.31	-6.92	-0.32	1.72e-11	Breast cancer;
LUAD	cis	rs10821973	0.527	rs4266956	chr10:64026108	C/T	cg09941381	chr10:64027924	RTKN2	-0.35	-6.85	-0.32	2.64e-11	Hypothyroidism;
LUAD	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg15448220	chr1:150897856	SETDB1	0.46	7.97	0.36	1.47e-14	Tonsillectomy;
LUAD	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.06e-11	Depression;
LUAD	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg24399712	chr22:39784796	NA	-0.79	-14.92	-0.59	9.14e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg01475377	chr6:109611718	NA	-0.51	-9.43	-0.42	2.74e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs11585357	0.895	rs112208664	chr1:17632010	G/A	cg08277548	chr1:17600880	PADI3	-0.92	-13.84	-0.56	3.55e-36	Hair shape;
LUAD	trans	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg14791747	chr16:20752902	THUMPD1	0.73	9.88	0.43	7.26e-21	Cognitive test performance;
LUAD	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3781426	0.793	rs4962722	chr10:126702698	A/T	cg04494136	chr10:126703576	CTBP2	-0.36	-7.08	-0.33	6.18e-12	Height;
LUAD	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg16325326	chr1:53192061	ZYG11B	-0.6	-10.91	-0.47	1.44e-24	Monocyte count;
LUAD	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15664640	chr17:80829946	TBCD	-0.84	-17.0	-0.64	8.87e-50	Breast cancer;
LUAD	cis	rs6479527	0.840	rs2225458	chr9:96756805	A/G	cg14459158	chr9:96720562	NA	0.38	6.67	0.31	8.07e-11	Esophageal adenocarcinoma;
LUAD	trans	rs6076960	0.684	rs6054055	chr20:6257517	C/G	cg21095983	chr6:86352623	SYNCRIP	0.45	7.19	0.33	2.94e-12	Smooth-surface caries;
LUAD	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg10518543	chr12:38710700	ALG10B	-0.42	-6.94	-0.32	1.47e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.68	11.15	0.48	1.79e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.48	0.3	2.53e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs10193935	0.901	rs6733914	chr2:42674741	A/G	cg27598129	chr2:42591480	NA	0.73	9.28	0.41	9.22e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62283056	0.512	rs1079215	chr4:6282393	A/G	cg00701064	chr4:6280414	WFS1	0.58	10.93	0.47	1.19e-24	Cisplatin-induced ototoxicity;
LUAD	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg24818145	chr4:99064322	C4orf37	0.47	7.99	0.36	1.28e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9473147	0.516	rs7767350	chr6:47485126	C/T	cg02130027	chr6:47444894	CD2AP	0.38	7.1	0.33	5.44e-12	Platelet distribution width;Mean platelet volume;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17322163	chr12:51632344	DAZAP2	-0.54	-6.52	-0.3	2.02e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1003719	0.715	rs8128387	chr21:38556787	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.22	-0.37	2.56e-15	Eye color traits;
LUAD	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg08085267	chr17:45401833	C17orf57	-0.49	-7.99	-0.36	1.34e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.75	-12.62	-0.52	3.21e-31	Primary sclerosing cholangitis;
LUAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg07677032	chr17:61819896	STRADA	0.56	10.14	0.44	9.26e-22	Prudent dietary pattern;
LUAD	cis	rs4638749	0.677	rs1522021	chr2:108833263	C/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.3	-0.33	1.48e-12	Blood pressure;
LUAD	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg07537917	chr2:241836409	C2orf54	-0.32	-9.07	-0.4	4.64e-18	Urinary metabolites;
LUAD	cis	rs7737355	0.947	rs17167760	chr5:130782699	A/G	cg06307176	chr5:131281290	NA	-0.44	-7.11	-0.33	4.9e-12	Life satisfaction;
LUAD	cis	rs9826463	0.582	rs114066728	chr3:142022265	T/C	cg20824294	chr3:142316082	PLS1	0.41	6.79	0.31	3.81e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11958404	0.615	rs7703242	chr5:157447920	T/C	cg05962755	chr5:157440814	NA	0.44	8.43	0.38	5.43e-16	IgG glycosylation;
LUAD	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg15448220	chr1:150897856	SETDB1	0.5	8.61	0.39	1.48e-16	Tonsillectomy;
LUAD	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg19761014	chr17:28927070	LRRC37B2	0.67	7.55	0.34	2.62e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg06060754	chr5:176797920	RGS14	0.54	10.24	0.45	4.06e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg14983838	chr19:29218262	NA	0.66	8.48	0.38	3.7e-16	Methadone dose in opioid dependence;
LUAD	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg08632164	chr7:65971372	NA	-0.5	-6.51	-0.3	2.08e-10	Diabetic kidney disease;
LUAD	cis	rs8010715	0.848	rs2277483	chr14:24591892	A/G	cg23112188	chr14:24563095	PCK2	-0.31	-6.46	-0.3	2.88e-10	IgG glycosylation;
LUAD	cis	rs2046867	0.818	rs17010215	chr3:72886965	A/G	cg25664220	chr3:72788482	NA	-0.66	-11.71	-0.49	1.24e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.735	rs6434955	chr2:198946551	G/A	cg00982548	chr2:198649783	BOLL	-0.66	-9.02	-0.4	6.39e-18	Ulcerative colitis;
LUAD	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.89	-0.4	1.72e-17	Initial pursuit acceleration;
LUAD	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg04287289	chr16:89883240	FANCA	0.47	7.68	0.35	1.08e-13	Vitiligo;
LUAD	cis	rs35883536	0.868	rs2484535	chr1:101107748	C/T	cg06223162	chr1:101003688	GPR88	-0.37	-6.92	-0.32	1.71e-11	Monocyte count;
LUAD	trans	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg08071915	chr8:12219732	FAM66A	-0.44	-7.16	-0.33	3.59e-12	Mood instability;
LUAD	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg02176678	chr2:219576539	TTLL4	-0.79	-15.5	-0.6	3.27e-43	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.02	-0.4	6.56e-18	Total body bone mineral density;
LUAD	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg03433033	chr1:76189801	ACADM	0.71	11.48	0.49	9.49e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg06092702	chr1:163392909	NA	-0.35	-7.72	-0.35	8.27e-14	Motion sickness;
LUAD	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg04450456	chr4:17643702	FAM184B	-0.4	-7.68	-0.35	1.09e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg25358565	chr5:93447407	FAM172A	0.64	7.62	0.35	1.63e-13	Diabetic retinopathy;
LUAD	cis	rs10465746	0.935	rs4907189	chr1:84374982	G/T	cg10977910	chr1:84465055	TTLL7	0.49	8.02	0.36	1.06e-14	Obesity-related traits;
LUAD	cis	rs12760731	0.565	rs16828608	chr1:178129899	C/T	cg00404053	chr1:178313656	RASAL2	0.56	7.42	0.34	6.65e-13	Obesity-related traits;
LUAD	trans	rs9354308	1.000	rs9354308	chr6:66565353	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.44	6.74	0.31	5.13e-11	Metabolite levels;
LUAD	cis	rs1950626	0.662	rs72700538	chr14:101441911	C/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.56	0.34	2.6e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg18806716	chr10:30721971	MAP3K8	-0.78	-16.63	-0.63	3.72e-48	Inflammatory bowel disease;
LUAD	cis	rs9341808	0.718	rs2874829	chr6:80856097	A/G	cg08355045	chr6:80787529	NA	0.54	9.74	0.43	2.28e-20	Sitting height ratio;
LUAD	cis	rs13315871	0.929	rs79813245	chr3:58318475	G/A	cg20936604	chr3:58311152	NA	-0.74	-7.4	-0.34	7.57e-13	Cholesterol, total;
LUAD	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg22349387	chr12:9600060	DDX12	-0.51	-9.07	-0.4	4.41e-18	Breast size;
LUAD	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg27170947	chr2:26402098	FAM59B	-0.8	-11.58	-0.49	4.07e-27	Gut microbiome composition (summer);
LUAD	cis	rs11671005	0.651	rs11878203	chr19:58920050	G/A	cg13877915	chr19:58951672	ZNF132	0.55	7.28	0.33	1.63e-12	Mean platelet volume;
LUAD	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs981844	0.740	rs12644642	chr4:154686550	G/C	cg10279832	chr4:154682576	RNF175	0.34	7.15	0.33	3.93e-12	Response to statins (LDL cholesterol change);
LUAD	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg12365402	chr11:9010492	NRIP3	-0.44	-8.38	-0.38	7.75e-16	Hemoglobin concentration;
LUAD	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg05991184	chr2:219186017	PNKD	0.37	7.01	0.32	9.56e-12	Colorectal cancer;
LUAD	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg18306943	chr3:40428807	ENTPD3	0.42	6.96	0.32	1.28e-11	Renal cell carcinoma;
LUAD	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg06558623	chr16:89946397	TCF25	1.18	11.02	0.47	5.28e-25	Skin colour saturation;
LUAD	cis	rs7640424	0.659	rs7639774	chr3:107816216	T/G	cg09227934	chr3:107805635	CD47	-0.68	-10.8	-0.47	3.39e-24	Body mass index;
LUAD	cis	rs11249608	0.548	rs6875622	chr5:178451397	C/T	cg01312482	chr5:178451176	ZNF879	-0.44	-6.79	-0.31	3.79e-11	Pubertal anthropometrics;
LUAD	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg22029157	chr1:209979665	IRF6	0.75	10.72	0.46	6.8e-24	Cleft lip with or without cleft palate;
LUAD	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.5	8.41	0.38	6.55e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.51e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs16866061	1.000	rs11694987	chr2:225397409	C/G	cg12698349	chr2:225449008	CUL3	0.76	12.33	0.51	4.5e-30	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg19717773	chr7:2847554	GNA12	0.46	7.83	0.36	3.94e-14	Height;
LUAD	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg25985355	chr7:65971099	NA	-0.38	-6.89	-0.32	2.02e-11	Aortic root size;
LUAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-9.52	-0.42	1.32e-19	Longevity;Endometriosis;
LUAD	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg20019720	chr6:154832845	CNKSR3	0.65	12.71	0.53	1.42e-31	Lipoprotein (a) levels;
LUAD	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg18180107	chr4:99064573	C4orf37	0.42	6.76	0.31	4.64e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1829883	1.000	rs2461989	chr5:98793999	T/A	cg08333243	chr5:99726346	NA	-0.37	-7.1	-0.33	5.45e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs4888262	0.545	rs8052923	chr16:74680105	C/T	cg01733217	chr16:74700730	RFWD3	0.51	8.61	0.39	1.5e-16	Testicular germ cell tumor;
LUAD	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg18876405	chr7:65276391	NA	0.62	10.71	0.46	7.9e-24	Calcium levels;
LUAD	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	8.51	0.38	3.13e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.24	-0.33	2.13e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg12935359	chr14:103987150	CKB	0.44	6.99	0.32	1.08e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg17264618	chr3:40429014	ENTPD3	0.4	8.86	0.4	2.27e-17	Renal cell carcinoma;
LUAD	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.48	-0.34	4.26e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg23283495	chr1:209979779	IRF6	0.71	9.36	0.41	4.74e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg18446336	chr7:2847575	GNA12	-0.38	-7.12	-0.33	4.63e-12	Height;
LUAD	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.63	0.31	1.05e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg17724175	chr1:150552817	MCL1	0.32	7.25	0.33	1.94e-12	Melanoma;
LUAD	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg08916839	chr5:415575	AHRR	0.87	10.04	0.44	2.07e-21	Fat distribution (HIV);
LUAD	cis	rs12545109	0.837	rs1437277	chr8:57356734	T/C	cg07776626	chr8:57350775	NA	-0.67	-9.34	-0.41	5.61e-19	Obesity-related traits;
LUAD	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg27144592	chr16:783916	NARFL	0.35	6.47	0.3	2.75e-10	Height;
LUAD	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.4	-6.45	-0.3	3.01e-10	Tonsillectomy;
LUAD	cis	rs656900	0.740	rs644315	chr15:80113549	C/T	cg02196730	chr15:80188777	MTHFS	-0.39	-6.42	-0.3	3.56e-10	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7210086	0.730	rs76126194	chr17:70638724	G/A	cg04206342	chr17:70636940	NA	-0.34	-6.46	-0.3	2.84e-10	Ulcerative colitis;
LUAD	cis	rs62229266	0.804	rs998383	chr21:37445739	C/G	cg08632701	chr21:37451849	NA	-0.47	-7.74	-0.35	7.37e-14	Mitral valve prolapse;
LUAD	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg19678392	chr7:94953810	PON1	-0.57	-7.92	-0.36	2.06e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6906287	0.647	rs6936178	chr6:118718242	C/T	cg18833306	chr6:118973337	C6orf204	0.47	8.33	0.38	1.12e-15	Electrocardiographic conduction measures;
LUAD	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg05725404	chr16:58534157	NDRG4	-0.72	-7.53	-0.34	3.05e-13	Schizophrenia;
LUAD	cis	rs9296092	0.538	rs35381461	chr6:33519751	T/C	cg13560919	chr6:33536144	NA	-0.89	-16.71	-0.63	1.64e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7809950	1.000	rs2057837	chr7:107222725	C/G	cg23024343	chr7:107201750	COG5	0.71	12.0	0.5	9.45e-29	Coronary artery disease;
LUAD	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg05896524	chr21:47604654	C21orf56	0.55	9.18	0.41	1.89e-18	Testicular germ cell tumor;
LUAD	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg24308560	chr3:49941425	MST1R	-0.55	-9.01	-0.4	6.88e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg00750074	chr16:89608354	SPG7	-0.56	-9.82	-0.43	1.17e-20	Multiple myeloma (IgH translocation);
LUAD	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11890956	chr21:40555474	PSMG1	0.66	11.52	0.49	6.62e-27	Cognitive function;
LUAD	cis	rs3784262	0.631	rs4646560	chr15:58353546	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.69	-0.35	1.03e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg26587870	chr6:27730563	NA	-0.76	-8.31	-0.37	1.32e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg23254163	chr1:152506842	NA	0.26	7.2	0.33	2.76e-12	Hair morphology;
LUAD	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg03609598	chr5:56110824	MAP3K1	0.48	7.24	0.33	2.2e-12	Coronary artery disease;
LUAD	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.53	-8.99	-0.4	8.23e-18	Tonsillectomy;
LUAD	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg26597838	chr10:835615	NA	-0.53	-8.42	-0.38	6e-16	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs853679	0.607	rs35749575	chr6:28114818	G/T	cg06606381	chr12:133084897	FBRSL1	-1.22	-10.86	-0.47	2.15e-24	Depression;
LUAD	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.47	-8.16	-0.37	3.8e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg00933542	chr6:150070202	PCMT1	0.44	9.02	0.4	6.61e-18	Lung cancer;
LUAD	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg20587970	chr11:113659929	NA	-1.17	-17.5	-0.65	5.58e-52	Hip circumference adjusted for BMI;
LUAD	trans	rs2262909	0.893	rs4244912	chr19:22203237	T/A	cg17074339	chr11:11642133	GALNTL4	-0.43	-6.79	-0.31	3.76e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs943466	0.956	rs11758463	chr6:33762625	A/G	cg16010596	chr6:33739607	LEMD2	-0.41	-7.74	-0.35	7.51e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg02990361	chr1:107599529	PRMT6	-0.52	-8.76	-0.39	4.64e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.14	-15.15	-0.59	1.01e-41	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2029213	0.523	rs3773739	chr3:53268429	A/G	cg16894138	chr3:53270350	TKT	-0.34	-7.97	-0.36	1.51e-14	Heart rate;
LUAD	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg25811766	chr13:21894605	NA	0.67	8.93	0.4	1.28e-17	White matter hyperintensity burden;
LUAD	cis	rs6678622	0.863	rs12409958	chr1:78314478	A/G	cg21968580	chr1:78470640	DNAJB4	0.42	6.88	0.32	2.16e-11	Hip circumference;
LUAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg21724239	chr8:58056113	NA	0.65	8.41	0.38	6.32e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	8.43	0.38	5.31e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs12519773	0.525	rs57542119	chr5:92538853	T/C	cg18783429	chr5:92414398	NA	0.43	7.65	0.35	1.39e-13	Migraine;
LUAD	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.92	-0.32	1.66e-11	Type 2 diabetes;
LUAD	cis	rs2455799	0.613	rs2470542	chr3:15724133	A/C	cg16303742	chr3:15540471	COLQ	-0.51	-9.3	-0.41	7.5e-19	Mean platelet volume;
LUAD	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg12062639	chr20:23401060	NAPB	-1.12	-11.5	-0.49	7.87e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg10909506	chr17:38081995	ORMDL3	0.37	6.45	0.3	3.08e-10	Self-reported allergy;
LUAD	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg13770153	chr20:60521292	NA	-0.47	-8.08	-0.37	6.91e-15	Body mass index;
LUAD	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.43	7.86	0.36	3.2e-14	Systemic lupus erythematosus;
LUAD	trans	rs4650994	0.816	rs2761470	chr1:178596033	G/C	cg05059571	chr16:84539110	KIAA1609	0.49	8.23	0.37	2.4e-15	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs11048434	0.723	rs1805737	chr12:9084670	A/T	cg26114124	chr12:9217669	LOC144571	0.37	6.73	0.31	5.71e-11	Sjögren's syndrome;
LUAD	cis	rs16910800	0.954	rs2449440	chr11:23200335	T/G	cg20040320	chr11:23191996	NA	0.48	7.26	0.33	1.93e-12	Cancer;
LUAD	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.07	0.33	6.28e-12	Platelet count;
LUAD	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-25.01	-0.77	2.01e-85	Height;
LUAD	cis	rs9372498	0.536	rs9481808	chr6:118784571	G/A	cg07617317	chr6:118971624	C6orf204	0.55	8.66	0.39	1.02e-16	Diastolic blood pressure;
LUAD	cis	rs868036	0.957	rs9920662	chr15:68104297	G/A	cg08079166	chr15:68083412	MAP2K5	0.3	6.5	0.3	2.33e-10	Restless legs syndrome;
LUAD	trans	rs5756813	1.000	rs1129448	chr22:38170026	G/A	cg19894588	chr14:64061835	NA	0.59	9.51	0.42	1.47e-19	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg01324343	chr3:183735012	ABCC5	0.96	25.69	0.78	2.13e-88	Anterior chamber depth;
LUAD	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg08847533	chr14:75593920	NEK9	0.42	7.22	0.33	2.5e-12	Height;
LUAD	cis	rs3774830	0.846	rs11732645	chr4:5454829	C/T	cg26943120	chr4:5472116	STK32B	0.36	7.4	0.34	7.53e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg23231163	chr10:75533350	FUT11	-0.53	-9.83	-0.43	1.09e-20	Inflammatory bowel disease;
LUAD	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.38	0.38	7.62e-16	Menarche (age at onset);
LUAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg06753367	chr22:24256600	NA	0.38	6.84	0.32	2.83e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08048268	chr3:133502702	NA	-0.52	-10.44	-0.45	7.66e-23	Iron status biomarkers;
LUAD	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg08807101	chr21:30365312	RNF160	-0.44	-7.71	-0.35	8.94e-14	Dental caries;
LUAD	cis	rs12618769	0.597	rs3769725	chr2:99105967	A/G	cg10123293	chr2:99228465	UNC50	0.46	8.34	0.38	1.03e-15	Bipolar disorder;
LUAD	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg15181151	chr6:150070149	PCMT1	0.41	8.39	0.38	7.62e-16	Lung cancer;
LUAD	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg12310025	chr6:25882481	NA	-0.58	-9.55	-0.42	1.06e-19	Blood metabolite levels;
LUAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00166722	chr3:10149974	C3orf24	0.74	12.74	0.53	1.12e-31	Alzheimer's disease;
LUAD	cis	rs6138458	0.546	rs6050118	chr20:24891895	C/T	cg26195577	chr20:24973756	C20orf3	-0.69	-7.74	-0.35	7.2e-14	Blood protein levels;
LUAD	cis	rs2204008	0.539	rs2703682	chr12:38107969	A/G	cg26384229	chr12:38710491	ALG10B	0.39	6.43	0.3	3.38e-10	Bladder cancer;
LUAD	trans	rs4714291	0.963	rs847743	chr6:40087154	C/G	cg02267698	chr19:7991119	CTXN1	0.43	6.61	0.31	1.17e-10	Strep throat;
LUAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.4	-7.31	-0.34	1.32e-12	Longevity;Endometriosis;
LUAD	cis	rs17102423	0.594	rs7159443	chr14:65550816	T/A	cg11161011	chr14:65562177	MAX	-0.44	-7.42	-0.34	6.52e-13	Obesity-related traits;
LUAD	cis	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg08601574	chr20:25228251	PYGB	-0.45	-8.22	-0.37	2.49e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg02734326	chr4:10020555	SLC2A9	0.64	11.46	0.49	1.15e-26	Bone mineral density;
LUAD	trans	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.57	-0.3	1.46e-10	Depression;
LUAD	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg02038168	chr22:39784481	NA	-0.55	-9.12	-0.41	3.11e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg21475434	chr5:93447410	FAM172A	0.75	8.28	0.37	1.67e-15	Diabetic retinopathy;
LUAD	cis	rs6761276	0.934	rs11682107	chr2:113835522	G/A	cg02343335	chr2:113785852	IL1F8	-0.35	-7.03	-0.32	8.11e-12	Protein quantitative trait loci;
LUAD	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.32	0.41	6.48e-19	Colorectal cancer;
LUAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.47	-0.38	4.1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6426558	0.559	rs485234	chr1:227317747	A/G	cg10327440	chr1:227177885	CDC42BPA	0.55	8.94	0.4	1.24e-17	Neutrophil percentage of white cells;
LUAD	cis	rs1784581	0.588	rs9885762	chr6:162411954	G/A	cg17173639	chr6:162384350	PARK2	0.46	8.21	0.37	2.65e-15	Itch intensity from mosquito bite;
LUAD	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.39	6.9	0.32	1.94e-11	Neutrophil percentage of white cells;
LUAD	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg12034118	chr1:209979487	IRF6	0.58	7.72	0.35	8.38e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg15369054	chr17:80825471	TBCD	0.54	6.59	0.31	1.3100000000000001e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16773127	chr15:35280714	ZNF770	-0.47	-7.37	-0.34	8.92e-13	Height;
LUAD	cis	rs7582720	1.000	rs79633844	chr2:203683990	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	9.53	0.42	1.28e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73198271	0.740	rs10112989	chr8:8647334	A/C	cg01851573	chr8:8652454	MFHAS1	0.48	8.54	0.38	2.53e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.62	0.31	1.06e-10	Prudent dietary pattern;
LUAD	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg02505535	chr3:195703920	SDHAP1	-0.34	-7.08	-0.33	6.23e-12	Pancreatic cancer;
LUAD	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg21427119	chr20:30132790	HM13	-0.59	-8.82	-0.39	2.93e-17	Mean corpuscular hemoglobin;
LUAD	trans	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg12400702	chr3:12838781	CAND2	0.31	6.38	0.3	4.7e-10	Parkinson's disease;
LUAD	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg18138036	chr10:133769891	PPP2R2D	0.41	6.65	0.31	9.17e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs13064411	0.696	rs9814395	chr3:113188885	C/T	cg18753928	chr3:113234510	CCDC52	-0.69	-11.81	-0.5	5.2e-28	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7193541	0.965	rs28616016	chr16:74676964	T/C	cg01733217	chr16:74700730	RFWD3	0.59	10.26	0.45	3.26e-22	Multiple myeloma;
LUAD	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg07870213	chr5:140052090	DND1	-0.77	-10.42	-0.45	8.58e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9322817	0.583	rs9377667	chr6:105154880	G/A	cg02098413	chr6:105308735	HACE1	-0.38	-7.86	-0.36	3.31e-14	Thyroid stimulating hormone;
LUAD	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg18252515	chr7:66147081	NA	-0.6	-6.72	-0.31	5.73e-11	Diabetic kidney disease;
LUAD	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg24558204	chr6:135376177	HBS1L	0.42	7.05	0.32	7.32e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs300774	1.000	rs300692	chr2:181415	C/T	cg21211680	chr2:198530	NA	-0.58	-8.54	-0.38	2.39e-16	Suicide attempts in bipolar disorder;
LUAD	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg14784868	chr12:69753453	YEATS4	0.47	7.92	0.36	2.09e-14	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg25795535	chr2:68384749	WDR92;PNO1	-0.41	-6.69	-0.31	6.94e-11	Cancer;
LUAD	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02018176	chr4:1364513	KIAA1530	0.67	11.71	0.49	1.31e-27	Longevity;
LUAD	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg19622623	chr12:86230825	RASSF9	-0.39	-6.99	-0.32	1.06e-11	Major depressive disorder;
LUAD	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg17074396	chr22:49843754	NA	-0.33	-6.88	-0.32	2.12e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9584850	0.915	rs7983438	chr13:99103317	T/C	cg20750642	chr13:99100586	FARP1	-0.32	-6.72	-0.31	5.86e-11	Neuroticism;
LUAD	cis	rs2406342	0.511	rs10469087	chr18:74575538	A/C	cg00539368	chr18:74514137	NA	0.43	6.64	0.31	9.72e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LUAD	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg00071950	chr4:10020882	SLC2A9	-0.58	-10.76	-0.46	5.16e-24	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1003719	0.788	rs2835574	chr21:38455324	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.49	8.44	0.38	5.27e-16	Eye color traits;
LUAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.68	-13.13	-0.54	2.93e-33	Longevity;Endometriosis;
LUAD	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg22618164	chr12:122356400	WDR66	0.75	13.85	0.56	3.22e-36	Mean corpuscular volume;
LUAD	cis	rs9487051	0.698	rs11153168	chr6:109629420	A/T	cg21918786	chr6:109611834	NA	-0.42	-6.8	-0.31	3.66e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs3772130	0.962	rs17742508	chr3:121559895	C/T	cg20356878	chr3:121714668	ILDR1	0.52	8.36	0.38	8.93e-16	Cognitive performance;
LUAD	cis	rs8060686	0.516	rs4567701	chr16:68163662	T/C	cg09835421	chr16:68378352	PRMT7	-0.56	-7.02	-0.32	8.65e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg13319975	chr6:146136371	FBXO30	-0.64	-11.02	-0.47	5.45e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs28374715	0.627	rs28516832	chr15:41367036	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.83	-14.46	-0.58	8.51e-39	Ulcerative colitis;
LUAD	trans	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg18335740	chr13:41363409	SLC25A15	0.57	10.51	0.46	4.27e-23	Lewy body disease;
LUAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	7.82	0.36	4.19e-14	Alzheimer's disease;
LUAD	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg02461776	chr11:598696	PHRF1	0.47	6.66	0.31	8.37e-11	Systemic lupus erythematosus;
LUAD	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg23719950	chr11:63933701	MACROD1	-0.59	-6.95	-0.32	1.43e-11	Mean platelet volume;
LUAD	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg02886208	chr11:14281011	SPON1	-0.38	-7.53	-0.34	3.17e-13	Mitochondrial DNA levels;
LUAD	trans	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg26043149	chr18:55253948	FECH	-0.58	-9.61	-0.42	6.62e-20	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.86	-14.5	-0.58	5.67e-39	Homoarginine levels;
LUAD	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg03676636	chr4:99064102	C4orf37	0.28	6.78	0.31	4.1e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.55	-0.34	2.64e-13	Total cholesterol levels;
LUAD	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg07636037	chr3:49044803	WDR6	0.58	9.32	0.41	6.71e-19	Menarche (age at onset);
LUAD	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg11663144	chr21:46675770	NA	-0.61	-12.29	-0.51	6.85e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg23950597	chr19:37808831	NA	-0.61	-7.51	-0.34	3.54e-13	Coronary artery calcification;
LUAD	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	6.81	0.31	3.46e-11	Menarche (age at onset);
LUAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03452623	chr4:187889614	NA	0.81	16.83	0.63	4.84e-49	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg25482853	chr8:67687455	SGK3	1.18	18.2	0.66	4.58e-55	Lung disease severity in cystic fibrosis;
LUAD	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.35	-7.0	-0.32	1.01e-11	Cystic fibrosis severity;
LUAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg11494091	chr17:61959527	GH2	0.74	18.11	0.66	1.11e-54	Prudent dietary pattern;
LUAD	cis	rs9362426	0.708	rs9342112	chr6:88092491	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	6.74	0.31	5.17e-11	Depressive episodes in bipolar disorder;
LUAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.63	-9.91	-0.43	5.65e-21	Renal function-related traits (BUN);
LUAD	cis	rs17102423	0.594	rs2781374	chr14:65568563	C/T	cg11161011	chr14:65562177	MAX	-0.46	-7.68	-0.35	1.15e-13	Obesity-related traits;
LUAD	trans	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg06606381	chr12:133084897	FBRSL1	-1.06	-9.95	-0.44	4.09e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg14092571	chr14:90743983	NA	-0.51	-8.93	-0.4	1.27e-17	Mortality in heart failure;
LUAD	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg01874867	chr7:94954059	PON1	-0.49	-6.69	-0.31	6.94e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg03929089	chr4:120376271	NA	-0.92	-17.08	-0.64	3.99e-50	Height;
LUAD	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.89	0.32	2e-11	Colorectal cancer;
LUAD	cis	rs1595825	0.786	rs16826740	chr2:198893927	A/G	cg00982548	chr2:198649783	BOLL	-0.65	-9.18	-0.41	1.88e-18	Ulcerative colitis;
LUAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.75	-0.31	4.78e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs1595825	0.945	rs73056883	chr2:198824638	A/G	cg11031976	chr2:198649780	BOLL	-0.47	-6.94	-0.32	1.5e-11	Ulcerative colitis;
LUAD	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.55	9.22	0.41	1.4e-18	Breast cancer;
LUAD	cis	rs790123	0.579	rs9881748	chr3:122391934	A/T	cg15604389	chr3:122379662	NA	0.44	6.93	0.32	1.56e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs6484504	0.576	rs208066	chr11:31156206	C/G	cg06552810	chr11:31128660	NA	-0.33	-6.41	-0.3	3.86e-10	Red blood cell count;
LUAD	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg11247378	chr22:39784982	NA	0.63	10.68	0.46	1.01e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg17595323	chr11:93583763	C11orf90	-0.43	-9.07	-0.4	4.68e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	8.8	0.39	3.59e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs2380220	0.574	rs9400526	chr6:95998441	T/C	cg21865736	chr4:2628771	FAM193A	-0.42	-6.55	-0.3	1.68e-10	Behavioural disinhibition (generation interaction);
LUAD	cis	rs4604732	0.631	rs12036460	chr1:247626928	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.44	0.34	5.65e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg05283184	chr6:79620031	NA	-0.61	-12.21	-0.51	1.42e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg22431228	chr1:16359049	CLCNKA	-0.41	-7.95	-0.36	1.77e-14	Systolic blood pressure;
LUAD	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.73	0.31	5.55e-11	Colorectal cancer;
LUAD	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg14008862	chr17:28927542	LRRC37B2	0.63	6.37	0.3	4.88e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg03948781	chr1:205179583	DSTYK	0.35	6.42	0.3	3.64e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg25358565	chr5:93447407	FAM172A	0.57	6.5	0.3	2.31e-10	Diabetic retinopathy;
LUAD	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg10589385	chr1:150898437	SETDB1	0.43	8.29	0.37	1.56e-15	Melanoma;
LUAD	cis	rs11077998	0.967	rs7502945	chr17:80495039	T/C	cg10255544	chr17:80519551	FOXK2	0.35	7.02	0.32	9.08e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs4776059	1.000	rs2414166	chr15:52901977	C/T	cg24008177	chr15:52972085	KIAA1370	0.25	6.85	0.32	2.64e-11	Schizophrenia;
LUAD	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg00310523	chr12:86230176	RASSF9	0.39	8.32	0.37	1.24e-15	Major depressive disorder;
LUAD	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.29	6.58	0.3	1.4e-10	Systemic lupus erythematosus;
LUAD	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg17366294	chr4:99064904	C4orf37	0.53	9.78	0.43	1.68e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg21226059	chr5:178986404	RUFY1	-0.67	-11.64	-0.49	2.31e-27	Lung cancer;
LUAD	cis	rs9486719	1.000	rs2499807	chr6:96864053	T/G	cg06623918	chr6:96969491	KIAA0776	0.71	9.96	0.44	3.8e-21	Migraine;Coronary artery disease;
LUAD	cis	rs13223928	0.516	rs1872880	chr7:3148389	G/C	cg19214707	chr7:3157722	NA	-0.51	-8.98	-0.4	8.7e-18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg10518543	chr12:38710700	ALG10B	-0.42	-6.92	-0.32	1.64e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2268241	0.938	rs7283827	chr21:34769904	A/G	cg14850771	chr21:34775459	IFNGR2	0.6	7.14	0.33	4.05e-12	Obesity-related traits;
LUAD	cis	rs7665090	0.870	rs228615	chr4:103579460	A/T	cg07973026	chr4:103553119	MANBA	-0.4	-6.9	-0.32	1.95e-11	Primary biliary cholangitis;
LUAD	cis	rs7975161	0.638	rs10861170	chr12:104615957	A/G	cg25273343	chr12:104657179	TXNRD1	-0.52	-7.92	-0.36	2.15e-14	Toenail selenium levels;
LUAD	cis	rs12122100	0.696	rs12752148	chr1:146557073	T/C	cg03526459	chr1:146549940	NA	-0.39	-7.21	-0.33	2.54e-12	HIV-1 control;
LUAD	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg04025307	chr7:1156635	C7orf50	0.52	6.83	0.32	2.98e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.5	6.88	0.32	2.22e-11	Platelet count;
LUAD	trans	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg06175025	chr14:78082992	SPTLC2	-0.41	-6.66	-0.31	8.37e-11	Bone mineral density;
LUAD	cis	rs4588572	0.644	rs10805920	chr5:77698222	G/A	cg11547950	chr5:77652471	NA	-0.64	-10.91	-0.47	1.4e-24	Triglycerides;
LUAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.74	-0.35	7.45e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg15992532	chr8:142229932	SLC45A4	0.47	8.25	0.37	2e-15	Immature fraction of reticulocytes;
LUAD	cis	rs4774899	1.000	rs12914425	chr15:57476285	C/G	cg14026238	chr15:57616123	NA	0.35	6.58	0.3	1.35e-10	Urinary tract infection frequency;
LUAD	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg27490568	chr2:178487706	NA	0.44	7.27	0.33	1.72e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08109568	chr15:31115862	NA	-0.61	-10.46	-0.45	6.42e-23	Huntington's disease progression;
LUAD	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.91	12.62	0.52	3.34e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg12483005	chr1:23474871	LUZP1	0.52	9.12	0.41	2.97e-18	Height;
LUAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.62	0.31	1.06e-10	Prudent dietary pattern;
LUAD	trans	rs10802346	0.545	rs10802347	chr1:246374268	G/A	cg22732515	chr19:44031385	ETHE1	0.58	9.31	0.41	7.18e-19	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13012494	chr21:47604986	C21orf56	0.66	11.53	0.49	6.45e-27	Testicular germ cell tumor;
LUAD	cis	rs7132746	0.620	rs61928911	chr12:86195973	A/G	cg18827107	chr12:86230957	RASSF9	-0.5	-6.74	-0.31	5.32e-11	Lewy body disease;
LUAD	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-12.99	-0.53	1.04e-32	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg14343924	chr8:8086146	FLJ10661	-0.44	-7.01	-0.32	9.56e-12	Mood instability;
LUAD	cis	rs4481887	0.927	rs4390208	chr1:248472211	C/T	cg00666640	chr1:248458726	OR2T12	0.29	7.06	0.32	6.96e-12	Common traits (Other);
LUAD	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg26677194	chr12:130822605	PIWIL1	-0.62	-10.05	-0.44	1.84e-21	Menopause (age at onset);
LUAD	trans	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg14917512	chr19:3094685	GNA11	0.36	6.48	0.3	2.55e-10	Aortic root size;
LUAD	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.04	0.32	7.86e-12	Prostate cancer;
LUAD	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-7.1	-0.33	5.26e-12	Triglycerides;
LUAD	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg18099408	chr3:52552593	STAB1	-0.48	-8.45	-0.38	4.62e-16	Bipolar disorder;
LUAD	cis	rs11971779	0.680	rs3924296	chr7:139041927	T/C	cg23387468	chr7:139079360	LUC7L2	0.28	6.49	0.3	2.47e-10	Diisocyanate-induced asthma;
LUAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg07806771	chr7:64541737	NA	-0.44	-7.08	-0.33	6.03e-12	Calcium levels;
LUAD	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg21951975	chr1:209979733	IRF6	0.53	6.95	0.32	1.36e-11	Cleft lip with or without cleft palate;
LUAD	trans	rs683250	0.931	rs671321	chr11:83292373	G/T	cg18766056	chr1:39457186	AKIRIN1	0.41	7.05	0.32	7.4e-12	Subcortical brain region volumes;
LUAD	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.37	-0.34	9.19e-13	Breast cancer;
LUAD	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.42	7.31	0.34	1.32e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg14668632	chr7:2872130	GNA12	-0.76	-13.71	-0.55	1.22e-35	Height;
LUAD	cis	rs933688	0.583	rs6882172	chr5:90576958	C/T	cg00335715	chr5:90575459	NA	-0.48	-7.51	-0.34	3.44e-13	Smoking behavior;
LUAD	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.46	0.52	1.48e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg25811766	chr13:21894605	NA	-0.62	-7.38	-0.34	8.73e-13	White matter hyperintensity burden;
LUAD	cis	rs11153730	0.503	rs283042	chr6:118631282	G/A	cg18833306	chr6:118973337	C6orf204	0.51	9.21	0.41	1.57e-18	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg03340356	chr1:67600835	NA	0.41	7.09	0.33	5.52e-12	Psoriasis;
LUAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-8.03	-0.36	9.72e-15	Monocyte percentage of white cells;
LUAD	cis	rs17095355	1.000	rs17126877	chr10:111672786	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-7.71	-0.35	9.18e-14	Biliary atresia;
LUAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.16	0.41	2.31e-18	Alzheimer's disease;
LUAD	cis	rs11051970	0.704	rs7312698	chr12:32554695	G/T	cg02745156	chr12:32552066	NA	0.31	6.63	0.31	1.01e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.36	7.68	0.35	1.14e-13	Hemoglobin concentration;
LUAD	cis	rs762407	0.608	rs762398	chr21:45170813	A/G	cg19815989	chr21:45161359	PDXK	-0.4	-7.08	-0.33	5.93e-12	Systolic blood pressure change trajectories;
LUAD	cis	rs2637266	1.000	rs3923670	chr10:78375001	C/G	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	trans	rs587242	0.528	rs66533250	chr1:97206852	G/A	cg10631902	chr5:14652156	NA	0.39	6.65	0.31	9.33e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg07923666	chr12:49932857	KCNH3	-0.49	-6.38	-0.3	4.57e-10	Resting heart rate;
LUAD	cis	rs231513	1.000	rs231519	chr17:41961051	C/T	cg26893861	chr17:41843967	DUSP3	0.6	7.24	0.33	2.15e-12	Cognitive function;
LUAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	8.68	0.39	8.69e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.98	-0.36	1.4e-14	Gout;
LUAD	cis	rs9902453	0.765	rs2729448	chr17:28091953	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.52	-0.46	3.72e-23	Coffee consumption (cups per day);
LUAD	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7072216	0.691	rs10786419	chr10:100180940	T/C	cg26618903	chr10:100175079	PYROXD2	-0.31	-6.72	-0.31	6.06e-11	Metabolite levels;
LUAD	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg09491104	chr22:46646882	C22orf40	-0.59	-7.47	-0.34	4.56e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg20119798	chr7:94954144	PON1	-0.51	-9.21	-0.41	1.52e-18	Paraoxonase activity;
LUAD	cis	rs6881634	0.501	rs13347329	chr5:77692125	A/G	cg11547950	chr5:77652471	NA	-0.37	-6.67	-0.31	8.19e-11	Hippocampal atrophy;
LUAD	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg06740227	chr12:86229804	RASSF9	-0.41	-7.36	-0.34	9.88e-13	Major depressive disorder;
LUAD	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg19761014	chr17:28927070	LRRC37B2	0.76	8.98	0.4	9.31e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg18876405	chr7:65276391	NA	0.4	6.6	0.31	1.2e-10	Calcium levels;
LUAD	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg10523679	chr1:76189770	ACADM	0.77	11.44	0.49	1.37e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs986417	1.000	rs1313249	chr14:60881997	C/G	cg27398547	chr14:60952738	C14orf39	-0.64	-7.79	-0.35	5.1e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-7.92	-0.36	2.07e-14	Neutrophil percentage of white cells;
LUAD	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg21100191	chr22:23484243	RTDR1	0.71	12.75	0.53	1e-31	Bone mineral density;
LUAD	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg21138405	chr5:131827807	IRF1	-0.58	-12.68	-0.52	1.84e-31	Asthma (sex interaction);
LUAD	cis	rs4006360	0.522	rs2874188	chr17:39244590	T/C	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.27	0.37	1.75e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg09455208	chr3:40491958	NA	0.64	13.7	0.55	1.3e-35	Renal cell carcinoma;
LUAD	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.57	8.2	0.37	3.01e-15	Platelet count;
LUAD	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	7.1	0.33	5.3e-12	Rheumatoid arthritis;
LUAD	cis	rs11214589	0.620	rs34601878	chr11:113260898	G/A	cg14159747	chr11:113255604	NA	0.66	13.77	0.56	6.66e-36	Neuroticism;
LUAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg08132940	chr7:1081526	C7orf50	-0.78	-10.38	-0.45	1.28e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7149337	0.780	rs4369569	chr14:51689181	C/G	cg23942311	chr14:51606299	NA	-0.87	-20.36	-0.7	9.98e-65	Cancer;
LUAD	cis	rs9369695	0.883	rs9381581	chr6:47580695	G/A	cg02130027	chr6:47444894	CD2AP	0.36	6.78	0.31	4.02e-11	Reticulocyte count;
LUAD	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg10591111	chr5:226296	SDHA	-0.56	-7.24	-0.33	2.14e-12	Breast cancer;
LUAD	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg21153622	chr11:89784906	NA	-0.35	-6.68	-0.31	7.6e-11	Coronary artery disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07393655	chr5:43122148	ZNF131	-0.44	-6.75	-0.31	4.89e-11	Height;
LUAD	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg25566285	chr7:158114605	PTPRN2	-0.43	-8.01	-0.36	1.15e-14	Response to amphetamines;
LUAD	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg14671364	chr1:107599128	PRMT6	0.49	7.78	0.35	5.44e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs116248771	0.739	rs4680455	chr3:158384883	C/A	cg16708174	chr3:158430962	RARRES1	0.47	6.79	0.31	3.78e-11	diarrhoeal disease at age 2;
LUAD	cis	rs10197940	0.510	rs7557092	chr2:152423459	T/A	cg06191203	chr2:152266755	RIF1	-0.52	-7.13	-0.33	4.43e-12	Lung cancer;
LUAD	cis	rs6906287	0.647	rs2356492	chr6:118809437	C/G	cg05564266	chr6:118973597	C6orf204	0.35	7.38	0.34	8.25e-13	Electrocardiographic conduction measures;
LUAD	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg23758822	chr17:41437982	NA	1.0	20.92	0.71	3.2e-67	Menopause (age at onset);
LUAD	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-7.82	-0.36	4.26e-14	Neutrophil percentage of white cells;
LUAD	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg09359103	chr1:154839909	KCNN3	-0.72	-14.41	-0.57	1.37e-38	Prostate cancer;
LUAD	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg15704280	chr7:45808275	SEPT13	-0.52	-8.21	-0.37	2.74e-15	HDL cholesterol;
LUAD	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg23887609	chr12:130822674	PIWIL1	0.4	6.66	0.31	8.62e-11	Menopause (age at onset);
LUAD	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg01689657	chr7:91764605	CYP51A1	0.38	9.29	0.41	8.18e-19	Breast cancer;
LUAD	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg25427524	chr10:38739819	LOC399744	-0.64	-8.87	-0.4	2.14e-17	Obesity (extreme);
LUAD	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg14779329	chr11:130786720	SNX19	0.37	6.47	0.3	2.73e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.67	0.39	9.19e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4462272	0.554	rs7899288	chr10:101848444	C/T	cg19754520	chr10:101825118	CPN1	-0.31	-6.54	-0.3	1.78e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs3750082	0.889	rs1817050	chr7:32931906	T/G	cg05721444	chr7:32995514	FKBP9	0.35	6.35	0.3	5.49e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12310025	chr6:25882481	NA	0.52	7.53	0.34	3.1e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs17092148	1.000	rs910871	chr20:33333208	C/A	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.34	-0.38	1.05e-15	Neuroticism;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg27417846	chr2:88927289	EIF2AK3	0.39	6.6	0.31	1.23e-10	Anger;
LUAD	cis	rs34245846	0.769	rs12058931	chr1:154825093	C/A	cg06221963	chr1:154839813	KCNN3	0.47	7.24	0.33	2.18e-12	Atrial fibrillation;
LUAD	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg04731861	chr2:219085781	ARPC2	-0.27	-8.25	-0.37	2.07e-15	Colorectal cancer;
LUAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg05457628	chr5:178986728	RUFY1	0.75	13.25	0.54	9.27e-34	Lung cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg15650170	chr7:150783791	AGAP3	-0.39	-6.38	-0.3	4.59e-10	Schizophrenia;
LUAD	cis	rs10193935	1.000	rs13399869	chr2:42386041	C/G	cg27598129	chr2:42591480	NA	-0.72	-9.44	-0.42	2.59e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg08601574	chr20:25228251	PYGB	0.48	8.86	0.4	2.27e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg17200465	chr3:40428508	ENTPD3	0.29	7.2	0.33	2.8e-12	Renal cell carcinoma;
LUAD	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	25.4	0.78	4.02e-87	Chronic sinus infection;
LUAD	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg07828340	chr4:882639	GAK	1.04	10.37	0.45	1.32e-22	Intelligence (multi-trait analysis);
LUAD	trans	rs10411161	0.702	rs8110073	chr19:52383123	C/A	cg22319618	chr22:45562946	NUP50	-0.59	-8.31	-0.37	1.36e-15	Breast cancer;
LUAD	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg00277334	chr10:82204260	NA	-0.51	-7.94	-0.36	1.89e-14	Post bronchodilator FEV1;
LUAD	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg00071950	chr4:10020882	SLC2A9	0.85	18.61	0.67	6.8e-57	Bone mineral density;
LUAD	cis	rs7833986	1.000	rs34516759	chr8:57097138	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	10.04	0.44	2.03e-21	Height;
LUAD	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg04369109	chr6:150039330	LATS1	-0.46	-7.8	-0.35	4.79e-14	Lung cancer;
LUAD	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg13639937	chr1:92012655	NA	0.43	6.67	0.31	7.9e-11	Eosinophil percentage of white cells;
LUAD	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.32	-7.12	-0.33	4.63e-12	Lung cancer;
LUAD	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.06	-0.32	6.69e-12	Blood metabolite levels;
LUAD	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	8.75e-12	Aortic root size;
LUAD	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg05673287	chr15:77411982	SGK269	-0.42	-7.26	-0.33	1.88e-12	Type 2 diabetes;
LUAD	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg09184832	chr6:79620586	NA	-0.39	-6.68	-0.31	7.55e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs13064411	0.696	rs1486897	chr3:113215818	G/A	cg10517650	chr3:113235015	CCDC52	-0.55	-9.4	-0.42	3.38e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs3008870	0.816	rs1118392	chr1:67366549	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.49	-7.68	-0.35	1.11e-13	Lymphocyte percentage of white cells;
LUAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08677398	chr8:58056175	NA	0.45	6.45	0.3	3.07e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2282300	0.739	rs10835648	chr11:30320506	A/G	cg25418670	chr11:30344373	C11orf46	0.5	6.96	0.32	1.29e-11	Morning vs. evening chronotype;
LUAD	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg08470875	chr2:26401718	FAM59B	0.66	7.9	0.36	2.45e-14	Gut microbiome composition (summer);
LUAD	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg08989290	chr16:615782	NHLRC4	0.31	6.8	0.31	3.6e-11	Height;
LUAD	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg05665937	chr4:1216051	CTBP1	-0.48	-7.84	-0.36	3.66e-14	Obesity-related traits;
LUAD	cis	rs941873	0.772	rs2000404	chr10:81109708	T/C	cg08514558	chr10:81106712	PPIF	0.48	9.2	0.41	1.71e-18	Height;
LUAD	cis	rs12545109	0.643	rs1119707	chr8:57411548	T/C	cg07776626	chr8:57350775	NA	-0.62	-8.7	-0.39	7.41e-17	Obesity-related traits;
LUAD	cis	rs2235649	0.623	rs8048162	chr16:1848918	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-6.73	-0.31	5.59e-11	Blood metabolite levels;
LUAD	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.79e-18	Life satisfaction;
LUAD	cis	rs11674184	0.714	rs9789525	chr2:11724580	G/T	cg07314298	chr2:11723111	GREB1	-0.82	-17.83	-0.66	1.91e-53	Endometriosis;
LUAD	cis	rs859767	0.704	rs7570717	chr2:135361035	C/T	cg12500956	chr2:135428796	TMEM163	-0.27	-7.18	-0.33	3.17e-12	Neuroticism;
LUAD	cis	rs1784581	0.775	rs7755404	chr6:162427731	T/C	cg17173639	chr6:162384350	PARK2	0.49	8.83	0.39	2.89e-17	Itch intensity from mosquito bite;
LUAD	cis	rs7027203	0.964	rs7854075	chr9:96571211	G/A	cg14598338	chr9:96623480	NA	0.39	7.8	0.35	4.75e-14	DNA methylation (variation);
LUAD	cis	rs72634258	0.945	rs12735338	chr1:8078569	T/C	cg26816564	chr1:7831052	VAMP3	0.54	6.95	0.32	1.4e-11	Inflammatory bowel disease;
LUAD	cis	rs6028335	0.674	rs16987779	chr20:37671455	C/T	cg27660920	chr20:37554817	FAM83D	0.53	6.67	0.31	7.98e-11	Alcohol and nicotine co-dependence;
LUAD	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg06558623	chr16:89946397	TCF25	1.14	10.58	0.46	2.2e-23	Skin colour saturation;
LUAD	cis	rs7927771	0.524	rs7124396	chr11:47787434	T/G	cg18512352	chr11:47633146	NA	-0.36	-6.5	-0.3	2.29e-10	Subjective well-being;
LUAD	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Parkinson's disease;
LUAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11079969	chr15:82339920	NA	-0.36	-6.38	-0.3	4.55e-10	Height;
LUAD	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg22117172	chr7:91764530	CYP51A1	0.33	7.28	0.33	1.68e-12	Breast cancer;
LUAD	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg02158880	chr13:53174818	NA	0.59	10.29	0.45	2.62e-22	Lewy body disease;
LUAD	trans	rs3942852	0.868	rs7122335	chr11:48106486	C/T	cg03929089	chr4:120376271	NA	-0.52	-6.87	-0.32	2.38e-11	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg07917127	chr4:99064746	C4orf37	0.41	6.72	0.31	6.05e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg17652424	chr22:38574118	PLA2G6	-0.33	-10.13	-0.44	9.75e-22	Cutaneous nevi;
LUAD	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg07636037	chr3:49044803	WDR6	0.54	10.18	0.44	6.26e-22	Menarche (age at onset);
LUAD	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg13319975	chr6:146136371	FBXO30	-0.59	-9.98	-0.44	3.44e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg11189052	chr15:85197271	WDR73	-0.61	-7.65	-0.35	1.39e-13	Schizophrenia;
LUAD	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg11707310	chr1:2537719	MMEL1	-0.4	-8.62	-0.39	1.37e-16	Ulcerative colitis;
LUAD	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg18827107	chr12:86230957	RASSF9	-0.48	-8.55	-0.38	2.33e-16	Major depressive disorder;
LUAD	trans	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg20587970	chr11:113659929	NA	-0.89	-13.06	-0.54	5.67e-33	Hip circumference adjusted for BMI;
LUAD	cis	rs10979	1.000	rs1416205	chr6:143889397	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-10.3	-0.45	2.33e-22	Hypospadias;
LUAD	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg04450456	chr4:17643702	FAM184B	0.39	7.63	0.35	1.55e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg18016565	chr1:150552671	MCL1	0.37	6.37	0.3	4.87e-10	Melanoma;
LUAD	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg24088639	chr11:34937564	PDHX;APIP	-0.44	-7.08	-0.33	6e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11890956	chr21:40555474	PSMG1	0.81	14.22	0.57	8.6e-38	Cognitive function;
LUAD	cis	rs11048434	0.761	rs2110190	chr12:9128289	A/C	cg04155231	chr12:9217510	LOC144571	0.4	7.51	0.34	3.63e-13	Sjögren's syndrome;
LUAD	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg00745463	chr17:30367425	LRRC37B	-0.86	-10.85	-0.47	2.35e-24	Hip circumference adjusted for BMI;
LUAD	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg12011299	chr4:100065546	ADH4	0.52	10.37	0.45	1.35e-22	Alcohol dependence;
LUAD	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg16342193	chr10:102329863	NA	-0.38	-6.67	-0.31	8.13e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.39	0.34	7.92e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg15383120	chr6:291909	DUSP22	-0.49	-7.95	-0.36	1.76e-14	Menopause (age at onset);
LUAD	cis	rs12541635	0.966	rs7819327	chr8:106986003	A/C	cg10147462	chr8:107024639	NA	0.48	8.46	0.38	4.51e-16	Age of smoking initiation;
LUAD	cis	rs41311933	0.710	rs76009660	chr9:123688026	G/A	cg13567360	chr9:123745713	C5	-0.83	-7.22	-0.33	2.36e-12	Coronary artery disease;
LUAD	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg20291162	chr17:40259547	DHX58	-0.68	-10.5	-0.45	4.51e-23	Fibrinogen levels;
LUAD	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19346786	chr7:2764209	NA	-0.39	-8.41	-0.38	6.44e-16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	trans	rs4650994	1.000	rs4650995	chr1:178517316	C/T	cg05059571	chr16:84539110	KIAA1609	-0.61	-10.43	-0.45	7.89e-23	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg02018176	chr4:1364513	KIAA1530	0.46	8.61	0.39	1.45e-16	Longevity;
LUAD	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg09222892	chr1:25734099	RHCE	-0.5	-9.18	-0.41	1.88e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg02079420	chr8:82753780	SNX16	0.4	8.11	0.37	5.36e-15	Diastolic blood pressure;
LUAD	cis	rs250677	0.524	rs183140	chr5:148438803	G/T	cg18129178	chr5:148520854	ABLIM3	-0.49	-8.23	-0.37	2.4e-15	Breast cancer;
LUAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg02725872	chr8:58115012	NA	-0.33	-6.47	-0.3	2.69e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg20203395	chr5:56204925	C5orf35	-0.41	-6.41	-0.3	3.78e-10	Coronary artery disease;
LUAD	cis	rs8060686	0.623	rs7205935	chr16:68152157	A/G	cg26727032	chr16:67993705	SLC12A4	-0.46	-7.71	-0.35	9.28e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.61	-10.65	-0.46	1.23e-23	Homoarginine levels;
LUAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg11062466	chr8:58055876	NA	0.67	8.87	0.4	2.01e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7017914	0.967	rs13264669	chr8:71626772	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs1595825	0.838	rs73058854	chr2:198885060	G/A	cg11031976	chr2:198649780	BOLL	-0.47	-6.78	-0.31	4.09e-11	Ulcerative colitis;
LUAD	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	7.22	0.33	2.36e-12	Breast cancer;
LUAD	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.15	0.33	3.73e-12	Prostate cancer;
LUAD	cis	rs5756813	0.661	rs2285177	chr22:38205894	A/G	cg06521852	chr22:38141419	TRIOBP	0.43	7.96	0.36	1.6e-14	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs2274273	0.870	rs66696758	chr14:55766509	G/A	cg04306507	chr14:55594613	LGALS3	0.42	8.63	0.39	1.21e-16	Protein biomarker;
LUAD	cis	rs7607369	0.714	rs4674338	chr2:219647487	A/G	cg02176678	chr2:219576539	TTLL4	0.67	13.6	0.55	3.26e-35	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg08888203	chr3:10149979	C3orf24	0.75	13.08	0.54	4.53e-33	Alzheimer's disease;
LUAD	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.45	0.34	5.23e-13	Bipolar disorder;
LUAD	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg10523679	chr1:76189770	ACADM	-0.45	-6.38	-0.3	4.69e-10	Daytime sleep phenotypes;
LUAD	cis	rs12612619	0.732	rs6716275	chr2:27227707	C/T	cg00617064	chr2:27272375	NA	0.36	7.08	0.33	6.03e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg25554036	chr4:6271136	WFS1	0.67	11.03	0.47	5.03e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2296342	0.522	rs1536036	chr6:33632014	A/G	cg14003231	chr6:33640908	ITPR3	0.46	9.37	0.41	4.39e-19	Schizophrenia;
LUAD	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg06131755	chr6:160182447	ACAT2	0.43	6.48	0.3	2.57e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg17200465	chr3:40428508	ENTPD3	0.28	6.79	0.31	3.75e-11	Renal cell carcinoma;
LUAD	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs6546550	0.743	rs6731941	chr2:70018496	A/G	cg02498382	chr2:70120550	SNRNP27	-0.53	-9.29	-0.41	7.95e-19	Prevalent atrial fibrillation;
LUAD	cis	rs11671005	0.735	rs1122955	chr19:58946203	C/T	cg13877915	chr19:58951672	ZNF132	0.58	7.73	0.35	8.16e-14	Mean platelet volume;
LUAD	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11644478	chr21:40555479	PSMG1	-0.42	-6.94	-0.32	1.47e-11	Menarche (age at onset);
LUAD	cis	rs9902453	0.780	rs57037139	chr17:28173283	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.85	0.43	9.57e-21	Coffee consumption (cups per day);
LUAD	trans	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	11.0	0.47	6.32e-25	Mean corpuscular volume;
LUAD	cis	rs3858704	0.517	rs7297186	chr12:111778178	C/T	cg24530795	chr12:111807189	FAM109A	-0.39	-6.81	-0.31	3.34e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08219700	chr8:58056026	NA	0.59	8.31	0.37	1.33e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2625529	0.730	rs1481860	chr15:72241857	T/C	cg16672083	chr15:72433130	SENP8	0.66	11.98	0.5	1.15e-28	Red blood cell count;
LUAD	cis	rs7122539	0.734	rs2513658	chr11:66628249	G/A	cg24851651	chr11:66362959	CCS	-0.38	-6.88	-0.32	2.16e-11	HIV-1 susceptibility;
LUAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg07677032	chr17:61819896	STRADA	0.57	10.39	0.45	1.14e-22	Prudent dietary pattern;
LUAD	cis	rs367943	0.665	rs13180704	chr5:112969261	A/T	cg12552261	chr5:112820674	MCC	-0.36	-6.51	-0.3	2.07e-10	Type 2 diabetes;
LUAD	cis	rs2777491	0.522	rs7173571	chr15:41712807	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.43	-7.39	-0.34	7.87e-13	Ulcerative colitis;
LUAD	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22496380	chr5:211416	CCDC127	-0.93	-13.12	-0.54	3.15e-33	Breast cancer;
LUAD	cis	rs1044826	0.642	rs176983	chr3:139213755	G/A	cg00490450	chr3:139108681	COPB2	0.41	6.48	0.3	2.49e-10	Obesity-related traits;
LUAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg24642844	chr7:1081250	C7orf50	-0.85	-13.39	-0.55	2.5e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2230307	0.656	rs568089	chr1:100495392	A/G	cg20868668	chr1:100435035	SLC35A3	0.62	7.47	0.34	4.71e-13	Carotid intima media thickness;
LUAD	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg10589385	chr1:150898437	SETDB1	0.4	7.42	0.34	6.35e-13	Tonsillectomy;
LUAD	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg03289416	chr15:75166202	SCAMP2	0.4	7.02	0.32	8.88e-12	Caffeine consumption;
LUAD	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg10755058	chr3:40428713	ENTPD3	0.36	6.64	0.31	9.47e-11	Renal cell carcinoma;
LUAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg22963979	chr7:1858916	MAD1L1	-0.6	-10.63	-0.46	1.48e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg19626725	chr5:178986131	RUFY1	0.4	7.56	0.35	2.51e-13	Lung cancer;
LUAD	cis	rs2992756	0.663	rs3007718	chr1:18808465	T/A	cg14356550	chr1:18808102	KLHDC7A	-0.56	-9.85	-0.43	9.67e-21	Breast cancer;
LUAD	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.09	0.33	5.67e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11651000	0.761	rs11079788	chr17:45820723	C/T	cg06532163	chr17:45867833	NA	0.46	7.43	0.34	6.25e-13	IgG glycosylation;
LUAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14159672	chr1:205819179	PM20D1	0.79	16.18	0.62	3.65e-46	Menarche (age at onset);
LUAD	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg15790184	chr11:494944	RNH1	0.56	6.83	0.32	2.9e-11	Body mass index;
LUAD	cis	rs4638749	1.000	rs12616140	chr2:108867728	A/G	cg06795125	chr2:108905320	SULT1C2	-0.41	-6.46	-0.3	2.9e-10	Blood pressure;
LUAD	cis	rs986417	1.000	rs6573318	chr14:61087985	A/G	cg27398547	chr14:60952738	C14orf39	0.64	7.09	0.33	5.66e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs1298062	0.790	rs1274597	chr19:50973259	T/C	cg11430371	chr19:50961752	MYBPC2	0.33	6.77	0.31	4.25e-11	Age of smoking initiation;
LUAD	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.62	0.35	1.73e-13	Platelet count;
LUAD	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg08999081	chr20:33150536	PIGU	-0.63	-14.12	-0.57	2.25e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg02773041	chr1:40204384	PPIE	0.53	8.81	0.39	3.29e-17	Blood protein levels;
LUAD	cis	rs60154123	0.614	rs628423	chr1:210460137	C/T	cg22029157	chr1:209979665	IRF6	0.49	6.36	0.3	5.33e-10	Coronary artery disease;
LUAD	cis	rs877282	0.891	rs12357999	chr10:796468	A/C	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg13047869	chr3:10149882	C3orf24	0.67	9.99	0.44	3.17e-21	Alzheimer's disease;
LUAD	cis	rs6901250	1.000	rs6924002	chr6:117114223	A/T	cg12892004	chr6:117198278	RFX6	0.33	6.73	0.31	5.58e-11	C-reactive protein levels;
LUAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg14893161	chr1:205819251	PM20D1	-0.52	-8.68	-0.39	8.62e-17	Parkinson's disease;
LUAD	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg17063962	chr7:91808500	NA	0.67	11.96	0.5	1.32e-28	Breast cancer;
LUAD	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg25358565	chr5:93447407	FAM172A	-0.59	-6.79	-0.31	3.77e-11	Diabetic retinopathy;
LUAD	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg08601574	chr20:25228251	PYGB	0.46	8.82	0.39	2.94e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9462027	0.606	rs2038841	chr6:34738203	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.84	-0.39	2.55e-17	Systemic lupus erythematosus;
LUAD	cis	rs1559088	1.000	rs28803235	chr19:33561804	G/A	cg03563238	chr19:33554763	RHPN2	-0.38	-8.89	-0.4	1.73e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg22532475	chr10:104410764	TRIM8	-0.44	-8.72	-0.39	6.46e-17	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	8.62	0.39	1.34e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg27446573	chr6:127587934	RNF146	0.41	6.36	0.3	5.28e-10	Breast cancer;
LUAD	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg00071950	chr4:10020882	SLC2A9	-0.78	-15.84	-0.61	1.03e-44	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg13770153	chr20:60521292	NA	-0.58	-9.11	-0.4	3.4e-18	Body mass index;
LUAD	cis	rs7843479	0.931	rs1031883	chr8:21788936	G/A	cg03445287	chr8:21823731	XPO7	-0.47	-8.46	-0.38	4.32e-16	Mean corpuscular volume;
LUAD	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg25233709	chr10:116636983	FAM160B1	0.41	8.26	0.37	1.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.73	-14.15	-0.57	1.74e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg26752003	chr8:145688521	CYHR1	-0.45	-7.84	-0.36	3.75e-14	Age at first birth;
LUAD	cis	rs72627123	0.582	rs62005101	chr14:74500585	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.59	7.8	0.35	4.87e-14	Morning vs. evening chronotype;
LUAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg09033563	chr22:24373618	LOC391322	-0.5	-7.88	-0.36	2.72e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg15485101	chr11:133734466	NA	0.39	8.61	0.39	1.48e-16	Childhood ear infection;
LUAD	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg09915433	chr19:53449742	NA	-0.67	-12.55	-0.52	6.32e-31	Psoriasis;
LUAD	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03452623	chr4:187889614	NA	-0.83	-16.87	-0.63	3.37e-49	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-9.07	-0.4	4.47e-18	Bipolar disorder;
LUAD	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg04546413	chr19:29218101	NA	0.59	7.64	0.35	1.47e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg13854012	chr2:162103682	NA	-0.46	-9.08	-0.4	4.05e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg09509183	chr1:209979624	IRF6	0.56	7.07	0.32	6.53e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg18099408	chr3:52552593	STAB1	-0.39	-6.75	-0.31	4.78e-11	Bipolar disorder;
LUAD	cis	rs7737355	0.773	rs184949	chr5:130815593	A/G	cg06307176	chr5:131281290	NA	-0.44	-7.37	-0.34	9e-13	Life satisfaction;
LUAD	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg23262351	chr6:79576851	IRAK1BP1	-0.41	-6.95	-0.32	1.36e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.46	0.52	1.48e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11230563	1.000	rs11230563	chr11:60776209	C/T	cg10158843	chr11:60776172	CD6	0.41	7.32	0.34	1.3e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs12681287	0.752	rs4282548	chr8:87270792	A/T	cg00550725	chr8:87521180	FAM82B	0.45	6.43	0.3	3.36e-10	Caudate activity during reward;
LUAD	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg01616529	chr11:638424	DRD4	-0.43	-6.42	-0.3	3.67e-10	Systemic lupus erythematosus;
LUAD	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg14784868	chr12:69753453	YEATS4	0.46	7.71	0.35	9.16e-14	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs10392	0.543	rs6028208	chr20:37556075	T/A	cg27552599	chr20:37590471	DHX35	0.4	6.85	0.32	2.61e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg04025307	chr7:1156635	C7orf50	0.58	7.2	0.33	2.7e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.64	11.29	0.48	5.05e-26	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.88	0.32	2.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7177699	0.557	rs6495335	chr15:79117133	G/T	cg15571903	chr15:79123663	NA	0.38	7.6	0.35	1.87e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg09555818	chr19:45449301	APOC2	0.58	12.86	0.53	3.47e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15884411	chr2:96932403	CIAO1;TMEM127	-0.44	-6.92	-0.32	1.72e-11	Height;
LUAD	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg22705602	chr4:152727874	NA	-0.4	-7.18	-0.33	3.16e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg17173187	chr15:85201210	NMB	0.51	9.09	0.4	3.75e-18	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg01017244	chr2:74357527	NA	0.91	13.5	0.55	8.87e-35	Gestational age at birth (maternal effect);
LUAD	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg04727924	chr7:799746	HEATR2	-0.57	-7.03	-0.32	8.27e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.4	-0.42	3.49e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7683537	0.673	rs1401363	chr4:185643862	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.7	0.55	1.26e-35	Systemic lupus erythematosus;
LUAD	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg17173187	chr15:85201210	NMB	0.48	8.47	0.38	4.02e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.77	-0.31	4.24e-11	Longevity;
LUAD	cis	rs12286929	0.610	rs11606838	chr11:115042859	C/A	cg04055981	chr11:115044050	NA	0.43	7.69	0.35	1.05e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg19077165	chr18:44547161	KATNAL2	-0.41	-7.08	-0.33	6.07e-12	Personality dimensions;
LUAD	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.14	0.48	1.9e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-9.61	-0.42	6.52e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs13095912	0.778	rs11914529	chr3:185296513	C/T	cg11274856	chr3:185301563	NA	0.48	8.98	0.4	8.91e-18	Systolic blood pressure;
LUAD	cis	rs73086581	0.947	rs11906612	chr20:3903634	C/T	cg02187196	chr20:3869020	PANK2	0.47	6.66	0.31	8.55e-11	Response to antidepressants in depression;
LUAD	cis	rs6761276	0.837	rs11887823	chr2:113835311	T/A	cg06383401	chr2:113825234	IL1F10	-0.3	-6.41	-0.3	3.97e-10	Protein quantitative trait loci;
LUAD	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.19	-0.41	1.81e-18	Bipolar disorder;
LUAD	cis	rs35883536	0.588	rs114540631	chr1:101101249	A/G	cg06223162	chr1:101003688	GPR88	0.37	6.81	0.31	3.35e-11	Monocyte count;
LUAD	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg07402062	chr16:89894098	SPIRE2	0.47	12.25	0.51	9.73e-30	Vitiligo;
LUAD	cis	rs877282	0.898	rs2004478	chr10:770709	C/A	cg17470449	chr10:769945	NA	0.63	9.23	0.41	1.29e-18	Uric acid levels;
LUAD	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.64	-8.3	-0.37	1.41e-15	Iron status biomarkers;
LUAD	cis	rs7503807	0.967	rs12939549	chr17:78611724	C/T	cg09596252	chr17:78655493	RPTOR	-0.4	-7.8	-0.35	4.97e-14	Obesity;
LUAD	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.94	-0.36	1.9e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg05340658	chr4:99064831	C4orf37	0.54	9.23	0.41	1.27e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4372836	0.930	rs7589860	chr2:28967648	A/T	cg09522027	chr2:28974177	PPP1CB	-0.62	-10.05	-0.44	1.86e-21	Body mass index;
LUAD	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.04	0.32	7.79e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg06608945	chr2:219082296	ARPC2	0.47	7.85	0.36	3.44e-14	Colorectal cancer;
LUAD	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg04545296	chr12:48745243	ZNF641	0.39	9.95	0.44	4.14e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	trans	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.44	-6.7	-0.31	6.58e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs11088226	0.681	rs4547609	chr21:33953542	G/A	cg09050820	chr6:167586206	TCP10L2	0.93	13.2	0.54	1.43e-33	Gastritis;
LUAD	cis	rs2067615	0.507	rs11113083	chr12:107073316	C/A	cg15890332	chr12:107067104	RFX4	0.42	8.86	0.4	2.18e-17	Heart rate;
LUAD	cis	rs7582720	1.000	rs76298043	chr2:203814694	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg12623302	chr6:28058802	ZSCAN12L1	0.37	6.38	0.3	4.65e-10	Depression;
LUAD	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg27170947	chr2:26402098	FAM59B	-0.81	-11.51	-0.49	7.14e-27	Gut microbiome composition (summer);
LUAD	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.53	-10.93	-0.47	1.15e-24	Monocyte percentage of white cells;
LUAD	cis	rs7336332	0.598	rs74183666	chr13:28007765	A/T	cg22138327	chr13:27999177	GTF3A	0.76	9.83	0.43	1.1e-20	Weight;
LUAD	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.59	-6.75	-0.31	4.91e-11	Lung cancer in ever smokers;
LUAD	cis	rs62458065	0.513	rs7788809	chr7:32552622	T/A	cg20159608	chr7:32802032	NA	-0.68	-10.1	-0.44	1.22e-21	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg13393036	chr8:95962371	TP53INP1	0.29	6.6	0.31	1.2e-10	Alzheimer's disease (late onset);
LUAD	cis	rs68170813	0.652	rs117775624	chr7:107124113	C/T	cg23024343	chr7:107201750	COG5	0.51	6.43	0.3	3.55e-10	Coronary artery disease;
LUAD	cis	rs16910800	1.000	rs12420544	chr11:23200505	A/C	cg20040320	chr11:23191996	NA	-0.47	-7.01	-0.32	9.2e-12	Cancer;
LUAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.68	-0.35	1.14e-13	Personality dimensions;
LUAD	cis	rs4698790	0.635	rs17040826	chr4:110686776	C/G	cg07850274	chr4:110748770	RRH	-0.4	-6.58	-0.3	1.43e-10	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUAD	cis	rs12545109	0.879	rs2609994	chr8:57365844	A/G	cg19413350	chr8:57351067	NA	-0.47	-7.08	-0.33	5.97e-12	Obesity-related traits;
LUAD	cis	rs829883	0.966	rs249815	chr12:98893709	A/G	cg25150519	chr12:98850993	NA	0.67	11.08	0.47	3.26e-25	Colorectal adenoma (advanced);
LUAD	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.59	-11.35	-0.48	3.11e-26	Homoarginine levels;
LUAD	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg23758822	chr17:41437982	NA	0.99	20.48	0.71	2.94e-65	Menopause (age at onset);
LUAD	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg13390004	chr1:15929781	NA	0.47	7.91	0.36	2.22e-14	Systolic blood pressure;
LUAD	cis	rs4356932	1.000	rs7670789	chr4:76940381	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.35	-6.4	-0.3	4.13e-10	Blood protein levels;
LUAD	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg08677398	chr8:58056175	NA	0.53	6.8	0.31	3.48e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg27411982	chr8:10470053	RP1L1	-0.36	-6.71	-0.31	6.12e-11	Neuroticism;
LUAD	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	8.6	0.39	1.54e-16	Lung cancer in ever smokers;
LUAD	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg16686185	chr17:78078845	GAA	-0.39	-6.57	-0.3	1.45e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg00933542	chr6:150070202	PCMT1	0.5	10.48	0.45	5.3e-23	Lung cancer;
LUAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	cis	rs6076065	0.612	rs11905630	chr20:23326165	G/C	cg11657817	chr20:23433608	CST11	0.5	9.31	0.41	6.86e-19	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1483890	0.723	rs6549207	chr3:69412018	T/G	cg22125112	chr3:69402811	FRMD4B	0.45	7.57	0.35	2.31e-13	Resting heart rate;
LUAD	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg10295955	chr4:187884368	NA	-1.07	-24.25	-0.76	4.55e-82	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg05283184	chr6:79620031	NA	-0.43	-7.5	-0.34	3.85e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4812048	1.000	rs55905547	chr20:57589995	A/G	cg14073986	chr20:57617431	SLMO2	0.54	6.63	0.31	1.02e-10	Mean platelet volume;
LUAD	cis	rs4711350	0.765	rs1318691	chr6:33761884	G/A	cg18005901	chr6:33739558	LEMD2	-0.59	-9.4	-0.42	3.42e-19	Schizophrenia;
LUAD	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg26384229	chr12:38710491	ALG10B	0.48	7.72	0.35	8.24e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.62	8.3	0.37	1.39e-15	Gut microbiome composition (summer);
LUAD	cis	rs12545109	0.643	rs1119707	chr8:57411548	T/C	cg09654669	chr8:57350985	NA	-0.66	-9.4	-0.42	3.52e-19	Obesity-related traits;
LUAD	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg08999081	chr20:33150536	PIGU	-0.37	-7.44	-0.34	5.54e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg27005118	chr17:13972210	COX10	0.49	10.75	0.46	5.57e-24	Temperament;
LUAD	cis	rs921968	0.643	rs598701	chr2:219387005	C/G	cg02176678	chr2:219576539	TTLL4	-0.61	-11.86	-0.5	3.34e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg20891558	chr2:74357851	NA	0.98	17.37	0.65	2.2e-51	Gestational age at birth (maternal effect);
LUAD	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg18230493	chr5:56204884	C5orf35	-0.86	-12.44	-0.52	1.7e-30	Initial pursuit acceleration;
LUAD	cis	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg27411982	chr8:10470053	RP1L1	0.44	7.71	0.35	9.13e-14	Neuroticism;
LUAD	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg06060754	chr5:176797920	RGS14	-0.53	-10.22	-0.44	4.77e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.31	-0.41	7.2e-19	Life satisfaction;
LUAD	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.89	0.76	1.8e-80	Chronic sinus infection;
LUAD	cis	rs3106136	0.967	rs282449	chr4:95141228	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.6	-0.35	1.89e-13	Capecitabine sensitivity;
LUAD	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg11494091	chr17:61959527	GH2	0.74	18.38	0.67	6.8e-56	Prudent dietary pattern;
LUAD	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg15468180	chr1:107600409	PRMT6	0.45	7.76	0.35	6.44e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg00074818	chr8:8560427	CLDN23	0.66	10.13	0.44	9.68e-22	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg05340658	chr4:99064831	C4orf37	0.53	8.93	0.4	1.31e-17	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg21659725	chr3:3221576	CRBN	0.38	6.49	0.3	2.4e-10	Resting heart rate;
LUAD	cis	rs904251	0.523	rs2776874	chr6:37483197	C/T	cg25019722	chr6:37503610	NA	-0.32	-7.49	-0.34	3.98e-13	Cognitive performance;
LUAD	cis	rs11190604	0.767	rs3829162	chr10:102172752	T/G	cg07570687	chr10:102243282	WNT8B	0.44	6.35	0.3	5.43e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9522267	0.737	rs9522289	chr13:112232110	G/A	cg10483660	chr13:112241077	NA	-0.31	-6.5	-0.3	2.26e-10	Hepatitis;
LUAD	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg02527881	chr3:46936655	PTH1R	0.45	8.79	0.39	3.82e-17	Colorectal cancer;
LUAD	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg14668632	chr7:2872130	GNA12	-0.76	-13.64	-0.55	2.27e-35	Height;
LUAD	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg19336497	chr11:14380999	RRAS2	-0.69	-16.0	-0.61	2.17e-45	Sense of smell;
LUAD	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg22029157	chr1:209979665	IRF6	0.79	11.63	0.49	2.64e-27	Cleft lip with or without cleft palate;
LUAD	cis	rs4911259	0.513	rs4287835	chr20:31457337	T/C	cg13636640	chr20:31349939	DNMT3B	-0.58	-9.57	-0.42	9.26e-20	Inflammatory bowel disease;
LUAD	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg17372223	chr3:52568218	NT5DC2	0.38	6.97	0.32	1.26e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6906287	0.647	rs4027880	chr6:118734134	A/T	cg18833306	chr6:118973337	C6orf204	0.46	8.22	0.37	2.6e-15	Electrocardiographic conduction measures;
LUAD	trans	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg21659725	chr3:3221576	CRBN	0.38	6.47	0.3	2.74e-10	Resting heart rate;
LUAD	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg17644776	chr2:200775616	C2orf69	0.57	9.27	0.41	9.53e-19	Schizophrenia;
LUAD	cis	rs921968	0.565	rs3755045	chr2:219609162	T/G	cg02176678	chr2:219576539	TTLL4	-0.59	-12.0	-0.5	9.65e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs887829	0.569	rs4663333	chr2:234655303	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-8.45	-0.38	4.81e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg05665937	chr4:1216051	CTBP1	0.38	6.41	0.3	3.8e-10	Obesity-related traits;
LUAD	cis	rs3750965	1.000	rs61881024	chr11:68837794	A/G	cg06818126	chr11:68850279	TPCN2	-0.48	-6.97	-0.32	1.25e-11	Hair color;
LUAD	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.06	-0.4	4.71e-18	Total body bone mineral density;
LUAD	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg06630425	chr16:818451	MSLN	-0.44	-7.58	-0.35	2.18e-13	Mean corpuscular volume;
LUAD	trans	rs4714291	0.963	rs4714292	chr6:40003679	A/C	cg02267698	chr19:7991119	CTXN1	0.46	7.0	0.32	9.89e-12	Strep throat;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg27570636	chr1:214454189	SMYD2	0.43	7.18	0.33	3.24e-12	Bilirubin levels;
LUAD	trans	rs8002861	0.840	rs1819597	chr13:44429553	G/A	cg17145862	chr1:211918768	LPGAT1	0.73	16.48	0.63	1.74e-47	Leprosy;
LUAD	trans	rs2465065	0.666	rs13238018	chr7:104430466	T/C	cg14417498	chr1:165322199	LMX1A	-0.45	-6.7	-0.31	6.56e-11	Gout;
LUAD	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg20744362	chr22:50050164	C22orf34	0.42	9.12	0.41	3.17e-18	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg02743256	chr7:2109353	MAD1L1	-0.46	-6.59	-0.31	1.32e-10	Bipolar disorder;
LUAD	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg06640241	chr16:89574553	SPG7	0.45	7.15	0.33	3.73e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs10908458	0.743	rs7367207	chr1:155079477	C/T	cg23973274	chr1:155060172	NA	-0.45	-7.91	-0.36	2.32e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.83	-0.32	2.95e-11	Bipolar disorder;
LUAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg16031515	chr1:205743344	RAB7L1	-0.35	-7.0	-0.32	9.89e-12	Menarche (age at onset);
LUAD	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg05043794	chr9:111880884	C9orf5	-0.39	-6.56	-0.3	1.55e-10	Menarche (age at onset);
LUAD	cis	rs11178918	0.585	rs11178939	chr12:72160103	T/C	cg10168894	chr12:72148281	RAB21	-0.53	-6.58	-0.3	1.39e-10	Economic and political preferences (time);
LUAD	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg23985595	chr17:80112537	CCDC57	0.52	9.53	0.42	1.26e-19	Life satisfaction;
LUAD	trans	rs12517041	0.872	rs6887084	chr5:23307439	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg09035930	chr12:129282057	SLC15A4	0.75	17.91	0.66	8.5e-54	Systemic lupus erythematosus;
LUAD	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg03806693	chr22:41940476	POLR3H	0.71	9.53	0.42	1.2e-19	Vitiligo;
LUAD	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.12	0.33	4.7e-12	Motion sickness;
LUAD	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.34	6.81	0.31	3.39e-11	Obesity-related traits;
LUAD	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg06784218	chr1:46089804	CCDC17	-0.57	-12.09	-0.51	4.29e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg01516881	chr6:292596	DUSP22	-0.56	-9.42	-0.42	2.93e-19	Menopause (age at onset);
LUAD	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.87	-14.04	-0.56	5.08e-37	Homoarginine levels;
LUAD	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg06221963	chr1:154839813	KCNN3	-0.7	-14.82	-0.58	2.5e-40	Prostate cancer;
LUAD	cis	rs62238980	0.614	rs77896321	chr22:32413371	C/T	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21545522	chr1:205238299	TMCC2	0.39	7.25	0.33	1.94e-12	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg07234876	chr8:600039	NA	1.17	10.86	0.47	2.08e-24	IgG glycosylation;
LUAD	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg10518543	chr12:38710700	ALG10B	-0.49	-8.22	-0.37	2.44e-15	Morning vs. evening chronotype;
LUAD	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.43	0.42	2.76e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg15445000	chr17:37608096	MED1	0.42	7.74	0.35	7.44e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12667521	chr19:29218732	NA	0.6	8.88	0.4	1.91e-17	Methadone dose in opioid dependence;
LUAD	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.86	0.4	2.24e-17	Parkinson's disease;
LUAD	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.51	0.38	3.08e-16	Platelet count;
LUAD	cis	rs3818285	0.515	rs4918471	chr10:111660500	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.71	-11.09	-0.47	2.85e-25	Superior crus of antihelix expression;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg25858261	chr10:12085058	UPF2	0.39	6.53	0.3	1.85e-10	Bipolar disorder;
LUAD	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg09263875	chr16:632152	PIGQ	0.8	17.18	0.64	1.51e-50	Height;
LUAD	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg05896524	chr21:47604654	C21orf56	0.54	8.88	0.4	1.93e-17	Testicular germ cell tumor;
LUAD	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg23758822	chr17:41437982	NA	1.01	20.95	0.71	2.33e-67	Menopause (age at onset);
LUAD	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg24829409	chr8:58192753	C8orf71	-0.54	-8.28	-0.37	1.69e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg24644049	chr4:85504048	CDS1	0.93	7.81	0.36	4.5e-14	Skin colour saturation;
LUAD	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg08470875	chr2:26401718	FAM59B	0.76	9.55	0.42	1.04e-19	Gut microbiome composition (summer);
LUAD	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.38	6.36	0.3	5.11e-10	Rheumatoid arthritis;
LUAD	cis	rs4243830	0.677	rs6693922	chr1:6584804	A/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.69	9.02	0.4	6.83e-18	Body mass index;
LUAD	cis	rs6964587	0.507	rs12539439	chr7:91917365	A/C	cg01689657	chr7:91764605	CYP51A1	0.31	7.27	0.33	1.79e-12	Breast cancer;
LUAD	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg19635926	chr16:89946313	TCF25	0.78	6.89	0.32	2.01e-11	Skin colour saturation;
LUAD	cis	rs4706831	0.625	rs638056	chr6:80980808	G/A	cg08355045	chr6:80787529	NA	-0.5	-9.02	-0.4	6.67e-18	Joint mobility (Beighton score);
LUAD	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg27170947	chr2:26402098	FAM59B	-0.62	-8.96	-0.4	1.07e-17	Gut microbiome composition (summer);
LUAD	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg12588279	chr6:26043732	HIST1H2BB	0.38	6.47	0.3	2.68e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7040024	1.000	rs7040024	chr9:845516	A/C	cg14021170	chr9:826657	NA	-0.4	-6.41	-0.3	3.88e-10	Testicular germ cell tumor;Testicular cancer;
LUAD	cis	rs714515	0.586	rs4916263	chr1:172450689	A/C	cg13446689	chr1:172328377	DNM3	-0.32	-6.36	-0.3	5.35e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	trans	rs7181230	1.000	rs28587891	chr15:40365106	T/A	cg22705835	chr10:65332833	REEP3	-0.4	-8.3	-0.37	1.39e-15	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg09658497	chr7:2847517	GNA12	-0.42	-7.4	-0.34	7.42e-13	Height;
LUAD	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg09904177	chr6:26538194	HMGN4	0.42	7.05	0.32	7.49e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs806215	1.000	rs806215	chr7:127237312	T/C	cg25922125	chr7:127225783	GCC1	-0.48	-7.03	-0.32	8.22e-12	Type 2 diabetes;
LUAD	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.78	10.98	0.47	7.54e-25	Smoking behavior;
LUAD	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23158103	chr7:148848205	ZNF398	-0.65	-12.35	-0.51	3.78e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs738322	0.640	rs738321	chr22:38568833	C/G	cg25457927	chr22:38595422	NA	-0.53	-12.66	-0.52	2.17e-31	Cutaneous nevi;
LUAD	cis	rs8049603	0.812	rs12149898	chr16:23198054	C/T	cg09552652	chr16:23197569	SCNN1G	0.36	6.43	0.3	3.47e-10	Multiple sclerosis;
LUAD	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.62	0.31	1.12e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg22823121	chr1:150693482	HORMAD1	0.41	7.96	0.36	1.57e-14	Melanoma;
LUAD	cis	rs78707713	0.836	rs112843485	chr10:71211707	T/C	cg12610070	chr10:71211762	TSPAN15	-0.39	-7.17	-0.33	3.41e-12	Venous thromboembolism;
LUAD	cis	rs2901656	1.000	rs6691993	chr1:172426998	T/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.38	7.35	0.34	1.02e-12	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg14829155	chr15:31115871	NA	-0.49	-8.39	-0.38	7.59e-16	Huntington's disease progression;
LUAD	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg16102102	chr5:83017553	HAPLN1	0.6	10.41	0.45	9.21e-23	Prostate cancer;
LUAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	6.4	0.3	4.22e-10	Lung cancer in ever smokers;
LUAD	cis	rs2795502	0.564	rs3004259	chr10:43486041	A/G	cg08461752	chr10:43522343	NA	0.81	9.44	0.42	2.46e-19	Blood protein levels;
LUAD	cis	rs9929218	0.529	rs11640736	chr16:68738324	G/T	cg01251360	chr16:68772225	CDH1	-0.27	-8.48	-0.38	3.68e-16	Colorectal cancer;
LUAD	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg15445000	chr17:37608096	MED1	0.44	7.95	0.36	1.68e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs11771526	0.901	rs10244622	chr7:32302960	C/T	cg13207630	chr7:32358064	NA	0.6	7.32	0.34	1.27e-12	Body mass index;
LUAD	trans	rs7395662	0.963	rs11039950	chr11:48737471	G/A	cg15704280	chr7:45808275	SEPT13	0.43	6.61	0.31	1.17e-10	HDL cholesterol;
LUAD	cis	rs11958404	0.932	rs72818127	chr5:157452227	C/T	cg05962755	chr5:157440814	NA	0.69	9.3	0.41	7.89e-19	IgG glycosylation;
LUAD	cis	rs12545109	0.800	rs1440763	chr8:57410481	C/A	cg17761419	chr8:57350749	NA	-0.53	-7.51	-0.34	3.48e-13	Obesity-related traits;
LUAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-10.39	-0.45	1.11e-22	Lymphocyte counts;
LUAD	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg13798912	chr7:905769	UNC84A	-0.62	-7.12	-0.33	4.66e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs73198271	0.628	rs11783457	chr8:8588842	G/C	cg01851573	chr8:8652454	MFHAS1	0.48	6.75	0.31	4.9e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg20607798	chr8:58055168	NA	0.66	8.82	0.39	3.08e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.69	12.22	0.51	1.24e-29	Mean corpuscular volume;
LUAD	cis	rs7213347	0.799	rs216195	chr17:2203167	T/G	cg02569219	chr17:2266849	SGSM2	0.5	8.25	0.37	2.01e-15	Total body bone mineral density;
LUAD	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg24565620	chr2:194026	NA	-0.42	-6.93	-0.32	1.63e-11	Blood protein levels;
LUAD	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.43e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg02527881	chr3:46936655	PTH1R	-0.5	-10.21	-0.44	4.99e-22	Colorectal cancer;
LUAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg27454412	chr7:1067447	C7orf50	0.48	7.72	0.35	8.28e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7614311	0.636	rs3774702	chr3:63856870	G/A	cg22134162	chr3:63841271	THOC7	-0.36	-6.7	-0.31	6.47e-11	Lung function (FVC);Lung function (FEV1);
LUAD	trans	rs9467711	0.651	rs34197618	chr6:26083519	T/C	cg01620082	chr3:125678407	NA	-1.02	-8.07	-0.37	7.29e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6426558	0.537	rs7523167	chr1:227365304	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.56	-8.95	-0.4	1.11e-17	Neutrophil percentage of white cells;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11416597	chr1:33722623	ZNF362	-0.39	-6.36	-0.3	5.26e-10	Cancer;
LUAD	cis	rs4774899	0.715	rs2435907	chr15:57333416	A/G	cg14026238	chr15:57616123	NA	-0.41	-7.76	-0.35	6.43e-14	Urinary tract infection frequency;
LUAD	cis	rs10865541	0.902	rs12474836	chr2:3418874	A/G	cg13173536	chr2:3403300	TTC15	-0.34	-6.61	-0.31	1.16e-10	Obesity-related traits;
LUAD	cis	rs2235649	0.552	rs8056773	chr16:1959432	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.46	-7.08	-0.33	5.9e-12	Blood metabolite levels;
LUAD	cis	rs7187994	0.848	rs12443928	chr16:84780202	G/T	cg07647771	chr16:84786436	USP10	-0.37	-8.87	-0.4	2.15e-17	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs116095464	1.000	rs2721025	chr5:347444	G/C	cg22496380	chr5:211416	CCDC127	-1.01	-8.01	-0.36	1.1e-14	Breast cancer;
LUAD	cis	rs17655565	1.000	rs17126647	chr12:52706194	C/T	cg08257133	chr12:52711352	KRT83	0.4	6.91	0.32	1.76e-11	Plasma amyloid beta peptide concentrations (ABx-42);
LUAD	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	6.09e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg26898376	chr11:64110657	CCDC88B	0.37	6.81	0.31	3.26e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs35740288	0.731	rs2344440	chr15:86161565	T/C	cg13263323	chr15:86062960	AKAP13	-0.44	-7.08	-0.33	6.03e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	trans	rs12517041	1.000	rs1366453	chr5:23283409	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.47	-0.3	2.73e-10	Calcium levels;
LUAD	trans	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg03929089	chr4:120376271	NA	0.57	6.56	0.3	1.54e-10	Axial length;
LUAD	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg05043794	chr9:111880884	C9orf5	-0.42	-7.01	-0.32	9.47e-12	Menarche (age at onset);
LUAD	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg16988262	chr1:15930761	NA	0.42	6.97	0.32	1.19e-11	Systolic blood pressure;
LUAD	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg07917127	chr4:99064746	C4orf37	0.5	8.1	0.37	5.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12949688	1.000	rs4793566	chr17:55815469	T/C	cg12582317	chr17:55822272	NA	0.35	7.08	0.33	5.89e-12	Schizophrenia;
LUAD	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg09835421	chr16:68378352	PRMT7	-0.82	-8.85	-0.4	2.42e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs877282	0.891	rs11595385	chr10:800539	A/G	cg06581033	chr10:766294	NA	-0.55	-7.47	-0.34	4.5e-13	Uric acid levels;
LUAD	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg10356904	chr22:49881777	NA	-0.41	-8.16	-0.37	3.83e-15	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.24	-0.37	2.12e-15	Breast cancer;
LUAD	trans	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg18335740	chr13:41363409	SLC25A15	0.73	14.21	0.57	9.54e-38	Lewy body disease;
LUAD	cis	rs17135859	0.904	rs66580212	chr5:113002078	A/G	cg12552261	chr5:112820674	MCC	0.53	6.61	0.31	1.17e-10	F-cell distribution;
LUAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00166722	chr3:10149974	C3orf24	0.74	12.64	0.52	2.68e-31	Alzheimer's disease;
LUAD	cis	rs7793919	0.691	rs4077986	chr7:4766676	A/G	cg09789173	chr7:4769017	FOXK1	0.64	12.69	0.53	1.73e-31	Mosquito bite size;
LUAD	trans	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg14791747	chr16:20752902	THUMPD1	0.69	9.3	0.41	7.81e-19	Cognitive test performance;
LUAD	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg16325326	chr1:53192061	ZYG11B	-0.61	-10.92	-0.47	1.24e-24	Monocyte count;
LUAD	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg07636037	chr3:49044803	WDR6	0.54	8.46	0.38	4.38e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs7178572	0.568	rs10152181	chr15:77678346	A/G	cg15453836	chr15:77711506	NA	-0.36	-6.42	-0.3	3.59e-10	Type 2 diabetes;
LUAD	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg09904177	chr6:26538194	HMGN4	0.43	7.26	0.33	1.87e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg11693508	chr17:37793320	STARD3	0.82	10.45	0.45	6.64e-23	Bipolar disorder;
LUAD	cis	rs6062509	0.630	rs6011058	chr20:62356627	C/T	cg21849932	chr20:62369462	LIME1	-0.45	-7.06	-0.32	6.93e-12	Prostate cancer;
LUAD	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg17757837	chr7:157058334	UBE3C	-0.44	-7.79	-0.35	5.18e-14	Body mass index;
LUAD	trans	rs11039798	0.925	rs7929225	chr11:48931739	G/C	cg15704280	chr7:45808275	SEPT13	0.67	7.8	0.35	4.95e-14	Axial length;
LUAD	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg00074818	chr8:8560427	CLDN23	0.66	10.11	0.44	1.16e-21	Obesity-related traits;
LUAD	cis	rs6987853	0.933	rs6474401	chr8:42367068	T/C	cg09913449	chr8:42400586	C8orf40	-0.38	-6.86	-0.32	2.4e-11	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg11502198	chr6:26597334	ABT1	0.56	9.35	0.41	5.23e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg11766577	chr21:47581405	C21orf56	-0.64	-11.52	-0.49	6.72e-27	Testicular germ cell tumor;
LUAD	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg15181151	chr6:150070149	PCMT1	0.42	8.63	0.39	1.3e-16	Lung cancer;
LUAD	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg15448220	chr1:150897856	SETDB1	-0.42	-7.08	-0.33	6.08e-12	Tonsillectomy;
LUAD	cis	rs12681287	0.570	rs10956830	chr8:87430483	T/A	cg00550725	chr8:87521180	FAM82B	-0.45	-6.63	-0.31	1.02e-10	Caudate activity during reward;
LUAD	cis	rs9906944	0.707	rs1523136	chr17:47144532	A/G	cg14634687	chr17:47094252	IGF2BP1	0.27	6.75	0.31	4.89e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg23750338	chr8:142222470	SLC45A4	0.62	14.1	0.57	2.71e-37	Immature fraction of reticulocytes;
LUAD	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.31	6.37	0.3	5.09e-10	Depression;
LUAD	cis	rs9811920	0.683	rs10936003	chr3:99667565	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	7.19	0.33	2.88e-12	Axial length;
LUAD	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	7.56	0.34	2.6e-13	Menopause (age at onset);
LUAD	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	7.52	0.34	3.4e-13	Schizophrenia;
LUAD	cis	rs7927771	0.507	rs11039432	chr11:47873327	G/A	cg18512352	chr11:47633146	NA	0.36	6.38	0.3	4.72e-10	Subjective well-being;
LUAD	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg03714773	chr7:91764589	CYP51A1	0.27	6.48	0.3	2.59e-10	Breast cancer;
LUAD	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg17105886	chr17:28927953	LRRC37B2	0.79	7.88	0.36	2.81e-14	Body mass index;
LUAD	cis	rs955333	0.565	rs7770413	chr6:154904487	A/G	cg20019720	chr6:154832845	CNKSR3	0.36	7.02	0.32	8.73e-12	Diabetic kidney disease;
LUAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	13.02	0.53	7.98e-33	Lymphocyte counts;
LUAD	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.63	-0.35	1.56e-13	Blood metabolite levels;
LUAD	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs4713675	0.565	rs9348924	chr6:33705436	A/G	cg13859433	chr6:33739653	LEMD2	-0.3	-7.32	-0.34	1.23e-12	Plateletcrit;
LUAD	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg25344623	chr2:136566232	LCT	0.35	6.84	0.32	2.7e-11	Mosquito bite size;
LUAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg21782813	chr7:2030301	MAD1L1	0.6	10.56	0.46	2.7e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs7677751	0.767	rs11133315	chr4:55082158	G/A	cg17187183	chr4:55093834	PDGFRA	0.5	8.22	0.37	2.59e-15	Corneal astigmatism;
LUAD	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg18129178	chr5:148520854	ABLIM3	0.58	9.06	0.4	4.76e-18	Breast cancer;
LUAD	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg19302996	chr17:73780495	UNK	-0.42	-6.43	-0.3	3.41e-10	Psoriasis;
LUAD	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.63	-10.0	-0.44	2.92e-21	Primary sclerosing cholangitis;
LUAD	cis	rs829883	1.000	rs249837	chr12:98876535	A/G	cg25150519	chr12:98850993	NA	0.66	10.98	0.47	7.7e-25	Colorectal adenoma (advanced);
LUAD	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg11663144	chr21:46675770	NA	-0.57	-11.27	-0.48	6.08e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9362426	0.708	rs4707367	chr6:88101188	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.38	-0.3	4.58e-10	Depressive episodes in bipolar disorder;
LUAD	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg06740227	chr12:86229804	RASSF9	-0.4	-7.08	-0.33	6.06e-12	Major depressive disorder;
LUAD	cis	rs2425143	1.000	rs2425142	chr20:34350346	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.44	-0.34	5.49e-13	Blood protein levels;
LUAD	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	7.5	0.34	3.77e-13	Rheumatoid arthritis;
LUAD	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg17173187	chr15:85201210	NMB	0.5	8.67	0.39	9.55e-17	Schizophrenia;
LUAD	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg04756594	chr16:24857601	SLC5A11	0.72	12.09	0.51	4.04e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19346786	chr7:2764209	NA	-0.56	-12.19	-0.51	1.72e-29	Height;
LUAD	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg11057378	chr10:81107060	PPIF	0.38	7.14	0.33	4.11e-12	Height;
LUAD	cis	rs11650494	0.908	rs9907478	chr17:47395729	C/T	cg08112188	chr17:47440006	ZNF652	0.87	7.51	0.34	3.66e-13	Prostate cancer;
LUAD	cis	rs7616330	0.836	rs6780338	chr3:71029408	C/T	cg20891481	chr3:71115714	FOXP1	-0.42	-7.42	-0.34	6.67e-13	QT interval;
LUAD	cis	rs459571	0.606	rs457420	chr9:136909261	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.66	-11.89	-0.5	2.45e-28	Platelet distribution width;
LUAD	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg26924012	chr15:45694286	SPATA5L1	0.86	14.75	0.58	4.98e-40	Homoarginine levels;
LUAD	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg13319975	chr6:146136371	FBXO30	-0.65	-11.11	-0.48	2.41e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg15448220	chr1:150897856	SETDB1	0.56	9.56	0.42	9.56e-20	Melanoma;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg08424427	chr5:180670815	SNORD95;GNB2L1	0.39	6.44	0.3	3.23e-10	Optic cup area;
LUAD	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg15448220	chr1:150897856	SETDB1	-0.5	-8.71	-0.39	7.1e-17	Melanoma;
LUAD	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.96	0.44	3.84e-21	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg02782426	chr3:40428986	ENTPD3	0.4	8.7	0.39	7.45e-17	Renal cell carcinoma;
LUAD	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg08085267	chr17:45401833	C17orf57	-0.65	-11.61	-0.49	3.01e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs354225	0.544	rs10208219	chr2:54806047	G/A	cg01766943	chr2:54829624	SPTBN1	0.4	7.44	0.34	5.71e-13	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	8.49	0.38	3.54e-16	Breast cancer;
LUAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12016809	chr21:47604291	C21orf56	0.63	10.21	0.44	5.23e-22	Testicular germ cell tumor;
LUAD	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg01475377	chr6:109611718	NA	-0.53	-10.09	-0.44	1.4e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs4917833	0.789	rs10786427	chr10:100218382	G/A	cg25691326	chr10:100228212	HPSE2	0.35	6.36	0.3	5.21e-10	Pediatric bone mineral density (femoral neck);
LUAD	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10979	1.000	rs1416206	chr6:143889385	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-10.3	-0.45	2.33e-22	Hypospadias;
LUAD	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg11317459	chr13:21872234	NA	-1.09	-14.71	-0.58	7.3e-40	White matter hyperintensity burden;
LUAD	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.45	-0.34	5.31e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs367615	0.918	rs115145487	chr5:108888146	A/G	cg17395555	chr5:108820864	NA	0.53	8.65	0.39	1.07e-16	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs2625529	0.730	rs2929527	chr15:72282270	T/G	cg16672083	chr15:72433130	SENP8	0.62	11.4	0.48	1.89e-26	Red blood cell count;
LUAD	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.6	-0.35	1.95e-13	Blood trace element (Zn levels);
LUAD	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15664640	chr17:80829946	TBCD	-0.84	-17.14	-0.64	2.13e-50	Breast cancer;
LUAD	cis	rs17095355	1.000	rs734164	chr10:111698160	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.71	-9.69	-0.43	3.41e-20	Biliary atresia;
LUAD	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg03609598	chr5:56110824	MAP3K1	0.49	7.3	0.33	1.48e-12	Initial pursuit acceleration;
LUAD	cis	rs13191362	0.573	rs1877769	chr6:163252315	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.72	10.18	0.44	6.57e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10504073	0.647	rs10808744	chr8:49988984	A/G	cg00325661	chr8:49890786	NA	0.45	10.09	0.44	1.33e-21	Blood metabolite ratios;
LUAD	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.91	-0.36	2.3e-14	Blood metabolite levels;
LUAD	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg23933602	chr10:16859644	RSU1	0.66	10.06	0.44	1.7e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs12079745	0.793	rs12740226	chr1:169183257	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-1.06	-7.74	-0.35	7.17e-14	QT interval;
LUAD	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg03161606	chr19:29218774	NA	-0.57	-7.22	-0.33	2.42e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00166722	chr3:10149974	C3orf24	0.74	12.68	0.52	1.89e-31	Alzheimer's disease;
LUAD	cis	rs7107174	0.892	rs2510031	chr11:77969956	T/C	cg02023728	chr11:77925099	USP35	0.42	7.13	0.33	4.48e-12	Testicular germ cell tumor;
LUAD	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.44	0.34	5.74e-13	Tonsillectomy;
LUAD	trans	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg14917512	chr19:3094685	GNA11	0.57	6.81	0.31	3.4e-11	Diabetic kidney disease;
LUAD	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg03474202	chr17:45855739	NA	-0.38	-8.96	-0.4	1.09e-17	IgG glycosylation;
LUAD	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01570182	chr17:44337453	NA	-0.95	-13.97	-0.56	9.69e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg04995722	chr7:26192034	NFE2L3	-0.38	-6.4	-0.3	4.25e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10819733	chr22:24237672	NA	-0.39	-7.23	-0.33	2.3e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg18131467	chr2:239335373	ASB1	0.72	12.33	0.51	4.62e-30	Multiple system atrophy;
LUAD	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg26384229	chr12:38710491	ALG10B	-0.38	-6.53	-0.3	1.84e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2235649	0.833	rs9926962	chr16:1851826	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.4	-6.5	-0.3	2.27e-10	Blood metabolite levels;
LUAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg10729496	chr3:10149963	C3orf24	0.65	9.6	0.42	6.87e-20	Alzheimer's disease;
LUAD	trans	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg18187862	chr3:45730750	SACM1L	0.5	7.89	0.36	2.55e-14	Primary sclerosing cholangitis;
LUAD	cis	rs12950390	1.000	rs12950390	chr17:45830948	A/G	cg06532163	chr17:45867833	NA	0.41	6.5	0.3	2.29e-10	IgG glycosylation;
LUAD	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg00316803	chr15:76480434	C15orf27	-0.4	-7.61	-0.35	1.82e-13	Blood metabolite levels;
LUAD	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg09509183	chr1:209979624	IRF6	0.61	7.01	0.32	9.56e-12	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.45	0.3	3.12e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2663905	0.611	rs2663920	chr15:81396404	A/G	cg09888468	chr15:81410853	NA	-0.48	-8.09	-0.37	6.52e-15	QT interval (drug interaction);
LUAD	trans	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.35	0.54	3.51e-34	Exhaled nitric oxide output;
LUAD	cis	rs1965732	0.563	rs13390724	chr2:3721632	G/A	cg19052272	chr2:3704530	ALLC	-0.42	-7.82	-0.36	4.29e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs4713118	0.619	rs200486	chr6:27779506	C/T	cg21204522	chr6:27730016	NA	-0.48	-7.11	-0.33	4.89e-12	Parkinson's disease;
LUAD	cis	rs2224391	0.518	rs72815610	chr6:5283881	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.68	-8.49	-0.38	3.59e-16	Height;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg19740248	chr6:27114132	HIST1H2BK;HIST1H2AH	0.41	6.45	0.3	2.98e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7731657	0.537	rs12719432	chr5:130354295	C/T	cg08523029	chr5:130500466	HINT1	-0.54	-6.79	-0.31	3.77e-11	Fasting plasma glucose;
LUAD	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg23649088	chr2:200775458	C2orf69	0.64	8.44	0.38	5.1e-16	Schizophrenia;
LUAD	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.35	-0.34	1.01e-12	Type 2 diabetes;
LUAD	cis	rs12579753	0.917	rs12316644	chr12:82205497	C/T	cg07988820	chr12:82153109	PPFIA2	0.47	7.56	0.35	2.52e-13	Resting heart rate;
LUAD	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg11262906	chr1:85462892	MCOLN2	-0.48	-6.58	-0.3	1.38e-10	Serum sulfate level;
LUAD	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06022373	chr22:39101656	GTPBP1	0.45	7.14	0.33	4.04e-12	Menopause (age at onset);
LUAD	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg13870426	chr17:30244630	NA	-0.57	-6.63	-0.31	1.05e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.74	-8.81	-0.39	3.26e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13315871	0.929	rs1045115	chr3:58305199	C/T	cg12435725	chr3:58293450	RPP14	-0.69	-7.65	-0.35	1.42e-13	Cholesterol, total;
LUAD	cis	rs7771547	0.603	rs7344	chr6:36570366	A/G	cg04289385	chr6:36355825	ETV7	0.48	6.57	0.3	1.44e-10	Platelet distribution width;
LUAD	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg15485101	chr11:133734466	NA	0.34	7.69	0.35	1.05e-13	Childhood ear infection;
LUAD	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	13.57	0.55	4.64e-35	Lung cancer in ever smokers;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06938333	chr1:11740950	MAD2L2	-0.4	-6.48	-0.3	2.57e-10	Height;
LUAD	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1983170	0.673	rs61798836	chr1:92013622	T/C	cg25838465	chr1:92012736	NA	0.51	6.45	0.3	3.02e-10	Eosinophil percentage of white cells;
LUAD	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.51e-15	Bipolar disorder;
LUAD	cis	rs6906287	0.647	rs3798420	chr6:118786486	T/C	cg18833306	chr6:118973337	C6orf204	0.46	8.17	0.37	3.5e-15	Electrocardiographic conduction measures;
LUAD	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-8.08	-0.37	6.67e-15	HDL cholesterol;
LUAD	cis	rs12618769	0.597	rs11884553	chr2:99131206	T/C	cg10123293	chr2:99228465	UNC50	0.47	8.47	0.38	4.2e-16	Bipolar disorder;
LUAD	cis	rs2742417	1.000	rs2742385	chr3:45756270	G/A	cg10512202	chr3:45649293	LIMD1	0.36	6.45	0.3	3.03e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs11112613	0.713	rs871220	chr12:105938558	G/A	cg03607813	chr12:105948248	NA	0.83	13.03	0.54	7.2e-33	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs2692947	0.702	rs6717101	chr2:96505552	C/T	cg23100626	chr2:96804247	ASTL	0.31	7.74	0.35	7.14e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs12620999	1.000	rs10803655	chr2:238075551	C/T	cg23555395	chr2:238036564	NA	-0.6	-9.19	-0.41	1.75e-18	Systemic lupus erythematosus;
LUAD	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.34	-9.16	-0.41	2.24e-18	Total body bone mineral density;
LUAD	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg02423579	chr7:2872169	GNA12	-0.8	-14.02	-0.56	6.33e-37	Height;
LUAD	cis	rs7809950	0.954	rs3779494	chr7:107250355	G/A	cg23024343	chr7:107201750	COG5	0.76	12.36	0.52	3.56e-30	Coronary artery disease;
LUAD	trans	rs75804782	0.641	rs2340870	chr2:239356026	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	8.47	0.38	4.03e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg08888203	chr3:10149979	C3orf24	-0.72	-11.03	-0.47	4.98e-25	Alzheimer's disease;
LUAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg23992470	chr4:843637	GAK	0.77	8.04	0.36	9.41e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs859767	0.704	rs1818614	chr2:135356351	A/G	cg12500956	chr2:135428796	TMEM163	-0.3	-7.77	-0.35	6.04e-14	Neuroticism;
LUAD	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg19980929	chr12:42632907	YAF2	0.33	6.41	0.3	3.93e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg25894440	chr7:65020034	NA	-0.68	-7.36	-0.34	9.49e-13	Diabetic kidney disease;
LUAD	cis	rs7216064	1.000	rs8079754	chr17:65887896	A/G	cg08758996	chr17:66097529	LOC651250	0.44	6.75	0.31	4.91e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-14.98	-0.59	5.41e-41	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg24733560	chr20:60626293	TAF4	0.47	9.19	0.41	1.77e-18	Body mass index;
LUAD	cis	rs6005807	0.719	rs9625509	chr22:28989246	G/C	cg12565055	chr22:29076175	TTC28	0.71	7.98	0.36	1.41e-14	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs1215050	0.791	rs649866	chr4:98738826	T/C	cg24818145	chr4:99064322	C4orf37	0.41	6.88	0.32	2.19e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg12863693	chr15:85201151	NMB	0.37	6.5	0.3	2.28e-10	Schizophrenia;
LUAD	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg12573674	chr2:1569213	NA	-0.57	-7.93	-0.36	2.02e-14	IgG glycosylation;
LUAD	cis	rs77106637	0.789	rs76550717	chr11:72428172	A/G	cg03713592	chr11:72463424	ARAP1	0.92	12.09	0.51	4.15e-29	Type 2 diabetes;
LUAD	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg07636037	chr3:49044803	WDR6	0.36	6.55	0.3	1.65e-10	Resting heart rate;
LUAD	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg16405210	chr4:1374714	KIAA1530	-0.6	-9.29	-0.41	8.41e-19	Longevity;
LUAD	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg09137382	chr11:130731461	NA	0.4	7.42	0.34	6.48e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1595825	0.627	rs1435567	chr2:198748726	T/C	cg11031976	chr2:198649780	BOLL	-0.49	-7.19	-0.33	2.96e-12	Ulcerative colitis;
LUAD	cis	rs870825	0.616	rs10022834	chr4:185649431	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.63	-0.71	6.37e-66	Height;
LUAD	cis	rs6840360	0.571	rs62327278	chr4:152558790	G/C	cg22705602	chr4:152727874	NA	-0.43	-7.45	-0.34	5.16e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6712932	1.000	rs1978821	chr2:105833235	C/T	cg22878388	chr2:105853796	NA	-0.37	-6.51	-0.3	2.18e-10	Type 2 diabetes;
LUAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg04871131	chr7:94954202	PON1	-0.62	-10.72	-0.46	6.77e-24	Paraoxonase activity;
LUAD	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg15128208	chr22:42549153	NA	-0.42	-8.77	-0.39	4.31e-17	Cognitive function;
LUAD	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg26384229	chr12:38710491	ALG10B	-0.43	-7.19	-0.33	3.01e-12	Morning vs. evening chronotype;
LUAD	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg27426351	chr10:43362370	NA	-0.54	-8.28	-0.37	1.67e-15	Blood protein levels;
LUAD	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg12615879	chr12:58013172	SLC26A10	-0.57	-12.57	-0.52	5.32e-31	Multiple sclerosis;
LUAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg08027265	chr7:2291960	NA	-0.43	-7.21	-0.33	2.54e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg02176678	chr2:219576539	TTLL4	0.68	13.66	0.55	1.94e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg01475377	chr6:109611718	NA	0.51	10.18	0.44	6.3e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg16988262	chr1:15930761	NA	-0.41	-6.47	-0.3	2.76e-10	Systolic blood pressure;
LUAD	cis	rs2579500	0.807	rs11891926	chr2:97339781	A/G	cg23100626	chr2:96804247	ASTL	-0.27	-6.77	-0.31	4.29e-11	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs12208915	0.731	rs9361473	chr6:79657042	C/T	cg18132916	chr6:79620363	NA	0.53	6.98	0.32	1.12e-11	Left atrial antero-posterior diameter;
LUAD	cis	rs250677	0.522	rs10040598	chr5:148365720	C/A	cg18129178	chr5:148520854	ABLIM3	0.51	7.62	0.35	1.68e-13	Breast cancer;
LUAD	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg26384229	chr12:38710491	ALG10B	0.49	7.9	0.36	2.47e-14	Morning vs. evening chronotype;
LUAD	cis	rs7584330	0.554	rs3751105	chr2:238428459	G/A	cg14458575	chr2:238380390	NA	0.64	10.33	0.45	1.82e-22	Prostate cancer;
LUAD	cis	rs11771526	0.681	rs76949995	chr7:32414431	G/A	cg27532318	chr7:32358331	NA	0.68	7.2	0.33	2.85e-12	Body mass index;
LUAD	cis	rs2692947	0.537	rs4907274	chr2:96363682	G/A	cg23100626	chr2:96804247	ASTL	0.33	7.89	0.36	2.67e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg07741184	chr6:167504864	NA	0.33	7.77	0.35	6.15e-14	Crohn's disease;
LUAD	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.9	-0.47	1.47e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg17372223	chr3:52568218	NT5DC2	0.45	8.73	0.39	5.77e-17	Electroencephalogram traits;
LUAD	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg15448220	chr1:150897856	SETDB1	0.53	9.29	0.41	8.46e-19	Melanoma;
LUAD	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg15900387	chr1:150738905	CTSS	-0.35	-6.42	-0.3	3.67e-10	Melanoma;
LUAD	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg19875535	chr5:140030758	IK	-0.45	-7.58	-0.35	2.17e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2688608	0.698	rs2227578	chr10:75678715	C/T	cg23231163	chr10:75533350	FUT11	-0.36	-6.69	-0.31	7.29e-11	Inflammatory bowel disease;
LUAD	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg03929089	chr4:120376271	NA	0.54	6.94	0.32	1.47e-11	Axial length;
LUAD	cis	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg07460842	chr6:66804631	NA	1.08	17.28	0.64	5.45e-51	Exhaled nitric oxide output;
LUAD	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.62	-0.39	1.31e-16	Alzheimer's disease (late onset);
LUAD	cis	rs12545109	0.800	rs2576599	chr8:57388410	G/A	cg19413350	chr8:57351067	NA	-0.46	-7.0	-0.32	1.01e-11	Obesity-related traits;
LUAD	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg10589385	chr1:150898437	SETDB1	0.42	7.84	0.36	3.69e-14	Melanoma;
LUAD	cis	rs13315871	0.929	rs13080398	chr3:58300282	A/G	cg12435725	chr3:58293450	RPP14	-0.74	-7.88	-0.36	2.86e-14	Cholesterol, total;
LUAD	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg02176678	chr2:219576539	TTLL4	0.61	11.75	0.5	8.59e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4691139	0.901	rs9762579	chr4:165877990	G/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.48	-9.36	-0.41	4.82e-19	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg07549590	chr16:15018862	NA	-0.4	-7.52	-0.34	3.35e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs5756391	0.546	rs9607398	chr22:37316041	C/T	cg16356956	chr22:37317934	CSF2RB	0.3	6.45	0.3	3.09e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs8017423	0.904	rs11622257	chr14:90715014	C/T	cg14092571	chr14:90743983	NA	0.47	8.05	0.36	8.27e-15	Mortality in heart failure;
LUAD	cis	rs7617773	0.780	rs6782166	chr3:48351683	A/G	cg11946769	chr3:48343235	NME6	0.44	6.79	0.31	3.79e-11	Coronary artery disease;
LUAD	cis	rs4746822	0.559	rs4746825	chr10:70985645	C/T	cg14418922	chr10:70824840	NA	-0.41	-7.81	-0.35	4.58e-14	Glycemic traits (pregnancy);
LUAD	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg15017067	chr4:17643749	FAM184B	-0.35	-6.65	-0.31	9.06e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11947960	chr2:112655492	MERTK	0.42	6.49	0.3	2.41e-10	Gut microbiome composition (summer);
LUAD	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.6	-10.04	-0.44	2.12e-21	Menarche (age at onset);
LUAD	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg07636037	chr3:49044803	WDR6	0.48	8.15	0.37	4.23e-15	Menarche (age at onset);
LUAD	trans	rs9354308	0.899	rs2814153	chr6:66557611	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.53	8.04	0.36	9.08e-15	Metabolite levels;
LUAD	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg00784671	chr22:46762841	CELSR1	-0.58	-7.75	-0.35	6.77e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1448094	0.842	rs10863159	chr12:86459140	T/C	cg00310523	chr12:86230176	RASSF9	-0.35	-7.41	-0.34	7e-13	Major depressive disorder;
LUAD	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg25358565	chr5:93447407	FAM172A	0.57	6.74	0.31	5.19e-11	Diabetic retinopathy;
LUAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	13.29	0.54	6.48e-34	Lymphocyte counts;
LUAD	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg14324370	chr2:177042789	NA	0.37	6.82	0.31	3.09e-11	IgG glycosylation;
LUAD	cis	rs2249625	0.874	rs2463745	chr6:72876135	A/G	cg18830697	chr6:72922368	RIMS1	-0.36	-6.93	-0.32	1.59e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs7394190	0.748	rs78985317	chr10:75514465	C/T	cg02286717	chr10:75415704	SYNPO2L	-0.42	-7.16	-0.33	3.62e-12	Incident atrial fibrillation;
LUAD	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg14343924	chr8:8086146	FLJ10661	0.46	7.52	0.34	3.38e-13	Joint mobility (Beighton score);
LUAD	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg05082376	chr22:42548792	NA	-0.45	-7.94	-0.36	1.89e-14	Schizophrenia;
LUAD	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg00277334	chr10:82204260	NA	-0.48	-8.04	-0.36	9.14e-15	Post bronchodilator FEV1;
LUAD	cis	rs12989701	0.935	rs12994284	chr2:127874020	T/C	cg08168897	chr2:127865431	BIN1	0.44	7.13	0.33	4.35e-12	Alzheimer's disease (late onset);
LUAD	cis	rs8028313	0.731	rs4331293	chr15:67987801	A/G	cg24579218	chr15:68104479	NA	-0.5	-8.64	-0.39	1.13e-16	Obesity;
LUAD	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg17063962	chr7:91808500	NA	0.68	12.02	0.5	7.99e-29	Breast cancer;
LUAD	cis	rs7737355	0.947	rs244739	chr5:130806874	A/C	cg25547332	chr5:131281432	NA	-0.42	-6.39	-0.3	4.3e-10	Life satisfaction;
LUAD	cis	rs12986413	0.624	rs2159213	chr19:2136102	T/C	cg09261902	chr19:2140048	AP3D1	0.34	6.79	0.31	3.88e-11	Height;
LUAD	cis	rs6089584	0.586	rs2296087	chr20:60584328	T/A	cg13770153	chr20:60521292	NA	-0.45	-7.65	-0.35	1.38e-13	Body mass index;
LUAD	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg16342193	chr10:102329863	NA	-0.39	-6.87	-0.32	2.29e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg14196790	chr5:131705035	SLC22A5	0.39	7.0	0.32	1.04e-11	Blood metabolite levels;
LUAD	cis	rs10901296	0.660	rs11789055	chr9:133766295	T/C	cg13397898	chr9:133768931	QRFP	0.5	7.02	0.32	9.12e-12	Bilirubin levels;
LUAD	cis	rs9296092	0.500	rs35150558	chr6:33519612	T/A	cg13560919	chr6:33536144	NA	-0.89	-16.71	-0.63	1.64e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg04727924	chr7:799746	HEATR2	-0.52	-6.72	-0.31	5.79e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg24675056	chr1:15929824	NA	0.48	8.35	0.38	9.97e-16	Systolic blood pressure;
LUAD	cis	rs6831352	0.840	rs34634551	chr4:100067362	C/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.26	-0.54	8.48e-34	Alcohol dependence;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04517169	chr19:56111325	FIZ1;ZNF524	0.41	6.39	0.3	4.46e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg24813613	chr7:1882135	MAD1L1	-0.44	-6.97	-0.32	1.21e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00802000	chr16:706648	WDR90	-0.43	-8.15	-0.37	4.3e-15	Height;
LUAD	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg00898013	chr13:113819073	PROZ	-0.67	-11.99	-0.5	1.05e-28	Platelet distribution width;
LUAD	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg00933542	chr6:150070202	PCMT1	0.43	9.24	0.41	1.26e-18	Lung cancer;
LUAD	cis	rs7043114	0.525	rs7847929	chr9:95154244	C/T	cg14631576	chr9:95140430	CENPP	-0.39	-7.85	-0.36	3.51e-14	Height;
LUAD	cis	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg08601574	chr20:25228251	PYGB	0.49	8.99	0.4	8.08e-18	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10129255	0.536	rs17113249	chr14:107134290	A/G	cg23076370	chr14:107095027	NA	-0.41	-8.27	-0.37	1.76e-15	Kawasaki disease;
LUAD	cis	rs2688608	0.967	rs2633299	chr10:75656754	T/G	cg23231163	chr10:75533350	FUT11	-0.38	-7.16	-0.33	3.71e-12	Inflammatory bowel disease;
LUAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00149659	chr3:10157352	C3orf10	0.86	11.57	0.49	4.56e-27	Alzheimer's disease;
LUAD	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg01528321	chr10:82214614	TSPAN14	0.46	7.18	0.33	3.14e-12	Post bronchodilator FEV1;
LUAD	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg07414643	chr4:187882934	NA	0.34	6.95	0.32	1.42e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs754466	0.651	rs11002317	chr10:79617648	G/A	cg17075019	chr10:79541650	NA	-0.86	-17.87	-0.66	1.34e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg21775007	chr8:11205619	TDH	0.57	10.2	0.44	5.55e-22	Retinal vascular caliber;
LUAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11048434	0.736	rs34798934	chr12:9108444	C/T	cg26114124	chr12:9217669	LOC144571	0.36	6.5	0.3	2.33e-10	Sjögren's syndrome;
LUAD	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	7.11	0.33	5.12e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg03289416	chr15:75166202	SCAMP2	-0.55	-9.36	-0.41	4.93e-19	Breast cancer;
LUAD	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24308560	chr3:49941425	MST1R	-0.59	-9.86	-0.43	9.05e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg14671364	chr1:107599128	PRMT6	-0.63	-10.81	-0.47	3.22e-24	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4692589	0.606	rs12645495	chr4:170933909	T/C	cg19918862	chr4:170955249	NA	0.33	6.86	0.32	2.47e-11	Anxiety disorder;
LUAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.47	6.66	0.31	8.74e-11	Renal function-related traits (BUN);
LUAD	cis	rs7172809	0.573	rs60079927	chr15:77591614	T/C	cg11865553	chr15:77376250	NA	-0.38	-6.43	-0.3	3.53e-10	Glucose homeostasis traits;
LUAD	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg02574844	chr11:5959923	NA	-0.38	-6.65	-0.31	9.15e-11	DNA methylation (variation);
LUAD	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg05082376	chr22:42548792	NA	-0.38	-6.74	-0.31	5.27e-11	Cognitive function;
LUAD	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.52	-10.24	-0.45	3.99e-22	Social autistic-like traits;
LUAD	cis	rs2109514	0.967	rs4730743	chr7:116145957	A/T	cg12739419	chr7:116140593	CAV2	-0.37	-7.86	-0.36	3.16e-14	Prevalent atrial fibrillation;
LUAD	cis	rs10465746	0.780	rs12139191	chr1:84387871	A/C	cg10977910	chr1:84465055	TTLL7	0.59	9.65	0.42	4.93e-20	Obesity-related traits;
LUAD	cis	rs7731657	0.537	rs10076495	chr5:130362953	A/C	cg08523029	chr5:130500466	HINT1	-0.6	-7.74	-0.35	7.54e-14	Fasting plasma glucose;
LUAD	cis	rs11771526	0.551	rs1008540	chr7:32249622	A/G	cg27532318	chr7:32358331	NA	0.44	6.68	0.31	7.57e-11	Body mass index;
LUAD	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg04673462	chr1:38461896	NA	-0.4	-7.11	-0.33	5.06e-12	Coronary artery disease;
LUAD	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.5	-0.34	3.89e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg10729496	chr3:10149963	C3orf24	-0.58	-9.39	-0.42	3.68e-19	Alzheimer's disease;
LUAD	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg20891283	chr12:69753455	YEATS4	0.45	7.21	0.33	2.62e-12	Blood protein levels;
LUAD	cis	rs7224314	1.000	rs6504503	chr17:65386690	A/T	cg01507342	chr17:65387096	PITPNC1	-0.55	-9.17	-0.41	2.07e-18	Diisocyanate-induced asthma;
LUAD	cis	rs7551222	0.749	rs4951409	chr1:204560990	A/T	cg20240347	chr1:204465584	NA	-0.33	-6.54	-0.3	1.74e-10	Schizophrenia;
LUAD	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg26384229	chr12:38710491	ALG10B	0.48	7.72	0.35	8.7e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs11048434	0.736	rs2377672	chr12:9112414	A/G	cg23795048	chr12:9217529	LOC144571	0.42	7.76	0.35	6.61e-14	Sjögren's syndrome;
LUAD	cis	rs829883	0.664	rs829876	chr12:98842138	A/G	cg25150519	chr12:98850993	NA	0.72	13.67	0.55	1.78e-35	Colorectal adenoma (advanced);
LUAD	cis	rs2019216	0.521	rs12449447	chr17:21888786	C/T	cg05591447	chr17:21909280	FLJ36000	-0.28	-6.61	-0.31	1.16e-10	Pelvic organ prolapse;
LUAD	cis	rs1232027	0.700	rs1643649	chr5:79939449	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg07677032	chr17:61819896	STRADA	0.57	10.34	0.45	1.78e-22	Prudent dietary pattern;
LUAD	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg15208524	chr1:10270712	KIF1B	0.43	6.69	0.31	7.21e-11	Hepatocellular carcinoma;
LUAD	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg18490616	chr2:88469792	THNSL2	0.69	7.14	0.33	4.09e-12	Plasma clusterin levels;
LUAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg13047869	chr3:10149882	C3orf24	0.65	10.93	0.47	1.17e-24	Alzheimer's disease;
LUAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22857025	chr5:266934	NA	-0.96	-14.42	-0.57	1.24e-38	Breast cancer;
LUAD	cis	rs933688	0.532	rs10072084	chr5:90539203	A/G	cg17503389	chr5:90575422	NA	0.44	7.05	0.32	7.46e-12	Smoking behavior;
LUAD	cis	rs8077889	1.000	rs59044152	chr17:41888747	A/G	cg26893861	chr17:41843967	DUSP3	0.96	14.82	0.58	2.61e-40	Triglycerides;
LUAD	cis	rs9581857	0.547	rs9581872	chr13:28086058	C/T	cg22138327	chr13:27999177	GTF3A	0.82	8.75	0.39	5.16e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	trans	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	8.98	0.4	8.74e-18	Mean corpuscular volume;
LUAD	cis	rs57590327	0.555	rs13062054	chr3:81833906	A/G	cg07356753	chr3:81810745	GBE1	-0.62	-10.14	-0.44	8.78e-22	Extraversion;
LUAD	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-23.72	-0.76	1.02e-79	Height;
LUAD	cis	rs17152411	1.000	rs12569940	chr10:126592684	T/C	cg07906193	chr10:126599966	NA	0.56	7.81	0.35	4.6e-14	Height;
LUAD	trans	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg02002194	chr4:3960332	NA	0.27	6.4	0.3	4.03e-10	Retinal vascular caliber;
LUAD	trans	rs2288327	0.643	rs1559908	chr2:179336347	C/T	cg14011486	chr1:26737247	LIN28	-0.57	-7.92	-0.36	2.15e-14	Atrial fibrillation;
LUAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.53	0.3	1.88e-10	Prudent dietary pattern;
LUAD	cis	rs7089973	0.872	rs17092542	chr10:116630289	G/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.61	0.42	6.8e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg15790184	chr11:494944	RNH1	0.56	6.86	0.32	2.4e-11	Body mass index;
LUAD	cis	rs758324	0.812	rs2133706	chr5:131165216	T/G	cg06307176	chr5:131281290	NA	0.44	7.29	0.33	1.5e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg01788221	chr16:89496183	ANKRD11	-0.38	-7.29	-0.33	1.54e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg17971929	chr21:40555470	PSMG1	0.56	8.89	0.4	1.78e-17	Cognitive function;
LUAD	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg16049864	chr8:95962084	TP53INP1	0.53	10.19	0.44	5.82e-22	Type 2 diabetes;
LUAD	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg02734326	chr4:10020555	SLC2A9	-0.48	-8.09	-0.37	6.29e-15	Bone mineral density;
LUAD	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg13877915	chr19:58951672	ZNF132	0.73	13.49	0.55	9.9e-35	Uric acid clearance;
LUAD	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08109568	chr15:31115862	NA	0.78	13.47	0.55	1.21e-34	Huntington's disease progression;
LUAD	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.52	-10.79	-0.46	3.78e-24	Monocyte percentage of white cells;
LUAD	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg23231163	chr10:75533350	FUT11	-0.52	-9.46	-0.42	2.11e-19	Inflammatory bowel disease;
LUAD	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg02493740	chr2:85810744	VAMP5	-0.64	-11.83	-0.5	4.39e-28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.64	-0.42	4.99e-20	Alzheimer's disease;
LUAD	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg08213375	chr14:104286397	PPP1R13B	0.28	7.22	0.33	2.38e-12	Schizophrenia;
LUAD	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg21138405	chr5:131827807	IRF1	-0.57	-12.41	-0.52	2.25e-30	Asthma (sex interaction);
LUAD	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.26	-0.45	3.42e-22	Total body bone mineral density;
LUAD	cis	rs9811920	0.809	rs13059754	chr3:99678490	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	7.3	0.33	1.43e-12	Axial length;
LUAD	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg06608945	chr2:219082296	ARPC2	0.44	7.35	0.34	1.03e-12	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs4692589	1.000	rs4692784	chr4:170938581	A/G	cg19918862	chr4:170955249	NA	0.29	7.05	0.32	7.15e-12	Anxiety disorder;
LUAD	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg05564831	chr3:52568323	NT5DC2	-0.36	-6.62	-0.31	1.1e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg09436375	chr6:42928200	GNMT	-0.29	-8.24	-0.37	2.23e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs853679	0.607	rs13199772	chr6:27834085	A/G	cg06606381	chr12:133084897	FBRSL1	-1.13	-10.46	-0.45	6.49e-23	Depression;
LUAD	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg05342682	chr7:94953680	PON1	-0.52	-7.43	-0.34	6.16e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs782590	0.721	rs1084525	chr2:55929430	C/T	cg18811423	chr2:55921094	PNPT1	0.52	8.61	0.39	1.5e-16	Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.34	0.38	1.06e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6445967	1.000	rs13325699	chr3:58286870	T/C	cg23715586	chr3:58305044	RPP14	0.42	7.65	0.35	1.42e-13	Platelet count;
LUAD	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg03467027	chr4:99064603	C4orf37	0.42	6.82	0.31	3.12e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs420259	0.516	rs120962	chr16:23589986	A/G	cg00143387	chr16:23521605	GGA2	0.7	9.84	0.43	1.08e-20	Bipolar disorder;
LUAD	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.4	0.45	1.06e-22	Lymphocyte percentage of white cells;
LUAD	trans	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg17712092	chr4:129076599	LARP1B	-0.66	-10.75	-0.46	5.38e-24	Eosinophil percentage of white cells;
LUAD	cis	rs367943	0.666	rs6594705	chr5:112692851	T/G	cg12552261	chr5:112820674	MCC	0.46	9.05	0.4	5.42e-18	Type 2 diabetes;
LUAD	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19717773	chr7:2847554	GNA12	-0.56	-9.68	-0.43	3.62e-20	Height;
LUAD	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg04154034	chr17:28927549	LRRC37B2	0.57	6.67	0.31	8.05e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg07537917	chr2:241836409	C2orf54	-0.3	-8.44	-0.38	5.08e-16	Urinary metabolites;
LUAD	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs57920188	0.584	rs12080516	chr1:4089613	C/T	cg10510935	chr1:4059661	NA	0.44	6.75	0.31	4.82e-11	Interleukin-17 levels;
LUAD	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg05368731	chr17:41323189	NBR1	0.98	21.09	0.72	5.32e-68	Menopause (age at onset);
LUAD	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg20469991	chr17:27169893	C17orf63	-0.52	-6.57	-0.3	1.47e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg00631329	chr6:26305371	NA	-0.74	-14.35	-0.57	2.48e-38	Educational attainment;
LUAD	cis	rs732716	0.785	rs56272533	chr19:4420042	T/C	cg21934504	chr19:4445085	UBXN6	0.42	7.01	0.32	9.17e-12	Mean corpuscular volume;
LUAD	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.8	-0.35	4.79e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11756438	0.572	rs2638551	chr6:118998756	T/C	cg21191810	chr6:118973309	C6orf204	0.5	9.59	0.42	7.66e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg17724175	chr1:150552817	MCL1	0.39	9.39	0.42	3.82e-19	Tonsillectomy;
LUAD	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg21862992	chr11:68658383	NA	0.39	7.58	0.35	2.26e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs397969	0.596	rs9901294	chr17:19888501	G/A	cg04132472	chr17:19861366	AKAP10	0.31	6.48	0.3	2.52e-10	Platelet count;
LUAD	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg04282206	chr17:62833786	PLEKHM1P	0.6	9.15	0.41	2.53e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg04851639	chr8:1020857	NA	-0.39	-9.8	-0.43	1.42e-20	Schizophrenia;
LUAD	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.64	0.55	2.2e-35	Tonsillectomy;
LUAD	cis	rs72928364	0.860	rs62274067	chr3:100803474	T/C	cg10123952	chr3:100791384	NA	0.73	7.77	0.35	5.84e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs738321	0.757	rs4821748	chr22:38541936	G/A	cg25457927	chr22:38595422	NA	-0.54	-12.02	-0.5	7.93e-29	Breast cancer;
LUAD	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg16797656	chr11:68205561	LRP5	-0.47	-10.31	-0.45	2.23e-22	Total body bone mineral density;
LUAD	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg09085632	chr11:111637200	PPP2R1B	0.6	9.15	0.41	2.48e-18	Primary sclerosing cholangitis;
LUAD	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg05340658	chr4:99064831	C4orf37	0.54	8.71	0.39	6.66e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs731174	0.959	rs11264092	chr1:38190625	T/C	cg12339802	chr1:38156545	C1orf109	-0.46	-6.97	-0.32	1.19e-11	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg17366294	chr4:99064904	C4orf37	0.61	11.31	0.48	4.27e-26	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg02002194	chr4:3960332	NA	-0.27	-6.66	-0.31	8.52e-11	Neuroticism;
LUAD	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7809950	0.954	rs62482543	chr7:107080656	G/A	cg23024343	chr7:107201750	COG5	-0.75	-12.53	-0.52	7.51e-31	Coronary artery disease;
LUAD	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg10978503	chr1:24200527	CNR2	0.59	12.65	0.52	2.41e-31	Immature fraction of reticulocytes;
LUAD	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg06713675	chr4:122721982	EXOSC9	-0.61	-11.48	-0.49	9.83e-27	Type 2 diabetes;
LUAD	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.47	6.36	0.3	5.22e-10	Schizophrenia;
LUAD	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg03233332	chr7:66118400	NA	-0.43	-6.42	-0.3	3.64e-10	Aortic root size;
LUAD	cis	rs6545883	0.965	rs766447	chr2:61735569	C/T	cg15711740	chr2:61764176	XPO1	-0.39	-6.39	-0.3	4.38e-10	Tuberculosis;
LUAD	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.54	0.3	1.77e-10	Depression;
LUAD	cis	rs7851660	0.839	rs7027221	chr9:100662379	T/C	cg13688889	chr9:100608707	NA	-0.54	-9.17	-0.41	2.08e-18	Strep throat;
LUAD	cis	rs7107174	1.000	rs2511169	chr11:77965321	T/C	cg02023728	chr11:77925099	USP35	0.39	6.58	0.3	1.4e-10	Testicular germ cell tumor;
LUAD	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.33	7.19	0.33	2.98e-12	Cardiac Troponin-T levels;
LUAD	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg12011299	chr4:100065546	ADH4	0.73	13.45	0.55	1.43e-34	Alcohol dependence;
LUAD	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg18451016	chr1:38461880	NA	-0.47	-9.4	-0.42	3.34e-19	Coronary artery disease;
LUAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.5e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs12618769	0.652	rs1516085	chr2:99232312	G/A	cg10123293	chr2:99228465	UNC50	0.47	8.69	0.39	8.33e-17	Bipolar disorder;
LUAD	cis	rs61990749	0.597	rs2267759	chr14:78147615	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.49	-6.51	-0.3	2.14e-10	Fibroblast growth factor basic levels;
LUAD	cis	rs1595825	0.786	rs77773624	chr2:198514845	G/A	cg10547527	chr2:198650123	BOLL	-0.54	-7.74	-0.35	7.64e-14	Ulcerative colitis;
LUAD	trans	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11644478	chr21:40555479	PSMG1	-0.4	-6.59	-0.31	1.3100000000000001e-10	Menarche (age at onset);
LUAD	cis	rs7493	0.901	rs13226149	chr7:95025600	G/A	cg07404485	chr7:94953653	PON1	-0.5	-7.53	-0.34	3.06e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7107174	0.792	rs10751287	chr11:78072476	T/C	cg19901956	chr11:77921274	USP35	-0.48	-6.83	-0.32	2.94e-11	Testicular germ cell tumor;
LUAD	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg15448220	chr1:150897856	SETDB1	0.57	10.03	0.44	2.29e-21	Melanoma;
LUAD	cis	rs7527798	0.592	rs1323722	chr1:207823405	C/T	cg09232269	chr1:207846808	CR1L	-0.34	-6.54	-0.3	1.81e-10	Erythrocyte sedimentation rate;
LUAD	cis	rs877282	0.945	rs11253398	chr10:790012	T/C	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg09436375	chr6:42928200	GNMT	-0.29	-8.41	-0.38	6.5e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg18187862	chr3:45730750	SACM1L	0.55	8.83	0.39	2.78e-17	Primary sclerosing cholangitis;
LUAD	cis	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg07460842	chr6:66804631	NA	0.61	9.56	0.42	9.66e-20	Type 2 diabetes;
LUAD	cis	rs4711336	0.935	rs3818529	chr6:33661106	T/C	cg13859433	chr6:33739653	LEMD2	-0.31	-7.24	-0.33	2.18e-12	Height;
LUAD	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg18252515	chr7:66147081	NA	-0.6	-6.63	-0.31	1.03e-10	Diabetic kidney disease;
LUAD	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg15448220	chr1:150897856	SETDB1	0.51	8.78	0.39	3.98e-17	Melanoma;
LUAD	cis	rs7771547	0.519	rs2057351	chr6:36361682	G/A	cg04289385	chr6:36355825	ETV7	0.5	7.4	0.34	7.37e-13	Platelet distribution width;
LUAD	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg14343924	chr8:8086146	FLJ10661	0.39	6.37	0.3	4.85e-10	Neuroticism;
LUAD	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg00933542	chr6:150070202	PCMT1	0.42	8.68	0.39	8.82e-17	Lung cancer;
LUAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.72	-0.31	5.78e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs677665	0.537	rs6688233	chr1:9335745	A/G	cg25755851	chr1:9335794	NA	-0.81	-14.43	-0.57	1.2e-38	Eosinophil percentage of white cells;
LUAD	cis	rs10129255	0.500	rs34326748	chr14:107190760	G/C	cg23076370	chr14:107095027	NA	-0.43	-8.61	-0.39	1.41e-16	Kawasaki disease;
LUAD	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg17366294	chr4:99064904	C4orf37	0.66	12.76	0.53	9e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg01324343	chr3:183735012	ABCC5	0.94	25.24	0.78	2.14e-86	Anterior chamber depth;
LUAD	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg02951883	chr7:2050386	MAD1L1	-0.75	-12.75	-0.53	1e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg13319975	chr6:146136371	FBXO30	-0.61	-10.5	-0.45	4.62e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.45	0.3	2.98e-10	Depression;
LUAD	trans	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg00953403	chr17:74099816	EXOC7	-0.47	-7.3	-0.33	1.48e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg14828511	chr1:107599125	PRMT6	0.59	10.39	0.45	1.17e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs28374715	0.532	rs7168431	chr15:41672384	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.12	-23.63	-0.75	2.58e-79	Ulcerative colitis;
LUAD	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg12011299	chr4:100065546	ADH4	0.69	12.49	0.52	1.07e-30	Smoking initiation;
LUAD	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg05283184	chr6:79620031	NA	-0.6	-12.12	-0.51	3.28e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg08742575	chr21:47604166	C21orf56	0.51	8.57	0.38	1.91e-16	Testicular germ cell tumor;
LUAD	trans	rs62103177	0.564	rs3930043	chr18:77723832	G/A	cg05926928	chr17:57297772	GDPD1	0.72	8.79	0.39	3.69e-17	Opioid sensitivity;
LUAD	cis	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg07460842	chr6:66804631	NA	0.7	12.73	0.53	1.23e-31	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg06608945	chr2:219082296	ARPC2	0.47	8.28	0.37	1.61e-15	Colorectal cancer;
LUAD	cis	rs367943	0.608	rs2914170	chr5:112982616	C/T	cg12552261	chr5:112820674	MCC	-0.43	-7.95	-0.36	1.73e-14	Type 2 diabetes;
LUAD	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg15017067	chr4:17643749	FAM184B	0.36	7.12	0.33	4.53e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg03609598	chr5:56110824	MAP3K1	-0.62	-8.35	-0.38	9.55e-16	Initial pursuit acceleration;
LUAD	cis	rs3806843	0.576	rs246046	chr5:140329264	T/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.18	-0.37	3.39e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg24558204	chr6:135376177	HBS1L	0.46	8.56	0.38	2.11e-16	Red blood cell count;
LUAD	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg11494091	chr17:61959527	GH2	0.42	7.71	0.35	9.37e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6087990	0.735	rs2424928	chr20:31388636	T/C	cg13636640	chr20:31349939	DNMT3B	0.74	13.18	0.54	1.75e-33	Ulcerative colitis;
LUAD	trans	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg11693508	chr17:37793320	STARD3	0.77	10.13	0.44	9.49e-22	Bipolar disorder;
LUAD	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-14.21	-0.57	1.01e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs56283067	0.847	rs2128543	chr6:44685552	G/A	cg20913747	chr6:44695427	NA	-0.43	-7.31	-0.34	1.3e-12	Total body bone mineral density;
LUAD	cis	rs731174	0.959	rs7527344	chr1:38191560	C/A	cg12339802	chr1:38156545	C1orf109	-0.46	-6.95	-0.32	1.42e-11	Prostate cancer (SNP x SNP interaction);
LUAD	trans	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	10.57	0.46	2.51e-23	Type 2 diabetes;
LUAD	cis	rs10203711	0.966	rs4293520	chr2:239567184	A/C	cg14580085	chr2:239553406	NA	0.41	8.9	0.4	1.64e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg07917127	chr4:99064746	C4orf37	0.4	6.64	0.31	9.73e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9296092	0.538	rs3916674	chr6:33522975	C/T	cg13560919	chr6:33536144	NA	-0.87	-15.58	-0.6	1.35e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg06627628	chr2:24431161	ITSN2	-0.56	-9.33	-0.41	6.08e-19	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs4460629	0.521	rs7367897	chr1:155083289	A/T	cg23973274	chr1:155060172	NA	-0.45	-7.89	-0.36	2.69e-14	Serum magnesium levels;
LUAD	cis	rs344364	0.576	rs238680	chr16:1872160	G/A	cg07386859	chr16:1872102	HAGH	-0.53	-7.83	-0.36	3.88e-14	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs12530845	0.887	rs79100776	chr7:135315817	G/A	cg23117316	chr7:135346802	PL-5283	-0.5	-8.81	-0.39	3.35e-17	Red blood cell traits;
LUAD	cis	rs220324	0.688	rs9975464	chr21:43560055	T/C	cg08841829	chr21:43638893	ABCG1	-0.48	-6.62	-0.31	1.07e-10	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.05	0.36	8.46e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4368243	1.000	rs11082212	chr18:38383174	A/G	cg27304043	chr4:124317966	SPRY1	0.4	6.6	0.31	1.26e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11890956	chr21:40555474	PSMG1	0.75	13.19	0.54	1.7e-33	Cognitive function;
LUAD	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg01017244	chr2:74357527	NA	0.88	14.46	0.58	8.69e-39	Gestational age at birth (maternal effect);
LUAD	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	9.57	0.42	9.18e-20	Lung cancer in ever smokers;
LUAD	cis	rs2455799	1.000	rs2455799	chr3:15701184	G/T	cg16303742	chr3:15540471	COLQ	-0.38	-6.61	-0.31	1.19e-10	Mean platelet volume;
LUAD	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg14671364	chr1:107599128	PRMT6	-0.59	-10.14	-0.44	9.28e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg17279839	chr7:150038598	RARRES2	0.45	7.81	0.35	4.7e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg19678392	chr7:94953810	PON1	-0.58	-7.82	-0.36	4.13e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg27446573	chr6:127587934	RNF146	0.47	6.91	0.32	1.75e-11	Breast cancer;
LUAD	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.47	-0.52	1.29e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs921968	0.565	rs6745700	chr2:219639862	T/C	cg02176678	chr2:219576539	TTLL4	-0.58	-11.72	-0.5	1.18e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg27454412	chr7:1067447	C7orf50	0.39	7.52	0.34	3.28e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs9296095	0.950	rs5745587	chr6:33545125	A/G	cg24505687	chr6:33548425	BAK1	0.42	6.99	0.32	1.07e-11	Platelet count;
LUAD	trans	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg04775059	chr7:64541387	NA	0.53	7.35	0.34	1.02e-12	Aortic root size;
LUAD	trans	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.18	0.51	1.77e-29	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg02527881	chr3:46936655	PTH1R	0.37	6.85	0.32	2.62e-11	QT interval;
LUAD	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg20933634	chr6:27740509	NA	0.53	8.13	0.37	4.83e-15	Parkinson's disease;
LUAD	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06028808	chr11:68637592	NA	0.47	7.59	0.35	2.09e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg02017074	chr12:117425053	FBXW8	0.65	8.57	0.38	2.03e-16	Subcortical brain region volumes;Hippocampal volume;
LUAD	trans	rs2840044	0.711	rs225301	chr17:33922411	T/A	cg19694781	chr19:47549865	TMEM160	-0.86	-12.93	-0.53	1.87e-32	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg18129178	chr5:148520854	ABLIM3	-0.63	-9.66	-0.42	4.55e-20	Breast cancer;
LUAD	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg27411982	chr8:10470053	RP1L1	0.4	7.03	0.32	8.26e-12	Retinal vascular caliber;
LUAD	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg14583973	chr4:3374767	RGS12	0.29	7.12	0.33	4.8e-12	Serum sulfate level;
LUAD	trans	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	10.46	0.45	6.2e-23	Type 2 diabetes;
LUAD	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg09184832	chr6:79620586	NA	-0.48	-9.11	-0.4	3.4e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14159672	chr1:205819179	PM20D1	0.79	16.16	0.62	4.14e-46	Menarche (age at onset);
LUAD	cis	rs4478037	0.822	rs9827863	chr3:33118951	C/T	cg19404215	chr3:33155277	CRTAP	-0.61	-6.76	-0.31	4.65e-11	Major depressive disorder;
LUAD	cis	rs868036	0.718	rs7170185	chr15:68117300	T/A	cg24579218	chr15:68104479	NA	-0.54	-9.25	-0.41	1.14e-18	Restless legs syndrome;
LUAD	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg04450456	chr4:17643702	FAM184B	0.39	7.65	0.35	1.35e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg09365446	chr1:150670422	GOLPH3L	0.64	11.1	0.48	2.6e-25	Melanoma;
LUAD	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg11645453	chr3:52864694	ITIH4	-0.36	-7.41	-0.34	7.13e-13	Bipolar disorder;
LUAD	cis	rs2286885	1.000	rs1537987	chr9:129242112	T/C	cg15282417	chr9:129245246	FAM125B	0.43	8.86	0.4	2.3e-17	Intraocular pressure;
LUAD	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg17366294	chr4:99064904	C4orf37	0.64	12.21	0.51	1.43e-29	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg21681030	chr2:46777652	RHOQ	0.45	7.39	0.34	7.73e-13	Height;
LUAD	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg05434287	chr7:2030229	MAD1L1	0.4	6.68	0.31	7.55e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.9	-0.36	2.43e-14	Menopause (age at onset);
LUAD	cis	rs10979	0.894	rs6924940	chr6:143906183	C/T	cg25407410	chr6:143891975	LOC285740	-0.6	-9.38	-0.41	4.09e-19	Hypospadias;
LUAD	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg15147215	chr3:52552868	STAB1	-0.39	-7.16	-0.33	3.57e-12	Bipolar disorder;
LUAD	cis	rs494562	0.892	rs547963	chr6:86118743	T/C	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs9443645	0.527	rs1415859	chr6:79794858	A/G	cg05283184	chr6:79620031	NA	-0.45	-7.81	-0.35	4.64e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs13064411	0.660	rs1872747	chr3:113175785	T/A	cg10517650	chr3:113235015	CCDC52	-0.56	-9.36	-0.41	4.73e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7731657	0.509	rs11950036	chr5:130350876	T/C	cg08523029	chr5:130500466	HINT1	0.59	7.79	0.35	5.38e-14	Fasting plasma glucose;
LUAD	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg07507251	chr3:52567010	NT5DC2	0.38	7.49	0.34	3.94e-13	Bipolar disorder;
LUAD	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg11266682	chr4:10021025	SLC2A9	0.68	15.84	0.61	1.02e-44	Bone mineral density;
LUAD	cis	rs9811920	0.683	rs7650727	chr3:99688976	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-9.79	-0.43	1.6e-20	Axial length;
LUAD	cis	rs2274273	1.000	rs61508494	chr14:55587297	T/C	cg04306507	chr14:55594613	LGALS3	0.37	7.78	0.35	5.42e-14	Protein biomarker;
LUAD	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg22920501	chr2:26401640	FAM59B	-0.95	-15.05	-0.59	2.65e-41	Gut microbiome composition (summer);
LUAD	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.5	6.87	0.32	2.35e-11	Platelet count;
LUAD	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs1957429	0.572	rs3813421	chr14:65347239	G/A	cg23373153	chr14:65346875	NA	0.55	6.45	0.3	2.99e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.46	-7.76	-0.35	6.65e-14	Tonsillectomy;
LUAD	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg26384229	chr12:38710491	ALG10B	0.45	7.39	0.34	7.76e-13	Bladder cancer;
LUAD	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg07636037	chr3:49044803	WDR6	0.64	12.58	0.52	4.63e-31	Parkinson's disease;
LUAD	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg09367891	chr1:107599246	PRMT6	-0.48	-8.19	-0.37	3.19e-15	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs3540	0.920	rs7182658	chr15:91019248	A/T	cg10434728	chr15:90938212	IQGAP1	0.39	7.35	0.34	1.02e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg26647111	chr11:31128758	NA	-0.44	-7.67	-0.35	1.24e-13	Red blood cell count;
LUAD	trans	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg26043149	chr18:55253948	FECH	0.43	7.13	0.33	4.33e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.14	-0.33	4.05e-12	Breast cancer;
LUAD	trans	rs1941687	0.831	rs1353168	chr18:31359762	A/G	cg27147174	chr7:100797783	AP1S1	-0.54	-9.21	-0.41	1.48e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs6840360	0.550	rs62327349	chr4:152627230	G/C	cg22705602	chr4:152727874	NA	-0.45	-7.9	-0.36	2.52e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.91	0.36	2.35e-14	Depression;
LUAD	cis	rs3862030	0.720	rs7342070	chr10:104223628	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-8.02	-0.36	1.04e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg11148817	chr5:312970	AHRR;PDCD6	-0.46	-6.38	-0.3	4.7e-10	Breast cancer;
LUAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg25243455	chr2:114033360	PAX8;LOC440839	-0.39	-8.78	-0.39	4.14e-17	Lymphocyte counts;
LUAD	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg22823121	chr1:150693482	HORMAD1	0.37	7.53	0.34	3.04e-13	Tonsillectomy;
LUAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg15242686	chr22:24348715	GSTTP1	0.4	6.78	0.31	4.11e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg21724239	chr8:58056113	NA	0.74	9.62	0.42	5.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs354225	0.584	rs7586311	chr2:54810762	A/G	cg01766943	chr2:54829624	SPTBN1	0.39	7.31	0.33	1.33e-12	Schizophrenia;
LUAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg02951883	chr7:2050386	MAD1L1	-0.64	-10.32	-0.45	1.95e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg05665937	chr4:1216051	CTBP1	0.42	7.01	0.32	9.46e-12	Obesity-related traits;
LUAD	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg12403142	chr1:92012408	NA	-0.39	-7.27	-0.33	1.71e-12	Breast cancer;
LUAD	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07636037	chr3:49044803	WDR6	0.47	7.9	0.36	2.51e-14	Menarche (age at onset);
LUAD	cis	rs11811982	0.793	rs74877892	chr1:227355545	T/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic disc area;
LUAD	cis	rs240764	0.711	rs240148	chr6:101076767	C/T	cg09795085	chr6:101329169	ASCC3	0.42	7.24	0.33	2.08e-12	Neuroticism;
LUAD	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg17105886	chr17:28927953	LRRC37B2	0.79	7.74	0.35	7.5e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg06641503	chr3:48959341	ARIH2	-0.41	-8.12	-0.37	5.07e-15	Parkinson's disease;
LUAD	cis	rs673604	0.649	rs12049512	chr1:35684214	A/G	cg12633102	chr1:35676489	NA	-0.62	-8.74	-0.39	5.39e-17	Endometrial cancer;
LUAD	trans	rs7395662	1.000	rs7482176	chr11:48604620	C/G	cg15704280	chr7:45808275	SEPT13	-0.44	-6.98	-0.32	1.18e-11	HDL cholesterol;
LUAD	cis	rs2629540	0.889	rs17624662	chr10:126408146	A/C	cg08799069	chr10:126477246	METTL10	0.47	6.9	0.32	1.87e-11	Cocaine dependence;
LUAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg22105103	chr4:187893119	NA	0.54	11.62	0.49	2.76e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3106136	0.967	rs12646184	chr4:95183216	A/G	cg11021082	chr4:95130006	SMARCAD1	0.41	7.54	0.34	2.96e-13	Capecitabine sensitivity;
LUAD	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg08132940	chr7:1081526	C7orf50	-0.76	-7.75	-0.35	7.12e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6062509	0.965	rs1056441	chr20:62370349	T/C	cg21849932	chr20:62369462	LIME1	-0.48	-7.41	-0.34	6.99e-13	Prostate cancer;
LUAD	cis	rs7428	0.527	rs1053560	chr2:85546192	C/T	cg24342717	chr2:85555507	TGOLN2	-0.49	-8.03	-0.36	9.79e-15	Ear protrusion;
LUAD	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.54	0.3	1.77e-10	Parkinson's disease;
LUAD	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg11502198	chr6:26597334	ABT1	0.54	9.1	0.4	3.68e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg10356904	chr22:49881777	NA	-0.34	-7.1	-0.33	5.34e-12	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg02527881	chr3:46936655	PTH1R	-0.49	-9.65	-0.42	4.75e-20	Colorectal cancer;
LUAD	cis	rs2404602	0.647	rs11072626	chr15:77090826	A/G	cg23625390	chr15:77176239	SCAPER	-0.53	-8.6	-0.39	1.62e-16	Blood metabolite levels;
LUAD	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg06547715	chr2:218990976	CXCR2	0.44	10.48	0.45	5.37e-23	Ulcerative colitis;
LUAD	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg18129748	chr3:49941408	MST1R	-0.4	-6.42	-0.3	3.56e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg16724585	chr3:197361211	NA	-0.55	-8.0	-0.36	1.24e-14	Pancreatic cancer;
LUAD	cis	rs12541635	0.966	rs12674846	chr8:107007178	A/G	cg10147462	chr8:107024639	NA	0.51	9.21	0.41	1.48e-18	Age of smoking initiation;
LUAD	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg25566285	chr7:158114605	PTPRN2	0.53	10.88	0.47	1.83e-24	Calcium levels;
LUAD	cis	rs1006703	0.544	rs10153291	chr17:3833740	G/A	cg06463185	chr17:3833770	ATP2A3	-0.75	-8.61	-0.39	1.46e-16	Glucose homeostasis traits;
LUAD	cis	rs12286929	0.577	rs7101437	chr11:115063641	A/G	cg04055981	chr11:115044050	NA	-0.45	-8.16	-0.37	3.78e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10489202	0.632	rs275143	chr1:168056724	A/G	cg25738037	chr1:168025549	DCAF6	-0.53	-7.77	-0.35	5.96e-14	Schizophrenia;
LUAD	cis	rs938554	0.558	rs4697701	chr4:9946095	C/T	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.63	-0.31	1.04e-10	Blood metabolite levels;
LUAD	cis	rs4891159	0.790	rs8087557	chr18:74116848	G/C	cg24786174	chr18:74118243	ZNF516	-0.85	-17.11	-0.64	3.05e-50	Longevity;
LUAD	cis	rs9473147	0.516	rs13212790	chr6:47576367	T/C	cg20196966	chr6:47445060	CD2AP	0.43	6.81	0.31	3.45e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg14983838	chr19:29218262	NA	0.64	7.97	0.36	1.51e-14	Methadone dose in opioid dependence;
LUAD	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg02569458	chr12:86230093	RASSF9	0.42	7.99	0.36	1.29e-14	Major depressive disorder;
LUAD	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg27129171	chr3:47204927	SETD2	0.4	6.46	0.3	2.94e-10	Colorectal cancer;
LUAD	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg18132916	chr6:79620363	NA	-0.44	-7.67	-0.35	1.16e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg19635926	chr16:89946313	TCF25	0.75	6.76	0.31	4.56e-11	Skin colour saturation;
LUAD	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg08470875	chr2:26401718	FAM59B	-0.62	-8.49	-0.38	3.43e-16	Gut microbiome composition (summer);
LUAD	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg25256661	chr17:7137939	DVL2	0.65	12.69	0.53	1.71e-31	Diastolic blood pressure;
LUAD	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg15790184	chr11:494944	RNH1	0.57	7.06	0.32	7.02e-12	Body mass index;
LUAD	trans	rs9951602	0.512	rs4798994	chr18:76654327	T/G	cg02800362	chr5:177631904	HNRNPAB	0.91	14.57	0.58	3.06e-39	Obesity-related traits;
LUAD	trans	rs4650994	0.593	rs7552110	chr1:178542154	A/T	cg05059571	chr16:84539110	KIAA1609	0.44	6.75	0.31	4.85e-11	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg02782426	chr3:40428986	ENTPD3	0.44	9.28	0.41	8.73e-19	Renal cell carcinoma;
LUAD	cis	rs62238980	0.614	rs76348022	chr22:32412186	C/A	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg02782426	chr3:40428986	ENTPD3	-0.4	-8.65	-0.39	1.06e-16	Renal cell carcinoma;
LUAD	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.88	-0.32	2.12e-11	Neuroticism;
LUAD	cis	rs6489882	0.703	rs6489865	chr12:113360302	A/G	cg20102336	chr12:113376681	OAS3	-0.55	-8.33	-0.38	1.13e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.55	-8.83	-0.39	2.85e-17	Longevity;Endometriosis;
LUAD	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg10792982	chr14:105748885	BRF1	-0.42	-9.24	-0.41	1.24e-18	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs220324	0.688	rs56184115	chr21:43560554	G/T	cg08841829	chr21:43638893	ABCG1	-0.47	-6.47	-0.3	2.73e-10	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs62229266	0.626	rs2835268	chr21:37449136	C/G	cg08632701	chr21:37451849	NA	-0.68	-12.34	-0.51	4.17e-30	Mitral valve prolapse;
LUAD	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg18569988	chr3:195679450	NA	0.4	6.38	0.3	4.65e-10	Pancreatic cancer;
LUAD	trans	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg14917512	chr19:3094685	GNA11	0.56	6.69	0.31	7e-11	Diabetic kidney disease;
LUAD	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg01299579	chr2:10830716	NOL10	-0.42	-7.4	-0.34	7.33e-13	Prostate cancer;
LUAD	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg21605333	chr4:119757512	SEC24D	0.92	8.42	0.38	6.08e-16	Cannabis dependence symptom count;
LUAD	trans	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg26043149	chr18:55253948	FECH	-0.43	-6.95	-0.32	1.42e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.45	-0.34	5.19e-13	Heart rate;
LUAD	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg11317459	chr13:21872234	NA	1.09	13.99	0.56	8.35e-37	White matter hyperintensity burden;
LUAD	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg20469991	chr17:27169893	C17orf63	-0.52	-6.58	-0.3	1.37e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg23758822	chr17:41437982	NA	1.01	20.82	0.71	8.65e-67	Menopause (age at onset);
LUAD	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg00277334	chr10:82204260	NA	-0.51	-7.94	-0.36	1.89e-14	Post bronchodilator FEV1;
LUAD	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg17063962	chr7:91808500	NA	0.64	10.82	0.47	2.89e-24	Breast cancer;
LUAD	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7937890	0.559	rs2597208	chr11:14472329	A/C	cg06199346	chr11:14280333	SPON1	-0.34	-6.77	-0.31	4.35e-11	Mitochondrial DNA levels;
LUAD	cis	rs35096708	1.000	rs35096708	chr16:89887249	G/A	cg03809021	chr16:89831123	FANCA	0.49	7.72	0.35	8.75e-14	Skin aging (microtopography measurement);
LUAD	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg07936489	chr17:37558343	FBXL20	0.44	6.83	0.32	2.9e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg22598563	chr5:131563921	P4HA2	0.33	8.18	0.37	3.45e-15	Blood metabolite levels;
LUAD	trans	rs9929218	0.953	rs16260	chr16:68771034	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-15.34	-0.6	1.52e-42	Colorectal cancer;
LUAD	cis	rs731174	0.797	rs679742	chr1:38156190	C/G	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.29	-6.47	-0.3	2.72e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs2274273	0.840	rs10136596	chr14:55836773	A/G	cg04306507	chr14:55594613	LGALS3	0.45	9.53	0.42	1.2e-19	Protein biomarker;
LUAD	cis	rs2795502	0.554	rs1620395	chr10:43341185	G/A	cg20628663	chr10:43360327	NA	-0.43	-8.1	-0.37	5.96e-15	Blood protein levels;
LUAD	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9309473	0.607	rs6546826	chr2:73599808	A/G	cg20560298	chr2:73613845	ALMS1	0.42	6.51	0.3	2.07e-10	Metabolite levels;
LUAD	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg04287289	chr16:89883240	FANCA	0.78	6.91	0.32	1.74e-11	Skin colour saturation;
LUAD	cis	rs2731664	0.819	rs449351	chr5:176872591	T/C	cg23176889	chr5:176863531	GRK6	-0.75	-14.63	-0.58	1.59e-39	Intelligence (multi-trait analysis);
LUAD	trans	rs56341938	0.566	rs6805879	chr3:168811680	A/G	cg17364872	chr12:10704009	NA	-0.49	-6.52	-0.3	2.01e-10	Lung function (FEV1/FVC);
LUAD	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.52	-9.51	-0.42	1.49e-19	Longevity;Endometriosis;
LUAD	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg20476274	chr7:133979776	SLC35B4	0.82	15.98	0.61	2.5e-45	Mean platelet volume;
LUAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00166722	chr3:10149974	C3orf24	0.75	12.77	0.53	8.3e-32	Alzheimer's disease;
LUAD	trans	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg02030672	chr11:45687055	CHST1	-0.38	-6.79	-0.31	3.93e-11	Obesity-related traits;
LUAD	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg14779329	chr11:130786720	SNX19	0.39	6.83	0.32	2.93e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.54	-8.33	-0.38	1.11e-15	Gut microbiome composition (summer);
LUAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.32	-0.38	1.19e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1595825	0.838	rs73056856	chr2:198801209	C/G	cg10547527	chr2:198650123	BOLL	-0.52	-7.31	-0.33	1.33e-12	Ulcerative colitis;
LUAD	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg20476274	chr7:133979776	SLC35B4	0.84	16.9	0.63	2.51e-49	Mean platelet volume;
LUAD	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg16479474	chr6:28041457	NA	0.48	7.88	0.36	2.73e-14	Depression;
LUAD	cis	rs89107	0.544	rs11968176	chr6:118900940	C/A	cg21191810	chr6:118973309	C6orf204	0.39	7.14	0.33	4.21e-12	Cardiac structure and function;
LUAD	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg00071950	chr4:10020882	SLC2A9	-0.75	-15.34	-0.6	1.47e-42	Bone mineral density;
LUAD	cis	rs7809799	0.571	rs67546174	chr7:98938254	C/T	cg12290671	chr7:99195819	NA	-0.75	-6.76	-0.31	4.66e-11	Ulcerative colitis;
LUAD	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg07061783	chr6:25882402	NA	0.57	8.87	0.4	2.04e-17	Blood metabolite levels;
LUAD	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.85	-0.32	2.56e-11	Crohn's disease;
LUAD	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg05340658	chr4:99064831	C4orf37	0.54	9.23	0.41	1.32e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.39	-8.37	-0.38	8.37e-16	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs10392	0.706	rs72623596	chr20:37585212	T/C	cg27660920	chr20:37554817	FAM83D	0.56	7.17	0.33	3.39e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg13047869	chr3:10149882	C3orf24	0.59	9.99	0.44	2.95e-21	Alzheimer's disease;
LUAD	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.98	-0.4	8.9e-18	Total body bone mineral density;
LUAD	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-11.92	-0.5	1.87e-28	Hemoglobin concentration;
LUAD	trans	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.82	-0.31	3.12e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg01191920	chr7:158217561	PTPRN2	-0.75	-16.81	-0.63	6.06e-49	Obesity-related traits;
LUAD	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg16647868	chr5:131706066	SLC22A5	0.37	6.56	0.3	1.54e-10	Blood metabolite levels;
LUAD	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg07266350	chr3:49460521	AMT;NICN1	-0.38	-6.73	-0.31	5.52e-11	Menarche (age at onset);
LUAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07157834	chr1:205819609	PM20D1	0.63	11.77	0.5	7.21e-28	Monocyte percentage of white cells;
LUAD	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg00666640	chr1:248458726	OR2T12	0.33	7.91	0.36	2.33e-14	Common traits (Other);
LUAD	cis	rs427394	0.659	rs274725	chr5:6717408	C/G	cg14682080	chr5:6737778	POLS	0.34	7.26	0.33	1.92e-12	Menopause (age at onset);
LUAD	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg18132916	chr6:79620363	NA	-0.44	-7.57	-0.35	2.42e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg25703541	chr22:24373054	LOC391322	-0.91	-17.85	-0.66	1.53e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg06641503	chr3:48959341	ARIH2	-0.41	-8.11	-0.37	5.72e-15	Parkinson's disease;
LUAD	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.42	-0.38	6.04e-16	Prostate cancer;
LUAD	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.06	-0.7	2.23e-63	Height;
LUAD	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg25767906	chr1:53392781	SCP2	0.41	7.53	0.34	3e-13	Monocyte count;
LUAD	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg13119609	chr19:45449297	APOC2	0.63	12.75	0.53	1e-31	Blood protein levels;
LUAD	cis	rs4711336	1.000	rs764752	chr6:33658066	G/C	cg14003231	chr6:33640908	ITPR3	0.53	10.03	0.44	2.23e-21	Height;
LUAD	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg00784671	chr22:46762841	CELSR1	-0.43	-6.59	-0.3	1.34e-10	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg27539214	chr16:67997921	SLC12A4	-0.67	-8.47	-0.38	4.2e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg02018176	chr4:1364513	KIAA1530	0.7	12.19	0.51	1.7e-29	Longevity;
LUAD	cis	rs6445967	1.000	rs2292674	chr3:58302404	A/T	cg23715586	chr3:58305044	RPP14	0.42	7.59	0.35	2.03e-13	Platelet count;
LUAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg12419862	chr22:24373484	LOC391322	-0.71	-12.91	-0.53	2.33e-32	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg06671706	chr8:8559999	CLDN23	0.63	10.9	0.47	1.57e-24	Obesity-related traits;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01078248	chr7:123197661	NDUFA5	0.41	6.36	0.3	5.33e-10	Gut microbiome composition (summer);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26858605	chr17:45771108	NA	0.44	6.76	0.31	4.65e-11	Gut microbiome composition (summer);
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg09755102	chr1:33283495	S100PBP;YARS	0.47	7.61	0.35	1.82e-13	Diastolic blood pressure;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05422897	chr2:113403145	SLC20A1	-0.47	-7.2	-0.33	2.77e-12	Height;
LUAD	cis	rs6076065	0.963	rs2424543	chr20:23389955	G/T	cg11657817	chr20:23433608	CST11	0.48	9.87	0.43	7.89e-21	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg14558114	chr2:88469736	THNSL2	0.86	9.28	0.41	9.13e-19	Plasma clusterin levels;
LUAD	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24095222	chr5:161178787	NA	-0.41	-6.84	-0.32	2.82e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg05896524	chr21:47604654	C21orf56	0.54	9.05	0.4	5.28e-18	Testicular germ cell tumor;
LUAD	cis	rs11048434	0.736	rs56130437	chr12:9093001	G/A	cg04155231	chr12:9217510	LOC144571	0.38	7.22	0.33	2.41e-12	Sjögren's syndrome;
LUAD	cis	rs62238980	0.614	rs4820067	chr22:32430097	G/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.87	-0.36	3.09e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01481784	chr1:161369725	NA	-0.4	-6.45	-0.3	3.08e-10	Cancer;
LUAD	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg16102102	chr5:83017553	HAPLN1	0.64	11.17	0.48	1.4e-25	Prostate cancer;
LUAD	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	8.98	0.4	9.27e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg20503657	chr10:835505	NA	0.79	10.59	0.46	2.15e-23	Eosinophil percentage of granulocytes;
LUAD	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg20503657	chr10:835505	NA	0.79	10.59	0.46	2.15e-23	Eosinophil percentage of granulocytes;
LUAD	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg15704280	chr7:45808275	SEPT13	0.69	9.17	0.41	2.06e-18	Axial length;
LUAD	trans	rs12406019	0.548	rs11579434	chr1:78610022	T/C	cg20826526	chr3:156266748	SSR3	-0.5	-8.46	-0.38	4.28e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg25985355	chr7:65971099	NA	0.38	7.1	0.33	5.24e-12	Aortic root size;
LUAD	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25427524	chr10:38739819	LOC399744	-0.79	-14.22	-0.57	8.83e-38	Extrinsic epigenetic age acceleration;
LUAD	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg00717180	chr2:96193071	NA	-0.39	-7.27	-0.33	1.8e-12	HDL cholesterol;
LUAD	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.44	-0.42	2.63e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.94	-0.32	1.47e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg09455208	chr3:40491958	NA	-0.59	-13.13	-0.54	2.72e-33	Renal cell carcinoma;
LUAD	cis	rs116139393	0.536	rs13247186	chr7:6769155	A/G	cg09896999	chr7:6746977	ZNF12	-0.47	-6.59	-0.31	1.29e-10	Alzheimer's disease (APOE e4 interaction);
LUAD	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg02176678	chr2:219576539	TTLL4	0.75	15.09	0.59	1.71e-41	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.39	6.5	0.3	2.29e-10	Systemic lupus erythematosus;
LUAD	trans	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg26043149	chr18:55253948	FECH	0.44	7.14	0.33	4.08e-12	Bone mineral density;
LUAD	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg04800585	chr6:26043546	HIST1H2BB	-0.34	-6.37	-0.3	4.93e-10	Blood metabolite levels;
LUAD	cis	rs240764	0.658	rs10457077	chr6:101196767	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-8.38	-0.38	7.87e-16	Neuroticism;
LUAD	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.49	-0.3	2.47e-10	Aortic root size;
LUAD	cis	rs3931020	0.548	rs2134836	chr1:75271646	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.44	6.98	0.32	1.15e-11	Resistin levels;
LUAD	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg03676636	chr4:99064102	C4orf37	0.32	8.31	0.37	1.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg17509989	chr5:176798049	RGS14	0.58	10.59	0.46	2.13e-23	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs1595825	0.838	rs60079260	chr2:198673636	G/A	cg00982548	chr2:198649783	BOLL	-0.67	-9.07	-0.4	4.43e-18	Ulcerative colitis;
LUAD	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg09021430	chr5:549028	NA	-0.58	-13.12	-0.54	3.25e-33	Obesity-related traits;
LUAD	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.17	-0.33	3.39e-12	Glomerular filtration rate;
LUAD	cis	rs7737355	0.704	rs11749484	chr5:131061607	T/C	cg06307176	chr5:131281290	NA	0.46	7.76	0.35	6.48e-14	Life satisfaction;
LUAD	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.15	-0.41	2.39e-18	Type 2 diabetes;
LUAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	7.51	0.34	3.45e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg23758822	chr17:41437982	NA	1.02	21.21	0.72	1.59e-68	Menopause (age at onset);
LUAD	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg19622623	chr12:86230825	RASSF9	0.53	9.41	0.42	3.32e-19	Major depressive disorder;
LUAD	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.59	-0.31	1.33e-10	Prostate cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26485174	chr5:159200676	NA	-0.65	-6.36	-0.3	5.22e-10	Type 2 diabetes;
LUAD	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.77e-11	Parkinson's disease;
LUAD	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg09455208	chr3:40491958	NA	0.52	10.93	0.47	1.14e-24	Renal cell carcinoma;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06376522	chr11:58347088	LPXN;ZFP91;ZFP91-CNTF	-0.41	-6.54	-0.3	1.74e-10	Cancer;
LUAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg25192855	chr1:209979283	IRF6	0.35	8.36	0.38	9.26e-16	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUAD	cis	rs7017914	0.934	rs62530826	chr8:71641643	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg18446336	chr7:2847575	GNA12	-0.37	-6.91	-0.32	1.75e-11	Height;
LUAD	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.42	-6.6	-0.31	1.26e-10	Menarche (age at onset);
LUAD	cis	rs6594713	0.837	rs67693032	chr5:112708468	G/A	cg12552261	chr5:112820674	MCC	0.48	6.94	0.32	1.46e-11	Brain cytoarchitecture;
LUAD	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	7.03	0.32	8.26e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-11.68	-0.49	1.6e-27	Bipolar disorder;
LUAD	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg24154853	chr7:158122151	PTPRN2	0.48	9.24	0.41	1.21e-18	Calcium levels;
LUAD	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg21475434	chr5:93447410	FAM172A	-0.78	-8.62	-0.39	1.39e-16	Diabetic retinopathy;
LUAD	cis	rs3820068	0.705	rs16851727	chr1:15857918	C/T	cg24675056	chr1:15929824	NA	0.42	6.75	0.31	4.89e-11	Systolic blood pressure;
LUAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08280861	chr8:58055591	NA	0.78	9.47	0.42	1.93e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg21475434	chr5:93447410	FAM172A	-0.64	-7.9	-0.36	2.44e-14	Diabetic retinopathy;
LUAD	cis	rs727505	0.754	rs55905546	chr7:124783064	A/C	cg23710748	chr7:124431027	NA	-0.38	-7.77	-0.35	5.82e-14	Lewy body disease;
LUAD	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	trans	rs12517041	1.000	rs10052113	chr5:23287871	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.45	-0.3	3.1e-10	Calcium levels;
LUAD	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.812	rs32107	chr5:131039633	C/A	cg06307176	chr5:131281290	NA	0.46	7.71	0.35	9.31e-14	Life satisfaction;
LUAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg12419862	chr22:24373484	LOC391322	0.62	10.13	0.44	1e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs938554	0.571	rs7696092	chr4:10025320	C/A	cg02734326	chr4:10020555	SLC2A9	0.47	7.32	0.34	1.24e-12	Blood metabolite levels;
LUAD	cis	rs9462027	1.000	rs9689160	chr6:34749849	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.29	-6.91	-0.32	1.78e-11	Systemic lupus erythematosus;
LUAD	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg02038168	chr22:39784481	NA	-0.56	-9.88	-0.43	7.77e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg13607699	chr17:42295918	UBTF	0.61	10.13	0.44	9.95e-22	Total body bone mineral density;
LUAD	cis	rs57994353	0.897	rs3812594	chr9:139368953	G/A	cg13856295	chr9:139396418	NOTCH1	-0.43	-6.88	-0.32	2.13e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg23625390	chr15:77176239	SCAPER	0.41	7.04	0.32	7.92e-12	Blood metabolite levels;
LUAD	trans	rs1973993	0.691	rs1980684	chr1:96890636	A/G	cg10631902	chr5:14652156	NA	0.7	14.38	0.57	1.81e-38	Weight;
LUAD	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg04827223	chr11:72435913	ARAP1	-0.5	-7.54	-0.34	2.85e-13	Type 2 diabetes;
LUAD	cis	rs829883	0.664	rs865509	chr12:98854444	T/A	cg25150519	chr12:98850993	NA	0.75	14.01	0.56	6.58e-37	Colorectal adenoma (advanced);
LUAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.32	6.69	0.31	7.09e-11	Obesity-related traits;
LUAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg02869364	chr7:1081709	C7orf50	-0.47	-6.75	-0.31	4.95e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg07092213	chr7:1199455	ZFAND2A	-0.42	-7.41	-0.34	6.9e-13	Longevity;Endometriosis;
LUAD	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg24634471	chr8:143751801	JRK	0.48	7.65	0.35	1.37e-13	Schizophrenia;
LUAD	trans	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg07211511	chr3:129823064	LOC729375	-0.53	-7.31	-0.33	1.37e-12	Blood pressure (smoking interaction);
LUAD	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg04398451	chr17:18023971	MYO15A	-0.67	-12.16	-0.51	2.26e-29	Total body bone mineral density;
LUAD	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg10518543	chr12:38710700	ALG10B	0.42	6.42	0.3	3.68e-10	Bladder cancer;
LUAD	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.03e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-16.59	-0.63	5.46e-48	Colorectal cancer;
LUAD	cis	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg02807482	chr3:125708958	NA	-0.6	-6.8	-0.31	3.59e-11	Blood pressure (smoking interaction);
LUAD	cis	rs6847149	0.866	rs1978231	chr4:110798593	T/A	cg07850274	chr4:110748770	RRH	0.43	6.39	0.3	4.29e-10	Exercise treadmill test traits;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg24579258	chr15:66161593	RAB11A	0.37	6.54	0.3	1.74e-10	Bipolar disorder;
LUAD	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg02782426	chr3:40428986	ENTPD3	0.41	8.96	0.4	1.06e-17	Renal cell carcinoma;
LUAD	trans	rs9784649	1.000	rs7702197	chr5:24975778	A/G	cg11038491	chr20:34638489	LOC647979	0.59	7.79	0.35	5.14e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19748678	chr4:122722346	EXOSC9	0.43	6.76	0.31	4.64e-11	Type 2 diabetes;
LUAD	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg20203395	chr5:56204925	C5orf35	-0.77	-11.47	-0.49	1.09e-26	Initial pursuit acceleration;
LUAD	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg18230493	chr5:56204884	C5orf35	-0.58	-9.55	-0.42	1.06e-19	Coronary artery disease;
LUAD	cis	rs10465746	0.725	rs4907188	chr1:84361608	C/T	cg10977910	chr1:84465055	TTLL7	0.61	9.75	0.43	2.22e-20	Obesity-related traits;
LUAD	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg00814883	chr7:100076585	TSC22D4	-0.8	-11.63	-0.49	2.5e-27	Platelet count;
LUAD	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg07636037	chr3:49044803	WDR6	0.59	11.59	0.49	3.67e-27	Parkinson's disease;
LUAD	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg17173187	chr15:85201210	NMB	0.51	8.72	0.39	6.27e-17	Schizophrenia;
LUAD	cis	rs2992756	0.663	rs2992735	chr1:18800387	T/A	cg24076588	chr1:18808559	KLHDC7A	-0.46	-7.46	-0.34	5.06e-13	Breast cancer;
LUAD	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.23	-0.37	2.42e-15	Bipolar disorder;
LUAD	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg15147215	chr3:52552868	STAB1	-0.4	-7.08	-0.33	6.03e-12	Bipolar disorder;
LUAD	cis	rs17818399	0.926	rs35350086	chr2:46834036	C/G	cg21681030	chr2:46777652	RHOQ	0.41	7.26	0.33	1.87e-12	Height;
LUAD	cis	rs10129255	0.500	rs6576231	chr14:107191930	T/C	cg23076370	chr14:107095027	NA	-0.43	-8.5	-0.38	3.29e-16	Kawasaki disease;
LUAD	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.53	-0.34	3.11e-13	Resting heart rate;
LUAD	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg05342682	chr7:94953680	PON1	-0.5	-6.83	-0.32	2.9100000000000002e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg11098525	chr4:1320231	MAEA	0.37	6.51	0.3	2.07e-10	Obesity-related traits;
LUAD	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg15992532	chr8:142229932	SLC45A4	-0.44	-7.36	-0.34	9.85e-13	Immature fraction of reticulocytes;
LUAD	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg15147215	chr3:52552868	STAB1	-0.41	-7.49	-0.34	4.08e-13	Bipolar disorder;
LUAD	cis	rs6490294	0.583	rs1005902	chr12:112667675	G/T	cg10833066	chr12:111807467	FAM109A	-0.35	-6.46	-0.3	2.82e-10	Mean platelet volume;
LUAD	cis	rs758324	0.947	rs10054618	chr5:131195002	C/T	cg06307176	chr5:131281290	NA	0.5	7.95	0.36	1.76e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10802521	chr3:52805072	NEK4	-0.62	-11.2	-0.48	1.1e-25	Bipolar disorder;
LUAD	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg26513180	chr16:89883248	FANCA	0.71	13.46	0.55	1.28e-34	Vitiligo;
LUAD	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26314531	chr2:26401878	FAM59B	0.69	9.37	0.41	4.46e-19	Gut microbiome composition (summer);
LUAD	cis	rs7267979	0.586	rs6050431	chr20:25183908	C/T	cg08601574	chr20:25228251	PYGB	0.36	6.61	0.31	1.14e-10	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2404602	0.552	rs11072613	chr15:76961526	A/C	cg00316803	chr15:76480434	C15orf27	0.43	6.48	0.3	2.6e-10	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg18180107	chr4:99064573	C4orf37	0.42	6.83	0.32	3.02e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2073499	0.935	rs28365992	chr3:50340996	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.63	7.26	0.33	1.85e-12	Schizophrenia;
LUAD	cis	rs12135894	0.648	rs4648423	chr1:3765678	C/T	cg10555106	chr1:3691387	LOC388588	-0.37	-6.42	-0.3	3.67e-10	Mean corpuscular volume;
LUAD	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg18099408	chr3:52552593	STAB1	-0.43	-7.19	-0.33	2.95e-12	Bipolar disorder;
LUAD	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg03690763	chr11:133734501	NA	-0.35	-8.21	-0.37	2.69e-15	Childhood ear infection;
LUAD	cis	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg00071950	chr4:10020882	SLC2A9	0.48	6.85	0.32	2.63e-11	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg21475434	chr5:93447410	FAM172A	0.74	8.33	0.38	1.17e-15	Diabetic retinopathy;
LUAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-7.01	-0.32	9.21e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg20135002	chr11:47629003	NA	-0.42	-7.2	-0.33	2.69e-12	Subjective well-being;
LUAD	trans	rs853679	0.556	rs34706883	chr6:27805255	A/C	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.68	-0.46	9.8599999999999993e-24	Depression;
LUAD	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.48	-0.34	4.23e-13	Menarche (age at onset);
LUAD	cis	rs6545883	0.965	rs7421663	chr2:61753786	C/T	cg15711740	chr2:61764176	XPO1	-0.42	-6.71	-0.31	6.44e-11	Tuberculosis;
LUAD	cis	rs4280164	0.708	rs78269053	chr14:24794314	A/G	cg07162820	chr14:24837146	NFATC4	0.38	7.38	0.34	8.29e-13	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs986417	1.000	rs1956875	chr14:60846212	T/C	cg27398547	chr14:60952738	C14orf39	-0.61	-7.38	-0.34	8.37e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs7584330	0.504	rs11891426	chr2:238434702	T/G	cg14458575	chr2:238380390	NA	0.45	7.5	0.34	3.69e-13	Prostate cancer;
LUAD	cis	rs7100689	0.754	rs1934695	chr10:82125230	T/C	cg00277334	chr10:82204260	NA	-0.61	-9.65	-0.42	4.75e-20	Post bronchodilator FEV1;
LUAD	cis	rs739496	0.615	rs2339818	chr12:112046476	T/C	cg10833066	chr12:111807467	FAM109A	0.44	7.1	0.33	5.23e-12	Platelet count;
LUAD	trans	rs9354308	0.933	rs2802063	chr6:66564148	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.53	8.01	0.36	1.12e-14	Metabolite levels;
LUAD	cis	rs13315871	0.929	rs13075746	chr3:58293867	G/A	cg20936604	chr3:58311152	NA	-0.75	-7.61	-0.35	1.82e-13	Cholesterol, total;
LUAD	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg02527881	chr3:46936655	PTH1R	0.44	8.36	0.38	8.96e-16	Colorectal cancer;
LUAD	cis	rs743757	1.000	rs2073496	chr3:50431142	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	7.22	0.33	2.37e-12	Diastolic blood pressure;
LUAD	cis	rs7809615	0.892	rs58964157	chr7:99034055	G/A	cg12290671	chr7:99195819	NA	-0.67	-8.08	-0.37	6.99e-15	Blood metabolite ratios;
LUAD	cis	rs9392556	0.829	rs643232	chr6:4122249	C/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.4	-6.97	-0.32	1.21e-11	Blood metabolite levels;
LUAD	cis	rs2658782	0.789	rs2658776	chr11:93147927	A/G	cg15737290	chr11:93063684	CCDC67	0.47	6.78	0.31	4.02e-11	Pulmonary function decline;
LUAD	cis	rs10744422	0.748	rs2292138	chr12:123339712	A/G	cg16953816	chr12:123349952	VPS37B	0.59	6.54	0.3	1.75e-10	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg17366294	chr4:99064904	C4orf37	0.66	12.61	0.52	3.64e-31	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg15704280	chr7:45808275	SEPT13	0.63	7.5	0.34	3.88e-13	Intraocular pressure;
LUAD	cis	rs10128251	0.746	rs9424194	chr10:5724073	A/G	cg24097872	chr10:5724021	NA	0.51	9.44	0.42	2.48e-19	Childhood ear infection;
LUAD	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg17120908	chr11:65337727	SSSCA1	-0.6	-9.41	-0.42	3.18e-19	Bone mineral density;
LUAD	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg06671706	chr8:8559999	CLDN23	0.66	11.41	0.49	1.84e-26	Obesity-related traits;
LUAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg13397359	chr6:42928475	GNMT	0.62	11.67	0.49	1.86e-27	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs798766	1.000	rs2236786	chr4:1719294	T/C	cg05874882	chr4:1763078	NA	0.38	6.38	0.3	4.56e-10	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg15128208	chr22:42549153	NA	-0.43	-9.06	-0.4	4.83e-18	Cognitive function;
LUAD	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.27	0.41	9.88e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg02018176	chr4:1364513	KIAA1530	-0.37	-6.87	-0.32	2.37e-11	Obesity-related traits;
LUAD	cis	rs7737355	0.853	rs593767	chr5:131043660	T/G	cg06307176	chr5:131281290	NA	0.55	8.48	0.38	3.82e-16	Life satisfaction;
LUAD	trans	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg19862616	chr7:65841803	NCRNA00174	1.06	27.22	0.8	5.29e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs7939886	0.920	rs7946368	chr11:55804219	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.58	0.3	1.39e-10	Myopia (pathological);
LUAD	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	8.29	0.37	1.55e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.44	0.3	3.25e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs11771526	0.686	rs77847042	chr7:32277207	A/G	cg13207630	chr7:32358064	NA	0.54	7.05	0.32	7.41e-12	Body mass index;
LUAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg10150615	chr22:24372951	LOC391322	-0.54	-8.72	-0.39	6.24e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18876405	chr7:65276391	NA	0.45	7.17	0.33	3.29e-12	Aortic root size;
LUAD	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg06781209	chr11:61594997	FADS2	-0.49	-7.8	-0.35	4.86e-14	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs7116495	1.000	rs3793938	chr11:71823133	G/A	cg07596299	chr11:71824057	C11orf51	0.79	6.55	0.3	1.68e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs300703	0.542	rs376385	chr2:190245	G/A	cg21211680	chr2:198530	NA	0.54	7.81	0.36	4.51e-14	Blood protein levels;
LUAD	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg26924012	chr15:45694286	SPATA5L1	0.63	10.86	0.47	2.11e-24	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg03859395	chr2:55845619	SMEK2	-0.48	-7.59	-0.35	2.12e-13	Metabolic syndrome;
LUAD	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg15556689	chr8:8085844	FLJ10661	0.43	7.0	0.32	1.03e-11	Mood instability;
LUAD	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg11707310	chr1:2537719	MMEL1	0.38	7.92	0.36	2.16e-14	Ulcerative colitis;
LUAD	cis	rs9399401	0.626	rs1928528	chr6:142779109	T/G	cg03128060	chr6:142623767	GPR126	0.44	8.4	0.38	6.59e-16	Chronic obstructive pulmonary disease;
LUAD	cis	rs738322	0.600	rs7286105	chr22:38557821	A/G	cg25457927	chr22:38595422	NA	-0.54	-12.8	-0.53	6.38e-32	Cutaneous nevi;
LUAD	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.47	7.53	0.34	3.03e-13	Total body bone mineral density;
LUAD	cis	rs3931020	0.548	rs12145183	chr1:75272480	G/A	cg00121533	chr1:75199117	CRYZ;TYW3	0.46	7.38	0.34	8.27e-13	Resistin levels;
LUAD	cis	rs13315871	0.929	rs11130627	chr3:58315749	G/A	cg20936604	chr3:58311152	NA	-0.74	-7.4	-0.34	7.57e-13	Cholesterol, total;
LUAD	cis	rs1113500	0.548	rs9970655	chr1:108643537	G/T	cg06207961	chr1:108661230	NA	0.4	6.44	0.3	3.17e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg07460842	chr6:66804631	NA	1.08	17.28	0.64	5.45e-51	Exhaled nitric oxide output;
LUAD	cis	rs7851660	0.844	rs6478445	chr9:100624299	A/G	cg13688889	chr9:100608707	NA	-0.5	-8.46	-0.38	4.51e-16	Strep throat;
LUAD	cis	rs9462027	1.000	rs6457796	chr6:34828553	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.3	-7.19	-0.33	2.89e-12	Systemic lupus erythematosus;
LUAD	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg22532475	chr10:104410764	TRIM8	-0.48	-9.21	-0.41	1.53e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg27454412	chr7:1067447	C7orf50	0.4	7.04	0.32	7.84e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg11494091	chr17:61959527	GH2	0.41	7.2	0.33	2.78e-12	Height;
LUAD	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg11871910	chr12:69753446	YEATS4	0.7	12.23	0.51	1.16e-29	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.29e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg07967210	chr17:47022446	SNF8	0.36	6.45	0.3	3.03e-10	Type 2 diabetes;
LUAD	cis	rs7786808	0.552	rs12539355	chr7:158187565	C/T	cg09998033	chr7:158218633	PTPRN2	-0.42	-7.37	-0.34	9.32e-13	Obesity-related traits;
LUAD	cis	rs9467160	1.000	rs12198188	chr6:24442482	A/G	cg20631270	chr6:24437470	GPLD1	0.44	6.43	0.3	3.39e-10	Liver enzyme levels;
LUAD	cis	rs35205176	1.000	rs17636421	chr7:51633059	T/C	cg20478239	chr7:51544475	NA	-0.34	-6.5	-0.3	2.29e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg13057898	chr1:3703894	LRRC47	0.61	10.29	0.45	2.68e-22	Red cell distribution width;
LUAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg01851573	chr8:8652454	MFHAS1	-0.4	-7.03	-0.32	8.18e-12	Neuroticism;
LUAD	cis	rs7000551	0.663	rs11778844	chr8:22335170	C/T	cg12081754	chr8:22256438	SLC39A14	0.45	7.37	0.34	8.9e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg06606381	chr12:133084897	FBRSL1	-1.14	-10.42	-0.45	8.76e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs853679	0.607	rs34691223	chr6:28258208	C/A	cg06606381	chr12:133084897	FBRSL1	-1.19	-11.36	-0.48	2.75e-26	Depression;
LUAD	cis	rs4631830	0.832	rs11005089	chr10:51510813	C/A	cg20129853	chr10:51489980	NA	0.35	6.71	0.31	6.2e-11	Prostate-specific antigen levels;
LUAD	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21028142	chr17:79581711	NPLOC4	0.44	9.44	0.42	2.59e-19	Eye color traits;
LUAD	trans	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	17.37	0.65	2.14e-51	Exhaled nitric oxide output;
LUAD	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg04369109	chr6:150039330	LATS1	-0.44	-7.25	-0.33	1.94e-12	Lung cancer;
LUAD	cis	rs8017423	1.000	rs769044	chr14:90671138	A/G	cg14092571	chr14:90743983	NA	-0.48	-8.62	-0.39	1.35e-16	Mortality in heart failure;
LUAD	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg16205897	chr5:131564050	P4HA2	-0.37	-7.84	-0.36	3.79e-14	Breast cancer;Mosquito bite size;
LUAD	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg07167872	chr1:205819463	PM20D1	-0.4	-6.46	-0.3	2.97e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg00280220	chr17:61926910	NA	0.36	6.94	0.32	1.45e-11	Prudent dietary pattern;
LUAD	trans	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04565464	chr8:145669602	NFKBIL2	0.48	7.06	0.32	7.08e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg06641503	chr3:48959341	ARIH2	-0.42	-8.22	-0.37	2.6e-15	Parkinson's disease;
LUAD	cis	rs1566497	0.681	rs7440345	chr4:169741981	G/A	cg20607169	chr4:169750834	PALLD	0.37	6.72	0.31	6e-11	Pulse pressure;
LUAD	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg05340658	chr4:99064831	C4orf37	0.53	8.55	0.38	2.23e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg22907277	chr7:1156413	C7orf50	0.78	12.08	0.51	4.49e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg18436788	chr1:3704244	LRRC47	0.31	6.39	0.3	4.33e-10	Red cell distribution width;
LUAD	cis	rs9394152	0.845	rs9380367	chr6:33474975	G/A	cg13560919	chr6:33536144	NA	0.51	8.57	0.38	1.94e-16	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs490234	0.702	rs3814129	chr9:128365953	A/G	cg14078157	chr9:128172775	NA	-0.43	-7.46	-0.34	5.09e-13	Mean arterial pressure;
LUAD	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg26597838	chr10:835615	NA	1.09	17.13	0.64	2.42e-50	Eosinophil percentage of granulocytes;
LUAD	cis	rs790123	0.933	rs1092556	chr3:122387354	T/G	cg17380795	chr3:122379686	NA	0.61	11.1	0.47	2.74e-25	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7020830	0.867	rs13301916	chr9:37361455	A/C	cg14294708	chr9:37120828	ZCCHC7	0.84	16.44	0.62	2.52e-47	Schizophrenia;
LUAD	trans	rs9929218	0.954	rs12924033	chr16:68822599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.7	-0.53	1.6e-31	Colorectal cancer;
LUAD	cis	rs1524976	0.943	rs113722510	chr3:65529435	G/A	cg16238336	chr3:65465873	MAGI1	-0.62	-6.51	-0.3	2.13e-10	PR interval;
LUAD	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg18209359	chr17:80159595	CCDC57	-0.4	-6.93	-0.32	1.59e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.39	6.36	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg15557168	chr22:42548783	NA	0.49	9.1	0.4	3.66e-18	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.43e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12155623	0.803	rs7011862	chr8:49817333	C/G	cg22283653	chr8:49824208	NA	0.49	9.07	0.4	4.65e-18	Sudden cardiac arrest;
LUAD	cis	rs17253792	0.822	rs80085988	chr14:56096173	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.24e-10	Putamen volume;
LUAD	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg08885076	chr2:99613938	TSGA10	0.36	6.53	0.3	1.86e-10	Chronic sinus infection;
LUAD	cis	rs9811920	0.965	rs6767441	chr3:99863183	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.14	0.48	1.87e-25	Axial length;
LUAD	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg04036182	chr15:45458818	NA	-0.38	-6.55	-0.3	1.67e-10	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg02574844	chr11:5959923	NA	-0.44	-7.44	-0.34	5.61e-13	DNA methylation (variation);
LUAD	cis	rs1997103	0.834	rs10274457	chr7:55390199	G/A	cg17469321	chr7:55412551	NA	0.68	11.6	0.49	3.38e-27	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg06740227	chr12:86229804	RASSF9	0.38	6.8	0.31	3.58e-11	Major depressive disorder;
LUAD	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg23533926	chr12:111358616	MYL2	-0.42	-7.31	-0.33	1.39e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9486719	1.000	rs12205655	chr6:96891733	T/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.04	-0.44	2.05e-21	Migraine;Coronary artery disease;
LUAD	cis	rs10504073	0.584	rs4873304	chr8:49922733	G/A	cg00325661	chr8:49890786	NA	0.48	10.54	0.46	3.16e-23	Blood metabolite ratios;
LUAD	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg05340658	chr4:99064831	C4orf37	0.54	9.17	0.41	2.02e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg02683114	chr2:24398427	C2orf84	-0.42	-7.12	-0.33	4.74e-12	Asthma;
LUAD	cis	rs1448094	0.802	rs56391398	chr12:86424114	C/T	cg19622623	chr12:86230825	RASSF9	-0.36	-6.43	-0.3	3.46e-10	Major depressive disorder;
LUAD	cis	rs2735413	0.752	rs11642442	chr16:78080800	A/C	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg00634984	chr7:65235879	NA	0.49	6.55	0.3	1.67e-10	Aortic root size;
LUAD	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg27432699	chr2:27873401	GPN1	0.58	10.28	0.45	2.92e-22	Oral cavity cancer;
LUAD	cis	rs3785574	0.650	rs3815358	chr17:62010270	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.36	-0.34	9.9e-13	Height;
LUAD	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs1595825	1.000	rs73058832	chr2:198873214	G/T	cg00982548	chr2:198649783	BOLL	-0.67	-9.33	-0.41	5.97e-19	Ulcerative colitis;
LUAD	trans	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg19694781	chr19:47549865	TMEM160	-0.46	-7.54	-0.34	2.93e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs10744422	1.000	rs3852536	chr12:123333824	C/T	cg16953816	chr12:123349952	VPS37B	0.59	6.65	0.31	9.3e-11	Schizophrenia;
LUAD	cis	rs7074356	0.569	rs1832683	chr10:82032331	C/T	cg27171509	chr10:82033454	MAT1A	-0.48	-7.02	-0.32	8.67e-12	Borderline personality disorder;
LUAD	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg16205897	chr5:131564050	P4HA2	0.32	7.28	0.33	1.66e-12	Blood metabolite levels;
LUAD	cis	rs2795502	0.564	rs72777187	chr10:43432224	C/T	cg27426351	chr10:43362370	NA	0.55	6.86	0.32	2.44e-11	Blood protein levels;
LUAD	cis	rs3784262	0.904	rs3784260	chr15:58253269	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.45	-9.17	-0.41	2.15e-18	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg13789015	chr9:136890014	NCRNA00094	-0.87	-14.57	-0.58	2.8e-39	Platelet distribution width;
LUAD	cis	rs4285028	0.948	rs73855481	chr3:121676951	C/A	cg20356878	chr3:121714668	ILDR1	-0.5	-6.76	-0.31	4.51e-11	Multiple sclerosis;
LUAD	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	24.46	0.77	5.54e-83	Chronic sinus infection;
LUAD	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg09323728	chr8:95962352	TP53INP1	-0.36	-8.95	-0.4	1.14e-17	Type 2 diabetes;
LUAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg18402987	chr7:1209562	NA	0.62	8.93	0.4	1.3e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg27411982	chr8:10470053	RP1L1	-0.42	-7.3	-0.33	1.42e-12	Joint mobility (Beighton score);
LUAD	cis	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg21775007	chr8:11205619	TDH	0.42	7.07	0.33	6.32e-12	Neuroticism;
LUAD	trans	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg00953403	chr17:74099816	EXOC7	0.47	7.46	0.34	4.98e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg18230493	chr5:56204884	C5orf35	-0.64	-10.23	-0.45	4.32e-22	Coronary artery disease;
LUAD	cis	rs2278491	0.557	rs10283129	chr8:117778673	G/A	cg23513447	chr8:117778558	UTP23	-0.54	-7.65	-0.35	1.32e-13	Body mass index;
LUAD	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.55	-9.29	-0.41	8.06e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.4	-6.39	-0.3	4.45e-10	Alzheimer's disease (late onset);
LUAD	trans	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg18834416	chr8:37888184	EIF4EBP1	0.51	8.58	0.39	1.79e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10979	1.000	rs9376756	chr6:143886125	C/T	cg25407410	chr6:143891975	LOC285740	-0.6	-9.47	-0.42	1.96e-19	Hypospadias;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01171360	chr6:293285	DUSP22	-0.76	-13.47	-0.55	1.19e-34	Menopause (age at onset);
LUAD	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.08	0.33	5.93e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg22875332	chr1:76189707	ACADM	0.85	15.42	0.6	6.87e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg25358565	chr5:93447407	FAM172A	0.62	7.83	0.36	3.86e-14	Diabetic retinopathy;
LUAD	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg13770153	chr20:60521292	NA	-0.58	-9.64	-0.42	5.3e-20	Body mass index;
LUAD	cis	rs743757	1.000	rs2236984	chr3:50495487	A/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.42	6.59	0.3	1.35e-10	Diastolic blood pressure;
LUAD	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg17264618	chr3:40429014	ENTPD3	0.34	7.4	0.34	7.25e-13	Renal cell carcinoma;
LUAD	trans	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg02030672	chr11:45687055	CHST1	0.45	8.27	0.37	1.79e-15	Obesity-related traits;
LUAD	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg21427119	chr20:30132790	HM13	-0.59	-9.36	-0.41	4.59e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.55e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg09184832	chr6:79620586	NA	-0.49	-9.01	-0.4	7.04e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg12179176	chr11:130786555	SNX19	0.45	7.32	0.34	1.23e-12	Schizophrenia;
LUAD	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.0	13.28	0.54	6.79e-34	Lung cancer in ever smokers;
LUAD	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.11	0.33	4.89e-12	Menopause (age at onset);
LUAD	cis	rs9309473	0.607	rs2421488	chr2:73590625	C/T	cg20560298	chr2:73613845	ALMS1	-0.43	-6.7	-0.31	6.47e-11	Metabolite levels;
LUAD	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg18105134	chr13:113819100	PROZ	-1.04	-19.48	-0.69	8.75e-61	Platelet distribution width;
LUAD	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg09035930	chr12:129282057	SLC15A4	-0.68	-15.32	-0.6	1.83e-42	Systemic lupus erythematosus;
LUAD	cis	rs2425143	1.000	rs2425143	chr20:34350666	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.61	-0.35	1.81e-13	Blood protein levels;
LUAD	cis	rs9341808	0.667	rs806783	chr6:80942943	A/C	cg08355045	chr6:80787529	NA	-0.46	-8.31	-0.37	1.35e-15	Sitting height ratio;
LUAD	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg11822812	chr5:140052017	DND1	-0.43	-7.85	-0.36	3.54e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3820068	0.705	rs4646103	chr1:15819827	T/A	cg17177755	chr1:15930204	NA	0.43	6.43	0.3	3.41e-10	Systolic blood pressure;
LUAD	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg10053473	chr17:62856997	LRRC37A3	0.79	11.18	0.48	1.29e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6993813	0.843	rs1586273	chr8:120022886	C/T	cg01975934	chr8:119970761	NA	-0.37	-7.15	-0.33	3.82e-12	Bone mineral density (hip);
LUAD	trans	rs2735413	0.881	rs12920025	chr16:78083005	C/T	cg01028844	chr5:122736986	CEP120	0.41	6.5	0.3	2.24e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg21823605	chr1:152486609	CRCT1	0.28	6.52	0.3	2.01e-10	Hair morphology;
LUAD	cis	rs11958404	0.932	rs72816552	chr5:157422376	G/A	cg05962755	chr5:157440814	NA	0.57	8.24	0.37	2.26e-15	IgG glycosylation;
LUAD	cis	rs8067545	0.750	rs888423	chr17:19999409	G/A	cg04132472	chr17:19861366	AKAP10	0.3	7.19	0.33	2.88e-12	Schizophrenia;
LUAD	cis	rs77741769	0.571	rs11065283	chr12:121266453	A/G	cg02419362	chr12:121203948	SPPL3	0.44	9.06	0.4	5.01e-18	Mean corpuscular volume;
LUAD	cis	rs4481887	0.893	rs1934544	chr1:248505582	G/A	cg00666640	chr1:248458726	OR2T12	0.28	7.05	0.32	7.15e-12	Common traits (Other);
LUAD	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg18200150	chr17:30822561	MYO1D	0.67	13.39	0.55	2.58e-34	Schizophrenia;
LUAD	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.4	-0.42	3.56e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7147624	0.938	rs7151148	chr14:65936665	G/C	cg03016385	chr14:66212404	NA	-0.57	-6.78	-0.31	3.93e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs897984	0.568	rs11862962	chr16:30909706	C/G	cg02466173	chr16:30829666	NA	-0.61	-9.33	-0.41	5.99e-19	Dementia with Lewy bodies;
LUAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg27454412	chr7:1067447	C7orf50	0.44	7.0	0.32	1e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg00046913	chr16:1877150	HAGH;FAHD1	0.65	7.38	0.34	8.45e-13	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.63	0.35	1.61e-13	Breast cancer;
LUAD	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg10589385	chr1:150898437	SETDB1	0.43	8.18	0.37	3.29e-15	Melanoma;
LUAD	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg23985595	chr17:80112537	CCDC57	0.53	9.72	0.43	2.77e-20	Life satisfaction;
LUAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg16308533	chr17:40838983	CNTNAP1	0.57	10.94	0.47	1.08e-24	Colorectal or endometrial cancer;
LUAD	cis	rs10465746	0.905	rs34274953	chr1:84415011	G/A	cg10977910	chr1:84465055	TTLL7	0.49	7.79	0.35	5.07e-14	Obesity-related traits;
LUAD	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg24531977	chr5:56204891	C5orf35	-0.47	-7.85	-0.36	3.49e-14	Coronary artery disease;
LUAD	cis	rs6594713	0.796	rs6896843	chr5:112681157	T/C	cg12552261	chr5:112820674	MCC	0.45	6.38	0.3	4.73e-10	Brain cytoarchitecture;
LUAD	cis	rs9469913	0.604	rs2814948	chr6:34653413	G/A	cg14254433	chr6:34482411	PACSIN1	-0.43	-6.83	-0.32	2.93e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-10.38	-0.45	1.2e-22	Electroencephalogram traits;
LUAD	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.65	9.43	0.42	2.82e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg23927983	chr2:179315956	PRKRA;MIR548N;DFNB59	-0.77	-7.54	-0.34	2.94e-13	Type 2 diabetes;
LUAD	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg13685833	chr1:53393034	SCP2	0.49	7.59	0.35	2.02e-13	Monocyte count;
LUAD	trans	rs7395662	0.963	rs4882112	chr11:48561083	G/C	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.81e-10	HDL cholesterol;
LUAD	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg02527881	chr3:46936655	PTH1R	0.36	6.7	0.31	6.51e-11	Colorectal cancer;
LUAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg18621852	chr3:10150065	C3orf24	0.49	8.83	0.39	2.72e-17	Alzheimer's disease;
LUAD	cis	rs11696501	0.739	rs4812933	chr20:44230792	C/A	cg11783356	chr20:44313418	WFDC10B	-0.46	-7.31	-0.33	1.34e-12	Brain structure;
LUAD	cis	rs2658782	0.789	rs1456238	chr11:93117370	G/C	cg15737290	chr11:93063684	CCDC67	0.47	6.8	0.31	3.54e-11	Pulmonary function decline;
LUAD	trans	rs12210905	0.925	rs72838258	chr6:27007681	G/A	cg08851530	chr6:28072375	NA	0.69	6.35	0.3	5.63e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg16205897	chr5:131564050	P4HA2	-0.43	-9.79	-0.43	1.6e-20	Blood metabolite levels;
LUAD	cis	rs11971779	0.648	rs9642121	chr7:139092621	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.72	-13.42	-0.55	1.77e-34	Menarche (age at onset);
LUAD	cis	rs1448094	0.872	rs7305869	chr12:86440114	A/G	cg18827107	chr12:86230957	RASSF9	-0.44	-8.12	-0.37	5.03e-15	Major depressive disorder;
LUAD	cis	rs250585	1.000	rs250585	chr16:23401076	A/G	cg00143387	chr16:23521605	GGA2	-0.56	-7.24	-0.33	2.15e-12	Egg allergy;
LUAD	trans	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg19862616	chr7:65841803	NCRNA00174	1.06	27.22	0.8	5.29e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	0.53	7.74	0.35	7.27e-14	IgG glycosylation;
LUAD	cis	rs240764	0.817	rs12201852	chr6:101149576	T/C	cg09795085	chr6:101329169	ASCC3	-0.44	-7.59	-0.35	2.09e-13	Neuroticism;
LUAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg07414643	chr4:187882934	NA	0.32	6.65	0.31	8.94e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs68170813	0.559	rs11764448	chr7:106924928	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-10.76	-0.46	5.09e-24	Coronary artery disease;
LUAD	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg25427524	chr10:38739819	LOC399744	-0.7	-12.79	-0.53	6.79e-32	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg17366294	chr4:99064904	C4orf37	-0.66	-12.76	-0.53	8.86e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg25985355	chr7:65971099	NA	-0.54	-6.64	-0.31	9.78e-11	Diabetic kidney disease;
LUAD	cis	rs76878669	0.561	rs4930179	chr11:66157432	C/T	cg10616300	chr11:66138557	SLC29A2	0.36	7.61	0.35	1.83e-13	Educational attainment (years of education);
LUAD	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg03929089	chr4:120376271	NA	0.67	9.58	0.42	8.29e-20	Coronary artery disease;
LUAD	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg25358565	chr5:93447407	FAM172A	0.64	7.66	0.35	1.24e-13	Diabetic retinopathy;
LUAD	cis	rs4964805	0.657	rs1866294	chr12:104186795	A/G	cg02344784	chr12:104178138	NT5DC3	0.45	9.23	0.41	1.34e-18	Attention deficit hyperactivity disorder;
LUAD	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.41	-0.6	7.61e-43	Chronic sinus infection;
LUAD	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg04944784	chr2:26401820	FAM59B	0.92	13.61	0.55	2.98e-35	Gut microbiome composition (summer);
LUAD	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg19622623	chr12:86230825	RASSF9	0.43	7.59	0.35	2e-13	Major depressive disorder;
LUAD	cis	rs7692976	0.552	rs7440841	chr4:110946249	C/A	cg06981781	chr4:110842888	EGF	-0.43	-7.0	-0.32	1.04e-11	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg00757033	chr12:89920650	WDR51B	0.63	11.12	0.48	2.33e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05890377	chr2:74357713	NA	0.82	12.76	0.53	9.23e-32	Gestational age at birth (maternal effect);
LUAD	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg04727924	chr7:799746	HEATR2	-0.54	-6.4	-0.3	4.22e-10	Cerebrospinal P-tau181p levels;
LUAD	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg13511324	chr14:104056883	C14orf153	0.27	6.56	0.3	1.59e-10	Reticulocyte count;
LUAD	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg03806693	chr22:41940476	POLR3H	-0.75	-9.79	-0.43	1.5e-20	Vitiligo;
LUAD	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg05697835	chr1:2722811	NA	0.32	6.72	0.31	5.87e-11	Ulcerative colitis;
LUAD	trans	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg13560548	chr3:10150139	C3orf24	0.41	6.93	0.32	1.53e-11	Alzheimer's disease;
LUAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02353165	chr6:42928485	GNMT	0.4	7.1	0.33	5.39e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	7.94e-19	Tonsillectomy;
LUAD	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg05590025	chr7:65112418	INTS4L2	0.77	8.2	0.37	2.98e-15	Diabetic kidney disease;
LUAD	cis	rs977987	0.966	rs11643207	chr16:75498793	C/T	cg03315344	chr16:75512273	CHST6	0.66	14.43	0.57	1.16e-38	Dupuytren's disease;
LUAD	cis	rs2012796	0.956	rs7147254	chr14:81820503	G/A	cg02996355	chr14:81879375	NA	0.43	6.4	0.3	4.18e-10	Night sleep phenotypes;
LUAD	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg15445000	chr17:37608096	MED1	0.43	8.06	0.37	7.67e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg14413466	chr17:79170920	AZI1	0.42	9.31	0.41	7.17e-19	Frontotemporal dementia;
LUAD	cis	rs10916814	0.632	rs12409100	chr1:20903207	G/A	cg24502330	chr1:20914028	CDA	-0.36	-7.02	-0.32	8.98e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs10916814	0.632	rs4439331	chr1:20897091	T/C	cg24502330	chr1:20914028	CDA	-0.36	-7.13	-0.33	4.3e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2016266	0.855	rs1379610	chr12:53681683	A/G	cg26875137	chr12:53738046	NA	-0.34	-6.73	-0.31	5.51e-11	Bone mineral density (spine);Bone mineral density;
LUAD	trans	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg06606381	chr12:133084897	FBRSL1	-0.68	-7.09	-0.33	5.49e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7843479	0.965	rs1564305	chr8:21803816	A/C	cg03445287	chr8:21823731	XPO7	-0.47	-8.53	-0.38	2.64e-16	Mean corpuscular volume;
LUAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-6.91	-0.32	1.77e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg22823121	chr1:150693482	HORMAD1	0.45	9.17	0.41	2.15e-18	Tonsillectomy;
LUAD	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.62	-0.31	1.1e-10	Retinal vascular caliber;
LUAD	cis	rs7107174	0.892	rs10431155	chr11:78121978	T/C	cg02023728	chr11:77925099	USP35	0.42	6.71	0.31	6.14e-11	Testicular germ cell tumor;
LUAD	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg17971929	chr21:40555470	PSMG1	0.5	7.62	0.35	1.72e-13	Cognitive function;
LUAD	cis	rs4764487	0.735	rs2159521	chr12:6349328	A/G	cg08284733	chr12:6341482	CD9	0.41	7.45	0.34	5.23e-13	Mean platelet volume;
LUAD	cis	rs315934	0.664	rs7574787	chr2:113837416	G/T	cg09040174	chr2:113837401	NA	-0.62	-7.49	-0.34	3.99e-13	Dysmenorrheic pain;
LUAD	cis	rs3760982	0.585	rs11083724	chr19:44298988	A/G	cg21496419	chr19:44306685	LYPD5	0.34	7.59	0.35	2.1e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs28374715	0.662	rs10851403	chr15:41466087	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.89	-16.67	-0.63	2.53e-48	Ulcerative colitis;
LUAD	cis	rs2839627	0.638	rs28567463	chr21:44275457	G/A	cg03543861	chr21:44258195	NA	0.62	7.73	0.35	8.01e-14	Information processing speed;
LUAD	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg04545296	chr12:48745243	ZNF641	0.39	10.05	0.44	1.84e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg08132940	chr7:1081526	C7orf50	-0.8	-10.73	-0.46	6.49e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62400317	0.859	rs10948211	chr6:45156767	G/A	cg20913747	chr6:44695427	NA	-0.43	-6.74	-0.31	5.13e-11	Total body bone mineral density;
LUAD	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg21385522	chr1:16154831	NA	0.58	8.58	0.39	1.81e-16	Dilated cardiomyopathy;
LUAD	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg10523679	chr1:76189770	ACADM	0.9	16.06	0.62	1.23e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs77861329	0.748	rs747343	chr3:52109407	T/C	cg08692210	chr3:52188851	WDR51A	0.55	6.83	0.32	2.99e-11	Macrophage inflammatory protein 1b levels;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg27470027	chr11:63684601	RCOR2	-0.38	-6.94	-0.32	1.52e-11	Vertical cup-disc ratio;
LUAD	cis	rs208520	0.690	rs207077	chr6:66769855	A/C	cg07460842	chr6:66804631	NA	-1.06	-16.26	-0.62	1.61e-46	Exhaled nitric oxide output;
LUAD	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2688608	0.901	rs2459446	chr10:75601596	C/T	cg19442545	chr10:75533431	FUT11	0.44	7.36	0.34	9.69e-13	Inflammatory bowel disease;
LUAD	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg24324837	chr19:49891574	CCDC155	0.6	9.24	0.41	1.22e-18	Multiple sclerosis;
LUAD	cis	rs4072705	1.000	rs10760372	chr9:127468816	T/C	cg13476313	chr9:127244764	NR5A1	0.32	7.74	0.35	7.23e-14	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06873352	chr17:61820015	STRADA	-0.8	-17.89	-0.66	1.01e-53	Prudent dietary pattern;
LUAD	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg00071950	chr4:10020882	SLC2A9	0.56	10.89	0.47	1.61e-24	Bone mineral density;
LUAD	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg13385794	chr1:248469461	NA	0.25	6.57	0.3	1.47e-10	Common traits (Other);
LUAD	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.4	-6.47	-0.3	2.79e-10	Tonsillectomy;
LUAD	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg08470875	chr2:26401718	FAM59B	-0.63	-8.55	-0.38	2.33e-16	Gut microbiome composition (summer);
LUAD	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg16414030	chr3:133502952	NA	-0.67	-12.96	-0.53	1.34e-32	Iron status biomarkers;
LUAD	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.56	-0.3	1.58e-10	Aortic root size;
LUAD	cis	rs58799304	0.531	rs12035615	chr1:156055344	C/T	cg25208724	chr1:156163844	SLC25A44	0.5	6.51	0.3	2.09e-10	Ischemic stroke;
LUAD	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.05	0.47	4.15e-25	Eosinophil percentage of white cells;
LUAD	cis	rs9467160	0.559	rs2753911	chr6:24442288	C/T	cg20631270	chr6:24437470	GPLD1	0.42	7.09	0.33	5.76e-12	Liver enzyme levels;
LUAD	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg15181151	chr6:150070149	PCMT1	0.36	7.19	0.33	2.92e-12	Lung cancer;
LUAD	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22857025	chr5:266934	NA	0.94	14.0	0.56	7.43e-37	Breast cancer;
LUAD	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.03	-0.44	2.15e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs735539	0.521	rs2818992	chr13:21398087	G/A	cg27499820	chr13:21296301	IL17D	0.44	7.28	0.33	1.64e-12	Dental caries;
LUAD	cis	rs933688	0.583	rs6882172	chr5:90576958	C/T	cg17503389	chr5:90575422	NA	-0.46	-6.99	-0.32	1.1e-11	Smoking behavior;
LUAD	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg21385522	chr1:16154831	NA	-1.02	-21.02	-0.71	1.12e-67	Dilated cardiomyopathy;
LUAD	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg23985595	chr17:80112537	CCDC57	0.53	9.73	0.43	2.45e-20	Life satisfaction;
LUAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-9.51	-0.42	1.46e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs713477	0.967	rs6573032	chr14:55913776	A/G	cg13175173	chr14:55914753	NA	-0.35	-7.4	-0.34	7.41e-13	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs8099014	1.000	rs8092062	chr18:56127875	C/T	cg12907477	chr18:56117327	MIR122	0.38	6.45	0.3	3.15e-10	Platelet count;
LUAD	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg26924012	chr15:45694286	SPATA5L1	0.87	14.78	0.58	3.94e-40	Homoarginine levels;
LUAD	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg13263323	chr15:86062960	AKAP13	-0.48	-8.92	-0.4	1.44e-17	Coronary artery disease;
LUAD	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg05425664	chr17:57184151	TRIM37	0.43	7.66	0.35	1.24e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs438465	1.000	rs433756	chr6:169813309	T/C	cg11181693	chr6:169825345	NA	-0.67	-8.24	-0.37	2.1e-15	Corneal astigmatism;
LUAD	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg14008862	chr17:28927542	LRRC37B2	0.78	7.49	0.34	3.98e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4700695	0.841	rs251294	chr5:65261848	A/G	cg21114390	chr5:65439923	SFRS12	0.62	7.48	0.34	4.4e-13	Facial morphology (factor 19);
LUAD	cis	rs7731657	0.537	rs4705996	chr5:130355586	C/G	cg08523029	chr5:130500466	HINT1	0.58	7.58	0.35	2.22e-13	Fasting plasma glucose;
LUAD	trans	rs225245	0.755	rs8078905	chr17:34009029	T/C	cg19694781	chr19:47549865	TMEM160	-0.46	-7.66	-0.35	1.31e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs10489202	1.000	rs4657727	chr1:167965241	T/C	cg24449463	chr1:168025552	DCAF6	-0.54	-6.94	-0.32	1.52e-11	Schizophrenia;
LUAD	cis	rs2046867	0.908	rs62251650	chr3:72809823	T/C	cg04365224	chr3:72788183	NA	-0.46	-6.95	-0.32	1.43e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg04511125	chr2:88470314	THNSL2	0.88	9.72	0.43	2.69e-20	Plasma clusterin levels;
LUAD	cis	rs1113500	0.524	rs11185270	chr1:108654362	G/A	cg06207961	chr1:108661230	NA	0.42	6.79	0.31	3.91e-11	Growth-regulated protein alpha levels;
LUAD	cis	rs9914988	0.943	rs28847895	chr17:27172520	T/C	cg07195577	chr17:27052828	TLCD1	0.46	6.48	0.3	2.55e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs12681287	0.577	rs10481197	chr8:87546551	A/T	cg00550725	chr8:87521180	FAM82B	-0.46	-6.54	-0.3	1.76e-10	Caudate activity during reward;
LUAD	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg27068330	chr11:65405492	SIPA1	-0.71	-11.55	-0.49	5.37e-27	Non-alcoholic fatty liver disease histology (lobular);
LUAD	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.46	-7.21	-0.33	2.64e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06873352	chr17:61820015	STRADA	0.82	18.41	0.67	5.36e-56	Prudent dietary pattern;
LUAD	cis	rs8170	0.603	rs971693	chr19:17422649	G/C	cg12247222	chr19:17403313	ABHD8	0.43	6.65	0.31	9.27e-11	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUAD	cis	rs1034435	0.755	rs9615336	chr22:48893090	G/C	cg05992904	chr22:48892994	FAM19A5	-0.75	-16.59	-0.63	5.86e-48	Late-onset Alzheimer's disease;
LUAD	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg11266682	chr4:10021025	SLC2A9	0.68	15.49	0.6	3.32e-43	Bone mineral density;
LUAD	cis	rs1728785	1.000	rs11647432	chr16:68565426	C/T	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.3100000000000001e-10	Ulcerative colitis;
LUAD	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg08085267	chr17:45401833	C17orf57	-0.52	-8.7	-0.39	7.34e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.5	0.3	2.24e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4767364	0.961	rs2051801	chr12:112943197	A/G	cg10833066	chr12:111807467	FAM109A	0.35	6.68	0.31	7.64e-11	Oral cavity and pharyngeal cancer;
LUAD	cis	rs4372836	0.518	rs4632297	chr2:29008425	T/A	cg09522027	chr2:28974177	PPP1CB	-0.64	-11.13	-0.48	2.1e-25	Body mass index;
LUAD	cis	rs7586879	0.828	rs9631061	chr2:25109804	C/T	cg04586622	chr2:25135609	ADCY3	0.35	7.16	0.33	3.7e-12	Body mass index;
LUAD	cis	rs11971779	0.648	rs59791374	chr7:139116962	C/T	cg23387468	chr7:139079360	LUC7L2	0.3	6.98	0.32	1.17e-11	Diisocyanate-induced asthma;
LUAD	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg17105886	chr17:28927953	LRRC37B2	-0.69	-8.01	-0.36	1.1e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	8.92	0.4	1.47e-17	Total body bone mineral density;
LUAD	cis	rs9796	0.870	rs7162992	chr15:41290861	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.39	-7.4	-0.34	7.44e-13	Menopause (age at onset);
LUAD	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg22532475	chr10:104410764	TRIM8	-0.44	-8.67	-0.39	9.33e-17	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6076065	0.651	rs6114085	chr20:23419276	T/A	cg11657817	chr20:23433608	CST11	0.48	9.37	0.41	4.35e-19	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs356992	0.874	rs168565	chr2:60744331	A/G	cg08426369	chr2:60753602	BCL11A	0.47	7.89	0.36	2.55e-14	Educational attainment (years of education);
LUAD	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg20701182	chr2:24300061	SF3B14	0.58	6.5	0.3	2.26e-10	Lymphocyte counts;
LUAD	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg25753631	chr6:25732923	NA	-0.37	-6.43	-0.3	3.49e-10	Iron status biomarkers;
LUAD	trans	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg18187862	chr3:45730750	SACM1L	-0.53	-7.86	-0.36	3.14e-14	Primary sclerosing cholangitis;
LUAD	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.19	-0.37	3.14e-15	Total body bone mineral density;
LUAD	trans	rs11165623	0.564	rs6673207	chr1:96999259	C/G	cg10631902	chr5:14652156	NA	-0.4	-7.3	-0.33	1.45e-12	Hip circumference;Waist circumference;
LUAD	trans	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg06606381	chr12:133084897	FBRSL1	-0.48	-6.68	-0.31	7.49e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg17063962	chr7:91808500	NA	-0.64	-11.07	-0.47	3.36e-25	Breast cancer;
LUAD	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.7	-12.97	-0.53	1.24e-32	Ulcerative colitis;
LUAD	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg27539214	chr16:67997921	SLC12A4	-0.68	-8.43	-0.38	5.39e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg02551604	chr5:131831745	NA	-0.61	-10.02	-0.44	2.39e-21	Asthma (sex interaction);
LUAD	cis	rs7177699	0.526	rs7165042	chr15:79123338	C/G	cg15571903	chr15:79123663	NA	0.42	8.82	0.39	3e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.59	11.49	0.49	9.2e-27	Birth weight;
LUAD	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg05887092	chr17:76393375	PGS1	0.41	7.25	0.33	1.95e-12	HDL cholesterol levels;
LUAD	cis	rs7582720	1.000	rs72936872	chr2:203790889	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	trans	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	17.77	0.65	3.51e-53	Exhaled nitric oxide output;
LUAD	cis	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.75	-0.35	6.92e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg09184832	chr6:79620586	NA	-0.48	-8.86	-0.4	2.18e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-7.13	-0.33	4.4e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs12541635	0.677	rs1496180	chr8:106973877	T/G	cg10147462	chr8:107024639	NA	0.53	9.59	0.42	8.01e-20	Age of smoking initiation;
LUAD	trans	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg07817883	chr1:32538562	TMEM39B	1.18	12.44	0.52	1.65e-30	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs6921919	0.789	rs11970439	chr6:28303464	C/G	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.21	-0.33	2.67e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg05835009	chr4:710272	PCGF3	0.57	8.4	0.38	6.98e-16	White blood cell count;
LUAD	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg06191203	chr2:152266755	RIF1	-0.46	-7.21	-0.33	2.65e-12	Lung cancer;
LUAD	cis	rs500891	0.547	rs1144178	chr6:84029716	A/G	cg08257003	chr6:84140564	ME1	0.34	6.38	0.3	4.57e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs71478720	0.953	rs5744258	chr11:112021767	C/G	cg26534425	chr11:112034925	IL18	0.47	7.12	0.33	4.75e-12	Interleukin-18 levels;
LUAD	cis	rs897984	0.806	rs8050588	chr16:30937799	G/A	cg02466173	chr16:30829666	NA	-0.67	-12.39	-0.52	2.59e-30	Dementia with Lewy bodies;
LUAD	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg09537434	chr19:41945824	ATP5SL	-0.5	-7.93	-0.36	1.92e-14	Height;
LUAD	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg12311346	chr5:56204834	C5orf35	-0.55	-8.81	-0.39	3.25e-17	Coronary artery disease;
LUAD	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg27539214	chr16:67997921	SLC12A4	-0.72	-9.19	-0.41	1.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-10.82	-0.47	2.97e-24	Bipolar disorder and schizophrenia;
LUAD	trans	rs3857536	0.776	rs9363560	chr6:66949686	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	cis	rs7903847	0.656	rs12218483	chr10:99141484	C/T	cg20016023	chr10:99160130	RRP12	-0.34	-7.39	-0.34	7.68e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg23018236	chr17:30244563	NA	-0.68	-8.24	-0.37	2.19e-15	Hip circumference adjusted for BMI;
LUAD	trans	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg04154034	chr17:28927549	LRRC37B2	0.7	6.9	0.32	1.88e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1873147	1.000	rs12443285	chr15:63313596	C/T	cg12160578	chr15:63334699	TPM1	-0.34	-6.37	-0.3	5.08e-10	Orofacial clefts;
LUAD	cis	rs5756391	0.568	rs2280976	chr22:37318426	C/T	cg16356956	chr22:37317934	CSF2RB	0.3	6.39	0.3	4.44e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg22907277	chr7:1156413	C7orf50	0.41	6.87	0.32	2.31e-11	Longevity;Endometriosis;
LUAD	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg24558204	chr6:135376177	HBS1L	0.49	8.3	0.37	1.42e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg25985355	chr7:65971099	NA	-0.53	-6.58	-0.3	1.41e-10	Diabetic kidney disease;
LUAD	cis	rs13064411	0.518	rs2669909	chr3:113265727	A/G	cg10517650	chr3:113235015	CCDC52	0.35	6.66	0.31	8.76e-11	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs6906287	0.647	rs12203006	chr6:118917086	C/T	cg05564266	chr6:118973597	C6orf204	0.36	7.55	0.34	2.63e-13	Electrocardiographic conduction measures;
LUAD	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.71	-12.5	-0.52	9.86e-31	Axial length;
LUAD	cis	rs2806561	0.929	rs2746556	chr1:23524541	G/A	cg19743168	chr1:23544995	NA	0.43	8.14	0.37	4.4e-15	Height;
LUAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg09033563	chr22:24373618	LOC391322	-0.64	-10.65	-0.46	1.22e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.04	-0.36	9.23e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs10992471	0.603	rs7865019	chr9:95325631	A/G	cg14631576	chr9:95140430	CENPP	-0.5	-10.21	-0.44	5.17e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.71	-0.35	8.94e-14	Total body bone mineral density;
LUAD	cis	rs6782228	0.527	rs2712371	chr3:128346214	G/A	cg16766828	chr3:128327626	NA	-0.39	-7.22	-0.33	2.42e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg15445000	chr17:37608096	MED1	-0.45	-8.36	-0.38	9.19e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs2274273	0.870	rs10139000	chr14:55849876	G/T	cg04306507	chr14:55594613	LGALS3	0.42	8.86	0.4	2.24e-17	Protein biomarker;
LUAD	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg03037974	chr15:76606532	NA	0.38	8.06	0.36	7.76e-15	Blood metabolite levels;
LUAD	cis	rs7937890	0.559	rs2575829	chr11:14485021	C/T	cg02886208	chr11:14281011	SPON1	-0.34	-6.52	-0.3	2.05e-10	Mitochondrial DNA levels;
LUAD	cis	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg07460842	chr6:66804631	NA	0.9	12.14	0.51	2.56e-29	Exhaled nitric oxide output;
LUAD	trans	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.52	-0.34	3.4e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg12483005	chr1:23474871	LUZP1	0.53	9.17	0.41	2.01e-18	Height;
LUAD	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg25324976	chr17:61989376	CSHL1	0.37	7.14	0.33	4.1e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	10.15	0.44	8.49e-22	Electrocardiographic conduction measures;
LUAD	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.56e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg18198730	chr1:247681584	NA	0.47	8.05	0.36	8.37e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9914988	0.945	rs9279	chr17:27187636	G/T	cg02049041	chr17:27085579	C17orf63	-0.6	-8.02	-0.36	1.06e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs36096196	0.891	rs12081179	chr1:2251119	A/G	cg06784691	chr1:2245988	NA	-0.31	-6.49	-0.3	2.43e-10	Coronary artery disease;
LUAD	cis	rs7830933	0.955	rs57220043	chr8:23602763	A/T	cg04349084	chr8:23602677	NA	0.51	7.34	0.34	1.1e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05673432	chr3:15919505	NA	0.56	6.67	0.31	8.05e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg07936489	chr17:37558343	FBXL20	-0.44	-6.88	-0.32	2.11e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs2692947	0.666	rs10183151	chr2:96774786	T/G	cg23100626	chr2:96804247	ASTL	-0.35	-9.05	-0.4	5.3e-18	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg00204512	chr16:28754710	NA	0.35	7.49	0.34	4.06e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7819412	0.522	rs4642600	chr8:11013025	C/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.48	-0.3	2.53e-10	Triglycerides;
LUAD	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg02428538	chr16:24856791	SLC5A11	-0.53	-7.3	-0.33	1.47e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.85	0.61	9.7e-45	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12667521	chr19:29218732	NA	0.53	6.48	0.3	2.53e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg26769984	chr7:1090371	C7orf50	0.45	7.24	0.33	2.09e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg13560548	chr3:10150139	C3orf24	0.44	7.47	0.34	4.67e-13	Alzheimer's disease;
LUAD	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08109568	chr15:31115862	NA	-0.79	-13.64	-0.55	2.35e-35	Huntington's disease progression;
LUAD	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg16850897	chr7:100343110	ZAN	-0.64	-11.2	-0.48	1.13e-25	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06112835	chr11:68658793	MRPL21	0.5	9.05	0.4	5.44e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg07507251	chr3:52567010	NT5DC2	0.39	7.58	0.35	2.21e-13	Bipolar disorder;
LUAD	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg05044414	chr3:183734942	ABCC5	0.41	8.45	0.38	4.84e-16	Anterior chamber depth;
LUAD	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg23719950	chr11:63933701	MACROD1	-0.62	-7.41	-0.34	7.01e-13	Mean platelet volume;
LUAD	cis	rs2456568	0.835	rs8181533	chr11:93638614	C/T	cg26875233	chr11:93583750	C11orf90	-0.29	-6.4	-0.3	4.07e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs7000551	0.751	rs1116085	chr8:22394920	A/G	cg12081754	chr8:22256438	SLC39A14	0.43	7.23	0.33	2.34e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2932538	0.922	rs7551933	chr1:113086706	C/T	cg22162597	chr1:113214053	CAPZA1	-0.44	-6.73	-0.31	5.66e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs4378999	0.800	rs751075	chr3:51377300	C/T	cg12934382	chr3:51741135	GRM2	0.43	6.73	0.31	5.45e-11	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-15.99	-0.61	2.45e-45	Chronic sinus infection;
LUAD	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg19610905	chr11:61596333	FADS2	-0.81	-10.38	-0.45	1.28e-22	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.51	-0.38	3.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg11645453	chr3:52864694	ITIH4	0.36	6.85	0.32	2.62e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs791888	0.858	rs2180968	chr10:89418730	A/C	cg13926569	chr10:89418898	PAPSS2	0.53	10.08	0.44	1.45e-21	Magnesium levels;
LUAD	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg15110403	chr19:17392923	ANKLE1	-0.46	-7.29	-0.33	1.51e-12	Systemic lupus erythematosus;
LUAD	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg22676075	chr6:135203613	NA	0.51	8.94	0.4	1.25e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs12545109	0.800	rs1437278	chr8:57357024	T/C	cg07776626	chr8:57350775	NA	-0.67	-9.3	-0.41	7.88e-19	Obesity-related traits;
LUAD	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg15556689	chr8:8085844	FLJ10661	0.45	7.53	0.34	3.18e-13	Mood instability;
LUAD	cis	rs4771122	0.728	rs7992289	chr13:28036430	G/A	cg22138327	chr13:27999177	GTF3A	-0.59	-8.48	-0.38	3.8e-16	Body mass index;
LUAD	cis	rs3847687	0.901	rs12370258	chr12:131527301	G/T	cg06093039	chr12:131527216	GPR133	0.32	6.52	0.3	1.95e-10	Longevity;
LUAD	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.91	-0.5	2.11e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg16329650	chr2:213403929	ERBB4	0.6	10.88	0.47	1.72e-24	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9948	0.529	rs62152773	chr2:97448073	T/C	cg20312557	chr2:97357134	FER1L5	-0.63	-7.36	-0.34	9.71e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg08501054	chr8:9413133	TNKS	0.41	6.47	0.3	2.67e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg17644776	chr2:200775616	C2orf69	0.54	8.93	0.4	1.34e-17	Osteoporosis;
LUAD	cis	rs2742234	0.911	rs3004214	chr10:43631698	C/T	cg02780029	chr10:43622663	RET	-0.46	-7.44	-0.34	5.77e-13	Hirschsprung disease;
LUAD	cis	rs11771526	0.892	rs62457539	chr7:32364604	G/A	cg13207630	chr7:32358064	NA	0.66	7.36	0.34	9.44e-13	Body mass index;
LUAD	cis	rs35740288	0.770	rs11635190	chr15:86148531	C/T	cg13263323	chr15:86062960	AKAP13	-0.44	-7.02	-0.32	8.78e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg17264618	chr3:40429014	ENTPD3	0.42	8.98	0.4	9.26e-18	Renal cell carcinoma;
LUAD	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg21775007	chr8:11205619	TDH	-0.53	-9.54	-0.42	1.18e-19	Retinal vascular caliber;
LUAD	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg19163074	chr7:65112434	INTS4L2	0.41	6.45	0.3	2.99e-10	Aortic root size;
LUAD	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.35e-11	Breast cancer;
LUAD	cis	rs7072216	0.763	rs2274245	chr10:100175082	C/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.7	-0.39	7.57e-17	Metabolite levels;
LUAD	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg00074818	chr8:8560427	CLDN23	0.59	9.51	0.42	1.45e-19	Obesity-related traits;
LUAD	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23583168	chr7:148888333	NA	-0.9	-18.52	-0.67	1.58e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg05623727	chr3:50126028	RBM5	-0.33	-7.19	-0.33	3.05e-12	Body mass index;
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg18110333	chr6:292329	DUSP22	-0.78	-13.28	-0.54	7.18e-34	Menopause (age at onset);
LUAD	cis	rs10992471	0.580	rs4743875	chr9:95423674	T/C	cg14631576	chr9:95140430	CENPP	-0.46	-8.85	-0.4	2.38e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg17063962	chr7:91808500	NA	0.7	12.76	0.53	9.37e-32	Breast cancer;
LUAD	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg00898013	chr13:113819073	PROZ	0.84	14.96	0.59	6.25e-41	Platelet distribution width;
LUAD	cis	rs6752107	0.503	rs2304774	chr2:234235749	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.45	7.65	0.35	1.35e-13	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg17366294	chr4:99064904	C4orf37	0.47	8.32	0.38	1.19e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg00129232	chr17:37814104	STARD3	-0.46	-7.73	-0.35	7.94e-14	Asthma;
LUAD	trans	rs877282	0.898	rs12358513	chr10:757571	A/G	cg22713356	chr15:30763199	NA	1.23	15.56	0.6	1.71e-43	Uric acid levels;
LUAD	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg07741184	chr6:167504864	NA	0.28	6.6	0.31	1.2e-10	Crohn's disease;
LUAD	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg12454169	chr2:30669597	LCLAT1	-0.57	-7.94	-0.36	1.79e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08677398	chr8:58056175	NA	0.48	6.67	0.31	8.02e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg09998033	chr7:158218633	PTPRN2	0.42	7.46	0.34	4.88e-13	Obesity-related traits;
LUAD	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg19761014	chr17:28927070	LRRC37B2	0.7	6.43	0.3	3.37e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs62103177	0.608	rs34383580	chr18:77833263	A/G	cg05926928	chr17:57297772	GDPD1	-0.81	-10.02	-0.44	2.46e-21	Opioid sensitivity;
LUAD	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg21963583	chr11:68658836	MRPL21	0.67	11.74	0.5	9.87e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg17279839	chr7:150038598	RARRES2	0.46	7.72	0.35	8.28e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs12540874	0.794	rs1470750	chr7:50576648	C/G	cg18232548	chr7:50535776	DDC	-0.6	-10.15	-0.44	8.36e-22	Systemic sclerosis;
LUAD	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.99	-0.32	1.1e-11	Obesity-related traits;
LUAD	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg12292205	chr6:26970375	C6orf41	-0.46	-6.87	-0.32	2.35e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg05043794	chr9:111880884	C9orf5	-0.44	-7.62	-0.35	1.71e-13	Menarche (age at onset);
LUAD	cis	rs9341808	0.527	rs7453746	chr6:80810013	T/G	cg08355045	chr6:80787529	NA	0.59	11.01	0.47	6.02e-25	Sitting height ratio;
LUAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14893161	chr1:205819251	PM20D1	-0.73	-14.23	-0.57	8.05e-38	Menarche (age at onset);
LUAD	cis	rs1395	0.778	rs56364136	chr2:27451429	T/C	cg23587288	chr2:27483067	SLC30A3	-0.38	-7.69	-0.35	1.03e-13	Blood metabolite levels;
LUAD	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg15208524	chr1:10270712	KIF1B	0.52	7.62	0.35	1.71e-13	Hepatocellular carcinoma;
LUAD	cis	rs12681287	0.640	rs28561640	chr8:87425638	G/A	cg00550725	chr8:87521180	FAM82B	-0.47	-6.7	-0.31	6.74e-11	Caudate activity during reward;
LUAD	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg00074818	chr8:8560427	CLDN23	0.62	9.55	0.42	1.05e-19	Obesity-related traits;
LUAD	cis	rs11696501	0.739	rs2235600	chr20:44238299	T/G	cg11783356	chr20:44313418	WFDC10B	-0.51	-8.27	-0.37	1.78e-15	Brain structure;
LUAD	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg21951975	chr1:209979733	IRF6	-0.48	-7.32	-0.34	1.25e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs17092148	1.000	rs6088579	chr20:33284624	A/G	cg16810054	chr20:33298113	TP53INP2	-0.53	-7.92	-0.36	2.17e-14	Neuroticism;
LUAD	trans	rs3857536	0.611	rs7748258	chr6:66932840	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.35	-0.3	5.66e-10	Blood trace element (Cu levels);
LUAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg07677032	chr17:61819896	STRADA	-0.58	-10.9	-0.47	1.52e-24	Prudent dietary pattern;
LUAD	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.43	0.52	1.8e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg04546413	chr19:29218101	NA	0.67	8.51	0.38	3.13e-16	Methadone dose in opioid dependence;
LUAD	trans	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	26.66	0.79	1.38e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg02951883	chr7:2050386	MAD1L1	-0.83	-14.75	-0.58	5.07e-40	Bipolar disorder and schizophrenia;
LUAD	trans	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.48	-0.34	4.34e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg03929089	chr4:120376271	NA	-0.91	-17.23	-0.64	8.69e-51	Coronary artery disease;
LUAD	cis	rs494562	0.892	rs547052	chr6:86118840	G/A	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg18016565	chr1:150552671	MCL1	-0.41	-7.95	-0.36	1.7e-14	Tonsillectomy;
LUAD	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.79	0.53	6.64e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg00933542	chr6:150070202	PCMT1	0.44	9.47	0.42	2.03e-19	Lung cancer;
LUAD	cis	rs243505	0.559	rs10215794	chr7:148478895	C/G	cg09806900	chr7:148480153	CUL1	0.52	8.95	0.4	1.13e-17	Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs12517041	1.000	rs1428629	chr5:23311989	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.49	-6.92	-0.32	1.73e-11	Calcium levels;
LUAD	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg18129748	chr3:49941408	MST1R	0.4	6.54	0.3	1.73e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7737355	0.853	rs31586	chr5:131000696	A/G	cg25547332	chr5:131281432	NA	0.4	6.49	0.3	2.38e-10	Life satisfaction;
LUAD	cis	rs1870323	0.527	rs748102	chr11:86206203	G/T	cg01663953	chr11:86133777	CCDC81	0.36	6.62	0.31	1.12e-10	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule);
LUAD	cis	rs2742417	1.000	rs2742390	chr3:45756722	A/G	cg10512202	chr3:45649293	LIMD1	-0.38	-6.76	-0.31	4.63e-11	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	10.02	0.44	2.5e-21	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9283706	0.608	rs12522430	chr5:66339522	T/C	cg11590213	chr5:66331682	MAST4	0.4	6.38	0.3	4.62e-10	Coronary artery disease;
LUAD	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.68	-10.38	-0.45	1.22e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg12016809	chr21:47604291	C21orf56	0.44	7.36	0.34	9.74e-13	Testicular germ cell tumor;
LUAD	cis	rs7705042	0.828	rs1835966	chr5:141501508	C/T	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.7	-0.31	6.61e-11	Asthma;
LUAD	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.61	-0.31	1.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg22532475	chr10:104410764	TRIM8	-0.42	-8.31	-0.37	1.32e-15	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg03609598	chr5:56110824	MAP3K1	-0.68	-9.21	-0.41	1.59e-18	Initial pursuit acceleration;
LUAD	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg10468373	chr11:64009913	FKBP2	0.51	6.37	0.3	5.05e-10	Mean platelet volume;
LUAD	cis	rs35995292	0.534	rs10274968	chr7:38939254	C/T	cg19327137	chr7:38886074	VPS41	0.76	16.4	0.62	3.88e-47	Subjective well-being (multi-trait analysis);
LUAD	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06544989	chr22:39130855	UNC84B	0.45	8.25	0.37	1.96e-15	Menopause (age at onset);
LUAD	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg23172400	chr8:95962367	TP53INP1	0.32	7.6	0.35	1.93e-13	Type 2 diabetes;
LUAD	cis	rs6484504	0.576	rs208067	chr11:31153578	C/T	cg14844989	chr11:31128820	NA	-0.44	-8.12	-0.37	5.12e-15	Red blood cell count;
LUAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06873352	chr17:61820015	STRADA	0.82	18.2	0.66	4.32e-55	Prudent dietary pattern;
LUAD	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg09658497	chr7:2847517	GNA12	-0.51	-9.21	-0.41	1.52e-18	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg08470875	chr2:26401718	FAM59B	-0.77	-10.37	-0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg11494091	chr17:61959527	GH2	0.43	8.31	0.37	1.34e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg15448220	chr1:150897856	SETDB1	-0.43	-7.22	-0.33	2.45e-12	Lymphocyte counts;
LUAD	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg17346650	chr17:80929145	B3GNTL1	0.39	6.68	0.31	7.72e-11	Glycated hemoglobin levels;
LUAD	cis	rs601339	1.000	rs601339	chr12:123174743	A/G	cg11919336	chr12:123188078	GPR109A	0.46	6.91	0.32	1.79e-11	Adiponectin levels;
LUAD	cis	rs9393692	0.620	rs9393691	chr6:26272829	T/C	cg13736514	chr6:26305472	NA	-0.53	-9.05	-0.4	5.13e-18	Educational attainment;
LUAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs34172651	0.917	rs12599643	chr16:24832693	C/T	cg00339695	chr16:24857497	SLC5A11	0.48	8.86	0.4	2.21e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg07936489	chr17:37558343	FBXL20	0.44	6.9	0.32	1.92e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7945705	0.806	rs12224436	chr11:8815825	C/A	cg09997546	chr11:8931473	C11orf17;ST5	0.33	6.49	0.3	2.36e-10	Hemoglobin concentration;
LUAD	cis	rs73206853	0.841	rs57821814	chr12:110829254	A/C	cg12870014	chr12:110450643	ANKRD13A	0.61	6.68	0.31	7.46e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs12900413	0.603	rs2882678	chr15:90299542	A/G	cg24249390	chr15:90295951	MESP1	-0.36	-6.9	-0.32	1.85e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg20503657	chr10:835505	NA	0.47	7.19	0.33	3.05e-12	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg03929089	chr4:120376271	NA	0.67	10.02	0.44	2.33e-21	Coronary artery disease;
LUAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.57	-9.73	-0.43	2.49e-20	Longevity;Endometriosis;
LUAD	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg21487550	chr3:127056955	NA	-0.55	-7.52	-0.34	3.38e-13	Interleukin-10 levels;Interleukin-13 levels;
LUAD	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg11663144	chr21:46675770	NA	-0.61	-12.04	-0.51	6.53e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg07606381	chr6:8435919	SLC35B3	0.41	6.68	0.31	7.42e-11	Motion sickness;
LUAD	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.84	-0.32	2.8e-11	Personality dimensions;
LUAD	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg23544223	chr18:12777786	NA	0.66	8.46	0.38	4.54e-16	Inflammatory skin disease;
LUAD	cis	rs6445967	1.000	rs12633655	chr3:58306321	T/C	cg23715586	chr3:58305044	RPP14	0.42	7.64	0.35	1.46e-13	Platelet count;
LUAD	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg00071950	chr4:10020882	SLC2A9	0.85	18.22	0.66	3.55e-55	Bone mineral density;
LUAD	cis	rs892085	0.681	rs10417071	chr19:10872431	G/T	cg17710535	chr19:10819994	QTRT1	0.36	6.72	0.31	5.91e-11	Psoriasis vulgaris;Psoriasis;
LUAD	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg22875332	chr1:76189707	ACADM	0.84	15.08	0.59	1.96e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs1493916	0.721	rs4471760	chr18:31374233	G/A	cg15819921	chr19:927150	ARID3A	-0.48	-8.1	-0.37	5.83e-15	Life satisfaction;
LUAD	cis	rs6564851	0.506	rs7187615	chr16:81254052	G/A	cg00908271	chr16:81254010	PKD1L2	0.34	6.97	0.32	1.24e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs9296092	0.517	rs113111213	chr6:33520790	A/G	cg13560919	chr6:33536144	NA	-0.89	-16.71	-0.63	1.64e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg09455208	chr3:40491958	NA	0.55	12.26	0.51	9.08e-30	Renal cell carcinoma;
LUAD	cis	rs938554	0.657	rs7679724	chr4:9985376	G/T	cg02734326	chr4:10020555	SLC2A9	0.45	7.1	0.33	5.19e-12	Blood metabolite levels;
LUAD	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg19774624	chr17:42201019	HDAC5	-0.4	-6.86	-0.32	2.43e-11	Total body bone mineral density;
LUAD	cis	rs36051895	0.659	rs2149555	chr9:5053743	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-6.88	-0.32	2.15e-11	Pediatric autoimmune diseases;
LUAD	cis	rs7107174	1.000	rs11237480	chr11:78110385	C/A	cg19901956	chr11:77921274	USP35	-0.46	-6.51	-0.3	2.08e-10	Testicular germ cell tumor;
LUAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg25703541	chr22:24373054	LOC391322	0.81	14.77	0.58	4.19e-40	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	10.26	0.45	3.46e-22	Type 2 diabetes;
LUAD	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg15110403	chr19:17392923	ANKLE1	0.44	7.18	0.33	3.09e-12	Systemic lupus erythematosus;
LUAD	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg02527881	chr3:46936655	PTH1R	-0.57	-12.0	-0.5	9.56e-29	Colorectal cancer;
LUAD	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21659725	chr3:3221576	CRBN	0.85	17.83	0.66	2.03e-53	Intelligence (multi-trait analysis);
LUAD	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.42	6.68	0.31	7.57e-11	Schizophrenia;
LUAD	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.54	0.3	1.78e-10	Colorectal cancer;
LUAD	cis	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg27411982	chr8:10470053	RP1L1	0.36	6.68	0.31	7.48e-11	Triglycerides;
LUAD	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg19773385	chr1:10388646	KIF1B	-0.39	-6.49	-0.3	2.35e-10	Hepatocellular carcinoma;
LUAD	cis	rs7191868	1	rs7191868	chr16:536090	G/C	cg00676925	chr16:540266	RAB11FIP3	-0.65	-7.14	-0.33	4.04e-12	Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg18180107	chr4:99064573	C4orf37	0.42	6.76	0.31	4.64e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs686320	1.000	rs686320	chr11:65244538	G/C	cg21890820	chr11:65308645	LTBP3	0.81	8.69	0.39	8.09e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs2274273	0.653	rs1209087	chr14:55493220	C/T	cg04306507	chr14:55594613	LGALS3	-0.34	-6.92	-0.32	1.66e-11	Protein biomarker;
LUAD	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg26384229	chr12:38710491	ALG10B	0.43	6.52	0.3	2.03e-10	Heart rate;
LUAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg10729496	chr3:10149963	C3orf24	0.58	9.39	0.42	3.74e-19	Alzheimer's disease;
LUAD	trans	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg04995722	chr7:26192034	NFE2L3	-0.44	-7.62	-0.35	1.68e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg04111992	chr7:158790115	NA	-0.45	-7.62	-0.35	1.7e-13	Facial morphology (factor 20);
LUAD	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	7.67	0.35	1.2e-13	Tonsillectomy;
LUAD	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.49	0.34	3.94e-13	Bipolar disorder;
LUAD	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg12935359	chr14:103987150	CKB	-0.49	-7.85	-0.36	3.52e-14	Body mass index;
LUAD	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg08085267	chr17:45401833	C17orf57	-0.49	-8.16	-0.37	3.87e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.16	-0.48	1.56e-25	Type 2 diabetes;
LUAD	cis	rs9487051	0.768	rs351752	chr6:109536034	C/A	cg01475377	chr6:109611718	NA	-0.38	-6.94	-0.32	1.51e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg21724239	chr8:58056113	NA	0.73	8.78	0.39	4.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7680126	0.633	rs4697745	chr4:10305081	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-7.35	-0.34	9.99e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs8028313	0.609	rs28735117	chr15:67933892	C/T	cg24579218	chr15:68104479	NA	-0.49	-8.13	-0.37	4.79e-15	Obesity;
LUAD	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg01579765	chr21:45077557	HSF2BP	-0.63	-14.64	-0.58	1.45e-39	Mean corpuscular volume;
LUAD	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11890956	chr21:40555474	PSMG1	0.82	14.66	0.58	1.25e-39	Cognitive function;
LUAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03760483	chr17:6899297	ALOX12	0.35	6.65	0.31	9.15e-11	Tonsillectomy;
LUAD	cis	rs2387326	0.717	rs12261194	chr10:129944464	T/C	cg16087940	chr10:129947807	NA	-0.63	-8.98	-0.4	9.14e-18	Select biomarker traits;
LUAD	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11644478	chr21:40555479	PSMG1	0.7	11.8	0.5	5.71e-28	Cognitive function;
LUAD	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs669446	0.533	rs7543520	chr1:44243866	T/C	cg12908607	chr1:44402522	ARTN	-0.37	-7.05	-0.32	7.22e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs7651039	0.619	rs7640807	chr3:15685137	A/G	cg16303742	chr3:15540471	COLQ	0.62	12.16	0.51	2.12e-29	Coronary heart disease;
LUAD	cis	rs2734839	0.964	rs2234690	chr11:113291748	T/A	cg14159747	chr11:113255604	NA	0.54	10.4	0.45	1e-22	Information processing speed;
LUAD	cis	rs9394841	0.692	rs9369312	chr6:41841535	A/T	cg17623882	chr6:41773611	USP49	-0.48	-6.66	-0.31	8.56e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg06784218	chr1:46089804	CCDC17	-0.59	-13.07	-0.54	5.14e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.9	-0.36	2.45e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	12.82	0.53	5.16e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs7395662	0.926	rs11039893	chr11:48657754	G/A	cg00717180	chr2:96193071	NA	-0.43	-8.28	-0.37	1.68e-15	HDL cholesterol;
LUAD	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg24596788	chr1:163392923	NA	-0.34	-7.31	-0.33	1.38e-12	Motion sickness;
LUAD	cis	rs9826463	0.582	rs11720007	chr3:142134712	T/G	cg20824294	chr3:142316082	PLS1	0.37	6.56	0.3	1.61e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7178572	0.568	rs11072653	chr15:77693934	C/T	cg15453836	chr15:77711506	NA	-0.36	-6.4	-0.3	4.24e-10	Type 2 diabetes;
LUAD	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg20398880	chr6:41068722	NFYA;LOC221442	-0.38	-6.68	-0.31	7.45e-11	Alzheimer's disease (late onset);
LUAD	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg20291162	chr17:40259547	DHX58	-0.67	-10.23	-0.45	4.16e-22	Fibrinogen levels;
LUAD	cis	rs6545883	0.868	rs2518933	chr2:61797030	C/A	cg15711740	chr2:61764176	XPO1	-0.42	-6.68	-0.31	7.32e-11	Tuberculosis;
LUAD	cis	rs10203711	1.000	rs907103	chr2:239564541	A/G	cg14580085	chr2:239553406	NA	0.4	8.46	0.38	4.26e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6076065	0.707	rs2424555	chr20:23417705	A/G	cg11657817	chr20:23433608	CST11	0.56	11.75	0.5	8.58e-28	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.76	-14.24	-0.57	7.15e-38	Lymphocyte counts;
LUAD	cis	rs3784262	0.935	rs4646563	chr15:58353335	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.48	-9.64	-0.42	5.01e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg08132940	chr7:1081526	C7orf50	-0.72	-10.07	-0.44	1.58e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg20607798	chr8:58055168	NA	0.57	7.28	0.33	1.69e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg24503407	chr1:205819492	PM20D1	0.78	16.02	0.61	1.81e-45	Menarche (age at onset);
LUAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.61	-0.31	1.16e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg17178900	chr1:205818956	PM20D1	-0.46	-7.17	-0.33	3.28e-12	Menarche (age at onset);
LUAD	cis	rs6138458	0.887	rs227622	chr20:24910597	T/C	cg06937882	chr20:24974362	C20orf3	-0.33	-6.43	-0.3	3.52e-10	Blood protein levels;
LUAD	cis	rs1395	0.778	rs17005956	chr2:27451099	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	8.48	0.38	3.79e-16	Blood metabolite levels;
LUAD	cis	rs11249608	0.789	rs903989	chr5:178434434	C/T	cg01312482	chr5:178451176	ZNF879	-0.42	-6.37	-0.3	5.03e-10	Pubertal anthropometrics;
LUAD	cis	rs4638749	0.677	rs2100407	chr2:108830188	G/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.3	-0.33	1.48e-12	Blood pressure;
LUAD	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg11189052	chr15:85197271	WDR73	0.63	7.97	0.36	1.48e-14	Schizophrenia;
LUAD	cis	rs240764	0.658	rs7746947	chr6:101188708	G/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.55	-0.38	2.24e-16	Neuroticism;
LUAD	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg23172400	chr8:95962367	TP53INP1	-0.37	-8.89	-0.4	1.77e-17	Type 2 diabetes;
LUAD	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg22166914	chr1:53195759	ZYG11B	0.4	6.66	0.31	8.55e-11	Monocyte count;
LUAD	cis	rs7264396	0.563	rs6060560	chr20:34278890	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.87	-0.36	2.9e-14	Total cholesterol levels;
LUAD	cis	rs758324	0.947	rs6861732	chr5:131156462	A/C	cg06307176	chr5:131281290	NA	0.5	7.82	0.36	4.38e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1395	1.000	rs7593448	chr2:27449293	C/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.39	7.31	0.33	1.33e-12	Blood metabolite levels;
LUAD	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg00071950	chr4:10020882	SLC2A9	0.8	16.52	0.63	1.1e-47	Bone mineral density;
LUAD	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg08859206	chr1:53392774	SCP2	0.85	15.55	0.6	1.81e-43	Monocyte count;
LUAD	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg16797656	chr11:68205561	LRP5	0.45	9.36	0.41	4.82e-19	Total body bone mineral density;
LUAD	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg10434728	chr15:90938212	IQGAP1	0.37	7.4	0.34	7.56e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg09835421	chr16:68378352	PRMT7	-1.07	-12.53	-0.52	7.65e-31	Schizophrenia;
LUAD	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg25036284	chr2:26402008	FAM59B	-0.6	-8.37	-0.38	8.7e-16	Gut microbiome composition (summer);
LUAD	cis	rs9322817	0.691	rs17680345	chr6:105337409	A/T	cg02098413	chr6:105308735	HACE1	0.42	9.12	0.41	3.1e-18	Thyroid stimulating hormone;
LUAD	trans	rs2840044	1.000	rs9913003	chr17:33893904	C/A	cg19694781	chr19:47549865	TMEM160	0.62	9.97	0.44	3.69e-21	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs9473147	0.516	rs9367284	chr6:47516369	A/G	cg02130027	chr6:47444894	CD2AP	0.37	7.06	0.32	6.94e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs478304	0.718	rs61744384	chr11:65387378	T/A	cg05805236	chr11:65401703	PCNXL3	-0.48	-8.28	-0.37	1.64e-15	Acne (severe);
LUAD	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	7.09	0.33	5.68e-12	Schizophrenia;
LUAD	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg08422745	chr4:174089978	GALNT7	-0.93	-16.56	-0.63	8.06e-48	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs2251260	0.629	rs1088672	chr14:62004299	G/T	cg13564459	chr14:62004353	PRKCH	0.45	7.03	0.32	8.4e-12	Yeast infection;
LUAD	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg07917127	chr4:99064746	C4orf37	0.39	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg04218760	chr10:45406644	TMEM72	-0.29	-7.32	-0.34	1.25e-12	Mean corpuscular volume;
LUAD	trans	rs10411161	0.752	rs4584941	chr19:52392141	C/T	cg22319618	chr22:45562946	NUP50	-0.64	-8.42	-0.38	6.09e-16	Breast cancer;
LUAD	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs921968	0.545	rs2433738	chr2:219551036	T/A	cg02176678	chr2:219576539	TTLL4	-0.59	-11.83	-0.5	4.21e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg11062466	chr8:58055876	NA	0.67	9.02	0.4	6.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg20673091	chr1:2541236	MMEL1	-0.41	-8.79	-0.39	3.88e-17	Ulcerative colitis;
LUAD	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18099408	chr3:52552593	STAB1	-0.41	-7.16	-0.33	3.64e-12	Bipolar disorder;
LUAD	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg22189786	chr22:42395067	WBP2NL	0.45	6.5	0.3	2.22e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg25809561	chr17:30822961	MYO1D	0.75	15.65	0.61	6.8e-44	Schizophrenia;
LUAD	cis	rs4727443	0.899	rs886453	chr7:99588225	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.41	6.91	0.32	1.76e-11	Interstitial lung disease;
LUAD	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs6987853	0.787	rs2923413	chr8:42455308	A/G	cg09913449	chr8:42400586	C8orf40	0.44	8.36	0.38	9.13e-16	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03452623	chr4:187889614	NA	-0.84	-18.22	-0.66	3.66e-55	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs783540	0.843	rs9652567	chr15:83368514	T/G	cg18393722	chr15:85113863	UBE2QP1	0.43	7.04	0.32	7.75e-12	Schizophrenia;
LUAD	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/A	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.71	10.12	0.44	1.05e-21	Type 2 diabetes;
LUAD	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg26384229	chr12:38710491	ALG10B	0.44	7.11	0.33	5.06e-12	Bladder cancer;
LUAD	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.44	7.78	0.35	5.56e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08219700	chr8:58056026	NA	0.54	7.51	0.34	3.66e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg18932078	chr1:2524107	MMEL1	0.38	7.19	0.33	2.92e-12	Ulcerative colitis;
LUAD	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg14552801	chr7:65878734	NA	0.37	6.37	0.3	5.05e-10	Aortic root size;
LUAD	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg21963583	chr11:68658836	MRPL21	-0.62	-10.96	-0.47	9.01e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3857067	0.772	rs4438731	chr4:95091384	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.38	-6.69	-0.31	7.25e-11	QT interval;
LUAD	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg03929089	chr4:120376271	NA	0.58	7.59	0.35	2.02e-13	Axial length;
LUAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg24642844	chr7:1081250	C7orf50	-0.87	-13.64	-0.55	2.4e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs68170813	0.559	rs12535258	chr7:106971050	T/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.02	-0.44	2.38e-21	Coronary artery disease;
LUAD	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.48	-0.38	3.74e-16	Height;
LUAD	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg05665937	chr4:1216051	CTBP1	0.42	7.61	0.35	1.82e-13	Obesity-related traits;
LUAD	cis	rs7107174	1.000	rs2512542	chr11:77981780	G/A	cg19901956	chr11:77921274	USP35	-0.46	-6.51	-0.3	2.09e-10	Testicular germ cell tumor;
LUAD	cis	rs600626	0.947	rs559355	chr11:75451281	A/T	cg24262691	chr11:75473276	NA	0.4	6.41	0.3	4.01e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs4948275	0.530	rs10994747	chr10:63149922	A/G	cg02461363	chr10:63212496	TMEM26	-0.32	-6.77	-0.31	4.26e-11	Night sleep phenotypes;
LUAD	cis	rs12545109	0.836	rs2196586	chr8:57347126	C/T	cg09654669	chr8:57350985	NA	0.66	9.49	0.42	1.67e-19	Obesity-related traits;
LUAD	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg20607798	chr8:58055168	NA	0.79	9.69	0.43	3.43e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg10755058	chr3:40428713	ENTPD3	-0.39	-7.75	-0.35	6.89e-14	Renal cell carcinoma;
LUAD	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg21856205	chr7:94953877	PON1	-0.56	-7.98	-0.36	1.39e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg23018236	chr17:30244563	NA	-0.7	-8.68	-0.39	8.97e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs6500395	1.000	rs4785536	chr16:48712980	C/T	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg16989719	chr2:238392110	NA	-0.32	-6.69	-0.31	7.24e-11	Prostate cancer;
LUAD	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg21475434	chr5:93447410	FAM172A	-0.61	-7.78	-0.35	5.57e-14	Diabetic retinopathy;
LUAD	cis	rs10242455	0.702	rs73711280	chr7:99039604	C/T	cg18809830	chr7:99032528	PTCD1	-0.99	-7.18	-0.33	3.17e-12	Blood metabolite levels;
LUAD	cis	rs743757	0.697	rs763030	chr3:50528092	G/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.46	6.69	0.31	7.31e-11	Diastolic blood pressure;
LUAD	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg27539214	chr16:67997921	SLC12A4	-0.72	-9.19	-0.41	1.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg11673840	chr17:47092156	IGF2BP1	-0.34	-6.7	-0.31	6.49e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg13334819	chr7:99746414	C7orf59	-0.66	-10.05	-0.44	1.87e-21	Coronary artery disease;
LUAD	trans	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg01620082	chr3:125678407	NA	-0.46	-6.76	-0.31	4.61e-11	Depression;
LUAD	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg05340658	chr4:99064831	C4orf37	0.49	8.17	0.37	3.56e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg18854424	chr1:2615690	NA	-0.42	-9.18	-0.41	1.89e-18	Ulcerative colitis;
LUAD	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg26513180	chr16:89883248	FANCA	0.78	6.73	0.31	5.65e-11	Skin colour saturation;
LUAD	cis	rs9329221	0.686	rs60755617	chr8:10243327	T/G	cg21775007	chr8:11205619	TDH	0.39	6.43	0.3	3.49e-10	Neuroticism;
LUAD	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg03929089	chr4:120376271	NA	-0.51	-6.7	-0.31	6.64e-11	Axial length;
LUAD	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg18180107	chr4:99064573	C4orf37	-0.41	-6.67	-0.31	8.12e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg18252515	chr7:66147081	NA	-0.63	-6.96	-0.32	1.34e-11	Diabetic kidney disease;
LUAD	trans	rs2018683	0.707	rs7799357	chr7:28970118	A/G	cg19402173	chr7:128379420	CALU	-0.51	-8.15	-0.37	4.08e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12801636	0.557	rs3741378	chr11:65408937	C/T	cg16535667	chr11:65410126	SIPA1	-0.47	-6.62	-0.31	1.11e-10	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.53	-0.46	3.6e-23	Total body bone mineral density;
LUAD	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-24.12	-0.76	1.69e-81	Height;
LUAD	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg15147215	chr3:52552868	STAB1	0.35	6.42	0.3	3.67e-10	Bipolar disorder;
LUAD	cis	rs10465746	0.846	rs12146038	chr1:84405065	A/T	cg10977910	chr1:84465055	TTLL7	0.48	7.77	0.35	6e-14	Obesity-related traits;
LUAD	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.15	0.33	3.89e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.88	-0.36	2.81e-14	Diabetic kidney disease;
LUAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg07414643	chr4:187882934	NA	0.34	6.94	0.32	1.45e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg27170947	chr2:26402098	FAM59B	-0.82	-11.34	-0.48	3.22e-26	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg05340658	chr4:99064831	C4orf37	0.56	9.65	0.42	4.68e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg26924012	chr15:45694286	SPATA5L1	0.64	11.01	0.47	5.78e-25	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	9.4e-15	Tonsillectomy;
LUAD	cis	rs738321	0.757	rs3788534	chr22:38533971	A/T	cg25457927	chr22:38595422	NA	-0.48	-10.89	-0.47	1.63e-24	Breast cancer;
LUAD	cis	rs886126	1.000	rs886126	chr12:111679214	C/T	cg10833066	chr12:111807467	FAM109A	0.58	11.22	0.48	9.24e-26	Coronary heart disease;
LUAD	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg19912559	chr1:40204330	PPIE	0.56	9.63	0.42	5.47e-20	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.8	0.35	4.94e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05744073	chr17:1953268	MIR132	0.44	6.76	0.31	4.62e-11	Monocyte percentage of white cells;
LUAD	cis	rs9902453	0.817	rs55758314	chr17:28173978	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.85	0.43	9.57e-21	Coffee consumption (cups per day);
LUAD	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg02176678	chr2:219576539	TTLL4	-0.6	-11.55	-0.49	5.14e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg23985595	chr17:80112537	CCDC57	-0.53	-9.51	-0.42	1.43e-19	Life satisfaction;
LUAD	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg01802117	chr1:53393560	SCP2	-0.34	-6.73	-0.31	5.63e-11	Monocyte count;
LUAD	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.05	-0.56	4.73e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg03188948	chr7:1209495	NA	0.81	9.86	0.43	8.57e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg14403583	chr14:105418241	AHNAK2	-0.43	-8.08	-0.37	6.9e-15	Rheumatoid arthritis;
LUAD	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.5	0.52	1.02e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg25894440	chr7:65020034	NA	-0.67	-7.22	-0.33	2.47e-12	Diabetic kidney disease;
LUAD	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06544989	chr22:39130855	UNC84B	0.45	8.38	0.38	7.99e-16	Menopause (age at onset);
LUAD	cis	rs9473147	0.516	rs9381575	chr6:47528764	C/G	cg02130027	chr6:47444894	CD2AP	0.37	7.06	0.32	6.94e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg05425664	chr17:57184151	TRIM37	-0.36	-6.36	-0.3	5.36e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05776053	chr2:74358815	NA	0.44	6.9	0.32	1.89e-11	Gestational age at birth (maternal effect);
LUAD	trans	rs7939886	0.920	rs17150095	chr11:55902900	A/G	cg15704280	chr7:45808275	SEPT13	0.66	6.38	0.3	4.79e-10	Myopia (pathological);
LUAD	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26119090	chr2:26468346	HADHA;HADHB	0.61	8.6	0.39	1.61e-16	Gut microbiome composition (summer);
LUAD	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg18190219	chr22:46762943	CELSR1	-0.44	-6.35	-0.3	5.4e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg02574844	chr11:5959923	NA	-0.45	-8.4	-0.38	6.59e-16	DNA methylation (variation);
LUAD	cis	rs870825	0.655	rs12502771	chr4:185635834	T/C	cg04058563	chr4:185651563	MLF1IP	0.89	14.3	0.57	3.91e-38	Blood protein levels;
LUAD	cis	rs447921	0.861	rs117544870	chr17:74415206	T/G	cg17201438	chr17:74438067	UBE2O	0.66	8.46	0.38	4.31e-16	Mitochondrial DNA levels;
LUAD	cis	rs1403694	0.515	rs1648697	chr3:186449194	A/G	cg12454167	chr3:186435060	KNG1	0.41	8.5	0.38	3.18e-16	Blood protein levels;
LUAD	cis	rs6964587	0.507	rs12539439	chr7:91917365	A/C	cg17063962	chr7:91808500	NA	0.65	10.76	0.46	4.92e-24	Breast cancer;
LUAD	cis	rs10992471	0.603	rs10992342	chr9:95212068	C/T	cg14631576	chr9:95140430	CENPP	-0.56	-11.5	-0.49	8.06e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg07936489	chr17:37558343	FBXL20	0.43	6.88	0.32	2.18e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs17253792	0.822	rs9972178	chr14:56073480	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs1799810	0.899	rs7599210	chr2:128164177	G/A	cg09760422	chr2:128146352	NA	0.41	7.02	0.32	8.75e-12	Self-rated health;
LUAD	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-6.94	-0.32	1.52e-11	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs75920871	0.800	rs1900198	chr11:116784486	G/T	cg04087571	chr11:116723030	SIK3	0.32	6.97	0.32	1.19e-11	Subjective well-being;
LUAD	cis	rs6906287	0.573	rs12205899	chr6:118699928	C/G	cg21191810	chr6:118973309	C6orf204	0.49	9.54	0.42	1.17e-19	Electrocardiographic conduction measures;
LUAD	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg19196401	chr6:110721138	DDO	-0.47	-9.0	-0.4	7.71e-18	Platelet distribution width;
LUAD	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg23985595	chr17:80112537	CCDC57	-0.51	-9.39	-0.42	3.82e-19	Life satisfaction;
LUAD	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg24069376	chr3:38537580	EXOG	0.34	7.78	0.35	5.56e-14	Electrocardiographic conduction measures;
LUAD	cis	rs2688608	0.672	rs2227576	chr10:75678276	T/G	cg23231163	chr10:75533350	FUT11	-0.37	-6.78	-0.31	3.96e-11	Inflammatory bowel disease;
LUAD	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg14779329	chr11:130786720	SNX19	0.39	6.9	0.32	1.85e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.5	7.22	0.33	2.39e-12	Cognitive test performance;
LUAD	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg26384229	chr12:38710491	ALG10B	0.48	7.78	0.35	5.55e-14	Bladder cancer;
LUAD	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg17063962	chr7:91808500	NA	0.65	10.96	0.47	8.81e-25	Breast cancer;
LUAD	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg10755058	chr3:40428713	ENTPD3	0.37	7.21	0.33	2.55e-12	Renal cell carcinoma;
LUAD	cis	rs59104589	0.617	rs3771567	chr2:242358619	G/A	cg08645257	chr2:242211290	HDLBP	0.43	7.02	0.32	8.92e-12	Fibrinogen levels;
LUAD	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg11645453	chr3:52864694	ITIH4	0.61	11.46	0.49	1.18e-26	Schizophrenia;
LUAD	cis	rs968567	0.689	rs61897795	chr11:61618169	A/G	cg00603274	chr11:61596626	FADS2	-0.7	-9.26	-0.41	1e-18	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs240764	0.687	rs239248	chr6:101088315	T/A	cg09795085	chr6:101329169	ASCC3	0.43	7.48	0.34	4.29e-13	Neuroticism;
LUAD	cis	rs367615	0.552	rs2416210	chr5:108741137	C/T	cg17395555	chr5:108820864	NA	-0.47	-9.01	-0.4	7.19e-18	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg06558623	chr16:89946397	TCF25	1.14	10.37	0.45	1.38e-22	Skin colour saturation;
LUAD	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg14581129	chr12:53358946	NA	-0.9	-15.96	-0.61	3.21e-45	Cancer (pleiotropy);
LUAD	cis	rs6028335	0.610	rs28578430	chr20:37542467	G/A	cg27660920	chr20:37554817	FAM83D	0.53	6.88	0.32	2.13e-11	Alcohol and nicotine co-dependence;
LUAD	cis	rs4713675	0.565	rs3818524	chr6:33660695	G/C	cg14003231	chr6:33640908	ITPR3	0.5	9.57	0.42	8.92e-20	Plateletcrit;
LUAD	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg21862992	chr11:68658383	NA	0.52	9.54	0.42	1.11e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg23254163	chr1:152506842	NA	0.24	6.62	0.31	1.11e-10	Hair morphology;
LUAD	cis	rs2274273	0.686	rs11624679	chr14:55624244	G/A	cg04306507	chr14:55594613	LGALS3	0.42	7.66	0.35	1.26e-13	Protein biomarker;
LUAD	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.47	7.27	0.33	1.73e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg09365446	chr1:150670422	GOLPH3L	0.66	12.57	0.52	5.38e-31	Tonsillectomy;
LUAD	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.59	0.39	1.64e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10916814	0.546	rs10799644	chr1:20903195	G/T	cg24502330	chr1:20914028	CDA	-0.36	-7.02	-0.32	8.98e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg15921436	chr17:44337874	NA	-0.7	-9.22	-0.41	1.42e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.79	-0.31	3.92e-11	Aortic root size;
LUAD	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.92	-0.36	2.11e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1950500	0.509	rs12879087	chr14:24826900	A/T	cg22990158	chr14:24802150	ADCY4	-0.41	-7.32	-0.34	1.29e-12	Height;
LUAD	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg15704280	chr7:45808275	SEPT13	-1.06	-23.72	-0.76	1.02e-79	Height;
LUAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg11494091	chr17:61959527	GH2	0.75	18.49	0.67	2.35e-56	Prudent dietary pattern;
LUAD	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02475777	chr4:1388615	CRIPAK	-0.65	-9.17	-0.41	2.13e-18	Longevity;
LUAD	cis	rs4462272	0.503	rs11593131	chr10:101843608	G/A	cg19754520	chr10:101825118	CPN1	-0.34	-7.4	-0.34	7.57e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs912057	0.833	rs1294418	chr6:6742185	A/G	cg06612196	chr6:6737390	NA	0.55	12.65	0.52	2.44e-31	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg25985355	chr7:65971099	NA	-0.38	-6.92	-0.32	1.63e-11	Aortic root size;
LUAD	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-7.4	-0.34	7.18e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs55665837	0.961	rs11023226	chr11:14458817	C/T	cg19336497	chr11:14380999	RRAS2	-0.5	-10.1	-0.44	1.27e-21	Vitamin D levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14431266	chr11:67057003	ANKRD13D	-0.45	-7.0	-0.32	9.97e-12	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14128173	chr9:131115745	SLC27A4	0.52	6.81	0.31	3.37e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs3219090	0.962	rs1865221	chr1:226601974	G/T	cg27539482	chr13:111589090	NA	0.43	7.15	0.33	3.76e-12	Melanoma;
LUAD	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.28	-7.5	-0.34	3.79e-13	Total body bone mineral density;
LUAD	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg23262073	chr20:60523788	NA	-0.46	-7.38	-0.34	8.43e-13	Body mass index;
LUAD	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg20607798	chr8:58055168	NA	0.67	8.56	0.38	2.19e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.62	-10.91	-0.47	1.36e-24	Longevity;Endometriosis;
LUAD	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg09197432	chr4:183729176	NA	0.54	6.79	0.31	3.72e-11	Pediatric autoimmune diseases;
LUAD	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21028142	chr17:79581711	NPLOC4	0.43	8.89	0.4	1.83e-17	Eye color traits;
LUAD	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg06641503	chr3:48959341	ARIH2	-0.4	-7.67	-0.35	1.16e-13	Parkinson's disease;
LUAD	cis	rs910873	0.656	rs4911442	chr20:33355046	G/A	cg16810054	chr20:33298113	TP53INP2	-0.59	-6.92	-0.32	1.73e-11	Melanoma;
LUAD	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg12011299	chr4:100065546	ADH4	0.72	12.73	0.53	1.22e-31	Alcohol dependence;
LUAD	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.39	7.73	0.35	7.9e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10193935	1.000	rs72796507	chr2:42409840	A/G	cg27598129	chr2:42591480	NA	-0.74	-9.71	-0.43	2.87e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg17724175	chr1:150552817	MCL1	0.39	9.41	0.42	3.1e-19	Tonsillectomy;
LUAD	cis	rs7680126	0.500	rs11735668	chr4:10148655	C/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-7.58	-0.35	2.27e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.43	0.3	3.43e-10	Depression;
LUAD	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg02990361	chr1:107599529	PRMT6	0.62	10.31	0.45	2.23e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg13334819	chr7:99746414	C7orf59	-0.66	-10.41	-0.45	9.88e-23	Coronary artery disease;
LUAD	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg24308560	chr3:49941425	MST1R	-0.52	-8.72	-0.39	6.52e-17	Body mass index;
LUAD	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg22598563	chr5:131563921	P4HA2	-0.3	-7.49	-0.34	3.96e-13	Blood metabolite levels;
LUAD	cis	rs7953508	0.711	rs3825199	chr12:93976954	A/G	cg18151635	chr12:93972918	NA	-0.7	-10.82	-0.47	3.01e-24	Pubertal anthropometrics;
LUAD	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.19	-0.33	2.96e-12	Total body bone mineral density;
LUAD	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg22117172	chr7:91764530	CYP51A1	0.34	7.54	0.34	2.98e-13	Breast cancer;
LUAD	cis	rs12545109	0.800	rs2582404	chr8:57387368	C/T	cg11919837	chr8:57350735	NA	-0.46	-6.55	-0.3	1.65e-10	Obesity-related traits;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01250320	chr2:18742004	RDH14	-0.4	-6.65	-0.31	9.28e-11	Cancer;
LUAD	cis	rs11229555	0.645	rs12786744	chr11:58177549	T/C	cg15696309	chr11:58395628	NA	-0.77	-10.53	-0.46	3.58e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-6.66	-0.31	8.78e-11	Morning vs. evening chronotype;
LUAD	trans	rs701145	0.640	rs2122365	chr3:153930808	T/G	cg14299572	chr10:34021103	NA	-0.39	-6.49	-0.3	2.35e-10	Coronary artery disease;
LUAD	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.7	-0.31	6.77e-11	Total body bone mineral density;
LUAD	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg13271783	chr10:134563150	INPP5A	-0.42	-6.59	-0.3	1.35e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg00634984	chr7:65235879	NA	0.5	6.71	0.31	6.12e-11	Aortic root size;
LUAD	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.06	13.19	0.54	1.59e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg04772025	chr11:68637568	NA	0.54	8.8	0.39	3.63e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.48	-0.45	5.41e-23	Total body bone mineral density;
LUAD	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg09509183	chr1:209979624	IRF6	0.66	7.68	0.35	1.09e-13	Cleft lip with or without cleft palate;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08620789	chr7:157129638	DNAJB6	-0.52	-6.42	-0.3	3.72e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7945705	0.791	rs7944560	chr11:8817276	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.41	7.41	0.34	6.84e-13	Hemoglobin concentration;
LUAD	trans	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg03929089	chr4:120376271	NA	-0.45	-6.93	-0.32	1.61e-11	HDL cholesterol;
LUAD	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg08885076	chr2:99613938	TSGA10	-0.36	-6.53	-0.3	1.9e-10	Chronic sinus infection;
LUAD	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg15395560	chr15:45543142	SLC28A2	0.37	6.36	0.3	5.28e-10	Uric acid levels;
LUAD	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg10544611	chr16:67998164	SLC12A4	-0.55	-6.94	-0.32	1.47e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg13902645	chr11:5959945	NA	-0.5	-8.59	-0.39	1.7e-16	DNA methylation (variation);
LUAD	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg03878208	chr11:72483293	STARD10	0.56	7.97	0.36	1.5e-14	Type 2 diabetes;
LUAD	cis	rs5756391	0.546	rs9607390	chr22:37314533	C/T	cg16356956	chr22:37317934	CSF2RB	0.33	7.23	0.33	2.22e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg20290983	chr6:43655470	MRPS18A	0.79	15.99	0.61	2.27e-45	IgG glycosylation;
LUAD	cis	rs11051970	0.679	rs2733696	chr12:32554635	A/G	cg02745156	chr12:32552066	NA	0.31	6.63	0.31	1.01e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg07460842	chr6:66804631	NA	-0.86	-13.88	-0.56	2.41e-36	Exhaled nitric oxide output;
LUAD	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg15819921	chr19:927150	ARID3A	-0.46	-7.73	-0.35	8.01e-14	Life satisfaction;
LUAD	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg02734326	chr4:10020555	SLC2A9	0.63	11.3	0.48	4.66e-26	Bone mineral density;
LUAD	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2387326	0.717	rs10829340	chr10:129943941	G/T	cg16087940	chr10:129947807	NA	-0.63	-8.99	-0.4	8.38e-18	Select biomarker traits;
LUAD	cis	rs2242663	0.603	rs610293	chr11:66310380	C/T	cg18002602	chr11:66138449	SLC29A2	-0.33	-6.59	-0.3	1.35e-10	Bipolar disorder;
LUAD	cis	rs3764563	1.000	rs4239617	chr19:15741537	C/T	cg20725493	chr19:15740067	CYP4F8	-0.76	-8.82	-0.39	2.92e-17	Inflammatory biomarkers;
LUAD	cis	rs9309473	0.607	rs2421489	chr2:73593448	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-6.75	-0.31	4.92e-11	Metabolite levels;
LUAD	cis	rs1105228	0.644	rs9457059	chr6:165699810	G/A	cg12582777	chr6:165658423	NA	-0.32	-6.51	-0.3	2.1e-10	Number of pregnancies;Number of children;
LUAD	cis	rs4774899	0.966	rs12904070	chr15:57286011	A/G	cg14026238	chr15:57616123	NA	0.34	6.4	0.3	4.12e-10	Urinary tract infection frequency;
LUAD	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg02551604	chr5:131831745	NA	-0.61	-9.98	-0.44	3.28e-21	Asthma (sex interaction);
LUAD	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg23950597	chr19:37808831	NA	-0.65	-7.63	-0.35	1.58e-13	Coronary artery calcification;
LUAD	cis	rs754466	0.651	rs10824582	chr10:79603688	T/C	cg17075019	chr10:79541650	NA	-0.87	-18.15	-0.66	7.61e-55	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg02269571	chr22:50332266	NA	-0.84	-9.3	-0.41	7.36e-19	Schizophrenia;
LUAD	trans	rs9747201	1.000	rs4280305	chr17:80177069	A/C	cg07393940	chr7:158741817	NA	0.69	11.46	0.49	1.14e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1697139	0.583	rs11739587	chr5:66540481	A/C	cg11553311	chr5:66541588	NA	-0.43	-8.13	-0.37	4.86e-15	Breast cancer;
LUAD	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg18129748	chr3:49941408	MST1R	-0.4	-6.53	-0.3	1.95e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg10645314	chr2:3704589	ALLC	-0.94	-13.25	-0.54	9.33e-34	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg25173405	chr17:45401733	C17orf57	-0.54	-9.41	-0.42	3.19e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg20587970	chr11:113659929	NA	-1.2	-18.08	-0.66	1.49e-54	Hip circumference adjusted for BMI;
LUAD	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg11645453	chr3:52864694	ITIH4	0.37	7.42	0.34	6.2800000000000005e-13	Bipolar disorder;
LUAD	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg01958934	chr19:45449099	APOC2	0.35	6.87	0.32	2.29e-11	Blood protein levels;
LUAD	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg23533926	chr12:111358616	MYL2	-0.42	-7.18	-0.33	3.2e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg14092988	chr3:52407081	DNAH1	-0.33	-6.76	-0.31	4.65e-11	Bipolar disorder;
LUAD	cis	rs354225	0.544	rs12713265	chr2:54805409	C/T	cg26097391	chr2:54893211	SPTBN1	0.42	6.47	0.3	2.77e-10	Schizophrenia;
LUAD	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg06636551	chr8:101224915	SPAG1	-0.37	-6.67	-0.31	8.12e-11	Atrioventricular conduction;
LUAD	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg09537434	chr19:41945824	ATP5SL	-0.46	-7.26	-0.33	1.84e-12	Height;
LUAD	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg02371401	chr5:676784	TPPP	-0.48	-7.83	-0.36	3.9e-14	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7267979	0.780	rs2500413	chr20:25241155	T/C	cg08601574	chr20:25228251	PYGB	0.45	8.35	0.38	9.69e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg26338869	chr17:61819248	STRADA	-0.38	-6.37	-0.3	4.94e-10	Prudent dietary pattern;
LUAD	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg12011299	chr4:100065546	ADH4	0.7	12.61	0.52	3.55e-31	Smoking initiation;
LUAD	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg17105886	chr17:28927953	LRRC37B2	0.59	6.64	0.31	9.83e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4604732	0.588	rs7552443	chr1:247628583	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.1	0.33	5.32e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg27446573	chr6:127587934	RNF146	0.4	6.39	0.3	4.46e-10	Breast cancer;
LUAD	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg24818145	chr4:99064322	C4orf37	-0.4	-6.75	-0.31	4.87e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1018836	0.632	rs7017630	chr8:91482604	A/G	cg16814680	chr8:91681699	NA	-0.65	-10.84	-0.47	2.61e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9303401	0.573	rs67378767	chr17:57194237	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	7.38	0.34	8.67e-13	Cognitive test performance;
LUAD	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg25036284	chr2:26402008	FAM59B	-0.83	-11.68	-0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg14582100	chr15:45693742	SPATA5L1	0.64	12.5	0.52	9.64e-31	Homoarginine levels;
LUAD	cis	rs6738485	0.552	rs62146770	chr2:106854277	C/T	cg16099169	chr2:106886729	NA	-0.41	-7.16	-0.33	3.54e-12	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg07460842	chr6:66804631	NA	0.92	14.75	0.58	5.19e-40	Exhaled nitric oxide levels;
LUAD	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg15226275	chr6:116381976	FRK	0.22	7.06	0.32	6.96e-12	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg14664628	chr15:75095509	CSK	-0.58	-9.39	-0.42	3.82e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg00684032	chr4:1343700	KIAA1530	0.42	6.95	0.32	1.42e-11	Obesity-related traits;
LUAD	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg27411982	chr8:10470053	RP1L1	-0.4	-7.15	-0.33	3.83e-12	Joint mobility (Beighton score);
LUAD	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg09658497	chr7:2847517	GNA12	-0.56	-9.68	-0.43	3.61e-20	Height;
LUAD	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg02389323	chr16:88786976	FAM38A	0.98	9.71	0.43	2.84e-20	Plateletcrit;
LUAD	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg13319975	chr6:146136371	FBXO30	-0.63	-10.92	-0.47	1.3e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs75920871	0.920	rs61907594	chr11:116801811	C/T	cg04087571	chr11:116723030	SIK3	-0.32	-6.46	-0.3	2.86e-10	Subjective well-being;
LUAD	cis	rs2882667	0.964	rs12108892	chr5:138299630	G/A	cg04439458	chr5:138467593	SIL1	-0.39	-7.24	-0.33	2.06e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs853679	0.599	rs13193295	chr6:28003228	C/G	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.05	-0.47	4.11e-25	Depression;
LUAD	cis	rs9467773	1.000	rs6913462	chr6:26577530	A/G	cg09904177	chr6:26538194	HMGN4	0.44	7.03	0.32	8.25e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9902453	0.619	rs2255489	chr17:28084974	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.51	-8.26	-0.37	1.88e-15	Coffee consumption (cups per day);
LUAD	cis	rs6684514	1.000	rs10908499	chr1:156279176	G/C	cg16558208	chr1:156270281	VHLL	0.53	9.65	0.42	4.74e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs6758955	1.000	rs1558628	chr2:10478422	C/T	cg15773312	chr2:10472214	HPCAL1	0.39	6.36	0.3	5.35e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs986417	0.901	rs1950313	chr14:60997782	A/G	cg27398547	chr14:60952738	C14orf39	0.65	7.83	0.36	4.01e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg11062466	chr8:58055876	NA	0.76	9.34	0.41	5.65e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs7395662	0.895	rs1945183	chr11:48502427	T/A	cg00717180	chr2:96193071	NA	-0.4	-7.4	-0.34	7.36e-13	HDL cholesterol;
LUAD	trans	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg11887960	chr12:57824829	NA	0.5	6.57	0.3	1.49e-10	Obesity-related traits;
LUAD	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg27624424	chr6:160112604	SOD2	0.43	6.43	0.3	3.44e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg01689657	chr7:91764605	CYP51A1	0.38	9.46	0.42	2.13e-19	Breast cancer;
LUAD	cis	rs7215564	0.908	rs59252837	chr17:78717155	A/G	cg09596252	chr17:78655493	RPTOR	0.54	6.55	0.3	1.66e-10	Myopia (pathological);
LUAD	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06022373	chr22:39101656	GTPBP1	-0.4	-6.38	-0.3	4.52e-10	Menopause (age at onset);
LUAD	trans	rs4368243	1.000	rs11082212	chr18:38383174	A/G	cg02219360	chr11:2721409	KCNQ1OT1;KCNQ1	0.43	6.48	0.3	2.63e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs10744422	0.800	rs2343110	chr12:123343571	T/G	cg16953816	chr12:123349952	VPS37B	0.58	6.36	0.3	5.15e-10	Schizophrenia;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg11453546	chr21:43990049	SLC37A1	-0.42	-6.65	-0.31	9.27e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.31	-0.33	1.37e-12	Lung cancer;
LUAD	trans	rs8002861	0.664	rs1808097	chr13:44424766	A/G	cg17145862	chr1:211918768	LPGAT1	0.64	12.94	0.53	1.74e-32	Leprosy;
LUAD	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21659725	chr3:3221576	CRBN	-0.86	-18.24	-0.66	2.79e-55	Intelligence (multi-trait analysis);
LUAD	trans	rs2262909	0.962	rs439574	chr19:22232024	A/C	cg17074339	chr11:11642133	GALNTL4	-0.39	-6.55	-0.3	1.71e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg14983838	chr19:29218262	NA	0.67	9.82	0.43	1.21e-20	Methadone dose in opioid dependence;
LUAD	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg24531977	chr5:56204891	C5orf35	1.25	20.44	0.7	4.27e-65	Initial pursuit acceleration;
LUAD	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.78	-0.5	6.88e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg11266682	chr4:10021025	SLC2A9	0.68	15.8	0.61	1.55e-44	Bone mineral density;
LUAD	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18876405	chr7:65276391	NA	-0.44	-6.98	-0.32	1.15e-11	Aortic root size;
LUAD	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.33	0.48	3.51e-26	Height;
LUAD	trans	rs10802346	0.514	rs4443861	chr1:246372574	G/T	cg22732515	chr19:44031385	ETHE1	0.58	9.39	0.42	3.7e-19	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs1387259	0.723	rs2732488	chr12:48771444	G/A	cg04545296	chr12:48745243	ZNF641	0.39	9.96	0.44	3.8e-21	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs12145833	0.596	rs12123491	chr1:243297924	C/G	cg02356786	chr1:243265016	LOC731275	0.74	8.0	0.36	1.22e-14	Obesity (early onset extreme);
LUAD	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15664640	chr17:80829946	TBCD	0.58	11.21	0.48	1.06e-25	Breast cancer;
LUAD	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg18512352	chr11:47633146	NA	-0.4	-7.04	-0.32	7.58e-12	Subjective well-being;
LUAD	cis	rs2688608	0.592	rs7080579	chr10:75504029	T/A	cg19442545	chr10:75533431	FUT11	-0.48	-7.87	-0.36	3.08e-14	Inflammatory bowel disease;
LUAD	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg13327785	chr12:132219529	SFRS8	-0.38	-6.96	-0.32	1.34e-11	Migraine;
LUAD	cis	rs1451375	0.669	rs4512339	chr7:50646977	C/T	cg18232548	chr7:50535776	DDC	-0.52	-8.38	-0.38	8.04e-16	Malaria;
LUAD	cis	rs72799341	1.000	rs7200879	chr16:30947572	A/G	cg05768032	chr16:30646687	NA	0.42	6.41	0.3	3.8e-10	Diastolic blood pressure;
LUAD	trans	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg21582582	chr3:182698605	DCUN1D1	0.46	7.57	0.35	2.34e-13	Body mass index;
LUAD	cis	rs1448094	0.842	rs12809288	chr12:86455427	C/T	cg19622623	chr12:86230825	RASSF9	0.35	6.35	0.3	5.4e-10	Major depressive disorder;
LUAD	cis	rs12210905	0.614	rs12199685	chr6:27323486	G/A	cg08851530	chr6:28072375	NA	1.09	7.97	0.36	1.45e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg05187965	chr10:45406764	TMEM72	-0.43	-8.79	-0.39	3.77e-17	Mean corpuscular volume;
LUAD	cis	rs13394619	0.605	rs12476152	chr2:11747960	T/C	cg07314298	chr2:11723111	GREB1	0.39	7.34	0.34	1.07e-12	Endometriosis;
LUAD	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg21918786	chr6:109611834	NA	-0.58	-10.65	-0.46	1.24e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg20908204	chr19:46285434	DMPK	-0.34	-7.47	-0.34	4.79e-13	Coronary artery disease;
LUAD	trans	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	11.42	0.49	1.69e-26	Exhaled nitric oxide output;
LUAD	cis	rs758324	0.812	rs519240	chr5:131269453	G/A	cg25547332	chr5:131281432	NA	-0.4	-6.53	-0.3	1.89e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg21017887	chr14:105400489	NA	0.75	14.36	0.57	2.22e-38	Rheumatoid arthritis;
LUAD	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg26587870	chr6:27730563	NA	-0.49	-8.28	-0.37	1.65e-15	Parkinson's disease;
LUAD	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg04450456	chr4:17643702	FAM184B	0.37	6.91	0.32	1.74e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg12432903	chr7:1882776	MAD1L1	-0.41	-6.77	-0.31	4.31e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs3219090	0.861	rs1341335	chr1:226605081	C/T	cg27539482	chr13:111589090	NA	0.43	7.26	0.33	1.82e-12	Melanoma;
LUAD	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.52	-7.86	-0.36	3.23e-14	Birth weight;
LUAD	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg20487152	chr13:99095054	FARP1	0.42	7.42	0.34	6.58e-13	Neuroticism;
LUAD	cis	rs986417	0.901	rs1956558	chr14:60975956	T/C	cg27398547	chr14:60952738	C14orf39	0.67	7.84	0.36	3.74e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.33	-0.34	1.2e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs1003719	0.707	rs9976360	chr21:38587860	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.32	-0.37	1.26e-15	Eye color traits;
LUAD	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.05	-0.32	7.52e-12	Height;
LUAD	cis	rs9341808	0.718	rs4437429	chr6:80828592	A/G	cg08355045	chr6:80787529	NA	0.56	10.05	0.44	1.94e-21	Sitting height ratio;
LUAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg07362569	chr17:61921086	SMARCD2	0.39	6.73	0.31	5.37e-11	Prudent dietary pattern;
LUAD	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg22681709	chr2:178499509	PDE11A	-0.55	-9.6	-0.42	7.3e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.25	6.44	0.3	3.35e-10	Parkinson's disease;
LUAD	cis	rs68170813	0.652	rs6958969	chr7:107197755	A/T	cg02696742	chr7:106810147	HBP1	-0.76	-8.96	-0.4	1.05e-17	Coronary artery disease;
LUAD	cis	rs4604732	0.527	rs60444724	chr1:247623164	T/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	9.11	0.4	3.36e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs75804782	0.641	rs72983834	chr2:239319895	G/A	cg01134436	chr17:81009848	B3GNTL1	0.8	8.62	0.39	1.33e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg17644776	chr2:200775616	C2orf69	0.56	7.5	0.34	3.75e-13	Schizophrenia;
LUAD	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg26384229	chr12:38710491	ALG10B	-0.42	-7.12	-0.33	4.73e-12	Morning vs. evening chronotype;
LUAD	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg17366294	chr4:99064904	C4orf37	0.51	9.24	0.41	1.2e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg15208524	chr1:10270712	KIF1B	-0.54	-7.93	-0.36	1.95e-14	Hepatocellular carcinoma;
LUAD	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg22508957	chr16:3507546	NAT15	-0.49	-8.16	-0.37	3.98e-15	Body mass index (adult);
LUAD	cis	rs240764	0.658	rs7753317	chr6:101220433	G/A	cg09795085	chr6:101329169	ASCC3	-0.43	-7.48	-0.34	4.29e-13	Neuroticism;
LUAD	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg27068330	chr11:65405492	SIPA1	-0.64	-10.23	-0.45	4.41e-22	Acne (severe);
LUAD	trans	rs877282	0.898	rs11253341	chr10:765008	G/C	cg22713356	chr15:30763199	NA	1.27	17.4	0.65	1.56e-51	Uric acid levels;
LUAD	cis	rs2279817	0.913	rs2270979	chr1:18023290	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.55	9.18	0.41	1.98e-18	Neuroticism;
LUAD	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg03929089	chr4:120376271	NA	-0.88	-16.96	-0.64	1.31e-49	Height;
LUAD	cis	rs78487399	0.808	rs6761129	chr2:43735713	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-6.9	-0.32	1.89e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg00717180	chr2:96193071	NA	-0.41	-7.73	-0.35	8.14e-14	Height;
LUAD	cis	rs57502260	0.704	rs60538784	chr11:68386735	G/A	cg16797656	chr11:68205561	LRP5	0.44	6.65	0.31	8.84e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.76	0.31	4.55e-11	Rheumatoid arthritis;
LUAD	cis	rs6564851	0.506	rs56353925	chr16:81258368	A/G	cg00908271	chr16:81254010	PKD1L2	0.34	6.85	0.32	2.56e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg18138036	chr10:133769891	PPP2R2D	0.41	6.57	0.3	1.5e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs7737355	0.812	rs244735	chr5:130818061	C/T	cg25547332	chr5:131281432	NA	0.41	6.54	0.3	1.73e-10	Life satisfaction;
LUAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg20607798	chr8:58055168	NA	0.55	7.73	0.35	7.8500000000000006e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.77	-10.15	-0.44	8.59e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg09165964	chr15:75287851	SCAMP5	-0.46	-6.96	-0.32	1.32e-11	Blood trace element (Zn levels);
LUAD	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10802521	chr3:52805072	NEK4	-0.62	-11.08	-0.47	3.05e-25	Bipolar disorder;
LUAD	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-7.33	-0.34	1.18e-12	Morning vs. evening chronotype;
LUAD	cis	rs3125734	0.633	rs1864836	chr10:64028538	C/G	cg19640130	chr10:64028056	RTKN2	-0.37	-8.1	-0.37	6.03e-15	Rheumatoid arthritis;
LUAD	cis	rs367943	0.799	rs10057321	chr5:112974729	A/G	cg12552261	chr5:112820674	MCC	0.53	9.13	0.41	2.86e-18	Type 2 diabetes;
LUAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.62	-10.89	-0.47	1.67e-24	Lymphocyte counts;
LUAD	cis	rs68170813	0.641	rs61511581	chr7:106948091	T/A	cg02696742	chr7:106810147	HBP1	-0.76	-10.75	-0.46	5.3e-24	Coronary artery disease;
LUAD	cis	rs17095355	1.000	rs12267714	chr10:111722052	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.69	-9.35	-0.41	5.32e-19	Biliary atresia;
LUAD	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.47	0.3	2.68e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg06784218	chr1:46089804	CCDC17	0.56	12.25	0.51	9.58e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	7.29	0.33	1.51e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg07741184	chr6:167504864	NA	-0.27	-6.38	-0.3	4.71e-10	Primary biliary cholangitis;
LUAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-8.88	-0.4	1.96e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg23758822	chr17:41437982	NA	1.01	20.91	0.71	3.37e-67	Menopause (age at onset);
LUAD	cis	rs6066835	1.000	rs6066832	chr20:47354132	C/A	cg18078177	chr20:47281410	PREX1	0.69	6.41	0.3	3.84e-10	Multiple myeloma;
LUAD	trans	rs11039798	1.000	rs6485848	chr11:48541517	G/T	cg15704280	chr7:45808275	SEPT13	0.63	7.24	0.33	2.18e-12	Axial length;
LUAD	cis	rs344364	0.602	rs8044343	chr16:1881145	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.42	-7.15	-0.33	3.85e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	trans	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-16.92	-0.64	1.94e-49	Exhaled nitric oxide output;
LUAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.67	-0.31	8.19e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11971779	0.648	rs7799165	chr7:139084957	G/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.42e-10	Diisocyanate-induced asthma;
LUAD	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg16797656	chr11:68205561	LRP5	0.47	8.88	0.4	1.94e-17	Total body bone mineral density;
LUAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.63	-7.96	-0.36	1.6e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg20276088	chr3:133502917	NA	0.36	6.37	0.3	5.06e-10	Iron status biomarkers;
LUAD	cis	rs4700695	1.000	rs3846481	chr5:65417803	T/C	cg21114390	chr5:65439923	SFRS12	-0.58	-6.64	-0.31	9.46e-11	Facial morphology (factor 19);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04633058	chr17:48474099	LRRC59	-0.45	-7.17	-0.33	3.37e-12	Height;
LUAD	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.8	0.35	4.77e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00166722	chr3:10149974	C3orf24	0.63	10.42	0.45	8.88e-23	Alzheimer's disease;
LUAD	cis	rs9788721	0.836	rs55983731	chr15:78735269	C/T	cg18825076	chr15:78729989	IREB2	-0.57	-10.01	-0.44	2.55e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg07636037	chr3:49044803	WDR6	0.42	6.5	0.3	2.32e-10	Menarche (age at onset);
LUAD	cis	rs17095355	0.901	rs11194947	chr10:111763731	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.22	-0.37	2.57e-15	Biliary atresia;
LUAD	cis	rs7779181	1.000	rs10951331	chr7:32354374	A/G	cg13207630	chr7:32358064	NA	0.45	7.06	0.32	6.71e-12	Body mass index;
LUAD	trans	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.46	0.34	4.99e-13	Resting heart rate;
LUAD	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg03929089	chr4:120376271	NA	-0.83	-14.86	-0.59	1.74e-40	Coronary artery disease;
LUAD	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg07256732	chr16:621771	PIGQ	-0.32	-6.54	-0.3	1.8e-10	Height;
LUAD	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg02683114	chr2:24398427	C2orf84	-0.5	-7.34	-0.34	1.1e-12	Asthma;
LUAD	trans	rs564343	0.545	rs2241303	chr11:65819661	C/A	cg26701943	chr11:108369231	KDELC2	-0.5	-8.16	-0.37	3.93e-15	Obesity (early onset extreme);
LUAD	cis	rs698833	0.828	rs6748528	chr2:44517752	G/A	cg04920474	chr2:44395004	PPM1B	0.37	6.72	0.31	5.85e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg21385522	chr1:16154831	NA	0.62	9.47	0.42	1.96e-19	Dilated cardiomyopathy;
LUAD	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg20503657	chr10:835505	NA	1.01	14.78	0.58	3.74e-40	Eosinophil percentage of granulocytes;
LUAD	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.27	-0.6	2.95e-42	Chronic sinus infection;
LUAD	cis	rs6011002	0.636	rs2427536	chr20:62372813	G/A	cg01176363	chr20:62369445	LIME1	-0.78	-6.44	-0.3	3.18e-10	Dental caries;
LUAD	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg10523679	chr1:76189770	ACADM	0.9	16.27	0.62	1.46e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs17152411	1.000	rs17152377	chr10:126592852	T/G	cg07906193	chr10:126599966	NA	0.53	7.6	0.35	1.95e-13	Height;
LUAD	cis	rs9296095	1.000	rs5745568	chr6:33548394	G/T	cg14003231	chr6:33640908	ITPR3	0.57	9.97	0.44	3.73e-21	Platelet count;
LUAD	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg00271210	chr6:167070053	RPS6KA2	0.35	6.66	0.31	8.57e-11	Crohn's disease;
LUAD	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg00321850	chr1:175162397	KIAA0040	-0.52	-11.13	-0.48	2.05e-25	Alcohol dependence;
LUAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg13126279	chr21:47581558	C21orf56	-0.43	-7.48	-0.34	4.43e-13	Testicular germ cell tumor;
LUAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	9.03	0.4	5.91e-18	Alzheimer's disease;
LUAD	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg14835575	chr10:16859367	RSU1	0.75	11.11	0.48	2.38e-25	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs4378999	0.589	rs4234644	chr3:51695865	G/C	cg12934382	chr3:51741135	GRM2	0.38	6.78	0.31	4.03e-11	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg12365402	chr11:9010492	NRIP3	0.45	8.39	0.38	7.17e-16	Hemoglobin concentration;
LUAD	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.95	-0.4	1.16e-17	Gut microbiome composition (summer);
LUAD	cis	rs6992820	1.000	rs6992820	chr8:56764456	A/G	cg06880721	chr8:56792545	LYN	-0.5	-8.33	-0.38	1.17e-15	Mean platelet volume;
LUAD	cis	rs9462027	0.628	rs9296131	chr6:34776361	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.88	-0.4	1.98e-17	Systemic lupus erythematosus;
LUAD	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg02683114	chr2:24398427	C2orf84	-0.43	-6.69	-0.31	6.9e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs6121246	0.609	rs6088997	chr20:30289824	A/G	cg21427119	chr20:30132790	HM13	0.36	6.47	0.3	2.79e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs72634258	0.786	rs12563704	chr1:8033837	G/A	cg26816564	chr1:7831052	VAMP3	0.47	6.59	0.3	1.35e-10	Inflammatory bowel disease;
LUAD	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1595825	0.891	rs80178661	chr2:198582442	A/G	cg11031976	chr2:198649780	BOLL	-0.44	-6.71	-0.31	6.15e-11	Ulcerative colitis;
LUAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6842047	1.000	rs4862665	chr4:187136142	C/T	cg09526685	chr4:187126073	CYP4V2	-0.8	-9.03	-0.4	5.99e-18	Blood protein levels;
LUAD	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg27129171	chr3:47204927	SETD2	0.45	7.22	0.33	2.45e-12	Colorectal cancer;
LUAD	cis	rs6005807	0.588	rs6519751	chr22:28845498	G/T	cg12565055	chr22:29076175	TTC28	0.55	7.19	0.33	2.97e-12	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.6	11.41	0.48	1.86e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs870825	0.929	rs72689278	chr4:185593718	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	11.23	0.48	8.44e-26	Blood protein levels;
LUAD	cis	rs7120118	0.517	rs11530168	chr11:47322986	A/G	cg13308137	chr11:47528955	CUGBP1	0.36	6.53	0.3	1.93e-10	HDL cholesterol;
LUAD	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	9.86	0.43	8.52e-21	Lymphocyte percentage of white cells;
LUAD	cis	rs3784262	0.709	rs4080	chr15:58201341	C/G	cg12031962	chr15:58353849	ALDH1A2	0.35	6.69	0.31	7.07e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg10556349	chr10:835070	NA	-0.48	-7.36	-0.34	9.37e-13	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs2019216	0.500	rs12946184	chr17:21944675	A/C	cg22648282	chr17:21454238	C17orf51	-0.41	-6.38	-0.3	4.65e-10	Pelvic organ prolapse;
LUAD	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg02423579	chr7:2872169	GNA12	0.55	9.48	0.42	1.89e-19	Height;
LUAD	cis	rs2425143	1.000	rs6058304	chr20:34299851	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.43	-0.34	6.01e-13	Blood protein levels;
LUAD	cis	rs11229555	0.645	rs11229436	chr11:58186009	G/A	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs4795519	0.528	rs8081588	chr17:22234406	A/G	cg22648282	chr17:21454238	C17orf51	-0.38	-6.61	-0.31	1.15e-10	Chronic myeloid leukemia;
LUAD	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg08999081	chr20:33150536	PIGU	-0.37	-7.45	-0.34	5.48e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs7512552	0.839	rs486275	chr1:150282784	G/A	cg15654264	chr1:150340011	RPRD2	-0.6	-11.31	-0.48	4.41e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.79	-10.36	-0.45	1.41e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9826463	0.582	rs73238161	chr3:142081981	A/C	cg20824294	chr3:142316082	PLS1	0.43	7.29	0.33	1.52e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11671005	0.735	rs11668420	chr19:58937836	G/A	cg13877915	chr19:58951672	ZNF132	0.55	7.34	0.34	1.13e-12	Mean platelet volume;
LUAD	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-7.3	-0.33	1.45e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs16910800	0.954	rs7123141	chr11:23203403	G/A	cg20040320	chr11:23191996	NA	-0.49	-7.36	-0.34	9.78e-13	Cancer;
LUAD	cis	rs1941023	0.503	rs11230288	chr11:60128968	G/A	cg08716584	chr11:60157161	MS4A7	-0.45	-8.61	-0.39	1.42e-16	Congenital heart disease (maternal effect);
LUAD	cis	rs4700695	0.764	rs251327	chr5:65269464	A/G	cg21114390	chr5:65439923	SFRS12	0.56	6.37	0.3	4.95e-10	Facial morphology (factor 19);
LUAD	cis	rs2070488	0.662	rs7652475	chr3:38481341	C/T	cg24069376	chr3:38537580	EXOG	0.31	6.66	0.31	8.3e-11	Electrocardiographic conduction measures;
LUAD	cis	rs113835537	0.935	rs15969	chr11:66394387	C/T	cg24851651	chr11:66362959	CCS	0.58	8.0	0.36	1.24e-14	Airway imaging phenotypes;
LUAD	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg22676075	chr6:135203613	NA	0.43	8.07	0.37	7.55e-15	Red blood cell count;
LUAD	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg04727924	chr7:799746	HEATR2	-0.55	-7.41	-0.34	6.98e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg07460842	chr6:66804631	NA	1.07	17.06	0.64	4.98e-50	Exhaled nitric oxide output;
LUAD	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-9.9	-0.43	6.46e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs2274273	0.870	rs8013713	chr14:55841252	A/G	cg04306507	chr14:55594613	LGALS3	-0.41	-8.65	-0.39	1.07e-16	Protein biomarker;
LUAD	cis	rs7512552	0.839	rs4581308	chr1:150276872	A/G	cg15654264	chr1:150340011	RPRD2	-0.6	-11.38	-0.48	2.33e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.56e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12049351	0.675	rs754024	chr1:229637414	C/T	cg11742688	chr1:229674241	ABCB10	-0.42	-6.74	-0.31	5.32e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.23	0.54	1.13e-33	Prudent dietary pattern;
LUAD	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg14396892	chr9:96623032	NA	-0.43	-8.45	-0.38	4.84e-16	DNA methylation (variation);
LUAD	cis	rs2274273	0.805	rs28612464	chr14:55816411	T/C	cg04306507	chr14:55594613	LGALS3	0.43	9.04	0.4	5.72e-18	Protein biomarker;
LUAD	cis	rs977987	0.843	rs10459859	chr16:75381950	T/C	cg03315344	chr16:75512273	CHST6	0.65	14.08	0.56	3.5e-37	Dupuytren's disease;
LUAD	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg06784218	chr1:46089804	CCDC17	0.6	13.33	0.54	4.38e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg25036284	chr2:26402008	FAM59B	0.83	11.61	0.49	3.1e-27	Gut microbiome composition (summer);
LUAD	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg14186256	chr22:23484241	RTDR1	0.46	7.88	0.36	2.88e-14	Bone mineral density;
LUAD	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg15445000	chr17:37608096	MED1	-0.45	-8.36	-0.38	9.44e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg19193384	chr17:30244184	NA	-0.51	-6.57	-0.3	1.49e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs16854884	0.710	rs6782558	chr3:143817462	G/C	cg01302019	chr3:143689584	C3orf58	-0.4	-6.38	-0.3	4.55e-10	Economic and political preferences (feminism/equality);
LUAD	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.55	-9.86	-0.43	8.93e-21	Urate levels in overweight individuals;
LUAD	cis	rs12545109	0.879	rs1513317	chr8:57372966	C/G	cg07776626	chr8:57350775	NA	-0.67	-9.28	-0.41	8.66e-19	Obesity-related traits;
LUAD	cis	rs17270561	0.636	rs9379779	chr6:25695441	G/T	cg25753631	chr6:25732923	NA	-0.4	-6.87	-0.32	2.31e-11	Iron status biomarkers;
LUAD	cis	rs727505	1.000	rs7801661	chr7:124483222	C/T	cg23710748	chr7:124431027	NA	0.45	9.17	0.41	2.07e-18	Lewy body disease;
LUAD	cis	rs11048434	0.673	rs1124402	chr12:9062606	C/T	cg26114124	chr12:9217669	LOC144571	0.36	6.53	0.3	1.84e-10	Sjögren's syndrome;
LUAD	cis	rs1595825	0.891	rs60582020	chr2:198520555	A/C	cg00982548	chr2:198649783	BOLL	-0.62	-8.82	-0.39	3.11e-17	Ulcerative colitis;
LUAD	cis	rs595982	0.501	rs112370206	chr19:49396623	C/T	cg21252483	chr19:49399788	TULP2	-0.53	-10.14	-0.44	8.76e-22	Red cell distribution width;
LUAD	cis	rs4849845	0.598	rs3889223	chr2:121024432	A/G	cg24070213	chr2:121070622	NA	0.4	7.59	0.35	2.09e-13	Mean platelet volume;
LUAD	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg13334819	chr7:99746414	C7orf59	-0.65	-10.47	-0.45	5.66e-23	Coronary artery disease;
LUAD	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg08885076	chr2:99613938	TSGA10	-0.41	-7.21	-0.33	2.63e-12	Chronic sinus infection;
LUAD	cis	rs4589502	0.512	rs4395023	chr15:67097208	G/A	cg09911534	chr15:67153556	NA	-0.43	-8.15	-0.37	4.12e-15	Lung cancer (smoking interaction);
LUAD	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg19875535	chr5:140030758	IK	0.45	7.56	0.34	2.59e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9341808	0.667	rs2505944	chr6:80888410	T/C	cg08355045	chr6:80787529	NA	0.5	8.91	0.4	1.48e-17	Sitting height ratio;
LUAD	trans	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg26043149	chr18:55253948	FECH	0.48	7.72	0.35	8.24e-14	Bone mineral density;
LUAD	cis	rs11971779	0.648	rs10085708	chr7:139110954	A/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	7.16e-11	Diisocyanate-induced asthma;
LUAD	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg00981070	chr1:2046702	PRKCZ	0.33	6.84	0.32	2.87e-11	Height;
LUAD	cis	rs1232027	0.656	rs6151612	chr5:79961288	G/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs9976767	0.637	rs9984108	chr21:43825628	T/G	cg23042151	chr21:43824109	UBASH3A	-0.3	-6.58	-0.3	1.37e-10	Type 1 diabetes;
LUAD	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19346786	chr7:2764209	NA	-0.58	-12.91	-0.53	2.25e-32	Height;
LUAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg13047869	chr3:10149882	C3orf24	0.65	10.99	0.47	6.89e-25	Alzheimer's disease;
LUAD	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg22467129	chr15:76604101	ETFA	-0.59	-10.76	-0.46	4.94e-24	Blood metabolite levels;
LUAD	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg08280861	chr8:58055591	NA	0.56	7.04	0.32	7.6e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22590775	chr19:49891494	CCDC155	0.72	11.76	0.5	8.08e-28	Multiple sclerosis;
LUAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg07362569	chr17:61921086	SMARCD2	0.39	6.77	0.31	4.35e-11	Prudent dietary pattern;
LUAD	cis	rs6714710	0.603	rs12995673	chr2:98409046	G/A	cg26665480	chr2:98280029	ACTR1B	0.55	8.97	0.4	9.7e-18	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg22823121	chr1:150693482	HORMAD1	-0.4	-7.76	-0.35	6.5e-14	Tonsillectomy;
LUAD	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg08219700	chr8:58056026	NA	0.59	8.51	0.38	3.1e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2224391	1.000	rs2753247	chr6:5261987	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-9.86	-0.43	8.54e-21	Height;
LUAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06873352	chr17:61820015	STRADA	0.81	18.22	0.66	3.7e-55	Prudent dietary pattern;
LUAD	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg07936489	chr17:37558343	FBXL20	0.46	7.32	0.34	1.3e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.85	0.36	3.43e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4891159	0.548	rs609487	chr18:74134382	C/G	cg24786174	chr18:74118243	ZNF516	-0.87	-21.6	-0.72	2.92e-70	Longevity;
LUAD	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg00147160	chr1:26503991	CNKSR1	0.37	8.7	0.39	7.27e-17	Height;
LUAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg02951883	chr7:2050386	MAD1L1	-0.85	-15.15	-0.59	1.01e-41	Bipolar disorder and schizophrenia;
LUAD	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.52	-0.34	3.36e-13	Bipolar disorder;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15133824	chr2:97523823	ANKRD39	-0.48	-7.25	-0.33	1.97e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3106136	0.967	rs61514245	chr4:95165053	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.44	-0.34	5.56e-13	Capecitabine sensitivity;
LUAD	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg03859395	chr2:55845619	SMEK2	0.65	11.12	0.48	2.34e-25	Metabolic syndrome;
LUAD	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18876405	chr7:65276391	NA	-0.41	-6.62	-0.31	1.08e-10	Aortic root size;
LUAD	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg15790184	chr11:494944	RNH1	0.56	7.28	0.33	1.68e-12	Body mass index;
LUAD	cis	rs73206853	0.563	rs9706102	chr12:111185391	A/G	cg12870014	chr12:110450643	ANKRD13A	0.57	6.4	0.3	4.11e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg10518543	chr12:38710700	ALG10B	-0.46	-7.42	-0.34	6.67e-13	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg17366294	chr4:99064904	C4orf37	0.65	12.62	0.52	3.18e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.68	0.31	7.71e-11	Depression;
LUAD	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg03983476	chr2:10830698	NOL10	0.48	8.41	0.38	6.25e-16	Prostate cancer;
LUAD	cis	rs7528419	0.895	rs602633	chr1:109821511	T/G	cg00908766	chr1:109817496	CELSR2	0.67	13.24	0.54	9.8e-34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUAD	cis	rs7903847	0.620	rs11189165	chr10:99123457	A/G	cg20016023	chr10:99160130	RRP12	-0.28	-6.81	-0.31	3.41e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg04450456	chr4:17643702	FAM184B	0.4	7.86	0.36	3.18e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7589728	0.748	rs35051888	chr2:88482258	G/A	cg04511125	chr2:88470314	THNSL2	0.91	9.97	0.44	3.63e-21	Plasma clusterin levels;
LUAD	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg13798912	chr7:905769	UNC84A	-0.65	-6.79	-0.31	3.91e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg00255919	chr5:131827918	IRF1	0.5	11.92	0.5	1.97e-28	Asthma (sex interaction);
LUAD	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	11.74	0.5	9.84e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6062509	0.630	rs6011058	chr20:62356627	C/T	cg02966332	chr20:62369605	LIME1	-0.46	-7.26	-0.33	1.91e-12	Prostate cancer;
LUAD	cis	rs11690462	0.963	rs12471804	chr2:26559717	C/G	cg13255216	chr2:26625047	C2orf39	0.39	6.73	0.31	5.57e-11	Coronary artery disease;
LUAD	cis	rs9914544	0.545	rs9912568	chr17:18792719	G/A	cg25390199	chr17:18761479	PRPSAP2	-0.37	-6.43	-0.3	3.39e-10	Educational attainment (years of education);
LUAD	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg21204522	chr6:27730016	NA	-0.47	-7.52	-0.34	3.22e-13	Parkinson's disease;
LUAD	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.7	-0.46	8.33e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21659725	chr3:3221576	CRBN	-0.87	-18.5	-0.67	2.05e-56	Intelligence (multi-trait analysis);
LUAD	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg11344533	chr11:111475393	SIK2	0.34	6.47	0.3	2.72e-10	Primary sclerosing cholangitis;
LUAD	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.58	0.39	1.79e-16	Menarche (age at onset);
LUAD	cis	rs7017914	0.967	rs13255735	chr8:71859739	C/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.31	-6.38	-0.3	4.77e-10	Bone mineral density;
LUAD	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg02527881	chr3:46936655	PTH1R	-0.47	-9.09	-0.4	3.87e-18	Colorectal cancer;
LUAD	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg11502198	chr6:26597334	ABT1	-0.46	-7.22	-0.33	2.44e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg10589385	chr1:150898437	SETDB1	-0.45	-8.62	-0.39	1.38e-16	Melanoma;
LUAD	cis	rs9487051	0.738	rs449850	chr6:109525045	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.8	-0.31	3.63e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg22823121	chr1:150693482	HORMAD1	0.41	7.96	0.36	1.57e-14	Melanoma;
LUAD	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg08989290	chr16:615782	NHLRC4	0.31	6.52	0.3	2.01e-10	Height;
LUAD	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg15448220	chr1:150897856	SETDB1	0.46	7.98	0.36	1.39e-14	Tonsillectomy;
LUAD	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg18944383	chr4:111397179	ENPEP	-0.51	-9.36	-0.41	4.85e-19	Height;
LUAD	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	8.45	0.38	4.65e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs4988958	0.565	rs6732138	chr2:103009662	G/A	cg03938978	chr2:103052716	IL18RAP	0.45	10.24	0.45	3.94e-22	Asthma (childhood onset);
LUAD	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26314531	chr2:26401878	FAM59B	-0.56	-7.99	-0.36	1.33e-14	Gut microbiome composition (summer);
LUAD	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs208520	0.690	rs851467	chr6:66802721	A/G	cg07460842	chr6:66804631	NA	-1.09	-17.03	-0.64	6.56e-50	Exhaled nitric oxide output;
LUAD	cis	rs9487051	0.768	rs435611	chr6:109527755	C/T	cg21918786	chr6:109611834	NA	-0.42	-7.27	-0.33	1.75e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg25767906	chr1:53392781	SCP2	-0.35	-6.48	-0.3	2.56e-10	Monocyte count;
LUAD	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10089	0.953	rs1985268	chr5:127375931	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	10.05	0.44	1.91e-21	Ileal carcinoids;
LUAD	cis	rs6499255	0.951	rs7198242	chr16:69648495	C/T	cg15192750	chr16:69999425	NA	-0.51	-7.81	-0.36	4.51e-14	IgE levels;
LUAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02353165	chr6:42928485	GNMT	0.4	7.21	0.33	2.55e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg01851573	chr8:8652454	MFHAS1	-0.36	-6.47	-0.3	2.67e-10	Mood instability;
LUAD	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg14558114	chr2:88469736	THNSL2	-0.42	-6.8	-0.31	3.69e-11	Response to metformin (IC50);
LUAD	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.87	0.32	2.33e-11	Cardiac Troponin-T levels;
LUAD	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.42	-0.3	3.67e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7267979	0.844	rs35735333	chr20:25337205	T/G	cg08601574	chr20:25228251	PYGB	-0.41	-7.67	-0.35	1.18e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg21862992	chr11:68658383	NA	0.5	8.93	0.4	1.27e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs752010	0.967	rs2038978	chr1:42094719	A/G	cg06885757	chr1:42089581	HIVEP3	0.4	8.41	0.38	6.15e-16	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs1950626	0.577	rs35097045	chr14:101454403	G/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.38	7.57	0.35	2.34e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg00750074	chr16:89608354	SPG7	-0.56	-9.68	-0.43	3.91e-20	Multiple myeloma (IgH translocation);
LUAD	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg06074448	chr4:187884817	NA	0.36	7.29	0.33	1.51e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2230307	0.536	rs834164	chr1:100603948	A/C	cg20868668	chr1:100435035	SLC35A3	-0.51	-7.78	-0.35	5.63e-14	Carotid intima media thickness;
LUAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg10351095	chr21:47802916	PCNT	0.39	6.44	0.3	3.3e-10	Testicular germ cell tumor;
LUAD	cis	rs7149337	0.752	rs8021773	chr14:51691528	C/T	cg23942311	chr14:51606299	NA	0.86	19.99	0.7	4.37e-63	Cancer;
LUAD	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg22166914	chr1:53195759	ZYG11B	0.42	7.38	0.34	8.47e-13	Monocyte count;
LUAD	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	8.64	0.39	1.17e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs4803468	0.967	rs2304243	chr19:41942708	C/G	cg09537434	chr19:41945824	ATP5SL	0.5	7.89	0.36	2.61e-14	Height;
LUAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg24642844	chr7:1081250	C7orf50	-0.59	-9.5	-0.42	1.52e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs240764	0.578	rs11155613	chr6:101176642	T/C	cg09795085	chr6:101329169	ASCC3	0.45	8.0	0.36	1.22e-14	Neuroticism;
LUAD	cis	rs2882667	0.898	rs11749944	chr5:138412779	T/C	cg04439458	chr5:138467593	SIL1	-0.39	-7.16	-0.33	3.5e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg23649088	chr2:200775458	C2orf69	0.62	10.13	0.44	1e-21	Schizophrenia;
LUAD	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	13.68	0.55	1.51e-35	Lung cancer in ever smokers;
LUAD	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg08470875	chr2:26401718	FAM59B	-0.79	-11.16	-0.48	1.6e-25	Gut microbiome composition (summer);
LUAD	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg19163074	chr7:65112434	INTS4L2	0.43	6.83	0.32	2.9e-11	Aortic root size;
LUAD	cis	rs6545883	1.000	rs6742276	chr2:61768745	G/A	cg15711740	chr2:61764176	XPO1	-0.43	-6.99	-0.32	1.07e-11	Tuberculosis;
LUAD	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg13319975	chr6:146136371	FBXO30	0.59	9.96	0.44	4.08e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2997447	0.846	rs2997446	chr1:26388241	C/G	cg00147160	chr1:26503991	CNKSR1	0.35	6.7	0.31	6.48e-11	QRS complex (12-leadsum);
LUAD	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg06064525	chr11:970664	AP2A2	-0.54	-11.06	-0.47	3.79e-25	Alzheimer's disease (late onset);
LUAD	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.97	0.4	9.39e-18	Menopause (age at onset);
LUAD	cis	rs877426	0.634	rs7329801	chr13:114824560	G/A	cg21461300	chr13:114830702	RASA3	-0.44	-6.8	-0.31	3.63e-11	Facial morphology (factor 14, intercanthal width);
LUAD	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg20607798	chr8:58055168	NA	0.6	9.89	0.43	6.77e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs6504249	0.893	rs2521827	chr17:62692728	T/G	cg02097616	chr17:62675921	NA	0.75	12.4	0.52	2.56e-30	Joint mobility (Beighton score);
LUAD	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg27284194	chr4:1044797	NA	0.7	10.07	0.44	1.55e-21	Recombination rate (females);
LUAD	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11890956	chr21:40555474	PSMG1	0.79	13.1	0.54	3.69e-33	Cognitive function;
LUAD	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg03929089	chr4:120376271	NA	-0.85	-14.92	-0.59	9.72e-41	Height;
LUAD	cis	rs4730250	0.707	rs257385	chr7:106807448	T/C	cg02696742	chr7:106810147	HBP1	-0.88	-11.56	-0.49	4.81e-27	Osteoarthritis;
LUAD	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg03233332	chr7:66118400	NA	-0.45	-6.64	-0.31	9.75e-11	Aortic root size;
LUAD	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg22535103	chr8:58192502	C8orf71	-0.71	-10.02	-0.44	2.32e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg07010633	chr17:73824396	UNC13D	0.33	6.67	0.31	8.07e-11	White matter hyperintensity burden;
LUAD	cis	rs1032833	0.557	rs74550225	chr2:179968346	C/A	cg23883738	chr2:179974586	SESTD1	-0.72	-8.3	-0.37	1.39e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg01579765	chr21:45077557	HSF2BP	-0.64	-14.89	-0.59	1.31e-40	Mean corpuscular volume;
LUAD	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg09998033	chr7:158218633	PTPRN2	-0.52	-9.23	-0.41	1.3e-18	Obesity-related traits;
LUAD	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg20673091	chr1:2541236	MMEL1	-0.4	-8.57	-0.38	2.03e-16	Ulcerative colitis;
LUAD	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg08470875	chr2:26401718	FAM59B	0.51	6.97	0.32	1.2e-11	Gut microbiome composition (summer);
LUAD	cis	rs9399401	0.667	rs1329707	chr6:142724439	T/C	cg03128060	chr6:142623767	GPR126	0.51	9.96	0.44	3.96e-21	Chronic obstructive pulmonary disease;
LUAD	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.55	0.38	2.25e-16	Parkinson's disease;
LUAD	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18876405	chr7:65276391	NA	0.57	9.43	0.42	2.75e-19	Aortic root size;
LUAD	trans	rs13086611	1	rs13086611	chr3:49385417	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.47	-7.18	-0.33	3.11e-12	Educational attainment;
LUAD	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg22823121	chr1:150693482	HORMAD1	0.43	8.42	0.38	6.11e-16	Blood protein levels;
LUAD	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg17074396	chr22:49843754	NA	-0.33	-6.86	-0.32	2.53e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg11266682	chr4:10021025	SLC2A9	0.68	15.8	0.61	1.55e-44	Bone mineral density;
LUAD	trans	rs1972460	0.506	rs62012050	chr15:82532274	T/G	cg04831495	chr15:85060580	GOLGA6L5	-0.54	-8.5	-0.38	3.26e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg27211696	chr2:191398769	TMEM194B	-0.67	-9.06	-0.4	4.82e-18	Diastolic blood pressure;
LUAD	trans	rs1941687	0.831	rs35740221	chr18:31387714	T/G	cg27147174	chr7:100797783	AP1S1	-0.53	-8.87	-0.4	2.15e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs4243830	0.826	rs12565181	chr1:6620545	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.59	6.96	0.32	1.32e-11	Body mass index;
LUAD	trans	rs6426551	1.000	rs6668851	chr1:226545866	C/A	cg27539482	chr13:111589090	NA	-0.47	-6.78	-0.31	3.95e-11	Coronary artery disease;
LUAD	trans	rs2262909	0.925	rs73019900	chr19:22286680	G/A	cg05197062	chr11:11642011	GALNTL4	0.59	9.11	0.4	3.42e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.96e-19	Life satisfaction;
LUAD	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg09904177	chr6:26538194	HMGN4	-0.39	-6.46	-0.3	2.86e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1829883	1.000	rs1916599	chr5:98774240	C/G	cg08333243	chr5:99726346	NA	-0.34	-6.65	-0.31	8.8e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11644478	chr21:40555479	PSMG1	-0.4	-6.48	-0.3	2.57e-10	Menarche (age at onset);
LUAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg08027265	chr7:2291960	NA	-0.43	-7.2	-0.33	2.76e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs9503551	0.642	rs4640930	chr6:3329954	C/G	cg13915676	chr9:139305538	SDCCAG3;PMPCA	0.48	6.37	0.3	4.87e-10	Nicotine dependence;
LUAD	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.18	0.54	1.73e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-6.77	-0.31	4.44e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.34	0.34	1.14e-12	Menopause (age at onset);
LUAD	cis	rs6060717	0.536	rs3787173	chr20:34472105	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.06	-0.32	7.08e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs10781543	0.776	rs11145760	chr9:139382594	G/A	cg14169450	chr9:139327907	INPP5E	0.43	7.79	0.35	5.16e-14	Monocyte percentage of white cells;
LUAD	trans	rs9393777	0.778	rs35608615	chr6:27040402	G/C	cg06606381	chr12:133084897	FBRSL1	-1.0	-9.73	-0.43	2.55e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs17401966	0.838	rs4846207	chr1:10313811	T/C	cg15208524	chr1:10270712	KIF1B	0.44	6.83	0.32	2.9100000000000002e-11	Hepatocellular carcinoma;
LUAD	trans	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.46	0.34	4.99e-13	Resting heart rate;
LUAD	cis	rs117623576	0.680	rs72777120	chr10:32367608	A/G	cg03047570	chr10:32398778	NA	-0.62	-7.65	-0.35	1.33e-13	Anti-saccade response;
LUAD	cis	rs7584330	0.554	rs56881028	chr2:238446678	C/G	cg14458575	chr2:238380390	NA	0.55	8.49	0.38	3.61e-16	Prostate cancer;
LUAD	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg27454412	chr7:1067447	C7orf50	-0.45	-7.82	-0.36	4.16e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.55	-9.71	-0.43	3.05e-20	Lymphocyte counts;
LUAD	cis	rs68170813	0.523	rs79619227	chr7:107025335	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-10.7	-0.46	8.41e-24	Coronary artery disease;
LUAD	cis	rs13395090	0.967	rs12105179	chr2:3721729	C/T	cg19052272	chr2:3704530	ALLC	0.34	6.67	0.31	8.2e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs4650994	0.525	rs4651000	chr1:178532223	A/G	cg05059571	chr16:84539110	KIAA1609	-0.68	-12.43	-0.52	1.95e-30	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg22535103	chr8:58192502	C8orf71	-0.59	-7.04	-0.32	7.87e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg07741184	chr6:167504864	NA	0.36	8.24	0.37	2.11e-15	Primary biliary cholangitis;
LUAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.47	6.62	0.31	1.08e-10	Renal function-related traits (BUN);
LUAD	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg02569458	chr12:86230093	RASSF9	0.41	7.63	0.35	1.62e-13	Major depressive disorder;
LUAD	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg13334819	chr7:99746414	C7orf59	-0.6	-8.94	-0.4	1.18e-17	Coronary artery disease;
LUAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg20637647	chr7:64974828	NA	0.38	6.45	0.3	3.05e-10	Calcium levels;
LUAD	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg05425664	chr17:57184151	TRIM37	-0.43	-7.76	-0.35	6.53e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7301016	0.846	rs11174571	chr12:63022329	C/T	cg11441379	chr12:63026424	NA	0.64	7.86	0.36	3.21e-14	IgG glycosylation;
LUAD	cis	rs8027181	0.839	rs8025333	chr15:73025121	A/G	cg25632853	chr15:73088954	NA	0.31	6.74	0.31	5.17e-11	Triglyceride levels;
LUAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00149659	chr3:10157352	C3orf10	0.58	8.1	0.37	5.92e-15	Alzheimer's disease;
LUAD	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg24803719	chr17:45855879	NA	-0.33	-7.56	-0.35	2.47e-13	IgG glycosylation;
LUAD	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.37	0.34	8.95e-13	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg03676636	chr4:99064102	C4orf37	0.29	6.91	0.32	1.75e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg17063962	chr7:91808500	NA	-0.68	-12.06	-0.51	5.43e-29	Breast cancer;
LUAD	cis	rs657075	0.757	rs3792876	chr5:131637309	C/T	cg21138405	chr5:131827807	IRF1	0.56	6.91	0.32	1.84e-11	Rheumatoid arthritis;
LUAD	cis	rs2004318	1.000	rs77024125	chr19:55077406	G/A	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.93e-13	Blood protein levels;
LUAD	cis	rs986417	0.901	rs6573315	chr14:60996831	A/C	cg27398547	chr14:60952738	C14orf39	0.66	8.07	0.37	7.54e-15	Gut microbiota (bacterial taxa);
LUAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08219700	chr8:58056026	NA	0.69	8.89	0.4	1.82e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg21699342	chr2:239360505	ASB1	0.56	10.71	0.46	7.52e-24	Multiple system atrophy;
LUAD	cis	rs752010	0.644	rs7541348	chr1:42113215	T/G	cg06885757	chr1:42089581	HIVEP3	0.46	10.34	0.45	1.66e-22	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg13606994	chr1:44402422	ARTN	-0.32	-6.62	-0.31	1.07e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg18180107	chr4:99064573	C4orf37	0.42	6.81	0.31	3.41e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9863	0.828	rs34114498	chr12:124480373	G/C	cg17723958	chr12:124429295	CCDC92	-0.41	-6.83	-0.32	3.02e-11	White blood cell count;
LUAD	cis	rs9487051	0.735	rs419106	chr6:109520067	C/G	cg21918786	chr6:109611834	NA	-0.41	-7.54	-0.34	2.84e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.58	0.52	4.73e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg13354988	chr2:263656	ACP1;SH3YL1	0.29	6.41	0.3	3.99e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg08885076	chr2:99613938	TSGA10	-0.37	-6.35	-0.3	5.48e-10	Chronic sinus infection;
LUAD	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg12623302	chr6:28058802	ZSCAN12L1	0.3	6.38	0.3	4.69e-10	Parkinson's disease;
LUAD	trans	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.92	-16.11	-0.62	7.19e-46	Colorectal cancer;
LUAD	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.51e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg11070056	chr1:107600091	PRMT6	-0.65	-11.37	-0.48	2.52e-26	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg27432699	chr2:27873401	GPN1	-0.38	-6.41	-0.3	3.96e-10	Total body bone mineral density;
LUAD	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg18105139	chr6:28058856	ZSCAN12L1	0.27	6.36	0.3	5.18e-10	Parkinson's disease;
LUAD	cis	rs11626933	1.000	rs11626933	chr14:90754311	A/G	cg14092571	chr14:90743983	NA	-0.95	-17.89	-0.66	1.01e-53	Gut microbiota (bacterial taxa);
LUAD	cis	rs7326068	0.647	rs2818978	chr13:21319537	C/G	cg27499820	chr13:21296301	IL17D	0.53	7.87	0.36	2.91e-14	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg14092571	chr14:90743983	NA	0.49	8.44	0.38	5.13e-16	Mortality in heart failure;
LUAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg23283495	chr1:209979779	IRF6	0.7	11.19	0.48	1.24e-25	Cleft lip with or without cleft palate;
LUAD	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg20203395	chr5:56204925	C5orf35	-0.82	-11.58	-0.49	4.04e-27	Initial pursuit acceleration;
LUAD	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg18827107	chr12:86230957	RASSF9	0.58	10.25	0.45	3.53e-22	Major depressive disorder;
LUAD	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg12119029	chr16:89752879	CDK10	-0.35	-7.41	-0.34	6.78e-13	Vitiligo;
LUAD	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.59	11.43	0.49	1.45e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg06641503	chr3:48959341	ARIH2	-0.34	-6.69	-0.31	7.11e-11	Parkinson's disease;
LUAD	cis	rs2067615	0.524	rs4964186	chr12:107080235	C/T	cg15890332	chr12:107067104	RFX4	0.42	8.77	0.39	4.55e-17	Heart rate;
LUAD	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg10057126	chr4:77819792	ANKRD56	0.55	9.62	0.42	6.09e-20	Emphysema distribution in smoking;
LUAD	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg25319279	chr11:5960081	NA	-0.38	-7.25	-0.33	1.93e-12	DNA methylation (variation);
LUAD	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg17105886	chr17:28927953	LRRC37B2	0.83	7.92	0.36	2.14e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3784262	0.669	rs4646626	chr15:58256127	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.4	-8.08	-0.37	6.86e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.44	0.3	3.28e-10	Depression;
LUAD	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg03714773	chr7:91764589	CYP51A1	0.29	6.76	0.31	4.48e-11	Breast cancer;
LUAD	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg13319975	chr6:146136371	FBXO30	-0.79	-13.54	-0.55	5.77e-35	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6500395	1.000	rs904819	chr16:48622583	C/A	cg04672837	chr16:48644449	N4BP1	0.38	6.57	0.3	1.46e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs5771069	0.931	rs5771222	chr22:50445704	C/T	cg27068297	chr22:50451975	IL17REL	-0.33	-6.73	-0.31	5.4e-11	Ulcerative colitis;
LUAD	trans	rs8002861	0.905	rs12429722	chr13:44412466	T/A	cg17145862	chr1:211918768	LPGAT1	-0.66	-14.41	-0.57	1.4e-38	Leprosy;
LUAD	cis	rs6993813	0.843	rs28621599	chr8:120030694	C/T	cg01975934	chr8:119970761	NA	-0.37	-7.24	-0.33	2.09e-12	Bone mineral density (hip);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21517261	chr7:38217791	STARD3NL	-0.42	-6.66	-0.31	8.55e-11	Height;
LUAD	cis	rs12579753	0.917	rs10862360	chr12:82187411	A/G	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.66	-0.35	1.29e-13	Resting heart rate;
LUAD	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg19901468	chr14:105411992	AHNAK2	-0.54	-10.44	-0.45	7.46e-23	Rheumatoid arthritis;
LUAD	cis	rs990171	0.538	rs11690932	chr2:103119029	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	6.53	0.3	1.94e-10	Lymphocyte counts;
LUAD	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg06784218	chr1:46089804	CCDC17	-0.53	-11.48	-0.49	9.64e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs367615	0.704	rs60538082	chr5:108829101	A/G	cg17395555	chr5:108820864	NA	0.67	14.61	0.58	2.04e-39	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg13319975	chr6:146136371	FBXO30	-0.57	-9.76	-0.43	1.93e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2795502	0.515	rs116848302	chr10:43367783	G/A	cg08461752	chr10:43522343	NA	-0.83	-8.64	-0.39	1.16e-16	Blood protein levels;
LUAD	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.22	16.1	0.62	8.09e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7264396	0.563	rs2425136	chr20:34344782	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-7.78	-0.35	5.45e-14	Total cholesterol levels;
LUAD	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg11915388	chr22:42470451	FAM109B	0.41	7.38	0.34	8.67e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7072216	0.763	rs7910247	chr10:100172252	C/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.67	-0.39	9.52e-17	Metabolite levels;
LUAD	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg06060754	chr5:176797920	RGS14	-0.56	-9.19	-0.41	1.73e-18	Urate levels in lean individuals;
LUAD	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.64	-0.35	1.45e-13	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.5	0.3	2.22e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg11189052	chr15:85197271	WDR73	0.59	7.42	0.34	6.2800000000000005e-13	Schizophrenia;
LUAD	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg23262073	chr20:60523788	NA	-0.38	-6.88	-0.32	2.2e-11	Body mass index;
LUAD	cis	rs62229266	0.771	rs62230790	chr21:37388911	A/G	cg12218747	chr21:37451666	NA	-0.48	-8.19	-0.37	3.07e-15	Mitral valve prolapse;
LUAD	cis	rs10089	1.000	rs17764954	chr5:127514436	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.58	8.06	0.36	7.79e-15	Ileal carcinoids;
LUAD	cis	rs6489882	0.836	rs7967461	chr12:113369759	G/C	cg20102336	chr12:113376681	OAS3	-0.61	-9.47	-0.42	1.96e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27286337	chr10:134555280	INPP5A	0.69	10.87	0.47	2e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6558530	0.692	rs6558522	chr8:1702370	C/G	cg19131313	chr8:1704013	NA	0.42	6.36	0.3	5.29e-10	Systolic blood pressure;
LUAD	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg00631329	chr6:26305371	NA	-0.74	-14.19	-0.57	1.15e-37	Educational attainment;
LUAD	cis	rs56283067	0.811	rs62435997	chr6:44692169	C/T	cg20913747	chr6:44695427	NA	-0.44	-7.45	-0.34	5.16e-13	Total body bone mineral density;
LUAD	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg19761014	chr17:28927070	LRRC37B2	0.7	6.61	0.31	1.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.99e-14	Parkinson's disease;
LUAD	cis	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg16735072	chr8:11994639	FAM66D	-0.41	-6.47	-0.3	2.64e-10	Neuroticism;
LUAD	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	cis	rs7809615	0.901	rs11555142	chr7:99032593	G/T	cg12290671	chr7:99195819	NA	-0.71	-8.12	-0.37	5.12e-15	Blood metabolite ratios;
LUAD	cis	rs7665090	1.000	rs2866406	chr4:103554019	G/A	cg07973026	chr4:103553119	MANBA	0.48	8.59	0.39	1.73e-16	Primary biliary cholangitis;
LUAD	cis	rs225245	0.791	rs6505492	chr17:34026597	C/T	cg05299278	chr17:33885742	SLFN14	0.5	11.35	0.48	2.94e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg01788221	chr16:89496183	ANKRD11	-0.35	-6.73	-0.31	5.43e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg24069376	chr3:38537580	EXOG	0.45	11.06	0.47	3.73e-25	Electrocardiographic conduction measures;
LUAD	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg23985595	chr17:80112537	CCDC57	0.53	9.73	0.43	2.45e-20	Life satisfaction;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg11039808	chr5:77591002	AP3B1	-0.39	-6.73	-0.31	5.62e-11	Subcortical brain region volumes;
LUAD	cis	rs2637266	0.783	rs860165	chr10:78492807	A/G	cg18941641	chr10:78392320	NA	0.32	6.69	0.31	7.29e-11	Pulmonary function;
LUAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.22	0.54	1.26e-33	Prudent dietary pattern;
LUAD	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg10544611	chr16:67998164	SLC12A4	-0.54	-6.75	-0.31	5.04e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg03289416	chr15:75166202	SCAMP2	0.49	8.16	0.37	3.85e-15	Breast cancer;
LUAD	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg17863274	chr19:49399704	TULP2	-0.64	-9.78	-0.43	1.74e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg22105103	chr4:187893119	NA	0.58	12.68	0.52	1.88e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs739496	0.843	rs848129	chr12:111997502	G/C	cg10833066	chr12:111807467	FAM109A	0.42	6.58	0.3	1.39e-10	Platelet count;
LUAD	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg17105886	chr17:28927953	LRRC37B2	0.78	7.73	0.35	7.66e-14	Body mass index;
LUAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08219700	chr8:58056026	NA	0.57	8.08	0.37	6.8e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs629535	0.590	rs62513426	chr8:70136843	T/G	cg21567404	chr3:27674614	NA	-1.01	-16.48	-0.63	1.65e-47	Dupuytren's disease;
LUAD	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg25036284	chr2:26402008	FAM59B	0.63	8.78	0.39	3.95e-17	Gut microbiome composition (summer);
LUAD	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22857025	chr5:266934	NA	-0.97	-14.47	-0.58	7.55e-39	Breast cancer;
LUAD	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg19622623	chr12:86230825	RASSF9	-0.55	-9.87	-0.43	7.98e-21	Major depressive disorder;
LUAD	trans	rs2797160	1.000	rs6934435	chr6:126017481	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.86	0.4	2.17e-17	Endometrial cancer;
LUAD	cis	rs1451375	0.959	rs17133878	chr7:50620927	T/C	cg18232548	chr7:50535776	DDC	0.52	8.57	0.38	2.03e-16	Malaria;
LUAD	trans	rs6561151	0.957	rs7995004	chr13:44478820	C/T	cg17145862	chr1:211918768	LPGAT1	0.54	9.15	0.41	2.45e-18	Crohn's disease;
LUAD	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.62	-7.04	-0.32	7.84e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg13385794	chr1:248469461	NA	0.25	6.95	0.32	1.35e-11	Common traits (Other);
LUAD	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg00933542	chr6:150070202	PCMT1	0.44	9.32	0.41	6.46e-19	Lung cancer;
LUAD	cis	rs847577	0.569	rs12674083	chr7:97696334	C/T	cg21770322	chr7:97807741	LMTK2	0.31	7.2	0.33	2.69e-12	Breast cancer;
LUAD	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg18016565	chr1:150552671	MCL1	-0.39	-7.2	-0.33	2.85e-12	Tonsillectomy;
LUAD	cis	rs2274273	0.805	rs8012156	chr14:55552500	G/T	cg04306507	chr14:55594613	LGALS3	0.33	6.57	0.3	1.45e-10	Protein biomarker;
LUAD	cis	rs10540	0.584	rs10751659	chr11:437559	C/T	cg08200582	chr11:442649	ANO9	0.57	8.01	0.36	1.15e-14	Body mass index;
LUAD	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg16479474	chr6:28041457	NA	0.35	6.53	0.3	1.94e-10	Parkinson's disease;
LUAD	cis	rs10992471	0.528	rs1535754	chr9:95201917	T/G	cg14631576	chr9:95140430	CENPP	-0.49	-10.03	-0.44	2.22e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg23422044	chr7:1970798	MAD1L1	-0.58	-7.17	-0.33	3.33e-12	Bipolar disorder;
LUAD	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg03388025	chr16:89894329	SPIRE2	0.29	6.36	0.3	5.12e-10	Vitiligo;
LUAD	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.59	-7.04	-0.32	7.73e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg18252515	chr7:66147081	NA	-0.62	-6.81	-0.31	3.45e-11	Diabetic kidney disease;
LUAD	trans	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.19	0.51	1.65e-29	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg02454025	chr1:11042201	C1orf127	1.02	17.81	0.65	2.37e-53	Ewing sarcoma;
LUAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg27094323	chr7:1216898	NA	-0.36	-6.44	-0.3	3.28e-10	Longevity;Endometriosis;
LUAD	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.5	6.88	0.32	2.22e-11	Platelet count;
LUAD	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11677416	0.961	rs3783557	chr2:113530712	C/T	cg27083787	chr2:113543245	IL1A	0.4	6.52	0.3	2e-10	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	trans	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg18187862	chr3:45730750	SACM1L	0.51	7.75	0.35	7.09e-14	Primary sclerosing cholangitis;
LUAD	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg22681709	chr2:178499509	PDE11A	-0.56	-9.67	-0.43	4.07e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs17193922	0.876	rs55813797	chr16:53551310	A/G	cg04059762	chr16:53544020	NA	-0.41	-6.48	-0.3	2.6200000000000003e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs6489882	0.867	rs2384072	chr12:113367422	T/C	cg20102336	chr12:113376681	OAS3	-0.6	-9.37	-0.41	4.37e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg03714773	chr7:91764589	CYP51A1	0.3	6.8	0.31	3.52e-11	Breast cancer;
LUAD	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.92	-0.5	1.91e-28	Bipolar disorder;
LUAD	cis	rs1003719	0.788	rs1543749	chr21:38446621	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.44	0.38	5.28e-16	Eye color traits;
LUAD	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.54	-8.76	-0.39	4.93e-17	Total body bone mineral density;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07881982	chr3:156878112	CCNL1	-0.42	-6.51	-0.3	2.11e-10	Height;
LUAD	cis	rs9788682	0.792	rs35031105	chr15:78772806	C/T	cg18825076	chr15:78729989	IREB2	0.54	7.47	0.34	4.53e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs11048434	0.736	rs12812913	chr12:9110836	C/G	cg04155231	chr12:9217510	LOC144571	0.39	7.45	0.34	5.24e-13	Sjögren's syndrome;
LUAD	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	9.27	0.41	9.48e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs847577	0.630	rs2132276	chr7:97826340	G/A	cg24562669	chr7:97807699	LMTK2	0.34	8.06	0.36	7.73e-15	Breast cancer;
LUAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg08027265	chr7:2291960	NA	-0.42	-7.24	-0.33	2.18e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg14807363	chr15:63366820	NA	0.34	6.41	0.3	3.88e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs4853036	1.000	rs56223710	chr2:70049715	C/T	cg02498382	chr2:70120550	SNRNP27	-0.51	-8.16	-0.37	3.93e-15	Colorectal or endometrial cancer;
LUAD	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg24324837	chr19:49891574	CCDC155	0.57	6.39	0.3	4.26e-10	Multiple sclerosis;
LUAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg01448562	chr3:133502909	NA	-0.67	-12.23	-0.51	1.14e-29	Iron status biomarkers;
LUAD	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg15181151	chr6:150070149	PCMT1	0.42	8.61	0.39	1.48e-16	Lung cancer;
LUAD	cis	rs9283706	0.623	rs10055631	chr5:66305438	A/C	cg11590213	chr5:66331682	MAST4	0.39	6.57	0.3	1.48e-10	Coronary artery disease;
LUAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg24101359	chr6:42928495	GNMT	0.47	8.74	0.39	5.47e-17	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg17372223	chr3:52568218	NT5DC2	0.4	7.73	0.35	7.69e-14	Bipolar disorder;
LUAD	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-25.09	-0.77	8.9e-86	Height;
LUAD	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg18932078	chr1:2524107	MMEL1	0.37	6.96	0.32	1.33e-11	Ulcerative colitis;
LUAD	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg23254163	chr1:152506842	NA	0.26	7.17	0.33	3.32e-12	Hair morphology;
LUAD	cis	rs3784262	1.000	rs9325	chr15:58245986	A/T	cg12031962	chr15:58353849	ALDH1A2	0.47	9.58	0.42	8.24e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02018176	chr4:1364513	KIAA1530	0.67	11.82	0.5	4.51e-28	Longevity;
LUAD	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg06623918	chr6:96969491	KIAA0776	0.89	17.75	0.65	4.23e-53	Headache;
LUAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg23131131	chr22:24373011	LOC391322	-0.47	-7.73	-0.35	7.75e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg07817883	chr1:32538562	TMEM39B	-0.52	-7.15	-0.33	3.94e-12	Monocyte percentage of white cells;
LUAD	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg00898013	chr13:113819073	PROZ	-0.68	-12.05	-0.51	5.8e-29	Platelet distribution width;
LUAD	cis	rs62400317	0.859	rs12199871	chr6:45307682	C/T	cg18551225	chr6:44695536	NA	-0.56	-8.82	-0.39	3.03e-17	Total body bone mineral density;
LUAD	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.78	10.51	0.46	4.06e-23	Smoking behavior;
LUAD	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	trans	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	11.64	0.49	2.29e-27	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs6906287	0.631	rs9320663	chr6:118986172	A/G	cg21191810	chr6:118973309	C6orf204	0.5	9.64	0.42	5.29e-20	Electrocardiographic conduction measures;
LUAD	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg06627628	chr2:24431161	ITSN2	0.58	9.34	0.41	5.6e-19	Asthma;
LUAD	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg24579218	chr15:68104479	NA	0.56	9.86	0.43	8.55e-21	Restless legs syndrome;
LUAD	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg17063962	chr7:91808500	NA	-0.65	-11.12	-0.48	2.26e-25	Breast cancer;
LUAD	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg11189052	chr15:85197271	WDR73	0.67	8.76	0.39	4.76e-17	Schizophrenia;
LUAD	cis	rs7000551	0.653	rs4872504	chr8:22326717	A/G	cg12081754	chr8:22256438	SLC39A14	0.47	7.74	0.35	7.5e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg02569458	chr12:86230093	RASSF9	0.41	7.73	0.35	7.86e-14	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg10591111	chr5:226296	SDHA	-0.53	-7.21	-0.33	2.64e-12	Breast cancer;
LUAD	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg11645453	chr3:52864694	ITIH4	0.51	10.04	0.44	2.11e-21	Bipolar disorder;
LUAD	cis	rs4604732	0.588	rs74154678	chr1:247626202	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg24642844	chr7:1081250	C7orf50	-0.98	-14.75	-0.58	4.92e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg18252515	chr7:66147081	NA	-0.63	-6.85	-0.32	2.58e-11	Diabetic kidney disease;
LUAD	cis	rs2274273	0.624	rs7151754	chr14:55788501	C/T	cg04306507	chr14:55594613	LGALS3	0.43	8.16	0.37	3.97e-15	Protein biomarker;
LUAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg05434287	chr7:2030229	MAD1L1	0.39	6.42	0.3	3.63e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs7395662	1.000	rs4882015	chr11:48565573	A/T	cg00717180	chr2:96193071	NA	-0.4	-7.46	-0.34	4.97e-13	HDL cholesterol;
LUAD	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg05590025	chr7:65112418	INTS4L2	0.74	7.84	0.36	3.66e-14	Diabetic kidney disease;
LUAD	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.51	8.33	0.38	1.13e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg11859384	chr17:80120422	CCDC57	-0.42	-7.54	-0.34	2.91e-13	Life satisfaction;
LUAD	cis	rs11893307	0.537	rs61345672	chr2:191507014	A/C	cg27211696	chr2:191398769	TMEM194B	-0.42	-6.41	-0.3	3.82e-10	Mean platelet volume;
LUAD	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg01802117	chr1:53393560	SCP2	-0.37	-7.19	-0.33	2.99e-12	Monocyte count;
LUAD	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17095355	0.901	rs61881586	chr10:111758419	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.0	-0.36	1.23e-14	Biliary atresia;
LUAD	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.42	-0.49	1.63e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg25753631	chr6:25732923	NA	-0.42	-7.31	-0.33	1.36e-12	Iron status biomarkers;
LUAD	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg18180107	chr4:99064573	C4orf37	0.42	6.81	0.31	3.47e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg12863693	chr15:85201151	NMB	0.39	6.82	0.31	3.08e-11	Schizophrenia;
LUAD	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg24069376	chr3:38537580	EXOG	0.45	10.91	0.47	1.35e-24	Electrocardiographic conduction measures;
LUAD	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg00717180	chr2:96193071	NA	-0.45	-8.58	-0.39	1.8e-16	HDL cholesterol;
LUAD	cis	rs9381040	0.701	rs722442	chr6:41089681	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.6	-0.31	1.2e-10	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg03676636	chr4:99064102	C4orf37	0.27	6.87	0.32	2.27e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg18876405	chr7:65276391	NA	0.4	6.61	0.31	1.14e-10	Calcium levels;
LUAD	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg27170947	chr2:26402098	FAM59B	-0.82	-11.49	-0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg18827107	chr12:86230957	RASSF9	-0.44	-8.1	-0.37	6e-15	Major depressive disorder;
LUAD	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg07636037	chr3:49044803	WDR6	0.48	7.97	0.36	1.48e-14	Menarche (age at onset);
LUAD	cis	rs758324	0.947	rs1604080	chr5:131176644	A/G	cg06307176	chr5:131281290	NA	-0.53	-8.53	-0.38	2.65e-16	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.56	0.34	2.59e-13	Cannabis dependence symptom count;
LUAD	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg16680214	chr1:154839983	KCNN3	-0.63	-13.17	-0.54	1.95e-33	Prostate cancer;
LUAD	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg05234568	chr11:5960015	NA	-0.56	-10.07	-0.44	1.61e-21	DNA methylation (variation);
LUAD	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg07930552	chr6:133119739	C6orf192	0.67	7.96	0.36	1.57e-14	Type 2 diabetes nephropathy;
LUAD	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg18105134	chr13:113819100	PROZ	-0.86	-15.19	-0.59	6.8e-42	Platelet distribution width;
LUAD	cis	rs7224314	1.000	rs62084082	chr17:65388046	A/G	cg01507342	chr17:65387096	PITPNC1	-0.54	-8.81	-0.39	3.3e-17	Diisocyanate-induced asthma;
LUAD	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg01851573	chr8:8652454	MFHAS1	-0.46	-8.37	-0.38	8.81e-16	Mood instability;
LUAD	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg09537434	chr19:41945824	ATP5SL	0.54	8.46	0.38	4.39e-16	Height;
LUAD	cis	rs17152411	0.843	rs7904691	chr10:126582927	G/T	cg07906193	chr10:126599966	NA	0.53	7.49	0.34	4.12e-13	Height;
LUAD	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg04282206	chr17:62833786	PLEKHM1P	0.39	6.47	0.3	2.64e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs8044995	0.636	rs12447119	chr16:68297928	G/A	cg05110241	chr16:68378359	PRMT7	-0.93	-9.44	-0.42	2.5e-19	Schizophrenia;
LUAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg14092988	chr3:52407081	DNAH1	0.38	7.5	0.34	3.74e-13	Electroencephalogram traits;
LUAD	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg02569458	chr12:86230093	RASSF9	-0.45	-8.15	-0.37	4.09e-15	Major depressive disorder;
LUAD	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg04731861	chr2:219085781	ARPC2	0.25	7.42	0.34	6.47e-13	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs11153730	0.503	rs283049	chr6:118635122	G/C	cg18833306	chr6:118973337	C6orf204	0.54	10.0	0.44	2.72e-21	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg00343986	chr7:65444356	GUSB	-0.41	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg23625390	chr15:77176239	SCAPER	0.37	6.56	0.3	1.58e-10	Blood metabolite levels;
LUAD	cis	rs4493873	0.869	rs4501550	chr8:92088212	A/G	cg16814680	chr8:91681699	NA	0.41	6.67	0.31	8.23e-11	Migraine - clinic-based;
LUAD	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.13	-0.41	2.81e-18	Bipolar disorder;
LUAD	cis	rs7089973	0.966	rs17721283	chr10:116644141	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	8.31	0.37	1.29e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	7.55	0.34	2.62e-13	Neutrophil percentage of white cells;
LUAD	trans	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg24644049	chr4:85504048	CDS1	0.85	7.8	0.35	4.95e-14	Skin colour saturation;
LUAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10150615	chr22:24372951	LOC391322	-0.55	-8.91	-0.4	1.56e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg05805236	chr11:65401703	PCNXL3	-0.59	-9.76	-0.43	2e-20	Acne (severe);
LUAD	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg24733560	chr20:60626293	TAF4	0.46	8.12	0.37	5.21e-15	Body mass index;
LUAD	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg19622623	chr12:86230825	RASSF9	-0.41	-7.46	-0.34	4.95e-13	Major depressive disorder;
LUAD	trans	rs853679	0.607	rs68188794	chr6:28080777	T/C	cg01620082	chr3:125678407	NA	-1.1	-10.56	-0.46	2.69e-23	Depression;
LUAD	trans	rs877282	0.945	rs12782447	chr10:771870	C/T	cg22713356	chr15:30763199	NA	1.3	18.61	0.67	6.92e-57	Uric acid levels;
LUAD	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg03676636	chr4:99064102	C4orf37	0.29	7.59	0.35	2.03e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg02551604	chr5:131831745	NA	-0.61	-10.02	-0.44	2.39e-21	Asthma (sex interaction);
LUAD	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg16479474	chr6:28041457	NA	0.39	6.99	0.32	1.1e-11	Parkinson's disease;
LUAD	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg27532560	chr4:187881888	NA	-0.4	-7.77	-0.35	6.09e-14	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg04398451	chr17:18023971	MYO15A	0.66	11.89	0.5	2.48e-28	Total body bone mineral density;
LUAD	cis	rs4462272	0.557	rs17668255	chr10:102000701	C/T	cg19754520	chr10:101825118	CPN1	-0.3	-6.39	-0.3	4.37e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg11822812	chr5:140052017	DND1	-0.41	-7.46	-0.34	4.88e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg04906043	chr13:21280425	IL17D	0.4	7.21	0.33	2.55e-12	Dental caries;
LUAD	cis	rs7937890	0.559	rs2597219	chr11:14530866	C/G	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.15e-12	Mitochondrial DNA levels;
LUAD	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg03874509	chr1:107600012	PRMT6	-0.58	-10.18	-0.44	6.51e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs8060686	0.623	rs6499157	chr16:68105474	A/C	cg05110241	chr16:68378359	PRMT7	-0.57	-7.48	-0.34	4.47e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6076065	0.723	rs2252824	chr20:23354748	C/T	cg11657817	chr20:23433608	CST11	0.47	8.11	0.37	5.63e-15	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg08029281	chr1:67600428	NA	0.37	6.89	0.32	1.97e-11	Psoriasis;
LUAD	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg25358565	chr5:93447407	FAM172A	0.6	7.55	0.34	2.63e-13	Diabetic retinopathy;
LUAD	cis	rs7192380	0.767	rs8061725	chr16:69581077	G/A	cg26679644	chr16:69762563	NA	0.38	6.91	0.32	1.75e-11	Sjögren's syndrome;
LUAD	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.98	-0.4	8.9e-18	Total body bone mineral density;
LUAD	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg05535760	chr7:792225	HEATR2	0.84	11.19	0.48	1.18e-25	Cerebrospinal P-tau181p levels;
LUAD	cis	rs897984	0.553	rs2125293	chr16:30863875	T/C	cg02466173	chr16:30829666	NA	0.7	11.07	0.47	3.5e-25	Dementia with Lewy bodies;
LUAD	cis	rs10193935	0.901	rs3755304	chr2:42589921	A/G	cg27598129	chr2:42591480	NA	0.71	9.32	0.41	6.3e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg00933542	chr6:150070202	PCMT1	0.44	9.6	0.42	6.92e-20	Lung cancer;
LUAD	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.43	-8.56	-0.38	2.18e-16	Parkinson's disease;
LUAD	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg02574844	chr11:5959923	NA	0.39	7.12	0.33	4.66e-12	DNA methylation (variation);
LUAD	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg03929089	chr4:120376271	NA	-0.45	-6.93	-0.32	1.56e-11	HDL cholesterol;
LUAD	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg15664640	chr17:80829946	TBCD	-0.51	-9.67	-0.43	3.99e-20	Breast cancer;
LUAD	trans	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg10518543	chr12:38710700	ALG10B	0.41	6.53	0.3	1.91e-10	Morning vs. evening chronotype;
LUAD	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.61	9.01	0.4	7.42e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs12478296	0.591	rs7573042	chr2:242996589	A/G	cg06360820	chr2:242988706	NA	-0.58	-8.63	-0.39	1.3e-16	Obesity-related traits;
LUAD	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg12365402	chr11:9010492	NRIP3	0.5	9.4	0.42	3.37e-19	Hemoglobin concentration;
LUAD	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg15445000	chr17:37608096	MED1	0.44	8.24	0.37	2.18e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg03477792	chr4:77819574	ANKRD56	0.49	7.53	0.34	3.15e-13	Emphysema distribution in smoking;
LUAD	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.43	-7.6	-0.35	1.99e-13	Alzheimer's disease (late onset);
LUAD	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg22823121	chr1:150693482	HORMAD1	-0.4	-7.44	-0.34	5.78e-13	Urate levels;
LUAD	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg05731713	chr7:157510257	PTPRN2	0.4	8.25	0.37	2.02e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg16325326	chr1:53192061	ZYG11B	0.65	12.12	0.51	3.08e-29	Monocyte count;
LUAD	cis	rs6684514	1.000	rs12045339	chr1:156294211	C/T	cg16558208	chr1:156270281	VHLL	0.53	9.77	0.43	1.81e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs1696756	0.638	rs1290396	chr17:77830767	C/T	cg01306824	chr17:77834118	NA	0.42	6.71	0.31	6.24e-11	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg22920501	chr2:26401640	FAM59B	-0.8	-11.98	-0.5	1.1e-28	Gut microbiome composition (summer);
LUAD	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg05665937	chr4:1216051	CTBP1	0.41	6.73	0.31	5.7e-11	Obesity-related traits;
LUAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg16590910	chr6:42928470	GNMT	0.36	6.99	0.32	1.06e-11	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs7200543	1.000	rs55727637	chr16:15145252	C/T	cg24683922	chr1:11983373	KIAA2013	-0.46	-7.44	-0.34	5.77e-13	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg19077165	chr18:44547161	KATNAL2	0.44	7.57	0.35	2.31e-13	Personality dimensions;
LUAD	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.47	-6.45	-0.3	3.15e-10	Gut microbiome composition (summer);
LUAD	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.55	0.6	1.85e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg22963979	chr7:1858916	MAD1L1	-0.68	-12.22	-0.51	1.32e-29	Bipolar disorder and schizophrenia;
LUAD	cis	rs8099014	0.814	rs9966765	chr18:56116790	C/G	cg12907477	chr18:56117327	MIR122	0.52	8.51	0.38	3e-16	Platelet count;
LUAD	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08219700	chr8:58056026	NA	0.7	9.08	0.4	4.1e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg05623727	chr3:50126028	RBM5	-0.31	-6.75	-0.31	4.91e-11	Body mass index;
LUAD	cis	rs1776421	0.760	rs115926538	chr1:53910631	C/T	cg10892335	chr1:53966318	NA	0.5	7.38	0.34	8.72e-13	PR interval in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1881396	0.947	rs10173720	chr2:27855397	A/T	cg27432699	chr2:27873401	GPN1	-0.45	-6.44	-0.3	3.15e-10	Nonalcoholic fatty liver disease;
LUAD	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg18252515	chr7:66147081	NA	-0.6	-6.73	-0.31	5.43e-11	Diabetic kidney disease;
LUAD	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.35	-6.7	-0.31	6.81e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.62	0.52	3.18e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.96	0.36	1.57e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg04287289	chr16:89883240	FANCA	0.84	7.21	0.33	2.62e-12	Skin colour saturation;
LUAD	cis	rs72730918	0.590	rs2606143	chr15:51942455	C/T	cg14296394	chr15:51910925	DMXL2	-0.45	-6.56	-0.3	1.6e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6445967	0.530	rs56267535	chr3:58397399	A/G	cg13750441	chr3:58318267	PXK	-0.33	-6.79	-0.31	3.81e-11	Platelet count;
LUAD	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg06636551	chr8:101224915	SPAG1	-0.37	-6.63	-0.31	1.02e-10	Atrioventricular conduction;
LUAD	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03264133	chr6:25882463	NA	-0.6	-8.73	-0.39	6.01e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03517284	chr6:25882590	NA	-0.58	-9.56	-0.42	1.02e-19	Blood metabolite levels;
LUAD	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg23649088	chr2:200775458	C2orf69	-0.6	-8.54	-0.38	2.38e-16	Schizophrenia;
LUAD	cis	rs17021463	0.966	rs1565062	chr4:95183000	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.5	-9.32	-0.41	6.71e-19	Testicular germ cell tumor;
LUAD	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	7.05	0.32	7.16e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg01788221	chr16:89496183	ANKRD11	-0.38	-7.27	-0.33	1.71e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg27432699	chr2:27873401	GPN1	-0.68	-12.18	-0.51	1.77e-29	Oral cavity cancer;
LUAD	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg18138036	chr10:133769891	PPP2R2D	0.42	6.83	0.32	2.89e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg00129232	chr17:37814104	STARD3	-0.45	-7.63	-0.35	1.6e-13	Asthma;
LUAD	trans	rs7200543	1.000	rs1121	chr16:15131076	G/A	cg24683922	chr1:11983373	KIAA2013	-0.48	-8.09	-0.37	6.22e-15	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.44	-0.49	1.35e-26	Type 2 diabetes;
LUAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg06740227	chr12:86229804	RASSF9	0.46	8.02	0.36	1.05e-14	Major depressive disorder;
LUAD	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg18252515	chr7:66147081	NA	-0.6	-6.73	-0.31	5.43e-11	Diabetic kidney disease;
LUAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.41	-0.38	6.57e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg06484146	chr7:12443880	VWDE	-0.53	-6.76	-0.31	4.56e-11	Coronary artery disease;
LUAD	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg07305463	chr2:136567211	LCT	-0.39	-7.41	-0.34	6.81e-13	Mosquito bite size;
LUAD	cis	rs710865	1.000	rs710865	chr1:19568972	A/G	cg13387374	chr1:19411106	UBR4	0.43	7.06	0.32	6.67e-12	Brain structure;
LUAD	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg19678392	chr7:94953810	PON1	0.59	8.26	0.37	1.94e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg07936489	chr17:37558343	FBXL20	0.45	7.11	0.33	5e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg15997130	chr1:24165203	NA	0.55	9.69	0.43	3.44e-20	Immature fraction of reticulocytes;
LUAD	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg05368731	chr17:41323189	NBR1	0.84	16.05	0.62	1.24e-45	Menopause (age at onset);
LUAD	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg05425664	chr17:57184151	TRIM37	0.39	6.88	0.32	2.11e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg10560079	chr2:191398806	TMEM194B	-0.53	-6.93	-0.32	1.56e-11	Diastolic blood pressure;
LUAD	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg24399712	chr22:39784796	NA	-0.76	-13.13	-0.54	2.76e-33	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg23260525	chr10:116636907	FAM160B1	0.47	10.72	0.46	6.95e-24	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg18512352	chr11:47633146	NA	-0.49	-8.33	-0.38	1.13e-15	Subjective well-being;
LUAD	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg22491629	chr6:157744540	C6orf35	-0.8	-8.86	-0.4	2.19e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs938554	0.612	rs4385059	chr4:9989233	A/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-8.91	-0.4	1.48e-17	Blood metabolite levels;
LUAD	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.52	-0.3	1.96e-10	Breast cancer;
LUAD	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg06781209	chr11:61594997	FADS2	-0.49	-8.87	-0.4	2.1e-17	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg14343924	chr8:8086146	FLJ10661	-0.46	-7.35	-0.34	1.03e-12	Joint mobility (Beighton score);
LUAD	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-11.22	-0.48	9.46e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg16414030	chr3:133502952	NA	-0.52	-9.44	-0.42	2.61e-19	Iron status biomarkers;
LUAD	cis	rs2617583	0.509	rs4738	chr5:1461568	C/T	cg13982541	chr5:1466431	LPCAT1	0.61	9.71	0.43	2.93e-20	Breast cancer;
LUAD	cis	rs2901656	0.629	rs10752946	chr1:172376632	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.48	9.56	0.42	9.57e-20	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg20503657	chr10:835505	NA	0.95	14.42	0.57	1.28e-38	Eosinophil percentage of granulocytes;
LUAD	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg08645402	chr16:4508243	NA	0.5	8.09	0.37	6.3e-15	Schizophrenia;
LUAD	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg13010199	chr12:38710504	ALG10B	-0.38	-6.45	-0.3	3.1e-10	Bladder cancer;
LUAD	cis	rs12928939	0.517	rs12149325	chr16:71968147	G/C	cg03805757	chr16:71968109	PKD1L3	-0.54	-8.53	-0.38	2.69e-16	Post bronchodilator FEV1;
LUAD	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg02421172	chr7:1938701	MAD1L1	-0.44	-6.68	-0.31	7.7e-11	Bipolar disorder;
LUAD	cis	rs10905065	0.931	rs11255228	chr10:5837671	T/C	cg11519256	chr10:5708881	ASB13	0.42	6.99	0.32	1.09e-11	Menopause (age at onset);
LUAD	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg08514558	chr10:81106712	PPIF	0.48	9.52	0.42	1.39e-19	Height;
LUAD	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg06671706	chr8:8559999	CLDN23	0.69	11.85	0.5	3.47e-28	Obesity-related traits;
LUAD	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg08213375	chr14:104286397	PPP1R13B	0.26	6.89	0.32	1.97e-11	Schizophrenia;
LUAD	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg21427119	chr20:30132790	HM13	-0.5	-8.02	-0.36	1.04e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs4711350	0.862	rs602399	chr6:33713779	C/T	cg07979401	chr6:33739406	LEMD2	0.49	7.82	0.36	4.23e-14	Schizophrenia;
LUAD	cis	rs7771547	0.574	rs9394361	chr6:36551370	A/C	cg04289385	chr6:36355825	ETV7	0.5	6.62	0.31	1.11e-10	Platelet distribution width;
LUAD	cis	rs2235649	0.833	rs9922139	chr16:1848329	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-8.15	-0.37	4.02e-15	Blood metabolite levels;
LUAD	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg23649088	chr2:200775458	C2orf69	-0.48	-8.39	-0.38	7.43e-16	Asthma (bronchodilator response);
LUAD	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.17	16.13	0.62	6.05e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4713675	0.584	rs509539	chr6:33708190	A/C	cg14003231	chr6:33640908	ITPR3	-0.36	-6.89	-0.32	2.05e-11	Plateletcrit;
LUAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg22907277	chr7:1156413	C7orf50	0.59	10.0	0.44	2.72e-21	Longevity;Endometriosis;
LUAD	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg25233709	chr10:116636983	FAM160B1	0.42	8.24	0.37	2.12e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg14092988	chr3:52407081	DNAH1	0.44	8.94	0.4	1.26e-17	Bipolar disorder;
LUAD	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg02782426	chr3:40428986	ENTPD3	0.43	9.01	0.4	7.19e-18	Renal cell carcinoma;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02203922	chr6:657011	HUS1B;EXOC2	0.53	6.38	0.3	4.55e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs1965732	0.588	rs11682334	chr2:3716780	G/T	cg25251562	chr2:3704773	ALLC	-0.34	-6.44	-0.3	3.32e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg18129748	chr3:49941408	MST1R	0.39	6.38	0.3	4.77e-10	Body mass index;
LUAD	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg11663144	chr21:46675770	NA	-0.61	-11.81	-0.5	4.96e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.75	-0.31	4.83e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-7.26	-0.33	1.91e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7181230	0.885	rs3923235	chr15:40371121	A/G	cg22705835	chr10:65332833	REEP3	-0.39	-7.24	-0.33	2.12e-12	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs6541297	0.941	rs6690424	chr1:230278892	C/T	cg20703242	chr1:230279135	GALNT2	0.66	12.26	0.51	8.85e-30	Coronary artery disease;
LUAD	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg20290983	chr6:43655470	MRPS18A	1.08	27.53	0.8	2.39e-96	IgG glycosylation;
LUAD	cis	rs9837602	1.000	rs2291494	chr3:99781805	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.91	-0.32	1.79e-11	Breast cancer;
LUAD	cis	rs68170813	0.559	rs6971774	chr7:106834139	A/G	cg23024343	chr7:107201750	COG5	0.46	6.75	0.31	4.87e-11	Coronary artery disease;
LUAD	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg24675056	chr1:15929824	NA	0.48	8.4	0.38	6.98e-16	Systolic blood pressure;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13713052	chr3:122102218	FAM162A;CCDC58	0.42	6.46	0.3	2.81e-10	Gut microbiome composition (summer);
LUAD	cis	rs4891159	0.824	rs17059362	chr18:74144307	G/A	cg24786174	chr18:74118243	ZNF516	-0.8	-14.76	-0.58	4.61e-40	Longevity;
LUAD	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg12483005	chr1:23474871	LUZP1	0.52	9.11	0.4	3.44e-18	Height;
LUAD	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg07741184	chr6:167504864	NA	0.33	7.1	0.33	5.45e-12	Crohn's disease;
LUAD	cis	rs7173743	0.967	rs28694044	chr15:79134718	A/T	cg00540400	chr15:79124168	NA	-0.34	-6.7	-0.31	6.77e-11	Coronary artery disease;
LUAD	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg16060761	chr17:80687452	NA	0.8	14.9	0.59	1.12e-40	Glycated hemoglobin levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27202037	chr11:130298544	ADAMTS8	-0.52	-6.42	-0.3	3.67e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs231513	0.954	rs231500	chr17:41973374	T/C	cg26893861	chr17:41843967	DUSP3	-0.55	-6.67	-0.31	7.95e-11	Cognitive function;
LUAD	trans	rs11039798	0.920	rs11039848	chr11:48598243	C/T	cg03929089	chr4:120376271	NA	0.65	6.57	0.3	1.45e-10	Axial length;
LUAD	cis	rs36051895	0.659	rs3780366	chr9:5068596	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-6.56	-0.3	1.62e-10	Pediatric autoimmune diseases;
LUAD	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.47	-8.03	-0.36	9.9e-15	Age at first birth;
LUAD	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg00495681	chr13:53174319	NA	0.52	9.74	0.43	2.34e-20	Lewy body disease;
LUAD	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg01802117	chr1:53393560	SCP2	-0.39	-7.45	-0.34	5.45e-13	Monocyte count;
LUAD	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-7.66	-0.35	1.27e-13	Total cholesterol levels;
LUAD	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg01416388	chr22:39784598	NA	-0.47	-7.37	-0.34	9e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg22907277	chr7:1156413	C7orf50	0.68	7.97	0.36	1.49e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1595825	0.945	rs6736825	chr2:198854224	C/T	cg10547527	chr2:198650123	BOLL	-0.52	-7.28	-0.33	1.65e-12	Ulcerative colitis;
LUAD	cis	rs6665290	0.669	rs34267809	chr1:227176162	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.13	-31.41	-0.84	1.23e-112	Myeloid white cell count;
LUAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg02725872	chr8:58115012	NA	-0.34	-6.57	-0.3	1.5e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6076065	0.723	rs2424530	chr20:23369354	A/G	cg11657817	chr20:23433608	CST11	0.47	8.83	0.39	2.89e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.68	0.39	8.95e-17	Breast cancer;
LUAD	cis	rs9972944	0.729	rs10083872	chr17:63773474	A/G	cg07283582	chr17:63770753	CCDC46	0.47	10.24	0.45	3.88e-22	Total body bone mineral density;
LUAD	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg22823121	chr1:150693482	HORMAD1	-0.41	-7.46	-0.34	4.86e-13	Blood protein levels;
LUAD	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10802521	chr3:52805072	NEK4	-0.55	-9.18	-0.41	1.91e-18	Bipolar disorder;
LUAD	cis	rs68170813	0.559	rs78064065	chr7:106967440	G/A	cg23024343	chr7:107201750	COG5	0.48	6.76	0.31	4.52e-11	Coronary artery disease;
LUAD	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.06e-11	Depression;
LUAD	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg16989719	chr2:238392110	NA	-0.36	-6.63	-0.31	9.99e-11	Prostate cancer;
LUAD	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-16.36	-0.62	5.58e-47	Schizophrenia;
LUAD	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg11189052	chr15:85197271	WDR73	0.67	8.92	0.4	1.47e-17	Schizophrenia;
LUAD	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg00495681	chr13:53174319	NA	0.5	8.87	0.4	2.07e-17	Lewy body disease;
LUAD	cis	rs7903847	0.642	rs11189206	chr10:99167802	T/C	cg20016023	chr10:99160130	RRP12	-0.27	-6.6	-0.31	1.24e-10	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg04703951	chr17:43578652	NA	-0.57	-8.13	-0.37	4.65e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg08885076	chr2:99613938	TSGA10	-0.39	-6.97	-0.32	1.24e-11	Chronic sinus infection;
LUAD	cis	rs1461503	0.932	rs10790544	chr11:122838330	T/C	cg27398637	chr11:122830231	C11orf63	-0.37	-7.25	-0.33	2.06e-12	Menarche (age at onset);
LUAD	trans	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg14406256	chr12:34175567	ALG10	-0.39	-6.35	-0.3	5.46e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg09491104	chr22:46646882	C22orf40	-0.57	-8.37	-0.38	8.25e-16	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg18424115	chr14:24768909	DHRS1;C14orf21	-0.71	-6.87	-0.32	2.35e-11	Type 2 diabetes;
LUAD	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg25233709	chr10:116636983	FAM160B1	0.41	8.26	0.37	1.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs11167764	0.945	rs891985	chr5:141466066	C/G	cg23435118	chr5:141488016	NDFIP1	-0.47	-6.95	-0.32	1.39e-11	Crohn's disease;
LUAD	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-6.53	-0.3	1.89e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg26751094	chr13:95954534	ABCC4	-0.5	-10.76	-0.46	5.16e-24	Blood metabolite levels;
LUAD	cis	rs7681423	1.000	rs2066861	chr4:155527436	C/T	cg20735720	chr4:155535218	FGG	-0.52	-7.67	-0.35	1.16e-13	Fibrinogen;
LUAD	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg25173405	chr17:45401733	C17orf57	-0.4	-6.48	-0.3	2.5e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg07677032	chr17:61819896	STRADA	0.56	10.19	0.44	5.84e-22	Prudent dietary pattern;
LUAD	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg25358565	chr5:93447407	FAM172A	0.61	7.68	0.35	1.13e-13	Diabetic retinopathy;
LUAD	trans	rs1904173	0.599	rs34649614	chr5:25071861	C/T	cg04802221	chr16:67223955	EXOC3L	0.5	6.99	0.32	1.07e-11	IgG glycosylation;
LUAD	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg05665937	chr4:1216051	CTBP1	0.42	7.55	0.34	2.77e-13	Obesity-related traits;
LUAD	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg06784218	chr1:46089804	CCDC17	0.5	11.17	0.48	1.45e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg17063962	chr7:91808500	NA	0.69	12.21	0.51	1.39e-29	Breast cancer;
LUAD	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	10.63	0.46	1.46e-23	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.25	-0.37	2.05e-15	Alzheimer's disease;
LUAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs9479482	0.967	rs763574	chr6:150349415	G/C	cg25797454	chr6:150327115	RAET1K	0.36	7.67	0.35	1.21e-13	Alopecia areata;
LUAD	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01570182	chr17:44337453	NA	0.86	12.81	0.53	5.79e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg12935359	chr14:103987150	CKB	-0.48	-7.77	-0.35	5.86e-14	Body mass index;
LUAD	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg06623918	chr6:96969491	KIAA0776	-0.88	-17.38	-0.65	1.88e-51	Headache;
LUAD	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg21782813	chr7:2030301	MAD1L1	0.51	8.74	0.39	5.5e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg14917512	chr19:3094685	GNA11	-0.59	-6.95	-0.32	1.41e-11	Diabetic kidney disease;
LUAD	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18404041	chr3:52824283	ITIH1	0.58	12.1	0.51	3.69e-29	Bipolar disorder;
LUAD	cis	rs11630290	1.000	rs72750987	chr15:63999112	G/C	cg12036633	chr15:63758958	NA	-0.51	-6.86	-0.32	2.47e-11	Iris characteristics;
LUAD	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg06623918	chr6:96969491	KIAA0776	0.65	10.03	0.44	2.14e-21	Migraine;Coronary artery disease;
LUAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	9.36	0.41	4.76e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6714710	0.663	rs71429376	chr2:98534412	T/C	cg26665480	chr2:98280029	ACTR1B	0.48	7.88	0.36	2.78e-14	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg07507251	chr3:52567010	NT5DC2	-0.38	-7.45	-0.34	5.14e-13	Bipolar disorder;
LUAD	cis	rs10484885	0.878	rs111664889	chr6:90566427	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.64	-6.38	-0.3	4.54e-10	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg08742575	chr21:47604166	C21orf56	0.43	7.14	0.33	4.12e-12	Testicular germ cell tumor;
LUAD	cis	rs7786808	0.579	rs12669482	chr7:158188813	G/A	cg09998033	chr7:158218633	PTPRN2	-0.44	-7.63	-0.35	1.61e-13	Obesity-related traits;
LUAD	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg01448562	chr3:133502909	NA	-0.52	-9.08	-0.4	4.02e-18	Iron status biomarkers;
LUAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg24829409	chr8:58192753	C8orf71	-0.6	-7.09	-0.33	5.72e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs3800461	0.544	rs76990047	chr6:34504042	T/G	cg14254433	chr6:34482411	PACSIN1	-0.81	-10.26	-0.45	3.31e-22	Chronic lymphocytic leukemia;
LUAD	cis	rs10493773	1.000	rs3767163	chr1:86121895	T/G	cg17807903	chr1:86174739	ZNHIT6	-0.54	-8.96	-0.4	1.05e-17	Urate levels in overweight individuals;
LUAD	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.36	0.41	4.91e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs7707921	0.846	rs4293895	chr5:81425592	T/C	cg15871215	chr5:81402204	ATG10	-0.68	-9.65	-0.42	4.61e-20	Breast cancer;
LUAD	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-11.28	-0.48	5.81e-26	Asthma;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26823989	chr1:87380673	SEP15;HS2ST1	-0.5	-6.53	-0.3	1.84e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg05368731	chr17:41323189	NBR1	0.98	20.29	0.7	2e-64	Menopause (age at onset);
LUAD	cis	rs739496	1.000	rs739496	chr12:111887659	A/G	cg10833066	chr12:111807467	FAM109A	0.45	7.93	0.36	1.96e-14	Platelet count;
LUAD	cis	rs7107174	1.000	rs9651768	chr11:77996020	C/T	cg02023728	chr11:77925099	USP35	0.4	6.75	0.31	4.92e-11	Testicular germ cell tumor;
LUAD	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg11189052	chr15:85197271	WDR73	0.72	9.52	0.42	1.38e-19	Schizophrenia;
LUAD	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.49	-0.3	2.47e-10	Aortic root size;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00395995	chr8:674959	ERICH1	0.47	6.42	0.3	3.75e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg26924012	chr15:45694286	SPATA5L1	0.86	14.72	0.58	7.01e-40	Homoarginine levels;
LUAD	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg15181151	chr6:150070149	PCMT1	0.42	8.68	0.39	8.62e-17	Lung cancer;
LUAD	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs9902453	0.765	rs2259857	chr17:28097780	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.54	-0.46	3.08e-23	Coffee consumption (cups per day);
LUAD	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg22823121	chr1:150693482	HORMAD1	0.47	9.05	0.4	5.39e-18	Melanoma;
LUAD	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.33	7.1	0.33	5.34e-12	Cardiac Troponin-T levels;
LUAD	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg06131755	chr6:160182447	ACAT2	0.43	6.5	0.3	2.2e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg07617317	chr6:118971624	C6orf204	0.55	8.1	0.37	5.98e-15	Diastolic blood pressure;
LUAD	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.7	0.39	7.29e-17	Menopause (age at onset);
LUAD	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg21775007	chr8:11205619	TDH	-0.49	-9.03	-0.4	5.96e-18	Retinal vascular caliber;
LUAD	cis	rs4321325	0.733	rs13421996	chr2:127934812	G/T	cg11380483	chr2:127933992	NA	0.52	6.9	0.32	1.92e-11	Protein C levels;
LUAD	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs6669072	0.739	rs3843305	chr1:91243376	G/A	cg08895590	chr1:91227319	NA	-0.34	-7.13	-0.33	4.31e-12	Cognitive function;
LUAD	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg09137382	chr11:130731461	NA	0.44	8.24	0.37	2.18e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2464469	0.654	rs4646570	chr15:58343146	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.29	-0.33	1.51e-12	Barrett's esophagus  or Esophageal adenocarcinoma;
LUAD	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg17372223	chr3:52568218	NT5DC2	0.35	6.66	0.31	8.59e-11	Cognitive function;
LUAD	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg17551891	chr7:1960795	MAD1L1	-0.41	-7.16	-0.33	3.63e-12	Neuroticism;
LUAD	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg05697835	chr1:2722811	NA	0.33	7.04	0.32	7.69e-12	Ulcerative colitis;
LUAD	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg09904177	chr6:26538194	HMGN4	0.44	7.39	0.34	7.96e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.39	-7.24	-0.33	2.17e-12	Longevity;Endometriosis;
LUAD	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg13870426	chr17:30244630	NA	-0.57	-6.62	-0.31	1.12e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg25985355	chr7:65971099	NA	-0.49	-6.99	-0.32	1.09e-11	Diabetic kidney disease;
LUAD	cis	rs7809950	0.678	rs3801966	chr7:106824580	G/A	cg23024343	chr7:107201750	COG5	-0.82	-13.41	-0.55	2.06e-34	Coronary artery disease;
LUAD	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11890956	chr21:40555474	PSMG1	0.78	13.58	0.55	4.12e-35	Cognitive function;
LUAD	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg00898013	chr13:113819073	PROZ	-0.81	-14.94	-0.59	7.74e-41	Platelet distribution width;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg10169971	chr6:83902988	RWDD2A;PGM3	-0.48	-7.69	-0.35	1.01e-13	Vertical cup-disc ratio;
LUAD	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08280861	chr8:58055591	NA	0.64	8.44	0.38	5.21e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs10465746	0.780	rs10874424	chr1:84424033	C/T	cg10977910	chr1:84465055	TTLL7	0.59	9.72	0.43	2.75e-20	Obesity-related traits;
LUAD	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg14092988	chr3:52407081	DNAH1	0.45	8.98	0.4	8.87e-18	Bipolar disorder;
LUAD	cis	rs6540559	0.551	rs17389436	chr1:209972297	A/T	cg22029157	chr1:209979665	IRF6	0.76	8.13	0.37	4.84e-15	Cleft lip with or without cleft palate;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21829265	chr6:56911139	KIAA1586	0.4	6.41	0.3	3.84e-10	Gut microbiome composition (summer);
LUAD	cis	rs1003719	0.680	rs767998	chr21:38525652	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.41	-0.38	6.34e-16	Eye color traits;
LUAD	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg16989719	chr2:238392110	NA	-0.37	-6.84	-0.32	2.75e-11	Prostate cancer;
LUAD	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg21823605	chr1:152486609	CRCT1	0.28	6.4	0.3	4.11e-10	Hair morphology;
LUAD	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg13722127	chr7:150037890	RARRES2	0.5	8.29	0.37	1.55e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4664304	0.802	rs62175470	chr2:160858255	G/C	cg06573604	chr2:160760825	LY75	-0.39	-6.44	-0.3	3.26e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs11229555	0.609	rs7927730	chr11:58187906	G/A	cg15696309	chr11:58395628	NA	-0.72	-9.96	-0.44	3.87e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1003719	0.591	rs2018521	chr21:38517264	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.42	-7.22	-0.33	2.4e-12	Eye color traits;
LUAD	cis	rs231513	0.911	rs231517	chr17:41961789	C/T	cg26893861	chr17:41843967	DUSP3	-0.59	-7.5	-0.34	3.85e-13	Cognitive function;
LUAD	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg14530993	chr4:882597	GAK	0.69	6.59	0.31	1.28e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg03563238	chr19:33554763	RHPN2	-0.39	-9.17	-0.41	2.14e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg21709803	chr11:61594965	FADS2	-0.39	-6.72	-0.31	5.98e-11	Bipolar disorder;
LUAD	cis	rs7147624	0.608	rs4902413	chr14:66187091	T/C	cg03016385	chr14:66212404	NA	-0.58	-6.97	-0.32	1.2e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg27124370	chr19:33622961	WDR88	0.43	6.44	0.3	3.17e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg11663144	chr21:46675770	NA	-0.61	-12.19	-0.51	1.67e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12079745	0.793	rs10919110	chr1:169214293	G/C	cg09363564	chr1:169337483	NME7;BLZF1	-1.1	-8.06	-0.36	7.95e-15	QT interval;
LUAD	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	12.3	0.51	6.34e-30	Lung cancer in ever smokers;
LUAD	cis	rs12545109	0.800	rs2576599	chr8:57388410	G/A	cg07776626	chr8:57350775	NA	-0.65	-9.12	-0.41	2.98e-18	Obesity-related traits;
LUAD	cis	rs6087990	1.000	rs2018002	chr20:31351623	A/T	cg13636640	chr20:31349939	DNMT3B	0.85	16.81	0.63	6.17e-49	Ulcerative colitis;
LUAD	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.08	0.37	7.01e-15	Menarche (age at onset);
LUAD	cis	rs11948739	0.501	rs3981332	chr5:130372203	A/T	cg08523029	chr5:130500466	HINT1	-0.59	-7.65	-0.35	1.38e-13	Pediatric bone mineral content (hip);
LUAD	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg14779329	chr11:130786720	SNX19	0.37	6.37	0.3	4.88e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg25019722	chr6:37503610	NA	-0.31	-7.01	-0.32	9.29e-12	Cognitive performance;
LUAD	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg18306943	chr3:40428807	ENTPD3	0.42	7.05	0.32	7.27e-12	Renal cell carcinoma;
LUAD	cis	rs1298062	0.861	rs2431821	chr19:50995098	G/A	cg11430371	chr19:50961752	MYBPC2	0.32	6.57	0.3	1.48e-10	Age of smoking initiation;
LUAD	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg12863693	chr15:85201151	NMB	0.43	7.99	0.36	1.28e-14	Schizophrenia;
LUAD	cis	rs9297145	0.916	rs6969140	chr7:98753900	G/A	cg05967295	chr7:98741636	SMURF1	-0.91	-16.58	-0.63	6.19e-48	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg12927641	chr6:109611667	NA	-0.54	-9.38	-0.41	4.05e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.05	-22.43	-0.74	5.48e-74	Chronic sinus infection;
LUAD	cis	rs4319547	0.695	rs7301515	chr12:122949673	T/C	cg23029597	chr12:123009494	RSRC2	-0.54	-7.87	-0.36	3e-14	Body mass index;
LUAD	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg08999081	chr20:33150536	PIGU	-0.63	-13.86	-0.56	2.93e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg10589385	chr1:150898437	SETDB1	0.44	7.92	0.36	2.11e-14	Melanoma;
LUAD	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg06784218	chr1:46089804	CCDC17	0.55	12.03	0.5	7.42e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg27454412	chr7:1067447	C7orf50	0.38	6.51	0.3	2.16e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg17863274	chr19:49399704	TULP2	-0.65	-9.93	-0.43	5.05e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.53e-11	Crohn's disease;
LUAD	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.54	0.46	3.24e-23	Colorectal cancer;
LUAD	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	8.93	0.4	1.35e-17	Menopause (age at onset);
LUAD	cis	rs478304	0.718	rs1144789	chr11:65389631	A/G	cg27068330	chr11:65405492	SIPA1	0.61	9.5	0.42	1.53e-19	Acne (severe);
LUAD	cis	rs10849893	0.538	rs4980986	chr12:121914808	A/T	cg01154721	chr12:121881891	KDM2B	-0.47	-8.08	-0.37	6.63e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs5167	0.743	rs57204168	chr19:45496776	A/G	cg13119609	chr19:45449297	APOC2	0.4	7.27	0.33	1.71e-12	Blood protein levels;
LUAD	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21659725	chr3:3221576	CRBN	0.67	11.48	0.49	9.49e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs3106136	0.967	rs4693377	chr4:95157256	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.34	-0.34	1.12e-12	Capecitabine sensitivity;
LUAD	cis	rs73206853	0.764	rs12311093	chr12:110978032	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.75	-11.02	-0.47	5.27e-25	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg19318889	chr4:1322082	MAEA	0.47	7.91	0.36	2.32e-14	Obesity-related traits;
LUAD	cis	rs10638925	1	rs10638925	chr3:194119749	C/CCATAAA	cg00834899	chr3:194121120	GP5	0.7	12.86	0.53	3.58e-32	Platelet distribution width;
LUAD	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg15147215	chr3:52552868	STAB1	-0.41	-7.43	-0.34	6.08e-13	Bipolar disorder;
LUAD	cis	rs1215050	0.682	rs6839343	chr4:98839732	G/A	cg17366294	chr4:99064904	C4orf37	0.44	7.2	0.33	2.78e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6519955	0.897	rs4073601	chr22:46434686	A/G	cg05468064	chr22:46423449	NA	0.5	11.08	0.47	3.05e-25	Dupuytren's disease;
LUAD	cis	rs9920506	0.518	rs11072774	chr15:78952697	C/T	cg05914723	chr15:78953907	NA	0.58	8.01	0.36	1.14e-14	Post bronchodilator FEV1;
LUAD	trans	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg27411982	chr8:10470053	RP1L1	0.38	6.69	0.31	7.2e-11	Neuroticism;
LUAD	cis	rs10242455	0.571	rs55830753	chr7:99292222	A/G	cg18809830	chr7:99032528	PTCD1	-0.97	-8.05	-0.36	8.5e-15	Blood metabolite levels;
LUAD	cis	rs3862030	0.694	rs1984795	chr10:104226830	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-8.01	-0.36	1.14e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg08999081	chr20:33150536	PIGU	-0.34	-6.57	-0.3	1.51e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs7274811	0.516	rs3213141	chr20:32274380	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.48	-6.59	-0.31	1.32e-10	Height;
LUAD	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.58	8.18	0.37	3.41e-15	Gut microbiome composition (summer);
LUAD	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18876405	chr7:65276391	NA	0.43	6.75	0.31	4.89e-11	Aortic root size;
LUAD	cis	rs2762353	0.574	rs4419666	chr6:25693274	C/T	cg15691649	chr6:25882328	NA	0.67	10.06	0.44	1.77e-21	Blood metabolite levels;
LUAD	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.14	-0.41	2.57e-18	Life satisfaction;
LUAD	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg00310523	chr12:86230176	RASSF9	0.41	8.6	0.39	1.61e-16	Major depressive disorder;
LUAD	trans	rs11989744	1.000	rs17782264	chr8:23570489	C/T	cg03492747	chr16:86543808	FOXF1	0.38	6.65	0.31	8.92e-11	Waist-hip ratio;
LUAD	cis	rs7264396	0.563	rs2225950	chr20:34333015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.07	-0.37	7.53e-15	Total cholesterol levels;
LUAD	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg22676075	chr6:135203613	NA	-0.58	-10.25	-0.45	3.65e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs868036	1.000	rs1026736	chr15:68101813	T/C	cg24579218	chr15:68104479	NA	-0.4	-7.45	-0.34	5.44e-13	Restless legs syndrome;
LUAD	cis	rs3823572	0.542	rs10271889	chr7:133635846	A/G	cg03336402	chr7:133662267	EXOC4	0.42	7.63	0.35	1.56e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs2270927	0.510	rs4352583	chr5:75576716	A/G	cg13563193	chr19:33072644	PDCD5	0.93	9.09	0.4	3.94e-18	Mean corpuscular volume;
LUAD	cis	rs1524976	1.000	rs4688240	chr3:65522392	A/G	cg16238336	chr3:65465873	MAGI1	-0.59	-6.87	-0.32	2.3e-11	PR interval;
LUAD	trans	rs10411161	0.702	rs892039	chr19:52396541	G/A	cg22319618	chr22:45562946	NUP50	-0.66	-9.44	-0.42	2.52e-19	Breast cancer;
LUAD	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.71	0.31	6.08e-11	Depression;
LUAD	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06544989	chr22:39130855	UNC84B	0.42	7.75	0.35	6.91e-14	Menopause (age at onset);
LUAD	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg15997130	chr1:24165203	NA	0.56	9.55	0.42	1.1e-19	Immature fraction of reticulocytes;
LUAD	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg08773314	chr2:239334832	ASB1	0.45	10.28	0.45	2.8e-22	Multiple system atrophy;
LUAD	cis	rs2274273	0.901	rs68046603	chr14:55762803	T/A	cg04306507	chr14:55594613	LGALS3	0.42	8.69	0.39	8.16e-17	Protein biomarker;
LUAD	cis	rs2274273	1.000	rs74617736	chr14:55620919	C/T	cg04306507	chr14:55594613	LGALS3	0.35	7.07	0.32	6.64e-12	Protein biomarker;
LUAD	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg15704280	chr7:45808275	SEPT13	-1.05	-25.02	-0.77	1.82e-85	Height;
LUAD	cis	rs62400317	0.556	rs10948196	chr6:44959384	A/T	cg18551225	chr6:44695536	NA	-0.46	-7.79	-0.35	5.06e-14	Total body bone mineral density;
LUAD	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg18129178	chr5:148520854	ABLIM3	0.64	9.89	0.43	6.89e-21	Breast cancer;
LUAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.43	-0.38	5.34e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.02	21.9	0.73	1.29e-71	Colorectal cancer;
LUAD	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg27147174	chr7:100797783	AP1S1	-0.68	-12.64	-0.52	2.68e-31	Life satisfaction;
LUAD	cis	rs6087990	0.865	rs6058859	chr20:31335157	A/G	cg13636640	chr20:31349939	DNMT3B	0.77	14.2	0.57	1.11e-37	Ulcerative colitis;
LUAD	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg02176678	chr2:219576539	TTLL4	-0.82	-17.2	-0.64	1.15e-50	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs11048434	0.736	rs1805761	chr12:9099533	T/C	cg26114124	chr12:9217669	LOC144571	0.36	6.47	0.3	2.68e-10	Sjögren's syndrome;
LUAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg24813613	chr7:1882135	MAD1L1	0.43	6.95	0.32	1.4e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg21475434	chr5:93447410	FAM172A	0.73	8.48	0.38	3.93e-16	Diabetic retinopathy;
LUAD	cis	rs11971779	0.648	rs28754644	chr7:139065057	C/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.46	-0.3	2.86e-10	Diisocyanate-induced asthma;
LUAD	cis	rs62400317	0.859	rs72860105	chr6:45265201	A/T	cg18551225	chr6:44695536	NA	-0.53	-8.36	-0.38	9.31e-16	Total body bone mineral density;
LUAD	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg02931644	chr1:25747376	RHCE	0.41	8.49	0.38	3.64e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg02038168	chr22:39784481	NA	0.59	10.77	0.46	4.47e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9503598	0.636	rs6596978	chr6:3468878	C/T	cg00476032	chr6:3446245	SLC22A23	0.31	6.69	0.31	7.01e-11	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg24503407	chr1:205819492	PM20D1	0.78	15.79	0.61	1.68e-44	Menarche (age at onset);
LUAD	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg25173405	chr17:45401733	C17orf57	-0.58	-9.97	-0.44	3.71e-21	Glaucoma (primary open-angle);
LUAD	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg11822812	chr5:140052017	DND1	0.39	6.97	0.32	1.24e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg08222618	chr4:941054	TMEM175	0.78	14.11	0.57	2.5e-37	Sjögren's syndrome;
LUAD	cis	rs11809207	0.903	rs17257148	chr1:26526348	G/C	cg00300879	chr1:26503847	CNKSR1	0.28	6.75	0.31	4.83e-11	Height;
LUAD	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg24154853	chr7:158122151	PTPRN2	0.56	11.17	0.48	1.4e-25	Calcium levels;
LUAD	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg22681709	chr2:178499509	PDE11A	0.4	7.38	0.34	8.48e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg04545296	chr12:48745243	ZNF641	0.39	9.87	0.43	7.92e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs7274811	0.681	rs291707	chr20:31964256	G/A	cg13403462	chr20:32256071	NECAB3;C20orf134	0.47	7.23	0.33	2.3e-12	Height;
LUAD	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg10876282	chr6:28092338	ZSCAN16	0.43	6.4	0.3	4.01e-10	Parkinson's disease;
LUAD	cis	rs7017914	0.967	rs10089583	chr8:71849484	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.42	-0.3	3.7e-10	Bone mineral density;
LUAD	cis	rs4930561	0.765	rs34493482	chr11:67969508	T/C	cg04465784	chr11:67976953	SUV420H1	-0.27	-8.25	-0.37	2.06e-15	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.13	-0.41	2.78e-18	Total body bone mineral density;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22541098	chr19:47747364	NA	-0.44	-7.19	-0.33	2.89e-12	Height;
LUAD	cis	rs4852324	1.000	rs4852324	chr2:74202578	A/G	cg19729930	chr2:74357872	NA	0.54	6.6	0.31	1.22e-10	Systemic lupus erythematosus;
LUAD	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg17757837	chr7:157058334	UBE3C	0.48	8.47	0.38	4.2e-16	Body mass index;
LUAD	cis	rs9914988	0.943	rs3181215	chr17:27077331	C/T	cg07195577	chr17:27052828	TLCD1	-0.43	-6.37	-0.3	5.04e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs870825	0.929	rs72689269	chr4:185592085	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	10.1	0.44	1.21e-21	Blood protein levels;
LUAD	cis	rs1784581	0.588	rs4131681	chr6:162422167	T/G	cg17173639	chr6:162384350	PARK2	0.43	7.73	0.35	8.1e-14	Itch intensity from mosquito bite;
LUAD	cis	rs2034088	0.833	rs4968120	chr17:431364	T/G	cg13332499	chr17:408570	NA	0.44	9.88	0.43	7.4e-21	Hip circumference adjusted for BMI;
LUAD	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.48	-7.75	-0.35	6.82e-14	Alzheimer's disease (late onset);
LUAD	trans	rs2774920	0.614	rs6673184	chr1:94669307	C/T	cg24762501	chr19:51530751	KLK11	-0.7	-6.71	-0.31	6.43e-11	D-dimer levels;
LUAD	cis	rs3784262	0.904	rs3784263	chr15:58253062	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.44	-9.06	-0.4	4.88e-18	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9902453	1.000	rs6505158	chr17:28403348	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-8.87	-0.4	2.01e-17	Coffee consumption (cups per day);
LUAD	cis	rs250677	0.522	rs998304	chr5:148382365	C/A	cg12140854	chr5:148520817	ABLIM3	-0.55	-8.65	-0.39	1.12e-16	Breast cancer;
LUAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg08888203	chr3:10149979	C3orf24	0.72	12.87	0.53	3.25e-32	Alzheimer's disease;
LUAD	cis	rs2985684	0.894	rs7152110	chr14:50018218	T/C	cg04989706	chr14:50066350	PPIL5	-0.5	-7.45	-0.34	5.19e-13	Carotid intima media thickness;
LUAD	cis	rs2275731	0.505	rs7910712	chr10:16479256	T/C	cg04254609	chr10:16479192	PTER	-0.55	-9.21	-0.41	1.58e-18	Bone fracture in osteoporosis;
LUAD	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg08704250	chr15:31115839	NA	0.48	7.37	0.34	9.07e-13	Huntington's disease progression;
LUAD	cis	rs4889855	0.530	rs4889872	chr17:78621306	G/A	cg16591659	chr17:78472290	NA	0.45	7.76	0.35	6.57e-14	Fractional excretion of uric acid;
LUAD	cis	rs4523957	0.928	rs11869805	chr17:2176532	A/G	cg16513277	chr17:2031491	SMG6	-0.77	-14.49	-0.58	6.36e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.87	0.36	3.05e-14	Morning vs. evening chronotype;
LUAD	cis	rs10489202	1.000	rs12407660	chr1:167954363	C/T	cg24449463	chr1:168025552	DCAF6	-0.55	-7.16	-0.33	3.54e-12	Schizophrenia;
LUAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.4	-7.46	-0.34	4.87e-13	Longevity;Endometriosis;
LUAD	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg05991184	chr2:219186017	PNKD	-0.35	-6.64	-0.31	9.49e-11	Colorectal cancer;
LUAD	cis	rs7615952	0.611	rs79405914	chr3:125723623	C/T	cg05084668	chr3:125655381	ALG1L	-0.81	-8.84	-0.39	2.56e-17	Blood pressure (smoking interaction);
LUAD	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg06627628	chr2:24431161	ITSN2	0.43	7.28	0.33	1.63e-12	Asthma;
LUAD	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg00933542	chr6:150070202	PCMT1	0.37	7.37	0.34	8.78e-13	Lung cancer;
LUAD	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-12.09	-0.51	4.22e-29	Mean corpuscular volume;
LUAD	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg17031739	chr1:67600172	NA	0.51	9.01	0.4	7.03e-18	Psoriasis;
LUAD	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg02390115	chr1:21767211	NBPF3	0.42	7.04	0.32	7.76e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs758324	0.947	rs6886188	chr5:131178252	C/T	cg25547332	chr5:131281432	NA	0.43	6.61	0.31	1.19e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg18180107	chr4:99064573	C4orf37	0.42	6.88	0.32	2.19e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.871	rs74539603	chr1:15809601	C/T	cg13390004	chr1:15929781	NA	0.44	6.64	0.31	9.45e-11	Systolic blood pressure;
LUAD	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg03037974	chr15:76606532	NA	0.38	8.48	0.38	3.69e-16	Blood metabolite levels;
LUAD	cis	rs68170813	0.559	rs6946036	chr7:106853659	G/A	cg02696742	chr7:106810147	HBP1	-0.78	-10.78	-0.46	4.12e-24	Coronary artery disease;
LUAD	cis	rs72949976	0.864	rs62186566	chr2:214024421	G/A	cg08319019	chr2:214017104	IKZF2	-0.55	-8.32	-0.37	1.25e-15	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg12311346	chr5:56204834	C5orf35	-0.92	-13.64	-0.55	2.32e-35	Initial pursuit acceleration;
LUAD	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg22532475	chr10:104410764	TRIM8	-0.44	-8.56	-0.38	2.09e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg13902645	chr11:5959945	NA	-0.53	-9.38	-0.41	4.13e-19	DNA methylation (variation);
LUAD	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.83	0.53	4.85e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs494562	0.892	rs7767800	chr6:86124526	G/A	cg21730993	chr6:86159210	NT5E	0.71	7.75	0.35	6.84e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.59	0.42	7.97e-20	Cognitive ability;
LUAD	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg19635926	chr16:89946313	TCF25	0.78	6.88	0.32	2.19e-11	Skin colour saturation;
LUAD	cis	rs9296092	0.538	rs62407565	chr6:33535739	A/G	cg13560919	chr6:33536144	NA	-0.91	-17.25	-0.64	7.22e-51	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-7.06	-0.32	7.05e-12	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9902453	0.791	rs7219163	chr17:28210703	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	10.1	0.44	1.29e-21	Coffee consumption (cups per day);
LUAD	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	11.26	0.48	6.61e-26	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg12993740	chr5:65476531	SFRS12	-0.4	-7.02	-0.32	9.03e-12	Subcortical brain region volumes;
LUAD	trans	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg26043149	chr18:55253948	FECH	0.49	7.88	0.36	2.85e-14	Bone mineral density;
LUAD	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg11301795	chr4:187892539	NA	-0.77	-15.15	-0.59	9.56e-42	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9914544	0.545	rs4924940	chr17:18800092	T/C	cg21372672	chr17:16614065	CCDC144A	-0.36	-6.35	-0.3	5.72e-10	Educational attainment (years of education);
LUAD	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg05110241	chr16:68378359	PRMT7	-0.62	-6.41	-0.3	3.82e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg18196295	chr10:418757	DIP2C	0.49	8.27	0.37	1.81e-15	Psychosis in Alzheimer's disease;
LUAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg22535103	chr8:58192502	C8orf71	-0.79	-8.93	-0.4	1.28e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.61e-18	Life satisfaction;
LUAD	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.12	-25.35	-0.78	6.5e-87	Ulcerative colitis;
LUAD	cis	rs7640424	0.649	rs17233248	chr3:107899513	T/C	cg09227934	chr3:107805635	CD47	-0.48	-8.5	-0.38	3.4e-16	Body mass index;
LUAD	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg18132916	chr6:79620363	NA	-0.44	-7.57	-0.35	2.42e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1232027	0.656	rs1650651	chr5:79965580	T/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.33	-0.34	1.16e-12	Huntington's disease progression;
LUAD	cis	rs7607369	0.536	rs6436090	chr2:219669002	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-10.42	-0.45	8.54e-23	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.27e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10927875	0.619	rs7546589	chr1:16129530	A/G	cg21385522	chr1:16154831	NA	-0.6	-10.79	-0.46	4e-24	Dilated cardiomyopathy;
LUAD	trans	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg03886242	chr7:26192032	NFE2L3	-0.47	-8.33	-0.38	1.17e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg14752069	chr8:11977206	FAM66D	-0.31	-6.76	-0.31	4.48e-11	Neuroticism;
LUAD	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg17724175	chr1:150552817	MCL1	0.39	9.43	0.42	2.64e-19	Tonsillectomy;
LUAD	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	12.91	0.53	2.29e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.36	0.34	9.67e-13	Bipolar disorder;
LUAD	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg12365402	chr11:9010492	NRIP3	0.46	8.66	0.39	1.02e-16	Hemoglobin concentration;
LUAD	cis	rs477692	0.792	rs12762024	chr10:131441055	G/C	cg26102564	chr10:131424627	MGMT	-0.36	-6.79	-0.31	3.83e-11	Response to temozolomide;
LUAD	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg06618935	chr21:46677482	NA	-0.49	-10.03	-0.44	2.21e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs965604	1.000	rs8043227	chr15:78768871	C/G	cg18825076	chr15:78729989	IREB2	-0.42	-7.04	-0.32	7.78e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	trans	rs6076960	0.811	rs6053960	chr20:6176778	T/C	cg17788362	chr6:86352627	SYNCRIP	0.5	8.29	0.37	1.56e-15	Smooth-surface caries;
LUAD	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg26924012	chr15:45694286	SPATA5L1	1.02	18.93	0.68	2.46e-58	Homoarginine levels;
LUAD	cis	rs17401966	1.000	rs12129035	chr1:10291166	G/A	cg15208524	chr1:10270712	KIF1B	0.55	8.28	0.37	1.63e-15	Hepatocellular carcinoma;
LUAD	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.95	-0.36	1.67e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7009516	0.587	rs2291577	chr8:24256470	C/T	cg01759110	chr8:24241694	ADAMDEC1	-0.43	-8.57	-0.38	2.02e-16	Hair greying;
LUAD	cis	rs113835537	0.529	rs4930379	chr11:66255674	G/A	cg24851651	chr11:66362959	CCS	0.56	9.85	0.43	9.57e-21	Airway imaging phenotypes;
LUAD	cis	rs7759001	0.817	rs6913122	chr6:27355292	G/A	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.83e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs953387	1.000	rs1401687	chr2:136908062	G/C	cg05194412	chr2:137003533	NA	-0.44	-7.21	-0.33	2.55e-12	Arthritis (juvenile idiopathic);
LUAD	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg08085267	chr17:45401833	C17orf57	-0.56	-10.02	-0.44	2.34e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12893668	0.667	rs11844466	chr14:104066422	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.52	-8.18	-0.37	3.34e-15	Reticulocyte count;
LUAD	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.53	-7.41	-0.34	6.93e-13	Platelet count;
LUAD	cis	rs9399401	0.626	rs9373347	chr6:142779885	C/T	cg04461802	chr6:142623433	GPR126	0.37	7.18	0.33	3.12e-12	Chronic obstructive pulmonary disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01720705	chr1:231175557	FAM89A	-0.72	-6.89	-0.32	2.04e-11	Type 2 diabetes;
LUAD	trans	rs8002861	0.727	rs9533652	chr13:44419532	A/G	cg12856521	chr11:46389249	DGKZ	-0.48	-8.29	-0.37	1.5e-15	Leprosy;
LUAD	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg27539214	chr16:67997921	SLC12A4	-0.69	-8.82	-0.39	3.01e-17	HDL cholesterol;
LUAD	cis	rs34638657	0.687	rs2303265	chr16:82203705	A/C	cg09439754	chr16:82129088	HSD17B2	-0.34	-6.46	-0.3	2.95e-10	Lung adenocarcinoma;
LUAD	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg03983476	chr2:10830698	NOL10	-0.47	-8.31	-0.37	1.35e-15	Prostate cancer;
LUAD	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg10556349	chr10:835070	NA	0.49	6.76	0.31	4.52e-11	Eosinophil percentage of granulocytes;
LUAD	cis	rs847577	0.550	rs12670686	chr7:97708397	A/G	cg21770322	chr7:97807741	LMTK2	0.31	7.32	0.34	1.24e-12	Breast cancer;
LUAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08219700	chr8:58056026	NA	0.59	8.43	0.38	5.51e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg07153921	chr17:41440717	NA	-0.4	-6.63	-0.31	1.02e-10	Menopause (age at onset);
LUAD	cis	rs7274811	0.711	rs291680	chr20:32022251	A/C	cg03904042	chr20:32255491	NECAB3;C20orf134	0.52	7.71	0.35	9.01e-14	Height;
LUAD	cis	rs2658782	0.756	rs3019205	chr11:93109553	A/G	cg15737290	chr11:93063684	CCDC67	0.48	6.94	0.32	1.5e-11	Pulmonary function decline;
LUAD	cis	rs220324	0.688	rs9976212	chr21:43567270	G/A	cg08841829	chr21:43638893	ABCG1	-0.48	-6.84	-0.32	2.77e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg14668632	chr7:2872130	GNA12	-0.48	-8.39	-0.38	7.11e-16	Height;
LUAD	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg03929089	chr4:120376271	NA	-0.99	-20.65	-0.71	4.76e-66	Height;
LUAD	cis	rs4523957	0.614	rs7212964	chr17:2059319	C/T	cg16513277	chr17:2031491	SMG6	-0.96	-19.02	-0.68	9.6e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg22852734	chr6:133119734	C6orf192	-0.74	-8.77	-0.39	4.53e-17	Type 2 diabetes nephropathy;
LUAD	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg05110241	chr16:68378359	PRMT7	-0.8	-8.78	-0.39	4.06e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg00206168	chr11:65308501	LTBP3	1.26	10.13	0.44	1e-21	Height;
LUAD	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg20503657	chr10:835505	NA	0.66	8.41	0.38	6.16e-16	Eosinophil percentage of granulocytes;
LUAD	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg09835421	chr16:68378352	PRMT7	-0.97	-11.61	-0.49	3.11e-27	Schizophrenia;
LUAD	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg22875332	chr1:76189707	ACADM	0.92	19.13	0.68	3.05e-59	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg18252515	chr7:66147081	NA	0.59	6.66	0.31	8.5e-11	Diabetic kidney disease;
LUAD	trans	rs853679	0.607	rs67040724	chr6:27905509	T/C	cg01620082	chr3:125678407	NA	-1.1	-10.29	-0.45	2.56e-22	Depression;
LUAD	cis	rs9837602	1.000	rs6806178	chr3:99780393	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	9.02	0.4	6.52e-18	Breast cancer;
LUAD	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg07936489	chr17:37558343	FBXL20	-0.45	-7.07	-0.33	6.36e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg17264618	chr3:40429014	ENTPD3	0.38	8.28	0.37	1.65e-15	Renal cell carcinoma;
LUAD	cis	rs4711350	1.000	rs2395447	chr6:33743174	T/C	cg13859433	chr6:33739653	LEMD2	-0.36	-6.89	-0.32	1.97e-11	Schizophrenia;
LUAD	cis	rs977987	0.806	rs12448947	chr16:75462954	G/A	cg03315344	chr16:75512273	CHST6	0.64	13.99	0.56	7.87e-37	Dupuytren's disease;
LUAD	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.91	13.17	0.54	2.05e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7572644	0.699	rs1506537	chr2:28181901	G/C	cg27432699	chr2:27873401	GPN1	-0.41	-6.37	-0.3	5e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUAD	cis	rs4631830	0.900	rs7075009	chr10:51544143	T/G	cg20129853	chr10:51489980	NA	-0.34	-6.54	-0.3	1.77e-10	Prostate-specific antigen levels;
LUAD	cis	rs12545109	0.800	rs1837620	chr8:57399473	C/A	cg07776626	chr8:57350775	NA	-0.61	-8.96	-0.4	1.04e-17	Obesity-related traits;
LUAD	cis	rs61774743	0.681	rs10889959	chr1:41849735	T/C	cg08462924	chr1:41848221	NA	0.47	8.62	0.39	1.39e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg10755058	chr3:40428713	ENTPD3	0.41	8.11	0.37	5.73e-15	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.51	0.34	3.53e-13	Bipolar disorder;
LUAD	cis	rs3125734	0.633	rs4979754	chr10:64048959	G/A	cg09941381	chr10:64027924	RTKN2	-0.3	-7.09	-0.33	5.49e-12	Rheumatoid arthritis;
LUAD	cis	rs6961069	0.868	rs1194177	chr7:80235095	A/G	cg04458919	chr7:80252533	CD36	-0.35	-6.51	-0.3	2.1e-10	Platelet count;
LUAD	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg20119798	chr7:94954144	PON1	-0.48	-6.67	-0.31	8.02e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.58	10.26	0.45	3.29e-22	Brugada syndrome;
LUAD	trans	rs1941687	0.764	rs4799357	chr18:31366442	T/C	cg27147174	chr7:100797783	AP1S1	-0.54	-9.37	-0.41	4.48e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs2274273	0.624	rs7154796	chr14:55771458	T/C	cg04306507	chr14:55594613	LGALS3	0.4	7.79	0.35	5.15e-14	Protein biomarker;
LUAD	cis	rs7192380	1.000	rs7192380	chr16:69704342	T/C	cg26679644	chr16:69762563	NA	0.5	9.66	0.43	4.5e-20	Sjögren's syndrome;
LUAD	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg24112000	chr20:60950667	NA	-0.63	-8.97	-0.4	9.37e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs62238980	0.614	rs79592563	chr22:32425982	T/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.64	-7.84	-0.36	3.61e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	9.21	0.41	1.5e-18	Tonsillectomy;
LUAD	cis	rs6782228	0.606	rs6775270	chr3:128403498	A/G	cg16766828	chr3:128327626	NA	-0.4	-7.64	-0.35	1.43e-13	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg17063962	chr7:91808500	NA	-0.68	-12.07	-0.51	4.93e-29	Breast cancer;
LUAD	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg06064525	chr11:970664	AP2A2	-0.54	-11.04	-0.47	4.6e-25	Alzheimer's disease (late onset);
LUAD	cis	rs1873147	0.569	rs12593573	chr15:63309919	G/A	cg21584241	chr15:63341463	TPM1	0.42	6.36	0.3	5.09e-10	Orofacial clefts;
LUAD	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.31	-7.04	-0.32	7.59e-12	Dupuytren's disease;
LUAD	cis	rs1816752	0.905	rs9581026	chr13:24997926	C/A	cg02811702	chr13:24901961	NA	0.41	7.03	0.32	8.22e-12	Obesity-related traits;
LUAD	cis	rs943466	1.000	rs11754690	chr6:33744157	G/A	cg16010596	chr6:33739607	LEMD2	-0.41	-7.76	-0.35	6.36e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg25767906	chr1:53392781	SCP2	0.42	7.89	0.36	2.53e-14	Monocyte count;
LUAD	cis	rs7084921	0.608	rs11597390	chr10:101861435	A/G	cg19754520	chr10:101825118	CPN1	0.3	6.36	0.3	5.3e-10	Bone mineral density;
LUAD	cis	rs9549328	0.800	rs9549617	chr13:113628070	C/A	cg17524180	chr13:113633600	MCF2L	-0.4	-7.89	-0.36	2.7e-14	Systolic blood pressure;
LUAD	cis	rs17152411	1.000	rs7083336	chr10:126590771	T/C	cg07906193	chr10:126599966	NA	0.53	7.6	0.35	1.95e-13	Height;
LUAD	cis	rs28595532	0.920	rs116668854	chr4:119707642	A/G	cg02775129	chr4:119771670	NA	-0.99	-7.97	-0.36	1.49e-14	Cannabis dependence symptom count;
LUAD	trans	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.71	12.75	0.53	9.87e-32	Mean corpuscular volume;
LUAD	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg18404041	chr3:52824283	ITIH1	0.43	7.82	0.36	4.16e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08677398	chr8:58056175	NA	0.47	6.57	0.3	1.52e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	8.5	0.38	3.29e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg27113419	chr16:58533979	NDRG4	-0.75	-6.72	-0.31	5.76e-11	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08677398	chr8:58056175	NA	0.48	6.81	0.31	3.26e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4601821	0.635	rs12282356	chr11:113208382	A/G	cg14159747	chr11:113255604	NA	0.37	7.02	0.32	9.16e-12	Alcoholic chronic pancreatitis;
LUAD	cis	rs12545109	0.879	rs1513317	chr8:57372966	C/G	cg11919837	chr8:57350735	NA	-0.49	-6.81	-0.31	3.28e-11	Obesity-related traits;
LUAD	cis	rs3812762	0.917	rs905289	chr11:8753552	A/G	cg03980550	chr11:8754370	ST5	0.37	6.57	0.3	1.49e-10	Hypospadias;
LUAD	trans	rs10411161	0.702	rs8113584	chr19:52383874	A/G	cg22319618	chr22:45562946	NUP50	-0.59	-8.24	-0.37	2.13e-15	Breast cancer;
LUAD	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.36	-7.51	-0.34	3.56e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7017914	0.967	rs13254801	chr8:71688984	T/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.46	-0.3	2.82e-10	Bone mineral density;
LUAD	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.25	-0.37	2.06e-15	Total body bone mineral density;
LUAD	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.93	-0.5	1.76e-28	Bipolar disorder;
LUAD	cis	rs89107	0.575	rs11153768	chr6:118988152	A/G	cg21191810	chr6:118973309	C6orf204	-0.37	-6.71	-0.31	6.28e-11	Cardiac structure and function;
LUAD	trans	rs17685	0.767	rs10954732	chr7:75611149	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.92	-19.77	-0.69	4.16e-62	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg00277334	chr10:82204260	NA	-0.96	-22.17	-0.73	8.33e-73	Post bronchodilator FEV1;
LUAD	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg23840854	chr1:161414152	NA	-0.83	-10.84	-0.47	2.52e-24	Rheumatoid arthritis;
LUAD	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.58	-0.52	4.8e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.8	-0.31	3.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg04218760	chr10:45406644	TMEM72	-0.28	-6.99	-0.32	1.09e-11	Mean corpuscular volume;
LUAD	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.48	-8.13	-0.37	4.78e-15	Multiple sclerosis;
LUAD	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg02527881	chr3:46936655	PTH1R	-0.45	-8.6	-0.39	1.62e-16	Colorectal cancer;
LUAD	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-6.86	-0.32	2.46e-11	Total body bone mineral density;
LUAD	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg08742575	chr21:47604166	C21orf56	0.43	7.2	0.33	2.77e-12	Testicular germ cell tumor;
LUAD	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg16797656	chr11:68205561	LRP5	0.47	8.93	0.4	1.36e-17	Total body bone mineral density;
LUAD	cis	rs34311866	0.577	rs11736181	chr4:877412	C/T	cg07828340	chr4:882639	GAK	0.59	6.87	0.32	2.36e-11	Parkinson's disease;
LUAD	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg04727924	chr7:799746	HEATR2	-0.56	-6.93	-0.32	1.6e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs889398	0.874	rs2917677	chr16:69750849	C/T	cg26679644	chr16:69762563	NA	-0.37	-6.64	-0.31	9.38e-11	Body mass index;
LUAD	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg07636037	chr3:49044803	WDR6	0.56	8.67	0.39	9.52e-17	Menarche (age at onset);
LUAD	cis	rs151234	0.800	rs231974	chr16:28540322	A/T	cg04609801	chr16:28609176	SULT1A2	0.56	7.45	0.34	5.42e-13	Platelet distribution width;
LUAD	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg18944383	chr4:111397179	ENPEP	0.41	8.19	0.37	3.15e-15	Height;
LUAD	cis	rs7107174	0.901	rs2912	chr11:77926292	G/A	cg02023728	chr11:77925099	USP35	0.53	8.07	0.37	7.43e-15	Testicular germ cell tumor;
LUAD	cis	rs4321325	0.733	rs111245735	chr2:127942522	A/C	cg11380483	chr2:127933992	NA	0.5	6.44	0.3	3.25e-10	Protein C levels;
LUAD	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg02038168	chr22:39784481	NA	-0.49	-7.23	-0.33	2.34e-12	IgG glycosylation;
LUAD	cis	rs9616064	0.889	rs7284276	chr22:46996137	G/C	cg05621596	chr22:47072043	GRAMD4	-0.57	-9.12	-0.41	3.13e-18	Urate levels in obese individuals;
LUAD	cis	rs1975974	0.872	rs17052344	chr17:21717543	A/G	cg18423549	chr17:21743878	NA	0.75	13.3	0.54	5.58e-34	Psoriasis;
LUAD	cis	rs870825	0.616	rs10428373	chr4:185639002	A/T	cg04058563	chr4:185651563	MLF1IP	0.88	14.12	0.57	2.26e-37	Blood protein levels;
LUAD	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg10556349	chr10:835070	NA	0.58	7.13	0.33	4.28e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4650994	0.593	rs12735140	chr1:178544218	C/A	cg05059571	chr16:84539110	KIAA1609	0.44	6.72	0.31	5.74e-11	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs9287719	0.601	rs1861299	chr2:10763757	C/G	cg02196655	chr2:10830764	NOL10	-0.38	-6.54	-0.3	1.76e-10	Prostate cancer;
LUAD	cis	rs13082711	0.522	rs586229	chr3:27354520	A/G	cg02860705	chr3:27208620	NA	0.5	8.42	0.38	5.7e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs68170813	0.523	rs79607134	chr7:107033619	A/T	cg23024343	chr7:107201750	COG5	0.47	6.77	0.31	4.26e-11	Coronary artery disease;
LUAD	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs806794	0.727	rs9358913	chr6:26239404	A/G	cg13736514	chr6:26305472	NA	-0.47	-6.99	-0.32	1.09e-11	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUAD	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg15208524	chr1:10270712	KIF1B	0.46	7.2	0.33	2.8e-12	Hepatocellular carcinoma;
LUAD	cis	rs7107174	1.000	rs72931690	chr11:78073192	G/A	cg02023728	chr11:77925099	USP35	0.46	7.33	0.34	1.2e-12	Testicular germ cell tumor;
LUAD	cis	rs10089	0.953	rs1432615	chr5:127395371	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	10.09	0.44	1.35e-21	Ileal carcinoids;
LUAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.5	6.67	0.31	8.22e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.84	-0.32	2.76e-11	Personality dimensions;
LUAD	cis	rs4148087	1.000	rs9984673	chr21:43615709	T/C	cg08841829	chr21:43638893	ABCG1	-0.58	-7.53	-0.34	3.03e-13	Eating disorder in bipolar disorder;
LUAD	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg14228332	chr4:119757509	SEC24D	0.87	8.17	0.37	3.71e-15	Cannabis dependence symptom count;
LUAD	cis	rs12765878	0.967	rs34887477	chr10:105643436	C/T	cg11005552	chr10:105648138	OBFC1	0.44	8.26	0.37	1.91e-15	Coronary artery disease;
LUAD	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg04450456	chr4:17643702	FAM184B	-0.42	-8.42	-0.38	6.05e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.19	-0.41	1.81e-18	Bipolar disorder;
LUAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg24101359	chr6:42928495	GNMT	0.52	9.95	0.44	4.1e-21	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs593982	0.920	rs1108922	chr11:65423930	C/T	cg08755490	chr11:65554678	OVOL1	-1.23	-12.37	-0.52	3.29e-30	Atopic dermatitis;
LUAD	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs68170813	0.652	rs763386	chr7:107196723	T/C	cg02696742	chr7:106810147	HBP1	-0.76	-8.96	-0.4	1.05e-17	Coronary artery disease;
LUAD	cis	rs868036	1.000	rs3784719	chr15:68098180	C/T	cg08079166	chr15:68083412	MAP2K5	0.3	6.43	0.3	3.36e-10	Restless legs syndrome;
LUAD	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg05434287	chr7:2030229	MAD1L1	0.39	6.45	0.3	3.07e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs10193935	0.792	rs6735571	chr2:42491951	C/T	cg27598129	chr2:42591480	NA	-0.62	-8.26	-0.37	1.89e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.559	rs77671232	chr7:106939202	A/G	cg23024343	chr7:107201750	COG5	0.44	6.6	0.31	1.25e-10	Coronary artery disease;
LUAD	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-7.79	-0.35	5.12e-14	Total cholesterol levels;
LUAD	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg00684032	chr4:1343700	KIAA1530	0.42	6.94	0.32	1.46e-11	Obesity-related traits;
LUAD	cis	rs1232027	0.582	rs1677628	chr5:79961781	C/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	trans	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg02030672	chr11:45687055	CHST1	0.37	6.6	0.31	1.26e-10	Obesity-related traits;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21513757	chr7:95951635	SLC25A13	0.41	6.51	0.3	2.08e-10	Gut microbiome composition (summer);
LUAD	cis	rs10097731	0.901	rs9298344	chr8:82043063	C/T	cg25230327	chr8:82042993	NA	-0.66	-11.7	-0.49	1.35e-27	Serum total protein level;
LUAD	trans	rs9951602	0.541	rs7243702	chr18:76645637	G/A	cg02800362	chr5:177631904	HNRNPAB	0.91	14.11	0.57	2.52e-37	Obesity-related traits;
LUAD	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg25535316	chr11:579198	PHRF1	-0.4	-6.54	-0.3	1.77e-10	Systemic lupus erythematosus;
LUAD	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg05182265	chr7:156933206	UBE3C	0.69	13.38	0.55	2.62e-34	Body mass index;
LUAD	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg05340658	chr4:99064831	C4orf37	0.53	8.95	0.4	1.12e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.32	6.68	0.31	7.4e-11	Depression;
LUAD	cis	rs8192282	0.739	rs10908844	chr1:154500857	G/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.46	-7.08	-0.33	6.18e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs12210905	0.764	rs72835248	chr6:26931817	G/A	cg11502198	chr6:26597334	ABT1	-0.81	-6.73	-0.31	5.5e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg10729496	chr3:10149963	C3orf24	0.57	9.51	0.42	1.49e-19	Alzheimer's disease;
LUAD	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg21681030	chr2:46777652	RHOQ	0.41	7.41	0.34	6.73e-13	Height;
LUAD	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg17074396	chr22:49843754	NA	-0.31	-6.5	-0.3	2.26e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg14668632	chr7:2872130	GNA12	-0.68	-12.38	-0.52	3.06e-30	Height;
LUAD	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg04414720	chr1:150670196	GOLPH3L	0.73	13.62	0.55	2.78e-35	Tonsillectomy;
LUAD	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg18196295	chr10:418757	DIP2C	0.46	7.58	0.35	2.24e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs7647973	0.922	rs56049603	chr3:49585243	C/G	cg07636037	chr3:49044803	WDR6	-0.55	-8.46	-0.38	4.38e-16	Menarche (age at onset);
LUAD	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg11189052	chr15:85197271	WDR73	-0.77	-13.25	-0.54	8.9e-34	P wave terminal force;
LUAD	trans	rs7395662	0.963	rs4882109	chr11:48557685	C/T	cg15704280	chr7:45808275	SEPT13	-0.41	-6.37	-0.3	4.81e-10	HDL cholesterol;
LUAD	cis	rs6594499	0.500	rs12514810	chr5:110455357	T/A	cg17157872	chr5:110408788	TSLP	0.33	6.36	0.3	5.16e-10	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg13180566	chr4:1052158	NA	-0.4	-6.68	-0.31	7.67e-11	Recombination rate (females);
LUAD	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg20628663	chr10:43360327	NA	0.74	11.29	0.48	5.14e-26	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11644478	chr21:40555479	PSMG1	-0.46	-7.36	-0.34	9.49e-13	Cognitive function;
LUAD	trans	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.41	0.42	3.23e-19	Mean corpuscular volume;
LUAD	cis	rs117623576	0.680	rs16932874	chr10:32358438	T/C	cg03047570	chr10:32398778	NA	-0.61	-7.59	-0.35	2.1e-13	Anti-saccade response;
LUAD	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.09	0.37	6.3e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4774899	1.000	rs1430823	chr15:57323279	T/G	cg14026238	chr15:57616123	NA	0.34	6.36	0.3	5.19e-10	Urinary tract infection frequency;
LUAD	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg05805236	chr11:65401703	PCNXL3	-0.52	-8.69	-0.39	8.11e-17	Acne (severe);
LUAD	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01570182	chr17:44337453	NA	-0.94	-13.87	-0.56	2.62e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	9.77	0.43	1.83e-20	Ileal carcinoids;
LUAD	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg03474202	chr17:45855739	NA	-0.37	-8.71	-0.39	7.04e-17	IgG glycosylation;
LUAD	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.02	-0.36	1.08e-14	Diabetic kidney disease;
LUAD	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg00277334	chr10:82204260	NA	-0.53	-8.54	-0.38	2.49e-16	Post bronchodilator FEV1;
LUAD	trans	rs11088226	0.681	rs2833912	chr21:33949822	G/A	cg09050820	chr6:167586206	TCP10L2	0.94	13.94	0.56	1.25e-36	Gastritis;
LUAD	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg14582100	chr15:45693742	SPATA5L1	0.64	12.56	0.52	5.49e-31	Homoarginine levels;
LUAD	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.6	11.2	0.48	1.1e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2050392	0.630	rs303427	chr10:30739780	G/A	cg18806716	chr10:30721971	MAP3K8	-0.56	-10.66	-0.46	1.14e-23	Inflammatory bowel disease;
LUAD	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg13319975	chr6:146136371	FBXO30	0.68	11.96	0.5	1.32e-28	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.15	0.33	3.9e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7932354	0.528	rs6485739	chr11:47145072	G/A	cg19486271	chr11:47235900	DDB2	-0.41	-6.68	-0.31	7.39e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg02734326	chr4:10020555	SLC2A9	-0.53	-9.08	-0.4	4.15e-18	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs727505	0.821	rs67167896	chr7:124614127	T/C	cg23710748	chr7:124431027	NA	-0.42	-8.41	-0.38	6.41e-16	Lewy body disease;
LUAD	trans	rs629535	0.748	rs58675625	chr8:70034924	T/C	cg21567404	chr3:27674614	NA	1.01	18.57	0.67	9.52e-57	Dupuytren's disease;
LUAD	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg19678392	chr7:94953810	PON1	-0.55	-7.32	-0.34	1.22e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg04414720	chr1:150670196	GOLPH3L	0.67	11.78	0.5	6.79e-28	Melanoma;
LUAD	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	cis	rs7171869	1	rs7171869	chr15:78900909	A/G	cg18825076	chr15:78729989	IREB2	-0.44	-6.4	-0.3	4.19e-10	Post bronchodilator FEV1;
LUAD	cis	rs12079745	0.590	rs12065030	chr1:169258201	A/G	cg09363564	chr1:169337483	NME7;BLZF1	1.1	7.84	0.36	3.73e-14	QT interval;
LUAD	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg03909863	chr11:638404	DRD4	-0.47	-6.51	-0.3	2.1e-10	Systemic lupus erythematosus;
LUAD	cis	rs12618769	0.597	rs12622341	chr2:99074680	A/T	cg10123293	chr2:99228465	UNC50	0.47	8.28	0.37	1.61e-15	Bipolar disorder;
LUAD	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-25.09	-0.77	8.9e-86	Height;
LUAD	cis	rs7937890	0.504	rs2575847	chr11:14471172	C/T	cg06199346	chr11:14280333	SPON1	-0.33	-6.61	-0.31	1.17e-10	Mitochondrial DNA levels;
LUAD	cis	rs36715	1.000	rs181850	chr5:127547487	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	6.86	0.32	2.46e-11	Breast cancer;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg15877295	chr7:138915876	UBN2	0.45	7.13	0.33	4.35e-12	Monocyte percentage of white cells;
LUAD	cis	rs2742417	0.603	rs1962800	chr3:45779943	C/T	cg10512202	chr3:45649293	LIMD1	0.47	8.83	0.39	2.8e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22857025	chr5:266934	NA	-0.97	-14.47	-0.58	7.55e-39	Breast cancer;
LUAD	trans	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg01620082	chr3:125678407	NA	-0.62	-7.83	-0.36	3.92e-14	Lung cancer in ever smokers;
LUAD	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg05425664	chr17:57184151	TRIM37	0.39	6.72	0.31	5.97e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7937890	0.532	rs2575833	chr11:14492505	A/C	cg22961513	chr11:14280813	SPON1	-0.37	-7.22	-0.33	2.45e-12	Mitochondrial DNA levels;
LUAD	cis	rs17155006	0.664	rs410866	chr7:107744543	C/T	cg05962710	chr7:107745446	LAMB4	0.35	7.3	0.33	1.46e-12	Pneumococcal bacteremia;
LUAD	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg18132916	chr6:79620363	NA	-0.44	-7.67	-0.35	1.16e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.17	-0.33	3.3e-12	Blood metabolite levels;
LUAD	cis	rs986417	0.901	rs8020867	chr14:61093246	A/T	cg27398547	chr14:60952738	C14orf39	0.56	6.48	0.3	2.55e-10	Gut microbiota (bacterial taxa);
LUAD	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg27068330	chr11:65405492	SIPA1	0.57	9.02	0.4	6.48e-18	Acne (severe);
LUAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg02869364	chr7:1081709	C7orf50	-0.51	-6.55	-0.3	1.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2075165	0.901	rs2274226	chr1:156314627	C/T	cg20302342	chr1:156215951	PAQR6	-0.39	-8.72	-0.39	6.39e-17	Tonsillectomy;
LUAD	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg08742575	chr21:47604166	C21orf56	0.42	6.56	0.3	1.56e-10	Testicular germ cell tumor;
LUAD	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg26343298	chr8:95960752	TP53INP1	0.38	8.02	0.36	1.08e-14	Type 2 diabetes;
LUAD	cis	rs3806843	0.520	rs246051	chr5:140326464	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg09650180	chr20:62225654	GMEB2	-0.46	-6.69	-0.31	7.03e-11	Glioblastoma;
LUAD	cis	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg07460842	chr6:66804631	NA	-0.65	-9.41	-0.42	3.24e-19	Blood trace element (Cu levels);
LUAD	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg14829155	chr15:31115871	NA	-0.58	-9.61	-0.42	6.72e-20	Huntington's disease progression;
LUAD	cis	rs1595825	0.891	rs57340905	chr2:198565823	C/T	cg11031976	chr2:198649780	BOLL	-0.46	-6.79	-0.31	3.81e-11	Ulcerative colitis;
LUAD	trans	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg06606381	chr12:133084897	FBRSL1	-0.64	-6.82	-0.31	3.11e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1957429	0.731	rs28370916	chr14:65346094	A/G	cg23373153	chr14:65346875	NA	0.56	6.42	0.3	3.57e-10	Pediatric areal bone mineral density (radius);
LUAD	trans	rs9393777	0.777	rs56114371	chr6:27274834	C/T	cg01620082	chr3:125678407	NA	-0.99	-9.58	-0.42	8.59e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2795502	0.630	rs3004257	chr10:43480529	C/T	cg08461752	chr10:43522343	NA	-0.82	-9.32	-0.41	6.33e-19	Blood protein levels;
LUAD	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg18132916	chr6:79620363	NA	-0.46	-7.79	-0.35	5.37e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9513627	0.748	rs61525545	chr13:100118261	T/C	cg25919922	chr13:100150906	NA	-0.63	-6.57	-0.3	1.46e-10	Obesity-related traits;
LUAD	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg02493740	chr2:85810744	VAMP5	-0.65	-11.92	-0.5	1.86e-28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs7107174	0.892	rs4945273	chr11:78096977	T/C	cg02023728	chr11:77925099	USP35	0.47	7.26	0.33	1.86e-12	Testicular germ cell tumor;
LUAD	trans	rs1997103	1.000	rs6957984	chr7:55397331	G/A	cg20935933	chr6:143382018	AIG1	0.53	7.46	0.34	4.94e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6672530	0.518	rs4653850	chr1:227737888	C/T	cg12133451	chr1:227746453	NA	0.37	6.82	0.31	3.08e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs7301016	0.947	rs10877862	chr12:62888647	T/C	cg11441379	chr12:63026424	NA	0.53	6.52	0.3	1.97e-10	IgG glycosylation;
LUAD	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg08847533	chr14:75593920	NEK9	0.42	7.18	0.33	3.14e-12	Height;
LUAD	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.33	-0.51	4.83e-30	Hip circumference adjusted for BMI;
LUAD	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.58	-0.3	1.41e-10	Height;
LUAD	cis	rs9811920	0.683	rs793439	chr3:99637783	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.51	9.87	0.43	8.45e-21	Axial length;
LUAD	cis	rs3849570	0.695	rs1851930	chr3:81895318	T/G	cg07356753	chr3:81810745	GBE1	-0.55	-8.83	-0.39	2.85e-17	Waist circumference;Body mass index;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg08024766	chr17:76777877	CYTH1	0.36	6.35	0.3	5.64e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12667521	chr19:29218732	NA	0.6	8.49	0.38	3.42e-16	Methadone dose in opioid dependence;
LUAD	cis	rs77972916	0.609	rs72790903	chr2:43561985	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-6.89	-0.32	2.08e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs367615	0.550	rs10060801	chr5:108881782	A/G	cg17395555	chr5:108820864	NA	0.43	9.16	0.41	2.31e-18	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.46	0.3	2.89e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs4372836	1.000	rs4372836	chr2:28973883	T/C	cg09522027	chr2:28974177	PPP1CB	-0.62	-10.01	-0.44	2.57e-21	Body mass index;
LUAD	cis	rs1448094	0.842	rs12318815	chr12:86452281	T/C	cg06740227	chr12:86229804	RASSF9	-0.36	-6.59	-0.31	1.28e-10	Major depressive disorder;
LUAD	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg22875332	chr1:76189707	ACADM	0.73	11.2	0.48	1.08e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs17092148	1.000	rs6060043	chr20:33364584	C/T	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.19	-0.37	3.09e-15	Neuroticism;
LUAD	cis	rs7943203	1.000	rs11212638	chr11:108312080	T/C	cg04873221	chr11:107992290	ACAT1	-0.43	-6.99	-0.32	1.07e-11	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg00933542	chr6:150070202	PCMT1	0.45	9.5	0.42	1.56e-19	Lung cancer;
LUAD	cis	rs6496044	0.568	rs11855789	chr15:86066403	G/A	cg13263323	chr15:86062960	AKAP13	-0.58	-10.9	-0.47	1.55e-24	Interstitial lung disease;
LUAD	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg14530993	chr4:882597	GAK	0.75	7.12	0.33	4.66e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg11057378	chr10:81107060	PPIF	0.4	7.39	0.34	8.02e-13	Height;
LUAD	cis	rs8028313	0.731	rs4776964	chr15:68016955	T/G	cg24579218	chr15:68104479	NA	-0.49	-8.26	-0.37	1.86e-15	Obesity;
LUAD	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23583168	chr7:148888333	NA	-0.9	-18.04	-0.66	2.28e-54	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.32	-6.57	-0.3	1.45e-10	Hemoglobin concentration;
LUAD	trans	rs6426551	0.958	rs6702917	chr1:226547174	C/T	cg27539482	chr13:111589090	NA	-0.5	-7.32	-0.34	1.27e-12	Coronary artery disease;
LUAD	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg12615879	chr12:58013172	SLC26A10	0.52	10.95	0.47	9.98e-25	Multiple sclerosis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03700121	chr11:60610004	CCDC86	-0.55	-6.89	-0.32	2.06e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg26769984	chr7:1090371	C7orf50	0.67	10.38	0.45	1.19e-22	Bronchopulmonary dysplasia;
LUAD	cis	rs9837602	1.000	rs17379739	chr3:99724792	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-7.71	-0.35	9.27e-14	Breast cancer;
LUAD	cis	rs999737	0.821	rs12889251	chr14:68994140	C/G	cg04147497	chr14:69052728	RAD51L1	-0.49	-7.46	-0.34	5.03e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs11168351	0.517	rs10875754	chr12:48557922	G/C	cg24011408	chr12:48396354	COL2A1	0.39	8.53	0.38	2.71e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs12681287	0.640	rs7846090	chr8:87467724	A/T	cg27223183	chr8:87520930	FAM82B	-0.68	-9.6	-0.42	7.24e-20	Caudate activity during reward;
LUAD	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg18827107	chr12:86230957	RASSF9	-0.71	-13.05	-0.54	6.13e-33	Major depressive disorder;
LUAD	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg00495681	chr13:53174319	NA	0.72	14.58	0.58	2.58e-39	Lewy body disease;
LUAD	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.11	-24.32	-0.76	2.23e-82	Ulcerative colitis;
LUAD	cis	rs2235649	0.585	rs238679	chr16:1872479	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.5	7.31	0.34	1.31e-12	Blood metabolite levels;
LUAD	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg11578532	chr1:161008127	TSTD1	0.4	8.71	0.39	7.04e-17	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.07	-27.41	-0.8	7.69e-96	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg01689657	chr7:91764605	CYP51A1	0.39	9.38	0.42	4.02e-19	Breast cancer;
LUAD	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.02	0.36	1.03e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg06766960	chr11:133703094	NA	-0.46	-8.8	-0.39	3.65e-17	Childhood ear infection;
LUAD	cis	rs7107174	0.748	rs2063730	chr11:78048524	A/C	cg02023728	chr11:77925099	USP35	0.45	7.13	0.33	4.46e-12	Testicular germ cell tumor;
LUAD	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg07936489	chr17:37558343	FBXL20	-0.47	-7.5	-0.34	3.91e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg08859206	chr1:53392774	SCP2	-0.6	-10.66	-0.46	1.19e-23	Monocyte count;
LUAD	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.94	-0.4	1.26e-17	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.36	-18.49	-0.67	2.21e-56	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg12863693	chr15:85201151	NMB	0.45	8.17	0.37	3.65e-15	Schizophrenia;
LUAD	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23158103	chr7:148848205	ZNF398	0.64	12.29	0.51	6.65e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg26168469	chr14:96505617	C14orf132	-0.38	-6.36	-0.3	5.1e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-8.04	-0.36	8.99e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs332507	0.830	rs4678144	chr3:124404399	C/T	cg05980111	chr3:124395277	KALRN	-0.43	-6.93	-0.32	1.57e-11	Plateletcrit;
LUAD	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.02	0.32	8.8e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg01299579	chr2:10830716	NOL10	-0.42	-7.38	-0.34	8.52e-13	Prostate cancer;
LUAD	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg05872129	chr22:39784769	NA	-0.79	-14.71	-0.58	7.22e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg00071950	chr4:10020882	SLC2A9	0.47	6.67	0.31	8.24e-11	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg05340658	chr4:99064831	C4orf37	-0.44	-7.33	-0.34	1.14e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05776053	chr2:74358815	NA	0.44	6.84	0.32	2.8e-11	Gestational age at birth (maternal effect);
LUAD	trans	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg04995722	chr7:26192034	NFE2L3	0.38	6.62	0.31	1.1e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2882667	0.898	rs6882583	chr5:138385796	C/T	cg04439458	chr5:138467593	SIL1	-0.39	-7.08	-0.33	6.09e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs117623576	0.941	rs7098334	chr10:32418501	G/T	cg03047570	chr10:32398778	NA	-0.82	-10.76	-0.46	4.84e-24	Anti-saccade response;
LUAD	cis	rs72634258	0.945	rs7522911	chr1:8097145	C/T	cg26816564	chr1:7831052	VAMP3	0.52	6.51	0.3	2.11e-10	Inflammatory bowel disease;
LUAD	cis	rs870825	0.860	rs2705899	chr4:185596219	A/G	cg04058563	chr4:185651563	MLF1IP	0.8	10.79	0.46	3.94e-24	Blood protein levels;
LUAD	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg00852783	chr1:26633632	UBXN11	0.41	7.11	0.33	5e-12	Obesity-related traits;
LUAD	trans	rs1864729	1.000	rs2635161	chr8:98282907	A/C	cg08679828	chr8:102218111	ZNF706	0.78	8.53	0.38	2.61e-16	Estradiol plasma levels (breast cancer);
LUAD	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg05304507	chr6:116381966	FRK	-0.2	-6.75	-0.31	4.97e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08280861	chr8:58055591	NA	0.63	8.3	0.37	1.42e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg15128208	chr22:42549153	NA	-0.43	-8.77	-0.39	4.3e-17	Cognitive function;
LUAD	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.32	0.34	1.24e-12	Tonsillectomy;
LUAD	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg25237894	chr2:233734115	C2orf82	0.61	11.45	0.49	1.31e-26	Coronary artery disease;
LUAD	trans	rs11039798	0.588	rs643668	chr11:48413399	C/G	cg15704280	chr7:45808275	SEPT13	-0.58	-7.79	-0.35	5.12e-14	Axial length;
LUAD	cis	rs7759001	0.857	rs10080555	chr6:27362866	C/T	cg18711553	chr6:27366782	ZNF391	0.39	6.54	0.3	1.81e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg15448220	chr1:150897856	SETDB1	0.48	8.16	0.37	3.79e-15	Tonsillectomy;
LUAD	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg05714579	chr10:131428358	MGMT	-0.39	-6.46	-0.3	2.94e-10	Response to temozolomide;
LUAD	cis	rs9581857	0.547	rs17753763	chr13:28077734	A/G	cg22138327	chr13:27999177	GTF3A	0.89	9.27	0.41	9.26e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	7.3	0.33	1.45e-12	Menarche (age at onset);
LUAD	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg03037974	chr15:76606532	NA	0.34	7.05	0.32	7.17e-12	Blood metabolite levels;
LUAD	trans	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg18187862	chr3:45730750	SACM1L	0.5	7.89	0.36	2.55e-14	Primary sclerosing cholangitis;
LUAD	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg22166914	chr1:53195759	ZYG11B	0.45	7.63	0.35	1.6e-13	Monocyte count;
LUAD	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg07404485	chr7:94953653	PON1	-0.48	-7.24	-0.33	2.15e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg10560079	chr2:191398806	TMEM194B	0.44	7.9	0.36	2.45e-14	Pulse pressure;
LUAD	cis	rs36051895	0.659	rs62541540	chr9:5040080	A/G	cg02405213	chr9:5042618	JAK2	-0.52	-7.32	-0.34	1.3e-12	Pediatric autoimmune diseases;
LUAD	cis	rs1950626	0.623	rs34603287	chr14:101433831	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.37	7.44	0.34	5.54e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg18132916	chr6:79620363	NA	-0.46	-8.08	-0.37	6.94e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs778371	0.723	rs10210953	chr2:233698830	G/A	cg08000102	chr2:233561755	GIGYF2	-0.4	-6.73	-0.31	5.56e-11	Schizophrenia;
LUAD	trans	rs75804782	0.641	rs41264155	chr2:239342096	G/A	cg01134436	chr17:81009848	B3GNTL1	0.8	8.37	0.38	8.44e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg00310523	chr12:86230176	RASSF9	0.41	8.01	0.36	1.16e-14	Major depressive disorder;
LUAD	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg01802117	chr1:53393560	SCP2	-0.37	-7.18	-0.33	3.06e-12	Monocyte count;
LUAD	trans	rs4650994	0.525	rs4076563	chr1:178516901	C/T	cg05059571	chr16:84539110	KIAA1609	-0.73	-13.07	-0.54	5.19e-33	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg09455208	chr3:40491958	NA	0.65	14.12	0.57	2.36e-37	Renal cell carcinoma;
LUAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg03188948	chr7:1209495	NA	0.81	9.85	0.43	9.21e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs11039798	0.920	rs7478904	chr11:48630323	C/T	cg03929089	chr4:120376271	NA	0.64	6.35	0.3	5.6e-10	Axial length;
LUAD	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg20587970	chr11:113659929	NA	-1.29	-18.36	-0.67	8.95e-56	Hip circumference adjusted for BMI;
LUAD	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg08470875	chr2:26401718	FAM59B	0.74	9.53	0.42	1.26e-19	Gut microbiome composition (summer);
LUAD	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg21214613	chr1:16344536	HSPB7	0.5	8.69	0.39	7.88e-17	Dilated cardiomyopathy;
LUAD	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.55	-10.25	-0.45	3.53e-22	Axial length;
LUAD	cis	rs4730250	0.595	rs7789500	chr7:106915723	A/C	cg02696742	chr7:106810147	HBP1	-0.68	-8.83	-0.39	2.78e-17	Osteoarthritis;
LUAD	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg07578070	chr6:150326732	RAET1K	0.38	6.6	0.31	1.27e-10	Alopecia areata;
LUAD	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg06636551	chr8:101224915	SPAG1	-0.39	-7.08	-0.33	5.97e-12	Atrioventricular conduction;
LUAD	cis	rs790123	1.000	rs790116	chr3:122380923	G/C	cg22896480	chr3:122379438	NA	0.4	6.68	0.31	7.4e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg07266350	chr3:49460521	AMT;NICN1	-0.36	-6.42	-0.3	3.77e-10	Menarche (age at onset);
LUAD	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.75	-0.35	6.89e-14	Monocyte percentage of white cells;
LUAD	cis	rs240764	0.658	rs10223467	chr6:101207589	A/G	cg09795085	chr6:101329169	ASCC3	-0.42	-7.38	-0.34	8.74e-13	Neuroticism;
LUAD	trans	rs7246760	1.000	rs59771283	chr19:9854958	G/A	cg02900749	chr2:68251473	NA	-0.67	-7.11	-0.33	5.01e-12	Pursuit maintenance gain;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg02777535	chr7:152161078	LOC100128822	-0.71	-6.89	-0.32	1.98e-11	Type 2 diabetes;
LUAD	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg21475434	chr5:93447410	FAM172A	0.73	8.33	0.38	1.15e-15	Diabetic retinopathy;
LUAD	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg18512352	chr11:47633146	NA	-0.54	-9.57	-0.42	8.83e-20	Subjective well-being;
LUAD	cis	rs2625529	0.712	rs2054601	chr15:72184968	T/C	cg16672083	chr15:72433130	SENP8	-0.75	-12.64	-0.52	2.67e-31	Red blood cell count;
LUAD	cis	rs925255	0.776	rs2279990	chr2:28636740	C/T	cg01273330	chr2:28605224	NA	-0.32	-6.55	-0.3	1.68e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6430585	0.527	rs6753232	chr2:136436317	C/T	cg07169764	chr2:136633963	MCM6	-0.57	-6.76	-0.31	4.47e-11	Corneal structure;
LUAD	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-9.8	-0.43	1.43e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1267303	0.636	rs1267310	chr1:46987307	A/T	cg16387850	chr1:46982889	NA	0.47	7.93	0.36	1.95e-14	Monobrow;
LUAD	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg24558204	chr6:135376177	HBS1L	0.46	8.49	0.38	3.51e-16	Red blood cell count;
LUAD	cis	rs1003719	0.715	rs13046581	chr21:38551985	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.42	-0.38	5.76e-16	Eye color traits;
LUAD	cis	rs6543140	0.964	rs918000	chr2:103067862	C/T	cg04239558	chr2:103089729	SLC9A4	0.36	7.33	0.34	1.15e-12	Blood protein levels;
LUAD	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg01299579	chr2:10830716	NOL10	-0.42	-7.42	-0.34	6.34e-13	Prostate cancer;
LUAD	cis	rs9811920	0.809	rs1387647	chr3:99826942	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.57	10.7	0.46	7.99e-24	Axial length;
LUAD	cis	rs2067615	0.560	rs10861671	chr12:107220927	T/C	cg15890332	chr12:107067104	RFX4	0.41	8.86	0.4	2.17e-17	Heart rate;
LUAD	cis	rs3806843	0.576	rs155361	chr5:140307284	G/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.4	-0.3	4.18e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg09581197	chr16:75406896	CFDP1	0.41	6.35	0.3	5.42e-10	Menopause (age at onset);
LUAD	cis	rs9837602	1.000	rs6790877	chr3:99779658	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	9.22	0.41	1.42e-18	Breast cancer;
LUAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg26818010	chr10:134567672	INPP5A	-0.96	-15.78	-0.61	1.83e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	trans	rs1997103	1.000	rs6973450	chr7:55396537	A/G	cg20935933	chr6:143382018	AIG1	0.53	7.46	0.34	4.94e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg02683114	chr2:24398427	C2orf84	-0.52	-7.75	-0.35	7.02e-14	Asthma;
LUAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.32e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.69	-0.31	7.25e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2554380	0.628	rs4843156	chr15:84457345	G/T	cg14598478	chr15:84363061	ADAMTSL3	-0.4	-7.19	-0.33	3.05e-12	Height;
LUAD	cis	rs2274273	0.662	rs60445539	chr14:55624245	C/T	cg04306507	chr14:55594613	LGALS3	0.42	7.66	0.35	1.26e-13	Protein biomarker;
LUAD	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03934478	chr11:495069	RNH1	0.73	8.85	0.4	2.38e-17	Body mass index;
LUAD	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg05776053	chr2:74358815	NA	0.45	6.61	0.31	1.17e-10	Gestational age at birth (maternal effect);
LUAD	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg03037974	chr15:76606532	NA	0.4	8.84	0.39	2.62e-17	Blood metabolite levels;
LUAD	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg11494091	chr17:61959527	GH2	0.45	8.55	0.38	2.27e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg17633681	chr16:88106987	BANP	0.42	7.18	0.33	3.21e-12	Menopause (age at onset);
LUAD	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg00255919	chr5:131827918	IRF1	0.49	11.85	0.5	3.74e-28	Asthma (sex interaction);
LUAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02353165	chr6:42928485	GNMT	0.39	7.07	0.32	6.59e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6604026	0.656	rs9651257	chr1:93385136	A/G	cg17283838	chr1:93427260	FAM69A	0.42	6.38	0.3	4.74e-10	Multiple sclerosis;
LUAD	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.13	-0.33	4.26e-12	Breast cancer;
LUAD	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg01475377	chr6:109611718	NA	-0.54	-10.22	-0.45	4.59e-22	Reticulocyte fraction of red cells;
LUAD	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg03929089	chr4:120376271	NA	-0.98	-20.96	-0.71	1.99e-67	Height;
LUAD	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg09654669	chr8:57350985	NA	-0.66	-10.03	-0.44	2.29e-21	Obesity-related traits;
LUAD	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg15445000	chr17:37608096	MED1	-0.44	-7.98	-0.36	1.35e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg20607287	chr7:12443886	VWDE	-0.55	-7.21	-0.33	2.53e-12	Coronary artery disease;
LUAD	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg14186256	chr22:23484241	RTDR1	0.46	7.99	0.36	1.28e-14	Bone mineral density;
LUAD	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg00495681	chr13:53174319	NA	0.59	10.87	0.47	1.88e-24	Lewy body disease;
LUAD	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg25358565	chr5:93447407	FAM172A	0.62	7.26	0.33	1.91e-12	Diabetic retinopathy;
LUAD	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg11266682	chr4:10021025	SLC2A9	0.58	12.34	0.51	4.47e-30	Bone mineral density;
LUAD	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg08847533	chr14:75593920	NEK9	0.42	7.15	0.33	3.76e-12	Height;
LUAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg20607798	chr8:58055168	NA	0.58	7.41	0.34	6.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg04944784	chr2:26401820	FAM59B	0.85	12.7	0.53	1.55e-31	Gut microbiome composition (summer);
LUAD	cis	rs654384	0.864	rs651245	chr7:4167336	C/T	cg26275264	chr7:4183598	SDK1	0.4	7.69	0.35	1.07e-13	Positive affect;
LUAD	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.13	0.37	4.68e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6545883	0.929	rs13413337	chr2:61747123	A/G	cg15711740	chr2:61764176	XPO1	-0.41	-6.74	-0.31	5.16e-11	Tuberculosis;
LUAD	cis	rs4481887	0.893	rs28579823	chr1:248506881	C/T	cg00666640	chr1:248458726	OR2T12	0.28	7.05	0.32	7.15e-12	Common traits (Other);
LUAD	trans	rs7246760	0.737	rs73501268	chr19:9803081	G/A	cg02900749	chr2:68251473	NA	-0.59	-6.51	-0.3	2.07e-10	Pursuit maintenance gain;
LUAD	cis	rs8044868	0.566	rs3812984	chr16:72207797	C/T	cg23815491	chr16:72088622	HP	0.46	8.52	0.38	2.8e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg15395560	chr15:45543142	SLC28A2	0.37	6.36	0.3	5.22e-10	Uric acid levels;
LUAD	trans	rs853679	0.607	rs35345226	chr6:28091580	A/G	cg01620082	chr3:125678407	NA	-1.09	-10.25	-0.45	3.5e-22	Depression;
LUAD	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.79	-10.36	-0.45	1.41e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg05865280	chr17:75406074	SEPT9	0.51	8.76	0.39	4.69e-17	Airflow obstruction;
LUAD	cis	rs7187994	0.848	rs62050862	chr16:84781949	G/A	cg07647771	chr16:84786436	USP10	-0.38	-9.64	-0.42	5.19e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.38	0.34	8.64e-13	Menopause (age at onset);
LUAD	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg22868518	chr11:507468	RNH1	-0.67	-6.67	-0.31	8.18e-11	Body mass index;
LUAD	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg08280861	chr8:58055591	NA	0.55	7.6	0.35	1.86e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-9.95	-0.44	4.14e-21	Monocyte percentage of white cells;
LUAD	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg06873352	chr17:61820015	STRADA	0.41	7.02	0.32	9.13e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.16	0.37	3.89e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs75920871	0.920	rs61907605	chr11:116820071	T/A	cg04087571	chr11:116723030	SIK3	-0.32	-6.5	-0.3	2.33e-10	Subjective well-being;
LUAD	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg14458575	chr2:238380390	NA	0.65	12.03	0.5	7.33e-29	Prostate cancer;
LUAD	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.83	-0.47	2.69e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.88	0.4	1.97e-17	Menopause (age at onset);
LUAD	cis	rs2625529	0.938	rs4238447	chr15:72131880	C/T	cg16672083	chr15:72433130	SENP8	-0.72	-11.66	-0.49	1.89e-27	Red blood cell count;
LUAD	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg15128208	chr22:42549153	NA	0.37	7.57	0.35	2.41e-13	Cognitive function;
LUAD	cis	rs73206853	0.698	rs59574270	chr12:111112098	A/C	cg12870014	chr12:110450643	ANKRD13A	0.58	6.44	0.3	3.2e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg24818145	chr4:99064322	C4orf37	0.43	7.18	0.33	3.22e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18099408	chr3:52552593	STAB1	-0.51	-9.4	-0.42	3.53e-19	Electroencephalogram traits;
LUAD	cis	rs12620999	0.774	rs13402764	chr2:237951984	C/T	cg23555395	chr2:238036564	NA	-0.48	-7.32	-0.34	1.23e-12	Systemic lupus erythematosus;
LUAD	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-6.97	-0.32	1.19e-11	Alzheimer's disease (late onset);
LUAD	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg25894440	chr7:65020034	NA	-0.67	-7.19	-0.33	2.98e-12	Diabetic kidney disease;
LUAD	cis	rs11048434	0.736	rs34798934	chr12:9108444	C/T	cg13575925	chr12:9217583	LOC144571	0.36	6.78	0.31	3.95e-11	Sjögren's syndrome;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00846248	chr7:86849067	C7orf23	-0.53	-6.48	-0.3	2.56e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg10518543	chr12:38710700	ALG10B	0.42	6.42	0.3	3.68e-10	Bladder cancer;
LUAD	cis	rs11229555	0.645	rs12274866	chr11:58177129	C/T	cg15696309	chr11:58395628	NA	-0.73	-10.21	-0.44	5.12e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs12579753	0.917	rs10129029	chr12:82180324	G/A	cg07988820	chr12:82153109	PPFIA2	-0.45	-7.31	-0.33	1.38e-12	Resting heart rate;
LUAD	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg11062466	chr8:58055876	NA	0.47	6.73	0.31	5.53e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg26958806	chr6:27640298	NA	0.65	6.48	0.3	2.49e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg11062466	chr8:58055876	NA	0.66	8.31	0.37	1.36e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg25358565	chr5:93447407	FAM172A	0.62	7.22	0.33	2.46e-12	Diabetic retinopathy;
LUAD	cis	rs11811982	0.793	rs74688907	chr1:227568238	T/C	cg24860534	chr1:227506868	CDC42BPA	0.66	7.2	0.33	2.8e-12	Optic disc area;
LUAD	cis	rs17789174	0.694	rs62049871	chr16:85090203	C/T	cg27466129	chr16:85060822	KIAA0513	0.31	6.85	0.32	2.66e-11	Dysphagia;
LUAD	trans	rs7944735	0.671	rs1228044	chr11:48011180	A/G	cg03929089	chr4:120376271	NA	0.59	8.03	0.36	9.86e-15	Intraocular pressure;
LUAD	cis	rs10097731	0.908	rs77317991	chr8:82032468	C/T	cg25230327	chr8:82042993	NA	-0.55	-9.44	-0.42	2.47e-19	Serum total protein level;
LUAD	trans	rs9354308	0.966	rs1909533	chr6:66565658	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.5	7.57	0.35	2.34e-13	Metabolite levels;
LUAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12210905	0.688	rs10456051	chr6:27463436	T/C	cg08851530	chr6:28072375	NA	1.03	7.92	0.36	2.19e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg16479474	chr6:28041457	NA	0.37	6.65	0.31	9.33e-11	Cardiac Troponin-T levels;
LUAD	trans	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg01620082	chr3:125678407	NA	-0.58	-7.3	-0.33	1.42e-12	Lung cancer in ever smokers;
LUAD	cis	rs17253792	0.822	rs79022053	chr14:56071721	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg00074818	chr8:8560427	CLDN23	0.68	10.52	0.46	3.85e-23	Obesity-related traits;
LUAD	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg25767906	chr1:53392781	SCP2	0.39	7.48	0.34	4.27e-13	Monocyte count;
LUAD	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg11833968	chr6:79620685	NA	-0.44	-8.26	-0.37	1.88e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg08132940	chr7:1081526	C7orf50	-0.7	-10.03	-0.44	2.25e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12410462	1.000	rs1587158	chr1:227658753	G/A	cg04117972	chr1:227635322	NA	-0.57	-6.42	-0.3	3.77e-10	Major depressive disorder;
LUAD	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg04455712	chr21:45112962	RRP1B	-0.45	-8.91	-0.4	1.49e-17	Mean corpuscular volume;
LUAD	cis	rs735539	0.645	rs1329518	chr13:21203611	C/G	cg27499820	chr13:21296301	IL17D	0.52	8.62	0.39	1.37e-16	Dental caries;
LUAD	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg08085267	chr17:45401833	C17orf57	0.72	13.28	0.54	6.97e-34	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg27532560	chr4:187881888	NA	-0.35	-6.6	-0.31	1.23e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg21963583	chr11:68658836	MRPL21	-0.44	-7.82	-0.36	4.26e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.49	6.89	0.32	2e-11	Cognitive test performance;
LUAD	trans	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg13319975	chr6:146136371	FBXO30	0.59	10.04	0.44	1.99e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg26513180	chr16:89883248	FANCA	0.45	7.22	0.33	2.49e-12	Vitiligo;
LUAD	cis	rs6445967	0.569	rs9862934	chr3:58281676	A/G	cg23715586	chr3:58305044	RPP14	0.39	6.5	0.3	2.29e-10	Platelet count;
LUAD	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg18190219	chr22:46762943	CELSR1	-0.46	-6.84	-0.32	2.82e-11	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg17788362	chr6:86352627	SYNCRIP	0.4	6.4	0.3	4.06e-10	Smooth-surface caries;
LUAD	cis	rs1865721	1.000	rs1865721	chr18:73192446	C/T	cg26385618	chr18:73139727	C18orf62	-0.41	-7.48	-0.34	4.31e-13	Intelligence;
LUAD	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg11301795	chr4:187892539	NA	-0.75	-14.84	-0.59	2.09e-40	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs35123781	0.696	rs10067965	chr5:139071353	T/C	cg10513866	chr5:139070639	NA	0.54	8.79	0.39	3.74e-17	Schizophrenia;
LUAD	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9372498	0.536	rs72952761	chr6:118866758	A/C	cg07617317	chr6:118971624	C6orf204	0.56	8.68	0.39	8.5e-17	Diastolic blood pressure;
LUAD	cis	rs12541635	0.677	rs12546875	chr8:107012915	C/T	cg10147462	chr8:107024639	NA	0.56	10.33	0.45	1.84e-22	Age of smoking initiation;
LUAD	cis	rs1018836	0.923	rs10956749	chr8:91621573	G/A	cg16814680	chr8:91681699	NA	-0.72	-12.2	-0.51	1.58e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6499255	0.951	rs56316408	chr16:69658776	A/G	cg15192750	chr16:69999425	NA	0.53	8.27	0.37	1.71e-15	IgE levels;
LUAD	cis	rs9296092	0.517	rs7775914	chr6:33518110	T/C	cg13560919	chr6:33536144	NA	-0.88	-16.62	-0.63	4.2e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs9900062	0.586	rs2676307	chr17:62690713	C/G	cg02097616	chr17:62675921	NA	0.75	12.49	0.52	1.08e-30	QT interval;
LUAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg11062466	chr8:58055876	NA	0.7	9.27	0.41	9.52e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs250677	0.524	rs250665	chr5:148454394	A/C	cg18129178	chr5:148520854	ABLIM3	-0.49	-7.96	-0.36	1.54e-14	Breast cancer;
LUAD	cis	rs738322	0.646	rs132972	chr22:38562056	T/C	cg25457927	chr22:38595422	NA	-0.46	-10.91	-0.47	1.44e-24	Cutaneous nevi;
LUAD	cis	rs9914544	0.545	rs68046274	chr17:18785126	G/A	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.49	-0.3	2.45e-10	Educational attainment (years of education);
LUAD	cis	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.41	7.91	0.36	2.21e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg13393036	chr8:95962371	TP53INP1	-0.4	-9.67	-0.43	4.11e-20	Type 2 diabetes;
LUAD	cis	rs738321	0.762	rs4820321	chr22:38579569	T/A	cg03162506	chr22:38580953	NA	0.34	6.43	0.3	3.35e-10	Breast cancer;
LUAD	cis	rs9486719	0.895	rs12190520	chr6:96928620	A/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.15	-0.44	8.44e-22	Migraine;Coronary artery disease;
LUAD	cis	rs1032833	0.732	rs80339028	chr2:180119936	A/G	cg23883738	chr2:179974586	SESTD1	-0.72	-8.07	-0.37	7.41e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg16850897	chr7:100343110	ZAN	-0.59	-8.39	-0.38	7.37e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg03188948	chr7:1209495	NA	0.65	9.46	0.42	2.19e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4711350	1.000	rs751727	chr6:33764158	A/G	cg07979401	chr6:33739406	LEMD2	-0.51	-8.44	-0.38	5.12e-16	Schizophrenia;
LUAD	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg14828511	chr1:107599125	PRMT6	0.59	10.37	0.45	1.3e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.59e-12	Crohn's disease;
LUAD	cis	rs155346	1.000	rs2560711	chr5:139394941	T/C	cg01090482	chr5:139365336	NRG2	-0.34	-6.61	-0.31	1.16e-10	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUAD	trans	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg04565464	chr8:145669602	NFKBIL2	0.44	6.57	0.3	1.45e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg23711669	chr6:146136114	FBXO30	0.38	6.46	0.3	2.82e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg01620082	chr3:125678407	NA	-0.71	-7.15	-0.33	3.79e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg22681709	chr2:178499509	PDE11A	-0.5	-7.67	-0.35	1.21e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg17063962	chr7:91808500	NA	0.67	11.58	0.49	3.94e-27	Breast cancer;
LUAD	cis	rs7944584	0.655	rs2856653	chr11:47361084	T/C	cg20307385	chr11:47447363	PSMC3	-0.41	-6.46	-0.3	2.8e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73198271	0.641	rs34473848	chr8:8649837	C/T	cg01851573	chr8:8652454	MFHAS1	0.5	8.74	0.39	5.53e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-7.55	-0.34	2.66e-13	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg03467027	chr4:99064603	C4orf37	0.43	7.01	0.32	9.69e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7072216	0.881	rs2147896	chr10:100148176	A/G	cg26618903	chr10:100175079	PYROXD2	-0.32	-7.07	-0.33	6.49e-12	Metabolite levels;
LUAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-9.57	-0.42	8.74e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs4650994	0.593	rs12074085	chr1:178504163	G/A	cg05059571	chr16:84539110	KIAA1609	0.44	6.54	0.3	1.73e-10	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg16486109	chr11:613632	IRF7	0.5	7.66	0.35	1.32e-13	Systemic lupus erythematosus;
LUAD	cis	rs4699052	0.963	rs4698890	chr4:104181878	T/C	cg16532752	chr4:104119610	CENPE	-0.48	-7.31	-0.33	1.33e-12	Testicular germ cell tumor;
LUAD	trans	rs800082	0.690	rs2575191	chr3:144279228	G/A	cg24215973	chr2:240111563	HDAC4	0.59	9.67	0.43	4.04e-20	Smoking behavior;
LUAD	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg26384229	chr12:38710491	ALG10B	0.41	6.91	0.32	1.83e-11	Morning vs. evening chronotype;
LUAD	cis	rs7107174	1.000	rs7116611	chr11:78030046	A/G	cg19901956	chr11:77921274	USP35	-0.53	-6.47	-0.3	2.68e-10	Testicular germ cell tumor;
LUAD	cis	rs9644630	0.813	rs4922036	chr8:19328219	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.34	-8.31	-0.37	1.32e-15	Oropharynx cancer;
LUAD	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg25985355	chr7:65971099	NA	-0.38	-7.02	-0.32	8.69e-12	Aortic root size;
LUAD	cis	rs7582720	1.000	rs72932557	chr2:203846817	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.64	0.42	5.27e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs938554	0.784	rs13102218	chr4:9976113	G/T	cg00071950	chr4:10020882	SLC2A9	0.53	8.24	0.37	2.24e-15	Blood metabolite levels;
LUAD	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg07741184	chr6:167504864	NA	0.31	7.34	0.34	1.09e-12	Primary biliary cholangitis;
LUAD	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24308560	chr3:49941425	MST1R	0.58	9.94	0.44	4.55e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs8170	0.603	rs11086068	chr19:17420165	T/C	cg12247222	chr19:17403313	ABHD8	0.42	6.51	0.3	2.15e-10	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUAD	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.76	0.31	4.49e-11	Platelet count;
LUAD	cis	rs367615	0.879	rs4351197	chr5:108866667	A/G	cg17395555	chr5:108820864	NA	0.55	9.23	0.41	1.34e-18	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.8	0.39	3.48e-17	Menopause (age at onset);
LUAD	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.64	-0.35	1.47e-13	Menarche (age at onset);
LUAD	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.25	-0.33	2.02e-12	Lung cancer;
LUAD	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg11766577	chr21:47581405	C21orf56	-0.49	-8.11	-0.37	5.57e-15	Testicular germ cell tumor;
LUAD	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg09640425	chr7:158790006	NA	-0.54	-9.36	-0.41	4.75e-19	Facial morphology (factor 20);
LUAD	cis	rs813218	0.584	rs1718240	chr3:99536937	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.44	-7.83	-0.36	3.89e-14	Orofacial clefts;
LUAD	cis	rs1079204	0.793	rs76394798	chr2:219178595	A/T	cg05728596	chr2:219128475	GPBAR1	0.96	8.07	0.37	7.58e-15	Smooth-surface caries;
LUAD	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg10755058	chr3:40428713	ENTPD3	0.43	8.29	0.37	1.48e-15	Renal cell carcinoma;
LUAD	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.28	-7.63	-0.35	1.5700000000000001e-13	Total body bone mineral density;
LUAD	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg11189052	chr15:85197271	WDR73	0.67	9.04	0.4	5.71e-18	Schizophrenia;
LUAD	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg07570687	chr10:102243282	WNT8B	0.46	7.09	0.33	5.53e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg08859206	chr1:53392774	SCP2	-0.58	-10.64	-0.46	1.43e-23	Monocyte count;
LUAD	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg14343924	chr8:8086146	FLJ10661	0.44	6.84	0.32	2.81e-11	Mood instability;
LUAD	cis	rs3106136	0.967	rs7435106	chr4:95169772	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.44	-0.34	5.67e-13	Capecitabine sensitivity;
LUAD	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg23950597	chr19:37808831	NA	-0.62	-7.42	-0.34	6.54e-13	Coronary artery calcification;
LUAD	cis	rs9549367	0.577	rs776904	chr13:113810542	C/T	cg18105134	chr13:113819100	PROZ	-0.96	-14.38	-0.57	1.83e-38	Platelet distribution width;
LUAD	cis	rs13082711	0.834	rs2172297	chr3:27428423	C/T	cg02860705	chr3:27208620	NA	0.54	8.52	0.38	2.8e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7617773	0.674	rs13069029	chr3:48355024	A/G	cg11946769	chr3:48343235	NME6	0.44	6.76	0.31	4.58e-11	Coronary artery disease;
LUAD	cis	rs7833986	0.501	rs2719258	chr8:56941389	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.92	15.95	0.61	3.53e-45	Height;
LUAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg13560548	chr3:10150139	C3orf24	-0.4	-6.62	-0.31	1.06e-10	Alzheimer's disease;
LUAD	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18099408	chr3:52552593	STAB1	-0.5	-8.88	-0.4	1.88e-17	Electroencephalogram traits;
LUAD	cis	rs2932538	0.922	rs12138335	chr1:113122760	T/C	cg22162597	chr1:113214053	CAPZA1	0.45	6.7	0.31	6.77e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs4356932	1.000	rs6819597	chr4:76957171	C/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.54	-0.3	1.78e-10	Blood protein levels;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20600338	chr14:71786811	NA	0.42	6.57	0.3	1.53e-10	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg17366294	chr4:99064904	C4orf37	0.55	10.07	0.44	1.6e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.947	rs31240	chr5:130811146	T/A	cg06307176	chr5:131281290	NA	0.49	7.87	0.36	2.98e-14	Life satisfaction;
LUAD	trans	rs74417235	0.684	rs71590150	chr5:154060512	A/T	cg19469189	chr11:128781035	KCNJ5	-0.41	-6.41	-0.3	3.8e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg08125733	chr17:73851984	WBP2	0.68	9.97	0.44	3.55e-21	Psoriasis;
LUAD	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg23758822	chr17:41437982	NA	1.0	20.68	0.71	3.65e-66	Menopause (age at onset);
LUAD	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg06740227	chr12:86229804	RASSF9	0.39	6.97	0.32	1.19e-11	Major depressive disorder;
LUAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg20607798	chr8:58055168	NA	0.72	9.44	0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg19767477	chr5:127420684	SLC12A2	-0.41	-6.41	-0.3	3.91e-10	Ileal carcinoids;
LUAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg13560548	chr3:10150139	C3orf24	0.44	6.87	0.32	2.25e-11	Alzheimer's disease;
LUAD	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.06e-11	Depression;
LUAD	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg12935359	chr14:103987150	CKB	-0.46	-7.84	-0.36	3.61e-14	Body mass index;
LUAD	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg23649088	chr2:200775458	C2orf69	0.53	8.34	0.38	1.03e-15	Osteoporosis;
LUAD	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg12179176	chr11:130786555	SNX19	0.55	9.29	0.41	8.21e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg27432699	chr2:27873401	GPN1	0.38	6.42	0.3	3.58e-10	Total body bone mineral density;
LUAD	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-20.27	-0.7	2.52e-64	Height;
LUAD	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg00321850	chr1:175162397	KIAA0040	-0.53	-11.37	-0.48	2.55e-26	Alcohol dependence;
LUAD	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg09658497	chr7:2847517	GNA12	-0.56	-9.59	-0.42	7.81e-20	Height;
LUAD	cis	rs12347191	0.500	rs925486	chr9:100619733	C/T	cg13688889	chr9:100608707	NA	-0.63	-10.21	-0.44	4.95e-22	Orofacial clefts;
LUAD	cis	rs13144136	0.687	rs11723949	chr4:10658093	G/T	cg10242279	chr4:10666415	CLNK	-0.3	-6.39	-0.3	4.38e-10	Resistance to antihypertensive treatment in hypertension;
LUAD	cis	rs71403859	0.502	rs17280181	chr16:71523514	C/T	cg08717414	chr16:71523259	ZNF19	-0.64	-8.01	-0.36	1.09e-14	Post bronchodilator FEV1;
LUAD	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg00852783	chr1:26633632	UBXN11	0.43	7.68	0.35	1.14e-13	Obesity-related traits;
LUAD	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg16850897	chr7:100343110	ZAN	0.42	7.37	0.34	8.84e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg27588902	chr6:42928151	GNMT	0.36	9.61	0.42	6.53e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18099408	chr3:52552593	STAB1	-0.42	-7.45	-0.34	5.24e-13	Bipolar disorder;
LUAD	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.32e-15	Prostate cancer;
LUAD	cis	rs2386661	0.826	rs10795723	chr10:5675983	C/T	cg26603656	chr10:5671107	NA	0.42	7.13	0.33	4.34e-12	Breast cancer;
LUAD	cis	rs17401966	0.838	rs946502	chr1:10309279	G/C	cg19773385	chr1:10388646	KIF1B	-0.39	-6.52	-0.3	2.06e-10	Hepatocellular carcinoma;
LUAD	cis	rs8038465	0.622	rs56712926	chr15:73886849	G/T	cg15420318	chr15:73925796	NPTN	0.45	7.31	0.33	1.35e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs67981189	0.613	rs221892	chr14:71611606	C/A	cg15816911	chr14:71606274	NA	-0.37	-6.89	-0.32	2.08e-11	Schizophrenia;
LUAD	cis	rs57994353	0.861	rs13301660	chr9:139340802	C/T	cg14169450	chr9:139327907	INPP5E	0.41	6.38	0.3	4.52e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs11971779	0.584	rs10236055	chr7:139069991	A/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.46	-0.3	2.86e-10	Diisocyanate-induced asthma;
LUAD	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	6.45	0.3	3.05e-10	Obesity-related traits;
LUAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg21724239	chr8:58056113	NA	0.73	9.64	0.42	5.35e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs684232	0.800	rs2002015	chr17:534525	G/T	cg15660573	chr17:549704	VPS53	0.51	8.42	0.38	6.1e-16	Prostate cancer;
LUAD	cis	rs6594713	0.577	rs10078214	chr5:112915702	A/C	cg12552261	chr5:112820674	MCC	0.54	8.61	0.39	1.42e-16	Brain cytoarchitecture;
LUAD	cis	rs644148	0.836	rs2571110	chr19:45000712	T/C	cg15540054	chr19:45004280	ZNF180	-0.41	-6.5	-0.3	2.21e-10	Personality dimensions;
LUAD	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.78	-0.39	4.19e-17	Total body bone mineral density;
LUAD	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg14583973	chr4:3374767	RGS12	0.28	7.12	0.33	4.73e-12	Serum sulfate level;
LUAD	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.42	-0.42	2.86e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.04e-13	Morning vs. evening chronotype;
LUAD	cis	rs8018808	0.905	rs4903586	chr14:77938633	C/G	cg20045696	chr14:77926864	AHSA1	-0.37	-6.52	-0.3	1.96e-10	Myeloid white cell count;
LUAD	cis	rs12681287	0.609	rs13279850	chr8:87477800	C/T	cg00550725	chr8:87521180	FAM82B	0.43	6.41	0.3	3.92e-10	Caudate activity during reward;
LUAD	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg05368731	chr17:41323189	NBR1	0.94	19.54	0.69	4.53e-61	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.82	0.53	5.17e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2652834	0.904	rs34786874	chr15:63397504	A/G	cg25406657	chr15:63342033	TPM1	-0.43	-6.91	-0.32	1.84e-11	HDL cholesterol;
LUAD	cis	rs907683	0.584	rs2854903	chr2:220288979	C/T	cg15015639	chr2:220282977	DES	-0.49	-8.97	-0.4	9.73e-18	Resting heart rate;
LUAD	cis	rs12618769	0.656	rs56091613	chr2:99103761	A/G	cg10123293	chr2:99228465	UNC50	0.46	8.12	0.37	5.1e-15	Bipolar disorder;
LUAD	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg24450063	chr1:156163899	SLC25A44	1.04	20.39	0.7	7.36e-65	Testicular germ cell tumor;
LUAD	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg20503657	chr10:835505	NA	0.66	9.48	0.42	1.88e-19	Eosinophil percentage of granulocytes;
LUAD	cis	rs490234	0.841	rs512445	chr9:128329179	T/C	cg14078157	chr9:128172775	NA	0.35	6.53	0.3	1.89e-10	Mean arterial pressure;
LUAD	cis	rs7818345	0.637	rs4599829	chr8:19358434	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.26	-6.47	-0.3	2.65e-10	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg13511324	chr14:104056883	C14orf153	0.26	6.62	0.31	1.11e-10	Coronary artery disease;
LUAD	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg03396347	chr1:1875803	NA	0.52	12.72	0.53	1.32e-31	Body mass index;
LUAD	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-9.27	-0.41	9.87e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg01119278	chr6:110721349	DDO	-0.5	-9.3	-0.41	7.41e-19	Platelet distribution width;
LUAD	cis	rs7937890	0.559	rs2167160	chr11:14507449	C/A	cg06199346	chr11:14280333	SPON1	-0.32	-6.41	-0.3	3.86e-10	Mitochondrial DNA levels;
LUAD	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg07386859	chr16:1872102	HAGH	-0.5	-7.97	-0.36	1.48e-14	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg20991723	chr1:152506922	NA	0.35	6.84	0.32	2.72e-11	Hair morphology;
LUAD	cis	rs367943	0.666	rs10051834	chr5:112693803	C/T	cg12552261	chr5:112820674	MCC	0.46	9.04	0.4	5.69e-18	Type 2 diabetes;
LUAD	cis	rs600231	0.542	rs34527830	chr11:65240863	G/A	cg17120908	chr11:65337727	SSSCA1	-0.63	-8.24	-0.37	2.2e-15	Bone mineral density;
LUAD	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg23985595	chr17:80112537	CCDC57	0.53	9.74	0.43	2.39e-20	Life satisfaction;
LUAD	cis	rs11229555	0.645	rs4517537	chr11:58213695	G/A	cg15696309	chr11:58395628	NA	-0.74	-10.19	-0.44	5.81e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg24818145	chr4:99064322	C4orf37	0.45	7.52	0.34	3.22e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322817	0.583	rs6941988	chr6:105146656	C/T	cg02098413	chr6:105308735	HACE1	0.4	8.69	0.39	7.9e-17	Thyroid stimulating hormone;
LUAD	cis	rs9341808	0.718	rs2322636	chr6:80897436	C/T	cg08355045	chr6:80787529	NA	0.58	10.55	0.46	2.98e-23	Sitting height ratio;
LUAD	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg18854424	chr1:2615690	NA	-0.41	-9.09	-0.4	3.73e-18	Ulcerative colitis;
LUAD	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg22681709	chr2:178499509	PDE11A	-0.43	-7.02	-0.32	9.14e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg20476274	chr7:133979776	SLC35B4	0.75	12.85	0.53	3.9e-32	Mean platelet volume;
LUAD	cis	rs12618769	0.597	rs72819981	chr2:99040696	T/C	cg10123293	chr2:99228465	UNC50	0.45	7.92	0.36	2.19e-14	Bipolar disorder;
LUAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.87	16.79	0.63	7.76e-49	Lymphocyte counts;
LUAD	cis	rs7944584	0.588	rs2697923	chr11:47363215	G/T	cg20307385	chr11:47447363	PSMC3	-0.42	-6.73	-0.31	5.67e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.24	0.37	2.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.842	rs7309725	chr12:86440612	T/C	cg19622623	chr12:86230825	RASSF9	-0.36	-6.62	-0.31	1.08e-10	Major depressive disorder;
LUAD	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg00933542	chr6:150070202	PCMT1	0.44	9.15	0.41	2.42e-18	Lung cancer;
LUAD	cis	rs6835098	0.924	rs13125240	chr4:174151619	T/C	cg08422745	chr4:174089978	GALNT7	0.96	16.93	0.64	1.81e-49	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg03714773	chr7:91764589	CYP51A1	0.32	7.43	0.34	5.9e-13	Breast cancer;
LUAD	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg12908607	chr1:44402522	ARTN	-0.45	-8.95	-0.4	1.1e-17	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs6732160	0.934	rs2421390	chr2:73379103	T/C	cg01422370	chr2:73384389	NA	0.34	6.84	0.32	2.74e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs877282	0.945	rs11253396	chr10:789754	C/T	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg25319279	chr11:5960081	NA	-0.35	-6.5	-0.3	2.33e-10	DNA methylation (variation);
LUAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00166722	chr3:10149974	C3orf24	0.63	10.31	0.45	2.23e-22	Alzheimer's disease;
LUAD	trans	rs1493916	1.000	rs7238717	chr18:31395186	C/T	cg27147174	chr7:100797783	AP1S1	-0.68	-11.96	-0.5	1.35e-28	Life satisfaction;
LUAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg04450456	chr4:17643702	FAM184B	0.37	6.95	0.32	1.37e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11958404	1.000	rs72816532	chr5:157413130	C/T	cg05962755	chr5:157440814	NA	0.44	6.99	0.32	1.07e-11	IgG glycosylation;
LUAD	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg26384229	chr12:38710491	ALG10B	-0.4	-6.72	-0.31	5.8e-11	Bladder cancer;
LUAD	cis	rs9309473	0.687	rs6546827	chr2:73606493	C/T	cg20560298	chr2:73613845	ALMS1	-0.42	-6.58	-0.3	1.38e-10	Metabolite levels;
LUAD	cis	rs986417	0.818	rs2351173	chr14:61008755	C/T	cg27398547	chr14:60952738	C14orf39	0.66	7.85	0.36	3.45e-14	Gut microbiota (bacterial taxa);
LUAD	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg15704280	chr7:45808275	SEPT13	0.9	17.49	0.65	6.15e-52	Coronary artery disease;
LUAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg22907277	chr7:1156413	C7orf50	0.68	8.01	0.36	1.12e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs834811	0.797	rs2633365	chr7:135879797	A/G	cg01726295	chr7:135938950	NA	0.28	6.89	0.32	2.01e-11	Post-traumatic stress disorder;
LUAD	trans	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-10.39	-0.45	1.1e-22	Obesity-related traits;
LUAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg21782813	chr7:2030301	MAD1L1	0.51	8.84	0.4	2.52e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs7301016	1.000	rs11520127	chr12:62906965	C/G	cg11441379	chr12:63026424	NA	0.55	6.77	0.31	4.36e-11	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.94e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21659725	chr3:3221576	CRBN	0.7	10.88	0.47	1.79e-24	Resting heart rate;
LUAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18099408	chr3:52552593	STAB1	-0.5	-9.29	-0.41	8.17e-19	Electroencephalogram traits;
LUAD	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg08470875	chr2:26401718	FAM59B	0.78	10.37	0.45	1.28e-22	Gut microbiome composition (summer);
LUAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg04352962	chr1:209979756	IRF6	0.46	6.44	0.3	3.2e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg23260525	chr10:116636907	FAM160B1	0.49	11.52	0.49	6.77e-27	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs754466	0.830	rs61854186	chr10:79703255	G/A	cg17075019	chr10:79541650	NA	-0.8	-12.98	-0.53	1.14e-32	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg17652424	chr22:38574118	PLA2G6	-0.33	-10.19	-0.44	6.1e-22	Cutaneous nevi;
LUAD	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg21775007	chr8:11205619	TDH	0.51	9.1	0.4	3.53e-18	Retinal vascular caliber;
LUAD	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg09509183	chr1:209979624	IRF6	-0.51	-6.61	-0.31	1.17e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg05082376	chr22:42548792	NA	0.38	7.02	0.32	8.86e-12	Cognitive function;
LUAD	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg17279839	chr7:150038598	RARRES2	0.47	8.02	0.36	1.03e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.51	-8.87	-0.4	2.08e-17	Alzheimer's disease (late onset);
LUAD	cis	rs1018836	0.595	rs2223010	chr8:91480068	A/G	cg16814680	chr8:91681699	NA	-0.64	-10.6	-0.46	1.88e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.85	0.56	3.1e-36	Prudent dietary pattern;
LUAD	cis	rs7301826	0.610	rs4759791	chr12:131296495	A/G	cg11011512	chr12:131303247	STX2	0.44	7.41	0.34	6.76e-13	Plasma plasminogen activator levels;
LUAD	cis	rs2735413	0.918	rs4888731	chr16:78080418	A/G	cg04733911	chr16:78082701	NA	-0.35	-8.38	-0.38	8.05e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs751728	1.000	rs4713682	chr6:33757047	G/C	cg13859433	chr6:33739653	LEMD2	-0.38	-8.82	-0.39	3.04e-17	Crohn's disease;
LUAD	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	8.13	0.37	4.9e-15	Blood metabolite levels;
LUAD	trans	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg26043149	chr18:55253948	FECH	-0.41	-6.71	-0.31	6.19e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg25566285	chr7:158114605	PTPRN2	0.5	10.21	0.44	4.86e-22	Calcium levels;
LUAD	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg08213375	chr14:104286397	PPP1R13B	0.26	6.84	0.32	2.82e-11	Schizophrenia;
LUAD	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg08798685	chr6:27730294	NA	-0.43	-6.97	-0.32	1.23e-11	Parkinson's disease;
LUAD	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.91	-0.5	2.11e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg02527881	chr3:46936655	PTH1R	0.5	9.97	0.44	3.68e-21	Colorectal cancer;
LUAD	cis	rs68170813	0.559	rs12537730	chr7:106844281	T/C	cg23024343	chr7:107201750	COG5	0.49	7.01	0.32	9.61e-12	Coronary artery disease;
LUAD	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.37	-0.38	8.76e-16	Prostate cancer;
LUAD	cis	rs6489882	0.867	rs6489875	chr12:113368030	G/A	cg20102336	chr12:113376681	OAS3	-0.58	-8.95	-0.4	1.09e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs7937890	0.559	rs2575831	chr11:14486194	A/T	cg02886208	chr11:14281011	SPON1	-0.34	-6.52	-0.3	2.05e-10	Mitochondrial DNA levels;
LUAD	cis	rs10865541	0.902	rs10173635	chr2:3421213	G/A	cg13173536	chr2:3403300	TTC15	-0.33	-6.42	-0.3	3.68e-10	Obesity-related traits;
LUAD	cis	rs2046867	0.818	rs2208	chr3:72871773	A/G	cg04365224	chr3:72788183	NA	0.42	6.37	0.3	4.88e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4474742	1	rs4474742	chr17:28065578	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.31	-0.41	7e-19	Monocyte count;
LUAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg08888203	chr3:10149979	C3orf24	0.75	13.03	0.54	6.95e-33	Alzheimer's disease;
LUAD	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg02461776	chr11:598696	PHRF1	0.46	6.48	0.3	2.58e-10	Systemic lupus erythematosus;
LUAD	trans	rs853679	0.607	rs34218844	chr6:28290647	T/C	cg01620082	chr3:125678407	NA	-1.1	-10.47	-0.45	5.58e-23	Depression;
LUAD	cis	rs1062753	0.771	rs5751245	chr22:42620940	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.39	7.07	0.33	6.26e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg23750338	chr8:142222470	SLC45A4	0.46	9.62	0.42	6.17e-20	Immature fraction of reticulocytes;
LUAD	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg23711669	chr6:146136114	FBXO30	0.37	6.37	0.3	4.82e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	8.02	0.36	1.08e-14	Parkinson's disease;
LUAD	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg15181151	chr6:150070149	PCMT1	-0.34	-6.46	-0.3	2.91e-10	Lung cancer;
LUAD	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.54	-0.34	2.81e-13	Total cholesterol levels;
LUAD	cis	rs41271951	0.512	rs77306500	chr1:151080096	G/C	cg11822372	chr1:151115635	SEMA6C	-0.82	-6.97	-0.32	1.24e-11	Blood protein levels;
LUAD	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg04545296	chr12:48745243	ZNF641	0.39	9.87	0.43	7.92e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg26647111	chr11:31128758	NA	-0.44	-7.65	-0.35	1.36e-13	Red blood cell count;
LUAD	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg27129171	chr3:47204927	SETD2	0.42	6.93	0.32	1.57e-11	Colorectal cancer;
LUAD	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg15208524	chr1:10270712	KIF1B	0.43	6.59	0.31	1.33e-10	Hepatocellular carcinoma;
LUAD	trans	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21582582	chr3:182698605	DCUN1D1	0.48	8.07	0.37	7.13e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs752010	1.000	rs2077172	chr1:42093340	A/G	cg06885757	chr1:42089581	HIVEP3	0.44	9.51	0.42	1.5e-19	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs75920871	0.623	rs17120244	chr11:116919511	C/T	cg04087571	chr11:116723030	SIK3	-0.29	-6.57	-0.3	1.48e-10	Subjective well-being;
LUAD	trans	rs1547374	0.960	rs4920090	chr21:43777897	A/G	cg09521743	chr10:75415752	SYNPO2L	-0.41	-7.08	-0.33	6.23e-12	Pancreatic cancer;
LUAD	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg12923728	chr3:195709715	SDHAP1	0.41	6.54	0.3	1.74e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.87	-0.36	2.92e-14	Type 2 diabetes;
LUAD	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.89	-0.5	2.59e-28	Bipolar disorder;
LUAD	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.49	-7.85	-0.36	3.54e-14	Schizophrenia;
LUAD	cis	rs7818345	0.935	rs4333618	chr8:19283442	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.33	7.21	0.33	2.65e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.69	-13.45	-0.55	1.42e-34	Ulcerative colitis;
LUAD	cis	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg09650180	chr20:62225654	GMEB2	-0.47	-6.69	-0.31	6.91e-11	Glioblastoma;
LUAD	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg03874509	chr1:107600012	PRMT6	-0.57	-9.92	-0.43	5.27e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg08470875	chr2:26401718	FAM59B	-0.62	-8.52	-0.38	2.89e-16	Gut microbiome composition (summer);
LUAD	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg21280719	chr6:42927975	GNMT	-0.38	-11.77	-0.5	7.68e-28	Plasma homocysteine levels (post-methionine load test);
LUAD	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg08514558	chr10:81106712	PPIF	0.48	9.55	0.42	1.07e-19	Height;
LUAD	cis	rs250585	0.736	rs4968006	chr16:23488031	A/G	cg00143387	chr16:23521605	GGA2	-0.64	-7.95	-0.36	1.68e-14	Egg allergy;
LUAD	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg04450456	chr4:17643702	FAM184B	0.4	7.96	0.36	1.6e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06022373	chr22:39101656	GTPBP1	0.47	7.32	0.34	1.23e-12	Menopause (age at onset);
LUAD	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg13334819	chr7:99746414	C7orf59	0.63	9.87	0.43	7.92e-21	Coronary artery disease;
LUAD	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg25919922	chr13:100150906	NA	-0.65	-8.28	-0.37	1.64e-15	Obesity-related traits;
LUAD	cis	rs887829	0.570	rs6736743	chr2:234595950	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.67	-0.43	4e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.57e-12	Crohn's disease;
LUAD	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg03433033	chr1:76189801	ACADM	0.86	15.72	0.61	3.35e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg02527881	chr3:46936655	PTH1R	0.45	8.77	0.39	4.36e-17	Colorectal cancer;
LUAD	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.07e-12	Diabetic kidney disease;
LUAD	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21659725	chr3:3221576	CRBN	0.71	11.77	0.5	7.35e-28	Resting heart rate;
LUAD	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg22532475	chr10:104410764	TRIM8	0.34	6.77	0.31	4.23e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs13315871	0.790	rs115288459	chr3:58324283	A/G	cg12435725	chr3:58293450	RPP14	-0.76	-8.4	-0.38	6.7e-16	Cholesterol, total;
LUAD	trans	rs2270927	0.510	rs6876070	chr5:75579237	T/A	cg13563193	chr19:33072644	PDCD5	1.04	9.47	0.42	2.02e-19	Mean corpuscular volume;
LUAD	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg17761419	chr8:57350749	NA	-0.51	-7.67	-0.35	1.17e-13	Obesity-related traits;
LUAD	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg04976154	chr16:1532411	NA	0.37	8.23	0.37	2.26e-15	Bone mineral density;
LUAD	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg24558204	chr6:135376177	HBS1L	0.47	8.67	0.39	9.21e-17	Red blood cell count;
LUAD	trans	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg24644049	chr4:85504048	CDS1	0.92	7.94	0.36	1.78e-14	Skin colour saturation;
LUAD	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs459571	0.920	rs417142	chr9:136891370	G/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.64	-9.33	-0.41	6.11e-19	Platelet distribution width;
LUAD	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg11915388	chr22:42470451	FAM109B	0.41	7.37	0.34	8.84e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg19163074	chr7:65112434	INTS4L2	0.44	6.67	0.31	7.8e-11	Aortic root size;
LUAD	trans	rs1493916	0.807	rs10775455	chr18:31310761	A/C	cg27147174	chr7:100797783	AP1S1	-0.58	-9.97	-0.44	3.62e-21	Life satisfaction;
LUAD	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg26384229	chr12:38710491	ALG10B	0.47	7.55	0.34	2.72e-13	Bladder cancer;
LUAD	cis	rs68170813	0.559	rs7803290	chr7:106907353	T/C	cg23024343	chr7:107201750	COG5	0.5	7.25	0.33	1.98e-12	Coronary artery disease;
LUAD	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.81	-0.36	4.48e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg24675658	chr1:53192096	ZYG11B	0.45	7.14	0.33	4.07e-12	Monocyte count;
LUAD	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg06784218	chr1:46089804	CCDC17	0.6	13.4	0.55	2.3e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs904251	0.504	rs9380677	chr6:37480366	A/G	cg25019722	chr6:37503610	NA	-0.32	-7.28	-0.33	1.62e-12	Cognitive performance;
LUAD	cis	rs727505	0.954	rs59673207	chr7:124596982	G/C	cg23710748	chr7:124431027	NA	-0.43	-8.51	-0.38	3e-16	Lewy body disease;
LUAD	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg00769240	chr8:12517080	NA	-0.42	-7.75	-0.35	6.77e-14	Blood pressure (smoking interaction);
LUAD	cis	rs1865721	0.771	rs7228890	chr18:73137492	C/A	cg26385618	chr18:73139727	C18orf62	-0.51	-10.31	-0.45	2.17e-22	Intelligence;
LUAD	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.94	-0.44	4.66e-21	Monocyte percentage of white cells;
LUAD	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg24558204	chr6:135376177	HBS1L	0.49	8.45	0.38	4.66e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs17092148	1.000	rs57131731	chr20:33392739	C/T	cg16810054	chr20:33298113	TP53INP2	0.53	8.3	0.37	1.44e-15	Neuroticism;
LUAD	cis	rs6543140	0.964	rs6543136	chr2:103065547	G/A	cg03938978	chr2:103052716	IL18RAP	0.35	6.77	0.31	4.44e-11	Blood protein levels;
LUAD	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23158103	chr7:148848205	ZNF398	-0.65	-12.24	-0.51	1.05e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs3960554	0.808	rs111764601	chr7:75706141	T/C	cg19862616	chr7:65841803	NCRNA00174	0.81	11.08	0.47	3.11e-25	Eotaxin levels;
LUAD	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg08873628	chr1:175162347	KIAA0040	0.39	6.55	0.3	1.72e-10	Alcohol dependence;
LUAD	cis	rs4629710	0.592	rs11758994	chr6:131582022	A/C	cg12606694	chr6:131520996	AKAP7	0.5	7.27	0.33	1.73e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.18	-0.41	1.96e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12200560	0.505	rs211171	chr6:97070579	T/G	cg06623918	chr6:96969491	KIAA0776	0.46	7.07	0.33	6.52e-12	Coronary heart disease;
LUAD	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.87	-11.94	-0.5	1.61e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs758324	0.947	rs4705903	chr5:131206594	A/C	cg25547332	chr5:131281432	NA	0.44	6.8	0.31	3.59e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg21856205	chr7:94953877	PON1	-0.57	-7.77	-0.35	5.82e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4903604	0.513	rs12880891	chr14:78035233	T/C	cg18872420	chr14:78023429	SPTLC2	0.47	8.47	0.38	4e-16	Gut microbiome composition (winter);
LUAD	cis	rs89107	0.550	rs17226667	chr6:118721628	A/G	cg18833306	chr6:118973337	C6orf204	0.38	6.43	0.3	3.54e-10	Cardiac structure and function;
LUAD	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.45	-0.34	5.36e-13	Type 2 diabetes;
LUAD	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg09365446	chr1:150670422	GOLPH3L	-0.55	-9.05	-0.4	5.32e-18	Urate levels;
LUAD	cis	rs2637266	0.967	rs4553314	chr10:78358244	C/T	cg18941641	chr10:78392320	NA	0.34	7.2	0.33	2.77e-12	Pulmonary function;
LUAD	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg18944383	chr4:111397179	ENPEP	0.42	8.22	0.37	2.45e-15	Height;
LUAD	cis	rs8060686	0.623	rs58388686	chr16:68075439	A/G	cg26727032	chr16:67993705	SLC12A4	-0.48	-8.1	-0.37	5.86e-15	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs7395662	0.963	rs2135681	chr11:48728388	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	2.03e-12	HDL cholesterol;
LUAD	cis	rs7625357	0.599	rs9814415	chr3:169322325	T/C	cg14572252	chr3:169309425	MECOM	-0.47	-7.88	-0.36	2.89e-14	Childhood and early adolescence aggressive behavior;
LUAD	cis	rs57920188	0.584	rs12062024	chr1:4089259	A/T	cg10510935	chr1:4059661	NA	-0.44	-6.81	-0.31	3.41e-11	Interleukin-17 levels;
LUAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.04e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg15448220	chr1:150897856	SETDB1	0.57	9.88	0.43	7.45e-21	Melanoma;
LUAD	cis	rs12545109	0.800	rs2576599	chr8:57388410	G/A	cg11919837	chr8:57350735	NA	-0.46	-6.46	-0.3	2.89e-10	Obesity-related traits;
LUAD	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11890956	chr21:40555474	PSMG1	0.78	13.65	0.55	2.17e-35	Cognitive function;
LUAD	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg13685833	chr1:53393034	SCP2	-0.41	-6.82	-0.31	3.09e-11	Monocyte count;
LUAD	cis	rs6594713	0.921	rs7714760	chr5:112735231	T/C	cg12552261	chr5:112820674	MCC	0.54	8.56	0.38	2.09e-16	Brain cytoarchitecture;
LUAD	cis	rs62400317	0.826	rs12205642	chr6:45331765	T/C	cg18551225	chr6:44695536	NA	-0.52	-8.15	-0.37	4.25e-15	Total body bone mineral density;
LUAD	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg17644776	chr2:200775616	C2orf69	0.54	7.06	0.32	6.9e-12	Schizophrenia;
LUAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg10150615	chr22:24372951	LOC391322	-0.47	-7.74	-0.35	7.6e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs12517041	1.000	rs12517041	chr5:23301908	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.57	-0.3	1.47e-10	Calcium levels;
LUAD	cis	rs494562	0.892	rs573737	chr6:86118233	A/G	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	trans	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg00953403	chr17:74099816	EXOC7	-0.42	-6.47	-0.3	2.71e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg03396347	chr1:1875803	NA	-0.59	-15.21	-0.59	5.63e-42	Body mass index;
LUAD	cis	rs89107	1.000	rs89107	chr6:118578043	G/A	cg21191810	chr6:118973309	C6orf204	0.46	8.98	0.4	8.94e-18	Cardiac structure and function;
LUAD	cis	rs3823572	0.525	rs6946805	chr7:133714482	T/C	cg03336402	chr7:133662267	EXOC4	-0.42	-7.33	-0.34	1.21e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.19	-0.51	1.7e-29	Platelet count;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06622468	chr19:10491460	TYK2	-0.54	-6.6	-0.31	1.26e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg25358565	chr5:93447407	FAM172A	0.57	6.62	0.31	1.12e-10	Diabetic retinopathy;
LUAD	cis	rs11098699	0.732	rs4833897	chr4:124242829	C/A	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg12011299	chr4:100065546	ADH4	-0.64	-11.55	-0.49	5.37e-27	Alcohol dependence;
LUAD	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg20503657	chr10:835505	NA	0.82	11.13	0.48	2.03e-25	Eosinophil percentage of granulocytes;
LUAD	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg02574844	chr11:5959923	NA	-0.43	-7.36	-0.34	9.66e-13	DNA methylation (variation);
LUAD	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18876405	chr7:65276391	NA	-0.43	-6.82	-0.31	3.17e-11	Aortic root size;
LUAD	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg08885076	chr2:99613938	TSGA10	-0.39	-6.85	-0.32	2.58e-11	Chronic sinus infection;
LUAD	cis	rs743757	1.000	rs9835537	chr3:50464335	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.44	6.84	0.32	2.87e-11	Diastolic blood pressure;
LUAD	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg02018176	chr4:1364513	KIAA1530	-0.38	-7.08	-0.33	5.98e-12	Obesity-related traits;
LUAD	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg12365402	chr11:9010492	NRIP3	-0.5	-9.99	-0.44	3.08e-21	Hemoglobin concentration;
LUAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	12.95	0.53	1.47e-32	Prudent dietary pattern;
LUAD	cis	rs2992756	0.553	rs2992745	chr1:18809896	A/T	cg14356550	chr1:18808102	KLHDC7A	-0.47	-8.23	-0.37	2.34e-15	Breast cancer;
LUAD	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg24675056	chr1:15929824	NA	0.49	8.59	0.39	1.68e-16	Systolic blood pressure;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg25134345	chr5:134240255	PCBD2	-0.39	-6.47	-0.3	2.77e-10	Cancer;
LUAD	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg25894440	chr7:65020034	NA	-0.69	-7.25	-0.33	1.97e-12	Diabetic kidney disease;
LUAD	cis	rs2637266	0.935	rs4353214	chr10:78393149	C/T	cg18941641	chr10:78392320	NA	-0.35	-7.47	-0.34	4.77e-13	Pulmonary function;
LUAD	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg06740227	chr12:86229804	RASSF9	0.37	6.83	0.31	3.06e-11	Major depressive disorder;
LUAD	cis	rs9419702	0.568	rs10782366	chr10:133557866	G/A	cg04492858	chr10:133558786	NA	0.38	7.46	0.34	5.02e-13	Survival in rectal cancer;
LUAD	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg09263875	chr16:632152	PIGQ	0.82	17.62	0.65	1.65e-52	Height;
LUAD	cis	rs870825	0.616	rs6552801	chr4:185620623	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg12908607	chr1:44402522	ARTN	-0.53	-10.5	-0.45	4.55e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg26384229	chr12:38710491	ALG10B	-0.42	-7.25	-0.33	1.94e-12	Morning vs. evening chronotype;
LUAD	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg12573674	chr2:1569213	NA	-0.61	-6.86	-0.32	2.39e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs35883536	1.000	rs12566507	chr1:101089679	T/A	cg06223162	chr1:101003688	GPR88	0.34	6.35	0.3	5.56e-10	Monocyte count;
LUAD	cis	rs6961069	0.837	rs1722505	chr7:80240689	T/C	cg04458919	chr7:80252533	CD36	-0.36	-6.85	-0.32	2.6e-11	Platelet count;
LUAD	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05731713	chr7:157510257	PTPRN2	0.45	10.35	0.45	1.58e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	9.47	0.42	2.07e-19	Electrocardiographic conduction measures;
LUAD	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg06064525	chr11:970664	AP2A2	-0.56	-11.52	-0.49	6.7399999999999993e-27	Alzheimer's disease (late onset);
LUAD	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg00431813	chr7:1051703	C7orf50	-0.66	-13.96	-0.56	1.13e-36	Longevity;Endometriosis;
LUAD	trans	rs2840044	0.534	rs167691	chr17:33885826	G/A	cg19694781	chr19:47549865	TMEM160	-0.43	-7.05	-0.32	7.55e-12	Response to radiotherapy in cancer (late toxicity);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg26649251	chr19:44598564	ZNF224	0.41	6.52	0.3	1.98e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6474412	0.505	rs1530850	chr8:42504953	C/G	cg25026480	chr8:42547641	NA	-0.37	-6.45	-0.3	3.11e-10	Smoking behavior;
LUAD	cis	rs12900413	0.687	rs6496601	chr15:90317694	C/T	cg24249390	chr15:90295951	MESP1	-0.34	-6.87	-0.32	2.34e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg18404041	chr3:52824283	ITIH1	-0.57	-10.55	-0.46	3.05e-23	Bipolar disorder;
LUAD	cis	rs7586879	0.828	rs12986610	chr2:25106265	A/G	cg04586622	chr2:25135609	ADCY3	-0.33	-6.79	-0.31	3.75e-11	Body mass index;
LUAD	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg06387496	chr7:2775674	GNA12	-0.39	-6.66	-0.31	8.62e-11	Height;
LUAD	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg13319975	chr6:146136371	FBXO30	-0.63	-10.9	-0.47	1.51e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg15448220	chr1:150897856	SETDB1	0.57	9.59	0.42	7.78e-20	Melanoma;
LUAD	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg10589385	chr1:150898437	SETDB1	0.39	7.36	0.34	9.6e-13	Tonsillectomy;
LUAD	cis	rs4900069	0.764	rs12433069	chr14:91594186	A/G	cg12167284	chr14:91592793	SNORA11B;C14orf159	-0.4	-6.42	-0.3	3.68e-10	Resting heart rate;
LUAD	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg02782426	chr3:40428986	ENTPD3	0.44	9.29	0.41	8.24e-19	Renal cell carcinoma;
LUAD	cis	rs356992	0.915	rs356977	chr2:60748758	A/G	cg08426369	chr2:60753602	BCL11A	0.45	7.69	0.35	1.04e-13	Educational attainment (years of education);
LUAD	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg09455208	chr3:40491958	NA	0.57	12.56	0.52	5.69e-31	Renal cell carcinoma;
LUAD	trans	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg11693508	chr17:37793320	STARD3	0.75	10.15	0.44	8.17e-22	Bipolar disorder;
LUAD	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg26384229	chr12:38710491	ALG10B	0.45	7.13	0.33	4.42e-12	Heart rate;
LUAD	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg12311346	chr5:56204834	C5orf35	-0.95	-13.92	-0.56	1.56e-36	Initial pursuit acceleration;
LUAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00149659	chr3:10157352	C3orf10	0.6	8.34	0.38	1.06e-15	Alzheimer's disease;
LUAD	cis	rs13315871	1.000	rs9869940	chr3:58401523	G/A	cg20936604	chr3:58311152	NA	-0.69	-6.9	-0.32	1.86e-11	Cholesterol, total;
LUAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.62	-10.89	-0.47	1.57e-24	Lymphocyte counts;
LUAD	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-8.69	-0.39	8.06e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg06002616	chr8:101225028	SPAG1	-0.41	-8.28	-0.37	1.6e-15	Atrioventricular conduction;
LUAD	cis	rs6500395	1.000	rs7198773	chr16:48606091	T/C	cg04672837	chr16:48644449	N4BP1	0.38	6.61	0.31	1.17e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18402987	chr7:1209562	NA	0.45	7.45	0.34	5.18e-13	Longevity;Endometriosis;
LUAD	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg05373962	chr22:49881684	NA	-0.5	-9.86	-0.43	8.63e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14159672	chr1:205819179	PM20D1	0.78	15.71	0.61	3.96e-44	Menarche (age at onset);
LUAD	cis	rs28655083	0.956	rs4088757	chr16:77071545	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.39	6.63	0.31	9.97e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg22598563	chr5:131563921	P4HA2	0.27	6.67	0.31	8.26e-11	Blood metabolite levels;
LUAD	cis	rs870825	0.616	rs28445002	chr4:185648977	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs7680126	0.500	rs4697935	chr4:10149593	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.47	-0.34	4.49e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs921968	0.541	rs933995	chr2:219650718	G/A	cg02176678	chr2:219576539	TTLL4	-0.57	-11.38	-0.48	2.32e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg05457628	chr5:178986728	RUFY1	-0.77	-13.63	-0.55	2.49e-35	Lung cancer;
LUAD	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.5	7.64	0.35	1.45e-13	Schizophrenia;
LUAD	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg03354898	chr7:1950403	MAD1L1	-0.39	-7.41	-0.34	7.15e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs490234	0.805	rs562004	chr9:128321771	T/C	cg14078157	chr9:128172775	NA	0.43	7.99	0.36	1.3e-14	Mean arterial pressure;
LUAD	cis	rs7020830	0.830	rs13296413	chr9:37258105	C/T	cg14294708	chr9:37120828	ZCCHC7	0.89	18.01	0.66	3.04e-54	Schizophrenia;
LUAD	cis	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg08601574	chr20:25228251	PYGB	-0.44	-8.16	-0.37	4e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.47	-7.99	-0.36	1.27e-14	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8130944	0.859	rs1515755	chr21:44118958	T/A	cg16784985	chr21:44105474	PDE9A	-0.38	-6.5	-0.3	2.22e-10	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg06784218	chr1:46089804	CCDC17	0.57	12.81	0.53	5.73e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9392556	0.533	rs619439	chr6:4113929	G/A	cg10424681	chr6:4079350	C6orf201;C6orf146	0.28	6.79	0.31	3.75e-11	Blood metabolite levels;
LUAD	cis	rs1160297	0.609	rs1597653	chr2:53100420	A/G	cg07782112	chr2:53107842	NA	-0.4	-8.61	-0.39	1.46e-16	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg11494091	chr17:61959527	GH2	0.41	7.8	0.35	4.91e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg15790184	chr11:494944	RNH1	0.56	6.73	0.31	5.52e-11	Body mass index;
LUAD	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	6.95	0.32	1.42e-11	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg00316803	chr15:76480434	C15orf27	0.41	6.41	0.3	3.83e-10	Blood metabolite levels;
LUAD	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.86	0.32	2.49e-11	Depression;
LUAD	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg12863693	chr15:85201151	NMB	0.38	6.65	0.31	8.98e-11	Schizophrenia;
LUAD	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg06558623	chr16:89946397	TCF25	1.18	11.02	0.47	5.28e-25	Skin colour saturation;
LUAD	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg26022315	chr17:47021804	SNF8	0.4	7.27	0.33	1.77e-12	Type 2 diabetes;
LUAD	cis	rs113835537	0.529	rs17495838	chr11:66196265	T/C	cg24851651	chr11:66362959	CCS	0.61	10.3	0.45	2.4e-22	Airway imaging phenotypes;
LUAD	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg09658497	chr7:2847517	GNA12	-0.48	-8.25	-0.37	2.02e-15	Height;
LUAD	cis	rs61897795	0.628	rs93923	chr11:61613745	C/T	cg06781209	chr11:61594997	FADS2	-0.47	-7.37	-0.34	9.02e-13	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg20276088	chr3:133502917	NA	0.43	7.84	0.36	3.78e-14	Iron status biomarkers;
LUAD	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg10523679	chr1:76189770	ACADM	0.91	16.3	0.62	1.1e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs943466	1.000	rs2395400	chr6:33770076	G/A	cg16010596	chr6:33739607	LEMD2	-0.41	-7.76	-0.35	6.28e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg23950597	chr19:37808831	NA	-0.61	-7.55	-0.34	2.74e-13	Coronary artery calcification;
LUAD	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg04731861	chr2:219085781	ARPC2	0.23	7.09	0.33	5.58e-12	Colorectal cancer;
LUAD	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg16479474	chr6:28041457	NA	-0.44	-7.73	-0.35	7.72e-14	Depression;
LUAD	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg00310523	chr12:86230176	RASSF9	-0.36	-7.21	-0.33	2.53e-12	Major depressive disorder;
LUAD	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg10356904	chr22:49881777	NA	-0.38	-7.34	-0.34	1.07e-12	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs11255291	0.668	rs4749169	chr10:7737661	G/C	cg13340899	chr10:7670827	ITIH5	0.41	7.12	0.33	4.74e-12	Ovarian reserve;
LUAD	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg15017067	chr4:17643749	FAM184B	0.37	7.28	0.33	1.64e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg06671706	chr8:8559999	CLDN23	0.65	11.38	0.48	2.42e-26	Obesity-related traits;
LUAD	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.53	0.34	3.07e-13	Bipolar disorder;
LUAD	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg07153921	chr17:41440717	NA	-0.4	-6.63	-0.31	1.02e-10	Menopause (age at onset);
LUAD	cis	rs2688608	0.967	rs2688609	chr10:75658181	A/G	cg23231163	chr10:75533350	FUT11	0.41	7.52	0.34	3.34e-13	Inflammatory bowel disease;
LUAD	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.17e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg17528648	chr5:38846100	OSMR	-0.38	-6.35	-0.3	5.46e-10	Schizophrenia;
LUAD	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg13385794	chr1:248469461	NA	0.26	7.12	0.33	4.76e-12	Common traits (Other);
LUAD	cis	rs2242073	0.660	rs6751246	chr2:209002331	T/C	cg06181187	chr2:209010896	CRYGB	-0.33	-6.67	-0.31	8.24e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.6	0.31	1.21e-10	Prudent dietary pattern;
LUAD	cis	rs9902453	0.765	rs1531553	chr17:28066752	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.43	-0.45	8.15e-23	Coffee consumption (cups per day);
LUAD	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg12564285	chr5:131593104	PDLIM4	-0.38	-6.6	-0.31	1.23e-10	Breast cancer;
LUAD	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.42	-7.03	-0.32	8.45e-12	Total body bone mineral density;
LUAD	cis	rs2262909	0.924	rs4290587	chr19:22164646	A/G	cg11619707	chr19:22235551	ZNF257	-0.43	-6.45	-0.3	2.98e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-7.72	-0.35	8.65e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg21918786	chr6:109611834	NA	-0.6	-11.01	-0.47	5.62e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.58e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg23387056	chr11:14280742	SPON1	-0.44	-8.87	-0.4	2.06e-17	Mitochondrial DNA levels;
LUAD	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg26513180	chr16:89883248	FANCA	0.84	7.36	0.34	9.58e-13	Skin colour saturation;
LUAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg07362569	chr17:61921086	SMARCD2	0.39	6.74	0.31	5.12e-11	Prudent dietary pattern;
LUAD	cis	rs4285028	0.948	rs34158925	chr3:121678465	C/A	cg11130432	chr3:121712080	ILDR1	-0.59	-8.44	-0.38	5.05e-16	Multiple sclerosis;
LUAD	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg09904177	chr6:26538194	HMGN4	0.44	7.44	0.34	5.59e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7943203	0.525	rs920679	chr11:108038477	C/T	cg04873221	chr11:107992290	ACAT1	0.48	7.41	0.34	6.88e-13	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg20307385	chr11:47447363	PSMC3	0.67	11.51	0.49	7.18e-27	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg02990361	chr1:107599529	PRMT6	0.54	8.75	0.39	5.15e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg18944383	chr4:111397179	ENPEP	0.38	7.62	0.35	1.66e-13	Height;
LUAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg08132940	chr7:1081526	C7orf50	-0.79	-10.66	-0.46	1.14e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.21	0.44	4.89e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs12618769	0.597	rs3769730	chr2:99101453	T/C	cg10123293	chr2:99228465	UNC50	0.46	8.06	0.36	8.04e-15	Bipolar disorder;
LUAD	cis	rs12612619	0.704	rs7602823	chr2:27309406	G/A	cg00617064	chr2:27272375	NA	0.35	6.39	0.3	4.49e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg15147215	chr3:52552868	STAB1	-0.37	-7.0	-0.32	1.01e-11	Bipolar disorder;
LUAD	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg27284194	chr4:1044797	NA	-0.71	-10.32	-0.45	2.04e-22	Recombination rate (females);
LUAD	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg05182265	chr7:156933206	UBE3C	-0.8	-17.28	-0.64	5.14e-51	Body mass index;
LUAD	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg19049616	chr17:58042270	RNFT1	-0.44	-6.51	-0.3	2.12e-10	Thyroid stimulating hormone;
LUAD	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg15839431	chr19:19639596	YJEFN3	-0.53	-8.65	-0.39	1.08e-16	Bipolar disorder;
LUAD	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.29	6.73	0.31	5.55e-11	Prostate cancer;
LUAD	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg09640425	chr7:158790006	NA	0.54	9.51	0.42	1.41e-19	Facial morphology (factor 20);
LUAD	trans	rs6964492	0.510	rs6956766	chr7:134436349	C/T	cg20826792	chr1:29425	WASH5P	0.41	6.45	0.3	3e-10	Tonsillectomy;
LUAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg12432903	chr7:1882776	MAD1L1	-0.49	-7.78	-0.35	5.61e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg26513180	chr16:89883248	FANCA	0.72	6.9	0.32	1.86e-11	Skin colour saturation;
LUAD	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg03433033	chr1:76189801	ACADM	0.76	12.34	0.51	4.17e-30	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs727505	1.000	rs2286175	chr7:124431032	G/A	cg23710748	chr7:124431027	NA	-0.48	-9.33	-0.41	6.02e-19	Lewy body disease;
LUAD	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg11494091	chr17:61959527	GH2	0.74	18.31	0.66	1.47e-55	Prudent dietary pattern;
LUAD	cis	rs2041840	0.538	rs4670692	chr2:37573246	G/A	cg25727520	chr2:37576821	QPCT	-0.33	-7.18	-0.33	3.12e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs4242434	0.819	rs1871902	chr8:22470710	G/A	cg03733263	chr8:22462867	KIAA1967	0.67	11.48	0.49	9.78e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs4378999	0.748	rs2127655	chr3:51398958	A/G	cg12934382	chr3:51741135	GRM2	0.41	6.43	0.3	3.55e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs6684514	1.000	rs10494304	chr1:156285764	C/G	cg16558208	chr1:156270281	VHLL	-0.52	-9.81	-0.43	1.36e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.15	0.37	4.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg05731713	chr7:157510257	PTPRN2	0.44	10.07	0.44	1.57e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg22532475	chr10:104410764	TRIM8	0.34	6.92	0.32	1.66e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7827545	0.545	rs16905172	chr8:135556373	A/G	cg17885191	chr8:135476712	NA	0.56	7.85	0.36	3.4e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs4774899	0.752	rs2920269	chr15:57363922	G/C	cg14026238	chr15:57616123	NA	0.44	8.32	0.37	1.26e-15	Urinary tract infection frequency;
LUAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg13397359	chr6:42928475	GNMT	0.58	10.96	0.47	8.87e-25	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.74	-8.83	-0.39	2.86e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg12573674	chr2:1569213	NA	-0.55	-6.61	-0.31	1.19e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg06037631	chr2:74942369	NA	-0.41	-7.24	-0.33	2.08e-12	Subcortical brain region volumes;
LUAD	cis	rs954108	0.809	rs1592060	chr13:29368944	T/C	cg11788234	chr13:29393811	NA	-0.33	-6.78	-0.31	4.07e-11	Obesity-related traits;
LUAD	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.82	-0.36	4.36e-14	Total body bone mineral density;
LUAD	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg19163074	chr7:65112434	INTS4L2	-0.45	-6.75	-0.31	4.82e-11	Aortic root size;
LUAD	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.95	-0.32	1.37e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs10242455	0.571	rs28365067	chr7:99272310	G/A	cg18809830	chr7:99032528	PTCD1	-1.07	-8.35	-0.38	1e-15	Blood metabolite levels;
LUAD	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg07570687	chr10:102243282	WNT8B	0.46	7.09	0.33	5.53e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg11062466	chr8:58055876	NA	0.59	7.66	0.35	1.27e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg14784868	chr12:69753453	YEATS4	0.44	6.98	0.32	1.16e-11	Blood protein levels;
LUAD	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg22508957	chr16:3507546	NAT15	0.81	13.86	0.56	2.79e-36	Tuberculosis;
LUAD	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg06671706	chr8:8559999	CLDN23	0.57	9.81	0.43	1.28e-20	Obesity-related traits;
LUAD	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg20607798	chr8:58055168	NA	0.66	8.42	0.38	5.9e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg06608945	chr2:219082296	ARPC2	0.48	8.28	0.37	1.62e-15	Colorectal cancer;
LUAD	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg26354017	chr1:205819088	PM20D1	-0.54	-8.26	-0.37	1.88e-15	Menarche (age at onset);
LUAD	cis	rs684232	0.666	rs425961	chr17:573714	G/A	cg12384639	chr17:618140	VPS53	0.5	8.56	0.38	2.08e-16	Prostate cancer;
LUAD	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg21214613	chr1:16344536	HSPB7	-0.42	-7.65	-0.35	1.39e-13	Systolic blood pressure;
LUAD	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.53	0.46	3.59e-23	Colorectal cancer;
LUAD	cis	rs9807989	0.507	rs6710034	chr2:103023678	G/A	cg03938978	chr2:103052716	IL18RAP	0.45	10.32	0.45	2.05e-22	Asthma;
LUAD	cis	rs4711350	0.862	rs570749	chr6:33710229	C/T	cg07979401	chr6:33739406	LEMD2	0.51	8.13	0.37	4.66e-15	Schizophrenia;
LUAD	trans	rs7944735	0.702	rs60515486	chr11:47682725	A/T	cg03929089	chr4:120376271	NA	0.5	6.51	0.3	2.18e-10	Intraocular pressure;
LUAD	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg10556349	chr10:835070	NA	0.58	7.55	0.34	2.78e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-7.53	-0.34	3.12e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg03395511	chr6:291903	DUSP22	-0.53	-8.85	-0.4	2.49e-17	Menopause (age at onset);
LUAD	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg22823121	chr1:150693482	HORMAD1	0.4	7.79	0.35	5.19e-14	Melanoma;
LUAD	cis	rs2485376	0.528	rs11191242	chr10:103983087	T/C	cg20641465	chr10:103991465	PITX3	0.46	8.2	0.37	2.96e-15	QT interval;
LUAD	cis	rs938554	0.784	rs11726102	chr4:9951664	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.33	-0.34	1.21e-12	Blood metabolite levels;
LUAD	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg27490568	chr2:178487706	NA	-0.49	-7.96	-0.36	1.64e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs939658	0.805	rs11638625	chr15:79434787	T/G	cg17916960	chr15:79447300	NA	-0.51	-10.6	-0.46	1.92e-23	Refractive error;
LUAD	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg01097406	chr16:89675127	NA	-0.32	-6.37	-0.3	4.86e-10	Vitiligo;
LUAD	cis	rs427941	0.632	rs201498	chr7:101756262	G/A	cg06246474	chr7:101738831	CUX1	0.37	6.44	0.3	3.28e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg09184832	chr6:79620586	NA	-0.51	-9.72	-0.43	2.68e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg12908607	chr1:44402522	ARTN	-0.46	-9.15	-0.41	2.36e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1018836	0.828	rs10086462	chr8:91558089	A/G	cg16814680	chr8:91681699	NA	-0.61	-10.21	-0.44	4.87e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg26354017	chr1:205819088	PM20D1	-0.74	-15.03	-0.59	3.22e-41	Monocyte percentage of white cells;
LUAD	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg09491104	chr22:46646882	C22orf40	0.6	10.71	0.46	7.68e-24	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg20701182	chr2:24300061	SF3B14	0.91	13.49	0.55	9.17e-35	Lymphocyte counts;
LUAD	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg03733263	chr8:22462867	KIAA1967	0.74	12.54	0.52	6.95e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg21775007	chr8:11205619	TDH	0.4	6.71	0.31	6.3e-11	Neuroticism;
LUAD	cis	rs58688157	0.626	rs7941198	chr11:571681	A/G	cg16486109	chr11:613632	IRF7	0.54	8.88	0.4	1.9e-17	Systemic lupus erythematosus;
LUAD	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg17971929	chr21:40555470	PSMG1	-0.47	-7.34	-0.34	1.12e-12	Cognitive function;
LUAD	cis	rs354225	0.513	rs10187338	chr2:54806611	A/G	cg01766943	chr2:54829624	SPTBN1	0.39	7.4	0.34	7.65e-13	Schizophrenia;
LUAD	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg03929089	chr4:120376271	NA	-0.96	-19.52	-0.69	5.95e-61	Height;
LUAD	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg23283495	chr1:209979779	IRF6	0.42	7.42	0.34	6.59e-13	Monobrow;
LUAD	cis	rs7975161	0.572	rs4614534	chr12:104597917	C/T	cg25273343	chr12:104657179	TXNRD1	0.62	6.84	0.32	2.77e-11	Toenail selenium levels;
LUAD	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg24675056	chr1:15929824	NA	0.46	7.97	0.36	1.49e-14	Systolic blood pressure;
LUAD	cis	rs7759001	0.857	rs10946913	chr6:27369873	C/T	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs6547631	0.622	rs10192752	chr2:85926142	T/G	cg21473183	chr2:85925749	GNLY	0.35	7.49	0.34	4.02e-13	Blood protein levels;
LUAD	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.99	17.25	0.64	6.77e-51	IgG glycosylation;
LUAD	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg19622623	chr12:86230825	RASSF9	-0.55	-9.83	-0.43	1.15e-20	Major depressive disorder;
LUAD	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.4	0.45	1.01e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs7517126	1.000	rs6428364	chr1:196844049	C/T	cg07209298	chr1:196795943	CFHR1	0.48	6.5	0.3	2.26e-10	Blood protein levels;
LUAD	cis	rs7680126	0.536	rs7661701	chr4:10064098	C/T	cg00071950	chr4:10020882	SLC2A9	0.6	7.72	0.35	8.36e-14	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg14343924	chr8:8086146	FLJ10661	0.45	6.88	0.32	2.18e-11	Joint mobility (Beighton score);
LUAD	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg03929089	chr4:120376271	NA	-0.93	-17.47	-0.65	7.35e-52	Height;
LUAD	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.85	-0.32	2.6e-11	IgG glycosylation;
LUAD	cis	rs17155006	0.664	rs378334	chr7:107739658	A/C	cg05962710	chr7:107745446	LAMB4	-0.35	-6.96	-0.32	1.34e-11	Pneumococcal bacteremia;
LUAD	cis	rs6005807	0.719	rs7293232	chr22:29015590	T/G	cg12565055	chr22:29076175	TTC28	0.75	8.76	0.39	4.71e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00149659	chr3:10157352	C3orf10	0.57	8.06	0.36	7.87e-15	Alzheimer's disease;
LUAD	cis	rs9394841	0.692	rs56215622	chr6:41892457	G/A	cg17623882	chr6:41773611	USP49	-0.52	-7.03	-0.32	8.36e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs9399401	1.000	rs7756305	chr6:142670955	T/C	cg03128060	chr6:142623767	GPR126	0.32	7.0	0.32	9.96e-12	Chronic obstructive pulmonary disease;
LUAD	cis	rs12216545	0.695	rs10276888	chr7:150230326	T/C	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.5	-0.3	2.28e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	12.2	0.51	1.58e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10865541	0.902	rs7558487	chr2:3425514	G/C	cg22182287	chr2:3452347	TTC15	0.45	7.68	0.35	1.1e-13	Obesity-related traits;
LUAD	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg09796270	chr17:17721594	SREBF1	0.38	7.56	0.34	2.61e-13	Total body bone mineral density;
LUAD	cis	rs2637266	1.000	rs12251543	chr10:78345465	G/A	cg18941641	chr10:78392320	NA	0.33	6.82	0.31	3.24e-11	Pulmonary function;
LUAD	cis	rs7809950	0.862	rs58391518	chr7:107030787	T/C	cg23024343	chr7:107201750	COG5	-0.71	-12.22	-0.51	1.24e-29	Coronary artery disease;
LUAD	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg17652424	chr22:38574118	PLA2G6	-0.33	-10.19	-0.44	6.1e-22	Cutaneous nevi;
LUAD	cis	rs1018836	0.923	rs9694450	chr8:91618292	G/A	cg16814680	chr8:91681699	NA	-0.71	-12.11	-0.51	3.35e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3789045	0.528	rs61817953	chr1:204462612	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.43	-7.13	-0.33	4.25e-12	Educational attainment (college completion);
LUAD	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg23229984	chr5:148520753	ABLIM3	-0.44	-6.99	-0.32	1.07e-11	Breast cancer;
LUAD	cis	rs1784581	1.000	rs1615717	chr6:162400612	C/T	cg17173639	chr6:162384350	PARK2	-0.57	-10.42	-0.45	8.52e-23	Itch intensity from mosquito bite;
LUAD	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg18811423	chr2:55921094	PNPT1	0.51	8.43	0.38	5.32e-16	Metabolic syndrome;
LUAD	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg03806693	chr22:41940476	POLR3H	-0.53	-7.9	-0.36	2.44e-14	Vitiligo;
LUAD	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.04	0.36	9.24e-15	Rheumatoid arthritis;
LUAD	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg13813247	chr22:41461852	NA	-0.48	-7.63	-0.35	1.6e-13	Neuroticism;
LUAD	cis	rs2070433	0.800	rs11700596	chr21:47874054	G/C	cg12379764	chr21:47803548	PCNT	0.5	6.55	0.3	1.64e-10	Lymphocyte counts;
LUAD	cis	rs12286929	0.617	rs11607928	chr11:115102224	A/G	cg04055981	chr11:115044050	NA	0.44	7.67	0.35	1.21e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs56283067	0.811	rs62435997	chr6:44692169	C/T	cg18551225	chr6:44695536	NA	-0.61	-10.15	-0.44	8.03e-22	Total body bone mineral density;
LUAD	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg02079420	chr8:82753780	SNX16	0.42	8.51	0.38	3.11e-16	Diastolic blood pressure;
LUAD	cis	rs17095355	0.901	rs10399964	chr10:111654109	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.65	-7.84	-0.36	3.82e-14	Biliary atresia;
LUAD	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg06532163	chr17:45867833	NA	0.48	8.32	0.37	1.26e-15	IgG glycosylation;
LUAD	cis	rs6761276	0.934	rs11682107	chr2:113835522	G/A	cg10479672	chr2:113810641	IL1F8	-0.37	-7.65	-0.35	1.38e-13	Protein quantitative trait loci;
LUAD	cis	rs11958404	0.929	rs6890364	chr5:157380519	T/G	cg05962755	chr5:157440814	NA	0.6	8.09	0.37	6.59e-15	IgG glycosylation;
LUAD	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06544989	chr22:39130855	UNC84B	0.46	9.05	0.4	5.15e-18	Menopause (age at onset);
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg22718914	chr6:147525462	STXBP5	0.38	6.68	0.31	7.67e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs4889855	0.530	rs72856551	chr17:78552267	G/T	cg16591659	chr17:78472290	NA	0.45	7.77	0.35	6.1e-14	Fractional excretion of uric acid;
LUAD	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg08859206	chr1:53392774	SCP2	0.59	10.6	0.46	1.98e-23	Monocyte count;
LUAD	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg22598563	chr5:131563921	P4HA2	-0.32	-7.88	-0.36	2.85e-14	Blood metabolite levels;
LUAD	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03264133	chr6:25882463	NA	0.83	13.82	0.56	4.24e-36	Blood metabolite levels;
LUAD	cis	rs2625529	0.591	rs7172158	chr15:72405313	T/C	cg16672083	chr15:72433130	SENP8	0.65	11.64	0.49	2.27e-27	Red blood cell count;
LUAD	cis	rs6445967	0.569	rs1913714	chr3:58307829	G/T	cg23715586	chr3:58305044	RPP14	0.4	6.56	0.3	1.55e-10	Platelet count;
LUAD	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg27535305	chr1:53392650	SCP2	0.46	9.12	0.41	3e-18	Monocyte count;
LUAD	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg18827107	chr12:86230957	RASSF9	-0.63	-11.26	-0.48	6.95e-26	Major depressive disorder;
LUAD	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg22491629	chr6:157744540	C6orf35	-0.78	-8.99	-0.4	8.53e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg13722127	chr7:150037890	RARRES2	0.45	7.62	0.35	1.63e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg02569458	chr12:86230093	RASSF9	-0.41	-7.69	-0.35	1.02e-13	Major depressive disorder;
LUAD	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg19761014	chr17:28927070	LRRC37B2	0.82	8.38	0.38	8.06e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4332037	0.523	rs11770148	chr7:1899447	A/G	cg02421172	chr7:1938701	MAD1L1	0.5	6.94	0.32	1.46e-11	Bipolar disorder;
LUAD	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg25767906	chr1:53392781	SCP2	-0.35	-6.61	-0.31	1.15e-10	Monocyte count;
LUAD	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg08514558	chr10:81106712	PPIF	0.52	10.22	0.45	4.54e-22	Height;
LUAD	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg19761014	chr17:28927070	LRRC37B2	0.78	9.47	0.42	2.03e-19	Body mass index;
LUAD	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg27219399	chr15:67835830	MAP2K5	0.42	6.65	0.31	9.22e-11	Restless legs syndrome;
LUAD	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg11062466	chr8:58055876	NA	0.77	9.38	0.42	3.93e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg12444411	chr7:2802554	GNA12	-0.37	-6.68	-0.31	7.67e-11	Height;
LUAD	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09263875	chr16:632152	PIGQ	0.82	17.76	0.65	3.98e-53	Height;
LUAD	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	11.84	0.5	4.09e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs734999	0.967	rs2495365	chr1:2498027	A/G	cg18854424	chr1:2615690	NA	0.34	7.91	0.36	2.2e-14	Ulcerative colitis;
LUAD	cis	rs909002	0.889	rs4949456	chr1:32140039	G/A	cg13919466	chr1:32135498	COL16A1	0.32	6.92	0.32	1.72e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs5756391	0.524	rs2413436	chr22:37312561	A/G	cg16356956	chr22:37317934	CSF2RB	0.36	7.8	0.35	4.8e-14	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg21918786	chr6:109611834	NA	-0.58	-10.76	-0.46	4.92e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg27411982	chr8:10470053	RP1L1	-0.39	-6.81	-0.31	3.27e-11	Triglycerides;
LUAD	trans	rs1325195	0.881	rs3813642	chr1:179070120	C/T	cg11624085	chr17:8464688	MYH10	-0.42	-6.37	-0.3	4.95e-10	IgE grass sensitization;
LUAD	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg20503657	chr10:835505	NA	0.81	12.41	0.52	2.35e-30	Eosinophil percentage of granulocytes;
LUAD	cis	rs7274811	0.554	rs6120299	chr20:32133491	T/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.48	-7.02	-0.32	9.05e-12	Height;
LUAD	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg07636037	chr3:49044803	WDR6	0.63	12.17	0.51	1.99e-29	Parkinson's disease;
LUAD	cis	rs6594713	0.717	rs8180416	chr5:112868440	A/G	cg12552261	chr5:112820674	MCC	0.61	9.31	0.41	6.8e-19	Brain cytoarchitecture;
LUAD	trans	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg01620082	chr3:125678407	NA	-0.44	-6.48	-0.3	2.55e-10	Depression;
LUAD	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg17724175	chr1:150552817	MCL1	0.33	7.68	0.35	1.12e-13	Melanoma;
LUAD	cis	rs9462027	0.585	rs2814976	chr6:34576237	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.78	-0.39	4.11e-17	Systemic lupus erythematosus;
LUAD	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.76	-0.65	3.86e-53	Height;
LUAD	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21582582	chr3:182698605	DCUN1D1	0.57	9.8	0.43	1.4e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg01874867	chr7:94954059	PON1	-0.53	-7.53	-0.34	3.16e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg27411982	chr8:10470053	RP1L1	-0.36	-6.5	-0.3	2.27e-10	Mood instability;
LUAD	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg22963979	chr7:1858916	MAD1L1	-0.48	-8.06	-0.36	8.03e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7759001	0.857	rs10807022	chr6:27362598	T/C	cg18711553	chr6:27366782	ZNF391	0.39	6.54	0.3	1.81e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg25769590	chr7:158789503	NA	-0.4	-7.22	-0.33	2.43e-12	Facial morphology (factor 20);
LUAD	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg01145583	chr6:160211477	TCP1;MRPL18	-0.45	-6.57	-0.3	1.49e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.29	0.37	1.55e-15	Alzheimer's disease;
LUAD	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg05872129	chr22:39784769	NA	-0.8	-15.01	-0.59	4.01e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg17724175	chr1:150552817	MCL1	0.35	8.1	0.37	5.91e-15	Melanoma;
LUAD	cis	rs1941023	0.503	rs4939348	chr11:60135871	A/C	cg08716584	chr11:60157161	MS4A7	-0.49	-9.39	-0.42	3.84e-19	Congenital heart disease (maternal effect);
LUAD	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21582582	chr3:182698605	DCUN1D1	0.72	14.11	0.57	2.63e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg12179176	chr11:130786555	SNX19	0.55	9.29	0.41	8.21e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg06263672	chr7:65235340	NA	0.47	7.61	0.35	1.75e-13	Calcium levels;
LUAD	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg09658497	chr7:2847517	GNA12	-0.47	-7.83	-0.36	3.98e-14	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01936430	chr1:204380496	PPP1R15B	-0.57	-6.75	-0.31	4.89e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg10591111	chr5:226296	SDHA	-0.54	-7.07	-0.32	6.64e-12	Breast cancer;
LUAD	cis	rs62400317	0.859	rs10948219	chr6:45229307	A/T	cg20913747	chr6:44695427	NA	-0.41	-6.57	-0.3	1.44e-10	Total body bone mineral density;
LUAD	cis	rs354033	0.837	rs56402950	chr7:149180219	C/T	cg24335155	chr7:149193227	ZNF746	0.38	6.36	0.3	5.2e-10	Multiple sclerosis;
LUAD	cis	rs16866061	1.000	rs1568750	chr2:225342597	A/T	cg12698349	chr2:225449008	CUL3	0.74	12.83	0.53	4.69e-32	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs7779181	1.000	rs7778788	chr7:32346974	A/C	cg27532318	chr7:32358331	NA	0.44	6.99	0.32	1.09e-11	Body mass index;
LUAD	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg06740227	chr12:86229804	RASSF9	0.4	6.9	0.32	1.96e-11	Major depressive disorder;
LUAD	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg03037974	chr15:76606532	NA	0.47	11.08	0.47	3.19e-25	Blood metabolite levels;
LUAD	cis	rs6564851	0.506	rs11648145	chr16:81257977	T/C	cg00908271	chr16:81254010	PKD1L2	0.34	6.84	0.32	2.73e-11	Carotenoid and tocopherol levels;
LUAD	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.27	-0.37	1.7e-15	Height;
LUAD	trans	rs1728785	0.901	rs1170437	chr16:68607943	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.71	0.46	7.71e-24	Ulcerative colitis;
LUAD	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg03467027	chr4:99064603	C4orf37	0.41	6.57	0.3	1.52e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs73086581	0.787	rs67724338	chr20:3869057	A/G	cg02187196	chr20:3869020	PANK2	0.54	7.58	0.35	2.28e-13	Response to antidepressants in depression;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22455342	chr2:225449267	CUL3	-0.39	-6.41	-0.3	3.92e-10	Cancer;
LUAD	cis	rs813218	0.565	rs6805884	chr3:99684808	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	6.55	0.3	1.71e-10	Orofacial clefts;
LUAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.04	-0.32	7.57e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg04586622	chr2:25135609	ADCY3	0.37	8.55	0.38	2.29e-16	Body mass index;
LUAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg24846343	chr22:24311635	DDTL	-0.71	-15.73	-0.61	3.17e-44	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg08888203	chr3:10149979	C3orf24	0.74	13.07	0.54	5.1e-33	Alzheimer's disease;
LUAD	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg03690763	chr11:133734501	NA	-0.34	-8.02	-0.36	1.08e-14	Childhood ear infection;
LUAD	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg07936489	chr17:37558343	FBXL20	-0.56	-7.56	-0.34	2.59e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg06108461	chr20:60628389	TAF4	-0.79	-13.24	-0.54	9.81e-34	Body mass index;
LUAD	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg10589385	chr1:150898437	SETDB1	0.41	7.84	0.36	3.75e-14	Tonsillectomy;
LUAD	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg00666640	chr1:248458726	OR2T12	0.3	7.24	0.33	2.14e-12	Common traits (Other);
LUAD	cis	rs8192282	0.584	rs6427724	chr1:154502499	T/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.37	-0.34	8.86e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.63	-10.34	-0.45	1.65e-22	Longevity;Endometriosis;
LUAD	trans	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-8.76	-0.39	4.86e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg11301795	chr4:187892539	NA	-0.75	-15.11	-0.59	1.55e-41	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs494562	0.892	rs550499	chr6:86115602	G/C	cg21730993	chr6:86159210	NT5E	0.71	8.06	0.36	7.76e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.79e-18	Life satisfaction;
LUAD	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg19622623	chr12:86230825	RASSF9	-0.43	-7.55	-0.34	2.65e-13	Major depressive disorder;
LUAD	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.78	-0.35	5.45e-14	Blood trace element (Zn levels);
LUAD	cis	rs12765878	1.000	rs1980653	chr10:105654164	A/G	cg11005552	chr10:105648138	OBFC1	0.44	8.39	0.38	7.49e-16	Coronary artery disease;
LUAD	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg20307385	chr11:47447363	PSMC3	0.63	10.77	0.46	4.42e-24	Diastolic blood pressure;Systolic blood pressure;
LUAD	trans	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg04565464	chr8:145669602	NFKBIL2	0.45	6.92	0.32	1.68e-11	Schizophrenia;
LUAD	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg06608945	chr2:219082296	ARPC2	0.42	6.96	0.32	1.32e-11	Colorectal cancer;
LUAD	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.61	-0.31	1.18e-10	Prostate cancer;
LUAD	trans	rs7395662	1.000	rs6485875	chr11:48581034	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.12e-12	HDL cholesterol;
LUAD	cis	rs73416724	1.000	rs74766084	chr6:43287804	G/A	cg26312998	chr6:43337775	ZNF318	0.57	6.83	0.32	2.97e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg14458575	chr2:238380390	NA	0.84	12.59	0.52	4.35e-31	Prostate cancer;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01516881	chr6:292596	DUSP22	-0.8	-13.89	-0.56	2.03e-36	Menopause (age at onset);
LUAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg00431813	chr7:1051703	C7orf50	-0.44	-8.42	-0.38	5.88e-16	Longevity;Endometriosis;
LUAD	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg14927855	chr7:155151427	NA	0.41	8.93	0.4	1.35e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.78	0.39	4e-17	Menopause (age at onset);
LUAD	trans	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.42e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg24450063	chr1:156163899	SLC25A44	1.05	17.19	0.64	1.25e-50	Testicular germ cell tumor;
LUAD	cis	rs7010267	0.570	rs35746859	chr8:120039139	G/C	cg01975934	chr8:119970761	NA	-0.34	-6.43	-0.3	3.5e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs11048434	0.723	rs2080117	chr12:9138341	C/T	cg26114124	chr12:9217669	LOC144571	0.38	6.9	0.32	1.89e-11	Sjögren's syndrome;
LUAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg22963979	chr7:1858916	MAD1L1	-0.71	-12.62	-0.52	3.37e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs76419734	0.510	rs2553446	chr4:106696476	G/A	cg05309399	chr4:106552544	FLJ20184	0.51	6.84	0.32	2.72e-11	Post bronchodilator FEV1;
LUAD	cis	rs62238980	0.614	rs75074953	chr22:32374314	C/A	cg00543991	chr22:32367038	NA	0.91	8.21	0.37	2.8e-15	Childhood ear infection;
LUAD	cis	rs868036	1.000	rs9972436	chr15:68098027	G/C	cg24579218	chr15:68104479	NA	-0.4	-7.43	-0.34	6.23e-13	Restless legs syndrome;
LUAD	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg09117114	chr16:67998030	SLC12A4	-0.51	-6.64	-0.31	9.55e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11229555	0.598	rs1893902	chr11:58190747	A/G	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs8073060	0.963	rs11080353	chr17:33871281	C/T	cg19694781	chr19:47549865	TMEM160	0.78	12.4	0.52	2.39e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs12545109	0.613	rs6998873	chr8:57299697	A/G	cg17761419	chr8:57350749	NA	0.54	7.46	0.34	5.02e-13	Obesity-related traits;
LUAD	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg00071950	chr4:10020882	SLC2A9	-0.7	-14.18	-0.57	1.24e-37	Bone mineral density;
LUAD	cis	rs513349	0.964	rs210141	chr6:33546825	T/C	cg24505687	chr6:33548425	BAK1	0.47	9.08	0.4	4.23e-18	Platelet count;
LUAD	cis	rs713587	0.776	rs1172294	chr2:25169200	A/G	cg04586622	chr2:25135609	ADCY3	0.31	6.71	0.31	6.39e-11	Body mass index in non-asthmatics;
LUAD	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg00750074	chr16:89608354	SPG7	-0.57	-9.99	-0.44	2.96e-21	Multiple myeloma (IgH translocation);
LUAD	trans	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-11.01	-0.47	6.04e-25	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg08807101	chr21:30365312	RNF160	-0.52	-8.83	-0.39	2.84e-17	Dental caries;
LUAD	trans	rs6499188	1.000	rs6499188	chr16:68674788	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.68	10.53	0.46	3.58e-23	Ulcerative colitis;
LUAD	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.25	6.41	0.3	3.96e-10	Parkinson's disease;
LUAD	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg02018176	chr4:1364513	KIAA1530	-0.37	-6.79	-0.31	3.81e-11	Obesity-related traits;
LUAD	cis	rs1448094	0.935	rs4919775	chr12:86339985	T/C	cg00310523	chr12:86230176	RASSF9	0.36	7.73	0.35	7.93e-14	Major depressive disorder;
LUAD	cis	rs10821973	0.527	rs4979761	chr10:63989784	G/A	cg09941381	chr10:64027924	RTKN2	-0.34	-6.79	-0.31	3.91e-11	Hypothyroidism;
LUAD	cis	rs758324	0.773	rs2404776	chr5:131168937	C/T	cg06307176	chr5:131281290	NA	0.43	7.25	0.33	2e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg14196790	chr5:131705035	SLC22A5	0.5	8.64	0.39	1.17e-16	Breast cancer;Mosquito bite size;
LUAD	cis	rs7614311	0.636	rs77639204	chr3:64005452	C/T	cg22134162	chr3:63841271	THOC7	-0.5	-8.62	-0.39	1.31e-16	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs6543140	0.964	rs6761350	chr2:103030776	A/G	cg04239558	chr2:103089729	SLC9A4	0.35	7.01	0.32	9.26e-12	Blood protein levels;
LUAD	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg01851573	chr8:8652454	MFHAS1	-0.44	-8.0	-0.36	1.19e-14	Mood instability;
LUAD	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg06713675	chr4:122721982	EXOSC9	-0.6	-11.47	-0.49	1.06e-26	Type 2 diabetes;
LUAD	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg09904177	chr6:26538194	HMGN4	0.42	6.92	0.32	1.68e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg17178900	chr1:205818956	PM20D1	-0.4	-6.8	-0.31	3.47e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg24801067	chr17:62843696	NA	-0.54	-7.44	-0.34	5.83e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	7.04	0.32	7.8e-12	Depression;
LUAD	cis	rs654950	0.875	rs55865698	chr1:41986758	C/T	cg06885757	chr1:42089581	HIVEP3	-0.34	-7.12	-0.33	4.57e-12	Airway imaging phenotypes;
LUAD	cis	rs877282	0.898	rs12358966	chr10:758703	A/G	cg17470449	chr10:769945	NA	0.58	8.13	0.37	4.65e-15	Uric acid levels;
LUAD	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg11062466	chr8:58055876	NA	0.59	7.65	0.35	1.33e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg09491104	chr22:46646882	C22orf40	-0.55	-7.51	-0.34	3.55e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs11166629	1.000	rs3739423	chr8:135614705	A/G	cg27224718	chr8:135614730	ZFAT	0.6	10.41	0.45	9.93e-23	Smoking quantity;
LUAD	cis	rs1032833	0.732	rs17363183	chr2:179973673	A/T	cg23883738	chr2:179974586	SESTD1	0.66	8.0	0.36	1.24e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg07460842	chr6:66804631	NA	-1.05	-16.27	-0.62	1.45e-46	Exhaled nitric oxide output;
LUAD	trans	rs4650994	1.000	rs4354501	chr1:178524596	T/C	cg05059571	chr16:84539110	KIAA1609	-0.6	-10.26	-0.45	3.24e-22	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg07828340	chr4:882639	GAK	1.08	11.2	0.48	1.16e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg06002616	chr8:101225028	SPAG1	-0.41	-8.31	-0.37	1.31e-15	Atrioventricular conduction;
LUAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg13047869	chr3:10149882	C3orf24	-0.65	-11.22	-0.48	9.39e-26	Alzheimer's disease;
LUAD	trans	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg13565492	chr6:43139072	SRF	-0.6	-6.4	-0.3	4.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.98	0.32	1.12e-11	Hypertriglyceridemia;
LUAD	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.82	-0.47	3.09e-24	Total body bone mineral density;
LUAD	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg22875332	chr1:76189707	ACADM	0.78	12.87	0.53	3.09e-32	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg01236616	chr12:121019343	POP5	1.29	19.31	0.68	4.78e-60	Type 1 diabetes nephropathy;
LUAD	cis	rs1957429	0.808	rs4902327	chr14:65344803	C/T	cg23373153	chr14:65346875	NA	0.61	6.86	0.32	2.41e-11	Pediatric areal bone mineral density (radius);
LUAD	cis	rs739496	0.843	rs621899	chr12:111984851	T/C	cg10833066	chr12:111807467	FAM109A	0.41	6.57	0.3	1.52e-10	Platelet count;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg03762505	chr1:171750926	METTL13	-0.4	-6.61	-0.31	1.18e-10	Subcortical brain region volumes;
LUAD	cis	rs56283067	0.847	rs10807302	chr6:44710152	G/C	cg20913747	chr6:44695427	NA	-0.42	-7.1	-0.33	5.24e-12	Total body bone mineral density;
LUAD	cis	rs67311347	0.524	rs7649168	chr3:40356158	T/C	cg02782426	chr3:40428986	ENTPD3	0.35	7.51	0.34	3.61e-13	Renal cell carcinoma;
LUAD	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg01528321	chr10:82214614	TSPAN14	0.65	10.19	0.44	6.12e-22	Post bronchodilator FEV1;
LUAD	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg08514558	chr10:81106712	PPIF	0.51	9.64	0.42	5.01e-20	Height;
LUAD	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg23803603	chr1:2058230	PRKCZ	0.4	6.5	0.3	2.28e-10	Height;
LUAD	cis	rs35306767	0.623	rs36062650	chr10:1142571	T/C	cg20503657	chr10:835505	NA	0.58	8.4	0.38	6.72e-16	Eosinophil percentage of granulocytes;
LUAD	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg09137382	chr11:130731461	NA	0.43	8.08	0.37	6.82e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05815685	chr19:36036576	TMEM147	-0.67	-6.48	-0.3	2.53e-10	Type 2 diabetes;
LUAD	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.2	0.33	2.86e-12	Lung cancer;
LUAD	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-15.21	-0.59	5.52e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg06808227	chr14:105710500	BRF1	-0.43	-6.59	-0.31	1.33e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs938554	0.736	rs13125646	chr4:9982330	A/G	cg00071950	chr4:10020882	SLC2A9	0.51	7.94	0.36	1.84e-14	Blood metabolite levels;
LUAD	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg03605463	chr16:89740564	NA	0.66	11.28	0.48	5.77e-26	Vitiligo;
LUAD	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg05535760	chr7:792225	HEATR2	-0.81	-9.53	-0.42	1.24e-19	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg00666640	chr1:248458726	OR2T12	0.33	7.98	0.36	1.37e-14	Common traits (Other);
LUAD	cis	rs2074585	0.713	rs2589941	chr15:90931457	C/T	cg10434728	chr15:90938212	IQGAP1	0.39	7.83	0.36	4.1e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg25358565	chr5:93447407	FAM172A	-0.49	-6.68	-0.31	7.73e-11	Diabetic retinopathy;
LUAD	cis	rs4642101	0.824	rs9820977	chr3:12842932	G/A	cg24848339	chr3:12840334	CAND2	0.39	7.86	0.36	3.16e-14	QRS complex (12-leadsum);
LUAD	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19717773	chr7:2847554	GNA12	-0.57	-9.76	-0.43	2.02e-20	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22024508	chr19:16771032	TMEM38A;C19orf42	-0.43	-6.57	-0.3	1.45e-10	Height;
LUAD	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg17425144	chr1:10567563	PEX14	0.62	12.97	0.53	1.28e-32	Breast size;
LUAD	cis	rs76419734	0.558	rs11735330	chr4:106521870	T/A	cg05309399	chr4:106552544	FLJ20184	-0.55	-6.82	-0.31	3.15e-11	Post bronchodilator FEV1;
LUAD	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg07570687	chr10:102243282	WNT8B	0.42	6.39	0.3	4.31e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs8051149	0.793	rs2287122	chr16:87872488	G/A	cg10099957	chr16:87869757	SLC7A5	0.44	7.12	0.33	4.55e-12	Blood metabolite levels;
LUAD	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg12179176	chr11:130786555	SNX19	-0.42	-6.95	-0.32	1.41e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1160297	0.575	rs6715857	chr2:53097395	T/G	cg07782112	chr2:53107842	NA	0.42	8.93	0.4	1.28e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7903847	0.642	rs1537646	chr10:99149922	T/C	cg20016023	chr10:99160130	RRP12	-0.31	-7.59	-0.35	2.12e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs5771069	0.933	rs137848	chr22:50440296	A/G	cg27467552	chr22:50353597	PIM3	-0.42	-7.49	-0.34	4.17e-13	Ulcerative colitis;
LUAD	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg09033577	chr2:88485744	THNSL2	-0.56	-6.61	-0.31	1.14e-10	Plasma clusterin levels;
LUAD	cis	rs4601821	0.965	rs10891543	chr11:113255895	A/G	cg14159747	chr11:113255604	NA	0.5	9.37	0.41	4.49e-19	Alcoholic chronic pancreatitis;
LUAD	cis	rs12210905	0.688	rs79018549	chr6:27513460	G/A	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs73086581	0.947	rs73084531	chr20:3878429	G/A	cg02187196	chr20:3869020	PANK2	0.46	6.45	0.3	3.05e-10	Response to antidepressants in depression;
LUAD	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg08773314	chr2:239334832	ASB1	0.46	10.59	0.46	2.14e-23	Multiple system atrophy;
LUAD	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg04455712	chr21:45112962	RRP1B	0.43	8.73	0.39	5.88e-17	Mean corpuscular volume;
LUAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg09060608	chr5:178986726	RUFY1	0.64	10.35	0.45	1.57e-22	Lung cancer;
LUAD	cis	rs1044826	0.642	rs9826544	chr3:139162831	A/G	cg00490450	chr3:139108681	COPB2	0.44	7.04	0.32	7.74e-12	Obesity-related traits;
LUAD	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.64	0.39	1.17e-16	Menopause (age at onset);
LUAD	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg04365224	chr3:72788183	NA	-0.46	-6.9	-0.32	1.87e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg03709012	chr19:19516395	GATAD2A	0.5	6.62	0.31	1.1e-10	Nonalcoholic fatty liver disease;
LUAD	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg01448562	chr3:133502909	NA	0.55	9.83	0.43	1.11e-20	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg25894440	chr7:65020034	NA	-0.61	-6.58	-0.3	1.39e-10	Diabetic kidney disease;
LUAD	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg24578937	chr1:2090814	PRKCZ	0.78	16.35	0.62	6.14e-47	Height;
LUAD	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg07332563	chr6:291687	DUSP22	-0.48	-8.12	-0.37	5.2e-15	Menopause (age at onset);
LUAD	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg13073564	chr4:8508604	NA	0.63	11.46	0.49	1.2e-26	Response to antineoplastic agents;
LUAD	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg05044414	chr3:183734942	ABCC5	0.49	10.44	0.45	7.72e-23	Anterior chamber depth;
LUAD	cis	rs2281636	1.000	rs2281636	chr10:101492403	T/G	cg17885402	chr10:101492224	COX15;CUTC	0.4	6.79	0.31	3.93e-11	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10802521	chr3:52805072	NEK4	-0.62	-11.07	-0.47	3.33e-25	Bipolar disorder;
LUAD	cis	rs11098699	0.821	rs931708	chr4:124202363	G/A	cg09941581	chr4:124220074	SPATA5	0.45	7.27	0.33	1.72e-12	Mosquito bite size;
LUAD	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg03806693	chr22:41940476	POLR3H	-0.49	-7.25	-0.33	1.98e-12	Vitiligo;
LUAD	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08219700	chr8:58056026	NA	0.7	9.08	0.4	4.1e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg07362569	chr17:61921086	SMARCD2	-0.39	-6.87	-0.32	2.28e-11	Prudent dietary pattern;
LUAD	cis	rs12681287	0.752	rs34279109	chr8:87247944	G/A	cg27223183	chr8:87520930	FAM82B	-0.58	-8.13	-0.37	4.71e-15	Caudate activity during reward;
LUAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg20607798	chr8:58055168	NA	0.58	7.41	0.34	6.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.27e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg17105886	chr17:28927953	LRRC37B2	0.66	7.25	0.33	2e-12	Body mass index;
LUAD	cis	rs9549367	0.569	rs3024719	chr13:113814225	G/A	cg00898013	chr13:113819073	PROZ	-0.83	-13.01	-0.53	9.02e-33	Platelet distribution width;
LUAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00166722	chr3:10149974	C3orf24	0.71	12.14	0.51	2.67e-29	Alzheimer's disease;
LUAD	cis	rs1983170	0.736	rs13447479	chr1:91970464	T/G	cg02896835	chr1:92012615	NA	0.59	7.89	0.36	2.65e-14	Eosinophil percentage of white cells;
LUAD	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.31	6.73	0.31	5.63e-11	Cardiac Troponin-T levels;
LUAD	cis	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg21775007	chr8:11205619	TDH	0.42	7.28	0.33	1.69e-12	Neuroticism;
LUAD	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11890956	chr21:40555474	PSMG1	0.81	14.57	0.58	2.93e-39	Cognitive function;
LUAD	cis	rs6714710	0.603	rs35424768	chr2:98395653	A/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.17	0.37	3.49e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs863345	0.604	rs1342945	chr1:158512912	C/A	cg12129480	chr1:158549410	OR10X1	-0.25	-6.57	-0.3	1.5e-10	Pneumococcal bacteremia;
LUAD	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg08027265	chr7:2291960	NA	-0.4	-7.09	-0.33	5.5e-12	Schizophrenia;
LUAD	cis	rs12681287	0.608	rs13273338	chr8:87453361	T/G	cg27223183	chr8:87520930	FAM82B	-0.68	-9.59	-0.42	7.69e-20	Caudate activity during reward;
LUAD	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg01528321	chr10:82214614	TSPAN14	0.48	7.54	0.34	2.9e-13	Post bronchodilator FEV1;
LUAD	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg11859384	chr17:80120422	CCDC57	0.52	9.27	0.41	9.34e-19	Life satisfaction;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg01171360	chr6:293285	DUSP22	-0.74	-13.12	-0.54	3.04e-33	Menopause (age at onset);
LUAD	cis	rs7107174	0.892	rs3018313	chr11:77989644	C/T	cg19901956	chr11:77921274	USP35	-0.51	-6.48	-0.3	2.58e-10	Testicular germ cell tumor;
LUAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg21385606	chr21:47601150	C21orf56	-0.36	-6.45	-0.3	3.04e-10	Testicular germ cell tumor;
LUAD	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.19	-0.37	3.2e-15	Cannabis dependence symptom count;
LUAD	cis	rs9469913	0.799	rs2744972	chr6:34659054	C/T	cg14254433	chr6:34482411	PACSIN1	-0.44	-7.05	-0.32	7.12e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs4776059	1.000	rs10851521	chr15:52942111	G/A	cg24008177	chr15:52972085	KIAA1370	0.24	6.57	0.3	1.51e-10	Schizophrenia;
LUAD	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg08999081	chr20:33150536	PIGU	-0.58	-12.88	-0.53	3.08e-32	Glomerular filtration rate (creatinine);
LUAD	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12667521	chr19:29218732	NA	0.6	8.49	0.38	3.42e-16	Methadone dose in opioid dependence;
LUAD	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.13	-0.33	4.29e-12	Blood metabolite levels;
LUAD	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg06002616	chr8:101225028	SPAG1	0.4	8.07	0.37	7.3e-15	Atrioventricular conduction;
LUAD	cis	rs1881396	0.945	rs1881397	chr2:27832285	A/G	cg27432699	chr2:27873401	GPN1	0.43	6.43	0.3	3.55e-10	Nonalcoholic fatty liver disease;
LUAD	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg25828445	chr12:7781288	NA	-0.56	-7.89	-0.36	2.65e-14	HDL cholesterol levels;
LUAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg27454412	chr7:1067447	C7orf50	0.42	6.63	0.31	1.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg05887092	chr17:76393375	PGS1	0.42	7.41	0.34	7.1e-13	HDL cholesterol levels;
LUAD	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg26343298	chr8:95960752	TP53INP1	0.37	7.82	0.36	4.12e-14	Type 2 diabetes;
LUAD	cis	rs4664304	0.754	rs67504285	chr2:160821211	C/T	cg23995753	chr2:160760732	LY75	-0.39	-7.0	-0.32	9.95e-12	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg12615879	chr12:58013172	SLC26A10	-0.34	-6.41	-0.3	3.79e-10	Celiac disease or Rheumatoid arthritis;
LUAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.47e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11252926	0.797	rs61837235	chr10:489363	G/A	cg18196295	chr10:418757	DIP2C	-0.48	-7.19	-0.33	2.87e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs3823572	0.504	rs2953633	chr7:133644052	A/C	cg03336402	chr7:133662267	EXOC4	-0.41	-7.56	-0.34	2.54e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg26587870	chr6:27730563	NA	-0.48	-7.85	-0.36	3.43e-14	Parkinson's disease;
LUAD	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg00701064	chr4:6280414	WFS1	0.68	14.56	0.58	3.37e-39	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg24642844	chr7:1081250	C7orf50	-0.93	-13.89	-0.56	2.02e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg24644049	chr4:85504048	CDS1	0.89	7.32	0.34	1.22e-12	Skin colour saturation;
LUAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg08132940	chr7:1081526	C7orf50	-0.77	-10.29	-0.45	2.49e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs73198271	0.515	rs11906	chr8:8641259	C/T	cg01851573	chr8:8652454	MFHAS1	0.56	7.58	0.35	2.17e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg09359103	chr1:154839909	KCNN3	-0.94	-22.09	-0.73	1.8e-72	Prostate cancer;
LUAD	trans	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.42e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs73198271	0.737	rs506960	chr8:8630269	A/C	cg01851573	chr8:8652454	MFHAS1	0.4	7.23	0.33	2.35e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg12034118	chr1:209979487	IRF6	0.49	7.04	0.32	7.63e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs6496044	0.963	rs7165300	chr15:86070069	G/C	cg13263323	chr15:86062960	AKAP13	-0.53	-9.27	-0.41	9.29e-19	Interstitial lung disease;
LUAD	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg11502198	chr6:26597334	ABT1	0.55	9.09	0.4	3.73e-18	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg18944383	chr4:111397179	ENPEP	0.38	7.76	0.35	6.25e-14	Height;
LUAD	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg25482853	chr8:67687455	SGK3	1.14	17.98	0.66	3.97e-54	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7799006	0.929	rs6951493	chr7:2257612	G/A	cg12745145	chr7:2261452	MAD1L1	-0.33	-6.42	-0.3	3.74e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs8002861	0.967	rs9533690	chr13:44480598	T/C	cg17145862	chr1:211918768	LPGAT1	0.75	17.76	0.65	3.8e-53	Leprosy;
LUAD	trans	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.26	-0.37	1.93e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg21433313	chr16:3507492	NAT15	0.78	14.47	0.58	8.08e-39	Tuberculosis;
LUAD	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg12140854	chr5:148520817	ABLIM3	-0.67	-10.72	-0.46	7.08e-24	Breast cancer;
LUAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.43	-7.4	-0.34	7.4e-13	Longevity;Endometriosis;
LUAD	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg16205897	chr5:131564050	P4HA2	0.32	7.02	0.32	8.61e-12	Blood metabolite levels;
LUAD	cis	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg14019146	chr3:50243930	SLC38A3	0.38	7.4	0.34	7.51e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg15181151	chr6:150070149	PCMT1	0.41	7.83	0.36	4.1e-14	Lung cancer;
LUAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg25243455	chr2:114033360	PAX8;LOC440839	-0.38	-8.49	-0.38	3.64e-16	Lymphocyte counts;
LUAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.47	-0.34	4.55e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7731657	0.537	rs33962216	chr5:130290180	T/C	cg08523029	chr5:130500466	HINT1	-0.58	-7.5	-0.34	3.81e-13	Fasting plasma glucose;
LUAD	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg00129232	chr17:37814104	STARD3	-0.46	-7.47	-0.34	4.71e-13	Asthma;
LUAD	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.39	6.35	0.3	5.55e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg06740227	chr12:86229804	RASSF9	-0.41	-7.23	-0.33	2.27e-12	Major depressive disorder;
LUAD	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg11189052	chr15:85197271	WDR73	-0.79	-13.62	-0.55	2.91e-35	P wave terminal force;
LUAD	cis	rs1018836	0.923	rs10956720	chr8:91576222	C/T	cg16814680	chr8:91681699	NA	-0.68	-11.88	-0.5	2.78e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1997103	1.000	rs2331064	chr7:55408610	C/G	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg23950597	chr19:37808831	NA	-0.64	-7.68	-0.35	1.11e-13	Coronary artery calcification;
LUAD	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg06697600	chr4:7070879	GRPEL1	0.56	7.95	0.36	1.73e-14	Monocyte percentage of white cells;
LUAD	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg01028140	chr2:1542097	TPO	-0.6	-7.72	-0.35	8.57e-14	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7107174	0.892	rs2510033	chr11:77941771	T/G	cg02023728	chr11:77925099	USP35	0.51	7.8	0.35	5.05e-14	Testicular germ cell tumor;
LUAD	cis	rs494562	0.892	rs567686	chr6:86124164	A/T	cg13315970	chr6:86159197	NT5E	0.73	8.21	0.37	2.7e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg05768032	chr16:30646687	NA	0.46	8.11	0.37	5.55e-15	Multiple myeloma;
LUAD	trans	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg16724585	chr3:197361211	NA	-0.47	-7.09	-0.33	5.75e-12	Pancreatic cancer;
LUAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg07677032	chr17:61819896	STRADA	-0.52	-9.19	-0.41	1.75e-18	Prudent dietary pattern;
LUAD	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg09537434	chr19:41945824	ATP5SL	-0.49	-7.92	-0.36	2.05e-14	Height;
LUAD	cis	rs11771526	0.686	rs28399034	chr7:32272898	A/G	cg27532318	chr7:32358331	NA	0.52	7.08	0.33	6.1e-12	Body mass index;
LUAD	cis	rs4906332	1.000	rs2246490	chr14:103984294	G/T	cg19000871	chr14:103996768	TRMT61A	0.41	7.03	0.32	8.08e-12	Coronary artery disease;
LUAD	cis	rs13082711	0.911	rs77685358	chr3:27519158	C/T	cg02860705	chr3:27208620	NA	0.61	9.15	0.41	2.45e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs9549328	0.670	rs61963562	chr13:113616523	T/G	cg17524180	chr13:113633600	MCF2L	0.3	6.41	0.3	3.88e-10	Systolic blood pressure;
LUAD	cis	rs6987853	0.933	rs2923430	chr8:42391195	T/C	cg09913449	chr8:42400586	C8orf40	0.43	8.13	0.37	4.86e-15	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19554565	chr14:31028155	G2E3	-0.41	-6.67	-0.31	8.01e-11	Cancer;
LUAD	cis	rs3823572	0.526	rs2971967	chr7:133642595	A/G	cg03336402	chr7:133662267	EXOC4	-0.43	-7.74	-0.35	7.14e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.44	-0.38	5.16e-16	Total cholesterol levels;
LUAD	cis	rs1395	0.744	rs1122227	chr2:27544285	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.33	-6.98	-0.32	1.16e-11	Blood metabolite levels;
LUAD	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	4.04e-11	Parkinson's disease;
LUAD	trans	rs2262909	0.962	rs12610034	chr19:22314528	G/A	cg17074339	chr11:11642133	GALNTL4	0.47	7.49	0.34	3.97e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg13047869	chr3:10149882	C3orf24	0.65	10.97	0.47	8.14e-25	Alzheimer's disease;
LUAD	trans	rs35110281	0.540	rs55840436	chr21:45118541	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	9.84	0.43	1.05e-20	Mean corpuscular volume;
LUAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg07362569	chr17:61921086	SMARCD2	0.39	6.68	0.31	7.4e-11	Prudent dietary pattern;
LUAD	cis	rs2734839	0.537	rs10891549	chr11:113278447	T/C	cg14159747	chr11:113255604	NA	0.62	12.55	0.52	5.98e-31	Information processing speed;
LUAD	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg26727032	chr16:67993705	SLC12A4	-0.54	-7.03	-0.32	8.55e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg14343924	chr8:8086146	FLJ10661	-0.46	-7.34	-0.34	1.09e-12	Joint mobility (Beighton score);
LUAD	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg03690763	chr11:133734501	NA	-0.34	-7.84	-0.36	3.67e-14	Childhood ear infection;
LUAD	cis	rs6998277	1.000	rs6998277	chr8:103639941	T/C	cg10187029	chr8:103597600	NA	0.67	10.35	0.45	1.56e-22	Migraine;
LUAD	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg25767906	chr1:53392781	SCP2	-0.48	-8.94	-0.4	1.22e-17	Monocyte count;
LUAD	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg09455208	chr3:40491958	NA	-0.53	-11.69	-0.49	1.53e-27	Renal cell carcinoma;
LUAD	cis	rs6066825	0.666	rs6019374	chr20:47303812	A/G	cg18078177	chr20:47281410	PREX1	0.4	6.44	0.3	3.21e-10	Colorectal cancer;
LUAD	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg15900387	chr1:150738905	CTSS	0.35	6.5	0.3	2.27e-10	Melanoma;
LUAD	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg09365446	chr1:150670422	GOLPH3L	0.66	12.57	0.52	5.38e-31	Tonsillectomy;
LUAD	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg06453172	chr10:134556979	INPP5A	-0.78	-10.62	-0.46	1.68e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg03395511	chr6:291903	DUSP22	-0.5	-8.12	-0.37	5.32e-15	Menopause (age at onset);
LUAD	trans	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg19862616	chr7:65841803	NCRNA00174	1.05	25.94	0.78	1.75e-89	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.22	-0.33	2.42e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7394579	1	rs7394579	chr11:61581450	A/G	cg19610905	chr11:61596333	FADS2	-0.65	-9.38	-0.42	3.92e-19	Red cell distribution width;Mean platelet volume;
LUAD	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg07685180	chr8:600429	NA	0.99	9.25	0.41	1.09e-18	IgG glycosylation;
LUAD	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg15997130	chr1:24165203	NA	0.55	9.5	0.42	1.54e-19	Immature fraction of reticulocytes;
LUAD	cis	rs7903847	0.642	rs11189182	chr10:99144186	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-7.15	-0.33	3.85e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg27588902	chr6:42928151	GNMT	-0.35	-9.41	-0.42	3.24e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.51	7.01	0.32	9.24e-12	Platelet count;
LUAD	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6489882	0.867	rs4767032	chr12:113363077	T/G	cg20102336	chr12:113376681	OAS3	-0.6	-9.34	-0.41	5.6e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs9811920	0.683	rs813218	chr3:99592596	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-7.05	-0.32	7.5e-12	Axial length;
LUAD	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18099408	chr3:52552593	STAB1	0.4	6.94	0.32	1.47e-11	Bipolar disorder;
LUAD	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-7.73	-0.35	7.82e-14	Blood metabolite levels;
LUAD	cis	rs2408955	0.522	rs2051851	chr12:48485940	G/C	cg04545296	chr12:48745243	ZNF641	-0.33	-8.57	-0.38	1.92e-16	Glycated hemoglobin levels;
LUAD	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg13722127	chr7:150037890	RARRES2	0.44	7.97	0.36	1.54e-14	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs1973993	0.689	rs17375929	chr1:96962246	A/T	cg10631902	chr5:14652156	NA	-0.45	-7.8	-0.35	4.91e-14	Weight;
LUAD	cis	rs78487399	0.808	rs13405776	chr2:43739121	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.52	-0.3	2.06e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs12210905	0.688	rs12212632	chr6:27472416	T/C	cg08851530	chr6:28072375	NA	1.03	7.92	0.36	2.19e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs9900062	0.844	rs9908143	chr17:62754586	T/C	cg02097616	chr17:62675921	NA	0.62	8.62	0.39	1.37e-16	QT interval;
LUAD	cis	rs3784262	0.934	rs7164408	chr15:58259336	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.48	-9.94	-0.44	4.58e-21	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7584330	0.554	rs80151891	chr2:238398826	G/T	cg14458575	chr2:238380390	NA	0.77	11.39	0.48	2.16e-26	Prostate cancer;
LUAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs708547	0.578	rs781665	chr4:57831461	G/A	cg00922110	chr4:57842668	C4orf14	-0.39	-7.2	-0.33	2.73e-12	Response to bleomycin (chromatid breaks);
LUAD	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.89	-0.53	2.75e-32	Breast cancer;
LUAD	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg25457927	chr22:38595422	NA	-0.53	-13.87	-0.56	2.48e-36	Cutaneous nevi;
LUAD	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg25036284	chr2:26402008	FAM59B	-0.61	-8.38	-0.38	7.68e-16	Gut microbiome composition (summer);
LUAD	cis	rs4523957	0.553	rs2131703	chr17:2025360	G/T	cg16513277	chr17:2031491	SMG6	-0.98	-19.9	-0.7	1.2e-62	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14986359	chr19:59085030	MZF1;LOC100131691	0.41	6.65	0.31	8.84e-11	Survival in pancreatic cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01083340	chr11:66176265	NA	-0.46	-7.15	-0.33	3.75e-12	Height;
LUAD	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg05082376	chr22:42548792	NA	0.45	7.72	0.35	8.19e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg11859384	chr17:80120422	CCDC57	-0.47	-8.33	-0.38	1.13e-15	Life satisfaction;
LUAD	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.09	-0.33	5.65e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg18811423	chr2:55921094	PNPT1	0.56	9.4	0.42	3.5e-19	Metabolic syndrome;
LUAD	trans	rs7246760	0.867	rs12462694	chr19:9778032	C/T	cg02900749	chr2:68251473	NA	-0.6	-6.55	-0.3	1.71e-10	Pursuit maintenance gain;
LUAD	trans	rs12517041	1.000	rs4701365	chr5:23315034	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.73	-0.31	5.37e-11	Calcium levels;
LUAD	cis	rs2073300	0.609	rs6132617	chr20:23420151	G/C	cg12062639	chr20:23401060	NAPB	0.98	10.83	0.47	2.83e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6489785	0.551	rs594507	chr12:121280522	A/G	cg02419362	chr12:121203948	SPPL3	-0.35	-6.7	-0.31	6.74e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg25566285	chr7:158114605	PTPRN2	0.52	11.0	0.47	6.55e-25	Calcium levels;
LUAD	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg05865280	chr17:75406074	SEPT9	0.61	19.41	0.69	1.72e-60	Airflow obstruction;
LUAD	trans	rs11039798	1.000	rs7131020	chr11:48642132	A/G	cg15704280	chr7:45808275	SEPT13	0.66	7.53	0.34	3.19e-13	Axial length;
LUAD	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs8073060	0.586	rs188959	chr17:34021307	C/A	cg19694781	chr19:47549865	TMEM160	-1.22	-19.42	-0.69	1.67e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg25036284	chr2:26402008	FAM59B	-0.57	-7.99	-0.36	1.33e-14	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	9.83	0.43	1.14e-20	Lung cancer in ever smokers;
LUAD	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6445967	0.569	rs1135089	chr3:58304112	C/T	cg23715586	chr3:58305044	RPP14	0.41	6.72	0.31	6e-11	Platelet count;
LUAD	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg00071950	chr4:10020882	SLC2A9	-0.61	-12.05	-0.51	6.19e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1941023	0.503	rs4939349	chr11:60135880	G/A	cg08716584	chr11:60157161	MS4A7	-0.49	-9.48	-0.42	1.9e-19	Congenital heart disease (maternal effect);
LUAD	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg18806716	chr10:30721971	MAP3K8	0.79	16.64	0.63	3.41e-48	Inflammatory bowel disease;
LUAD	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg25985355	chr7:65971099	NA	0.53	6.72	0.31	6e-11	Diabetic kidney disease;
LUAD	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg26513180	chr16:89883248	FANCA	0.75	6.44	0.3	3.2e-10	Skin colour saturation;
LUAD	cis	rs7944584	0.632	rs11606683	chr11:47302733	C/T	cg20307385	chr11:47447363	PSMC3	0.44	6.81	0.31	3.42e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg12908607	chr1:44402522	ARTN	0.53	10.36	0.45	1.46e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.93	0.53	1.89e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg04731861	chr2:219085781	ARPC2	-0.24	-7.52	-0.34	3.39e-13	Colorectal cancer;
LUAD	cis	rs6484504	0.576	rs208091	chr11:31190099	G/C	cg14844989	chr11:31128820	NA	-0.44	-8.07	-0.37	7.56e-15	Red blood cell count;
LUAD	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01570182	chr17:44337453	NA	1.14	17.49	0.65	5.96e-52	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.56	6.67	0.31	7.8e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs790123	0.553	rs7612991	chr3:122351791	T/C	cg22896480	chr3:122379438	NA	0.41	7.08	0.33	6e-12	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs75804782	0.630	rs56108200	chr2:239276888	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	6.73	0.31	5.44e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg04492858	chr10:133558786	NA	0.39	7.81	0.36	4.41e-14	Survival in rectal cancer;
LUAD	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg11301795	chr4:187892539	NA	-0.76	-14.93	-0.59	8.46e-41	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-6.39	-0.3	4.36e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7586879	0.521	rs1865689	chr2:25108197	C/T	cg04586622	chr2:25135609	ADCY3	-0.4	-9.3	-0.41	7.37e-19	Body mass index;
LUAD	cis	rs28595532	0.925	rs28627331	chr4:119665345	T/C	cg14228332	chr4:119757509	SEC24D	0.82	7.5	0.34	3.71e-13	Cannabis dependence symptom count;
LUAD	cis	rs1032833	0.732	rs79532902	chr2:180046666	G/T	cg23883738	chr2:179974586	SESTD1	-0.72	-8.01	-0.36	1.12e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.43	-7.03	-0.32	8.35e-12	Tonsillectomy;
LUAD	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg18129748	chr3:49941408	MST1R	-0.4	-6.53	-0.3	1.86e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg08355456	chr11:67383691	NA	0.37	6.49	0.3	2.45e-10	Mean corpuscular volume;
LUAD	cis	rs870825	0.587	rs6826883	chr4:185616167	A/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.09	0.57	3.19e-37	Blood protein levels;
LUAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg03354898	chr7:1950403	MAD1L1	-0.46	-8.6	-0.39	1.63e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg19748678	chr4:122722346	EXOSC9	0.44	6.93	0.32	1.55e-11	Type 2 diabetes;
LUAD	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg21138405	chr5:131827807	IRF1	0.58	13.16	0.54	2.12e-33	Asthma (sex interaction);
LUAD	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg18230493	chr5:56204884	C5orf35	1.06	15.73	0.61	3.04e-44	Initial pursuit acceleration;
LUAD	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg08601574	chr20:25228251	PYGB	-0.47	-8.8	-0.39	3.43e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs798766	1.000	rs798756	chr4:1707447	T/C	cg03947459	chr4:1685442	FAM53A	0.5	6.82	0.31	3.25e-11	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27286337	chr10:134555280	INPP5A	0.68	9.72	0.43	2.8e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg27411982	chr8:10470053	RP1L1	0.38	6.58	0.3	1.36e-10	Retinal vascular caliber;
LUAD	cis	rs66731853	0.557	rs576968	chr1:20901246	A/G	cg04087271	chr1:20915334	CDA	-0.45	-7.98	-0.36	1.38e-14	Mean corpuscular volume;
LUAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg22907277	chr7:1156413	C7orf50	0.57	9.65	0.42	4.94e-20	Longevity;Endometriosis;
LUAD	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg00666640	chr1:248458726	OR2T12	0.32	7.63	0.35	1.54e-13	Common traits (Other);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20826792	chr1:29425	WASH5P	-0.65	-8.06	-0.36	7.85e-15	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9467160	1.000	rs9467166	chr6:24444435	G/A	cg16211469	chr6:24423932	MRS2	0.44	7.01	0.32	9.66e-12	Liver enzyme levels;
LUAD	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.53	9.04	0.4	5.55e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-8.47	-0.38	4.17e-16	Neutrophil percentage of white cells;
LUAD	cis	rs7945705	0.967	rs2568090	chr11:8849495	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.47	8.48	0.38	3.91e-16	Hemoglobin concentration;
LUAD	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg25753631	chr6:25732923	NA	-0.45	-7.89	-0.36	2.52e-14	Iron status biomarkers;
LUAD	trans	rs7395662	0.791	rs4347396	chr11:48895929	T/C	cg00717180	chr2:96193071	NA	0.39	7.42	0.34	6.66e-13	HDL cholesterol;
LUAD	cis	rs1997103	0.954	rs940880	chr7:55392619	C/G	cg17469321	chr7:55412551	NA	0.68	11.55	0.49	5.13e-27	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg18230493	chr5:56204884	C5orf35	0.99	13.84	0.56	3.29e-36	Initial pursuit acceleration;
LUAD	trans	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg18944383	chr4:111397179	ENPEP	-0.5	-9.15	-0.41	2.52e-18	Coronary artery disease;
LUAD	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg15445000	chr17:37608096	MED1	0.44	8.21	0.37	2.74e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs17433780	0.808	rs1074541	chr1:89509499	A/G	cg09516651	chr1:89888402	LOC400759	0.55	10.51	0.46	4.08e-23	Carotid intima media thickness;
LUAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg03388025	chr16:89894329	SPIRE2	0.49	12.87	0.53	3.27e-32	Vitiligo;
LUAD	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg19346786	chr7:2764209	NA	-0.49	-10.54	-0.46	3.22e-23	Height;
LUAD	cis	rs7940866	0.678	rs61909201	chr11:130839547	C/T	cg12179176	chr11:130786555	SNX19	0.45	6.86	0.32	2.47e-11	Schizophrenia;
LUAD	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg20933634	chr6:27740509	NA	0.46	7.27	0.33	1.77e-12	Parkinson's disease;
LUAD	cis	rs9787249	0.533	rs1883649	chr1:40246549	C/T	cg02773041	chr1:40204384	PPIE	0.45	7.69	0.35	1.06e-13	Blood protein levels;
LUAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.16	-0.41	2.34e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs701145	0.938	rs701131	chr3:154086138	C/G	cg17054900	chr3:154042577	DHX36	0.66	7.19	0.33	2.97e-12	Coronary artery disease;
LUAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.59	-10.01	-0.44	2.66e-21	Lymphocyte counts;
LUAD	trans	rs78049276	0.512	rs6855875	chr4:148402737	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.59	-8.05	-0.36	8.62e-15	Pulse pressure;
LUAD	trans	rs7395662	0.963	rs12800770	chr11:48604927	T/G	cg00717180	chr2:96193071	NA	-0.39	-7.27	-0.33	1.72e-12	HDL cholesterol;
LUAD	cis	rs12200560	0.505	rs211162	chr6:97067344	G/A	cg06623918	chr6:96969491	KIAA0776	0.44	6.64	0.31	9.42e-11	Coronary heart disease;
LUAD	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.72	-0.31	5.93e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9487051	0.768	rs386696	chr6:109520166	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.87	-0.32	2.26e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18099408	chr3:52552593	STAB1	0.47	8.27	0.37	1.75e-15	Bipolar disorder;
LUAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.41	0.55	2.12e-34	Prudent dietary pattern;
LUAD	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg08999081	chr20:33150536	PIGU	0.49	9.44	0.42	2.59e-19	Coronary artery disease;
LUAD	cis	rs2274273	0.588	rs7158791	chr14:55828607	A/G	cg04306507	chr14:55594613	LGALS3	0.42	8.18	0.37	3.3e-15	Protein biomarker;
LUAD	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg20607798	chr8:58055168	NA	0.65	8.45	0.38	4.6e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg06074448	chr4:187884817	NA	-0.38	-7.53	-0.34	3.15e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg02508848	chr16:68573721	ZFP90	-0.42	-6.57	-0.3	1.45e-10	Ulcerative colitis;
LUAD	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	12.41	0.52	2.29e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg20283391	chr11:68216788	NA	-0.42	-6.56	-0.3	1.56e-10	Total body bone mineral density;
LUAD	cis	rs7107174	1.000	rs1942352	chr11:77970563	T/G	cg02023728	chr11:77925099	USP35	0.47	7.93	0.36	1.93e-14	Testicular germ cell tumor;
LUAD	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.45	8.54	0.38	2.53e-16	Neutrophil percentage of white cells;
LUAD	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs13315871	0.929	rs35004361	chr3:58313394	T/C	cg20936604	chr3:58311152	NA	-0.77	-8.41	-0.38	6.4e-16	Cholesterol, total;
LUAD	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg04025307	chr7:1156635	C7orf50	0.57	8.17	0.37	3.59e-15	Bronchopulmonary dysplasia;
LUAD	cis	rs7216064	1.000	rs2046323	chr17:65849927	T/G	cg08758996	chr17:66097529	LOC651250	0.47	7.25	0.33	2.05e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00149659	chr3:10157352	C3orf10	0.6	8.36	0.38	9.17e-16	Alzheimer's disease;
LUAD	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg08761264	chr16:28874980	SH2B1	-0.42	-6.5	-0.3	2.32e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg05590025	chr7:65112418	INTS4L2	-0.72	-6.59	-0.31	1.32e-10	Diabetic kidney disease;
LUAD	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.98	0.32	1.18e-11	Colorectal cancer;
LUAD	cis	rs35123781	0.696	rs904612	chr5:139070952	G/A	cg10513866	chr5:139070639	NA	0.55	9.01	0.4	6.92e-18	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.35e-11	Breast cancer;
LUAD	cis	rs6942407	0.592	rs4728689	chr7:86851097	T/G	cg02420886	chr7:86849541	C7orf23	0.65	7.51	0.34	3.64e-13	Food allergy;
LUAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg08219700	chr8:58056026	NA	0.43	6.87	0.32	2.34e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs367943	0.712	rs7734304	chr5:112730165	G/A	cg12552261	chr5:112820674	MCC	0.48	9.41	0.42	3.09e-19	Type 2 diabetes;
LUAD	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg26408565	chr15:76604113	ETFA	-0.45	-7.3	-0.33	1.43e-12	Blood metabolite levels;
LUAD	cis	rs4819852	0.958	rs2238786	chr22:19975444	A/G	cg07821417	chr22:19972146	ARVCF	0.4	7.64	0.35	1.45e-13	Pulse pressure;
LUAD	cis	rs1595825	0.891	rs58409972	chr2:198897061	A/T	cg10547527	chr2:198650123	BOLL	-0.55	-7.21	-0.33	2.52e-12	Ulcerative colitis;
LUAD	cis	rs3823572	0.542	rs62470445	chr7:133630961	T/C	cg03336402	chr7:133662267	EXOC4	0.41	7.57	0.35	2.29e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs8017423	1.000	rs8015379	chr14:90679432	C/T	cg14092571	chr14:90743983	NA	-0.48	-8.55	-0.38	2.28e-16	Mortality in heart failure;
LUAD	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg10426581	chr7:100472382	SRRT	0.77	10.2	0.44	5.46e-22	Resting heart rate;
LUAD	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.6	10.94	0.47	1.1e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg21865736	chr4:2628771	FAM193A	-0.41	-6.4	-0.3	4.15e-10	Behavioural disinhibition (generation interaction);
LUAD	cis	rs612683	0.690	rs11166440	chr1:100808363	C/T	cg06223162	chr1:101003688	GPR88	-0.36	-6.76	-0.31	4.61e-11	Breast cancer;
LUAD	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.68e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7301016	1.000	rs11174504	chr12:62877036	A/G	cg11441379	chr12:63026424	NA	0.52	6.46	0.3	2.8e-10	IgG glycosylation;
LUAD	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg13393036	chr8:95962371	TP53INP1	-0.43	-10.37	-0.45	1.32e-22	Type 2 diabetes;
LUAD	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg02527881	chr3:46936655	PTH1R	0.42	8.04	0.36	9.36e-15	Colorectal cancer;
LUAD	cis	rs220324	0.618	rs9975331	chr21:43559892	T/C	cg09727148	chr21:43560719	UMODL1	0.59	8.92	0.4	1.45e-17	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs71478720	1.000	rs5744276	chr11:112016871	C/G	cg04929355	chr11:112034997	IL18	0.44	6.82	0.31	3.18e-11	Interleukin-18 levels;
LUAD	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg06713675	chr4:122721982	EXOSC9	-0.83	-17.6	-0.65	1.98e-52	Type 2 diabetes;
LUAD	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg06108461	chr20:60628389	TAF4	0.93	14.17	0.57	1.36e-37	Body mass index;
LUAD	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg07157834	chr1:205819609	PM20D1	-0.52	-9.1	-0.4	3.52e-18	Menarche (age at onset);
LUAD	cis	rs9487051	0.735	rs351745	chr6:109529169	C/T	cg21918786	chr6:109611834	NA	0.45	8.19	0.37	3.19e-15	Reticulocyte fraction of red cells;
LUAD	cis	rs3823572	0.542	rs28529474	chr7:133634908	C/T	cg03336402	chr7:133662267	EXOC4	0.42	7.63	0.35	1.56e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg02002194	chr4:3960332	NA	0.29	6.89	0.32	2e-11	Mood instability;
LUAD	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg15790184	chr11:494944	RNH1	0.42	6.77	0.31	4.33e-11	Systemic lupus erythematosus;
LUAD	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg08999081	chr20:33150536	PIGU	0.47	8.95	0.4	1.14e-17	Coronary artery disease;
LUAD	cis	rs735539	0.645	rs9550663	chr13:21174053	C/T	cg27499820	chr13:21296301	IL17D	0.54	8.88	0.4	1.98e-17	Dental caries;
LUAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.58	9.99	0.44	2.96e-21	Lymphocyte counts;
LUAD	cis	rs72928364	1.000	rs35617051	chr3:100662816	A/C	cg10123952	chr3:100791384	NA	0.65	7.51	0.34	3.55e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg11517269	chr6:28058789	ZSCAN12L1	0.26	6.65	0.31	9.11e-11	Parkinson's disease;
LUAD	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg18099408	chr3:52552593	STAB1	-0.39	-6.89	-0.32	2.09e-11	Bipolar disorder;
LUAD	cis	rs73086581	1.000	rs17286768	chr20:3924569	A/G	cg02187196	chr20:3869020	PANK2	0.49	6.78	0.31	4.14e-11	Response to antidepressants in depression;
LUAD	trans	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg07211511	chr3:129823064	LOC729375	-0.53	-6.94	-0.32	1.46e-11	Blood pressure (smoking interaction);
LUAD	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.67	-10.31	-0.45	2.15e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.45	-0.52	1.54e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg15117754	chr3:10150083	C3orf24	0.44	7.09	0.33	5.76e-12	Alzheimer's disease;
LUAD	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg18105134	chr13:113819100	PROZ	-0.87	-15.14	-0.59	1.1e-41	Platelet distribution width;
LUAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg06608945	chr2:219082296	ARPC2	-0.42	-6.85	-0.32	2.59e-11	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18876405	chr7:65276391	NA	-0.43	-6.81	-0.31	3.27e-11	Aortic root size;
LUAD	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg00204512	chr16:28754710	NA	0.36	7.93	0.36	1.98e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg27411982	chr8:10470053	RP1L1	0.38	6.82	0.31	3.2e-11	Systolic blood pressure;
LUAD	cis	rs11756438	0.572	rs2638552	chr6:118999412	C/T	cg18833306	chr6:118973337	C6orf204	0.54	9.67	0.43	4.03e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-7.45	-0.34	5.2e-13	Alzheimer's disease (late onset);
LUAD	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg02660097	chr11:68866761	NA	0.46	6.45	0.3	3.01e-10	Blond vs. brown hair color;
LUAD	cis	rs6430585	0.528	rs614193	chr2:136653925	A/T	cg07169764	chr2:136633963	MCM6	0.71	8.73	0.39	6.01e-17	Corneal structure;
LUAD	cis	rs751837	0.591	rs17101096	chr14:103414293	G/A	cg10087771	chr14:103399429	CDC42BPB	0.69	6.69	0.31	7.26e-11	Large B-cell lymphoma;
LUAD	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg18135555	chr8:22132992	PIWIL2	0.43	7.82	0.36	4.11e-14	Hypertriglyceridemia;
LUAD	cis	rs11771526	0.892	rs1376282	chr7:32370492	A/G	cg27532318	chr7:32358331	NA	0.68	7.97	0.36	1.44e-14	Body mass index;
LUAD	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg02990361	chr1:107599529	PRMT6	0.52	8.63	0.39	1.21e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.61e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4523957	0.928	rs216180	chr17:2172416	C/G	cg16513277	chr17:2031491	SMG6	0.76	14.55	0.58	3.65e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs354225	0.544	rs13391522	chr2:54805854	T/C	cg26097391	chr2:54893211	SPTBN1	0.42	6.43	0.3	3.48e-10	Schizophrenia;
LUAD	trans	rs8002861	0.870	rs4942251	chr13:44440048	G/T	cg17145862	chr1:211918768	LPGAT1	0.74	17.37	0.65	2.19e-51	Leprosy;
LUAD	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg09503522	chr19:53445286	ZNF321	0.37	6.39	0.3	4.39e-10	Psoriasis;
LUAD	cis	rs11811982	0.744	rs79392739	chr1:227459572	C/T	cg24860534	chr1:227506868	CDC42BPA	0.63	7.11	0.33	4.92e-12	Optic disc area;
LUAD	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.51	0.3	2.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.03	-0.36	9.99e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg03929089	chr4:120376271	NA	0.67	9.6	0.42	7.23e-20	Coronary artery disease;
LUAD	trans	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg01620082	chr3:125678407	NA	-0.63	-7.26	-0.33	1.87e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01773951	chr1:247094386	AHCTF1	-0.42	-6.68	-0.31	7.6e-11	Height;
LUAD	cis	rs4073416	0.542	rs3825639	chr14:66028505	T/C	cg10998611	chr14:65879393	FUT8;LOC645431	-0.42	-6.41	-0.3	3.87e-10	N-glycan levels;
LUAD	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg26818010	chr10:134567672	INPP5A	-0.86	-14.77	-0.58	4e-40	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10746514	0.841	rs9725652	chr1:232245997	T/A	cg09506761	chr1:232265262	NA	0.41	7.67	0.35	1.16e-13	Response to statin therapy;
LUAD	cis	rs1595825	0.891	rs60484833	chr2:198812181	C/T	cg00982548	chr2:198649783	BOLL	-0.63	-8.98	-0.4	8.75e-18	Ulcerative colitis;
LUAD	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg09365446	chr1:150670422	GOLPH3L	0.62	10.97	0.47	8.1e-25	Melanoma;
LUAD	cis	rs791888	1.000	rs791888	chr10:89412575	G/T	cg13926569	chr10:89418898	PAPSS2	-0.45	-8.46	-0.38	4.53e-16	Magnesium levels;
LUAD	cis	rs6842047	0.563	rs10025990	chr4:187146258	T/C	cg09526685	chr4:187126073	CYP4V2	0.86	8.83	0.39	2.87e-17	Blood protein levels;
LUAD	trans	rs7395662	0.581	rs10769445	chr11:48765594	A/C	cg00717180	chr2:96193071	NA	0.35	6.49	0.3	2.38e-10	HDL cholesterol;
LUAD	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg07828340	chr4:882639	GAK	1.05	10.84	0.47	2.47e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.585	rs201001	chr6:27808899	T/C	cg20933634	chr6:27740509	NA	0.51	7.6	0.35	1.96e-13	Depression;
LUAD	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg10523679	chr1:76189770	ACADM	0.83	13.15	0.54	2.47e-33	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg22535103	chr8:58192502	C8orf71	-0.65	-9.26	-0.41	1.06e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg11833968	chr6:79620685	NA	-0.44	-8.16	-0.37	3.96e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2629540	0.847	rs10901811	chr10:126417914	G/A	cg08799069	chr10:126477246	METTL10	0.44	6.49	0.3	2.45e-10	Cocaine dependence;
LUAD	cis	rs151234	0.565	rs9924471	chr16:28591530	G/A	cg04643524	chr16:28609220	SULT1A2	0.46	7.43	0.34	5.86e-13	Platelet distribution width;
LUAD	cis	rs2629540	0.847	rs12247543	chr10:126419743	G/C	cg08799069	chr10:126477246	METTL10	0.44	6.49	0.3	2.34e-10	Cocaine dependence;
LUAD	cis	rs2688608	0.933	rs2633307	chr10:75653881	G/A	cg23231163	chr10:75533350	FUT11	-0.39	-7.18	-0.33	3.07e-12	Inflammatory bowel disease;
LUAD	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg07075026	chr17:47091521	IGF2BP1	0.32	6.44	0.3	3.27e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-9.67	-0.43	4.19e-20	Lymphocyte counts;
LUAD	cis	rs2908197	0.713	rs2961037	chr7:75952212	G/T	cg24580635	chr7:76178542	LOC100133091	-0.43	-6.72	-0.31	6e-11	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-8.33	-0.38	1.15e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs8099014	0.861	rs17669	chr18:56118493	C/T	cg12907477	chr18:56117327	MIR122	0.47	7.81	0.36	4.43e-14	Platelet count;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06521597	chr19:2783551	SGTA	-0.42	-6.41	-0.3	3.78e-10	Height;
LUAD	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg09796270	chr17:17721594	SREBF1	-0.38	-7.54	-0.34	2.8e-13	Total body bone mineral density;
LUAD	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg02493798	chr17:6899577	ALOX12	0.37	6.96	0.32	1.27e-11	Tonsillectomy;
LUAD	cis	rs262150	0.545	rs73167302	chr7:158789762	G/A	cg12257156	chr7:158823799	VIPR2	0.48	7.16	0.33	3.71e-12	Facial morphology (factor 20);
LUAD	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.4	-0.38	6.59e-16	Menopause (age at onset);
LUAD	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22590775	chr19:49891494	CCDC155	0.59	8.43	0.38	5.55e-16	Multiple sclerosis;
LUAD	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg17366294	chr4:99064904	C4orf37	0.62	11.39	0.48	2.17e-26	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg12310025	chr6:25882481	NA	0.82	13.6	0.55	3.47e-35	Blood metabolite levels;
LUAD	cis	rs4975616	0.773	rs10078017	chr5:1314009	C/T	cg06550200	chr5:1325588	CLPTM1L	0.71	13.37	0.54	3.07e-34	Lung cancer;
LUAD	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg23950597	chr19:37808831	NA	-0.6	-7.52	-0.34	3.32e-13	Coronary artery calcification;
LUAD	cis	rs9462027	0.628	rs6937314	chr6:34799308	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.73	-0.39	5.74e-17	Systemic lupus erythematosus;
LUAD	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg19336497	chr11:14380999	RRAS2	-0.7	-16.04	-0.62	1.37e-45	Sense of smell;
LUAD	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg26597838	chr10:835615	NA	1.02	16.15	0.62	4.79e-46	Eosinophil percentage of granulocytes;
LUAD	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg01145583	chr6:160211477	TCP1;MRPL18	-0.44	-6.36	-0.3	5.17e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs4629710	0.592	rs11759926	chr6:131571269	G/T	cg12606694	chr6:131520996	AKAP7	0.5	7.35	0.34	1e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.88	0.4	1.91e-17	Menopause (age at onset);
LUAD	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg11871910	chr12:69753446	YEATS4	0.7	11.89	0.5	2.41e-28	Blood protein levels;
LUAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg24642844	chr7:1081250	C7orf50	-0.86	-13.49	-0.55	9.14e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg17644776	chr2:200775616	C2orf69	0.52	7.52	0.34	3.3e-13	Schizophrenia;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg04248573	chr6:37226124	TMEM217;TBC1D22B	-0.41	-6.76	-0.31	4.55e-11	Subcortical brain region volumes;
LUAD	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg12160578	chr15:63334699	TPM1	-0.37	-6.89	-0.32	2.02e-11	Platelet count;
LUAD	cis	rs654950	1.000	rs621680	chr1:41984584	C/T	cg06885757	chr1:42089581	HIVEP3	-0.36	-7.8	-0.35	4.83e-14	Airway imaging phenotypes;
LUAD	cis	rs3784262	0.669	rs4646580	chr15:58329211	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.56	-0.35	2.45e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg05425664	chr17:57184151	TRIM37	0.43	7.65	0.35	1.4e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg21280719	chr6:42927975	GNMT	-0.39	-12.17	-0.51	1.99e-29	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs735539	0.645	rs9552251	chr13:21180247	A/G	cg27499820	chr13:21296301	IL17D	-0.5	-8.49	-0.38	3.63e-16	Dental caries;
LUAD	cis	rs4692589	0.965	rs6847470	chr4:170954468	T/C	cg19918862	chr4:170955249	NA	0.3	7.04	0.32	7.61e-12	Anxiety disorder;
LUAD	cis	rs1127311	1.000	rs9427094	chr1:154557685	C/T	cg17218026	chr1:154582156	ADAR	0.5	9.74	0.43	2.28e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg10523679	chr1:76189770	ACADM	0.9	15.54	0.6	2.04e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg12011299	chr4:100065546	ADH4	-0.74	-13.68	-0.55	1.58e-35	Alcohol dependence;
LUAD	trans	rs2797160	1.000	rs1777195	chr6:126006861	A/C	cg05039488	chr6:79577232	IRAK1BP1	0.52	8.36	0.38	9.24e-16	Endometrial cancer;
LUAD	cis	rs829661	0.532	rs12621663	chr2:30784540	G/A	cg12454169	chr2:30669597	LCLAT1	-0.44	-6.76	-0.31	4.62e-11	Midgestational circulating levels of PBDEs (fetal genetic effect);
LUAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg23743428	chr13:21893420	NA	-0.49	-8.71	-0.39	7.08e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-10.72	-0.46	6.86e-24	Height;
LUAD	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg18404041	chr3:52824283	ITIH1	-0.33	-6.38	-0.3	4.67e-10	Electroencephalogram traits;
LUAD	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg04450456	chr4:17643702	FAM184B	0.37	7.17	0.33	3.35e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg02782426	chr3:40428986	ENTPD3	0.43	9.18	0.41	1.91e-18	Renal cell carcinoma;
LUAD	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.55	-9.36	-0.41	4.68e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.01	0.32	9.35e-12	Depression;
LUAD	cis	rs7943203	1.000	rs7943063	chr11:108336907	G/T	cg04873221	chr11:107992290	ACAT1	-0.4	-6.49	-0.3	2.36e-10	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg00431813	chr7:1051703	C7orf50	-0.34	-6.48	-0.3	2.48e-10	Longevity;Endometriosis;
LUAD	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg21016266	chr12:122356598	WDR66	0.7	13.0	0.53	9.64e-33	Mean corpuscular volume;
LUAD	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg22875332	chr1:76189707	ACADM	0.85	17.3	0.64	4.12e-51	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg06713675	chr4:122721982	EXOSC9	-0.83	-17.86	-0.66	1.48e-53	Type 2 diabetes;
LUAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22338127	chr1:209979572	IRF6	0.49	6.86	0.32	2.49e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.42	6.68	0.31	7.4e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg12575136	chr18:32820987	ZNF397	0.45	7.15	0.33	3.72e-12	White blood cell count;
LUAD	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg02696790	chr15:75250997	RPP25	0.35	6.91	0.32	1.74e-11	Caffeine consumption;
LUAD	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg13319975	chr6:146136371	FBXO30	-0.63	-10.69	-0.46	9.29e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg07217954	chr7:1067459	C7orf50	-0.44	-7.56	-0.34	2.56e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg19729930	chr2:74357872	NA	0.99	17.37	0.65	2.18e-51	Gestational age at birth (maternal effect);
LUAD	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-8.73	-0.39	5.93e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg15147215	chr3:52552868	STAB1	-0.38	-7.13	-0.33	4.3e-12	Electroencephalogram traits;
LUAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg02136620	chr5:178986620	RUFY1	0.44	7.35	0.34	1.06e-12	Lung cancer;
LUAD	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg14582100	chr15:45693742	SPATA5L1	0.62	11.99	0.5	1.04e-28	Homoarginine levels;
LUAD	cis	rs612683	0.694	rs6688364	chr1:101000874	G/A	cg06223162	chr1:101003688	GPR88	0.52	10.1	0.44	1.22e-21	Breast cancer;
LUAD	cis	rs11696501	0.688	rs1487310	chr20:44308789	A/G	cg11783356	chr20:44313418	WFDC10B	-0.51	-8.28	-0.37	1.58e-15	Brain structure;
LUAD	cis	rs2839627	0.598	rs56098337	chr21:44271365	G/T	cg03543861	chr21:44258195	NA	0.65	9.34	0.41	5.53e-19	Information processing speed;
LUAD	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg04546413	chr19:29218101	NA	0.62	8.44	0.38	5.16e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg02951883	chr7:2050386	MAD1L1	0.65	11.17	0.48	1.46e-25	Schizophrenia;
LUAD	cis	rs1127311	0.875	rs9427102	chr1:154586957	A/G	cg17218026	chr1:154582156	ADAR	0.5	9.71	0.43	2.95e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs10504073	0.584	rs10957356	chr8:49980634	G/A	cg00325661	chr8:49890786	NA	0.46	10.35	0.45	1.6e-22	Blood metabolite ratios;
LUAD	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg00530320	chr1:46809349	NSUN4	0.51	7.86	0.36	3.16e-14	Menopause (age at onset);
LUAD	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg07741184	chr6:167504864	NA	0.39	8.8	0.39	3.63e-17	Primary biliary cholangitis;
LUAD	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg00814883	chr7:100076585	TSC22D4	-0.87	-13.12	-0.54	3.02e-33	Platelet count;
LUAD	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.06	-0.37	7.64e-15	Diabetic kidney disease;
LUAD	cis	rs59104589	0.617	rs73002114	chr2:242280924	G/A	cg08645257	chr2:242211290	HDLBP	0.46	7.25	0.33	1.98e-12	Fibrinogen levels;
LUAD	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-6.48	-0.3	2.6e-10	Height;
LUAD	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg11901034	chr3:128598214	ACAD9	-0.48	-7.5	-0.34	3.72e-13	IgG glycosylation;
LUAD	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg22681709	chr2:178499509	PDE11A	-0.55	-9.26	-0.41	1.01e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6714710	0.603	rs11680321	chr2:98379267	C/T	cg26665480	chr2:98280029	ACTR1B	0.5	8.27	0.37	1.75e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg13699009	chr12:122356056	WDR66	0.32	7.04	0.32	7.68e-12	Mean corpuscular volume;
LUAD	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg22117172	chr7:91764530	CYP51A1	0.34	7.51	0.34	3.46e-13	Breast cancer;
LUAD	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6761276	0.899	rs13398125	chr2:113834835	G/A	cg10479672	chr2:113810641	IL1F8	-0.38	-7.72	-0.35	8.74e-14	Protein quantitative trait loci;
LUAD	cis	rs4638749	0.677	rs12712017	chr2:108843556	C/T	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.43	-0.34	6.13e-13	Blood pressure;
LUAD	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg18827107	chr12:86230957	RASSF9	-0.7	-12.92	-0.53	2.12e-32	Major depressive disorder;
LUAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg21724239	chr8:58056113	NA	0.46	6.68	0.31	7.48e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg16479474	chr6:28041457	NA	-0.39	-6.61	-0.31	1.14e-10	Depression;
LUAD	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg18105134	chr13:113819100	PROZ	0.91	16.48	0.63	1.8e-47	Platelet distribution width;
LUAD	cis	rs17102423	0.594	rs942628	chr14:65539463	C/G	cg11161011	chr14:65562177	MAX	-0.41	-6.87	-0.32	2.27e-11	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.12e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg05754148	chr16:3507555	NAT15	-0.4	-6.47	-0.3	2.79e-10	Body mass index (adult);
LUAD	cis	rs6564851	0.506	rs72831381	chr16:81258083	C/G	cg00908271	chr16:81254010	PKD1L2	0.34	6.84	0.32	2.73e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs1048238	0.506	rs848194	chr1:16285342	G/A	cg22431228	chr1:16359049	CLCNKA	0.42	7.76	0.35	6.51e-14	Systolic blood pressure;
LUAD	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg02423579	chr7:2872169	GNA12	-0.76	-12.73	-0.53	1.22e-31	Height;
LUAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.6	0.31	1.26e-10	Prudent dietary pattern;
LUAD	cis	rs7909074	0.714	rs10900129	chr10:45398609	G/C	cg05187965	chr10:45406764	TMEM72	-0.4	-8.04	-0.36	9.33e-15	Mean corpuscular volume;
LUAD	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg09509183	chr1:209979624	IRF6	0.38	6.52	0.3	1.97e-10	Monobrow;
LUAD	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg04282206	chr17:62833786	PLEKHM1P	-0.54	-8.22	-0.37	2.51e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg27411982	chr8:10470053	RP1L1	-0.36	-6.68	-0.31	7.39e-11	Triglycerides;
LUAD	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg25358565	chr5:93447407	FAM172A	0.63	7.75	0.35	6.88e-14	Diabetic retinopathy;
LUAD	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg24801067	chr17:62843696	NA	0.61	8.65	0.39	1.08e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg04455712	chr21:45112962	RRP1B	0.45	9.26	0.41	1.04e-18	Mean corpuscular volume;
LUAD	cis	rs7709909	0.553	rs151886	chr5:80024077	G/A	cg24059623	chr5:79951536	MSH3;DHFR	0.49	7.44	0.34	5.8e-13	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg03340356	chr1:67600835	NA	0.41	7.02	0.32	8.63e-12	Psoriasis;
LUAD	cis	rs5758511	0.731	rs5751186	chr22:42349710	G/A	cg00645731	chr22:42541494	CYP2D7P1	-0.38	-6.43	-0.3	3.45e-10	Birth weight;
LUAD	cis	rs367943	0.966	rs451425	chr5:112808637	A/G	cg12552261	chr5:112820674	MCC	-0.59	-11.1	-0.47	2.72e-25	Type 2 diabetes;
LUAD	trans	rs2262909	0.962	rs73019889	chr19:22277826	C/G	cg17074339	chr11:11642133	GALNTL4	0.48	7.73	0.35	7.68e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs494562	0.892	rs7767626	chr6:86124394	G/A	cg21730993	chr6:86159210	NT5E	0.72	7.99	0.36	1.31e-14	Blood metabolite levels;Metabolic traits;
LUAD	trans	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg13565492	chr6:43139072	SRF	-0.59	-6.54	-0.3	1.77e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg05340658	chr4:99064831	C4orf37	0.54	9.15	0.41	2.49e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg00933542	chr6:150070202	PCMT1	-0.45	-10.03	-0.44	2.15e-21	Lung cancer;
LUAD	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg00684032	chr4:1343700	KIAA1530	0.39	6.45	0.3	3.05e-10	Obesity-related traits;
LUAD	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg27286337	chr10:134555280	INPP5A	0.7	9.98	0.44	3.36e-21	Migraine;
LUAD	cis	rs6496044	0.547	rs8039929	chr15:86080962	C/T	cg13263323	chr15:86062960	AKAP13	-0.52	-9.33	-0.41	6.06e-19	Interstitial lung disease;
LUAD	cis	rs12545109	0.800	rs2609979	chr8:57390066	G/A	cg09654669	chr8:57350985	NA	-0.68	-10.07	-0.44	1.59e-21	Obesity-related traits;
LUAD	cis	rs3789045	0.819	rs16854023	chr1:204551830	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.44	-7.5	-0.34	3.83e-13	Educational attainment (college completion);
LUAD	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg04450456	chr4:17643702	FAM184B	-0.4	-8.11	-0.37	5.34e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22857025	chr5:266934	NA	-0.96	-14.39	-0.57	1.75e-38	Breast cancer;
LUAD	trans	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.44	-0.3	3.27e-10	Aortic root size;
LUAD	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg14530993	chr4:882597	GAK	0.69	6.52	0.3	1.96e-10	Parkinson's disease;
LUAD	cis	rs427394	1.000	rs274672	chr5:6744176	G/A	cg10857441	chr5:6722123	POLS	-0.6	-11.36	-0.48	2.73e-26	Menopause (age at onset);
LUAD	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10802521	chr3:52805072	NEK4	-0.53	-8.91	-0.4	1.5e-17	Bipolar disorder;
LUAD	cis	rs870825	0.932	rs10034861	chr4:185577450	C/T	cg04058563	chr4:185651563	MLF1IP	0.75	9.27	0.41	9.34e-19	Blood protein levels;
LUAD	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg00504896	chr12:9437009	LOC642846	-0.57	-9.74	-0.43	2.24e-20	Breast size;
LUAD	cis	rs2625529	0.652	rs2957361	chr15:72345218	G/A	cg16672083	chr15:72433130	SENP8	0.61	11.13	0.48	2.06e-25	Red blood cell count;
LUAD	cis	rs904251	0.523	rs1776455	chr6:37482923	A/T	cg25019722	chr6:37503610	NA	-0.33	-7.58	-0.35	2.19e-13	Cognitive performance;
LUAD	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg25985355	chr7:65971099	NA	-0.36	-6.64	-0.31	9.68e-11	Aortic root size;
LUAD	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg25452165	chr22:42524984	CYP2D6	0.39	6.42	0.3	3.77e-10	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.63e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6546550	0.901	rs4144081	chr2:70155482	G/A	cg02498382	chr2:70120550	SNRNP27	-0.57	-10.88	-0.47	1.71e-24	Prevalent atrial fibrillation;
LUAD	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg24112000	chr20:60950667	NA	-0.64	-8.61	-0.39	1.45e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg01256987	chr12:42539512	GXYLT1	-0.5	-10.34	-0.45	1.71e-22	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg21028142	chr17:79581711	NPLOC4	0.37	7.55	0.34	2.78e-13	Eye color traits;
LUAD	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21659725	chr3:3221576	CRBN	-0.59	-9.57	-0.42	9.39e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg07570687	chr10:102243282	WNT8B	0.46	6.8	0.31	3.51e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg16606324	chr3:10149918	C3orf24	0.67	9.78	0.43	1.69e-20	Alzheimer's disease;
LUAD	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	22.58	0.74	1.17e-74	Chronic sinus infection;
LUAD	cis	rs7512552	0.839	rs698916	chr1:150388385	A/G	cg15654264	chr1:150340011	RPRD2	0.58	11.13	0.48	2.15e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg15790184	chr11:494944	RNH1	0.55	6.75	0.31	4.88e-11	Body mass index;
LUAD	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.4	-0.34	7.53e-13	Schizophrenia;
LUAD	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg14582100	chr15:45693742	SPATA5L1	0.63	12.28	0.51	7.24e-30	Homoarginine levels;
LUAD	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg03959625	chr15:84868606	LOC388152	0.4	6.48	0.3	2.6200000000000003e-10	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg08888203	chr3:10149979	C3orf24	0.71	11.52	0.49	6.73e-27	Alzheimer's disease;
LUAD	cis	rs9807989	0.524	rs2110662	chr2:103020139	A/T	cg03938978	chr2:103052716	IL18RAP	0.45	10.29	0.45	2.54e-22	Asthma;
LUAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg08027265	chr7:2291960	NA	-0.38	-6.55	-0.3	1.66e-10	Schizophrenia;
LUAD	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg26408565	chr15:76604113	ETFA	0.4	6.55	0.3	1.66e-10	Blood metabolite levels;
LUAD	cis	rs1595825	0.891	rs16825786	chr2:198794681	G/T	cg00982548	chr2:198649783	BOLL	-0.63	-9.06	-0.4	5.02e-18	Ulcerative colitis;
LUAD	cis	rs9462027	0.628	rs7739771	chr6:34779801	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.76	-0.39	4.66e-17	Systemic lupus erythematosus;
LUAD	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.98	-0.4	9.15e-18	Total body bone mineral density;
LUAD	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg14582100	chr15:45693742	SPATA5L1	0.37	7.09	0.33	5.82e-12	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg11859384	chr17:80120422	CCDC57	0.51	9.22	0.41	1.42e-18	Life satisfaction;
LUAD	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg25173405	chr17:45401733	C17orf57	0.44	7.29	0.33	1.57e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7215564	0.908	rs35434628	chr17:78714760	C/T	cg11222173	chr17:78748019	RPTOR	-0.55	-6.58	-0.3	1.37e-10	Myopia (pathological);
LUAD	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg18230493	chr5:56204884	C5orf35	-0.86	-12.6	-0.52	3.85e-31	Initial pursuit acceleration;
LUAD	cis	rs1215050	0.776	rs1627946	chr4:98844416	G/A	cg24818145	chr4:99064322	C4orf37	-0.42	-6.87	-0.32	2.27e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	1e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12292205	chr6:26970375	C6orf41	-0.47	-6.57	-0.3	1.47e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1215050	0.791	rs165241	chr4:98681112	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.94	0.36	1.86e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg06718696	chr17:78121285	EIF4A3	0.59	8.73	0.39	5.9e-17	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.74	0.31	5.14e-11	Cognitive test performance;
LUAD	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg19418458	chr7:158789849	NA	-0.62	-10.71	-0.46	7.34e-24	Facial morphology (factor 20);
LUAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	7.02	0.32	8.79e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.33	6.65	0.31	8.85e-11	Obesity-related traits;
LUAD	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg17063962	chr7:91808500	NA	-0.63	-10.84	-0.47	2.55e-24	Breast cancer;
LUAD	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg04287289	chr16:89883240	FANCA	0.6	6.55	0.3	1.63e-10	Skin colour saturation;
LUAD	cis	rs17092148	0.945	rs17092080	chr20:33335657	A/G	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.34	-0.38	1.05e-15	Neuroticism;
LUAD	trans	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg02002194	chr4:3960332	NA	-0.26	-6.4	-0.3	4.08e-10	Joint mobility (Beighton score);
LUAD	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg07432352	chr17:45403706	C17orf57	-0.39	-7.67	-0.35	1.21e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.61	9.42	0.42	2.92e-19	Lung function (FEV1/FVC);
LUAD	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.98	-0.36	1.41e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg02158880	chr13:53174818	NA	0.51	9.02	0.4	6.76e-18	Lewy body disease;
LUAD	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	4.04e-11	Depression;
LUAD	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg03732007	chr1:2071316	PRKCZ	-0.35	-6.6	-0.31	1.2e-10	Height;
LUAD	cis	rs6761276	0.837	rs11887823	chr2:113835311	T/A	cg10479672	chr2:113810641	IL1F8	-0.38	-7.65	-0.35	1.39e-13	Protein quantitative trait loci;
LUAD	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg02228675	chr17:40259724	DHX58	-0.44	-7.09	-0.33	5.79e-12	Fibrinogen levels;
LUAD	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg14552801	chr7:65878734	NA	0.38	6.38	0.3	4.71e-10	Aortic root size;
LUAD	cis	rs11166629	1.000	rs2873014	chr8:135645860	C/T	cg27224718	chr8:135614730	ZFAT	-0.58	-10.31	-0.45	2.27e-22	Smoking quantity;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg17420218	chr2:20102066	TTC32	0.4	6.52	0.3	2.03e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg18187862	chr3:45730750	SACM1L	0.52	8.16	0.37	3.93e-15	Primary sclerosing cholangitis;
LUAD	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg15704280	chr7:45808275	SEPT13	-1.0	-19.95	-0.7	6.64e-63	Height;
LUAD	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg16049864	chr8:95962084	TP53INP1	-0.54	-11.59	-0.49	3.81e-27	Type 2 diabetes;
LUAD	cis	rs6758955	1.000	rs57128023	chr2:10477224	T/C	cg15773312	chr2:10472214	HPCAL1	-0.41	-6.47	-0.3	2.65e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2455799	0.552	rs2470516	chr3:15759050	T/G	cg16303742	chr3:15540471	COLQ	-0.53	-9.68	-0.43	3.85e-20	Mean platelet volume;
LUAD	cis	rs7809950	1.000	rs2178497	chr7:107278901	T/C	cg23024343	chr7:107201750	COG5	0.75	11.92	0.5	1.92e-28	Coronary artery disease;
LUAD	cis	rs7818345	0.663	rs11786904	chr8:19327267	C/G	cg06699216	chr8:19333253	CSGALNACT1	-0.31	-7.42	-0.34	6.63e-13	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg19318889	chr4:1322082	MAEA	0.57	9.72	0.43	2.76e-20	Longevity;
LUAD	cis	rs2859741	1.000	rs4653239	chr1:37509872	C/G	cg09363841	chr1:37513479	NA	0.33	8.02	0.36	1.04e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs1757171	0.542	rs1757186	chr6:37484111	A/G	cg25019722	chr6:37503610	NA	-0.33	-7.6	-0.35	1.99e-13	Cognitive performance;
LUAD	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg23387056	chr11:14280742	SPON1	-0.44	-9.19	-0.41	1.78e-18	Mitochondrial DNA levels;
LUAD	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg18944383	chr4:111397179	ENPEP	0.42	8.22	0.37	2.45e-15	Height;
LUAD	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg15704280	chr7:45808275	SEPT13	-1.01	-20.16	-0.7	7.69e-64	Height;
LUAD	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg12011299	chr4:100065546	ADH4	0.66	12.08	0.51	4.41e-29	Alcohol dependence;
LUAD	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.35	0.38	9.94e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10979	1.000	rs9496678	chr6:143896664	C/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.26	-0.45	3.46e-22	Hypospadias;
LUAD	trans	rs9951602	0.512	rs73494176	chr18:76644895	T/C	cg02800362	chr5:177631904	HNRNPAB	0.91	14.11	0.57	2.52e-37	Obesity-related traits;
LUAD	cis	rs1395	0.778	rs11693001	chr2:27412744	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.51	8.9	0.4	1.64e-17	Blood metabolite levels;
LUAD	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg06784218	chr1:46089804	CCDC17	0.54	12.04	0.51	6.34e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7582720	0.943	rs72936866	chr2:203787120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg11822812	chr5:140052017	DND1	-0.4	-7.3	-0.33	1.4e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs494562	0.892	rs1322404	chr6:86126912	T/A	cg17966619	chr6:86160162	NT5E	0.66	7.83	0.36	4.05e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs11190604	0.767	rs3750723	chr10:102172989	T/C	cg07570687	chr10:102243282	WNT8B	0.44	6.35	0.3	5.43e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg04369109	chr6:150039330	LATS1	-0.46	-7.81	-0.36	4.41e-14	Lung cancer;
LUAD	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.83	-0.32	3e-11	Retinal vascular caliber;
LUAD	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21659725	chr3:3221576	CRBN	-0.86	-18.31	-0.66	1.4e-55	Intelligence (multi-trait analysis);
LUAD	cis	rs938554	0.744	rs6449137	chr4:9932479	A/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.99	-0.4	8.19e-18	Blood metabolite levels;
LUAD	trans	rs7395662	1.000	rs11039817	chr11:48561480	A/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.81e-10	HDL cholesterol;
LUAD	cis	rs9308433	0.529	rs11800749	chr1:214499754	A/G	cg06198575	chr1:214491504	SMYD2	-0.46	-7.84	-0.36	3.63e-14	IgG glycosylation;
LUAD	cis	rs17052344	0.543	rs2342183	chr17:21738349	G/T	cg18423549	chr17:21743878	NA	-0.83	-14.82	-0.58	2.48e-40	Cutaneous psoriasis;
LUAD	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg04455712	chr21:45112962	RRP1B	0.4	7.78	0.35	5.56e-14	Mean corpuscular volume;
LUAD	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.92	0.36	2.07e-14	Depression;
LUAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.67	0.55	1.66e-35	Prudent dietary pattern;
LUAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.92	11.07	0.47	3.62e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6430585	0.640	rs6716070	chr2:136544651	G/T	cg07169764	chr2:136633963	MCM6	-0.74	-8.91	-0.4	1.59e-17	Corneal structure;
LUAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg05368731	chr17:41323189	NBR1	0.98	20.39	0.7	6.97e-65	Menopause (age at onset);
LUAD	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.85e-14	Depression;
LUAD	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg21016266	chr12:122356598	WDR66	0.71	13.1	0.54	3.66e-33	Mean corpuscular volume;
LUAD	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg01200585	chr1:228362443	C1orf69	-0.38	-7.02	-0.32	9.17e-12	Diastolic blood pressure;
LUAD	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg05304507	chr6:116381966	FRK	0.2	6.93	0.32	1.55e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.36	-0.34	9.54e-13	Electroencephalogram traits;
LUAD	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg07741184	chr6:167504864	NA	0.4	9.25	0.41	1.15e-18	Crohn's disease;
LUAD	trans	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg21284400	chr1:149981654	OTUD7B	-0.39	-6.75	-0.31	4.81e-11	Longevity;Endometriosis;
LUAD	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg11344533	chr11:111475393	SIK2	-0.37	-6.78	-0.31	4.04e-11	Primary sclerosing cholangitis;
LUAD	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg11502198	chr6:26597334	ABT1	0.55	9.1	0.4	3.71e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs367943	0.965	rs463249	chr5:112797430	A/C	cg12552261	chr5:112820674	MCC	-0.58	-10.72	-0.46	7.15e-24	Type 2 diabetes;
LUAD	cis	rs10227331	0.846	rs12673606	chr7:157297518	C/G	cg04156418	chr7:157293606	NA	0.36	7.7	0.35	9.44e-14	Inattentive symptoms;
LUAD	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.64	-10.79	-0.46	3.75e-24	Glomerular filtration rate;
LUAD	cis	rs11828289	0.660	rs79045664	chr11:23238737	G/A	cg20040320	chr11:23191996	NA	-0.69	-7.87	-0.36	3.05e-14	Cancer;
LUAD	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.76	0.35	6.46e-14	Platelet count;
LUAD	cis	rs72772090	0.539	rs11750934	chr5:96118487	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-7.18	-0.33	3.2e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg05234568	chr11:5960015	NA	-0.51	-9.16	-0.41	2.19e-18	DNA methylation (variation);
LUAD	cis	rs36093924	0.586	rs6002561	chr22:42359204	A/G	cg15128208	chr22:42549153	NA	0.34	6.64	0.31	9.87e-11	Intelligence;
LUAD	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	8.6	0.39	1.6e-16	Total body bone mineral density;
LUAD	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg20476274	chr7:133979776	SLC35B4	0.82	15.99	0.61	2.34e-45	Mean platelet volume;
LUAD	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg02551604	chr5:131831745	NA	0.58	8.46	0.38	4.32e-16	Asthma (sex interaction);
LUAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg17063962	chr7:91808500	NA	0.67	11.92	0.5	1.89e-28	Breast cancer;
LUAD	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg01028140	chr2:1542097	TPO	-0.6	-7.72	-0.35	8.39e-14	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.76	-9.6	-0.42	6.98e-20	Body mass index;
LUAD	cis	rs6758955	0.850	rs73161279	chr2:10481001	T/G	cg15773312	chr2:10472214	HPCAL1	-0.49	-7.34	-0.34	1.12e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg25985355	chr7:65971099	NA	-0.54	-6.73	-0.31	5.5e-11	Diabetic kidney disease;
LUAD	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg08859206	chr1:53392774	SCP2	-0.5	-8.97	-0.4	9.61e-18	Monocyte count;
LUAD	cis	rs4409675	0.576	rs6679432	chr1:28227665	T/C	cg23691781	chr1:28212827	C1orf38	0.39	11.38	0.48	2.26e-26	Corneal astigmatism;
LUAD	cis	rs11167764	1.000	rs13354528	chr5:141476769	C/T	cg08523384	chr5:141488047	NDFIP1	-0.48	-7.23	-0.33	2.35e-12	Crohn's disease;
LUAD	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg05425664	chr17:57184151	TRIM37	-0.41	-7.4	-0.34	7.33e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg17178900	chr1:205818956	PM20D1	0.41	6.7	0.31	6.8e-11	Parkinson's disease;
LUAD	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg17063962	chr7:91808500	NA	0.68	12.05	0.51	5.76e-29	Breast cancer;
LUAD	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg02038168	chr22:39784481	NA	-0.57	-10.18	-0.44	6.21e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs35883536	0.647	rs1335765	chr1:101048612	A/T	cg06223162	chr1:101003688	GPR88	-0.49	-9.51	-0.42	1.48e-19	Monocyte count;
LUAD	cis	rs3823572	0.525	rs2002866	chr7:133690378	C/T	cg03336402	chr7:133662267	EXOC4	0.43	7.41	0.34	6.92e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg20119798	chr7:94954144	PON1	-0.49	-6.5	-0.3	2.28e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs490234	0.841	rs497531	chr9:128314664	C/T	cg14078157	chr9:128172775	NA	0.43	8.02	0.36	1.07e-14	Mean arterial pressure;
LUAD	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.7	-0.31	6.54e-11	Neuroticism;
LUAD	cis	rs754466	0.651	rs11818687	chr10:79637709	C/T	cg17075019	chr10:79541650	NA	-0.86	-17.67	-0.65	9.83e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.68	-11.4	-0.48	2e-26	Primary sclerosing cholangitis;
LUAD	cis	rs4925114	0.568	rs941448	chr17:17654542	C/G	cg04398451	chr17:18023971	MYO15A	0.41	6.57	0.3	1.45e-10	Body mass index;
LUAD	cis	rs7707921	0.881	rs2407153	chr5:81555328	T/G	cg15871215	chr5:81402204	ATG10	0.7	10.02	0.44	2.5e-21	Breast cancer;
LUAD	cis	rs7779181	0.953	rs215607	chr7:32338337	G/A	cg13207630	chr7:32358064	NA	-0.45	-7.04	-0.32	7.84e-12	Body mass index;
LUAD	cis	rs17169635	0.642	rs4732064	chr7:134552146	T/G	cg07876788	chr7:134849633	TMEM140	-0.45	-6.69	-0.31	7.06e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.23	0.54	1.09e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs73086581	0.787	rs67633417	chr20:3868257	C/G	cg02187196	chr20:3869020	PANK2	0.54	7.65	0.35	1.38e-13	Response to antidepressants in depression;
LUAD	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg26513180	chr16:89883248	FANCA	0.72	6.9	0.32	1.86e-11	Skin colour saturation;
LUAD	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg20607798	chr8:58055168	NA	0.59	8.17	0.37	3.49e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs35771425	0.642	rs3767380	chr1:211452845	A/G	cg26515805	chr1:211431828	RCOR3	-0.41	-7.55	-0.34	2.69e-13	Educational attainment (years of education);
LUAD	cis	rs17401966	0.838	rs4846212	chr1:10370312	T/C	cg15208524	chr1:10270712	KIF1B	0.44	6.76	0.31	4.5e-11	Hepatocellular carcinoma;
LUAD	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg11317459	chr13:21872234	NA	-1.14	-14.97	-0.59	5.89e-41	White matter hyperintensity burden;
LUAD	cis	rs4730250	0.707	rs10953537	chr7:107027905	G/A	cg23024343	chr7:107201750	COG5	0.52	7.2	0.33	2.84e-12	Osteoarthritis;
LUAD	cis	rs2230307	0.536	rs2784173	chr1:100639752	A/G	cg20868668	chr1:100435035	SLC35A3	-0.52	-7.43	-0.34	5.97e-13	Carotid intima media thickness;
LUAD	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg00666640	chr1:248458726	OR2T12	0.31	7.96	0.36	1.61e-14	Common traits (Other);
LUAD	cis	rs1395	0.925	rs1659701	chr2:27414877	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.44	-8.24	-0.37	2.19e-15	Blood metabolite levels;
LUAD	cis	rs72928364	1.000	rs62273928	chr3:100652200	C/T	cg10123952	chr3:100791384	NA	0.65	7.37	0.34	8.86e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg15556689	chr8:8085844	FLJ10661	0.4	6.53	0.3	1.9e-10	Mood instability;
LUAD	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03352830	chr11:487213	PTDSS2	0.78	9.71	0.43	2.98e-20	Body mass index;
LUAD	cis	rs2637266	0.967	rs12246436	chr10:78352914	C/T	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs7737355	1.000	rs798415	chr5:130693723	T/G	cg06307176	chr5:131281290	NA	-0.46	-7.35	-0.34	1e-12	Life satisfaction;
LUAD	cis	rs240764	0.658	rs11155659	chr6:101222568	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-8.32	-0.38	1.22e-15	Neuroticism;
LUAD	cis	rs2692947	0.644	rs772178	chr2:96963684	C/T	cg23100626	chr2:96804247	ASTL	-0.37	-9.48	-0.42	1.91e-19	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg00316803	chr15:76480434	C15orf27	-0.41	-7.77	-0.35	6.09e-14	Blood metabolite levels;
LUAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg10729496	chr3:10149963	C3orf24	0.66	9.63	0.42	5.82e-20	Alzheimer's disease;
LUAD	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg14530993	chr4:882597	GAK	0.73	7.06	0.32	7.03e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg04995722	chr7:26192034	NFE2L3	0.42	7.3	0.33	1.45e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg00933542	chr6:150070202	PCMT1	0.45	9.75	0.43	2.13e-20	Lung cancer;
LUAD	cis	rs17401966	0.838	rs4475756	chr1:10387788	A/G	cg19773385	chr1:10388646	KIF1B	-0.41	-6.84	-0.32	2.78e-11	Hepatocellular carcinoma;
LUAD	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs731174	0.959	rs12747993	chr1:38190852	T/C	cg06917450	chr1:38156652	C1orf109	-0.43	-7.25	-0.33	2.05e-12	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs1232027	0.700	rs1677687	chr5:79938336	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg05082376	chr22:42548792	NA	-0.36	-6.35	-0.3	5.5e-10	Cognitive function;
LUAD	cis	rs11585357	0.895	rs4625336	chr1:17630964	G/T	cg08277548	chr1:17600880	PADI3	-0.87	-13.34	-0.54	3.89e-34	Hair shape;
LUAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg10729496	chr3:10149963	C3orf24	0.58	9.34	0.41	5.58e-19	Alzheimer's disease;
LUAD	cis	rs2235649	0.833	rs9939766	chr16:1852808	C/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.48	-7.9	-0.36	2.46e-14	Blood metabolite levels;
LUAD	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg04756594	chr16:24857601	SLC5A11	0.57	10.57	0.46	2.48e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.58	-0.38	1.83e-16	Total body bone mineral density;
LUAD	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg05342682	chr7:94953680	PON1	-0.48	-6.5	-0.3	2.28e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs1997103	0.911	rs10238738	chr7:55412359	T/C	cg20935933	chr6:143382018	AIG1	0.55	7.81	0.36	4.5e-14	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg19767650	chr1:183605181	ARPC5;RGL1	0.45	7.35	0.34	1.01e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6546550	0.835	rs3755389	chr2:70119469	T/C	cg02498382	chr2:70120550	SNRNP27	-0.59	-11.21	-0.48	1.03e-25	Prevalent atrial fibrillation;
LUAD	cis	rs7191700	0.836	rs12708722	chr16:11428905	T/A	cg00044050	chr16:11439710	C16orf75	0.66	9.47	0.42	2.08e-19	Multiple sclerosis;
LUAD	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg09035930	chr12:129282057	SLC15A4	0.7	15.92	0.61	4.57e-45	Systemic lupus erythematosus;
LUAD	cis	rs4917300	0.549	rs902819	chr8:143098548	C/T	cg25363559	chr8:143086065	NA	-0.48	-9.53	-0.42	1.21e-19	Amyotrophic lateral sclerosis;
LUAD	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg25237894	chr2:233734115	C2orf82	0.61	11.46	0.49	1.16e-26	Coronary artery disease;
LUAD	cis	rs5758659	0.716	rs2143138	chr22:42618340	T/C	cg15128208	chr22:42549153	NA	-0.39	-7.86	-0.36	3.15e-14	Cognitive function;
LUAD	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	14.98	0.59	5.27e-41	Lung cancer in ever smokers;
LUAD	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg08859206	chr1:53392774	SCP2	0.54	10.23	0.45	4.33e-22	Monocyte count;
LUAD	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg27279351	chr12:120934652	DYNLL1	0.45	6.77	0.31	4.19e-11	High light scatter reticulocyte count;
LUAD	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15541040	chr2:3486749	NA	-0.43	-7.4	-0.34	7.21e-13	Neurofibrillary tangles;
LUAD	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.25	0.37	1.97e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4662945	0.603	rs10496678	chr2:130262209	C/T	cg05962382	chr2:130345044	NA	-0.39	-7.29	-0.33	1.53e-12	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs7010267	0.602	rs4313185	chr8:120052549	G/A	cg01975934	chr8:119970761	NA	-0.34	-6.43	-0.3	3.41e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg17063962	chr7:91808500	NA	0.68	12.15	0.51	2.5e-29	Breast cancer;
LUAD	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg25817165	chr18:72167213	CNDP2	-0.82	-14.17	-0.57	1.39e-37	Refractive error;
LUAD	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.48	0.3	2.5e-10	Aortic root size;
LUAD	cis	rs1873147	1.000	rs12440411	chr15:63313581	T/G	cg12160578	chr15:63334699	TPM1	-0.34	-6.37	-0.3	5.08e-10	Orofacial clefts;
LUAD	cis	rs2251260	0.685	rs2246850	chr14:62009606	C/T	cg13564459	chr14:62004353	PRKCH	0.4	6.42	0.3	3.71e-10	Yeast infection;
LUAD	cis	rs7818345	0.613	rs13261732	chr8:19330215	T/C	cg06699216	chr8:19333253	CSGALNACT1	-0.29	-6.81	-0.31	3.39e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg15704280	chr7:45808275	SEPT13	-0.91	-16.71	-0.63	1.74e-48	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22190090	chr17:36955626	PIP4K2B	-0.42	-6.51	-0.3	2.12e-10	Height;
LUAD	trans	rs8002861	0.641	rs6561148	chr13:44426269	C/T	cg12856521	chr11:46389249	DGKZ	0.47	7.68	0.35	1.15e-13	Leprosy;
LUAD	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg04800585	chr6:26043546	HIST1H2BB	-0.35	-6.54	-0.3	1.81e-10	Blood metabolite levels;
LUAD	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg13732083	chr21:47605072	C21orf56	0.43	6.79	0.31	3.72e-11	Testicular germ cell tumor;
LUAD	cis	rs7089973	0.966	rs36089581	chr10:116623059	G/C	cg25233709	chr10:116636983	FAM160B1	0.37	6.9	0.32	1.9e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg17063962	chr7:91808500	NA	0.71	12.42	0.52	2.01e-30	Breast cancer;
LUAD	cis	rs1448094	0.842	rs7301280	chr12:86455752	G/T	cg02569458	chr12:86230093	RASSF9	-0.38	-7.27	-0.33	1.72e-12	Major depressive disorder;
LUAD	cis	rs9837602	1.000	rs4571265	chr3:99705111	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	6.98	0.32	1.18e-11	Breast cancer;
LUAD	cis	rs2046867	0.908	rs68142603	chr3:72790220	A/C	cg25664220	chr3:72788482	NA	-0.68	-12.18	-0.51	1.87e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs2262909	0.719	rs12461632	chr19:22245089	G/A	cg05197062	chr11:11642011	GALNTL4	0.59	9.09	0.4	3.99e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.61	10.4	0.45	1.06e-22	Cognitive ability;
LUAD	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.65	0.31	9.01e-11	Menarche (age at onset);
LUAD	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.31	6.4	0.3	4.22e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg10755058	chr3:40428713	ENTPD3	0.46	8.62	0.39	1.36e-16	Renal cell carcinoma;
LUAD	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg23625390	chr15:77176239	SCAPER	-0.51	-7.86	-0.36	3.21e-14	Blood metabolite levels;
LUAD	cis	rs12681287	0.640	rs2953516	chr8:87332545	C/T	cg27223183	chr8:87520930	FAM82B	-0.65	-8.76	-0.39	4.81e-17	Caudate activity during reward;
LUAD	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg15448220	chr1:150897856	SETDB1	0.46	7.99	0.36	1.32e-14	Tonsillectomy;
LUAD	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.48e-10	Prostate cancer;
LUAD	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg16262614	chr3:133464971	TF	0.34	6.39	0.3	4.42e-10	Iron status biomarkers;
LUAD	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg16647868	chr5:131706066	SLC22A5	0.41	7.05	0.32	7.4e-12	Blood metabolite levels;
LUAD	cis	rs9394841	0.646	rs9369313	chr6:41847065	C/T	cg17623882	chr6:41773611	USP49	-0.52	-7.09	-0.33	5.64e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	trans	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.89	-0.32	2e-11	Systolic blood pressure;
LUAD	cis	rs113835537	0.529	rs57724777	chr11:66236431	G/A	cg26679405	chr11:66247800	DPP3	-0.46	-6.45	-0.3	3.1e-10	Airway imaging phenotypes;
LUAD	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg16479474	chr6:28041457	NA	0.46	7.67	0.35	1.2e-13	Parkinson's disease;
LUAD	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg22823121	chr1:150693482	HORMAD1	0.45	8.71	0.39	7.03e-17	Melanoma;
LUAD	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg24955955	chr5:415729	AHRR	0.71	7.98	0.36	1.38e-14	Fat distribution (HIV);
LUAD	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg08632164	chr7:65971372	NA	-0.38	-6.62	-0.31	1.09e-10	Aortic root size;
LUAD	cis	rs6761276	0.649	rs3811057	chr2:113831188	C/A	cg09040174	chr2:113837401	NA	0.64	9.77	0.43	1.76e-20	Protein quantitative trait loci;
LUAD	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg11707310	chr1:2537719	MMEL1	-0.4	-8.61	-0.39	1.45e-16	Ulcerative colitis;
LUAD	cis	rs6005807	0.719	rs12166245	chr22:28999890	C/T	cg12565055	chr22:29076175	TTC28	0.75	8.76	0.39	4.71e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg21171335	chr12:122356390	WDR66	0.74	13.5	0.55	8.48e-35	Mean corpuscular volume;
LUAD	cis	rs4072705	0.615	rs7028021	chr9:127249022	A/G	cg14219918	chr9:127249562	NR5A1	0.29	6.53	0.3	1.88e-10	Menarche (age at onset);
LUAD	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg22875332	chr1:76189707	ACADM	-0.66	-10.45	-0.45	6.78e-23	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg02951344	chr11:85522279	SYTL2	-0.63	-6.55	-0.3	1.62e-10	Type 2 diabetes;
LUAD	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.43	-0.34	6.08e-13	Bipolar disorder;
LUAD	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-9.97	-0.44	3.56e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4988958	0.584	rs12712149	chr2:103045193	A/G	cg03938978	chr2:103052716	IL18RAP	0.46	10.49	0.45	4.89e-23	Asthma (childhood onset);
LUAD	cis	rs7927771	0.524	rs7110300	chr11:47848442	T/G	cg18512352	chr11:47633146	NA	0.36	6.38	0.3	4.61e-10	Subjective well-being;
LUAD	cis	rs6674176	0.932	rs12410334	chr1:44442521	A/C	cg12908607	chr1:44402522	ARTN	-0.55	-10.05	-0.44	1.86e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg03037974	chr15:76606532	NA	0.37	7.74	0.35	7.62e-14	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg03676636	chr4:99064102	C4orf37	0.32	8.34	0.38	1.06e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg08558340	chr7:100472263	SRRT	0.5	6.48	0.3	2.58e-10	Resting heart rate;
LUAD	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.08	-0.4	4.31e-18	Total body bone mineral density;
LUAD	cis	rs9494145	0.680	rs4895440	chr6:135426558	A/T	cg22676075	chr6:135203613	NA	0.52	7.98	0.36	1.43e-14	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUAD	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.6	-0.39	1.61e-16	Alzheimer's disease (late onset);
LUAD	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg02733842	chr7:1102375	C7orf50	-0.69	-10.28	-0.45	2.82e-22	Bronchopulmonary dysplasia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13232424	chr2:128849480	UGGT1	-0.37	-6.51	-0.3	2.17e-10	Cancer;
LUAD	cis	rs7274811	0.723	rs6120329	chr20:32210238	T/G	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.43	-6.48	-0.3	2.6e-10	Height;
LUAD	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.54	0.42	1.17e-19	Lung cancer in ever smokers;
LUAD	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.01	-0.32	9.75e-12	Height;
LUAD	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg00484396	chr16:3507460	NAT15	0.74	9.82	0.43	1.26e-20	Tuberculosis;
LUAD	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg03037974	chr15:76606532	NA	0.38	8.14	0.37	4.33e-15	Blood metabolite levels;
LUAD	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg24596788	chr1:163392923	NA	-0.31	-6.51	-0.3	2.17e-10	Motion sickness;
LUAD	cis	rs6685188	0.843	rs1775139	chr1:205672357	C/G	cg26354017	chr1:205819088	PM20D1	0.4	6.56	0.3	1.56e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg13722127	chr7:150037890	RARRES2	0.49	8.29	0.37	1.57e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg25456477	chr12:86230367	RASSF9	0.32	6.48	0.3	2.59e-10	Major depressive disorder;
LUAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg00450029	chr8:599525	NA	0.82	7.97	0.36	1.53e-14	IgG glycosylation;
LUAD	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.91	-17.97	-0.66	4.71e-54	Ulcerative colitis;
LUAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.67	0.31	8.08e-11	Prudent dietary pattern;
LUAD	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg23649088	chr2:200775458	C2orf69	0.67	11.47	0.49	1.1e-26	Osteoporosis;
LUAD	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.75	-15.32	-0.6	1.84e-42	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg21475434	chr5:93447410	FAM172A	-0.59	-7.77	-0.35	5.86e-14	Diabetic retinopathy;
LUAD	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg07570687	chr10:102243282	WNT8B	0.46	6.94	0.32	1.5e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.86	0.32	2.52e-11	Obesity-related traits;
LUAD	cis	rs279910	0.862	rs279899	chr9:965006	A/T	cg13952963	chr9:998547	NA	-0.37	-6.46	-0.3	2.92e-10	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUAD	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10802521	chr3:52805072	NEK4	-0.53	-8.93	-0.4	1.34e-17	Bipolar disorder;
LUAD	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-9.12	-0.41	2.97e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.93	-0.36	1.97e-14	Personality dimensions;
LUAD	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg12310025	chr6:25882481	NA	-0.58	-9.53	-0.42	1.24e-19	Blood metabolite levels;
LUAD	cis	rs12976411	0.867	rs34877796	chr19:32829045	C/T	cg02282382	chr19:32836354	ZNF507	0.71	6.66	0.31	8.66e-11	Coronary artery disease;
LUAD	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18876405	chr7:65276391	NA	-0.58	-9.91	-0.43	5.83e-21	Aortic root size;
LUAD	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-8.42	-0.38	5.7e-16	Gut microbiome composition (summer);
LUAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg16606324	chr3:10149918	C3orf24	0.7	11.51	0.49	7.19e-27	Alzheimer's disease;
LUAD	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26314531	chr2:26401878	FAM59B	-0.56	-7.89	-0.36	2.52e-14	Gut microbiome composition (summer);
LUAD	cis	rs250585	0.736	rs3096175	chr16:23457583	C/T	cg00143387	chr16:23521605	GGA2	0.64	9.41	0.42	3.09e-19	Egg allergy;
LUAD	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg15962314	chr1:44399869	ARTN	0.3	6.87	0.32	2.36e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs991427	1.000	rs17018694	chr12:91474052	G/T	cg11428724	chr1:18957632	PAX7	0.42	6.49	0.3	2.37e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg18621852	chr3:10150065	C3orf24	0.48	8.45	0.38	4.89e-16	Alzheimer's disease;
LUAD	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg16205897	chr5:131564050	P4HA2	-0.32	-7.18	-0.33	3.19e-12	Blood metabolite levels;
LUAD	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg04568274	chr7:158649319	WDR60	-0.44	-6.69	-0.31	7.31e-11	Height;
LUAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.87	-0.32	2.28e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00149659	chr3:10157352	C3orf10	0.53	7.35	0.34	1.06e-12	Alzheimer's disease;
LUAD	cis	rs4660306	0.884	rs7543076	chr1:45964238	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-8.04	-0.36	8.88e-15	Homocysteine levels;
LUAD	cis	rs7193541	1.000	rs7193541	chr16:74664743	C/T	cg01733217	chr16:74700730	RFWD3	-0.55	-9.37	-0.41	4.43e-19	Multiple myeloma;
LUAD	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg22681709	chr2:178499509	PDE11A	-0.38	-6.85	-0.32	2.67e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs55665837	1.000	rs11023229	chr11:14461001	G/C	cg19336497	chr11:14380999	RRAS2	-0.5	-10.1	-0.44	1.27e-21	Vitamin D levels;
LUAD	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg16060761	chr17:80687452	NA	0.7	11.34	0.48	3.24e-26	Glycated hemoglobin levels;
LUAD	trans	rs62103177	0.714	rs7227962	chr18:77603283	T/G	cg05926928	chr17:57297772	GDPD1	0.82	11.65	0.49	2.11e-27	Opioid sensitivity;
LUAD	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg20891283	chr12:69753455	YEATS4	0.43	7.05	0.32	7.21e-12	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg04155289	chr7:94953770	PON1	-0.5	-6.54	-0.3	1.81e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg03605463	chr16:89740564	NA	0.62	10.26	0.45	3.35e-22	Vitiligo;
LUAD	cis	rs72799341	1.000	rs1458201	chr16:30916129	G/A	cg02466173	chr16:30829666	NA	-0.59	-8.81	-0.39	3.2e-17	Diastolic blood pressure;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03969997	chr7:73256865	WBSCR27	-0.42	-6.77	-0.31	4.39e-11	Cancer;
LUAD	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg15445000	chr17:37608096	MED1	-0.44	-8.22	-0.37	2.44e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg27432699	chr2:27873401	GPN1	0.57	10.19	0.44	6.1e-22	Oral cavity cancer;
LUAD	cis	rs62400317	0.762	rs756	chr6:44795772	C/T	cg18551225	chr6:44695536	NA	-0.6	-9.15	-0.41	2.52e-18	Total body bone mineral density;
LUAD	cis	rs559928	0.502	rs11231787	chr11:64179813	T/C	cg05555928	chr11:63887634	MACROD1	-0.48	-7.56	-0.35	2.46e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUAD	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg27661571	chr11:113659931	NA	-0.73	-8.28	-0.37	1.63e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs2625529	0.652	rs8040216	chr15:72255249	C/T	cg16672083	chr15:72433130	SENP8	0.6	11.01	0.47	5.78e-25	Red blood cell count;
LUAD	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26314531	chr2:26401878	FAM59B	-0.56	-7.65	-0.35	1.39e-13	Gut microbiome composition (summer);
LUAD	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg00255919	chr5:131827918	IRF1	0.49	11.44	0.49	1.4e-26	Asthma (sex interaction);
LUAD	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg18277682	chr1:228362509	C1orf69	-0.38	-6.36	-0.3	5.37e-10	Diastolic blood pressure;
LUAD	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg05340658	chr4:99064831	C4orf37	0.54	9.18	0.41	1.86e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg02508848	chr16:68573721	ZFP90	-0.42	-6.6	-0.31	1.22e-10	Ulcerative colitis;
LUAD	trans	rs225245	0.791	rs7406966	chr17:34013636	A/C	cg19694781	chr19:47549865	TMEM160	-0.46	-7.52	-0.34	3.35e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs4481887	0.861	rs4309013	chr1:248480768	C/T	cg13385794	chr1:248469461	NA	0.26	7.0	0.32	1.01e-11	Common traits (Other);
LUAD	cis	rs6687430	0.543	rs7512495	chr1:10631237	C/T	cg17425144	chr1:10567563	PEX14	0.54	10.4	0.45	1.01e-22	Hand grip strength;
LUAD	cis	rs7582720	1.000	rs114899426	chr2:203771652	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg09365446	chr1:150670422	GOLPH3L	0.62	10.91	0.47	1.38e-24	Melanoma;
LUAD	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg22166914	chr1:53195759	ZYG11B	-0.44	-7.62	-0.35	1.64e-13	Monocyte count;
LUAD	cis	rs9326248	0.520	rs10892060	chr11:116881662	C/A	cg20608306	chr11:116969690	SIK3	0.3	6.65	0.31	9.09e-11	Blood protein levels;
LUAD	cis	rs11723261	0.582	rs4582104	chr4:136942	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	8.07	0.37	7.39e-15	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg25237894	chr2:233734115	C2orf82	0.64	12.01	0.5	8.48e-29	Coronary artery disease;
LUAD	cis	rs72634258	0.945	rs2294889	chr1:8075934	A/G	cg26816564	chr1:7831052	VAMP3	0.59	7.92	0.36	2.06e-14	Inflammatory bowel disease;
LUAD	cis	rs2806561	0.578	rs6702719	chr1:23302576	T/C	cg12483005	chr1:23474871	LUZP1	0.44	7.22	0.33	2.5e-12	Height;
LUAD	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg09184832	chr6:79620586	NA	-0.53	-9.78	-0.43	1.74e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg03037974	chr15:76606532	NA	0.37	7.74	0.35	7.19e-14	Blood metabolite levels;
LUAD	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg02574844	chr11:5959923	NA	-0.45	-8.45	-0.38	4.72e-16	DNA methylation (variation);
LUAD	trans	rs11083241	0.570	rs7243677	chr18:25558198	C/T	cg23834254	chr4:169931521	CBR4	-0.4	-6.71	-0.31	6.41e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs897984	0.513	rs17839568	chr16:31099783	T/C	cg02466173	chr16:30829666	NA	-0.56	-9.64	-0.42	5.39e-20	Dementia with Lewy bodies;
LUAD	cis	rs7493	0.901	rs17882539	chr7:95026408	G/A	cg20119798	chr7:94954144	PON1	-0.49	-6.9	-0.32	1.94e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9462027	0.628	rs7741437	chr6:34737553	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.94	-0.4	1.27e-17	Systemic lupus erythematosus;
LUAD	cis	rs7584330	0.554	rs62186170	chr2:238425883	C/T	cg14458575	chr2:238380390	NA	0.61	9.83	0.43	1.1e-20	Prostate cancer;
LUAD	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg09491104	chr22:46646882	C22orf40	-0.7	-12.44	-0.52	1.66e-30	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs3930017	1.000	rs56225549	chr7:76722395	G/A	cg05913257	chr4:53525745	USP46	-0.4	-6.53	-0.3	1.94e-10	Body mass index;
LUAD	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg06074448	chr4:187884817	NA	-0.4	-8.12	-0.37	5.12e-15	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg14092988	chr3:52407081	DNAH1	0.41	8.1	0.37	6.13e-15	Electroencephalogram traits;
LUAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg18621852	chr3:10150065	C3orf24	0.48	8.3	0.37	1.44e-15	Alzheimer's disease;
LUAD	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg20607798	chr8:58055168	NA	0.6	7.8	0.35	4.85e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs4481887	0.604	rs4430368	chr1:248411573	A/G	cg00666640	chr1:248458726	OR2T12	0.34	7.48	0.34	4.44e-13	Common traits (Other);
LUAD	trans	rs564343	0.560	rs4930170	chr11:65811208	G/T	cg26701943	chr11:108369231	KDELC2	-0.46	-7.27	-0.33	1.75e-12	Obesity (early onset extreme);
LUAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg12432903	chr7:1882776	MAD1L1	-0.4	-6.61	-0.31	1.17e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg06064525	chr11:970664	AP2A2	-0.57	-11.75	-0.5	8.89e-28	Alzheimer's disease (late onset);
LUAD	cis	rs356992	0.915	rs356976	chr2:60748945	C/T	cg08426369	chr2:60753602	BCL11A	-0.48	-7.69	-0.35	1.01e-13	Educational attainment (years of education);
LUAD	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.46	0.42	2.24e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg22571038	chr17:48585470	MYCBPAP	0.5	6.76	0.31	4.65e-11	Visceral fat;
LUAD	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg09904177	chr6:26538194	HMGN4	0.41	6.94	0.32	1.48e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1395	1.000	rs1275528	chr2:27430781	A/G	cg23587288	chr2:27483067	SLC30A3	0.39	7.98	0.36	1.38e-14	Blood metabolite levels;
LUAD	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg10518543	chr12:38710700	ALG10B	-0.44	-7.21	-0.33	2.55e-12	Morning vs. evening chronotype;
LUAD	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.81	11.31	0.48	4.2e-26	Smoking behavior;
LUAD	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg17971929	chr21:40555470	PSMG1	0.57	9.17	0.41	2.14e-18	Cognitive function;
LUAD	cis	rs730566	1.000	rs4858819	chr3:48478088	C/T	cg07636037	chr3:49044803	WDR6	-0.42	-6.4	-0.3	4.18e-10	Prion diseases;
LUAD	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.85	-0.4	2.5e-17	Total body bone mineral density;
LUAD	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg11673840	chr17:47092156	IGF2BP1	0.32	6.46	0.3	2.88e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg22920501	chr2:26401640	FAM59B	-0.82	-11.51	-0.49	7.66e-27	Gut microbiome composition (summer);
LUAD	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.39	8.29	0.37	1.53e-15	Hemoglobin concentration;
LUAD	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg26513180	chr16:89883248	FANCA	0.77	6.43	0.3	3.5e-10	Skin colour saturation;
LUAD	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg07967210	chr17:47022446	SNF8	0.36	6.45	0.3	3.11e-10	Type 2 diabetes;
LUAD	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg17200465	chr3:40428508	ENTPD3	0.28	7.17	0.33	3.27e-12	Renal cell carcinoma;
LUAD	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg02549819	chr16:58548995	SETD6	0.8	6.68	0.31	7.67e-11	Schizophrenia;
LUAD	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg02423579	chr7:2872169	GNA12	-0.91	-16.54	-0.63	9.83e-48	Height;
LUAD	cis	rs8067545	0.641	rs203466	chr17:19809953	C/G	cg04132472	chr17:19861366	AKAP10	-0.4	-9.46	-0.42	2.11e-19	Schizophrenia;
LUAD	trans	rs8073060	0.544	rs2626626	chr17:34026717	A/G	cg19694781	chr19:47549865	TMEM160	-1.23	-19.63	-0.69	1.8e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg15181151	chr6:150070149	PCMT1	0.4	8.1	0.37	5.75e-15	Lung cancer;
LUAD	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.32	-6.67	-0.31	8.18e-11	Hemoglobin concentration;
LUAD	cis	rs6460942	1.000	rs6948314	chr7:12418363	T/A	cg06484146	chr7:12443880	VWDE	-0.55	-7.18	-0.33	3.18e-12	Coronary artery disease;
LUAD	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg27535305	chr1:53392650	SCP2	0.32	6.63	0.31	1.02e-10	Monocyte count;
LUAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg09436375	chr6:42928200	GNMT	-0.28	-8.2	-0.37	3e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11644478	chr21:40555479	PSMG1	-0.55	-8.76	-0.39	4.7e-17	Cognitive function;
LUAD	cis	rs12208915	0.848	rs7757382	chr6:79502277	C/G	cg05283184	chr6:79620031	NA	0.5	6.76	0.31	4.69e-11	Left atrial antero-posterior diameter;
LUAD	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg19193384	chr17:30244184	NA	-0.54	-6.39	-0.3	4.26e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs2242073	1.000	rs62192854	chr2:208992553	G/A	cg24664470	chr2:208976933	NA	0.48	6.66	0.31	8.4e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs4774899	0.869	rs2733176	chr15:57336589	G/A	cg14026238	chr15:57616123	NA	-0.34	-6.4	-0.3	4.23e-10	Urinary tract infection frequency;
LUAD	cis	rs2735413	0.881	rs12927515	chr16:78080141	T/G	cg04733911	chr16:78082701	NA	-0.35	-8.3	-0.37	1.37e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.2	-0.48	1.08e-25	Type 2 diabetes;
LUAD	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg16405210	chr4:1374714	KIAA1530	-0.51	-8.25	-0.37	2.01e-15	Longevity;
LUAD	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg04287289	chr16:89883240	FANCA	0.72	13.27	0.54	7.57e-34	Vitiligo;
LUAD	cis	rs11166629	1.000	rs4909330	chr8:135644369	T/C	cg27224718	chr8:135614730	ZFAT	0.59	10.6	0.46	1.91e-23	Smoking quantity;
LUAD	cis	rs56283067	0.847	rs1552196	chr6:44698265	A/G	cg20913747	chr6:44695427	NA	0.39	6.63	0.31	1.04e-10	Total body bone mineral density;
LUAD	cis	rs1395	0.922	rs1561535	chr2:27471025	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.37	6.65	0.31	9.09e-11	Blood metabolite levels;
LUAD	cis	rs9302635	0.745	rs35549608	chr16:72227398	T/C	cg23815491	chr16:72088622	HP	0.53	6.54	0.3	1.73e-10	Blood protein levels;
LUAD	cis	rs4285028	0.948	rs71329246	chr3:121680170	T/C	cg11130432	chr3:121712080	ILDR1	-0.59	-8.44	-0.38	5.05e-16	Multiple sclerosis;
LUAD	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03352830	chr11:487213	PTDSS2	0.8	10.12	0.44	1.08e-21	Body mass index;
LUAD	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg20628663	chr10:43360327	NA	0.66	10.41	0.45	9.44e-23	Blood protein levels;
LUAD	cis	rs3125734	0.633	rs12217669	chr10:63988456	A/G	cg19640130	chr10:64028056	RTKN2	0.34	7.24	0.33	2.11e-12	Rheumatoid arthritis;
LUAD	cis	rs6489882	0.613	rs1131454	chr12:113348870	C/T	cg20102336	chr12:113376681	OAS3	-0.43	-6.84	-0.32	2.87e-11	Chronic lymphocytic leukemia;
LUAD	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg26513180	chr16:89883248	FANCA	0.52	8.86	0.4	2.21e-17	Vitiligo;
LUAD	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-8.44	-0.38	5.09e-16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg21226059	chr5:178986404	RUFY1	-0.52	-8.7	-0.39	7.36e-17	Lung cancer;
LUAD	cis	rs12681287	0.547	rs13267858	chr8:87510871	G/A	cg27223183	chr8:87520930	FAM82B	-0.71	-10.12	-0.44	1.07e-21	Caudate activity during reward;
LUAD	cis	rs17539620	0.624	rs62432751	chr6:154841027	A/G	cg20019720	chr6:154832845	CNKSR3	0.63	11.46	0.49	1.17e-26	Lipoprotein (a) levels;
LUAD	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg25358565	chr5:93447407	FAM172A	0.65	7.69	0.35	1.07e-13	Diabetic retinopathy;
LUAD	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg06740227	chr12:86229804	RASSF9	0.46	8.0	0.36	1.21e-14	Major depressive disorder;
LUAD	cis	rs7107174	1.000	rs1399196	chr11:78071876	A/G	cg19901956	chr11:77921274	USP35	-0.47	-6.84	-0.32	2.82e-11	Testicular germ cell tumor;
LUAD	cis	rs4389656	0.743	rs34681760	chr5:6712834	T/C	cg10857441	chr5:6722123	POLS	-0.46	-7.54	-0.34	2.85e-13	Coronary artery disease;
LUAD	cis	rs7937890	0.504	rs2575822	chr11:14519851	C/A	cg06199346	chr11:14280333	SPON1	-0.32	-6.42	-0.3	3.58e-10	Mitochondrial DNA levels;
LUAD	cis	rs7043114	0.507	rs10761154	chr9:95144086	A/G	cg14631576	chr9:95140430	CENPP	-0.42	-8.61	-0.39	1.51e-16	Height;
LUAD	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg17031739	chr1:67600172	NA	0.45	7.89	0.36	2.58e-14	Psoriasis;
LUAD	trans	rs9357271	0.956	rs7748599	chr6:38363213	A/G	cg01381795	chr19:54496611	CACNG6	0.32	6.53	0.3	1.92e-10	Restless legs syndrome;
LUAD	cis	rs2455601	0.608	rs10840137	chr11:8890079	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-8.32	-0.37	1.24e-15	Schizophrenia;
LUAD	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg09517075	chr8:22133004	PIWIL2	0.5	9.21	0.41	1.51e-18	Hypertriglyceridemia;
LUAD	trans	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.65	-0.46	1.24e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7000551	0.638	rs2469771	chr8:22376627	T/C	cg12081754	chr8:22256438	SLC39A14	0.43	7.0	0.32	1e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg25894440	chr7:65020034	NA	-0.67	-7.14	-0.33	4.2e-12	Diabetic kidney disease;
LUAD	cis	rs28595532	0.920	rs17323034	chr4:119606518	G/A	cg14228332	chr4:119757509	SEC24D	0.77	7.07	0.32	6.56e-12	Cannabis dependence symptom count;
LUAD	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg16325326	chr1:53192061	ZYG11B	-0.5	-8.66	-0.39	1e-16	Monocyte count;
LUAD	trans	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.1	0.51	3.91e-29	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs698833	0.892	rs786418	chr2:44688413	C/T	cg04920474	chr2:44395004	PPM1B	0.38	6.81	0.31	3.47e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs367943	0.698	rs9764191	chr5:112961088	T/C	cg12552261	chr5:112820674	MCC	0.37	6.51	0.3	2.1e-10	Type 2 diabetes;
LUAD	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg01689657	chr7:91764605	CYP51A1	0.3	7.29	0.33	1.57e-12	Breast cancer;
LUAD	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-9.6	-0.42	7.27e-20	Height;
LUAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg25703541	chr22:24373054	LOC391322	-0.79	-13.86	-0.56	2.86e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg04025307	chr7:1156635	C7orf50	0.66	12.13	0.51	2.9e-29	Longevity;Endometriosis;
LUAD	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg02931644	chr1:25747376	RHCE	-0.47	-10.31	-0.45	2.12e-22	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg00933542	chr6:150070202	PCMT1	0.46	9.82	0.43	1.26e-20	Lung cancer;
LUAD	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.5	9.03	0.4	6.17e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg12400702	chr3:12838781	CAND2	0.31	6.42	0.3	3.56e-10	Parkinson's disease;
LUAD	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg05340658	chr4:99064831	C4orf37	0.46	7.52	0.34	3.42e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg18806716	chr10:30721971	MAP3K8	-0.61	-11.78	-0.5	7.01e-28	Inflammatory bowel disease;
LUAD	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg18512352	chr11:47633146	NA	-0.49	-8.8	-0.39	3.63e-17	Subjective well-being;
LUAD	cis	rs10979	0.965	rs9496674	chr6:143886106	G/T	cg25407410	chr6:143891975	LOC285740	-0.62	-9.75	-0.43	2.15e-20	Hypospadias;
LUAD	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg08436684	chr16:88034427	BANP	-0.48	-6.39	-0.3	4.36e-10	Menopause (age at onset);
LUAD	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg22875332	chr1:76189707	ACADM	-0.63	-10.26	-0.45	3.27e-22	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	8.1	0.37	5.91e-15	Alzheimer's disease;
LUAD	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg01765077	chr12:122356316	WDR66	-0.52	-9.03	-0.4	6.29e-18	Mean corpuscular volume;
LUAD	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg13679303	chr9:96623674	NA	-0.38	-7.74	-0.35	7.61e-14	DNA methylation (variation);
LUAD	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg27489772	chr12:121021490	NA	0.58	7.01	0.32	9.22e-12	Type 1 diabetes nephropathy;
LUAD	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg05991184	chr2:219186017	PNKD	-0.34	-6.48	-0.3	2.5e-10	Colorectal cancer;
LUAD	cis	rs10129255	0.500	rs2027903	chr14:107215283	A/C	cg07958169	chr14:107095056	NA	-0.37	-7.24	-0.33	2.07e-12	Kawasaki disease;
LUAD	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg10544611	chr16:67998164	SLC12A4	-0.54	-6.87	-0.32	2.38e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg09184832	chr6:79620586	NA	-0.5	-9.3	-0.41	7.68e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.63	-12.13	-0.51	2.93e-29	Longevity;Endometriosis;
LUAD	cis	rs2475553	1.000	rs2475553	chr6:158533560	G/T	cg07165851	chr6:158734300	TULP4	-0.56	-6.43	-0.3	3.53e-10	Lipoprotein (a) - cholesterol levels;
LUAD	cis	rs9863	0.861	rs11057397	chr12:124419728	C/T	cg17723958	chr12:124429295	CCDC92	-0.42	-6.58	-0.3	1.38e-10	White blood cell count;
LUAD	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	8.15	0.37	4.01e-15	Breast cancer;
LUAD	cis	rs2109514	1.000	rs2109514	chr7:116159961	G/A	cg12739419	chr7:116140593	CAV2	-0.37	-7.95	-0.36	1.77e-14	Prevalent atrial fibrillation;
LUAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg02136620	chr5:178986620	RUFY1	-0.56	-9.49	-0.42	1.66e-19	Lung cancer;
LUAD	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg23229984	chr5:148520753	ABLIM3	0.49	7.68	0.35	1.08e-13	Breast cancer;
LUAD	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg08885076	chr2:99613938	TSGA10	0.4	7.07	0.33	6.44e-12	Chronic sinus infection;
LUAD	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg00784671	chr22:46762841	CELSR1	-0.57	-7.68	-0.35	1.11e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs250585	1.000	rs375237	chr16:23462639	A/C	cg00143387	chr16:23521605	GGA2	-0.65	-7.88	-0.36	2.71e-14	Egg allergy;
LUAD	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg02660097	chr11:68866761	NA	0.5	7.06	0.32	7.01e-12	Blond vs. brown hair color;
LUAD	cis	rs1020064	0.895	rs2250659	chr2:105889684	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.42	6.71	0.31	6.14e-11	AIDS;
LUAD	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg06064525	chr11:970664	AP2A2	-0.56	-11.49	-0.49	9.13e-27	Alzheimer's disease (late onset);
LUAD	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg06197492	chr11:2016605	H19	-0.36	-7.37	-0.34	9.07e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs78487399	0.808	rs13431070	chr2:43721954	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.57	7.02	0.32	9.06e-12	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.15	-0.37	4.24e-15	Cannabis dependence symptom count;
LUAD	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg19717773	chr7:2847554	GNA12	-0.51	-9.36	-0.41	4.59e-19	Height;
LUAD	cis	rs732716	0.853	rs72990643	chr19:4454736	C/T	cg21934504	chr19:4445085	UBXN6	0.47	7.86	0.36	3.25e-14	Mean corpuscular volume;
LUAD	cis	rs12545109	0.800	rs1437278	chr8:57357024	T/C	cg19413350	chr8:57351067	NA	-0.47	-7.02	-0.32	8.87e-12	Obesity-related traits;
LUAD	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg17173187	chr15:85201210	NMB	0.44	7.32	0.34	1.25e-12	Schizophrenia;
LUAD	cis	rs62458065	0.513	rs10268149	chr7:32575499	T/C	cg20159608	chr7:32802032	NA	-0.68	-10.19	-0.44	5.94e-22	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs4588572	0.643	rs10075726	chr5:77669053	T/A	cg11547950	chr5:77652471	NA	0.78	11.81	0.5	4.99e-28	Triglycerides;
LUAD	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg11266682	chr4:10021025	SLC2A9	0.69	15.69	0.61	4.93e-44	Bone mineral density;
LUAD	cis	rs6987853	0.787	rs2923448	chr8:42406008	G/A	cg09913449	chr8:42400586	C8orf40	0.52	10.42	0.45	8.46e-23	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg21823605	chr1:152486609	CRCT1	0.3	6.74	0.31	5.25e-11	Hair morphology;
LUAD	cis	rs8038465	0.622	rs7182124	chr15:73915254	C/T	cg15420318	chr15:73925796	NPTN	0.45	7.52	0.34	3.33e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs933688	0.532	rs2973478	chr5:90553428	C/T	cg17503389	chr5:90575422	NA	-0.44	-6.61	-0.31	1.2e-10	Smoking behavior;
LUAD	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg08712631	chr7:1960676	MAD1L1	-0.41	-6.68	-0.31	7.56e-11	Neuroticism;
LUAD	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg21385522	chr1:16154831	NA	0.57	9.65	0.42	4.61e-20	Systolic blood pressure;
LUAD	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg19318889	chr4:1322082	MAEA	0.45	7.31	0.33	1.37e-12	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg18180107	chr4:99064573	C4orf37	0.42	6.79	0.31	3.87e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs113835537	0.529	rs75683511	chr11:66275026	A/G	cg24851651	chr11:66362959	CCS	0.58	9.86	0.43	9.09e-21	Airway imaging phenotypes;
LUAD	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-8.12	-0.37	5.18e-15	Neutrophil percentage of white cells;
LUAD	cis	rs13112683	0.560	rs10009067	chr4:140784235	C/T	cg02876341	chr4:140783585	MAML3	0.31	6.7	0.31	6.49e-11	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LUAD	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg07493874	chr5:1342172	CLPTM1L	0.33	7.53	0.34	3.18e-13	Lung cancer;
LUAD	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg08470875	chr2:26401718	FAM59B	0.77	10.29	0.45	2.49e-22	Gut microbiome composition (summer);
LUAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.57	-9.31	-0.41	7.09e-19	Renal function-related traits (BUN);
LUAD	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg27170947	chr2:26402098	FAM59B	0.57	8.08	0.37	6.77e-15	Gut microbiome composition (summer);
LUAD	cis	rs7917772	0.582	rs3977756	chr10:104398582	G/A	cg22532475	chr10:104410764	TRIM8	0.41	8.19	0.37	3.17e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg02734326	chr4:10020555	SLC2A9	-0.45	-7.35	-0.34	1.03e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs977987	0.778	rs8057849	chr16:75443816	T/C	cg03315344	chr16:75512273	CHST6	0.64	14.07	0.56	3.87e-37	Dupuytren's disease;
LUAD	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg15557168	chr22:42548783	NA	0.51	9.41	0.42	3.33e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	9.4e-15	Tonsillectomy;
LUAD	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.47	-0.42	1.94e-19	Dilated cardiomyopathy;
LUAD	cis	rs12545109	0.800	rs1371936	chr8:57422715	A/G	cg09654669	chr8:57350985	NA	-0.67	-9.59	-0.42	7.74e-20	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg08470875	chr2:26401718	FAM59B	0.64	8.82	0.39	3.13e-17	Gut microbiome composition (summer);
LUAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg06263672	chr7:65235340	NA	0.49	7.94	0.36	1.8e-14	Calcium levels;
LUAD	cis	rs346785	0.692	rs2279054	chr17:74287594	G/A	cg09812376	chr17:74270190	QRICH2	-0.31	-6.42	-0.3	3.67e-10	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg22852734	chr6:133119734	C6orf192	0.7	8.07	0.37	7.32e-15	Type 2 diabetes nephropathy;
LUAD	cis	rs6500395	0.926	rs1039343	chr16:48577507	T/G	cg04672837	chr16:48644449	N4BP1	0.38	6.51	0.3	2.14e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg27124370	chr19:33622961	WDR88	0.44	7.12	0.33	4.54e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg26924012	chr15:45694286	SPATA5L1	1.02	18.85	0.68	5.65e-58	Homoarginine levels;
LUAD	cis	rs6690583	0.623	rs7522239	chr1:85484366	C/T	cg22153463	chr1:85462885	MCOLN2	0.59	7.09	0.33	5.6e-12	Serum sulfate level;
LUAD	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg02734326	chr4:10020555	SLC2A9	-0.49	-8.63	-0.39	1.28e-16	Bone mineral density;
LUAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg13047869	chr3:10149882	C3orf24	0.63	9.47	0.42	2.07e-19	Alzheimer's disease;
LUAD	cis	rs933688	0.532	rs28637141	chr5:90538743	C/T	cg00335715	chr5:90575459	NA	-0.39	-6.37	-0.3	4.92e-10	Smoking behavior;
LUAD	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg25452165	chr22:42524984	CYP2D6	0.39	6.44	0.3	3.22e-10	Schizophrenia;
LUAD	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg08847533	chr14:75593920	NEK9	-0.39	-6.59	-0.31	1.34e-10	Height;
LUAD	cis	rs476633	0.573	rs6492995	chr15:41529712	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.63	-11.63	-0.49	2.67e-27	Glomerular filtration rate (creatinine);
LUAD	cis	rs10203711	1.000	rs7590907	chr2:239550312	T/C	cg14580085	chr2:239553406	NA	0.39	8.25	0.37	2.07e-15	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg13319975	chr6:146136371	FBXO30	0.62	10.71	0.46	7.73e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg18827107	chr12:86230957	RASSF9	-0.48	-8.49	-0.38	3.58e-16	Major depressive disorder;
LUAD	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg02734326	chr4:10020555	SLC2A9	-0.42	-7.43	-0.34	6.18e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg13319975	chr6:146136371	FBXO30	-0.57	-9.48	-0.42	1.91e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg04398451	chr17:18023971	MYO15A	-0.91	-18.25	-0.66	2.66e-55	Total body bone mineral density;
LUAD	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg25358565	chr5:93447407	FAM172A	0.63	7.78	0.35	5.58e-14	Diabetic retinopathy;
LUAD	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg14847009	chr1:175162515	KIAA0040	0.3	7.75	0.35	6.78e-14	Alcohol dependence;
LUAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg23978390	chr7:1156363	C7orf50	0.52	8.27	0.37	1.8e-15	Longevity;Endometriosis;
LUAD	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg26441486	chr22:50317300	CRELD2	0.43	6.45	0.3	3.1e-10	Schizophrenia;
LUAD	cis	rs11756438	0.572	rs1857312	chr6:119001526	A/C	cg18833306	chr6:118973337	C6orf204	0.53	9.47	0.42	1.98e-19	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg21226059	chr5:178986404	RUFY1	0.68	12.08	0.51	4.48e-29	Lung cancer;
LUAD	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.61	-0.31	1.18e-10	Prostate cancer;
LUAD	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.44	6.69	0.31	7e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg06532163	chr17:45867833	NA	0.45	8.08	0.37	6.99e-15	IgG glycosylation;
LUAD	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg25767906	chr1:53392781	SCP2	-0.41	-7.44	-0.34	5.81e-13	Monocyte count;
LUAD	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg09537434	chr19:41945824	ATP5SL	-0.52	-8.27	-0.37	1.71e-15	Height;
LUAD	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg10544611	chr16:67998164	SLC12A4	-0.61	-7.39	-0.34	7.78e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2050392	0.861	rs1042058	chr10:30728101	T/C	cg18806716	chr10:30721971	MAP3K8	-0.54	-10.73	-0.46	6.17e-24	Inflammatory bowel disease;
LUAD	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg09021430	chr5:549028	NA	-0.69	-13.45	-0.55	1.43e-34	Lung disease severity in cystic fibrosis;
LUAD	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg00757033	chr12:89920650	WDR51B	0.69	12.09	0.51	3.99e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg12863693	chr15:85201151	NMB	0.44	8.17	0.37	3.6e-15	Schizophrenia;
LUAD	cis	rs12681287	0.604	rs7017716	chr8:87429001	A/C	cg00550725	chr8:87521180	FAM82B	0.43	6.52	0.3	1.95e-10	Caudate activity during reward;
LUAD	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.46	8.04	0.36	9.16e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg25894440	chr7:65020034	NA	0.68	7.58	0.35	2.23e-13	Diabetic kidney disease;
LUAD	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg04450456	chr4:17643702	FAM184B	0.37	6.95	0.32	1.39e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg13047869	chr3:10149882	C3orf24	0.64	9.6	0.42	6.98e-20	Alzheimer's disease;
LUAD	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.46	0.34	4.83e-13	Tonsillectomy;
LUAD	cis	rs35123781	0.654	rs356486	chr5:139085103	C/G	cg10513866	chr5:139070639	NA	-0.5	-7.87	-0.36	2.93e-14	Schizophrenia;
LUAD	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg03948781	chr1:205179583	DSTYK	0.34	6.46	0.3	2.83e-10	Red blood cell count;
LUAD	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg21100191	chr22:23484243	RTDR1	0.67	11.84	0.5	3.93e-28	Bone mineral density;
LUAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg00080972	chr5:178986291	RUFY1	0.55	9.8	0.43	1.41e-20	Lung cancer;
LUAD	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg09367891	chr1:107599246	PRMT6	-0.59	-9.87	-0.43	8.21e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs220324	0.688	rs9981522	chr21:43568247	A/C	cg09727148	chr21:43560719	UMODL1	0.48	7.55	0.34	2.7e-13	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg06718696	chr17:78121285	EIF4A3	0.57	8.63	0.39	1.28e-16	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg11266682	chr4:10021025	SLC2A9	0.67	15.52	0.6	2.67e-43	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg23803603	chr1:2058230	PRKCZ	-0.38	-6.83	-0.32	2.97e-11	Height;
LUAD	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.48	0.3	2.6e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg21475434	chr5:93447410	FAM172A	0.76	8.43	0.38	5.66e-16	Diabetic retinopathy;
LUAD	trans	rs11039798	0.858	rs11039730	chr11:48440495	A/G	cg15704280	chr7:45808275	SEPT13	0.75	7.75	0.35	6.9e-14	Axial length;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05335030	chr22:50632819	TRABD	0.51	6.52	0.3	1.95e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg14345882	chr6:26364793	BTN3A2	0.7	7.14	0.33	4.13e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg13722127	chr7:150037890	RARRES2	0.43	7.22	0.33	2.38e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg22535103	chr8:58192502	C8orf71	-0.65	-6.99	-0.32	1.11e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg00106254	chr7:1943704	MAD1L1	-0.59	-8.81	-0.39	3.22e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs12760731	0.720	rs67857740	chr1:178402250	A/G	cg00404053	chr1:178313656	RASAL2	0.62	7.94	0.36	1.88e-14	Obesity-related traits;
LUAD	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg24803719	chr17:45855879	NA	-0.34	-7.52	-0.34	3.27e-13	IgG glycosylation;
LUAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg20607798	chr8:58055168	NA	0.82	9.86	0.43	9.07e-21	Developmental language disorder (linguistic errors);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg01190915	chr16:56642761	MT2A	-0.44	-7.46	-0.34	4.98e-13	Subcortical brain region volumes;
LUAD	cis	rs6445967	1.000	rs35495842	chr3:58310250	T/C	cg23715586	chr3:58305044	RPP14	0.46	8.15	0.37	4.07e-15	Platelet count;
LUAD	cis	rs698833	0.892	rs1067363	chr2:44658401	G/T	cg04920474	chr2:44395004	PPM1B	0.38	6.92	0.32	1.65e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs6684514	1.000	rs12563631	chr1:156258953	T/C	cg16558208	chr1:156270281	VHLL	0.52	9.47	0.42	1.95e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg03733263	chr8:22462867	KIAA1967	0.65	10.98	0.47	7.88e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg20283391	chr11:68216788	NA	-0.42	-6.81	-0.31	3.41e-11	Total body bone mineral density;
LUAD	cis	rs7043114	0.525	rs10761161	chr9:95262342	C/G	cg14631576	chr9:95140430	CENPP	-0.43	-8.7	-0.39	7.62e-17	Height;
LUAD	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg04155289	chr7:94953770	PON1	-0.51	-6.81	-0.31	3.32e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg14530993	chr4:882597	GAK	0.7	6.72	0.31	5.97e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs747650	0.961	rs7945315	chr11:47110652	A/C	cg19486271	chr11:47235900	DDB2	-0.45	-7.19	-0.33	3.05e-12	Acne (severe);
LUAD	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg08601574	chr20:25228251	PYGB	0.47	8.89	0.4	1.77e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg07677032	chr17:61819896	STRADA	0.58	10.68	0.46	1e-23	Prudent dietary pattern;
LUAD	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg20203395	chr5:56204925	C5orf35	0.64	9.83	0.43	1.14e-20	Initial pursuit acceleration;
LUAD	trans	rs6446298	0.738	rs6446296	chr3:49838052	G/A	cg21659725	chr3:3221576	CRBN	0.48	6.38	0.3	4.53e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs58804349	0.605	rs72779330	chr10:43522315	C/G	cg08461752	chr10:43522343	NA	-0.85	-9.0	-0.4	7.86e-18	Pediatric bone mineral content (radius);
LUAD	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg17633681	chr16:88106987	BANP	0.39	6.68	0.31	7.41e-11	Menopause (age at onset);
LUAD	cis	rs910187	0.678	rs6018329	chr20:45813184	A/G	cg27589058	chr20:45804311	EYA2	-0.31	-6.93	-0.32	1.54e-11	Migraine;
LUAD	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg04414720	chr1:150670196	GOLPH3L	0.65	11.24	0.48	7.93e-26	Melanoma;
LUAD	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg10057126	chr4:77819792	ANKRD56	0.55	9.62	0.42	6.09e-20	Emphysema distribution in smoking;
LUAD	cis	rs427941	0.703	rs1637257	chr7:101740606	T/G	cg06246474	chr7:101738831	CUX1	0.42	7.32	0.34	1.25e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs800082	1.000	rs62275526	chr3:144291707	G/A	cg24215973	chr2:240111563	HDAC4	-0.41	-6.42	-0.3	3.67e-10	Smoking behavior;
LUAD	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg13385794	chr1:248469461	NA	0.26	7.08	0.33	5.93e-12	Common traits (Other);
LUAD	cis	rs35146811	0.555	rs2525539	chr7:99545309	A/G	cg13334819	chr7:99746414	C7orf59	0.55	8.2	0.37	2.88e-15	Coronary artery disease;
LUAD	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg14343924	chr8:8086146	FLJ10661	0.46	7.32	0.34	1.28e-12	Mood instability;
LUAD	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg05340658	chr4:99064831	C4orf37	0.54	9.23	0.41	1.32e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs875971	0.545	rs313828	chr7:65552614	T/C	cg04775059	chr7:64541387	NA	-0.52	-6.79	-0.31	3.79e-11	Aortic root size;
LUAD	cis	rs16866061	0.926	rs1523919	chr2:225403615	G/A	cg12698349	chr2:225449008	CUL3	0.76	12.95	0.53	1.6e-32	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs11229555	0.645	rs7945992	chr11:58187755	T/A	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg24818145	chr4:99064322	C4orf37	0.45	7.11	0.33	4.85e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25427524	chr10:38739819	LOC399744	-0.74	-13.61	-0.55	3.15e-35	Extrinsic epigenetic age acceleration;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00207389	chr20:18569003	DTD1	-0.42	-6.4	-0.3	4.22e-10	Height;
LUAD	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg12623918	chr2:306882	NA	0.35	6.97	0.32	1.25e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.99	-0.4	8.35e-18	Total body bone mineral density;
LUAD	cis	rs6546550	0.900	rs897122	chr2:70140271	C/T	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.97	-0.47	8.24e-25	Prevalent atrial fibrillation;
LUAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00166722	chr3:10149974	C3orf24	0.74	12.68	0.52	1.89e-31	Alzheimer's disease;
LUAD	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg13870426	chr17:30244630	NA	-0.57	-6.48	-0.3	2.56e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs8099014	0.954	rs28497563	chr18:56134147	C/A	cg12907477	chr18:56117327	MIR122	0.38	6.39	0.3	4.34e-10	Platelet count;
LUAD	cis	rs7193541	0.684	rs9929496	chr16:74668473	G/A	cg01733217	chr16:74700730	RFWD3	0.69	13.58	0.55	4.21e-35	Multiple myeloma;
LUAD	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.17	0.37	3.53e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06873352	chr17:61820015	STRADA	0.82	18.12	0.66	1e-54	Prudent dietary pattern;
LUAD	cis	rs62238980	0.614	rs78818509	chr22:32447582	A/G	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs6754311	0.517	rs60453613	chr2:136527120	G/C	cg07169764	chr2:136633963	MCM6	0.64	8.1	0.37	5.87e-15	Mosquito bite size;
LUAD	trans	rs11088226	0.581	rs2236430	chr21:33973408	A/G	cg09050820	chr6:167586206	TCP10L2	-0.62	-10.35	-0.45	1.6e-22	Gastritis;
LUAD	cis	rs3815700	0.841	rs10410895	chr19:33093655	T/G	cg02997394	chr19:33096574	ANKRD27	0.66	8.7	0.39	7.31e-17	Eosinophilic esophagitis;
LUAD	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg22963979	chr7:1858916	MAD1L1	-0.49	-8.25	-0.37	2e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs11088226	0.681	rs2833903	chr21:33940819	C/T	cg09050820	chr6:167586206	TCP10L2	0.91	12.5	0.52	9.46e-31	Gastritis;
LUAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00149659	chr3:10157352	C3orf10	0.58	7.98	0.36	1.44e-14	Alzheimer's disease;
LUAD	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg15448220	chr1:150897856	SETDB1	-0.45	-7.57	-0.35	2.41e-13	Tonsillectomy;
LUAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg13047869	chr3:10149882	C3orf24	0.66	11.43	0.49	1.54e-26	Alzheimer's disease;
LUAD	cis	rs2734839	0.964	rs12808482	chr11:113294998	T/A	cg14159747	chr11:113255604	NA	0.53	10.34	0.45	1.7e-22	Information processing speed;
LUAD	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg02951883	chr7:2050386	MAD1L1	-0.73	-12.52	-0.52	8.46e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs9326248	0.539	rs10892058	chr11:116876621	C/T	cg20608306	chr11:116969690	SIK3	0.29	6.57	0.3	1.48e-10	Blood protein levels;
LUAD	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg14396892	chr9:96623032	NA	-0.45	-8.76	-0.39	4.76e-17	DNA methylation (variation);
LUAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg11062466	chr8:58055876	NA	0.67	9.02	0.4	6.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6733011	0.578	rs1878585	chr2:99501698	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.76	-0.31	4.68e-11	Bipolar disorder;
LUAD	cis	rs17401966	0.838	rs946501	chr1:10309580	C/G	cg15208524	chr1:10270712	KIF1B	0.43	6.74	0.31	5.18e-11	Hepatocellular carcinoma;
LUAD	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg00316803	chr15:76480434	C15orf27	-0.37	-7.28	-0.33	1.69e-12	Blood metabolite levels;
LUAD	trans	rs1941687	0.797	rs8096533	chr18:31383889	A/C	cg27147174	chr7:100797783	AP1S1	-0.53	-8.97	-0.4	9.76e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs3106136	0.967	rs2171381	chr4:95224768	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.25	-0.33	1.99e-12	Capecitabine sensitivity;
LUAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg21782813	chr7:2030301	MAD1L1	0.41	6.76	0.31	4.6e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs17092148	0.945	rs6058115	chr20:33358397	T/G	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.19	-0.37	3.09e-15	Neuroticism;
LUAD	cis	rs9811920	0.695	rs1287284	chr3:99516962	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.54	-9.97	-0.44	3.47e-21	Axial length;
LUAD	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg17105886	chr17:28927953	LRRC37B2	0.84	7.75	0.35	6.72e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2485376	0.842	rs11597439	chr10:104184953	C/G	cg20641465	chr10:103991465	PITX3	-0.53	-9.21	-0.41	1.51e-18	QT interval;
LUAD	cis	rs6076065	0.676	rs6076057	chr20:23335982	G/T	cg11657817	chr20:23433608	CST11	-0.49	-9.18	-0.41	1.86e-18	Facial morphology (factor 15, philtrum width);
LUAD	trans	rs11227306	0.812	rs11227310	chr11:65584733	A/T	cg17712092	chr4:129076599	LARP1B	0.66	10.26	0.45	3.43e-22	DNA methylation (variation);
LUAD	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg06784218	chr1:46089804	CCDC17	-0.53	-11.48	-0.49	9.64e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08704250	chr15:31115839	NA	-0.56	-10.35	-0.45	1.6e-22	Huntington's disease progression;
LUAD	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg09658497	chr7:2847517	GNA12	-0.56	-9.51	-0.42	1.47e-19	Height;
LUAD	cis	rs250677	0.522	rs919731	chr5:148352150	T/C	cg18129178	chr5:148520854	ABLIM3	0.53	8.19	0.37	3.01e-15	Breast cancer;
LUAD	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.82	-0.36	4.31e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7640424	0.835	rs1561029	chr3:107822245	A/C	cg09227934	chr3:107805635	CD47	0.37	6.97	0.32	1.24e-11	Body mass index;
LUAD	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg20119798	chr7:94954144	PON1	-0.47	-6.42	-0.3	3.76e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg19336497	chr11:14380999	RRAS2	-0.6	-13.06	-0.54	5.64e-33	Sense of smell;
LUAD	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg07138768	chr7:917805	C7orf20	0.41	8.16	0.37	3.92e-15	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs8112211	0.682	rs11671779	chr19:38833350	C/T	cg01275006	chr19:38876250	GGN	-0.51	-6.6	-0.31	1.24e-10	Blood protein levels;
LUAD	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg15704280	chr7:45808275	SEPT13	0.89	14.65	0.58	1.29e-39	Height;
LUAD	cis	rs1030877	0.521	rs2576747	chr2:105978676	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.41	7.5	0.34	3.72e-13	Obesity-related traits;
LUAD	trans	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.2	-0.33	2.83e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg22906224	chr7:99728672	NA	-0.62	-10.86	-0.47	2.08e-24	Coronary artery disease;
LUAD	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.59	10.01	0.44	2.57e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs4700695	0.841	rs251305	chr5:65249859	C/T	cg21114390	chr5:65439923	SFRS12	0.63	8.17	0.37	3.52e-15	Facial morphology (factor 19);
LUAD	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.35	-18.54	-0.67	1.33e-56	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg03929089	chr4:120376271	NA	-0.85	-14.92	-0.59	9.47e-41	Height;
LUAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.8	-0.31	3.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg18005901	chr6:33739558	LEMD2	-0.59	-9.34	-0.41	5.57e-19	Schizophrenia;
LUAD	trans	rs7781370	1.000	rs7781370	chr7:96133531	A/G	cg22015966	chr11:47198573	ARFGAP2	-0.39	-6.48	-0.3	2.61e-10	Bone mineral density (hip);
LUAD	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-7.58	-0.35	2.14e-13	Personality dimensions;
LUAD	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg25237894	chr2:233734115	C2orf82	0.61	11.7	0.49	1.32e-27	Coronary artery disease;
LUAD	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.43	7.85	0.36	3.45e-14	Type 2 diabetes;
LUAD	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg19318889	chr4:1322082	MAEA	0.46	7.38	0.34	8.46e-13	Obesity-related traits;
LUAD	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg20701182	chr2:24300061	SF3B14	0.89	13.3	0.54	5.76e-34	Lymphocyte counts;
LUAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06873352	chr17:61820015	STRADA	0.81	18.04	0.66	2.33e-54	Prudent dietary pattern;
LUAD	trans	rs629535	0.862	rs655028	chr8:70049047	T/C	cg21567404	chr3:27674614	NA	1.01	18.57	0.67	9.52e-57	Dupuytren's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20081767	chr19:53193466	ZNF83	-0.45	-6.95	-0.32	1.41e-11	Height;
LUAD	cis	rs12612619	0.732	rs920433	chr2:27212526	A/C	cg00617064	chr2:27272375	NA	-0.35	-6.73	-0.31	5.54e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs11734570	0.581	rs79354477	chr4:38597448	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.45	6.39	0.3	4.32e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg23283495	chr1:209979779	IRF6	0.71	9.36	0.41	4.74e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg06641503	chr3:48959341	ARIH2	-0.37	-7.33	-0.34	1.18e-12	Parkinson's disease;
LUAD	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg24578937	chr1:2090814	PRKCZ	0.59	12.28	0.51	7.52e-30	Height;
LUAD	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg23173402	chr1:227635558	NA	0.91	8.57	0.38	1.95e-16	Major depressive disorder;
LUAD	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg22823121	chr1:150693482	HORMAD1	-0.4	-7.86	-0.36	3.25e-14	Tonsillectomy;
LUAD	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg01145583	chr6:160211477	TCP1;MRPL18	-0.45	-6.51	-0.3	2.08e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	trans	rs208520	0.874	rs208491	chr6:66928459	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-14.06	-0.56	4.08e-37	Exhaled nitric oxide output;
LUAD	trans	rs637571	0.528	rs566266	chr11:65573587	A/C	cg17712092	chr4:129076599	LARP1B	-0.65	-10.15	-0.44	8.61e-22	Eosinophil percentage of white cells;
LUAD	cis	rs1729407	0.649	rs2849176	chr11:116696921	C/T	cg08985259	chr11:116699649	APOC3	0.32	6.55	0.3	1.65e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg04398451	chr17:18023971	MYO15A	-0.77	-14.1	-0.57	2.74e-37	Total body bone mineral density;
LUAD	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg23950597	chr19:37808831	NA	-0.59	-7.25	-0.33	2.01e-12	Coronary artery calcification;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18382590	chr9:131219195	ODF2	-0.49	-7.65	-0.35	1.35e-13	Height;
LUAD	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg13770153	chr20:60521292	NA	-0.65	-10.06	-0.44	1.74e-21	Body mass index;
LUAD	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg22920501	chr2:26401640	FAM59B	0.96	13.88	0.56	2.24e-36	Gut microbiome composition (summer);
LUAD	cis	rs733592	0.507	rs10875739	chr12:48480919	C/T	cg24011408	chr12:48396354	COL2A1	0.39	8.68	0.39	8.77e-17	Plateletcrit;
LUAD	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg06547715	chr2:218990976	CXCR2	0.28	6.55	0.3	1.72e-10	Colorectal cancer;
LUAD	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.76	0.31	4.64e-11	Depression;
LUAD	cis	rs62064224	0.554	rs9901737	chr17:30681354	C/G	cg25809561	chr17:30822961	MYO1D	0.48	8.91	0.4	1.5e-17	Schizophrenia;
LUAD	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18099408	chr3:52552593	STAB1	-0.49	-8.55	-0.38	2.27e-16	Bipolar disorder;
LUAD	cis	rs1997103	0.911	rs10238738	chr7:55412359	T/C	cg17469321	chr7:55412551	NA	0.66	11.31	0.48	4.49e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04067506	chr5:176943966	DDX41	-0.58	-7.07	-0.33	6.43e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg23254163	chr1:152506842	NA	0.25	7.05	0.32	7.24e-12	Hair morphology;
LUAD	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg26513180	chr16:89883248	FANCA	0.76	6.92	0.32	1.64e-11	Skin colour saturation;
LUAD	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.42	0.38	5.75e-16	Platelet count;
LUAD	trans	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.29	0.45	2.62e-22	Mean corpuscular volume;
LUAD	cis	rs1395	0.778	rs62128747	chr2:27412605	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.51	8.9	0.4	1.64e-17	Blood metabolite levels;
LUAD	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg06618935	chr21:46677482	NA	0.48	9.83	0.43	1.15e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1595825	0.891	rs16824264	chr2:198675917	T/C	cg10547527	chr2:198650123	BOLL	-0.54	-7.5	-0.34	3.86e-13	Ulcerative colitis;
LUAD	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11644478	chr21:40555479	PSMG1	0.7	11.85	0.5	3.72e-28	Cognitive function;
LUAD	cis	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.3	-0.33	1.46e-12	Resting heart rate;
LUAD	cis	rs2932538	0.922	rs6673930	chr1:113104887	A/G	cg22162597	chr1:113214053	CAPZA1	0.46	6.99	0.32	1.09e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs704	0.585	rs3093680	chr17:26664806	T/C	cg10342447	chr17:26645325	TMEM97	-0.4	-7.98	-0.36	1.4e-14	Osteoprotegerin levels;
LUAD	trans	rs1459104	0.759	rs7939392	chr11:55257285	C/T	cg15704280	chr7:45808275	SEPT13	0.62	7.3	0.33	1.45e-12	Body mass index;
LUAD	cis	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.63	7.7	0.35	9.62e-14	Schizophrenia;
LUAD	cis	rs8099014	1.000	rs8096440	chr18:56127985	T/A	cg12907477	chr18:56117327	MIR122	0.38	6.45	0.3	3.15e-10	Platelet count;
LUAD	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg25767906	chr1:53392781	SCP2	0.38	6.86	0.32	2.39e-11	Monocyte count;
LUAD	trans	rs7395662	0.895	rs3903506	chr11:48718513	G/A	cg00717180	chr2:96193071	NA	0.39	7.23	0.33	2.27e-12	HDL cholesterol;
LUAD	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg10591111	chr5:226296	SDHA	-0.55	-7.18	-0.33	3.21e-12	Breast cancer;
LUAD	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.21	0.37	2.79e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg11062466	chr8:58055876	NA	0.45	6.47	0.3	2.66e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs11048434	0.736	rs12823100	chr12:9108908	C/A	cg13575925	chr12:9217583	LOC144571	0.36	6.83	0.32	2.92e-11	Sjögren's syndrome;
LUAD	cis	rs4642101	0.669	rs1467026	chr3:12830775	G/A	cg24848339	chr3:12840334	CAND2	0.43	8.69	0.39	7.86e-17	QRS complex (12-leadsum);
LUAD	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg00631329	chr6:26305371	NA	-0.58	-10.24	-0.45	4.08e-22	Mosquito bite size;
LUAD	cis	rs3931020	0.566	rs1409782	chr1:75272935	T/A	cg00121533	chr1:75199117	CRYZ;TYW3	0.46	7.38	0.34	8.27e-13	Resistin levels;
LUAD	cis	rs644148	0.836	rs2571111	chr19:45000581	C/A	cg15540054	chr19:45004280	ZNF180	-0.4	-6.43	-0.3	3.51e-10	Personality dimensions;
LUAD	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg09455208	chr3:40491958	NA	0.53	11.53	0.49	6.43e-27	Renal cell carcinoma;
LUAD	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg24558204	chr6:135376177	HBS1L	0.46	8.56	0.38	2.1e-16	Red blood cell count;
LUAD	cis	rs9837602	0.872	rs4928234	chr3:99704861	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.63	-9.02	-0.4	6.64e-18	Breast cancer;
LUAD	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg09826364	chr7:158789723	NA	0.36	6.51	0.3	2.07e-10	Facial morphology (factor 20);
LUAD	cis	rs677665	0.537	rs72641831	chr1:9335173	G/T	cg25755851	chr1:9335794	NA	0.8	13.88	0.56	2.29e-36	Eosinophil percentage of white cells;
LUAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg24503407	chr1:205819492	PM20D1	0.6	11.07	0.47	3.42e-25	Menarche (age at onset);
LUAD	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg12310025	chr6:25882481	NA	0.59	9.81	0.43	1.35e-20	Blood metabolite levels;
LUAD	cis	rs863345	0.625	rs11264978	chr1:158447921	T/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.36	-0.3	5.33e-10	Pneumococcal bacteremia;
LUAD	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg03948781	chr1:205179583	DSTYK	0.35	6.6	0.31	1.26e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs9287719	0.601	rs9287718	chr2:10701629	A/T	cg02196655	chr2:10830764	NOL10	0.38	6.58	0.3	1.37e-10	Prostate cancer;
LUAD	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-8.55	-0.38	2.22e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs11771526	0.901	rs11764193	chr7:32272200	C/T	cg27532318	chr7:32358331	NA	0.52	7.08	0.33	6.1e-12	Body mass index;
LUAD	cis	rs1595825	0.891	rs75946628	chr2:198546239	C/T	cg10547527	chr2:198650123	BOLL	-0.53	-7.26	-0.33	1.86e-12	Ulcerative colitis;
LUAD	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg09904177	chr6:26538194	HMGN4	0.41	6.84	0.32	2.73e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7100689	0.754	rs1934695	chr10:82125230	T/C	cg01528321	chr10:82214614	TSPAN14	0.67	10.21	0.44	5.03e-22	Post bronchodilator FEV1;
LUAD	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.61	-0.55	2.96e-35	Alcohol dependence;
LUAD	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.9	-0.32	1.9e-11	Height;
LUAD	cis	rs1113500	0.548	rs11185271	chr1:108659933	A/G	cg06207961	chr1:108661230	NA	0.41	6.41	0.3	3.9e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg18306943	chr3:40428807	ENTPD3	-0.38	-6.53	-0.3	1.92e-10	Renal cell carcinoma;
LUAD	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22857025	chr5:266934	NA	-1.04	-13.43	-0.55	1.64e-34	Breast cancer;
LUAD	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.94	-0.4	1.26e-17	Total body bone mineral density;
LUAD	cis	rs472402	0.580	rs3736316	chr5:6656210	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.41	-6.37	-0.3	4.93e-10	Response to amphetamines;
LUAD	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg23840854	chr1:161414152	NA	0.85	11.18	0.48	1.32e-25	Rheumatoid arthritis;
LUAD	cis	rs7192380	0.737	rs11641722	chr16:69580402	C/T	cg26679644	chr16:69762563	NA	0.38	6.97	0.32	1.2e-11	Sjögren's syndrome;
LUAD	cis	rs12681287	0.577	rs13257414	chr8:87494138	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-10.15	-0.44	8.15e-22	Caudate activity during reward;
LUAD	cis	rs4722404	0.592	rs6461820	chr7:3118246	T/C	cg19214707	chr7:3157722	NA	-0.43	-7.06	-0.32	6.98e-12	Atopic dermatitis;
LUAD	cis	rs10733682	0.659	rs13292976	chr9:129467340	C/T	cg00232160	chr9:129468157	NA	0.52	9.39	0.42	3.89e-19	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7216064	0.953	rs62086044	chr17:65970837	G/T	cg08758996	chr17:66097529	LOC651250	0.42	6.62	0.31	1.12e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg11941060	chr3:133502564	NA	-0.64	-11.46	-0.49	1.2e-26	Iron status biomarkers;
LUAD	cis	rs11118844	0.843	rs4601596	chr1:221914458	C/T	cg04222084	chr1:221915650	DUSP10	-0.79	-8.49	-0.38	3.5e-16	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg14983838	chr19:29218262	NA	0.68	10.46	0.45	6.21e-23	Methadone dose in opioid dependence;
LUAD	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg13319975	chr6:146136371	FBXO30	0.64	10.95	0.47	1.01e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs757647	0.723	rs57618921	chr5:137736480	T/C	cg10676309	chr5:137685565	NA	0.42	7.52	0.34	3.22e-13	Menarche (age at onset);
LUAD	cis	rs6901250	0.851	rs339324	chr6:117195024	C/T	cg12892004	chr6:117198278	RFX6	-0.32	-6.86	-0.32	2.44e-11	C-reactive protein levels;
LUAD	cis	rs59104589	0.517	rs62186360	chr2:242166212	C/T	cg08645257	chr2:242211290	HDLBP	0.47	7.17	0.33	3.34e-12	Fibrinogen levels;
LUAD	cis	rs7737355	0.947	rs4996522	chr5:130761470	G/A	cg06307176	chr5:131281290	NA	-0.5	-7.67	-0.35	1.17e-13	Life satisfaction;
LUAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg18621852	chr3:10150065	C3orf24	0.51	9.11	0.4	3.39e-18	Alzheimer's disease;
LUAD	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	7.53	0.34	3.13e-13	Menarche (age at onset);
LUAD	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg14634687	chr17:47094252	IGF2BP1	0.27	6.75	0.31	4.99e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg00745463	chr17:30367425	LRRC37B	-0.89	-9.5	-0.42	1.6e-19	Hip circumference adjusted for BMI;
LUAD	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg00121533	chr1:75199117	CRYZ;TYW3	0.45	7.56	0.35	2.5e-13	Resistin levels;
LUAD	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.87	-0.32	2.25e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg07570687	chr10:102243282	WNT8B	0.44	6.36	0.3	5.16e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27297192	chr10:134578999	INPP5A	0.39	6.87	0.32	2.3e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2404618	0.593	rs7829532	chr8:1485190	C/A	cg13402656	chr8:1511478	DLGAP2	-0.71	-14.44	-0.57	9.96e-39	Lung cancer;
LUAD	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg20503657	chr10:835505	NA	0.93	13.95	0.56	1.14e-36	Eosinophil percentage of granulocytes;
LUAD	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg24818145	chr4:99064322	C4orf37	0.43	7.07	0.33	6.24e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg25036284	chr2:26402008	FAM59B	0.83	11.61	0.49	3.1e-27	Gut microbiome composition (summer);
LUAD	cis	rs11048434	0.761	rs10842662	chr12:9139344	G/A	cg13575925	chr12:9217583	LOC144571	0.39	7.28	0.33	1.69e-12	Sjögren's syndrome;
LUAD	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg26022315	chr17:47021804	SNF8	0.41	7.43	0.34	6.13e-13	Type 2 diabetes;
LUAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	trans	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg14917512	chr19:3094685	GNA11	0.57	6.81	0.31	3.47e-11	Diabetic kidney disease;
LUAD	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg06641503	chr3:48959341	ARIH2	-0.41	-8.11	-0.37	5.7e-15	Parkinson's disease;
LUAD	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg24558204	chr6:135376177	HBS1L	-0.46	-8.53	-0.38	2.65e-16	Red blood cell count;
LUAD	cis	rs3789045	0.774	rs4252733	chr1:204516918	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.44	-7.24	-0.33	2.2e-12	Educational attainment (college completion);
LUAD	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg03037974	chr15:76606532	NA	-0.33	-6.95	-0.32	1.37e-11	Blood metabolite levels;
LUAD	cis	rs2902440	0.502	rs4655527	chr1:67664491	G/A	cg03340356	chr1:67600835	NA	0.37	6.67	0.31	8.27e-11	Crohn's disease;
LUAD	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg01802117	chr1:53393560	SCP2	-0.34	-6.68	-0.31	7.65e-11	Monocyte count;
LUAD	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.18	-0.41	1.87e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg16512390	chr1:228756714	NA	0.5	8.22	0.37	2.55e-15	Chronic lymphocytic leukemia;
LUAD	trans	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg07393940	chr7:158741817	NA	-0.68	-11.63	-0.49	2.6e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15229027	chr14:64805542	ESR2	0.42	6.59	0.31	1.3100000000000001e-10	Gut microbiome composition (summer);
LUAD	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg07741184	chr6:167504864	NA	0.3	7.26	0.33	1.9e-12	Crohn's disease;
LUAD	cis	rs7731657	0.537	rs72801793	chr5:130376936	A/T	cg08523029	chr5:130500466	HINT1	-0.59	-7.43	-0.34	6e-13	Fasting plasma glucose;
LUAD	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg15790184	chr11:494944	RNH1	0.56	6.79	0.31	3.73e-11	Body mass index;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23694959	chr6:26597126	ABT1	-0.41	-6.82	-0.31	3.2e-11	Cancer;
LUAD	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.76	0.31	4.48e-11	Platelet count;
LUAD	cis	rs986417	0.892	rs11628559	chr14:61038153	G/C	cg27398547	chr14:60952738	C14orf39	0.68	7.96	0.36	1.62e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg25809561	chr17:30822961	MYO1D	0.71	14.54	0.58	3.83e-39	Schizophrenia;
LUAD	trans	rs877282	1.000	rs71491304	chr10:772982	C/T	cg22713356	chr15:30763199	NA	1.17	16.73	0.63	1.35e-48	Uric acid levels;
LUAD	cis	rs116248771	0.690	rs73156439	chr3:158359462	G/C	cg16708174	chr3:158430962	RARRES1	0.46	6.8	0.31	3.58e-11	diarrhoeal disease at age 2;
LUAD	cis	rs62458065	0.513	rs10245103	chr7:32534829	T/G	cg20159608	chr7:32802032	NA	-0.57	-8.62	-0.39	1.38e-16	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg22105103	chr4:187893119	NA	-0.52	-11.35	-0.48	2.91e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.68	-0.35	1.15e-13	Fear of minor pain;
LUAD	cis	rs2806561	1.000	rs1757048	chr1:23510601	A/C	cg12483005	chr1:23474871	LUZP1	0.39	6.79	0.31	3.89e-11	Height;
LUAD	trans	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg19894588	chr14:64061835	NA	0.49	7.69	0.35	1.07e-13	Glioblastoma;Glioma;
LUAD	cis	rs3125734	0.633	rs4979774	chr10:63967795	A/T	cg09941381	chr10:64027924	RTKN2	-0.3	-7.02	-0.32	9.15e-12	Rheumatoid arthritis;
LUAD	cis	rs9399401	0.626	rs3817928	chr6:142750516	A/G	cg04461802	chr6:142623433	GPR126	0.4	7.51	0.34	3.5e-13	Chronic obstructive pulmonary disease;
LUAD	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg25985355	chr7:65971099	NA	-0.51	-6.36	-0.3	5.25e-10	Diabetic kidney disease;
LUAD	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg13010199	chr12:38710504	ALG10B	0.41	6.74	0.31	5.07e-11	Bladder cancer;
LUAD	cis	rs4523957	0.890	rs2281727	chr17:2117945	A/G	cg16513277	chr17:2031491	SMG6	-0.82	-15.56	-0.6	1.74e-43	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg21483475	chr3:154042025	DHX36	-0.42	-7.1	-0.33	5.38e-12	Subcortical brain region volumes;
LUAD	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg11822812	chr5:140052017	DND1	-0.44	-7.9	-0.36	2.47e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02353165	chr6:42928485	GNMT	0.46	8.39	0.38	7.37e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg04282206	chr17:62833786	PLEKHM1P	0.61	9.09	0.4	3.8e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7677751	0.806	rs73252942	chr4:55104604	T/C	cg17187183	chr4:55093834	PDGFRA	0.5	8.52	0.38	2.92e-16	Corneal astigmatism;
LUAD	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg25036284	chr2:26402008	FAM59B	-0.68	-9.24	-0.41	1.26e-18	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.35e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg19875535	chr5:140030758	IK	-0.48	-8.08	-0.37	6.91e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg01256987	chr12:42539512	GXYLT1	-0.36	-7.16	-0.33	3.69e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg09137382	chr11:130731461	NA	0.4	7.43	0.34	6.19e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.2	-30.96	-0.83	8.65e-111	Exhaled nitric oxide output;
LUAD	cis	rs3789045	0.913	rs55678522	chr1:204573481	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.39	-6.61	-0.31	1.13e-10	Educational attainment (college completion);
LUAD	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg23649088	chr2:200775458	C2orf69	0.52	8.32	0.38	1.21e-15	Osteoporosis;
LUAD	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg22823121	chr1:150693482	HORMAD1	0.46	8.76	0.39	4.91e-17	Melanoma;
LUAD	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg14552801	chr7:65878734	NA	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	trans	rs853679	1.000	rs1679709	chr6:28228342	A/G	cg06606381	chr12:133084897	FBRSL1	0.55	6.86	0.32	2.47e-11	Depression;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg15199754	chr20:37064006	LOC388796;SNORA71D	0.42	6.68	0.31	7.41e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg10729496	chr3:10149963	C3orf24	0.47	6.78	0.31	4.02e-11	Alzheimer's disease;
LUAD	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg07870213	chr5:140052090	DND1	-0.83	-11.37	-0.48	2.43e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs11828289	0.660	rs79043125	chr11:23203646	T/A	cg20040320	chr11:23191996	NA	-0.68	-7.78	-0.35	5.76e-14	Cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg24623068	chr5:154317667	GEMIN5	-0.39	-6.65	-0.31	9.24e-11	Schizophrenia;
LUAD	cis	rs4243830	1.000	rs11811007	chr1:6584657	T/C	cg05709478	chr1:6581295	PLEKHG5	0.59	6.86	0.32	2.52e-11	Body mass index;
LUAD	cis	rs7827545	0.620	rs6578009	chr8:135522989	T/C	cg17885191	chr8:135476712	NA	-0.59	-9.43	-0.42	2.66e-19	Hypertension (SNP x SNP interaction);
LUAD	cis	rs12541635	0.934	rs60482457	chr8:106970504	A/G	cg10147462	chr8:107024639	NA	0.49	8.76	0.39	4.9e-17	Age of smoking initiation;
LUAD	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg09467607	chr2:36825704	FEZ2	0.6	11.79	0.5	6.25e-28	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06819775	chr12:69004359	RAP1B	-0.56	-6.74	-0.31	5.2e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg24163568	chr5:669837	TPPP	0.36	6.8	0.31	3.58e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14240646	chr10:27532245	ACBD5	0.92	12.09	0.51	4.17e-29	Breast cancer;
LUAD	trans	rs8002861	0.846	rs12428112	chr13:44475821	C/A	cg17145862	chr1:211918768	LPGAT1	-0.67	-14.23	-0.57	7.74e-38	Leprosy;
LUAD	cis	rs1003719	0.688	rs2835662	chr21:38568967	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.2	-0.37	2.89e-15	Eye color traits;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg16920189	chr15:100105709	MEF2A	-0.7	-6.65	-0.31	9.33e-11	Type 2 diabetes;
LUAD	trans	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.42	-0.38	5.7e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs977987	0.933	rs1834014	chr16:75501274	G/A	cg03315344	chr16:75512273	CHST6	0.66	14.49	0.58	6.17e-39	Dupuytren's disease;
LUAD	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg07936489	chr17:37558343	FBXL20	0.44	6.94	0.32	1.46e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg01391022	chr12:122360665	WDR66	0.39	6.46	0.3	2.91e-10	Mean corpuscular volume;
LUAD	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg26384229	chr12:38710491	ALG10B	0.49	7.88	0.36	2.71e-14	Bladder cancer;
LUAD	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.15	0.37	4.06e-15	Menopause (age at onset);
LUAD	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg23262073	chr20:60523788	NA	-0.45	-7.15	-0.33	3.73e-12	Body mass index;
LUAD	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg02551604	chr5:131831745	NA	-0.61	-10.02	-0.44	2.39e-21	Asthma (sex interaction);
LUAD	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg26924012	chr15:45694286	SPATA5L1	0.98	17.86	0.66	1.4e-53	Homoarginine levels;
LUAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg11062466	chr8:58055876	NA	0.66	8.64	0.39	1.15e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg07936489	chr17:37558343	FBXL20	0.41	6.44	0.3	3.31e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg05991184	chr2:219186017	PNKD	0.37	7.0	0.32	9.96e-12	Colorectal cancer;
LUAD	cis	rs4700695	0.925	rs4700090	chr5:65412434	C/T	cg21114390	chr5:65439923	SFRS12	-0.55	-6.39	-0.3	4.49e-10	Facial morphology (factor 19);
LUAD	cis	rs1232027	0.616	rs6151620	chr5:79961742	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.96	-0.32	1.31e-11	Huntington's disease progression;
LUAD	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg00278107	chr5:1061253	SLC12A7	-0.56	-10.03	-0.44	2.25e-21	QT interval;
LUAD	cis	rs4846217	0.920	rs4846204	chr1:10308958	C/T	cg17425144	chr1:10567563	PEX14	-0.57	-7.31	-0.34	1.31e-12	Platelet count;
LUAD	cis	rs79349575	0.756	rs3848460	chr17:47047114	A/G	cg22482690	chr17:47019901	SNF8	-0.41	-8.09	-0.37	6.38e-15	Type 2 diabetes;
LUAD	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.91	-0.36	2.24e-14	Monocyte percentage of white cells;
LUAD	cis	rs16910800	0.689	rs4491218	chr11:23163977	G/A	cg20040320	chr11:23191996	NA	-0.63	-7.82	-0.36	4.29e-14	Cancer;
LUAD	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg10523679	chr1:76189770	ACADM	0.92	18.22	0.66	3.43e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05508062	chr3:62110348	ID2B;PTPRG	-0.4	-6.36	-0.3	5.31e-10	Cancer;
LUAD	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.56	-9.45	-0.42	2.41e-19	Glomerular filtration rate;
LUAD	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-8.03	-0.36	9.57e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg17330251	chr7:94953956	PON1	-0.53	-7.32	-0.34	1.26e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1965732	0.588	rs4849976	chr2:3717567	A/C	cg00999904	chr2:3704751	ALLC	-0.38	-7.48	-0.34	4.36e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg05283184	chr6:79620031	NA	-0.59	-11.74	-0.5	9.57e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg18854424	chr1:2615690	NA	0.41	9.08	0.4	4.03e-18	Ulcerative colitis;
LUAD	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26314531	chr2:26401878	FAM59B	-0.62	-8.84	-0.4	2.53e-17	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs897984	0.609	rs17839567	chr16:31057945	A/G	cg02466173	chr16:30829666	NA	-0.55	-9.58	-0.42	8.36e-20	Dementia with Lewy bodies;
LUAD	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.6	-0.42	7.19e-20	Life satisfaction;
LUAD	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.41	-0.34	7.13e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.45	-0.34	5.31e-13	Breast cancer;
LUAD	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg00071950	chr4:10020882	SLC2A9	0.85	18.61	0.67	6.84e-57	Bone mineral density;
LUAD	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg16205897	chr5:131564050	P4HA2	-0.35	-8.37	-0.38	8.44e-16	Blood metabolite levels;
LUAD	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.73	-14.18	-0.57	1.31e-37	Lung cancer;
LUAD	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg25985355	chr7:65971099	NA	0.5	6.39	0.3	4.41e-10	Diabetic kidney disease;
LUAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg08027265	chr7:2291960	NA	0.41	7.11	0.33	4.93e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs3858526	0.527	rs10839168	chr11:6002798	A/G	cg05234568	chr11:5960015	NA	0.37	7.06	0.32	6.96e-12	DNA methylation (variation);
LUAD	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.09	-24.41	-0.76	9.49e-83	Ulcerative colitis;
LUAD	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg14416269	chr4:6271139	WFS1	0.62	13.33	0.54	4.42e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg12419862	chr22:24373484	LOC391322	-0.64	-10.79	-0.46	3.74e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg05340658	chr4:99064831	C4orf37	0.54	8.98	0.4	9.16e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18876405	chr7:65276391	NA	-0.67	-11.34	-0.48	3.18e-26	Aortic root size;
LUAD	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23583168	chr7:148888333	NA	-0.89	-17.9	-0.66	9.52e-54	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg05425664	chr17:57184151	TRIM37	-0.45	-7.96	-0.36	1.61e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg18350739	chr11:68623251	NA	-0.37	-6.37	-0.3	4.95e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs8177876	0.822	rs76948085	chr16:81112804	G/A	cg08591886	chr16:81111003	C16orf46	-0.76	-7.01	-0.32	9.76e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg09509183	chr1:209979624	IRF6	0.59	7.35	0.34	1.02e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg07917127	chr4:99064746	C4orf37	0.4	6.66	0.31	8.67e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg18806716	chr10:30721971	MAP3K8	0.54	10.32	0.45	2.09e-22	Inflammatory bowel disease;
LUAD	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg13334819	chr7:99746414	C7orf59	0.64	9.83	0.43	1.14e-20	Coronary artery disease;
LUAD	cis	rs16867335	0.625	rs7573877	chr2:181478111	A/G	cg23363182	chr2:181467187	NA	-0.42	-7.32	-0.34	1.29e-12	Survival in rectal cancer;
LUAD	trans	rs1941687	0.527	rs6507059	chr18:31303643	A/G	cg27147174	chr7:100797783	AP1S1	-0.6	-9.96	-0.44	3.77e-21	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	trans	rs7395662	0.963	rs6485865	chr11:48575989	G/T	cg00717180	chr2:96193071	NA	-0.4	-7.47	-0.34	4.76e-13	HDL cholesterol;
LUAD	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.74	13.61	0.55	2.92e-35	Axial length;
LUAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg17330251	chr7:94953956	PON1	-0.63	-11.72	-0.5	1.13e-27	Paraoxonase activity;
LUAD	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg27284194	chr4:1044797	NA	0.69	9.31	0.41	7.12e-19	Recombination rate (females);
LUAD	cis	rs11792861	0.546	rs7873569	chr9:111796753	A/T	cg05043794	chr9:111880884	C9orf5	-0.35	-6.72	-0.31	5.78e-11	Menarche (age at onset);
LUAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	cis	rs4889855	0.505	rs7501740	chr17:78610345	A/G	cg16591659	chr17:78472290	NA	-0.43	-7.56	-0.34	2.57e-13	Fractional excretion of uric acid;
LUAD	cis	rs11030122	0.687	rs10835521	chr11:4056004	A/T	cg18678763	chr11:4115507	RRM1	-0.42	-7.0	-0.32	9.93e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg25769590	chr7:158789503	NA	0.39	7.1	0.33	5.15e-12	Facial morphology (factor 20);
LUAD	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg12935359	chr14:103987150	CKB	-0.48	-7.79	-0.35	5.26e-14	Body mass index;
LUAD	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg00701064	chr4:6280414	WFS1	-0.64	-14.05	-0.56	4.4e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg23978390	chr7:1156363	C7orf50	-0.44	-6.94	-0.32	1.51e-11	Longevity;Endometriosis;
LUAD	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg20019720	chr6:154832845	CNKSR3	0.65	12.83	0.53	4.88e-32	Lipoprotein (a) levels;
LUAD	cis	rs4947962	0.618	rs73131825	chr7:55098150	G/A	cg23757825	chr7:55092271	EGFR	-0.55	-7.64	-0.35	1.47e-13	Subjective response to lithium treatment;
LUAD	cis	rs17818399	0.781	rs13024534	chr2:46859386	C/T	cg09399716	chr2:46890238	NA	-0.41	-7.79	-0.35	5.22e-14	Height;
LUAD	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg00316803	chr15:76480434	C15orf27	0.44	6.88	0.32	2.2e-11	Blood metabolite levels;
LUAD	trans	rs11088226	0.681	rs2833906	chr21:33945521	G/T	cg09050820	chr6:167586206	TCP10L2	0.92	12.77	0.53	8.17e-32	Gastritis;
LUAD	cis	rs847577	0.630	rs3801294	chr7:97822210	G/A	cg21770322	chr7:97807741	LMTK2	0.35	8.33	0.38	1.16e-15	Breast cancer;
LUAD	cis	rs829883	0.621	rs11109516	chr12:98921035	G/A	cg25150519	chr12:98850993	NA	-0.51	-8.1	-0.37	6.11e-15	Colorectal adenoma (advanced);
LUAD	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.39	7.47	0.34	4.74e-13	Depressive symptoms;
LUAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg18305652	chr10:134549665	INPP5A	0.6	11.74	0.5	9.85e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1003719	0.646	rs9985082	chr21:38501021	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.53	-8.93	-0.4	1.28e-17	Eye color traits;
LUAD	cis	rs4901869	0.966	rs431343	chr14:59345530	C/T	cg02291164	chr14:59296302	NA	0.59	14.07	0.56	3.73e-37	Panic disorder;
LUAD	cis	rs4660214	0.724	rs12117785	chr1:39628411	G/T	cg27567593	chr1:39956653	BMP8A	0.36	7.09	0.33	5.66e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.8	-0.35	5.01e-14	Prostate cancer;
LUAD	cis	rs9341808	0.754	rs10733162	chr6:81023389	G/A	cg08355045	chr6:80787529	NA	0.54	9.46	0.42	2.08e-19	Sitting height ratio;
LUAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg21724239	chr8:58056113	NA	0.45	6.55	0.3	1.72e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1950626	0.623	rs66722144	chr14:101457434	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.38	7.57	0.35	2.34e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.24	-0.41	1.21e-18	Bipolar disorder;
LUAD	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.28	-0.33	1.61e-12	Glomerular filtration rate;
LUAD	cis	rs17102423	0.755	rs11158574	chr14:65579467	T/G	cg11161011	chr14:65562177	MAX	-0.52	-8.07	-0.37	7.32e-15	Obesity-related traits;
LUAD	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg00981070	chr1:2046702	PRKCZ	0.36	6.82	0.31	3.17e-11	Height;
LUAD	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11644478	chr21:40555479	PSMG1	0.69	11.54	0.49	5.83e-27	Cognitive function;
LUAD	cis	rs7552167	0.636	rs4090311	chr1:24513768	G/A	cg01960748	chr1:24522592	NA	-0.76	-10.2	-0.44	5.33e-22	Psoriasis vulgaris;
LUAD	cis	rs727505	1.000	rs10464529	chr7:124520308	G/A	cg23710748	chr7:124431027	NA	-0.47	-9.57	-0.42	8.81e-20	Lewy body disease;
LUAD	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg18477163	chr1:228402036	OBSCN	0.42	8.23	0.37	2.41e-15	Diastolic blood pressure;
LUAD	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg23262073	chr20:60523788	NA	-0.46	-7.41	-0.34	6.72e-13	Body mass index;
LUAD	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg10164272	chr16:89456328	ANKRD11	0.41	6.51	0.3	2.2e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs11048434	0.698	rs7300767	chr12:9123477	T/G	cg26114124	chr12:9217669	LOC144571	0.36	6.54	0.3	1.76e-10	Sjögren's syndrome;
LUAD	cis	rs4900538	0.963	rs1190553	chr14:102915331	G/T	cg18135206	chr14:102964638	TECPR2	-1.06	-24.23	-0.76	5.9e-82	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22857025	chr5:266934	NA	-0.99	-13.11	-0.54	3.59e-33	Breast cancer;
LUAD	cis	rs3916	0.641	rs7964786	chr12:121132100	C/T	cg13914990	chr12:121174878	ACADS	0.36	6.94	0.32	1.45e-11	Urinary metabolites (H-NMR features);
LUAD	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg14668632	chr7:2872130	GNA12	0.73	13.32	0.54	4.55e-34	Height;
LUAD	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-8.75	-0.39	5.19e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9341808	0.718	rs9443734	chr6:80820293	C/T	cg08355045	chr6:80787529	NA	0.56	10.04	0.44	2.04e-21	Sitting height ratio;
LUAD	cis	rs7173743	0.730	rs6495340	chr15:79128396	A/G	cg15571903	chr15:79123663	NA	0.44	8.84	0.39	2.56e-17	Coronary artery disease;
LUAD	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg26384229	chr12:38710491	ALG10B	0.39	6.84	0.32	2.77e-11	Heart rate;
LUAD	cis	rs4845570	1.000	rs11586946	chr1:151769806	G/A	cg07092448	chr1:151763213	TDRKH	-0.76	-8.94	-0.4	1.23e-17	Coronary artery disease;
LUAD	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg00666640	chr1:248458726	OR2T12	0.31	7.6	0.35	1.94e-13	Common traits (Other);
LUAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	12.88	0.53	2.89e-32	Prudent dietary pattern;
LUAD	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs6752107	0.967	rs11680130	chr2:234157258	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.53	9.01	0.4	7.16e-18	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24308560	chr3:49941425	MST1R	-0.56	-9.31	-0.41	6.76e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs9372498	0.536	rs1319988	chr6:118782379	G/A	cg21191810	chr6:118973309	C6orf204	-0.48	-7.71	-0.35	9.23e-14	Diastolic blood pressure;
LUAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg04267008	chr7:1944627	MAD1L1	-0.75	-12.29	-0.51	7.05e-30	Bipolar disorder and schizophrenia;
LUAD	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg06108461	chr20:60628389	TAF4	-0.97	-17.7	-0.65	7.21e-53	Body mass index;
LUAD	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg02951883	chr7:2050386	MAD1L1	-0.73	-12.51	-0.52	8.98e-31	Schizophrenia;
LUAD	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg13385794	chr1:248469461	NA	0.24	6.35	0.3	5.48e-10	Common traits (Other);
LUAD	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-10.92	-0.47	1.24e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6992820	0.967	rs7816303	chr8:56723278	A/G	cg06880721	chr8:56792545	LYN	-0.45	-7.4	-0.34	7.3e-13	Mean platelet volume;
LUAD	cis	rs1448094	1.000	rs1448094	chr12:86343135	G/T	cg18827107	chr12:86230957	RASSF9	-0.45	-8.03	-0.36	9.84e-15	Major depressive disorder;
LUAD	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06022373	chr22:39101656	GTPBP1	0.48	7.89	0.36	2.68e-14	Menopause (age at onset);
LUAD	cis	rs6993813	0.843	rs4422806	chr8:120022768	C/T	cg01975934	chr8:119970761	NA	-0.37	-7.15	-0.33	3.82e-12	Bone mineral density (hip);
LUAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg18538332	chr22:24372958	LOC391322	-0.54	-8.87	-0.4	2.02e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg10645314	chr2:3704589	ALLC	-0.44	-7.73	-0.35	7.98e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-20.06	-0.7	2.23e-63	Height;
LUAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg21724239	chr8:58056113	NA	0.66	8.66	0.39	9.86e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg07936489	chr17:37558343	FBXL20	-0.52	-6.87	-0.32	2.37e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs11048434	0.736	rs12821842	chr12:9108984	G/A	cg23795048	chr12:9217529	LOC144571	0.42	7.77	0.35	5.88e-14	Sjögren's syndrome;
LUAD	trans	rs561341	0.689	rs578635	chr17:30289897	A/C	cg20587970	chr11:113659929	NA	-0.75	-11.46	-0.49	1.17e-26	Hip circumference adjusted for BMI;
LUAD	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.56	6.45	0.3	3.13e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg17306686	chr7:157230923	NA	0.34	6.41	0.3	3.86e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg08071915	chr8:12219732	FAM66A	0.44	7.22	0.33	2.46e-12	Neuroticism;
LUAD	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg25797454	chr6:150327115	RAET1K	-0.34	-7.43	-0.34	6.21e-13	Alopecia areata;
LUAD	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg13073564	chr4:8508604	NA	0.62	11.33	0.48	3.49e-26	Response to antineoplastic agents;
LUAD	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg03037974	chr15:76606532	NA	0.37	7.81	0.35	4.62e-14	Blood metabolite levels;
LUAD	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg01851573	chr8:8652454	MFHAS1	-0.37	-6.74	-0.31	5.26e-11	Neuroticism;
LUAD	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg03806693	chr22:41940476	POLR3H	-0.57	-8.04	-0.36	8.81e-15	Vitiligo;
LUAD	cis	rs9469913	0.866	rs2744942	chr6:34643752	T/C	cg14254433	chr6:34482411	PACSIN1	-0.43	-6.83	-0.32	2.93e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg18932078	chr1:2524107	MMEL1	0.37	7.03	0.32	8.24e-12	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.13	-0.33	4.44e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs151234	0.676	rs231970	chr16:28567004	A/G	cg04643524	chr16:28609220	SULT1A2	0.62	8.79	0.39	3.91e-17	Platelet distribution width;
LUAD	cis	rs17092148	0.945	rs6142237	chr20:33340993	C/T	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.34	-0.38	1.05e-15	Neuroticism;
LUAD	trans	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg00953403	chr17:74099816	EXOC7	0.49	7.76	0.35	6.32e-14	Psychosis in Alzheimer's disease;
LUAD	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg00757033	chr12:89920650	WDR51B	0.64	11.02	0.47	5.48e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs6545883	0.929	rs6545877	chr2:61741947	T/C	cg15711740	chr2:61764176	XPO1	-0.4	-6.48	-0.3	2.57e-10	Tuberculosis;
LUAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.64	-0.42	4.99e-20	Alzheimer's disease;
LUAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg23131131	chr22:24373011	LOC391322	-0.49	-8.18	-0.37	3.39e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg03929089	chr4:120376271	NA	0.79	14.08	0.56	3.23e-37	Coronary artery disease;
LUAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg02869364	chr7:1081709	C7orf50	-0.51	-6.51	-0.3	2.16e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.14	15.74	0.61	2.73e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7809950	1.000	rs3801948	chr7:107238447	A/T	cg23024343	chr7:107201750	COG5	-0.71	-11.78	-0.5	6.61e-28	Coronary artery disease;
LUAD	cis	rs9341808	0.538	rs613588	chr6:80978928	A/C	cg08355045	chr6:80787529	NA	-0.44	-7.52	-0.34	3.33e-13	Sitting height ratio;
LUAD	cis	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.19	-0.33	2.92e-12	Coronary artery disease;
LUAD	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg23018236	chr17:30244563	NA	-0.62	-8.07	-0.37	7.57e-15	Hip circumference adjusted for BMI;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00333020	chr10:2932299	NA	0.41	6.45	0.3	3.1e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg01884057	chr2:25150051	NA	0.31	6.42	0.3	3.57e-10	Body mass index;
LUAD	cis	rs3820068	0.580	rs12760698	chr1:16009814	G/A	cg13390004	chr1:15929781	NA	0.46	7.69	0.35	1.03e-13	Systolic blood pressure;
LUAD	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg08132940	chr7:1081526	C7orf50	-0.62	-6.76	-0.31	4.47e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg07432352	chr17:45403706	C17orf57	0.37	7.21	0.33	2.61e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7191439	0.722	rs6500491	chr16:88783521	T/C	cg02389323	chr16:88786976	FAM38A	1.04	10.02	0.44	2.42e-21	Plateletcrit;
LUAD	cis	rs7116495	1.000	rs585228	chr11:71773289	G/C	cg07596299	chr11:71824057	C11orf51	-0.79	-6.69	-0.31	7.28e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.57	-0.3	1.5e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs394563	0.559	rs7752555	chr6:149671116	A/G	cg07828024	chr6:149772892	ZC3H12D	0.29	6.38	0.3	4.79e-10	Dupuytren's disease;
LUAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-10.31	-0.45	2.26e-22	Lymphocyte counts;
LUAD	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg03526776	chr6:41159608	TREML2	-0.34	-7.17	-0.33	3.35e-12	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.75e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg24069376	chr3:38537580	EXOG	0.33	7.46	0.34	4.9e-13	Electrocardiographic conduction measures;
LUAD	cis	rs7020830	0.861	rs6476622	chr9:37308049	T/A	cg14294708	chr9:37120828	ZCCHC7	0.87	17.72	0.65	6.24e-53	Schizophrenia;
LUAD	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg18854424	chr1:2615690	NA	0.35	8.09	0.37	6.19e-15	Ulcerative colitis;
LUAD	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg16797656	chr11:68205561	LRP5	0.47	8.95	0.4	1.16e-17	Total body bone mineral density;
LUAD	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg06713675	chr4:122721982	EXOSC9	-0.84	-18.16	-0.66	6.49e-55	Type 2 diabetes;
LUAD	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg11859384	chr17:80120422	CCDC57	-0.52	-9.35	-0.41	5.05e-19	Life satisfaction;
LUAD	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg08085267	chr17:45401833	C17orf57	-0.66	-11.9	-0.5	2.32e-28	Glaucoma (primary open-angle);
LUAD	cis	rs6987853	0.787	rs2923437	chr8:42425399	A/C	cg09913449	chr8:42400586	C8orf40	0.52	10.56	0.46	2.7e-23	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2806561	1.000	rs2806558	chr1:23503456	T/C	cg19743168	chr1:23544995	NA	0.4	7.35	0.34	1.02e-12	Height;
LUAD	cis	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg02951883	chr7:2050386	MAD1L1	0.51	7.39	0.34	7.99e-13	Neuroticism;
LUAD	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg17633681	chr16:88106987	BANP	0.41	7.11	0.33	4.98e-12	Menopause (age at onset);
LUAD	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.22	-0.37	2.45e-15	Bipolar disorder;
LUAD	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg18132916	chr6:79620363	NA	-0.44	-7.57	-0.35	2.42e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg00647820	chr17:40259828	DHX58	-0.44	-6.9	-0.32	1.94e-11	Fibrinogen levels;
LUAD	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg02221422	chr11:68192511	LRP5	-0.41	-6.61	-0.31	1.15e-10	Bone mineral density (spine);
LUAD	cis	rs72928364	1.000	rs13091757	chr3:100741624	A/G	cg10123952	chr3:100791384	NA	0.64	7.49	0.34	4.12e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg13560548	chr3:10150139	C3orf24	0.45	7.33	0.34	1.22e-12	Alzheimer's disease;
LUAD	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg17105886	chr17:28927953	LRRC37B2	0.76	7.18	0.33	3.14e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07930192	chr7:1003750	NA	0.38	7.39	0.34	8.01e-13	Longevity;Endometriosis;
LUAD	cis	rs2073300	0.609	rs6137951	chr20:23429459	T/C	cg12062639	chr20:23401060	NAPB	1.05	10.27	0.45	3.14e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.84	-0.39	2.55e-17	Total body bone mineral density;
LUAD	cis	rs2731664	0.792	rs385981	chr5:176886539	C/T	cg23176889	chr5:176863531	GRK6	-0.76	-15.1	-0.59	1.62e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg05182265	chr7:156933206	UBE3C	0.8	17.31	0.64	3.72e-51	Body mass index;
LUAD	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-13.44	-0.55	1.52e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9296095	1.000	rs9296095	chr6:33542523	A/G	cg24505687	chr6:33548425	BAK1	0.4	6.9	0.32	1.9e-11	Platelet count;
LUAD	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg05082376	chr22:42548792	NA	-0.39	-6.95	-0.32	1.4e-11	Cognitive function;
LUAD	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg06618935	chr21:46677482	NA	-0.45	-8.58	-0.38	1.86e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7737355	0.853	rs26004	chr5:130988955	G/T	cg06307176	chr5:131281290	NA	0.44	7.23	0.33	2.23e-12	Life satisfaction;
LUAD	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg16049864	chr8:95962084	TP53INP1	-0.58	-12.55	-0.52	6.4e-31	Type 2 diabetes;
LUAD	trans	rs4650994	0.967	rs4650998	chr1:178531850	G/A	cg05059571	chr16:84539110	KIAA1609	-0.57	-10.01	-0.44	2.59e-21	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg17509989	chr5:176798049	RGS14	0.55	9.78	0.43	1.63e-20	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg18827107	chr12:86230957	RASSF9	0.47	8.65	0.39	1.05e-16	Major depressive disorder;
LUAD	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg08132940	chr7:1081526	C7orf50	-0.77	-10.31	-0.45	2.21e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.54	-0.3	1.77e-10	Breast cancer;
LUAD	cis	rs72634258	0.945	rs34466510	chr1:8147412	T/C	cg26816564	chr1:7831052	VAMP3	0.55	7.0	0.32	1.03e-11	Inflammatory bowel disease;
LUAD	cis	rs2040771	0.745	rs2283646	chr22:19273902	A/G	cg02655711	chr22:19163373	SLC25A1	-0.52	-9.74	-0.43	2.36e-20	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg27129171	chr3:47204927	SETD2	0.42	6.89	0.32	2.07e-11	Colorectal cancer;
LUAD	cis	rs12618769	0.597	rs6753515	chr2:99128965	T/A	cg10123293	chr2:99228465	UNC50	0.47	8.47	0.38	4.2e-16	Bipolar disorder;
LUAD	cis	rs887829	0.569	rs3806597	chr2:234637569	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.49	8.49	0.38	3.42e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs11153730	0.503	rs369383	chr6:118618400	T/A	cg05564266	chr6:118973597	C6orf204	0.3	6.37	0.3	4.82e-10	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg08601574	chr20:25228251	PYGB	-0.44	-8.06	-0.36	8.04e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg19318889	chr4:1322082	MAEA	0.82	13.49	0.55	9.84e-35	Longevity;
LUAD	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg08201673	chr17:18167551	SMCR7	0.46	7.65	0.35	1.37e-13	Multiple sclerosis;
LUAD	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg27144592	chr16:783916	NARFL	0.35	6.47	0.3	2.75e-10	Height;
LUAD	cis	rs6484504	0.576	rs176373	chr11:31136026	G/T	cg06552810	chr11:31128660	NA	-0.33	-6.43	-0.3	3.54e-10	Red blood cell count;
LUAD	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg08470875	chr2:26401718	FAM59B	-0.78	-10.51	-0.45	4.3e-23	Gut microbiome composition (summer);
LUAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg11494091	chr17:61959527	GH2	0.73	18.08	0.66	1.49e-54	Prudent dietary pattern;
LUAD	cis	rs6564851	0.545	rs12149068	chr16:81252903	T/G	cg00908271	chr16:81254010	PKD1L2	-0.41	-8.58	-0.39	1.82e-16	Carotenoid and tocopherol levels;
LUAD	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.35	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.64	-11.98	-0.5	1.08e-28	Prudent dietary pattern;
LUAD	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08109568	chr15:31115862	NA	-0.59	-10.09	-0.44	1.36e-21	Huntington's disease progression;
LUAD	cis	rs6545883	0.929	rs10193666	chr2:61629408	C/T	cg15711740	chr2:61764176	XPO1	0.41	6.48	0.3	2.54e-10	Tuberculosis;
LUAD	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.58	9.86	0.43	9.07e-21	Cognitive ability;
LUAD	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg04414720	chr1:150670196	GOLPH3L	0.72	12.85	0.53	3.76e-32	Melanoma;
LUAD	trans	rs853679	0.546	rs200952	chr6:27836976	C/T	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.08	-0.37	6.63e-15	Depression;
LUAD	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg00933542	chr6:150070202	PCMT1	-0.42	-9.25	-0.41	1.14e-18	Lung cancer;
LUAD	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg25208724	chr1:156163844	SLC25A44	0.97	15.28	0.6	2.7e-42	Testicular germ cell tumor;
LUAD	cis	rs2274273	0.868	rs1572611	chr14:55833874	T/A	cg04306507	chr14:55594613	LGALS3	0.44	9.3	0.41	7.87e-19	Protein biomarker;
LUAD	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg26528668	chr16:1614120	IFT140	0.49	8.72	0.39	6.61e-17	Coronary artery disease;
LUAD	cis	rs10821973	0.527	rs4979778	chr10:63981919	G/A	cg09941381	chr10:64027924	RTKN2	-0.34	-6.76	-0.31	4.48e-11	Hypothyroidism;
LUAD	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg19622623	chr12:86230825	RASSF9	-0.38	-6.77	-0.31	4.28e-11	Major depressive disorder;
LUAD	cis	rs2070677	0.935	rs7907312	chr10:135417364	A/G	cg20169779	chr10:135381914	SYCE1	-0.51	-8.2	-0.37	2.99e-15	Gout;
LUAD	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg09399716	chr2:46890238	NA	-0.39	-6.96	-0.32	1.28e-11	Height;
LUAD	cis	rs3806843	0.548	rs246057	chr5:140325583	A/G	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg00129232	chr17:37814104	STARD3	-0.47	-7.37	-0.34	9.21e-13	Asthma;
LUAD	cis	rs11811982	0.793	rs11804271	chr1:227563700	T/A	cg24860534	chr1:227506868	CDC42BPA	0.66	7.2	0.33	2.8e-12	Optic disc area;
LUAD	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg08280861	chr8:58055591	NA	0.65	8.38	0.38	7.96e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg02176678	chr2:219576539	TTLL4	-0.82	-16.68	-0.63	2.31e-48	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1816752	0.774	rs55888616	chr13:25016092	C/T	cg02811702	chr13:24901961	NA	0.45	7.77	0.35	6.03e-14	Obesity-related traits;
LUAD	cis	rs1595825	0.891	rs35817167	chr2:198718928	A/T	cg00361562	chr2:198649771	BOLL	-0.49	-6.92	-0.32	1.63e-11	Ulcerative colitis;
LUAD	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg23985595	chr17:80112537	CCDC57	0.53	9.68	0.43	3.62e-20	Life satisfaction;
LUAD	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg11189052	chr15:85197271	WDR73	-0.6	-9.95	-0.44	4.16e-21	P wave terminal force;
LUAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	6.63	0.31	1e-10	Electroencephalogram traits;
LUAD	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg11266682	chr4:10021025	SLC2A9	-0.64	-14.98	-0.59	5.4e-41	Bone mineral density;
LUAD	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.35	-0.34	1e-12	Breast cancer;
LUAD	cis	rs7809950	0.678	rs62483641	chr7:106901741	T/C	cg23024343	chr7:107201750	COG5	-0.81	-13.75	-0.56	7.78e-36	Coronary artery disease;
LUAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg06375148	chr1:209958343	C1orf74	0.38	6.4	0.3	4.2e-10	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUAD	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg22753661	chr15:79092743	ADAMTS7	-0.7	-11.62	-0.49	2.92e-27	Diastolic blood pressure;
LUAD	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg00666640	chr1:248458726	OR2T12	0.33	7.96	0.36	1.56e-14	Common traits (Other);
LUAD	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg04248312	chr19:17393744	ANKLE1	-0.99	-18.55	-0.67	1.23e-56	Systemic lupus erythematosus;
LUAD	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22307029	chr19:49891270	CCDC155	-0.77	-11.5	-0.49	8.42e-27	Multiple sclerosis;
LUAD	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06558623	chr16:89946397	TCF25	0.81	8.51	0.38	2.94e-16	Skin colour saturation;
LUAD	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.38	0.3	4.64e-10	Lung cancer in ever smokers;
LUAD	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg10518543	chr12:38710700	ALG10B	0.41	6.39	0.3	4.29e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs68170813	0.559	rs78610616	chr7:106951369	T/C	cg23024343	chr7:107201750	COG5	0.49	7.0	0.32	1.01e-11	Coronary artery disease;
LUAD	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg25566285	chr7:158114605	PTPRN2	-0.53	-11.54	-0.49	5.59e-27	Calcium levels;
LUAD	cis	rs17789174	0.700	rs3794679	chr16:85104588	A/C	cg27466129	chr16:85060822	KIAA0513	0.29	7.34	0.34	1.08e-12	Dysphagia;
LUAD	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	18.61	0.67	6.8e-57	Bone mineral density;
LUAD	cis	rs11319879	1	rs11319879	chr10:94453475	TA/T	cg25093409	chr10:94429542	NA	0.35	6.41	0.3	3.84e-10	Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;
LUAD	cis	rs3750965	0.959	rs11228490	chr11:68860872	C/G	cg06818126	chr11:68850279	TPCN2	0.48	7.19	0.33	2.96e-12	Hair color;
LUAD	trans	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg04775059	chr7:64541387	NA	0.52	6.83	0.32	2.89e-11	Aortic root size;
LUAD	cis	rs2230307	0.536	rs11166407	chr1:100637708	C/T	cg20868668	chr1:100435035	SLC35A3	0.52	7.84	0.36	3.67e-14	Carotid intima media thickness;
LUAD	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg17264618	chr3:40429014	ENTPD3	-0.3	-6.43	-0.3	3.54e-10	Renal cell carcinoma;
LUAD	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	11.1	0.47	2.74e-25	Eosinophil percentage of white cells;
LUAD	cis	rs4006360	0.546	rs6416912	chr17:39253337	A/G	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.3	0.37	1.4e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs10411161	0.702	rs8110461	chr19:52383569	A/C	cg22319618	chr22:45562946	NUP50	-0.6	-8.32	-0.38	1.24e-15	Breast cancer;
LUAD	cis	rs2274273	0.870	rs59629906	chr14:55781189	T/C	cg04306507	chr14:55594613	LGALS3	0.43	8.89	0.4	1.79e-17	Protein biomarker;
LUAD	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg14631576	chr9:95140430	CENPP	-0.48	-9.71	-0.43	2.97e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Parkinson's disease;
LUAD	cis	rs2109514	0.650	rs12531767	chr7:116129005	T/A	cg12739419	chr7:116140593	CAV2	-0.33	-6.84	-0.32	2.85e-11	Prevalent atrial fibrillation;
LUAD	cis	rs4888262	0.526	rs7205992	chr16:74590578	T/A	cg01733217	chr16:74700730	RFWD3	0.48	8.01	0.36	1.15e-14	Testicular germ cell tumor;
LUAD	cis	rs4588572	0.688	rs2115436	chr5:77692617	A/T	cg11547950	chr5:77652471	NA	-0.6	-10.34	-0.45	1.78e-22	Triglycerides;
LUAD	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg05731713	chr7:157510257	PTPRN2	0.32	6.54	0.3	1.77e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg00898013	chr13:113819073	PROZ	-0.81	-14.69	-0.58	9.4e-40	Platelet distribution width;
LUAD	cis	rs1953600	0.870	rs2789695	chr10:81946840	C/T	cg04850286	chr10:81895943	PLAC9	0.36	6.48	0.3	2.6e-10	Sarcoidosis;
LUAD	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg22823121	chr1:150693482	HORMAD1	-0.39	-7.7	-0.35	9.6e-14	Tonsillectomy;
LUAD	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg13770153	chr20:60521292	NA	-0.62	-9.47	-0.42	1.93e-19	Body mass index;
LUAD	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg08999081	chr20:33150536	PIGU	0.63	13.99	0.56	8.1e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs7487075	0.578	rs10880967	chr12:46812023	T/C	cg23829395	chr12:46796953	NA	0.32	6.98	0.32	1.16e-11	Itch intensity from mosquito bite;
LUAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.11	0.33	4.84e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg15432903	chr11:17409602	KCNJ11	0.54	10.23	0.45	4.3e-22	Type 2 diabetes;
LUAD	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs4273100	0.834	rs59415593	chr17:19223224	T/G	cg03910582	chr17:19030146	GRAPL	0.57	7.07	0.32	6.65e-12	Schizophrenia;
LUAD	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg21427119	chr20:30132790	HM13	-0.64	-9.53	-0.42	1.28e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs3784262	0.631	rs4646566	chr15:58348173	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.4	-7.74	-0.35	7.43e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	17.39	0.65	1.65e-51	Homoarginine levels;
LUAD	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg07870213	chr5:140052090	DND1	1.01	14.41	0.57	1.33e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4700695	0.668	rs20768	chr5:65484805	C/T	cg21114390	chr5:65439923	SFRS12	-0.91	-13.97	-0.56	9.85e-37	Facial morphology (factor 19);
LUAD	cis	rs6601450	0.540	rs7824231	chr8:10273958	G/A	cg27411982	chr8:10470053	RP1L1	-0.36	-6.59	-0.31	1.3e-10	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14240646	chr10:27532245	ACBD5	-1.03	-19.72	-0.69	7.61e-62	Breast cancer;
LUAD	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg15557168	chr22:42548783	NA	0.51	9.47	0.42	1.95e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg09835421	chr16:68378352	PRMT7	-0.82	-8.83	-0.39	2.73e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg02269571	chr22:50332266	NA	-0.67	-9.57	-0.42	9.14e-20	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg15117754	chr3:10150083	C3orf24	0.4	6.66	0.31	8.79e-11	Alzheimer's disease;
LUAD	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg03233332	chr7:66118400	NA	-0.44	-6.64	-0.31	9.76e-11	Aortic root size;
LUAD	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg07402062	chr16:89894098	SPIRE2	0.45	11.67	0.49	1.8e-27	Vitiligo;
LUAD	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg04827223	chr11:72435913	ARAP1	-0.55	-8.27	-0.37	1.79e-15	Type 2 diabetes;
LUAD	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg26384229	chr12:38710491	ALG10B	0.51	8.04	0.36	8.78e-15	Bladder cancer;
LUAD	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg24069376	chr3:38537580	EXOG	0.36	8.3	0.37	1.38e-15	Electrocardiographic conduction measures;
LUAD	cis	rs68170813	0.652	rs75136686	chr7:107180949	G/A	cg23024343	chr7:107201750	COG5	0.53	6.68	0.31	7.62e-11	Coronary artery disease;
LUAD	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg16680214	chr1:154839983	KCNN3	-0.66	-13.39	-0.55	2.52e-34	Prostate cancer;
LUAD	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg25985355	chr7:65971099	NA	-0.35	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs9616064	0.740	rs6520049	chr22:46996309	C/T	cg25730555	chr22:47059586	GRAMD4	0.39	6.84	0.32	2.83e-11	Urate levels in obese individuals;
LUAD	cis	rs829883	0.724	rs3168521	chr12:98908547	C/T	cg25150519	chr12:98850993	NA	-0.52	-8.26	-0.37	1.88e-15	Colorectal adenoma (advanced);
LUAD	cis	rs6005807	0.920	rs73430136	chr22:28940864	T/C	cg12565055	chr22:29076175	TTC28	0.69	6.62	0.31	1.09e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg22598563	chr5:131563921	P4HA2	-0.26	-6.4	-0.3	4.15e-10	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg20607798	chr8:58055168	NA	0.72	9.44	0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9322817	0.691	rs2499652	chr6:105269959	G/A	cg02098413	chr6:105308735	HACE1	0.41	8.71	0.39	6.83e-17	Thyroid stimulating hormone;
LUAD	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg08712631	chr7:1960676	MAD1L1	-0.41	-6.66	-0.31	8.56e-11	Neuroticism;
LUAD	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.92	-0.4	1.46e-17	Total body bone mineral density;
LUAD	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.56	0.34	2.58e-13	Menopause (age at onset);
LUAD	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg26314531	chr2:26401878	FAM59B	0.72	9.48	0.42	1.81e-19	Gut microbiome composition (summer);
LUAD	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg22676075	chr6:135203613	NA	-0.6	-11.34	-0.48	3.17e-26	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg08027265	chr7:2291960	NA	-0.42	-7.19	-0.33	2.87e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs68170813	0.559	rs1018947	chr7:106851939	A/T	cg23024343	chr7:107201750	COG5	0.5	7.25	0.33	2.01e-12	Coronary artery disease;
LUAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14159672	chr1:205819179	PM20D1	0.58	10.62	0.46	1.62e-23	Menarche (age at onset);
LUAD	cis	rs977987	0.737	rs8046697	chr16:75442144	T/C	cg03315344	chr16:75512273	CHST6	0.64	13.72	0.55	1.11e-35	Dupuytren's disease;
LUAD	cis	rs17135859	1.000	rs7707681	chr5:112996226	A/T	cg12552261	chr5:112820674	MCC	0.58	7.49	0.34	4.03e-13	F-cell distribution;
LUAD	cis	rs62229266	0.625	rs62230813	chr21:37403432	C/T	cg12218747	chr21:37451666	NA	-0.44	-7.64	-0.35	1.5e-13	Mitral valve prolapse;
LUAD	cis	rs12210905	0.688	rs72845027	chr6:27528199	T/C	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg22532475	chr10:104410764	TRIM8	-0.53	-9.66	-0.43	4.48e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg20673091	chr1:2541236	MMEL1	-0.4	-8.57	-0.38	1.97e-16	Ulcerative colitis;
LUAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-6.84	-0.32	2.84e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg07719772	chr16:32360419	NA	-0.47	-7.34	-0.34	1.1e-12	Menopause (age at onset);
LUAD	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg14159672	chr1:205819179	PM20D1	-0.52	-7.75	-0.35	7.08e-14	Menarche (age at onset);
LUAD	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg17177755	chr1:15930204	NA	0.46	7.41	0.34	6.87e-13	Systolic blood pressure;
LUAD	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg07507251	chr3:52567010	NT5DC2	0.37	7.35	0.34	1.04e-12	Bipolar disorder;
LUAD	cis	rs13082711	0.911	rs74279676	chr3:27512944	G/A	cg02860705	chr3:27208620	NA	0.61	9.28	0.41	8.99e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.25	-0.41	1.1e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs6076065	0.723	rs2424544	chr20:23390314	C/T	cg11657817	chr20:23433608	CST11	0.47	8.92	0.4	1.37e-17	Facial morphology (factor 15, philtrum width);
LUAD	trans	rs225245	0.817	rs225284	chr17:33933006	A/C	cg19694781	chr19:47549865	TMEM160	-0.45	-7.43	-0.34	5.91e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs12765878	1.000	rs12765878	chr10:105669622	C/T	cg11005552	chr10:105648138	OBFC1	-0.43	-8.21	-0.37	2.8e-15	Coronary artery disease;
LUAD	cis	rs11671005	0.693	rs11666928	chr19:58914231	A/G	cg13877915	chr19:58951672	ZNF132	0.54	6.92	0.32	1.71e-11	Mean platelet volume;
LUAD	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg05425664	chr17:57184151	TRIM37	-0.44	-7.83	-0.36	3.89e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs3942852	0.712	rs10742828	chr11:48104555	A/G	cg03929089	chr4:120376271	NA	-0.51	-7.46	-0.34	4.83e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7474896	0.559	rs1735641	chr10:38184852	C/A	cg25427524	chr10:38739819	LOC399744	0.6	8.46	0.38	4.25e-16	Obesity (extreme);
LUAD	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24308560	chr3:49941425	MST1R	0.55	9.37	0.41	4.35e-19	Body mass index;
LUAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg04025307	chr7:1156635	C7orf50	0.6	6.78	0.31	3.97e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1497406	0.744	rs4537547	chr1:16510798	C/T	cg02998240	chr1:16508668	NA	0.24	7.08	0.33	6.08e-12	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg07636037	chr3:49044803	WDR6	0.62	11.99	0.5	1.04e-28	Parkinson's disease;
LUAD	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg18306943	chr3:40428807	ENTPD3	0.42	7.1	0.33	5.47e-12	Renal cell carcinoma;
LUAD	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.82	0.31	3.14e-11	Rheumatoid arthritis;
LUAD	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg07757535	chr4:1339547	NA	0.32	7.14	0.33	4.16e-12	Longevity;
LUAD	cis	rs10203711	1.000	rs4663941	chr2:239574279	A/G	cg14580085	chr2:239553406	NA	0.42	9.09	0.4	3.88e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.48	-8.65	-0.39	1.04e-16	Menarche (age at onset);
LUAD	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg18105134	chr13:113819100	PROZ	0.87	15.2	0.59	5.93e-42	Platelet distribution width;
LUAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg27535305	chr1:53392650	SCP2	-0.4	-8.21	-0.37	2.71e-15	Monocyte count;
LUAD	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-9.78	-0.43	1.63e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs986417	1.000	rs1951114	chr14:60922005	C/G	cg27398547	chr14:60952738	C14orf39	-0.63	-7.71	-0.35	9.21e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs9899728	0.665	rs2307008	chr17:73042682	G/A	cg27626185	chr17:73056755	KCTD2	-0.57	-6.99	-0.32	1.06e-11	Alzheimer's disease or small vessel stroke;
LUAD	trans	rs4650994	0.816	rs2811301	chr1:178594196	T/C	cg05059571	chr16:84539110	KIAA1609	0.5	8.27	0.37	1.71e-15	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg11859384	chr17:80120422	CCDC57	-0.48	-8.67	-0.39	9.17e-17	Life satisfaction;
LUAD	cis	rs2737618	0.722	rs2737680	chr1:200088559	C/A	cg21825944	chr1:200113062	NR5A2	-0.37	-6.36	-0.3	5.34e-10	Uric acid levels;
LUAD	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.18	-0.37	3.32e-15	Breast cancer;
LUAD	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs11696501	0.793	rs4812909	chr20:44167244	G/A	cg11783356	chr20:44313418	WFDC10B	-0.46	-6.94	-0.32	1.51e-11	Brain structure;
LUAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg24101359	chr6:42928495	GNMT	0.53	10.5	0.45	4.6e-23	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs1018836	0.828	rs7012741	chr8:91536065	A/G	cg16814680	chr8:91681699	NA	-0.58	-9.77	-0.43	1.85e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs938554	0.876	rs6855911	chr4:9935910	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-7.51	-0.34	3.45e-13	Blood metabolite levels;
LUAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06873352	chr17:61820015	STRADA	0.82	18.0	0.66	3.29e-54	Prudent dietary pattern;
LUAD	cis	rs4594175	0.962	rs8008182	chr14:51608357	C/T	cg23942311	chr14:51606299	NA	0.64	11.01	0.47	5.71e-25	Cancer;
LUAD	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg14343924	chr8:8086146	FLJ10661	0.51	8.24	0.37	2.19e-15	Systolic blood pressure;
LUAD	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg05865280	chr17:75406074	SEPT9	0.61	19.3	0.68	5.44e-60	Airflow obstruction;
LUAD	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg02753203	chr1:228287806	NA	0.56	10.27	0.45	3.16e-22	Diastolic blood pressure;
LUAD	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.34	-7.27	-0.33	1.71e-12	Hemoglobin concentration;
LUAD	cis	rs11112613	0.762	rs73184077	chr12:105949999	G/A	cg03607813	chr12:105948248	NA	0.82	13.87	0.56	2.64e-36	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg16325326	chr1:53192061	ZYG11B	0.65	12.12	0.51	3.08e-29	Monocyte count;
LUAD	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg18854424	chr1:2615690	NA	0.42	9.09	0.4	3.9e-18	Ulcerative colitis;
LUAD	cis	rs11249608	0.789	rs7700958	chr5:178436617	G/A	cg01312482	chr5:178451176	ZNF879	-0.42	-6.5	-0.3	2.32e-10	Pubertal anthropometrics;
LUAD	cis	rs2346177	0.554	rs36006825	chr2:46708945	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-7.73	-0.35	7.99e-14	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.42e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg06608945	chr2:219082296	ARPC2	0.45	7.43	0.34	5.99e-13	Colorectal cancer;
LUAD	cis	rs3931020	0.657	rs7522428	chr1:75178360	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.49	6.41	0.3	3.89e-10	Resistin levels;
LUAD	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg08677398	chr8:58056175	NA	0.53	6.82	0.31	3.26e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg04282206	chr17:62833786	PLEKHM1P	-0.53	-8.08	-0.37	6.78e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23583168	chr7:148888333	NA	-0.9	-18.13	-0.66	8.8e-55	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.41	0.38	6.12e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.46	9.5	0.42	1.56e-19	Monocyte percentage of white cells;
LUAD	cis	rs6087990	0.735	rs2424907	chr20:31359819	C/T	cg13636640	chr20:31349939	DNMT3B	0.75	13.44	0.55	1.48e-34	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.99	0.32	1.07e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10465746	0.935	rs12406984	chr1:84416215	C/G	cg10977910	chr1:84465055	TTLL7	0.49	7.97	0.36	1.5e-14	Obesity-related traits;
LUAD	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05665937	chr4:1216051	CTBP1	-0.45	-7.2	-0.33	2.74e-12	Obesity-related traits;
LUAD	cis	rs7107174	1.000	rs2511182	chr11:77982130	G/C	cg19901956	chr11:77921274	USP35	-0.51	-6.46	-0.3	2.9e-10	Testicular germ cell tumor;
LUAD	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg08439880	chr3:133502540	NA	-0.36	-6.89	-0.32	2.05e-11	Iron status biomarkers;
LUAD	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	11.75	0.5	9.08e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.16	-0.33	3.59e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg17200465	chr3:40428508	ENTPD3	0.27	6.49	0.3	2.38e-10	Renal cell carcinoma;
LUAD	trans	rs877282	0.853	rs7079450	chr10:755932	T/A	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg12623918	chr2:306882	NA	0.34	7.0	0.32	9.91e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg24801067	chr17:62843696	NA	0.53	8.39	0.38	7.33e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10106298	0.935	rs3191333	chr8:103662219	G/A	cg10187029	chr8:103597600	NA	0.49	8.01	0.36	1.09e-14	Schizophrenia;
LUAD	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-6.82	-0.31	3.22e-11	Personality dimensions;
LUAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg08219700	chr8:58056026	NA	-0.47	-6.82	-0.31	3.13e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg08071915	chr8:12219732	FAM66A	-0.42	-7.16	-0.33	3.53e-12	Neuroticism;
LUAD	cis	rs7680126	0.633	rs4697743	chr4:10294833	A/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-8.16	-0.37	3.84e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs11077998	0.967	rs60488670	chr17:80522667	T/C	cg10255544	chr17:80519551	FOXK2	0.34	6.69	0.31	7.18e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs9650315	0.530	rs35399441	chr8:57089431	A/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	8.12	0.37	5e-15	Height;
LUAD	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.49	-8.23	-0.37	2.31e-15	Longevity;Endometriosis;
LUAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg08888203	chr3:10149979	C3orf24	-0.68	-11.89	-0.5	2.5e-28	Alzheimer's disease;
LUAD	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg03609598	chr5:56110824	MAP3K1	0.49	7.11	0.33	4.92e-12	Initial pursuit acceleration;
LUAD	cis	rs701145	0.730	rs701141	chr3:154061053	G/A	cg17054900	chr3:154042577	DHX36	0.63	7.05	0.32	7.4e-12	Coronary artery disease;
LUAD	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg13334819	chr7:99746414	C7orf59	0.63	9.9	0.43	6.48e-21	Coronary artery disease;
LUAD	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	10.43	0.45	8.13e-23	Smoking behavior;
LUAD	cis	rs4790333	0.562	rs2447108	chr17:2257993	C/T	cg27406664	chr17:2294951	MNT	0.4	8.09	0.37	6.2e-15	Proinsulin levels;
LUAD	cis	rs4588572	0.643	rs7700390	chr5:77789532	T/C	cg11547950	chr5:77652471	NA	-0.78	-12.6	-0.52	3.78e-31	Triglycerides;
LUAD	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg12011299	chr4:100065546	ADH4	0.7	12.61	0.52	3.55e-31	Smoking initiation;
LUAD	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05535760	chr7:792225	HEATR2	1.01	12.97	0.53	1.33e-32	Cerebrospinal P-tau181p levels;
LUAD	cis	rs10193935	0.792	rs10204778	chr2:42498121	G/T	cg27598129	chr2:42591480	NA	-0.78	-9.64	-0.42	5.21e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4906332	0.966	rs34372508	chr14:103977515	G/A	cg19000871	chr14:103996768	TRMT61A	-0.41	-6.87	-0.32	2.28e-11	Coronary artery disease;
LUAD	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg03037974	chr15:76606532	NA	0.38	8.2	0.37	3e-15	Blood metabolite levels;
LUAD	cis	rs4711350	1.000	rs2395447	chr6:33743174	T/C	cg18005901	chr6:33739558	LEMD2	-0.53	-7.62	-0.35	1.69e-13	Schizophrenia;
LUAD	cis	rs12681287	0.640	rs7833049	chr8:87445898	T/C	cg00550725	chr8:87521180	FAM82B	-0.45	-6.59	-0.31	1.3100000000000001e-10	Caudate activity during reward;
LUAD	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.56	7.48	0.34	4.24e-13	Gut microbiome composition (summer);
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg00235645	chr15:40886408	CASC5	0.37	6.55	0.3	1.69e-10	Bipolar disorder;
LUAD	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	cg06064525	chr11:970664	AP2A2	-0.46	-9.11	-0.4	3.39e-18	Alzheimer's disease (late onset);
LUAD	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg12908607	chr1:44402522	ARTN	-0.52	-9.95	-0.44	4.2e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.49	6.61	0.31	1.14e-10	Platelet count;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25223263	chr11:119020168	ABCG4	-0.54	-6.59	-0.31	1.33e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg04756594	chr16:24857601	SLC5A11	0.51	10.16	0.44	7.42e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg00933542	chr6:150070202	PCMT1	0.39	8.28	0.37	1.69e-15	Lung cancer;
LUAD	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg19980929	chr12:42632907	YAF2	0.35	6.73	0.31	5.49e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs12530845	1.000	rs12540325	chr7:135334111	T/C	cg23117316	chr7:135346802	PL-5283	-0.51	-9.18	-0.41	1.98e-18	Red blood cell traits;
LUAD	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg26384229	chr12:38710491	ALG10B	0.46	7.5	0.34	3.79e-13	Morning vs. evening chronotype;
LUAD	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg05754148	chr16:3507555	NAT15	-0.39	-6.71	-0.31	6.31e-11	Body mass index (adult);
LUAD	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21582582	chr3:182698605	DCUN1D1	0.6	9.79	0.43	1.58e-20	Resting heart rate;
LUAD	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg17063962	chr7:91808500	NA	0.68	12.16	0.51	2.29e-29	Breast cancer;
LUAD	cis	rs60154123	0.730	rs10779528	chr1:210457378	C/T	cg22029157	chr1:209979665	IRF6	0.55	6.56	0.3	1.59e-10	Coronary artery disease;
LUAD	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg12458913	chr13:53173898	NA	0.41	7.39	0.34	8.02e-13	Lewy body disease;
LUAD	cis	rs3741798	1.000	rs61922045	chr12:12494394	A/C	cg08615371	chr12:12503544	MANSC1	0.68	6.38	0.3	4.57e-10	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.49	-0.34	4.18e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.64	-10.09	-0.44	1.39e-21	Chronic sinus infection;
LUAD	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg23533926	chr12:111358616	MYL2	-0.41	-6.95	-0.32	1.36e-11	Extrinsic epigenetic age acceleration;
LUAD	trans	rs10411161	0.702	rs7247017	chr19:52391769	T/C	cg22319618	chr22:45562946	NUP50	-0.66	-9.44	-0.42	2.52e-19	Breast cancer;
LUAD	cis	rs959260	0.528	rs9909443	chr17:73308346	C/T	cg07104495	chr17:73266070	MIF4GD	0.3	7.35	0.34	1.06e-12	Systemic lupus erythematosus;
LUAD	cis	rs7809950	0.817	rs2712230	chr7:107294151	G/A	cg23024343	chr7:107201750	COG5	0.75	12.26	0.51	9.07e-30	Coronary artery disease;
LUAD	cis	rs7851660	0.805	rs4255258	chr9:100647545	A/G	cg13688889	chr9:100608707	NA	-0.53	-8.83	-0.39	2.76e-17	Strep throat;
LUAD	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg02527881	chr3:46936655	PTH1R	-0.54	-11.28	-0.48	5.68e-26	Colorectal cancer;
LUAD	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg24069376	chr3:38537580	EXOG	-0.32	-7.36	-0.34	9.45e-13	Electrocardiographic conduction measures;
LUAD	cis	rs3845702	0.736	rs3843323	chr2:180856459	T/C	cg01881094	chr2:180872142	CWC22	-0.8	-8.54	-0.38	2.38e-16	Schizophrenia;
LUAD	cis	rs754466	0.580	rs10824577	chr10:79577408	G/C	cg17075019	chr10:79541650	NA	-0.92	-20.05	-0.7	2.36e-63	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.75	-15.76	-0.61	2.32e-44	Lung cancer;
LUAD	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg08847533	chr14:75593920	NEK9	-0.38	-6.47	-0.3	2.66e-10	Height;
LUAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg10862848	chr6:42927986	GNMT	-0.32	-9.13	-0.41	2.9e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg24712243	chr11:61310195	SYT7	-0.39	-6.49	-0.3	2.36e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg06753367	chr22:24256600	NA	0.4	7.44	0.34	5.61e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.17	-0.37	3.71e-15	Personality dimensions;
LUAD	cis	rs7903847	0.642	rs11812223	chr10:99158455	T/C	cg20016023	chr10:99160130	RRP12	-0.32	-7.85	-0.36	3.42e-14	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7241530	0.636	rs4799273	chr18:75898963	C/T	cg14642773	chr18:75888474	NA	0.35	6.35	0.3	5.46e-10	Educational attainment (years of education);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05662684	chr11:32915131	QSER1	-0.43	-6.62	-0.31	1.1e-10	Height;
LUAD	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.85e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8018808	0.935	rs2364156	chr14:77916746	G/A	cg20045696	chr14:77926864	AHSA1	0.36	6.35	0.3	5.57e-10	Myeloid white cell count;
LUAD	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg07636037	chr3:49044803	WDR6	0.64	12.55	0.52	6.41e-31	Parkinson's disease;
LUAD	cis	rs427941	0.632	rs201492	chr7:101754138	C/T	cg06246474	chr7:101738831	CUX1	0.37	6.44	0.3	3.28e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg08807101	chr21:30365312	RNF160	0.41	7.14	0.33	4.12e-12	Dental caries;
LUAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg15242686	chr22:24348715	GSTTP1	0.45	7.93	0.36	2.04e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs56283067	0.847	rs56300373	chr6:44690904	C/T	cg20913747	chr6:44695427	NA	-0.45	-7.58	-0.35	2.16e-13	Total body bone mineral density;
LUAD	cis	rs73206853	0.841	rs73206883	chr12:110849549	A/G	cg12870014	chr12:110450643	ANKRD13A	0.63	7.02	0.32	8.9e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg20891283	chr12:69753455	YEATS4	-0.45	-7.36	-0.34	9.4e-13	Blood protein levels;
LUAD	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.45	-0.52	1.62e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs6499255	0.904	rs10852458	chr16:69672410	G/A	cg15192750	chr16:69999425	NA	0.46	7.13	0.33	4.24e-12	IgE levels;
LUAD	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs11811982	1.000	rs115414844	chr1:227509265	C/A	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg01028140	chr2:1542097	TPO	-0.49	-6.43	-0.3	3.42e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg16590910	chr6:42928470	GNMT	0.35	6.54	0.3	1.82e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.98	23.2	0.75	2.15e-77	Birth weight;
LUAD	cis	rs11771526	0.901	rs62457473	chr7:32306990	G/A	cg13207630	chr7:32358064	NA	0.6	7.53	0.34	3.02e-13	Body mass index;
LUAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg07685180	chr8:600429	NA	0.89	8.69	0.39	8.32e-17	IgG glycosylation;
LUAD	trans	rs11039798	0.688	rs12277029	chr11:48852833	G/T	cg02254774	chr11:50257496	LOC441601	0.53	6.68	0.31	7.63e-11	Axial length;
LUAD	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg07741184	chr6:167504864	NA	0.3	7.19	0.33	2.96e-12	Crohn's disease;
LUAD	cis	rs8099014	0.731	rs9966665	chr18:56099407	A/C	cg12907477	chr18:56117327	MIR122	-0.44	-6.48	-0.3	2.58e-10	Platelet count;
LUAD	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg07636037	chr3:49044803	WDR6	0.61	11.38	0.48	2.37e-26	Parkinson's disease;
LUAD	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.47	0.3	2.73e-10	Breast cancer;
LUAD	cis	rs35883536	0.708	rs34689792	chr1:101097753	A/G	cg06223162	chr1:101003688	GPR88	0.36	6.68	0.31	7.66e-11	Monocyte count;
LUAD	cis	rs28595532	0.748	rs17594978	chr4:119336398	T/C	cg02775129	chr4:119771670	NA	-0.66	-6.5	-0.3	2.2e-10	Cannabis dependence symptom count;
LUAD	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.4	-6.75	-0.31	5.03e-11	Colorectal cancer;
LUAD	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06112835	chr11:68658793	MRPL21	0.54	9.64	0.42	5.26e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7216064	1.000	rs62084246	chr17:65867911	G/C	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs7180079	0.844	rs11071791	chr15:64602270	C/A	cg08069370	chr15:64387884	SNX1	0.51	6.45	0.3	3.1e-10	Monocyte count;
LUAD	cis	rs12545109	0.800	rs2609979	chr8:57390066	G/A	cg17761419	chr8:57350749	NA	-0.57	-8.37	-0.38	8.47e-16	Obesity-related traits;
LUAD	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.81e-11	Crohn's disease;
LUAD	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06028808	chr11:68637592	NA	0.47	7.57	0.35	2.28e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs7395662	0.750	rs10838985	chr11:48645085	A/G	cg00717180	chr2:96193071	NA	-0.36	-6.53	-0.3	1.85e-10	HDL cholesterol;
LUAD	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	6.55	0.3	1.71e-10	Personality dimensions;
LUAD	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg00277334	chr10:82204260	NA	-0.66	-11.99	-0.5	9.99e-29	Post bronchodilator FEV1;
LUAD	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg16797656	chr11:68205561	LRP5	0.45	9.32	0.41	6.38e-19	Total body bone mineral density;
LUAD	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg24531977	chr5:56204891	C5orf35	-0.39	-6.46	-0.3	2.89e-10	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg23758822	chr17:41437982	NA	1.02	21.5	0.72	7.54e-70	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.48e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg22403471	chr8:68256159	ARFGEF1	-0.36	-6.44	-0.3	3.16e-10	Schizophrenia;
LUAD	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg08470875	chr2:26401718	FAM59B	-0.62	-8.52	-0.38	2.89e-16	Gut microbiome composition (summer);
LUAD	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg05234568	chr11:5960015	NA	-0.52	-9.36	-0.41	4.58e-19	DNA methylation (variation);
LUAD	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.86	0.32	2.52e-11	Obesity-related traits;
LUAD	cis	rs7043114	0.563	rs987554	chr9:95298738	A/G	cg14631576	chr9:95140430	CENPP	-0.4	-8.04	-0.36	9.07e-15	Height;
LUAD	cis	rs2455826	0.520	rs2700002	chr3:15776524	G/A	cg16303742	chr3:15540471	COLQ	-0.38	-6.49	-0.3	2.42e-10	Inflammatory skin disease;
LUAD	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25427524	chr10:38739819	LOC399744	-0.8	-14.36	-0.57	2.26e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05535760	chr7:792225	HEATR2	1.0	12.52	0.52	8.33e-31	Cerebrospinal P-tau181p levels;
LUAD	cis	rs8051149	0.793	rs12927136	chr16:87873577	A/G	cg10099957	chr16:87869757	SLC7A5	0.42	6.72	0.31	5.91e-11	Blood metabolite levels;
LUAD	trans	rs372883	0.648	rs368322	chr21:30717151	C/T	cg14791747	chr16:20752902	THUMPD1	0.48	7.04	0.32	7.98e-12	Pancreatic cancer;
LUAD	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg27532560	chr4:187881888	NA	-0.41	-8.11	-0.37	5.45e-15	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg27170947	chr2:26402098	FAM59B	-0.64	-8.92	-0.4	1.38e-17	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.42	-0.42	3e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2625529	0.689	rs8178	chr15:72114747	G/A	cg16672083	chr15:72433130	SENP8	-0.59	-10.23	-0.45	4.18e-22	Red blood cell count;
LUAD	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg03929089	chr4:120376271	NA	-0.92	-17.34	-0.64	2.99e-51	Height;
LUAD	cis	rs9400271	0.632	rs6899616	chr6:109584885	A/G	cg01475377	chr6:109611718	NA	-0.36	-6.38	-0.3	4.56e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg17264618	chr3:40429014	ENTPD3	0.39	8.68	0.39	8.62e-17	Renal cell carcinoma;
LUAD	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg26384229	chr12:38710491	ALG10B	0.43	7.35	0.34	1.01e-12	Morning vs. evening chronotype;
LUAD	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg13699009	chr12:122356056	WDR66	0.3	6.52	0.3	1.99e-10	Mean corpuscular volume;
LUAD	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg26513180	chr16:89883248	FANCA	0.78	6.97	0.32	1.2e-11	Skin colour saturation;
LUAD	cis	rs9341808	0.500	rs2322629	chr6:80811540	C/T	cg08355045	chr6:80787529	NA	0.55	9.66	0.43	4.36e-20	Sitting height ratio;
LUAD	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg02450064	chr17:40260053	DHX58	-0.44	-7.43	-0.34	5.95e-13	Fibrinogen levels;
LUAD	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg05805236	chr11:65401703	PCNXL3	0.53	8.52	0.38	2.91e-16	Acne (severe);
LUAD	cis	rs2242073	0.598	rs62192820	chr2:208967597	T/C	cg24664470	chr2:208976933	NA	0.48	6.63	0.31	1.05e-10	Attention deficit hyperactivity disorder;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02984193	chr15:91260561	BLM	-0.56	-6.67	-0.31	8.07e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11958404	1.000	rs56175756	chr5:157391080	T/C	cg05962755	chr5:157440814	NA	0.57	7.69	0.35	1.07e-13	IgG glycosylation;
LUAD	cis	rs73198271	0.694	rs114184516	chr8:8647082	A/G	cg01851573	chr8:8652454	MFHAS1	0.48	8.49	0.38	3.53e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6076065	0.723	rs2275787	chr20:23338486	A/G	cg11657817	chr20:23433608	CST11	0.49	9.08	0.4	4.04e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg06784218	chr1:46089804	CCDC17	-0.55	-11.94	-0.5	1.67e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg18490616	chr2:88469792	THNSL2	-0.41	-6.43	-0.3	3.41e-10	Response to metformin (IC50);
LUAD	trans	rs3857536	0.813	rs2188589	chr6:66939570	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15369054	chr17:80825471	TBCD	0.66	11.04	0.47	4.6e-25	Breast cancer;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg10130446	chr14:55658398	DLGAP5	-0.47	-6.41	-0.3	3.83e-10	Testicular germ cell tumor;
LUAD	cis	rs654950	1.000	rs654950	chr1:41987868	G/C	cg06885757	chr1:42089581	HIVEP3	-0.45	-9.84	-0.43	1.06e-20	Airway imaging phenotypes;
LUAD	cis	rs354225	0.544	rs10205410	chr2:54799599	G/T	cg01766943	chr2:54829624	SPTBN1	0.37	6.74	0.31	5.25e-11	Schizophrenia;
LUAD	cis	rs10864907	0.614	rs7557537	chr2:113702530	T/C	cg12858261	chr2:113808755	IL1F8	0.39	7.17	0.33	3.27e-12	Pulmonary function;
LUAD	trans	rs1728785	1.000	rs821167	chr16:68577222	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.72	10.7	0.46	8.43e-24	Ulcerative colitis;
LUAD	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg03037974	chr15:76606532	NA	0.33	6.9	0.32	1.95e-11	Blood metabolite levels;
LUAD	cis	rs782590	0.607	rs2061032	chr2:55679490	T/C	cg18811423	chr2:55921094	PNPT1	0.43	6.77	0.31	4.36e-11	Metabolic syndrome;
LUAD	trans	rs1728785	1.000	rs11075680	chr16:68565700	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.78	0.43	1.69e-20	Ulcerative colitis;
LUAD	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg18105134	chr13:113819100	PROZ	-1.05	-19.41	-0.69	1.83e-60	Platelet distribution width;
LUAD	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg25767906	chr1:53392781	SCP2	-0.6	-11.25	-0.48	7.56e-26	Monocyte count;
LUAD	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg09796270	chr17:17721594	SREBF1	-0.39	-7.71	-0.35	9.27e-14	Total body bone mineral density;
LUAD	cis	rs28595532	1.000	rs115004746	chr4:119642137	C/T	cg21605333	chr4:119757512	SEC24D	0.87	8.03	0.36	1.01e-14	Cannabis dependence symptom count;
LUAD	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg25535316	chr11:579198	PHRF1	-0.38	-6.67	-0.31	7.81e-11	Systemic lupus erythematosus;
LUAD	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg17158414	chr2:27665306	KRTCAP3	0.33	8.83	0.39	2.73e-17	Total body bone mineral density;
LUAD	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg06108461	chr20:60628389	TAF4	-0.81	-13.67	-0.55	1.68e-35	Body mass index;
LUAD	cis	rs6076065	0.723	rs4815203	chr20:23395633	C/G	cg11657817	chr20:23433608	CST11	0.46	8.59	0.39	1.65e-16	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs10992471	0.627	rs4744138	chr9:95291909	A/G	cg14631576	chr9:95140430	CENPP	-0.5	-9.67	-0.43	4.01e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs1692580	0.682	rs12045693	chr1:2205581	A/C	cg24578937	chr1:2090814	PRKCZ	-0.5	-9.98	-0.44	3.35e-21	Coronary artery disease;
LUAD	cis	rs796364	0.616	rs2689762	chr2:200687204	G/T	cg23649088	chr2:200775458	C2orf69	0.52	6.5	0.3	2.33e-10	Schizophrenia;
LUAD	cis	rs68170813	0.617	rs117884147	chr7:107177593	T/C	cg23024343	chr7:107201750	COG5	0.53	6.68	0.31	7.62e-11	Coronary artery disease;
LUAD	cis	rs10100465	0.961	rs2202793	chr8:118633557	C/T	cg09430518	chr8:118662568	NA	-0.33	-6.66	-0.31	8.54e-11	Leprosy;
LUAD	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg21775007	chr8:11205619	TDH	0.53	9.61	0.42	6.82e-20	Retinal vascular caliber;
LUAD	cis	rs953387	1.000	rs4954566	chr2:136901513	A/G	cg05194412	chr2:137003533	NA	0.41	6.83	0.32	3.01e-11	Arthritis (juvenile idiopathic);
LUAD	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg23649088	chr2:200775458	C2orf69	-0.62	-7.79	-0.35	5.38e-14	Schizophrenia;
LUAD	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg11915388	chr22:42470451	FAM109B	0.39	6.93	0.32	1.59e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg07978099	chr16:83986941	OSGIN1	-0.48	-6.74	-0.31	5.34e-11	Pursuit maintenance gain;
LUAD	cis	rs758324	0.947	rs10052255	chr5:131173106	C/T	cg06307176	chr5:131281290	NA	0.5	7.86	0.36	3.17e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.55	-0.3	1.71e-10	Total cholesterol levels;
LUAD	cis	rs1018836	0.923	rs7837230	chr8:91574281	C/T	cg16814680	chr8:91681699	NA	-0.73	-12.52	-0.52	8.4e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg13560548	chr3:10150139	C3orf24	0.46	7.49	0.34	3.98e-13	Alzheimer's disease;
LUAD	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg05082376	chr22:42548792	NA	-0.44	-7.68	-0.35	1.08e-13	Schizophrenia;
LUAD	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.04	0.36	8.83e-15	Rheumatoid arthritis;
LUAD	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg09455208	chr3:40491958	NA	-0.59	-13.05	-0.54	5.91e-33	Renal cell carcinoma;
LUAD	cis	rs6690583	0.623	rs6679539	chr1:85479457	G/T	cg22153463	chr1:85462885	MCOLN2	-0.6	-7.14	-0.33	4.17e-12	Serum sulfate level;
LUAD	cis	rs1113500	0.933	rs10881498	chr1:108634984	C/A	cg06207961	chr1:108661230	NA	0.45	8.39	0.38	7.25e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg11062466	chr8:58055876	NA	0.71	8.9	0.4	1.6e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg12863693	chr15:85201151	NMB	0.42	7.59	0.35	2.09e-13	Schizophrenia;
LUAD	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg05872129	chr22:39784769	NA	-0.82	-15.79	-0.61	1.76e-44	Intelligence (multi-trait analysis);
LUAD	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg20290983	chr6:43655470	MRPS18A	1.06	26.97	0.8	6.08e-94	IgG glycosylation;
LUAD	cis	rs7020830	0.867	rs56098516	chr9:37362220	A/G	cg14294708	chr9:37120828	ZCCHC7	0.88	17.82	0.65	2.14e-53	Schizophrenia;
LUAD	cis	rs7737355	1.000	rs12521320	chr5:130755920	A/G	cg06307176	chr5:131281290	NA	-0.51	-7.86	-0.36	3.16e-14	Life satisfaction;
LUAD	cis	rs2996428	0.561	rs2275833	chr1:3745721	C/T	cg17848003	chr1:3704513	LRRC47	0.48	9.81	0.43	1.38e-20	Red cell distribution width;
LUAD	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg20607287	chr7:12443886	VWDE	-0.54	-6.83	-0.32	2.97e-11	Coronary artery disease;
LUAD	cis	rs9875589	0.509	rs1601868	chr3:14065450	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	6.55	0.3	1.66e-10	Ovarian reserve;
LUAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02353165	chr6:42928485	GNMT	0.4	7.15	0.33	3.92e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.81	0.35	4.6e-14	Depression;
LUAD	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg09365446	chr1:150670422	GOLPH3L	0.63	11.12	0.48	2.34e-25	Melanoma;
LUAD	cis	rs7809950	0.954	rs2520247	chr7:107143946	A/T	cg23024343	chr7:107201750	COG5	-0.73	-12.47	-0.52	1.27e-30	Coronary artery disease;
LUAD	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg26168224	chr5:2018326	NA	0.79	18.04	0.66	2.2e-54	Gut microbiome composition (winter);
LUAD	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.13	-0.37	4.83e-15	Resting heart rate;
LUAD	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg03445287	chr8:21823731	XPO7	0.43	7.81	0.36	4.49e-14	Lung cancer in ever smokers;
LUAD	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg26597838	chr10:835615	NA	1.06	16.86	0.63	3.87e-49	Eosinophil percentage of granulocytes;
LUAD	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg08885076	chr2:99613938	TSGA10	0.4	7.56	0.34	2.61e-13	Chronic sinus infection;
LUAD	cis	rs13064411	0.542	rs1463643	chr3:113215447	A/G	cg10517650	chr3:113235015	CCDC52	-0.45	-8.25	-0.37	2.01e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg08645402	chr16:4508243	NA	0.52	9.78	0.43	1.69e-20	Schizophrenia;
LUAD	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg26513180	chr16:89883248	FANCA	0.78	6.74	0.31	5.14e-11	Skin colour saturation;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21878890	chr14:75725895	NA	-0.37	-6.52	-0.3	2.05e-10	Cancer;
LUAD	cis	rs2387326	0.629	rs12261739	chr10:129945520	A/G	cg16087940	chr10:129947807	NA	-0.64	-9.14	-0.41	2.69e-18	Select biomarker traits;
LUAD	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg08219700	chr8:58056026	NA	0.49	7.05	0.32	7.17e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg03395511	chr6:291903	DUSP22	0.72	12.45	0.52	1.53e-30	Menopause (age at onset);
LUAD	cis	rs17490626	0.568	rs12413529	chr10:71211644	G/T	cg12610070	chr10:71211762	TSPAN15	-0.41	-10.97	-0.47	8.59e-25	Thrombosis;
LUAD	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg12927641	chr6:109611667	NA	-0.47	-7.91	-0.36	2.27e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs9837602	0.938	rs1021341	chr3:99786289	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.55	8.44	0.38	5.12e-16	Breast cancer;
LUAD	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg27572855	chr1:25598939	RHD	0.56	12.67	0.52	2.02e-31	Erythrocyte sedimentation rate;
LUAD	cis	rs9837602	1.000	rs1038294	chr3:99503728	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.49	0.34	3.94e-13	Breast cancer;
LUAD	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg14196790	chr5:131705035	SLC22A5	0.37	6.55	0.3	1.69e-10	Blood metabolite levels;
LUAD	cis	rs6785206	0.803	rs2712380	chr3:128338661	A/C	cg16766828	chr3:128327626	NA	-0.84	-9.53	-0.42	1.25e-19	Lymphocyte percentage of white cells;
LUAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08219700	chr8:58056026	NA	0.61	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg17063962	chr7:91808500	NA	0.68	12.36	0.52	3.55e-30	Breast cancer;
LUAD	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg00701064	chr4:6280414	WFS1	-0.68	-15.01	-0.59	3.93e-41	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs8067545	0.720	rs6587206	chr17:19881587	T/C	cg04132472	chr17:19861366	AKAP10	0.36	8.41	0.38	6.31e-16	Schizophrenia;
LUAD	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg08916839	chr5:415575	AHRR	0.84	10.15	0.44	8.43e-22	Fat distribution (HIV);
LUAD	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.4	6.82	0.31	3.1e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9902453	1.000	rs62070270	chr17:28263980	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.57	0.42	8.85e-20	Coffee consumption (cups per day);
LUAD	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg05313129	chr8:58192883	C8orf71	-0.57	-8.39	-0.38	7.53e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7582720	0.943	rs72934762	chr2:203756677	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg06784218	chr1:46089804	CCDC17	0.6	13.37	0.55	2.89e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9972944	0.729	rs10083877	chr17:63773623	T/C	cg07283582	chr17:63770753	CCDC46	0.46	10.03	0.44	2.28e-21	Total body bone mineral density;
LUAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08280861	chr8:58055591	NA	0.54	6.91	0.32	1.81e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12541635	0.677	rs10808408	chr8:107005034	C/T	cg10147462	chr8:107024639	NA	0.52	9.38	0.42	3.91e-19	Age of smoking initiation;
LUAD	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg12193833	chr17:30244370	NA	-0.55	-7.14	-0.33	4.2e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg05110241	chr16:68378359	PRMT7	-0.68	-7.67	-0.35	1.23e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg08859206	chr1:53392774	SCP2	-0.6	-10.72	-0.46	7.06e-24	Monocyte count;
LUAD	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg13180566	chr4:1052158	NA	-0.38	-6.54	-0.3	1.75e-10	Recombination rate (females);
LUAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19626725	chr5:178986131	RUFY1	-0.53	-10.19	-0.44	5.89e-22	Lung cancer;
LUAD	cis	rs7010267	0.642	rs11992136	chr8:120003727	C/G	cg01975934	chr8:119970761	NA	-0.35	-6.8	-0.31	3.57e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg19912559	chr1:40204330	PPIE	0.57	9.86	0.43	8.78e-21	Blood protein levels;
LUAD	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg21782813	chr7:2030301	MAD1L1	0.52	8.98	0.4	9.17e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg25985355	chr7:65971099	NA	-0.39	-7.14	-0.33	4.11e-12	Aortic root size;
LUAD	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg25237894	chr2:233734115	C2orf82	-0.59	-11.8	-0.5	5.71e-28	Coronary artery disease;
LUAD	cis	rs7216064	0.773	rs74541577	chr17:65853651	C/T	cg08758996	chr17:66097529	LOC651250	0.47	7.14	0.33	4.13e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg27284194	chr4:1044797	NA	0.71	10.27	0.45	2.96e-22	Recombination rate (females);
LUAD	cis	rs2692947	0.860	rs2579520	chr2:96660300	C/T	cg23100626	chr2:96804247	ASTL	-0.29	-7.65	-0.35	1.4e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.28	-0.48	5.6e-26	Primary sclerosing cholangitis;
LUAD	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg24733560	chr20:60626293	TAF4	-0.42	-8.43	-0.38	5.58e-16	Body mass index;
LUAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg23978390	chr7:1156363	C7orf50	0.58	9.23	0.41	1.27e-18	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg20607798	chr8:58055168	NA	0.67	8.77	0.39	4.44e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1823874	0.720	rs1993296	chr15:100363588	T/A	cg16400843	chr15:100339927	C15orf51	0.3	7.03	0.32	8.08e-12	IgG glycosylation;
LUAD	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg15445000	chr17:37608096	MED1	-0.45	-8.38	-0.38	8.03e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs10465746	0.967	rs942849	chr1:84427499	G/A	cg10977910	chr1:84465055	TTLL7	0.5	8.07	0.37	7.53e-15	Obesity-related traits;
LUAD	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg25985355	chr7:65971099	NA	-0.35	-6.41	-0.3	3.95e-10	Aortic root size;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg11028409	chr10:104192462	CUEDC2	0.42	6.86	0.32	2.48e-11	Bipolar disorder;
LUAD	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-8.32	-0.38	1.22e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.64	-8.98	-0.4	8.99e-18	IgG glycosylation;
LUAD	cis	rs9811920	0.603	rs2638948	chr3:99501539	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.55	-10.33	-0.45	1.94e-22	Axial length;
LUAD	cis	rs7937890	0.559	rs2597187	chr11:14517019	C/G	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.12e-10	Mitochondrial DNA levels;
LUAD	cis	rs11167764	0.895	rs6882824	chr5:141474300	A/G	cg08523384	chr5:141488047	NDFIP1	-0.48	-7.14	-0.33	4.06e-12	Crohn's disease;
LUAD	cis	rs6840360	0.593	rs59350867	chr4:152695935	G/A	cg22705602	chr4:152727874	NA	-0.48	-9.24	-0.41	1.25e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg09835421	chr16:68378352	PRMT7	-0.72	-8.15	-0.37	4.25e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2742417	0.603	rs2064064	chr3:45759995	C/T	cg10512202	chr3:45649293	LIMD1	0.48	8.89	0.4	1.84e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg10356904	chr22:49881777	NA	-0.35	-7.47	-0.34	4.78e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7524258	0.900	rs7544004	chr1:7314529	A/C	cg07173049	chr1:7289937	CAMTA1	0.39	7.04	0.32	7.84e-12	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs2637266	0.756	rs7079818	chr10:78469935	T/A	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.7e-11	Pulmonary function;
LUAD	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg04282206	chr17:62833786	PLEKHM1P	0.41	6.94	0.32	1.52e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9462027	0.628	rs9689820	chr6:34752963	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.91	-0.4	1.57e-17	Systemic lupus erythematosus;
LUAD	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg06784218	chr1:46089804	CCDC17	0.57	12.94	0.53	1.61e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs877282	1.000	rs12763443	chr10:771941	G/A	cg17470449	chr10:769945	NA	0.68	9.93	0.43	4.86e-21	Uric acid levels;
LUAD	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg09365446	chr1:150670422	GOLPH3L	0.65	12.11	0.51	3.3600000000000003e-29	Tonsillectomy;
LUAD	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg22532475	chr10:104410764	TRIM8	-0.44	-8.56	-0.38	2.09e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg06064525	chr11:970664	AP2A2	-0.55	-11.28	-0.48	5.65e-26	Alzheimer's disease (late onset);
LUAD	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg03433033	chr1:76189801	ACADM	-0.47	-6.99	-0.32	1.09e-11	Daytime sleep phenotypes;
LUAD	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg13385794	chr1:248469461	NA	0.24	6.81	0.31	3.4e-11	Common traits (Other);
LUAD	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg12935359	chr14:103987150	CKB	0.5	7.76	0.35	6.56e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs72781680	1.000	rs55773155	chr2:24255081	A/G	cg20701182	chr2:24300061	SF3B14	0.68	7.33	0.34	1.18e-12	Lymphocyte counts;
LUAD	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg17178900	chr1:205818956	PM20D1	0.65	12.98	0.53	1.12e-32	Monocyte percentage of white cells;
LUAD	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg04455712	chr21:45112962	RRP1B	0.42	8.68	0.39	8.8e-17	Mean corpuscular volume;
LUAD	cis	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg12623302	chr6:28058802	ZSCAN12L1	0.37	6.38	0.3	4.65e-10	Depression;
LUAD	cis	rs2692947	0.763	rs7570074	chr2:96407037	T/C	cg23100626	chr2:96804247	ASTL	0.31	7.72	0.35	8.74e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg05082376	chr22:42548792	NA	0.45	7.86	0.36	3.18e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12210905	0.841	rs72839470	chr6:27309304	T/A	cg08851530	chr6:28072375	NA	0.79	6.39	0.3	4.34e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.44	-0.49	1.38e-26	Primary sclerosing cholangitis;
LUAD	cis	rs62238980	0.614	rs733908	chr22:32462505	C/T	cg00543991	chr22:32367038	NA	0.9	8.54	0.38	2.48e-16	Childhood ear infection;
LUAD	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg03929089	chr4:120376271	NA	-0.9	-17.26	-0.64	6.32e-51	Coronary artery disease;
LUAD	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg04287289	chr16:89883240	FANCA	0.77	6.77	0.31	4.21e-11	Skin colour saturation;
LUAD	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg11247378	chr22:39784982	NA	-0.65	-10.35	-0.45	1.61e-22	Post bronchodilator FEV1;
LUAD	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg10523679	chr1:76189770	ACADM	-0.9	-16.08	-0.62	9.3e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06544989	chr22:39130855	UNC84B	0.4	8.19	0.37	3.03e-15	Menopause (age at onset);
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg06589161	chr5:180618230	NA	-0.44	-6.97	-0.32	1.24e-11	Vertical cup-disc ratio;
LUAD	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg26597838	chr10:835615	NA	-0.83	-12.57	-0.52	5.04e-31	Eosinophil percentage of granulocytes;
LUAD	cis	rs68170813	0.652	rs76924513	chr7:107205887	T/C	cg23024343	chr7:107201750	COG5	0.52	6.62	0.31	1.11e-10	Coronary artery disease;
LUAD	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg09117114	chr16:67998030	SLC12A4	-0.48	-6.82	-0.31	3.06e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7818345	1.000	rs11204041	chr8:19291371	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.3	6.76	0.31	4.59e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs9341808	0.754	rs3805885	chr6:80996751	C/G	cg08355045	chr6:80787529	NA	-0.5	-9.01	-0.4	7.05e-18	Sitting height ratio;
LUAD	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg20469991	chr17:27169893	C17orf63	-0.52	-6.55	-0.3	1.63e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs13064411	0.735	rs6438158	chr3:113217290	C/T	cg18753928	chr3:113234510	CCDC52	-0.73	-12.43	-0.52	1.82e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03719694	chr4:146403972	SMAD1	-0.4	-6.38	-0.3	4.68e-10	Cancer;
LUAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.7	10.6	0.46	1.93e-23	Renal function-related traits (BUN);
LUAD	cis	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05901451	chr6:126070800	HEY2	0.44	6.39	0.3	4.45e-10	Endometrial cancer;
LUAD	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg09365446	chr1:150670422	GOLPH3L	0.67	12.75	0.53	9.77e-32	Tonsillectomy;
LUAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg08888203	chr3:10149979	C3orf24	0.74	13.07	0.54	5.1e-33	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.15e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg23978390	chr7:1156363	C7orf50	0.42	6.46	0.3	2.9e-10	Longevity;Endometriosis;
LUAD	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg04450456	chr4:17643702	FAM184B	0.43	8.45	0.38	4.86e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7202877	0.706	rs4888393	chr16:75413673	C/T	cg03315344	chr16:75512273	CHST6	0.48	6.52	0.3	2.04e-10	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs28735056	0.591	rs62101204	chr18:77712832	G/A	cg20368463	chr18:77673604	PQLC1	0.46	7.69	0.35	1.04e-13	Schizophrenia;
LUAD	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg02743256	chr7:2109353	MAD1L1	-0.46	-6.59	-0.31	1.32e-10	Neuroticism;
LUAD	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.39	-6.53	-0.3	1.86e-10	Platelet count;
LUAD	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.58	-0.35	2.17e-13	Lung cancer;
LUAD	cis	rs6840360	0.533	rs13119490	chr4:152713412	A/G	cg22705602	chr4:152727874	NA	0.46	8.91	0.4	1.55e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.34	-6.44	-0.3	3.2e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg25894440	chr7:65020034	NA	0.64	6.92	0.32	1.65e-11	Diabetic kidney disease;
LUAD	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg11941060	chr3:133502564	NA	-0.44	-7.35	-0.34	1.06e-12	Iron status biomarkers;
LUAD	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-12.8	-0.53	6.09e-32	Breast cancer;
LUAD	cis	rs870825	0.860	rs2696052	chr4:185604356	G/A	cg04058563	chr4:185651563	MLF1IP	-0.69	-10.04	-0.44	2.04e-21	Blood protein levels;
LUAD	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.65	0.31	8.98e-11	Menarche (age at onset);
LUAD	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg26513180	chr16:89883248	FANCA	0.72	13.82	0.56	4.06e-36	Vitiligo;
LUAD	cis	rs9814567	0.752	rs1534030	chr3:134330083	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg26924012	chr15:45694286	SPATA5L1	0.59	9.92	0.43	5.29e-21	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg26769984	chr7:1090371	C7orf50	0.66	10.55	0.46	2.83e-23	Bronchopulmonary dysplasia;
LUAD	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg22676075	chr6:135203613	NA	0.4	7.32	0.34	1.25e-12	Red blood cell count;
LUAD	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg12310025	chr6:25882481	NA	-0.51	-7.55	-0.34	2.7e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.85	0.4	2.46e-17	Menopause (age at onset);
LUAD	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.92	-0.53	2.07e-32	Dilated cardiomyopathy;
LUAD	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg05082376	chr22:42548792	NA	-0.41	-6.92	-0.32	1.67e-11	Schizophrenia;
LUAD	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg09658497	chr7:2847517	GNA12	-0.54	-9.3	-0.41	7.45e-19	Height;
LUAD	cis	rs859767	0.741	rs10803548	chr2:135396738	C/A	cg12500956	chr2:135428796	TMEM163	-0.29	-7.8	-0.35	4.73e-14	Neuroticism;
LUAD	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg23254163	chr1:152506842	NA	0.28	7.8	0.35	4.98e-14	Hair morphology;
LUAD	cis	rs6961069	0.742	rs1722502	chr7:80241874	A/C	cg04458919	chr7:80252533	CD36	-0.36	-6.85	-0.32	2.59e-11	Platelet count;
LUAD	cis	rs9715521	0.900	rs7440797	chr4:59809260	C/T	cg11281224	chr4:60001000	NA	0.44	7.36	0.34	9.38e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg01528321	chr10:82214614	TSPAN14	0.67	10.24	0.45	3.9e-22	Post bronchodilator FEV1;
LUAD	cis	rs2235649	0.592	rs11647980	chr16:1959753	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-7.01	-0.32	9.71e-12	Blood metabolite levels;
LUAD	cis	rs1915146	0.656	rs10794201	chr10:126846531	C/T	cg23000734	chr10:126850823	CTBP2	0.52	9.84	0.43	1.06e-20	Menarche (age at onset);
LUAD	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg12035532	chr1:1886765	KIAA1751	0.41	6.96	0.32	1.33e-11	Body mass index;
LUAD	cis	rs7607369	0.719	rs12613545	chr2:219623504	C/T	cg02176678	chr2:219576539	TTLL4	-0.59	-12.07	-0.51	4.76e-29	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs8017423	1.000	rs8011810	chr14:90685669	A/G	cg14092571	chr14:90743983	NA	-0.48	-8.55	-0.38	2.28e-16	Mortality in heart failure;
LUAD	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg03806693	chr22:41940476	POLR3H	0.74	10.04	0.44	1.97e-21	Cannabis dependence symptom count;
LUAD	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.58	9.71	0.43	3.01e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs7107174	0.892	rs2512534	chr11:77970039	T/A	cg02023728	chr11:77925099	USP35	0.54	8.26	0.37	1.84e-15	Testicular germ cell tumor;
LUAD	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg19413350	chr8:57351067	NA	-0.4	-6.52	-0.3	1.95e-10	Obesity-related traits;
LUAD	cis	rs12208915	0.848	rs955765	chr6:79532610	C/T	cg05283184	chr6:79620031	NA	0.5	7.0	0.32	9.85e-12	Left atrial antero-posterior diameter;
LUAD	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg03396347	chr1:1875803	NA	0.31	6.67	0.31	8.12e-11	Body mass index;
LUAD	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.3	0.33	1.43e-12	Bladder cancer;
LUAD	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg23422044	chr7:1970798	MAD1L1	-0.58	-7.24	-0.33	2.15e-12	Bipolar disorder;
LUAD	cis	rs7072216	0.770	rs7909131	chr10:100171471	A/G	cg26618903	chr10:100175079	PYROXD2	-0.35	-7.74	-0.35	7.14e-14	Metabolite levels;
LUAD	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg08755490	chr11:65554678	OVOL1	0.47	7.07	0.32	6.54e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUAD	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg22532475	chr10:104410764	TRIM8	-0.42	-7.96	-0.36	1.6e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg14917512	chr19:3094685	GNA11	-0.37	-6.37	-0.3	4.98e-10	Aortic root size;
LUAD	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg23283495	chr1:209979779	IRF6	0.41	7.32	0.34	1.27e-12	Monobrow;
LUAD	cis	rs7089973	0.872	rs3180654	chr10:116615045	T/C	cg25233709	chr10:116636983	FAM160B1	0.39	7.7	0.35	9.75e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg24675056	chr1:15929824	NA	0.47	8.27	0.37	1.69e-15	Systolic blood pressure;
LUAD	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.58	0.42	8.17e-20	Cognitive ability;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13077517	chr20:2082435	STK35	-0.55	-6.54	-0.3	1.73e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9796	0.870	rs2927061	chr15:41302219	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.39	-7.4	-0.34	7.39e-13	Menopause (age at onset);
LUAD	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.51	-0.38	3.02e-16	Alzheimer's disease (late onset);
LUAD	cis	rs1018836	0.570	rs6471084	chr8:91463666	T/C	cg16814680	chr8:91681699	NA	-0.55	-8.88	-0.4	1.88e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7614311	0.636	rs3733126	chr3:63988171	C/T	cg22134162	chr3:63841271	THOC7	-0.43	-7.76	-0.35	6.49e-14	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg24733560	chr20:60626293	TAF4	0.47	8.4	0.38	6.95e-16	Body mass index;
LUAD	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg25237894	chr2:233734115	C2orf82	0.61	11.39	0.48	2.12e-26	Coronary artery disease;
LUAD	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg02690316	chr19:47249517	FKRP;STRN4	-0.51	-6.71	-0.31	6.17e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg24733560	chr20:60626293	TAF4	0.47	8.4	0.38	6.71e-16	Body mass index;
LUAD	cis	rs17152411	0.947	rs733400	chr10:126594340	G/A	cg07906193	chr10:126599966	NA	0.53	7.6	0.35	1.95e-13	Height;
LUAD	cis	rs7137828	0.901	rs3184504	chr12:111884608	T/C	cg10833066	chr12:111807467	FAM109A	0.35	6.83	0.32	2.93e-11	Glaucoma (primary open-angle);Coronary artery disease;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-11.37	-0.48	2.58e-26	Schizophrenia;
LUAD	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg08508325	chr11:3079039	CARS	-0.59	-12.92	-0.53	2.09e-32	Longevity;
LUAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg18621852	chr3:10150065	C3orf24	0.42	7.46	0.34	5.08e-13	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs738322	0.775	rs4375	chr22:38539041	T/C	cg17652424	chr22:38574118	PLA2G6	-0.28	-8.17	-0.37	3.56e-15	Cutaneous nevi;
LUAD	cis	rs2686555	0.553	rs1616213	chr12:121077508	C/T	cg13504434	chr12:121088311	CABP1	0.4	6.57	0.3	1.46e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs8192282	0.739	rs12124333	chr1:154478292	T/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.31	-0.33	1.33e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg04025307	chr7:1156635	C7orf50	0.66	7.47	0.34	4.64e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7395662	1.000	rs4882136	chr11:48615311	T/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.48	-0.3	2.57e-10	HDL cholesterol;
LUAD	cis	rs778371	0.723	rs12999865	chr2:233627250	T/C	cg08000102	chr2:233561755	GIGYF2	0.41	6.71	0.31	6.08e-11	Schizophrenia;
LUAD	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg05283184	chr6:79620031	NA	-0.61	-12.26	-0.51	9.26e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	7.14	0.33	4.2e-12	Platelet count;
LUAD	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg25767906	chr1:53392781	SCP2	0.41	7.54	0.34	2.95e-13	Monocyte count;
LUAD	cis	rs790123	1.000	rs790115	chr3:122381117	C/T	cg15604389	chr3:122379662	NA	0.47	8.3	0.37	1.43e-15	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs1965732	0.588	rs11682334	chr2:3716780	G/T	cg00999904	chr2:3704751	ALLC	-0.36	-7.07	-0.32	6.6e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg17971929	chr21:40555470	PSMG1	0.53	8.2	0.37	2.92e-15	Cognitive function;
LUAD	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg20891558	chr2:74357851	NA	0.97	15.44	0.6	5.48e-43	Gestational age at birth (maternal effect);
LUAD	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg10518543	chr12:38710700	ALG10B	-0.43	-7.12	-0.33	4.73e-12	Bladder cancer;
LUAD	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg01475377	chr6:109611718	NA	-0.49	-8.83	-0.39	2.88e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs9434723	0.920	rs9434725	chr1:9293861	C/T	cg04199779	chr1:9294473	H6PD	0.67	7.56	0.34	2.59e-13	Height;
LUAD	trans	rs360929	0.816	rs171506	chr4:152903546	C/A	cg22822647	chr19:16771056	TMEM38A;C19orf42	-0.52	-6.52	-0.3	2.02e-10	Volumetric brain MRI;
LUAD	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26314531	chr2:26401878	FAM59B	0.69	8.76	0.39	4.63e-17	Gut microbiome composition (summer);
LUAD	cis	rs13315871	1.000	rs71311868	chr3:58392874	A/G	cg20936604	chr3:58311152	NA	-0.69	-6.88	-0.32	2.16e-11	Cholesterol, total;
LUAD	cis	rs7213347	0.707	rs216181	chr17:2172753	A/T	cg16513277	chr17:2031491	SMG6	0.44	6.38	0.3	4.74e-10	Total body bone mineral density;
LUAD	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	6.98	0.32	1.18e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg09323728	chr8:95962352	TP53INP1	-0.33	-7.19	-0.33	3.05e-12	Type 2 diabetes;
LUAD	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg09737314	chr17:6899359	ALOX12	0.39	7.49	0.34	4.16e-13	Tonsillectomy;
LUAD	cis	rs7572644	0.640	rs4555299	chr2:28071190	A/G	cg27432699	chr2:27873401	GPN1	0.42	6.45	0.3	3.07e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUAD	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg22535103	chr8:58192502	C8orf71	-0.57	-7.51	-0.34	3.45e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18876405	chr7:65276391	NA	-0.6	-10.1	-0.44	1.25e-21	Aortic root size;
LUAD	cis	rs56283067	0.847	rs1552196	chr6:44698265	A/G	cg18551225	chr6:44695536	NA	0.57	9.37	0.41	4.52e-19	Total body bone mineral density;
LUAD	cis	rs2880765	0.835	rs7180213	chr15:86021187	G/A	cg13263323	chr15:86062960	AKAP13	-0.5	-9.25	-0.41	1.12e-18	Coronary artery disease;
LUAD	trans	rs2735413	0.881	rs12923218	chr16:78080274	C/G	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg06610368	chr5:86564371	RASA1	0.44	6.95	0.32	1.41e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg09365446	chr1:150670422	GOLPH3L	0.55	9.62	0.42	6.27e-20	Melanoma;
LUAD	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg03161606	chr19:29218774	NA	0.62	8.75	0.39	5.04e-17	Methadone dose in opioid dependence;
LUAD	cis	rs6484504	0.625	rs10835766	chr11:31374329	C/A	cg26647111	chr11:31128758	NA	0.43	7.59	0.35	2.11e-13	Red blood cell count;
LUAD	cis	rs2046867	0.818	rs60228315	chr3:72805034	C/A	cg04365224	chr3:72788183	NA	-0.48	-7.07	-0.33	6.42e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg24562669	chr7:97807699	LMTK2	0.3	7.03	0.32	8.37e-12	Breast cancer;
LUAD	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg18944383	chr4:111397179	ENPEP	-0.38	-7.02	-0.32	8.99e-12	Coronary artery disease;
LUAD	cis	rs6688613	1.000	rs10918605	chr1:166955638	A/G	cg07049167	chr1:166818506	POGK	0.41	6.9	0.32	1.92e-11	Refractive astigmatism;
LUAD	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg09455208	chr3:40491958	NA	0.65	14.12	0.57	2.36e-37	Renal cell carcinoma;
LUAD	cis	rs12505328	0.966	rs13108546	chr4:174359827	C/A	cg12145043	chr4:174357286	NA	0.57	10.28	0.45	2.81e-22	Chin dimples;
LUAD	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg16405210	chr4:1374714	KIAA1530	0.6	9.16	0.41	2.27e-18	Longevity;
LUAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.29	0.37	1.55e-15	Alzheimer's disease;
LUAD	cis	rs7809615	0.901	rs10808111	chr7:99070884	T/A	cg03133378	chr7:99195931	NA	-0.58	-6.63	-0.31	1.04e-10	Blood metabolite ratios;
LUAD	cis	rs367943	0.723	rs1965429	chr5:112679373	G/T	cg12552261	chr5:112820674	MCC	-0.51	-9.96	-0.44	3.9e-21	Type 2 diabetes;
LUAD	cis	rs2882667	0.898	rs10079634	chr5:138413053	T/C	cg04439458	chr5:138467593	SIL1	-0.39	-7.25	-0.33	2.04e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg02807482	chr3:125708958	NA	-0.55	-6.36	-0.3	5.12e-10	Blood pressure (smoking interaction);
LUAD	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg08508325	chr11:3079039	CARS	-0.58	-12.41	-0.52	2.25e-30	Longevity;
LUAD	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg22117172	chr7:91764530	CYP51A1	-0.36	-8.13	-0.37	4.69e-15	Breast cancer;
LUAD	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg27661571	chr11:113659931	NA	-0.55	-6.77	-0.31	4.42e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs3857067	0.806	rs12505596	chr4:95109600	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.36	-6.35	-0.3	5.46e-10	QT interval;
LUAD	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg14458575	chr2:238380390	NA	0.65	12.22	0.51	1.24e-29	Prostate cancer;
LUAD	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06112835	chr11:68658793	MRPL21	0.53	10.0	0.44	2.87e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs6561151	0.957	rs3764147	chr13:44457925	C/T	cg17145862	chr1:211918768	LPGAT1	-0.52	-8.64	-0.39	1.2e-16	Crohn's disease;
LUAD	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg23758822	chr17:41437982	NA	0.93	19.09	0.68	4.56e-59	Menopause (age at onset);
LUAD	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg02951883	chr7:2050386	MAD1L1	-0.71	-12.05	-0.51	5.81e-29	Bipolar disorder and schizophrenia;
LUAD	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg18129748	chr3:49941408	MST1R	0.42	7.04	0.32	8.06e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg12573674	chr2:1569213	NA	-0.61	-7.87	-0.36	3.09e-14	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg00310523	chr12:86230176	RASSF9	0.38	7.81	0.35	4.7e-14	Major depressive disorder;
LUAD	cis	rs9341808	0.718	rs9448898	chr6:80845341	T/A	cg08355045	chr6:80787529	NA	0.55	9.81	0.43	1.31e-20	Sitting height ratio;
LUAD	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg01475377	chr6:109611718	NA	-0.5	-9.42	-0.42	2.86e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs113835537	0.529	rs79798028	chr11:66199362	T/G	cg24851651	chr11:66362959	CCS	0.58	10.46	0.45	6.1e-23	Airway imaging phenotypes;
LUAD	cis	rs2425143	1.000	rs7261284	chr20:34244104	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.18	-0.33	3.07e-12	Blood protein levels;
LUAD	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg08085267	chr17:45401833	C17orf57	0.57	10.1	0.44	1.27e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs77741769	0.549	rs57697145	chr12:121333552	T/G	cg02419362	chr12:121203948	SPPL3	0.41	8.27	0.37	1.71e-15	Mean corpuscular volume;
LUAD	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg02527881	chr3:46936655	PTH1R	0.43	8.33	0.38	1.17e-15	Colorectal cancer;
LUAD	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	10.45	0.45	6.55e-23	Electrocardiographic conduction measures;
LUAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.71	0.39	6.72e-17	Menopause (age at onset);
LUAD	cis	rs9581857	0.579	rs79904593	chr13:27996893	G/A	cg22138327	chr13:27999177	GTF3A	0.97	11.14	0.48	1.92e-25	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05279707	chr20:49547986	ADNP	-0.42	-7.03	-0.32	8.39e-12	Cancer;
LUAD	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg19767477	chr5:127420684	SLC12A2	-0.42	-6.44	-0.3	3.27e-10	Ileal carcinoids;
LUAD	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg21475434	chr5:93447410	FAM172A	0.57	7.22	0.33	2.41e-12	Diabetic retinopathy;
LUAD	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg10167378	chr1:228756711	NA	0.67	9.07	0.4	4.47e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg24579218	chr15:68104479	NA	0.37	6.76	0.31	4.61e-11	Restless legs syndrome;
LUAD	cis	rs41311933	1.000	rs12683026	chr9:123758632	A/G	cg13567360	chr9:123745713	C5	-0.81	-9.09	-0.4	3.93e-18	Coronary artery disease;
LUAD	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-8.03	-0.36	9.54e-15	Total body bone mineral density;
LUAD	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.3	-0.33	1.43e-12	Electroencephalogram traits;
LUAD	cis	rs57920188	0.584	rs57277002	chr1:4092054	T/G	cg10510935	chr1:4059661	NA	0.46	7.03	0.32	8.6e-12	Interleukin-17 levels;
LUAD	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg11292332	chr7:45801988	SEPT13	-0.31	-6.93	-0.32	1.55e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs924607	0.583	rs12516251	chr5:608939	C/T	cg08291854	chr5:608798	NA	-0.31	-6.46	-0.3	2.92e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg22117172	chr7:91764530	CYP51A1	-0.34	-7.59	-0.35	2.1e-13	Breast cancer;
LUAD	cis	rs751837	0.518	rs17101146	chr14:103463599	A/G	cg10087771	chr14:103399429	CDC42BPB	-0.54	-6.9	-0.32	1.92e-11	Large B-cell lymphoma;
LUAD	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg16414030	chr3:133502952	NA	-0.37	-6.72	-0.31	5.97e-11	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg17279839	chr7:150038598	RARRES2	0.42	7.16	0.33	3.49e-12	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs587242	0.866	rs12037267	chr1:96904093	C/T	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs2012796	0.665	rs72703728	chr14:81834523	G/A	cg02996355	chr14:81879375	NA	0.53	8.01	0.36	1.09e-14	Night sleep phenotypes;
LUAD	cis	rs2249625	0.761	rs2496500	chr6:72884438	G/C	cg18830697	chr6:72922368	RIMS1	-0.35	-6.66	-0.31	8.28e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs240764	0.658	rs9322213	chr6:101248480	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-7.56	-0.34	2.55e-13	Neuroticism;
LUAD	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg01579765	chr21:45077557	HSF2BP	-0.57	-12.86	-0.53	3.64e-32	Mean corpuscular volume;
LUAD	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-9.16	-0.41	2.26e-18	Life satisfaction;
LUAD	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg02423579	chr7:2872169	GNA12	-0.87	-15.18	-0.59	7.4e-42	Height;
LUAD	cis	rs7084921	0.608	rs12779818	chr10:101866118	G/A	cg19754520	chr10:101825118	CPN1	-0.32	-6.45	-0.3	3.11e-10	Bone mineral density;
LUAD	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg12927641	chr6:109611667	NA	-0.52	-9.23	-0.41	1.28e-18	Reticulocyte fraction of red cells;
LUAD	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg21548813	chr6:291882	DUSP22	-0.54	-8.85	-0.4	2.42e-17	Menopause (age at onset);
LUAD	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg09455208	chr3:40491958	NA	0.58	12.35	0.51	3.87e-30	Renal cell carcinoma;
LUAD	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.42	6.98	0.32	1.17e-11	Type 2 diabetes;
LUAD	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg06532163	chr17:45867833	NA	0.47	8.39	0.38	7.42e-16	IgG glycosylation;
LUAD	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.36	0.34	9.98e-13	Tonsillectomy;
LUAD	cis	rs10489202	1.000	rs718885	chr1:167954659	A/G	cg24449463	chr1:168025552	DCAF6	-0.55	-7.16	-0.33	3.54e-12	Schizophrenia;
LUAD	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg05340658	chr4:99064831	C4orf37	0.53	9.0	0.4	7.9e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.7	-13.65	-0.55	2.09e-35	Prudent dietary pattern;
LUAD	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg20744362	chr22:50050164	C22orf34	0.35	6.42	0.3	3.68e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg05084668	chr3:125655381	ALG1L	0.65	10.88	0.47	1.78e-24	Blood pressure (smoking interaction);
LUAD	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg24675056	chr1:15929824	NA	0.49	8.48	0.38	3.92e-16	Systolic blood pressure;
LUAD	cis	rs10908458	0.808	rs10908456	chr1:155086148	A/G	cg23973274	chr1:155060172	NA	0.46	8.08	0.37	6.65e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs733592	0.599	rs12819124	chr12:48409054	G/T	cg04545296	chr12:48745243	ZNF641	0.26	6.91	0.32	1.84e-11	Plateletcrit;
LUAD	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg17200465	chr3:40428508	ENTPD3	0.26	6.47	0.3	2.66e-10	Renal cell carcinoma;
LUAD	trans	rs28595532	0.557	rs12498329	chr4:119311524	C/T	cg26518628	chr1:97050305	NA	-0.48	-6.48	-0.3	2.49e-10	Cannabis dependence symptom count;
LUAD	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22590775	chr19:49891494	CCDC155	0.61	9.95	0.44	4.34e-21	Multiple sclerosis;
LUAD	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg08645402	chr16:4508243	NA	0.56	9.41	0.42	3.18e-19	Schizophrenia;
LUAD	cis	rs2357013	0.809	rs6746354	chr2:53237889	C/T	cg07782112	chr2:53107842	NA	-0.34	-6.76	-0.31	4.67e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg07677032	chr17:61819896	STRADA	0.57	10.4	0.45	1.04e-22	Prudent dietary pattern;
LUAD	cis	rs4774899	0.752	rs2920264	chr15:57321065	T/C	cg14026238	chr15:57616123	NA	-0.42	-7.94	-0.36	1.79e-14	Urinary tract infection frequency;
LUAD	cis	rs11771526	0.901	rs2191000	chr7:32275098	C/A	cg27532318	chr7:32358331	NA	0.62	7.6	0.35	1.87e-13	Body mass index;
LUAD	trans	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-8.84	-0.39	2.67e-17	Brugada syndrome;
LUAD	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg11814155	chr7:99998594	ZCWPW1	0.42	7.24	0.33	2.18e-12	Platelet count;
LUAD	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg01475377	chr6:109611718	NA	-0.48	-8.75	-0.39	5.18e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs6665290	0.545	rs6426584	chr1:227374949	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.76	-12.98	-0.53	1.17e-32	Myeloid white cell count;
LUAD	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg12863693	chr15:85201151	NMB	-0.41	-7.78	-0.35	5.43e-14	Schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10075436	chr19:59084928	MZF1;LOC100131691	-0.43	-6.75	-0.31	4.85e-11	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26163375	chr1:1209720	UBE2J2	-0.54	-6.73	-0.31	5.6e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2882667	0.690	rs11954103	chr5:138269148	G/A	cg04439458	chr5:138467593	SIL1	-0.38	-6.53	-0.3	1.9e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg09904177	chr6:26538194	HMGN4	0.45	7.46	0.34	5e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs11771526	0.686	rs62457501	chr7:32329946	A/G	cg27511599	chr7:32358540	NA	0.58	7.14	0.33	4.22e-12	Body mass index;
LUAD	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg14835575	chr10:16859367	RSU1	0.51	7.86	0.36	3.12e-14	Platelet distribution width;
LUAD	cis	rs11771526	0.892	rs11764802	chr7:32372978	C/T	cg27511599	chr7:32358540	NA	0.61	7.05	0.32	7.29e-12	Body mass index;
LUAD	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg08470875	chr2:26401718	FAM59B	-0.6	-8.42	-0.38	5.91e-16	Gut microbiome composition (summer);
LUAD	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg11344533	chr11:111475393	SIK2	-0.35	-6.5	-0.3	2.23e-10	Primary sclerosing cholangitis;
LUAD	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg05342682	chr7:94953680	PON1	-0.51	-7.01	-0.32	9.46e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg00310523	chr12:86230176	RASSF9	0.39	7.76	0.35	6.25e-14	Major depressive disorder;
LUAD	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg10802521	chr3:52805072	NEK4	-0.46	-7.75	-0.35	7.02e-14	Electroencephalogram traits;
LUAD	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg24733560	chr20:60626293	TAF4	0.38	6.98	0.32	1.16e-11	Body mass index;
LUAD	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg07395648	chr5:131743802	NA	0.38	6.43	0.3	3.48e-10	Breast cancer;
LUAD	cis	rs17095355	1.000	rs7905306	chr10:111712902	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.72	-9.98	-0.44	3.29e-21	Biliary atresia;
LUAD	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg02423579	chr7:2872169	GNA12	-0.71	-11.45	-0.49	1.24e-26	Height;
LUAD	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.46	7.52	0.34	3.33e-13	Lung cancer in ever smokers;
LUAD	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.8	0.31	3.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-6.9	-0.32	1.88e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg24022402	chr3:9834453	ARPC4;TADA3	0.44	6.73	0.31	5.46e-11	Monocyte percentage of white cells;
LUAD	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg11859384	chr17:80120422	CCDC57	0.49	8.88	0.4	1.9e-17	Life satisfaction;
LUAD	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg06221963	chr1:154839813	KCNN3	-0.83	-19.22	-0.68	1.22e-59	Prostate cancer;
LUAD	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.85	-0.36	3.34e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs834811	0.871	rs834819	chr7:135895281	G/A	cg01726295	chr7:135938950	NA	0.27	6.7	0.31	6.65e-11	Post-traumatic stress disorder;
LUAD	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg06784218	chr1:46089804	CCDC17	0.5	11.13	0.48	2.11e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7937890	0.559	rs2167160	chr11:14507449	C/A	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.01e-10	Mitochondrial DNA levels;
LUAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg10729496	chr3:10149963	C3orf24	0.53	8.76	0.39	4.72e-17	Alzheimer's disease;
LUAD	cis	rs220324	0.954	rs511045	chr21:43581865	T/C	cg08841829	chr21:43638893	ABCG1	0.41	6.55	0.3	1.72e-10	Idiopathic osteonecrosis of the femoral head;
LUAD	trans	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.62	0.49	2.76e-27	Mean corpuscular volume;
LUAD	cis	rs3823572	0.542	rs62470438	chr7:133625504	A/G	cg03336402	chr7:133662267	EXOC4	0.45	8.01	0.36	1.13e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.5	-8.35	-0.38	9.75e-16	Reticulocyte count;
LUAD	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.46	0.34	4.8e-13	Breast cancer;
LUAD	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg04455712	chr21:45112962	RRP1B	-0.42	-8.53	-0.38	2.56e-16	Mean corpuscular volume;
LUAD	cis	rs7851660	0.839	rs10818213	chr9:100648631	T/C	cg13688889	chr9:100608707	NA	-0.54	-9.0	-0.4	7.58e-18	Strep throat;
LUAD	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.38	6.76	0.31	4.72e-11	Blood metabolite levels;
LUAD	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg07617317	chr6:118971624	C6orf204	0.55	8.08	0.37	6.98e-15	Diastolic blood pressure;
LUAD	cis	rs2652834	0.718	rs2729829	chr15:63395484	C/T	cg25406657	chr15:63342033	TPM1	-0.37	-6.46	-0.3	2.88e-10	HDL cholesterol;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15993354	chr19:12912590	PRDX2	-0.58	-7.26	-0.33	1.92e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7192380	0.965	rs4633710	chr16:69632961	A/G	cg00738113	chr16:70207722	CLEC18C	-0.34	-6.95	-0.32	1.42e-11	Sjögren's syndrome;
LUAD	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg04287289	chr16:89883240	FANCA	0.71	13.21	0.54	1.33e-33	Vitiligo;
LUAD	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg03467027	chr4:99064603	C4orf37	0.42	6.79	0.31	3.9e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg23649088	chr2:200775458	C2orf69	-0.6	-7.15	-0.33	3.8e-12	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.47	0.52	1.27e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg16680214	chr1:154839983	KCNN3	-0.63	-13.23	-0.54	1.11e-33	Prostate cancer;
LUAD	cis	rs7561273	0.586	rs11900665	chr2:24298198	T/C	cg20701182	chr2:24300061	SF3B14	0.41	6.83	0.32	2.96e-11	Quantitative traits;
LUAD	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg13877915	chr19:58951672	ZNF132	0.57	10.05	0.44	1.92e-21	Uric acid clearance;
LUAD	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	7.43	0.34	5.92e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg22663859	chr13:21900854	NA	0.46	7.6	0.35	1.93e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg26384229	chr12:38710491	ALG10B	0.48	7.72	0.35	8.7e-14	Bladder cancer;
LUAD	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg06618935	chr21:46677482	NA	-0.5	-10.3	-0.45	2.37e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.2	-0.41	1.59e-18	Alcohol dependence;
LUAD	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg12062639	chr20:23401060	NAPB	1.08	10.86	0.47	2.14e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1950626	0.833	rs67456801	chr14:101399169	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.37	7.14	0.33	4.13e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07266350	chr3:49460521	AMT;NICN1	0.38	6.63	0.31	1.02e-10	Menarche (age at onset);
LUAD	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-7.25	-0.33	1.99e-12	Platelet count;
LUAD	cis	rs1847202	0.592	rs13073005	chr3:72951007	C/T	cg25664220	chr3:72788482	NA	-0.42	-7.32	-0.34	1.24e-12	Motion sickness;
LUAD	cis	rs7524258	0.868	rs916393	chr1:7272250	T/C	cg07173049	chr1:7289937	CAMTA1	0.49	9.39	0.42	3.77e-19	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.96	0.36	1.58e-14	Morning vs. evening chronotype;
LUAD	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg18306943	chr3:40428807	ENTPD3	0.41	7.04	0.32	8.07e-12	Renal cell carcinoma;
LUAD	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg01874867	chr7:94954059	PON1	-0.48	-6.62	-0.31	1.1e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs62238980	0.614	rs17682819	chr22:32424794	T/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs6499255	0.951	rs10163235	chr16:69739867	G/T	cg15192750	chr16:69999425	NA	0.55	8.3	0.37	1.41e-15	IgE levels;
LUAD	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg05368731	chr17:41323189	NBR1	0.94	19.41	0.69	1.74e-60	Menopause (age at onset);
LUAD	cis	rs3820068	0.637	rs4646080	chr1:15826627	A/T	cg13390004	chr1:15929781	NA	0.4	6.51	0.3	2.15e-10	Systolic blood pressure;
LUAD	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg27624424	chr6:160112604	SOD2	0.44	6.36	0.3	5.19e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs2735413	0.918	rs56397244	chr16:78081366	A/T	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg19825600	chr2:3704501	ALLC	-0.57	-9.55	-0.42	1.05e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs2404602	0.735	rs11629888	chr15:76719880	A/T	cg23625390	chr15:77176239	SCAPER	-0.46	-7.24	-0.33	2.11e-12	Blood metabolite levels;
LUAD	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg06784218	chr1:46089804	CCDC17	0.35	7.69	0.35	1.03e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs11723261	0.582	rs11732336	chr4:140512	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.42	7.53	0.34	3.16e-13	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg25344623	chr2:136566232	LCT	0.35	6.8	0.31	3.64e-11	Mosquito bite size;
LUAD	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg05340658	chr4:99064831	C4orf37	0.53	8.62	0.39	1.39e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg08847533	chr14:75593920	NEK9	0.41	7.01	0.32	9.58e-12	Height;
LUAD	cis	rs2274273	0.773	rs28430823	chr14:55816560	C/G	cg04306507	chr14:55594613	LGALS3	0.43	9.04	0.4	5.72e-18	Protein biomarker;
LUAD	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg00933542	chr6:150070202	PCMT1	0.36	7.51	0.34	3.52e-13	Testicular germ cell tumor;
LUAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-8.7	-0.39	7.31e-17	Alzheimer's disease;
LUAD	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg03388025	chr16:89894329	SPIRE2	0.33	7.62	0.35	1.67e-13	Vitiligo;
LUAD	cis	rs4356932	1.000	rs1554013	chr4:76933484	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.46	-0.3	2.82e-10	Blood protein levels;
LUAD	cis	rs6011002	0.590	rs1291212	chr20:62340115	C/G	cg01176363	chr20:62369445	LIME1	-0.8	-6.68	-0.31	7.7e-11	Dental caries;
LUAD	trans	rs7395662	0.782	rs66468703	chr11:48738773	T/C	cg15704280	chr7:45808275	SEPT13	-0.45	-7.09	-0.33	5.52e-12	HDL cholesterol;
LUAD	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.5	8.41	0.38	6.39e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.25	-0.37	2.05e-15	Alzheimer's disease;
LUAD	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.48	0.3	2.58e-10	Parkinson's disease;
LUAD	cis	rs2067615	0.560	rs12298717	chr12:107099883	C/T	cg15890332	chr12:107067104	RFX4	-0.4	-8.44	-0.38	5.13e-16	Heart rate;
LUAD	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg22920501	chr2:26401640	FAM59B	-0.76	-10.95	-0.47	9.86e-25	Gut microbiome composition (summer);
LUAD	cis	rs3820068	0.705	rs4646096	chr1:15820758	A/G	cg24675056	chr1:15929824	NA	0.41	6.58	0.3	1.39e-10	Systolic blood pressure;
LUAD	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg26338869	chr17:61819248	STRADA	-0.39	-6.55	-0.3	1.72e-10	Prudent dietary pattern;
LUAD	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg04756594	chr16:24857601	SLC5A11	-0.77	-13.68	-0.55	1.58e-35	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg03433033	chr1:76189801	ACADM	-0.44	-6.4	-0.3	4.16e-10	Daytime sleep phenotypes;
LUAD	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg02493740	chr2:85810744	VAMP5	-0.45	-8.13	-0.37	4.88e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg07636037	chr3:49044803	WDR6	-0.6	-10.79	-0.46	3.77e-24	Parkinson's disease;
LUAD	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.49	8.04	0.36	9.05e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs13315871	1.000	rs13066269	chr3:58449244	T/C	cg20936604	chr3:58311152	NA	-0.68	-6.96	-0.32	1.3e-11	Cholesterol, total;
LUAD	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg27532560	chr4:187881888	NA	-0.35	-6.56	-0.3	1.62e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9925964	0.933	rs2359612	chr16:31103796	A/G	cg02466173	chr16:30829666	NA	-0.4	-6.59	-0.31	1.3100000000000001e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs57920188	0.535	rs4520388	chr1:4092671	T/G	cg10510935	chr1:4059661	NA	0.45	6.9	0.32	1.97e-11	Interleukin-17 levels;
LUAD	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg25452165	chr22:42524984	CYP2D6	-0.38	-6.36	-0.3	5.15e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg02807482	chr3:125708958	NA	-0.66	-8.81	-0.39	3.26e-17	Blood pressure (smoking interaction);
LUAD	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg06108461	chr20:60628389	TAF4	-0.94	-16.8	-0.63	6.65e-49	Body mass index;
LUAD	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg04586622	chr2:25135609	ADCY3	0.37	8.54	0.38	2.45e-16	Body mass index;
LUAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.48	-9.18	-0.41	1.93e-18	Longevity;Endometriosis;
LUAD	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg02569458	chr12:86230093	RASSF9	0.42	7.8	0.35	5.05e-14	Major depressive disorder;
LUAD	cis	rs62238980	0.614	rs79022443	chr22:32456717	T/C	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg08885076	chr2:99613938	TSGA10	0.35	6.39	0.3	4.33e-10	Chronic sinus infection;
LUAD	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.45	-0.38	4.62e-16	Bipolar disorder;
LUAD	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg11941060	chr3:133502564	NA	-0.4	-6.64	-0.31	9.93e-11	Iron status biomarkers;
LUAD	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg00310523	chr12:86230176	RASSF9	-0.38	-7.67	-0.35	1.21e-13	Major depressive disorder;
LUAD	cis	rs68170813	1.000	rs35061190	chr7:107249844	C/T	cg02696742	chr7:106810147	HBP1	-0.5	-6.66	-0.31	8.32e-11	Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg21605333	chr4:119757512	SEC24D	0.93	8.74	0.39	5.54e-17	Cannabis dependence symptom count;
LUAD	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg20607798	chr8:58055168	NA	0.59	7.83	0.36	3.99e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs2835872	0.727	rs2835894	chr21:39066042	A/G	cg06728970	chr21:39037746	KCNJ6	-0.39	-6.65	-0.31	8.87e-11	Electroencephalographic traits in alcoholism;
LUAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg11301795	chr4:187892539	NA	-0.76	-15.18	-0.59	7.68e-42	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2882667	0.858	rs11242442	chr5:138380489	C/T	cg04439458	chr5:138467593	SIL1	-0.51	-9.23	-0.41	1.35e-18	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.61	9.58	0.42	8.05e-20	Colorectal cancer;
LUAD	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg27124370	chr19:33622961	WDR88	0.43	6.92	0.32	1.72e-11	Bone properties (heel);
LUAD	cis	rs55665837	1.000	rs10832254	chr11:14434698	A/G	cg19336497	chr11:14380999	RRAS2	-0.5	-10.21	-0.44	5.18e-22	Vitamin D levels;
LUAD	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg03609598	chr5:56110824	MAP3K1	-0.68	-9.21	-0.41	1.59e-18	Initial pursuit acceleration;
LUAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18402987	chr7:1209562	NA	0.38	6.45	0.3	3.09e-10	Longevity;Endometriosis;
LUAD	cis	rs11098699	0.784	rs2291933	chr4:124247183	A/G	cg09941581	chr4:124220074	SPATA5	0.43	6.83	0.32	2.93e-11	Mosquito bite size;
LUAD	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg15147215	chr3:52552868	STAB1	-0.39	-7.46	-0.34	4.83e-13	Bipolar disorder;
LUAD	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg05872129	chr22:39784769	NA	-0.75	-12.1	-0.51	3.92e-29	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg24154853	chr7:158122151	PTPRN2	-0.45	-7.89	-0.36	2.52e-14	Calcium levels;
LUAD	cis	rs11650494	0.908	rs77338752	chr17:47372328	A/C	cg08112188	chr17:47440006	ZNF652	0.96	8.01	0.36	1.1e-14	Prostate cancer;
LUAD	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg20500540	chr8:101228448	SPAG1	-0.41	-7.5	-0.34	3.73e-13	Atrioventricular conduction;
LUAD	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg05182265	chr7:156933206	UBE3C	-0.81	-17.4	-0.65	1.48e-51	Body mass index;
LUAD	cis	rs55665837	1.000	rs7121171	chr11:14446420	A/G	cg19336497	chr11:14380999	RRAS2	-0.5	-10.12	-0.44	1.04e-21	Vitamin D levels;
LUAD	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg15900387	chr1:150738905	CTSS	-0.36	-6.4	-0.3	4.11e-10	Melanoma;
LUAD	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.13	-0.41	2.83e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg04352962	chr1:209979756	IRF6	0.5	6.42	0.3	3.65e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.55	0.3	1.72e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg04287289	chr16:89883240	FANCA	0.45	6.9	0.32	1.91e-11	Hemoglobin concentration;
LUAD	cis	rs73198271	0.531	rs56100346	chr8:8652844	C/T	cg01851573	chr8:8652454	MFHAS1	0.71	11.37	0.48	2.56e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs12286929	0.609	rs45614535	chr11:115090866	G/A	cg04055981	chr11:115044050	NA	0.41	7.16	0.33	3.63e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6498142	0.569	rs9926433	chr16:11080586	C/G	cg04616529	chr16:11181986	CLEC16A	-0.41	-6.38	-0.3	4.66e-10	Immunoglobulin A;
LUAD	trans	rs1493916	0.905	rs34165207	chr18:31400153	G/A	cg27147174	chr7:100797783	AP1S1	-0.66	-11.37	-0.48	2.57e-26	Life satisfaction;
LUAD	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg06873352	chr17:61820015	STRADA	0.41	6.88	0.32	2.22e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-15.1	-0.59	1.56e-41	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.1	-0.37	6.04e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg03806693	chr22:41940476	POLR3H	-0.61	-9.13	-0.41	2.88e-18	Vitiligo;
LUAD	cis	rs2637266	1.000	rs2579750	chr10:78340260	C/G	cg18941641	chr10:78392320	NA	-0.32	-6.75	-0.31	4.96e-11	Pulmonary function;
LUAD	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.67	12.85	0.53	3.74e-32	Cognitive ability;
LUAD	cis	rs2404602	0.552	rs11630185	chr15:76959783	A/T	cg00316803	chr15:76480434	C15orf27	0.44	6.46	0.3	2.8e-10	Blood metabolite levels;
LUAD	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.41	-0.45	9.39e-23	Total body bone mineral density;
LUAD	cis	rs7177699	0.557	rs3971829	chr15:79109052	A/G	cg15571903	chr15:79123663	NA	0.37	7.26	0.33	1.87e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg13180566	chr4:1052158	NA	-0.38	-6.54	-0.3	1.75e-10	Recombination rate (females);
LUAD	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg18005901	chr6:33739558	LEMD2	-0.59	-9.48	-0.42	1.82e-19	Schizophrenia;
LUAD	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg12035532	chr1:1886765	KIAA1751	0.39	6.45	0.3	2.98e-10	Body mass index;
LUAD	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg00631329	chr6:26305371	NA	0.46	7.75	0.35	6.96e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs870825	0.616	rs72703531	chr4:185611092	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	11.97	0.5	1.25e-28	Blood protein levels;
LUAD	cis	rs12541635	0.677	rs4734892	chr8:106990088	G/C	cg10147462	chr8:107024639	NA	0.54	9.53	0.42	1.25e-19	Age of smoking initiation;
LUAD	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg13390004	chr1:15929781	NA	0.46	8.29	0.37	1.53e-15	Systolic blood pressure;
LUAD	cis	rs9372498	0.572	rs62422230	chr6:118959436	T/C	cg18833306	chr6:118973337	C6orf204	-0.55	-7.66	-0.35	1.25e-13	Diastolic blood pressure;
LUAD	cis	rs7503807	0.967	rs12947696	chr17:78596793	C/T	cg09596252	chr17:78655493	RPTOR	0.41	7.93	0.36	1.91e-14	Obesity;
LUAD	cis	rs12711979	0.513	rs1454241	chr2:3851675	A/G	cg17052675	chr2:3827356	NA	0.39	7.45	0.34	5.44e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg21252483	chr19:49399788	TULP2	-0.88	-14.3	-0.57	3.88e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs870825	0.616	rs6844146	chr4:185636396	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	14.04	0.56	4.87e-37	Blood protein levels;
LUAD	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg11494091	chr17:61959527	GH2	0.74	18.35	0.67	9.02e-56	Prudent dietary pattern;
LUAD	trans	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg18187862	chr3:45730750	SACM1L	-0.5	-7.93	-0.36	1.91e-14	Primary sclerosing cholangitis;
LUAD	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg20608306	chr11:116969690	SIK3	0.29	6.47	0.3	2.75e-10	Blood protein levels;
LUAD	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg10523679	chr1:76189770	ACADM	0.95	18.6	0.67	7.17e-57	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.8	0.35	4.79e-14	Morning vs. evening chronotype;
LUAD	trans	rs853679	0.607	rs35098436	chr6:28134221	T/C	cg01620082	chr3:125678407	NA	-1.1	-10.38	-0.45	1.25e-22	Depression;
LUAD	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg16405210	chr4:1374714	KIAA1530	-0.63	-9.66	-0.43	4.45e-20	Longevity;
LUAD	cis	rs10865541	0.778	rs10779975	chr2:3420032	A/G	cg22182287	chr2:3452347	TTC15	0.46	8.04	0.36	9.02e-15	Obesity-related traits;
LUAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg00280220	chr17:61926910	NA	0.37	7.13	0.33	4.23e-12	Prudent dietary pattern;
LUAD	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg00310523	chr12:86230176	RASSF9	0.37	7.34	0.34	1.08e-12	Major depressive disorder;
LUAD	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg08085267	chr17:45401833	C17orf57	0.58	10.41	0.45	9.28e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg24644049	chr4:85504048	CDS1	0.92	7.94	0.36	1.78e-14	Skin colour saturation;
LUAD	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg09658497	chr7:2847517	GNA12	-0.44	-8.02	-0.36	1.03e-14	Height;
LUAD	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.51	10.61	0.46	1.74e-23	Monocyte percentage of white cells;
LUAD	cis	rs68170813	0.641	rs12539895	chr7:107091849	C/A	cg23024343	chr7:107201750	COG5	0.51	7.05	0.32	7.13e-12	Coronary artery disease;
LUAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg11905131	chr22:24372483	LOC391322	-0.57	-9.77	-0.43	1.88e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg12311346	chr5:56204834	C5orf35	-0.92	-13.71	-0.55	1.22e-35	Initial pursuit acceleration;
LUAD	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg03354898	chr7:1950403	MAD1L1	-0.42	-7.97	-0.36	1.49e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg27129171	chr3:47204927	SETD2	0.43	7.11	0.33	5.12e-12	Colorectal cancer;
LUAD	cis	rs16958440	0.867	rs75481537	chr18:44719946	C/T	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg08989290	chr16:615782	NHLRC4	0.32	6.85	0.32	2.59e-11	Height;
LUAD	cis	rs2386661	0.826	rs4427479	chr10:5682855	T/C	cg26603656	chr10:5671107	NA	-0.4	-6.75	-0.31	4.96e-11	Breast cancer;
LUAD	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-6.57	-0.3	1.46e-10	Personality dimensions;
LUAD	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg00933542	chr6:150070202	PCMT1	0.43	9.24	0.41	1.26e-18	Lung cancer;
LUAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg07677032	chr17:61819896	STRADA	-0.54	-9.91	-0.43	5.75e-21	Prudent dietary pattern;
LUAD	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	trans	rs11989744	0.957	rs61099147	chr8:23573953	A/G	cg03492747	chr16:86543808	FOXF1	0.4	6.39	0.3	4.31e-10	Waist-hip ratio;
LUAD	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22590775	chr19:49891494	CCDC155	0.59	8.55	0.38	2.19e-16	Multiple sclerosis;
LUAD	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg13319975	chr6:146136371	FBXO30	-0.59	-9.9	-0.43	6.42e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	trans	rs9929218	0.817	rs8055912	chr16:68802068	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.69	-0.55	1.48e-35	Colorectal cancer;
LUAD	trans	rs6561151	0.681	rs61209988	chr13:44416335	G/C	cg17145862	chr1:211918768	LPGAT1	0.53	7.32	0.34	1.3e-12	Crohn's disease;
LUAD	trans	rs11088226	0.915	rs76390535	chr21:33903631	T/C	cg09050820	chr6:167586206	TCP10L2	0.6	7.86	0.36	3.13e-14	Gastritis;
LUAD	trans	rs7944735	0.628	rs4752879	chr11:47897772	C/T	cg15704280	chr7:45808275	SEPT13	0.59	8.03	0.36	1e-14	Intraocular pressure;
LUAD	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg13385794	chr1:248469461	NA	0.27	7.35	0.34	1.05e-12	Common traits (Other);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg13775054	chr21:47648555	LSS;MCM3APAS	-0.37	-6.48	-0.3	2.48e-10	Schizophrenia;
LUAD	cis	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg21775007	chr8:11205619	TDH	0.57	10.11	0.44	1.13e-21	Retinal vascular caliber;
LUAD	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg02423579	chr7:2872169	GNA12	-0.88	-15.47	-0.6	4.01e-43	Height;
LUAD	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.92	0.32	1.71e-11	Depression;
LUAD	cis	rs2066819	1.000	rs74496027	chr12:56726340	C/T	cg26714650	chr12:56694279	CS	-0.85	-7.1	-0.33	5.17e-12	Psoriasis vulgaris;
LUAD	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg18721089	chr20:30220636	NA	-0.49	-7.03	-0.32	8.37e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs875971	0.545	rs316323	chr7:65610989	C/T	cg04775059	chr7:64541387	NA	-0.49	-6.73	-0.31	5.69e-11	Aortic root size;
LUAD	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg18490616	chr2:88469792	THNSL2	-0.43	-6.83	-0.32	3.03e-11	Response to metformin (IC50);
LUAD	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg17264618	chr3:40429014	ENTPD3	0.42	8.85	0.4	2.4e-17	Renal cell carcinoma;
LUAD	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg02990361	chr1:107599529	PRMT6	-0.63	-10.51	-0.46	4.04e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg01657329	chr11:68192670	LRP5	-0.47	-8.2	-0.37	2.91e-15	Total body bone mineral density;
LUAD	trans	rs7395662	1.000	rs10838971	chr11:48606624	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.27	-0.33	1.72e-12	HDL cholesterol;
LUAD	cis	rs8038465	0.594	rs55816897	chr15:73869767	G/T	cg15420318	chr15:73925796	NPTN	0.43	7.38	0.34	8.24e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2262909	0.962	rs12610034	chr19:22314528	G/A	cg11619707	chr19:22235551	ZNF257	0.48	7.17	0.33	3.38e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs593982	1.000	rs74638829	chr11:65495571	C/T	cg08755490	chr11:65554678	OVOL1	-1.34	-16.18	-0.62	3.65e-46	Atopic dermatitis;
LUAD	cis	rs524023	0.957	rs528211	chr11:64351721	C/T	cg19131476	chr11:64387923	NRXN2	0.37	7.01	0.32	9.57e-12	Urate levels in obese individuals;
LUAD	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg14829155	chr15:31115871	NA	-0.59	-9.99	-0.44	3.09e-21	Huntington's disease progression;
LUAD	trans	rs8002861	0.664	rs2218497	chr13:44428793	G/A	cg12856521	chr11:46389249	DGKZ	0.48	8.04	0.36	9.06e-15	Leprosy;
LUAD	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg17063962	chr7:91808500	NA	0.68	12.12	0.51	3.26e-29	Breast cancer;
LUAD	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.4	0.48	1.96e-26	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg11062466	chr8:58055876	NA	0.71	8.89	0.4	1.79e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg03690763	chr11:133734501	NA	-0.34	-7.8	-0.35	4.96e-14	Childhood ear infection;
LUAD	cis	rs986417	1.000	rs1072328	chr14:60876439	C/G	cg27398547	chr14:60952738	C14orf39	-0.64	-7.84	-0.36	3.73e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg01849466	chr14:104193079	ZFYVE21	0.53	9.61	0.42	6.77e-20	Schizophrenia;
LUAD	cis	rs7953508	0.506	rs1316740	chr12:93968288	C/A	cg18151635	chr12:93972918	NA	-0.78	-11.79	-0.5	6.39e-28	Pubertal anthropometrics;
LUAD	cis	rs736408	1.000	rs4687552	chr3:52838402	T/C	cg18404041	chr3:52824283	ITIH1	-0.62	-12.66	-0.52	2.25e-31	Bipolar disorder;
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg01986883	chr4:164087009	NAF1	-0.37	-6.63	-0.31	1.05e-10	Migraine with aura;
LUAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg22029157	chr1:209979665	IRF6	0.74	12.09	0.51	4.17e-29	Cleft lip with or without cleft palate;
LUAD	cis	rs17155006	0.530	rs408867	chr7:107743244	C/T	cg05962710	chr7:107745446	LAMB4	-0.35	-7.52	-0.34	3.34e-13	Pneumococcal bacteremia;
LUAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.29	0.66	1.79e-55	Prudent dietary pattern;
LUAD	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg13685833	chr1:53393034	SCP2	-0.49	-7.92	-0.36	2.15e-14	Monocyte count;
LUAD	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg00750074	chr16:89608354	SPG7	-0.58	-9.99	-0.44	3.16e-21	Multiple myeloma (IgH translocation);
LUAD	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg22117172	chr7:91764530	CYP51A1	0.38	8.3	0.37	1.4e-15	Breast cancer;
LUAD	cis	rs9323205	0.861	rs56137183	chr14:51693463	C/A	cg23942311	chr14:51606299	NA	-0.63	-10.1	-0.44	1.29e-21	Cancer;
LUAD	cis	rs3750082	0.817	rs2060731	chr7:32968346	G/A	cg05721444	chr7:32995514	FKBP9	-0.41	-7.58	-0.35	2.16e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02018176	chr4:1364513	KIAA1530	0.67	11.73	0.5	1.07e-27	Longevity;
LUAD	cis	rs1395	0.925	rs2580754	chr2:27398196	A/T	cg23587288	chr2:27483067	SLC30A3	-0.41	-8.23	-0.37	2.33e-15	Blood metabolite levels;
LUAD	cis	rs9914988	0.576	rs67777803	chr17:27323322	G/T	cg02049041	chr17:27085579	C17orf63	0.51	6.38	0.3	4.54e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs977987	0.835	rs11641532	chr16:75329480	T/C	cg03315344	chr16:75512273	CHST6	0.62	13.4	0.55	2.24e-34	Dupuytren's disease;
LUAD	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4698790	0.635	rs3822272	chr4:110683550	C/T	cg07850274	chr4:110748770	RRH	0.42	6.78	0.31	3.98e-11	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUAD	cis	rs6460942	0.915	rs2216051	chr7:12304054	G/A	cg20607287	chr7:12443886	VWDE	-0.45	-6.83	-0.32	2.99e-11	Coronary artery disease;
LUAD	cis	rs11771526	0.579	rs77818421	chr7:32375129	G/T	cg27532318	chr7:32358331	NA	0.72	7.78	0.35	5.8e-14	Body mass index;
LUAD	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg14092988	chr3:52407081	DNAH1	0.45	9.1	0.4	3.54e-18	Bipolar disorder;
LUAD	cis	rs6089584	0.546	rs6089308	chr20:60583529	C/T	cg13770153	chr20:60521292	NA	-0.44	-7.55	-0.34	2.63e-13	Body mass index;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10078639	chr10:116286586	ABLIM1	-0.54	-6.47	-0.3	2.7e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6484504	0.625	rs7940420	chr11:31366700	T/A	cg14844989	chr11:31128820	NA	0.44	8.16	0.37	3.77e-15	Red blood cell count;
LUAD	trans	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg14917512	chr19:3094685	GNA11	-0.58	-6.91	-0.32	1.8e-11	Gout;
LUAD	cis	rs11048434	0.736	rs933462	chr12:9103665	T/G	cg23795048	chr12:9217529	LOC144571	0.42	7.63	0.35	1.58e-13	Sjögren's syndrome;
LUAD	cis	rs6854137	0.758	rs1392755	chr4:169741521	A/G	cg20607169	chr4:169750834	PALLD	0.47	8.43	0.38	5.59e-16	Vein graft stenosis in coronary artery bypass grafting;
LUAD	trans	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	8.88	0.4	1.96e-17	Mean corpuscular volume;
LUAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-10.21	-0.44	4.89e-22	Electroencephalogram traits;
LUAD	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg05368731	chr17:41323189	NBR1	0.98	20.49	0.71	2.59e-65	Menopause (age at onset);
LUAD	cis	rs7683537	0.887	rs4540092	chr4:185633546	A/G	cg04058563	chr4:185651563	MLF1IP	0.9	14.41	0.57	1.39e-38	Systemic lupus erythematosus;
LUAD	cis	rs9296092	0.538	rs62405948	chr6:33522753	A/C	cg13560919	chr6:33536144	NA	-0.88	-16.77	-0.63	8.82e-49	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg17644776	chr2:200775616	C2orf69	-0.52	-6.53	-0.3	1.9e-10	Schizophrenia;
LUAD	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg18105134	chr13:113819100	PROZ	-1.0	-18.51	-0.67	1.79e-56	Platelet distribution width;
LUAD	cis	rs80319144	1.000	rs11680774	chr2:159245985	T/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.83	0.32	2.95e-11	Restless legs syndrome;
LUAD	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg00603274	chr11:61596626	FADS2	-0.71	-10.18	-0.44	6.67e-22	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14751398	chr6:20402153	E2F3	-0.47	-7.7	-0.35	9.62e-14	Height;
LUAD	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg20203395	chr5:56204925	C5orf35	-0.84	-12.06	-0.51	5.44e-29	Initial pursuit acceleration;
LUAD	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg09936400	chr10:82049201	MAT1A	-0.36	-6.6	-0.31	1.25e-10	Post bronchodilator FEV1;
LUAD	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg02158880	chr13:53174818	NA	0.46	8.04	0.36	9.08e-15	Lewy body disease;
LUAD	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg17724175	chr1:150552817	MCL1	0.38	9.23	0.41	1.31e-18	Tonsillectomy;
LUAD	cis	rs7584330	0.554	rs6706729	chr2:238398580	T/C	cg14458575	chr2:238380390	NA	0.89	12.79	0.53	7.11e-32	Prostate cancer;
LUAD	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg15556689	chr8:8085844	FLJ10661	0.43	7.05	0.32	7.28e-12	Mood instability;
LUAD	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg12311346	chr5:56204834	C5orf35	1.07	15.14	0.59	1.09e-41	Initial pursuit acceleration;
LUAD	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg10589385	chr1:150898437	SETDB1	0.39	7.36	0.34	9.55e-13	Tonsillectomy;
LUAD	cis	rs73206853	0.698	rs871922	chr12:111114942	T/C	cg12870014	chr12:110450643	ANKRD13A	0.58	6.47	0.3	2.74e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg05754148	chr16:3507555	NAT15	-0.77	-8.58	-0.38	1.85e-16	Tuberculosis;
LUAD	cis	rs240764	0.817	rs11155610	chr6:101170233	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-7.43	-0.34	6e-13	Neuroticism;
LUAD	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg00310523	chr12:86230176	RASSF9	-0.4	-8.71	-0.39	6.81e-17	Major depressive disorder;
LUAD	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg02569458	chr12:86230093	RASSF9	0.45	8.22	0.37	2.43e-15	Major depressive disorder;
LUAD	cis	rs921968	0.613	rs2303566	chr2:219557738	C/T	cg02176678	chr2:219576539	TTLL4	-0.58	-11.58	-0.49	3.86e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7575217	0.643	rs2309996	chr2:101735838	T/G	cg23907051	chr2:101730305	TBC1D8	-0.28	-6.43	-0.3	3.47e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg18230493	chr5:56204884	C5orf35	-1.01	-15.4	-0.6	8.22e-43	Initial pursuit acceleration;
LUAD	cis	rs741677	0.663	rs441438	chr17:491006	C/T	cg15660573	chr17:549704	VPS53	0.54	8.93	0.4	1.33e-17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	trans	rs853679	0.517	rs868987	chr6:28110148	A/G	cg01620082	chr3:125678407	NA	0.45	6.68	0.31	7.35e-11	Depression;
LUAD	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg27572855	chr1:25598939	RHD	0.53	11.42	0.49	1.58e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg17366294	chr4:99064904	C4orf37	-0.47	-8.24	-0.37	2.17e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1475718	0.563	rs1041608	chr9:137116205	C/T	cg21243944	chr9:137118148	NA	-0.38	-8.16	-0.37	3.95e-15	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg18306943	chr3:40428807	ENTPD3	0.43	7.23	0.33	2.28e-12	Renal cell carcinoma;
LUAD	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg03289416	chr15:75166202	SCAMP2	0.54	9.43	0.42	2.72e-19	Breast cancer;
LUAD	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs9462027	0.561	rs2235568	chr6:34570094	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.73	-0.39	6.17e-17	Systemic lupus erythematosus;
LUAD	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg24801067	chr17:62843696	NA	0.64	8.77	0.39	4.56e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg08742575	chr21:47604166	C21orf56	0.42	7.09	0.33	5.76e-12	Testicular germ cell tumor;
LUAD	cis	rs1595825	0.891	rs76637837	chr2:198529496	G/A	cg10547527	chr2:198650123	BOLL	-0.54	-7.66	-0.35	1.3e-13	Ulcerative colitis;
LUAD	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg03037974	chr15:76606532	NA	0.38	8.12	0.37	5.25e-15	Blood metabolite levels;
LUAD	cis	rs7274811	0.711	rs291697	chr20:31985248	T/C	cg13403462	chr20:32256071	NECAB3;C20orf134	0.43	6.56	0.3	1.54e-10	Height;
LUAD	cis	rs3916	0.794	rs10431386	chr12:121128926	A/G	cg21892295	chr12:121157589	UNC119B	0.38	6.53	0.3	1.87e-10	Urinary metabolites (H-NMR features);
LUAD	cis	rs6696239	0.513	rs2201571	chr1:227719951	T/G	cg12133451	chr1:227746453	NA	0.36	6.58	0.3	1.36e-10	Height;
LUAD	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg05872129	chr22:39784769	NA	0.8	13.7	0.55	1.3e-35	Intelligence (multi-trait analysis);
LUAD	cis	rs4588572	0.644	rs6873144	chr5:77741784	C/T	cg11547950	chr5:77652471	NA	-0.62	-10.54	-0.46	3.15e-23	Triglycerides;
LUAD	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg14092571	chr14:90743983	NA	-0.49	-8.64	-0.39	1.16e-16	Mortality in heart failure;
LUAD	cis	rs738321	0.725	rs4821747	chr22:38538856	T/C	cg17652424	chr22:38574118	PLA2G6	-0.28	-7.31	-0.34	1.31e-12	Breast cancer;
LUAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg06753367	chr22:24256600	NA	-0.39	-6.89	-0.32	2.03e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs9929218	0.911	rs4783685	chr16:68834107	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-12.71	-0.53	1.46e-31	Colorectal cancer;
LUAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg20849893	chr7:64541193	NA	0.56	9.13	0.41	2.77e-18	Calcium levels;
LUAD	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-15.16	-0.59	8.76e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg23985595	chr17:80112537	CCDC57	-0.53	-9.51	-0.42	1.43e-19	Life satisfaction;
LUAD	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.16	0.48	1.59e-25	Height;
LUAD	cis	rs739496	0.947	rs7299849	chr12:111855461	A/T	cg10833066	chr12:111807467	FAM109A	0.42	6.7	0.31	6.87e-11	Platelet count;
LUAD	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg18252515	chr7:66147081	NA	-0.63	-6.89	-0.32	2.01e-11	Diabetic kidney disease;
LUAD	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg14343924	chr8:8086146	FLJ10661	0.43	6.61	0.31	1.19e-10	Mean corpuscular hemoglobin;
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg14645856	chr6:18368844	NA	-0.42	-6.42	-0.3	3.68e-10	Height;
LUAD	cis	rs526821	0.595	rs4938937	chr11:55305507	T/A	cg04317927	chr11:55418816	OR4S2	0.38	6.97	0.32	1.22e-11	Pediatric bone mineral density (spine);
LUAD	cis	rs988712	0.672	rs16917237	chr11:27702383	A/C	cg10635145	chr11:27742435	BDNF	0.45	6.5	0.3	2.23e-10	Obesity;
LUAD	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.26	6.84	0.32	2.87e-11	Schizophrenia;
LUAD	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	7.01	0.32	9.46e-12	Schizophrenia;
LUAD	cis	rs10911363	0.615	rs9286848	chr1:183426249	C/G	cg09173681	chr1:183549694	NCF2	-0.55	-9.97	-0.44	3.65e-21	Systemic lupus erythematosus;
LUAD	cis	rs2692947	0.770	rs12471925	chr2:96555522	C/A	cg23100626	chr2:96804247	ASTL	0.31	7.66	0.35	1.27e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs57920188	0.537	rs4440829	chr1:4080780	A/G	cg10510935	chr1:4059661	NA	-0.49	-7.44	-0.34	5.71e-13	Interleukin-17 levels;
LUAD	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg03806693	chr22:41940476	POLR3H	-0.62	-8.8	-0.39	3.61e-17	Vitiligo;
LUAD	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.34	0.38	1.06e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg23933602	chr10:16859644	RSU1	0.6	8.16	0.37	3.9e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	7.48	0.34	4.2e-13	Schizophrenia;
LUAD	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-10.38	-0.45	1.21e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg20628663	chr10:43360327	NA	0.59	8.88	0.4	1.86e-17	Blood protein levels;
LUAD	cis	rs4253772	0.530	rs9615362	chr22:46795141	A/C	cg09491104	chr22:46646882	C22orf40	0.5	7.33	0.34	1.15e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06112835	chr11:68658793	MRPL21	0.53	9.55	0.42	1.1e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs113835537	0.559	rs11227498	chr11:66269714	A/G	cg24851651	chr11:66362959	CCS	0.54	9.72	0.43	2.79e-20	Airway imaging phenotypes;
LUAD	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24308560	chr3:49941425	MST1R	0.51	8.66	0.39	9.92e-17	Body mass index;
LUAD	cis	rs2282300	0.739	rs12577729	chr11:30257377	C/T	cg06241208	chr11:30344200	C11orf46	-0.59	-7.78	-0.35	5.63e-14	Morning vs. evening chronotype;
LUAD	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21659725	chr3:3221576	CRBN	-0.63	-10.96	-0.47	9.15e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg26898376	chr11:64110657	CCDC88B	0.36	6.49	0.3	2.43e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs7625357	1.000	rs7653417	chr3:169350023	G/A	cg14572252	chr3:169309425	MECOM	-0.38	-6.65	-0.31	9.24e-11	Childhood and early adolescence aggressive behavior;
LUAD	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg04944784	chr2:26401820	FAM59B	-0.81	-11.02	-0.47	5.52e-25	Gut microbiome composition (summer);
LUAD	cis	rs10504073	0.647	rs9643394	chr8:50014427	A/G	cg00325661	chr8:49890786	NA	0.43	9.72	0.43	2.64e-20	Blood metabolite ratios;
LUAD	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg02782426	chr3:40428986	ENTPD3	0.43	9.6	0.42	7.15e-20	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.99	0.32	1.09e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1950500	0.550	rs7148384	chr14:24828814	C/T	cg01658259	chr14:24837143	NFATC4	0.41	7.15	0.33	3.74e-12	Height;
LUAD	trans	rs1268789	0.571	rs949507	chr4:79394086	C/T	cg04364194	chr1:202114085	ARL8A	-0.38	-6.38	-0.3	4.64e-10	Hair shape;Hair morphology;
LUAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.18	0.37	3.39e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg16797656	chr11:68205561	LRP5	0.52	11.25	0.48	7.58e-26	Total body bone mineral density;
LUAD	cis	rs7561273	0.586	rs4149372	chr2:24305512	T/G	cg20701182	chr2:24300061	SF3B14	0.51	8.19	0.37	3.16e-15	Quantitative traits;
LUAD	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg09184832	chr6:79620586	NA	0.51	9.55	0.42	1.08e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.53	-0.34	3e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg02951883	chr7:2050386	MAD1L1	-0.82	-14.32	-0.57	3.38e-38	Bipolar disorder and schizophrenia;
LUAD	cis	rs4253772	0.550	rs9615347	chr22:46728153	A/G	cg00784671	chr22:46762841	CELSR1	-0.61	-7.08	-0.33	6e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1018836	0.608	rs1015994	chr8:91465011	T/C	cg16814680	chr8:91681699	NA	-0.54	-8.85	-0.4	2.44e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1865721	0.755	rs3213875	chr18:73184048	C/T	cg26385618	chr18:73139727	C18orf62	-0.33	-6.55	-0.3	1.63e-10	Intelligence;
LUAD	cis	rs13064411	0.627	rs9825827	chr3:113182231	T/C	cg10517650	chr3:113235015	CCDC52	-0.51	-8.97	-0.4	9.88e-18	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11644478	chr21:40555479	PSMG1	-0.61	-10.48	-0.45	5.24e-23	Cognitive function;
LUAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08439880	chr3:133502540	NA	-0.46	-9.15	-0.41	2.41e-18	Iron status biomarkers;
LUAD	cis	rs7593730	1.000	rs4452095	chr2:161200221	C/T	cg22609984	chr2:161126801	NA	0.44	7.18	0.33	3.21e-12	Type 2 diabetes;
LUAD	cis	rs7481584	1.000	rs12786344	chr11:3021392	G/A	cg11201177	chr11:2961805	NA	0.39	6.55	0.3	1.7e-10	Calcium levels;
LUAD	cis	rs12210905	0.688	rs12195783	chr6:27444345	A/G	cg08851530	chr6:28072375	NA	0.97	7.48	0.34	4.38e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg00083206	chr6:110721305	DDO	-0.42	-7.68	-0.35	1.14e-13	Platelet distribution width;
LUAD	trans	rs9747201	1.000	rs4239020	chr17:80176641	C/T	cg07393940	chr7:158741817	NA	0.69	11.47	0.49	1.01e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg16205897	chr5:131564050	P4HA2	-0.33	-7.45	-0.34	5.24e-13	Blood metabolite levels;
LUAD	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.46	8.16	0.37	3.86e-15	Alzheimer's disease (late onset);
LUAD	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg18477163	chr1:228402036	OBSCN	-0.36	-7.17	-0.33	3.43e-12	Diastolic blood pressure;
LUAD	cis	rs16882447	0.683	rs16882424	chr5:53492282	T/C	cg06461071	chr5:53490839	ARL15	0.39	6.59	0.31	1.32e-10	Systolic blood pressure (dietary potassium intake interaction);
LUAD	cis	rs2455799	0.613	rs6795100	chr3:15793798	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-9.72	-0.43	2.83e-20	Mean platelet volume;
LUAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg18944383	chr4:111397179	ENPEP	0.42	8.35	0.38	9.53e-16	Height;
LUAD	trans	rs1941687	0.509	rs2282632	chr18:31320229	A/G	cg27147174	chr7:100797783	AP1S1	-0.63	-11.35	-0.48	2.91e-26	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs261532	0.817	rs261534	chr5:138943690	T/C	cg11459648	chr5:138714337	SLC23A1	-0.41	-6.9	-0.32	1.87e-11	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg00634984	chr7:65235879	NA	0.48	6.52	0.3	1.97e-10	Aortic root size;
LUAD	cis	rs7584330	0.780	rs10176842	chr2:238428256	T/C	cg14458575	chr2:238380390	NA	0.56	10.76	0.46	4.88e-24	Prostate cancer;
LUAD	cis	rs711245	0.732	rs848643	chr2:36782387	G/A	cg09467607	chr2:36825704	FEZ2	0.56	10.85	0.47	2.39e-24	Height;
LUAD	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg06046430	chr4:77819534	ANKRD56	0.55	8.84	0.4	2.52e-17	Emphysema distribution in smoking;
LUAD	cis	rs17102423	0.652	rs4902361	chr14:65548470	G/T	cg11161011	chr14:65562177	MAX	-0.45	-7.57	-0.35	2.3e-13	Obesity-related traits;
LUAD	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg18180107	chr4:99064573	C4orf37	0.43	7.01	0.32	9.74e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg24450063	chr1:156163899	SLC25A44	1.23	30.09	0.83	3.59e-107	Testicular germ cell tumor;
LUAD	cis	rs72627123	0.582	rs62005102	chr14:74500586	T/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.59	7.8	0.35	4.87e-14	Morning vs. evening chronotype;
LUAD	cis	rs12134245	0.755	rs11164928	chr1:92012678	G/A	cg21854759	chr1:92012499	NA	-0.54	-9.93	-0.43	5.15e-21	Breast cancer;
LUAD	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.56	-0.42	9.54e-20	Alzheimer's disease;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg05886006	chr1:161359784	NA	0.39	6.44	0.3	3.34e-10	Monocyte percentage of white cells;
LUAD	cis	rs4243830	0.677	rs6693922	chr1:6584804	A/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.54	6.69	0.31	7e-11	Body mass index;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg19105961	chr17:4046223	CYB5D2;ZZEF1	-0.48	-7.85	-0.36	3.42e-14	Vertical cup-disc ratio;
LUAD	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.86	-0.36	3.31e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.93	0.53	1.89e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg17264618	chr3:40429014	ENTPD3	0.39	8.83	0.39	2.88e-17	Renal cell carcinoma;
LUAD	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg22482690	chr17:47019901	SNF8	0.47	9.1	0.4	3.6e-18	Type 2 diabetes;
LUAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg11062466	chr8:58055876	NA	-0.63	-8.22	-0.37	2.59e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg10978503	chr1:24200527	CNR2	0.59	12.62	0.52	3.41e-31	Immature fraction of reticulocytes;
LUAD	cis	rs367615	0.659	rs13435970	chr5:108884660	C/T	cg17395555	chr5:108820864	NA	0.53	8.59	0.39	1.73e-16	Colorectal cancer (SNP x SNP interaction);
LUAD	trans	rs7939886	0.920	rs11534518	chr11:55808146	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.46	0.3	2.82e-10	Myopia (pathological);
LUAD	trans	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg26043149	chr18:55253948	FECH	-0.44	-7.23	-0.33	2.21e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg21823605	chr1:152486609	CRCT1	0.29	6.61	0.31	1.19e-10	Hair morphology;
LUAD	cis	rs735539	0.521	rs2585902	chr13:21417636	A/C	cg27499820	chr13:21296301	IL17D	0.44	7.33	0.34	1.17e-12	Dental caries;
LUAD	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	6.92	0.32	1.64e-11	Schizophrenia;
LUAD	cis	rs2880765	0.506	rs719138	chr15:86055062	T/G	cg13263323	chr15:86062960	AKAP13	-0.5	-8.38	-0.38	7.96e-16	Coronary artery disease;
LUAD	cis	rs41271951	0.512	rs41266632	chr1:151042980	C/T	cg11822372	chr1:151115635	SEMA6C	-0.82	-6.97	-0.32	1.24e-11	Blood protein levels;
LUAD	cis	rs6960043	0.689	rs12538003	chr7:15058692	G/A	cg19272540	chr7:15055459	NA	0.4	8.84	0.39	2.59e-17	Type 2 diabetes;
LUAD	cis	rs9479482	1.000	rs9478380	chr6:150354665	A/G	cg25797454	chr6:150327115	RAET1K	-0.36	-7.63	-0.35	1.61e-13	Alopecia areata;
LUAD	cis	rs4809627	1	rs4809627	chr20:45757655	C/T	cg27589058	chr20:45804311	EYA2	-0.31	-6.77	-0.31	4.29e-11	Type 2 diabetes;
LUAD	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg03733263	chr8:22462867	KIAA1967	0.65	11.01	0.47	5.87e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.48	0.34	4.24e-13	Menopause (age at onset);
LUAD	cis	rs3760982	0.585	rs11083724	chr19:44298988	A/G	cg12072164	chr19:44306565	LYPD5	0.42	8.71	0.39	6.99e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19748678	chr4:122722346	EXOSC9	0.43	6.82	0.31	3.1e-11	Type 2 diabetes;
LUAD	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg06611532	chr13:114900021	NA	0.38	9.12	0.41	3.02e-18	Schizophrenia;
LUAD	cis	rs490234	0.841	rs13291593	chr9:128228483	A/G	cg14078157	chr9:128172775	NA	-0.43	-7.81	-0.35	4.67e-14	Mean arterial pressure;
LUAD	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg17063962	chr7:91808500	NA	0.67	11.92	0.5	1.89e-28	Breast cancer;
LUAD	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg06925179	chr17:43578568	NA	0.45	6.35	0.3	5.65e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs7395662	0.864	rs12366262	chr11:48563472	T/A	cg00717180	chr2:96193071	NA	-0.4	-7.42	-0.34	6.44e-13	HDL cholesterol;
LUAD	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg04398451	chr17:18023971	MYO15A	-0.64	-11.66	-0.49	2.04e-27	Total body bone mineral density;
LUAD	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg02371401	chr5:676784	TPPP	-0.48	-7.83	-0.36	3.9e-14	Lung disease severity in cystic fibrosis;
LUAD	cis	rs9837602	1.000	rs6799379	chr3:99762840	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	9.14	0.41	2.72e-18	Breast cancer;
LUAD	trans	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg02030672	chr11:45687055	CHST1	0.41	7.58	0.35	2.13e-13	Obesity-related traits;
LUAD	trans	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg13684625	chr10:60475332	BICC1;LOC728640	-0.38	-6.39	-0.3	4.33e-10	Leprosy;
LUAD	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.91	-14.21	-0.57	9.52e-38	Red cell distribution width;
LUAD	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.33	0.38	1.11e-15	Rheumatoid arthritis;
LUAD	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg12292205	chr6:26970375	C6orf41	-0.38	-6.73	-0.31	5.6e-11	Schizophrenia;
LUAD	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg26373071	chr5:1325741	CLPTM1L	0.35	7.03	0.32	8.21e-12	Lung cancer;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01516881	chr6:292596	DUSP22	-0.8	-13.88	-0.56	2.4e-36	Menopause (age at onset);
LUAD	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg18190219	chr22:46762943	CELSR1	-0.48	-6.69	-0.31	7.23e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg04546413	chr19:29218101	NA	0.57	7.39	0.34	8e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg14582100	chr15:45693742	SPATA5L1	0.64	12.56	0.52	5.85e-31	Homoarginine levels;
LUAD	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg05896524	chr21:47604654	C21orf56	0.53	8.94	0.4	1.22e-17	Testicular germ cell tumor;
LUAD	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg07741184	chr6:167504864	NA	0.29	7.03	0.32	8.43e-12	Crohn's disease;
LUAD	trans	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	17.28	0.64	5e-51	Exhaled nitric oxide output;
LUAD	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg00666640	chr1:248458726	OR2T12	0.33	8.05	0.36	8.2e-15	Common traits (Other);
LUAD	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg18138036	chr10:133769891	PPP2R2D	0.42	6.82	0.31	3.25e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg25482853	chr8:67687455	SGK3	1.18	18.25	0.66	2.68e-55	Lung disease severity in cystic fibrosis;
LUAD	trans	rs853679	1.000	rs853694	chr6:28279100	A/T	cg01620082	chr3:125678407	NA	-0.53	-6.72	-0.31	5.77e-11	Depression;
LUAD	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg22105103	chr4:187893119	NA	0.51	11.14	0.48	1.86e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg22963979	chr7:1858916	MAD1L1	-0.71	-12.51	-0.52	9.38e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs16958440	0.867	rs80064497	chr18:44669653	A/G	cg17192377	chr18:44677553	HDHD2	0.84	7.85	0.36	3.48e-14	Sitting height ratio;
LUAD	cis	rs11686934	0.780	rs6731423	chr2:70173327	A/C	cg02498382	chr2:70120550	SNRNP27	-0.51	-9.48	-0.42	1.85e-19	High light scatter reticulocyte count;
LUAD	trans	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.54	8.91	0.4	1.56e-17	Endometrial cancer;
LUAD	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.65	-0.35	1.35e-13	Breast cancer;
LUAD	cis	rs300703	0.592	rs300800	chr2:105493	T/C	cg21211680	chr2:198530	NA	-0.62	-7.68	-0.35	1.1e-13	Blood protein levels;
LUAD	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg01802117	chr1:53393560	SCP2	-0.34	-6.47	-0.3	2.64e-10	Monocyte count;
LUAD	cis	rs1595825	0.786	rs75619425	chr2:198537281	A/G	cg00982548	chr2:198649783	BOLL	-0.62	-8.78	-0.39	4.17e-17	Ulcerative colitis;
LUAD	cis	rs7705042	0.828	rs7737631	chr5:141506615	T/G	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.9	-0.32	1.93e-11	Asthma;
LUAD	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg03676636	chr4:99064102	C4orf37	0.32	8.28	0.37	1.59e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.46	-0.38	4.38e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg21782813	chr7:2030301	MAD1L1	0.45	7.64	0.35	1.44e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg09060608	chr5:178986726	RUFY1	-0.64	-11.11	-0.48	2.52e-25	Lung cancer;
LUAD	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg16049864	chr8:95962084	TP53INP1	-0.62	-14.03	-0.56	5.36e-37	Type 2 diabetes;
LUAD	cis	rs11249608	0.548	rs62393074	chr5:178450476	G/C	cg01312482	chr5:178451176	ZNF879	-0.44	-6.88	-0.32	2.1e-11	Pubertal anthropometrics;
LUAD	cis	rs2286503	0.780	rs929464	chr7:22874770	T/C	cg06496272	chr7:22895283	SNORD93	-0.42	-7.3	-0.33	1.45e-12	Fibrinogen;
LUAD	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10802521	chr3:52805072	NEK4	-0.52	-8.9	-0.4	1.66e-17	Bipolar disorder;
LUAD	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg26446133	chr18:72167187	CNDP2	-0.77	-11.11	-0.48	2.56e-25	Refractive error;
LUAD	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg05340658	chr4:99064831	C4orf37	0.54	9.13	0.41	2.92e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg00484396	chr16:3507460	NAT15	-0.76	-8.42	-0.38	6.04e-16	Tuberculosis;
LUAD	cis	rs977987	0.931	rs8057084	chr16:75492706	G/T	cg03315344	chr16:75512273	CHST6	-0.63	-14.48	-0.58	7.36e-39	Dupuytren's disease;
LUAD	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.68	0.31	7.77e-11	Rheumatoid arthritis;
LUAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.85	16.25	0.62	1.75e-46	Lymphocyte counts;
LUAD	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.25	-0.51	1.01e-29	Platelet count;
LUAD	cis	rs367943	0.556	rs7709820	chr5:112991327	G/A	cg12552261	chr5:112820674	MCC	0.43	7.86	0.36	3.11e-14	Type 2 diabetes;
LUAD	cis	rs240764	0.717	rs6904959	chr6:101157916	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-7.11	-0.33	5.13e-12	Neuroticism;
LUAD	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.41	-7.02	-0.32	9.04e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6543140	0.964	rs2310301	chr2:103072935	C/T	cg04239558	chr2:103089729	SLC9A4	0.36	7.34	0.34	1.11e-12	Blood protein levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20818191	chr4:866154	GAK	0.53	6.54	0.3	1.81e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg08523384	chr5:141488047	NDFIP1	-0.47	-7.13	-0.33	4.31e-12	Crohn's disease;
LUAD	cis	rs8177876	0.658	rs75422577	chr16:81088166	G/A	cg08591886	chr16:81111003	C16orf46	-0.79	-6.96	-0.32	1.31e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7020830	0.789	rs17408112	chr9:37114065	A/G	cg14294708	chr9:37120828	ZCCHC7	0.83	16.32	0.62	8.21e-47	Schizophrenia;
LUAD	cis	rs6011002	0.745	rs4809331	chr20:62370890	A/G	cg01176363	chr20:62369445	LIME1	-0.79	-6.6	-0.31	1.21e-10	Dental caries;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01045986	chr18:29671767	RNF138	-0.68	-6.44	-0.3	3.31e-10	Type 2 diabetes;
LUAD	cis	rs9039	1.000	rs11075212	chr16:9203899	G/A	cg08831531	chr16:9218945	NA	-0.4	-6.67	-0.31	7.8e-11	Menopause (age at onset);
LUAD	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg13010199	chr12:38710504	ALG10B	0.4	6.57	0.3	1.46e-10	Morning vs. evening chronotype;
LUAD	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg18230493	chr5:56204884	C5orf35	-0.45	-7.56	-0.35	2.49e-13	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.63	-0.31	1.04e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg22764044	chr5:178986830	RUFY1	0.5	8.46	0.38	4.36e-16	Lung cancer;
LUAD	cis	rs113835537	0.529	rs3819247	chr11:66293779	T/C	cg24851651	chr11:66362959	CCS	0.58	10.28	0.45	2.8e-22	Airway imaging phenotypes;
LUAD	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg06641503	chr3:48959341	ARIH2	-0.33	-6.46	-0.3	2.93e-10	Parkinson's disease;
LUAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg20607798	chr8:58055168	NA	0.56	6.88	0.32	2.17e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg15181151	chr6:150070149	PCMT1	-0.38	-7.86	-0.36	3.25e-14	Lung cancer;
LUAD	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg13073564	chr4:8508604	NA	0.48	7.9	0.36	2.5e-14	Response to antineoplastic agents;
LUAD	trans	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg14791747	chr16:20752902	THUMPD1	0.76	10.47	0.45	5.86e-23	Cognitive test performance;
LUAD	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg22705602	chr4:152727874	NA	-0.48	-9.07	-0.4	4.5e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg27129171	chr3:47204927	SETD2	0.41	6.5	0.3	2.32e-10	Colorectal cancer;
LUAD	cis	rs11696501	0.739	rs6104250	chr20:44251479	C/T	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.16	-0.37	3.85e-15	Brain structure;
LUAD	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg21204522	chr6:27730016	NA	-0.48	-7.63	-0.35	1.54e-13	Parkinson's disease;
LUAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg17372223	chr3:52568218	NT5DC2	0.53	10.8	0.46	3.53e-24	Electroencephalogram traits;
LUAD	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	7.98	0.36	1.37e-14	Tonsillectomy;
LUAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg04025307	chr7:1156635	C7orf50	0.6	6.77	0.31	4.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.66	-0.31	8.53e-11	Systolic blood pressure;
LUAD	cis	rs9902453	0.845	rs12452201	chr17:28214173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.34	0.41	5.55e-19	Coffee consumption (cups per day);
LUAD	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg24531977	chr5:56204891	C5orf35	-0.48	-8.06	-0.36	7.99e-15	Coronary artery disease;
LUAD	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg24558204	chr6:135376177	HBS1L	0.47	8.67	0.39	9.21e-17	Red blood cell count;
LUAD	cis	rs6714710	0.603	rs34149969	chr2:98342323	C/A	cg26665480	chr2:98280029	ACTR1B	0.54	8.76	0.39	4.82e-17	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg17761419	chr8:57350749	NA	-0.52	-7.88	-0.36	2.81e-14	Obesity-related traits;
LUAD	cis	rs7474896	0.537	rs598857	chr10:38302926	A/G	cg25427524	chr10:38739819	LOC399744	0.58	8.33	0.38	1.16e-15	Obesity (extreme);
LUAD	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg08805041	chr16:621841	PIGQ	-0.31	-6.36	-0.3	5.19e-10	Height;
LUAD	cis	rs4711336	0.664	rs4713662	chr6:33674188	A/G	cg14003231	chr6:33640908	ITPR3	0.5	9.55	0.42	1.04e-19	Height;
LUAD	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg20607287	chr7:12443886	VWDE	-0.54	-6.9	-0.32	1.93e-11	Coronary artery disease;
LUAD	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg12884169	chr21:40033163	ERG	0.5	10.74	0.46	5.82e-24	Coronary artery disease;
LUAD	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg16988262	chr1:15930761	NA	0.41	6.88	0.32	2.18e-11	Systolic blood pressure;
LUAD	cis	rs71478720	1.000	rs3882892	chr11:112014986	C/T	cg26534425	chr11:112034925	IL18	0.47	7.07	0.33	6.32e-12	Interleukin-18 levels;
LUAD	cis	rs10489202	0.608	rs16828093	chr1:168078384	C/T	cg25738037	chr1:168025549	DCAF6	-0.44	-6.61	-0.31	1.16e-10	Schizophrenia;
LUAD	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg03388025	chr16:89894329	SPIRE2	0.48	12.25	0.51	9.98e-30	Vitiligo;
LUAD	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg13770153	chr20:60521292	NA	-0.54	-8.91	-0.4	1.5e-17	Body mass index;
LUAD	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg00316803	chr15:76480434	C15orf27	-0.4	-7.61	-0.35	1.79e-13	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg04111992	chr7:158790115	NA	-0.49	-8.29	-0.37	1.48e-15	Facial morphology (factor 20);
LUAD	cis	rs6500395	1.000	rs12933948	chr16:48705825	C/G	cg04672837	chr16:48644449	N4BP1	-0.38	-6.51	-0.3	2.17e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg01528321	chr10:82214614	TSPAN14	0.65	10.46	0.45	6.49e-23	Post bronchodilator FEV1;
LUAD	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg02389323	chr16:88786976	FAM38A	-0.94	-9.7	-0.43	3.11e-20	Plateletcrit;
LUAD	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg04117972	chr1:227635322	NA	0.85	7.75	0.35	6.7e-14	Major depressive disorder;
LUAD	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg17279839	chr7:150038598	RARRES2	0.45	7.39	0.34	7.85e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg23954153	chr1:44402353	ARTN	-0.34	-6.73	-0.31	5.62e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6752107	0.967	rs56227616	chr2:234157741	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.53	9.04	0.4	5.52e-18	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9644630	0.696	rs13261824	chr8:19313912	C/G	cg06562184	chr8:19319451	CSGALNACT1	0.38	6.88	0.32	2.12e-11	Oropharynx cancer;
LUAD	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.84	-11.64	-0.49	2.32e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg07741184	chr6:167504864	NA	0.31	7.13	0.33	4.3e-12	Crohn's disease;
LUAD	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg02390115	chr1:21767211	NBPF3	0.42	7.0	0.32	1.02e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6908034	0.607	rs78774173	chr6:19820686	T/C	cg02682789	chr6:19804855	NA	0.93	8.5	0.38	3.17e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	trans	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg24644049	chr4:85504048	CDS1	0.86	7.4	0.34	7.43e-13	Skin colour saturation;
LUAD	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.18	-0.33	3.09e-12	Glomerular filtration rate;
LUAD	cis	rs12618769	0.652	rs4851145	chr2:99222916	A/G	cg10123293	chr2:99228465	UNC50	-0.49	-8.78	-0.39	4.11e-17	Bipolar disorder;
LUAD	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg12935359	chr14:103987150	CKB	0.52	8.08	0.37	6.82e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg19761014	chr17:28927070	LRRC37B2	0.66	6.44	0.3	3.24e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.32	-0.34	1.24e-12	Coronary artery disease;
LUAD	cis	rs67981189	0.529	rs2526850	chr14:71417249	A/T	cg15910301	chr14:71632612	NA	-0.41	-6.36	-0.3	5.27e-10	Schizophrenia;
LUAD	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.18	0.33	3.18e-12	Blood metabolite levels;
LUAD	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg19336497	chr11:14380999	RRAS2	0.36	7.47	0.34	4.49e-13	Mitochondrial DNA levels;
LUAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14159672	chr1:205819179	PM20D1	0.92	20.99	0.71	1.51e-67	Menarche (age at onset);
LUAD	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg24531977	chr5:56204891	C5orf35	-0.58	-9.3	-0.41	7.66e-19	Coronary artery disease;
LUAD	cis	rs738322	0.511	rs2267371	chr22:38577119	T/G	cg17652424	chr22:38574118	PLA2G6	-0.33	-9.07	-0.4	4.39e-18	Cutaneous nevi;
LUAD	trans	rs1941687	0.509	rs6507060	chr18:31322278	C/T	cg27147174	chr7:100797783	AP1S1	0.66	11.8	0.5	5.47e-28	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs7781266	0.501	rs10274077	chr7:133624271	C/T	cg03336402	chr7:133662267	EXOC4	0.45	7.92	0.36	2.11e-14	Educational attainment (college completion);
LUAD	trans	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg25482853	chr8:67687455	SGK3	1.03	16.38	0.62	4.76e-47	Obesity-related traits;
LUAD	cis	rs9863	0.794	rs7978610	chr12:124468572	C/G	cg17723958	chr12:124429295	CCDC92	0.38	6.48	0.3	2.52e-10	White blood cell count;
LUAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg05552183	chr6:42928497	GNMT	0.36	6.56	0.3	1.61e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2692947	0.832	rs62153679	chr2:96558400	C/T	cg23100626	chr2:96804247	ASTL	0.3	7.73	0.35	7.9e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs6696239	0.513	rs2999746	chr1:227793485	C/T	cg12133451	chr1:227746453	NA	-0.36	-6.39	-0.3	4.32e-10	Height;
LUAD	cis	rs62229266	0.609	rs2835253	chr21:37419745	T/C	cg08632701	chr21:37451849	NA	-0.38	-6.41	-0.3	3.84e-10	Mitral valve prolapse;
LUAD	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg07936489	chr17:37558343	FBXL20	-0.41	-6.39	-0.3	4.33e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg00530320	chr1:46809349	NSUN4	0.53	8.17	0.37	3.49e-15	Menopause (age at onset);
LUAD	cis	rs2742234	0.554	rs1254963	chr10:43696086	C/T	cg15436174	chr10:43711423	RASGEF1A	0.52	8.72	0.39	6.42e-17	Hirschsprung disease;
LUAD	cis	rs11048434	0.761	rs12827055	chr12:9130861	G/T	cg13575925	chr12:9217583	LOC144571	0.38	7.01	0.32	9.25e-12	Sjögren's syndrome;
LUAD	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg27494647	chr7:150038898	RARRES2	0.43	7.07	0.32	6.56e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9837602	1.000	rs35844878	chr3:99796626	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	9.39	0.42	3.82e-19	Breast cancer;
LUAD	cis	rs1997103	0.954	rs10246216	chr7:55390479	C/T	cg17469321	chr7:55412551	NA	0.68	11.6	0.49	3.38e-27	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs17401966	0.838	rs1013952	chr1:10319247	G/A	cg15208524	chr1:10270712	KIF1B	0.44	6.83	0.32	2.9100000000000002e-11	Hepatocellular carcinoma;
LUAD	cis	rs6430585	0.527	rs57530667	chr2:136444338	A/G	cg07169764	chr2:136633963	MCM6	0.59	6.92	0.32	1.66e-11	Corneal structure;
LUAD	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.53	0.52	7.6e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10106298	0.846	rs1550005	chr8:103681662	C/G	cg10187029	chr8:103597600	NA	0.42	6.9	0.32	1.92e-11	Schizophrenia;
LUAD	cis	rs1127311	1.000	rs1127313	chr1:154556425	A/G	cg17218026	chr1:154582156	ADAR	-0.5	-9.81	-0.43	1.3e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg18876405	chr7:65276391	NA	0.46	7.44	0.34	5.5e-13	Aortic root size;
LUAD	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg07402062	chr16:89894098	SPIRE2	0.45	11.47	0.49	1.05e-26	Vitiligo;
LUAD	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg12140854	chr5:148520817	ABLIM3	-0.67	-10.69	-0.46	9.25e-24	Breast cancer;
LUAD	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg27129171	chr3:47204927	SETD2	0.43	6.96	0.32	1.28e-11	Colorectal cancer;
LUAD	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.44	-0.42	2.51e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs41271473	0.526	rs56043220	chr1:228783474	G/C	cg10167378	chr1:228756711	NA	0.66	8.68	0.39	8.4e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg10819733	chr22:24237672	NA	-0.41	-7.64	-0.35	1.51e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg14835575	chr10:16859367	RSU1	0.93	13.55	0.55	5.57e-35	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg15704280	chr7:45808275	SEPT13	0.63	8.42	0.38	5.9e-16	Axial length;
LUAD	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg05991184	chr2:219186017	PNKD	-0.38	-7.54	-0.34	2.92e-13	Colorectal cancer;
LUAD	cis	rs11676348	0.808	rs12694430	chr2:219015799	T/C	cg06547715	chr2:218990976	CXCR2	0.32	7.2	0.33	2.8e-12	Ulcerative colitis;
LUAD	cis	rs17155006	0.655	rs424978	chr7:107724747	C/G	cg05962710	chr7:107745446	LAMB4	-0.3	-6.61	-0.31	1.14e-10	Pneumococcal bacteremia;
LUAD	cis	rs1018836	0.923	rs12680211	chr8:91633434	C/T	cg16814680	chr8:91681699	NA	-0.65	-11.0	-0.47	6.35e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9972944	0.756	rs7223214	chr17:63761473	C/T	cg07283582	chr17:63770753	CCDC46	-0.52	-11.72	-0.5	1.17e-27	Total body bone mineral density;
LUAD	cis	rs7814319	0.600	rs111300519	chr8:97262939	G/A	cg20787634	chr8:97240163	UQCRB	-0.35	-6.42	-0.3	3.63e-10	Lung function (FVC);
LUAD	cis	rs6564851	0.506	rs11644611	chr16:81260494	T/G	cg00908271	chr16:81254010	PKD1L2	0.33	6.73	0.31	5.64e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18402987	chr7:1209562	NA	0.42	6.73	0.31	5.46e-11	Longevity;Endometriosis;
LUAD	cis	rs4285028	0.948	rs76593525	chr3:121690477	G/A	cg20356878	chr3:121714668	ILDR1	-0.49	-6.64	-0.31	9.57e-11	Multiple sclerosis;
LUAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg05313129	chr8:58192883	C8orf71	-0.54	-6.74	-0.31	5.33e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg14092988	chr3:52407081	DNAH1	0.45	8.97	0.4	1e-17	Bipolar disorder;
LUAD	cis	rs56283067	0.887	rs7765371	chr6:44777204	G/A	cg18551225	chr6:44695536	NA	-0.49	-7.61	-0.35	1.82e-13	Total body bone mineral density;
LUAD	cis	rs2281636	0.894	rs2297446	chr10:101370015	T/C	cg17885402	chr10:101492224	COX15;CUTC	-0.38	-6.52	-0.3	1.96e-10	Obesity-related traits;
LUAD	trans	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg07211511	chr3:129823064	LOC729375	-0.53	-6.73	-0.31	5.7e-11	Blood pressure (smoking interaction);
LUAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.45	-0.38	4.68e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg14791747	chr16:20752902	THUMPD1	-0.47	-7.21	-0.33	2.68e-12	Dental caries;
LUAD	cis	rs2573652	0.963	rs2573649	chr15:100514040	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.49	-8.71	-0.39	7.03e-17	Height;
LUAD	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg03676636	chr4:99064102	C4orf37	0.31	8.21	0.37	2.79e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4077515	0.874	rs3812560	chr9:139269905	T/C	cg14169450	chr9:139327907	INPP5E	0.4	7.33	0.34	1.18e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg25767906	chr1:53392781	SCP2	0.44	8.17	0.37	3.64e-15	Monocyte count;
LUAD	cis	rs4462272	0.557	rs1327578	chr10:101967410	G/A	cg19754520	chr10:101825118	CPN1	-0.31	-6.48	-0.3	2.52e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06028808	chr11:68637592	NA	0.45	7.56	0.34	2.53e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg02551604	chr5:131831745	NA	-0.61	-10.08	-0.44	1.46e-21	Asthma (sex interaction);
LUAD	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg18306943	chr3:40428807	ENTPD3	0.36	6.38	0.3	4.66e-10	Renal cell carcinoma;
LUAD	cis	rs13082711	0.555	rs73149363	chr3:27265394	C/A	cg02860705	chr3:27208620	NA	0.61	9.32	0.41	6.66e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs367943	0.712	rs7734061	chr5:112700175	A/G	cg12552261	chr5:112820674	MCC	0.49	9.63	0.42	5.44e-20	Type 2 diabetes;
LUAD	trans	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg19862616	chr7:65841803	NCRNA00174	1.06	27.46	0.8	4.59e-96	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg15704280	chr7:45808275	SEPT13	0.62	8.27	0.37	1.79e-15	Axial length;
LUAD	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06505273	chr16:24850292	NA	0.51	7.4	0.34	7.19e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg11502198	chr6:26597334	ABT1	0.56	9.35	0.41	5.23e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg06636551	chr8:101224915	SPAG1	-0.37	-6.67	-0.31	8.12e-11	Atrioventricular conduction;
LUAD	cis	rs9976767	0.932	rs7283281	chr21:43825519	C/G	cg00134539	chr21:43824071	UBASH3A	0.3	6.45	0.3	3.06e-10	Type 1 diabetes;
LUAD	cis	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg05084668	chr3:125655381	ALG1L	-0.61	-8.95	-0.4	1.16e-17	Blood pressure (smoking interaction);
LUAD	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg13732083	chr21:47605072	C21orf56	0.42	6.95	0.32	1.39e-11	Testicular germ cell tumor;
LUAD	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-6.83	-0.32	3.01e-11	Morning vs. evening chronotype;
LUAD	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg08601574	chr20:25228251	PYGB	-0.46	-8.55	-0.38	2.35e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4766566	0.651	rs933307	chr12:111735537	A/C	cg10833066	chr12:111807467	FAM109A	-0.65	-13.4	-0.55	2.31e-34	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUAD	cis	rs9494145	0.680	rs9402686	chr6:135427817	G/A	cg22676075	chr6:135203613	NA	0.58	8.64	0.39	1.14e-16	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUAD	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg05590025	chr7:65112418	INTS4L2	-0.78	-8.26	-0.37	1.9e-15	Diabetic kidney disease;
LUAD	cis	rs1865721	0.804	rs7243462	chr18:73147998	A/T	cg26385618	chr18:73139727	C18orf62	-0.51	-10.05	-0.44	1.92e-21	Intelligence;
LUAD	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg14159672	chr1:205819179	PM20D1	-0.51	-7.66	-0.35	1.24e-13	Menarche (age at onset);
LUAD	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg22532475	chr10:104410764	TRIM8	-0.48	-9.29	-0.41	8.48e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.48	-0.3	2.55e-10	Depression;
LUAD	cis	rs6881634	0.501	rs10452490	chr5:77695040	A/G	cg11547950	chr5:77652471	NA	-0.37	-6.63	-0.31	1.04e-10	Hippocampal atrophy;
LUAD	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg00922110	chr4:57842668	C4orf14	-0.45	-8.66	-0.39	9.86e-17	Response to bleomycin (chromatid breaks);
LUAD	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg07708487	chr16:89387014	ANKRD11	0.33	6.79	0.31	3.84e-11	Multiple myeloma (IgH translocation);
LUAD	trans	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg06606381	chr12:133084897	FBRSL1	-0.57	-7.17	-0.33	3.33e-12	Depression;
LUAD	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg19500851	chr17:37840957	PGAP3	-0.33	-6.57	-0.3	1.47e-10	Asthma;
LUAD	cis	rs16858210	0.648	rs79478990	chr3:183587094	C/T	cg01324343	chr3:183735012	ABCC5	0.42	6.5	0.3	2.3e-10	Menopause (age at onset);
LUAD	cis	rs62458065	0.850	rs10273165	chr7:32460840	G/A	cg20159608	chr7:32802032	NA	-0.53	-7.0	-0.32	9.79e-12	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg18306943	chr3:40428807	ENTPD3	0.36	6.41	0.3	3.96e-10	Renal cell carcinoma;
LUAD	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg00684032	chr4:1343700	KIAA1530	0.39	6.68	0.31	7.55e-11	Obesity-related traits;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg19626500	chr19:17445531	ANO8	-0.63	-6.4	-0.3	4.03e-10	Type 2 diabetes;
LUAD	trans	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg13565492	chr6:43139072	SRF	-0.6	-6.4	-0.3	4.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1941687	0.563	rs1586987	chr18:31338661	A/G	cg27147174	chr7:100797783	AP1S1	-0.67	-12.43	-0.52	1.88e-30	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs89107	0.688	rs372237	chr6:118608979	G/T	cg18833306	chr6:118973337	C6orf204	0.51	9.23	0.41	1.33e-18	Cardiac structure and function;
LUAD	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.37	-7.34	-0.34	1.14e-12	Total body bone mineral density;
LUAD	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg16797656	chr11:68205561	LRP5	0.48	9.39	0.42	3.87e-19	Total body bone mineral density;
LUAD	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg03690763	chr11:133734501	NA	-0.33	-7.84	-0.36	3.75e-14	Childhood ear infection;
LUAD	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg22920501	chr2:26401640	FAM59B	-0.76	-10.95	-0.47	9.94e-25	Gut microbiome composition (summer);
LUAD	cis	rs4523957	0.583	rs2984939	chr17:2023965	T/C	cg16513277	chr17:2031491	SMG6	-0.95	-19.14	-0.68	2.98e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg05865280	chr17:75406074	SEPT9	0.62	19.62	0.69	2.12e-61	Airflow obstruction;
LUAD	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg07507251	chr3:52567010	NT5DC2	0.32	6.47	0.3	2.8e-10	Bipolar disorder;
LUAD	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg22681709	chr2:178499509	PDE11A	-0.47	-7.79	-0.35	5.2e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24531977	chr5:56204891	C5orf35	1.25	20.51	0.71	2.15e-65	Initial pursuit acceleration;
LUAD	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.58e-12	Crohn's disease;
LUAD	cis	rs9283706	0.689	rs10041705	chr5:66317222	C/T	cg11590213	chr5:66331682	MAST4	-0.4	-6.67	-0.31	8e-11	Coronary artery disease;
LUAD	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg11901034	chr3:128598214	ACAD9	-0.5	-7.6	-0.35	1.98e-13	IgG glycosylation;
LUAD	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.76	0.31	4.64e-11	Depression;
LUAD	trans	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.91	-0.32	1.8e-11	Gout;
LUAD	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg00933542	chr6:150070202	PCMT1	0.41	8.01	0.36	1.1e-14	Lung cancer;
LUAD	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.41	0.38	6.12e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22857025	chr5:266934	NA	-0.98	-12.52	-0.52	8.2e-31	Breast cancer;
LUAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03452623	chr4:187889614	NA	-0.81	-16.53	-0.63	1.03e-47	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs2281636	0.894	rs12782208	chr10:101376976	T/C	cg17885402	chr10:101492224	COX15;CUTC	-0.39	-6.65	-0.31	8.85e-11	Obesity-related traits;
LUAD	cis	rs11676348	0.967	rs4672873	chr2:219005210	A/G	cg06547715	chr2:218990976	CXCR2	0.4	9.28	0.41	8.56e-19	Ulcerative colitis;
LUAD	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg26022315	chr17:47021804	SNF8	0.4	7.28	0.33	1.63e-12	Type 2 diabetes;
LUAD	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg02527881	chr3:46936655	PTH1R	-0.42	-8.17	-0.37	3.63e-15	Colorectal cancer;
LUAD	cis	rs3772130	0.564	rs28620947	chr3:121585631	G/A	cg20356878	chr3:121714668	ILDR1	0.68	14.09	0.57	3.18e-37	Cognitive performance;
LUAD	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10802521	chr3:52805072	NEK4	-0.53	-9.1	-0.4	3.69e-18	Bipolar disorder;
LUAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg13047869	chr3:10149882	C3orf24	0.66	11.14	0.48	1.93e-25	Alzheimer's disease;
LUAD	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.35	7.01	0.32	9.42e-12	Obesity-related traits;
LUAD	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg08847533	chr14:75593920	NEK9	-0.4	-6.99	-0.32	1.09e-11	Height;
LUAD	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.8	-0.35	4.94e-14	Blood metabolite levels;
LUAD	cis	rs7771547	0.573	rs629721	chr6:36398229	T/C	cg04289385	chr6:36355825	ETV7	0.43	6.61	0.31	1.14e-10	Platelet distribution width;
LUAD	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg09491104	chr22:46646882	C22orf40	-0.6	-9.58	-0.42	8.05e-20	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg05535760	chr7:792225	HEATR2	0.87	11.28	0.48	5.6e-26	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	1.95e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg24324837	chr19:49891574	CCDC155	0.59	9.13	0.41	2.9e-18	Multiple sclerosis;
LUAD	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg18305652	chr10:134549665	INPP5A	0.59	12.54	0.52	6.69e-31	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg09455208	chr3:40491958	NA	-0.6	-13.3	-0.54	5.61e-34	Renal cell carcinoma;
LUAD	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg04568274	chr7:158649319	WDR60	0.42	6.77	0.31	4.45e-11	Height;
LUAD	cis	rs9768139	0.935	rs62480865	chr7:158122307	A/C	cg24154853	chr7:158122151	PTPRN2	-0.59	-11.75	-0.5	9.2e-28	Calcium levels;
LUAD	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	7.03	0.32	8.19e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12681287	0.640	rs13253296	chr8:87448245	C/T	cg00550725	chr8:87521180	FAM82B	0.45	6.63	0.31	1.02e-10	Caudate activity during reward;
LUAD	cis	rs55788414	0.932	rs12103358	chr16:81185844	C/G	cg06400318	chr16:81190750	PKD1L2	-0.59	-8.51	-0.38	3.07e-16	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs9346649	0.591	rs1873338	chr6:168492087	T/C	cg02770688	chr6:168491649	NA	0.53	10.11	0.44	1.12e-21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs4523957	0.690	rs4790884	chr17:2105299	G/C	cg16513277	chr17:2031491	SMG6	-0.79	-15.21	-0.59	5.59e-42	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7216064	0.911	rs12449442	chr17:65947640	G/A	cg08758996	chr17:66097529	LOC651250	0.45	6.88	0.32	2.19e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg24675658	chr1:53192096	ZYG11B	0.4	6.49	0.3	2.46e-10	Monocyte count;
LUAD	cis	rs36096196	0.945	rs12080256	chr1:2251357	C/A	cg17974515	chr1:2252516	NA	0.41	6.75	0.31	4.8e-11	Coronary artery disease;
LUAD	cis	rs12760731	0.565	rs34593395	chr1:178129488	C/T	cg00404053	chr1:178313656	RASAL2	0.71	8.97	0.4	9.92e-18	Obesity-related traits;
LUAD	cis	rs2996428	0.667	rs2368534	chr1:3740640	C/T	cg17443473	chr1:3703550	LRRC47	0.45	7.37	0.34	8.87e-13	Red cell distribution width;
LUAD	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg17063962	chr7:91808500	NA	0.71	12.44	0.52	1.68e-30	Breast cancer;
LUAD	cis	rs427941	0.703	rs201448	chr7:101738860	T/C	cg06246474	chr7:101738831	CUX1	0.42	7.3	0.33	1.48e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs11167764	0.945	rs891985	chr5:141466066	C/G	cg08523384	chr5:141488047	NDFIP1	-0.46	-6.74	-0.31	5.23e-11	Crohn's disease;
LUAD	cis	rs250677	1.000	rs190378	chr5:148434275	G/T	cg18129178	chr5:148520854	ABLIM3	-0.51	-7.83	-0.36	3.96e-14	Breast cancer;
LUAD	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg15123519	chr2:136567270	LCT	0.38	7.0	0.32	9.89e-12	Mosquito bite size;
LUAD	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg10589385	chr1:150898437	SETDB1	0.41	7.77	0.35	6.15e-14	Tonsillectomy;
LUAD	cis	rs457287	0.772	rs844511	chr9:4822521	C/G	cg14182974	chr9:4791918	RCL1	0.46	6.65	0.31	9.19e-11	Platelet count;
LUAD	cis	rs89107	0.576	rs763254	chr6:118886615	T/C	cg21191810	chr6:118973309	C6orf204	0.41	7.54	0.34	2.85e-13	Cardiac structure and function;
LUAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg11766577	chr21:47581405	C21orf56	0.56	9.5	0.42	1.56e-19	Testicular germ cell tumor;
LUAD	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10802521	chr3:52805072	NEK4	-0.62	-11.08	-0.47	3.05e-25	Bipolar disorder;
LUAD	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06022373	chr22:39101656	GTPBP1	0.46	7.04	0.32	8.04e-12	Menopause (age at onset);
LUAD	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg21862992	chr11:68658383	NA	0.52	9.76	0.43	2.03e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg11070056	chr1:107600091	PRMT6	-0.66	-11.6	-0.49	3.48e-27	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg13126279	chr21:47581558	C21orf56	-0.43	-7.42	-0.34	6.66e-13	Testicular germ cell tumor;
LUAD	cis	rs2625529	0.503	rs7162299	chr15:72414065	A/G	cg16672083	chr15:72433130	SENP8	0.66	12.43	0.52	1.96e-30	Red blood cell count;
LUAD	trans	rs877282	1.000	rs11253362	chr10:770979	G/T	cg22713356	chr15:30763199	NA	1.3	19.25	0.68	9.34e-60	Uric acid levels;
LUAD	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	7.0	0.32	9.92e-12	Depression;
LUAD	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg05590025	chr7:65112418	INTS4L2	0.64	7.57	0.35	2.44e-13	Diabetic kidney disease;
LUAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.41	-8.56	-0.38	2.17e-16	Lymphocyte counts;
LUAD	cis	rs12200560	0.505	rs211183	chr6:97074723	G/T	cg06623918	chr6:96969491	KIAA0776	-0.43	-6.59	-0.3	1.34e-10	Coronary heart disease;
LUAD	trans	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg01620082	chr3:125678407	NA	-0.6	-7.31	-0.33	1.35e-12	Lung cancer in ever smokers;
LUAD	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg23758822	chr17:41437982	NA	0.97	20.68	0.71	3.54e-66	Menopause (age at onset);
LUAD	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg22467129	chr15:76604101	ETFA	-0.48	-8.52	-0.38	2.81e-16	Blood metabolite levels;
LUAD	trans	rs1598848	0.772	rs9305318	chr21:28946062	C/T	cg24494009	chr15:101926307	PCSK6	-0.32	-6.38	-0.3	4.68e-10	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg24675658	chr1:53192096	ZYG11B	0.43	6.93	0.32	1.6e-11	Monocyte count;
LUAD	cis	rs7020830	0.931	rs3802422	chr9:37097172	G/A	cg14294708	chr9:37120828	ZCCHC7	0.83	16.36	0.62	6e-47	Schizophrenia;
LUAD	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg23262073	chr20:60523788	NA	-0.44	-7.66	-0.35	1.29e-13	Body mass index;
LUAD	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg04511125	chr2:88470314	THNSL2	1.0	11.01	0.47	6.06e-25	Plasma clusterin levels;
LUAD	trans	rs2270927	0.510	rs7730153	chr5:75579762	A/G	cg13563193	chr19:33072644	PDCD5	-0.9	-8.91	-0.4	1.55e-17	Mean corpuscular volume;
LUAD	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg09365446	chr1:150670422	GOLPH3L	0.55	9.62	0.42	6.27e-20	Tonsillectomy;
LUAD	cis	rs2046867	0.818	rs6808341	chr3:72914847	A/G	cg25664220	chr3:72788482	NA	-0.56	-9.9	-0.43	6.4e-21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg18944383	chr4:111397179	ENPEP	0.38	7.76	0.35	6.25e-14	Height;
LUAD	trans	rs7395662	0.745	rs10838830	chr11:48233932	A/G	cg15704280	chr7:45808275	SEPT13	0.42	6.51	0.3	2.15e-10	HDL cholesterol;
LUAD	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg26408565	chr15:76604113	ETFA	-0.47	-7.63	-0.35	1.59e-13	Blood metabolite levels;
LUAD	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06112835	chr11:68658793	MRPL21	0.5	9.16	0.41	2.26e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.77	-0.43	1.86e-20	Schizophrenia;
LUAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14893161	chr1:205819251	PM20D1	0.82	17.23	0.64	8.85e-51	Menarche (age at onset);
LUAD	trans	rs3960554	1.000	rs78663390	chr7:75845837	C/A	cg19862616	chr7:65841803	NCRNA00174	0.82	10.68	0.46	9.76e-24	Eotaxin levels;
LUAD	cis	rs904251	0.523	rs2776872	chr6:37482787	C/G	cg25019722	chr6:37503610	NA	-0.33	-7.65	-0.35	1.34e-13	Cognitive performance;
LUAD	cis	rs2625529	0.824	rs35167572	chr15:72378960	A/G	cg16672083	chr15:72433130	SENP8	-0.75	-12.66	-0.52	2.33e-31	Red blood cell count;
LUAD	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg04990556	chr1:26633338	UBXN11	0.4	6.51	0.3	2.16e-10	Obesity-related traits;
LUAD	trans	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg07817883	chr1:32538562	TMEM39B	1.36	13.22	0.54	1.23e-33	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg00310523	chr12:86230176	RASSF9	0.39	7.8	0.35	4.9e-14	Major depressive disorder;
LUAD	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg13770153	chr20:60521292	NA	-0.47	-7.99	-0.36	1.29e-14	Body mass index;
LUAD	cis	rs4891159	0.790	rs59762437	chr18:74153146	G/A	cg24786174	chr18:74118243	ZNF516	-0.81	-15.04	-0.59	3.05e-41	Longevity;
LUAD	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg23245007	chr3:195682326	NA	-0.43	-6.89	-0.32	2.08e-11	Pancreatic cancer;
LUAD	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg12524338	chr4:183729343	NA	0.57	6.5	0.3	2.22e-10	Pediatric autoimmune diseases;
LUAD	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg04398451	chr17:18023971	MYO15A	0.64	11.71	0.49	1.2100000000000001e-27	Total body bone mineral density;
LUAD	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	7.38	0.34	8.62e-13	Renal cell carcinoma;
LUAD	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg22496339	chr2:162101262	NA	0.47	7.44	0.34	5.64e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs938554	0.736	rs13125646	chr4:9982330	A/G	cg11266682	chr4:10021025	SLC2A9	0.42	7.4	0.34	7.49e-13	Blood metabolite levels;
LUAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg15147215	chr3:52552868	STAB1	-0.48	-9.06	-0.4	4.98e-18	Electroencephalogram traits;
LUAD	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg00666640	chr1:248458726	OR2T12	0.3	7.27	0.33	1.8e-12	Common traits (Other);
LUAD	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg23254163	chr1:152506842	NA	0.24	6.62	0.31	1.11e-10	Hair morphology;
LUAD	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	8.55	0.38	2.22e-16	Breast cancer;
LUAD	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg11317459	chr13:21872234	NA	-1.09	-14.7	-0.58	8.44e-40	White matter hyperintensity burden;
LUAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg14926445	chr8:58193284	C8orf71	-0.47	-6.85	-0.32	2.62e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg01246254	chr10:124134882	PLEKHA1	-0.5	-6.39	-0.3	4.26e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg20891283	chr12:69753455	YEATS4	0.43	6.8	0.31	3.56e-11	Blood protein levels;
LUAD	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg04025307	chr7:1156635	C7orf50	0.55	9.44	0.42	2.44e-19	Longevity;Endometriosis;
LUAD	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg10518543	chr12:38710700	ALG10B	-0.42	-6.91	-0.32	1.82e-11	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-8.4	-0.38	7.06e-16	Endometrial cancer;
LUAD	cis	rs72772090	0.634	rs17401901	chr5:96091925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-8.05	-0.36	8.19e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4356932	1.000	rs10021768	chr4:76951764	C/T	cg00809888	chr4:76862425	NAAA	-0.42	-7.0	-0.32	1.03e-11	Blood protein levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22498987	chr12:120427182	CCDC64	-0.62	-7.64	-0.35	1.5e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg21659725	chr3:3221576	CRBN	0.51	8.3	0.37	1.42e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.13	-0.37	4.78e-15	Cystic fibrosis severity;
LUAD	cis	rs490234	0.966	rs534214	chr9:128369224	A/G	cg14078157	chr9:128172775	NA	-0.37	-6.76	-0.31	4.64e-11	Mean arterial pressure;
LUAD	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.04	0.32	7.83e-12	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg07936489	chr17:37558343	FBXL20	-0.51	-6.73	-0.31	5.6e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg12311346	chr5:56204834	C5orf35	-0.93	-13.61	-0.55	3.03e-35	Initial pursuit acceleration;
LUAD	cis	rs9341808	0.935	rs9343974	chr6:80924645	A/G	cg08355045	chr6:80787529	NA	0.47	8.43	0.38	5.4e-16	Sitting height ratio;
LUAD	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg13906792	chr15:75199810	C15orf17	-0.35	-6.38	-0.3	4.64e-10	Breast cancer;
LUAD	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg27068330	chr11:65405492	SIPA1	-0.79	-12.89	-0.53	2.64e-32	Acne (severe);
LUAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg09436375	chr6:42928200	GNMT	-0.29	-8.08	-0.37	7.07e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg09365446	chr1:150670422	GOLPH3L	0.54	9.47	0.42	1.97e-19	Tonsillectomy;
LUAD	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-9.47	-0.42	2.07e-19	Life satisfaction;
LUAD	cis	rs727505	0.866	rs66650870	chr7:124713194	T/C	cg23710748	chr7:124431027	NA	-0.41	-8.47	-0.38	4.1e-16	Lewy body disease;
LUAD	cis	rs4072705	0.646	rs10120967	chr9:127244134	C/T	cg01786973	chr9:127249749	NR5A1	0.31	6.98	0.32	1.14e-11	Menarche (age at onset);
LUAD	cis	rs72772090	0.634	rs72773906	chr5:96092274	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-8.05	-0.36	8.19e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs367943	0.666	rs7717422	chr5:112704089	A/G	cg21806985	chr5:112824646	MCC	0.24	6.51	0.3	2.17e-10	Type 2 diabetes;
LUAD	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg18252515	chr7:66147081	NA	0.62	6.77	0.31	4.25e-11	Diabetic kidney disease;
LUAD	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg10909506	chr17:38081995	ORMDL3	0.38	6.8	0.31	3.51e-11	Self-reported allergy;
LUAD	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg24803719	chr17:45855879	NA	-0.31	-6.93	-0.32	1.58e-11	IgG glycosylation;
LUAD	cis	rs72928364	0.860	rs62274066	chr3:100801179	A/C	cg10123952	chr3:100791384	NA	0.74	8.35	0.38	9.85e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg10755058	chr3:40428713	ENTPD3	-0.37	-6.95	-0.32	1.39e-11	Renal cell carcinoma;
LUAD	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.41	7.26	0.33	1.92e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg07460842	chr6:66804631	NA	1.17	28.37	0.81	6.4e-100	Exhaled nitric oxide output;
LUAD	cis	rs597539	0.690	rs1249359	chr11:68618279	C/T	cg06028808	chr11:68637592	NA	0.5	8.19	0.37	3.22e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg00071950	chr4:10020882	SLC2A9	0.74	14.9	0.59	1.18e-40	Bone mineral density;
LUAD	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg23387056	chr11:14280742	SPON1	-0.42	-8.73	-0.39	5.8e-17	Mitochondrial DNA levels;
LUAD	cis	rs7512552	0.809	rs1694363	chr1:150368677	T/G	cg15654264	chr1:150340011	RPRD2	0.62	11.66	0.49	1.99e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs427941	0.703	rs201456	chr7:101741059	C/G	cg06246474	chr7:101738831	CUX1	0.41	7.29	0.33	1.57e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs7395662	0.963	rs12418254	chr11:48988262	G/A	cg00717180	chr2:96193071	NA	-0.4	-7.6	-0.35	1.96e-13	HDL cholesterol;
LUAD	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg17724175	chr1:150552817	MCL1	0.31	7.17	0.33	3.41e-12	Melanoma;
LUAD	trans	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.43	0.55	1.68e-34	Exhaled nitric oxide output;
LUAD	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg19875535	chr5:140030758	IK	-0.47	-7.83	-0.36	3.85e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg10207240	chr12:122356781	WDR66	0.46	7.89	0.36	2.56e-14	Mean corpuscular volume;
LUAD	cis	rs863345	0.526	rs863931	chr1:158612236	A/G	cg12129480	chr1:158549410	OR10X1	-0.24	-6.39	-0.3	4.41e-10	Pneumococcal bacteremia;
LUAD	cis	rs494562	0.730	rs9450271	chr6:86114837	G/A	cg13315970	chr6:86159197	NT5E	0.59	6.86	0.32	2.39e-11	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs4660214	0.614	rs10888715	chr1:39699244	C/T	cg27567593	chr1:39956653	BMP8A	0.33	6.41	0.3	3.99e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg18105134	chr13:113819100	PROZ	-0.81	-14.33	-0.57	3.07e-38	Platelet distribution width;
LUAD	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06544989	chr22:39130855	UNC84B	0.43	8.03	0.36	9.95e-15	Menopause (age at onset);
LUAD	trans	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg27411982	chr8:10470053	RP1L1	0.4	7.09	0.33	5.65e-12	Mood instability;
LUAD	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg15128208	chr22:42549153	NA	-0.42	-8.67	-0.39	9.13e-17	Cognitive function;
LUAD	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg06484146	chr7:12443880	VWDE	-0.58	-7.33	-0.34	1.17e-12	Coronary artery disease;
LUAD	cis	rs62400317	0.731	rs17288320	chr6:45338703	T/C	cg18551225	chr6:44695536	NA	-0.54	-7.96	-0.36	1.56e-14	Total body bone mineral density;
LUAD	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg04546413	chr19:29218101	NA	0.67	8.84	0.39	2.69e-17	Methadone dose in opioid dependence;
LUAD	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg12119029	chr16:89752879	CDK10	0.34	6.92	0.32	1.72e-11	Vitiligo;
LUAD	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg01657329	chr11:68192670	LRP5	-0.42	-6.62	-0.31	1.09e-10	Total body bone mineral density;
LUAD	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg22823121	chr1:150693482	HORMAD1	0.45	9.13	0.41	2.95e-18	Tonsillectomy;
LUAD	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22968622	chr17:43663579	NA	-1.2	-20.04	-0.7	2.55e-63	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2235642	0.507	rs2235643	chr16:1585115	A/G	cg03034668	chr16:1723424	CRAMP1L	0.44	6.72	0.31	6.06e-11	Coronary artery disease;
LUAD	cis	rs868036	0.718	rs28587941	chr15:68122509	T/C	cg24579218	chr15:68104479	NA	-0.54	-9.25	-0.41	1.08e-18	Restless legs syndrome;
LUAD	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	7.52	0.34	3.36e-13	Menarche (age at onset);
LUAD	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.36	-0.34	9.57e-13	Resting heart rate;
LUAD	trans	rs1493916	1.000	rs12457802	chr18:31389865	A/G	cg15819921	chr19:927150	ARID3A	0.43	7.09	0.33	5.55e-12	Life satisfaction;
LUAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg10729496	chr3:10149963	C3orf24	0.58	9.43	0.42	2.76e-19	Alzheimer's disease;
LUAD	cis	rs62238980	0.614	rs4821027	chr22:32442074	G/A	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04071446	chr10:115933849	C10orf118	-0.47	-7.28	-0.33	1.63e-12	Height;
LUAD	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg08754654	chr5:154026448	NA	0.47	7.92	0.36	2.05e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.4	7.92	0.36	2.11e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7786808	0.579	rs55701656	chr7:158188812	G/A	cg01191920	chr7:158217561	PTPRN2	-0.62	-12.81	-0.53	5.53e-32	Obesity-related traits;
LUAD	cis	rs7614311	0.636	rs73117045	chr3:63910613	A/G	cg22134162	chr3:63841271	THOC7	-0.51	-8.31	-0.37	1.34e-15	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs2795502	0.564	rs11239826	chr10:43403097	T/C	cg08461752	chr10:43522343	NA	-0.79	-8.45	-0.38	4.72e-16	Blood protein levels;
LUAD	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg08645402	chr16:4508243	NA	0.55	9.59	0.42	7.43e-20	Schizophrenia;
LUAD	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg21681030	chr2:46777652	RHOQ	0.4	7.18	0.33	3.08e-12	Height;
LUAD	cis	rs17021463	0.902	rs2865352	chr4:95253263	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.08	-0.37	6.9e-15	Testicular germ cell tumor;
LUAD	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg20891283	chr12:69753455	YEATS4	0.44	7.13	0.33	4.3e-12	Blood protein levels;
LUAD	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22496380	chr5:211416	CCDC127	-0.93	-13.14	-0.54	2.51e-33	Breast cancer;
LUAD	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.9	-0.36	2.43e-14	Total body bone mineral density;
LUAD	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg22906224	chr7:99728672	NA	0.61	10.36	0.45	1.48e-22	Coronary artery disease;
LUAD	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg05132306	chr1:1846340	CALML6	-0.36	-7.78	-0.35	5.57e-14	Body mass index;
LUAD	cis	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg12964065	chr18:77638022	KCNG2	0.55	6.84	0.32	2.85e-11	Opioid sensitivity;
LUAD	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg18016565	chr1:150552671	MCL1	-0.46	-8.39	-0.38	7.14e-16	Urate levels;
LUAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg26338869	chr17:61819248	STRADA	-0.39	-6.58	-0.3	1.37e-10	Prudent dietary pattern;
LUAD	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg15309053	chr8:964076	NA	0.32	6.91	0.32	1.84e-11	Schizophrenia;
LUAD	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg06740227	chr12:86229804	RASSF9	0.4	7.01	0.32	9.27e-12	Major depressive disorder;
LUAD	cis	rs62400317	0.762	rs12212190	chr6:44926271	T/C	cg18551225	chr6:44695536	NA	-0.58	-8.88	-0.4	1.92e-17	Total body bone mineral density;
LUAD	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg18305652	chr10:134549665	INPP5A	0.37	8.23	0.37	2.3e-15	Migraine;
LUAD	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg11189052	chr15:85197271	WDR73	0.64	8.68	0.39	8.61e-17	Schizophrenia;
LUAD	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg10589385	chr1:150898437	SETDB1	0.39	7.42	0.34	6.64e-13	Tonsillectomy;
LUAD	cis	rs4285028	0.948	rs35415993	chr3:121669236	C/A	cg11130432	chr3:121712080	ILDR1	-0.58	-8.12	-0.37	5.33e-15	Multiple sclerosis;
LUAD	trans	rs7395662	0.713	rs2865668	chr11:48745046	T/C	cg00717180	chr2:96193071	NA	-0.38	-7.12	-0.33	4.74e-12	HDL cholesterol;
LUAD	cis	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg07460842	chr6:66804631	NA	-1.06	-16.53	-0.63	1e-47	Exhaled nitric oxide output;
LUAD	cis	rs7943203	0.568	rs228593	chr11:108141134	G/A	cg04873221	chr11:107992290	ACAT1	-0.49	-7.46	-0.34	4.83e-13	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-6.61	-0.31	1.15e-10	Lung cancer;
LUAD	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg21153622	chr11:89784906	NA	0.34	6.72	0.31	5.98e-11	Coronary artery disease;
LUAD	cis	rs7264396	0.563	rs2425089	chr20:34304036	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2.04e-15	Total cholesterol levels;
LUAD	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.11	-0.37	5.34e-15	Total body bone mineral density;
LUAD	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg20291162	chr17:40259547	DHX58	-0.68	-10.5	-0.45	4.51e-23	Fibrinogen levels;
LUAD	trans	rs11039798	1.000	rs11039978	chr11:48760237	A/G	cg02254774	chr11:50257496	LOC441601	0.53	6.61	0.31	1.19e-10	Axial length;
LUAD	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg14396892	chr9:96623032	NA	0.44	8.46	0.38	4.46e-16	DNA methylation (variation);
LUAD	cis	rs10864907	0.614	rs12468164	chr2:113712783	C/T	cg12858261	chr2:113808755	IL1F8	-0.37	-6.82	-0.31	3.23e-11	Pulmonary function;
LUAD	cis	rs1113500	0.730	rs1361829	chr1:108593895	A/G	cg06207961	chr1:108661230	NA	-0.33	-6.4	-0.3	4.09e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg16606324	chr3:10149918	C3orf24	0.67	9.78	0.43	1.69e-20	Alzheimer's disease;
LUAD	cis	rs2230307	0.706	rs12127209	chr1:100562955	T/C	cg20868668	chr1:100435035	SLC35A3	0.64	6.76	0.31	4.56e-11	Carotid intima media thickness;
LUAD	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg00933542	chr6:150070202	PCMT1	0.45	9.98	0.44	3.28e-21	Lung cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05863534	chr17:34948351	DHRS11	-0.73	-6.98	-0.32	1.17e-11	Type 2 diabetes;
LUAD	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg18827107	chr12:86230957	RASSF9	0.67	12.91	0.53	2.27e-32	Major depressive disorder;
LUAD	trans	rs1941687	0.527	rs2000945	chr18:31365336	A/G	cg15819921	chr19:927150	ARID3A	-0.47	-8.0	-0.36	1.17e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs73058052	1.000	rs12462756	chr19:50098423	G/A	cg21913888	chr19:50084626	PRRG2;NOSIP	0.35	7.78	0.35	5.44e-14	Fibrinogen levels;
LUAD	cis	rs806215	0.950	rs2073561	chr7:127227769	G/C	cg25922125	chr7:127225783	GCC1	-0.49	-6.86	-0.32	2.5e-11	Type 2 diabetes;
LUAD	cis	rs2070433	0.539	rs2839312	chr21:47958225	T/C	cg12379764	chr21:47803548	PCNT	0.46	6.83	0.32	2.9100000000000002e-11	Lymphocyte counts;
LUAD	cis	rs72615157	0.539	rs2261360	chr7:99692993	G/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.46	6.79	0.31	3.89e-11	Lung function (FEV1/FVC);
LUAD	trans	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg21659725	chr3:3221576	CRBN	0.39	6.59	0.31	1.32e-10	Resting heart rate;
LUAD	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg11331556	chr5:32312356	MTMR12	-0.36	-6.35	-0.3	5.53e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg24399712	chr22:39784796	NA	-0.8	-15.14	-0.59	1.06e-41	Intelligence (multi-trait analysis);
LUAD	trans	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-8.87	-0.4	2.09e-17	Brugada syndrome;
LUAD	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.13	-0.37	4.77e-15	Total body bone mineral density;
LUAD	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	8.87	0.4	2.03e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs8048589	1.000	rs12599090	chr16:12187341	C/G	cg03816625	chr16:12192430	SNX29	0.55	8.14	0.37	4.52e-15	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg05044414	chr3:183734942	ABCC5	0.47	9.94	0.44	4.58e-21	Anterior chamber depth;
LUAD	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg25319279	chr11:5960081	NA	-0.38	-7.28	-0.33	1.68e-12	DNA methylation (variation);
LUAD	cis	rs4523957	0.928	rs177567	chr17:2197637	A/G	cg16513277	chr17:2031491	SMG6	-0.77	-14.32	-0.57	3.41e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg18621852	chr3:10150065	C3orf24	0.42	7.36	0.34	9.46e-13	Alzheimer's disease;
LUAD	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg03676636	chr4:99064102	C4orf37	0.34	8.89	0.4	1.83e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7010267	0.542	rs4618726	chr8:120009385	C/A	cg01975934	chr8:119970761	NA	-0.36	-6.74	-0.31	5.14e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg06191203	chr2:152266755	RIF1	-0.55	-7.94	-0.36	1.8e-14	Squamous cell lung carcinoma;
LUAD	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg18932078	chr1:2524107	MMEL1	0.36	6.76	0.31	4.48e-11	Ulcerative colitis;
LUAD	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg20203395	chr5:56204925	C5orf35	-0.82	-11.96	-0.5	1.33e-28	Initial pursuit acceleration;
LUAD	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg22491629	chr6:157744540	C6orf35	-0.79	-9.06	-0.4	4.72e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg08859206	chr1:53392774	SCP2	0.59	10.6	0.46	1.98e-23	Monocyte count;
LUAD	cis	rs859767	0.709	rs7575742	chr2:135429002	A/G	cg12500956	chr2:135428796	TMEM163	-0.32	-8.36	-0.38	9.48e-16	Neuroticism;
LUAD	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg04455712	chr21:45112962	RRP1B	0.38	7.58	0.35	2.23e-13	Mean corpuscular volume;
LUAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-9.2	-0.41	1.69e-18	Alzheimer's disease;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg18493069	chr6:108582623	SNX3	-0.41	-6.8	-0.31	3.52e-11	Subcortical brain region volumes;
LUAD	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg17633681	chr16:88106987	BANP	0.35	6.66	0.31	8.51e-11	Menopause (age at onset);
LUAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.5	6.74	0.31	5.13e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06028808	chr11:68637592	NA	0.44	7.37	0.34	8.84e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg20503657	chr10:835505	NA	1.04	15.87	0.61	7.5e-45	Eosinophil percentage of granulocytes;
LUAD	cis	rs2652834	1.000	rs2652833	chr15:63396885	C/A	cg25406657	chr15:63342033	TPM1	-0.43	-6.88	-0.32	2.13e-11	HDL cholesterol;
LUAD	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg18512352	chr11:47633146	NA	-0.43	-7.5	-0.34	3.83e-13	Subjective well-being;
LUAD	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.18	0.54	1.73e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-7.71	-0.35	9.32e-14	Total body bone mineral density;
LUAD	trans	rs7395662	1.000	rs115224187	chr11:48757499	G/A	cg00717180	chr2:96193071	NA	0.37	6.71	0.31	6.46e-11	HDL cholesterol;
LUAD	trans	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg07817883	chr1:32538562	TMEM39B	1.5	12.56	0.52	5.74e-31	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg13685833	chr1:53393034	SCP2	0.46	7.32	0.34	1.23e-12	Monocyte count;
LUAD	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg04450456	chr4:17643702	FAM184B	0.42	8.07	0.37	7.37e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6906287	0.609	rs13191610	chr6:118945317	G/A	cg18833306	chr6:118973337	C6orf204	0.49	8.57	0.38	2e-16	Electrocardiographic conduction measures;
LUAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg07507251	chr3:52567010	NT5DC2	0.48	10.32	0.45	1.99e-22	Electroencephalogram traits;
LUAD	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg06263672	chr7:65235340	NA	0.51	6.76	0.31	4.49e-11	Aortic root size;
LUAD	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg14779329	chr11:130786720	SNX19	0.37	6.46	0.3	2.89e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	8.81	0.39	3.24e-17	Ileal carcinoids;
LUAD	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg15921436	chr17:44337874	NA	-0.73	-9.67	-0.43	4.2e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg05043794	chr9:111880884	C9orf5	-0.44	-7.45	-0.34	5.23e-13	Menarche (age at onset);
LUAD	cis	rs7072216	0.652	rs11189600	chr10:100179274	A/G	cg26618903	chr10:100175079	PYROXD2	0.31	6.78	0.31	4.06e-11	Metabolite levels;
LUAD	cis	rs8017423	0.765	rs8017170	chr14:90721849	T/A	cg14092571	chr14:90743983	NA	-0.5	-8.78	-0.39	4.22e-17	Mortality in heart failure;
LUAD	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	9.38	0.41	4.07e-19	Melanoma;
LUAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg11050988	chr7:1952600	MAD1L1	-0.36	-7.37	-0.34	8.87e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg05342682	chr7:94953680	PON1	-0.52	-7.43	-0.34	6.16e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1267303	0.675	rs1267312	chr1:46986748	C/G	cg16387850	chr1:46982889	NA	0.47	7.86	0.36	3.23e-14	Monobrow;
LUAD	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22455342	chr2:225449267	CUL3	0.65	9.96	0.44	4.06e-21	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg15448220	chr1:150897856	SETDB1	-0.46	-7.98	-0.36	1.42e-14	Tonsillectomy;
LUAD	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.46	0.3	2.84e-10	Parkinson's disease;
LUAD	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg02428538	chr16:24856791	SLC5A11	-0.56	-7.68	-0.35	1.1e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4268898	0.636	rs72803210	chr2:24615710	A/G	cg06627628	chr2:24431161	ITSN2	-0.7	-10.92	-0.47	1.27e-24	Asthma;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg15459742	chr9:111775564	CTNNAL1	0.4	6.42	0.3	3.75e-10	Diastolic blood pressure;
LUAD	trans	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg01620082	chr3:125678407	NA	-1.0	-9.42	-0.42	3.03e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg16049864	chr8:95962084	TP53INP1	-0.6	-13.2	-0.54	1.51e-33	Type 2 diabetes;
LUAD	cis	rs1215050	0.765	rs1588018	chr4:98756324	G/C	cg24818145	chr4:99064322	C4orf37	0.41	6.95	0.32	1.38e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg07741184	chr6:167504864	NA	0.36	8.14	0.37	4.6e-15	Primary biliary cholangitis;
LUAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg18402987	chr7:1209562	NA	0.43	7.08	0.33	5.86e-12	Longevity;Endometriosis;
LUAD	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg15181151	chr6:150070149	PCMT1	0.38	7.75	0.35	7.12e-14	Lung cancer;
LUAD	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg21475434	chr5:93447410	FAM172A	0.78	8.63	0.39	1.23e-16	Diabetic retinopathy;
LUAD	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg17724175	chr1:150552817	MCL1	0.4	9.7	0.43	3.13e-20	Tonsillectomy;
LUAD	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg03806693	chr22:41940476	POLR3H	-0.71	-9.43	-0.42	2.66e-19	Vitiligo;
LUAD	cis	rs6601327	0.607	rs6992666	chr8:9586704	A/C	cg27411982	chr8:10470053	RP1L1	-0.36	-6.37	-0.3	4.84e-10	Multiple myeloma (hyperdiploidy);
LUAD	cis	rs7587476	0.531	rs35933323	chr2:215674090	T/G	cg04004882	chr2:215674386	BARD1	-0.54	-7.28	-0.33	1.63e-12	Neuroblastoma;
LUAD	cis	rs10129255	0.556	rs6576222	chr14:107184681	G/A	cg07958169	chr14:107095056	NA	-0.37	-7.24	-0.33	2.07e-12	Kawasaki disease;
LUAD	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg07741184	chr6:167504864	NA	0.33	7.83	0.36	3.93e-14	Primary biliary cholangitis;
LUAD	cis	rs4148087	1.000	rs73225405	chr21:43613428	C/T	cg08841829	chr21:43638893	ABCG1	-0.59	-7.66	-0.35	1.24e-13	Eating disorder in bipolar disorder;
LUAD	trans	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs7771547	0.573	rs629297	chr6:36398146	C/T	cg07856975	chr6:36356162	ETV7	0.49	7.68	0.35	1.11e-13	Platelet distribution width;
LUAD	cis	rs13315871	0.929	rs13080508	chr3:58300116	G/A	cg12435725	chr3:58293450	RPP14	-0.75	-8.52	-0.38	2.81e-16	Cholesterol, total;
LUAD	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	7.67	0.35	1.18e-13	Schizophrenia;
LUAD	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg12310025	chr6:25882481	NA	-0.56	-9.13	-0.41	2.75e-18	Blood metabolite levels;
LUAD	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg21699342	chr2:239360505	ASB1	0.51	9.93	0.43	5.13e-21	Multiple system atrophy;
LUAD	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg12011299	chr4:100065546	ADH4	0.65	12.0	0.5	9.1e-29	Alcohol dependence;
LUAD	cis	rs11112613	0.713	rs12307351	chr12:105955634	T/A	cg03607813	chr12:105948248	NA	0.81	12.95	0.53	1.51e-32	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs6430585	0.527	rs12467569	chr2:136413847	T/C	cg07169764	chr2:136633963	MCM6	0.57	6.77	0.31	4.19e-11	Corneal structure;
LUAD	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg20673091	chr1:2541236	MMEL1	-0.41	-8.65	-0.39	1.04e-16	Ulcerative colitis;
LUAD	cis	rs72928364	0.725	rs2053861	chr3:100781229	C/T	cg10123952	chr3:100791384	NA	0.47	6.45	0.3	2.98e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs868943	0.743	rs1890425	chr6:116339295	T/C	cg15226275	chr6:116381976	FRK	0.23	6.45	0.3	3.1e-10	Total cholesterol levels;
LUAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06873352	chr17:61820015	STRADA	0.84	18.74	0.67	1.78e-57	Prudent dietary pattern;
LUAD	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg19622623	chr12:86230825	RASSF9	-0.54	-9.62	-0.42	6.23e-20	Major depressive disorder;
LUAD	cis	rs11771526	0.892	rs62457534	chr7:32357652	G/A	cg13207630	chr7:32358064	NA	0.7	7.77	0.35	5.88e-14	Body mass index;
LUAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg07677032	chr17:61819896	STRADA	0.57	10.22	0.44	4.66e-22	Prudent dietary pattern;
LUAD	cis	rs7614311	0.731	rs1053338	chr3:63967900	A/G	cg22134162	chr3:63841271	THOC7	-0.54	-9.2	-0.41	1.67e-18	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs250677	0.522	rs1432801	chr5:148390979	T/C	cg18129178	chr5:148520854	ABLIM3	-0.53	-7.92	-0.36	2.11e-14	Breast cancer;
LUAD	cis	rs2046867	0.908	rs113001746	chr3:72824260	C/T	cg04365224	chr3:72788183	NA	-0.45	-6.79	-0.31	3.89e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg23254163	chr1:152506842	NA	0.25	7.13	0.33	4.3e-12	Hair morphology;
LUAD	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.56e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7828089	1.000	rs34542820	chr8:22264079	C/T	cg12081754	chr8:22256438	SLC39A14	0.54	9.33	0.41	5.93e-19	Verbal declarative memory;
LUAD	cis	rs1451375	0.657	rs7802148	chr7:50648284	T/C	cg18232548	chr7:50535776	DDC	0.5	8.23	0.37	2.27e-15	Malaria;
LUAD	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg11494091	chr17:61959527	GH2	0.4	7.13	0.33	4.26e-12	Height;
LUAD	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg03859395	chr2:55845619	SMEK2	0.75	14.19	0.57	1.23e-37	Metabolic syndrome;
LUAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg05457628	chr5:178986728	RUFY1	0.67	11.77	0.5	7.23e-28	Lung cancer;
LUAD	cis	rs9341808	0.718	rs11962614	chr6:80823306	A/T	cg08355045	chr6:80787529	NA	0.56	10.1	0.44	1.26e-21	Sitting height ratio;
LUAD	cis	rs2239547	0.525	rs2246556	chr3:53027983	T/C	cg11645453	chr3:52864694	ITIH4	-0.45	-8.99	-0.4	8.05e-18	Schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg17168242	chr1:149982704	OTUD7B	-0.68	-6.75	-0.31	4.8e-11	Type 2 diabetes;
LUAD	cis	rs4711350	0.871	rs1998949	chr6:33721457	T/C	cg18005901	chr6:33739558	LEMD2	-0.43	-6.37	-0.3	4.84e-10	Schizophrenia;
LUAD	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2979489	0.945	rs11993146	chr8:30319537	G/A	cg26383811	chr8:30366931	RBPMS	-0.67	-10.63	-0.46	1.51e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg01851573	chr8:8652454	MFHAS1	0.43	7.75	0.35	7.1e-14	Mood instability;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg08965527	chr16:84178213	HSDL1;LRRC50	-0.39	-6.5	-0.3	2.22e-10	Subcortical brain region volumes;
LUAD	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg27170947	chr2:26402098	FAM59B	-0.8	-11.61	-0.49	3.19e-27	Gut microbiome composition (summer);
LUAD	cis	rs7072216	0.587	rs2296435	chr10:100182285	C/T	cg26618903	chr10:100175079	PYROXD2	0.37	7.16	0.33	3.62e-12	Metabolite levels;
LUAD	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-6.47	-0.3	2.66e-10	Personality dimensions;
LUAD	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg01181863	chr3:195395398	SDHAP2	-0.74	-10.75	-0.46	5.59e-24	Pancreatic cancer;
LUAD	cis	rs72781680	1.000	rs11125372	chr2:24257582	A/T	cg20701182	chr2:24300061	SF3B14	-0.56	-6.49	-0.3	2.35e-10	Lymphocyte counts;
LUAD	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg04287289	chr16:89883240	FANCA	0.79	7.06	0.32	6.75e-12	Skin colour saturation;
LUAD	cis	rs684232	0.666	rs838372	chr17:566428	C/T	cg12384639	chr17:618140	VPS53	0.49	8.46	0.38	4.31e-16	Prostate cancer;
LUAD	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg13010199	chr12:38710504	ALG10B	0.39	6.47	0.3	2.68e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg07677032	chr17:61819896	STRADA	0.57	10.39	0.45	1.14e-22	Prudent dietary pattern;
LUAD	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg24399712	chr22:39784796	NA	-0.82	-16.39	-0.62	4.33e-47	Intelligence (multi-trait analysis);
LUAD	cis	rs6684514	0.961	rs68170055	chr1:156332331	C/G	cg16558208	chr1:156270281	VHLL	0.5	8.97	0.4	9.48e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg21862992	chr11:68658383	NA	0.52	9.54	0.42	1.11e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2274471	0.679	rs10815161	chr9:5120803	T/C	cg03390472	chr9:5043263	JAK2	-0.55	-7.18	-0.33	3.25e-12	Crohn's disease;
LUAD	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	7.11	0.33	4.83e-12	Schizophrenia;
LUAD	cis	rs6840360	0.615	rs4696097	chr4:152479765	C/T	cg22705602	chr4:152727874	NA	0.37	6.75	0.31	4.75e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2408955	0.521	rs7301003	chr12:48550227	A/G	cg04545296	chr12:48745243	ZNF641	0.31	8.0	0.36	1.21e-14	Glycated hemoglobin levels;
LUAD	cis	rs1032833	0.732	rs79496068	chr2:180032423	T/C	cg23883738	chr2:179974586	SESTD1	-0.65	-7.32	-0.34	1.28e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1451375	0.617	rs10277662	chr7:50594836	C/T	cg18232548	chr7:50535776	DDC	0.62	8.5	0.38	3.21e-16	Malaria;
LUAD	cis	rs6906287	0.573	rs6928210	chr6:118699394	C/G	cg05564266	chr6:118973597	C6orf204	0.33	7.06	0.32	6.9e-12	Electrocardiographic conduction measures;
LUAD	trans	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg27411982	chr8:10470053	RP1L1	0.44	7.9	0.36	2.4e-14	Mood instability;
LUAD	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg15181151	chr6:150070149	PCMT1	0.42	8.63	0.39	1.27e-16	Lung cancer;
LUAD	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26314531	chr2:26401878	FAM59B	-0.64	-8.73	-0.39	5.91e-17	Gut microbiome composition (summer);
LUAD	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg25985355	chr7:65971099	NA	-0.56	-6.91	-0.32	1.79e-11	Gout;
LUAD	cis	rs6479527	0.840	rs1411860	chr9:96763932	T/G	cg14459158	chr9:96720562	NA	0.37	6.61	0.31	1.19e-10	Esophageal adenocarcinoma;
LUAD	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg25237894	chr2:233734115	C2orf82	-0.49	-9.25	-0.41	1.14e-18	Coronary artery disease;
LUAD	trans	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-8.84	-0.39	2.67e-17	Brugada syndrome;
LUAD	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg10518543	chr12:38710700	ALG10B	0.44	7.43	0.34	5.87e-13	Heart rate;
LUAD	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg03676636	chr4:99064102	C4orf37	0.3	7.19	0.33	2.99e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2249625	0.545	rs2496487	chr6:72875226	G/C	cg18830697	chr6:72922368	RIMS1	-0.45	-8.37	-0.38	8.67e-16	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13126279	chr21:47581558	C21orf56	0.62	11.43	0.49	1.47e-26	Testicular germ cell tumor;
LUAD	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg11266682	chr4:10021025	SLC2A9	-0.51	-10.83	-0.47	2.64e-24	Bone mineral density;
LUAD	cis	rs7493	0.950	rs11977702	chr7:95029767	C/T	cg17330251	chr7:94953956	PON1	-0.56	-7.66	-0.35	1.26e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.19	-0.51	1.63e-29	Platelet count;
LUAD	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg22532475	chr10:104410764	TRIM8	-0.53	-9.71	-0.43	2.93e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-7.42	-0.34	6.34e-13	Alzheimer's disease (late onset);
LUAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg07677032	chr17:61819896	STRADA	0.58	10.49	0.45	4.87e-23	Prudent dietary pattern;
LUAD	trans	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11169225	1.000	rs11169225	chr12:50345671	T/A	cg23855989	chr12:50355821	AQP5	0.66	8.57	0.38	2.01e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg00074818	chr8:8560427	CLDN23	0.63	9.69	0.43	3.56e-20	Obesity-related traits;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00794038	chr20:48808334	CEBPB	0.41	6.44	0.3	3.16e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	trans	rs1997103	0.705	rs56301138	chr7:55396555	G/T	cg20935933	chr6:143382018	AIG1	0.53	7.48	0.34	4.34e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg07217954	chr7:1067459	C7orf50	0.39	6.44	0.3	3.29e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1448094	0.967	rs10779222	chr12:86330775	G/A	cg00310523	chr12:86230176	RASSF9	0.35	7.56	0.34	2.58e-13	Major depressive disorder;
LUAD	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	6.45	0.3	3.09e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg16950941	chr11:66035639	RAB1B	0.43	7.25	0.33	2e-12	Gout;
LUAD	cis	rs79349575	0.756	rs4793605	chr17:47035869	T/C	cg26022315	chr17:47021804	SNF8	0.41	7.32	0.34	1.28e-12	Type 2 diabetes;
LUAD	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06221963	chr1:154839813	KCNN3	-0.89	-21.38	-0.72	2.68e-69	Prostate cancer;
LUAD	cis	rs2274273	0.901	rs12050099	chr14:55764331	G/C	cg04306507	chr14:55594613	LGALS3	0.42	8.69	0.39	8.16e-17	Protein biomarker;
LUAD	cis	rs7851660	0.967	rs3758248	chr9:100614601	G/A	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	cis	rs2115630	0.902	rs8023276	chr15:85219638	C/T	cg11189052	chr15:85197271	WDR73	-0.64	-10.63	-0.46	1.46e-23	P wave terminal force;
LUAD	cis	rs11048434	0.761	rs12828902	chr12:9132231	C/T	cg26114124	chr12:9217669	LOC144571	0.39	7.19	0.33	2.94e-12	Sjögren's syndrome;
LUAD	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg05926928	chr17:57297772	GDPD1	1.38	17.09	0.64	3.49e-50	Opioid sensitivity;
LUAD	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg06064525	chr11:970664	AP2A2	-0.55	-11.27	-0.48	6.09e-26	Alzheimer's disease (late onset);
LUAD	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03517284	chr6:25882590	NA	-0.76	-10.72	-0.46	6.96e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg26384229	chr12:38710491	ALG10B	0.46	7.44	0.34	5.59e-13	Bladder cancer;
LUAD	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.32	6.69	0.31	7.09e-11	Obesity-related traits;
LUAD	cis	rs986417	1.000	rs1254291	chr14:60863570	A/T	cg27398547	chr14:60952738	C14orf39	-0.64	-7.79	-0.35	5.1e-14	Gut microbiota (bacterial taxa);
LUAD	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21582582	chr3:182698605	DCUN1D1	0.61	10.28	0.45	2.91e-22	Intelligence (multi-trait analysis);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14308291	chr1:36396265	EIF2C3	-0.42	-7.08	-0.33	6.12e-12	Cancer;
LUAD	cis	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg12964065	chr18:77638022	KCNG2	0.55	6.8	0.31	3.66e-11	Opioid sensitivity;
LUAD	cis	rs6748734	0.948	rs9973366	chr2:241838151	T/C	cg04034577	chr2:241836375	C2orf54	-0.47	-10.39	-0.45	1.16e-22	Urinary metabolites;
LUAD	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg22681709	chr2:178499509	PDE11A	-0.43	-7.11	-0.33	4.82e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs3858145	0.588	rs731063	chr10:70043190	A/G	cg04882175	chr6:131122610	NA	0.54	6.59	0.31	1.3100000000000001e-10	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUAD	cis	rs13082711	0.911	rs11709954	chr3:27421427	C/T	cg02860705	chr3:27208620	NA	0.64	9.54	0.42	1.11e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs9487051	0.768	rs2483913	chr6:109521042	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.79	-0.31	3.92e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs7072216	0.727	rs6584199	chr10:100169983	A/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.68	-0.39	8.56e-17	Metabolite levels;
LUAD	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg18232548	chr7:50535776	DDC	-0.65	-11.78	-0.5	6.49e-28	Systemic sclerosis;
LUAD	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg15704280	chr7:45808275	SEPT13	0.69	9.2	0.41	1.67e-18	Axial length;
LUAD	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03264133	chr6:25882463	NA	0.88	14.48	0.58	7.02e-39	Blood metabolite levels;
LUAD	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26314531	chr2:26401878	FAM59B	-0.55	-7.71	-0.35	9.38e-14	Gut microbiome composition (summer);
LUAD	cis	rs7593730	0.515	rs6722321	chr2:161224230	C/T	cg22609984	chr2:161126801	NA	0.48	8.78	0.39	4.02e-17	Type 2 diabetes;
LUAD	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-7.5	-0.34	3.85e-13	Platelet count;
LUAD	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg24675056	chr1:15929824	NA	0.46	7.92	0.36	2.09e-14	Systolic blood pressure;
LUAD	cis	rs34638657	0.646	rs72628279	chr16:82199664	A/C	cg09439754	chr16:82129088	HSD17B2	-0.37	-7.1	-0.33	5.39e-12	Lung adenocarcinoma;
LUAD	cis	rs6087990	0.965	rs2424904	chr20:31352316	T/C	cg13636640	chr20:31349939	DNMT3B	0.84	16.14	0.62	5.42e-46	Ulcerative colitis;
LUAD	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg02038168	chr22:39784481	NA	-0.58	-10.22	-0.44	4.65e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.58	0.52	4.73e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg07917127	chr4:99064746	C4orf37	0.5	8.19	0.37	3.22e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg01028140	chr2:1542097	TPO	-0.54	-8.17	-0.37	3.68e-15	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs870825	0.616	rs9631782	chr4:185626379	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs2734839	0.964	rs11214605	chr11:113300601	C/T	cg14159747	chr11:113255604	NA	0.53	10.04	0.44	2.04e-21	Information processing speed;
LUAD	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg25767906	chr1:53392781	SCP2	0.41	7.65	0.35	1.42e-13	Monocyte count;
LUAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.49	-8.72	-0.39	6.41e-17	Lymphocyte counts;
LUAD	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.83	-14.0	-0.56	7.01e-37	IgG glycosylation;
LUAD	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg12179176	chr11:130786555	SNX19	0.55	9.26	0.41	1.07e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg02951883	chr7:2050386	MAD1L1	-0.7	-11.39	-0.48	2.22e-26	Testicular germ cell tumor;
LUAD	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg03929089	chr4:120376271	NA	0.56	7.47	0.34	4.71e-13	Axial length;
LUAD	cis	rs12049351	0.774	rs6681212	chr1:229639084	A/C	cg11742688	chr1:229674241	ABCB10	-0.41	-6.55	-0.3	1.65e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs4638749	0.677	rs6713634	chr2:108827907	T/G	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.27	-0.33	1.76e-12	Blood pressure;
LUAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg18402987	chr7:1209562	NA	0.88	11.77	0.5	7.51e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg14169450	chr9:139327907	INPP5E	0.41	6.43	0.3	3.48e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.29	-0.33	1.53e-12	Morning vs. evening chronotype;
LUAD	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg10356904	chr22:49881777	NA	-0.35	-7.41	-0.34	7.06e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.91	13.14	0.54	2.63e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg18833306	chr6:118973337	C6orf204	-0.53	-7.56	-0.35	2.5e-13	Diastolic blood pressure;
LUAD	cis	rs3823572	0.525	rs4546584	chr7:133704270	A/C	cg03336402	chr7:133662267	EXOC4	0.43	7.39	0.34	7.98e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg09904177	chr6:26538194	HMGN4	0.39	6.36	0.3	5.37e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs8002861	0.875	rs12867890	chr13:44423088	A/G	cg17145862	chr1:211918768	LPGAT1	-0.67	-14.71	-0.58	7.36e-40	Leprosy;
LUAD	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg09491104	chr22:46646882	C22orf40	-0.59	-7.72	-0.35	8.2e-14	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs9914544	0.545	rs3826380	chr17:18793225	A/G	cg21372672	chr17:16614065	CCDC144A	-0.36	-6.45	-0.3	3.04e-10	Educational attainment (years of education);
LUAD	cis	rs36051895	0.632	rs117896567	chr9:5141281	C/G	cg02405213	chr9:5042618	JAK2	-0.48	-6.55	-0.3	1.69e-10	Pediatric autoimmune diseases;
LUAD	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.49	-0.34	3.99e-13	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg08885076	chr2:99613938	TSGA10	0.35	6.39	0.3	4.32e-10	Chronic sinus infection;
LUAD	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.15	0.37	4.06e-15	Menopause (age at onset);
LUAD	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg14345882	chr6:26364793	BTN3A2	0.7	7.17	0.33	3.35e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs9914544	0.545	rs8077775	chr17:18809543	A/G	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.7	-0.31	6.83e-11	Educational attainment (years of education);
LUAD	cis	rs2455826	0.716	rs2470526	chr3:15681646	T/A	cg16303742	chr3:15540471	COLQ	0.41	6.55	0.3	1.66e-10	Inflammatory skin disease;
LUAD	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	9.34	0.41	5.63e-19	Melanoma;
LUAD	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.51	-8.93	-0.4	1.29e-17	Eosinophil percentage of white cells;
LUAD	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.16	0.33	3.68e-12	Prostate cancer;
LUAD	cis	rs7487075	0.619	rs10880970	chr12:46830420	A/G	cg23829395	chr12:46796953	NA	0.32	7.11	0.33	5e-12	Itch intensity from mosquito bite;
LUAD	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.3	0.48	4.62e-26	Eosinophil percentage of white cells;
LUAD	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg14196790	chr5:131705035	SLC22A5	0.52	9.46	0.42	2.12e-19	Blood metabolite levels;
LUAD	cis	rs2012796	0.743	rs61986598	chr14:81856865	G/A	cg02996355	chr14:81879375	NA	0.52	8.01	0.36	1.1e-14	Night sleep phenotypes;
LUAD	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg04586622	chr2:25135609	ADCY3	0.31	7.02	0.32	8.98e-12	Body mass index in non-asthmatics;
LUAD	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg02527881	chr3:46936655	PTH1R	0.46	8.91	0.4	1.53e-17	Colorectal cancer;
LUAD	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg06784218	chr1:46089804	CCDC17	0.5	10.97	0.47	8.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg26039829	chr8:22132926	PIWIL2	0.57	10.6	0.46	1.93e-23	Hypertriglyceridemia;
LUAD	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg04990556	chr1:26633338	UBXN11	-0.39	-6.4	-0.3	4.25e-10	Obesity-related traits;
LUAD	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg05313129	chr8:58192883	C8orf71	-0.51	-7.41	-0.34	7.12e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs367615	0.704	rs4286723	chr5:108835959	G/A	cg17395555	chr5:108820864	NA	0.66	14.39	0.57	1.61e-38	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7020830	0.823	rs13285624	chr9:37129496	T/G	cg14294708	chr9:37120828	ZCCHC7	0.86	16.53	0.63	9.98e-48	Schizophrenia;
LUAD	cis	rs977987	0.778	rs2865528	chr16:75455942	T/C	cg03315344	chr16:75512273	CHST6	0.63	13.84	0.56	3.32e-36	Dupuytren's disease;
LUAD	cis	rs7487075	0.578	rs1492895	chr12:46808755	C/T	cg23829395	chr12:46796953	NA	0.32	6.98	0.32	1.16e-11	Itch intensity from mosquito bite;
LUAD	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg00634984	chr7:65235879	NA	0.49	6.83	0.32	2.95e-11	Aortic root size;
LUAD	trans	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg16006296	chr10:38738647	LOC399744	0.35	6.36	0.3	5.3e-10	Diastolic blood pressure;
LUAD	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg24069376	chr3:38537580	EXOG	0.45	10.91	0.47	1.41e-24	Electrocardiographic conduction measures;
LUAD	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg11833968	chr6:79620685	NA	-0.43	-8.02	-0.36	1.03e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg20607798	chr8:58055168	NA	0.67	8.81	0.39	3.32e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7737355	0.812	rs10059807	chr5:130877684	T/C	cg06307176	chr5:131281290	NA	0.44	7.18	0.33	3.16e-12	Life satisfaction;
LUAD	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg12623302	chr6:28058802	ZSCAN12L1	0.46	7.44	0.34	5.5e-13	Lung cancer in ever smokers;
LUAD	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg27411982	chr8:10470053	RP1L1	0.4	7.39	0.34	8.02e-13	Retinal vascular caliber;
LUAD	cis	rs17135859	1.000	rs34045110	chr5:113010739	G/A	cg12552261	chr5:112820674	MCC	0.5	6.75	0.31	4.87e-11	F-cell distribution;
LUAD	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg08999081	chr20:33150536	PIGU	0.62	13.96	0.56	1.12e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs9393692	0.557	rs7755741	chr6:26337264	G/A	cg00631329	chr6:26305371	NA	-0.52	-8.32	-0.37	1.23e-15	Educational attainment;
LUAD	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg14416269	chr4:6271139	WFS1	0.59	10.97	0.47	7.99e-25	Cisplatin-induced ototoxicity;
LUAD	cis	rs11971779	0.584	rs6942519	chr7:139070090	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.76	0.31	4.63e-11	Diisocyanate-induced asthma;
LUAD	cis	rs11771526	0.901	rs7357161	chr7:32302475	A/C	cg27532318	chr7:32358331	NA	0.59	7.42	0.34	6.66e-13	Body mass index;
LUAD	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.32e-15	Prostate cancer;
LUAD	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg07570687	chr10:102243282	WNT8B	0.44	6.72	0.31	6.03e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg03806693	chr22:41940476	POLR3H	0.73	9.86	0.43	8.64e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg06873352	chr17:61820015	STRADA	0.43	7.21	0.33	2.67e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg11062466	chr8:58055876	NA	0.65	8.52	0.38	2.81e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs10791323	0.517	rs1120245	chr11:133745290	A/G	cg15485101	chr11:133734466	NA	0.31	6.72	0.31	5.77e-11	Childhood ear infection;
LUAD	cis	rs71478720	0.953	rs5744256	chr11:112022848	A/G	cg04929355	chr11:112034997	IL18	0.45	7.02	0.32	9.17e-12	Interleukin-18 levels;
LUAD	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg04369109	chr6:150039330	LATS1	-0.42	-7.21	-0.33	2.55e-12	Lung cancer;
LUAD	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg18351406	chr4:77819688	ANKRD56	0.61	9.8	0.43	1.48e-20	Emphysema distribution in smoking;
LUAD	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.42	7.61	0.35	1.77e-13	Systemic lupus erythematosus;
LUAD	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg08470875	chr2:26401718	FAM59B	-0.62	-8.49	-0.38	3.43e-16	Gut microbiome composition (summer);
LUAD	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg17689763	chr4:710664	PCGF3	-0.58	-10.08	-0.44	1.53e-21	White blood cell count;
LUAD	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg15704280	chr7:45808275	SEPT13	-0.53	-8.37	-0.38	8.75e-16	HDL cholesterol;
LUAD	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg19163074	chr7:65112434	INTS4L2	-0.45	-6.87	-0.32	2.37e-11	Aortic root size;
LUAD	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg16322792	chr1:120165303	ZNF697	0.72	18.84	0.68	6.44e-58	Systemic lupus erythematosus;
LUAD	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	15.35	0.6	1.41e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6005807	0.843	rs73430155	chr22:28952823	G/A	cg12565055	chr22:29076175	TTC28	0.67	6.63	0.31	1.01e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.86	-0.5	3.43e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs75804782	0.625	rs13421922	chr2:239467430	T/C	cg01134436	chr17:81009848	B3GNTL1	0.71	7.28	0.33	1.64e-12	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg15448220	chr1:150897856	SETDB1	-0.41	-6.78	-0.31	4.05e-11	Urate levels;
LUAD	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.75	-15.69	-0.61	4.48e-44	Lung cancer;
LUAD	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg08027265	chr7:2291960	NA	-0.41	-7.24	-0.33	2.19e-12	Schizophrenia;
LUAD	cis	rs1031925	0.935	rs4067	chr3:51738256	A/G	cg12934382	chr3:51741135	GRM2	0.41	6.41	0.3	3.84e-10	Melanoma;
LUAD	cis	rs7189233	1.000	rs62048543	chr16:53534624	T/C	cg04059762	chr16:53544020	NA	-0.41	-6.64	-0.31	9.7e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs17155006	0.718	rs370533	chr7:107746215	G/C	cg05962710	chr7:107745446	LAMB4	-0.34	-7.16	-0.33	3.64e-12	Pneumococcal bacteremia;
LUAD	cis	rs7659604	0.540	rs4833775	chr4:122716826	T/C	cg06713675	chr4:122721982	EXOSC9	0.46	8.38	0.38	7.69e-16	Type 2 diabetes;
LUAD	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.39	-0.34	7.88e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg17971929	chr21:40555470	PSMG1	-0.41	-6.49	-0.3	2.44e-10	Cognitive function;
LUAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg22535103	chr8:58192502	C8orf71	0.72	8.8	0.39	3.5e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7737355	0.738	rs3776001	chr5:130957992	T/A	cg06307176	chr5:131281290	NA	0.41	6.66	0.31	8.39e-11	Life satisfaction;
LUAD	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg06609049	chr19:2785107	THOP1	0.71	11.72	0.5	1.17e-27	Total cholesterol levels;
LUAD	cis	rs7592578	0.537	rs62180982	chr2:191264485	G/T	cg11845111	chr2:191398756	TMEM194B	-0.65	-7.94	-0.36	1.81e-14	Diastolic blood pressure;
LUAD	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg20607798	chr8:58055168	NA	0.74	9.24	0.41	1.2e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg21775007	chr8:11205619	TDH	-0.5	-9.01	-0.4	7.16e-18	Retinal vascular caliber;
LUAD	cis	rs3752645	0.649	rs10241141	chr7:106744514	T/C	cg02696742	chr7:106810147	HBP1	-0.66	-6.55	-0.3	1.7e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg17063962	chr7:91808500	NA	-0.68	-12.1	-0.51	3.7e-29	Breast cancer;
LUAD	cis	rs2762353	0.574	rs4409177	chr6:25694491	T/G	cg07061783	chr6:25882402	NA	0.53	8.36	0.38	9.42e-16	Blood metabolite levels;
LUAD	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg24733560	chr20:60626293	TAF4	0.37	6.82	0.31	3.13e-11	Body mass index;
LUAD	cis	rs300703	0.515	rs300693	chr2:181748	C/A	cg21211680	chr2:198530	NA	-0.53	-7.88	-0.36	2.86e-14	Blood protein levels;
LUAD	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg03929089	chr4:120376271	NA	-0.44	-6.76	-0.31	4.63e-11	HDL cholesterol;
LUAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg22963979	chr7:1858916	MAD1L1	-0.57	-10.02	-0.44	2.33e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg09365446	chr1:150670422	GOLPH3L	0.65	11.85	0.5	3.46e-28	Tonsillectomy;
LUAD	cis	rs62400317	0.859	rs10456542	chr6:45107579	G/A	cg18551225	chr6:44695536	NA	-0.56	-8.65	-0.39	1.09e-16	Total body bone mineral density;
LUAD	trans	rs11885103	0.791	rs4402801	chr2:585333	G/A	cg12228919	chr15:44955936	SPG11	-0.44	-6.67	-0.31	7.91e-11	Heschl's gyrus morphology;
LUAD	trans	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.7	-13.92	-0.56	1.57e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs56283067	0.847	rs10948156	chr6:44689459	G/A	cg20913747	chr6:44695427	NA	-0.45	-7.54	-0.34	2.91e-13	Total body bone mineral density;
LUAD	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18876405	chr7:65276391	NA	-0.44	-6.98	-0.32	1.16e-11	Aortic root size;
LUAD	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22968622	chr17:43663579	NA	-0.93	-16.09	-0.62	8.35e-46	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25820224	chr2:95787551	MRPS5	-0.5	-6.66	-0.31	8.53e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1535500	0.967	rs11756070	chr6:39282748	G/A	cg03252829	chr6:39282164	KCNK17	-0.31	-6.59	-0.31	1.28e-10	Type 2 diabetes;
LUAD	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg23277830	chr1:3704460	LRRC47	0.44	9.28	0.41	8.54e-19	Red cell distribution width;
LUAD	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg17074396	chr22:49843754	NA	-0.33	-6.87	-0.32	2.3e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg26384229	chr12:38710491	ALG10B	0.45	7.34	0.34	1.08e-12	Bladder cancer;
LUAD	cis	rs13064411	0.542	rs2087130	chr3:113226983	T/A	cg10517650	chr3:113235015	CCDC52	-0.45	-8.28	-0.37	1.61e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg08236123	chr12:132219811	SFRS8	-0.37	-6.62	-0.31	1.11e-10	Migraine;
LUAD	trans	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg10208301	chr11:6592745	DNHD1	0.49	6.45	0.3	3.03e-10	Coronary artery calcification;
LUAD	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg23815491	chr16:72088622	HP	-0.4	-7.2	-0.33	2.69e-12	Prostate cancer;
LUAD	trans	rs12210905	0.925	rs12214640	chr6:26762080	G/A	cg08851530	chr6:28072375	NA	0.72	6.57	0.3	1.53e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs897984	0.806	rs11150600	chr16:30940331	C/T	cg02466173	chr16:30829666	NA	0.67	12.48	0.52	1.2e-30	Dementia with Lewy bodies;
LUAD	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg22875332	chr1:76189707	ACADM	0.75	11.62	0.49	2.77e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24345138	chr15:86337433	KLHL25	-0.43	-6.71	-0.31	6.12e-11	Height;
LUAD	cis	rs897984	0.770	rs3813020	chr16:30934075	G/A	cg02466173	chr16:30829666	NA	0.67	12.52	0.52	8.3e-31	Dementia with Lewy bodies;
LUAD	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.33	-0.34	1.15e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg05044414	chr3:183734942	ABCC5	0.49	10.08	0.44	1.5e-21	Anterior chamber depth;
LUAD	cis	rs859767	0.741	rs6430529	chr2:135433023	G/T	cg12500956	chr2:135428796	TMEM163	-0.31	-8.18	-0.37	3.29e-15	Neuroticism;
LUAD	cis	rs8077889	0.871	rs8081101	chr17:41904332	C/T	cg26893861	chr17:41843967	DUSP3	0.9	14.95	0.59	7.33e-41	Triglycerides;
LUAD	trans	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg25894440	chr7:65020034	NA	-0.64	-6.79	-0.31	3.88e-11	Gout;
LUAD	cis	rs3947	0.906	rs1692821	chr8:11699988	C/T	cg02840367	chr8:11660030	FDFT1	0.46	6.88	0.32	2.14e-11	Blood protein levels;
LUAD	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg21475434	chr5:93447410	FAM172A	0.76	8.36	0.38	9.07e-16	Diabetic retinopathy;
LUAD	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg26384229	chr12:38710491	ALG10B	0.46	7.74	0.35	7.21e-14	Bladder cancer;
LUAD	trans	rs11039798	0.614	rs8188910	chr11:48825740	C/T	cg15704280	chr7:45808275	SEPT13	0.67	7.83	0.36	3.98e-14	Axial length;
LUAD	trans	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17712092	chr4:129076599	LARP1B	0.88	16.52	0.63	1.1e-47	Eosinophil percentage of white cells;
LUAD	cis	rs6960043	0.905	rs2215381	chr7:15054935	G/T	cg19272540	chr7:15055459	NA	0.37	8.27	0.37	1.76e-15	Type 2 diabetes;
LUAD	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg16797656	chr11:68205561	LRP5	0.45	8.69	0.39	8.23e-17	Total body bone mineral density;
LUAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg02524346	chr8:600233	NA	1.08	10.68	0.46	9.96e-24	IgG glycosylation;
LUAD	cis	rs68170813	0.652	rs17482543	chr7:107169174	C/G	cg23024343	chr7:107201750	COG5	0.53	6.68	0.31	7.62e-11	Coronary artery disease;
LUAD	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.97	20.85	0.71	6.08e-67	Chronic sinus infection;
LUAD	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg09365446	chr1:150670422	GOLPH3L	0.63	11.04	0.47	4.38e-25	Melanoma;
LUAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	6.49	0.3	2.42e-10	Electroencephalogram traits;
LUAD	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.41	-0.52	2.19e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg27539214	chr16:67997921	SLC12A4	-0.54	-7.49	-0.34	4.13e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg11266682	chr4:10021025	SLC2A9	0.65	14.6	0.58	2.14e-39	Bone mineral density;
LUAD	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg16479474	chr6:28041457	NA	0.48	7.88	0.36	2.73e-14	Depression;
LUAD	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg11317459	chr13:21872234	NA	-1.1	-14.59	-0.58	2.49e-39	White matter hyperintensity burden;
LUAD	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg21823605	chr1:152486609	CRCT1	0.29	6.42	0.3	3.64e-10	Hair morphology;
LUAD	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg27494647	chr7:150038898	RARRES2	0.52	9.07	0.4	4.68e-18	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.42	-6.41	-0.3	3.86e-10	Renal function-related traits (BUN);
LUAD	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg13334819	chr7:99746414	C7orf59	-0.62	-9.21	-0.41	1.59e-18	Coronary artery disease;
LUAD	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg17971929	chr21:40555470	PSMG1	0.54	8.46	0.38	4.55e-16	Cognitive function;
LUAD	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg03037974	chr15:76606532	NA	0.39	8.68	0.39	8.68e-17	Blood metabolite levels;
LUAD	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-7.42	-0.34	6.52e-13	Major depressive disorder;
LUAD	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.41	-0.34	7.13e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2742234	0.955	rs2435385	chr10:43665750	A/G	cg02780029	chr10:43622663	RET	-0.45	-7.31	-0.33	1.36e-12	Hirschsprung disease;
LUAD	cis	rs6782228	0.606	rs6439135	chr3:128358633	G/A	cg16766828	chr3:128327626	NA	-0.38	-7.12	-0.33	4.61e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.33	0.38	1.15e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs698833	0.886	rs4953091	chr2:44565266	A/C	cg04920474	chr2:44395004	PPM1B	-0.38	-6.77	-0.31	4.45e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.91	12.62	0.52	3.34e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs4650994	0.623	rs7534394	chr1:178622760	G/A	cg05059571	chr16:84539110	KIAA1609	0.47	7.79	0.35	5.17e-14	HDL cholesterol levels;HDL cholesterol;
LUAD	trans	rs877282	0.898	rs12357016	chr10:765675	C/T	cg22713356	chr15:30763199	NA	1.28	17.3	0.64	4.19e-51	Uric acid levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21694044	chr22:41215540	SLC25A17	-0.57	-6.99	-0.32	1.09e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10791323	0.521	rs10894756	chr11:133745852	G/A	cg03690763	chr11:133734501	NA	-0.27	-6.41	-0.3	3.86e-10	Childhood ear infection;
LUAD	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg26513180	chr16:89883248	FANCA	-0.45	-7.08	-0.33	6.23e-12	Vitiligo;
LUAD	cis	rs938554	0.876	rs737267	chr4:9934744	G/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.16	-0.37	3.98e-15	Blood metabolite levels;
LUAD	cis	rs11077998	0.967	rs4789786	chr17:80504352	A/G	cg10255544	chr17:80519551	FOXK2	-0.34	-6.95	-0.32	1.43e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.51	6.93	0.32	1.55e-11	Platelet count;
LUAD	cis	rs2806561	0.894	rs1738475	chr1:23536891	C/G	cg12483005	chr1:23474871	LUZP1	0.38	6.42	0.3	3.7e-10	Height;
LUAD	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg04414720	chr1:150670196	GOLPH3L	0.75	13.58	0.55	3.92e-35	Tonsillectomy;
LUAD	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg19318889	chr4:1322082	MAEA	0.41	6.69	0.31	7.18e-11	Obesity-related traits;
LUAD	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg10523679	chr1:76189770	ACADM	0.87	15.4	0.6	8.72e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4972806	0.814	rs966801	chr2:177037827	G/A	cg14324370	chr2:177042789	NA	0.42	7.73	0.35	7.89e-14	IgG glycosylation;
LUAD	cis	rs10929159	0.928	rs7596780	chr2:236924303	C/T	cg14895183	chr2:236924282	AGAP1	0.37	6.36	0.3	5.19e-10	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.75	0.31	4.81e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg19912559	chr1:40204330	PPIE	0.57	9.66	0.43	4.34e-20	Blood protein levels;
LUAD	cis	rs8192282	0.739	rs4845641	chr1:154497930	C/G	cg16683920	chr1:154474344	TDRD10;SHE	-0.45	-6.98	-0.32	1.16e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	trans	rs12517041	1.000	rs10805750	chr5:23300753	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.49	-0.3	2.4e-10	Calcium levels;
LUAD	cis	rs6044003	0.786	rs56347736	chr20:16477866	T/G	cg12117660	chr20:16555778	NA	0.69	6.41	0.3	3.78e-10	Intelligence;
LUAD	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg08859206	chr1:53392774	SCP2	-0.65	-11.77	-0.5	7.1e-28	Monocyte count;
LUAD	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg00074818	chr8:8560427	CLDN23	0.69	10.56	0.46	2.75e-23	Obesity-related traits;
LUAD	cis	rs4604732	0.631	rs74154672	chr1:247625625	C/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.56	-9.52	-0.42	1.38e-19	Glomerular filtration rate;
LUAD	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg07917127	chr4:99064746	C4orf37	0.4	6.51	0.3	2.1e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg02574844	chr11:5959923	NA	-0.39	-6.74	-0.31	5.32e-11	DNA methylation (variation);
LUAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg02136620	chr5:178986620	RUFY1	0.52	8.83	0.39	2.73e-17	Lung cancer;
LUAD	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs35306767	0.668	rs35657988	chr10:1103590	A/G	cg26597838	chr10:835615	NA	0.71	10.09	0.44	1.4e-21	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.95	0.36	1.71e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08661693	chr20:49574504	DPM1;MOCS3	-0.38	-6.42	-0.3	3.61e-10	Cancer;
LUAD	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.08e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.37	-0.3	4.82e-10	Breast cancer;
LUAD	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg03806693	chr22:41940476	POLR3H	-0.54	-8.02	-0.36	1.08e-14	Vitiligo;
LUAD	cis	rs7394190	0.748	rs11000728	chr10:75404300	C/G	cg02286717	chr10:75415704	SYNPO2L	-0.4	-7.31	-0.34	1.31e-12	Incident atrial fibrillation;
LUAD	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11644478	chr21:40555479	PSMG1	0.62	9.96	0.44	3.78e-21	Cognitive function;
LUAD	trans	rs75804782	0.521	rs72982596	chr2:239454919	G/C	cg01134436	chr17:81009848	B3GNTL1	0.72	8.06	0.36	8.16e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs6545883	0.831	rs9309336	chr2:61763165	T/C	cg15711740	chr2:61764176	XPO1	-0.42	-6.71	-0.31	6.44e-11	Tuberculosis;
LUAD	trans	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs73206853	0.841	rs73206854	chr12:110731375	C/T	cg12870014	chr12:110450643	ANKRD13A	0.65	7.24	0.33	2.17e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg03609598	chr5:56110824	MAP3K1	-0.56	-7.86	-0.36	3.17e-14	Initial pursuit acceleration;
LUAD	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	9.85	0.43	9.87e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs644148	0.836	rs2686775	chr19:45000059	C/T	cg15540054	chr19:45004280	ZNF180	-0.4	-6.4	-0.3	4.23e-10	Personality dimensions;
LUAD	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg15704280	chr7:45808275	SEPT13	-0.91	-17.54	-0.65	3.63e-52	Coronary artery disease;
LUAD	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.44	8.81	0.39	3.23e-17	Monocyte percentage of white cells;
LUAD	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg07708487	chr16:89387014	ANKRD11	-0.33	-6.58	-0.3	1.38e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03647317	chr4:187891568	NA	-0.34	-6.47	-0.3	2.66e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.46	-9.5	-0.42	1.56e-19	Total body bone mineral density;
LUAD	cis	rs4638749	0.677	rs6711297	chr2:108818357	A/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.39	-0.34	8.1e-13	Blood pressure;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg19312536	chr1:154540535	CHRNB2	-0.46	-6.81	-0.31	3.31e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg24768116	chr2:27665128	KRTCAP3	0.25	6.35	0.3	5.5e-10	Oral cavity cancer;
LUAD	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	11.35	0.48	3.11e-26	Resting heart rate;
LUAD	cis	rs710865	0.516	rs12062540	chr1:19529204	A/G	cg13387374	chr1:19411106	UBR4	0.49	8.11	0.37	5.47e-15	Brain structure;
LUAD	trans	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg14917512	chr19:3094685	GNA11	0.36	6.35	0.3	5.72e-10	Aortic root size;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12774746	chr13:41768782	KBTBD7	-0.41	-6.6	-0.31	1.26e-10	Cancer;
LUAD	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg04450456	chr4:17643702	FAM184B	0.4	7.93	0.36	1.91e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg11301795	chr4:187892539	NA	0.77	16.19	0.62	3.19e-46	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg06627557	chr7:32535165	LSM5;AVL9	0.68	12.96	0.53	1.39e-32	Cognitive ability;
LUAD	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.88	-0.36	2.84e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg15704280	chr7:45808275	SEPT13	-0.93	-18.23	-0.66	3.32e-55	Coronary artery disease;
LUAD	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg17200465	chr3:40428508	ENTPD3	-0.28	-6.67	-0.31	7.93e-11	Renal cell carcinoma;
LUAD	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.64	0.39	1.15e-16	Parkinson's disease;
LUAD	cis	rs7737355	1.000	rs11242077	chr5:130771037	G/A	cg06307176	chr5:131281290	NA	-0.49	-7.67	-0.35	1.21e-13	Life satisfaction;
LUAD	cis	rs733175	0.857	rs3796835	chr4:10011530	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	9.25	0.41	1.14e-18	Psychosis and Alzheimer's disease;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg22358856	chr18:12991346	CEP192	-0.36	-6.39	-0.3	4.42e-10	Schizophrenia;
LUAD	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.28	6.61	0.31	1.18e-10	Prostate cancer;
LUAD	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-6.73	-0.31	5.53e-11	Immature fraction of reticulocytes;Schizophrenia;
LUAD	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg23649088	chr2:200775458	C2orf69	0.56	8.03	0.36	1e-14	Schizophrenia;
LUAD	cis	rs9462027	0.651	rs9469884	chr6:34758703	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.91	-0.4	1.53e-17	Systemic lupus erythematosus;
LUAD	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg23229984	chr5:148520753	ABLIM3	0.5	7.8	0.35	4.9e-14	Breast cancer;
LUAD	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.08	0.37	6.91e-15	Rheumatoid arthritis;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg01963885	chr22:20004367	ARVCF	-0.44	-7.52	-0.34	3.35e-13	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg15557168	chr22:42548783	NA	-0.5	-9.42	-0.42	2.94e-19	Schizophrenia;
LUAD	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.71	-0.39	7.08e-17	Alzheimer's disease (late onset);
LUAD	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg27284194	chr4:1044797	NA	0.55	9.12	0.41	2.99e-18	Recombination rate (males);
LUAD	trans	rs747782	0.527	rs7113857	chr11:48141859	G/T	cg15704280	chr7:45808275	SEPT13	0.67	7.22	0.33	2.46e-12	Intraocular pressure;
LUAD	trans	rs11039798	0.920	rs9667596	chr11:48691193	T/C	cg03929089	chr4:120376271	NA	0.59	6.8	0.31	3.49e-11	Axial length;
LUAD	cis	rs877282	0.898	rs11253347	chr10:765769	A/G	cg17470449	chr10:769945	NA	0.61	8.47	0.38	4.14e-16	Uric acid levels;
LUAD	cis	rs10193935	0.901	rs7605782	chr2:42502332	C/T	cg27598129	chr2:42591480	NA	-0.78	-9.38	-0.41	4.19e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs758324	0.947	rs7708140	chr5:131252396	A/G	cg06307176	chr5:131281290	NA	0.48	7.5	0.34	3.76e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs747782	0.527	rs3741410	chr11:48168664	A/C	cg15704280	chr7:45808275	SEPT13	0.58	6.92	0.32	1.73e-11	Intraocular pressure;
LUAD	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg13010199	chr12:38710504	ALG10B	0.39	6.49	0.3	2.44e-10	Bladder cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21408716	chr3:52279700	PPM1M	-0.51	-6.35	-0.3	5.48e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg03806693	chr22:41940476	POLR3H	0.62	9.09	0.4	3.79e-18	Vitiligo;
LUAD	cis	rs7727544	0.508	rs10900804	chr5:131401845	C/T	cg16205897	chr5:131564050	P4HA2	-0.34	-7.44	-0.34	5.67e-13	Blood metabolite levels;
LUAD	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg15900387	chr1:150738905	CTSS	-0.34	-6.52	-0.3	2.05e-10	Melanoma;
LUAD	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.63	-0.31	1.06e-10	Breast cancer;
LUAD	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11890956	chr21:40555474	PSMG1	0.82	14.66	0.58	1.21e-39	Cognitive function;
LUAD	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg09658497	chr7:2847517	GNA12	-0.53	-10.03	-0.44	2.25e-21	Height;
LUAD	trans	rs4714291	0.698	rs2983144	chr6:40046724	G/A	cg02267698	chr19:7991119	CTXN1	-0.47	-7.37	-0.34	9.15e-13	Strep throat;
LUAD	cis	rs17789174	0.903	rs1392525	chr16:85075774	A/C	cg27466129	chr16:85060822	KIAA0513	0.35	7.78	0.35	5.5e-14	Dysphagia;
LUAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg24642844	chr7:1081250	C7orf50	-0.93	-13.99	-0.56	7.87e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg00933542	chr6:150070202	PCMT1	0.43	9.19	0.41	1.84e-18	Lung cancer;
LUAD	cis	rs6430585	0.591	rs12477421	chr2:136433740	A/G	cg07169764	chr2:136633963	MCM6	0.68	7.73	0.35	7.69e-14	Corneal structure;
LUAD	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg23719950	chr11:63933701	MACROD1	-0.55	-6.67	-0.31	7.99e-11	Mean platelet volume;
LUAD	cis	rs11048434	0.736	rs12823100	chr12:9108908	C/A	cg26114124	chr12:9217669	LOC144571	0.36	6.57	0.3	1.45e-10	Sjögren's syndrome;
LUAD	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg18490616	chr2:88469792	THNSL2	-0.4	-6.42	-0.3	3.7e-10	Response to metformin (IC50);
LUAD	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg13073564	chr4:8508604	NA	0.6	11.04	0.47	4.49e-25	Response to antineoplastic agents;
LUAD	cis	rs8112211	1.000	rs73043010	chr19:38823202	T/G	cg14299480	chr19:38876666	GGN	-0.43	-7.61	-0.35	1.79e-13	Blood protein levels;
LUAD	cis	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg07460842	chr6:66804631	NA	0.97	12.96	0.53	1.35e-32	Exhaled nitric oxide output;
LUAD	cis	rs10791323	0.517	rs1120247	chr11:133745180	T/G	cg15485101	chr11:133734466	NA	0.31	6.72	0.31	5.77e-11	Childhood ear infection;
LUAD	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg20991723	chr1:152506922	NA	0.32	6.43	0.3	3.42e-10	Hair morphology;
LUAD	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg22676075	chr6:135203613	NA	0.42	7.79	0.35	5.41e-14	Red blood cell count;
LUAD	cis	rs6516091	0.706	rs62199230	chr20:6050124	G/C	cg25325723	chr20:6104886	FERMT1	-0.59	-6.68	-0.31	7.54e-11	Abdominal aortic aneurysm;
LUAD	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg07870213	chr5:140052090	DND1	-0.81	-11.05	-0.47	4.17e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg24308560	chr3:49941425	MST1R	0.5	8.16	0.37	3.77e-15	Body mass index;
LUAD	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg24531977	chr5:56204891	C5orf35	0.77	12.46	0.52	1.44e-30	Initial pursuit acceleration;
LUAD	trans	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg06606381	chr12:133084897	FBRSL1	0.51	6.96	0.32	1.26e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs76878669	0.538	rs73489638	chr11:66127639	C/T	cg10616300	chr11:66138557	SLC29A2	-0.36	-7.53	-0.34	3.15e-13	Educational attainment (years of education);
LUAD	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg06671706	chr8:8559999	CLDN23	0.64	10.95	0.47	9.59e-25	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	5.84e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg22482690	chr17:47019901	SNF8	0.45	8.44	0.38	4.97e-16	Type 2 diabetes;
LUAD	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg18827107	chr12:86230957	RASSF9	-0.53	-9.31	-0.41	7.2e-19	Major depressive disorder;
LUAD	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg17264618	chr3:40429014	ENTPD3	0.42	9.08	0.4	4.23e-18	Renal cell carcinoma;
LUAD	cis	rs7187994	0.848	rs34327141	chr16:84776991	C/T	cg07647771	chr16:84786436	USP10	-0.37	-9.42	-0.42	2.86e-19	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs701145	0.938	rs813141	chr3:154066521	T/C	cg17054900	chr3:154042577	DHX36	0.63	7.05	0.32	7.4e-12	Coronary artery disease;
LUAD	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg07936489	chr17:37558343	FBXL20	-0.45	-7.07	-0.33	6.4e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg06618935	chr21:46677482	NA	-0.53	-10.36	-0.45	1.49e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg09835421	chr16:68378352	PRMT7	-0.82	-8.81	-0.39	3.21e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6545883	0.965	rs3771258	chr2:61764140	C/T	cg15711740	chr2:61764176	XPO1	-0.43	-6.8	-0.31	3.69e-11	Tuberculosis;
LUAD	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg17420585	chr12:42539391	GXYLT1	-0.38	-6.8	-0.31	3.63e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg09222892	chr1:25734099	RHCE	0.51	9.41	0.42	3.25e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg16647868	chr5:131706066	SLC22A5	0.41	6.76	0.31	4.63e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs4604732	0.578	rs12038656	chr1:247623816	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	6.96	0.32	1.34e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs897984	0.572	rs4889526	chr16:31030344	C/A	cg02466173	chr16:30829666	NA	-0.57	-10.02	-0.44	2.47e-21	Dementia with Lewy bodies;
LUAD	cis	rs62458065	0.850	rs10239812	chr7:32460348	A/G	cg20159608	chr7:32802032	NA	-0.53	-6.83	-0.32	3e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7107174	1.000	rs2512537	chr11:77971947	T/C	cg02023728	chr11:77925099	USP35	0.52	7.96	0.36	1.61e-14	Testicular germ cell tumor;
LUAD	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg02493740	chr2:85810744	VAMP5	-0.51	-9.31	-0.41	6.88e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs877282	0.853	rs4579862	chr10:753298	A/C	cg06581033	chr10:766294	NA	-0.55	-7.27	-0.33	1.74e-12	Uric acid levels;
LUAD	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25427524	chr10:38739819	LOC399744	-0.71	-13.16	-0.54	2.15e-33	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg18621852	chr3:10150065	C3orf24	0.49	8.83	0.39	2.72e-17	Alzheimer's disease;
LUAD	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg09835421	chr16:68378352	PRMT7	-0.97	-11.13	-0.48	2.04e-25	Magnesium levels;
LUAD	cis	rs8014204	0.819	rs2003490	chr14:75377555	C/A	cg03030879	chr14:75389066	RPS6KL1	-0.37	-6.52	-0.3	2e-10	Caffeine consumption;
LUAD	cis	rs1371867	0.846	rs2919471	chr8:101232701	T/C	cg20500540	chr8:101228448	SPAG1	-0.38	-6.74	-0.31	5.21e-11	Atrioventricular conduction;
LUAD	cis	rs73206853	0.841	rs56122570	chr12:110816291	G/A	cg12870014	chr12:110450643	ANKRD13A	0.61	6.74	0.31	5.25e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7010267	0.935	rs6415470	chr8:119955111	G/A	cg01975934	chr8:119970761	NA	-0.4	-7.73	-0.35	7.95e-14	Total body bone mineral density (age 45-60);
LUAD	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26314531	chr2:26401878	FAM59B	-0.64	-8.7	-0.39	7.27e-17	Gut microbiome composition (summer);
LUAD	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg03477792	chr4:77819574	ANKRD56	0.48	7.27	0.33	1.74e-12	Emphysema distribution in smoking;
LUAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg24846343	chr22:24311635	DDTL	0.67	14.71	0.58	7.15e-40	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs261532	0.953	rs446588	chr5:138987756	G/C	cg11459648	chr5:138714337	SLC23A1	-0.4	-6.77	-0.31	4.27e-11	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06022373	chr22:39101656	GTPBP1	0.47	7.32	0.34	1.23e-12	Menopause (age at onset);
LUAD	cis	rs11671005	0.779	rs55875034	chr19:58983558	T/G	cg13877915	chr19:58951672	ZNF132	0.56	6.93	0.32	1.54e-11	Mean platelet volume;
LUAD	cis	rs4074961	0.527	rs6704190	chr1:38010751	C/T	cg12696750	chr1:38022466	DNALI1	0.39	6.61	0.31	1.18e-10	Axial length;
LUAD	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg04287289	chr16:89883240	FANCA	0.74	7.52	0.34	3.4e-13	Interleukin-17 levels;
LUAD	cis	rs6840360	0.615	rs12647586	chr4:152607568	G/C	cg22705602	chr4:152727874	NA	-0.48	-8.97	-0.4	1e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs4713675	0.524	rs4713672	chr6:33705066	G/A	cg14003231	chr6:33640908	ITPR3	0.4	7.5	0.34	3.73e-13	Plateletcrit;
LUAD	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg07636037	chr3:49044803	WDR6	0.57	8.79	0.39	3.68e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.69	13.1	0.54	3.88e-33	Cognitive ability;
LUAD	cis	rs9296092	0.517	rs11752179	chr6:33534713	G/T	cg13560919	chr6:33536144	NA	-0.9	-16.19	-0.62	3.28e-46	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs4713675	0.584	rs509539	chr6:33708190	A/C	cg13859433	chr6:33739653	LEMD2	0.28	6.67	0.31	8.01e-11	Plateletcrit;
LUAD	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.93	-0.36	1.92e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg05925327	chr15:68127851	NA	-0.45	-6.75	-0.31	4.81e-11	Restless legs syndrome;
LUAD	cis	rs8099014	1.000	rs4464160	chr18:56111830	T/G	cg12907477	chr18:56117327	MIR122	0.4	6.86	0.32	2.42e-11	Platelet count;
LUAD	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	cis	rs11048434	0.736	rs34798934	chr12:9108444	C/T	cg04155231	chr12:9217510	LOC144571	0.39	7.29	0.33	1.52e-12	Sjögren's syndrome;
LUAD	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg14983838	chr19:29218262	NA	0.67	9.9	0.43	6.62e-21	Methadone dose in opioid dependence;
LUAD	cis	rs1595825	0.891	rs4491721	chr2:198521407	C/G	cg11031976	chr2:198649780	BOLL	-0.46	-6.84	-0.32	2.82e-11	Ulcerative colitis;
LUAD	cis	rs9900497	0.604	rs12949049	chr17:19653310	A/G	cg22552966	chr17:19620595	SLC47A2	0.38	7.58	0.35	2.25e-13	Response to paliperidone in schizophrenia (CGI-S score);
LUAD	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-7.31	-0.33	1.34e-12	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.57e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg15133208	chr4:90757351	SNCA	-0.46	-7.01	-0.32	9.76e-12	Neuroticism;
LUAD	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg04989706	chr14:50066350	PPIL5	-0.51	-7.55	-0.34	2.64e-13	Carotid intima media thickness;
LUAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg08742575	chr21:47604166	C21orf56	-0.63	-11.1	-0.47	2.74e-25	Testicular germ cell tumor;
LUAD	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg10556349	chr10:835070	NA	0.58	7.31	0.34	1.3e-12	Eosinophil percentage of granulocytes;
LUAD	trans	rs7200543	1.000	rs3803575	chr16:15138447	T/C	cg24683922	chr1:11983373	KIAA2013	-0.46	-7.7	-0.35	9.5e-14	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	trans	rs75804782	0.625	rs72984533	chr2:239470005	T/C	cg01134436	chr17:81009848	B3GNTL1	0.75	7.67	0.35	1.19e-13	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2346177	0.844	rs34791442	chr2:46655169	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.42	-6.58	-0.3	1.37e-10	HDL cholesterol;
LUAD	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg11057378	chr10:81107060	PPIF	0.39	7.25	0.33	2.05e-12	Height;
LUAD	cis	rs17092148	1.000	rs6088603	chr20:33370945	A/G	cg16810054	chr20:33298113	TP53INP2	-0.52	-8.11	-0.37	5.7e-15	Neuroticism;
LUAD	cis	rs2030114	0.531	rs8052429	chr16:51598560	A/G	cg03758633	chr16:51611768	NA	0.32	6.66	0.31	8.63e-11	Blood pressure measurement (high sodium and potassium intervention);
LUAD	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg26384229	chr12:38710491	ALG10B	0.49	7.96	0.36	1.64e-14	Heart rate;
LUAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg07677032	chr17:61819896	STRADA	0.55	10.09	0.44	1.41e-21	Prudent dietary pattern;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21497602	chr12:12715811	DUSP16	-0.43	-6.67	-0.31	8.26e-11	Height;
LUAD	cis	rs1509123	0.609	rs78980938	chr17:6703825	T/C	cg12642237	chr17:6703447	TEKT1	-0.51	-7.62	-0.35	1.68e-13	Blood metabolite levels;
LUAD	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg05110241	chr16:68378359	PRMT7	-0.61	-6.99	-0.32	1.1e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg02527881	chr3:46936655	PTH1R	-0.45	-8.88	-0.4	1.95e-17	Colorectal cancer;
LUAD	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg10589385	chr1:150898437	SETDB1	0.45	8.42	0.38	6e-16	Melanoma;
LUAD	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg24324837	chr19:49891574	CCDC155	0.47	6.76	0.31	4.63e-11	Multiple sclerosis;
LUAD	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg11766577	chr21:47581405	C21orf56	-0.47	-8.07	-0.37	7.1e-15	Testicular germ cell tumor;
LUAD	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.21	0.44	5.05e-22	Ileal carcinoids;
LUAD	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg10523679	chr1:76189770	ACADM	0.89	15.32	0.6	1.84e-42	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg11693508	chr17:37793320	STARD3	0.55	7.82	0.36	4.18e-14	Neuroticism;
LUAD	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg17264618	chr3:40429014	ENTPD3	-0.4	-8.68	-0.39	8.7e-17	Renal cell carcinoma;
LUAD	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg13385794	chr1:248469461	NA	0.26	6.97	0.32	1.23e-11	Common traits (Other);
LUAD	cis	rs16854884	0.657	rs35085196	chr3:143712210	C/T	cg01302019	chr3:143689584	C3orf58	-0.39	-6.6	-0.31	1.26e-10	Economic and political preferences (feminism/equality);
LUAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg10295955	chr4:187884368	NA	-1.1	-26.09	-0.79	4.2e-90	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg27051686	chr2:238398490	MLPH	0.42	6.42	0.3	3.74e-10	Prostate cancer;
LUAD	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg06623918	chr6:96969491	KIAA0776	0.88	17.24	0.64	7.83e-51	Headache;
LUAD	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.61	-8.68	-0.39	8.87e-17	Gut microbiome composition (summer);
LUAD	cis	rs7274811	0.711	rs291691	chr20:32002878	G/C	cg03904042	chr20:32255491	NECAB3;C20orf134	0.48	7.16	0.33	3.54e-12	Height;
LUAD	cis	rs1215050	0.791	rs165244	chr4:98687889	C/T	cg05340658	chr4:99064831	C4orf37	0.42	6.97	0.32	1.21e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg25036284	chr2:26402008	FAM59B	-0.85	-12.6	-0.52	3.93e-31	Gut microbiome composition (summer);
LUAD	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.73	-14.2	-0.57	1.04e-37	Ulcerative colitis;
LUAD	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg03948781	chr1:205179583	DSTYK	0.33	6.47	0.3	2.76e-10	Red blood cell count;
LUAD	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg13385794	chr1:248469461	NA	0.25	6.95	0.32	1.35e-11	Common traits (Other);
LUAD	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.19	-0.37	3.14e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs12200560	0.505	rs927271	chr6:97075910	T/G	cg06623918	chr6:96969491	KIAA0776	0.44	6.77	0.31	4.23e-11	Coronary heart disease;
LUAD	cis	rs4268898	0.516	rs7597149	chr2:24371962	C/T	cg06627628	chr2:24431161	ITSN2	0.44	7.52	0.34	3.4e-13	Asthma;
LUAD	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg09904177	chr6:26538194	HMGN4	0.43	7.21	0.33	2.51e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs8014204	0.836	rs12588415	chr14:75278211	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.34	-6.41	-0.3	3.8e-10	Caffeine consumption;
LUAD	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg04772025	chr11:68637568	NA	0.55	8.59	0.39	1.69e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	-0.42	-6.61	-0.31	1.17e-10	Resistin levels;
LUAD	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg18105134	chr13:113819100	PROZ	-1.05	-19.41	-0.69	1.85e-60	Platelet distribution width;
LUAD	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-10.93	-0.47	1.18e-24	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg03929089	chr4:120376271	NA	-0.69	-10.39	-0.45	1.12e-22	Coronary artery disease;
LUAD	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg00701064	chr4:6280414	WFS1	0.58	11.3	0.48	4.68e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6496044	0.507	rs1471455	chr15:86154727	T/A	cg13263323	chr15:86062960	AKAP13	0.39	6.75	0.31	4.75e-11	Interstitial lung disease;
LUAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg22535103	chr8:58192502	C8orf71	-0.6	-7.1	-0.33	5.22e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs684232	0.583	rs2657626	chr17:603052	A/G	cg12384639	chr17:618140	VPS53	0.49	8.57	0.38	1.97e-16	Prostate cancer;
LUAD	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg03467027	chr4:99064603	C4orf37	0.45	7.11	0.33	5.07e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg10645314	chr2:3704589	ALLC	-0.44	-7.68	-0.35	1.12e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.16	0.54	2.11e-33	Exhaled nitric oxide output;
LUAD	trans	rs3857536	0.776	rs4710583	chr6:66940101	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs12545109	0.571	rs1370306	chr8:57299137	C/G	cg09654669	chr8:57350985	NA	-0.69	-9.68	-0.43	3.74e-20	Obesity-related traits;
LUAD	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg07636037	chr3:49044803	WDR6	0.64	12.53	0.52	7.68e-31	Parkinson's disease;
LUAD	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg24531977	chr5:56204891	C5orf35	-0.41	-6.66	-0.31	8.79e-11	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs59698941	0.882	rs66537260	chr5:132309237	C/T	cg14825688	chr5:132208181	LEAP2	-0.48	-6.4	-0.3	4.23e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs733175	0.951	rs6846692	chr4:10031133	C/G	cg00071950	chr4:10020882	SLC2A9	0.55	8.31	0.37	1.33e-15	Psychosis and Alzheimer's disease;
LUAD	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.16	-0.41	2.31e-18	Total body bone mineral density;
LUAD	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.36	-0.3	5.16e-10	Total body bone mineral density;
LUAD	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg23840854	chr1:161414152	NA	-0.86	-11.14	-0.48	1.95e-25	Rheumatoid arthritis;
LUAD	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08280861	chr8:58055591	NA	0.7	8.75	0.39	5.08e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs868036	0.958	rs4261478	chr15:68074084	G/A	cg08079166	chr15:68083412	MAP2K5	0.3	6.42	0.3	3.74e-10	Restless legs syndrome;
LUAD	cis	rs2734839	0.964	rs1076563	chr11:113295909	A/C	cg14159747	chr11:113255604	NA	0.53	10.35	0.45	1.6400000000000001e-22	Information processing speed;
LUAD	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18404041	chr3:52824283	ITIH1	-0.58	-11.78	-0.5	6.48e-28	Bipolar disorder;
LUAD	cis	rs8072100	0.720	rs4794057	chr17:45786452	C/T	cg08085267	chr17:45401833	C17orf57	-0.55	-9.75	-0.43	2.19e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg11905131	chr22:24372483	LOC391322	0.5	7.31	0.33	1.33e-12	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg00933542	chr6:150070202	PCMT1	0.45	10.09	0.44	1.37e-21	Lung cancer;
LUAD	cis	rs7666738	0.539	rs13150465	chr4:99094892	C/T	cg17366294	chr4:99064904	C4orf37	-0.6	-7.66	-0.35	1.32e-13	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg04100724	chr12:92539208	BTG1	0.39	6.36	0.3	5.26e-10	Bilirubin levels;
LUAD	cis	rs7851660	0.967	rs6478437	chr9:100607497	A/G	cg13688889	chr9:100608707	NA	-0.53	-9.76	-0.43	1.99e-20	Strep throat;
LUAD	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg19592336	chr6:28129416	ZNF389	-0.44	-6.45	-0.3	3.02e-10	Depression;
LUAD	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.79	0.31	3.78e-11	Cardiac Troponin-T levels;
LUAD	cis	rs35740288	0.770	rs11631449	chr15:86148653	T/C	cg13263323	chr15:86062960	AKAP13	-0.44	-7.02	-0.32	8.78e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.91	0.4	1.48e-17	Cognitive ability;
LUAD	cis	rs68170813	0.652	rs76924513	chr7:107205887	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-9.03	-0.4	6.3e-18	Coronary artery disease;
LUAD	cis	rs73416724	1.000	rs41281798	chr6:43325787	C/A	cg26312998	chr6:43337775	ZNF318	0.55	6.69	0.31	7.26e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22455342	chr2:225449267	CUL3	0.64	9.93	0.43	4.82e-21	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs7809950	1.000	rs67982599	chr7:107100104	T/G	cg23024343	chr7:107201750	COG5	-0.71	-11.99	-0.5	1.05e-28	Coronary artery disease;
LUAD	trans	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg06606381	chr12:133084897	FBRSL1	-0.52	-7.01	-0.32	9.46e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7927771	0.524	rs10742820	chr11:47781057	C/T	cg18512352	chr11:47633146	NA	-0.36	-6.5	-0.3	2.29e-10	Subjective well-being;
LUAD	cis	rs2485376	0.967	rs1541048	chr10:103997644	G/C	cg20641465	chr10:103991465	PITX3	0.56	10.13	0.44	9.77e-22	QT interval;
LUAD	cis	rs9616064	0.506	rs6008944	chr22:47060976	C/T	cg25730555	chr22:47059586	GRAMD4	0.39	7.06	0.32	7.08e-12	Urate levels in obese individuals;
LUAD	cis	rs7536201	1.000	rs10751775	chr1:25296478	T/C	cg23273869	chr1:25296894	NA	-0.37	-7.32	-0.34	1.27e-12	Psoriasis vulgaris;
LUAD	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg21605333	chr4:119757512	SEC24D	0.93	8.76	0.39	4.9e-17	Cannabis dependence symptom count;
LUAD	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.17e-25	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg22963979	chr7:1858916	MAD1L1	-0.57	-10.02	-0.44	2.33e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.25	-0.33	2.02e-12	Lung cancer;
LUAD	trans	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.83	-0.36	3.97e-14	Breast cancer;
LUAD	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg20891283	chr12:69753455	YEATS4	-0.43	-7.0	-0.32	1.02e-11	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg01200585	chr1:228362443	C1orf69	-0.39	-7.19	-0.33	2.92e-12	Diastolic blood pressure;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25154581	chr3:183853494	EIF2B5	-0.41	-6.48	-0.3	2.5e-10	Height;
LUAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg22442454	chr1:209979470	IRF6	0.51	7.17	0.33	3.45e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs12618769	0.597	rs55900716	chr2:99109132	G/A	cg10123293	chr2:99228465	UNC50	0.46	8.12	0.37	5.1e-15	Bipolar disorder;
LUAD	cis	rs4774899	0.752	rs2951898	chr15:57383139	G/A	cg14026238	chr15:57616123	NA	0.43	8.12	0.37	5.29e-15	Urinary tract infection frequency;
LUAD	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg15181151	chr6:150070149	PCMT1	0.41	8.38	0.38	8.19e-16	Lung cancer;
LUAD	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg23260525	chr10:116636907	FAM160B1	0.53	12.6	0.52	3.87e-31	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs28655083	0.913	rs7190129	chr16:77071456	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-7.08	-0.33	5.89e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4954585	0.708	rs6430612	chr2:137006198	C/T	cg05194412	chr2:137003533	NA	0.53	9.56	0.42	9.75e-20	Colorectal cancer;
LUAD	cis	rs6087990	0.806	rs6088008	chr20:31382860	A/G	cg13636640	chr20:31349939	DNMT3B	0.77	13.62	0.55	2.7900000000000003e-35	Ulcerative colitis;
LUAD	cis	rs12928939	0.517	rs8049508	chr16:71978313	C/T	cg03805757	chr16:71968109	PKD1L3	-0.53	-8.43	-0.38	5.57e-16	Post bronchodilator FEV1;
LUAD	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.49	-8.46	-0.38	4.47e-16	Tonsillectomy;
LUAD	trans	rs6561151	0.957	rs3764147	chr13:44457925	C/T	cg12856521	chr11:46389249	DGKZ	-0.66	-10.43	-0.45	7.97e-23	Crohn's disease;
LUAD	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg06784218	chr1:46089804	CCDC17	0.6	13.39	0.55	2.41e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-8.02	-0.36	1.02e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg04369109	chr6:150039330	LATS1	-0.4	-6.41	-0.3	3.83e-10	Lung cancer;
LUAD	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg16647868	chr5:131706066	SLC22A5	0.47	7.81	0.36	4.52e-14	Blood metabolite levels;
LUAD	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs7084921	0.608	rs1853700	chr10:101862694	T/C	cg19754520	chr10:101825118	CPN1	-0.32	-6.39	-0.3	4.39e-10	Bone mineral density;
LUAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg09436375	chr6:42928200	GNMT	-0.29	-8.19	-0.37	3.08e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg08601574	chr20:25228251	PYGB	0.47	8.56	0.38	2.17e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg11494091	chr17:61959527	GH2	0.69	16.06	0.62	1.19e-45	Prudent dietary pattern;
LUAD	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.8	0.31	3.63e-11	Schizophrenia;
LUAD	cis	rs559928	0.502	rs4963223	chr11:64193418	A/G	cg05555928	chr11:63887634	MACROD1	-0.45	-7.09	-0.33	5.62e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUAD	cis	rs701145	0.878	rs187357	chr3:153958876	C/A	cg17054900	chr3:154042577	DHX36	0.66	7.1	0.33	5.4e-12	Coronary artery disease;
LUAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg21782813	chr7:2030301	MAD1L1	0.51	8.69	0.39	7.75e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg05340658	chr4:99064831	C4orf37	0.53	8.93	0.4	1.31e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs231513	0.954	rs231524	chr17:41953212	G/A	cg26893861	chr17:41843967	DUSP3	-0.55	-6.62	-0.31	1.11e-10	Cognitive function;
LUAD	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg13319975	chr6:146136371	FBXO30	0.63	10.89	0.47	1.62e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-7.65	-0.35	1.37e-13	Major depressive disorder;
LUAD	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21582582	chr3:182698605	DCUN1D1	0.71	14.01	0.56	6.76e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg19875535	chr5:140030758	IK	-0.48	-8.07	-0.37	7.14e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg04034577	chr2:241836375	C2orf54	-0.47	-10.27	-0.45	3.02e-22	Urinary metabolites;
LUAD	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg02734326	chr4:10020555	SLC2A9	0.63	11.23	0.48	8.65e-26	Bone mineral density;
LUAD	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	6.83	0.31	3.06e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4523957	0.928	rs1122645	chr17:2170858	A/G	cg16513277	chr17:2031491	SMG6	-0.77	-14.7	-0.58	7.93e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg12419862	chr22:24373484	LOC391322	-0.79	-14.48	-0.58	7.08e-39	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs13191362	0.507	rs13210000	chr6:163176944	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.46	7.09	0.33	5.78e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg16797656	chr11:68205561	LRP5	-0.42	-8.13	-0.37	4.73e-15	Total body bone mineral density;
LUAD	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg18827107	chr12:86230957	RASSF9	0.54	9.74	0.43	2.24e-20	Major depressive disorder;
LUAD	cis	rs2282300	0.739	rs1631451	chr11:30349133	G/C	cg06241208	chr11:30344200	C11orf46	-0.55	-6.94	-0.32	1.53e-11	Morning vs. evening chronotype;
LUAD	cis	rs897984	0.542	rs59061704	chr16:31062704	G/C	cg02466173	chr16:30829666	NA	-0.56	-9.78	-0.43	1.75e-20	Dementia with Lewy bodies;
LUAD	cis	rs7737355	0.947	rs1422081	chr5:130776053	A/C	cg25547332	chr5:131281432	NA	0.41	6.43	0.3	3.44e-10	Life satisfaction;
LUAD	cis	rs986417	0.818	rs12880313	chr14:60935504	T/C	cg27398547	chr14:60952738	C14orf39	0.65	7.69	0.35	1.02e-13	Gut microbiota (bacterial taxa);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg09824706	chr7:6487775	DAGLB	-0.39	-6.6	-0.31	1.21e-10	Subcortical brain region volumes;
LUAD	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg13319975	chr6:146136371	FBXO30	0.55	9.06	0.4	4.79e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg25828334	chr19:18545568	ISYNA1	-0.38	-7.62	-0.35	1.68e-13	Breast cancer;
LUAD	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg15921436	chr17:44337874	NA	0.64	9.46	0.42	2.19e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs62238980	0.522	rs117246042	chr22:32454080	T/C	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.66e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg19862616	chr7:65841803	NCRNA00174	1.03	23.47	0.75	1.27e-78	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs887829	0.570	rs4347832	chr2:234593041	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.6	-0.42	7.26e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs12444979	0.517	rs720173	chr16:19721806	C/T	cg01578585	chr16:19721878	C16orf88	0.53	7.55	0.34	2.77e-13	Body mass index;
LUAD	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg21951975	chr1:209979733	IRF6	0.55	6.84	0.32	2.86e-11	Coronary artery disease;
LUAD	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.3	-0.33	1.4e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg08885076	chr2:99613938	TSGA10	-0.39	-6.94	-0.32	1.44e-11	Chronic sinus infection;
LUAD	trans	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg19336497	chr11:14380999	RRAS2	-0.65	-14.07	-0.56	3.75e-37	Sense of smell;
LUAD	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.41	6.61	0.31	1.15e-10	Tonsillectomy;
LUAD	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.2	-0.51	1.59e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg01620082	chr3:125678407	NA	-0.71	-7.15	-0.33	3.78e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg16988262	chr1:15930761	NA	0.41	6.91	0.32	1.82e-11	Systolic blood pressure;
LUAD	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg14835575	chr10:16859367	RSU1	0.78	11.76	0.5	8.05e-28	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13126279	chr21:47581558	C21orf56	0.54	9.15	0.41	2.44e-18	Testicular germ cell tumor;
LUAD	cis	rs7326068	0.524	rs2497484	chr13:21199265	C/T	cg27499820	chr13:21296301	IL17D	-0.42	-7.65	-0.35	1.37e-13	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg24642844	chr7:1081250	C7orf50	-0.6	-7.3	-0.33	1.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4414128	0.832	rs1573	chr10:5680896	A/G	cg12223502	chr10:5658492	NA	0.44	6.81	0.31	3.26e-11	Breast cancer;
LUAD	trans	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg18187862	chr3:45730750	SACM1L	0.5	7.89	0.36	2.55e-14	Primary sclerosing cholangitis;
LUAD	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg18196295	chr10:418757	DIP2C	-0.56	-9.51	-0.42	1.48e-19	Psychosis in Alzheimer's disease;
LUAD	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg16797656	chr11:68205561	LRP5	0.48	10.46	0.45	6.21e-23	Total body bone mineral density;
LUAD	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24531977	chr5:56204891	C5orf35	-0.79	-12.95	-0.53	1.52e-32	Initial pursuit acceleration;
LUAD	cis	rs4700695	0.719	rs27584	chr5:65445232	G/A	cg21114390	chr5:65439923	SFRS12	-0.92	-14.45	-0.57	9.46e-39	Facial morphology (factor 19);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg01307007	chr19:3522587	FZR1	0.38	6.52	0.3	2.01e-10	Schizophrenia;
LUAD	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg00898013	chr13:113819073	PROZ	0.67	11.97	0.5	1.18e-28	Platelet distribution width;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12653922	chr1:235668002	B3GALNT2	-0.4	-6.56	-0.3	1.56e-10	Cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17896097	chr9:125693949	ZBTB26	-0.41	-6.58	-0.3	1.38e-10	Cancer;
LUAD	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg05754148	chr16:3507555	NAT15	-0.83	-9.41	-0.42	3.17e-19	Tuberculosis;
LUAD	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg03233332	chr7:66118400	NA	0.46	6.86	0.32	2.49e-11	Aortic root size;
LUAD	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.95	-0.53	1.47e-32	Dilated cardiomyopathy;
LUAD	cis	rs7173743	0.756	rs8034804	chr15:79129600	C/T	cg00540400	chr15:79124168	NA	0.38	7.67	0.35	1.18e-13	Coronary artery disease;
LUAD	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg23752985	chr2:85803571	VAMP8	-0.34	-6.83	-0.32	2.93e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	cis	rs2732480	0.500	rs11168464	chr12:48602115	C/T	cg04545296	chr12:48745243	ZNF641	0.39	10.04	0.44	1.96e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs6489785	0.522	rs1718188	chr12:121343893	T/A	cg02419362	chr12:121203948	SPPL3	-0.34	-6.83	-0.32	3.01e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs28735056	0.904	rs62103183	chr18:77626564	A/G	cg05926928	chr17:57297772	GDPD1	0.5	7.36	0.34	9.38e-13	Schizophrenia;
LUAD	cis	rs912057	0.965	rs1294409	chr6:6738355	A/G	cg06612196	chr6:6737390	NA	-0.54	-12.24	-0.51	1.06e-29	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	trans	rs6076960	0.652	rs6085467	chr20:6259004	T/C	cg21095983	chr6:86352623	SYNCRIP	0.4	6.37	0.3	5e-10	Smooth-surface caries;
LUAD	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg09085632	chr11:111637200	PPP2R1B	0.64	9.78	0.43	1.71e-20	Primary sclerosing cholangitis;
LUAD	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg02569458	chr12:86230093	RASSF9	0.45	8.24	0.37	2.25e-15	Major depressive disorder;
LUAD	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg22467129	chr15:76604101	ETFA	-0.5	-8.6	-0.39	1.53e-16	Blood metabolite levels;
LUAD	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg10589385	chr1:150898437	SETDB1	0.41	7.75	0.35	7.13e-14	Tonsillectomy;
LUAD	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg11494091	chr17:61959527	GH2	0.44	8.4	0.38	6.98e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg26408565	chr15:76604113	ETFA	-0.56	-9.77	-0.43	1.77e-20	Blood metabolite levels;
LUAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg11494091	chr17:61959527	GH2	0.74	18.52	0.67	1.62e-56	Prudent dietary pattern;
LUAD	cis	rs78487399	0.710	rs7590220	chr2:43702151	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-6.43	-0.3	3.4e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.7	11.4	0.48	1.88e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg03188948	chr7:1209495	NA	0.81	9.86	0.43	9.06e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs4714291	0.698	rs9296321	chr6:40118352	C/T	cg02267698	chr19:7991119	CTXN1	-0.41	-6.65	-0.31	9.27e-11	Strep throat;
LUAD	trans	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg06606381	chr12:133084897	FBRSL1	-0.61	-6.46	-0.3	2.88e-10	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg01620082	chr3:125678407	NA	-0.42	-6.44	-0.3	3.28e-10	Parkinson's disease;
LUAD	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg13511324	chr14:104056883	C14orf153	0.25	6.38	0.3	4.53e-10	Coronary artery disease;
LUAD	trans	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.75	0.31	5.03e-11	Systolic blood pressure;
LUAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg06753367	chr22:24256600	NA	0.36	6.38	0.3	4.58e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg04287289	chr16:89883240	FANCA	0.43	6.65	0.31	9.14e-11	Vitiligo;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg12680326	chr20:2821316	VPS16;FAM113A	-0.41	-7.04	-0.32	7.99e-12	Schizophrenia;
LUAD	cis	rs7172809	0.573	rs17468413	chr15:77544510	T/A	cg11865553	chr15:77376250	NA	-0.39	-6.42	-0.3	3.62e-10	Glucose homeostasis traits;
LUAD	cis	rs1847202	0.859	rs13096870	chr3:72948172	G/A	cg25664220	chr3:72788482	NA	-0.43	-7.54	-0.34	2.91e-13	Motion sickness;
LUAD	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg12062639	chr20:23401060	NAPB	-1.05	-10.89	-0.47	1.61e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs1681630	1.000	rs1681630	chr11:47969152	A/G	cg03929089	chr4:120376271	NA	-0.44	-6.48	-0.3	2.59e-10	Height;
LUAD	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg06623918	chr6:96969491	KIAA0776	-0.76	-11.99	-0.5	9.93e-29	Migraine;Coronary artery disease;
LUAD	cis	rs524023	0.958	rs12802649	chr11:64359627	C/T	cg19131476	chr11:64387923	NRXN2	-0.36	-6.8	-0.31	3.5e-11	Urate levels in obese individuals;
LUAD	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.93	-0.36	2.01e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg00316803	chr15:76480434	C15orf27	0.4	6.59	0.31	1.28e-10	Blood metabolite levels;
LUAD	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.3	-0.45	2.43e-22	Total body bone mineral density;
LUAD	cis	rs6076065	0.723	rs743023	chr20:23400852	T/C	cg11657817	chr20:23433608	CST11	0.49	8.85	0.4	2.48e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg14835575	chr10:16859367	RSU1	0.51	7.7	0.35	9.69e-14	Platelet distribution width;
LUAD	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg09085632	chr11:111637200	PPP2R1B	0.62	9.34	0.41	5.37e-19	Primary sclerosing cholangitis;
LUAD	cis	rs250585	0.736	rs30014	chr16:23415898	C/T	cg00143387	chr16:23521605	GGA2	0.61	8.77	0.39	4.38e-17	Egg allergy;
LUAD	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg18854424	chr1:2615690	NA	-0.41	-8.95	-0.4	1.14e-17	Ulcerative colitis;
LUAD	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg17063962	chr7:91808500	NA	-0.68	-12.25	-0.51	9.82e-30	Breast cancer;
LUAD	cis	rs6738485	0.861	rs13014335	chr2:106802805	A/G	cg15412446	chr2:106886593	NA	-0.38	-6.56	-0.3	1.61e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs6687430	0.526	rs12127400	chr1:10613660	C/T	cg17425144	chr1:10567563	PEX14	0.55	10.62	0.46	1.63e-23	Hand grip strength;
LUAD	cis	rs7833986	0.501	rs2976018	chr8:57014752	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	1.02	18.03	0.66	2.59e-54	Height;
LUAD	cis	rs2901656	0.934	rs2285176	chr1:172421744	G/A	cg03748243	chr1:172413542	C1orf105;PIGC	0.45	8.7	0.39	7.73e-17	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-8.07	-0.37	7.42e-15	Body mass index;
LUAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg22764044	chr5:178986830	RUFY1	-0.57	-9.67	-0.43	4.21e-20	Lung cancer;
LUAD	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21659725	chr3:3221576	CRBN	-0.63	-10.93	-0.47	1.12e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs12545109	0.879	rs1975285	chr8:57358682	G/C	cg21220214	chr8:57350948	NA	-0.66	-9.08	-0.4	4.15e-18	Obesity-related traits;
LUAD	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.51	0.34	3.57e-13	Tonsillectomy;
LUAD	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg20701182	chr2:24300061	SF3B14	0.59	6.67	0.31	8.06e-11	Lymphocyte counts;
LUAD	cis	rs10746514	0.786	rs9308486	chr1:232246418	A/G	cg09506761	chr1:232265262	NA	0.41	7.69	0.35	1.03e-13	Response to statin therapy;
LUAD	cis	rs929596	0.755	rs887829	chr2:234668570	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.71	12.57	0.52	5.3e-31	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs3806933	0.522	rs11241100	chr5:110460958	C/T	cg17157872	chr5:110408788	TSLP	0.35	6.56	0.3	1.58e-10	Eosinophilic esophagitis;
LUAD	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg21385522	chr1:16154831	NA	-0.57	-9.51	-0.42	1.49e-19	Systolic blood pressure;
LUAD	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg04414720	chr1:150670196	GOLPH3L	0.72	12.71	0.53	1.49e-31	Melanoma;
LUAD	cis	rs7107174	0.901	rs2450136	chr11:77925273	T/G	cg19901956	chr11:77921274	USP35	-0.49	-6.36	-0.3	5.33e-10	Testicular germ cell tumor;
LUAD	cis	rs12545109	0.800	rs2610058	chr8:57409120	G/A	cg21220214	chr8:57350948	NA	-0.62	-8.61	-0.39	1.51e-16	Obesity-related traits;
LUAD	cis	rs7089973	0.872	rs11818115	chr10:116634891	G/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.57	0.42	9.13e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg10978503	chr1:24200527	CNR2	-0.45	-8.54	-0.38	2.45e-16	Immature fraction of reticulocytes;
LUAD	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	24.35	0.76	1.76e-82	Chronic sinus infection;
LUAD	cis	rs11828289	0.660	rs28825707	chr11:23224075	G/A	cg20040320	chr11:23191996	NA	-0.69	-8.04	-0.36	9.36e-15	Cancer;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg11726572	chr18:658602	TYMS;C18orf56	0.44	6.78	0.31	4.02e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2882667	0.858	rs11741150	chr5:138431457	C/T	cg04439458	chr5:138467593	SIL1	-0.54	-9.75	-0.43	2.19e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg20607798	chr8:58055168	NA	0.57	6.85	0.32	2.65e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg04906043	chr13:21280425	IL17D	0.39	7.19	0.33	2.88e-12	Dental caries;
LUAD	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.64	-0.31	9.48e-11	Coronary artery disease;
LUAD	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.93	0.32	1.6e-11	Rheumatoid arthritis;
LUAD	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-14.51	-0.58	5.23e-39	Extrinsic epigenetic age acceleration;
LUAD	trans	rs587242	1.000	rs12744194	chr1:96898486	T/G	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs73198271	0.562	rs112717383	chr8:8663216	T/C	cg01851573	chr8:8652454	MFHAS1	0.69	10.47	0.45	5.75e-23	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg03188948	chr7:1209495	NA	0.83	10.1	0.44	1.29e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs870825	0.616	rs72705689	chr4:185639894	A/G	cg04058563	chr4:185651563	MLF1IP	0.88	14.12	0.57	2.26e-37	Blood protein levels;
LUAD	cis	rs11214589	0.747	rs10891536	chr11:113209428	C/G	cg14159747	chr11:113255604	NA	0.61	12.57	0.52	5.13e-31	Neuroticism;
LUAD	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.49	7.73	0.35	8.17e-14	Total body bone mineral density;
LUAD	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg05991184	chr2:219186017	PNKD	-0.36	-6.89	-0.32	2.05e-11	Colorectal cancer;
LUAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg11965913	chr1:205819406	PM20D1	-0.78	-16.4	-0.62	3.97e-47	Menarche (age at onset);
LUAD	cis	rs1535500	0.967	rs11756091	chr6:39282806	G/T	cg03252829	chr6:39282164	KCNK17	-0.31	-6.64	-0.31	9.81e-11	Type 2 diabetes;
LUAD	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg25358565	chr5:93447407	FAM172A	0.66	7.78	0.35	5.63e-14	Diabetic retinopathy;
LUAD	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg12458913	chr13:53173898	NA	0.45	7.84	0.36	3.83e-14	Lewy body disease;
LUAD	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08219700	chr8:58056026	NA	0.67	8.36	0.38	9.23e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs12541635	0.966	rs62525734	chr8:106984056	T/C	cg10147462	chr8:107024639	NA	0.47	8.18	0.37	3.32e-15	Age of smoking initiation;
LUAD	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg21194808	chr1:2205498	SKI	0.41	6.4	0.3	4.01e-10	Height;
LUAD	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg09085632	chr11:111637200	PPP2R1B	0.61	9.18	0.41	1.91e-18	Primary sclerosing cholangitis;
LUAD	cis	rs6459788	0.934	rs10237947	chr7:157258109	G/T	cg06271696	chr7:157225062	NA	0.34	6.8	0.31	3.53e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg00717180	chr2:96193071	NA	-0.42	-7.74	-0.35	7.47e-14	HDL cholesterol;
LUAD	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg04450456	chr4:17643702	FAM184B	0.39	7.64	0.35	1.5e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg23283495	chr1:209979779	IRF6	0.65	8.7	0.39	7.67e-17	Cleft lip with or without cleft palate;
LUAD	trans	rs258892	0.947	rs266446	chr5:72182030	T/G	cg14879065	chr14:104662468	NA	-0.35	-6.39	-0.3	4.45e-10	Small cell lung carcinoma;
LUAD	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10150615	chr22:24372951	LOC391322	-0.57	-9.27	-0.41	9.25e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg00129232	chr17:37814104	STARD3	-0.46	-7.36	-0.34	9.48e-13	Asthma;
LUAD	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.83	-0.36	3.97e-14	Diabetic kidney disease;
LUAD	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg11707310	chr1:2537719	MMEL1	-0.37	-7.89	-0.36	2.64e-14	Ulcerative colitis;
LUAD	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg02782426	chr3:40428986	ENTPD3	0.42	8.9	0.4	1.64e-17	Renal cell carcinoma;
LUAD	cis	rs2742417	1.000	rs2742392	chr3:45757282	T/C	cg10512202	chr3:45649293	LIMD1	0.4	7.17	0.33	3.47e-12	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg14458575	chr2:238380390	NA	0.86	12.88	0.53	2.93e-32	Prostate cancer;
LUAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-8.07	-0.37	7.12e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.54	6.66	0.31	8.48e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9487051	0.743	rs388526	chr6:109543425	C/G	cg21918786	chr6:109611834	NA	-0.41	-6.92	-0.32	1.67e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.56	-0.35	2.48e-13	Lung cancer;
LUAD	cis	rs999737	1.000	rs10483813	chr14:69031284	T/A	cg04147497	chr14:69052728	RAD51L1	-0.43	-6.35	-0.3	5.48e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg09537434	chr19:41945824	ATP5SL	-0.5	-8.02	-0.36	1.06e-14	Height;
LUAD	cis	rs3916	0.910	rs7306541	chr12:121130046	A/G	cg27246729	chr12:121163418	ACADS	0.45	7.34	0.34	1.08e-12	Urinary metabolites (H-NMR features);
LUAD	trans	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	10.02	0.44	2.38e-21	Type 2 diabetes;
LUAD	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg07169764	chr2:136633963	MCM6	0.8	9.37	0.41	4.55e-19	Corneal structure;
LUAD	cis	rs2637266	1.000	rs12414151	chr10:78359041	T/G	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.91e-11	Pulmonary function;
LUAD	trans	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg11693508	chr17:37793320	STARD3	0.61	8.51	0.38	2.96e-16	Neuroticism;
LUAD	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg20476274	chr7:133979776	SLC35B4	0.57	9.96	0.44	3.85e-21	Mean platelet volume;
LUAD	cis	rs6847149	0.929	rs6847467	chr4:110800020	G/A	cg07850274	chr4:110748770	RRH	0.44	6.97	0.32	1.22e-11	Exercise treadmill test traits;
LUAD	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.39	-0.34	8.08e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.47	-7.65	-0.35	1.39e-13	Multiple sclerosis;
LUAD	cis	rs7474896	0.559	rs1208645	chr10:38132087	C/T	cg25427524	chr10:38739819	LOC399744	0.6	8.63	0.39	1.26e-16	Obesity (extreme);
LUAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-6.5	-0.3	2.28e-10	Longevity;Endometriosis;
LUAD	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg19622623	chr12:86230825	RASSF9	-0.42	-7.49	-0.34	3.94e-13	Major depressive disorder;
LUAD	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg00204512	chr16:28754710	NA	0.3	6.5	0.3	2.27e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg06640241	chr16:89574553	SPG7	0.49	7.98	0.36	1.42e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.68	-11.31	-0.48	4.17e-26	Primary sclerosing cholangitis;
LUAD	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg22338127	chr1:209979572	IRF6	0.51	6.42	0.3	3.59e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg24838063	chr12:130822603	PIWIL1	0.64	10.68	0.46	9.9899999999999993e-24	Menopause (age at onset);
LUAD	cis	rs4243830	0.677	rs1556035	chr1:6579607	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.68	-8.39	-0.38	7.39e-16	Body mass index;
LUAD	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg01802117	chr1:53393560	SCP2	-0.35	-7.0	-0.32	1.01e-11	Monocyte count;
LUAD	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-8.85	-0.4	2.47e-17	Gut microbiome composition (summer);
LUAD	cis	rs62238980	0.614	rs77886759	chr22:32390956	A/G	cg00543991	chr22:32367038	NA	0.92	8.16	0.37	3.95e-15	Childhood ear infection;
LUAD	cis	rs9715521	0.775	rs62301198	chr4:59848776	C/T	cg11281224	chr4:60001000	NA	-0.6	-10.24	-0.45	3.85e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg05283184	chr6:79620031	NA	-0.58	-11.68	-0.49	1.65e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg14092571	chr14:90743983	NA	-0.49	-8.59	-0.39	1.63e-16	Mortality in heart failure;
LUAD	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg25894440	chr7:65020034	NA	-0.63	-6.7	-0.31	6.86e-11	Diabetic kidney disease;
LUAD	cis	rs7119	0.667	rs2867312	chr15:77902293	A/G	cg27398640	chr15:77910606	LINGO1	-0.37	-7.3	-0.33	1.45e-12	Type 2 diabetes;
LUAD	cis	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05901451	chr6:126070800	HEY2	-0.44	-6.56	-0.3	1.58e-10	Endometrial cancer;
LUAD	cis	rs6993813	0.843	rs1905779	chr8:120041165	C/T	cg01975934	chr8:119970761	NA	-0.37	-7.2	-0.33	2.83e-12	Bone mineral density (hip);
LUAD	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-8.71	-0.39	6.69e-17	Cognitive function;
LUAD	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	7.74e-16	Body mass index;
LUAD	cis	rs62238980	0.614	rs77099614	chr22:32452759	A/G	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07636037	chr3:49044803	WDR6	0.49	8.35	0.38	1.01e-15	Menarche (age at onset);
LUAD	cis	rs1816752	0.583	rs6490918	chr13:25002115	G/A	cg02811702	chr13:24901961	NA	-0.38	-6.51	-0.3	2.18e-10	Obesity-related traits;
LUAD	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg05535760	chr7:792225	HEATR2	-0.84	-9.93	-0.43	4.98e-21	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7512552	0.839	rs2867894	chr1:150452912	T/A	cg15654264	chr1:150340011	RPRD2	0.55	10.69	0.46	9.06e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg18404041	chr3:52824283	ITIH1	0.52	8.89	0.4	1.85e-17	Schizophrenia;
LUAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08677398	chr8:58056175	NA	-0.44	-6.37	-0.3	4.95e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.8	-0.35	5.01e-14	Prostate cancer;
LUAD	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.6	8.45	0.38	4.86e-16	Gut microbiome composition (summer);
LUAD	trans	rs3960554	0.529	rs7793844	chr7:75883147	C/T	cg19862616	chr7:65841803	NCRNA00174	0.52	8.09	0.37	6.31e-15	Eotaxin levels;
LUAD	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	8.37	0.38	8.43e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg22467129	chr15:76604101	ETFA	-0.47	-8.05	-0.36	8.37e-15	Blood metabolite levels;
LUAD	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg18446336	chr7:2847575	GNA12	-0.36	-6.83	-0.32	2.92e-11	Height;
LUAD	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg23260525	chr10:116636907	FAM160B1	0.51	11.64	0.49	2.4e-27	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.523	rs12532447	chr7:106940476	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.84	-0.47	2.46e-24	Coronary artery disease;
LUAD	trans	rs3780486	0.846	rs10971438	chr9:33180308	A/G	cg20290983	chr6:43655470	MRPS18A	0.96	18.68	0.67	3.09e-57	IgG glycosylation;
LUAD	cis	rs657075	0.639	rs3792885	chr5:131652248	T/A	cg21138405	chr5:131827807	IRF1	0.5	6.42	0.3	3.76e-10	Rheumatoid arthritis;
LUAD	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg03233332	chr7:66118400	NA	0.43	6.62	0.31	1.12e-10	Aortic root size;
LUAD	cis	rs877282	0.891	rs34383514	chr10:800181	T/C	cg17470449	chr10:769945	NA	0.64	9.4	0.42	3.34e-19	Uric acid levels;
LUAD	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg09367891	chr1:107599246	PRMT6	0.59	9.76	0.43	2.01e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6604026	0.740	rs6604031	chr1:93400766	T/G	cg17283838	chr1:93427260	FAM69A	-0.44	-6.72	-0.31	6.05e-11	Multiple sclerosis;
LUAD	cis	rs12545109	0.671	rs35500854	chr8:57424303	G/A	cg11919837	chr8:57350735	NA	-0.45	-6.37	-0.3	5.07e-10	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.58	0.3	1.41e-10	Depression;
LUAD	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg25554036	chr4:6271136	WFS1	0.73	14.99	0.59	4.95e-41	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg01191920	chr7:158217561	PTPRN2	0.61	12.74	0.53	1.05e-31	Obesity-related traits;
LUAD	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg22920501	chr2:26401640	FAM59B	-0.73	-10.5	-0.45	4.53e-23	Gut microbiome composition (summer);
LUAD	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg08027265	chr7:2291960	NA	-0.52	-9.15	-0.41	2.41e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg08645402	chr16:4508243	NA	0.57	10.7	0.46	8.03e-24	Schizophrenia;
LUAD	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg00204512	chr16:28754710	NA	0.35	7.49	0.34	4.06e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs76878669	0.538	rs4930360	chr11:66143247	T/A	cg10616300	chr11:66138557	SLC29A2	0.35	7.45	0.34	5.15e-13	Educational attainment (years of education);
LUAD	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg21385522	chr1:16154831	NA	0.6	8.74	0.39	5.53e-17	Dilated cardiomyopathy;
LUAD	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.16	-0.33	3.51e-12	Neuroticism;
LUAD	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg15556689	chr8:8085844	FLJ10661	0.42	6.82	0.31	3.14e-11	Mood instability;
LUAD	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg04896959	chr15:78267971	NA	0.65	12.75	0.53	1.02e-31	Coronary artery disease or large artery stroke;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg02784696	chr2:24270586	C2orf44	0.6	10.06	0.44	1.75e-21	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23158103	chr7:148848205	ZNF398	-0.59	-10.86	-0.47	2.14e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg03929089	chr4:120376271	NA	-0.88	-16.89	-0.63	2.74e-49	Height;
LUAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.72	-0.31	6.05e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg02698600	chr1:201450009	NA	-0.4	-6.65	-0.31	9.29e-11	Schizophrenia;
LUAD	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.31	-7.95	-0.36	1.75e-14	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg21220214	chr8:57350948	NA	-0.6	-8.77	-0.39	4.52e-17	Obesity-related traits;
LUAD	cis	rs4711350	1.000	rs2395401	chr6:33759471	T/C	cg18005901	chr6:33739558	LEMD2	-0.52	-7.52	-0.34	3.33e-13	Schizophrenia;
LUAD	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg04944784	chr2:26401820	FAM59B	-0.89	-13.77	-0.56	6.72e-36	Gut microbiome composition (summer);
LUAD	cis	rs1784581	0.532	rs7767219	chr6:162423088	T/C	cg17173639	chr6:162384350	PARK2	0.43	7.73	0.35	8.1e-14	Itch intensity from mosquito bite;
LUAD	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg09796270	chr17:17721594	SREBF1	-0.37	-7.09	-0.33	5.51e-12	Total body bone mineral density;
LUAD	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-12.0	-0.5	9.42e-29	Bipolar disorder;
LUAD	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg06641503	chr3:48959341	ARIH2	-0.4	-6.87	-0.32	2.31e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	trans	rs2018683	0.711	rs917214	chr7:28968293	T/C	cg19402173	chr7:128379420	CALU	-0.58	-9.3	-0.41	7.85e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg21918786	chr6:109611834	NA	-0.56	-10.4	-0.45	1.03e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14240646	chr10:27532245	ACBD5	-0.92	-11.87	-0.5	3.02e-28	Breast cancer;
LUAD	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg25664220	chr3:72788482	NA	-0.67	-11.72	-0.5	1.14e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs17155006	0.563	rs451416	chr7:107738531	A/G	cg05962710	chr7:107745446	LAMB4	-0.35	-7.27	-0.33	1.78e-12	Pneumococcal bacteremia;
LUAD	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg15485101	chr11:133734466	NA	0.33	7.53	0.34	3.12e-13	Childhood ear infection;
LUAD	cis	rs11118844	0.843	rs11118848	chr1:221926826	A/G	cg04222084	chr1:221915650	DUSP10	0.66	7.33	0.34	1.18e-12	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	11.72	0.5	1.16e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg23625390	chr15:77176239	SCAPER	0.37	6.62	0.31	1.09e-10	Blood metabolite levels;
LUAD	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg07936489	chr17:37558343	FBXL20	-0.5	-6.86	-0.32	2.53e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.38e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.57e-13	Tonsillectomy;
LUAD	cis	rs17095355	0.579	rs72828224	chr10:111702047	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.71	-9.82	-0.43	1.23e-20	Biliary atresia;
LUAD	cis	rs7843479	0.601	rs10453141	chr8:21847235	T/C	cg03445287	chr8:21823731	XPO7	-0.49	-9.26	-0.41	1.04e-18	Mean corpuscular volume;
LUAD	cis	rs250677	0.522	rs6872701	chr5:148359086	C/G	cg12140854	chr5:148520817	ABLIM3	0.56	8.8	0.39	3.59e-17	Breast cancer;
LUAD	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg13010199	chr12:38710504	ALG10B	0.38	6.36	0.3	5.09e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2274471	0.699	rs12551254	chr9:5043007	C/T	cg03390472	chr9:5043263	JAK2	-0.61	-9.22	-0.41	1.4e-18	Crohn's disease;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg20732367	chr2:238601467	LRRFIP1	-0.52	-7.38	-0.34	8.25e-13	Blood protein levels;
LUAD	cis	rs1832871	0.683	rs11756200	chr6:158657736	A/G	cg07165851	chr6:158734300	TULP4	0.69	10.23	0.45	4.13e-22	Height;
LUAD	cis	rs7258465	0.965	rs10408290	chr19:18542701	C/T	cg01065977	chr19:18549689	ISYNA1	-0.37	-7.04	-0.32	7.99e-12	Breast cancer;
LUAD	trans	rs1997103	1.000	rs10252413	chr7:55396740	C/G	cg20935933	chr6:143382018	AIG1	0.53	7.46	0.34	4.82e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs8099014	0.906	rs4940695	chr18:56106483	T/G	cg12907477	chr18:56117327	MIR122	0.52	8.34	0.38	1.02e-15	Platelet count;
LUAD	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg08999081	chr20:33150536	PIGU	-0.58	-12.57	-0.52	5.16e-31	Glomerular filtration rate (creatinine);
LUAD	cis	rs7789940	1.000	rs758944	chr7:75953297	G/T	cg10167463	chr7:75959203	YWHAG	-0.7	-12.7	-0.53	1.59e-31	Multiple sclerosis;
LUAD	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg11062466	chr8:58055876	NA	0.81	9.96	0.44	3.84e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs1941023	0.584	rs10750937	chr11:60172087	C/T	cg08716584	chr11:60157161	MS4A7	-0.45	-8.55	-0.38	2.29e-16	Congenital heart disease (maternal effect);
LUAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg18402987	chr7:1209562	NA	0.79	9.73	0.43	2.52e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg09904177	chr6:26538194	HMGN4	0.43	7.21	0.33	2.51e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2625529	0.668	rs8192431	chr15:72492352	G/A	cg16672083	chr15:72433130	SENP8	-0.79	-13.35	-0.54	3.71e-34	Red blood cell count;
LUAD	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg25767906	chr1:53392781	SCP2	0.65	11.98	0.5	1.12e-28	Monocyte count;
LUAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg22676075	chr6:135203613	NA	0.41	7.41	0.34	6.94e-13	Red blood cell count;
LUAD	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg05110241	chr16:68378359	PRMT7	-0.58	-7.34	-0.34	1.07e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.7	0.31	6.49e-11	Breast cancer;
LUAD	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg21709803	chr11:61594965	FADS2	-0.41	-7.63	-0.35	1.59e-13	Trans fatty acid levels;
LUAD	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg06074448	chr4:187884817	NA	0.41	8.64	0.39	1.19e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg08999081	chr20:33150536	PIGU	-0.62	-13.83	-0.56	3.88e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg25703541	chr22:24373054	LOC391322	-0.83	-15.43	-0.6	6.49e-43	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg12292205	chr6:26970375	C6orf41	0.39	6.86	0.32	2.45e-11	Schizophrenia;
LUAD	cis	rs4588572	0.615	rs4143070	chr5:77769094	G/C	cg11547950	chr5:77652471	NA	-0.64	-10.81	-0.47	3.19e-24	Triglycerides;
LUAD	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg07570687	chr10:102243282	WNT8B	0.44	6.78	0.31	4.06e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7771547	0.607	rs6923993	chr6:36427276	A/G	cg07856975	chr6:36356162	ETV7	0.43	6.55	0.3	1.63e-10	Platelet distribution width;
LUAD	cis	rs9462027	0.628	rs2814945	chr6:34647978	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-8.58	-0.38	1.86e-16	Systemic lupus erythematosus;
LUAD	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg05043794	chr9:111880884	C9orf5	-0.45	-7.86	-0.36	3.13e-14	Menarche (age at onset);
LUAD	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.21	0.33	2.57e-12	Menopause (age at onset);
LUAD	cis	rs3789045	0.560	rs4626956	chr1:204407298	T/C	cg17419461	chr1:204415978	PIK3C2B	-0.57	-9.22	-0.41	1.43e-18	Educational attainment (college completion);
LUAD	cis	rs9341808	0.727	rs9352809	chr6:80999316	C/T	cg08355045	chr6:80787529	NA	0.53	9.49	0.42	1.69e-19	Sitting height ratio;
LUAD	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg23533926	chr12:111358616	MYL2	-0.4	-6.85	-0.32	2.66e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9462027	0.628	rs2814970	chr6:34713500	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.12	-0.41	3.03e-18	Systemic lupus erythematosus;
LUAD	cis	rs7709909	0.553	rs6151629	chr5:79965735	T/C	cg24059623	chr5:79951536	MSH3;DHFR	0.47	7.1	0.33	5.32e-12	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg21427119	chr20:30132790	HM13	-0.48	-7.68	-0.35	1.12e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg09324608	chr17:30823087	MYO1D	0.43	7.7	0.35	9.69e-14	Schizophrenia;
LUAD	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg08470875	chr2:26401718	FAM59B	-0.67	-8.95	-0.4	1.1e-17	Gut microbiome composition (summer);
LUAD	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg23109721	chr2:106886537	NA	-0.48	-6.79	-0.31	3.8e-11	Facial morphology (factor 23);
LUAD	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg26924012	chr15:45694286	SPATA5L1	0.62	10.76	0.46	4.82e-24	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg03474202	chr17:45855739	NA	-0.37	-8.97	-0.4	9.51e-18	IgG glycosylation;
LUAD	cis	rs1137	1.000	rs205638	chr2:74950067	C/T	cg19285774	chr2:74907978	SEMA4F	0.39	7.57	0.35	2.42e-13	Myopia (pathological);
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg05109266	chr11:810147	RPLP2	0.46	6.81	0.31	3.33e-11	QT interval;
LUAD	trans	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21659725	chr3:3221576	CRBN	-0.42	-6.94	-0.32	1.48e-11	Menarche (age at onset);
LUAD	trans	rs853679	0.607	rs13208096	chr6:28225311	C/G	cg06606381	chr12:133084897	FBRSL1	-1.23	-10.87	-0.47	2.02e-24	Depression;
LUAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.47	6.69	0.31	7.06e-11	Renal function-related traits (BUN);
LUAD	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	11.6	0.49	3.28e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg07757535	chr4:1339547	NA	0.31	6.99	0.32	1.1e-11	Longevity;
LUAD	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg16405210	chr4:1374714	KIAA1530	-0.61	-9.68	-0.43	3.74e-20	Longevity;
LUAD	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg17330251	chr7:94953956	PON1	-0.53	-7.22	-0.33	2.38e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg00277334	chr10:82204260	NA	-0.61	-9.69	-0.43	3.56e-20	Post bronchodilator FEV1;
LUAD	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg27284194	chr4:1044797	NA	0.7	10.08	0.44	1.46e-21	Recombination rate (females);
LUAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19626725	chr5:178986131	RUFY1	0.57	10.76	0.46	4.97e-24	Lung cancer;
LUAD	trans	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg15704280	chr7:45808275	SEPT13	-0.54	-8.51	-0.38	3.03e-16	Height;
LUAD	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg07741184	chr6:167504864	NA	0.29	6.87	0.32	2.34e-11	Crohn's disease;
LUAD	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg18105134	chr13:113819100	PROZ	0.91	16.42	0.62	3.26e-47	Platelet distribution width;
LUAD	cis	rs427394	0.632	rs2279656	chr5:6737576	G/A	cg10857441	chr5:6722123	POLS	-0.6	-10.65	-0.46	1.25e-23	Menopause (age at onset);
LUAD	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg20119798	chr7:94954144	PON1	-0.47	-6.43	-0.3	3.37e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.72	0.35	8.69e-14	Resting heart rate;
LUAD	cis	rs7267979	0.932	rs928121	chr20:25534818	A/G	cg08601574	chr20:25228251	PYGB	0.41	7.47	0.34	4.62e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg07507251	chr3:52567010	NT5DC2	0.39	7.64	0.35	1.45e-13	Electroencephalogram traits;
LUAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-9.2	-0.41	1.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg12062639	chr20:23401060	NAPB	1.1	11.43	0.49	1.54e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7809950	0.862	rs12112877	chr7:106941324	T/C	cg23024343	chr7:107201750	COG5	-0.69	-11.64	-0.49	2.32e-27	Coronary artery disease;
LUAD	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg20476274	chr7:133979776	SLC35B4	0.55	9.73	0.43	2.56e-20	Mean platelet volume;
LUAD	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18099408	chr3:52552593	STAB1	-0.46	-8.12	-0.37	5e-15	Bipolar disorder;
LUAD	cis	rs6484504	0.625	rs6484501	chr11:31373100	G/T	cg26647111	chr11:31128758	NA	0.45	7.84	0.36	3.6e-14	Red blood cell count;
LUAD	cis	rs4711350	0.765	rs6921772	chr6:33749686	A/G	cg13859433	chr6:33739653	LEMD2	-0.35	-7.24	-0.33	2.19e-12	Schizophrenia;
LUAD	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg20701182	chr2:24300061	SF3B14	0.67	7.66	0.35	1.24e-13	Lymphocyte counts;
LUAD	trans	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg26043149	chr18:55253948	FECH	0.51	8.35	0.38	1.01e-15	Bone mineral density;
LUAD	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg24558204	chr6:135376177	HBS1L	0.44	7.81	0.35	4.64e-14	Red blood cell count;
LUAD	cis	rs751728	0.965	rs2296743	chr6:33740025	C/T	cg13859433	chr6:33739653	LEMD2	-0.39	-9.2	-0.41	1.65e-18	Crohn's disease;
LUAD	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg00530320	chr1:46809349	NSUN4	0.53	8.14	0.37	4.46e-15	Menopause (age at onset);
LUAD	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg00300879	chr1:26503847	CNKSR1	0.29	8.53	0.38	2.57e-16	Height;
LUAD	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg11859384	chr17:80120422	CCDC57	0.48	8.58	0.38	1.88e-16	Life satisfaction;
LUAD	cis	rs986417	1.000	rs996285	chr14:60869837	T/G	cg27398547	chr14:60952738	C14orf39	-0.63	-7.33	-0.34	1.14e-12	Gut microbiota (bacterial taxa);
LUAD	trans	rs2877832	0.722	rs1982531	chr14:27823806	A/C	cg09477895	chr3:18140683	NA	0.4	6.68	0.31	7.69e-11	Diabetes related insulin traits;
LUAD	cis	rs758324	0.947	rs72793242	chr5:131242506	A/T	cg06307176	chr5:131281290	NA	-0.54	-8.61	-0.39	1.48e-16	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg16797656	chr11:68205561	LRP5	0.45	8.62	0.39	1.34e-16	Total body bone mineral density;
LUAD	cis	rs7665090	0.967	rs5026471	chr4:103554733	G/A	cg07973026	chr4:103553119	MANBA	0.47	8.43	0.38	5.43e-16	Primary biliary cholangitis;
LUAD	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.53e-11	Depression;
LUAD	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.7	-0.31	6.57e-11	Menopause (age at onset);
LUAD	cis	rs73198271	0.603	rs570364	chr8:8593638	G/T	cg01851573	chr8:8652454	MFHAS1	0.44	7.99	0.36	1.28e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg14345882	chr6:26364793	BTN3A2	0.69	6.97	0.32	1.23e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10992471	0.528	rs6479423	chr9:95265580	A/T	cg14631576	chr9:95140430	CENPP	-0.49	-10.18	-0.44	6.34e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs77741769	0.571	rs11065324	chr12:121346795	C/G	cg02419362	chr12:121203948	SPPL3	-0.41	-8.45	-0.38	4.61e-16	Mean corpuscular volume;
LUAD	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg14752069	chr8:11977206	FAM66D	-0.29	-6.49	-0.3	2.47e-10	Triglycerides;
LUAD	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg27661571	chr11:113659931	NA	-0.69	-8.14	-0.37	4.43e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs2859741	0.967	rs522481	chr1:37488337	C/T	cg09363841	chr1:37513479	NA	-0.32	-7.99	-0.36	1.29e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg12011299	chr4:100065546	ADH4	-0.75	-14.94	-0.59	8.05e-41	Alcohol dependence;
LUAD	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg18944383	chr4:111397179	ENPEP	0.38	7.64	0.35	1.43e-13	Height;
LUAD	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.8	0.39	3.54e-17	Menopause (age at onset);
LUAD	trans	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg07211511	chr3:129823064	LOC729375	-0.53	-7.26	-0.33	1.85e-12	Blood pressure (smoking interaction);
LUAD	cis	rs4604732	0.527	rs77361748	chr1:247626475	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg07967210	chr17:47022446	SNF8	0.35	6.38	0.3	4.54e-10	Type 2 diabetes;
LUAD	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Body mass index;
LUAD	cis	rs3784262	0.669	rs4646609	chr15:58274989	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-6.98	-0.32	1.12e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg14343924	chr8:8086146	FLJ10661	0.5	7.93	0.36	2.03e-14	Mood instability;
LUAD	cis	rs6546550	0.901	rs6546558	chr2:70145717	C/T	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.23	-0.48	8.42e-26	Prevalent atrial fibrillation;
LUAD	cis	rs60154123	0.541	rs76216762	chr1:210345621	A/G	cg22029157	chr1:209979665	IRF6	0.69	6.86	0.32	2.42e-11	Coronary artery disease;
LUAD	cis	rs6494488	0.500	rs56239505	chr15:64675422	T/G	cg08069370	chr15:64387884	SNX1	-0.75	-6.73	-0.31	5.5e-11	Coronary artery disease;
LUAD	trans	rs853679	0.607	rs34166054	chr6:28065801	T/C	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.09	-0.47	3.02e-25	Depression;
LUAD	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg26727032	chr16:67993705	SLC12A4	-0.46	-6.83	-0.31	3.04e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg22166914	chr1:53195759	ZYG11B	0.4	6.66	0.31	8.55e-11	Monocyte count;
LUAD	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg14558114	chr2:88469736	THNSL2	-0.43	-6.84	-0.32	2.87e-11	Response to metformin (IC50);
LUAD	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg21214613	chr1:16344536	HSPB7	0.62	11.9	0.5	2.26e-28	Dilated cardiomyopathy;
LUAD	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg19413350	chr8:57351067	NA	-0.41	-6.54	-0.3	1.75e-10	Obesity-related traits;
LUAD	cis	rs4664308	0.810	rs62175552	chr2:160937220	T/G	cg03641300	chr2:160917029	PLA2R1	-0.38	-6.5	-0.3	2.21e-10	Idiopathic membranous nephropathy;
LUAD	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg02421172	chr7:1938701	MAD1L1	0.47	6.66	0.31	8.6e-11	Bipolar disorder;
LUAD	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06873352	chr17:61820015	STRADA	0.56	9.05	0.4	5.13e-18	Height;
LUAD	cis	rs9595066	0.941	rs9533777	chr13:44708720	C/T	cg04068111	chr13:44716778	NA	0.52	10.52	0.46	3.78e-23	Schizophrenia;
LUAD	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03264133	chr6:25882463	NA	0.83	13.87	0.56	2.47e-36	Blood metabolite levels;
LUAD	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg08999081	chr20:33150536	PIGU	-0.6	-13.39	-0.55	2.42e-34	Glomerular filtration rate (creatinine);
LUAD	cis	rs2109514	0.902	rs7810505	chr7:116111078	G/T	cg12739419	chr7:116140593	CAV2	-0.33	-6.82	-0.31	3.15e-11	Prevalent atrial fibrillation;
LUAD	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	9.13	0.41	2.78e-18	Ileal carcinoids;
LUAD	cis	rs7607369	0.536	rs4674344	chr2:219669875	A/T	cg02176678	chr2:219576539	TTLL4	-0.53	-10.22	-0.44	4.74e-22	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs9972944	0.656	rs10083855	chr17:63773139	T/C	cg07283582	chr17:63770753	CCDC46	0.47	10.24	0.45	3.88e-22	Total body bone mineral density;
LUAD	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg06671706	chr8:8559999	CLDN23	0.64	10.97	0.47	8.09e-25	Obesity-related traits;
LUAD	cis	rs7301826	0.651	rs4759519	chr12:131289508	G/A	cg11011512	chr12:131303247	STX2	0.44	7.43	0.34	6.21e-13	Plasma plasminogen activator levels;
LUAD	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	6.67	0.31	8.07e-11	Cognitive test performance;
LUAD	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg25753631	chr6:25732923	NA	-0.45	-7.99	-0.36	1.32e-14	Iron status biomarkers;
LUAD	cis	rs116248771	0.739	rs7648050	chr3:158377470	G/A	cg16708174	chr3:158430962	RARRES1	0.47	6.83	0.32	3.03e-11	diarrhoeal disease at age 2;
LUAD	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg26384229	chr12:38710491	ALG10B	0.43	7.37	0.34	9.16e-13	Morning vs. evening chronotype;
LUAD	cis	rs748404	0.697	rs567357	chr15:43571390	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.39	0.34	8.05e-13	Lung cancer;
LUAD	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg02775129	chr4:119771670	NA	-0.75	-7.28	-0.33	1.66e-12	Cannabis dependence symptom count;
LUAD	trans	rs4824093	0.610	rs73443986	chr22:50321193	C/T	cg09872104	chr7:134855509	C7orf49	-0.79	-6.81	-0.31	3.31e-11	Amyotrophic lateral sclerosis (sporadic);
LUAD	trans	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.58e-17	Endometrial cancer;
LUAD	cis	rs9658691	0.607	rs12411452	chr10:90780607	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.59	-7.28	-0.33	1.62e-12	Mosquito bite size;
LUAD	trans	rs11885103	0.791	rs17042062	chr2:585129	C/T	cg12228919	chr15:44955936	SPG11	-0.44	-6.67	-0.31	7.91e-11	Heschl's gyrus morphology;
LUAD	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg25358565	chr5:93447407	FAM172A	0.61	7.12	0.33	4.63e-12	Diabetic retinopathy;
LUAD	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg15782153	chr7:917662	C7orf20	0.56	10.46	0.45	6.38e-23	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs2652834	1.000	rs11637852	chr15:63397151	G/A	cg25406657	chr15:63342033	TPM1	-0.42	-6.63	-0.31	1.05e-10	HDL cholesterol;
LUAD	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg09323728	chr8:95962352	TP53INP1	-0.32	-7.64	-0.35	1.43e-13	Type 2 diabetes;
LUAD	cis	rs2447097	0.935	rs2447095	chr17:2293420	A/G	cg27406664	chr17:2294951	MNT	0.63	13.66	0.55	1.95e-35	Autism spectrum disorder;
LUAD	trans	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg06606381	chr12:133084897	FBRSL1	-1.12	-10.26	-0.45	3.42e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs494562	0.892	rs7767626	chr6:86124394	G/A	cg13315970	chr6:86159197	NT5E	0.73	8.21	0.37	2.7e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg18180107	chr4:99064573	C4orf37	0.46	6.44	0.3	3.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg15467112	chr14:75489610	MLH3	0.36	6.47	0.3	2.64e-10	Height;
LUAD	cis	rs1953600	0.818	rs2152546	chr10:81906384	G/T	cg04850286	chr10:81895943	PLAC9	-0.41	-7.71	-0.35	9.37e-14	Sarcoidosis;
LUAD	cis	rs13082711	0.871	rs35701251	chr3:27529753	T/A	cg02860705	chr3:27208620	NA	0.61	8.84	0.4	2.53e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3816788	0.792	rs729180	chr8:21817245	C/T	cg03445287	chr8:21823731	XPO7	-0.49	-9.34	-0.41	5.49e-19	Lung cancer in ever smokers;
LUAD	cis	rs9372498	0.536	rs9489436	chr6:118873817	A/C	cg07617317	chr6:118971624	C6orf204	0.56	8.6	0.39	1.51e-16	Diastolic blood pressure;
LUAD	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg00071950	chr4:10020882	SLC2A9	0.84	17.88	0.66	1.17e-53	Bone mineral density;
LUAD	cis	rs7945705	0.967	rs7943377	chr11:8848700	C/T	cg12365402	chr11:9010492	NRIP3	0.37	6.55	0.3	1.67e-10	Hemoglobin concentration;
LUAD	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg12419862	chr22:24373484	LOC391322	-0.68	-12.25	-0.51	9.89e-30	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg21724239	chr8:58056113	NA	0.66	8.13	0.37	4.9e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg18306943	chr3:40428807	ENTPD3	0.43	7.28	0.33	1.67e-12	Renal cell carcinoma;
LUAD	cis	rs9649213	0.614	rs10953254	chr7:97914305	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.76	-11.04	-0.47	4.6e-25	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs57920188	0.584	rs10915654	chr1:4091419	C/A	cg20703997	chr1:4087676	NA	0.46	8.2	0.37	2.99e-15	Interleukin-17 levels;
LUAD	cis	rs2019216	0.564	rs907707	chr17:21910083	G/C	cg05591447	chr17:21909280	FLJ36000	-0.26	-6.53	-0.3	1.89e-10	Pelvic organ prolapse;
LUAD	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg03806693	chr22:41940476	POLR3H	0.77	10.28	0.45	2.78e-22	Vitiligo;
LUAD	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg00933542	chr6:150070202	PCMT1	0.44	9.59	0.42	7.47e-20	Lung cancer;
LUAD	cis	rs68170813	0.559	rs80017637	chr7:107050660	T/C	cg23024343	chr7:107201750	COG5	0.52	7.19	0.33	2.96e-12	Coronary artery disease;
LUAD	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg11494091	chr17:61959527	GH2	-0.44	-8.35	-0.38	9.75e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.85e-14	Depression;
LUAD	cis	rs6426558	0.537	rs4653813	chr1:227461510	G/C	cg10327440	chr1:227177885	CDC42BPA	0.55	8.94	0.4	1.24e-17	Neutrophil percentage of white cells;
LUAD	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg07979401	chr6:33739406	LEMD2	-0.55	-9.84	-0.43	1.04e-20	Schizophrenia;
LUAD	cis	rs68170813	0.559	rs2894459	chr7:106960166	C/T	cg23024343	chr7:107201750	COG5	0.44	6.37	0.3	5.04e-10	Coronary artery disease;
LUAD	cis	rs7274811	0.652	rs291672	chr20:31951168	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	0.52	7.98	0.36	1.4e-14	Height;
LUAD	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg11833968	chr6:79620685	NA	-0.41	-7.84	-0.36	3.78e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9399401	0.614	rs262125	chr6:142838355	A/T	cg03128060	chr6:142623767	GPR126	0.42	7.7	0.35	9.43e-14	Chronic obstructive pulmonary disease;
LUAD	cis	rs1461503	0.932	rs10892934	chr11:122837950	C/T	cg27398637	chr11:122830231	C11orf63	-0.37	-7.25	-0.33	2.06e-12	Menarche (age at onset);
LUAD	cis	rs599083	0.590	rs10791984	chr11:68407835	T/G	cg16797656	chr11:68205561	LRP5	-0.44	-8.99	-0.4	8.26e-18	Bone mineral density (spine);
LUAD	cis	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg27411982	chr8:10470053	RP1L1	-0.45	-8.23	-0.37	2.31e-15	Neuroticism;
LUAD	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg06784218	chr1:46089804	CCDC17	0.51	11.15	0.48	1.71e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7107174	1.000	rs10899458	chr11:78007451	A/T	cg19901956	chr11:77921274	USP35	-0.56	-6.86	-0.32	2.53e-11	Testicular germ cell tumor;
LUAD	cis	rs2479724	0.811	rs6905726	chr6:41750812	T/C	cg17623882	chr6:41773611	USP49	0.66	12.17	0.51	2.04e-29	Menarche (age at onset);
LUAD	cis	rs2535633	0.602	rs2581816	chr3:53014657	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.8	-0.31	3.6e-11	Body mass index;
LUAD	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.4	0.55	2.3e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1348850	0.507	rs10186934	chr2:178425998	T/C	cg27490568	chr2:178487706	NA	0.58	7.32	0.34	1.29e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13370280	chr6:137539688	IFNGR1	0.43	6.81	0.31	3.47e-11	Gut microbiome composition (summer);
LUAD	trans	rs208520	0.690	rs864314	chr6:66814830	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-32.14	-0.84	1.38e-115	Exhaled nitric oxide output;
LUAD	trans	rs1997103	1.000	rs6976824	chr7:55396115	A/C	cg20935933	chr6:143382018	AIG1	0.54	7.58	0.35	2.23e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9473147	0.516	rs6904764	chr6:47503497	A/T	cg20196966	chr6:47445060	CD2AP	0.44	7.02	0.32	8.78e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg15123519	chr2:136567270	LCT	0.39	7.0	0.32	1.01e-11	Mosquito bite size;
LUAD	cis	rs2730245	0.550	rs10258339	chr7:158670243	T/C	cg14689365	chr7:158441557	NCAPG2	0.45	7.65	0.35	1.35e-13	Height;
LUAD	trans	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg13565492	chr6:43139072	SRF	-0.59	-6.38	-0.3	4.65e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs17433780	0.808	rs12122780	chr1:89508916	T/C	cg09516651	chr1:89888402	LOC400759	0.55	10.51	0.46	4.08e-23	Carotid intima media thickness;
LUAD	cis	rs2445762	0.659	rs12443032	chr15:51670305	T/C	cg20344442	chr15:51633704	GLDN	0.39	7.01	0.32	9.64e-12	Hormone measurements;
LUAD	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg05665937	chr4:1216051	CTBP1	0.38	6.37	0.3	4.89e-10	Obesity-related traits;
LUAD	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg07570687	chr10:102243282	WNT8B	0.43	6.53	0.3	1.86e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs921968	0.565	rs13408305	chr2:219628183	G/A	cg02176678	chr2:219576539	TTLL4	-0.59	-12.09	-0.51	4.12e-29	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg03929089	chr4:120376271	NA	-0.99	-20.65	-0.71	4.76e-66	Height;
LUAD	cis	rs6543140	0.964	rs6543138	chr2:103066132	G/A	cg03938978	chr2:103052716	IL18RAP	0.35	6.81	0.31	3.43e-11	Blood protein levels;
LUAD	cis	rs2262909	0.925	rs404822	chr19:22215967	A/C	cg11619707	chr19:22235551	ZNF257	-0.43	-6.39	-0.3	4.37e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	trans	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg18187862	chr3:45730750	SACM1L	0.52	8.16	0.37	3.93e-15	Primary sclerosing cholangitis;
LUAD	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg22166914	chr1:53195759	ZYG11B	-0.51	-8.73	-0.39	6.1e-17	Monocyte count;
LUAD	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg13902645	chr11:5959945	NA	-0.53	-9.37	-0.41	4.56e-19	DNA methylation (variation);
LUAD	cis	rs4493873	1.000	rs10095630	chr8:92071264	C/A	cg16814680	chr8:91681699	NA	0.44	6.84	0.32	2.86e-11	Migraine - clinic-based;
LUAD	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2996428	0.561	rs12134919	chr1:3744641	G/A	cg13057898	chr1:3703894	LRRC47	0.57	9.85	0.43	9.21e-21	Red cell distribution width;
LUAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.78	-9.45	-0.42	2.38e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7709909	0.720	rs408626	chr5:79951133	T/C	cg24059623	chr5:79951536	MSH3;DHFR	0.53	9.79	0.43	1.5e-20	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs7291412	0.929	rs7289457	chr22:46456603	C/T	cg23691090	chr22:46449981	C22orf26;LOC150381	0.36	6.53	0.3	1.89e-10	Dupuytren's disease;Subjective well-being;
LUAD	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg22117172	chr7:91764530	CYP51A1	-0.34	-7.29	-0.33	1.58e-12	Breast cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14014890	chr2:11295833	PQLC3	-0.55	-6.97	-0.32	1.23e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg14186256	chr22:23484241	RTDR1	0.44	7.56	0.35	2.49e-13	Bone mineral density;
LUAD	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg22875332	chr1:76189707	ACADM	-0.69	-11.12	-0.48	2.32e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg03806693	chr22:41940476	POLR3H	-0.61	-8.97	-0.4	9.71e-18	Vitiligo;
LUAD	cis	rs7336332	0.628	rs9581854	chr13:28017782	C/T	cg22138327	chr13:27999177	GTF3A	0.72	9.64	0.42	5.05e-20	Weight;
LUAD	cis	rs7528419	0.927	rs660240	chr1:109817838	T/C	cg00908766	chr1:109817496	CELSR2	0.75	14.68	0.58	9.66e-40	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08280861	chr8:58055591	NA	0.54	6.91	0.32	1.79e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs490234	0.676	rs13299008	chr9:128213966	T/G	cg14078157	chr9:128172775	NA	-0.5	-8.8	-0.39	3.55e-17	Mean arterial pressure;
LUAD	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg10523679	chr1:76189770	ACADM	0.81	12.95	0.53	1.5e-32	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1497406	0.773	rs7538833	chr1:16504381	T/C	cg02998240	chr1:16508668	NA	-0.24	-7.1	-0.33	5.22e-12	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg10295955	chr4:187884368	NA	-1.15	-29.11	-0.82	4.5e-103	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg12310025	chr6:25882481	NA	-0.56	-9.43	-0.42	2.66e-19	Blood metabolite levels;
LUAD	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	24.11	0.76	1.99e-81	Chronic sinus infection;
LUAD	trans	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	17.37	0.65	2.14e-51	Exhaled nitric oxide output;
LUAD	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg18105134	chr13:113819100	PROZ	-0.82	-14.58	-0.58	2.73e-39	Platelet distribution width;
LUAD	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg12011299	chr4:100065546	ADH4	-0.56	-11.48	-0.49	9.92e-27	Alcohol dependence;
LUAD	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg19622623	chr12:86230825	RASSF9	-0.4	-7.11	-0.33	4.93e-12	Major depressive disorder;
LUAD	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg23887609	chr12:130822674	PIWIL1	0.4	6.72	0.31	5.72e-11	Menopause (age at onset);
LUAD	cis	rs672059	0.513	rs627064	chr1:183165716	C/T	cg05929019	chr1:183155154	LAMC2	-0.36	-7.9	-0.36	2.39e-14	Hypertriglyceridemia;
LUAD	cis	rs2268241	0.938	rs2268242	chr21:34781104	C/T	cg14850771	chr21:34775459	IFNGR2	0.6	6.95	0.32	1.4e-11	Obesity-related traits;
LUAD	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg27490568	chr2:178487706	NA	0.41	6.76	0.31	4.64e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg24308560	chr3:49941425	MST1R	-0.53	-8.92	-0.4	1.44e-17	Body mass index;
LUAD	trans	rs7939886	0.920	rs11231885	chr11:55804022	T/A	cg15704280	chr7:45808275	SEPT13	0.68	6.58	0.3	1.39e-10	Myopia (pathological);
LUAD	cis	rs9473147	0.516	rs9381575	chr6:47528764	C/G	cg20196966	chr6:47445060	CD2AP	0.46	7.3	0.33	1.45e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1904096	0.506	rs3113863	chr4:95147827	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.15	-0.44	8.11e-22	Type 2 diabetes;
LUAD	cis	rs7771547	0.573	rs546272	chr6:36398562	G/A	cg07856975	chr6:36356162	ETV7	0.47	7.27	0.33	1.79e-12	Platelet distribution width;
LUAD	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg24069376	chr3:38537580	EXOG	-0.35	-7.98	-0.36	1.38e-14	Electrocardiographic conduction measures;
LUAD	cis	rs17021463	0.902	rs13102926	chr4:95245527	C/T	cg11021082	chr4:95130006	SMARCAD1	0.42	7.51	0.34	3.46e-13	Testicular germ cell tumor;
LUAD	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg09021430	chr5:549028	NA	-0.67	-14.31	-0.57	3.8e-38	Obesity-related traits;
LUAD	cis	rs9394841	0.692	rs9394837	chr6:41848088	G/A	cg17623882	chr6:41773611	USP49	-0.48	-6.58	-0.3	1.36e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs870825	0.616	rs6552808	chr4:185642865	G/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.03	0.56	5.61e-37	Blood protein levels;
LUAD	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg08219700	chr8:58056026	NA	0.41	6.38	0.3	4.71e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.11	0.37	5.59e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg07930552	chr6:133119739	C6orf192	-0.63	-7.58	-0.35	2.2e-13	Type 2 diabetes nephropathy;
LUAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg07217954	chr7:1067459	C7orf50	0.46	7.16	0.33	3.62e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg13319975	chr6:146136371	FBXO30	0.74	12.26	0.51	8.86e-30	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg00484396	chr16:3507460	NAT15	0.71	11.86	0.5	3.2e-28	Tuberculosis;
LUAD	cis	rs1904096	0.506	rs8336	chr4:95211610	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-9.72	-0.43	2.81e-20	Type 2 diabetes;
LUAD	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg11663144	chr21:46675770	NA	-0.61	-11.18	-0.48	1.29e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1395	0.922	rs11608	chr2:27435374	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.43	-8.12	-0.37	5.04e-15	Blood metabolite levels;
LUAD	cis	rs4285028	0.948	rs34181646	chr3:121705373	T/A	cg11130432	chr3:121712080	ILDR1	-0.58	-8.41	-0.38	6.48e-16	Multiple sclerosis;
LUAD	cis	rs4660214	0.666	rs3116398	chr1:39779802	C/T	cg27567593	chr1:39956653	BMP8A	0.36	7.14	0.33	4.08e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11890956	chr21:40555474	PSMG1	-0.49	-7.81	-0.36	4.44e-14	Menarche (age at onset);
LUAD	cis	rs1509123	0.609	rs55709508	chr17:6718356	T/C	cg12642237	chr17:6703447	TEKT1	-0.45	-6.4	-0.3	4.24e-10	Blood metabolite levels;
LUAD	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18876405	chr7:65276391	NA	-0.56	-9.45	-0.42	2.43e-19	Aortic root size;
LUAD	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg03676636	chr4:99064102	C4orf37	0.3	7.28	0.33	1.61e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg17031739	chr1:67600172	NA	0.5	9.06	0.4	4.86e-18	Psoriasis;
LUAD	cis	rs7520050	0.966	rs1707321	chr1:46505309	A/G	cg06784218	chr1:46089804	CCDC17	-0.31	-6.71	-0.31	6.23e-11	Red blood cell count;Reticulocyte count;
LUAD	trans	rs1941687	0.831	rs12965856	chr18:31344080	A/G	cg27147174	chr7:100797783	AP1S1	-0.55	-9.29	-0.41	8.21e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs3935685	0.874	rs11072663	chr15:77999542	A/G	cg25212270	chr15:78015279	NA	0.32	7.04	0.32	7.57e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg13468214	chr4:1046988	NA	-0.39	-8.99	-0.4	8.55e-18	Recombination rate (males);
LUAD	trans	rs12517041	1.000	rs113660280	chr5:23302289	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.57	-0.3	1.47e-10	Calcium levels;
LUAD	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg26384229	chr12:38710491	ALG10B	-0.43	-7.3	-0.33	1.41e-12	Morning vs. evening chronotype;
LUAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.5	6.93	0.32	1.55e-11	Renal function-related traits (BUN);
LUAD	cis	rs7020830	0.931	rs7034554	chr9:37081301	A/G	cg14294708	chr9:37120828	ZCCHC7	0.82	16.26	0.62	1.5e-46	Schizophrenia;
LUAD	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg12011299	chr4:100065546	ADH4	-0.72	-13.31	-0.54	5.28e-34	Alcohol dependence;
LUAD	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.4	-0.45	1.06e-22	Total body bone mineral density;
LUAD	cis	rs2692947	0.832	rs2579519	chr2:96675166	T/C	cg23100626	chr2:96804247	ASTL	0.34	8.63	0.39	1.29e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.83	-12.91	-0.53	2.18e-32	Chronic sinus infection;
LUAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg05434287	chr7:2030229	MAD1L1	0.41	6.72	0.31	5.96e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03579761	chr19:893299	MED16	-0.44	-6.76	-0.31	4.48e-11	Height;
LUAD	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg17971929	chr21:40555470	PSMG1	0.55	8.69	0.39	7.77e-17	Cognitive function;
LUAD	cis	rs11112613	0.713	rs12296355	chr12:105953321	C/A	cg03607813	chr12:105948248	NA	0.74	12.83	0.53	4.49e-32	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs10193935	1.000	rs10185742	chr2:42429666	A/G	cg27598129	chr2:42591480	NA	-0.79	-10.4	-0.45	1.04e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg19622623	chr12:86230825	RASSF9	-0.56	-9.94	-0.44	4.76e-21	Major depressive disorder;
LUAD	cis	rs28830936	1.000	rs9672298	chr15:41912368	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.74	-0.31	5.27e-11	Diastolic blood pressure;
LUAD	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg10523679	chr1:76189770	ACADM	0.81	12.77	0.53	8.21e-32	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs62103177	0.564	rs59188178	chr18:77723435	T/C	cg20368463	chr18:77673604	PQLC1	0.56	7.3	0.33	1.45e-12	Opioid sensitivity;
LUAD	cis	rs10896135	0.526	rs12795774	chr11:66381517	T/C	cg24851651	chr11:66362959	CCS	-0.49	-7.93	-0.36	1.98e-14	Bipolar disorder;
LUAD	cis	rs7659604	0.502	rs28522256	chr4:122709266	C/T	cg06713675	chr4:122721982	EXOSC9	0.45	8.31	0.37	1.28e-15	Type 2 diabetes;
LUAD	cis	rs6961069	0.743	rs3211870	chr7:80287209	C/T	cg04458919	chr7:80252533	CD36	-0.35	-6.61	-0.31	1.18e-10	Platelet count;
LUAD	cis	rs9322817	0.691	rs2499658	chr6:105291412	A/G	cg02098413	chr6:105308735	HACE1	0.42	9.01	0.4	7.34e-18	Thyroid stimulating hormone;
LUAD	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg09455208	chr3:40491958	NA	0.52	11.08	0.47	3.26e-25	Renal cell carcinoma;
LUAD	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06028808	chr11:68637592	NA	-0.5	-8.48	-0.38	3.94e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.62	8.34	0.38	1.06e-15	Renal function-related traits (BUN);
LUAD	cis	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg07460842	chr6:66804631	NA	-0.62	-10.88	-0.47	1.71e-24	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08109568	chr15:31115862	NA	-0.59	-9.9	-0.43	6.52e-21	Huntington's disease progression;
LUAD	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.62	0.31	1.09e-10	Hypertriglyceridemia;
LUAD	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1953600	0.805	rs2819947	chr10:81947757	T/C	cg00277334	chr10:82204260	NA	0.4	6.76	0.31	4.68e-11	Sarcoidosis;
LUAD	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg00106254	chr7:1943704	MAD1L1	0.52	7.73	0.35	7.74e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs877282	0.797	rs11253329	chr10:753200	A/T	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs733175	0.830	rs6812851	chr4:10058703	G/C	cg00071950	chr4:10020882	SLC2A9	0.46	7.14	0.33	4.09e-12	Psychosis and Alzheimer's disease;
LUAD	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg05234568	chr11:5960015	NA	-0.5	-8.94	-0.4	1.25e-17	DNA methylation (variation);
LUAD	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	7.97	0.36	1.45e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg03517284	chr6:25882590	NA	0.49	7.86	0.36	3.26e-14	Blood metabolite levels;
LUAD	cis	rs870825	0.655	rs67798981	chr4:185619567	A/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg26850624	chr5:429559	AHRR	-0.42	-6.68	-0.31	7.71e-11	Cystic fibrosis severity;
LUAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08677398	chr8:58056175	NA	0.47	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg19622623	chr12:86230825	RASSF9	-0.44	-7.79	-0.35	5.09e-14	Major depressive disorder;
LUAD	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg17264618	chr3:40429014	ENTPD3	0.42	8.99	0.4	8.15e-18	Renal cell carcinoma;
LUAD	cis	rs62025270	0.547	rs338536	chr15:86197240	G/A	cg13263323	chr15:86062960	AKAP13	0.45	7.32	0.34	1.24e-12	Idiopathic pulmonary fibrosis;
LUAD	cis	rs752010	0.905	rs2038977	chr1:42094659	A/G	cg16096631	chr1:42092165	HIVEP3	0.3	6.44	0.3	3.17e-10	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.17	0.33	3.46e-12	Obesity-related traits;
LUAD	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.03	-0.44	2.15e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg09323728	chr8:95962352	TP53INP1	-0.33	-7.95	-0.36	1.75e-14	Type 2 diabetes;
LUAD	trans	rs4650994	0.593	rs28445692	chr1:178511892	G/C	cg05059571	chr16:84539110	KIAA1609	0.46	6.95	0.32	1.37e-11	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg10167378	chr1:228756711	NA	0.67	9.51	0.42	1.41e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg16325326	chr1:53192061	ZYG11B	0.6	10.72	0.46	6.92e-24	Monocyte count;
LUAD	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11644478	chr21:40555479	PSMG1	-0.39	-6.39	-0.3	4.31e-10	Menarche (age at onset);
LUAD	cis	rs4917300	0.647	rs2201176	chr8:143118987	A/G	cg25363559	chr8:143086065	NA	-0.38	-7.9	-0.36	2.38e-14	Amyotrophic lateral sclerosis;
LUAD	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg05966235	chr16:28915196	ATP2A1	0.47	7.63	0.35	1.52e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2882667	0.537	rs13181793	chr5:138408956	G/A	cg04439458	chr5:138467593	SIL1	-0.36	-6.83	-0.31	3.05e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs4891159	0.757	rs11665018	chr18:74123589	C/T	cg24786174	chr18:74118243	ZNF516	-0.81	-15.39	-0.6	9.7e-43	Longevity;
LUAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-9.8	-0.43	1.48e-20	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10992471	0.564	rs10491804	chr9:95487407	G/A	cg14631576	chr9:95140430	CENPP	-0.45	-8.52	-0.38	2.78e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7827545	1.000	rs4909909	chr8:135564627	T/C	cg17885191	chr8:135476712	NA	0.5	7.97	0.36	1.53e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg23283495	chr1:209979779	IRF6	0.75	9.11	0.41	3.19e-18	Cleft lip with or without cleft palate;
LUAD	trans	rs1493916	0.837	rs9949631	chr18:31410567	G/A	cg15819921	chr19:927150	ARID3A	-0.42	-6.86	-0.32	2.44e-11	Life satisfaction;
LUAD	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	7.97	0.36	1.53e-14	Rheumatoid arthritis;
LUAD	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg22875332	chr1:76189707	ACADM	0.89	18.05	0.66	2.09e-54	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18876405	chr7:65276391	NA	0.43	6.84	0.32	2.85e-11	Aortic root size;
LUAD	cis	rs6906287	0.647	rs13219555	chr6:118816364	G/A	cg18833306	chr6:118973337	C6orf204	0.47	8.42	0.38	5.76e-16	Electrocardiographic conduction measures;
LUAD	cis	rs1160297	0.576	rs1451456	chr2:53092604	A/C	cg07782112	chr2:53107842	NA	0.41	8.7	0.39	7.33e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	cis	rs7481584	1.000	rs2239898	chr11:3024462	G/A	cg11201177	chr11:2961805	NA	0.4	6.66	0.31	8.47e-11	Calcium levels;
LUAD	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.55	-0.34	2.7e-13	Total cholesterol levels;
LUAD	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7395662	0.890	rs4882133	chr11:48593450	T/C	cg00717180	chr2:96193071	NA	-0.38	-7.23	-0.33	2.3e-12	HDL cholesterol;
LUAD	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-6.73	-0.31	5.39e-11	Bladder cancer;
LUAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg16031515	chr1:205743344	RAB7L1	-0.37	-7.47	-0.34	4.7e-13	Menarche (age at onset);
LUAD	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg12927641	chr6:109611667	NA	-0.52	-9.05	-0.4	5.21e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18099408	chr3:52552593	STAB1	-0.46	-8.09	-0.37	6.46e-15	Bipolar disorder;
LUAD	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg22676075	chr6:135203613	NA	0.42	7.7	0.35	9.43e-14	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg03609598	chr5:56110824	MAP3K1	0.48	7.11	0.33	4.92e-12	Initial pursuit acceleration;
LUAD	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg14092988	chr3:52407081	DNAH1	-0.33	-6.56	-0.3	1.59e-10	Bipolar disorder;
LUAD	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg12863693	chr15:85201151	NMB	0.39	7.32	0.34	1.3e-12	Schizophrenia;
LUAD	cis	rs7178572	0.568	rs1602925	chr15:77685857	T/C	cg15453836	chr15:77711506	NA	-0.36	-6.42	-0.3	3.59e-10	Type 2 diabetes;
LUAD	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg00316803	chr15:76480434	C15orf27	0.4	7.59	0.35	2.09e-13	Blood metabolite levels;
LUAD	cis	rs939658	1.000	rs939658	chr15:79451869	A/G	cg17916960	chr15:79447300	NA	0.46	9.53	0.42	1.24e-19	Refractive error;
LUAD	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg00339695	chr16:24857497	SLC5A11	0.72	10.91	0.47	1.41e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg02527881	chr3:46936655	PTH1R	-0.56	-11.63	-0.49	2.47e-27	Colorectal cancer;
LUAD	cis	rs1497406	0.744	rs12057175	chr1:16508375	A/G	cg20430773	chr1:16534157	ARHGEF19	0.4	6.84	0.32	2.82e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-11.01	-0.47	5.9e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs80207740	1.000	rs76008177	chr8:21802272	C/T	cg25597362	chr8:21767310	DOK2	-0.65	-8.08	-0.37	7.02e-15	Mean corpuscular hemoglobin;
LUAD	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	10.62	0.46	1.7e-23	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7814319	0.700	rs871798	chr8:97257982	T/C	cg20787634	chr8:97240163	UQCRB	-0.37	-6.8	-0.31	3.52e-11	Lung function (FVC);
LUAD	trans	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg12400702	chr3:12838781	CAND2	0.31	6.58	0.3	1.4e-10	Parkinson's disease;
LUAD	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg13319975	chr6:146136371	FBXO30	-0.57	-9.86	-0.43	8.9e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7116495	0.737	rs670802	chr11:71799668	A/C	cg07596299	chr11:71824057	C11orf51	-0.75	-6.51	-0.3	2.12e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs7833986	0.941	rs13278255	chr8:57067975	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.78	10.22	0.44	4.64e-22	Height;
LUAD	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg17366294	chr4:99064904	C4orf37	0.53	9.73	0.43	2.59e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12464483	0.524	rs2602772	chr2:30885263	C/A	cg12454169	chr2:30669597	LCLAT1	0.55	7.69	0.35	1.04e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs11023332	0.706	rs11023380	chr11:14930058	A/G	cg19336497	chr11:14380999	RRAS2	-0.39	-7.38	-0.34	8.57e-13	Adiponectin levels;Vitamin D levels;
LUAD	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg26597838	chr10:835615	NA	0.83	11.24	0.48	8.04e-26	Eosinophil percentage of granulocytes;
LUAD	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg06641503	chr3:48959341	ARIH2	-0.33	-6.53	-0.3	1.89e-10	Parkinson's disease;
LUAD	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg26924012	chr15:45694286	SPATA5L1	1.03	19.2	0.68	1.47e-59	Homoarginine levels;
LUAD	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg12623918	chr2:306882	NA	0.36	7.3	0.33	1.43e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs7746199	0.736	rs13193542	chr6:27702425	G/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-10.05	-0.44	1.88e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.72	-14.22	-0.57	9.05e-38	Lung cancer;
LUAD	cis	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05901451	chr6:126070800	HEY2	-0.42	-6.45	-0.3	3.03e-10	Endometrial cancer;
LUAD	cis	rs752010	0.543	rs7545381	chr1:42044183	T/A	cg06885757	chr1:42089581	HIVEP3	0.39	8.54	0.38	2.5e-16	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs3760982	0.813	rs8104447	chr19:44293278	T/C	cg11993925	chr19:44307056	LYPD5	-0.44	-8.36	-0.38	9.22e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg26823989	chr1:87380673	SEP15;HS2ST1	-0.37	-6.59	-0.31	1.3e-10	Schizophrenia;
LUAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg00431813	chr7:1051703	C7orf50	-0.43	-8.66	-0.39	9.7e-17	Longevity;Endometriosis;
LUAD	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg25894440	chr7:65020034	NA	0.6	6.46	0.3	2.8e-10	Diabetic kidney disease;
LUAD	cis	rs938554	1.000	rs16890979	chr4:9922167	C/T	cg11266682	chr4:10021025	SLC2A9	-0.43	-7.5	-0.34	3.73e-13	Blood metabolite levels;
LUAD	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg19635926	chr16:89946313	TCF25	0.75	7.06	0.32	6.81e-12	Skin colour saturation;
LUAD	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07256732	chr16:621771	PIGQ	-0.32	-6.49	-0.3	2.45e-10	Height;
LUAD	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg17063962	chr7:91808500	NA	0.68	12.32	0.51	5.02e-30	Breast cancer;
LUAD	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg15445000	chr17:37608096	MED1	0.45	8.29	0.37	1.51e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs420259	0.516	rs2040573	chr16:23529732	C/T	cg00143387	chr16:23521605	GGA2	-0.67	-9.24	-0.41	1.17e-18	Bipolar disorder;
LUAD	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg04287289	chr16:89883240	FANCA	0.54	9.26	0.41	1.03e-18	Vitiligo;
LUAD	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg06618935	chr21:46677482	NA	-0.49	-9.89	-0.43	6.82e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4523957	0.928	rs11657644	chr17:2175210	C/G	cg16513277	chr17:2031491	SMG6	-0.78	-14.79	-0.58	3.28e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg13870426	chr17:30244630	NA	-0.57	-6.63	-0.31	1.05e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg18232548	chr7:50535776	DDC	-0.71	-13.25	-0.54	9.66e-34	Systemic sclerosis;
LUAD	cis	rs7432375	0.610	rs56695781	chr3:136510601	G/T	cg15507776	chr3:136538369	TMEM22	0.39	7.05	0.32	7.2e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg05564831	chr3:52568323	NT5DC2	-0.4	-7.33	-0.34	1.15e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06873352	chr17:61820015	STRADA	0.82	18.02	0.66	2.83e-54	Prudent dietary pattern;
LUAD	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg04842962	chr6:43655489	MRPS18A	1.05	26.88	0.79	1.44e-93	IgG glycosylation;
LUAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03407747	chr17:6899364	ALOX12	-0.35	-6.82	-0.31	3.12e-11	Tonsillectomy;
LUAD	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.8	-0.39	3.43e-17	Alcohol dependence;
LUAD	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg17761419	chr8:57350749	NA	-0.56	-8.3	-0.37	1.45e-15	Obesity-related traits;
LUAD	cis	rs10911363	0.592	rs10797886	chr1:183479090	T/C	cg09173681	chr1:183549694	NCF2	0.53	9.96	0.44	3.95e-21	Systemic lupus erythematosus;
LUAD	cis	rs490234	0.783	rs13283793	chr9:128441641	C/T	cg14078157	chr9:128172775	NA	-0.45	-8.34	-0.38	1.06e-15	Mean arterial pressure;
LUAD	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	6.92	0.32	1.64e-11	Platelet count;
LUAD	cis	rs9393692	0.577	rs9358914	chr6:26262063	G/T	cg13736514	chr6:26305472	NA	-0.48	-7.44	-0.34	5.57e-13	Educational attainment;
LUAD	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg07936489	chr17:37558343	FBXL20	0.42	6.63	0.31	1.04e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg03732007	chr1:2071316	PRKCZ	0.35	7.01	0.32	9.37e-12	Height;
LUAD	cis	rs6714710	0.603	rs116309486	chr2:98493359	A/G	cg26665480	chr2:98280029	ACTR1B	0.5	8.22	0.37	2.55e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg06002616	chr8:101225028	SPAG1	-0.41	-8.28	-0.37	1.6e-15	Atrioventricular conduction;
LUAD	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg04731861	chr2:219085781	ARPC2	0.24	7.36	0.34	9.81e-13	Colorectal cancer;
LUAD	cis	rs763121	0.853	rs2072794	chr22:39150543	G/T	cg06022373	chr22:39101656	GTPBP1	0.46	7.15	0.33	3.76e-12	Menopause (age at onset);
LUAD	cis	rs4523957	0.820	rs7212249	chr17:2135980	A/T	cg16513277	chr17:2031491	SMG6	-0.79	-14.67	-0.58	1.15e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs975210	0.656	rs16954106	chr15:70357918	C/T	cg01666796	chr15:70364327	TLE3	-0.45	-6.53	-0.3	1.94e-10	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LUAD	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg17712092	chr4:129076599	LARP1B	0.51	6.56	0.3	1.54e-10	Glomerular filtration rate (creatinine);Chronic kidney disease;
LUAD	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.43	-7.09	-0.33	5.62e-12	Tonsillectomy;
LUAD	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg12292205	chr6:26970375	C6orf41	-0.39	-6.69	-0.31	7.3e-11	Schizophrenia;
LUAD	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg14689365	chr7:158441557	NCAPG2	0.47	8.1	0.37	6.11e-15	Height;
LUAD	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg18527919	chr2:24398170	C2orf84	0.4	6.65	0.31	8.82e-11	Asthma;
LUAD	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg22676075	chr6:135203613	NA	0.41	7.52	0.34	3.39e-13	Red blood cell count;
LUAD	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.92	-0.36	2.07e-14	Monocyte percentage of white cells;
LUAD	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg17264618	chr3:40429014	ENTPD3	-0.39	-8.51	-0.38	3.14e-16	Renal cell carcinoma;
LUAD	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26314531	chr2:26401878	FAM59B	-0.71	-9.61	-0.42	6.33e-20	Gut microbiome composition (summer);
LUAD	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg06558623	chr16:89946397	TCF25	1.14	10.58	0.46	2.35e-23	Skin colour saturation;
LUAD	trans	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg18335740	chr13:41363409	SLC25A15	0.58	10.48	0.45	5.16e-23	Lewy body disease;
LUAD	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-7.75	-0.35	7.08e-14	Arsenic metabolism;
LUAD	cis	rs3007168	0.951	rs3007074	chr14:51604731	T/A	cg23942311	chr14:51606299	NA	0.53	7.31	0.33	1.35e-12	Cancer;
LUAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.76e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg15704280	chr7:45808275	SEPT13	-0.57	-9.49	-0.42	1.66e-19	HDL cholesterol;
LUAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg03188948	chr7:1209495	NA	0.44	7.03	0.32	8.5e-12	Longevity;Endometriosis;
LUAD	cis	rs7709909	0.904	rs6887400	chr5:79958700	A/G	cg24059623	chr5:79951536	MSH3;DHFR	0.41	6.95	0.32	1.37e-11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs62229266	0.633	rs743420	chr21:37387402	A/G	cg12218747	chr21:37451666	NA	-0.43	-7.43	-0.34	5.96e-13	Mitral valve prolapse;
LUAD	cis	rs3087591	0.922	rs9892839	chr17:29618990	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.6	-0.31	1.23e-10	Hip circumference;
LUAD	trans	rs9393777	0.841	rs34332556	chr6:27357414	C/G	cg01620082	chr3:125678407	NA	-0.78	-8.33	-0.38	1.11e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg25811766	chr13:21894605	NA	-0.57	-7.12	-0.33	4.7e-12	White matter hyperintensity burden;
LUAD	cis	rs10089	1.000	rs6595800	chr5:127411647	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	10.45	0.45	6.67e-23	Ileal carcinoids;
LUAD	cis	rs4700695	0.841	rs251614	chr5:65228251	C/G	cg21114390	chr5:65439923	SFRS12	-0.62	-8.26	-0.37	1.84e-15	Facial morphology (factor 19);
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg02386725	chr1:162467755	UHMK1	-0.4	-6.36	-0.3	5.37e-10	Vertical cup-disc ratio;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07655450	chr19:1269248	CIRBP;C19orf23	-0.63	-6.45	-0.3	3.06e-10	Type 2 diabetes;
LUAD	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-14.83	-0.58	2.34e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9467160	0.734	rs35901848	chr6:24443640	G/A	cg20631270	chr6:24437470	GPLD1	0.43	6.7	0.31	6.47e-11	Liver enzyme levels;
LUAD	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.85	-0.36	3.44e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg19761014	chr17:28927070	LRRC37B2	0.83	8.49	0.38	3.63e-16	Body mass index;
LUAD	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15369054	chr17:80825471	TBCD	-0.61	-10.7	-0.46	8.06e-24	Breast cancer;
LUAD	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg03467027	chr4:99064603	C4orf37	0.43	7.06	0.32	7.06e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4790333	0.537	rs2447106	chr17:2257819	A/T	cg27406664	chr17:2294951	MNT	-0.39	-7.8	-0.35	4.97e-14	Proinsulin levels;
LUAD	cis	rs11166629	1.000	rs7003870	chr8:135616586	A/G	cg27224718	chr8:135614730	ZFAT	0.6	10.43	0.45	7.8e-23	Smoking quantity;
LUAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.86	0.56	2.91e-36	Prudent dietary pattern;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg21548813	chr6:291882	DUSP22	-0.81	-13.88	-0.56	2.42e-36	Menopause (age at onset);
LUAD	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg06636551	chr8:101224915	SPAG1	-0.38	-6.98	-0.32	1.17e-11	Atrioventricular conduction;
LUAD	cis	rs4481887	0.893	rs7528645	chr1:248427291	T/A	cg00666640	chr1:248458726	OR2T12	0.31	7.86	0.36	3.33e-14	Common traits (Other);
LUAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.53	0.3	1.94e-10	Prudent dietary pattern;
LUAD	cis	rs1215050	0.791	rs7681599	chr4:98664109	C/T	cg24818145	chr4:99064322	C4orf37	-0.41	-6.77	-0.31	4.2e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.62e-13	Menopause (age at onset);
LUAD	cis	rs10089	0.953	rs6595807	chr5:127531603	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	8.62	0.39	1.36e-16	Ileal carcinoids;
LUAD	cis	rs7223966	0.810	rs2665838	chr17:61966465	C/G	cg11494091	chr17:61959527	GH2	0.43	7.88	0.36	2.86e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6901250	0.851	rs9374624	chr6:117145837	A/C	cg12892004	chr6:117198278	RFX6	0.34	7.34	0.34	1.12e-12	C-reactive protein levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09299307	chr5:86709023	CCNH	-0.43	-6.67	-0.31	7.8e-11	Height;
LUAD	cis	rs10788264	0.504	rs10749451	chr10:124028040	C/T	cg09507567	chr10:124027408	NA	0.53	11.97	0.5	1.23e-28	Total body bone mineral density;
LUAD	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg03929089	chr4:120376271	NA	-0.6	-9.4	-0.42	3.6e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4638749	0.677	rs13423385	chr2:108826435	C/G	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.26	-0.33	1.88e-12	Blood pressure;
LUAD	trans	rs75804782	0.630	rs57435966	chr2:239311369	C/T	cg01134436	chr17:81009848	B3GNTL1	0.77	6.88	0.32	2.14e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg09365446	chr1:150670422	GOLPH3L	-0.42	-7.26	-0.33	1.81e-12	Tonsillectomy;
LUAD	cis	rs7593730	1.000	rs6724146	chr2:161210655	T/C	cg22609984	chr2:161126801	NA	0.44	7.11	0.33	4.96e-12	Type 2 diabetes;
LUAD	cis	rs4481887	0.676	rs7520659	chr1:248527586	C/A	cg00666640	chr1:248458726	OR2T12	0.27	6.73	0.31	5.38e-11	Common traits (Other);
LUAD	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg18230493	chr5:56204884	C5orf35	-0.86	-12.44	-0.52	1.7e-30	Initial pursuit acceleration;
LUAD	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg15557168	chr22:42548783	NA	0.35	6.37	0.3	4.94e-10	Cognitive function;
LUAD	cis	rs6714710	0.603	rs1470483	chr2:98393894	C/T	cg26665480	chr2:98280029	ACTR1B	0.55	9.04	0.4	5.6e-18	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs9469913	0.799	rs16894959	chr6:34825662	T/C	cg14254433	chr6:34482411	PACSIN1	-0.41	-6.53	-0.3	1.88e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg05754148	chr16:3507555	NAT15	-0.4	-6.64	-0.31	9.95e-11	Body mass index (adult);
LUAD	cis	rs4948275	0.550	rs10994749	chr10:63156222	G/C	cg03237606	chr10:63212265	TMEM26	-0.35	-7.2	-0.33	2.73e-12	Night sleep phenotypes;
LUAD	cis	rs7584330	0.554	rs10185109	chr2:238435546	T/C	cg14458575	chr2:238380390	NA	0.54	8.84	0.39	2.55e-17	Prostate cancer;
LUAD	cis	rs3733418	0.929	rs7657444	chr4:165886559	G/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.48	-6.6	-0.31	1.22e-10	Obesity-related traits;
LUAD	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.91	0.36	2.27e-14	Bladder cancer;
LUAD	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg07507251	chr3:52567010	NT5DC2	0.37	7.28	0.33	1.64e-12	Electroencephalogram traits;
LUAD	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg09526685	chr4:187126073	CYP4V2	1.0	10.48	0.45	5.39e-23	Blood protein levels;
LUAD	trans	rs8073060	0.586	rs3859284	chr17:34012792	C/T	cg19694781	chr19:47549865	TMEM160	-1.22	-19.42	-0.69	1.67e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg03874509	chr1:107600012	PRMT6	0.57	9.93	0.43	5.1e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg02527881	chr3:46936655	PTH1R	-0.54	-11.1	-0.47	2.77e-25	Colorectal cancer;
LUAD	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18404041	chr3:52824283	ITIH1	-0.45	-9.19	-0.41	1.85e-18	Bipolar disorder;
LUAD	cis	rs12760731	0.565	rs12406779	chr1:178088936	C/G	cg00404053	chr1:178313656	RASAL2	0.71	9.18	0.41	1.88e-18	Obesity-related traits;
LUAD	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg14196790	chr5:131705035	SLC22A5	0.49	8.56	0.38	2.18e-16	Breast cancer;Mosquito bite size;
LUAD	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg02775129	chr4:119771670	NA	-0.78	-7.71	-0.35	9.12e-14	Cannabis dependence symptom count;
LUAD	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg21951975	chr1:209979733	IRF6	0.54	7.76	0.35	6.58e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg22907277	chr7:1156413	C7orf50	0.68	8.0	0.36	1.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.57	-6.84	-0.32	2.8e-11	Body mass index;
LUAD	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg08048268	chr3:133502702	NA	-0.38	-7.13	-0.33	4.28e-12	Iron status biomarkers;
LUAD	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg06263672	chr7:65235340	NA	0.48	6.44	0.3	3.33e-10	Aortic root size;
LUAD	cis	rs868036	0.958	rs11635424	chr15:68037578	C/T	cg24579218	chr15:68104479	NA	-0.4	-7.17	-0.33	3.32e-12	Restless legs syndrome;
LUAD	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg12311346	chr5:56204834	C5orf35	0.42	6.9	0.32	1.96e-11	Coronary artery disease;
LUAD	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.3	6.99	0.32	1.09e-11	Prostate cancer;
LUAD	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg13319975	chr6:146136371	FBXO30	0.66	11.29	0.48	5.17e-26	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.96	-0.32	1.31e-11	Mood instability;
LUAD	trans	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg11693508	chr17:37793320	STARD3	0.45	6.69	0.31	7.08e-11	Neuroticism;
LUAD	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg25173405	chr17:45401733	C17orf57	0.52	9.07	0.4	4.59e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg11871910	chr12:69753446	YEATS4	0.7	12.21	0.51	1.35e-29	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.29	0.41	8.04e-19	Alzheimer's disease;
LUAD	cis	rs877282	0.945	rs11253398	chr10:790012	T/C	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg16405210	chr4:1374714	KIAA1530	0.62	9.78	0.43	1.7e-20	Longevity;
LUAD	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.76	0.31	4.46e-11	Depression;
LUAD	cis	rs742132	0.520	rs4712950	chr6:25657590	A/G	cg03517284	chr6:25882590	NA	0.56	6.44	0.3	3.3e-10	Uric acid levels;
LUAD	cis	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg05084668	chr3:125655381	ALG1L	-0.61	-8.95	-0.4	1.16e-17	Blood pressure (smoking interaction);
LUAD	trans	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-11.02	-0.47	5.44e-25	Ulcerative colitis;
LUAD	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-6.61	-0.31	1.15e-10	Lung cancer;
LUAD	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg02880119	chr16:3481970	NA	0.62	9.19	0.41	1.78e-18	Body mass index (adult);
LUAD	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg03806693	chr22:41940476	POLR3H	0.67	9.52	0.42	1.39e-19	Vitiligo;
LUAD	cis	rs4077468	0.963	rs1342064	chr1:205913073	T/C	cg14159672	chr1:205819179	PM20D1	-0.39	-6.83	-0.32	3e-11	Cystic fibrosis-related diabetes;
LUAD	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg00852783	chr1:26633632	UBXN11	0.42	7.6	0.35	1.98e-13	Obesity-related traits;
LUAD	cis	rs6496044	0.568	rs7176291	chr15:86067398	T/C	cg13263323	chr15:86062960	AKAP13	-0.58	-10.76	-0.46	5.14e-24	Interstitial lung disease;
LUAD	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg03929089	chr4:120376271	NA	-0.92	-17.83	-0.66	2.01e-53	Height;
LUAD	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg18252515	chr7:66147081	NA	0.6	6.51	0.3	2.19e-10	Diabetic kidney disease;
LUAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg11062466	chr8:58055876	NA	0.67	8.45	0.38	4.68e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg26597838	chr10:835615	NA	0.82	12.75	0.53	9.98e-32	Eosinophil percentage of granulocytes;
LUAD	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg17863274	chr19:49399704	TULP2	-0.64	-9.78	-0.43	1.74e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg04450456	chr4:17643702	FAM184B	0.41	8.12	0.37	5.19e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg03456755	chr17:75084957	SCARNA16;C17orf86	-0.4	-6.38	-0.3	4.74e-10	Vertical cup-disc ratio;
LUAD	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg10589385	chr1:150898437	SETDB1	0.43	8.23	0.37	2.32e-15	Tonsillectomy;
LUAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.9	10.92	0.47	1.3e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	12.28	0.51	7.24e-30	Homoarginine levels;
LUAD	cis	rs9467773	0.511	rs17278688	chr6:26890136	G/C	cg18867708	chr6:26865862	GUSBL1	0.41	6.85	0.32	2.55e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg27411982	chr8:10470053	RP1L1	-0.46	-8.21	-0.37	2.78e-15	Triglycerides;
LUAD	cis	rs75920871	0.925	rs11826651	chr11:116920693	T/A	cg04087571	chr11:116723030	SIK3	-0.33	-6.75	-0.31	5.04e-11	Subjective well-being;
LUAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg13560548	chr3:10150139	C3orf24	0.45	7.5	0.34	3.74e-13	Alzheimer's disease;
LUAD	cis	rs12618769	0.625	rs12618524	chr2:99064029	T/A	cg10123293	chr2:99228465	UNC50	0.46	8.11	0.37	5.48e-15	Bipolar disorder;
LUAD	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg12908607	chr1:44402522	ARTN	-0.44	-9.0	-0.4	7.87e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg02782426	chr3:40428986	ENTPD3	0.43	9.0	0.4	7.49e-18	Renal cell carcinoma;
LUAD	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg24399712	chr22:39784796	NA	-0.53	-9.05	-0.4	5.27e-18	IgG glycosylation;
LUAD	cis	rs7617773	0.817	rs13068265	chr3:48301614	A/C	cg11946769	chr3:48343235	NME6	0.44	6.75	0.31	4.74e-11	Coronary artery disease;
LUAD	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg20307385	chr11:47447363	PSMC3	0.67	11.68	0.49	1.6e-27	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg13271783	chr10:134563150	INPP5A	-0.44	-7.23	-0.33	2.33e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg26924012	chr15:45694286	SPATA5L1	1.03	19.24	0.68	1.05e-59	Homoarginine levels;
LUAD	cis	rs11229555	0.645	rs7931394	chr11:58212617	T/A	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg22532475	chr10:104410764	TRIM8	-0.61	-11.41	-0.49	1.81e-26	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs669446	0.561	rs516790	chr1:44081712	G/T	cg12908607	chr1:44402522	ARTN	0.36	6.69	0.31	6.99e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs4774899	0.966	rs12917247	chr15:57363575	G/C	cg14026238	chr15:57616123	NA	0.36	6.69	0.31	6.98e-11	Urinary tract infection frequency;
LUAD	cis	rs9826463	0.757	rs73240323	chr3:142294803	T/A	cg20824294	chr3:142316082	PLS1	0.47	8.3	0.37	1.43e-15	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-8.87	-0.4	2.14e-17	Gut microbiome composition (summer);
LUAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg11301795	chr4:187892539	NA	-0.77	-15.68	-0.61	5.23e-44	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg24324837	chr19:49891574	CCDC155	0.46	7.44	0.34	5.7e-13	Multiple sclerosis;
LUAD	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg10876282	chr6:28092338	ZSCAN16	0.46	7.11	0.33	5.07e-12	Cardiac Troponin-T levels;
LUAD	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg07386859	chr16:1872102	HAGH	-0.51	-8.02	-0.36	1.04e-14	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs1461503	0.966	rs4936764	chr11:122844492	G/A	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.78	-14.42	-0.57	1.3e-38	Lymphocyte counts;
LUAD	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19717773	chr7:2847554	GNA12	-0.55	-9.54	-0.42	1.17e-19	Height;
LUAD	trans	rs74338693	0.619	rs2045692	chr2:166807600	C/T	cg23494533	chr22:19712750	NA	-0.35	-6.36	-0.3	5.3e-10	Schizophrenia;
LUAD	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg19500098	chr13:21900506	NA	0.38	6.49	0.3	2.47e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs62400317	0.762	rs62436376	chr6:44885817	C/T	cg20913747	chr6:44695427	NA	-0.45	-7.03	-0.32	8.32e-12	Total body bone mineral density;
LUAD	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg22681709	chr2:178499509	PDE11A	-0.46	-7.59	-0.35	2.05e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1595825	0.891	rs59938443	chr2:198497105	C/T	cg10547527	chr2:198650123	BOLL	-0.54	-7.65	-0.35	1.42e-13	Ulcerative colitis;
LUAD	cis	rs7215564	0.908	rs8074870	chr17:78684132	T/C	cg09596252	chr17:78655493	RPTOR	0.56	6.87	0.32	2.32e-11	Myopia (pathological);
LUAD	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg16797656	chr11:68205561	LRP5	-0.38	-7.14	-0.33	4.14e-12	Bone mineral density (spine);
LUAD	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18876405	chr7:65276391	NA	-0.43	-6.81	-0.31	3.39e-11	Aortic root size;
LUAD	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg00166722	chr3:10149974	C3orf24	0.64	8.77	0.39	4.52e-17	Alzheimer's disease;
LUAD	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg04568274	chr7:158649319	WDR60	0.43	7.02	0.32	8.9e-12	Height;
LUAD	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg06453172	chr10:134556979	INPP5A	-0.65	-10.22	-0.44	4.7e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg14061069	chr19:46274453	DMPK	-0.47	-9.76	-0.43	1.98e-20	Coronary artery disease;
LUAD	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg15962314	chr1:44399869	ARTN	0.3	7.17	0.33	3.36e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg27284194	chr4:1044797	NA	0.43	7.23	0.33	2.24e-12	Obesity-related traits;
LUAD	cis	rs7267979	0.816	rs404775	chr20:25481117	A/G	cg08601574	chr20:25228251	PYGB	0.41	7.72	0.35	8.48e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7903847	0.701	rs11189173	chr10:99138792	T/C	cg20016023	chr10:99160130	RRP12	-0.35	-7.6	-0.35	1.96e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg20476274	chr7:133979776	SLC35B4	0.72	12.59	0.52	4.13e-31	Mean platelet volume;
LUAD	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg04850017	chr11:63683019	RCOR2	0.37	8.04	0.36	8.78e-15	Pulse pressure;
LUAD	cis	rs332507	0.830	rs2242425	chr3:124398644	A/G	cg05980111	chr3:124395277	KALRN	0.46	7.25	0.33	2.04e-12	Plateletcrit;
LUAD	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg01416388	chr22:39784598	NA	-0.53	-9.15	-0.41	2.37e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg18180107	chr4:99064573	C4orf37	0.42	6.76	0.31	4.64e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17378563	chr5:133861150	PHF15	-0.44	-6.87	-0.32	2.31e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9875589	0.509	rs2733555	chr3:14099649	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.37	6.8	0.31	3.53e-11	Ovarian reserve;
LUAD	cis	rs12024301	0.557	rs12043560	chr1:183594102	G/T	cg19264170	chr1:183622470	APOBEC4;RGL1	0.66	6.67	0.31	7.88e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs698833	0.886	rs4953086	chr2:44561532	G/A	cg04920474	chr2:44395004	PPM1B	0.41	7.3	0.33	1.44e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs7665939	1.000	rs11942826	chr4:190109362	C/T	cg01790032	chr4:190285510	NA	-0.49	-6.48	-0.3	2.61e-10	Amyotrophic lateral sclerosis;
LUAD	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg09165964	chr15:75287851	SCAMP5	-0.44	-6.72	-0.31	5.95e-11	Blood trace element (Zn levels);
LUAD	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg25319279	chr11:5960081	NA	0.4	7.54	0.34	2.82e-13	DNA methylation (variation);
LUAD	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg14416269	chr4:6271139	WFS1	-0.58	-12.15	-0.51	2.51e-29	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg18230493	chr5:56204884	C5orf35	-0.85	-12.54	-0.52	6.65e-31	Initial pursuit acceleration;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12112058	chr1:224622605	WDR26	-0.47	-7.51	-0.34	3.58e-13	Height;
LUAD	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.02	-0.4	6.56e-18	Total body bone mineral density;
LUAD	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg11062466	chr8:58055876	NA	0.76	9.26	0.41	1.04e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs11039798	0.764	rs76882342	chr11:48939091	A/T	cg03929089	chr4:120376271	NA	0.59	6.79	0.31	3.9e-11	Axial length;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg02985366	chr16:32360428	NA	-0.41	-7.19	-0.33	3.02e-12	Menopause (age at onset);
LUAD	cis	rs10823500	0.748	rs7072230	chr10:71978144	A/G	cg02100629	chr10:71892760	AIFM2	-0.38	-7.61	-0.35	1.83e-13	Blood protein levels;
LUAD	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg23625390	chr15:77176239	SCAPER	0.37	6.46	0.3	2.95e-10	Blood metabolite levels;
LUAD	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.6	-0.46	2e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg04772025	chr11:68637568	NA	0.51	7.95	0.36	1.66e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23583168	chr7:148888333	NA	-0.93	-19.37	-0.69	2.73e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg00933542	chr6:150070202	PCMT1	0.42	8.46	0.38	4.36e-16	Lung cancer;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg03390569	chr2:54013802	LOC100302652;ASB3;ERLEC1	0.42	6.88	0.32	2.13e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg04772025	chr11:68637568	NA	0.59	9.41	0.42	3.24e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs367615	0.918	rs10070104	chr5:108866438	C/T	cg17395555	chr5:108820864	NA	-0.54	-9.02	-0.4	6.69e-18	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs3739034	0.642	rs842356	chr2:135344994	A/G	cg12500956	chr2:135428796	TMEM163	0.37	6.76	0.31	4.69e-11	Gut microbiome composition (winter);
LUAD	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg23758822	chr17:41437982	NA	1.01	20.86	0.71	5.56e-67	Menopause (age at onset);
LUAD	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg22029157	chr1:209979665	IRF6	0.46	8.31	0.37	1.27e-15	Monobrow;
LUAD	cis	rs2282300	0.696	rs12578061	chr11:30249365	T/A	cg25418670	chr11:30344373	C11orf46	-0.53	-7.15	-0.33	3.94e-12	Morning vs. evening chronotype;
LUAD	trans	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg18335740	chr13:41363409	SLC25A15	0.55	9.28	0.41	8.66e-19	Lewy body disease;
LUAD	cis	rs6489785	0.547	rs625228	chr12:121278266	G/A	cg02419362	chr12:121203948	SPPL3	-0.32	-6.58	-0.3	1.44e-10	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-23.62	-0.75	2.87e-79	Height;
LUAD	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg00745463	chr17:30367425	LRRC37B	0.83	9.67	0.43	4.02e-20	Hip circumference adjusted for BMI;
LUAD	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.74	-0.35	7.18e-14	Lung cancer;
LUAD	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg22117172	chr7:91764530	CYP51A1	0.31	6.67	0.31	8.05e-11	Breast cancer;
LUAD	cis	rs4727963	0.511	rs846655	chr7:122645560	A/G	cg03640110	chr7:122635026	TAS2R16	-0.32	-6.99	-0.32	1.06e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
LUAD	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg12714757	chr17:73874637	TRIM47	-0.41	-6.41	-0.3	3.96e-10	Psoriasis;
LUAD	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg13319975	chr6:146136371	FBXO30	0.63	10.83	0.47	2.68e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg11905131	chr22:24372483	LOC391322	-0.51	-8.66	-0.39	9.75e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs1997103	1.000	rs6954474	chr7:55404847	A/G	cg20935933	chr6:143382018	AIG1	0.54	7.57	0.35	2.32e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1894633	0.574	rs17369011	chr1:172321641	A/T	cg13446689	chr1:172328377	DNM3	0.4	6.49	0.3	2.41e-10	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg10518543	chr12:38710700	ALG10B	-0.49	-8.15	-0.37	4.15e-15	Morning vs. evening chronotype;
LUAD	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg15445000	chr17:37608096	MED1	0.45	8.31	0.37	1.32e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg21285383	chr16:89894308	SPIRE2	0.42	10.13	0.44	1.01e-21	Vitiligo;
LUAD	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg18129748	chr3:49941408	MST1R	0.4	6.55	0.3	1.63e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7927771	0.524	rs4752860	chr11:47705015	C/A	cg18512352	chr11:47633146	NA	-0.37	-6.62	-0.31	1.06e-10	Subjective well-being;
LUAD	cis	rs669446	0.561	rs641365	chr1:44083507	A/G	cg12908607	chr1:44402522	ARTN	-0.37	-7.01	-0.32	9.37e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg12483005	chr1:23474871	LUZP1	0.52	9.12	0.41	2.97e-18	Height;
LUAD	cis	rs10203711	1.000	rs4663940	chr2:239570382	C/T	cg14580085	chr2:239553406	NA	0.42	9.02	0.4	6.82e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg06064525	chr11:970664	AP2A2	-0.56	-11.49	-0.49	8.88e-27	Alzheimer's disease (late onset);
LUAD	cis	rs17253792	0.822	rs75991559	chr14:56092419	A/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg17724175	chr1:150552817	MCL1	0.32	7.41	0.34	7e-13	Melanoma;
LUAD	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg03037974	chr15:76606532	NA	0.38	8.1	0.37	5.98e-15	Blood metabolite levels;
LUAD	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.66	-0.31	8.51e-11	Crohn's disease;
LUAD	cis	rs4711350	0.749	rs7752348	chr6:33718252	C/G	cg07979401	chr6:33739406	LEMD2	-0.48	-8.19	-0.37	3.12e-15	Schizophrenia;
LUAD	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg05564831	chr3:52568323	NT5DC2	-0.39	-7.07	-0.32	6.61e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9467160	1.000	rs9295624	chr6:24439600	A/G	cg16211469	chr6:24423932	MRS2	-0.46	-7.13	-0.33	4.27e-12	Liver enzyme levels;
LUAD	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg22598563	chr5:131563921	P4HA2	-0.29	-7.21	-0.33	2.57e-12	Blood metabolite levels;
LUAD	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg12179176	chr11:130786555	SNX19	0.64	10.7	0.46	8e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg00086871	chr4:6988644	TBC1D14	0.74	6.4	0.3	4.13e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.53	-8.61	-0.39	1.45e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg02782426	chr3:40428986	ENTPD3	-0.35	-7.39	-0.34	7.72e-13	Renal cell carcinoma;
LUAD	cis	rs28493229	0.708	rs10407889	chr19:41161078	T/C	cg21869046	chr19:41225005	ITPKC	0.51	8.76	0.39	4.75e-17	Kawasaki disease;
LUAD	cis	rs12530845	0.623	rs73721662	chr7:135341314	G/A	cg23117316	chr7:135346802	PL-5283	-0.58	-8.86	-0.4	2.17e-17	Red blood cell traits;
LUAD	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24308560	chr3:49941425	MST1R	0.55	9.37	0.41	4.35e-19	Body mass index;
LUAD	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.85	0.32	2.7e-11	Colorectal cancer;
LUAD	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg06484146	chr7:12443880	VWDE	-0.57	-7.54	-0.34	2.88e-13	Coronary artery disease;
LUAD	cis	rs62458065	0.850	rs73096034	chr7:32472048	A/G	cg20159608	chr7:32802032	NA	-0.56	-7.36	-0.34	9.55e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.88	-0.5	2.86e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.81	-0.31	3.45e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7818345	0.967	rs13258090	chr8:19285726	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.32	-6.95	-0.32	1.36e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg19875535	chr5:140030758	IK	-0.4	-6.71	-0.31	6.23e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs28595532	1.000	rs115915387	chr4:119640854	C/T	cg14228332	chr4:119757509	SEC24D	0.78	7.21	0.33	2.54e-12	Cannabis dependence symptom count;
LUAD	cis	rs1595825	0.891	rs17520121	chr2:198898718	T/G	cg10547527	chr2:198650123	BOLL	-0.53	-7.21	-0.33	2.66e-12	Ulcerative colitis;
LUAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.71e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs8002861	0.664	rs2184882	chr13:44450346	C/T	cg17145862	chr1:211918768	LPGAT1	0.65	13.62	0.55	2.69e-35	Leprosy;
LUAD	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg11266682	chr4:10021025	SLC2A9	0.68	15.56	0.6	1.69e-43	Bone mineral density;
LUAD	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	8.42	0.38	6.11e-16	Parkinson's disease;
LUAD	cis	rs8060686	0.623	rs7204208	chr16:68069416	A/G	cg05110241	chr16:68378359	PRMT7	-0.53	-6.85	-0.32	2.61e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg11266682	chr4:10021025	SLC2A9	0.67	14.78	0.58	3.89e-40	Bone mineral density;
LUAD	cis	rs231513	0.954	rs231516	chr17:41963205	G/A	cg26893861	chr17:41843967	DUSP3	-0.54	-6.63	-0.31	1.04e-10	Cognitive function;
LUAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg22244940	chr12:132335942	MMP17	0.4	7.05	0.32	7.45e-12	Migraine;
LUAD	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg23505145	chr19:12996616	KLF1	0.55	9.06	0.4	4.69e-18	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg09455208	chr3:40491958	NA	-0.57	-12.49	-0.52	1.0500000000000001e-30	Renal cell carcinoma;
LUAD	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.34	-6.37	-0.3	4.89e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4664304	0.966	rs925407	chr2:160767502	A/C	cg06573604	chr2:160760825	LY75	-0.38	-6.44	-0.3	3.34e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg19052272	chr2:3704530	ALLC	-0.89	-14.14	-0.57	1.9e-37	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.83	0.31	3.04e-11	Cognitive test performance;
LUAD	cis	rs41311933	0.708	rs62578402	chr9:123702639	T/C	cg13567360	chr9:123745713	C5	-0.83	-7.22	-0.33	2.36e-12	Coronary artery disease;
LUAD	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg25324976	chr17:61989376	CSHL1	0.38	7.39	0.34	7.83e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg24818145	chr4:99064322	C4orf37	0.39	6.51	0.3	2.08e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs8073060	0.544	rs8071584	chr17:33999435	G/A	cg19694781	chr19:47549865	TMEM160	-1.22	-19.51	-0.69	6.52e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs897984	0.568	rs56083427	chr16:30881298	C/T	cg05768032	chr16:30646687	NA	0.41	6.63	0.31	1.01e-10	Dementia with Lewy bodies;
LUAD	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg02527881	chr3:46936655	PTH1R	-0.74	-16.96	-0.64	1.31e-49	Birth weight;
LUAD	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg22532475	chr10:104410764	TRIM8	-0.45	-8.74	-0.39	5.54e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg06697600	chr4:7070879	GRPEL1	0.52	8.42	0.38	5.74e-16	Monocyte percentage of white cells;
LUAD	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg23172400	chr8:95962367	TP53INP1	0.31	6.63	0.31	1.04e-10	Type 2 diabetes;
LUAD	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.44	-0.57	1e-38	Schizophrenia;
LUAD	cis	rs73198271	0.562	rs76702427	chr8:8660141	G/T	cg01851573	chr8:8652454	MFHAS1	0.7	10.65	0.46	1.23e-23	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs17253792	0.822	rs75509578	chr14:56133493	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.45	-0.3	3.13e-10	Putamen volume;
LUAD	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg20362242	chr5:692897	TPPP	-0.58	-7.33	-0.34	1.19e-12	Obesity-related traits;
LUAD	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg11494091	chr17:61959527	GH2	0.44	8.66	0.39	1.01e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11644478	chr21:40555479	PSMG1	0.6	9.5	0.42	1.63e-19	Cognitive function;
LUAD	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg15432903	chr11:17409602	KCNJ11	0.6	11.26	0.48	6.43e-26	Type 2 diabetes;
LUAD	cis	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.98	-0.36	1.37e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg04896959	chr15:78267971	NA	0.56	10.73	0.46	6.36e-24	Coronary artery disease or large artery stroke;
LUAD	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg21862992	chr11:68658383	NA	0.54	9.68	0.43	3.66e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg12615879	chr12:58013172	SLC26A10	0.52	11.06	0.47	3.93e-25	Multiple sclerosis;
LUAD	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg15181151	chr6:150070149	PCMT1	0.38	7.7	0.35	9.98e-14	Lung cancer;
LUAD	cis	rs3750082	0.855	rs12536402	chr7:32936419	C/G	cg05721444	chr7:32995514	FKBP9	-0.36	-6.52	-0.3	2.06e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs6489785	0.521	rs668622	chr12:121198299	G/A	cg02419362	chr12:121203948	SPPL3	0.33	6.6	0.31	1.25e-10	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg11663144	chr21:46675770	NA	-0.6	-11.66	-0.49	1.98e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7737355	0.773	rs184949	chr5:130815593	A/G	cg25547332	chr5:131281432	NA	-0.42	-6.82	-0.31	3.15e-11	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg03467027	chr4:99064603	C4orf37	0.42	6.82	0.31	3.12e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1696756	0.877	rs2587500	chr17:77827362	A/T	cg00646381	chr17:77835854	NA	0.47	7.62	0.35	1.71e-13	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs6484504	0.652	rs578666	chr11:31404484	C/T	cg26647111	chr11:31128758	NA	0.42	7.33	0.34	1.21e-12	Red blood cell count;
LUAD	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg03929089	chr4:120376271	NA	0.53	6.82	0.31	3.13e-11	Axial length;
LUAD	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg25838465	chr1:92012736	NA	-0.7	-14.78	-0.58	3.63e-40	Breast cancer;
LUAD	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg22482690	chr17:47019901	SNF8	0.45	8.46	0.38	4.31e-16	Type 2 diabetes;
LUAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg05564831	chr3:52568323	NT5DC2	0.39	7.4	0.34	7.32e-13	Electroencephalogram traits;
LUAD	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg11871910	chr12:69753446	YEATS4	0.45	6.88	0.32	2.16e-11	Response to diuretic therapy;
LUAD	cis	rs870825	0.616	rs6852082	chr4:185645783	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg09491104	chr22:46646882	C22orf40	-0.56	-7.3	-0.33	1.48e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg25894440	chr7:65020034	NA	-0.66	-7.16	-0.33	3.5e-12	Diabetic kidney disease;
LUAD	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg12564285	chr5:131593104	PDLIM4	0.37	6.96	0.32	1.33e-11	Acylcarnitine levels;
LUAD	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg18277682	chr1:228362509	C1orf69	-0.38	-6.44	-0.3	3.25e-10	Diastolic blood pressure;
LUAD	cis	rs9322817	0.691	rs9486015	chr6:105254000	C/T	cg02098413	chr6:105308735	HACE1	-0.41	-8.84	-0.4	2.51e-17	Thyroid stimulating hormone;
LUAD	trans	rs9784649	1.000	rs11738315	chr5:24967891	T/C	cg08600765	chr20:34638493	LOC647979	-0.59	-7.7	-0.35	9.84e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg10589385	chr1:150898437	SETDB1	0.41	7.54	0.34	2.9e-13	Melanoma;
LUAD	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg23625390	chr15:77176239	SCAPER	-0.49	-7.4	-0.34	7.54e-13	Blood metabolite levels;
LUAD	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg00277334	chr10:82204260	NA	-0.57	-9.47	-0.42	2.07e-19	Post bronchodilator FEV1;
LUAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg02869364	chr7:1081709	C7orf50	-0.5	-6.43	-0.3	3.45e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7107174	1.000	rs7111986	chr11:78102266	G/T	cg02023728	chr11:77925099	USP35	0.47	7.27	0.33	1.74e-12	Testicular germ cell tumor;
LUAD	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg15448220	chr1:150897856	SETDB1	0.54	9.13	0.41	2.81e-18	Urate levels;
LUAD	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg11822812	chr5:140052017	DND1	-0.41	-7.48	-0.34	4.24e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg07917127	chr4:99064746	C4orf37	0.4	6.64	0.31	9.47e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg10356904	chr22:49881777	NA	-0.41	-7.98	-0.36	1.4e-14	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9394841	0.667	rs3747749	chr6:41770604	G/A	cg17623882	chr6:41773611	USP49	-0.53	-7.36	-0.34	9.9e-13	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg22467129	chr15:76604101	ETFA	-0.5	-8.59	-0.39	1.67e-16	Blood metabolite levels;
LUAD	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg06453172	chr10:134556979	INPP5A	-0.65	-9.6	-0.42	7.13e-20	Migraine;
LUAD	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg11766577	chr21:47581405	C21orf56	-0.45	-7.73	-0.35	7.69e-14	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-7.78	-0.35	5.43e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg17366294	chr4:99064904	C4orf37	-0.51	-8.92	-0.4	1.4e-17	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs7374732	0.692	rs6800955	chr3:23139179	C/T	cg14257814	chr17:30470253	RHOT1	0.4	6.98	0.32	1.11e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI;Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs10746514	1.000	rs61835640	chr1:232245014	G/A	cg09506761	chr1:232265262	NA	0.38	6.95	0.32	1.42e-11	Response to statin therapy;
LUAD	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7903847	0.656	rs11189208	chr10:99169172	C/G	cg20016023	chr10:99160130	RRP12	-0.27	-6.37	-0.3	5.03e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg03188948	chr7:1209495	NA	0.44	7.19	0.33	3.02e-12	Longevity;Endometriosis;
LUAD	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	7.41	0.34	6.72e-13	Rheumatoid arthritis;
LUAD	cis	rs7584330	0.740	rs7586312	chr2:238439389	G/A	cg14458575	chr2:238380390	NA	0.62	11.44	0.49	1.37e-26	Prostate cancer;
LUAD	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg20908204	chr19:46285434	DMPK	-0.42	-9.33	-0.41	6.25e-19	Coronary artery disease;
LUAD	cis	rs9902453	0.904	rs7208579	chr17:28263067	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.33	0.45	1.94e-22	Coffee consumption (cups per day);
LUAD	trans	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs7833986	0.501	rs72653981	chr8:57027814	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.99	17.76	0.65	4.05e-53	Height;
LUAD	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg15448220	chr1:150897856	SETDB1	0.47	8.1	0.37	5.81e-15	Tonsillectomy;
LUAD	cis	rs9633740	1.000	rs10748526	chr10:82273079	T/C	cg00277334	chr10:82204260	NA	-0.63	-8.68	-0.39	8.45e-17	Post bronchodilator FEV1;
LUAD	cis	rs897984	0.759	rs13708	chr16:31000809	G/A	cg02466173	chr16:30829666	NA	0.66	12.09	0.51	4.3e-29	Dementia with Lewy bodies;
LUAD	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02475777	chr4:1388615	CRIPAK	0.68	9.74	0.43	2.39e-20	Longevity;
LUAD	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg01689657	chr7:91764605	CYP51A1	-0.38	-9.49	-0.42	1.76e-19	Breast cancer;
LUAD	cis	rs7665090	1.000	rs6810869	chr4:103558514	T/A	cg07973026	chr4:103553119	MANBA	0.47	8.41	0.38	6.57e-16	Primary biliary cholangitis;
LUAD	cis	rs933688	0.532	rs997737	chr5:90567031	C/G	cg00335715	chr5:90575459	NA	-0.44	-7.17	-0.33	3.36e-12	Smoking behavior;
LUAD	cis	rs4819852	1.000	rs2073743	chr22:19989612	C/G	cg07821417	chr22:19972146	ARVCF	0.42	7.7	0.35	9.64e-14	Pulse pressure;
LUAD	cis	rs8017423	0.967	rs2277515	chr14:90723000	A/G	cg14092571	chr14:90743983	NA	-0.5	-8.87	-0.4	2.08e-17	Mortality in heart failure;
LUAD	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs875622	0.556	rs4808047	chr19:16527834	T/C	cg05286348	chr19:16641544	CHERP	-0.54	-6.83	-0.32	2.98e-11	White matter integrity;Neutrophil percentage of white cells;
LUAD	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg07371521	chr5:154026371	NA	0.48	7.74	0.35	7.23e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs12216545	0.765	rs7792574	chr7:150224206	T/C	cg08960815	chr7:150264767	GIMAP4	-0.31	-6.64	-0.31	9.46e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg24011408	chr12:48396354	COL2A1	-0.43	-9.58	-0.42	8.67e-20	Plateletcrit;
LUAD	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg17177755	chr1:15930204	NA	0.46	7.4	0.34	7.33e-13	Systolic blood pressure;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26643908	chr2:36825150	FEZ2	-0.55	-6.65	-0.31	9.25e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg22482690	chr17:47019901	SNF8	0.45	8.58	0.38	1.86e-16	Type 2 diabetes;
LUAD	cis	rs73198271	0.515	rs113524005	chr8:8634672	C/A	cg01851573	chr8:8652454	MFHAS1	0.6	8.04	0.36	9.13e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.9	13.84	0.56	3.42e-36	Smoking behavior;
LUAD	cis	rs7512552	0.839	rs11587575	chr1:150451863	T/C	cg15654264	chr1:150340011	RPRD2	0.58	11.22	0.48	9.44e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg00631329	chr6:26305371	NA	-0.69	-13.12	-0.54	3.11e-33	Educational attainment;
LUAD	cis	rs240764	0.782	rs369125	chr6:101118400	G/A	cg09795085	chr6:101329169	ASCC3	0.43	7.41	0.34	6.98e-13	Neuroticism;
LUAD	cis	rs938554	0.806	rs4447862	chr4:9931645	C/G	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.99	-0.4	8.19e-18	Blood metabolite levels;
LUAD	cis	rs75920871	0.800	rs723953	chr11:116924978	A/C	cg04087571	chr11:116723030	SIK3	-0.32	-6.77	-0.31	4.19e-11	Subjective well-being;
LUAD	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg26384229	chr12:38710491	ALG10B	0.42	7.34	0.34	1.09e-12	Morning vs. evening chronotype;
LUAD	trans	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg13565492	chr6:43139072	SRF	-0.58	-6.76	-0.31	4.68e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7659604	0.540	rs13113421	chr4:122670064	G/A	cg06713675	chr4:122721982	EXOSC9	0.41	7.44	0.34	5.75e-13	Type 2 diabetes;
LUAD	cis	rs12210905	0.688	rs72845005	chr6:27492378	T/G	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg21016266	chr12:122356598	WDR66	0.63	10.83	0.47	2.66e-24	Mean corpuscular volume;
LUAD	cis	rs1969363	0.531	rs11495331	chr12:38110702	A/G	cg26384229	chr12:38710491	ALG10B	0.39	6.52	0.3	1.99e-10	Morning vs. evening chronotype;
LUAD	cis	rs8060686	0.516	rs9938020	chr16:68251784	C/G	cg05110241	chr16:68378359	PRMT7	-0.58	-7.35	-0.34	1.06e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg24818145	chr4:99064322	C4orf37	0.46	7.9	0.36	2.44e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg10468373	chr11:64009913	FKBP2	0.53	6.7	0.31	6.85e-11	Mean platelet volume;
LUAD	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg07741184	chr6:167504864	NA	0.31	7.42	0.34	6.42e-13	Crohn's disease;
LUAD	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg06108461	chr20:60628389	TAF4	-0.94	-16.88	-0.63	2.99e-49	Body mass index;
LUAD	trans	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg01620082	chr3:125678407	NA	-0.68	-7.15	-0.33	3.95e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4604732	0.631	rs74154676	chr1:247625894	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg05340658	chr4:99064831	C4orf37	0.54	9.15	0.41	2.47e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14893161	chr1:205819251	PM20D1	0.82	17.29	0.64	4.94e-51	Menarche (age at onset);
LUAD	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-9.58	-0.42	8.65e-20	Height;
LUAD	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg18110333	chr6:292329	DUSP22	-0.52	-8.52	-0.38	2.88e-16	Menopause (age at onset);
LUAD	cis	rs3784262	0.669	rs12148281	chr15:58311061	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.44	-0.34	5.75e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03452623	chr4:187889614	NA	-0.83	-17.45	-0.65	9.79e-52	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg06002616	chr8:101225028	SPAG1	0.38	7.77	0.35	6.04e-14	Atrioventricular conduction;
LUAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg06074448	chr4:187884817	NA	-0.36	-7.35	-0.34	1.05e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs240764	0.621	rs11155623	chr6:101184373	A/G	cg09795085	chr6:101329169	ASCC3	-0.48	-8.58	-0.39	1.77e-16	Neuroticism;
LUAD	cis	rs7512552	0.809	rs2794679	chr1:150324857	G/A	cg15654264	chr1:150340011	RPRD2	0.58	11.1	0.47	2.73e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs2262909	0.962	rs73019844	chr19:22249925	T/C	cg17074339	chr11:11642133	GALNTL4	0.47	7.7	0.35	9.49e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.39	0.55	2.39e-34	Prudent dietary pattern;
LUAD	trans	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-10.18	-0.44	6.37e-22	Brugada syndrome;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23486179	chr3:49466665	NICN1	-0.54	-6.5	-0.3	2.32e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9972944	0.639	rs2052153	chr17:63800382	G/T	cg07283582	chr17:63770753	CCDC46	-0.45	-9.59	-0.42	7.63e-20	Total body bone mineral density;
LUAD	trans	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.76	0.5	8.36e-28	Mean corpuscular volume;
LUAD	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg07741184	chr6:167504864	NA	-0.3	-7.12	-0.33	4.52e-12	Crohn's disease;
LUAD	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.37	-0.41	4.57e-19	Type 2 diabetes;
LUAD	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg18932078	chr1:2524107	MMEL1	0.35	6.59	0.31	1.28e-10	Ulcerative colitis;
LUAD	cis	rs17362650	1.000	rs17362650	chr2:9676413	T/C	cg12832956	chr2:9616023	IAH1	-0.47	-7.4	-0.34	7.6e-13	Alcohol dependence (age at onset);
LUAD	cis	rs28595532	1.000	rs114039398	chr4:119631627	T/C	cg21605333	chr4:119757512	SEC24D	0.86	7.93	0.36	2e-14	Cannabis dependence symptom count;
LUAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg08219700	chr8:58056026	NA	0.55	6.93	0.32	1.55e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg04842962	chr6:43655489	MRPS18A	1.08	27.28	0.8	2.86e-95	IgG glycosylation;
LUAD	cis	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg07460842	chr6:66804631	NA	-0.96	-12.92	-0.53	2e-32	Exhaled nitric oxide output;
LUAD	cis	rs427941	0.632	rs201475	chr7:101745883	G/T	cg06246474	chr7:101738831	CUX1	0.4	6.91	0.32	1.84e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg07169764	chr2:136633963	MCM6	0.66	7.9	0.36	2.49e-14	Corneal structure;
LUAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08280861	chr8:58055591	NA	0.54	6.91	0.32	1.79e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg16797656	chr11:68205561	LRP5	0.47	8.88	0.4	1.94e-17	Total body bone mineral density;
LUAD	cis	rs28735056	0.508	rs67651675	chr18:77673562	A/G	cg20368463	chr18:77673604	PQLC1	-0.73	-13.56	-0.55	4.72e-35	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.86	-0.36	3.15e-14	Diabetic kidney disease;
LUAD	trans	rs6561151	0.681	rs4942249	chr13:44426804	C/A	cg17145862	chr1:211918768	LPGAT1	0.53	7.32	0.34	1.3e-12	Crohn's disease;
LUAD	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg00290607	chr11:67383545	NA	0.4	6.57	0.3	1.51e-10	Mean corpuscular volume;
LUAD	cis	rs231513	0.954	rs231479	chr17:41983616	A/G	cg26893861	chr17:41843967	DUSP3	-0.62	-6.84	-0.32	2.85e-11	Cognitive function;
LUAD	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg06558623	chr16:89946397	TCF25	1.14	10.37	0.45	1.38e-22	Skin colour saturation;
LUAD	cis	rs1832871	0.711	rs7747669	chr6:158664345	A/G	cg07165851	chr6:158734300	TULP4	0.7	10.57	0.46	2.44e-23	Height;
LUAD	cis	rs57590327	0.503	rs13073613	chr3:81888512	C/A	cg07356753	chr3:81810745	GBE1	-0.55	-8.95	-0.4	1.09e-17	Extraversion;
LUAD	cis	rs912057	0.526	rs201061	chr6:6730512	C/T	cg06612196	chr6:6737390	NA	-0.63	-15.91	-0.61	5.04e-45	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg00898013	chr13:113819073	PROZ	-0.66	-11.77	-0.5	7.41e-28	Platelet distribution width;
LUAD	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg11057378	chr10:81107060	PPIF	0.36	6.85	0.32	2.7e-11	Height;
LUAD	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg02753203	chr1:228287806	NA	-0.48	-8.58	-0.38	1.89e-16	Diastolic blood pressure;
LUAD	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg05754148	chr16:3507555	NAT15	0.81	10.75	0.46	5.4e-24	Tuberculosis;
LUAD	cis	rs7089973	0.872	rs36036948	chr10:116631649	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	7.46	0.34	5.08e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg07305463	chr2:136567211	LCT	0.36	6.88	0.32	2.16e-11	Mosquito bite size;
LUAD	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.13	0.33	4.46e-12	Hypertriglyceridemia;
LUAD	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg11247378	chr22:39784982	NA	-0.66	-10.37	-0.45	1.37e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs6906287	0.609	rs767139	chr6:118884799	A/G	cg21191810	chr6:118973309	C6orf204	0.51	9.97	0.44	3.59e-21	Electrocardiographic conduction measures;
LUAD	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg16479474	chr6:28041457	NA	0.47	8.01	0.36	1.11e-14	Depression;
LUAD	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.32e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1941687	0.509	rs2282632	chr18:31320229	A/G	cg15819921	chr19:927150	ARID3A	-0.43	-7.31	-0.33	1.34e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg04398451	chr17:18023971	MYO15A	-0.63	-11.51	-0.49	7.13e-27	Total body bone mineral density;
LUAD	cis	rs2742234	0.955	rs2503841	chr10:43675721	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.44	-7.9	-0.36	2.46e-14	Hirschsprung disease;
LUAD	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg03929089	chr4:120376271	NA	-0.65	-10.59	-0.46	2.19e-23	Height;
LUAD	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg06558623	chr16:89946397	TCF25	1.22	12.45	0.52	1.6e-30	Skin colour saturation;
LUAD	cis	rs1564271	0.704	rs1780191	chr10:26994412	T/C	cg13837822	chr10:26931731	LOC731789	0.46	9.52	0.42	1.36e-19	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUAD	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg08470875	chr2:26401718	FAM59B	-0.62	-8.52	-0.38	2.89e-16	Gut microbiome composition (summer);
LUAD	cis	rs6499255	1.000	rs11075734	chr16:69801397	G/T	cg15192750	chr16:69999425	NA	0.55	8.6	0.39	1.54e-16	IgE levels;
LUAD	trans	rs55986470	0.817	rs72993054	chr2:239404244	C/T	cg01134436	chr17:81009848	B3GNTL1	0.77	8.46	0.38	4.55e-16	Chronotype;
LUAD	cis	rs778371	0.697	rs4973564	chr2:233718440	A/G	cg08000102	chr2:233561755	GIGYF2	-0.41	-6.57	-0.3	1.51e-10	Schizophrenia;
LUAD	cis	rs57502260	0.790	rs7128942	chr11:68387984	C/T	cg16797656	chr11:68205561	LRP5	0.44	6.96	0.32	1.31e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs4481887	0.927	rs4341391	chr1:248475720	A/G	cg00666640	chr1:248458726	OR2T12	0.31	7.08	0.33	5.85e-12	Common traits (Other);
LUAD	cis	rs9633740	0.945	rs6586030	chr10:82254047	C/T	cg01528321	chr10:82214614	TSPAN14	-0.69	-8.17	-0.37	3.73e-15	Post bronchodilator FEV1;
LUAD	cis	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg05084668	chr3:125655381	ALG1L	-0.61	-9.7	-0.43	3.14e-20	Blood pressure (smoking interaction);
LUAD	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg23711669	chr6:146136114	FBXO30	0.38	6.6	0.31	1.27e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.65	9.01	0.4	7.11e-18	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg24818145	chr4:99064322	C4orf37	0.41	6.8	0.31	3.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg19318889	chr4:1322082	MAEA	0.44	7.07	0.33	6.32e-12	Obesity-related traits;
LUAD	cis	rs7786808	0.530	rs7780796	chr7:158183330	C/T	cg01191920	chr7:158217561	PTPRN2	0.56	11.2	0.48	1.1e-25	Obesity-related traits;
LUAD	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg06582575	chr6:163149167	PACRG;PARK2	1.16	15.42	0.6	6.85e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs62458065	0.640	rs79619897	chr7:32514819	C/T	cg00845942	chr12:64062724	DPY19L2	-0.58	-7.82	-0.36	4.35e-14	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg26039829	chr8:22132926	PIWIL2	0.58	11.01	0.47	6.08e-25	Hypertriglyceridemia;
LUAD	cis	rs9469913	0.740	rs2744964	chr6:34591320	G/C	cg14254433	chr6:34482411	PACSIN1	-0.43	-6.76	-0.31	4.72e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs2286885	0.965	rs10760440	chr9:129250831	C/T	cg15282417	chr9:129245246	FAM125B	0.46	9.27	0.41	9.79e-19	Intraocular pressure;
LUAD	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg04842962	chr6:43655489	MRPS18A	1.07	27.27	0.8	3.18e-95	IgG glycosylation;
LUAD	cis	rs738322	0.805	rs2016755	chr22:38539604	A/G	cg25457927	chr22:38595422	NA	-0.53	-13.13	-0.54	2.82e-33	Cutaneous nevi;
LUAD	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.12	-0.33	4.61e-12	Morning vs. evening chronotype;
LUAD	cis	rs4691139	0.873	rs12509081	chr4:165892964	A/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.42	-8.11	-0.37	5.48e-15	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg03859395	chr2:55845619	SMEK2	0.75	13.51	0.55	7.69e-35	Metabolic syndrome;
LUAD	cis	rs7598759	0.548	rs1584462	chr2:232369798	A/G	cg19187155	chr2:232395269	NMUR1	0.51	9.7	0.43	3.12e-20	Noise-induced hearing loss;
LUAD	cis	rs11048434	0.673	rs11611106	chr12:9060204	A/C	cg23795048	chr12:9217529	LOC144571	-0.4	-7.02	-0.32	8.72e-12	Sjögren's syndrome;
LUAD	cis	rs7301016	1.000	rs7301016	chr12:62886123	A/G	cg11441379	chr12:63026424	NA	0.53	6.52	0.3	1.97e-10	IgG glycosylation;
LUAD	cis	rs4252707	1	rs4252707	chr1:204508147	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.42	-7.03	-0.32	8.37e-12	Glioma;Non-glioblastoma glioma;
LUAD	cis	rs1018836	0.892	rs1476428	chr8:91555603	G/T	cg16814680	chr8:91681699	NA	-0.61	-9.92	-0.43	5.39e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg10729496	chr3:10149963	C3orf24	0.58	9.44	0.42	2.6e-19	Alzheimer's disease;
LUAD	cis	rs599083	0.793	rs471966	chr11:68173861	C/T	cg02221422	chr11:68192511	LRP5	0.43	6.71	0.31	6.17e-11	Bone mineral density (spine);
LUAD	trans	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg11693508	chr17:37793320	STARD3	0.49	7.23	0.33	2.25e-12	Neuroticism;
LUAD	trans	rs783540	0.835	rs783522	chr15:83280613	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.47	-0.3	2.65e-10	Schizophrenia;
LUAD	cis	rs9633740	1.000	rs10748526	chr10:82273079	T/C	cg01528321	chr10:82214614	TSPAN14	0.71	9.45	0.42	2.26e-19	Post bronchodilator FEV1;
LUAD	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg03929089	chr4:120376271	NA	-0.52	-7.7	-0.35	1e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6545883	0.868	rs6752938	chr2:61841588	C/T	cg15711740	chr2:61764176	XPO1	-0.43	-6.85	-0.32	2.67e-11	Tuberculosis;
LUAD	cis	rs2554380	0.943	rs979543	chr15:84352564	C/A	cg14598478	chr15:84363061	ADAMTSL3	-0.49	-7.97	-0.36	1.49e-14	Height;
LUAD	cis	rs12422267	0.609	rs11246940	chr12:132623473	A/G	cg09764611	chr12:132620959	NA	-0.65	-11.34	-0.48	3.42e-26	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg26384229	chr12:38710491	ALG10B	0.44	7.36	0.34	9.42e-13	Morning vs. evening chronotype;
LUAD	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg20476274	chr7:133979776	SLC35B4	0.58	9.48	0.42	1.84e-19	Mean platelet volume;
LUAD	cis	rs938554	0.501	rs7671266	chr4:10056376	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.64	-0.39	1.13e-16	Blood metabolite levels;
LUAD	cis	rs7537052	0.646	rs1748399	chr1:36655652	C/T	cg24686825	chr1:36642396	MAP7D1	-0.36	-6.4	-0.3	4.06e-10	Schizophrenia;
LUAD	trans	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	9.97e-11	Diabetic kidney disease;
LUAD	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg00852783	chr1:26633632	UBXN11	0.42	7.43	0.34	6.04e-13	Obesity-related traits;
LUAD	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg08885076	chr2:99613938	TSGA10	-0.39	-6.82	-0.31	3.12e-11	Chronic sinus infection;
LUAD	cis	rs62400317	0.859	rs62436780	chr6:45128261	A/T	cg18551225	chr6:44695536	NA	-0.56	-8.73	-0.39	5.77e-17	Total body bone mineral density;
LUAD	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg21827317	chr3:136751795	NA	0.36	6.6	0.31	1.21e-10	Neuroticism;
LUAD	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.56	7.55	0.34	2.74e-13	Platelet count;
LUAD	cis	rs11811982	0.793	rs11804807	chr1:227354001	C/A	cg24860534	chr1:227506868	CDC42BPA	0.69	7.39	0.34	7.72e-13	Optic disc area;
LUAD	cis	rs12079745	0.793	rs76254504	chr1:169182779	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.06	-7.74	-0.35	7.54e-14	QT interval;
LUAD	cis	rs897984	0.806	rs4889571	chr16:30949047	A/G	cg02466173	chr16:30829666	NA	0.67	12.47	0.52	1.35e-30	Dementia with Lewy bodies;
LUAD	cis	rs4795519	0.701	rs35275057	chr17:22173784	A/T	cg22648282	chr17:21454238	C17orf51	-0.4	-6.5	-0.3	2.22e-10	Chronic myeloid leukemia;
LUAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.99	0.47	7.04e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg18367735	chr17:79674897	NA	0.54	6.82	0.31	3.14e-11	Dental caries;
LUAD	cis	rs8067545	0.641	rs203460	chr17:19815286	G/C	cg04132472	chr17:19861366	AKAP10	0.39	9.21	0.41	1.5e-18	Schizophrenia;
LUAD	cis	rs490234	0.867	rs829181	chr9:128288002	A/G	cg14078157	chr9:128172775	NA	0.37	6.83	0.32	2.9100000000000002e-11	Mean arterial pressure;
LUAD	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg23719950	chr11:63933701	MACROD1	0.6	7.37	0.34	8.81e-13	Mean platelet volume;
LUAD	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg13334819	chr7:99746414	C7orf59	-0.65	-10.47	-0.45	5.66e-23	Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg02775129	chr4:119771670	NA	-0.88	-8.19	-0.37	3.21e-15	Cannabis dependence symptom count;
LUAD	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.59	-0.49	3.54e-27	Primary sclerosing cholangitis;
LUAD	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg13607699	chr17:42295918	UBTF	-0.51	-8.28	-0.37	1.66e-15	Red cell distribution width;Reticulocyte count;
LUAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg17372223	chr3:52568218	NT5DC2	0.4	7.5	0.34	3.67e-13	Electroencephalogram traits;
LUAD	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg02696790	chr15:75250997	RPP25	0.36	6.66	0.31	8.35e-11	Breast cancer;
LUAD	trans	rs3857536	0.813	rs7743965	chr6:66941346	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08677398	chr8:58056175	NA	0.47	6.6	0.31	1.26e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	10.59	0.46	2.09e-23	Type 2 diabetes;
LUAD	cis	rs7000551	0.560	rs4872483	chr8:22255684	C/T	cg12081754	chr8:22256438	SLC39A14	0.86	15.47	0.6	4.38e-43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg26677194	chr12:130822605	PIWIL1	0.55	9.04	0.4	5.6e-18	Menopause (age at onset);
LUAD	cis	rs68170813	0.559	rs12536491	chr7:106978024	T/G	cg02696742	chr7:106810147	HBP1	-0.77	-10.47	-0.45	5.75e-23	Coronary artery disease;
LUAD	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg27446573	chr6:127587934	RNF146	0.45	6.58	0.3	1.39e-10	Breast cancer;
LUAD	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg06953865	chr19:18549723	ISYNA1	0.36	6.78	0.31	3.95e-11	Breast cancer;
LUAD	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg00071950	chr4:10020882	SLC2A9	0.84	17.91	0.66	8.44e-54	Bone mineral density;
LUAD	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg03929089	chr4:120376271	NA	-0.82	-15.03	-0.59	3.2e-41	Coronary artery disease;
LUAD	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg13902645	chr11:5959945	NA	-0.51	-8.97	-0.4	9.34e-18	DNA methylation (variation);
LUAD	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg15900387	chr1:150738905	CTSS	-0.37	-6.71	-0.31	6.25e-11	Melanoma;
LUAD	cis	rs7945718	0.875	rs9888258	chr11:12782716	A/G	cg25843174	chr11:12811716	TEAD1	0.25	7.41	0.34	7e-13	Educational attainment (years of education);
LUAD	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg07538946	chr5:131705188	SLC22A5	-0.46	-7.62	-0.35	1.67e-13	Blood metabolite levels;
LUAD	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-14.21	-0.57	1.01e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7759001	0.857	rs2206251	chr6:27358392	C/T	cg18711553	chr6:27366782	ZNF391	0.4	6.67	0.31	7.98e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.95	0.36	1.74e-14	Depression;
LUAD	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg17264618	chr3:40429014	ENTPD3	0.42	9.03	0.4	6.15e-18	Renal cell carcinoma;
LUAD	cis	rs7843479	0.601	rs10866827	chr8:21801141	G/A	cg03445287	chr8:21823731	XPO7	-0.5	-9.41	-0.42	3.3e-19	Mean corpuscular volume;
LUAD	cis	rs1007738	0.507	rs10742797	chr11:47240490	A/T	cg19486271	chr11:47235900	DDB2	0.44	6.39	0.3	4.37e-10	Bone mineral density (hip);
LUAD	trans	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg01620082	chr3:125678407	NA	-0.44	-6.6	-0.31	1.27e-10	Depression;
LUAD	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg14458575	chr2:238380390	NA	0.67	12.41	0.52	2.31e-30	Prostate cancer;
LUAD	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg11584989	chr19:19387371	SF4	0.35	6.36	0.3	5.11e-10	Tonsillectomy;
LUAD	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg09035930	chr12:129282057	SLC15A4	0.76	17.76	0.65	3.94e-53	Systemic lupus erythematosus;
LUAD	cis	rs17362650	1.000	rs4464248	chr2:9691320	A/G	cg12832956	chr2:9616023	IAH1	0.47	7.41	0.34	6.8e-13	Alcohol dependence (age at onset);
LUAD	cis	rs1912483	0.545	rs35161461	chr17:45401757	A/G	cg08085267	chr17:45401833	C17orf57	-0.69	-11.45	-0.49	1.3e-26	Coronary artery disease;
LUAD	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-8.58	-0.39	1.78e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs909002	0.849	rs10914453	chr1:32075036	A/G	cg13919466	chr1:32135498	COL16A1	-0.35	-7.95	-0.36	1.69e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg02002194	chr4:3960332	NA	-0.32	-7.61	-0.35	1.77e-13	Mood instability;
LUAD	cis	rs1712517	0.771	rs11191676	chr10:105155066	C/A	cg05636881	chr10:105038444	INA	0.32	6.36	0.3	5.39e-10	Migraine;
LUAD	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18404041	chr3:52824283	ITIH1	-0.58	-12.0	-0.5	9.42e-29	Bipolar disorder;
LUAD	cis	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg21775007	chr8:11205619	TDH	0.52	9.34	0.41	5.54e-19	Retinal vascular caliber;
LUAD	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25427524	chr10:38739819	LOC399744	-0.78	-14.37	-0.57	2.06e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg00277334	chr10:82204260	NA	-0.96	-22.11	-0.73	1.46e-72	Post bronchodilator FEV1;
LUAD	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg19318889	chr4:1322082	MAEA	0.43	6.91	0.32	1.83e-11	Obesity-related traits;
LUAD	cis	rs7132746	0.553	rs11831936	chr12:86193148	C/T	cg18827107	chr12:86230957	RASSF9	0.46	6.63	0.31	1.01e-10	Lewy body disease;
LUAD	cis	rs73416724	1.000	rs41281796	chr6:43323917	G/A	cg26312998	chr6:43337775	ZNF318	0.55	6.69	0.31	7.26e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg07217954	chr7:1067459	C7orf50	0.43	6.61	0.31	1.14e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs262150	0.501	rs1017034	chr7:158820460	A/G	cg25769590	chr7:158789503	NA	-0.41	-7.39	-0.34	7.75e-13	Facial morphology (factor 20);
LUAD	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg03929089	chr4:120376271	NA	-0.79	-13.91	-0.56	1.69e-36	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7208859	0.614	rs216477	chr17:28866744	A/C	cg19761014	chr17:28927070	LRRC37B2	-0.68	-7.12	-0.33	4.71e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg03684893	chr10:554711	DIP2C	0.38	6.58	0.3	1.41e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs73198271	0.595	rs56152067	chr8:8592992	G/A	cg01851573	chr8:8652454	MFHAS1	0.48	6.89	0.32	1.98e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg20090143	chr19:45452003	APOC2	0.38	8.54	0.38	2.54e-16	Blood protein levels;
LUAD	cis	rs698813	0.637	rs7579841	chr2:44498887	T/A	cg00619915	chr2:44497795	NA	-0.43	-6.46	-0.3	2.93e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUAD	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-8.71	-0.39	6.87e-17	Heart rate;
LUAD	cis	rs68170813	0.559	rs76020313	chr7:106877468	A/G	cg23024343	chr7:107201750	COG5	0.5	7.36	0.34	9.41e-13	Coronary artery disease;
LUAD	cis	rs6908034	0.607	rs111533721	chr6:19803745	C/G	cg02682789	chr6:19804855	NA	0.95	9.37	0.41	4.34e-19	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21800906	chr11:32914818	QSER1	-0.5	-8.1	-0.37	6.08e-15	Height;
LUAD	trans	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg14917512	chr19:3094685	GNA11	-0.56	-6.5	-0.3	2.21e-10	Diabetic kidney disease;
LUAD	cis	rs7830933	0.955	rs1550280	chr8:23601830	C/T	cg04349084	chr8:23602677	NA	0.51	7.24	0.33	2.12e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
LUAD	cis	rs654950	0.875	rs687835	chr1:41998904	G/C	cg06885757	chr1:42089581	HIVEP3	0.32	6.68	0.31	7.65e-11	Airway imaging phenotypes;
LUAD	cis	rs61774743	0.636	rs1892423	chr1:41849340	A/C	cg08462924	chr1:41848221	NA	0.47	8.62	0.39	1.39e-16	Intelligence (multi-trait analysis);
LUAD	trans	rs1493916	0.777	rs1493910	chr18:31318376	A/G	cg15819921	chr19:927150	ARID3A	-0.43	-7.17	-0.33	3.38e-12	Life satisfaction;
LUAD	cis	rs1595825	0.891	rs59990242	chr2:198895868	G/A	cg00361562	chr2:198649771	BOLL	-0.47	-6.52	-0.3	1.96e-10	Ulcerative colitis;
LUAD	cis	rs9443645	0.527	rs7756996	chr6:79509367	A/C	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.4	-0.3	4.2e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg10755058	chr3:40428713	ENTPD3	0.47	8.69	0.39	7.97e-17	Renal cell carcinoma;
LUAD	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.87	-0.32	2.37e-11	Height;
LUAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg04352962	chr1:209979756	IRF6	0.51	7.3	0.33	1.46e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg13319975	chr6:146136371	FBXO30	-0.63	-11.08	-0.47	3.11e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg05872129	chr22:39784769	NA	0.74	13.88	0.56	2.22e-36	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.42	0.38	5.87e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg27490568	chr2:178487706	NA	0.44	7.17	0.33	3.35e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13126279	chr21:47581558	C21orf56	0.62	11.35	0.48	2.91e-26	Testicular germ cell tumor;
LUAD	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg03806693	chr22:41940476	POLR3H	0.76	10.14	0.44	9.01e-22	Vitiligo;
LUAD	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	6.68	0.31	7.59e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3784262	0.528	rs4238327	chr15:58336218	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.36	-0.34	9.7e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg11070056	chr1:107600091	PRMT6	0.59	10.22	0.44	4.72e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg23281280	chr6:28129359	ZNF389	0.46	6.45	0.3	3e-10	Depression;
LUAD	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg11941060	chr3:133502564	NA	-0.65	-11.32	-0.48	3.85e-26	Iron status biomarkers;
LUAD	cis	rs7737355	0.812	rs11242084	chr5:130935777	T/C	cg25547332	chr5:131281432	NA	0.41	6.47	0.3	2.75e-10	Life satisfaction;
LUAD	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg06552810	chr11:31128660	NA	-0.34	-6.64	-0.31	9.81e-11	Red blood cell count;
LUAD	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg22681709	chr2:178499509	PDE11A	-0.45	-7.5	-0.34	3.74e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7705042	0.865	rs12655465	chr5:141522213	C/T	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.89	-0.32	2.01e-11	Asthma;
LUAD	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg10518543	chr12:38710700	ALG10B	-0.53	-8.71	-0.39	6.88e-17	Morning vs. evening chronotype;
LUAD	cis	rs926938	0.520	rs6671984	chr1:115257521	C/T	cg12756093	chr1:115239321	AMPD1	-0.41	-6.63	-0.31	1.03e-10	Autism;
LUAD	cis	rs652260	0.967	rs569175	chr19:7901160	T/G	cg26014689	chr19:7917955	EVI5L	-0.43	-8.0	-0.36	1.2e-14	Menarche (age at onset);
LUAD	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg25985355	chr7:65971099	NA	-0.56	-6.94	-0.32	1.49e-11	Diabetic kidney disease;
LUAD	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg14668632	chr7:2872130	GNA12	-0.74	-13.54	-0.55	5.92e-35	Height;
LUAD	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg08677398	chr8:58056175	NA	0.53	6.91	0.32	1.76e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6087990	0.735	rs2424922	chr20:31386449	T/C	cg13636640	chr20:31349939	DNMT3B	0.73	13.1	0.54	3.61e-33	Ulcerative colitis;
LUAD	cis	rs896543	0.702	rs6711222	chr2:237494444	C/T	cg25295825	chr2:237489920	CXCR7	0.48	8.8	0.39	3.59e-17	Alcohol dependence (age at onset);
LUAD	cis	rs16910800	1.000	rs16910800	chr11:23202785	C/T	cg20040320	chr11:23191996	NA	-0.48	-7.21	-0.33	2.66e-12	Cancer;
LUAD	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg12473912	chr3:136751656	NA	0.34	6.79	0.31	3.92e-11	Schizophrenia;
LUAD	cis	rs438465	1.000	rs425239	chr6:169813758	A/C	cg11181693	chr6:169825345	NA	-0.66	-8.14	-0.37	4.55e-15	Corneal astigmatism;
LUAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-10.02	-0.44	2.33e-21	Lymphocyte counts;
LUAD	cis	rs68092024	0.704	rs792832	chr3:99474862	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	7.69	0.35	1.03e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg22875332	chr1:76189707	ACADM	-0.7	-11.55	-0.49	5.2e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.4	7.75	0.35	7.04e-14	Lung cancer in ever smokers;
LUAD	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.78	-0.35	5.7e-14	Blood metabolite levels;
LUAD	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg12365402	chr11:9010492	NRIP3	0.46	8.44	0.38	5.25e-16	Hemoglobin concentration;
LUAD	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg04398451	chr17:18023971	MYO15A	-0.76	-13.87	-0.56	2.58e-36	Total body bone mineral density;
LUAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg11494091	chr17:61959527	GH2	0.74	18.66	0.67	3.9e-57	Prudent dietary pattern;
LUAD	cis	rs7665090	0.967	rs4019	chr4:103552830	G/A	cg07973026	chr4:103553119	MANBA	0.48	8.53	0.38	2.69e-16	Primary biliary cholangitis;
LUAD	cis	rs2692947	0.537	rs12471472	chr2:96205455	G/A	cg23100626	chr2:96804247	ASTL	0.34	8.45	0.38	4.89e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg02221750	chr19:17393354	ANKLE1	-0.79	-12.73	-0.53	1.19e-31	Systemic lupus erythematosus;
LUAD	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg06808227	chr14:105710500	BRF1	-0.43	-6.55	-0.3	1.68e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg22105103	chr4:187893119	NA	0.58	12.76	0.53	8.61e-32	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg14895029	chr7:2775587	GNA12	-0.39	-6.41	-0.3	3.82e-10	Height;
LUAD	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg07402062	chr16:89894098	SPIRE2	0.41	10.19	0.44	5.71e-22	Vitiligo;
LUAD	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg21252483	chr19:49399788	TULP2	-0.89	-14.65	-0.58	1.34e-39	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs76419734	0.558	rs2305212	chr4:106534691	A/G	cg05309399	chr4:106552544	FLJ20184	-0.56	-6.8	-0.31	3.57e-11	Post bronchodilator FEV1;
LUAD	cis	rs897984	0.683	rs729482	chr16:31016970	T/C	cg02466173	chr16:30829666	NA	-0.52	-8.73	-0.39	5.88e-17	Dementia with Lewy bodies;
LUAD	cis	rs657075	0.595	rs35719560	chr5:131584395	T/C	cg21138405	chr5:131827807	IRF1	0.45	6.46	0.3	2.9e-10	Rheumatoid arthritis;
LUAD	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg18404041	chr3:52824283	ITIH1	-0.68	-14.93	-0.59	8.85e-41	Bipolar disorder;
LUAD	cis	rs13190036	0.551	rs9313751	chr5:176644175	G/A	cg06733329	chr5:176740039	MXD3	0.44	6.49	0.3	2.41e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg13606994	chr1:44402422	ARTN	0.35	7.08	0.33	6.09e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	cis	rs6087990	0.836	rs2424909	chr20:31361861	T/C	cg13636640	chr20:31349939	DNMT3B	0.82	15.36	0.6	1.22e-42	Ulcerative colitis;
LUAD	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg07389463	chr12:132296394	NA	-0.57	-10.93	-0.47	1.18e-24	Migraine;
LUAD	cis	rs7216064	1.000	rs62084249	chr17:65874998	A/G	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg18833306	chr6:118973337	C6orf204	-0.53	-7.54	-0.34	2.99e-13	Diastolic blood pressure;
LUAD	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-16.36	-0.62	5.58e-47	Schizophrenia;
LUAD	cis	rs8028313	0.731	rs6494678	chr15:67946247	C/T	cg24579218	chr15:68104479	NA	-0.5	-8.62	-0.39	1.31e-16	Obesity;
LUAD	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg25173405	chr17:45401733	C17orf57	-0.43	-7.19	-0.33	2.98e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17761864	0.579	rs12452074	chr17:2051730	G/T	cg16513277	chr17:2031491	SMG6	0.47	7.69	0.35	1.07e-13	Esophageal cancer (squamous cell);
LUAD	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg00603274	chr11:61596626	FADS2	-0.69	-9.74	-0.43	2.25e-20	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-7.25	-0.33	2.05e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	7.88	0.36	2.82e-14	Tonsillectomy;
LUAD	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg08085267	chr17:45401833	C17orf57	-0.51	-8.42	-0.38	6e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4077468	0.927	rs1342063	chr1:205912859	C/T	cg11965913	chr1:205819406	PM20D1	-0.38	-6.8	-0.31	3.47e-11	Cystic fibrosis-related diabetes;
LUAD	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	ch.11.42038R	chr11:967971	AP2A2	0.41	7.35	0.34	1.02e-12	Alzheimer's disease (late onset);
LUAD	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg26384229	chr12:38710491	ALG10B	-0.38	-6.44	-0.3	3.19e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	6.75	0.31	4.95e-11	Lung cancer in ever smokers;
LUAD	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg25985355	chr7:65971099	NA	-0.52	-6.48	-0.3	2.53e-10	Diabetic kidney disease;
LUAD	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg04414720	chr1:150670196	GOLPH3L	0.67	11.79	0.5	6.3e-28	Melanoma;
LUAD	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg00634984	chr7:65235879	NA	-0.5	-6.61	-0.31	1.14e-10	Aortic root size;
LUAD	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06873352	chr17:61820015	STRADA	0.5	8.08	0.37	6.62e-15	Height;
LUAD	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.83	0.36	3.98e-14	Bladder cancer;
LUAD	cis	rs727505	0.607	rs10464674	chr7:124791551	A/G	cg23710748	chr7:124431027	NA	-0.38	-7.72	-0.35	8.31e-14	Lewy body disease;
LUAD	cis	rs35995292	0.500	rs8180877	chr7:38931258	G/A	cg19327137	chr7:38886074	VPS41	0.71	14.39	0.57	1.75e-38	Subjective well-being (multi-trait analysis);
LUAD	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg26528668	chr16:1614120	IFT140	0.5	8.93	0.4	1.36e-17	Coronary artery disease;
LUAD	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg05665937	chr4:1216051	CTBP1	0.41	6.97	0.32	1.24e-11	Obesity-related traits;
LUAD	trans	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-9.76	-0.43	2e-20	Brugada syndrome;
LUAD	trans	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.96	-16.94	-0.64	1.71e-49	Colorectal cancer;
LUAD	cis	rs7524258	0.868	rs4908607	chr1:7269323	A/G	cg04342483	chr1:7259290	CAMTA1	-0.27	-6.48	-0.3	2.63e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg19622623	chr12:86230825	RASSF9	-0.55	-9.7	-0.43	3.09e-20	Major depressive disorder;
LUAD	cis	rs868036	0.918	rs4238411	chr15:68079424	A/T	cg24579218	chr15:68104479	NA	-0.35	-6.42	-0.3	3.71e-10	Restless legs syndrome;
LUAD	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg27124370	chr19:33622961	WDR88	0.46	7.15	0.33	3.92e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs59104589	0.617	rs62193220	chr2:242353493	G/A	cg08645257	chr2:242211290	HDLBP	0.42	6.97	0.32	1.23e-11	Fibrinogen levels;
LUAD	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg19610905	chr11:61596333	FADS2	-0.59	-10.12	-0.44	1.03e-21	Trans fatty acid levels;
LUAD	cis	rs7809950	1.000	rs2520264	chr7:107179344	T/C	cg23024343	chr7:107201750	COG5	-0.72	-12.17	-0.51	2.07e-29	Coronary artery disease;
LUAD	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg15383120	chr6:291909	DUSP22	-0.48	-7.93	-0.36	1.99e-14	Menopause (age at onset);
LUAD	cis	rs494562	0.892	rs1322403	chr6:86127162	A/G	cg13315970	chr6:86159197	NT5E	0.71	7.86	0.36	3.15e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.4	0.67	5.43e-56	Prudent dietary pattern;
LUAD	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg20503657	chr10:835505	NA	0.96	14.74	0.58	5.86e-40	Eosinophil percentage of granulocytes;
LUAD	cis	rs12579753	0.917	rs10862361	chr12:82197946	T/C	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.28	-0.33	1.6e-12	Resting heart rate;
LUAD	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22307029	chr19:49891270	CCDC155	0.65	10.39	0.45	1.09e-22	Multiple sclerosis;
LUAD	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg03161606	chr19:29218774	NA	0.61	8.7	0.39	7.49e-17	Methadone dose in opioid dependence;
LUAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07167872	chr1:205819463	PM20D1	0.78	15.86	0.61	8.72e-45	Menarche (age at onset);
LUAD	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg20891558	chr2:74357851	NA	0.94	14.77	0.58	3.99e-40	Gestational age at birth (maternal effect);
LUAD	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg07606381	chr6:8435919	SLC35B3	0.42	6.95	0.32	1.38e-11	Motion sickness;
LUAD	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg18477163	chr1:228402036	OBSCN	-0.35	-7.07	-0.33	6.32e-12	Diastolic blood pressure;
LUAD	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg23982607	chr1:1823379	GNB1	-0.91	-18.93	-0.68	2.53e-58	Body mass index;
LUAD	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg13319975	chr6:146136371	FBXO30	-0.61	-10.41	-0.45	9.87e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg04414720	chr1:150670196	GOLPH3L	0.74	13.85	0.56	3.17e-36	Tonsillectomy;
LUAD	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg27432699	chr2:27873401	GPN1	0.57	10.07	0.44	1.53e-21	Oral cavity cancer;
LUAD	cis	rs7809950	0.862	rs62482502	chr7:106987810	A/C	cg23024343	chr7:107201750	COG5	-0.7	-11.84	-0.5	3.86e-28	Coronary artery disease;
LUAD	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-6.52	-0.3	2.06e-10	Tonsillectomy;
LUAD	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.74	-0.46	5.96e-24	Total body bone mineral density;
LUAD	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	25.33	0.78	8.57e-87	Chronic sinus infection;
LUAD	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg04369109	chr6:150039330	LATS1	-0.44	-7.43	-0.34	6.01e-13	Lung cancer;
LUAD	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg09904177	chr6:26538194	HMGN4	0.42	6.92	0.32	1.73e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs62238980	0.614	rs77167216	chr22:32386313	G/C	cg00543991	chr22:32367038	NA	0.8	7.39	0.34	8.17e-13	Childhood ear infection;
LUAD	trans	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg27411982	chr8:10470053	RP1L1	0.44	7.81	0.36	4.57e-14	Mood instability;
LUAD	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg01256987	chr12:42539512	GXYLT1	-0.34	-6.64	-0.31	9.41e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg03948781	chr1:205179583	DSTYK	0.35	6.4	0.3	4.17e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs10992471	0.603	rs10820974	chr9:95211876	T/C	cg14631576	chr9:95140430	CENPP	-0.5	-10.24	-0.45	4.02e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.42	6.97	0.32	1.2e-11	Total body bone mineral density;
LUAD	trans	rs2018683	0.870	rs13232487	chr7:28985119	C/A	cg19402173	chr7:128379420	CALU	-0.61	-10.24	-0.45	3.99e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg06606381	chr12:133084897	FBRSL1	0.68	6.75	0.31	4.96e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg19635926	chr16:89946313	TCF25	0.73	6.37	0.3	4.99e-10	Skin colour saturation;
LUAD	cis	rs11229555	0.609	rs12286421	chr11:58174898	A/G	cg15696309	chr11:58395628	NA	-0.73	-10.3	-0.45	2.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.47	6.56	0.3	1.54e-10	Renal function-related traits (BUN);
LUAD	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.39	-6.41	-0.3	3.89e-10	Personality dimensions;
LUAD	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg24531977	chr5:56204891	C5orf35	-0.39	-6.49	-0.3	2.47e-10	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs68170813	0.559	rs11764448	chr7:106924928	A/G	cg23024343	chr7:107201750	COG5	0.49	7.15	0.33	3.78e-12	Coronary artery disease;
LUAD	cis	rs6076065	0.748	rs2295239	chr20:23387550	C/T	cg11657817	chr20:23433608	CST11	0.57	12.07	0.51	4.82e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1865721	1.000	rs72977879	chr18:73193696	T/C	cg26385618	chr18:73139727	C18orf62	-0.41	-7.48	-0.34	4.31e-13	Intelligence;
LUAD	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18876405	chr7:65276391	NA	-0.57	-9.64	-0.42	5.17e-20	Aortic root size;
LUAD	cis	rs7512552	0.839	rs834231	chr1:150389392	A/T	cg15654264	chr1:150340011	RPRD2	-0.57	-11.01	-0.47	6.07e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7177699	0.534	rs4387568	chr15:79109514	C/G	cg15571903	chr15:79123663	NA	-0.37	-7.27	-0.33	1.74e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs2075371	0.796	rs35336643	chr7:134010640	G/A	cg20476274	chr7:133979776	SLC35B4	0.68	11.99	0.5	1.01e-28	Mean platelet volume;
LUAD	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23583168	chr7:148888333	NA	-0.86	-17.06	-0.64	5.15e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs71478720	0.779	rs12420140	chr11:112071294	C/T	cg04929355	chr11:112034997	IL18	0.4	6.52	0.3	2.07e-10	Interleukin-18 levels;
LUAD	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg10639395	chr11:8710044	RPL27A	0.33	6.52	0.3	2.03e-10	Hemoglobin concentration;
LUAD	cis	rs7487075	0.619	rs4768710	chr12:46808104	G/A	cg23829395	chr12:46796953	NA	0.32	6.98	0.32	1.16e-11	Itch intensity from mosquito bite;
LUAD	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg01448562	chr3:133502909	NA	-0.68	-12.41	-0.52	2.19e-30	Iron status biomarkers;
LUAD	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg25985355	chr7:65971099	NA	-0.55	-6.9	-0.32	1.91e-11	Gout;
LUAD	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.91	0.76	1.53e-80	Chronic sinus infection;
LUAD	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg16049864	chr8:95962084	TP53INP1	-0.54	-11.61	-0.49	2.99e-27	Type 2 diabetes;
LUAD	trans	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.64	10.56	0.46	2.76e-23	Endometrial cancer;
LUAD	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg20607798	chr8:58055168	NA	0.57	7.67	0.35	1.16e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs12701220	0.595	rs12532837	chr7:1122851	T/A	cg23978390	chr7:1156363	C7orf50	0.52	6.43	0.3	3.36e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg02880119	chr16:3481970	NA	-0.54	-8.23	-0.37	2.4e-15	Body mass index (adult);
LUAD	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg24818145	chr4:99064322	C4orf37	0.42	6.98	0.32	1.13e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg16325326	chr1:53192061	ZYG11B	-0.61	-10.85	-0.47	2.39e-24	Monocyte count;
LUAD	cis	rs10493773	0.928	rs12741600	chr1:86191172	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.55	-9.38	-0.42	3.99e-19	Urate levels in overweight individuals;
LUAD	cis	rs806215	1.000	rs2106187	chr7:127241353	C/T	cg25922125	chr7:127225783	GCC1	0.48	6.93	0.32	1.58e-11	Type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.21	0.37	2.75e-15	Breast cancer;
LUAD	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg12365402	chr11:9010492	NRIP3	-0.45	-8.14	-0.37	4.57e-15	Hemoglobin concentration;
LUAD	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg25753631	chr6:25732923	NA	-0.45	-7.94	-0.36	1.9e-14	Iron status biomarkers;
LUAD	cis	rs6489882	0.836	rs10774676	chr12:113362407	C/T	cg20102336	chr12:113376681	OAS3	0.58	8.89	0.4	1.72e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs3916	1.000	rs1799958	chr12:121176083	G/A	cg27246729	chr12:121163418	ACADS	0.47	7.44	0.34	5.74e-13	Urinary metabolites (H-NMR features);
LUAD	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg22920501	chr2:26401640	FAM59B	0.97	14.19	0.57	1.17e-37	Gut microbiome composition (summer);
LUAD	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.59	0.3	1.35e-10	Cardiac Troponin-T levels;
LUAD	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11890956	chr21:40555474	PSMG1	0.72	11.33	0.48	3.54e-26	Cognitive function;
LUAD	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.62	-0.31	1.12e-10	Morning vs. evening chronotype;
LUAD	cis	rs3849570	1.000	rs7638516	chr3:81826249	A/C	cg07356753	chr3:81810745	GBE1	-0.63	-10.78	-0.46	4.37e-24	Waist circumference;Body mass index;
LUAD	cis	rs7116495	1.000	rs17161991	chr11:71839960	T/C	cg07596299	chr11:71824057	C11orf51	0.77	6.69	0.31	7.27e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg20701182	chr2:24300061	SF3B14	0.48	7.57	0.35	2.38e-13	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs739496	0.843	rs616668	chr12:111974280	T/G	cg10833066	chr12:111807467	FAM109A	0.42	6.61	0.31	1.19e-10	Platelet count;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06742600	chr17:71307380	CDC42EP4	-0.42	-6.88	-0.32	2.15e-11	Cancer;
LUAD	cis	rs6840360	0.571	rs62327277	chr4:152555905	C/T	cg22705602	chr4:152727874	NA	-0.39	-6.87	-0.32	2.35e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1784581	0.894	rs1790001	chr6:162387504	G/T	cg17173639	chr6:162384350	PARK2	-0.58	-10.64	-0.46	1.34e-23	Itch intensity from mosquito bite;
LUAD	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg13385794	chr1:248469461	NA	0.27	7.28	0.33	1.63e-12	Common traits (Other);
LUAD	cis	rs28595532	0.702	rs72670238	chr4:119322751	C/T	cg02775129	chr4:119771670	NA	-0.63	-6.49	-0.3	2.4e-10	Cannabis dependence symptom count;
LUAD	cis	rs10129255	0.500	rs988133	chr14:107184963	A/G	cg07958169	chr14:107095056	NA	-0.37	-7.34	-0.34	1.08e-12	Kawasaki disease;
LUAD	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg06623918	chr6:96969491	KIAA0776	-0.85	-15.57	-0.6	1.55e-43	Headache;
LUAD	cis	rs11229555	0.598	rs12276438	chr11:58185419	G/A	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs11811982	0.793	rs80313225	chr1:227510751	T/C	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg20701182	chr2:24300061	SF3B14	0.57	6.77	0.31	4.27e-11	Lymphocyte counts;
LUAD	cis	rs6028335	0.610	rs12624452	chr20:37554781	G/T	cg27660920	chr20:37554817	FAM83D	0.57	7.47	0.34	4.63e-13	Alcohol and nicotine co-dependence;
LUAD	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg03948781	chr1:205179583	DSTYK	0.35	6.43	0.3	3.36e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs859767	0.741	rs1467194	chr2:135430621	A/G	cg12500956	chr2:135428796	TMEM163	-0.32	-8.44	-0.38	5.12e-16	Neuroticism;
LUAD	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.13	0.33	4.3e-12	Menopause (age at onset);
LUAD	cis	rs11771526	0.686	rs62457501	chr7:32329946	A/G	cg27532318	chr7:32358331	NA	0.66	8.17	0.37	3.52e-15	Body mass index;
LUAD	cis	rs4604732	0.631	rs56704806	chr1:247626148	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9811920	0.598	rs793470	chr3:99548274	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.6	-0.39	1.54e-16	Axial length;
LUAD	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg00204512	chr16:28754710	NA	0.33	7.12	0.33	4.52e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg05187965	chr10:45406764	TMEM72	-0.44	-8.67	-0.39	9.53e-17	Mean corpuscular volume;
LUAD	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg12863693	chr15:85201151	NMB	0.39	7.31	0.33	1.33e-12	Schizophrenia;
LUAD	cis	rs11696845	0.666	rs13042905	chr20:43379454	T/C	cg25301532	chr20:43378953	KCNK15	0.46	7.77	0.35	5.93e-14	Obesity-related traits;
LUAD	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg23758822	chr17:41437982	NA	1.01	20.9	0.71	3.66e-67	Menopause (age at onset);
LUAD	cis	rs4073416	0.542	rs2898814	chr14:66023961	T/C	cg10998611	chr14:65879393	FUT8;LOC645431	-0.43	-6.52	-0.3	2.07e-10	N-glycan levels;
LUAD	cis	rs62400317	0.826	rs12216308	chr6:45342305	T/G	cg20913747	chr6:44695427	NA	-0.41	-6.68	-0.31	7.55e-11	Total body bone mineral density;
LUAD	cis	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg08601574	chr20:25228251	PYGB	-0.45	-8.44	-0.38	5.06e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs11039798	0.764	rs12418936	chr11:48986418	T/C	cg15704280	chr7:45808275	SEPT13	0.74	7.47	0.34	4.73e-13	Axial length;
LUAD	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.26	0.33	1.82e-12	Parkinson's disease;
LUAD	cis	rs4711336	1.000	rs2229642	chr6:33659472	C/G	cg14003231	chr6:33640908	ITPR3	0.5	9.54	0.42	1.13e-19	Height;
LUAD	cis	rs4852324	0.536	rs17009553	chr2:74220035	A/G	cg20891558	chr2:74357851	NA	-0.83	-7.68	-0.35	1.1e-13	Systemic lupus erythematosus;
LUAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg15242686	chr22:24348715	GSTTP1	0.51	8.86	0.4	2.25e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg10518543	chr12:38710700	ALG10B	-0.48	-8.08	-0.37	6.73e-15	Morning vs. evening chronotype;
LUAD	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg12193833	chr17:30244370	NA	-0.55	-7.06	-0.32	6.87e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg20135002	chr11:47629003	NA	-0.41	-7.27	-0.33	1.7e-12	Subjective well-being;
LUAD	cis	rs1451375	0.756	rs11761683	chr7:50542879	C/T	cg18232548	chr7:50535776	DDC	-0.65	-10.94	-0.47	1.06e-24	Malaria;
LUAD	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg07636037	chr3:49044803	WDR6	-0.48	-7.55	-0.34	2.77e-13	Menarche (age at onset);
LUAD	cis	rs12216545	0.961	rs111350935	chr7:150209733	G/C	cg08960815	chr7:150264767	GIMAP4	0.31	6.51	0.3	2.07e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs897984	0.645	rs9938550	chr16:30999142	A/G	cg02466173	chr16:30829666	NA	0.66	12.07	0.51	5.01e-29	Dementia with Lewy bodies;
LUAD	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-8.0	-0.36	1.22e-14	Morning vs. evening chronotype;
LUAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.19	-0.41	1.78e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9487051	0.803	rs11153161	chr6:109541774	A/G	cg21918786	chr6:109611834	NA	-0.41	-6.92	-0.32	1.67e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg02807482	chr3:125708958	NA	-0.68	-9.5	-0.42	1.62e-19	Blood pressure (smoking interaction);
LUAD	cis	rs4372836	0.729	rs6547882	chr2:29037001	T/C	cg09522027	chr2:28974177	PPP1CB	-0.68	-12.47	-0.52	1.33e-30	Body mass index;
LUAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg03188948	chr7:1209495	NA	0.41	6.46	0.3	2.82e-10	Longevity;Endometriosis;
LUAD	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.24	-0.45	3.77e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7680126	0.596	rs10022911	chr4:10140551	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.6	-0.35	1.92e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs10129255	0.500	rs2105991	chr14:107138039	C/G	cg23076370	chr14:107095027	NA	-0.41	-8.15	-0.37	4.21e-15	Kawasaki disease;
LUAD	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg23758822	chr17:41437982	NA	1.0	20.98	0.71	1.6e-67	Menopause (age at onset);
LUAD	cis	rs9486719	0.947	rs2472908	chr6:96875998	A/T	cg06623918	chr6:96969491	KIAA0776	0.71	10.02	0.44	2.32e-21	Migraine;Coronary artery disease;
LUAD	cis	rs3845702	1.000	rs3768839	chr2:180835992	G/A	cg01881094	chr2:180872142	CWC22	-0.57	-7.01	-0.32	9.76e-12	Schizophrenia;
LUAD	cis	rs62238980	0.614	rs2018440	chr22:32433889	G/A	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg03433033	chr1:76189801	ACADM	-0.48	-6.98	-0.32	1.14e-11	Daytime sleep phenotypes;
LUAD	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	9.71	0.43	3.07e-20	Ileal carcinoids;
LUAD	cis	rs28374715	0.662	rs513280	chr15:41482800	T/C	cg18705301	chr15:41695430	NDUFAF1	0.83	15.05	0.59	2.74e-41	Ulcerative colitis;
LUAD	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg11645453	chr3:52864694	ITIH4	-0.38	-7.61	-0.35	1.78e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9811920	0.965	rs9837131	chr3:99854514	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.18	0.48	1.34e-25	Axial length;
LUAD	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg06618935	chr21:46677482	NA	-0.51	-10.02	-0.44	2.32e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00166722	chr3:10149974	C3orf24	0.68	12.02	0.5	8.08e-29	Alzheimer's disease;
LUAD	cis	rs9372498	0.572	rs62422230	chr6:118959436	T/C	cg21191810	chr6:118973309	C6orf204	-0.54	-8.14	-0.37	4.36e-15	Diastolic blood pressure;
LUAD	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.16	0.37	3.85e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg11663144	chr21:46675770	NA	-0.61	-12.12	-0.51	3.24e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	10.06	0.44	1.77e-21	Colorectal cancer;
LUAD	cis	rs3733418	0.929	rs12507869	chr4:165895674	T/C	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-7.16	-0.33	3.71e-12	Obesity-related traits;
LUAD	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.41	0.3	3.85e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg11871910	chr12:69753446	YEATS4	0.48	7.41	0.34	6.77e-13	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs1784581	0.802	rs2156747	chr6:162430000	C/G	cg17173639	chr6:162384350	PARK2	-0.48	-8.92	-0.4	1.37e-17	Itch intensity from mosquito bite;
LUAD	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-10.17	-0.44	7.23e-22	Electrocardiographic conduction measures;
LUAD	cis	rs9487051	0.768	rs12176068	chr6:109521629	C/T	cg21918786	chr6:109611834	NA	-0.4	-7.18	-0.33	3.09e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504073	0.584	rs72641612	chr8:49947986	C/T	cg00325661	chr8:49890786	NA	0.48	10.44	0.45	7.2e-23	Blood metabolite ratios;
LUAD	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.83	-14.77	-0.58	4.24e-40	IgG glycosylation;
LUAD	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	6.97	0.32	1.21e-11	Menopause (age at onset);
LUAD	cis	rs12976411	0.867	rs8110851	chr19:32828455	C/G	cg18253629	chr19:32836317	ZNF507	0.66	7.25	0.33	2.02e-12	Coronary artery disease;
LUAD	cis	rs6541297	0.645	rs4846918	chr1:230300586	A/G	cg20703242	chr1:230279135	GALNT2	-0.53	-7.81	-0.35	4.56e-14	Coronary artery disease;
LUAD	trans	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.77	-0.35	6.09e-14	Depression;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg03749777	chr12:106533046	NUAK1	-0.49	-6.54	-0.3	1.76e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg14345882	chr6:26364793	BTN3A2	-0.69	-7.07	-0.33	6.47e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg10578777	chr12:7781093	NA	-0.54	-7.58	-0.35	2.14e-13	HDL cholesterol levels;
LUAD	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg09263875	chr16:632152	PIGQ	0.8	17.44	0.65	1.07e-51	Height;
LUAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27297192	chr10:134578999	INPP5A	0.37	6.73	0.31	5.52e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg04989706	chr14:50066350	PPIL5	-0.5	-7.23	-0.33	2.25e-12	Carotid intima media thickness;
LUAD	cis	rs28595532	0.545	rs72677057	chr4:119264162	A/T	cg02775129	chr4:119771670	NA	-0.57	-6.41	-0.3	3.78e-10	Cannabis dependence symptom count;
LUAD	trans	rs8073060	0.544	rs8072676	chr17:33999517	C/T	cg19694781	chr19:47549865	TMEM160	-1.21	-19.47	-0.69	9.47e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs3916	0.955	rs2066938	chr12:121160615	A/G	cg27246729	chr12:121163418	ACADS	0.44	7.12	0.33	4.52e-12	Urinary metabolites (H-NMR features);
LUAD	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.82	-0.36	4.31e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg12927641	chr6:109611667	NA	-0.53	-9.29	-0.41	8.04e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg21475434	chr5:93447410	FAM172A	0.8	8.82	0.39	3.07e-17	Diabetic retinopathy;
LUAD	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg01416388	chr22:39784598	NA	-0.51	-8.62	-0.39	1.32e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs1595825	0.891	rs78835808	chr2:198669110	G/A	cg00982548	chr2:198649783	BOLL	-0.67	-9.07	-0.4	4.43e-18	Ulcerative colitis;
LUAD	cis	rs4588572	0.643	rs7716529	chr5:77738637	A/T	cg11547950	chr5:77652471	NA	-0.77	-12.57	-0.52	5.32e-31	Triglycerides;
LUAD	cis	rs1832871	0.672	rs7750011	chr6:158746802	A/C	cg07165851	chr6:158734300	TULP4	0.73	11.15	0.48	1.7e-25	Height;
LUAD	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg06618935	chr21:46677482	NA	-0.51	-10.04	-0.44	2.09e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs877282	0.853	rs11593836	chr10:756715	G/A	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg13770153	chr20:60521292	NA	-0.59	-9.76	-0.43	1.94e-20	Body mass index;
LUAD	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg22676075	chr6:135203613	NA	0.5	8.7	0.39	7.52e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	7.15	0.33	3.73e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg14416269	chr4:6271139	WFS1	0.6	12.46	0.52	1.42e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg11317459	chr13:21872234	NA	-1.09	-14.87	-0.59	1.49e-40	White matter hyperintensity burden;
LUAD	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg08508325	chr11:3079039	CARS	-0.61	-13.17	-0.54	2.04e-33	Longevity;
LUAD	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg17724175	chr1:150552817	MCL1	-0.4	-9.07	-0.4	4.4e-18	Urate levels;
LUAD	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.39	-7.17	-0.33	3.47e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg12437481	chr16:420112	MRPL28	-0.47	-6.55	-0.3	1.71e-10	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.08e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs78761021	0.867	rs17681684	chr17:9792768	A/G	cg26853458	chr17:9805074	RCVRN	-0.34	-6.75	-0.31	4.87e-11	Type 2 diabetes;
LUAD	cis	rs7267979	0.866	rs6138609	chr20:25570985	T/A	cg08601574	chr20:25228251	PYGB	0.41	7.58	0.35	2.26e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	trans	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.47	0.34	4.76e-13	Resting heart rate;
LUAD	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg17200465	chr3:40428508	ENTPD3	0.28	7.15	0.33	3.84e-12	Renal cell carcinoma;
LUAD	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.72	-0.31	6e-11	Breast cancer;
LUAD	cis	rs9354308	0.933	rs2022856	chr6:66568235	G/T	cg07460842	chr6:66804631	NA	0.49	7.28	0.33	1.66e-12	Metabolite levels;
LUAD	cis	rs72928364	0.929	rs35999953	chr3:100620180	T/C	cg10123952	chr3:100791384	NA	0.59	6.95	0.32	1.4e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9826463	0.582	rs116196326	chr3:142059684	A/T	cg20824294	chr3:142316082	PLS1	0.43	7.29	0.33	1.54e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg15147215	chr3:52552868	STAB1	-0.4	-7.48	-0.34	4.38e-13	Electroencephalogram traits;
LUAD	cis	rs367615	0.918	rs17161889	chr5:108855251	A/G	cg17395555	chr5:108820864	NA	-0.54	-9.42	-0.42	2.86e-19	Colorectal cancer (SNP x SNP interaction);
LUAD	trans	rs12517041	1.000	rs1428619	chr5:23282426	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.47	-0.3	2.73e-10	Calcium levels;
LUAD	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg11502198	chr6:26597334	ABT1	0.68	11.86	0.5	3.38e-28	Intelligence (multi-trait analysis);
LUAD	trans	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg27411982	chr8:10470053	RP1L1	-0.36	-6.38	-0.3	4.72e-10	Mood instability;
LUAD	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg00857998	chr1:205179979	DSTYK	0.4	6.68	0.31	7.41e-11	Red blood cell count;
LUAD	cis	rs4702	0.611	rs2071382	chr15:91428197	T/C	cg05469396	chr15:91419421	FURIN	0.47	7.96	0.36	1.62e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg04455712	chr21:45112962	RRP1B	0.48	9.57	0.42	9.33e-20	Mean corpuscular volume;
LUAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg12432903	chr7:1882776	MAD1L1	-0.5	-8.39	-0.38	7.21e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs2455799	0.594	rs11928773	chr3:15925135	A/G	cg16303742	chr3:15540471	COLQ	-0.49	-8.86	-0.4	2.16e-17	Mean platelet volume;
LUAD	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.2	-0.37	2.8e-15	Breast cancer;
LUAD	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg22508957	chr16:3507546	NAT15	0.82	10.97	0.47	8.29e-25	Tuberculosis;
LUAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg24813613	chr7:1882135	MAD1L1	-0.4	-6.38	-0.3	4.68e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7119	0.667	rs1058129	chr15:77905661	A/G	cg27398640	chr15:77910606	LINGO1	0.43	8.24	0.37	2.23e-15	Type 2 diabetes;
LUAD	trans	rs9408928	0.778	rs9409230	chr9:123967760	A/T	cg26649251	chr19:44598564	ZNF224	0.66	6.47	0.3	2.78e-10	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg08888203	chr3:10149979	C3orf24	0.73	11.17	0.48	1.44e-25	Alzheimer's disease;
LUAD	cis	rs6684514	1.000	rs11264467	chr1:156273061	A/G	cg16558208	chr1:156270281	VHLL	-0.47	-8.8	-0.39	3.49e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg00666640	chr1:248458726	OR2T12	0.29	7.14	0.33	4.14e-12	Common traits (Other);
LUAD	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg00898013	chr13:113819073	PROZ	-0.64	-11.52	-0.49	6.71e-27	Platelet distribution width;
LUAD	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11890956	chr21:40555474	PSMG1	-0.56	-9.98	-0.44	3.38e-21	Menarche (age at onset);
LUAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.54	-9.36	-0.41	4.61e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9296092	0.560	rs7765263	chr6:33525559	A/G	cg13560919	chr6:33536144	NA	-0.9	-16.72	-0.63	1.49e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-6.68	-0.31	7.38e-11	Tonsillectomy;
LUAD	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg03929089	chr4:120376271	NA	-0.98	-20.38	-0.7	7.83e-65	Height;
LUAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08677398	chr8:58056175	NA	-0.48	-6.9	-0.32	1.89e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.44e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13732083	chr21:47605072	C21orf56	-0.62	-10.48	-0.45	5.51e-23	Testicular germ cell tumor;
LUAD	cis	rs3087591	1.000	rs984125	chr17:29547254	A/G	cg24425628	chr17:29625626	OMG;NF1	0.41	6.76	0.31	4.64e-11	Hip circumference;
LUAD	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.78	-0.35	5.7e-14	Blood metabolite levels;
LUAD	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.35	6.54	0.3	1.76e-10	Coronary artery disease;
LUAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg25811766	chr13:21894605	NA	0.62	10.09	0.44	1.31e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs3087591	0.922	rs2905806	chr17:29502507	A/G	cg24425628	chr17:29625626	OMG;NF1	0.42	6.81	0.31	3.31e-11	Hip circumference;
LUAD	cis	rs2637266	0.935	rs12414653	chr10:78394071	C/G	cg18941641	chr10:78392320	NA	0.35	7.28	0.33	1.68e-12	Pulmonary function;
LUAD	cis	rs908922	0.676	rs4112785	chr1:152533115	G/C	cg23254163	chr1:152506842	NA	0.25	6.76	0.31	4.47e-11	Hair morphology;
LUAD	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg05340658	chr4:99064831	C4orf37	0.44	6.75	0.31	4.95e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.24	-0.33	2.13e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg23109721	chr2:106886537	NA	-0.61	-9.9	-0.43	6.61e-21	Facial morphology (factor 23);
LUAD	cis	rs6499129	0.558	rs16957489	chr16:67651879	G/A	cg26727032	chr16:67993705	SLC12A4	-0.41	-6.59	-0.3	1.34e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4700695	1.000	rs12518359	chr5:65397909	T/C	cg21114390	chr5:65439923	SFRS12	-0.64	-8.86	-0.4	2.24e-17	Facial morphology (factor 19);
LUAD	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg05768032	chr16:30646687	NA	0.46	8.24	0.37	2.23e-15	Multiple myeloma;
LUAD	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg10802521	chr3:52805072	NEK4	-0.47	-6.76	-0.31	4.53e-11	Schizophrenia;
LUAD	trans	rs11039798	0.925	rs6485831	chr11:48455031	A/T	cg15704280	chr7:45808275	SEPT13	0.66	7.81	0.36	4.46e-14	Axial length;
LUAD	cis	rs909685	1.000	rs909685	chr22:39747671	T/A	cg24268161	chr22:39747459	SYNGR1	-0.43	-8.8	-0.39	3.51e-17	Rheumatoid arthritis;
LUAD	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg05865280	chr17:75406074	SEPT9	0.61	19.3	0.68	5.44e-60	Airflow obstruction;
LUAD	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.53	9.47	0.42	2.07e-19	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs3849570	0.925	rs6798680	chr3:81905441	C/A	cg07356753	chr3:81810745	GBE1	-0.61	-10.69	-0.46	9.12e-24	Waist circumference;Body mass index;
LUAD	cis	rs438034	1.000	rs448617	chr1:214831287	A/G	cg16144317	chr1:214725524	PTPN14	-0.35	-6.43	-0.3	3.41e-10	Response to antineoplastic agents;
LUAD	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg02269571	chr22:50332266	NA	-0.69	-9.94	-0.44	4.73e-21	Schizophrenia;
LUAD	cis	rs909002	0.800	rs3753613	chr1:32082000	C/T	cg13919466	chr1:32135498	COL16A1	0.34	7.96	0.36	1.61e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4589502	1.000	rs7170743	chr15:67126339	T/G	cg09911534	chr15:67153556	NA	-0.51	-6.38	-0.3	4.52e-10	Lung cancer (smoking interaction);
LUAD	trans	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg04565464	chr8:145669602	NFKBIL2	0.46	6.71	0.31	6.43e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9393692	0.599	rs9358920	chr6:26292029	C/T	cg00631329	chr6:26305371	NA	-0.54	-9.37	-0.41	4.36e-19	Educational attainment;
LUAD	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg07636037	chr3:49044803	WDR6	-0.5	-8.31	-0.37	1.28e-15	Menarche (age at onset);
LUAD	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg25804541	chr17:80189381	SLC16A3	0.31	6.88	0.32	2.16e-11	Life satisfaction;
LUAD	cis	rs1232027	0.656	rs1677690	chr5:79957099	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.02	-0.32	8.69e-12	Huntington's disease progression;
LUAD	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg17328964	chr8:145687451	CYHR1	0.69	12.62	0.52	3.28e-31	Age at first birth;
LUAD	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg26373071	chr5:1325741	CLPTM1L	0.33	6.61	0.31	1.15e-10	Lung cancer;
LUAD	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg17173187	chr15:85201210	NMB	0.51	8.68	0.39	8.86e-17	Schizophrenia;
LUAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg16414030	chr3:133502952	NA	0.62	12.05	0.51	5.98e-29	Iron status biomarkers;
LUAD	cis	rs713477	1.000	rs12893964	chr14:55912268	T/C	cg13175173	chr14:55914753	NA	-0.34	-7.09	-0.33	5.71e-12	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.41	-0.3	3.82e-10	Breast cancer;
LUAD	cis	rs4662945	0.525	rs28819474	chr2:130264623	T/C	cg05903289	chr2:130345205	NA	-0.31	-6.72	-0.31	5.93e-11	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.49	-7.95	-0.36	1.7e-14	Multiple sclerosis;
LUAD	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06544989	chr22:39130855	UNC84B	0.46	8.63	0.39	1.28e-16	Menopause (age at onset);
LUAD	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg15704280	chr7:45808275	SEPT13	-1.09	-25.52	-0.78	1.28e-87	Height;
LUAD	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg00310523	chr12:86230176	RASSF9	0.38	7.73	0.35	7.94e-14	Major depressive disorder;
LUAD	cis	rs10489202	1.000	rs7535138	chr1:167931462	T/G	cg24449463	chr1:168025552	DCAF6	-0.56	-7.25	-0.33	1.98e-12	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg22117172	chr7:91764530	CYP51A1	0.33	7.37	0.34	9.07e-13	Breast cancer;
LUAD	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.68	13.24	0.54	1.04e-33	Cognitive ability;
LUAD	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg01788221	chr16:89496183	ANKRD11	-0.36	-7.12	-0.33	4.53e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg15017067	chr4:17643749	FAM184B	0.33	6.49	0.3	2.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.41	7.14	0.33	4.04e-12	Body mass index (adult);
LUAD	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg11663144	chr21:46675770	NA	-0.62	-12.41	-0.52	2.26e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.25	6.4	0.3	4.25e-10	Cardiac Troponin-T levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19256675	chr7:74988891	PMS2L2;STAG3L1	-0.43	-7.04	-0.32	7.77e-12	Cancer;
LUAD	trans	rs10838798	0.563	rs2870080	chr11:48144224	G/A	cg21153622	chr11:89784906	NA	-0.35	-7.02	-0.32	8.66e-12	Height;
LUAD	cis	rs1003719	0.788	rs7277657	chr21:38469523	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.64	0.39	1.13e-16	Eye color traits;
LUAD	cis	rs9341808	0.754	rs3812126	chr6:80952701	A/G	cg08355045	chr6:80787529	NA	-0.59	-11.03	-0.47	4.75e-25	Sitting height ratio;
LUAD	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-6.39	-0.3	4.43e-10	Personality dimensions;
LUAD	trans	rs587242	1.000	rs12036050	chr1:96917491	T/C	cg10631902	chr5:14652156	NA	0.44	7.33	0.34	1.2e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs28493229	0.708	rs10407431	chr19:41160870	T/C	cg21869046	chr19:41225005	ITPKC	0.52	9.0	0.4	7.92e-18	Kawasaki disease;
LUAD	cis	rs727505	0.826	rs11532793	chr7:124747952	A/G	cg23710748	chr7:124431027	NA	-0.41	-8.43	-0.38	5.66e-16	Lewy body disease;
LUAD	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg02269571	chr22:50332266	NA	0.59	8.96	0.4	1.05e-17	Schizophrenia;
LUAD	cis	rs7567389	0.740	rs1604817	chr2:127999921	C/T	cg09760422	chr2:128146352	NA	-0.39	-6.41	-0.3	3.86e-10	Self-rated health;
LUAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.5e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2625529	0.618	rs6494992	chr15:72420750	G/C	cg16672083	chr15:72433130	SENP8	0.64	11.77	0.5	7.2e-28	Red blood cell count;
LUAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg18538332	chr22:24372958	LOC391322	-0.54	-9.0	-0.4	7.76e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg17346650	chr17:80929145	B3GNTL1	-0.39	-6.78	-0.31	4.16e-11	Glycated hemoglobin levels;
LUAD	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg27068330	chr11:65405492	SIPA1	-0.79	-12.89	-0.53	2.64e-32	Acne (severe);
LUAD	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.5	-9.27	-0.41	9.3e-19	Schizophrenia;
LUAD	cis	rs1018836	0.851	rs10808620	chr8:91622940	T/C	cg16814680	chr8:91681699	NA	-0.69	-11.84	-0.5	3.9e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg04842962	chr6:43655489	MRPS18A	1.05	26.56	0.79	3.65e-92	IgG glycosylation;
LUAD	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg24578937	chr1:2090814	PRKCZ	0.56	11.55	0.49	5.37e-27	Height;
LUAD	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg08916839	chr5:415575	AHRR	0.86	9.97	0.44	3.49e-21	Fat distribution (HIV);
LUAD	cis	rs6761276	0.899	rs12711750	chr2:113835380	C/A	cg09040174	chr2:113837401	NA	0.81	15.75	0.61	2.68e-44	Protein quantitative trait loci;
LUAD	cis	rs4766566	0.609	rs1344438	chr12:111735954	C/G	cg24530795	chr12:111807189	FAM109A	0.38	6.61	0.31	1.13e-10	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUAD	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg26384229	chr12:38710491	ALG10B	0.46	7.49	0.34	4.03e-13	Morning vs. evening chronotype;
LUAD	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg23758822	chr17:41437982	NA	1.01	20.86	0.71	5.96e-67	Menopause (age at onset);
LUAD	cis	rs11671005	0.735	rs3764529	chr19:58945089	A/G	cg13877915	chr19:58951672	ZNF132	0.59	7.77	0.35	6.18e-14	Mean platelet volume;
LUAD	cis	rs9462027	0.628	rs9296127	chr6:34719628	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.72	-0.39	6.25e-17	Systemic lupus erythematosus;
LUAD	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg25324976	chr17:61989376	CSHL1	0.38	7.35	0.34	1.06e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs490234	1.000	rs490234	chr9:128303734	T/C	cg14078157	chr9:128172775	NA	0.38	7.09	0.33	5.68e-12	Mean arterial pressure;
LUAD	cis	rs12545109	0.700	rs2670045	chr8:57393695	A/G	cg21220214	chr8:57350948	NA	-0.61	-8.89	-0.4	1.79e-17	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg24818145	chr4:99064322	C4orf37	0.47	7.88	0.36	2.89e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.68	-0.35	1.14e-13	Lung cancer;
LUAD	cis	rs7731657	0.537	rs10073197	chr5:130373090	C/T	cg08523029	chr5:130500466	HINT1	-0.61	-7.85	-0.36	3.42e-14	Fasting plasma glucose;
LUAD	cis	rs7107174	0.901	rs7110387	chr11:78117875	A/G	cg19901956	chr11:77921274	USP35	-0.5	-6.36	-0.3	5.1e-10	Testicular germ cell tumor;
LUAD	cis	rs6087990	0.584	rs6058897	chr20:31398105	G/T	cg13636640	chr20:31349939	DNMT3B	-0.66	-11.4	-0.48	1.89e-26	Ulcerative colitis;
LUAD	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg22618164	chr12:122356400	WDR66	0.65	11.2	0.48	1.14e-25	Mean corpuscular volume;
LUAD	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg03929089	chr4:120376271	NA	-0.97	-19.76	-0.69	5e-62	Height;
LUAD	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg00383909	chr3:49044727	WDR6	0.91	9.99	0.44	3.19e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg17372223	chr3:52568218	NT5DC2	0.4	7.46	0.34	4.95e-13	Electroencephalogram traits;
LUAD	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg27446573	chr6:127587934	RNF146	0.43	6.47	0.3	2.7e-10	Breast cancer;
LUAD	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg22532475	chr10:104410764	TRIM8	-0.49	-9.68	-0.43	3.71e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08677398	chr8:58056175	NA	0.46	6.54	0.3	1.76e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg26384229	chr12:38710491	ALG10B	0.47	7.49	0.34	4.18e-13	Bladder cancer;
LUAD	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg04036182	chr15:45458818	NA	-0.39	-6.91	-0.32	1.8e-11	Glomerular filtration rate;
LUAD	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.74	0.35	7.5e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2455601	0.608	rs10840137	chr11:8890079	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.43	-8.08	-0.37	7.07e-15	Schizophrenia;
LUAD	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg23029597	chr12:123009494	RSRC2	-0.57	-9.23	-0.41	1.33e-18	Body mass index;
LUAD	cis	rs3008870	1.000	rs3008855	chr1:67386204	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.63	-9.28	-0.41	8.74e-19	Lymphocyte percentage of white cells;
LUAD	cis	rs748404	0.697	rs505249	chr15:43559960	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.58	0.35	2.21e-13	Lung cancer;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg12299026	chr11:67195829	RPS6KB2	0.41	6.51	0.3	2.18e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg20135002	chr11:47629003	NA	-0.42	-7.35	-0.34	1.02e-12	Subjective well-being;
LUAD	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	7.89	0.36	2.58e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg16797656	chr11:68205561	LRP5	0.45	8.41	0.38	6.15e-16	Total body bone mineral density;
LUAD	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg05991184	chr2:219186017	PNKD	-0.36	-6.98	-0.32	1.12e-11	Colorectal cancer;
LUAD	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.41	-6.94	-0.32	1.44e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs12537733	chr7:106965447	A/T	cg23024343	chr7:107201750	COG5	0.45	6.5	0.3	2.23e-10	Coronary artery disease;
LUAD	cis	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.91	-0.36	2.26e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg01689657	chr7:91764605	CYP51A1	0.34	8.51	0.38	2.99e-16	Breast cancer;
LUAD	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg09835421	chr16:68378352	PRMT7	-0.73	-8.28	-0.37	1.58e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg17724175	chr1:150552817	MCL1	0.34	7.87	0.36	3.01e-14	Melanoma;
LUAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg15242686	chr22:24348715	GSTTP1	0.41	7.19	0.33	2.98e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03578541	chr16:72128063	TXNL4B;DHX38	0.44	7.04	0.32	7.65e-12	Gut microbiome composition (summer);
LUAD	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg22117172	chr7:91764530	CYP51A1	-0.35	-7.77	-0.35	6.08e-14	Breast cancer;
LUAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.56	7.82	0.36	4.38e-14	Renal function-related traits (BUN);
LUAD	cis	rs8099014	1.000	rs1806761	chr18:56132499	A/C	cg12907477	chr18:56117327	MIR122	0.4	6.68	0.31	7.48e-11	Platelet count;
LUAD	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg20556744	chr2:9614537	IAH1	0.66	6.56	0.3	1.55e-10	Opioid sensitivity;
LUAD	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.25	17.21	0.64	1.03e-50	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg24596788	chr1:163392923	NA	-0.34	-7.14	-0.33	4.08e-12	Motion sickness;
LUAD	cis	rs931127	0.505	rs2306362	chr11:65405510	G/T	cg05805236	chr11:65401703	PCNXL3	-0.6	-9.8	-0.43	1.45e-20	Systemic lupus erythematosus;
LUAD	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21582582	chr3:182698605	DCUN1D1	0.6	9.73	0.43	2.54e-20	Resting heart rate;
LUAD	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg21028142	chr17:79581711	NPLOC4	0.42	8.83	0.39	2.91e-17	Eye color traits;
LUAD	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg19717773	chr7:2847554	GNA12	-0.49	-8.32	-0.38	1.18e-15	Height;
LUAD	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg21856205	chr7:94953877	PON1	-0.53	-7.34	-0.34	1.09e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs57920188	0.537	rs4440829	chr1:4080780	A/G	cg20703997	chr1:4087676	NA	-0.41	-7.28	-0.33	1.67e-12	Interleukin-17 levels;
LUAD	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.39	6.64	0.31	9.52e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs9837602	1.000	rs793472	chr3:99546110	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.41	0.34	7.11e-13	Breast cancer;
LUAD	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg10645314	chr2:3704589	ALLC	-0.6	-9.54	-0.42	1.14e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs2282300	0.956	rs1717779	chr11:30376698	A/T	cg25418670	chr11:30344373	C11orf46	-0.47	-6.49	-0.3	2.36e-10	Morning vs. evening chronotype;
LUAD	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.58	0.3	1.35e-10	Cardiac Troponin-T levels;
LUAD	trans	rs62103177	0.673	rs55852342	chr18:77594109	G/C	cg05926928	chr17:57297772	GDPD1	0.83	11.55	0.49	5.3e-27	Opioid sensitivity;
LUAD	cis	rs13064411	0.696	rs13066742	chr3:113208423	T/C	cg10517650	chr3:113235015	CCDC52	-0.55	-9.4	-0.42	3.38e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg15448220	chr1:150897856	SETDB1	0.47	8.12	0.37	5.15e-15	Tonsillectomy;
LUAD	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg12193833	chr17:30244370	NA	-0.5	-6.57	-0.3	1.51e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg13560548	chr3:10150139	C3orf24	0.42	6.99	0.32	1.09e-11	Alzheimer's disease;
LUAD	cis	rs9287719	0.556	rs10168351	chr2:10736810	T/C	cg03983476	chr2:10830698	NOL10	-0.39	-6.64	-0.31	9.95e-11	Prostate cancer;
LUAD	cis	rs11249608	0.510	rs6861539	chr5:178452307	A/G	cg01312482	chr5:178451176	ZNF879	-0.43	-6.6	-0.31	1.21e-10	Pubertal anthropometrics;
LUAD	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg08798685	chr6:27730294	NA	0.51	7.27	0.33	1.71e-12	Depression;
LUAD	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg23985595	chr17:80112537	CCDC57	0.42	7.46	0.34	4.93e-13	Life satisfaction;
LUAD	cis	rs9905704	0.718	rs4793953	chr17:56613104	C/G	cg19466818	chr17:56409534	MIR142	0.34	6.56	0.3	1.56e-10	Testicular germ cell tumor;
LUAD	cis	rs12545109	0.671	rs35500854	chr8:57424303	G/A	cg09654669	chr8:57350985	NA	-0.67	-9.55	-0.42	1.06e-19	Obesity-related traits;
LUAD	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg12292205	chr6:26970375	C6orf41	0.45	7.85	0.36	3.55e-14	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs4954585	0.708	rs13034241	chr2:137021263	G/A	cg05194412	chr2:137003533	NA	0.62	11.2	0.48	1.16e-25	Colorectal cancer;
LUAD	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg12311346	chr5:56204834	C5orf35	1.07	15.61	0.6	1.1e-43	Initial pursuit acceleration;
LUAD	cis	rs7561273	0.609	rs6545285	chr2:24340029	T/C	cg20701182	chr2:24300061	SF3B14	0.47	7.7	0.35	9.93e-14	Quantitative traits;
LUAD	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg08999081	chr20:33150536	PIGU	-0.62	-13.96	-0.56	1.08e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs2979489	0.945	rs34960391	chr8:30332723	G/A	cg26383811	chr8:30366931	RBPMS	-0.67	-10.35	-0.45	1.53e-22	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs6840360	0.593	rs2089811	chr4:152685171	C/T	cg22705602	chr4:152727874	NA	0.46	8.86	0.4	2.19e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs629535	0.508	rs56207225	chr8:70146628	C/A	cg21567404	chr3:27674614	NA	-1.01	-16.38	-0.62	4.8e-47	Dupuytren's disease;
LUAD	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23583168	chr7:148888333	NA	-0.94	-19.29	-0.68	5.95e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg24562669	chr7:97807699	LMTK2	0.33	7.9	0.36	2.44e-14	Breast cancer;
LUAD	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.62	0.39	1.32e-16	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs494562	0.892	rs638745	chr6:86115587	C/G	cg13315970	chr6:86159197	NT5E	0.71	8.06	0.36	8.06e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs10193935	0.901	rs10200353	chr2:42509554	A/G	cg27598129	chr2:42591480	NA	-0.76	-9.24	-0.41	1.23e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg06532163	chr17:45867833	NA	0.47	8.41	0.38	6.49e-16	IgG glycosylation;
LUAD	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg10518543	chr12:38710700	ALG10B	0.52	8.54	0.38	2.48e-16	Morning vs. evening chronotype;
LUAD	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.54	7.52	0.34	3.21e-13	Platelet count;
LUAD	cis	rs1003719	0.699	rs1015549	chr21:38448880	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.54	0.38	2.42e-16	Eye color traits;
LUAD	cis	rs62400317	0.762	rs12202704	chr6:44819614	G/T	cg18551225	chr6:44695536	NA	-0.6	-8.97	-0.4	9.39e-18	Total body bone mineral density;
LUAD	cis	rs6546550	0.713	rs6718517	chr2:70018462	T/C	cg02498382	chr2:70120550	SNRNP27	-0.51	-8.83	-0.39	2.87e-17	Prevalent atrial fibrillation;
LUAD	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg21918786	chr6:109611834	NA	-0.58	-10.69	-0.46	9.02e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg07606381	chr6:8435919	SLC35B3	0.41	6.92	0.32	1.64e-11	Motion sickness;
LUAD	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg02038168	chr22:39784481	NA	-0.59	-10.6	-0.46	1.98e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	7.46	0.34	4.87e-13	Alzheimer's disease;
LUAD	cis	rs62238980	0.614	rs78940018	chr22:32419975	C/T	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-7.08	-0.33	6.23e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg21856205	chr7:94953877	PON1	-0.54	-7.4	-0.34	7.33e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs13064411	0.696	rs3732803	chr3:113211957	T/C	cg10517650	chr3:113235015	CCDC52	-0.55	-9.4	-0.42	3.38e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg18404041	chr3:52824283	ITIH1	-0.42	-7.63	-0.35	1.56e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6424115	0.830	rs12744386	chr1:24168019	C/T	cg10978503	chr1:24200527	CNR2	-0.58	-12.04	-0.51	6.79e-29	Immature fraction of reticulocytes;
LUAD	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg00933542	chr6:150070202	PCMT1	0.45	9.67	0.43	3.95e-20	Lung cancer;
LUAD	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1298908	0.639	rs2236568	chr10:82035923	C/A	cg01528321	chr10:82214614	TSPAN14	0.42	6.56	0.3	1.58e-10	Diabetic kidney disease;
LUAD	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg20991723	chr1:152506922	NA	0.34	6.66	0.31	8.76e-11	Hair morphology;
LUAD	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg18811423	chr2:55921094	PNPT1	-0.4	-6.55	-0.3	1.65e-10	Metabolic syndrome;
LUAD	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg23533926	chr12:111358616	MYL2	0.4	7.02	0.32	8.92e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2625529	0.824	rs4777475	chr15:72218206	C/T	cg16672083	chr15:72433130	SENP8	-0.75	-12.62	-0.52	3.21e-31	Red blood cell count;
LUAD	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg02951883	chr7:2050386	MAD1L1	0.79	13.63	0.55	2.51e-35	Bipolar disorder and schizophrenia;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg17103929	chr8:101225361	SPAG1	0.41	6.4	0.3	4.13e-10	Diastolic blood pressure;
LUAD	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg04154034	chr17:28927549	LRRC37B2	0.59	7.19	0.33	2.93e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.87	-0.36	3.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg15485101	chr11:133734466	NA	0.39	8.4	0.38	6.65e-16	Childhood ear infection;
LUAD	cis	rs8064454	0.870	rs11263763	chr17:36103565	C/T	cg04198914	chr17:36106025	HNF1B	-0.35	-7.0	-0.32	9.93e-12	Prostate cancer;
LUAD	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg15181151	chr6:150070149	PCMT1	0.42	8.63	0.39	1.27e-16	Lung cancer;
LUAD	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg26875233	chr11:93583750	C11orf90	-0.39	-8.69	-0.39	7.9e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg00129232	chr17:37814104	STARD3	-0.44	-7.62	-0.35	1.69e-13	Asthma;
LUAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00166722	chr3:10149974	C3orf24	0.63	10.46	0.45	6.19e-23	Alzheimer's disease;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg13429675	chr15:75628126	COMMD4	0.39	6.86	0.32	2.42e-11	Bipolar disorder;
LUAD	cis	rs7267979	1.000	rs13038834	chr20:25441433	C/T	cg08601574	chr20:25228251	PYGB	0.43	7.92	0.36	2.08e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs12802200	0.535	rs35391985	chr11:570280	T/C	cg16486109	chr11:613632	IRF7	0.53	8.78	0.39	3.97e-17	Systemic lupus erythematosus;
LUAD	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg23982607	chr1:1823379	GNB1	0.89	18.88	0.68	3.97e-58	Body mass index;
LUAD	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg14196790	chr5:131705035	SLC22A5	0.49	8.85	0.4	2.48e-17	Blood metabolite levels;
LUAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02353165	chr6:42928485	GNMT	0.4	7.2	0.33	2.73e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg06074448	chr4:187884817	NA	-0.37	-7.28	-0.33	1.59e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg21856205	chr7:94953877	PON1	-0.57	-7.77	-0.35	5.82e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs490234	0.812	rs17259739	chr9:128456639	C/T	cg14078157	chr9:128172775	NA	0.45	8.04	0.36	9.38e-15	Mean arterial pressure;
LUAD	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.61	-0.55	2.96e-35	Alcohol dependence;
LUAD	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg22166914	chr1:53195759	ZYG11B	-0.51	-8.86	-0.4	2.28e-17	Monocyte count;
LUAD	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs76419734	0.558	rs17035939	chr4:106526544	T/C	cg05309399	chr4:106552544	FLJ20184	-0.54	-6.72	-0.31	6.04e-11	Post bronchodilator FEV1;
LUAD	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	7.46	0.34	5.09e-13	Platelet count;
LUAD	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg13319975	chr6:146136371	FBXO30	-0.62	-10.83	-0.47	2.7e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs73206853	0.841	rs17792048	chr12:110866543	C/A	cg12870014	chr12:110450643	ANKRD13A	0.61	6.58	0.3	1.35e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg21016266	chr12:122356598	WDR66	-0.66	-11.87	-0.5	2.95e-28	Mean corpuscular volume;
LUAD	cis	rs4730250	0.707	rs3729876	chr7:106786952	T/C	cg02696742	chr7:106810147	HBP1	0.82	10.9	0.47	1.49e-24	Osteoarthritis;
LUAD	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg18230493	chr5:56204884	C5orf35	-0.86	-12.63	-0.52	3.11e-31	Initial pursuit acceleration;
LUAD	trans	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg01620082	chr3:125678407	NA	-0.59	-7.46	-0.34	4.81e-13	Lung cancer in ever smokers;
LUAD	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.43	-0.45	7.96e-23	Monocyte percentage of white cells;
LUAD	cis	rs8192282	0.691	rs4845635	chr1:154474131	C/G	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.36	-0.34	9.94e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs4072705	1.000	rs4836981	chr9:127340145	T/C	cg13476313	chr9:127244764	NR5A1	0.3	7.29	0.33	1.5e-12	Menarche (age at onset);
LUAD	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg14458575	chr2:238380390	NA	0.66	12.51	0.52	8.94e-31	Prostate cancer;
LUAD	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg08470875	chr2:26401718	FAM59B	0.79	11.21	0.48	1.02e-25	Gut microbiome composition (summer);
LUAD	cis	rs17169635	0.601	rs2347900	chr7:134546405	G/T	cg07876788	chr7:134849633	TMEM140	-0.4	-6.87	-0.32	2.27e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg23950597	chr19:37808831	NA	-0.64	-7.68	-0.35	1.11e-13	Coronary artery calcification;
LUAD	cis	rs8192282	0.698	rs6427729	chr1:154518874	G/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.47	-7.14	-0.33	4.04e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg22508957	chr16:3507546	NAT15	0.48	7.75	0.35	6.93e-14	Body mass index (adult);
LUAD	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg15704280	chr7:45808275	SEPT13	-0.81	-13.8	-0.56	4.88e-36	Coronary artery disease;
LUAD	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg05805236	chr11:65401703	PCNXL3	0.4	6.67	0.31	7.88e-11	Acne (severe);
LUAD	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg07741184	chr6:167504864	NA	0.42	9.46	0.42	2.11e-19	Crohn's disease;
LUAD	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22590775	chr19:49891494	CCDC155	0.72	11.7	0.49	1.4e-27	Multiple sclerosis;
LUAD	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.53	-0.3	1.87e-10	Total body bone mineral density;
LUAD	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg05991184	chr2:219186017	PNKD	-0.39	-7.53	-0.34	2.99e-13	Colorectal cancer;
LUAD	trans	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg24644049	chr4:85504048	CDS1	0.84	6.89	0.32	2.09e-11	Skin colour saturation;
LUAD	cis	rs250677	0.522	rs4431331	chr5:148353574	A/C	cg12140854	chr5:148520817	ABLIM3	-0.53	-8.28	-0.37	1.64e-15	Breast cancer;
LUAD	cis	rs757110	0.900	rs2074314	chr11:17411821	C/T	cg04705435	chr11:17411270	KCNJ11	0.47	7.64	0.35	1.49e-13	Type 2 diabetes;
LUAD	cis	rs4774899	0.966	rs11853331	chr15:57431471	C/T	cg14026238	chr15:57616123	NA	0.37	6.98	0.32	1.15e-11	Urinary tract infection frequency;
LUAD	cis	rs13394619	0.533	rs12615856	chr2:11746177	C/T	cg07314298	chr2:11723111	GREB1	0.43	7.83	0.36	3.92e-14	Endometriosis;
LUAD	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg20701182	chr2:24300061	SF3B14	0.64	7.5	0.34	3.79e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.98	-0.32	1.13e-11	Breast cancer;
LUAD	cis	rs4006360	0.545	rs365738	chr17:39279082	C/T	cg12981595	chr17:39254427	KRTAP4-8	0.32	6.43	0.3	3.52e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg22676075	chr6:135203613	NA	0.39	6.99	0.32	1.05e-11	Red blood cell count;
LUAD	trans	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg26043149	chr18:55253948	FECH	0.51	8.31	0.37	1.36e-15	Bone mineral density;
LUAD	cis	rs807669	0.742	rs1206544	chr22:19215039	C/T	cg24911827	chr22:19170109	CLTCL1	0.31	6.52	0.3	2e-10	Metabolite levels;
LUAD	cis	rs55728055	0.661	rs7286496	chr22:31983760	G/A	cg01338084	chr22:32026380	PISD	0.89	6.89	0.32	1.98e-11	Age-related hearing impairment;
LUAD	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	-0.37	-7.41	-0.34	7.1e-13	Menopause (age at onset);
LUAD	cis	rs3820068	0.705	rs72643683	chr1:15824905	C/A	cg24675056	chr1:15929824	NA	0.41	6.49	0.3	2.45e-10	Systolic blood pressure;
LUAD	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.45	-7.35	-0.34	1.04e-12	Body mass index;
LUAD	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg09826364	chr7:158789723	NA	-0.36	-6.44	-0.3	3.34e-10	Facial morphology (factor 20);
LUAD	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	7.58	0.35	2.18e-13	Neuroticism;
LUAD	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg05340658	chr4:99064831	C4orf37	0.54	9.24	0.41	1.2e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg07936489	chr17:37558343	FBXL20	0.44	6.94	0.32	1.46e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7107174	1.000	rs2510035	chr11:77953175	A/C	cg19901956	chr11:77921274	USP35	-0.55	-6.94	-0.32	1.52e-11	Testicular germ cell tumor;
LUAD	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg02683114	chr2:24398427	C2orf84	-0.52	-7.75	-0.35	6.95e-14	Asthma;
LUAD	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27286337	chr10:134555280	INPP5A	0.7	9.29	0.41	8.05e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg23029597	chr12:123009494	RSRC2	-0.56	-8.51	-0.38	3.07e-16	Body mass index;
LUAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.77	-0.31	4.31e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg06558623	chr16:89946397	TCF25	1.15	9.93	0.43	4.92e-21	Skin colour saturation;
LUAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.83	0.43	1.14e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg04024692	chr11:16760046	C11orf58	-0.47	-6.51	-0.3	2.1e-10	Testicular germ cell tumor;
LUAD	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.6	11.31	0.48	4.33e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg18490616	chr2:88469792	THNSL2	0.8	8.39	0.38	7.12e-16	Plasma clusterin levels;
LUAD	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.4e-12	Lung cancer;
LUAD	cis	rs10992471	0.603	rs11794346	chr9:95247288	C/T	cg14631576	chr9:95140430	CENPP	-0.56	-11.54	-0.49	5.93e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7301016	0.947	rs11174517	chr12:62899757	A/G	cg11441379	chr12:63026424	NA	-0.54	-6.44	-0.3	3.29e-10	IgG glycosylation;
LUAD	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg06547715	chr2:218990976	CXCR2	0.27	6.43	0.3	3.5e-10	Colorectal cancer;
LUAD	cis	rs4713675	0.584	rs6938056	chr6:33669577	C/T	cg13859433	chr6:33739653	LEMD2	-0.31	-7.24	-0.33	2.1e-12	Plateletcrit;
LUAD	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg20556744	chr2:9614537	IAH1	0.66	6.64	0.31	9.47e-11	Opioid sensitivity;
LUAD	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg06263672	chr7:65235340	NA	0.51	6.76	0.31	4.49e-11	Aortic root size;
LUAD	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg11766577	chr21:47581405	C21orf56	-0.46	-7.87	-0.36	2.98e-14	Testicular germ cell tumor;
LUAD	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs741677	0.927	rs2586117	chr17:483887	G/A	cg06217071	chr17:408420	NA	0.33	6.49	0.3	2.46e-10	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg19678392	chr7:94953810	PON1	-0.6	-7.94	-0.36	1.81e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg09796270	chr17:17721594	SREBF1	0.38	7.51	0.34	3.43e-13	Total body bone mineral density;
LUAD	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg24768116	chr2:27665128	KRTCAP3	0.27	6.58	0.3	1.41e-10	Oral cavity cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16189954	chr22:29138267	HSCB;CHEK2	-0.44	-6.8	-0.31	3.48e-11	Height;
LUAD	cis	rs708547	0.874	rs1713984	chr4:57886493	C/T	cg00922110	chr4:57842668	C4orf14	-0.41	-6.56	-0.3	1.55e-10	Response to bleomycin (chromatid breaks);
LUAD	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg23985595	chr17:80112537	CCDC57	-0.53	-9.51	-0.42	1.43e-19	Life satisfaction;
LUAD	cis	rs8018808	1.000	rs176767	chr14:77865614	A/G	cg20045696	chr14:77926864	AHSA1	0.37	6.56	0.3	1.61e-10	Myeloid white cell count;
LUAD	cis	rs2046867	0.862	rs2322612	chr3:72830058	A/G	cg25664220	chr3:72788482	NA	-0.68	-12.25	-0.51	9.99e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg26408565	chr15:76604113	ETFA	-0.43	-6.94	-0.32	1.5e-11	Blood metabolite levels;
LUAD	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg25358565	chr5:93447407	FAM172A	-0.47	-6.37	-0.3	5.06e-10	Diabetic retinopathy;
LUAD	cis	rs2882667	0.931	rs7706391	chr5:138349164	G/A	cg04439458	chr5:138467593	SIL1	-0.41	-7.46	-0.34	4.89e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg17063962	chr7:91808500	NA	0.68	12.31	0.51	5.78e-30	Breast cancer;
LUAD	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15541040	chr2:3486749	NA	-0.42	-7.36	-0.34	9.46e-13	Neurofibrillary tangles;
LUAD	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg01657329	chr11:68192670	LRP5	0.41	6.48	0.3	2.63e-10	Total body bone mineral density;
LUAD	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg25067162	chr17:41277974	BRCA1;NBR2	-0.33	-6.73	-0.31	5.59e-11	Menopause (age at onset);
LUAD	cis	rs1371614	0.566	rs11695406	chr2:27178129	A/G	cg00617064	chr2:27272375	NA	0.37	7.17	0.33	3.31e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg17644776	chr2:200775616	C2orf69	0.53	7.73	0.35	7.92e-14	Schizophrenia;
LUAD	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg22442454	chr1:209979470	IRF6	0.57	6.37	0.3	5.03e-10	Coronary artery disease;
LUAD	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg06484146	chr7:12443880	VWDE	-0.58	-7.48	-0.34	4.3e-13	Coronary artery disease;
LUAD	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg16205897	chr5:131564050	P4HA2	-0.43	-9.94	-0.44	4.75e-21	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23162967	chr3:105587981	CBLB	-0.52	-6.36	-0.3	5.38e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08280861	chr8:58055591	NA	0.67	8.72	0.39	6.27e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs7200543	1.000	rs16966947	chr16:15141045	T/C	cg24683922	chr1:11983373	KIAA2013	-0.44	-7.25	-0.33	2e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs314370	1.000	rs10278546	chr7:100516003	G/T	cg10426581	chr7:100472382	SRRT	-0.58	-8.08	-0.37	6.7e-15	Resting heart rate;
LUAD	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg25036284	chr2:26402008	FAM59B	0.57	8.28	0.37	1.61e-15	Gut microbiome composition (summer);
LUAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06873352	chr17:61820015	STRADA	0.82	18.12	0.66	1e-54	Prudent dietary pattern;
LUAD	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg26677194	chr12:130822605	PIWIL1	-0.61	-9.77	-0.43	1.78e-20	Menopause (age at onset);
LUAD	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg09359103	chr1:154839909	KCNN3	-0.72	-14.41	-0.57	1.37e-38	Prostate cancer;
LUAD	cis	rs4660306	0.961	rs7546268	chr1:45965340	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-8.04	-0.36	8.88e-15	Homocysteine levels;
LUAD	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg21399703	chr1:247681439	NA	0.43	7.77	0.35	5.82e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2030114	0.583	rs7195329	chr16:51590733	G/A	cg03758633	chr16:51611768	NA	0.48	9.78	0.43	1.62e-20	Blood pressure measurement (high sodium and potassium intervention);
LUAD	cis	rs9796	0.621	rs11858678	chr15:41467932	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.61	-0.39	1.51e-16	Menopause (age at onset);
LUAD	cis	rs2692947	0.832	rs4907212	chr2:96410048	T/A	cg23100626	chr2:96804247	ASTL	0.31	7.72	0.35	8.45e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg24846343	chr22:24311635	DDTL	-0.78	-17.61	-0.65	1.75e-52	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7630877	0.719	rs1524514	chr3:179673066	T/C	cg18765712	chr3:179670323	PEX5L	0.57	9.56	0.42	9.83e-20	Type 2 diabetes;
LUAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-7.15	-0.33	3.91e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg27541892	chr1:1571801	CDK11B	-0.59	-10.45	-0.45	6.58e-23	Body mass index;
LUAD	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg08508325	chr11:3079039	CARS	-0.62	-13.29	-0.54	6.53e-34	Longevity;
LUAD	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.51	-0.42	1.51e-19	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs10411161	0.810	rs76098421	chr19:52404645	T/C	cg22319618	chr22:45562946	NUP50	-0.66	-7.46	-0.34	4.86e-13	Breast cancer;
LUAD	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg21681030	chr2:46777652	RHOQ	0.39	7.12	0.33	4.75e-12	Height;
LUAD	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg00071950	chr4:10020882	SLC2A9	0.72	14.06	0.56	4.28e-37	Bone mineral density;
LUAD	cis	rs9473147	0.516	rs2151975	chr6:47515663	T/C	cg02130027	chr6:47444894	CD2AP	0.36	6.93	0.32	1.54e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs67311347	1.000	rs67311347	chr3:40533243	G/A	cg10755058	chr3:40428713	ENTPD3	0.4	7.35	0.34	1.03e-12	Renal cell carcinoma;
LUAD	cis	rs796364	0.616	rs7574313	chr2:200681040	C/G	cg23649088	chr2:200775458	C2orf69	0.52	6.5	0.3	2.33e-10	Schizophrenia;
LUAD	cis	rs2236521	0.617	rs2236520	chr20:60892172	T/C	cg09594475	chr20:60884601	LAMA5	0.42	6.59	0.31	1.3100000000000001e-10	Pelvic organ prolapse;
LUAD	cis	rs57590327	0.503	rs6802480	chr3:81906671	G/A	cg07356753	chr3:81810745	GBE1	-0.63	-9.93	-0.43	4.95e-21	Extraversion;
LUAD	cis	rs7107174	1.000	rs2511190	chr11:77988310	T/C	cg19901956	chr11:77921274	USP35	-0.51	-6.48	-0.3	2.58e-10	Testicular germ cell tumor;
LUAD	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg16325326	chr1:53192061	ZYG11B	0.69	13.25	0.54	9.26e-34	Monocyte count;
LUAD	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg03806693	chr22:41940476	POLR3H	-0.8	-11.11	-0.48	2.4e-25	Vitiligo;
LUAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.66	12.13	0.51	2.99e-29	Lymphocyte counts;
LUAD	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg09835421	chr16:68378352	PRMT7	-0.71	-8.19	-0.37	3.02e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7512552	0.839	rs1260421	chr1:150357780	G/A	cg15654264	chr1:150340011	RPRD2	0.61	11.64	0.49	2.4e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg20503657	chr10:835505	NA	1.05	16.02	0.61	1.75e-45	Eosinophil percentage of granulocytes;
LUAD	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.21e-19	Life satisfaction;
LUAD	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.4	-0.38	6.71e-16	Bipolar disorder;
LUAD	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg14196790	chr5:131705035	SLC22A5	0.38	6.85	0.32	2.69e-11	Breast cancer;
LUAD	cis	rs68170813	0.559	rs4730239	chr7:107056960	A/T	cg23024343	chr7:107201750	COG5	0.52	7.19	0.33	2.96e-12	Coronary artery disease;
LUAD	trans	rs587242	1.000	rs1830868	chr1:96895906	G/A	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg13560548	chr3:10150139	C3orf24	0.42	6.82	0.31	3.19e-11	Alzheimer's disease;
LUAD	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.78	-0.31	4.01e-11	Post bronchodilator FEV1;
LUAD	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg26384229	chr12:38710491	ALG10B	0.46	7.37	0.34	8.92e-13	Bladder cancer;
LUAD	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg01579765	chr21:45077557	HSF2BP	-0.56	-12.61	-0.52	3.65e-31	Mean corpuscular volume;
LUAD	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg18252515	chr7:66147081	NA	-0.62	-6.91	-0.32	1.84e-11	Diabetic kidney disease;
LUAD	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg17063962	chr7:91808500	NA	0.62	10.3	0.45	2.34e-22	Breast cancer;
LUAD	cis	rs8067545	0.750	rs36077949	chr17:19985782	C/T	cg04132472	chr17:19861366	AKAP10	0.28	6.62	0.31	1.1e-10	Schizophrenia;
LUAD	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg13813247	chr22:41461852	NA	-0.47	-7.48	-0.34	4.38e-13	Neuroticism;
LUAD	cis	rs12541635	0.677	rs11781234	chr8:107012342	G/T	cg10147462	chr8:107024639	NA	0.56	10.33	0.45	1.84e-22	Age of smoking initiation;
LUAD	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg21918786	chr6:109611834	NA	-0.6	-11.33	-0.48	3.69e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs7524258	0.868	rs4908448	chr1:7269283	A/G	cg07173049	chr1:7289937	CAMTA1	-0.36	-6.75	-0.31	4.92e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg11965913	chr1:205819406	PM20D1	0.82	17.16	0.64	1.79e-50	Menarche (age at onset);
LUAD	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg08999081	chr20:33150536	PIGU	0.61	13.71	0.55	1.16e-35	Glomerular filtration rate (creatinine);
LUAD	cis	rs1595825	0.735	rs16827465	chr2:198945680	G/T	cg00361562	chr2:198649771	BOLL	-0.47	-6.46	-0.3	2.93e-10	Ulcerative colitis;
LUAD	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg04414720	chr1:150670196	GOLPH3L	0.72	12.76	0.53	8.99e-32	Melanoma;
LUAD	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg15691649	chr6:25882328	NA	0.46	7.41	0.34	6.98e-13	Blood metabolite levels;
LUAD	trans	rs11039798	1.000	rs7125559	chr11:48984207	C/G	cg15704280	chr7:45808275	SEPT13	0.66	7.61	0.35	1.84e-13	Axial length;
LUAD	cis	rs2692947	0.550	rs4613327	chr2:96583823	G/A	cg23100626	chr2:96804247	ASTL	0.32	7.8	0.35	4.76e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7809950	1.000	rs2520268	chr7:107191161	T/A	cg23024343	chr7:107201750	COG5	-0.76	-12.82	-0.53	5.16e-32	Coronary artery disease;
LUAD	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg12311346	chr5:56204834	C5orf35	0.76	12.0	0.5	9.52e-29	Initial pursuit acceleration;
LUAD	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21028142	chr17:79581711	NPLOC4	0.45	9.79	0.43	1.54e-20	Eye color traits;
LUAD	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08704250	chr15:31115839	NA	-0.47	-8.81	-0.39	3.32e-17	Huntington's disease progression;
LUAD	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg11494091	chr17:61959527	GH2	0.44	8.42	0.38	5.88e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs9929218	0.954	rs9929239	chr16:68821126	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.51	-0.55	7.89e-35	Colorectal cancer;
LUAD	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.12e-14	Prostate cancer;
LUAD	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.56	0.3	1.55e-10	Menarche (age at onset);
LUAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.62	-11.0	-0.47	6.13e-25	Longevity;Endometriosis;
LUAD	trans	rs7944735	0.507	rs10742827	chr11:48102350	C/T	cg03929089	chr4:120376271	NA	0.61	8.56	0.38	2.14e-16	Intraocular pressure;
LUAD	cis	rs7177699	0.557	rs4380028	chr15:79111093	C/T	cg15571903	chr15:79123663	NA	-0.38	-7.6	-0.35	1.93e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg07936489	chr17:37558343	FBXL20	0.5	6.77	0.31	4.22e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18099408	chr3:52552593	STAB1	-0.46	-8.01	-0.36	1.11e-14	Bipolar disorder;
LUAD	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11153730	0.503	rs188181	chr6:118620094	C/T	cg21191810	chr6:118973309	C6orf204	0.52	10.52	0.46	3.87e-23	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg12179176	chr11:130786555	SNX19	0.45	7.27	0.33	1.71e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg25894440	chr7:65020034	NA	-0.64	-6.89	-0.32	2.03e-11	Diabetic kidney disease;
LUAD	cis	rs1878931	0.580	rs7194596	chr16:3404408	T/A	cg22508957	chr16:3507546	NAT15	-0.43	-7.23	-0.33	2.21e-12	Body mass index (adult);
LUAD	cis	rs72634258	0.520	rs12078018	chr1:7857309	G/A	cg26816564	chr1:7831052	VAMP3	0.69	9.38	0.41	4.13e-19	Inflammatory bowel disease;
LUAD	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg17063962	chr7:91808500	NA	-0.7	-12.56	-0.52	5.86e-31	Breast cancer;
LUAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg22764044	chr5:178986830	RUFY1	-0.5	-8.45	-0.38	4.84e-16	Lung cancer;
LUAD	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg16099169	chr2:106886729	NA	-0.79	-11.88	-0.5	2.85e-28	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.67	-12.16	-0.51	2.21e-29	Longevity;Endometriosis;
LUAD	cis	rs887829	0.641	rs10179094	chr2:234597825	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-9.86	-0.43	8.74e-21	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs7773004	0.905	rs6932727	chr6:26327087	C/A	cg00631329	chr6:26305371	NA	-0.52	-8.97	-0.4	9.44e-18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	trans	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg12575136	chr18:32820987	ZNF397	0.44	6.95	0.32	1.42e-11	White blood cell count;
LUAD	cis	rs986417	1.000	rs1951115	chr14:60922006	G/C	cg27398547	chr14:60952738	C14orf39	-0.63	-7.71	-0.35	9.21e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs1003719	0.788	rs2835575	chr21:38455936	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.44	0.38	5.25e-16	Eye color traits;
LUAD	cis	rs9863	0.896	rs4765148	chr12:124478637	G/T	cg17723958	chr12:124429295	CCDC92	-0.41	-6.68	-0.31	7.7e-11	White blood cell count;
LUAD	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg03605463	chr16:89740564	NA	0.63	10.99	0.47	7.03e-25	Vitiligo;
LUAD	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg12179176	chr11:130786555	SNX19	0.55	9.27	0.41	9.37e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg25767906	chr1:53392781	SCP2	-0.52	-9.72	-0.43	2.67e-20	Monocyte count;
LUAD	trans	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg01620082	chr3:125678407	NA	-0.82	-8.32	-0.38	1.24e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.95	-0.44	4.09e-21	Monocyte percentage of white cells;
LUAD	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-8.33	-0.38	1.17e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg04944784	chr2:26401820	FAM59B	0.88	11.6	0.49	3.28e-27	Gut microbiome composition (summer);
LUAD	cis	rs71191701	1.000	rs71191701	chr9:139322257	G/C	cg14019695	chr9:139328340	INPP5E	0.39	6.83	0.32	2.92e-11	Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LUAD	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg14582100	chr15:45693742	SPATA5L1	0.5	9.36	0.41	4.73e-19	Homoarginine levels;
LUAD	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg21214613	chr1:16344536	HSPB7	0.6	11.59	0.49	3.61e-27	Dilated cardiomyopathy;
LUAD	cis	rs7187994	0.848	rs16974558	chr16:84787111	G/A	cg07647771	chr16:84786436	USP10	-0.37	-9.7	-0.43	3.09e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03270376	chr2:219536588	RNF25;STK36	0.43	6.93	0.32	1.58e-11	Gut microbiome composition (summer);
LUAD	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg17063962	chr7:91808500	NA	0.68	12.02	0.5	7.99e-29	Breast cancer;
LUAD	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg27494647	chr7:150038898	RARRES2	0.45	7.29	0.33	1.56e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg08027265	chr7:2291960	NA	-0.42	-6.86	-0.32	2.39e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg25173405	chr17:45401733	C17orf57	0.53	9.02	0.4	6.86e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg07393940	chr7:158741817	NA	-0.68	-11.63	-0.49	2.6e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs13315871	1.000	rs13076951	chr3:58436703	C/T	cg12435725	chr3:58293450	RPP14	-0.67	-7.44	-0.34	5.6e-13	Cholesterol, total;
LUAD	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10802521	chr3:52805072	NEK4	-0.52	-8.92	-0.4	1.45e-17	Bipolar disorder;
LUAD	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	7.98	0.36	1.37e-14	Tonsillectomy;
LUAD	cis	rs4888262	0.545	rs58136167	chr16:74700628	G/A	cg01733217	chr16:74700730	RFWD3	0.52	8.62	0.39	1.37e-16	Testicular germ cell tumor;
LUAD	cis	rs10865541	0.869	rs13020433	chr2:3417577	G/A	cg22182287	chr2:3452347	TTC15	0.41	7.0	0.32	1.01e-11	Obesity-related traits;
LUAD	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg07917127	chr4:99064746	C4orf37	0.5	7.2	0.33	2.7e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.33	0.34	1.18e-12	Tonsillectomy;
LUAD	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.9	-0.32	1.96e-11	Diabetic kidney disease;
LUAD	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg07371521	chr5:154026371	NA	0.53	8.82	0.39	3.1e-17	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg10235275	chr10:65225544	JMJD1C;LOC84989	-0.37	-6.45	-0.3	3.04e-10	Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01011614	chr20:44600351	ZNF335	-0.47	-8.13	-0.37	4.96e-15	Cancer;
LUAD	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg26924012	chr15:45694286	SPATA5L1	1.02	18.85	0.68	5.65e-58	Homoarginine levels;
LUAD	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg12935359	chr14:103987150	CKB	0.51	7.95	0.36	1.69e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs55665837	1.000	rs10832257	chr11:14443316	A/G	cg19336497	chr11:14380999	RRAS2	-0.51	-10.33	-0.45	1.85e-22	Vitamin D levels;
LUAD	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg14019146	chr3:50243930	SLC38A3	-0.43	-7.07	-0.32	6.64e-12	Menarche (age at onset);
LUAD	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg17182837	chr8:41585554	ANK1	-0.34	-7.08	-0.33	5.92e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUAD	trans	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg18187862	chr3:45730750	SACM1L	-0.53	-7.68	-0.35	1.14e-13	Primary sclerosing cholangitis;
LUAD	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg21204522	chr6:27730016	NA	-0.48	-7.68	-0.35	1.13e-13	Parkinson's disease;
LUAD	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg03609598	chr5:56110824	MAP3K1	0.44	6.72	0.31	6e-11	Coronary artery disease;
LUAD	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg22535103	chr8:58192502	C8orf71	-0.63	-6.8	-0.31	3.57e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg17480646	chr11:65405466	SIPA1	-0.45	-6.77	-0.31	4.44e-11	Acne (severe);
LUAD	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.86	-0.4	2.23e-17	Menopause (age at onset);
LUAD	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg07708487	chr16:89387014	ANKRD11	-0.33	-6.42	-0.3	3.64e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg17063962	chr7:91808500	NA	-0.66	-11.91	-0.5	2.15e-28	Breast cancer;
LUAD	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.37	-6.39	-0.3	4.35e-10	Glaucoma (primary open-angle);
LUAD	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg05623727	chr3:50126028	RBM5	-0.3	-6.63	-0.31	1.05e-10	Body mass index;
LUAD	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg24829409	chr8:58192753	C8orf71	-0.58	-8.76	-0.39	4.73e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs870825	0.616	rs67641203	chr4:185623845	A/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg19318889	chr4:1322082	MAEA	0.41	6.92	0.32	1.63e-11	Obesity-related traits;
LUAD	trans	rs5760842	0.517	rs2076930	chr22:25495138	T/C	cg16733866	chr21:42792609	MX1	0.65	9.05	0.4	5.43e-18	Recurrent major depressive disorder;
LUAD	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.37	6.58	0.3	1.38e-10	Multiple sclerosis or amyotrophic lateral sclerosis;
LUAD	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg05044414	chr3:183734942	ABCC5	0.48	10.05	0.44	1.94e-21	Anterior chamber depth;
LUAD	cis	rs4845570	0.834	rs7007	chr1:151735576	T/C	cg07092448	chr1:151763213	TDRKH	-0.72	-8.01	-0.36	1.11e-14	Coronary artery disease;
LUAD	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg22868518	chr11:507468	RNH1	-0.68	-6.75	-0.31	4.82e-11	Body mass index;
LUAD	cis	rs250585	1.000	rs250587	chr16:23400194	A/G	cg00143387	chr16:23521605	GGA2	-0.5	-6.67	-0.31	8.12e-11	Egg allergy;
LUAD	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21028142	chr17:79581711	NPLOC4	0.45	9.79	0.43	1.54e-20	Eye color traits;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg22723209	chr5:156570043	MED7	0.36	6.36	0.3	5.2e-10	Bipolar disorder;
LUAD	cis	rs2688608	0.933	rs2688614	chr10:75652876	G/A	cg23231163	chr10:75533350	FUT11	-0.39	-7.18	-0.33	3.13e-12	Inflammatory bowel disease;
LUAD	cis	rs4523957	0.928	rs216206	chr17:2196088	C/T	cg16513277	chr17:2031491	SMG6	0.76	14.33	0.57	3.07e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg14668632	chr7:2872130	GNA12	-0.47	-8.24	-0.37	2.18e-15	Height;
LUAD	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.6	-0.35	1.98e-13	Coronary artery disease;
LUAD	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.29	-7.21	-0.33	2.59e-12	Coronary artery disease;
LUAD	trans	rs6561151	1.000	rs6561151	chr13:44484706	G/A	cg12856521	chr11:46389249	DGKZ	0.64	10.03	0.44	2.3e-21	Crohn's disease;
LUAD	cis	rs11209185	0.509	rs9436356	chr1:68447202	A/G	cg22082780	chr1:68452167	NA	0.51	10.54	0.46	3.27e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06544989	chr22:39130855	UNC84B	0.42	7.94	0.36	1.9e-14	Menopause (age at onset);
LUAD	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg11502198	chr6:26597334	ABT1	0.67	11.87	0.5	3.07e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs887829	0.570	rs10171367	chr2:234597667	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.67	-0.43	4e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs4285028	0.948	rs35737776	chr3:121677856	G/A	cg11130432	chr3:121712080	ILDR1	-0.59	-8.44	-0.38	5.05e-16	Multiple sclerosis;
LUAD	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.29	-6.91	-0.32	1.82e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs2742234	0.955	rs2435384	chr10:43673731	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.47	-8.4	-0.38	6.83e-16	Hirschsprung disease;
LUAD	trans	rs1493916	0.967	rs9953768	chr18:31399468	A/G	cg27147174	chr7:100797783	AP1S1	-0.67	-11.7	-0.49	1.36e-27	Life satisfaction;
LUAD	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg13319975	chr6:146136371	FBXO30	-0.59	-9.99	-0.44	3.11e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg12016809	chr21:47604291	C21orf56	0.59	10.26	0.45	3.4e-22	Testicular germ cell tumor;
LUAD	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg06028808	chr11:68637592	NA	0.5	8.24	0.37	2.21e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4638749	0.677	rs998186	chr2:108844237	C/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.33	-0.34	1.19e-12	Blood pressure;
LUAD	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.88	-0.43	7.43e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg20607798	chr8:58055168	NA	0.73	8.97	0.4	9.69e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.19	0.54	1.68e-33	Prudent dietary pattern;
LUAD	cis	rs2882667	0.893	rs10044672	chr5:138290479	C/G	cg04439458	chr5:138467593	SIL1	-0.36	-6.53	-0.3	1.93e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs56283067	0.847	rs12208621	chr6:44752003	G/C	cg20913747	chr6:44695427	NA	-0.44	-7.42	-0.34	6.65e-13	Total body bone mineral density;
LUAD	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg22117172	chr7:91764530	CYP51A1	0.33	7.31	0.33	1.32e-12	Breast cancer;
LUAD	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg19761014	chr17:28927070	LRRC37B2	0.82	8.28	0.37	1.6e-15	Body mass index;
LUAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg07677032	chr17:61819896	STRADA	0.54	9.78	0.43	1.75e-20	Prudent dietary pattern;
LUAD	cis	rs4664308	0.935	rs58354887	chr2:160927112	C/T	cg03641300	chr2:160917029	PLA2R1	-0.38	-6.4	-0.3	4.1e-10	Idiopathic membranous nephropathy;
LUAD	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg05754148	chr16:3507555	NAT15	-0.42	-6.39	-0.3	4.43e-10	Body mass index (adult);
LUAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg09060608	chr5:178986726	RUFY1	-0.68	-12.0	-0.5	9.61e-29	Lung cancer;
LUAD	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg25324976	chr17:61989376	CSHL1	0.37	7.27	0.33	1.72e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs17092148	0.887	rs2144956	chr20:33145868	G/A	cg16810054	chr20:33298113	TP53INP2	-0.47	-7.11	-0.33	5.01e-12	Neuroticism;
LUAD	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg26384229	chr12:38710491	ALG10B	0.44	6.96	0.32	1.29e-11	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs931812	1.000	rs931812	chr8:101919321	A/G	cg20993868	chr7:22813445	NA	-0.56	-11.3	-0.48	4.67e-26	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs7737355	0.947	rs1422871	chr5:130942481	G/A	cg06307176	chr5:131281290	NA	0.51	7.92	0.36	2.14e-14	Life satisfaction;
LUAD	cis	rs7107174	1.000	rs7941617	chr11:78021146	C/T	cg19901956	chr11:77921274	USP35	-0.47	-6.46	-0.3	2.84e-10	Testicular germ cell tumor;
LUAD	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.63	-0.31	1.05e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7771547	0.519	rs58153398	chr6:36370394	A/C	cg07856975	chr6:36356162	ETV7	0.54	8.03	0.36	1.01e-14	Platelet distribution width;
LUAD	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg12034118	chr1:209979487	IRF6	0.55	7.26	0.33	1.91e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs4523957	0.890	rs216217	chr17:2145090	G/A	cg16513277	chr17:2031491	SMG6	0.76	14.33	0.57	2.9e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg22349387	chr12:9600060	DDX12	-0.4	-6.98	-0.32	1.16e-11	Breast size;
LUAD	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg09085632	chr11:111637200	PPP2R1B	0.63	9.41	0.42	3.31e-19	Primary sclerosing cholangitis;
LUAD	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg16680214	chr1:154839983	KCNN3	-0.64	-13.33	-0.54	4.22e-34	Prostate cancer;
LUAD	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg24733560	chr20:60626293	TAF4	0.41	7.81	0.36	4.46e-14	Body mass index;
LUAD	cis	rs4389656	0.857	rs274719	chr5:6720916	A/G	cg10857441	chr5:6722123	POLS	-0.45	-7.89	-0.36	2.7e-14	Coronary artery disease;
LUAD	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg22535103	chr8:58192502	C8orf71	-0.65	-9.26	-0.41	1.06e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg05283184	chr6:79620031	NA	-0.47	-8.26	-0.37	1.83e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs853679	0.546	rs200995	chr6:27813694	C/T	cg01620082	chr3:125678407	NA	0.78	8.88	0.4	1.91e-17	Depression;
LUAD	cis	rs7508679	1.000	rs4804411	chr19:7222377	G/C	cg00428638	chr19:7224713	INSR	0.69	14.48	0.58	7.34e-39	Hypothyroidism;
LUAD	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.47	7.11	0.33	5.12e-12	Schizophrenia;
LUAD	cis	rs4764487	0.685	rs740839	chr12:6338637	C/T	cg08284733	chr12:6341482	CD9	0.38	6.84	0.32	2.86e-11	Mean platelet volume;
LUAD	cis	rs62400317	0.859	rs72869127	chr6:45071712	T/C	cg20913747	chr6:44695427	NA	-0.41	-6.56	-0.3	1.62e-10	Total body bone mineral density;
LUAD	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg04218760	chr10:45406644	TMEM72	-0.32	-8.1	-0.37	5.83e-15	Mean corpuscular volume;
LUAD	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.43	6.82	0.31	3.17e-11	Platelet count;
LUAD	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg17063962	chr7:91808500	NA	0.71	12.58	0.52	4.85e-31	Breast cancer;
LUAD	cis	rs9902453	1.000	rs8065261	chr17:28418041	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.15	-0.41	2.46e-18	Coffee consumption (cups per day);
LUAD	cis	rs910873	0.505	rs6058099	chr20:33249134	C/T	cg16810054	chr20:33298113	TP53INP2	-0.52	-7.63	-0.35	1.53e-13	Melanoma;
LUAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00166722	chr3:10149974	C3orf24	0.71	12.14	0.51	2.67e-29	Alzheimer's disease;
LUAD	cis	rs367943	1.000	rs460079	chr5:112800525	G/A	cg12552261	chr5:112820674	MCC	-0.59	-11.22	-0.48	9.41e-26	Type 2 diabetes;
LUAD	cis	rs1595825	0.891	rs76308665	chr2:198518062	C/T	cg00982548	chr2:198649783	BOLL	-0.62	-8.83	-0.39	2.89e-17	Ulcerative colitis;
LUAD	cis	rs12681287	0.570	rs4961188	chr8:87383033	T/C	cg00550725	chr8:87521180	FAM82B	-0.47	-6.73	-0.31	5.71e-11	Caudate activity during reward;
LUAD	cis	rs8060686	0.668	rs8046355	chr16:68205214	T/A	cg26727032	chr16:67993705	SLC12A4	-0.44	-7.29	-0.33	1.49e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.9	-0.61	5.71e-45	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs713587	0.875	rs6746013	chr2:25143649	C/G	cg01884057	chr2:25150051	NA	0.39	8.41	0.38	6.28e-16	Body mass index in non-asthmatics;
LUAD	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg24818145	chr4:99064322	C4orf37	-0.47	-8.06	-0.36	8.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg15691649	chr6:25882328	NA	0.43	6.82	0.31	3.09e-11	Blood metabolite levels;
LUAD	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg24675056	chr1:15929824	NA	0.49	8.5	0.38	3.32e-16	Systolic blood pressure;
LUAD	cis	rs17433780	0.897	rs12142922	chr1:89489915	A/G	cg09516651	chr1:89888402	LOC400759	0.53	9.52	0.42	1.3e-19	Carotid intima media thickness;
LUAD	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg10544611	chr16:67998164	SLC12A4	-0.57	-7.12	-0.33	4.72e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs17095355	0.642	rs57822924	chr10:111702078	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.69	-9.29	-0.41	8.03e-19	Biliary atresia;
LUAD	cis	rs7809950	0.678	rs62482499	chr7:106975059	C/G	cg23024343	chr7:107201750	COG5	-0.79	-13.53	-0.55	6.31e-35	Coronary artery disease;
LUAD	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg03929089	chr4:120376271	NA	-0.88	-17.05	-0.64	5.22e-50	Height;
LUAD	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg16325326	chr1:53192061	ZYG11B	-0.63	-11.72	-0.5	1.12e-27	Monocyte count;
LUAD	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg09085632	chr11:111637200	PPP2R1B	0.61	9.09	0.4	3.95e-18	Primary sclerosing cholangitis;
LUAD	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg05966235	chr16:28915196	ATP2A1	0.49	7.98	0.36	1.38e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.48	-0.38	3.74e-16	Height;
LUAD	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.59	11.5	0.49	8.31e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3007168	1.000	rs3007075	chr14:51604860	A/G	cg23942311	chr14:51606299	NA	0.54	7.37	0.34	8.94e-13	Cancer;
LUAD	cis	rs11030122	0.702	rs10767713	chr11:3950157	T/C	cg18678763	chr11:4115507	RRM1	-0.42	-7.14	-0.33	4.06e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07157834	chr1:205819609	PM20D1	0.83	17.56	0.65	3.04e-52	Menarche (age at onset);
LUAD	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg05110241	chr16:68378359	PRMT7	-0.68	-7.69	-0.35	1.01e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg03284175	chr1:146643471	PRKAB2	-0.47	-6.53	-0.3	1.88e-10	Testicular germ cell tumor;
LUAD	cis	rs1443512	0.947	rs894739	chr12:54346869	T/C	cg17410650	chr12:54324560	NA	-0.47	-8.61	-0.39	1.43e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg17724175	chr1:150552817	MCL1	0.39	9.04	0.4	5.6e-18	Blood protein levels;
LUAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs9972944	0.691	rs7225471	chr17:63777913	T/C	cg07283582	chr17:63770753	CCDC46	0.49	10.61	0.46	1.81e-23	Total body bone mineral density;
LUAD	cis	rs12545109	0.671	rs35500854	chr8:57424303	G/A	cg17761419	chr8:57350749	NA	-0.56	-7.88	-0.36	2.82e-14	Obesity-related traits;
LUAD	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.2	-0.37	2.88e-15	Total cholesterol levels;
LUAD	cis	rs62229266	0.771	rs2835232	chr21:37393427	G/A	cg12218747	chr21:37451666	NA	-0.47	-8.1	-0.37	5.89e-15	Mitral valve prolapse;
LUAD	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.14	-0.33	4.01e-12	Lung cancer;
LUAD	cis	rs2239547	0.522	rs2581779	chr3:53056199	T/C	cg11645453	chr3:52864694	ITIH4	-0.55	-10.07	-0.44	1.54e-21	Schizophrenia;
LUAD	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00934597	chr7:893267	UNC84A	-0.59	-9.54	-0.42	1.19e-19	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs9399401	0.667	rs17071756	chr6:142715195	C/T	cg03128060	chr6:142623767	GPR126	-0.48	-9.96	-0.44	3.89e-21	Chronic obstructive pulmonary disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03944810	chr2:208031995	KLF7	-0.4	-6.37	-0.3	5.01e-10	Height;
LUAD	cis	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg27411982	chr8:10470053	RP1L1	0.38	6.63	0.31	1.02e-10	Triglycerides;
LUAD	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg08029281	chr1:67600428	NA	0.35	6.83	0.32	2.9100000000000002e-11	Psoriasis;
LUAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg22907277	chr7:1156413	C7orf50	0.71	8.26	0.37	1.84e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6908034	0.607	rs75060331	chr6:19812956	C/T	cg02682789	chr6:19804855	NA	0.91	9.09	0.4	3.9e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs2535633	0.631	rs2710314	chr3:52969128	T/C	cg18404041	chr3:52824283	ITIH1	0.39	6.71	0.31	6.44e-11	Body mass index;
LUAD	cis	rs6543140	0.964	rs1523205	chr2:103070176	G/T	cg04239558	chr2:103089729	SLC9A4	0.36	7.29	0.33	1.49e-12	Blood protein levels;
LUAD	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14893161	chr1:205819251	PM20D1	-0.56	-10.17	-0.44	7.08e-22	Menarche (age at onset);
LUAD	cis	rs8072100	0.537	rs9912450	chr17:45402208	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.44	-7.96	-0.36	1.54e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg00106254	chr7:1943704	MAD1L1	-0.52	-8.1	-0.37	6e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg07828340	chr4:882639	GAK	1.1	11.83	0.5	4.34e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs11126435	0.858	rs9679457	chr2:74930736	G/A	cg19285774	chr2:74907978	SEMA4F	0.37	6.49	0.3	2.45e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg06532163	chr17:45867833	NA	-0.45	-8.17	-0.37	3.64e-15	IgG glycosylation;
LUAD	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18876405	chr7:65276391	NA	-0.58	-9.91	-0.43	5.83e-21	Aortic root size;
LUAD	cis	rs6546550	0.658	rs10186725	chr2:70015491	A/G	cg02498382	chr2:70120550	SNRNP27	-0.53	-9.54	-0.42	1.17e-19	Prevalent atrial fibrillation;
LUAD	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg04369109	chr6:150039330	LATS1	-0.46	-7.61	-0.35	1.8e-13	Lung cancer;
LUAD	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25427524	chr10:38739819	LOC399744	0.73	13.42	0.55	1.94e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	trans	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg27411982	chr8:10470053	RP1L1	0.43	7.45	0.34	5.36e-13	Mood instability;
LUAD	cis	rs73206853	0.841	rs4131852	chr12:110812657	C/G	cg12870014	chr12:110450643	ANKRD13A	0.59	6.5	0.3	2.21e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.37	0.3	4.94e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg04851639	chr8:1020857	NA	-0.38	-9.41	-0.42	3.19e-19	Schizophrenia;
LUAD	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg06271696	chr7:157225062	NA	-0.63	-14.59	-0.58	2.42e-39	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs12760731	0.565	rs12027396	chr1:178149200	T/C	cg00404053	chr1:178313656	RASAL2	0.72	9.06	0.4	5e-18	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg23281280	chr6:28129359	ZNF389	-0.46	-6.56	-0.3	1.55e-10	Depression;
LUAD	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg15448220	chr1:150897856	SETDB1	0.53	8.97	0.4	9.4e-18	Melanoma;
LUAD	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg18252515	chr7:66147081	NA	-0.62	-6.83	-0.32	3.03e-11	Diabetic kidney disease;
LUAD	trans	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21659725	chr3:3221576	CRBN	0.49	8.21	0.37	2.64e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-8.22	-0.37	2.53e-15	Hemoglobin concentration;
LUAD	cis	rs9914988	0.559	rs1109024	chr17:27189971	C/T	cg02049041	chr17:27085579	C17orf63	-0.61	-8.14	-0.37	4.58e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg05085585	chr16:30420623	ZNF771	-0.38	-6.47	-0.3	2.75e-10	Tonsillectomy;
LUAD	cis	rs7582720	1.000	rs72928620	chr2:203840973	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.38	0.41	4.22e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.5	6.63	0.31	1.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg12365402	chr11:9010492	NRIP3	-0.44	-8.32	-0.38	1.21e-15	Hemoglobin concentration;
LUAD	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg00277334	chr10:82204260	NA	-0.63	-9.95	-0.44	4.34e-21	Post bronchodilator FEV1;
LUAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg02951883	chr7:2050386	MAD1L1	-0.64	-10.34	-0.45	1.66e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs4730250	0.708	rs3801965	chr7:106825628	G/T	cg02696742	chr7:106810147	HBP1	-0.79	-11.09	-0.47	3.01e-25	Osteoarthritis;
LUAD	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg20587970	chr11:113659929	NA	1.18	14.55	0.58	3.55e-39	Hip circumference adjusted for BMI;
LUAD	cis	rs73416724	1.000	rs75320251	chr6:43395101	G/A	cg26312998	chr6:43337775	ZNF318	0.56	6.79	0.31	3.78e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2797160	1.000	rs1777226	chr6:126017691	C/A	cg05901451	chr6:126070800	HEY2	0.46	6.73	0.31	5.61e-11	Endometrial cancer;
LUAD	trans	rs4824093	0.610	rs9627799	chr22:50317989	C/T	cg09872104	chr7:134855509	C7orf49	-0.77	-6.91	-0.32	1.77e-11	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8063160	0.688	rs75570604	chr16:89846677	G/C	cg07984980	chr16:89898383	SPIRE2	0.9	8.81	0.39	3.16e-17	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LUAD	cis	rs7818345	0.967	rs11784873	chr8:19281113	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.32	7.24	0.33	2.1e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs225245	0.541	rs321612	chr17:33881631	T/C	cg05299278	chr17:33885742	SLFN14	0.37	7.3	0.33	1.45e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg21709803	chr11:61594965	FADS2	-0.4	-7.34	-0.34	1.14e-12	Trans fatty acid levels;
LUAD	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.38e-13	Menopause (age at onset);
LUAD	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg18944383	chr4:111397179	ENPEP	0.39	7.84	0.36	3.75e-14	Height;
LUAD	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.52	-10.66	-0.46	1.18e-23	Monocyte percentage of white cells;
LUAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg16606324	chr3:10149918	C3orf24	0.67	10.9	0.47	1.49e-24	Alzheimer's disease;
LUAD	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg15181151	chr6:150070149	PCMT1	0.41	8.22	0.37	2.6e-15	Lung cancer;
LUAD	cis	rs2294693	0.530	rs35105472	chr6:41062689	C/G	cg14769373	chr6:40998127	UNC5CL	-0.58	-8.22	-0.37	2.45e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs28595532	1.000	rs114039398	chr4:119631627	T/C	cg14228332	chr4:119757509	SEC24D	0.77	7.07	0.33	6.46e-12	Cannabis dependence symptom count;
LUAD	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg17724175	chr1:150552817	MCL1	0.29	6.74	0.31	5.26e-11	Melanoma;
LUAD	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg24531977	chr5:56204891	C5orf35	-0.52	-8.23	-0.37	2.4e-15	Coronary artery disease;
LUAD	cis	rs8060686	0.623	rs6499163	chr16:68243486	G/T	cg26727032	chr16:67993705	SLC12A4	-0.44	-7.21	-0.33	2.68e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8067545	0.693	rs8066150	chr17:19886948	G/A	cg04132472	chr17:19861366	AKAP10	0.35	8.07	0.37	7.39e-15	Schizophrenia;
LUAD	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg16479474	chr6:28041457	NA	0.35	6.39	0.3	4.34e-10	Parkinson's disease;
LUAD	cis	rs9902453	0.780	rs10445384	chr17:28182685	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	9.37	0.41	4.33e-19	Coffee consumption (cups per day);
LUAD	cis	rs1448094	0.967	rs7961782	chr12:86326461	T/C	cg02569458	chr12:86230093	RASSF9	0.37	7.07	0.33	6.27e-12	Major depressive disorder;
LUAD	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg22753661	chr15:79092743	ADAMTS7	0.57	8.65	0.39	1.09e-16	Coronary artery disease or large artery stroke;
LUAD	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg18240062	chr17:79603768	NPLOC4	0.36	6.38	0.3	4.69e-10	Eye color traits;
LUAD	trans	rs10178094	0.504	rs6707514	chr2:161155246	G/T	cg14706852	chr2:127976351	NA	-0.37	-6.43	-0.3	3.38e-10	White blood cell count;
LUAD	cis	rs17095355	0.901	rs12572168	chr10:111764786	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.22	-0.33	2.5e-12	Biliary atresia;
LUAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg04025307	chr7:1156635	C7orf50	0.68	9.54	0.42	1.16e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg07169764	chr2:136633963	MCM6	0.69	8.97	0.4	9.5e-18	Corneal structure;
LUAD	cis	rs2249625	0.844	rs2496497	chr6:72884121	T/C	cg18830697	chr6:72922368	RIMS1	-0.35	-6.64	-0.31	9.78e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg03477792	chr4:77819574	ANKRD56	0.48	7.22	0.33	2.45e-12	Emphysema distribution in smoking;
LUAD	cis	rs7731657	0.537	rs10073487	chr5:130373397	G/A	cg08523029	chr5:130500466	HINT1	-0.6	-7.68	-0.35	1.08e-13	Fasting plasma glucose;
LUAD	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg03651054	chr13:50194643	NA	0.39	7.98	0.36	1.36e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	trans	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg06606381	chr12:133084897	FBRSL1	-0.71	-6.74	-0.31	5.36e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg00898013	chr13:113819073	PROZ	-0.65	-11.91	-0.5	2.13e-28	Platelet distribution width;
LUAD	trans	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg01620082	chr3:125678407	NA	-0.76	-6.46	-0.3	2.91e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg12564285	chr5:131593104	PDLIM4	-0.39	-6.66	-0.31	8.41e-11	Breast cancer;
LUAD	cis	rs62238980	0.522	rs77418985	chr22:32380919	C/G	cg00543991	chr22:32367038	NA	0.94	8.78	0.39	4.09e-17	Childhood ear infection;
LUAD	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg06781209	chr11:61594997	FADS2	-0.39	-7.19	-0.33	2.89e-12	Trans fatty acid levels;
LUAD	cis	rs6011002	0.745	rs1758206	chr20:62336334	T/C	cg01176363	chr20:62369445	LIME1	-0.75	-6.64	-0.31	9.86e-11	Dental caries;
LUAD	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2996428	0.561	rs12134919	chr1:3744641	G/A	cg17443473	chr1:3703550	LRRC47	0.44	7.71	0.35	8.99e-14	Red cell distribution width;
LUAD	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg03929089	chr4:120376271	NA	-0.99	-20.65	-0.71	4.76e-66	Height;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg12304441	chr12:62653866	USP15	0.38	6.53	0.3	1.85e-10	Bipolar disorder;
LUAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.47	6.55	0.3	1.66e-10	Renal function-related traits (BUN);
LUAD	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg00898013	chr13:113819073	PROZ	-0.84	-15.12	-0.59	1.34e-41	Platelet distribution width;
LUAD	cis	rs1975974	0.511	rs56935892	chr17:21754089	A/G	cg18423549	chr17:21743878	NA	-0.82	-14.14	-0.57	1.98e-37	Psoriasis;
LUAD	cis	rs1595825	0.891	rs16823148	chr2:198584209	G/A	cg11031976	chr2:198649780	BOLL	-0.43	-6.61	-0.31	1.13e-10	Ulcerative colitis;
LUAD	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.4	-0.34	7.26e-13	Total body bone mineral density;
LUAD	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg06064525	chr11:970664	AP2A2	-0.53	-10.86	-0.47	2.05e-24	Alzheimer's disease (late onset);
LUAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg05434287	chr7:2030229	MAD1L1	0.4	6.64	0.31	9.81e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg22166914	chr1:53195759	ZYG11B	0.47	8.32	0.38	1.2e-15	Monocyte count;
LUAD	trans	rs3219090	0.861	rs2570369	chr1:226605765	T/C	cg27539482	chr13:111589090	NA	0.43	7.14	0.33	4.04e-12	Melanoma;
LUAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.25	0.41	1.08e-18	Alzheimer's disease;
LUAD	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.09	-0.54	4.03e-33	Chronic sinus infection;
LUAD	cis	rs10979	1.000	rs10979	chr6:143890039	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.3	-0.45	2.33e-22	Hypospadias;
LUAD	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg13390004	chr1:15929781	NA	0.47	8.4	0.38	6.93e-16	Systolic blood pressure;
LUAD	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg03340356	chr1:67600835	NA	0.43	7.53	0.34	3.08e-13	Psoriasis;
LUAD	trans	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17712092	chr4:129076599	LARP1B	0.93	17.57	0.65	2.68e-52	Eosinophil percentage of white cells;
LUAD	cis	rs77972916	0.536	rs11694173	chr2:43590899	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.54	6.75	0.31	5.02e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg27426351	chr10:43362370	NA	0.53	8.57	0.38	1.98e-16	Blood protein levels;
LUAD	cis	rs790123	1.000	rs790113	chr3:122383276	T/A	cg22896480	chr3:122379438	NA	0.4	6.63	0.31	1.03e-10	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs5756813	0.754	rs11705616	chr22:38180487	G/T	cg19894588	chr14:64061835	NA	-0.46	-6.54	-0.3	1.73e-10	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg05872129	chr22:39784769	NA	0.82	15.22	0.59	4.77e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg10556349	chr10:835070	NA	0.52	6.95	0.32	1.35e-11	Eosinophil percentage of granulocytes;
LUAD	cis	rs17095355	0.688	rs1349348	chr10:111794554	T/C	cg00817464	chr10:111662876	XPNPEP1	0.59	7.48	0.34	4.47e-13	Biliary atresia;
LUAD	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	7.02	0.32	9.06e-12	Renal cell carcinoma;
LUAD	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg20607798	chr8:58055168	NA	0.59	7.83	0.36	3.99e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs8077889	0.956	rs55768269	chr17:41888997	C/T	cg26893861	chr17:41843967	DUSP3	0.96	14.82	0.58	2.61e-40	Triglycerides;
LUAD	cis	rs9902453	0.845	rs2321493	chr17:28230359	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.33	0.41	5.88e-19	Coffee consumption (cups per day);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02884346	chr4:6271501	WFS1	-0.62	-7.65	-0.35	1.34e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg26354017	chr1:205819088	PM20D1	0.75	15.56	0.6	1.66e-43	Menarche (age at onset);
LUAD	cis	rs36096196	0.891	rs12082516	chr1:2251160	C/T	cg17974515	chr1:2252516	NA	-0.42	-7.31	-0.33	1.33e-12	Coronary artery disease;
LUAD	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg26408565	chr15:76604113	ETFA	-0.56	-9.86	-0.43	8.65e-21	Blood metabolite levels;
LUAD	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg21775007	chr8:11205619	TDH	-0.5	-9.05	-0.4	5.4e-18	Retinal vascular caliber;
LUAD	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg16414030	chr3:133502952	NA	-0.52	-9.44	-0.42	2.61e-19	Iron status biomarkers;
LUAD	cis	rs8017423	0.967	rs4900030	chr14:90689813	T/A	cg14092571	chr14:90743983	NA	-0.49	-8.54	-0.38	2.43e-16	Mortality in heart failure;
LUAD	trans	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg21659725	chr3:3221576	CRBN	-0.57	-9.17	-0.41	2.14e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg07917127	chr4:99064746	C4orf37	0.41	6.89	0.32	2.01e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7771547	0.574	rs9368943	chr6:36566575	C/T	cg04289385	chr6:36355825	ETV7	0.5	6.64	0.31	9.88e-11	Platelet distribution width;
LUAD	cis	rs752010	0.630	rs12134174	chr1:42105942	C/T	cg06885757	chr1:42089581	HIVEP3	0.37	7.78	0.35	5.73e-14	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg09462578	chr12:12878428	APOLD1	-0.56	-8.71	-0.39	6.93e-17	Lymphocyte counts;
LUAD	cis	rs877282	0.898	rs10904546	chr10:757222	A/G	cg06581033	chr10:766294	NA	-0.55	-7.14	-0.33	4.19e-12	Uric acid levels;
LUAD	cis	rs4268898	0.795	rs12470303	chr2:24619883	C/T	cg06627628	chr2:24431161	ITSN2	-0.41	-7.26	-0.33	1.92e-12	Asthma;
LUAD	trans	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg04565464	chr8:145669602	NFKBIL2	0.42	6.4	0.3	4.13e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs240764	0.621	rs10457844	chr6:101196532	T/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.49	-0.38	3.62e-16	Neuroticism;
LUAD	cis	rs12976411	0.575	rs35367178	chr19:32825503	G/A	cg02282382	chr19:32836354	ZNF507	0.71	6.44	0.3	3.24e-10	Coronary artery disease;
LUAD	trans	rs3198697	0.617	rs11075253	chr16:15148646	C/A	cg04146151	chr16:2155961	PKD1	-0.5	-7.72	-0.35	8.29e-14	Triglycerides;
LUAD	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg04414720	chr1:150670196	GOLPH3L	0.72	13.51	0.55	7.87e-35	Tonsillectomy;
LUAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg22105103	chr4:187893119	NA	0.56	12.16	0.51	2.13e-29	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg12193833	chr17:30244370	NA	-0.55	-7.1	-0.33	5.3e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg01579765	chr21:45077557	HSF2BP	-0.63	-15.2	-0.59	5.94e-42	Mean corpuscular volume;
LUAD	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.7	0.31	6.76e-11	Colorectal cancer;
LUAD	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg18230493	chr5:56204884	C5orf35	-0.86	-12.63	-0.52	3.11e-31	Initial pursuit acceleration;
LUAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg24642844	chr7:1081250	C7orf50	-0.98	-14.71	-0.58	7.71e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg12000995	chr2:27665139	KRTCAP3	0.34	8.62	0.39	1.34e-16	Total body bone mineral density;
LUAD	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg24675056	chr1:15929824	NA	0.48	8.47	0.38	3.96e-16	Systolic blood pressure;
LUAD	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg20476274	chr7:133979776	SLC35B4	0.86	17.68	0.65	9.28e-53	Mean platelet volume;
LUAD	cis	rs10193935	1.000	rs13386385	chr2:42436928	G/T	cg27598129	chr2:42591480	NA	-0.79	-10.43	-0.45	8.25e-23	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.858	rs1476306	chr16:67973171	C/T	cg04539111	chr16:67997858	SLC12A4	-0.43	-6.44	-0.3	3.21e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4988958	0.525	rs3771159	chr2:103004958	T/C	cg03938978	chr2:103052716	IL18RAP	0.45	10.24	0.45	3.99e-22	Asthma (childhood onset);
LUAD	trans	rs58106596	0.800	rs11693819	chr2:232566206	G/A	cg01370599	chr3:116745421	NA	0.67	8.84	0.39	2.65e-17	White blood cell count;Lymphocyte counts;
LUAD	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg09904177	chr6:26538194	HMGN4	0.42	6.92	0.32	1.66e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg10523679	chr1:76189770	ACADM	1.05	24.98	0.77	2.92e-85	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg11517269	chr6:28058789	ZSCAN12L1	0.39	7.26	0.33	1.85e-12	Lung cancer in ever smokers;
LUAD	cis	rs7089973	0.872	rs7918253	chr10:116614501	T/C	cg25233709	chr10:116636983	FAM160B1	0.39	7.64	0.35	1.49e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4523957	0.614	rs2316512	chr17:2064710	A/T	cg16513277	chr17:2031491	SMG6	-0.96	-18.93	-0.68	2.56e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7072216	0.727	rs3750603	chr10:100175536	A/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.64	-0.39	1.19e-16	Metabolite levels;
LUAD	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg07404485	chr7:94953653	PON1	-0.5	-7.26	-0.33	1.89e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7617773	0.817	rs11709691	chr3:48303669	A/G	cg11946769	chr3:48343235	NME6	0.44	6.76	0.31	4.72e-11	Coronary artery disease;
LUAD	cis	rs2580764	0.565	rs35631428	chr2:55244438	G/A	cg09592903	chr2:55203963	RTN4	-0.44	-10.22	-0.45	4.59e-22	Mean platelet volume;
LUAD	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg06627628	chr2:24431161	ITSN2	-0.67	-10.68	-0.46	9.52e-24	Asthma;
LUAD	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg23216685	chr1:86174607	ZNHIT6	-0.39	-7.15	-0.33	3.73e-12	Urate levels in overweight individuals;
LUAD	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg09359103	chr1:154839909	KCNN3	-0.92	-19.97	-0.7	5.37e-63	Prostate cancer;
LUAD	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg27426351	chr10:43362370	NA	-0.55	-8.4	-0.38	6.59e-16	Blood protein levels;
LUAD	cis	rs2108225	0.872	rs2051955	chr7:107441154	C/T	cg18560240	chr7:107437656	SLC26A3	-0.42	-6.99	-0.32	1.08e-11	Ulcerative colitis;
LUAD	cis	rs2688608	0.901	rs2633312	chr10:75631755	T/A	cg19442545	chr10:75533431	FUT11	-0.42	-6.97	-0.32	1.21e-11	Inflammatory bowel disease;
LUAD	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.23	0.37	2.35e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg26597838	chr10:835615	NA	1.06	16.43	0.62	2.99e-47	Eosinophil percentage of granulocytes;
LUAD	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg06784218	chr1:46089804	CCDC17	-0.55	-11.74	-0.5	9.69e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg20744362	chr22:50050164	C22orf34	0.35	6.69	0.31	7.07e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg15704280	chr7:45808275	SEPT13	-0.66	-8.94	-0.4	1.25e-17	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg22467129	chr15:76604101	ETFA	-0.59	-10.91	-0.47	1.41e-24	Blood metabolite levels;
LUAD	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.83	0.32	2.93e-11	Hypertriglyceridemia;
LUAD	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11644478	chr21:40555479	PSMG1	-0.54	-8.69	-0.39	8.14e-17	Cognitive function;
LUAD	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg25208724	chr1:156163844	SLC25A44	0.89	14.58	0.58	2.57e-39	Testicular germ cell tumor;
LUAD	cis	rs2302190	0.882	rs11650710	chr17:56583547	C/T	cg25885038	chr17:56607967	SEPT4	-0.52	-8.24	-0.37	2.18e-15	Vitamin D levels;
LUAD	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg17105886	chr17:28927953	LRRC37B2	-0.82	-8.26	-0.37	1.85e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg03213289	chr20:61660250	NA	0.69	14.76	0.58	4.6e-40	Prostate cancer (SNP x SNP interaction);
LUAD	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg03929089	chr4:120376271	NA	-0.92	-17.67	-0.65	9.8e-53	Height;
LUAD	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg19318889	chr4:1322082	MAEA	0.47	7.8	0.35	4.92e-14	Obesity-related traits;
LUAD	trans	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg18335740	chr13:41363409	SLC25A15	0.62	11.7	0.49	1.37e-27	Lewy body disease;
LUAD	cis	rs2820315	0.540	rs10920259	chr1:201797696	C/T	cg11586189	chr1:201857591	SHISA4	-0.29	-7.41	-0.34	6.79e-13	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUAD	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg27427491	chr17:78079615	GAA	-0.39	-7.07	-0.33	6.41e-12	Yeast infection;
LUAD	cis	rs73086581	0.891	rs11907503	chr20:3887590	C/T	cg02187196	chr20:3869020	PANK2	0.44	6.45	0.3	3.14e-10	Response to antidepressants in depression;
LUAD	cis	rs55665837	0.520	rs10766189	chr11:14733923	G/A	cg19336497	chr11:14380999	RRAS2	-0.41	-7.84	-0.36	3.77e-14	Vitamin D levels;
LUAD	cis	rs9807989	0.507	rs6710528	chr2:103016142	A/G	cg03938978	chr2:103052716	IL18RAP	-0.44	-10.3	-0.45	2.37e-22	Asthma;
LUAD	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	9.83	0.43	1.17e-20	Axial length;
LUAD	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18876405	chr7:65276391	NA	-0.45	-7.15	-0.33	3.74e-12	Aortic root size;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg21795699	chr17:15903687	ZSWIM7;TTC19	-0.38	-6.39	-0.3	4.52e-10	Subcortical brain region volumes;
LUAD	cis	rs10795061	0.576	rs6601744	chr10:3711563	C/A	cg22632523	chr10:3711048	NA	0.45	7.6	0.35	1.91e-13	Subjective well-being;
LUAD	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01570182	chr17:44337453	NA	0.89	13.22	0.54	1.17e-33	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs71478720	0.903	rs12797880	chr11:112049191	T/C	cg26534425	chr11:112034925	IL18	0.44	6.6	0.31	1.23e-10	Interleukin-18 levels;
LUAD	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03452623	chr4:187889614	NA	-0.82	-16.85	-0.63	4.12e-49	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs612683	0.599	rs2809823	chr1:101003762	C/A	cg09408571	chr1:101003634	GPR88	0.38	7.84	0.36	3.63e-14	Breast cancer;
LUAD	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg14530993	chr4:882597	GAK	0.79	7.91	0.36	2.32e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.82	0.43	1.26e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	trans	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg25482853	chr8:67687455	SGK3	0.96	15.77	0.61	2.15e-44	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7843479	1.000	rs66824050	chr8:21815425	T/G	cg03445287	chr8:21823731	XPO7	-0.47	-8.7	-0.39	7.65e-17	Mean corpuscular volume;
LUAD	cis	rs2235649	0.663	rs6600168	chr16:1848927	C/T	cg08610935	chr16:1836813	NUBP2	-0.5	-7.71	-0.35	8.96e-14	Blood metabolite levels;
LUAD	cis	rs7617773	0.817	rs9837228	chr3:48324466	A/T	cg11946769	chr3:48343235	NME6	-0.42	-6.77	-0.31	4.29e-11	Coronary artery disease;
LUAD	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.98	0.32	1.17e-11	Lung cancer;
LUAD	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18876405	chr7:65276391	NA	-0.45	-7.15	-0.33	3.74e-12	Aortic root size;
LUAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg16414030	chr3:133502952	NA	-0.72	-14.0	-0.56	7.36e-37	Iron status biomarkers;
LUAD	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg18190219	chr22:46762943	CELSR1	-0.48	-6.64	-0.31	9.53e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg25554036	chr4:6271136	WFS1	0.65	12.73	0.53	1.18e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.42	-7.57	-0.35	2.44e-13	Longevity;Endometriosis;
LUAD	cis	rs877282	1.000	rs11253361	chr10:770387	T/C	cg17470449	chr10:769945	NA	0.61	8.79	0.39	3.68e-17	Uric acid levels;
LUAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg22764044	chr5:178986830	RUFY1	0.56	8.74	0.39	5.44e-17	Lung cancer;
LUAD	cis	rs7799006	0.929	rs35629140	chr7:2257171	G/C	cg08027265	chr7:2291960	NA	-0.61	-10.99	-0.47	7.22e-25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg10802521	chr3:52805072	NEK4	-0.52	-8.66	-0.39	9.92e-17	Bipolar disorder;
LUAD	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.74	0.39	5.73e-17	Menarche (age at onset);
LUAD	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg25985355	chr7:65971099	NA	-0.54	-6.71	-0.31	6.4e-11	Diabetic kidney disease;
LUAD	cis	rs9788721	0.836	rs17483929	chr15:78742376	C/T	cg18825076	chr15:78729989	IREB2	-0.57	-9.68	-0.43	3.68e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	trans	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.46	0.34	4.99e-13	Resting heart rate;
LUAD	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg16414030	chr3:133502952	NA	-0.52	-9.46	-0.42	2.18e-19	Iron status biomarkers;
LUAD	cis	rs909002	0.772	rs10914452	chr1:32074575	G/A	cg13919466	chr1:32135498	COL16A1	-0.38	-8.75	-0.39	5.24e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08677398	chr8:58056175	NA	0.47	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7943203	1.000	rs4754322	chr11:108311655	T/C	cg04873221	chr11:107992290	ACAT1	-0.43	-6.98	-0.32	1.17e-11	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg24101359	chr6:42928495	GNMT	0.45	8.34	0.38	1.05e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg05110241	chr16:68378359	PRMT7	-0.77	-8.25	-0.37	1.98e-15	HDL cholesterol;
LUAD	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg05393297	chr12:53359155	NA	-0.85	-16.32	-0.62	8.85e-47	Prostate cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06659889	chr3:12599050	MKRN2	-0.42	-7.07	-0.33	6.65e-12	Cancer;
LUAD	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg17330251	chr7:94953956	PON1	-0.53	-7.1	-0.33	5.36e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg21220214	chr8:57350948	NA	-0.58	-8.65	-0.39	1.06e-16	Obesity-related traits;
LUAD	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg04827223	chr11:72435913	ARAP1	-0.49	-6.73	-0.31	5.52e-11	Type 2 diabetes;
LUAD	cis	rs17401966	0.838	rs8019	chr1:10366487	T/G	cg15208524	chr1:10270712	KIF1B	0.42	6.52	0.3	1.98e-10	Hepatocellular carcinoma;
LUAD	cis	rs12612619	0.732	rs1053609	chr2:27293150	G/T	cg00617064	chr2:27272375	NA	-0.37	-7.12	-0.33	4.71e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs4964805	0.581	rs7312825	chr12:104188388	G/C	cg02344784	chr12:104178138	NT5DC3	0.45	9.15	0.41	2.4e-18	Attention deficit hyperactivity disorder;
LUAD	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg08742575	chr21:47604166	C21orf56	-0.53	-8.58	-0.38	1.86e-16	Testicular germ cell tumor;
LUAD	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg18806716	chr10:30721971	MAP3K8	-0.73	-15.8	-0.61	1.65e-44	Inflammatory bowel disease;
LUAD	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.14	14.75	0.58	5.24e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg05926928	chr17:57297772	GDPD1	0.69	10.62	0.46	1.65e-23	Schizophrenia;
LUAD	cis	rs2816062	0.813	rs2816050	chr1:18894432	A/G	cg18795169	chr1:18902165	NA	-0.94	-22.53	-0.74	2.07e-74	Urate levels in lean individuals;
LUAD	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg13385794	chr1:248469461	NA	0.25	6.83	0.32	2.94e-11	Common traits (Other);
LUAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-9.5	-0.42	1.52e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg12400702	chr3:12838781	CAND2	0.31	6.36	0.3	5.3e-10	Parkinson's disease;
LUAD	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg15147215	chr3:52552868	STAB1	-0.38	-7.0	-0.32	9.91e-12	Bipolar disorder;
LUAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-10.4	-0.45	1.08e-22	Lymphocyte counts;
LUAD	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg02527881	chr3:46936655	PTH1R	-0.7	-15.3	-0.6	2.26e-42	Birth weight;
LUAD	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg26022315	chr17:47021804	SNF8	0.4	7.27	0.33	1.77e-12	Type 2 diabetes;
LUAD	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg21475434	chr5:93447410	FAM172A	0.72	8.23	0.37	2.32e-15	Diabetic retinopathy;
LUAD	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg06131755	chr6:160182447	ACAT2	0.44	6.74	0.31	5.33e-11	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs7177699	0.550	rs4468572	chr15:79124475	C/T	cg15571903	chr15:79123663	NA	-0.41	-8.64	-0.39	1.18e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs2795502	0.766	rs947549	chr10:43265880	G/C	cg27426351	chr10:43362370	NA	-0.53	-7.2	-0.33	2.85e-12	Blood protein levels;
LUAD	cis	rs2657888	0.628	rs2638285	chr12:56886361	A/G	cg23002907	chr12:56915593	RBMS2	0.43	7.94	0.36	1.82e-14	Adiponectin levels;
LUAD	cis	rs12545109	0.876	rs4738494	chr8:57327438	G/T	cg09654669	chr8:57350985	NA	-0.67	-9.35	-0.41	5.01e-19	Obesity-related traits;
LUAD	cis	rs6594713	0.531	rs13362189	chr5:112940706	A/G	cg12552261	chr5:112820674	MCC	0.6	8.85	0.4	2.44e-17	Brain cytoarchitecture;
LUAD	cis	rs6740322	0.748	rs6544636	chr2:43487486	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.76	-11.13	-0.48	2.13e-25	Coronary artery disease;
LUAD	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg10755058	chr3:40428713	ENTPD3	0.37	6.83	0.31	3.04e-11	Renal cell carcinoma;
LUAD	cis	rs2239547	0.522	rs2581780	chr3:53058960	C/T	cg11645453	chr3:52864694	ITIH4	-0.55	-10.12	-0.44	1.05e-21	Schizophrenia;
LUAD	cis	rs35883536	0.528	rs1414414	chr1:101028907	T/C	cg06223162	chr1:101003688	GPR88	0.57	11.75	0.5	8.91e-28	Monocyte count;
LUAD	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.11	-0.37	5.52e-15	Diabetic kidney disease;
LUAD	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.55	-0.3	1.64e-10	Mood instability;
LUAD	trans	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.71	-13.08	-0.54	4.61e-33	Initial pursuit acceleration in psychotic disorders;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg13498872	chr1:65720083	NA	-0.74	-7.22	-0.33	2.45e-12	Type 2 diabetes;
LUAD	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg18132916	chr6:79620363	NA	-0.45	-7.72	-0.35	8.4e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg13012494	chr21:47604986	C21orf56	0.46	7.69	0.35	1.03e-13	Testicular germ cell tumor;
LUAD	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg06618935	chr21:46677482	NA	-0.51	-10.32	-0.45	1.97e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg00431813	chr7:1051703	C7orf50	-0.42	-7.87	-0.36	2.92e-14	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.02	0.36	1.04e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.49	0.3	2.34e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.85	0.36	3.35e-14	Bladder cancer;
LUAD	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg18477163	chr1:228402036	OBSCN	-0.36	-7.16	-0.33	3.61e-12	Diastolic blood pressure;
LUAD	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs3087591	0.762	rs7502029	chr17:29590791	T/A	cg24425628	chr17:29625626	OMG;NF1	0.4	6.46	0.3	2.96e-10	Hip circumference;
LUAD	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.59	-12.09	-0.51	4.06e-29	Monocyte percentage of white cells;
LUAD	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg00757033	chr12:89920650	WDR51B	0.69	12.15	0.51	2.5e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg08601574	chr20:25228251	PYGB	-0.46	-8.65	-0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg27068330	chr11:65405492	SIPA1	-0.78	-12.66	-0.52	2.19e-31	Acne (severe);
LUAD	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg23978390	chr7:1156363	C7orf50	0.58	7.9	0.36	2.47e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.39	-6.97	-0.32	1.26e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg20276088	chr3:133502917	NA	-0.38	-6.7	-0.31	6.64e-11	Iron status biomarkers;
LUAD	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.13	0.33	4.29e-12	Renal cell carcinoma;
LUAD	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.14	-0.37	4.48e-15	Prostate cancer;
LUAD	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg04727924	chr7:799746	HEATR2	-0.55	-7.47	-0.34	4.77e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14240646	chr10:27532245	ACBD5	1.02	12.28	0.51	7.15e-30	Breast cancer;
LUAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg21724239	chr8:58056113	NA	0.74	9.62	0.42	5.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6988985	0.765	rs4736317	chr8:143982753	A/G	cg10324643	chr8:143916377	GML	0.31	6.47	0.3	2.72e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg23978390	chr7:1156363	C7orf50	0.57	8.96	0.4	1.03e-17	Longevity;Endometriosis;
LUAD	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg14343924	chr8:8086146	FLJ10661	0.45	6.68	0.31	7.69e-11	Mood instability;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02185971	chr7:6388334	C7orf70	-0.57	-6.91	-0.32	1.82e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg13722127	chr7:150037890	RARRES2	0.51	9.02	0.4	6.81e-18	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg23625390	chr15:77176239	SCAPER	0.38	6.72	0.31	5.76e-11	Blood metabolite levels;
LUAD	trans	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg18335740	chr13:41363409	SLC25A15	0.6	11.06	0.47	3.87e-25	Lewy body disease;
LUAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.66	-0.31	8.33e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24531977	chr5:56204891	C5orf35	-0.85	-12.88	-0.53	3.08e-32	Initial pursuit acceleration;
LUAD	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg26513180	chr16:89883248	FANCA	-0.77	-7.29	-0.33	1.56e-12	Skin colour saturation;
LUAD	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg03467027	chr4:99064603	C4orf37	0.39	6.37	0.3	5.05e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-24.12	-0.76	1.69e-81	Height;
LUAD	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg07810366	chr2:100720526	AFF3	-0.34	-6.95	-0.32	1.37e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs9549328	0.564	rs34556022	chr13:113617437	G/A	cg17524180	chr13:113633600	MCF2L	0.31	6.61	0.31	1.16e-10	Systolic blood pressure;
LUAD	cis	rs2230307	0.536	rs580678	chr1:100483009	C/A	cg20868668	chr1:100435035	SLC35A3	0.54	7.72	0.35	8.45e-14	Carotid intima media thickness;
LUAD	cis	rs62400317	0.826	rs12216308	chr6:45342305	T/G	cg18551225	chr6:44695536	NA	-0.52	-8.13	-0.37	4.9e-15	Total body bone mineral density;
LUAD	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg23815491	chr16:72088622	HP	0.54	9.89	0.43	7e-21	Fibrinogen levels;
LUAD	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg06197492	chr11:2016605	H19	0.42	8.56	0.38	2.11e-16	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs10821973	0.527	rs3852409	chr10:64031676	G/A	cg09941381	chr10:64027924	RTKN2	-0.35	-6.89	-0.32	2.05e-11	Hypothyroidism;
LUAD	cis	rs490234	0.934	rs13284832	chr9:128435126	A/C	cg14078157	chr9:128172775	NA	-0.39	-6.95	-0.32	1.4e-11	Mean arterial pressure;
LUAD	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.3	6.7	0.31	6.62e-11	Depression;
LUAD	cis	rs35883536	0.588	rs955338	chr1:101108794	G/C	cg06223162	chr1:101003688	GPR88	0.37	6.77	0.31	4.26e-11	Monocyte count;
LUAD	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11644478	chr21:40555479	PSMG1	0.7	11.81	0.5	5.37e-28	Cognitive function;
LUAD	cis	rs113835537	0.529	rs2298806	chr11:66282095	G/A	cg26679405	chr11:66247800	DPP3	-0.46	-6.67	-0.31	8.26e-11	Airway imaging phenotypes;
LUAD	cis	rs9341808	0.622	rs682482	chr6:80961139	A/G	cg08355045	chr6:80787529	NA	-0.47	-8.33	-0.38	1.14e-15	Sitting height ratio;
LUAD	cis	rs7000551	0.689	rs2122878	chr8:22311916	T/C	cg12081754	chr8:22256438	SLC39A14	0.44	7.27	0.33	1.8e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11890956	chr21:40555474	PSMG1	0.79	13.85	0.56	3.18e-36	Cognitive function;
LUAD	cis	rs752010	0.619	rs7539238	chr1:42113572	A/C	cg06885757	chr1:42089581	HIVEP3	0.53	12.0	0.5	9.04e-29	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs8072100	0.807	rs4561509	chr17:45781799	G/A	cg07432352	chr17:45403706	C17orf57	0.41	7.72	0.35	8.67e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg06387496	chr7:2775674	GNA12	-0.39	-6.56	-0.3	1.61e-10	Height;
LUAD	cis	rs9486719	0.843	rs2472876	chr6:96845723	A/G	cg06623918	chr6:96969491	KIAA0776	0.71	9.3	0.41	7.58e-19	Migraine;Coronary artery disease;
LUAD	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg06784218	chr1:46089804	CCDC17	-0.51	-11.31	-0.48	4.16e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg18944383	chr4:111397179	ENPEP	0.39	7.81	0.36	4.43e-14	Height;
LUAD	cis	rs7607369	0.526	rs10498060	chr2:219431291	G/A	cg02176678	chr2:219576539	TTLL4	-0.76	-12.43	-0.52	1.88e-30	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.645	rs8181635	chr12:86465136	C/T	cg18827107	chr12:86230957	RASSF9	0.48	8.46	0.38	4.39e-16	Major depressive disorder;
LUAD	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.51	-0.3	2.17e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2554380	0.843	rs7182216	chr15:84422506	C/G	cg14598478	chr15:84363061	ADAMTSL3	0.51	7.99	0.36	1.33e-14	Height;
LUAD	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg04365224	chr3:72788183	NA	-0.44	-6.43	-0.3	3.35e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg12379764	chr21:47803548	PCNT	-0.39	-6.62	-0.31	1.12e-10	Testicular germ cell tumor;
LUAD	trans	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg04565464	chr8:145669602	NFKBIL2	0.46	6.71	0.31	6.43e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs939658	0.935	rs12903747	chr15:79449627	A/C	cg17916960	chr15:79447300	NA	0.46	9.63	0.42	5.65e-20	Refractive error;
LUAD	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.51	-8.25	-0.37	1.96e-15	Platelet count;
LUAD	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.42	-0.34	6.46e-13	Electroencephalogram traits;
LUAD	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg09263875	chr16:632152	PIGQ	0.82	17.1	0.64	3.23e-50	Height;
LUAD	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-10.41	-0.45	9.69e-23	Bone mineral density;
LUAD	cis	rs4523957	0.928	rs216223	chr17:2155948	C/T	cg16513277	chr17:2031491	SMG6	0.75	14.36	0.57	2.2e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.55	0.42	1.08e-19	Monocyte percentage of white cells;
LUAD	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03352830	chr11:487213	PTDSS2	0.73	9.23	0.41	1.34e-18	Body mass index;
LUAD	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg17333051	chr19:2783644	SGTA	0.44	6.99	0.32	1.09e-11	Total cholesterol levels;
LUAD	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg14779329	chr11:130786720	SNX19	0.39	6.84	0.32	2.74e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg11502198	chr6:26597334	ABT1	-0.66	-11.43	-0.49	1.54e-26	Intelligence (multi-trait analysis);
LUAD	trans	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg01620082	chr3:125678407	NA	-0.71	-7.22	-0.33	2.44e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	14.81	0.58	2.75e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg20307385	chr11:47447363	PSMC3	0.67	11.6	0.49	3.47e-27	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg15445000	chr17:37608096	MED1	0.44	8.17	0.37	3.6e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg11871910	chr12:69753446	YEATS4	0.49	7.32	0.34	1.25e-12	Response to diuretic therapy;
LUAD	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg23992470	chr4:843637	GAK	0.7	7.28	0.33	1.65e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1113500	0.614	rs11185243	chr1:108597141	T/C	cg06207961	chr1:108661230	NA	0.44	7.27	0.33	1.76e-12	Growth-regulated protein alpha levels;
LUAD	cis	rs11098699	0.784	rs56129659	chr4:124242326	T/A	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11644478	chr21:40555479	PSMG1	-0.55	-8.86	-0.4	2.21e-17	Cognitive function;
LUAD	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg08493051	chr2:3487164	NA	-0.45	-7.81	-0.35	4.63e-14	Neurofibrillary tangles;
LUAD	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg00701064	chr4:6280414	WFS1	0.59	11.34	0.48	3.28e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg22431228	chr1:16359049	CLCNKA	0.42	8.17	0.37	3.7e-15	Systolic blood pressure;
LUAD	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg12483801	chr4:183727862	NA	0.55	6.78	0.31	4.11e-11	Pediatric autoimmune diseases;
LUAD	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.42e-11	Breast cancer;
LUAD	cis	rs13394619	0.605	rs12476319	chr2:11748406	A/G	cg07314298	chr2:11723111	GREB1	0.41	7.65	0.35	1.33e-13	Endometriosis;
LUAD	cis	rs72772090	0.539	rs2042386	chr5:96156783	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-6.57	-0.3	1.46e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs79911532	0.515	rs79131789	chr7:75756463	C/A	cg19862616	chr7:65841803	NCRNA00174	0.84	8.66	0.39	1.01e-16	Mononucleosis;
LUAD	cis	rs6545883	0.931	rs9807965	chr2:61732159	T/C	cg15711740	chr2:61764176	XPO1	-0.41	-6.63	-0.31	1.03e-10	Tuberculosis;
LUAD	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg27284194	chr4:1044797	NA	0.7	10.1	0.44	1.21e-21	Recombination rate (females);
LUAD	cis	rs494562	0.892	rs544403	chr6:86119116	G/T	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg04511125	chr2:88470314	THNSL2	-0.49	-8.36	-0.38	9.03e-16	Response to metformin (IC50);
LUAD	cis	rs35146811	0.586	rs34213597	chr7:99591021	C/T	cg19636519	chr7:99541626	NA	0.41	6.94	0.32	1.53e-11	Coronary artery disease;
LUAD	cis	rs8067545	0.750	rs11870111	chr17:19992738	G/A	cg04132472	chr17:19861366	AKAP10	0.29	6.99	0.32	1.05e-11	Schizophrenia;
LUAD	cis	rs9868809	0.881	rs3806694	chr3:48672334	G/C	cg00383909	chr3:49044727	WDR6	0.65	7.09	0.33	5.56e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	6.64	0.31	9.66e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg15017067	chr4:17643749	FAM184B	0.35	6.87	0.32	2.36e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs250585	0.736	rs250551	chr16:23440611	C/G	cg00143387	chr16:23521605	GGA2	0.61	8.9	0.4	1.69e-17	Egg allergy;
LUAD	trans	rs7395662	0.929	rs11039903	chr11:48679705	G/T	cg00717180	chr2:96193071	NA	-0.4	-7.39	-0.34	7.75e-13	HDL cholesterol;
LUAD	cis	rs7192380	0.639	rs7186296	chr16:69808998	A/G	cg00738113	chr16:70207722	CLEC18C	0.4	7.92	0.36	2.13e-14	Sjögren's syndrome;
LUAD	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg18477163	chr1:228402036	OBSCN	0.43	8.52	0.38	2.75e-16	Diastolic blood pressure;
LUAD	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg19418458	chr7:158789849	NA	-0.58	-10.08	-0.44	1.42e-21	Facial morphology (factor 20);
LUAD	cis	rs8017423	0.647	rs11623736	chr14:90746471	G/T	cg14092571	chr14:90743983	NA	0.48	8.06	0.36	7.79e-15	Mortality in heart failure;
LUAD	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg10556349	chr10:835070	NA	0.59	7.52	0.34	3.26e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs757647	0.723	rs6894775	chr5:137706422	T/C	cg10676309	chr5:137685565	NA	0.43	7.61	0.35	1.85e-13	Menarche (age at onset);
LUAD	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03264133	chr6:25882463	NA	-0.56	-8.99	-0.4	8.07e-18	Blood metabolite levels;
LUAD	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg02951883	chr7:2050386	MAD1L1	-0.92	-16.7	-0.63	1.93e-48	Bipolar disorder and schizophrenia;
LUAD	trans	rs9784649	1.000	rs56205870	chr5:24958870	A/G	cg08600765	chr20:34638493	LOC647979	-0.59	-7.71	-0.35	9.36e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06529459	chr11:67397595	NUDT8	-0.67	-6.52	-0.3	2.02e-10	Type 2 diabetes;
LUAD	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg13319975	chr6:146136371	FBXO30	-0.82	-14.28	-0.57	4.72e-38	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg23625390	chr15:77176239	SCAPER	-0.51	-7.83	-0.36	3.85e-14	Blood metabolite levels;
LUAD	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg05234568	chr11:5960015	NA	-0.56	-10.07	-0.44	1.61e-21	DNA methylation (variation);
LUAD	trans	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.67	-12.74	-0.53	1.06e-31	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg14668632	chr7:2872130	GNA12	-0.75	-13.15	-0.54	2.34e-33	Height;
LUAD	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg04414720	chr1:150670196	GOLPH3L	0.73	13.41	0.55	2.13e-34	Tonsillectomy;
LUAD	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11890956	chr21:40555474	PSMG1	-0.58	-9.44	-0.42	2.55e-19	Cognitive function;
LUAD	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg24848339	chr3:12840334	CAND2	0.49	10.41	0.45	9.86e-23	QRS complex (12-leadsum);
LUAD	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg03034668	chr16:1723424	CRAMP1L	-0.38	-6.54	-0.3	1.78e-10	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg02248941	chr16:2239361	CASKIN1	0.61	12.46	0.52	1.38e-30	Height;
LUAD	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg25324976	chr17:61989376	CSHL1	0.41	7.85	0.36	3.38e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9863	0.931	rs11057407	chr12:124449829	G/A	cg17723958	chr12:124429295	CCDC92	-0.41	-6.55	-0.3	1.65e-10	White blood cell count;
LUAD	cis	rs2731664	0.792	rs335452	chr5:176879671	C/T	cg23176889	chr5:176863531	GRK6	-0.76	-14.95	-0.59	6.87e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg15704280	chr7:45808275	SEPT13	-0.78	-12.05	-0.51	6.12e-29	Coronary artery disease;
LUAD	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg11502198	chr6:26597334	ABT1	0.67	11.78	0.5	6.62e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs12681287	0.640	rs7833049	chr8:87445898	T/C	cg27223183	chr8:87520930	FAM82B	0.67	9.56	0.42	9.76e-20	Caudate activity during reward;
LUAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg07432352	chr17:45403706	C17orf57	-0.4	-7.69	-0.35	1.02e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7586879	0.828	rs13387053	chr2:25103025	G/A	cg04586622	chr2:25135609	ADCY3	0.35	7.25	0.33	2.03e-12	Body mass index;
LUAD	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg19761014	chr17:28927070	LRRC37B2	0.83	8.21	0.37	2.8e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg17366294	chr4:99064904	C4orf37	0.65	12.53	0.52	7.61e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6543140	0.964	rs6748390	chr2:103062175	A/G	cg03938978	chr2:103052716	IL18RAP	0.36	7.02	0.32	8.9e-12	Blood protein levels;
LUAD	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg13319975	chr6:146136371	FBXO30	-0.54	-9.28	-0.41	9.13e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg13319975	chr6:146136371	FBXO30	-0.6	-10.27	-0.45	2.97e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs654950	0.875	rs116747365	chr1:41994792	C/T	cg06885757	chr1:42089581	HIVEP3	-0.32	-6.75	-0.31	4.74e-11	Airway imaging phenotypes;
LUAD	trans	rs7746199	0.736	rs13202295	chr6:27698837	C/T	cg06606381	chr12:133084897	FBRSL1	-1.21	-10.9	-0.47	1.45e-24	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg20203395	chr5:56204925	C5orf35	-0.82	-11.8	-0.5	5.55e-28	Initial pursuit acceleration;
LUAD	cis	rs4332037	0.722	rs4721140	chr7:1917635	A/T	cg23422044	chr7:1970798	MAD1L1	-0.5	-7.01	-0.32	9.41e-12	Bipolar disorder;
LUAD	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg13385794	chr1:248469461	NA	0.25	6.9	0.32	1.92e-11	Common traits (Other);
LUAD	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg06641503	chr3:48959341	ARIH2	-0.4	-7.85	-0.36	3.56e-14	Parkinson's disease;
LUAD	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	12.74	0.53	1.09e-31	Melanoma;
LUAD	cis	rs9434723	0.841	rs9435152	chr1:9308249	C/T	cg04199779	chr1:9294473	H6PD	0.58	6.4	0.3	4.23e-10	Height;
LUAD	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg06022373	chr22:39101656	GTPBP1	0.48	7.95	0.36	1.66e-14	Menopause (age at onset);
LUAD	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg14668632	chr7:2872130	GNA12	0.46	8.37	0.38	8.52e-16	Height;
LUAD	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03956646	chr8:143750859	JRK	0.41	6.57	0.3	1.47e-10	Survival in pancreatic cancer;
LUAD	cis	rs6060717	0.536	rs6060683	chr20:34507921	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.06	-0.32	7.08e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg26597838	chr10:835615	NA	1.28	19.87	0.69	1.55e-62	Eosinophil percentage of granulocytes;
LUAD	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg20701182	chr2:24300061	SF3B14	0.47	7.54	0.34	2.84e-13	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg10755058	chr3:40428713	ENTPD3	0.39	7.49	0.34	4.14e-13	Renal cell carcinoma;
LUAD	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg06713675	chr4:122721982	EXOSC9	-0.59	-11.34	-0.48	3.29e-26	Type 2 diabetes;
LUAD	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg01017244	chr2:74357527	NA	0.9	14.43	0.57	1.17e-38	Gestational age at birth (maternal effect);
LUAD	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg09117114	chr16:67998030	SLC12A4	-0.6	-7.52	-0.34	3.4e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3820068	0.655	rs11587521	chr1:15839206	T/C	cg13390004	chr1:15929781	NA	0.41	6.71	0.31	6.1e-11	Systolic blood pressure;
LUAD	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg01299579	chr2:10830716	NOL10	-0.43	-7.72	-0.35	8.67e-14	Prostate cancer;
LUAD	cis	rs2637266	1.000	rs11001830	chr10:78346396	G/A	cg18941641	chr10:78392320	NA	0.33	6.82	0.31	3.24e-11	Pulmonary function;
LUAD	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.23	0.37	2.28e-15	Breast cancer;
LUAD	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg01884057	chr2:25150051	NA	0.32	6.85	0.32	2.6e-11	Body mass index;
LUAD	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg05340658	chr4:99064831	C4orf37	-0.56	-9.62	-0.42	5.86e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg15017067	chr4:17643749	FAM184B	-0.38	-7.44	-0.34	5.75e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs60787346	0.883	rs3788070	chr21:45068077	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.09	-0.33	5.66e-12	Coronary artery disease;
LUAD	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg21028142	chr17:79581711	NPLOC4	0.42	8.82	0.39	2.98e-17	Eye color traits;
LUAD	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg25767906	chr1:53392781	SCP2	0.43	7.85	0.36	3.49e-14	Monocyte count;
LUAD	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19717773	chr7:2847554	GNA12	-0.56	-9.68	-0.43	3.63e-20	Height;
LUAD	cis	rs68170813	0.559	rs4730231	chr7:106942039	G/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.48	-0.45	5.46e-23	Coronary artery disease;
LUAD	trans	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg18187862	chr3:45730750	SACM1L	0.5	7.81	0.36	4.45e-14	Primary sclerosing cholangitis;
LUAD	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg12863693	chr15:85201151	NMB	0.39	7.33	0.34	1.19e-12	Schizophrenia;
LUAD	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg09021430	chr5:549028	NA	-0.49	-12.23	-0.51	1.2e-29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg23598886	chr18:12777645	NA	0.63	7.93	0.36	2.03e-14	Inflammatory skin disease;
LUAD	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg21028142	chr17:79581711	NPLOC4	-0.38	-7.71	-0.35	8.96e-14	Eye color traits;
LUAD	cis	rs2554380	0.628	rs7179507	chr15:84473531	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.36	-6.48	-0.3	2.56e-10	Height;
LUAD	cis	rs10748180	0.502	rs1048897	chr12:72094959	T/C	cg10168894	chr12:72148281	RAB21	-0.42	-6.45	-0.3	3.02e-10	Economic and political preferences (time);
LUAD	cis	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg21775007	chr8:11205619	TDH	-0.39	-6.75	-0.31	4.96e-11	Neuroticism;
LUAD	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	7.3	0.33	1.48e-12	Renal cell carcinoma;
LUAD	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg13319975	chr6:146136371	FBXO30	-0.64	-11.31	-0.48	4.29e-26	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs11088226	0.645	rs2833917	chr21:33957544	C/T	cg09050820	chr6:167586206	TCP10L2	0.92	13.17	0.54	1.91e-33	Gastritis;
LUAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08280861	chr8:58055591	NA	0.55	7.16	0.33	3.53e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	cis	rs9393692	0.557	rs9366648	chr6:26306282	T/C	cg13736514	chr6:26305472	NA	-0.54	-8.81	-0.39	3.16e-17	Educational attainment;
LUAD	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg10518543	chr12:38710700	ALG10B	0.41	6.39	0.3	4.29e-10	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg18944383	chr4:111397179	ENPEP	-0.37	-7.03	-0.32	8.21e-12	Coronary artery disease;
LUAD	cis	rs7731657	0.537	rs6595968	chr5:130284843	G/C	cg08523029	chr5:130500466	HINT1	0.58	7.45	0.34	5.29e-13	Fasting plasma glucose;
LUAD	cis	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg23422044	chr7:1970798	MAD1L1	-0.5	-7.14	-0.33	4.07e-12	Bipolar disorder;
LUAD	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.68	-0.31	7.59e-11	Bipolar disorder;
LUAD	cis	rs494562	0.892	rs9294335	chr6:86126680	C/T	cg17966619	chr6:86160162	NT5E	0.66	7.83	0.36	4.05e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1232027	0.700	rs1677700	chr5:79931419	T/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg15556689	chr8:8085844	FLJ10661	0.43	6.92	0.32	1.69e-11	Mood instability;
LUAD	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-8.57	-0.38	2.01e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	13.98	0.56	8.76e-37	Smoking behavior;
LUAD	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.51	-0.3	2.17e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11229555	0.645	rs12272911	chr11:58183839	G/C	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg05283184	chr6:79620031	NA	-0.61	-12.27	-0.51	7.82e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg03526776	chr6:41159608	TREML2	0.35	7.33	0.34	1.21e-12	Alzheimer's disease (late onset);
LUAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.88	-0.32	2.16e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7274811	0.688	rs6141400	chr20:32056087	C/T	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.49	-7.43	-0.34	5.88e-13	Height;
LUAD	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg22920501	chr2:26401640	FAM59B	1.0	14.38	0.57	1.85e-38	Gut microbiome composition (summer);
LUAD	cis	rs9644630	0.897	rs28671342	chr8:19352420	C/T	cg06699216	chr8:19333253	CSGALNACT1	0.3	7.15	0.33	3.8e-12	Oropharynx cancer;
LUAD	cis	rs931127	0.505	rs2306362	chr11:65405510	G/T	cg27068330	chr11:65405492	SIPA1	-0.82	-12.91	-0.53	2.16e-32	Systemic lupus erythematosus;
LUAD	trans	rs783540	0.656	rs783538	chr15:83253143	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.54	-8.42	-0.38	5.91e-16	Schizophrenia;
LUAD	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg18404041	chr3:52824283	ITIH1	-0.61	-10.89	-0.47	1.6e-24	Bipolar disorder;
LUAD	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg12365402	chr11:9010492	NRIP3	-0.46	-8.92	-0.4	1.38e-17	Hemoglobin concentration;
LUAD	cis	rs9486719	0.947	rs12210834	chr6:96890407	A/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.04	-0.44	2.05e-21	Migraine;Coronary artery disease;
LUAD	trans	rs9951602	0.703	rs2959407	chr18:76682915	A/G	cg02800362	chr5:177631904	HNRNPAB	0.59	8.1	0.37	6.05e-15	Obesity-related traits;
LUAD	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg18827107	chr12:86230957	RASSF9	-0.62	-10.9	-0.47	1.45e-24	Major depressive disorder;
LUAD	cis	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg23422044	chr7:1970798	MAD1L1	-0.5	-7.05	-0.32	7.49e-12	Bipolar disorder;
LUAD	cis	rs2806561	0.929	rs628096	chr1:23537676	C/G	cg12483005	chr1:23474871	LUZP1	0.38	6.42	0.3	3.7e-10	Height;
LUAD	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg27494647	chr7:150038898	RARRES2	0.43	7.14	0.33	4.12e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg06641503	chr3:48959341	ARIH2	-0.36	-6.42	-0.3	3.6e-10	Menarche (age at onset);
LUAD	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg08885076	chr2:99613938	TSGA10	0.36	6.46	0.3	2.91e-10	Chronic sinus infection;
LUAD	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg02734326	chr4:10020555	SLC2A9	0.63	11.35	0.48	3.08e-26	Bone mineral density;
LUAD	cis	rs10203711	0.933	rs11883643	chr2:239586885	A/G	cg07725849	chr2:239542273	NA	-0.32	-6.63	-0.31	1.01e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg00769240	chr8:12517080	NA	-0.39	-6.53	-0.3	1.87e-10	Blood pressure (smoking interaction);
LUAD	cis	rs17102423	0.594	rs8010213	chr14:65552182	C/T	cg16583315	chr14:65563665	MAX	-0.35	-6.58	-0.3	1.36e-10	Obesity-related traits;
LUAD	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9469913	0.799	rs2744954	chr6:34621470	A/G	cg14254433	chr6:34482411	PACSIN1	-0.42	-6.53	-0.3	1.9e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08280861	chr8:58055591	NA	0.76	9.44	0.42	2.45e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2882667	0.867	rs6868085	chr5:138432446	G/A	cg04439458	chr5:138467593	SIL1	-0.41	-7.25	-0.33	1.99e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs10484885	0.878	rs72921934	chr6:90579464	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.64	-6.41	-0.3	3.98e-10	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg18402987	chr7:1209562	NA	0.69	9.48	0.42	1.87e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg05887092	chr17:76393375	PGS1	0.41	7.28	0.33	1.65e-12	HDL cholesterol levels;
LUAD	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg02423579	chr7:2872169	GNA12	-0.58	-9.84	-0.43	1.06e-20	Height;
LUAD	cis	rs17789174	0.646	rs62049877	chr16:85092451	G/A	cg27466129	chr16:85060822	KIAA0513	0.3	6.58	0.3	1.41e-10	Dysphagia;
LUAD	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg20891558	chr2:74357851	NA	1.01	16.12	0.62	6.18e-46	Gestational age at birth (maternal effect);
LUAD	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg05042697	chr2:10830656	NOL10	-0.37	-6.38	-0.3	4.66e-10	Prostate cancer;
LUAD	cis	rs568617	0.716	rs77779142	chr11:65599656	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.67	7.64	0.35	1.48e-13	Crohn's disease;
LUAD	cis	rs12348691	0.503	rs10739513	chr9:100592705	C/T	cg13688889	chr9:100608707	NA	-0.62	-10.44	-0.45	7.37e-23	Alopecia areata;
LUAD	cis	rs36051895	0.632	rs7469563	chr9:5139489	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-6.48	-0.3	2.51e-10	Pediatric autoimmune diseases;
LUAD	cis	rs7927592	0.546	rs497261	chr11:68192244	T/C	cg01657329	chr11:68192670	LRP5	-0.54	-9.28	-0.41	8.66e-19	Total body bone mineral density;
LUAD	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg22117172	chr7:91764530	CYP51A1	0.35	7.43	0.34	5.99e-13	Breast cancer;
LUAD	cis	rs3106136	1.000	rs2664871	chr4:95146281	A/G	cg11021082	chr4:95130006	SMARCAD1	0.4	7.46	0.34	4.87e-13	Capecitabine sensitivity;
LUAD	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs12760731	0.565	rs12040475	chr1:178185651	G/A	cg00404053	chr1:178313656	RASAL2	0.74	9.23	0.41	1.28e-18	Obesity-related traits;
LUAD	cis	rs12545109	0.917	rs10098993	chr8:57323116	T/C	cg07776626	chr8:57350775	NA	-0.64	-8.84	-0.39	2.58e-17	Obesity-related traits;
LUAD	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03517284	chr6:25882590	NA	0.55	9.25	0.41	1.09e-18	Blood metabolite levels;
LUAD	cis	rs1847202	0.859	rs13068268	chr3:72938132	G/A	cg25664220	chr3:72788482	NA	-0.42	-7.61	-0.35	1.79e-13	Motion sickness;
LUAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg10729496	chr3:10149963	C3orf24	0.49	7.93	0.36	1.92e-14	Alzheimer's disease;
LUAD	cis	rs2046867	0.908	rs11927166	chr3:72795149	C/G	cg04365224	chr3:72788183	NA	-0.46	-7.12	-0.33	4.57e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7107174	0.892	rs2510038	chr11:77966034	C/T	cg19901956	chr11:77921274	USP35	-0.53	-6.66	-0.31	8.71e-11	Testicular germ cell tumor;
LUAD	trans	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.64	-12.19	-0.51	1.6800000000000001e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.62	-12.28	-0.51	7.22e-30	Homoarginine levels;
LUAD	cis	rs10193935	0.901	rs222468	chr2:42642531	C/T	cg27598129	chr2:42591480	NA	-0.68	-8.83	-0.39	2.72e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg13699009	chr12:122356056	WDR66	0.39	8.8	0.39	3.62e-17	Mean corpuscular volume;
LUAD	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg03433033	chr1:76189801	ACADM	-0.85	-15.64	-0.61	7.39e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27286337	chr10:134555280	INPP5A	0.7	9.34	0.41	5.71e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs3018712	0.532	rs2513280	chr11:68416907	C/G	cg16797656	chr11:68205561	LRP5	-0.42	-6.46	-0.3	2.86e-10	Total body bone mineral density;
LUAD	trans	rs7395662	1.000	rs4929903	chr11:48913332	T/G	cg00717180	chr2:96193071	NA	-0.43	-8.39	-0.38	7.59e-16	HDL cholesterol;
LUAD	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg20891558	chr2:74357851	NA	0.94	15.12	0.59	1.38e-41	Gestational age at birth (maternal effect);
LUAD	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg07570687	chr10:102243282	WNT8B	0.43	6.56	0.3	1.54e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.4	-7.41	-0.34	6.93e-13	IgG glycosylation;
LUAD	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg04727924	chr7:799746	HEATR2	-0.55	-7.35	-0.34	1.04e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg18306943	chr3:40428807	ENTPD3	0.4	7.09	0.33	5.68e-12	Renal cell carcinoma;
LUAD	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg15017067	chr4:17643749	FAM184B	0.37	7.29	0.33	1.53e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg06784218	chr1:46089804	CCDC17	0.53	11.37	0.48	2.44e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.56	9.72	0.43	2.65e-20	Lymphocyte counts;
LUAD	trans	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg07211511	chr3:129823064	LOC729375	-0.5	-6.58	-0.3	1.39e-10	Blood pressure (smoking interaction);
LUAD	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg10876282	chr6:28092338	ZSCAN16	0.46	7.23	0.33	2.35e-12	Cardiac Troponin-T levels;
LUAD	cis	rs1003719	0.715	rs2835640	chr21:38537380	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.43	-0.38	5.42e-16	Eye color traits;
LUAD	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg11502198	chr6:26597334	ABT1	0.67	11.66	0.49	1.95e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.87	0.36	2.95e-14	Depression;
LUAD	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg15412446	chr2:106886593	NA	-0.8	-12.14	-0.51	2.72e-29	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	trans	rs7395662	1.000	rs11039821	chr11:48562875	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.31	-0.33	1.32e-12	HDL cholesterol;
LUAD	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg16329650	chr2:213403929	ERBB4	0.6	10.88	0.47	1.72e-24	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg18944383	chr4:111397179	ENPEP	0.39	7.84	0.36	3.75e-14	Height;
LUAD	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg03560586	chr2:239334908	ASB1	-0.3	-6.57	-0.3	1.44e-10	Multiple system atrophy;
LUAD	cis	rs1448094	0.842	rs10863159	chr12:86459140	T/C	cg02569458	chr12:86230093	RASSF9	-0.36	-6.9	-0.32	1.9e-11	Major depressive disorder;
LUAD	trans	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg00953403	chr17:74099816	EXOC7	0.45	7.17	0.33	3.37e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg27427491	chr17:78079615	GAA	-0.39	-7.45	-0.34	5.2e-13	Yeast infection;
LUAD	cis	rs7737355	0.812	rs10515455	chr5:130878789	C/T	cg25547332	chr5:131281432	NA	0.43	6.9	0.32	1.91e-11	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	15.83	0.61	1.13e-44	Exhaled nitric oxide levels;
LUAD	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg07570687	chr10:102243282	WNT8B	0.48	7.28	0.33	1.6e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg07606381	chr6:8435919	SLC35B3	-0.42	-7.19	-0.33	3.03e-12	Motion sickness;
LUAD	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg26597838	chr10:835615	NA	0.95	14.14	0.57	1.88e-37	Eosinophil percentage of granulocytes;
LUAD	cis	rs7264396	0.563	rs6060558	chr20:34271092	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.87	-0.36	2.9e-14	Total cholesterol levels;
LUAD	trans	rs12310956	0.532	rs10772114	chr12:33853970	G/A	cg10518543	chr12:38710700	ALG10B	0.42	6.78	0.31	4.01e-11	Morning vs. evening chronotype;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08215925	chr3:71633214	FOXP1	0.5	6.4	0.3	4.1e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg02951883	chr7:2050386	MAD1L1	0.85	15.6	0.6	1.11e-43	Bipolar disorder and schizophrenia;
LUAD	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg19336497	chr11:14380999	RRAS2	-0.7	-16.31	-0.62	9.45e-47	Sense of smell;
LUAD	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg13319975	chr6:146136371	FBXO30	0.59	10.05	0.44	1.92e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg23131131	chr22:24373011	LOC391322	-0.59	-9.96	-0.44	3.95e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2742417	0.967	rs2742426	chr3:45735901	A/G	cg10512202	chr3:45649293	LIMD1	0.37	6.52	0.3	2.04e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.1	-0.51	3.68e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs11112613	0.653	rs941101	chr12:105937098	T/G	cg03607813	chr12:105948248	NA	0.84	12.37	0.52	3.33e-30	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs986417	1.000	rs7159212	chr14:61068725	T/C	cg27398547	chr14:60952738	C14orf39	0.64	7.12	0.33	4.64e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.83	0.32	2.93e-11	Colorectal cancer;
LUAD	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg15782153	chr7:917662	C7orf20	0.62	11.64	0.49	2.44e-27	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11644478	chr21:40555479	PSMG1	0.67	11.23	0.48	8.8e-26	Cognitive function;
LUAD	cis	rs986417	1.000	rs1956549	chr14:60928201	G/A	cg27398547	chr14:60952738	C14orf39	0.63	7.72	0.35	8.34e-14	Gut microbiota (bacterial taxa);
LUAD	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg20587970	chr11:113659929	NA	1.12	15.24	0.6	3.9e-42	Hip circumference adjusted for BMI;
LUAD	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg20203395	chr5:56204925	C5orf35	-0.84	-11.94	-0.5	1.64e-28	Initial pursuit acceleration;
LUAD	cis	rs2274273	0.712	rs7144652	chr14:55537718	G/A	cg04306507	chr14:55594613	LGALS3	0.31	6.45	0.3	3.13e-10	Protein biomarker;
LUAD	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg05887092	chr17:76393375	PGS1	0.42	7.44	0.34	5.83e-13	HDL cholesterol levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21680979	chr1:204485559	MDM4	-0.53	-6.43	-0.3	3.5e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg00277334	chr10:82204260	NA	-0.57	-9.5	-0.42	1.62e-19	Post bronchodilator FEV1;
LUAD	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1493916	0.601	rs7237379	chr18:31322540	C/T	cg27147174	chr7:100797783	AP1S1	0.68	11.97	0.5	1.21e-28	Life satisfaction;
LUAD	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg20607798	chr8:58055168	NA	0.79	9.69	0.43	3.43e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg23985595	chr17:80112537	CCDC57	-0.53	-9.92	-0.43	5.5e-21	Life satisfaction;
LUAD	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	7.94e-19	Tonsillectomy;
LUAD	trans	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.48	-0.34	4.45e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2230307	0.656	rs114775204	chr1:100463030	T/C	cg20868668	chr1:100435035	SLC35A3	0.63	7.58	0.35	2.21e-13	Carotid intima media thickness;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg09346547	chr7:75189280	HIP1	0.39	6.6	0.31	1.23e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg26408565	chr15:76604113	ETFA	-0.46	-7.4	-0.34	7.18e-13	Blood metabolite levels;
LUAD	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg24154853	chr7:158122151	PTPRN2	0.58	11.6	0.49	3.49e-27	Calcium levels;
LUAD	cis	rs9902453	0.619	rs2617866	chr17:28076217	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.37	-0.41	4.25e-19	Coffee consumption (cups per day);
LUAD	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg15147215	chr3:52552868	STAB1	-0.4	-7.47	-0.34	4.69e-13	Bipolar disorder;
LUAD	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.35	-0.38	9.63e-16	Prostate cancer;
LUAD	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.18	-0.41	1.96e-18	Total body bone mineral density;
LUAD	cis	rs6062509	0.965	rs2315008	chr20:62343956	T/G	cg01176363	chr20:62369445	LIME1	-0.48	-7.78	-0.35	5.67e-14	Prostate cancer;
LUAD	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.23	-0.33	2.29e-12	Height;
LUAD	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg04369109	chr6:150039330	LATS1	-0.46	-7.97	-0.36	1.52e-14	Lung cancer;
LUAD	cis	rs1497406	0.744	rs4537547	chr1:16510798	C/T	cg20430773	chr1:16534157	ARHGEF19	-0.39	-6.66	-0.31	8.66e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.85	10.01	0.44	2.65e-21	Yeast infection;
LUAD	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.39	6.38	0.3	4.72e-10	Multiple sclerosis;
LUAD	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg23954153	chr1:44402353	ARTN	-0.34	-6.73	-0.31	5.62e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-7.18	-0.33	3.18e-12	Monocyte percentage of white cells;
LUAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg22535103	chr8:58192502	C8orf71	-0.77	-9.11	-0.4	3.36e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs13315871	0.929	rs13097873	chr3:58267924	C/T	cg20936604	chr3:58311152	NA	-0.58	-6.51	-0.3	2.16e-10	Cholesterol, total;
LUAD	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-7.84	-0.36	3.69e-14	Breast cancer;
LUAD	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg17849569	chr6:28058911	ZSCAN12L1	0.33	7.06	0.32	7.03e-12	Depression;
LUAD	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.9	-0.47	1.53e-24	Total body bone mineral density;
LUAD	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.78	-0.39	4.19e-17	Total body bone mineral density;
LUAD	cis	rs9462027	0.606	rs2814981	chr6:34581055	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.72	-0.39	6.64e-17	Systemic lupus erythematosus;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06282462	chr4:128886421	MFSD8;C4orf29	-0.67	-6.7	-0.31	6.67e-11	Type 2 diabetes;
LUAD	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg13722127	chr7:150037890	RARRES2	0.42	7.09	0.33	5.57e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg00701064	chr4:6280414	WFS1	0.52	8.92	0.4	1.38e-17	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7640424	0.649	rs62262371	chr3:107896108	C/T	cg09227934	chr3:107805635	CD47	-0.48	-8.5	-0.38	3.4e-16	Body mass index;
LUAD	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg20476274	chr7:133979776	SLC35B4	0.83	16.79	0.63	7.34e-49	Mean platelet volume;
LUAD	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg23985595	chr17:80112537	CCDC57	0.52	9.54	0.42	1.11e-19	Life satisfaction;
LUAD	cis	rs11792861	0.591	rs11791855	chr9:111684139	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.37	6.43	0.3	3.37e-10	Menarche (age at onset);
LUAD	trans	rs3960554	0.808	rs59882870	chr7:75638421	G/A	cg19862616	chr7:65841803	NCRNA00174	0.79	10.43	0.45	7.88e-23	Eotaxin levels;
LUAD	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg20290983	chr6:43655470	MRPS18A	1.07	27.14	0.8	1.12e-94	IgG glycosylation;
LUAD	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg17849569	chr6:28058911	ZSCAN12L1	-0.29	-6.43	-0.3	3.48e-10	Depression;
LUAD	cis	rs4285028	0.948	rs13067270	chr3:121673901	A/C	cg11130432	chr3:121712080	ILDR1	-0.59	-8.41	-0.38	6.16e-16	Multiple sclerosis;
LUAD	cis	rs1018836	0.923	rs4734266	chr8:91628147	C/T	cg16814680	chr8:91681699	NA	-0.7	-11.77	-0.5	7.15e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg07677032	chr17:61819896	STRADA	0.58	10.59	0.46	2.07e-23	Prudent dietary pattern;
LUAD	cis	rs506338	0.517	rs530252	chr11:64443465	T/C	cg19395706	chr11:64412079	NRXN2	0.35	6.47	0.3	2.66e-10	Body mass index;Urate levels;
LUAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06873352	chr17:61820015	STRADA	0.83	18.32	0.67	1.32e-55	Prudent dietary pattern;
LUAD	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg15147215	chr3:52552868	STAB1	-0.52	-9.96	-0.44	4.08e-21	Electroencephalogram traits;
LUAD	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg05110241	chr16:68378359	PRMT7	-0.69	-7.83	-0.36	3.89e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4356932	0.967	rs7436646	chr4:76955229	T/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.54	-0.3	1.78e-10	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2387326	0.671	rs10829346	chr10:129946104	C/T	cg16087940	chr10:129947807	NA	-0.64	-9.0	-0.4	7.75e-18	Select biomarker traits;
LUAD	cis	rs6543140	0.964	rs10200081	chr2:103091556	T/C	cg03938978	chr2:103052716	IL18RAP	0.35	6.72	0.31	6.04e-11	Blood protein levels;
LUAD	trans	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.72	-10.31	-0.45	2.23e-22	Obesity-related traits;
LUAD	trans	rs9929218	0.539	rs1125557	chr16:68809599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.0	20.92	0.71	3.14e-67	Colorectal cancer;
LUAD	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg00898013	chr13:113819073	PROZ	0.59	10.64	0.46	1.35e-23	Platelet distribution width;
LUAD	trans	rs17604090	0.557	rs10279965	chr7:29717082	C/G	cg27349345	chr7:35225932	NA	-0.45	-6.46	-0.3	2.97e-10	Facial emotion recognition;Facial emotion recognition (sad faces);
LUAD	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg27068330	chr11:65405492	SIPA1	0.55	8.66	0.39	1.03e-16	Acne (severe);
LUAD	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18876405	chr7:65276391	NA	-0.58	-9.92	-0.43	5.61e-21	Aortic root size;
LUAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08280861	chr8:58055591	NA	0.63	8.31	0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs57590327	0.503	rs13079104	chr3:81886039	A/T	cg07356753	chr3:81810745	GBE1	-0.52	-8.28	-0.37	1.68e-15	Extraversion;
LUAD	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg03037974	chr15:76606532	NA	0.37	7.95	0.36	1.73e-14	Blood metabolite levels;
LUAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg26354017	chr1:205819088	PM20D1	0.81	17.06	0.64	5.12e-50	Menarche (age at onset);
LUAD	cis	rs948562	0.647	rs71486418	chr11:58240133	C/T	cg15696309	chr11:58395628	NA	-0.4	-6.67	-0.31	7.8e-11	Lymphoma;
LUAD	trans	rs8002861	0.875	rs12869697	chr13:44439169	T/C	cg17145862	chr1:211918768	LPGAT1	-0.67	-14.56	-0.58	3.29e-39	Leprosy;
LUAD	cis	rs758324	0.773	rs2404777	chr5:131172803	C/A	cg06307176	chr5:131281290	NA	0.44	7.4	0.34	7.55e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg24112000	chr20:60950667	NA	0.71	11.62	0.49	2.89e-27	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs77972916	0.505	rs34247383	chr2:43532780	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-9.63	-0.42	5.52e-20	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.14	-0.33	4.01e-12	Lung cancer;
LUAD	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.13e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg18833306	chr6:118973337	C6orf204	-0.54	-7.64	-0.35	1.44e-13	Diastolic blood pressure;
LUAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.57	-9.09	-0.4	3.74e-18	Renal function-related traits (BUN);
LUAD	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg26446133	chr18:72167187	CNDP2	-0.82	-12.26	-0.51	9.24e-30	Refractive error;
LUAD	cis	rs698833	0.892	rs698796	chr2:44689669	C/A	cg04920474	chr2:44395004	PPM1B	0.41	7.39	0.34	8.03e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	trans	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg01620082	chr3:125678407	NA	-1.01	-9.6	-0.42	7.4e-20	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg24011408	chr12:48396354	COL2A1	-0.33	-6.45	-0.3	3.03e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg00406319	chr10:126851303	NA	-0.36	-7.31	-0.34	1.31e-12	Menarche (age at onset);
LUAD	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg18105139	chr6:28058856	ZSCAN12L1	0.25	6.36	0.3	5.25e-10	Cardiac Troponin-T levels;
LUAD	cis	rs6542838	0.583	rs12712040	chr2:99513416	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.65	-0.31	9.3e-11	Fear of minor pain;
LUAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg05717871	chr11:638507	DRD4	-0.41	-6.42	-0.3	3.73e-10	Systemic lupus erythematosus;
LUAD	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg22875332	chr1:76189707	ACADM	-0.89	-15.87	-0.61	7.83e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs240764	0.782	rs239231	chr6:101105022	G/A	cg09795085	chr6:101329169	ASCC3	0.44	7.51	0.34	3.56e-13	Neuroticism;
LUAD	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg23625390	chr15:77176239	SCAPER	-0.52	-8.07	-0.37	7.15e-15	Blood metabolite levels;
LUAD	cis	rs77861329	1.000	rs352151	chr3:52210272	C/G	cg08692210	chr3:52188851	WDR51A	0.86	8.03	0.36	1.01e-14	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs68170813	0.559	rs60255281	chr7:106963913	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.63	-0.46	1.46e-23	Coronary artery disease;
LUAD	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.58	-9.96	-0.44	3.96e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg27432699	chr2:27873401	GPN1	0.57	10.19	0.44	5.95e-22	Oral cavity cancer;
LUAD	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.08	-0.33	5.91e-12	Total body bone mineral density;
LUAD	cis	rs2281636	0.929	rs7913190	chr10:101498396	T/G	cg17885402	chr10:101492224	COX15;CUTC	-0.38	-6.57	-0.3	1.47e-10	Obesity-related traits;
LUAD	cis	rs4700695	0.614	rs153374	chr5:65424875	A/G	cg21114390	chr5:65439923	SFRS12	0.64	6.61	0.31	1.17e-10	Facial morphology (factor 19);
LUAD	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg18477163	chr1:228402036	OBSCN	-0.35	-7.01	-0.32	9.26e-12	Diastolic blood pressure;
LUAD	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.44	-0.38	5.08e-16	Prostate cancer;
LUAD	cis	rs7107174	1.000	rs1006441	chr11:77932126	G/C	cg19901956	chr11:77921274	USP35	-0.53	-6.58	-0.3	1.42e-10	Testicular germ cell tumor;
LUAD	cis	rs2901656	0.652	rs3213563	chr1:172412995	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.51	9.86	0.43	8.5e-21	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs7149337	0.836	rs11622116	chr14:51670744	C/T	cg23942311	chr14:51606299	NA	0.85	19.36	0.69	3e-60	Cancer;
LUAD	cis	rs12135894	0.648	rs4648423	chr1:3765678	C/T	cg17848003	chr1:3704513	LRRC47	-0.46	-10.2	-0.44	5.44e-22	Mean corpuscular volume;
LUAD	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18876405	chr7:65276391	NA	0.43	6.75	0.31	4.85e-11	Aortic root size;
LUAD	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg23625390	chr15:77176239	SCAPER	0.4	7.22	0.33	2.41e-12	Blood metabolite levels;
LUAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg00106254	chr7:1943704	MAD1L1	-0.54	-7.64	-0.35	1.44e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.17	0.37	3.57e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg27432699	chr2:27873401	GPN1	0.58	10.18	0.44	6.3e-22	Oral cavity cancer;
LUAD	cis	rs2479724	0.870	rs6902650	chr6:41764080	G/A	cg17623882	chr6:41773611	USP49	0.7	13.18	0.54	1.86e-33	Menarche (age at onset);
LUAD	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24308560	chr3:49941425	MST1R	0.59	10.11	0.44	1.19e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06544989	chr22:39130855	UNC84B	0.46	9.19	0.41	1.8e-18	Menopause (age at onset);
LUAD	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg03467027	chr4:99064603	C4orf37	0.39	6.45	0.3	3.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg08027265	chr7:2291960	NA	-0.43	-7.06	-0.32	6.87e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg01475377	chr6:109611718	NA	-0.5	-9.41	-0.42	3.17e-19	Reticulocyte fraction of red cells;
LUAD	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21659725	chr3:3221576	CRBN	0.69	11.48	0.49	9.5e-27	Resting heart rate;
LUAD	cis	rs4711350	0.749	rs7752348	chr6:33718252	C/G	cg18005901	chr6:33739558	LEMD2	-0.46	-6.83	-0.31	3.04e-11	Schizophrenia;
LUAD	cis	rs758324	0.617	rs9717078	chr5:131170891	G/A	cg25547332	chr5:131281432	NA	0.43	6.62	0.31	1.07e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg15445000	chr17:37608096	MED1	0.45	8.22	0.37	2.5e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs6743376	0.556	rs6748448	chr2:113819419	A/G	cg09040174	chr2:113837401	NA	0.51	7.85	0.36	3.48e-14	Inflammatory biomarkers;
LUAD	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg05768032	chr16:30646687	NA	0.44	7.87	0.36	3.1e-14	Multiple myeloma;
LUAD	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg21951975	chr1:209979733	IRF6	0.5	6.67	0.31	8.1e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg03806693	chr22:41940476	POLR3H	0.55	8.1	0.37	5.83e-15	Vitiligo;
LUAD	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs72901758	0.700	rs1109279	chr17:76248130	T/C	cg26068271	chr17:76253126	NA	0.44	7.56	0.34	2.55e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg16647868	chr5:131706066	SLC22A5	-0.4	-6.93	-0.32	1.55e-11	Blood metabolite levels;
LUAD	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs117623576	0.941	rs67225815	chr10:32408946	C/T	cg03047570	chr10:32398778	NA	-0.88	-11.11	-0.48	2.52e-25	Anti-saccade response;
LUAD	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg09491104	chr22:46646882	C22orf40	-0.65	-11.46	-0.49	1.16e-26	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs75804782	0.641	rs57080728	chr2:239350487	T/C	cg01134436	chr17:81009848	B3GNTL1	0.74	8.12	0.37	5.27e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.55	-0.34	2.66e-13	Blood metabolite levels;
LUAD	cis	rs2742417	0.603	rs6807438	chr3:45778623	G/A	cg10512202	chr3:45649293	LIMD1	0.46	8.65	0.39	1.12e-16	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10802521	chr3:52805072	NEK4	-0.62	-11.08	-0.47	3.05e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.8	14.73	0.58	5.92e-40	Lymphocyte counts;
LUAD	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06873352	chr17:61820015	STRADA	0.83	18.55	0.67	1.2e-56	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12286929	0.702	rs11215419	chr11:115081810	A/T	cg04055981	chr11:115044050	NA	0.41	7.26	0.33	1.9e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9837602	0.592	rs694429	chr3:99459669	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	6.76	0.31	4.46e-11	Breast cancer;
LUAD	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg08645402	chr16:4508243	NA	0.58	10.76	0.46	5.15e-24	Schizophrenia;
LUAD	cis	rs1018836	0.700	rs7824511	chr8:91521545	T/C	cg16814680	chr8:91681699	NA	-0.71	-11.95	-0.5	1.41e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18404041	chr3:52824283	ITIH1	-0.6	-12.11	-0.51	3.62e-29	Bipolar disorder;
LUAD	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg18867708	chr6:26865862	GUSBL1	0.39	6.57	0.3	1.48e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg22920501	chr2:26401640	FAM59B	-0.73	-10.5	-0.45	4.66e-23	Gut microbiome composition (summer);
LUAD	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-9.66	-0.43	4.53e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs11039798	1.000	rs12223271	chr11:48417420	G/C	cg03929089	chr4:120376271	NA	0.55	6.4	0.3	4.22e-10	Axial length;
LUAD	cis	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg08601574	chr20:25228251	PYGB	0.42	7.73	0.35	8e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg16797656	chr11:68205561	LRP5	0.52	11.08	0.47	3.13e-25	Total body bone mineral density;
LUAD	cis	rs2456568	0.802	rs10831136	chr11:93636860	T/C	cg26875233	chr11:93583750	C11orf90	-0.29	-6.39	-0.3	4.36e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.61	0.31	1.14e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg14092988	chr3:52407081	DNAH1	-0.35	-7.06	-0.32	7.02e-12	Electroencephalogram traits;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10624784	chr7:77427913	PHTF2;TMEM60	-0.55	-6.64	-0.31	9.92e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.47	-7.49	-0.34	4.08e-13	Tonsillectomy;
LUAD	trans	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg26043149	chr18:55253948	FECH	-0.42	-6.87	-0.32	2.35e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg05283184	chr6:79620031	NA	-0.61	-12.47	-0.52	1.28e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg07607921	chr17:4047574	ZZEF1;CYB5D2	-0.43	-7.34	-0.34	1.08e-12	Type 2 diabetes;
LUAD	cis	rs5758511	0.689	rs17002947	chr22:42688532	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.49	-8.06	-0.36	8.01e-15	Birth weight;
LUAD	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg07936489	chr17:37558343	FBXL20	-0.54	-7.1	-0.33	5.44e-12	Glomerular filtration rate (creatinine);
LUAD	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg21153622	chr11:89784906	NA	-0.32	-6.35	-0.3	5.56e-10	Coronary artery disease;
LUAD	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg07606381	chr6:8435919	SLC35B3	-0.42	-7.21	-0.33	2.55e-12	Motion sickness;
LUAD	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.23	0.33	2.29e-12	Platelet count;
LUAD	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.42	-0.42	3e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg14582100	chr15:45693742	SPATA5L1	0.38	7.43	0.34	6.07e-13	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs11118844	0.843	rs12403995	chr1:221921377	C/A	cg04222084	chr1:221915650	DUSP10	-0.69	-7.8	-0.35	4.92e-14	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg17644776	chr2:200775616	C2orf69	-0.51	-7.28	-0.33	1.67e-12	Schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24546083	chr1:154155925	TPM3	-0.54	-6.54	-0.3	1.73e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs8067545	0.720	rs11204419	chr17:19888997	A/G	cg04132472	chr17:19861366	AKAP10	0.35	8.07	0.37	7.3e-15	Schizophrenia;
LUAD	cis	rs7809950	1.000	rs986994	chr7:107104115	G/T	cg23024343	chr7:107201750	COG5	-0.74	-12.31	-0.51	5.66e-30	Coronary artery disease;
LUAD	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.0	0.36	1.18e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg24503407	chr1:205819492	PM20D1	0.78	15.75	0.61	2.55e-44	Menarche (age at onset);
LUAD	cis	rs11622475	1.000	rs1187448	chr14:104406627	C/T	cg12183467	chr14:104352244	NA	-0.38	-6.92	-0.32	1.65e-11	Bipolar disorder;
LUAD	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg08029281	chr1:67600428	NA	0.35	6.64	0.31	9.43e-11	Psoriasis;
LUAD	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.06	-0.32	6.83e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs78487399	0.808	rs13395290	chr2:43706319	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-6.92	-0.32	1.71e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs79349575	0.655	rs62078384	chr17:47044463	C/T	cg07967210	chr17:47022446	SNF8	0.36	6.43	0.3	3.37e-10	Type 2 diabetes;
LUAD	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg15181151	chr6:150070149	PCMT1	0.42	8.63	0.39	1.24e-16	Lung cancer;
LUAD	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg10978503	chr1:24200527	CNR2	-0.55	-11.96	-0.5	1.3e-28	Immature fraction of reticulocytes;
LUAD	cis	rs743757	1.000	rs2282752	chr3:50433967	G/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	7.26	0.33	1.92e-12	Diastolic blood pressure;
LUAD	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg02734326	chr4:10020555	SLC2A9	0.63	11.28	0.48	5.66e-26	Bone mineral density;
LUAD	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg13813247	chr22:41461852	NA	-0.44	-7.15	-0.33	3.84e-12	Neuroticism;
LUAD	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg11141692	chr4:111866916	NA	-0.45	-6.41	-0.3	3.98e-10	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1823874	0.581	rs12905599	chr15:100339938	C/T	cg16400843	chr15:100339927	C15orf51	0.35	7.22	0.33	2.41e-12	IgG glycosylation;
LUAD	trans	rs1493916	0.905	rs10460051	chr18:31413679	C/T	cg13755796	chr4:20253514	NA	-0.43	-7.34	-0.34	1.1e-12	Life satisfaction;
LUAD	trans	rs2797160	1.000	rs1739347	chr6:126014157	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.5e-17	Endometrial cancer;
LUAD	cis	rs9878978	0.964	rs17194406	chr3:2488631	T/C	cg21928760	chr3:2462534	CNTN4	-0.34	-6.85	-0.32	2.56e-11	Blood pressure (smoking interaction);
LUAD	cis	rs7089973	0.872	rs7909657	chr10:116629096	C/G	cg25233709	chr10:116636983	FAM160B1	0.39	7.56	0.35	2.48e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg07075026	chr17:47091521	IGF2BP1	-0.35	-6.54	-0.3	1.79e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg06221963	chr1:154839813	KCNN3	-0.87	-18.52	-0.67	1.69e-56	Prostate cancer;
LUAD	cis	rs3823572	0.586	rs2971969	chr7:133656264	G/T	cg03336402	chr7:133662267	EXOC4	-0.4	-7.35	-0.34	1.04e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.49	8.34	0.38	1.03e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2455799	0.613	rs4685269	chr3:15942354	A/G	cg16303742	chr3:15540471	COLQ	-0.46	-8.26	-0.37	1.92e-15	Mean platelet volume;
LUAD	trans	rs9467711	0.591	rs9467621	chr6:25851338	G/A	cg06606381	chr12:133084897	FBRSL1	-0.8	-6.67	-0.31	7.88e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg25324976	chr17:61989376	CSHL1	0.4	7.45	0.34	5.23e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg02551604	chr5:131831745	NA	-0.65	-10.3	-0.45	2.47e-22	Asthma (sex interaction);
LUAD	trans	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg03886242	chr7:26192032	NFE2L3	-0.46	-8.03	-0.36	9.76e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs35150201	0.818	rs7810260	chr7:135311120	G/A	cg23117316	chr7:135346802	PL-5283	-0.42	-9.25	-0.41	1.14e-18	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
LUAD	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg15704280	chr7:45808275	SEPT13	-0.78	-12.17	-0.51	1.96e-29	Coronary artery disease;
LUAD	cis	rs1215050	0.791	rs1585088	chr4:98675071	C/A	cg17366294	chr4:99064904	C4orf37	-0.45	-7.93	-0.36	1.97e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg01448562	chr3:133502909	NA	-0.69	-12.93	-0.53	1.78e-32	Iron status biomarkers;
LUAD	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg25237894	chr2:233734115	C2orf82	0.61	11.45	0.49	1.31e-26	Coronary artery disease;
LUAD	cis	rs137699	1.000	rs5757632	chr22:39756097	A/C	cg02038168	chr22:39784481	NA	-0.39	-6.57	-0.3	1.48e-10	IgG glycosylation;
LUAD	trans	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.33	-0.41	5.78e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6708413	0.521	rs6543153	chr2:103114203	T/C	cg03938978	chr2:103052716	IL18RAP	0.34	6.62	0.31	1.09e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.0	0.36	1.23e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06022373	chr22:39101656	GTPBP1	0.46	7.21	0.33	2.6e-12	Menopause (age at onset);
LUAD	cis	rs7937890	0.559	rs2575852	chr11:14533368	G/A	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.25e-11	Mitochondrial DNA levels;
LUAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg02869364	chr7:1081709	C7orf50	-0.51	-6.56	-0.3	1.53e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7017914	0.934	rs56043721	chr8:71630427	A/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg08859206	chr1:53392774	SCP2	-0.72	-13.6	-0.55	3.31e-35	Monocyte count;
LUAD	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg15557168	chr22:42548783	NA	-0.45	-8.18	-0.37	3.32e-15	Cognitive function;
LUAD	cis	rs4409675	1.000	rs61789695	chr1:28255693	G/A	cg23691781	chr1:28212827	C1orf38	0.28	6.67	0.31	8.19e-11	Corneal astigmatism;
LUAD	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg04450456	chr4:17643702	FAM184B	0.42	8.29	0.37	1.51e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.02	-0.36	1.01e-14	Total body bone mineral density;
LUAD	cis	rs4911259	0.552	rs13041458	chr20:31467376	G/T	cg13636640	chr20:31349939	DNMT3B	-0.57	-9.37	-0.41	4.52e-19	Inflammatory bowel disease;
LUAD	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18404041	chr3:52824283	ITIH1	-0.72	-16.22	-0.62	2.25e-46	Bipolar disorder;
LUAD	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-8.63	-0.39	1.29e-16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg22117172	chr7:91764530	CYP51A1	-0.32	-7.02	-0.32	8.9e-12	Breast cancer;
LUAD	trans	rs877282	0.898	rs12356744	chr10:757477	G/C	cg22713356	chr15:30763199	NA	1.23	15.56	0.6	1.71e-43	Uric acid levels;
LUAD	cis	rs938554	0.826	rs7376960	chr4:9970570	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-7.54	-0.34	2.98e-13	Blood metabolite levels;
LUAD	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg09137382	chr11:130731461	NA	0.41	7.46	0.34	4.82e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg02221422	chr11:68192511	LRP5	-0.43	-7.11	-0.33	4.94e-12	Total body bone mineral density;
LUAD	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.31	6.36	0.3	5.22e-10	Menopause (age at onset);
LUAD	cis	rs11687659	0.515	rs6725611	chr2:191579025	G/A	cg27211696	chr2:191398769	TMEM194B	-0.41	-6.83	-0.32	2.92e-11	Immature fraction of reticulocytes;
LUAD	cis	rs6484504	0.600	rs7122895	chr11:31346620	G/C	cg26647111	chr11:31128758	NA	0.44	7.83	0.36	4.05e-14	Red blood cell count;
LUAD	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.23	-0.33	2.34e-12	Height;
LUAD	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg21775007	chr8:11205619	TDH	0.5	9.15	0.41	2.47e-18	Retinal vascular caliber;
LUAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg00634984	chr7:65235879	NA	0.54	8.79	0.39	3.79e-17	Calcium levels;
LUAD	trans	rs6921919	0.789	rs17301128	chr6:28308034	C/G	cg06606381	chr12:133084897	FBRSL1	-0.49	-6.81	-0.31	3.41e-11	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg06175025	chr14:78082992	SPTLC2	-0.41	-6.66	-0.31	8.37e-11	Bone mineral density;
LUAD	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg15448220	chr1:150897856	SETDB1	0.46	7.97	0.36	1.47e-14	Tonsillectomy;
LUAD	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg06271696	chr7:157225062	NA	-0.52	-10.97	-0.47	8.25e-25	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs864537	0.622	rs2949661	chr1:167424924	C/T	cg22356347	chr1:167427500	CD247	-0.52	-10.52	-0.46	3.85e-23	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg05110241	chr16:68378359	PRMT7	-0.96	-10.84	-0.47	2.54e-24	Schizophrenia;
LUAD	cis	rs965513	0.524	rs1443432	chr9:100583195	C/T	cg13688889	chr9:100608707	NA	-0.39	-6.67	-0.31	7.92e-11	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUAD	cis	rs59104589	0.617	rs3755395	chr2:242294116	A/G	cg08645257	chr2:242211290	HDLBP	0.49	7.41	0.34	6.94e-13	Fibrinogen levels;
LUAD	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg24818145	chr4:99064322	C4orf37	0.45	7.01	0.32	9.25e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.765	rs2617883	chr17:28120488	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.61	-0.46	1.8e-23	Coffee consumption (cups per day);
LUAD	cis	rs73206853	0.841	rs57299791	chr12:110954021	G/A	cg12870014	chr12:110450643	ANKRD13A	0.61	6.93	0.32	1.59e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7246865	0.859	rs7252102	chr19:17197012	A/G	cg19418318	chr19:17219073	MYO9B	0.44	7.38	0.34	8.7e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs243505	0.898	rs243540	chr7:148403312	A/G	cg09806900	chr7:148480153	CUL1	-0.4	-6.96	-0.32	1.33e-11	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg00310523	chr12:86230176	RASSF9	0.4	7.91	0.36	2.32e-14	Major depressive disorder;
LUAD	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg14343924	chr8:8086146	FLJ10661	0.45	6.93	0.32	1.55e-11	Mood instability;
LUAD	cis	rs3820068	0.705	rs57440988	chr1:15879034	T/C	cg24675056	chr1:15929824	NA	0.43	6.78	0.31	4.1e-11	Systolic blood pressure;
LUAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg24503407	chr1:205819492	PM20D1	0.59	10.84	0.47	2.46e-24	Menarche (age at onset);
LUAD	cis	rs1595825	0.838	rs73058878	chr2:198895078	T/G	cg11031976	chr2:198649780	BOLL	-0.45	-6.58	-0.3	1.4e-10	Ulcerative colitis;
LUAD	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg09936400	chr10:82049201	MAT1A	0.37	6.66	0.31	8.64e-11	Post bronchodilator FEV1;
LUAD	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21582582	chr3:182698605	DCUN1D1	0.72	14.1	0.57	2.78e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.25	0.33	2.06e-12	Menopause (age at onset);
LUAD	cis	rs12912251	0.591	rs3102118	chr15:39003475	A/C	cg01338139	chr15:38987640	C15orf53	0.51	6.8	0.31	3.47e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg09365446	chr1:150670422	GOLPH3L	0.66	12.3	0.51	6.1e-30	Tonsillectomy;
LUAD	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg17063962	chr7:91808500	NA	0.71	12.67	0.52	1.98e-31	Breast cancer;
LUAD	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.14	0.33	4.07e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs6496044	0.568	rs7166642	chr15:86061271	A/G	cg13263323	chr15:86062960	AKAP13	-0.58	-10.84	-0.47	2.42e-24	Interstitial lung disease;
LUAD	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.36	-6.96	-0.32	1.27e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg23283495	chr1:209979779	IRF6	0.4	7.21	0.33	2.53e-12	Monobrow;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19633353	chr4:3530501	LRPAP1	0.46	6.73	0.31	5.62e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.28	-0.54	7.08e-34	Chronic sinus infection;
LUAD	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg05110241	chr16:68378359	PRMT7	0.89	10.23	0.45	4.17e-22	Schizophrenia;
LUAD	cis	rs2692947	0.673	rs4907279	chr2:96399968	G/C	cg23100626	chr2:96804247	ASTL	0.33	8.07	0.37	7.55e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs9826463	0.759	rs17623058	chr3:142344039	G/A	cg20824294	chr3:142316082	PLS1	0.47	6.87	0.32	2.28e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg07538946	chr5:131705188	SLC22A5	-0.53	-8.84	-0.39	2.63e-17	Blood metabolite levels;
LUAD	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg18932078	chr1:2524107	MMEL1	0.36	6.61	0.31	1.18e-10	Ulcerative colitis;
LUAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.49	-7.95	-0.36	1.7e-14	Renal function-related traits (BUN);
LUAD	cis	rs151349	1.000	rs151346	chr20:57587040	C/A	cg23907860	chr20:57583709	CTSZ	-0.56	-10.37	-0.45	1.32e-22	Platelet distribution width;
LUAD	cis	rs62238980	0.614	rs4821020	chr22:32414089	G/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg02466173	chr16:30829666	NA	-0.85	-17.11	-0.64	3.03e-50	Dementia with Lewy bodies;
LUAD	cis	rs240764	0.531	rs1070990	chr6:101264412	T/A	cg09795085	chr6:101329169	ASCC3	0.48	8.29	0.37	1.5e-15	Neuroticism;
LUAD	cis	rs11696501	0.694	rs6073827	chr20:44265556	T/C	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.23	-0.37	2.34e-15	Brain structure;
LUAD	trans	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg03402775	chr3:108308147	DZIP3;KIAA1524	-0.4	-6.36	-0.3	5.13e-10	Sudden cardiac arrest;
LUAD	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.05	0.36	8.46e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.791	rs57719820	chr17:28335088	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-9.07	-0.4	4.67e-18	Coffee consumption (cups per day);
LUAD	cis	rs11756438	0.572	rs1771755	chr6:119018877	A/T	cg18833306	chr6:118973337	C6orf204	-0.5	-9.12	-0.41	2.96e-18	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg02569458	chr12:86230093	RASSF9	0.42	8.04	0.36	9.06e-15	Major depressive disorder;
LUAD	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg17264618	chr3:40429014	ENTPD3	0.43	9.06	0.4	4.86e-18	Renal cell carcinoma;
LUAD	cis	rs6688613	0.685	rs10800276	chr1:166858941	A/G	cg07049167	chr1:166818506	POGK	-0.55	-8.67	-0.39	9.64e-17	Refractive astigmatism;
LUAD	cis	rs7737355	0.773	rs9327616	chr5:130902196	C/T	cg25547332	chr5:131281432	NA	0.42	6.72	0.31	5.72e-11	Life satisfaction;
LUAD	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg10755058	chr3:40428713	ENTPD3	-0.42	-8.04	-0.36	8.95e-15	Renal cell carcinoma;
LUAD	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg19761014	chr17:28927070	LRRC37B2	0.81	8.13	0.37	4.79e-15	Body mass index;
LUAD	trans	rs2018683	0.707	rs2391718	chr7:28974988	T/C	cg19402173	chr7:128379420	CALU	-0.51	-8.31	-0.37	1.32e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2840044	1.000	rs17637907	chr17:33891386	A/G	cg05299278	chr17:33885742	SLFN14	-0.43	-8.87	-0.4	2.05e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg08999081	chr20:33150536	PIGU	0.63	14.19	0.57	1.21e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs9513627	1.000	rs7317330	chr13:100119876	T/G	cg25919922	chr13:100150906	NA	-0.69	-6.6	-0.31	1.25e-10	Obesity-related traits;
LUAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg20607798	chr8:58055168	NA	0.82	9.81	0.43	1.27e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6504663	0.558	rs2412325	chr17:48546232	G/C	cg03168497	chr17:48586147	MYCBPAP	0.48	6.41	0.3	3.94e-10	Visceral fat;
LUAD	cis	rs7737355	0.947	rs2108871	chr5:131089044	A/C	cg06307176	chr5:131281290	NA	0.52	8.14	0.37	4.32e-15	Life satisfaction;
LUAD	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	7.07	0.32	6.56e-12	Tonsillectomy;
LUAD	cis	rs6992820	0.967	rs13263466	chr8:56648474	T/C	cg06880721	chr8:56792545	LYN	-0.43	-7.1	-0.33	5.4e-12	Mean platelet volume;
LUAD	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18876405	chr7:65276391	NA	-0.42	-6.7	-0.31	6.86e-11	Aortic root size;
LUAD	cis	rs68170813	0.641	rs12538848	chr7:106984569	G/T	cg02696742	chr7:106810147	HBP1	-0.73	-10.24	-0.45	3.92e-22	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg03467027	chr4:99064603	C4orf37	0.43	7.06	0.32	7.06e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg24690094	chr11:67383802	NA	0.38	6.77	0.31	4.37e-11	Mean corpuscular volume;
LUAD	cis	rs12579753	0.917	rs7138895	chr12:82203280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.45	-7.09	-0.33	5.68e-12	Resting heart rate;
LUAD	cis	rs73198271	0.694	rs73201840	chr8:8647067	G/T	cg01851573	chr8:8652454	MFHAS1	0.48	8.49	0.38	3.53e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs3087591	1.000	rs7216033	chr17:29574642	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.4	-6.56	-0.3	1.56e-10	Hip circumference;
LUAD	cis	rs73198271	0.740	rs10105920	chr8:8648737	A/G	cg01851573	chr8:8652454	MFHAS1	-0.48	-8.35	-0.38	9.87e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6500395	1.000	rs871903	chr16:48593643	A/C	cg04672837	chr16:48644449	N4BP1	0.37	6.37	0.3	4.93e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg13902645	chr11:5959945	NA	-0.57	-9.99	-0.44	2.95e-21	DNA methylation (variation);
LUAD	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg04842962	chr6:43655489	MRPS18A	-0.8	-15.67	-0.61	5.89e-44	IgG glycosylation;
LUAD	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg12927641	chr6:109611667	NA	0.52	9.29	0.41	8.43e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg16414030	chr3:133502952	NA	-0.69	-12.91	-0.53	2.14e-32	Iron status biomarkers;
LUAD	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg27535305	chr1:53392650	SCP2	-0.34	-7.05	-0.32	7.38e-12	Monocyte count;
LUAD	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-14.86	-0.59	1.7e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs1997103	1.000	rs10249105	chr7:55412405	A/G	cg20935933	chr6:143382018	AIG1	-0.52	-7.39	-0.34	8.12e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22496380	chr5:211416	CCDC127	-0.93	-13.03	-0.54	6.94e-33	Breast cancer;
LUAD	cis	rs4730250	0.707	rs257382	chr7:106804249	A/G	cg23024343	chr7:107201750	COG5	0.49	6.59	0.31	1.3e-10	Osteoarthritis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01750847	chr16:30007184	HIRIP3;INO80E	-0.53	-6.41	-0.3	3.93e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.03	0.32	8.1e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9863	0.828	rs12827409	chr12:124476706	C/G	cg17723958	chr12:124429295	CCDC92	-0.4	-6.63	-0.31	1.06e-10	White blood cell count;
LUAD	cis	rs155346	0.901	rs265179	chr5:139365452	C/G	cg01090482	chr5:139365336	NRG2	-0.36	-6.96	-0.32	1.27e-11	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUAD	cis	rs5756813	0.754	rs8137848	chr22:38185994	T/G	cg06521852	chr22:38141419	TRIOBP	0.48	9.02	0.4	6.42e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	9.29	0.41	8.13e-19	Melanoma;
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg26668828	chr6:292823	DUSP22	-0.81	-14.48	-0.58	7.03e-39	Menopause (age at onset);
LUAD	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg21918786	chr6:109611834	NA	-0.6	-11.21	-0.48	1.04e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg07570687	chr10:102243282	WNT8B	-0.41	-6.36	-0.3	5.19e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg26513180	chr16:89883248	FANCA	0.78	6.97	0.32	1.2e-11	Skin colour saturation;
LUAD	cis	rs2421770	0.560	rs7114936	chr11:35374075	A/G	cg13971030	chr11:35366721	SLC1A2	-0.44	-6.39	-0.3	4.31e-10	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs2070677	0.932	rs2987786	chr10:135365303	C/T	cg20169779	chr10:135381914	SYCE1	-0.53	-8.41	-0.38	6.33e-16	Gout;
LUAD	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs12989701	1.000	rs13009551	chr2:127889118	C/T	cg08168897	chr2:127865431	BIN1	0.46	6.85	0.32	2.56e-11	Alzheimer's disease (late onset);
LUAD	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-8.83	-0.39	2.75e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7520050	1.000	rs12143096	chr1:46469763	G/A	cg06784218	chr1:46089804	CCDC17	-0.3	-6.49	-0.3	2.44e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs3820068	0.656	rs72645829	chr1:15889748	A/G	cg13390004	chr1:15929781	NA	0.43	6.86	0.32	2.45e-11	Systolic blood pressure;
LUAD	cis	rs9323205	0.871	rs8008599	chr14:51670057	A/G	cg23942311	chr14:51606299	NA	0.58	9.72	0.43	2.76e-20	Cancer;
LUAD	cis	rs2262909	0.962	rs11673195	chr19:22313814	T/C	cg11619707	chr19:22235551	ZNF257	0.49	7.52	0.34	3.33e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs17094222	0.504	rs12267029	chr10:102458677	C/A	cg26540559	chr10:102447443	NA	0.4	8.2	0.37	2.91e-15	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg11247378	chr22:39784982	NA	-0.75	-14.13	-0.57	2.19e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs6138458	0.743	rs3746330	chr20:24999795	A/G	cg26195577	chr20:24973756	C20orf3	0.73	12.28	0.51	7.65e-30	Blood protein levels;
LUAD	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg24069376	chr3:38537580	EXOG	0.32	7.38	0.34	8.49e-13	Electrocardiographic conduction measures;
LUAD	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg14019146	chr3:50243930	SLC38A3	-0.43	-7.07	-0.32	6.63e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg09835421	chr16:68378352	PRMT7	-0.67	-7.85	-0.36	3.38e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3936840	0.861	rs1044502	chr14:102965897	G/A	cg18135206	chr14:102964638	TECPR2	0.55	8.5	0.38	3.28e-16	Plateletcrit;
LUAD	cis	rs2204008	0.527	rs8189480	chr12:38345648	C/T	cg10518543	chr12:38710700	ALG10B	-0.42	-6.88	-0.32	2.13e-11	Bladder cancer;
LUAD	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg17366294	chr4:99064904	C4orf37	0.68	12.68	0.52	1.85e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg23018236	chr17:30244563	NA	-0.68	-8.33	-0.38	1.14e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg00321850	chr1:175162397	KIAA0040	-0.51	-10.8	-0.46	3.6e-24	Alcohol dependence;
LUAD	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg09835421	chr16:68378352	PRMT7	-1.03	-11.71	-0.49	1.31e-27	Schizophrenia;
LUAD	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg22431228	chr1:16359049	CLCNKA	-0.54	-9.61	-0.42	6.38e-20	Dilated cardiomyopathy;
LUAD	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg10167378	chr1:228756711	NA	0.64	8.72	0.39	6.21e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs2625529	0.824	rs4776586	chr15:72430503	C/A	cg16672083	chr15:72433130	SENP8	-0.79	-13.44	-0.55	1.56e-34	Red blood cell count;
LUAD	cis	rs10489202	0.632	rs12410730	chr1:168069477	T/C	cg25738037	chr1:168025549	DCAF6	-0.47	-6.86	-0.32	2.52e-11	Schizophrenia;
LUAD	cis	rs17092148	1.000	rs6060025	chr20:33326876	A/G	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.33	-0.38	1.15e-15	Neuroticism;
LUAD	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg19163074	chr7:65112434	INTS4L2	0.49	7.97	0.36	1.46e-14	Calcium levels;
LUAD	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg09835421	chr16:68378352	PRMT7	-0.74	-8.48	-0.38	3.69e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg21681030	chr2:46777652	RHOQ	0.4	6.68	0.31	7.72e-11	Height;
LUAD	cis	rs10089	0.953	rs1036171	chr5:127402798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	9.8	0.43	1.42e-20	Ileal carcinoids;
LUAD	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg26587870	chr6:27730563	NA	-0.69	-7.35	-0.34	1.01e-12	Depression;
LUAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg05434287	chr7:2030229	MAD1L1	0.39	6.56	0.3	1.56e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs9354308	0.868	rs2882754	chr6:66537341	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.4	6.37	0.3	4.92e-10	Metabolite levels;
LUAD	cis	rs4243830	0.850	rs12760251	chr1:6601336	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.74	-9.24	-0.41	1.25e-18	Body mass index;
LUAD	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg08798685	chr6:27730294	NA	-0.43	-6.97	-0.32	1.23e-11	Parkinson's disease;
LUAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg25243455	chr2:114033360	PAX8;LOC440839	-0.39	-8.74	-0.39	5.7e-17	Lymphocyte counts;
LUAD	cis	rs28655083	1.000	rs1843457	chr16:77072400	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-7.11	-0.33	4.98e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg00933542	chr6:150070202	PCMT1	0.45	9.79	0.43	1.6e-20	Lung cancer;
LUAD	cis	rs2882667	0.858	rs11957527	chr5:138404895	T/C	cg04439458	chr5:138467593	SIL1	-0.5	-9.14	-0.41	2.56e-18	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg04025307	chr7:1156635	C7orf50	0.51	7.26	0.33	1.9e-12	Bronchopulmonary dysplasia;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg09054362	chr11:62380222	EML3;ROM1	0.45	6.68	0.31	7.67e-11	QT interval;
LUAD	cis	rs9948	0.655	rs62156212	chr2:97399096	C/T	cg20312557	chr2:97357134	FER1L5	-0.72	-8.08	-0.37	6.78e-15	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg16479474	chr6:28041457	NA	-0.39	-7.0	-0.32	1.03e-11	Depression;
LUAD	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg05110241	chr16:68378359	PRMT7	-0.59	-7.46	-0.34	4.88e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg22482690	chr17:47019901	SNF8	0.45	8.77	0.39	4.31e-17	Type 2 diabetes;
LUAD	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg12927641	chr6:109611667	NA	-0.52	-9.21	-0.41	1.5e-18	Reticulocyte fraction of red cells;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06853325	chr19:12792223	DHPS	-0.39	-6.46	-0.3	2.92e-10	Cancer;
LUAD	cis	rs2625529	0.652	rs2957745	chr15:72288077	T/C	cg16672083	chr15:72433130	SENP8	0.61	11.33	0.48	3.5e-26	Red blood cell count;
LUAD	cis	rs7000551	0.659	rs2280521	chr8:22271995	G/T	cg12081754	chr8:22256438	SLC39A14	-0.49	-7.48	-0.34	4.43e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-11.31	-0.48	4.43e-26	Monocyte percentage of white cells;
LUAD	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.47	-6.39	-0.3	4.48e-10	Gut microbiome composition (summer);
LUAD	trans	rs11989744	0.500	rs1438456	chr8:23566909	T/C	cg03492747	chr16:86543808	FOXF1	-0.54	-11.42	-0.49	1.71e-26	Waist-hip ratio;
LUAD	trans	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	7.66	0.35	1.27e-13	Resting heart rate;
LUAD	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg22618164	chr12:122356400	WDR66	-0.72	-13.16	-0.54	2.16e-33	Mean corpuscular volume;
LUAD	cis	rs6835098	1.000	rs10011724	chr4:174088865	A/G	cg08422745	chr4:174089978	GALNT7	-0.95	-17.93	-0.66	7e-54	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.88	-0.32	2.16e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.7	-13.16	-0.54	2.06e-33	Axial length;
LUAD	cis	rs7017914	0.967	rs1596566	chr8:71698576	A/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.43	-0.3	3.46e-10	Bone mineral density;
LUAD	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg11494091	chr17:61959527	GH2	0.41	7.06	0.32	6.89e-12	Height;
LUAD	cis	rs77861329	1.000	rs352148	chr3:52208898	A/G	cg08692210	chr3:52188851	WDR51A	0.8	7.63	0.35	1.58e-13	Macrophage inflammatory protein 1b levels;
LUAD	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg20290983	chr6:43655470	MRPS18A	1.06	27.5	0.8	3.36e-96	IgG glycosylation;
LUAD	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg08213375	chr14:104286397	PPP1R13B	0.28	7.33	0.34	1.21e-12	Schizophrenia;
LUAD	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg14983838	chr19:29218262	NA	0.67	9.91	0.43	5.99e-21	Methadone dose in opioid dependence;
LUAD	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06002616	chr8:101225028	SPAG1	-0.4	-8.2	-0.37	3e-15	Atrioventricular conduction;
LUAD	cis	rs6906287	0.647	rs11153763	chr6:118938738	G/A	cg18833306	chr6:118973337	C6orf204	0.49	8.49	0.38	3.43e-16	Electrocardiographic conduction measures;
LUAD	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Parkinson's disease;
LUAD	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg04414720	chr1:150670196	GOLPH3L	0.72	13.36	0.54	3.17e-34	Tonsillectomy;
LUAD	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg21862992	chr11:68658383	NA	0.53	9.57	0.42	9.15e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.63	-0.31	1.05e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg18305652	chr10:134549665	INPP5A	-0.4	-8.97	-0.4	1e-17	Migraine;
LUAD	cis	rs59104589	0.517	rs3821281	chr2:242385340	A/G	cg08645257	chr2:242211290	HDLBP	0.46	7.45	0.34	5.23e-13	Fibrinogen levels;
LUAD	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg01689657	chr7:91764605	CYP51A1	0.3	7.29	0.33	1.56e-12	Breast cancer;
LUAD	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg09222892	chr1:25734099	RHCE	0.51	9.55	0.42	1.04e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs4243830	1.000	rs11811007	chr1:6584657	T/C	cg04093404	chr1:6614507	TAS1R1;NOL9	0.72	8.14	0.37	4.48e-15	Body mass index;
LUAD	trans	rs7944735	0.786	rs7123436	chr11:48013484	G/A	cg03929089	chr4:120376271	NA	0.62	7.82	0.36	4.12e-14	Intraocular pressure;
LUAD	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.47	6.67	0.31	7.88e-11	Platelet count;
LUAD	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.31	-0.45	2.18e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs250677	0.522	rs11954893	chr5:148392362	A/G	cg18129178	chr5:148520854	ABLIM3	-0.53	-7.94	-0.36	1.88e-14	Breast cancer;
LUAD	cis	rs2479724	0.846	rs2254805	chr6:41846110	T/G	cg17623882	chr6:41773611	USP49	-0.62	-11.56	-0.49	4.83e-27	Menarche (age at onset);
LUAD	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg12311346	chr5:56204834	C5orf35	-0.8	-12.51	-0.52	8.86e-31	Initial pursuit acceleration;
LUAD	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg24801067	chr17:62843696	NA	0.54	8.55	0.38	2.24e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1595825	1.000	rs56765024	chr2:198876286	G/T	cg00982548	chr2:198649783	BOLL	-0.63	-9.01	-0.4	7.29e-18	Ulcerative colitis;
LUAD	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.23	0.37	2.38e-15	Gut microbiome composition (summer);
LUAD	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg17279839	chr7:150038598	RARRES2	0.45	7.5	0.34	3.9e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs10193935	0.901	rs72798529	chr2:42537471	C/T	cg27598129	chr2:42591480	NA	-0.79	-9.8	-0.43	1.47e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg10356904	chr22:49881777	NA	-0.39	-8.42	-0.38	5.93e-16	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs877282	0.898	rs11253352	chr10:766598	C/A	cg17470449	chr10:769945	NA	0.63	9.04	0.4	5.67e-18	Uric acid levels;
LUAD	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.51	-0.3	2.18e-10	Bladder cancer;
LUAD	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg18306943	chr3:40428807	ENTPD3	0.36	6.37	0.3	4.98e-10	Renal cell carcinoma;
LUAD	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg16205897	chr5:131564050	P4HA2	-0.31	-6.96	-0.32	1.34e-11	Blood metabolite levels;
LUAD	cis	rs62238980	0.614	rs75179575	chr22:32426433	C/G	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-9.07	-0.4	4.4e-18	Life satisfaction;
LUAD	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg06953865	chr19:18549723	ISYNA1	0.37	6.97	0.32	1.23e-11	Breast cancer;
LUAD	cis	rs7301826	0.966	rs10734980	chr12:131294626	T/C	cg11011512	chr12:131303247	STX2	0.39	6.71	0.31	6.14e-11	Plasma plasminogen activator levels;
LUAD	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg15309053	chr8:964076	NA	0.46	10.28	0.45	2.72e-22	Schizophrenia;
LUAD	cis	rs13315871	0.790	rs13071148	chr3:58310838	A/C	cg20936604	chr3:58311152	NA	-0.73	-7.37	-0.34	8.92e-13	Cholesterol, total;
LUAD	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg18209359	chr17:80159595	CCDC57	0.4	6.91	0.32	1.79e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg22024508	chr19:16771032	TMEM38A;C19orf42	0.43	6.5	0.3	2.27e-10	Monocyte percentage of white cells;
LUAD	cis	rs7220401	0.789	rs3760456	chr17:27948844	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-9.58	-0.42	8.1e-20	Coronary artery disease;
LUAD	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg02569458	chr12:86230093	RASSF9	0.41	7.69	0.35	1.05e-13	Major depressive disorder;
LUAD	cis	rs4713675	0.709	rs626156	chr6:33670482	A/G	cg14003231	chr6:33640908	ITPR3	-0.41	-7.3	-0.33	1.41e-12	Plateletcrit;
LUAD	cis	rs7677751	0.806	rs4864857	chr4:55089814	T/C	cg17187183	chr4:55093834	PDGFRA	0.51	8.53	0.38	2.6e-16	Corneal astigmatism;
LUAD	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg01579765	chr21:45077557	HSF2BP	-0.57	-13.17	-0.54	1.94e-33	Mean corpuscular volume;
LUAD	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg23254163	chr1:152506842	NA	0.27	7.31	0.34	1.32e-12	Hair morphology;
LUAD	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg22920501	chr2:26401640	FAM59B	-0.73	-10.49	-0.45	4.71e-23	Gut microbiome composition (summer);
LUAD	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg04398451	chr17:18023971	MYO15A	-0.74	-13.6	-0.55	3.32e-35	Total body bone mineral density;
LUAD	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg10755058	chr3:40428713	ENTPD3	0.45	8.44	0.38	5.03e-16	Renal cell carcinoma;
LUAD	trans	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg09904177	chr6:26538194	HMGN4	0.43	7.23	0.33	2.31e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7274811	0.681	rs210074	chr20:31949756	A/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.52	7.87	0.36	3.06e-14	Height;
LUAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg11062466	chr8:58055876	NA	0.67	8.82	0.39	3.01e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg23029597	chr12:123009494	RSRC2	-0.53	-8.29	-0.37	1.51e-15	Body mass index;
LUAD	cis	rs1784581	0.588	rs7765624	chr6:162427462	C/A	cg17173639	chr6:162384350	PARK2	0.45	7.96	0.36	1.62e-14	Itch intensity from mosquito bite;
LUAD	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.02	-0.32	9.02e-12	Total cholesterol levels;
LUAD	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg21918786	chr6:109611834	NA	-0.58	-10.76	-0.46	4.83e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.78	-13.42	-0.55	1.82e-34	Chronic sinus infection;
LUAD	cis	rs4919694	1.000	rs4917379	chr10:104752831	A/T	cg04362960	chr10:104952993	NT5C2	0.71	7.55	0.34	2.63e-13	Arsenic metabolism;
LUAD	trans	rs783540	0.500	rs7163840	chr15:83398303	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.49	-6.94	-0.32	1.52e-11	Schizophrenia;
LUAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg03188948	chr7:1209495	NA	0.81	9.86	0.43	8.91e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7487075	0.578	rs4768713	chr12:46814047	A/G	cg23829395	chr12:46796953	NA	0.32	7.04	0.32	7.99e-12	Itch intensity from mosquito bite;
LUAD	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.42	0.38	5.75e-16	Platelet count;
LUAD	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg21856205	chr7:94953877	PON1	-0.53	-7.34	-0.34	1.09e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-8.53	-0.38	2.69e-16	Height;
LUAD	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.81	-0.36	4.52e-14	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg22216069	chr7:36406739	KIAA0895	-0.63	-6.39	-0.3	4.28e-10	Type 2 diabetes;
LUAD	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg15432903	chr11:17409602	KCNJ11	0.54	10.29	0.45	2.64e-22	Type 2 diabetes;
LUAD	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	trans	rs7746199	0.736	rs72845070	chr6:27668300	A/C	cg01620082	chr3:125678407	NA	-1.06	-10.21	-0.44	5.06e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7799006	0.789	rs4719468	chr7:2285019	G/C	cg08027265	chr7:2291960	NA	-0.74	-14.23	-0.57	8.31e-38	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20916646	chr4:852691	GAK	0.54	7.52	0.34	3.24e-13	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg13047869	chr3:10149882	C3orf24	0.67	11.61	0.49	2.95e-27	Alzheimer's disease;
LUAD	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg06792262	chr3:44622596	ZNF167	0.36	6.92	0.32	1.65e-11	Depressive symptoms;
LUAD	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg11502198	chr6:26597334	ABT1	0.54	9.14	0.41	2.56e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg15921436	chr17:44337874	NA	0.86	11.32	0.48	3.98e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg18187862	chr3:45730750	SACM1L	-0.51	-7.08	-0.33	6.04e-12	Primary sclerosing cholangitis;
LUAD	cis	rs17102423	0.660	rs7152277	chr14:65535391	G/C	cg11161011	chr14:65562177	MAX	-0.38	-6.38	-0.3	4.76e-10	Obesity-related traits;
LUAD	cis	rs7512552	0.780	rs55823828	chr1:150467296	G/C	cg15654264	chr1:150340011	RPRD2	0.58	11.14	0.48	1.84e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.56	0.3	1.54e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs7707921	1.000	rs749402	chr5:81561325	C/T	cg15871215	chr5:81402204	ATG10	-0.7	-10.01	-0.44	2.67e-21	Breast cancer;
LUAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.9	10.85	0.47	2.36e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3096299	0.933	rs2930219	chr16:89492049	G/A	cg00750074	chr16:89608354	SPG7	-0.4	-6.5	-0.3	2.32e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs7737355	0.812	rs245796	chr5:130680184	G/A	cg06307176	chr5:131281290	NA	-0.39	-6.58	-0.3	1.36e-10	Life satisfaction;
LUAD	cis	rs9796	0.621	rs557864	chr15:41471358	T/C	cg18705301	chr15:41695430	NDUFAF1	0.47	8.37	0.38	8.67e-16	Menopause (age at onset);
LUAD	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.773	rs13154452	chr5:130623358	G/A	cg06307176	chr5:131281290	NA	0.39	6.59	0.31	1.33e-10	Life satisfaction;
LUAD	cis	rs28595532	1.000	rs114778020	chr4:119662584	C/A	cg02775129	chr4:119771670	NA	-0.87	-7.9	-0.36	2.48e-14	Cannabis dependence symptom count;
LUAD	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg05872129	chr22:39784769	NA	-0.75	-12.15	-0.51	2.4e-29	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs7737355	0.947	rs17167760	chr5:130782699	A/G	cg25547332	chr5:131281432	NA	-0.42	-6.6	-0.31	1.21e-10	Life satisfaction;
LUAD	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg10356904	chr22:49881777	NA	-0.4	-7.55	-0.34	2.69e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4691139	0.903	rs13127188	chr4:165918676	C/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.44	-8.48	-0.38	3.85e-16	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg19163074	chr7:65112434	INTS4L2	0.44	6.76	0.31	4.56e-11	Aortic root size;
LUAD	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg26513180	chr16:89883248	FANCA	0.48	7.88	0.36	2.76e-14	Vitiligo;
LUAD	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.09	-0.44	1.38e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg15485101	chr11:133734466	NA	-0.36	-8.11	-0.37	5.39e-15	Childhood ear infection;
LUAD	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg04287289	chr16:89883240	FANCA	0.76	6.72	0.31	5.74e-11	Skin colour saturation;
LUAD	cis	rs7274811	0.625	rs293723	chr20:31927706	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.44	-6.38	-0.3	4.59e-10	Height;
LUAD	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg15557168	chr22:42548783	NA	-0.5	-9.21	-0.41	1.58e-18	Schizophrenia;
LUAD	cis	rs6005807	0.719	rs58542867	chr22:28988260	A/G	cg12565055	chr22:29076175	TTC28	0.75	8.74	0.39	5.53e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.25	-0.41	1.09e-18	Life satisfaction;
LUAD	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg06640241	chr16:89574553	SPG7	0.51	8.41	0.38	6.31e-16	Multiple myeloma (IgH translocation);
LUAD	trans	rs11039798	1.000	rs6485908	chr11:48652198	C/T	cg15704280	chr7:45808275	SEPT13	-0.61	-7.16	-0.33	3.53e-12	Axial length;
LUAD	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg07570687	chr10:102243282	WNT8B	0.44	6.54	0.3	1.79e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg11822812	chr5:140052017	DND1	-0.41	-7.48	-0.34	4.24e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12681287	0.547	rs56752411	chr8:87515156	C/T	cg27223183	chr8:87520930	FAM82B	-0.73	-10.28	-0.45	2.86e-22	Caudate activity during reward;
LUAD	cis	rs11811982	0.793	rs75213165	chr1:227280520	T/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.44	0.34	5.54e-13	Optic disc area;
LUAD	cis	rs68170813	0.559	rs17427849	chr7:106864237	A/G	cg02696742	chr7:106810147	HBP1	-0.78	-10.78	-0.46	4.15e-24	Coronary artery disease;
LUAD	cis	rs12618769	0.625	rs72821955	chr2:99159792	G/A	cg10123293	chr2:99228465	UNC50	0.5	8.93	0.4	1.32e-17	Bipolar disorder;
LUAD	cis	rs12545109	0.800	rs1996105	chr8:57413123	A/G	cg21220214	chr8:57350948	NA	-0.63	-8.81	-0.39	3.27e-17	Obesity-related traits;
LUAD	cis	rs738321	0.757	rs6001020	chr22:38538246	C/G	cg25457927	chr22:38595422	NA	-0.46	-10.34	-0.45	1.76e-22	Breast cancer;
LUAD	cis	rs13082711	0.595	rs6778612	chr3:27370789	T/C	cg02860705	chr3:27208620	NA	-0.67	-11.09	-0.47	2.81e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs673604	1.000	rs7520747	chr1:35678139	G/T	cg12633102	chr1:35676489	NA	-0.68	-8.35	-0.38	9.84e-16	Endometrial cancer;
LUAD	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg22875332	chr1:76189707	ACADM	0.86	15.48	0.6	3.75e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1595825	0.735	rs2053394	chr2:198946335	C/T	cg00982548	chr2:198649783	BOLL	-0.68	-9.3	-0.41	7.79e-19	Ulcerative colitis;
LUAD	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18876405	chr7:65276391	NA	-0.41	-6.5	-0.3	2.24e-10	Aortic root size;
LUAD	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg23172400	chr8:95962367	TP53INP1	-0.33	-6.83	-0.32	2.95e-11	Type 2 diabetes;
LUAD	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.52	-8.35	-0.38	9.81e-16	Platelet count;
LUAD	cis	rs6546550	0.901	rs6754896	chr2:70138170	T/C	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.97	-0.47	8.24e-25	Prevalent atrial fibrillation;
LUAD	cis	rs6840360	0.615	rs58977077	chr4:152470239	T/G	cg22705602	chr4:152727874	NA	-0.37	-6.71	-0.31	6.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg17849569	chr6:28058911	ZSCAN12L1	0.43	7.45	0.34	5.33e-13	Lung cancer in ever smokers;
LUAD	cis	rs7680126	0.671	rs7663044	chr4:10023939	C/G	cg00071950	chr4:10020882	SLC2A9	0.6	7.88	0.36	2.78e-14	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.47	0.38	4.01e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs490234	0.841	rs2790035	chr9:128439923	C/T	cg14078157	chr9:128172775	NA	0.43	7.79	0.35	5.08e-14	Mean arterial pressure;
LUAD	cis	rs1595825	0.735	rs6752454	chr2:198938959	T/G	cg00361562	chr2:198649771	BOLL	-0.48	-6.67	-0.31	8.23e-11	Ulcerative colitis;
LUAD	cis	rs12543725	0.799	rs13252660	chr8:142239381	C/T	cg23301539	chr8:142222248	SLC45A4	-0.43	-7.3	-0.33	1.44e-12	Birth weight;
LUAD	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.86	-0.5	3.42e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg13385794	chr1:248469461	NA	0.26	6.89	0.32	2.04e-11	Common traits (Other);
LUAD	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg26408565	chr15:76604113	ETFA	-0.44	-7.1	-0.33	5.32e-12	Blood metabolite levels;
LUAD	cis	rs2235649	0.833	rs7189070	chr16:1850813	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.47	-7.85	-0.36	3.57e-14	Blood metabolite levels;
LUAD	cis	rs3849570	0.696	rs13092157	chr3:81875332	T/A	cg07356753	chr3:81810745	GBE1	-0.61	-9.97	-0.44	3.72e-21	Waist circumference;Body mass index;
LUAD	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg21854759	chr1:92012499	NA	-0.5	-9.13	-0.41	2.75e-18	Breast cancer;
LUAD	cis	rs11190604	1.000	rs11190596	chr10:102293238	C/G	cg16342193	chr10:102329863	NA	-0.37	-6.4	-0.3	4.23e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs669446	0.562	rs4660259	chr1:44194534	A/G	cg12908607	chr1:44402522	ARTN	-0.35	-7.09	-0.33	5.55e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg03676636	chr4:99064102	C4orf37	0.27	6.95	0.32	1.39e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg18944383	chr4:111397179	ENPEP	0.41	8.19	0.37	3.15e-15	Height;
LUAD	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06544989	chr22:39130855	UNC84B	0.46	9.2	0.41	1.68e-18	Menopause (age at onset);
LUAD	cis	rs7084921	0.521	rs11592640	chr10:101878409	C/T	cg19754520	chr10:101825118	CPN1	-0.32	-6.73	-0.31	5.43e-11	Bone mineral density;
LUAD	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg25233709	chr10:116636983	FAM160B1	0.39	7.65	0.35	1.39e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10831391	chr10:3109765	PFKP	-0.58	-7.06	-0.32	7.07e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7193541	0.564	rs4888274	chr16:74706298	A/T	cg01733217	chr16:74700730	RFWD3	0.7	13.42	0.55	1.85e-34	Multiple myeloma;
LUAD	cis	rs11771526	0.901	rs17161084	chr7:32293192	G/C	cg13207630	chr7:32358064	NA	0.58	7.35	0.34	1.02e-12	Body mass index;
LUAD	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg26408565	chr15:76604113	ETFA	-0.46	-7.68	-0.35	1.13e-13	Blood metabolite levels;
LUAD	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg20701182	chr2:24300061	SF3B14	0.57	6.88	0.32	2.14e-11	Lymphocyte counts;
LUAD	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg13319975	chr6:146136371	FBXO30	-0.62	-10.6	-0.46	1.87e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9837602	0.688	rs11537816	chr3:99886662	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	7.94	0.36	1.9e-14	Breast cancer;
LUAD	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg12568669	chr8:11666485	FDFT1	-0.24	-6.56	-0.3	1.61e-10	Morning vs. evening chronotype;
LUAD	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg09654669	chr8:57350985	NA	-0.65	-10.02	-0.44	2.42e-21	Obesity-related traits;
LUAD	cis	rs55665837	0.540	rs11023302	chr11:14693935	C/G	cg19336497	chr11:14380999	RRAS2	-0.41	-7.88	-0.36	2.72e-14	Vitamin D levels;
LUAD	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg02176678	chr2:219576539	TTLL4	0.75	15.25	0.6	3.8e-42	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg00106254	chr7:1943704	MAD1L1	0.49	7.49	0.34	4.06e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg06641503	chr3:48959341	ARIH2	-0.36	-7.23	-0.33	2.3e-12	Menarche (age at onset);
LUAD	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.42	-19.76	-0.69	4.77e-62	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6256	0.932	rs75849294	chr11:13501392	G/A	cg11976911	chr11:13509032	NA	-0.52	-6.39	-0.3	4.48e-10	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
LUAD	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg04545296	chr12:48745243	ZNF641	0.38	9.66	0.42	4.58e-20	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg08470875	chr2:26401718	FAM59B	-0.62	-8.49	-0.38	3.51e-16	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg04450456	chr4:17643702	FAM184B	0.37	6.84	0.32	2.79e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10739663	0.520	rs1566362	chr9:128163132	C/T	cg14078157	chr9:128172775	NA	0.48	8.71	0.39	6.74e-17	Resting heart rate;
LUAD	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg25554036	chr4:6271136	WFS1	0.66	13.03	0.54	7.46e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg10792982	chr14:105748885	BRF1	0.45	9.66	0.42	4.56e-20	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9811920	0.535	rs792837	chr3:99477182	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.77	-0.39	4.55e-17	Axial length;
LUAD	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg25767906	chr1:53392781	SCP2	-0.6	-11.24	-0.48	7.69e-26	Monocyte count;
LUAD	cis	rs1215050	0.791	rs6813619	chr4:98830768	C/T	cg05340658	chr4:99064831	C4orf37	-0.45	-7.46	-0.34	5.1e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-8.44	-0.38	5.09e-16	Endometrial cancer;
LUAD	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg22705602	chr4:152727874	NA	-0.42	-7.26	-0.33	1.88e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs375066	0.551	rs11880651	chr19:44331798	T/C	cg12072164	chr19:44306565	LYPD5	-0.34	-6.54	-0.3	1.79e-10	Breast cancer;
LUAD	cis	rs11167764	0.945	rs4912619	chr5:141471847	G/A	cg08523384	chr5:141488047	NDFIP1	-0.47	-7.14	-0.33	3.98e-12	Crohn's disease;
LUAD	cis	rs1451375	0.617	rs1376524	chr7:50563582	G/A	cg18232548	chr7:50535776	DDC	-0.65	-9.04	-0.4	5.5e-18	Malaria;
LUAD	cis	rs4380275	0.782	rs11691064	chr2:755718	T/G	cg21665850	chr2:731073	NA	0.37	6.58	0.3	1.42e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUAD	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.53	7.43	0.34	5.9e-13	Platelet count;
LUAD	cis	rs57590327	0.508	rs4399914	chr3:81965477	C/T	cg07356753	chr3:81810745	GBE1	-0.49	-8.29	-0.37	1.47e-15	Extraversion;
LUAD	cis	rs59104589	0.617	rs7568	chr2:242291743	A/G	cg08645257	chr2:242211290	HDLBP	0.5	7.9	0.36	2.39e-14	Fibrinogen levels;
LUAD	cis	rs9494145	0.680	rs4895441	chr6:135426573	C/T	cg22676075	chr6:135203613	NA	-0.53	-8.18	-0.37	3.47e-15	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUAD	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.66	0.31	8.63e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.48	0.3	2.54e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4942242	0.640	rs17538959	chr13:44229911	T/G	cg19169023	chr15:41853346	TYRO3	-0.69	-11.77	-0.5	7.47e-28	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg02423579	chr7:2872169	GNA12	-0.87	-15.21	-0.59	5.71e-42	Height;
LUAD	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg04155231	chr12:9217510	LOC144571	0.42	7.88	0.36	2.82e-14	Sjögren's syndrome;
LUAD	cis	rs2652834	1.000	rs2134265	chr15:63398196	G/A	cg25406657	chr15:63342033	TPM1	-0.42	-6.81	-0.31	3.36e-11	HDL cholesterol;
LUAD	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg05896524	chr21:47604654	C21orf56	0.45	6.88	0.32	2.11e-11	Testicular germ cell tumor;
LUAD	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg02560186	chr11:3602584	NA	-0.34	-6.51	-0.3	2.15e-10	Blood pressure (smoking interaction);
LUAD	trans	rs7615952	0.546	rs4428131	chr3:125346479	C/T	cg17147758	chr8:6949321	NA	-0.48	-7.31	-0.33	1.31e-12	Blood pressure (smoking interaction);
LUAD	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-6.54	-0.3	1.8e-10	Neutrophil percentage of white cells;
LUAD	cis	rs35306767	0.501	rs4880763	chr10:1147045	G/A	cg20503657	chr10:835505	NA	0.63	7.65	0.35	1.41e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs4523957	0.928	rs7406247	chr17:2157925	G/A	cg16513277	chr17:2031491	SMG6	0.76	14.59	0.58	2.53e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg11530693	chr1:120165357	ZNF697	-0.86	-18.38	-0.67	7.12e-56	Systemic lupus erythematosus;
LUAD	cis	rs752010	0.714	rs6664708	chr1:42083070	G/A	cg06885757	chr1:42089581	HIVEP3	0.47	11.13	0.48	2.09e-25	Lupus nephritis in systemic lupus erythematosus;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01738168	chr15:59397053	CCNB2	-0.41	-6.79	-0.31	3.78e-11	Cancer;
LUAD	cis	rs11626933	1.000	rs7149083	chr14:90754006	G/A	cg14092571	chr14:90743983	NA	-0.96	-18.18	-0.66	5.52e-55	Gut microbiota (bacterial taxa);
LUAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg02869364	chr7:1081709	C7orf50	-0.51	-6.6	-0.31	1.25e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.91	0.4	1.48e-17	Cognitive ability;
LUAD	cis	rs7000551	0.715	rs1530874	chr8:22347777	G/C	cg12081754	chr8:22256438	SLC39A14	0.45	7.47	0.34	4.79e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs4853525	0.859	rs6434425	chr2:191722316	A/G	cg27211696	chr2:191398769	TMEM194B	0.37	6.51	0.3	2.12e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08704250	chr15:31115839	NA	-0.55	-9.97	-0.44	3.68e-21	Huntington's disease progression;
LUAD	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg20362242	chr5:692897	TPPP	0.57	6.98	0.32	1.15e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg09222892	chr1:25734099	RHCE	-0.5	-9.12	-0.41	3.13e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg13319975	chr6:146136371	FBXO30	-0.81	-14.29	-0.57	4.52e-38	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7107174	0.892	rs4944196	chr11:78008731	G/A	cg19901956	chr11:77921274	USP35	-0.56	-6.86	-0.32	2.53e-11	Testicular germ cell tumor;
LUAD	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.23	0.33	2.25e-12	Blood metabolite levels;
LUAD	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg24768116	chr2:27665128	KRTCAP3	0.26	6.36	0.3	5.3e-10	Oral cavity cancer;
LUAD	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg03676636	chr4:99064102	C4orf37	0.32	8.36	0.38	9.08e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	7.14	0.33	4.18e-12	Tonsillectomy;
LUAD	cis	rs6494488	0.500	rs111737146	chr15:65004840	C/T	cg08069370	chr15:64387884	SNX1	-0.76	-6.77	-0.31	4.23e-11	Coronary artery disease;
LUAD	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg14541582	chr5:601475	NA	-0.36	-7.58	-0.35	2.19e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs2971970	0.519	rs4728303	chr7:133633518	G/T	cg03336402	chr7:133662267	EXOC4	0.39	7.13	0.33	4.39e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg07936489	chr17:37558343	FBXL20	-0.48	-7.58	-0.35	2.26e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg05665937	chr4:1216051	CTBP1	0.41	6.74	0.31	5.18e-11	Obesity-related traits;
LUAD	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg18105134	chr13:113819100	PROZ	-0.81	-14.59	-0.58	2.35e-39	Platelet distribution width;
LUAD	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg18105134	chr13:113819100	PROZ	-0.85	-14.95	-0.59	7.28e-41	Platelet distribution width;
LUAD	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06112835	chr11:68658793	MRPL21	0.54	9.67	0.43	4.1e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-9.03	-0.4	6.3e-18	Lymphocyte counts;
LUAD	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg05616858	chr17:37843591	ERBB2;PGAP3	0.33	6.69	0.31	7.15e-11	Asthma;
LUAD	cis	rs2274273	0.901	rs8011288	chr14:55735112	C/T	cg04306507	chr14:55594613	LGALS3	0.43	8.99	0.4	8.5e-18	Protein biomarker;
LUAD	cis	rs7927771	0.524	rs11039329	chr11:47684908	A/G	cg18512352	chr11:47633146	NA	0.38	6.72	0.31	5.94e-11	Subjective well-being;
LUAD	cis	rs2286503	1.000	rs1029740	chr7:22873586	C/A	cg06496272	chr7:22895283	SNORD93	-0.42	-7.56	-0.35	2.48e-13	Fibrinogen;
LUAD	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs6669919	0.967	rs6678844	chr1:211674774	G/T	cg10512769	chr1:211675356	NA	-0.32	-6.82	-0.31	3.24e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7474896	0.537	rs1208591	chr10:38212502	A/T	cg25427524	chr10:38739819	LOC399744	-0.55	-7.94	-0.36	1.89e-14	Obesity (extreme);
LUAD	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg20848291	chr7:100343083	ZAN	-0.61	-10.22	-0.45	4.51e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg06002616	chr8:101225028	SPAG1	-0.39	-7.92	-0.36	2.06e-14	Atrioventricular conduction;
LUAD	cis	rs1816752	0.819	rs7317504	chr13:24985425	C/T	cg02811702	chr13:24901961	NA	0.43	7.38	0.34	8.61e-13	Obesity-related traits;
LUAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs5756813	0.688	rs34891095	chr22:38126582	C/T	cg06521852	chr22:38141419	TRIOBP	0.5	8.72	0.39	6.32e-17	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg05044414	chr3:183734942	ABCC5	0.47	9.81	0.43	1.34e-20	Anterior chamber depth;
LUAD	trans	rs747782	0.528	rs11039674	chr11:48336116	C/T	cg15704280	chr7:45808275	SEPT13	0.65	7.61	0.35	1.79e-13	Intraocular pressure;
LUAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg04025307	chr7:1156635	C7orf50	0.67	7.71	0.35	8.8e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg13870426	chr17:30244630	NA	-0.57	-6.62	-0.31	1.12e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs68170813	0.559	rs12533767	chr7:106860245	A/C	cg02696742	chr7:106810147	HBP1	-0.78	-10.66	-0.46	1.15e-23	Coronary artery disease;
LUAD	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg00666640	chr1:248458726	OR2T12	0.31	7.62	0.35	1.64e-13	Common traits (Other);
LUAD	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg04287289	chr16:89883240	FANCA	0.82	7.27	0.33	1.72e-12	Skin colour saturation;
LUAD	cis	rs59698941	0.943	rs67551921	chr5:132289033	G/A	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	2.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.77	-10.19	-0.44	6.04e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg13271783	chr10:134563150	INPP5A	-0.4	-7.1	-0.33	5.2e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg26384229	chr12:38710491	ALG10B	0.46	7.44	0.34	5.59e-13	Bladder cancer;
LUAD	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11644478	chr21:40555479	PSMG1	-0.53	-8.49	-0.38	3.53e-16	Cognitive function;
LUAD	cis	rs7582720	1.000	rs72934514	chr2:203933339	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	9.77	0.43	1.9e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	trans	rs7395662	0.824	rs4882180	chr11:48749357	C/A	cg00717180	chr2:96193071	NA	-0.39	-7.2	-0.33	2.69e-12	HDL cholesterol;
LUAD	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg08601574	chr20:25228251	PYGB	0.45	8.34	0.38	1.04e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.81	0.43	1.32e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11677370	0.561	rs12986995	chr2:3826965	G/A	cg17052675	chr2:3827356	NA	-0.63	-10.71	-0.46	7.35e-24	Type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.27	0.37	1.74e-15	Breast cancer;
LUAD	cis	rs9788721	0.775	rs8040868	chr15:78911181	C/T	cg18825076	chr15:78729989	IREB2	0.47	7.81	0.35	4.71e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg19901468	chr14:105411992	AHNAK2	-0.54	-10.44	-0.45	7.46e-23	Rheumatoid arthritis;
LUAD	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg10356904	chr22:49881777	NA	-0.41	-7.83	-0.36	4.05e-14	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg14829155	chr15:31115871	NA	-0.64	-10.0	-0.44	2.85e-21	Huntington's disease progression;
LUAD	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.45	-8.87	-0.4	2.08e-17	Glomerular filtration rate;
LUAD	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg07538946	chr5:131705188	SLC22A5	0.42	6.92	0.32	1.66e-11	Blood metabolite levels;
LUAD	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg11292332	chr7:45801988	SEPT13	-0.31	-6.84	-0.32	2.81e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.61	0.31	1.19e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs986417	0.748	rs4381505	chr14:61035968	C/T	cg27398547	chr14:60952738	C14orf39	0.52	6.64	0.31	9.65e-11	Gut microbiota (bacterial taxa);
LUAD	cis	rs4903604	0.581	rs4903606	chr14:78036935	A/G	cg18872420	chr14:78023429	SPTLC2	0.46	8.47	0.38	3.99e-16	Gut microbiome composition (winter);
LUAD	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg00316803	chr15:76480434	C15orf27	-0.39	-7.4	-0.34	7.63e-13	Blood metabolite levels;
LUAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg14789911	chr21:47582049	C21orf56	-0.5	-9.05	-0.4	5.42e-18	Testicular germ cell tumor;
LUAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg16606324	chr3:10149918	C3orf24	0.56	8.13	0.37	4.83e-15	Alzheimer's disease;
LUAD	cis	rs9905704	0.633	rs2632511	chr17:56490989	G/A	cg19466818	chr17:56409534	MIR142	-0.34	-6.67	-0.31	8.11e-11	Testicular germ cell tumor;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24675879	chr17:28444056	MIR423;CCDC55	-0.42	-6.71	-0.31	6.31e-11	Height;
LUAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13732083	chr21:47605072	C21orf56	0.59	9.61	0.42	6.75e-20	Testicular germ cell tumor;
LUAD	cis	rs7156960	1.000	rs7152893	chr14:76711185	T/G	cg13981132	chr14:76734493	NA	-0.41	-6.48	-0.3	2.56e-10	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7737355	0.947	rs2021774	chr5:130920831	G/A	cg25547332	chr5:131281432	NA	0.43	6.58	0.3	1.44e-10	Life satisfaction;
LUAD	cis	rs2455601	0.935	rs12049908	chr11:8919309	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-7.17	-0.33	3.36e-12	Schizophrenia;
LUAD	cis	rs6489882	0.966	rs2010604	chr12:113408208	C/G	cg20102336	chr12:113376681	OAS3	-0.45	-6.88	-0.32	2.16e-11	Chronic lymphocytic leukemia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg23313650	chr7:123389169	WASL	-0.76	-7.74	-0.35	7.42e-14	Type 2 diabetes;
LUAD	cis	rs7512552	0.839	rs1694385	chr1:150377960	G/A	cg15654264	chr1:150340011	RPRD2	0.59	11.2	0.48	1.17e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg05340658	chr4:99064831	C4orf37	0.44	6.73	0.31	5.55e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02359409	chr6:42947317	PEX6	-0.39	-6.86	-0.32	2.44e-11	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs67981189	0.529	rs17108808	chr14:71441552	T/C	cg15910301	chr14:71632612	NA	0.41	6.37	0.3	4.96e-10	Schizophrenia;
LUAD	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg21475434	chr5:93447410	FAM172A	0.77	8.69	0.39	7.78e-17	Diabetic retinopathy;
LUAD	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06022373	chr22:39101656	GTPBP1	0.46	7.4	0.34	7.26e-13	Menopause (age at onset);
LUAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.9	0.47	1.51e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1692580	0.840	rs263526	chr1:2173504	T/C	cg24578937	chr1:2090814	PRKCZ	0.53	10.08	0.44	1.45e-21	Coronary artery disease;
LUAD	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg03929089	chr4:120376271	NA	-0.94	-17.18	-0.64	1.52e-50	Height;
LUAD	cis	rs62400317	0.826	rs17288327	chr6:45349877	A/G	cg18551225	chr6:44695536	NA	-0.5	-8.01	-0.36	1.09e-14	Total body bone mineral density;
LUAD	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg03929089	chr4:120376271	NA	-0.53	-7.73	-0.35	7.71e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg15181151	chr6:150070149	PCMT1	0.42	8.84	0.39	2.58e-17	Lung cancer;
LUAD	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.45	-0.52	1.6e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg07256732	chr16:621771	PIGQ	-0.32	-6.54	-0.3	1.8e-10	Height;
LUAD	cis	rs6920965	0.509	rs575811	chr6:126162282	T/C	cg05901451	chr6:126070800	HEY2	0.43	7.01	0.32	9.65e-12	High light scatter reticulocyte count;
LUAD	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg04455712	chr21:45112962	RRP1B	0.54	10.83	0.47	2.75e-24	Mean corpuscular volume;
LUAD	cis	rs7870753	0.628	rs10820597	chr9:99188347	C/A	cg13563390	chr9:99253610	HABP4	-0.38	-6.36	-0.3	5.38e-10	Height;
LUAD	cis	rs859767	0.501	rs11898465	chr2:135431449	G/T	cg12500956	chr2:135428796	TMEM163	-0.27	-7.36	-0.34	9.88e-13	Neuroticism;
LUAD	cis	rs2742234	0.578	rs2742241	chr10:43625223	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.51	-8.64	-0.39	1.15e-16	Hirschsprung disease;
LUAD	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg16647868	chr5:131706066	SLC22A5	0.47	7.01	0.32	9.63e-12	Breast cancer;
LUAD	cis	rs12711979	0.509	rs10200764	chr2:3827772	C/G	cg17052675	chr2:3827356	NA	-0.85	-20.56	-0.71	1.25e-65	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs1595825	0.891	rs3851979	chr2:198707638	A/T	cg11031976	chr2:198649780	BOLL	0.46	6.89	0.32	2.09e-11	Ulcerative colitis;
LUAD	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg18944383	chr4:111397179	ENPEP	0.39	7.83	0.36	3.87e-14	Height;
LUAD	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg10560079	chr2:191398806	TMEM194B	-0.56	-7.33	-0.34	1.17e-12	Diastolic blood pressure;
LUAD	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg17644776	chr2:200775616	C2orf69	0.53	7.56	0.34	2.61e-13	Schizophrenia;
LUAD	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs2346177	0.513	rs1530625	chr2:46658067	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.38	-6.37	-0.3	4.93e-10	HDL cholesterol;
LUAD	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg16988262	chr1:15930761	NA	0.41	6.85	0.32	2.61e-11	Systolic blood pressure;
LUAD	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg01849466	chr14:104193079	ZFYVE21	0.53	9.6	0.42	7.01e-20	Schizophrenia;
LUAD	cis	rs2625529	0.824	rs10518979	chr15:72268986	A/G	cg16672083	chr15:72433130	SENP8	-0.76	-12.73	-0.53	1.18e-31	Red blood cell count;
LUAD	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg17971929	chr21:40555470	PSMG1	0.56	8.87	0.4	2.04e-17	Cognitive function;
LUAD	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg23029597	chr12:123009494	RSRC2	-0.58	-9.23	-0.41	1.28e-18	Body mass index;
LUAD	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.34	-6.38	-0.3	4.62e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg00431813	chr7:1051703	C7orf50	-0.45	-8.43	-0.38	5.64e-16	Longevity;Endometriosis;
LUAD	cis	rs9517320	0.967	rs9517337	chr13:99181647	A/C	cg20487152	chr13:99095054	FARP1	0.35	6.37	0.3	4.92e-10	Longevity;
LUAD	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg02733842	chr7:1102375	C7orf50	-0.55	-8.68	-0.39	8.68e-17	Bronchopulmonary dysplasia;
LUAD	trans	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.26	-0.33	1.9e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2455601	1.000	rs11042108	chr11:8906021	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.46	-6.6	-0.31	1.22e-10	Schizophrenia;
LUAD	cis	rs1696756	0.816	rs2650242	chr17:77827360	A/T	cg01306824	chr17:77834118	NA	0.44	6.73	0.31	5.65e-11	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg21775007	chr8:11205619	TDH	0.37	6.41	0.3	3.83e-10	Myopia (pathological);
LUAD	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg00204512	chr16:28754710	NA	0.35	7.49	0.34	4.06e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg01620082	chr3:125678407	NA	-0.46	-6.64	-0.31	9.91e-11	Depression;
LUAD	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg05564831	chr3:52568323	NT5DC2	-0.36	-6.64	-0.31	9.59e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	trans	rs8073060	0.586	rs4795086	chr17:34042190	G/A	cg19694781	chr19:47549865	TMEM160	1.21	18.83	0.68	7e-58	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15688767	chr3:125093330	ZNF148	-0.44	-6.84	-0.32	2.86e-11	Height;
LUAD	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg21782813	chr7:2030301	MAD1L1	0.45	8.08	0.37	6.76e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7258465	1.000	rs3810429	chr19:18543270	G/T	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.54	-0.34	2.81e-13	Breast cancer;
LUAD	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg17848003	chr1:3704513	LRRC47	0.53	10.66	0.46	1.14e-23	Red cell distribution width;
LUAD	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs778371	0.723	rs1022329	chr2:233591239	T/C	cg08000102	chr2:233561755	GIGYF2	0.39	6.45	0.3	3.05e-10	Schizophrenia;
LUAD	cis	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg23950597	chr19:37808831	NA	-0.61	-7.51	-0.34	3.54e-13	Coronary artery calcification;
LUAD	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07911682	chr1:51425659	FAF1	-0.51	-6.37	-0.3	5.08e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4077515	0.967	rs3812558	chr9:139269135	A/G	cg14019695	chr9:139328340	INPP5E	0.4	7.68	0.35	1.12e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2067615	0.599	rs1579808	chr12:107239947	A/G	cg15890332	chr12:107067104	RFX4	-0.39	-8.27	-0.37	1.7e-15	Heart rate;
LUAD	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg06740227	chr12:86229804	RASSF9	0.38	6.8	0.31	3.58e-11	Major depressive disorder;
LUAD	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.16	-0.41	2.32e-18	Alcohol dependence;
LUAD	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg03929089	chr4:120376271	NA	-0.88	-16.09	-0.62	9.04e-46	Coronary artery disease;
LUAD	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg24450063	chr1:156163899	SLC25A44	-1.12	-26.32	-0.79	4.01e-91	Testicular germ cell tumor;
LUAD	cis	rs597583	0.715	rs1940040	chr11:117393294	G/C	cg27161313	chr11:117392002	DSCAML1	-0.58	-9.4	-0.42	3.57e-19	Putamen volume;
LUAD	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg15691649	chr6:25882328	NA	-0.75	-11.91	-0.5	2.1e-28	Urate levels;
LUAD	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg18721089	chr20:30220636	NA	-0.45	-6.5	-0.3	2.24e-10	Mean corpuscular hemoglobin;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01237807	chr1:46215957	IPP	-0.41	-6.93	-0.32	1.53e-11	Cancer;
LUAD	cis	rs7680126	0.596	rs12511337	chr4:10311972	A/G	cg00071950	chr4:10020882	SLC2A9	0.53	7.4	0.34	7.33e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9462027	0.628	rs2744957	chr6:34618516	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.68	-0.39	8.44e-17	Systemic lupus erythematosus;
LUAD	cis	rs220324	0.738	rs1026400	chr21:43587824	C/T	cg09727148	chr21:43560719	UMODL1	0.51	7.25	0.33	2.01e-12	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs12681287	0.604	rs34227066	chr8:87449366	C/T	cg00550725	chr8:87521180	FAM82B	0.45	6.63	0.31	1.02e-10	Caudate activity during reward;
LUAD	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg00898013	chr13:113819073	PROZ	-0.66	-11.64	-0.49	2.32e-27	Platelet distribution width;
LUAD	cis	rs10821973	0.527	rs10740069	chr10:63982984	A/G	cg09941381	chr10:64027924	RTKN2	-0.34	-6.77	-0.31	4.23e-11	Hypothyroidism;
LUAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg27454412	chr7:1067447	C7orf50	0.45	7.09	0.33	5.53e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg04025307	chr7:1156635	C7orf50	0.65	7.41	0.34	6.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2997447	0.739	rs3008224	chr1:26389647	G/A	cg00147160	chr1:26503991	CNKSR1	0.36	6.83	0.32	3e-11	QRS complex (12-leadsum);
LUAD	cis	rs12681287	0.604	rs6471316	chr8:87403587	G/C	cg27223183	chr8:87520930	FAM82B	0.67	9.53	0.42	1.22e-19	Caudate activity during reward;
LUAD	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg05991184	chr2:219186017	PNKD	-0.38	-7.39	-0.34	8.07e-13	Colorectal cancer;
LUAD	cis	rs2073300	1.000	rs6036411	chr20:23441706	A/C	cg12062639	chr20:23401060	NAPB	0.71	6.94	0.32	1.45e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg08470875	chr2:26401718	FAM59B	0.66	8.27	0.37	1.81e-15	Gut microbiome composition (summer);
LUAD	cis	rs11083475	0.557	rs2368519	chr19:39259241	C/T	cg17759274	chr19:39260954	NA	0.43	7.55	0.34	2.79e-13	Heart rate;
LUAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13012494	chr21:47604986	C21orf56	-0.67	-11.87	-0.5	2.9e-28	Testicular germ cell tumor;
LUAD	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg21475434	chr5:93447410	FAM172A	0.74	8.62	0.39	1.39e-16	Diabetic retinopathy;
LUAD	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.36	-6.38	-0.3	4.72e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	8.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg17173187	chr15:85201210	NMB	0.55	9.51	0.42	1.48e-19	Schizophrenia;
LUAD	trans	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-17.46	-0.65	8.8e-52	Exhaled nitric oxide output;
LUAD	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.68e-14	Iron status biomarkers;
LUAD	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg15147215	chr3:52552868	STAB1	-0.38	-7.06	-0.32	7.06e-12	Bipolar disorder;
LUAD	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg06618935	chr21:46677482	NA	-0.48	-9.9	-0.43	6.41e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg13815390	chr20:61568896	DIDO1;C20orf11	0.4	6.41	0.3	4.01e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg19318889	chr4:1322082	MAEA	0.44	7.02	0.32	8.86e-12	Obesity-related traits;
LUAD	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg18932078	chr1:2524107	MMEL1	0.38	7.22	0.33	2.47e-12	Ulcerative colitis;
LUAD	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg11494091	chr17:61959527	GH2	0.41	7.2	0.33	2.78e-12	Height;
LUAD	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg06784218	chr1:46089804	CCDC17	0.52	11.35	0.48	3e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg01884057	chr2:25150051	NA	0.33	7.12	0.33	4.59e-12	Body mass index in non-asthmatics;
LUAD	cis	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-8.03	-0.36	9.7e-15	Neuroticism;
LUAD	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg12311346	chr5:56204834	C5orf35	0.89	13.48	0.55	1.06e-34	Initial pursuit acceleration;
LUAD	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg23281280	chr6:28129359	ZNF389	0.46	6.58	0.3	1.39e-10	Depression;
LUAD	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.73e-16	Neutrophil percentage of white cells;
LUAD	cis	rs1534166	1.000	rs1534166	chr3:133537067	C/T	cg27366882	chr3:133540807	NA	0.41	7.15	0.33	3.74e-12	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg16205897	chr5:131564050	P4HA2	-0.35	-7.67	-0.35	1.18e-13	Breast cancer;
LUAD	cis	rs12893597	0.541	rs12589755	chr14:76841939	A/C	cg20290672	chr14:76816747	NA	-0.4	-6.54	-0.3	1.8e-10	Maximal oxygen uptake response;
LUAD	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.43	0.34	5.91e-13	Bipolar disorder;
LUAD	cis	rs12367572	1.000	rs12367572	chr12:45290466	C/T	cg04608330	chr12:45269318	NELL2	0.37	6.86	0.32	2.52e-11	Gut microbiome composition (summer);
LUAD	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19346786	chr7:2764209	NA	-0.49	-10.65	-0.46	1.3e-23	Height;
LUAD	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg04944784	chr2:26401820	FAM59B	0.78	10.63	0.46	1.44e-23	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg03676636	chr4:99064102	C4orf37	0.31	8.21	0.37	2.79e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-8.2	-0.37	3e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg03690763	chr11:133734501	NA	-0.34	-7.81	-0.36	4.55e-14	Childhood ear infection;
LUAD	cis	rs1375194	0.606	rs935625	chr2:33811516	C/G	cg04131969	chr2:33951647	MYADML	-0.56	-8.77	-0.39	4.32e-17	Response to antidepressants in depression;
LUAD	cis	rs3806843	0.576	rs246003	chr5:140340865	C/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.51	-0.3	2.09e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs59698941	0.943	rs10491278	chr5:132220436	A/C	cg14825688	chr5:132208181	LEAP2	-0.47	-6.65	-0.31	8.85e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg09835421	chr16:68378352	PRMT7	-0.84	-9.13	-0.41	2.88e-18	HDL cholesterol;
LUAD	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg00321850	chr1:175162397	KIAA0040	-0.52	-11.03	-0.47	4.85e-25	Alcohol dependence;
LUAD	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg11189052	chr15:85197271	WDR73	0.64	8.21	0.37	2.75e-15	Schizophrenia;
LUAD	cis	rs7512552	0.839	rs11205357	chr1:150267798	T/C	cg15654264	chr1:150340011	RPRD2	-0.59	-11.33	-0.48	3.76e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg20476274	chr7:133979776	SLC35B4	0.84	15.82	0.61	1.24e-44	Mean platelet volume;
LUAD	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg09365446	chr1:150670422	GOLPH3L	0.57	9.95	0.44	4.42e-21	Melanoma;
LUAD	cis	rs5756813	0.782	rs3171656	chr22:38172213	G/A	cg06521852	chr22:38141419	TRIOBP	0.49	9.25	0.41	1.1e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg14345882	chr6:26364793	BTN3A2	0.65	6.49	0.3	2.36e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg17105886	chr17:28927953	LRRC37B2	0.79	7.88	0.36	2.81e-14	Body mass index;
LUAD	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg15556689	chr8:8085844	FLJ10661	0.44	7.27	0.33	1.76e-12	Mood instability;
LUAD	cis	rs3806843	0.612	rs246075	chr5:140300557	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.66	-0.31	8.49e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.57	7.64	0.35	1.49e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	7.81	0.36	4.54e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg04539111	chr16:67997858	SLC12A4	-0.52	-6.38	-0.3	4.62e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg21252483	chr19:49399788	TULP2	-0.87	-14.17	-0.57	1.37e-37	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs3823572	0.564	rs2953624	chr7:133659125	C/G	cg03336402	chr7:133662267	EXOC4	-0.43	-7.84	-0.36	3.67e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg25227274	chr19:9648995	ZNF426	-0.49	-6.35	-0.3	5.66e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg15664640	chr17:80829946	TBCD	-0.65	-8.73	-0.39	5.9e-17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs12200560	0.505	rs60879781	chr6:97075466	A/T	cg06623918	chr6:96969491	KIAA0776	0.48	7.36	0.34	9.4e-13	Coronary heart disease;
LUAD	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg16647868	chr5:131706066	SLC22A5	0.38	6.39	0.3	4.26e-10	Blood metabolite levels;
LUAD	cis	rs420259	0.556	rs7187920	chr16:23563501	C/T	cg00143387	chr16:23521605	GGA2	-0.7	-9.81	-0.43	1.32e-20	Bipolar disorder;
LUAD	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.77	-0.35	5.95e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	9.34	0.41	5.46e-19	Melanoma;
LUAD	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg03474202	chr17:45855739	NA	-0.38	-9.04	-0.4	5.54e-18	IgG glycosylation;
LUAD	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg18854424	chr1:2615690	NA	0.34	8.03	0.36	9.98e-15	Ulcerative colitis;
LUAD	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.38	0.34	8.57e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs34638657	0.732	rs2911425	chr16:82203026	T/C	cg09439754	chr16:82129088	HSD17B2	-0.34	-6.4	-0.3	4.09e-10	Lung adenocarcinoma;
LUAD	trans	rs587242	0.911	rs61786490	chr1:96897274	T/G	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs714515	0.546	rs9425573	chr1:172330437	G/T	cg13446689	chr1:172328377	DNM3	0.32	6.35	0.3	5.43e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs9616064	0.506	rs737135	chr22:47061791	C/T	cg25730555	chr22:47059586	GRAMD4	0.39	7.12	0.33	4.56e-12	Urate levels in obese individuals;
LUAD	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg25324976	chr17:61989376	CSHL1	0.37	7.06	0.32	7.03e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg21862992	chr11:68658383	NA	0.51	9.38	0.41	4.08e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7707921	0.881	rs73134722	chr5:81326622	G/A	cg15871215	chr5:81402204	ATG10	-0.7	-9.84	-0.43	1.06e-20	Breast cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09288780	chr6:10413394	TFAP2A	-0.75	-7.34	-0.34	1.09e-12	Type 2 diabetes;
LUAD	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.79	-0.5	6.01e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg10523679	chr1:76189770	ACADM	-0.77	-11.33	-0.48	3.5e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg25358565	chr5:93447407	FAM172A	0.62	7.51	0.34	3.59e-13	Diabetic retinopathy;
LUAD	cis	rs9487051	0.703	rs351755	chr6:109538073	G/A	cg01475377	chr6:109611718	NA	0.41	7.59	0.35	2.05e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg24596788	chr1:163392923	NA	0.33	6.75	0.31	4.87e-11	Motion sickness;
LUAD	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg07404485	chr7:94953653	PON1	-0.51	-7.53	-0.34	3.1400000000000003e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4356932	1.000	rs4859600	chr4:76959967	C/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.52	-0.3	2.05e-10	Blood protein levels;
LUAD	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs13082711	0.871	rs34209332	chr3:27434061	A/T	cg02860705	chr3:27208620	NA	0.6	9.28	0.41	8.64e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6835098	1.000	rs28477433	chr4:174085820	T/C	cg08422745	chr4:174089978	GALNT7	-0.96	-18.57	-0.67	9.94e-57	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.76	-0.31	4.59e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13247069	chr12:49961998	MCRS1	-0.38	-6.4	-0.3	4.12e-10	Cancer;
LUAD	cis	rs4604732	0.588	rs7549955	chr1:247628321	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	9.11	0.41	3.23e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs875971	1.000	rs778699	chr7:65868290	G/A	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.87	-0.32	2.37e-11	Height;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg10534439	chr2:69969029	ANXA4	-0.69	-6.44	-0.3	3.16e-10	Type 2 diabetes;
LUAD	cis	rs9462027	0.606	rs4624858	chr6:34802301	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.68	-0.39	8.41e-17	Systemic lupus erythematosus;
LUAD	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.43	-0.34	5.94e-13	Type 2 diabetes;
LUAD	cis	rs11971779	0.617	rs66652773	chr7:139109573	C/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.38e-10	Diisocyanate-induced asthma;
LUAD	cis	rs9473147	0.516	rs6904764	chr6:47503497	A/T	cg02130027	chr6:47444894	CD2AP	0.36	6.88	0.32	2.11e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg17173187	chr15:85201210	NMB	0.41	6.7	0.31	6.87e-11	Schizophrenia;
LUAD	cis	rs7809950	0.798	rs10281535	chr7:107229618	T/G	cg23024343	chr7:107201750	COG5	0.67	11.21	0.48	1.05e-25	Coronary artery disease;
LUAD	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg26924012	chr15:45694286	SPATA5L1	1.02	18.96	0.68	1.78e-58	Homoarginine levels;
LUAD	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15506890	chr2:3487001	NA	-0.45	-7.84	-0.36	3.73e-14	Neurofibrillary tangles;
LUAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg20607798	chr8:58055168	NA	0.56	6.89	0.32	2.02e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.87e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.54	-0.34	2.81e-13	Total cholesterol levels;
LUAD	cis	rs10210302	0.502	rs880116	chr2:234246264	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.4	6.56	0.3	1.6e-10	Crohn's disease;
LUAD	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.79	-0.31	3.8e-11	Fear of minor pain;
LUAD	cis	rs9837602	0.938	rs34922392	chr3:99794730	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.58	8.93	0.4	1.36e-17	Breast cancer;
LUAD	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg17346650	chr17:80929145	B3GNTL1	0.39	6.62	0.31	1.07e-10	Glycated hemoglobin levels;
LUAD	cis	rs4743820	0.651	rs10739912	chr9:93929115	A/G	cg14446406	chr9:93919335	NA	-0.52	-8.78	-0.39	4.06e-17	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs2346177	0.605	rs7598712	chr2:46660452	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.38	-6.46	-0.3	2.85e-10	HDL cholesterol;
LUAD	trans	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg07817883	chr1:32538562	TMEM39B	1.25	11.92	0.5	1.9e-28	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg23260525	chr10:116636907	FAM160B1	0.44	10.23	0.45	4.17e-22	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7224314	1.000	rs8066725	chr17:65387326	G/A	cg01507342	chr17:65387096	PITPNC1	-0.54	-8.81	-0.39	3.3e-17	Diisocyanate-induced asthma;
LUAD	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs755249	0.510	rs613511	chr1:39833473	C/T	cg27567593	chr1:39956653	BMP8A	-0.36	-7.31	-0.34	1.31e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg19761014	chr17:28927070	LRRC37B2	0.82	8.34	0.38	1.09e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs877282	1.000	rs12775643	chr10:773242	G/A	cg22713356	chr15:30763199	NA	1.18	16.81	0.63	6.06e-49	Uric acid levels;
LUAD	cis	rs657075	0.757	rs13175394	chr5:131641206	G/A	cg21138405	chr5:131827807	IRF1	0.53	6.67	0.31	7.89e-11	Rheumatoid arthritis;
LUAD	trans	rs3857536	0.813	rs1891599	chr6:66941699	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.56	7.95	0.36	1.76e-14	Platelet count;
LUAD	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg09796270	chr17:17721594	SREBF1	0.39	7.65	0.35	1.36e-13	Total body bone mineral density;
LUAD	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg07636037	chr3:49044803	WDR6	0.64	12.52	0.52	8.6e-31	Parkinson's disease;
LUAD	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg09137382	chr11:130731461	NA	0.41	7.49	0.34	4.1e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6076065	0.723	rs2424539	chr20:23384904	C/T	cg11657817	chr20:23433608	CST11	-0.49	-9.12	-0.41	2.99e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg26924012	chr15:45694286	SPATA5L1	1.02	18.35	0.67	9.25e-56	Homoarginine levels;
LUAD	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg22166914	chr1:53195759	ZYG11B	0.51	8.74	0.39	5.57e-17	Monocyte count;
LUAD	cis	rs62400317	0.859	rs11965520	chr6:45259431	T/A	cg20913747	chr6:44695427	NA	-0.41	-6.6	-0.31	1.23e-10	Total body bone mineral density;
LUAD	trans	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg18187862	chr3:45730750	SACM1L	0.51	7.78	0.35	5.66e-14	Primary sclerosing cholangitis;
LUAD	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.65	-10.4	-0.45	1.04e-22	IgG glycosylation;
LUAD	cis	rs7705042	0.865	rs249643	chr5:141524746	C/G	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.93	-0.32	1.57e-11	Asthma;
LUAD	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg22681709	chr2:178499509	PDE11A	-0.51	-8.12	-0.37	5.04e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg26677194	chr12:130822605	PIWIL1	0.57	9.03	0.4	5.99e-18	Menopause (age at onset);
LUAD	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.9	-0.47	1.56e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs250677	0.958	rs10056942	chr5:148416114	C/A	cg12140854	chr5:148520817	ABLIM3	-0.62	-9.74	-0.43	2.3e-20	Breast cancer;
LUAD	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg20203395	chr5:56204925	C5orf35	0.64	9.86	0.43	9.17e-21	Initial pursuit acceleration;
LUAD	cis	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.91	-0.32	1.78e-11	Triglycerides;
LUAD	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs4853036	0.904	rs2278934	chr2:70121197	T/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-8.04	-0.36	9.12e-15	Colorectal or endometrial cancer;
LUAD	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.5	-0.38	3.38e-16	Height;
LUAD	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11890956	chr21:40555474	PSMG1	-0.52	-8.93	-0.4	1.31e-17	Menarche (age at onset);
LUAD	cis	rs4774899	0.752	rs28648502	chr15:57400749	T/C	cg14026238	chr15:57616123	NA	-0.43	-8.1	-0.37	5.93e-15	Urinary tract infection frequency;
LUAD	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg20135002	chr11:47629003	NA	-0.41	-7.13	-0.33	4.32e-12	Subjective well-being;
LUAD	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg15900387	chr1:150738905	CTSS	-0.36	-6.63	-0.31	1.05e-10	Melanoma;
LUAD	cis	rs1371614	0.566	rs1440042	chr2:27187814	G/A	cg00617064	chr2:27272375	NA	-0.38	-7.33	-0.34	1.18e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs986417	0.901	rs11627533	chr14:61037801	C/T	cg27398547	chr14:60952738	C14orf39	0.68	7.96	0.36	1.62e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg05340658	chr4:99064831	C4orf37	-0.47	-7.74	-0.35	7.23e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12549902	0.966	rs716199	chr8:41515531	A/G	cg17182837	chr8:41585554	ANK1	-0.36	-7.28	-0.33	1.62e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUAD	trans	rs11650494	1.000	rs11650494	chr17:47345186	G/A	cg11430096	chr6:110968061	CDK19	0.78	6.59	0.31	1.28e-10	Prostate cancer;
LUAD	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-7.82	-0.36	4.19e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.53	0.3	1.84e-10	Menarche (age at onset);
LUAD	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.67	10.86	0.47	2.08e-24	Height;
LUAD	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg22455342	chr2:225449267	CUL3	0.45	7.54	0.34	2.89e-13	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg25036284	chr2:26402008	FAM59B	0.64	8.22	0.37	2.48e-15	Gut microbiome composition (summer);
LUAD	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg22535103	chr8:58192502	C8orf71	-0.78	-11.06	-0.47	3.66e-25	Developmental language disorder (linguistic errors);
LUAD	cis	rs9902453	0.716	rs3098949	chr17:27978694	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	10.64	0.46	1.39e-23	Coffee consumption (cups per day);
LUAD	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg16325326	chr1:53192061	ZYG11B	0.68	13.15	0.54	2.32e-33	Monocyte count;
LUAD	cis	rs2742417	0.603	rs2064063	chr3:45759924	T/A	cg10512202	chr3:45649293	LIMD1	0.48	8.89	0.4	1.84e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs938554	0.784	rs10939638	chr4:9977675	T/A	cg00071950	chr4:10020882	SLC2A9	0.53	8.24	0.37	2.24e-15	Blood metabolite levels;
LUAD	trans	rs8073060	0.586	rs7212488	chr17:33993476	A/T	cg19694781	chr19:47549865	TMEM160	-1.23	-19.69	-0.69	1.02e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs6696239	0.513	rs28407112	chr1:227736752	A/G	cg12133451	chr1:227746453	NA	0.37	6.78	0.31	4.05e-11	Height;
LUAD	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg26597838	chr10:835615	NA	1.3	19.6	0.69	2.58e-61	Eosinophil percentage of granulocytes;
LUAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06873352	chr17:61820015	STRADA	0.82	18.03	0.66	2.59e-54	Prudent dietary pattern;
LUAD	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg10523679	chr1:76189770	ACADM	0.77	11.41	0.49	1.79e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs758324	0.773	rs804058	chr5:131266362	T/C	cg06307176	chr5:131281290	NA	-0.45	-7.54	-0.34	2.9e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-6.59	-0.31	1.33e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12422267	0.609	rs10128884	chr12:132621624	C/T	cg09764611	chr12:132620959	NA	-0.54	-9.53	-0.42	1.2e-19	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg17031739	chr1:67600172	NA	0.51	8.94	0.4	1.26e-17	Psoriasis;
LUAD	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg22482690	chr17:47019901	SNF8	0.45	8.46	0.38	4.31e-16	Type 2 diabetes;
LUAD	cis	rs6504663	0.558	rs2412325	chr17:48546232	G/C	cg00901687	chr17:48585270	MYCBPAP	0.53	7.48	0.34	4.39e-13	Visceral fat;
LUAD	cis	rs17641971	0.684	rs6984804	chr8:49987910	G/A	cg00325661	chr8:49890786	NA	0.31	6.97	0.32	1.19e-11	Blood metabolite levels;
LUAD	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg19717773	chr7:2847554	GNA12	-0.55	-10.41	-0.45	9.16e-23	Height;
LUAD	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg26446133	chr18:72167187	CNDP2	-0.79	-11.32	-0.48	4.11e-26	Refractive error;
LUAD	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg09137382	chr11:130731461	NA	0.37	6.43	0.3	3.49e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7759001	0.857	rs10080569	chr6:27363076	G/A	cg18711553	chr6:27366782	ZNF391	0.39	6.47	0.3	2.73e-10	Glomerular filtration rate (creatinine);
LUAD	trans	rs61332075	0.503	rs113377546	chr2:239303870	G/A	cg01134436	chr17:81009848	B3GNTL1	0.77	6.82	0.31	3.19e-11	Lung function (FEV1/FVC);
LUAD	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg05340658	chr4:99064831	C4orf37	-0.46	-7.51	-0.34	3.57e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg14828511	chr1:107599125	PRMT6	0.5	8.23	0.37	2.36e-15	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs12530845	0.623	rs73721664	chr7:135343575	A/C	cg23117316	chr7:135346802	PL-5283	-0.6	-9.12	-0.41	3.1e-18	Red blood cell traits;
LUAD	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg21775007	chr8:11205619	TDH	0.47	8.11	0.37	5.36e-15	Retinal vascular caliber;
LUAD	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg05132306	chr1:1846340	CALML6	-0.35	-7.51	-0.34	3.65e-13	Body mass index;
LUAD	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg07061783	chr6:25882402	NA	0.51	8.02	0.36	1.04e-14	Blood metabolite levels;
LUAD	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg04369109	chr6:150039330	LATS1	-0.44	-7.26	-0.33	1.88e-12	Lung cancer;
LUAD	cis	rs1030877	0.889	rs2576746	chr2:105909559	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.6	11.91	0.5	2.08e-28	Obesity-related traits;
LUAD	cis	rs17641971	0.684	rs7005693	chr8:49987965	A/C	cg00325661	chr8:49890786	NA	0.3	6.8	0.31	3.68e-11	Blood metabolite levels;
LUAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg11062466	chr8:58055876	NA	0.66	8.66	0.39	1.01e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg18196295	chr10:418757	DIP2C	0.47	7.8	0.35	4.84e-14	Psychosis in Alzheimer's disease;
LUAD	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg03676636	chr4:99064102	C4orf37	0.31	7.38	0.34	8.41e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs7587476	0.601	rs17489231	chr2:215673739	T/G	cg04004882	chr2:215674386	BARD1	-0.55	-7.38	-0.34	8.67e-13	Neuroblastoma;
LUAD	trans	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04565464	chr8:145669602	NFKBIL2	0.45	6.72	0.31	6.06e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12977448	chr10:14920832	SUV39H2	0.4	6.4	0.3	4.16e-10	Gut microbiome composition (summer);
LUAD	cis	rs2742234	0.541	rs11238476	chr10:43711436	G/T	cg15436174	chr10:43711423	RASGEF1A	0.55	9.07	0.4	4.43e-18	Hirschsprung disease;
LUAD	cis	rs8050755	0.649	rs2516737	chr16:2101749	A/G	cg04515572	chr16:2107413	TSC2	0.71	7.75	0.35	6.86e-14	Major depressive disorder;
LUAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg10729496	chr3:10149963	C3orf24	0.58	9.41	0.42	3.26e-19	Alzheimer's disease;
LUAD	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg09796270	chr17:17721594	SREBF1	-0.38	-7.27	-0.33	1.71e-12	Total body bone mineral density;
LUAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-7.15	-0.33	3.91e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4774899	0.752	rs2951895	chr15:57357266	C/T	cg14026238	chr15:57616123	NA	0.44	8.37	0.38	8.72e-16	Urinary tract infection frequency;
LUAD	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg22117172	chr7:91764530	CYP51A1	0.33	7.29	0.33	1.57e-12	Breast cancer;
LUAD	cis	rs12145833	0.538	rs10926977	chr1:243411367	T/G	cg02356786	chr1:243265016	LOC731275	0.67	7.22	0.33	2.5e-12	Obesity (early onset extreme);
LUAD	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg09065629	chr16:1709722	CRAMP1L	0.42	7.22	0.33	2.4e-12	Coronary artery disease;
LUAD	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg13319975	chr6:146136371	FBXO30	-0.58	-9.71	-0.43	3.02e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg23758822	chr17:41437982	NA	0.99	20.7	0.71	2.9e-66	Menopause (age at onset);
LUAD	cis	rs9807989	0.507	rs6726985	chr2:103048580	G/A	cg03938978	chr2:103052716	IL18RAP	0.46	10.49	0.45	4.89e-23	Asthma;
LUAD	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg26384229	chr12:38710491	ALG10B	-0.38	-6.37	-0.3	4.81e-10	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg18202627	chr2:200776533	C2orf69	0.41	6.45	0.3	3.09e-10	Bilirubin levels;
LUAD	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00475322	chr7:917719	C7orf20	-0.57	-10.48	-0.45	5.19e-23	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg27170947	chr2:26402098	FAM59B	-0.64	-8.81	-0.39	3.21e-17	Gut microbiome composition (summer);
LUAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.58e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1448094	0.842	rs7966352	chr12:86438705	A/C	cg18827107	chr12:86230957	RASSF9	-0.45	-8.18	-0.37	3.24e-15	Major depressive disorder;
LUAD	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg17757837	chr7:157058334	UBE3C	0.46	8.16	0.37	3.91e-15	Body mass index;
LUAD	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg18621852	chr3:10150065	C3orf24	0.42	7.36	0.34	9.46e-13	Alzheimer's disease;
LUAD	cis	rs11811982	0.793	rs75284290	chr1:227450092	C/T	cg24860534	chr1:227506868	CDC42BPA	0.7	7.34	0.34	1.13e-12	Optic disc area;
LUAD	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg01324343	chr3:183735012	ABCC5	0.95	25.87	0.78	3.75e-89	Anterior chamber depth;
LUAD	cis	rs6060717	0.536	rs11696912	chr20:34497660	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.62	7.24	0.33	2.07e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg27411982	chr8:10470053	RP1L1	0.43	8.23	0.37	2.31e-15	Neuroticism;
LUAD	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.58	-11.18	-0.48	1.28e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs11165623	0.585	rs55896436	chr1:96994162	G/A	cg10631902	chr5:14652156	NA	-0.42	-7.65	-0.35	1.37e-13	Hip circumference;Waist circumference;
LUAD	cis	rs332507	0.830	rs12639478	chr3:124404958	T/A	cg05980111	chr3:124395277	KALRN	0.44	6.97	0.32	1.24e-11	Plateletcrit;
LUAD	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg09365446	chr1:150670422	GOLPH3L	0.59	10.32	0.45	2e-22	Melanoma;
LUAD	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.32	0.38	1.19e-15	Rheumatoid arthritis;
LUAD	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg23985595	chr17:80112537	CCDC57	-0.53	-9.73	-0.43	2.54e-20	Life satisfaction;
LUAD	cis	rs113835537	0.529	rs4542420	chr11:66277610	G/C	cg24851651	chr11:66362959	CCS	0.57	10.14	0.44	9.19e-22	Airway imaging phenotypes;
LUAD	cis	rs6494488	0.500	rs72744739	chr15:65049926	T/C	cg08069370	chr15:64387884	SNX1	-0.72	-6.64	-0.31	9.61e-11	Coronary artery disease;
LUAD	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg06781209	chr11:61594997	FADS2	-0.4	-7.32	-0.34	1.26e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg05655935	chr10:93683722	BTAF1	-0.39	-6.42	-0.3	3.61e-10	Schizophrenia;
LUAD	cis	rs8013055	0.846	rs11624007	chr14:105992183	A/C	cg19700328	chr14:106028568	NA	-0.41	-7.05	-0.32	7.54e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs72634258	0.554	rs35307738	chr1:7919839	C/G	cg26816564	chr1:7831052	VAMP3	0.59	8.09	0.37	6.29e-15	Inflammatory bowel disease;
LUAD	cis	rs754466	0.580	rs12357670	chr10:79558180	T/C	cg17075019	chr10:79541650	NA	-0.92	-19.67	-0.69	1.27e-61	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg16414030	chr3:133502952	NA	-0.66	-12.79	-0.53	6.82e-32	Iron status biomarkers;
LUAD	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg00383909	chr3:49044727	WDR6	0.65	7.12	0.33	4.52e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg08085267	chr17:45401833	C17orf57	0.58	9.79	0.43	1.55e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1044826	0.642	rs4683464	chr3:139196961	C/T	cg00490450	chr3:139108681	COPB2	0.41	6.58	0.3	1.38e-10	Obesity-related traits;
LUAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.07e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7187994	0.895	rs12598223	chr16:84783873	A/G	cg07647771	chr16:84786436	USP10	-0.34	-8.82	-0.39	3.05e-17	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg21427119	chr20:30132790	HM13	0.47	7.62	0.35	1.66e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg06263672	chr7:65235340	NA	0.57	9.32	0.41	6.4e-19	Calcium levels;
LUAD	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg10802521	chr3:52805072	NEK4	-0.47	-7.81	-0.35	4.63e-14	Electroencephalogram traits;
LUAD	cis	rs4730250	0.654	rs12705405	chr7:106792517	C/T	cg23024343	chr7:107201750	COG5	-0.5	-6.87	-0.32	2.3e-11	Osteoarthritis;
LUAD	cis	rs7903847	0.642	rs3814553	chr10:99155984	G/A	cg20016023	chr10:99160130	RRP12	-0.31	-7.42	-0.34	6.64e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.702	rs56217716	chr4:119338490	T/G	cg21605333	chr4:119757512	SEC24D	0.69	6.75	0.31	4.82e-11	Cannabis dependence symptom count;
LUAD	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21659725	chr3:3221576	CRBN	0.51	8.43	0.38	5.58e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs758324	0.891	rs491624	chr5:131270222	A/T	cg06307176	chr5:131281290	NA	-0.52	-8.23	-0.37	2.27e-15	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.27	6.4	0.3	4.03e-10	Depression;
LUAD	cis	rs9283706	0.623	rs3857275	chr5:66315536	T/C	cg11590213	chr5:66331682	MAST4	0.36	6.39	0.3	4.48e-10	Coronary artery disease;
LUAD	trans	rs12200782	0.790	rs72836480	chr6:26358596	C/A	cg08851530	chr6:28072375	NA	0.81	6.56	0.3	1.59e-10	Small cell lung carcinoma;
LUAD	cis	rs56283067	0.847	rs62435999	chr6:44695273	T/G	cg18551225	chr6:44695536	NA	-0.6	-9.98	-0.44	3.3e-21	Total body bone mineral density;
LUAD	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg01299579	chr2:10830716	NOL10	0.38	6.67	0.31	7.87e-11	Prostate cancer;
LUAD	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg00933542	chr6:150070202	PCMT1	0.44	9.05	0.4	5.25e-18	Lung cancer;
LUAD	cis	rs34390795	1	rs34390795	chr12:133112394	CGT/C	cg06183872	chr12:133049993	NA	0.53	8.47	0.38	4.05e-16	Red blood cell count;
LUAD	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg17063962	chr7:91808500	NA	0.64	10.81	0.47	3.28e-24	Breast cancer;
LUAD	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-8.56	-0.38	2.14e-16	Gut microbiome composition (summer);
LUAD	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg25358565	chr5:93447407	FAM172A	0.64	7.84	0.36	3.65e-14	Diabetic retinopathy;
LUAD	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.25	0.33	1.98e-12	Parkinson's disease;
LUAD	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg22705602	chr4:152727874	NA	0.48	9.34	0.41	5.76e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.24	-0.48	7.95e-26	Type 2 diabetes;
LUAD	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.14	0.33	4.16e-12	Parkinson's disease;
LUAD	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg12311346	chr5:56204834	C5orf35	0.74	11.88	0.5	2.86e-28	Initial pursuit acceleration;
LUAD	cis	rs17095355	0.748	rs2501577	chr10:111846687	C/T	cg00817464	chr10:111662876	XPNPEP1	0.61	8.72	0.39	6.64e-17	Biliary atresia;
LUAD	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08439880	chr3:133502540	NA	-0.45	-8.98	-0.4	9e-18	Iron status biomarkers;
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg18110333	chr6:292329	DUSP22	-0.75	-12.79	-0.53	7.03e-32	Menopause (age at onset);
LUAD	cis	rs7561273	0.586	rs13418279	chr2:24349218	G/T	cg20701182	chr2:24300061	SF3B14	0.47	7.63	0.35	1.6e-13	Quantitative traits;
LUAD	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg18944383	chr4:111397179	ENPEP	0.41	8.19	0.37	3.15e-15	Height;
LUAD	cis	rs7809950	0.817	rs2222845	chr7:107281829	C/T	cg23024343	chr7:107201750	COG5	0.81	12.99	0.53	1.05e-32	Coronary artery disease;
LUAD	trans	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.86	-0.36	3.21e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg22823121	chr1:150693482	HORMAD1	0.44	8.91	0.4	1.55e-17	Tonsillectomy;
LUAD	cis	rs2050392	1.000	rs2253585	chr10:30696503	C/T	cg18806716	chr10:30721971	MAP3K8	-0.51	-10.2	-0.44	5.41e-22	Inflammatory bowel disease;
LUAD	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg04025307	chr7:1156635	C7orf50	0.52	8.75	0.39	4.99e-17	Longevity;Endometriosis;
LUAD	cis	rs7503807	0.967	rs12949279	chr17:78558411	T/C	cg09596252	chr17:78655493	RPTOR	0.37	6.94	0.32	1.45e-11	Obesity;
LUAD	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg00316803	chr15:76480434	C15orf27	-0.36	-6.57	-0.3	1.49e-10	Blood metabolite levels;
LUAD	cis	rs758324	0.891	rs635164	chr5:131312874	C/T	cg06307176	chr5:131281290	NA	-0.51	-7.74	-0.35	7.3e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg25809561	chr17:30822961	MYO1D	-0.48	-8.86	-0.4	2.23e-17	Schizophrenia;
LUAD	cis	rs3823572	0.526	rs2971966	chr7:133642559	A/G	cg03336402	chr7:133662267	EXOC4	-0.42	-7.66	-0.35	1.27e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg03433033	chr1:76189801	ACADM	0.86	17.43	0.65	1.19e-51	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg02869364	chr7:1081709	C7orf50	-0.47	-6.47	-0.3	2.69e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg18827107	chr12:86230957	RASSF9	0.54	9.63	0.42	5.64e-20	Major depressive disorder;
LUAD	cis	rs1371614	0.632	rs3820823	chr2:27164806	C/T	cg00617064	chr2:27272375	NA	-0.34	-6.6	-0.31	1.2e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.8	0.35	4.77e-14	Breast cancer;
LUAD	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg20607798	chr8:58055168	NA	0.82	9.86	0.43	9.07e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs62064224	0.614	rs2286645	chr17:30696292	C/T	cg18200150	chr17:30822561	MYO1D	0.41	7.57	0.35	2.31e-13	Schizophrenia;
LUAD	cis	rs2908296	0.515	rs12673242	chr7:44207494	T/C	cg03639919	chr7:44191311	GCK	0.42	6.39	0.3	4.42e-10	Body mass index;
LUAD	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg08989290	chr16:615782	NHLRC4	0.33	7.06	0.32	6.71e-12	Height;
LUAD	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg13180566	chr4:1052158	NA	-0.39	-6.63	-0.31	1.02e-10	Recombination rate (females);
LUAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg27454412	chr7:1067447	C7orf50	0.44	7.02	0.32	8.71e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4728302	0.583	rs58955798	chr7:133158420	C/T	cg10665199	chr7:133106180	EXOC4	0.67	11.75	0.5	8.81e-28	Intelligence;Intelligence (multi-trait analysis);
LUAD	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg18721089	chr20:30220636	NA	-0.49	-7.06	-0.32	6.99e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs2425143	0.512	rs2425126	chr20:34331730	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.03	-0.36	9.75e-15	Blood protein levels;
LUAD	cis	rs6519955	0.897	rs4073601	chr22:46434686	A/G	cg11242978	chr22:46423387	NA	0.36	6.66	0.31	8.31e-11	Dupuytren's disease;
LUAD	trans	rs17685	0.753	rs869804	chr7:75688954	A/G	cg19862616	chr7:65841803	NCRNA00174	1.07	27.64	0.8	8.2e-97	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs17685	0.535	rs6953065	chr7:75601169	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.66	-11.79	-0.5	6.3e-28	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg16405210	chr4:1374714	KIAA1530	-0.63	-9.72	-0.43	2.64e-20	Longevity;
LUAD	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg26677194	chr12:130822605	PIWIL1	0.53	8.82	0.39	3.08e-17	Menopause (age at onset);
LUAD	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg16102102	chr5:83017553	HAPLN1	-0.76	-13.25	-0.54	9.41e-34	Prostate cancer;
LUAD	trans	rs9929218	0.954	rs2059254	chr16:68817439	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-13.0	-0.53	9.47e-33	Colorectal cancer;
LUAD	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg20673091	chr1:2541236	MMEL1	-0.39	-8.41	-0.38	6.33e-16	Ulcerative colitis;
LUAD	cis	rs9535307	0.799	rs2146143	chr13:50245620	A/C	cg04663916	chr13:50265991	EBPL	0.54	6.7	0.31	6.77e-11	Obesity-related traits;
LUAD	cis	rs11098699	0.821	rs2047584	chr4:124232182	A/T	cg09941581	chr4:124220074	SPATA5	0.45	7.31	0.33	1.33e-12	Mosquito bite size;
LUAD	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg04727924	chr7:799746	HEATR2	0.55	7.34	0.34	1.13e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg07636037	chr3:49044803	WDR6	-0.5	-8.28	-0.37	1.62e-15	Menarche (age at onset);
LUAD	cis	rs7659604	0.502	rs4315813	chr4:122674866	G/A	cg06713675	chr4:122721982	EXOSC9	0.42	7.69	0.35	1.03e-13	Type 2 diabetes;
LUAD	cis	rs4144027	0.935	rs10139856	chr14:104354505	T/C	cg12183467	chr14:104352244	NA	-0.36	-6.73	-0.31	5.65e-11	Blood metabolite levels;
LUAD	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg12140854	chr5:148520817	ABLIM3	0.64	9.61	0.42	6.37e-20	Breast cancer;
LUAD	cis	rs4853525	0.859	rs1882397	chr2:191720132	A/C	cg27211696	chr2:191398769	TMEM194B	-0.37	-6.61	-0.31	1.13e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs4242434	1.000	rs4242434	chr8:22501830	C/A	cg03733263	chr8:22462867	KIAA1967	0.69	11.12	0.48	2.35e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg02002194	chr4:3960332	NA	0.27	6.37	0.3	4.89e-10	Myopia (pathological);
LUAD	trans	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg26043149	chr18:55253948	FECH	1.05	17.81	0.65	2.29e-53	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs1395	0.744	rs11679220	chr2:27476378	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.47	7.97	0.36	1.48e-14	Blood metabolite levels;
LUAD	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	9.4e-15	Tonsillectomy;
LUAD	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg25985355	chr7:65971099	NA	-0.51	-6.36	-0.3	5.25e-10	Diabetic kidney disease;
LUAD	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg03563238	chr19:33554763	RHPN2	-0.34	-8.26	-0.37	1.91e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7771547	0.632	rs79102826	chr6:36555814	C/T	cg07856975	chr6:36356162	ETV7	0.45	6.39	0.3	4.41e-10	Platelet distribution width;
LUAD	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg09658497	chr7:2847517	GNA12	-0.54	-9.18	-0.41	1.91e-18	Height;
LUAD	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg11062466	chr8:58055876	NA	0.67	8.65	0.39	1.08e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.51e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs68170813	0.652	rs6957186	chr7:107200592	T/C	cg02696742	chr7:106810147	HBP1	-0.76	-8.96	-0.4	1.05e-17	Coronary artery disease;
LUAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.38	-6.99	-0.32	1.09e-11	Longevity;Endometriosis;
LUAD	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg00280220	chr17:61926910	NA	0.38	7.41	0.34	6.99e-13	Prudent dietary pattern;
LUAD	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg23933602	chr10:16859644	RSU1	0.65	10.08	0.44	1.46e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs62400317	0.859	rs4267941	chr6:45241302	A/C	cg18551225	chr6:44695536	NA	-0.56	-8.7	-0.39	7.44e-17	Total body bone mineral density;
LUAD	cis	rs11696501	0.688	rs6073848	chr20:44298550	G/A	cg11783356	chr20:44313418	WFDC10B	-0.48	-7.94	-0.36	1.9e-14	Brain structure;
LUAD	trans	rs1973993	0.967	rs6679458	chr1:96946253	G/T	cg10631902	chr5:14652156	NA	0.51	9.67	0.43	4.06e-20	Weight;
LUAD	cis	rs922692	0.744	rs11072806	chr15:79079074	G/A	cg12645284	chr15:79092878	ADAMTS7	0.43	7.31	0.33	1.36e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg13390004	chr1:15929781	NA	0.49	8.61	0.39	1.49e-16	Systolic blood pressure;
LUAD	cis	rs2282300	0.739	rs1222221	chr11:30342738	A/G	cg06241208	chr11:30344200	C11orf46	-0.54	-7.05	-0.32	7.4e-12	Morning vs. evening chronotype;
LUAD	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg02782426	chr3:40428986	ENTPD3	-0.38	-8.43	-0.38	5.41e-16	Renal cell carcinoma;
LUAD	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg06484146	chr7:12443880	VWDE	-0.51	-6.53	-0.3	1.83e-10	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.47	7.95	0.36	1.67e-14	Lung cancer in ever smokers;
LUAD	trans	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg14343924	chr8:8086146	FLJ10661	0.45	6.72	0.31	6.07e-11	Neuroticism;
LUAD	cis	rs72960926	0.590	rs72955114	chr6:74753250	C/T	cg03266952	chr6:74778945	NA	-0.83	-7.24	-0.33	2.08e-12	Metabolite levels (MHPG);
LUAD	cis	rs4851254	0.660	rs1821830	chr2:100680279	C/T	cg04109781	chr2:100722022	AFF3	0.36	6.4	0.3	4.01e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs11771526	0.901	rs10252303	chr7:32304438	C/T	cg27532318	chr7:32358331	NA	0.57	7.32	0.34	1.22e-12	Body mass index;
LUAD	cis	rs999737	0.922	rs17756000	chr14:69019538	C/T	cg04147497	chr14:69052728	RAD51L1	-0.43	-6.43	-0.3	3.49e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg01299579	chr2:10830716	NOL10	-0.43	-7.51	-0.34	3.49e-13	Prostate cancer;
LUAD	trans	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.47	-0.34	4.49e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	cis	rs7630877	0.886	rs59018122	chr3:179602512	C/A	cg18765712	chr3:179670323	PEX5L	0.37	6.4	0.3	4.25e-10	Type 2 diabetes;
LUAD	trans	rs853679	0.607	rs61742093	chr6:27879982	A/G	cg06606381	chr12:133084897	FBRSL1	-1.24	-10.91	-0.47	1.36e-24	Depression;
LUAD	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs72960926	0.590	rs11754945	chr6:74732673	A/C	cg03266952	chr6:74778945	NA	0.78	7.36	0.34	9.98e-13	Metabolite levels (MHPG);
LUAD	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg21545522	chr1:205238299	TMCC2	0.38	7.02	0.32	9.15e-12	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg07776626	chr8:57350775	NA	-0.6	-8.85	-0.4	2.45e-17	Obesity-related traits;
LUAD	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.6	0.35	1.95e-13	Tonsillectomy;
LUAD	cis	rs4774899	0.932	rs1037958	chr15:57523542	A/G	cg14026238	chr15:57616123	NA	0.35	6.65	0.31	9.24e-11	Urinary tract infection frequency;
LUAD	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.02	-0.32	8.82e-12	Type 2 diabetes;
LUAD	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg24531977	chr5:56204891	C5orf35	0.76	12.59	0.52	4.21e-31	Initial pursuit acceleration;
LUAD	cis	rs2086824	0.538	rs4785673	chr16:89536545	A/G	cg00750074	chr16:89608354	SPG7	-0.5	-8.44	-0.38	5.05e-16	Multiple myeloma (IgH translocation);
LUAD	cis	rs9658691	0.607	rs9658788	chr10:90776486	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.58	-7.22	-0.33	2.46e-12	Mosquito bite size;
LUAD	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg03233332	chr7:66118400	NA	0.44	6.73	0.31	5.44e-11	Aortic root size;
LUAD	cis	rs12765878	1.000	rs4918067	chr10:105644636	A/C	cg11005552	chr10:105648138	OBFC1	0.44	8.26	0.37	1.91e-15	Coronary artery disease;
LUAD	cis	rs6732160	0.967	rs6760964	chr2:73387386	C/G	cg01422370	chr2:73384389	NA	0.32	6.55	0.3	1.67e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.32	0.34	1.24e-12	Blood metabolite levels;
LUAD	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg05616858	chr17:37843591	ERBB2;PGAP3	0.34	6.77	0.31	4.29e-11	Asthma;
LUAD	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg13535736	chr9:111863775	C9orf5	-0.42	-6.45	-0.3	3.09e-10	Menarche (age at onset);
LUAD	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg08999081	chr20:33150536	PIGU	0.55	11.69	0.49	1.57e-27	Coronary artery disease;
LUAD	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.46	-0.34	4.98e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24503407	chr1:205819492	PM20D1	0.91	20.88	0.71	4.51e-67	Menarche (age at onset);
LUAD	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg01579765	chr21:45077557	HSF2BP	-0.61	-14.73	-0.58	5.94e-40	Mean corpuscular volume;
LUAD	cis	rs2066819	1.000	rs2306693	chr12:56680531	T/C	cg26714650	chr12:56694279	CS	-0.86	-7.23	-0.33	2.25e-12	Psoriasis vulgaris;
LUAD	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg14784868	chr12:69753453	YEATS4	0.47	7.75	0.35	6.81e-14	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs9837602	1.000	rs1688771	chr3:99503359	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.51	7.53	0.34	3.07e-13	Breast cancer;
LUAD	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.92	-19.07	-0.68	5.91e-59	Ulcerative colitis;
LUAD	cis	rs2412208	1.000	rs2412208	chr1:7092782	T/G	cg20434152	chr1:7120926	CAMTA1	-0.3	-6.53	-0.3	1.85e-10	Survival in sporadic amyotrophic lateral sclerosis;
LUAD	cis	rs2797160	0.967	rs1777182	chr6:126013614	T/A	cg05901451	chr6:126070800	HEY2	0.47	7.15	0.33	3.77e-12	Endometrial cancer;
LUAD	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg04775059	chr7:64541387	NA	-0.53	-6.81	-0.31	3.34e-11	Aortic root size;
LUAD	trans	rs2797160	0.967	rs1777182	chr6:126013614	T/A	cg05039488	chr6:79577232	IRAK1BP1	0.54	8.7	0.39	7.72e-17	Endometrial cancer;
LUAD	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg15819921	chr19:927150	ARID3A	0.49	8.02	0.36	1.03e-14	Life satisfaction;
LUAD	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.38	6.49	0.3	2.37e-10	Rheumatoid arthritis;
LUAD	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg22166914	chr1:53195759	ZYG11B	0.39	6.39	0.3	4.49e-10	Monocyte count;
LUAD	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg04450456	chr4:17643702	FAM184B	0.37	7.1	0.33	5.35e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-8.19	-0.37	3.19e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs3096299	0.934	rs9927904	chr16:89462847	G/A	cg06640241	chr16:89574553	SPG7	0.48	7.72	0.35	8.64e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.3	-6.61	-0.31	1.17e-10	Blood metabolite levels;
LUAD	cis	rs7107174	1.000	rs2512535	chr11:77971468	C/T	cg02023728	chr11:77925099	USP35	0.42	7.06	0.32	6.87e-12	Testicular germ cell tumor;
LUAD	cis	rs35146811	0.844	rs2070215	chr7:99696797	T/C	cg13334819	chr7:99746414	C7orf59	-0.66	-9.44	-0.42	2.6e-19	Coronary artery disease;
LUAD	cis	rs1371614	0.611	rs3843322	chr2:27131849	G/T	cg00617064	chr2:27272375	NA	-0.34	-6.65	-0.31	9.34e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg14186256	chr22:23484241	RTDR1	0.46	7.87	0.36	2.99e-14	Bone mineral density;
LUAD	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg19302996	chr17:73780495	UNK	-0.43	-6.53	-0.3	1.89e-10	Psoriasis;
LUAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10871290	0.650	rs2288054	chr16:74491733	A/G	cg01733217	chr16:74700730	RFWD3	0.46	7.1	0.33	5.48e-12	Breast cancer;
LUAD	cis	rs11264213	0.591	rs3754076	chr1:36549157	A/G	cg27506609	chr1:36549197	TEKT2	-0.62	-7.35	-0.34	1.03e-12	Schizophrenia;
LUAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg11062466	chr8:58055876	NA	0.77	13.75	0.56	8.27e-36	Developmental language disorder (linguistic errors);
LUAD	cis	rs3820068	0.705	rs2145396	chr1:15875184	A/G	cg13390004	chr1:15929781	NA	0.43	6.8	0.31	3.67e-11	Systolic blood pressure;
LUAD	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.73	-12.99	-0.53	1.04e-32	Axial length;
LUAD	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	7.17	0.33	3.32e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.559	rs75932578	chr7:106844694	C/T	cg02696742	chr7:106810147	HBP1	-0.83	-10.8	-0.46	3.65e-24	Coronary artery disease;
LUAD	cis	rs10911363	0.592	rs2761581	chr1:183474850	G/C	cg09173681	chr1:183549694	NCF2	0.56	10.21	0.44	4.88e-22	Systemic lupus erythematosus;
LUAD	cis	rs7937890	0.681	rs4756784	chr11:14270904	G/A	cg22961513	chr11:14280813	SPON1	0.35	6.82	0.31	3.14e-11	Mitochondrial DNA levels;
LUAD	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.41	7.12	0.33	4.79e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg13732083	chr21:47605072	C21orf56	0.44	7.25	0.33	2.02e-12	Testicular germ cell tumor;
LUAD	cis	rs76878669	0.561	rs4930179	chr11:66157432	C/T	cg18002602	chr11:66138449	SLC29A2	0.48	10.4	0.45	1.04e-22	Educational attainment (years of education);
LUAD	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg17105886	chr17:28927953	LRRC37B2	0.76	7.66	0.35	1.27e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg25769590	chr7:158789503	NA	-0.37	-6.66	-0.31	8.75e-11	Facial morphology (factor 20);
LUAD	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg07741184	chr6:167504864	NA	-0.3	-7.12	-0.33	4.53e-12	Crohn's disease;
LUAD	cis	rs7044106	0.887	rs1359328	chr9:123370822	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	7.71	0.35	8.79e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.58	-7.87	-0.36	2.99e-14	Body mass index;
LUAD	cis	rs17021463	0.902	rs11097413	chr4:95249286	C/T	cg11021082	chr4:95130006	SMARCAD1	0.45	8.38	0.38	7.79e-16	Testicular germ cell tumor;
LUAD	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg05590025	chr7:65112418	INTS4L2	0.74	7.87	0.36	3.03e-14	Diabetic kidney disease;
LUAD	trans	rs853679	0.546	rs35016036	chr6:28314880	C/T	cg06606381	chr12:133084897	FBRSL1	-1.24	-10.97	-0.47	8.15e-25	Depression;
LUAD	cis	rs9341808	0.586	rs3805869	chr6:81045917	T/C	cg08355045	chr6:80787529	NA	0.46	7.88	0.36	2.79e-14	Sitting height ratio;
LUAD	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg05434287	chr7:2030229	MAD1L1	0.41	6.69	0.31	7.09e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg18305652	chr10:134549665	INPP5A	0.58	11.81	0.5	5.16e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9325144	0.872	rs11183390	chr12:38729942	G/T	cg10518543	chr12:38710700	ALG10B	-0.44	-6.86	-0.32	2.5e-11	Morning vs. evening chronotype;
LUAD	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg23260525	chr10:116636907	FAM160B1	-0.46	-10.39	-0.45	1.14e-22	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21659725	chr3:3221576	CRBN	-0.5	-8.3	-0.37	1.38e-15	Body mass index;
LUAD	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg27490568	chr2:178487706	NA	0.39	6.37	0.3	4.89e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs807669	0.903	rs1771540	chr22:19173933	T/A	cg02655711	chr22:19163373	SLC25A1	0.87	19.19	0.68	1.73e-59	Metabolite levels;
LUAD	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg08470875	chr2:26401718	FAM59B	-0.6	-8.15	-0.37	4.07e-15	Gut microbiome composition (summer);
LUAD	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05665937	chr4:1216051	CTBP1	0.48	7.5	0.34	3.75e-13	Longevity;
LUAD	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.73	0.35	7.65e-14	Breast cancer;
LUAD	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg03433033	chr1:76189801	ACADM	0.73	10.92	0.47	1.23e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs250585	0.915	rs2369011	chr16:23529806	C/T	cg00143387	chr16:23521605	GGA2	-0.63	-7.49	-0.34	4.01e-13	Egg allergy;
LUAD	cis	rs10979	1.000	rs12738	chr6:143890049	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.3	-0.45	2.33e-22	Hypospadias;
LUAD	cis	rs7771547	0.603	rs9296193	chr6:36601456	C/G	cg04289385	chr6:36355825	ETV7	-0.48	-6.57	-0.3	1.46e-10	Platelet distribution width;
LUAD	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg18512352	chr11:47633146	NA	0.4	7.14	0.33	4.21e-12	Subjective well-being;
LUAD	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.54	-6.91	-0.32	1.78e-11	Body mass index;
LUAD	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg26898376	chr11:64110657	CCDC88B	0.38	7.16	0.33	3.59e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg19743168	chr1:23544995	NA	0.44	8.1	0.37	6.09e-15	Height;
LUAD	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg04842962	chr6:43655489	MRPS18A	1.07	27.23	0.8	4.82e-95	IgG glycosylation;
LUAD	cis	rs595982	0.546	rs10401443	chr19:49402059	C/A	cg21252483	chr19:49399788	TULP2	-0.49	-9.2	-0.41	1.63e-18	Red cell distribution width;
LUAD	cis	rs3806843	0.576	rs246041	chr5:140331128	C/G	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.61e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg21724239	chr8:58056113	NA	0.74	9.62	0.42	5.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg06740227	chr12:86229804	RASSF9	0.38	6.74	0.31	5.19e-11	Major depressive disorder;
LUAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg13271783	chr10:134563150	INPP5A	-0.43	-6.9	-0.32	1.93e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg10591111	chr5:226296	SDHA	0.54	6.87	0.32	2.35e-11	Breast cancer;
LUAD	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg11707310	chr1:2537719	MMEL1	0.38	7.93	0.36	1.99e-14	Ulcerative colitis;
LUAD	cis	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg06360820	chr2:242988706	NA	-0.9	-11.91	-0.5	2.06e-28	Obesity-related traits;
LUAD	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg11887960	chr12:57824829	NA	0.53	6.59	0.31	1.32e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.49	7.89	0.36	2.58e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6494488	0.500	rs72744738	chr15:65048334	C/G	cg08069370	chr15:64387884	SNX1	-0.74	-6.64	-0.31	9.68e-11	Coronary artery disease;
LUAD	cis	rs6743376	0.556	rs1800930	chr2:113820530	A/G	cg09040174	chr2:113837401	NA	0.46	7.17	0.33	3.41e-12	Inflammatory biomarkers;
LUAD	cis	rs11958404	0.932	rs72816587	chr5:157434144	T/A	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs10979	1.000	rs1054752	chr6:143890097	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.3	-0.45	2.33e-22	Hypospadias;
LUAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00149659	chr3:10157352	C3orf10	0.88	11.48	0.49	9.52e-27	Alzheimer's disease;
LUAD	cis	rs12618769	0.597	rs3769737	chr2:99088873	C/G	cg10123293	chr2:99228465	UNC50	-0.45	-8.06	-0.36	8.13e-15	Bipolar disorder;
LUAD	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg19622623	chr12:86230825	RASSF9	0.55	10.04	0.44	2.11e-21	Major depressive disorder;
LUAD	cis	rs4285028	0.747	rs11928871	chr3:121483388	G/C	cg11130432	chr3:121712080	ILDR1	-0.57	-8.0	-0.36	1.2e-14	Multiple sclerosis;
LUAD	cis	rs34311866	0.577	rs11736181	chr4:877412	C/T	cg23992470	chr4:843637	GAK	0.51	6.37	0.3	4.95e-10	Parkinson's disease;
LUAD	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg25025879	chr12:53359317	NA	-0.75	-13.47	-0.55	1.11e-34	Cancer (pleiotropy);
LUAD	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg12119029	chr16:89752879	CDK10	-0.34	-7.43	-0.34	6.26e-13	Hemoglobin concentration;
LUAD	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg26816564	chr1:7831052	VAMP3	0.69	9.53	0.42	1.21e-19	Inflammatory bowel disease;
LUAD	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg12403142	chr1:92012408	NA	0.37	6.81	0.31	3.33e-11	Breast cancer;
LUAD	cis	rs300703	0.719	rs385909	chr2:199678	A/G	cg21211680	chr2:198530	NA	0.59	7.9	0.36	2.36e-14	Blood protein levels;
LUAD	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg01689657	chr7:91764605	CYP51A1	0.37	8.87	0.4	2.05e-17	Breast cancer;
LUAD	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg10518543	chr12:38710700	ALG10B	0.41	6.4	0.3	4.2e-10	Bladder cancer;
LUAD	cis	rs1595825	0.786	rs74484541	chr2:198894223	T/C	cg11031976	chr2:198649780	BOLL	-0.45	-6.53	-0.3	1.84e-10	Ulcerative colitis;
LUAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg00280220	chr17:61926910	NA	0.37	6.97	0.32	1.19e-11	Prudent dietary pattern;
LUAD	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg06740227	chr12:86229804	RASSF9	0.48	8.41	0.38	6.35e-16	Major depressive disorder;
LUAD	trans	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg00953403	chr17:74099816	EXOC7	-0.5	-7.6	-0.35	1.95e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg14752069	chr8:11977206	FAM66D	-0.29	-6.47	-0.3	2.74e-10	Triglycerides;
LUAD	cis	rs151234	0.565	rs9924471	chr16:28591530	G/A	cg04609801	chr16:28609176	SULT1A2	0.48	7.84	0.36	3.64e-14	Platelet distribution width;
LUAD	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg13607699	chr17:42295918	UBTF	0.52	8.34	0.38	1.04e-15	Red cell distribution width;Reticulocyte count;
LUAD	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg19163074	chr7:65112434	INTS4L2	0.43	6.42	0.3	3.65e-10	Aortic root size;
LUAD	trans	rs3858145	0.588	rs61854833	chr10:70037327	C/G	cg04882175	chr6:131122610	NA	-0.59	-7.13	-0.33	4.24e-12	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUAD	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg04800585	chr6:26043546	HIST1H2BB	0.37	6.84	0.32	2.77e-11	Blood metabolite levels;
LUAD	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg07741184	chr6:167504864	NA	0.4	9.05	0.4	5.36e-18	Crohn's disease;
LUAD	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg17031739	chr1:67600172	NA	0.5	8.88	0.4	1.95e-17	Psoriasis;
LUAD	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg03474202	chr17:45855739	NA	-0.38	-8.86	-0.4	2.28e-17	IgG glycosylation;
LUAD	cis	rs73206853	0.841	rs9783428	chr12:111068096	C/T	cg12870014	chr12:110450643	ANKRD13A	0.6	6.7	0.31	6.84e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs4680	1.000	rs4680	chr22:19951271	C/T	cg01335087	chr22:19950166	COMT	0.24	6.67	0.31	7.79e-11	Blood metabolite levels;
LUAD	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg26513180	chr16:89883248	FANCA	0.79	7.26	0.33	1.82e-12	Skin colour saturation;
LUAD	trans	rs11638815	0.581	rs783537	chr15:83252807	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.48	-7.28	-0.33	1.68e-12	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	trans	rs2797160	1.000	rs1418948	chr6:126007018	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.55	8.65	0.39	1.08e-16	Endometrial cancer;
LUAD	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23158103	chr7:148848205	ZNF398	-0.64	-12.29	-0.51	6.87e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg13698153	chr12:118541722	VSIG10	-0.43	-6.53	-0.3	1.89e-10	Vitiligo;
LUAD	cis	rs2050392	0.799	rs303429	chr10:30708441	C/T	cg18806716	chr10:30721971	MAP3K8	-0.53	-10.47	-0.45	5.81e-23	Inflammatory bowel disease;
LUAD	cis	rs12478296	1.000	rs12474070	chr2:243039738	C/T	cg06360820	chr2:242988706	NA	-0.84	-9.69	-0.43	3.39e-20	Obesity-related traits;
LUAD	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg09796270	chr17:17721594	SREBF1	-0.4	-7.88	-0.36	2.8e-14	Total body bone mineral density;
LUAD	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.79	-0.35	5.18e-14	Blood metabolite levels;
LUAD	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg07423050	chr13:99094983	FARP1	-0.55	-9.43	-0.42	2.68e-19	Neuroticism;
LUAD	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg02176678	chr2:219576539	TTLL4	0.74	14.81	0.58	2.68e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs12618769	0.597	rs3769740	chr2:99069208	A/G	cg10123293	chr2:99228465	UNC50	-0.42	-7.97	-0.36	1.49e-14	Bipolar disorder;
LUAD	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg15819921	chr19:927150	ARID3A	-0.47	-7.95	-0.36	1.76e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg04586622	chr2:25135609	ADCY3	0.37	8.45	0.38	4.7e-16	Body mass index;
LUAD	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg10518543	chr12:38710700	ALG10B	0.42	6.46	0.3	2.83e-10	Bladder cancer;
LUAD	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.97	13.67	0.55	1.78e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.8	-0.31	3.54e-11	Neuroticism;
LUAD	cis	rs3823572	0.504	rs2971977	chr7:133648347	C/G	cg03336402	chr7:133662267	EXOC4	-0.41	-7.62	-0.35	1.64e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg22681709	chr2:178499509	PDE11A	-0.43	-7.19	-0.33	2.95e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg11859384	chr17:80120422	CCDC57	-0.52	-9.22	-0.41	1.42e-18	Life satisfaction;
LUAD	cis	rs9463078	0.683	rs227851	chr6:44699209	A/C	cg25276700	chr6:44698697	NA	0.34	6.38	0.3	4.79e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUAD	cis	rs11249608	0.548	rs62393076	chr5:178450646	C/G	cg01312482	chr5:178451176	ZNF879	-0.44	-6.8	-0.31	3.62e-11	Pubertal anthropometrics;
LUAD	trans	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg07817883	chr1:32538562	TMEM39B	-0.52	-7.16	-0.33	3.66e-12	Monocyte percentage of white cells;
LUAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg13047869	chr3:10149882	C3orf24	0.63	10.51	0.45	4.26e-23	Alzheimer's disease;
LUAD	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg26384229	chr12:38710491	ALG10B	0.5	7.98	0.36	1.43e-14	Bladder cancer;
LUAD	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.15	0.33	3.76e-12	Parkinson's disease;
LUAD	cis	rs870825	0.929	rs10015218	chr4:185589789	T/C	cg04058563	chr4:185651563	MLF1IP	0.74	9.41	0.42	3.18e-19	Blood protein levels;
LUAD	cis	rs7289126	0.966	rs5995554	chr22:38630272	T/C	cg25457927	chr22:38595422	NA	-0.44	-10.39	-0.45	1.11e-22	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18876405	chr7:65276391	NA	0.41	6.39	0.3	4.42e-10	Aortic root size;
LUAD	cis	rs791888	0.965	rs791876	chr10:89406527	G/A	cg13926569	chr10:89418898	PAPSS2	-0.46	-8.62	-0.39	1.36e-16	Magnesium levels;
LUAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg20119798	chr7:94954144	PON1	-0.64	-11.38	-0.48	2.26e-26	Paraoxonase activity;
LUAD	cis	rs7100689	0.646	rs10736345	chr10:82134140	C/T	cg01528321	chr10:82214614	TSPAN14	0.65	10.26	0.45	3.26e-22	Post bronchodilator FEV1;
LUAD	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.62e-13	Menopause (age at onset);
LUAD	cis	rs12545109	0.800	rs1371936	chr8:57422715	A/G	cg17761419	chr8:57350749	NA	-0.55	-7.78	-0.35	5.76e-14	Obesity-related traits;
LUAD	cis	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg01251360	chr16:68772225	CDH1	-0.28	-9.01	-0.4	7.41e-18	Colorectal cancer;
LUAD	cis	rs7809950	1.000	rs2520269	chr7:107191327	T/C	cg23024343	chr7:107201750	COG5	-0.75	-12.67	-0.52	2.06e-31	Coronary artery disease;
LUAD	cis	rs10788264	0.544	rs911786	chr10:124017583	C/G	cg09507567	chr10:124027408	NA	0.54	12.36	0.52	3.62e-30	Total body bone mineral density;
LUAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg11494091	chr17:61959527	GH2	0.75	18.56	0.67	1.15e-56	Prudent dietary pattern;
LUAD	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg20503657	chr10:835505	NA	0.81	12.41	0.52	2.35e-30	Eosinophil percentage of granulocytes;
LUAD	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg20290983	chr6:43655470	MRPS18A	0.87	13.69	0.55	1.43e-35	IgG glycosylation;
LUAD	cis	rs76878669	0.561	rs905770	chr11:66156765	A/G	cg18002602	chr11:66138449	SLC29A2	0.49	10.71	0.46	7.49e-24	Educational attainment (years of education);
LUAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.22	0.41	1.43e-18	Alzheimer's disease;
LUAD	cis	rs735539	0.521	rs2585895	chr13:21396967	A/T	cg27499820	chr13:21296301	IL17D	0.47	7.14	0.33	4.04e-12	Dental caries;
LUAD	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10802521	chr3:52805072	NEK4	0.58	10.61	0.46	1.81e-23	Electroencephalogram traits;
LUAD	cis	rs12519773	0.555	rs2578490	chr5:92389236	C/T	cg18783429	chr5:92414398	NA	0.49	8.4	0.38	6.99e-16	Migraine;
LUAD	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg09835421	chr16:68378352	PRMT7	-1.05	-12.02	-0.5	7.48e-29	Schizophrenia;
LUAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.56	7.52	0.34	3.34e-13	Renal function-related traits (BUN);
LUAD	cis	rs3772130	1.000	rs3732408	chr3:121421179	G/A	cg20356878	chr3:121714668	ILDR1	0.5	7.82	0.36	4.36e-14	Cognitive performance;
LUAD	cis	rs56283067	0.887	rs12197593	chr6:44740895	C/T	cg20913747	chr6:44695427	NA	-0.39	-6.71	-0.31	6.44e-11	Total body bone mineral density;
LUAD	cis	rs1079204	1.000	rs1017697	chr2:219170462	C/T	cg05728596	chr2:219128475	GPBAR1	0.83	7.69	0.35	1.07e-13	Smooth-surface caries;
LUAD	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.95	14.05	0.56	4.58e-37	Smoking behavior;
LUAD	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg27284194	chr4:1044797	NA	0.9	18.95	0.68	2.1e-58	Recombination rate (males);
LUAD	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg05340658	chr4:99064831	C4orf37	0.56	9.53	0.42	1.28e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.96	0.76	9e-81	Chronic sinus infection;
LUAD	cis	rs2882667	0.931	rs13153618	chr5:138352776	C/A	cg04439458	chr5:138467593	SIL1	-0.4	-7.34	-0.34	1.09e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg11534937	chr7:5463750	TNRC18	-0.36	-6.37	-0.3	4.96e-10	Schizophrenia;
LUAD	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg17177755	chr1:15930204	NA	0.44	7.17	0.33	3.32e-12	Systolic blood pressure;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	ch.10.132646605F	chr10:132756615	NA	-0.41	-6.68	-0.31	7.37e-11	Cancer;
LUAD	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg16049864	chr8:95962084	TP53INP1	-0.6	-13.43	-0.55	1.72e-34	Type 2 diabetes;
LUAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.11	-0.33	5.08e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.51e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.38	7.37	0.34	9.34e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.03	-0.36	9.69e-15	Diabetic kidney disease;
LUAD	cis	rs6494488	0.500	rs72744730	chr15:65040065	C/G	cg08069370	chr15:64387884	SNX1	-0.73	-6.47	-0.3	2.78e-10	Coronary artery disease;
LUAD	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg22823121	chr1:150693482	HORMAD1	0.37	7.25	0.33	1.96e-12	Tonsillectomy;
LUAD	cis	rs7586879	0.616	rs916485	chr2:25082273	T/C	cg01884057	chr2:25150051	NA	0.32	6.88	0.32	2.2e-11	Body mass index;
LUAD	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg24578937	chr1:2090814	PRKCZ	0.78	16.4	0.62	4.03e-47	Height;
LUAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg14789911	chr21:47582049	C21orf56	-0.42	-7.07	-0.32	6.61e-12	Testicular germ cell tumor;
LUAD	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg03609598	chr5:56110824	MAP3K1	-0.48	-7.05	-0.32	7.42e-12	Initial pursuit acceleration;
LUAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.19	0.54	1.6e-33	Prudent dietary pattern;
LUAD	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg01171360	chr6:293285	DUSP22	-0.53	-9.04	-0.4	5.87e-18	Menopause (age at onset);
LUAD	cis	rs208520	0.690	rs207114	chr6:66791703	C/T	cg07460842	chr6:66804631	NA	-1.06	-17.13	-0.64	2.37e-50	Exhaled nitric oxide output;
LUAD	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.25	-0.33	1.95e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.01	0.32	9.52e-12	Motion sickness;
LUAD	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg10556349	chr10:835070	NA	0.67	7.97	0.36	1.48e-14	Eosinophil percentage of granulocytes;
LUAD	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-6.96	-0.32	1.34e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg22532475	chr10:104410764	TRIM8	-0.44	-8.26	-0.37	1.87e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg14847009	chr1:175162515	KIAA0040	-0.33	-8.68	-0.39	8.67e-17	Alcohol dependence;
LUAD	cis	rs977987	0.835	rs1010630	chr16:75328591	G/T	cg03315344	chr16:75512273	CHST6	0.62	13.55	0.55	5.4e-35	Dupuytren's disease;
LUAD	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg15704280	chr7:45808275	SEPT13	0.64	8.49	0.38	3.6e-16	Axial length;
LUAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19626725	chr5:178986131	RUFY1	-0.55	-9.93	-0.43	4.81e-21	Lung cancer;
LUAD	cis	rs7680126	0.596	rs11731652	chr4:10292984	T/C	cg00071950	chr4:10020882	SLC2A9	-0.59	-8.42	-0.38	6.03e-16	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06544989	chr22:39130855	UNC84B	0.41	7.64	0.35	1.5e-13	Menopause (age at onset);
LUAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00149659	chr3:10157352	C3orf10	-0.6	-8.28	-0.37	1.66e-15	Alzheimer's disease;
LUAD	cis	rs1160297	0.609	rs1376563	chr2:53104749	C/G	cg07782112	chr2:53107842	NA	0.39	8.34	0.38	1.07e-15	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg18512352	chr11:47633146	NA	-0.57	-10.26	-0.45	3.43e-22	Subjective well-being;
LUAD	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.51	8.11	0.37	5.66e-15	Total body bone mineral density;
LUAD	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg14983838	chr19:29218262	NA	0.67	9.9	0.43	6.62e-21	Methadone dose in opioid dependence;
LUAD	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg06636551	chr8:101224915	SPAG1	-0.38	-6.98	-0.32	1.17e-11	Atrioventricular conduction;
LUAD	cis	rs7818345	0.967	rs4412390	chr8:19270143	A/T	cg11303988	chr8:19266685	CSGALNACT1	-0.31	-6.71	-0.31	6.25e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg05368731	chr17:41323189	NBR1	0.91	19.02	0.68	9.92e-59	Menopause (age at onset);
LUAD	cis	rs3087591	0.960	rs11870097	chr17:29448097	C/T	cg24425628	chr17:29625626	OMG;NF1	0.43	6.88	0.32	2.22e-11	Hip circumference;
LUAD	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.61	-11.64	-0.49	2.41e-27	Schizophrenia;
LUAD	cis	rs870825	0.860	rs28799091	chr4:185598594	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	12.48	0.52	1.22e-30	Blood protein levels;
LUAD	cis	rs2294693	0.581	rs9462670	chr6:41014309	G/C	cg14769373	chr6:40998127	UNC5CL	-0.46	-7.3	-0.33	1.41e-12	Gastric cancer;Non-cardia gastric cancer;
LUAD	trans	rs8073060	0.544	rs1080352	chr17:34002362	A/G	cg19694781	chr19:47549865	TMEM160	-1.22	-19.7	-0.69	9.2e-62	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs240764	0.853	rs10457809	chr6:100984400	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-7.15	-0.33	3.89e-12	Neuroticism;
LUAD	cis	rs2282300	0.739	rs34224414	chr11:30251041	T/G	cg25418670	chr11:30344373	C11orf46	-0.52	-7.25	-0.33	2.01e-12	Morning vs. evening chronotype;
LUAD	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.99	-0.36	1.33e-14	Neuroticism;
LUAD	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg09936142	chr19:10668400	KRI1	-0.47	-6.55	-0.3	1.63e-10	Red cell distribution width;
LUAD	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg24308560	chr3:49941425	MST1R	-0.52	-8.59	-0.39	1.74e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.43	-0.45	7.96e-23	Monocyte percentage of white cells;
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg13426340	chr1:167131977	NA	-0.41	-6.41	-0.3	3.81e-10	Height;
LUAD	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg23625390	chr15:77176239	SCAPER	-0.47	-7.54	-0.34	2.96e-13	Blood metabolite levels;
LUAD	cis	rs2067615	0.524	rs9971765	chr12:107092299	G/A	cg15890332	chr12:107067104	RFX4	0.4	8.42	0.38	5.96e-16	Heart rate;
LUAD	cis	rs9326248	0.559	rs10892064	chr11:116896553	G/C	cg20608306	chr11:116969690	SIK3	0.32	7.1	0.33	5.47e-12	Blood protein levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17976065	chr17:15902694	ZSWIM7;TTC19	-0.39	-6.38	-0.3	4.65e-10	Cancer;
LUAD	cis	rs240764	0.658	rs9390681	chr6:101218994	A/T	cg09795085	chr6:101329169	ASCC3	-0.43	-7.57	-0.35	2.31e-13	Neuroticism;
LUAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg25703541	chr22:24373054	LOC391322	0.75	14.36	0.57	2.34e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3857067	0.804	rs6821438	chr4:95091911	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.36	-6.36	-0.3	5.37e-10	QT interval;
LUAD	trans	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.24	0.45	4.02e-22	Mean corpuscular volume;
LUAD	cis	rs55665837	0.540	rs4144487	chr11:14750451	C/G	cg19336497	chr11:14380999	RRAS2	-0.41	-7.8	-0.35	4.76e-14	Vitamin D levels;
LUAD	cis	rs68170813	0.559	rs10953531	chr7:106827867	A/G	cg02696742	chr7:106810147	HBP1	0.79	11.04	0.47	4.38e-25	Coronary artery disease;
LUAD	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg23505145	chr19:12996616	KLF1	0.61	9.97	0.44	3.56e-21	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.77	-0.31	4.27e-11	Diabetic kidney disease;
LUAD	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg11344533	chr11:111475393	SIK2	-0.35	-6.56	-0.3	1.59e-10	Primary sclerosing cholangitis;
LUAD	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg08027265	chr7:2291960	NA	-0.48	-8.48	-0.38	3.88e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.52	0.3	2.05e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.43	8.21	0.37	2.63e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg08462924	chr1:41848221	NA	0.48	8.92	0.4	1.44e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg19077165	chr18:44547161	KATNAL2	-0.44	-7.63	-0.35	1.61e-13	Personality dimensions;
LUAD	cis	rs4356932	0.967	rs4241581	chr4:76962055	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.52	-0.3	2.05e-10	Blood protein levels;
LUAD	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg11235426	chr6:292522	DUSP22	-0.56	-9.25	-0.41	1.15e-18	Menopause (age at onset);
LUAD	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg26384229	chr12:38710491	ALG10B	-0.41	-7.05	-0.32	7.1e-12	Heart rate;
LUAD	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.89	-0.36	2.66e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs7786808	0.530	rs7780796	chr7:158183330	C/T	cg02030672	chr11:45687055	CHST1	-0.37	-6.54	-0.3	1.83e-10	Obesity-related traits;
LUAD	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg08219700	chr8:58056026	NA	0.51	7.31	0.33	1.33e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg23254163	chr1:152506842	NA	0.24	6.65	0.31	8.99e-11	Hair morphology;
LUAD	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg00784671	chr22:46762841	CELSR1	-0.62	-7.47	-0.34	4.77e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg24399712	chr22:39784796	NA	-0.74	-12.25	-0.51	9.64e-30	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10802521	chr3:52805072	NEK4	-0.54	-9.1	-0.4	3.69e-18	Bipolar disorder;
LUAD	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.82	-0.39	2.94e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9473147	0.543	rs4715019	chr6:47447041	T/A	cg20196966	chr6:47445060	CD2AP	0.42	6.44	0.3	3.3e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.66e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg21545522	chr1:205238299	TMCC2	0.38	7.02	0.32	9.15e-12	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs9948	0.521	rs62156207	chr2:97359236	C/A	cg20312557	chr2:97357134	FER1L5	-0.64	-7.7	-0.35	9.8e-14	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs62400317	1.000	rs62400317	chr6:45284923	C/T	cg20913747	chr6:44695427	NA	-0.41	-6.64	-0.31	9.51e-11	Total body bone mineral density;
LUAD	cis	rs4698790	0.635	rs7439356	chr4:110684744	T/C	cg07850274	chr4:110748770	RRH	0.41	6.8	0.31	3.56e-11	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUAD	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg21918786	chr6:109611834	NA	-0.58	-10.66	-0.46	1.18e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg22508957	chr16:3507546	NAT15	0.74	13.55	0.55	5.6e-35	Tuberculosis;
LUAD	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	6.45	0.3	3.14e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg11494091	chr17:61959527	GH2	-0.74	-18.39	-0.67	6.07e-56	Prudent dietary pattern;
LUAD	cis	rs4285028	1.000	rs4285028	chr3:121660664	A/C	cg11130432	chr3:121712080	ILDR1	-0.57	-8.15	-0.37	4.2e-15	Multiple sclerosis;
LUAD	trans	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.23	-0.33	2.27e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg05457628	chr5:178986728	RUFY1	-0.72	-12.48	-0.52	1.24e-30	Lung cancer;
LUAD	trans	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	9.98	0.44	3.38e-21	Mean corpuscular volume;
LUAD	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg17200465	chr3:40428508	ENTPD3	0.27	6.48	0.3	2.51e-10	Renal cell carcinoma;
LUAD	cis	rs10242455	0.702	rs73403286	chr7:99154865	A/C	cg18809830	chr7:99032528	PTCD1	-1.1	-7.97	-0.36	1.51e-14	Blood metabolite levels;
LUAD	cis	rs1403694	0.966	rs1656908	chr3:186437342	T/C	cg12454167	chr3:186435060	KNG1	0.4	8.01	0.36	1.16e-14	Blood protein levels;
LUAD	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg08859206	chr1:53392774	SCP2	-0.59	-10.49	-0.45	4.94e-23	Monocyte count;
LUAD	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg02158880	chr13:53174818	NA	0.57	9.96	0.44	3.89e-21	Lewy body disease;
LUAD	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg00255919	chr5:131827918	IRF1	-0.3	-6.75	-0.31	5.01e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg01579765	chr21:45077557	HSF2BP	0.55	12.48	0.52	1.22e-30	Mean corpuscular volume;
LUAD	cis	rs155346	1.000	rs645850	chr5:139393417	T/C	cg01090482	chr5:139365336	NRG2	-0.32	-6.36	-0.3	5.26e-10	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUAD	trans	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg01620082	chr3:125678407	NA	-1.06	-8.53	-0.38	2.62e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg10518543	chr12:38710700	ALG10B	0.44	7.52	0.34	3.32e-13	Heart rate;
LUAD	cis	rs7116495	0.881	rs615000	chr11:71802952	A/C	cg07596299	chr11:71824057	C11orf51	-0.81	-6.91	-0.32	1.83e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg18132916	chr6:79620363	NA	-0.46	-7.97	-0.36	1.45e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg00852783	chr1:26633632	UBXN11	0.46	7.62	0.35	1.64e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1030268	0.651	rs12707118	chr7:133474900	C/T	cg10665199	chr7:133106180	EXOC4	-0.45	-6.47	-0.3	2.64e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17712092	chr4:129076599	LARP1B	0.88	16.44	0.62	2.56e-47	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg08761264	chr16:28874980	SH2B1	-0.45	-6.9	-0.32	1.88e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs7395662	0.963	rs2135681	chr11:48728388	T/C	cg15704280	chr7:45808275	SEPT13	-0.41	-6.35	-0.3	5.43e-10	HDL cholesterol;
LUAD	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg27427491	chr17:78079615	GAA	-0.39	-7.27	-0.33	1.79e-12	Yeast infection;
LUAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg16031515	chr1:205743344	RAB7L1	-0.38	-7.6	-0.35	1.95e-13	Menarche (age at onset);
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08289482	chr15:59969074	BNIP2	-0.41	-6.7	-0.31	6.6e-11	Schizophrenia;
LUAD	cis	rs17362650	0.694	rs67261055	chr2:9571984	G/T	cg12832956	chr2:9616023	IAH1	-0.5	-8.66	-0.39	1.02e-16	Alcohol dependence (age at onset);
LUAD	cis	rs67385638	1.000	rs2855036	chr11:5272682	C/T	cg12559170	chr11:5275217	HBG2	0.33	6.91	0.32	1.76e-11	Hemoglobin levels;
LUAD	cis	rs1448094	0.935	rs11117108	chr12:86322310	T/A	cg00310523	chr12:86230176	RASSF9	0.35	7.56	0.34	2.58e-13	Major depressive disorder;
LUAD	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg14835575	chr10:16859367	RSU1	0.97	14.43	0.57	1.1e-38	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg14926445	chr8:58193284	C8orf71	-0.47	-6.66	-0.31	8.63e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg10356904	chr22:49881777	NA	-0.4	-7.62	-0.35	1.64e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7851660	0.809	rs10512255	chr9:100652582	C/T	cg13688889	chr9:100608707	NA	-0.53	-8.89	-0.4	1.81e-17	Strep throat;
LUAD	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.59	-0.35	2.04e-13	Breast cancer;
LUAD	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg09085632	chr11:111637200	PPP2R1B	0.64	9.85	0.43	9.68e-21	Primary sclerosing cholangitis;
LUAD	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg08807101	chr21:30365312	RNF160	-0.43	-7.37	-0.34	9.17e-13	Dental caries;
LUAD	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg00339695	chr16:24857497	SLC5A11	0.49	9.25	0.41	1.13e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg08645402	chr16:4508243	NA	0.55	9.83	0.43	1.11e-20	Schizophrenia;
LUAD	cis	rs1799949	0.757	rs9915489	chr17:41173226	A/T	cg23758822	chr17:41437982	NA	0.96	19.16	0.68	2.39e-59	Menopause (age at onset);
LUAD	trans	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.17	27.59	0.8	1.29e-96	Exhaled nitric oxide output;
LUAD	cis	rs11229555	0.645	rs7926682	chr11:58189495	A/G	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.35	6.78	0.31	4.11e-11	Depression;
LUAD	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg17724175	chr1:150552817	MCL1	-0.33	-7.55	-0.34	2.64e-13	Melanoma;
LUAD	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-8.31	-0.37	1.32e-15	HDL cholesterol;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07714476	chr19:6516817	NA	-0.4	-6.59	-0.31	1.3100000000000001e-10	Cancer;
LUAD	cis	rs11771526	1.000	rs62457533	chr7:32355334	G/A	cg27511599	chr7:32358540	NA	0.61	7.0	0.32	9.88e-12	Body mass index;
LUAD	cis	rs2387326	0.717	rs10829334	chr10:129943402	C/T	cg16087940	chr10:129947807	NA	-0.65	-9.09	-0.4	3.81e-18	Select biomarker traits;
LUAD	cis	rs3807375	1.000	rs3807375	chr7:150667210	C/T	cg10636020	chr7:150656979	KCNH2	-0.38	-6.85	-0.32	2.63e-11	Electrocardiographic traits;QT interval;
LUAD	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg00666640	chr1:248458726	OR2T12	0.32	7.6	0.35	1.91e-13	Common traits (Other);
LUAD	cis	rs734999	0.549	rs867436	chr1:2523723	C/T	cg18854424	chr1:2615690	NA	0.41	8.89	0.4	1.79e-17	Ulcerative colitis;
LUAD	cis	rs28595532	0.920	rs115226628	chr4:119639818	A/G	cg21605333	chr4:119757512	SEC24D	0.86	7.93	0.36	2e-14	Cannabis dependence symptom count;
LUAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.57	-0.35	2.41e-13	Tonsillectomy;
LUAD	cis	rs754466	0.580	rs11002294	chr10:79540588	T/C	cg17075019	chr10:79541650	NA	-0.92	-19.6	-0.69	2.48e-61	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg18811423	chr2:55921094	PNPT1	0.43	6.87	0.32	2.26e-11	Metabolic syndrome;
LUAD	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg01528321	chr10:82214614	TSPAN14	-0.54	-8.41	-0.38	6.38e-16	Post bronchodilator FEV1;
LUAD	cis	rs3849570	0.615	rs9817070	chr3:81982936	A/G	cg07356753	chr3:81810745	GBE1	-0.48	-8.03	-0.36	9.94e-15	Waist circumference;Body mass index;
LUAD	cis	rs113835537	1.000	rs113835537	chr11:66339639	A/G	cg24851651	chr11:66362959	CCS	0.55	8.04	0.36	9.22e-15	Airway imaging phenotypes;
LUAD	cis	rs8049603	0.715	rs34243485	chr16:23189947	T/C	cg09552652	chr16:23197569	SCNN1G	0.37	6.43	0.3	3.44e-10	Multiple sclerosis;
LUAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-7.59	-0.35	2.09e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg01028140	chr2:1542097	TPO	-0.49	-6.43	-0.3	3.42e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg06627628	chr2:24431161	ITSN2	-0.56	-9.49	-0.42	1.76e-19	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg26384229	chr12:38710491	ALG10B	0.44	6.97	0.32	1.21e-11	Heart rate;
LUAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg04025307	chr7:1156635	C7orf50	0.66	9.46	0.42	2.21e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.08	-14.96	-0.59	6.7e-41	Schizophrenia;
LUAD	trans	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-15.12	-0.59	1.35e-41	Exhaled nitric oxide output;
LUAD	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg02176678	chr2:219576539	TTLL4	0.75	15.09	0.59	1.71e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs490234	0.812	rs12553699	chr9:128294526	C/G	cg14078157	chr9:128172775	NA	-0.4	-7.04	-0.32	8.05e-12	Mean arterial pressure;
LUAD	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg02176678	chr2:219576539	TTLL4	0.61	11.95	0.5	1.44e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg02683114	chr2:24398427	C2orf84	-0.52	-7.72	-0.35	8.48e-14	Asthma;
LUAD	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.24	0.33	2.1e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg05340658	chr4:99064831	C4orf37	0.54	8.71	0.39	6.8e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73416724	1.000	rs75782458	chr6:43340810	G/A	cg26312998	chr6:43337775	ZNF318	0.55	6.69	0.31	7.22e-11	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg03886242	chr7:26192032	NFE2L3	-0.44	-7.56	-0.35	2.5e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg19635926	chr16:89946313	TCF25	0.72	6.42	0.3	3.73e-10	Skin colour saturation;
LUAD	trans	rs3857536	0.813	rs6455090	chr6:66948909	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.56	-0.3	1.57e-10	Blood trace element (Cu levels);
LUAD	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.38	-0.34	8.42e-13	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs1448094	0.872	rs7975457	chr12:86410404	C/T	cg19622623	chr12:86230825	RASSF9	-0.39	-6.99	-0.32	1.11e-11	Major depressive disorder;
LUAD	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg22676075	chr6:135203613	NA	0.41	7.69	0.35	1.08e-13	Red blood cell count;
LUAD	cis	rs2979489	0.891	rs2915592	chr8:30396417	C/T	cg26383811	chr8:30366931	RBPMS	-0.69	-10.64	-0.46	1.4e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-14.01	-0.56	6.67e-37	Chronic sinus infection;
LUAD	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg09537434	chr19:41945824	ATP5SL	-0.52	-8.23	-0.37	2.4e-15	Height;
LUAD	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg02049041	chr17:27085579	C17orf63	0.65	8.58	0.38	1.82e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg06618935	chr21:46677482	NA	-0.49	-9.84	-0.43	1.04e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21582582	chr3:182698605	DCUN1D1	0.56	9.6	0.42	7.03e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg05590025	chr7:65112418	INTS4L2	0.66	7.04	0.32	8e-12	Diabetic kidney disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00735744	chr16:3767168	TRAP1	-0.38	-6.39	-0.3	4.38e-10	Cancer;
LUAD	cis	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.99	-0.36	1.29e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.98	-0.36	1.35e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs113835537	0.529	rs2305533	chr11:66298623	A/C	cg24851651	chr11:66362959	CCS	0.57	10.01	0.44	2.64e-21	Airway imaging phenotypes;
LUAD	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.1	0.37	5.9e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg04565464	chr8:145669602	NFKBIL2	0.44	6.59	0.31	1.34e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs8177876	0.658	rs12444747	chr16:81074904	C/G	cg08591886	chr16:81111003	C16orf46	-0.8	-6.83	-0.32	3.03e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs9549328	0.542	rs36172983	chr13:113616582	T/C	cg17524180	chr13:113633600	MCF2L	0.3	6.43	0.3	3.51e-10	Systolic blood pressure;
LUAD	cis	rs36051895	0.658	rs10974912	chr9:5010885	A/C	cg02405213	chr9:5042618	JAK2	-0.51	-7.02	-0.32	9.01e-12	Pediatric autoimmune diseases;
LUAD	cis	rs2795502	0.630	rs2282443	chr10:43474169	A/G	cg08461752	chr10:43522343	NA	-0.83	-8.97	-0.4	9.57e-18	Blood protein levels;
LUAD	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg23533926	chr12:111358616	MYL2	-0.41	-7.01	-0.32	9.73e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg17366294	chr4:99064904	C4orf37	0.58	8.76	0.39	4.62e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg04772025	chr11:68637568	NA	0.59	9.38	0.41	4.07e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs13266463	0.858	rs13255588	chr8:143384727	C/G	cg16886403	chr8:143471632	TSNARE1	0.45	6.66	0.31	8.78e-11	Schizophrenia;
LUAD	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg21191810	chr6:118973309	C6orf204	-0.53	-8.2	-0.37	2.98e-15	Diastolic blood pressure;
LUAD	cis	rs13064411	0.696	rs6787026	chr3:113162117	A/G	cg10517650	chr3:113235015	CCDC52	-0.56	-9.3	-0.41	7.87e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs889398	0.967	rs1437134	chr16:69730426	A/G	cg26679644	chr16:69762563	NA	0.36	6.63	0.31	1.05e-10	Body mass index;
LUAD	cis	rs79976124	0.879	rs78012385	chr6:66618091	G/A	cg07460842	chr6:66804631	NA	0.61	9.5	0.42	1.58e-19	Type 2 diabetes;
LUAD	cis	rs7254827	0.784	rs4808570	chr19:17220720	G/A	cg19418318	chr19:17219073	MYO9B	-0.56	-6.55	-0.3	1.7e-10	Mean platelet volume;
LUAD	cis	rs1997103	0.954	rs9649780	chr7:55411741	A/C	cg17469321	chr7:55412551	NA	0.67	11.31	0.48	4.46e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.64	-11.71	-0.49	1.28e-27	Urate levels in overweight individuals;
LUAD	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg10802521	chr3:52805072	NEK4	-0.5	-8.28	-0.37	1.59e-15	Electroencephalogram traits;
LUAD	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18867708	chr6:26865862	GUSBL1	-0.42	-6.53	-0.3	1.87e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg14019146	chr3:50243930	SLC38A3	-0.55	-10.89	-0.47	1.65e-24	Intelligence (multi-trait analysis);
LUAD	trans	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg26043149	chr18:55253948	FECH	0.5	7.99	0.36	1.31e-14	Bone mineral density;
LUAD	cis	rs6758955	1.000	rs12328290	chr2:10477964	T/C	cg15773312	chr2:10472214	HPCAL1	-0.41	-6.74	-0.31	5.17e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9914988	0.832	rs11650788	chr17:27174523	T/A	cg20469991	chr17:27169893	C17orf63	-0.52	-6.62	-0.31	1.08e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs684232	0.800	rs371318	chr17:555816	A/G	cg15660573	chr17:549704	VPS53	-0.51	-8.21	-0.37	2.62e-15	Prostate cancer;
LUAD	cis	rs7100689	0.622	rs10749595	chr10:82172975	C/T	cg01528321	chr10:82214614	TSPAN14	0.72	10.91	0.47	1.33e-24	Post bronchodilator FEV1;
LUAD	cis	rs953387	0.824	rs6716987	chr2:136963494	G/T	cg05194412	chr2:137003533	NA	-0.42	-6.82	-0.31	3.22e-11	Arthritis (juvenile idiopathic);
LUAD	cis	rs7119038	0.818	rs10892294	chr11:118667357	C/G	cg19308663	chr11:118741387	NA	-0.45	-6.77	-0.31	4.32e-11	Sjögren's syndrome;
LUAD	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4243830	0.850	rs1010584	chr1:6579843	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.53	-6.88	-0.32	2.23e-11	Body mass index;
LUAD	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg09491104	chr22:46646882	C22orf40	-0.73	-13.43	-0.55	1.75e-34	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg00071950	chr4:10020882	SLC2A9	0.86	18.81	0.67	8.69e-58	Bone mineral density;
LUAD	cis	rs8044868	0.530	rs9932951	chr16:72075341	A/G	cg23815491	chr16:72088622	HP	0.51	9.33	0.41	6.14e-19	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs62229266	0.659	rs7275820	chr21:37409414	G/A	cg12218747	chr21:37451666	NA	-0.43	-7.53	-0.34	3.02e-13	Mitral valve prolapse;
LUAD	cis	rs1595825	0.891	rs996427	chr2:198685609	G/A	cg10547527	chr2:198650123	BOLL	-0.55	-7.91	-0.36	2.34e-14	Ulcerative colitis;
LUAD	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg22431228	chr1:16359049	CLCNKA	0.47	8.22	0.37	2.46e-15	Dilated cardiomyopathy;
LUAD	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg20119798	chr7:94954144	PON1	-0.49	-7.05	-0.32	7.2e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg11833968	chr6:79620685	NA	-0.42	-7.86	-0.36	3.12e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg00634984	chr7:65235879	NA	0.47	6.37	0.3	4.91e-10	Aortic root size;
LUAD	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg18451016	chr1:38461880	NA	0.53	11.0	0.47	6.1e-25	Coronary artery disease;
LUAD	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg09359103	chr1:154839909	KCNN3	-0.87	-17.29	-0.64	4.73e-51	Prostate cancer;
LUAD	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg09324608	chr17:30823087	MYO1D	0.44	8.15	0.37	4.2e-15	Schizophrenia;
LUAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg04234412	chr22:24373322	LOC391322	-0.8	-14.21	-0.57	9.29e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg17264618	chr3:40429014	ENTPD3	0.4	9.12	0.41	2.96e-18	Renal cell carcinoma;
LUAD	cis	rs12681287	0.752	rs10112123	chr8:87302328	T/C	cg00550725	chr8:87521180	FAM82B	0.45	6.54	0.3	1.75e-10	Caudate activity during reward;
LUAD	trans	rs7395662	0.625	rs11040006	chr11:48774302	G/A	cg00717180	chr2:96193071	NA	0.35	6.42	0.3	3.61e-10	HDL cholesterol;
LUAD	cis	rs4523957	0.522	rs8081921	chr17:2021490	C/A	cg16513277	chr17:2031491	SMG6	-0.95	-19.14	-0.68	2.98e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg19318889	chr4:1322082	MAEA	0.47	7.78	0.35	5.45e-14	Obesity-related traits;
LUAD	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg18512352	chr11:47633146	NA	-0.46	-8.11	-0.37	5.39e-15	Subjective well-being;
LUAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg04025307	chr7:1156635	C7orf50	0.58	9.32	0.41	6.35e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.41	6.66	0.31	8.41e-11	Tonsillectomy;
LUAD	cis	rs7582720	1.000	rs7605484	chr2:203724495	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.71	8.78	0.39	3.94e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg09184832	chr6:79620586	NA	-0.4	-6.8	-0.31	3.53e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs877282	0.947	rs4133015	chr10:774131	T/C	cg17470449	chr10:769945	NA	0.68	10.73	0.46	6.64e-24	Uric acid levels;
LUAD	cis	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg07460842	chr6:66804631	NA	0.58	9.34	0.41	5.59e-19	Type 2 diabetes;
LUAD	trans	rs11039798	1.000	rs115429994	chr11:48761183	C/G	cg03929089	chr4:120376271	NA	0.59	6.8	0.31	3.49e-11	Axial length;
LUAD	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg21214613	chr1:16344536	HSPB7	0.61	12.05	0.51	6e-29	Systolic blood pressure;
LUAD	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg18404041	chr3:52824283	ITIH1	0.49	8.26	0.37	1.89e-15	Schizophrenia;
LUAD	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-8.88	-0.4	1.86e-17	Blood metabolite levels;
LUAD	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.4	-0.45	1.06e-22	Total body bone mineral density;
LUAD	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg08645402	chr16:4508243	NA	0.53	9.69	0.43	3.39e-20	Schizophrenia;
LUAD	trans	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg05926928	chr17:57297772	GDPD1	-0.51	-7.68	-0.35	1.09e-13	Schizophrenia;
LUAD	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg00666640	chr1:248458726	OR2T12	0.31	7.6	0.35	1.94e-13	Common traits (Other);
LUAD	cis	rs7927771	0.524	rs7943213	chr11:47715524	T/C	cg18512352	chr11:47633146	NA	0.37	6.63	0.31	9.96e-11	Subjective well-being;
LUAD	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg09137382	chr11:130731461	NA	0.4	7.43	0.34	6.19e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg20790798	chr5:1857306	NA	-0.47	-7.84	-0.36	3.82e-14	Cardiovascular disease risk factors;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	ch.1.928723R	chr1:28176880	PPP1R8	-0.38	-6.39	-0.3	4.29e-10	Cancer;
LUAD	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg06623918	chr6:96969491	KIAA0776	0.88	17.34	0.64	2.91e-51	Headache;
LUAD	cis	rs11247915	0.644	rs11588739	chr1:26653319	G/A	cg15628303	chr1:26608928	UBXN11	0.54	9.53	0.42	1.27e-19	Obesity-related traits;
LUAD	cis	rs12545109	0.800	rs1530218	chr8:57407864	C/G	cg19413350	chr8:57351067	NA	-0.44	-6.58	-0.3	1.36e-10	Obesity-related traits;
LUAD	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg19041857	chr6:27730383	NA	-0.4	-6.78	-0.31	4.13e-11	Parkinson's disease;
LUAD	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.61	-0.35	1.81e-13	Breast cancer;
LUAD	cis	rs13064411	0.735	rs6438157	chr3:113207316	G/T	cg18753928	chr3:113234510	CCDC52	-0.73	-12.43	-0.52	1.82e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg15691649	chr6:25882328	NA	-0.45	-7.15	-0.33	3.91e-12	Blood metabolite levels;
LUAD	cis	rs12545109	0.800	rs2118260	chr8:57393481	T/C	cg19413350	chr8:57351067	NA	-0.47	-7.1	-0.33	5.22e-12	Obesity-related traits;
LUAD	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg11494091	chr17:61959527	GH2	0.41	7.15	0.33	3.76e-12	Height;
LUAD	cis	rs7010267	0.570	rs2326193	chr8:120029709	A/C	cg01975934	chr8:119970761	NA	-0.35	-7.03	-0.32	8.17e-12	Total body bone mineral density (age 45-60);
LUAD	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg06263672	chr7:65235340	NA	-0.48	-6.58	-0.3	1.4e-10	Aortic root size;
LUAD	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.4e-13	Menopause (age at onset);
LUAD	cis	rs10489202	0.608	rs10918827	chr1:168077044	A/G	cg24449463	chr1:168025552	DCAF6	0.62	9.94	0.44	4.53e-21	Schizophrenia;
LUAD	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg17724175	chr1:150552817	MCL1	0.39	8.82	0.39	2.96e-17	Melanoma;
LUAD	cis	rs2742234	0.541	rs11238479	chr10:43717423	C/T	cg15436174	chr10:43711423	RASGEF1A	0.55	9.02	0.4	6.55e-18	Hirschsprung disease;
LUAD	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg20814179	chr4:940893	TMEM175	0.73	13.09	0.54	4.34e-33	Sjögren's syndrome;
LUAD	cis	rs7705042	0.865	rs4912622	chr5:141490587	A/G	cg23435118	chr5:141488016	NDFIP1	0.39	6.67	0.31	8.15e-11	Asthma;
LUAD	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg15017067	chr4:17643749	FAM184B	0.38	7.43	0.34	6.14e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg22681709	chr2:178499509	PDE11A	-0.43	-7.1	-0.33	5.28e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg09796270	chr17:17721594	SREBF1	0.34	6.36	0.3	5.25e-10	Total body bone mineral density;
LUAD	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg01200585	chr1:228362443	C1orf69	-0.38	-7.0	-0.32	1.04e-11	Diastolic blood pressure;
LUAD	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg11211951	chr8:145729740	GPT	0.38	7.13	0.33	4.47e-12	Age at first birth;
LUAD	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg14582100	chr15:45693742	SPATA5L1	0.42	8.26	0.37	1.9e-15	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg18621852	chr3:10150065	C3orf24	0.45	7.08	0.33	5.94e-12	Alzheimer's disease;
LUAD	cis	rs3784262	1.000	rs12915901	chr15:58279432	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.46	-9.32	-0.41	6.39e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9469913	0.674	rs2744965	chr6:34589632	C/T	cg17674042	chr6:34482479	PACSIN1	-0.42	-6.4	-0.3	4.09e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg07460842	chr6:66804631	NA	0.62	9.73	0.43	2.45e-20	Type 2 diabetes;
LUAD	cis	rs62238980	0.614	rs117439638	chr22:32438225	T/C	cg00543991	chr22:32367038	NA	0.81	7.87	0.36	2.91e-14	Childhood ear infection;
LUAD	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg15704280	chr7:45808275	SEPT13	-0.62	-9.34	-0.41	5.63e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg04539111	chr16:67997858	SLC12A4	-0.55	-6.84	-0.32	2.83e-11	HDL cholesterol;
LUAD	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.66	0.31	8.8e-11	Breast cancer;
LUAD	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.14	0.41	2.65e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs738321	0.725	rs5756926	chr22:38542613	T/C	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.91	-0.32	1.83e-11	Breast cancer;
LUAD	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg07432352	chr17:45403706	C17orf57	-0.42	-8.12	-0.37	5.09e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	7.92	0.36	2.11e-14	Menarche (age at onset);
LUAD	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg09658497	chr7:2847517	GNA12	-0.49	-8.93	-0.4	1.32e-17	Height;
LUAD	cis	rs72772090	0.539	rs72773969	chr5:96145196	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-6.83	-0.31	3.04e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9811920	0.809	rs6806323	chr3:99722564	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-11.35	-0.48	2.93e-26	Axial length;
LUAD	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg20283391	chr11:68216788	NA	-0.42	-6.6	-0.31	1.24e-10	Total body bone mineral density;
LUAD	cis	rs1403694	0.515	rs1622922	chr3:186449884	C/T	cg12454167	chr3:186435060	KNG1	0.41	8.52	0.38	2.74e-16	Blood protein levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg13131519	chr7:127032423	ZNF800	-0.39	-6.45	-0.3	3.02e-10	Schizophrenia;
LUAD	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22496380	chr5:211416	CCDC127	-0.94	-13.18	-0.54	1.73e-33	Breast cancer;
LUAD	cis	rs73206853	0.841	rs4131851	chr12:110812345	T/C	cg12870014	chr12:110450643	ANKRD13A	0.61	6.72	0.31	6.02e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.36	-0.34	9.4e-13	Resting heart rate;
LUAD	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	8.75e-12	Aortic root size;
LUAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.85	-0.32	2.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg11941060	chr3:133502564	NA	-0.65	-11.3	-0.48	4.82e-26	Iron status biomarkers;
LUAD	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg02527881	chr3:46936655	PTH1R	-0.48	-9.36	-0.41	4.61e-19	Colorectal cancer;
LUAD	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	6.99	0.32	1.06e-11	Motion sickness;
LUAD	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg09998033	chr7:158218633	PTPRN2	-0.42	-7.49	-0.34	4.02e-13	Obesity-related traits;
LUAD	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-8.32	-0.37	1.23e-15	Total body bone mineral density;
LUAD	cis	rs74181299	0.819	rs2723086	chr2:65297686	C/T	cg05010058	chr2:65284262	CEP68	0.3	6.64	0.31	9.41e-11	Pulse pressure;
LUAD	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg22676075	chr6:135203613	NA	0.41	7.66	0.35	1.26e-13	Red blood cell count;
LUAD	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg23254163	chr1:152506842	NA	0.25	7.01	0.32	9.51e-12	Hair morphology;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16373290	chr4:155471803	PLRG1	-0.38	-6.36	-0.3	5.35e-10	Cancer;
LUAD	cis	rs2932538	0.922	rs4838961	chr1:113163967	T/C	cg22162597	chr1:113214053	CAPZA1	-0.44	-6.64	-0.31	9.94e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg17689763	chr4:710664	PCGF3	-0.57	-9.84	-0.43	1.03e-20	White blood cell count;
LUAD	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg24397884	chr7:158709396	WDR60	0.68	9.35	0.41	5.29e-19	Height;
LUAD	cis	rs13315871	0.929	rs11706920	chr3:58279672	C/T	cg20936604	chr3:58311152	NA	-0.7	-7.11	-0.33	4.91e-12	Cholesterol, total;
LUAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg21385606	chr21:47601150	C21orf56	-0.38	-6.85	-0.32	2.64e-11	Testicular germ cell tumor;
LUAD	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg08601574	chr20:25228251	PYGB	0.48	8.11	0.37	5.69e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg19622623	chr12:86230825	RASSF9	-0.55	-9.87	-0.43	7.98e-21	Major depressive disorder;
LUAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg05434287	chr7:2030229	MAD1L1	0.39	6.37	0.3	5.07e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Parkinson's disease;
LUAD	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg19717773	chr7:2847554	GNA12	0.42	7.39	0.34	7.82e-13	Loneliness (linear analysis);
LUAD	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg23216685	chr1:86174607	ZNHIT6	-0.4	-7.28	-0.33	1.61e-12	Urate levels in overweight individuals;
LUAD	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg06191203	chr2:152266755	RIF1	0.55	8.19	0.37	3.08e-15	Lung cancer;
LUAD	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.38	6.51	0.3	2.14e-10	Menarche (age at onset);
LUAD	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg27572855	chr1:25598939	RHD	-0.53	-11.38	-0.48	2.43e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs853679	0.546	rs36092177	chr6:28357807	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.59	6.8	0.31	3.47e-11	Depression;
LUAD	cis	rs68170813	0.559	rs997311	chr7:106953033	G/A	cg23024343	chr7:107201750	COG5	0.49	6.99	0.32	1.05e-11	Coronary artery disease;
LUAD	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg12311346	chr5:56204834	C5orf35	-0.95	-13.82	-0.56	3.96e-36	Type 2 diabetes;
LUAD	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg11663144	chr21:46675770	NA	0.6	11.79	0.5	6.18e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2479724	0.591	rs2479723	chr6:41890835	G/A	cg17623882	chr6:41773611	USP49	-0.47	-7.0	-0.32	1.02e-11	Menarche (age at onset);
LUAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg14893161	chr1:205819251	PM20D1	0.59	10.63	0.46	1.44e-23	Prostate cancer;
LUAD	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg05665937	chr4:1216051	CTBP1	0.42	7.63	0.35	1.58e-13	Obesity-related traits;
LUAD	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	ch.11.42038R	chr11:967971	AP2A2	0.39	6.92	0.32	1.64e-11	Alzheimer's disease (late onset);
LUAD	trans	rs12200782	1.000	rs12213722	chr6:26473083	A/G	cg08851530	chr6:28072375	NA	0.75	6.74	0.31	5.17e-11	Small cell lung carcinoma;
LUAD	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs77861329	1.000	rs9847073	chr3:52144947	C/T	cg08692210	chr3:52188851	WDR51A	-0.85	-7.79	-0.35	5.26e-14	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg17480646	chr11:65405466	SIPA1	-0.45	-6.65	-0.31	9.29e-11	Acne (severe);
LUAD	cis	rs11030122	0.702	rs67300156	chr11:3953949	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.24	-0.33	2.17e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7089973	0.872	rs34683721	chr10:116619849	G/A	cg25233709	chr10:116636983	FAM160B1	0.39	7.56	0.34	2.55e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg09455208	chr3:40491958	NA	0.55	12.05	0.51	6.01e-29	Renal cell carcinoma;
LUAD	cis	rs17095355	1.000	rs11194933	chr10:111725862	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.68	-9.16	-0.41	2.21e-18	Biliary atresia;
LUAD	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg12458913	chr13:53173898	NA	0.52	9.16	0.41	2.28e-18	Lewy body disease;
LUAD	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg25344623	chr2:136566232	LCT	-0.38	-7.32	-0.34	1.23e-12	Mosquito bite size;
LUAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg24846343	chr22:24311635	DDTL	0.78	17.46	0.65	8.58e-52	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4253772	0.678	rs1055659	chr22:46638298	C/T	cg09491104	chr22:46646882	C22orf40	-0.53	-9.83	-0.43	1.11e-20	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs12620999	0.941	rs62183342	chr2:237979140	C/A	cg23555395	chr2:238036564	NA	0.59	9.08	0.4	4.27e-18	Systemic lupus erythematosus;
LUAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08280861	chr8:58055591	NA	0.78	9.33	0.41	6.16e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7582720	1.000	rs72926794	chr2:203827432	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg00383909	chr3:49044727	WDR6	0.44	6.68	0.31	7.47e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1997103	1.000	rs6953509	chr7:55412179	G/A	cg17469321	chr7:55412551	NA	0.67	11.32	0.48	3.95e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.87	0.36	3.06e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.32e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg14752069	chr8:11977206	FAM66D	-0.3	-6.58	-0.3	1.38e-10	Triglycerides;
LUAD	cis	rs1062746	0.771	rs10514621	chr16:87369578	G/T	cg02258303	chr16:87377426	FBXO31	-0.41	-7.22	-0.33	2.4e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg27454412	chr7:1067447	C7orf50	-0.44	-7.75	-0.35	6.72e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg01528321	chr10:82214614	TSPAN14	0.64	10.19	0.44	6e-22	Post bronchodilator FEV1;
LUAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08439880	chr3:133502540	NA	0.48	9.39	0.42	3.7e-19	Iron status biomarkers;
LUAD	cis	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.87	-0.36	2.94e-14	Neuroticism;
LUAD	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.5	-0.3	2.29e-10	Coronary artery disease;
LUAD	cis	rs1065656	0.563	rs391546	chr16:1915581	T/G	cg08610935	chr16:1836813	NUBP2	0.47	7.27	0.33	1.8e-12	Insulin-like growth factors;
LUAD	cis	rs6546550	1.000	rs6546550	chr2:70038232	C/G	cg02498382	chr2:70120550	SNRNP27	-0.53	-9.76	-0.43	2.01e-20	Prevalent atrial fibrillation;
LUAD	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg09035930	chr12:129282057	SLC15A4	0.42	8.73	0.39	5.97e-17	Systemic lupus erythematosus;
LUAD	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.89	0.32	1.98e-11	Hypertriglyceridemia;
LUAD	cis	rs4789939	0.528	rs2377003	chr17:76878902	T/C	cg13694343	chr17:76876206	TIMP2	-0.72	-8.07	-0.37	7.51e-15	Dupuytren's disease;
LUAD	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg27490568	chr2:178487706	NA	0.42	6.91	0.32	1.74e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6987853	0.966	rs2974349	chr8:42404040	A/G	cg09913449	chr8:42400586	C8orf40	-0.38	-7.0	-0.32	9.91e-12	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg12140854	chr5:148520817	ABLIM3	0.66	10.41	0.45	9.66e-23	Breast cancer;
LUAD	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg00255919	chr5:131827918	IRF1	0.5	11.9	0.5	2.21e-28	Asthma (sex interaction);
LUAD	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12618769	0.625	rs72819984	chr2:99044762	G/C	cg10123293	chr2:99228465	UNC50	0.46	8.25	0.37	1.99e-15	Bipolar disorder;
LUAD	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg23254163	chr1:152506842	NA	0.25	7.13	0.33	4.3e-12	Hair morphology;
LUAD	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg10755058	chr3:40428713	ENTPD3	-0.42	-7.97	-0.36	1.53e-14	Renal cell carcinoma;
LUAD	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg08885076	chr2:99613938	TSGA10	0.36	6.48	0.3	2.56e-10	Chronic sinus infection;
LUAD	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18876405	chr7:65276391	NA	-0.54	-9.28	-0.41	8.89e-19	Aortic root size;
LUAD	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg26727032	chr16:67993705	SLC12A4	0.44	6.61	0.31	1.16e-10	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg00717180	chr2:96193071	NA	-0.41	-7.23	-0.33	2.34e-12	Coronary artery disease;
LUAD	cis	rs1595825	1.000	rs56765024	chr2:198876286	G/T	cg11031976	chr2:198649780	BOLL	-0.43	-6.39	-0.3	4.34e-10	Ulcerative colitis;
LUAD	cis	rs7771547	0.642	rs605684	chr6:36493265	T/C	cg07856975	chr6:36356162	ETV7	0.42	6.49	0.3	2.42e-10	Platelet distribution width;
LUAD	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	9.1	0.4	3.57e-18	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.13e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg02002194	chr4:3960332	NA	-0.28	-6.68	-0.31	7.44e-11	Joint mobility (Beighton score);
LUAD	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	8.72	0.39	6.51e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg26384229	chr12:38710491	ALG10B	0.48	7.69	0.35	1.01e-13	Bladder cancer;
LUAD	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg14582100	chr15:45693742	SPATA5L1	0.38	7.53	0.34	3.03e-13	Glomerular filtration rate;
LUAD	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg27446573	chr6:127587934	RNF146	0.43	6.47	0.3	2.7e-10	Breast cancer;
LUAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg13047869	chr3:10149882	C3orf24	0.53	7.91	0.36	2.27e-14	Alzheimer's disease;
LUAD	trans	rs3812049	0.667	rs6888037	chr5:127406259	G/T	cg16011800	chr17:1958478	HIC1	-0.6	-8.48	-0.38	3.76e-16	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg25427524	chr10:38739819	LOC399744	0.56	10.0	0.44	2.8e-21	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6754311	0.593	rs313528	chr2:136445869	G/A	cg07305463	chr2:136567211	LCT	-0.34	-6.4	-0.3	4.13e-10	Mosquito bite size;
LUAD	cis	rs4629710	0.592	rs9492865	chr6:131534403	T/A	cg12606694	chr6:131520996	AKAP7	0.48	7.23	0.33	2.28e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg11814155	chr7:99998594	ZCWPW1	0.45	7.82	0.36	4.35e-14	Platelet count;
LUAD	cis	rs7215564	0.908	rs35128297	chr17:78652909	A/C	cg09596252	chr17:78655493	RPTOR	0.56	6.91	0.32	1.81e-11	Myopia (pathological);
LUAD	cis	rs17067123	0.614	rs72712851	chr4:180066258	A/G	cg26610307	chr4:180072759	NA	-0.52	-6.75	-0.31	4.86e-11	Response to hepatitis C treatment;
LUAD	cis	rs17102423	0.826	rs17825846	chr14:65598752	C/G	cg11161011	chr14:65562177	MAX	-0.44	-6.91	-0.32	1.83e-11	Obesity-related traits;
LUAD	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19717773	chr7:2847554	GNA12	-0.56	-9.65	-0.42	4.79e-20	Height;
LUAD	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg09263875	chr16:632152	PIGQ	0.8	17.18	0.64	1.51e-50	Height;
LUAD	cis	rs2235649	0.798	rs4100646	chr16:1850446	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-7.58	-0.35	2.27e-13	Blood metabolite levels;
LUAD	cis	rs61990749	0.597	rs2267758	chr14:78147429	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.5	-6.43	-0.3	3.42e-10	Fibroblast growth factor basic levels;
LUAD	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg13126279	chr21:47581558	C21orf56	-0.44	-7.56	-0.35	2.46e-13	Testicular germ cell tumor;
LUAD	cis	rs7241530	0.662	rs9946782	chr18:75888634	C/T	cg14642773	chr18:75888474	NA	0.33	6.7	0.31	6.47e-11	Educational attainment (years of education);
LUAD	cis	rs9837602	1.000	rs62285461	chr3:99767642	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.97	-0.32	1.25e-11	Breast cancer;
LUAD	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.85e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9341808	0.600	rs668329	chr6:80968578	G/A	cg08355045	chr6:80787529	NA	-0.47	-8.33	-0.38	1.1e-15	Sitting height ratio;
LUAD	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg15358701	chr1:161410459	NA	-0.72	-7.38	-0.34	8.67e-13	Rheumatoid arthritis;
LUAD	cis	rs10950821	0.505	rs6949755	chr7:20688042	C/G	cg02470904	chr7:20686108	ABCB5	0.43	7.84	0.36	3.6e-14	Response to statin therapy;
LUAD	trans	rs9929218	1.000	rs9282650	chr16:68809640	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.93	-0.56	1.47e-36	Colorectal cancer;
LUAD	cis	rs657075	0.697	rs57600888	chr5:131654053	C/A	cg21138405	chr5:131827807	IRF1	0.5	6.42	0.3	3.76e-10	Rheumatoid arthritis;
LUAD	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg08807101	chr21:30365312	RNF160	0.41	7.01	0.32	9.3e-12	Dental caries;
LUAD	cis	rs977987	0.806	rs4993970	chr16:75411619	G/A	cg03315344	chr16:75512273	CHST6	0.65	14.19	0.57	1.12e-37	Dupuytren's disease;
LUAD	cis	rs62229266	0.659	rs2835243	chr21:37413946	C/T	cg08632701	chr21:37451849	NA	-0.38	-6.44	-0.3	3.3e-10	Mitral valve prolapse;
LUAD	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg13319975	chr6:146136371	FBXO30	-0.64	-10.97	-0.47	8.3e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg21918786	chr6:109611834	NA	-0.51	-8.94	-0.4	1.25e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg14983838	chr19:29218262	NA	0.67	9.9	0.43	6.62e-21	Methadone dose in opioid dependence;
LUAD	cis	rs2279817	1.000	rs905389	chr1:18021406	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.58	9.74	0.43	2.31e-20	Neuroticism;
LUAD	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg09491104	chr22:46646882	C22orf40	-0.64	-7.95	-0.36	1.68e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg06808227	chr14:105710500	BRF1	0.39	6.38	0.3	4.69e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.19	0.37	3.05e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg17971929	chr21:40555470	PSMG1	0.51	7.77	0.35	6.2e-14	Cognitive function;
LUAD	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg02807482	chr3:125708958	NA	-0.64	-8.5	-0.38	3.4e-16	Blood pressure (smoking interaction);
LUAD	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg21194808	chr1:2205498	SKI	0.41	6.45	0.3	3.13e-10	Height;
LUAD	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-9.56	-0.42	1.02e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7771547	0.603	rs9296193	chr6:36601456	C/G	cg12173498	chr6:36355764	ETV7	-0.47	-6.42	-0.3	3.7e-10	Platelet distribution width;
LUAD	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg00071950	chr4:10020882	SLC2A9	-0.74	-14.58	-0.58	2.67e-39	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs17095355	1.000	rs7904096	chr10:111755319	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.77	-10.93	-0.47	1.16e-24	Biliary atresia;
LUAD	cis	rs1712517	0.873	rs1163083	chr10:105038455	T/A	cg05636881	chr10:105038444	INA	0.32	6.42	0.3	3.66e-10	Migraine;
LUAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02359409	chr6:42947317	PEX6	-0.38	-6.49	-0.3	2.41e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg22875332	chr1:76189707	ACADM	0.76	12.46	0.52	1.42e-30	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg19413350	chr8:57351067	NA	-0.42	-6.7	-0.31	6.48e-11	Obesity-related traits;
LUAD	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg07741184	chr6:167504864	NA	-0.3	-7.12	-0.33	4.52e-12	Crohn's disease;
LUAD	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.93	-0.32	1.61e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs1422110	0.641	rs12514639	chr5:85523929	C/T	cg01787110	chr1:109008453	NBPF6	-0.76	-12.47	-0.52	1.29e-30	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs490234	0.776	rs10115455	chr9:128458850	T/C	cg14078157	chr9:128172775	NA	-0.45	-8.44	-0.38	5.15e-16	Mean arterial pressure;
LUAD	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.49	8.05	0.36	8.71e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs4588572	0.644	rs7714871	chr5:77754268	G/T	cg11547950	chr5:77652471	NA	-0.63	-10.65	-0.46	1.23e-23	Triglycerides;
LUAD	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg24101359	chr6:42928495	GNMT	0.44	8.25	0.37	1.99e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg13722127	chr7:150037890	RARRES2	0.52	9.16	0.41	2.2e-18	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs17067123	0.614	rs6813463	chr4:180068739	A/T	cg26610307	chr4:180072759	NA	-0.52	-6.75	-0.31	4.86e-11	Response to hepatitis C treatment;
LUAD	cis	rs10950821	0.734	rs11769236	chr7:20685786	G/A	cg02470904	chr7:20686108	ABCB5	0.38	6.46	0.3	2.87e-10	Response to statin therapy;
LUAD	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg03983476	chr2:10830698	NOL10	-0.47	-8.19	-0.37	3.08e-15	Prostate cancer;
LUAD	cis	rs13082711	0.911	rs36101969	chr3:27438181	G/A	cg02860705	chr3:27208620	NA	0.6	9.28	0.41	8.64e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs4660214	0.666	rs10888682	chr1:39623307	A/T	cg27567593	chr1:39956653	BMP8A	0.32	6.36	0.3	5.35e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2425143	0.908	rs74784474	chr20:34422464	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.78	-0.31	4.12e-11	Blood protein levels;
LUAD	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg12035532	chr1:1886765	KIAA1751	0.41	6.77	0.31	4.35e-11	Body mass index;
LUAD	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.3	-6.49	-0.3	2.46e-10	Blood metabolite levels;
LUAD	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2735413	0.918	rs12598024	chr16:78079114	G/A	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs1816752	0.870	rs7320102	chr13:25011573	T/C	cg02811702	chr13:24901961	NA	0.46	7.95	0.36	1.7e-14	Obesity-related traits;
LUAD	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	9.42	0.42	2.87e-19	Lung cancer in ever smokers;
LUAD	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.21	-0.33	2.52e-12	Blood metabolite levels;
LUAD	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg13870426	chr17:30244630	NA	-0.56	-6.61	-0.31	1.18e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg17757837	chr7:157058334	UBE3C	0.47	8.25	0.37	1.96e-15	Body mass index;
LUAD	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg17346650	chr17:80929145	B3GNTL1	0.39	6.83	0.32	3.01e-11	Glycated hemoglobin levels;
LUAD	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg20203395	chr5:56204925	C5orf35	0.64	9.84	0.43	1.02e-20	Initial pursuit acceleration;
LUAD	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg00316803	chr15:76480434	C15orf27	-0.39	-7.28	-0.33	1.6e-12	Blood metabolite levels;
LUAD	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.44	-6.73	-0.31	5.56e-11	Bronchopulmonary dysplasia;
LUAD	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-19.92	-0.7	9.21e-63	Height;
LUAD	cis	rs4523957	0.583	rs2957926	chr17:2024030	C/T	cg16513277	chr17:2031491	SMG6	-0.95	-19.14	-0.68	2.98e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.53	-0.3	1.94e-10	Prostate cancer;
LUAD	cis	rs2692947	0.740	rs4907280	chr2:96402126	A/G	cg23100626	chr2:96804247	ASTL	0.31	7.6	0.35	1.97e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg01579765	chr21:45077557	HSF2BP	-0.58	-13.47	-0.55	1.11e-34	Mean corpuscular volume;
LUAD	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.21	0.33	2.63e-12	Motion sickness;
LUAD	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23158103	chr7:148848205	ZNF398	-0.44	-7.62	-0.35	1.7e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg13319975	chr6:146136371	FBXO30	-0.55	-9.13	-0.41	2.75e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg02683114	chr2:24398427	C2orf84	-0.52	-7.7	-0.35	9.92e-14	Asthma;
LUAD	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06873352	chr17:61820015	STRADA	0.53	8.72	0.39	6.34e-17	Height;
LUAD	cis	rs10992471	0.528	rs7031567	chr9:95241363	A/G	cg14631576	chr9:95140430	CENPP	-0.49	-10.1	-0.44	1.21e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11644478	chr21:40555479	PSMG1	0.56	9.12	0.41	3.15e-18	Cognitive function;
LUAD	cis	rs6684514	1.000	rs12041164	chr1:156279811	G/A	cg16558208	chr1:156270281	VHLL	0.53	9.65	0.42	4.74e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg08601574	chr20:25228251	PYGB	0.48	9.0	0.4	7.68e-18	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs3960554	0.808	rs78587454	chr7:75688672	G/A	cg19862616	chr7:65841803	NCRNA00174	0.82	11.03	0.47	4.74e-25	Eotaxin levels;
LUAD	cis	rs8072100	0.869	rs4439799	chr17:45781599	C/T	cg07432352	chr17:45403706	C17orf57	0.39	7.43	0.34	6.18e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07003055	chr20:3776921	CDC25B	-0.4	-6.63	-0.31	1.01e-10	Cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13165422	chr6:52926772	ICK	-0.54	-6.42	-0.3	3.57e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs55665837	0.961	rs12795972	chr11:14443775	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-10.33	-0.45	1.85e-22	Vitamin D levels;
LUAD	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg15445000	chr17:37608096	MED1	-0.45	-8.37	-0.38	8.21e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs17155006	0.664	rs402113	chr7:107743664	A/G	cg05962710	chr7:107745446	LAMB4	-0.35	-7.33	-0.34	1.18e-12	Pneumococcal bacteremia;
LUAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg24829409	chr8:58192753	C8orf71	-0.6	-7.14	-0.33	4.09e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg05991184	chr2:219186017	PNKD	-0.38	-7.39	-0.34	8.12e-13	Colorectal cancer;
LUAD	cis	rs6714710	0.580	rs57681139	chr2:98454473	C/T	cg26665480	chr2:98280029	ACTR1B	0.5	8.19	0.37	3.17e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg02569458	chr12:86230093	RASSF9	0.44	8.17	0.37	3.69e-15	Major depressive disorder;
LUAD	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.18	0.37	3.33e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg03213289	chr20:61660250	NA	0.68	14.81	0.58	2.79e-40	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg18827107	chr12:86230957	RASSF9	-0.54	-9.58	-0.42	8.58e-20	Major depressive disorder;
LUAD	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-12.87	-0.53	3.16e-32	Breast cancer;
LUAD	cis	rs2030114	0.531	rs1072858	chr16:51593364	C/T	cg03758633	chr16:51611768	NA	0.33	6.87	0.32	2.28e-11	Blood pressure measurement (high sodium and potassium intervention);
LUAD	cis	rs9972944	0.756	rs6504350	chr17:63764336	G/A	cg07283582	chr17:63770753	CCDC46	-0.5	-11.19	-0.48	1.24e-25	Total body bone mineral density;
LUAD	cis	rs1003719	0.688	rs2835660	chr21:38568882	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.2	-0.37	2.89e-15	Eye color traits;
LUAD	cis	rs897984	0.520	rs12928081	chr16:30885159	T/G	cg02466173	chr16:30829666	NA	0.64	10.2	0.44	5.31e-22	Dementia with Lewy bodies;
LUAD	cis	rs5758511	0.514	rs5751240	chr22:42595258	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.66	11.21	0.48	9.9e-26	Birth weight;
LUAD	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg14983838	chr19:29218262	NA	0.64	10.05	0.44	1.88e-21	Methadone dose in opioid dependence;
LUAD	cis	rs1497828	0.912	rs2646825	chr1:217539194	A/G	cg04411442	chr1:217543379	NA	-0.38	-6.81	-0.31	3.43e-11	Dialysis-related mortality;
LUAD	cis	rs7520050	0.966	rs12405451	chr1:46384326	T/A	cg06784218	chr1:46089804	CCDC17	-0.3	-6.35	-0.3	5.43e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs921968	1.000	rs56191141	chr2:219272145	A/G	cg02176678	chr2:219576539	TTLL4	-0.67	-12.69	-0.53	1.76e-31	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	8.62	0.39	1.35e-16	Lung cancer in ever smokers;
LUAD	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg13319975	chr6:146136371	FBXO30	0.62	11.03	0.47	4.92e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04063615	chr12:132293388	NA	-0.44	-8.4	-0.38	6.73e-16	Migraine;
LUAD	trans	rs7395662	0.816	rs11039764	chr11:48484616	T/C	cg00717180	chr2:96193071	NA	-0.4	-7.46	-0.34	4.93e-13	HDL cholesterol;
LUAD	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg20362242	chr5:692897	TPPP	0.6	7.38	0.34	8.64e-13	Obesity-related traits;
LUAD	cis	rs6594713	0.851	rs13171482	chr5:112701966	G/A	cg12552261	chr5:112820674	MCC	0.49	8.07	0.37	7.1e-15	Brain cytoarchitecture;
LUAD	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg21153622	chr11:89784906	NA	-0.34	-6.52	-0.3	1.97e-10	Coronary artery disease;
LUAD	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg08859206	chr1:53392774	SCP2	-0.59	-10.76	-0.46	4.86e-24	Monocyte count;
LUAD	cis	rs2286885	1.000	rs4837093	chr9:129254443	G/A	cg15282417	chr9:129245246	FAM125B	0.43	8.82	0.39	2.97e-17	Intraocular pressure;
LUAD	cis	rs6740322	0.644	rs11690918	chr2:43474112	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-10.13	-0.44	9.41e-22	Coronary artery disease;
LUAD	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg00074818	chr8:8560427	CLDN23	0.66	10.17	0.44	6.95e-22	Obesity-related traits;
LUAD	cis	rs10489202	0.608	rs35059151	chr1:168079393	C/A	cg25738037	chr1:168025549	DCAF6	-0.44	-6.62	-0.31	1.12e-10	Schizophrenia;
LUAD	cis	rs4072705	0.615	rs7851737	chr9:127247931	G/A	cg01786973	chr9:127249749	NR5A1	-0.29	-6.4	-0.3	4.14e-10	Menarche (age at onset);
LUAD	trans	rs9929218	0.954	rs2961	chr16:68818903	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.64	-0.55	2.37e-35	Colorectal cancer;
LUAD	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	8.03	0.36	9.54e-15	Menopause (age at onset);
LUAD	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg24069376	chr3:38537580	EXOG	0.46	11.21	0.48	1.02e-25	Electrocardiographic conduction measures;
LUAD	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg17177755	chr1:15930204	NA	0.45	7.26	0.33	1.82e-12	Systolic blood pressure;
LUAD	cis	rs9972944	0.691	rs10083837	chr17:63775311	C/G	cg07283582	chr17:63770753	CCDC46	0.47	10.1	0.44	1.2e-21	Total body bone mineral density;
LUAD	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg08779649	chr13:50194554	NA	0.41	8.19	0.37	3.18e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs2455799	0.896	rs2470533	chr3:15698093	G/A	cg16303742	chr3:15540471	COLQ	-0.39	-6.54	-0.3	1.83e-10	Mean platelet volume;
LUAD	trans	rs783540	0.967	rs4779044	chr15:83339353	A/C	cg18393722	chr15:85113863	UBE2QP1	0.45	7.35	0.34	1.02e-12	Schizophrenia;
LUAD	cis	rs9326248	0.581	rs12804122	chr11:116902616	C/G	cg20608306	chr11:116969690	SIK3	0.32	7.11	0.33	5.12e-12	Blood protein levels;
LUAD	cis	rs6546550	0.901	rs6546559	chr2:70145833	G/A	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.0	-0.47	6.47e-25	Prevalent atrial fibrillation;
LUAD	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.82	-0.56	4.08e-36	Breast cancer;
LUAD	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg00745463	chr17:30367425	LRRC37B	-0.83	-10.22	-0.44	4.68e-22	Hip circumference adjusted for BMI;
LUAD	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg11344533	chr11:111475393	SIK2	-0.35	-6.68	-0.31	7.77e-11	Primary sclerosing cholangitis;
LUAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg24846343	chr22:24311635	DDTL	0.78	17.36	0.65	2.31e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6061231	0.597	rs624313	chr20:60927412	G/A	cg24112000	chr20:60950667	NA	0.76	13.0	0.53	9.65e-33	Colorectal cancer;
LUAD	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg02569458	chr12:86230093	RASSF9	0.42	7.99	0.36	1.29e-14	Major depressive disorder;
LUAD	cis	rs1697139	0.935	rs1627990	chr5:66513326	C/T	cg11553311	chr5:66541588	NA	0.35	6.64	0.31	9.61e-11	Breast cancer;
LUAD	cis	rs7267979	0.816	rs6138593	chr20:25504492	A/G	cg08601574	chr20:25228251	PYGB	0.4	7.46	0.34	4.83e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg20503657	chr10:835505	NA	1.25	18.38	0.67	7.13e-56	Eosinophil percentage of granulocytes;
LUAD	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg23711669	chr6:146136114	FBXO30	-0.38	-6.44	-0.3	3.35e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg14779329	chr11:130786720	SNX19	0.39	6.84	0.32	2.74e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg01765077	chr12:122356316	WDR66	0.53	9.17	0.41	2.02e-18	Mean corpuscular volume;
LUAD	trans	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg21659725	chr3:3221576	CRBN	0.71	10.93	0.47	1.13e-24	Resting heart rate;
LUAD	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg04000281	chr11:63949212	NA	-0.29	-6.64	-0.31	9.36e-11	Platelet count;
LUAD	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg24675658	chr1:53192096	ZYG11B	-0.42	-6.99	-0.32	1.11e-11	Monocyte count;
LUAD	cis	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.9	-0.36	2.45e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs970548	0.688	rs2082109	chr10:45931102	T/C	cg14222797	chr10:16859974	RSU1	-0.54	-6.65	-0.31	9.25e-11	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUAD	trans	rs12517041	1.000	rs7737671	chr5:23288400	C/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.48	-0.3	2.61e-10	Calcium levels;
LUAD	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg05283184	chr6:79620031	NA	-0.61	-12.28	-0.51	7.22e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg14196790	chr5:131705035	SLC22A5	-0.46	-8.31	-0.37	1.31e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs13315871	0.929	rs11720747	chr3:58267833	G/A	cg12435725	chr3:58293450	RPP14	-0.7	-7.33	-0.34	1.15e-12	Cholesterol, total;
LUAD	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg21918786	chr6:109611834	NA	-0.59	-11.21	-0.48	1.01e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg00530320	chr1:46809349	NSUN4	0.52	7.89	0.36	2.56e-14	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7665090	0.806	rs434644	chr4:103583189	A/C	cg07973026	chr4:103553119	MANBA	-0.41	-7.1	-0.33	5.2e-12	Primary biliary cholangitis;
LUAD	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.19	-0.41	1.81e-18	Bipolar disorder;
LUAD	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.2	0.33	2.86e-12	Hip circumference adjusted for BMI;
LUAD	trans	rs629535	0.862	rs598548	chr8:70032438	C/T	cg21567404	chr3:27674614	NA	1.01	18.57	0.67	9.52e-57	Dupuytren's disease;
LUAD	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.52	-0.34	3.39e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg26587870	chr6:27730563	NA	-0.68	-7.31	-0.33	1.37e-12	Depression;
LUAD	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg16479474	chr6:28041457	NA	0.46	7.94	0.36	1.8e-14	Depression;
LUAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg27454412	chr7:1067447	C7orf50	0.48	7.72	0.35	8.28e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg12436631	chr1:155007014	DCST1;DCST2	0.29	6.73	0.31	5.55e-11	Prostate cancer;
LUAD	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg06873352	chr17:61820015	STRADA	0.41	6.85	0.32	2.62e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.55	-10.26	-0.45	3.41e-22	Longevity;Endometriosis;
LUAD	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	10.93	0.47	1.15e-24	Hip circumference adjusted for BMI;
LUAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg22105103	chr4:187893119	NA	0.57	12.61	0.52	3.6e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7119	0.651	rs12905044	chr15:77846215	G/A	cg27398640	chr15:77910606	LINGO1	-0.36	-6.61	-0.31	1.13e-10	Type 2 diabetes;
LUAD	cis	rs754466	1.000	rs67059283	chr10:79683235	C/T	cg17075019	chr10:79541650	NA	-0.83	-13.74	-0.56	8.56e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg15605315	chr1:45957053	TESK2	0.5	7.8	0.35	4.84e-14	High light scatter reticulocyte count;
LUAD	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg18016565	chr1:150552671	MCL1	0.41	7.58	0.35	2.14e-13	Tonsillectomy;
LUAD	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg26898376	chr11:64110657	CCDC88B	0.36	6.49	0.3	2.47e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg00933542	chr6:150070202	PCMT1	0.41	8.35	0.38	9.69e-16	Lung cancer;
LUAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg16606324	chr3:10149918	C3orf24	0.59	9.52	0.42	1.37e-19	Alzheimer's disease;
LUAD	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg17346650	chr17:80929145	B3GNTL1	0.41	7.12	0.33	4.68e-12	Glycated hemoglobin levels;
LUAD	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14240646	chr10:27532245	ACBD5	-0.79	-11.06	-0.47	3.92e-25	Breast cancer;
LUAD	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg09323728	chr8:95962352	TP53INP1	-0.27	-6.45	-0.3	3.06e-10	Type 2 diabetes;
LUAD	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18876405	chr7:65276391	NA	-0.44	-6.91	-0.32	1.83e-11	Aortic root size;
LUAD	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg19442545	chr10:75533431	FUT11	-0.48	-7.95	-0.36	1.74e-14	Inflammatory bowel disease;
LUAD	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg15704280	chr7:45808275	SEPT13	-1.07	-24.46	-0.77	5.37e-83	Height;
LUAD	cis	rs2535633	0.631	rs2245424	chr3:53003021	G/C	cg11645453	chr3:52864694	ITIH4	-0.37	-7.13	-0.33	4.27e-12	Body mass index;
LUAD	cis	rs2455601	0.638	rs11042148	chr11:9008674	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.49	-8.81	-0.39	3.38e-17	Schizophrenia;
LUAD	cis	rs9925964	0.591	rs11649653	chr16:30918487	C/G	cg02466173	chr16:30829666	NA	0.44	7.65	0.35	1.34e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg07776626	chr8:57350775	NA	-0.6	-8.85	-0.4	2.45e-17	Obesity-related traits;
LUAD	cis	rs62238980	0.614	rs77511414	chr22:32406941	A/T	cg00543991	chr22:32367038	NA	0.96	9.05	0.4	5.32e-18	Childhood ear infection;
LUAD	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.42	-6.76	-0.31	4.66e-11	Tonsillectomy;
LUAD	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg00316803	chr15:76480434	C15orf27	-0.39	-7.32	-0.34	1.25e-12	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08677398	chr8:58056175	NA	0.47	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7759001	0.857	rs4713094	chr6:27373078	G/A	cg18711553	chr6:27366782	ZNF391	0.39	6.41	0.3	3.97e-10	Glomerular filtration rate (creatinine);
LUAD	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg03929089	chr4:120376271	NA	-0.93	-17.47	-0.65	7.35e-52	Height;
LUAD	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg26384229	chr12:38710491	ALG10B	0.43	7.02	0.32	8.81e-12	Morning vs. evening chronotype;
LUAD	cis	rs12286929	0.609	rs7479259	chr11:115090715	T/A	cg04055981	chr11:115044050	NA	0.41	7.16	0.33	3.63e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg01765077	chr12:122356316	WDR66	0.51	8.63	0.39	1.24e-16	Mean corpuscular volume;
LUAD	cis	rs2109514	0.561	rs4273775	chr7:116094656	T/C	cg04696780	chr7:116139425	CAV2	-0.32	-7.27	-0.33	1.7e-12	Prevalent atrial fibrillation;
LUAD	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg01191920	chr7:158217561	PTPRN2	-0.7	-15.52	-0.6	2.48e-43	Obesity-related traits;
LUAD	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg01849466	chr14:104193079	ZFYVE21	0.46	7.84	0.36	3.61e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg08805041	chr16:621841	PIGQ	-0.32	-6.53	-0.3	1.88e-10	Height;
LUAD	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg05727186	chr17:43697356	MGC57346	-0.53	-6.67	-0.31	8.02e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06028808	chr11:68637592	NA	0.48	8.09	0.37	6.31e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.12	0.33	4.65e-12	Motion sickness;
LUAD	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	8.67	0.39	9.24e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.27	-0.33	1.77e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-14.78	-0.58	3.73e-40	Schizophrenia;
LUAD	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg22467129	chr15:76604101	ETFA	-0.47	-7.79	-0.35	5.38e-14	Blood metabolite levels;
LUAD	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg19761014	chr17:28927070	LRRC37B2	0.86	8.36	0.38	9.21e-16	Body mass index;
LUAD	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.59e-12	Crohn's disease;
LUAD	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg06671706	chr8:8559999	CLDN23	0.6	10.16	0.44	7.45e-22	Obesity-related traits;
LUAD	trans	rs7246760	0.867	rs889177	chr19:9846225	C/T	cg02900749	chr2:68251473	NA	-0.65	-6.93	-0.32	1.59e-11	Pursuit maintenance gain;
LUAD	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg09033577	chr2:88485744	THNSL2	0.56	6.58	0.3	1.43e-10	Plasma clusterin levels;
LUAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg18621852	chr3:10150065	C3orf24	-0.48	-8.38	-0.38	8.08e-16	Alzheimer's disease;
LUAD	cis	rs4660306	1.000	rs1044717	chr1:45976587	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.52	-8.17	-0.37	3.71e-15	Homocysteine levels;
LUAD	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.58	0.3	1.35e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.88	-0.32	2.16e-11	Reticulocyte count;
LUAD	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg18305652	chr10:134549665	INPP5A	0.62	11.94	0.5	1.65e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6693567	0.565	rs1313570	chr1:150342642	T/C	cg15654264	chr1:150340011	RPRD2	0.36	6.4	0.3	4.24e-10	Migraine;
LUAD	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21659725	chr3:3221576	CRBN	-0.86	-18.46	-0.67	3.21e-56	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg26314531	chr2:26401878	FAM59B	0.61	7.72	0.35	8.55e-14	Gut microbiome composition (summer);
LUAD	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg04414720	chr1:150670196	GOLPH3L	0.74	13.83	0.56	3.6e-36	Tonsillectomy;
LUAD	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg05373962	chr22:49881684	NA	-0.48	-9.99	-0.44	3.08e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg13732083	chr21:47605072	C21orf56	0.41	6.82	0.31	3.2e-11	Testicular germ cell tumor;
LUAD	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.61	-0.35	1.83e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs853679	0.607	rs72846780	chr6:28119055	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.56	6.53	0.3	1.91e-10	Depression;
LUAD	cis	rs6901004	0.935	rs1150078	chr6:111560301	C/T	cg15721981	chr6:111408429	SLC16A10	0.39	6.53	0.3	1.92e-10	Blood metabolite levels;
LUAD	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg13854012	chr2:162103682	NA	-0.46	-9.09	-0.4	3.94e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	cis	rs1595825	0.891	rs77706948	chr2:198608441	T/G	cg00361562	chr2:198649771	BOLL	-0.5	-6.74	-0.31	5.06e-11	Ulcerative colitis;
LUAD	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.52	8.62	0.39	1.33e-16	Electrocardiographic conduction measures;
LUAD	trans	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg16011800	chr17:1958478	HIC1	-0.58	-8.19	-0.37	3.24e-15	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1003719	0.751	rs10154032	chr21:38453459	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.45	0.38	4.63e-16	Eye color traits;
LUAD	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg07741184	chr6:167504864	NA	0.36	8.17	0.37	3.66e-15	Primary biliary cholangitis;
LUAD	cis	rs8062405	0.931	rs12928404	chr16:28847246	T/C	cg05966235	chr16:28915196	ATP2A1	0.43	6.87	0.32	2.37e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2806561	0.929	rs2867315	chr1:23541286	C/T	cg19743168	chr1:23544995	NA	-0.45	-8.39	-0.38	7.55e-16	Height;
LUAD	cis	rs6674970	0.627	rs2864700	chr1:151028929	C/T	cg11822372	chr1:151115635	SEMA6C	0.43	6.97	0.32	1.23e-11	Childhood ear infection;
LUAD	cis	rs2797685	0.945	rs1773138	chr1:7891797	C/T	cg04725166	chr1:7887271	PER3	-0.48	-7.09	-0.33	5.75e-12	Crohn's disease;
LUAD	cis	rs6500395	1.000	rs1872654	chr16:48671050	C/T	cg04672837	chr16:48644449	N4BP1	0.39	6.73	0.31	5.71e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg16060761	chr17:80687452	NA	0.48	7.18	0.33	3.13e-12	Breast cancer;
LUAD	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.45	-0.38	4.65e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg22823121	chr1:150693482	HORMAD1	0.45	8.99	0.4	8.07e-18	Tonsillectomy;
LUAD	cis	rs6546550	0.901	rs11893500	chr2:70154187	T/C	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.0	-0.47	6.47e-25	Prevalent atrial fibrillation;
LUAD	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg05340658	chr4:99064831	C4orf37	0.53	8.98	0.4	8.67e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg12927641	chr6:109611667	NA	-0.47	-8.04	-0.36	9.31e-15	Reticulocyte fraction of red cells;
LUAD	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs7107174	1.000	rs2511171	chr11:77930935	G/A	cg19901956	chr11:77921274	USP35	-0.53	-6.48	-0.3	2.61e-10	Testicular germ cell tumor;
LUAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg13560548	chr3:10150139	C3orf24	0.39	6.41	0.3	3.81e-10	Alzheimer's disease;
LUAD	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.53	-9.18	-0.41	1.86e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg22676075	chr6:135203613	NA	0.52	9.15	0.41	2.45e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg07538946	chr5:131705188	SLC22A5	0.47	7.69	0.35	1.08e-13	Blood metabolite levels;
LUAD	cis	rs11112613	0.713	rs68053161	chr12:105950035	G/C	cg03607813	chr12:105948248	NA	0.82	13.87	0.56	2.64e-36	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs2485376	0.900	rs56115161	chr10:104079091	C/A	cg20641465	chr10:103991465	PITX3	-0.57	-10.64	-0.46	1.38e-23	QT interval;
LUAD	cis	rs7759001	0.857	rs10080567	chr6:27363058	G/C	cg18711553	chr6:27366782	ZNF391	0.39	6.54	0.3	1.81e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg19700328	chr14:106028568	NA	-0.46	-7.82	-0.36	4.26e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-7.6	-0.35	1.91e-13	Neutrophil percentage of white cells;
LUAD	cis	rs738322	0.555	rs5750547	chr22:38546700	A/G	cg25457927	chr22:38595422	NA	0.52	12.0	0.5	9.73e-29	Cutaneous nevi;
LUAD	cis	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg07460842	chr6:66804631	NA	0.95	12.62	0.52	3.33e-31	Exhaled nitric oxide output;
LUAD	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg07757535	chr4:1339547	NA	0.3	6.68	0.31	7.59e-11	Longevity;
LUAD	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg06640241	chr16:89574553	SPG7	0.71	12.76	0.53	8.76e-32	Multiple myeloma (IgH translocation);
LUAD	cis	rs35883536	0.647	rs10875315	chr1:101044062	G/A	cg06223162	chr1:101003688	GPR88	-0.47	-9.21	-0.41	1.51e-18	Monocyte count;
LUAD	cis	rs10504073	0.669	rs57085792	chr8:50018355	T/C	cg00325661	chr8:49890786	NA	0.43	9.81	0.43	1.34e-20	Blood metabolite ratios;
LUAD	cis	rs7769051	0.521	rs9321367	chr6:133084359	G/T	cg22852734	chr6:133119734	C6orf192	0.64	6.39	0.3	4.47e-10	Type 2 diabetes nephropathy;
LUAD	trans	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-9.63	-0.42	5.71e-20	Endometrial cancer;
LUAD	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg00852783	chr1:26633632	UBXN11	0.42	7.45	0.34	5.34e-13	Obesity-related traits;
LUAD	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.44	8.03	0.36	9.56e-15	Type 2 diabetes;
LUAD	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg21220214	chr8:57350948	NA	-0.6	-8.9	-0.4	1.68e-17	Obesity-related traits;
LUAD	cis	rs7737355	0.755	rs1151481	chr5:130926374	A/C	cg06307176	chr5:131281290	NA	0.42	6.77	0.31	4.37e-11	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.773	rs32111	chr5:131046708	T/C	cg06307176	chr5:131281290	NA	0.46	7.64	0.35	1.48e-13	Life satisfaction;
LUAD	cis	rs12347191	0.500	rs907582	chr9:100621926	T/C	cg13688889	chr9:100608707	NA	-0.62	-10.09	-0.44	1.38e-21	Orofacial clefts;
LUAD	cis	rs870825	0.929	rs2310102	chr4:185595141	C/G	cg04058563	chr4:185651563	MLF1IP	-0.75	-10.79	-0.46	3.99e-24	Blood protein levels;
LUAD	cis	rs2742234	0.590	rs2257767	chr10:43657811	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.53	-8.98	-0.4	8.68e-18	Hirschsprung disease;
LUAD	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg04287289	chr16:89883240	FANCA	0.79	7.04	0.32	7.89e-12	Skin colour saturation;
LUAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	6.42	0.3	3.57e-10	Prudent dietary pattern;
LUAD	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11890956	chr21:40555474	PSMG1	-0.64	-10.83	-0.47	2.73e-24	Cognitive function;
LUAD	trans	rs1493916	0.606	rs10432168	chr18:31312106	T/C	cg27147174	chr7:100797783	AP1S1	-0.59	-9.83	-0.43	1.16e-20	Life satisfaction;
LUAD	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg07828340	chr4:882639	GAK	0.98	10.05	0.44	1.9e-21	Parkinson's disease;
LUAD	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg18230493	chr5:56204884	C5orf35	-0.87	-12.62	-0.52	3.35e-31	Initial pursuit acceleration;
LUAD	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg11502198	chr6:26597334	ABT1	0.56	9.24	0.41	1.22e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs9487051	0.735	rs351745	chr6:109529169	C/T	cg12927641	chr6:109611667	NA	0.38	6.59	0.31	1.28e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs8177876	0.908	rs80187824	chr16:81118680	T/C	cg08591886	chr16:81111003	C16orf46	-0.8	-7.39	-0.34	7.72e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7127900	0.583	rs11043140	chr11:2233951	T/C	cg25635251	chr11:2234043	NA	1.04	20.99	0.71	1.58e-67	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
LUAD	cis	rs68170813	0.652	rs12533694	chr7:107102817	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-8.99	-0.4	8.3e-18	Coronary artery disease;
LUAD	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg03037974	chr15:76606532	NA	0.39	8.3	0.37	1.41e-15	Blood metabolite levels;
LUAD	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg19774624	chr17:42201019	HDAC5	0.4	6.98	0.32	1.14e-11	Total body bone mineral density;
LUAD	cis	rs2048656	0.598	rs7846399	chr8:9493129	T/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.75	-0.31	4.79e-11	Schizophrenia;
LUAD	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg11707310	chr1:2537719	MMEL1	0.38	7.91	0.36	2.33e-14	Ulcerative colitis;
LUAD	cis	rs2046867	0.908	rs28822756	chr3:72825011	C/T	cg25664220	chr3:72788482	NA	-0.6	-10.95	-0.47	9.49e-25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg08523384	chr5:141488047	NDFIP1	-0.48	-7.28	-0.33	1.62e-12	Crohn's disease;
LUAD	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg04944784	chr2:26401820	FAM59B	-0.87	-12.58	-0.52	4.71e-31	Gut microbiome composition (summer);
LUAD	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg08355456	chr11:67383691	NA	-0.46	-6.54	-0.3	1.83e-10	Mean corpuscular volume;
LUAD	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg13385794	chr1:248469461	NA	0.26	7.14	0.33	4.14e-12	Common traits (Other);
LUAD	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg08773314	chr2:239334832	ASB1	0.44	10.29	0.45	2.61e-22	Multiple system atrophy;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg04729594	chr2:33172444	LTBP1	-0.44	-6.78	-0.31	4.12e-11	Blood protein levels;
LUAD	cis	rs1595825	1.000	rs73058832	chr2:198873214	G/T	cg11031976	chr2:198649780	BOLL	-0.46	-6.65	-0.31	8.92e-11	Ulcerative colitis;
LUAD	cis	rs12200560	0.505	rs1988040	chr6:97076271	G/A	cg06623918	chr6:96969491	KIAA0776	0.47	7.3	0.33	1.44e-12	Coronary heart disease;
LUAD	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.49	0.52	1.0500000000000001e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg01620082	chr3:125678407	NA	-0.66	-7.53	-0.34	3.06e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06544989	chr22:39130855	UNC84B	0.44	8.19	0.37	3.06e-15	Menopause (age at onset);
LUAD	cis	rs7520050	0.966	rs11211199	chr1:46287869	T/C	cg06784218	chr1:46089804	CCDC17	-0.3	-6.37	-0.3	4.88e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg13319975	chr6:146136371	FBXO30	-0.65	-11.34	-0.48	3.32e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg02951883	chr7:2050386	MAD1L1	-0.8	-13.21	-0.54	1.28e-33	Bipolar disorder and schizophrenia;
LUAD	cis	rs9462027	0.583	rs2814949	chr6:34656722	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-8.44	-0.38	5.27e-16	Systemic lupus erythematosus;
LUAD	cis	rs11168351	0.927	rs7971880	chr12:48391055	C/T	cg04545296	chr12:48745243	ZNF641	0.32	8.11	0.37	5.46e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.56	0.38	2.15e-16	Menarche (age at onset);
LUAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.47	0.3	2.78e-10	Prudent dietary pattern;
LUAD	cis	rs68170813	0.617	rs2283041	chr7:107190415	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-8.83	-0.39	2.71e-17	Coronary artery disease;
LUAD	cis	rs10865541	0.869	rs6711292	chr2:3422170	A/T	cg22182287	chr2:3452347	TTC15	0.46	7.81	0.35	4.56e-14	Obesity-related traits;
LUAD	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg22496339	chr2:162101262	NA	0.73	13.52	0.55	7.32e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	cis	rs12618769	0.597	rs72821951	chr2:99157009	A/C	cg10123293	chr2:99228465	UNC50	0.49	8.87	0.4	2.1e-17	Bipolar disorder;
LUAD	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.45	0.3	2.98e-10	Depression;
LUAD	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg26384229	chr12:38710491	ALG10B	0.52	8.61	0.39	1.47e-16	Heart rate;
LUAD	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.79	-0.35	5.37e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg08601574	chr20:25228251	PYGB	-0.47	-8.83	-0.39	2.84e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg18230493	chr5:56204884	C5orf35	-0.49	-7.84	-0.36	3.81e-14	Coronary artery disease;
LUAD	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg03733263	chr8:22462867	KIAA1967	0.56	9.35	0.41	4.95e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg24531977	chr5:56204891	C5orf35	-0.58	-9.41	-0.42	3.3e-19	Coronary artery disease;
LUAD	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg08999081	chr20:33150536	PIGU	-0.57	-12.42	-0.52	2.11e-30	Glomerular filtration rate (creatinine);
LUAD	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.61	0.35	1.8e-13	Cannabis dependence symptom count;
LUAD	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.59e-12	Crohn's disease;
LUAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07167872	chr1:205819463	PM20D1	0.6	11.03	0.47	4.86e-25	Menarche (age at onset);
LUAD	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg07636037	chr3:49044803	WDR6	0.63	12.12	0.51	3.31e-29	Parkinson's disease;
LUAD	cis	rs7584330	0.554	rs56853932	chr2:238428327	T/C	cg14458575	chr2:238380390	NA	0.64	10.33	0.45	1.82e-22	Prostate cancer;
LUAD	cis	rs11048434	0.761	rs12824380	chr12:9132017	A/G	cg23795048	chr12:9217529	LOC144571	0.45	8.28	0.37	1.59e-15	Sjögren's syndrome;
LUAD	cis	rs7017914	0.967	rs6987007	chr8:71600942	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.61	-0.31	1.13e-10	Bone mineral density;
LUAD	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg12062639	chr20:23401060	NAPB	1.1	11.43	0.49	1.54e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs701145	0.537	rs377565	chr3:153921953	A/G	cg17054900	chr3:154042577	DHX36	0.66	7.49	0.34	3.95e-13	Coronary artery disease;
LUAD	cis	rs1478897	0.898	rs2248700	chr8:11393745	G/A	cg27411982	chr8:10470053	RP1L1	-0.37	-6.4	-0.3	4.22e-10	Systemic lupus erythematosus;
LUAD	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.66	-0.61	6.36e-44	Eye color traits;
LUAD	cis	rs12900413	0.673	rs35308090	chr15:90308026	G/T	cg24249390	chr15:90295951	MESP1	-0.34	-6.57	-0.3	1.52e-10	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg17644776	chr2:200775616	C2orf69	0.53	7.68	0.35	1.15e-13	Schizophrenia;
LUAD	cis	rs731174	0.797	rs678511	chr1:38156427	T/C	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.29	-6.59	-0.3	1.34e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs12912251	1.000	rs35102843	chr15:38988107	C/A	cg01338139	chr15:38987640	C15orf53	-0.6	-9.39	-0.42	3.9e-19	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg13271783	chr10:134563150	INPP5A	-0.41	-6.43	-0.3	3.37e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00734724	chr15:41408630	INO80	-0.41	-6.71	-0.31	6.3e-11	Cancer;
LUAD	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.0	0.36	1.25e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7705042	0.897	rs7718955	chr5:141521459	A/G	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.8	-0.31	3.62e-11	Asthma;
LUAD	trans	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg25894440	chr7:65020034	NA	-0.63	-6.67	-0.31	8.12e-11	Diabetic kidney disease;
LUAD	trans	rs587242	0.528	rs34575842	chr1:97207040	A/G	cg10631902	chr5:14652156	NA	0.39	6.65	0.31	9.33e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg06713675	chr4:122721982	EXOSC9	-0.74	-14.69	-0.58	8.93e-40	Type 2 diabetes;
LUAD	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.58	0.3	1.35e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11229555	0.609	rs4519113	chr11:58216825	T/C	cg15696309	chr11:58395628	NA	-0.75	-10.42	-0.45	9.08e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01570182	chr17:44337453	NA	0.78	12.55	0.52	6.29e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg00074818	chr8:8560427	CLDN23	0.66	10.1	0.44	1.27e-21	Obesity-related traits;
LUAD	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg12311346	chr5:56204834	C5orf35	-0.43	-7.05	-0.32	7.11e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs11958404	1.000	rs72816538	chr5:157414303	A/G	cg05962755	chr5:157440814	NA	0.44	7.02	0.32	9.06e-12	IgG glycosylation;
LUAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg00784671	chr22:46762841	CELSR1	-0.53	-7.29	-0.33	1.52e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs428668	0.681	rs428064	chr5:150696498	G/A	cg14086364	chr5:150678334	SLC36A3	0.34	6.66	0.31	8.64e-11	Skin aging (microtopography measurement);
LUAD	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg22117172	chr7:91764530	CYP51A1	0.34	7.46	0.34	5.1e-13	Breast cancer;
LUAD	cis	rs2455799	0.573	rs2470523	chr3:15768091	G/C	cg16303742	chr3:15540471	COLQ	-0.5	-9.26	-0.41	1.06e-18	Mean platelet volume;
LUAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg04025307	chr7:1156635	C7orf50	0.65	9.12	0.41	3.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.71	6.36	0.3	5.3e-10	Amyotrophic lateral sclerosis (sporadic);
LUAD	trans	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg14917512	chr19:3094685	GNA11	0.37	6.48	0.3	2.54e-10	Aortic root size;
LUAD	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg24818145	chr4:99064322	C4orf37	0.38	6.45	0.3	3.05e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg04154034	chr17:28927549	LRRC37B2	0.59	7.22	0.33	2.44e-12	Body mass index;
LUAD	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg02734326	chr4:10020555	SLC2A9	0.51	8.75	0.39	5.04e-17	Bone mineral density;
LUAD	trans	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg03886242	chr7:26192032	NFE2L3	0.4	6.8	0.31	3.56e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg05313129	chr8:58192883	C8orf71	-0.53	-6.8	-0.31	3.62e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs3981351	0.763	rs4595501	chr10:115491565	A/T	cg24846397	chr10:115438155	CASP7	0.38	6.39	0.3	4.31e-10	Obesity-related traits;
LUAD	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.57	10.49	0.45	4.96e-23	Axial length;
LUAD	cis	rs4919694	1.000	rs4917382	chr10:104838510	G/A	cg04362960	chr10:104952993	NT5C2	0.75	7.93	0.36	1.94e-14	Arsenic metabolism;
LUAD	cis	rs9323205	0.677	rs11620820	chr14:51734445	C/T	cg23942311	chr14:51606299	NA	-0.56	-8.26	-0.37	1.92e-15	Cancer;
LUAD	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg22961513	chr11:14280813	SPON1	0.44	9.0	0.4	7.44e-18	Mitochondrial DNA levels;
LUAD	cis	rs10203711	0.933	rs2334025	chr2:239564114	A/G	cg14580085	chr2:239553406	NA	-0.39	-8.27	-0.37	1.77e-15	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg18105134	chr13:113819100	PROZ	-1.0	-18.49	-0.67	2.23e-56	Platelet distribution width;
LUAD	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	7.0	0.32	1.03e-11	Rheumatoid arthritis;
LUAD	cis	rs15676	0.783	rs3829057	chr9:131567982	A/G	cg00228799	chr9:131580591	ENDOG	0.46	7.09	0.33	5.64e-12	Blood metabolite levels;
LUAD	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.89	0.36	2.63e-14	Depression;
LUAD	cis	rs1348850	0.597	rs13014512	chr2:178470851	T/A	cg27490568	chr2:178487706	NA	0.65	10.05	0.44	1.93e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6460942	1.000	rs75333414	chr7:12303829	T/A	cg20607287	chr7:12443886	VWDE	-0.5	-6.56	-0.3	1.58e-10	Coronary artery disease;
LUAD	cis	rs9868809	1.000	rs9868809	chr3:48681053	C/T	cg00383909	chr3:49044727	WDR6	0.66	7.01	0.32	9.34e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg24503407	chr1:205819492	PM20D1	-0.42	-6.69	-0.31	6.99e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	trans	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.63	-0.31	9.97e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs601339	1.000	rs1798219	chr12:123180061	A/C	cg11919336	chr12:123188078	GPR109A	0.47	7.32	0.34	1.26e-12	Adiponectin levels;
LUAD	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02463440	chr8:22132932	PIWIL2	-0.55	-9.94	-0.44	4.61e-21	Hypertriglyceridemia;
LUAD	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg15181151	chr6:150070149	PCMT1	0.42	8.7	0.39	7.56e-17	Lung cancer;
LUAD	cis	rs1941023	0.584	rs2241921	chr11:60164302	C/T	cg08716584	chr11:60157161	MS4A7	-0.48	-9.34	-0.41	5.73e-19	Congenital heart disease (maternal effect);
LUAD	trans	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	10.61	0.46	1.77e-23	Type 2 diabetes;
LUAD	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg02423579	chr7:2872169	GNA12	-0.57	-9.7	-0.43	3.25e-20	Height;
LUAD	cis	rs9584850	0.874	rs3742136	chr13:99102607	C/T	cg17380943	chr13:99100506	FARP1	-0.35	-6.56	-0.3	1.56e-10	Neuroticism;
LUAD	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg07741184	chr6:167504864	NA	0.29	7.03	0.32	8.43e-12	Crohn's disease;
LUAD	cis	rs12422267	0.609	rs11246940	chr12:132623473	A/G	cg05134918	chr12:132603531	EP400NL	-0.49	-6.44	-0.3	3.23e-10	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs9341808	0.500	rs806851	chr6:81030831	A/C	cg08355045	chr6:80787529	NA	-0.39	-6.61	-0.31	1.13e-10	Sitting height ratio;
LUAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg18402987	chr7:1209562	NA	0.61	8.92	0.4	1.43e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg11707310	chr1:2537719	MMEL1	0.36	7.63	0.35	1.55e-13	Ulcerative colitis;
LUAD	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg10978503	chr1:24200527	CNR2	-0.6	-13.24	-0.54	9.76e-34	Immature fraction of reticulocytes;
LUAD	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg22705602	chr4:152727874	NA	-0.37	-6.58	-0.3	1.37e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs9393777	0.778	rs4452638	chr6:27229265	A/G	cg01620082	chr3:125678407	NA	0.84	9.17	0.41	2.02e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg00376283	chr12:123451042	ABCB9	0.41	6.68	0.31	7.77e-11	Platelet count;
LUAD	cis	rs67981189	0.634	rs221896	chr14:71606668	C/G	cg15816911	chr14:71606274	NA	-0.38	-7.1	-0.33	5.48e-12	Schizophrenia;
LUAD	cis	rs7737355	0.947	rs3776027	chr5:130802970	T/C	cg25547332	chr5:131281432	NA	-0.43	-6.67	-0.31	8.09e-11	Life satisfaction;
LUAD	cis	rs938554	0.692	rs13111638	chr4:9996890	A/G	cg11266682	chr4:10021025	SLC2A9	0.5	8.13	0.37	4.65e-15	Blood metabolite levels;
LUAD	cis	rs11971779	0.680	rs2355786	chr7:139065622	A/C	cg24109934	chr7:139138155	KLRG2	0.32	6.65	0.31	9.15e-11	Diisocyanate-induced asthma;
LUAD	trans	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg07211511	chr3:129823064	LOC729375	-0.69	-9.71	-0.43	2.97e-20	Blood pressure (smoking interaction);
LUAD	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg26597838	chr10:835615	NA	1.04	15.53	0.6	2.36e-43	Eosinophil percentage of granulocytes;
LUAD	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg23018236	chr17:30244563	NA	-0.69	-8.51	-0.38	3.04e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs7737355	1.000	rs59808242	chr5:130754894	G/A	cg06307176	chr5:131281290	NA	-0.49	-7.67	-0.35	1.2e-13	Life satisfaction;
LUAD	trans	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-14.54	-0.58	3.83e-39	Exhaled nitric oxide output;
LUAD	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.31	0.37	1.33e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.6	0.31	1.23e-10	Colorectal cancer;
LUAD	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg04842962	chr6:43655489	MRPS18A	1.08	27.75	0.8	2.77e-97	IgG glycosylation;
LUAD	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg04545296	chr12:48745243	ZNF641	0.4	10.08	0.44	1.5e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg02696790	chr15:75250997	RPP25	-0.34	-6.87	-0.32	2.24e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.77	-10.19	-0.44	6.04e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg09835421	chr16:68378352	PRMT7	-0.73	-8.35	-0.38	9.71e-16	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg01620082	chr3:125678407	NA	-1.02	-10.29	-0.45	2.49e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.71	-12.11	-0.51	3.52e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs2063714	0.658	rs12196864	chr6:157212862	C/T	cg23222435	chr6:157204239	ARID1B	-0.36	-6.4	-0.3	4.11e-10	Sitting height ratio;
LUAD	cis	rs1448094	0.872	rs10863147	chr12:86408441	G/C	cg06740227	chr12:86229804	RASSF9	0.38	6.92	0.32	1.67e-11	Major depressive disorder;
LUAD	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg01657329	chr11:68192670	LRP5	-0.47	-8.19	-0.37	3.14e-15	Total body bone mineral density;
LUAD	cis	rs7927771	0.524	rs7122182	chr11:47843133	A/C	cg18512352	chr11:47633146	NA	-0.37	-6.66	-0.31	8.61e-11	Subjective well-being;
LUAD	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg26408565	chr15:76604113	ETFA	-0.45	-7.32	-0.34	1.23e-12	Blood metabolite levels;
LUAD	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg26924012	chr15:45694286	SPATA5L1	0.64	10.92	0.47	1.23e-24	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg00310523	chr12:86230176	RASSF9	0.39	7.82	0.36	4.19e-14	Major depressive disorder;
LUAD	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.91	0.32	1.82e-11	Hypertriglyceridemia;
LUAD	trans	rs11039798	0.925	rs7929225	chr11:48931739	G/C	cg02254774	chr11:50257496	LOC441601	0.52	6.56	0.3	1.62e-10	Axial length;
LUAD	cis	rs1160297	0.643	rs6737483	chr2:53041627	G/A	cg07782112	chr2:53107842	NA	0.38	7.95	0.36	1.73e-14	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6445967	0.530	rs12631656	chr3:58409063	T/C	cg13750441	chr3:58318267	PXK	-0.33	-6.78	-0.31	4.09e-11	Platelet count;
LUAD	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg22532475	chr10:104410764	TRIM8	0.34	6.85	0.32	2.57e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg25985355	chr7:65971099	NA	0.55	6.84	0.32	2.8e-11	Diabetic kidney disease;
LUAD	cis	rs10992471	0.528	rs7860786	chr9:95245473	C/T	cg14631576	chr9:95140430	CENPP	-0.47	-9.59	-0.42	7.59e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg14092988	chr3:52407081	DNAH1	0.42	8.32	0.37	1.27e-15	Bipolar disorder;
LUAD	cis	rs6906287	0.552	rs7740645	chr6:118929208	T/A	cg18833306	chr6:118973337	C6orf204	0.49	8.49	0.38	3.51e-16	Electrocardiographic conduction measures;
LUAD	cis	rs7107174	1.000	rs10899486	chr11:78072398	A/G	cg02023728	chr11:77925099	USP35	0.46	7.31	0.34	1.3e-12	Testicular germ cell tumor;
LUAD	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg23625390	chr15:77176239	SCAPER	-0.52	-7.9	-0.36	2.41e-14	Blood metabolite levels;
LUAD	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.39	-7.57	-0.35	2.31e-13	Total body bone mineral density;
LUAD	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11890956	chr21:40555474	PSMG1	0.67	12.39	0.52	2.76e-30	Cognitive function;
LUAD	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg12193833	chr17:30244370	NA	-0.55	-7.13	-0.33	4.33e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7043114	0.525	rs9299404	chr9:95170338	A/G	cg14631576	chr9:95140430	CENPP	0.42	8.61	0.39	1.46e-16	Height;
LUAD	cis	rs7187994	0.848	rs8051512	chr16:84781101	C/G	cg07647771	chr16:84786436	USP10	-0.35	-9.05	-0.4	5.1e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg18512352	chr11:47633146	NA	-0.55	-9.72	-0.43	2.64e-20	Subjective well-being;
LUAD	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg11148817	chr5:312970	AHRR;PDCD6	-0.47	-6.44	-0.3	3.23e-10	Breast cancer;
LUAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg12432903	chr7:1882776	MAD1L1	-0.4	-6.46	-0.3	2.95e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg12573674	chr2:1569213	NA	-0.56	-8.32	-0.38	1.21e-15	IgG glycosylation;
LUAD	cis	rs3809566	0.637	rs8026047	chr15:63323347	C/G	cg21584241	chr15:63341463	TPM1	0.37	6.84	0.32	2.84e-11	Platelet count;
LUAD	cis	rs854765	0.624	rs12938501	chr17:17737258	A/C	cg09796270	chr17:17721594	SREBF1	-0.38	-7.38	-0.34	8.44e-13	Total body bone mineral density;
LUAD	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg02269571	chr22:50332266	NA	-0.67	-9.6	-0.42	7.1e-20	Schizophrenia;
LUAD	cis	rs9902453	0.967	rs12602065	chr17:28482488	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.57	0.38	2.01e-16	Coffee consumption (cups per day);
LUAD	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg08280861	chr8:58055591	NA	0.72	8.4	0.38	6.97e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs34734847	0.750	rs3829290	chr12:121126438	T/C	cg13914990	chr12:121174878	ACADS	0.4	7.83	0.36	3.98e-14	Mean corpuscular volume;
LUAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.25	-0.37	2.05e-15	Alzheimer's disease;
LUAD	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg22496339	chr2:162101262	NA	0.48	7.69	0.35	1.05e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12667521	chr19:29218732	NA	0.59	8.45	0.38	4.9e-16	Methadone dose in opioid dependence;
LUAD	trans	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17712092	chr4:129076599	LARP1B	-0.82	-14.91	-0.59	1.03e-40	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs7216064	1.000	rs62084251	chr17:65878736	G/A	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg23625390	chr15:77176239	SCAPER	-0.5	-7.96	-0.36	1.65e-14	Blood metabolite levels;
LUAD	cis	rs7178572	0.568	rs1389436	chr15:77665848	G/T	cg15453836	chr15:77711506	NA	-0.36	-6.44	-0.3	3.15e-10	Type 2 diabetes;
LUAD	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg04731861	chr2:219085781	ARPC2	-0.21	-6.46	-0.3	2.96e-10	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg23815491	chr16:72088622	HP	0.53	9.74	0.43	2.38e-20	Fibrinogen levels;
LUAD	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg21385522	chr1:16154831	NA	0.56	8.23	0.37	2.33e-15	Dilated cardiomyopathy;
LUAD	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg22535103	chr8:58192502	C8orf71	-0.75	-10.6	-0.46	1.93e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg13560548	chr3:10150139	C3orf24	0.4	6.64	0.31	9.53e-11	Alzheimer's disease;
LUAD	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg24397884	chr7:158709396	WDR60	-0.74	-13.61	-0.55	3.15e-35	Height;
LUAD	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg23301539	chr8:142222248	SLC45A4	0.48	8.76	0.39	4.64e-17	Immature fraction of reticulocytes;
LUAD	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg05717871	chr11:638507	DRD4	-0.44	-6.53	-0.3	1.85e-10	Systemic lupus erythematosus;
LUAD	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg08645402	chr16:4508243	NA	0.54	10.08	0.44	1.5e-21	Schizophrenia;
LUAD	cis	rs2294693	0.945	rs9369255	chr6:40989503	T/C	cg14769373	chr6:40998127	UNC5CL	-0.53	-7.79	-0.35	5.17e-14	Gastric cancer;Non-cardia gastric cancer;
LUAD	trans	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg01620082	chr3:125678407	NA	-0.91	-7.21	-0.33	2.58e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7737355	0.812	rs152789	chr5:131026590	C/A	cg25547332	chr5:131281432	NA	0.44	7.11	0.33	5.12e-12	Life satisfaction;
LUAD	cis	rs7814319	0.899	rs1878638	chr8:97258719	C/T	cg20787634	chr8:97240163	UQCRB	-0.38	-7.49	-0.34	4.13e-13	Lung function (FVC);
LUAD	cis	rs938554	0.876	rs6823324	chr4:9932359	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.55	-0.34	2.7e-13	Blood metabolite levels;
LUAD	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg20290983	chr6:43655470	MRPS18A	1.07	27.12	0.8	1.36e-94	IgG glycosylation;
LUAD	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-7.02	-0.32	8.83e-12	Menarche (age at onset);
LUAD	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg10876282	chr6:28092338	ZSCAN16	0.46	7.31	0.33	1.34e-12	Parkinson's disease;
LUAD	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg25358565	chr5:93447407	FAM172A	0.61	7.31	0.33	1.34e-12	Diabetic retinopathy;
LUAD	cis	rs77741769	0.571	rs11065300	chr12:121298512	G/C	cg02419362	chr12:121203948	SPPL3	0.43	8.79	0.39	3.66e-17	Mean corpuscular volume;
LUAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.95e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg12927641	chr6:109611667	NA	-0.51	-8.76	-0.39	4.78e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.5	-10.21	-0.44	5.14e-22	Monocyte percentage of white cells;
LUAD	trans	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg03886242	chr7:26192032	NFE2L3	0.36	6.47	0.3	2.69e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4604732	0.631	rs74154672	chr1:247625625	C/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7020830	0.898	rs6476617	chr9:37200103	G/A	cg14294708	chr9:37120828	ZCCHC7	0.84	16.71	0.63	1.76e-48	Schizophrenia;
LUAD	cis	rs2479724	0.901	rs2185798	chr6:41773576	G/C	cg17623882	chr6:41773611	USP49	0.7	13.48	0.55	1.07e-34	Menarche (age at onset);
LUAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg24101359	chr6:42928495	GNMT	0.49	9.05	0.4	5.35e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11905131	chr22:24372483	LOC391322	0.56	9.68	0.43	3.77e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg17757837	chr7:157058334	UBE3C	0.46	8.15	0.37	4.07e-15	Body mass index;
LUAD	cis	rs55788414	0.932	rs35852981	chr16:81180897	G/A	cg06400318	chr16:81190750	PKD1L2	-0.72	-8.58	-0.39	1.75e-16	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs7274811	0.744	rs6141962	chr20:32110312	T/C	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.48	-7.26	-0.33	1.92e-12	Height;
LUAD	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg01528321	chr10:82214614	TSPAN14	-0.67	-11.05	-0.47	4.13e-25	Post bronchodilator FEV1;
LUAD	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23158103	chr7:148848205	ZNF398	-0.5	-9.08	-0.4	4.26e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg05529236	chr11:62341449	EEF1G	-0.49	-6.81	-0.31	3.4e-11	Testicular germ cell tumor;
LUAD	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg17120908	chr11:65337727	SSSCA1	-0.61	-9.62	-0.42	6.29e-20	Bone mineral density;
LUAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg02869364	chr7:1081709	C7orf50	-0.51	-6.61	-0.31	1.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11087358	chr12:57940980	DCTN2	-0.42	-6.55	-0.3	1.66e-10	Height;
LUAD	cis	rs3772130	0.527	rs2141614	chr3:121590173	G/A	cg20356878	chr3:121714668	ILDR1	0.69	14.14	0.57	1.98e-37	Cognitive performance;
LUAD	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg22467129	chr15:76604101	ETFA	0.45	7.68	0.35	1.11e-13	Blood metabolite levels;
LUAD	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg09997546	chr11:8931473	C11orf17;ST5	0.38	8.11	0.37	5.53e-15	Hemoglobin concentration;
LUAD	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg05182265	chr7:156933206	UBE3C	-0.8	-17.24	-0.64	8.17e-51	Body mass index;
LUAD	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg14784868	chr12:69753453	YEATS4	0.43	6.81	0.31	3.41e-11	Blood protein levels;
LUAD	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg11663144	chr21:46675770	NA	-0.59	-11.7	-0.49	1.34e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.87	-0.36	2.92e-14	Type 2 diabetes;
LUAD	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg02527881	chr3:46936655	PTH1R	-0.5	-10.2	-0.44	5.26e-22	Colorectal cancer;
LUAD	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg00277334	chr10:82204260	NA	-0.6	-10.26	-0.45	3.23e-22	Post bronchodilator FEV1;
LUAD	cis	rs73198271	0.640	rs7838012	chr8:8656630	A/G	cg01851573	chr8:8652454	MFHAS1	0.48	8.52	0.38	2.76e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg07157834	chr1:205819609	PM20D1	0.47	7.13	0.33	4.51e-12	Parkinson's disease;
LUAD	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg22532475	chr10:104410764	TRIM8	0.4	7.86	0.36	3.29e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs72928364	0.860	rs16843216	chr3:100796879	C/T	cg10123952	chr3:100791384	NA	0.55	7.0	0.32	1.04e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs17155006	0.664	rs401487	chr7:107743409	A/G	cg05962710	chr7:107745446	LAMB4	-0.34	-7.49	-0.34	4.11e-13	Pneumococcal bacteremia;
LUAD	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11644478	chr21:40555479	PSMG1	0.66	10.8	0.47	3.41e-24	Cognitive function;
LUAD	trans	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.54	-8.79	-0.39	3.67e-17	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9863	0.861	rs55990776	chr12:124447466	A/G	cg17723958	chr12:124429295	CCDC92	-0.42	-6.88	-0.32	2.19e-11	White blood cell count;
LUAD	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg11916186	chr1:36689760	THRAP3	-0.42	-6.4	-0.3	4.17e-10	Protein C levels;
LUAD	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg19077165	chr18:44547161	KATNAL2	0.47	8.17	0.37	3.6e-15	Personality dimensions;
LUAD	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg05623727	chr3:50126028	RBM5	-0.32	-6.91	-0.32	1.75e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7258465	1.000	rs8111708	chr19:18558876	A/G	cg01065977	chr19:18549689	ISYNA1	-0.35	-6.41	-0.3	3.86e-10	Breast cancer;
LUAD	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.42	-0.38	6.04e-16	Prostate cancer;
LUAD	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg05425664	chr17:57184151	TRIM37	-0.37	-6.39	-0.3	4.38e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg20991723	chr1:152506922	NA	0.35	6.85	0.32	2.54e-11	Hair morphology;
LUAD	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg11645453	chr3:52864694	ITIH4	-0.33	-6.36	-0.3	5.38e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg11189052	chr15:85197271	WDR73	0.59	7.5	0.34	3.83e-13	Schizophrenia;
LUAD	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg25817165	chr18:72167213	CNDP2	-0.69	-10.31	-0.45	2.11e-22	Refractive error;
LUAD	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs731174	0.802	rs504518	chr1:38182333	G/T	cg06917450	chr1:38156652	C1orf109	-0.41	-6.53	-0.3	1.86e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg13699009	chr12:122356056	WDR66	0.3	6.6	0.31	1.26e-10	Mean corpuscular volume;
LUAD	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg03929089	chr4:120376271	NA	-0.89	-17.06	-0.64	5.1e-50	Height;
LUAD	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22455342	chr2:225449267	CUL3	0.7	10.69	0.46	9.12e-24	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs6541297	0.645	rs4846920	chr1:230301574	A/G	cg20703242	chr1:230279135	GALNT2	0.43	6.55	0.3	1.63e-10	Coronary artery disease;
LUAD	cis	rs9811920	0.809	rs35422475	chr3:99711545	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-11.38	-0.48	2.24e-26	Axial length;
LUAD	cis	rs2835872	0.828	rs66815183	chr21:39032828	C/T	cg06728970	chr21:39037746	KCNJ6	-0.42	-7.48	-0.34	4.21e-13	Electroencephalographic traits in alcoholism;
LUAD	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	7.71	0.35	8.86e-14	Breast cancer;
LUAD	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg05373962	chr22:49881684	NA	-0.5	-10.3	-0.45	2.3e-22	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs1113500	0.965	rs10881495	chr1:108610986	C/A	cg06207961	chr1:108661230	NA	0.43	8.14	0.37	4.34e-15	Growth-regulated protein alpha levels;
LUAD	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.01	0.32	9.52e-12	Motion sickness;
LUAD	cis	rs471144	0.881	rs12089980	chr1:152431931	C/T	cg02754945	chr1:152161885	NA	0.62	6.39	0.3	4.42e-10	Inflammatory skin disease;
LUAD	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.35	-0.38	1.01e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs1493916	0.870	rs7235698	chr18:31382486	A/G	cg27147174	chr7:100797783	AP1S1	-0.68	-12.28	-0.51	7.45e-30	Life satisfaction;
LUAD	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg08999081	chr20:33150536	PIGU	0.44	8.45	0.38	4.76e-16	Coronary artery disease;
LUAD	cis	rs2996428	0.709	rs6424052	chr1:3713746	A/G	cg22529645	chr1:3704559	LRRC47	0.55	10.12	0.44	1.03e-21	Red cell distribution width;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg12503235	chr19:42637513	POU2F2	0.44	6.57	0.3	1.51e-10	QT interval;
LUAD	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg00383909	chr3:49044727	WDR6	0.72	8.32	0.38	1.2e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg16011800	chr17:1958478	HIC1	0.54	7.8	0.35	4.84e-14	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg24101359	chr6:42928495	GNMT	-0.46	-8.57	-0.38	2.02e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg23982607	chr1:1823379	GNB1	-0.9	-18.8	-0.67	9.44e-58	Body mass index;
LUAD	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg15448220	chr1:150897856	SETDB1	-0.46	-7.97	-0.36	1.52e-14	Tonsillectomy;
LUAD	cis	rs28493229	0.522	rs2233152	chr19:41281016	C/T	cg21869046	chr19:41225005	ITPKC	0.54	9.61	0.42	6.71e-20	Kawasaki disease;
LUAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg23958373	chr8:599963	NA	1.07	10.5	0.45	4.32e-23	IgG glycosylation;
LUAD	cis	rs9902453	0.817	rs1038089	chr17:28178724	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.44	0.42	2.56e-19	Coffee consumption (cups per day);
LUAD	cis	rs17197710	0.673	rs41310332	chr11:47348057	C/T	cg13308137	chr11:47528955	CUGBP1	0.45	7.22	0.33	2.5e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg24562669	chr7:97807699	LMTK2	-0.31	-7.32	-0.34	1.3e-12	Breast cancer;
LUAD	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.53	-0.3	1.89e-10	Retinal vascular caliber;
LUAD	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-8.38	-0.38	7.93e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg25208724	chr1:156163844	SLC25A44	1.18	26.35	0.79	3.05e-91	Testicular germ cell tumor;
LUAD	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.88	0.32	2.13e-11	Motion sickness;
LUAD	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg08773314	chr2:239334832	ASB1	0.42	9.29	0.41	7.99e-19	Multiple system atrophy;
LUAD	cis	rs870825	0.616	rs2141257	chr4:185609463	C/T	cg04058563	chr4:185651563	MLF1IP	-0.84	-12.37	-0.52	3.41e-30	Blood protein levels;
LUAD	cis	rs4072705	0.900	rs4836992	chr9:127558290	G/C	cg13476313	chr9:127244764	NR5A1	0.3	6.9	0.32	1.94e-11	Menarche (age at onset);
LUAD	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg09491104	chr22:46646882	C22orf40	-0.59	-7.47	-0.34	4.76e-13	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg13063040	chr8:145669623	NFKBIL2	-0.74	-6.93	-0.32	1.58e-11	Type 2 diabetes;
LUAD	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg23758822	chr17:41437982	NA	0.99	19.85	0.69	1.99e-62	Menopause (age at onset);
LUAD	cis	rs2109514	0.967	rs10271007	chr7:116145849	A/G	cg12739419	chr7:116140593	CAV2	-0.37	-7.86	-0.36	3.16e-14	Prevalent atrial fibrillation;
LUAD	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg02228675	chr17:40259724	DHX58	-0.46	-7.49	-0.34	3.93e-13	Fibrinogen levels;
LUAD	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25427524	chr10:38739819	LOC399744	-0.77	-14.47	-0.58	7.78e-39	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs11169225	0.756	rs3759124	chr12:50343166	G/A	cg23855989	chr12:50355821	AQP5	0.57	7.93	0.36	1.99e-14	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs240764	0.578	rs6925065	chr6:101178856	C/T	cg09795085	chr6:101329169	ASCC3	0.43	7.74	0.35	7.16e-14	Neuroticism;
LUAD	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg06641503	chr3:48959341	ARIH2	0.38	6.66	0.31	8.42e-11	Menarche (age at onset);
LUAD	cis	rs6456156	0.716	rs6905911	chr6:167521624	C/T	cg07741184	chr6:167504864	NA	0.29	6.68	0.31	7.35e-11	Primary biliary cholangitis;
LUAD	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg09085632	chr11:111637200	PPP2R1B	0.75	12.73	0.53	1.22e-31	Primary sclerosing cholangitis;
LUAD	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg21918786	chr6:109611834	NA	-0.6	-11.27	-0.48	5.97e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg17644776	chr2:200775616	C2orf69	-0.55	-6.64	-0.31	9.85e-11	Schizophrenia;
LUAD	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg20203395	chr5:56204925	C5orf35	-0.59	-9.11	-0.41	3.25e-18	Coronary artery disease;
LUAD	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.76	-9.53	-0.42	1.28e-19	Body mass index;
LUAD	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg13334819	chr7:99746414	C7orf59	0.64	9.98	0.44	3.3e-21	Coronary artery disease;
LUAD	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg14835575	chr10:16859367	RSU1	0.53	8.05	0.36	8.21e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg17178900	chr1:205818956	PM20D1	-0.53	-9.65	-0.42	4.76e-20	Menarche (age at onset);
LUAD	cis	rs7527798	0.501	rs12125256	chr1:207851361	C/T	cg09232269	chr1:207846808	CR1L	-0.36	-6.7	-0.31	6.66e-11	Erythrocyte sedimentation rate;
LUAD	cis	rs17253792	0.822	rs9972180	chr14:56073732	G/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg18252515	chr7:66147081	NA	-0.61	-6.75	-0.31	4.99e-11	Diabetic kidney disease;
LUAD	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg02018176	chr4:1364513	KIAA1530	0.47	8.7	0.39	7.71e-17	Longevity;
LUAD	cis	rs7705042	0.865	rs6580228	chr5:141510448	C/T	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.87	-0.32	2.32e-11	Asthma;
LUAD	cis	rs2637266	0.729	rs1099883	chr10:78516158	G/T	cg18941641	chr10:78392320	NA	0.31	6.38	0.3	4.77e-10	Pulmonary function;
LUAD	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg09021430	chr5:549028	NA	-0.69	-13.3	-0.54	5.59e-34	Lung disease severity in cystic fibrosis;
LUAD	cis	rs11771526	0.551	rs6462344	chr7:32254889	T/C	cg27532318	chr7:32358331	NA	-0.47	-6.78	-0.31	4.04e-11	Body mass index;
LUAD	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.5	0.42	1.62e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg06558623	chr16:89946397	TCF25	0.89	9.44	0.42	2.47e-19	Skin colour saturation;
LUAD	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.9	-0.36	2.47e-14	Diabetic kidney disease;
LUAD	cis	rs4986172	0.539	rs12603813	chr17:43196584	T/C	cg10701640	chr17:43249399	NA	0.5	8.28	0.37	1.62e-15	Height;
LUAD	trans	rs877282	0.891	rs11253406	chr10:796297	G/A	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg02549819	chr16:58548995	SETD6	0.8	6.63	0.31	1.05e-10	Schizophrenia;
LUAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg07677032	chr17:61819896	STRADA	0.57	10.3	0.45	2.42e-22	Prudent dietary pattern;
LUAD	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg19825600	chr2:3704501	ALLC	-0.39	-7.53	-0.34	3.2e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg23815491	chr16:72088622	HP	0.53	9.77	0.43	1.88e-20	Fibrinogen levels;
LUAD	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg17366294	chr4:99064904	C4orf37	0.62	11.49	0.49	8.68e-27	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.67	0.39	9.26e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.39	-6.81	-0.31	3.43e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9361491	0.543	rs1507153	chr6:79484386	C/A	cg05283184	chr6:79620031	NA	-0.39	-6.98	-0.32	1.13e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10924309	0.889	rs10924308	chr1:245858131	C/T	cg00036263	chr1:245852353	KIF26B	-0.48	-7.49	-0.34	4.09e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg02782426	chr3:40428986	ENTPD3	0.36	7.88	0.36	2.79e-14	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs380904	0.519	rs10102146	chr8:144649156	G/A	cg13399544	chr8:144649678	C8orf73	0.52	7.29	0.33	1.56e-12	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg00981070	chr1:2046702	PRKCZ	0.36	6.96	0.32	1.28e-11	Height;
LUAD	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg23625390	chr15:77176239	SCAPER	-0.53	-8.08	-0.37	6.9e-15	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg16414030	chr3:133502952	NA	-0.61	-10.44	-0.45	7.66e-23	Iron status biomarkers;
LUAD	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg26384229	chr12:38710491	ALG10B	0.51	8.27	0.37	1.76e-15	Heart rate;
LUAD	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.75	-8.97	-0.4	9.38e-18	Lung cancer in ever smokers;
LUAD	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg01689657	chr7:91764605	CYP51A1	-0.3	-7.31	-0.33	1.37e-12	Breast cancer;
LUAD	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg04369109	chr6:150039330	LATS1	-0.46	-7.6	-0.35	1.98e-13	Lung cancer;
LUAD	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg06558623	chr16:89946397	TCF25	1.16	10.95	0.47	9.95e-25	Skin colour saturation;
LUAD	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg15691649	chr6:25882328	NA	-0.44	-7.03	-0.32	8.13e-12	Blood metabolite levels;
LUAD	cis	rs6738485	1.000	rs6738485	chr2:106809960	C/T	cg15412446	chr2:106886593	NA	-0.39	-6.54	-0.3	1.76e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg13319975	chr6:146136371	FBXO30	0.59	9.96	0.44	4.05e-21	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06777853	chr14:61201602	MNAT1	-0.5	-7.9	-0.36	2.45e-14	Height;
LUAD	cis	rs36051895	0.695	rs1327494	chr9:4999303	A/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.89	-0.32	2.01e-11	Pediatric autoimmune diseases;
LUAD	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg22618164	chr12:122356400	WDR66	0.74	13.74	0.56	9.24e-36	Mean corpuscular volume;
LUAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg24101359	chr6:42928495	GNMT	-0.38	-7.1	-0.33	5.2e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg04539111	chr16:67997858	SLC12A4	-0.57	-6.56	-0.3	1.59e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs62238980	0.614	rs79110727	chr22:32377455	A/G	cg02631450	chr22:32366979	NA	0.82	6.68	0.31	7.7e-11	Childhood ear infection;
LUAD	cis	rs8017423	0.586	rs2896134	chr14:90831293	G/A	cg14092571	chr14:90743983	NA	0.39	6.48	0.3	2.58e-10	Mortality in heart failure;
LUAD	cis	rs7000551	0.700	rs2461491	chr8:22361252	C/T	cg12081754	chr8:22256438	SLC39A14	-0.38	-6.4	-0.3	4.11e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.54	0.42	1.17e-19	Lung cancer in ever smokers;
LUAD	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg11833968	chr6:79620685	NA	-0.44	-8.27	-0.37	1.75e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg02038168	chr22:39784481	NA	-0.58	-10.41	-0.45	9.95e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg01528321	chr10:82214614	TSPAN14	0.54	8.72	0.39	6.3e-17	Post bronchodilator FEV1;
LUAD	cis	rs220324	0.688	rs56326363	chr21:43560295	G/A	cg09727148	chr21:43560719	UMODL1	0.57	8.73	0.39	6.15e-17	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg01765077	chr12:122356316	WDR66	0.47	8.04	0.36	9.09e-15	Mean corpuscular volume;
LUAD	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg06627628	chr2:24431161	ITSN2	-0.7	-11.22	-0.48	9.77e-26	Asthma;
LUAD	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22968622	chr17:43663579	NA	-1.18	-19.66	-0.69	1.34e-61	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4372836	0.893	rs745645	chr2:28931571	G/T	cg09522027	chr2:28974177	PPP1CB	0.57	8.98	0.4	8.98e-18	Body mass index;
LUAD	trans	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-10.43	-0.45	7.83e-23	Obesity-related traits;
LUAD	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg22875332	chr1:76189707	ACADM	0.77	12.28	0.51	7.27e-30	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06544989	chr22:39130855	UNC84B	0.45	9.05	0.4	5.15e-18	Menopause (age at onset);
LUAD	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg27490568	chr2:178487706	NA	0.55	8.53	0.38	2.54e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg19622623	chr12:86230825	RASSF9	-0.44	-7.76	-0.35	6.54e-14	Major depressive disorder;
LUAD	trans	rs7944735	0.517	rs7952205	chr11:48199227	A/G	cg15704280	chr7:45808275	SEPT13	0.67	7.64	0.35	1.43e-13	Intraocular pressure;
LUAD	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg25208724	chr1:156163844	SLC25A44	1.19	27.28	0.8	2.87e-95	Testicular germ cell tumor;
LUAD	cis	rs3540	0.533	rs1869179	chr15:90895564	A/C	cg10434728	chr15:90938212	IQGAP1	0.38	7.38	0.34	8.7e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs36051895	0.659	rs59225790	chr9:5042757	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-6.75	-0.31	4.75e-11	Pediatric autoimmune diseases;
LUAD	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.84	-0.32	2.78e-11	Neuroticism;
LUAD	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg00757033	chr12:89920650	WDR51B	0.7	12.2	0.51	1.59e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-6.97	-0.32	1.26e-11	Lung cancer;
LUAD	cis	rs6906287	0.647	rs12192682	chr6:118863594	A/G	cg21191810	chr6:118973309	C6orf204	0.5	9.77	0.43	1.85e-20	Electrocardiographic conduction measures;
LUAD	cis	rs6489882	0.867	rs2384073	chr12:113367595	A/G	cg20102336	chr12:113376681	OAS3	-0.6	-9.37	-0.41	4.39e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg18132916	chr6:79620363	NA	-0.42	-6.78	-0.31	4.03e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg04025307	chr7:1156635	C7orf50	0.55	9.31	0.41	7.01e-19	Longevity;Endometriosis;
LUAD	cis	rs11677416	1.000	rs2856836	chr2:113532083	A/G	cg27083787	chr2:113543245	IL1A	0.39	6.57	0.3	1.44e-10	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg22166914	chr1:53195759	ZYG11B	-0.4	-6.56	-0.3	1.55e-10	Monocyte count;
LUAD	cis	rs2067615	0.579	rs1922435	chr12:107082455	A/G	cg15890332	chr12:107067104	RFX4	0.4	8.58	0.39	1.79e-16	Heart rate;
LUAD	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.61	-11.49	-0.49	9.09e-27	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.0	-0.36	1.17e-14	Diabetic kidney disease;
LUAD	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg00310523	chr12:86230176	RASSF9	0.35	7.06	0.32	6.87e-12	Major depressive disorder;
LUAD	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg13870426	chr17:30244630	NA	-0.57	-6.63	-0.31	1.05e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs6894268	1.000	rs6894268	chr5:179032488	A/G	cg26135573	chr5:179059668	NA	0.52	7.9	0.36	2.38e-14	Eating disorders;
LUAD	trans	rs2544390	1.000	rs2673172	chr2:170204800	A/C	cg22333733	chr11:31391482	DNAJC24;DCDC1	-0.36	-6.35	-0.3	5.71e-10	Urate levels;
LUAD	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg11901034	chr3:128598214	ACAD9	-0.5	-7.86	-0.36	3.19e-14	IgG glycosylation;
LUAD	cis	rs4604732	0.588	rs7552461	chr1:247628644	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	9.17	0.41	2.14e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg15555402	chr12:19593456	AEBP2	0.37	6.48	0.3	2.59e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg05805236	chr11:65401703	PCNXL3	0.42	7.28	0.33	1.66e-12	Acne (severe);
LUAD	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg23625390	chr15:77176239	SCAPER	0.4	7.03	0.32	8.32e-12	Blood metabolite levels;
LUAD	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg05043794	chr9:111880884	C9orf5	-0.44	-7.57	-0.35	2.39e-13	Menarche (age at onset);
LUAD	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg09796270	chr17:17721594	SREBF1	-0.38	-7.63	-0.35	1.6e-13	Total body bone mineral density;
LUAD	cis	rs6547631	0.622	rs10187164	chr2:85928209	G/C	cg21473183	chr2:85925749	GNLY	0.35	7.49	0.34	3.92e-13	Blood protein levels;
LUAD	cis	rs2404618	0.561	rs4242536	chr8:1477225	A/G	cg13402656	chr8:1511478	DLGAP2	-0.71	-13.88	-0.56	2.24e-36	Lung cancer;
LUAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00149659	chr3:10157352	C3orf10	0.63	8.82	0.39	2.97e-17	Alzheimer's disease;
LUAD	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-23.27	-0.75	1e-77	Height;
LUAD	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg06046430	chr4:77819534	ANKRD56	-0.53	-8.82	-0.39	3.06e-17	Emphysema distribution in smoking;
LUAD	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg03188948	chr7:1209495	NA	0.75	6.83	0.32	3.01e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg18200150	chr17:30822561	MYO1D	0.65	13.14	0.54	2.7e-33	Schizophrenia;
LUAD	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg24562669	chr7:97807699	LMTK2	0.32	7.61	0.35	1.77e-13	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00699235	chr12:49962218	MCRS1	-0.44	-6.79	-0.31	3.81e-11	Height;
LUAD	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg25173405	chr17:45401733	C17orf57	-0.48	-8.21	-0.37	2.72e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4481887	0.732	rs6703399	chr1:248416343	T/C	cg00666640	chr1:248458726	OR2T12	0.33	7.91	0.36	2.31e-14	Common traits (Other);
LUAD	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.82	-12.86	-0.53	3.57e-32	Homoarginine levels;
LUAD	cis	rs68170813	0.559	rs77671232	chr7:106939202	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.98	-0.47	7.45e-25	Coronary artery disease;
LUAD	cis	rs10189230	0.967	rs13012331	chr2:222350600	G/A	cg14652038	chr2:222343519	EPHA4	0.44	8.79	0.39	3.74e-17	Urate levels in lean individuals;
LUAD	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg12623918	chr2:306882	NA	0.37	7.32	0.34	1.27e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg23286353	chr2:97523832	ANKRD39	-0.53	-6.52	-0.3	2.05e-10	Colorectal cancer;
LUAD	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg25036284	chr2:26402008	FAM59B	-0.68	-9.25	-0.41	1.16e-18	Gut microbiome composition (summer);
LUAD	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.65	-0.31	9.35e-11	Breast cancer;
LUAD	cis	rs2996428	0.536	rs12126653	chr1:3773815	C/G	cg23277830	chr1:3704460	LRRC47	0.4	7.98	0.36	1.37e-14	Red cell distribution width;
LUAD	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg07917127	chr4:99064746	C4orf37	0.42	6.97	0.32	1.24e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg27411982	chr8:10470053	RP1L1	-0.41	-7.37	-0.34	9.34e-13	Morning vs. evening chronotype;
LUAD	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg10589385	chr1:150898437	SETDB1	0.39	7.39	0.34	8e-13	Tonsillectomy;
LUAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg18538332	chr22:24372958	LOC391322	0.52	8.96	0.4	1.05e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg12573674	chr2:1569213	NA	-0.6	-7.77	-0.35	5.81e-14	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs62577244	0.645	rs111342974	chr9:138434448	G/A	cg24524451	chr7:140372725	ADCK2	-0.5	-6.35	-0.3	5.59e-10	Subcutaneous adipose tissue (sex interaction);Subcutaneous adipose tissue;
LUAD	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.46	8.09	0.37	6.48e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg14343924	chr8:8086146	FLJ10661	0.41	6.43	0.3	3.52e-10	Mood instability;
LUAD	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg15605315	chr1:45957053	TESK2	0.49	7.79	0.35	5.4e-14	High light scatter reticulocyte count;
LUAD	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg23505145	chr19:12996616	KLF1	0.61	9.97	0.44	3.56e-21	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg07423050	chr13:99094983	FARP1	-0.56	-9.44	-0.42	2.44e-19	Longevity;
LUAD	cis	rs6665290	0.904	rs6684821	chr1:227190233	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.04	-0.88	2.55e-142	Myeloid white cell count;
LUAD	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg22676075	chr6:135203613	NA	0.44	8.2	0.37	2.81e-15	Red blood cell count;
LUAD	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg19346786	chr7:2764209	NA	-0.53	-11.09	-0.47	2.81e-25	Height;
LUAD	cis	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.03	-0.36	1.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg11344533	chr11:111475393	SIK2	-0.36	-6.61	-0.31	1.13e-10	Primary sclerosing cholangitis;
LUAD	cis	rs11112613	0.609	rs4991814	chr12:106046709	G/A	cg03607813	chr12:105948248	NA	0.51	6.83	0.32	2.92e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs4664304	0.802	rs62175470	chr2:160858255	G/C	cg23995753	chr2:160760732	LY75	-0.45	-7.82	-0.36	4.23e-14	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs8067287	0.708	rs1004439	chr17:16841924	A/G	cg26910001	chr17:16838321	NA	-0.48	-6.74	-0.31	5.23e-11	Diabetic kidney disease;
LUAD	cis	rs9972944	0.756	rs7212901	chr17:63766499	T/C	cg07283582	chr17:63770753	CCDC46	-0.51	-11.29	-0.48	5.27e-26	Total body bone mineral density;
LUAD	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-7.55	-0.34	2.64e-13	Blood metabolite levels;
LUAD	cis	rs7617773	0.780	rs79089926	chr3:48348564	A/C	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs6906287	0.647	rs11153748	chr6:118773609	A/G	cg05564266	chr6:118973597	C6orf204	0.33	7.08	0.33	6.18e-12	Electrocardiographic conduction measures;
LUAD	cis	rs3820068	0.871	rs11585808	chr1:15805662	C/T	cg17177755	chr1:15930204	NA	0.46	6.55	0.3	1.69e-10	Systolic blood pressure;
LUAD	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg23649088	chr2:200775458	C2orf69	0.58	8.24	0.37	2.2e-15	Schizophrenia;
LUAD	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg18404041	chr3:52824283	ITIH1	0.52	8.99	0.4	8.16e-18	Schizophrenia;
LUAD	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg17328964	chr8:145687451	CYHR1	0.7	12.71	0.53	1.42e-31	Age at first birth;
LUAD	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg02733842	chr7:1102375	C7orf50	-0.62	-9.81	-0.43	1.31e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	10.33	0.45	1.82e-22	Lung cancer in ever smokers;
LUAD	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg03609598	chr5:56110824	MAP3K1	-0.49	-6.43	-0.3	3.4e-10	Type 2 diabetes;
LUAD	trans	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg19862616	chr7:65841803	NCRNA00174	1.04	25.7	0.78	2.02e-88	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs62238980	0.614	rs116872567	chr22:32460255	G/A	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg02782426	chr3:40428986	ENTPD3	-0.34	-7.34	-0.34	1.1e-12	Renal cell carcinoma;
LUAD	cis	rs12286929	0.637	rs7125361	chr11:115080042	C/G	cg04055981	chr11:115044050	NA	0.43	7.74	0.35	7.16e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg02782426	chr3:40428986	ENTPD3	0.36	7.45	0.34	5.13e-13	Renal cell carcinoma;
LUAD	trans	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg26043149	chr18:55253948	FECH	0.42	7.25	0.33	1.95e-12	Bone mineral density;
LUAD	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-8.37	-0.38	8.57e-16	Monocyte percentage of white cells;
LUAD	cis	rs12472274	0.941	rs36066920	chr2:239074480	T/G	cg17459225	chr2:239074497	NA	0.65	8.89	0.4	1.76e-17	Phospholipid levels (plasma);
LUAD	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg07741184	chr6:167504864	NA	0.36	8.17	0.37	3.66e-15	Primary biliary cholangitis;
LUAD	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg15468180	chr1:107600409	PRMT6	0.45	7.6	0.35	1.93e-13	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg25985355	chr7:65971099	NA	-0.55	-6.67	-0.31	8.05e-11	Diabetic kidney disease;
LUAD	trans	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg07211511	chr3:129823064	LOC729375	-0.69	-9.72	-0.43	2.63e-20	Blood pressure (smoking interaction);
LUAD	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg03474202	chr17:45855739	NA	-0.38	-9.28	-0.41	8.81e-19	IgG glycosylation;
LUAD	cis	rs2455601	0.786	rs3763914	chr11:8940703	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-7.76	-0.35	6.45e-14	Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg10823157	chr18:76829834	ATP9B	-0.4	-6.94	-0.32	1.52e-11	Cancer;
LUAD	trans	rs12439619	0.739	rs4778988	chr15:82540337	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.51	-8.01	-0.36	1.1e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-8.01	-0.36	1.14e-14	Monocyte percentage of white cells;
LUAD	cis	rs68170813	0.559	rs11761181	chr7:106954879	T/C	cg02696742	chr7:106810147	HBP1	-0.78	-10.59	-0.46	2.11e-23	Coronary artery disease;
LUAD	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg19761014	chr17:28927070	LRRC37B2	0.86	8.36	0.38	9.28e-16	Body mass index;
LUAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg26354017	chr1:205819088	PM20D1	0.59	10.79	0.46	3.83e-24	Prostate cancer;
LUAD	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg16647868	chr5:131706066	SLC22A5	0.4	6.52	0.3	1.96e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs420259	0.516	rs2097662	chr16:23523345	C/A	cg00143387	chr16:23521605	GGA2	-0.72	-10.09	-0.44	1.37e-21	Bipolar disorder;
LUAD	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg07776626	chr8:57350775	NA	-0.61	-9.05	-0.4	5.25e-18	Obesity-related traits;
LUAD	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg19193384	chr17:30244184	NA	-0.53	-6.36	-0.3	5.37e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs4953318	0.619	rs10198247	chr2:46362677	C/T	cg12428440	chr2:46370979	PRKCE	-0.42	-6.88	-0.32	2.18e-11	Red blood cell count;Hematocrit;Red blood cell traits;
LUAD	cis	rs78707713	0.841	rs79069746	chr10:71205473	T/C	cg12610070	chr10:71211762	TSPAN15	-0.42	-7.43	-0.34	6.06e-13	Venous thromboembolism;
LUAD	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.67	10.86	0.47	2.03e-24	Height;
LUAD	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg04455712	chr21:45112962	RRP1B	-0.46	-8.89	-0.4	1.73e-17	Mean corpuscular volume;
LUAD	trans	rs853679	0.546	rs2232423	chr6:28366151	A/G	cg06606381	chr12:133084897	FBRSL1	-1.23	-10.69	-0.46	9.35e-24	Depression;
LUAD	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg19761014	chr17:28927070	LRRC37B2	0.85	8.27	0.37	1.79e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7617773	0.780	rs6793239	chr3:48351618	G/T	cg11946769	chr3:48343235	NME6	0.44	6.79	0.31	3.79e-11	Coronary artery disease;
LUAD	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg20701182	chr2:24300061	SF3B14	0.9	13.55	0.55	5.63e-35	Lymphocyte counts;
LUAD	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg27494647	chr7:150038898	RARRES2	0.5	8.61	0.39	1.48e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg07570687	chr10:102243282	WNT8B	0.44	6.76	0.31	4.6e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg05340658	chr4:99064831	C4orf37	0.44	7.34	0.34	1.07e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.74	13.57	0.55	4.45e-35	Axial length;
LUAD	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg14949292	chr17:78079608	GAA	-0.35	-6.5	-0.3	2.29e-10	Yeast infection;
LUAD	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg21782813	chr7:2030301	MAD1L1	-0.42	-6.72	-0.31	6.02e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg11301795	chr4:187892539	NA	-0.76	-15.15	-0.59	9.69e-42	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg08916839	chr5:415575	AHRR	0.78	9.31	0.41	7.05e-19	Fat distribution (HIV);
LUAD	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg25985355	chr7:65971099	NA	-0.54	-6.65	-0.31	9.04e-11	Diabetic kidney disease;
LUAD	cis	rs7520050	0.801	rs6703960	chr1:46232723	C/T	cg06784218	chr1:46089804	CCDC17	-0.35	-7.56	-0.34	2.61e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg23978390	chr7:1156363	C7orf50	0.52	8.27	0.37	1.8e-15	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg18180107	chr4:99064573	C4orf37	0.42	6.68	0.31	7.57e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11229555	0.645	rs56228632	chr11:58187444	A/G	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2735413	0.918	rs7197254	chr16:78063353	C/G	cg04733911	chr16:78082701	NA	-0.34	-7.9	-0.36	2.42e-14	Systolic blood pressure (alcohol consumption interaction);
LUAD	trans	rs7395662	0.853	rs4882054	chr11:48399899	A/G	cg00717180	chr2:96193071	NA	-0.38	-7.05	-0.32	7.55e-12	HDL cholesterol;
LUAD	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg18129748	chr3:49941408	MST1R	0.41	6.9	0.32	1.86e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg18761221	chr20:60518478	NA	0.37	6.48	0.3	2.51e-10	Body mass index;
LUAD	cis	rs7582720	1.000	rs72934753	chr2:203750272	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	trans	rs9503551	0.642	rs4451182	chr6:3333156	A/G	cg13915676	chr9:139305538	SDCCAG3;PMPCA	0.49	6.48	0.3	2.52e-10	Nicotine dependence;
LUAD	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg14668632	chr7:2872130	GNA12	0.7	12.64	0.52	2.82e-31	Height;
LUAD	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg26384229	chr12:38710491	ALG10B	0.4	6.49	0.3	2.46e-10	Morning vs. evening chronotype;
LUAD	trans	rs7395662	0.833	rs1963073	chr11:48975094	T/A	cg00717180	chr2:96193071	NA	-0.44	-8.53	-0.38	2.62e-16	HDL cholesterol;
LUAD	trans	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.57	0.46	2.51e-23	Ulcerative colitis;
LUAD	cis	rs7692976	0.552	rs7698924	chr4:110942102	C/G	cg06981781	chr4:110842888	EGF	0.43	7.49	0.34	4.04e-13	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg13736514	chr6:26305472	NA	-0.54	-9.62	-0.42	6.06e-20	Educational attainment;
LUAD	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg03806693	chr22:41940476	POLR3H	0.73	9.89	0.43	6.67e-21	Vitiligo;
LUAD	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg26373071	chr5:1325741	CLPTM1L	0.35	7.51	0.34	3.47e-13	Lung cancer;
LUAD	cis	rs657075	0.697	rs71583478	chr5:131688824	C/T	cg21138405	chr5:131827807	IRF1	0.55	6.54	0.3	1.75e-10	Rheumatoid arthritis;
LUAD	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg07607921	chr17:4047574	ZZEF1;CYB5D2	-0.39	-6.78	-0.31	3.98e-11	Type 2 diabetes;
LUAD	cis	rs7487075	0.619	rs11183478	chr12:46824066	G/A	cg23829395	chr12:46796953	NA	0.3	6.36	0.3	5.11e-10	Itch intensity from mosquito bite;
LUAD	cis	rs500891	0.525	rs4706991	chr6:84109088	C/T	cg08257003	chr6:84140564	ME1	0.34	6.39	0.3	4.26e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg17971929	chr21:40555470	PSMG1	0.56	8.88	0.4	1.97e-17	Cognitive function;
LUAD	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg17652424	chr22:38574118	PLA2G6	-0.32	-9.74	-0.43	2.36e-20	Cutaneous nevi;
LUAD	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg26384229	chr12:38710491	ALG10B	0.45	7.55	0.34	2.67e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08219700	chr8:58056026	NA	0.7	9.12	0.41	3.03e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs859767	0.704	rs7558554	chr2:135357203	C/G	cg12500956	chr2:135428796	TMEM163	0.3	7.56	0.35	2.49e-13	Neuroticism;
LUAD	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg02993280	chr1:107599747	PRMT6	-0.55	-8.94	-0.4	1.19e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs12532878	0.652	rs62482223	chr7:100198878	C/A	cg16850897	chr7:100343110	ZAN	-0.48	-7.27	-0.33	1.72e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs727505	1.000	rs67552763	chr7:124517857	A/G	cg23710748	chr7:124431027	NA	-0.47	-9.57	-0.42	8.81e-20	Lewy body disease;
LUAD	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg09491104	chr22:46646882	C22orf40	-0.55	-7.7	-0.35	9.53e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs758324	0.812	rs667419	chr5:131282064	A/G	cg06307176	chr5:131281290	NA	0.45	7.56	0.34	2.6e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-11.11	-0.48	2.4e-25	Bipolar disorder and schizophrenia;
LUAD	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg00717180	chr2:96193071	NA	-0.4	-7.4	-0.34	7.32e-13	HDL cholesterol;
LUAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19717773	chr7:2847554	GNA12	-0.56	-9.64	-0.42	5.25e-20	Height;
LUAD	cis	rs7831492	0.564	rs6981979	chr8:41612255	C/T	cg17182837	chr8:41585554	ANK1	-0.41	-8.72	-0.39	6.59e-17	Colorectal cancer;
LUAD	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg11814155	chr7:99998594	ZCWPW1	0.4	6.89	0.32	1.99e-11	Platelet count;
LUAD	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg09537434	chr19:41945824	ATP5SL	0.54	8.57	0.38	1.91e-16	Height;
LUAD	cis	rs34734847	0.787	rs1814851	chr12:121128633	C/G	cg27246729	chr12:121163418	ACADS	0.37	6.81	0.31	3.42e-11	Mean corpuscular volume;
LUAD	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg02160872	chr5:212506	CCDC127	-0.51	-6.59	-0.31	1.3100000000000001e-10	Breast cancer;
LUAD	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg14668632	chr7:2872130	GNA12	-0.74	-13.49	-0.55	9.61e-35	Height;
LUAD	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg19761014	chr17:28927070	LRRC37B2	0.86	8.28	0.37	1.62e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.85	0.56	3.1e-36	Prudent dietary pattern;
LUAD	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg09035930	chr12:129282057	SLC15A4	0.68	14.79	0.58	3.48e-40	Systemic lupus erythematosus;
LUAD	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg05340658	chr4:99064831	C4orf37	0.44	6.73	0.31	5.55e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs735539	0.958	rs1075690	chr13:21279690	G/A	cg04906043	chr13:21280425	IL17D	-0.39	-6.94	-0.32	1.48e-11	Dental caries;
LUAD	trans	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg20542592	chr8:11973495	FAM66D	-0.42	-6.71	-0.31	6.42e-11	Parkinson's disease;
LUAD	cis	rs2742234	0.910	rs2505511	chr10:43641029	T/A	cg02780029	chr10:43622663	RET	-0.44	-7.18	-0.33	3.18e-12	Hirschsprung disease;
LUAD	cis	rs73206853	0.563	rs7301769	chr12:111171026	T/C	cg12870014	chr12:110450643	ANKRD13A	0.6	7.0	0.32	1.02e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg09509183	chr1:209979624	IRF6	0.37	6.52	0.3	1.96e-10	Monobrow;
LUAD	cis	rs684232	0.602	rs384628	chr17:554912	G/A	cg12384639	chr17:618140	VPS53	0.48	8.23	0.37	2.29e-15	Prostate cancer;
LUAD	cis	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg20368463	chr18:77673604	PQLC1	-0.51	-7.43	-0.34	6.11e-13	Opioid sensitivity;
LUAD	cis	rs6847149	1.000	rs6852679	chr4:110804414	T/C	cg07850274	chr4:110748770	RRH	0.49	6.97	0.32	1.2e-11	Exercise treadmill test traits;
LUAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.5	-0.38	3.27e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg13012494	chr21:47604986	C21orf56	-0.52	-8.55	-0.38	2.3e-16	Testicular germ cell tumor;
LUAD	cis	rs3849570	0.615	rs6766011	chr3:81986136	G/A	cg07356753	chr3:81810745	GBE1	-0.48	-7.91	-0.36	2.34e-14	Waist circumference;Body mass index;
LUAD	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg21475434	chr5:93447410	FAM172A	0.57	7.54	0.34	2.96e-13	Diabetic retinopathy;
LUAD	cis	rs367943	0.712	rs1850407	chr5:112721569	C/A	cg12552261	chr5:112820674	MCC	0.47	9.21	0.41	1.58e-18	Type 2 diabetes;
LUAD	cis	rs9863	0.896	rs12311114	chr12:124460703	A/C	cg17723958	chr12:124429295	CCDC92	0.4	6.56	0.3	1.59e-10	White blood cell count;
LUAD	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg23985595	chr17:80112537	CCDC57	0.53	9.73	0.43	2.45e-20	Life satisfaction;
LUAD	trans	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg17712092	chr4:129076599	LARP1B	-0.67	-10.82	-0.47	3.06e-24	DNA methylation (variation);
LUAD	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg23855989	chr12:50355821	AQP5	0.48	7.45	0.34	5.3e-13	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-9.23	-0.41	1.32e-18	Total body bone mineral density;
LUAD	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg03289416	chr15:75166202	SCAMP2	0.58	10.25	0.45	3.76e-22	Breast cancer;
LUAD	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg27170947	chr2:26402098	FAM59B	-0.82	-11.49	-0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg06064525	chr11:970664	AP2A2	-0.54	-11.28	-0.48	5.52e-26	Alzheimer's disease (late onset);
LUAD	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.4	-0.3	4.24e-10	Systemic lupus erythematosus;
LUAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.49	6.52	0.3	2.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.84	-0.32	2.85e-11	Schizophrenia;
LUAD	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg22532475	chr10:104410764	TRIM8	-0.44	-8.56	-0.38	2.09e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2742234	0.955	rs2075910	chr10:43614230	G/A	cg02780029	chr10:43622663	RET	-0.42	-6.84	-0.32	2.79e-11	Hirschsprung disease;
LUAD	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg01528321	chr10:82214614	TSPAN14	0.68	11.11	0.48	2.5e-25	Post bronchodilator FEV1;
LUAD	cis	rs12042107	0.818	rs12568187	chr1:91193691	T/C	cg13456504	chr1:91191583	NA	0.32	6.53	0.3	1.93e-10	Educational attainment;
LUAD	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg02018176	chr4:1364513	KIAA1530	-0.58	-10.44	-0.45	7.59e-23	Obesity-related traits;
LUAD	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg09796270	chr17:17721594	SREBF1	-0.39	-7.59	-0.35	2.13e-13	Total body bone mineral density;
LUAD	cis	rs7833986	0.501	rs2953898	chr8:56980803	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	1.01	18.4	0.67	5.68e-56	Height;
LUAD	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg06623918	chr6:96969491	KIAA0776	0.87	17.25	0.64	7.12e-51	Headache;
LUAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-8.21	-0.37	2.76e-15	Alzheimer's disease;
LUAD	cis	rs2274273	0.870	rs4496026	chr14:55790512	A/G	cg04306507	chr14:55594613	LGALS3	0.44	9.18	0.41	1.99e-18	Protein biomarker;
LUAD	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg05110241	chr16:68378359	PRMT7	-0.69	-7.85	-0.36	3.34e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26314531	chr2:26401878	FAM59B	-0.7	-9.53	-0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg17063962	chr7:91808500	NA	0.67	12.13	0.51	2.93e-29	Breast cancer;
LUAD	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg17063962	chr7:91808500	NA	0.72	12.76	0.53	8.62e-32	Breast cancer;
LUAD	cis	rs9393692	0.620	rs12525187	chr6:26337537	A/G	cg13736514	chr6:26305472	NA	-0.49	-8.34	-0.38	1.05e-15	Educational attainment;
LUAD	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg04398451	chr17:18023971	MYO15A	0.88	16.77	0.63	9.36e-49	Total body bone mineral density;
LUAD	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg00339695	chr16:24857497	SLC5A11	0.72	11.6	0.49	3.45e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg14582100	chr15:45693742	SPATA5L1	0.52	9.72	0.43	2.84e-20	Homoarginine levels;
LUAD	trans	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs1451375	0.583	rs11575320	chr7:50605298	A/G	cg18232548	chr7:50535776	DDC	-0.63	-8.93	-0.4	1.33e-17	Malaria;
LUAD	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.4	6.84	0.32	2.74e-11	Type 2 diabetes;
LUAD	cis	rs35146811	0.586	rs34213597	chr7:99591021	C/T	cg22906224	chr7:99728672	NA	0.54	8.34	0.38	1.02e-15	Coronary artery disease;
LUAD	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg04944784	chr2:26401820	FAM59B	0.9	13.27	0.54	7.57e-34	Gut microbiome composition (summer);
LUAD	cis	rs35205176	0.644	rs35026323	chr7:51579192	G/A	cg20478239	chr7:51544475	NA	-0.34	-6.45	-0.3	3.09e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg17063962	chr7:91808500	NA	0.65	11.02	0.47	5.43e-25	Breast cancer;
LUAD	cis	rs6484504	0.600	rs942272	chr11:31364368	C/T	cg14844989	chr11:31128820	NA	0.45	8.36	0.38	9.13e-16	Red blood cell count;
LUAD	trans	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.94	0.44	4.58e-21	Ulcerative colitis;
LUAD	cis	rs11168351	0.864	rs10875743	chr12:48498413	C/T	cg04545296	chr12:48745243	ZNF641	-0.33	-8.58	-0.38	1.86e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	10.55	0.46	3e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg06002616	chr8:101225028	SPAG1	-0.39	-8.04	-0.36	8.91e-15	Atrioventricular conduction;
LUAD	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg08439880	chr3:133502540	NA	0.36	6.82	0.31	3.2e-11	Iron status biomarkers;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg16390570	chr7:100860924	PLOD3;ZNHIT1	-0.64	-8.01	-0.36	1.12e-14	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg21385522	chr1:16154831	NA	0.44	6.66	0.31	8.76e-11	Dilated cardiomyopathy;
LUAD	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-7.31	-0.33	1.38e-12	Morning vs. evening chronotype;
LUAD	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg17346650	chr17:80929145	B3GNTL1	0.38	6.42	0.3	3.59e-10	Glycated hemoglobin levels;
LUAD	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg21699342	chr2:239360505	ASB1	-0.45	-7.25	-0.33	2.04e-12	Multiple system atrophy;
LUAD	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg24818145	chr4:99064322	C4orf37	0.48	7.85	0.36	3.34e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs208520	0.802	rs208499	chr6:66932146	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-14.37	-0.57	2.14e-38	Exhaled nitric oxide output;
LUAD	trans	rs208520	0.690	rs207112	chr6:66792092	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.32	-0.64	3.48e-51	Exhaled nitric oxide output;
LUAD	cis	rs2880765	0.835	rs7163958	chr15:86045215	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.37	-6.35	-0.3	5.56e-10	Coronary artery disease;
LUAD	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg05425664	chr17:57184151	TRIM37	-0.45	-8.0	-0.36	1.19e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg21153622	chr11:89784906	NA	-0.35	-6.86	-0.32	2.4e-11	HDL cholesterol;
LUAD	cis	rs601339	1.000	rs11059384	chr12:123170301	C/A	cg11919336	chr12:123188078	GPR109A	0.48	7.18	0.33	3.25e-12	Adiponectin levels;
LUAD	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg09491104	chr22:46646882	C22orf40	-0.73	-13.2	-0.54	1.46e-33	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg07169764	chr2:136633963	MCM6	0.65	7.87	0.36	3.04e-14	Corneal structure;
LUAD	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg23301539	chr8:142222248	SLC45A4	0.49	8.87	0.4	2.11e-17	Immature fraction of reticulocytes;
LUAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg20607798	chr8:58055168	NA	0.8	10.02	0.44	2.31e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs4774899	0.902	rs2414491	chr15:57465775	A/G	cg14026238	chr15:57616123	NA	0.37	6.93	0.32	1.62e-11	Urinary tract infection frequency;
LUAD	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg09455208	chr3:40491958	NA	0.65	14.24	0.57	6.94e-38	Renal cell carcinoma;
LUAD	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg02734326	chr4:10020555	SLC2A9	-0.45	-7.64	-0.35	1.42e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2479724	0.901	rs6458244	chr6:41790455	C/T	cg17623882	chr6:41773611	USP49	0.68	12.63	0.52	2.86e-31	Menarche (age at onset);
LUAD	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.76	-0.5	8.33e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1483890	0.723	rs12629224	chr3:69411188	T/C	cg22125112	chr3:69402811	FRMD4B	0.45	7.55	0.34	2.79e-13	Resting heart rate;
LUAD	cis	rs6835098	0.924	rs2332669	chr4:174163398	G/A	cg08422745	chr4:174089978	GALNT7	-0.82	-14.54	-0.58	3.92e-39	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs2279817	0.743	rs12023874	chr1:18025612	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.55	9.24	0.41	1.2e-18	Neuroticism;
LUAD	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs12210905	0.688	rs72845011	chr6:27500822	T/G	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs939658	1.000	rs17175798	chr15:79463960	A/G	cg17916960	chr15:79447300	NA	0.48	9.99	0.44	3.11e-21	Refractive error;
LUAD	trans	rs12517041	0.935	rs35858834	chr5:23325233	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.48	-6.87	-0.32	2.34e-11	Calcium levels;
LUAD	cis	rs6987853	0.787	rs2923402	chr8:42445400	G/A	cg09913449	chr8:42400586	C8orf40	0.47	9.23	0.41	1.34e-18	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10819733	chr22:24237672	NA	-0.39	-7.18	-0.33	3.2e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg16988262	chr1:15930761	NA	0.4	6.81	0.31	3.37e-11	Systolic blood pressure;
LUAD	cis	rs4699052	0.826	rs17033498	chr4:104179961	C/G	cg16532752	chr4:104119610	CENPE	-0.48	-7.19	-0.33	2.93e-12	Testicular germ cell tumor;
LUAD	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.85e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg11859384	chr17:80120422	CCDC57	0.5	8.95	0.4	1.15e-17	Life satisfaction;
LUAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg12432903	chr7:1882776	MAD1L1	-0.58	-9.34	-0.41	5.7e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs62238980	0.522	rs117129307	chr22:32519810	A/C	cg00543991	chr22:32367038	NA	0.88	8.51	0.38	3.06e-16	Childhood ear infection;
LUAD	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg02079420	chr8:82753780	SNX16	0.4	8.02	0.36	1.01e-14	Diastolic blood pressure;
LUAD	cis	rs11048434	0.666	rs12371786	chr12:9090086	G/A	cg13575925	chr12:9217583	LOC144571	0.39	7.26	0.33	1.93e-12	Sjögren's syndrome;
LUAD	cis	rs6906287	0.647	rs12199463	chr6:118826695	A/G	cg05564266	chr6:118973597	C6orf204	-0.35	-7.43	-0.34	6.06e-13	Electrocardiographic conduction measures;
LUAD	cis	rs4638749	1.000	rs10209928	chr2:108863898	C/T	cg06795125	chr2:108905320	SULT1C2	-0.42	-6.62	-0.31	1.1e-10	Blood pressure;
LUAD	cis	rs732716	0.889	rs11085074	chr19:4386352	A/G	cg21934504	chr19:4445085	UBXN6	0.46	7.71	0.35	9.19e-14	Mean corpuscular volume;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg11408656	chr1:226497275	LIN9	-0.73	-7.06	-0.32	6.77e-12	Type 2 diabetes;
LUAD	cis	rs2651899	0.902	rs1736522	chr1:3080940	C/G	cg22396632	chr1:3079212	PRDM16	-0.38	-8.75	-0.39	5.31e-17	Migraine;
LUAD	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06022373	chr22:39101656	GTPBP1	0.5	8.3	0.37	1.38e-15	Menopause (age at onset);
LUAD	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06028808	chr11:68637592	NA	0.4	6.58	0.3	1.39e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4523957	0.890	rs11078024	chr17:2189324	T/C	cg16513277	chr17:2031491	SMG6	0.77	14.36	0.57	2.28e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg02421172	chr7:1938701	MAD1L1	0.45	6.73	0.31	5.41e-11	Bipolar disorder;
LUAD	cis	rs11971779	0.618	rs6943788	chr7:139087697	C/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.18	0.48	1.36e-25	Eosinophil percentage of white cells;
LUAD	cis	rs55823223	0.648	rs72860389	chr17:73866071	C/T	cg04225089	chr17:73874465	TRIM47	-0.45	-7.78	-0.35	5.46e-14	Psoriasis;
LUAD	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg21918786	chr6:109611834	NA	-0.61	-11.39	-0.48	2.21e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg19163074	chr7:65112434	INTS4L2	0.44	6.76	0.31	4.62e-11	Aortic root size;
LUAD	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg06263672	chr7:65235340	NA	0.48	6.59	0.31	1.33e-10	Aortic root size;
LUAD	cis	rs9878978	1.000	rs13074392	chr3:2485795	A/G	cg21928760	chr3:2462534	CNTN4	-0.33	-6.54	-0.3	1.81e-10	Blood pressure (smoking interaction);
LUAD	cis	rs9462027	0.628	rs1998702	chr6:34741917	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.1	-0.4	3.57e-18	Systemic lupus erythematosus;
LUAD	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg12940439	chr1:67600707	NA	0.5	9.53	0.42	1.29e-19	Psoriasis;
LUAD	cis	rs1034435	0.962	rs1894542	chr22:48890335	G/C	cg05992904	chr22:48892994	FAM19A5	-0.71	-14.76	-0.58	4.68e-40	Late-onset Alzheimer's disease;
LUAD	cis	rs9972944	0.692	rs8071561	chr17:63763434	C/T	cg07283582	chr17:63770753	CCDC46	-0.5	-11.39	-0.48	2.2e-26	Total body bone mineral density;
LUAD	cis	rs1509123	0.609	rs7224971	chr17:6713999	A/T	cg12642237	chr17:6703447	TEKT1	0.53	7.56	0.34	2.6e-13	Blood metabolite levels;
LUAD	cis	rs240764	0.658	rs705584	chr6:101261553	C/T	cg09795085	chr6:101329169	ASCC3	0.46	8.11	0.37	5.72e-15	Neuroticism;
LUAD	cis	rs9394841	0.667	rs9367112	chr6:41769920	T/C	cg25600774	chr6:41776562	USP49	-0.44	-6.7	-0.31	6.63e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg11965913	chr1:205819406	PM20D1	0.53	9.02	0.4	6.54e-18	Menarche (age at onset);
LUAD	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg03609598	chr5:56110824	MAP3K1	-0.68	-9.23	-0.41	1.26e-18	Initial pursuit acceleration;
LUAD	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg23262073	chr20:60523788	NA	-0.66	-10.77	-0.46	4.49e-24	Obesity-related traits;
LUAD	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg05110241	chr16:68378359	PRMT7	-0.69	-7.9	-0.36	2.52e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg12698349	chr2:225449008	CUL3	-0.65	-9.94	-0.44	4.52e-21	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg27211696	chr2:191398769	TMEM194B	-0.58	-7.67	-0.35	1.19e-13	Diastolic blood pressure;
LUAD	cis	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.77	-0.35	6.14e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.65	11.51	0.49	7.22e-27	Breast cancer;
LUAD	cis	rs909341	0.537	rs11696871	chr20:62387417	C/T	cg14758556	chr20:62440591	NA	0.48	7.09	0.33	5.73e-12	Atopic dermatitis;
LUAD	trans	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg26597838	chr10:835615	NA	0.68	8.87	0.4	2.09e-17	Eosinophil percentage of granulocytes;
LUAD	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg00071950	chr4:10020882	SLC2A9	0.85	18.61	0.67	6.8e-57	Bone mineral density;
LUAD	cis	rs7827545	1.000	rs4909911	chr8:135565255	G/A	cg17885191	chr8:135476712	NA	0.5	7.97	0.36	1.53e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg09658497	chr7:2847517	GNA12	0.53	9.08	0.4	4.27e-18	Height;
LUAD	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg11189052	chr15:85197271	WDR73	-0.58	-9.58	-0.42	8.63e-20	P wave terminal force;
LUAD	cis	rs2625529	0.529	rs1552133	chr15:72232897	T/A	cg16672083	chr15:72433130	SENP8	0.62	11.47	0.49	1.07e-26	Red blood cell count;
LUAD	trans	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg20587970	chr11:113659929	NA	1.06	13.67	0.55	1.72e-35	Hip circumference adjusted for BMI;
LUAD	cis	rs4372836	0.504	rs13030945	chr2:29087799	C/A	cg09522027	chr2:28974177	PPP1CB	-0.6	-10.66	-0.46	1.17e-23	Body mass index;
LUAD	cis	rs1692580	0.870	rs263532	chr1:2164116	T/C	cg21194808	chr1:2205498	SKI	0.49	8.59	0.39	1.67e-16	Coronary artery disease;
LUAD	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.36	-0.6	1.23e-42	Chronic sinus infection;
LUAD	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.78	-0.39	4.19e-17	Total body bone mineral density;
LUAD	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.54	-9.98	-0.44	3.4e-21	Axial length;
LUAD	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.32	-7.11	-0.33	4.92e-12	Dupuytren's disease;
LUAD	cis	rs6500395	1.000	rs1004909	chr16:48725580	C/G	cg04672837	chr16:48644449	N4BP1	-0.36	-6.35	-0.3	5.49e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg18187862	chr3:45730750	SACM1L	0.5	7.9	0.36	2.36e-14	Primary sclerosing cholangitis;
LUAD	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg05709478	chr1:6581295	PLEKHG5	0.58	6.4	0.3	4.19e-10	Body mass index;
LUAD	trans	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg18187862	chr3:45730750	SACM1L	0.58	9.1	0.4	3.5e-18	Primary sclerosing cholangitis;
LUAD	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg00634984	chr7:65235879	NA	-0.51	-6.87	-0.32	2.36e-11	Aortic root size;
LUAD	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg23625390	chr15:77176239	SCAPER	0.4	7.25	0.33	1.97e-12	Blood metabolite levels;
LUAD	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg22117172	chr7:91764530	CYP51A1	0.33	7.29	0.33	1.57e-12	Breast cancer;
LUAD	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg02896835	chr1:92012615	NA	-0.6	-12.64	-0.52	2.64e-31	Breast cancer;
LUAD	cis	rs8051149	0.738	rs2287120	chr16:87871582	G/A	cg10099957	chr16:87869757	SLC7A5	0.43	6.98	0.32	1.12e-11	Blood metabolite levels;
LUAD	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg25703541	chr22:24373054	LOC391322	-0.75	-13.12	-0.54	3.12e-33	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6992820	0.902	rs6999008	chr8:56768236	G/A	cg06880721	chr8:56792545	LYN	-0.5	-8.23	-0.37	2.38e-15	Mean platelet volume;
LUAD	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-6.65	-0.31	8.8e-11	IgG glycosylation;
LUAD	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-8.92	-0.4	1.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4285028	0.898	rs12491991	chr3:121706021	A/C	cg20356878	chr3:121714668	ILDR1	0.5	6.78	0.31	4.08e-11	Multiple sclerosis;
LUAD	cis	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg24476569	chr13:95954382	ABCC4	-0.59	-10.92	-0.47	1.25e-24	Blood metabolite levels;
LUAD	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg11494091	chr17:61959527	GH2	0.41	7.07	0.33	6.39e-12	Height;
LUAD	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg24818145	chr4:99064322	C4orf37	0.47	7.98	0.36	1.37e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10992471	0.603	rs7045572	chr9:95137964	T/C	cg14631576	chr9:95140430	CENPP	-0.56	-11.46	-0.49	1.18e-26	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg26022315	chr17:47021804	SNF8	0.4	7.22	0.33	2.51e-12	Type 2 diabetes;
LUAD	cis	rs8177876	0.822	rs28672349	chr16:81114373	T/C	cg08591886	chr16:81111003	C16orf46	-0.76	-6.97	-0.32	1.26e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg24644049	chr4:85504048	CDS1	0.92	8.03	0.36	1.01e-14	Skin colour saturation;
LUAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.91e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg02569458	chr12:86230093	RASSF9	0.44	8.29	0.37	1.53e-15	Major depressive disorder;
LUAD	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg09365446	chr1:150670422	GOLPH3L	0.66	12.3	0.51	6.1e-30	Tonsillectomy;
LUAD	cis	rs7264396	0.563	rs6058302	chr20:34290037	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.26	-0.37	1.85e-15	Total cholesterol levels;
LUAD	cis	rs6987853	0.527	rs3935700	chr8:42364121	T/C	cg09913449	chr8:42400586	C8orf40	-0.34	-6.48	-0.3	2.49e-10	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.17	0.33	3.34e-12	Motion sickness;
LUAD	cis	rs6424115	0.867	rs4649119	chr1:24171543	C/G	cg15997130	chr1:24165203	NA	-0.55	-9.37	-0.41	4.46e-19	Immature fraction of reticulocytes;
LUAD	trans	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.86	0.36	3.25e-14	Resting heart rate;
LUAD	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg24154853	chr7:158122151	PTPRN2	0.56	11.17	0.48	1.4e-25	Calcium levels;
LUAD	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg15448220	chr1:150897856	SETDB1	0.49	8.49	0.38	3.56e-16	Tonsillectomy;
LUAD	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg04414720	chr1:150670196	GOLPH3L	0.6	10.36	0.45	1.48e-22	Melanoma;
LUAD	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg21856205	chr7:94953877	PON1	-0.55	-7.75	-0.35	7.14e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4713675	0.565	rs9394161	chr6:33669793	G/C	cg14003231	chr6:33640908	ITPR3	0.49	9.41	0.42	3.29e-19	Plateletcrit;
LUAD	cis	rs2377058	0.882	rs11646741	chr16:89730084	G/C	cg03605463	chr16:89740564	NA	-0.59	-10.23	-0.45	4.1e-22	Hip circumference adjusted for BMI;
LUAD	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg04944784	chr2:26401820	FAM59B	-0.88	-12.58	-0.52	4.91e-31	Gut microbiome composition (summer);
LUAD	cis	rs62025270	0.547	rs386346	chr15:86194559	A/T	cg13263323	chr15:86062960	AKAP13	0.45	7.34	0.34	1.11e-12	Idiopathic pulmonary fibrosis;
LUAD	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg06784218	chr1:46089804	CCDC17	-0.53	-11.59	-0.49	3.71e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.18	-0.33	3.16e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs34734847	0.703	rs3794215	chr12:121168083	T/C	cg27246729	chr12:121163418	ACADS	0.35	6.5	0.3	2.25e-10	Mean corpuscular volume;
LUAD	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg23283495	chr1:209979779	IRF6	-0.64	-8.62	-0.39	1.31e-16	Cleft lip with or without cleft palate;
LUAD	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-7.95	-0.36	1.67e-14	Diabetic kidney disease;
LUAD	cis	rs7536201	1.000	rs7536848	chr1:25294345	A/C	cg23273869	chr1:25296894	NA	-0.36	-7.19	-0.33	2.87e-12	Psoriasis vulgaris;
LUAD	cis	rs11051970	0.655	rs7298381	chr12:32530257	G/T	cg02745156	chr12:32552066	NA	0.31	6.67	0.31	7.96e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.44	0.38	5.28e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs6426558	0.559	rs7549520	chr1:227258858	G/C	cg10327440	chr1:227177885	CDC42BPA	0.57	9.12	0.41	3.1e-18	Neutrophil percentage of white cells;
LUAD	cis	rs4766566	0.694	rs3847952	chr12:111746678	T/G	cg10833066	chr12:111807467	FAM109A	0.68	13.91	0.56	1.77e-36	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUAD	cis	rs1832871	0.711	rs6920506	chr6:158695017	T/A	cg07165851	chr6:158734300	TULP4	0.7	10.88	0.47	1.85e-24	Height;
LUAD	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg24675056	chr1:15929824	NA	0.49	8.53	0.38	2.66e-16	Systolic blood pressure;
LUAD	cis	rs6906287	0.647	rs11153763	chr6:118938738	G/A	cg21191810	chr6:118973309	C6orf204	0.5	9.57	0.42	9.03e-20	Electrocardiographic conduction measures;
LUAD	cis	rs62238980	0.614	rs117655982	chr22:32461141	T/C	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg05313129	chr8:58192883	C8orf71	-0.57	-8.41	-0.38	6.38e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg25036284	chr2:26402008	FAM59B	-0.58	-8.17	-0.37	3.48e-15	Gut microbiome composition (summer);
LUAD	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.28	-0.33	1.62e-12	Total body bone mineral density;
LUAD	cis	rs1448094	0.842	rs10779231	chr12:86462237	T/C	cg18827107	chr12:86230957	RASSF9	0.44	7.95	0.36	1.76e-14	Major depressive disorder;
LUAD	cis	rs9527	0.830	rs3740392	chr10:104636855	T/C	cg15744005	chr10:104629667	AS3MT	-0.4	-6.95	-0.32	1.37e-11	Arsenic metabolism;
LUAD	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg18129748	chr3:49941408	MST1R	-0.42	-6.86	-0.32	2.53e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.24	-0.33	2.18e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6496044	0.547	rs7173125	chr15:86055445	C/G	cg13263323	chr15:86062960	AKAP13	0.55	10.04	0.44	2.09e-21	Interstitial lung disease;
LUAD	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg23649088	chr2:200775458	C2orf69	0.62	8.47	0.38	4.24e-16	Schizophrenia;
LUAD	cis	rs2485376	0.967	rs72845670	chr10:104106200	T/C	cg20641465	chr10:103991465	PITX3	-0.53	-9.88	-0.43	7.63e-21	QT interval;
LUAD	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg27068330	chr11:65405492	SIPA1	-0.78	-12.77	-0.53	8.18e-32	Acne (severe);
LUAD	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-11.34	-0.48	3.22e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg23018236	chr17:30244563	NA	0.62	7.79	0.35	5.19e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg15242686	chr22:24348715	GSTTP1	0.39	6.66	0.31	8.38e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.9	0.36	2.43e-14	Breast cancer;
LUAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05901451	chr6:126070800	HEY2	0.59	9.18	0.41	1.99e-18	Endometrial cancer;
LUAD	trans	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg20587970	chr11:113659929	NA	1.11	15.17	0.59	7.85e-42	Hip circumference adjusted for BMI;
LUAD	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.45	-6.88	-0.32	2.22e-11	Breast cancer;
LUAD	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg05187965	chr10:45406764	TMEM72	-0.47	-9.18	-0.41	1.95e-18	Mean corpuscular volume;
LUAD	cis	rs427394	0.582	rs274665	chr5:6707981	C/T	cg10857441	chr5:6722123	POLS	-0.59	-10.45	-0.45	6.74e-23	Menopause (age at onset);
LUAD	cis	rs807669	0.869	rs1061325	chr22:19184095	T/C	cg02655711	chr22:19163373	SLC25A1	0.63	12.66	0.52	2.22e-31	Metabolite levels;
LUAD	cis	rs89107	0.688	rs283087	chr6:118596207	C/T	cg21191810	chr6:118973309	C6orf204	0.5	9.89	0.43	6.84e-21	Cardiac structure and function;
LUAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	6.75	0.31	4.99e-11	Renal function-related traits (BUN);
LUAD	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-7.88	-0.36	2.82e-14	Blood metabolite levels;
LUAD	cis	rs1003719	0.715	rs8130643	chr21:38551715	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.4	-0.38	6.71e-16	Eye color traits;
LUAD	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg02734326	chr4:10020555	SLC2A9	0.57	9.82	0.43	1.2e-20	Bone mineral density;
LUAD	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg06873352	chr17:61820015	STRADA	0.42	6.99	0.32	1.07e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs250677	0.522	rs62378210	chr5:148384885	G/A	cg18129178	chr5:148520854	ABLIM3	-0.51	-7.61	-0.35	1.79e-13	Breast cancer;
LUAD	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg11822812	chr5:140052017	DND1	0.36	6.45	0.3	3.14e-10	Schizophrenia;
LUAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.68	-13.22	-0.54	1.27e-33	Prudent dietary pattern;
LUAD	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg00666640	chr1:248458726	OR2T12	-0.31	-7.82	-0.36	4.22e-14	Common traits (Other);
LUAD	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg11189052	chr15:85197271	WDR73	0.58	7.28	0.33	1.65e-12	Schizophrenia;
LUAD	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg21204522	chr6:27730016	NA	-0.43	-6.92	-0.32	1.66e-11	Parkinson's disease;
LUAD	cis	rs2131877	0.913	rs950256	chr3:194847752	C/T	cg19760965	chr3:194868843	C3orf21	0.43	6.7	0.31	6.65e-11	Non-small cell lung cancer;
LUAD	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg03433033	chr1:76189801	ACADM	0.78	15.51	0.6	2.94e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.83	-0.32	2.95e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg25767906	chr1:53392781	SCP2	0.41	7.3	0.33	1.45e-12	Monocyte count;
LUAD	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg21138405	chr5:131827807	IRF1	0.6	13.77	0.56	6.51e-36	Asthma (sex interaction);
LUAD	trans	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.71	12.31	0.51	5.78e-30	Mean corpuscular volume;
LUAD	cis	rs7301826	0.651	rs4759521	chr12:131297313	C/T	cg11011512	chr12:131303247	STX2	0.44	7.41	0.34	6.76e-13	Plasma plasminogen activator levels;
LUAD	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg25233709	chr10:116636983	FAM160B1	0.42	8.48	0.38	3.86e-16	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg07685180	chr8:600429	NA	0.87	8.71	0.39	6.87e-17	IgG glycosylation;
LUAD	cis	rs4911259	0.552	rs6057663	chr20:31463071	G/T	cg13636640	chr20:31349939	DNMT3B	-0.57	-9.37	-0.41	4.5e-19	Inflammatory bowel disease;
LUAD	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg18806716	chr10:30721971	MAP3K8	-0.78	-16.6	-0.63	5.04e-48	Inflammatory bowel disease;
LUAD	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.4	0.45	1.06e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	7.05	0.32	7.25e-12	Tonsillectomy;
LUAD	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg03948781	chr1:205179583	DSTYK	0.35	6.43	0.3	3.38e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.22	-0.54	1.24e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.87	0.32	2.34e-11	Cognitive test performance;
LUAD	cis	rs747650	0.892	rs12291341	chr11:47242761	G/A	cg19486271	chr11:47235900	DDB2	0.44	7.19	0.33	2.92e-12	Acne (severe);
LUAD	cis	rs7264396	0.623	rs6060507	chr20:34198334	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-7.35	-0.34	1.04e-12	Total cholesterol levels;
LUAD	trans	rs1493916	0.967	rs1389532	chr18:31392323	C/T	cg15819921	chr19:927150	ARID3A	-0.44	-7.21	-0.33	2.54e-12	Life satisfaction;
LUAD	cis	rs7520050	0.743	rs61789988	chr1:46085242	G/C	cg06784218	chr1:46089804	CCDC17	-0.34	-7.29	-0.33	1.53e-12	Red blood cell count;Reticulocyte count;
LUAD	cis	rs3784262	0.740	rs1441829	chr15:58289739	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-8.29	-0.37	1.56e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7043114	0.525	rs4744134	chr9:95246833	A/G	cg14631576	chr9:95140430	CENPP	0.4	8.16	0.37	3.83e-15	Height;
LUAD	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.15	-0.48	1.71e-25	Type 2 diabetes;
LUAD	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.74	0.31	5.29e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg11822812	chr5:140052017	DND1	-0.4	-7.51	-0.34	3.55e-13	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs875971	0.545	rs316328	chr7:65608838	A/G	cg04775059	chr7:64541387	NA	-0.46	-6.55	-0.3	1.64e-10	Aortic root size;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23141333	chr1:115212619	DENND2C	-0.39	-6.61	-0.31	1.19e-10	Cancer;
LUAD	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg06092702	chr1:163392909	NA	-0.4	-9.08	-0.4	4.23e-18	Motion sickness;
LUAD	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg06608945	chr2:219082296	ARPC2	0.52	9.04	0.4	5.81e-18	Colorectal cancer;
LUAD	cis	rs2067615	0.579	rs10778506	chr12:107143260	T/C	cg15890332	chr12:107067104	RFX4	0.39	8.2	0.37	2.91e-15	Heart rate;
LUAD	cis	rs4444235	0.752	rs2071047	chr14:54418411	C/T	cg16720578	chr14:54410717	NA	0.49	9.05	0.4	5.17e-18	Colorectal cancer;
LUAD	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg23649088	chr2:200775458	C2orf69	-0.54	-7.09	-0.33	5.61e-12	Schizophrenia;
LUAD	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.77	-14.8	-0.58	3.19e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	12.36	0.52	3.62e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4481887	0.927	rs12039929	chr1:248482018	G/A	cg13385794	chr1:248469461	NA	0.26	7.02	0.32	8.96e-12	Common traits (Other);
LUAD	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg18252515	chr7:66147081	NA	-0.6	-6.73	-0.31	5.43e-11	Diabetic kidney disease;
LUAD	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03264133	chr6:25882463	NA	-0.49	-7.33	-0.34	1.19e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg16060761	chr17:80687452	NA	-0.57	-8.08	-0.37	6.74e-15	Glycated hemoglobin levels;
LUAD	trans	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg04995722	chr7:26192034	NFE2L3	0.36	6.42	0.3	3.63e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.57	-0.42	8.75e-20	Life satisfaction;
LUAD	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-9.48	-0.42	1.83e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg26446133	chr18:72167187	CNDP2	-0.82	-12.25	-0.51	9.91e-30	Refractive error;
LUAD	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.49	8.21	0.37	2.62e-15	Alzheimer's disease (late onset);
LUAD	cis	rs6906287	0.647	rs6569015	chr6:118686344	C/T	cg18833306	chr6:118973337	C6orf204	0.44	7.71	0.35	8.94e-14	Electrocardiographic conduction measures;
LUAD	cis	rs2249625	0.504	rs2496508	chr6:72891398	A/G	cg18830697	chr6:72922368	RIMS1	-0.44	-8.05	-0.36	8.76e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs28595532	0.545	rs17516582	chr4:119296763	C/G	cg02775129	chr4:119771670	NA	-0.62	-6.55	-0.3	1.62e-10	Cannabis dependence symptom count;
LUAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-9.67	-0.43	4.19e-20	Lymphocyte counts;
LUAD	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg13319975	chr6:146136371	FBXO30	-0.59	-9.97	-0.44	3.49e-21	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg20290983	chr6:43655470	MRPS18A	0.93	17.52	0.65	4.6e-52	IgG glycosylation;
LUAD	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg07538946	chr5:131705188	SLC22A5	0.48	7.88	0.36	2.82e-14	Blood metabolite levels;
LUAD	cis	rs7584330	0.554	rs76980036	chr2:238426750	G/A	cg14458575	chr2:238380390	NA	0.61	9.85	0.43	9.8e-21	Prostate cancer;
LUAD	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg23533926	chr12:111358616	MYL2	-0.41	-7.02	-0.32	8.71e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2732480	1.000	rs2732480	chr12:48736303	A/C	cg04545296	chr12:48745243	ZNF641	-0.28	-7.64	-0.35	1.46e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	13.39	0.55	2.53e-34	Lung cancer in ever smokers;
LUAD	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg23625390	chr15:77176239	SCAPER	0.42	7.34	0.34	1.07e-12	Blood metabolite levels;
LUAD	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg06784218	chr1:46089804	CCDC17	0.35	7.61	0.35	1.78e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg11663144	chr21:46675770	NA	-0.51	-9.49	-0.42	1.67e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg08798685	chr6:27730294	NA	-0.67	-7.09	-0.33	5.83e-12	Breast cancer;
LUAD	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.57	0.3	1.5e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	9.29	0.41	8.36e-19	Melanoma;
LUAD	cis	rs813218	0.523	rs10935917	chr3:99441241	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.43	-8.02	-0.36	1.05e-14	Orofacial clefts;
LUAD	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-6.94	-0.32	1.44e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg01528321	chr10:82214614	TSPAN14	0.65	10.39	0.45	1.09e-22	Post bronchodilator FEV1;
LUAD	cis	rs7705042	0.828	rs181826	chr5:141526057	C/A	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.93	-0.32	1.57e-11	Asthma;
LUAD	cis	rs870825	0.616	rs28442259	chr4:185646962	T/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	trans	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg25894440	chr7:65020034	NA	-0.64	-6.79	-0.31	3.88e-11	Gout;
LUAD	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg00784671	chr22:46762841	CELSR1	-0.43	-6.59	-0.3	1.34e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs62064224	0.554	rs9901737	chr17:30681354	C/G	cg18200150	chr17:30822561	MYO1D	0.41	7.76	0.35	6.41e-14	Schizophrenia;
LUAD	cis	rs9487051	0.768	rs386696	chr6:109520166	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.28	-0.33	1.59e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs11229555	0.645	rs61889554	chr11:58424081	C/A	cg15696309	chr11:58395628	NA	-0.57	-7.01	-0.32	9.59e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg17724175	chr1:150552817	MCL1	0.39	9.43	0.42	2.64e-19	Tonsillectomy;
LUAD	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg16205897	chr5:131564050	P4HA2	-0.31	-6.46	-0.3	2.82e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs1232027	0.700	rs1643641	chr5:79951491	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.9	-0.36	2.36e-14	Huntington's disease progression;
LUAD	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg22532475	chr10:104410764	TRIM8	-0.51	-9.29	-0.41	8.39e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg21214613	chr1:16344536	HSPB7	0.6	11.6	0.49	3.35e-27	Dilated cardiomyopathy;
LUAD	cis	rs6445967	0.554	rs62259787	chr3:58435688	A/C	cg13750441	chr3:58318267	PXK	-0.31	-6.42	-0.3	3.73e-10	Platelet count;
LUAD	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg14343924	chr8:8086146	FLJ10661	0.52	8.35	0.38	1.01e-15	Systolic blood pressure;
LUAD	cis	rs4006360	0.504	rs7502045	chr17:39252972	T/C	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.29	0.37	1.48e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs986417	0.748	rs4901986	chr14:60969333	T/C	cg27398547	chr14:60952738	C14orf39	0.52	6.65	0.31	9.17e-11	Gut microbiota (bacterial taxa);
LUAD	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.53	-8.95	-0.4	1.1e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg04756594	chr16:24857601	SLC5A11	-0.76	-13.31	-0.54	5.34e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg02753203	chr1:228287806	NA	0.8	15.71	0.61	3.82e-44	Diastolic blood pressure;
LUAD	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.8	-0.35	4.79e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.07	0.37	7.1e-15	Menopause (age at onset);
LUAD	cis	rs74181299	0.892	rs2540945	chr2:65289825	A/G	cg05010058	chr2:65284262	CEP68	0.29	6.41	0.3	3.85e-10	Pulse pressure;
LUAD	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg03676636	chr4:99064102	C4orf37	0.3	7.23	0.33	2.26e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4389656	0.857	rs274679	chr5:6751426	A/C	cg10857441	chr5:6722123	POLS	-0.45	-7.77	-0.35	5.86e-14	Coronary artery disease;
LUAD	cis	rs77741769	0.571	rs11065292	chr12:121289155	T/C	cg02419362	chr12:121203948	SPPL3	0.43	8.76	0.39	4.59e-17	Mean corpuscular volume;
LUAD	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.67	10.91	0.47	1.34e-24	Height;
LUAD	cis	rs6494488	0.500	rs72744749	chr15:65062819	G/C	cg08069370	chr15:64387884	SNX1	-0.74	-6.64	-0.31	9.68e-11	Coronary artery disease;
LUAD	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2742417	1.000	rs2742379	chr3:45787835	G/A	cg10512202	chr3:45649293	LIMD1	0.39	6.85	0.32	2.68e-11	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs6545883	0.965	rs6734830	chr2:61731112	G/A	cg15711740	chr2:61764176	XPO1	-0.4	-6.38	-0.3	4.64e-10	Tuberculosis;
LUAD	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg21918786	chr6:109611834	NA	-0.59	-10.9	-0.47	1.54e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg07936489	chr17:37558343	FBXL20	0.45	7.14	0.33	4.05e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs3862030	0.694	rs12781742	chr10:104227469	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-8.01	-0.36	1.14e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.41	0.34	6.74e-13	Menopause (age at onset);
LUAD	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	7.62	0.35	1.64e-13	Tonsillectomy;
LUAD	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg06608945	chr2:219082296	ARPC2	-0.42	-6.83	-0.32	2.93e-11	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg05283184	chr6:79620031	NA	-0.55	-10.45	-0.45	7.03e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg24642844	chr7:1081250	C7orf50	-0.98	-14.74	-0.58	5.52e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2274273	0.686	rs68083077	chr14:55574428	G/A	cg04306507	chr14:55594613	LGALS3	0.38	6.93	0.32	1.57e-11	Protein biomarker;
LUAD	cis	rs6701037	1.000	rs6677097	chr1:175123897	C/G	cg14847009	chr1:175162515	KIAA0040	-0.32	-8.53	-0.38	2.57e-16	Alcohol dependence;
LUAD	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.76	0.46	5.11e-24	Smoking behavior;
LUAD	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.76	-0.39	4.58e-17	Total body bone mineral density;
LUAD	cis	rs9902453	0.817	rs880749	chr17:28059970	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-9.51	-0.42	1.45e-19	Coffee consumption (cups per day);
LUAD	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg03563238	chr19:33554763	RHPN2	-0.37	-8.78	-0.39	4.21e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg05042697	chr2:10830656	NOL10	0.39	6.66	0.31	8.32e-11	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.09e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.52	-0.34	3.33e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg11266682	chr4:10021025	SLC2A9	0.65	14.69	0.58	9.19e-40	Bone mineral density;
LUAD	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15664640	chr17:80829946	TBCD	-0.82	-16.49	-0.63	1.54e-47	Breast cancer;
LUAD	cis	rs11971779	0.650	rs10085842	chr7:139064582	A/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.46	-0.3	2.86e-10	Diisocyanate-induced asthma;
LUAD	cis	rs11811982	0.793	rs79505001	chr1:227578302	C/T	cg24860534	chr1:227506868	CDC42BPA	0.63	7.0	0.32	1e-11	Optic disc area;
LUAD	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg23262073	chr20:60523788	NA	-0.46	-7.35	-0.34	1.06e-12	Body mass index;
LUAD	cis	rs12681287	0.785	rs13263353	chr8:87244582	C/T	cg27223183	chr8:87520930	FAM82B	-0.55	-8.11	-0.37	5.59e-15	Caudate activity during reward;
LUAD	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg03806693	chr22:41940476	POLR3H	-0.45	-6.98	-0.32	1.18e-11	Neuroticism;
LUAD	cis	rs12681287	0.752	rs6985427	chr8:87302745	C/T	cg00550725	chr8:87521180	FAM82B	0.47	6.69	0.31	6.97e-11	Caudate activity during reward;
LUAD	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg15181151	chr6:150070149	PCMT1	0.39	7.78	0.35	5.72e-14	Lung cancer;
LUAD	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg02569458	chr12:86230093	RASSF9	0.44	8.04	0.36	9.04e-15	Major depressive disorder;
LUAD	cis	rs2625529	0.823	rs11072332	chr15:72108307	G/T	cg16672083	chr15:72433130	SENP8	-0.63	-9.89	-0.43	6.68e-21	Red blood cell count;
LUAD	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06544989	chr22:39130855	UNC84B	0.48	9.78	0.43	1.72e-20	Menopause (age at onset);
LUAD	cis	rs6728861	1	rs6728861	chr2:203873743	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.28	0.41	8.55e-19	Coronary artery disease;
LUAD	cis	rs7095607	0.560	rs7095238	chr10:69913203	T/C	cg18986048	chr10:69913749	MYPN	0.47	8.09	0.37	6.24e-15	Lung function (FVC);
LUAD	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.05	0.36	8.68e-15	Breast cancer;
LUAD	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1997103	0.954	rs9649780	chr7:55411741	A/C	cg20935933	chr6:143382018	AIG1	0.53	7.36	0.34	9.81e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs1941687	0.510	rs1452649	chr18:31410858	A/G	cg27147174	chr7:100797783	AP1S1	-0.62	-10.88	-0.47	1.73e-24	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs73198271	0.562	rs35432123	chr8:8671018	G/T	cg01851573	chr8:8652454	MFHAS1	0.68	10.35	0.45	1.62e-22	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg24733560	chr20:60626293	TAF4	0.46	8.11	0.37	5.66e-15	Body mass index;
LUAD	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.44	0.34	5.52e-13	Menopause (age at onset);
LUAD	cis	rs9462027	0.607	rs205259	chr6:34564066	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.79	-0.39	3.71e-17	Systemic lupus erythematosus;
LUAD	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg08316699	chr6:150357289	NA	0.36	7.45	0.34	5.15e-13	Alopecia areata;
LUAD	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg18512352	chr11:47633146	NA	0.46	8.17	0.37	3.69e-15	Subjective well-being;
LUAD	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg27211696	chr2:191398769	TMEM194B	0.77	16.48	0.63	1.78e-47	Pulse pressure;
LUAD	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg12016809	chr21:47604291	C21orf56	0.48	7.95	0.36	1.66e-14	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg05283184	chr6:79620031	NA	-0.45	-7.86	-0.36	3.26e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg09658497	chr7:2847517	GNA12	-0.53	-8.92	-0.4	1.46e-17	Height;
LUAD	cis	rs494562	1.000	rs527670	chr6:86115779	T/C	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00149659	chr3:10157352	C3orf10	0.55	7.57	0.35	2.41e-13	Alzheimer's disease;
LUAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg16414030	chr3:133502952	NA	-0.66	-12.67	-0.52	2.01e-31	Iron status biomarkers;
LUAD	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg18404041	chr3:52824283	ITIH1	-0.63	-12.83	-0.53	4.68e-32	Bipolar disorder;
LUAD	trans	rs931812	0.895	rs4236763	chr8:101913022	G/A	cg20993868	chr7:22813445	NA	0.6	11.95	0.5	1.53e-28	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.3	6.52	0.3	2.06e-10	Parkinson's disease;
LUAD	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.3	-0.45	2.32e-22	Total body bone mineral density;
LUAD	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg26384229	chr12:38710491	ALG10B	0.5	8.27	0.37	1.71e-15	Heart rate;
LUAD	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg15448220	chr1:150897856	SETDB1	0.47	8.12	0.37	5.15e-15	Tonsillectomy;
LUAD	cis	rs9503598	0.517	rs11242860	chr6:3463536	A/C	cg00476032	chr6:3446245	SLC22A23	0.32	6.84	0.32	2.7e-11	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs9326248	0.581	rs10892061	chr11:116886114	C/T	cg20608306	chr11:116969690	SIK3	0.32	7.12	0.33	4.74e-12	Blood protein levels;
LUAD	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.56	-9.47	-0.42	2.07e-19	Glomerular filtration rate;
LUAD	cis	rs7692976	0.503	rs62325265	chr4:110923592	T/C	cg06981781	chr4:110842888	EGF	-0.39	-6.58	-0.3	1.41e-10	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs3815700	1.000	rs8113165	chr19:33096316	C/T	cg02997394	chr19:33096574	ANKRD27	0.66	8.95	0.4	1.13e-17	Eosinophilic esophagitis;
LUAD	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg12062639	chr20:23401060	NAPB	1.08	11.36	0.48	2.76e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.86	0.32	2.52e-11	Obesity-related traits;
LUAD	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg16486109	chr11:613632	IRF7	0.54	9.02	0.4	6.84e-18	Systemic lupus erythematosus;
LUAD	cis	rs28374715	0.662	rs113913466	chr15:41483100	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.9	-16.6	-0.63	4.98e-48	Ulcerative colitis;
LUAD	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg26384229	chr12:38710491	ALG10B	0.48	7.71	0.35	9.24e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg15445000	chr17:37608096	MED1	0.44	8.16	0.37	3.97e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.41	6.49	0.3	2.38e-10	Platelet count;
LUAD	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg08085267	chr17:45401833	C17orf57	0.59	10.75	0.46	5.35e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.94	0.32	1.44e-11	Rheumatoid arthritis;
LUAD	cis	rs55788414	1.000	rs9921827	chr16:81181869	T/C	cg06400318	chr16:81190750	PKD1L2	-0.6	-7.9	-0.36	2.46e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg03676636	chr4:99064102	C4orf37	0.32	8.36	0.38	9.18e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg06641503	chr3:48959341	ARIH2	-0.41	-8.12	-0.37	5.3e-15	Parkinson's disease;
LUAD	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	cis	rs7903847	0.642	rs10786341	chr10:99158607	G/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.81	-0.36	4.51e-14	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg05187965	chr10:45406764	TMEM72	-0.49	-9.88	-0.43	7.72e-21	Mean corpuscular volume;
LUAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg00431813	chr7:1051703	C7orf50	0.45	8.22	0.37	2.44e-15	Longevity;Endometriosis;
LUAD	cis	rs1395	1.000	rs1275528	chr2:27430781	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.42	-8.0	-0.36	1.19e-14	Blood metabolite levels;
LUAD	cis	rs921968	0.565	rs3821035	chr2:219620223	T/G	cg02176678	chr2:219576539	TTLL4	-0.59	-12.0	-0.5	9.65e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg18827107	chr12:86230957	RASSF9	-0.71	-13.19	-0.54	1.62e-33	Major depressive disorder;
LUAD	cis	rs3820068	0.705	rs4646083	chr1:15825564	G/A	cg17385448	chr1:15911702	AGMAT	0.39	6.36	0.3	5.39e-10	Systolic blood pressure;
LUAD	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg13813247	chr22:41461852	NA	-0.46	-7.52	-0.34	3.39e-13	Neuroticism;
LUAD	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-10.5	-0.45	4.31e-23	Chronic sinus infection;
LUAD	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg16989719	chr2:238392110	NA	0.34	6.56	0.3	1.6e-10	Prostate cancer;
LUAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg27454412	chr7:1067447	C7orf50	0.48	7.75	0.35	6.7e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7677751	0.806	rs4864858	chr4:55089953	T/A	cg17187183	chr4:55093834	PDGFRA	0.52	8.77	0.39	4.57e-17	Corneal astigmatism;
LUAD	trans	rs11039798	0.858	rs7121333	chr11:48332138	C/T	cg15704280	chr7:45808275	SEPT13	0.65	7.61	0.35	1.79e-13	Axial length;
LUAD	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg09253696	chr17:73873529	TRIM47	-0.42	-7.38	-0.34	8.54e-13	Psoriasis;
LUAD	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg07371521	chr5:154026371	NA	0.48	7.71	0.35	9.13e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg10518543	chr12:38710700	ALG10B	-0.45	-7.11	-0.33	5.03e-12	Morning vs. evening chronotype;
LUAD	cis	rs7731657	0.537	rs9327578	chr5:130181064	C/T	cg08523029	chr5:130500466	HINT1	-0.58	-7.51	-0.34	3.56e-13	Fasting plasma glucose;
LUAD	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg24818145	chr4:99064322	C4orf37	0.42	6.89	0.32	2.03e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.2	-0.33	2.8e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg01017244	chr2:74357527	NA	0.82	13.54	0.55	5.77e-35	Gestational age at birth (maternal effect);
LUAD	trans	rs7246760	0.867	rs59616842	chr19:9792245	G/A	cg02900749	chr2:68251473	NA	-0.59	-6.56	-0.3	1.59e-10	Pursuit maintenance gain;
LUAD	trans	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg15704280	chr7:45808275	SEPT13	0.66	7.62	0.35	1.66e-13	Axial length;
LUAD	cis	rs738322	0.555	rs731821	chr22:38559448	C/A	cg17652424	chr22:38574118	PLA2G6	-0.27	-7.21	-0.33	2.61e-12	Cutaneous nevi;
LUAD	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg24818145	chr4:99064322	C4orf37	0.49	8.07	0.37	7.57e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09964670	chr19:5720572	TMEM146;LONP1	-0.53	-6.4	-0.3	4.02e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7009516	0.604	rs13259526	chr8:24263957	G/C	cg01759110	chr8:24241694	ADAMDEC1	-0.42	-8.53	-0.38	2.68e-16	Hair greying;
LUAD	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg05044414	chr3:183734942	ABCC5	0.46	9.82	0.43	1.25e-20	Anterior chamber depth;
LUAD	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11644478	chr21:40555479	PSMG1	0.61	9.53	0.42	1.27e-19	Cognitive function;
LUAD	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg16325326	chr1:53192061	ZYG11B	0.58	10.24	0.45	3.99e-22	Monocyte count;
LUAD	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.12	-0.37	5.24e-15	Prostate cancer;
LUAD	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg20701182	chr2:24300061	SF3B14	0.66	7.34	0.34	1.08e-12	Lymphocyte counts;
LUAD	cis	rs9837602	0.592	rs629120	chr3:99425767	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-7.51	-0.34	3.57e-13	Breast cancer;
LUAD	cis	rs4700695	0.841	rs152994	chr5:65262989	A/G	cg21114390	chr5:65439923	SFRS12	0.62	7.48	0.34	4.4e-13	Facial morphology (factor 19);
LUAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg22029157	chr1:209979665	IRF6	0.78	12.66	0.52	2.34e-31	Cleft lip with or without cleft palate;
LUAD	cis	rs8060686	0.623	rs74024145	chr16:68153382	G/C	cg09835421	chr16:68378352	PRMT7	-0.53	-6.75	-0.31	4.84e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg02734326	chr4:10020555	SLC2A9	0.63	11.28	0.48	5.67e-26	Bone mineral density;
LUAD	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.44	-0.49	1.35e-26	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg17366294	chr4:99064904	C4orf37	-0.66	-12.86	-0.53	3.56e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11039798	0.920	rs11040013	chr11:48782862	G/A	cg02254774	chr11:50257496	LOC441601	0.53	6.44	0.3	3.25e-10	Axial length;
LUAD	cis	rs1865721	1.000	rs72977888	chr18:73195250	C/T	cg26385618	chr18:73139727	C18orf62	-0.41	-7.51	-0.34	3.5e-13	Intelligence;
LUAD	cis	rs870825	0.929	rs1405940	chr4:185591481	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	10.12	0.44	1.06e-21	Blood protein levels;
LUAD	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg11965913	chr1:205819406	PM20D1	-0.55	-8.25	-0.37	2.01e-15	Menarche (age at onset);
LUAD	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.9	-0.32	1.86e-11	Retinal vascular caliber;
LUAD	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg00933542	chr6:150070202	PCMT1	0.46	10.03	0.44	2.25e-21	Lung cancer;
LUAD	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg05434287	chr7:2030229	MAD1L1	0.41	6.53	0.3	1.89e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg20891283	chr12:69753455	YEATS4	0.45	7.29	0.33	1.53e-12	Blood protein levels;
LUAD	trans	rs877282	0.583	rs10904562	chr10:819058	T/C	cg22713356	chr15:30763199	NA	0.9	11.3	0.48	4.53e-26	Uric acid levels;
LUAD	cis	rs738321	0.694	rs4821749	chr22:38542074	A/G	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.9	-0.32	1.96e-11	Breast cancer;
LUAD	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg11189052	chr15:85197271	WDR73	0.59	7.5	0.34	3.82e-13	Schizophrenia;
LUAD	cis	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.02	-0.36	1.07e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg15900387	chr1:150738905	CTSS	-0.36	-6.56	-0.3	1.58e-10	Melanoma;
LUAD	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg25894440	chr7:65020034	NA	0.63	6.82	0.31	3.19e-11	Diabetic kidney disease;
LUAD	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg26924012	chr15:45694286	SPATA5L1	1.02	19.06	0.68	6.2e-59	Homoarginine levels;
LUAD	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg15017067	chr4:17643749	FAM184B	0.35	6.9	0.32	1.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21254171	chr4:78783977	MRPL1	-0.39	-6.5	-0.3	2.32e-10	Cancer;
LUAD	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.95	-0.36	1.76e-14	Prostate cancer;
LUAD	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24308560	chr3:49941425	MST1R	-0.57	-9.44	-0.42	2.51e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg03690763	chr11:133734501	NA	-0.35	-8.03	-0.36	9.95e-15	Childhood ear infection;
LUAD	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg14019146	chr3:50243930	SLC38A3	-0.4	-6.58	-0.3	1.37e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs11048434	0.736	rs1805761	chr12:9099533	T/C	cg13575925	chr12:9217583	LOC144571	0.38	7.1	0.33	5.4e-12	Sjögren's syndrome;
LUAD	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg02807482	chr3:125708958	NA	-0.66	-8.76	-0.39	4.84e-17	Blood pressure (smoking interaction);
LUAD	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg04673462	chr1:38461896	NA	0.4	7.59	0.35	2.07e-13	Coronary artery disease;
LUAD	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg00316803	chr15:76480434	C15orf27	-0.39	-7.29	-0.33	1.55e-12	Blood metabolite levels;
LUAD	cis	rs2282802	0.660	rs6873248	chr5:139683762	A/G	cg26211634	chr5:139558579	C5orf32	-0.35	-6.42	-0.3	3.71e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg05697835	chr1:2722811	NA	0.29	6.59	0.31	1.29e-10	Ulcerative colitis;
LUAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.55	7.49	0.34	4.17e-13	Renal function-related traits (BUN);
LUAD	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg12863693	chr15:85201151	NMB	0.45	8.15	0.37	4.14e-15	Schizophrenia;
LUAD	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-7.11	-0.33	4.92e-12	Longevity;Endometriosis;
LUAD	cis	rs2731664	0.792	rs335434	chr5:176867276	A/G	cg23176889	chr5:176863531	GRK6	-0.73	-13.85	-0.56	3.14e-36	Intelligence (multi-trait analysis);
LUAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.3	-6.75	-0.31	4.86e-11	Lymphocyte counts;
LUAD	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.36	-7.25	-0.33	2.01e-12	Hemoglobin concentration;
LUAD	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7945705	0.875	rs10769947	chr11:8758114	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.32	6.64	0.31	9.54e-11	Hemoglobin concentration;
LUAD	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg03433033	chr1:76189801	ACADM	0.88	17.6	0.65	1.99e-52	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg17644776	chr2:200775616	C2orf69	0.55	7.31	0.34	1.31e-12	Schizophrenia;
LUAD	cis	rs7107174	1.000	rs55825352	chr11:78034424	C/T	cg02023728	chr11:77925099	USP35	0.44	6.8	0.31	3.65e-11	Testicular germ cell tumor;
LUAD	cis	rs13315871	0.929	rs13322156	chr3:58287620	C/T	cg20936604	chr3:58311152	NA	-0.75	-7.61	-0.35	1.82e-13	Cholesterol, total;
LUAD	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg00074818	chr8:8560427	CLDN23	0.62	9.55	0.42	1.05e-19	Obesity-related traits;
LUAD	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg12311346	chr5:56204834	C5orf35	-0.92	-13.64	-0.55	2.32e-35	Initial pursuit acceleration;
LUAD	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg21153622	chr11:89784906	NA	-0.35	-6.7	-0.31	6.78e-11	Coronary artery disease;
LUAD	cis	rs2625529	0.667	rs16956381	chr15:72193237	A/C	cg16672083	chr15:72433130	SENP8	-0.75	-12.38	-0.52	2.88e-30	Red blood cell count;
LUAD	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg11494091	chr17:61959527	GH2	0.4	6.89	0.32	2.06e-11	Height;
LUAD	trans	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg24644049	chr4:85504048	CDS1	0.89	7.31	0.33	1.37e-12	Skin colour saturation;
LUAD	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg21733973	chr7:65235735	NA	0.48	6.4	0.3	4.07e-10	Aortic root size;
LUAD	cis	rs2116941	1.000	rs2033493	chr19:10340854	A/C	cg01850179	chr19:10340795	S1PR2	-0.85	-13.66	-0.55	1.81e-35	Pulse pressure;
LUAD	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg02269571	chr22:50332266	NA	-0.63	-9.23	-0.41	1.28e-18	Schizophrenia;
LUAD	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg19636519	chr7:99541626	NA	0.39	7.0	0.32	1.03e-11	Coronary artery disease;
LUAD	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg04455712	chr21:45112962	RRP1B	0.43	8.66	0.39	9.82e-17	Mean corpuscular volume;
LUAD	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg04155289	chr7:94953770	PON1	-0.52	-6.89	-0.32	2.09e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs17095355	1.000	rs56273398	chr10:111708183	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.67	-8.54	-0.38	2.36e-16	Biliary atresia;
LUAD	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg13732083	chr21:47605072	C21orf56	0.41	6.82	0.31	3.2e-11	Testicular germ cell tumor;
LUAD	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg08999081	chr20:33150536	PIGU	0.61	13.65	0.55	2.02e-35	Glomerular filtration rate (creatinine);
LUAD	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg22676075	chr6:135203613	NA	0.4	7.28	0.33	1.63e-12	Red blood cell count;
LUAD	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg14582100	chr15:45693742	SPATA5L1	0.54	9.65	0.42	4.74e-20	Homoarginine levels;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg20796556	chr18:21032774	RIOK3	0.41	6.58	0.3	1.4e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs7395662	0.926	rs7122869	chr11:48727999	G/T	cg00717180	chr2:96193071	NA	0.39	7.23	0.33	2.27e-12	HDL cholesterol;
LUAD	cis	rs7394579	1	rs7394579	chr11:61581450	A/G	cg14725641	chr11:61582763	MIR1908;FADS1	-0.48	-6.87	-0.32	2.38e-11	Red cell distribution width;Mean platelet volume;
LUAD	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg01200585	chr1:228362443	C1orf69	-0.44	-8.13	-0.37	4.81e-15	Diastolic blood pressure;
LUAD	cis	rs7937890	0.531	rs2575859	chr11:14510736	C/T	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.15e-12	Mitochondrial DNA levels;
LUAD	trans	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg11693508	chr17:37793320	STARD3	-0.77	-9.83	-0.43	1.16e-20	Bipolar disorder;
LUAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs10489202	0.683	rs2294817	chr1:168073601	C/A	cg24449463	chr1:168025552	DCAF6	-0.61	-9.22	-0.41	1.44e-18	Schizophrenia;
LUAD	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg22920501	chr2:26401640	FAM59B	0.79	11.93	0.5	1.79e-28	Gut microbiome composition (summer);
LUAD	cis	rs6489882	0.671	rs4767027	chr12:113359157	T/C	cg20102336	chr12:113376681	OAS3	-0.54	-8.13	-0.37	4.95e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.45	0.3	3e-10	Depression;
LUAD	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg06766960	chr11:133703094	NA	-0.43	-8.37	-0.38	8.46e-16	Childhood ear infection;
LUAD	cis	rs367943	0.698	rs4538600	chr5:112963488	T/C	cg12552261	chr5:112820674	MCC	0.43	7.76	0.35	6.39e-14	Type 2 diabetes;
LUAD	cis	rs4343996	0.870	rs4722712	chr7:3389147	C/T	cg21248987	chr7:3385318	SDK1	-0.36	-6.81	-0.31	3.45e-11	Motion sickness;
LUAD	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg11833968	chr6:79620685	NA	-0.42	-7.87	-0.36	2.92e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs73198271	0.515	rs78600128	chr8:8628706	C/A	cg01851573	chr8:8652454	MFHAS1	0.58	7.65	0.35	1.39e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	1.000	rs1448094	chr12:86343135	G/T	cg19622623	chr12:86230825	RASSF9	-0.36	-6.39	-0.3	4.38e-10	Major depressive disorder;
LUAD	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.7	0.53	1.52e-31	Cognitive ability;
LUAD	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg21823605	chr1:152486609	CRCT1	0.3	6.89	0.32	2.1e-11	Hair morphology;
LUAD	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg23281280	chr6:28129359	ZNF389	0.46	6.65	0.31	9.18e-11	Depression;
LUAD	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg12927641	chr6:109611667	NA	-0.5	-8.86	-0.4	2.18e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg16060761	chr17:80687452	NA	-0.59	-8.32	-0.38	1.21e-15	Glycated hemoglobin levels;
LUAD	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg14784868	chr12:69753453	YEATS4	0.47	7.75	0.35	6.98e-14	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs4650994	1.000	rs10798619	chr1:178532517	A/G	cg05059571	chr16:84539110	KIAA1609	-0.57	-9.95	-0.44	4.12e-21	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg25809561	chr17:30822961	MYO1D	0.49	8.86	0.4	2.28e-17	Schizophrenia;
LUAD	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.55	0.34	2.79e-13	Menopause (age at onset);
LUAD	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg02569458	chr12:86230093	RASSF9	0.43	8.11	0.37	5.53e-15	Major depressive disorder;
LUAD	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg07343612	chr16:622815	PIGQ	-0.8	-16.02	-0.61	1.76e-45	Height;
LUAD	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs244731	1.000	rs244729	chr5:176539018	C/G	cg17509989	chr5:176798049	RGS14	0.55	8.67	0.39	9.63e-17	Urate levels in lean individuals;
LUAD	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11644478	chr21:40555479	PSMG1	-0.42	-6.97	-0.32	1.22e-11	Menarche (age at onset);
LUAD	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg02018176	chr4:1364513	KIAA1530	-0.37	-6.96	-0.32	1.3e-11	Obesity-related traits;
LUAD	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18876405	chr7:65276391	NA	-0.44	-6.95	-0.32	1.43e-11	Aortic root size;
LUAD	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.25	6.36	0.3	5.35e-10	Cardiac Troponin-T levels;
LUAD	cis	rs1232027	0.616	rs6151615	chr5:79961432	G/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.46	-7.19	-0.33	2.87e-12	Huntington's disease progression;
LUAD	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-12.49	-0.52	1.08e-30	Breast cancer;
LUAD	cis	rs6066835	1.000	rs6095272	chr20:47357517	A/G	cg18078177	chr20:47281410	PREX1	0.72	6.55	0.3	1.64e-10	Multiple myeloma;
LUAD	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08045932	chr20:61659980	NA	-0.51	-9.64	-0.42	5.19e-20	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg22482690	chr17:47019901	SNF8	0.45	8.58	0.38	1.86e-16	Type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg22117172	chr7:91764530	CYP51A1	0.34	7.67	0.35	1.16e-13	Breast cancer;
LUAD	cis	rs7274811	0.652	rs291672	chr20:31951168	G/A	cg13403462	chr20:32256071	NECAB3;C20orf134	0.49	7.5	0.34	3.84e-13	Height;
LUAD	cis	rs59698941	0.943	rs60545802	chr5:132204577	T/G	cg14825688	chr5:132208181	LEAP2	-0.47	-6.64	-0.31	9.5e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.77	0.31	4.24e-11	Parkinson's disease;
LUAD	cis	rs7953508	0.506	rs3869308	chr12:93959918	A/G	cg18151635	chr12:93972918	NA	-0.76	-11.53	-0.49	6.13e-27	Pubertal anthropometrics;
LUAD	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg02886208	chr11:14281011	SPON1	0.39	8.2	0.37	2.86e-15	Mitochondrial DNA levels;
LUAD	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg02753203	chr1:228287806	NA	-0.46	-8.57	-0.38	2e-16	Diastolic blood pressure;
LUAD	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg27529037	chr20:44575021	PCIF1	-0.48	-8.43	-0.38	5.51e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs4006360	0.579	rs1817965	chr17:39244724	A/T	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.27	0.37	1.75e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg16325326	chr1:53192061	ZYG11B	0.63	12.17	0.51	2.04e-29	Monocyte count;
LUAD	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03264133	chr6:25882463	NA	-0.48	-7.13	-0.33	4.44e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1784581	0.569	rs9365357	chr6:162414913	A/G	cg17173639	chr6:162384350	PARK2	0.45	8.07	0.37	7.33e-15	Itch intensity from mosquito bite;
LUAD	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-8.34	-0.38	1.08e-15	Monocyte percentage of white cells;
LUAD	cis	rs4932217	0.579	rs150302	chr15:89946789	C/G	cg25932290	chr15:89939252	LOC254559	-0.39	-6.6	-0.31	1.23e-10	Height;
LUAD	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg15181151	chr6:150070149	PCMT1	0.42	8.57	0.38	1.98e-16	Lung cancer;
LUAD	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg09936400	chr10:82049201	MAT1A	0.37	6.73	0.31	5.4e-11	Post bronchodilator FEV1;
LUAD	cis	rs3784262	0.669	rs12909423	chr15:58292433	C/G	cg12031962	chr15:58353849	ALDH1A2	0.39	7.63	0.35	1.58e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg05110241	chr16:68378359	PRMT7	-0.7	-7.99	-0.36	1.26e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg04414720	chr1:150670196	GOLPH3L	0.67	11.52	0.49	6.71e-27	Melanoma;
LUAD	cis	rs12681288	0.550	rs58295701	chr8:962136	T/C	cg15309053	chr8:964076	NA	0.5	11.31	0.48	4.22e-26	Schizophrenia;
LUAD	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12588279	chr6:26043732	HIST1H2BB	-0.39	-6.49	-0.3	2.45e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs208520	1.000	rs208520	chr6:66952828	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-13.49	-0.55	9.7e-35	Exhaled nitric oxide output;
LUAD	cis	rs1953600	0.754	rs2573348	chr10:81925785	C/T	cg00277334	chr10:82204260	NA	-0.4	-6.82	-0.31	3.24e-11	Sarcoidosis;
LUAD	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.41	-0.45	9.51e-23	Monocyte percentage of white cells;
LUAD	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg04248312	chr19:17393744	ANKLE1	-1.0	-18.24	-0.66	2.88e-55	Systemic lupus erythematosus;
LUAD	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg07305463	chr2:136567211	LCT	0.39	7.39	0.34	7.81e-13	Mosquito bite size;
LUAD	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-7.33	-0.34	1.17e-12	Coronary artery disease;
LUAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg23958373	chr8:599963	NA	-1.13	-9.57	-0.42	9.34e-20	IgG glycosylation;
LUAD	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg22961513	chr11:14280813	SPON1	0.44	9.11	0.4	3.38e-18	Mitochondrial DNA levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg07944736	chr1:28908226	SNHG12;SNORA44;SNORA16A	-0.39	-6.38	-0.3	4.54e-10	Schizophrenia;
LUAD	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg18477163	chr1:228402036	OBSCN	-0.35	-6.92	-0.32	1.72e-11	Diastolic blood pressure;
LUAD	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg19635926	chr16:89946313	TCF25	0.74	6.97	0.32	1.18e-11	Skin colour saturation;
LUAD	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg03388025	chr16:89894329	SPIRE2	0.33	7.29	0.33	1.58e-12	Vitiligo;
LUAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs4888262	0.526	rs4404098	chr16:74570050	G/A	cg01733217	chr16:74700730	RFWD3	0.49	8.49	0.38	3.62e-16	Testicular germ cell tumor;
LUAD	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.43	7.89	0.36	2.6e-14	Systemic lupus erythematosus;
LUAD	cis	rs8060686	0.516	rs7193701	chr16:68185160	A/G	cg09835421	chr16:68378352	PRMT7	0.51	6.76	0.31	4.49e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08704250	chr15:31115839	NA	-0.55	-9.84	-0.43	1.02e-20	Huntington's disease progression;
LUAD	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.95	0.32	1.42e-11	Aortic root size;
LUAD	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg07741184	chr6:167504864	NA	0.31	7.42	0.34	6.42e-13	Crohn's disease;
LUAD	cis	rs3790645	1.000	rs369385	chr1:26893229	C/T	cg23229016	chr1:26872525	RPS6KA1	0.21	6.88	0.32	2.12e-11	Glucose homeostasis traits;
LUAD	cis	rs10950821	0.843	rs73684577	chr7:20665781	A/G	cg02470904	chr7:20686108	ABCB5	0.38	6.54	0.3	1.78e-10	Response to statin therapy;
LUAD	cis	rs62064224	0.589	rs6505295	chr17:30687522	G/C	cg18200150	chr17:30822561	MYO1D	0.41	7.59	0.35	2.02e-13	Schizophrenia;
LUAD	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs870825	0.616	rs12502860	chr4:185636105	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.04	0.56	4.87e-37	Blood protein levels;
LUAD	cis	rs2279817	1.000	rs10788680	chr1:18019454	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.56	9.39	0.42	3.61e-19	Neuroticism;
LUAD	cis	rs13315871	1.000	rs35621601	chr3:58323174	A/G	cg12435725	chr3:58293450	RPP14	-0.73	-7.68	-0.35	1.1e-13	Cholesterol, total;
LUAD	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.3	-7.62	-0.35	1.65e-13	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.52	-0.3	2.06e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg05754148	chr16:3507555	NAT15	0.47	7.77	0.35	5.82e-14	Body mass index (adult);
LUAD	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg02423579	chr7:2872169	GNA12	0.87	15.62	0.6	9.85e-44	Height;
LUAD	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg13575925	chr12:9217583	LOC144571	-0.4	-7.65	-0.35	1.39e-13	Sjögren's syndrome;
LUAD	cis	rs80319144	1.000	rs77920408	chr2:159227919	G/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.36	6.72	0.31	5.85e-11	Restless legs syndrome;
LUAD	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03181514	chr16:30933937	NCRNA00095	-0.42	-6.59	-0.31	1.35e-10	Height;
LUAD	cis	rs8112211	0.691	rs77912794	chr19:38808512	A/G	cg14299480	chr19:38876666	GGN	-0.4	-6.83	-0.32	2.9100000000000002e-11	Blood protein levels;
LUAD	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03264133	chr6:25882463	NA	0.54	8.87	0.4	2.05e-17	Blood metabolite levels;
LUAD	trans	rs853679	0.546	rs34546986	chr6:28362309	G/A	cg01620082	chr3:125678407	NA	-1.1	-10.07	-0.44	1.57e-21	Depression;
LUAD	trans	rs931812	0.825	rs35472498	chr8:101894167	G/A	cg20993868	chr7:22813445	NA	0.63	12.38	0.52	2.84e-30	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs6484504	0.625	rs4922859	chr11:31382517	A/G	cg14844989	chr11:31128820	NA	0.43	7.94	0.36	1.79e-14	Red blood cell count;
LUAD	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg02423579	chr7:2872169	GNA12	0.54	9.24	0.41	1.24e-18	Height;
LUAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg06606381	chr12:133084897	FBRSL1	-0.68	-7.1	-0.33	5.24e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg10523679	chr1:76189770	ACADM	0.93	18.51	0.67	1.85e-56	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.39	-10.09	-0.44	1.4e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg15485101	chr11:133734466	NA	0.37	7.94	0.36	1.87e-14	Childhood ear infection;
LUAD	cis	rs6738485	0.763	rs11681976	chr2:106841591	C/A	cg15412446	chr2:106886593	NA	-0.44	-7.54	-0.34	2.86e-13	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg17863274	chr19:49399704	TULP2	0.53	8.58	0.38	1.86e-16	Red cell distribution width;
LUAD	cis	rs4664308	1.000	rs17831251	chr2:160914156	C/T	cg03641300	chr2:160917029	PLA2R1	-0.4	-6.94	-0.32	1.52e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg13397359	chr6:42928475	GNMT	0.66	13.06	0.54	5.52e-33	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg00631329	chr6:26305371	NA	-0.43	-7.25	-0.33	1.99e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs332507	0.711	rs3772793	chr3:124405723	A/G	cg05980111	chr3:124395277	KALRN	0.44	6.93	0.32	1.54e-11	Plateletcrit;
LUAD	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg17105886	chr17:28927953	LRRC37B2	0.82	7.87	0.36	2.9e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg12365402	chr11:9010492	NRIP3	-0.52	-10.53	-0.46	3.57e-23	Hemoglobin concentration;
LUAD	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg03690763	chr11:133734501	NA	-0.34	-7.8	-0.35	4.96e-14	Childhood ear infection;
LUAD	cis	rs11247915	1.000	rs11247915	chr1:26650550	G/T	cg15628303	chr1:26608928	UBXN11	-0.35	-6.62	-0.31	1.07e-10	Obesity-related traits;
LUAD	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg20673091	chr1:2541236	MMEL1	0.44	9.49	0.42	1.65e-19	Ulcerative colitis;
LUAD	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg18252515	chr7:66147081	NA	-0.63	-6.96	-0.32	1.34e-11	Diabetic kidney disease;
LUAD	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg00750074	chr16:89608354	SPG7	-0.55	-9.53	-0.42	1.26e-19	Multiple myeloma (IgH translocation);
LUAD	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg26597838	chr10:835615	NA	0.84	13.1	0.54	3.71e-33	Eosinophil percentage of granulocytes;
LUAD	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg23950597	chr19:37808831	NA	-0.6	-7.46	-0.34	4.88e-13	Coronary artery calcification;
LUAD	cis	rs240764	0.697	rs239194	chr6:101131959	G/A	cg09795085	chr6:101329169	ASCC3	0.42	7.05	0.32	7.47e-12	Neuroticism;
LUAD	cis	rs5756391	0.546	rs4820262	chr22:37317109	T/C	cg16356956	chr22:37317934	CSF2RB	0.31	6.53	0.3	1.85e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg00316803	chr15:76480434	C15orf27	0.39	6.36	0.3	5.15e-10	Blood metabolite levels;
LUAD	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg23649088	chr2:200775458	C2orf69	-0.63	-8.15	-0.37	4.31e-15	Schizophrenia;
LUAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13126279	chr21:47581558	C21orf56	0.57	10.33	0.45	1.84e-22	Testicular germ cell tumor;
LUAD	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	7.93	0.36	2.03e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg10556349	chr10:835070	NA	0.49	6.36	0.3	5.19e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs4713118	0.581	rs200504	chr6:27785820	T/C	cg21204522	chr6:27730016	NA	-0.48	-7.15	-0.33	3.81e-12	Parkinson's disease;
LUAD	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-9.16	-0.41	2.3e-18	Bipolar disorder;
LUAD	cis	rs3106136	0.967	rs13132963	chr4:95219780	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.71	-0.35	8.92e-14	Capecitabine sensitivity;
LUAD	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg02734326	chr4:10020555	SLC2A9	-0.45	-7.6	-0.35	1.98e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18876405	chr7:65276391	NA	-0.41	-6.47	-0.3	2.71e-10	Aortic root size;
LUAD	trans	rs1493916	0.905	rs4799727	chr18:31393095	T/G	cg27147174	chr7:100797783	AP1S1	-0.72	-13.15	-0.54	2.32e-33	Life satisfaction;
LUAD	cis	rs12618769	0.597	rs4599165	chr2:99144483	G/A	cg10123293	chr2:99228465	UNC50	0.46	8.21	0.37	2.77e-15	Bipolar disorder;
LUAD	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg04772025	chr11:68637568	NA	0.56	8.72	0.39	6.44e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7607369	0.536	rs6436089	chr2:219668813	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-10.28	-0.45	2.8e-22	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg11292332	chr7:45801988	SEPT13	-0.28	-6.36	-0.3	5.26e-10	Extrinsic epigenetic age acceleration;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	-0.4	-6.46	-0.3	2.82e-10	Subcortical brain region volumes;
LUAD	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg06873352	chr17:61820015	STRADA	0.42	7.01	0.32	9.4e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg13319975	chr6:146136371	FBXO30	0.62	10.6	0.46	2e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6831352	0.879	rs7434491	chr4:100069847	G/C	cg12011299	chr4:100065546	ADH4	-0.73	-13.26	-0.54	8.48e-34	Alcohol dependence;
LUAD	cis	rs13315871	0.929	rs13094898	chr3:58290143	G/A	cg12435725	chr3:58293450	RPP14	-0.74	-7.88	-0.36	2.86e-14	Cholesterol, total;
LUAD	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg00981070	chr1:2046702	PRKCZ	-0.34	-6.73	-0.31	5.62e-11	Height;
LUAD	cis	rs2652834	0.851	rs7170462	chr15:63345622	A/G	cg25406657	chr15:63342033	TPM1	-0.43	-6.95	-0.32	1.37e-11	HDL cholesterol;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05655935	chr10:93683722	BTAF1	-0.69	-6.63	-0.31	1.01e-10	Type 2 diabetes;
LUAD	cis	rs2692947	0.509	rs79546441	chr2:96218872	C/A	cg23100626	chr2:96804247	ASTL	0.3	7.26	0.33	1.88e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs239198	0.602	rs9377236	chr6:101289960	A/G	cg09795085	chr6:101329169	ASCC3	0.41	7.0	0.32	9.88e-12	Menarche (age at onset);
LUAD	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg20701182	chr2:24300061	SF3B14	0.54	6.54	0.3	1.76e-10	Lymphocyte counts;
LUAD	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11890956	chr21:40555474	PSMG1	-0.59	-10.29	-0.45	2.55e-22	Menarche (age at onset);
LUAD	cis	rs28595532	0.920	rs115226628	chr4:119639818	A/G	cg14228332	chr4:119757509	SEC24D	0.77	7.07	0.33	6.46e-12	Cannabis dependence symptom count;
LUAD	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg16797656	chr11:68205561	LRP5	0.48	9.39	0.42	3.87e-19	Total body bone mineral density;
LUAD	cis	rs4853525	0.522	rs1860167	chr2:191582387	G/A	cg11845111	chr2:191398756	TMEM194B	-0.45	-7.12	-0.33	4.52e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg13902645	chr11:5959945	NA	-0.51	-9.03	-0.4	6.26e-18	DNA methylation (variation);
LUAD	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1018836	0.828	rs12547016	chr8:91563847	T/C	cg16814680	chr8:91681699	NA	-0.59	-9.97	-0.44	3.75e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.29	6.6	0.31	1.23e-10	Parkinson's disease;
LUAD	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg22532475	chr10:104410764	TRIM8	-0.48	-9.19	-0.41	1.8e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg23625390	chr15:77176239	SCAPER	-0.52	-8.11	-0.37	5.4e-15	Blood metabolite levels;
LUAD	cis	rs870825	0.860	rs72703529	chr4:185607351	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	10.21	0.44	4.85e-22	Blood protein levels;
LUAD	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg17264618	chr3:40429014	ENTPD3	0.39	8.92	0.4	1.47e-17	Renal cell carcinoma;
LUAD	cis	rs418053	0.648	rs204226	chr6:13706250	C/G	cg02206980	chr6:13574034	SIRT5	0.34	7.31	0.34	1.31e-12	Breast cancer;
LUAD	cis	rs16910800	1.000	rs73479585	chr11:23197391	T/C	cg20040320	chr11:23191996	NA	-0.48	-7.19	-0.33	2.93e-12	Cancer;
LUAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00149659	chr3:10157352	C3orf10	0.57	7.96	0.36	1.55e-14	Alzheimer's disease;
LUAD	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg00310523	chr12:86230176	RASSF9	0.41	8.14	0.37	4.54e-15	Major depressive disorder;
LUAD	cis	rs3772130	0.923	rs3805127	chr3:121556751	G/A	cg20356878	chr3:121714668	ILDR1	0.53	8.38	0.38	8.15e-16	Cognitive performance;
LUAD	cis	rs4899554	0.640	rs72719935	chr14:75724345	C/T	cg18117039	chr14:75741733	NA	0.65	9.3	0.41	7.69e-19	Inflammatory bowel disease;
LUAD	cis	rs9549328	0.800	rs9549616	chr13:113627762	T/G	cg17524180	chr13:113633600	MCF2L	-0.4	-7.95	-0.36	1.76e-14	Systolic blood pressure;
LUAD	cis	rs11958404	0.932	rs11950297	chr5:157419938	T/G	cg05962755	chr5:157440814	NA	0.62	8.67	0.39	9.15e-17	IgG glycosylation;
LUAD	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg16262614	chr3:133464971	TF	0.44	8.91	0.4	1.59e-17	Iron status biomarkers (transferrin levels);
LUAD	trans	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.51	0.42	1.49e-19	Mean corpuscular volume;
LUAD	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg19717773	chr7:2847554	GNA12	-0.53	-9.92	-0.43	5.64e-21	Height;
LUAD	cis	rs7568458	0.905	rs10198569	chr2:85794415	C/T	cg02493740	chr2:85810744	VAMP5	0.42	7.64	0.35	1.49e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg23260525	chr10:116636907	FAM160B1	0.47	10.84	0.47	2.48e-24	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg21775007	chr8:11205619	TDH	0.39	6.43	0.3	3.47e-10	Neuroticism;
LUAD	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg23158103	chr7:148848205	ZNF398	-0.6	-10.89	-0.47	1.66e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2464469	0.654	rs2067062	chr15:58341954	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-6.88	-0.32	2.2e-11	Barrett's esophagus  or Esophageal adenocarcinoma;
LUAD	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg03733263	chr8:22462867	KIAA1967	0.73	12.41	0.52	2.18e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg13770153	chr20:60521292	NA	-0.48	-8.05	-0.36	8.63e-15	Body mass index;
LUAD	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg21231944	chr12:82153410	PPFIA2	-0.35	-6.42	-0.3	3.59e-10	Resting heart rate;
LUAD	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg09658497	chr7:2847517	GNA12	-0.47	-7.97	-0.36	1.44e-14	Height;
LUAD	trans	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9296092	0.560	rs9469500	chr6:33526196	C/T	cg13560919	chr6:33536144	NA	-0.87	-15.59	-0.6	1.29e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg14324370	chr2:177042789	NA	0.43	8.1	0.37	5.87e-15	IgG glycosylation;
LUAD	trans	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg27411982	chr8:10470053	RP1L1	0.43	7.78	0.35	5.62e-14	Mood instability;
LUAD	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg18252515	chr7:66147081	NA	-0.61	-6.68	-0.31	7.65e-11	Diabetic kidney disease;
LUAD	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.85	0.32	2.55e-11	Lung cancer;
LUAD	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg04414720	chr1:150670196	GOLPH3L	0.72	13.36	0.54	3.28e-34	Tonsillectomy;
LUAD	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg17077180	chr1:38461687	NA	0.44	8.21	0.37	2.7e-15	Coronary artery disease;
LUAD	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg04034577	chr2:241836375	C2orf54	-0.47	-10.45	-0.45	7.1e-23	Urinary metabolites;
LUAD	cis	rs7809950	0.817	rs3779495	chr7:107250260	G/A	cg23024343	chr7:107201750	COG5	0.87	14.26	0.57	6.12e-38	Coronary artery disease;
LUAD	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg26168224	chr5:2018326	NA	-0.81	-18.26	-0.66	2.42e-55	Gut microbiome composition (winter);
LUAD	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-11.61	-0.49	2.94e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg05768032	chr16:30646687	NA	0.44	7.81	0.35	4.68e-14	Multiple myeloma;
LUAD	cis	rs9473147	0.571	rs9369717	chr6:47554468	T/G	cg20196966	chr6:47445060	CD2AP	0.43	6.73	0.31	5.61e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs11671005	0.693	rs11669665	chr19:58931885	G/A	cg13877915	chr19:58951672	ZNF132	0.56	7.35	0.34	1.04e-12	Mean platelet volume;
LUAD	cis	rs6906287	0.647	rs12207209	chr6:118850375	T/G	cg05564266	chr6:118973597	C6orf204	0.34	7.15	0.33	3.82e-12	Electrocardiographic conduction measures;
LUAD	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22857025	chr5:266934	NA	-1.03	-13.36	-0.54	3.39e-34	Breast cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg10205287	chr4:100815590	MAPKSP1	-0.38	-6.46	-0.3	2.89e-10	Cancer;
LUAD	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg14582100	chr15:45693742	SPATA5L1	0.63	12.48	0.52	1.21e-30	Homoarginine levels;
LUAD	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg22681709	chr2:178499509	PDE11A	-0.55	-9.29	-0.41	8.43e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.18	-0.37	3.36e-15	Bipolar disorder;
LUAD	cis	rs2882667	0.537	rs7701338	chr5:138405994	C/T	cg04439458	chr5:138467593	SIL1	-0.36	-6.78	-0.31	4e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg04990556	chr1:26633338	UBXN11	-0.4	-6.65	-0.31	8.99e-11	Obesity-related traits;
LUAD	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg18138036	chr10:133769891	PPP2R2D	0.41	6.65	0.31	8.98e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11890956	chr21:40555474	PSMG1	0.77	12.92	0.53	1.95e-32	Cognitive function;
LUAD	cis	rs11048434	0.736	rs11048190	chr12:9104939	C/T	cg13575925	chr12:9217583	LOC144571	0.37	6.84	0.32	2.85e-11	Sjögren's syndrome;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22129906	chr2:220119239	TUBA4B;TUBA4A	-0.4	-6.82	-0.31	3.23e-11	Cancer;
LUAD	cis	rs11677370	0.574	rs10190477	chr2:3862738	A/G	cg17052675	chr2:3827356	NA	0.61	10.3	0.45	2.34e-22	Type 2 diabetes;
LUAD	cis	rs4006360	0.646	rs8080447	chr17:39301276	T/A	cg12981595	chr17:39254427	KRTAP4-8	0.32	6.57	0.3	1.45e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6906287	0.647	rs4027880	chr6:118734134	A/T	cg21191810	chr6:118973309	C6orf204	0.5	9.8	0.43	1.48e-20	Electrocardiographic conduction measures;
LUAD	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg05966235	chr16:28915196	ATP2A1	0.42	6.8	0.31	3.67e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs12618769	0.597	rs72819965	chr2:99023719	G/C	cg10123293	chr2:99228465	UNC50	0.45	8.08	0.37	7.07e-15	Bipolar disorder;
LUAD	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg27279351	chr12:120934652	DYNLL1	0.44	6.66	0.31	8.45e-11	High light scatter reticulocyte count;
LUAD	trans	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.78	-0.31	4.08e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg15181151	chr6:150070149	PCMT1	0.41	8.1	0.37	6.08e-15	Lung cancer;
LUAD	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg01802117	chr1:53393560	SCP2	-0.4	-7.45	-0.34	5.36e-13	Monocyte count;
LUAD	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.57	0.52	5.27e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg06558623	chr16:89946397	TCF25	1.14	10.58	0.46	2.2e-23	Skin colour saturation;
LUAD	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg27411982	chr8:10470053	RP1L1	0.45	8.32	0.37	1.26e-15	Neuroticism;
LUAD	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg00999904	chr2:3704751	ALLC	0.5	8.51	0.38	3.16e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs2625529	0.824	rs11072346	chr15:72400434	G/A	cg16672083	chr15:72433130	SENP8	-0.74	-12.57	-0.52	5.03e-31	Red blood cell count;
LUAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03452623	chr4:187889614	NA	0.81	17.0	0.64	8.72e-50	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg13560548	chr3:10150139	C3orf24	-0.44	-7.22	-0.33	2.49e-12	Alzheimer's disease;
LUAD	cis	rs9972944	0.729	rs6504351	chr17:63765275	C/T	cg07283582	chr17:63770753	CCDC46	-0.5	-11.33	-0.48	3.53e-26	Total body bone mineral density;
LUAD	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg00071950	chr4:10020882	SLC2A9	-0.74	-14.76	-0.58	4.49e-40	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg18833306	chr6:118973337	C6orf204	0.5	6.8	0.31	3.47e-11	Diastolic blood pressure;
LUAD	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-11.1	-0.47	2.75e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg19336497	chr11:14380999	RRAS2	-0.66	-14.24	-0.57	7.22e-38	Sense of smell;
LUAD	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.82	-0.36	4.36e-14	Total body bone mineral density;
LUAD	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg03609598	chr5:56110824	MAP3K1	-0.69	-9.32	-0.41	6.72e-19	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.09e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg22529645	chr1:3704559	LRRC47	0.57	10.5	0.45	4.43e-23	Red cell distribution width;
LUAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg13047869	chr3:10149882	C3orf24	0.6	10.36	0.45	1.49e-22	Alzheimer's disease;
LUAD	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg00701064	chr4:6280414	WFS1	0.64	13.92	0.56	1.59e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg22508957	chr16:3507546	NAT15	-0.84	-9.25	-0.41	1.16e-18	Tuberculosis;
LUAD	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.9	-0.5	2.24e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg16479474	chr6:28041457	NA	-0.41	-7.07	-0.33	6.4e-12	Parkinson's disease;
LUAD	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg11189052	chr15:85197271	WDR73	0.64	8.02	0.36	1.02e-14	Schizophrenia;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg03909821	chr3:150422049	FAM194A	-0.39	-6.71	-0.31	6.35e-11	Subcortical brain region volumes;
LUAD	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg02018176	chr4:1364513	KIAA1530	0.46	8.39	0.38	7.44e-16	Longevity;
LUAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg26554054	chr8:600488	NA	0.81	8.02	0.36	1.04e-14	IgG glycosylation;
LUAD	cis	rs10744422	1.000	rs7294991	chr12:123286780	C/T	cg16953816	chr12:123349952	VPS37B	0.66	7.07	0.32	6.55e-12	Schizophrenia;
LUAD	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03352830	chr11:487213	PTDSS2	0.78	10.65	0.46	1.27e-23	Body mass index;
LUAD	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.09	0.33	5.56e-12	Menopause (age at onset);
LUAD	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg15181151	chr6:150070149	PCMT1	0.36	7.14	0.33	4.13e-12	Lung cancer;
LUAD	cis	rs3733418	0.929	rs13149738	chr4:165905697	T/C	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.55	-7.18	-0.33	3.11e-12	Obesity-related traits;
LUAD	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02475777	chr4:1388615	CRIPAK	-0.5	-7.2	-0.33	2.78e-12	Obesity-related traits;
LUAD	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.61	-0.39	1.49e-16	Alzheimer's disease (late onset);
LUAD	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg13770153	chr20:60521292	NA	-0.47	-7.88	-0.36	2.86e-14	Body mass index;
LUAD	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg12458913	chr13:53173898	NA	0.39	7.08	0.33	6.14e-12	Lewy body disease;
LUAD	cis	rs9902453	1.000	rs7223786	chr17:28332107	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-9.07	-0.4	4.67e-18	Coffee consumption (cups per day);
LUAD	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg27411982	chr8:10470053	RP1L1	-0.39	-7.21	-0.33	2.65e-12	Neuroticism;
LUAD	cis	rs1595825	0.891	rs111340803	chr2:198612877	A/G	cg00982548	chr2:198649783	BOLL	-0.66	-9.4	-0.42	3.55e-19	Ulcerative colitis;
LUAD	cis	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.33e-10	Ulcerative colitis;
LUAD	cis	rs8060686	0.516	rs4567701	chr16:68163662	T/C	cg26727032	chr16:67993705	SLC12A4	-0.47	-7.71	-0.35	9.12e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2294693	0.947	rs736795	chr6:40998141	G/A	cg14769373	chr6:40998127	UNC5CL	-0.55	-8.52	-0.38	2.74e-16	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg04568274	chr7:158649319	WDR60	0.42	6.74	0.31	5.34e-11	Height;
LUAD	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg22823121	chr1:150693482	HORMAD1	-0.35	-6.73	-0.31	5.54e-11	Tonsillectomy;
LUAD	cis	rs4713675	0.565	rs4713674	chr6:33708169	C/T	cg14003231	chr6:33640908	ITPR3	-0.41	-7.77	-0.35	6.2e-14	Plateletcrit;
LUAD	cis	rs6684428	1.000	rs55769330	chr1:56357825	G/C	cg11651538	chr1:56320950	NA	-0.4	-6.44	-0.3	3.34e-10	Airflow obstruction;
LUAD	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg08859206	chr1:53392774	SCP2	0.63	11.43	0.49	1.44e-26	Monocyte count;
LUAD	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg27494647	chr7:150038898	RARRES2	0.53	9.37	0.41	4.24e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs11811982	0.793	rs114098136	chr1:227235510	A/G	cg24860534	chr1:227506868	CDC42BPA	0.65	6.99	0.32	1.06e-11	Optic disc area;
LUAD	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg06263672	chr7:65235340	NA	-0.47	-6.56	-0.3	1.55e-10	Aortic root size;
LUAD	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.46	9.09	0.4	3.82e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18876405	chr7:65276391	NA	-0.56	-9.45	-0.42	2.41e-19	Aortic root size;
LUAD	cis	rs12541635	0.739	rs1896915	chr8:107083520	G/T	cg10147462	chr8:107024639	NA	0.47	8.26	0.37	1.9e-15	Age of smoking initiation;
LUAD	cis	rs1030877	0.557	rs2576752	chr2:105978761	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.41	7.47	0.34	4.61e-13	Obesity-related traits;
LUAD	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg22963979	chr7:1858916	MAD1L1	-0.57	-9.62	-0.42	5.97e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg27068330	chr11:65405492	SIPA1	-0.76	-11.38	-0.48	2.3e-26	Acne (severe);
LUAD	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg25019722	chr6:37503610	NA	-0.32	-7.19	-0.33	3.03e-12	Cognitive performance;
LUAD	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg27411982	chr8:10470053	RP1L1	-0.39	-6.87	-0.32	2.35e-11	Retinal vascular caliber;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg14737296	chr12:133212394	POLE	0.39	6.79	0.31	3.74e-11	Schizophrenia;
LUAD	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg23029597	chr12:123009494	RSRC2	-0.52	-8.21	-0.37	2.73e-15	Body mass index;
LUAD	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg01849466	chr14:104193079	ZFYVE21	0.45	7.46	0.34	5.1e-13	Body mass index;
LUAD	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2046867	0.862	rs57396880	chr3:72844785	G/A	cg25664220	chr3:72788482	NA	-0.7	-12.39	-0.52	2.68e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg08085267	chr17:45401833	C17orf57	0.59	10.92	0.47	1.3e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-11.16	-0.48	1.6e-25	Monocyte percentage of white cells;
LUAD	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg12923728	chr3:195709715	SDHAP1	0.42	6.5	0.3	2.29e-10	Mean corpuscular volume;
LUAD	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg24818145	chr4:99064322	C4orf37	0.39	6.58	0.3	1.35e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg16486109	chr11:613632	IRF7	0.53	7.81	0.35	4.59e-14	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg15181151	chr6:150070149	PCMT1	0.39	7.98	0.36	1.38e-14	Lung cancer;
LUAD	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg11871910	chr12:69753446	YEATS4	0.55	8.63	0.39	1.23e-16	Blood protein levels;
LUAD	cis	rs57920188	0.535	rs58051771	chr1:4092146	T/C	cg20703997	chr1:4087676	NA	0.48	9.02	0.4	6.84e-18	Interleukin-17 levels;
LUAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg10729496	chr3:10149963	C3orf24	0.49	7.92	0.36	2.15e-14	Alzheimer's disease;
LUAD	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.73	-0.31	5.7e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg14634687	chr17:47094252	IGF2BP1	0.29	7.53	0.34	3.01e-13	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.5	-8.27	-0.37	1.72e-15	Reticulocyte count;
LUAD	cis	rs7177699	0.557	rs7165075	chr15:79115965	G/A	cg00540400	chr15:79124168	NA	0.44	9.62	0.42	6.23e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg05283184	chr6:79620031	NA	-0.61	-12.47	-0.52	1.32e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg24578937	chr1:2090814	PRKCZ	-0.59	-11.43	-0.49	1.45e-26	Height;
LUAD	cis	rs17253792	0.822	rs74968702	chr14:56076818	A/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg01579765	chr21:45077557	HSF2BP	-0.6	-13.37	-0.54	3.06e-34	Mean corpuscular volume;
LUAD	trans	rs7395662	1.000	rs1605364	chr11:48684843	G/T	cg15704280	chr7:45808275	SEPT13	-0.41	-6.4	-0.3	4.17e-10	HDL cholesterol;
LUAD	cis	rs6901250	0.851	rs339361	chr6:117162515	C/T	cg12892004	chr6:117198278	RFX6	0.35	7.47	0.34	4.67e-13	C-reactive protein levels;
LUAD	cis	rs6459804	0.967	rs11762822	chr7:157507684	C/G	cg05731713	chr7:157510257	PTPRN2	0.44	10.03	0.44	2.2e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs10992471	0.729	rs6479418	chr9:95064762	G/A	cg14631576	chr9:95140430	CENPP	-0.48	-9.83	-0.43	1.17e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg27661571	chr11:113659931	NA	-0.7	-8.17	-0.37	3.56e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg12927641	chr6:109611667	NA	-0.48	-7.96	-0.36	1.62e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg27411982	chr8:10470053	RP1L1	-0.4	-7.23	-0.33	2.21e-12	Retinal vascular caliber;
LUAD	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg13319975	chr6:146136371	FBXO30	-0.66	-11.52	-0.49	6.99e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg12016809	chr21:47604291	C21orf56	0.53	8.99	0.4	8.39e-18	Testicular germ cell tumor;
LUAD	cis	rs1232027	0.588	rs245331	chr5:80026377	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.47	-7.48	-0.34	4.26e-13	Huntington's disease progression;
LUAD	trans	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg16006296	chr10:38738647	LOC399744	0.35	6.36	0.3	5.3e-10	Diastolic blood pressure;
LUAD	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg22467129	chr15:76604101	ETFA	-0.59	-10.86	-0.47	2.09e-24	Blood metabolite levels;
LUAD	trans	rs11700980	0.636	rs114711857	chr21:30260199	T/C	cg14791747	chr16:20752902	THUMPD1	0.62	6.79	0.31	3.81e-11	QRS complex (12-leadsum);
LUAD	cis	rs6717918	0.924	rs6718438	chr2:233155566	T/C	ch.2.233013039R	chr2:233304795	NA	0.46	6.72	0.31	5.84e-11	Height;
LUAD	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.6	7.34	0.34	1.11e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg05340658	chr4:99064831	C4orf37	-0.43	-6.7	-0.31	6.72e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg06611532	chr13:114900021	NA	0.39	9.09	0.4	4.01e-18	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.5	-0.38	3.38e-16	Height;
LUAD	trans	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg01620082	chr3:125678407	NA	-0.67	-6.93	-0.32	1.6e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg15992532	chr8:142229932	SLC45A4	-0.46	-8.28	-0.37	1.66e-15	Immature fraction of reticulocytes;
LUAD	cis	rs11955175	1.000	rs75929994	chr5:40821816	T/C	cg04002187	chr5:40835754	RPL37	0.77	6.57	0.3	1.52e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg12935359	chr14:103987150	CKB	-0.47	-7.92	-0.36	2.1e-14	Body mass index;
LUAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg22963979	chr7:1858916	MAD1L1	-0.74	-12.93	-0.53	1.77e-32	Bipolar disorder and schizophrenia;
LUAD	cis	rs7274811	0.688	rs6141400	chr20:32056087	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.52	-7.68	-0.35	1.1e-13	Height;
LUAD	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg21100191	chr22:23484243	RTDR1	0.69	11.88	0.5	2.66e-28	Bone mineral density;
LUAD	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg00933542	chr6:150070202	PCMT1	0.44	9.6	0.42	6.92e-20	Lung cancer;
LUAD	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg23533926	chr12:111358616	MYL2	-0.42	-7.25	-0.33	2.01e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg12310025	chr6:25882481	NA	0.5	7.27	0.33	1.78e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg11965913	chr1:205819406	PM20D1	0.51	7.83	0.36	3.83e-14	Parkinson's disease;
LUAD	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg12444411	chr7:2802554	GNA12	-0.37	-6.62	-0.31	1.07e-10	Height;
LUAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg20607798	chr8:58055168	NA	0.58	7.41	0.34	6.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg19622623	chr12:86230825	RASSF9	-0.36	-6.68	-0.31	7.75e-11	Major depressive disorder;
LUAD	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.42	-0.34	6.63e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7582720	1.000	rs72934545	chr2:203975958	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.63	0.42	5.52e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1448094	0.967	rs7961782	chr12:86326461	T/C	cg18827107	chr12:86230957	RASSF9	-0.44	-7.93	-0.36	1.94e-14	Major depressive disorder;
LUAD	cis	rs3733418	0.929	rs4691138	chr4:165908641	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.49	-6.8	-0.31	3.51e-11	Obesity-related traits;
LUAD	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-15.24	-0.6	4.28e-42	Schizophrenia;
LUAD	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg04398451	chr17:18023971	MYO15A	0.7	12.25	0.51	1.01e-29	Total body bone mineral density;
LUAD	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.73	0.31	5.58e-11	Motion sickness;
LUAD	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg01256987	chr12:42539512	GXYLT1	-0.35	-6.82	-0.31	3.2e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg06784218	chr1:46089804	CCDC17	0.56	12.36	0.52	3.63e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg06640241	chr16:89574553	SPG7	0.55	8.22	0.37	2.46e-15	Multiple myeloma (IgH translocation);
LUAD	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.6	-10.38	-0.45	1.21e-22	Menarche (age at onset);
LUAD	cis	rs9296092	0.538	rs9461881	chr6:33520041	C/T	cg13560919	chr6:33536144	NA	-0.89	-16.71	-0.63	1.64e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg14343924	chr8:8086146	FLJ10661	-0.48	-7.94	-0.36	1.8e-14	Mood instability;
LUAD	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg00290607	chr11:67383545	NA	0.4	6.58	0.3	1.38e-10	Mean corpuscular volume;
LUAD	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg09905732	chr16:928154	LMF1	-0.37	-6.56	-0.3	1.53e-10	Educational attainment (years of education);
LUAD	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg23985595	chr17:80112537	CCDC57	-0.53	-9.51	-0.42	1.43e-19	Life satisfaction;
LUAD	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11890956	chr21:40555474	PSMG1	0.79	13.81	0.56	4.68e-36	Cognitive function;
LUAD	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg14926445	chr8:58193284	C8orf71	-0.51	-7.4	-0.34	7.28e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg21214613	chr1:16344536	HSPB7	-0.41	-6.5	-0.3	2.26e-10	Dilated cardiomyopathy;
LUAD	cis	rs12997796	0.556	rs35594332	chr2:86982651	G/A	cg23743911	chr2:86949715	RMND5A	0.45	6.48	0.3	2.6200000000000003e-10	Schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11355319	chr5:89825117	LYSMD3	-0.43	-7.0	-0.32	1.04e-11	Height;
LUAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg23978390	chr7:1156363	C7orf50	0.65	10.4	0.45	1.07e-22	Longevity;Endometriosis;
LUAD	cis	rs367943	0.688	rs1464163	chr5:112691815	A/G	cg12552261	chr5:112820674	MCC	0.47	9.19	0.41	1.82e-18	Type 2 diabetes;
LUAD	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg02493740	chr2:85810744	VAMP5	-0.63	-11.51	-0.49	7.39e-27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg13560548	chr3:10150139	C3orf24	0.43	7.24	0.33	2.09e-12	Alzheimer's disease;
LUAD	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg07527032	chr15:84868466	LOC388152	0.44	6.64	0.31	9.82e-11	Schizophrenia;
LUAD	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25427524	chr10:38739819	LOC399744	-0.79	-14.38	-0.57	1.93e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.56	-0.34	2.59e-13	Total cholesterol levels;
LUAD	cis	rs7793919	0.726	rs4720401	chr7:4780943	G/A	cg09789173	chr7:4769017	FOXK1	0.74	15.05	0.59	2.58e-41	Mosquito bite size;
LUAD	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg22920501	chr2:26401640	FAM59B	-0.96	-15.46	-0.6	4.63e-43	Gut microbiome composition (summer);
LUAD	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg26850624	chr5:429559	AHRR	-0.42	-6.65	-0.31	9.22e-11	Cystic fibrosis severity;
LUAD	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg08508325	chr11:3079039	CARS	0.44	9.14	0.41	2.72e-18	Calcium levels;
LUAD	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg03161606	chr19:29218774	NA	0.6	8.66	0.39	1.04e-16	Methadone dose in opioid dependence;
LUAD	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg21433313	chr16:3507492	NAT15	-0.75	-8.4	-0.38	6.82e-16	Tuberculosis;
LUAD	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.66	-0.31	8.53e-11	Bipolar disorder;
LUAD	trans	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg01620082	chr3:125678407	NA	-0.88	-8.94	-0.4	1.19e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg12573674	chr2:1569213	NA	-0.61	-6.89	-0.32	2.08e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs877282	1.000	rs12773872	chr10:771939	T/C	cg22713356	chr15:30763199	NA	1.32	18.6	0.67	7.03e-57	Uric acid levels;
LUAD	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg12119029	chr16:89752879	CDK10	0.36	7.41	0.34	6.74e-13	Vitiligo;
LUAD	cis	rs9902453	0.874	rs7220004	chr17:28369548	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.53	-0.46	3.46e-23	Coffee consumption (cups per day);
LUAD	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	9.07	0.4	4.53e-18	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06022373	chr22:39101656	GTPBP1	0.49	8.03	0.36	9.65e-15	Menopause (age at onset);
LUAD	cis	rs6842047	1.000	rs4862668	chr4:187136443	A/T	cg09526685	chr4:187126073	CYP4V2	0.88	9.82	0.43	1.18e-20	Blood protein levels;
LUAD	cis	rs4853036	0.723	rs2312557	chr2:70090243	G/A	cg02498382	chr2:70120550	SNRNP27	-0.51	-7.25	-0.33	1.99e-12	Colorectal or endometrial cancer;
LUAD	cis	rs2901656	0.677	rs2269615	chr1:172415451	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.52	10.19	0.44	5.9e-22	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs1564271	0.528	rs2489589	chr10:26983095	A/G	cg13837822	chr10:26931731	LOC731789	0.47	10.02	0.44	2.46e-21	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUAD	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg10518543	chr12:38710700	ALG10B	0.5	8.39	0.38	7.38e-16	Morning vs. evening chronotype;
LUAD	cis	rs35883536	1.000	rs2297716	chr1:101092526	G/C	cg06223162	chr1:101003688	GPR88	0.34	6.44	0.3	3.31e-10	Monocyte count;
LUAD	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg23752985	chr2:85803571	VAMP8	0.34	6.73	0.31	5.38e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs7180079	0.920	rs11071790	chr15:64601979	G/A	cg08069370	chr15:64387884	SNX1	0.54	6.7	0.31	6.83e-11	Monocyte count;
LUAD	trans	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg01620082	chr3:125678407	NA	-0.42	-6.42	-0.3	3.6e-10	Parkinson's disease;
LUAD	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-7.86	-0.36	3.14e-14	Type 2 diabetes;
LUAD	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.39	6.78	0.31	3.95e-11	Menarche (age at onset);
LUAD	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg02221750	chr19:17393354	ANKLE1	-0.76	-12.3	-0.51	6.03e-30	Systemic lupus erythematosus;
LUAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg27454412	chr7:1067447	C7orf50	0.48	7.73	0.35	7.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	6.42	0.3	3.59e-10	Prudent dietary pattern;
LUAD	cis	rs1997103	1.000	rs6950311	chr7:55400990	G/A	cg17469321	chr7:55412551	NA	0.67	11.39	0.48	2.05e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg08470875	chr2:26401718	FAM59B	-0.61	-8.28	-0.37	1.62e-15	Gut microbiome composition (summer);
LUAD	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg00757033	chr12:89920650	WDR51B	0.63	11.46	0.49	1.16e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs236907	0.859	rs35930163	chr1:171768184	G/A	cg13482142	chr2:234261155	NA	0.49	6.38	0.3	4.56e-10	Mean platelet volume;
LUAD	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7582720	1.000	rs72934512	chr2:203926271	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.83	0.43	1.1e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs12618769	0.652	rs72823794	chr2:99216593	T/A	cg10123293	chr2:99228465	UNC50	0.5	8.87	0.4	2.09e-17	Bipolar disorder;
LUAD	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg22004693	chr7:99632812	ZKSCAN1	0.6	9.57	0.42	9.29e-20	Lung function (FEV1/FVC);
LUAD	trans	rs11039798	1.000	rs3902928	chr11:48581458	A/T	cg02254774	chr11:50257496	LOC441601	0.52	6.57	0.3	1.48e-10	Axial length;
LUAD	cis	rs6960043	0.875	rs10249299	chr7:15054391	C/T	cg19272540	chr7:15055459	NA	0.36	8.25	0.37	2.01e-15	Type 2 diabetes;
LUAD	cis	rs2387326	0.717	rs10829341	chr10:129944226	G/A	cg16087940	chr10:129947807	NA	-0.63	-8.99	-0.4	8.02e-18	Select biomarker traits;
LUAD	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg21016266	chr12:122356598	WDR66	0.67	11.88	0.5	2.64e-28	Mean corpuscular volume;
LUAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg10862848	chr6:42927986	GNMT	-0.31	-9.1	-0.4	3.57e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg10862848	chr6:42927986	GNMT	-0.33	-9.4	-0.42	3.61e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.34	6.82	0.31	3.16e-11	Obesity-related traits;
LUAD	cis	rs9462027	0.606	rs2744959	chr6:34616654	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.76	-0.39	4.79e-17	Systemic lupus erythematosus;
LUAD	cis	rs6594713	0.717	rs13174075	chr5:112795352	A/T	cg12552261	chr5:112820674	MCC	0.59	8.88	0.4	1.93e-17	Brain cytoarchitecture;
LUAD	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg00316803	chr15:76480434	C15orf27	0.4	6.37	0.3	5e-10	Blood metabolite levels;
LUAD	cis	rs7582720	1.000	rs72936870	chr2:203789679	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg03605463	chr16:89740564	NA	-0.42	-6.71	-0.31	6.32e-11	Vitiligo;
LUAD	trans	rs877282	0.945	rs12776447	chr10:790625	A/G	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg21427119	chr20:30132790	HM13	-0.58	-9.23	-0.41	1.3e-18	Mean corpuscular hemoglobin;
LUAD	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg04455712	chr21:45112962	RRP1B	0.42	8.12	0.37	5.19e-15	Mean corpuscular volume;
LUAD	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg18209359	chr17:80159595	CCDC57	0.41	6.97	0.32	1.19e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2742234	1.000	rs2742234	chr10:43612609	A/G	cg15436174	chr10:43711423	RASGEF1A	0.42	7.71	0.35	9.34e-14	Hirschsprung disease;
LUAD	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg22920501	chr2:26401640	FAM59B	0.96	13.91	0.56	1.82e-36	Gut microbiome composition (summer);
LUAD	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	8.03	0.36	9.56e-15	Breast cancer;
LUAD	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg24801067	chr17:62843696	NA	-0.54	-8.74	-0.39	5.64e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg11057378	chr10:81107060	PPIF	0.36	6.82	0.31	3.21e-11	Height;
LUAD	cis	rs9322817	0.607	rs9404572	chr6:105149439	T/C	cg02098413	chr6:105308735	HACE1	-0.37	-7.87	-0.36	2.94e-14	Thyroid stimulating hormone;
LUAD	cis	rs2019216	0.967	rs1606426	chr17:21927959	A/G	cg05591447	chr17:21909280	FLJ36000	-0.3	-7.89	-0.36	2.65e-14	Pelvic organ prolapse;
LUAD	cis	rs78761021	0.755	rs17743980	chr17:9793839	G/A	cg26853458	chr17:9805074	RCVRN	0.38	7.13	0.33	4.34e-12	Type 2 diabetes;
LUAD	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg19442545	chr10:75533431	FUT11	-0.47	-7.7	-0.35	1e-13	Psoriasis vulgaris;Psoriasis;
LUAD	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg15790184	chr11:494944	RNH1	0.51	6.39	0.3	4.46e-10	Body mass index;
LUAD	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg07395648	chr5:131743802	NA	-0.37	-6.35	-0.3	5.53e-10	Breast cancer;
LUAD	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01570182	chr17:44337453	NA	-0.76	-12.44	-0.52	1.75e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs75804782	0.625	rs10929278	chr2:239468643	A/G	cg01134436	chr17:81009848	B3GNTL1	0.71	7.28	0.33	1.64e-12	Morning vs. evening chronotype;Chronotype;
LUAD	trans	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg27411982	chr8:10470053	RP1L1	0.41	7.76	0.35	6.28e-14	Mood instability;
LUAD	cis	rs17102423	0.594	rs1124752	chr14:65567515	G/T	cg11161011	chr14:65562177	MAX	-0.46	-7.84	-0.36	3.66e-14	Obesity-related traits;
LUAD	cis	rs870825	0.929	rs870822	chr4:185588200	C/T	cg04058563	chr4:185651563	MLF1IP	0.66	8.79	0.39	3.9e-17	Blood protein levels;
LUAD	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg07570687	chr10:102243282	WNT8B	0.44	6.5	0.3	2.22e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg20307385	chr11:47447363	PSMC3	-0.68	-11.84	-0.5	3.83e-28	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs796825	0.530	rs1492272	chr3:119962322	G/C	cg21790991	chr3:120137480	FSTL1	-0.43	-7.35	-0.34	1.01e-12	HIV-1 susceptibility;
LUAD	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg15448220	chr1:150897856	SETDB1	-0.43	-7.23	-0.33	2.23e-12	Tonsillectomy;
LUAD	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg14668632	chr7:2872130	GNA12	-0.75	-13.57	-0.55	4.6e-35	Height;
LUAD	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg15017067	chr4:17643749	FAM184B	0.35	6.86	0.32	2.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	18.68	0.67	3.2e-57	Bone mineral density;
LUAD	cis	rs2274273	1.000	rs15870	chr14:55619311	A/G	cg04306507	chr14:55594613	LGALS3	0.37	7.49	0.34	4.04e-13	Protein biomarker;
LUAD	cis	rs7177699	0.557	rs11072807	chr15:79111517	A/G	cg00540400	chr15:79124168	NA	0.46	9.82	0.43	1.17e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg11494091	chr17:61959527	GH2	0.4	7.01	0.32	9.55e-12	Height;
LUAD	trans	rs10411161	0.702	rs7250193	chr19:52385520	C/T	cg22319618	chr22:45562946	NUP50	0.6	8.74	0.39	5.7e-17	Breast cancer;
LUAD	cis	rs262150	0.536	rs4909109	chr7:158787168	C/G	cg19418458	chr7:158789849	NA	0.58	8.37	0.38	8.26e-16	Facial morphology (factor 20);
LUAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	cis	rs7100689	0.646	rs9804236	chr10:82135100	T/C	cg01528321	chr10:82214614	TSPAN14	0.65	10.26	0.45	3.26e-22	Post bronchodilator FEV1;
LUAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg21724239	chr8:58056113	NA	0.66	8.66	0.39	9.86e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg21427119	chr20:30132790	HM13	-0.63	-9.78	-0.43	1.63e-20	Mean corpuscular hemoglobin;
LUAD	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.41	-6.56	-0.3	1.57e-10	Schizophrenia;
LUAD	cis	rs2019216	0.542	rs7217513	chr17:21933536	C/A	cg22648282	chr17:21454238	C17orf51	-0.48	-8.29	-0.37	1.51e-15	Pelvic organ prolapse;
LUAD	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg00857998	chr1:205179979	DSTYK	0.4	6.66	0.31	8.4e-11	Red blood cell count;
LUAD	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.32	-8.2	-0.37	2.91e-15	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg02985366	chr16:32360428	NA	-0.4	-6.92	-0.32	1.7e-11	Menopause (age at onset);
LUAD	cis	rs9517313	0.591	rs17574543	chr13:99172893	G/A	cg07423050	chr13:99094983	FARP1	-0.6	-9.82	-0.43	1.27e-20	Neuroticism;
LUAD	cis	rs9549328	0.611	rs72661939	chr13:113617498	C/T	cg17524180	chr13:113633600	MCF2L	0.31	6.61	0.31	1.16e-10	Systolic blood pressure;
LUAD	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.35	0.38	9.62e-16	Menarche (age at onset);
LUAD	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-7.63	-0.35	1.5700000000000001e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.29	-7.01	-0.32	9.22e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.58	-0.35	2.24e-13	Breast cancer;
LUAD	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg25208724	chr1:156163844	SLC25A44	-1.09	-24.65	-0.77	8.13e-84	Testicular germ cell tumor;
LUAD	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg06740227	chr12:86229804	RASSF9	0.44	7.71	0.35	9.14e-14	Major depressive disorder;
LUAD	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg14581129	chr12:53358946	NA	-0.8	-14.89	-0.59	1.3e-40	Prostate cancer;
LUAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.59	-10.3	-0.45	2.33e-22	Lymphocyte counts;
LUAD	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg09455208	chr3:40491958	NA	0.54	11.18	0.48	1.3e-25	Renal cell carcinoma;
LUAD	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg02176678	chr2:219576539	TTLL4	0.69	13.4	0.55	2.17e-34	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg08754478	chr10:133766260	PPP2R2D	0.71	12.35	0.51	3.76e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg22532475	chr10:104410764	TRIM8	0.44	8.46	0.38	4.3e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.19	0.33	2.95e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-7.17	-0.33	3.4e-12	IgG glycosylation;
LUAD	cis	rs11048434	0.736	rs11048190	chr12:9104939	C/T	cg04155231	chr12:9217510	LOC144571	0.38	7.21	0.33	2.63e-12	Sjögren's syndrome;
LUAD	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.75	0.31	4.92e-11	Parkinson's disease;
LUAD	cis	rs9372498	0.536	rs62422224	chr6:118941116	G/A	cg21191810	chr6:118973309	C6orf204	-0.54	-8.1	-0.37	5.74e-15	Diastolic blood pressure;
LUAD	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg17724175	chr1:150552817	MCL1	0.4	9.85	0.43	9.68e-21	Melanoma;
LUAD	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18404041	chr3:52824283	ITIH1	-0.59	-11.71	-0.49	1.22e-27	Bipolar disorder;
LUAD	trans	rs12439619	1.000	rs35152457	chr15:82546548	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.51	-8.18	-0.37	3.31e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.62	-7.8	-0.35	4.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg24818145	chr4:99064322	C4orf37	0.5	8.08	0.37	6.89e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4523957	0.893	rs12950555	chr17:2156910	C/G	cg16513277	chr17:2031491	SMG6	0.76	14.53	0.58	4.22e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.4	7.11	0.33	5.13e-12	Systemic lupus erythematosus;
LUAD	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg18721089	chr20:30220636	NA	-0.48	-6.98	-0.32	1.13e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.77	-0.35	5.98e-14	Personality dimensions;
LUAD	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03934478	chr11:495069	RNH1	0.78	9.39	0.42	3.78e-19	Body mass index;
LUAD	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg04731861	chr2:219085781	ARPC2	0.24	7.19	0.33	2.97e-12	Colorectal cancer;
LUAD	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.13	-0.33	4.34e-12	Breast cancer;
LUAD	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg02733842	chr7:1102375	C7orf50	0.62	9.03	0.4	6.01e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg03733263	chr8:22462867	KIAA1967	0.63	10.73	0.46	6.26e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23583168	chr7:148888333	NA	-0.91	-18.7	-0.67	2.49e-57	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08280861	chr8:58055591	NA	0.63	8.31	0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs12612619	0.732	rs4665366	chr2:27212596	G/A	cg00617064	chr2:27272375	NA	0.35	6.53	0.3	1.9e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs2455601	0.766	rs1109304	chr11:8955455	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-7.69	-0.35	1.05e-13	Schizophrenia;
LUAD	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg11663144	chr21:46675770	NA	0.6	11.69	0.49	1.56e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg20587970	chr11:113659929	NA	-1.4	-20.93	-0.71	2.68e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg23587288	chr2:27483067	SLC30A3	-0.43	-8.28	-0.37	1.65e-15	Blood metabolite levels;
LUAD	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg07570687	chr10:102243282	WNT8B	0.43	6.42	0.3	3.75e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg05590025	chr7:65112418	INTS4L2	0.71	8.13	0.37	4.71e-15	Diabetic kidney disease;
LUAD	cis	rs9300255	0.722	rs12298826	chr12:123829028	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.4	6.87	0.32	2.33e-11	Neutrophil percentage of white cells;
LUAD	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg11266682	chr4:10021025	SLC2A9	0.68	15.5	0.6	3.05e-43	Bone mineral density;
LUAD	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg08999081	chr20:33150536	PIGU	0.63	13.99	0.56	8.1e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs12618769	0.597	rs1587835	chr2:99041269	A/C	cg10123293	chr2:99228465	UNC50	0.45	7.92	0.36	2.19e-14	Bipolar disorder;
LUAD	cis	rs4737010	0.501	rs10099197	chr8:41654458	C/T	cg08923054	chr8:41654455	ANK1	0.39	6.39	0.3	4.48e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUAD	trans	rs11083241	0.570	rs7243677	chr18:25558198	C/T	cg02784696	chr2:24270586	C2orf44	-0.44	-6.94	-0.32	1.49e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-7.18	-0.33	3.12e-12	Retinal vascular caliber;
LUAD	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg13271783	chr10:134563150	INPP5A	-0.41	-7.12	-0.33	4.8e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7737355	0.947	rs42264	chr5:130810028	T/G	cg06307176	chr5:131281290	NA	0.51	8.06	0.36	7.97e-15	Life satisfaction;
LUAD	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.82	-0.39	3.1e-17	Initial pursuit acceleration;
LUAD	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg02493740	chr2:85810744	VAMP5	-0.53	-9.94	-0.44	4.6e-21	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg26513180	chr16:89883248	FANCA	-0.48	-7.9	-0.36	2.38e-14	Vitiligo;
LUAD	cis	rs9644630	0.930	rs6586839	chr8:19365543	A/T	cg06699216	chr8:19333253	CSGALNACT1	0.34	8.3	0.37	1.39e-15	Oropharynx cancer;
LUAD	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg11279151	chr3:101281821	RG9MTD1	0.39	6.76	0.31	4.49e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18404041	chr3:52824283	ITIH1	0.58	11.65	0.49	2.18e-27	Bipolar disorder;
LUAD	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg01849466	chr14:104193079	ZFYVE21	0.45	7.68	0.35	1.09e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg15017067	chr4:17643749	FAM184B	0.37	7.05	0.32	7.26e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7587476	0.784	rs36086595	chr2:215680293	A/G	cg04004882	chr2:215674386	BARD1	0.51	6.42	0.3	3.7e-10	Neuroblastoma;
LUAD	cis	rs4077515	0.870	rs10781510	chr9:139279173	G/A	cg14019695	chr9:139328340	INPP5E	0.4	7.51	0.34	3.62e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22907165	chr6:13328662	TBC1D7	-0.55	-6.68	-0.31	7.36e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2730260	0.537	rs55662704	chr7:158864184	T/C	cg13710308	chr7:158854763	VIPR2	-0.51	-6.45	-0.3	3.15e-10	Myopia (pathological);
LUAD	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg12615879	chr12:58013172	SLC26A10	0.35	7.01	0.32	9.73e-12	Rheumatoid arthritis;
LUAD	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg00530320	chr1:46809349	NSUN4	0.53	8.14	0.37	4.46e-15	Menopause (age at onset);
LUAD	cis	rs2455601	0.744	rs11042133	chr11:8966511	A/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.54	-9.11	-0.41	3.22e-18	Schizophrenia;
LUAD	cis	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg21775007	chr8:11205619	TDH	0.55	9.85	0.43	9.95e-21	Retinal vascular caliber;
LUAD	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-15.42	-0.6	6.59e-43	Chronic sinus infection;
LUAD	cis	rs4076764	0.522	rs4265409	chr1:163414559	C/T	cg06092702	chr1:163392909	NA	-0.32	-7.28	-0.33	1.64e-12	Motion sickness;
LUAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg04025307	chr7:1156635	C7orf50	0.81	14.4	0.57	1.52e-38	Longevity;Endometriosis;
LUAD	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg19622623	chr12:86230825	RASSF9	-0.44	-7.85	-0.36	3.39e-14	Major depressive disorder;
LUAD	cis	rs11971779	0.680	rs6946393	chr7:139106169	C/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.38e-10	Diisocyanate-induced asthma;
LUAD	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg11941060	chr3:133502564	NA	-0.41	-7.04	-0.32	7.6e-12	Iron status biomarkers;
LUAD	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.65	-0.35	1.36e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7927771	0.524	rs1563820	chr11:47833398	A/T	cg18512352	chr11:47633146	NA	-0.37	-6.66	-0.31	8.61e-11	Subjective well-being;
LUAD	cis	rs4523957	0.614	rs2760736	chr17:2036653	A/G	cg16513277	chr17:2031491	SMG6	-0.98	-19.94	-0.7	7.73e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg00933542	chr6:150070202	PCMT1	0.44	9.57	0.42	8.99e-20	Lung cancer;
LUAD	cis	rs12618769	0.597	rs3769712	chr2:99153443	A/T	cg10123293	chr2:99228465	UNC50	0.5	8.75	0.39	5.07e-17	Bipolar disorder;
LUAD	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.31	0.34	1.32e-12	Obesity-related traits;
LUAD	cis	rs6543140	0.964	rs2080288	chr2:103022166	G/A	cg04239558	chr2:103089729	SLC9A4	0.34	6.75	0.31	4.89e-11	Blood protein levels;
LUAD	cis	rs12971120	0.588	rs12606654	chr18:72126710	C/T	cg26446133	chr18:72167187	CNDP2	-0.68	-7.61	-0.35	1.82e-13	Refractive error;
LUAD	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg22532475	chr10:104410764	TRIM8	-0.43	-8.66	-0.39	1.02e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs79911532	0.515	rs76760929	chr7:75625968	T/G	cg19862616	chr7:65841803	NCRNA00174	0.84	8.69	0.39	8.14e-17	Mononucleosis;
LUAD	cis	rs9837602	0.688	rs28394036	chr3:99911103	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.56	7.45	0.34	5.32e-13	Breast cancer;
LUAD	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18099408	chr3:52552593	STAB1	-0.43	-7.7	-0.35	1e-13	Bipolar disorder;
LUAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	cis	rs243505	0.559	rs7802887	chr7:148494758	C/T	cg09806900	chr7:148480153	CUL1	0.49	8.35	0.38	9.61e-16	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02018176	chr4:1364513	KIAA1530	0.69	11.98	0.5	1.14e-28	Longevity;
LUAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg22963979	chr7:1858916	MAD1L1	-0.62	-10.58	-0.46	2.33e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs1448094	0.802	rs56391398	chr12:86424114	C/T	cg18827107	chr12:86230957	RASSF9	-0.46	-8.23	-0.37	2.27e-15	Major depressive disorder;
LUAD	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg08219700	chr8:58056026	NA	0.69	8.99	0.4	8.39e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg21153622	chr11:89784906	NA	-0.32	-6.41	-0.3	3.85e-10	Coronary artery disease;
LUAD	trans	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.91	-0.32	1.8e-11	Gout;
LUAD	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.95	-0.36	1.67e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg17366294	chr4:99064904	C4orf37	-0.48	-8.54	-0.38	2.49e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10781543	0.776	rs4378078	chr9:139375962	A/G	cg14019695	chr9:139328340	INPP5E	0.53	10.34	0.45	1.68e-22	Monocyte percentage of white cells;
LUAD	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.54	0.38	2.44e-16	Breast cancer;
LUAD	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg09021430	chr5:549028	NA	-0.69	-13.3	-0.54	5.59e-34	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg16797656	chr11:68205561	LRP5	0.43	8.74	0.39	5.38e-17	Total body bone mineral density;
LUAD	cis	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.3	-0.48	4.86e-26	Mean corpuscular volume;
LUAD	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg02743256	chr7:2109353	MAD1L1	-0.48	-6.62	-0.31	1.12e-10	Bipolar disorder;
LUAD	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24531977	chr5:56204891	C5orf35	-0.93	-13.79	-0.56	5.55e-36	Initial pursuit acceleration;
LUAD	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg16325326	chr1:53192061	ZYG11B	-0.61	-10.92	-0.47	1.24e-24	Monocyte count;
LUAD	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg18252515	chr7:66147081	NA	-0.62	-6.93	-0.32	1.62e-11	Diabetic kidney disease;
LUAD	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg02196655	chr2:10830764	NOL10	0.45	8.2	0.37	2.93e-15	Prostate cancer;
LUAD	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg00634984	chr7:65235879	NA	0.5	6.88	0.32	2.11e-11	Aortic root size;
LUAD	cis	rs7107174	0.792	rs12291726	chr11:78088210	A/G	cg02023728	chr11:77925099	USP35	0.43	6.83	0.32	2.9e-11	Testicular germ cell tumor;
LUAD	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg01808030	chr22:45809952	RIBC2;SMC1B	0.76	8.88	0.4	1.86e-17	Tonsillectomy;
LUAD	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg11584989	chr19:19387371	SF4	0.58	9.34	0.41	5.66e-19	Bipolar disorder;
LUAD	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg08847533	chr14:75593920	NEK9	0.39	6.68	0.31	7.41e-11	Height;
LUAD	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg08470875	chr2:26401718	FAM59B	0.76	10.08	0.44	1.47e-21	Gut microbiome composition (summer);
LUAD	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg23719950	chr11:63933701	MACROD1	-0.63	-7.44	-0.34	5.65e-13	Mean platelet volume;
LUAD	cis	rs9814567	0.752	rs4306899	chr3:134334513	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	13.53	0.55	6.25e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs17095355	1.000	rs734163	chr10:111698192	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.68	-9.79	-0.43	1.51e-20	Biliary atresia;
LUAD	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg07936489	chr17:37558343	FBXL20	-0.45	-6.99	-0.32	1.05e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs4589502	0.800	rs12595796	chr15:67202599	A/G	cg09911534	chr15:67153556	NA	0.4	6.92	0.32	1.69e-11	Lung cancer (smoking interaction);
LUAD	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg14343924	chr8:8086146	FLJ10661	0.43	6.7	0.31	6.66e-11	Neuroticism;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16803707	chr20:1099736	PSMF1	-0.41	-6.62	-0.31	1.06e-10	Height;
LUAD	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22307029	chr19:49891270	CCDC155	0.66	9.54	0.42	1.13e-19	Multiple sclerosis;
LUAD	cis	rs62400317	0.859	rs62400326	chr6:45287465	T/C	cg18551225	chr6:44695536	NA	-0.54	-8.48	-0.38	3.68e-16	Total body bone mineral density;
LUAD	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg11663144	chr21:46675770	NA	-0.61	-11.63	-0.49	2.46e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.26	6.85	0.32	2.6e-11	Schizophrenia;
LUAD	cis	rs67981189	0.529	rs2158996	chr14:71529599	G/A	cg15910301	chr14:71632612	NA	0.41	6.48	0.3	2.61e-10	Schizophrenia;
LUAD	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg13319975	chr6:146136371	FBXO30	-0.6	-10.23	-0.45	4.3e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg04851639	chr8:1020857	NA	-0.34	-8.04	-0.36	9.41e-15	Schizophrenia;
LUAD	cis	rs8192282	0.691	rs6696177	chr1:154477263	G/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.44	-6.77	-0.31	4.36e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs4481887	0.927	rs4390208	chr1:248472211	C/T	cg13385794	chr1:248469461	NA	0.25	6.77	0.31	4.24e-11	Common traits (Other);
LUAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg22907277	chr7:1156413	C7orf50	0.68	7.98	0.36	1.35e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2282300	0.739	rs34951229	chr11:30265166	C/G	cg25418670	chr11:30344373	C11orf46	-0.53	-7.23	-0.33	2.23e-12	Morning vs. evening chronotype;
LUAD	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4700695	0.719	rs27078	chr5:65445331	G/C	cg21114390	chr5:65439923	SFRS12	-0.93	-14.51	-0.58	5.5e-39	Facial morphology (factor 19);
LUAD	cis	rs10744422	1.000	rs7309225	chr12:123288439	A/G	cg16953816	chr12:123349952	VPS37B	0.65	6.92	0.32	1.63e-11	Schizophrenia;
LUAD	cis	rs9467773	1.000	rs1570061	chr6:26575986	T/C	cg11502198	chr6:26597334	ABT1	0.61	10.06	0.44	1.76e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg15790184	chr11:494944	RNH1	0.52	6.49	0.3	2.43e-10	Body mass index;
LUAD	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg15557168	chr22:42548783	NA	0.36	6.68	0.31	7.74e-11	Cognitive function;
LUAD	cis	rs68170813	0.559	rs4730232	chr7:106942382	G/C	cg02696742	chr7:106810147	HBP1	-0.77	-10.76	-0.46	5.12e-24	Coronary artery disease;
LUAD	cis	rs7116495	1.000	rs548961	chr11:71793887	G/A	cg07596299	chr11:71824057	C11orf51	-0.77	-6.53	-0.3	1.86e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06873352	chr17:61820015	STRADA	0.83	18.4	0.67	5.49e-56	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9811920	0.893	rs720688	chr3:99880569	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.57	10.31	0.45	2.29e-22	Axial length;
LUAD	trans	rs877282	0.898	rs2004478	chr10:770709	C/A	cg22713356	chr15:30763199	NA	1.24	17.21	0.64	1.07e-50	Uric acid levels;
LUAD	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	13.17	0.54	1.95e-33	Monocyte percentage of white cells;
LUAD	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg14847009	chr1:175162515	KIAA0040	-0.33	-8.91	-0.4	1.55e-17	Alcohol dependence;
LUAD	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg12623302	chr6:28058802	ZSCAN12L1	0.36	6.97	0.32	1.22e-11	Depression;
LUAD	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.72	0.39	6.61e-17	Parkinson's disease;
LUAD	cis	rs11811982	0.793	rs79246828	chr1:227508935	T/C	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg09491104	chr22:46646882	C22orf40	-0.57	-8.37	-0.38	8.25e-16	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs28374715	0.733	rs7167706	chr15:41569644	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.06	-21.24	-0.72	1.2e-68	Ulcerative colitis;
LUAD	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg17652424	chr22:38574118	PLA2G6	-0.33	-10.13	-0.44	9.75e-22	Cutaneous nevi;
LUAD	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg20607798	chr8:58055168	NA	0.8	10.01	0.44	2.51e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg07587117	chr16:2239488	CASKIN1	0.43	8.35	0.38	9.84e-16	Height;
LUAD	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.95	-0.36	1.78e-14	Monocyte percentage of white cells;
LUAD	cis	rs6684514	0.961	rs10908503	chr1:156300683	C/T	cg16558208	chr1:156270281	VHLL	0.53	9.64	0.42	5e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg02158880	chr13:53174818	NA	0.58	10.14	0.44	8.8e-22	Lewy body disease;
LUAD	cis	rs4389656	0.857	rs274713	chr5:6723560	A/C	cg10857441	chr5:6722123	POLS	-0.44	-7.62	-0.35	1.69e-13	Coronary artery disease;
LUAD	cis	rs9902453	0.765	rs2264303	chr17:28055348	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.32	-0.45	1.94e-22	Coffee consumption (cups per day);
LUAD	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg04117972	chr1:227635322	NA	0.64	6.49	0.3	2.47e-10	Major depressive disorder;
LUAD	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg06618935	chr21:46677482	NA	-0.45	-8.47	-0.38	3.97e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.6	-8.6	-0.39	1.57e-16	Gut microbiome composition (summer);
LUAD	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg03433033	chr1:76189801	ACADM	-0.5	-7.48	-0.34	4.43e-13	Daytime sleep phenotypes;
LUAD	cis	rs7759001	0.857	rs6904883	chr6:27357308	T/C	cg18711553	chr6:27366782	ZNF391	0.4	6.54	0.3	1.74e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs733175	0.855	rs9291640	chr4:10007086	C/T	cg02734326	chr4:10020555	SLC2A9	0.44	6.49	0.3	2.46e-10	Psychosis and Alzheimer's disease;
LUAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg02527881	chr3:46936655	PTH1R	-0.49	-9.89	-0.43	7.19e-21	Colorectal cancer;
LUAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27297192	chr10:134578999	INPP5A	-0.38	-6.66	-0.31	8.28e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.61	-9.54	-0.42	1.12e-19	Primary sclerosing cholangitis;
LUAD	cis	rs7771547	0.573	rs664370	chr6:36393816	A/G	cg04289385	chr6:36355825	ETV7	0.42	6.48	0.3	2.52e-10	Platelet distribution width;
LUAD	cis	rs4727443	1.000	rs6974373	chr7:99590893	C/G	cg22004693	chr7:99632812	ZKSCAN1	0.39	6.64	0.31	9.62e-11	Interstitial lung disease;
LUAD	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22857025	chr5:266934	NA	-0.96	-14.39	-0.57	1.75e-38	Breast cancer;
LUAD	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.83e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4523957	0.690	rs11867782	chr17:2090507	T/G	cg16513277	chr17:2031491	SMG6	-0.94	-18.25	-0.66	2.72e-55	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg14689365	chr7:158441557	NCAPG2	0.41	6.94	0.32	1.49e-11	Height;
LUAD	cis	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg20368463	chr18:77673604	PQLC1	0.6	10.38	0.45	1.27e-22	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUAD	cis	rs7267979	0.714	rs6132825	chr20:25238309	A/T	cg08601574	chr20:25228251	PYGB	0.44	8.23	0.37	2.34e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs55665837	0.961	rs60622588	chr11:14456998	T/C	cg19336497	chr11:14380999	RRAS2	-0.5	-10.21	-0.44	5.12e-22	Vitamin D levels;
LUAD	trans	rs2797160	1.000	rs1739357	chr6:126019655	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.54	8.51	0.38	3.12e-16	Endometrial cancer;
LUAD	cis	rs977987	0.806	rs12449170	chr16:75463012	C/T	cg03315344	chr16:75512273	CHST6	0.64	13.99	0.56	7.87e-37	Dupuytren's disease;
LUAD	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg11189052	chr15:85197271	WDR73	0.67	9.06	0.4	4.94e-18	Schizophrenia;
LUAD	cis	rs10129255	0.518	rs10150460	chr14:107133196	C/G	cg07958169	chr14:107095056	NA	0.35	6.98	0.32	1.15e-11	Kawasaki disease;
LUAD	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg08645402	chr16:4508243	NA	0.59	11.01	0.47	5.75e-25	Schizophrenia;
LUAD	cis	rs35771425	0.536	rs6656860	chr1:211620805	A/G	cg25617285	chr1:211431773	RCOR3	-0.53	-10.8	-0.47	3.41e-24	Educational attainment (years of education);
LUAD	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg16680214	chr1:154839983	KCNN3	-0.64	-13.64	-0.55	2.31e-35	Prostate cancer;
LUAD	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg23992470	chr4:843637	GAK	0.69	7.53	0.34	3e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg06387496	chr7:2775674	GNA12	-0.39	-6.59	-0.31	1.33e-10	Height;
LUAD	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg11822812	chr5:140052017	DND1	-0.38	-7.07	-0.32	6.63e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4711350	1.000	rs4711350	chr6:33741716	A/G	cg07979401	chr6:33739406	LEMD2	-0.52	-8.61	-0.39	1.42e-16	Schizophrenia;
LUAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg07677032	chr17:61819896	STRADA	0.58	10.63	0.46	1.44e-23	Prudent dietary pattern;
LUAD	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.96e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05901451	chr6:126070800	HEY2	0.59	9.14	0.41	2.72e-18	Endometrial cancer;
LUAD	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.54	0.42	1.12e-19	Monocyte percentage of white cells;
LUAD	cis	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg09085632	chr11:111637200	PPP2R1B	0.54	8.74	0.39	5.4e-17	Primary sclerosing cholangitis;
LUAD	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg24558204	chr6:135376177	HBS1L	0.48	8.85	0.4	2.42e-17	Red blood cell count;
LUAD	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg25985355	chr7:65971099	NA	-0.53	-6.66	-0.31	8.6e-11	Diabetic kidney disease;
LUAD	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18876405	chr7:65276391	NA	-0.54	-9.31	-0.41	6.83e-19	Calcium levels;
LUAD	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg07870213	chr5:140052090	DND1	0.72	11.09	0.47	3.04e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg01620082	chr3:125678407	NA	-0.44	-6.6	-0.31	1.27e-10	Depression;
LUAD	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg07708487	chr16:89387014	ANKRD11	-0.33	-6.73	-0.31	5.37e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs977987	0.836	rs35209155	chr16:75470496	G/A	cg03315344	chr16:75512273	CHST6	0.65	14.21	0.57	9.86e-38	Dupuytren's disease;
LUAD	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg15309053	chr8:964076	NA	0.33	7.28	0.33	1.66e-12	Schizophrenia;
LUAD	cis	rs7223966	0.729	rs7921	chr17:62006259	G/A	cg06873352	chr17:61820015	STRADA	0.43	6.61	0.31	1.18e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg00495681	chr13:53174319	NA	0.54	10.01	0.44	2.64e-21	Lewy body disease;
LUAD	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg02269571	chr22:50332266	NA	-0.61	-9.22	-0.41	1.46e-18	Schizophrenia;
LUAD	cis	rs6709815	0.841	rs6740004	chr2:219663153	G/A	cg02176678	chr2:219576539	TTLL4	-0.54	-10.58	-0.46	2.38e-23	Reticulocyte count;High light scatter reticulocyte count;
LUAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg11494091	chr17:61959527	GH2	0.74	18.31	0.66	1.47e-55	Prudent dietary pattern;
LUAD	cis	rs2742234	0.590	rs2075912	chr10:43622217	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.51	-8.72	-0.39	6.58e-17	Hirschsprung disease;
LUAD	cis	rs4713675	0.584	rs4711339	chr6:33667199	A/G	cg13859433	chr6:33739653	LEMD2	-0.3	-7.12	-0.33	4.54e-12	Plateletcrit;
LUAD	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg04287289	chr16:89883240	FANCA	0.76	6.37	0.3	4.97e-10	Skin colour saturation;
LUAD	cis	rs2235649	0.789	rs4567715	chr16:1849363	G/C	cg08610935	chr16:1836813	NUBP2	-0.5	-7.64	-0.35	1.49e-13	Blood metabolite levels;
LUAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg11416102	chr8:651193	ERICH1	0.94	8.98	0.4	8.67e-18	IgG glycosylation;
LUAD	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg11292332	chr7:45801988	SEPT13	-0.3	-6.66	-0.31	8.76e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4642101	0.611	rs6442331	chr3:12820636	T/G	cg24848339	chr3:12840334	CAND2	0.44	8.6	0.39	1.62e-16	QRS complex (12-leadsum);
LUAD	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.27	-0.45	2.98e-22	Glomerular filtration rate;
LUAD	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg24848339	chr3:12840334	CAND2	0.43	8.64	0.39	1.21e-16	QRS complex (12-leadsum);
LUAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg27532560	chr4:187881888	NA	-0.35	-6.66	-0.31	8.44e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6066825	0.644	rs2092492	chr20:47338650	A/G	cg18078177	chr20:47281410	PREX1	0.39	6.43	0.3	3.36e-10	Colorectal cancer;
LUAD	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg23173402	chr1:227635558	NA	0.76	8.12	0.37	5.08e-15	Major depressive disorder;
LUAD	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg26408565	chr15:76604113	ETFA	0.43	7.03	0.32	8.54e-12	Blood metabolite levels;
LUAD	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg18854424	chr1:2615690	NA	-0.42	-9.07	-0.4	4.49e-18	Ulcerative colitis;
LUAD	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg05425664	chr17:57184151	TRIM37	-0.42	-7.62	-0.35	1.65e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03517284	chr6:25882590	NA	-0.56	-8.2	-0.37	2.91e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg08470875	chr2:26401718	FAM59B	-0.63	-8.53	-0.38	2.62e-16	Gut microbiome composition (summer);
LUAD	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg03690763	chr11:133734501	NA	-0.34	-8.06	-0.36	7.75e-15	Childhood ear infection;
LUAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.55	-9.73	-0.43	2.6e-20	Lymphocyte counts;
LUAD	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg02176678	chr2:219576539	TTLL4	0.68	13.47	0.55	1.15e-34	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7617773	0.817	rs35456569	chr3:48250899	T/A	cg11946769	chr3:48343235	NME6	0.42	6.49	0.3	2.43e-10	Coronary artery disease;
LUAD	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg25985355	chr7:65971099	NA	-0.37	-6.67	-0.31	7.87e-11	Aortic root size;
LUAD	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg17177755	chr1:15930204	NA	0.44	7.11	0.33	5.08e-12	Systolic blood pressure;
LUAD	cis	rs922692	0.710	rs1994016	chr15:79080234	C/T	cg12645284	chr15:79092878	ADAMTS7	0.38	6.51	0.3	2.14e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg06784218	chr1:46089804	CCDC17	0.49	10.64	0.46	1.43e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4906332	1.000	rs8004780	chr14:103853360	A/C	cg19000871	chr14:103996768	TRMT61A	-0.37	-6.56	-0.3	1.56e-10	Coronary artery disease;
LUAD	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.36	-0.34	9.76e-13	Bipolar disorder;
LUAD	cis	rs68170813	1.000	rs34273277	chr7:107249020	A/G	cg02696742	chr7:106810147	HBP1	-0.5	-6.67	-0.31	7.89e-11	Coronary artery disease;
LUAD	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg22875332	chr1:76189707	ACADM	0.87	15.92	0.61	4.63e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg04586622	chr2:25135609	ADCY3	-0.36	-8.32	-0.37	1.25e-15	Body mass index;
LUAD	cis	rs8112211	0.911	rs60071299	chr19:38850246	G/A	cg14299480	chr19:38876666	GGN	-0.45	-7.87	-0.36	2.97e-14	Blood protein levels;
LUAD	cis	rs7072216	0.770	rs1061123	chr10:100176997	A/G	cg26618903	chr10:100175079	PYROXD2	-0.34	-7.56	-0.34	2.6e-13	Metabolite levels;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg07719772	chr16:32360419	NA	-0.46	-7.23	-0.33	2.24e-12	Menopause (age at onset);
LUAD	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22857025	chr5:266934	NA	-0.96	-14.39	-0.57	1.75e-38	Breast cancer;
LUAD	cis	rs9462027	0.628	rs6942040	chr6:34761809	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.91	-0.4	1.53e-17	Systemic lupus erythematosus;
LUAD	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.58	-0.35	2.2e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg19773385	chr1:10388646	KIF1B	-0.43	-6.9	-0.32	1.92e-11	Hepatocellular carcinoma;
LUAD	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg15181151	chr6:150070149	PCMT1	0.33	6.51	0.3	2.11e-10	Testicular germ cell tumor;
LUAD	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg24069376	chr3:38537580	EXOG	0.43	10.11	0.44	1.15e-21	Electrocardiographic conduction measures;
LUAD	cis	rs9902453	0.967	rs9913074	chr17:28481199	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.75	0.39	4.98e-17	Coffee consumption (cups per day);
LUAD	cis	rs4713675	0.584	rs4713667	chr6:33680016	G/C	cg13859433	chr6:33739653	LEMD2	-0.3	-7.14	-0.33	4.15e-12	Plateletcrit;
LUAD	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg22823121	chr1:150693482	HORMAD1	0.44	8.91	0.4	1.55e-17	Tonsillectomy;
LUAD	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.4	6.56	0.3	1.59e-10	Platelet count;
LUAD	cis	rs9297145	0.565	rs6952161	chr7:98733337	A/G	cg05967295	chr7:98741636	SMURF1	0.73	13.52	0.55	7.25e-35	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg21609526	chr1:3105151	PRDM16	0.32	6.54	0.3	1.77e-10	Migraine;
LUAD	trans	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg01620082	chr3:125678407	NA	-1.0	-9.58	-0.42	8.31e-20	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg13397359	chr6:42928475	GNMT	0.6	11.52	0.49	6.52e-27	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg15704280	chr7:45808275	SEPT13	0.74	10.8	0.46	3.5e-24	Coronary artery disease;
LUAD	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg12373951	chr3:133503437	NA	-0.33	-6.66	-0.31	8.34e-11	Iron status biomarkers;
LUAD	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg25554036	chr4:6271136	WFS1	0.66	12.78	0.53	7.59e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06873352	chr17:61820015	STRADA	0.82	18.18	0.66	5.3e-55	Prudent dietary pattern;
LUAD	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg20607287	chr7:12443886	VWDE	-0.55	-8.16	-0.37	3.98e-15	Coronary artery disease;
LUAD	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.73	-14.15	-0.57	1.74e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg00750074	chr16:89608354	SPG7	-0.38	-6.43	-0.3	3.39e-10	Multiple myeloma (IgH translocation);
LUAD	trans	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg26043149	chr18:55253948	FECH	0.44	7.1	0.33	5.32e-12	Bone mineral density;
LUAD	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg18755752	chr8:142205143	DENND3	-0.56	-10.37	-0.45	1.37e-22	Immature fraction of reticulocytes;
LUAD	cis	rs6005807	0.719	rs9620810	chr22:29053727	T/C	cg12565055	chr22:29076175	TTC28	0.74	8.71	0.39	6.98e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs60154123	0.541	rs76216762	chr1:210345621	A/G	cg23283495	chr1:209979779	IRF6	0.64	6.42	0.3	3.77e-10	Coronary artery disease;
LUAD	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg03526776	chr6:41159608	TREML2	0.31	6.56	0.3	1.59e-10	Alzheimer's disease (late onset);
LUAD	cis	rs469568	0.673	rs338876	chr5:178669870	A/G	cg08999896	chr5:178685787	ADAMTS2	0.33	6.89	0.32	2.02e-11	Stroke (pediatric);
LUAD	cis	rs6714710	0.580	rs1838797	chr2:98454572	G/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.19	0.37	3.17e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg11845111	chr2:191398756	TMEM194B	-0.86	-11.28	-0.48	5.81e-26	Diastolic blood pressure;
LUAD	cis	rs7809615	0.901	rs10215765	chr7:99101280	G/C	cg03133378	chr7:99195931	NA	-0.57	-6.79	-0.31	3.72e-11	Blood metabolite ratios;
LUAD	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg11247378	chr22:39784982	NA	-0.74	-12.8	-0.53	6.12e-32	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-6.47	-0.3	2.75e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg22166914	chr1:53195759	ZYG11B	0.44	7.55	0.34	2.78e-13	Monocyte count;
LUAD	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6545883	1.000	rs778758	chr2:61782161	T/C	cg15711740	chr2:61764176	XPO1	-0.43	-6.93	-0.32	1.56e-11	Tuberculosis;
LUAD	cis	rs6543140	0.964	rs10200081	chr2:103091556	T/C	cg04239558	chr2:103089729	SLC9A4	0.36	7.19	0.33	2.93e-12	Blood protein levels;
LUAD	cis	rs2637266	0.935	rs2579751	chr10:78339890	G/A	cg18941641	chr10:78392320	NA	0.32	6.61	0.31	1.14e-10	Pulmonary function;
LUAD	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg15445000	chr17:37608096	MED1	-0.44	-8.26	-0.37	1.87e-15	Glomerular filtration rate (creatinine);
LUAD	trans	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg01620082	chr3:125678407	NA	-0.63	-7.26	-0.33	1.87e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1546060	0.683	rs34421578	chr3:56448726	C/T	cg24436196	chr3:56448270	ERC2	0.35	6.5	0.3	2.31e-10	Night sleep phenotypes;
LUAD	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.03	0.32	8.12e-12	Menopause (age at onset);
LUAD	cis	rs12410462	1.000	rs12410243	chr1:227669474	A/G	cg23173402	chr1:227635558	NA	0.68	7.49	0.34	4.08e-13	Major depressive disorder;
LUAD	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg22681709	chr2:178499509	PDE11A	-0.42	-6.99	-0.32	1.07e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg26924012	chr15:45694286	SPATA5L1	0.64	10.85	0.47	2.41e-24	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg26408565	chr15:76604113	ETFA	-0.47	-7.39	-0.34	7.9e-13	Blood metabolite levels;
LUAD	cis	rs4888262	0.526	rs7201105	chr16:74590603	A/G	cg01733217	chr16:74700730	RFWD3	0.48	8.01	0.36	1.15e-14	Testicular germ cell tumor;
LUAD	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.17e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg20578329	chr17:80767326	TBCD	-0.65	-7.53	-0.34	3.04e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg20135002	chr11:47629003	NA	-0.41	-7.14	-0.33	4.21e-12	Subjective well-being;
LUAD	cis	rs6714710	0.603	rs13023980	chr2:98502987	T/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.25	0.37	2.05e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs12681287	0.752	rs13262673	chr8:87293600	G/A	cg27223183	chr8:87520930	FAM82B	-0.6	-8.22	-0.37	2.45e-15	Caudate activity during reward;
LUAD	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07988820	chr12:82153109	PPFIA2	0.52	8.41	0.38	6.54e-16	Resting heart rate;
LUAD	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.69	-0.35	1.07e-13	Alzheimer's disease (late onset);
LUAD	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06873352	chr17:61820015	STRADA	0.8	17.69	0.65	8.22e-53	Prudent dietary pattern;
LUAD	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.68	0.35	1.1e-13	Lung cancer;
LUAD	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg18306943	chr3:40428807	ENTPD3	-0.36	-6.42	-0.3	3.75e-10	Renal cell carcinoma;
LUAD	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg12365402	chr11:9010492	NRIP3	0.46	8.66	0.39	9.71e-17	Hemoglobin concentration;
LUAD	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg15557168	chr22:42548783	NA	-0.45	-8.41	-0.38	6.57e-16	Cognitive function;
LUAD	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg14926445	chr8:58193284	C8orf71	-0.5	-7.25	-0.33	1.99e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg11822812	chr5:140052017	DND1	-0.44	-7.92	-0.36	2.18e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg06713675	chr4:122721982	EXOSC9	-0.6	-11.56	-0.49	4.62e-27	Type 2 diabetes;
LUAD	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17344932	chr17:38183730	MED24;SNORD124	0.33	6.39	0.3	4.26e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	2.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10744422	1.000	rs10744434	chr12:123368419	T/A	cg16953816	chr12:123349952	VPS37B	0.61	7.1	0.33	5.36e-12	Schizophrenia;
LUAD	cis	rs6738485	0.695	rs28750217	chr2:106770898	G/A	cg15412446	chr2:106886593	NA	-0.39	-6.4	-0.3	4.25e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg03929089	chr4:120376271	NA	-0.44	-6.93	-0.32	1.53e-11	Height;
LUAD	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg22491629	chr6:157744540	C6orf35	-0.8	-8.8	-0.39	3.4e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7937890	0.559	rs2575836	chr11:14497864	T/G	cg06199346	chr11:14280333	SPON1	-0.32	-6.42	-0.3	3.58e-10	Mitochondrial DNA levels;
LUAD	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.47e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg15181151	chr6:150070149	PCMT1	0.41	8.02	0.36	1.06e-14	Lung cancer;
LUAD	cis	rs208520	0.874	rs208517	chr6:66947040	G/T	cg07460842	chr6:66804631	NA	-1.0	-14.54	-0.58	4.06e-39	Exhaled nitric oxide output;
LUAD	cis	rs4889855	0.556	rs9897453	chr17:78634300	C/T	cg16591659	chr17:78472290	NA	-0.44	-7.8	-0.35	4.74e-14	Fractional excretion of uric acid;
LUAD	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg09904177	chr6:26538194	HMGN4	0.44	7.46	0.34	4.93e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1371614	0.566	rs11887401	chr2:27181112	G/T	cg00617064	chr2:27272375	NA	-0.4	-7.94	-0.36	1.85e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs4713675	0.546	rs10947434	chr6:33691501	G/T	cg13859433	chr6:33739653	LEMD2	-0.3	-7.21	-0.33	2.67e-12	Plateletcrit;
LUAD	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.74	0.31	5.13e-11	Depression;
LUAD	cis	rs727505	0.954	rs1568883	chr7:124710761	G/A	cg23710748	chr7:124431027	NA	-0.43	-8.48	-0.38	3.73e-16	Lewy body disease;
LUAD	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg13813247	chr22:41461852	NA	-0.49	-7.88	-0.36	2.9e-14	Neuroticism;
LUAD	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg11031976	chr2:198649780	BOLL	-0.47	-6.99	-0.32	1.06e-11	Ulcerative colitis;
LUAD	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.55	0.34	2.69e-13	Breast cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg27350783	chr17:79479834	ACTG1	-0.41	-7.0	-0.32	9.91e-12	Schizophrenia;
LUAD	cis	rs12949688	1.000	rs7211686	chr17:55816300	T/C	cg12582317	chr17:55822272	NA	0.35	7.08	0.33	5.89e-12	Schizophrenia;
LUAD	cis	rs11249608	0.548	rs62393072	chr5:178450056	C/T	cg01312482	chr5:178451176	ZNF879	-0.44	-6.8	-0.31	3.59e-11	Pubertal anthropometrics;
LUAD	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg02428538	chr16:24856791	SLC5A11	-0.52	-7.14	-0.33	4.22e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg12935359	chr14:103987150	CKB	-0.48	-7.49	-0.34	4.15e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg21823605	chr1:152486609	CRCT1	-0.3	-6.76	-0.31	4.49e-11	Hair morphology;
LUAD	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg06627628	chr2:24431161	ITSN2	-0.55	-6.52	-0.3	2.05e-10	Lymphocyte counts;
LUAD	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg16414030	chr3:133502952	NA	0.72	14.8	0.58	2.98e-40	Iron status biomarkers;
LUAD	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.34	-0.34	1.1e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.85	-0.32	2.54e-11	Diabetic kidney disease;
LUAD	cis	rs2067615	0.560	rs4964485	chr12:107121952	A/G	cg15890332	chr12:107067104	RFX4	0.4	8.6	0.39	1.59e-16	Heart rate;
LUAD	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg00339695	chr16:24857497	SLC5A11	0.53	9.71	0.43	3.05e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg21775007	chr8:11205619	TDH	0.55	9.76	0.43	1.93e-20	Retinal vascular caliber;
LUAD	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg07389463	chr12:132296394	NA	0.41	7.38	0.34	8.57e-13	Migraine;
LUAD	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg08645402	chr16:4508243	NA	0.57	10.29	0.45	2.59e-22	Schizophrenia;
LUAD	cis	rs9462027	0.630	rs2744943	chr6:34643179	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-8.58	-0.38	1.86e-16	Systemic lupus erythematosus;
LUAD	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	9.33	0.41	6.08e-19	Total body bone mineral density;
LUAD	cis	rs7107174	0.901	rs866901	chr11:77926309	C/T	cg02023728	chr11:77925099	USP35	0.53	8.07	0.37	7.43e-15	Testicular germ cell tumor;
LUAD	cis	rs60871478	1.000	rs62432224	chr7:788284	G/A	cg05535760	chr7:792225	HEATR2	0.89	11.6	0.49	3.45e-27	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg07404485	chr7:94953653	PON1	0.46	7.16	0.33	3.71e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.83	0.43	1.16e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10193935	1.000	rs62144748	chr2:42419468	C/T	cg27598129	chr2:42591480	NA	-0.78	-10.27	-0.45	3.09e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9560113	1.000	rs11620313	chr13:112179363	G/A	cg14154082	chr13:112174009	NA	0.37	6.86	0.32	2.41e-11	Menarche (age at onset);
LUAD	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-9.24	-0.41	1.21e-18	Bipolar disorder;
LUAD	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg02375832	chr11:62437615	C11orf48	-0.31	-6.49	-0.3	2.38e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg13073564	chr4:8508604	NA	0.53	9.88	0.43	7.65e-21	Response to antineoplastic agents;
LUAD	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg02569458	chr12:86230093	RASSF9	0.37	6.71	0.31	6.44e-11	Major depressive disorder;
LUAD	cis	rs10203711	0.933	rs4994754	chr2:239567218	A/G	cg14580085	chr2:239553406	NA	0.41	8.9	0.4	1.64e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.61	0.35	1.85e-13	Tonsillectomy;
LUAD	cis	rs12530845	0.673	rs4073627	chr7:135312572	A/G	cg23117316	chr7:135346802	PL-5283	0.52	8.65	0.39	1.1e-16	Red blood cell traits;
LUAD	cis	rs2692947	0.644	rs772154	chr2:97021664	G/T	cg23100626	chr2:96804247	ASTL	0.34	8.56	0.38	2.05e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26314531	chr2:26401878	FAM59B	0.71	9.49	0.42	1.7e-19	Gut microbiome composition (summer);
LUAD	cis	rs12200560	0.505	rs4839849	chr6:97076673	T/C	cg06623918	chr6:96969491	KIAA0776	0.47	7.35	0.34	1.01e-12	Coronary heart disease;
LUAD	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.91	-0.4	1.58e-17	Total body bone mineral density;
LUAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.39	0.55	2.39e-34	Prudent dietary pattern;
LUAD	cis	rs6906287	0.609	rs13191610	chr6:118945317	G/A	cg05564266	chr6:118973597	C6orf204	0.37	7.67	0.35	1.21e-13	Electrocardiographic conduction measures;
LUAD	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.17	-0.37	3.72e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg06627628	chr2:24431161	ITSN2	-0.56	-9.33	-0.41	6.08e-19	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg25036284	chr2:26402008	FAM59B	-0.56	-8.1	-0.37	5.77e-15	Gut microbiome composition (summer);
LUAD	cis	rs2455799	1.000	rs6773547	chr3:15882245	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.72	-0.31	5.98e-11	Mean platelet volume;
LUAD	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-10.43	-0.45	7.89e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs137699	1.000	rs5757632	chr22:39756097	A/C	cg24399712	chr22:39784796	NA	-0.53	-9.05	-0.4	5.27e-18	IgG glycosylation;
LUAD	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg15181151	chr6:150070149	PCMT1	0.38	7.02	0.32	8.9e-12	Lung cancer;
LUAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.61	8.14	0.37	4.55e-15	Renal function-related traits (BUN);
LUAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg21724239	chr8:58056113	NA	0.8	9.48	0.42	1.87e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg01256987	chr12:42539512	GXYLT1	-0.49	-10.06	-0.44	1.71e-21	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg26039829	chr8:22132926	PIWIL2	0.56	10.39	0.45	1.13e-22	Hypertriglyceridemia;
LUAD	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg14019146	chr3:50243930	SLC38A3	0.57	11.68	0.49	1.6e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.78	-0.39	4.19e-17	Total body bone mineral density;
LUAD	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg15445000	chr17:37608096	MED1	0.44	8.28	0.37	1.59e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1691799	0.899	rs1168315	chr12:66746694	A/G	cg16791601	chr12:66731901	HELB	-0.36	-6.47	-0.3	2.78e-10	White blood cell count (basophil);
LUAD	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg12645284	chr15:79092878	ADAMTS7	0.5	7.84	0.36	3.58e-14	Coronary artery disease or large artery stroke;
LUAD	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21582582	chr3:182698605	DCUN1D1	0.59	10.09	0.44	1.38e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs13315871	1.000	rs9850717	chr3:58351875	C/T	cg20936604	chr3:58311152	NA	-0.69	-6.78	-0.31	4.15e-11	Cholesterol, total;
LUAD	cis	rs10785877	0.570	rs7043538	chr9:137109051	A/G	cg21243944	chr9:137118148	NA	0.31	6.48	0.3	2.59e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LUAD	cis	rs11971779	0.680	rs6467848	chr7:139080205	T/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg10518543	chr12:38710700	ALG10B	0.41	6.83	0.32	2.99e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	7.03	0.32	8.22e-12	Lung cancer;
LUAD	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg00898013	chr13:113819073	PROZ	-0.68	-12.11	-0.51	3.38e-29	Platelet distribution width;
LUAD	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg21433313	chr16:3507492	NAT15	0.73	13.12	0.54	3.14e-33	Tuberculosis;
LUAD	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg18876405	chr7:65276391	NA	-0.46	-7.27	-0.33	1.76e-12	Aortic root size;
LUAD	trans	rs800082	0.646	rs2717394	chr3:144280612	A/T	cg24215973	chr2:240111563	HDAC4	0.58	9.35	0.41	5.03e-19	Smoking behavior;
LUAD	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg00802000	chr16:706648	WDR90	-0.37	-6.94	-0.32	1.45e-11	Height;
LUAD	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg03609598	chr5:56110824	MAP3K1	0.48	7.07	0.33	6.3e-12	Initial pursuit acceleration;
LUAD	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg11189052	chr15:85197271	WDR73	0.59	7.62	0.35	1.7e-13	Schizophrenia;
LUAD	cis	rs2580764	0.503	rs2972097	chr2:55267545	T/C	cg09592903	chr2:55203963	RTN4	0.43	9.84	0.43	1.07e-20	Mean platelet volume;
LUAD	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg04450456	chr4:17643702	FAM184B	0.37	6.88	0.32	2.23e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg24858658	chr1:33502741	AK2	-0.36	-6.43	-0.3	3.52e-10	Migraine with aura;
LUAD	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	cg06064525	chr11:970664	AP2A2	-0.44	-8.5	-0.38	3.27e-16	Alzheimer's disease (late onset);
LUAD	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg02038168	chr22:39784481	NA	-0.58	-10.44	-0.45	7.58e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs7156960	1.000	rs7156960	chr14:76703351	C/G	cg13981132	chr14:76734493	NA	0.44	7.24	0.33	2.14e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs698813	0.674	rs7590224	chr2:44501209	T/G	cg00619915	chr2:44497795	NA	-0.43	-6.35	-0.3	5.51e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUAD	trans	rs9512637	0.929	rs1815365	chr13:27917585	A/C	cg05717685	chr21:40752891	WRB	0.38	6.65	0.31	9.2e-11	Alcoholism (heaviness of drinking);
LUAD	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg13180566	chr4:1052158	NA	-0.4	-6.48	-0.3	2.48e-10	Recombination rate (females);
LUAD	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg26384229	chr12:38710491	ALG10B	-0.38	-6.4	-0.3	4.1e-10	Morning vs. evening chronotype;
LUAD	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.45	-0.3	3.13e-10	Alzheimer's disease (late onset);
LUAD	cis	rs7017914	0.967	rs13261712	chr8:71732264	T/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.53	-0.3	1.93e-10	Bone mineral density;
LUAD	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg00504896	chr12:9437009	LOC642846	-0.57	-9.76	-0.43	1.95e-20	Breast size;
LUAD	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg14458575	chr2:238380390	NA	0.71	13.08	0.54	4.63e-33	Prostate cancer;
LUAD	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg22868518	chr11:507468	RNH1	-0.69	-6.7	-0.31	6.57e-11	Body mass index;
LUAD	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg02782426	chr3:40428986	ENTPD3	0.35	7.63	0.35	1.59e-13	Renal cell carcinoma;
LUAD	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.67	-9.34	-0.41	5.52e-19	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs55788414	0.860	rs1806875	chr16:81184069	T/C	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.91	-0.36	2.31e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg05340658	chr4:99064831	C4orf37	0.51	8.52	0.38	2.9e-16	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg03929089	chr4:120376271	NA	-0.88	-16.94	-0.64	1.66e-49	Height;
LUAD	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.48e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12681287	0.752	rs12681438	chr8:87293089	G/A	cg00550725	chr8:87521180	FAM82B	0.46	6.63	0.31	1.05e-10	Caudate activity during reward;
LUAD	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg03983476	chr2:10830698	NOL10	-0.45	-7.87	-0.36	3.08e-14	Prostate cancer;
LUAD	trans	rs7712671	0.840	rs11241418	chr5:116527405	C/T	cg06153893	chr6:25963109	TRIM38	0.4	6.53	0.3	1.93e-10	Schizophrenia;
LUAD	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-20.28	-0.7	2.34e-64	Ulcerative colitis;
LUAD	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg22153745	chr1:153894579	GATAD2B	-0.51	-7.72	-0.35	8.37e-14	Total cholesterol levels;
LUAD	cis	rs7517126	1.000	rs2336503	chr1:196843420	G/T	cg07209298	chr1:196795943	CFHR1	0.48	6.47	0.3	2.75e-10	Blood protein levels;
LUAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.71	13.29	0.54	6.27e-34	Lymphocyte counts;
LUAD	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg17105886	chr17:28927953	LRRC37B2	0.69	6.97	0.32	1.24e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.17	-0.41	2.16e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg07806771	chr7:64541737	NA	0.54	8.65	0.39	1.04e-16	Calcium levels;
LUAD	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-7.44	-0.34	5.74e-13	Personality dimensions;
LUAD	cis	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg07460842	chr6:66804631	NA	0.91	13.17	0.54	1.94e-33	Exhaled nitric oxide output;
LUAD	trans	rs1493916	0.967	rs9953768	chr18:31399468	A/G	cg15819921	chr19:927150	ARID3A	-0.44	-7.2	-0.33	2.81e-12	Life satisfaction;
LUAD	cis	rs813218	0.523	rs652026	chr3:99442809	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.43	-8.1	-0.37	5.98e-15	Orofacial clefts;
LUAD	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg18806716	chr10:30721971	MAP3K8	-0.79	-16.87	-0.63	3.28e-49	Inflammatory bowel disease;
LUAD	cis	rs684232	0.623	rs417171	chr17:576941	A/G	cg15660573	chr17:549704	VPS53	-0.78	-15.13	-0.59	1.24e-41	Prostate cancer;
LUAD	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg11822812	chr5:140052017	DND1	-0.44	-7.79	-0.35	5.26e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg27490568	chr2:178487706	NA	0.4	6.68	0.31	7.67e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs11671005	0.735	rs11667591	chr19:58937637	G/A	cg13877915	chr19:58951672	ZNF132	0.55	7.4	0.34	7.3e-13	Mean platelet volume;
LUAD	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg06713675	chr4:122721982	EXOSC9	-0.81	-16.64	-0.63	3.29e-48	Type 2 diabetes;
LUAD	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg14541582	chr5:601475	NA	-0.38	-8.07	-0.37	7.47e-15	Obesity-related traits;
LUAD	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg21385522	chr1:16154831	NA	-1.07	-22.79	-0.74	1.41e-75	Dilated cardiomyopathy;
LUAD	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.91	9.59	0.42	7.78e-20	Initial pursuit acceleration;
LUAD	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg11502198	chr6:26597334	ABT1	0.48	7.67	0.35	1.19e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg14092571	chr14:90743983	NA	-0.47	-8.3	-0.37	1.44e-15	Mortality in heart failure;
LUAD	cis	rs829661	0.512	rs11676852	chr2:30792898	A/C	cg12454169	chr2:30669597	LCLAT1	-0.44	-6.73	-0.31	5.42e-11	Midgestational circulating levels of PBDEs (fetal genetic effect);
LUAD	trans	rs2735413	0.918	rs11646244	chr16:78082453	T/C	cg01028844	chr5:122736986	CEP120	0.41	6.5	0.3	2.24e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg22431228	chr1:16359049	CLCNKA	0.42	8.17	0.37	3.72e-15	Systolic blood pressure;
LUAD	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-12.0	-0.5	9.42e-29	Bipolar disorder;
LUAD	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.45	-6.39	-0.3	4.46e-10	Cognitive test performance;
LUAD	cis	rs57590327	0.528	rs11707026	chr3:81694044	C/A	cg07356753	chr3:81810745	GBE1	-0.65	-10.23	-0.45	4.2e-22	Extraversion;
LUAD	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg16797656	chr11:68205561	LRP5	0.48	10.05	0.44	1.95e-21	Total body bone mineral density;
LUAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg20607798	chr8:58055168	NA	0.69	7.71	0.35	9.11e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.61	0.31	1.14e-10	Colorectal cancer;
LUAD	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg00634984	chr7:65235879	NA	0.5	6.71	0.31	6.12e-11	Aortic root size;
LUAD	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg00206168	chr11:65308501	LTBP3	1.3	10.63	0.46	1.44e-23	Height;
LUAD	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg03806693	chr22:41940476	POLR3H	-0.63	-9.04	-0.4	5.89e-18	Vitiligo;
LUAD	cis	rs1595825	0.891	rs77706948	chr2:198608441	T/G	cg00982548	chr2:198649783	BOLL	-0.67	-9.08	-0.4	4.29e-18	Ulcerative colitis;
LUAD	trans	rs853679	0.546	rs200952	chr6:27836976	C/T	cg01620082	chr3:125678407	NA	-0.83	-8.92	-0.4	1.44e-17	Depression;
LUAD	cis	rs4642101	0.793	rs13320486	chr3:12822069	C/A	cg24848339	chr3:12840334	CAND2	0.43	8.61	0.39	1.48e-16	QRS complex (12-leadsum);
LUAD	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.68	0.43	3.7799999999999997e-20	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2835872	0.758	rs1709821	chr21:39035622	T/C	cg06728970	chr21:39037746	KCNJ6	0.4	7.69	0.35	1.01e-13	Electroencephalographic traits in alcoholism;
LUAD	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg18932078	chr1:2524107	MMEL1	-0.37	-6.95	-0.32	1.37e-11	Ulcerative colitis;
LUAD	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg04455712	chr21:45112962	RRP1B	0.47	9.24	0.41	1.21e-18	Mean corpuscular volume;
LUAD	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.37	-9.72	-0.43	2.68e-20	Total body bone mineral density;
LUAD	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg17063962	chr7:91808500	NA	0.68	12.32	0.51	5.02e-30	Breast cancer;
LUAD	cis	rs3204270	0.639	rs62080213	chr17:79642531	C/T	cg18367735	chr17:79674897	NA	0.59	7.27	0.33	1.71e-12	Dental caries;
LUAD	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg00277334	chr10:82204260	NA	-0.96	-22.01	-0.73	4.33e-72	Post bronchodilator FEV1;
LUAD	cis	rs12519773	0.555	rs2009416	chr5:92415111	C/T	cg18783429	chr5:92414398	NA	0.49	8.42	0.38	5.84e-16	Migraine;
LUAD	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg00634984	chr7:65235879	NA	-0.5	-7.01	-0.32	9.57e-12	Aortic root size;
LUAD	cis	rs593982	0.688	rs3897552	chr11:65560880	C/T	cg08755490	chr11:65554678	OVOL1	-1.31	-14.82	-0.58	2.45e-40	Atopic dermatitis;
LUAD	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06544989	chr22:39130855	UNC84B	0.45	8.38	0.38	7.89e-16	Menopause (age at onset);
LUAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.45e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs68170813	0.559	rs6949961	chr7:106850755	G/T	cg23024343	chr7:107201750	COG5	-0.49	-7.0	-0.32	1.02e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg23301539	chr8:142222248	SLC45A4	0.41	6.85	0.32	2.66e-11	Immature fraction of reticulocytes;
LUAD	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.23	0.33	2.25e-12	Blood metabolite levels;
LUAD	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg05340658	chr4:99064831	C4orf37	0.49	7.08	0.33	6.11e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg03859395	chr2:55845619	SMEK2	-0.61	-10.76	-0.46	5.11e-24	Metabolic syndrome;
LUAD	cis	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg27411982	chr8:10470053	RP1L1	0.41	7.75	0.35	7.07e-14	Neuroticism;
LUAD	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg00645731	chr22:42541494	CYP2D7P1	-0.55	-8.07	-0.37	7.32e-15	Birth weight;
LUAD	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	12.26	0.51	9.09e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02729805	chr20:30865674	KIF3B	-0.4	-6.63	-0.31	1.01e-10	Cancer;
LUAD	cis	rs4268898	1.000	rs4268898	chr2:24490413	C/T	cg06627628	chr2:24431161	ITSN2	0.45	7.65	0.35	1.4e-13	Asthma;
LUAD	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg10792982	chr14:105748885	BRF1	0.45	9.49	0.42	1.68e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18876405	chr7:65276391	NA	0.45	7.11	0.33	4.84e-12	Aortic root size;
LUAD	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.35	-0.3	5.46e-10	Coronary artery disease;
LUAD	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg08885076	chr2:99613938	TSGA10	0.35	6.44	0.3	3.19e-10	Chronic sinus infection;
LUAD	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg19318889	chr4:1322082	MAEA	0.51	8.37	0.38	8.52e-16	Longevity;
LUAD	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg07917127	chr4:99064746	C4orf37	0.4	6.54	0.3	1.79e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2658782	1.000	rs2658779	chr11:93163137	G/T	cg15737290	chr11:93063684	CCDC67	-0.52	-7.51	-0.34	3.56e-13	Pulmonary function decline;
LUAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg18351406	chr4:77819688	ANKRD56	0.61	9.8	0.43	1.48e-20	Emphysema distribution in smoking;
LUAD	cis	rs6782228	0.606	rs6807019	chr3:128405934	G/A	cg16766828	chr3:128327626	NA	-0.39	-7.45	-0.34	5.2e-13	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs500891	0.525	rs9766300	chr6:84083733	T/A	cg08257003	chr6:84140564	ME1	0.34	6.65	0.31	9.21e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg24505687	chr6:33548425	BAK1	0.6	10.36	0.45	1.45e-22	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
LUAD	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg13319975	chr6:146136371	FBXO30	-0.59	-10.0	-0.44	2.78e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg05340658	chr4:99064831	C4orf37	0.56	9.53	0.42	1.22e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg17595323	chr11:93583763	C11orf90	-0.43	-9.06	-0.4	4.81e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg02734326	chr4:10020555	SLC2A9	0.56	9.82	0.43	1.2e-20	Bone mineral density;
LUAD	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg21191810	chr6:118973309	C6orf204	-0.53	-7.96	-0.36	1.57e-14	Diastolic blood pressure;
LUAD	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg18876405	chr7:65276391	NA	-0.44	-6.81	-0.31	3.38e-11	Aortic root size;
LUAD	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg27113419	chr16:58533979	NDRG4	-0.73	-6.5	-0.3	2.32e-10	Schizophrenia;
LUAD	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg02782426	chr3:40428986	ENTPD3	-0.42	-9.22	-0.41	1.45e-18	Renal cell carcinoma;
LUAD	cis	rs10979	1.000	rs12215667	chr6:143893213	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-10.26	-0.45	3.37e-22	Hypospadias;
LUAD	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg03433033	chr1:76189801	ACADM	-0.84	-15.06	-0.59	2.41e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-6.93	-0.32	1.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs600626	0.588	rs10899112	chr11:75458518	T/C	cg24262691	chr11:75473276	NA	0.58	7.95	0.36	1.72e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs713477	1.000	rs7148481	chr14:55909267	G/A	cg13175173	chr14:55914753	NA	-0.33	-6.95	-0.32	1.41e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs1882538	0.596	rs10281827	chr7:133081810	A/G	cg10665199	chr7:133106180	EXOC4	0.65	11.18	0.48	1.29e-25	Intelligence (multi-trait analysis);
LUAD	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-15.02	-0.59	3.58e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs921968	0.565	rs6436084	chr2:219639782	A/G	cg02176678	chr2:219576539	TTLL4	-0.58	-11.8	-0.5	5.42e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.16e-13	Tonsillectomy;
LUAD	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg01616529	chr11:638424	DRD4	-0.45	-6.5	-0.3	2.26e-10	Systemic lupus erythematosus;
LUAD	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.63	0.42	5.44e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73198271	0.740	rs10098636	chr8:8647324	C/T	cg01851573	chr8:8652454	MFHAS1	0.48	8.54	0.38	2.53e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg11965913	chr1:205819406	PM20D1	0.82	17.16	0.64	1.79e-50	Menarche (age at onset);
LUAD	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg05340658	chr4:99064831	C4orf37	0.45	7.45	0.34	5.13e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg06873352	chr17:61820015	STRADA	-0.69	-13.05	-0.54	6e-33	Prudent dietary pattern;
LUAD	cis	rs6743376	0.532	rs2251872	chr2:113818632	G/A	cg09040174	chr2:113837401	NA	0.52	8.02	0.36	1.02e-14	Inflammatory biomarkers;
LUAD	cis	rs10792830	0.771	rs629343	chr11:85811138	C/T	cg07180834	chr11:85838833	NA	0.32	6.67	0.31	8.02e-11	Psychosis and Alzheimer's disease;
LUAD	cis	rs1232027	0.656	rs863214	chr5:79984714	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.39	-6.39	-0.3	4.32e-10	Huntington's disease progression;
LUAD	cis	rs1371614	0.588	rs13017554	chr2:27170982	C/T	cg00617064	chr2:27272375	NA	-0.37	-7.12	-0.33	4.52e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs6717918	0.620	rs7570112	chr2:233150452	A/G	ch.2.233013039R	chr2:233304795	NA	0.52	7.24	0.33	2.07e-12	Height;
LUAD	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg13385794	chr1:248469461	NA	0.26	6.94	0.32	1.46e-11	Common traits (Other);
LUAD	cis	rs12681288	0.676	rs34282191	chr8:991290	G/A	cg04851639	chr8:1020857	NA	-0.42	-9.77	-0.43	1.87e-20	Schizophrenia;
LUAD	cis	rs7072216	0.922	rs4539242	chr10:100148058	T/C	cg26618903	chr10:100175079	PYROXD2	-0.32	-6.92	-0.32	1.73e-11	Metabolite levels;
LUAD	cis	rs78366141	0.649	rs78179026	chr4:89657456	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.91	6.39	0.3	4.33e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.87	-0.36	2.92e-14	Total body bone mineral density;
LUAD	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.26	6.61	0.31	1.14e-10	Parkinson's disease;
LUAD	cis	rs354225	0.615	rs12713274	chr2:54848728	C/T	cg01766943	chr2:54829624	SPTBN1	-0.36	-6.61	-0.31	1.14e-10	Schizophrenia;
LUAD	cis	rs41311933	0.803	rs62578395	chr9:123698332	T/A	cg13567360	chr9:123745713	C5	-0.83	-7.22	-0.33	2.36e-12	Coronary artery disease;
LUAD	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg24813613	chr7:1882135	MAD1L1	-0.44	-6.95	-0.32	1.38e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs513349	0.964	rs210139	chr6:33543409	A/C	cg13560919	chr6:33536144	NA	0.37	6.62	0.31	1.06e-10	Platelet count;
LUAD	cis	rs1232027	0.588	rs1677641	chr5:79962919	A/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.08	-0.33	6.22e-12	Huntington's disease progression;
LUAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.63	-11.15	-0.48	1.71e-25	Lymphocyte counts;
LUAD	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg24733560	chr20:60626293	TAF4	0.41	8.15	0.37	4.06e-15	Body mass index;
LUAD	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg15448220	chr1:150897856	SETDB1	0.46	7.97	0.36	1.47e-14	Tonsillectomy;
LUAD	cis	rs28493229	0.786	rs3815912	chr19:41190726	G/A	cg21869046	chr19:41225005	ITPKC	0.52	8.37	0.38	8.38e-16	Kawasaki disease;
LUAD	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg22532475	chr10:104410764	TRIM8	-0.48	-9.21	-0.41	1.53e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00177013	chr20:62339100	ARFRP1;ZGPAT	-0.43	-6.9	-0.32	1.97e-11	Height;
LUAD	cis	rs7809615	0.901	rs28862110	chr7:99183531	T/C	cg12290671	chr7:99195819	NA	-0.67	-7.56	-0.34	2.57e-13	Blood metabolite ratios;
LUAD	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg25767906	chr1:53392781	SCP2	-0.41	-7.4	-0.34	7.17e-13	Monocyte count;
LUAD	cis	rs2742234	0.955	rs1272142	chr10:43695484	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.45	-8.3	-0.37	1.42e-15	Hirschsprung disease;
LUAD	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg26408565	chr15:76604113	ETFA	-0.43	-6.96	-0.32	1.29e-11	Blood metabolite levels;
LUAD	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22857025	chr5:266934	NA	-0.97	-14.09	-0.57	3.02e-37	Breast cancer;
LUAD	cis	rs13064411	0.542	rs9846539	chr3:113228688	A/G	cg18753928	chr3:113234510	CCDC52	-0.56	-9.76	-0.43	2.03e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg15448220	chr1:150897856	SETDB1	0.51	8.65	0.39	1.11e-16	Melanoma;
LUAD	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg13319975	chr6:146136371	FBXO30	-0.59	-9.91	-0.43	5.68e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg11901034	chr3:128598214	ACAD9	-0.55	-8.87	-0.4	2.1e-17	IgG glycosylation;
LUAD	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg05991184	chr2:219186017	PNKD	-0.38	-7.29	-0.33	1.55e-12	Colorectal cancer;
LUAD	cis	rs3936840	0.964	rs10150698	chr14:102977876	A/G	cg18135206	chr14:102964638	TECPR2	0.54	8.83	0.39	2.89e-17	Plateletcrit;
LUAD	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.22	0.41	1.4e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg13722127	chr7:150037890	RARRES2	0.44	7.19	0.33	3.01e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs2742234	0.915	rs2742233	chr10:43610558	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.45	-7.98	-0.36	1.37e-14	Hirschsprung disease;
LUAD	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg15181151	chr6:150070149	PCMT1	0.4	7.94	0.36	1.81e-14	Lung cancer;
LUAD	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg06713675	chr4:122721982	EXOSC9	-0.8	-16.16	-0.62	4.09e-46	Type 2 diabetes;
LUAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08048268	chr3:133502702	NA	-0.55	-11.17	-0.48	1.46e-25	Iron status biomarkers;
LUAD	cis	rs17253792	0.822	rs77676035	chr14:56096229	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg24308560	chr3:49941425	MST1R	-0.54	-9.08	-0.4	4.22e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs12681287	0.752	rs4427148	chr8:87250668	G/A	cg27223183	chr8:87520930	FAM82B	-0.59	-8.21	-0.37	2.75e-15	Caudate activity during reward;
LUAD	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.47	-0.52	1.29e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4964805	1.000	rs1866295	chr12:104186946	G/T	cg02344784	chr12:104178138	NT5DC3	0.38	6.57	0.3	1.5e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.41	-6.35	-0.3	5.56e-10	Schizophrenia;
LUAD	cis	rs2455601	0.786	rs56680262	chr11:8971555	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-7.87	-0.36	3.01e-14	Schizophrenia;
LUAD	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg13556452	chr1:2391241	NA	-0.44	-10.27	-0.45	3.11e-22	Schizophrenia;
LUAD	cis	rs3106136	0.967	rs12645192	chr4:95181525	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.43	-0.34	6.06e-13	Capecitabine sensitivity;
LUAD	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.41	-6.95	-0.32	1.38e-11	Longevity;Endometriosis;
LUAD	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg01528321	chr10:82214614	TSPAN14	0.68	11.08	0.47	3.27e-25	Post bronchodilator FEV1;
LUAD	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg00981070	chr1:2046702	PRKCZ	0.35	7.62	0.35	1.72e-13	Height;
LUAD	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg27661571	chr11:113659931	NA	-0.69	-8.14	-0.37	4.43e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.48	-8.8	-0.39	3.46e-17	Menarche (age at onset);
LUAD	cis	rs9467773	1.000	rs9467798	chr6:26575697	G/A	cg09904177	chr6:26538194	HMGN4	0.44	7.03	0.32	8.25e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.88	0.53	3.02e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7903847	0.692	rs7900255	chr10:99157575	G/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.59	-0.35	2.04e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg12373951	chr3:133503437	NA	0.36	7.29	0.33	1.52e-12	Iron status biomarkers;
LUAD	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg18180107	chr4:99064573	C4orf37	0.42	6.8	0.31	3.49e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2073300	1.000	rs6137957	chr20:23437384	G/A	cg12062639	chr20:23401060	NAPB	1.0	9.23	0.41	1.27e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs758324	0.947	rs10052255	chr5:131173106	C/T	cg25547332	chr5:131281432	NA	0.43	6.62	0.31	1.07e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg18209359	chr17:80159595	CCDC57	0.39	6.66	0.31	8.74e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg19980929	chr12:42632907	YAF2	0.34	6.59	0.3	1.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg10518543	chr12:38710700	ALG10B	-0.51	-8.34	-0.38	1.09e-15	Morning vs. evening chronotype;
LUAD	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-7.65	-0.35	1.38e-13	Blood metabolite levels;
LUAD	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.19	-0.37	3.18e-15	Total cholesterol levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg20024234	chr21:43431083	ZNF295	-0.68	-6.79	-0.31	3.83e-11	Type 2 diabetes;
LUAD	cis	rs2797160	1.000	rs983543	chr6:126005767	G/A	cg05901451	chr6:126070800	HEY2	-0.45	-6.66	-0.31	8.37e-11	Endometrial cancer;
LUAD	cis	rs2274273	0.967	rs17832359	chr14:55615941	T/C	cg04306507	chr14:55594613	LGALS3	0.38	7.66	0.35	1.32e-13	Protein biomarker;
LUAD	cis	rs1461503	0.966	rs10790546	chr11:122838426	C/A	cg27398637	chr11:122830231	C11orf63	-0.36	-7.01	-0.32	9.34e-12	Menarche (age at onset);
LUAD	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg07936489	chr17:37558343	FBXL20	-0.45	-7.15	-0.33	3.91e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg14039649	chr22:38352398	POLR2F	0.35	6.37	0.3	4.93e-10	Glioblastoma;Glioma;
LUAD	cis	rs7084921	0.578	rs11190393	chr10:101869988	C/T	cg19754520	chr10:101825118	CPN1	-0.33	-6.61	-0.31	1.19e-10	Bone mineral density;
LUAD	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg22508957	chr16:3507546	NAT15	-0.43	-6.62	-0.31	1.07e-10	Body mass index (adult);
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg04498032	chr1:155242826	CLK2	0.42	6.42	0.3	3.72e-10	Monocyte percentage of white cells;
LUAD	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg18721089	chr20:30220636	NA	-0.46	-6.57	-0.3	1.47e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs7216064	1.000	rs11870068	chr17:65944515	A/C	cg08758996	chr17:66097529	LOC651250	0.47	7.2	0.33	2.68e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.81	11.14	0.48	1.91e-25	Smoking behavior;
LUAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg06877462	chr1:205807181	PM20D1	0.38	7.21	0.33	2.61e-12	Menarche (age at onset);
LUAD	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg02527881	chr3:46936655	PTH1R	-0.44	-8.46	-0.38	4.43e-16	Colorectal cancer;
LUAD	cis	rs3790645	1.000	rs897641	chr1:26881806	C/A	cg23229016	chr1:26872525	RPS6KA1	0.21	6.97	0.32	1.22e-11	Glucose homeostasis traits;
LUAD	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1550582	1.000	rs76091740	chr8:135514419	C/T	cg17885191	chr8:135476712	NA	0.72	10.28	0.45	2.72e-22	Educational attainment;
LUAD	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.11	-0.33	4.98e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6487679	0.526	rs972111	chr12:9374373	A/G	cg08997352	chr12:9597637	DDX12	-0.49	-7.43	-0.34	6.17e-13	Non-alcoholic fatty liver disease histology (AST);
LUAD	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg23649088	chr2:200775458	C2orf69	0.66	9.57	0.42	8.95e-20	Schizophrenia;
LUAD	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.1	0.33	5.37e-12	Hypertriglyceridemia;
LUAD	trans	rs8073060	0.586	rs72829922	chr17:34044809	G/A	cg19694781	chr19:47549865	TMEM160	1.2	18.62	0.67	6e-57	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg23229984	chr5:148520753	ABLIM3	0.5	7.73	0.35	7.88e-14	Breast cancer;
LUAD	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg09796270	chr17:17721594	SREBF1	-0.39	-7.49	-0.34	4e-13	Total body bone mineral density;
LUAD	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23158103	chr7:148848205	ZNF398	-0.65	-12.0	-0.5	9.27e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg18335740	chr13:41363409	SLC25A15	0.51	8.95	0.4	1.14e-17	Lewy body disease;
LUAD	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg18944383	chr4:111397179	ENPEP	0.51	9.36	0.41	4.85e-19	Coronary artery disease;
LUAD	cis	rs4919694	0.901	rs12264456	chr10:104830634	C/T	cg04362960	chr10:104952993	NT5C2	0.73	7.86	0.36	3.28e-14	Arsenic metabolism;
LUAD	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg15704280	chr7:45808275	SEPT13	0.87	16.51	0.63	1.31e-47	Height;
LUAD	cis	rs7937890	0.560	rs2597194	chr11:14497269	C/T	cg23387056	chr11:14280742	SPON1	-0.35	-6.6	-0.31	1.24e-10	Mitochondrial DNA levels;
LUAD	cis	rs3087591	0.887	rs7503395	chr17:29440554	C/T	cg24425628	chr17:29625626	OMG;NF1	0.41	6.54	0.3	1.82e-10	Hip circumference;
LUAD	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg15017067	chr4:17643749	FAM184B	0.37	7.09	0.33	5.53e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg14779329	chr11:130786720	SNX19	0.39	6.83	0.32	2.93e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg01097406	chr16:89675127	NA	-0.3	-6.4	-0.3	4.04e-10	Vitiligo;
LUAD	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg15147215	chr3:52552868	STAB1	-0.39	-7.17	-0.33	3.31e-12	Bipolar disorder;
LUAD	cis	rs4343996	0.870	rs4722708	chr7:3382563	A/T	cg21248987	chr7:3385318	SDK1	-0.35	-6.53	-0.3	1.92e-10	Motion sickness;
LUAD	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg07936489	chr17:37558343	FBXL20	0.43	6.72	0.31	6.02e-11	Glomerular filtration rate (creatinine);
LUAD	trans	rs2262909	0.962	rs411020	chr19:22231102	G/A	cg17074339	chr11:11642133	GALNTL4	-0.47	-7.73	-0.35	8.11e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs939658	0.935	rs34859518	chr15:79450422	A/G	cg17916960	chr15:79447300	NA	-0.5	-10.27	-0.45	3.01e-22	Refractive error;
LUAD	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg24558204	chr6:135376177	HBS1L	0.45	8.14	0.37	4.63e-15	Red blood cell count;
LUAD	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg23281280	chr6:28129359	ZNF389	0.48	6.7	0.31	6.8e-11	Depression;
LUAD	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg13556452	chr1:2391241	NA	-0.4	-7.86	-0.36	3.25e-14	Non-obstructive azoospermia;
LUAD	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg06623918	chr6:96969491	KIAA0776	0.64	10.28	0.45	2.74e-22	Migraine;Coronary artery disease;
LUAD	trans	rs1681630	0.545	rs12790666	chr11:47983477	G/A	cg21153622	chr11:89784906	NA	-0.32	-6.36	-0.3	5.28e-10	Height;
LUAD	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.19	-0.33	3.02e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg24642844	chr7:1081250	C7orf50	-0.48	-7.82	-0.36	4.39e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1941687	0.797	rs12963024	chr18:31389547	A/G	cg27147174	chr7:100797783	AP1S1	-0.54	-9.12	-0.41	3.06e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11905131	chr22:24372483	LOC391322	-0.56	-9.69	-0.43	3.46e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08280861	chr8:58055591	NA	0.76	9.08	0.4	4.14e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg20283391	chr11:68216788	NA	-0.41	-6.5	-0.3	2.3e-10	Total body bone mineral density;
LUAD	cis	rs739496	0.843	rs4766462	chr12:111871141	A/T	cg10833066	chr12:111807467	FAM109A	0.45	8.13	0.37	4.65e-15	Platelet count;
LUAD	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.63	-0.35	1.52e-13	Breast cancer;
LUAD	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg15147215	chr3:52552868	STAB1	-0.38	-7.04	-0.32	7.85e-12	Bipolar disorder;
LUAD	cis	rs9341808	0.538	rs12176343	chr6:81027387	G/A	cg08355045	chr6:80787529	NA	-0.45	-7.64	-0.35	1.51e-13	Sitting height ratio;
LUAD	cis	rs1843834	0.734	rs1908251	chr2:225487865	T/C	cg22455342	chr2:225449267	CUL3	0.44	6.79	0.31	3.88e-11	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs9653442	0.622	rs11685341	chr2:100636757	A/G	cg22139774	chr2:100720529	AFF3	0.35	6.8	0.31	3.61e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg10518543	chr12:38710700	ALG10B	0.48	8.03	0.36	9.64e-15	Morning vs. evening chronotype;
LUAD	cis	rs2692947	0.655	rs60090597	chr2:96406266	G/A	cg23100626	chr2:96804247	ASTL	0.32	7.71	0.35	9.34e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	trans	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.99	-0.32	1.11e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9905704	0.633	rs917016	chr17:56454156	C/T	cg19466818	chr17:56409534	MIR142	0.35	6.99	0.32	1.05e-11	Testicular germ cell tumor;
LUAD	cis	rs7799006	0.862	rs733611	chr7:2256779	G/A	cg02951883	chr7:2050386	MAD1L1	-0.48	-7.48	-0.34	4.3e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09580882	chr1:226890942	ITPKB	-0.43	-6.79	-0.31	3.92e-11	Height;
LUAD	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg10053473	chr17:62856997	LRRC37A3	0.65	10.4	0.45	9.97e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg11494091	chr17:61959527	GH2	0.74	18.38	0.67	6.8e-56	Prudent dietary pattern;
LUAD	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg13319975	chr6:146136371	FBXO30	-0.55	-9.16	-0.41	2.33e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6761276	0.899	rs12466799	chr2:113835999	T/C	cg06383401	chr2:113825234	IL1F10	-0.3	-6.41	-0.3	3.97e-10	Protein quantitative trait loci;
LUAD	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg22431228	chr1:16359049	CLCNKA	-0.46	-8.02	-0.36	1.06e-14	Dilated cardiomyopathy;
LUAD	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg11502198	chr6:26597334	ABT1	0.66	11.48	0.49	9.8e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.842	rs10863155	chr12:86446416	T/C	cg18827107	chr12:86230957	RASSF9	0.45	8.23	0.37	2.39e-15	Major depressive disorder;
LUAD	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.86	-0.5	3.36e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg13073564	chr4:8508604	NA	0.62	11.39	0.48	2.17e-26	Response to antineoplastic agents;
LUAD	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg12140854	chr5:148520817	ABLIM3	-0.61	-10.16	-0.44	7.48e-22	Breast cancer;
LUAD	cis	rs9914544	0.564	rs4334348	chr17:18787004	G/T	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.49	-0.3	2.45e-10	Educational attainment (years of education);
LUAD	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.29	0.54	6.06e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs7395662	1.000	rs12361812	chr11:48563104	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.31	-0.33	1.32e-12	HDL cholesterol;
LUAD	cis	rs12711979	0.513	rs11676551	chr2:3836782	A/G	cg17052675	chr2:3827356	NA	-0.38	-6.9	-0.32	1.96e-11	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs11811982	0.793	rs75790780	chr1:227569460	C/T	cg24860534	chr1:227506868	CDC42BPA	0.66	7.2	0.33	2.8e-12	Optic disc area;
LUAD	cis	rs11676348	0.751	rs6715591	chr2:219019871	T/C	cg06547715	chr2:218990976	CXCR2	0.3	6.87	0.32	2.32e-11	Ulcerative colitis;
LUAD	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg11057378	chr10:81107060	PPIF	0.38	7.07	0.32	6.64e-12	Height;
LUAD	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg23533926	chr12:111358616	MYL2	-0.4	-6.77	-0.31	4.23e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	15.92	0.61	4.64e-45	Bone mineral density;
LUAD	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg18806716	chr10:30721971	MAP3K8	-0.67	-13.4	-0.55	2.19e-34	Inflammatory bowel disease;
LUAD	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg07636037	chr3:49044803	WDR6	0.63	12.04	0.51	6.37e-29	Parkinson's disease;
LUAD	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg16325326	chr1:53192061	ZYG11B	-0.55	-10.37	-0.45	1.31e-22	Monocyte count;
LUAD	cis	rs3087591	1.000	rs2952982	chr17:29470646	A/C	cg24425628	chr17:29625626	OMG;NF1	0.42	6.84	0.32	2.81e-11	Hip circumference;
LUAD	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg17177755	chr1:15930204	NA	0.45	7.37	0.34	9.03e-13	Systolic blood pressure;
LUAD	cis	rs57590327	0.503	rs9852235	chr3:81508355	A/G	cg07356753	chr3:81810745	GBE1	0.48	7.59	0.35	2e-13	Extraversion;
LUAD	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg01851573	chr8:8652454	MFHAS1	-0.46	-8.24	-0.37	2.16e-15	Mood instability;
LUAD	cis	rs2274273	0.624	rs7157308	chr14:55782043	A/G	cg04306507	chr14:55594613	LGALS3	0.42	8.14	0.37	4.38e-15	Protein biomarker;
LUAD	cis	rs9811920	0.809	rs923472	chr3:99758029	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-11.38	-0.48	2.4e-26	Axial length;
LUAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg02136620	chr5:178986620	RUFY1	-0.49	-8.16	-0.37	3.79e-15	Lung cancer;
LUAD	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg24813613	chr7:1882135	MAD1L1	-0.45	-7.02	-0.32	9.04e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg07917127	chr4:99064746	C4orf37	0.49	7.96	0.36	1.54e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg18198730	chr1:247681584	NA	-0.46	-8.28	-0.37	1.6e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9443645	0.507	rs9352633	chr6:79462623	C/G	cg05283184	chr6:79620031	NA	-0.39	-7.08	-0.33	5.87e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.44	7.31	0.33	1.36e-12	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg12935359	chr14:103987150	CKB	-0.45	-7.6	-0.35	1.97e-13	Body mass index;
LUAD	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg18944383	chr4:111397179	ENPEP	0.41	7.95	0.36	1.73e-14	Height;
LUAD	cis	rs9487051	0.768	rs463503	chr6:109525757	T/C	cg21918786	chr6:109611834	NA	-0.41	-7.1	-0.33	5.45e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14159672	chr1:205819179	PM20D1	-0.75	-15.34	-0.6	1.53e-42	Menarche (age at onset);
LUAD	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg27170947	chr2:26402098	FAM59B	-0.81	-11.51	-0.49	7.14e-27	Gut microbiome composition (summer);
LUAD	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	8.77	0.39	4.54e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs17401966	0.964	rs6674843	chr1:10458378	A/T	cg19773385	chr1:10388646	KIF1B	-0.41	-6.5	-0.3	2.3e-10	Hepatocellular carcinoma;
LUAD	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg09127314	chr1:152161683	NA	0.41	6.72	0.31	5.91e-11	Inflammatory skin disease;
LUAD	cis	rs10465746	1.000	rs10465746	chr1:84387632	T/G	cg10977910	chr1:84465055	TTLL7	0.5	8.08	0.37	6.64e-15	Obesity-related traits;
LUAD	cis	rs1696756	0.638	rs1290396	chr17:77830767	C/T	cg02876276	chr17:77834299	NA	0.49	7.72	0.35	8.29e-14	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg11915388	chr22:42470451	FAM109B	-0.4	-7.25	-0.33	1.98e-12	Schizophrenia;
LUAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg04025307	chr7:1156635	C7orf50	0.83	15.37	0.6	1.14e-42	Longevity;Endometriosis;
LUAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg23978390	chr7:1156363	C7orf50	0.43	6.7	0.31	6.61e-11	Longevity;Endometriosis;
LUAD	cis	rs9796	0.624	rs9920619	chr15:41318845	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.49	-9.17	-0.41	2.1e-18	Menopause (age at onset);
LUAD	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-12.21	-0.51	1.37e-29	Breast cancer;
LUAD	cis	rs1595825	0.891	rs16866940	chr2:198509058	C/T	cg11031976	chr2:198649780	BOLL	-0.46	-6.81	-0.31	3.32e-11	Ulcerative colitis;
LUAD	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg14019146	chr3:50243930	SLC38A3	0.49	9.47	0.42	2.03e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg16479474	chr6:28041457	NA	0.44	7.4	0.34	7.22e-13	Depression;
LUAD	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg24450063	chr1:156163899	SLC25A44	1.03	18.79	0.67	9.96e-58	Testicular germ cell tumor;
LUAD	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg23625390	chr15:77176239	SCAPER	0.37	6.62	0.31	1.12e-10	Blood metabolite levels;
LUAD	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.81	-0.36	4.44e-14	Type 2 diabetes;
LUAD	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg14668632	chr7:2872130	GNA12	-0.76	-13.91	-0.56	1.82e-36	Height;
LUAD	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg25173405	chr17:45401733	C17orf57	0.45	7.75	0.35	6.83e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg02951883	chr7:2050386	MAD1L1	-0.8	-14.41	-0.57	1.42e-38	Bipolar disorder and schizophrenia;
LUAD	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08048268	chr3:133502702	NA	-0.51	-9.99	-0.44	3.15e-21	Iron status biomarkers;
LUAD	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05776053	chr2:74358815	NA	0.42	6.64	0.31	9.75e-11	Gestational age at birth (maternal effect);
LUAD	cis	rs1003719	0.788	rs8133549	chr21:38447489	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.53	0.38	2.73e-16	Eye color traits;
LUAD	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg09650180	chr20:62225654	GMEB2	-0.46	-6.44	-0.3	3.34e-10	Glioblastoma;
LUAD	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22496380	chr5:211416	CCDC127	-0.95	-13.32	-0.54	4.88e-34	Breast cancer;
LUAD	cis	rs526821	0.595	rs565859	chr11:55297367	T/C	cg04317927	chr11:55418816	OR4S2	0.39	7.3	0.33	1.48e-12	Pediatric bone mineral density (spine);
LUAD	cis	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg21775007	chr8:11205619	TDH	0.56	10.25	0.45	3.72e-22	Retinal vascular caliber;
LUAD	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg23978390	chr7:1156363	C7orf50	0.53	6.37	0.3	4.89e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg03188948	chr7:1209495	NA	0.44	7.05	0.32	7.13e-12	Longevity;Endometriosis;
LUAD	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg12034118	chr1:209979487	IRF6	0.57	6.43	0.3	3.44e-10	Coronary artery disease;
LUAD	trans	rs1493916	0.721	rs4799723	chr18:31367050	T/G	cg13755796	chr4:20253514	NA	-0.41	-6.96	-0.32	1.27e-11	Life satisfaction;
LUAD	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg16797656	chr11:68205561	LRP5	0.49	9.42	0.42	2.87e-19	Total body bone mineral density;
LUAD	cis	rs494562	0.892	rs490079	chr6:86117599	T/C	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	9.55	0.42	1.05e-19	Lung cancer in ever smokers;
LUAD	cis	rs13266463	1.000	rs13266463	chr8:143403693	A/G	cg16886403	chr8:143471632	TSNARE1	-0.47	-7.16	-0.33	3.55e-12	Schizophrenia;
LUAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg18402987	chr7:1209562	NA	0.63	9.3	0.41	7.42e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6987853	0.814	rs2923447	chr8:42439848	G/T	cg09913449	chr8:42400586	C8orf40	0.48	9.37	0.41	4.47e-19	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs16989760	0.661	rs67935422	chr22:32020413	G/A	cg01338084	chr22:32026380	PISD	0.79	6.48	0.3	2.59e-10	Age-related hearing impairment;
LUAD	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg00074818	chr8:8560427	CLDN23	0.66	10.24	0.45	4.06e-22	Obesity-related traits;
LUAD	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.03	-0.56	5.31e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs7177699	0.557	rs7178051	chr15:79118296	A/G	cg00540400	chr15:79124168	NA	0.45	9.47	0.42	2.03e-19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs13223928	0.516	rs11763949	chr7:3150279	A/C	cg19214707	chr7:3157722	NA	-0.51	-9.26	-0.41	1.03e-18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs6541297	1.000	rs11122405	chr1:230282997	C/A	cg20703242	chr1:230279135	GALNT2	0.66	11.96	0.5	1.35e-28	Coronary artery disease;
LUAD	cis	rs9843304	0.528	rs9860963	chr3:149197465	A/G	cg08667024	chr3:149219783	TM4SF4	0.38	6.9	0.32	1.9e-11	Gallstone disease;
LUAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg03188948	chr7:1209495	NA	0.81	9.86	0.43	9.06e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22857025	chr5:266934	NA	-0.97	-14.63	-0.58	1.67e-39	Breast cancer;
LUAD	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.41	-0.34	6.71e-13	Educational attainment;
LUAD	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg06092702	chr1:163392909	NA	-0.36	-8.3	-0.37	1.42e-15	Motion sickness;
LUAD	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.29	0.33	1.53e-12	Menopause (age at onset);
LUAD	cis	rs1395	0.778	rs11126918	chr2:27438710	G/A	cg23587288	chr2:27483067	SLC30A3	-0.39	-7.55	-0.34	2.67e-13	Blood metabolite levels;
LUAD	cis	rs7843479	0.965	rs11135763	chr8:21813962	A/G	cg03445287	chr8:21823731	XPO7	-0.47	-8.61	-0.39	1.49e-16	Mean corpuscular volume;
LUAD	cis	rs7258465	1.000	rs3810429	chr19:18543270	G/T	cg06953865	chr19:18549723	ISYNA1	-0.33	-6.36	-0.3	5.2e-10	Breast cancer;
LUAD	cis	rs11585357	0.793	rs11587669	chr1:17616259	C/T	cg08277548	chr1:17600880	PADI3	-0.9	-13.34	-0.54	4.13e-34	Hair shape;
LUAD	trans	rs1941687	0.527	rs1493914	chr18:31362327	C/T	cg27147174	chr7:100797783	AP1S1	-0.71	-12.96	-0.53	1.34e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg23229984	chr5:148520753	ABLIM3	0.5	7.75	0.35	6.91e-14	Breast cancer;
LUAD	cis	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg21775007	chr8:11205619	TDH	0.56	9.8	0.43	1.39e-20	Retinal vascular caliber;
LUAD	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg07507251	chr3:52567010	NT5DC2	0.37	7.35	0.34	1.04e-12	Bipolar disorder;
LUAD	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg03467027	chr4:99064603	C4orf37	0.43	6.82	0.31	3.11e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg25358565	chr5:93447407	FAM172A	0.62	7.61	0.35	1.74e-13	Diabetic retinopathy;
LUAD	cis	rs10129255	0.518	rs7143784	chr14:107143294	A/G	cg23076370	chr14:107095027	NA	-0.42	-8.42	-0.38	5.7e-16	Kawasaki disease;
LUAD	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.66	-0.31	8.29e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg06002616	chr8:101225028	SPAG1	0.4	8.42	0.38	5.82e-16	Atrioventricular conduction;
LUAD	cis	rs10883723	0.962	rs1056741	chr10:104236640	A/C	cg22532475	chr10:104410764	TRIM8	-0.42	-7.82	-0.36	4.29e-14	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-8.35	-0.38	9.75e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg08645402	chr16:4508243	NA	0.58	10.81	0.47	3.34e-24	Schizophrenia;
LUAD	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg13870426	chr17:30244630	NA	-0.57	-6.48	-0.3	2.56e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg14582100	chr15:45693742	SPATA5L1	-0.62	-12.28	-0.51	7.26e-30	Homoarginine levels;
LUAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg21782813	chr7:2030301	MAD1L1	-0.57	-10.17	-0.44	7.03e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg14500267	chr11:67383377	NA	-0.39	-7.06	-0.32	6.69e-12	Mean corpuscular volume;
LUAD	cis	rs2267137	0.836	rs2283855	chr22:29796775	T/C	cg07256473	chr22:29710276	RASL10A	0.37	6.48	0.3	2.6e-10	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg06640241	chr16:89574553	SPG7	-0.49	-8.05	-0.36	8.45e-15	Multiple myeloma (IgH translocation);
LUAD	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg06636551	chr8:101224915	SPAG1	-0.38	-6.97	-0.32	1.23e-11	Atrioventricular conduction;
LUAD	cis	rs4713675	0.584	rs9394163	chr6:33682414	A/G	cg13859433	chr6:33739653	LEMD2	-0.28	-6.62	-0.31	1.09e-10	Plateletcrit;
LUAD	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	10.97	0.47	8.08e-25	Homoarginine levels;
LUAD	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg15181151	chr6:150070149	PCMT1	0.39	7.84	0.36	3.79e-14	Lung cancer;
LUAD	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg18131467	chr2:239335373	ASB1	0.73	12.44	0.52	1.78e-30	Multiple system atrophy;
LUAD	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg00495681	chr13:53174319	NA	0.58	10.74	0.46	5.89e-24	Lewy body disease;
LUAD	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg18944383	chr4:111397179	ENPEP	0.39	7.63	0.35	1.55e-13	Height;
LUAD	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg11766577	chr21:47581405	C21orf56	-0.45	-7.69	-0.35	1.06e-13	Testicular germ cell tumor;
LUAD	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg02269571	chr22:50332266	NA	0.62	9.45	0.42	2.28e-19	Schizophrenia;
LUAD	cis	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-7.43	-0.34	6.06e-13	Neuroticism;
LUAD	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg02880119	chr16:3481970	NA	0.55	8.18	0.37	3.42e-15	Body mass index (adult);
LUAD	cis	rs89107	0.688	rs283082	chr6:118605441	A/C	cg21191810	chr6:118973309	C6orf204	0.48	9.38	0.41	4.02e-19	Cardiac structure and function;
LUAD	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg09035930	chr12:129282057	SLC15A4	0.54	10.31	0.45	2.27e-22	Systemic lupus erythematosus;
LUAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg07234876	chr8:600039	NA	-1.13	-9.63	-0.42	5.76e-20	IgG glycosylation;
LUAD	cis	rs1215050	0.791	rs165244	chr4:98687889	C/T	cg24818145	chr4:99064322	C4orf37	0.4	6.65	0.31	9.02e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	7.4	0.34	7.24e-13	Cognitive test performance;
LUAD	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg26513180	chr16:89883248	FANCA	0.79	7.19	0.33	2.92e-12	Skin colour saturation;
LUAD	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg01579765	chr21:45077557	HSF2BP	0.55	12.13	0.51	2.85e-29	Mean corpuscular volume;
LUAD	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.79	10.98	0.47	7.24e-25	Smoking behavior;
LUAD	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.48	-0.42	1.79e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg08422745	chr4:174089978	GALNT7	-0.93	-16.52	-0.63	1.15e-47	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg22029157	chr1:209979665	IRF6	0.79	10.05	0.44	1.93e-21	Cleft lip with or without cleft palate;
LUAD	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg16384552	chr7:74938386	SPDYE8P	-0.61	-9.67	-0.43	3.98e-20	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2249625	0.545	rs2496495	chr6:72882414	G/A	cg18830697	chr6:72922368	RIMS1	-0.44	-8.04	-0.36	8.97e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs7301826	1.000	rs10773822	chr12:131289107	C/G	cg11011512	chr12:131303247	STX2	0.39	6.74	0.31	5.31e-11	Plasma plasminogen activator levels;
LUAD	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg07305463	chr2:136567211	LCT	0.38	7.1	0.33	5.14e-12	Mosquito bite size;
LUAD	cis	rs67311347	0.544	rs2278929	chr3:40351008	C/G	cg09455208	chr3:40491958	NA	-0.49	-10.31	-0.45	2.22e-22	Renal cell carcinoma;
LUAD	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg16797656	chr11:68205561	LRP5	0.45	8.62	0.39	1.34e-16	Total body bone mineral density;
LUAD	cis	rs6847149	0.929	rs4698752	chr4:110780964	A/G	cg07850274	chr4:110748770	RRH	0.52	7.76	0.35	6.58e-14	Exercise treadmill test traits;
LUAD	trans	rs6561151	0.681	rs2325088	chr13:44424063	T/C	cg17145862	chr1:211918768	LPGAT1	0.53	7.32	0.34	1.3e-12	Crohn's disease;
LUAD	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg17147758	chr8:6949321	NA	-0.5	-8.97	-0.4	9.59e-18	Blood pressure (smoking interaction);
LUAD	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.68e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26314531	chr2:26401878	FAM59B	-0.55	-7.85	-0.36	3.38e-14	Gut microbiome composition (summer);
LUAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg00106254	chr7:1943704	MAD1L1	-0.54	-8.13	-0.37	4.91e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.37	0.67	7.38e-56	Prudent dietary pattern;
LUAD	cis	rs990171	0.538	rs12987295	chr2:103115838	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	6.51	0.3	2.13e-10	Lymphocyte counts;
LUAD	cis	rs9462027	0.597	rs6940215	chr6:34706358	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.27	-6.54	-0.3	1.8e-10	Systemic lupus erythematosus;
LUAD	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg25894440	chr7:65020034	NA	-0.61	-6.58	-0.3	1.39e-10	Diabetic kidney disease;
LUAD	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg10909506	chr17:38081995	ORMDL3	0.37	6.45	0.3	3.1e-10	Self-reported allergy;
LUAD	cis	rs8067545	0.641	rs203482	chr17:19827210	G/A	cg04132472	chr17:19861366	AKAP10	0.39	9.21	0.41	1.49e-18	Schizophrenia;
LUAD	cis	rs62238980	0.614	rs78443579	chr22:32449283	A/G	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg17724175	chr1:150552817	MCL1	0.32	7.32	0.34	1.25e-12	Melanoma;
LUAD	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.22	-0.54	1.18e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg11148817	chr5:312970	AHRR;PDCD6	-0.47	-6.51	-0.3	2.19e-10	Breast cancer;
LUAD	cis	rs8112211	0.731	rs11673012	chr19:38823971	C/A	cg01275006	chr19:38876250	GGN	-0.51	-6.65	-0.31	9.19e-11	Blood protein levels;
LUAD	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg02450064	chr17:40260053	DHX58	-0.45	-7.48	-0.34	4.26e-13	Fibrinogen levels;
LUAD	cis	rs72960926	0.590	rs56343698	chr6:74749564	C/T	cg03266952	chr6:74778945	NA	-0.8	-7.36	-0.34	9.73e-13	Metabolite levels (MHPG);
LUAD	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-7.08	-0.33	5.91e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg07362569	chr17:61921086	SMARCD2	0.39	6.76	0.31	4.46e-11	Prudent dietary pattern;
LUAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg18402987	chr7:1209562	NA	0.79	9.62	0.42	6.25e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg08885076	chr2:99613938	TSGA10	0.37	6.77	0.31	4.38e-11	Chronic sinus infection;
LUAD	trans	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg05926928	chr17:57297772	GDPD1	-0.63	-8.48	-0.38	3.73e-16	Opioid sensitivity;
LUAD	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg18016565	chr1:150552671	MCL1	-0.47	-8.19	-0.37	3.14e-15	Blood protein levels;
LUAD	cis	rs10465746	0.780	rs12145258	chr1:84401211	G/A	cg10977910	chr1:84465055	TTLL7	0.59	9.63	0.42	5.58e-20	Obesity-related traits;
LUAD	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00166722	chr3:10149974	C3orf24	0.72	12.22	0.51	1.33e-29	Alzheimer's disease;
LUAD	trans	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg01620082	chr3:125678407	NA	-0.98	-9.65	-0.42	4.92e-20	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg11693508	chr17:37793320	STARD3	0.55	7.64	0.35	1.52e-13	Bipolar disorder;
LUAD	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg14895029	chr7:2775587	GNA12	-0.46	-7.43	-0.34	6.2e-13	Height;
LUAD	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg18132916	chr6:79620363	NA	0.44	7.63	0.35	1.59e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs5756813	0.688	rs12484064	chr22:38126746	C/A	cg06521852	chr22:38141419	TRIOBP	0.5	8.8	0.39	3.63e-17	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg09117114	chr16:67998030	SLC12A4	-0.47	-6.52	-0.3	2.02e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg11909912	chr17:43974919	MAPT;LOC100130148	0.39	6.56	0.3	1.57e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg17761419	chr8:57350749	NA	-0.52	-7.84	-0.36	3.69e-14	Obesity-related traits;
LUAD	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg18240062	chr17:79603768	NPLOC4	-0.36	-6.43	-0.3	3.54e-10	Eye color traits;
LUAD	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg01028140	chr2:1542097	TPO	-0.43	-7.16	-0.33	3.56e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1493916	0.837	rs2123333	chr18:31410730	G/A	cg15819921	chr19:927150	ARID3A	-0.42	-6.86	-0.32	2.44e-11	Life satisfaction;
LUAD	cis	rs72634501	0.517	rs6600289	chr1:39613812	C/T	cg27567593	chr1:39956653	BMP8A	0.35	6.92	0.32	1.71e-11	HDL cholesterol;
LUAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.63	-11.9	-0.5	2.24e-28	Longevity;Endometriosis;
LUAD	trans	rs459571	0.959	rs455381	chr9:136905577	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-10.02	-0.44	2.33e-21	Platelet distribution width;
LUAD	cis	rs13112683	0.602	rs3106323	chr4:140786361	T/C	cg02876341	chr4:140783585	MAML3	0.33	7.03	0.32	8.22e-12	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LUAD	trans	rs10838798	0.563	rs11039516	chr11:48124157	T/A	cg00717180	chr2:96193071	NA	-0.39	-7.15	-0.33	3.91e-12	Height;
LUAD	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg15595755	chr5:1867978	NA	0.34	6.39	0.3	4.28e-10	Cardiovascular disease risk factors;
LUAD	cis	rs6867032	1.000	rs4975796	chr5:2015520	A/T	cg26168224	chr5:2018326	NA	-0.75	-17.21	-0.64	1.1e-50	Gut microbiome composition (winter);
LUAD	cis	rs13082711	0.911	rs2131205	chr3:27428501	A/G	cg02860705	chr3:27208620	NA	0.53	8.39	0.38	7.26e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6011002	0.683	rs6089966	chr20:62361250	A/G	cg01176363	chr20:62369445	LIME1	-0.79	-6.63	-0.31	1.05e-10	Dental caries;
LUAD	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03352830	chr11:487213	PTDSS2	0.82	10.47	0.45	5.68e-23	Body mass index;
LUAD	cis	rs864537	1.000	rs864537	chr1:167411384	A/G	cg22356347	chr1:167427500	CD247	-0.34	-6.56	-0.3	1.54e-10	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs56283067	0.847	rs12204270	chr6:44697502	A/T	cg20913747	chr6:44695427	NA	-0.42	-7.25	-0.33	1.99e-12	Total body bone mineral density;
LUAD	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg27432699	chr2:27873401	GPN1	0.58	10.36	0.45	1.4e-22	Oral cavity cancer;
LUAD	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg21475434	chr5:93447410	FAM172A	0.78	8.63	0.39	1.23e-16	Diabetic retinopathy;
LUAD	cis	rs9341808	0.935	rs2298307	chr6:80816296	A/G	cg08355045	chr6:80787529	NA	0.46	8.28	0.37	1.67e-15	Sitting height ratio;
LUAD	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg16049864	chr8:95962084	TP53INP1	-0.57	-12.3	-0.51	6.35e-30	Type 2 diabetes;
LUAD	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg04944784	chr2:26401820	FAM59B	-0.85	-12.69	-0.53	1.65e-31	Gut microbiome composition (summer);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16650896	chr7:64838774	ZNF92	-0.52	-8.05	-0.36	8.49e-15	Height;
LUAD	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.47	0.38	4.01e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg11062466	chr8:58055876	NA	0.45	6.45	0.3	3.04e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs35883536	1.000	rs1577504	chr1:101123913	A/T	cg06223162	chr1:101003688	GPR88	0.37	6.84	0.32	2.83e-11	Monocyte count;
LUAD	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.73	0.31	5.55e-11	Colorectal cancer;
LUAD	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg04673462	chr1:38461896	NA	-0.38	-7.3	-0.33	1.43e-12	Coronary artery disease;
LUAD	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg17366294	chr4:99064904	C4orf37	0.48	8.38	0.38	8.04e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg24920358	chr1:40204285	PPIE	0.7	12.47	0.52	1.29e-30	Blood protein levels;
LUAD	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-7.95	-0.36	1.7e-14	Neutrophil percentage of white cells;
LUAD	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg16479474	chr6:28041457	NA	0.38	6.67	0.31	7.84e-11	Parkinson's disease;
LUAD	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.75	-0.31	4.91e-11	Type 2 diabetes;
LUAD	trans	rs9914544	0.545	rs4924944	chr17:18810002	C/T	cg21372672	chr17:16614065	CCDC144A	-0.36	-6.51	-0.3	2.16e-10	Educational attainment (years of education);
LUAD	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg26373071	chr5:1325741	CLPTM1L	0.37	7.91	0.36	2.31e-14	Lung cancer;
LUAD	cis	rs12711979	0.509	rs12711972	chr2:3823786	T/C	cg17052675	chr2:3827356	NA	-0.83	-19.35	-0.69	3.11e-60	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg20019720	chr6:154832845	CNKSR3	0.65	12.84	0.53	4.41e-32	Lipoprotein (a) levels;
LUAD	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg27129171	chr3:47204927	SETD2	0.43	6.97	0.32	1.22e-11	Colorectal cancer;
LUAD	cis	rs4845570	0.764	rs12141652	chr1:151716711	A/T	cg07092448	chr1:151763213	TDRKH	-0.71	-7.94	-0.36	1.89e-14	Coronary artery disease;
LUAD	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg21724239	chr8:58056113	NA	0.54	7.26	0.33	1.89e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06544989	chr22:39130855	UNC84B	0.44	8.19	0.37	3.06e-15	Menopause (age at onset);
LUAD	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg16850897	chr7:100343110	ZAN	-0.62	-10.18	-0.44	6.64e-22	Other erythrocyte phenotypes;
LUAD	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.56	0.52	5.93e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.63	-10.58	-0.46	2.33e-23	Glomerular filtration rate;
LUAD	cis	rs346785	0.610	rs347674	chr17:74278548	C/G	cg09812376	chr17:74270190	QRICH2	-0.39	-9.6	-0.42	7.06e-20	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg07305463	chr2:136567211	LCT	0.38	7.16	0.33	3.54e-12	Mosquito bite size;
LUAD	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg00631329	chr6:26305371	NA	0.46	7.75	0.35	6.96e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11890956	chr21:40555474	PSMG1	-0.51	-8.65	-0.39	1.08e-16	Menarche (age at onset);
LUAD	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg12310025	chr6:25882481	NA	-0.57	-9.29	-0.41	8.52e-19	Blood metabolite levels;
LUAD	trans	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg27411982	chr8:10470053	RP1L1	0.38	6.67	0.31	7.92e-11	Neuroticism;
LUAD	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg06623918	chr6:96969491	KIAA0776	-0.79	-12.78	-0.53	7.71e-32	Migraine;Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-6.95	-0.32	1.41e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg14530993	chr4:882597	GAK	0.7	6.74	0.31	5.15e-11	Parkinson's disease;
LUAD	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.46	-8.05	-0.36	8.75e-15	Menopause (age at onset);
LUAD	trans	rs62103177	0.564	rs3930042	chr18:77723843	G/A	cg05926928	chr17:57297772	GDPD1	0.72	8.78	0.39	4.17e-17	Opioid sensitivity;
LUAD	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg08999081	chr20:33150536	PIGU	0.6	13.2	0.54	1.42e-33	Glomerular filtration rate (creatinine);
LUAD	cis	rs6758955	0.925	rs76748106	chr2:10480890	C/T	cg15773312	chr2:10472214	HPCAL1	-0.46	-7.19	-0.33	3.01e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs981844	0.740	rs1020702	chr4:154685712	A/C	cg10279832	chr4:154682576	RNF175	0.34	7.15	0.33	3.83e-12	Response to statins (LDL cholesterol change);
LUAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg03188948	chr7:1209495	NA	0.68	9.59	0.42	7.82e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg21709803	chr11:61594965	FADS2	-0.41	-7.24	-0.33	2.19e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.38	0.34	8.74e-13	Menopause (age at onset);
LUAD	cis	rs1451375	0.729	rs6593017	chr7:50644812	G/A	cg18232548	chr7:50535776	DDC	0.5	8.23	0.37	2.27e-15	Malaria;
LUAD	trans	rs11165623	0.715	rs1980769	chr1:96888201	A/T	cg10631902	chr5:14652156	NA	-0.59	-11.45	-0.49	1.29e-26	Hip circumference;Waist circumference;
LUAD	cis	rs4824093	0.545	rs58876234	chr22:50258868	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-7.58	-0.35	2.18e-13	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg12698349	chr2:225449008	CUL3	0.67	10.0	0.44	2.75e-21	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.5	-0.3	2.29e-10	Coronary artery disease;
LUAD	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg03690763	chr11:133734501	NA	0.35	8.22	0.37	2.53e-15	Childhood ear infection;
LUAD	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.57	0.3	1.46e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.92	0.36	2.18e-14	Bladder cancer;
LUAD	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg02782426	chr3:40428986	ENTPD3	0.42	9.28	0.41	9.21e-19	Renal cell carcinoma;
LUAD	trans	rs1941687	0.563	rs9953034	chr18:31335294	A/G	cg27147174	chr7:100797783	AP1S1	-0.68	-12.44	-0.52	1.75e-30	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs116248771	0.739	rs114379619	chr3:158338781	C/T	cg16708174	chr3:158430962	RARRES1	0.46	6.78	0.31	4.11e-11	diarrhoeal disease at age 2;
LUAD	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg22482690	chr17:47019901	SNF8	0.47	9.09	0.4	4.01e-18	Type 2 diabetes;
LUAD	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg25985355	chr7:65971099	NA	-0.55	-6.67	-0.31	8.05e-11	Diabetic kidney disease;
LUAD	cis	rs5756391	0.546	rs9607397	chr22:37315988	C/T	cg16356956	chr22:37317934	CSF2RB	0.33	7.21	0.33	2.64e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22338127	chr1:209979572	IRF6	0.47	6.52	0.3	2.02e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg13319975	chr6:146136371	FBXO30	0.6	10.08	0.44	1.45e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	12.28	0.51	7.24e-30	Homoarginine levels;
LUAD	cis	rs2797160	0.905	rs1418641	chr6:125999854	C/T	cg05901451	chr6:126070800	HEY2	-0.45	-6.73	-0.31	5.6e-11	Endometrial cancer;
LUAD	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg00852783	chr1:26633632	UBXN11	0.42	7.6	0.35	1.98e-13	Obesity-related traits;
LUAD	cis	rs2455826	0.544	rs2455848	chr3:15771372	C/T	cg16303742	chr3:15540471	COLQ	0.38	6.37	0.3	4.92e-10	Inflammatory skin disease;
LUAD	cis	rs748404	0.697	rs513970	chr15:43579566	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.53	0.34	3.09e-13	Lung cancer;
LUAD	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg17063962	chr7:91808500	NA	0.59	9.79	0.43	1.56e-20	Breast cancer;
LUAD	cis	rs8177876	0.822	rs4324142	chr16:81114903	G/C	cg08591886	chr16:81111003	C16orf46	-0.79	-7.37	-0.34	8.94e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg03467027	chr4:99064603	C4orf37	0.41	6.63	0.31	1.03e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs875971	0.520	rs160645	chr7:65556307	A/G	cg04775059	chr7:64541387	NA	-0.51	-6.62	-0.31	1.12e-10	Aortic root size;
LUAD	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg25894440	chr7:65020034	NA	-0.62	-6.63	-0.31	1.05e-10	Diabetic kidney disease;
LUAD	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg26022315	chr17:47021804	SNF8	0.4	7.22	0.33	2.51e-12	Type 2 diabetes;
LUAD	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg01324343	chr3:183735012	ABCC5	0.78	17.29	0.64	4.63e-51	Anterior chamber depth;
LUAD	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg24069376	chr3:38537580	EXOG	0.44	10.73	0.46	6.66e-24	Electrocardiographic conduction measures;
LUAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	cis	rs1692580	0.807	rs260508	chr1:2187085	T/G	cg24578937	chr1:2090814	PRKCZ	0.54	10.37	0.45	1.28e-22	Coronary artery disease;
LUAD	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06028808	chr11:68637592	NA	0.48	8.09	0.37	6.31e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg07153921	chr17:41440717	NA	-0.41	-6.97	-0.32	1.26e-11	Menopause (age at onset);
LUAD	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg27144592	chr16:783916	NARFL	0.37	6.71	0.31	6.39e-11	Height;
LUAD	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg18833306	chr6:118973337	C6orf204	-0.52	-7.49	-0.34	3.93e-13	Diastolic blood pressure;
LUAD	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.49	6.91	0.32	1.82e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4680	0.737	rs4818	chr22:19951207	C/G	cg01335087	chr22:19950166	COMT	-0.25	-6.5	-0.3	2.29e-10	Blood metabolite levels;
LUAD	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.16	-0.33	3.48e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs78761021	0.867	rs7223866	chr17:9785346	C/G	cg26853458	chr17:9805074	RCVRN	0.34	6.95	0.32	1.41e-11	Type 2 diabetes;
LUAD	cis	rs7614311	0.681	rs73117083	chr3:63948455	G/C	cg22134162	chr3:63841271	THOC7	-0.54	-9.07	-0.4	4.37e-18	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs4700695	0.719	rs36922	chr5:65464856	C/T	cg21114390	chr5:65439923	SFRS12	-0.9	-13.54	-0.55	5.73e-35	Facial morphology (factor 19);
LUAD	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg13319975	chr6:146136371	FBXO30	-0.79	-13.58	-0.55	3.95e-35	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4523957	0.620	rs9900587	chr17:2071097	G/A	cg16513277	chr17:2031491	SMG6	-1.0	-20.19	-0.7	5.63e-64	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4006360	0.629	rs7214220	chr17:39236627	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.36	7.83	0.36	4.04e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs7590720	0.704	rs7603645	chr2:216876949	C/G	cg12620499	chr2:216877984	MREG	0.61	10.48	0.45	5.38e-23	Alcohol dependence;
LUAD	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg20290983	chr6:43655470	MRPS18A	1.03	25.64	0.78	3.78e-88	IgG glycosylation;
LUAD	cis	rs4601821	0.635	rs11214579	chr11:113208186	A/C	cg14159747	chr11:113255604	NA	-0.4	-7.41	-0.34	6.75e-13	Alcoholic chronic pancreatitis;
LUAD	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg08493051	chr2:3487164	NA	-0.46	-8.12	-0.37	5.06e-15	Neurofibrillary tangles;
LUAD	cis	rs7301016	1.000	rs10877855	chr12:62870510	C/G	cg11441379	chr12:63026424	NA	0.52	6.39	0.3	4.45e-10	IgG glycosylation;
LUAD	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg00495681	chr13:53174319	NA	0.49	8.79	0.39	3.89e-17	Lewy body disease;
LUAD	cis	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg07460842	chr6:66804631	NA	1.08	16.84	0.63	4.38e-49	Exhaled nitric oxide output;
LUAD	cis	rs470119	1.000	rs131801	chr22:50966634	G/T	cg12969734	chr22:50962224	SCO2	0.41	7.66	0.35	1.3e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg07936489	chr17:37558343	FBXL20	0.52	7.05	0.32	7.41e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs11971779	0.648	rs10230407	chr7:139103893	A/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.44e-10	Diisocyanate-induced asthma;
LUAD	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg00204512	chr16:28754710	NA	0.31	6.36	0.3	5.21e-10	Tonsillectomy;Mean corpuscular volume;
LUAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.48	6.5	0.3	2.23e-10	Renal function-related traits (BUN);
LUAD	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg14668632	chr7:2872130	GNA12	-0.73	-13.05	-0.54	5.82e-33	Height;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg18493069	chr6:108582623	SNX3	0.44	6.87	0.32	2.25e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs854765	0.624	rs12938501	chr17:17737258	A/C	cg04398451	chr17:18023971	MYO15A	0.64	11.3	0.48	4.58e-26	Total body bone mineral density;
LUAD	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg20476274	chr7:133979776	SLC35B4	0.79	15.42	0.6	7.22e-43	Mean platelet volume;
LUAD	cis	rs3857067	0.806	rs9996975	chr4:95101338	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.38	-6.64	-0.31	9.81e-11	QT interval;
LUAD	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg02269571	chr22:50332266	NA	0.59	8.91	0.4	1.49e-17	Schizophrenia;
LUAD	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg23795048	chr12:9217529	LOC144571	0.45	8.27	0.37	1.79e-15	Sjögren's syndrome;
LUAD	cis	rs4268898	0.552	rs12621083	chr2:24367540	C/T	cg06627628	chr2:24431161	ITSN2	0.43	7.45	0.34	5.26e-13	Asthma;
LUAD	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg17279839	chr7:150038598	RARRES2	0.44	7.37	0.34	9.13e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs2282300	0.739	rs1765133	chr11:30339400	C/T	cg06241208	chr11:30344200	C11orf46	-0.61	-7.8	-0.35	5.02e-14	Morning vs. evening chronotype;
LUAD	cis	rs73195822	0.614	rs56259130	chr12:111225650	C/T	cg12870014	chr12:110450643	ANKRD13A	0.58	6.52	0.3	2.06e-10	Itch intensity from mosquito bite;
LUAD	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg10645314	chr2:3704589	ALLC	-0.43	-7.62	-0.35	1.73e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs3815700	1.000	rs8100168	chr19:33093084	G/A	cg02997394	chr19:33096574	ANKRD27	0.6	7.07	0.33	6.49e-12	Eosinophilic esophagitis;
LUAD	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.11	-0.33	4.84e-12	Blood metabolite levels;
LUAD	cis	rs12216545	0.737	rs2103034	chr7:150237917	T/C	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.38	-0.3	4.64e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg00933542	chr6:150070202	PCMT1	0.43	8.71	0.39	6.9e-17	Lung cancer;
LUAD	trans	rs8002861	0.870	rs2875541	chr13:44417441	G/T	cg17145862	chr1:211918768	LPGAT1	0.74	17.12	0.64	2.69e-50	Leprosy;
LUAD	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg15181151	chr6:150070149	PCMT1	0.42	8.16	0.37	3.81e-15	Lung cancer;
LUAD	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg27490568	chr2:178487706	NA	0.42	7.05	0.32	7.32e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg05182265	chr7:156933206	UBE3C	-0.79	-17.03	-0.64	6.7e-50	Body mass index;
LUAD	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg11502198	chr6:26597334	ABT1	0.55	9.17	0.41	2.12e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs3790645	1.000	rs396997	chr1:26893067	T/C	cg23229016	chr1:26872525	RPS6KA1	0.21	6.91	0.32	1.79e-11	Glucose homeostasis traits;
LUAD	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs12545109	0.800	rs1913278	chr8:57403725	T/C	cg17761419	chr8:57350749	NA	-0.54	-8.0	-0.36	1.24e-14	Obesity-related traits;
LUAD	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg07741184	chr6:167504864	NA	0.3	7.29	0.33	1.53e-12	Crohn's disease;
LUAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg22907277	chr7:1156413	C7orf50	0.68	7.97	0.36	1.49e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs89107	0.688	rs283081	chr6:118605821	G/A	cg18833306	chr6:118973337	C6orf204	0.51	9.19	0.41	1.79e-18	Cardiac structure and function;
LUAD	cis	rs75920871	0.925	rs4936362	chr11:116952200	C/T	cg04087571	chr11:116723030	SIK3	-0.33	-6.7	-0.31	6.77e-11	Subjective well-being;
LUAD	cis	rs2932538	0.885	rs6691025	chr1:113177070	G/T	cg22162597	chr1:113214053	CAPZA1	-0.43	-6.42	-0.3	3.74e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-7.49	-0.34	3.97e-13	Coronary artery disease;
LUAD	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg07432352	chr17:45403706	C17orf57	-0.4	-7.71	-0.35	8.92e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2625529	0.526	rs10851850	chr15:72486509	A/G	cg16672083	chr15:72433130	SENP8	0.6	10.92	0.47	1.26e-24	Red blood cell count;
LUAD	cis	rs17532515	0.652	rs17005995	chr4:141390110	A/G	cg19520234	chr4:141391053	NA	0.42	6.45	0.3	2.99e-10	Select biomarker traits;
LUAD	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg13902645	chr11:5959945	NA	-0.52	-9.06	-0.4	4.85e-18	DNA methylation (variation);
LUAD	cis	rs1965732	0.504	rs10170315	chr2:3715832	G/A	cg19052272	chr2:3704530	ALLC	-0.4	-7.41	-0.34	6.71e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.59	-0.52	4.41e-31	Monocyte count;
LUAD	trans	rs7395662	1.000	rs7949554	chr11:48581992	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.12e-12	HDL cholesterol;
LUAD	cis	rs1451375	0.652	rs7803788	chr7:50625898	A/G	cg18232548	chr7:50535776	DDC	-0.49	-7.07	-0.33	6.26e-12	Malaria;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24853765	chr1:109584962	WDR47	-0.54	-6.56	-0.3	1.61e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg08798685	chr6:27730294	NA	-0.49	-7.41	-0.34	6.86e-13	Breast cancer;
LUAD	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg15445000	chr17:37608096	MED1	-0.44	-8.23	-0.37	2.36e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	9.69	0.43	3.45e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs73198271	0.530	rs11778326	chr8:8651566	T/G	cg01851573	chr8:8652454	MFHAS1	0.71	11.41	0.49	1.77e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg18806716	chr10:30721971	MAP3K8	-0.73	-15.71	-0.61	3.9e-44	Inflammatory bowel disease;
LUAD	cis	rs2274273	1.000	rs3742566	chr14:55595839	T/A	cg04306507	chr14:55594613	LGALS3	0.37	7.53	0.34	3.11e-13	Protein biomarker;
LUAD	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg22681709	chr2:178499509	PDE11A	-0.47	-7.81	-0.35	4.71e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10802521	chr3:52805072	NEK4	-0.6	-10.91	-0.47	1.39e-24	Bipolar disorder;
LUAD	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg22467129	chr15:76604101	ETFA	-0.47	-7.86	-0.36	3.23e-14	Blood metabolite levels;
LUAD	cis	rs10392	0.543	rs4810245	chr20:37549309	G/A	cg27552599	chr20:37590471	DHX35	0.39	6.57	0.3	1.5e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg15557168	chr22:42548783	NA	-0.46	-8.58	-0.39	1.76e-16	Cognitive function;
LUAD	cis	rs62400317	0.859	rs11964690	chr6:45258068	A/G	cg18551225	chr6:44695536	NA	-0.51	-8.06	-0.36	8.03e-15	Total body bone mineral density;
LUAD	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg19875535	chr5:140030758	IK	0.43	7.35	0.34	1.07e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9715521	0.557	rs13146381	chr4:59853842	T/C	cg11281224	chr4:60001000	NA	-0.5	-8.3	-0.37	1.38e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10911251	0.528	rs10911263	chr1:183115018	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.68	0.31	7.58e-11	Colorectal cancer;
LUAD	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg27129171	chr3:47204927	SETD2	0.4	6.46	0.3	2.94e-10	Colorectal cancer;
LUAD	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg10150615	chr22:24372951	LOC391322	-0.54	-8.74	-0.39	5.7e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs13315871	1.000	rs9860970	chr3:58353781	C/T	cg12435725	chr3:58293450	RPP14	-0.69	-7.53	-0.34	3.08e-13	Cholesterol, total;
LUAD	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.64	-8.37	-0.38	8.56e-16	Yeast infection;
LUAD	trans	rs57046232	0.508	rs2148814	chr20:6352589	G/A	cg21095983	chr6:86352623	SYNCRIP	0.43	6.81	0.31	3.3e-11	Colorectal cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24419099	chr11:47270565	NR1H3;ACP2	-0.5	-7.81	-0.36	4.71e-14	Height;
LUAD	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg24642844	chr7:1081250	C7orf50	-0.76	-8.69	-0.39	7.76e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg09085632	chr11:111637200	PPP2R1B	0.64	9.89	0.43	6.97e-21	Primary sclerosing cholangitis;
LUAD	cis	rs7523050	0.730	rs72984614	chr1:109435848	T/C	cg08274380	chr1:109419600	GPSM2	0.71	6.57	0.3	1.49e-10	Fat distribution (HIV);
LUAD	cis	rs490234	0.783	rs13284243	chr9:128381785	A/G	cg14078157	chr9:128172775	NA	-0.4	-6.96	-0.32	1.34e-11	Mean arterial pressure;
LUAD	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg19163074	chr7:65112434	INTS4L2	0.42	6.52	0.3	2.01e-10	Aortic root size;
LUAD	cis	rs2652834	1.000	rs4344684	chr15:63397318	C/T	cg25406657	chr15:63342033	TPM1	-0.44	-7.04	-0.32	8.06e-12	HDL cholesterol;
LUAD	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.88	12.82	0.53	5.16e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg14779329	chr11:130786720	SNX19	-0.47	-8.59	-0.39	1.66e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6087990	0.965	rs6058869	chr20:31348750	C/T	cg13636640	chr20:31349939	DNMT3B	0.85	16.22	0.62	2.31e-46	Ulcerative colitis;
LUAD	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg06697600	chr4:7070879	GRPEL1	-0.51	-8.46	-0.38	4.45e-16	Monocyte percentage of white cells;
LUAD	trans	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg20587970	chr11:113659929	NA	1.11	15.17	0.59	7.85e-42	Hip circumference adjusted for BMI;
LUAD	cis	rs13040088	1.000	rs6090159	chr20:61531351	C/G	cg23096297	chr20:61557774	DIDO1	0.71	10.13	0.44	9.6e-22	Menopause (age at onset);
LUAD	cis	rs11951515	0.933	rs7701642	chr5:43394778	T/G	cg01983248	chr5:43482804	C5orf28	-0.33	-6.44	-0.3	3.16e-10	Metabolite levels  (X-11787);
LUAD	cis	rs72928364	0.932	rs2245473	chr3:100616136	G/A	cg10123952	chr3:100791384	NA	-0.54	-6.69	-0.31	7.03e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs887829	0.641	rs7586110	chr2:234590527	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-9.76	-0.43	1.97e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg10589385	chr1:150898437	SETDB1	0.42	7.74	0.35	7.23e-14	Melanoma;
LUAD	trans	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg14917512	chr19:3094685	GNA11	-0.56	-6.59	-0.31	1.35e-10	Diabetic kidney disease;
LUAD	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg06002616	chr8:101225028	SPAG1	-0.41	-8.29	-0.37	1.55e-15	Atrioventricular conduction;
LUAD	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg20587970	chr11:113659929	NA	-1.4	-20.91	-0.71	3.32e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg07305463	chr2:136567211	LCT	-0.36	-6.73	-0.31	5.7e-11	Mosquito bite size;
LUAD	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg03690763	chr11:133734501	NA	-0.3	-7.12	-0.33	4.8e-12	Childhood ear infection;
LUAD	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg15448220	chr1:150897856	SETDB1	0.46	7.98	0.36	1.39e-14	Urate levels;
LUAD	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg04586622	chr2:25135609	ADCY3	0.37	8.46	0.38	4.56e-16	Body mass index;
LUAD	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg03474202	chr17:45855739	NA	-0.38	-9.17	-0.41	2.14e-18	IgG glycosylation;
LUAD	cis	rs7937890	0.559	rs2575852	chr11:14533368	G/A	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.15e-12	Mitochondrial DNA levels;
LUAD	cis	rs10504073	0.584	rs7823690	chr8:49943831	G/A	cg00325661	chr8:49890786	NA	0.45	10.28	0.45	2.92e-22	Blood metabolite ratios;
LUAD	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg00666640	chr1:248458726	OR2T12	0.33	7.83	0.36	3.92e-14	Common traits (Other);
LUAD	cis	rs9323205	0.798	rs2999391	chr14:51655109	A/G	cg23942311	chr14:51606299	NA	0.56	9.91	0.43	5.91e-21	Cancer;
LUAD	cis	rs1816752	0.935	rs3816219	chr13:25017133	C/T	cg02811702	chr13:24901961	NA	0.45	7.45	0.34	5.13e-13	Obesity-related traits;
LUAD	cis	rs3823572	0.525	rs6467514	chr7:133687618	G/T	cg03336402	chr7:133662267	EXOC4	-0.42	-7.28	-0.33	1.69e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs11811982	0.793	rs114398201	chr1:227493378	T/C	cg24860534	chr1:227506868	CDC42BPA	0.64	7.02	0.32	8.81e-12	Optic disc area;
LUAD	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg11189052	chr15:85197271	WDR73	0.63	8.45	0.38	4.63e-16	Schizophrenia;
LUAD	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg02527881	chr3:46936655	PTH1R	0.45	8.73	0.39	6.16e-17	Colorectal cancer;
LUAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13732083	chr21:47605072	C21orf56	0.58	10.06	0.44	1.71e-21	Testicular germ cell tumor;
LUAD	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg16615211	chr3:44902933	MIR564;TMEM42	0.39	7.39	0.34	8.15e-13	Depressive symptoms;
LUAD	cis	rs2282300	0.739	rs7926465	chr11:30333016	C/T	cg25418670	chr11:30344373	C11orf46	0.51	6.95	0.32	1.43e-11	Morning vs. evening chronotype;
LUAD	cis	rs9354308	0.933	rs10455586	chr6:66571498	T/C	cg07460842	chr6:66804631	NA	0.49	7.28	0.33	1.66e-12	Metabolite levels;
LUAD	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg08027265	chr7:2291960	NA	-0.45	-7.77	-0.35	6.05e-14	Schizophrenia;
LUAD	cis	rs8177876	0.749	rs2549891	chr16:81080366	T/C	cg08591886	chr16:81111003	C16orf46	0.62	6.41	0.3	3.96e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs72845660	1.000	rs72845660	chr10:104071973	C/G	cg20641465	chr10:103991465	PITX3	-0.5	-7.12	-0.33	4.64e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg25809561	chr17:30822961	MYO1D	0.69	13.72	0.56	1.03e-35	Schizophrenia;
LUAD	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg12311346	chr5:56204834	C5orf35	-0.93	-13.61	-0.55	3.03e-35	Initial pursuit acceleration;
LUAD	cis	rs7582720	1.000	rs72932566	chr2:203855342	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.64	0.42	5.27e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg02880119	chr16:3481970	NA	-0.54	-8.24	-0.37	2.18e-15	Body mass index (adult);
LUAD	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.37	7.84	0.36	3.58e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-8.2	-0.37	2.94e-15	Blood metabolite levels;
LUAD	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg03433033	chr1:76189801	ACADM	-0.5	-7.46	-0.34	4.83e-13	Daytime sleep phenotypes;
LUAD	cis	rs922692	0.744	rs12899147	chr15:79079512	A/G	cg12645284	chr15:79092878	ADAMTS7	0.43	7.31	0.33	1.36e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg14789911	chr21:47582049	C21orf56	-0.41	-6.76	-0.31	4.67e-11	Testicular germ cell tumor;
LUAD	cis	rs11716531	0.574	rs13075192	chr3:27279235	C/T	cg02860705	chr3:27208620	NA	0.65	10.03	0.44	2.27e-21	Diastolic blood pressure;
LUAD	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg21782813	chr7:2030301	MAD1L1	0.42	6.97	0.32	1.22e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7274811	0.681	rs291707	chr20:31964256	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.52	7.97	0.36	1.52e-14	Height;
LUAD	cis	rs354225	0.544	rs3796017	chr2:54807452	T/A	cg01766943	chr2:54829624	SPTBN1	0.39	7.4	0.34	7.65e-13	Schizophrenia;
LUAD	cis	rs10744422	1.000	rs897386	chr12:123341289	A/C	cg16953816	chr12:123349952	VPS37B	0.62	7.06	0.32	6.9e-12	Schizophrenia;
LUAD	cis	rs12681287	0.640	rs7461413	chr8:87470978	C/G	cg00550725	chr8:87521180	FAM82B	0.45	6.52	0.3	1.98e-10	Caudate activity during reward;
LUAD	cis	rs8067545	0.750	rs4924804	chr17:19991839	C/T	cg04132472	chr17:19861366	AKAP10	0.29	6.96	0.32	1.34e-11	Schizophrenia;
LUAD	cis	rs7017914	0.967	rs2639919	chr8:71875128	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.45	-0.3	3.11e-10	Bone mineral density;
LUAD	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg26343298	chr8:95960752	TP53INP1	-0.37	-7.88	-0.36	2.82e-14	Type 2 diabetes;
LUAD	cis	rs727505	0.954	rs17327014	chr7:124709349	C/T	cg23710748	chr7:124431027	NA	-0.43	-8.5	-0.38	3.27e-16	Lewy body disease;
LUAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.79	-0.35	5.06e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.75	-0.35	6.93e-14	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg15704280	chr7:45808275	SEPT13	0.91	17.57	0.65	2.68e-52	Coronary artery disease;
LUAD	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg04155289	chr7:94953770	PON1	-0.52	-6.9	-0.32	1.88e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs853679	0.546	rs35016036	chr6:28314880	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.56	6.56	0.3	1.62e-10	Depression;
LUAD	cis	rs7575217	0.670	rs796061	chr2:101727327	T/C	cg23907051	chr2:101730305	TBC1D8	-0.27	-6.46	-0.3	2.91e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg20848291	chr7:100343083	ZAN	-0.62	-9.86	-0.43	8.89e-21	Other erythrocyte phenotypes;
LUAD	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg03526776	chr6:41159608	TREML2	0.33	6.85	0.32	2.58e-11	Alzheimer's disease (late onset);
LUAD	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg27432699	chr2:27873401	GPN1	-0.43	-7.19	-0.33	2.94e-12	Total body bone mineral density;
LUAD	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs714027	1.000	rs9614090	chr22:30269907	T/A	cg11564601	chr22:30592435	NA	0.36	7.36	0.34	9.47e-13	Lymphocyte counts;
LUAD	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-7.8	-0.35	4.99e-14	Breast cancer;
LUAD	cis	rs9811920	0.660	rs11719468	chr3:99671848	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	7.25	0.33	2.02e-12	Axial length;
LUAD	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg05110241	chr16:68378359	PRMT7	-0.69	-7.83	-0.36	3.89e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs931127	0.547	rs3886859	chr11:65458310	C/T	cg27068330	chr11:65405492	SIPA1	-0.42	-6.83	-0.32	2.89e-11	Systemic lupus erythematosus;
LUAD	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.39	0.34	7.75e-13	Bipolar disorder;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19777771	chr17:30676863	ZNF207;MIR632	-0.51	-6.63	-0.31	1.01e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg24596788	chr1:163392923	NA	-0.36	-7.8	-0.35	4.87e-14	Motion sickness;
LUAD	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.77	0.31	4.21e-11	Rheumatoid arthritis;
LUAD	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg07636037	chr3:49044803	WDR6	-0.49	-8.16	-0.37	3.76e-15	Menarche (age at onset);
LUAD	cis	rs7707921	0.587	rs2407156	chr5:81636368	A/G	cg15871215	chr5:81402204	ATG10	-0.56	-7.91	-0.36	2.21e-14	Breast cancer;
LUAD	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	6.76	0.31	4.58e-11	Lung cancer in ever smokers;
LUAD	cis	rs2425143	1.000	rs117010355	chr20:34343442	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.96	-0.32	1.33e-11	Blood protein levels;
LUAD	cis	rs2455799	0.613	rs1969095	chr3:15733552	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-9.25	-0.41	1.14e-18	Mean platelet volume;
LUAD	cis	rs2795502	0.630	rs2282443	chr10:43474169	A/G	cg20628663	chr10:43360327	NA	0.62	7.1	0.33	5.47e-12	Blood protein levels;
LUAD	trans	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg00953403	chr17:74099816	EXOC7	0.46	7.31	0.33	1.37e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06028808	chr11:68637592	NA	0.5	8.35	0.38	9.53e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	12.72	0.53	1.26e-31	Prudent dietary pattern;
LUAD	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg26408565	chr15:76604113	ETFA	-0.56	-9.9	-0.43	6.23e-21	Blood metabolite levels;
LUAD	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg12311346	chr5:56204834	C5orf35	-0.46	-7.61	-0.35	1.74e-13	Coronary artery disease;
LUAD	cis	rs56283067	0.887	rs12197593	chr6:44740895	C/T	cg18551225	chr6:44695536	NA	-0.54	-9.22	-0.41	1.46e-18	Total body bone mineral density;
LUAD	cis	rs89107	0.575	rs10872167	chr6:118988362	C/T	cg21191810	chr6:118973309	C6orf204	-0.37	-6.95	-0.32	1.42e-11	Cardiac structure and function;
LUAD	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg12599982	chr1:44399894	ARTN	0.35	6.73	0.31	5.4e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6489785	0.551	rs532703	chr12:121273143	C/G	cg02419362	chr12:121203948	SPPL3	-0.34	-6.49	-0.3	2.46e-10	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4280164	0.551	rs3212242	chr14:24810401	C/T	cg22990158	chr14:24802150	ADCY4	0.54	8.25	0.37	2.01e-15	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs9549328	0.614	rs35872678	chr13:113617231	A/T	cg17524180	chr13:113633600	MCF2L	0.3	6.46	0.3	2.81e-10	Systolic blood pressure;
LUAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg27588902	chr6:42928151	GNMT	-0.36	-9.44	-0.42	2.52e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1997103	1.000	rs10263552	chr7:55404747	C/T	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg12568669	chr8:11666485	FDFT1	-0.24	-6.5	-0.3	2.2e-10	Mood instability;
LUAD	cis	rs476633	0.691	rs11858115	chr15:41542591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.64	-0.39	1.17e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06022373	chr22:39101656	GTPBP1	0.39	6.41	0.3	3.81e-10	Menopause (age at onset);
LUAD	trans	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.53	8.02	0.36	1.04e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg22676075	chr6:135203613	NA	-0.52	-9.31	-0.41	6.96e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg22676075	chr6:135203613	NA	0.39	7.26	0.33	1.9e-12	Red blood cell count;
LUAD	cis	rs9581857	0.579	rs77187836	chr13:27998646	C/A	cg22138327	chr13:27999177	GTF3A	0.94	11.33	0.48	3.72e-26	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg01689657	chr7:91764605	CYP51A1	0.34	8.49	0.38	3.54e-16	Breast cancer;
LUAD	cis	rs8077889	0.871	rs8065043	chr17:41900984	G/A	cg26893861	chr17:41843967	DUSP3	0.92	15.52	0.6	2.46e-43	Triglycerides;
LUAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg04025307	chr7:1156635	C7orf50	0.65	7.38	0.34	8.34e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7089973	0.872	rs10490908	chr10:116616162	T/C	cg25233709	chr10:116636983	FAM160B1	0.39	7.7	0.35	9.75e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-6.56	-0.3	1.53e-10	Height;
LUAD	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg05709478	chr1:6581295	PLEKHG5	0.55	6.89	0.32	2.08e-11	Body mass index;
LUAD	trans	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg20587970	chr11:113659929	NA	-0.9	-13.19	-0.54	1.56e-33	Hip circumference adjusted for BMI;
LUAD	cis	rs7671266	0.571	rs4643800	chr4:10407572	G/T	cg00071950	chr4:10020882	SLC2A9	-0.49	-7.62	-0.35	1.67e-13	Cardiovascular disease risk factors;
LUAD	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg04287289	chr16:89883240	FANCA	0.55	9.71	0.43	2.87e-20	Vitiligo;
LUAD	trans	rs783540	0.900	rs4778686	chr15:83310835	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.49	-8.19	-0.37	3.03e-15	Schizophrenia;
LUAD	cis	rs1950626	0.623	rs3742401	chr14:101453344	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.38	7.57	0.35	2.34e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs2115536	0.692	rs6495451	chr15:80164053	C/T	cg11839771	chr15:80205821	ST20	-0.38	-6.79	-0.31	3.89e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg13334819	chr7:99746414	C7orf59	0.66	10.57	0.46	2.57e-23	Coronary artery disease;
LUAD	cis	rs11048434	0.736	rs12823100	chr12:9108908	C/A	cg04155231	chr12:9217510	LOC144571	0.38	7.26	0.33	1.82e-12	Sjögren's syndrome;
LUAD	cis	rs9486719	1.000	rs2142652	chr6:96868504	A/C	cg06623918	chr6:96969491	KIAA0776	0.71	10.01	0.44	2.62e-21	Migraine;Coronary artery disease;
LUAD	cis	rs656900	0.647	rs1615963	chr15:80115826	C/T	cg02196730	chr15:80188777	MTHFS	-0.44	-7.36	-0.34	9.97e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs1832871	0.672	rs9457337	chr6:158726292	C/T	cg07165851	chr6:158734300	TULP4	0.7	10.6	0.46	1.87e-23	Height;
LUAD	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg25457927	chr22:38595422	NA	-0.53	-13.87	-0.56	2.48e-36	Cutaneous nevi;
LUAD	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg23029597	chr12:123009494	RSRC2	-0.49	-7.7	-0.35	9.8e-14	Body mass index;
LUAD	trans	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg18876405	chr7:65276391	NA	0.51	8.2	0.37	2.86e-15	Corneal structure;
LUAD	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg14092988	chr3:52407081	DNAH1	0.44	8.87	0.4	2.08e-17	Bipolar disorder;
LUAD	cis	rs62229266	0.771	rs62230790	chr21:37388911	A/G	cg08632701	chr21:37451849	NA	-0.46	-7.55	-0.34	2.62e-13	Mitral valve prolapse;
LUAD	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.48	-0.34	4.3e-13	Menarche (age at onset);
LUAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08219700	chr8:58056026	NA	0.6	8.3	0.37	1.45e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg02733842	chr7:1102375	C7orf50	-0.83	-11.94	-0.5	1.61e-28	Bronchopulmonary dysplasia;
LUAD	trans	rs4942242	0.663	rs9525812	chr13:44200099	T/C	cg19169023	chr15:41853346	TYRO3	-0.67	-11.72	-0.5	1.14e-27	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg02136620	chr5:178986620	RUFY1	0.45	7.56	0.34	2.56e-13	Lung cancer;
LUAD	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10203711	0.966	rs10187949	chr2:239558408	T/C	cg14580085	chr2:239553406	NA	0.4	8.43	0.38	5.42e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg15445000	chr17:37608096	MED1	0.45	8.3	0.37	1.36e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg01028140	chr2:1542097	TPO	-0.43	-7.09	-0.33	5.62e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs10979	1.000	rs9386036	chr6:143890709	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.3	-0.45	2.33e-22	Hypospadias;
LUAD	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg15462221	chr8:8086144	FLJ10661	0.44	6.75	0.31	4.92e-11	Neuroticism;
LUAD	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg06641503	chr3:48959341	ARIH2	-0.36	-6.76	-0.31	4.5e-11	Menarche (age at onset);
LUAD	cis	rs9473147	0.543	rs9296559	chr6:47452270	T/C	cg02130027	chr6:47444894	CD2AP	0.37	6.95	0.32	1.35e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg02423579	chr7:2872169	GNA12	-0.6	-9.99	-0.44	2.96e-21	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg02251663	chr11:14281053	SPON1	0.34	6.68	0.31	7.43e-11	Mitochondrial DNA levels;
LUAD	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg02551604	chr5:131831745	NA	-0.61	-10.08	-0.44	1.46e-21	Asthma (sex interaction);
LUAD	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.31	-8.38	-0.38	7.98e-16	Total body bone mineral density;
LUAD	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg04450456	chr4:17643702	FAM184B	0.39	7.95	0.36	1.71e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.47	0.52	1.27e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5769707	0.632	rs135872	chr22:50009300	T/C	cg05373962	chr22:49881684	NA	-0.47	-9.67	-0.43	3.92e-20	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.63	0.35	1.5700000000000001e-13	Morning vs. evening chronotype;
LUAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg08888203	chr3:10149979	C3orf24	0.74	12.97	0.53	1.25e-32	Alzheimer's disease;
LUAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg06064525	chr11:970664	AP2A2	-0.54	-11.06	-0.47	3.79e-25	Alzheimer's disease (late onset);
LUAD	cis	rs1371614	0.632	rs6718978	chr2:27161591	G/A	cg00617064	chr2:27272375	NA	-0.34	-6.62	-0.31	1.08e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs250677	0.524	rs40521	chr5:148439639	C/T	cg12140854	chr5:148520817	ABLIM3	0.51	8.7	0.39	7.62e-17	Breast cancer;
LUAD	cis	rs9972944	0.702	rs6416947	chr17:63763970	C/A	cg07283582	chr17:63770753	CCDC46	-0.5	-11.17	-0.48	1.48e-25	Total body bone mineral density;
LUAD	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg05791153	chr7:19748676	TWISTNB	0.84	9.44	0.42	2.45e-19	Thyroid stimulating hormone;
LUAD	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg23262073	chr20:60523788	NA	-0.45	-7.22	-0.33	2.5e-12	Body mass index;
LUAD	cis	rs1448094	0.802	rs7487591	chr12:86434112	T/C	cg02569458	chr12:86230093	RASSF9	0.36	6.94	0.32	1.52e-11	Major depressive disorder;
LUAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-9.98	-0.44	3.45e-21	Lymphocyte counts;
LUAD	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.44	-6.71	-0.31	6.29e-11	Breast cancer;
LUAD	cis	rs986417	0.786	rs1254273	chr14:60843581	C/A	cg27398547	chr14:60952738	C14orf39	-0.61	-7.3	-0.33	1.43e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs7301826	0.651	rs10734979	chr12:131288954	T/C	cg11011512	chr12:131303247	STX2	0.44	7.42	0.34	6.38e-13	Plasma plasminogen activator levels;
LUAD	cis	rs7809799	0.571	rs67934834	chr7:98899464	C/T	cg12290671	chr7:99195819	NA	-0.73	-6.54	-0.3	1.74e-10	Ulcerative colitis;
LUAD	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg27572855	chr1:25598939	RHD	0.53	11.39	0.48	2.12e-26	Erythrocyte sedimentation rate;
LUAD	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg03929089	chr4:120376271	NA	-0.52	-8.35	-0.38	9.8e-16	Coronary artery disease;
LUAD	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg22683308	chr4:1340831	KIAA1530	-0.43	-6.94	-0.32	1.44e-11	Longevity;
LUAD	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg14092571	chr14:90743983	NA	0.91	17.66	0.65	1.06e-52	Gut microbiota (bacterial taxa);
LUAD	trans	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg21582582	chr3:182698605	DCUN1D1	0.49	8.02	0.36	1.03e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg06740227	chr12:86229804	RASSF9	0.45	7.91	0.36	2.31e-14	Major depressive disorder;
LUAD	cis	rs6445967	0.530	rs3922711	chr3:58384243	A/C	cg23715586	chr3:58305044	RPP14	0.39	6.42	0.3	3.75e-10	Platelet count;
LUAD	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg04944784	chr2:26401820	FAM59B	-0.75	-10.45	-0.45	6.97e-23	Gut microbiome composition (summer);
LUAD	cis	rs698833	0.962	rs1067387	chr2:44642797	A/C	cg04920474	chr2:44395004	PPM1B	0.38	6.82	0.31	3.17e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs208520	0.674	rs207103	chr6:66795568	G/T	cg07460842	chr6:66804631	NA	-1.06	-16.63	-0.63	3.97e-48	Exhaled nitric oxide output;
LUAD	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs447921	0.724	rs346803	chr17:74381567	G/A	cg17201438	chr17:74438067	UBE2O	-0.62	-7.98	-0.36	1.36e-14	Mitochondrial DNA levels;
LUAD	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg00852783	chr1:26633632	UBXN11	0.41	7.24	0.33	2.07e-12	Obesity-related traits;
LUAD	trans	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs938554	0.784	rs13131257	chr4:9981889	T/C	cg11266682	chr4:10021025	SLC2A9	0.43	7.59	0.35	2.03e-13	Blood metabolite levels;
LUAD	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.49	-0.3	2.46e-10	Mood instability;
LUAD	trans	rs7867456	0.546	rs10757178	chr9:21046674	A/G	cg01583365	chr2:172778734	HAT1	-0.45	-7.26	-0.33	1.91e-12	Axial length;
LUAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg26354017	chr1:205819088	PM20D1	0.93	22.24	0.73	3.97e-73	Menarche (age at onset);
LUAD	cis	rs8099014	0.648	rs7241335	chr18:56130297	G/A	cg12907477	chr18:56117327	MIR122	0.5	6.85	0.32	2.61e-11	Platelet count;
LUAD	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg20891558	chr2:74357851	NA	0.98	17.37	0.65	2.2e-51	Gestational age at birth (maternal effect);
LUAD	cis	rs3936840	0.565	rs8006911	chr14:102975265	A/G	cg18135206	chr14:102964638	TECPR2	0.46	6.95	0.32	1.37e-11	Plateletcrit;
LUAD	cis	rs10911363	0.592	rs2702178	chr1:183452545	G/A	cg09173681	chr1:183549694	NCF2	0.53	9.93	0.43	4.87e-21	Systemic lupus erythematosus;
LUAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg19626725	chr5:178986131	RUFY1	0.5	8.59	0.39	1.64e-16	Lung cancer;
LUAD	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.57	-9.82	-0.43	1.2e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg07423050	chr13:99094983	FARP1	-0.54	-9.3	-0.41	7.72e-19	Longevity;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg22911074	chr5:6632973	NSUN2;SRD5A1	-0.38	-6.36	-0.3	5.33e-10	Schizophrenia;
LUAD	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg09033577	chr2:88485744	THNSL2	-0.6	-6.95	-0.32	1.36e-11	Plasma clusterin levels;
LUAD	cis	rs2535633	0.631	rs2710314	chr3:52969128	T/C	cg11645453	chr3:52864694	ITIH4	-0.4	-7.49	-0.34	4.07e-13	Body mass index;
LUAD	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg15017067	chr4:17643749	FAM184B	0.36	7.16	0.33	3.57e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-23.63	-0.75	2.46e-79	Height;
LUAD	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg08470875	chr2:26401718	FAM59B	0.61	8.48	0.38	3.92e-16	Gut microbiome composition (summer);
LUAD	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg05709478	chr1:6581295	PLEKHG5	-0.55	-7.34	-0.34	1.08e-12	Body mass index;
LUAD	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.15	-0.37	4.24e-15	Cannabis dependence symptom count;
LUAD	trans	rs853679	0.599	rs202906	chr6:28011652	C/T	cg06606381	chr12:133084897	FBRSL1	0.63	7.71	0.35	9.13e-14	Depression;
LUAD	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.62e-18	Life satisfaction;
LUAD	cis	rs887829	0.570	rs6753320	chr2:234595615	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.54	9.29	0.41	8.32e-19	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg11057378	chr10:81107060	PPIF	-0.39	-7.13	-0.33	4.44e-12	Height;
LUAD	cis	rs889398	0.771	rs11075732	chr16:69766038	A/G	cg00738113	chr16:70207722	CLEC18C	0.33	6.55	0.3	1.65e-10	Body mass index;
LUAD	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg26343298	chr8:95960752	TP53INP1	0.38	7.77	0.35	5.85e-14	Type 2 diabetes;
LUAD	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg11645453	chr3:52864694	ITIH4	-0.38	-7.26	-0.33	1.82e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs747782	0.528	rs16905753	chr11:48285906	C/T	cg03929089	chr4:120376271	NA	0.57	6.66	0.31	8.69e-11	Intraocular pressure;
LUAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.97	0.47	8.47e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4953076	0.573	rs13008237	chr2:44404902	A/G	cg04920474	chr2:44395004	PPM1B	0.55	8.54	0.38	2.43e-16	Height;
LUAD	cis	rs6988985	0.560	rs5301	chr8:143955273	T/C	cg10324643	chr8:143916377	GML	0.3	6.38	0.3	4.61e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg27661571	chr11:113659931	NA	-0.55	-6.73	-0.31	5.51e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg11062466	chr8:58055876	NA	0.45	6.47	0.3	2.79e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg02569458	chr12:86230093	RASSF9	0.46	8.31	0.37	1.27e-15	Major depressive disorder;
LUAD	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.03	-0.36	9.69e-15	Diabetic kidney disease;
LUAD	cis	rs10465746	0.967	rs28445286	chr1:84430483	A/G	cg10977910	chr1:84465055	TTLL7	0.5	8.07	0.37	7.53e-15	Obesity-related traits;
LUAD	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	9.58	0.42	8.1e-20	Axial length;
LUAD	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.75	0.35	6.68e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg10556349	chr10:835070	NA	-0.54	-6.95	-0.32	1.43e-11	Eosinophil percentage of granulocytes;
LUAD	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.36	-6.6	-0.31	1.2e-10	Caffeine consumption;
LUAD	trans	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg04565464	chr8:145669602	NFKBIL2	0.44	6.57	0.3	1.45e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs8099014	0.859	rs11152072	chr18:56098912	A/G	cg12907477	chr18:56117327	MIR122	0.51	8.33	0.38	1.12e-15	Platelet count;
LUAD	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.85	0.36	3.48e-14	Breast cancer;
LUAD	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg13010199	chr12:38710504	ALG10B	0.41	6.71	0.31	6.4e-11	Bladder cancer;
LUAD	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-7.65	-0.35	1.42e-13	Total cholesterol levels;
LUAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg23958373	chr8:599963	NA	1.07	10.52	0.46	3.9e-23	IgG glycosylation;
LUAD	cis	rs3733418	0.929	rs13120990	chr4:165905118	A/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-7.16	-0.33	3.49e-12	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.26e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.49	-0.34	3.99e-13	Type 2 diabetes;
LUAD	cis	rs2251260	0.685	rs1088673	chr14:62005648	A/G	cg23386212	chr14:62041363	NA	-0.47	-6.65	-0.31	9.08e-11	Yeast infection;
LUAD	cis	rs13082711	0.522	rs9310842	chr3:27369765	A/T	cg02860705	chr3:27208620	NA	-0.56	-9.66	-0.43	4.26e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.54	0.3	1.77e-10	Parkinson's disease;
LUAD	cis	rs62400317	0.859	rs10948204	chr6:45124300	T/C	cg18551225	chr6:44695536	NA	-0.55	-8.66	-0.39	1.02e-16	Total body bone mineral density;
LUAD	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg24818145	chr4:99064322	C4orf37	0.49	8.38	0.38	7.99e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6890695	1	rs6890695	chr5:130888424	C/G	cg06307176	chr5:131281290	NA	0.5	7.87	0.36	3.03e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4713675	0.604	rs791902	chr6:33702617	G/A	cg13859433	chr6:33739653	LEMD2	0.29	6.96	0.32	1.28e-11	Plateletcrit;
LUAD	trans	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.28	-0.41	9.19e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg01416388	chr22:39784598	NA	-0.52	-8.51	-0.38	3.09e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs2066819	0.892	rs117305040	chr12:56657888	A/G	cg26714650	chr12:56694279	CS	-0.84	-7.01	-0.32	9.24e-12	Psoriasis vulgaris;
LUAD	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg20019720	chr6:154832845	CNKSR3	0.65	12.84	0.53	4.41e-32	Lipoprotein (a) levels;
LUAD	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg06064525	chr11:970664	AP2A2	-0.45	-8.89	-0.4	1.79e-17	Alzheimer's disease (late onset);
LUAD	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.4	7.06	0.32	6.72e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1172822	0.828	rs11668309	chr19:55833460	A/G	cg04391588	chr19:55832610	TMEM150B	-0.35	-6.81	-0.31	3.27e-11	Menarche and menopause (age at onset);Menopause (age at onset);
LUAD	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.7	12.83	0.53	4.69e-32	Axial length;
LUAD	cis	rs657075	0.697	rs71583477	chr5:131686040	A/G	cg21138405	chr5:131827807	IRF1	0.52	6.46	0.3	2.93e-10	Rheumatoid arthritis;
LUAD	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.89	-0.32	1.99e-11	Lung cancer;
LUAD	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg23803603	chr1:2058230	PRKCZ	0.44	6.98	0.32	1.13e-11	Height;
LUAD	trans	rs7395662	1.000	rs4882021	chr11:48615966	G/C	cg00717180	chr2:96193071	NA	-0.4	-7.41	-0.34	7.11e-13	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.85	0.53	3.78e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7107174	1.000	rs4945267	chr11:78037933	G/A	cg02023728	chr11:77925099	USP35	0.44	6.73	0.31	5.63e-11	Testicular germ cell tumor;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09509543	chr4:119757682	SEC24D	-0.43	-7.3	-0.33	1.45e-12	Cancer;
LUAD	trans	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg18187862	chr3:45730750	SACM1L	0.5	7.83	0.36	4.07e-14	Primary sclerosing cholangitis;
LUAD	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.64e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04565464	chr8:145669602	NFKBIL2	0.44	6.75	0.31	4.79e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs912057	0.526	rs737449	chr6:6733729	A/G	cg06612196	chr6:6737390	NA	-0.64	-16.07	-0.62	1.04e-45	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.64	-0.31	9.82e-11	Prostate cancer;
LUAD	cis	rs11971779	0.616	rs7779314	chr7:139112696	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.85	0.32	2.66e-11	Diisocyanate-induced asthma;
LUAD	cis	rs169738	1	rs169738	chr6:33537546	A/G	cg07679836	chr6:33548423	BAK1	0.39	6.86	0.32	2.42e-11	Platelet count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg22852734	chr6:133119734	C6orf192	0.89	6.93	0.32	1.56e-11	Type 2 diabetes nephropathy;
LUAD	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg25985355	chr7:65971099	NA	0.38	7.15	0.33	3.83e-12	Aortic root size;
LUAD	cis	rs72634258	0.554	rs34305100	chr1:7913029	A/G	cg26816564	chr1:7831052	VAMP3	0.64	9.0	0.4	7.51e-18	Inflammatory bowel disease;
LUAD	cis	rs1497828	0.956	rs2810779	chr1:217542866	G/A	cg04411442	chr1:217543379	NA	0.35	6.39	0.3	4.37e-10	Dialysis-related mortality;
LUAD	cis	rs1595825	0.891	rs75373125	chr2:198657044	G/A	cg00982548	chr2:198649783	BOLL	-0.68	-8.9	-0.4	1.64e-17	Ulcerative colitis;
LUAD	cis	rs6138458	1.000	rs6106984	chr20:24977006	T/C	cg06937882	chr20:24974362	C20orf3	-0.34	-6.81	-0.31	3.26e-11	Blood protein levels;
LUAD	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg02221422	chr11:68192511	LRP5	0.38	6.44	0.3	3.18e-10	Total body bone mineral density;
LUAD	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.96	0.36	1.57e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg03388025	chr16:89894329	SPIRE2	-0.28	-6.56	-0.3	1.6e-10	Vitiligo;
LUAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08677398	chr8:58056175	NA	-0.47	-6.64	-0.31	9.41e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg05342682	chr7:94953680	PON1	0.45	6.59	0.31	1.3100000000000001e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg23933602	chr10:16859644	RSU1	0.96	20.7	0.71	3.08e-66	Platelet distribution width;
LUAD	cis	rs57590327	0.555	rs3755713	chr3:81811224	A/G	cg07356753	chr3:81810745	GBE1	-0.63	-10.0	-0.44	2.77e-21	Extraversion;
LUAD	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg05110241	chr16:68378359	PRMT7	-0.95	-10.82	-0.47	2.86e-24	Schizophrenia;
LUAD	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg25804541	chr17:80189381	SLC16A3	0.32	7.12	0.33	4.82e-12	Life satisfaction;
LUAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9902453	0.904	rs55866125	chr17:28312993	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	10.22	0.44	4.7e-22	Coffee consumption (cups per day);
LUAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24503407	chr1:205819492	PM20D1	0.91	20.94	0.71	2.58e-67	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17712092	chr4:129076599	LARP1B	0.84	15.85	0.61	9.83e-45	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08677398	chr8:58056175	NA	0.47	6.51	0.3	2.19e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2230307	0.536	rs7530361	chr1:100462860	T/C	cg20868668	chr1:100435035	SLC35A3	0.51	7.72	0.35	8.7e-14	Carotid intima media thickness;
LUAD	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11890956	chr21:40555474	PSMG1	0.82	14.46	0.58	8.46e-39	Cognitive function;
LUAD	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg25566285	chr7:158114605	PTPRN2	0.54	11.61	0.49	3.07e-27	Calcium levels;
LUAD	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18876405	chr7:65276391	NA	-0.45	-7.29	-0.33	1.54e-12	Aortic root size;
LUAD	trans	rs7395662	0.926	rs12288788	chr11:48686863	A/G	cg00717180	chr2:96193071	NA	-0.35	-6.49	-0.3	2.47e-10	HDL cholesterol;
LUAD	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg15445000	chr17:37608096	MED1	-0.44	-8.31	-0.37	1.36e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs7818345	1.000	rs7833166	chr8:19294634	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.3	6.67	0.31	7.84e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs8017423	0.935	rs7160304	chr14:90752908	G/T	cg14092571	chr14:90743983	NA	-0.46	-7.92	-0.36	2.08e-14	Mortality in heart failure;
LUAD	cis	rs2066819	1.000	rs77447765	chr12:56690662	G/A	cg26714650	chr12:56694279	CS	-0.86	-7.23	-0.33	2.25e-12	Psoriasis vulgaris;
LUAD	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.79	-0.5	6.2e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2354432	0.882	rs11576360	chr1:146740576	G/A	cg25205988	chr1:146714368	CHD1L	0.57	7.02	0.32	9.01e-12	Mitochondrial DNA levels;
LUAD	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg18200150	chr17:30822561	MYO1D	0.74	16.29	0.62	1.21e-46	Schizophrenia;
LUAD	cis	rs11048434	0.736	rs7957321	chr12:9120154	C/T	cg13575925	chr12:9217583	LOC144571	0.36	6.7	0.31	6.51e-11	Sjögren's syndrome;
LUAD	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg20503657	chr10:835505	NA	0.61	8.44	0.38	5.1e-16	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs2297797	0.660	rs3820667	chr1:109968410	A/C	cg08367326	chr1:110052010	AMIGO1	0.38	6.53	0.3	1.92e-10	Cognitive function;
LUAD	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg20628663	chr10:43360327	NA	0.69	11.07	0.47	3.37e-25	Blood protein levels;
LUAD	cis	rs2455601	0.638	rs2742485	chr11:8986787	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.47	-8.29	-0.37	1.52e-15	Schizophrenia;
LUAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg27532560	chr4:187881888	NA	-0.36	-6.87	-0.32	2.35e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs698833	0.852	rs698761	chr2:44547574	A/G	cg04920474	chr2:44395004	PPM1B	-0.42	-7.59	-0.35	2.01e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg14343924	chr8:8086146	FLJ10661	0.43	7.06	0.32	6.92e-12	Joint mobility (Beighton score);
LUAD	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg09998033	chr7:158218633	PTPRN2	-0.46	-8.16	-0.37	3.92e-15	Obesity-related traits;
LUAD	cis	rs13064411	0.696	rs1486894	chr3:113211513	G/A	cg18753928	chr3:113234510	CCDC52	-0.73	-12.43	-0.52	1.82e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg27411982	chr8:10470053	RP1L1	0.38	7.02	0.32	8.71e-12	Retinal vascular caliber;
LUAD	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg14779329	chr11:130786720	SNX19	0.39	6.83	0.32	2.93e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg22166914	chr1:53195759	ZYG11B	-0.44	-7.47	-0.34	4.55e-13	Monocyte count;
LUAD	cis	rs12368653	0.544	rs11172304	chr12:58097862	T/C	cg12615879	chr12:58013172	SLC26A10	0.4	7.81	0.36	4.49e-14	Multiple sclerosis;
LUAD	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg00316803	chr15:76480434	C15orf27	0.39	6.4	0.3	4.19e-10	Blood metabolite levels;
LUAD	cis	rs7830933	0.780	rs11986562	chr8:23609098	T/C	cg04349084	chr8:23602677	NA	0.48	7.0	0.32	1.03e-11	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
LUAD	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg24675658	chr1:53192096	ZYG11B	-0.41	-6.8	-0.31	3.65e-11	Monocyte count;
LUAD	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg24112000	chr20:60950667	NA	-0.73	-10.49	-0.45	4.93e-23	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg17325912	chr2:97520089	ANKRD39	-0.4	-7.05	-0.32	7.33e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs8028313	0.731	rs13380201	chr15:67973665	A/G	cg24579218	chr15:68104479	NA	-0.49	-8.44	-0.38	4.94e-16	Obesity;
LUAD	cis	rs12681288	0.676	rs6983981	chr8:1016011	A/C	cg15309053	chr8:964076	NA	0.46	9.8	0.43	1.47e-20	Schizophrenia;
LUAD	cis	rs2386661	0.826	rs1132293	chr10:5681038	C/T	cg26603656	chr10:5671107	NA	0.41	7.13	0.33	4.29e-12	Breast cancer;
LUAD	cis	rs7107174	1.000	rs901104	chr11:77930499	C/T	cg19901956	chr11:77921274	USP35	-0.52	-6.44	-0.3	3.33e-10	Testicular germ cell tumor;
LUAD	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg02931644	chr1:25747376	RHCE	-0.44	-9.18	-0.41	1.89e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg11070056	chr1:107600091	PRMT6	0.54	8.95	0.4	1.09e-17	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs909002	0.849	rs4949449	chr1:32088534	T/G	cg13919466	chr1:32135498	COL16A1	-0.35	-8.23	-0.37	2.39e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03517284	chr6:25882590	NA	0.56	9.17	0.41	2.15e-18	Blood metabolite levels;
LUAD	cis	rs2580764	0.565	rs7562292	chr2:55230219	C/T	cg09592903	chr2:55203963	RTN4	-0.46	-10.65	-0.46	1.24e-23	Mean platelet volume;
LUAD	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg23262073	chr20:60523788	NA	0.69	10.44	0.45	7.19e-23	Obesity-related traits;
LUAD	cis	rs9649213	0.727	rs12113294	chr7:97910637	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.52	8.57	0.38	1.95e-16	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.47	-9.78	-0.43	1.69e-20	Monocyte percentage of white cells;
LUAD	cis	rs1564271	0.961	rs2927921	chr10:27016001	A/C	cg13837822	chr10:26931731	LOC731789	0.38	7.22	0.33	2.38e-12	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUAD	cis	rs600231	0.665	rs2105608	chr11:65228618	T/A	cg17120908	chr11:65337727	SSSCA1	-0.59	-9.0	-0.4	7.65e-18	Bone mineral density;
LUAD	cis	rs9878978	1.000	rs35941126	chr3:2477382	A/G	cg21928760	chr3:2462534	CNTN4	-0.35	-6.95	-0.32	1.39e-11	Blood pressure (smoking interaction);
LUAD	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg18230493	chr5:56204884	C5orf35	-0.46	-7.68	-0.35	1.11e-13	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-8.42	-0.38	5.91e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg08885076	chr2:99613938	TSGA10	0.4	7.55	0.34	2.79e-13	Chronic sinus infection;
LUAD	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg09367891	chr1:107599246	PRMT6	0.53	8.49	0.38	3.48e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg03037974	chr15:76606532	NA	0.39	8.68	0.39	8.68e-17	Blood metabolite levels;
LUAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg00634984	chr7:65235879	NA	-0.53	-8.77	-0.39	4.52e-17	Calcium levels;
LUAD	cis	rs11255291	1.000	rs11255291	chr10:7736904	C/T	cg13340899	chr10:7670827	ITIH5	0.38	6.58	0.3	1.43e-10	Ovarian reserve;
LUAD	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg26384229	chr12:38710491	ALG10B	0.49	7.97	0.36	1.53e-14	Bladder cancer;
LUAD	cis	rs4523957	0.620	rs9892754	chr17:2084565	G/T	cg16513277	chr17:2031491	SMG6	-0.95	-18.95	-0.68	2.08e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	9.76	0.43	2.01e-20	Total body bone mineral density;
LUAD	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-8.16	-0.37	3.86e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs986417	0.818	rs8008804	chr14:61082357	A/T	cg27398547	chr14:60952738	C14orf39	0.65	7.18	0.33	3.15e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg00634984	chr7:65235879	NA	0.5	6.71	0.31	6.12e-11	Aortic root size;
LUAD	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg25173405	chr17:45401733	C17orf57	-0.41	-6.9	-0.32	1.93e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2017305	0.749	rs7071782	chr10:70790763	G/C	cg01024728	chr10:70782572	NA	0.65	6.61	0.31	1.17e-10	Depression (quantitative trait);
LUAD	cis	rs72928364	1.000	rs62275200	chr3:100696631	C/T	cg10123952	chr3:100791384	NA	0.64	7.47	0.34	4.74e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg17264618	chr3:40429014	ENTPD3	-0.4	-8.94	-0.4	1.22e-17	Renal cell carcinoma;
LUAD	trans	rs3812049	0.784	rs2250127	chr5:127388844	G/A	cg16011800	chr17:1958478	HIC1	0.58	7.92	0.36	2.09e-14	Lymphocyte counts;Red cell distribution width;
LUAD	trans	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.06	16.87	0.63	3.53e-49	Exhaled nitric oxide output;
LUAD	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg00898013	chr13:113819073	PROZ	-0.68	-12.2	-0.51	1.55e-29	Platelet distribution width;
LUAD	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg17863274	chr19:49399704	TULP2	-0.64	-9.81	-0.43	1.35e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg06636551	chr8:101224915	SPAG1	-0.37	-6.68	-0.31	7.67e-11	Atrioventricular conduction;
LUAD	cis	rs2554380	0.800	rs8032414	chr15:84395969	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.49	-7.59	-0.35	2.09e-13	Height;
LUAD	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.92	0.32	1.66e-11	Schizophrenia;
LUAD	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg08027265	chr7:2291960	NA	-0.49	-8.6	-0.39	1.56e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg03354898	chr7:1950403	MAD1L1	-0.38	-6.95	-0.32	1.36e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs10899021	0.920	rs11236172	chr11:74330888	G/A	cg25880958	chr11:74394337	NA	-0.62	-8.42	-0.38	5.74e-16	Response to metformin (IC50);
LUAD	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.75	-0.31	5.03e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg17724175	chr1:150552817	MCL1	0.32	7.41	0.34	7.06e-13	Melanoma;
LUAD	cis	rs1443512	0.947	rs4759309	chr12:54342786	G/A	cg17410650	chr12:54324560	NA	-0.44	-8.18	-0.37	3.24e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	trans	rs111706465	1	rs111706465	chr2:239452382	A/C	cg01134436	chr17:81009848	B3GNTL1	0.79	8.63	0.39	1.29e-16	Morning vs. evening chronotype;
LUAD	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg07636037	chr3:49044803	WDR6	0.64	12.52	0.52	8.46e-31	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.87e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.95	-0.36	1.76e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg24818145	chr4:99064322	C4orf37	-0.48	-8.17	-0.37	3.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg05872129	chr22:39784769	NA	-0.77	-13.86	-0.56	2.74e-36	Intelligence (multi-trait analysis);
LUAD	cis	rs6960043	0.738	rs7798360	chr7:15055972	A/G	cg19272540	chr7:15055459	NA	0.41	9.1	0.4	3.56e-18	Type 2 diabetes;
LUAD	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg16414030	chr3:133502952	NA	-0.45	-8.17	-0.37	3.48e-15	Iron status biomarkers;
LUAD	cis	rs1595825	1.000	rs79508374	chr2:198864568	G/A	cg00982548	chr2:198649783	BOLL	-0.58	-8.39	-0.38	7.24e-16	Ulcerative colitis;
LUAD	trans	rs3857536	0.813	rs1029400	chr6:66952385	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.52	-0.3	2.04e-10	Blood trace element (Cu levels);
LUAD	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg15468180	chr1:107600409	PRMT6	-0.46	-7.78	-0.35	5.44e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg04816434	chr15:22945077	CYFIP1	-0.41	-6.66	-0.31	8.76e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg08888203	chr3:10149979	C3orf24	0.75	13.13	0.54	2.98e-33	Alzheimer's disease;
LUAD	cis	rs4588572	0.601	rs4305631	chr5:77668698	G/T	cg11547950	chr5:77652471	NA	0.78	11.81	0.5	4.99e-28	Triglycerides;
LUAD	cis	rs1497828	0.956	rs2815230	chr1:217536114	T/C	cg04411442	chr1:217543379	NA	-0.38	-6.95	-0.32	1.35e-11	Dialysis-related mortality;
LUAD	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	8.04	0.36	9.06e-15	Parkinson's disease;
LUAD	cis	rs3815700	1.000	rs3815700	chr19:33093252	T/C	cg02997394	chr19:33096574	ANKRD27	0.66	8.7	0.39	7.31e-17	Eosinophilic esophagitis;
LUAD	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.06	0.36	7.79e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.73	11.87	0.5	3.02e-28	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg06877462	chr1:205807181	PM20D1	0.38	7.21	0.33	2.61e-12	Menarche (age at onset);
LUAD	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg09455208	chr3:40491958	NA	-0.59	-12.89	-0.53	2.74e-32	Renal cell carcinoma;
LUAD	cis	rs7172809	0.524	rs4886857	chr15:77576567	T/C	cg11865553	chr15:77376250	NA	-0.39	-6.43	-0.3	3.49e-10	Glucose homeostasis traits;
LUAD	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg04450456	chr4:17643702	FAM184B	0.37	7.36	0.34	9.55e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs853679	0.546	rs175597	chr6:27810626	T/C	cg01620082	chr3:125678407	NA	-0.81	-8.76	-0.39	4.58e-17	Depression;
LUAD	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.82	-0.31	3.13e-11	Breast cancer;
LUAD	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg18252515	chr7:66147081	NA	-0.61	-6.79	-0.31	3.86e-11	Diabetic kidney disease;
LUAD	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg12311346	chr5:56204834	C5orf35	-0.92	-13.64	-0.55	2.32e-35	Initial pursuit acceleration;
LUAD	cis	rs2735413	0.846	rs12923290	chr16:78079956	A/G	cg04733911	chr16:78082701	NA	-0.35	-8.34	-0.38	1.02e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.62	0.35	1.71e-13	Platelet count;
LUAD	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg03676636	chr4:99064102	C4orf37	-0.38	-9.68	-0.43	3.69e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg22508957	chr16:3507546	NAT15	-0.39	-6.61	-0.31	1.15e-10	Body mass index (adult);
LUAD	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg00814883	chr7:100076585	TSC22D4	0.76	10.33	0.45	1.89e-22	Platelet count;
LUAD	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.12	0.33	4.7e-12	Motion sickness;
LUAD	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.5	-0.38	3.4e-16	Height;
LUAD	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.71	-0.31	6.37e-11	Personality dimensions;
LUAD	trans	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.71	-0.35	8.88e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs783540	0.681	rs1259178	chr15:83271876	T/C	cg16105309	chr15:79090380	ADAMTS7	0.41	7.4	0.34	7.34e-13	Schizophrenia;
LUAD	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg00074818	chr8:8560427	CLDN23	0.65	10.09	0.44	1.33e-21	Obesity-related traits;
LUAD	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08677398	chr8:58056175	NA	0.49	6.57	0.3	1.5e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6894268	0.722	rs6422331	chr5:179002951	G/T	cg26135573	chr5:179059668	NA	0.62	8.58	0.39	1.81e-16	Eating disorders;
LUAD	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg05697835	chr1:2722811	NA	0.31	6.54	0.3	1.75e-10	Ulcerative colitis;
LUAD	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg21153622	chr11:89784906	NA	-0.33	-6.57	-0.3	1.46e-10	Height;
LUAD	trans	rs11165623	0.765	rs11807955	chr1:96891623	C/T	cg10631902	chr5:14652156	NA	-0.64	-12.38	-0.52	2.88e-30	Hip circumference;Waist circumference;
LUAD	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg13126279	chr21:47581558	C21orf56	-0.44	-7.56	-0.35	2.46e-13	Testicular germ cell tumor;
LUAD	cis	rs1595825	0.891	rs73056859	chr2:198801720	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-7.26	-0.33	1.86e-12	Ulcerative colitis;
LUAD	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.39	0.34	7.87e-13	Hypertriglyceridemia;
LUAD	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg03714773	chr7:91764589	CYP51A1	0.31	7.27	0.33	1.75e-12	Breast cancer;
LUAD	cis	rs1997103	1.000	rs6948112	chr7:55411302	G/A	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg18827107	chr12:86230957	RASSF9	-0.54	-9.73	-0.43	2.42e-20	Major depressive disorder;
LUAD	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg03526776	chr6:41159608	TREML2	0.35	7.31	0.33	1.33e-12	Alzheimer's disease (late onset);
LUAD	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg25985355	chr7:65971099	NA	-0.54	-6.64	-0.31	9.45e-11	Diabetic kidney disease;
LUAD	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg18827107	chr12:86230957	RASSF9	-0.48	-8.43	-0.38	5.46e-16	Major depressive disorder;
LUAD	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg07930552	chr6:133119739	C6orf192	0.66	7.97	0.36	1.49e-14	Type 2 diabetes nephropathy;
LUAD	trans	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg11693508	chr17:37793320	STARD3	0.6	7.63	0.35	1.53e-13	Neuroticism;
LUAD	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg15704280	chr7:45808275	SEPT13	-1.05	-23.63	-0.75	2.46e-79	Height;
LUAD	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg13768953	chr17:7114967	DLG4	-0.39	-7.17	-0.33	3.28e-12	Diastolic blood pressure;
LUAD	trans	rs853679	0.546	rs36092177	chr6:28357807	C/T	cg06606381	chr12:133084897	FBRSL1	-1.23	-10.69	-0.46	9.35e-24	Depression;
LUAD	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.43	-7.06	-0.32	6.76e-12	Tonsillectomy;
LUAD	trans	rs9951602	0.541	rs12454297	chr18:76654445	A/G	cg02800362	chr5:177631904	HNRNPAB	0.91	14.57	0.58	3.06e-39	Obesity-related traits;
LUAD	cis	rs3784262	0.740	rs33960206	chr15:58288731	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.41	-8.18	-0.37	3.4e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg01191920	chr7:158217561	PTPRN2	0.61	12.99	0.53	1.01e-32	Obesity-related traits;
LUAD	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg17644776	chr2:200775616	C2orf69	0.56	9.04	0.4	5.48e-18	Schizophrenia;
LUAD	cis	rs7625357	0.964	rs7652404	chr3:169352458	A/G	cg14572252	chr3:169309425	MECOM	-0.38	-6.69	-0.31	7e-11	Childhood and early adolescence aggressive behavior;
LUAD	cis	rs7539409	0.651	rs970457	chr1:84296540	C/T	cg10977910	chr1:84465055	TTLL7	0.68	8.09	0.37	6.41e-15	Alzheimer's disease;
LUAD	cis	rs2235649	0.833	rs7190337	chr16:1850469	A/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.47	-7.85	-0.36	3.57e-14	Blood metabolite levels;
LUAD	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg14530993	chr4:882597	GAK	0.8	7.92	0.36	2.06e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.89e-14	Depression;
LUAD	cis	rs13040088	0.580	rs11905041	chr20:61563408	C/T	cg23096297	chr20:61557774	DIDO1	0.63	8.89	0.4	1.79e-17	Menopause (age at onset);
LUAD	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg22529645	chr1:3704559	LRRC47	0.57	10.68	0.46	1.02e-23	Red cell distribution width;
LUAD	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.55	0.42	1.04e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg03676636	chr4:99064102	C4orf37	0.37	9.46	0.42	2.13e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg08742575	chr21:47604166	C21orf56	0.45	7.43	0.34	5.93e-13	Testicular germ cell tumor;
LUAD	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg00316803	chr15:76480434	C15orf27	0.38	6.46	0.3	2.94e-10	Blood metabolite levels;
LUAD	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-7.7	-0.35	9.48e-14	Fear of minor pain;
LUAD	cis	rs4899554	0.640	rs4899555	chr14:75719834	T/C	cg18117039	chr14:75741733	NA	0.65	9.23	0.41	1.34e-18	Inflammatory bowel disease;
LUAD	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-7.92	-0.36	2.07e-14	Neutrophil percentage of white cells;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg11601748	chr5:443197	C5orf55;EXOC3	-0.4	-6.83	-0.32	2.93e-11	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.65	0.31	8.98e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg13319975	chr6:146136371	FBXO30	0.56	9.59	0.42	7.71e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs959260	0.588	rs7219	chr17:73315368	A/G	cg14668889	chr17:73230827	NUP85	0.54	8.94	0.4	1.19e-17	Systemic lupus erythematosus;
LUAD	cis	rs10465746	0.967	rs6576956	chr1:84343885	T/G	cg10977910	chr1:84465055	TTLL7	0.5	8.19	0.37	3.07e-15	Obesity-related traits;
LUAD	cis	rs7666738	0.657	rs13102002	chr4:98617794	T/C	cg24818145	chr4:99064322	C4orf37	0.51	7.42	0.34	6.45e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg14530993	chr4:882597	GAK	0.69	6.63	0.31	1.04e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg00745463	chr17:30367425	LRRC37B	-1.06	-12.59	-0.52	4.22e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg18827107	chr12:86230957	RASSF9	-0.62	-10.94	-0.47	1.03e-24	Major depressive disorder;
LUAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg08132940	chr7:1081526	C7orf50	-0.78	-10.56	-0.46	2.64e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg16797656	chr11:68205561	LRP5	0.47	9.23	0.41	1.31e-18	Total body bone mineral density;
LUAD	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg21153622	chr11:89784906	NA	0.33	6.51	0.3	2.1e-10	Coronary artery disease;
LUAD	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.3	-6.89	-0.32	1.99e-11	Dupuytren's disease;
LUAD	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg26597838	chr10:835615	NA	1.31	20.91	0.71	3.5e-67	Eosinophil percentage of granulocytes;
LUAD	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg09509183	chr1:209979624	IRF6	0.58	6.71	0.31	6.1e-11	Coronary artery disease;
LUAD	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg20108693	chr8:143823809	SLURP1	0.33	7.82	0.36	4.15e-14	Urinary tract infection frequency;
LUAD	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg11189052	chr15:85197271	WDR73	-0.78	-13.58	-0.55	4.25e-35	P wave terminal force;
LUAD	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg15226275	chr6:116381976	FRK	0.24	7.79	0.35	5.37e-14	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg21252483	chr19:49399788	TULP2	-0.89	-14.78	-0.58	3.62e-40	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9393692	0.620	rs9393696	chr6:26291591	T/C	cg13736514	chr6:26305472	NA	-0.52	-8.99	-0.4	8.65e-18	Educational attainment;
LUAD	cis	rs9902453	0.765	rs3102560	chr17:28029938	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.3	0.45	2.46e-22	Coffee consumption (cups per day);
LUAD	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg05110241	chr16:68378359	PRMT7	-0.86	-8.96	-0.4	1.08e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-7.25	-0.33	1.99e-12	Platelet count;
LUAD	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg05665937	chr4:1216051	CTBP1	-0.43	-7.72	-0.35	8.71e-14	Obesity-related traits;
LUAD	cis	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg21775007	chr8:11205619	TDH	0.37	6.5	0.3	2.32e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.19	-0.37	3.14e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1003719	0.680	rs3737540	chr21:38523266	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.38	-0.38	7.71e-16	Eye color traits;
LUAD	cis	rs9902453	0.845	rs3115101	chr17:28041627	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.37	0.41	4.35e-19	Coffee consumption (cups per day);
LUAD	cis	rs4891159	0.790	rs10514217	chr18:74144939	A/G	cg24786174	chr18:74118243	ZNF516	-0.7	-13.51	-0.55	8.1e-35	Longevity;
LUAD	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	8.3	0.37	1.39e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	9.97e-11	Diabetic kidney disease;
LUAD	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg02696790	chr15:75250997	RPP25	0.37	7.17	0.33	3.48e-12	Breast cancer;
LUAD	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg01689657	chr7:91764605	CYP51A1	0.35	8.8	0.39	3.4e-17	Breast cancer;
LUAD	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg25566285	chr7:158114605	PTPRN2	0.54	11.61	0.49	3.07e-27	Calcium levels;
LUAD	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg08859206	chr1:53392774	SCP2	-0.66	-12.06	-0.51	5.29e-29	Monocyte count;
LUAD	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg08999081	chr20:33150536	PIGU	0.54	11.44	0.49	1.38e-26	Coronary artery disease;
LUAD	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.18	0.33	3.08e-12	Menopause (age at onset);
LUAD	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg13390004	chr1:15929781	NA	0.46	8.13	0.37	4.71e-15	Systolic blood pressure;
LUAD	cis	rs7512552	0.839	rs1694362	chr1:150366963	T/A	cg15654264	chr1:150340011	RPRD2	0.61	11.61	0.49	3e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg26818010	chr10:134567672	INPP5A	-0.97	-15.56	-0.6	1.65e-43	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg03467027	chr4:99064603	C4orf37	0.4	6.48	0.3	2.57e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12079745	0.793	rs12089602	chr1:169180898	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-1.06	-7.74	-0.35	7.54e-14	QT interval;
LUAD	cis	rs8112211	1.000	rs7253960	chr19:38814725	C/T	cg14299480	chr19:38876666	GGN	-0.45	-7.81	-0.36	4.43e-14	Blood protein levels;
LUAD	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.84	-0.32	2.79e-11	Crohn's disease;
LUAD	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg01475377	chr6:109611718	NA	-0.49	-8.89	-0.4	1.77e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-15.36	-0.6	1.3e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg13319975	chr6:146136371	FBXO30	-0.59	-9.92	-0.43	5.61e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4638749	0.677	rs6755598	chr2:108827674	G/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.38	-0.34	8.2e-13	Blood pressure;
LUAD	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg18180107	chr4:99064573	C4orf37	0.43	7.01	0.32	9.59e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg17178900	chr1:205818956	PM20D1	0.74	15.31	0.6	2.09e-42	Menarche (age at onset);
LUAD	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg00933542	chr6:150070202	PCMT1	0.46	9.98	0.44	3.22e-21	Lung cancer;
LUAD	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg13319975	chr6:146136371	FBXO30	-0.62	-10.7	-0.46	8.44e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3784262	0.935	rs4646636	chr15:58251034	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.43	-8.59	-0.39	1.67e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs394563	0.591	rs6570963	chr6:149691355	T/G	cg03678062	chr6:149772716	ZC3H12D	0.29	6.37	0.3	4.96e-10	Dupuytren's disease;
LUAD	cis	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg06609049	chr19:2785107	THOP1	0.72	12.47	0.52	1.27e-30	Total cholesterol levels;
LUAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg18621852	chr3:10150065	C3orf24	0.46	7.17	0.33	3.44e-12	Alzheimer's disease;
LUAD	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg09835421	chr16:68378352	PRMT7	-0.74	-8.48	-0.38	3.69e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg03609598	chr5:56110824	MAP3K1	-0.66	-9.04	-0.4	5.85e-18	Initial pursuit acceleration;
LUAD	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.67	-8.64	-0.39	1.16e-16	Yeast infection;
LUAD	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg23283495	chr1:209979779	IRF6	0.72	10.6	0.46	1.96e-23	Cleft lip with or without cleft palate;
LUAD	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg09640425	chr7:158790006	NA	0.55	9.57	0.42	8.97e-20	Facial morphology (factor 20);
LUAD	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg03233332	chr7:66118400	NA	-0.47	-6.8	-0.31	3.49e-11	Aortic root size;
LUAD	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg22676075	chr6:135203613	NA	0.42	7.75	0.35	7.07e-14	Red blood cell count;
LUAD	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg10518543	chr12:38710700	ALG10B	0.44	7.52	0.34	3.32e-13	Heart rate;
LUAD	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg04545296	chr12:48745243	ZNF641	0.39	10.0	0.44	2.92e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg18811423	chr2:55921094	PNPT1	0.48	7.81	0.36	4.54e-14	Metabolic syndrome;
LUAD	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg16680214	chr1:154839983	KCNN3	-0.63	-13.26	-0.54	8.05e-34	Prostate cancer;
LUAD	cis	rs2262909	0.962	rs409439	chr19:22227432	C/T	cg11619707	chr19:22235551	ZNF257	-0.48	-7.4	-0.34	7.34e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.11	-0.37	5.52e-15	Diabetic kidney disease;
LUAD	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg07570687	chr10:102243282	WNT8B	0.46	6.7	0.31	6.48e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-19.75	-0.69	5.55e-62	Height;
LUAD	cis	rs4764487	0.760	rs733700	chr12:6337974	A/G	cg08284733	chr12:6341482	CD9	0.41	7.33	0.34	1.19e-12	Mean platelet volume;
LUAD	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg11822812	chr5:140052017	DND1	-0.41	-7.51	-0.34	3.49e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg06387496	chr7:2775674	GNA12	-0.39	-6.57	-0.3	1.46e-10	Height;
LUAD	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18876405	chr7:65276391	NA	0.57	9.43	0.42	2.73e-19	Aortic root size;
LUAD	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.4	-6.79	-0.31	3.71e-11	Rheumatoid arthritis;
LUAD	cis	rs2625529	0.652	rs8028115	chr15:72339503	C/T	cg16672083	chr15:72433130	SENP8	0.61	11.13	0.48	2.11e-25	Red blood cell count;
LUAD	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg22166914	chr1:53195759	ZYG11B	0.45	7.63	0.35	1.6e-13	Monocyte count;
LUAD	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg04398451	chr17:18023971	MYO15A	-0.77	-13.39	-0.55	2.45e-34	Total body bone mineral density;
LUAD	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg00129232	chr17:37814104	STARD3	-0.45	-7.7	-0.35	9.94e-14	Asthma;
LUAD	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg27087555	chr16:88793112	FAM38A	-0.86	-8.01	-0.36	1.13e-14	Plateletcrit;
LUAD	trans	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg13565492	chr6:43139072	SRF	-0.61	-7.06	-0.32	7e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg13385794	chr1:248469461	NA	0.26	7.11	0.33	5.13e-12	Common traits (Other);
LUAD	cis	rs2880765	0.835	rs7161880	chr15:86018746	C/T	cg13263323	chr15:86062960	AKAP13	-0.5	-9.19	-0.41	1.83e-18	Coronary artery disease;
LUAD	trans	rs7395662	0.816	rs12420341	chr11:48893384	C/T	cg00717180	chr2:96193071	NA	-0.4	-7.55	-0.34	2.72e-13	HDL cholesterol;
LUAD	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.54	-0.3	1.73e-10	Breast cancer;
LUAD	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg00339695	chr16:24857497	SLC5A11	-0.7	-11.14	-0.48	1.83e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs41311933	0.803	rs76701316	chr9:123708273	C/T	cg13567360	chr9:123745713	C5	-0.83	-7.22	-0.33	2.36e-12	Coronary artery disease;
LUAD	cis	rs999943	0.846	rs2274200	chr6:33625696	T/C	cg14003231	chr6:33640908	ITPR3	0.92	18.63	0.67	5.14e-57	Obesity (extreme);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11409205	chr12:48357772	TMEM106C	-0.45	-7.29	-0.33	1.53e-12	Cancer;
LUAD	cis	rs7851660	0.967	rs7851552	chr9:100610652	C/A	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	cis	rs1374313	0.586	rs7569379	chr2:120104119	C/G	cg23562675	chr2:120107745	C2orf76	-0.37	-6.38	-0.3	4.54e-10	Obesity-related traits;
LUAD	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg26597838	chr10:835615	NA	1.28	19.86	0.69	1.73e-62	Eosinophil percentage of granulocytes;
LUAD	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg17105886	chr17:28927953	LRRC37B2	0.87	8.35	0.38	1e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1113500	0.814	rs893983	chr1:108630338	C/T	cg06207961	chr1:108661230	NA	-0.34	-6.53	-0.3	1.87e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs3760982	0.585	rs62116964	chr19:44291986	T/C	cg12072164	chr19:44306565	LYPD5	0.43	8.66	0.39	9.92e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg24642844	chr7:1081250	C7orf50	-0.98	-14.82	-0.58	2.67e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg16797656	chr11:68205561	LRP5	0.47	8.93	0.4	1.36e-17	Total body bone mineral density;
LUAD	cis	rs6987853	0.712	rs2974343	chr8:42400679	G/A	cg09913449	chr8:42400586	C8orf40	0.53	10.68	0.46	9.84e-24	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2835872	0.758	rs8134288	chr21:39036989	T/C	cg06728970	chr21:39037746	KCNJ6	0.4	7.69	0.35	1.05e-13	Electroencephalographic traits in alcoholism;
LUAD	cis	rs10484885	0.648	rs2777848	chr6:90535993	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.63	-8.85	-0.4	2.5e-17	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.62	0.31	1.09e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg06064525	chr11:970664	AP2A2	-0.46	-9.14	-0.41	2.6e-18	Alzheimer's disease (late onset);
LUAD	trans	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg13565492	chr6:43139072	SRF	-0.6	-6.37	-0.3	4.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9323205	0.765	rs2999389	chr14:51654510	G/A	cg23942311	chr14:51606299	NA	0.54	9.74	0.43	2.39e-20	Cancer;
LUAD	trans	rs11039798	0.841	rs11500573	chr11:48713900	T/G	cg02254774	chr11:50257496	LOC441601	0.52	6.58	0.3	1.4e-10	Axial length;
LUAD	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg03433033	chr1:76189801	ACADM	0.88	18.18	0.66	5.59e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs2797160	1.000	rs984040	chr6:126021277	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.53	8.69	0.39	7.97e-17	Endometrial cancer;
LUAD	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg11915388	chr22:42470451	FAM109B	-0.41	-7.35	-0.34	9.99e-13	Schizophrenia;
LUAD	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg14828511	chr1:107599125	PRMT6	0.54	9.19	0.41	1.77e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg02527881	chr3:46936655	PTH1R	-0.52	-10.57	-0.46	2.43e-23	Colorectal cancer;
LUAD	cis	rs7536201	0.905	rs7525903	chr1:25294573	G/A	cg23273869	chr1:25296894	NA	-0.36	-7.07	-0.33	6.52e-12	Psoriasis vulgaris;
LUAD	cis	rs1728785	1.000	rs1645935	chr16:68563791	A/C	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.3100000000000001e-10	Ulcerative colitis;
LUAD	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg04287289	chr16:89883240	FANCA	0.78	6.92	0.32	1.73e-11	Skin colour saturation;
LUAD	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg21191810	chr6:118973309	C6orf204	-0.53	-8.03	-0.36	9.72e-15	Diastolic blood pressure;
LUAD	cis	rs155346	1.000	rs155346	chr5:139390377	C/T	cg01090482	chr5:139365336	NRG2	0.33	6.64	0.31	9.76e-11	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUAD	cis	rs59698941	0.943	rs41298946	chr5:132268390	A/G	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/C	cg13736514	chr6:26305472	NA	-0.53	-8.63	-0.39	1.23e-16	Educational attainment;
LUAD	trans	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg21372672	chr17:16614065	CCDC144A	-0.38	-6.39	-0.3	4.4e-10	Educational attainment (years of education);
LUAD	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg22117172	chr7:91764530	CYP51A1	0.37	8.06	0.36	7.93e-15	Breast cancer;
LUAD	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg12863693	chr15:85201151	NMB	0.39	6.77	0.31	4.22e-11	Schizophrenia;
LUAD	cis	rs6942407	0.546	rs10952896	chr7:86765763	G/A	cg02420886	chr7:86849541	C7orf23	0.64	7.28	0.33	1.62e-12	Food allergy;
LUAD	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg09222892	chr1:25734099	RHCE	0.51	9.37	0.41	4.27e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg11494091	chr17:61959527	GH2	-0.7	-16.87	-0.63	3.45e-49	Prudent dietary pattern;
LUAD	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg00049323	chr5:472564	LOC25845	0.43	7.09	0.33	5.6e-12	Cystic fibrosis severity;
LUAD	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg02782426	chr3:40428986	ENTPD3	0.35	7.63	0.35	1.59e-13	Renal cell carcinoma;
LUAD	cis	rs2932538	0.885	rs6693880	chr1:113110261	A/G	cg22162597	chr1:113214053	CAPZA1	0.46	6.88	0.32	2.1e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg06627628	chr2:24431161	ITSN2	-0.69	-10.99	-0.47	6.98e-25	Asthma;
LUAD	cis	rs2902440	0.502	rs58621044	chr1:67664840	G/C	cg12940439	chr1:67600707	NA	0.38	7.37	0.34	9.05e-13	Crohn's disease;
LUAD	cis	rs775227	0.574	rs34286076	chr3:113269695	G/C	cg18753928	chr3:113234510	CCDC52	-0.66	-8.95	-0.4	1.17e-17	Dental caries;
LUAD	cis	rs10267593	0.516	rs62435159	chr7:1911281	G/A	cg17551891	chr7:1960795	MAD1L1	-0.4	-6.79	-0.31	3.76e-11	Coronary artery disease;
LUAD	cis	rs447921	0.861	rs12950218	chr17:74409547	G/A	cg17201438	chr17:74438067	UBE2O	0.67	8.47	0.38	4.03e-16	Mitochondrial DNA levels;
LUAD	trans	rs9929218	1.000	rs2113200	chr16:68814948	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-13.05	-0.54	5.9e-33	Colorectal cancer;
LUAD	cis	rs12413816	0.517	rs4750400	chr10:13765923	A/G	cg16485048	chr10:13749193	FRMD4A	0.38	6.69	0.31	7.12e-11	Red cell distribution width;
LUAD	trans	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg03886242	chr7:26192032	NFE2L3	-0.47	-8.41	-0.38	6.49e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs149866169	1	rs149866169	chr6:27441723	T/A	cg06606381	chr12:133084897	FBRSL1	-0.91	-9.2	-0.41	1.6e-18	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs6964587	0.758	rs7798233	chr7:91500083	G/A	cg17063962	chr7:91808500	NA	-0.53	-7.44	-0.34	5.79e-13	Breast cancer;
LUAD	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.52	-8.73	-0.39	5.97e-17	Alzheimer's disease (late onset);
LUAD	trans	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg07211511	chr3:129823064	LOC729375	-0.87	-9.67	-0.43	4.18e-20	Blood pressure (smoking interaction);
LUAD	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg02527881	chr3:46936655	PTH1R	-0.56	-11.63	-0.49	2.47e-27	Colorectal cancer;
LUAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg04025307	chr7:1156635	C7orf50	0.68	12.18	0.51	1.9e-29	Longevity;Endometriosis;
LUAD	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg06064525	chr11:970664	AP2A2	-0.34	-6.69	-0.31	7.31e-11	Alzheimer's disease (late onset);
LUAD	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.5	7.91	0.36	2.32e-14	Electrocardiographic conduction measures;
LUAD	cis	rs6908034	0.660	rs7746588	chr6:19804640	C/T	cg02682789	chr6:19804855	NA	0.91	10.38	0.45	1.26e-22	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg07741184	chr6:167504864	NA	0.35	8.01	0.36	1.12e-14	Primary biliary cholangitis;
LUAD	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg23262073	chr20:60523788	NA	-0.44	-7.66	-0.35	1.29e-13	Body mass index;
LUAD	cis	rs11771526	0.901	rs11771230	chr7:32315546	C/T	cg27532318	chr7:32358331	NA	-0.63	-7.82	-0.36	4.13e-14	Body mass index;
LUAD	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.75	-0.43	2.07e-20	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs892961	0.720	rs103458	chr17:75416031	A/G	cg05865280	chr17:75406074	SEPT9	0.63	19.22	0.68	1.25e-59	Airflow obstruction;
LUAD	cis	rs6541297	0.941	rs6541294	chr1:230278826	A/G	cg20703242	chr1:230279135	GALNT2	0.66	12.26	0.51	8.85e-30	Coronary artery disease;
LUAD	cis	rs447921	0.861	rs423130	chr17:74416189	A/G	cg17201438	chr17:74438067	UBE2O	-0.61	-8.31	-0.37	1.3e-15	Mitochondrial DNA levels;
LUAD	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.51	-8.88	-0.4	1.96e-17	Alzheimer's disease (late onset);
LUAD	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg05865280	chr17:75406074	SEPT9	0.61	19.3	0.68	5.44e-60	Airflow obstruction;
LUAD	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg09455208	chr3:40491958	NA	0.64	14.02	0.56	5.98e-37	Renal cell carcinoma;
LUAD	cis	rs12530134	0.590	rs760492	chr6:170743989	A/G	cg18217622	chr6:170732253	NA	0.67	6.62	0.31	1.1e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg21659725	chr3:3221576	CRBN	-0.57	-9.17	-0.41	2.11e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs428668	0.681	rs430961	chr5:150700559	C/G	cg14086364	chr5:150678334	SLC36A3	0.38	7.32	0.34	1.25e-12	Skin aging (microtopography measurement);
LUAD	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg03354898	chr7:1950403	MAD1L1	-0.42	-7.94	-0.36	1.8e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg17425144	chr1:10567563	PEX14	0.62	12.9	0.53	2.53e-32	Breast cancer;
LUAD	trans	rs7395662	1.000	rs4882016	chr11:48570125	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.34	-0.34	1.14e-12	HDL cholesterol;
LUAD	cis	rs7010267	0.602	rs11995824	chr8:120012700	C/G	cg01975934	chr8:119970761	NA	-0.37	-7.16	-0.33	3.58e-12	Total body bone mineral density (age 45-60);
LUAD	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg00504896	chr12:9437009	LOC642846	-0.42	-6.62	-0.31	1.11e-10	Breast size;
LUAD	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.53	-8.76	-0.39	4.63e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs3823572	0.564	rs2953618	chr7:133672476	G/C	cg03336402	chr7:133662267	EXOC4	-0.43	-7.47	-0.34	4.55e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs11945232	1.000	rs4314250	chr4:88340969	A/G	cg23841344	chr4:88312519	HSD17B11	0.54	8.21	0.37	2.68e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7903847	0.620	rs61863815	chr10:99124389	A/G	cg20016023	chr10:99160130	RRP12	-0.28	-6.81	-0.31	3.41e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.56	8.11	0.37	5.72e-15	Platelet count;
LUAD	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg00074818	chr8:8560427	CLDN23	0.66	10.12	0.44	1.07e-21	Obesity-related traits;
LUAD	cis	rs17253792	0.822	rs10137364	chr14:56059987	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg18252515	chr7:66147081	NA	0.59	6.53	0.3	1.84e-10	Diabetic kidney disease;
LUAD	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg06784218	chr1:46089804	CCDC17	0.55	11.77	0.5	7.42e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs12210905	0.688	rs115309746	chr6:27491562	G/A	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg26384229	chr12:38710491	ALG10B	0.42	6.98	0.32	1.14e-11	Morning vs. evening chronotype;
LUAD	cis	rs78707713	0.560	rs12784882	chr10:71230334	C/G	cg12610070	chr10:71211762	TSPAN15	-0.38	-9.42	-0.42	2.95e-19	Venous thromboembolism;
LUAD	trans	rs9784649	0.760	rs17343923	chr5:25052414	G/A	cg08600765	chr20:34638493	LOC647979	-0.79	-10.7	-0.46	8.61e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg00953403	chr17:74099816	EXOC7	0.48	7.5	0.34	3.83e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg05754148	chr16:3507555	NAT15	-0.38	-6.53	-0.3	1.84e-10	Body mass index (adult);
LUAD	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.49	8.41	0.38	6.35e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg14769373	chr6:40998127	UNC5CL	-0.36	-6.46	-0.3	2.81e-10	Alzheimer's disease (late onset);
LUAD	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg20701182	chr2:24300061	SF3B14	0.88	13.43	0.55	1.71e-34	Lymphocyte counts;
LUAD	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-9.2	-0.41	1.64e-18	Gut microbiome composition (summer);
LUAD	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg17200465	chr3:40428508	ENTPD3	0.27	6.51	0.3	2.09e-10	Renal cell carcinoma;
LUAD	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg12193833	chr17:30244370	NA	-0.58	-7.04	-0.32	7.63e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs73198271	0.813	rs56007835	chr8:8610026	G/A	cg01851573	chr8:8652454	MFHAS1	0.46	7.66	0.35	1.25e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg11965913	chr1:205819406	PM20D1	0.81	16.56	0.63	7.81e-48	Menarche (age at onset);
LUAD	cis	rs62400317	0.826	rs4400216	chr6:45237955	T/G	cg18551225	chr6:44695536	NA	-0.56	-8.72	-0.39	6.46e-17	Total body bone mineral density;
LUAD	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg05590025	chr7:65112418	INTS4L2	-0.77	-8.33	-0.38	1.1e-15	Diabetic kidney disease;
LUAD	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.35	-6.94	-0.32	1.45e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg08085267	chr17:45401833	C17orf57	-0.59	-10.3	-0.45	2.41e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg24531977	chr5:56204891	C5orf35	-0.43	-7.02	-0.32	8.89e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg27454412	chr7:1067447	C7orf50	0.42	6.73	0.31	5.69e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6906287	0.647	rs10456917	chr6:118779419	A/C	cg21191810	chr6:118973309	C6orf204	0.49	9.55	0.42	1.05e-19	Electrocardiographic conduction measures;
LUAD	cis	rs12122100	0.651	rs12743228	chr1:146548275	G/A	cg03526459	chr1:146549940	NA	-0.39	-7.24	-0.33	2.08e-12	HIV-1 control;
LUAD	cis	rs1784581	0.546	rs1954917	chr6:162447490	C/T	cg17173639	chr6:162384350	PARK2	0.48	8.82	0.39	2.97e-17	Itch intensity from mosquito bite;
LUAD	cis	rs9522267	0.535	rs9515451	chr13:112234382	A/G	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.93e-11	Hepatitis;
LUAD	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg22166914	chr1:53195759	ZYG11B	0.44	7.6	0.35	1.91e-13	Monocyte count;
LUAD	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-7.45	-0.34	5.36e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg26043149	chr18:55253948	FECH	0.45	7.61	0.35	1.8e-13	Bone mineral density;
LUAD	cis	rs9462027	0.561	rs2262245	chr6:34567694	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.53	-0.38	2.64e-16	Systemic lupus erythematosus;
LUAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg12034118	chr1:209979487	IRF6	0.52	7.56	0.34	2.6e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.67e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg04398451	chr17:18023971	MYO15A	0.64	11.2	0.48	1.1e-25	Total body bone mineral density;
LUAD	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg18827107	chr12:86230957	RASSF9	-0.71	-13.05	-0.54	6.13e-33	Major depressive disorder;
LUAD	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg23985595	chr17:80112537	CCDC57	-0.51	-9.45	-0.42	2.43e-19	Life satisfaction;
LUAD	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg27490568	chr2:178487706	NA	0.61	9.16	0.41	2.33e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg05368731	chr17:41323189	NBR1	0.96	20.41	0.7	6.12e-65	Menopause (age at onset);
LUAD	cis	rs9560113	0.960	rs1163862	chr13:112174319	C/T	cg14154082	chr13:112174009	NA	0.4	8.03	0.36	9.5e-15	Menarche (age at onset);
LUAD	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg25566285	chr7:158114605	PTPRN2	0.53	11.45	0.49	1.3e-26	Calcium levels;
LUAD	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg13385794	chr1:248469461	NA	0.26	6.97	0.32	1.23e-11	Common traits (Other);
LUAD	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg10802521	chr3:52805072	NEK4	-0.63	-11.19	-0.48	1.24e-25	Bipolar disorder;
LUAD	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21659725	chr3:3221576	CRBN	0.51	8.29	0.37	1.47e-15	Body mass index;
LUAD	cis	rs2274273	0.870	rs7153645	chr14:55771518	C/G	cg04306507	chr14:55594613	LGALS3	0.42	8.62	0.39	1.38e-16	Protein biomarker;
LUAD	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.54	-9.0	-0.4	7.49e-18	Glomerular filtration rate;
LUAD	cis	rs7953508	0.750	rs11107119	chr12:93983132	T/A	cg18151635	chr12:93972918	NA	-0.72	-11.01	-0.47	5.7e-25	Pubertal anthropometrics;
LUAD	cis	rs1113500	0.548	rs3853497	chr1:108657184	C/T	cg06207961	chr1:108661230	NA	0.42	6.55	0.3	1.72e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs4588572	0.643	rs13359053	chr5:77690224	T/C	cg11547950	chr5:77652471	NA	0.74	11.61	0.49	3.05e-27	Triglycerides;
LUAD	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg06784218	chr1:46089804	CCDC17	-0.6	-13.21	-0.54	1.31e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg00495681	chr13:53174319	NA	0.57	10.71	0.46	7.33e-24	Lewy body disease;
LUAD	cis	rs933688	0.532	rs28693622	chr5:90538722	T/C	cg17503389	chr5:90575422	NA	-0.43	-6.78	-0.31	4.16e-11	Smoking behavior;
LUAD	cis	rs9341808	0.690	rs9343970	chr6:80881289	C/G	cg08355045	chr6:80787529	NA	0.57	10.31	0.45	2.17e-22	Sitting height ratio;
LUAD	cis	rs55823223	0.680	rs3744017	chr17:73871467	G/A	cg14955151	chr17:73874635	TRIM47	-0.43	-6.66	-0.31	8.51e-11	Psoriasis;
LUAD	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.65	10.0	0.44	2.76e-21	Lymphocyte percentage of white cells;
LUAD	cis	rs62400317	0.859	rs10948213	chr6:45158515	T/C	cg18551225	chr6:44695536	NA	-0.56	-8.57	-0.38	1.91e-16	Total body bone mineral density;
LUAD	cis	rs877282	1.000	rs11253366	chr10:773386	C/T	cg17470449	chr10:769945	NA	0.68	10.63	0.46	1.5e-23	Uric acid levels;
LUAD	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg21963583	chr11:68658836	MRPL21	0.64	11.43	0.49	1.47e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7258465	1.000	rs8105994	chr19:18593553	A/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.53	-0.34	3.11e-13	Breast cancer;
LUAD	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg03929089	chr4:120376271	NA	0.52	6.83	0.32	3.04e-11	Axial length;
LUAD	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg25319279	chr11:5960081	NA	-0.41	-7.27	-0.33	1.77e-12	DNA methylation (variation);
LUAD	cis	rs7737355	0.755	rs1151481	chr5:130926374	A/C	cg25547332	chr5:131281432	NA	0.41	6.47	0.3	2.75e-10	Life satisfaction;
LUAD	cis	rs12200782	1.000	rs72845509	chr6:26639865	T/C	cg11502198	chr6:26597334	ABT1	-0.77	-6.69	-0.31	7.16e-11	Small cell lung carcinoma;
LUAD	cis	rs9649213	0.614	rs4236537	chr7:97996593	T/C	cg09267113	chr7:98030324	BAIAP2L1	-0.74	-11.11	-0.48	2.42e-25	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs13082711	0.911	rs66694067	chr3:27477337	C/T	cg02860705	chr3:27208620	NA	0.62	9.31	0.41	6.9e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7103648	0.569	rs10769282	chr11:47626492	T/G	cg20307385	chr11:47447363	PSMC3	0.51	7.36	0.34	9.54e-13	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg12292205	chr6:26970375	C6orf41	-0.47	-6.93	-0.32	1.53e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs3858145	0.588	rs55888445	chr10:70036456	C/T	cg04882175	chr6:131122610	NA	-0.59	-7.04	-0.32	8.06e-12	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUAD	trans	rs7404843	0.789	rs222907	chr16:15498807	A/G	cg02716450	chr16:28638775	NA	0.65	8.47	0.38	4.15e-16	Testicular germ cell tumor;
LUAD	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg03929089	chr4:120376271	NA	0.54	7.02	0.32	9.02e-12	Axial length;
LUAD	cis	rs4852324	0.536	rs17009553	chr2:74220035	A/G	cg01017244	chr2:74357527	NA	-0.76	-6.81	-0.31	3.41e-11	Systemic lupus erythematosus;
LUAD	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg05110241	chr16:68378359	PRMT7	-0.95	-10.82	-0.47	2.86e-24	Schizophrenia;
LUAD	cis	rs11866815	0.817	rs9935993	chr16:401209	C/T	cg26913058	chr16:419975	MRPL28	0.39	6.35	0.3	5.48e-10	Body mass index;
LUAD	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg23815491	chr16:72088622	HP	0.59	11.17	0.48	1.4e-25	Fibrinogen levels;
LUAD	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg18854424	chr1:2615690	NA	-0.42	-9.04	-0.4	5.48e-18	Ulcerative colitis;
LUAD	cis	rs1497828	0.956	rs2818965	chr1:217569776	T/A	cg04411442	chr1:217543379	NA	0.38	6.75	0.31	4.86e-11	Dialysis-related mortality;
LUAD	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg23229984	chr5:148520753	ABLIM3	0.4	6.45	0.3	3.06e-10	Breast cancer;
LUAD	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.09	-0.33	5.65e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.68	-11.24	-0.48	8.22e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg21285383	chr16:89894308	SPIRE2	0.43	10.56	0.46	2.82e-23	Vitiligo;
LUAD	trans	rs1997103	1.000	rs2331063	chr7:55408914	A/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg19622623	chr12:86230825	RASSF9	-0.48	-8.25	-0.37	2e-15	Major depressive disorder;
LUAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg18538332	chr22:24372958	LOC391322	-0.46	-7.56	-0.34	2.6e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08048268	chr3:133502702	NA	-0.55	-11.41	-0.49	1.82e-26	Iron status biomarkers;
LUAD	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.29	0.37	1.53e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg20991723	chr1:152506922	NA	0.34	6.63	0.31	1.05e-10	Hair morphology;
LUAD	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.76	-0.35	6.54e-14	Personality dimensions;
LUAD	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg01171360	chr6:293285	DUSP22	-0.54	-9.17	-0.41	2.04e-18	Menopause (age at onset);
LUAD	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg13511324	chr14:104056883	C14orf153	0.26	6.69	0.31	7.28e-11	Coronary artery disease;
LUAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg22963979	chr7:1858916	MAD1L1	-0.54	-9.08	-0.4	4.11e-18	Testicular germ cell tumor;
LUAD	cis	rs9399401	0.667	rs11759653	chr6:142720354	G/A	cg04461802	chr6:142623433	GPR126	0.46	8.35	0.38	1.02e-15	Chronic obstructive pulmonary disease;
LUAD	cis	rs8060686	0.668	rs8046355	chr16:68205214	T/A	cg05110241	chr16:68378359	PRMT7	-0.55	-7.04	-0.32	7.91e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.84	0.32	2.84e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2294693	0.947	rs10456496	chr6:40988840	A/G	cg14769373	chr6:40998127	UNC5CL	0.51	8.16	0.37	3.87e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs6754311	0.593	rs10202489	chr2:136494186	G/A	cg07305463	chr2:136567211	LCT	0.38	7.06	0.32	6.85e-12	Mosquito bite size;
LUAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.61e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg00666640	chr1:248458726	OR2T12	0.32	7.7	0.35	9.92e-14	Common traits (Other);
LUAD	cis	rs4700695	0.668	rs253214	chr5:65499401	A/G	cg21114390	chr5:65439923	SFRS12	-0.93	-14.58	-0.58	2.57e-39	Facial morphology (factor 19);
LUAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg02951883	chr7:2050386	MAD1L1	-0.95	-17.7	-0.65	7.41e-53	Bipolar disorder and schizophrenia;
LUAD	trans	rs10838798	0.523	rs11039593	chr11:48240112	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.63	-0.35	1.59e-13	Height;
LUAD	cis	rs240764	0.621	rs6925840	chr6:101209386	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-8.29	-0.37	1.51e-15	Neuroticism;
LUAD	cis	rs6685188	0.843	rs1775139	chr1:205672357	C/G	cg24503407	chr1:205819492	PM20D1	0.4	6.47	0.3	2.74e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg05373962	chr22:49881684	NA	-0.52	-10.9	-0.47	1.57e-24	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs908922	0.676	rs7529136	chr1:152516389	T/C	cg23254163	chr1:152506842	NA	0.27	7.35	0.34	1.05e-12	Hair morphology;
LUAD	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.22	0.37	2.51e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg13902645	chr11:5959945	NA	-0.58	-10.11	-0.44	1.12e-21	DNA methylation (variation);
LUAD	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg06953865	chr19:18549723	ISYNA1	-0.36	-6.72	-0.31	5.99e-11	Breast cancer;
LUAD	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg09137382	chr11:130731461	NA	0.42	7.61	0.35	1.8e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg15181151	chr6:150070149	PCMT1	0.42	8.52	0.38	2.84e-16	Lung cancer;
LUAD	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg02228675	chr17:40259724	DHX58	0.46	7.57	0.35	2.32e-13	Fibrinogen levels;
LUAD	cis	rs12348691	0.503	rs3021523	chr9:100616583	T/C	cg13688889	chr9:100608707	NA	-0.63	-10.23	-0.45	4.25e-22	Alopecia areata;
LUAD	cis	rs1451375	0.617	rs10267323	chr7:50591424	A/G	cg18232548	chr7:50535776	DDC	0.62	8.47	0.38	3.99e-16	Malaria;
LUAD	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.67	-9.05	-0.4	5.22e-18	Yeast infection;
LUAD	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg02782426	chr3:40428986	ENTPD3	-0.44	-9.64	-0.42	5.17e-20	Renal cell carcinoma;
LUAD	cis	rs113835537	0.529	rs11227511	chr11:66281244	A/C	cg24851651	chr11:66362959	CCS	0.57	10.22	0.44	4.68e-22	Airway imaging phenotypes;
LUAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg10150615	chr22:24372951	LOC391322	-0.46	-7.28	-0.33	1.59e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04267008	chr7:1944627	MAD1L1	0.64	10.21	0.44	4.84e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg02931644	chr1:25747376	RHCE	0.43	8.93	0.4	1.36e-17	Erythrocyte sedimentation rate;
LUAD	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	cis	rs6808694	0.568	rs3913938	chr3:20221698	G/A	cg00235661	chr3:20228976	SGOL1	0.46	7.63	0.35	1.6e-13	Ischemic stroke;
LUAD	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22496380	chr5:211416	CCDC127	-1.2	-15.59	-0.6	1.3e-43	Breast cancer;
LUAD	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.62	-0.31	1.09e-10	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.42	0.38	5.87e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7809615	0.901	rs11981478	chr7:99163950	C/T	cg03133378	chr7:99195931	NA	-0.59	-6.55	-0.3	1.67e-10	Blood metabolite ratios;
LUAD	cis	rs921968	0.613	rs2303565	chr2:219545309	T/C	cg02176678	chr2:219576539	TTLL4	-0.59	-11.83	-0.5	4.21e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg22920501	chr2:26401640	FAM59B	-0.76	-10.89	-0.47	1.61e-24	Gut microbiome composition (summer);
LUAD	cis	rs2274273	0.624	rs4580079	chr14:55780366	G/A	cg04306507	chr14:55594613	LGALS3	0.41	7.98	0.36	1.44e-14	Protein biomarker;
LUAD	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06028808	chr11:68637592	NA	0.43	6.99	0.32	1.07e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg23172400	chr8:95962367	TP53INP1	-0.34	-8.11	-0.37	5.69e-15	Type 2 diabetes;
LUAD	cis	rs12760731	0.565	rs12028024	chr1:178087423	G/T	cg00404053	chr1:178313656	RASAL2	0.72	9.24	0.41	1.26e-18	Obesity-related traits;
LUAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg13047869	chr3:10149882	C3orf24	0.62	10.37	0.45	1.33e-22	Alzheimer's disease;
LUAD	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.57	10.95	0.47	9.54e-25	Hemoglobin concentration;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg06834434	chr14:75079333	LTBP2	-0.39	-6.42	-0.3	3.62e-10	Vertical cup-disc ratio;
LUAD	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg11645453	chr3:52864694	ITIH4	0.6	11.11	0.48	2.56e-25	Schizophrenia;
LUAD	cis	rs990171	0.513	rs6543152	chr2:103114043	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	6.56	0.3	1.53e-10	Lymphocyte counts;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11728900	chr10:13203459	MCM10	-0.38	-6.35	-0.3	5.59e-10	Cancer;
LUAD	cis	rs3806843	0.518	rs173471	chr5:140335226	A/G	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg18404041	chr3:52824283	ITIH1	0.39	6.99	0.32	1.05e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg17120908	chr11:65337727	SSSCA1	0.69	10.78	0.46	4.26e-24	Bone mineral density;
LUAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg19626725	chr5:178986131	RUFY1	0.56	10.63	0.46	1.53e-23	Lung cancer;
LUAD	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg12756686	chr19:29218302	NA	0.64	9.15	0.41	2.36e-18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs9399401	0.667	rs6922607	chr6:142703483	A/G	cg03128060	chr6:142623767	GPR126	0.49	10.04	0.44	1.99e-21	Chronic obstructive pulmonary disease;
LUAD	cis	rs2455799	0.613	rs6802048	chr3:15883933	A/G	cg16303742	chr3:15540471	COLQ	-0.49	-9.11	-0.41	3.23e-18	Mean platelet volume;
LUAD	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg03929089	chr4:120376271	NA	-0.98	-20.58	-0.71	1.01e-65	Height;
LUAD	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	12.47	0.52	1.32e-30	Monocyte percentage of white cells;
LUAD	trans	rs75804782	0.521	rs56176151	chr2:239440220	T/C	cg01134436	chr17:81009848	B3GNTL1	0.77	8.26	0.37	1.82e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg00999904	chr2:3704751	ALLC	0.38	7.11	0.33	4.89e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg00277334	chr10:82204260	NA	-0.44	-7.33	-0.34	1.16e-12	Post bronchodilator FEV1;
LUAD	cis	rs1535500	0.967	rs12663159	chr6:39282277	C/A	cg06347083	chr6:39282316	KCNK17	-0.36	-7.65	-0.35	1.37e-13	Type 2 diabetes;
LUAD	cis	rs4588572	0.644	rs891150	chr5:77761794	G/A	cg11547950	chr5:77652471	NA	-0.64	-10.86	-0.47	2.11e-24	Triglycerides;
LUAD	trans	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.83	-0.36	3.97e-14	Breast cancer;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg22015966	chr11:47198573	ARFGAP2	0.39	6.59	0.31	1.28e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs727505	0.954	rs66871687	chr7:124670475	A/G	cg23710748	chr7:124431027	NA	-0.43	-8.57	-0.38	2.02e-16	Lewy body disease;
LUAD	trans	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg11693508	chr17:37793320	STARD3	0.75	10.15	0.44	8.17e-22	Bipolar disorder;
LUAD	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg06925179	chr17:43578568	NA	0.44	6.66	0.31	8.69e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg00080972	chr5:178986291	RUFY1	0.69	12.29	0.51	6.91e-30	Lung cancer;
LUAD	cis	rs9972944	0.902	rs10512503	chr17:63772066	G/A	cg07283582	chr17:63770753	CCDC46	0.52	11.7	0.49	1.39e-27	Total body bone mineral density;
LUAD	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.31	6.37	0.3	4.94e-10	Obesity-related traits;
LUAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.42	-0.34	6.46e-13	Electroencephalogram traits;
LUAD	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg16049864	chr8:95962084	TP53INP1	-0.55	-11.77	-0.5	7.14e-28	Type 2 diabetes;
LUAD	cis	rs2742417	0.603	rs2742453	chr3:45765858	G/A	cg10512202	chr3:45649293	LIMD1	0.47	8.87	0.4	2.08e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg15181151	chr6:150070149	PCMT1	0.37	6.92	0.32	1.66e-11	Lung cancer;
LUAD	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg05768032	chr16:30646687	NA	0.41	7.0	0.32	9.97e-12	Multiple myeloma;
LUAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg00280220	chr17:61926910	NA	0.36	6.92	0.32	1.65e-11	Prudent dietary pattern;
LUAD	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg00666640	chr1:248458726	OR2T12	-0.33	-8.17	-0.37	3.61e-15	Common traits (Other);
LUAD	cis	rs9399401	0.633	rs6570511	chr6:142757368	G/A	cg03128060	chr6:142623767	GPR126	0.4	8.08	0.37	6.63e-15	Chronic obstructive pulmonary disease;
LUAD	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg26566898	chr11:117069891	TAGLN	-0.35	-6.85	-0.32	2.65e-11	Blood protein levels;
LUAD	trans	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg04775059	chr7:64541387	NA	0.51	6.91	0.32	1.8e-11	Aortic root size;
LUAD	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.3	-0.37	1.38e-15	Total body bone mineral density;
LUAD	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg02887458	chr19:19495540	GATAD2A	-0.38	-6.36	-0.3	5.33e-10	Bipolar disorder;
LUAD	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg24069376	chr3:38537580	EXOG	-0.43	-10.28	-0.45	2.72e-22	Electrocardiographic conduction measures;
LUAD	cis	rs4460629	0.742	rs7365544	chr1:155068748	C/A	cg23973274	chr1:155060172	NA	-0.37	-6.35	-0.3	5.46e-10	Serum magnesium levels;
LUAD	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg20673091	chr1:2541236	MMEL1	0.45	9.87	0.43	8.08e-21	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg16405210	chr4:1374714	KIAA1530	-0.44	-7.3	-0.33	1.47e-12	Longevity;
LUAD	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-6.52	-0.3	2.06e-10	Tonsillectomy;
LUAD	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.62e-18	Life satisfaction;
LUAD	cis	rs8177876	0.749	rs754429	chr16:81096179	C/T	cg08591886	chr16:81111003	C16orf46	-0.74	-6.72	-0.31	5.73e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs2046867	0.862	rs62251657	chr3:72832076	C/T	cg25664220	chr3:72788482	NA	-0.7	-12.17	-0.51	1.94e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs367615	0.679	rs10070786	chr5:108815081	T/G	cg17395555	chr5:108820864	NA	0.67	13.98	0.56	8.55e-37	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg06618935	chr21:46677482	NA	-0.5	-10.05	-0.44	1.93e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg18105134	chr13:113819100	PROZ	-0.84	-14.81	-0.58	2.76e-40	Platelet distribution width;
LUAD	cis	rs6542838	0.641	rs4499468	chr2:99475204	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.95	-0.32	1.42e-11	Fear of minor pain;
LUAD	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.59	0.52	4.49e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg05425664	chr17:57184151	TRIM37	0.43	7.7	0.35	1e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg27411982	chr8:10470053	RP1L1	0.41	7.76	0.35	6.43e-14	Neuroticism;
LUAD	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.69	-0.49	1.57e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg02880119	chr16:3481970	NA	0.54	8.26	0.37	1.84e-15	Body mass index (adult);
LUAD	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg19875535	chr5:140030758	IK	0.41	6.92	0.32	1.64e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6732160	0.932	rs13417029	chr2:73380423	T/G	cg01422370	chr2:73384389	NA	0.34	6.7	0.31	6.68e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg08847533	chr14:75593920	NEK9	0.4	6.83	0.32	2.94e-11	Height;
LUAD	cis	rs2011503	0.782	rs8113006	chr19:19669441	C/G	cg11584989	chr19:19387371	SF4	-0.52	-8.01	-0.36	1.13e-14	Bipolar disorder;
LUAD	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg07305463	chr2:136567211	LCT	-0.39	-7.43	-0.34	5.9e-13	Mosquito bite size;
LUAD	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.42	-7.58	-0.35	2.27e-13	Tonsillectomy;
LUAD	trans	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg04995722	chr7:26192034	NFE2L3	0.36	6.42	0.3	3.71e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3820068	0.705	rs2145397	chr1:15896199	G/A	cg13390004	chr1:15929781	NA	0.41	6.56	0.3	1.61e-10	Systolic blood pressure;
LUAD	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg05234568	chr11:5960015	NA	-0.51	-9.01	-0.4	7.18e-18	DNA methylation (variation);
LUAD	cis	rs1953600	0.870	rs2789690	chr10:81938204	G/T	cg04850286	chr10:81895943	PLAC9	0.36	6.44	0.3	3.25e-10	Sarcoidosis;
LUAD	cis	rs2485376	0.967	rs2485371	chr10:104034087	T/C	cg20641465	chr10:103991465	PITX3	-0.58	-10.7	-0.46	8.59e-24	QT interval;
LUAD	cis	rs7940866	0.803	rs1865296	chr11:130882944	C/T	cg12179176	chr11:130786555	SNX19	-0.4	-6.49	-0.3	2.34e-10	Schizophrenia;
LUAD	cis	rs2806561	0.606	rs10917335	chr1:23294136	A/G	cg12483005	chr1:23474871	LUZP1	0.42	6.87	0.32	2.35e-11	Height;
LUAD	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.06	24.2	0.76	8.03e-82	Chronic sinus infection;
LUAD	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg05342682	chr7:94953680	PON1	-0.53	-7.19	-0.33	2.94e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg25516544	chr12:100660816	SCYL2;DEPDC4	0.41	7.03	0.32	8.45e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg22442454	chr1:209979470	IRF6	-0.47	-6.64	-0.31	9.53e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg24846343	chr22:24311635	DDTL	0.7	15.27	0.6	3.03e-42	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1550582	1.000	rs754234	chr8:135512875	A/G	cg17885191	chr8:135476712	NA	0.72	10.21	0.44	4.96e-22	Educational attainment;
LUAD	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg26408565	chr15:76604113	ETFA	-0.43	-6.73	-0.31	5.52e-11	Blood metabolite levels;
LUAD	cis	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.89	-0.32	2.01e-11	Morning vs. evening chronotype;
LUAD	cis	rs7241530	0.636	rs4799270	chr18:75898528	G/T	cg14642773	chr18:75888474	NA	0.35	6.35	0.3	5.46e-10	Educational attainment (years of education);
LUAD	cis	rs7107174	0.901	rs10899496	chr11:78123831	A/G	cg19901956	chr11:77921274	USP35	-0.46	-6.68	-0.31	7.34e-11	Testicular germ cell tumor;
LUAD	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg10755058	chr3:40428713	ENTPD3	0.45	8.46	0.38	4.31e-16	Renal cell carcinoma;
LUAD	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg27279351	chr12:120934652	DYNLL1	0.44	6.72	0.31	5.89e-11	High light scatter reticulocyte count;
LUAD	cis	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.39	-0.3	4.43e-10	Neuroticism;
LUAD	trans	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.06	-0.4	4.77e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs714027	0.526	rs73164755	chr22:30590015	A/G	cg11564601	chr22:30592435	NA	0.32	6.36	0.3	5.16e-10	Lymphocyte counts;
LUAD	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg18252515	chr7:66147081	NA	-0.64	-7.02	-0.32	9.17e-12	Gout;
LUAD	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	12.57	0.52	5.08e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg26304593	chr6:42947056	PEX6	0.46	7.79	0.35	5.25e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.2	0.37	2.96e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7678296	0.649	rs73128366	chr4:37241908	T/C	cg06805348	chr4:37245195	KIAA1239	0.58	7.05	0.32	7.11e-12	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg01299579	chr2:10830716	NOL10	-0.43	-7.55	-0.34	2.68e-13	Prostate cancer;
LUAD	cis	rs7680126	0.632	rs6834645	chr4:10150174	G/A	cg00071950	chr4:10020882	SLC2A9	-0.58	-8.24	-0.37	2.22e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg03396347	chr1:1875803	NA	-0.61	-15.76	-0.61	2.3e-44	Body mass index;
LUAD	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-11.76	-0.5	8.23e-28	Hemoglobin concentration;
LUAD	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg02421172	chr7:1938701	MAD1L1	0.46	6.62	0.31	1.12e-10	Neuroticism;
LUAD	cis	rs34526934	0.566	rs1374325	chr2:177043971	G/A	cg14324370	chr2:177042789	NA	-0.41	-6.75	-0.31	4.97e-11	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg01191920	chr7:158217561	PTPRN2	0.63	13.09	0.54	4.06e-33	Obesity-related traits;
LUAD	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg16479474	chr6:28041457	NA	0.38	6.7	0.31	6.53e-11	Parkinson's disease;
LUAD	cis	rs864537	0.676	rs1773561	chr1:167421951	C/T	cg22356347	chr1:167427500	CD247	-0.52	-10.63	-0.46	1.55e-23	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	7.17	0.33	3.31e-12	Schizophrenia;
LUAD	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg00310523	chr12:86230176	RASSF9	0.42	8.36	0.38	8.93e-16	Major depressive disorder;
LUAD	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg03433033	chr1:76189801	ACADM	0.86	15.72	0.61	3.35e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg07936489	chr17:37558343	FBXL20	0.53	7.08	0.33	6.09e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg02569458	chr12:86230093	RASSF9	0.37	7.19	0.33	2.86e-12	Major depressive disorder;
LUAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg21724239	chr8:58056113	NA	0.72	9.58	0.42	8.12e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.57	7.48	0.34	4.45e-13	Alzheimer's disease;
LUAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg21782813	chr7:2030301	MAD1L1	-0.42	-6.99	-0.32	1.11e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg24596788	chr1:163392923	NA	-0.33	-7.06	-0.32	6.97e-12	Motion sickness;
LUAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg03188948	chr7:1209495	NA	0.74	9.44	0.42	2.54e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7100689	0.784	rs17678947	chr10:82136333	T/C	cg01528321	chr10:82214614	TSPAN14	0.66	10.02	0.44	2.45e-21	Post bronchodilator FEV1;
LUAD	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg08859206	chr1:53392774	SCP2	-0.52	-9.29	-0.41	8.16e-19	Monocyte count;
LUAD	cis	rs986417	1.000	rs12147690	chr14:60924009	A/G	cg27398547	chr14:60952738	C14orf39	0.63	7.71	0.35	9.21e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs2274273	0.615	rs67008693	chr14:55702693	T/C	cg04306507	chr14:55594613	LGALS3	0.44	8.17	0.37	3.56e-15	Protein biomarker;
LUAD	trans	rs75804782	0.630	rs79693451	chr2:239296473	A/G	cg01134436	chr17:81009848	B3GNTL1	0.74	6.46	0.3	2.91e-10	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg24675056	chr1:15929824	NA	0.46	7.95	0.36	1.77e-14	Systolic blood pressure;
LUAD	cis	rs3774830	0.714	rs55816120	chr4:5463350	C/T	cg26943120	chr4:5472116	STK32B	0.39	7.86	0.36	3.15e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg00129232	chr17:37814104	STARD3	-0.46	-7.81	-0.36	4.44e-14	Asthma;
LUAD	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg22676075	chr6:135203613	NA	0.64	11.04	0.47	4.39e-25	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs735539	0.636	rs9579928	chr13:21274807	C/G	cg27499820	chr13:21296301	IL17D	-0.44	-8.02	-0.36	1.07e-14	Dental caries;
LUAD	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg05044414	chr3:183734942	ABCC5	0.48	9.82	0.43	1.26e-20	Anterior chamber depth;
LUAD	cis	rs1595825	0.891	rs16826791	chr2:198895133	C/G	cg00361562	chr2:198649771	BOLL	-0.47	-6.53	-0.3	1.84e-10	Ulcerative colitis;
LUAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-6.77	-0.31	4.28e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7481584	0.924	rs12805661	chr11:3020740	C/T	cg11201177	chr11:2961805	NA	0.41	6.69	0.31	6.98e-11	Calcium levels;
LUAD	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg23649088	chr2:200775458	C2orf69	0.6	8.71	0.39	7.03e-17	Schizophrenia;
LUAD	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg15133208	chr4:90757351	SNCA	-0.46	-7.08	-0.33	5.94e-12	Neuroticism;
LUAD	cis	rs80319144	0.953	rs11686762	chr2:159195225	T/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.71	0.31	6.09e-11	Restless legs syndrome;
LUAD	cis	rs977987	0.806	rs11149832	chr16:75462713	C/T	cg03315344	chr16:75512273	CHST6	0.64	14.04	0.56	5.11e-37	Dupuytren's disease;
LUAD	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.26e-12	Tonsillectomy;
LUAD	trans	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg01620082	chr3:125678407	NA	-0.77	-8.29	-0.37	1.54e-15	Breast cancer;
LUAD	cis	rs12422267	0.536	rs58521339	chr12:132609486	T/C	cg09764611	chr12:132620959	NA	-0.64	-10.89	-0.47	1.67e-24	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs904251	0.504	rs12202664	chr6:37481198	A/G	cg25019722	chr6:37503610	NA	-0.34	-7.71	-0.35	8.92e-14	Cognitive performance;
LUAD	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg26162836	chr1:160232429	DCAF8	0.43	6.35	0.3	5.48e-10	Myopia (pathological);
LUAD	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg09365446	chr1:150670422	GOLPH3L	-0.42	-7.09	-0.33	5.68e-12	Monocyte chemoattractant protein-1 levels;
LUAD	cis	rs1048238	0.506	rs848194	chr1:16285342	G/A	cg21385522	chr1:16154831	NA	-0.54	-8.42	-0.38	5.7e-16	Systolic blood pressure;
LUAD	trans	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg14791747	chr16:20752902	THUMPD1	0.49	7.08	0.33	6.17e-12	Cognitive test performance;
LUAD	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg03264133	chr6:25882463	NA	-0.61	-8.94	-0.4	1.21e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.64	11.19	0.48	1.23e-25	Birth weight;
LUAD	trans	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg06606381	chr12:133084897	FBRSL1	-0.71	-7.84	-0.36	3.73e-14	Depression;
LUAD	cis	rs62238980	0.614	rs74399071	chr22:32455990	G/T	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09080729	chr16:81069740	ATMIN	-0.51	-6.84	-0.32	2.7e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg18404041	chr3:52824283	ITIH1	0.41	7.39	0.34	7.98e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg12588279	chr6:26043732	HIST1H2BB	0.35	6.37	0.3	4.87e-10	Blood metabolite levels;
LUAD	cis	rs79243044	0.695	rs1433567	chr11:5544512	C/T	cg24229750	chr11:5531283	UBQLN3	0.3	6.67	0.31	7.93e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg18404041	chr3:52824283	ITIH1	-0.51	-8.56	-0.38	2.16e-16	Schizophrenia;
LUAD	cis	rs11118844	0.843	rs7518806	chr1:221915633	T/A	cg04222084	chr1:221915650	DUSP10	-0.79	-8.49	-0.38	3.5e-16	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	cis	rs2274273	0.588	rs9919932	chr14:55814080	A/G	cg04306507	chr14:55594613	LGALS3	0.41	7.84	0.36	3.7e-14	Protein biomarker;
LUAD	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg18138036	chr10:133769891	PPP2R2D	0.42	6.81	0.31	3.41e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs34172651	0.545	rs7185291	chr16:24714679	C/T	cg00339695	chr16:24857497	SLC5A11	-0.42	-7.51	-0.34	3.5e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1375194	0.606	rs10188817	chr2:33815471	A/G	cg04131969	chr2:33951647	MYADML	-0.55	-8.58	-0.39	1.81e-16	Response to antidepressants in depression;
LUAD	cis	rs397969	0.646	rs403021	chr17:19806829	C/T	cg04132472	chr17:19861366	AKAP10	0.33	6.86	0.32	2.39e-11	Platelet count;
LUAD	cis	rs1971762	0.523	rs3852562	chr12:54085750	T/C	cg23533419	chr12:54090519	NA	-0.34	-6.46	-0.3	2.84e-10	Height;
LUAD	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg02990361	chr1:107599529	PRMT6	-0.62	-10.42	-0.45	8.82e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg03806693	chr22:41940476	POLR3H	-0.75	-9.77	-0.43	1.88e-20	Vitiligo;
LUAD	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.39	7.64	0.35	1.46e-13	Total body bone mineral density;
LUAD	cis	rs7709909	0.512	rs40592	chr5:80087876	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.45	-6.87	-0.32	2.28e-11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg21028142	chr17:79581711	NPLOC4	0.42	8.77	0.39	4.3e-17	Eye color traits;
LUAD	cis	rs4713675	0.584	rs9394163	chr6:33682414	A/G	cg14003231	chr6:33640908	ITPR3	0.5	9.8	0.43	1.48e-20	Plateletcrit;
LUAD	cis	rs4713675	0.565	rs4713671	chr6:33699899	A/G	cg13859433	chr6:33739653	LEMD2	-0.3	-7.26	-0.33	1.88e-12	Plateletcrit;
LUAD	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18876405	chr7:65276391	NA	-0.58	-9.91	-0.43	5.83e-21	Aortic root size;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg01246254	chr10:124134882	PLEKHA1	0.42	6.56	0.3	1.57e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg09436375	chr6:42928200	GNMT	-0.29	-8.24	-0.37	2.22e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6594713	0.732	rs13174206	chr5:112728482	C/T	cg12552261	chr5:112820674	MCC	-0.43	-6.5	-0.3	2.2e-10	Brain cytoarchitecture;
LUAD	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08816037	chr3:160167507	TRIM59	-0.49	-6.37	-0.3	4.92e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg09021430	chr5:549028	NA	0.48	12.14	0.51	2.67e-29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg05425664	chr17:57184151	TRIM37	-0.44	-7.86	-0.36	3.19e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg15147215	chr3:52552868	STAB1	-0.38	-7.06	-0.32	7.06e-12	Bipolar disorder;
LUAD	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-12.2	-0.51	1.5e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs4730250	0.707	rs257381	chr7:106803963	T/C	cg02696742	chr7:106810147	HBP1	-0.86	-11.48	-0.49	9.74e-27	Osteoarthritis;
LUAD	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg24920358	chr1:40204285	PPIE	-0.69	-12.35	-0.51	3.9e-30	Blood protein levels;
LUAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg04352962	chr1:209979756	IRF6	0.5	7.08	0.33	6.07e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6546550	0.901	rs6546553	chr2:70111711	C/A	cg02498382	chr2:70120550	SNRNP27	-0.57	-10.55	-0.46	2.83e-23	Prevalent atrial fibrillation;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26762056	chr11:32605413	EIF3M	-0.63	-6.5	-0.3	2.27e-10	Type 2 diabetes;
LUAD	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg27102117	chr16:15229624	NA	0.56	10.22	0.45	4.51e-22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg02158880	chr13:53174818	NA	0.61	10.77	0.46	4.52e-24	Lewy body disease;
LUAD	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.54e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937890	0.504	rs2575822	chr11:14519851	C/A	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.15e-12	Mitochondrial DNA levels;
LUAD	cis	rs12928939	0.517	rs11865456	chr16:71969497	C/T	cg03805757	chr16:71968109	PKD1L3	-0.54	-8.76	-0.39	4.77e-17	Post bronchodilator FEV1;
LUAD	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg05535760	chr7:792225	HEATR2	0.86	11.33	0.48	3.51e-26	Cerebrospinal P-tau181p levels;
LUAD	trans	rs12517041	1.000	rs1428620	chr5:23283138	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.47	-0.3	2.73e-10	Calcium levels;
LUAD	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.65	-9.18	-0.41	1.87e-18	IgG glycosylation;
LUAD	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15506890	chr2:3487001	NA	-0.47	-8.25	-0.37	2.05e-15	Neurofibrillary tangles;
LUAD	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg04248312	chr19:17393744	ANKLE1	-0.98	-18.47	-0.67	2.86e-56	Systemic lupus erythematosus;
LUAD	cis	rs4588572	0.643	rs1035950	chr5:77785858	G/A	cg11547950	chr5:77652471	NA	-0.76	-12.09	-0.51	4.17e-29	Triglycerides;
LUAD	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg15448220	chr1:150897856	SETDB1	0.51	8.82	0.39	2.92e-17	Melanoma;
LUAD	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg07305463	chr2:136567211	LCT	-0.36	-6.73	-0.31	5.45e-11	Mosquito bite size;
LUAD	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.62	0.31	1.09e-10	Depression;
LUAD	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg06558623	chr16:89946397	TCF25	0.62	7.07	0.33	6.41e-12	Skin colour saturation;
LUAD	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg08085267	chr17:45401833	C17orf57	0.66	12.16	0.51	2.16e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs8192282	0.739	rs4845641	chr1:154497930	C/G	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.36	-0.34	9.84e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06873352	chr17:61820015	STRADA	0.51	8.32	0.38	1.2e-15	Height;
LUAD	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg18944383	chr4:111397179	ENPEP	0.4	7.96	0.36	1.61e-14	Height;
LUAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg11645453	chr3:52864694	ITIH4	0.33	6.41	0.3	3.98e-10	Electroencephalogram traits;
LUAD	cis	rs2992756	0.625	rs2992752	chr1:18808526	A/C	cg24076588	chr1:18808559	KLHDC7A	-0.46	-7.59	-0.35	2.04e-13	Breast cancer;
LUAD	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg14092988	chr3:52407081	DNAH1	0.41	7.72	0.35	8.52e-14	Bipolar disorder;
LUAD	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg08873628	chr1:175162347	KIAA0040	-0.43	-7.4	-0.34	7.19e-13	Diastolic blood pressure;
LUAD	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg17105886	chr17:28927953	LRRC37B2	0.81	7.87	0.36	3.06e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg18811423	chr2:55921094	PNPT1	0.51	8.34	0.38	1.05e-15	Metabolic syndrome;
LUAD	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg17724175	chr1:150552817	MCL1	0.38	8.48	0.38	3.85e-16	Melanoma;
LUAD	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21582582	chr3:182698605	DCUN1D1	0.56	9.54	0.42	1.11e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs7659604	0.521	rs10001697	chr4:122677737	G/T	cg06713675	chr4:122721982	EXOSC9	0.42	7.67	0.35	1.23e-13	Type 2 diabetes;
LUAD	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg10295955	chr4:187884368	NA	-1.08	-23.55	-0.75	5.62e-79	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.05	-0.32	7.52e-12	Height;
LUAD	cis	rs4691139	1.000	rs9917978	chr4:165885143	A/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.44	-8.7	-0.39	7.41e-17	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg11494091	chr17:61959527	GH2	0.45	8.83	0.39	2.82e-17	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4889855	0.516	rs4890041	chr17:78521114	A/T	cg16591659	chr17:78472290	NA	0.42	7.42	0.34	6.38e-13	Fractional excretion of uric acid;
LUAD	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21582582	chr3:182698605	DCUN1D1	0.62	9.98	0.44	3.38e-21	Resting heart rate;
LUAD	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg11266682	chr4:10021025	SLC2A9	0.67	14.84	0.59	2.04e-40	Bone mineral density;
LUAD	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg06558623	chr16:89946397	TCF25	1.15	10.73	0.46	6.43e-24	Skin colour saturation;
LUAD	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg26408565	chr15:76604113	ETFA	-0.47	-7.41	-0.34	6.71e-13	Blood metabolite levels;
LUAD	trans	rs10838798	0.523	rs11039593	chr11:48240112	A/G	cg00717180	chr2:96193071	NA	-0.36	-6.54	-0.3	1.74e-10	Height;
LUAD	cis	rs7326068	0.524	rs2497488	chr13:21201476	A/T	cg27499820	chr13:21296301	IL17D	0.42	7.79	0.35	5.41e-14	Schizophrenia, bipolar disorder and depression (combined);
LUAD	trans	rs11039798	1.000	rs9667626	chr11:48485877	T/C	cg02254774	chr11:50257496	LOC441601	0.53	6.75	0.31	4.74e-11	Axial length;
LUAD	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs12620999	1.000	rs13004252	chr2:238035408	C/A	cg23555395	chr2:238036564	NA	-0.55	-7.75	-0.35	6.91e-14	Systemic lupus erythematosus;
LUAD	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.85e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7709909	0.553	rs6151651	chr5:79971464	G/A	cg24059623	chr5:79951536	MSH3;DHFR	0.47	6.97	0.32	1.22e-11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs6138458	0.961	rs11700073	chr20:24975215	C/G	cg26195577	chr20:24973756	C20orf3	0.97	17.48	0.65	6.81e-52	Blood protein levels;
LUAD	cis	rs13040088	0.935	rs62200158	chr20:61557906	C/T	cg23096297	chr20:61557774	DIDO1	0.76	10.66	0.46	1.18e-23	Menopause (age at onset);
LUAD	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg03161606	chr19:29218774	NA	0.59	7.91	0.36	2.23e-14	Methadone dose in opioid dependence;
LUAD	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg05991184	chr2:219186017	PNKD	0.37	7.14	0.33	4.21e-12	Colorectal cancer;
LUAD	cis	rs813218	0.523	rs1711554	chr3:99428998	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-7.93	-0.36	1.98e-14	Orofacial clefts;
LUAD	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg26874164	chr19:58962979	ZNF324B	0.44	6.54	0.3	1.76e-10	Mean platelet volume;
LUAD	cis	rs877282	0.583	rs11253441	chr10:828288	C/T	cg13775593	chr10:823151	NA	-0.37	-6.92	-0.32	1.65e-11	Uric acid levels;
LUAD	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg09658497	chr7:2847517	GNA12	-0.45	-8.2	-0.37	2.81e-15	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08265551	chr1:151032119	CDC42SE1;MLLT11	-0.48	-6.71	-0.31	6.38e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11062046	chr7:64254701	ZNF138	-0.51	-6.88	-0.32	2.15e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12541635	0.966	rs7812766	chr8:107057033	G/A	cg10147462	chr8:107024639	NA	0.48	8.6	0.39	1.56e-16	Age of smoking initiation;
LUAD	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.31	0.41	6.89e-19	Colorectal cancer;
LUAD	cis	rs7584330	0.518	rs80282956	chr2:238447929	G/A	cg14458575	chr2:238380390	NA	0.75	10.91	0.47	1.41e-24	Prostate cancer;
LUAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg13047869	chr3:10149882	C3orf24	0.62	11.02	0.47	5.56e-25	Alzheimer's disease;
LUAD	cis	rs1232027	0.666	rs1643646	chr5:79948641	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-8.09	-0.37	6.53e-15	Huntington's disease progression;
LUAD	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.84e-26	Alzheimer's disease (late onset);
LUAD	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg08219700	chr8:58056026	NA	0.67	8.61	0.39	1.45e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg26043149	chr18:55253948	FECH	0.43	7.03	0.32	8.56e-12	Bone mineral density;
LUAD	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg23018236	chr17:30244563	NA	-0.69	-8.3	-0.37	1.46e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg07677032	chr17:61819896	STRADA	0.56	10.08	0.44	1.47e-21	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.06e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03517284	chr6:25882590	NA	-0.58	-9.56	-0.42	9.84e-20	Blood metabolite levels;
LUAD	cis	rs17532515	0.505	rs1430578	chr4:141492786	G/A	cg09181644	chr4:141490428	UCP1	0.35	7.3	0.33	1.48e-12	Select biomarker traits;
LUAD	cis	rs68170813	0.562	rs78181351	chr7:106999301	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-10.4	-0.45	1.05e-22	Coronary artery disease;
LUAD	cis	rs684232	0.666	rs1227028	chr17:573298	G/A	cg15660573	chr17:549704	VPS53	-0.79	-15.27	-0.6	3.19e-42	Prostate cancer;
LUAD	cis	rs11681884	1.000	rs11684277	chr2:113844995	T/C	cg12858261	chr2:113808755	IL1F8	0.51	6.42	0.3	3.6e-10	Stroke;
LUAD	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg02551604	chr5:131831745	NA	0.64	10.38	0.45	1.2e-22	Asthma (sex interaction);
LUAD	cis	rs2996428	0.561	rs12134919	chr1:3744641	G/A	cg23277830	chr1:3704460	LRRC47	0.42	8.79	0.39	3.85e-17	Red cell distribution width;
LUAD	cis	rs7474896	0.515	rs2738203	chr10:38277596	G/A	cg25427524	chr10:38739819	LOC399744	0.56	7.54	0.34	2.91e-13	Obesity (extreme);
LUAD	cis	rs13095912	0.785	rs62291882	chr3:185313278	T/C	cg11274856	chr3:185301563	NA	0.49	9.32	0.41	6.64e-19	Systolic blood pressure;
LUAD	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg01802117	chr1:53393560	SCP2	-0.39	-7.74	-0.35	7.59e-14	Monocyte count;
LUAD	cis	rs9811920	0.809	rs6440967	chr3:99722396	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-7.11	-0.33	5.11e-12	Axial length;
LUAD	cis	rs9625935	0.748	rs1468177	chr22:30544559	C/T	cg11564601	chr22:30592435	NA	0.3	6.39	0.3	4.28e-10	Tonsillectomy;
LUAD	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs60154123	0.772	rs845452	chr1:210417861	C/T	cg22029157	chr1:209979665	IRF6	0.65	7.06	0.32	6.7e-12	Coronary artery disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14036097	chr4:190862158	FRG1	-0.5	-6.65	-0.31	9.15e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg26022315	chr17:47021804	SNF8	0.4	7.27	0.33	1.77e-12	Type 2 diabetes;
LUAD	cis	rs12422267	0.536	rs12303540	chr12:132609679	A/G	cg09764611	chr12:132620959	NA	0.62	10.73	0.46	6.26e-24	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	trans	rs9408928	0.778	rs9409230	chr9:123967760	A/T	cg18897905	chr6:160118539	NA	0.6	6.71	0.31	6.27e-11	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg07636037	chr3:49044803	WDR6	0.64	12.41	0.52	2.25e-30	Parkinson's disease;
LUAD	cis	rs12530845	1.000	rs6979439	chr7:135329004	A/G	cg23117316	chr7:135346802	PL-5283	-0.5	-9.3	-0.41	7.55e-19	Red blood cell traits;
LUAD	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg05340658	chr4:99064831	C4orf37	0.55	9.38	0.41	4.11e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg05283184	chr6:79620031	NA	-0.59	-11.93	-0.5	1.77e-28	Intelligence (multi-trait analysis);
LUAD	trans	rs2270927	0.510	rs1995381	chr5:75570658	C/T	cg13563193	chr19:33072644	PDCD5	-0.71	-7.58	-0.35	2.14e-13	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.94e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9308433	0.529	rs867445	chr1:214502230	C/G	cg06198575	chr1:214491504	SMYD2	0.44	7.59	0.35	2.04e-13	IgG glycosylation;
LUAD	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg08999081	chr20:33150536	PIGU	-0.63	-14.11	-0.57	2.49e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs1448094	0.935	rs11117108	chr12:86322310	T/A	cg02569458	chr12:86230093	RASSF9	0.37	7.07	0.33	6.27e-12	Major depressive disorder;
LUAD	cis	rs4891159	0.790	rs17059325	chr18:74119567	A/C	cg24786174	chr18:74118243	ZNF516	-0.74	-13.29	-0.54	6.59e-34	Longevity;
LUAD	cis	rs12541635	0.966	rs55729609	chr8:107056034	A/C	cg10147462	chr8:107024639	NA	0.48	8.6	0.39	1.56e-16	Age of smoking initiation;
LUAD	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg22117172	chr7:91764530	CYP51A1	0.35	7.7	0.35	9.65e-14	Breast cancer;
LUAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg01448562	chr3:133502909	NA	-0.77	-15.31	-0.6	1.99e-42	Iron status biomarkers;
LUAD	cis	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05901451	chr6:126070800	HEY2	0.51	8.05	0.36	8.27e-15	Endometrial cancer;
LUAD	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	12.93	0.53	1.94e-32	Prudent dietary pattern;
LUAD	trans	rs6940638	0.956	rs36048693	chr6:27032711	T/G	cg06606381	chr12:133084897	FBRSL1	-0.48	-6.44	-0.3	3.21e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1113500	0.548	rs7541433	chr1:108645641	G/A	cg06207961	chr1:108661230	NA	0.42	6.69	0.31	7.09e-11	Growth-regulated protein alpha levels;
LUAD	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.75	16.01	0.61	1.91e-45	White blood cell count;
LUAD	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg07917127	chr4:99064746	C4orf37	0.42	6.96	0.32	1.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs977987	0.806	rs12924920	chr16:75440133	G/A	cg03315344	chr16:75512273	CHST6	0.64	14.14	0.57	1.96e-37	Dupuytren's disease;
LUAD	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg26384229	chr12:38710491	ALG10B	0.4	6.5	0.3	2.29e-10	Morning vs. evening chronotype;
LUAD	cis	rs4919694	1.000	rs12261040	chr10:104665397	T/C	cg04362960	chr10:104952993	NT5C2	0.72	7.75	0.35	6.87e-14	Arsenic metabolism;
LUAD	trans	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg14917512	chr19:3094685	GNA11	-0.57	-6.8	-0.31	3.69e-11	Diabetic kidney disease;
LUAD	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg10544611	chr16:67998164	SLC12A4	-0.54	-6.87	-0.32	2.38e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg11266682	chr4:10021025	SLC2A9	0.68	15.8	0.61	1.55e-44	Bone mineral density;
LUAD	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg13902645	chr11:5959945	NA	-0.49	-8.35	-0.38	9.64e-16	DNA methylation (variation);
LUAD	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg02569458	chr12:86230093	RASSF9	0.44	8.05	0.36	8.3e-15	Major depressive disorder;
LUAD	cis	rs76419734	0.558	rs59936741	chr4:106518916	G/A	cg05309399	chr4:106552544	FLJ20184	-0.55	-6.82	-0.31	3.12e-11	Post bronchodilator FEV1;
LUAD	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.86	-0.36	3.15e-14	Diabetic kidney disease;
LUAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg27454412	chr7:1067447	C7orf50	0.48	7.75	0.35	6.7e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.26	0.37	1.85e-15	Alzheimer's disease;
LUAD	trans	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg04565464	chr8:145669602	NFKBIL2	0.43	6.56	0.3	1.56e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24308560	chr3:49941425	MST1R	-0.57	-9.44	-0.42	2.51e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg26924012	chr15:45694286	SPATA5L1	1.0	18.38	0.67	6.73e-56	Homoarginine levels;
LUAD	trans	rs7395662	0.853	rs4882062	chr11:48453271	A/G	cg00717180	chr2:96193071	NA	0.35	6.56	0.3	1.55e-10	HDL cholesterol;
LUAD	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg13319975	chr6:146136371	FBXO30	-0.62	-10.54	-0.46	3.11e-23	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01905589	chr1:26856408	RPS6KA1	-0.55	-6.49	-0.3	2.4e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg13385794	chr1:248469461	NA	0.25	6.95	0.32	1.35e-11	Common traits (Other);
LUAD	cis	rs7584330	0.740	rs11896232	chr2:238438124	T/C	cg14458575	chr2:238380390	NA	0.56	10.52	0.46	3.86e-23	Prostate cancer;
LUAD	cis	rs7665090	1.000	rs1054029	chr4:103553053	G/A	cg07973026	chr4:103553119	MANBA	0.48	8.52	0.38	2.74e-16	Primary biliary cholangitis;
LUAD	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg04756594	chr16:24857601	SLC5A11	0.52	9.84	0.43	1.02e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs938554	0.612	rs7669607	chr4:9997801	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.1	-0.4	3.45e-18	Blood metabolite levels;
LUAD	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg08514558	chr10:81106712	PPIF	0.49	9.3	0.41	7.83e-19	Height;
LUAD	cis	rs12618769	0.656	rs3820943	chr2:99123177	G/C	cg10123293	chr2:99228465	UNC50	0.46	8.12	0.37	5.1e-15	Bipolar disorder;
LUAD	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg26587870	chr6:27730563	NA	-0.66	-7.01	-0.32	9.66e-12	Breast cancer;
LUAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg18402987	chr7:1209562	NA	0.8	10.99	0.47	6.87e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9826463	0.582	rs73238158	chr3:142078215	G/A	cg20824294	chr3:142316082	PLS1	0.41	7.2	0.33	2.85e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06873352	chr17:61820015	STRADA	0.56	9.09	0.4	3.88e-18	Height;
LUAD	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg22676075	chr6:135203613	NA	0.42	7.76	0.35	6.66e-14	Red blood cell count;
LUAD	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg13180566	chr4:1052158	NA	-0.39	-6.69	-0.31	7.15e-11	Recombination rate (females);
LUAD	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg02423579	chr7:2872169	GNA12	-0.51	-8.66	-0.39	1.01e-16	Height;
LUAD	cis	rs11166629	0.651	rs7818130	chr8:135641806	G/A	cg27224718	chr8:135614730	ZFAT	0.44	7.96	0.36	1.6e-14	Smoking quantity;
LUAD	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg22079354	chr11:130786696	SNX19	0.37	6.38	0.3	4.67e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg13736514	chr6:26305472	NA	-0.54	-9.56	-0.42	9.98e-20	Educational attainment;
LUAD	cis	rs62400317	0.859	rs62436778	chr6:45120666	A/G	cg18551225	chr6:44695536	NA	-0.55	-8.68	-0.39	8.96e-17	Total body bone mineral density;
LUAD	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.77	14.75	0.58	4.99e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg15208524	chr1:10270712	KIF1B	0.45	6.94	0.32	1.51e-11	Hepatocellular carcinoma;
LUAD	trans	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg07211511	chr3:129823064	LOC729375	-0.92	-12.75	-0.53	9.55e-32	Blood pressure (smoking interaction);
LUAD	cis	rs17739167	0.550	rs6493014	chr15:42225008	A/G	cg20935245	chr15:42234343	EHD4	-0.43	-7.56	-0.35	2.49e-13	Monocyte count;
LUAD	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg11663144	chr21:46675770	NA	-0.59	-11.72	-0.5	1.14e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg04450456	chr4:17643702	FAM184B	0.38	7.4	0.34	7.27e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs76878669	0.561	rs4930362	chr11:66154360	T/C	cg18002602	chr11:66138449	SLC29A2	0.48	10.4	0.45	1.04e-22	Educational attainment (years of education);
LUAD	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg25985355	chr7:65971099	NA	-0.53	-6.58	-0.3	1.41e-10	Diabetic kidney disease;
LUAD	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.59	0.31	1.29e-10	Aortic root size;
LUAD	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg06766960	chr11:133703094	NA	-0.42	-7.93	-0.36	1.97e-14	Childhood ear infection;
LUAD	cis	rs2282300	0.739	rs1933342	chr11:30312825	C/T	cg06241208	chr11:30344200	C11orf46	0.59	7.61	0.35	1.76e-13	Morning vs. evening chronotype;
LUAD	cis	rs7809950	0.817	rs2712195	chr7:107127496	C/T	cg23024343	chr7:107201750	COG5	-0.85	-14.15	-0.57	1.79e-37	Coronary artery disease;
LUAD	cis	rs76878669	0.561	rs4930178	chr11:66129442	C/G	cg18002602	chr11:66138449	SLC29A2	0.47	10.16	0.44	7.74e-22	Educational attainment (years of education);
LUAD	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg00383909	chr3:49044727	WDR6	0.99	10.64	0.46	1.41e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg08999081	chr20:33150536	PIGU	-0.63	-14.1	-0.57	2.82e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg17366294	chr4:99064904	C4orf37	0.59	9.98	0.44	3.42e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs892085	0.654	rs8106691	chr19:10889469	C/A	cg17710535	chr19:10819994	QTRT1	0.36	6.58	0.3	1.39e-10	Psoriasis vulgaris;Psoriasis;
LUAD	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs6547631	0.527	rs55665393	chr2:85927727	T/C	cg21473183	chr2:85925749	GNLY	0.34	7.03	0.32	8.14e-12	Blood protein levels;
LUAD	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg22868518	chr11:507468	RNH1	-0.66	-6.47	-0.3	2.68e-10	Body mass index;
LUAD	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg08280861	chr8:58055591	NA	0.56	7.1	0.33	5.34e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg00310523	chr12:86230176	RASSF9	-0.33	-6.66	-0.31	8.76e-11	Major depressive disorder;
LUAD	cis	rs2286885	1.000	rs2277159	chr9:129243383	C/T	cg15282417	chr9:129245246	FAM125B	0.44	9.07	0.4	4.45e-18	Intraocular pressure;
LUAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg00106254	chr7:1943704	MAD1L1	-0.56	-8.37	-0.38	8.34e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.48	-0.34	4.45e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg16325326	chr1:53192061	ZYG11B	0.58	10.52	0.46	3.94e-23	Monocyte count;
LUAD	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.09	0.37	6.3e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.3	-0.37	1.38e-15	Height;
LUAD	trans	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.0	-0.4	7.63e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4700695	0.841	rs36301	chr5:65348940	A/G	cg21114390	chr5:65439923	SFRS12	0.62	7.57	0.35	2.32e-13	Facial morphology (factor 19);
LUAD	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg20701182	chr2:24300061	SF3B14	0.62	6.9	0.32	1.96e-11	Lymphocyte counts;
LUAD	cis	rs7264396	0.616	rs6142476	chr20:34581216	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.52	-0.3	2.02e-10	Total cholesterol levels;
LUAD	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg15133208	chr4:90757351	SNCA	-0.46	-7.05	-0.32	7.14e-12	Neuroticism;
LUAD	cis	rs62238980	0.614	rs2413064	chr22:32458536	G/T	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg23254163	chr1:152506842	NA	0.24	6.67	0.31	8.1e-11	Hair morphology;
LUAD	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.12	-0.44	1.04e-21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg04398451	chr17:18023971	MYO15A	-0.64	-11.72	-0.5	1.11e-27	Total body bone mineral density;
LUAD	cis	rs870825	0.616	rs3184982	chr4:185615768	T/G	cg04058563	chr4:185651563	MLF1IP	0.88	14.09	0.57	3.19e-37	Blood protein levels;
LUAD	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg24558204	chr6:135376177	HBS1L	0.49	8.97	0.4	9.38e-18	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg16989719	chr2:238392110	NA	-0.35	-6.87	-0.32	2.33e-11	Prostate cancer;
LUAD	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg17971929	chr21:40555470	PSMG1	0.52	7.8	0.35	4.84e-14	Cognitive function;
LUAD	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg06766960	chr11:133703094	NA	-0.45	-8.5	-0.38	3.25e-16	Childhood ear infection;
LUAD	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.26e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.62	9.17	0.41	2.06e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg24644049	chr4:85504048	CDS1	0.84	7.69	0.35	1.02e-13	Skin colour saturation;
LUAD	cis	rs9473147	0.543	rs9473119	chr6:47450618	G/A	cg02130027	chr6:47444894	CD2AP	0.36	6.76	0.31	4.52e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.98	0.36	1.35e-14	Depression;
LUAD	trans	rs4714291	0.862	rs2984433	chr6:39973445	T/G	cg02267698	chr19:7991119	CTXN1	-0.46	-7.19	-0.33	2.92e-12	Strep throat;
LUAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg27454412	chr7:1067447	C7orf50	0.44	7.03	0.32	8.56e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg21475434	chr5:93447410	FAM172A	0.74	8.28	0.37	1.65e-15	Diabetic retinopathy;
LUAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.62	-10.8	-0.46	3.55e-24	Lymphocyte counts;
LUAD	cis	rs10129255	0.500	rs6576226	chr14:107186374	G/A	cg23076370	chr14:107095027	NA	-0.44	-8.73	-0.39	6.02e-17	Kawasaki disease;
LUAD	cis	rs300774	1.000	rs300778	chr2:111964	C/A	cg21211680	chr2:198530	NA	-0.44	-6.41	-0.3	3.97e-10	Suicide attempts in bipolar disorder;
LUAD	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg06784218	chr1:46089804	CCDC17	-0.55	-11.77	-0.5	7.63e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs938554	0.876	rs6449139	chr4:9934111	A/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.2	-0.37	2.98e-15	Blood metabolite levels;
LUAD	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg21724239	chr8:58056113	NA	0.78	9.07	0.4	4.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7178572	0.568	rs4886515	chr15:77686886	G/A	cg15453836	chr15:77711506	NA	-0.36	-6.42	-0.3	3.59e-10	Type 2 diabetes;
LUAD	trans	rs9951602	0.512	rs4798995	chr18:76654344	T/G	cg02800362	chr5:177631904	HNRNPAB	0.91	14.57	0.58	3.06e-39	Obesity-related traits;
LUAD	trans	rs12517041	1.000	rs995215	chr5:23285366	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.47	-0.3	2.73e-10	Calcium levels;
LUAD	cis	rs9972944	0.756	rs9901885	chr17:63769559	T/C	cg07283582	chr17:63770753	CCDC46	-0.5	-11.12	-0.48	2.27e-25	Total body bone mineral density;
LUAD	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg19046167	chr17:80928561	B3GNTL1	0.42	6.67	0.31	8.1e-11	Glycated hemoglobin levels;
LUAD	cis	rs11048434	0.736	rs12423746	chr12:9113002	G/T	cg23795048	chr12:9217529	LOC144571	0.41	7.33	0.34	1.17e-12	Sjögren's syndrome;
LUAD	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.69	-13.54	-0.55	5.83e-35	Ulcerative colitis;
LUAD	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg09654669	chr8:57350985	NA	-0.65	-9.95	-0.44	4.35e-21	Obesity-related traits;
LUAD	cis	rs4700695	0.841	rs417152	chr5:65316205	G/A	cg21114390	chr5:65439923	SFRS12	0.65	7.91	0.36	2.32e-14	Facial morphology (factor 19);
LUAD	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg17366294	chr4:99064904	C4orf37	0.65	12.41	0.52	2.27e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	11.79	0.5	6.1e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs34734847	1.000	rs55730005	chr12:121157536	C/A	cg27246729	chr12:121163418	ACADS	0.39	7.41	0.34	6.75e-13	Mean corpuscular volume;
LUAD	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg01851573	chr8:8652454	MFHAS1	0.37	6.73	0.31	5.49e-11	Mood instability;
LUAD	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22496380	chr5:211416	CCDC127	-0.97	-13.46	-0.55	1.27e-34	Breast cancer;
LUAD	cis	rs13064411	0.696	rs2129434	chr3:113138763	A/C	cg10517650	chr3:113235015	CCDC52	-0.51	-8.74	-0.39	5.69e-17	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs981844	0.740	rs6858578	chr4:154682058	G/T	cg10279832	chr4:154682576	RNF175	0.34	6.98	0.32	1.15e-11	Response to statins (LDL cholesterol change);
LUAD	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg26022315	chr17:47021804	SNF8	0.41	7.37	0.34	9.33e-13	Type 2 diabetes;
LUAD	trans	rs1941687	0.563	rs7238931	chr18:31334993	G/A	cg27147174	chr7:100797783	AP1S1	-0.69	-12.47	-0.52	1.25e-30	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	trans	rs3219090	0.861	rs1341334	chr1:226605024	A/G	cg27539482	chr13:111589090	NA	0.43	7.26	0.33	1.82e-12	Melanoma;
LUAD	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21582582	chr3:182698605	DCUN1D1	0.59	10.12	0.44	1.06e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs10089	1.000	rs883074	chr5:127445823	C/T	cg19767477	chr5:127420684	SLC12A2	0.41	6.51	0.3	2.07e-10	Ileal carcinoids;
LUAD	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.11	-0.4	3.39e-18	Life satisfaction;
LUAD	cis	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg03474202	chr17:45855739	NA	-0.42	-8.82	-0.39	2.95e-17	IgG glycosylation;
LUAD	cis	rs68170813	0.562	rs7810216	chr7:107000353	G/A	cg23024343	chr7:107201750	COG5	0.52	7.39	0.34	8.04e-13	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.78	0.53	7.72e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.49	-0.34	4.08e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg14671364	chr1:107599128	PRMT6	0.6	10.14	0.44	9.14e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1775715	0.513	rs2808089	chr10:32145112	A/T	cg04359828	chr10:32216031	ARHGAP12	0.31	6.48	0.3	2.51e-10	Bipolar disorder with mood-incongruent psychosis;
LUAD	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.23	0.54	1.09e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg12964065	chr18:77638022	KCNG2	0.56	6.9	0.32	1.93e-11	Opioid sensitivity;
LUAD	cis	rs1448094	0.802	rs56391398	chr12:86424114	C/T	cg02569458	chr12:86230093	RASSF9	0.38	7.16	0.33	3.54e-12	Major depressive disorder;
LUAD	cis	rs34638657	0.833	rs7200628	chr16:82200747	C/T	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.58	-0.3	1.38e-10	Lung adenocarcinoma;
LUAD	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg23758822	chr17:41437982	NA	1.02	20.97	0.71	1.82e-67	Menopause (age at onset);
LUAD	cis	rs3916	1.000	rs3916	chr12:121177272	G/C	cg27246729	chr12:121163418	ACADS	0.46	7.38	0.34	8.51e-13	Urinary metabolites (H-NMR features);
LUAD	cis	rs490234	0.841	rs1755936	chr9:128388991	C/G	cg14078157	chr9:128172775	NA	-0.41	-7.68	-0.35	1.11e-13	Mean arterial pressure;
LUAD	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg16479474	chr6:28041457	NA	0.45	7.73	0.35	7.89e-14	Depression;
LUAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg00106254	chr7:1943704	MAD1L1	0.51	7.82	0.36	4.31e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs11514810	1.000	rs9648619	chr7:1427949	G/T	cg24899294	chr7:1481343	MICALL2	-0.74	-7.67	-0.35	1.19e-13	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LUAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07167872	chr1:205819463	PM20D1	0.77	15.52	0.6	2.68e-43	Menarche (age at onset);
LUAD	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg22029157	chr1:209979665	IRF6	0.77	9.25	0.41	1.15e-18	Coronary artery disease;
LUAD	cis	rs757647	0.723	rs2269949	chr5:137730183	G/C	cg10676309	chr5:137685565	NA	0.43	7.59	0.35	2.07e-13	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg18230493	chr5:56204884	C5orf35	0.51	8.13	0.37	4.82e-15	Type 2 diabetes;
LUAD	trans	rs4650994	0.935	rs12039531	chr1:178515612	G/A	cg05059571	chr16:84539110	KIAA1609	-0.61	-10.56	-0.46	2.79e-23	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.61	0.31	1.15e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg11098525	chr4:1320231	MAEA	-0.39	-6.49	-0.3	2.34e-10	Obesity-related traits;
LUAD	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-7.6	-0.35	1.9e-13	Lung cancer;
LUAD	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg08645402	chr16:4508243	NA	0.53	9.45	0.42	2.31e-19	Schizophrenia;
LUAD	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg11266682	chr4:10021025	SLC2A9	-0.59	-12.45	-0.52	1.56e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg00339695	chr16:24857497	SLC5A11	0.69	11.38	0.48	2.41e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9354308	0.933	rs2814134	chr6:66566658	C/G	cg07460842	chr6:66804631	NA	0.49	7.28	0.33	1.66e-12	Metabolite levels;
LUAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.51	-0.38	3.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10979	1.000	rs9484768	chr6:143887928	C/T	cg25407410	chr6:143891975	LOC285740	-0.64	-10.29	-0.45	2.66e-22	Hypospadias;
LUAD	cis	rs17092148	0.836	rs4322911	chr20:33182577	G/A	cg16810054	chr20:33298113	TP53INP2	-0.48	-7.39	-0.34	8.04e-13	Neuroticism;
LUAD	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg13319975	chr6:146136371	FBXO30	-0.64	-11.24	-0.48	8.14e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs57994353	0.828	rs11146021	chr9:139327858	A/G	cg14169450	chr9:139327907	INPP5E	-0.42	-7.24	-0.33	2.07e-12	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg14664628	chr15:75095509	CSK	-0.6	-9.66	-0.42	4.57e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg07570687	chr10:102243282	WNT8B	0.43	6.41	0.3	3.91e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg13047869	chr3:10149882	C3orf24	0.64	11.02	0.47	5.16e-25	Alzheimer's disease;
LUAD	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg20290983	chr6:43655470	MRPS18A	1.06	27.12	0.8	1.39e-94	IgG glycosylation;
LUAD	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg05368731	chr17:41323189	NBR1	0.83	15.83	0.61	1.16e-44	Menopause (age at onset);
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05535924	chr12:4430746	C12orf5	0.42	6.55	0.3	1.67e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.23	0.37	2.35e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg02782426	chr3:40428986	ENTPD3	0.4	8.31	0.37	1.33e-15	Renal cell carcinoma;
LUAD	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg11494091	chr17:61959527	GH2	0.44	8.26	0.37	1.87e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.6	-0.52	3.83e-31	Monocyte count;
LUAD	cis	rs6496044	0.963	rs11853972	chr15:86062440	A/G	cg13263323	chr15:86062960	AKAP13	-0.54	-9.47	-0.42	1.92e-19	Interstitial lung disease;
LUAD	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg15181151	chr6:150070149	PCMT1	0.33	6.56	0.3	1.59e-10	Lung cancer;
LUAD	cis	rs593982	0.719	rs11606668	chr11:65472758	A/G	cg08755490	chr11:65554678	OVOL1	-1.02	-12.73	-0.53	1.21e-31	Atopic dermatitis;
LUAD	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.48	-6.94	-0.32	1.49e-11	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg05340658	chr4:99064831	C4orf37	0.55	9.34	0.41	5.72e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg16950941	chr11:66035639	RAB1B	0.46	7.76	0.35	6.27e-14	Gout;
LUAD	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg00631329	chr6:26305371	NA	-0.71	-13.62	-0.55	2.81e-35	Educational attainment;
LUAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg05434287	chr7:2030229	MAD1L1	0.4	6.49	0.3	2.41e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2882667	0.931	rs10075039	chr5:138337854	A/G	cg04439458	chr5:138467593	SIL1	-0.39	-7.23	-0.33	2.26e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.37	6.92	0.32	1.71e-11	Depressive symptoms;
LUAD	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-13.67	-0.55	1.77e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg11266682	chr4:10021025	SLC2A9	0.62	14.51	0.58	5.27e-39	Bone mineral density;
LUAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg22535103	chr8:58192502	C8orf71	-0.75	-9.19	-0.41	1.85e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs775227	1.000	rs66518523	chr3:113004759	G/T	cg18753928	chr3:113234510	CCDC52	-0.48	-6.63	-0.31	1.03e-10	Dental caries;
LUAD	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.66	0.31	8.34e-11	Menarche (age at onset);
LUAD	trans	rs141342723	1	rs141342723	chr6:27622084	T/C	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.65	-0.46	1.24e-23	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7542375	0.507	rs2484697	chr1:221094718	A/G	cg16008148	chr1:221062819	NA	0.42	8.37	0.38	8.77e-16	Obesity-related traits;
LUAD	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg07741184	chr6:167504864	NA	0.29	7.03	0.32	8.43e-12	Crohn's disease;
LUAD	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg26384229	chr12:38710491	ALG10B	0.46	7.44	0.34	5.62e-13	Bladder cancer;
LUAD	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg04117972	chr1:227635322	NA	0.67	6.78	0.31	3.94e-11	Major depressive disorder;
LUAD	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg06547715	chr2:218990976	CXCR2	-0.28	-6.9	-0.32	1.93e-11	Colorectal cancer;
LUAD	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg17644776	chr2:200775616	C2orf69	0.54	7.22	0.33	2.36e-12	Schizophrenia;
LUAD	cis	rs986417	0.818	rs1010051	chr14:61002988	G/C	cg27398547	chr14:60952738	C14orf39	0.66	7.85	0.36	3.45e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-7.58	-0.35	2.28e-13	Blood metabolite levels;
LUAD	cis	rs459571	0.715	rs401826	chr9:136890591	C/T	cg13789015	chr9:136890014	NCRNA00094	0.84	14.12	0.57	2.41e-37	Platelet distribution width;
LUAD	cis	rs1595825	0.891	rs7587716	chr2:198630667	G/T	cg00982548	chr2:198649783	BOLL	-0.65	-9.06	-0.4	4.77e-18	Ulcerative colitis;
LUAD	cis	rs10788972	0.873	rs4926619	chr1:54558101	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.24	-6.77	-0.31	4.28e-11	Parkinson disease and lewy body pathology;
LUAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg11941060	chr3:133502564	NA	-0.69	-12.46	-0.52	1.45e-30	Iron status biomarkers;
LUAD	trans	rs1493916	0.777	rs1845385	chr18:31318336	T/C	cg15819921	chr19:927150	ARID3A	-0.43	-7.17	-0.33	3.33e-12	Life satisfaction;
LUAD	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg03433033	chr1:76189801	ACADM	-0.84	-14.6	-0.58	2.18e-39	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg22676075	chr6:135203613	NA	0.41	7.69	0.35	1.08e-13	Red blood cell count;
LUAD	cis	rs6546550	0.901	rs897119	chr2:70160658	T/C	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.1	-0.48	2.58e-25	Prevalent atrial fibrillation;
LUAD	cis	rs2073300	1.000	rs6132629	chr20:23451251	G/A	cg12062639	chr20:23401060	NAPB	0.75	6.96	0.32	1.28e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg23758822	chr17:41437982	NA	1.0	20.98	0.71	1.6e-67	Menopause (age at onset);
LUAD	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.54	-0.34	2.87e-13	Neutrophil percentage of white cells;
LUAD	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg07432352	chr17:45403706	C17orf57	-0.43	-8.31	-0.37	1.32e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg21385522	chr1:16154831	NA	0.57	9.6	0.42	7.31e-20	Systolic blood pressure;
LUAD	cis	rs12505328	0.966	rs1530304	chr4:174369401	A/T	cg12145043	chr4:174357286	NA	0.56	10.41	0.45	9.95e-23	Chin dimples;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg20266104	chr17:21116851	TMEM11	0.42	6.69	0.31	6.89e-11	Bilirubin levels;
LUAD	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg09165964	chr15:75287851	SCAMP5	-0.45	-6.84	-0.32	2.75e-11	Blood trace element (Zn levels);
LUAD	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg18721089	chr20:30220636	NA	-0.47	-6.72	-0.31	5.96e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg20607798	chr8:58055168	NA	0.81	9.79	0.43	1.6e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.56	-0.42	9.81e-20	Alzheimer's disease;
LUAD	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg18252515	chr7:66147081	NA	-0.63	-6.94	-0.32	1.5e-11	Gout;
LUAD	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg24642844	chr7:1081250	C7orf50	-0.7	-8.3	-0.37	1.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg09117114	chr16:67998030	SLC12A4	0.51	6.71	0.31	6.33e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg12035532	chr1:1886765	KIAA1751	-0.4	-6.76	-0.31	4.7e-11	Body mass index;
LUAD	trans	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	15.43	0.6	6.41e-43	Exhaled nitric oxide levels;
LUAD	trans	rs7395662	0.963	rs4882112	chr11:48561083	G/C	cg00717180	chr2:96193071	NA	-0.39	-7.31	-0.33	1.32e-12	HDL cholesterol;
LUAD	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg05368731	chr17:41323189	NBR1	0.98	20.4	0.7	6.3e-65	Menopause (age at onset);
LUAD	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06022373	chr22:39101656	GTPBP1	0.47	7.3	0.33	1.43e-12	Menopause (age at onset);
LUAD	cis	rs12681288	0.676	rs34435811	chr8:990630	T/A	cg15309053	chr8:964076	NA	0.43	9.02	0.4	6.48e-18	Schizophrenia;
LUAD	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg05991184	chr2:219186017	PNKD	-0.36	-6.93	-0.32	1.56e-11	Colorectal cancer;
LUAD	cis	rs752010	0.668	rs10890147	chr1:42089725	A/T	cg06885757	chr1:42089581	HIVEP3	0.64	14.51	0.58	5.42e-39	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs17655565	0.533	rs12825729	chr12:52706854	G/A	cg08257133	chr12:52711352	KRT83	0.41	9.9	0.43	6.65e-21	Plasma amyloid beta peptide concentrations (ABx-42);
LUAD	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08564027	chr20:61660810	NA	0.88	18.83	0.68	6.9e-58	Prostate cancer (SNP x SNP interaction);
LUAD	trans	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg07461501	chr17:79650226	HGS;ARL16	-0.72	-9.9	-0.43	6.41e-21	Obesity-related traits;
LUAD	cis	rs12545109	0.800	rs1595940	chr8:57398309	T/C	cg17761419	chr8:57350749	NA	-0.56	-8.01	-0.36	1.09e-14	Obesity-related traits;
LUAD	cis	rs798766	1.000	rs798767	chr4:1734281	A/G	cg05874882	chr4:1763078	NA	-0.36	-6.39	-0.3	4.5e-10	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg23887609	chr12:130822674	PIWIL1	0.39	6.37	0.3	4.97e-10	Menopause (age at onset);
LUAD	cis	rs4006360	0.578	rs9893220	chr17:39231963	C/A	cg20663846	chr17:39254439	KRTAP4-8	0.39	8.84	0.39	2.61e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg12310025	chr6:25882481	NA	-0.39	-6.38	-0.3	4.58e-10	Height;
LUAD	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg06640241	chr16:89574553	SPG7	0.52	8.31	0.37	1.31e-15	Multiple myeloma (IgH translocation);
LUAD	cis	rs4925114	0.568	rs11656775	chr17:17654319	A/G	cg04398451	chr17:18023971	MYO15A	0.41	6.54	0.3	1.76e-10	Body mass index;
LUAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27297192	chr10:134578999	INPP5A	0.37	6.73	0.31	5.52e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg09491104	chr22:46646882	C22orf40	-0.62	-10.29	-0.45	2.64e-22	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg09945482	chr18:12777974	NA	0.54	6.77	0.31	4.44e-11	Inflammatory skin disease;
LUAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	12.7	0.53	1.63e-31	Prudent dietary pattern;
LUAD	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg05991184	chr2:219186017	PNKD	-0.37	-7.36	-0.34	9.75e-13	Colorectal cancer;
LUAD	cis	rs4372836	0.929	rs11675572	chr2:28931376	G/T	cg09522027	chr2:28974177	PPP1CB	0.59	8.79	0.39	3.79e-17	Body mass index;
LUAD	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs853679	0.599	rs156743	chr6:27967089	T/C	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.46	-0.34	4.91e-13	Depression;
LUAD	cis	rs7945705	0.875	rs10769957	chr11:8809016	A/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.32	-6.54	-0.3	1.75e-10	Hemoglobin concentration;
LUAD	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03517284	chr6:25882590	NA	0.85	14.41	0.57	1.36e-38	Blood metabolite levels;
LUAD	cis	rs4601821	1.000	rs4601821	chr11:113250346	A/G	cg14159747	chr11:113255604	NA	0.49	9.37	0.41	4.31e-19	Alcoholic chronic pancreatitis;
LUAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12016809	chr21:47604291	C21orf56	-0.65	-10.96	-0.47	8.98e-25	Testicular germ cell tumor;
LUAD	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg20701182	chr2:24300061	SF3B14	0.89	13.25	0.54	9.46e-34	Lymphocyte counts;
LUAD	cis	rs7709909	0.553	rs32953	chr5:80021601	C/A	cg24059623	chr5:79951536	MSH3;DHFR	0.49	7.32	0.34	1.28e-12	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs977987	0.835	rs4888379	chr16:75340231	A/T	cg03315344	chr16:75512273	CHST6	0.61	13.51	0.55	8.24e-35	Dupuytren's disease;
LUAD	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg04267008	chr7:1944627	MAD1L1	-0.74	-11.89	-0.5	2.63e-28	Bipolar disorder and schizophrenia;
LUAD	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg17063962	chr7:91808500	NA	0.59	9.78	0.43	1.74e-20	Breast cancer;
LUAD	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.77	-0.53	8.14e-32	Monocyte count;
LUAD	cis	rs11077998	0.967	rs11657886	chr17:80516173	T/C	cg10255544	chr17:80519551	FOXK2	0.35	6.86	0.32	2.39e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs877282	1.000	rs112522746	chr10:772288	T/C	cg17470449	chr10:769945	NA	0.68	10.67	0.46	1.06e-23	Uric acid levels;
LUAD	cis	rs10788264	0.504	rs4751883	chr10:124018027	A/C	cg09507567	chr10:124027408	NA	0.49	10.83	0.47	2.71e-24	Total body bone mineral density;
LUAD	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg22963979	chr7:1858916	MAD1L1	-0.57	-9.59	-0.42	7.48e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg13012494	chr21:47604986	C21orf56	0.46	7.57	0.35	2.43e-13	Testicular germ cell tumor;
LUAD	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg21427119	chr20:30132790	HM13	-0.5	-8.09	-0.37	6.53e-15	Mean corpuscular hemoglobin;
LUAD	cis	rs6005807	0.719	rs12167434	chr22:29040821	C/T	cg12565055	chr22:29076175	TTC28	0.74	8.71	0.39	6.98e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs684232	0.623	rs2543779	chr17:576362	C/A	cg15660573	chr17:549704	VPS53	-0.77	-15.11	-0.59	1.46e-41	Prostate cancer;
LUAD	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg00071950	chr4:10020882	SLC2A9	0.82	17.08	0.64	4.06e-50	Bone mineral density;
LUAD	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg26597838	chr10:835615	NA	0.83	11.28	0.48	5.7e-26	Eosinophil percentage of granulocytes;
LUAD	cis	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg01251360	chr16:68772225	CDH1	-0.27	-8.61	-0.39	1.5e-16	Colorectal cancer;
LUAD	cis	rs7089973	0.966	rs55711292	chr10:116604870	T/G	cg25233709	chr10:116636983	FAM160B1	0.36	6.77	0.31	4.41e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7589728	0.748	rs3791357	chr2:88478664	C/T	cg18490616	chr2:88469792	THNSL2	0.73	6.97	0.32	1.23e-11	Plasma clusterin levels;
LUAD	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg14552801	chr7:65878734	NA	0.39	6.77	0.31	4.37e-11	Aortic root size;
LUAD	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg10802521	chr3:52805072	NEK4	0.49	8.44	0.38	5.14e-16	Bipolar disorder;
LUAD	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg03233332	chr7:66118400	NA	-0.44	-6.69	-0.31	6.95e-11	Aortic root size;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg23806609	chr7:66369525	NA	-0.39	-6.55	-0.3	1.63e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg07708487	chr16:89387014	ANKRD11	-0.33	-6.65	-0.31	9.34e-11	Multiple myeloma (IgH translocation);
LUAD	trans	rs75804782	0.625	rs72984535	chr2:239470022	T/C	cg01134436	chr17:81009848	B3GNTL1	0.75	7.67	0.35	1.19e-13	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg03340356	chr1:67600835	NA	0.43	7.45	0.34	5.42e-13	Psoriasis;
LUAD	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg17971929	chr21:40555470	PSMG1	0.56	8.87	0.4	2.04e-17	Cognitive function;
LUAD	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.64e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg03188948	chr7:1209495	NA	0.39	6.58	0.3	1.37e-10	Longevity;Endometriosis;
LUAD	cis	rs11809207	1.000	rs34587428	chr1:26522392	C/T	cg00300879	chr1:26503847	CNKSR1	0.28	6.87	0.32	2.34e-11	Height;
LUAD	trans	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg13565492	chr6:43139072	SRF	-0.62	-7.1	-0.33	5.28e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62238980	0.614	rs77407792	chr22:32461465	C/A	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs6840360	0.571	rs72728182	chr4:152487027	T/C	cg22705602	chr4:152727874	NA	-0.4	-7.01	-0.32	9.72e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4888262	0.508	rs7193583	chr16:74649589	C/G	cg01733217	chr16:74700730	RFWD3	0.51	8.62	0.39	1.4e-16	Testicular germ cell tumor;
LUAD	cis	rs4692589	0.965	rs6842442	chr4:170933203	C/T	cg19918862	chr4:170955249	NA	0.29	6.92	0.32	1.73e-11	Anxiety disorder;
LUAD	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg05187965	chr10:45406764	TMEM72	-0.5	-10.14	-0.44	9.16e-22	Mean corpuscular volume;
LUAD	cis	rs123509	0.687	rs73075301	chr3:42832650	C/T	cg10144569	chr3:42726640	KBTBD5	-0.48	-7.11	-0.33	5.06e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-10.36	-0.45	1.49e-22	Chronic sinus infection;
LUAD	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg04450456	chr4:17643702	FAM184B	0.36	6.89	0.32	2.05e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7737355	0.947	rs244733	chr5:130822778	T/C	cg25547332	chr5:131281432	NA	0.42	6.37	0.3	4.99e-10	Life satisfaction;
LUAD	trans	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg21659725	chr3:3221576	CRBN	0.38	6.45	0.3	3.15e-10	Resting heart rate;
LUAD	cis	rs847577	0.609	rs705308	chr7:97695363	C/A	cg21770322	chr7:97807741	LMTK2	-0.31	-7.37	-0.34	9.12e-13	Breast cancer;
LUAD	cis	rs6445967	0.530	rs62258095	chr3:58372462	T/C	cg23715586	chr3:58305044	RPP14	0.39	6.46	0.3	2.92e-10	Platelet count;
LUAD	cis	rs9469913	0.733	rs2814986	chr6:34602685	T/C	cg14254433	chr6:34482411	PACSIN1	-0.43	-6.61	-0.31	1.15e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg12311346	chr5:56204834	C5orf35	-0.51	-8.08	-0.37	7.06e-15	Coronary artery disease;
LUAD	cis	rs713587	0.776	rs3731623	chr2:25163783	T/C	cg01884057	chr2:25150051	NA	0.32	6.73	0.31	5.43e-11	Body mass index in non-asthmatics;
LUAD	trans	rs9393777	0.920	rs35120058	chr6:27358166	A/G	cg01620082	chr3:125678407	NA	-0.78	-8.39	-0.38	7.57e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00684032	chr4:1343700	KIAA1530	0.49	7.92	0.36	2.12e-14	Obesity-related traits;
LUAD	cis	rs10744422	1.000	rs4993320	chr12:123338092	T/C	cg16953816	chr12:123349952	VPS37B	0.59	6.49	0.3	2.47e-10	Schizophrenia;
LUAD	cis	rs2235649	0.746	rs113666107	chr16:1848642	C/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-6.72	-0.31	6.01e-11	Blood metabolite levels;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg12680326	chr20:2821316	VPS16;FAM113A	0.39	6.38	0.3	4.66e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.46	8.04	0.36	9.16e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7937682	0.562	rs955744	chr11:111374334	C/T	cg09085632	chr11:111637200	PPP2R1B	0.42	6.92	0.32	1.72e-11	Primary sclerosing cholangitis;
LUAD	cis	rs1018836	0.631	rs9987164	chr8:91470910	T/G	cg16814680	chr8:91681699	NA	-0.56	-9.26	-0.41	1.01e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs494562	0.892	rs9353310	chr6:86126199	C/T	cg17966619	chr6:86160162	NT5E	0.67	7.92	0.36	2.16e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg09184832	chr6:79620586	NA	-0.52	-9.9	-0.43	6.41e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg18876405	chr7:65276391	NA	-0.42	-6.71	-0.31	6.18e-11	Aortic root size;
LUAD	cis	rs1385374	0.858	rs12305142	chr12:129277490	C/T	cg09035930	chr12:129282057	SLC15A4	-0.6	-6.72	-0.31	5.98e-11	Systemic lupus erythematosus;
LUAD	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20456258	chr4:962124	DGKQ	0.4	6.82	0.31	3.18e-11	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.71	12.98	0.53	1.19e-32	Lymphocyte counts;
LUAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.61	-10.67	-0.46	1.06e-23	Lymphocyte counts;
LUAD	cis	rs2274471	0.680	rs10974907	chr9:5002188	C/A	cg03390472	chr9:5043263	JAK2	-0.58	-8.93	-0.4	1.36e-17	Crohn's disease;
LUAD	cis	rs3774830	0.776	rs195126	chr4:5429872	T/C	cg26943120	chr4:5472116	STK32B	-0.32	-6.36	-0.3	5.4e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12545109	0.800	rs1837617	chr8:57417592	C/T	cg07776626	chr8:57350775	NA	-0.61	-8.83	-0.39	2.83e-17	Obesity-related traits;
LUAD	cis	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.68	-0.31	7.59e-11	Retinal vascular caliber;
LUAD	cis	rs6499255	0.904	rs12447883	chr16:69722797	T/C	cg15192750	chr16:69999425	NA	0.54	8.05	0.36	8.41e-15	IgE levels;
LUAD	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg04455712	chr21:45112962	RRP1B	0.46	9.13	0.41	2.9e-18	Mean corpuscular volume;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg01585723	chr16:33734837	NA	0.35	6.35	0.3	5.64e-10	Menopause (age at onset);
LUAD	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg05368731	chr17:41323189	NBR1	0.96	20.23	0.7	3.7e-64	Menopause (age at onset);
LUAD	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg25173405	chr17:45401733	C17orf57	0.51	8.86	0.4	2.26e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg23173402	chr1:227635558	NA	0.74	7.99	0.36	1.27e-14	Major depressive disorder;
LUAD	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg12927641	chr6:109611667	NA	0.52	9.59	0.42	7.98e-20	Reticulocyte fraction of red cells;
LUAD	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg25985355	chr7:65971099	NA	-0.54	-6.63	-0.31	1.05e-10	Diabetic kidney disease;
LUAD	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg10755058	chr3:40428713	ENTPD3	0.44	8.52	0.38	2.75e-16	Renal cell carcinoma;
LUAD	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg00684032	chr4:1343700	KIAA1530	0.41	6.77	0.31	4.32e-11	Obesity-related traits;
LUAD	trans	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.69	-9.46	-0.42	2.16e-19	Obesity-related traits;
LUAD	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg21782813	chr7:2030301	MAD1L1	0.47	7.77	0.35	5.97e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg08885076	chr2:99613938	TSGA10	0.36	6.5	0.3	2.33e-10	Chronic sinus infection;
LUAD	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg17264618	chr3:40429014	ENTPD3	0.41	8.84	0.39	2.61e-17	Renal cell carcinoma;
LUAD	cis	rs938554	0.829	rs5028843	chr4:9940806	G/A	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.81	-0.35	4.58e-14	Blood metabolite levels;
LUAD	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg25173405	chr17:45401733	C17orf57	0.52	8.95	0.4	1.16e-17	Multiple sclerosis or amyotrophic lateral sclerosis;
LUAD	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg24675056	chr1:15929824	NA	0.48	8.39	0.38	7.12e-16	Systolic blood pressure;
LUAD	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.05e-19	Life satisfaction;
LUAD	cis	rs4072705	0.615	rs7028021	chr9:127249022	A/G	cg01786973	chr9:127249749	NR5A1	0.3	6.68	0.31	7.39e-11	Menarche (age at onset);
LUAD	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg24558204	chr6:135376177	HBS1L	0.45	8.32	0.38	1.21e-15	Red blood cell count;
LUAD	cis	rs813218	0.647	rs6788750	chr3:99774720	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.44	8.23	0.37	2.42e-15	Orofacial clefts;
LUAD	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.41	-0.52	2.21e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18918831	chr3:195489782	MUC4	0.6	7.17	0.33	3.33e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg26587870	chr6:27730563	NA	-0.46	-7.52	-0.34	3.33e-13	Parkinson's disease;
LUAD	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg05564831	chr3:52568323	NT5DC2	-0.38	-6.94	-0.32	1.49e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11971779	0.553	rs10085770	chr7:139100349	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	7.16e-11	Diisocyanate-induced asthma;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg05397039	chr1:243419179	SDCCAG8;CEP170	-0.4	-6.7	-0.31	6.6e-11	Subcortical brain region volumes;
LUAD	cis	rs76419734	0.510	rs961473	chr4:106535402	C/G	cg05309399	chr4:106552544	FLJ20184	-0.57	-6.94	-0.32	1.51e-11	Post bronchodilator FEV1;
LUAD	cis	rs12681287	0.640	rs7017706	chr8:87480890	C/T	cg27223183	chr8:87520930	FAM82B	-0.67	-9.61	-0.42	6.38e-20	Caudate activity during reward;
LUAD	cis	rs6484504	0.576	rs2756191	chr11:31135882	A/T	cg14844989	chr11:31128820	NA	0.44	8.07	0.37	7.41e-15	Red blood cell count;
LUAD	cis	rs2502731	0.539	rs3003608	chr9:130984430	C/A	cg09976142	chr9:130955436	CIZ1	0.41	7.59	0.35	2.05e-13	Attention deficit hyperactivity disorder;
LUAD	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.39	6.54	0.3	1.83e-10	Type 2 diabetes;
LUAD	cis	rs113835537	0.559	rs11227497	chr11:66269464	T/C	cg24851651	chr11:66362959	CCS	0.55	9.81	0.43	1.33e-20	Airway imaging phenotypes;
LUAD	cis	rs6500395	1.000	rs924476	chr16:48556847	C/T	cg04672837	chr16:48644449	N4BP1	0.36	6.36	0.3	5.25e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.11	16.0	0.61	2.05e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12681287	0.547	rs7837569	chr8:87507366	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-10.12	-0.44	1.07e-21	Caudate activity during reward;
LUAD	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg25894440	chr7:65020034	NA	-0.68	-7.18	-0.33	3.16e-12	Diabetic kidney disease;
LUAD	cis	rs6960043	0.738	rs10266209	chr7:15058691	C/T	cg19272540	chr7:15055459	NA	-0.38	-8.47	-0.38	4.01e-16	Type 2 diabetes;
LUAD	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg05110241	chr16:68378359	PRMT7	-0.83	-9.16	-0.41	2.3e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg02527881	chr3:46936655	PTH1R	0.43	8.12	0.37	5e-15	Colorectal cancer;
LUAD	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.09e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7809950	1.000	rs2520260	chr7:107172794	A/G	cg23024343	chr7:107201750	COG5	-0.7	-11.83	-0.5	4.19e-28	Coronary artery disease;
LUAD	cis	rs2806561	1.000	rs2746553	chr1:23493246	T/C	cg19743168	chr1:23544995	NA	0.39	7.18	0.33	3.16e-12	Height;
LUAD	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg06608945	chr2:219082296	ARPC2	0.43	7.36	0.34	9.86e-13	Colorectal cancer;
LUAD	cis	rs4730250	0.707	rs257382	chr7:106804249	A/G	cg02696742	chr7:106810147	HBP1	-0.86	-11.38	-0.48	2.34e-26	Osteoarthritis;
LUAD	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg00255919	chr5:131827918	IRF1	-0.28	-6.37	-0.3	5.01e-10	Blood metabolite levels;
LUAD	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg02049041	chr17:27085579	C17orf63	-0.64	-8.53	-0.38	2.59e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg20476274	chr7:133979776	SLC35B4	0.85	17.32	0.64	3.56e-51	Mean platelet volume;
LUAD	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18876405	chr7:65276391	NA	0.43	6.85	0.32	2.58e-11	Aortic root size;
LUAD	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg18512352	chr11:47633146	NA	-0.56	-10.04	-0.44	2.02e-21	Subjective well-being;
LUAD	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg09323728	chr8:95962352	TP53INP1	0.29	6.36	0.3	5.2400000000000005e-10	Type 2 diabetes;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05898928	chr22:22090066	YPEL1	-0.62	-6.4	-0.3	4.06e-10	Type 2 diabetes;
LUAD	cis	rs13095912	0.962	rs12374077	chr3:185317674	G/C	cg11274856	chr3:185301563	NA	0.37	7.48	0.34	4.24e-13	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.04e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg13319975	chr6:146136371	FBXO30	-0.8	-13.59	-0.55	3.7e-35	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg23649088	chr2:200775458	C2orf69	-0.6	-8.48	-0.38	3.78e-16	Schizophrenia;
LUAD	trans	rs877282	0.685	rs56234340	chr10:781339	A/G	cg22713356	chr15:30763199	NA	1.24	17.88	0.66	1.13e-53	Uric acid levels;
LUAD	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.22	-0.33	2.5e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6445967	0.554	rs7230	chr3:58413662	G/A	cg13750441	chr3:58318267	PXK	-0.31	-6.48	-0.3	2.55e-10	Platelet count;
LUAD	cis	rs9378688	1.000	rs9392374	chr6:2223002	T/G	cg12303981	chr6:2244766	GMDS	-0.45	-6.55	-0.3	1.68e-10	Caudate nucleus volume;
LUAD	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg23533926	chr12:111358616	MYL2	-0.4	-6.77	-0.31	4.23e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg26597838	chr10:835615	NA	0.68	8.87	0.4	2.09e-17	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg03467027	chr4:99064603	C4orf37	0.4	6.49	0.3	2.41e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg13385794	chr1:248469461	NA	0.26	7.04	0.32	7.78e-12	Common traits (Other);
LUAD	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg20607798	chr8:58055168	NA	0.78	9.53	0.42	1.28e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg05283184	chr6:79620031	NA	-0.61	-12.47	-0.52	1.28e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg02931644	chr1:25747376	RHCE	0.48	10.39	0.45	1.17e-22	Erythrocyte sedimentation rate;
LUAD	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg19636519	chr7:99541626	NA	0.4	6.91	0.32	1.78e-11	Coronary artery disease;
LUAD	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg26384229	chr12:38710491	ALG10B	0.45	7.13	0.33	4.42e-12	Heart rate;
LUAD	cis	rs6499255	0.951	rs7200935	chr16:69564497	T/C	cg15192750	chr16:69999425	NA	0.48	7.37	0.34	8.97e-13	IgE levels;
LUAD	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg08470875	chr2:26401718	FAM59B	-0.6	-8.2	-0.37	2.96e-15	Gut microbiome composition (summer);
LUAD	cis	rs7923837	0.687	rs2185756	chr10:94430497	A/C	cg25093409	chr10:94429542	NA	0.37	6.76	0.31	4.72e-11	Body mass index;Multiple sclerosis;
LUAD	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg00071950	chr4:10020882	SLC2A9	-0.62	-11.74	-0.5	9.24e-28	Bone mineral density;
LUAD	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg02569458	chr12:86230093	RASSF9	0.44	8.09	0.37	6.46e-15	Major depressive disorder;
LUAD	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg18105134	chr13:113819100	PROZ	1.0	18.37	0.67	7.5e-56	Platelet distribution width;
LUAD	cis	rs55788414	0.932	rs34110030	chr16:81185211	G/A	cg06400318	chr16:81190750	PKD1L2	-0.66	-8.36	-0.38	9.41e-16	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg26384229	chr12:38710491	ALG10B	0.44	7.18	0.33	3.14e-12	Bladder cancer;
LUAD	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.44	-6.39	-0.3	4.37e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg13010199	chr12:38710504	ALG10B	0.39	6.45	0.3	3e-10	Bladder cancer;
LUAD	trans	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg12400702	chr3:12838781	CAND2	0.31	6.51	0.3	2.14e-10	Parkinson's disease;
LUAD	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg15369054	chr17:80825471	TBCD	-0.43	-7.27	-0.33	1.8e-12	Breast cancer;
LUAD	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-15.21	-0.59	5.52e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg06547715	chr2:218990976	CXCR2	0.29	6.88	0.32	2.14e-11	Colorectal cancer;
LUAD	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg10518543	chr12:38710700	ALG10B	-0.5	-8.32	-0.37	1.24e-15	Morning vs. evening chronotype;
LUAD	cis	rs863345	0.604	rs10908665	chr1:158499889	T/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	10.4	0.45	1e-22	Electrocardiographic conduction measures;
LUAD	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg06671706	chr8:8559999	CLDN23	0.66	11.41	0.49	1.84e-26	Obesity-related traits;
LUAD	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06112835	chr11:68658793	MRPL21	0.54	9.68	0.43	3.74e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6546550	0.933	rs57278310	chr2:70093647	T/C	cg02498382	chr2:70120550	SNRNP27	-0.56	-10.91	-0.47	1.39e-24	Prevalent atrial fibrillation;
LUAD	cis	rs4619206	1	rs4619206	chr12:1002857	T/C	cg26282236	chr12:1025755	RAD52	0.38	7.0	0.32	1e-11	Lung cancer in ever smokers;
LUAD	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg20290983	chr6:43655470	MRPS18A	-0.83	-12.58	-0.52	4.86e-31	IgG glycosylation;
LUAD	cis	rs11230563	1.000	rs11230563	chr11:60776209	C/T	cg27098804	chr11:60776124	CD6	0.38	7.07	0.32	6.55e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2294693	0.947	rs9296351	chr6:40988102	T/C	cg14769373	chr6:40998127	UNC5CL	-0.52	-8.23	-0.37	2.38e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg19442545	chr10:75533431	FUT11	-0.47	-7.7	-0.35	1e-13	Inflammatory bowel disease;
LUAD	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg06221963	chr1:154839813	KCNN3	-0.88	-21.25	-0.72	1.04e-68	Prostate cancer;
LUAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.45	-6.56	-0.3	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2658782	0.951	rs2608215	chr11:93148817	G/A	cg15737290	chr11:93063684	CCDC67	0.51	7.09	0.33	5.66e-12	Pulmonary function decline;
LUAD	cis	rs420259	0.516	rs11642434	chr16:23540237	C/T	cg00143387	chr16:23521605	GGA2	0.69	9.58	0.42	8.59e-20	Bipolar disorder;
LUAD	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg08027265	chr7:2291960	NA	-0.42	-7.03	-0.32	8.21e-12	Schizophrenia;
LUAD	cis	rs9487051	0.735	rs1341272	chr6:109507533	C/T	cg01475377	chr6:109611718	NA	0.39	7.44	0.34	5.71e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs9354308	0.866	rs2814092	chr6:66547346	C/G	cg07460842	chr6:66804631	NA	0.49	7.47	0.34	4.73e-13	Metabolite levels;
LUAD	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg15790184	chr11:494944	RNH1	0.47	7.47	0.34	4.7e-13	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs3087591	0.960	rs2952999	chr17:29509801	G/T	cg24425628	chr17:29625626	OMG;NF1	0.4	6.51	0.3	2.14e-10	Hip circumference;
LUAD	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25427524	chr10:38739819	LOC399744	-0.77	-14.8	-0.58	3.24e-40	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9308433	0.505	rs867446	chr1:214502322	G/T	cg06198575	chr1:214491504	SMYD2	0.44	7.24	0.33	2.18e-12	IgG glycosylation;
LUAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg22105103	chr4:187893119	NA	0.58	12.77	0.53	7.88e-32	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg00814883	chr7:100076585	TSC22D4	-0.85	-12.41	-0.52	2.21e-30	Platelet count;
LUAD	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg09137382	chr11:130731461	NA	0.43	7.89	0.36	2.53e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.13	0.33	4.3e-12	Menopause (age at onset);
LUAD	cis	rs6062509	0.811	rs6062498	chr20:62339059	C/G	cg02966332	chr20:62369605	LIME1	-0.45	-7.36	-0.34	9.45e-13	Prostate cancer;
LUAD	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.98	0.36	1.42e-14	Parkinson's disease;
LUAD	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg10518543	chr12:38710700	ALG10B	0.44	7.52	0.34	3.32e-13	Heart rate;
LUAD	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg04398451	chr17:18023971	MYO15A	0.71	12.87	0.53	3.15e-32	Total body bone mineral density;
LUAD	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg20587970	chr11:113659929	NA	-1.4	-20.93	-0.71	2.68e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2735413	0.914	rs12448754	chr16:78066747	T/C	cg04733911	chr16:78082701	NA	-0.32	-7.48	-0.34	4.24e-13	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs8014204	0.566	rs752857	chr14:75130944	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.33	-6.36	-0.3	5.1e-10	Caffeine consumption;
LUAD	cis	rs7590720	1.000	rs6755934	chr2:216907198	C/A	cg12620499	chr2:216877984	MREG	0.57	8.89	0.4	1.83e-17	Alcohol dependence;
LUAD	cis	rs1843834	0.898	rs11887386	chr2:225526975	T/G	cg22455342	chr2:225449267	CUL3	0.45	6.69	0.31	6.95e-11	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.47	6.67	0.31	7.88e-11	Platelet count;
LUAD	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg10909506	chr17:38081995	ORMDL3	0.39	6.75	0.31	4.89e-11	Self-reported allergy;
LUAD	trans	rs7395662	0.929	rs10838982	chr11:48640168	C/T	cg15704280	chr7:45808275	SEPT13	-0.44	-6.84	-0.32	2.7e-11	HDL cholesterol;
LUAD	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg06740227	chr12:86229804	RASSF9	0.45	7.88	0.36	2.78e-14	Major depressive disorder;
LUAD	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	7.79	0.35	5.27e-14	Rheumatoid arthritis;
LUAD	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg08798685	chr6:27730294	NA	-0.69	-7.26	-0.33	1.88e-12	Depression;
LUAD	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg10053473	chr17:62856997	LRRC37A3	-0.84	-11.64	-0.49	2.39e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg20203395	chr5:56204925	C5orf35	-0.48	-7.38	-0.34	8.47e-13	Coronary artery disease;
LUAD	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg22532475	chr10:104410764	TRIM8	-0.45	-8.34	-0.38	1.08e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs2465065	0.666	rs12705278	chr7:104424615	A/G	cg14417498	chr1:165322199	LMX1A	-0.42	-6.44	-0.3	3.25e-10	Gout;
LUAD	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.52	-0.38	2.75e-16	Height;
LUAD	cis	rs5758511	0.773	rs8140869	chr22:42344297	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.37	-6.43	-0.3	3.47e-10	Birth weight;
LUAD	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg00757033	chr12:89920650	WDR51B	0.68	11.58	0.49	3.94e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg05234568	chr11:5960015	NA	-0.55	-9.91	-0.43	6.02e-21	DNA methylation (variation);
LUAD	cis	rs6060717	0.536	rs11697851	chr20:34524494	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.2	-0.33	2.74e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs2992756	0.663	rs2992735	chr1:18800387	T/A	cg14356550	chr1:18808102	KLHDC7A	-0.57	-9.73	-0.43	2.43e-20	Breast cancer;
LUAD	cis	rs2017305	0.834	rs118076009	chr10:70785933	C/T	cg01024728	chr10:70782572	NA	0.74	7.03	0.32	8.43e-12	Depression (quantitative trait);
LUAD	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg19635926	chr16:89946313	TCF25	0.79	6.76	0.31	4.67e-11	Skin colour saturation;
LUAD	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.5	6.88	0.32	2.22e-11	Platelet count;
LUAD	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-8.01	-0.36	1.12e-14	HDL cholesterol;
LUAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.44	0.55	1.59e-34	Prudent dietary pattern;
LUAD	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08965527	chr16:84178213	HSDL1;LRRC50	0.41	6.75	0.31	4.94e-11	Survival in pancreatic cancer;
LUAD	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06028808	chr11:68637592	NA	0.5	8.15	0.37	4.08e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.7	-0.31	6.8e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg18305652	chr10:134549665	INPP5A	0.54	12.11	0.51	3.45e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2880765	0.835	rs56406982	chr15:86036379	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.47	-0.3	2.67e-10	Coronary artery disease;
LUAD	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.96	-0.32	1.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg03806693	chr22:41940476	POLR3H	-0.58	-8.35	-0.38	9.8e-16	Vitiligo;
LUAD	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg17330251	chr7:94953956	PON1	-0.53	-7.26	-0.33	1.83e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3106136	0.872	rs2016476	chr4:95229004	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.4	-0.3	4.2e-10	Capecitabine sensitivity;
LUAD	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.11	0.33	4.98e-12	Menopause (age at onset);
LUAD	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs4853036	0.857	rs12613717	chr2:70039263	T/G	cg02498382	chr2:70120550	SNRNP27	-0.5	-7.9	-0.36	2.39e-14	Colorectal or endometrial cancer;
LUAD	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.8	0.31	3.54e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg26727032	chr16:67993705	SLC12A4	-0.51	-6.67	-0.31	7.86e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg26898376	chr11:64110657	CCDC88B	0.38	7.06	0.32	6.69e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg00316803	chr15:76480434	C15orf27	0.45	9.12	0.41	3.03e-18	Blood metabolite levels;
LUAD	cis	rs4006360	0.628	rs439075	chr17:39239467	A/C	cg20663846	chr17:39254439	KRTAP4-8	0.35	7.87	0.36	3.08e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg00701064	chr4:6280414	WFS1	0.64	13.97	0.56	9.77e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg19875535	chr5:140030758	IK	0.45	7.45	0.34	5.43e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12216545	0.737	rs4339548	chr7:150229315	G/T	cg08960815	chr7:150264767	GIMAP4	-0.31	-6.72	-0.31	5.98e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14893161	chr1:205819251	PM20D1	0.82	17.34	0.64	2.87e-51	Menarche (age at onset);
LUAD	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg03563238	chr19:33554763	RHPN2	0.33	7.72	0.35	8.62e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg18621852	chr3:10150065	C3orf24	0.48	8.27	0.37	1.76e-15	Alzheimer's disease;
LUAD	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.88	-0.36	2.86e-14	Monocyte percentage of white cells;
LUAD	cis	rs79839061	0.732	rs7657330	chr4:825156	C/T	cg07828340	chr4:882639	GAK	1.01	9.41	0.42	3.19e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.38	6.38	0.3	4.66e-10	Systemic lupus erythematosus;
LUAD	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg23625390	chr15:77176239	SCAPER	-0.57	-9.12	-0.41	3.01e-18	Blood metabolite levels;
LUAD	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.36	-7.12	-0.33	4.55e-12	Crohn's disease;
LUAD	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg04539111	chr16:67997858	SLC12A4	-0.63	-8.0	-0.36	1.24e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-9.46	-0.42	2.12e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	7.86	0.36	3.11e-14	Alzheimer's disease;
LUAD	cis	rs10465746	0.746	rs12749350	chr1:84456948	T/A	cg10977910	chr1:84465055	TTLL7	0.58	9.6	0.42	7.17e-20	Obesity-related traits;
LUAD	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg00634984	chr7:65235879	NA	0.48	6.57	0.3	1.5e-10	Aortic root size;
LUAD	cis	rs748404	0.697	rs501884	chr15:43553982	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.35	0.34	1.03e-12	Lung cancer;
LUAD	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	12.77	0.53	8.53e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs713587	0.967	rs6749422	chr2:25150011	C/G	cg04586622	chr2:25135609	ADCY3	0.32	7.08	0.33	6.17e-12	Body mass index in non-asthmatics;
LUAD	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.76	0.31	4.46e-11	Depression;
LUAD	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-7.99	-0.36	1.31e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg16205897	chr5:131564050	P4HA2	-0.32	-7.06	-0.32	6.66e-12	Breast cancer;
LUAD	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg02527881	chr3:46936655	PTH1R	0.51	10.13	0.44	9.48e-22	Colorectal cancer;
LUAD	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg06028605	chr16:24865363	SLC5A11	0.37	6.47	0.3	2.78e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7487075	0.619	rs2220727	chr12:46805069	G/A	cg23829395	chr12:46796953	NA	0.31	7.0	0.32	9.84e-12	Itch intensity from mosquito bite;
LUAD	cis	rs1595825	0.891	rs60484833	chr2:198812181	C/T	cg10547527	chr2:198650123	BOLL	-0.52	-7.31	-0.33	1.33e-12	Ulcerative colitis;
LUAD	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg23758822	chr17:41437982	NA	1.02	20.75	0.71	1.76e-66	Menopause (age at onset);
LUAD	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.41	-7.85	-0.36	3.52e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg13607699	chr17:42295918	UBTF	0.52	8.34	0.38	1.04e-15	Red cell distribution width;Reticulocyte count;
LUAD	cis	rs6987853	0.688	rs2923433	chr8:42418723	T/C	cg09913449	chr8:42400586	C8orf40	0.48	9.26	0.41	1.08e-18	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs3960554	0.932	rs60717745	chr7:75846083	C/G	cg19862616	chr7:65841803	NCRNA00174	0.86	10.85	0.47	2.26e-24	Eotaxin levels;
LUAD	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.47	0.38	4.01e-16	Platelet count;
LUAD	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg19717773	chr7:2847554	GNA12	-0.51	-9.61	-0.42	6.65e-20	Height;
LUAD	cis	rs147144681	1	rs147144681	chr15:78900908	C/T	cg18825076	chr15:78729989	IREB2	-0.57	-9.34	-0.41	5.4e-19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg09365446	chr1:150670422	GOLPH3L	0.63	10.99	0.47	6.79e-25	Melanoma;
LUAD	cis	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-6.91	-0.32	1.84e-11	Triglycerides;
LUAD	trans	rs7944735	0.507	rs17198607	chr11:48028343	A/C	cg15704280	chr7:45808275	SEPT13	-0.58	-6.61	-0.31	1.19e-10	Intraocular pressure;
LUAD	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	11.99	0.5	1.01e-28	Colorectal cancer;
LUAD	cis	rs6430585	0.941	rs6708957	chr2:136520043	C/T	cg07169764	chr2:136633963	MCM6	0.64	8.14	0.37	4.36e-15	Corneal structure;
LUAD	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg02371401	chr5:676784	TPPP	-0.47	-7.87	-0.36	2.9e-14	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.41	0.38	6.12e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116248771	0.739	rs73156489	chr3:158414026	C/T	cg16708174	chr3:158430962	RARRES1	0.46	6.76	0.31	4.73e-11	diarrhoeal disease at age 2;
LUAD	trans	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	7.6	0.35	1.88e-13	Resting heart rate;
LUAD	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg16325326	chr1:53192061	ZYG11B	0.58	10.24	0.45	3.99e-22	Monocyte count;
LUAD	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg08514558	chr10:81106712	PPIF	0.49	9.74	0.43	2.26e-20	Height;
LUAD	cis	rs9902453	0.817	rs17226179	chr17:28168573	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	8.94	0.4	1.18e-17	Coffee consumption (cups per day);
LUAD	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05901451	chr6:126070800	HEY2	-0.65	-11.0	-0.47	6.25e-25	Brugada syndrome;
LUAD	cis	rs6076065	0.630	rs2424559	chr20:23430519	A/G	cg11657817	chr20:23433608	CST11	0.61	12.63	0.52	3.12e-31	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg21724239	chr8:58056113	NA	0.77	9.66	0.43	4.34e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg16011800	chr17:1958478	HIC1	0.57	8.02	0.36	1.02e-14	Lymphocyte counts;Red cell distribution width;
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg07332563	chr6:291687	DUSP22	-0.7	-12.15	-0.51	2.32e-29	Menopause (age at onset);
LUAD	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg07776626	chr8:57350775	NA	-0.63	-9.51	-0.42	1.46e-19	Obesity-related traits;
LUAD	cis	rs240764	0.658	rs4839792	chr6:101253788	A/T	cg09795085	chr6:101329169	ASCC3	-0.43	-7.59	-0.35	2.04e-13	Neuroticism;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg01087382	chr6:91297190	MAP3K7	0.44	7.11	0.33	4.91e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg12927641	chr6:109611667	NA	-0.51	-8.81	-0.39	3.15e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs4356932	0.967	rs4859586	chr4:76943235	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.5	-0.3	2.23e-10	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg24818145	chr4:99064322	C4orf37	0.43	7.31	0.33	1.39e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62400317	0.859	rs12211519	chr6:45160530	C/A	cg20913747	chr6:44695427	NA	-0.43	-6.71	-0.31	6.21e-11	Total body bone mineral density;
LUAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.9	-0.36	2.42e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg03806693	chr22:41940476	POLR3H	-0.48	-7.07	-0.33	6.37e-12	Vitiligo;
LUAD	cis	rs6714710	0.580	rs11680018	chr2:98479581	C/A	cg26665480	chr2:98280029	ACTR1B	0.5	8.22	0.37	2.55e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg19163074	chr7:65112434	INTS4L2	0.44	6.73	0.31	5.56e-11	Aortic root size;
LUAD	cis	rs870825	0.929	rs72689256	chr4:185590174	C/T	cg04058563	chr4:185651563	MLF1IP	0.74	9.52	0.42	1.37e-19	Blood protein levels;
LUAD	cis	rs9393692	0.620	rs4412193	chr6:26338056	A/G	cg13736514	chr6:26305472	NA	-0.49	-8.35	-0.38	9.51e-16	Educational attainment;
LUAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg11494091	chr17:61959527	GH2	0.74	18.37	0.67	7.72e-56	Prudent dietary pattern;
LUAD	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg04545296	chr12:48745243	ZNF641	-0.43	-10.95	-0.47	9.81e-25	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs4006360	0.646	rs8080164	chr17:39292845	A/G	cg20663846	chr17:39254439	KRTAP4-8	0.4	9.11	0.41	3.25e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg05082376	chr22:42548792	NA	-0.39	-6.93	-0.32	1.61e-11	Cognitive function;
LUAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg16031515	chr1:205743344	RAB7L1	-0.38	-7.56	-0.35	2.47e-13	Menarche (age at onset);
LUAD	cis	rs7937890	0.572	rs2597218	chr11:14532338	C/T	cg23387056	chr11:14280742	SPON1	-0.34	-6.37	-0.3	4.84e-10	Mitochondrial DNA levels;
LUAD	cis	rs9399401	0.523	rs171915	chr6:142866845	C/T	cg03128060	chr6:142623767	GPR126	0.38	7.7	0.35	9.43e-14	Chronic obstructive pulmonary disease;
LUAD	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg26384229	chr12:38710491	ALG10B	0.51	8.38	0.38	7.67e-16	Heart rate;
LUAD	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg04282206	chr17:62833786	PLEKHM1P	0.61	9.13	0.41	2.85e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg00981070	chr1:2046702	PRKCZ	-0.34	-7.05	-0.32	7.55e-12	Height;
LUAD	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.23	-0.33	2.34e-12	Height;
LUAD	cis	rs2581828	0.656	rs2564921	chr3:53125585	C/T	cg24530246	chr3:53118167	NA	-0.31	-6.59	-0.31	1.28e-10	Crohn's disease;
LUAD	cis	rs62400317	0.762	rs12215263	chr6:44831364	C/A	cg20913747	chr6:44695427	NA	-0.44	-6.9	-0.32	1.86e-11	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.06	0.32	7.06e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg02951883	chr7:2050386	MAD1L1	0.78	13.74	0.56	8.93e-36	Bipolar disorder and schizophrenia;
LUAD	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg04719120	chr6:96025338	MANEA	0.45	6.39	0.3	4.43e-10	Behavioural disinhibition (generation interaction);
LUAD	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg13770153	chr20:60521292	NA	-0.57	-9.59	-0.42	7.53e-20	Body mass index;
LUAD	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg18230493	chr5:56204884	C5orf35	-0.85	-12.28	-0.51	7.56e-30	Initial pursuit acceleration;
LUAD	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg12564285	chr5:131593104	PDLIM4	0.4	7.48	0.34	4.24e-13	Acylcarnitine levels;
LUAD	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-11.52	-0.49	6.65e-27	Hemoglobin concentration;
LUAD	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg12940439	chr1:67600707	NA	0.49	9.24	0.41	1.18e-18	Psoriasis;
LUAD	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg26384229	chr12:38710491	ALG10B	0.46	7.77	0.35	5.94e-14	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg05340658	chr4:99064831	C4orf37	0.55	9.38	0.41	4.12e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg17724175	chr1:150552817	MCL1	0.32	7.27	0.33	1.8e-12	Melanoma;
LUAD	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	11.17	0.48	1.52e-25	Colorectal cancer;
LUAD	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.34	-9.21	-0.41	1.5e-18	Total body bone mineral density;
LUAD	cis	rs7582720	1.000	rs114527590	chr2:203787405	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg08999081	chr20:33150536	PIGU	-0.52	-10.98	-0.47	7.86e-25	Coronary artery disease;
LUAD	cis	rs73206853	0.534	rs73205062	chr12:110511136	G/C	cg12870014	chr12:110450643	ANKRD13A	0.8	8.02	0.36	1.03e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg03037974	chr15:76606532	NA	0.48	11.1	0.47	2.76e-25	Blood metabolite levels;
LUAD	trans	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg01620082	chr3:125678407	NA	-0.55	-8.66	-0.39	9.86e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04565464	chr8:145669602	NFKBIL2	0.45	6.88	0.32	2.12e-11	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs7944735	0.507	rs10838802	chr11:48102478	A/G	cg03929089	chr4:120376271	NA	0.62	9.38	0.41	3.98e-19	Intraocular pressure;
LUAD	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg12016809	chr21:47604291	C21orf56	0.45	7.37	0.34	8.97e-13	Testicular germ cell tumor;
LUAD	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.74	-0.31	5.2e-11	Breast cancer;
LUAD	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg00495681	chr13:53174319	NA	0.57	10.69	0.46	8.96e-24	Lewy body disease;
LUAD	cis	rs7103648	0.569	rs11039266	chr11:47532395	T/G	cg20307385	chr11:47447363	PSMC3	0.52	7.71	0.35	9.25e-14	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg13606994	chr1:44402422	ARTN	-0.37	-7.47	-0.34	4.65e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6867032	1.000	rs4398675	chr5:2015816	G/A	cg26168224	chr5:2018326	NA	0.8	18.21	0.66	4e-55	Gut microbiome composition (winter);
LUAD	cis	rs735539	1.000	rs735539	chr13:21280034	A/G	cg27499820	chr13:21296301	IL17D	-0.4	-7.08	-0.33	6.23e-12	Dental caries;
LUAD	cis	rs6906287	0.625	rs9320648	chr6:118690014	A/C	cg05564266	chr6:118973597	C6orf204	0.36	7.91	0.36	2.24e-14	Electrocardiographic conduction measures;
LUAD	cis	rs12760731	0.565	rs10913519	chr1:178196094	A/T	cg00404053	chr1:178313656	RASAL2	0.73	9.13	0.41	2.81e-18	Obesity-related traits;
LUAD	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03264133	chr6:25882463	NA	0.58	9.76	0.43	1.92e-20	Blood metabolite levels;
LUAD	cis	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-7.07	-0.33	6.25e-12	Morning vs. evening chronotype;
LUAD	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.35	0.34	1.07e-12	Menopause (age at onset);
LUAD	cis	rs62238980	0.522	rs117390331	chr22:32461489	T/C	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs62458065	0.513	rs10268803	chr7:32547835	A/G	cg20159608	chr7:32802032	NA	-0.67	-9.85	-0.43	9.96e-21	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg22907277	chr7:1156413	C7orf50	0.48	7.93	0.36	1.92e-14	Longevity;Endometriosis;
LUAD	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg11693508	chr17:37793320	STARD3	0.78	10.24	0.45	3.93e-22	Bipolar disorder;
LUAD	cis	rs863345	0.564	rs12145401	chr1:158494693	A/G	cg12129480	chr1:158549410	OR10X1	-0.24	-6.59	-0.3	1.34e-10	Pneumococcal bacteremia;
LUAD	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg18944383	chr4:111397179	ENPEP	0.39	7.81	0.36	4.43e-14	Height;
LUAD	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg24801067	chr17:62843696	NA	0.65	8.81	0.39	3.16e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs910187	0.678	rs3818009	chr20:45816514	C/T	cg27589058	chr20:45804311	EYA2	-0.3	-7.0	-0.32	9.83e-12	Migraine;
LUAD	cis	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg27411982	chr8:10470053	RP1L1	-0.43	-7.61	-0.35	1.79e-13	Triglycerides;
LUAD	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.82	-0.31	3.12e-11	Retinal vascular caliber;
LUAD	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg12034118	chr1:209979487	IRF6	-0.46	-6.59	-0.31	1.33e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg10518543	chr12:38710700	ALG10B	-0.42	-7.03	-0.32	8.21e-12	Bladder cancer;
LUAD	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-8.21	-0.37	2.68e-15	Menarche (age at onset);
LUAD	cis	rs9326248	0.581	rs6589590	chr11:116936081	A/C	cg20608306	chr11:116969690	SIK3	0.3	6.77	0.31	4.2e-11	Blood protein levels;
LUAD	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg24801067	chr17:62843696	NA	-0.54	-7.53	-0.34	3.1e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs13190036	1.000	rs17078781	chr5:176544228	G/A	cg06733329	chr5:176740039	MXD3	0.51	6.37	0.3	5.01e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg01528321	chr10:82214614	TSPAN14	0.66	10.64	0.46	1.44e-23	Post bronchodilator FEV1;
LUAD	cis	rs3087591	0.960	rs2952991	chr17:29526742	T/C	cg24425628	chr17:29625626	OMG;NF1	0.42	6.97	0.32	1.2e-11	Hip circumference;
LUAD	cis	rs123509	0.687	rs73077208	chr3:42835205	G/A	cg12982090	chr3:42733453	KBTBD5	-0.53	-9.07	-0.4	4.48e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg00383909	chr3:49044727	WDR6	0.76	8.62	0.39	1.32e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg07432352	chr17:45403706	C17orf57	-0.4	-7.8	-0.35	4.95e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg24818145	chr4:99064322	C4orf37	0.47	7.33	0.34	1.19e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg06484146	chr7:12443880	VWDE	-0.58	-7.36	-0.34	9.91e-13	Coronary artery disease;
LUAD	cis	rs762407	0.560	rs2838362	chr21:45189165	A/T	cg19815989	chr21:45161359	PDXK	-0.35	-6.39	-0.3	4.46e-10	Systolic blood pressure change trajectories;
LUAD	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.43	0.55	1.69e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg23625390	chr15:77176239	SCAPER	0.39	6.88	0.32	2.12e-11	Blood metabolite levels;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg05409276	chr17:73400549	GRB2	-0.39	-6.65	-0.31	8.88e-11	Subcortical brain region volumes;
LUAD	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg26384229	chr12:38710491	ALG10B	-0.4	-6.74	-0.31	5.14e-11	Morning vs. evening chronotype;
LUAD	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg21890820	chr11:65308645	LTBP3	0.48	7.63	0.35	1.59e-13	Bone mineral density;
LUAD	cis	rs6906287	0.647	rs6902812	chr6:118936294	A/G	cg21191810	chr6:118973309	C6orf204	0.52	9.93	0.43	4.95e-21	Electrocardiographic conduction measures;
LUAD	cis	rs8099014	1.000	rs7226817	chr18:56128289	T/A	cg12907477	chr18:56117327	MIR122	0.38	6.45	0.3	3.15e-10	Platelet count;
LUAD	cis	rs4604732	0.631	rs4436425	chr1:247632323	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.52	0.42	1.38e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg17182837	chr8:41585554	ANK1	-0.34	-7.05	-0.32	7.52e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUAD	cis	rs2795502	0.873	rs2795527	chr10:43270240	T/C	cg20628663	chr10:43360327	NA	-0.69	-9.15	-0.41	2.41e-18	Blood protein levels;
LUAD	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.49	-0.3	2.43e-10	Prostate cancer;
LUAD	trans	rs2797160	1.000	rs6933302	chr6:126016951	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.48e-17	Endometrial cancer;
LUAD	cis	rs447921	1.000	rs372126	chr17:74413216	A/G	cg17201438	chr17:74438067	UBE2O	-0.47	-6.69	-0.31	7.09e-11	Mitochondrial DNA levels;
LUAD	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-7.82	-0.36	4.26e-14	Neutrophil percentage of white cells;
LUAD	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.06	-0.32	6.83e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg06627628	chr2:24431161	ITSN2	-0.53	-6.44	-0.3	3.22e-10	Lymphocyte counts;
LUAD	cis	rs804280	0.662	rs810738	chr8:11611206	A/G	cg23972785	chr8:11611189	GATA4	0.46	7.52	0.34	3.21e-13	Myopia (pathological);
LUAD	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg05373962	chr22:49881684	NA	-0.5	-9.75	-0.43	2.22e-20	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7593730	1.000	rs2966379	chr2:161123251	C/T	cg22609984	chr2:161126801	NA	0.46	7.46	0.34	4.81e-13	Type 2 diabetes;
LUAD	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.83	0.32	3.02e-11	Blood metabolite levels;
LUAD	cis	rs7937890	0.561	rs2575849	chr11:14539639	T/A	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.25e-11	Mitochondrial DNA levels;
LUAD	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12756686	chr19:29218302	NA	0.67	9.78	0.43	1.7e-20	Methadone dose in opioid dependence;
LUAD	trans	rs853679	1.000	rs735765	chr6:28170297	G/A	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.95	-0.36	1.76e-14	Depression;
LUAD	cis	rs2487048	0.725	rs2246293	chr9:107690838	C/G	cg14019050	chr9:107690770	ABCA1	0.39	7.25	0.33	2.01e-12	Intraocular pressure;
LUAD	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg07636037	chr3:49044803	WDR6	0.35	6.4	0.3	4.18e-10	Resting heart rate;
LUAD	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg06547715	chr2:218990976	CXCR2	0.28	6.79	0.31	3.86e-11	Colorectal cancer;
LUAD	cis	rs1143633	0.566	rs2708932	chr2:113690675	C/A	cg12858261	chr2:113808755	IL1F8	-0.38	-6.98	-0.32	1.16e-11	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg03929089	chr4:120376271	NA	0.55	7.1	0.33	5.37e-12	Axial length;
LUAD	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg12740337	chr6:28058973	ZSCAN12L1	0.28	6.46	0.3	2.92e-10	Parkinson's disease;
LUAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg04234412	chr22:24373322	LOC391322	0.91	18.82	0.68	7.39e-58	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg13319975	chr6:146136371	FBXO30	0.69	11.97	0.5	1.19e-28	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.25	-0.37	2.06e-15	Bipolar disorder;
LUAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg24101359	chr6:42928495	GNMT	0.52	10.05	0.44	1.95e-21	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4700695	0.719	rs27084	chr5:65435286	G/A	cg21114390	chr5:65439923	SFRS12	-0.93	-14.22	-0.57	8.67e-38	Facial morphology (factor 19);
LUAD	trans	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg26043149	chr18:55253948	FECH	0.51	8.29	0.37	1.47e-15	Bone mineral density;
LUAD	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg11871910	chr12:69753446	YEATS4	0.5	7.38	0.34	8.38e-13	Response to diuretic therapy;
LUAD	cis	rs2230307	0.536	rs490669	chr1:100484430	C/T	cg20868668	chr1:100435035	SLC35A3	0.54	7.76	0.35	6.33e-14	Carotid intima media thickness;
LUAD	cis	rs59698941	0.943	rs66746130	chr5:132245615	A/G	cg14825688	chr5:132208181	LEAP2	-0.47	-6.41	-0.3	3.91e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs13266463	0.830	rs6983790	chr8:143406575	A/G	cg16886403	chr8:143471632	TSNARE1	0.46	7.13	0.33	4.26e-12	Schizophrenia;
LUAD	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg12193833	chr17:30244370	NA	-0.58	-6.95	-0.32	1.35e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.53	0.3	1.94e-10	Platelet count;
LUAD	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03517284	chr6:25882590	NA	-0.41	-6.76	-0.31	4.56e-11	Height;
LUAD	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg02734326	chr4:10020555	SLC2A9	-0.42	-7.33	-0.34	1.17e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1784581	0.855	rs1790002	chr6:162384397	G/T	cg17173639	chr6:162384350	PARK2	-0.59	-10.72	-0.46	6.96e-24	Itch intensity from mosquito bite;
LUAD	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	9.7	0.43	3.3e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.68	-13.4	-0.55	2.17e-34	Ulcerative colitis;
LUAD	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg02269571	chr22:50332266	NA	-0.67	-9.76	-0.43	2.01e-20	Schizophrenia;
LUAD	cis	rs11098699	0.784	rs6534393	chr4:124238947	C/T	cg09941581	chr4:124220074	SPATA5	-0.44	-7.05	-0.32	7.55e-12	Mosquito bite size;
LUAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg16031515	chr1:205743344	RAB7L1	-0.38	-7.67	-0.35	1.2e-13	Menarche (age at onset);
LUAD	cis	rs2274273	0.967	rs8009670	chr14:55583477	G/A	cg04306507	chr14:55594613	LGALS3	0.4	8.27	0.37	1.75e-15	Protein biomarker;
LUAD	cis	rs2046867	0.862	rs2174062	chr3:72826901	T/C	cg25664220	chr3:72788482	NA	-0.61	-10.88	-0.47	1.83e-24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg15017067	chr4:17643749	FAM184B	-0.37	-7.32	-0.34	1.24e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg18876405	chr7:65276391	NA	0.62	10.9	0.47	1.5e-24	Aortic root size;
LUAD	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg16479474	chr6:28041457	NA	0.46	7.67	0.35	1.2e-13	Depression;
LUAD	trans	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg24644049	chr4:85504048	CDS1	0.88	7.59	0.35	2.1e-13	Skin colour saturation;
LUAD	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.23	0.33	2.24e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg05082376	chr22:42548792	NA	-0.48	-8.78	-0.39	4.05e-17	Schizophrenia;
LUAD	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg18932078	chr1:2524107	MMEL1	0.37	7.03	0.32	8.24e-12	Ulcerative colitis;
LUAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg05564831	chr3:52568323	NT5DC2	0.49	9.69	0.43	3.38e-20	Hemoglobin concentration;
LUAD	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.32	-0.34	1.28e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.61	7.49	0.34	4.19e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.24	-0.41	1.22e-18	Life satisfaction;
LUAD	cis	rs8014204	0.804	rs35641442	chr14:75207263	G/A	cg06637938	chr14:75390232	RPS6KL1	0.35	6.4	0.3	4.11e-10	Caffeine consumption;
LUAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.79	-0.35	5.06e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs738322	0.555	rs731821	chr22:38559448	C/A	cg25457927	chr22:38595422	NA	-0.59	-13.85	-0.56	3.24e-36	Cutaneous nevi;
LUAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg10729496	chr3:10149963	C3orf24	0.58	9.43	0.42	2.76e-19	Alzheimer's disease;
LUAD	cis	rs6484504	0.576	rs208088	chr11:31192686	T/C	cg26647111	chr11:31128758	NA	-0.47	-8.3	-0.37	1.45e-15	Red blood cell count;
LUAD	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg16060761	chr17:80687452	NA	-0.56	-8.04	-0.36	8.99e-15	Glycated hemoglobin levels;
LUAD	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg24558204	chr6:135376177	HBS1L	0.5	8.64	0.39	1.14e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.75	-0.39	5.1e-17	Total body bone mineral density;
LUAD	trans	rs11671005	0.656	rs11672609	chr19:59006924	C/T	cg22037779	chr5:139682734	PFDN1	-0.59	-6.74	-0.31	5.36e-11	Mean platelet volume;
LUAD	cis	rs367943	0.667	rs13173069	chr5:113011778	T/G	cg12552261	chr5:112820674	MCC	0.43	7.3	0.33	1.41e-12	Type 2 diabetes;
LUAD	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23158103	chr7:148848205	ZNF398	0.64	11.87	0.5	2.91e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg27411982	chr8:10470053	RP1L1	-0.42	-7.53	-0.34	3.08e-13	Neuroticism;
LUAD	cis	rs1232027	0.656	rs836809	chr5:79972760	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.42	-6.74	-0.31	5.2e-11	Huntington's disease progression;
LUAD	cis	rs1816752	0.905	rs9511266	chr13:25012504	C/G	cg02811702	chr13:24901961	NA	0.46	7.96	0.36	1.61e-14	Obesity-related traits;
LUAD	cis	rs11811982	0.793	rs11808843	chr1:227535418	A/T	cg24860534	chr1:227506868	CDC42BPA	0.68	7.35	0.34	1.05e-12	Optic disc area;
LUAD	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg17971929	chr21:40555470	PSMG1	0.48	7.24	0.33	2.15e-12	Cognitive function;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg23570261	chr2:128284252	IWS1	-0.38	-6.53	-0.3	1.9e-10	Subcortical brain region volumes;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg21490755	chr8:66754279	PDE7A	-0.7	-7.55	-0.34	2.68e-13	Type 2 diabetes;
LUAD	cis	rs7617773	0.817	rs745116	chr3:48272536	T/G	cg11946769	chr3:48343235	NME6	0.41	6.55	0.3	1.7e-10	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg17366294	chr4:99064904	C4orf37	0.68	12.95	0.53	1.48e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.44	-0.49	1.35e-26	Type 2 diabetes;
LUAD	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg10909506	chr17:38081995	ORMDL3	0.38	6.87	0.32	2.33e-11	Self-reported allergy;
LUAD	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg14092988	chr3:52407081	DNAH1	0.34	6.75	0.31	4.78e-11	Bipolar disorder;
LUAD	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg17971929	chr21:40555470	PSMG1	0.54	8.46	0.38	4.55e-16	Cognitive function;
LUAD	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg00316803	chr15:76480434	C15orf27	-0.41	-8.05	-0.36	8.21e-15	Blood metabolite levels;
LUAD	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg03233332	chr7:66118400	NA	-0.46	-6.88	-0.32	2.22e-11	Aortic root size;
LUAD	cis	rs62400317	0.859	rs10948214	chr6:45170466	T/C	cg18551225	chr6:44695536	NA	-0.54	-8.41	-0.38	6.53e-16	Total body bone mineral density;
LUAD	cis	rs593982	0.858	rs663797	chr11:65552740	A/G	cg08755490	chr11:65554678	OVOL1	1.34	19.0	0.68	1.16e-58	Atopic dermatitis;
LUAD	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs17270561	0.636	rs3922681	chr6:25698481	C/T	cg25753631	chr6:25732923	NA	-0.4	-6.94	-0.32	1.51e-11	Iron status biomarkers;
LUAD	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.77	-0.35	6.05e-14	Breast cancer;
LUAD	cis	rs7586879	0.789	rs36029941	chr2:25127801	C/T	cg04586622	chr2:25135609	ADCY3	0.36	7.26	0.33	1.92e-12	Body mass index;
LUAD	cis	rs6842047	1.000	rs4862668	chr4:187136443	A/T	cg23442198	chr4:187126114	CYP4V2	0.93	9.87	0.43	7.98e-21	Blood protein levels;
LUAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06873352	chr17:61820015	STRADA	0.83	18.5	0.67	1.99e-56	Prudent dietary pattern;
LUAD	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg25233709	chr10:116636983	FAM160B1	0.45	8.81	0.39	3.2e-17	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1044826	0.642	rs6771831	chr3:139177585	C/T	cg00490450	chr3:139108681	COPB2	0.42	6.82	0.31	3.11e-11	Obesity-related traits;
LUAD	cis	rs968567	0.705	rs174575	chr11:61602003	C/G	cg19610905	chr11:61596333	FADS2	-0.67	-11.06	-0.47	3.68e-25	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg13319975	chr6:146136371	FBXO30	-0.6	-10.13	-0.44	9.79e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg21775007	chr8:11205619	TDH	-0.49	-9.04	-0.4	5.51e-18	Retinal vascular caliber;
LUAD	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-8.02	-0.36	1.05e-14	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg20129853	chr10:51489980	NA	0.4	8.36	0.38	8.83e-16	Prostate-specific antigen levels;
LUAD	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14557232	chr4:1368966	KIAA1530	0.53	6.47	0.3	2.73e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg17177755	chr1:15930204	NA	0.44	7.11	0.33	5.08e-12	Systolic blood pressure;
LUAD	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg15017067	chr4:17643749	FAM184B	0.36	6.97	0.32	1.21e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg11814155	chr7:99998594	ZCWPW1	0.4	7.07	0.33	6.31e-12	Platelet count;
LUAD	cis	rs73206853	0.841	rs55885183	chr12:110877682	A/G	cg12870014	chr12:110450643	ANKRD13A	0.59	6.4	0.3	4.03e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg15247329	chr7:2764246	NA	-0.35	-6.38	-0.3	4.53e-10	Height;
LUAD	cis	rs11048434	0.761	rs12828902	chr12:9132231	C/T	cg13575925	chr12:9217583	LOC144571	0.4	7.48	0.34	4.34e-13	Sjögren's syndrome;
LUAD	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg11663144	chr21:46675770	NA	-0.58	-11.54	-0.49	5.77e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.61	8.54	0.38	2.38e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26314531	chr2:26401878	FAM59B	-0.58	-7.99	-0.36	1.33e-14	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg07917127	chr4:99064746	C4orf37	0.45	7.29	0.33	1.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg11645453	chr3:52864694	ITIH4	-0.54	-10.32	-0.45	1.96e-22	Schizophrenia;
LUAD	cis	rs1868673	1.000	rs6810143	chr3:150174510	A/T	cg04908077	chr3:150187338	NA	0.31	6.37	0.3	5.01e-10	Waist circumference;
LUAD	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg09455208	chr3:40491958	NA	-0.42	-8.5	-0.38	3.24e-16	Renal cell carcinoma;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg02551797	chr4:2243986	HAUS3	-0.68	-6.71	-0.31	6.35e-11	Type 2 diabetes;
LUAD	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg16482183	chr6:26056742	HIST1H1C	0.56	7.77	0.35	6.05e-14	Iron status biomarkers;
LUAD	cis	rs3812049	0.784	rs3749748	chr5:127350549	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.53	-7.13	-0.33	4.24e-12	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg18404041	chr3:52824283	ITIH1	0.4	7.36	0.34	9.69e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-10.92	-0.47	1.3e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7336332	0.598	rs76790205	chr13:28002885	C/T	cg22138327	chr13:27999177	GTF3A	0.77	9.9	0.43	6.38e-21	Weight;
LUAD	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg03983476	chr2:10830698	NOL10	-0.49	-8.61	-0.39	1.5e-16	Prostate cancer;
LUAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.79	-0.43	1.59e-20	Alzheimer's disease;
LUAD	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg14829155	chr15:31115871	NA	0.51	7.22	0.33	2.5e-12	Huntington's disease progression;
LUAD	cis	rs981844	0.712	rs62325150	chr4:154728117	T/G	cg10279832	chr4:154682576	RNF175	-0.34	-6.41	-0.3	3.88e-10	Response to statins (LDL cholesterol change);
LUAD	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg17063962	chr7:91808500	NA	0.67	12.0	0.5	9.6e-29	Breast cancer;
LUAD	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg22683308	chr4:1340831	KIAA1530	-0.5	-8.39	-0.38	7.18e-16	Longevity;
LUAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg12432903	chr7:1882776	MAD1L1	-0.4	-6.54	-0.3	1.77e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.07	0.37	7.6e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.900	rs56195309	chr17:28453753	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.53	0.38	2.62e-16	Coffee consumption (cups per day);
LUAD	trans	rs6560039	1	rs6560039	chr9:90474946	C/T	cg24436365	chr6:63940138	NA	0.7	15.64	0.61	7.62e-44	Gait variability;
LUAD	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg23840854	chr1:161414152	NA	-0.86	-11.14	-0.48	1.95e-25	Rheumatoid arthritis;
LUAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg15147215	chr3:52552868	STAB1	-0.54	-10.4	-0.45	1.06e-22	Electroencephalogram traits;
LUAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.16	0.54	2.13e-33	Prudent dietary pattern;
LUAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg16606324	chr3:10149918	C3orf24	0.71	11.7	0.49	1.44e-27	Alzheimer's disease;
LUAD	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg23172400	chr8:95962367	TP53INP1	-0.34	-8.14	-0.37	4.33e-15	Type 2 diabetes;
LUAD	cis	rs11051970	0.679	rs2651377	chr12:32556919	A/C	cg02745156	chr12:32552066	NA	0.31	6.73	0.31	5.48e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	12.51	0.52	9.38e-31	Exhaled nitric oxide output;
LUAD	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg25324976	chr17:61989376	CSHL1	0.38	7.39	0.34	7.83e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.4	-6.63	-0.31	1.02e-10	Longevity;Endometriosis;
LUAD	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg00745463	chr17:30367425	LRRC37B	0.66	7.91	0.36	2.3e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg13770153	chr20:60521292	NA	-0.98	-16.88	-0.63	2.91e-49	Obesity-related traits;
LUAD	cis	rs1044826	0.642	rs1080371	chr3:139210894	C/T	cg00490450	chr3:139108681	COPB2	0.41	6.5	0.3	2.32e-10	Obesity-related traits;
LUAD	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg12454169	chr2:30669597	LCLAT1	0.68	8.49	0.38	3.66e-16	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs3784262	0.565	rs34676542	chr15:58318716	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.36	-6.96	-0.32	1.33e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg18351406	chr4:77819688	ANKRD56	0.61	9.92	0.43	5.28e-21	Emphysema distribution in smoking;
LUAD	cis	rs367943	0.966	rs364738	chr5:112808329	A/G	cg12552261	chr5:112820674	MCC	-0.59	-11.1	-0.47	2.72e-25	Type 2 diabetes;
LUAD	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg23262351	chr6:79576851	IRAK1BP1	-0.39	-6.57	-0.3	1.48e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg24829409	chr8:58192753	C8orf71	-0.61	-8.07	-0.37	7.12e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg10523679	chr1:76189770	ACADM	-0.9	-15.85	-0.61	9.09e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg01416388	chr22:39784598	NA	-0.48	-7.52	-0.34	3.41e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg09904177	chr6:26538194	HMGN4	0.44	7.39	0.34	7.96e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg00074818	chr8:8560427	CLDN23	0.67	10.39	0.45	1.14e-22	Obesity-related traits;
LUAD	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg06558623	chr16:89946397	TCF25	1.14	10.37	0.45	1.38e-22	Skin colour saturation;
LUAD	cis	rs7640424	1.000	rs7640424	chr3:107820063	C/T	cg09227934	chr3:107805635	CD47	-0.68	-11.43	-0.49	1.44e-26	Body mass index;
LUAD	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg03289416	chr15:75166202	SCAMP2	0.55	9.31	0.41	6.93e-19	Breast cancer;
LUAD	trans	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.35	0.45	1.6e-22	Mean corpuscular volume;
LUAD	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg23992470	chr4:843637	GAK	0.71	7.47	0.34	4.6e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg17644776	chr2:200775616	C2orf69	-0.57	-7.41	-0.34	6.71e-13	Schizophrenia;
LUAD	cis	rs2996428	0.709	rs12127399	chr1:3721609	G/A	cg13057898	chr1:3703894	LRRC47	0.63	10.67	0.46	1.08e-23	Red cell distribution width;
LUAD	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.47	0.38	4.01e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg18827107	chr12:86230957	RASSF9	-0.5	-8.85	-0.4	2.38e-17	Major depressive disorder;
LUAD	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg18306943	chr3:40428807	ENTPD3	-0.38	-6.53	-0.3	1.92e-10	Renal cell carcinoma;
LUAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg07685180	chr8:600429	NA	0.88	8.63	0.39	1.3e-16	IgG glycosylation;
LUAD	cis	rs947211	0.752	rs1572931	chr1:205744218	C/T	cg07167872	chr1:205819463	PM20D1	-0.53	-6.53	-0.3	1.93e-10	Parkinson's disease;
LUAD	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg00717180	chr2:96193071	NA	-0.4	-7.37	-0.34	9.3e-13	Height;
LUAD	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg09873201	chr16:3507582	NAT15	-0.6	-6.35	-0.3	5.52e-10	Tuberculosis;
LUAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg27286337	chr10:134555280	INPP5A	0.7	9.42	0.42	2.95e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs12545109	0.571	rs4237014	chr8:57284479	C/A	cg17761419	chr8:57350749	NA	-0.59	-8.08	-0.37	6.63e-15	Obesity-related traits;
LUAD	cis	rs76878669	0.606	rs1785639	chr11:66100430	G/A	cg10616300	chr11:66138557	SLC29A2	0.35	7.4	0.34	7.49e-13	Educational attainment (years of education);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21840599	chr3:196467454	PAK2	-0.39	-6.55	-0.3	1.65e-10	Cancer;
LUAD	trans	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.8	0.35	4.86e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4853036	0.951	rs35344582	chr2:70148093	C/T	cg02498382	chr2:70120550	SNRNP27	-0.55	-8.84	-0.39	2.62e-17	Colorectal or endometrial cancer;
LUAD	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.62	10.91	0.47	1.43e-24	Birth weight;
LUAD	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.4	6.39	0.3	4.4e-10	Tonsillectomy;
LUAD	cis	rs7737355	0.812	rs2108870	chr5:131088486	C/T	cg06307176	chr5:131281290	NA	0.46	7.79	0.35	5.31e-14	Life satisfaction;
LUAD	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg19622623	chr12:86230825	RASSF9	-0.42	-7.36	-0.34	9.55e-13	Major depressive disorder;
LUAD	cis	rs17608059	0.901	rs11078215	chr17:13906934	T/C	cg27005118	chr17:13972210	COX10	-0.31	-6.42	-0.3	3.65e-10	Temperament;
LUAD	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg27539214	chr16:67997921	SLC12A4	-0.69	-8.51	-0.38	3.16e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7737355	0.947	rs40400	chr5:130831365	C/T	cg06307176	chr5:131281290	NA	-0.47	-7.66	-0.35	1.32e-13	Life satisfaction;
LUAD	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg19761014	chr17:28927070	LRRC37B2	0.69	6.54	0.3	1.73e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.45	-0.49	1.22e-26	Primary sclerosing cholangitis;
LUAD	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.7	-0.31	6.64e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs28595532	0.545	rs55699931	chr4:119249835	G/A	cg02775129	chr4:119771670	NA	-0.58	-6.49	-0.3	2.42e-10	Cannabis dependence symptom count;
LUAD	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg12863693	chr15:85201151	NMB	0.38	6.61	0.31	1.15e-10	Schizophrenia;
LUAD	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg15557168	chr22:42548783	NA	-0.5	-9.4	-0.42	3.45e-19	Schizophrenia;
LUAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00149659	chr3:10157352	C3orf10	0.86	11.7	0.49	1.4e-27	Alzheimer's disease;
LUAD	cis	rs2281558	0.917	rs3787080	chr20:25232604	C/G	cg08601574	chr20:25228251	PYGB	0.49	6.97	0.32	1.23e-11	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUAD	cis	rs10992471	0.580	rs7852698	chr9:95396409	C/T	cg14631576	chr9:95140430	CENPP	-0.46	-8.77	-0.39	4.52e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg03684893	chr10:554711	DIP2C	-0.37	-6.45	-0.3	3.04e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg07636037	chr3:49044803	WDR6	0.63	12.17	0.51	1.99e-29	Parkinson's disease;
LUAD	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg04287289	chr16:89883240	FANCA	0.52	8.68	0.39	8.41e-17	Vitiligo;
LUAD	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg21191810	chr6:118973309	C6orf204	-0.52	-8.17	-0.37	3.57e-15	Diastolic blood pressure;
LUAD	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg05754148	chr16:3507555	NAT15	-0.48	-7.88	-0.36	2.89e-14	Body mass index (adult);
LUAD	trans	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.38	-0.38	7.69e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg19875535	chr5:140030758	IK	0.39	6.68	0.31	7.65e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg11344533	chr11:111475393	SIK2	-0.35	-6.64	-0.31	9.9e-11	Primary sclerosing cholangitis;
LUAD	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.19	0.54	1.66e-33	Prudent dietary pattern;
LUAD	trans	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg06606381	chr12:133084897	FBRSL1	-0.61	-6.45	-0.3	3e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.32	-0.34	1.28e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.36	0.52	3.62e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03264133	chr6:25882463	NA	0.89	14.73	0.58	6.19e-40	Blood metabolite levels;
LUAD	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg02807482	chr3:125708958	NA	-0.65	-8.39	-0.38	7.15e-16	Blood pressure (smoking interaction);
LUAD	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.45	0.3	3.08e-10	Cognitive test performance;
LUAD	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02018176	chr4:1364513	KIAA1530	0.69	11.96	0.5	1.37e-28	Longevity;
LUAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg00280220	chr17:61926910	NA	0.36	6.98	0.32	1.18e-11	Prudent dietary pattern;
LUAD	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg09455208	chr3:40491958	NA	-0.6	-13.24	-0.54	1.01e-33	Renal cell carcinoma;
LUAD	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-9.15	-0.41	2.41e-18	Bipolar disorder;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg25187227	chr4:40058080	N4BP2;LOC344967	-0.42	-6.98	-0.32	1.14e-11	Cancer;
LUAD	cis	rs6005807	0.719	rs134506	chr22:28752505	A/G	cg12565055	chr22:29076175	TTC28	0.72	8.39	0.38	7.38e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs11771526	0.892	rs62457541	chr7:32372566	G/A	cg13207630	chr7:32358064	NA	0.68	7.72	0.35	8.52e-14	Body mass index;
LUAD	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg09365446	chr1:150670422	GOLPH3L	0.62	10.65	0.46	1.31e-23	Urate levels;
LUAD	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg03929089	chr4:120376271	NA	-0.85	-15.79	-0.61	1.68e-44	Height;
LUAD	cis	rs9308433	0.505	rs958304	chr1:214474241	C/T	cg06198575	chr1:214491504	SMYD2	0.47	7.99	0.36	1.32e-14	IgG glycosylation;
LUAD	cis	rs243505	0.559	rs1558420	chr7:148480114	G/T	cg09806900	chr7:148480153	CUL1	0.5	8.57	0.38	2.01e-16	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs68170813	0.559	rs77727587	chr7:106815754	C/G	cg23024343	chr7:107201750	COG5	0.49	7.05	0.32	7.12e-12	Coronary artery disease;
LUAD	cis	rs7709909	0.967	rs6151709	chr5:80012969	A/G	cg24059623	chr5:79951536	MSH3;DHFR	0.39	6.58	0.3	1.43e-10	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.44	-0.34	5.5e-13	Bipolar disorder;
LUAD	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.29	-0.33	1.52e-12	Resting heart rate;
LUAD	cis	rs9878978	0.964	rs11718236	chr3:2478632	C/T	cg21928760	chr3:2462534	CNTN4	-0.35	-6.98	-0.32	1.14e-11	Blood pressure (smoking interaction);
LUAD	cis	rs12545109	0.800	rs1530217	chr8:57408097	C/T	cg07776626	chr8:57350775	NA	-0.61	-8.51	-0.38	3.13e-16	Obesity-related traits;
LUAD	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg03563238	chr19:33554763	RHPN2	-0.38	-8.85	-0.4	2.44e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10992471	0.580	rs1535756	chr9:95202032	G/A	cg14631576	chr9:95140430	CENPP	-0.56	-11.41	-0.49	1.8e-26	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs2625529	0.627	rs12902661	chr15:72480158	T/G	cg16672083	chr15:72433130	SENP8	-0.75	-12.58	-0.52	4.7e-31	Red blood cell count;
LUAD	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg03188948	chr7:1209495	NA	0.53	8.45	0.38	4.88e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs16858210	0.874	rs1879256	chr3:183609061	A/G	cg01324343	chr3:183735012	ABCC5	0.43	6.84	0.32	2.84e-11	Menopause (age at onset);
LUAD	cis	rs7210086	0.768	rs72849444	chr17:70637805	G/A	cg04206342	chr17:70636940	NA	-0.34	-6.37	-0.3	5.03e-10	Ulcerative colitis;
LUAD	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg02807482	chr3:125708958	NA	-0.62	-8.63	-0.39	1.28e-16	Blood pressure (smoking interaction);
LUAD	trans	rs2262909	0.853	rs56207853	chr19:22292357	C/T	cg17074339	chr11:11642133	GALNTL4	0.46	7.57	0.35	2.33e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-6.73	-0.31	5.45e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2235642	0.533	rs9922661	chr16:1605163	C/A	cg26528668	chr16:1614120	IFT140	0.45	6.81	0.31	3.38e-11	Coronary artery disease;
LUAD	cis	rs3540	0.960	rs2238325	chr15:91011262	C/T	cg10434728	chr15:90938212	IQGAP1	-0.36	-6.64	-0.31	9.49e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.49	-8.72	-0.39	6.41e-17	Lymphocyte counts;
LUAD	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18876405	chr7:65276391	NA	0.63	11.0	0.47	6.39e-25	Aortic root size;
LUAD	trans	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.13	-26.81	-0.79	3.12e-93	Exhaled nitric oxide output;
LUAD	cis	rs1448094	0.872	rs7311150	chr12:86435989	A/T	cg00310523	chr12:86230176	RASSF9	0.34	7.24	0.33	2.08e-12	Major depressive disorder;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg11786005	chr6:170863399	PSMB1;TBP	-0.39	-6.57	-0.3	1.44e-10	Subcortical brain region volumes;
LUAD	cis	rs4975616	0.807	rs28379291	chr5:1313701	A/G	cg26373071	chr5:1325741	CLPTM1L	-0.39	-7.68	-0.35	1.12e-13	Lung cancer;
LUAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg11766577	chr21:47581405	C21orf56	-0.64	-11.78	-0.5	6.91e-28	Testicular germ cell tumor;
LUAD	cis	rs1953600	0.837	rs3098105	chr10:81953266	C/T	cg04850286	chr10:81895943	PLAC9	0.36	6.48	0.3	2.6e-10	Sarcoidosis;
LUAD	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.38	-0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs877282	0.797	rs11253329	chr10:753200	A/T	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03264133	chr6:25882463	NA	-0.97	-17.3	-0.64	4.23e-51	Urate levels;
LUAD	trans	rs1547374	0.694	rs225349	chr21:43776890	C/T	cg09521743	chr10:75415752	SYNPO2L	0.5	9.32	0.41	6.75e-19	Pancreatic cancer;
LUAD	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.18	-0.33	3.06e-12	Glomerular filtration rate;
LUAD	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg08645402	chr16:4508243	NA	0.53	9.07	0.4	4.69e-18	Schizophrenia;
LUAD	cis	rs4713675	0.565	rs60704560	chr6:33713300	C/T	cg13859433	chr6:33739653	LEMD2	-0.3	-7.27	-0.33	1.77e-12	Plateletcrit;
LUAD	cis	rs652260	0.967	rs667295	chr19:7901634	G/A	cg26014689	chr19:7917955	EVI5L	-0.43	-8.1	-0.37	6.03e-15	Menarche (age at onset);
LUAD	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.56	-7.17	-0.33	3.4e-12	Body mass index;
LUAD	cis	rs9522267	0.535	rs9522290	chr13:112233130	A/G	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.93e-11	Hepatitis;
LUAD	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11890956	chr21:40555474	PSMG1	-0.58	-9.51	-0.42	1.41e-19	Cognitive function;
LUAD	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21028142	chr17:79581711	NPLOC4	0.45	9.79	0.43	1.54e-20	Eye color traits;
LUAD	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg27124370	chr19:33622961	WDR88	0.39	6.42	0.3	3.75e-10	Bone properties (heel);
LUAD	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg00898013	chr13:113819073	PROZ	-0.83	-13.46	-0.55	1.26e-34	Platelet distribution width;
LUAD	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg00750074	chr16:89608354	SPG7	-0.4	-6.55	-0.3	1.64e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	8.1	0.37	6e-15	Menopause (age at onset);
LUAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.48	6.57	0.3	1.49e-10	Renal function-related traits (BUN);
LUAD	trans	rs6561151	0.681	rs17462017	chr13:44472235	C/T	cg17145862	chr1:211918768	LPGAT1	0.54	6.82	0.31	3.11e-11	Crohn's disease;
LUAD	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg09904177	chr6:26538194	HMGN4	-0.42	-7.02	-0.32	8.72e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.74	0.35	7.61e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.75	-9.21	-0.41	1.54e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg13393036	chr8:95962371	TP53INP1	0.38	9.04	0.4	5.67e-18	Type 2 diabetes;
LUAD	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg09904177	chr6:26538194	HMGN4	0.41	6.84	0.32	2.73e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg02269571	chr22:50332266	NA	0.59	8.81	0.39	3.17e-17	Schizophrenia;
LUAD	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	10.35	0.45	1.55e-22	Electrocardiographic conduction measures;
LUAD	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg05590025	chr7:65112418	INTS4L2	0.74	8.06	0.36	8.13e-15	Diabetic kidney disease;
LUAD	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg16479474	chr6:28041457	NA	0.45	7.73	0.35	7.89e-14	Depression;
LUAD	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg14186256	chr22:23484241	RTDR1	0.43	7.19	0.33	2.94e-12	Bone mineral density;
LUAD	cis	rs6743376	0.532	rs2515403	chr2:113820732	T/C	cg09040174	chr2:113837401	NA	0.46	7.2	0.33	2.7e-12	Inflammatory biomarkers;
LUAD	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg04369109	chr6:150039330	LATS1	-0.46	-7.74	-0.35	7.36e-14	Lung cancer;
LUAD	cis	rs7122539	0.646	rs608248	chr11:66562248	C/T	cg24851651	chr11:66362959	CCS	-0.37	-6.79	-0.31	3.71e-11	HIV-1 susceptibility;
LUAD	cis	rs4664304	0.742	rs67017730	chr2:160732793	T/G	cg23995753	chr2:160760732	LY75	-0.45	-7.61	-0.35	1.83e-13	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.45	8.19	0.37	3.03e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg17105886	chr17:28927953	LRRC37B2	-0.64	-7.36	-0.34	9.65e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.54	0.38	2.46e-16	Platelet count;
LUAD	cis	rs3845702	0.736	rs1904850	chr2:180852767	A/G	cg01881094	chr2:180872142	CWC22	-0.89	-9.37	-0.41	4.47e-19	Schizophrenia;
LUAD	cis	rs9925964	0.933	rs56314408	chr16:31117389	T/C	cg03418659	chr16:31128414	MYST1	-0.42	-7.26	-0.33	1.85e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06544989	chr22:39130855	UNC84B	0.41	7.56	0.34	2.61e-13	Menopause (age at onset);
LUAD	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg26343298	chr8:95960752	TP53INP1	0.38	8.02	0.36	1.08e-14	Type 2 diabetes;
LUAD	trans	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg11693508	chr17:37793320	STARD3	0.82	10.58	0.46	2.27e-23	Bipolar disorder;
LUAD	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg23950597	chr19:37808831	NA	-0.59	-7.46	-0.34	4.88e-13	Coronary artery calcification;
LUAD	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-9.3	-0.41	7.38e-19	Monocyte percentage of white cells;
LUAD	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg00383909	chr3:49044727	WDR6	0.93	10.03	0.44	2.3e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.51	-0.34	3.51e-13	Coronary artery disease;
LUAD	cis	rs8067545	0.750	rs4925069	chr17:19953531	C/G	cg04132472	chr17:19861366	AKAP10	0.28	6.6	0.31	1.2e-10	Schizophrenia;
LUAD	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg06131755	chr6:160182447	ACAT2	0.46	6.98	0.32	1.14e-11	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg08847533	chr14:75593920	NEK9	0.4	6.87	0.32	2.26e-11	Height;
LUAD	cis	rs7474896	0.515	rs688608	chr10:38331624	G/A	cg25427524	chr10:38739819	LOC399744	0.58	7.82	0.36	4.23e-14	Obesity (extreme);
LUAD	cis	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.99	-0.36	1.34e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg23649088	chr2:200775458	C2orf69	-0.61	-7.88	-0.36	2.71e-14	Schizophrenia;
LUAD	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg03474795	chr5:176074466	TSPAN17	-0.39	-6.62	-0.31	1.08e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg20607798	chr8:58055168	NA	0.67	8.56	0.38	2.19e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg01528321	chr10:82214614	TSPAN14	0.53	8.5	0.38	3.28e-16	Post bronchodilator FEV1;
LUAD	cis	rs300703	0.654	rs393277	chr2:121539	G/T	cg24565620	chr2:194026	NA	0.45	6.8	0.31	3.49e-11	Blood protein levels;
LUAD	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.38	0.34	8.35e-13	Menopause (age at onset);
LUAD	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg08798685	chr6:27730294	NA	-0.42	-6.7	-0.31	6.5500000000000006e-11	Parkinson's disease;
LUAD	cis	rs4925114	0.532	rs11655029	chr17:17649172	T/C	cg04398451	chr17:18023971	MYO15A	0.39	6.42	0.3	3.61e-10	Body mass index;
LUAD	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg08798685	chr6:27730294	NA	-0.44	-7.05	-0.32	7.46e-12	Parkinson's disease;
LUAD	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg21823605	chr1:152486609	CRCT1	0.28	6.52	0.3	2.01e-10	Hair morphology;
LUAD	cis	rs7095607	0.704	rs1900013	chr10:69953929	A/G	cg18986048	chr10:69913749	MYPN	0.42	7.42	0.34	6.49e-13	Lung function (FVC);
LUAD	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg00204512	chr16:28754710	NA	0.3	6.54	0.3	1.73e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg07570687	chr10:102243282	WNT8B	0.41	6.37	0.3	5.02e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs2797160	1.000	rs1739374	chr6:126011825	C/T	cg05901451	chr6:126070800	HEY2	0.46	7.01	0.32	9.2e-12	Endometrial cancer;
LUAD	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg14829155	chr15:31115871	NA	0.5	8.8	0.39	3.53e-17	Huntington's disease progression;
LUAD	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.62	-0.35	1.73e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg00647820	chr17:40259828	DHX58	-0.46	-7.33	-0.34	1.16e-12	Fibrinogen levels;
LUAD	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg04450456	chr4:17643702	FAM184B	0.42	8.33	0.38	1.11e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg25251562	chr2:3704773	ALLC	-0.81	-12.53	-0.52	7.42e-31	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.06	0.32	6.96e-12	Motion sickness;
LUAD	cis	rs752092	0.802	rs2412005	chr15:101767591	T/A	cg19997662	chr15:101784653	CHSY1	-0.44	-8.18	-0.37	3.38e-15	Corneal structure;
LUAD	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg15664640	chr17:80829946	TBCD	-0.66	-8.34	-0.38	1.1e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs6906287	0.625	rs7764272	chr6:118692498	A/C	cg21191810	chr6:118973309	C6orf204	0.53	10.52	0.46	3.83e-23	Electrocardiographic conduction measures;
LUAD	trans	rs1728785	0.901	rs821169	chr16:68630184	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.3	0.45	2.3e-22	Ulcerative colitis;
LUAD	cis	rs36051895	0.623	rs62541541	chr9:5040817	G/C	cg02405213	chr9:5042618	JAK2	-0.49	-6.72	-0.31	5.79e-11	Pediatric autoimmune diseases;
LUAD	cis	rs7508679	1.000	rs10410204	chr19:7224350	C/T	cg09779027	chr19:7224513	INSR	0.79	17.85	0.66	1.52e-53	Hypothyroidism;
LUAD	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg22681709	chr2:178499509	PDE11A	-0.47	-7.72	-0.35	8.3e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9287719	0.774	rs4997811	chr2:10755538	T/C	cg02196655	chr2:10830764	NOL10	-0.42	-7.5	-0.34	3.7e-13	Prostate cancer;
LUAD	cis	rs5758511	0.773	rs62241023	chr22:42385429	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.43	7.14	0.33	4.18e-12	Birth weight;
LUAD	cis	rs6684514	1.000	rs2273833	chr1:156233189	C/T	cg16558208	chr1:156270281	VHLL	0.52	9.29	0.41	8.02e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.33	6.69	0.31	6.9e-11	Menopause (age at onset);
LUAD	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18876405	chr7:65276391	NA	-0.55	-9.02	-0.4	6.64e-18	Aortic root size;
LUAD	cis	rs990171	0.538	rs12712153	chr2:103111761	C/T	cg03938978	chr2:103052716	IL18RAP	0.34	6.6	0.31	1.25e-10	Lymphocyte counts;
LUAD	trans	rs56133113	0.710	rs79746021	chr11:72781835	C/T	cg01847441	chr14:69431073	ACTN1	-0.59	-6.58	-0.3	1.38e-10	Mean platelet volume;
LUAD	cis	rs9905704	0.560	rs2526375	chr17:56429094	A/G	cg19466818	chr17:56409534	MIR142	-0.37	-6.83	-0.32	2.96e-11	Testicular germ cell tumor;
LUAD	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg08742575	chr21:47604166	C21orf56	0.43	7.19	0.33	2.95e-12	Testicular germ cell tumor;
LUAD	trans	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg01620082	chr3:125678407	NA	-0.49	-7.01	-0.32	9.62e-12	Depression;
LUAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg24642844	chr7:1081250	C7orf50	-0.98	-14.8	-0.58	2.97e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2361710	0.611	rs3816257	chr17:78074446	G/T	cg06718696	chr17:78121285	EIF4A3	-0.44	-7.05	-0.32	7.39e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUAD	cis	rs7617773	0.780	rs4541431	chr3:48365218	G/C	cg11946769	chr3:48343235	NME6	0.45	6.89	0.32	2.05e-11	Coronary artery disease;
LUAD	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.68	12.44	0.52	1.74e-30	Cognitive ability;
LUAD	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg18446336	chr7:2847575	GNA12	-0.33	-6.7	-0.31	6.82e-11	Height;
LUAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg22963979	chr7:1858916	MAD1L1	-0.51	-8.67	-0.39	9.35e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs2880765	0.835	rs12910373	chr15:86046802	G/C	cg13263323	chr15:86062960	AKAP13	-0.5	-9.24	-0.41	1.21e-18	Coronary artery disease;
LUAD	cis	rs62238980	0.614	rs733908	chr22:32462505	C/T	cg02631450	chr22:32366979	NA	0.79	6.68	0.31	7.44e-11	Childhood ear infection;
LUAD	cis	rs4764487	0.760	rs740840	chr12:6337254	G/T	cg08284733	chr12:6341482	CD9	0.39	6.87	0.32	2.27e-11	Mean platelet volume;
LUAD	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg05340658	chr4:99064831	C4orf37	-0.44	-7.33	-0.34	1.14e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs12458462	0.509	rs3786241	chr18:77494328	A/C	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.47	-7.55	-0.34	2.65e-13	Monocyte count;
LUAD	trans	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg02030672	chr11:45687055	CHST1	-0.37	-6.49	-0.3	2.45e-10	Obesity-related traits;
LUAD	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg24675056	chr1:15929824	NA	0.49	8.5	0.38	3.39e-16	Systolic blood pressure;
LUAD	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg20307385	chr11:47447363	PSMC3	0.67	11.63	0.49	2.48e-27	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs6740322	0.748	rs6756625	chr2:43489313	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.69	10.89	0.47	1.63e-24	Coronary artery disease;
LUAD	trans	rs9302065	0.565	rs2993586	chr13:95962578	T/C	cg19955956	chr7:72299837	SBDSP;TYW1B	0.54	9.27	0.41	9.56e-19	Blood metabolite levels;
LUAD	cis	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg20368463	chr18:77673604	PQLC1	0.56	6.47	0.3	2.67e-10	Opioid sensitivity;
LUAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg18402987	chr7:1209562	NA	0.81	9.91	0.43	6.12e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1595825	0.891	rs16866980	chr2:198513009	A/C	cg11031976	chr2:198649780	BOLL	-0.46	-6.81	-0.31	3.32e-11	Ulcerative colitis;
LUAD	trans	rs4714291	0.722	rs9296320	chr6:40118298	C/G	cg02267698	chr19:7991119	CTXN1	0.41	6.7	0.31	6.53e-11	Strep throat;
LUAD	cis	rs494562	0.892	rs573892	chr6:86118189	A/C	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08280861	chr8:58055591	NA	0.64	8.45	0.38	4.9e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg17761419	chr8:57350749	NA	-0.54	-7.81	-0.35	4.58e-14	Obesity-related traits;
LUAD	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.33	-0.34	1.16e-12	Reticulocyte count;
LUAD	cis	rs68092024	0.704	rs793487	chr3:99495422	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	7.83	0.36	4.02e-14	Cleft lip with or without cleft palate;
LUAD	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.55	-9.29	-0.41	8e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.82	0.31	3.14e-11	Blood metabolite levels;
LUAD	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg00071950	chr4:10020882	SLC2A9	0.83	18.1	0.66	1.26e-54	Bone mineral density;
LUAD	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg22681709	chr2:178499509	PDE11A	-0.45	-7.37	-0.34	8.97e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg02421172	chr7:1938701	MAD1L1	0.49	6.69	0.31	7.26e-11	Bipolar disorder;
LUAD	cis	rs6499255	0.951	rs61310815	chr16:69701239	A/T	cg15192750	chr16:69999425	NA	0.5	7.88	0.36	2.71e-14	IgE levels;
LUAD	cis	rs6546550	0.867	rs1048266	chr2:70132676	A/G	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.97	-0.47	8.24e-25	Prevalent atrial fibrillation;
LUAD	trans	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	11.01	0.47	5.86e-25	Mean corpuscular volume;
LUAD	cis	rs6496044	0.568	rs6496066	chr15:86075462	A/C	cg13263323	chr15:86062960	AKAP13	-0.57	-10.6	-0.46	1.88e-23	Interstitial lung disease;
LUAD	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.28	-0.33	1.61e-12	Glomerular filtration rate;
LUAD	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg01851573	chr8:8652454	MFHAS1	-0.44	-7.91	-0.36	2.24e-14	Neuroticism;
LUAD	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg05805236	chr11:65401703	PCNXL3	0.41	6.99	0.32	1.08e-11	Acne (severe);
LUAD	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg23109721	chr2:106886537	NA	-0.53	-7.1	-0.33	5.37e-12	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs2281558	0.876	rs6107025	chr20:25279880	A/G	cg08601574	chr20:25228251	PYGB	0.44	6.37	0.3	4.89e-10	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUAD	cis	rs7000551	0.663	rs7827118	chr8:22334669	T/G	cg12081754	chr8:22256438	SLC39A14	0.44	7.33	0.34	1.21e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg00769240	chr8:12517080	NA	-0.43	-8.36	-0.38	9.46e-16	Blood pressure (smoking interaction);
LUAD	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.85	0.32	2.67e-11	Hypertriglyceridemia;
LUAD	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg02269571	chr22:50332266	NA	-0.59	-8.96	-0.4	1.08e-17	Schizophrenia;
LUAD	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg22618164	chr12:122356400	WDR66	0.75	13.72	0.55	1.12e-35	Mean corpuscular volume;
LUAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg27454412	chr7:1067447	C7orf50	0.48	7.75	0.35	6.7e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg27532560	chr4:187881888	NA	-0.39	-7.57	-0.35	2.31e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.96	-0.36	1.55e-14	Total body bone mineral density;
LUAD	cis	rs7712401	0.601	rs246303	chr5:122251717	C/G	cg19077854	chr5:122220652	SNX24	0.34	6.47	0.3	2.67e-10	Mean platelet volume;
LUAD	cis	rs16854884	0.586	rs4527375	chr3:143735515	A/T	cg01302019	chr3:143689584	C3orf58	0.36	6.51	0.3	2.14e-10	Economic and political preferences (feminism/equality);
LUAD	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg21770322	chr7:97807741	LMTK2	-0.31	-7.06	-0.32	7.04e-12	Breast cancer;
LUAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07167872	chr1:205819463	PM20D1	0.61	11.24	0.48	7.65e-26	Menarche (age at onset);
LUAD	cis	rs7017914	0.934	rs62508771	chr8:71692688	C/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.43	-0.3	3.46e-10	Bone mineral density;
LUAD	cis	rs7107174	1.000	rs10793295	chr11:77996521	C/G	cg02023728	chr11:77925099	USP35	-0.39	-6.56	-0.3	1.55e-10	Testicular germ cell tumor;
LUAD	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg24399712	chr22:39784796	NA	-0.8	-16.12	-0.62	6.49e-46	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs698833	0.886	rs698766	chr2:44574277	C/G	cg04920474	chr2:44395004	PPM1B	0.43	7.91	0.36	2.22e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs11696845	0.626	rs4810439	chr20:43377870	C/G	cg25301532	chr20:43378953	KCNK15	-0.48	-8.39	-0.38	7.56e-16	Obesity-related traits;
LUAD	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg24069376	chr3:38537580	EXOG	0.31	6.79	0.31	3.81e-11	Electrocardiographic conduction measures;
LUAD	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.73e-16	Neutrophil percentage of white cells;
LUAD	cis	rs4700695	0.719	rs27080	chr5:65442271	A/G	cg21114390	chr5:65439923	SFRS12	-0.93	-14.52	-0.58	4.6e-39	Facial morphology (factor 19);
LUAD	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg08470875	chr2:26401718	FAM59B	-0.77	-10.45	-0.45	7e-23	Gut microbiome composition (summer);
LUAD	cis	rs1670533	1.000	rs935972	chr4:1045171	A/G	cg27284194	chr4:1044797	NA	0.71	8.58	0.38	1.85e-16	Recombination rate (females);
LUAD	cis	rs1215050	0.791	rs11729826	chr4:98657190	G/T	cg17366294	chr4:99064904	C4orf37	-0.45	-7.94	-0.36	1.86e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.933	rs2054846	chr17:28507693	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.51	-8.64	-0.39	1.18e-16	Coffee consumption (cups per day);
LUAD	cis	rs7809950	0.954	rs12673675	chr7:107113220	T/C	cg23024343	chr7:107201750	COG5	-0.72	-12.34	-0.51	4.1e-30	Coronary artery disease;
LUAD	cis	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05901451	chr6:126070800	HEY2	0.45	6.65	0.31	9.09e-11	Endometrial cancer;
LUAD	cis	rs3784262	0.740	rs12898976	chr15:58276358	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.4	-7.9	-0.36	2.45e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.0	0.32	9.82e-12	Prostate cancer;
LUAD	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg14584255	chr6:163149320	PACRG;PARK2	-0.36	-6.98	-0.32	1.16e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.15	-0.33	3.75e-12	Height;
LUAD	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg24399712	chr22:39784796	NA	0.81	14.54	0.58	4.07e-39	Intelligence (multi-trait analysis);
LUAD	cis	rs909002	0.886	rs11807225	chr1:32083193	G/C	cg13919466	chr1:32135498	COL16A1	-0.34	-7.84	-0.36	3.82e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1832871	0.711	rs9459946	chr6:158707957	T/C	cg07165851	chr6:158734300	TULP4	0.7	11.17	0.48	1.45e-25	Height;
LUAD	cis	rs9487051	0.768	rs9480910	chr6:109521707	T/C	cg21918786	chr6:109611834	NA	-0.41	-7.23	-0.33	2.33e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg26343298	chr8:95960752	TP53INP1	0.37	7.82	0.36	4.12e-14	Type 2 diabetes;
LUAD	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg02038168	chr22:39784481	NA	0.6	11.13	0.48	2.03e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21659725	chr3:3221576	CRBN	-0.64	-11.04	-0.47	4.59e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg13047869	chr3:10149882	C3orf24	0.6	10.38	0.45	1.18e-22	Alzheimer's disease;
LUAD	cis	rs57502260	0.704	rs923346	chr11:68182375	T/C	cg16797656	chr11:68205561	LRP5	0.42	6.74	0.31	5.33e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg24503407	chr1:205819492	PM20D1	0.78	15.61	0.6	1.03e-43	Menarche (age at onset);
LUAD	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs12210905	0.688	rs72845025	chr6:27524443	G/C	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg11494091	chr17:61959527	GH2	0.71	17.36	0.65	2.22e-51	Prudent dietary pattern;
LUAD	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg11707310	chr1:2537719	MMEL1	0.39	8.34	0.38	1.08e-15	Ulcerative colitis;
LUAD	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg22676075	chr6:135203613	NA	0.49	8.64	0.39	1.16e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.06	0.47	3.91e-25	Height;
LUAD	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg26513180	chr16:89883248	FANCA	0.65	6.79	0.31	3.7e-11	Skin colour saturation;
LUAD	cis	rs727505	0.954	rs59283092	chr7:124678282	T/C	cg23710748	chr7:124431027	NA	-0.43	-8.69	-0.39	7.78e-17	Lewy body disease;
LUAD	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg20503657	chr10:835505	NA	-0.64	-10.82	-0.47	2.93e-24	Eosinophil percentage of granulocytes;
LUAD	cis	rs78487399	0.808	rs10180005	chr2:43737465	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.52	-0.3	2.06e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.34	-6.44	-0.3	3.27e-10	Crohn's disease;
LUAD	cis	rs796825	0.530	rs55762220	chr3:119956606	T/C	cg21790991	chr3:120137480	FSTL1	-0.43	-7.32	-0.34	1.27e-12	HIV-1 susceptibility;
LUAD	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg03676636	chr4:99064102	C4orf37	0.3	7.33	0.34	1.19e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.515	rs7287164	chr22:46781008	T/C	cg18190219	chr22:46762943	CELSR1	-0.58	-6.52	-0.3	2.04e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg08807101	chr21:30365312	RNF160	-0.43	-7.4	-0.34	7.32e-13	Dental caries;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27499259	chr13:28400924	NA	-0.43	-6.96	-0.32	1.31e-11	Height;
LUAD	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg16988262	chr1:15930761	NA	0.42	7.01	0.32	9.56e-12	Systolic blood pressure;
LUAD	cis	rs4604732	0.631	rs74154676	chr1:247625894	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs909002	0.800	rs3753612	chr1:32082410	C/G	cg13919466	chr1:32135498	COL16A1	-0.34	-7.86	-0.36	3.26e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.31e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg14829155	chr15:31115871	NA	-0.64	-9.93	-0.43	4.82e-21	Huntington's disease progression;
LUAD	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg09184832	chr6:79620586	NA	0.48	8.87	0.4	2.06e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09026875	chr17:60501189	METTL2A	-0.57	-7.08	-0.33	6e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg08213375	chr14:104286397	PPP1R13B	0.26	6.85	0.32	2.6e-11	Schizophrenia;
LUAD	cis	rs7617773	0.780	rs4130522	chr3:48352313	G/A	cg11946769	chr3:48343235	NME6	0.44	6.79	0.31	3.79e-11	Coronary artery disease;
LUAD	cis	rs698833	0.926	rs1067406	chr2:44674450	C/T	cg04920474	chr2:44395004	PPM1B	0.36	6.47	0.3	2.68e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg27432699	chr2:27873401	GPN1	0.57	10.15	0.44	8.27e-22	Oral cavity cancer;
LUAD	cis	rs6066835	1.000	rs73136396	chr20:47337174	T/A	cg18078177	chr20:47281410	PREX1	0.81	6.37	0.3	4.86e-10	Multiple myeloma;
LUAD	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg23985595	chr17:80112537	CCDC57	-0.51	-9.39	-0.42	3.85e-19	Life satisfaction;
LUAD	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg07010633	chr17:73824396	UNC13D	-0.32	-6.55	-0.3	1.72e-10	White matter hyperintensity burden;
LUAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.45	-0.38	4.57e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg08316699	chr6:150357289	NA	0.36	7.34	0.34	1.1e-12	Alopecia areata;
LUAD	trans	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg18187862	chr3:45730750	SACM1L	0.49	7.74	0.35	7.53e-14	Primary sclerosing cholangitis;
LUAD	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg25358565	chr5:93447407	FAM172A	-0.56	-7.14	-0.33	4.08e-12	Diabetic retinopathy;
LUAD	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg15992532	chr8:142229932	SLC45A4	0.48	8.49	0.38	3.47e-16	Immature fraction of reticulocytes;
LUAD	cis	rs1018836	0.828	rs1858673	chr8:91551526	C/A	cg16814680	chr8:91681699	NA	-0.59	-10.08	-0.44	1.46e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12545109	0.613	rs4541914	chr8:57254555	T/G	cg09654669	chr8:57350985	NA	-0.7	-9.23	-0.41	1.27e-18	Obesity-related traits;
LUAD	cis	rs807669	0.934	rs1780643	chr22:19191725	T/C	cg02655711	chr22:19163373	SLC25A1	0.84	17.8	0.65	2.54e-53	Metabolite levels;
LUAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg24813613	chr7:1882135	MAD1L1	-0.4	-6.48	-0.3	2.55e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg21782813	chr7:2030301	MAD1L1	0.57	10.16	0.44	7.66e-22	Bipolar disorder and schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12497007	chr16:29828301	C16orf53	-0.42	-6.76	-0.31	4.67e-11	Height;
LUAD	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg12062639	chr20:23401060	NAPB	1.09	11.16	0.48	1.64e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-11.22	-0.48	9.14e-26	Bone mineral density;
LUAD	cis	rs2625529	0.824	rs7182776	chr15:72462831	A/G	cg16672083	chr15:72433130	SENP8	0.73	13.17	0.54	1.94e-33	Red blood cell count;
LUAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs240764	0.658	rs11155666	chr6:101234841	G/C	cg09795085	chr6:101329169	ASCC3	-0.47	-8.18	-0.37	3.46e-15	Neuroticism;
LUAD	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg19875535	chr5:140030758	IK	0.47	7.71	0.35	8.78e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs59104589	0.521	rs62190404	chr2:242401422	C/T	cg08645257	chr2:242211290	HDLBP	0.39	6.48	0.3	2.53e-10	Fibrinogen levels;
LUAD	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg03806693	chr22:41940476	POLR3H	0.54	8.01	0.36	1.14e-14	Vitiligo;
LUAD	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.6	11.35	0.48	3.07e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg18944383	chr4:111397179	ENPEP	0.49	9.94	0.44	4.73e-21	Height;
LUAD	cis	rs17401966	1.000	rs4348727	chr1:10265606	G/A	cg15208524	chr1:10270712	KIF1B	0.54	7.89	0.36	2.67e-14	Hepatocellular carcinoma;
LUAD	trans	rs7395662	0.963	rs7483713	chr11:48629214	A/T	cg00717180	chr2:96193071	NA	-0.38	-7.13	-0.33	4.4e-12	HDL cholesterol;
LUAD	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg03037974	chr15:76606532	NA	0.39	8.53	0.38	2.68e-16	Blood metabolite levels;
LUAD	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg05044414	chr3:183734942	ABCC5	0.4	8.03	0.36	9.52e-15	Anterior chamber depth;
LUAD	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg10523679	chr1:76189770	ACADM	-0.46	-6.45	-0.3	3e-10	Daytime sleep phenotypes;
LUAD	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg13319975	chr6:146136371	FBXO30	-0.63	-10.82	-0.47	3.06e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-7.86	-0.36	3.22e-14	Bipolar disorder;
LUAD	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11890956	chr21:40555474	PSMG1	0.79	13.23	0.54	1.15e-33	Cognitive function;
LUAD	cis	rs7705042	0.865	rs449454	chr5:141533062	A/G	cg23435118	chr5:141488016	NDFIP1	-0.42	-7.03	-0.32	8.33e-12	Asthma;
LUAD	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg16479474	chr6:28041457	NA	0.37	6.62	0.31	1.11e-10	Cardiac Troponin-T levels;
LUAD	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.12e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1997103	1.000	rs6953494	chr7:55412157	G/A	cg20935933	chr6:143382018	AIG1	0.53	7.42	0.34	6.65e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs13095912	0.889	rs6778977	chr3:185302532	T/G	cg11274856	chr3:185301563	NA	0.37	7.46	0.34	4.81e-13	Systolic blood pressure;
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg18000306	chr6:288505	NA	0.43	8.03	0.36	9.59e-15	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg24818145	chr4:99064322	C4orf37	0.46	7.7	0.35	9.54e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg26818010	chr10:134567672	INPP5A	-0.96	-15.8	-0.61	1.63e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg00310523	chr12:86230176	RASSF9	0.42	8.32	0.38	1.18e-15	Major depressive disorder;
LUAD	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg23625390	chr15:77176239	SCAPER	0.39	6.82	0.31	3.25e-11	Blood metabolite levels;
LUAD	cis	rs17197710	0.608	rs12573962	chr11:47305660	G/C	cg13308137	chr11:47528955	CUGBP1	0.45	7.12	0.33	4.54e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs4650994	0.593	rs2761459	chr1:178551576	G/A	cg05059571	chr16:84539110	KIAA1609	0.43	6.58	0.3	1.4e-10	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg06609049	chr19:2785107	THOP1	0.74	12.25	0.51	9.48e-30	Total cholesterol levels;
LUAD	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg24558204	chr6:135376177	HBS1L	0.49	8.45	0.38	4.66e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg23131131	chr22:24373011	LOC391322	-0.63	-11.08	-0.47	3.09e-25	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg18854424	chr1:2615690	NA	0.41	9.09	0.4	3.73e-18	Ulcerative colitis;
LUAD	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg18721089	chr20:30220636	NA	-0.46	-6.73	-0.31	5.39e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06022373	chr22:39101656	GTPBP1	0.45	7.03	0.32	8.17e-12	Menopause (age at onset);
LUAD	cis	rs17761864	0.675	rs72815344	chr17:2046947	T/C	cg16513277	chr17:2031491	SMG6	0.47	7.39	0.34	7.86e-13	Esophageal cancer (squamous cell);
LUAD	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg19442545	chr10:75533431	FUT11	-0.49	-8.39	-0.38	7.42e-16	Inflammatory bowel disease;
LUAD	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg20607287	chr7:12443886	VWDE	-0.48	-6.95	-0.32	1.36e-11	Coronary artery disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04011897	chr2:240014762	HDAC4	0.52	6.66	0.31	8.36e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.58	-0.35	2.2e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6489882	0.703	rs10774674	chr12:113361174	A/G	cg20102336	chr12:113376681	OAS3	-0.53	-8.56	-0.38	2.05e-16	Chronic lymphocytic leukemia;
LUAD	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg19077165	chr18:44547161	KATNAL2	-0.43	-7.4	-0.34	7.51e-13	Personality dimensions;
LUAD	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	6.6	0.31	1.22e-10	Lung cancer in ever smokers;
LUAD	trans	rs75804782	0.641	rs72987309	chr2:239348025	A/G	cg01134436	chr17:81009848	B3GNTL1	0.65	7.25	0.33	2.05e-12	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg06558623	chr16:89946397	TCF25	1.16	10.75	0.46	5.64e-24	Skin colour saturation;
LUAD	cis	rs2904967	0.929	rs2904981	chr11:65003026	C/T	cg09225861	chr11:65069680	NA	-0.43	-6.36	-0.3	5.3e-10	Mean corpuscular volume;
LUAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg09060608	chr5:178986726	RUFY1	0.7	12.43	0.52	1.81e-30	Lung cancer;
LUAD	cis	rs3859192	0.557	rs12602514	chr17:38159745	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.74	15.77	0.61	2.21e-44	White blood cell count;
LUAD	cis	rs10504073	0.584	rs4873306	chr8:49950369	T/C	cg00325661	chr8:49890786	NA	0.44	10.25	0.45	3.76e-22	Blood metabolite ratios;
LUAD	trans	rs587242	1.000	rs12757257	chr1:96898302	G/A	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg14926445	chr8:58193284	C8orf71	-0.47	-6.85	-0.32	2.62e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg22823121	chr1:150693482	HORMAD1	0.37	7.25	0.33	1.96e-12	Melanoma;
LUAD	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.38	-0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	trans	rs9929218	1.000	rs11865026	chr16:68774283	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-15.36	-0.6	1.2e-42	Colorectal cancer;
LUAD	cis	rs2282300	0.739	rs1222221	chr11:30342738	A/G	cg25418670	chr11:30344373	C11orf46	-0.49	-6.79	-0.31	3.79e-11	Morning vs. evening chronotype;
LUAD	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11644478	chr21:40555479	PSMG1	0.4	6.71	0.31	6.16e-11	Menarche (age at onset);
LUAD	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg07570687	chr10:102243282	WNT8B	0.48	7.31	0.33	1.33e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg13319975	chr6:146136371	FBXO30	-0.8	-13.66	-0.55	1.85e-35	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	ch.11.42038R	chr11:967971	AP2A2	-0.39	-6.81	-0.31	3.46e-11	Alzheimer's disease (late onset);
LUAD	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg16479474	chr6:28041457	NA	0.44	7.4	0.34	7.22e-13	Depression;
LUAD	cis	rs2730260	0.537	rs73169233	chr7:158882201	C/T	cg13710308	chr7:158854763	VIPR2	-0.5	-6.39	-0.3	4.32e-10	Myopia (pathological);
LUAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.51	-9.48	-0.42	1.87e-19	Longevity;Endometriosis;
LUAD	cis	rs6445967	0.554	rs10866018	chr3:58446000	G/A	cg13750441	chr3:58318267	PXK	-0.31	-6.38	-0.3	4.68e-10	Platelet count;
LUAD	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03264133	chr6:25882463	NA	-0.83	-11.52	-0.49	6.88e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs7116495	1.000	rs542752	chr11:71810644	T/A	cg07596299	chr11:71824057	C11orf51	0.76	6.38	0.3	4.56e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs7301016	0.947	rs10877864	chr12:62893199	T/C	cg11441379	chr12:63026424	NA	0.53	6.52	0.3	1.97e-10	IgG glycosylation;
LUAD	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.37	7.35	0.34	1.02e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg04450456	chr4:17643702	FAM184B	0.39	7.83	0.36	4.02e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs220324	0.688	rs9975464	chr21:43560055	T/C	cg09727148	chr21:43560719	UMODL1	0.58	8.83	0.39	2.72e-17	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg02782426	chr3:40428986	ENTPD3	-0.42	-9.08	-0.4	4.22e-18	Renal cell carcinoma;
LUAD	cis	rs17789174	0.951	rs12596553	chr16:85104752	G/T	cg27466129	chr16:85060822	KIAA0513	0.3	6.35	0.3	5.42e-10	Dysphagia;
LUAD	cis	rs7487075	0.567	rs7486580	chr12:46828348	C/A	cg23829395	chr12:46796953	NA	0.32	7.04	0.32	7.61e-12	Itch intensity from mosquito bite;
LUAD	cis	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.65	-0.31	9.07e-11	Endometrial cancer;
LUAD	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg08999081	chr20:33150536	PIGU	-0.39	-7.78	-0.35	5.44e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.76	0.31	4.62e-11	Aortic root size;
LUAD	cis	rs2294693	0.947	rs9381025	chr6:40986623	C/T	cg14769373	chr6:40998127	UNC5CL	-0.53	-8.47	-0.38	4.12e-16	Gastric cancer;Non-cardia gastric cancer;
LUAD	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	8.64	0.39	1.2e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg05754148	chr16:3507555	NAT15	-0.48	-7.92	-0.36	2.15e-14	Body mass index (adult);
LUAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.31e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26314531	chr2:26401878	FAM59B	0.75	10.7	0.46	8.33e-24	Gut microbiome composition (summer);
LUAD	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg20290983	chr6:43655470	MRPS18A	1.08	27.29	0.8	2.51e-95	IgG glycosylation;
LUAD	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg06740227	chr12:86229804	RASSF9	0.42	7.24	0.33	2.1e-12	Major depressive disorder;
LUAD	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg00277334	chr10:82204260	NA	-0.54	-8.93	-0.4	1.28e-17	Post bronchodilator FEV1;
LUAD	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg17644776	chr2:200775616	C2orf69	-0.57	-7.41	-0.34	6.71e-13	Schizophrenia;
LUAD	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.46	-0.34	5.07e-13	Bipolar disorder;
LUAD	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg26513180	chr16:89883248	FANCA	0.82	7.41	0.34	6.99e-13	Skin colour saturation;
LUAD	cis	rs7927592	0.546	rs554734	chr11:68192518	T/G	cg02221422	chr11:68192511	LRP5	-0.46	-7.29	-0.33	1.56e-12	Total body bone mineral density;
LUAD	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg22823121	chr1:150693482	HORMAD1	0.44	8.58	0.38	1.85e-16	Melanoma;
LUAD	cis	rs4964805	0.802	rs934847	chr12:104185693	C/T	cg02344784	chr12:104178138	NT5DC3	0.41	7.28	0.33	1.61e-12	Attention deficit hyperactivity disorder;
LUAD	cis	rs62238980	0.614	rs78818509	chr22:32447582	A/G	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg23803603	chr1:2058230	PRKCZ	0.41	6.64	0.31	9.78e-11	Height;
LUAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06873352	chr17:61820015	STRADA	-0.72	-14.99	-0.59	4.83e-41	Prudent dietary pattern;
LUAD	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg13902645	chr11:5959945	NA	-0.53	-9.36	-0.41	4.86e-19	DNA methylation (variation);
LUAD	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg05283184	chr6:79620031	NA	-0.61	-12.04	-0.51	6.58e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg13385794	chr1:248469461	NA	0.26	7.07	0.33	6.48e-12	Common traits (Other);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg14716208	chr3:52089752	DUSP7	-0.37	-6.54	-0.3	1.77e-10	Schizophrenia;
LUAD	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.54	7.61	0.35	1.76e-13	Platelet count;
LUAD	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg07507251	chr3:52567010	NT5DC2	0.37	7.35	0.34	1.04e-12	Bipolar disorder;
LUAD	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg18512352	chr11:47633146	NA	-0.57	-10.16	-0.44	7.8e-22	Subjective well-being;
LUAD	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.75	-0.31	4.91e-11	Type 2 diabetes;
LUAD	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg02527881	chr3:46936655	PTH1R	0.42	8.03	0.36	9.68e-15	Colorectal cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20314438	chr6:126661369	C6orf173	-0.43	-6.55	-0.3	1.65e-10	Height;
LUAD	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.45	-6.85	-0.32	2.66e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg08761264	chr16:28874980	SH2B1	-0.45	-6.71	-0.31	6.15e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg07936489	chr17:37558343	FBXL20	-0.43	-6.75	-0.31	5.03e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs2658782	0.826	rs1975820	chr11:93081815	G/A	cg15737290	chr11:93063684	CCDC67	0.54	7.56	0.34	2.56e-13	Pulmonary function decline;
LUAD	cis	rs7107174	1.000	rs1942352	chr11:77970563	T/G	cg19901956	chr11:77921274	USP35	-0.47	-6.45	-0.3	3.13e-10	Testicular germ cell tumor;
LUAD	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg09065629	chr16:1709722	CRAMP1L	0.39	6.76	0.31	4.49e-11	Coronary artery disease;
LUAD	cis	rs11112613	0.818	rs73184099	chr12:106018143	A/G	cg03607813	chr12:105948248	NA	0.57	7.22	0.33	2.48e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg11247378	chr22:39784982	NA	-0.49	-7.26	-0.33	1.87e-12	IgG glycosylation;
LUAD	cis	rs10985070	0.507	rs12551347	chr9:123936594	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	6.65	0.31	8.99e-11	Rheumatoid arthritis;
LUAD	cis	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg03684893	chr10:554711	DIP2C	-0.37	-6.59	-0.31	1.33e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg16006841	chr5:176797999	RGS14	0.68	11.05	0.47	4.14e-25	Urinary electrolytes (magnesium/calcium ratio);
LUAD	cis	rs4372836	0.504	rs7601720	chr2:29032478	G/A	cg09522027	chr2:28974177	PPP1CB	-0.61	-10.87	-0.47	1.87e-24	Body mass index;
LUAD	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg18512352	chr11:47633146	NA	-0.5	-8.44	-0.38	5.04e-16	Subjective well-being;
LUAD	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.65e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs13315871	1.000	rs71311873	chr3:58447106	C/A	cg12435725	chr3:58293450	RPP14	-0.69	-7.45	-0.34	5.2e-13	Cholesterol, total;
LUAD	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg22532475	chr10:104410764	TRIM8	-0.46	-8.99	-0.4	8.25e-18	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg12884169	chr21:40033163	ERG	-0.37	-7.83	-0.36	3.85e-14	Coronary artery disease;
LUAD	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg01579765	chr21:45077557	HSF2BP	-0.58	-13.44	-0.55	1.6e-34	Mean corpuscular volume;
LUAD	cis	rs1448094	0.802	rs7487591	chr12:86434112	T/C	cg06740227	chr12:86229804	RASSF9	0.36	6.6	0.31	1.24e-10	Major depressive disorder;
LUAD	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg07936489	chr17:37558343	FBXL20	-0.47	-7.5	-0.34	3.91e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg08742575	chr21:47604166	C21orf56	0.43	7.26	0.33	1.93e-12	Testicular germ cell tumor;
LUAD	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19346786	chr7:2764209	NA	-0.55	-11.83	-0.5	4.46e-28	Height;
LUAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00166722	chr3:10149974	C3orf24	0.75	12.92	0.53	2.01e-32	Alzheimer's disease;
LUAD	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg01324343	chr3:183735012	ABCC5	0.97	26.08	0.79	4.36e-90	Anterior chamber depth;
LUAD	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg18138036	chr10:133769891	PPP2R2D	0.41	6.69	0.31	7.09e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs1018836	0.632	rs9642910	chr8:91475724	G/T	cg16814680	chr8:91681699	NA	-0.66	-10.95	-0.47	9.7e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs8002861	0.727	rs9525850	chr13:44402100	C/T	cg12856521	chr11:46389249	DGKZ	-0.5	-8.64	-0.39	1.17e-16	Leprosy;
LUAD	cis	rs1550582	0.917	rs7831961	chr8:135507060	C/G	cg17885191	chr8:135476712	NA	-0.71	-11.05	-0.47	4.16e-25	Educational attainment;
LUAD	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg00701064	chr4:6280414	WFS1	0.61	11.9	0.5	2.29e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg26446133	chr18:72167187	CNDP2	-0.82	-12.16	-0.51	2.16e-29	Refractive error;
LUAD	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg03678062	chr6:149772716	ZC3H12D	-0.31	-6.92	-0.32	1.67e-11	Dupuytren's disease;
LUAD	cis	rs7737355	0.738	rs3776001	chr5:130957992	T/A	cg25547332	chr5:131281432	NA	0.41	6.51	0.3	2.08e-10	Life satisfaction;
LUAD	trans	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg06606381	chr12:133084897	FBRSL1	-1.23	-10.79	-0.46	3.73e-24	Depression;
LUAD	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg05283184	chr6:79620031	NA	-0.43	-7.57	-0.35	2.37e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14157042	chr20:58515396	C20orf177;PPP1R3D	-0.39	-7.0	-0.32	1.03e-11	Cancer;
LUAD	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg00933542	chr6:150070202	PCMT1	0.45	9.79	0.43	1.53e-20	Lung cancer;
LUAD	cis	rs6545883	0.929	rs778140	chr2:61682976	C/T	cg15711740	chr2:61764176	XPO1	-0.41	-6.53	-0.3	1.84e-10	Tuberculosis;
LUAD	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg26587870	chr6:27730563	NA	-0.47	-7.95	-0.36	1.77e-14	Parkinson's disease;
LUAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg15117754	chr3:10150083	C3orf24	0.44	7.09	0.33	5.76e-12	Alzheimer's disease;
LUAD	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg15181151	chr6:150070149	PCMT1	0.42	8.75	0.39	5.26e-17	Lung cancer;
LUAD	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg13073564	chr4:8508604	NA	0.54	10.09	0.44	1.34e-21	Response to antineoplastic agents;
LUAD	cis	rs7274811	0.744	rs3746460	chr20:32248163	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.48	-6.66	-0.31	8.54e-11	Height;
LUAD	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg06387496	chr7:2775674	GNA12	-0.38	-6.36	-0.3	5.28e-10	Height;
LUAD	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.21e-16	Prostate cancer;
LUAD	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.42	-0.38	5.9e-16	Neutrophil percentage of white cells;
LUAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs875971	0.929	rs778692	chr7:65872449	A/G	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg07741184	chr6:167504864	NA	0.35	8.15	0.37	4.3e-15	Crohn's disease;
LUAD	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg13385794	chr1:248469461	NA	0.25	6.95	0.32	1.35e-11	Common traits (Other);
LUAD	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg19761014	chr17:28927070	LRRC37B2	0.7	6.61	0.31	1.17e-10	Body mass index;
LUAD	cis	rs2046867	0.628	rs7356055	chr3:72912878	A/C	cg25664220	chr3:72788482	NA	-0.57	-10.54	-0.46	3.12e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7737355	0.947	rs6895586	chr5:130588008	C/A	cg06307176	chr5:131281290	NA	0.43	6.97	0.32	1.23e-11	Life satisfaction;
LUAD	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg11502198	chr6:26597334	ABT1	0.83	11.92	0.5	1.99e-28	Small cell lung carcinoma;
LUAD	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg18305652	chr10:134549665	INPP5A	0.56	11.76	0.5	8.35e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg02975922	chr3:195473998	MUC4	-0.44	-7.25	-0.33	2.06e-12	Pancreatic cancer;
LUAD	cis	rs6847149	0.789	rs62324954	chr4:110751691	G/A	cg07850274	chr4:110748770	RRH	-0.58	-8.69	-0.39	7.95e-17	Exercise treadmill test traits;
LUAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg02951883	chr7:2050386	MAD1L1	-0.93	-18.25	-0.66	2.74e-55	Bipolar disorder and schizophrenia;
LUAD	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.8	0.31	3.54e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg14725641	chr11:61582763	MIR1908;FADS1	-0.55	-6.76	-0.31	4.68e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg18404041	chr3:52824283	ITIH1	0.4	7.19	0.33	2.99e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg26528668	chr16:1614120	IFT140	0.57	10.23	0.45	4.11e-22	Coronary artery disease;
LUAD	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg24069376	chr3:38537580	EXOG	-0.33	-7.56	-0.34	2.59e-13	Electrocardiographic conduction measures;
LUAD	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg06453172	chr10:134556979	INPP5A	-0.66	-9.75	-0.43	2.22e-20	Migraine;
LUAD	cis	rs6460942	0.915	rs6965564	chr7:12306013	C/T	cg06484146	chr7:12443880	VWDE	-0.44	-6.5	-0.3	2.22e-10	Coronary artery disease;
LUAD	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg06641503	chr3:48959341	ARIH2	-0.34	-6.58	-0.3	1.38e-10	Parkinson's disease;
LUAD	trans	rs11039798	0.687	rs11499938	chr11:48957297	G/A	cg03929089	chr4:120376271	NA	0.59	6.79	0.31	3.9e-11	Axial length;
LUAD	cis	rs747650	0.699	rs4237547	chr11:47236405	C/G	cg19486271	chr11:47235900	DDB2	-0.48	-7.7	-0.35	9.41e-14	Acne (severe);
LUAD	cis	rs2692947	0.644	rs1168970	chr2:96816606	C/T	cg23100626	chr2:96804247	ASTL	0.4	10.56	0.46	2.63e-23	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg03289416	chr15:75166202	SCAMP2	0.45	7.76	0.35	6.23e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg17971929	chr21:40555470	PSMG1	0.56	8.96	0.4	1.02e-17	Cognitive function;
LUAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.33	-0.34	1.2e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg24558204	chr6:135376177	HBS1L	0.46	8.58	0.38	1.83e-16	Red blood cell count;
LUAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg27588902	chr6:42928151	GNMT	-0.36	-9.26	-0.41	1.02e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg00666640	chr1:248458726	OR2T12	0.29	6.86	0.32	2.41e-11	Common traits (Other);
LUAD	cis	rs7465272	1.000	rs13259747	chr8:143683567	A/C	cg10104451	chr8:143696006	ARC	-0.55	-7.57	-0.35	2.31e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs1524976	1.000	rs62255280	chr3:65483527	T/C	cg16238336	chr3:65465873	MAGI1	-0.7	-7.88	-0.36	2.81e-14	PR interval;
LUAD	cis	rs1550582	1.000	rs16905157	chr8:135519964	C/T	cg17885191	chr8:135476712	NA	0.72	10.32	0.45	1.99e-22	Educational attainment;
LUAD	cis	rs10193935	0.901	rs6544536	chr2:42522042	G/A	cg27598129	chr2:42591480	NA	-0.61	-8.18	-0.37	3.36e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg01868782	chr6:126071099	HEY2	0.31	6.39	0.3	4.42e-10	Brugada syndrome;
LUAD	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg15147215	chr3:52552868	STAB1	-0.39	-7.06	-0.32	6.72e-12	Bipolar disorder;
LUAD	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	6.83	0.32	2.95e-11	Personality dimensions;
LUAD	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg04450456	chr4:17643702	FAM184B	-0.4	-7.64	-0.35	1.46e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6543140	0.964	rs62154972	chr2:103048738	G/A	cg04239558	chr2:103089729	SLC9A4	0.34	6.85	0.32	2.56e-11	Blood protein levels;
LUAD	cis	rs6484504	0.600	rs208063	chr11:31159777	C/T	cg14844989	chr11:31128820	NA	-0.43	-7.75	-0.35	7.13e-14	Red blood cell count;
LUAD	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg24803719	chr17:45855879	NA	-0.34	-7.65	-0.35	1.41e-13	IgG glycosylation;
LUAD	trans	rs9914544	0.564	rs9906799	chr17:18795317	A/G	cg21372672	chr17:16614065	CCDC144A	-0.36	-6.45	-0.3	3.04e-10	Educational attainment (years of education);
LUAD	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg11317459	chr13:21872234	NA	-1.09	-14.87	-0.59	1.49e-40	White matter hyperintensity burden;
LUAD	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg17747265	chr1:1875780	NA	0.4	8.23	0.37	2.39e-15	Body mass index;
LUAD	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg05132306	chr1:1846340	CALML6	-0.35	-7.59	-0.35	2.13e-13	Body mass index;
LUAD	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24308560	chr3:49941425	MST1R	0.57	9.76	0.43	2.06e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs56933300	chr7:106953278	A/AGGACCTCGGCAGAAGCC	cg02696742	chr7:106810147	HBP1	-0.79	-9.99	-0.44	3.02e-21	Coronary artery disease;
LUAD	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.57	-9.59	-0.42	8.01e-20	Glomerular filtration rate;
LUAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07167872	chr1:205819463	PM20D1	0.76	15.29	0.6	2.61e-42	Menarche (age at onset);
LUAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg00431813	chr7:1051703	C7orf50	-0.45	-8.65	-0.39	1.11e-16	Longevity;Endometriosis;
LUAD	trans	rs7395662	1.000	rs11039851	chr11:48600839	A/G	cg00717180	chr2:96193071	NA	-0.38	-7.2	-0.33	2.77e-12	HDL cholesterol;
LUAD	cis	rs2281636	0.824	rs2160620	chr10:101387018	C/A	cg17885402	chr10:101492224	COX15;CUTC	-0.37	-6.38	-0.3	4.78e-10	Obesity-related traits;
LUAD	cis	rs7512552	0.839	rs3896342	chr1:150411312	T/C	cg15654264	chr1:150340011	RPRD2	0.61	11.76	0.5	8.2e-28	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4950928	0.823	rs2486065	chr1:203167871	A/G	cg17014757	chr1:203156097	CHI3L1	-0.62	-8.78	-0.39	4.22e-17	YKL-40 levels;
LUAD	cis	rs922692	0.744	rs12903203	chr15:79084933	T/C	cg12645284	chr15:79092878	ADAMTS7	0.41	7.25	0.33	1.94e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg07917127	chr4:99064746	C4orf37	0.42	7.02	0.32	9.15e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.87	-16.65	-0.63	3.11e-48	Menarche (age at onset);
LUAD	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20814179	chr4:940893	TMEM175	0.63	9.94	0.44	4.66e-21	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg15147215	chr3:52552868	STAB1	-0.38	-7.16	-0.33	3.58e-12	Electroencephalogram traits;
LUAD	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg11098525	chr4:1320231	MAEA	-0.38	-6.52	-0.3	1.98e-10	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg12623302	chr6:28058802	ZSCAN12L1	0.35	7.01	0.32	9.51e-12	Depression;
LUAD	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.51	8.15	0.37	4.02e-15	Platelet count;
LUAD	cis	rs57994353	0.897	rs55824202	chr9:139357273	A/T	cg14364472	chr9:139394549	NOTCH1	-0.43	-6.47	-0.3	2.71e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs977987	0.750	rs4888414	chr16:75447233	A/G	cg03315344	chr16:75512273	CHST6	0.64	14.06	0.56	4.3e-37	Dupuytren's disease;
LUAD	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg08738300	chr3:44038990	NA	0.43	6.55	0.3	1.63e-10	Coronary artery disease;
LUAD	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg23018236	chr17:30244563	NA	-0.69	-8.47	-0.38	3.96e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs2535633	0.631	rs2257216	chr3:52968726	T/C	cg18404041	chr3:52824283	ITIH1	0.4	6.82	0.31	3.12e-11	Body mass index;
LUAD	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg17173187	chr15:85201210	NMB	0.47	8.18	0.37	3.36e-15	Schizophrenia;
LUAD	trans	rs10802346	0.545	rs12134404	chr1:246372144	A/G	cg22732515	chr19:44031385	ETHE1	0.59	9.53	0.42	1.28e-19	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs1595825	1.000	rs1440091	chr2:198879457	C/T	cg00982548	chr2:198649783	BOLL	-0.58	-8.38	-0.38	7.86e-16	Ulcerative colitis;
LUAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg07217954	chr7:1067459	C7orf50	0.43	6.61	0.31	1.14e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg22529645	chr1:3704559	LRRC47	0.56	10.52	0.46	3.7e-23	Red cell distribution width;
LUAD	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-9.66	-0.43	4.28e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06028808	chr11:68637592	NA	0.46	7.7	0.35	9.56e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg06558623	chr16:89946397	TCF25	1.17	10.64	0.46	1.34e-23	Skin colour saturation;
LUAD	trans	rs1728785	0.901	rs2862781	chr16:68639234	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.3	0.45	2.3e-22	Ulcerative colitis;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg01307007	chr19:3522587	FZR1	-0.38	-6.46	-0.3	2.87e-10	Optic cup area;
LUAD	trans	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg07393940	chr7:158741817	NA	0.68	11.3	0.48	4.77e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9814567	0.752	rs9848254	chr3:134330374	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.73	-0.53	1.2e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-15.16	-0.59	8.76e-42	Colorectal cancer;
LUAD	cis	rs2795502	0.564	rs72777192	chr10:43436778	G/A	cg27426351	chr10:43362370	NA	0.55	6.67	0.31	8.18e-11	Blood protein levels;
LUAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg14926445	chr8:58193284	C8orf71	-0.48	-6.93	-0.32	1.56e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg23758822	chr17:41437982	NA	1.01	21.22	0.72	1.4e-68	Menopause (age at onset);
LUAD	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-9.74	-0.43	2.36e-20	Gut microbiome composition (summer);
LUAD	cis	rs12545109	1.000	rs1975284	chr8:57314663	A/G	cg07776626	chr8:57350775	NA	-0.59	-8.26	-0.37	1.86e-15	Obesity-related traits;
LUAD	cis	rs657075	0.697	rs34689843	chr5:131685256	A/C	cg21138405	chr5:131827807	IRF1	0.52	6.46	0.3	2.93e-10	Rheumatoid arthritis;
LUAD	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg17863274	chr19:49399704	TULP2	-0.66	-10.18	-0.44	6.69e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg08999081	chr20:33150536	PIGU	-0.62	-13.96	-0.56	1.08e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs13064411	0.735	rs10511326	chr3:113216325	T/C	cg10517650	chr3:113235015	CCDC52	-0.56	-9.63	-0.42	5.58e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg02773041	chr1:40204384	PPIE	0.53	8.77	0.39	4.32e-17	Blood protein levels;
LUAD	cis	rs57994353	0.861	rs13301660	chr9:139340802	C/T	cg14019695	chr9:139328340	INPP5E	0.42	6.87	0.32	2.31e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01737507	chr5:122372093	PPIC	-0.54	-6.68	-0.31	7.32e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg11494091	chr17:61959527	GH2	0.74	18.38	0.67	7.09e-56	Prudent dietary pattern;
LUAD	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg08085267	chr17:45401833	C17orf57	-0.58	-10.06	-0.44	1.67e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2268241	0.938	rs9978223	chr21:34770358	G/A	cg14850771	chr21:34775459	IFNGR2	0.61	7.28	0.33	1.67e-12	Obesity-related traits;
LUAD	cis	rs12765878	1.000	rs4918068	chr10:105644736	T/G	cg11005552	chr10:105648138	OBFC1	0.44	8.26	0.37	1.91e-15	Coronary artery disease;
LUAD	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-8.22	-0.37	2.56e-15	Total body bone mineral density;
LUAD	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg05896524	chr21:47604654	C21orf56	0.54	8.87	0.4	2.05e-17	Testicular germ cell tumor;
LUAD	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg06002616	chr8:101225028	SPAG1	-0.41	-8.28	-0.37	1.6e-15	Atrioventricular conduction;
LUAD	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg09323728	chr8:95962352	TP53INP1	-0.35	-8.47	-0.38	4.12e-16	Type 2 diabetes;
LUAD	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.25	0.33	2.01e-12	Cannabis dependence symptom count;
LUAD	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg24596788	chr1:163392923	NA	-0.36	-7.63	-0.35	1.61e-13	Motion sickness;
LUAD	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg19622623	chr12:86230825	RASSF9	-0.55	-9.8	-0.43	1.46e-20	Major depressive disorder;
LUAD	cis	rs77861329	1.000	rs59890038	chr3:52147850	A/G	cg08692210	chr3:52188851	WDR51A	0.83	7.77	0.35	6.17e-14	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs12928939	0.517	rs10852507	chr16:71971900	G/A	cg03805757	chr16:71968109	PKD1L3	-0.54	-8.53	-0.38	2.69e-16	Post bronchodilator FEV1;
LUAD	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg15992532	chr8:142229932	SLC45A4	0.49	8.65	0.39	1.12e-16	Immature fraction of reticulocytes;
LUAD	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08280861	chr8:58055591	NA	0.73	8.83	0.39	2.82e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg12365402	chr11:9010492	NRIP3	-0.4	-6.87	-0.32	2.34e-11	Hematocrit;
LUAD	cis	rs7771547	0.573	rs566742	chr6:36395668	C/T	cg07856975	chr6:36356162	ETV7	0.5	7.84	0.36	3.8e-14	Platelet distribution width;
LUAD	cis	rs9394841	0.692	rs9357371	chr6:41885319	A/C	cg17623882	chr6:41773611	USP49	-0.47	-6.46	-0.3	2.86e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg17105886	chr17:28927953	LRRC37B2	0.72	7.05	0.32	7.19e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg12179176	chr11:130786555	SNX19	-0.48	-7.72	-0.35	8.39e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2637266	0.765	rs2395391	chr10:78359932	G/A	cg18941641	chr10:78392320	NA	0.32	6.63	0.31	1.06e-10	Pulmonary function;
LUAD	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg21823605	chr1:152486609	CRCT1	0.28	6.42	0.3	3.66e-10	Hair morphology;
LUAD	cis	rs2089162	1	rs2089162	chr15:78739763	A/G	cg18825076	chr15:78729989	IREB2	-0.6	-10.12	-0.44	1.09e-21	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs1997103	1.000	rs2331065	chr7:55408392	A/G	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9296095	0.554	rs12214883	chr6:33513968	A/G	cg14003231	chr6:33640908	ITPR3	0.51	9.15	0.41	2.42e-18	Platelet count;
LUAD	cis	rs77106637	0.929	rs74333814	chr11:72457487	C/T	cg03878208	chr11:72483293	STARD10	0.63	8.22	0.37	2.59e-15	Type 2 diabetes;
LUAD	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-7.15	-0.33	3.74e-12	Insulin-like growth factors;
LUAD	trans	rs7944735	0.817	rs6485788	chr11:47873883	C/T	cg15704280	chr7:45808275	SEPT13	-0.52	-7.12	-0.33	4.77e-12	Intraocular pressure;
LUAD	cis	rs12541635	1.000	rs12541635	chr8:107090000	C/T	cg10147462	chr8:107024639	NA	-0.41	-7.34	-0.34	1.09e-12	Age of smoking initiation;
LUAD	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg06608945	chr2:219082296	ARPC2	0.43	7.33	0.34	1.17e-12	Colorectal cancer;
LUAD	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg15448220	chr1:150897856	SETDB1	0.55	9.23	0.41	1.36e-18	Melanoma;
LUAD	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg11266682	chr4:10021025	SLC2A9	-0.55	-12.09	-0.51	4.19e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg16325326	chr1:53192061	ZYG11B	0.69	13.25	0.54	9.26e-34	Monocyte count;
LUAD	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg10057126	chr4:77819792	ANKRD56	0.53	8.88	0.4	1.9e-17	Emphysema distribution in smoking;
LUAD	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	15.08	0.59	1.96e-41	Smoking behavior;
LUAD	cis	rs12760731	0.720	rs10798607	chr1:178373110	C/T	cg00404053	chr1:178313656	RASAL2	0.73	9.24	0.41	1.19e-18	Obesity-related traits;
LUAD	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18404041	chr3:52824283	ITIH1	0.58	12.21	0.51	1.36e-29	Electroencephalogram traits;
LUAD	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg06740227	chr12:86229804	RASSF9	0.36	6.65	0.31	9.26e-11	Major depressive disorder;
LUAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg18621852	chr3:10150065	C3orf24	-0.47	-8.33	-0.38	1.14e-15	Alzheimer's disease;
LUAD	cis	rs7851660	0.844	rs10759975	chr9:100625193	C/T	cg13688889	chr9:100608707	NA	0.49	8.39	0.38	7.61e-16	Strep throat;
LUAD	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg14092988	chr3:52407081	DNAH1	0.34	6.66	0.31	8.78e-11	Electroencephalogram traits;
LUAD	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg09904177	chr6:26538194	HMGN4	0.44	7.4	0.34	7.41e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg20991723	chr1:152506922	NA	0.32	6.43	0.3	3.42e-10	Hair morphology;
LUAD	cis	rs1997103	1.000	rs4628219	chr7:55410449	A/G	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9902453	0.845	rs58606097	chr17:28020379	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.25	0.41	1.14e-18	Coffee consumption (cups per day);
LUAD	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg03806693	chr22:41940476	POLR3H	0.75	10.08	0.44	1.52e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.61	7.69	0.35	1.03e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg24803719	chr17:45855879	NA	-0.33	-7.24	-0.33	2.1e-12	IgG glycosylation;
LUAD	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18867708	chr6:26865862	GUSBL1	-0.41	-6.47	-0.3	2.73e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg14789911	chr21:47582049	C21orf56	-0.39	-6.83	-0.31	3.04e-11	Testicular germ cell tumor;
LUAD	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg20203395	chr5:56204925	C5orf35	-0.57	-8.72	-0.39	6.45e-17	Coronary artery disease;
LUAD	cis	rs7017914	0.902	rs35580034	chr8:71572073	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.52	-0.3	1.98e-10	Bone mineral density;
LUAD	cis	rs7408868	0.563	rs10423702	chr19:15300069	T/C	cg14696996	chr19:15285081	NOTCH3	0.65	8.61	0.39	1.44e-16	Pulse pressure;
LUAD	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06022373	chr22:39101656	GTPBP1	0.39	6.46	0.3	2.97e-10	Menopause (age at onset);
LUAD	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.71	-12.22	-0.51	1.27e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg18306943	chr3:40428807	ENTPD3	0.36	6.36	0.3	5.16e-10	Renal cell carcinoma;
LUAD	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	15.33	0.6	1.7e-42	Smoking behavior;
LUAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg07217954	chr7:1067459	C7orf50	0.45	7.03	0.32	8.3e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6906287	0.625	rs9489355	chr6:118685314	A/G	cg21191810	chr6:118973309	C6orf204	0.54	10.89	0.47	1.59e-24	Electrocardiographic conduction measures;
LUAD	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg23933602	chr10:16859644	RSU1	0.54	7.34	0.34	1.14e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg20933634	chr6:27740509	NA	-0.52	-8.39	-0.38	7.3e-16	Parkinson's disease;
LUAD	cis	rs701145	0.640	rs357499	chr3:153946463	C/G	cg17054900	chr3:154042577	DHX36	0.66	6.8	0.31	3.64e-11	Coronary artery disease;
LUAD	trans	rs6561151	0.957	rs1373904	chr13:44475398	A/G	cg17145862	chr1:211918768	LPGAT1	0.55	9.17	0.41	2.01e-18	Crohn's disease;
LUAD	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.66	0.31	8.63e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs910187	0.571	rs3746489	chr20:45801716	C/T	cg27589058	chr20:45804311	EYA2	-0.34	-7.66	-0.35	1.29e-13	Migraine;
LUAD	cis	rs12545109	0.800	rs1467125	chr8:57418638	C/T	cg07776626	chr8:57350775	NA	-0.63	-8.91	-0.4	1.49e-17	Obesity-related traits;
LUAD	cis	rs75920871	0.925	rs11823918	chr11:116960497	G/C	cg04087571	chr11:116723030	SIK3	-0.33	-6.69	-0.31	7.14e-11	Subjective well-being;
LUAD	trans	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg06606381	chr12:133084897	FBRSL1	-0.8	-6.85	-0.32	2.69e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10129255	0.500	rs7157975	chr14:107212287	G/A	cg07958169	chr14:107095056	NA	-0.38	-7.66	-0.35	1.28e-13	Kawasaki disease;
LUAD	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg19980929	chr12:42632907	YAF2	0.33	6.41	0.3	3.93e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg03859395	chr2:55845619	SMEK2	0.76	14.02	0.56	6e-37	Metabolic syndrome;
LUAD	cis	rs10979	1.000	rs9403506	chr6:143887805	C/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.2	-0.44	5.68e-22	Hypospadias;
LUAD	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg19622623	chr12:86230825	RASSF9	0.44	7.89	0.36	2.66e-14	Major depressive disorder;
LUAD	cis	rs4372836	0.964	rs4665431	chr2:28938168	T/C	cg09522027	chr2:28974177	PPP1CB	0.58	9.01	0.4	6.9e-18	Body mass index;
LUAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.41	-0.38	6.48e-16	Alzheimer's disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg27048959	chr17:74554276	SNORD1C	-0.39	-6.48	-0.3	2.6200000000000003e-10	Cancer;
LUAD	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg11915388	chr22:42470451	FAM109B	-0.43	-7.44	-0.34	5.54e-13	Schizophrenia;
LUAD	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg01324343	chr3:183735012	ABCC5	0.83	19.19	0.68	1.65e-59	Anterior chamber depth;
LUAD	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg07917127	chr4:99064746	C4orf37	0.4	6.56	0.3	1.54e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9314323	0.729	rs7007256	chr8:26203081	G/A	cg13160058	chr8:26243215	BNIP3L	-0.49	-10.03	-0.44	2.23e-21	Red cell distribution width;
LUAD	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg07917127	chr4:99064746	C4orf37	0.45	7.37	0.34	8.84e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7843479	0.601	rs2002941	chr8:21834366	A/C	cg03445287	chr8:21823731	XPO7	-0.49	-9.2	-0.41	1.69e-18	Mean corpuscular volume;
LUAD	cis	rs6906287	0.647	rs11755121	chr6:118828124	G/C	cg05564266	chr6:118973597	C6orf204	0.35	7.42	0.34	6.47e-13	Electrocardiographic conduction measures;
LUAD	cis	rs889398	0.771	rs1500337	chr16:69901884	C/T	cg00738113	chr16:70207722	CLEC18C	0.35	7.03	0.32	8.53e-12	Body mass index;
LUAD	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg26384229	chr12:38710491	ALG10B	0.4	6.43	0.3	3.53e-10	Morning vs. evening chronotype;
LUAD	cis	rs7536201	1.000	rs4649040	chr1:25293902	C/T	cg23273869	chr1:25296894	NA	-0.35	-6.93	-0.32	1.6e-11	Psoriasis vulgaris;
LUAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg24846343	chr22:24311635	DDTL	-0.76	-17.25	-0.64	6.84e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg16262614	chr3:133464971	TF	0.43	8.8	0.39	3.46e-17	Iron status biomarkers (transferrin levels);
LUAD	cis	rs9715521	0.900	rs7696259	chr4:59810032	T/A	cg11281224	chr4:60001000	NA	-0.46	-7.56	-0.34	2.61e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2235649	0.789	rs9929803	chr16:1852748	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.41	-6.5	-0.3	2.25e-10	Blood metabolite levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00742472	chr14:31889912	NA	0.38	6.37	0.3	4.81e-10	Cancer;
LUAD	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg13736514	chr6:26305472	NA	-0.59	-10.42	-0.45	8.58e-23	Mosquito bite size;
LUAD	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.62	-7.06	-0.32	7.01e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03395546	chr19:41222599	ADCK4;ITPKC	-0.53	-6.64	-0.31	9.8e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4523957	0.579	rs2270478	chr17:2089848	G/A	cg16513277	chr17:2031491	SMG6	-0.87	-16.61	-0.63	4.63e-48	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg13789015	chr9:136890014	NCRNA00094	0.8	13.29	0.54	6.25e-34	Platelet distribution width;
LUAD	trans	rs11039798	0.614	rs2174703	chr11:48788242	G/A	cg02254774	chr11:50257496	LOC441601	0.53	6.66	0.31	8.78e-11	Axial length;
LUAD	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg16447950	chr5:562315	NA	-0.41	-6.41	-0.3	3.91e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22857025	chr5:266934	NA	-0.96	-14.33	-0.57	2.98e-38	Breast cancer;
LUAD	cis	rs698833	0.509	rs12987415	chr2:44530423	C/T	cg04920474	chr2:44395004	PPM1B	0.4	6.64	0.31	9.44e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs3096299	0.809	rs2911264	chr16:89499272	A/C	cg00750074	chr16:89608354	SPG7	-0.4	-6.65	-0.31	9.08e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs2455601	0.507	rs2568044	chr11:9002477	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.36	6.72	0.31	5.92e-11	Schizophrenia;
LUAD	cis	rs1032833	0.732	rs17363603	chr2:180088505	A/T	cg23883738	chr2:179974586	SESTD1	-0.6	-7.25	-0.33	1.95e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs4730250	0.707	rs257378	chr7:106801395	C/G	cg23024343	chr7:107201750	COG5	0.51	6.83	0.32	2.9e-11	Osteoarthritis;
LUAD	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg02743256	chr7:2109353	MAD1L1	-0.52	-7.08	-0.33	6.21e-12	Bipolar disorder;
LUAD	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg27170947	chr2:26402098	FAM59B	-0.73	-11.14	-0.48	1.91e-25	Gut microbiome composition (summer);
LUAD	cis	rs10465746	0.933	rs2224990	chr1:84436275	C/A	cg10977910	chr1:84465055	TTLL7	0.5	8.1	0.37	5.87e-15	Obesity-related traits;
LUAD	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.59	-0.39	1.68e-16	Alcohol dependence;
LUAD	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.83	0.53	4.58e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7192380	1.000	rs2161630	chr16:69606461	C/T	cg26679644	chr16:69762563	NA	0.5	9.5	0.42	1.53e-19	Sjögren's syndrome;
LUAD	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg22508957	chr16:3507546	NAT15	0.48	7.94	0.36	1.89e-14	Body mass index (adult);
LUAD	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg17200465	chr3:40428508	ENTPD3	0.27	6.57	0.3	1.53e-10	Renal cell carcinoma;
LUAD	cis	rs977987	0.750	rs4888406	chr16:75432334	G/T	cg03315344	chr16:75512273	CHST6	0.63	13.81	0.56	4.4e-36	Dupuytren's disease;
LUAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.63	-10.42	-0.45	9.1e-23	Longevity;Endometriosis;
LUAD	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.21e-19	Life satisfaction;
LUAD	cis	rs739496	0.615	rs12582964	chr12:112090779	C/T	cg10833066	chr12:111807467	FAM109A	0.43	6.95	0.32	1.35e-11	Platelet count;
LUAD	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg25358565	chr5:93447407	FAM172A	-0.63	-7.55	-0.34	2.65e-13	Diabetic retinopathy;
LUAD	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg24112000	chr20:60950667	NA	0.72	12.33	0.51	4.62e-30	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg00999904	chr2:3704751	ALLC	-0.51	-8.95	-0.4	1.15e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg24503407	chr1:205819492	PM20D1	-0.52	-7.85	-0.36	3.57e-14	Menarche (age at onset);
LUAD	cis	rs6494488	0.500	rs72742950	chr15:64896397	T/C	cg08069370	chr15:64387884	SNX1	-0.75	-6.58	-0.3	1.37e-10	Coronary artery disease;
LUAD	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg06766960	chr11:133703094	NA	-0.45	-8.51	-0.38	3.08e-16	Childhood ear infection;
LUAD	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg25985355	chr7:65971099	NA	-0.55	-6.75	-0.31	4.77e-11	Diabetic kidney disease;
LUAD	trans	rs12048904	0.504	rs12135888	chr1:101296067	C/T	cg14530983	chr3:88190749	ZNF654	-0.39	-6.63	-0.31	1.01e-10	Multiple sclerosis;
LUAD	cis	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.22	-0.33	2.36e-12	Triglycerides;
LUAD	cis	rs2637266	1.000	rs755824	chr10:78381348	A/G	cg18941641	chr10:78392320	NA	0.34	7.21	0.33	2.65e-12	Pulmonary function;
LUAD	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg18016565	chr1:150552671	MCL1	0.42	7.73	0.35	8.04e-14	Tonsillectomy;
LUAD	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg19418458	chr7:158789849	NA	-0.63	-11.12	-0.48	2.17e-25	Facial morphology (factor 20);
LUAD	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg21823605	chr1:152486609	CRCT1	0.29	6.42	0.3	3.64e-10	Hair morphology;
LUAD	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg03806693	chr22:41940476	POLR3H	0.59	8.59	0.39	1.63e-16	Vitiligo;
LUAD	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.67	0.31	8.09e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11039798	1.000	rs7123704	chr11:48580535	G/A	cg15704280	chr7:45808275	SEPT13	0.64	7.64	0.35	1.51e-13	Axial length;
LUAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.56	8.11	0.37	5.53e-15	Alzheimer's disease;
LUAD	cis	rs6489785	0.574	rs619679	chr12:121291757	A/C	cg02419362	chr12:121203948	SPPL3	-0.34	-6.47	-0.3	2.65e-10	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.84	-0.32	2.81e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs10992471	0.580	rs7020104	chr9:95416524	A/G	cg14631576	chr9:95140430	CENPP	-0.46	-8.8	-0.39	3.48e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs4662945	0.603	rs10168574	chr2:130267823	C/T	cg05903289	chr2:130345205	NA	-0.34	-7.12	-0.33	4.63e-12	Response to cytidine analogues (gemcitabine);
LUAD	trans	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg04775059	chr7:64541387	NA	0.54	7.15	0.33	3.86e-12	Aortic root size;
LUAD	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.49	0.55	9.75e-35	Tonsillectomy;
LUAD	cis	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg08601574	chr20:25228251	PYGB	0.46	8.71	0.39	6.77e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.47	6.55	0.3	1.67e-10	Schizophrenia;
LUAD	cis	rs2835872	0.733	rs1787400	chr21:39038217	G/C	cg06728970	chr21:39037746	KCNJ6	0.41	7.81	0.36	4.51e-14	Electroencephalographic traits in alcoholism;
LUAD	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.45	0.3	3e-10	Depression;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg11427898	chr15:38544983	SPRED1	-0.67	-6.89	-0.32	2.07e-11	Type 2 diabetes;
LUAD	cis	rs73206853	0.764	rs16940881	chr12:110937818	G/C	cg12870014	chr12:110450643	ANKRD13A	0.64	7.38	0.34	8.36e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg14092571	chr14:90743983	NA	-0.49	-8.69	-0.39	8.06e-17	Mortality in heart failure;
LUAD	cis	rs12545109	0.959	rs12546307	chr8:57314790	T/A	cg09654669	chr8:57350985	NA	-0.66	-9.5	-0.42	1.61e-19	Obesity-related traits;
LUAD	cis	rs1448094	0.617	rs10863162	chr12:86474122	C/T	cg18827107	chr12:86230957	RASSF9	0.48	8.63	0.39	1.28e-16	Major depressive disorder;
LUAD	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.59	11.33	0.48	3.73e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9786986	0.665	rs10925942	chr1:235699585	C/T	cg08848088	chr1:235714526	GNG4	0.54	6.79	0.31	3.92e-11	Body mass index;
LUAD	cis	rs7851660	0.967	rs3758251	chr9:100613700	G/C	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg21724239	chr8:58056113	NA	0.74	9.62	0.42	5.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs8017423	0.935	rs11626869	chr14:90788985	A/G	cg14092571	chr14:90743983	NA	0.47	8.18	0.37	3.24e-15	Mortality in heart failure;
LUAD	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg18446336	chr7:2847575	GNA12	-0.37	-6.76	-0.31	4.69e-11	Height;
LUAD	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg07741184	chr6:167504864	NA	-0.3	-7.12	-0.33	4.53e-12	Crohn's disease;
LUAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.8	-17.07	-0.64	4.46e-50	Longevity;Endometriosis;
LUAD	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg25753631	chr6:25732923	NA	-0.44	-7.52	-0.34	3.29e-13	Iron status biomarkers;
LUAD	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.15	0.33	3.76e-12	Parkinson's disease;
LUAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg11494091	chr17:61959527	GH2	0.74	18.64	0.67	5.07e-57	Prudent dietary pattern;
LUAD	cis	rs28655083	1.000	rs28655083	chr16:77061214	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.41	-6.94	-0.32	1.5e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1395	0.571	rs114507490	chr2:27527246	T/A	cg23587288	chr2:27483067	SLC30A3	-0.38	-6.74	-0.31	5.07e-11	Blood metabolite levels;
LUAD	cis	rs4664308	0.967	rs34248629	chr2:160902497	C/T	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.69	-0.31	6.95e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs701145	0.640	rs1657621	chr3:153929795	T/C	cg17054900	chr3:154042577	DHX36	0.66	7.44	0.34	5.77e-13	Coronary artery disease;
LUAD	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg26597838	chr10:835615	NA	1.31	20.55	0.71	1.41e-65	Eosinophil percentage of granulocytes;
LUAD	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg00981070	chr1:2046702	PRKCZ	-0.37	-7.76	-0.35	6.61e-14	Height;
LUAD	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg09835421	chr16:68378352	PRMT7	-0.73	-8.35	-0.38	9.71e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg04450456	chr4:17643702	FAM184B	0.4	7.84	0.36	3.69e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg19743168	chr1:23544995	NA	0.36	6.44	0.3	3.23e-10	Height;
LUAD	cis	rs2108225	0.837	rs6959729	chr7:107446180	A/C	cg18560240	chr7:107437656	SLC26A3	-0.4	-6.6	-0.31	1.25e-10	Ulcerative colitis;
LUAD	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg02574844	chr11:5959923	NA	-0.43	-7.44	-0.34	5.71e-13	DNA methylation (variation);
LUAD	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg03433033	chr1:76189801	ACADM	-0.69	-10.94	-0.47	1.1e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7267979	0.586	rs1007708	chr20:25190959	C/T	cg08601574	chr20:25228251	PYGB	0.36	6.68	0.31	7.36e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs169738	1	rs169738	chr6:33537546	A/G	cg24505687	chr6:33548425	BAK1	0.4	6.96	0.32	1.33e-11	Platelet count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg12016809	chr21:47604291	C21orf56	0.45	7.51	0.34	3.64e-13	Testicular germ cell tumor;
LUAD	cis	rs68170813	0.599	rs6466162	chr7:106902625	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.71	-0.46	7.32e-24	Coronary artery disease;
LUAD	cis	rs7187994	0.848	rs16974515	chr16:84782510	T/G	cg07647771	chr16:84786436	USP10	-0.35	-9.09	-0.4	3.82e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg00106254	chr7:1943704	MAD1L1	0.57	8.72	0.39	6.55e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.73	9.01	0.4	6.88e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg05564831	chr3:52568323	NT5DC2	-0.37	-6.64	-0.31	9.5e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg04539111	chr16:67997858	SLC12A4	-0.51	-6.51	-0.3	2.16e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg24642844	chr7:1081250	C7orf50	-0.89	-13.88	-0.56	2.4e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg08085267	chr17:45401833	C17orf57	-0.75	-14.13	-0.57	2.09e-37	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg23985595	chr17:80112537	CCDC57	0.51	9.34	0.41	5.6e-19	Life satisfaction;
LUAD	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg01475377	chr6:109611718	NA	-0.54	-10.28	-0.45	2.71e-22	Reticulocyte fraction of red cells;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01279709	chr13:28196083	POLR1D;LNX2	-0.42	-6.69	-0.31	6.89e-11	Height;
LUAD	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg19622623	chr12:86230825	RASSF9	-0.56	-10.05	-0.44	1.93e-21	Major depressive disorder;
LUAD	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg21724239	chr8:58056113	NA	0.55	7.32	0.34	1.22e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs61897795	0.628	rs174579	chr11:61605613	C/T	cg19610905	chr11:61596333	FADS2	-0.71	-9.95	-0.44	4.29e-21	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg17063962	chr7:91808500	NA	0.68	12.3	0.51	6.37e-30	Breast cancer;
LUAD	cis	rs6906287	0.647	rs3752581	chr6:118869730	G/A	cg21191810	chr6:118973309	C6orf204	0.5	9.83	0.43	1.11e-20	Electrocardiographic conduction measures;
LUAD	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-8.01	-0.36	1.16e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg15181151	chr6:150070149	PCMT1	-0.39	-7.76	-0.35	6.53e-14	Lung cancer;
LUAD	trans	rs1422110	0.616	rs1862230	chr5:85444868	C/T	cg01787110	chr1:109008453	NBPF6	-0.64	-10.84	-0.47	2.45e-24	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs2734839	0.964	rs2587548	chr11:113292212	G/C	cg14159747	chr11:113255604	NA	0.54	10.4	0.45	1e-22	Information processing speed;
LUAD	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg21194808	chr1:2205498	SKI	-0.41	-6.57	-0.3	1.44e-10	Height;
LUAD	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.31	-0.45	2.13e-22	Platelet count;
LUAD	cis	rs28655083	1.000	rs8045658	chr16:77056343	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.41	-6.63	-0.31	1.01e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1371867	0.810	rs2919470	chr8:101233301	C/A	cg20500540	chr8:101228448	SPAG1	-0.38	-6.79	-0.31	3.77e-11	Atrioventricular conduction;
LUAD	trans	rs79911532	0.515	rs115332207	chr7:75635405	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	8.75	0.39	5e-17	Mononucleosis;
LUAD	cis	rs55665837	0.540	rs12788030	chr11:14764684	C/T	cg19336497	chr11:14380999	RRAS2	-0.4	-7.52	-0.34	3.26e-13	Vitamin D levels;
LUAD	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg02782426	chr3:40428986	ENTPD3	0.42	9.44	0.42	2.49e-19	Renal cell carcinoma;
LUAD	cis	rs938554	0.784	rs10939638	chr4:9977675	T/A	cg11266682	chr4:10021025	SLC2A9	0.43	7.58	0.35	2.17e-13	Blood metabolite levels;
LUAD	cis	rs6987853	0.931	rs2923444	chr8:42397004	C/T	cg09913449	chr8:42400586	C8orf40	0.43	7.92	0.36	2.14e-14	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs870825	0.655	rs67380800	chr4:185623788	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.99	0.56	8.3e-37	Blood protein levels;
LUAD	cis	rs7202877	0.706	rs4993971	chr16:75411634	C/G	cg03315344	chr16:75512273	CHST6	-0.47	-6.43	-0.3	3.37e-10	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs6494488	0.500	rs72742923	chr15:64855696	C/T	cg08069370	chr15:64387884	SNX1	-0.76	-6.77	-0.31	4.45e-11	Coronary artery disease;
LUAD	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg11062466	chr8:58055876	NA	0.75	9.21	0.41	1.52e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg20607798	chr8:58055168	NA	0.72	9.44	0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19626725	chr5:178986131	RUFY1	0.56	10.66	0.46	1.13e-23	Lung cancer;
LUAD	cis	rs6426558	0.537	rs2813950	chr1:227426072	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.51	-8.75	-0.39	4.96e-17	Neutrophil percentage of white cells;
LUAD	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg27113419	chr16:58533979	NDRG4	-0.73	-6.51	-0.3	2.15e-10	Schizophrenia;
LUAD	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg25036284	chr2:26402008	FAM59B	0.84	11.63	0.49	2.59e-27	Gut microbiome composition (summer);
LUAD	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg14668632	chr7:2872130	GNA12	-0.46	-7.88	-0.36	2.74e-14	Height;
LUAD	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg21252483	chr19:49399788	TULP2	-0.88	-14.3	-0.57	3.88e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg04944784	chr2:26401820	FAM59B	-0.7	-9.93	-0.43	5.07e-21	Gut microbiome composition (summer);
LUAD	cis	rs4073416	0.542	rs2411820	chr14:65946744	C/T	cg10998611	chr14:65879393	FUT8;LOC645431	-0.44	-6.51	-0.3	2.15e-10	N-glycan levels;
LUAD	cis	rs4662945	0.603	rs2406981	chr2:130305487	A/G	cg05903289	chr2:130345205	NA	-0.34	-7.3	-0.33	1.45e-12	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs11785400	0.928	rs2280878	chr8:143722366	G/A	cg24634471	chr8:143751801	JRK	0.46	7.36	0.34	9.81e-13	Schizophrenia;
LUAD	cis	rs7107174	1.000	rs2510039	chr11:77944480	G/A	cg19901956	chr11:77921274	USP35	-0.54	-6.53	-0.3	1.84e-10	Testicular germ cell tumor;
LUAD	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg23625390	chr15:77176239	SCAPER	0.4	7.16	0.33	3.59e-12	Blood metabolite levels;
LUAD	cis	rs346785	0.965	rs164009	chr17:74283669	C/T	cg09812376	chr17:74270190	QRICH2	0.32	7.53	0.34	3.01e-13	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs11696501	0.739	rs6073843	chr20:44293956	G/A	cg11783356	chr20:44313418	WFDC10B	-0.49	-8.22	-0.37	2.53e-15	Brain structure;
LUAD	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg02038168	chr22:39784481	NA	-0.6	-10.76	-0.46	5.02e-24	Intelligence (multi-trait analysis);
LUAD	trans	rs58106596	0.800	rs11675826	chr2:232565507	T/C	cg01370599	chr3:116745421	NA	0.6	8.59	0.39	1.73e-16	White blood cell count;Lymphocyte counts;
LUAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.41	-0.38	6.27e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1983170	0.736	rs4484968	chr1:92012005	C/A	cg25838465	chr1:92012736	NA	0.5	6.76	0.31	4.48e-11	Eosinophil percentage of white cells;
LUAD	cis	rs9633740	1.000	rs1870137	chr10:82269848	C/G	cg01528321	chr10:82214614	TSPAN14	0.75	9.84	0.43	1.08e-20	Post bronchodilator FEV1;
LUAD	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.24	16.03	0.61	1.56e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs16867321	0.614	rs12693245	chr2:181445110	T/C	cg23363182	chr2:181467187	NA	0.43	7.04	0.32	7.57e-12	Obesity;
LUAD	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.19	-0.33	2.92e-12	Lung cancer;
LUAD	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	7.17	0.33	3.29e-12	Renal cell carcinoma;
LUAD	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06544989	chr22:39130855	UNC84B	0.43	8.03	0.36	9.95e-15	Menopause (age at onset);
LUAD	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21016266	chr12:122356598	WDR66	0.6	10.95	0.47	9.7e-25	Mean corpuscular volume;
LUAD	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg27432699	chr2:27873401	GPN1	0.56	9.94	0.44	4.53e-21	Oral cavity cancer;
LUAD	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg20476274	chr7:133979776	SLC35B4	0.83	16.66	0.63	2.87e-48	Mean platelet volume;
LUAD	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-9.59	-0.42	7.89e-20	Platelet count;
LUAD	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.52	-8.28	-0.37	1.64e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg17279839	chr7:150038598	RARRES2	0.41	6.47	0.3	2.65e-10	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs12431939	1.000	rs7160729	chr14:51637241	C/T	cg23942311	chr14:51606299	NA	-0.59	-8.16	-0.37	3.89e-15	Cancer;
LUAD	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg06271696	chr7:157225062	NA	-0.63	-14.57	-0.58	2.92e-39	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs3739034	0.938	rs35220888	chr2:135479582	G/A	cg12500956	chr2:135428796	TMEM163	0.37	6.86	0.32	2.49e-11	Gut microbiome composition (winter);
LUAD	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg18827107	chr12:86230957	RASSF9	-0.54	-9.64	-0.42	5.31e-20	Major depressive disorder;
LUAD	cis	rs698813	0.674	rs6544752	chr2:44499049	G/A	cg00619915	chr2:44497795	NA	-0.43	-6.45	-0.3	3e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUAD	cis	rs3760982	0.585	rs61013802	chr19:44292142	A/T	cg11993925	chr19:44307056	LYPD5	0.57	11.74	0.5	9.89e-28	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs7582720	1.000	rs72936873	chr2:203791333	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1950626	0.833	rs12897114	chr14:101395140	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.37	7.08	0.33	5.93e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg08742575	chr21:47604166	C21orf56	0.55	8.85	0.4	2.35e-17	Testicular germ cell tumor;
LUAD	cis	rs6840360	0.615	rs66852535	chr4:152472227	C/A	cg22705602	chr4:152727874	NA	-0.37	-6.71	-0.31	6.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs61776719	0.810	rs34655914	chr1:38397341	G/A	cg17077180	chr1:38461687	NA	0.55	11.82	0.5	4.75e-28	Coronary artery disease;
LUAD	trans	rs11088226	0.645	rs7281844	chr21:33932435	T/C	cg09050820	chr6:167586206	TCP10L2	0.91	12.8	0.53	6.31e-32	Gastritis;
LUAD	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg09658497	chr7:2847517	GNA12	-0.48	-8.65	-0.39	1.09e-16	Height;
LUAD	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23158103	chr7:148848205	ZNF398	-0.66	-12.37	-0.52	3.19e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg13906792	chr15:75199810	C15orf17	-0.35	-6.53	-0.3	1.9e-10	Breast cancer;
LUAD	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg05709478	chr1:6581295	PLEKHG5	-0.58	-7.42	-0.34	6.47e-13	Body mass index;
LUAD	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg02782426	chr3:40428986	ENTPD3	0.41	8.84	0.39	2.64e-17	Renal cell carcinoma;
LUAD	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg22508957	chr16:3507546	NAT15	-0.49	-8.01	-0.36	1.13e-14	Body mass index (adult);
LUAD	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg09835421	chr16:68378352	PRMT7	-0.74	-8.51	-0.38	3e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg20368463	chr18:77673604	PQLC1	-0.59	-10.26	-0.45	3.38e-22	Schizophrenia;
LUAD	trans	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg19676328	chr12:49525230	TUBA1B	-0.69	-11.14	-0.48	1.88e-25	Total cholesterol levels;
LUAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg04025307	chr7:1156635	C7orf50	0.6	6.78	0.31	3.97e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2046867	0.908	rs62251640	chr3:72801605	T/C	cg04365224	chr3:72788183	NA	-0.48	-7.31	-0.33	1.38e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11971779	0.618	rs9640925	chr7:139085288	G/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.44	6.38	0.3	4.53e-10	Resistin levels;
LUAD	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg06740227	chr12:86229804	RASSF9	0.37	6.61	0.31	1.15e-10	Major depressive disorder;
LUAD	trans	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg20849893	chr7:64541193	NA	0.49	6.44	0.3	3.17e-10	Aortic root size;
LUAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.62	10.86	0.47	2.07e-24	Lymphocyte counts;
LUAD	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.5	0.3	2.24e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg17863274	chr19:49399704	TULP2	-0.66	-10.02	-0.44	2.43e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.37	-7.31	-0.33	1.35e-12	Total body bone mineral density;
LUAD	cis	rs7607369	0.536	rs6436092	chr2:219669148	T/A	cg02176678	chr2:219576539	TTLL4	-0.53	-10.22	-0.45	4.61e-22	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.35	-18.42	-0.67	4.84e-56	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg14092988	chr3:52407081	DNAH1	0.39	7.84	0.36	3.61e-14	Electroencephalogram traits;
LUAD	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg02176678	chr2:219576539	TTLL4	0.58	11.13	0.48	2.01e-25	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg10523679	chr1:76189770	ACADM	0.9	15.83	0.61	1.21e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg02734326	chr4:10020555	SLC2A9	0.56	9.91	0.43	5.81e-21	Bone mineral density;
LUAD	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg00634984	chr7:65235879	NA	0.48	6.5	0.3	2.24e-10	Aortic root size;
LUAD	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.65	-0.31	9.27e-11	Coronary artery disease;
LUAD	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg00321850	chr1:175162397	KIAA0040	0.52	11.06	0.47	3.84e-25	Alcohol dependence;
LUAD	cis	rs1215050	0.791	rs2865942	chr4:98737709	G/C	cg05340658	chr4:99064831	C4orf37	0.43	7.24	0.33	2.09e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs877282	1.000	rs7100358	chr10:773681	G/A	cg17470449	chr10:769945	NA	0.68	10.68	0.46	1.01e-23	Uric acid levels;
LUAD	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.74	0.53	1.05e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg25894440	chr7:65020034	NA	-0.69	-7.31	-0.33	1.34e-12	Diabetic kidney disease;
LUAD	cis	rs7614311	0.636	rs73117059	chr3:63916028	A/G	cg22134162	chr3:63841271	THOC7	-0.52	-8.45	-0.38	4.86e-16	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg16405210	chr4:1374714	KIAA1530	0.6	9.16	0.41	2.27e-18	Longevity;
LUAD	cis	rs10155981	0.510	rs4719705	chr7:22592707	C/T	cg05062323	chr7:22590069	NA	-0.74	-7.33	-0.34	1.21e-12	Bilirubin levels;
LUAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg07217954	chr7:1067459	C7orf50	0.39	6.47	0.3	2.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg08742575	chr21:47604166	C21orf56	0.56	9.33	0.41	5.85e-19	Testicular germ cell tumor;
LUAD	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg07402062	chr16:89894098	SPIRE2	0.46	11.6	0.49	3.39e-27	Vitiligo;
LUAD	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg05044414	chr3:183734942	ABCC5	0.48	10.07	0.44	1.64e-21	Anterior chamber depth;
LUAD	cis	rs1868673	0.964	rs2167177	chr3:150135186	C/T	cg04908077	chr3:150187338	NA	-0.31	-6.5	-0.3	2.21e-10	Waist circumference;
LUAD	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.67e-15	Bipolar disorder;
LUAD	cis	rs11771526	0.792	rs17161104	chr7:32298582	C/T	cg13207630	chr7:32358064	NA	0.61	7.64	0.35	1.43e-13	Body mass index;
LUAD	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12122100	0.862	rs6689542	chr1:146506881	G/C	cg03526459	chr1:146549940	NA	-0.36	-6.93	-0.32	1.6e-11	HIV-1 control;
LUAD	cis	rs68170813	0.641	rs74524528	chr7:107090979	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-10.51	-0.45	4.19e-23	Coronary artery disease;
LUAD	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg21918786	chr6:109611834	NA	-0.58	-10.76	-0.46	4.83e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.03	-0.36	9.67e-15	Total body bone mineral density;
LUAD	cis	rs4700695	0.686	rs251710	chr5:65347357	G/C	cg21114390	chr5:65439923	SFRS12	0.62	7.57	0.35	2.32e-13	Facial morphology (factor 19);
LUAD	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg02951883	chr7:2050386	MAD1L1	-0.82	-13.67	-0.55	1.67e-35	Bipolar disorder and schizophrenia;
LUAD	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.22	-0.33	2.48e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg12400702	chr3:12838781	CAND2	0.31	6.42	0.3	3.59e-10	Parkinson's disease;
LUAD	trans	rs1445130	1.000	rs16985413	chr2:18862140	C/T	cg04529938	chr17:73084494	SLC16A5	0.51	6.45	0.3	3e-10	Bulimia nervosa;
LUAD	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg02527881	chr3:46936655	PTH1R	-0.47	-9.26	-0.41	1.02e-18	Colorectal cancer;
LUAD	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg17264618	chr3:40429014	ENTPD3	-0.39	-8.75	-0.39	5.32e-17	Renal cell carcinoma;
LUAD	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg24801067	chr17:62843696	NA	0.55	7.28	0.33	1.69e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9535307	0.719	rs1198322	chr13:50380404	G/A	cg04663916	chr13:50265991	EBPL	-0.62	-6.98	-0.32	1.17e-11	Obesity-related traits;
LUAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg05313129	chr8:58192883	C8orf71	-0.54	-6.73	-0.31	5.66e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9788721	0.934	rs55676755	chr15:78898932	C/G	cg18825076	chr15:78729989	IREB2	-0.57	-9.33	-0.41	5.89e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs7671266	0.532	rs28730480	chr4:10048867	C/T	cg00071950	chr4:10020882	SLC2A9	0.56	7.92	0.36	2.11e-14	Cardiovascular disease risk factors;
LUAD	cis	rs9287719	0.614	rs10929678	chr2:10723095	T/C	cg03983476	chr2:10830698	NOL10	-0.39	-6.49	-0.3	2.34e-10	Prostate cancer;
LUAD	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	6.45	0.3	3.14e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9837602	0.592	rs1711557	chr3:99425669	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.49	-7.1	-0.33	5.2e-12	Breast cancer;
LUAD	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.45	-8.32	-0.37	1.23e-15	Menopause (age at onset);
LUAD	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg27535305	chr1:53392650	SCP2	-0.42	-8.5	-0.38	3.22e-16	Monocyte count;
LUAD	cis	rs10128251	0.743	rs2386636	chr10:5712087	G/T	cg24097872	chr10:5724021	NA	0.38	7.02	0.32	9.03e-12	Childhood ear infection;
LUAD	cis	rs34734847	1.000	rs3752531	chr12:121157851	A/G	cg27246729	chr12:121163418	ACADS	0.39	7.46	0.34	5.07e-13	Mean corpuscular volume;
LUAD	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg15704280	chr7:45808275	SEPT13	-0.54	-8.53	-0.38	2.73e-16	HDL cholesterol;
LUAD	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg04398451	chr17:18023971	MYO15A	0.66	11.87	0.5	3.01e-28	Total body bone mineral density;
LUAD	cis	rs6761276	0.899	rs11891557	chr2:113835319	G/A	cg02343335	chr2:113785852	IL1F8	-0.35	-7.01	-0.32	9.26e-12	Protein quantitative trait loci;
LUAD	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.69	0.31	7.18e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg19336497	chr11:14380999	RRAS2	-0.66	-14.28	-0.57	5.02e-38	Sense of smell;
LUAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.55	-0.38	2.22e-16	Renal function-related traits (BUN);
LUAD	cis	rs870825	0.860	rs72689284	chr4:185596680	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	11.46	0.49	1.17e-26	Blood protein levels;
LUAD	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg05665937	chr4:1216051	CTBP1	0.38	6.37	0.3	4.89e-10	Obesity-related traits;
LUAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22338127	chr1:209979572	IRF6	0.48	6.48	0.3	2.6200000000000003e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.54	-9.57	-0.42	9.41e-20	Axial length;
LUAD	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg05368731	chr17:41323189	NBR1	0.95	19.47	0.69	9.06e-61	Menopause (age at onset);
LUAD	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg13319975	chr6:146136371	FBXO30	0.61	10.14	0.44	9.16e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg17063962	chr7:91808500	NA	0.63	10.7	0.46	8.32e-24	Breast cancer;
LUAD	cis	rs10193935	0.892	rs13413028	chr2:42394865	C/G	cg27598129	chr2:42591480	NA	-0.77	-9.95	-0.44	4.19e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7301016	0.894	rs11174487	chr12:62849999	T/C	cg11441379	chr12:63026424	NA	0.58	7.28	0.33	1.61e-12	IgG glycosylation;
LUAD	cis	rs6594499	0.500	rs10491424	chr5:110453806	T/C	cg17157872	chr5:110408788	TSLP	0.34	6.88	0.32	2.12e-11	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs240764	0.658	rs9322183	chr6:101225121	G/A	cg09795085	chr6:101329169	ASCC3	-0.44	-7.83	-0.36	4.09e-14	Neuroticism;
LUAD	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.53	0.46	3.43e-23	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs494562	0.892	rs573737	chr6:86118233	A/G	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg13047869	chr3:10149882	C3orf24	0.64	9.6	0.42	6.98e-20	Alzheimer's disease;
LUAD	cis	rs7903847	0.642	rs10882908	chr10:99134970	T/C	cg20016023	chr10:99160130	RRP12	-0.3	-7.24	-0.33	2.12e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg22920501	chr2:26401640	FAM59B	-0.96	-14.2	-0.57	1.07e-37	Gut microbiome composition (summer);
LUAD	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg03859395	chr2:55845619	SMEK2	0.72	13.18	0.54	1.75e-33	Metabolic syndrome;
LUAD	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg23262073	chr20:60523788	NA	-0.45	-7.31	-0.34	1.32e-12	Body mass index;
LUAD	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05901451	chr6:126070800	HEY2	0.8	15.41	0.6	7.55e-43	Brugada syndrome;
LUAD	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.45	-7.58	-0.35	2.22e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs984440	0.961	rs7813366	chr8:139080406	C/T	cg03334052	chr1:168888044	NA	0.44	6.42	0.3	3.77e-10	Obesity-related traits;
LUAD	cis	rs7945705	0.782	rs3763918	chr11:8819683	T/A	cg21881798	chr11:8931708	C11orf17;ST5	0.5	9.12	0.41	3.08e-18	Hemoglobin concentration;
LUAD	cis	rs6460942	1.000	rs17668923	chr7:12302873	A/T	cg06484146	chr7:12443880	VWDE	-0.54	-7.27	-0.33	1.75e-12	Coronary artery disease;
LUAD	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg03433033	chr1:76189801	ACADM	0.68	9.8	0.43	1.49e-20	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6424115	0.546	rs35993651	chr1:24180613	C/G	cg10978503	chr1:24200527	CNR2	-0.57	-12.13	-0.51	2.87e-29	Immature fraction of reticulocytes;
LUAD	cis	rs9393692	0.557	rs62394769	chr6:26326182	C/T	cg13736514	chr6:26305472	NA	-0.52	-8.15	-0.37	4.17e-15	Educational attainment;
LUAD	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.27	-0.6	2.95e-42	Chronic sinus infection;
LUAD	cis	rs654950	0.934	rs641974	chr1:42002137	G/A	cg06885757	chr1:42089581	HIVEP3	-0.45	-10.12	-0.44	1.1e-21	Airway imaging phenotypes;
LUAD	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg21545522	chr1:205238299	TMCC2	-0.35	-6.59	-0.3	1.35e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs7187994	0.895	rs16974453	chr16:84758510	C/T	cg07647771	chr16:84786436	USP10	-0.39	-10.0	-0.44	2.79e-21	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs7945718	0.934	rs7114040	chr11:12781659	C/T	cg25843174	chr11:12811716	TEAD1	-0.22	-6.67	-0.31	8.27e-11	Educational attainment (years of education);
LUAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg08888203	chr3:10149979	C3orf24	0.74	11.04	0.47	4.43e-25	Alzheimer's disease;
LUAD	cis	rs7582720	1.000	rs72934519	chr2:203939640	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.62	0.42	6.19e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	trans	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg21659725	chr3:3221576	CRBN	0.4	6.71	0.31	6.2e-11	Resting heart rate;
LUAD	cis	rs35771425	1.000	rs34418448	chr1:211570581	A/G	cg25617285	chr1:211431773	RCOR3	-0.44	-6.46	-0.3	2.85e-10	Educational attainment (years of education);
LUAD	cis	rs9902453	0.619	rs1038088	chr17:28074563	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.36	-0.41	4.92e-19	Coffee consumption (cups per day);
LUAD	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.55	0.52	6.47e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9948	0.655	rs17119562	chr2:97381844	G/C	cg20312557	chr2:97357134	FER1L5	-0.65	-7.42	-0.34	6.6e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs1448094	0.802	rs7397730	chr12:86416212	T/C	cg18827107	chr12:86230957	RASSF9	-0.46	-8.4	-0.38	6.61e-16	Major depressive disorder;
LUAD	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg15147215	chr3:52552868	STAB1	0.4	7.44	0.34	5.59e-13	Bipolar disorder;
LUAD	trans	rs6561151	1.000	rs6561151	chr13:44484706	G/A	cg17145862	chr1:211918768	LPGAT1	0.55	9.19	0.41	1.74e-18	Crohn's disease;
LUAD	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg11301795	chr4:187892539	NA	-0.79	-16.6	-0.63	5.05e-48	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg16479474	chr6:28041457	NA	0.44	7.4	0.34	7.22e-13	Depression;
LUAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg09033563	chr22:24373618	LOC391322	-0.55	-8.67	-0.39	9.14e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11048434	0.761	rs12824380	chr12:9132017	A/G	cg20380214	chr12:9217688	LOC144571	0.34	6.38	0.3	4.54e-10	Sjögren's syndrome;
LUAD	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.89	-0.32	2.05e-11	Type 2 diabetes;
LUAD	cis	rs1983170	0.735	rs963910	chr1:92014136	T/C	cg02896835	chr1:92012615	NA	-0.51	-8.66	-0.39	1.03e-16	Eosinophil percentage of white cells;
LUAD	cis	rs7274811	0.625	rs293722	chr20:31927361	C/T	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.45	-6.79	-0.31	3.79e-11	Height;
LUAD	cis	rs727505	0.721	rs55890146	chr7:124755461	A/T	cg23710748	chr7:124431027	NA	-0.39	-8.05	-0.36	8.48e-15	Lewy body disease;
LUAD	cis	rs6499255	1.000	rs11075733	chr16:69773435	G/T	cg15192750	chr16:69999425	NA	0.55	8.71	0.39	6.96e-17	IgE levels;
LUAD	cis	rs2242663	0.581	rs2511224	chr11:66262606	T/C	cg18002602	chr11:66138449	SLC29A2	0.32	6.69	0.31	7.1e-11	Bipolar disorder;
LUAD	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.41	8.8	0.39	3.49e-17	Total body bone mineral density;
LUAD	cis	rs2734839	0.964	rs12800853	chr11:113302514	C/T	cg14159747	chr11:113255604	NA	0.53	9.82	0.43	1.26e-20	Information processing speed;
LUAD	cis	rs10733682	0.659	rs4358894	chr9:129464802	C/G	cg00232160	chr9:129468157	NA	0.51	9.22	0.41	1.39e-18	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg20607798	chr8:58055168	NA	0.56	7.84	0.36	3.7e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs7680126	0.596	rs10939723	chr4:10139105	G/T	cg26043149	chr18:55253948	FECH	-0.44	-6.39	-0.3	4.27e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs1232027	0.700	rs1382542	chr5:79953581	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.85	-0.36	3.51e-14	Huntington's disease progression;
LUAD	cis	rs2688608	0.967	rs9971040	chr10:75661162	G/C	cg23231163	chr10:75533350	FUT11	-0.38	-7.01	-0.32	9.23e-12	Inflammatory bowel disease;
LUAD	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg09222892	chr1:25734099	RHCE	-0.46	-8.43	-0.38	5.43e-16	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11890956	chr21:40555474	PSMG1	0.82	14.83	0.58	2.32e-40	Cognitive function;
LUAD	cis	rs12505328	0.966	rs13125589	chr4:174364807	T/A	cg12145043	chr4:174357286	NA	0.56	10.23	0.45	4.43e-22	Chin dimples;
LUAD	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg10560079	chr2:191398806	TMEM194B	0.57	7.34	0.34	1.11e-12	Diastolic blood pressure;
LUAD	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.43	-7.85	-0.36	3.37e-14	Cystic fibrosis severity;
LUAD	cis	rs5758511	0.817	rs133291	chr22:42269628	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.44	7.61	0.35	1.76e-13	Birth weight;
LUAD	cis	rs13082711	0.911	rs34098124	chr3:27451242	G/T	cg02860705	chr3:27208620	NA	0.6	8.98	0.4	9.12e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg02018176	chr4:1364513	KIAA1530	0.48	8.61	0.39	1.45e-16	Longevity;
LUAD	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg02493740	chr2:85810744	VAMP5	-0.62	-11.38	-0.48	2.32e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs16958440	0.867	rs75934126	chr18:44679781	T/C	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg13319975	chr6:146136371	FBXO30	-0.6	-10.09	-0.44	1.36e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs752010	0.967	rs6681441	chr1:42098321	G/A	cg06885757	chr1:42089581	HIVEP3	0.39	8.05	0.36	8.29e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.18	0.66	5.66e-55	Prudent dietary pattern;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg01524091	chr6:44281032	AARS2	-0.44	-6.91	-0.32	1.79e-11	Vertical cup-disc ratio;
LUAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg06627628	chr2:24431161	ITSN2	-0.57	-9.52	-0.42	1.33e-19	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs1595825	0.891	rs73061068	chr2:198908439	A/G	cg00361562	chr2:198649771	BOLL	-0.48	-6.6	-0.31	1.25e-10	Ulcerative colitis;
LUAD	trans	rs11700980	0.636	rs11702742	chr21:30254022	T/C	cg14791747	chr16:20752902	THUMPD1	0.63	6.94	0.32	1.44e-11	QRS complex (12-leadsum);
LUAD	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	14.28	0.57	5.1e-38	Lung cancer in ever smokers;
LUAD	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.89	-0.36	2.62e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg15467112	chr14:75489610	MLH3	0.35	6.37	0.3	5.05e-10	Height;
LUAD	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg03467027	chr4:99064603	C4orf37	0.41	6.67	0.31	8.18e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06873352	chr17:61820015	STRADA	0.82	18.34	0.67	1.09e-55	Prudent dietary pattern;
LUAD	cis	rs6433857	0.505	rs1542036	chr2:181350009	A/C	cg23363182	chr2:181467187	NA	-0.4	-6.62	-0.31	1.12e-10	Body mass index;
LUAD	cis	rs9788682	0.747	rs2568490	chr15:78738370	T/C	cg18825076	chr15:78729989	IREB2	-0.54	-7.58	-0.35	2.19e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs17092148	0.887	rs6059916	chr20:33148861	T/G	cg16810054	chr20:33298113	TP53INP2	-0.48	-7.24	-0.33	2.09e-12	Neuroticism;
LUAD	cis	rs7771547	0.574	rs9394361	chr6:36551370	A/C	cg07856975	chr6:36356162	ETV7	0.53	7.08	0.33	6.11e-12	Platelet distribution width;
LUAD	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.96	0.32	1.31e-11	Depression;
LUAD	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg18305652	chr10:134549665	INPP5A	0.61	12.75	0.53	1.01e-31	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.41	-6.53	-0.3	1.92e-10	Multiple sclerosis;
LUAD	cis	rs9952991	0.941	rs45450798	chr18:12792940	C/G	cg09945482	chr18:12777974	NA	-0.57	-6.82	-0.31	3.19e-11	Inflammatory skin disease;
LUAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg03676636	chr4:99064102	C4orf37	-0.29	-7.07	-0.33	6.38e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg09796270	chr17:17721594	SREBF1	-0.38	-7.49	-0.34	4.16e-13	Total body bone mineral density;
LUAD	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg06873352	chr17:61820015	STRADA	0.39	6.65	0.31	9.21e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg12379764	chr21:47803548	PCNT	-0.42	-6.93	-0.32	1.53e-11	Testicular germ cell tumor;
LUAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg03582285	chr17:40700314	NA	-0.41	-8.06	-0.36	7.8e-15	Colorectal or endometrial cancer;
LUAD	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg03168497	chr17:48586147	MYCBPAP	0.54	6.91	0.32	1.78e-11	Visceral fat;
LUAD	cis	rs1030268	0.620	rs2160746	chr7:133478204	G/C	cg10665199	chr7:133106180	EXOC4	0.46	6.48	0.3	2.48e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.89e-14	Depression;
LUAD	cis	rs3806843	0.576	rs246037	chr5:140331846	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.66	-0.31	8.76e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg15448220	chr1:150897856	SETDB1	0.46	7.97	0.36	1.47e-14	Tonsillectomy;
LUAD	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg24399712	chr22:39784796	NA	-0.82	-16.43	-0.62	2.72e-47	Intelligence (multi-trait analysis);
LUAD	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg21918786	chr6:109611834	NA	-0.59	-11.21	-0.48	1.01e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg12599982	chr1:44399894	ARTN	0.33	6.63	0.31	9.99e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1032833	0.732	rs116051947	chr2:180095061	T/C	cg23883738	chr2:179974586	SESTD1	-0.72	-8.1	-0.37	6.07e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs7809950	0.678	rs4730235	chr7:107022506	T/C	cg23024343	chr7:107201750	COG5	-0.82	-14.13	-0.57	2.14e-37	Coronary artery disease;
LUAD	cis	rs7107174	1.000	rs10899477	chr11:78052104	A/T	cg19901956	chr11:77921274	USP35	-0.51	-6.55	-0.3	1.7e-10	Testicular germ cell tumor;
LUAD	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	13.98	0.56	8.94e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.69	-13.6	-0.55	3.31e-35	Ulcerative colitis;
LUAD	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg05872129	chr22:39784769	NA	-0.81	-14.73	-0.58	5.92e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs7786877	0.953	rs7457024	chr7:100215220	A/G	cg16850897	chr7:100343110	ZAN	-0.56	-8.25	-0.37	2.07e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.71	-14.73	-0.58	6.4e-40	Longevity;Endometriosis;
LUAD	trans	rs8002861	0.765	rs12868462	chr13:44453480	C/T	cg17145862	chr1:211918768	LPGAT1	-0.7	-15.14	-0.59	1.14e-41	Leprosy;
LUAD	cis	rs798554	0.629	rs2533875	chr7:2882829	G/A	cg02423579	chr7:2872169	GNA12	-0.57	-9.55	-0.42	1.02e-19	Height;
LUAD	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg17644776	chr2:200775616	C2orf69	0.38	6.7	0.31	6.72e-11	Asthma (bronchodilator response);
LUAD	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg03395511	chr6:291903	DUSP22	-0.52	-8.67	-0.39	8.99e-17	Menopause (age at onset);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03609269	chr1:53393023	SCP2	0.44	6.74	0.31	5.17e-11	Gut microbiome composition (summer);
LUAD	cis	rs2387326	0.767	rs954651	chr10:129941353	T/C	cg16087940	chr10:129947807	NA	-0.62	-8.35	-0.38	9.73e-16	Select biomarker traits;
LUAD	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.81	-0.36	4.47e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg11905131	chr22:24372483	LOC391322	-0.65	-11.38	-0.48	2.41e-26	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.47	2.75e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs977987	0.815	rs11149818	chr16:75419373	G/A	cg03315344	chr16:75512273	CHST6	0.64	13.91	0.56	1.78e-36	Dupuytren's disease;
LUAD	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg09835421	chr16:68378352	PRMT7	-0.72	-8.15	-0.37	4.25e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.55	7.58	0.35	2.26e-13	Platelet count;
LUAD	cis	rs8017423	0.630	rs12589687	chr14:90819570	C/G	cg14092571	chr14:90743983	NA	0.39	6.63	0.31	1.04e-10	Mortality in heart failure;
LUAD	cis	rs57920188	0.535	rs10915664	chr1:4093700	G/A	cg10510935	chr1:4059661	NA	0.44	6.8	0.31	3.6e-11	Interleukin-17 levels;
LUAD	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg11915388	chr22:42470451	FAM109B	-0.42	-7.25	-0.33	2.06e-12	Schizophrenia;
LUAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg13047869	chr3:10149882	C3orf24	0.59	9.99	0.44	2.95e-21	Alzheimer's disease;
LUAD	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg00049323	chr5:472564	LOC25845	0.46	7.59	0.35	2.08e-13	Cystic fibrosis severity;
LUAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg21724239	chr8:58056113	NA	-0.52	-6.81	-0.31	3.45e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg12927641	chr6:109611667	NA	-0.52	-9.29	-0.41	8.42e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs1865721	0.771	rs7236311	chr18:73137450	A/G	cg26385618	chr18:73139727	C18orf62	-0.51	-10.45	-0.45	6.89e-23	Intelligence;
LUAD	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg10556349	chr10:835070	NA	0.54	7.25	0.33	1.96e-12	Eosinophil percentage of granulocytes;
LUAD	trans	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg26043149	chr18:55253948	FECH	1.05	18.1	0.66	1.27e-54	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19346786	chr7:2764209	NA	-0.58	-12.62	-0.52	3.39e-31	Height;
LUAD	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg15839431	chr19:19639596	YJEFN3	-0.53	-8.37	-0.38	8.4e-16	Bipolar disorder;
LUAD	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg25237894	chr2:233734115	C2orf82	-0.56	-10.51	-0.46	4.17e-23	Coronary artery disease;
LUAD	trans	rs7944735	0.817	rs7924699	chr11:47893120	A/T	cg15704280	chr7:45808275	SEPT13	0.51	7.17	0.33	3.3e-12	Intraocular pressure;
LUAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg22907277	chr7:1156413	C7orf50	0.58	7.13	0.33	4.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.15	-0.37	4.1e-15	Electroencephalogram traits;
LUAD	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg00071950	chr4:10020882	SLC2A9	0.86	18.29	0.66	1.72e-55	Bone mineral density;
LUAD	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg21775007	chr8:11205619	TDH	0.56	10.1	0.44	1.24e-21	Retinal vascular caliber;
LUAD	cis	rs477895	0.838	rs7111278	chr11:64016284	G/A	cg23719950	chr11:63933701	MACROD1	-0.58	-6.86	-0.32	2.4e-11	Mean platelet volume;
LUAD	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.32	-6.46	-0.3	2.91e-10	IgG glycosylation;
LUAD	cis	rs17152411	1.000	rs12571196	chr10:126597749	A/C	cg07906193	chr10:126599966	NA	0.54	7.17	0.33	3.46e-12	Height;
LUAD	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg15448220	chr1:150897856	SETDB1	0.49	8.54	0.38	2.47e-16	Tonsillectomy;
LUAD	cis	rs6484504	0.576	rs176373	chr11:31136026	G/T	cg26647111	chr11:31128758	NA	-0.48	-8.42	-0.38	6.11e-16	Red blood cell count;
LUAD	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg00814883	chr7:100076585	TSC22D4	-0.86	-12.96	-0.53	1.45e-32	Platelet count;
LUAD	cis	rs7809950	1.000	rs6976607	chr7:107223401	A/C	cg23024343	chr7:107201750	COG5	0.76	12.39	0.52	2.7e-30	Coronary artery disease;
LUAD	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg00277334	chr10:82204260	NA	-0.57	-9.47	-0.42	2.07e-19	Post bronchodilator FEV1;
LUAD	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg20380214	chr12:9217688	LOC144571	0.34	6.49	0.3	2.45e-10	Sjögren's syndrome;
LUAD	cis	rs9584850	0.874	rs3742137	chr13:99102449	C/T	cg20750642	chr13:99100586	FARP1	-0.33	-6.83	-0.32	2.88e-11	Neuroticism;
LUAD	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9323205	0.531	rs11623697	chr14:51548663	A/C	cg23942311	chr14:51606299	NA	-0.46	-7.09	-0.33	5.49e-12	Cancer;
LUAD	cis	rs2692947	0.568	rs57579941	chr2:96336253	T/C	cg23100626	chr2:96804247	ASTL	0.31	7.55	0.34	2.7e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg06310300	chr7:100076089	TSC22D4	0.39	6.55	0.3	1.67e-10	Monocyte percentage of white cells;
LUAD	cis	rs9902453	0.967	rs4994355	chr17:28386284	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.33	-0.41	6.06e-19	Coffee consumption (cups per day);
LUAD	cis	rs11948739	0.573	rs4705993	chr5:130333733	C/T	cg08523029	chr5:130500466	HINT1	0.46	6.37	0.3	5.06e-10	Pediatric bone mineral content (hip);
LUAD	cis	rs9326248	0.581	rs10892063	chr11:116896155	A/C	cg20608306	chr11:116969690	SIK3	0.32	7.09	0.33	5.64e-12	Blood protein levels;
LUAD	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg05991184	chr2:219186017	PNKD	0.39	7.73	0.35	8.03e-14	Colorectal cancer;
LUAD	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg06221963	chr1:154839813	KCNN3	-0.88	-20.71	-0.71	2.56e-66	Prostate cancer;
LUAD	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg10792982	chr14:105748885	BRF1	0.45	9.82	0.43	1.21e-20	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs74400468	0.529	rs10128322	chr10:43206700	G/T	cg18403995	chr10:43134038	ZNF33B	-0.86	-8.28	-0.37	1.65e-15	Cannabis dependence symptom count;
LUAD	cis	rs877282	0.945	rs71491303	chr10:772884	G/T	cg06581033	chr10:766294	NA	-0.48	-6.77	-0.31	4.2e-11	Uric acid levels;
LUAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg19130645	chr7:65235666	NA	-0.43	-7.3	-0.33	1.46e-12	Calcium levels;
LUAD	cis	rs7172809	0.548	rs75329354	chr15:77668065	C/T	cg11865553	chr15:77376250	NA	-0.39	-6.52	-0.3	2.02e-10	Glucose homeostasis traits;
LUAD	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg18131467	chr2:239335373	ASB1	0.71	12.29	0.51	6.52e-30	Multiple system atrophy;
LUAD	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg27170947	chr2:26402098	FAM59B	-0.82	-11.49	-0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.75	0.35	6.69e-14	Morning vs. evening chronotype;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg14668821	chr17:77704760	ENPP7	0.34	6.86	0.32	2.51e-11	Menopause (age at onset);
LUAD	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg25767906	chr1:53392781	SCP2	-0.47	-8.63	-0.39	1.24e-16	Monocyte count;
LUAD	trans	rs11039798	0.764	rs2089208	chr11:48899860	C/T	cg02254774	chr11:50257496	LOC441601	0.53	6.67	0.31	7.79e-11	Axial length;
LUAD	cis	rs1298062	0.825	rs1673018	chr19:50987694	A/G	cg11430371	chr19:50961752	MYBPC2	0.33	6.71	0.31	6.43e-11	Age of smoking initiation;
LUAD	cis	rs12530134	0.590	rs760492	chr6:170743989	A/G	cg07257824	chr6:170732353	NA	0.71	7.06	0.32	6.88e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg20607798	chr8:58055168	NA	0.78	9.37	0.41	4.44e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7851660	0.874	rs2417576	chr9:100628707	C/T	cg13688889	chr9:100608707	NA	-0.48	-8.26	-0.37	1.87e-15	Strep throat;
LUAD	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg06623918	chr6:96969491	KIAA0776	0.88	17.24	0.64	7.83e-51	Headache;
LUAD	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg13319975	chr6:146136371	FBXO30	-0.64	-11.14	-0.48	1.9e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs9826463	0.702	rs28365824	chr3:142315114	C/A	cg20824294	chr3:142316082	PLS1	0.48	8.32	0.37	1.25e-15	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg16262614	chr3:133464971	TF	0.34	6.39	0.3	4.42e-10	Iron status biomarkers;
LUAD	cis	rs34172651	0.917	rs11646987	chr16:24832408	G/T	cg06028605	chr16:24865363	SLC5A11	0.38	6.74	0.31	5.2e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg21862992	chr11:68658383	NA	0.53	9.72	0.43	2.76e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg25809561	chr17:30822961	MYO1D	0.64	12.1	0.51	3.87e-29	Schizophrenia;
LUAD	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.44	7.48	0.34	4.3e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs11048434	0.736	rs1049925	chr12:9086898	A/G	cg26114124	chr12:9217669	LOC144571	0.38	6.87	0.32	2.25e-11	Sjögren's syndrome;
LUAD	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg00933542	chr6:150070202	PCMT1	0.43	9.19	0.41	1.84e-18	Lung cancer;
LUAD	cis	rs6665290	0.566	rs1513617	chr1:227447213	C/T	cg10327440	chr1:227177885	CDC42BPA	0.75	12.93	0.53	1.83e-32	Myeloid white cell count;
LUAD	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg19418458	chr7:158789849	NA	-0.58	-10.09	-0.44	1.41e-21	Facial morphology (factor 20);
LUAD	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.29	0.45	2.49e-22	Ileal carcinoids;
LUAD	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.54	-9.1	-0.4	3.65e-18	Glomerular filtration rate;
LUAD	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24308560	chr3:49941425	MST1R	0.56	9.58	0.42	8.44e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.49	8.26	0.37	1.85e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg01851573	chr8:8652454	MFHAS1	-0.46	-8.29	-0.37	1.52e-15	Mood instability;
LUAD	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg22705602	chr4:152727874	NA	-0.4	-7.09	-0.33	5.71e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg17401720	chr7:158221031	PTPRN2	0.32	6.5	0.3	2.21e-10	Obesity-related traits;
LUAD	cis	rs2073300	1.000	rs6132622	chr20:23442240	A/T	cg12062639	chr20:23401060	NAPB	1.0	9.21	0.41	1.47e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6921919	0.673	rs13201681	chr6:28394680	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.61	6.97	0.32	1.24e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg15445000	chr17:37608096	MED1	0.44	8.17	0.37	3.48e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg07212818	chr11:638076	DRD4	-0.46	-6.87	-0.32	2.27e-11	Systemic lupus erythematosus;
LUAD	cis	rs4713675	0.584	rs6938056	chr6:33669577	C/T	cg14003231	chr6:33640908	ITPR3	0.49	9.39	0.42	3.64e-19	Plateletcrit;
LUAD	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg20368463	chr18:77673604	PQLC1	-0.42	-6.79	-0.31	3.86e-11	Schizophrenia;
LUAD	cis	rs11048434	0.736	rs7301381	chr12:9123932	T/C	cg04155231	chr12:9217510	LOC144571	0.4	7.48	0.34	4.34e-13	Sjögren's syndrome;
LUAD	cis	rs3806843	0.576	rs246043	chr5:140330924	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg13397359	chr6:42928475	GNMT	-0.49	-7.04	-0.32	7.67e-12	Blood protein levels;
LUAD	cis	rs7779181	1.000	rs7779181	chr7:32345283	T/C	cg27532318	chr7:32358331	NA	0.44	6.96	0.32	1.33e-11	Body mass index;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg15993354	chr19:12912590	PRDX2	0.42	6.76	0.31	4.66e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs16854884	0.586	rs4561830	chr3:143735572	C/T	cg01302019	chr3:143689584	C3orf58	-0.37	-6.63	-0.31	1.01e-10	Economic and political preferences (feminism/equality);
LUAD	cis	rs2235544	0.513	rs10158824	chr1:54480398	C/G	cg25741118	chr1:54482237	LDLRAD1	0.24	6.67	0.31	7.87e-11	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUAD	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.85e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10905065	0.965	rs10752110	chr10:5837038	T/C	cg11519256	chr10:5708881	ASB13	0.41	6.88	0.32	2.2e-11	Menopause (age at onset);
LUAD	cis	rs4891159	0.584	rs689878	chr18:74152017	C/T	cg24786174	chr18:74118243	ZNF516	0.89	21.54	0.72	5.05e-70	Longevity;
LUAD	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.37	-0.34	8.89e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg13770153	chr20:60521292	NA	-0.46	-7.62	-0.35	1.64e-13	Body mass index;
LUAD	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg20607798	chr8:58055168	NA	0.65	8.45	0.38	4.6e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9902453	0.934	rs11080120	chr17:28507021	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	8.37	0.38	8.4e-16	Coffee consumption (cups per day);
LUAD	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg06618935	chr21:46677482	NA	-0.47	-8.47	-0.38	4.23e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-9.66	-0.43	4.31e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg15242686	chr22:24348715	GSTTP1	0.4	6.73	0.31	5.55e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg09658497	chr7:2847517	GNA12	-0.54	-9.16	-0.41	2.33e-18	Height;
LUAD	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg00784671	chr22:46762841	CELSR1	0.42	6.51	0.3	2.12e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg03684893	chr10:554711	DIP2C	0.46	8.49	0.38	3.5e-16	Psychosis in Alzheimer's disease;
LUAD	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg15147215	chr3:52552868	STAB1	-0.4	-7.37	-0.34	9.03e-13	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg02158880	chr13:53174818	NA	0.51	8.96	0.4	1.06e-17	Lewy body disease;
LUAD	cis	rs7903847	0.642	rs11817852	chr10:99158426	C/T	cg20016023	chr10:99160130	RRP12	-0.32	-7.56	-0.35	2.5e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs4604732	0.527	rs77361748	chr1:247626475	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg14403583	chr14:105418241	AHNAK2	-0.44	-8.28	-0.37	1.64e-15	Rheumatoid arthritis;
LUAD	cis	rs743757	1.000	rs2236973	chr3:50474284	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	7.12	0.33	4.53e-12	Diastolic blood pressure;
LUAD	cis	rs13040088	1.000	rs13040088	chr20:61549202	A/G	cg23096297	chr20:61557774	DIDO1	0.77	11.13	0.48	1.98e-25	Menopause (age at onset);
LUAD	cis	rs698833	0.813	rs3768919	chr2:44512971	C/T	cg04920474	chr2:44395004	PPM1B	0.39	6.92	0.32	1.64e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs6504663	0.558	rs2412325	chr17:48546232	G/C	cg11440486	chr17:48585216	MYCBPAP	0.46	6.45	0.3	3.1e-10	Visceral fat;
LUAD	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg27211696	chr2:191398769	TMEM194B	-0.59	-8.05	-0.36	8.73e-15	Diastolic blood pressure;
LUAD	cis	rs6494488	0.500	rs951721	chr15:65044435	C/T	cg08069370	chr15:64387884	SNX1	-0.73	-6.47	-0.3	2.78e-10	Coronary artery disease;
LUAD	cis	rs6545883	0.895	rs796597	chr2:61681060	A/G	cg15711740	chr2:61764176	XPO1	-0.41	-6.53	-0.3	1.89e-10	Tuberculosis;
LUAD	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg10755058	chr3:40428713	ENTPD3	-0.44	-8.47	-0.38	3.96e-16	Renal cell carcinoma;
LUAD	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg20848291	chr7:100343083	ZAN	0.4	6.88	0.32	2.1e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg05182265	chr7:156933206	UBE3C	-0.8	-17.24	-0.64	8.1e-51	Body mass index;
LUAD	cis	rs7210086	0.808	rs6501558	chr17:70639488	T/C	cg04206342	chr17:70636940	NA	-0.39	-7.22	-0.33	2.46e-12	Ulcerative colitis;
LUAD	cis	rs10788264	0.504	rs7069328	chr10:124030741	G/C	cg09507567	chr10:124027408	NA	0.55	12.33	0.51	4.61e-30	Total body bone mineral density;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00355089	chr17:27053983	TLCD1	-0.42	-6.66	-0.31	8.47e-11	Height;
LUAD	trans	rs9354308	0.901	rs55832318	chr6:66560086	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.53	8.04	0.36	8.81e-15	Metabolite levels;
LUAD	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg05044414	chr3:183734942	ABCC5	0.48	9.88	0.43	7.52e-21	Anterior chamber depth;
LUAD	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg17063962	chr7:91808500	NA	-0.66	-11.1	-0.47	2.69e-25	Breast cancer;
LUAD	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg16797656	chr11:68205561	LRP5	0.47	9.39	0.42	3.89e-19	Total body bone mineral density;
LUAD	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg06784218	chr1:46089804	CCDC17	0.35	7.53	0.34	3.09e-13	Red blood cell count;Reticulocyte count;
LUAD	trans	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg24644049	chr4:85504048	CDS1	0.92	7.92	0.36	2.16e-14	Skin colour saturation;
LUAD	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg18252515	chr7:66147081	NA	-0.63	-6.94	-0.32	1.5e-11	Gout;
LUAD	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg04842962	chr6:43655489	MRPS18A	1.05	26.45	0.79	1.09e-91	IgG glycosylation;
LUAD	cis	rs11112613	0.713	rs17037317	chr12:105952058	T/C	cg03607813	chr12:105948248	NA	0.74	12.73	0.53	1.22e-31	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg18944383	chr4:111397179	ENPEP	0.41	8.26	0.37	1.87e-15	Height;
LUAD	cis	rs7119	0.604	rs1055691	chr15:77864625	G/C	cg27398640	chr15:77910606	LINGO1	0.35	6.76	0.31	4.64e-11	Type 2 diabetes;
LUAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.52	-8.86	-0.4	2.26e-17	Longevity;Endometriosis;
LUAD	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	9.44	0.42	2.56e-19	Melanoma;
LUAD	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg23750338	chr8:142222470	SLC45A4	-0.6	-13.95	-0.56	1.19e-36	Immature fraction of reticulocytes;
LUAD	trans	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg04492929	chr16:2155436	PKD1	-0.43	-7.85	-0.36	3.56e-14	Triglycerides;
LUAD	trans	rs7395662	1.000	rs6485903	chr11:48639004	G/A	cg00717180	chr2:96193071	NA	-0.4	-7.4	-0.34	7.56e-13	HDL cholesterol;
LUAD	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.67	11.14	0.48	1.96e-25	Height;
LUAD	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg21191810	chr6:118973309	C6orf204	-0.48	-7.66	-0.35	1.28e-13	Diastolic blood pressure;
LUAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg03452623	chr4:187889614	NA	-0.81	-16.82	-0.63	5.47e-49	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7582720	0.725	rs72934725	chr2:203725983	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.12	0.41	3.09e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg04455712	chr21:45112962	RRP1B	0.45	9.17	0.41	2.1e-18	Mean corpuscular volume;
LUAD	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg08236123	chr12:132219811	SFRS8	-0.41	-7.23	-0.33	2.28e-12	Migraine;
LUAD	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg16479474	chr6:28041457	NA	0.35	6.36	0.3	5.21e-10	Cardiac Troponin-T levels;
LUAD	cis	rs79976124	1.000	rs79976124	chr6:66618657	G/A	cg07460842	chr6:66804631	NA	0.6	9.14	0.41	2.58e-18	Type 2 diabetes;
LUAD	cis	rs877282	0.853	rs12777155	chr10:754731	G/C	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg21724239	chr8:58056113	NA	0.75	8.74	0.39	5.57e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg20673091	chr1:2541236	MMEL1	0.45	9.77	0.43	1.8e-20	Ulcerative colitis;
LUAD	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg22117172	chr7:91764530	CYP51A1	0.3	6.5	0.3	2.31e-10	Breast cancer;
LUAD	cis	rs7149337	1.000	rs35567150	chr14:51725944	A/G	cg23942311	chr14:51606299	NA	0.79	16.46	0.62	2.2e-47	Cancer;
LUAD	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg06131755	chr6:160182447	ACAT2	0.43	6.44	0.3	3.34e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs6740322	0.696	rs11685054	chr2:43474295	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-11.24	-0.48	7.94e-26	Coronary artery disease;
LUAD	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg16486109	chr11:613632	IRF7	0.5	7.66	0.35	1.32e-13	Systemic lupus erythematosus;
LUAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg22535103	chr8:58192502	C8orf71	-0.75	-9.2	-0.41	1.64e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-15.45	-0.6	4.98e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs3849570	0.643	rs10779986	chr3:81970818	C/G	cg07356753	chr3:81810745	GBE1	0.53	8.96	0.4	1.05e-17	Waist circumference;Body mass index;
LUAD	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.29	-0.33	1.54e-12	Total body bone mineral density;
LUAD	cis	rs2992756	0.663	rs12750779	chr1:18805048	G/A	cg24076588	chr1:18808559	KLHDC7A	-0.46	-7.54	-0.34	2.98e-13	Breast cancer;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00124175	chr20:17950611	SNX5;C20orf72	0.42	6.89	0.32	2.05e-11	Gut microbiome composition (summer);
LUAD	cis	rs62458065	0.850	rs7804998	chr7:32461197	T/C	cg20159608	chr7:32802032	NA	-0.53	-7.01	-0.32	9.28e-12	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs6445967	0.530	rs56041256	chr3:58391678	G/A	cg23715586	chr3:58305044	RPP14	0.41	6.76	0.31	4.58e-11	Platelet count;
LUAD	cis	rs6076065	0.723	rs6083099	chr20:23358233	A/G	cg11657817	chr20:23433608	CST11	-0.48	-9.14	-0.41	2.58e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-8.42	-0.38	5.98e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg05425664	chr17:57184151	TRIM37	-0.42	-7.46	-0.34	4.88e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs10089	1.000	rs4835944	chr5:127490870	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.63	-9.57	-0.42	8.87e-20	Ileal carcinoids;
LUAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.7	-8.39	-0.38	7.5e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs934734	0.752	rs268131	chr2:65610471	A/T	cg11674355	chr2:65610261	SPRED2	0.35	6.4	0.3	4.21e-10	Rheumatoid arthritis;
LUAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg00106254	chr7:1943704	MAD1L1	-0.63	-9.42	-0.42	3.05e-19	Bipolar disorder and schizophrenia;
LUAD	trans	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg26043149	chr18:55253948	FECH	0.51	8.3	0.37	1.4e-15	Bone mineral density;
LUAD	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg12483005	chr1:23474871	LUZP1	-0.53	-9.42	-0.42	2.96e-19	Height;
LUAD	trans	rs11885103	0.754	rs6712881	chr2:584745	G/A	cg12228919	chr15:44955936	SPG11	-0.44	-6.67	-0.31	7.97e-11	Heschl's gyrus morphology;
LUAD	cis	rs1595825	0.945	rs73056880	chr2:198822292	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-7.1	-0.33	5.43e-12	Ulcerative colitis;
LUAD	trans	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg02002194	chr4:3960332	NA	-0.32	-7.53	-0.34	3.06e-13	Neuroticism;
LUAD	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg22823121	chr1:150693482	HORMAD1	0.4	7.79	0.35	5.19e-14	Melanoma;
LUAD	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg08989290	chr16:615782	NHLRC4	0.3	6.41	0.3	3.98e-10	Height;
LUAD	cis	rs698833	0.710	rs1441048	chr2:44511929	T/C	cg04920474	chr2:44395004	PPM1B	0.37	6.57	0.3	1.45e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg17346650	chr17:80929145	B3GNTL1	0.39	6.84	0.32	2.76e-11	Glycated hemoglobin levels;
LUAD	cis	rs8017423	0.967	rs7146640	chr14:90720114	C/T	cg14092571	chr14:90743983	NA	0.48	8.31	0.37	1.34e-15	Mortality in heart failure;
LUAD	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg02782426	chr3:40428986	ENTPD3	0.42	9.16	0.41	2.26e-18	Renal cell carcinoma;
LUAD	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg15181151	chr6:150070149	PCMT1	0.42	8.84	0.39	2.58e-17	Lung cancer;
LUAD	trans	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.98	-0.36	1.4e-14	Gout;
LUAD	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg12407791	chr17:73824354	UNC13D	0.34	6.98	0.32	1.12e-11	White matter hyperintensity burden;
LUAD	cis	rs4660306	1.000	rs10157597	chr1:45990278	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.5	-8.02	-0.36	1.06e-14	Homocysteine levels;
LUAD	cis	rs17401966	1.000	rs1339458	chr1:10328338	C/T	cg15208524	chr1:10270712	KIF1B	0.56	8.65	0.39	1.05e-16	Hepatocellular carcinoma;
LUAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.43	-0.34	5.9e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7274811	0.681	rs291705	chr20:31969658	A/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.48	-7.43	-0.34	6.17e-13	Height;
LUAD	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg08888203	chr3:10149979	C3orf24	0.64	9.93	0.43	4.86e-21	Alzheimer's disease;
LUAD	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg21214613	chr1:16344536	HSPB7	0.6	11.6	0.49	3.35e-27	Dilated cardiomyopathy;
LUAD	cis	rs953387	1.000	rs4954564	chr2:136895508	A/G	cg05194412	chr2:137003533	NA	-0.44	-7.07	-0.33	6.46e-12	Arthritis (juvenile idiopathic);
LUAD	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg25324976	chr17:61989376	CSHL1	0.42	7.89	0.36	2.53e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg17330251	chr7:94953956	PON1	-0.51	-6.67	-0.31	8.18e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7805747	0.961	rs17173238	chr7:151406220	A/G	cg17611936	chr7:151411526	PRKAG2	0.46	6.69	0.31	7.29e-11	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LUAD	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg18230493	chr5:56204884	C5orf35	0.66	10.47	0.45	5.81e-23	Initial pursuit acceleration;
LUAD	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg22676075	chr6:135203613	NA	0.43	7.74	0.35	7.57e-14	Red blood cell count;
LUAD	cis	rs4409675	0.576	rs11247705	chr1:28212272	G/A	cg23691781	chr1:28212827	C1orf38	0.38	11.13	0.48	2.14e-25	Corneal astigmatism;
LUAD	cis	rs494562	0.892	rs632163	chr6:86122062	C/T	cg27297263	chr6:86160468	NT5E	0.63	7.41	0.34	6.87e-13	Blood metabolite levels;Metabolic traits;
LUAD	trans	rs2797160	0.967	rs984041	chr6:126021328	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.53	8.49	0.38	3.64e-16	Endometrial cancer;
LUAD	cis	rs6942407	0.545	rs6465101	chr7:86859065	C/G	cg02420886	chr7:86849541	C7orf23	0.62	6.62	0.31	1.09e-10	Food allergy;
LUAD	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg22079354	chr11:130786696	SNX19	0.37	6.41	0.3	3.97e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs17253792	0.822	rs79024594	chr14:56092997	T/G	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.35	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg00717180	chr2:96193071	NA	-0.44	-8.42	-0.38	6.05e-16	HDL cholesterol;
LUAD	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs9902453	0.845	rs62068583	chr17:28001482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.31	0.41	7.16e-19	Coffee consumption (cups per day);
LUAD	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-13.6	-0.55	3.45e-35	Chronic sinus infection;
LUAD	cis	rs2455799	0.573	rs2455812	chr3:15734096	C/G	cg16303742	chr3:15540471	COLQ	-0.44	-8.12	-0.37	5.32e-15	Mean platelet volume;
LUAD	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg25767906	chr1:53392781	SCP2	-0.54	-10.1	-0.44	1.24e-21	Monocyte count;
LUAD	cis	rs9584850	0.834	rs3783005	chr13:99111337	A/T	cg20750642	chr13:99100586	FARP1	0.34	7.16	0.33	3.59e-12	Neuroticism;
LUAD	cis	rs754466	0.605	rs10824578	chr10:79578244	G/C	cg17075019	chr10:79541650	NA	-0.92	-20.02	-0.7	3.47e-63	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs783540	0.500	rs7178459	chr15:83398384	T/C	cg18393722	chr15:85113863	UBE2QP1	0.52	7.51	0.34	3.53e-13	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg25894440	chr7:65020034	NA	-0.61	-6.8	-0.31	3.55e-11	Diabetic kidney disease;
LUAD	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.63	0.31	1.03e-10	Depression;
LUAD	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg21782813	chr7:2030301	MAD1L1	-0.48	-8.27	-0.37	1.7e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs4845570	1.000	rs4845579	chr1:151770138	C/T	cg07092448	chr1:151763213	TDRKH	-0.75	-10.26	-0.45	3.39e-22	Coronary artery disease;
LUAD	trans	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg24644049	chr4:85504048	CDS1	0.92	7.91	0.36	2.22e-14	Skin colour saturation;
LUAD	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18876405	chr7:65276391	NA	-0.44	-6.91	-0.32	1.83e-11	Aortic root size;
LUAD	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg01119278	chr6:110721349	DDO	-0.46	-8.46	-0.38	4.35e-16	Platelet distribution width;
LUAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg18402987	chr7:1209562	NA	0.81	9.91	0.43	6.12e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg17644776	chr2:200775616	C2orf69	-0.57	-7.41	-0.34	6.71e-13	Schizophrenia;
LUAD	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg27366882	chr3:133540807	NA	-0.42	-7.52	-0.34	3.35e-13	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	7.46	0.34	5.09e-13	Platelet count;
LUAD	trans	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg21051086	chr3:73046214	PPP4R2	-0.45	-7.53	-0.34	3.11e-13	Pancreatic cancer;
LUAD	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08677398	chr8:58056175	NA	0.46	6.65	0.31	9.21e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6701037	1.000	rs1057305	chr1:175126223	T/A	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.77	-0.39	4.48e-17	Alcohol dependence;
LUAD	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg16680214	chr1:154839983	KCNN3	-0.62	-11.98	-0.5	1.14e-28	Prostate cancer;
LUAD	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg06627628	chr2:24431161	ITSN2	-0.46	-6.4	-0.3	4.22e-10	Lymphocyte counts;
LUAD	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg14228332	chr4:119757509	SEC24D	0.76	7.38	0.34	8.21e-13	Cannabis dependence symptom count;
LUAD	cis	rs68170813	0.559	rs2299422	chr7:106959832	A/T	cg23024343	chr7:107201750	COG5	0.5	7.18	0.33	3.24e-12	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3007168	1.000	rs3007169	chr14:51607897	A/G	cg23942311	chr14:51606299	NA	0.54	7.54	0.34	2.86e-13	Cancer;
LUAD	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg02176678	chr2:219576539	TTLL4	0.6	11.69	0.49	1.54e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.3	-0.37	1.38e-15	Prostate cancer;
LUAD	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg12908607	chr1:44402522	ARTN	0.44	8.98	0.4	9e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7289126	0.966	rs2284072	chr22:38633666	A/C	cg17652424	chr22:38574118	PLA2G6	-0.25	-7.28	-0.33	1.63e-12	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg23649088	chr2:200775458	C2orf69	-0.58	-6.96	-0.32	1.29e-11	Schizophrenia;
LUAD	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg01324343	chr3:183735012	ABCC5	0.95	26.07	0.79	4.87e-90	Anterior chamber depth;
LUAD	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.53	-0.3	1.87e-10	Total body bone mineral density;
LUAD	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg07936489	chr17:37558343	FBXL20	0.44	6.83	0.32	2.89e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs243505	0.691	rs243486	chr7:148448221	A/C	cg09806900	chr7:148480153	CUL1	-0.43	-6.39	-0.3	4.35e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7493	0.901	rs13226149	chr7:95025600	G/A	cg01874867	chr7:94954059	PON1	-0.52	-7.3	-0.33	1.4e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg12573674	chr2:1569213	NA	-0.61	-6.89	-0.32	2.08e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs78487399	0.808	rs6731980	chr2:43703183	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-6.43	-0.3	3.4e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	trans	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg04775059	chr7:64541387	NA	0.48	7.71	0.35	9.03e-14	Aortic root size;
LUAD	cis	rs11811982	0.793	rs7535648	chr1:227306556	C/T	cg24860534	chr1:227506868	CDC42BPA	0.68	7.31	0.33	1.35e-12	Optic disc area;
LUAD	cis	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg08601574	chr20:25228251	PYGB	-0.46	-8.65	-0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1564271	1.000	rs1564271	chr10:27011112	G/A	cg13837822	chr10:26931731	LOC731789	0.38	7.44	0.34	5.86e-13	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUAD	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg27661571	chr11:113659931	NA	-0.71	-8.27	-0.37	1.77e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg00310523	chr12:86230176	RASSF9	0.4	7.84	0.36	3.78e-14	Major depressive disorder;
LUAD	trans	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg06606381	chr12:133084897	FBRSL1	-0.52	-7.12	-0.33	4.74e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg18105139	chr6:28058856	ZSCAN12L1	-0.26	-6.36	-0.3	5.35e-10	Depression;
LUAD	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg08601574	chr20:25228251	PYGB	0.46	8.6	0.39	1.57e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg25036284	chr2:26402008	FAM59B	-0.83	-11.78	-0.5	6.58e-28	Gut microbiome composition (summer);
LUAD	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg03684893	chr10:554711	DIP2C	-0.36	-6.39	-0.3	4.28e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs870825	0.860	rs2705886	chr4:185608591	T/C	cg04058563	chr4:185651563	MLF1IP	-0.83	-10.98	-0.47	7.26e-25	Blood protein levels;
LUAD	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg12863693	chr15:85201151	NMB	0.31	6.47	0.3	2.79e-10	P wave terminal force;
LUAD	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg12140854	chr5:148520817	ABLIM3	-0.7	-10.47	-0.45	5.77e-23	Breast cancer;
LUAD	cis	rs7100689	0.784	rs6585986	chr10:82171559	T/C	cg00277334	chr10:82204260	NA	-0.64	-10.09	-0.44	1.31e-21	Post bronchodilator FEV1;
LUAD	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-12.83	-0.53	4.57e-32	Bone mineral density;
LUAD	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg01741372	chr11:783889	NA	0.45	9.7	0.43	3.11e-20	Breast cancer;
LUAD	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg16797656	chr11:68205561	LRP5	0.45	8.66	0.39	1.02e-16	Total body bone mineral density;
LUAD	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.26	-0.54	8.48e-34	Chronic sinus infection;
LUAD	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg07305463	chr2:136567211	LCT	0.39	7.39	0.34	7.81e-13	Mosquito bite size;
LUAD	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-7.7	-0.35	9.52e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	26.66	0.79	1.38e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7818345	0.967	rs12678336	chr8:19280552	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.32	7.08	0.33	6.06e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.31	0.37	1.29e-15	Breast cancer;
LUAD	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg04036182	chr15:45458818	NA	-0.42	-7.28	-0.33	1.67e-12	Glomerular filtration rate;
LUAD	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.75	-12.51	-0.52	8.91e-31	Primary sclerosing cholangitis;
LUAD	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg02696790	chr15:75250997	RPP25	0.38	7.42	0.34	6.5e-13	Caffeine consumption;
LUAD	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg15790184	chr11:494944	RNH1	0.51	6.39	0.3	4.46e-10	Body mass index;
LUAD	cis	rs4523957	0.788	rs2169357	chr17:2096441	C/T	cg16513277	chr17:2031491	SMG6	-0.8	-15.54	-0.6	2.13e-43	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs57590327	0.503	rs11711024	chr3:81910207	T/C	cg07356753	chr3:81810745	GBE1	-0.58	-9.24	-0.41	1.18e-18	Extraversion;
LUAD	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg23281280	chr6:28129359	ZNF389	0.46	6.58	0.3	1.39e-10	Depression;
LUAD	cis	rs9625935	0.748	rs2412974	chr22:30539821	C/T	cg11564601	chr22:30592435	NA	-0.3	-6.53	-0.3	1.92e-10	Tonsillectomy;
LUAD	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	10.37	0.45	1.29e-22	Axial length;
LUAD	trans	rs9951602	0.512	rs12607561	chr18:76644284	G/A	cg02800362	chr5:177631904	HNRNPAB	0.92	14.22	0.57	8.94e-38	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.82e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg00701064	chr4:6280414	WFS1	0.64	13.92	0.56	1.59e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg05996236	chr5:178286857	ZNF354B	-0.38	-6.49	-0.3	2.35e-10	Schizophrenia;
LUAD	cis	rs1832871	0.672	rs56075516	chr6:158745752	G/A	cg07165851	chr6:158734300	TULP4	0.72	11.09	0.47	2.99e-25	Height;
LUAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg03188948	chr7:1209495	NA	0.8	9.76	0.43	2.04e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs494562	0.892	rs7771860	chr6:86130729	C/T	cg27297263	chr6:86160468	NT5E	0.59	6.61	0.31	1.19e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06544989	chr22:39130855	UNC84B	0.42	7.94	0.36	1.9e-14	Menopause (age at onset);
LUAD	cis	rs3812111	0.510	rs9387390	chr6:116584080	T/C	cg18828861	chr6:116576566	TSPYL4	0.37	7.15	0.33	3.81e-12	Age-related macular degeneration;
LUAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg02951883	chr7:2050386	MAD1L1	-0.66	-10.76	-0.46	4.8e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs9837602	1.000	rs4279135	chr3:99733096	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.65	9.43	0.42	2.64e-19	Breast cancer;
LUAD	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg26102564	chr10:131424627	MGMT	0.33	6.4	0.3	4.25e-10	Response to temozolomide;
LUAD	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7809950	0.678	rs6949634	chr7:106984684	G/T	cg23024343	chr7:107201750	COG5	-0.82	-13.96	-0.56	1.12e-36	Coronary artery disease;
LUAD	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg13319975	chr6:146136371	FBXO30	-0.63	-10.74	-0.46	5.94e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg26727032	chr16:67993705	SLC12A4	-0.54	-7.18	-0.33	3.21e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.91	0.32	1.78e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08109568	chr15:31115862	NA	-0.59	-10.09	-0.44	1.32e-21	Huntington's disease progression;
LUAD	cis	rs4285028	0.580	rs12496036	chr3:121640362	G/A	cg11130432	chr3:121712080	ILDR1	-0.45	-6.92	-0.32	1.64e-11	Multiple sclerosis;
LUAD	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg22153463	chr1:85462885	MCOLN2	-0.62	-8.99	-0.4	8.5e-18	Serum sulfate level;
LUAD	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg00717180	chr2:96193071	NA	-0.48	-9.16	-0.41	2.25e-18	Coronary artery disease;
LUAD	cis	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg07460842	chr6:66804631	NA	0.83	9.8	0.43	1.43e-20	Exhaled nitric oxide output;
LUAD	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg15369054	chr17:80825471	TBCD	0.55	6.44	0.3	3.32e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs5756391	0.546	rs9610607	chr22:37315759	T/C	cg16356956	chr22:37317934	CSF2RB	0.33	7.21	0.33	2.52e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.38	-6.8	-0.31	3.54e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2479724	0.591	rs2243605	chr6:41828070	T/A	cg17623882	chr6:41773611	USP49	-0.46	-6.81	-0.31	3.34e-11	Menarche (age at onset);
LUAD	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg20019720	chr6:154832845	CNKSR3	0.65	12.3	0.51	6.2e-30	Lipoprotein (a) levels;
LUAD	cis	rs986417	0.901	rs1989477	chr14:61024867	T/C	cg27398547	chr14:60952738	C14orf39	0.64	7.44	0.34	5.59e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg18932078	chr1:2524107	MMEL1	-0.36	-6.8	-0.31	3.56e-11	Ulcerative colitis;
LUAD	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg12935359	chr14:103987150	CKB	-0.44	-7.0	-0.32	9.95e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7584330	0.554	rs75559690	chr2:238428454	T/C	cg14458575	chr2:238380390	NA	0.74	11.11	0.48	2.52e-25	Prostate cancer;
LUAD	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2041840	0.538	rs10196818	chr2:37576852	A/G	cg25727520	chr2:37576821	QPCT	-0.36	-7.61	-0.35	1.79e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs6782228	0.527	rs6767383	chr3:128413587	C/A	cg16766828	chr3:128327626	NA	-0.38	-7.09	-0.33	5.73e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs72928364	0.929	rs35333915	chr3:100787061	T/C	cg10123952	chr3:100791384	NA	0.7	7.74	0.35	7.59e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg02711976	chr1:36023590	NCDN;KIAA0319L	-0.4	-6.6	-0.31	1.2e-10	Schizophrenia;
LUAD	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg27124370	chr19:33622961	WDR88	0.46	7.15	0.33	3.92e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg26384229	chr12:38710491	ALG10B	0.43	7.2	0.33	2.86e-12	Bladder cancer;
LUAD	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg25767906	chr1:53392781	SCP2	0.41	7.53	0.34	3e-13	Monocyte count;
LUAD	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg13180566	chr4:1052158	NA	-0.4	-6.73	-0.31	5.71e-11	Recombination rate (females);
LUAD	cis	rs7166081	0.704	rs2414952	chr15:67724392	A/T	cg27219399	chr15:67835830	MAP2K5	0.44	7.68	0.35	1.14e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	8.06	0.36	7.95e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg02423579	chr7:2872169	GNA12	-0.58	-9.82	-0.43	1.18e-20	Height;
LUAD	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg23262351	chr6:79576851	IRAK1BP1	-0.41	-6.95	-0.32	1.4e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg00071950	chr4:10020882	SLC2A9	0.49	7.1	0.33	5.41e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg25036284	chr2:26402008	FAM59B	-0.54	-7.5	-0.34	3.89e-13	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg00147172	chr22:46423604	NA	0.27	6.6	0.31	1.23e-10	Dupuytren's disease;
LUAD	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05535760	chr7:792225	HEATR2	1.0	12.71	0.53	1.46e-31	Cerebrospinal P-tau181p levels;
LUAD	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-20.3	-0.7	1.77e-64	Chronic sinus infection;
LUAD	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg11502198	chr6:26597334	ABT1	0.68	11.32	0.48	3.86e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg22117172	chr7:91764530	CYP51A1	0.37	7.93	0.36	1.97e-14	Breast cancer;
LUAD	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg13319975	chr6:146136371	FBXO30	0.66	11.72	0.5	1.12e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3087591	0.960	rs2071009	chr17:29558082	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.4	-6.44	-0.3	3.32e-10	Hip circumference;
LUAD	cis	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg23950597	chr19:37808831	NA	-0.59	-7.27	-0.33	1.77e-12	Coronary artery calcification;
LUAD	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24531977	chr5:56204891	C5orf35	-1.21	-20.62	-0.71	7.01e-66	Initial pursuit acceleration;
LUAD	cis	rs10736390	1.000	rs10736390	chr1:55103945	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.77	-14.8	-0.58	3.06e-40	Survival in pancreatic cancer;
LUAD	cis	rs2030114	0.531	rs4783838	chr16:51594238	G/A	cg03758633	chr16:51611768	NA	0.33	6.9	0.32	1.9e-11	Blood pressure measurement (high sodium and potassium intervention);
LUAD	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg20503657	chr10:835505	NA	1.22	17.94	0.66	6.16e-54	Eosinophil percentage of granulocytes;
LUAD	cis	rs10193935	1.000	rs4048	chr2:42424595	A/C	cg27598129	chr2:42591480	NA	-0.82	-9.74	-0.43	2.31e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg08885076	chr2:99613938	TSGA10	-0.4	-7.09	-0.33	5.53e-12	Chronic sinus infection;
LUAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.56	0.55	4.79e-35	Prudent dietary pattern;
LUAD	cis	rs739496	0.542	rs7300400	chr12:111792179	A/C	cg10833066	chr12:111807467	FAM109A	0.7	14.08	0.56	3.39e-37	Platelet count;
LUAD	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg09796270	chr17:17721594	SREBF1	0.36	6.65	0.31	9.23e-11	Total body bone mineral density;
LUAD	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg00981070	chr1:2046702	PRKCZ	-0.35	-7.42	-0.34	6.65e-13	Height;
LUAD	cis	rs25645	0.502	rs7207600	chr17:38091660	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.46	-8.36	-0.38	8.99e-16	Myeloid white cell count;
LUAD	cis	rs798554	0.629	rs2533875	chr7:2882829	G/A	cg14668632	chr7:2872130	GNA12	-0.5	-8.84	-0.39	2.68e-17	Height;
LUAD	cis	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg20045696	chr14:77926864	AHSA1	-0.46	-6.54	-0.3	1.79e-10	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUAD	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg23950597	chr19:37808831	NA	-0.59	-7.07	-0.33	6.44e-12	Coronary artery calcification;
LUAD	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg05623727	chr3:50126028	RBM5	0.3	6.58	0.3	1.41e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs17336368	1.000	rs17336368	chr6:44751668	G/A	cg20913747	chr6:44695427	NA	-0.44	-7.45	-0.34	5.32e-13	Chin dimples;
LUAD	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg23231163	chr10:75533350	FUT11	-0.51	-9.37	-0.41	4.29e-19	Inflammatory bowel disease;
LUAD	trans	rs783540	0.967	rs17158390	chr15:83293028	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.56	-0.3	1.57e-10	Schizophrenia;
LUAD	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg27411982	chr8:10470053	RP1L1	0.43	7.89	0.36	2.57e-14	Retinal vascular caliber;
LUAD	cis	rs2795502	0.630	rs1271547	chr10:43507665	C/T	cg15903213	chr10:43522190	NA	-0.62	-6.61	-0.31	1.15e-10	Blood protein levels;
LUAD	cis	rs1497828	0.956	rs2815229	chr1:217535088	T/C	cg04411442	chr1:217543379	NA	-0.38	-6.92	-0.32	1.72e-11	Dialysis-related mortality;
LUAD	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg12311346	chr5:56204834	C5orf35	0.74	11.7	0.49	1.33e-27	Initial pursuit acceleration;
LUAD	trans	rs3858145	0.588	rs76854765	chr10:70037456	C/T	cg04882175	chr6:131122610	NA	-0.58	-6.96	-0.32	1.32e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg11062466	chr8:58055876	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs250585	0.920	rs11074564	chr16:23532809	G/T	cg00143387	chr16:23521605	GGA2	-0.63	-7.49	-0.34	4.01e-13	Egg allergy;
LUAD	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg01689657	chr7:91764605	CYP51A1	-0.31	-7.58	-0.35	2.2e-13	Breast cancer;
LUAD	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg02782426	chr3:40428986	ENTPD3	-0.31	-6.53	-0.3	1.93e-10	Renal cell carcinoma;
LUAD	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg03709012	chr19:19516395	GATAD2A	0.53	7.05	0.32	7.15e-12	Nonalcoholic fatty liver disease;
LUAD	cis	rs9392556	0.829	rs7166	chr6:4116262	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.42	-7.3	-0.33	1.43e-12	Blood metabolite levels;
LUAD	cis	rs1003719	0.751	rs55740803	chr21:38542761	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.44	-0.38	5.25e-16	Eye color traits;
LUAD	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg18230493	chr5:56204884	C5orf35	-0.72	-10.58	-0.46	2.26e-23	Initial pursuit acceleration;
LUAD	trans	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg01620082	chr3:125678407	NA	-0.65	-7.66	-0.35	1.32e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg02176678	chr2:219576539	TTLL4	0.67	13.67	0.55	1.75e-35	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.47	8.44	0.38	5.16e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg07936489	chr17:37558343	FBXL20	-0.44	-6.95	-0.32	1.42e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg16989719	chr2:238392110	NA	-0.36	-7.43	-0.34	5.9e-13	Prostate cancer;
LUAD	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.83	-0.32	2.95e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg13918804	chr1:2043761	PRKCZ	0.4	6.76	0.31	4.47e-11	Height;
LUAD	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg15704280	chr7:45808275	SEPT13	-1.07	-24.81	-0.77	1.63e-84	Height;
LUAD	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08109568	chr15:31115862	NA	0.73	12.85	0.53	3.94e-32	Huntington's disease progression;
LUAD	cis	rs12618769	0.597	rs11888595	chr2:99084708	T/G	cg10123293	chr2:99228465	UNC50	0.47	8.35	0.38	9.92e-16	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11809207	1.000	rs55695238	chr1:26521931	C/G	cg00300879	chr1:26503847	CNKSR1	0.28	6.87	0.32	2.34e-11	Height;
LUAD	cis	rs2455799	0.964	rs6442548	chr3:15805165	A/G	cg16303742	chr3:15540471	COLQ	-0.38	-6.61	-0.31	1.15e-10	Mean platelet volume;
LUAD	trans	rs564343	0.545	rs576836	chr11:65823569	G/C	cg26701943	chr11:108369231	KDELC2	-0.49	-7.88	-0.36	2.75e-14	Obesity (early onset extreme);
LUAD	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg15017067	chr4:17643749	FAM184B	0.35	6.9	0.32	1.97e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs78487399	0.808	rs74608713	chr2:43763539	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-6.85	-0.32	2.61e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg22907277	chr7:1156413	C7orf50	0.52	8.72	0.39	6.57e-17	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg26554054	chr8:600488	NA	0.82	8.4	0.38	6.88e-16	IgG glycosylation;
LUAD	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg18944383	chr4:111397179	ENPEP	0.39	7.82	0.36	4.39e-14	Height;
LUAD	cis	rs7945718	0.806	rs7927346	chr11:12835835	C/T	cg25843174	chr11:12811716	TEAD1	0.22	6.75	0.31	4.89e-11	Educational attainment (years of education);
LUAD	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg04398451	chr17:18023971	MYO15A	0.66	11.89	0.5	2.59e-28	Total body bone mineral density;
LUAD	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12292205	chr6:26970375	C6orf41	-0.47	-6.53	-0.3	1.88e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs240764	0.817	rs2036052	chr6:101154909	G/A	cg09795085	chr6:101329169	ASCC3	-0.43	-7.39	-0.34	7.89e-13	Neuroticism;
LUAD	cis	rs796825	0.613	rs11554681	chr3:120045966	C/T	cg21790991	chr3:120137480	FSTL1	0.39	7.0	0.32	9.8e-12	HIV-1 susceptibility;
LUAD	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg27124370	chr19:33622961	WDR88	0.46	7.15	0.33	3.92e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg02038168	chr22:39784481	NA	-0.58	-10.61	-0.46	1.74e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	8.75e-12	Aortic root size;
LUAD	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg10523679	chr1:76189770	ACADM	0.85	15.39	0.6	9.47e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12681287	0.640	rs10095498	chr8:87425651	C/T	cg00550725	chr8:87521180	FAM82B	-0.46	-6.62	-0.31	1.08e-10	Caudate activity during reward;
LUAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10899021	0.920	rs11236174	chr11:74334201	G/A	cg25880958	chr11:74394337	NA	-0.62	-8.5	-0.38	3.36e-16	Response to metformin (IC50);
LUAD	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.21	0.37	2.66e-15	Platelet count;
LUAD	cis	rs7833986	1.000	rs34404111	chr8:57099190	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.76	10.2	0.44	5.57e-22	Height;
LUAD	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg02696790	chr15:75250997	RPP25	0.36	6.7	0.31	6.77e-11	Breast cancer;
LUAD	trans	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg24644049	chr4:85504048	CDS1	0.85	7.17	0.33	3.38e-12	Skin colour saturation;
LUAD	cis	rs990171	0.538	rs4851599	chr2:103116020	C/T	cg03938978	chr2:103052716	IL18RAP	0.33	6.47	0.3	2.72e-10	Lymphocyte counts;
LUAD	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg02734326	chr4:10020555	SLC2A9	0.44	7.65	0.35	1.4e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.72	-11.82	-0.5	4.79e-28	Primary sclerosing cholangitis;
LUAD	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg07741184	chr6:167504864	NA	-0.31	-7.48	-0.34	4.22e-13	Crohn's disease;
LUAD	cis	rs1232027	0.656	rs1650670	chr5:79960849	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs7589342	0.839	rs10192144	chr2:106439854	A/G	cg16077055	chr2:106428750	NCK2	0.35	6.37	0.3	4.84e-10	Addiction;
LUAD	cis	rs6840360	0.550	rs4696269	chr4:152481704	T/A	cg22705602	chr4:152727874	NA	-0.4	-6.95	-0.32	1.36e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg06740227	chr12:86229804	RASSF9	0.46	7.94	0.36	1.78e-14	Major depressive disorder;
LUAD	cis	rs7731657	0.537	rs6595972	chr5:130325265	T/G	cg08523029	chr5:130500466	HINT1	0.54	7.2	0.33	2.78e-12	Fasting plasma glucose;
LUAD	cis	rs9322817	0.691	rs7743022	chr6:105170381	G/T	cg02098413	chr6:105308735	HACE1	-0.42	-8.97	-0.4	9.55e-18	Thyroid stimulating hormone;
LUAD	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.63	0.31	9.95e-11	Parkinson's disease;
LUAD	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg02782426	chr3:40428986	ENTPD3	-0.38	-8.08	-0.37	6.62e-15	Renal cell carcinoma;
LUAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03188948	chr7:1209495	NA	0.5	8.88	0.4	1.9e-17	Longevity;Endometriosis;
LUAD	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.47e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg10729496	chr3:10149963	C3orf24	0.55	9.2	0.41	1.69e-18	Alzheimer's disease;
LUAD	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg10518543	chr12:38710700	ALG10B	-0.43	-7.08	-0.33	5.98e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg00495681	chr13:53174319	NA	0.46	8.07	0.37	7.39e-15	Lewy body disease;
LUAD	cis	rs2486012	0.826	rs1008137	chr1:44420754	A/G	cg12908607	chr1:44402522	ARTN	-0.51	-6.66	-0.31	8.42e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs11811982	0.655	rs114683993	chr1:227383157	G/A	cg24860534	chr1:227506868	CDC42BPA	0.67	7.33	0.34	1.22e-12	Optic disc area;
LUAD	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.42	-7.61	-0.35	1.84e-13	Tonsillectomy;
LUAD	cis	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.38	-0.34	8.66e-13	Resting heart rate;
LUAD	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg18811423	chr2:55921094	PNPT1	0.57	9.59	0.42	7.68e-20	Metabolic syndrome;
LUAD	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.83	-0.32	3e-11	Retinal vascular caliber;
LUAD	cis	rs8014671	0.597	rs8021180	chr14:70783943	A/G	cg25576086	chr14:70833871	SYNJ2BP	-0.37	-8.61	-0.39	1.46e-16	Prostate cancer;
LUAD	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg08742575	chr21:47604166	C21orf56	0.44	7.23	0.33	2.24e-12	Testicular germ cell tumor;
LUAD	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg16989719	chr2:238392110	NA	-0.36	-7.83	-0.36	4.03e-14	Prostate cancer;
LUAD	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg07685180	chr8:600429	NA	-0.95	-8.3	-0.37	1.43e-15	IgG glycosylation;
LUAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.68	-13.11	-0.54	3.36e-33	Longevity;Endometriosis;
LUAD	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg05665937	chr4:1216051	CTBP1	-0.46	-6.82	-0.31	3.25e-11	Longevity;
LUAD	cis	rs597539	0.690	rs1272609	chr11:68618182	T/C	cg06028808	chr11:68637592	NA	0.5	8.19	0.37	3.22e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg15226275	chr6:116381976	FRK	0.23	7.52	0.34	3.42e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg11584989	chr19:19387371	SF4	0.35	6.4	0.3	4.02e-10	Tonsillectomy;
LUAD	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg02423579	chr7:2872169	GNA12	-0.5	-8.35	-0.38	9.65e-16	Height;
LUAD	cis	rs3784262	1.000	rs3204689	chr15:58246802	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.44	-9.0	-0.4	7.74e-18	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9399401	0.710	rs10484733	chr6:142710988	C/G	cg03128060	chr6:142623767	GPR126	0.53	10.5	0.45	4.43e-23	Chronic obstructive pulmonary disease;
LUAD	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2280018	0.609	rs2941253	chr16:15173746	G/A	cg27102117	chr16:15229624	NA	0.72	13.42	0.55	1.89e-34	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs1788820	1.000	rs1788820	chr18:21101944	A/G	cg14672496	chr18:21087552	C18orf8	0.35	6.81	0.31	3.45e-11	Body mass index;
LUAD	trans	rs853679	0.546	rs35017208	chr6:28345282	C/T	cg06606381	chr12:133084897	FBRSL1	-1.23	-10.74	-0.46	5.94e-24	Depression;
LUAD	cis	rs11650175	0.835	rs11079584	chr17:63756638	T/C	cg07283582	chr17:63770753	CCDC46	0.4	7.95	0.36	1.76e-14	Chin dimples;
LUAD	cis	rs2274273	0.624	rs67386901	chr14:55757364	C/T	cg04306507	chr14:55594613	LGALS3	0.4	7.85	0.36	3.43e-14	Protein biomarker;
LUAD	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg19041857	chr6:27730383	NA	-0.44	-7.61	-0.35	1.82e-13	Parkinson's disease;
LUAD	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs9296092	0.538	rs9461882	chr6:33520221	A/C	cg13560919	chr6:33536144	NA	-0.87	-15.54	-0.6	2.02e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs72928364	0.860	rs17219986	chr3:100799670	G/A	cg10123952	chr3:100791384	NA	0.67	7.61	0.35	1.77e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg18240062	chr17:79603768	NPLOC4	0.36	6.41	0.3	3.81e-10	Eye color traits;
LUAD	cis	rs240764	0.717	rs6916468	chr6:101160325	G/C	cg09795085	chr6:101329169	ASCC3	-0.41	-7.19	-0.33	2.96e-12	Neuroticism;
LUAD	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg12863693	chr15:85201151	NMB	0.36	6.48	0.3	2.49e-10	Schizophrenia;
LUAD	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg06022373	chr22:39101656	GTPBP1	0.47	7.49	0.34	4.02e-13	Menopause (age at onset);
LUAD	cis	rs3761218	1.000	rs3761219	chr20:3776368	T/C	cg02737268	chr20:3780182	CDC25B	0.29	6.47	0.3	2.77e-10	Bipolar disorder;
LUAD	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg14668632	chr7:2872130	GNA12	-0.48	-8.67	-0.39	9.41e-17	Height;
LUAD	cis	rs8113142	0.550	rs66459748	chr19:29131294	T/G	cg12756686	chr19:29218302	NA	0.42	6.55	0.3	1.7e-10	Femoral neck bone geometry and menarche (age at onset);
LUAD	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg07570687	chr10:102243282	WNT8B	0.45	6.87	0.32	2.28e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs3784262	0.765	rs11631127	chr15:58270009	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.4	-7.92	-0.36	2.1e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg24733560	chr20:60626293	TAF4	0.47	8.42	0.38	5.78e-16	Body mass index;
LUAD	cis	rs943466	1.000	rs12524835	chr6:33730843	G/C	cg16010596	chr6:33739607	LEMD2	-0.36	-6.63	-0.31	1.05e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-8.01	-0.36	1.09e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg09796270	chr17:17721594	SREBF1	0.38	7.56	0.34	2.61e-13	Total body bone mineral density;
LUAD	cis	rs7267979	0.586	rs6050445	chr20:25195394	C/T	cg08601574	chr20:25228251	PYGB	0.37	6.71	0.31	6.09e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg09436375	chr6:42928200	GNMT	-0.27	-7.47	-0.34	4.68e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg09184832	chr6:79620586	NA	-0.48	-9.11	-0.4	3.4e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg02158880	chr13:53174818	NA	-0.6	-10.48	-0.45	5.34e-23	Lewy body disease;
LUAD	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg07936489	chr17:37558343	FBXL20	0.44	6.93	0.32	1.55e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.66	-0.31	8.51e-11	Crohn's disease;
LUAD	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg03929089	chr4:120376271	NA	-0.96	-19.52	-0.69	5.95e-61	Height;
LUAD	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg03467027	chr4:99064603	C4orf37	0.41	6.8	0.31	3.52e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg21775007	chr8:11205619	TDH	-0.36	-6.44	-0.3	3.19e-10	Neuroticism;
LUAD	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg27068330	chr11:65405492	SIPA1	-0.77	-12.65	-0.52	2.53e-31	Acne (severe);
LUAD	cis	rs11771526	0.901	rs34376799	chr7:32316932	T/C	cg27511599	chr7:32358540	NA	0.5	6.49	0.3	2.37e-10	Body mass index;
LUAD	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg02505535	chr3:195703920	SDHAP1	-0.36	-7.4	-0.34	7.32e-13	Pancreatic cancer;
LUAD	trans	rs12200782	0.790	rs72840194	chr6:26361369	A/G	cg08851530	chr6:28072375	NA	0.74	6.57	0.3	1.51e-10	Small cell lung carcinoma;
LUAD	cis	rs1816752	0.870	rs7981337	chr13:25015053	A/C	cg02811702	chr13:24901961	NA	0.45	7.88	0.36	2.72e-14	Obesity-related traits;
LUAD	cis	rs35883536	1.000	rs4907918	chr1:101094609	A/G	cg06223162	chr1:101003688	GPR88	-0.34	-6.35	-0.3	5.54e-10	Monocyte count;
LUAD	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg09137382	chr11:130731461	NA	0.41	7.44	0.34	5.66e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg04731861	chr2:219085781	ARPC2	0.23	7.13	0.33	4.31e-12	Colorectal cancer;
LUAD	cis	rs600626	0.636	rs11236515	chr11:75451411	A/G	cg24262691	chr11:75473276	NA	0.58	7.54	0.34	2.92e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg18827107	chr12:86230957	RASSF9	-0.54	-9.6	-0.42	7.19e-20	Major depressive disorder;
LUAD	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.8	-0.35	4.86e-14	Schizophrenia;
LUAD	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg19041857	chr6:27730383	NA	-0.44	-7.56	-0.34	2.56e-13	Parkinson's disease;
LUAD	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg00898013	chr13:113819073	PROZ	0.69	12.23	0.51	1.18e-29	Platelet distribution width;
LUAD	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.51	-10.66	-0.46	1.13e-23	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg07917127	chr4:99064746	C4orf37	0.39	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6840360	0.967	rs7667197	chr4:152613952	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.63	-0.31	1.02e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg27539214	chr16:67997921	SLC12A4	0.5	6.94	0.32	1.47e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg01251360	chr16:68772225	CDH1	-0.3	-9.2	-0.41	1.7e-18	Colorectal cancer;
LUAD	cis	rs6906287	0.647	rs11755121	chr6:118828124	G/C	cg21191810	chr6:118973309	C6orf204	0.48	9.32	0.41	6.37e-19	Electrocardiographic conduction measures;
LUAD	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg25894440	chr7:65020034	NA	0.61	6.37	0.3	4.96e-10	Diabetic kidney disease;
LUAD	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg15309053	chr8:964076	NA	0.46	10.33	0.45	1.93e-22	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.88	-0.32	2.23e-11	Diabetic kidney disease;
LUAD	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02788857	chr8:22132959	PIWIL2	0.54	10.1	0.44	1.24e-21	Hypertriglyceridemia;
LUAD	trans	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg11693508	chr17:37793320	STARD3	0.49	7.2	0.33	2.75e-12	Neuroticism;
LUAD	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg12011299	chr4:100065546	ADH4	0.76	15.55	0.6	1.92e-43	Alcohol dependence;
LUAD	cis	rs12530845	0.524	rs7795267	chr7:135308455	C/G	cg23117316	chr7:135346802	PL-5283	-0.51	-8.39	-0.38	7.38e-16	Red blood cell traits;
LUAD	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	6.76	0.31	4.58e-11	Lung cancer in ever smokers;
LUAD	cis	rs34638657	0.732	rs62045964	chr16:82200920	T/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.95	-0.32	1.43e-11	Lung adenocarcinoma;
LUAD	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.91	9.5	0.42	1.6e-19	Initial pursuit acceleration;
LUAD	cis	rs501916	1.000	rs586118	chr15:48049776	C/T	cg16110827	chr15:48056943	SEMA6D	-0.34	-6.72	-0.31	5.76e-11	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs9811920	0.931	rs7629487	chr3:99860401	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.61	11.23	0.48	8.32e-26	Axial length;
LUAD	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg00666640	chr1:248458726	OR2T12	0.32	7.58	0.35	2.28e-13	Common traits (Other);
LUAD	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.69	0.39	8e-17	Parkinson's disease;
LUAD	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg16447950	chr5:562315	NA	-0.38	-7.11	-0.33	5.09e-12	Obesity-related traits;
LUAD	cis	rs4702	0.611	rs1894401	chr15:91429042	C/T	cg05469396	chr15:91419421	FURIN	0.46	7.86	0.36	3.27e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg22467129	chr15:76604101	ETFA	-0.47	-7.84	-0.36	3.72e-14	Blood metabolite levels;
LUAD	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.78	-0.35	5.45e-14	Blood trace element (Zn levels);
LUAD	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12667521	chr19:29218732	NA	0.63	9.41	0.42	3.11e-19	Methadone dose in opioid dependence;
LUAD	cis	rs4713675	0.584	rs3227	chr6:33662295	G/C	cg14003231	chr6:33640908	ITPR3	0.49	9.33	0.41	6.04e-19	Plateletcrit;
LUAD	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg22079354	chr11:130786696	SNX19	0.37	6.38	0.3	4.67e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg08132940	chr7:1081526	C7orf50	-0.79	-10.64	-0.46	1.34e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg13126279	chr21:47581558	C21orf56	-0.44	-7.56	-0.35	2.46e-13	Testicular germ cell tumor;
LUAD	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg19729930	chr2:74357872	NA	1.01	18.77	0.67	1.21e-57	Gestational age at birth (maternal effect);
LUAD	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs1873147	0.569	rs8029221	chr15:63308583	C/T	cg12160578	chr15:63334699	TPM1	0.52	7.9	0.36	2.5e-14	Orofacial clefts;
LUAD	trans	rs2018683	0.707	rs917215	chr7:28971367	C/T	cg19402173	chr7:128379420	CALU	-0.51	-8.13	-0.37	4.96e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg02228675	chr17:40259724	DHX58	-0.45	-7.12	-0.33	4.54e-12	Fibrinogen levels;
LUAD	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg04287289	chr16:89883240	FANCA	0.64	6.39	0.3	4.45e-10	Skin colour saturation;
LUAD	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg06263672	chr7:65235340	NA	-0.51	-6.69	-0.31	6.94e-11	Aortic root size;
LUAD	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22496380	chr5:211416	CCDC127	-1.22	-15.6	-0.6	1.12e-43	Breast cancer;
LUAD	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	6.8	0.31	3.57e-11	Cognitive test performance;
LUAD	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg08601574	chr20:25228251	PYGB	0.46	8.42	0.38	6.11e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs73198271	0.603	rs546606	chr8:8595843	A/G	cg01851573	chr8:8652454	MFHAS1	0.43	7.75	0.35	6.79e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.31	6.49	0.3	2.43e-10	Menopause (age at onset);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg11197563	chr11:129872003	NCRNA00167;PRDM10	-0.63	-6.41	-0.3	3.95e-10	Type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.44	-0.42	2.51e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg06346307	chr22:19949965	COMT	0.38	7.44	0.34	5.58e-13	Blood metabolite levels;
LUAD	cis	rs12791968	0.765	rs2279359	chr11:44999605	A/G	cg11846598	chr11:44996168	LOC221122	0.6	9.03	0.4	6.11e-18	Inhibitory control;
LUAD	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg24813613	chr7:1882135	MAD1L1	-0.44	-7.05	-0.32	7.38e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.35	7.13	0.33	4.49e-12	Depression;
LUAD	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18876405	chr7:65276391	NA	-0.42	-6.7	-0.31	6.62e-11	Aortic root size;
LUAD	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg04036182	chr15:45458818	NA	-0.42	-7.37	-0.34	8.75e-13	Glomerular filtration rate;
LUAD	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg05725404	chr16:58534157	NDRG4	-0.7	-7.22	-0.33	2.4e-12	Schizophrenia;
LUAD	cis	rs9581857	0.547	rs9579086	chr13:28058537	T/A	cg22138327	chr13:27999177	GTF3A	0.81	9.05	0.4	5.09e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg20119798	chr7:94954144	PON1	-0.48	-6.53	-0.3	1.94e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.09	0.37	6.18e-15	Menopause (age at onset);
LUAD	trans	rs9929218	0.954	rs60302411	chr16:68824220	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.72	-0.53	1.32e-31	Colorectal cancer;
LUAD	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.4	-6.9	-0.32	1.88e-11	Prudent dietary pattern;
LUAD	cis	rs7640424	0.649	rs35710439	chr3:107913059	C/A	cg09227934	chr3:107805635	CD47	-0.48	-8.5	-0.38	3.19e-16	Body mass index;
LUAD	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg03929089	chr4:120376271	NA	-0.97	-20.33	-0.7	1.38e-64	Height;
LUAD	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg25319279	chr11:5960081	NA	-0.39	-6.89	-0.32	2.06e-11	DNA methylation (variation);
LUAD	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg25251562	chr2:3704773	ALLC	-0.51	-8.44	-0.38	4.96e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs3815700	1.000	rs8104726	chr19:33094675	G/A	cg02997394	chr19:33096574	ANKRD27	0.66	8.61	0.39	1.5e-16	Eosinophilic esophagitis;
LUAD	trans	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg11062466	chr8:58055876	NA	0.45	6.47	0.3	2.66e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg06131755	chr6:160182447	ACAT2	0.43	6.48	0.3	2.57e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg05132306	chr1:1846340	CALML6	-0.35	-7.42	-0.34	6.42e-13	Body mass index;
LUAD	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg23254163	chr1:152506842	NA	0.25	6.96	0.32	1.31e-11	Hair morphology;
LUAD	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.6	9.72	0.43	2.78e-20	Cognitive ability;
LUAD	cis	rs11958404	0.860	rs6868830	chr5:157442187	T/C	cg05962755	chr5:157440814	NA	0.71	9.95	0.44	4.36e-21	IgG glycosylation;
LUAD	cis	rs6761276	0.899	rs6759676	chr2:113836348	A/G	cg10479672	chr2:113810641	IL1F8	0.37	7.6	0.35	1.91e-13	Protein quantitative trait loci;
LUAD	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg10295955	chr4:187884368	NA	-1.11	-27.49	-0.8	3.64e-96	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg14779329	chr11:130786720	SNX19	0.39	6.77	0.31	4.23e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg11822812	chr5:140052017	DND1	0.37	6.45	0.3	3.11e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08048268	chr3:133502702	NA	-0.47	-9.63	-0.42	5.66e-20	Iron status biomarkers;
LUAD	cis	rs908922	0.605	rs3753448	chr1:152486407	A/C	cg20991723	chr1:152506922	NA	0.34	6.66	0.31	8.45e-11	Hair morphology;
LUAD	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg08125733	chr17:73851984	WBP2	0.55	8.3	0.37	1.43e-15	Psoriasis;
LUAD	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg20476274	chr7:133979776	SLC35B4	0.86	17.56	0.65	3.17e-52	Mean platelet volume;
LUAD	cis	rs375066	0.736	rs62114649	chr19:44416567	T/C	cg12072164	chr19:44306565	LYPD5	-0.32	-6.5	-0.3	2.31e-10	Breast cancer;
LUAD	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg10295955	chr4:187884368	NA	-1.1	-25.54	-0.78	9.5e-88	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg03859395	chr2:55845619	SMEK2	0.75	13.89	0.56	2.01e-36	Metabolic syndrome;
LUAD	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg00271210	chr6:167070053	RPS6KA2	0.35	6.66	0.31	8.57e-11	Crohn's disease;
LUAD	trans	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg18187862	chr3:45730750	SACM1L	-0.55	-8.22	-0.37	2.48e-15	Primary sclerosing cholangitis;
LUAD	cis	rs55728055	0.661	rs55894054	chr22:31976299	T/C	cg01338084	chr22:32026380	PISD	0.89	6.89	0.32	1.98e-11	Age-related hearing impairment;
LUAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.71e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.77	0.53	8.05e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.74	-13.58	-0.55	3.91e-35	Menarche (age at onset);
LUAD	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.38	-0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs28735056	0.592	rs2277725	chr18:77694168	A/C	cg20368463	chr18:77673604	PQLC1	-0.58	-9.67	-0.43	4.13e-20	Schizophrenia;
LUAD	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg17177755	chr1:15930204	NA	0.44	7.18	0.33	3.09e-12	Systolic blood pressure;
LUAD	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg18252515	chr7:66147081	NA	-0.62	-6.77	-0.31	4.25e-11	Diabetic kidney disease;
LUAD	cis	rs9296095	0.796	rs3846855	chr6:33555877	G/A	cg14003231	chr6:33640908	ITPR3	0.68	11.66	0.49	1.92e-27	Platelet count;
LUAD	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg11663144	chr21:46675770	NA	-0.5	-8.51	-0.38	2.99e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3733418	0.929	rs7656863	chr4:165883244	T/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.5	-7.0	-0.32	1.02e-11	Obesity-related traits;
LUAD	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06112835	chr11:68658793	MRPL21	0.5	9.05	0.4	5.44e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg00484396	chr16:3507460	NAT15	0.71	12.45	0.52	1.57e-30	Tuberculosis;
LUAD	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg21171335	chr12:122356390	WDR66	0.79	14.27	0.57	5.23e-38	Mean corpuscular volume;
LUAD	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg13271783	chr10:134563150	INPP5A	-0.41	-6.74	-0.31	5.27e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg08280861	chr8:58055591	NA	0.67	8.78	0.39	4.22e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs220324	0.738	rs28655628	chr21:43578317	C/T	cg08841829	chr21:43638893	ABCG1	-0.53	-6.92	-0.32	1.65e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg03806693	chr22:41940476	POLR3H	-0.79	-11.15	-0.48	1.76e-25	Vitiligo;
LUAD	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg22920501	chr2:26401640	FAM59B	0.75	10.69	0.46	8.78e-24	Gut microbiome composition (summer);
LUAD	cis	rs68170813	0.559	rs10953530	chr7:106827796	A/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.76	-0.46	5.03e-24	Coronary artery disease;
LUAD	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg09796270	chr17:17721594	SREBF1	-0.43	-8.31	-0.37	1.33e-15	Total body bone mineral density;
LUAD	cis	rs9584850	0.874	rs3742136	chr13:99102607	C/T	cg20750642	chr13:99100586	FARP1	-0.32	-6.75	-0.31	4.74e-11	Neuroticism;
LUAD	cis	rs8040855	0.599	rs6496795	chr15:85725853	G/T	cg04831495	chr15:85060580	GOLGA6L5	0.45	7.8	0.35	5.05e-14	Bulimia nervosa;
LUAD	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg22681709	chr2:178499509	PDE11A	-0.55	-9.24	-0.41	1.2e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs889398	0.741	rs6499268	chr16:69906529	G/A	cg00738113	chr16:70207722	CLEC18C	-0.35	-6.94	-0.32	1.49e-11	Body mass index;
LUAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	7.12	0.33	4.78e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs600626	0.588	rs10899116	chr11:75476195	C/T	cg24262691	chr11:75473276	NA	0.59	7.57	0.35	2.38e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.02	-0.56	6.09e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg03806693	chr22:41940476	POLR3H	0.72	10.25	0.45	3.52e-22	Vitiligo;
LUAD	cis	rs977987	0.872	rs4888422	chr16:75470576	A/G	cg03315344	chr16:75512273	CHST6	0.63	13.37	0.55	2.97e-34	Dupuytren's disease;
LUAD	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26314531	chr2:26401878	FAM59B	0.73	9.8	0.43	1.44e-20	Mean corpuscular hemoglobin;
LUAD	cis	rs7274811	0.625	rs293727	chr20:31933064	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.45	6.52	0.3	2e-10	Height;
LUAD	cis	rs7932354	0.528	rs11039105	chr11:47157677	A/T	cg19486271	chr11:47235900	DDB2	0.43	6.75	0.31	4.86e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg04181038	chr4:183730758	NA	0.63	8.72	0.39	6.63e-17	Pediatric autoimmune diseases;
LUAD	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg25036284	chr2:26402008	FAM59B	-0.69	-10.13	-0.44	9.8e-22	Gut microbiome composition (summer);
LUAD	cis	rs4638749	0.677	rs6741222	chr2:108841082	A/G	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.42	-0.34	6.35e-13	Blood pressure;
LUAD	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg03732007	chr1:2071316	PRKCZ	-0.35	-6.66	-0.31	8.63e-11	Height;
LUAD	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg10909506	chr17:38081995	ORMDL3	0.39	7.06	0.32	7.01e-12	Self-reported allergy;
LUAD	cis	rs12912251	1.000	rs12903120	chr15:38988097	G/T	cg01338139	chr15:38987640	C15orf53	-0.6	-9.39	-0.42	3.9e-19	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg19346786	chr7:2764209	NA	-0.51	-10.94	-0.47	1.1e-24	Height;
LUAD	cis	rs8040855	0.599	rs6496791	chr15:85725659	C/T	cg04831495	chr15:85060580	GOLGA6L5	0.45	7.66	0.35	1.31e-13	Bulimia nervosa;
LUAD	cis	rs7098414	0.531	rs3844126	chr10:82019997	T/G	cg00277334	chr10:82204260	NA	-0.38	-6.49	-0.3	2.43e-10	Post bronchodilator FEV1;
LUAD	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7937890	0.559	rs2167160	chr11:14507449	C/A	cg22961513	chr11:14280813	SPON1	-0.37	-7.06	-0.32	6.82e-12	Mitochondrial DNA levels;
LUAD	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg00310523	chr12:86230176	RASSF9	0.36	7.36	0.34	9.42e-13	Major depressive disorder;
LUAD	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-7.73	-0.35	7.79e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs10785877	0.717	rs7848602	chr9:137120763	T/C	cg21243944	chr9:137118148	NA	-0.33	-6.8	-0.31	3.66e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LUAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg10729496	chr3:10149963	C3orf24	0.49	7.88	0.36	2.73e-14	Alzheimer's disease;
LUAD	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg02176678	chr2:219576539	TTLL4	0.65	13.12	0.54	3.22e-33	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2456568	0.802	rs10765639	chr11:93636194	G/A	cg26875233	chr11:93583750	C11orf90	-0.29	-6.39	-0.3	4.35e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs494562	0.892	rs617483	chr6:86124008	C/T	cg21730993	chr6:86159210	NT5E	0.7	7.81	0.36	4.54e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg24818145	chr4:99064322	C4orf37	0.46	7.21	0.33	2.65e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.57	-0.35	2.33e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg19774624	chr17:42201019	HDAC5	-0.41	-7.1	-0.33	5.41e-12	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs231513	0.906	rs11657450	chr17:42002464	C/T	cg26893861	chr17:41843967	DUSP3	0.67	7.27	0.33	1.71e-12	Cognitive function;
LUAD	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg11344533	chr11:111475393	SIK2	-0.36	-6.71	-0.31	6.18e-11	Primary sclerosing cholangitis;
LUAD	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs2535633	0.631	rs2710326	chr3:52995444	T/C	cg18404041	chr3:52824283	ITIH1	0.39	6.68	0.31	7.57e-11	Body mass index;
LUAD	cis	rs4077515	0.839	rs10781518	chr9:139300547	C/T	cg14019695	chr9:139328340	INPP5E	-0.36	-6.52	-0.3	2.05e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs28374715	0.532	rs28535540	chr15:41659277	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.1	-25.35	-0.78	7.02e-87	Ulcerative colitis;
LUAD	cis	rs853679	0.585	rs201004	chr6:27804934	T/C	cg08798685	chr6:27730294	NA	-0.45	-6.79	-0.31	3.83e-11	Depression;
LUAD	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg00316803	chr15:76480434	C15orf27	-0.4	-7.62	-0.35	1.63e-13	Blood metabolite levels;
LUAD	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg13393036	chr8:95962371	TP53INP1	-0.41	-9.83	-0.43	1.15e-20	Type 2 diabetes;
LUAD	trans	rs75804782	0.641	rs72983853	chr2:239324210	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	8.29	0.37	1.57e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg06740227	chr12:86229804	RASSF9	0.4	6.98	0.32	1.14e-11	Major depressive disorder;
LUAD	cis	rs9486719	1.000	rs2472887	chr6:96865437	A/G	cg06623918	chr6:96969491	KIAA0776	0.71	10.01	0.44	2.62e-21	Migraine;Coronary artery disease;
LUAD	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-8.99	-0.4	8.43e-18	Bipolar disorder;
LUAD	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg09455208	chr3:40491958	NA	0.65	14.05	0.56	4.49e-37	Renal cell carcinoma;
LUAD	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.23	0.37	2.37e-15	Menopause (age at onset);
LUAD	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg17264618	chr3:40429014	ENTPD3	-0.4	-9.24	-0.41	1.18e-18	Renal cell carcinoma;
LUAD	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg22823121	chr1:150693482	HORMAD1	0.45	9.05	0.4	5.36e-18	Tonsillectomy;
LUAD	cis	rs953387	0.910	rs10928558	chr2:136926222	T/C	cg05194412	chr2:137003533	NA	-0.43	-6.86	-0.32	2.44e-11	Arthritis (juvenile idiopathic);
LUAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	6.75	0.31	4.86e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg13606994	chr1:44402422	ARTN	-0.39	-7.33	-0.34	1.21e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs3106136	0.934	rs35995707	chr4:95167150	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.47	-0.34	4.78e-13	Capecitabine sensitivity;
LUAD	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg24112000	chr20:60950667	NA	-0.67	-9.88	-0.43	7.42e-21	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.98	-0.36	1.35e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.47	-0.38	4.1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs853679	0.546	rs200950	chr6:27835772	A/G	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.08	-0.37	6.63e-15	Depression;
LUAD	cis	rs4903604	0.560	rs4903605	chr14:78035619	C/T	cg18872420	chr14:78023429	SPTLC2	0.46	8.25	0.37	2.09e-15	Gut microbiome composition (winter);
LUAD	trans	rs1941687	0.527	rs2000945	chr18:31365336	A/G	cg13755796	chr4:20253514	NA	-0.4	-6.9	-0.32	1.9e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs758324	0.648	rs152126	chr5:131383667	A/C	cg06307176	chr5:131281290	NA	-0.41	-6.84	-0.32	2.76e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg17178900	chr1:205818956	PM20D1	-0.65	-12.87	-0.53	3.31e-32	Monocyte percentage of white cells;
LUAD	cis	rs7589728	0.925	rs80065975	chr2:88502758	G/A	cg04511125	chr2:88470314	THNSL2	0.79	8.37	0.38	8.39e-16	Plasma clusterin levels;
LUAD	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg17724175	chr1:150552817	MCL1	0.33	7.64	0.35	1.46e-13	Melanoma;
LUAD	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg26536354	chr8:144654954	C8orf73	0.62	6.71	0.31	6.36e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg23954153	chr1:44402353	ARTN	-0.37	-6.95	-0.32	1.4e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.78	0.39	4.09e-17	Parkinson's disease;
LUAD	cis	rs8060686	0.925	rs9928531	chr16:67833171	T/C	cg26727032	chr16:67993705	SLC12A4	-0.51	-8.36	-0.38	9.05e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg11941060	chr3:133502564	NA	-0.54	-8.64	-0.39	1.19e-16	Iron status biomarkers;
LUAD	cis	rs9549328	0.731	rs7983602	chr13:113620482	A/G	cg17524180	chr13:113633600	MCF2L	-0.34	-6.91	-0.32	1.78e-11	Systolic blood pressure;
LUAD	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg08999081	chr20:33150536	PIGU	0.43	7.75	0.35	6.73e-14	Coronary artery disease;
LUAD	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg24578937	chr1:2090814	PRKCZ	0.59	12.3	0.51	6.05e-30	Height;
LUAD	cis	rs12200560	0.505	rs211164	chr6:97068140	G/T	cg06623918	chr6:96969491	KIAA0776	0.45	6.75	0.31	4.81e-11	Coronary heart disease;
LUAD	cis	rs9462027	0.628	rs9469917	chr6:34831369	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.0	-0.4	7.98e-18	Systemic lupus erythematosus;
LUAD	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.72	-13.28	-0.54	6.79e-34	Menarche (age at onset);
LUAD	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg23625390	chr15:77176239	SCAPER	-0.46	-7.49	-0.34	4.05e-13	Blood metabolite levels;
LUAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg26354017	chr1:205819088	PM20D1	0.79	16.35	0.62	6.55e-47	Menarche (age at onset);
LUAD	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.3	-7.64	-0.35	1.46e-13	Total body bone mineral density;
LUAD	cis	rs914187	1.000	rs914187	chr21:42619749	A/G	cg21268422	chr21:42620091	BACE2	0.37	7.13	0.33	4.48e-12	Body mass index;
LUAD	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg06627628	chr2:24431161	ITSN2	-0.69	-10.98	-0.47	7.72e-25	Asthma;
LUAD	cis	rs7512552	0.966	rs2147324	chr1:150255587	T/C	cg15654264	chr1:150340011	RPRD2	-0.43	-7.85	-0.36	3.56e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs12517041	1.000	rs1428625	chr5:23290664	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.49	-0.3	2.44e-10	Calcium levels;
LUAD	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg24558204	chr6:135376177	HBS1L	0.48	8.16	0.37	3.84e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7592578	0.603	rs12476782	chr2:191472880	G/A	cg27211696	chr2:191398769	TMEM194B	-0.63	-8.46	-0.38	4.54e-16	Diastolic blood pressure;
LUAD	trans	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg21659725	chr3:3221576	CRBN	0.44	7.26	0.33	1.83e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs7246760	0.867	rs57999229	chr19:9817357	C/T	cg02900749	chr2:68251473	NA	-0.6	-6.63	-0.31	1.04e-10	Pursuit maintenance gain;
LUAD	cis	rs9837602	1.000	rs62285478	chr3:99822135	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	9.32	0.41	6.32e-19	Breast cancer;
LUAD	cis	rs12210905	0.688	rs79395596	chr6:27490796	C/T	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	trans	rs747782	0.537	rs10838835	chr11:48246457	C/T	cg15704280	chr7:45808275	SEPT13	-0.53	-6.54	-0.3	1.82e-10	Intraocular pressure;
LUAD	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg15181151	chr6:150070149	PCMT1	0.36	6.94	0.32	1.45e-11	Lung cancer;
LUAD	cis	rs9426691	1	rs9426691	chr1:23484904	A/G	cg12483005	chr1:23474871	LUZP1	0.63	10.76	0.46	4.86e-24	Coenzyme Q10 levels;
LUAD	cis	rs2882667	0.893	rs10054796	chr5:138294344	G/A	cg04439458	chr5:138467593	SIL1	-0.38	-6.95	-0.32	1.43e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg20300514	chr1:2120985	C1orf86;LOC100128003	0.36	6.35	0.3	5.56e-10	Height;
LUAD	cis	rs9354308	0.899	rs2802058	chr6:66550787	T/G	cg07460842	chr6:66804631	NA	0.51	7.59	0.35	2.08e-13	Metabolite levels;
LUAD	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.78	0.39	4.07e-17	Menopause (age at onset);
LUAD	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg25482853	chr8:67687455	SGK3	1.13	17.37	0.65	2.16e-51	Lung disease severity in cystic fibrosis;
LUAD	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg06618935	chr21:46677482	NA	-0.51	-10.35	-0.45	1.55e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg07157834	chr1:205819609	PM20D1	0.69	13.02	0.53	8.13e-33	Monocyte percentage of white cells;
LUAD	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg19912559	chr1:40204330	PPIE	0.57	9.66	0.43	4.34e-20	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg05340658	chr4:99064831	C4orf37	0.53	9.13	0.41	2.9e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12908161	0.959	rs61074241	chr15:85333396	C/T	cg12863693	chr15:85201151	NMB	0.41	7.32	0.34	1.24e-12	Schizophrenia;
LUAD	trans	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg07817883	chr1:32538562	TMEM39B	-0.51	-7.05	-0.32	7.34e-12	Monocyte percentage of white cells;
LUAD	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg24846343	chr22:24311635	DDTL	0.48	7.73	0.35	7.8500000000000006e-14	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs834811	0.829	rs10252049	chr7:135903178	G/A	cg01726295	chr7:135938950	NA	-0.27	-6.64	-0.31	9.88e-11	Post-traumatic stress disorder;
LUAD	cis	rs7677751	0.806	rs1800810	chr4:55094031	C/G	cg17187183	chr4:55093834	PDGFRA	0.51	8.63	0.39	1.25e-16	Corneal astigmatism;
LUAD	cis	rs6500395	1.000	rs9931737	chr16:48623539	C/T	cg04672837	chr16:48644449	N4BP1	0.38	6.55	0.3	1.67e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.3	6.69	0.31	7.06e-11	Systemic lupus erythematosus;
LUAD	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg12160578	chr15:63334699	TPM1	-0.36	-6.71	-0.31	6.17e-11	Platelet count;
LUAD	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg07917127	chr4:99064746	C4orf37	0.39	6.57	0.3	1.5e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg08999081	chr20:33150536	PIGU	0.48	9.23	0.41	1.31e-18	Coronary artery disease;
LUAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02359409	chr6:42947317	PEX6	-0.38	-6.77	-0.31	4.36e-11	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg19622623	chr12:86230825	RASSF9	0.42	7.49	0.34	3.93e-13	Major depressive disorder;
LUAD	cis	rs7809950	0.954	rs11977187	chr7:107210383	C/T	cg23024343	chr7:107201750	COG5	0.73	11.93	0.5	1.72e-28	Coronary artery disease;
LUAD	cis	rs870825	0.698	rs2696046	chr4:185599972	G/A	cg04058563	chr4:185651563	MLF1IP	-0.81	-10.91	-0.47	1.39e-24	Blood protein levels;
LUAD	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg01028140	chr2:1542097	TPO	-0.56	-7.49	-0.34	4.02e-13	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg11301795	chr4:187892539	NA	-0.76	-15.18	-0.59	7.25e-42	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs35740288	0.731	rs12898964	chr15:86161277	G/A	cg13263323	chr15:86062960	AKAP13	-0.44	-7.08	-0.33	6.03e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg26384229	chr12:38710491	ALG10B	0.47	7.63	0.35	1.56e-13	Bladder cancer;
LUAD	cis	rs78761021	0.755	rs17681788	chr17:9794415	C/T	cg26853458	chr17:9805074	RCVRN	0.38	7.02	0.32	9.07e-12	Type 2 diabetes;
LUAD	cis	rs9581857	0.725	rs9581853	chr13:28016236	T/C	cg22138327	chr13:27999177	GTF3A	0.9	10.53	0.46	3.61e-23	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.32	6.54	0.3	1.77e-10	Parkinson's disease;
LUAD	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg01528321	chr10:82214614	TSPAN14	0.65	10.39	0.45	1.09e-22	Post bronchodilator FEV1;
LUAD	cis	rs4604732	0.631	rs12031694	chr1:247623653	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.43	7.17	0.33	3.35e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs727505	0.789	rs4731233	chr7:124736291	C/T	cg23710748	chr7:124431027	NA	-0.42	-8.57	-0.38	2.02e-16	Lewy body disease;
LUAD	trans	rs208520	0.874	rs208481	chr6:66922636	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-14.26	-0.57	5.72e-38	Exhaled nitric oxide output;
LUAD	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg18827107	chr12:86230957	RASSF9	-0.65	-12.49	-0.52	1.06e-30	Major depressive disorder;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg26668828	chr6:292823	DUSP22	-0.8	-14.28	-0.57	5.06e-38	Menopause (age at onset);
LUAD	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	3.96e-11	Parkinson's disease;
LUAD	cis	rs3820068	0.603	rs6429753	chr1:15900537	A/G	cg16988262	chr1:15930761	NA	0.44	6.52	0.3	1.95e-10	Systolic blood pressure;
LUAD	cis	rs9902453	0.967	rs12450956	chr17:28529025	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.3	0.37	1.43e-15	Coffee consumption (cups per day);
LUAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs4072705	1.000	rs7032937	chr9:127338173	C/A	cg13476313	chr9:127244764	NR5A1	0.32	7.55	0.34	2.67e-13	Menarche (age at onset);
LUAD	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.5	0.58	5.66e-39	Schizophrenia;
LUAD	cis	rs2742417	1.000	rs2742436	chr3:45741397	T/C	cg10512202	chr3:45649293	LIMD1	0.38	6.84	0.32	2.8e-11	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg21984481	chr17:79567631	NPLOC4	-0.54	-11.55	-0.49	5.3e-27	Eye color traits;
LUAD	cis	rs600626	0.578	rs10793126	chr11:75453982	C/T	cg24262691	chr11:75473276	NA	-0.6	-7.96	-0.36	1.64e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs68170813	0.559	rs77150993	chr7:106817100	G/T	cg23024343	chr7:107201750	COG5	0.49	7.09	0.33	5.65e-12	Coronary artery disease;
LUAD	cis	rs7870753	0.529	rs10760999	chr9:99174951	G/A	cg13563390	chr9:99253610	HABP4	-0.38	-6.36	-0.3	5.21e-10	Height;
LUAD	cis	rs2479724	0.870	rs7766817	chr6:41918104	T/A	cg17623882	chr6:41773611	USP49	-0.57	-10.09	-0.44	1.36e-21	Menarche (age at onset);
LUAD	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26314531	chr2:26401878	FAM59B	-0.68	-10.11	-0.44	1.12e-21	Gut microbiome composition (summer);
LUAD	cis	rs6495122	0.658	rs12909307	chr15:75061929	A/G	cg14664628	chr15:75095509	CSK	-0.5	-8.3	-0.37	1.43e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg00271210	chr6:167070053	RPS6KA2	0.34	6.6	0.31	1.27e-10	Crohn's disease;
LUAD	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.27	-6.68	-0.31	7.61e-11	Coronary artery disease;
LUAD	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg21017887	chr14:105400489	NA	0.73	13.43	0.55	1.71e-34	Rheumatoid arthritis;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg16266895	chr12:101674004	UTP20	0.4	6.6	0.31	1.24e-10	Bilirubin levels;
LUAD	cis	rs7274811	0.688	rs56234419	chr20:32086447	C/T	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.49	-7.31	-0.33	1.36e-12	Height;
LUAD	cis	rs62229266	0.652	rs7280551	chr21:37409609	T/A	cg08632701	chr21:37451849	NA	-0.39	-6.58	-0.3	1.38e-10	Mitral valve prolapse;
LUAD	cis	rs3789045	0.774	rs12041243	chr1:204490470	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.43	-7.28	-0.33	1.68e-12	Educational attainment (college completion);
LUAD	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg15181151	chr6:150070149	PCMT1	0.35	6.58	0.3	1.42e-10	Lung cancer;
LUAD	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.38	6.62	0.31	1.07e-10	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg20849893	chr7:64541193	NA	0.47	7.49	0.34	3.96e-13	Calcium levels;
LUAD	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.17	-0.33	3.4e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11051970	0.553	rs325419	chr12:32572460	A/G	cg24626660	chr12:32551988	NA	0.31	6.65	0.31	8.83e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg00271210	chr6:167070053	RPS6KA2	0.34	6.6	0.31	1.27e-10	Crohn's disease;
LUAD	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg06547715	chr2:218990976	CXCR2	0.42	10.41	0.45	9.68e-23	Ulcerative colitis;
LUAD	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg11266682	chr4:10021025	SLC2A9	0.6	12.93	0.53	1.81e-32	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs17818399	0.926	rs1824050	chr2:46839477	T/C	cg09399716	chr2:46890238	NA	-0.4	-7.42	-0.34	6.57e-13	Height;
LUAD	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg10755058	chr3:40428713	ENTPD3	0.46	8.6	0.39	1.6e-16	Renal cell carcinoma;
LUAD	cis	rs7705042	0.865	rs6863411	chr5:141513204	A/T	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.76	-0.31	4.58e-11	Asthma;
LUAD	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.791	rs62068629	chr17:28187596	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.51	0.42	1.41e-19	Coffee consumption (cups per day);
LUAD	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg05754148	chr16:3507555	NAT15	0.7	11.31	0.48	4.47e-26	Tuberculosis;
LUAD	cis	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg07460842	chr6:66804631	NA	-1.05	-16.61	-0.63	4.67e-48	Exhaled nitric oxide output;
LUAD	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg04455712	chr21:45112962	RRP1B	0.38	7.75	0.35	6.85e-14	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.85e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7771547	0.692	rs9296192	chr6:36601203	A/G	cg07856975	chr6:36356162	ETV7	0.45	6.91	0.32	1.83e-11	Platelet distribution width;
LUAD	cis	rs2274273	0.870	rs3783652	chr14:55854208	A/G	cg04306507	chr14:55594613	LGALS3	0.42	8.87	0.4	2.06e-17	Protein biomarker;
LUAD	cis	rs790123	1.000	rs790113	chr3:122383276	T/A	cg24850323	chr3:122379709	NA	0.36	6.45	0.3	3.14e-10	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg22907277	chr7:1156413	C7orf50	0.49	8.19	0.37	3.04e-15	Longevity;Endometriosis;
LUAD	cis	rs10901296	0.660	rs2772033	chr9:133757080	G/A	cg13397898	chr9:133768931	QRFP	0.54	6.99	0.32	1.06e-11	Bilirubin levels;
LUAD	cis	rs4285028	0.699	rs4676758	chr3:121583415	T/C	cg11130432	chr3:121712080	ILDR1	0.58	8.47	0.38	4.03e-16	Multiple sclerosis;
LUAD	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg26897989	chr16:1907736	C16orf73	-0.49	-6.65	-0.31	8.83e-11	Ankle injury;
LUAD	cis	rs1853665	0.580	rs6557200	chr6:150272532	C/T	cg16301758	chr6:150275521	NA	0.51	7.41	0.34	6.72e-13	Radiation response;
LUAD	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-6.89	-0.32	1.99e-11	Total body bone mineral density;
LUAD	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg08508325	chr11:3079039	CARS	-0.59	-12.73	-0.53	1.2e-31	Longevity;
LUAD	cis	rs453301	0.631	rs11780774	chr8:8799111	C/A	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.98	-0.32	1.15e-11	Joint mobility (Beighton score);
LUAD	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg18129748	chr3:49941408	MST1R	0.4	6.53	0.3	1.88e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg24818145	chr4:99064322	C4orf37	0.39	6.6	0.31	1.25e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg06606381	chr12:133084897	FBRSL1	-0.8	-6.73	-0.31	5.41e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg03611598	chr17:48586076	MYCBPAP	0.72	9.83	0.43	1.12e-20	Visceral fat;
LUAD	cis	rs7737355	0.812	rs548635	chr5:131055546	G/T	cg06307176	chr5:131281290	NA	-0.42	-7.05	-0.32	7.4e-12	Life satisfaction;
LUAD	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg12311346	chr5:56204834	C5orf35	-0.9	-13.44	-0.55	1.58e-34	Initial pursuit acceleration;
LUAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12923728	chr3:195709715	SDHAP1	-0.77	-13.08	-0.54	4.63e-33	Pancreatic cancer;
LUAD	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg03929089	chr4:120376271	NA	0.57	7.13	0.33	4.42e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs1997103	1.000	rs2009441	chr7:55405989	A/G	cg17469321	chr7:55412551	NA	0.67	11.4	0.48	2.01e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs8014204	0.804	rs7154845	chr14:75247746	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.35	-6.52	-0.3	2.04e-10	Caffeine consumption;
LUAD	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.82e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg22920501	chr2:26401640	FAM59B	-0.73	-10.49	-0.45	4.71e-23	Gut microbiome composition (summer);
LUAD	cis	rs8018808	0.967	rs10133896	chr14:77853806	C/T	cg20045696	chr14:77926864	AHSA1	-0.38	-6.75	-0.31	4.87e-11	Myeloid white cell count;
LUAD	cis	rs9902453	0.817	rs4294865	chr17:28205736	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	10.17	0.44	7.09e-22	Coffee consumption (cups per day);
LUAD	cis	rs11023332	1.000	rs11023332	chr11:14784110	G/C	cg19336497	chr11:14380999	RRAS2	-0.41	-7.68	-0.35	1.11e-13	Adiponectin levels;Vitamin D levels;
LUAD	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15320075	chr8:145703422	NA	-0.39	-6.49	-0.3	2.35e-10	Age at first birth;
LUAD	cis	rs2953174	0.507	rs2953172	chr2:241525316	C/T	cg07929629	chr2:241523174	NA	0.45	7.11	0.33	4.99e-12	Bipolar disorder;
LUAD	cis	rs7771547	0.603	rs7344	chr6:36570366	A/G	cg02952361	chr6:36355661	ETV7	0.47	6.61	0.31	1.16e-10	Platelet distribution width;
LUAD	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.91e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg04756594	chr16:24857601	SLC5A11	0.76	13.37	0.55	2.93e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-15.23	-0.6	4.39e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg02030672	chr11:45687055	CHST1	0.36	6.36	0.3	5.14e-10	Obesity-related traits;
LUAD	cis	rs2797160	1.000	rs1418642	chr6:125999768	G/A	cg05901451	chr6:126070800	HEY2	-0.45	-6.66	-0.31	8.5e-11	Endometrial cancer;
LUAD	cis	rs7584330	0.554	rs112402109	chr2:238429058	A/G	cg14458575	chr2:238380390	NA	0.72	11.39	0.48	2.1e-26	Prostate cancer;
LUAD	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg03929089	chr4:120376271	NA	-0.91	-17.53	-0.65	4.06e-52	Coronary artery disease;
LUAD	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg04218760	chr10:45406644	TMEM72	-0.32	-8.04	-0.36	9.4e-15	Mean corpuscular volume;
LUAD	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg00933542	chr6:150070202	PCMT1	0.44	9.24	0.41	1.21e-18	Lung cancer;
LUAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg07234876	chr8:600039	NA	1.04	10.21	0.44	5.07e-22	IgG glycosylation;
LUAD	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg10356904	chr22:49881777	NA	-0.34	-6.72	-0.31	5.75e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06458679	chr21:46974866	NA	-0.53	-6.37	-0.3	4.8e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.55	7.79	0.35	5.24e-14	Platelet count;
LUAD	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg12311346	chr5:56204834	C5orf35	-0.91	-13.58	-0.55	4.15e-35	Initial pursuit acceleration;
LUAD	cis	rs612683	0.524	rs584350	chr1:100908324	A/G	cg06223162	chr1:101003688	GPR88	0.36	6.79	0.31	3.91e-11	Breast cancer;
LUAD	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg00484396	chr16:3507460	NAT15	0.75	9.96	0.44	3.76e-21	Tuberculosis;
LUAD	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg14582100	chr15:45693742	SPATA5L1	0.64	12.5	0.52	9.64e-31	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg07217954	chr7:1067459	C7orf50	0.43	6.59	0.3	1.34e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg25482853	chr8:67687455	SGK3	1.18	18.2	0.66	4.58e-55	Lung disease severity in cystic fibrosis;
LUAD	cis	rs10744422	0.858	rs4759389	chr12:123308615	A/G	cg16953816	chr12:123349952	VPS37B	0.62	7.18	0.33	3.12e-12	Schizophrenia;
LUAD	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg07917127	chr4:99064746	C4orf37	0.45	7.34	0.34	1.1e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg06781209	chr11:61594997	FADS2	-0.43	-7.67	-0.35	1.16e-13	Trans fatty acid levels;
LUAD	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg23950597	chr19:37808831	NA	-0.6	-7.21	-0.33	2.53e-12	Coronary artery calcification;
LUAD	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg06092702	chr1:163392909	NA	-0.38	-8.43	-0.38	5.66e-16	Motion sickness;
LUAD	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg10518543	chr12:38710700	ALG10B	-0.49	-8.14	-0.37	4.33e-15	Morning vs. evening chronotype;
LUAD	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg17595323	chr11:93583763	C11orf90	-0.43	-9.14	-0.41	2.69e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg19163074	chr7:65112434	INTS4L2	0.43	6.47	0.3	2.74e-10	Aortic root size;
LUAD	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg24690094	chr11:67383802	NA	0.55	10.19	0.44	6.12e-22	Mean corpuscular volume;
LUAD	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.77	0.31	4.27e-11	Depression;
LUAD	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg27454412	chr7:1067447	C7orf50	-0.4	-7.42	-0.34	6.29e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg09163369	chr1:210001066	C1orf107	0.5	7.09	0.33	5.73e-12	Orofacial clefts;
LUAD	cis	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg08601574	chr20:25228251	PYGB	0.46	8.37	0.38	8.27e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9595066	0.548	rs9562537	chr13:44755787	G/A	cg04068111	chr13:44716778	NA	-0.55	-8.26	-0.37	1.86e-15	Schizophrenia;
LUAD	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg21475434	chr5:93447410	FAM172A	0.74	8.33	0.38	1.17e-15	Diabetic retinopathy;
LUAD	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11644478	chr21:40555479	PSMG1	0.66	10.55	0.46	3.03e-23	Cognitive function;
LUAD	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg15744005	chr10:104629667	AS3MT	-0.35	-6.8	-0.31	3.6e-11	Arsenic metabolism;
LUAD	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg00271210	chr6:167070053	RPS6KA2	0.35	6.65	0.31	9.31e-11	Crohn's disease;
LUAD	cis	rs62238980	0.614	rs79061246	chr22:32468866	G/C	cg00543991	chr22:32367038	NA	0.92	8.7	0.39	7.27e-17	Childhood ear infection;
LUAD	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.35	0.34	1.01e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.37	7.54	0.34	2.88e-13	Obesity-related traits;
LUAD	cis	rs2658782	0.547	rs10765602	chr11:93048165	G/T	cg15737290	chr11:93063684	CCDC67	0.57	9.45	0.42	2.28e-19	Pulmonary function decline;
LUAD	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.23	-0.41	1.3e-18	Type 2 diabetes;
LUAD	cis	rs4790333	1.000	rs4790332	chr17:2262611	G/A	cg02569219	chr17:2266849	SGSM2	0.72	14.72	0.58	7.04e-40	Proinsulin levels;
LUAD	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg24558204	chr6:135376177	HBS1L	0.51	8.71	0.39	6.82e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23375783	chr17:73008576	ICT1	-0.54	-6.45	-0.3	3.04e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs986417	0.901	rs10150982	chr14:60987006	T/G	cg27398547	chr14:60952738	C14orf39	0.66	7.95	0.36	1.71e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg12483005	chr1:23474871	LUZP1	0.54	9.11	0.41	3.3e-18	Height;
LUAD	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.43	8.33	0.38	1.1e-15	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg11062466	chr8:58055876	NA	0.67	9.02	0.4	6.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs3020333	0.875	rs3020336	chr6:152013760	G/T	cg22157087	chr6:152012887	ESR1	0.36	6.36	0.3	5.28e-10	Total body bone mineral density;
LUAD	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg21475434	chr5:93447410	FAM172A	0.73	8.45	0.38	4.78e-16	Diabetic retinopathy;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg24623068	chr5:154317667	GEMIN5	-0.64	-6.38	-0.3	4.53e-10	Type 2 diabetes;
LUAD	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg25985355	chr7:65971099	NA	-0.53	-6.68	-0.31	7.41e-11	Diabetic kidney disease;
LUAD	trans	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.58	-10.67	-0.46	1.1e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg15147215	chr3:52552868	STAB1	-0.38	-7.13	-0.33	4.45e-12	Electroencephalogram traits;
LUAD	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-11.56	-0.49	4.57e-27	Hemoglobin concentration;
LUAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.54	-0.42	1.15e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg05590025	chr7:65112418	INTS4L2	0.77	8.15	0.37	4.09e-15	Diabetic kidney disease;
LUAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg08219700	chr8:58056026	NA	0.41	6.47	0.3	2.64e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4481887	0.927	rs4341391	chr1:248475720	A/G	cg13385794	chr1:248469461	NA	0.25	6.47	0.3	2.69e-10	Common traits (Other);
LUAD	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg08859206	chr1:53392774	SCP2	0.57	10.18	0.44	6.28e-22	Monocyte count;
LUAD	cis	rs7586879	0.964	rs4077679	chr2:25122852	T/C	cg04586622	chr2:25135609	ADCY3	0.34	7.36	0.34	9.36e-13	Body mass index;
LUAD	trans	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg11693508	chr17:37793320	STARD3	-0.76	-9.79	-0.43	1.61e-20	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.67	0.43	4.1e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4072705	1.000	rs4838197	chr9:127364515	T/C	cg13476313	chr9:127244764	NR5A1	0.3	7.25	0.33	1.99e-12	Menarche (age at onset);
LUAD	trans	rs875971	0.964	rs778721	chr7:65845397	C/G	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg22117172	chr7:91764530	CYP51A1	-0.34	-7.41	-0.34	6.72e-13	Breast cancer;
LUAD	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.68e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg24642844	chr7:1081250	C7orf50	-0.77	-8.57	-0.38	1.94e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs7944735	0.507	rs10838802	chr11:48102478	A/G	cg15704280	chr7:45808275	SEPT13	0.65	9.92	0.43	5.56e-21	Intraocular pressure;
LUAD	cis	rs11771526	0.686	rs62457463	chr7:32289856	C/T	cg27511599	chr7:32358540	NA	0.55	6.79	0.31	3.7e-11	Body mass index;
LUAD	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.36	-0.34	9.73e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg23803603	chr1:2058230	PRKCZ	0.4	6.59	0.3	1.35e-10	Height;
LUAD	cis	rs75920871	0.764	rs1473327	chr11:116823996	A/T	cg04087571	chr11:116723030	SIK3	-0.32	-6.55	-0.3	1.64e-10	Subjective well-being;
LUAD	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg12179176	chr11:130786555	SNX19	-0.39	-6.39	-0.3	4.37e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg12564285	chr5:131593104	PDLIM4	-0.39	-6.66	-0.31	8.41e-11	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6840360	0.615	rs3828546	chr4:152679816	A/G	cg22705602	chr4:152727874	NA	-0.48	-9.28	-0.41	8.63e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03517284	chr6:25882590	NA	-0.59	-9.58	-0.42	8.59e-20	Blood metabolite levels;
LUAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27286337	chr10:134555280	INPP5A	0.72	9.72	0.43	2.76e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs62400317	0.859	rs6919873	chr6:45159336	A/G	cg20913747	chr6:44695427	NA	-0.4	-6.41	-0.3	3.94e-10	Total body bone mineral density;
LUAD	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg00277334	chr10:82204260	NA	-0.6	-10.15	-0.44	8.37e-22	Post bronchodilator FEV1;
LUAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08677398	chr8:58056175	NA	0.46	6.54	0.3	1.76e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-6.89	-0.32	2.07e-11	Cystic fibrosis severity;
LUAD	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs7085104	0.727	rs12773892	chr10:104631177	G/T	cg04362960	chr10:104952993	NT5C2	0.6	6.78	0.31	4.12e-11	Immature fraction of reticulocytes;Schizophrenia;
LUAD	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	9.63	0.42	5.79e-20	Electrocardiographic conduction measures;
LUAD	trans	rs783540	0.774	rs28415133	chr15:83264713	G/C	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.69	-0.31	6.95e-11	Schizophrenia;
LUAD	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg02975922	chr3:195473998	MUC4	-0.44	-7.35	-0.34	1.05e-12	Pancreatic cancer;
LUAD	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg12756686	chr19:29218302	NA	0.62	8.92	0.4	1.44e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs7582720	0.945	rs72934583	chr2:204009057	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.59	0.42	7.57e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.68	13.25	0.54	9.15e-34	Cognitive ability;
LUAD	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg18138036	chr10:133769891	PPP2R2D	0.42	6.69	0.31	7.01e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs12681287	0.752	rs13255058	chr8:87287445	G/A	cg27223183	chr8:87520930	FAM82B	-0.6	-8.31	-0.37	1.29e-15	Caudate activity during reward;
LUAD	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg20203395	chr5:56204925	C5orf35	-0.4	-6.54	-0.3	1.79e-10	Coronary artery disease;
LUAD	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg07636037	chr3:49044803	WDR6	0.48	8.2	0.37	2.85e-15	Menarche (age at onset);
LUAD	cis	rs17401966	0.838	rs4846206	chr1:10310258	G/C	cg19773385	chr1:10388646	KIF1B	-0.39	-6.51	-0.3	2.15e-10	Hepatocellular carcinoma;
LUAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.01	-0.32	9.27e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs9633740	0.947	rs1878036	chr10:82280137	T/G	cg00277334	chr10:82204260	NA	-0.63	-8.35	-0.38	1e-15	Post bronchodilator FEV1;
LUAD	trans	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg16006296	chr10:38738647	LOC399744	0.35	6.36	0.3	5.32e-10	Diastolic blood pressure;
LUAD	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.13	-0.33	4.26e-12	Total cholesterol levels;
LUAD	cis	rs7267979	0.844	rs6107027	chr20:25288632	A/G	cg08601574	chr20:25228251	PYGB	0.41	7.71	0.35	9.21e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7582720	0.945	rs116773016	chr2:203811902	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.47	9.14	0.41	2.64e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg08422745	chr4:174089978	GALNT7	0.94	16.26	0.62	1.54e-46	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-7.67	-0.35	1.22e-13	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg14343924	chr8:8086146	FLJ10661	-0.48	-7.49	-0.34	3.97e-13	Joint mobility (Beighton score);
LUAD	cis	rs7095607	0.785	rs7081820	chr10:69914009	C/T	cg18986048	chr10:69913749	MYPN	0.38	6.49	0.3	2.35e-10	Lung function (FVC);
LUAD	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg07167872	chr1:205819463	PM20D1	-0.53	-8.09	-0.37	6.4e-15	Menarche (age at onset);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14857596	chr12:72233493	TBC1D15	-0.59	-7.21	-0.33	2.55e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00802000	chr16:706648	WDR90	-0.41	-7.62	-0.35	1.63e-13	Height;
LUAD	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24034412	chr19:49122294	RPL18;SPHK2	-0.59	-7.1	-0.33	5.35e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs8027181	1.000	rs4776613	chr15:73080731	C/T	cg25632853	chr15:73088954	NA	0.37	8.13	0.37	4.68e-15	Triglyceride levels;
LUAD	cis	rs854765	0.624	rs11657423	chr17:17728574	T/C	cg09796270	chr17:17721594	SREBF1	-0.38	-7.48	-0.34	4.29e-13	Total body bone mineral density;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg26236440	chr2:113341947	CHCHD5	-0.37	-6.52	-0.3	1.98e-10	Subcortical brain region volumes;
LUAD	cis	rs7009516	0.669	rs12674766	chr8:24241732	C/T	cg01759110	chr8:24241694	ADAMDEC1	-0.43	-8.76	-0.39	4.78e-17	Hair greying;
LUAD	cis	rs1595825	0.838	rs16823400	chr2:198603229	A/G	cg10547527	chr2:198650123	BOLL	-0.54	-7.5	-0.34	3.82e-13	Ulcerative colitis;
LUAD	cis	rs2880765	0.835	rs7169429	chr15:86036648	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.67	-0.31	7.81e-11	Coronary artery disease;
LUAD	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg04772025	chr11:68637568	NA	0.5	7.81	0.36	4.43e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg06002616	chr8:101225028	SPAG1	-0.39	-7.9	-0.36	2.35e-14	Atrioventricular conduction;
LUAD	cis	rs1215050	0.755	rs9991112	chr4:98651479	A/C	cg05340658	chr4:99064831	C4orf37	-0.45	-7.31	-0.34	1.3e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19346786	chr7:2764209	NA	-0.57	-12.21	-0.51	1.43e-29	Height;
LUAD	cis	rs9393692	0.557	rs989133	chr6:26336300	T/C	cg00631329	chr6:26305371	NA	-0.52	-8.34	-0.38	1.08e-15	Educational attainment;
LUAD	cis	rs9486719	1.000	rs11153070	chr6:97039720	C/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-9.53	-0.42	1.23e-19	Migraine;Coronary artery disease;
LUAD	cis	rs9296092	0.538	rs9469487	chr6:33516943	G/T	cg13560919	chr6:33536144	NA	-0.88	-16.53	-0.63	1e-47	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs758324	0.947	rs687816	chr5:131262077	C/T	cg25547332	chr5:131281432	NA	-0.44	-6.72	-0.31	6.05e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg10167378	chr1:228756711	NA	-0.39	-6.56	-0.3	1.62e-10	Chronic lymphocytic leukemia;
LUAD	cis	rs4285028	0.948	rs34181646	chr3:121705373	T/A	cg20356878	chr3:121714668	ILDR1	-0.5	-6.79	-0.31	3.75e-11	Multiple sclerosis;
LUAD	cis	rs4891159	0.790	rs7234653	chr18:74111988	C/T	cg24786174	chr18:74118243	ZNF516	-0.8	-15.16	-0.59	9.07e-42	Longevity;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07328115	chr20:25228580	PYGB	-0.42	-6.49	-0.3	2.34e-10	Height;
LUAD	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg19196401	chr6:110721138	DDO	-0.48	-9.32	-0.41	6.31e-19	Platelet distribution width;
LUAD	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg09137382	chr11:130731461	NA	0.4	7.42	0.34	6.48e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2882667	0.838	rs11958529	chr5:138395068	C/T	cg04439458	chr5:138467593	SIL1	-0.4	-7.16	-0.33	3.59e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs375066	0.592	rs349047	chr19:44300884	G/A	cg12072164	chr19:44306565	LYPD5	-0.4	-8.18	-0.37	3.28e-15	Breast cancer;
LUAD	cis	rs11971779	0.680	rs4732373	chr7:139086535	T/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.97	-15.51	-0.6	2.78e-43	Homoarginine levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07921777	chr16:67062970	CBFB	-0.64	-6.4	-0.3	4.24e-10	Type 2 diabetes;
LUAD	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg04025307	chr7:1156635	C7orf50	-0.55	-9.37	-0.41	4.23e-19	Longevity;Endometriosis;
LUAD	cis	rs7586879	0.964	rs6545795	chr2:25116783	C/T	cg04586622	chr2:25135609	ADCY3	0.34	7.35	0.34	1.05e-12	Body mass index;
LUAD	cis	rs68170813	0.559	rs17429146	chr7:106964281	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.28	-0.45	2.81e-22	Coronary artery disease;
LUAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg24503407	chr1:205819492	PM20D1	0.77	15.43	0.6	6.14e-43	Menarche (age at onset);
LUAD	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg08807101	chr21:30365312	RNF160	-0.43	-7.42	-0.34	6.53e-13	Dental caries;
LUAD	cis	rs6484504	0.600	rs1323738	chr11:31344898	T/C	cg14844989	chr11:31128820	NA	0.45	8.26	0.37	1.86e-15	Red blood cell count;
LUAD	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.44	-8.47	-0.38	4.19e-16	Longevity;Endometriosis;
LUAD	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg15445000	chr17:37608096	MED1	-0.44	-7.85	-0.36	3.39e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg04944784	chr2:26401820	FAM59B	-0.89	-12.57	-0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs7178572	0.962	rs1022172	chr15:77793359	A/G	cg22256960	chr15:77711686	NA	-0.4	-6.37	-0.3	5.07e-10	Type 2 diabetes;
LUAD	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg10518543	chr12:38710700	ALG10B	-0.44	-7.22	-0.33	2.42e-12	Bladder cancer;
LUAD	cis	rs68170813	0.527	rs78133594	chr7:107025260	T/C	cg02696742	chr7:106810147	HBP1	-0.78	-10.89	-0.47	1.67e-24	Coronary artery disease;
LUAD	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.53	-11.01	-0.47	6.04e-25	Monocyte percentage of white cells;
LUAD	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg25554036	chr4:6271136	WFS1	0.72	14.3	0.57	4.06e-38	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7089973	0.966	rs61867966	chr10:116584362	T/C	cg25233709	chr10:116636983	FAM160B1	0.36	6.62	0.31	1.09e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2485376	1.000	rs7923183	chr10:103992569	A/G	cg20641465	chr10:103991465	PITX3	0.56	10.3	0.45	2.45e-22	QT interval;
LUAD	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.78e-11	Crohn's disease;
LUAD	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-7.26	-0.33	1.82e-12	Neutrophil percentage of white cells;
LUAD	cis	rs6577655	0.501	rs7004326	chr8:135610915	G/T	cg17885191	chr8:135476712	NA	-0.5	-7.85	-0.36	3.34e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg03859395	chr2:55845619	SMEK2	0.72	13.29	0.54	6.4e-34	Metabolic syndrome;
LUAD	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg07537917	chr2:241836409	C2orf54	-0.31	-9.05	-0.4	5.15e-18	Urinary metabolites;
LUAD	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg11344533	chr11:111475393	SIK2	-0.36	-6.57	-0.3	1.44e-10	Primary sclerosing cholangitis;
LUAD	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg11266682	chr4:10021025	SLC2A9	0.63	14.15	0.57	1.71e-37	Bone mineral density;
LUAD	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg02423579	chr7:2872169	GNA12	-0.53	-9.02	-0.4	6.45e-18	Height;
LUAD	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.58	0.38	1.86e-16	Menarche (age at onset);
LUAD	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg07606381	chr6:8435919	SLC35B3	-0.4	-6.71	-0.31	6.36e-11	Motion sickness;
LUAD	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg25358565	chr5:93447407	FAM172A	0.63	7.78	0.35	5.58e-14	Diabetic retinopathy;
LUAD	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg01874867	chr7:94954059	PON1	-0.51	-7.05	-0.32	7.41e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9811920	0.928	rs9865713	chr3:99870299	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.57	10.27	0.45	2.97e-22	Axial length;
LUAD	cis	rs36715	1.000	rs36697	chr5:127549613	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.47	6.52	0.3	1.99e-10	Breast cancer;
LUAD	cis	rs1832871	0.541	rs10945546	chr6:158892209	A/G	cg07165851	chr6:158734300	TULP4	0.49	7.31	0.34	1.32e-12	Height;
LUAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg00431813	chr7:1051703	C7orf50	-0.46	-8.69	-0.39	8.21e-17	Longevity;Endometriosis;
LUAD	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg02421172	chr7:1938701	MAD1L1	0.48	6.78	0.31	4.12e-11	Neuroticism;
LUAD	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.41	-6.44	-0.3	3.21e-10	Glycated hemoglobin levels;
LUAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-9.98	-0.44	3.45e-21	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.63	-0.35	1.54e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs12517041	1.000	rs6874000	chr5:23304235	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	0.47	6.74	0.31	5.09e-11	Calcium levels;
LUAD	trans	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.68	-0.46	9.8599999999999993e-24	Depression;
LUAD	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg21028142	chr17:79581711	NPLOC4	0.37	7.45	0.34	5.2e-13	Eye color traits;
LUAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08219700	chr8:58056026	NA	0.58	8.06	0.36	7.95e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg05425664	chr17:57184151	TRIM37	-0.44	-7.82	-0.36	4.23e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs8077889	0.917	rs58283314	chr17:41905963	T/G	cg26893861	chr17:41843967	DUSP3	0.9	14.95	0.59	7.33e-41	Triglycerides;
LUAD	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg13319975	chr6:146136371	FBXO30	-0.76	-12.67	-0.52	1.99e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4253772	0.575	rs9615983	chr22:46793314	G/A	cg09491104	chr22:46646882	C22orf40	-0.53	-6.85	-0.32	2.59e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4889855	0.530	rs7220588	chr17:78598231	G/A	cg16591659	chr17:78472290	NA	-0.43	-7.48	-0.34	4.38e-13	Fractional excretion of uric acid;
LUAD	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg22117172	chr7:91764530	CYP51A1	0.36	7.72	0.35	8.68e-14	Breast cancer;
LUAD	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg06618935	chr21:46677482	NA	-0.48	-9.73	-0.43	2.56e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12545109	0.879	rs893234	chr8:57363885	G/A	cg07776626	chr8:57350775	NA	-0.67	-9.32	-0.41	6.58e-19	Obesity-related traits;
LUAD	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg10164272	chr16:89456328	ANKRD11	0.43	6.66	0.31	8.76e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg07362569	chr17:61921086	SMARCD2	0.39	6.74	0.31	5.29e-11	Prudent dietary pattern;
LUAD	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg09365446	chr1:150670422	GOLPH3L	0.61	10.91	0.47	1.39e-24	Melanoma;
LUAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.49	0.3	2.35e-10	Prudent dietary pattern;
LUAD	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg15921436	chr17:44337874	NA	-0.72	-9.48	-0.42	1.82e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.62	0.31	1.09e-10	Parkinson's disease;
LUAD	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg23758822	chr17:41437982	NA	0.98	19.52	0.69	5.7e-61	Menopause (age at onset);
LUAD	cis	rs3820068	0.705	rs4646091	chr1:15822043	T/C	cg13390004	chr1:15929781	NA	0.4	6.51	0.3	2.15e-10	Systolic blood pressure;
LUAD	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg02896835	chr1:92012615	NA	-0.52	-8.83	-0.39	2.7e-17	Eosinophil percentage of white cells;
LUAD	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg00204512	chr16:28754710	NA	0.33	7.11	0.33	4.84e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg15147215	chr3:52552868	STAB1	-0.41	-7.43	-0.34	6.08e-13	Bipolar disorder;
LUAD	trans	rs4714291	1.000	rs1546965	chr6:39999149	C/T	cg02267698	chr19:7991119	CTXN1	-0.45	-6.46	-0.3	2.93e-10	Strep throat;
LUAD	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg11707310	chr1:2537719	MMEL1	0.38	7.87	0.36	2.93e-14	Multiple sclerosis;
LUAD	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg22920501	chr2:26401640	FAM59B	-0.96	-14.34	-0.57	2.81e-38	Gut microbiome composition (summer);
LUAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg02951883	chr7:2050386	MAD1L1	-0.67	-11.13	-0.48	2.07e-25	Bipolar disorder and schizophrenia;
LUAD	trans	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg19955956	chr7:72299837	SBDSP;TYW1B	0.57	10.26	0.45	3.34e-22	Blood metabolite levels;
LUAD	trans	rs2797160	1.000	rs1777194	chr6:126004883	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.65	-0.39	1.08e-16	Endometrial cancer;
LUAD	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg19622623	chr12:86230825	RASSF9	-0.44	-7.79	-0.35	5.09e-14	Major depressive disorder;
LUAD	cis	rs9914988	1.000	rs6803	chr17:27187789	C/T	cg20469991	chr17:27169893	C17orf63	0.51	6.54	0.3	1.74e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7630877	0.719	rs12489992	chr3:179664925	A/C	cg18765712	chr3:179670323	PEX5L	0.54	9.1	0.4	3.72e-18	Type 2 diabetes;
LUAD	cis	rs427394	0.659	rs274725	chr5:6717408	C/G	cg10857441	chr5:6722123	POLS	-0.62	-11.14	-0.48	1.93e-25	Menopause (age at onset);
LUAD	trans	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg10208301	chr11:6592745	DNHD1	0.5	6.43	0.3	3.53e-10	Coronary artery calcification;
LUAD	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg14668632	chr7:2872130	GNA12	-0.45	-7.95	-0.36	1.7e-14	Height;
LUAD	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.4	0.34	7.17e-13	Tonsillectomy;
LUAD	cis	rs11048434	0.736	rs7301381	chr12:9123932	T/C	cg13575925	chr12:9217583	LOC144571	0.38	7.13	0.33	4.48e-12	Sjögren's syndrome;
LUAD	cis	rs6748734	0.857	rs4675857	chr2:241842326	T/C	cg04034577	chr2:241836375	C2orf54	-0.49	-10.6	-0.46	2.01e-23	Urinary metabolites;
LUAD	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg11502198	chr6:26597334	ABT1	0.5	7.95	0.36	1.75e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg08132940	chr7:1081526	C7orf50	-0.78	-10.56	-0.46	2.64e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs472402	0.580	rs3822430	chr5:6651970	A/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.41	-6.36	-0.3	5.22e-10	Response to amphetamines;
LUAD	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg14893161	chr1:205819251	PM20D1	0.47	7.77	0.35	5.82e-14	Parkinson's disease;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26714410	chr13:45150072	TSC22D1	0.4	6.43	0.3	3.35e-10	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg06784218	chr1:46089804	CCDC17	0.6	13.39	0.55	2.41e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21659725	chr3:3221576	CRBN	0.66	11.38	0.48	2.28e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs8017423	0.647	rs10132599	chr14:90815342	C/T	cg14092571	chr14:90743983	NA	0.4	6.94	0.32	1.5e-11	Mortality in heart failure;
LUAD	cis	rs7937890	0.559	rs1548074	chr11:14534825	A/G	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.15e-12	Mitochondrial DNA levels;
LUAD	cis	rs68170813	0.559	rs80341862	chr7:106934731	C/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.48	-0.45	5.22e-23	Coronary artery disease;
LUAD	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.25	-0.33	2.06e-12	Total cholesterol levels;
LUAD	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg25358565	chr5:93447407	FAM172A	0.59	6.93	0.32	1.55e-11	Diabetic retinopathy;
LUAD	trans	rs877282	0.898	rs71489279	chr10:760510	T/C	cg22713356	chr15:30763199	NA	1.26	17.38	0.65	1.91e-51	Uric acid levels;
LUAD	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg01475377	chr6:109611718	NA	-0.48	-8.71	-0.39	6.92e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs4953076	0.573	rs9973609	chr2:44450435	T/C	cg04920474	chr2:44395004	PPM1B	0.52	7.81	0.35	4.7e-14	Height;
LUAD	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg02423579	chr7:2872169	GNA12	-0.83	-14.28	-0.57	4.68e-38	Height;
LUAD	cis	rs6121246	0.559	rs6058462	chr20:30367674	C/T	cg21427119	chr20:30132790	HM13	-0.36	-6.46	-0.3	2.92e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg02269571	chr22:50332266	NA	0.59	8.96	0.4	1.05e-17	Schizophrenia;
LUAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.66	0.31	8.75e-11	Prudent dietary pattern;
LUAD	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg18944383	chr4:111397179	ENPEP	0.32	6.39	0.3	4.38e-10	Height;
LUAD	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg14779329	chr11:130786720	SNX19	0.39	6.83	0.32	2.93e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs909002	0.849	rs10753257	chr1:32086089	G/A	cg13919466	chr1:32135498	COL16A1	-0.35	-8.03	-0.36	9.47e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs62229266	0.618	rs11088334	chr21:37466829	A/T	cg12218747	chr21:37451666	NA	-0.49	-8.55	-0.38	2.19e-16	Mitral valve prolapse;
LUAD	cis	rs62400317	0.826	rs11970412	chr6:45037516	C/T	cg18551225	chr6:44695536	NA	-0.57	-8.69	-0.39	8.16e-17	Total body bone mineral density;
LUAD	cis	rs35883536	0.528	rs1414414	chr1:101028907	T/C	cg09408571	chr1:101003634	GPR88	0.35	7.03	0.32	8.19e-12	Monocyte count;
LUAD	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.35	-0.38	9.87e-16	Total body bone mineral density;
LUAD	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg23281280	chr6:28129359	ZNF389	0.48	6.7	0.31	6.8e-11	Depression;
LUAD	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg04731861	chr2:219085781	ARPC2	-0.2	-6.4	-0.3	4.19e-10	Colorectal cancer;
LUAD	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg26597838	chr10:835615	NA	0.99	15.55	0.6	1.86e-43	Eosinophil percentage of granulocytes;
LUAD	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg05991184	chr2:219186017	PNKD	-0.37	-7.24	-0.33	2.18e-12	Colorectal cancer;
LUAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg15117754	chr3:10150083	C3orf24	0.45	7.46	0.34	4.87e-13	Alzheimer's disease;
LUAD	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg23803603	chr1:2058230	PRKCZ	-0.39	-7.21	-0.33	2.67e-12	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23715700	chr19:16188274	TPM4	-0.47	-7.35	-0.34	1.03e-12	Height;
LUAD	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg23096020	chr7:158799433	NA	0.38	7.11	0.33	4.84e-12	Facial morphology (factor 20);
LUAD	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg09904177	chr6:26538194	HMGN4	0.44	7.39	0.34	7.96e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2425143	1.000	rs6060572	chr20:34294015	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.48	-0.34	4.42e-13	Blood protein levels;
LUAD	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg02176678	chr2:219576539	TTLL4	-0.82	-17.07	-0.64	4.29e-50	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21659725	chr3:3221576	CRBN	0.86	18.2	0.66	4.47e-55	Intelligence (multi-trait analysis);
LUAD	trans	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg26384229	chr12:38710491	ALG10B	0.39	6.38	0.3	4.55e-10	Morning vs. evening chronotype;
LUAD	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg22705602	chr4:152727874	NA	-0.37	-6.59	-0.3	1.35e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	6.99	0.32	1.08e-11	Tonsillectomy;
LUAD	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.97	-0.32	1.25e-11	Joint mobility (Beighton score);
LUAD	cis	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.53	6.49	0.3	2.38e-10	Depression;
LUAD	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03264133	chr6:25882463	NA	0.49	7.18	0.33	3.13e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.88	-0.4	1.98e-17	Total body bone mineral density;
LUAD	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg03874509	chr1:107600012	PRMT6	0.56	9.75	0.43	2.15e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7903847	0.642	rs1547328	chr10:99109729	G/T	cg20016023	chr10:99160130	RRP12	-0.31	-6.8	-0.31	3.67e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	trans	rs7939886	0.920	rs1905069	chr11:55887135	T/C	cg15704280	chr7:45808275	SEPT13	0.67	6.56	0.3	1.59e-10	Myopia (pathological);
LUAD	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg27284194	chr4:1044797	NA	0.69	9.93	0.43	4.92e-21	Recombination rate (females);
LUAD	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg16647868	chr5:131706066	SLC22A5	0.48	7.75	0.35	7.12e-14	Breast cancer;
LUAD	cis	rs2629540	0.731	rs11245341	chr10:126408777	G/C	cg08799069	chr10:126477246	METTL10	0.47	6.97	0.32	1.24e-11	Cocaine dependence;
LUAD	cis	rs56104184	0.578	rs7254608	chr19:49395774	G/T	cg21252483	chr19:49399788	TULP2	-0.52	-9.96	-0.44	3.83e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg02527881	chr3:46936655	PTH1R	-0.69	-15.16	-0.59	8.72e-42	Birth weight;
LUAD	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	6.89	0.32	2.04e-11	Schizophrenia;
LUAD	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01570182	chr17:44337453	NA	1.12	17.17	0.64	1.59e-50	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg08999081	chr20:33150536	PIGU	0.63	14.37	0.57	2.1e-38	Coronary artery disease;
LUAD	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg26408565	chr15:76604113	ETFA	-0.44	-7.1	-0.33	5.28e-12	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.76	0.53	9e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2522056	0.808	rs7704457	chr5:131744790	C/T	cg16647868	chr5:131706066	SLC22A5	0.46	6.37	0.3	5.04e-10	Lymphocyte counts;Fibrinogen;
LUAD	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs9929218	0.748	rs34592833	chr16:68739125	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-16.32	-0.62	8.97e-47	Colorectal cancer;
LUAD	cis	rs4601821	1.000	rs6589375	chr11:113255111	C/A	cg14159747	chr11:113255604	NA	0.5	9.41	0.42	3.19e-19	Alcoholic chronic pancreatitis;
LUAD	trans	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg14406256	chr12:34175567	ALG10	-0.39	-6.37	-0.3	4.85e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg24558204	chr6:135376177	HBS1L	0.48	8.86	0.4	2.22e-17	Red blood cell count;
LUAD	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg06214716	chr4:10118677	WDR1	-0.43	-6.86	-0.32	2.48e-11	Bone mineral density;
LUAD	cis	rs1595825	0.628	rs6760078	chr2:198563742	A/T	cg00982548	chr2:198649783	BOLL	-0.61	-9.01	-0.4	7.2e-18	Ulcerative colitis;
LUAD	cis	rs61897795	0.657	rs174587	chr11:61612830	C/T	cg00603274	chr11:61596626	FADS2	-0.48	-7.29	-0.33	1.56e-12	Neutrophil count;Sum basophil neutrophil counts;
LUAD	trans	rs875971	1.000	rs709595	chr7:65817333	G/C	cg14917512	chr19:3094685	GNA11	-0.37	-6.44	-0.3	3.29e-10	Aortic root size;
LUAD	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.42	-6.82	-0.31	3.13e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg00316803	chr15:76480434	C15orf27	0.4	6.38	0.3	4.55e-10	Blood metabolite levels;
LUAD	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg04545296	chr12:48745243	ZNF641	0.34	8.49	0.38	3.46e-16	Glycated hemoglobin levels;
LUAD	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg05425664	chr17:57184151	TRIM37	0.44	7.87	0.36	2.94e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg27211696	chr2:191398769	TMEM194B	0.79	16.8	0.63	6.56e-49	Pulse pressure;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg13214185	chr14:107219616	NA	0.42	7.25	0.33	2.02e-12	Menopause (age at onset);
LUAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.58	-11.32	-0.48	4.02e-26	Longevity;Endometriosis;
LUAD	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg05313129	chr8:58192883	C8orf71	-0.58	-8.73	-0.39	5.95e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg08798685	chr6:27730294	NA	-0.43	-6.97	-0.32	1.23e-11	Parkinson's disease;
LUAD	cis	rs7192380	0.651	rs13337236	chr16:69664919	T/A	cg26679644	chr16:69762563	NA	0.43	6.98	0.32	1.14e-11	Sjögren's syndrome;
LUAD	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17532515	0.628	rs12502572	chr4:141485134	C/T	cg09181644	chr4:141490428	UCP1	0.31	6.95	0.32	1.38e-11	Select biomarker traits;
LUAD	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg05768032	chr16:30646687	NA	0.44	7.81	0.35	4.68e-14	Multiple myeloma;
LUAD	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-7.66	-0.35	1.27e-13	Total cholesterol levels;
LUAD	cis	rs8060686	0.623	rs2301814	chr16:68105171	C/G	cg05110241	chr16:68378359	PRMT7	-0.55	-7.11	-0.33	5e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.43	0.34	5.99e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg17971929	chr21:40555470	PSMG1	0.55	8.5	0.38	3.28e-16	Cognitive function;
LUAD	cis	rs6993813	0.653	rs4355805	chr8:120016374	A/G	cg01975934	chr8:119970761	NA	-0.35	-6.64	-0.31	9.56e-11	Bone mineral density (hip);
LUAD	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs78707713	0.841	rs7475662	chr10:71210744	G/C	cg12610070	chr10:71211762	TSPAN15	-0.39	-7.2	-0.33	2.81e-12	Venous thromboembolism;
LUAD	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg06608945	chr2:219082296	ARPC2	-0.42	-6.94	-0.32	1.48e-11	Colorectal cancer;
LUAD	cis	rs2235649	0.833	rs2011088	chr16:1850091	T/C	cg08610935	chr16:1836813	NUBP2	-0.48	-7.37	-0.34	8.86e-13	Blood metabolite levels;
LUAD	cis	rs3092073	0.819	rs3848715	chr20:44564682	G/A	cg27529037	chr20:44575021	PCIF1	-0.45	-8.13	-0.37	4.71e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	1.000	rs114039398	chr4:119631627	T/C	cg02775129	chr4:119771670	NA	-0.84	-7.8	-0.35	4.94e-14	Cannabis dependence symptom count;
LUAD	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.98	0.36	1.42e-14	Parkinson's disease;
LUAD	cis	rs7737355	0.812	rs10063264	chr5:130898197	C/G	cg25547332	chr5:131281432	NA	0.43	6.84	0.32	2.84e-11	Life satisfaction;
LUAD	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg07305463	chr2:136567211	LCT	0.39	7.38	0.34	8.38e-13	Mosquito bite size;
LUAD	cis	rs9814567	0.752	rs6779294	chr3:134329821	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-12.92	-0.53	2.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs12517041	1.000	rs28600340	chr5:23301774	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.57	-0.3	1.47e-10	Calcium levels;
LUAD	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg14092988	chr3:52407081	DNAH1	0.37	7.53	0.34	3.17e-13	Bipolar disorder;
LUAD	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg22906224	chr7:99728672	NA	-0.58	-9.68	-0.43	3.75e-20	Coronary artery disease;
LUAD	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg11070056	chr1:107600091	PRMT6	-0.55	-9.59	-0.42	7.7e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg09253696	chr17:73873529	TRIM47	-0.41	-7.21	-0.33	2.58e-12	Psoriasis;
LUAD	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.55	-0.34	2.76e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1403694	0.695	rs67173199	chr3:186432858	G/A	cg12454167	chr3:186435060	KNG1	0.52	10.62	0.46	1.58e-23	Blood protein levels;
LUAD	trans	rs62458065	0.713	rs3801329	chr7:32496956	A/C	cg00845942	chr12:64062724	DPY19L2	-0.55	-7.53	-0.34	3.01e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18876405	chr7:65276391	NA	0.41	6.39	0.3	4.42e-10	Aortic root size;
LUAD	cis	rs4711336	1.000	rs4711337	chr6:33659987	T/C	cg14003231	chr6:33640908	ITPR3	0.5	9.54	0.42	1.13e-19	Height;
LUAD	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg25173405	chr17:45401733	C17orf57	0.45	7.67	0.35	1.19e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg15445000	chr17:37608096	MED1	0.43	7.98	0.36	1.42e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10802521	chr3:52805072	NEK4	-0.53	-8.93	-0.4	1.3e-17	Bipolar disorder;
LUAD	cis	rs34172651	0.917	rs12599643	chr16:24832693	C/T	cg06028605	chr16:24865363	SLC5A11	0.38	6.74	0.31	5.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03762994	chr17:6899332	ALOX12	0.36	6.64	0.31	9.61e-11	Tonsillectomy;
LUAD	cis	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg07460842	chr6:66804631	NA	0.9	14.19	0.57	1.22e-37	Exhaled nitric oxide levels;
LUAD	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg02880119	chr16:3481970	NA	-0.53	-8.03	-0.36	9.72e-15	Body mass index (adult);
LUAD	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg12432903	chr7:1882776	MAD1L1	-0.53	-8.9	-0.4	1.64e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg23625390	chr15:77176239	SCAPER	-0.54	-8.7	-0.39	7.7e-17	Blood metabolite levels;
LUAD	cis	rs1497828	0.871	rs2815238	chr1:217543384	T/A	cg04411442	chr1:217543379	NA	0.41	7.27	0.33	1.75e-12	Dialysis-related mortality;
LUAD	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg21231944	chr12:82153410	PPFIA2	-0.34	-6.46	-0.3	2.94e-10	Resting heart rate;
LUAD	cis	rs6484504	0.576	rs208066	chr11:31156206	C/G	cg26647111	chr11:31128758	NA	-0.38	-6.46	-0.3	2.8e-10	Red blood cell count;
LUAD	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg26384229	chr12:38710491	ALG10B	0.42	7.02	0.32	8.91e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs240764	0.817	rs239229	chr6:101105975	T/C	cg09795085	chr6:101329169	ASCC3	0.44	7.51	0.34	3.56e-13	Neuroticism;
LUAD	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg05579598	chr16:88989069	CBFA2T3	0.31	6.37	0.3	4.85e-10	Social autistic-like traits;
LUAD	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg13918804	chr1:2043761	PRKCZ	-0.4	-6.94	-0.32	1.5e-11	Height;
LUAD	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg20933634	chr6:27740509	NA	0.49	7.73	0.35	7.69e-14	Parkinson's disease;
LUAD	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg27446573	chr6:127587934	RNF146	0.44	6.72	0.31	5.8e-11	Breast cancer;
LUAD	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.05	-0.32	7.33e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6665290	0.904	rs10916075	chr1:227184074	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.06	-0.88	2.19e-142	Myeloid white cell count;
LUAD	cis	rs36051895	0.659	rs1575285	chr9:5267440	A/G	cg02405213	chr9:5042618	JAK2	-0.45	-6.46	-0.3	2.95e-10	Pediatric autoimmune diseases;
LUAD	cis	rs832540	0.519	rs10940518	chr5:56270794	C/T	cg18230493	chr5:56204884	C5orf35	-0.5	-8.08	-0.37	6.83e-15	Coronary artery disease;
LUAD	cis	rs1595825	0.891	rs76637837	chr2:198529496	G/A	cg00982548	chr2:198649783	BOLL	-0.62	-8.83	-0.39	2.89e-17	Ulcerative colitis;
LUAD	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg03859395	chr2:55845619	SMEK2	0.75	13.9	0.56	1.96e-36	Metabolic syndrome;
LUAD	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg01689657	chr7:91764605	CYP51A1	-0.29	-6.88	-0.32	2.23e-11	Breast cancer;
LUAD	cis	rs6060717	0.654	rs6058347	chr20:34483781	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-6.98	-0.32	1.18e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg16205897	chr5:131564050	P4HA2	0.29	6.39	0.3	4.39e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs7827545	0.545	rs57219802	chr8:135554231	C/T	cg17885191	chr8:135476712	NA	0.71	9.09	0.4	3.76e-18	Hypertension (SNP x SNP interaction);
LUAD	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26314531	chr2:26401878	FAM59B	0.72	9.7	0.43	3.21e-20	Gut microbiome composition (summer);
LUAD	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg20701182	chr2:24300061	SF3B14	0.91	13.72	0.56	1.04e-35	Lymphocyte counts;
LUAD	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg23625390	chr15:77176239	SCAPER	0.39	6.98	0.32	1.12e-11	Blood metabolite levels;
LUAD	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg06740227	chr12:86229804	RASSF9	0.41	7.29	0.33	1.57e-12	Major depressive disorder;
LUAD	cis	rs1448094	0.967	rs10047659	chr12:86338278	C/A	cg06740227	chr12:86229804	RASSF9	0.36	6.53	0.3	1.91e-10	Major depressive disorder;
LUAD	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg04727924	chr7:799746	HEATR2	-0.56	-6.93	-0.32	1.6e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg22920501	chr2:26401640	FAM59B	-0.76	-10.97	-0.47	8.37e-25	Gut microbiome composition (summer);
LUAD	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg20135002	chr11:47629003	NA	-0.42	-7.27	-0.33	1.73e-12	Body mass index;
LUAD	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg01579765	chr21:45077557	HSF2BP	-0.57	-12.72	-0.53	1.25e-31	Mean corpuscular volume;
LUAD	cis	rs3087591	0.922	rs12950506	chr17:29598392	A/G	cg24425628	chr17:29625626	OMG;NF1	0.41	6.64	0.31	9.46e-11	Hip circumference;
LUAD	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.73	-12.01	-0.5	8.8e-29	Primary sclerosing cholangitis;
LUAD	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg22482690	chr17:47019901	SNF8	0.45	8.45	0.38	4.67e-16	Type 2 diabetes;
LUAD	trans	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg01620082	chr3:125678407	NA	-0.74	-7.7	-0.35	9.99e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4638749	0.627	rs6542753	chr2:108815852	T/A	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.39	-0.34	7.97e-13	Blood pressure;
LUAD	cis	rs7737355	0.773	rs3756291	chr5:130926822	T/C	cg06307176	chr5:131281290	NA	0.41	6.73	0.31	5.71e-11	Life satisfaction;
LUAD	trans	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg06606381	chr12:133084897	FBRSL1	-1.07	-7.9	-0.36	2.42e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7737355	0.812	rs9687376	chr5:130918037	A/C	cg25547332	chr5:131281432	NA	0.41	6.47	0.3	2.75e-10	Life satisfaction;
LUAD	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg15900387	chr1:150738905	CTSS	-0.37	-6.69	-0.31	7.3e-11	Melanoma;
LUAD	cis	rs16958440	0.867	rs16949157	chr18:44691324	A/G	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs7731657	0.537	rs6867710	chr5:130201260	A/C	cg08523029	chr5:130500466	HINT1	-0.58	-7.53	-0.34	3.1400000000000003e-13	Fasting plasma glucose;
LUAD	cis	rs12431939	0.626	rs8015848	chr14:51715021	G/A	cg23942311	chr14:51606299	NA	0.43	6.52	0.3	1.96e-10	Cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22020752	chr12:22697546	KIAA0528	-0.42	-6.89	-0.32	2.08e-11	Cancer;
LUAD	cis	rs10193935	0.901	rs13384404	chr2:42601147	G/T	cg27598129	chr2:42591480	NA	-0.76	-9.9	-0.43	6.32e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6942407	0.592	rs6964225	chr7:86775235	A/G	cg10579408	chr7:86850525	C7orf23	0.47	6.41	0.3	3.86e-10	Food allergy;
LUAD	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg22117172	chr7:91764530	CYP51A1	0.33	7.36	0.34	9.49e-13	Breast cancer;
LUAD	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg10755058	chr3:40428713	ENTPD3	0.46	8.47	0.38	4.12e-16	Renal cell carcinoma;
LUAD	cis	rs10858096	0.608	rs413582	chr1:109851126	C/T	cg08367326	chr1:110052010	AMIGO1	0.43	7.32	0.34	1.3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.41	0.3	3.89e-10	Cognitive test performance;
LUAD	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg20891283	chr12:69753455	YEATS4	0.45	7.41	0.34	6.96e-13	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg26102564	chr10:131424627	MGMT	0.33	6.37	0.3	5.08e-10	Response to temozolomide;
LUAD	cis	rs870825	0.550	rs10000507	chr4:185619281	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	13.59	0.55	3.78e-35	Blood protein levels;
LUAD	cis	rs89107	0.688	rs281861	chr6:118579357	T/G	cg21191810	chr6:118973309	C6orf204	0.49	9.6	0.42	7.38e-20	Cardiac structure and function;
LUAD	cis	rs9308433	0.643	rs7412913	chr1:214463228	G/A	cg06198575	chr1:214491504	SMYD2	0.41	7.12	0.33	4.58e-12	IgG glycosylation;
LUAD	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg12623918	chr2:306882	NA	0.35	7.25	0.33	2.02e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.04e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs3789045	0.866	rs11584700	chr1:204576983	C/T	cg17419461	chr1:204415978	PIK3C2B	0.38	6.5	0.3	2.29e-10	Educational attainment (college completion);
LUAD	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg01884057	chr2:25150051	NA	0.34	7.22	0.33	2.49e-12	Body mass index;
LUAD	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg11494091	chr17:61959527	GH2	0.41	7.2	0.33	2.78e-12	Height;
LUAD	cis	rs733175	0.794	rs7678211	chr4:10057583	T/G	cg00071950	chr4:10020882	SLC2A9	0.45	6.86	0.32	2.47e-11	Psychosis and Alzheimer's disease;
LUAD	cis	rs5756813	0.727	rs4820303	chr22:38134166	G/A	cg06521852	chr22:38141419	TRIOBP	0.49	8.86	0.4	2.18e-17	Optic cup area;Vertical cup-disc ratio;
LUAD	trans	rs3857536	0.813	rs6455091	chr6:66949127	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg06753227	chr18:9475508	RALBP1	-0.39	-6.66	-0.31	8.34e-11	Schizophrenia;
LUAD	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	7.69	0.35	1.04e-13	Menopause (age at onset);
LUAD	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg08508325	chr11:3079039	CARS	0.44	8.85	0.4	2.46e-17	Calcium levels;
LUAD	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg14196790	chr5:131705035	SLC22A5	0.56	10.42	0.45	8.8e-23	Blood metabolite levels;
LUAD	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg22906224	chr7:99728672	NA	0.68	11.79	0.5	5.92e-28	Coronary artery disease;
LUAD	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg13319975	chr6:146136371	FBXO30	-0.6	-10.09	-0.44	1.36e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4594175	0.926	rs10135534	chr14:51617970	C/A	cg23942311	chr14:51606299	NA	0.64	11.21	0.48	1e-25	Cancer;
LUAD	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg04944784	chr2:26401820	FAM59B	0.88	12.38	0.52	3.05e-30	Gut microbiome composition (summer);
LUAD	cis	rs2386661	0.591	rs11255051	chr10:5653450	A/G	cg17085576	chr10:5658249	NA	-0.4	-6.56	-0.3	1.61e-10	Breast cancer;
LUAD	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg15704280	chr7:45808275	SEPT13	0.64	8.17	0.37	3.52e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg09367891	chr1:107599246	PRMT6	-0.48	-8.22	-0.37	2.57e-15	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg25985355	chr7:65971099	NA	0.54	6.72	0.31	5.74e-11	Diabetic kidney disease;
LUAD	cis	rs10465746	0.725	rs6694752	chr1:84389960	C/T	cg10977910	chr1:84465055	TTLL7	0.6	9.74	0.43	2.28e-20	Obesity-related traits;
LUAD	cis	rs2692947	0.537	rs12468117	chr2:96194583	C/G	cg23100626	chr2:96804247	ASTL	0.33	8.08	0.37	6.68e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs113835537	0.597	rs7939759	chr11:66337964	C/T	cg24851651	chr11:66362959	CCS	0.6	10.56	0.46	2.77e-23	Airway imaging phenotypes;
LUAD	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg03388025	chr16:89894329	SPIRE2	0.51	13.4	0.55	2.23e-34	Vitiligo;
LUAD	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg08508325	chr11:3079039	CARS	0.51	11.14	0.48	1.84e-25	Longevity;
LUAD	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg07404485	chr7:94953653	PON1	-0.49	-7.05	-0.32	7.28e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs12216545	0.765	rs4607525	chr7:150229350	A/T	cg08960815	chr7:150264767	GIMAP4	-0.31	-6.72	-0.31	5.98e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg08859206	chr1:53392774	SCP2	-0.59	-10.4	-0.45	1.06e-22	Monocyte count;
LUAD	cis	rs760805	1.000	rs3845302	chr1:25259884	C/G	cg22509179	chr1:25234806	RUNX3	-0.72	-12.59	-0.52	4.37e-31	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10802521	chr3:52805072	NEK4	-0.53	-9.0	-0.4	7.89e-18	Bipolar disorder;
LUAD	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.5	-8.27	-0.37	1.75e-15	Reticulocyte count;
LUAD	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg16049864	chr8:95962084	TP53INP1	-0.37	-6.56	-0.3	1.55e-10	Type 2 diabetes;
LUAD	cis	rs9899728	0.539	rs12938889	chr17:73039929	A/C	cg27626185	chr17:73056755	KCTD2	0.95	11.1	0.48	2.59e-25	Alzheimer's disease or small vessel stroke;
LUAD	cis	rs7737355	0.773	rs4706023	chr5:130882379	T/C	cg06307176	chr5:131281290	NA	0.44	7.14	0.33	4.19e-12	Life satisfaction;
LUAD	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg24675658	chr1:53192096	ZYG11B	-0.42	-7.06	-0.32	6.87e-12	Monocyte count;
LUAD	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg07537917	chr2:241836409	C2orf54	-0.32	-9.18	-0.41	1.92e-18	Urinary metabolites;
LUAD	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.66	-0.35	1.29e-13	Alzheimer's disease (late onset);
LUAD	trans	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg26043149	chr18:55253948	FECH	-0.41	-6.58	-0.3	1.36e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.57	7.91	0.36	2.21e-14	Renal function-related traits (BUN);
LUAD	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	10.95	0.47	9.74e-25	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.04e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg06671706	chr8:8559999	CLDN23	0.61	10.68	0.46	9.89e-24	Obesity-related traits;
LUAD	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-8.48	-0.38	3.89e-16	Monocyte percentage of white cells;
LUAD	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg26597838	chr10:835615	NA	0.84	13.01	0.53	8.81e-33	Eosinophil percentage of granulocytes;
LUAD	cis	rs1595825	0.891	rs16826873	chr2:198898222	A/C	cg00361562	chr2:198649771	BOLL	0.47	6.58	0.3	1.36e-10	Ulcerative colitis;
LUAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg18621852	chr3:10150065	C3orf24	0.51	9.11	0.4	3.39e-18	Alzheimer's disease;
LUAD	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg05535760	chr7:792225	HEATR2	0.87	11.65	0.49	2.07e-27	Cerebrospinal P-tau181p levels;
LUAD	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27297192	chr10:134578999	INPP5A	0.38	6.72	0.31	6.05e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg26039829	chr8:22132926	PIWIL2	0.58	10.78	0.46	4.12e-24	Hypertriglyceridemia;
LUAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.62	-10.89	-0.47	1.57e-24	Lymphocyte counts;
LUAD	trans	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	6.07e-11	Depression;
LUAD	cis	rs9581857	0.685	rs11839899	chr13:28041780	G/A	cg22138327	chr13:27999177	GTF3A	0.84	9.65	0.42	4.63e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.81	0.31	3.3e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs1113500	0.862	rs2336129	chr1:108640669	A/G	cg06207961	chr1:108661230	NA	-0.45	-8.33	-0.38	1.14e-15	Growth-regulated protein alpha levels;
LUAD	cis	rs10821973	0.527	rs7092746	chr10:63971245	T/C	cg09941381	chr10:64027924	RTKN2	-0.35	-6.83	-0.32	3.03e-11	Hypothyroidism;
LUAD	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-8.51	-0.38	3.14e-16	Type 2 diabetes;
LUAD	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg14779329	chr11:130786720	SNX19	-0.38	-6.66	-0.31	8.66e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4555082	1.000	rs66777564	chr14:105760245	A/G	cg10792982	chr14:105748885	BRF1	0.41	8.9	0.4	1.67e-17	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg19041857	chr6:27730383	NA	-0.45	-7.69	-0.35	1.07e-13	Parkinson's disease;
LUAD	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg00769240	chr8:12517080	NA	-0.4	-6.82	-0.31	3.14e-11	Blood pressure (smoking interaction);
LUAD	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg18240062	chr17:79603768	NPLOC4	0.44	7.57	0.35	2.37e-13	Eye color traits;
LUAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.4	-8.53	-0.38	2.62e-16	Lymphocyte counts;
LUAD	trans	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.23	-0.33	2.21e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg23018236	chr17:30244563	NA	-0.68	-8.3	-0.37	1.45e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg21798802	chr22:38057573	PDXP	0.37	7.59	0.35	2.06e-13	Fat distribution (HIV);
LUAD	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18099408	chr3:52552593	STAB1	-0.4	-7.2	-0.33	2.78e-12	Bipolar disorder;
LUAD	trans	rs3942852	0.869	rs4752806	chr11:48118199	G/C	cg03929089	chr4:120376271	NA	-0.53	-7.01	-0.32	9.21e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs71636778	0.543	rs10493037	chr1:27248645	A/G	cg12203394	chr1:27248618	NUDC	0.52	6.65	0.31	8.83e-11	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg02631126	chr6:28058918	ZSCAN12L1	-0.39	-7.96	-0.36	1.59e-14	Depression;
LUAD	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.55e-13	Menopause (age at onset);
LUAD	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-9.31	-0.41	7.23e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg27327370	chr2:192746685	NA	-0.42	-6.42	-0.3	3.77e-10	Height;
LUAD	cis	rs7301826	0.651	rs10744483	chr12:131298206	C/A	cg11011512	chr12:131303247	STX2	0.44	7.42	0.34	6.59e-13	Plasma plasminogen activator levels;
LUAD	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg01299579	chr2:10830716	NOL10	0.41	7.15	0.33	3.86e-12	Prostate cancer;
LUAD	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg24069376	chr3:38537580	EXOG	0.43	10.17	0.44	6.87e-22	Electrocardiographic conduction measures;
LUAD	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg24675658	chr1:53192096	ZYG11B	-0.38	-6.45	-0.3	3.01e-10	Monocyte count;
LUAD	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg23262073	chr20:60523788	NA	-0.47	-7.72	-0.35	8.45e-14	Body mass index;
LUAD	trans	rs783540	0.835	rs8030185	chr15:83391537	G/A	cg18393722	chr15:85113863	UBE2QP1	0.47	7.62	0.35	1.69e-13	Schizophrenia;
LUAD	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg13319975	chr6:146136371	FBXO30	-0.57	-9.68	-0.43	3.88e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18876405	chr7:65276391	NA	-0.58	-9.72	-0.43	2.82e-20	Aortic root size;
LUAD	cis	rs4924935	0.509	rs8074020	chr17:18801380	T/C	cg25390199	chr17:18761479	PRPSAP2	-0.4	-6.88	-0.32	2.15e-11	Pancreatic cancer;
LUAD	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.39	-7.06	-0.32	6.85e-12	Cystic fibrosis severity;
LUAD	cis	rs6740322	1.000	rs11693666	chr2:43562479	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.71	10.52	0.46	3.85e-23	Coronary artery disease;
LUAD	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg13319975	chr6:146136371	FBXO30	-0.58	-9.71	-0.43	2.94e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2742234	0.541	rs871763	chr10:43734188	C/T	cg15436174	chr10:43711423	RASGEF1A	0.54	9.04	0.4	5.59e-18	Hirschsprung disease;
LUAD	cis	rs870825	0.616	rs10006828	chr4:185651416	C/T	cg04058563	chr4:185651563	MLF1IP	0.9	14.58	0.58	2.63e-39	Blood protein levels;
LUAD	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg20129853	chr10:51489980	NA	-0.36	-7.18	-0.33	3.17e-12	Prostate-specific antigen levels;
LUAD	cis	rs7267979	0.932	rs6107052	chr20:25530838	G/A	cg08601574	chr20:25228251	PYGB	0.42	7.62	0.35	1.64e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.28	0.37	1.66e-15	Rheumatoid arthritis;
LUAD	cis	rs240764	0.548	rs12206838	chr6:101180128	G/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.55	-0.38	2.24e-16	Neuroticism;
LUAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg22535103	chr8:58192502	C8orf71	-0.72	-8.94	-0.4	1.24e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10155981	0.510	rs78815495	chr7:22584529	C/T	cg05062323	chr7:22590069	NA	-0.62	-6.48	-0.3	2.5e-10	Bilirubin levels;
LUAD	cis	rs4072705	1.000	rs4838203	chr9:127498374	T/C	cg13476313	chr9:127244764	NR5A1	0.29	6.9	0.32	1.9e-11	Menarche (age at onset);
LUAD	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-13.39	-0.55	2.38e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6669072	0.967	rs12130887	chr1:91240696	G/T	cg08895590	chr1:91227319	NA	-0.34	-6.81	-0.31	3.32e-11	Cognitive function;
LUAD	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12756686	chr19:29218302	NA	0.68	9.85	0.43	9.4e-21	Methadone dose in opioid dependence;
LUAD	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg04756594	chr16:24857601	SLC5A11	-0.75	-13.31	-0.54	5e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18876405	chr7:65276391	NA	0.56	9.43	0.42	2.84e-19	Aortic root size;
LUAD	cis	rs7937890	0.559	rs2597197	chr11:14489832	G/A	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.44e-11	Mitochondrial DNA levels;
LUAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.29	0.66	1.79e-55	Prudent dietary pattern;
LUAD	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg05340658	chr4:99064831	C4orf37	0.45	7.47	0.34	4.69e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.41	-7.53	-0.34	3.1e-13	Longevity;Endometriosis;
LUAD	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg07343612	chr16:622815	PIGQ	-0.79	-15.58	-0.6	1.46e-43	Height;
LUAD	cis	rs938554	0.692	rs6449213	chr4:9994215	A/G	cg02734326	chr4:10020555	SLC2A9	-0.46	-6.54	-0.3	1.77e-10	Blood metabolite levels;
LUAD	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg02176678	chr2:219576539	TTLL4	-0.82	-17.35	-0.64	2.51e-51	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.55	0.52	6.47e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.617	rs1502799	chr12:86474921	T/C	cg19622623	chr12:86230825	RASSF9	0.41	7.39	0.34	8.03e-13	Major depressive disorder;
LUAD	cis	rs6087990	1.000	rs1007123	chr20:31345840	G/A	cg13636640	chr20:31349939	DNMT3B	0.84	15.88	0.61	7e-45	Ulcerative colitis;
LUAD	trans	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.6	-10.5	-0.45	4.59e-23	Mean corpuscular volume;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01669482	chr16:25043131	NA	-0.44	-6.93	-0.32	1.59e-11	Height;
LUAD	cis	rs10419226	0.555	rs3829671	chr19:18777667	T/C	cg22001208	chr19:18782374	NA	-0.49	-8.13	-0.37	4.78e-15	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg16405210	chr4:1374714	KIAA1530	-0.61	-9.31	-0.41	6.84e-19	Longevity;
LUAD	cis	rs1448094	1.000	rs7305284	chr12:86343786	C/T	cg19622623	chr12:86230825	RASSF9	-0.36	-6.52	-0.3	2.03e-10	Major depressive disorder;
LUAD	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.29	6.86	0.32	2.38e-11	Prostate cancer;
LUAD	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg18451016	chr1:38461880	NA	-0.45	-8.0	-0.36	1.25e-14	Coronary artery disease;
LUAD	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg04155231	chr12:9217510	LOC144571	-0.44	-8.37	-0.38	8.52e-16	Sjögren's syndrome;
LUAD	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	6.49	0.3	2.34e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1941023	0.503	rs10792269	chr11:60117126	C/T	cg08716584	chr11:60157161	MS4A7	-0.44	-8.59	-0.39	1.69e-16	Congenital heart disease (maternal effect);
LUAD	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg08798685	chr6:27730294	NA	-0.62	-7.16	-0.33	3.56e-12	Breast cancer;
LUAD	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg20701182	chr2:24300061	SF3B14	0.57	6.83	0.32	2.9e-11	Lymphocyte counts;
LUAD	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.78	-0.39	4.19e-17	Total body bone mineral density;
LUAD	cis	rs2625529	0.730	rs7177242	chr15:72184114	A/G	cg16672083	chr15:72433130	SENP8	0.66	12.0	0.5	9.2e-29	Red blood cell count;
LUAD	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg05082376	chr22:42548792	NA	-0.44	-7.68	-0.35	1.08e-13	Schizophrenia;
LUAD	cis	rs939658	0.967	rs7172074	chr15:79452726	T/C	cg17916960	chr15:79447300	NA	0.46	9.42	0.42	2.98e-19	Refractive error;
LUAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg15242686	chr22:24348715	GSTTP1	0.4	6.74	0.31	5.08e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg27661571	chr11:113659931	NA	-0.69	-8.12	-0.37	5.29e-15	Hip circumference adjusted for BMI;
LUAD	trans	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg20587970	chr11:113659929	NA	0.9	11.8	0.5	5.46e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg02734326	chr4:10020555	SLC2A9	0.6	10.75	0.46	5.61e-24	Bone mineral density;
LUAD	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg06636551	chr8:101224915	SPAG1	0.4	7.21	0.33	2.54e-12	Atrioventricular conduction;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg23104823	chr14:45553408	PRPF39	0.42	6.68	0.31	7.46e-11	Monocyte percentage of white cells;
LUAD	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.07	0.33	6.37e-12	Menopause (age at onset);
LUAD	trans	rs12517041	0.873	rs6886748	chr5:23307271	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.49	-6.92	-0.32	1.73e-11	Calcium levels;
LUAD	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg04944784	chr2:26401820	FAM59B	-0.69	-9.75	-0.43	2.15e-20	Gut microbiome composition (summer);
LUAD	cis	rs7188873	1	rs7188873	chr16:24727064	A/G	cg04756594	chr16:24857601	SLC5A11	-0.44	-8.64	-0.39	1.18e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06022373	chr22:39101656	GTPBP1	0.44	6.82	0.31	3.11e-11	Menopause (age at onset);
LUAD	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg12193833	chr17:30244370	NA	-0.54	-6.97	-0.32	1.24e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs4242434	0.819	rs6999893	chr8:22465427	T/C	cg03733263	chr8:22462867	KIAA1967	0.71	12.51	0.52	9.29e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg02993280	chr1:107599747	PRMT6	0.53	8.61	0.39	1.51e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.43	-8.03	-0.36	9.85e-15	IgG glycosylation;
LUAD	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-23.73	-0.76	9.7e-80	Height;
LUAD	cis	rs2486012	1.000	rs2428953	chr1:44443459	G/A	cg12908607	chr1:44402522	ARTN	0.5	6.49	0.3	2.4e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6076065	0.723	rs6137940	chr20:23397491	G/C	cg11657817	chr20:23433608	CST11	0.46	8.62	0.39	1.34e-16	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs4523957	0.855	rs12602764	chr17:2123200	A/T	cg16513277	chr17:2031491	SMG6	-0.81	-15.06	-0.59	2.36e-41	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs877282	0.945	rs12767287	chr10:787310	A/G	cg17470449	chr10:769945	NA	0.61	8.57	0.38	2.01e-16	Uric acid levels;
LUAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg24813613	chr7:1882135	MAD1L1	-0.4	-6.57	-0.3	1.48e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg16606324	chr3:10149918	C3orf24	0.67	11.03	0.47	4.77e-25	Alzheimer's disease;
LUAD	cis	rs4604732	0.631	rs75320597	chr1:247626751	T/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg20607798	chr8:58055168	NA	0.66	8.74	0.39	5.64e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs11650175	0.855	rs8067054	chr17:63720840	C/T	cg07283582	chr17:63770753	CCDC46	-0.34	-6.49	-0.3	2.38e-10	Chin dimples;
LUAD	cis	rs35883536	0.967	rs1582091	chr1:101177133	G/T	cg06223162	chr1:101003688	GPR88	0.36	6.78	0.31	4.18e-11	Monocyte count;
LUAD	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg09455208	chr3:40491958	NA	0.53	11.34	0.48	3.34e-26	Renal cell carcinoma;
LUAD	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg11242978	chr22:46423387	NA	0.4	6.92	0.32	1.72e-11	Dupuytren's disease;
LUAD	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg13319975	chr6:146136371	FBXO30	-0.59	-9.97	-0.44	3.68e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg00757033	chr12:89920650	WDR51B	0.69	12.12	0.51	3.22e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg25456477	chr12:86230367	RASSF9	0.32	6.48	0.3	2.59e-10	Major depressive disorder;
LUAD	cis	rs3806843	0.576	rs251368	chr5:140241027	G/T	cg18668511	chr5:140557227	PCDHB8	0.4	7.47	0.34	4.74e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1509123	0.609	rs17804635	chr17:6703985	A/G	cg12642237	chr17:6703447	TEKT1	0.53	8.04	0.36	8.93e-15	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11948739	0.610	rs994957	chr5:130291595	A/G	cg08523029	chr5:130500466	HINT1	-0.58	-7.5	-0.34	3.81e-13	Pediatric bone mineral content (hip);
LUAD	cis	rs12681287	0.571	rs10097450	chr8:87358677	G/A	cg27223183	chr8:87520930	FAM82B	0.69	9.65	0.42	4.81e-20	Caudate activity during reward;
LUAD	cis	rs62238980	0.614	rs4821018	chr22:32403318	A/G	cg00543991	chr22:32367038	NA	-0.76	-7.9	-0.36	2.45e-14	Childhood ear infection;
LUAD	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg10589385	chr1:150898437	SETDB1	-0.37	-6.57	-0.3	1.47e-10	Urate levels;
LUAD	cis	rs494562	0.892	rs7771860	chr6:86130729	C/T	cg21730993	chr6:86159210	NT5E	0.72	8.26	0.37	1.91e-15	Blood metabolite levels;Metabolic traits;
LUAD	trans	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg26043149	chr18:55253948	FECH	0.5	8.36	0.38	8.83e-16	Bone mineral density;
LUAD	cis	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg00071950	chr4:10020882	SLC2A9	0.54	8.04	0.36	9.2e-15	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs1950626	0.532	rs61991120	chr14:101455222	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.38	7.57	0.35	2.34e-13	Pelvic organ prolapse (moderate/severe);
LUAD	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg18944383	chr4:111397179	ENPEP	0.38	7.76	0.35	6.25e-14	Height;
LUAD	cis	rs12681287	0.640	rs67123356	chr8:87453992	A/C	cg00550725	chr8:87521180	FAM82B	0.46	6.61	0.31	1.13e-10	Caudate activity during reward;
LUAD	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg07570687	chr10:102243282	WNT8B	0.48	7.11	0.33	5.11e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs2573652	1.000	rs2581365	chr15:100513318	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.48	-8.44	-0.38	4.95e-16	Height;
LUAD	cis	rs2274273	0.686	rs2182207	chr14:55589803	G/A	cg04306507	chr14:55594613	LGALS3	0.4	7.46	0.34	5.1e-13	Protein biomarker;
LUAD	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.43	-0.42	2.81e-19	Life satisfaction;
LUAD	cis	rs2425143	1.000	rs73902914	chr20:34432882	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.84	-0.32	2.86e-11	Blood protein levels;
LUAD	cis	rs8048589	1.000	rs11642386	chr16:12184064	C/A	cg03816625	chr16:12192430	SNX29	0.54	8.0	0.36	1.17e-14	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-7.2	-0.33	2.84e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs2249625	0.523	rs1969530	chr6:72861276	A/C	cg18830697	chr6:72922368	RIMS1	-0.38	-7.35	-0.34	1.02e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg05590025	chr7:65112418	INTS4L2	-0.78	-8.24	-0.37	2.12e-15	Diabetic kidney disease;
LUAD	cis	rs17154702	0.506	rs28583936	chr8:8647160	C/T	cg01851573	chr8:8652454	MFHAS1	0.6	7.47	0.34	4.56e-13	Neurocognitive impairment in HIV-1 infection (continuous);
LUAD	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	12.46	0.52	1.39e-30	Bone mineral density;
LUAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg18621852	chr3:10150065	C3orf24	0.49	8.83	0.39	2.72e-17	Alzheimer's disease;
LUAD	cis	rs1451375	0.617	rs2329371	chr7:50615440	G/A	cg18232548	chr7:50535776	DDC	0.61	8.54	0.38	2.46e-16	Malaria;
LUAD	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.48	0.3	2.53e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs1232027	0.656	rs1650688	chr5:79956129	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.47	-7.49	-0.34	4.06e-13	Huntington's disease progression;
LUAD	cis	rs490234	0.934	rs12553637	chr9:128277258	A/G	cg14078157	chr9:128172775	NA	-0.37	-6.75	-0.31	4.74e-11	Mean arterial pressure;
LUAD	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.06e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03264133	chr6:25882463	NA	-0.48	-7.14	-0.33	4.16e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs12545109	0.671	rs35500854	chr8:57424303	G/A	cg19413350	chr8:57351067	NA	-0.46	-6.87	-0.32	2.33e-11	Obesity-related traits;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26371787	chr6:7910221	TXNDC5	-0.63	-7.68	-0.35	1.1e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7937890	0.535	rs2575857	chr11:14501296	C/T	cg22961513	chr11:14280813	SPON1	-0.37	-7.22	-0.33	2.49e-12	Mitochondrial DNA levels;
LUAD	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.43	0.42	2.64e-19	Tonsillectomy;
LUAD	cis	rs11048434	0.761	rs2377675	chr12:9124765	C/T	cg26114124	chr12:9217669	LOC144571	0.4	7.27	0.33	1.7e-12	Sjögren's syndrome;
LUAD	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg11189052	chr15:85197271	WDR73	0.59	7.51	0.34	3.54e-13	Schizophrenia;
LUAD	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg22143856	chr6:28129313	ZNF389	-0.46	-6.67	-0.31	7.86e-11	Depression;
LUAD	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg18944383	chr4:111397179	ENPEP	0.39	7.52	0.34	3.22e-13	Height;
LUAD	trans	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg03886242	chr7:26192032	NFE2L3	-0.39	-6.39	-0.3	4.34e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7264396	0.836	rs1886695	chr20:34180535	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.43	6.53	0.3	1.94e-10	Total cholesterol levels;
LUAD	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg14196790	chr5:131705035	SLC22A5	0.47	8.59	0.39	1.64e-16	Blood metabolite levels;
LUAD	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-9.95	-0.44	4.42e-21	Schizophrenia;
LUAD	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg01689657	chr7:91764605	CYP51A1	-0.3	-7.29	-0.33	1.58e-12	Breast cancer;
LUAD	cis	rs2455601	0.786	rs3763914	chr11:8940703	G/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-8.87	-0.4	2.12e-17	Schizophrenia;
LUAD	cis	rs73416724	0.920	rs76088627	chr6:43311851	G/A	cg26312998	chr6:43337775	ZNF318	0.55	6.69	0.31	7.26e-11	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg14917512	chr19:3094685	GNA11	-0.56	-6.55	-0.3	1.72e-10	Diabetic kidney disease;
LUAD	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.69	12.84	0.53	4.31e-32	Cognitive ability;
LUAD	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg07305463	chr2:136567211	LCT	0.39	7.39	0.34	7.81e-13	Mosquito bite size;
LUAD	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg04568274	chr7:158649319	WDR60	0.42	6.87	0.32	2.26e-11	Height;
LUAD	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg18944383	chr4:111397179	ENPEP	0.49	8.86	0.4	2.21e-17	Height;
LUAD	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.47	-0.34	4.7e-13	Bone mineral density;
LUAD	cis	rs11696501	0.688	rs2072974	chr20:44313401	G/A	cg11783356	chr20:44313418	WFDC10B	-0.48	-7.79	-0.35	5.38e-14	Brain structure;
LUAD	cis	rs10781543	0.839	rs6560632	chr9:139371786	A/C	cg14019695	chr9:139328340	INPP5E	0.53	10.37	0.45	1.32e-22	Monocyte percentage of white cells;
LUAD	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg10518543	chr12:38710700	ALG10B	-0.5	-8.41	-0.38	6.14e-16	Morning vs. evening chronotype;
LUAD	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg04455712	chr21:45112962	RRP1B	0.47	9.33	0.41	6.1e-19	Mean corpuscular volume;
LUAD	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg18569988	chr3:195679450	NA	0.4	6.35	0.3	5.56e-10	Pancreatic cancer;
LUAD	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.1	0.33	5.41e-12	Motion sickness;
LUAD	cis	rs2880765	0.835	rs4843062	chr15:86040137	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.57	-0.3	1.49e-10	Coronary artery disease;
LUAD	trans	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg19862616	chr7:65841803	NCRNA00174	1.01	24.39	0.76	1.17e-82	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2046867	0.818	rs67355490	chr3:72830935	T/C	cg04365224	chr3:72788183	NA	-0.47	-6.96	-0.32	1.32e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7786808	0.552	rs4909205	chr7:158185283	G/A	cg09998033	chr7:158218633	PTPRN2	-0.44	-7.76	-0.35	6.24e-14	Obesity-related traits;
LUAD	cis	rs7264396	1.000	rs6060479	chr20:34165723	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.41	6.53	0.3	1.89e-10	Total cholesterol levels;
LUAD	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg13319975	chr6:146136371	FBXO30	-0.58	-9.78	-0.43	1.71e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg17063962	chr7:91808500	NA	-0.69	-11.98	-0.5	1.09e-28	Breast cancer;
LUAD	cis	rs2554380	0.628	rs919069	chr15:84444528	G/C	cg14598478	chr15:84363061	ADAMTSL3	-0.4	-7.14	-0.33	3.99e-12	Height;
LUAD	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.71	9.76	0.43	2.06e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.88	-0.36	2.78e-14	Monocyte percentage of white cells;
LUAD	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22857025	chr5:266934	NA	-0.97	-14.68	-0.58	1.01e-39	Breast cancer;
LUAD	cis	rs8027181	1.000	rs8030477	chr15:73085815	C/T	cg25632853	chr15:73088954	NA	0.37	8.2	0.37	2.89e-15	Triglyceride levels;
LUAD	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-8.67	-0.39	9.4e-17	Monocyte percentage of white cells;
LUAD	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg02160872	chr5:212506	CCDC127	-0.51	-6.61	-0.31	1.16e-10	Breast cancer;
LUAD	trans	rs79911532	0.515	rs117982500	chr7:75758907	C/A	cg19862616	chr7:65841803	NCRNA00174	0.83	8.52	0.38	2.76e-16	Mononucleosis;
LUAD	trans	rs87938	1.000	rs385905	chr3:41127511	C/T	cg11224624	chr8:145049280	PLEC1	-0.39	-6.47	-0.3	2.78e-10	Bone mineral density (hip);
LUAD	cis	rs807669	0.807	rs807431	chr22:19242361	G/A	cg02655711	chr22:19163373	SLC25A1	0.7	14.92	0.59	1e-40	Metabolite levels;
LUAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.79	-16.84	-0.63	4.56e-49	Longevity;Endometriosis;
LUAD	cis	rs12519773	0.501	rs4449514	chr5:92521022	T/C	cg18783429	chr5:92414398	NA	0.43	7.63	0.35	1.5700000000000001e-13	Migraine;
LUAD	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg09491104	chr22:46646882	C22orf40	-0.74	-13.44	-0.55	1.6e-34	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs758324	0.773	rs630044	chr5:131258378	G/T	cg06307176	chr5:131281290	NA	0.44	7.45	0.34	5.22e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs11971779	0.680	rs10261557	chr7:139099037	G/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs16958440	0.867	rs74845165	chr18:44690852	T/C	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs7589342	0.929	rs13024715	chr2:106433950	A/G	cg16077055	chr2:106428750	NCK2	0.36	6.39	0.3	4.26e-10	Addiction;
LUAD	trans	rs2045966	0.881	rs1714401	chr8:98482437	A/G	cg12935937	chr20:4804718	RASSF2	-0.68	-6.65	-0.31	8.83e-11	nicotine metabolite ratio in current smokers;
LUAD	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg10589385	chr1:150898437	SETDB1	0.45	8.44	0.38	5.11e-16	Melanoma;
LUAD	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg15128208	chr22:42549153	NA	0.37	7.59	0.35	2.01e-13	Cognitive function;
LUAD	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg03289416	chr15:75166202	SCAMP2	0.45	7.76	0.35	6.31e-14	Breast cancer;
LUAD	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg07211511	chr3:129823064	LOC729375	-0.47	-6.78	-0.31	4.09e-11	Blood pressure (smoking interaction);
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg26563553	chr8:23261731	LOXL2	-0.52	-6.92	-0.32	1.64e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs739496	0.947	rs2301622	chr12:111895203	C/G	cg10833066	chr12:111807467	FAM109A	0.45	8.27	0.37	1.79e-15	Platelet count;
LUAD	trans	rs7786808	0.552	rs12539355	chr7:158187565	C/T	cg02030672	chr11:45687055	CHST1	0.43	7.64	0.35	1.45e-13	Obesity-related traits;
LUAD	cis	rs11901793	0.505	rs34446892	chr2:237495452	C/T	cg25295825	chr2:237489920	CXCR7	0.49	6.96	0.32	1.29e-11	Total mean fractional anisotropy measurement in first episode schizophrenia;
LUAD	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg24733560	chr20:60626293	TAF4	0.46	8.24	0.37	2.13e-15	Body mass index;
LUAD	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg14530993	chr4:882597	GAK	0.76	7.24	0.33	2.09e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7291412	0.929	rs7289457	chr22:46456603	C/T	cg24349631	chr22:46449752	C22orf26;LOC150381	0.36	6.65	0.31	8.92e-11	Dupuytren's disease;Subjective well-being;
LUAD	cis	rs1215050	0.791	rs2865942	chr4:98737709	G/C	cg17366294	chr4:99064904	C4orf37	0.48	8.68	0.39	8.6e-17	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg25251562	chr2:3704773	ALLC	-0.51	-8.34	-0.38	1.04e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg12935359	chr14:103987150	CKB	-0.45	-7.38	-0.34	8.62e-13	Body mass index;
LUAD	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg06221963	chr1:154839813	KCNN3	0.88	21.08	0.72	6.02e-68	Prostate cancer;
LUAD	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg25804541	chr17:80189381	SLC16A3	0.3	6.52	0.3	1.97e-10	Life satisfaction;
LUAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg05896524	chr21:47604654	C21orf56	0.73	12.88	0.53	2.91e-32	Testicular germ cell tumor;
LUAD	cis	rs6842047	0.520	rs4253425	chr4:187205929	T/C	cg02012338	chr4:187126139	CYP4V2	0.71	6.77	0.31	4.41e-11	Blood protein levels;
LUAD	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg23352942	chr3:46931381	PTH1R	-0.37	-7.51	-0.34	3.54e-13	Birth weight;
LUAD	cis	rs6840360	0.593	rs10013612	chr4:152693622	A/G	cg22705602	chr4:152727874	NA	-0.48	-9.28	-0.41	9.03e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg18621852	chr3:10150065	C3orf24	0.42	7.36	0.34	9.46e-13	Alzheimer's disease;
LUAD	trans	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.42	0.55	1.77e-34	Exhaled nitric oxide output;
LUAD	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg18944383	chr4:111397179	ENPEP	0.47	8.29	0.37	1.56e-15	Coronary artery disease;
LUAD	cis	rs7737355	0.773	rs3776006	chr5:130875538	C/T	cg25547332	chr5:131281432	NA	0.43	6.91	0.32	1.82e-11	Life satisfaction;
LUAD	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg17849569	chr6:28058911	ZSCAN12L1	0.31	7.01	0.32	9.66e-12	Parkinson's disease;
LUAD	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg07952391	chr2:88470173	THNSL2	0.77	8.44	0.38	4.92e-16	Plasma clusterin levels;
LUAD	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03517284	chr6:25882590	NA	-0.53	-8.07	-0.37	7.29e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs332507	0.830	rs2173852	chr3:124420102	C/G	cg05980111	chr3:124395277	KALRN	-0.4	-6.53	-0.3	1.93e-10	Plateletcrit;
LUAD	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg17863274	chr19:49399704	TULP2	-0.54	-8.86	-0.4	2.25e-17	Red cell distribution width;
LUAD	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg03563238	chr19:33554763	RHPN2	-0.38	-8.85	-0.4	2.44e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg04944784	chr2:26401820	FAM59B	-0.87	-12.55	-0.52	6.19e-31	Gut microbiome composition (summer);
LUAD	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg10544611	chr16:67998164	SLC12A4	-0.57	-7.12	-0.33	4.72e-12	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg27411982	chr8:10470053	RP1L1	0.38	6.66	0.31	8.63e-11	Morning vs. evening chronotype;
LUAD	cis	rs2625529	0.824	rs2306488	chr15:72292115	A/G	cg16672083	chr15:72433130	SENP8	-0.76	-12.71	-0.53	1.49e-31	Red blood cell count;
LUAD	trans	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg14791747	chr16:20752902	THUMPD1	0.73	9.9	0.43	6.33e-21	Cognitive test performance;
LUAD	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs12765878	1.000	rs10883943	chr10:105651416	G/T	cg11005552	chr10:105648138	OBFC1	0.44	8.34	0.38	1.05e-15	Coronary artery disease;
LUAD	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg03526776	chr6:41159608	TREML2	-0.33	-6.78	-0.31	3.99e-11	Alzheimer's disease (late onset);
LUAD	cis	rs738321	0.794	rs6001026	chr22:38545363	C/T	cg25457927	chr22:38595422	NA	-0.56	-12.51	-0.52	8.93e-31	Breast cancer;
LUAD	trans	rs10411161	0.938	rs17778649	chr19:52381616	C/T	cg22319618	chr22:45562946	NUP50	-0.57	-7.3	-0.33	1.47e-12	Breast cancer;
LUAD	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	6.94	0.32	1.47e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg00898013	chr13:113819073	PROZ	0.63	11.27	0.48	5.93e-26	Platelet distribution width;
LUAD	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-6.88	-0.32	2.14e-11	Breast cancer;
LUAD	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg23815491	chr16:72088622	HP	0.55	9.92	0.43	5.42e-21	Fibrinogen levels;
LUAD	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg15083037	chr5:83017644	HAPLN1	-0.53	-7.72	-0.35	8.55e-14	Prostate cancer;
LUAD	cis	rs9948	0.867	rs62152860	chr2:97516818	C/A	cg20312557	chr2:97357134	FER1L5	-0.62	-6.97	-0.32	1.24e-11	Erectile dysfunction and prostate cancer treatment;
LUAD	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.18	-0.33	3.12e-12	Height;
LUAD	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg19875535	chr5:140030758	IK	-0.4	-6.64	-0.31	9.5e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.42	7.64	0.35	1.43e-13	Lung cancer in ever smokers;
LUAD	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.98	0.36	1.42e-14	Parkinson's disease;
LUAD	trans	rs2548003	0.518	rs2014316	chr5:28723711	T/C	cg12623145	chr2:97778927	ANKRD36	0.46	6.4	0.3	4.08e-10	Hip geometry;
LUAD	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg00898013	chr13:113819073	PROZ	-0.65	-11.66	-0.49	1.97e-27	Platelet distribution width;
LUAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.83	-0.32	3.03e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg23262351	chr6:79576851	IRAK1BP1	-0.41	-6.69	-0.31	7.12e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg08219700	chr8:58056026	NA	0.6	8.47	0.38	3.98e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs2836633	0.931	rs2836635	chr21:40069850	A/G	cg12884169	chr21:40033163	ERG	0.39	8.26	0.37	1.84e-15	Coronary artery disease;
LUAD	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg04944784	chr2:26401820	FAM59B	0.88	12.18	0.51	1.8e-29	Gut microbiome composition (summer);
LUAD	trans	rs783540	0.869	rs783521	chr15:83280445	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.47	-0.3	2.65e-10	Schizophrenia;
LUAD	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs1448094	1.000	rs7305284	chr12:86343786	C/T	cg00310523	chr12:86230176	RASSF9	0.35	7.41	0.34	7.11e-13	Major depressive disorder;
LUAD	cis	rs6445967	0.569	rs9986	chr3:58280406	A/G	cg23715586	chr3:58305044	RPP14	0.41	6.87	0.32	2.25e-11	Platelet count;
LUAD	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg04414720	chr1:150670196	GOLPH3L	0.74	13.85	0.56	3.17e-36	Tonsillectomy;
LUAD	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg00129232	chr17:37814104	STARD3	-0.44	-6.96	-0.32	1.27e-11	Asthma;
LUAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg05313129	chr8:58192883	C8orf71	-0.54	-7.04	-0.32	7.65e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg20891558	chr2:74357851	NA	0.94	15.12	0.59	1.38e-41	Gestational age at birth (maternal effect);
LUAD	cis	rs5771069	0.897	rs137858	chr22:50445601	T/C	cg27068297	chr22:50451975	IL17REL	0.34	6.66	0.31	8.43e-11	Ulcerative colitis;
LUAD	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg12310025	chr6:25882481	NA	0.55	8.92	0.4	1.44e-17	Blood metabolite levels;
LUAD	cis	rs7759001	0.857	rs6935118	chr6:27354958	T/A	cg18711553	chr6:27366782	ZNF391	0.39	6.4	0.3	4.15e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg09117114	chr16:67998030	SLC12A4	-0.48	-6.89	-0.32	2.06e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg03929089	chr4:120376271	NA	-0.91	-17.47	-0.65	7.94e-52	Coronary artery disease;
LUAD	cis	rs3772130	0.961	rs13072618	chr3:121391833	G/A	cg20356878	chr3:121714668	ILDR1	0.49	7.58	0.35	2.27e-13	Cognitive performance;
LUAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.74	-0.35	7.33e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.61	-10.44	-0.45	7.71e-23	Cognitive ability;
LUAD	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg00280220	chr17:61926910	NA	0.37	7.07	0.33	6.42e-12	Prudent dietary pattern;
LUAD	cis	rs9972944	1.000	rs9972944	chr17:63771079	A/G	cg07283582	chr17:63770753	CCDC46	0.52	11.77	0.5	7.19e-28	Total body bone mineral density;
LUAD	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg06002616	chr8:101225028	SPAG1	-0.39	-8.11	-0.37	5.42e-15	Atrioventricular conduction;
LUAD	cis	rs11696501	0.694	rs2272961	chr20:44259549	A/G	cg11783356	chr20:44313418	WFDC10B	0.5	8.35	0.38	9.62e-16	Brain structure;
LUAD	trans	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg00953403	chr17:74099816	EXOC7	0.48	7.52	0.34	3.33e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs13315871	1.000	rs1131052	chr3:58411530	A/T	cg20936604	chr3:58311152	NA	-0.69	-7.25	-0.33	1.94e-12	Cholesterol, total;
LUAD	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.82	-0.36	4.14e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9329289	0.510	rs35854428	chr10:2554280	T/C	cg15501526	chr10:2543763	NA	0.53	11.3	0.48	4.55e-26	Age-related hearing impairment;
LUAD	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg22467129	chr15:76604101	ETFA	-0.51	-8.91	-0.4	1.48e-17	Blood metabolite levels;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg08330117	chr8:90770456	RIPK2	0.42	6.68	0.31	7.58e-11	Bilirubin levels;
LUAD	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg17366294	chr4:99064904	C4orf37	0.65	12.55	0.52	6.47e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2732480	0.967	rs2732469	chr12:48712932	T/A	cg00796672	chr12:48596817	OR10AD1	0.33	6.8	0.31	3.63e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.7	-14.04	-0.56	4.8e-37	Longevity;Endometriosis;
LUAD	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18867708	chr6:26865862	GUSBL1	-0.43	-6.67	-0.31	8.06e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg25753631	chr6:25732923	NA	0.38	6.67	0.31	8.03e-11	Iron status biomarkers;
LUAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg10819733	chr22:24237672	NA	-0.39	-7.51	-0.34	3.56e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg04414720	chr1:150670196	GOLPH3L	0.67	11.57	0.49	4.52e-27	Melanoma;
LUAD	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg01868782	chr6:126071099	HEY2	0.32	6.74	0.31	5.24e-11	Brugada syndrome;
LUAD	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg00277334	chr10:82204260	NA	-0.47	-7.57	-0.35	2.37e-13	Post bronchodilator FEV1;
LUAD	cis	rs10744422	1.000	rs1587856	chr12:123342229	A/G	cg16953816	chr12:123349952	VPS37B	0.59	6.51	0.3	2.17e-10	Schizophrenia;
LUAD	trans	rs2735413	0.875	rs12925138	chr16:78083923	C/T	cg01028844	chr5:122736986	CEP120	0.41	6.46	0.3	2.87e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-6.59	-0.31	1.3e-10	Personality dimensions;
LUAD	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27286337	chr10:134555280	INPP5A	0.7	9.99	0.44	3.11e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.74	0.43	2.28e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg11189052	chr15:85197271	WDR73	-0.6	-9.92	-0.43	5.37e-21	P wave terminal force;
LUAD	cis	rs76419734	0.510	rs1447097	chr4:106528633	C/A	cg05309399	chr4:106552544	FLJ20184	-0.52	-6.89	-0.32	2.06e-11	Post bronchodilator FEV1;
LUAD	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg00666640	chr1:248458726	OR2T12	0.33	8.07	0.37	7.35e-15	Common traits (Other);
LUAD	trans	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg00953403	chr17:74099816	EXOC7	0.45	7.05	0.32	7.4e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs6011002	0.636	rs7267230	chr20:62354572	G/A	cg01176363	chr20:62369445	LIME1	-0.79	-6.64	-0.31	9.47e-11	Dental caries;
LUAD	cis	rs8010715	0.636	rs3825584	chr14:24587639	C/T	cg23112188	chr14:24563095	PCK2	-0.36	-7.18	-0.33	3.11e-12	IgG glycosylation;
LUAD	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg27432699	chr2:27873401	GPN1	-0.4	-6.5	-0.3	2.2e-10	Total body bone mineral density;
LUAD	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg26587870	chr6:27730563	NA	-0.49	-8.18	-0.37	3.36e-15	Parkinson's disease;
LUAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08219700	chr8:58056026	NA	0.77	9.98	0.44	3.39e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs11893307	0.509	rs4368360	chr2:191536053	C/G	cg11845111	chr2:191398756	TMEM194B	-0.48	-6.94	-0.32	1.51e-11	Mean platelet volume;
LUAD	cis	rs17767294	0.541	rs72845044	chr6:27572479	G/A	cg08851530	chr6:28072375	NA	1.01	7.47	0.34	4.71e-13	Parkinson's disease;
LUAD	cis	rs1816752	0.870	rs2033954	chr13:25010567	C/T	cg02811702	chr13:24901961	NA	0.44	7.53	0.34	3.13e-13	Obesity-related traits;
LUAD	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22307029	chr19:49891270	CCDC155	0.69	9.86	0.43	8.84e-21	Multiple sclerosis;
LUAD	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg14019146	chr3:50243930	SLC38A3	0.33	6.48	0.3	2.63e-10	Menarche (age at onset);
LUAD	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg15448220	chr1:150897856	SETDB1	-0.49	-8.36	-0.38	9.46e-16	Melanoma;
LUAD	cis	rs7975161	0.882	rs4964270	chr12:104652398	A/G	cg25273343	chr12:104657179	TXNRD1	-0.7	-8.58	-0.38	1.86e-16	Toenail selenium levels;
LUAD	cis	rs8067287	0.802	rs62065417	chr17:16820679	T/C	cg26910001	chr17:16838321	NA	-0.48	-6.72	-0.31	5.77e-11	Diabetic kidney disease;
LUAD	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.36	-18.27	-0.66	2.12e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.56	9.69	0.43	3.55e-20	Menarche (age at onset);
LUAD	cis	rs775227	1.000	rs35341359	chr3:112994937	A/G	cg18753928	chr3:113234510	CCDC52	-0.44	-6.35	-0.3	5.41e-10	Dental caries;
LUAD	cis	rs113835537	0.529	rs11227495	chr11:66263243	C/T	cg24851651	chr11:66362959	CCS	0.55	9.8	0.43	1.47e-20	Airway imaging phenotypes;
LUAD	cis	rs73072330	1.000	rs17729010	chr3:47912703	A/G	cg04507495	chr3:47563649	NA	-1.0	-7.91	-0.36	2.29e-14	Stem cell growth factor beta levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07852735	chr8:63951642	GGH	-0.64	-6.38	-0.3	4.62e-10	Type 2 diabetes;
LUAD	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg23262073	chr20:60523788	NA	-0.38	-6.76	-0.31	4.58e-11	Body mass index;
LUAD	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.3	-0.41	7.8e-19	Life satisfaction;
LUAD	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg02423579	chr7:2872169	GNA12	-0.57	-9.66	-0.43	4.52e-20	Height;
LUAD	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg17200465	chr3:40428508	ENTPD3	0.27	6.63	0.31	1.01e-10	Renal cell carcinoma;
LUAD	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg00020340	chr7:910388	UNC84A	0.66	7.12	0.33	4.72e-12	Initial pursuit acceleration;
LUAD	cis	rs6426558	0.537	rs2670462	chr1:227432923	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.54	-8.75	-0.39	5.14e-17	Neutrophil percentage of white cells;
LUAD	trans	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg17147758	chr8:6949321	NA	-0.42	-6.35	-0.3	5.42e-10	Blood pressure (smoking interaction);
LUAD	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg06766960	chr11:133703094	NA	-0.44	-8.4	-0.38	6.97e-16	Childhood ear infection;
LUAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13732083	chr21:47605072	C21orf56	0.6	10.37	0.45	1.34e-22	Testicular germ cell tumor;
LUAD	cis	rs877282	0.898	rs12357995	chr10:765739	T/C	cg17470449	chr10:769945	NA	0.61	8.47	0.38	4.14e-16	Uric acid levels;
LUAD	cis	rs6688613	0.729	rs10918603	chr1:166936503	T/C	cg07049167	chr1:166818506	POGK	0.58	8.37	0.38	8.72e-16	Refractive astigmatism;
LUAD	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg23625390	chr15:77176239	SCAPER	0.38	6.6	0.31	1.22e-10	Blood metabolite levels;
LUAD	cis	rs1018836	0.847	rs2285231	chr8:91545387	G/T	cg16814680	chr8:91681699	NA	-0.76	-13.23	-0.54	1.14e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg22508957	chr16:3507546	NAT15	0.82	10.84	0.47	2.44e-24	Tuberculosis;
LUAD	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg06002616	chr8:101225028	SPAG1	-0.38	-7.86	-0.36	3.28e-14	Atrioventricular conduction;
LUAD	cis	rs1232027	0.656	rs1677645	chr5:79964419	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.45	-7.36	-0.34	9.57e-13	Huntington's disease progression;
LUAD	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06873352	chr17:61820015	STRADA	0.82	18.4	0.67	5.43e-56	Prudent dietary pattern;
LUAD	trans	rs58521262	0.556	rs289347	chr19:23147938	A/T	cg00849052	chr8:23570444	NA	0.36	6.38	0.3	4.72e-10	Testicular germ cell tumor;
LUAD	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg05187965	chr10:45406764	TMEM72	-0.48	-9.64	-0.42	5.36e-20	Mean corpuscular volume;
LUAD	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18099408	chr3:52552593	STAB1	-0.42	-7.44	-0.34	5.5e-13	Electroencephalogram traits;
LUAD	cis	rs9535307	0.769	rs9535306	chr13:50290817	A/G	cg04663916	chr13:50265991	EBPL	0.65	8.77	0.39	4.35e-17	Obesity-related traits;
LUAD	cis	rs9826463	0.582	rs55687115	chr3:142148372	G/A	cg20824294	chr3:142316082	PLS1	0.37	6.56	0.3	1.58e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg21138405	chr5:131827807	IRF1	0.6	13.89	0.56	2.17e-36	Asthma (sex interaction);
LUAD	cis	rs4631830	0.863	rs57263518	chr10:51519154	A/G	cg20129853	chr10:51489980	NA	-0.33	-6.47	-0.3	2.69e-10	Prostate-specific antigen levels;
LUAD	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03517284	chr6:25882590	NA	-0.4	-6.48	-0.3	2.59e-10	Height;
LUAD	trans	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.77	-0.35	6.16e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.4e-12	Lung cancer;
LUAD	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg27539214	chr16:67997921	SLC12A4	-0.69	-8.92	-0.4	1.42e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg00310523	chr12:86230176	RASSF9	0.4	7.95	0.36	1.74e-14	Major depressive disorder;
LUAD	cis	rs2651899	0.902	rs1736522	chr1:3080940	C/G	cg24679453	chr1:3079069	PRDM16	-0.29	-6.65	-0.31	9.31e-11	Migraine;
LUAD	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg15485101	chr11:133734466	NA	0.38	8.47	0.38	4.21e-16	Childhood ear infection;
LUAD	trans	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg14227996	chr4:17616232	MED28	0.79	8.55	0.38	2.23e-16	Opioid sensitivity;
LUAD	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg04756594	chr16:24857601	SLC5A11	0.72	12.31	0.51	5.58e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18099408	chr3:52552593	STAB1	-0.45	-7.98	-0.36	1.36e-14	Bipolar disorder;
LUAD	cis	rs79839061	0.611	rs2279183	chr4:882404	T/C	cg07828340	chr4:882639	GAK	0.58	7.18	0.33	3.15e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs35123781	0.502	rs261532	chr5:138949362	A/C	cg11459648	chr5:138714337	SLC23A1	0.41	7.05	0.32	7.24e-12	Schizophrenia;
LUAD	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg25664220	chr3:72788482	NA	-0.69	-12.13	-0.51	2.82e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9902453	0.967	rs34323226	chr17:28517454	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.37	0.38	8.81e-16	Coffee consumption (cups per day);
LUAD	cis	rs1950626	0.743	rs12889283	chr14:101466001	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.55	0.34	2.66e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-11.11	-0.48	2.39e-25	Hemoglobin concentration;
LUAD	trans	rs800082	0.501	rs9878902	chr3:144220319	A/T	cg24215973	chr2:240111563	HDAC4	0.49	7.91	0.36	2.26e-14	Smoking behavior;
LUAD	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg00933542	chr6:150070202	PCMT1	0.34	7.21	0.33	2.52e-12	Testicular germ cell tumor;
LUAD	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06873352	chr17:61820015	STRADA	0.56	9.09	0.4	3.92e-18	Height;
LUAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg22907277	chr7:1156413	C7orf50	0.68	8.0	0.36	1.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18099408	chr3:52552593	STAB1	0.47	8.49	0.38	3.42e-16	Electroencephalogram traits;
LUAD	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg12599982	chr1:44399894	ARTN	0.34	6.93	0.32	1.59e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg01849466	chr14:104193079	ZFYVE21	0.48	8.01	0.36	1.09e-14	Body mass index;
LUAD	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg00316803	chr15:76480434	C15orf27	-0.4	-7.58	-0.35	2.15e-13	Blood metabolite levels;
LUAD	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg18446336	chr7:2847575	GNA12	-0.36	-6.53	-0.3	1.86e-10	Height;
LUAD	cis	rs8017423	0.935	rs2104704	chr14:90696609	A/G	cg14092571	chr14:90743983	NA	0.47	7.98	0.36	1.4e-14	Mortality in heart failure;
LUAD	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg26513180	chr16:89883248	FANCA	0.75	6.76	0.31	4.55e-11	Skin colour saturation;
LUAD	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg19766460	chr21:43528205	UMODL1;C21orf128	1.03	19.22	0.68	1.29e-59	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.78	0.31	4.11e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg22907277	chr7:1156413	C7orf50	0.46	7.68	0.35	1.13e-13	Longevity;Endometriosis;
LUAD	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg14541582	chr5:601475	NA	-0.36	-7.66	-0.35	1.31e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs490234	0.615	rs2819625	chr9:128156648	A/G	cg14078157	chr9:128172775	NA	-0.42	-7.8	-0.35	4.89e-14	Mean arterial pressure;
LUAD	cis	rs1595825	0.891	rs79845692	chr2:198523541	T/C	cg00982548	chr2:198649783	BOLL	-0.62	-8.83	-0.39	2.89e-17	Ulcerative colitis;
LUAD	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	7.88	0.36	2.84e-14	Rheumatoid arthritis;
LUAD	trans	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg13565492	chr6:43139072	SRF	-0.74	-10.08	-0.44	1.42e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg07570687	chr10:102243282	WNT8B	-0.46	-7.16	-0.33	3.58e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs2224391	0.628	rs9405260	chr6:5249612	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-7.98	-0.36	1.4e-14	Height;
LUAD	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.64	-9.76	-0.43	1.98e-20	IgG glycosylation;
LUAD	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.97	-0.36	1.5e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-6.87	-0.32	2.27e-11	Menarche (age at onset);
LUAD	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg14582100	chr15:45693742	SPATA5L1	0.43	8.64	0.39	1.13e-16	Response to fenofibrate (adiponectin levels);
LUAD	trans	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg00953403	chr17:74099816	EXOC7	0.45	7.05	0.32	7.22e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg24813613	chr7:1882135	MAD1L1	-0.4	-6.48	-0.3	2.55e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs5756391	0.568	rs4821567	chr22:37316388	T/G	cg16356956	chr22:37317934	CSF2RB	0.31	6.53	0.3	1.84e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg22764044	chr5:178986830	RUFY1	0.52	8.62	0.39	1.39e-16	Lung cancer;
LUAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27297192	chr10:134578999	INPP5A	0.37	6.73	0.31	5.52e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.73	0.31	5.54e-11	Colorectal cancer;
LUAD	trans	rs747782	0.527	rs76142260	chr11:48331068	T/C	cg03929089	chr4:120376271	NA	0.66	6.66	0.31	8.32e-11	Intraocular pressure;
LUAD	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg02176678	chr2:219576539	TTLL4	0.61	11.96	0.5	1.35e-28	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg03929089	chr4:120376271	NA	-0.86	-15.78	-0.61	1.9e-44	Coronary artery disease;
LUAD	cis	rs939584	1.000	rs10193244	chr2:647580	T/C	cg03444855	chr2:621920	NA	-0.39	-6.49	-0.3	2.37e-10	Body mass index;
LUAD	cis	rs7945718	0.905	rs7124484	chr11:12745271	G/A	cg25843174	chr11:12811716	TEAD1	0.25	7.42	0.34	6.65e-13	Educational attainment (years of education);
LUAD	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg01119278	chr6:110721349	DDO	-0.41	-7.47	-0.34	4.73e-13	Platelet distribution width;
LUAD	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.56	-0.49	4.86e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg27219399	chr15:67835830	MAP2K5	0.4	6.78	0.31	4.09e-11	Obesity;
LUAD	cis	rs4853525	0.818	rs4853520	chr2:191719498	A/G	cg11845111	chr2:191398756	TMEM194B	-0.39	-6.52	-0.3	2.03e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg09455208	chr3:40491958	NA	0.53	11.75	0.5	8.76e-28	Renal cell carcinoma;
LUAD	cis	rs8060686	0.858	rs11553287	chr16:67905407	A/G	cg26727032	chr16:67993705	SLC12A4	-0.51	-8.63	-0.39	1.26e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.82	-0.39	3.1e-17	Initial pursuit acceleration;
LUAD	cis	rs12210905	1.000	rs12192049	chr6:27056739	T/C	cg11502198	chr6:26597334	ABT1	-0.78	-6.46	-0.3	2.86e-10	Hip circumference adjusted for BMI;
LUAD	trans	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg04565464	chr8:145669602	NFKBIL2	0.46	6.84	0.32	2.8e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24308560	chr3:49941425	MST1R	-0.56	-9.43	-0.42	2.69e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03328750	chr5:142150401	ARHGAP26	-0.42	-6.46	-0.3	2.86e-10	Height;
LUAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-9.78	-0.43	1.69e-20	Bipolar disorder and schizophrenia;
LUAD	trans	rs2840044	1.000	rs10068	chr17:33901965	C/G	cg19694781	chr19:47549865	TMEM160	0.64	10.38	0.45	1.25e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.57	-10.41	-0.45	9.29e-23	Axial length;
LUAD	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg11766577	chr21:47581405	C21orf56	-0.45	-7.72	-0.35	8.72e-14	Testicular germ cell tumor;
LUAD	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg21475434	chr5:93447410	FAM172A	0.71	8.4	0.38	7.06e-16	Diabetic retinopathy;
LUAD	cis	rs1816752	0.819	rs1981276	chr13:24983499	C/A	cg02811702	chr13:24901961	NA	0.42	7.38	0.34	8.7e-13	Obesity-related traits;
LUAD	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg15445000	chr17:37608096	MED1	0.45	8.29	0.37	1.56e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1983170	0.736	rs745731	chr1:92011467	G/T	cg25838465	chr1:92012736	NA	0.5	6.76	0.31	4.48e-11	Eosinophil percentage of white cells;
LUAD	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg24069376	chr3:38537580	EXOG	0.43	10.38	0.45	1.23e-22	Electrocardiographic conduction measures;
LUAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg08132940	chr7:1081526	C7orf50	-0.67	-9.22	-0.41	1.39e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	14.33	0.57	3.02e-38	Lung cancer in ever smokers;
LUAD	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg21770322	chr7:97807741	LMTK2	0.33	7.47	0.34	4.65e-13	Breast cancer;
LUAD	trans	rs11722228	0.594	rs10939663	chr4:10032516	T/G	cg26043149	chr18:55253948	FECH	0.89	15.08	0.59	1.9e-41	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg21775007	chr8:11205619	TDH	0.47	8.18	0.37	3.24e-15	Retinal vascular caliber;
LUAD	cis	rs7254827	0.868	rs4808569	chr19:17218970	C/A	cg19418318	chr19:17219073	MYO9B	-0.55	-6.36	-0.3	5.4e-10	Mean platelet volume;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25994883	chr1:235490339	ARID4B;GGPS1	-0.41	-6.35	-0.3	5.68e-10	Height;
LUAD	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg00784671	chr22:46762841	CELSR1	-0.62	-7.17	-0.33	3.27e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs600626	0.529	rs11236525	chr11:75467545	C/G	cg24262691	chr11:75473276	NA	0.59	7.94	0.36	1.88e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs3125734	0.582	rs7904465	chr10:64002393	G/A	cg09941381	chr10:64027924	RTKN2	-0.31	-7.24	-0.33	2.15e-12	Rheumatoid arthritis;
LUAD	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg22920501	chr2:26401640	FAM59B	-0.77	-11.0	-0.47	6.27e-25	Gut microbiome composition (summer);
LUAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.78	-0.31	3.95e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18404041	chr3:52824283	ITIH1	-0.7	-14.78	-0.58	3.81e-40	Bipolar disorder;
LUAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	12.72	0.53	1.25e-31	Prudent dietary pattern;
LUAD	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg07266350	chr3:49460521	AMT;NICN1	-0.36	-6.52	-0.3	2.06e-10	Menarche (age at onset);
LUAD	cis	rs1816752	0.837	rs7139748	chr13:24985669	G/A	cg02811702	chr13:24901961	NA	0.4	6.92	0.32	1.67e-11	Obesity-related traits;
LUAD	trans	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17712092	chr4:129076599	LARP1B	0.85	15.86	0.61	8.99e-45	Eosinophil percentage of white cells;
LUAD	cis	rs11098699	0.784	rs7687083	chr4:124246602	T/C	cg09941581	chr4:124220074	SPATA5	0.42	6.75	0.31	5.01e-11	Mosquito bite size;
LUAD	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg21918786	chr6:109611834	NA	-0.56	-9.93	-0.43	4.94e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs6867032	0.527	rs4975720	chr5:2010455	C/G	cg26168224	chr5:2018326	NA	0.47	9.19	0.41	1.73e-18	Gut microbiome composition (winter);
LUAD	cis	rs4664308	0.935	rs877200	chr2:160903723	G/C	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.83	-0.32	2.89e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs35883536	0.609	rs1577513	chr1:101044402	C/A	cg06223162	chr1:101003688	GPR88	0.49	9.68	0.43	3.64e-20	Monocyte count;
LUAD	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg13319975	chr6:146136371	FBXO30	-0.63	-10.84	-0.47	2.45e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	2.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg00784671	chr22:46762841	CELSR1	-0.53	-7.29	-0.33	1.52e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg03433033	chr1:76189801	ACADM	-0.87	-15.78	-0.61	1.98e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs758324	0.947	rs56081930	chr5:131235274	T/G	cg25547332	chr5:131281432	NA	-0.44	-6.62	-0.31	1.12e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs12541635	1.000	rs1896918	chr8:107090500	G/A	cg10147462	chr8:107024639	NA	-0.41	-7.41	-0.34	6.94e-13	Age of smoking initiation;
LUAD	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg21252483	chr19:49399788	TULP2	-0.7	-10.89	-0.47	1.7e-24	Red cell distribution width;
LUAD	cis	rs2625529	0.730	rs3759900	chr15:72451827	A/C	cg16672083	chr15:72433130	SENP8	0.67	12.19	0.51	1.74e-29	Red blood cell count;
LUAD	cis	rs2658782	1.000	rs2605583	chr11:93164957	T/A	cg15737290	chr11:93063684	CCDC67	0.51	7.09	0.33	5.78e-12	Pulmonary function decline;
LUAD	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg00634984	chr7:65235879	NA	0.49	6.64	0.31	9.66e-11	Aortic root size;
LUAD	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg14343924	chr8:8086146	FLJ10661	0.42	6.55	0.3	1.7e-10	Joint mobility (Beighton score);
LUAD	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg21475434	chr5:93447410	FAM172A	0.74	8.24	0.37	2.22e-15	Diabetic retinopathy;
LUAD	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg13334819	chr7:99746414	C7orf59	-0.65	-10.44	-0.45	7.12e-23	Coronary artery disease;
LUAD	cis	rs62238980	0.614	rs79497892	chr22:32434359	C/A	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs4604732	0.588	rs4925551	chr1:247631724	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	9.33	0.41	5.82e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs758324	0.947	rs1500114	chr5:131138120	C/A	cg06307176	chr5:131281290	NA	0.51	8.0	0.36	1.18e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg15117754	chr3:10150083	C3orf24	0.4	6.66	0.31	8.79e-11	Alzheimer's disease;
LUAD	cis	rs231513	0.911	rs124721	chr17:41959808	T/C	cg26893861	chr17:41843967	DUSP3	-0.66	-7.49	-0.34	4.19e-13	Cognitive function;
LUAD	cis	rs16910800	1.000	rs7114414	chr11:23201509	A/G	cg20040320	chr11:23191996	NA	-0.48	-7.19	-0.33	3.03e-12	Cancer;
LUAD	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.45	-0.34	5.26e-13	Bone mineral density;
LUAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg00106254	chr7:1943704	MAD1L1	-0.56	-8.54	-0.38	2.45e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg20203395	chr5:56204925	C5orf35	-0.81	-11.68	-0.49	1.6e-27	Initial pursuit acceleration;
LUAD	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg23982607	chr1:1823379	GNB1	-0.9	-17.86	-0.66	1.49e-53	Body mass index;
LUAD	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg08807101	chr21:30365312	RNF160	0.51	8.77	0.39	4.51e-17	Dental caries;
LUAD	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg03859395	chr2:55845619	SMEK2	0.75	13.92	0.56	1.59e-36	Metabolic syndrome;
LUAD	trans	rs9467711	0.651	rs34888489	chr6:26073375	C/A	cg06606381	chr12:133084897	FBRSL1	-1.16	-8.64	-0.39	1.13e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg12927641	chr6:109611667	NA	-0.45	-7.59	-0.35	2.11e-13	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
LUAD	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg13870426	chr17:30244630	NA	-0.5	-6.39	-0.3	4.33e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg14092571	chr14:90743983	NA	-0.69	-12.49	-0.52	1.1e-30	Gut microbiota (bacterial taxa);
LUAD	cis	rs75920871	0.858	rs78857232	chr11:116727465	C/T	cg04087571	chr11:116723030	SIK3	-0.34	-6.7	-0.31	6.88e-11	Subjective well-being;
LUAD	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg13319975	chr6:146136371	FBXO30	0.66	11.46	0.49	1.2e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg05697835	chr1:2722811	NA	0.3	6.44	0.3	3.28e-10	Ulcerative colitis;
LUAD	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.63	0.31	1.06e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8099014	0.731	rs4940391	chr18:56105868	A/G	cg12907477	chr18:56117327	MIR122	0.52	7.35	0.34	1.07e-12	Platelet count;
LUAD	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	trans	rs2797160	1.000	rs2747725	chr6:126012397	A/C	cg05039488	chr6:79577232	IRAK1BP1	0.49	7.49	0.34	3.98e-13	Endometrial cancer;
LUAD	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11644478	chr21:40555479	PSMG1	-0.39	-6.46	-0.3	2.81e-10	Menarche (age at onset);
LUAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.72	13.42	0.55	1.86e-34	Lymphocyte counts;
LUAD	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg23815491	chr16:72088622	HP	0.55	10.02	0.44	2.5e-21	Fibrinogen levels;
LUAD	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg25804541	chr17:80189381	SLC16A3	0.32	7.07	0.33	6.5e-12	Life satisfaction;
LUAD	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg24690094	chr11:67383802	NA	-0.44	-7.15	-0.33	3.81e-12	Mean corpuscular volume;
LUAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg08219700	chr8:58056026	NA	0.41	6.54	0.3	1.8e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg15017067	chr4:17643749	FAM184B	0.35	6.93	0.32	1.61e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg14159672	chr1:205819179	PM20D1	-0.52	-7.86	-0.36	3.31e-14	Menarche (age at onset);
LUAD	cis	rs12545109	0.613	rs6998873	chr8:57299697	A/G	cg21220214	chr8:57350948	NA	0.62	8.29	0.37	1.53e-15	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12200560	0.505	rs984520	chr6:97076454	A/G	cg06623918	chr6:96969491	KIAA0776	-0.47	-7.43	-0.34	6.1e-13	Coronary heart disease;
LUAD	cis	rs6761276	0.649	rs10169599	chr2:113838652	A/G	cg10479672	chr2:113810641	IL1F8	0.35	6.96	0.32	1.31e-11	Protein quantitative trait loci;
LUAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg20607798	chr8:58055168	NA	0.67	8.71	0.39	7.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs11971779	0.618	rs13068	chr7:139104141	G/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.49	-0.3	2.38e-10	Diisocyanate-induced asthma;
LUAD	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-10.04	-0.44	2.1e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg03474202	chr17:45855739	NA	-0.37	-7.77	-0.35	6.2e-14	IgG glycosylation;
LUAD	cis	rs74925218	1	rs74925218	chr15:78796732	C/T	cg18825076	chr15:78729989	IREB2	0.54	7.48	0.34	4.32e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg19318889	chr4:1322082	MAEA	0.41	6.81	0.31	3.26e-11	Obesity-related traits;
LUAD	cis	rs9649213	0.614	rs12539761	chr7:98013839	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.72	-10.42	-0.45	9.14e-23	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg07988820	chr12:82153109	PPFIA2	-0.49	-7.47	-0.34	4.69e-13	Resting heart rate;
LUAD	cis	rs72781680	0.752	rs72796114	chr2:23906133	C/G	cg20701182	chr2:24300061	SF3B14	0.6	6.42	0.3	3.6e-10	Lymphocyte counts;
LUAD	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg06641503	chr3:48959341	ARIH2	-0.37	-7.31	-0.33	1.38e-12	Menarche (age at onset);
LUAD	cis	rs2455799	1.000	rs12488913	chr3:15847941	C/A	cg16303742	chr3:15540471	COLQ	-0.39	-6.74	-0.31	5.17e-11	Mean platelet volume;
LUAD	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg15839431	chr19:19639596	YJEFN3	-0.53	-8.65	-0.39	1.11e-16	Bipolar disorder;
LUAD	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg23283495	chr1:209979779	IRF6	0.41	7.35	0.34	1.02e-12	Monobrow;
LUAD	cis	rs10992471	0.603	rs10761163	chr9:95313287	A/T	cg14631576	chr9:95140430	CENPP	-0.5	-10.14	-0.44	9.26e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg18833306	chr6:118973337	C6orf204	-0.52	-7.61	-0.35	1.75e-13	Diastolic blood pressure;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05929132	chr15:66586024	DIS3L	-0.59	-7.27	-0.33	1.75e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg00310523	chr12:86230176	RASSF9	0.37	7.47	0.34	4.73e-13	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.86	0.32	2.48e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7945718	0.967	rs11022490	chr11:12773526	C/G	cg25843174	chr11:12811716	TEAD1	-0.24	-7.14	-0.33	4.03e-12	Educational attainment (years of education);
LUAD	cis	rs4660214	0.666	rs2275187	chr1:39763242	C/T	cg27567593	chr1:39956653	BMP8A	0.35	7.07	0.33	6.26e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2286503	0.901	rs10950922	chr7:22854006	C/T	cg06496272	chr7:22895283	SNORD93	-0.4	-7.15	-0.33	3.91e-12	Fibrinogen;
LUAD	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg26384229	chr12:38710491	ALG10B	0.47	7.65	0.35	1.34e-13	Bladder cancer;
LUAD	cis	rs6693567	0.565	rs1260398	chr1:150279876	T/C	cg15654264	chr1:150340011	RPRD2	-0.35	-6.36	-0.3	5.3e-10	Migraine;
LUAD	cis	rs4478137	0.824	rs4691907	chr4:164223658	G/T	cg06758707	chr4:164254230	NPY1R	0.42	6.52	0.3	2.03e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.59	-7.8	-0.35	4.84e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs524023	0.914	rs2360872	chr11:64353405	T/C	cg19131476	chr11:64387923	NRXN2	-0.37	-7.1	-0.33	5.4e-12	Urate levels in obese individuals;
LUAD	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg18099408	chr3:52552593	STAB1	-0.43	-7.45	-0.34	5.41e-13	Bipolar disorder;
LUAD	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg05805236	chr11:65401703	PCNXL3	0.42	7.28	0.33	1.62e-12	Acne (severe);
LUAD	trans	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg05926928	chr17:57297772	GDPD1	-0.49	-6.75	-0.31	4.77e-11	Schizophrenia;
LUAD	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.54	8.81	0.39	3.19e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg06108461	chr20:60628389	TAF4	-0.71	-11.81	-0.5	5.13e-28	Body mass index;
LUAD	cis	rs4713675	0.584	rs3818527	chr6:33661035	A/G	cg14003231	chr6:33640908	ITPR3	-0.47	-9.2	-0.41	1.66e-18	Plateletcrit;
LUAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg16606324	chr3:10149918	C3orf24	0.68	11.41	0.49	1.78e-26	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.49e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	7.18	0.33	3.23e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg27094323	chr7:1216898	NA	-0.37	-6.66	-0.31	8.65e-11	Longevity;Endometriosis;
LUAD	cis	rs7119038	0.629	rs10892272	chr11:118602707	C/G	cg19308663	chr11:118741387	NA	0.42	6.4	0.3	4.12e-10	Sjögren's syndrome;
LUAD	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg13397359	chr6:42928475	GNMT	0.5	7.9	0.36	2.37e-14	Blood protein levels;
LUAD	cis	rs3815700	1.000	rs8104328	chr19:33094371	G/A	cg02997394	chr19:33096574	ANKRD27	0.67	8.76	0.39	4.7e-17	Eosinophilic esophagitis;
LUAD	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg07636037	chr3:49044803	WDR6	0.35	6.35	0.3	5.53e-10	Resting heart rate;
LUAD	cis	rs2834081	0.536	rs11702285	chr21:34474294	G/A	cg00274965	chr21:34405681	NA	0.37	6.85	0.32	2.64e-11	Sum eosinophil basophil counts;
LUAD	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg25985355	chr7:65971099	NA	-0.53	-6.58	-0.3	1.41e-10	Diabetic kidney disease;
LUAD	cis	rs68170813	0.617	rs2283041	chr7:107190415	A/G	cg23024343	chr7:107201750	COG5	0.51	6.52	0.3	2.02e-10	Coronary artery disease;
LUAD	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21659725	chr3:3221576	CRBN	-0.86	-18.59	-0.67	7.87e-57	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2070433	0.539	rs721131	chr21:47957767	T/C	cg12379764	chr21:47803548	PCNT	0.46	6.83	0.32	2.9100000000000002e-11	Lymphocyte counts;
LUAD	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.6	-0.35	1.93e-13	Blood metabolite levels;
LUAD	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg11707310	chr1:2537719	MMEL1	0.37	7.84	0.36	3.8e-14	Ulcerative colitis;
LUAD	cis	rs4332037	0.722	rs4721140	chr7:1917635	A/T	cg25834613	chr7:1915315	MAD1L1	-0.4	-6.48	-0.3	2.54e-10	Bipolar disorder;
LUAD	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg04568274	chr7:158649319	WDR60	0.42	6.79	0.31	3.93e-11	Height;
LUAD	cis	rs7493	0.901	rs17882539	chr7:95026408	G/A	cg17330251	chr7:94953956	PON1	-0.57	-8.02	-0.36	1.08e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg13607699	chr17:42295918	UBTF	0.56	9.16	0.41	2.22e-18	Total body bone mineral density;
LUAD	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg22676075	chr6:135203613	NA	0.52	9.05	0.4	5.22e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.56	0.34	2.59e-13	Cannabis dependence symptom count;
LUAD	cis	rs5758511	0.773	rs7288749	chr22:42356430	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.37	6.36	0.3	5.17e-10	Birth weight;
LUAD	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg17252645	chr8:143867129	LY6D	-0.35	-6.49	-0.3	2.35e-10	Urinary tract infection frequency;
LUAD	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg24955955	chr5:415729	AHRR	0.78	8.87	0.4	2.14e-17	Fat distribution (HIV);
LUAD	cis	rs1232027	0.632	rs863215	chr5:79948005	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-8.07	-0.37	7.25e-15	Huntington's disease progression;
LUAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg13047869	chr3:10149882	C3orf24	0.66	11.16	0.48	1.63e-25	Alzheimer's disease;
LUAD	cis	rs4713675	0.565	rs2274458	chr6:33679596	A/C	cg13859433	chr6:33739653	LEMD2	-0.3	-7.1	-0.33	5.28e-12	Plateletcrit;
LUAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg06877462	chr1:205807181	PM20D1	0.37	7.02	0.32	8.64e-12	Menarche (age at onset);
LUAD	cis	rs151349	0.555	rs151343	chr20:57583298	C/G	cg23907860	chr20:57583709	CTSZ	0.64	12.29	0.51	6.85e-30	Platelet distribution width;
LUAD	cis	rs7107174	1.000	rs10793302	chr11:78040961	C/T	cg02023728	chr11:77925099	USP35	0.42	7.0	0.32	1e-11	Testicular germ cell tumor;
LUAD	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg11266682	chr4:10021025	SLC2A9	-0.59	-12.57	-0.52	5.39e-31	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg09658497	chr7:2847517	GNA12	-0.55	-9.59	-0.42	7.57e-20	Height;
LUAD	cis	rs7851660	0.967	rs10818133	chr9:100610348	C/G	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg00504896	chr12:9437009	LOC642846	-0.57	-9.62	-0.42	6.27e-20	Breast size;
LUAD	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.13	-0.33	4.26e-12	Total cholesterol levels;
LUAD	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg02569458	chr12:86230093	RASSF9	0.43	8.2	0.37	2.86e-15	Major depressive disorder;
LUAD	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.9e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6489882	0.902	rs1156361	chr12:113375983	T/C	cg20102336	chr12:113376681	OAS3	-0.58	-8.91	-0.4	1.57e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg27490568	chr2:178487706	NA	0.39	6.37	0.3	4.88e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10744422	1.000	rs10744422	chr12:123336789	T/C	cg16953816	chr12:123349952	VPS37B	0.59	6.48	0.3	2.5e-10	Schizophrenia;
LUAD	cis	rs7536201	0.936	rs11249215	chr1:25297184	C/T	cg23273869	chr1:25296894	NA	-0.35	-7.03	-0.32	8.25e-12	Psoriasis vulgaris;
LUAD	cis	rs1232027	0.656	rs1650664	chr5:79963023	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.15	-0.33	3.76e-12	Huntington's disease progression;
LUAD	cis	rs910187	0.571	rs3827049	chr20:45801319	T/A	cg27589058	chr20:45804311	EYA2	-0.37	-8.46	-0.38	4.44e-16	Migraine;
LUAD	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg10876282	chr6:28092338	ZSCAN16	0.45	7.31	0.33	1.39e-12	Parkinson's disease;
LUAD	cis	rs6960043	0.818	rs2191348	chr7:15064255	G/T	cg19272540	chr7:15055459	NA	-0.36	-7.88	-0.36	2.71e-14	Type 2 diabetes;
LUAD	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.85e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs75229567	0.618	rs11177849	chr12:70182473	C/T	cg10114359	chr12:70132523	RAB3IP	-0.82	-7.07	-0.32	6.57e-12	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.55	-7.52	-0.34	3.32e-13	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg00310523	chr12:86230176	RASSF9	0.4	7.91	0.36	2.27e-14	Major depressive disorder;
LUAD	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg10518543	chr12:38710700	ALG10B	0.41	6.37	0.3	4.88e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg07636037	chr3:49044803	WDR6	0.46	7.61	0.35	1.75e-13	Menarche (age at onset);
LUAD	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg06092702	chr1:163392909	NA	0.35	8.48	0.38	3.92e-16	Motion sickness;
LUAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22029157	chr1:209979665	IRF6	0.75	11.93	0.5	1.8e-28	Cleft lip with or without cleft palate;
LUAD	cis	rs13223928	0.565	rs10240820	chr7:3154415	T/C	cg19214707	chr7:3157722	NA	-0.5	-8.92	-0.4	1.45e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg04287289	chr16:89883240	FANCA	0.73	6.77	0.31	4.38e-11	Skin colour saturation;
LUAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-10.14	-0.44	9.07e-22	Electroencephalogram traits;
LUAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00166722	chr3:10149974	C3orf24	0.68	11.81	0.5	5.37e-28	Alzheimer's disease;
LUAD	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg17480646	chr11:65405466	SIPA1	-0.46	-6.89	-0.32	2.07e-11	Acne (severe);
LUAD	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg26343298	chr8:95960752	TP53INP1	0.37	7.77	0.35	6.16e-14	Type 2 diabetes;
LUAD	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg03676636	chr4:99064102	C4orf37	0.32	8.24	0.37	2.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.85	-0.4	2.44e-17	Lymphocyte counts;
LUAD	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg16031515	chr1:205743344	RAB7L1	-0.35	-6.83	-0.32	2.96e-11	Monocyte percentage of white cells;
LUAD	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg14779329	chr11:130786720	SNX19	0.39	6.83	0.32	2.93e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs60154123	0.614	rs645311	chr1:210459984	A/C	cg22029157	chr1:209979665	IRF6	0.49	6.37	0.3	4.93e-10	Coronary artery disease;
LUAD	cis	rs16882447	0.723	rs10079659	chr5:53498322	C/T	cg06461071	chr5:53490839	ARL15	0.39	6.5	0.3	2.23e-10	Systolic blood pressure (dietary potassium intake interaction);
LUAD	cis	rs6748734	0.948	rs4675858	chr2:241840558	G/A	cg04034577	chr2:241836375	C2orf54	-0.49	-10.48	-0.45	5.09e-23	Urinary metabolites;
LUAD	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg12623918	chr2:306882	NA	0.35	6.92	0.32	1.73e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs68170813	0.559	rs78267892	chr7:106823734	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-11.2	-0.48	1.09e-25	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg03467027	chr4:99064603	C4orf37	0.42	6.81	0.31	3.32e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7394190	1.000	rs10824026	chr10:75421208	A/G	cg04833713	chr10:74871078	NUDT13	0.38	7.21	0.33	2.64e-12	Incident atrial fibrillation;
LUAD	cis	rs17789174	0.744	rs3794677	chr16:85099654	C/A	cg01715842	chr16:85045600	ZDHHC7	-0.37	-6.45	-0.3	3.02e-10	Dysphagia;
LUAD	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg17252645	chr8:143867129	LY6D	-0.36	-6.82	-0.31	3.16e-11	Urinary tract infection frequency;
LUAD	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg05368731	chr17:41323189	NBR1	0.95	19.47	0.69	9.06e-61	Menopause (age at onset);
LUAD	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	12.0	0.5	9.41e-29	Hip circumference adjusted for BMI;
LUAD	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg08999081	chr20:33150536	PIGU	0.39	7.82	0.36	4.25e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-12.39	-0.52	2.74e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-7.08	-0.33	6e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2882667	0.652	rs6596463	chr5:138444926	A/G	cg04439458	chr5:138467593	SIL1	-0.47	-8.64	-0.39	1.18e-16	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7107174	1.000	rs2511180	chr11:77937255	A/G	cg19901956	chr11:77921274	USP35	-0.54	-6.79	-0.31	3.77e-11	Testicular germ cell tumor;
LUAD	trans	rs9914544	0.545	rs57035178	chr17:18797767	C/T	cg21372672	chr17:16614065	CCDC144A	-0.36	-6.46	-0.3	2.9e-10	Educational attainment (years of education);
LUAD	cis	rs1595825	0.945	rs73056880	chr2:198822292	G/A	cg00361562	chr2:198649771	BOLL	-0.47	-6.72	-0.31	5.79e-11	Ulcerative colitis;
LUAD	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg06550200	chr5:1325588	CLPTM1L	0.74	15.49	0.6	3.6e-43	Lung cancer;
LUAD	cis	rs75920871	0.925	rs7112191	chr11:116902056	G/A	cg04087571	chr11:116723030	SIK3	-0.32	-6.4	-0.3	4.24e-10	Subjective well-being;
LUAD	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg06064525	chr11:970664	AP2A2	-0.54	-11.18	-0.48	1.32e-25	Alzheimer's disease (late onset);
LUAD	cis	rs3925075	0.531	rs4608351	chr16:31348848	T/C	cg10451425	chr16:31478370	ARMC5	0.4	6.49	0.3	2.47e-10	IgA nephropathy;
LUAD	cis	rs758324	0.812	rs667437	chr5:131275509	C/T	cg25547332	chr5:131281432	NA	-0.42	-6.95	-0.32	1.43e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg00280220	chr17:61926910	NA	0.37	7.08	0.33	6.15e-12	Prudent dietary pattern;
LUAD	cis	rs887829	0.569	rs7574296	chr2:234638249	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-9.2	-0.41	1.63e-18	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg03676636	chr4:99064102	C4orf37	0.29	7.05	0.32	7.2e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg17366294	chr4:99064904	C4orf37	0.71	13.41	0.55	2.04e-34	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10821973	0.527	rs7092005	chr10:63979909	A/G	cg09941381	chr10:64027924	RTKN2	-0.35	-6.84	-0.32	2.87e-11	Hypothyroidism;
LUAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07157834	chr1:205819609	PM20D1	0.84	17.51	0.65	5.31e-52	Menarche (age at onset);
LUAD	cis	rs7178572	0.568	rs7175674	chr15:77670910	C/T	cg15453836	chr15:77711506	NA	-0.36	-6.43	-0.3	3.41e-10	Type 2 diabetes;
LUAD	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg21918786	chr6:109611834	NA	-0.56	-10.59	-0.46	2.03e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-10.55	-0.46	3.07e-23	Lymphocyte counts;
LUAD	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg03433033	chr1:76189801	ACADM	-0.67	-10.71	-0.46	7.59e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2067615	0.579	rs4964486	chr12:107140790	A/G	cg15890332	chr12:107067104	RFX4	0.38	8.07	0.37	7.34e-15	Heart rate;
LUAD	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg18230493	chr5:56204884	C5orf35	-0.83	-12.22	-0.51	1.26e-29	Initial pursuit acceleration;
LUAD	cis	rs7737355	0.812	rs4705890	chr5:130855000	A/G	cg06307176	chr5:131281290	NA	0.41	6.85	0.32	2.65e-11	Life satisfaction;
LUAD	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg22920501	chr2:26401640	FAM59B	-0.78	-11.26	-0.48	6.9e-26	Gut microbiome composition (summer);
LUAD	trans	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg00953403	chr17:74099816	EXOC7	-0.51	-7.32	-0.34	1.3e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg22963979	chr7:1858916	MAD1L1	-0.68	-12.17	-0.51	2.08e-29	Bipolar disorder and schizophrenia;
LUAD	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg07776626	chr8:57350775	NA	-0.61	-9.05	-0.4	5.25e-18	Obesity-related traits;
LUAD	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg13180566	chr4:1052158	NA	-0.39	-6.69	-0.31	7.15e-11	Recombination rate (females);
LUAD	cis	rs2692947	0.832	rs2438978	chr2:96679740	G/C	cg23100626	chr2:96804247	ASTL	0.34	8.35	0.38	9.54e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06873352	chr17:61820015	STRADA	0.8	17.99	0.66	3.83e-54	Prudent dietary pattern;
LUAD	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.68	-0.43	3.72e-20	Bone mineral density;
LUAD	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-6.42	-0.3	3.62e-10	Tonsillectomy;
LUAD	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg07741184	chr6:167504864	NA	0.32	7.04	0.32	7.61e-12	Crohn's disease;
LUAD	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg09650180	chr20:62225654	GMEB2	-0.48	-6.93	-0.32	1.53e-11	Glioblastoma;
LUAD	cis	rs12760731	0.565	rs34303391	chr1:178178126	T/A	cg00404053	chr1:178313656	RASAL2	0.73	9.2	0.41	1.61e-18	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg18252515	chr7:66147081	NA	-0.63	-6.89	-0.32	2.01e-11	Diabetic kidney disease;
LUAD	cis	rs7771547	0.573	rs517890	chr6:36397786	G/C	cg07856975	chr6:36356162	ETV7	0.49	7.77	0.35	6.21e-14	Platelet distribution width;
LUAD	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs9902453	0.836	rs62070337	chr17:28466257	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.6	0.39	1.59e-16	Coffee consumption (cups per day);
LUAD	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg11845111	chr2:191398756	TMEM194B	-0.72	-9.14	-0.41	2.58e-18	Diastolic blood pressure;
LUAD	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21659725	chr3:3221576	CRBN	-0.58	-9.46	-0.42	2.12e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7107174	1.000	rs7104222	chr11:78007169	G/A	cg19901956	chr11:77921274	USP35	-0.5	-6.63	-0.31	9.96e-11	Testicular germ cell tumor;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg22395253	chr7:104941898	SRPK2	-0.4	-6.75	-0.31	5.01e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06028808	chr11:68637592	NA	0.43	6.9	0.32	1.96e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs925255	0.713	rs9309662	chr2:28629892	A/G	cg01273330	chr2:28605224	NA	0.32	6.89	0.32	1.98e-11	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-7.26	-0.33	1.87e-12	Neutrophil percentage of white cells;
LUAD	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg04731861	chr2:219085781	ARPC2	0.24	7.59	0.35	2.08e-13	Colorectal cancer;
LUAD	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg06221963	chr1:154839813	KCNN3	0.67	14.22	0.57	9.05e-38	Prostate cancer;
LUAD	cis	rs9914544	0.564	rs9906799	chr17:18795317	A/G	cg25390199	chr17:18761479	PRPSAP2	-0.37	-6.43	-0.3	3.39e-10	Educational attainment (years of education);
LUAD	cis	rs6430585	0.527	rs12465544	chr2:136451676	C/T	cg07169764	chr2:136633963	MCM6	0.59	6.92	0.32	1.66e-11	Corneal structure;
LUAD	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg03676636	chr4:99064102	C4orf37	0.3	7.68	0.35	1.11e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2795502	0.564	rs72777192	chr10:43436778	G/A	cg08461752	chr10:43522343	NA	-0.77	-8.26	-0.37	1.84e-15	Blood protein levels;
LUAD	cis	rs10128251	0.625	rs9424204	chr10:5726376	C/G	cg24097872	chr10:5724021	NA	0.46	8.6	0.39	1.63e-16	Childhood ear infection;
LUAD	cis	rs3820068	0.822	rs11581917	chr1:15805722	G/A	cg24675056	chr1:15929824	NA	0.44	6.62	0.31	1.12e-10	Systolic blood pressure;
LUAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.62	-10.89	-0.47	1.62e-24	Lymphocyte counts;
LUAD	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg26384229	chr12:38710491	ALG10B	-0.4	-6.84	-0.32	2.86e-11	Heart rate;
LUAD	cis	rs12711979	0.765	rs7559461	chr2:3818623	G/A	cg17052675	chr2:3827356	NA	-0.51	-10.46	-0.45	6.07e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs6138458	0.626	rs6132789	chr20:25012809	C/T	cg26195577	chr20:24973756	C20orf3	-0.69	-11.54	-0.49	5.9e-27	Blood protein levels;
LUAD	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg17063962	chr7:91808500	NA	-0.68	-12.19	-0.51	1.63e-29	Breast cancer;
LUAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-7.15	-0.33	3.91e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg15485817	chr17:79791312	FAM195B	-0.36	-6.5	-0.3	2.3e-10	Schizophrenia;
LUAD	cis	rs6541297	0.703	rs650808	chr1:230317820	G/A	cg20703242	chr1:230279135	GALNT2	-0.47	-6.99	-0.32	1.09e-11	Coronary artery disease;
LUAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg19130645	chr7:65235666	NA	-0.42	-7.22	-0.33	2.39e-12	Calcium levels;
LUAD	cis	rs3806843	0.548	rs246057	chr5:140325583	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg03030879	chr14:75389066	RPS6KL1	0.36	6.75	0.31	4.82e-11	Caffeine consumption;
LUAD	cis	rs62229266	0.804	rs11088331	chr21:37421872	T/C	cg12218747	chr21:37451666	NA	-0.48	-8.19	-0.37	3.06e-15	Mitral valve prolapse;
LUAD	cis	rs3812831	0.654	rs9314900	chr13:114937618	A/C	cg06611532	chr13:114900021	NA	0.3	6.79	0.31	3.92e-11	Schizophrenia;
LUAD	cis	rs1045714	0.895	rs61729413	chr7:2646796	G/A	cg20813462	chr7:2646259	IQCE	0.65	7.22	0.33	2.43e-12	Urate levels in lean individuals;
LUAD	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06544989	chr22:39130855	UNC84B	0.39	8.01	0.36	1.13e-14	Menopause (age at onset);
LUAD	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg09796270	chr17:17721594	SREBF1	0.39	7.84	0.36	3.76e-14	Total body bone mineral density;
LUAD	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg22852734	chr6:133119734	C6orf192	0.69	8.07	0.37	7.18e-15	Type 2 diabetes nephropathy;
LUAD	cis	rs1882538	0.569	rs11562037	chr7:133076885	A/G	cg10665199	chr7:133106180	EXOC4	0.62	10.66	0.46	1.17e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg03676636	chr4:99064102	C4orf37	0.31	8.24	0.37	2.17e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg23758822	chr17:41437982	NA	-0.92	-18.65	-0.67	4.58e-57	Menopause (age at onset);
LUAD	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs887829	0.570	rs12623271	chr2:234599941	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.69	-0.43	3.53e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21659725	chr3:3221576	CRBN	0.86	18.2	0.66	4.47e-55	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg04944784	chr2:26401820	FAM59B	0.91	13.67	0.55	1.67e-35	Gut microbiome composition (summer);
LUAD	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg04414720	chr1:150670196	GOLPH3L	0.44	7.44	0.34	5.72e-13	Tonsillectomy;
LUAD	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-11.02	-0.47	5.27e-25	Coronary artery disease;
LUAD	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg08949735	chr16:89699720	DPEP1	-0.32	-7.27	-0.33	1.7e-12	Vitiligo;
LUAD	cis	rs7107174	1.000	rs1485483	chr11:77930138	T/C	cg19901956	chr11:77921274	USP35	-0.55	-6.57	-0.3	1.45e-10	Testicular germ cell tumor;
LUAD	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg05872129	chr22:39784769	NA	0.81	16.0	0.61	2.17e-45	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg16262614	chr3:133464971	TF	0.34	6.39	0.3	4.42e-10	Iron status biomarkers;
LUAD	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg12863693	chr15:85201151	NMB	0.39	7.16	0.33	3.49e-12	Schizophrenia;
LUAD	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg03474202	chr17:45855739	NA	0.39	9.52	0.42	1.39e-19	IgG glycosylation;
LUAD	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg27490568	chr2:178487706	NA	0.42	7.01	0.32	9.2e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9487051	0.698	rs59502176	chr6:109644719	T/C	cg01475377	chr6:109611718	NA	-0.39	-6.53	-0.3	1.88e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg23649088	chr2:200775458	C2orf69	-0.63	-8.15	-0.37	4.31e-15	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg03467027	chr4:99064603	C4orf37	0.4	6.48	0.3	2.59e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg03467027	chr4:99064603	C4orf37	0.42	6.8	0.31	3.57e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg13441142	chr10:134499734	INPP5A	0.47	7.06	0.32	7.03e-12	Primary sclerosing cholangitis;
LUAD	cis	rs2658782	0.547	rs3020065	chr11:93059899	A/G	cg15737290	chr11:93063684	CCDC67	0.58	9.78	0.43	1.73e-20	Pulmonary function decline;
LUAD	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.16	0.33	3.67e-12	Prostate cancer;
LUAD	cis	rs494562	0.892	rs550499	chr6:86115602	G/C	cg17966619	chr6:86160162	NT5E	0.65	7.88	0.36	2.78e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-8.47	-0.38	4.18e-16	Menarche (age at onset);
LUAD	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg07395648	chr5:131743802	NA	0.38	6.51	0.3	2.17e-10	Breast cancer;
LUAD	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.84	12.21	0.51	1.38e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg15704280	chr7:45808275	SEPT13	-0.64	-9.79	-0.43	1.52e-20	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs5167	0.677	rs12709889	chr19:45453239	A/G	cg09555818	chr19:45449301	APOC2	-0.35	-6.42	-0.3	3.61e-10	Blood protein levels;
LUAD	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.38e-13	Menopause (age at onset);
LUAD	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.54	7.61	0.35	1.75e-13	Platelet count;
LUAD	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	24.46	0.77	5.54e-83	Chronic sinus infection;
LUAD	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg02269571	chr22:50332266	NA	-0.61	-9.4	-0.42	3.35e-19	Schizophrenia;
LUAD	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.42	0.34	6.46e-13	Bipolar disorder;
LUAD	cis	rs4594175	0.926	rs4901084	chr14:51634131	G/A	cg23942311	chr14:51606299	NA	0.65	11.35	0.48	2.96e-26	Cancer;
LUAD	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03352830	chr11:487213	PTDSS2	0.8	10.23	0.45	4.42e-22	Body mass index;
LUAD	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg07617317	chr6:118971624	C6orf204	0.56	8.39	0.38	7.23e-16	Diastolic blood pressure;
LUAD	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg09165964	chr15:75287851	SCAMP5	-0.44	-6.72	-0.31	5.95e-11	Blood trace element (Zn levels);
LUAD	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24531977	chr5:56204891	C5orf35	-0.98	-15.45	-0.6	5.31e-43	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg07776626	chr8:57350775	NA	-0.6	-8.95	-0.4	1.13e-17	Obesity-related traits;
LUAD	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg02782426	chr3:40428986	ENTPD3	0.43	9.19	0.41	1.8e-18	Renal cell carcinoma;
LUAD	cis	rs9399401	0.601	rs9321870	chr6:142800758	A/T	cg03128060	chr6:142623767	GPR126	0.4	7.53	0.34	3.1400000000000003e-13	Chronic obstructive pulmonary disease;
LUAD	cis	rs12681288	0.748	rs2701932	chr8:1026946	C/G	cg04851639	chr8:1020857	NA	-0.44	-10.32	-0.45	1.99e-22	Schizophrenia;
LUAD	cis	rs6489882	0.867	rs4766664	chr12:113362997	T/G	cg20102336	chr12:113376681	OAS3	-0.61	-9.39	-0.42	3.76e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs1032833	0.660	rs17454458	chr2:180058043	T/G	cg23883738	chr2:179974586	SESTD1	-0.71	-7.87	-0.36	2.97e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg22681709	chr2:178499509	PDE11A	-0.51	-8.14	-0.37	4.4e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs3845702	0.736	rs72960701	chr2:180851202	A/T	cg01881094	chr2:180872142	CWC22	0.81	8.71	0.39	6.69e-17	Schizophrenia;
LUAD	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg16797656	chr11:68205561	LRP5	0.45	9.31	0.41	6.94e-19	Total body bone mineral density;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg16903122	chr1:44584429	KLF17	-0.4	-7.76	-0.35	6.61e-14	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg21017887	chr14:105400489	NA	0.75	14.42	0.57	1.27e-38	Rheumatoid arthritis;
LUAD	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg25767906	chr1:53392781	SCP2	0.62	11.64	0.49	2.44e-27	Monocyte count;
LUAD	cis	rs2230307	0.572	rs6677080	chr1:100633469	A/T	cg20868668	chr1:100435035	SLC35A3	0.49	7.07	0.33	6.25e-12	Carotid intima media thickness;
LUAD	trans	rs3857536	0.785	rs1935895	chr6:66936606	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	trans	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg14917512	chr19:3094685	GNA11	0.56	6.69	0.31	7e-11	Diabetic kidney disease;
LUAD	trans	rs5756813	0.754	rs15691	chr22:38172380	C/A	cg19894588	chr14:64061835	NA	-0.45	-6.37	-0.3	4.91e-10	Optic cup area;Vertical cup-disc ratio;
LUAD	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg11292332	chr7:45801988	SEPT13	-0.31	-6.84	-0.32	2.81e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg15181151	chr6:150070149	PCMT1	0.33	6.56	0.3	1.62e-10	Testicular germ cell tumor;
LUAD	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg26513180	chr16:89883248	FANCA	0.44	6.96	0.32	1.3e-11	Hemoglobin concentration;
LUAD	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg00981070	chr1:2046702	PRKCZ	0.36	6.83	0.32	2.97e-11	Height;
LUAD	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg00383909	chr3:49044727	WDR6	0.94	9.32	0.41	6.73e-19	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg07636037	chr3:49044803	WDR6	0.61	10.35	0.45	1.57e-22	Menarche (age at onset);
LUAD	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg16325326	chr1:53192061	ZYG11B	-0.72	-14.1	-0.57	2.88e-37	Monocyte count;
LUAD	trans	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.65	-11.06	-0.47	3.86e-25	Mean corpuscular volume;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04237075	chr9:34637949	SIGMAR1	-0.41	-6.36	-0.3	5.38e-10	Height;
LUAD	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.95	-0.4	1.16e-17	Gut microbiome composition (summer);
LUAD	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg15962314	chr1:44399869	ARTN	0.3	6.87	0.32	2.36e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7640424	0.517	rs13099364	chr3:108022663	T/C	cg09227934	chr3:107805635	CD47	-0.39	-6.37	-0.3	4.97e-10	Body mass index;
LUAD	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg23625390	chr15:77176239	SCAPER	-0.55	-8.76	-0.39	4.89e-17	Blood metabolite levels;
LUAD	trans	rs1997103	1.000	rs10263552	chr7:55404747	C/T	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg03929089	chr4:120376271	NA	0.54	7.2	0.33	2.86e-12	Axial length;
LUAD	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg11887960	chr12:57824829	NA	0.53	6.59	0.31	1.32e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg02896835	chr1:92012615	NA	0.56	11.61	0.49	3.12e-27	Breast cancer;
LUAD	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg22823121	chr1:150693482	HORMAD1	0.41	7.96	0.36	1.57e-14	Melanoma;
LUAD	cis	rs7680126	0.596	rs17418478	chr4:10316851	G/A	cg00071950	chr4:10020882	SLC2A9	-0.58	-7.38	-0.34	8.49e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.76	-0.31	4.59e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs908922	0.628	rs488393	chr1:152489548	C/T	cg23254163	chr1:152506842	NA	0.25	6.9	0.32	1.89e-11	Hair morphology;
LUAD	trans	rs3930017	1.000	rs3930017	chr7:76720582	A/G	cg05913257	chr4:53525745	USP46	-0.41	-6.64	-0.31	9.58e-11	Body mass index;
LUAD	cis	rs7512552	0.803	rs7513205	chr1:150472781	A/G	cg15654264	chr1:150340011	RPRD2	0.58	11.1	0.47	2.69e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg05082376	chr22:42548792	NA	-0.45	-8.32	-0.38	1.22e-15	Schizophrenia;
LUAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04155289	chr7:94953770	PON1	-0.73	-13.44	-0.55	1.48e-34	Paraoxonase activity;
LUAD	cis	rs10911363	0.592	rs2702205	chr1:183457198	A/G	cg09173681	chr1:183549694	NCF2	0.53	9.96	0.44	3.95e-21	Systemic lupus erythematosus;
LUAD	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg02493740	chr2:85810744	VAMP5	-0.46	-8.44	-0.38	5.26e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg24558204	chr6:135376177	HBS1L	0.46	8.58	0.38	1.83e-16	Red blood cell count;
LUAD	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg15691649	chr6:25882328	NA	-0.45	-7.21	-0.33	2.56e-12	Blood metabolite levels;
LUAD	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg19980929	chr12:42632907	YAF2	0.35	6.65	0.31	9.03e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg07917127	chr4:99064746	C4orf37	0.41	6.63	0.31	9.97e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg12292205	chr6:26970375	C6orf41	-0.6	-10.35	-0.45	1.51e-22	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.15	0.33	3.89e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs870825	0.616	rs55685500	chr4:185614810	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	12.66	0.52	2.37e-31	Blood protein levels;
LUAD	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22968622	chr17:43663579	NA	-0.93	-16.14	-0.62	5.35e-46	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs16910800	0.731	rs16910759	chr11:23192131	C/G	cg20040320	chr11:23191996	NA	-0.73	-9.83	-0.43	1.17e-20	Cancer;
LUAD	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg03388025	chr16:89894329	SPIRE2	0.48	12.35	0.51	3.81e-30	Vitiligo;
LUAD	cis	rs6445967	0.554	rs12494710	chr3:58430207	C/T	cg13750441	chr3:58318267	PXK	-0.32	-6.54	-0.3	1.74e-10	Platelet count;
LUAD	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg20607287	chr7:12443886	VWDE	-0.48	-6.95	-0.32	1.37e-11	Coronary artery disease;
LUAD	cis	rs13126513	0.519	rs12641768	chr4:100558594	C/A	cg05468953	chr4:100565104	NA	0.41	8.3	0.37	1.38e-15	Metabolite levels (MHPG);
LUAD	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg24578937	chr1:2090814	PRKCZ	-0.57	-10.99	-0.47	6.95e-25	Height;
LUAD	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg02753203	chr1:228287806	NA	-0.48	-8.61	-0.39	1.41e-16	Diastolic blood pressure;
LUAD	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg25319279	chr11:5960081	NA	-0.39	-6.87	-0.32	2.28e-11	DNA methylation (variation);
LUAD	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg03233332	chr7:66118400	NA	-0.45	-6.69	-0.31	6.93e-11	Aortic root size;
LUAD	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg18131467	chr2:239335373	ASB1	0.7	11.9	0.5	2.32e-28	Multiple system atrophy;
LUAD	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg15445000	chr17:37608096	MED1	0.44	8.23	0.37	2.43e-15	Glomerular filtration rate (creatinine);
LUAD	trans	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg14791747	chr16:20752902	THUMPD1	0.45	6.74	0.31	5.04e-11	Dental caries;
LUAD	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg06221963	chr1:154839813	KCNN3	-0.85	-20.1	-0.7	1.48e-63	Prostate cancer;
LUAD	cis	rs2996428	0.561	rs2275833	chr1:3745721	C/T	cg22529645	chr1:3704559	LRRC47	0.52	9.88	0.43	7.28e-21	Red cell distribution width;
LUAD	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	3.01e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg07211511	chr3:129823064	LOC729375	-0.44	-6.51	-0.3	2.14e-10	Blood pressure (smoking interaction);
LUAD	trans	rs6901152	0.525	rs4896651	chr6:143691393	A/G	cg00214056	chr18:46478384	SMAD7	-0.4	-6.54	-0.3	1.77e-10	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg15900387	chr1:150738905	CTSS	-0.35	-6.59	-0.31	1.28e-10	Melanoma;
LUAD	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg02782426	chr3:40428986	ENTPD3	0.43	9.51	0.42	1.42e-19	Renal cell carcinoma;
LUAD	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg24324837	chr19:49891574	CCDC155	-0.55	-7.98	-0.36	1.34e-14	Multiple sclerosis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02759888	chr15:63449753	RPS27L	-0.58	-6.92	-0.32	1.64e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9863	0.896	rs76283024	chr12:124466779	G/T	cg17723958	chr12:124429295	CCDC92	-0.4	-6.39	-0.3	4.41e-10	White blood cell count;
LUAD	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg08470875	chr2:26401718	FAM59B	-0.56	-7.77	-0.35	6.11e-14	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg05340658	chr4:99064831	C4orf37	0.46	6.91	0.32	1.82e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg10295955	chr4:187884368	NA	-1.14	-30.31	-0.83	4.24e-108	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12519773	0.611	rs6873704	chr5:92490864	A/C	cg18783429	chr5:92414398	NA	0.39	6.75	0.31	4.83e-11	Migraine;
LUAD	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg03676636	chr4:99064102	C4orf37	0.31	8.19	0.37	3.16e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg06784218	chr1:46089804	CCDC17	0.54	11.67	0.49	1.86e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7870753	0.530	rs117847766	chr9:99191655	A/T	cg13563390	chr9:99253610	HABP4	-0.38	-6.4	-0.3	4.23e-10	Height;
LUAD	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-20.58	-0.71	1.06e-65	Height;
LUAD	cis	rs2554380	0.628	rs2401131	chr15:84470896	A/T	cg14598478	chr15:84363061	ADAMTSL3	-0.39	-6.71	-0.31	6.27e-11	Height;
LUAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg15147215	chr3:52552868	STAB1	-0.5	-9.89	-0.43	6.87e-21	Hemoglobin concentration;
LUAD	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg05340658	chr4:99064831	C4orf37	0.53	8.96	0.4	1.04e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23158103	chr7:148848205	ZNF398	-0.67	-12.48	-0.52	1.17e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg03806693	chr22:41940476	POLR3H	-0.59	-8.64	-0.39	1.13e-16	Vitiligo;
LUAD	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg18016565	chr1:150552671	MCL1	0.41	7.55	0.34	2.78e-13	Tonsillectomy;
LUAD	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.78e-19	Life satisfaction;
LUAD	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.33	-0.41	6.06e-19	Type 2 diabetes;
LUAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23602909	chr7:157956050	PTPRN2	-0.59	-12.61	-0.52	3.56e-31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg24733560	chr20:60626293	TAF4	0.47	8.31	0.37	1.28e-15	Body mass index;
LUAD	cis	rs55665837	1.000	rs12276938	chr11:14463488	C/G	cg19336497	chr11:14380999	RRAS2	-0.5	-10.03	-0.44	2.26e-21	Vitamin D levels;
LUAD	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg07570687	chr10:102243282	WNT8B	0.46	7.06	0.32	6.77e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2018683	0.835	rs7782264	chr7:28978986	A/G	cg19402173	chr7:128379420	CALU	0.59	9.87	0.43	7.93e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1953600	1.000	rs2789679	chr10:81907884	A/T	cg00277334	chr10:82204260	NA	-0.43	-7.36	-0.34	9.48e-13	Sarcoidosis;
LUAD	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg05966235	chr16:28915196	ATP2A1	0.5	8.05	0.36	8.19e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg08645402	chr16:4508243	NA	-0.53	-9.58	-0.42	8.68e-20	Schizophrenia;
LUAD	cis	rs427941	0.632	rs201527	chr7:101774451	T/C	cg06246474	chr7:101738831	CUX1	0.37	6.45	0.3	2.98e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1003719	0.715	rs2252893	chr21:38507572	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-9.06	-0.4	4.8e-18	Eye color traits;
LUAD	cis	rs25422	0.938	rs9489443	chr6:118886163	T/A	cg21191810	chr6:118973309	C6orf204	-0.51	-8.1	-0.37	6.11e-15	Renal cell carcinoma;
LUAD	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg12623302	chr6:28058802	ZSCAN12L1	0.29	6.54	0.3	1.73e-10	Parkinson's disease;
LUAD	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg24450063	chr1:156163899	SLC25A44	1.02	18.39	0.67	6e-56	Testicular germ cell tumor;
LUAD	cis	rs11229555	1.000	rs12787765	chr11:58400686	G/A	cg15696309	chr11:58395628	NA	-0.72	-10.9	-0.47	1.54e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs4372836	1.000	rs11127188	chr2:28972852	G/A	cg09522027	chr2:28974177	PPP1CB	-0.63	-10.17	-0.44	7.28e-22	Body mass index;
LUAD	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg21918786	chr6:109611834	NA	-0.59	-10.85	-0.47	2.24e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22857025	chr5:266934	NA	-0.98	-14.33	-0.57	2.97e-38	Breast cancer;
LUAD	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg15448220	chr1:150897856	SETDB1	0.53	9.32	0.41	6.74e-19	Melanoma;
LUAD	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg11189052	chr15:85197271	WDR73	-0.77	-13.31	-0.54	5.19e-34	Schizophrenia;
LUAD	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg20933634	chr6:27740509	NA	0.52	8.01	0.36	1.15e-14	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.78	0.35	5.45e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg27284194	chr4:1044797	NA	0.55	8.99	0.4	8.16e-18	Recombination rate (males);
LUAD	cis	rs7665090	1.000	rs4579121	chr4:103558169	C/G	cg07973026	chr4:103553119	MANBA	0.47	8.41	0.38	6.57e-16	Primary biliary cholangitis;
LUAD	cis	rs6430585	0.527	rs60966546	chr2:136401843	C/T	cg07169764	chr2:136633963	MCM6	0.57	6.76	0.31	4.51e-11	Corneal structure;
LUAD	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg02527881	chr3:46936655	PTH1R	0.46	8.82	0.39	3.12e-17	Colorectal cancer;
LUAD	cis	rs4700695	0.614	rs394828	chr5:65209552	C/T	cg21114390	chr5:65439923	SFRS12	0.65	7.33	0.34	1.16e-12	Facial morphology (factor 19);
LUAD	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs6960043	0.818	rs10807778	chr7:15054190	C/G	cg19272540	chr7:15055459	NA	0.4	8.97	0.4	9.6e-18	Type 2 diabetes;
LUAD	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.49	-0.58	6.09e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs3806843	0.576	rs246024	chr5:140333952	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	9.02e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs250677	1.000	rs36079	chr5:148430504	G/A	cg12140854	chr5:148520817	ABLIM3	-0.62	-10.37	-0.45	1.34e-22	Breast cancer;
LUAD	cis	rs9581857	0.585	rs9581875	chr13:28099678	A/G	cg22138327	chr13:27999177	GTF3A	0.88	9.26	0.41	1.01e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg14583973	chr4:3374767	RGS12	0.29	7.17	0.33	3.39e-12	Serum sulfate level;
LUAD	cis	rs7267979	0.844	rs6083851	chr20:25401235	G/A	cg08601574	chr20:25228251	PYGB	-0.42	-7.91	-0.36	2.34e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs859767	0.741	rs7571113	chr2:135427392	A/G	cg12500956	chr2:135428796	TMEM163	-0.33	-8.56	-0.38	2.19e-16	Neuroticism;
LUAD	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg27171569	chr16:83987465	OSGIN1	-0.53	-10.17	-0.44	7.05e-22	Pursuit maintenance gain;
LUAD	cis	rs7274811	0.744	rs209665	chr20:32128889	T/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.49	-7.54	-0.34	2.89e-13	Height;
LUAD	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg18854424	chr1:2615690	NA	0.43	9.31	0.41	7.11e-19	Ulcerative colitis;
LUAD	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg10589385	chr1:150898437	SETDB1	0.45	8.44	0.38	5.11e-16	Melanoma;
LUAD	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.63	0.31	1.02e-10	Menarche (age at onset);
LUAD	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg08742575	chr21:47604166	C21orf56	-0.55	-9.58	-0.42	8.51e-20	Testicular germ cell tumor;
LUAD	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg06022373	chr22:39101656	GTPBP1	0.45	7.3	0.33	1.42e-12	Menopause (age at onset);
LUAD	cis	rs1232027	0.700	rs1677691	chr5:79937028	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg26384229	chr12:38710491	ALG10B	0.48	7.74	0.35	7.49e-14	Bladder cancer;
LUAD	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg19052272	chr2:3704530	ALLC	-0.63	-10.73	-0.46	6.25e-24	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-7.5	-0.34	3.87e-13	Longevity;Endometriosis;
LUAD	cis	rs17095355	1.000	rs7079713	chr10:111755416	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.77	-10.82	-0.47	2.9e-24	Biliary atresia;
LUAD	cis	rs7551222	0.749	rs10900600	chr1:204559707	G/T	cg20240347	chr1:204465584	NA	-0.33	-6.41	-0.3	3.85e-10	Schizophrenia;
LUAD	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg07741184	chr6:167504864	NA	0.35	7.99	0.36	1.28e-14	Primary biliary cholangitis;
LUAD	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg01689657	chr7:91764605	CYP51A1	0.35	8.83	0.39	2.86e-17	Breast cancer;
LUAD	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg14844989	chr11:31128820	NA	0.45	8.22	0.37	2.47e-15	Red blood cell count;
LUAD	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg04025307	chr7:1156635	C7orf50	0.52	8.82	0.39	3.11e-17	Longevity;Endometriosis;
LUAD	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg02176678	chr2:219576539	TTLL4	0.68	13.51	0.55	7.69e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07167872	chr1:205819463	PM20D1	0.77	15.33	0.6	1.69e-42	Menarche (age at onset);
LUAD	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.37	6.63	0.31	1.04e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg26513180	chr16:89883248	FANCA	0.7	6.73	0.31	5.66e-11	Skin colour saturation;
LUAD	cis	rs6684514	1.000	rs6679145	chr1:156256000	T/C	cg16558208	chr1:156270281	VHLL	0.53	9.58	0.42	8.12e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	9.55	0.42	1.08e-19	Axial length;
LUAD	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg09253696	chr17:73873529	TRIM47	-0.42	-7.29	-0.33	1.58e-12	Psoriasis;
LUAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08219700	chr8:58056026	NA	-0.53	-7.36	-0.34	9.41e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg12011299	chr4:100065546	ADH4	0.7	13.63	0.55	2.42e-35	Alcohol dependence;
LUAD	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	10.0	0.44	2.86e-21	Lung cancer in ever smokers;
LUAD	cis	rs739496	0.579	rs10774640	chr12:112295190	T/C	cg10833066	chr12:111807467	FAM109A	0.43	6.83	0.32	2.98e-11	Platelet count;
LUAD	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg22961513	chr11:14280813	SPON1	-0.42	-8.4	-0.38	6.63e-16	Mitochondrial DNA levels;
LUAD	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06022373	chr22:39101656	GTPBP1	0.48	8.13	0.37	4.87e-15	Menopause (age at onset);
LUAD	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg20503657	chr10:835505	NA	0.97	14.77	0.58	4.11e-40	Eosinophil percentage of granulocytes;
LUAD	cis	rs7520050	0.933	rs6680211	chr1:46315007	C/G	cg06784218	chr1:46089804	CCDC17	-0.3	-6.38	-0.3	4.76e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg01874867	chr7:94954059	PON1	-0.48	-6.47	-0.3	2.65e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2422052	0.766	rs1583330	chr2:118650028	T/C	cg22545206	chr2:118617499	NA	0.39	6.72	0.31	5.98e-11	Mosquito bite size;
LUAD	cis	rs2742540	0.503	rs7106539	chr11:8897533	T/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.45	-7.46	-0.34	5.01e-13	Hematocrit;
LUAD	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg27490568	chr2:178487706	NA	0.59	9.74	0.43	2.37e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2235649	0.828	rs9938694	chr16:1849872	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.47	-7.73	-0.35	7.72e-14	Blood metabolite levels;
LUAD	cis	rs3815700	1.000	rs7247420	chr19:33096786	G/A	cg02997394	chr19:33096574	ANKRD27	0.66	8.78	0.39	4.23e-17	Eosinophilic esophagitis;
LUAD	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.63	9.31	0.41	7.24e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9393692	0.557	rs9358924	chr6:26322473	G/A	cg13736514	chr6:26305472	NA	-0.52	-8.22	-0.37	2.58e-15	Educational attainment;
LUAD	cis	rs41307935	0.722	rs12724052	chr1:27234682	G/A	cg12203394	chr1:27248618	NUDC	0.52	6.56	0.3	1.59e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg01689657	chr7:91764605	CYP51A1	0.33	8.2	0.37	3e-15	Breast cancer;
LUAD	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg17063962	chr7:91808500	NA	0.68	12.32	0.51	5.02e-30	Breast cancer;
LUAD	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg09035930	chr12:129282057	SLC15A4	0.76	17.75	0.65	4.6e-53	Systemic lupus erythematosus;
LUAD	cis	rs17095355	1.000	rs12254785	chr10:111699607	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.71	-9.81	-0.43	1.37e-20	Biliary atresia;
LUAD	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg04287289	chr16:89883240	FANCA	0.72	13.25	0.54	9.44e-34	Vitiligo;
LUAD	cis	rs7590720	0.851	rs13006614	chr2:216876204	C/T	cg12620499	chr2:216877984	MREG	0.56	9.11	0.41	3.27e-18	Alcohol dependence;
LUAD	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg15181151	chr6:150070149	PCMT1	0.42	8.55	0.38	2.31e-16	Lung cancer;
LUAD	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg05425664	chr17:57184151	TRIM37	-0.42	-7.46	-0.34	4.86e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg18225595	chr11:63971243	STIP1	0.4	7.08	0.33	6.14e-12	Platelet count;
LUAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg21724239	chr8:58056113	NA	0.71	9.36	0.41	4.75e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg06028808	chr11:68637592	NA	0.45	7.29	0.33	1.52e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg13319975	chr6:146136371	FBXO30	0.81	13.98	0.56	9.22e-37	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg13319975	chr6:146136371	FBXO30	0.63	10.85	0.47	2.25e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg23958373	chr8:599963	NA	-0.84	-8.01	-0.36	1.11e-14	IgG glycosylation;
LUAD	cis	rs1829883	1.000	rs2511973	chr5:98807871	T/A	cg08333243	chr5:99726346	NA	-0.38	-7.25	-0.33	2.01e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg13010199	chr12:38710504	ALG10B	0.4	6.65	0.31	8.96e-11	Bladder cancer;
LUAD	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.12e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg19536664	chr17:6899085	ALOX12	0.57	11.24	0.48	7.75e-26	Tonsillectomy;
LUAD	trans	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg26043149	chr18:55253948	FECH	0.43	7.12	0.33	4.65e-12	Bone mineral density;
LUAD	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg04450456	chr4:17643702	FAM184B	0.38	7.37	0.34	8.86e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7809950	1.000	rs2712201	chr7:107145564	T/C	cg23024343	chr7:107201750	COG5	-0.73	-12.35	-0.51	3.76e-30	Coronary artery disease;
LUAD	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg03676636	chr4:99064102	C4orf37	0.31	8.17	0.37	3.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg04025307	chr7:1156635	C7orf50	0.72	12.93	0.53	1.81e-32	Longevity;Endometriosis;
LUAD	cis	rs2294693	0.945	rs9369253	chr6:40986538	A/G	cg14769373	chr6:40998127	UNC5CL	-0.54	-8.08	-0.37	6.78e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg15448220	chr1:150897856	SETDB1	0.46	8.03	0.36	9.6e-15	Tonsillectomy;
LUAD	cis	rs68170813	0.559	rs10953534	chr7:106913718	A/G	cg02696742	chr7:106810147	HBP1	0.69	9.18	0.41	1.95e-18	Coronary artery disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09658066	chr6:35995354	MAPK14	-0.57	-6.79	-0.31	3.73e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs240764	0.658	rs9404054	chr6:101256597	A/G	cg09795085	chr6:101329169	ASCC3	-0.43	-7.61	-0.35	1.85e-13	Neuroticism;
LUAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.54	-9.65	-0.42	4.62e-20	Lymphocyte counts;
LUAD	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg15083037	chr5:83017644	HAPLN1	-0.51	-7.72	-0.35	8.41e-14	Prostate cancer;
LUAD	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg23029597	chr12:123009494	RSRC2	-0.51	-7.75	-0.35	7.1e-14	Body mass index;
LUAD	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg19761014	chr17:28927070	LRRC37B2	0.7	6.61	0.31	1.17e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg21782813	chr7:2030301	MAD1L1	0.59	10.17	0.44	6.85e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs9914544	0.524	rs8071147	chr17:18790678	A/G	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.49	-0.3	2.45e-10	Educational attainment (years of education);
LUAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg12419862	chr22:24373484	LOC391322	-0.65	-10.87	-0.47	1.93e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs3779273	1.000	rs3807648	chr7:77828434	T/C	cg05596911	chr5:118502651	DMXL1	-0.4	-7.05	-0.32	7.19e-12	Body mass index;
LUAD	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.02	0.47	5.48e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg04414720	chr1:150670196	GOLPH3L	-0.68	-11.39	-0.48	2.11e-26	Urate levels;
LUAD	cis	rs55788414	0.932	rs8059559	chr16:81185684	G/A	cg06400318	chr16:81190750	PKD1L2	0.62	8.79	0.39	3.83e-17	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs7945718	0.806	rs7480572	chr11:12787048	T/C	cg25843174	chr11:12811716	TEAD1	0.22	6.71	0.31	6.41e-11	Educational attainment (years of education);
LUAD	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg26373071	chr5:1325741	CLPTM1L	0.36	7.71	0.35	8.93e-14	Lung cancer;
LUAD	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg06671706	chr8:8559999	CLDN23	0.67	11.77	0.5	7.61e-28	Obesity-related traits;
LUAD	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-19.86	-0.69	1.64e-62	Height;
LUAD	cis	rs6881634	0.501	rs11949403	chr5:77719319	A/G	cg11547950	chr5:77652471	NA	-0.35	-6.42	-0.3	3.67e-10	Hippocampal atrophy;
LUAD	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg03929089	chr4:120376271	NA	-0.45	-6.93	-0.32	1.61e-11	HDL cholesterol;
LUAD	trans	rs8002861	0.846	rs12867732	chr13:44483084	C/A	cg17145862	chr1:211918768	LPGAT1	-0.66	-13.98	-0.56	9.22e-37	Leprosy;
LUAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg02524346	chr8:600233	NA	-0.96	-10.45	-0.45	6.69e-23	IgG glycosylation;
LUAD	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg17480646	chr11:65405466	SIPA1	-0.45	-6.65	-0.31	9.29e-11	Acne (severe);
LUAD	cis	rs9837602	0.935	rs4928149	chr3:99685686	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.57	-8.08	-0.37	6.64e-15	Breast cancer;
LUAD	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg06718696	chr17:78121285	EIF4A3	0.57	8.63	0.39	1.28e-16	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg19318889	chr4:1322082	MAEA	0.44	6.98	0.32	1.17e-11	Obesity-related traits;
LUAD	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg21153622	chr11:89784906	NA	-0.35	-6.77	-0.31	4.41e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.49	0.3	2.38e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1941687	0.797	rs7228309	chr18:31412519	A/G	cg27147174	chr7:100797783	AP1S1	0.52	8.87	0.4	2.05e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg02734326	chr4:10020555	SLC2A9	0.44	6.87	0.32	2.26e-11	Blood metabolite levels;
LUAD	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg22676075	chr6:135203613	NA	0.53	9.46	0.42	2.15e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg08470875	chr2:26401718	FAM59B	-0.77	-10.21	-0.44	5.12e-22	Gut microbiome composition (summer);
LUAD	cis	rs7000551	0.725	rs2249098	chr8:22400098	T/C	cg12081754	chr8:22256438	SLC39A14	0.44	7.16	0.33	3.54e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2455799	0.634	rs62243671	chr3:15921098	C/T	cg16303742	chr3:15540471	COLQ	-0.49	-8.73	-0.39	5.85e-17	Mean platelet volume;
LUAD	cis	rs2249625	0.564	rs2463734	chr6:72882558	C/T	cg18830697	chr6:72922368	RIMS1	-0.45	-8.13	-0.37	4.91e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg06484146	chr7:12443880	VWDE	-0.5	-7.12	-0.33	4.55e-12	Coronary artery disease;
LUAD	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.34	0.51	4.22e-30	Tonsillectomy;
LUAD	cis	rs4523957	0.928	rs216202	chr17:2197387	T/C	cg16513277	chr17:2031491	SMG6	0.77	14.4	0.57	1.57e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg02423579	chr7:2872169	GNA12	-0.53	-8.94	-0.4	1.25e-17	Height;
LUAD	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg09455208	chr3:40491958	NA	0.6	12.98	0.53	1.13e-32	Renal cell carcinoma;
LUAD	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.38	-0.34	8.48e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-8.69	-0.39	7.98e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg17366294	chr4:99064904	C4orf37	0.58	9.99	0.44	3.02e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg12011299	chr4:100065546	ADH4	0.66	12.08	0.51	4.41e-29	Alcohol dependence;
LUAD	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg04756594	chr16:24857601	SLC5A11	0.51	10.1	0.44	1.25e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg13647721	chr17:30228624	UTP6	0.47	6.51	0.3	2.14e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs7512552	0.803	rs11582423	chr1:150493925	C/G	cg15654264	chr1:150340011	RPRD2	0.56	10.67	0.46	1.08e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs243505	0.559	rs2072408	chr7:148508197	A/G	cg09806900	chr7:148480153	CUL1	0.52	9.01	0.4	6.98e-18	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs11771526	1.000	rs10231440	chr7:32299435	C/A	cg13207630	chr7:32358064	NA	0.58	7.23	0.33	2.21e-12	Body mass index;
LUAD	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.43	-0.42	2.72e-19	Life satisfaction;
LUAD	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03934478	chr11:495069	RNH1	0.78	9.36	0.41	4.83e-19	Body mass index;
LUAD	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg00898013	chr13:113819073	PROZ	-0.84	-15.22	-0.59	4.83e-42	Platelet distribution width;
LUAD	cis	rs9462027	0.628	rs7769961	chr6:34760162	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.91	-0.4	1.53e-17	Systemic lupus erythematosus;
LUAD	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg05368731	chr17:41323189	NBR1	0.97	20.35	0.7	1.06e-64	Menopause (age at onset);
LUAD	cis	rs6740322	0.895	rs6738717	chr2:43573670	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.78	-11.36	-0.48	2.7e-26	Coronary artery disease;
LUAD	trans	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg02002194	chr4:3960332	NA	0.27	6.4	0.3	4.03e-10	Retinal vascular caliber;
LUAD	trans	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg18834416	chr8:37888184	EIF4EBP1	0.39	6.39	0.3	4.39e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs72772090	0.539	rs11739020	chr5:96113838	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.62	7.56	0.35	2.51e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2625529	0.878	rs16956302	chr15:72136243	C/T	cg16672083	chr15:72433130	SENP8	-0.73	-11.49	-0.49	8.51e-27	Red blood cell count;
LUAD	cis	rs738321	0.711	rs5995541	chr22:38553411	C/T	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.32	1.44e-11	Breast cancer;
LUAD	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg04944784	chr2:26401820	FAM59B	0.68	9.65	0.42	4.69e-20	Gut microbiome composition (summer);
LUAD	cis	rs13315871	0.858	rs4075404	chr3:58411419	C/T	cg12435725	chr3:58293450	RPP14	-0.69	-7.66	-0.35	1.31e-13	Cholesterol, total;
LUAD	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg23887609	chr12:130822674	PIWIL1	0.4	6.56	0.3	1.62e-10	Menopause (age at onset);
LUAD	cis	rs11958404	0.932	rs113494689	chr5:157428078	G/T	cg05962755	chr5:157440814	NA	0.5	7.78	0.35	5.67e-14	IgG glycosylation;
LUAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg08132940	chr7:1081526	C7orf50	-0.76	-10.27	-0.45	3.19e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg21138405	chr5:131827807	IRF1	-0.61	-13.8	-0.56	4.92e-36	Asthma (sex interaction);
LUAD	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg01200585	chr1:228362443	C1orf69	-0.38	-7.02	-0.32	9.17e-12	Diastolic blood pressure;
LUAD	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg07432352	chr17:45403706	C17orf57	0.41	7.79	0.35	5.27e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.94	-0.36	1.78e-14	Prostate cancer;
LUAD	cis	rs9399401	0.633	rs262118	chr6:142843054	C/A	cg04461802	chr6:142623433	GPR126	0.39	6.61	0.31	1.14e-10	Chronic obstructive pulmonary disease;
LUAD	cis	rs12208915	0.848	rs77415956	chr6:79514757	G/A	cg05283184	chr6:79620031	NA	0.49	6.4	0.3	4.09e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg25767906	chr1:53392781	SCP2	0.41	7.43	0.34	6.26e-13	Monocyte count;
LUAD	trans	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.91	-0.43	5.67e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg19875535	chr5:140030758	IK	-0.49	-8.06	-0.36	7.89e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.65	-0.35	1.37e-13	Monocyte count;
LUAD	cis	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg13293535	chr8:11597251	GATA4	0.28	6.51	0.3	2.14e-10	Neuroticism;
LUAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03647317	chr4:187891568	NA	-0.34	-6.39	-0.3	4.51e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg03806693	chr22:41940476	POLR3H	-0.8	-11.22	-0.48	9.43e-26	Vitiligo;
LUAD	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg10253484	chr15:75165896	SCAMP2	-0.41	-6.45	-0.3	3.04e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs2230307	0.572	rs11805428	chr1:100641716	T/C	cg20868668	chr1:100435035	SLC35A3	-0.51	-7.19	-0.33	3e-12	Carotid intima media thickness;
LUAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg11494091	chr17:61959527	GH2	0.74	18.34	0.67	1.07e-55	Prudent dietary pattern;
LUAD	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg00310523	chr12:86230176	RASSF9	0.34	7.37	0.34	9.13e-13	Major depressive disorder;
LUAD	cis	rs2996428	0.709	rs6667255	chr1:3711689	T/C	cg22529645	chr1:3704559	LRRC47	0.56	10.23	0.45	4.32e-22	Red cell distribution width;
LUAD	trans	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg19862616	chr7:65841803	NCRNA00174	1.04	25.75	0.78	1.24e-88	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs62458065	0.850	rs62458099	chr7:32472395	C/T	cg20159608	chr7:32802032	NA	-0.56	-7.36	-0.34	9.55e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.12	14.65	0.58	1.29e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs375066	0.762	rs1073654	chr19:44411420	T/C	cg12072164	chr19:44306565	LYPD5	-0.32	-6.44	-0.3	3.27e-10	Breast cancer;
LUAD	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.19	-0.51	1.7e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg16325326	chr1:53192061	ZYG11B	0.61	12.11	0.51	3.32e-29	Monocyte count;
LUAD	cis	rs1595825	0.891	rs7585709	chr2:198883682	C/T	cg00982548	chr2:198649783	BOLL	-0.65	-9.14	-0.41	2.63e-18	Ulcerative colitis;
LUAD	cis	rs73086581	1.000	rs73086505	chr20:3921571	A/G	cg02187196	chr20:3869020	PANK2	0.49	6.78	0.31	4.14e-11	Response to antidepressants in depression;
LUAD	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.67	-0.31	8.13e-11	Personality dimensions;
LUAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg26554054	chr8:600488	NA	0.89	8.34	0.38	1.06e-15	IgG glycosylation;
LUAD	trans	rs4332037	0.707	rs11763813	chr7:1896690	C/T	cg11693508	chr17:37793320	STARD3	0.78	10.11	0.44	1.14e-21	Bipolar disorder;
LUAD	cis	rs7536201	1.000	rs10751776	chr1:25296743	A/C	cg23273869	chr1:25296894	NA	-0.38	-7.61	-0.35	1.74e-13	Psoriasis vulgaris;
LUAD	cis	rs11030122	0.673	rs10767767	chr11:4003678	C/T	cg18678763	chr11:4115507	RRM1	-0.41	-6.75	-0.31	4.87e-11	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg25208724	chr1:156163844	SLC25A44	1.01	18.16	0.66	6.3e-55	Testicular germ cell tumor;
LUAD	cis	rs4523957	0.620	rs8070272	chr17:2063117	A/G	cg16513277	chr17:2031491	SMG6	-0.97	-19.27	-0.68	7.43e-60	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg05340658	chr4:99064831	C4orf37	0.45	7.44	0.34	5.81e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg17747265	chr1:1875780	NA	-0.75	-17.97	-0.66	4.84e-54	Body mass index;
LUAD	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.71e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg14598338	chr9:96623480	NA	-0.42	-8.95	-0.4	1.13e-17	DNA methylation (variation);
LUAD	trans	rs17060993	1.000	rs6557978	chr8:26959780	A/T	cg21519804	chr5:178978460	RUFY1	0.77	7.04	0.32	8.01e-12	Musician's dystonia;
LUAD	cis	rs7116495	1.000	rs7937582	chr11:71744613	C/T	cg07596299	chr11:71824057	C11orf51	-0.78	-6.45	-0.3	2.99e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg02734326	chr4:10020555	SLC2A9	0.64	11.48	0.49	9.32e-27	Bone mineral density;
LUAD	cis	rs3845702	0.736	rs9288045	chr2:180814194	G/A	cg01881094	chr2:180872142	CWC22	-0.8	-8.38	-0.38	7.78e-16	Schizophrenia;
LUAD	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg09184832	chr6:79620586	NA	-0.52	-9.7	-0.43	3.08e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg19761014	chr17:28927070	LRRC37B2	0.88	8.38	0.38	7.72e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg06608945	chr2:219082296	ARPC2	-0.42	-7.06	-0.32	6.82e-12	Colorectal cancer;
LUAD	cis	rs8078723	0.546	rs8067817	chr17:38163936	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.48	-9.8	-0.43	1.45e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg09137382	chr11:130731461	NA	0.4	7.42	0.34	6.48e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg15557168	chr22:42548783	NA	0.49	9.1	0.4	3.66e-18	Schizophrenia;
LUAD	cis	rs11166629	0.679	rs1583969	chr8:135661484	C/T	cg27224718	chr8:135614730	ZFAT	0.39	6.46	0.3	2.86e-10	Smoking quantity;
LUAD	cis	rs11214589	0.905	rs2186799	chr11:113242533	G/T	cg14159747	chr11:113255604	NA	0.68	14.78	0.58	3.83e-40	Neuroticism;
LUAD	cis	rs11696501	1.000	rs11696501	chr20:44124523	A/G	cg11783356	chr20:44313418	WFDC10B	-0.4	-6.61	-0.31	1.15e-10	Brain structure;
LUAD	cis	rs8044868	0.530	rs7940	chr16:72146441	C/G	cg23815491	chr16:72088622	HP	0.5	9.26	0.41	1.08e-18	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs4899554	0.640	rs1569328	chr14:75741751	A/G	cg18117039	chr14:75741733	NA	-0.65	-9.73	-0.43	2.6e-20	Inflammatory bowel disease;
LUAD	cis	rs12681287	0.752	rs12677470	chr8:87260559	G/A	cg27223183	chr8:87520930	FAM82B	-0.59	-8.11	-0.37	5.7e-15	Caudate activity during reward;
LUAD	cis	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg06609049	chr19:2785107	THOP1	0.75	12.22	0.51	1.25e-29	Total cholesterol levels;
LUAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg00450029	chr8:599525	NA	0.76	7.37	0.34	9.16e-13	IgG glycosylation;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg27077143	chr5:68666458	TAF9;RAD17	-0.7	-6.63	-0.31	1.05e-10	Type 2 diabetes;
LUAD	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg07538946	chr5:131705188	SLC22A5	-0.49	-8.21	-0.37	2.73e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs4782309	0.544	rs8060579	chr16:88751667	G/C	cg09381666	chr16:88757816	NA	0.78	6.41	0.3	3.89e-10	Hair color;
LUAD	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	6.72	0.31	5.99e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11229555	0.645	rs10466679	chr11:58188257	T/C	cg15696309	chr11:58395628	NA	-0.73	-10.06	-0.44	1.68e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs3106136	0.546	rs2664880	chr4:95144177	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.54	-10.38	-0.45	1.23e-22	Capecitabine sensitivity;
LUAD	cis	rs7705042	0.796	rs1835965	chr5:141501771	G/A	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.78	-0.31	3.98e-11	Asthma;
LUAD	cis	rs73198271	0.515	rs11779327	chr8:8624955	G/C	cg01851573	chr8:8652454	MFHAS1	0.54	7.01	0.32	9.6e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7665090	1.000	rs11727546	chr4:103557664	A/G	cg07973026	chr4:103553119	MANBA	0.47	8.46	0.38	4.33e-16	Primary biliary cholangitis;
LUAD	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg16479474	chr6:28041457	NA	0.45	7.73	0.35	7.89e-14	Parkinson's disease;
LUAD	cis	rs17102423	0.731	rs1957949	chr14:65542607	C/T	cg11161011	chr14:65562177	MAX	-0.4	-6.7	-0.31	6.7e-11	Obesity-related traits;
LUAD	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg03188948	chr7:1209495	NA	0.81	9.91	0.43	5.78e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg23754390	chr11:835074	CD151	0.35	6.41	0.3	3.95e-10	Mean platelet volume;
LUAD	trans	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg14791747	chr16:20752902	THUMPD1	0.71	10.2	0.44	5.31e-22	Cognitive test performance;
LUAD	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.1	0.37	5.93e-15	Menopause (age at onset);
LUAD	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg12311346	chr5:56204834	C5orf35	-0.94	-13.89	-0.56	2.12e-36	Initial pursuit acceleration;
LUAD	cis	rs57994353	0.897	rs72775778	chr9:139381128	G/A	cg14364472	chr9:139394549	NOTCH1	-0.45	-6.75	-0.31	4.86e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg07432352	chr17:45403706	C17orf57	-0.41	-7.94	-0.36	1.79e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg06608945	chr2:219082296	ARPC2	-0.52	-8.82	-0.39	3.02e-17	Colorectal cancer;
LUAD	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.43	-0.34	6.12e-13	Breast cancer;
LUAD	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg01689657	chr7:91764605	CYP51A1	-0.36	-8.89	-0.4	1.76e-17	Breast cancer;
LUAD	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg05340658	chr4:99064831	C4orf37	0.45	7.36	0.34	9.65e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs28493229	0.881	rs59459325	chr19:41175390	C/T	cg21869046	chr19:41225005	ITPKC	0.55	8.66	0.39	1.02e-16	Kawasaki disease;
LUAD	cis	rs4845570	1.000	rs7542898	chr1:151753622	T/G	cg07092448	chr1:151763213	TDRKH	-0.75	-8.8	-0.39	3.46e-17	Coronary artery disease;
LUAD	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg03037974	chr15:76606532	NA	0.48	11.19	0.48	1.23e-25	Blood metabolite levels;
LUAD	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg03929089	chr4:120376271	NA	-0.43	-6.62	-0.31	1.1e-10	HDL cholesterol;
LUAD	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg15181151	chr6:150070149	PCMT1	0.37	7.35	0.34	1.04e-12	Lung cancer;
LUAD	cis	rs4662945	0.525	rs28819474	chr2:130264623	T/C	cg05962382	chr2:130345044	NA	-0.37	-6.86	-0.32	2.38e-11	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs2797685	1.000	rs697691	chr1:7885354	A/G	cg04725166	chr1:7887271	PER3	-0.48	-7.18	-0.33	3.24e-12	Crohn's disease;
LUAD	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg15605315	chr1:45957053	TESK2	0.49	7.7	0.35	9.44e-14	High light scatter reticulocyte count;
LUAD	cis	rs558133	1.000	rs694290	chr5:78421780	G/A	cg25119155	chr5:78426943	BHMT	0.49	8.79	0.39	3.67e-17	Blood and toenail selenium levels;
LUAD	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg09537434	chr19:41945824	ATP5SL	-0.51	-8.09	-0.37	6.18e-15	Height;
LUAD	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg20673091	chr1:2541236	MMEL1	0.4	8.53	0.38	2.69e-16	Multiple sclerosis;
LUAD	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg16205897	chr5:131564050	P4HA2	0.29	6.45	0.3	3.15e-10	Blood metabolite levels;
LUAD	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg00074818	chr8:8560427	CLDN23	0.66	10.17	0.44	6.95e-22	Obesity-related traits;
LUAD	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.58	0.52	4.9e-31	Tonsillectomy;
LUAD	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg06637938	chr14:75390232	RPS6KL1	0.35	6.4	0.3	4.07e-10	Caffeine consumption;
LUAD	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg17063962	chr7:91808500	NA	0.68	12.15	0.51	2.4e-29	Breast cancer;
LUAD	cis	rs72700829	0.507	rs11204766	chr1:151018060	G/C	cg11822372	chr1:151115635	SEMA6C	-0.8	-6.5	-0.3	2.25e-10	Schizophrenia;
LUAD	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg18404041	chr3:52824283	ITIH1	-0.61	-9.96	-0.44	3.81e-21	Schizophrenia;
LUAD	trans	rs9467711	0.651	rs34555420	chr6:26090270	G/T	cg01620082	chr3:125678407	NA	-1.02	-8.07	-0.37	7.29e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9837602	0.872	rs34996634	chr3:99738219	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.53	-0.3	1.86e-10	Breast cancer;
LUAD	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg25036284	chr2:26402008	FAM59B	0.84	11.63	0.49	2.59e-27	Gut microbiome composition (summer);
LUAD	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg24879335	chr3:133465180	TF	0.39	8.04	0.36	8.82e-15	Iron status biomarkers (transferrin levels);
LUAD	cis	rs2742234	0.955	rs2435384	chr10:43673731	G/T	cg02780029	chr10:43622663	RET	-0.45	-7.23	-0.33	2.32e-12	Hirschsprung disease;
LUAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg24829409	chr8:58192753	C8orf71	-0.49	-6.57	-0.3	1.48e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg07234876	chr8:600039	NA	0.87	8.22	0.37	2.53e-15	IgG glycosylation;
LUAD	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg22467129	chr15:76604101	ETFA	-0.47	-7.84	-0.36	3.79e-14	Blood metabolite levels;
LUAD	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg08280861	chr8:58055591	NA	0.55	7.48	0.34	4.21e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs870825	0.616	rs55674580	chr4:185626605	C/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg09365446	chr1:150670422	GOLPH3L	0.66	12.4	0.52	2.42e-30	Tonsillectomy;
LUAD	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-7.65	-0.35	1.36e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.55	-9.72	-0.43	2.75e-20	Lymphocyte counts;
LUAD	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-13.39	-0.55	2.38e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs500891	0.525	rs12215595	chr6:84055783	A/G	cg08257003	chr6:84140564	ME1	0.34	6.68	0.31	7.45e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs8017423	0.872	rs7492857	chr14:90684867	T/G	cg14092571	chr14:90743983	NA	0.46	7.91	0.36	2.26e-14	Mortality in heart failure;
LUAD	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg12615879	chr12:58013172	SLC26A10	-0.4	-8.23	-0.37	2.3e-15	Multiple sclerosis;
LUAD	trans	rs11165623	0.792	rs1125358	chr1:96971800	T/C	cg10631902	chr5:14652156	NA	-0.57	-10.88	-0.47	1.8e-24	Hip circumference;Waist circumference;
LUAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg00106254	chr7:1943704	MAD1L1	-0.59	-8.99	-0.4	8.18e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg24838063	chr12:130822603	PIWIL1	0.62	10.47	0.45	5.94e-23	Menopause (age at onset);
LUAD	cis	rs3087591	0.708	rs67065748	chr17:29605631	T/A	cg24425628	chr17:29625626	OMG;NF1	0.41	6.62	0.31	1.07e-10	Hip circumference;
LUAD	cis	rs4774899	0.869	rs2733174	chr15:57331666	C/T	cg14026238	chr15:57616123	NA	-0.34	-6.48	-0.3	2.52e-10	Urinary tract infection frequency;
LUAD	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg20673091	chr1:2541236	MMEL1	0.45	9.95	0.44	4.18e-21	Ulcerative colitis;
LUAD	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg24037166	chr10:75255724	PPP3CB	0.39	6.83	0.32	3.02e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg12458913	chr13:53173898	NA	-0.43	-7.78	-0.35	5.66e-14	Lewy body disease;
LUAD	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg14196790	chr5:131705035	SLC22A5	-0.57	-10.41	-0.45	9.41e-23	Blood metabolite levels;
LUAD	trans	rs629535	0.773	rs72654090	chr8:70118666	G/A	cg21567404	chr3:27674614	NA	-0.96	-16.98	-0.64	1.09e-49	Dupuytren's disease;
LUAD	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22968622	chr17:43663579	NA	-1.22	-20.05	-0.7	2.42e-63	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08048268	chr3:133502702	NA	0.54	11.08	0.47	3.15e-25	Iron status biomarkers;
LUAD	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg21016266	chr12:122356598	WDR66	0.62	10.8	0.47	3.44e-24	Mean corpuscular volume;
LUAD	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg18944383	chr4:111397179	ENPEP	0.37	7.57	0.35	2.29e-13	Height;
LUAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg22963979	chr7:1858916	MAD1L1	-0.57	-9.88	-0.43	7.25e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00149659	chr3:10157352	C3orf10	0.55	7.0	0.32	1.03e-11	Alzheimer's disease;
LUAD	cis	rs9400271	0.632	rs4427037	chr6:109585612	G/C	cg01475377	chr6:109611718	NA	-0.37	-6.44	-0.3	3.3e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.04	23.47	0.75	1.34e-78	Chronic sinus infection;
LUAD	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg02158880	chr13:53174818	NA	0.47	7.97	0.36	1.46e-14	Lewy body disease;
LUAD	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.64	9.57	0.42	9.35e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg14019146	chr3:50243930	SLC38A3	-0.34	-6.49	-0.3	2.4e-10	Body mass index;
LUAD	cis	rs859767	0.812	rs842357	chr2:135345059	G/A	cg12500956	chr2:135428796	TMEM163	0.3	7.85	0.36	3.34e-14	Neuroticism;
LUAD	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg03388025	chr16:89894329	SPIRE2	0.52	13.71	0.55	1.19e-35	Vitiligo;
LUAD	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg14664628	chr15:75095509	CSK	-0.4	-6.52	-0.3	1.95e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg06002616	chr8:101225028	SPAG1	-0.4	-8.06	-0.36	7.99e-15	Atrioventricular conduction;
LUAD	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg18252515	chr7:66147081	NA	-0.57	-6.41	-0.3	3.91e-10	Diabetic kidney disease;
LUAD	cis	rs4638749	0.677	rs13022268	chr2:108837320	A/G	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.32	-0.34	1.25e-12	Blood pressure;
LUAD	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg07266350	chr3:49460521	AMT;NICN1	0.36	6.39	0.3	4.5e-10	Menarche (age at onset);
LUAD	cis	rs2455799	0.896	rs2455795	chr3:15698212	G/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.66	-0.31	8.57e-11	Mean platelet volume;
LUAD	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg09197432	chr4:183729176	NA	0.55	7.67	0.35	1.23e-13	Pediatric autoimmune diseases;
LUAD	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg12257156	chr7:158823799	VIPR2	0.5	7.43	0.34	5.97e-13	Facial morphology (factor 20);
LUAD	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03452623	chr4:187889614	NA	0.78	15.35	0.6	1.41e-42	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg14583973	chr4:3374767	RGS12	-0.31	-7.81	-0.36	4.53e-14	Serum sulfate level;
LUAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg07217954	chr7:1067459	C7orf50	0.46	7.16	0.33	3.62e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg13319975	chr6:146136371	FBXO30	-0.61	-10.59	-0.46	2.17e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg12311346	chr5:56204834	C5orf35	0.74	11.75	0.5	8.75e-28	Initial pursuit acceleration;
LUAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg15242686	chr22:24348715	GSTTP1	0.5	8.98	0.4	8.79e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg19622623	chr12:86230825	RASSF9	-0.39	-7.02	-0.32	9.09e-12	Major depressive disorder;
LUAD	cis	rs34734847	0.703	rs3794215	chr12:121168083	T/C	cg13914990	chr12:121174878	ACADS	0.4	7.69	0.35	1.05e-13	Mean corpuscular volume;
LUAD	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg17845761	chr1:175162550	KIAA0040	0.37	9.82	0.43	1.2e-20	Alcohol dependence;
LUAD	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg25828334	chr19:18545568	ISYNA1	-0.36	-7.23	-0.33	2.24e-12	Breast cancer;
LUAD	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg17063962	chr7:91808500	NA	0.67	11.54	0.49	5.87e-27	Breast cancer;
LUAD	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.43	-0.3	3.52e-10	Aortic root size;
LUAD	cis	rs9796	0.870	rs72737704	chr15:41323575	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.37	-7.02	-0.32	8.98e-12	Menopause (age at onset);
LUAD	cis	rs7799006	1.000	rs7810970	chr7:2276385	A/G	cg02951883	chr7:2050386	MAD1L1	-0.5	-7.93	-0.36	1.98e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg19825600	chr2:3704501	ALLC	-0.41	-7.76	-0.35	6.41e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-7.15	-0.33	3.91e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs1941687	0.831	rs55671114	chr18:31386284	C/A	cg27147174	chr7:100797783	AP1S1	-0.55	-9.16	-0.41	2.24e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs4700695	0.841	rs251608	chr5:65247893	C/T	cg21114390	chr5:65439923	SFRS12	0.63	8.17	0.37	3.52e-15	Facial morphology (factor 19);
LUAD	cis	rs2046867	0.862	rs7648954	chr3:72838756	C/A	cg25664220	chr3:72788482	NA	-0.67	-12.3	-0.51	6.16e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs2274273	0.870	rs61210954	chr14:55765402	T/C	cg04306507	chr14:55594613	LGALS3	0.41	8.53	0.38	2.58e-16	Protein biomarker;
LUAD	trans	rs75804782	0.521	rs72993034	chr2:239385895	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	8.77	0.39	4.27e-17	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg03676636	chr4:99064102	C4orf37	0.31	7.41	0.34	6.75e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg23625390	chr15:77176239	SCAPER	-0.46	-7.36	-0.34	9.57e-13	Blood metabolite levels;
LUAD	trans	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.51	-0.34	3.63e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01570182	chr17:44337453	NA	-0.65	-10.22	-0.44	4.78e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2625529	0.824	rs2279283	chr15:72243666	T/C	cg16672083	chr15:72433130	SENP8	-0.74	-12.2	-0.51	1.59e-29	Red blood cell count;
LUAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg11494091	chr17:61959527	GH2	0.74	18.48	0.67	2.58e-56	Prudent dietary pattern;
LUAD	cis	rs2242073	1.000	rs2242073	chr2:208994045	A/C	cg24664470	chr2:208976933	NA	0.47	6.97	0.32	1.21e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs494562	1.000	rs494562	chr6:86117129	A/G	cg13315970	chr6:86159197	NT5E	0.72	8.26	0.37	1.94e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs11247915	0.600	rs3795686	chr1:26582091	G/A	cg01568347	chr1:26488053	GRRP1	0.35	6.52	0.3	2.01e-10	Obesity-related traits;
LUAD	cis	rs9811920	0.683	rs4928230	chr3:99661963	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	7.29	0.33	1.53e-12	Axial length;
LUAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg00106254	chr7:1943704	MAD1L1	-0.59	-8.74	-0.39	5.44e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg11871910	chr12:69753446	YEATS4	-0.56	-8.49	-0.38	3.51e-16	Blood protein levels;
LUAD	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.25	0.48	7.02e-26	Eosinophil percentage of white cells;
LUAD	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg02782426	chr3:40428986	ENTPD3	0.42	8.9	0.4	1.68e-17	Renal cell carcinoma;
LUAD	cis	rs7027203	1.000	rs7856374	chr9:96529791	G/A	cg14396892	chr9:96623032	NA	0.39	7.1	0.33	5.2e-12	DNA methylation (variation);
LUAD	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg05434287	chr7:2030229	MAD1L1	0.41	6.64	0.31	9.67e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs3849570	0.925	rs7641973	chr3:81910489	G/A	cg07356753	chr3:81810745	GBE1	-0.61	-10.71	-0.46	7.57e-24	Waist circumference;Body mass index;
LUAD	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg13511324	chr14:104056883	C14orf153	0.25	6.38	0.3	4.53e-10	Coronary artery disease;
LUAD	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg14092988	chr3:52407081	DNAH1	0.36	7.05	0.32	7.54e-12	Electroencephalogram traits;
LUAD	trans	rs2797160	1.000	rs1739348	chr6:126014573	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.58e-17	Endometrial cancer;
LUAD	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-8.27	-0.37	1.72e-15	Blood metabolite levels;
LUAD	cis	rs1595825	0.891	rs74265511	chr2:198494782	C/T	cg00982548	chr2:198649783	BOLL	-0.62	-8.69	-0.39	8.17e-17	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.2	0.33	2.69e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4594175	0.926	rs11851960	chr14:51598610	A/G	cg23942311	chr14:51606299	NA	0.64	11.09	0.47	3e-25	Cancer;
LUAD	cis	rs9925964	0.900	rs56813533	chr16:31070481	A/T	cg03418659	chr16:31128414	MYST1	0.37	6.38	0.3	4.63e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs2795502	0.935	rs2744060	chr10:43262616	C/G	cg20628663	chr10:43360327	NA	-0.68	-8.96	-0.4	1.02e-17	Blood protein levels;
LUAD	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg13722127	chr7:150037890	RARRES2	0.44	7.11	0.33	4.9e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9372498	0.536	rs10484286	chr6:118956447	T/C	cg21191810	chr6:118973309	C6orf204	-0.53	-7.9	-0.36	2.37e-14	Diastolic blood pressure;
LUAD	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg03732007	chr1:2071316	PRKCZ	-0.34	-6.4	-0.3	4.12e-10	Height;
LUAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg15242686	chr22:24348715	GSTTP1	0.4	6.73	0.31	5.49e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg08470875	chr2:26401718	FAM59B	0.79	11.03	0.47	4.89e-25	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.76e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	13.65	0.55	2.06e-35	Lung cancer in ever smokers;
LUAD	cis	rs9972944	0.651	rs7222415	chr17:63765137	T/C	cg07283582	chr17:63770753	CCDC46	-0.5	-11.1	-0.48	2.62e-25	Total body bone mineral density;
LUAD	cis	rs1595825	0.891	rs73058864	chr2:198889587	C/T	cg00982548	chr2:198649783	BOLL	-0.65	-9.08	-0.4	4.06e-18	Ulcerative colitis;
LUAD	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg20203395	chr5:56204925	C5orf35	-0.44	-6.8	-0.31	3.58e-11	Coronary artery disease;
LUAD	cis	rs62238980	0.614	rs74928243	chr22:32439681	C/T	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg22431228	chr1:16359049	CLCNKA	0.41	6.71	0.31	6.13e-11	Dilated cardiomyopathy;
LUAD	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg09467607	chr2:36825704	FEZ2	-0.59	-11.86	-0.5	3.37e-28	Height;
LUAD	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg11909912	chr17:43974919	MAPT;LOC100130148	0.38	6.49	0.3	2.37e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs8177876	0.658	rs11150337	chr16:81069317	G/A	cg08591886	chr16:81111003	C16orf46	-0.69	-6.56	-0.3	1.58e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs12545109	0.842	rs10958482	chr8:57389331	G/T	cg21220214	chr8:57350948	NA	-0.63	-8.98	-0.4	8.93e-18	Obesity-related traits;
LUAD	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg17863274	chr19:49399704	TULP2	-0.56	-8.71	-0.39	7.12e-17	Red cell distribution width;
LUAD	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg06108461	chr20:60628389	TAF4	-1.12	-20.54	-0.71	1.59e-65	Body mass index;
LUAD	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg15900387	chr1:150738905	CTSS	-0.36	-6.49	-0.3	2.41e-10	Melanoma;
LUAD	cis	rs921968	0.565	rs7586384	chr2:219582897	T/C	cg02176678	chr2:219576539	TTLL4	-0.58	-11.38	-0.48	2.33e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4308124	0.708	rs6749633	chr2:111988016	A/G	cg04571233	chr2:111982156	NA	0.46	6.54	0.3	1.83e-10	Vitiligo;
LUAD	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.31	6.35	0.3	5.52e-10	Obesity-related traits;
LUAD	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg27286337	chr10:134555280	INPP5A	-0.94	-18.91	-0.68	2.93e-58	Migraine;
LUAD	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg14689365	chr7:158441557	NCAPG2	0.39	6.47	0.3	2.78e-10	Height;
LUAD	cis	rs11971779	0.555	rs4728466	chr7:139096365	T/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs9322817	0.691	rs9404586	chr6:105332814	A/G	cg02098413	chr6:105308735	HACE1	0.41	8.93	0.4	1.27e-17	Thyroid stimulating hormone;
LUAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.9	10.82	0.47	3.07e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg11901034	chr3:128598214	ACAD9	-0.49	-7.36	-0.34	9.66e-13	IgG glycosylation;
LUAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08280861	chr8:58055591	NA	0.67	8.72	0.39	6.27e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg21951975	chr1:209979733	IRF6	0.55	8.8	0.39	3.59e-17	Cleft lip with or without cleft palate;
LUAD	cis	rs9902453	0.817	rs59420007	chr17:28196114	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.47	0.42	1.95e-19	Coffee consumption (cups per day);
LUAD	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg26384229	chr12:38710491	ALG10B	0.44	7.28	0.33	1.63e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg18129748	chr3:49941408	MST1R	0.42	7.06	0.32	7.06e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2050392	0.762	rs306587	chr10:30722908	G/C	cg18806716	chr10:30721971	MAP3K8	-0.55	-10.89	-0.47	1.67e-24	Inflammatory bowel disease;
LUAD	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg23625390	chr15:77176239	SCAPER	-0.45	-7.07	-0.33	6.29e-12	Blood metabolite levels;
LUAD	trans	rs28551159	1	rs28551159	chr6:26376368	A/G	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.4	-0.38	7.05e-16	Urinary tract infection frequency;
LUAD	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg17264618	chr3:40429014	ENTPD3	0.43	9.14	0.41	2.58e-18	Renal cell carcinoma;
LUAD	cis	rs78761021	0.829	rs17810376	chr17:9787845	A/G	cg26853458	chr17:9805074	RCVRN	0.37	7.2	0.33	2.78e-12	Type 2 diabetes;
LUAD	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg15704280	chr7:45808275	SEPT13	0.78	12.99	0.53	1.08e-32	Coronary artery disease;
LUAD	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg15395560	chr15:45543142	SLC28A2	0.37	6.36	0.3	5.22e-10	Uric acid levels;
LUAD	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg22705602	chr4:152727874	NA	-0.42	-7.3	-0.33	1.43e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.83	-0.36	3.97e-14	Personality dimensions;
LUAD	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-20.52	-0.71	1.83e-65	Height;
LUAD	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg09658497	chr7:2847517	GNA12	-0.45	-7.62	-0.35	1.63e-13	Height;
LUAD	cis	rs938554	0.737	rs10939637	chr4:9977577	A/G	cg00071950	chr4:10020882	SLC2A9	0.53	8.24	0.37	2.24e-15	Blood metabolite levels;
LUAD	cis	rs7731657	0.510	rs10045858	chr5:130251039	C/T	cg08523029	chr5:130500466	HINT1	0.59	7.61	0.35	1.84e-13	Fasting plasma glucose;
LUAD	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg14773178	chr5:1868261	NA	0.33	6.44	0.3	3.16e-10	Cardiovascular disease risk factors;
LUAD	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.74	-0.35	7.27e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.25	0.33	2.06e-12	Menopause (age at onset);
LUAD	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg02466173	chr16:30829666	NA	-0.72	-12.55	-0.52	6.03e-31	Multiple myeloma;
LUAD	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg13319975	chr6:146136371	FBXO30	0.6	10.34	0.45	1.78e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	11.36	0.48	2.67e-26	Lung cancer in ever smokers;
LUAD	trans	rs877282	0.945	rs11253388	chr10:787852	A/G	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	cis	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg02508848	chr16:68573721	ZFP90	-0.42	-6.55	-0.3	1.66e-10	Ulcerative colitis;
LUAD	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.57	9.86	0.43	8.71e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-6.64	-0.31	9.43e-11	Neuroticism;
LUAD	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg03806693	chr22:41940476	POLR3H	-0.62	-9.05	-0.4	5.45e-18	Vitiligo;
LUAD	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg17330251	chr7:94953956	PON1	-0.55	-7.61	-0.35	1.85e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	7.02	0.32	8.79e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs17401966	0.809	rs12406943	chr1:10308545	T/C	cg15208524	chr1:10270712	KIF1B	0.42	6.51	0.3	2.13e-10	Hepatocellular carcinoma;
LUAD	cis	rs9535307	0.929	rs9535310	chr13:50296026	T/C	cg04663916	chr13:50265991	EBPL	0.58	6.89	0.32	2.03e-11	Obesity-related traits;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07164266	chr3:149470245	COMMD2	-0.46	-7.06	-0.32	6.86e-12	Height;
LUAD	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg26022315	chr17:47021804	SNF8	0.41	7.3	0.33	1.47e-12	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.9	-13.25	-0.54	9.6e-34	Red cell distribution width;
LUAD	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg10053473	chr17:62856997	LRRC37A3	0.77	10.9	0.47	1.45e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg05283184	chr6:79620031	NA	-0.6	-12.07	-0.51	4.94e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs4372836	0.929	rs55883854	chr2:28929541	C/T	cg09522027	chr2:28974177	PPP1CB	0.61	9.06	0.4	4.86e-18	Body mass index;
LUAD	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg22532475	chr10:104410764	TRIM8	-0.47	-9.29	-0.41	8.3e-19	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs75804782	0.641	rs55740938	chr2:239332647	G/A	cg01134436	chr17:81009848	B3GNTL1	0.79	8.2	0.37	2.99e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-8.01	-0.36	1.14e-14	Morning vs. evening chronotype;
LUAD	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg20203395	chr5:56204925	C5orf35	-0.49	-7.75	-0.35	6.87e-14	Coronary artery disease;
LUAD	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg01416388	chr22:39784598	NA	-0.5	-8.37	-0.38	8.54e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg07343612	chr16:622815	PIGQ	-0.83	-16.5	-0.63	1.36e-47	Height;
LUAD	cis	rs7771547	0.574	rs11756557	chr6:36597695	A/G	cg07856975	chr6:36356162	ETV7	0.56	7.5	0.34	3.75e-13	Platelet distribution width;
LUAD	cis	rs4285028	0.747	rs9817818	chr3:121466826	C/A	cg11130432	chr3:121712080	ILDR1	-0.46	-6.6	-0.31	1.26e-10	Multiple sclerosis;
LUAD	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg26384229	chr12:38710491	ALG10B	0.46	7.47	0.34	4.77e-13	Bladder cancer;
LUAD	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg11909912	chr17:43974919	MAPT;LOC100130148	0.39	6.62	0.31	1.08e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.74	0.31	5.18e-11	Cardiac Troponin-T levels;
LUAD	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg00857998	chr1:205179979	DSTYK	0.41	6.76	0.31	4.51e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg24818145	chr4:99064322	C4orf37	-0.46	-7.83	-0.36	4.1e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.64	-0.39	1.16e-16	Height;
LUAD	cis	rs73086581	1.000	rs17214621	chr20:3925924	T/C	cg02187196	chr20:3869020	PANK2	0.49	6.78	0.31	4.14e-11	Response to antidepressants in depression;
LUAD	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg27411982	chr8:10470053	RP1L1	-0.39	-7.01	-0.32	9.62e-12	Retinal vascular caliber;
LUAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg02018176	chr4:1364513	KIAA1530	0.36	6.41	0.3	3.85e-10	Obesity-related traits;
LUAD	cis	rs7224314	1.000	rs8070284	chr17:65387400	A/G	cg01507342	chr17:65387096	PITPNC1	-0.54	-8.81	-0.39	3.3e-17	Diisocyanate-induced asthma;
LUAD	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg22618164	chr12:122356400	WDR66	0.63	11.25	0.48	7.45e-26	Mean corpuscular volume;
LUAD	trans	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg24644049	chr4:85504048	CDS1	0.9	7.6	0.35	1.93e-13	Skin colour saturation;
LUAD	cis	rs7677751	0.806	rs4864862	chr4:55100489	G/A	cg17187183	chr4:55093834	PDGFRA	0.51	8.63	0.39	1.23e-16	Corneal astigmatism;
LUAD	trans	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg21582582	chr3:182698605	DCUN1D1	0.58	8.61	0.39	1.46e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs59698941	0.943	rs66732439	chr5:132234702	A/G	cg14825688	chr5:132208181	LEAP2	-0.47	-6.7	-0.31	6.52e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg23029597	chr12:123009494	RSRC2	-0.59	-9.5	-0.42	1.62e-19	Body mass index;
LUAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg18402987	chr7:1209562	NA	0.77	9.45	0.42	2.3e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3821902	0.646	rs66672237	chr3:64012172	C/A	cg22134162	chr3:63841271	THOC7	-0.4	-6.65	-0.31	8.87e-11	Breast cancer;
LUAD	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg03676636	chr4:99064102	C4orf37	0.33	8.52	0.38	2.91e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4730250	0.707	rs10253291	chr7:106786550	C/A	cg23024343	chr7:107201750	COG5	-0.48	-6.73	-0.31	5.7e-11	Osteoarthritis;
LUAD	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg08888203	chr3:10149979	C3orf24	0.74	12.81	0.53	5.57e-32	Alzheimer's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02237493	chr19:21949978	ZNF100	-0.48	-7.79	-0.35	5.15e-14	Height;
LUAD	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg24550644	chr17:30846204	MYO1D	-0.36	-6.39	-0.3	4.39e-10	Schizophrenia;
LUAD	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18876405	chr7:65276391	NA	0.46	7.3	0.33	1.4e-12	Aortic root size;
LUAD	cis	rs17532515	0.652	rs66785231	chr4:141381530	T/G	cg03645522	chr4:141391200	NA	0.4	6.42	0.3	3.57e-10	Select biomarker traits;
LUAD	cis	rs1172822	0.965	rs4806660	chr19:55824634	A/G	cg04391588	chr19:55832610	TMEM150B	0.36	7.16	0.33	3.67e-12	Menarche and menopause (age at onset);Menopause (age at onset);
LUAD	cis	rs8177876	0.749	rs12444969	chr16:81083816	A/G	cg08591886	chr16:81111003	C16orf46	-0.82	-7.0	-0.32	1.03e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs3809566	1.000	rs10851721	chr15:63332383	T/C	cg12160578	chr15:63334699	TPM1	-0.35	-6.52	-0.3	1.95e-10	Platelet count;
LUAD	cis	rs17095355	0.901	rs12240333	chr10:111743972	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.69	-9.27	-0.41	9.35e-19	Biliary atresia;
LUAD	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg02038168	chr22:39784481	NA	-0.6	-10.76	-0.46	5.02e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.03	-0.36	1.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg24558204	chr6:135376177	HBS1L	0.46	8.48	0.38	3.84e-16	Red blood cell count;
LUAD	cis	rs7187994	0.848	rs8046664	chr16:84749859	T/C	cg07647771	chr16:84786436	USP10	-0.38	-9.76	-0.43	2.03e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.59	0.31	1.32e-10	Menarche (age at onset);
LUAD	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg25797454	chr6:150327115	RAET1K	0.36	7.8	0.35	4.9e-14	Alopecia areata;
LUAD	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.98	-0.32	1.15e-11	Height;
LUAD	cis	rs9400271	0.632	rs9374070	chr6:109586455	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.41	-0.3	3.98e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg05805236	chr11:65401703	PCNXL3	-0.6	-9.42	-0.42	3.08e-19	Acne (severe);
LUAD	cis	rs12208915	0.806	rs9361444	chr6:79500073	T/C	cg05283184	chr6:79620031	NA	0.51	6.75	0.31	4.95e-11	Left atrial antero-posterior diameter;
LUAD	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg08085267	chr17:45401833	C17orf57	-0.53	-8.85	-0.4	2.5e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg17105886	chr17:28927953	LRRC37B2	0.83	7.92	0.36	2.14e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg18811423	chr2:55921094	PNPT1	0.51	8.39	0.38	7.14e-16	Metabolic syndrome;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg21910821	chr19:52407881	ZNF649	-0.39	-6.41	-0.3	3.95e-10	Subcortical brain region volumes;
LUAD	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.79	10.93	0.47	1.12e-24	Smoking behavior;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg11652947	chr17:80605508	WDR45L	-0.38	-6.43	-0.3	3.45e-10	Subcortical brain region volumes;
LUAD	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	1.33	25.21	0.77	2.8e-86	IgG glycosylation;
LUAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg08027265	chr7:2291960	NA	-0.38	-6.37	-0.3	4.96e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.15	-0.44	8.22e-22	Platelet count;
LUAD	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg11502198	chr6:26597334	ABT1	0.55	9.17	0.41	2.13e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg03161606	chr19:29218774	NA	0.59	9.05	0.4	5.36e-18	Methadone dose in opioid dependence;
LUAD	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg13736514	chr6:26305472	NA	-0.72	-13.66	-0.55	1.96e-35	Educational attainment;
LUAD	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18876405	chr7:65276391	NA	-0.43	-6.76	-0.31	4.46e-11	Aortic root size;
LUAD	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg16647868	chr5:131706066	SLC22A5	0.39	6.64	0.31	9.88e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg10645314	chr2:3704589	ALLC	-0.6	-9.54	-0.42	1.15e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs2479724	0.598	rs4415146	chr6:41941980	G/T	cg17623882	chr6:41773611	USP49	0.47	8.27	0.37	1.75e-15	Menarche (age at onset);
LUAD	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg13770153	chr20:60521292	NA	-0.59	-9.18	-0.41	2e-18	Body mass index;
LUAD	cis	rs898097	0.567	rs8076119	chr17:80910061	A/G	cg19046167	chr17:80928561	B3GNTL1	0.39	6.49	0.3	2.35e-10	Breast cancer;
LUAD	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.37	-7.18	-0.33	3.21e-12	Caffeine consumption;
LUAD	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11890956	chr21:40555474	PSMG1	0.75	12.49	0.52	1.0500000000000001e-30	Cognitive function;
LUAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg09033563	chr22:24373618	LOC391322	-0.64	-10.63	-0.46	1.51e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg18105134	chr13:113819100	PROZ	-0.81	-14.33	-0.57	3.05e-38	Platelet distribution width;
LUAD	cis	rs9297145	0.565	rs56132062	chr7:98778198	C/T	cg05967295	chr7:98741636	SMURF1	-0.75	-13.73	-0.56	9.48e-36	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	trans	rs3774749	0.565	rs1005678	chr3:50210289	C/G	cg21659725	chr3:3221576	CRBN	0.42	6.95	0.32	1.39e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg19041857	chr6:27730383	NA	-0.42	-7.44	-0.34	5.75e-13	Parkinson's disease;
LUAD	cis	rs9951698	0.518	rs476191	chr18:13095401	A/T	cg12848697	chr18:13133368	NA	0.36	6.83	0.31	3.05e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.41	-0.34	6.73e-13	Lung cancer;
LUAD	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.15	0.41	2.39e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg04455712	chr21:45112962	RRP1B	0.49	9.16	0.41	2.17e-18	Mean corpuscular volume;
LUAD	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.58	-7.55	-0.34	2.79e-13	Menarche (age at onset);
LUAD	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.46	0.34	4.94e-13	Bipolar disorder;
LUAD	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg11344533	chr11:111475393	SIK2	0.35	6.64	0.31	9.44e-11	Primary sclerosing cholangitis;
LUAD	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	9.34	0.41	5.47e-19	Melanoma;
LUAD	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08677398	chr8:58056175	NA	0.54	7.03	0.32	8.54e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg02527881	chr3:46936655	PTH1R	-0.46	-8.91	-0.4	1.51e-17	Colorectal cancer;
LUAD	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.88	-9.05	-0.4	5.14e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg10164272	chr16:89456328	ANKRD11	0.42	6.73	0.31	5.45e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	8.86	0.4	2.19e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.8	-10.14	-0.44	8.87e-22	Body mass index;
LUAD	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.83	-0.39	2.82e-17	Menopause (age at onset);
LUAD	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg22920501	chr2:26401640	FAM59B	-0.96	-14.2	-0.57	1.07e-37	Gut microbiome composition (summer);
LUAD	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.55	0.6	1.85e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg10591111	chr5:226296	SDHA	-0.54	-6.91	-0.32	1.83e-11	Breast cancer;
LUAD	cis	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg02807482	chr3:125708958	NA	-0.62	-6.41	-0.3	3.99e-10	Blood pressure (smoking interaction);
LUAD	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg16060761	chr17:80687452	NA	0.46	6.89	0.32	2.04e-11	Breast cancer;
LUAD	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.23	-0.33	2.21e-12	Morning vs. evening chronotype;
LUAD	cis	rs68170813	0.559	rs2249043	chr7:106960515	C/T	cg02696742	chr7:106810147	HBP1	-0.78	-10.8	-0.46	3.67e-24	Coronary artery disease;
LUAD	trans	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg14791747	chr16:20752902	THUMPD1	0.73	10.1	0.44	1.23e-21	Cognitive test performance;
LUAD	cis	rs7677751	0.806	rs1800813	chr4:55094467	G/A	cg00691999	chr4:55094011	PDGFRA	0.34	6.49	0.3	2.39e-10	Corneal astigmatism;
LUAD	cis	rs684232	0.602	rs448465	chr17:559888	A/T	cg12384639	chr17:618140	VPS53	0.47	8.04	0.36	8.78e-15	Prostate cancer;
LUAD	cis	rs427394	0.802	rs274694	chr5:6734079	A/G	cg10857441	chr5:6722123	POLS	-0.64	-12.46	-0.52	1.45e-30	Menopause (age at onset);
LUAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06873352	chr17:61820015	STRADA	0.81	18.02	0.66	2.74e-54	Prudent dietary pattern;
LUAD	cis	rs758324	0.812	rs477086	chr5:131284610	C/T	cg25547332	chr5:131281432	NA	-0.39	-6.44	-0.3	3.3e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs7246760	1.000	rs113915533	chr19:9881379	A/C	cg02900749	chr2:68251473	NA	-0.64	-7.01	-0.32	9.44e-12	Pursuit maintenance gain;
LUAD	cis	rs754466	0.580	rs10762763	chr10:79560803	C/G	cg17075019	chr10:79541650	NA	-0.9	-19.16	-0.68	2.43e-59	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2742417	1.000	rs2742431	chr3:45737121	C/G	cg10512202	chr3:45649293	LIMD1	-0.36	-6.53	-0.3	1.9e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs9487051	1.000	rs6568571	chr6:109613252	A/T	cg21918786	chr6:109611834	NA	-0.54	-9.17	-0.41	2.06e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs7843479	0.582	rs13439690	chr8:21778082	T/C	cg03445287	chr8:21823731	XPO7	-0.49	-8.92	-0.4	1.44e-17	Mean corpuscular volume;
LUAD	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg05966235	chr16:28915196	ATP2A1	0.47	7.56	0.35	2.45e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.71	11.75	0.5	8.9e-28	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg07460842	chr6:66804631	NA	0.95	15.37	0.6	1.11e-42	Exhaled nitric oxide levels;
LUAD	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg08085267	chr17:45401833	C17orf57	-0.49	-8.1	-0.37	6.05e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg00260888	chr20:30865478	KIF3B	-0.7	-6.84	-0.32	2.78e-11	Type 2 diabetes;
LUAD	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21659725	chr3:3221576	CRBN	0.51	8.65	0.39	1.11e-16	Body mass index;
LUAD	cis	rs6754311	0.544	rs11678022	chr2:136809033	A/T	cg05194412	chr2:137003533	NA	0.48	7.43	0.34	6.05e-13	Mosquito bite size;
LUAD	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.26e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2033711	0.503	rs6510141	chr19:58885786	C/G	cg13877915	chr19:58951672	ZNF132	-0.5	-8.71	-0.39	6.73e-17	Uric acid clearance;
LUAD	cis	rs870825	0.655	rs35764203	chr4:185639078	C/A	cg04058563	chr4:185651563	MLF1IP	0.87	13.97	0.56	9.31e-37	Blood protein levels;
LUAD	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg18721089	chr20:30220636	NA	-0.49	-7.06	-0.32	6.99e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg04568274	chr7:158649319	WDR60	0.44	7.22	0.33	2.5e-12	Height;
LUAD	trans	rs9393777	0.778	rs66841633	chr6:27382386	G/T	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.81	-0.36	4.59e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg13732083	chr21:47605072	C21orf56	0.4	6.51	0.3	2.08e-10	Testicular germ cell tumor;
LUAD	cis	rs7680126	0.596	rs917826	chr4:10295595	C/G	cg00071950	chr4:10020882	SLC2A9	-0.59	-8.34	-0.38	1.05e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs12431939	0.598	rs4268678	chr14:51736185	G/T	cg23942311	chr14:51606299	NA	0.45	7.01	0.32	9.43e-12	Cancer;
LUAD	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg25828334	chr19:18545568	ISYNA1	-0.36	-7.24	-0.33	2.12e-12	Breast cancer;
LUAD	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg17911788	chr17:44343683	NA	-0.52	-7.28	-0.33	1.6e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs35883536	0.513	rs6577180	chr1:101016939	G/A	cg06223162	chr1:101003688	GPR88	0.54	11.0	0.47	6.28e-25	Monocyte count;
LUAD	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.43	-0.3	3.47e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.55	9.62	0.42	5.95e-20	Axial length;
LUAD	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg23283495	chr1:209979779	IRF6	0.65	8.65	0.39	1.07e-16	Cleft lip with or without cleft palate;
LUAD	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.82	-0.31	3.09e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg18187862	chr3:45730750	SACM1L	0.5	7.87	0.36	3.04e-14	Primary sclerosing cholangitis;
LUAD	cis	rs59104589	0.517	rs1064767	chr2:242167337	T/C	cg08645257	chr2:242211290	HDLBP	0.41	6.43	0.3	3.5e-10	Fibrinogen levels;
LUAD	cis	rs6906287	0.647	rs11153767	chr6:118960519	C/T	cg18833306	chr6:118973337	C6orf204	0.48	8.34	0.38	1.06e-15	Electrocardiographic conduction measures;
LUAD	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg01324343	chr3:183735012	ABCC5	0.63	12.26	0.51	8.78e-30	Anterior chamber depth;
LUAD	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg16479474	chr6:28041457	NA	0.36	6.7	0.31	6.64e-11	Parkinson's disease;
LUAD	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.39	8.24	0.37	2.22e-15	Hemoglobin concentration;
LUAD	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg17761419	chr8:57350749	NA	-0.52	-7.83	-0.36	4.07e-14	Obesity-related traits;
LUAD	cis	rs2637266	0.935	rs2252652	chr10:78405022	C/T	cg18941641	chr10:78392320	NA	0.36	7.57	0.35	2.28e-13	Pulmonary function;
LUAD	cis	rs3784262	0.669	rs3204690	chr15:58246768	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.42	-0.34	6.6e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg18827107	chr12:86230957	RASSF9	-0.48	-8.54	-0.38	2.38e-16	Major depressive disorder;
LUAD	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg08999081	chr20:33150536	PIGU	0.47	9.19	0.41	1.73e-18	Coronary artery disease;
LUAD	cis	rs9715521	0.588	rs11731207	chr4:59852246	G/A	cg11281224	chr4:60001000	NA	-0.59	-10.73	-0.46	6.38e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4919694	1.000	rs17881215	chr10:104629236	G/C	cg04362960	chr10:104952993	NT5C2	0.6	6.71	0.31	6.19e-11	Arsenic metabolism;
LUAD	cis	rs12216545	0.765	rs10237569	chr7:150249527	C/T	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.39	-0.3	4.27e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg15744005	chr10:104629667	AS3MT	0.39	6.65	0.31	8.81e-11	Arsenic metabolism;
LUAD	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg07757535	chr4:1339547	NA	0.31	7.04	0.32	7.59e-12	Longevity;
LUAD	cis	rs969930	0.526	rs4738043	chr8:70775307	T/A	cg03719092	chr8:70744881	SLCO5A1	-0.42	-6.89	-0.32	2.05e-11	Lower body strength;
LUAD	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.28	-0.51	7.22e-30	Platelet count;
LUAD	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg17063962	chr7:91808500	NA	0.69	12.16	0.51	2.22e-29	Breast cancer;
LUAD	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg13319975	chr6:146136371	FBXO30	0.64	11.12	0.48	2.32e-25	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg02002194	chr4:3960332	NA	-0.29	-7.06	-0.32	6.96e-12	Mood instability;
LUAD	cis	rs2235642	0.671	rs2235641	chr16:1608177	A/G	cg26528668	chr16:1614120	IFT140	0.48	7.88	0.36	2.77e-14	Coronary artery disease;
LUAD	cis	rs62400317	0.826	rs12194682	chr6:45320520	T/A	cg20913747	chr6:44695427	NA	-0.41	-6.59	-0.31	1.28e-10	Total body bone mineral density;
LUAD	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg19875535	chr5:140030758	IK	-0.46	-7.71	-0.35	9.03e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-9.59	-0.42	7.63e-20	Migraine;Coronary artery disease;
LUAD	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg08085267	chr17:45401833	C17orf57	0.55	9.05	0.4	5.42e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.61	-10.39	-0.45	1.17e-22	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg17366294	chr4:99064904	C4orf37	0.66	12.71	0.53	1.46e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10979	0.557	rs9376767	chr6:143909380	G/A	cg25407410	chr6:143891975	LOC285740	-0.52	-7.32	-0.34	1.26e-12	Hypospadias;
LUAD	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg08508325	chr11:3079039	CARS	-0.51	-10.7	-0.46	8.26e-24	Type 2 diabetes;
LUAD	cis	rs4642101	1.000	rs7650482	chr3:12841804	A/G	cg24848339	chr3:12840334	CAND2	0.33	6.41	0.3	3.99e-10	QRS complex (12-leadsum);
LUAD	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg14582100	chr15:45693742	SPATA5L1	0.64	12.48	0.52	1.23e-30	Homoarginine levels;
LUAD	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.32e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg06028808	chr11:68637592	NA	0.5	8.2	0.37	2.89e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs4714291	0.925	rs847784	chr6:40053272	A/G	cg02267698	chr19:7991119	CTXN1	0.44	6.72	0.31	5.78e-11	Strep throat;
LUAD	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg10356904	chr22:49881777	NA	-0.39	-7.23	-0.33	2.27e-12	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg14634687	chr17:47094252	IGF2BP1	0.29	7.34	0.34	1.12e-12	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs7809950	1.000	rs2107713	chr7:107232369	C/T	cg23024343	chr7:107201750	COG5	-0.59	-9.62	-0.42	6.21e-20	Coronary artery disease;
LUAD	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg12615879	chr12:58013172	SLC26A10	0.52	11.1	0.47	2.77e-25	Multiple sclerosis;
LUAD	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg02423579	chr7:2872169	GNA12	-0.78	-13.31	-0.54	5.43e-34	Height;
LUAD	cis	rs3026401	0.562	rs762972	chr11:31797603	A/G	cg14844989	chr11:31128820	NA	0.41	7.2	0.33	2.75e-12	Body mass index;
LUAD	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.08e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-7.95	-0.36	1.78e-14	Total body bone mineral density;
LUAD	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.61	-0.31	1.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00166722	chr3:10149974	C3orf24	0.71	12.36	0.52	3.47e-30	Alzheimer's disease;
LUAD	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg12927641	chr6:109611667	NA	0.54	9.6	0.42	7.12e-20	Reticulocyte fraction of red cells;
LUAD	cis	rs754466	0.580	rs1054608	chr10:79543308	T/G	cg17075019	chr10:79541650	NA	-0.93	-20.42	-0.7	5.48e-65	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg26924012	chr15:45694286	SPATA5L1	1.03	19.14	0.68	2.95e-59	Homoarginine levels;
LUAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg25243455	chr2:114033360	PAX8;LOC440839	-0.39	-8.8	-0.39	3.6e-17	Lymphocyte counts;
LUAD	cis	rs36051895	0.659	rs59668095	chr9:5043688	C/G	cg02405213	chr9:5042618	JAK2	-0.49	-6.69	-0.31	7.12e-11	Pediatric autoimmune diseases;
LUAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg24813613	chr7:1882135	MAD1L1	-0.43	-7.03	-0.32	8.55e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs10838798	0.504	rs11039530	chr11:48145746	C/T	cg15704280	chr7:45808275	SEPT13	-0.52	-8.26	-0.37	1.95e-15	Height;
LUAD	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg24069376	chr3:38537580	EXOG	0.46	11.18	0.48	1.29e-25	Electrocardiographic conduction measures;
LUAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00166722	chr3:10149974	C3orf24	-0.68	-11.45	-0.49	1.23e-26	Alzheimer's disease;
LUAD	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg08885076	chr2:99613938	TSGA10	0.37	6.7	0.31	6.51e-11	Chronic sinus infection;
LUAD	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg18230493	chr5:56204884	C5orf35	-0.44	-7.48	-0.34	4.32e-13	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg03684893	chr10:554711	DIP2C	-0.43	-7.7	-0.35	9.43e-14	Psychosis in Alzheimer's disease;
LUAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg25703541	chr22:24373054	LOC391322	-0.8	-14.29	-0.57	4.25e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg04850017	chr11:63683019	RCOR2	0.35	7.62	0.35	1.7e-13	Pulse pressure;
LUAD	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg03037974	chr15:76606532	NA	0.38	8.48	0.38	3.69e-16	Blood metabolite levels;
LUAD	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06544989	chr22:39130855	UNC84B	0.48	9.51	0.42	1.51e-19	Menopause (age at onset);
LUAD	cis	rs56346965	0.761	rs4853727	chr2:191547991	T/G	cg27211696	chr2:191398769	TMEM194B	-0.43	-7.59	-0.35	2.05e-13	Bone mineral density (Ward's triangle area);
LUAD	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg01145583	chr6:160211477	TCP1;MRPL18	-0.44	-6.36	-0.3	5.17e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs6993813	0.678	rs7824837	chr8:120008736	A/C	cg01975934	chr8:119970761	NA	-0.36	-6.88	-0.32	2.21e-11	Bone mineral density (hip);
LUAD	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.16	-0.33	3.71e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg21220214	chr8:57350948	NA	-0.59	-8.66	-0.39	1.03e-16	Obesity-related traits;
LUAD	cis	rs62400317	0.762	rs12211922	chr6:44847210	A/G	cg20913747	chr6:44695427	NA	-0.44	-6.91	-0.32	1.84e-11	Total body bone mineral density;
LUAD	cis	rs2797160	0.967	rs926854	chr6:126021780	A/G	cg05901451	chr6:126070800	HEY2	0.43	6.41	0.3	3.8e-10	Endometrial cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24539604	chr2:191184750	HIBCH	-0.42	-6.51	-0.3	2.19e-10	Height;
LUAD	cis	rs2882667	0.898	rs13163536	chr5:138377219	A/G	cg04439458	chr5:138467593	SIL1	-0.38	-6.93	-0.32	1.56e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg15247329	chr7:2764246	NA	0.36	6.65	0.31	8.96e-11	Height;
LUAD	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg00530320	chr1:46809349	NSUN4	0.52	8.01	0.36	1.13e-14	Menopause (age at onset);
LUAD	cis	rs12760731	0.720	rs12037817	chr1:178261750	A/G	cg00404053	chr1:178313656	RASAL2	0.68	8.8	0.39	3.48e-17	Obesity-related traits;
LUAD	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.47	-0.3	2.72e-10	Neuroticism;
LUAD	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.58	0.3	1.41e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7264396	0.561	rs2064725	chr20:34569142	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-6.49	-0.3	2.44e-10	Total cholesterol levels;
LUAD	trans	rs800082	0.698	rs800073	chr3:144347599	G/A	cg24215973	chr2:240111563	HDAC4	-0.68	-10.9	-0.47	1.54e-24	Smoking behavior;
LUAD	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg27426351	chr10:43362370	NA	0.54	8.31	0.37	1.3e-15	Blood protein levels;
LUAD	cis	rs12711979	0.875	rs11686157	chr2:3855020	C/G	cg17052675	chr2:3827356	NA	-0.44	-8.25	-0.37	1.97e-15	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs832540	0.519	rs10940518	chr5:56270794	C/T	cg24531977	chr5:56204891	C5orf35	-0.54	-8.8	-0.39	3.48e-17	Coronary artery disease;
LUAD	cis	rs6674176	0.518	rs917294	chr1:44249485	A/G	cg12908607	chr1:44402522	ARTN	-0.41	-7.49	-0.34	3.93e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4730250	0.655	rs75243311	chr7:106890791	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.44	-0.45	7.23e-23	Osteoarthritis;
LUAD	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg25324976	chr17:61989376	CSHL1	0.38	7.45	0.34	5.25e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.65	-0.31	9.31e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg11266682	chr4:10021025	SLC2A9	0.6	13.56	0.55	4.71e-35	Bone mineral density;
LUAD	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg25457927	chr22:38595422	NA	-0.53	-13.67	-0.55	1.66e-35	Cutaneous nevi;
LUAD	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg18230493	chr5:56204884	C5orf35	-0.54	-8.31	-0.37	1.28e-15	Type 2 diabetes;
LUAD	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21028142	chr17:79581711	NPLOC4	-0.45	-9.79	-0.43	1.54e-20	Eye color traits;
LUAD	trans	rs9951602	0.512	rs12607938	chr18:76651887	A/C	cg02800362	chr5:177631904	HNRNPAB	0.9	14.29	0.57	4.33e-38	Obesity-related traits;
LUAD	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg22618164	chr12:122356400	WDR66	0.76	13.58	0.55	4.02e-35	Mean corpuscular volume;
LUAD	cis	rs11756438	0.658	rs6937176	chr6:119007308	A/G	cg18833306	chr6:118973337	C6orf204	0.42	6.93	0.32	1.55e-11	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg22868518	chr11:507468	RNH1	-0.68	-6.71	-0.31	6.14e-11	Body mass index;
LUAD	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg13319975	chr6:146136371	FBXO30	-0.75	-12.61	-0.52	3.5e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg27494647	chr7:150038898	RARRES2	0.54	8.97	0.4	9.41e-18	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18402987	chr7:1209562	NA	0.45	7.46	0.34	4.86e-13	Longevity;Endometriosis;
LUAD	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg17063962	chr7:91808500	NA	0.73	13.25	0.54	9.27e-34	Breast cancer;
LUAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00149659	chr3:10157352	C3orf10	0.58	8.11	0.37	5.58e-15	Alzheimer's disease;
LUAD	trans	rs853679	0.607	rs35001169	chr6:28187632	T/G	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.13	-0.48	1.99e-25	Depression;
LUAD	cis	rs1267303	0.682	rs1886117	chr1:46964909	T/A	cg16387850	chr1:46982889	NA	0.41	7.22	0.33	2.41e-12	Monobrow;
LUAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg02951883	chr7:2050386	MAD1L1	-0.81	-14.0	-0.56	7.51e-37	Bipolar disorder and schizophrenia;
LUAD	trans	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg01620082	chr3:125678407	NA	-0.46	-6.86	-0.32	2.43e-11	Depression;
LUAD	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg26408565	chr15:76604113	ETFA	-0.45	-7.3	-0.33	1.43e-12	Blood metabolite levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02018089	chr14:78174742	ALKBH1;C14orf156	-0.44	-6.7	-0.31	6.73e-11	Height;
LUAD	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.5e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26770187	chr3:14693171	C3orf19	-0.42	-6.39	-0.3	4.39e-10	Height;
LUAD	cis	rs3924048	0.559	rs4075304	chr1:12626803	C/T	cg00291366	chr1:12616550	NA	0.33	6.74	0.31	5.06e-11	Optic cup area;
LUAD	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg26554054	chr8:600488	NA	0.76	7.45	0.34	5.2e-13	IgG glycosylation;
LUAD	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg15556689	chr8:8085844	FLJ10661	0.49	8.14	0.37	4.38e-15	Mood instability;
LUAD	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg06002616	chr8:101225028	SPAG1	-0.39	-7.81	-0.36	4.5e-14	Atrioventricular conduction;
LUAD	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg09455208	chr3:40491958	NA	0.56	12.52	0.52	8.32e-31	Renal cell carcinoma;
LUAD	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.8	0.35	4.99e-14	Bladder cancer;
LUAD	cis	rs4680	0.737	rs4818	chr22:19951207	C/G	cg22546130	chr22:19950026	COMT	-0.41	-8.47	-0.38	4.21e-16	Blood metabolite levels;
LUAD	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg06558623	chr16:89946397	TCF25	0.92	9.25	0.41	1.13e-18	Skin colour saturation;
LUAD	cis	rs12079745	0.793	rs12074013	chr1:169133621	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-1.09	-7.74	-0.35	7.2e-14	QT interval;
LUAD	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg02734326	chr4:10020555	SLC2A9	0.63	11.36	0.48	2.7e-26	Bone mineral density;
LUAD	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg04154034	chr17:28927549	LRRC37B2	-0.6	-7.01	-0.32	9.5e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.36e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12618769	0.597	rs3769743	chr2:99063653	C/T	cg10123293	chr2:99228465	UNC50	0.46	8.43	0.38	5.42e-16	Bipolar disorder;
LUAD	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg07080864	chr8:57359956	PENK	-0.38	-6.58	-0.3	1.43e-10	Obesity-related traits;
LUAD	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.61	8.11	0.37	5.66e-15	Renal function-related traits (BUN);
LUAD	cis	rs9786986	0.665	rs1874129	chr1:235700023	T/G	cg08848088	chr1:235714526	GNG4	0.53	6.58	0.3	1.39e-10	Body mass index;
LUAD	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg02734326	chr4:10020555	SLC2A9	0.56	9.91	0.43	5.81e-21	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs7246760	0.867	rs61580479	chr19:9782940	G/A	cg02900749	chr2:68251473	NA	-0.59	-6.55	-0.3	1.72e-10	Pursuit maintenance gain;
LUAD	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg05313129	chr8:58192883	C8orf71	-0.57	-8.5	-0.38	3.25e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6998277	1.000	rs4734648	chr8:103635994	G/A	cg10187029	chr8:103597600	NA	0.76	12.05	0.51	5.72e-29	Migraine;
LUAD	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21659725	chr3:3221576	CRBN	-0.86	-18.31	-0.66	1.4e-55	Intelligence (multi-trait analysis);
LUAD	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg10518543	chr12:38710700	ALG10B	-0.49	-8.08	-0.37	6.85e-15	Morning vs. evening chronotype;
LUAD	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.88	-16.94	-0.64	1.66e-49	Menarche (age at onset);
LUAD	cis	rs4629710	0.592	rs13200165	chr6:131549167	G/C	cg12606694	chr6:131520996	AKAP7	0.48	7.09	0.33	5.84e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs10901296	0.660	rs2855198	chr9:133764606	T/C	cg03924115	chr9:133768966	QRFP	0.51	6.55	0.3	1.63e-10	Bilirubin levels;
LUAD	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg15226275	chr6:116381976	FRK	0.23	7.64	0.35	1.44e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs6601327	0.613	rs12682175	chr8:9479161	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-7.11	-0.33	5.07e-12	Multiple myeloma (hyperdiploidy);
LUAD	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg01579765	chr21:45077557	HSF2BP	-0.61	-13.6	-0.55	3.3e-35	Mean corpuscular volume;
LUAD	trans	rs877282	0.947	rs7904978	chr10:768078	C/T	cg22713356	chr15:30763199	NA	1.3	17.85	0.66	1.61e-53	Uric acid levels;
LUAD	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg26343298	chr8:95960752	TP53INP1	0.37	7.92	0.36	2.13e-14	Type 2 diabetes;
LUAD	cis	rs2249625	0.545	rs2463743	chr6:72874741	C/T	cg18830697	chr6:72922368	RIMS1	-0.45	-8.35	-0.38	9.57e-16	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg18305652	chr10:134549665	INPP5A	-0.39	-8.7	-0.39	7.26e-17	Migraine;
LUAD	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg22166914	chr1:53195759	ZYG11B	-0.4	-6.56	-0.3	1.55e-10	Monocyte count;
LUAD	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg13319975	chr6:146136371	FBXO30	-0.64	-11.05	-0.47	4.19e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg09835421	chr16:68378352	PRMT7	-0.74	-8.5	-0.38	3.38e-16	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs7395662	1.000	rs7478900	chr11:48544003	T/C	cg15704280	chr7:45808275	SEPT13	-0.41	-6.38	-0.3	4.56e-10	HDL cholesterol;
LUAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg25985355	chr7:65971099	NA	-0.56	-6.91	-0.32	1.79e-11	Gout;
LUAD	trans	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.59	10.61	0.46	1.72e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7394190	0.748	rs11541237	chr10:75530962	C/T	cg02286717	chr10:75415704	SYNPO2L	-0.36	-6.37	-0.3	4.93e-10	Incident atrial fibrillation;
LUAD	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg06558623	chr16:89946397	TCF25	0.94	10.27	0.45	3.12e-22	Skin colour saturation;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22156867	chr6:37467762	C6orf129	-0.44	-6.84	-0.32	2.78e-11	Height;
LUAD	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg22349387	chr12:9600060	DDX12	-0.5	-8.86	-0.4	2.3e-17	Breast size;
LUAD	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.18	-0.33	3.12e-12	Height;
LUAD	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg19761014	chr17:28927070	LRRC37B2	0.86	8.36	0.38	9.21e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg12062639	chr20:23401060	NAPB	1.08	11.0	0.47	6.14e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg21153622	chr11:89784906	NA	-0.34	-6.73	-0.31	5.44e-11	Height;
LUAD	cis	rs4638749	0.651	rs13385677	chr2:108826152	T/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.35	-0.34	1.03e-12	Blood pressure;
LUAD	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg25036284	chr2:26402008	FAM59B	0.67	9.01	0.4	7.14e-18	Gut microbiome composition (summer);
LUAD	trans	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.78	-0.31	4.13e-11	Diabetic kidney disease;
LUAD	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-25.09	-0.77	8.9e-86	Height;
LUAD	cis	rs490234	0.676	rs12202	chr9:128200299	C/G	cg14078157	chr9:128172775	NA	-0.49	-9.04	-0.4	5.6e-18	Mean arterial pressure;
LUAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.8	-0.31	3.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg04398451	chr17:18023971	MYO15A	0.76	13.78	0.56	6.05e-36	Schizophrenia;
LUAD	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg21890820	chr11:65308645	LTBP3	0.46	7.38	0.34	8.38e-13	Bone mineral density;
LUAD	trans	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-9.16	-0.41	2.18e-18	Brugada syndrome;
LUAD	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg24503407	chr1:205819492	PM20D1	0.41	6.47	0.3	2.72e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg21724239	chr8:58056113	NA	0.54	7.22	0.33	2.4e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10465746	0.967	rs11163861	chr1:84354282	T/C	cg10977910	chr1:84465055	TTLL7	0.5	8.19	0.37	3.07e-15	Obesity-related traits;
LUAD	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.74	-13.45	-0.55	1.43e-34	Axial length;
LUAD	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.43	-7.46	-0.34	5.12e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12145833	0.538	rs12026408	chr1:243366805	G/A	cg02356786	chr1:243265016	LOC731275	0.72	7.57	0.35	2.36e-13	Obesity (early onset extreme);
LUAD	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg07917127	chr4:99064746	C4orf37	0.42	7.01	0.32	9.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11890956	chr21:40555474	PSMG1	-0.55	-9.53	-0.42	1.2e-19	Menarche (age at onset);
LUAD	cis	rs8018808	1.000	rs12435136	chr14:77856184	G/A	cg20045696	chr14:77926864	AHSA1	-0.36	-6.56	-0.3	1.54e-10	Myeloid white cell count;
LUAD	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg02734326	chr4:10020555	SLC2A9	0.64	11.44	0.49	1.4e-26	Bone mineral density;
LUAD	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg06064525	chr11:970664	AP2A2	-0.42	-8.2	-0.37	2.94e-15	Alzheimer's disease (late onset);
LUAD	cis	rs13064411	0.542	rs9846539	chr3:113228688	A/G	cg10517650	chr3:113235015	CCDC52	-0.45	-8.28	-0.37	1.63e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs1973993	0.567	rs2800431	chr1:97000998	C/T	cg10631902	chr5:14652156	NA	0.59	11.39	0.48	2.18e-26	Weight;
LUAD	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg22920501	chr2:26401640	FAM59B	-0.96	-14.21	-0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg01475377	chr6:109611718	NA	-0.46	-8.33	-0.38	1.17e-15	Reticulocyte fraction of red cells;
LUAD	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.23	-0.33	2.31e-12	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg08888203	chr3:10149979	C3orf24	0.63	10.72	0.46	7.04e-24	Alzheimer's disease;
LUAD	trans	rs11700980	0.636	rs118001912	chr21:30210959	C/A	cg14791747	chr16:20752902	THUMPD1	0.6	6.64	0.31	9.74e-11	QRS complex (12-leadsum);
LUAD	cis	rs1595825	0.891	rs59617443	chr2:198653204	C/A	cg10547527	chr2:198650123	BOLL	-0.54	-7.52	-0.34	3.24e-13	Ulcerative colitis;
LUAD	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg15181151	chr6:150070149	PCMT1	0.38	7.03	0.32	8.11e-12	Lung cancer;
LUAD	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg20503657	chr10:835505	NA	0.96	14.55	0.58	3.42e-39	Eosinophil percentage of granulocytes;
LUAD	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg25554036	chr4:6271136	WFS1	0.69	13.52	0.55	7.2e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs11671005	0.779	rs3794971	chr19:58985866	T/C	cg13877915	chr19:58951672	ZNF132	0.56	7.12	0.33	4.66e-12	Mean platelet volume;
LUAD	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg07305463	chr2:136567211	LCT	0.37	6.88	0.32	2.16e-11	Mosquito bite size;
LUAD	cis	rs2692947	0.673	rs2692894	chr2:96784934	T/G	cg23100626	chr2:96804247	ASTL	-0.37	-9.76	-0.43	1.94e-20	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.41	-7.88	-0.36	2.85e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg11822812	chr5:140052017	DND1	-0.4	-7.3	-0.33	1.41e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4629710	0.568	rs9492880	chr6:131565962	G/T	cg12606694	chr6:131520996	AKAP7	0.49	7.19	0.33	2.93e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg05283184	chr6:79620031	NA	-0.45	-7.83	-0.36	3.88e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs877282	0.853	rs10904545	chr10:757100	G/A	cg17470449	chr10:769945	NA	0.59	8.02	0.36	1.07e-14	Uric acid levels;
LUAD	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	7.0	0.32	1.03e-11	Schizophrenia;
LUAD	cis	rs6960043	1.000	rs6980437	chr7:15054916	T/G	cg19272540	chr7:15055459	NA	-0.3	-6.4	-0.3	4.04e-10	Type 2 diabetes;
LUAD	cis	rs10782582	0.592	rs7513194	chr1:76382664	A/C	cg03433033	chr1:76189801	ACADM	0.45	6.67	0.31	8.18e-11	Daytime sleep phenotypes;
LUAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg21724239	chr8:58056113	NA	0.67	8.63	0.39	1.29e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.06e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17712092	chr4:129076599	LARP1B	0.86	16.24	0.62	1.97e-46	Eosinophil percentage of white cells;
LUAD	cis	rs116248771	0.739	rs4680454	chr3:158377913	C/T	cg16708174	chr3:158430962	RARRES1	0.47	6.83	0.32	3.03e-11	diarrhoeal disease at age 2;
LUAD	cis	rs853679	0.527	rs9461443	chr6:28194629	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.32	6.68	0.31	7.5e-11	Depression;
LUAD	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg18404041	chr3:52824283	ITIH1	0.4	7.19	0.33	2.99e-12	Body mass index;
LUAD	cis	rs7107174	1.000	rs10899456	chr11:78000155	C/G	cg19901956	chr11:77921274	USP35	-0.52	-6.85	-0.32	2.59e-11	Testicular germ cell tumor;
LUAD	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg12863693	chr15:85201151	NMB	0.36	6.42	0.3	3.75e-10	Schizophrenia;
LUAD	cis	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-7.22	-0.33	2.48e-12	Neuroticism;
LUAD	trans	rs11039798	0.925	rs7482967	chr11:48613527	T/A	cg02254774	chr11:50257496	LOC441601	0.51	6.53	0.3	1.86e-10	Axial length;
LUAD	cis	rs9650657	0.682	rs6989160	chr8:10705360	A/C	cg27411982	chr8:10470053	RP1L1	-0.36	-6.35	-0.3	5.52e-10	Neuroticism;
LUAD	cis	rs11809207	0.859	rs61776644	chr1:26505548	T/C	cg00300879	chr1:26503847	CNKSR1	0.3	7.13	0.33	4.5e-12	Height;
LUAD	cis	rs4588572	0.645	rs10059940	chr5:77680873	T/C	cg11547950	chr5:77652471	NA	0.76	12.07	0.51	5.11e-29	Triglycerides;
LUAD	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg18944383	chr4:111397179	ENPEP	0.39	7.59	0.35	2.01e-13	Height;
LUAD	cis	rs61863818	0.709	rs10786343	chr10:99159465	C/A	cg20016023	chr10:99160130	RRP12	-0.31	-7.32	-0.34	1.23e-12	Monocyte percentage of white cells;
LUAD	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg06608945	chr2:219082296	ARPC2	0.42	6.96	0.32	1.32e-11	Colorectal cancer;
LUAD	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg22906224	chr7:99728672	NA	-0.55	-9.56	-0.42	9.51e-20	Coronary artery disease;
LUAD	cis	rs4849845	0.653	rs3933618	chr2:121035552	T/G	cg24070213	chr2:121070622	NA	0.4	7.63	0.35	1.62e-13	Mean platelet volume;
LUAD	cis	rs4713675	0.624	rs482786	chr6:33707599	T/C	cg07979401	chr6:33739406	LEMD2	0.42	7.53	0.34	3.2e-13	Plateletcrit;
LUAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.3	0.54	5.87e-34	Prudent dietary pattern;
LUAD	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg19622623	chr12:86230825	RASSF9	-0.39	-6.92	-0.32	1.67e-11	Major depressive disorder;
LUAD	cis	rs10746514	1.000	rs10746514	chr1:232246027	G/A	cg09506761	chr1:232265262	NA	0.38	6.98	0.32	1.18e-11	Response to statin therapy;
LUAD	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg26597838	chr10:835615	NA	0.97	13.55	0.55	5.63e-35	Eosinophil percentage of granulocytes;
LUAD	trans	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg20849893	chr7:64541193	NA	0.45	7.1	0.33	5.48e-12	Aortic root size;
LUAD	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg19635926	chr16:89946313	TCF25	0.72	6.41	0.3	3.85e-10	Skin colour saturation;
LUAD	cis	rs7714584	1.000	rs1000113	chr5:150240076	C/T	cg22134413	chr5:150180641	NA	0.53	6.49	0.3	2.46e-10	Crohn's disease;
LUAD	cis	rs9302690	1.000	rs62037108	chr16:57443171	G/A	cg27017172	chr16:57497170	POLR2C	1.02	8.38	0.38	7.86e-16	Blood protein levels;
LUAD	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.96	0.32	1.3e-11	Depression;
LUAD	trans	rs877282	0.583	rs11253424	chr10:813426	C/T	cg22713356	chr15:30763199	NA	0.76	10.95	0.47	9.69e-25	Uric acid levels;
LUAD	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-12.3	-0.51	6.15e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.79	-0.35	5.4e-14	Personality dimensions;
LUAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.97	0.47	8.47e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9486719	0.690	rs2092094	chr6:96844123	G/C	cg06623918	chr6:96969491	KIAA0776	0.71	9.3	0.41	7.58e-19	Migraine;Coronary artery disease;
LUAD	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg18129178	chr5:148520854	ABLIM3	-0.54	-8.51	-0.38	3.11e-16	Breast cancer;
LUAD	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.41	-7.36	-0.34	9.84e-13	IgG glycosylation;
LUAD	trans	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg12400702	chr3:12838781	CAND2	0.31	6.38	0.3	4.7e-10	Parkinson's disease;
LUAD	cis	rs1232027	0.656	rs836810	chr5:79972212	G/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.42	-6.74	-0.31	5.2e-11	Huntington's disease progression;
LUAD	cis	rs17155006	0.746	rs446800	chr7:107747928	A/C	cg05962710	chr7:107745446	LAMB4	-0.34	-7.31	-0.33	1.37e-12	Pneumococcal bacteremia;
LUAD	trans	rs8002861	0.664	rs4942246	chr13:44404853	A/G	cg12856521	chr11:46389249	DGKZ	0.46	7.69	0.35	1.06e-13	Leprosy;
LUAD	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.34	0.51	4.22e-30	Tonsillectomy;
LUAD	cis	rs4006360	0.646	rs9902561	chr17:39295384	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.39	9.09	0.4	3.84e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11890956	chr21:40555474	PSMG1	-0.51	-8.65	-0.39	1.08e-16	Menarche (age at onset);
LUAD	trans	rs12517041	1.000	rs6879795	chr5:23305275	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.48	-6.86	-0.32	2.51e-11	Calcium levels;
LUAD	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg05991184	chr2:219186017	PNKD	-0.35	-6.74	-0.31	5.17e-11	Colorectal cancer;
LUAD	trans	rs11165623	0.564	rs6669908	chr1:96998261	G/A	cg10631902	chr5:14652156	NA	-0.41	-7.48	-0.34	4.48e-13	Hip circumference;Waist circumference;
LUAD	cis	rs780096	1.000	rs780095	chr2:27741105	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.24	-6.37	-0.3	5.07e-10	Total body bone mineral density;
LUAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg21724239	chr8:58056113	NA	0.72	9.49	0.42	1.73e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs56133113	0.792	rs80119927	chr11:72758804	A/G	cg01847441	chr14:69431073	ACTN1	-0.59	-6.61	-0.31	1.19e-10	Mean platelet volume;
LUAD	cis	rs896543	0.702	rs12692189	chr2:237496112	A/G	cg25295825	chr2:237489920	CXCR7	-0.46	-8.56	-0.38	2.05e-16	Alcohol dependence (age at onset);
LUAD	cis	rs12545109	0.879	rs1581129	chr8:57377476	T/C	cg09654669	chr8:57350985	NA	-0.7	-9.92	-0.43	5.4e-21	Obesity-related traits;
LUAD	cis	rs2839627	0.513	rs67571721	chr21:44306446	A/T	cg03543861	chr21:44258195	NA	0.67	8.08	0.37	6.96e-15	Information processing speed;
LUAD	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg11901034	chr3:128598214	ACAD9	-0.54	-8.74	-0.39	5.43e-17	IgG glycosylation;
LUAD	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg00933542	chr6:150070202	PCMT1	0.35	7.41	0.34	7.13e-13	Testicular germ cell tumor;
LUAD	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg21427119	chr20:30132790	HM13	-0.6	-9.1	-0.4	3.7e-18	Mean corpuscular hemoglobin;
LUAD	cis	rs7582720	1.000	rs77230711	chr2:203805552	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6445967	0.530	rs62258095	chr3:58372462	T/C	cg13750441	chr3:58318267	PXK	-0.33	-6.77	-0.31	4.19e-11	Platelet count;
LUAD	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg17443473	chr1:3703550	LRRC47	0.47	7.88	0.36	2.74e-14	Red cell distribution width;
LUAD	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg08048268	chr3:133502702	NA	0.38	7.77	0.35	5.88e-14	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg05991184	chr2:219186017	PNKD	0.34	6.44	0.3	3.24e-10	Colorectal cancer;
LUAD	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg02176678	chr2:219576539	TTLL4	0.64	12.8	0.53	5.97e-32	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg18180107	chr4:99064573	C4orf37	0.43	6.96	0.32	1.27e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg04025307	chr7:1156635	C7orf50	0.65	7.52	0.34	3.39e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2777491	0.957	rs1757454	chr15:41777934	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.7	-13.03	-0.54	7.26e-33	Ulcerative colitis;
LUAD	cis	rs2404602	0.575	rs11633309	chr15:76962349	C/A	cg00316803	chr15:76480434	C15orf27	0.46	7.0	0.32	1e-11	Blood metabolite levels;
LUAD	trans	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg11887960	chr12:57824829	NA	0.5	6.51	0.3	2.13e-10	Obesity-related traits;
LUAD	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg06740227	chr12:86229804	RASSF9	0.38	6.8	0.31	3.58e-11	Major depressive disorder;
LUAD	trans	rs3780486	0.846	rs10813960	chr9:33180362	C/T	cg20290983	chr6:43655470	MRPS18A	0.95	18.16	0.66	6.3e-55	IgG glycosylation;
LUAD	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg15445000	chr17:37608096	MED1	-0.44	-8.1	-0.37	6.01e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg22705602	chr4:152727874	NA	-0.42	-7.23	-0.33	2.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs7617773	0.780	rs4511916	chr3:48350366	G/A	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs7680126	0.585	rs34768406	chr4:10118350	C/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-7.53	-0.34	3.01e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9811920	0.809	rs923472	chr3:99758029	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	7.64	0.35	1.44e-13	Axial length;
LUAD	cis	rs938554	0.736	rs11734219	chr4:9977154	C/T	cg11266682	chr4:10021025	SLC2A9	0.43	7.58	0.35	2.17e-13	Blood metabolite levels;
LUAD	cis	rs3931020	0.548	rs12145183	chr1:75272480	G/A	cg26855724	chr1:75198818	TYW3;CRYZ	0.41	6.49	0.3	2.47e-10	Resistin levels;
LUAD	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg15181151	chr6:150070149	PCMT1	0.42	8.61	0.39	1.48e-16	Lung cancer;
LUAD	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg01416388	chr22:39784598	NA	-0.47	-7.12	-0.33	4.67e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg21775007	chr8:11205619	TDH	-0.5	-9.08	-0.4	4.26e-18	Retinal vascular caliber;
LUAD	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg07636037	chr3:49044803	WDR6	0.43	6.85	0.32	2.56e-11	Menarche (age at onset);
LUAD	cis	rs4911259	0.593	rs6058924	chr20:31464467	G/A	cg13636640	chr20:31349939	DNMT3B	-0.58	-9.52	-0.42	1.4e-19	Inflammatory bowel disease;
LUAD	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg10596483	chr8:143751796	JRK	0.45	7.29	0.33	1.53e-12	Schizophrenia;
LUAD	cis	rs78761021	0.720	rs731541	chr17:9799162	A/C	cg26853458	chr17:9805074	RCVRN	0.43	8.24	0.37	2.15e-15	Type 2 diabetes;
LUAD	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.14	15.65	0.61	6.71e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.61	-8.05	-0.36	8.57e-15	Iron status biomarkers;
LUAD	cis	rs332507	0.789	rs13097459	chr3:124398112	C/T	cg05980111	chr3:124395277	KALRN	0.46	7.25	0.33	2.04e-12	Plateletcrit;
LUAD	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg03929089	chr4:120376271	NA	-0.97	-19.75	-0.69	5.18e-62	Height;
LUAD	cis	rs910187	0.641	rs6018327	chr20:45813126	C/T	cg27589058	chr20:45804311	EYA2	-0.31	-7.08	-0.33	6.09e-12	Migraine;
LUAD	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg10876282	chr6:28092338	ZSCAN16	0.46	7.5	0.34	3.7e-13	Parkinson's disease;
LUAD	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg24562669	chr7:97807699	LMTK2	0.33	8.0	0.36	1.2e-14	Prostate cancer (SNP x SNP interaction);Prostate cancer;
LUAD	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg14829155	chr15:31115871	NA	-0.59	-9.63	-0.42	5.52e-20	Huntington's disease progression;
LUAD	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18099408	chr3:52552593	STAB1	-0.43	-7.7	-0.35	1e-13	Bipolar disorder;
LUAD	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.12e-14	Prostate cancer;
LUAD	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg22444338	chr7:1054449	C7orf50	0.47	7.74	0.35	7.21e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs7799006	0.657	rs10447540	chr7:2301484	A/G	cg08027265	chr7:2291960	NA	-0.74	-14.92	-0.59	9.48e-41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg23172400	chr8:95962367	TP53INP1	-0.37	-8.8	-0.39	3.46e-17	Type 2 diabetes;
LUAD	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03517284	chr6:25882590	NA	-0.59	-8.5	-0.38	3.29e-16	Intelligence (multi-trait analysis);
LUAD	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21582582	chr3:182698605	DCUN1D1	0.56	9.54	0.42	1.11e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23158103	chr7:148848205	ZNF398	-0.65	-12.06	-0.51	5.36e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs250677	0.522	rs6580590	chr5:148360374	C/T	cg12140854	chr5:148520817	ABLIM3	0.57	8.98	0.4	9.03e-18	Breast cancer;
LUAD	cis	rs490234	0.812	rs10121109	chr9:128455206	C/A	cg14078157	chr9:128172775	NA	-0.45	-8.44	-0.38	4.95e-16	Mean arterial pressure;
LUAD	cis	rs3849570	0.961	rs3849571	chr3:81777716	A/C	cg07356753	chr3:81810745	GBE1	-0.7	-12.45	-0.52	1.6e-30	Waist circumference;Body mass index;
LUAD	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg18876405	chr7:65276391	NA	-0.42	-6.71	-0.31	6.18e-11	Aortic root size;
LUAD	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg14582100	chr15:45693742	SPATA5L1	0.55	10.49	0.45	4.97e-23	Homoarginine levels;
LUAD	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg09467607	chr2:36825704	FEZ2	0.6	11.52	0.49	7e-27	Height;
LUAD	cis	rs10979	0.597	rs10782290	chr6:143906340	T/C	cg25407410	chr6:143891975	LOC285740	-0.56	-7.87	-0.36	3.04e-14	Hypospadias;
LUAD	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg10876282	chr6:28092338	ZSCAN16	0.47	7.65	0.35	1.36e-13	Parkinson's disease;
LUAD	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9308433	0.643	rs955920	chr1:214464309	G/A	cg06198575	chr1:214491504	SMYD2	0.42	7.07	0.33	6.48e-12	IgG glycosylation;
LUAD	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg08677398	chr8:58056175	NA	0.53	7.11	0.33	5.05e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg26554054	chr8:600488	NA	0.82	8.02	0.36	1.07e-14	IgG glycosylation;
LUAD	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08736216	chr1:53307985	ZYG11A	-0.33	-6.58	-0.3	1.42e-10	Monocyte count;
LUAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-8.15	-0.37	4.11e-15	Electroencephalogram traits;
LUAD	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg22166914	chr1:53195759	ZYG11B	0.45	8.02	0.36	1.07e-14	Monocyte count;
LUAD	trans	rs11039798	0.920	rs61448762	chr11:48923756	G/A	cg15704280	chr7:45808275	SEPT13	0.76	7.7	0.35	9.92e-14	Axial length;
LUAD	trans	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.9	0.5	2.22e-28	Mean corpuscular volume;
LUAD	cis	rs2279817	1.000	rs10888048	chr1:18019742	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.59	10.07	0.44	1.64e-21	Neuroticism;
LUAD	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg00933542	chr6:150070202	PCMT1	0.44	9.62	0.42	6.04e-20	Lung cancer;
LUAD	cis	rs12989701	1.000	rs12989701	chr2:127887985	C/A	cg08168897	chr2:127865431	BIN1	0.44	6.61	0.31	1.14e-10	Alzheimer's disease (late onset);
LUAD	cis	rs208520	0.874	rs208469	chr6:66915891	T/C	cg07460842	chr6:66804631	NA	-0.97	-13.97	-0.56	9.5e-37	Exhaled nitric oxide output;
LUAD	cis	rs2839627	0.564	rs57692532	chr21:44305283	C/T	cg03543861	chr21:44258195	NA	0.65	7.73	0.35	7.77e-14	Information processing speed;
LUAD	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg05754148	chr16:3507555	NAT15	-0.44	-7.22	-0.33	2.49e-12	Body mass index (adult);
LUAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	8.35	0.38	9.99e-16	Alzheimer's disease;
LUAD	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg12432903	chr7:1882776	MAD1L1	-0.41	-6.7	-0.31	6.62e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg18446336	chr7:2847575	GNA12	-0.35	-6.57	-0.3	1.44e-10	Height;
LUAD	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg20135002	chr11:47629003	NA	-0.41	-7.19	-0.33	3.02e-12	Subjective well-being;
LUAD	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18876405	chr7:65276391	NA	0.41	6.39	0.3	4.42e-10	Aortic root size;
LUAD	cis	rs9560113	0.573	rs9560134	chr13:112244011	C/T	cg10483660	chr13:112241077	NA	0.47	9.41	0.42	3.15e-19	Menarche (age at onset);
LUAD	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg07217954	chr7:1067459	C7orf50	-0.38	-6.76	-0.31	4.61e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.54	-0.34	2.81e-13	Total cholesterol levels;
LUAD	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.88	0.36	2.75e-14	Depression;
LUAD	cis	rs11625487	0.957	rs28820314	chr14:77963272	A/C	cg20045696	chr14:77926864	AHSA1	-0.47	-6.71	-0.31	6.13e-11	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUAD	cis	rs10979	1.000	rs9386037	chr6:143891950	T/C	cg25407410	chr6:143891975	LOC285740	-0.65	-10.32	-0.45	2.05e-22	Hypospadias;
LUAD	cis	rs2985684	0.894	rs10147029	chr14:50020232	G/T	cg04989706	chr14:50066350	PPIL5	0.49	7.37	0.34	9.31e-13	Carotid intima media thickness;
LUAD	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.53	-9.32	-0.41	6.43e-19	Prudent dietary pattern;
LUAD	cis	rs7180079	1.000	rs8028184	chr15:64515543	G/A	cg08069370	chr15:64387884	SNX1	-0.51	-6.55	-0.3	1.72e-10	Monocyte count;
LUAD	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg14196790	chr5:131705035	SLC22A5	0.5	9.04	0.4	5.51e-18	Blood metabolite levels;
LUAD	trans	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg26043149	chr18:55253948	FECH	0.49	7.88	0.36	2.85e-14	Bone mineral density;
LUAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.84	-0.4	2.53e-17	Lymphocyte counts;
LUAD	cis	rs870825	0.698	rs7673203	chr4:185625397	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs17608059	0.545	rs736261	chr17:13936404	A/G	cg27005118	chr17:13972210	COX10	-0.36	-7.39	-0.34	7.67e-13	Temperament;
LUAD	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg21856205	chr7:94953877	PON1	-0.54	-7.42	-0.34	6.56e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.94	-0.36	1.83e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg09085632	chr11:111637200	PPP2R1B	0.63	9.72	0.43	2.79e-20	Primary sclerosing cholangitis;
LUAD	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg06641503	chr3:48959341	ARIH2	-0.4	-7.97	-0.36	1.52e-14	Parkinson's disease;
LUAD	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg26022315	chr17:47021804	SNF8	0.41	7.33	0.34	1.17e-12	Type 2 diabetes;
LUAD	trans	rs12517041	1.000	rs10072527	chr5:23318246	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.73	-0.31	5.37e-11	Calcium levels;
LUAD	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg05084668	chr3:125655381	ALG1L	-0.43	-6.4	-0.3	4.03e-10	Blood pressure (smoking interaction);
LUAD	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg15704280	chr7:45808275	SEPT13	-0.66	-10.78	-0.46	4.1e-24	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg14092988	chr3:52407081	DNAH1	0.45	8.88	0.4	1.9e-17	Bipolar disorder;
LUAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg22535103	chr8:58192502	C8orf71	-0.75	-10.68	-0.46	9.66e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg26022315	chr17:47021804	SNF8	0.41	7.36	0.34	9.46e-13	Type 2 diabetes;
LUAD	cis	rs2581828	0.656	rs1078968	chr3:53123486	G/A	cg24530246	chr3:53118167	NA	0.3	6.39	0.3	4.4e-10	Crohn's disease;
LUAD	cis	rs7666738	0.657	rs13102002	chr4:98617794	T/C	cg05340658	chr4:99064831	C4orf37	0.49	7.08	0.33	6.23e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg27170947	chr2:26402098	FAM59B	-0.69	-9.5	-0.42	1.62e-19	Gut microbiome composition (summer);
LUAD	cis	rs28655083	0.957	rs2171096	chr16:77079043	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-7.06	-0.32	6.8e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13064411	0.696	rs6786974	chr3:113190149	T/A	cg18753928	chr3:113234510	CCDC52	-0.67	-10.29	-0.45	2.69e-22	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg07234876	chr8:600039	NA	0.79	8.04	0.36	9.41e-15	IgG glycosylation;
LUAD	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.68	-10.29	-0.45	2.52e-22	Chronic sinus infection;
LUAD	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.62	-0.31	1.1e-10	Obesity-related traits;
LUAD	cis	rs7759001	0.857	rs3734575	chr6:27371011	C/T	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs2425143	0.730	rs6058354	chr20:34491110	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.06	-0.32	7.08e-12	Blood protein levels;
LUAD	cis	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg00383909	chr3:49044727	WDR6	0.46	6.81	0.31	3.31e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg16479474	chr6:28041457	NA	0.46	7.94	0.36	1.8e-14	Depression;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg26574964	chr11:117049906	SIDT2	0.42	6.57	0.3	1.5e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1894633	0.574	rs56340136	chr1:172326143	A/T	cg13446689	chr1:172328377	DNM3	0.41	6.7	0.31	6.52e-11	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12421382	0.507	rs2186673	chr11:109285519	G/A	cg27471124	chr11:109292789	C11orf87	0.34	6.84	0.32	2.72e-11	Schizophrenia;
LUAD	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg17644776	chr2:200775616	C2orf69	-0.51	-6.56	-0.3	1.59e-10	Schizophrenia;
LUAD	trans	rs3942852	0.955	rs4752897	chr11:48136990	C/T	cg03929089	chr4:120376271	NA	-0.53	-7.41	-0.34	7.11e-13	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg03929089	chr4:120376271	NA	-0.53	-7.69	-0.35	1.07e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.17	0.37	3.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs332507	0.673	rs2242426	chr3:124398031	A/G	cg05980111	chr3:124395277	KALRN	0.45	7.17	0.33	3.31e-12	Plateletcrit;
LUAD	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg02782426	chr3:40428986	ENTPD3	0.35	7.73	0.35	7.9e-14	Renal cell carcinoma;
LUAD	trans	rs8002861	0.905	rs6561149	chr13:44456782	T/G	cg17145862	chr1:211918768	LPGAT1	-0.7	-15.23	-0.6	4.4e-42	Leprosy;
LUAD	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18099408	chr3:52552593	STAB1	-0.43	-7.7	-0.35	1e-13	Electroencephalogram traits;
LUAD	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.57	10.87	0.47	1.95e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.3	6.67	0.31	8.07e-11	Systemic lupus erythematosus;
LUAD	cis	rs3020333	0.846	rs3020335	chr6:152013223	G/T	cg22157087	chr6:152012887	ESR1	0.36	6.52	0.3	2.03e-10	Total body bone mineral density;
LUAD	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.78	0.31	3.93e-11	Cardiac Troponin-T levels;
LUAD	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg03467027	chr4:99064603	C4orf37	0.46	7.37	0.34	9.17e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg02782426	chr3:40428986	ENTPD3	0.35	7.6	0.35	1.97e-13	Renal cell carcinoma;
LUAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg21782813	chr7:2030301	MAD1L1	0.57	9.85	0.43	9.73e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs17401966	0.838	rs4846212	chr1:10370312	T/C	cg19773385	chr1:10388646	KIF1B	-0.39	-6.38	-0.3	4.7e-10	Hepatocellular carcinoma;
LUAD	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg18490616	chr2:88469792	THNSL2	0.8	8.36	0.38	9.13e-16	Plasma clusterin levels;
LUAD	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.41	-8.86	-0.4	2.32e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg26597838	chr10:835615	NA	1.31	20.91	0.71	3.5e-67	Eosinophil percentage of granulocytes;
LUAD	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg04287289	chr16:89883240	FANCA	0.7	12.95	0.53	1.54e-32	Vitiligo;
LUAD	cis	rs1278769	1.000	rs1278769	chr13:113536627	C/T	cg00823993	chr13:113535758	ATP11A	0.53	8.48	0.38	3.7e-16	Interstitial lung disease;
LUAD	trans	rs4332037	0.615	rs62435134	chr7:1895463	T/G	cg11693508	chr17:37793320	STARD3	0.77	9.85	0.43	9.53e-21	Bipolar disorder;
LUAD	cis	rs76878669	0.754	rs10896113	chr11:66117111	C/T	cg18002602	chr11:66138449	SLC29A2	-0.42	-7.54	-0.34	2.85e-13	Educational attainment (years of education);
LUAD	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg08085267	chr17:45401833	C17orf57	-0.59	-10.33	-0.45	1.86e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg03886242	chr7:26192032	NFE2L3	0.41	6.94	0.32	1.47e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg22875332	chr1:76189707	ACADM	0.86	15.8	0.61	1.51e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg20135002	chr11:47629003	NA	-0.41	-7.3	-0.33	1.41e-12	Subjective well-being;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19539481	chr11:66475652	SPTBN2	0.47	6.47	0.3	2.78e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3806843	0.576	rs246064	chr5:140324309	C/G	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1045714	0.895	rs2293405	chr7:2644607	G/T	cg20813462	chr7:2646259	IQCE	0.65	7.21	0.33	2.65e-12	Urate levels in lean individuals;
LUAD	cis	rs35123781	0.654	rs356484	chr5:139084438	T/A	cg10513866	chr5:139070639	NA	0.5	7.71	0.35	8.88e-14	Schizophrenia;
LUAD	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg03732007	chr1:2071316	PRKCZ	-0.35	-6.45	-0.3	3.07e-10	Height;
LUAD	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg03433033	chr1:76189801	ACADM	0.79	12.93	0.53	1.9e-32	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg08236123	chr12:132219811	SFRS8	-0.36	-6.54	-0.3	1.75e-10	Migraine;
LUAD	cis	rs56161922	1.000	rs55883147	chr1:207840002	C/T	cg11752769	chr1:207818423	CR1L	-0.66	-7.0	-0.32	1.04e-11	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs9715521	0.677	rs67500083	chr4:59862419	C/T	cg11281224	chr4:60001000	NA	-0.61	-10.77	-0.46	4.76e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg06618935	chr21:46677482	NA	-0.49	-10.11	-0.44	1.19e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.43	0.38	5.49e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.35	7.62	0.35	1.68e-13	Parkinson's disease;
LUAD	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg20991723	chr1:152506922	NA	0.34	6.66	0.31	8.76e-11	Hair morphology;
LUAD	trans	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg07211511	chr3:129823064	LOC729375	-0.8	-10.06	-0.44	1.73e-21	Blood pressure (smoking interaction);
LUAD	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg20848291	chr7:100343083	ZAN	0.39	6.79	0.31	3.84e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg25985355	chr7:65971099	NA	0.38	7.02	0.32	8.92e-12	Aortic root size;
LUAD	cis	rs8192282	0.739	rs4474240	chr1:154457855	A/C	cg16683920	chr1:154474344	TDRD10;SHE	-0.44	-6.92	-0.32	1.69e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg03037974	chr15:76606532	NA	0.38	8.06	0.36	7.75e-15	Blood metabolite levels;
LUAD	trans	rs4925166	1	rs4925166	chr17:18210810	T/G	cg15088880	chr17:26084080	NOS2	-0.36	-6.44	-0.3	3.26e-10	Multiple sclerosis;
LUAD	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg14092988	chr3:52407081	DNAH1	0.38	7.56	0.34	2.58e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03452623	chr4:187889614	NA	-0.82	-17.12	-0.64	2.72e-50	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg20701182	chr2:24300061	SF3B14	0.62	6.83	0.31	3.06e-11	Lymphocyte counts;
LUAD	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg16262614	chr3:133464971	TF	0.38	7.56	0.34	2.55e-13	Iron status biomarkers (transferrin levels);
LUAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02359409	chr6:42947317	PEX6	-0.38	-6.79	-0.31	3.84e-11	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.36	7.1	0.33	5.39e-12	Obesity-related traits;
LUAD	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06544989	chr22:39130855	UNC84B	-0.39	-7.9	-0.36	2.48e-14	Menopause (age at onset);
LUAD	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg03929089	chr4:120376271	NA	-0.96	-19.69	-0.69	9.6e-62	Height;
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg13214185	chr14:107219616	NA	-0.41	-7.21	-0.33	2.62e-12	Menopause (age at onset);
LUAD	cis	rs3820068	0.705	rs4646087	chr1:15822404	A/G	cg17385448	chr1:15911702	AGMAT	0.39	6.36	0.3	5.39e-10	Systolic blood pressure;
LUAD	cis	rs986417	0.901	rs1061108	chr14:60978071	C/G	cg27398547	chr14:60952738	C14orf39	0.66	7.82	0.36	4.21e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.47	-6.38	-0.3	4.74e-10	Gut microbiome composition (summer);
LUAD	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.77	-0.35	6.02e-14	Monocyte count;
LUAD	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.39	0.45	1.09e-22	Post bronchodilator FEV1;
LUAD	cis	rs6577655	0.517	rs11998030	chr8:135585325	C/T	cg17885191	chr8:135476712	NA	0.61	8.33	0.38	1.12e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg18477163	chr1:228402036	OBSCN	0.4	8.07	0.37	7.53e-15	Diastolic blood pressure;
LUAD	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23583168	chr7:148888333	NA	-0.89	-17.53	-0.65	4.23e-52	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg06108461	chr20:60628389	TAF4	-0.93	-16.72	-0.63	1.52e-48	Body mass index;
LUAD	cis	rs7671266	0.559	rs7681212	chr4:10358964	C/G	cg00071950	chr4:10020882	SLC2A9	0.45	6.8	0.31	3.63e-11	Cardiovascular disease risk factors;
LUAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg27588902	chr6:42928151	GNMT	-0.37	-9.81	-0.43	1.3e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-10.8	-0.46	3.54e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg01028140	chr2:1542097	TPO	0.49	6.64	0.31	9.74e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg14345882	chr6:26364793	BTN3A2	0.7	7.14	0.33	4.13e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7943203	0.568	rs11212614	chr11:108281089	T/C	cg04873221	chr11:107992290	ACAT1	-0.48	-7.31	-0.33	1.35e-12	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-7.99	-0.36	1.32e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs9467711	0.559	rs13214027	chr6:26573631	C/G	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.49	-0.34	4.02e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.37	-0.38	8.44e-16	Breast cancer;
LUAD	cis	rs3739034	0.652	rs35865359	chr2:135374595	C/T	cg12500956	chr2:135428796	TMEM163	0.39	7.44	0.34	5.79e-13	Gut microbiome composition (winter);
LUAD	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg13560548	chr3:10150139	C3orf24	0.4	6.56	0.3	1.53e-10	Alzheimer's disease;
LUAD	cis	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.98	-0.36	1.35e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9302065	0.681	rs59108692	chr13:95962424	C/A	cg24476569	chr13:95954382	ABCC4	-0.58	-10.74	-0.46	5.87e-24	Blood metabolite levels;
LUAD	cis	rs59104589	0.521	rs60988810	chr2:242430084	C/A	cg08645257	chr2:242211290	HDLBP	0.38	6.38	0.3	4.66e-10	Fibrinogen levels;
LUAD	cis	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg27411982	chr8:10470053	RP1L1	0.42	7.96	0.36	1.63e-14	Neuroticism;
LUAD	cis	rs7593730	1.000	rs4589705	chr2:161176136	A/T	cg22609984	chr2:161126801	NA	0.43	7.03	0.32	8.1e-12	Type 2 diabetes;
LUAD	cis	rs847577	0.609	rs11765552	chr7:97822115	T/A	cg24562669	chr7:97807699	LMTK2	0.34	8.06	0.37	7.68e-15	Breast cancer;
LUAD	cis	rs10744422	0.920	rs3896871	chr12:123333610	G/T	cg16953816	chr12:123349952	VPS37B	0.59	6.64	0.31	9.46e-11	Schizophrenia;
LUAD	trans	rs877282	0.853	rs11253332	chr10:755262	G/C	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg22920501	chr2:26401640	FAM59B	0.96	13.91	0.56	1.82e-36	Gut microbiome composition (summer);
LUAD	cis	rs7705042	0.865	rs6882226	chr5:141503870	T/A	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.59	-0.31	1.29e-10	Asthma;
LUAD	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg18016565	chr1:150552671	MCL1	0.38	6.95	0.32	1.35e-11	Tonsillectomy;
LUAD	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg20673091	chr1:2541236	MMEL1	0.44	9.49	0.42	1.65e-19	Ulcerative colitis;
LUAD	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs859767	0.501	rs71348712	chr2:135391590	T/A	cg12500956	chr2:135428796	TMEM163	-0.27	-7.14	-0.33	4.19e-12	Neuroticism;
LUAD	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg18105134	chr13:113819100	PROZ	-1.0	-18.58	-0.67	8.93e-57	Platelet distribution width;
LUAD	cis	rs35146811	0.555	rs1981549	chr7:99541636	A/G	cg13334819	chr7:99746414	C7orf59	-0.56	-8.24	-0.37	2.14e-15	Coronary artery disease;
LUAD	cis	rs4786125	0.555	rs7196838	chr16:6920457	A/G	cg03623568	chr16:6915990	A2BP1	-0.47	-10.16	-0.44	7.59e-22	Heart rate variability traits (SDNN);
LUAD	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.32e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11644478	chr21:40555479	PSMG1	0.68	11.25	0.48	7.37e-26	Cognitive function;
LUAD	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg22431228	chr1:16359049	CLCNKA	0.47	8.47	0.38	4e-16	Dilated cardiomyopathy;
LUAD	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.42	-9.14	-0.41	2.72e-18	Hemoglobin concentration;
LUAD	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg26513180	chr16:89883248	FANCA	0.7	13.28	0.54	6.94e-34	Vitiligo;
LUAD	trans	rs875971	1.000	rs778706	chr7:65860424	A/G	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs367943	0.608	rs6859352	chr5:113007384	A/C	cg12552261	chr5:112820674	MCC	0.44	7.41	0.34	6.79e-13	Type 2 diabetes;
LUAD	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08219700	chr8:58056026	NA	0.71	9.15	0.41	2.38e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg09365446	chr1:150670422	GOLPH3L	0.65	11.92	0.5	1.89e-28	Tonsillectomy;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08659621	chr20:48552817	RNF114	-0.41	-6.36	-0.3	5.22e-10	Height;
LUAD	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg01884057	chr2:25150051	NA	0.32	6.85	0.32	2.6e-11	Body mass index;
LUAD	cis	rs6992820	0.967	rs13265995	chr8:56684796	C/A	cg06880721	chr8:56792545	LYN	-0.4	-6.4	-0.3	4.12e-10	Mean platelet volume;
LUAD	cis	rs4901869	0.966	rs60800733	chr14:59337778	A/G	cg02291164	chr14:59296302	NA	0.64	15.93	0.61	4.15e-45	Panic disorder;
LUAD	cis	rs12681288	0.676	rs935819	chr8:1021814	T/C	cg04851639	chr8:1020857	NA	-0.41	-9.69	-0.43	3.49e-20	Schizophrenia;
LUAD	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.58	-0.3	1.41e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4774899	0.966	rs12914481	chr15:57484613	G/A	cg14026238	chr15:57616123	NA	0.35	6.56	0.3	1.56e-10	Urinary tract infection frequency;
LUAD	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg11915388	chr22:42470451	FAM109B	-0.38	-6.7	-0.31	6.76e-11	Schizophrenia;
LUAD	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg04842962	chr6:43655489	MRPS18A	0.91	17.01	0.64	8.18e-50	IgG glycosylation;
LUAD	cis	rs62400317	0.821	rs62400269	chr6:45200634	C/T	cg18551225	chr6:44695536	NA	-0.56	-8.42	-0.38	5.81e-16	Total body bone mineral density;
LUAD	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg11189052	chr15:85197271	WDR73	0.68	8.96	0.4	1.06e-17	Schizophrenia;
LUAD	cis	rs10392	0.850	rs725322	chr20:37563352	C/T	cg27660920	chr20:37554817	FAM83D	0.51	6.48	0.3	2.6e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg11822812	chr5:140052017	DND1	-0.39	-7.07	-0.32	6.6e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg06740227	chr12:86229804	RASSF9	0.39	7.01	0.32	9.42e-12	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg18446336	chr7:2847575	GNA12	-0.33	-6.62	-0.31	1.09e-10	Height;
LUAD	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg15448220	chr1:150897856	SETDB1	0.53	8.93	0.4	1.3e-17	Melanoma;
LUAD	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.38	1.21e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	13.7	0.55	1.35e-35	Smoking behavior;
LUAD	cis	rs2625529	0.878	rs2929511	chr15:72231682	C/T	cg16672083	chr15:72433130	SENP8	0.64	12.04	0.51	6.39e-29	Red blood cell count;
LUAD	cis	rs2455799	1.000	rs13078364	chr3:15855507	T/A	cg16303742	chr3:15540471	COLQ	-0.39	-6.78	-0.31	4.02e-11	Mean platelet volume;
LUAD	cis	rs11971779	0.648	rs7799165	chr7:139084957	G/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.77e-11	Diisocyanate-induced asthma;
LUAD	cis	rs1712517	0.771	rs59744322	chr10:105146692	G/T	cg05636881	chr10:105038444	INA	0.33	6.53	0.3	1.85e-10	Migraine;
LUAD	cis	rs16858210	0.837	rs1879254	chr3:183609471	C/T	cg01324343	chr3:183735012	ABCC5	0.42	6.39	0.3	4.28e-10	Menopause (age at onset);
LUAD	cis	rs7123876	0.587	rs11602616	chr11:72364077	T/C	cg03713592	chr11:72463424	ARAP1	0.54	6.64	0.31	9.95e-11	Body mass index;
LUAD	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs9616064	0.520	rs875559	chr22:47034838	T/C	cg05621596	chr22:47072043	GRAMD4	-0.65	-10.6	-0.46	1.99e-23	Urate levels in obese individuals;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg23806609	chr7:66369525	NA	0.43	7.18	0.33	3.23e-12	Vertical cup-disc ratio;
LUAD	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.66	-0.31	8.61e-11	Schizophrenia;
LUAD	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg11494091	chr17:61959527	GH2	0.4	7.03	0.32	8.36e-12	Height;
LUAD	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg26022315	chr17:47021804	SNF8	0.4	7.18	0.33	3.16e-12	Type 2 diabetes;
LUAD	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg11707310	chr1:2537719	MMEL1	-0.38	-7.92	-0.36	2.12e-14	Ulcerative colitis;
LUAD	cis	rs34638657	0.732	rs61111557	chr16:82201102	A/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.95	-0.32	1.43e-11	Lung adenocarcinoma;
LUAD	cis	rs7072216	0.621	rs3750605	chr10:100175654	C/T	cg26618903	chr10:100175079	PYROXD2	-0.4	-8.29	-0.37	1.55e-15	Metabolite levels;
LUAD	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10924309	0.737	rs6701023	chr1:245854503	C/G	cg00036263	chr1:245852353	KIF26B	0.47	7.86	0.36	3.16e-14	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg21475434	chr5:93447410	FAM172A	0.74	8.62	0.39	1.39e-16	Diabetic retinopathy;
LUAD	cis	rs1113500	0.836	rs1539553	chr1:108589998	C/T	cg06207961	chr1:108661230	NA	-0.42	-7.8	-0.35	4.74e-14	Growth-regulated protein alpha levels;
LUAD	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg27432699	chr2:27873401	GPN1	-0.38	-6.44	-0.3	3.21e-10	Total body bone mineral density;
LUAD	cis	rs1881396	0.783	rs10181342	chr2:27757343	A/G	cg27432699	chr2:27873401	GPN1	0.46	6.39	0.3	4.48e-10	Nonalcoholic fatty liver disease;
LUAD	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg14847009	chr1:175162515	KIAA0040	0.32	8.51	0.38	3.16e-16	Alcohol dependence;
LUAD	trans	rs3219090	0.962	rs2695235	chr1:226602556	A/G	cg27539482	chr13:111589090	NA	0.43	7.22	0.33	2.5e-12	Melanoma;
LUAD	cis	rs3784262	0.669	rs3784257	chr15:58262974	C/T	cg12031962	chr15:58353849	ALDH1A2	0.39	7.72	0.35	8.42e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs4588572	0.688	rs11743511	chr5:77692819	C/T	cg11547950	chr5:77652471	NA	-0.63	-10.94	-0.47	1.1e-24	Triglycerides;
LUAD	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg26384229	chr12:38710491	ALG10B	-0.41	-6.98	-0.32	1.18e-11	Heart rate;
LUAD	cis	rs7617773	0.817	rs4131361	chr3:48328812	T/C	cg11946769	chr3:48343235	NME6	0.43	6.65	0.31	8.89e-11	Coronary artery disease;
LUAD	cis	rs12681287	0.640	rs13280468	chr8:87338452	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-9.51	-0.42	1.48e-19	Caudate activity during reward;
LUAD	trans	rs2262909	0.962	rs11669110	chr19:22296485	A/G	cg05197062	chr11:11642011	GALNTL4	0.6	9.34	0.41	5.48e-19	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1865721	1.000	rs3813080	chr18:73186227	C/T	cg26385618	chr18:73139727	C18orf62	-0.43	-7.79	-0.35	5.38e-14	Intelligence;
LUAD	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg26587870	chr6:27730563	NA	-0.48	-7.98	-0.36	1.39e-14	Parkinson's disease;
LUAD	cis	rs62238980	0.614	rs116903413	chr22:32398342	C/T	cg00543991	chr22:32367038	NA	0.9	8.54	0.38	2.39e-16	Childhood ear infection;
LUAD	trans	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.89	-0.32	2e-11	Systolic blood pressure;
LUAD	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs11640533	0.901	rs2908792	chr16:53412419	A/G	cg02380802	chr16:53407808	NA	0.38	6.75	0.31	4.82e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs78456975	0.607	rs72776258	chr2:1530732	C/G	cg01028140	chr2:1542097	TPO	-0.6	-7.74	-0.35	7.35e-14	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs4900538	0.963	rs1998422	chr14:102980993	G/C	cg18135206	chr14:102964638	TECPR2	1.02	22.0	0.73	4.76e-72	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg27631724	chr1:11040367	C1orf127	0.53	8.98	0.4	8.82e-18	Ewing sarcoma;
LUAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.57	-10.83	-0.47	2.74e-24	Longevity;Endometriosis;
LUAD	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg02807482	chr3:125708958	NA	-0.66	-8.57	-0.38	1.91e-16	Blood pressure (smoking interaction);
LUAD	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg09796270	chr17:17721594	SREBF1	0.38	7.51	0.34	3.43e-13	Total body bone mineral density;
LUAD	cis	rs6005807	0.583	rs134514	chr22:28762034	C/T	cg12565055	chr22:29076175	TTC28	-0.71	-8.29	-0.37	1.52e-15	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs2933343	0.951	rs796862	chr3:128593040	G/A	cg11901034	chr3:128598214	ACAD9	-0.46	-6.36	-0.3	5.37e-10	IgG glycosylation;
LUAD	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg03806693	chr22:41940476	POLR3H	0.59	8.59	0.39	1.63e-16	Vitiligo;
LUAD	cis	rs367943	1.000	rs348960	chr5:112820651	C/A	cg12552261	chr5:112820674	MCC	0.59	11.13	0.48	2.02e-25	Type 2 diabetes;
LUAD	cis	rs6445967	0.530	rs12492472	chr3:58409972	A/C	cg23715586	chr3:58305044	RPP14	0.41	6.66	0.31	8.54e-11	Platelet count;
LUAD	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg03806693	chr22:41940476	POLR3H	-0.58	-8.35	-0.38	9.94e-16	Vitiligo;
LUAD	cis	rs758324	0.947	rs4705838	chr5:131150593	G/T	cg25547332	chr5:131281432	NA	0.43	6.52	0.3	2.03e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs11828289	0.660	rs11027043	chr11:23212893	C/T	cg20040320	chr11:23191996	NA	-0.69	-7.85	-0.36	3.42e-14	Cancer;
LUAD	cis	rs367943	0.688	rs255877	chr5:112753584	A/G	cg12552261	chr5:112820674	MCC	0.5	9.71	0.43	2.96e-20	Type 2 diabetes;
LUAD	cis	rs7773004	0.905	rs3778279	chr6:26325463	T/C	cg13736514	chr6:26305472	NA	-0.48	-8.04	-0.36	9.15e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06544989	chr22:39130855	UNC84B	0.46	8.75	0.39	5e-17	Menopause (age at onset);
LUAD	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.45	-7.4	-0.34	7.25e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.84e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg22920501	chr2:26401640	FAM59B	-0.8	-11.22	-0.48	9.68e-26	Gut microbiome composition (summer);
LUAD	cis	rs6969780	0.632	rs11762730	chr7:27190398	A/C	cg05579037	chr7:27184853	NA	0.44	6.39	0.3	4.35e-10	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUAD	cis	rs3784262	1.000	rs10851630	chr15:58242148	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.46	-9.4	-0.42	3.53e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg00316803	chr15:76480434	C15orf27	-0.4	-7.52	-0.34	3.35e-13	Blood metabolite levels;
LUAD	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg17724175	chr1:150552817	MCL1	0.38	9.23	0.41	1.31e-18	Tonsillectomy;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19463885	chr2:242626846	DTYMK	-0.43	-6.6	-0.31	1.23e-10	Height;
LUAD	cis	rs727505	1.000	rs988699	chr7:124409814	C/T	cg23710748	chr7:124431027	NA	-0.44	-8.5	-0.38	3.3e-16	Lewy body disease;
LUAD	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg23950597	chr19:37808831	NA	-0.58	-6.93	-0.32	1.6e-11	Coronary artery calcification;
LUAD	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19346786	chr7:2764209	NA	-0.56	-12.26	-0.51	8.71e-30	Height;
LUAD	cis	rs684232	0.666	rs461521	chr17:622497	G/T	cg12384639	chr17:618140	VPS53	0.46	8.02	0.36	1.04e-14	Prostate cancer;
LUAD	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg19318889	chr4:1322082	MAEA	0.54	9.03	0.4	5.94e-18	Longevity;
LUAD	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg04058563	chr4:185651563	MLF1IP	-0.41	-7.44	-0.34	5.52e-13	Kawasaki disease;
LUAD	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg05090351	chr10:126851162	NA	0.53	10.26	0.45	3.22e-22	Menarche (age at onset);
LUAD	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg15445000	chr17:37608096	MED1	-0.45	-8.35	-0.38	1e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs4680	1.000	rs4633	chr22:19950235	C/T	cg01335087	chr22:19950166	COMT	0.23	6.55	0.3	1.72e-10	Blood metabolite levels;
LUAD	cis	rs78487399	0.808	rs7578597	chr2:43732823	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.52	-0.3	1.98e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg09509183	chr1:209979624	IRF6	0.57	7.76	0.35	6.48e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26314531	chr2:26401878	FAM59B	0.54	7.59	0.35	2.11e-13	Gut microbiome composition (summer);
LUAD	cis	rs41311933	0.656	rs41309856	chr9:123776390	G/C	cg13567360	chr9:123745713	C5	-0.67	-8.06	-0.37	7.7e-15	Coronary artery disease;
LUAD	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg09035930	chr12:129282057	SLC15A4	0.75	17.37	0.65	2.03e-51	Systemic lupus erythematosus;
LUAD	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg05313129	chr8:58192883	C8orf71	-0.5	-7.57	-0.35	2.42e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg23978390	chr7:1156363	C7orf50	0.66	10.63	0.46	1.48e-23	Longevity;Endometriosis;
LUAD	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg20701182	chr2:24300061	SF3B14	0.68	7.64	0.35	1.51e-13	Lymphocyte counts;
LUAD	cis	rs9487051	0.735	rs396000	chr6:109519611	A/G	cg01475377	chr6:109611718	NA	0.39	7.49	0.34	3.92e-13	Reticulocyte fraction of red cells;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07936931	chr19:21933455	LOC641367;ZNF100	0.57	6.94	0.32	1.51e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs250677	0.522	rs7702695	chr5:148402550	T/A	cg18129178	chr5:148520854	ABLIM3	-0.54	-7.95	-0.36	1.77e-14	Breast cancer;
LUAD	cis	rs4917833	0.789	rs1060447	chr10:100218532	C/T	cg25691326	chr10:100228212	HPSE2	0.36	6.44	0.3	3.26e-10	Pediatric bone mineral density (femoral neck);
LUAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg11344533	chr11:111475393	SIK2	0.37	6.56	0.3	1.56e-10	Primary sclerosing cholangitis;
LUAD	trans	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg14917512	chr19:3094685	GNA11	-0.57	-6.84	-0.32	2.82e-11	Diabetic kidney disease;
LUAD	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg00666640	chr1:248458726	OR2T12	0.28	6.6	0.31	1.22e-10	Common traits (Other);
LUAD	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.5e-19	Life satisfaction;
LUAD	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg11822812	chr5:140052017	DND1	-0.43	-7.82	-0.36	4.34e-14	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs4698048	0.506	rs2080072	chr4:10235622	G/C	cg26043149	chr18:55253948	FECH	-0.53	-8.76	-0.39	4.8e-17	Skin aging (microtopography measurement);
LUAD	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12541635	0.677	rs62527405	chr8:107058109	G/C	cg10147462	chr8:107024639	NA	0.52	9.27	0.41	9.25e-19	Age of smoking initiation;
LUAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg14092988	chr3:52407081	DNAH1	0.34	6.85	0.32	2.62e-11	Electroencephalogram traits;
LUAD	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg21770322	chr7:97807741	LMTK2	0.35	8.32	0.38	1.18e-15	Breast cancer;
LUAD	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg00901687	chr17:48585270	MYCBPAP	-0.51	-6.91	-0.32	1.81e-11	Visceral fat;
LUAD	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg05373962	chr22:49881684	NA	-0.56	-13.47	-0.55	1.14e-34	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.53	0.3	1.85e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.44	7.34	0.34	1.1e-12	Cognitive ability;
LUAD	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.37	-6.67	-0.31	8.02e-11	Caffeine consumption;
LUAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14893161	chr1:205819251	PM20D1	0.84	18.07	0.66	1.64e-54	Menarche (age at onset);
LUAD	cis	rs9473147	0.516	rs2151975	chr6:47515663	T/C	cg20196966	chr6:47445060	CD2AP	0.44	7.04	0.32	7.64e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs986417	0.901	rs11158292	chr14:61043183	G/T	cg27398547	chr14:60952738	C14orf39	0.61	7.71	0.35	9.11e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-10.86	-0.47	2.06e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs73198271	0.562	rs2048420	chr8:8667603	G/A	cg01851573	chr8:8652454	MFHAS1	0.68	10.19	0.44	6.12e-22	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2580764	0.565	rs2044291	chr2:55247954	A/G	cg09592903	chr2:55203963	RTN4	-0.46	-10.42	-0.45	8.95e-23	Mean platelet volume;
LUAD	cis	rs10739663	0.520	rs3122937	chr9:128154808	A/G	cg14078157	chr9:128172775	NA	-0.45	-8.4	-0.38	6.85e-16	Resting heart rate;
LUAD	trans	rs3219090	0.861	rs9426568	chr1:226603897	T/G	cg27539482	chr13:111589090	NA	-0.43	-7.26	-0.33	1.85e-12	Melanoma;
LUAD	cis	rs2735413	0.875	rs8045975	chr16:78090187	C/G	cg04733911	chr16:78082701	NA	0.35	8.19	0.37	3.05e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	trans	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs9796	0.621	rs9972349	chr15:41491656	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-8.3	-0.37	1.43e-15	Menopause (age at onset);
LUAD	cis	rs55728055	0.661	rs9619215	chr22:32042732	A/G	cg01338084	chr22:32026380	PISD	0.77	6.65	0.31	9.01e-11	Age-related hearing impairment;
LUAD	cis	rs1535500	0.935	rs11753141	chr6:39283083	G/A	cg06347083	chr6:39282316	KCNK17	-0.37	-7.88	-0.36	2.71e-14	Type 2 diabetes;
LUAD	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg08999081	chr20:33150536	PIGU	0.51	10.91	0.47	1.38e-24	Coronary artery disease;
LUAD	cis	rs78761021	0.829	rs55789050	chr17:9793417	A/T	cg26853458	chr17:9805074	RCVRN	0.36	6.75	0.31	5.04e-11	Type 2 diabetes;
LUAD	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.47	7.98	0.36	1.37e-14	Tonsillectomy;
LUAD	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg06618935	chr21:46677482	NA	-0.51	-10.11	-0.44	1.2e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg23625390	chr15:77176239	SCAPER	0.38	6.79	0.31	3.82e-11	Blood metabolite levels;
LUAD	cis	rs877282	0.945	rs10904550	chr10:774177	C/T	cg06581033	chr10:766294	NA	-0.47	-6.64	-0.31	9.46e-11	Uric acid levels;
LUAD	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg14403583	chr14:105418241	AHNAK2	-0.44	-8.27	-0.37	1.75e-15	Rheumatoid arthritis;
LUAD	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg27433088	chr4:174089019	GALNT7	0.39	7.57	0.35	2.31e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs6138458	0.961	rs227625	chr20:24911618	T/C	cg26195577	chr20:24973756	C20orf3	0.96	16.32	0.62	8.79e-47	Blood protein levels;
LUAD	trans	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.94	0.44	4.72e-21	Ulcerative colitis;
LUAD	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg09117114	chr16:67998030	SLC12A4	-0.61	-8.2	-0.37	2.97e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4917300	0.605	rs4917279	chr8:143095690	C/T	cg25363559	chr8:143086065	NA	-0.48	-9.62	-0.42	5.93e-20	Amyotrophic lateral sclerosis;
LUAD	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg13319975	chr6:146136371	FBXO30	0.64	10.97	0.47	7.93e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1853665	0.580	rs4242283	chr6:150273406	C/G	cg16301758	chr6:150275521	NA	0.52	7.72	0.35	8.19e-14	Radiation response;
LUAD	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg17420585	chr12:42539391	GXYLT1	-0.5	-9.19	-0.41	1.75e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs62238980	0.614	rs76363976	chr22:32383968	C/T	cg00543991	chr22:32367038	NA	0.92	8.48	0.38	3.7e-16	Childhood ear infection;
LUAD	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg15445000	chr17:37608096	MED1	0.45	8.31	0.37	1.32e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25427524	chr10:38739819	LOC399744	0.77	14.86	0.59	1.73e-40	Extrinsic epigenetic age acceleration;
LUAD	cis	rs11030122	0.702	rs11030276	chr11:3946134	A/G	cg18678763	chr11:4115507	RRM1	-0.44	-7.22	-0.33	2.37e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs6594499	0.542	rs4530809	chr5:110462230	A/G	cg17157872	chr5:110408788	TSLP	0.32	6.41	0.3	3.91e-10	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg15704280	chr7:45808275	SEPT13	-0.52	-8.26	-0.37	1.9e-15	HDL cholesterol;
LUAD	cis	rs13223928	0.621	rs10228451	chr7:3150859	C/G	cg19214707	chr7:3157722	NA	0.48	8.79	0.39	3.74e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.85	0.36	3.39e-14	Bladder cancer;
LUAD	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg18944383	chr4:111397179	ENPEP	0.4	7.8	0.35	4.96e-14	Height;
LUAD	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg04450456	chr4:17643702	FAM184B	0.4	7.96	0.36	1.6e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg15309053	chr8:964076	NA	0.43	8.95	0.4	1.13e-17	Schizophrenia;
LUAD	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.8	0.31	3.57e-11	Motion sickness;
LUAD	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.77	0.35	6.01e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg03233332	chr7:66118400	NA	-0.45	-6.7	-0.31	6.7e-11	Aortic root size;
LUAD	cis	rs513349	0.964	rs210139	chr6:33543409	A/C	cg07679836	chr6:33548423	BAK1	0.45	8.71	0.39	7.11e-17	Platelet count;
LUAD	cis	rs6558530	0.932	rs4370560	chr8:1708194	G/A	cg17159058	chr8:1704075	NA	-0.39	-6.4	-0.3	4.1e-10	Systolic blood pressure;
LUAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	cis	rs10788264	0.569	rs10749454	chr10:124029654	C/T	cg09507567	chr10:124027408	NA	0.56	12.94	0.53	1.69e-32	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg18180107	chr4:99064573	C4orf37	0.42	6.79	0.31	3.87e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg04876069	chr12:132293656	NA	-0.43	-7.46	-0.34	4.86e-13	Migraine;
LUAD	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg24578937	chr1:2090814	PRKCZ	0.59	12.35	0.51	3.96e-30	Height;
LUAD	cis	rs4072705	0.967	rs4144630	chr9:127439200	A/G	cg13476313	chr9:127244764	NR5A1	0.27	6.56	0.3	1.59e-10	Menarche (age at onset);
LUAD	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.39	0.45	1.09e-22	Post bronchodilator FEV1;
LUAD	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg03433033	chr1:76189801	ACADM	0.58	9.14	0.41	2.64e-18	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg11494091	chr17:61959527	GH2	0.42	7.75	0.35	6.8e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg15445000	chr17:37608096	MED1	-0.45	-8.33	-0.38	1.15e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg17509989	chr5:176798049	RGS14	-0.6	-9.04	-0.4	5.72e-18	Urate levels in lean individuals;
LUAD	trans	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg14917512	chr19:3094685	GNA11	0.38	6.66	0.31	8.52e-11	Aortic root size;
LUAD	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg16405210	chr4:1374714	KIAA1530	-0.62	-9.53	-0.42	1.22e-19	Longevity;
LUAD	cis	rs3764563	0.935	rs585680	chr19:15687802	T/G	cg20725493	chr19:15740067	CYP4F8	0.6	6.47	0.3	2.66e-10	Inflammatory biomarkers;
LUAD	cis	rs12210905	0.748	rs6901225	chr6:26670491	A/G	cg11502198	chr6:26597334	ABT1	-0.77	-7.63	-0.35	1.6e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs6489882	0.867	rs7316586	chr12:113365828	C/T	cg20102336	chr12:113376681	OAS3	-0.61	-9.4	-0.42	3.36e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs6005807	0.843	rs9625481	chr22:28873048	C/T	cg12565055	chr22:29076175	TTC28	0.67	6.45	0.3	2.97e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs10504073	0.669	rs341809	chr8:50042557	C/T	cg00325661	chr8:49890786	NA	0.42	9.41	0.42	3.25e-19	Blood metabolite ratios;
LUAD	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg18833306	chr6:118973337	C6orf204	-0.54	-7.7	-0.35	9.96e-14	Diastolic blood pressure;
LUAD	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg09222892	chr1:25734099	RHCE	-0.46	-8.47	-0.38	3.96e-16	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs3849570	0.673	rs13068700	chr3:81975817	G/C	cg07356753	chr3:81810745	GBE1	-0.55	-9.24	-0.41	1.22e-18	Waist circumference;Body mass index;
LUAD	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg11494091	chr17:61959527	GH2	0.38	6.62	0.31	1.08e-10	Height;
LUAD	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg01324343	chr3:183735012	ABCC5	-0.69	-9.07	-0.4	4.42e-18	Body mass index;
LUAD	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.77e-11	Depression;
LUAD	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg10950924	chr17:47092072	IGF2BP1	0.39	7.64	0.35	1.51e-13	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg16606324	chr3:10149918	C3orf24	-0.61	-10.02	-0.44	2.43e-21	Alzheimer's disease;
LUAD	cis	rs558133	1.000	rs621678	chr5:78418416	A/G	cg25119155	chr5:78426943	BHMT	0.53	9.24	0.41	1.17e-18	Blood and toenail selenium levels;
LUAD	cis	rs6426558	0.515	rs7521110	chr1:227384459	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.56	-8.98	-0.4	9.06e-18	Neutrophil percentage of white cells;
LUAD	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.27e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg27490568	chr2:178487706	NA	0.38	6.38	0.3	4.55e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg15208524	chr1:10270712	KIF1B	0.42	6.38	0.3	4.54e-10	Hepatocellular carcinoma;
LUAD	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg11845111	chr2:191398756	TMEM194B	-0.69	-8.96	-0.4	1.08e-17	Diastolic blood pressure;
LUAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13732083	chr21:47605072	C21orf56	0.6	10.36	0.45	1.43e-22	Testicular germ cell tumor;
LUAD	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg12444411	chr7:2802554	GNA12	0.35	6.39	0.3	4.29e-10	Height;
LUAD	trans	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg24644049	chr4:85504048	CDS1	0.89	7.33	0.34	1.17e-12	Skin colour saturation;
LUAD	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-7.25	-0.33	1.93e-12	Joint mobility (Beighton score);
LUAD	cis	rs6445967	0.530	rs62258074	chr3:58353966	C/G	cg23715586	chr3:58305044	RPP14	0.41	6.62	0.31	1.1e-10	Platelet count;
LUAD	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.87e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4006360	0.574	rs35944108	chr17:39238561	C/T	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.16	0.37	3.85e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg21475434	chr5:93447410	FAM172A	0.78	8.57	0.38	1.95e-16	Diabetic retinopathy;
LUAD	cis	rs925255	0.810	rs7574996	chr2:28643523	G/C	cg01273330	chr2:28605224	NA	-0.32	-6.47	-0.3	2.67e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs356992	0.915	rs76673	chr2:60749078	G/T	cg08426369	chr2:60753602	BCL11A	-0.44	-7.52	-0.34	3.29e-13	Educational attainment (years of education);
LUAD	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg05926928	chr17:57297772	GDPD1	1.41	17.58	0.65	2.43e-52	Opioid sensitivity;
LUAD	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg18827107	chr12:86230957	RASSF9	-0.7	-13.05	-0.54	6.18e-33	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg03467027	chr4:99064603	C4orf37	0.43	7.07	0.33	6.38e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12155623	0.592	rs12682003	chr8:49865454	G/T	cg22283653	chr8:49824208	NA	0.42	7.91	0.36	2.25e-14	Sudden cardiac arrest;
LUAD	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg13736514	chr6:26305472	NA	-0.61	-11.42	-0.49	1.58e-26	Educational attainment;
LUAD	cis	rs965604	1.000	rs1062980	chr15:78792527	T/C	cg18825076	chr15:78729989	IREB2	0.43	7.36	0.34	9.83e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.61e-10	Prudent dietary pattern;
LUAD	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg09654669	chr8:57350985	NA	-0.65	-10.02	-0.44	2.42e-21	Obesity-related traits;
LUAD	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg13319975	chr6:146136371	FBXO30	-0.62	-10.83	-0.47	2.75e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg09796270	chr17:17721594	SREBF1	0.38	7.7	0.35	9.64e-14	Total body bone mineral density;
LUAD	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg27113419	chr16:58533979	NDRG4	-0.74	-6.54	-0.3	1.74e-10	Schizophrenia;
LUAD	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg24558204	chr6:135376177	HBS1L	0.46	7.86	0.36	3.32e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7680126	0.633	rs11728093	chr4:10296407	A/C	cg00071950	chr4:10020882	SLC2A9	-0.6	-8.23	-0.37	2.38e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg14343924	chr8:8086146	FLJ10661	-0.47	-7.3	-0.33	1.46e-12	Neuroticism;
LUAD	cis	rs7809950	1.000	rs2395883	chr7:107089670	T/C	cg23024343	chr7:107201750	COG5	-0.72	-12.28	-0.51	7.3e-30	Coronary artery disease;
LUAD	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg24579218	chr15:68104479	NA	-0.64	-9.92	-0.43	5.37e-21	Restless legs syndrome;
LUAD	cis	rs9394841	0.667	rs9471667	chr6:41776681	T/C	cg17623882	chr6:41773611	USP49	-0.51	-7.23	-0.33	2.35e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg26384229	chr12:38710491	ALG10B	0.5	8.37	0.38	8.25e-16	Heart rate;
LUAD	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg25985355	chr7:65971099	NA	0.55	6.84	0.32	2.8e-11	Diabetic kidney disease;
LUAD	cis	rs3752645	1.000	rs6971393	chr7:106781068	G/A	cg02696742	chr7:106810147	HBP1	-0.69	-6.46	-0.3	2.88e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs1395	0.710	rs72817533	chr2:27482612	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.47	8.03	0.36	9.87e-15	Blood metabolite levels;
LUAD	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg23625390	chr15:77176239	SCAPER	0.37	6.61	0.31	1.13e-10	Blood metabolite levels;
LUAD	cis	rs6987853	0.712	rs56220385	chr8:42428862	A/T	cg09913449	chr8:42400586	C8orf40	0.51	10.16	0.44	7.47e-22	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7027203	0.964	rs6479512	chr9:96556985	G/A	cg14598338	chr9:96623480	NA	0.38	7.59	0.35	2.12e-13	DNA methylation (variation);
LUAD	cis	rs4790333	0.562	rs2447104	chr17:2257532	C/T	cg27406664	chr17:2294951	MNT	0.4	7.93	0.36	1.93e-14	Proinsulin levels;
LUAD	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg16950941	chr11:66035639	RAB1B	0.43	7.25	0.33	2e-12	Gout;
LUAD	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg03467027	chr4:99064603	C4orf37	0.46	7.26	0.33	1.84e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.6e-10	Prudent dietary pattern;
LUAD	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.87	-0.32	2.37e-11	Height;
LUAD	trans	rs7395662	0.892	rs11040010	chr11:48776929	G/T	cg15704280	chr7:45808275	SEPT13	0.43	6.66	0.31	8.54e-11	HDL cholesterol;
LUAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08280861	chr8:58055591	NA	0.78	9.5	0.42	1.61e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg07917127	chr4:99064746	C4orf37	0.46	7.51	0.34	3.44e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg04772025	chr11:68637568	NA	0.56	9.01	0.4	7.03e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg26039829	chr8:22132926	PIWIL2	0.58	10.71	0.46	7.75e-24	Hypertriglyceridemia;
LUAD	cis	rs6842047	0.809	rs3087505	chr4:187179486	A/G	cg23442198	chr4:187126114	CYP4V2	0.96	9.57	0.42	8.84e-20	Blood protein levels;
LUAD	cis	rs17102423	0.594	rs942626	chr14:65550082	C/T	cg16583315	chr14:65563665	MAX	-0.35	-6.58	-0.3	1.36e-10	Obesity-related traits;
LUAD	cis	rs13095912	1.000	rs4686666	chr3:185342847	T/C	cg11274856	chr3:185301563	NA	0.38	7.59	0.35	2.03e-13	Systolic blood pressure;
LUAD	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.56	10.77	0.46	4.65e-24	Hemoglobin concentration;
LUAD	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg08601574	chr20:25228251	PYGB	-0.44	-8.05	-0.36	8.28e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg02421172	chr7:1938701	MAD1L1	0.46	6.67	0.31	7.89e-11	Bipolar disorder;
LUAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-8.02	-0.36	1.02e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs17253792	0.731	rs28587929	chr14:56097492	C/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs7945705	0.846	rs11042055	chr11:8756856	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.33	6.64	0.31	9.8e-11	Hemoglobin concentration;
LUAD	cis	rs11924390	0.800	rs5030059	chr3:186452455	C/G	cg12454167	chr3:186435060	KNG1	0.4	8.34	0.38	1.09e-15	Adiponectin levels;
LUAD	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg17480646	chr11:65405466	SIPA1	-0.44	-6.44	-0.3	3.19e-10	Acne (severe);
LUAD	cis	rs77972916	0.505	rs6756575	chr2:43528519	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.75	-10.6	-0.46	1.85e-23	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg22117172	chr7:91764530	CYP51A1	0.36	7.81	0.35	4.67e-14	Breast cancer;
LUAD	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg04756594	chr16:24857601	SLC5A11	0.5	9.95	0.44	4.21e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs7833986	0.501	rs2667978	chr8:56897951	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.85	13.56	0.55	4.69e-35	Height;
LUAD	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg07395648	chr5:131743802	NA	-0.38	-6.43	-0.3	3.53e-10	Breast cancer;
LUAD	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27297192	chr10:134578999	INPP5A	0.39	6.91	0.32	1.74e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.18	-0.33	3.19e-12	Blood metabolite levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18202627	chr2:200776533	C2orf69	-0.45	-6.9	-0.32	1.92e-11	Height;
LUAD	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg25817165	chr18:72167213	CNDP2	-0.72	-10.5	-0.45	4.49e-23	Refractive error;
LUAD	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.12	-0.33	4.66e-12	Coronary artery disease;
LUAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg02524346	chr8:600233	NA	1.1	10.6	0.46	1.92e-23	IgG glycosylation;
LUAD	cis	rs116248771	0.739	rs10276	chr3:158415166	C/T	cg16708174	chr3:158430962	RARRES1	0.46	6.65	0.31	9.19e-11	diarrhoeal disease at age 2;
LUAD	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg10518543	chr12:38710700	ALG10B	-0.51	-8.52	-0.38	2.83e-16	Morning vs. evening chronotype;
LUAD	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg02423579	chr7:2872169	GNA12	-0.54	-8.9	-0.4	1.62e-17	Height;
LUAD	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg26924012	chr15:45694286	SPATA5L1	1.02	19.06	0.68	6.2e-59	Homoarginine levels;
LUAD	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg03433033	chr1:76189801	ACADM	0.87	17.59	0.65	2.17e-52	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4906332	1.000	rs8004501	chr14:103981662	G/A	cg13511324	chr14:104056883	C14orf153	0.26	6.46	0.3	2.93e-10	Coronary artery disease;
LUAD	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.39	0.34	7.8e-13	Colorectal cancer;
LUAD	cis	rs12824058	0.737	rs2398508	chr12:130816460	G/A	cg24838063	chr12:130822603	PIWIL1	0.63	10.58	0.46	2.27e-23	Menopause (age at onset);
LUAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.45e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9341808	0.538	rs615585	chr6:80986153	T/C	cg08355045	chr6:80787529	NA	-0.4	-6.97	-0.32	1.22e-11	Sitting height ratio;
LUAD	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26314531	chr2:26401878	FAM59B	0.58	7.99	0.36	1.3e-14	Gut microbiome composition (summer);
LUAD	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg08742575	chr21:47604166	C21orf56	0.42	7.09	0.33	5.76e-12	Testicular germ cell tumor;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg10193671	chr17:79846205	THOC4	-0.36	-6.4	-0.3	4.02e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg02423579	chr7:2872169	GNA12	-0.55	-9.17	-0.41	2.1e-18	Height;
LUAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg11494091	chr17:61959527	GH2	0.74	18.45	0.67	3.25e-56	Prudent dietary pattern;
LUAD	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg25985355	chr7:65971099	NA	-0.5	-7.01	-0.32	9.23e-12	Diabetic kidney disease;
LUAD	cis	rs6087990	0.765	rs6058900	chr20:31400673	T/C	cg13636640	chr20:31349939	DNMT3B	0.74	13.72	0.55	1.07e-35	Ulcerative colitis;
LUAD	cis	rs2213920	0.516	rs13301972	chr9:118158086	C/T	cg13918206	chr9:118159781	DEC1	-0.61	-6.74	-0.31	5.17e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LUAD	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg14671364	chr1:107599128	PRMT6	0.52	8.08	0.37	6.73e-15	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg08885076	chr2:99613938	TSGA10	0.36	6.48	0.3	2.56e-10	Chronic sinus infection;
LUAD	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg13057898	chr1:3703894	LRRC47	0.63	10.69	0.46	8.72e-24	Red cell distribution width;
LUAD	cis	rs2735413	0.918	rs7190752	chr16:78077430	T/C	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs6456156	0.846	rs204293	chr6:167514481	T/C	cg07741184	chr6:167504864	NA	0.28	6.4	0.3	4.24e-10	Primary biliary cholangitis;
LUAD	cis	rs11229555	0.609	rs12575080	chr11:58224917	A/G	cg15696309	chr11:58395628	NA	-0.8	-10.78	-0.46	4.04e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs909002	0.849	rs10914456	chr1:32088171	T/C	cg13919466	chr1:32135498	COL16A1	-0.35	-8.18	-0.37	3.35e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg21775007	chr8:11205619	TDH	0.38	6.84	0.32	2.85e-11	Retinal vascular caliber;
LUAD	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg05340658	chr4:99064831	C4orf37	0.58	9.82	0.43	1.23e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg00280220	chr17:61926910	NA	0.36	6.96	0.32	1.34e-11	Prudent dietary pattern;
LUAD	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.91	-0.4	1.59e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.77	-0.35	5.84e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7665090	0.870	rs228614	chr4:103578637	G/A	cg07973026	chr4:103553119	MANBA	-0.38	-6.6	-0.31	1.25e-10	Primary biliary cholangitis;
LUAD	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg13511324	chr14:104056883	C14orf153	-0.29	-7.11	-0.33	5.11e-12	Reticulocyte count;
LUAD	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg24578937	chr1:2090814	PRKCZ	-0.59	-11.43	-0.49	1.5e-26	Height;
LUAD	cis	rs4790333	0.571	rs2012068	chr17:2255351	C/T	cg27406664	chr17:2294951	MNT	0.42	8.31	0.37	1.35e-15	Proinsulin levels;
LUAD	trans	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.59	10.1	0.44	1.22e-21	Brugada syndrome;
LUAD	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg25566285	chr7:158114605	PTPRN2	-0.45	-8.47	-0.38	4.05e-16	Calcium levels;
LUAD	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.54	-9.12	-0.41	2.96e-18	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg17366294	chr4:99064904	C4orf37	0.65	12.41	0.52	2.33e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6840360	0.555	rs4554052	chr4:152726610	T/C	cg22705602	chr4:152727874	NA	0.45	8.64	0.39	1.16e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs62238980	0.614	rs117441849	chr22:32489297	T/A	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs6496044	0.507	rs8034676	chr15:86159262	C/T	cg13263323	chr15:86062960	AKAP13	-0.39	-6.82	-0.31	3.21e-11	Interstitial lung disease;
LUAD	cis	rs1595825	0.735	rs2164327	chr2:198726773	C/T	cg10547527	chr2:198650123	BOLL	-0.54	-7.8	-0.35	4.87e-14	Ulcerative colitis;
LUAD	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg22852734	chr6:133119734	C6orf192	0.96	7.23	0.33	2.32e-12	Type 2 diabetes nephropathy;
LUAD	cis	rs4523957	0.820	rs216193	chr17:2203453	A/G	cg16513277	chr17:2031491	SMG6	0.74	14.07	0.56	3.82e-37	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6684514	1.000	rs3806408	chr1:156252137	C/A	cg16558208	chr1:156270281	VHLL	0.53	9.58	0.42	8.12e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs7731657	0.537	rs72801791	chr5:130374799	T/C	cg08523029	chr5:130500466	HINT1	-0.59	-7.59	-0.35	2e-13	Fasting plasma glucose;
LUAD	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg17173187	chr15:85201210	NMB	0.4	6.36	0.3	5.21e-10	Schizophrenia;
LUAD	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg13606994	chr1:44402422	ARTN	-0.37	-7.24	-0.33	2.09e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs807669	0.525	rs2073740	chr22:19196112	A/C	cg02655711	chr22:19163373	SLC25A1	-0.58	-11.19	-0.48	1.22e-25	Metabolite levels;
LUAD	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg23758822	chr17:41437982	NA	0.89	17.7	0.65	7.13e-53	Menopause (age at onset);
LUAD	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg23758822	chr17:41437982	NA	0.87	13.45	0.55	1.34e-34	Menopause (age at onset);
LUAD	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.46	7.64	0.35	1.47e-13	Lung cancer in ever smokers;
LUAD	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg24531977	chr5:56204891	C5orf35	-0.63	-10.23	-0.45	4.21e-22	Coronary artery disease;
LUAD	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg01475377	chr6:109611718	NA	-0.55	-10.25	-0.45	3.66e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.61	0.31	1.14e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg10591111	chr5:226296	SDHA	-0.55	-7.19	-0.33	3e-12	Breast cancer;
LUAD	trans	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg12400702	chr3:12838781	CAND2	0.31	6.38	0.3	4.7e-10	Parkinson's disease;
LUAD	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg16797656	chr11:68205561	LRP5	0.53	11.49	0.49	8.53e-27	Total body bone mineral density;
LUAD	trans	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg26043149	chr18:55253948	FECH	1.07	18.27	0.66	2.25e-55	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg27284194	chr4:1044797	NA	0.69	9.51	0.42	1.51e-19	Recombination rate (females);
LUAD	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg07917127	chr4:99064746	C4orf37	0.42	6.89	0.32	2.05e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6785206	0.892	rs6439143	chr3:128425132	C/T	cg16766828	chr3:128327626	NA	-0.79	-8.56	-0.38	2.17e-16	Lymphocyte percentage of white cells;
LUAD	cis	rs62400317	0.826	rs62400290	chr6:45209788	C/T	cg20913747	chr6:44695427	NA	-0.42	-6.51	-0.3	2.14e-10	Total body bone mineral density;
LUAD	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg02551604	chr5:131831745	NA	-0.58	-9.9	-0.43	6.18e-21	Asthma (sex interaction);
LUAD	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03352830	chr11:487213	PTDSS2	0.82	10.47	0.45	5.68e-23	Body mass index;
LUAD	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg03676636	chr4:99064102	C4orf37	0.31	8.06	0.36	7.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.16	-0.41	2.26e-18	Life satisfaction;
LUAD	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.56	-9.55	-0.42	1.1e-19	Menarche (age at onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11814422	chr18:47018265	SNORD58A;RPL17;SNORD58B	-0.47	-7.83	-0.36	3.95e-14	Height;
LUAD	cis	rs13064411	0.518	rs9852703	chr3:113189368	C/T	cg10517650	chr3:113235015	CCDC52	0.38	7.22	0.33	2.42e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08677398	chr8:58056175	NA	0.48	6.84	0.32	2.87e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg10792982	chr14:105748885	BRF1	0.44	8.84	0.39	2.65e-17	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.33e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg00666640	chr1:248458726	OR2T12	0.29	7.1	0.33	5.37e-12	Common traits (Other);
LUAD	cis	rs2274273	0.870	rs10147434	chr14:55674847	C/T	cg04306507	chr14:55594613	LGALS3	0.41	8.48	0.38	3.89e-16	Protein biomarker;
LUAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg10802521	chr3:52805072	NEK4	-0.46	-7.78	-0.35	5.72e-14	Electroencephalogram traits;
LUAD	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg26597838	chr10:835615	NA	0.84	11.61	0.49	3.06e-27	Eosinophil percentage of granulocytes;
LUAD	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg18827107	chr12:86230957	RASSF9	-0.54	-9.52	-0.42	1.35e-19	Major depressive disorder;
LUAD	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg23229984	chr5:148520753	ABLIM3	0.49	7.68	0.35	1.13e-13	Breast cancer;
LUAD	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg11845111	chr2:191398756	TMEM194B	-0.84	-10.69	-0.46	9.17e-24	Diastolic blood pressure;
LUAD	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg05754148	chr16:3507555	NAT15	0.79	10.53	0.46	3.59e-23	Tuberculosis;
LUAD	cis	rs9826463	0.702	rs73228757	chr3:142320081	A/G	cg20824294	chr3:142316082	PLS1	0.47	7.98	0.36	1.43e-14	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	trans	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.67	-12.78	-0.53	7.66e-32	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg00933542	chr6:150070202	PCMT1	0.42	8.96	0.4	1.01e-17	Lung cancer;
LUAD	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg23625390	chr15:77176239	SCAPER	0.39	6.83	0.31	3.05e-11	Blood metabolite levels;
LUAD	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	10.64	0.46	1.41e-23	Hip circumference adjusted for BMI;
LUAD	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg01788221	chr16:89496183	ANKRD11	0.34	6.48	0.3	2.49e-10	Multiple myeloma (IgH translocation);
LUAD	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg00717180	chr2:96193071	NA	-0.46	-8.44	-0.38	5.21e-16	Coronary artery disease;
LUAD	trans	rs7395662	1.000	rs11039819	chr11:48562181	G/T	cg15704280	chr7:45808275	SEPT13	-0.43	-6.69	-0.31	7.17e-11	HDL cholesterol;
LUAD	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12667521	chr19:29218732	NA	0.51	7.14	0.33	4.07e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.38	-6.5	-0.3	2.25e-10	Platelet count;
LUAD	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg14895029	chr7:2775587	GNA12	-0.42	-6.85	-0.32	2.67e-11	Height;
LUAD	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg19717773	chr7:2847554	GNA12	-0.52	-10.09	-0.44	1.32e-21	Height;
LUAD	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.36	7.6	0.35	1.92e-13	Parkinson's disease;
LUAD	cis	rs7737355	0.898	rs2161414	chr5:131063073	C/T	cg06307176	chr5:131281290	NA	0.52	8.19	0.37	3.21e-15	Life satisfaction;
LUAD	cis	rs4711350	0.765	rs2395446	chr6:33743264	C/T	cg18005901	chr6:33739558	LEMD2	-0.62	-10.16	-0.44	7.67e-22	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg03676636	chr4:99064102	C4orf37	0.32	8.43	0.38	5.45e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg03453431	chr7:157225567	NA	-0.41	-7.01	-0.32	9.3e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.5	6.88	0.32	2.22e-11	Platelet count;
LUAD	cis	rs72772090	0.539	rs3334	chr5:96115085	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.33	-0.34	1.15e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs57590327	0.527	rs11917558	chr3:81610805	G/A	cg07356753	chr3:81810745	GBE1	-0.49	-7.52	-0.34	3.23e-13	Extraversion;
LUAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg00383909	chr3:49044727	WDR6	0.89	9.19	0.41	1.76e-18	Blood protein levels;
LUAD	cis	rs9287719	0.625	rs7567304	chr2:10790029	T/C	cg03983476	chr2:10830698	NOL10	0.4	6.68	0.31	7.36e-11	Prostate cancer;
LUAD	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg17480646	chr11:65405466	SIPA1	-0.46	-6.85	-0.32	2.57e-11	Acne (severe);
LUAD	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg04586622	chr2:25135609	ADCY3	0.37	8.54	0.38	2.41e-16	Body mass index;
LUAD	cis	rs17095355	1.000	rs752584	chr10:111682934	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.64	-7.73	-0.35	8.1e-14	Biliary atresia;
LUAD	cis	rs7833986	1.000	rs7833986	chr8:57100149	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	8.28	0.37	1.64e-15	Height;
LUAD	cis	rs7945705	0.818	rs10769948	chr11:8761782	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-8.04	-0.36	9.25e-15	Hemoglobin concentration;
LUAD	cis	rs17152411	0.895	rs7086128	chr10:126587373	A/G	cg07906193	chr10:126599966	NA	0.5	7.17	0.33	3.3e-12	Height;
LUAD	cis	rs77741769	0.571	rs1696357	chr12:121348649	A/G	cg02419362	chr12:121203948	SPPL3	0.37	7.53	0.34	3.16e-13	Mean corpuscular volume;
LUAD	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg19041857	chr6:27730383	NA	-0.43	-7.39	-0.34	8.11e-13	Parkinson's disease;
LUAD	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	7.49	0.34	4.07e-13	Cognitive test performance;
LUAD	cis	rs959260	0.588	rs7219	chr17:73315368	A/G	cg07104495	chr17:73266070	MIF4GD	0.32	7.85	0.36	3.34e-14	Systemic lupus erythematosus;
LUAD	cis	rs12505328	1.000	rs12505328	chr4:174378004	C/T	cg12145043	chr4:174357286	NA	0.58	10.63	0.46	1.44e-23	Chin dimples;
LUAD	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10802521	chr3:52805072	NEK4	0.54	9.07	0.4	4.37e-18	Bipolar disorder;
LUAD	cis	rs2797160	1.000	rs13328298	chr6:126016580	G/A	cg05901451	chr6:126070800	HEY2	0.44	6.52	0.3	2.03e-10	Endometrial cancer;
LUAD	cis	rs4691139	0.903	rs6812776	chr4:165920249	T/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.44	-8.48	-0.38	3.85e-16	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs1003719	1.000	rs1003719	chr21:38491095	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.49	8.09	0.37	6.43e-15	Eye color traits;
LUAD	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg11189052	chr15:85197271	WDR73	0.6	7.83	0.36	3.93e-14	Schizophrenia;
LUAD	cis	rs9868809	0.881	rs13096357	chr3:48675856	C/A	cg00383909	chr3:49044727	WDR6	0.62	6.91	0.32	1.74e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg20302342	chr1:156215951	PAQR6	0.39	8.68	0.39	8.92e-17	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.67	0.35	1.16e-13	Bladder cancer;
LUAD	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg26668828	chr6:292823	DUSP22	-0.58	-9.97	-0.44	3.54e-21	Menopause (age at onset);
LUAD	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg06558623	chr16:89946397	TCF25	1.14	10.37	0.45	1.38e-22	Skin colour saturation;
LUAD	cis	rs870825	0.616	rs7667449	chr4:185641711	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.64	0.55	2.32e-35	Blood protein levels;
LUAD	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg02493740	chr2:85810744	VAMP5	-0.45	-8.14	-0.37	4.58e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg25456477	chr12:86230367	RASSF9	0.33	6.36	0.3	5.15e-10	Major depressive disorder;
LUAD	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg05579598	chr16:88989069	CBFA2T3	-0.32	-6.72	-0.31	5.93e-11	Social autistic-like traits;
LUAD	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg22920501	chr2:26401640	FAM59B	-0.96	-14.49	-0.58	6.58e-39	Gut microbiome composition (summer);
LUAD	cis	rs2996428	0.593	rs7513053	chr1:3709487	A/G	cg17848003	chr1:3704513	LRRC47	0.49	9.69	0.43	3.56e-20	Red cell distribution width;
LUAD	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4891159	0.756	rs8084155	chr18:74134952	A/G	cg24786174	chr18:74118243	ZNF516	-0.82	-18.23	-0.66	3.32e-55	Longevity;
LUAD	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg16988262	chr1:15930761	NA	0.41	6.82	0.31	3.07e-11	Systolic blood pressure;
LUAD	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.62	-0.31	1.11e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs12612619	0.732	rs11681562	chr2:27250603	A/G	cg00617064	chr2:27272375	NA	-0.37	-6.79	-0.31	3.88e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs89107	0.576	rs17825652	chr6:118788986	G/A	cg21191810	chr6:118973309	C6orf204	0.41	7.55	0.34	2.7e-13	Cardiac structure and function;
LUAD	trans	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-9.61	-0.42	6.76e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.63e-10	Prudent dietary pattern;
LUAD	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg02807482	chr3:125708958	NA	-0.56	-7.9	-0.36	2.5e-14	Blood pressure (smoking interaction);
LUAD	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg16479474	chr6:28041457	NA	0.44	7.4	0.34	7.22e-13	Depression;
LUAD	trans	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg01620082	chr3:125678407	NA	-0.46	-6.76	-0.31	4.61e-11	Depression;
LUAD	trans	rs7395662	0.791	rs12273724	chr11:48845710	G/A	cg15704280	chr7:45808275	SEPT13	0.42	6.62	0.31	1.06e-10	HDL cholesterol;
LUAD	cis	rs8058578	1.000	rs67128646	chr16:30672097	A/C	cg02466173	chr16:30829666	NA	-0.7	-11.83	-0.5	4.17e-28	Multiple myeloma;
LUAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg11965913	chr1:205819406	PM20D1	0.64	11.84	0.5	4.12e-28	Menarche (age at onset);
LUAD	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg26384229	chr12:38710491	ALG10B	0.41	6.52	0.3	1.99e-10	Morning vs. evening chronotype;
LUAD	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg18755752	chr8:142205143	DENND3	-0.45	-7.76	-0.35	6.59e-14	Immature fraction of reticulocytes;
LUAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg18402987	chr7:1209562	NA	0.8	9.85	0.43	9.51e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg08027265	chr7:2291960	NA	-0.43	-7.23	-0.33	2.3e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg25703541	chr22:24373054	LOC391322	-0.85	-16.45	-0.62	2.35e-47	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	14.38	0.57	1.92e-38	Smoking behavior;
LUAD	trans	rs747782	0.528	rs4370963	chr11:48433943	C/G	cg03929089	chr4:120376271	NA	0.55	6.45	0.3	3.1e-10	Intraocular pressure;
LUAD	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg08523384	chr5:141488047	NDFIP1	-0.48	-7.31	-0.33	1.32e-12	Crohn's disease;
LUAD	cis	rs4903604	0.505	rs11623595	chr14:78037547	A/G	cg18872420	chr14:78023429	SPTLC2	0.47	8.55	0.38	2.28e-16	Gut microbiome composition (winter);
LUAD	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.79	0.31	3.92e-11	Parkinson's disease;
LUAD	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg22535103	chr8:58192502	C8orf71	-0.62	-6.67	-0.31	7.84e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7300001	0.504	rs12318462	chr12:110504717	C/A	cg12870014	chr12:110450643	ANKRD13A	0.89	8.09	0.37	6.5e-15	Headache;
LUAD	cis	rs2050392	0.590	rs303433	chr10:30714963	A/T	cg18806716	chr10:30721971	MAP3K8	-0.76	-16.19	-0.62	3.22e-46	Inflammatory bowel disease;
LUAD	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg15790184	chr11:494944	RNH1	0.48	7.64	0.35	1.42e-13	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs2742234	0.590	rs741968	chr10:43611708	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.5	-8.44	-0.38	5.15e-16	Hirschsprung disease;
LUAD	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg11871910	chr12:69753446	YEATS4	0.71	12.0	0.5	9.02e-29	Blood protein levels;
LUAD	cis	rs7932354	0.528	rs10838660	chr11:47152273	C/T	cg19486271	chr11:47235900	DDB2	-0.47	-7.46	-0.34	5.02e-13	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg18132916	chr6:79620363	NA	-0.44	-7.56	-0.34	2.59e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg19761014	chr17:28927070	LRRC37B2	0.74	7.6	0.35	1.87e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg19622623	chr12:86230825	RASSF9	-0.47	-8.1	-0.37	5.96e-15	Major depressive disorder;
LUAD	cis	rs8040855	0.599	rs4577058	chr15:85726458	T/C	cg04831495	chr15:85060580	GOLGA6L5	0.45	7.8	0.35	5.05e-14	Bulimia nervosa;
LUAD	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19346786	chr7:2764209	NA	-0.55	-12.34	-0.51	4.31e-30	Height;
LUAD	cis	rs9463078	0.665	rs227849	chr6:44698708	C/T	cg25276700	chr6:44698697	NA	0.36	6.83	0.32	2.98e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUAD	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg23815491	chr16:72088622	HP	0.48	8.52	0.38	2.87e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs12612619	0.732	rs10432697	chr2:27272052	T/C	cg00617064	chr2:27272375	NA	-0.37	-7.12	-0.33	4.8e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg26354017	chr1:205819088	PM20D1	0.63	11.86	0.5	3.37e-28	Menarche (age at onset);
LUAD	cis	rs12912251	0.591	rs2643216	chr15:39003809	C/G	cg01338139	chr15:38987640	C15orf53	0.49	6.59	0.3	1.34e-10	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg17264618	chr3:40429014	ENTPD3	0.42	9.08	0.4	4.23e-18	Renal cell carcinoma;
LUAD	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.72	-0.35	8.21e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2485376	0.904	rs10786662	chr10:103989812	G/C	cg20641465	chr10:103991465	PITX3	0.52	9.49	0.42	1.73e-19	QT interval;
LUAD	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg22532475	chr10:104410764	TRIM8	-0.47	-9.26	-0.41	1.06e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2387326	0.717	rs10829337	chr10:129943548	T/C	cg16087940	chr10:129947807	NA	-0.65	-9.09	-0.4	3.81e-18	Select biomarker traits;
LUAD	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg05768032	chr16:30646687	NA	0.46	7.97	0.36	1.45e-14	Multiple myeloma;
LUAD	cis	rs1371614	0.592	rs12613534	chr2:27138594	C/A	cg00617064	chr2:27272375	NA	0.34	6.5	0.3	2.32e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg18132916	chr6:79620363	NA	-0.44	-7.57	-0.35	2.42e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4642101	0.680	rs7626609	chr3:12806080	A/G	cg24848339	chr3:12840334	CAND2	-0.34	-6.57	-0.3	1.45e-10	QRS complex (12-leadsum);
LUAD	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg15557168	chr22:42548783	NA	-0.36	-6.4	-0.3	4.07e-10	Cognitive function;
LUAD	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg24558204	chr6:135376177	HBS1L	0.47	7.9	0.36	2.39e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg23018236	chr17:30244563	NA	0.67	8.07	0.37	7.43e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg12310025	chr6:25882481	NA	-0.97	-17.39	-0.65	1.66e-51	Urate levels;
LUAD	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg02734326	chr4:10020555	SLC2A9	0.54	9.72	0.43	2.73e-20	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg14582100	chr15:45693742	SPATA5L1	0.64	12.5	0.52	9.64e-31	Homoarginine levels;
LUAD	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.66	-0.39	9.95e-17	Total body bone mineral density;
LUAD	cis	rs7927771	0.524	rs11039345	chr11:47720228	A/G	cg18512352	chr11:47633146	NA	0.37	6.51	0.3	2.19e-10	Subjective well-being;
LUAD	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-7.65	-0.35	1.38e-13	Blood metabolite levels;
LUAD	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg03388025	chr16:89894329	SPIRE2	0.5	13.14	0.54	2.65e-33	Vitiligo;
LUAD	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.84	12.21	0.51	1.38e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg17724175	chr1:150552817	MCL1	0.38	8.69	0.39	7.78e-17	Melanoma;
LUAD	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12588279	chr6:26043732	HIST1H2BB	0.39	6.44	0.3	3.31e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06028808	chr11:68637592	NA	0.43	7.33	0.34	1.21e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg06623918	chr6:96969491	KIAA0776	0.89	17.65	0.65	1.27e-52	Headache;
LUAD	cis	rs490234	0.586	rs3122934	chr9:128154100	C/G	cg14078157	chr9:128172775	NA	0.42	7.9	0.36	2.42e-14	Mean arterial pressure;
LUAD	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg24690094	chr11:67383802	NA	-0.43	-6.69	-0.31	7.08e-11	Mean corpuscular volume;
LUAD	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg23587288	chr2:27483067	SLC30A3	-0.4	-7.23	-0.33	2.22e-12	Blood metabolite levels;
LUAD	cis	rs12900413	0.687	rs12903462	chr15:90304075	C/T	cg24249390	chr15:90295951	MESP1	-0.36	-7.12	-0.33	4.66e-12	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg25753631	chr6:25732923	NA	-0.44	-7.76	-0.35	6.26e-14	Iron status biomarkers;
LUAD	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg16060761	chr17:80687452	NA	-0.6	-8.7	-0.39	7.49e-17	Glycated hemoglobin levels;
LUAD	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg07870213	chr5:140052090	DND1	1.04	14.68	0.58	9.9e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg19901956	chr11:77921274	USP35	-0.47	-6.62	-0.31	1.12e-10	Testicular germ cell tumor;
LUAD	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg25985355	chr7:65971099	NA	-0.55	-6.74	-0.31	5.08e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg03467027	chr4:99064603	C4orf37	0.41	6.75	0.31	4.81e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg18944383	chr4:111397179	ENPEP	0.39	7.83	0.36	3.87e-14	Height;
LUAD	cis	rs9560113	0.580	rs9560115	chr13:112193619	G/A	cg10483660	chr13:112241077	NA	0.42	8.28	0.37	1.63e-15	Menarche (age at onset);
LUAD	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg04398451	chr17:18023971	MYO15A	0.7	12.65	0.52	2.53e-31	Total body bone mineral density;
LUAD	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg25427524	chr10:38739819	LOC399744	-0.79	-13.58	-0.55	4.02e-35	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg14784868	chr12:69753453	YEATS4	0.41	6.58	0.3	1.42e-10	Blood protein levels;
LUAD	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg27432699	chr2:27873401	GPN1	0.63	11.65	0.49	2.12e-27	Oral cavity cancer;
LUAD	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.39	-6.98	-0.32	1.17e-11	Tonsillectomy;
LUAD	cis	rs7107174	1.000	rs2511170	chr11:77980582	A/G	cg02023728	chr11:77925099	USP35	0.5	7.97	0.36	1.44e-14	Testicular germ cell tumor;
LUAD	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg04450456	chr4:17643702	FAM184B	0.36	6.75	0.31	5.03e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg07776626	chr8:57350775	NA	-0.65	-9.42	-0.42	3.02e-19	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.62	0.31	1.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg17602776	chr5:178977377	RUFY1	-0.6	-6.56	-0.3	1.55e-10	Type 2 diabetes;
LUAD	trans	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg14917512	chr19:3094685	GNA11	0.56	6.69	0.31	7e-11	Diabetic kidney disease;
LUAD	trans	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	10.52	0.46	3.64e-23	Type 2 diabetes;
LUAD	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg09796270	chr17:17721594	SREBF1	0.37	6.97	0.32	1.19e-11	Total body bone mineral density;
LUAD	cis	rs656900	0.715	rs673018	chr15:80115347	C/T	cg02196730	chr15:80188777	MTHFS	-0.4	-6.83	-0.32	3e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg15226275	chr6:116381976	FRK	0.23	7.64	0.35	1.49e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.55	-9.99	-0.44	3.06e-21	Longevity;Endometriosis;
LUAD	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg22681709	chr2:178499509	PDE11A	-0.47	-7.75	-0.35	7.05e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26342734	chr17:7211307	EIF5A	-0.72	-7.27	-0.33	1.72e-12	Type 2 diabetes;
LUAD	trans	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg06606381	chr12:133084897	FBRSL1	-0.59	-8.56	-0.38	2.17e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs500891	0.525	rs12697921	chr6:84071913	G/C	cg08257003	chr6:84140564	ME1	0.35	6.78	0.31	4.17e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.99	0.32	1.08e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2996428	0.628	rs6667526	chr1:3774603	G/A	cg22529645	chr1:3704559	LRRC47	0.56	10.04	0.44	2e-21	Red cell distribution width;
LUAD	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	10.03	0.44	2.29e-21	Ileal carcinoids;
LUAD	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6138458	1.000	rs227627	chr20:24912107	T/C	cg06937882	chr20:24974362	C20orf3	-0.33	-6.43	-0.3	3.52e-10	Blood protein levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg17605604	chr5:102612899	C5orf30	0.42	7.07	0.33	6.28e-12	Schizophrenia;
LUAD	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23158103	chr7:148848205	ZNF398	-0.65	-12.34	-0.51	4.42e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7010267	0.744	rs2062377	chr8:120007420	T/A	cg01975934	chr8:119970761	NA	-0.37	-6.89	-0.32	1.99e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.35	6.92	0.32	1.73e-11	Obesity-related traits;
LUAD	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg05342682	chr7:94953680	PON1	-0.5	-6.94	-0.32	1.44e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg26384229	chr12:38710491	ALG10B	0.49	7.93	0.36	2.03e-14	Morning vs. evening chronotype;
LUAD	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg23992470	chr4:843637	GAK	0.7	7.28	0.33	1.65e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2692947	0.683	rs62153700	chr2:96581338	C/T	cg23100626	chr2:96804247	ASTL	0.34	7.75	0.35	7.05e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg24818145	chr4:99064322	C4orf37	0.5	7.38	0.34	8.39e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg17849569	chr6:28058911	ZSCAN12L1	-0.32	-7.2	-0.33	2.72e-12	Parkinson's disease;
LUAD	cis	rs12618769	0.652	rs3203856	chr2:99226021	C/T	cg10123293	chr2:99228465	UNC50	0.51	8.79	0.39	3.88e-17	Bipolar disorder;
LUAD	cis	rs939658	0.805	rs35462901	chr15:79442201	C/T	cg17916960	chr15:79447300	NA	-0.54	-11.31	-0.48	4.22e-26	Refractive error;
LUAD	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg07570687	chr10:102243282	WNT8B	0.46	6.78	0.31	4.11e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs62238980	0.614	rs77017871	chr22:32382145	T/C	cg02631450	chr22:32366979	NA	0.79	6.46	0.3	2.9e-10	Childhood ear infection;
LUAD	cis	rs2692947	0.566	rs11676901	chr2:96370571	A/C	cg23100626	chr2:96804247	ASTL	0.33	8.04	0.36	8.98e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2485376	1.000	rs772021	chr10:104036449	A/T	cg20641465	chr10:103991465	PITX3	-0.53	-9.3	-0.41	7.63e-19	QT interval;
LUAD	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg08645402	chr16:4508243	NA	0.57	10.67	0.46	1.05e-23	Schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04587886	chr11:719633	EPS8L2	0.48	6.4	0.3	4.12e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs62458065	0.640	rs10241303	chr7:32534203	T/G	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.65	-0.35	1.41e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03207732	chr7:54826613	SEC61G	-0.54	-6.63	-0.31	1.01e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg25894440	chr7:65020034	NA	-0.61	-6.61	-0.31	1.15e-10	Diabetic kidney disease;
LUAD	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.47	6.95	0.32	1.36e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-6.97	-0.32	1.24e-11	Longevity;Endometriosis;
LUAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00149659	chr3:10157352	C3orf10	0.61	8.68	0.39	8.54e-17	Alzheimer's disease;
LUAD	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg11645453	chr3:52864694	ITIH4	-0.34	-6.47	-0.3	2.79e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg14893161	chr1:205819251	PM20D1	-0.44	-7.42	-0.34	6.38e-13	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-7.08	-0.33	5.91e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-6.41	-0.3	3.78e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12760731	0.720	rs10913560	chr1:178452629	A/G	cg00404053	chr1:178313656	RASAL2	0.66	8.3	0.37	1.39e-15	Obesity-related traits;
LUAD	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg08280861	chr8:58055591	NA	-0.53	-6.93	-0.32	1.62e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs928736	0.599	rs1000005	chr21:34433051	C/G	cg10915739	chr21:34405733	NA	0.3	6.39	0.3	4.32e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg20290983	chr6:43655470	MRPS18A	0.93	13.51	0.55	7.89e-35	IgG glycosylation;
LUAD	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg18350739	chr11:68623251	NA	-0.37	-6.38	-0.3	4.69e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg26587870	chr6:27730563	NA	-0.5	-8.42	-0.38	6.01e-16	Parkinson's disease;
LUAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg07217954	chr7:1067459	C7orf50	0.43	6.59	0.3	1.34e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.52	-9.17	-0.41	2.09e-18	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg11301795	chr4:187892539	NA	-0.77	-15.57	-0.6	1.59e-43	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12545109	0.917	rs10098993	chr8:57323116	T/C	cg09654669	chr8:57350985	NA	-0.67	-9.3	-0.41	7.59e-19	Obesity-related traits;
LUAD	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg15557168	chr22:42548783	NA	0.37	6.4	0.3	4.24e-10	Cognitive function;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg02768471	chr1:155231827	SCAMP3	-0.43	-6.36	-0.3	5.2e-10	Blood protein levels;
LUAD	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-12.05	-0.51	6.11e-29	Bone mineral density;
LUAD	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.54	-0.34	2.96e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.12e-14	Prostate cancer;
LUAD	trans	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg14917512	chr19:3094685	GNA11	-0.55	-6.52	-0.3	1.95e-10	Diabetic kidney disease;
LUAD	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg06641503	chr3:48959341	ARIH2	-0.41	-7.98	-0.36	1.38e-14	Parkinson's disease;
LUAD	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg11707310	chr1:2537719	MMEL1	-0.37	-7.86	-0.36	3.16e-14	Ulcerative colitis;
LUAD	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11644478	chr21:40555479	PSMG1	-0.42	-7.0	-0.32	1.03e-11	Menarche (age at onset);
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09581281	chr1:15853227	DNAJC16	0.42	6.5	0.3	2.29e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	trans	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg26043149	chr18:55253948	FECH	-0.42	-6.89	-0.32	2.04e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg27170947	chr2:26402098	FAM59B	-0.82	-11.49	-0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs3736594	0.513	rs62131881	chr2:27764781	G/T	cg27432699	chr2:27873401	GPN1	0.47	6.43	0.3	3.55e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg06558623	chr16:89946397	TCF25	0.7	7.94	0.36	1.9e-14	Skin colour saturation;
LUAD	cis	rs2455601	0.638	rs11042148	chr11:9008674	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-8.14	-0.37	4.52e-15	Schizophrenia;
LUAD	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.66	-0.35	1.29e-13	Alzheimer's disease (late onset);
LUAD	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.38	-0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs7799006	0.755	rs12534131	chr7:2294123	C/T	cg08027265	chr7:2291960	NA	-0.73	-14.98	-0.59	5.24e-41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs72772090	0.710	rs11745122	chr5:96060738	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-6.78	-0.31	4.05e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg06558623	chr16:89946397	TCF25	1.18	10.43	0.45	8.3e-23	Skin colour saturation;
LUAD	cis	rs939584	1.000	rs7570198	chr2:648198	C/T	cg03444855	chr2:621920	NA	-0.39	-6.53	-0.3	1.91e-10	Body mass index;
LUAD	cis	rs1670533	1.000	rs935971	chr4:1045265	G/A	cg27284194	chr4:1044797	NA	0.72	9.84	0.43	1.03e-20	Recombination rate (females);
LUAD	trans	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg04775059	chr7:64541387	NA	0.52	6.77	0.31	4.39e-11	Aortic root size;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10719100	chr8:146078187	COMMD5	-0.54	-6.46	-0.3	2.96e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-10.44	-0.45	7.57e-23	Bipolar disorder;
LUAD	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg09117114	chr16:67998030	SLC12A4	-0.53	-6.88	-0.32	2.1e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs68170813	0.559	rs76843318	chr7:106863173	A/G	cg02696742	chr7:106810147	HBP1	-0.78	-10.71	-0.46	7.76e-24	Coronary artery disease;
LUAD	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.11	-0.37	5.52e-15	Diabetic kidney disease;
LUAD	cis	rs7584330	0.554	rs13431733	chr2:238430275	A/G	cg14458575	chr2:238380390	NA	0.63	9.91	0.43	5.95e-21	Prostate cancer;
LUAD	cis	rs1953600	0.645	rs2819950	chr10:81935279	G/A	cg00277334	chr10:82204260	NA	0.42	7.3	0.33	1.46e-12	Sarcoidosis;
LUAD	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg03037974	chr15:76606532	NA	0.38	8.48	0.38	3.69e-16	Blood metabolite levels;
LUAD	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.49	-7.98	-0.36	1.39e-14	Multiple sclerosis;
LUAD	cis	rs10540	0.584	rs10751658	chr11:437401	C/G	cg03934478	chr11:495069	RNH1	-0.49	-6.67	-0.31	7.84e-11	Body mass index;
LUAD	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg05616858	chr17:37843591	ERBB2;PGAP3	0.35	6.83	0.32	2.99e-11	Asthma;
LUAD	cis	rs17532515	0.505	rs1472268	chr4:141492943	A/T	cg09181644	chr4:141490428	UCP1	-0.38	-7.83	-0.36	4.03e-14	Select biomarker traits;
LUAD	cis	rs2742417	1.000	rs2249357	chr3:45758381	C/A	cg10512202	chr3:45649293	LIMD1	0.39	7.08	0.33	6.21e-12	Response to anti-depressant treatment in major depressive disorder;
LUAD	trans	rs800082	0.668	rs7643301	chr3:144293612	G/A	cg24215973	chr2:240111563	HDAC4	-0.6	-9.92	-0.43	5.57e-21	Smoking behavior;
LUAD	cis	rs728616	0.681	rs56184245	chr10:82018556	C/T	cg27171509	chr10:82033454	MAT1A	-0.59	-6.4	-0.3	4.25e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs4336470	0.547	rs9499924	chr6:105142638	C/G	cg02098413	chr6:105308735	HACE1	-0.41	-8.53	-0.38	2.61e-16	Neuroblastoma;
LUAD	cis	rs7818345	1.000	rs4430112	chr8:19293365	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.29	6.54	0.3	1.77e-10	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs7300001	0.538	rs7968848	chr12:110941059	T/A	cg12870014	chr12:110450643	ANKRD13A	0.64	7.38	0.34	8.36e-13	Headache;
LUAD	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03264133	chr6:25882463	NA	-0.56	-8.99	-0.4	8.07e-18	Blood metabolite levels;
LUAD	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg15900387	chr1:150738905	CTSS	-0.38	-6.81	-0.31	3.28e-11	Melanoma;
LUAD	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg16486109	chr11:613632	IRF7	0.49	8.14	0.37	4.35e-15	Systemic lupus erythematosus;
LUAD	cis	rs6076065	0.748	rs6048784	chr20:23382652	A/T	cg11657817	chr20:23433608	CST11	0.57	12.07	0.51	4.8e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.31	0.34	1.3e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.46	-0.34	5e-13	Schizophrenia;
LUAD	cis	rs7043114	0.525	rs12353096	chr9:95031144	T/C	cg14631576	chr9:95140430	CENPP	-0.41	-8.32	-0.38	1.18e-15	Height;
LUAD	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg02896835	chr1:92012615	NA	-0.53	-8.26	-0.37	1.89e-15	Eosinophil percentage of white cells;
LUAD	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg23815491	chr16:72088622	HP	0.52	9.56	0.42	9.44e-20	Fibrinogen levels;
LUAD	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg12501888	chr15:85177176	SCAND2	-0.42	-6.45	-0.3	3e-10	P wave terminal force;
LUAD	cis	rs367615	0.537	rs1965670	chr5:108649798	A/T	cg17395555	chr5:108820864	NA	-0.5	-9.61	-0.42	6.71e-20	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs2730260	0.537	rs3793224	chr7:158876573	G/A	cg13710308	chr7:158854763	VIPR2	-0.5	-6.41	-0.3	3.79e-10	Myopia (pathological);
LUAD	cis	rs7010267	0.570	rs7004539	chr8:120040499	C/T	cg01975934	chr8:119970761	NA	-0.34	-6.4	-0.3	4.07e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg04455712	chr21:45112962	RRP1B	-0.45	-8.4	-0.38	6.79e-16	Mean corpuscular volume;
LUAD	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg10802521	chr3:52805072	NEK4	-0.46	-6.63	-0.31	1.05e-10	Schizophrenia;
LUAD	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg20503657	chr10:835505	NA	0.93	13.96	0.56	1.04e-36	Eosinophil percentage of granulocytes;
LUAD	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.48	-0.45	5.41e-23	Total body bone mineral density;
LUAD	cis	rs870825	0.616	rs4615214	chr4:185624129	G/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg21028142	chr17:79581711	NPLOC4	-0.35	-6.92	-0.32	1.71e-11	Eye color traits;
LUAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg26354017	chr1:205819088	PM20D1	0.84	18.27	0.66	2.07e-55	Menarche (age at onset);
LUAD	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg14092988	chr3:52407081	DNAH1	0.45	9.13	0.41	2.84e-18	Bipolar disorder;
LUAD	cis	rs684232	0.602	rs445268	chr17:563338	G/A	cg15660573	chr17:549704	VPS53	-0.89	-18.22	-0.66	3.55e-55	Prostate cancer;
LUAD	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg04455712	chr21:45112962	RRP1B	0.49	9.55	0.42	1.04e-19	Mean corpuscular volume;
LUAD	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg11859384	chr17:80120422	CCDC57	0.5	9.12	0.41	3.16e-18	Life satisfaction;
LUAD	cis	rs7737355	0.681	rs11242094	chr5:131072622	A/G	cg06307176	chr5:131281290	NA	0.46	7.73	0.35	7.92e-14	Life satisfaction;
LUAD	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg22823121	chr1:150693482	HORMAD1	-0.41	-7.46	-0.34	4.86e-13	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg24818145	chr4:99064322	C4orf37	0.46	7.84	0.36	3.59e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg04267008	chr7:1944627	MAD1L1	-0.68	-10.77	-0.46	4.69e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg11814155	chr7:99998594	ZCWPW1	0.45	7.82	0.36	4.35e-14	Platelet count;
LUAD	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg25894440	chr7:65020034	NA	-0.7	-7.45	-0.34	5.26e-13	Diabetic kidney disease;
LUAD	cis	rs7903847	0.620	rs61863813	chr10:99112786	T/C	cg20016023	chr10:99160130	RRP12	-0.32	-7.56	-0.35	2.5e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg02269571	chr22:50332266	NA	-0.68	-10.27	-0.45	3e-22	Schizophrenia;
LUAD	cis	rs2274273	0.588	rs7155054	chr14:55750662	A/G	cg04306507	chr14:55594613	LGALS3	0.42	8.12	0.37	5.01e-15	Protein biomarker;
LUAD	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.85	-0.36	3.5e-14	Total body bone mineral density;
LUAD	cis	rs62238980	0.614	rs4821015	chr22:32402549	G/A	cg00543991	chr22:32367038	NA	0.96	9.05	0.4	5.32e-18	Childhood ear infection;
LUAD	cis	rs7668190	0.924	rs4864504	chr4:55097835	G/C	cg17187183	chr4:55093834	PDGFRA	0.37	6.51	0.3	2.12e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-6.89	-0.32	1.99e-11	Lung cancer;
LUAD	cis	rs89107	1.000	rs9489327	chr6:118561889	T/C	cg21191810	chr6:118973309	C6orf204	0.44	8.59	0.39	1.73e-16	Cardiac structure and function;
LUAD	cis	rs12369179	0.737	rs116896792	chr12:122948907	T/C	cg18578876	chr12:123200353	GPR109B	-1.04	-9.25	-0.41	1.15e-18	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
LUAD	cis	rs7561273	0.586	rs6545264	chr2:24310105	A/G	cg20701182	chr2:24300061	SF3B14	0.5	8.2	0.37	2.91e-15	Quantitative traits;
LUAD	cis	rs3820068	0.524	rs34094056	chr1:15824154	G/T	cg17385448	chr1:15911702	AGMAT	0.39	6.37	0.3	4.92e-10	Systolic blood pressure;
LUAD	trans	rs2898857	0.504	rs35822701	chr17:47422317	C/T	cg11430096	chr6:110968061	CDK19	-0.49	-7.35	-0.34	1.04e-12	Cancer;
LUAD	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg02176678	chr2:219576539	TTLL4	-0.83	-17.34	-0.64	2.96e-51	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg25985355	chr7:65971099	NA	-0.39	-7.19	-0.33	2.89e-12	Aortic root size;
LUAD	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg21475434	chr5:93447410	FAM172A	0.74	8.31	0.37	1.32e-15	Diabetic retinopathy;
LUAD	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.63	-0.31	1.04e-10	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg05590025	chr7:65112418	INTS4L2	0.67	7.34	0.34	1.08e-12	Diabetic kidney disease;
LUAD	cis	rs2455799	0.533	rs2470513	chr3:15750056	G/A	cg16303742	chr3:15540471	COLQ	-0.5	-9.17	-0.41	2.02e-18	Mean platelet volume;
LUAD	trans	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.19	0.41	1.72e-18	Mean corpuscular volume;
LUAD	cis	rs7659604	0.540	rs4240264	chr4:122683818	A/G	cg06713675	chr4:122721982	EXOSC9	0.4	7.11	0.33	4.82e-12	Type 2 diabetes;
LUAD	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg19196401	chr6:110721138	DDO	-0.44	-8.32	-0.37	1.24e-15	Platelet distribution width;
LUAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg13047869	chr3:10149882	C3orf24	0.59	9.94	0.44	4.62e-21	Alzheimer's disease;
LUAD	trans	rs1941687	0.797	rs12607190	chr18:31394699	G/A	cg27147174	chr7:100797783	AP1S1	-0.51	-8.35	-0.38	9.95e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs735539	1.000	rs9579929	chr13:21282724	C/T	cg04906043	chr13:21280425	IL17D	0.39	7.08	0.33	5.88e-12	Dental caries;
LUAD	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-8.8	-0.39	3.48e-17	Hemoglobin concentration;
LUAD	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.98	0.36	1.35e-14	Heart rate;
LUAD	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.38	6.37	0.3	4.89e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs1788820	0.917	rs1788785	chr18:21142340	T/C	cg14672496	chr18:21087552	C18orf8	0.36	6.78	0.31	3.99e-11	Body mass index;
LUAD	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg18944383	chr4:111397179	ENPEP	0.32	6.42	0.3	3.68e-10	Height;
LUAD	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs4730250	0.711	rs117026964	chr7:107063656	C/A	cg23024343	chr7:107201750	COG5	0.51	6.66	0.31	8.44e-11	Osteoarthritis;
LUAD	cis	rs12519773	0.526	rs4469186	chr5:92520266	T/C	cg18783429	chr5:92414398	NA	0.42	7.45	0.34	5.46e-13	Migraine;
LUAD	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg03806693	chr22:41940476	POLR3H	0.74	10.01	0.44	2.61e-21	Vitiligo;
LUAD	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.38	-0.3	4.66e-10	Neutrophil percentage of white cells;
LUAD	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg23029597	chr12:123009494	RSRC2	0.55	8.59	0.39	1.69e-16	Body mass index;
LUAD	cis	rs9914988	1.000	rs9916866	chr17:27183155	C/G	cg20469991	chr17:27169893	C17orf63	0.49	6.4	0.3	4.04e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs758324	0.812	rs667437	chr5:131275509	C/T	cg06307176	chr5:131281290	NA	-0.45	-7.63	-0.35	1.6e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-9.65	-0.42	4.7e-20	Gut microbiome composition (summer);
LUAD	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg10518543	chr12:38710700	ALG10B	0.47	8.03	0.36	9.45e-15	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs986417	0.818	rs7144656	chr14:61032909	A/G	cg27398547	chr14:60952738	C14orf39	0.63	7.45	0.34	5.3e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg12935359	chr14:103987150	CKB	-0.47	-7.89	-0.36	2.66e-14	Bone mineral density;
LUAD	cis	rs1448094	1.000	rs1448094	chr12:86343135	G/T	cg02569458	chr12:86230093	RASSF9	0.36	6.85	0.32	2.62e-11	Major depressive disorder;
LUAD	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.54	-0.34	2.87e-13	Neutrophil percentage of white cells;
LUAD	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg22029157	chr1:209979665	IRF6	0.45	8.05	0.36	8.2e-15	Monobrow;
LUAD	cis	rs6906287	0.647	rs12194555	chr6:118819212	C/A	cg05564266	chr6:118973597	C6orf204	0.34	7.17	0.33	3.29e-12	Electrocardiographic conduction measures;
LUAD	cis	rs9863	0.828	rs71458830	chr12:124476561	C/T	cg17723958	chr12:124429295	CCDC92	-0.4	-6.63	-0.31	1.06e-10	White blood cell count;
LUAD	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-7.0	-0.32	1.01e-11	Morning vs. evening chronotype;
LUAD	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.21	0.33	2.57e-12	Hip circumference adjusted for BMI;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24508996	chr1:16057163	PLEKHM2	0.53	6.94	0.32	1.44e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs17401966	0.838	rs1013953	chr1:10319459	T/A	cg15208524	chr1:10270712	KIF1B	0.43	6.68	0.31	7.38e-11	Hepatocellular carcinoma;
LUAD	trans	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg24644049	chr4:85504048	CDS1	0.85	7.81	0.36	4.42e-14	Skin colour saturation;
LUAD	trans	rs11088226	1.000	rs11701627	chr21:33927794	T/A	cg09050820	chr6:167586206	TCP10L2	0.59	8.2	0.37	2.87e-15	Gastritis;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08028629	chr4:146539993	MMAA	-0.39	-6.37	-0.3	4.91e-10	Cancer;
LUAD	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg05043794	chr9:111880884	C9orf5	-0.44	-7.64	-0.35	1.47e-13	Menarche (age at onset);
LUAD	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg13770153	chr20:60521292	NA	-0.58	-9.09	-0.4	3.91e-18	Body mass index;
LUAD	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg18446336	chr7:2847575	GNA12	0.43	8.34	0.38	1.02e-15	Loneliness (linear analysis);
LUAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg24642844	chr7:1081250	C7orf50	-0.98	-14.74	-0.58	5.83e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg19041857	chr6:27730383	NA	-0.43	-7.3	-0.33	1.43e-12	Parkinson's disease;
LUAD	cis	rs73206853	0.764	rs56838584	chr12:110666136	A/G	cg12870014	chr12:110450643	ANKRD13A	0.66	8.04	0.36	8.84e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg18512352	chr11:47633146	NA	-0.56	-10.04	-0.44	2.02e-21	Subjective well-being;
LUAD	cis	rs4891159	0.790	rs56077581	chr18:74116865	T/G	cg24786174	chr18:74118243	ZNF516	-0.79	-14.74	-0.58	5.5e-40	Longevity;
LUAD	cis	rs80207740	0.941	rs2076940	chr8:21836020	A/G	cg25597362	chr8:21767310	DOK2	-0.65	-7.67	-0.35	1.22e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs7709909	0.512	rs6864493	chr5:79985702	T/C	cg24059623	chr5:79951536	MSH3;DHFR	0.48	7.27	0.33	1.8e-12	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs1967309	0.604	rs8061182	chr16:4070333	A/G	cg00061520	chr16:4070371	ADCY9	0.51	9.08	0.4	4.27e-18	Response to Dalcetrapib treatment in acute coronary syndrome;
LUAD	cis	rs739496	0.615	rs1544396	chr12:112062875	C/T	cg10833066	chr12:111807467	FAM109A	-0.41	-6.77	-0.31	4.29e-11	Platelet count;
LUAD	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg17971929	chr21:40555470	PSMG1	0.56	8.89	0.4	1.78e-17	Cognitive function;
LUAD	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg25036284	chr2:26402008	FAM59B	-0.6	-8.34	-0.38	1.02e-15	Gut microbiome composition (summer);
LUAD	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg07741184	chr6:167504864	NA	0.35	8.34	0.38	1.07e-15	Primary biliary cholangitis;
LUAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.27	6.53	0.3	1.89e-10	Depression;
LUAD	cis	rs7524258	0.903	rs4908608	chr1:7292772	T/C	cg07173049	chr1:7289937	CAMTA1	0.55	10.33	0.45	1.87e-22	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs6669919	0.516	rs11577717	chr1:211668920	C/T	cg10512769	chr1:211675356	NA	-0.4	-7.95	-0.36	1.72e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg01620082	chr3:125678407	NA	-1.08	-10.66	-0.46	1.16e-23	Depression;
LUAD	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg09399716	chr2:46890238	NA	-0.38	-6.65	-0.31	9.01e-11	Height;
LUAD	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg26513180	chr16:89883248	FANCA	0.78	7.09	0.33	5.78e-12	Skin colour saturation;
LUAD	cis	rs3790645	1.000	rs657227	chr1:26892104	T/A	cg23229016	chr1:26872525	RPS6KA1	0.21	6.8	0.31	3.68e-11	Glucose homeostasis traits;
LUAD	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9341808	0.667	rs2490251	chr6:80895164	A/G	cg08355045	chr6:80787529	NA	0.48	8.55	0.38	2.31e-16	Sitting height ratio;
LUAD	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg23301539	chr8:142222248	SLC45A4	0.47	8.53	0.38	2.58e-16	Immature fraction of reticulocytes;
LUAD	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg02734326	chr4:10020555	SLC2A9	0.43	6.99	0.32	1.09e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4444359	0.722	rs12923384	chr16:11550211	T/C	cg08104224	chr16:11588532	NA	0.37	6.4	0.3	4.05e-10	Facial morphology (factor 17, height of vermillion upper lip);
LUAD	trans	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg06606381	chr12:133084897	FBRSL1	-0.63	-7.53	-0.34	3.2e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg23283495	chr1:209979779	IRF6	0.41	7.45	0.34	5.39e-13	Monobrow;
LUAD	cis	rs4588572	0.606	rs2362828	chr5:77718835	C/T	cg11547950	chr5:77652471	NA	-0.62	-10.72	-0.46	6.89e-24	Triglycerides;
LUAD	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg00530320	chr1:46809349	NSUN4	0.53	8.17	0.37	3.49e-15	Menopause (age at onset);
LUAD	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg19318889	chr4:1322082	MAEA	0.48	7.87	0.36	3.08e-14	Obesity-related traits;
LUAD	cis	rs760794	0.577	rs17483277	chr6:19790571	G/A	cg02682789	chr6:19804855	NA	0.43	6.79	0.31	3.87e-11	Endometriosis;
LUAD	cis	rs10504073	0.584	rs60449482	chr8:49974865	G/A	cg00325661	chr8:49890786	NA	0.48	10.54	0.46	3.31e-23	Blood metabolite ratios;
LUAD	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg14582100	chr15:45693742	SPATA5L1	0.43	8.64	0.39	1.12e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs7191439	0.858	rs2290902	chr16:88782676	A/G	cg02389323	chr16:88786976	FAM38A	1.02	9.98	0.44	3.41e-21	Plateletcrit;
LUAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg06877462	chr1:205807181	PM20D1	0.35	6.55	0.3	1.65e-10	Menarche (age at onset);
LUAD	cis	rs4676380	0.927	rs1583259	chr2:241644934	G/T	cg21930842	chr2:241631663	AQP12A	0.37	6.72	0.31	5.84e-11	Response to metformin (IC50);
LUAD	cis	rs7258465	0.965	rs10409003	chr19:18543054	C/T	cg25828334	chr19:18545568	ISYNA1	-0.38	-7.77	-0.35	5.85e-14	Breast cancer;
LUAD	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg01228410	chr5:493893	SLC9A3	-0.53	-6.96	-0.32	1.3e-11	Cystic fibrosis severity;
LUAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg03188948	chr7:1209495	NA	0.8	9.76	0.43	2.04e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.6	11.33	0.48	3.68e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.36	-0.34	9.5e-13	Resting heart rate;
LUAD	cis	rs1003719	0.715	rs58008706	chr21:38540506	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.45	-7.48	-0.34	4.47e-13	Eye color traits;
LUAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.62	-8.13	-0.37	4.81e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg05043794	chr9:111880884	C9orf5	-0.44	-7.69	-0.35	1.07e-13	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.85	0.32	2.56e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg02574844	chr11:5959923	NA	-0.39	-6.69	-0.31	7.22e-11	DNA methylation (variation);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13265914	chr8:21999630	REEP4	-0.42	-6.93	-0.32	1.57e-11	Height;
LUAD	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg14202850	chr17:43974869	MAPT;LOC100130148	0.38	6.41	0.3	3.9e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.78	-0.31	4.07e-11	Post bronchodilator FEV1;
LUAD	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.57	-0.35	2.34e-13	Blood metabolite levels;
LUAD	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg18446336	chr7:2847575	GNA12	-0.38	-7.08	-0.33	6.01e-12	Height;
LUAD	cis	rs7428	0.527	rs1554110	chr2:85547963	C/T	cg24342717	chr2:85555507	TGOLN2	-0.48	-7.81	-0.36	4.42e-14	Ear protrusion;
LUAD	cis	rs4604732	0.631	rs34443739	chr1:247626913	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.45	7.33	0.34	1.16e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs68170813	0.562	rs11770061	chr7:107071310	A/G	cg02696742	chr7:106810147	HBP1	-0.8	-10.68	-0.46	9.46e-24	Coronary artery disease;
LUAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg08132940	chr7:1081526	C7orf50	-0.79	-10.71	-0.46	7.69e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.31	0.45	2.28e-22	Ileal carcinoids;
LUAD	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12756686	chr19:29218302	NA	0.66	9.71	0.43	2.87e-20	Methadone dose in opioid dependence;
LUAD	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg24596788	chr1:163392923	NA	-0.33	-7.06	-0.32	6.97e-12	Motion sickness;
LUAD	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg13902645	chr11:5959945	NA	0.53	9.86	0.43	8.81e-21	DNA methylation (variation);
LUAD	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg22153745	chr1:153894579	GATAD2B	-0.49	-7.63	-0.35	1.55e-13	Total cholesterol levels;
LUAD	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.13e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4953404	0.613	rs1531132	chr2:46892315	A/G	cg09399716	chr2:46890238	NA	-0.35	-6.93	-0.32	1.62e-11	Pulse pressure (alcohol consumption interaction);
LUAD	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg11057378	chr10:81107060	PPIF	0.4	7.45	0.34	5.47e-13	Height;
LUAD	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg17173187	chr15:85201210	NMB	0.51	9.11	0.41	3.29e-18	Schizophrenia;
LUAD	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg13073564	chr4:8508604	NA	0.5	8.4	0.38	6.97e-16	Response to antineoplastic agents;
LUAD	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg18876405	chr7:65276391	NA	-0.6	-10.47	-0.45	5.57e-23	Corneal structure;
LUAD	cis	rs6009527	0.752	rs7288176	chr22:49568462	A/G	cg12746016	chr22:49560550	NA	-0.48	-9.42	-0.42	3.05e-19	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUAD	cis	rs3845702	1.000	rs3845697	chr2:180798553	C/T	cg01881094	chr2:180872142	CWC22	0.6	7.59	0.35	2.08e-13	Schizophrenia;
LUAD	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg16479474	chr6:28041457	NA	0.46	7.94	0.36	1.8e-14	Depression;
LUAD	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-6.56	-0.3	1.57e-10	IgG glycosylation;
LUAD	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg06808227	chr14:105710500	BRF1	-0.41	-6.61	-0.31	1.13e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs12541635	0.966	rs1603363	chr8:107031319	A/G	cg10147462	chr8:107024639	NA	0.51	9.28	0.41	8.66e-19	Age of smoking initiation;
LUAD	cis	rs28595532	0.920	rs56389935	chr4:119683571	G/A	cg21605333	chr4:119757512	SEC24D	0.83	7.78	0.35	5.59e-14	Cannabis dependence symptom count;
LUAD	trans	rs7395662	1.000	rs4881994	chr11:48498139	G/T	cg00717180	chr2:96193071	NA	-0.39	-7.37	-0.34	9.12e-13	HDL cholesterol;
LUAD	cis	rs738322	0.555	rs6001029	chr22:38555193	C/A	cg17652424	chr22:38574118	PLA2G6	-0.27	-7.23	-0.33	2.26e-12	Cutaneous nevi;
LUAD	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.41	0.6	7.52e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs12530845	0.943	rs60858457	chr7:135336918	T/C	cg23117316	chr7:135346802	PL-5283	-0.48	-8.45	-0.38	4.62e-16	Red blood cell traits;
LUAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg12034118	chr1:209979487	IRF6	0.46	6.75	0.31	4.82e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs1497828	0.956	rs1007737	chr1:217547872	G/C	cg04411442	chr1:217543379	NA	0.39	6.96	0.32	1.31e-11	Dialysis-related mortality;
LUAD	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg14926445	chr8:58193284	C8orf71	-0.5	-7.25	-0.33	1.99e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg17279839	chr7:150038598	RARRES2	0.42	7.12	0.33	4.75e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs8177876	0.822	rs9938965	chr16:81113163	G/C	cg08591886	chr16:81111003	C16orf46	-0.76	-7.01	-0.32	9.76e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs738322	0.805	rs2235344	chr22:38518083	G/A	cg17652424	chr22:38574118	PLA2G6	-0.26	-7.45	-0.34	5.3e-13	Cutaneous nevi;
LUAD	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg23758822	chr17:41437982	NA	0.95	18.91	0.68	3.08e-58	Menopause (age at onset);
LUAD	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg18944383	chr4:111397179	ENPEP	0.38	7.66	0.35	1.24e-13	Height;
LUAD	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg15704280	chr7:45808275	SEPT13	-0.76	-10.95	-0.47	9.7e-25	Coronary artery disease;
LUAD	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg07395648	chr5:131743802	NA	-0.39	-6.53	-0.3	1.86e-10	Blood metabolite levels;
LUAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg10729496	chr3:10149963	C3orf24	0.61	9.91	0.43	6.12e-21	Alzheimer's disease;
LUAD	trans	rs1493916	0.905	rs1586988	chr18:31396001	G/C	cg15819921	chr19:927150	ARID3A	-0.49	-8.17	-0.37	3.5e-15	Life satisfaction;
LUAD	trans	rs1493916	0.905	rs34910379	chr18:31400047	A/G	cg27147174	chr7:100797783	AP1S1	-0.69	-12.19	-0.51	1.65e-29	Life satisfaction;
LUAD	cis	rs1232027	0.622	rs1650683	chr5:79957147	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.02	-0.32	8.67e-12	Huntington's disease progression;
LUAD	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg06740227	chr12:86229804	RASSF9	0.4	7.09	0.33	5.79e-12	Major depressive disorder;
LUAD	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.89	0.36	2.54e-14	Bladder cancer;
LUAD	trans	rs116939006	1.000	rs6530767	chr8:14263619	C/A	cg16330849	chr6:10694809	C6orf52;PAK1IP1	0.83	7.17	0.33	3.34e-12	Response to paliperidone in schizophrenia (negative Marder score);
LUAD	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg03526776	chr6:41159608	TREML2	0.33	6.85	0.32	2.58e-11	Alzheimer's disease (late onset);
LUAD	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06544989	chr22:39130855	UNC84B	0.42	7.62	0.35	1.73e-13	Menopause (age at onset);
LUAD	cis	rs3784262	0.528	rs4144005	chr15:58330094	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.4	-7.59	-0.35	2.12e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs2040771	0.740	rs9605960	chr22:19214636	G/C	cg02655711	chr22:19163373	SLC25A1	0.56	10.64	0.46	1.37e-23	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg14345882	chr6:26364793	BTN3A2	0.7	7.15	0.33	3.76e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg06138931	chr13:21896616	NA	0.41	6.81	0.31	3.34e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs7223966	0.621	rs28571160	chr17:61638723	G/T	cg11494091	chr17:61959527	GH2	0.35	6.49	0.3	2.38e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03517284	chr6:25882590	NA	-0.51	-7.35	-0.34	1.02e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2067615	0.560	rs10467028	chr12:107076405	A/G	cg15890332	chr12:107067104	RFX4	0.4	8.57	0.38	1.9e-16	Heart rate;
LUAD	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg24818145	chr4:99064322	C4orf37	0.41	6.91	0.32	1.78e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg21385522	chr1:16154831	NA	-1.07	-23.18	-0.75	2.58e-77	Dilated cardiomyopathy;
LUAD	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg12311346	chr5:56204834	C5orf35	-0.49	-8.08	-0.37	6.88e-15	Coronary artery disease;
LUAD	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg04455712	chr21:45112962	RRP1B	0.45	8.95	0.4	1.11e-17	Mean corpuscular volume;
LUAD	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg17366294	chr4:99064904	C4orf37	0.48	8.63	0.39	1.29e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg24829409	chr8:58192753	C8orf71	0.54	6.39	0.3	4.37e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg20019720	chr6:154832845	CNKSR3	0.65	12.84	0.53	4.41e-32	Lipoprotein (a) levels;
LUAD	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg14092988	chr3:52407081	DNAH1	0.46	9.05	0.4	5.41e-18	Bipolar disorder;
LUAD	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg15181151	chr6:150070149	PCMT1	0.42	8.65	0.39	1.1e-16	Lung cancer;
LUAD	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg27572855	chr1:25598939	RHD	0.55	12.17	0.51	2.03e-29	Erythrocyte sedimentation rate;
LUAD	cis	rs3093024	0.839	rs968334	chr6:167526096	T/C	cg07741184	chr6:167504864	NA	-0.28	-6.6	-0.31	1.21e-10	Rheumatoid arthritis;
LUAD	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg25324976	chr17:61989376	CSHL1	0.36	6.91	0.32	1.78e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg16414030	chr3:133502952	NA	-0.7	-14.02	-0.56	6.26e-37	Iron status biomarkers;
LUAD	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg22920501	chr2:26401640	FAM59B	-0.73	-10.49	-0.45	4.71e-23	Gut microbiome composition (summer);
LUAD	cis	rs2274273	0.804	rs28428911	chr14:55843596	G/T	cg04306507	chr14:55594613	LGALS3	0.41	8.66	0.39	1e-16	Protein biomarker;
LUAD	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.41	-6.86	-0.32	2.48e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2455601	1.000	rs12223690	chr11:8901824	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.46	-6.56	-0.3	1.55e-10	Schizophrenia;
LUAD	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg02527881	chr3:46936655	PTH1R	-0.48	-9.63	-0.42	5.74e-20	Colorectal cancer;
LUAD	trans	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg05926928	chr17:57297772	GDPD1	-0.64	-8.61	-0.39	1.47e-16	Opioid sensitivity;
LUAD	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg09263875	chr16:632152	PIGQ	0.83	17.86	0.66	1.47e-53	Height;
LUAD	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg07636037	chr3:49044803	WDR6	0.54	8.35	0.38	9.68e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs1003719	0.715	rs7277820	chr21:38580309	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-7.95	-0.36	1.66e-14	Eye color traits;
LUAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg10729496	chr3:10149963	C3orf24	0.64	9.56	0.42	9.9e-20	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1941687	0.800	rs1845387	chr18:31358940	T/G	cg27147174	chr7:100797783	AP1S1	-0.56	-9.43	-0.42	2.75e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg17863274	chr19:49399704	TULP2	-0.64	-9.78	-0.43	1.74e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg07636037	chr3:49044803	WDR6	-0.48	-8.03	-0.36	9.96e-15	Menarche (age at onset);
LUAD	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg06784218	chr1:46089804	CCDC17	-0.54	-11.8	-0.5	5.62e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg14829155	chr15:31115871	NA	-0.59	-9.64	-0.42	5.29e-20	Huntington's disease progression;
LUAD	cis	rs7843479	0.965	rs733543	chr8:21835465	A/G	cg03445287	chr8:21823731	XPO7	-0.45	-8.18	-0.37	3.26e-15	Mean corpuscular volume;
LUAD	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg24818145	chr4:99064322	C4orf37	0.46	7.83	0.36	3.95e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	9.54	0.42	1.11e-19	Colorectal cancer;
LUAD	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg00280220	chr17:61926910	NA	0.37	7.06	0.32	7.05e-12	Prudent dietary pattern;
LUAD	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	12.6	0.52	3.77e-31	Monocyte percentage of white cells;
LUAD	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg00495681	chr13:53174319	NA	0.61	11.51	0.49	7.29e-27	Lewy body disease;
LUAD	trans	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4730250	0.707	rs3729876	chr7:106786952	T/C	cg23024343	chr7:107201750	COG5	-0.5	-6.79	-0.31	3.73e-11	Osteoarthritis;
LUAD	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg17173187	chr15:85201210	NMB	0.51	8.73	0.39	5.74e-17	Schizophrenia;
LUAD	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	7.45	0.34	5.19e-13	Rheumatoid arthritis;
LUAD	cis	rs9323205	0.634	rs61987266	chr14:51734909	C/T	cg23942311	chr14:51606299	NA	-0.58	-8.77	-0.39	4.47e-17	Cancer;
LUAD	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg11494091	chr17:61959527	GH2	0.74	18.49	0.67	2.28e-56	Prudent dietary pattern;
LUAD	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg17173187	chr15:85201210	NMB	0.53	9.33	0.41	6.09e-19	Schizophrenia;
LUAD	cis	rs938554	0.692	rs6449213	chr4:9994215	A/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-9.02	-0.4	6.71e-18	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25215298	chr1:860022	SAMD11	-0.64	-8.04	-0.36	8.83e-15	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs113835537	0.935	rs1127145	chr11:66373305	G/A	cg24851651	chr11:66362959	CCS	0.58	8.03	0.36	9.48e-15	Airway imaging phenotypes;
LUAD	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg03929089	chr4:120376271	NA	-0.96	-19.69	-0.69	9.6e-62	Height;
LUAD	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.99	-0.5	1.06e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg18200150	chr17:30822561	MYO1D	-0.42	-7.97	-0.36	1.52e-14	Schizophrenia;
LUAD	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg20430773	chr1:16534157	ARHGEF19	0.4	6.91	0.32	1.83e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2732480	0.538	rs2732462	chr12:48696384	A/G	cg04545296	chr12:48745243	ZNF641	0.41	10.28	0.45	2.79e-22	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs62238980	0.520	rs77155221	chr22:32514092	G/A	cg00543991	chr22:32367038	NA	0.88	8.51	0.38	3.06e-16	Childhood ear infection;
LUAD	cis	rs7274811	0.652	rs291672	chr20:31951168	G/A	cg07470512	chr20:32255052	NECAB3;C20orf134	0.43	6.42	0.3	3.65e-10	Height;
LUAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg27432699	chr2:27873401	GPN1	-0.38	-6.44	-0.3	3.21e-10	Total body bone mineral density;
LUAD	cis	rs62400317	0.859	rs4267941	chr6:45241302	A/C	cg20913747	chr6:44695427	NA	-0.41	-6.57	-0.3	1.44e-10	Total body bone mineral density;
LUAD	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg18621852	chr3:10150065	C3orf24	0.42	7.46	0.34	5.08e-13	Alzheimer's disease;
LUAD	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18876405	chr7:65276391	NA	-0.41	-6.62	-0.31	1.06e-10	Aortic root size;
LUAD	cis	rs921968	0.540	rs7582329	chr2:219620909	C/T	cg02176678	chr2:219576539	TTLL4	-0.59	-12.0	-0.5	9.65e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg11247378	chr22:39784982	NA	-0.76	-14.21	-0.57	9.75e-38	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg19875535	chr5:140030758	IK	-0.4	-6.68	-0.31	7.69e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs11039798	0.841	rs12221667	chr11:48548549	G/T	cg15704280	chr7:45808275	SEPT13	0.73	7.32	0.34	1.23e-12	Axial length;
LUAD	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg16647868	chr5:131706066	SLC22A5	0.4	6.69	0.31	7.13e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg04414720	chr1:150670196	GOLPH3L	0.7	11.95	0.5	1.5e-28	Urate levels;
LUAD	trans	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg21659725	chr3:3221576	CRBN	-0.6	-9.61	-0.42	6.76e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs977987	0.843	rs7499872	chr16:75426529	G/A	cg03315344	chr16:75512273	CHST6	0.63	13.79	0.56	5.42e-36	Dupuytren's disease;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg03169527	chr3:11888582	C3orf31	0.51	8.3	0.37	1.39e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12545109	0.571	rs7002482	chr8:57295200	C/T	cg07776626	chr8:57350775	NA	-0.64	-8.86	-0.4	2.29e-17	Obesity-related traits;
LUAD	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg11502198	chr6:26597334	ABT1	0.56	9.32	0.41	6.74e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-6.44	-0.3	3.32e-10	Personality dimensions;
LUAD	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg00769240	chr8:12517080	NA	-0.43	-8.39	-0.38	7.61e-16	Blood pressure (smoking interaction);
LUAD	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg17971929	chr21:40555470	PSMG1	-0.56	-8.95	-0.4	1.16e-17	Cognitive function;
LUAD	cis	rs7072216	0.922	rs10786415	chr10:100151266	A/G	cg26618903	chr10:100175079	PYROXD2	-0.33	-7.09	-0.33	5.81e-12	Metabolite levels;
LUAD	cis	rs6499255	0.951	rs2361838	chr16:69676086	T/C	cg15192750	chr16:69999425	NA	0.49	7.68	0.35	1.15e-13	IgE levels;
LUAD	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg04586622	chr2:25135609	ADCY3	0.36	8.22	0.37	2.55e-15	Body mass index;
LUAD	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg22676075	chr6:135203613	NA	0.43	8.0	0.36	1.18e-14	Red blood cell count;
LUAD	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg02782426	chr3:40428986	ENTPD3	0.35	7.33	0.34	1.19e-12	Renal cell carcinoma;
LUAD	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg26597838	chr10:835615	NA	0.82	12.83	0.53	4.77e-32	Eosinophil percentage of granulocytes;
LUAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg03188948	chr7:1209495	NA	0.83	10.13	0.44	9.87e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6500395	1.000	rs4785535	chr16:48707659	A/G	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12618769	0.597	rs4851133	chr2:99050519	T/C	cg10123293	chr2:99228465	UNC50	0.46	8.43	0.38	5.42e-16	Bipolar disorder;
LUAD	cis	rs12472274	0.646	rs34989058	chr2:239074698	C/T	cg17459225	chr2:239074497	NA	0.61	7.04	0.32	8.06e-12	Phospholipid levels (plasma);
LUAD	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg17120908	chr11:65337727	SSSCA1	-0.6	-9.42	-0.42	2.94e-19	Bone mineral density;
LUAD	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg26597838	chr10:835615	NA	0.69	8.91	0.4	1.56e-17	Eosinophil percentage of granulocytes;
LUAD	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg22482690	chr17:47019901	SNF8	0.45	8.45	0.38	4.8e-16	Type 2 diabetes;
LUAD	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg03213289	chr20:61660250	NA	0.69	14.77	0.58	4.01e-40	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs11971779	0.680	rs7805824	chr7:139111169	C/G	cg24109934	chr7:139138155	KLRG2	0.31	6.4	0.3	4.22e-10	Diisocyanate-induced asthma;
LUAD	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg18252515	chr7:66147081	NA	0.62	6.77	0.31	4.25e-11	Diabetic kidney disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10822418	chr8:61430157	RAB2A	-0.42	-6.68	-0.31	7.39e-11	Height;
LUAD	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg00105475	chr2:10696890	NA	0.38	6.84	0.32	2.76e-11	Prostate cancer;
LUAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg19536664	chr17:6899085	ALOX12	-0.58	-11.14	-0.48	1.85e-25	Tonsillectomy;
LUAD	trans	rs7944735	0.517	rs1827503	chr11:48225115	G/T	cg15704280	chr7:45808275	SEPT13	0.68	7.49	0.34	4.17e-13	Intraocular pressure;
LUAD	cis	rs11640533	0.901	rs11862250	chr16:53415038	C/A	cg02380802	chr16:53407808	NA	0.41	7.2	0.33	2.79e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2067615	0.579	rs10778509	chr12:107162918	G/A	cg15890332	chr12:107067104	RFX4	0.4	8.47	0.38	3.95e-16	Heart rate;
LUAD	cis	rs3823572	0.525	rs28588750	chr7:133629138	A/G	cg03336402	chr7:133662267	EXOC4	0.39	7.07	0.33	6.39e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2579500	0.885	rs2579501	chr2:97199251	G/A	cg23100626	chr2:96804247	ASTL	0.26	6.52	0.3	1.97e-10	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs3820068	0.705	rs11584209	chr1:15885041	G/T	cg13390004	chr1:15929781	NA	0.42	6.68	0.31	7.39e-11	Systolic blood pressure;
LUAD	cis	rs7208859	0.614	rs216474	chr17:28865091	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.74	-7.44	-0.34	5.56e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg10518543	chr12:38710700	ALG10B	-0.41	-6.42	-0.3	3.7e-10	Bladder cancer;
LUAD	cis	rs367615	0.506	rs246102	chr5:108699695	C/G	cg17395555	chr5:108820864	NA	-0.46	-8.66	-0.39	1.02e-16	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs2046867	0.908	rs9811830	chr3:72809591	A/G	cg04365224	chr3:72788183	NA	-0.42	-6.52	-0.3	2.06e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg01620082	chr3:125678407	NA	-0.71	-8.28	-0.37	1.66e-15	Breast cancer;
LUAD	trans	rs7786808	0.552	rs4909205	chr7:158185283	G/A	cg02030672	chr11:45687055	CHST1	0.43	7.81	0.36	4.45e-14	Obesity-related traits;
LUAD	cis	rs7264396	0.513	rs2425092	chr20:34306815	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2.04e-15	Total cholesterol levels;
LUAD	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg06636551	chr8:101224915	SPAG1	-0.37	-6.76	-0.31	4.62e-11	Atrioventricular conduction;
LUAD	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg26536354	chr8:144654954	C8orf73	0.62	6.71	0.31	6.36e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs2274273	0.713	rs56725788	chr14:55540101	A/G	cg04306507	chr14:55594613	LGALS3	0.31	6.53	0.3	1.85e-10	Protein biomarker;
LUAD	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg07741184	chr6:167504864	NA	0.31	7.47	0.34	4.74e-13	Crohn's disease;
LUAD	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.91	0.4	1.48e-17	Cognitive ability;
LUAD	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg24634471	chr8:143751801	JRK	0.48	7.81	0.35	4.59e-14	Schizophrenia;
LUAD	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg07570687	chr10:102243282	WNT8B	0.48	7.19	0.33	2.94e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg17633681	chr16:88106987	BANP	0.4	6.82	0.31	3.13e-11	Menopause (age at onset);
LUAD	cis	rs8060686	0.623	rs12599178	chr16:68128104	A/G	cg05110241	chr16:68378359	PRMT7	-0.57	-7.43	-0.34	6.06e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg00376283	chr12:123451042	ABCB9	-0.42	-6.87	-0.32	2.31e-11	Platelet count;
LUAD	cis	rs863345	0.604	rs975118	chr1:158511445	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.6	-0.31	1.21e-10	Pneumococcal bacteremia;
LUAD	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg19052272	chr2:3704530	ALLC	-0.95	-14.48	-0.58	6.83e-39	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs593982	1.000	rs650619	chr11:65506483	G/A	cg08755490	chr11:65554678	OVOL1	1.32	19.4	0.69	1.93e-60	Atopic dermatitis;
LUAD	cis	rs965513	0.524	rs6478413	chr9:100582024	A/G	cg13688889	chr9:100608707	NA	-0.38	-6.67	-0.31	8.25e-11	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUAD	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg19761014	chr17:28927070	LRRC37B2	0.81	8.13	0.37	4.79e-15	Body mass index;
LUAD	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg26441486	chr22:50317300	CRELD2	0.44	6.53	0.3	1.89e-10	Schizophrenia;
LUAD	cis	rs5758511	0.689	rs17002947	chr22:42688532	C/T	cg26169700	chr22:42538906	CYP2D7P1	0.55	7.43	0.34	6.07e-13	Birth weight;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg07332563	chr6:291687	DUSP22	-0.7	-12.26	-0.51	8.69e-30	Menopause (age at onset);
LUAD	cis	rs9287719	0.601	rs6751436	chr2:10723862	C/T	cg03983476	chr2:10830698	NOL10	-0.39	-6.48	-0.3	2.63e-10	Prostate cancer;
LUAD	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg03474202	chr17:45855739	NA	-0.38	-9.04	-0.4	5.87e-18	IgG glycosylation;
LUAD	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs6594713	0.837	rs6594715	chr5:112741593	T/C	cg12552261	chr5:112820674	MCC	0.55	8.91	0.4	1.57e-17	Brain cytoarchitecture;
LUAD	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.62	-0.31	1.09e-10	Height;
LUAD	cis	rs11676348	0.774	rs4672870	chr2:218941916	C/T	cg06547715	chr2:218990976	CXCR2	0.31	6.94	0.32	1.45e-11	Ulcerative colitis;
LUAD	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg20291162	chr17:40259547	DHX58	-0.69	-10.93	-0.47	1.2e-24	Fibrinogen levels;
LUAD	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.54	-0.38	2.4e-16	Alzheimer's disease (late onset);
LUAD	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg05896524	chr21:47604654	C21orf56	0.45	6.94	0.32	1.52e-11	Testicular germ cell tumor;
LUAD	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03919644	chr3:101443603	CEP97	0.42	6.74	0.31	5.08e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.7	0.31	6.66e-11	Depression;
LUAD	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg03467027	chr4:99064603	C4orf37	0.42	6.84	0.32	2.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg10518543	chr12:38710700	ALG10B	-0.46	-7.42	-0.34	6.42e-13	Morning vs. evening chronotype;
LUAD	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.77	0.5	7.05e-28	Colorectal cancer;
LUAD	trans	rs3942852	0.910	rs11603850	chr11:48140900	G/A	cg15704280	chr7:45808275	SEPT13	-0.59	-8.12	-0.37	5.19e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs12681287	0.752	rs12548328	chr8:87311219	G/A	cg27223183	chr8:87520930	FAM82B	-0.62	-8.45	-0.38	4.9e-16	Caudate activity during reward;
LUAD	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg00530320	chr1:46809349	NSUN4	0.53	8.23	0.37	2.33e-15	Menopause (age at onset);
LUAD	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg03859395	chr2:55845619	SMEK2	0.76	14.04	0.56	4.76e-37	Metabolic syndrome;
LUAD	cis	rs16958440	0.867	rs12326465	chr18:44678645	A/G	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-7.18	-0.33	3.25e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg02880119	chr16:3481970	NA	0.53	7.08	0.33	5.99e-12	Body mass index (adult);
LUAD	trans	rs208520	1.000	rs208521	chr6:66953625	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-13.5	-0.55	8.62e-35	Exhaled nitric oxide output;
LUAD	cis	rs6761276	0.899	rs11891557	chr2:113835319	G/A	cg09040174	chr2:113837401	NA	0.81	15.75	0.61	2.68e-44	Protein quantitative trait loci;
LUAD	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg02158880	chr13:53174818	NA	-0.49	-8.12	-0.37	4.99e-15	Lewy body disease;
LUAD	cis	rs939658	0.728	rs8031638	chr15:79422726	C/T	cg17916960	chr15:79447300	NA	-0.49	-9.6	-0.42	7.22e-20	Refractive error;
LUAD	cis	rs17253792	0.822	rs77315200	chr14:56072643	C/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.42	-0.3	3.71e-10	Putamen volume;
LUAD	cis	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg21775007	chr8:11205619	TDH	-0.48	-8.46	-0.38	4.34e-16	Triglycerides;
LUAD	cis	rs513349	1.000	rs210145	chr6:33547440	G/C	cg24505687	chr6:33548425	BAK1	0.44	8.53	0.38	2.57e-16	Platelet count;
LUAD	cis	rs67072384	1.000	rs7120700	chr11:72444676	A/G	cg04827223	chr11:72435913	ARAP1	-0.58	-7.48	-0.34	4.21e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg05872129	chr22:39784769	NA	-0.77	-13.86	-0.56	2.74e-36	Intelligence (multi-trait analysis);
LUAD	cis	rs7680126	0.596	rs4698032	chr4:10316582	T/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.52	-0.3	2.05e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs2688608	0.967	rs9971040	chr10:75661162	G/C	cg19442545	chr10:75533431	FUT11	-0.4	-6.87	-0.32	2.33e-11	Inflammatory bowel disease;
LUAD	cis	rs6906287	0.647	rs6936178	chr6:118718242	C/T	cg05564266	chr6:118973597	C6orf204	0.33	6.97	0.32	1.23e-11	Electrocardiographic conduction measures;
LUAD	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.45	-7.44	-0.34	5.73e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg02505535	chr3:195703920	SDHAP1	-0.36	-7.47	-0.34	4.7e-13	Pancreatic cancer;
LUAD	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.02	0.32	8.93e-12	Motion sickness;
LUAD	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg07157834	chr1:205819609	PM20D1	-0.4	-6.39	-0.3	4.31e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.71	0.53	1.43e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8028313	0.630	rs8035989	chr15:67965620	G/A	cg24579218	chr15:68104479	NA	-0.49	-8.4	-0.38	6.64e-16	Obesity;
LUAD	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg07606381	chr6:8435919	SLC35B3	-0.42	-6.94	-0.32	1.51e-11	Motion sickness;
LUAD	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.47	0.3	2.64e-10	Parkinson's disease;
LUAD	cis	rs1003719	0.715	rs2212742	chr21:38578685	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.2	-0.37	2.93e-15	Eye color traits;
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg05064044	chr6:292385	DUSP22	-0.83	-14.24	-0.57	7.11e-38	Menopause (age at onset);
LUAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06873352	chr17:61820015	STRADA	0.83	18.59	0.67	8.47e-57	Prudent dietary pattern;
LUAD	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg14779329	chr11:130786720	SNX19	0.38	6.82	0.31	3.24e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	12.12	0.51	3.11e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg20607287	chr7:12443886	VWDE	-0.54	-6.78	-0.31	3.96e-11	Coronary artery disease;
LUAD	trans	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg01620082	chr3:125678407	NA	-0.68	-7.67	-0.35	1.16e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2046867	0.818	rs17010184	chr3:72870242	A/T	cg04365224	chr3:72788183	NA	0.44	6.64	0.31	9.36e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg03676636	chr4:99064102	C4orf37	0.32	8.4	0.38	6.82e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg10802521	chr3:52805072	NEK4	-0.56	-9.72	-0.43	2.63e-20	Bipolar disorder;
LUAD	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg26408565	chr15:76604113	ETFA	-0.45	-7.71	-0.35	9.22e-14	Blood metabolite levels;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg20997463	chr12:53689079	PFDN5	0.41	6.48	0.3	2.57e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17264417	chr4:123844248	SPATA5;NUDT6	0.42	6.57	0.3	1.48e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs13394619	1.000	rs2884374	chr2:11731846	C/T	cg07314298	chr2:11723111	GREB1	0.51	9.5	0.42	1.5700000000000001e-19	Endometriosis;
LUAD	trans	rs853679	0.607	rs56189111	chr6:28271973	C/A	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.16	-0.48	1.54e-25	Depression;
LUAD	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg19318889	chr4:1322082	MAEA	0.48	8.12	0.37	5.26e-15	Obesity-related traits;
LUAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg15117754	chr3:10150083	C3orf24	0.41	6.61	0.31	1.19e-10	Alzheimer's disease;
LUAD	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg02569458	chr12:86230093	RASSF9	0.44	7.96	0.36	1.58e-14	Major depressive disorder;
LUAD	cis	rs478304	0.934	rs509206	chr11:65493807	C/T	cg05805236	chr11:65401703	PCNXL3	0.45	7.6	0.35	1.96e-13	Acne (severe);
LUAD	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	6.51	0.3	2.17e-10	Rheumatoid arthritis;
LUAD	cis	rs2652834	0.808	rs11071723	chr15:63355275	A/T	cg25406657	chr15:63342033	TPM1	-0.44	-7.01	-0.32	9.27e-12	HDL cholesterol;
LUAD	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.06	-0.7	2.23e-63	Height;
LUAD	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg03161606	chr19:29218774	NA	0.61	8.68	0.39	8.9e-17	Methadone dose in opioid dependence;
LUAD	cis	rs7975161	1.000	rs7960443	chr12:104645363	G/A	cg25273343	chr12:104657179	TXNRD1	-0.68	-9.09	-0.4	3.91e-18	Toenail selenium levels;
LUAD	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03352830	chr11:487213	PTDSS2	0.79	10.17	0.44	7.04e-22	Body mass index;
LUAD	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg10589385	chr1:150898437	SETDB1	0.39	7.42	0.34	6.51e-13	Tonsillectomy;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02196458	chr15:90809250	NGRN	-0.49	-7.62	-0.35	1.67e-13	Height;
LUAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00166722	chr3:10149974	C3orf24	0.74	12.5	0.52	1.01e-30	Alzheimer's disease;
LUAD	cis	rs9469890	0.604	rs77587944	chr6:34503644	T/G	cg17674042	chr6:34482479	PACSIN1	-0.53	-7.24	-0.33	2.2e-12	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs4845570	1.000	rs3811415	chr1:151763767	C/T	cg07092448	chr1:151763213	TDRKH	-0.76	-8.75	-0.39	5.14e-17	Coronary artery disease;
LUAD	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.79	-0.39	3.85e-17	Total body bone mineral density;
LUAD	cis	rs7592578	0.603	rs12476782	chr2:191472880	G/A	cg11845111	chr2:191398756	TMEM194B	-0.71	-9.27	-0.41	9.3e-19	Diastolic blood pressure;
LUAD	cis	rs1595825	0.891	rs1968488	chr2:198721827	C/A	cg10547527	chr2:198650123	BOLL	-0.56	-7.91	-0.36	2.23e-14	Ulcerative colitis;
LUAD	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg12011299	chr4:100065546	ADH4	0.84	20.51	0.71	2.14e-65	HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs11048434	0.761	rs12824380	chr12:9132017	A/G	cg26114124	chr12:9217669	LOC144571	0.4	7.3	0.33	1.4e-12	Sjögren's syndrome;
LUAD	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.6	11.34	0.48	3.24e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs10411161	0.702	rs11878586	chr19:52388576	A/G	cg22319618	chr22:45562946	NUP50	-0.65	-9.45	-0.42	2.39e-19	Breast cancer;
LUAD	cis	rs75557865	1	rs75557865	chr3:121652141	G/A	cg20356878	chr3:121714668	ILDR1	0.76	16.38	0.62	4.52e-47	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg04183933	chr2:198363868	HSPD1;HSPE1	0.39	6.36	0.3	5.18e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.33	-0.45	1.89e-22	Total body bone mineral density;
LUAD	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg17333051	chr19:2783644	SGTA	0.44	6.99	0.32	1.09e-11	Total cholesterol levels;
LUAD	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg03732007	chr1:2071316	PRKCZ	-0.35	-6.66	-0.31	8.63e-11	Height;
LUAD	cis	rs7851660	0.506	rs1912996	chr9:100598261	G/T	cg13688889	chr9:100608707	NA	-0.62	-10.19	-0.44	5.75e-22	Strep throat;
LUAD	cis	rs3733418	0.929	rs4690797	chr4:165908505	G/C	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-6.99	-0.32	1.08e-11	Obesity-related traits;
LUAD	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg27211696	chr2:191398769	TMEM194B	-0.65	-8.73	-0.39	5.79e-17	Diastolic blood pressure;
LUAD	cis	rs1957429	0.808	rs7149922	chr14:65334541	C/T	cg23373153	chr14:65346875	NA	0.61	6.73	0.31	5.42e-11	Pediatric areal bone mineral density (radius);
LUAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg25703541	chr22:24373054	LOC391322	-0.74	-12.39	-0.52	2.62e-30	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg03714773	chr7:91764589	CYP51A1	0.28	6.7	0.31	6.49e-11	Breast cancer;
LUAD	trans	rs7542767	1.000	rs10911561	chr1:184305874	G/T	cg20099968	chr4:1364147	KIAA1530	0.5	6.37	0.3	4.89e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs877282	0.947	rs7475589	chr10:767479	C/G	cg17470449	chr10:769945	NA	0.61	8.66	0.39	1.03e-16	Uric acid levels;
LUAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg19626725	chr5:178986131	RUFY1	-0.54	-9.6	-0.42	7.02e-20	Lung cancer;
LUAD	cis	rs4692589	0.540	rs1904823	chr4:170956772	C/T	cg19918862	chr4:170955249	NA	0.34	6.81	0.31	3.39e-11	Anxiety disorder;
LUAD	cis	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-7.19	-0.33	3.03e-12	Neuroticism;
LUAD	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg16680214	chr1:154839983	KCNN3	-0.63	-13.31	-0.54	5.27e-34	Prostate cancer;
LUAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg22535103	chr8:58192502	C8orf71	-0.75	-9.17	-0.41	2.16e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg10435618	chr10:838112	NA	0.47	6.48	0.3	2.5e-10	Eosinophil percentage of granulocytes;
LUAD	trans	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg03886242	chr7:26192032	NFE2L3	-0.47	-8.37	-0.38	8.51e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg16647868	chr5:131706066	SLC22A5	0.38	6.46	0.3	2.82e-10	Acylcarnitine levels;
LUAD	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg15448220	chr1:150897856	SETDB1	0.54	9.12	0.41	3.08e-18	Melanoma;
LUAD	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg17724175	chr1:150552817	MCL1	0.37	8.66	0.39	9.68e-17	Melanoma;
LUAD	cis	rs8060686	0.623	rs6499162	chr16:68239460	T/C	cg05110241	chr16:68378359	PRMT7	-0.56	-7.17	-0.33	3.34e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg07917127	chr4:99064746	C4orf37	0.42	6.99	0.32	1.05e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1865721	0.728	rs8087297	chr18:73136221	T/A	cg26385618	chr18:73139727	C18orf62	-0.51	-10.33	-0.45	1.88e-22	Intelligence;
LUAD	cis	rs12579753	0.917	rs7306043	chr12:82191282	G/A	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.28	-0.33	1.6e-12	Resting heart rate;
LUAD	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg26195577	chr20:24973756	C20orf3	0.97	16.73	0.63	1.41e-48	Blood protein levels;
LUAD	cis	rs12618769	0.652	rs7588254	chr2:99217785	G/T	cg10123293	chr2:99228465	UNC50	0.47	8.55	0.38	2.28e-16	Bipolar disorder;
LUAD	cis	rs7665090	0.840	rs7674640	chr4:103540780	C/T	cg07973026	chr4:103553119	MANBA	0.48	8.14	0.37	4.49e-15	Primary biliary cholangitis;
LUAD	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07685180	chr8:600429	NA	-0.83	-8.61	-0.39	1.47e-16	IgG glycosylation;
LUAD	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01570182	chr17:44337453	NA	1.12	17.45	0.65	9.64e-52	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs11083241	0.570	rs7243677	chr18:25558198	C/T	cg06642177	chr6:134496341	SGK1	-0.4	-6.75	-0.31	4.86e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22455342	chr2:225449267	CUL3	0.68	10.48	0.45	5.34e-23	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg11062466	chr8:58055876	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10465746	0.725	rs2024591	chr1:84329235	C/T	cg10977910	chr1:84465055	TTLL7	0.61	9.92	0.43	5.25e-21	Obesity-related traits;
LUAD	cis	rs986417	1.000	rs1254302	chr14:60885343	A/C	cg27398547	chr14:60952738	C14orf39	-0.65	-7.72	-0.35	8.48e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs6831352	0.879	rs56222233	chr4:100069627	T/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.26	-0.54	8.48e-34	Alcohol dependence;
LUAD	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg03467027	chr4:99064603	C4orf37	0.41	6.67	0.31	8.11e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg00394040	chr11:117856785	IL10RA	-0.4	-6.35	-0.3	5.62e-10	Protein C levels;
LUAD	cis	rs11361923	1	rs11361923	chr14:77862679	GC/G	cg20045696	chr14:77926864	AHSA1	-0.36	-6.46	-0.3	2.92e-10	Sum basophil neutrophil counts;White blood cell count;Granulocyte count;
LUAD	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg24101359	chr6:42928495	GNMT	0.45	8.36	0.38	9.13e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2637266	1.000	rs7101318	chr10:78379780	T/C	cg18941641	chr10:78392320	NA	0.34	7.06	0.32	6.66e-12	Pulmonary function;
LUAD	cis	rs62400317	0.762	rs12208332	chr6:44903221	C/T	cg18551225	chr6:44695536	NA	-0.58	-8.87	-0.4	2.13e-17	Total body bone mineral density;
LUAD	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg15962314	chr1:44399869	ARTN	0.31	6.8	0.31	3.64e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs72928364	1.000	rs13100301	chr3:100651722	C/T	cg10123952	chr3:100791384	NA	0.65	7.37	0.34	8.86e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg13319975	chr6:146136371	FBXO30	0.59	9.85	0.43	9.58e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg25566285	chr7:158114605	PTPRN2	0.51	10.84	0.47	2.6e-24	Calcium levels;
LUAD	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.92	9.59	0.42	7.93e-20	Initial pursuit acceleration;
LUAD	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg10518543	chr12:38710700	ALG10B	-0.41	-6.86	-0.32	2.45e-11	Bladder cancer;
LUAD	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg17264618	chr3:40429014	ENTPD3	0.43	8.96	0.4	1.04e-17	Renal cell carcinoma;
LUAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg11494091	chr17:61959527	GH2	0.74	18.66	0.67	3.9e-57	Prudent dietary pattern;
LUAD	cis	rs4285028	0.948	rs73855481	chr3:121676951	C/A	cg11130432	chr3:121712080	ILDR1	-0.59	-8.44	-0.38	5.05e-16	Multiple sclerosis;
LUAD	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg08989290	chr16:615782	NHLRC4	0.31	6.72	0.31	5.85e-11	Height;
LUAD	cis	rs977987	0.806	rs6564258	chr16:75447363	G/A	cg03315344	chr16:75512273	CHST6	0.64	14.06	0.56	4.3e-37	Dupuytren's disease;
LUAD	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg25811766	chr13:21894605	NA	0.67	8.93	0.4	1.28e-17	White matter hyperintensity burden;
LUAD	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg13319975	chr6:146136371	FBXO30	-0.57	-9.35	-0.41	5.1e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs943466	1.000	rs55775340	chr6:33751784	C/G	cg16010596	chr6:33739607	LEMD2	-0.39	-7.34	-0.34	1.11e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05013942	chr17:36003336	DDX52	-0.42	-6.39	-0.3	4.43e-10	Height;
LUAD	cis	rs938554	0.735	rs12498742	chr4:9944052	A/G	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.5	-0.34	3.88e-13	Blood metabolite levels;
LUAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.13	-0.41	2.77e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.88	0.4	1.99e-17	Lung cancer in ever smokers;
LUAD	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg07828340	chr4:882639	GAK	1.0	10.06	0.44	1.72e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.91	-0.32	1.83e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg22117172	chr7:91764530	CYP51A1	0.33	7.28	0.33	1.61e-12	Breast cancer;
LUAD	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg08601574	chr20:25228251	PYGB	0.46	8.8	0.39	3.41e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7119038	0.818	rs56043232	chr11:118648373	C/T	cg19308663	chr11:118741387	NA	0.48	6.74	0.31	5.14e-11	Sjögren's syndrome;
LUAD	cis	rs220324	1.000	rs220324	chr21:43586699	C/T	cg08841829	chr21:43638893	ABCG1	0.4	6.49	0.3	2.45e-10	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg14008862	chr17:28927542	LRRC37B2	0.55	6.39	0.3	4.32e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg08645402	chr16:4508243	NA	0.53	9.03	0.4	6.17e-18	Schizophrenia;
LUAD	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg22920501	chr2:26401640	FAM59B	-0.82	-11.58	-0.49	4e-27	Gut microbiome composition (summer);
LUAD	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg12564285	chr5:131593104	PDLIM4	0.37	6.45	0.3	3.08e-10	Breast cancer;
LUAD	cis	rs3820068	0.677	rs72643691	chr1:15856251	T/C	cg13390004	chr1:15929781	NA	0.42	6.77	0.31	4.28e-11	Systolic blood pressure;
LUAD	cis	rs7394190	0.748	rs11000766	chr10:75512952	C/T	cg02286717	chr10:75415704	SYNPO2L	-0.38	-6.64	-0.31	9.46e-11	Incident atrial fibrillation;
LUAD	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg21545522	chr1:205238299	TMCC2	0.38	6.94	0.32	1.52e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	trans	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg12575136	chr18:32820987	ZNF397	0.45	7.01	0.32	9.21e-12	White blood cell count;
LUAD	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.82	11.48	0.49	9.94e-27	Smoking behavior;
LUAD	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg06611532	chr13:114900021	NA	-0.36	-8.44	-0.38	5.11e-16	Schizophrenia;
LUAD	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg25036284	chr2:26402008	FAM59B	-0.61	-8.47	-0.38	4.02e-16	Gut microbiome composition (summer);
LUAD	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg15128208	chr22:42549153	NA	0.37	7.57	0.35	2.41e-13	Cognitive function;
LUAD	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14240646	chr10:27532245	ACBD5	-0.86	-11.78	-0.5	6.45e-28	Breast cancer;
LUAD	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05776053	chr2:74358815	NA	0.51	7.22	0.33	2.47e-12	Gestational age at birth (maternal effect);
LUAD	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg07362569	chr17:61921086	SMARCD2	0.39	6.73	0.31	5.52e-11	Prudent dietary pattern;
LUAD	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg01028140	chr2:1542097	TPO	-0.49	-6.63	-0.31	1.03e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs72781680	0.821	rs72790304	chr2:24108557	G/A	cg20701182	chr2:24300061	SF3B14	0.5	6.41	0.3	3.81e-10	Lymphocyte counts;
LUAD	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg16060761	chr17:80687452	NA	-0.58	-8.42	-0.38	5.92e-16	Glycated hemoglobin levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg05881776	chr2:235860554	SH3BP4	-0.4	-7.33	-0.34	1.19e-12	Schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22253313	chr4:2011099	WHSC2	-0.54	-6.43	-0.3	3.47e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg00750074	chr16:89608354	SPG7	-0.57	-9.68	-0.43	3.9e-20	Multiple myeloma (IgH translocation);
LUAD	cis	rs2446066	0.605	rs7314664	chr12:53957586	T/C	cg20730629	chr12:53886622	MAP3K12	-0.52	-6.71	-0.31	6.23e-11	Red blood cell count;
LUAD	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg13319975	chr6:146136371	FBXO30	-0.59	-9.97	-0.44	3.57e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.37	0.48	2.49e-26	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs679087	0.659	rs302318	chr12:29921667	T/C	cg14258853	chr12:29935411	TMTC1	-0.5	-8.85	-0.4	2.33e-17	Schizophrenia;
LUAD	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg23281280	chr6:28129359	ZNF389	0.48	6.71	0.31	6.44e-11	Depression;
LUAD	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.18	-0.37	3.32e-15	Height;
LUAD	cis	rs7903847	0.602	rs7916665	chr10:99157573	T/G	cg20016023	chr10:99160130	RRP12	-0.31	-7.38	-0.34	8.37e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7786808	0.508	rs896765	chr7:158182809	G/A	cg09998033	chr7:158218633	PTPRN2	0.44	7.77	0.35	6.02e-14	Obesity-related traits;
LUAD	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg15147215	chr3:52552868	STAB1	-0.39	-7.03	-0.32	8.47e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs71478720	0.953	rs7131094	chr11:112044917	C/T	cg26534425	chr11:112034925	IL18	0.43	6.57	0.3	1.47e-10	Interleukin-18 levels;
LUAD	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg25287198	chr4:183728479	NA	0.54	6.36	0.3	5.11e-10	Pediatric autoimmune diseases;
LUAD	cis	rs1868673	1.000	rs6770424	chr3:150174304	A/G	cg04908077	chr3:150187338	NA	-0.32	-6.62	-0.31	1.12e-10	Waist circumference;
LUAD	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06112835	chr11:68658793	MRPL21	0.51	9.37	0.41	4.35e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg00769240	chr8:12517080	NA	-0.43	-8.44	-0.38	5.24e-16	Blood pressure (smoking interaction);
LUAD	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12756686	chr19:29218302	NA	0.66	10.16	0.44	7.65e-22	Methadone dose in opioid dependence;
LUAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-8.28	-0.37	1.6e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.08	-0.44	1.5e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg06002616	chr8:101225028	SPAG1	0.38	7.82	0.36	4.3e-14	Atrioventricular conduction;
LUAD	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs12478296	0.786	rs55876934	chr2:243033816	C/T	cg06360820	chr2:242988706	NA	-0.8	-9.06	-0.4	4.7e-18	Obesity-related traits;
LUAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg10729496	chr3:10149963	C3orf24	0.48	7.81	0.36	4.42e-14	Alzheimer's disease;
LUAD	cis	rs3768617	0.565	rs2022392	chr1:183104863	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.06	0.32	6.76e-12	Fuchs's corneal dystrophy;
LUAD	trans	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.9	-0.36	2.51e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9814567	0.806	rs9857242	chr3:134316378	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.07	0.54	4.88e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg12365402	chr11:9010492	NRIP3	-0.44	-8.36	-0.38	8.96e-16	Hemoglobin concentration;
LUAD	cis	rs896543	0.702	rs12692188	chr2:237495929	A/G	cg25295825	chr2:237489920	CXCR7	0.46	8.33	0.38	1.18e-15	Alcohol dependence (age at onset);
LUAD	cis	rs7771547	0.607	rs614028	chr6:36484252	G/A	cg07856975	chr6:36356162	ETV7	0.42	6.43	0.3	3.46e-10	Platelet distribution width;
LUAD	cis	rs6669119	0.668	rs17354622	chr1:19087996	G/T	cg19637330	chr1:19110922	NA	0.63	7.32	0.34	1.25e-12	Percentage gas trapping;
LUAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.68	0.31	7.6e-11	Prudent dietary pattern;
LUAD	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.25	-0.51	9.53e-30	Platelet count;
LUAD	cis	rs1595825	0.891	rs58111212	chr2:198889896	T/C	cg00361562	chr2:198649771	BOLL	-0.47	-6.5	-0.3	2.29e-10	Ulcerative colitis;
LUAD	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg05340658	chr4:99064831	C4orf37	-0.46	-7.63	-0.35	1.61e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.43	-7.08	-0.33	6.09e-12	Tonsillectomy;
LUAD	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg22681709	chr2:178499509	PDE11A	-0.45	-7.36	-0.34	9.54e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7192380	0.965	rs4633710	chr16:69632961	A/G	cg26679644	chr16:69762563	NA	0.48	9.43	0.42	2.8e-19	Sjögren's syndrome;
LUAD	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-6.42	-0.3	3.65e-10	Tonsillectomy;
LUAD	cis	rs790123	0.604	rs16834903	chr3:122379614	G/A	cg15604389	chr3:122379662	NA	0.42	6.87	0.32	2.36e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs1232027	0.622	rs1346463	chr5:79967652	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.82	-0.31	3.06e-11	Huntington's disease progression;
LUAD	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18404041	chr3:52824283	ITIH1	-0.57	-11.98	-0.5	1.15e-28	Electroencephalogram traits;
LUAD	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg10518543	chr12:38710700	ALG10B	0.41	6.36	0.3	5.13e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg06028808	chr11:68637592	NA	0.44	6.98	0.32	1.14e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg11344533	chr11:111475393	SIK2	-0.36	-6.69	-0.31	6.88e-11	Primary sclerosing cholangitis;
LUAD	cis	rs1832871	0.672	rs9456286	chr6:158734315	A/G	cg07165851	chr6:158734300	TULP4	0.72	10.96	0.47	8.77e-25	Height;
LUAD	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.39	-10.09	-0.44	1.4e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg08470875	chr2:26401718	FAM59B	0.63	8.11	0.37	5.61e-15	Gut microbiome composition (summer);
LUAD	cis	rs2268241	0.877	rs17887186	chr21:34779202	G/A	cg14850771	chr21:34775459	IFNGR2	0.58	6.78	0.31	4.11e-11	Obesity-related traits;
LUAD	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-8.39	-0.38	7.37e-16	Total body bone mineral density;
LUAD	cis	rs262150	0.625	rs55882200	chr7:158769280	G/C	cg09640425	chr7:158790006	NA	0.54	6.63	0.31	1.03e-10	Facial morphology (factor 20);
LUAD	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg07305463	chr2:136567211	LCT	0.38	7.15	0.33	3.85e-12	Mosquito bite size;
LUAD	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg13770153	chr20:60521292	NA	-0.43	-7.04	-0.32	7.62e-12	Body mass index;
LUAD	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.49	6.65	0.31	9.19e-11	Platelet count;
LUAD	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg04267008	chr7:1944627	MAD1L1	-0.72	-11.14	-0.48	1.9e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs8017423	0.900	rs11625870	chr14:90693396	C/T	cg14092571	chr14:90743983	NA	0.46	7.85	0.36	3.41e-14	Mortality in heart failure;
LUAD	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg15123519	chr2:136567270	LCT	0.39	7.11	0.33	4.99e-12	Mosquito bite size;
LUAD	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg21252483	chr19:49399788	TULP2	-0.88	-14.31	-0.57	3.61e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs78761021	0.867	rs62067562	chr17:9785946	T/A	cg26853458	chr17:9805074	RCVRN	0.37	7.36	0.34	9.97e-13	Type 2 diabetes;
LUAD	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Colorectal cancer;
LUAD	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg06740227	chr12:86229804	RASSF9	0.47	8.15	0.37	4.17e-15	Major depressive disorder;
LUAD	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg17633681	chr16:88106987	BANP	0.39	6.9	0.32	1.9e-11	Menopause (age at onset);
LUAD	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.45	-7.42	-0.34	6.36e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg09117114	chr16:67998030	SLC12A4	-0.63	-8.22	-0.37	2.59e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs300703	0.515	rs300695	chr2:182644	C/A	cg21211680	chr2:198530	NA	-0.53	-7.88	-0.36	2.86e-14	Blood protein levels;
LUAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg11494091	chr17:61959527	GH2	0.75	18.75	0.67	1.64e-57	Prudent dietary pattern;
LUAD	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23158103	chr7:148848205	ZNF398	0.46	8.03	0.36	9.58e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg13736514	chr6:26305472	NA	-0.44	-7.22	-0.33	2.51e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7771547	0.603	rs10947615	chr6:36599596	T/C	cg07856975	chr6:36356162	ETV7	0.53	7.09	0.33	5.61e-12	Platelet distribution width;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg23526055	chr8:74884794	TCEB1	-0.39	-6.75	-0.31	4.74e-11	Subcortical brain region volumes;
LUAD	cis	rs9796	0.558	rs4445868	chr15:41531991	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.46	-8.48	-0.38	3.71e-16	Menopause (age at onset);
LUAD	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg26408565	chr15:76604113	ETFA	-0.43	-6.95	-0.32	1.43e-11	Blood metabolite levels;
LUAD	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg21427119	chr20:30132790	HM13	-0.49	-7.72	-0.35	8.73e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs7945705	0.846	rs905290	chr11:8753729	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.48	8.55	0.38	2.24e-16	Hemoglobin concentration;
LUAD	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg12403142	chr1:92012408	NA	-0.35	-6.53	-0.3	1.92e-10	Breast cancer;
LUAD	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg18404041	chr3:52824283	ITIH1	0.41	7.44	0.34	5.7e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg11247378	chr22:39784982	NA	-0.74	-13.48	-0.55	1.05e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg08859206	chr1:53392774	SCP2	-0.59	-10.75	-0.46	5.26e-24	Monocyte count;
LUAD	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg10356904	chr22:49881777	NA	-0.39	-7.1	-0.33	5.25e-12	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs1728785	1.000	rs698719	chr16:68560125	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	9.51	0.42	1.44e-19	Ulcerative colitis;
LUAD	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg00495681	chr13:53174319	NA	0.87	17.96	0.66	5.39e-54	Lewy body disease;
LUAD	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg12935359	chr14:103987150	CKB	-0.47	-7.42	-0.34	6.53e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg03609598	chr5:56110824	MAP3K1	-0.56	-6.56	-0.3	1.59e-10	Type 2 diabetes;
LUAD	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-6.68	-0.31	7.38e-11	Tonsillectomy;
LUAD	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg24324837	chr19:49891574	CCDC155	0.46	6.49	0.3	2.36e-10	Multiple sclerosis;
LUAD	cis	rs698833	0.886	rs1056865	chr2:44546741	A/G	cg04920474	chr2:44395004	PPM1B	0.39	6.76	0.31	4.47e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg26587870	chr6:27730563	NA	-0.44	-7.15	-0.33	3.76e-12	Parkinson's disease;
LUAD	cis	rs4604732	0.578	rs12038656	chr1:247623816	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.43	7.0	0.32	9.95e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg16342193	chr10:102329863	NA	-0.39	-6.76	-0.31	4.72e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18404041	chr3:52824283	ITIH1	-0.63	-12.7	-0.53	1.58e-31	Bipolar disorder;
LUAD	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.37	-0.3	4.96e-10	Bladder cancer;
LUAD	cis	rs7677751	0.806	rs7673853	chr4:55096606	T/C	cg17187183	chr4:55093834	PDGFRA	0.51	8.63	0.39	1.23e-16	Corneal astigmatism;
LUAD	trans	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg06606381	chr12:133084897	FBRSL1	-0.9	-8.49	-0.38	3.45e-16	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg14791747	chr16:20752902	THUMPD1	0.45	6.53	0.3	1.89e-10	Cognitive test performance;
LUAD	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg02158880	chr13:53174818	NA	-0.49	-8.16	-0.37	3.94e-15	Lewy body disease;
LUAD	cis	rs9372498	0.505	rs62422248	chr6:118987610	T/C	cg07617317	chr6:118971624	C6orf204	0.54	8.2	0.37	2.89e-15	Diastolic blood pressure;
LUAD	cis	rs11030122	0.673	rs10835596	chr11:4099666	C/T	cg18678763	chr11:4115507	RRM1	-0.47	-7.66	-0.35	1.26e-13	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2294693	0.541	rs11756247	chr6:40944111	A/G	cg14769373	chr6:40998127	UNC5CL	-0.47	-6.46	-0.3	2.96e-10	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.87	-0.36	2.99e-14	Diabetic kidney disease;
LUAD	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg13385794	chr1:248469461	NA	0.26	6.76	0.31	4.7e-11	Common traits (Other);
LUAD	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg06608945	chr2:219082296	ARPC2	0.44	7.14	0.33	4.14e-12	Colorectal cancer;
LUAD	cis	rs6840360	0.571	rs11939356	chr4:152505234	G/C	cg22705602	chr4:152727874	NA	-0.43	-7.47	-0.34	4.78e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7582720	0.943	rs115628302	chr2:203690047	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.38	0.41	4.03e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7274811	0.625	rs293725	chr20:31929643	C/G	cg14921437	chr20:32255988	NECAB3;C20orf134	0.44	6.36	0.3	5.12e-10	Height;
LUAD	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02788857	chr8:22132959	PIWIL2	0.58	10.61	0.46	1.81e-23	Hypertriglyceridemia;
LUAD	cis	rs4774899	1.000	rs12899588	chr15:57476858	A/G	cg14026238	chr15:57616123	NA	0.36	6.71	0.31	6.08e-11	Urinary tract infection frequency;
LUAD	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg18944383	chr4:111397179	ENPEP	0.37	7.68	0.35	1.12e-13	Height;
LUAD	cis	rs3087591	1.000	rs2107360	chr17:29697901	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.4	-6.43	-0.3	3.43e-10	Hip circumference;
LUAD	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg06873352	chr17:61820015	STRADA	0.41	6.84	0.32	2.71e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-11.11	-0.48	2.4e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg20607798	chr8:58055168	NA	0.63	7.99	0.36	1.27e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg06641503	chr3:48959341	ARIH2	-0.41	-8.03	-0.36	9.54e-15	Parkinson's disease;
LUAD	cis	rs2274273	0.805	rs28660594	chr14:55846174	T/C	cg04306507	chr14:55594613	LGALS3	0.41	8.72	0.39	6.57e-17	Protein biomarker;
LUAD	cis	rs478304	0.718	rs1144789	chr11:65389631	A/G	cg05805236	chr11:65401703	PCNXL3	0.47	7.89	0.36	2.58e-14	Acne (severe);
LUAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg26354017	chr1:205819088	PM20D1	0.92	22.29	0.73	2.25e-73	Menarche (age at onset);
LUAD	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7267979	0.714	rs3787082	chr20:25235736	A/T	cg08601574	chr20:25228251	PYGB	0.45	8.35	0.38	1e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg04756594	chr16:24857601	SLC5A11	0.5	9.78	0.43	1.75e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg07741184	chr6:167504864	NA	0.35	8.15	0.37	4.3e-15	Crohn's disease;
LUAD	cis	rs7172809	0.599	rs2307141	chr15:77756418	A/G	cg11865553	chr15:77376250	NA	-0.39	-6.39	-0.3	4.51e-10	Glucose homeostasis traits;
LUAD	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg05865280	chr17:75406074	SEPT9	0.61	19.3	0.68	5.44e-60	Airflow obstruction;
LUAD	trans	rs4650994	0.524	rs2476558	chr1:178580953	C/T	cg05059571	chr16:84539110	KIAA1609	0.66	11.49	0.49	8.83e-27	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs56283067	0.847	rs10456118	chr6:44692825	G/T	cg20913747	chr6:44695427	NA	-0.44	-7.45	-0.34	5.16e-13	Total body bone mineral density;
LUAD	cis	rs243505	0.528	rs1558419	chr7:148480233	C/T	cg09806900	chr7:148480153	CUL1	0.45	7.97	0.36	1.5e-14	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg27490568	chr2:178487706	NA	-0.39	-6.36	-0.3	5.18e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg15412446	chr2:106886593	NA	-0.63	-9.66	-0.43	4.5e-20	Facial morphology (factor 23);
LUAD	cis	rs10489202	0.657	rs3767478	chr1:168069626	G/A	cg25738037	chr1:168025549	DCAF6	-0.45	-6.36	-0.3	5.22e-10	Schizophrenia;
LUAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg03188948	chr7:1209495	NA	0.41	6.57	0.3	1.45e-10	Longevity;Endometriosis;
LUAD	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18099408	chr3:52552593	STAB1	-0.46	-8.09	-0.37	6.6e-15	Bipolar disorder;
LUAD	cis	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg07460842	chr6:66804631	NA	-1.06	-16.78	-0.63	8.55e-49	Exhaled nitric oxide output;
LUAD	cis	rs240764	0.658	rs7451736	chr6:101189901	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.55	-0.38	2.24e-16	Neuroticism;
LUAD	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg07917127	chr4:99064746	C4orf37	0.44	7.22	0.33	2.45e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12760731	0.565	rs7541122	chr1:178199214	G/C	cg00404053	chr1:178313656	RASAL2	0.72	9.09	0.4	4.02e-18	Obesity-related traits;
LUAD	trans	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.08	26.01	0.78	9.34e-90	Colorectal cancer;
LUAD	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	7.21	0.33	2.58e-12	Hypertriglyceridemia;
LUAD	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg13385794	chr1:248469461	NA	0.26	7.03	0.32	8.6e-12	Common traits (Other);
LUAD	cis	rs469568	0.935	rs468723	chr5:178667778	A/G	cg08999896	chr5:178685787	ADAMTS2	0.36	7.39	0.34	7.89e-13	Stroke (pediatric);
LUAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg16606324	chr3:10149918	C3orf24	0.7	11.68	0.49	1.64e-27	Alzheimer's disease;
LUAD	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg19442545	chr10:75533431	FUT11	-0.5	-8.48	-0.38	3.71e-16	Inflammatory bowel disease;
LUAD	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	7.13	0.33	4.42e-12	Tonsillectomy;
LUAD	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.89	-0.66	1.08e-53	Height;
LUAD	trans	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg27411982	chr8:10470053	RP1L1	0.37	6.8	0.31	3.5e-11	Monocyte count;
LUAD	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg17264618	chr3:40429014	ENTPD3	0.43	9.08	0.4	4.26e-18	Renal cell carcinoma;
LUAD	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg22906224	chr7:99728672	NA	-0.67	-11.74	-0.5	9.85e-28	Coronary artery disease;
LUAD	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg18811423	chr2:55921094	PNPT1	0.47	7.59	0.35	2.08e-13	Metabolic syndrome;
LUAD	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg18827107	chr12:86230957	RASSF9	-0.54	-9.47	-0.42	1.97e-19	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg15962314	chr1:44399869	ARTN	0.31	6.92	0.32	1.7e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.32	-7.77	-0.35	6.21e-14	Prostate cancer;
LUAD	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg06618935	chr21:46677482	NA	-0.49	-10.03	-0.44	2.16e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12505328	0.514	rs1442158	chr4:174390045	C/G	cg12145043	chr4:174357286	NA	0.42	6.68	0.31	7.44e-11	Chin dimples;
LUAD	trans	rs7069733	0.877	rs1884931	chr10:105300343	A/G	cg23983269	chr5:175815749	HIGD2A;NOP16	-0.51	-6.55	-0.3	1.63e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg06606381	chr12:133084897	FBRSL1	-0.96	-9.29	-0.41	8.06e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg23758822	chr17:41437982	NA	0.99	20.05	0.7	2.44e-63	Menopause (age at onset);
LUAD	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg14458575	chr2:238380390	NA	0.79	16.24	0.62	1.89e-46	Prostate cancer;
LUAD	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg23954153	chr1:44402353	ARTN	0.38	7.28	0.33	1.65e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.84	9.6	0.42	6.95e-20	Initial pursuit acceleration;
LUAD	trans	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg19469189	chr11:128781035	KCNJ5	-0.42	-6.59	-0.31	1.28e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2279817	1.000	rs4920619	chr1:18023112	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.58	9.51	0.42	1.47e-19	Neuroticism;
LUAD	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	9.45	0.42	2.29e-19	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs909002	0.789	rs2139539	chr1:32117779	C/T	cg13919466	chr1:32135498	COL16A1	-0.39	-9.24	-0.41	1.24e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs4237845	0.680	rs10877033	chr12:58283731	T/C	cg12615879	chr12:58013172	SLC26A10	-0.34	-6.91	-0.32	1.84e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg05082376	chr22:42548792	NA	-0.45	-7.79	-0.35	5.21e-14	Schizophrenia;
LUAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22338127	chr1:209979572	IRF6	0.48	6.64	0.31	9.6e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs6445967	0.522	rs62259322	chr3:58291007	T/A	cg13750441	chr3:58318267	PXK	-0.3	-6.37	-0.3	4.96e-10	Platelet count;
LUAD	cis	rs743757	0.938	rs2236981	chr3:50488845	A/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.43	6.79	0.31	3.78e-11	Diastolic blood pressure;
LUAD	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	trans	rs875971	1.000	rs811880	chr7:65818646	T/C	cg14917512	chr19:3094685	GNA11	-0.37	-6.44	-0.3	3.29e-10	Aortic root size;
LUAD	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg05342682	chr7:94953680	PON1	-0.5	-6.91	-0.32	1.83e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.55	8.11	0.37	5.34e-15	Gut microbiome composition (summer);
LUAD	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11890956	chr21:40555474	PSMG1	0.78	13.58	0.55	4.02e-35	Cognitive function;
LUAD	cis	rs1829883	0.931	rs7713876	chr5:98878187	C/G	cg08333243	chr5:99726346	NA	-0.37	-7.05	-0.32	7.22e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs77972916	0.561	rs10167415	chr2:43552460	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-8.24	-0.37	2.12e-15	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg02269571	chr22:50332266	NA	0.63	9.59	0.42	7.99e-20	Schizophrenia;
LUAD	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg26384229	chr12:38710491	ALG10B	0.49	8.0	0.36	1.24e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-8.92	-0.4	1.46e-17	Gut microbiome composition (summer);
LUAD	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg05283184	chr6:79620031	NA	0.6	12.3	0.51	6.26e-30	Intelligence (multi-trait analysis);
LUAD	trans	rs412658	0.668	rs7253490	chr19:22293706	A/C	cg17074339	chr11:11642133	GALNTL4	0.35	6.57	0.3	1.52e-10	Telomere length;
LUAD	cis	rs589691	0.502	rs487662	chr11:64481880	G/A	cg19131476	chr11:64387923	NRXN2	-0.38	-6.91	-0.32	1.85e-11	Urate levels;
LUAD	cis	rs2573652	0.722	rs12595247	chr15:100541689	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.37	-6.84	-0.32	2.87e-11	Height;
LUAD	cis	rs7552167	1.000	rs7552167	chr1:24518643	A/G	cg01960748	chr1:24522592	NA	-0.74	-10.09	-0.44	1.38e-21	Psoriasis vulgaris;
LUAD	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg01206211	chr2:36825736	FEZ2	0.52	9.95	0.44	4.15e-21	Height;
LUAD	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg14983838	chr19:29218262	NA	0.63	9.69	0.43	3.54e-20	Methadone dose in opioid dependence;
LUAD	trans	rs2665103	0.715	rs16973457	chr15:82563991	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.47	-7.61	-0.35	1.85e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs877282	0.628	rs11253435	chr10:824169	T/C	cg22713356	chr15:30763199	NA	0.88	10.85	0.47	2.39e-24	Uric acid levels;
LUAD	cis	rs78761021	0.688	rs55811931	chr17:9796537	G/A	cg26853458	chr17:9805074	RCVRN	0.41	7.9	0.36	2.49e-14	Type 2 diabetes;
LUAD	cis	rs739496	0.947	rs11608565	chr12:111921926	T/A	cg10833066	chr12:111807467	FAM109A	0.42	6.77	0.31	4.34e-11	Platelet count;
LUAD	trans	rs2262909	0.962	rs390730	chr19:22233509	C/A	cg05197062	chr11:11642011	GALNTL4	-0.58	-9.12	-0.41	3.1e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg24679453	chr1:3079069	PRDM16	0.28	6.36	0.3	5.09e-10	Migraine;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01588776	chr1:155881290	RIT1	-0.38	-6.47	-0.3	2.75e-10	Cancer;
LUAD	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg00271210	chr6:167070053	RPS6KA2	0.34	6.52	0.3	1.96e-10	Crohn's disease;
LUAD	cis	rs10992471	0.603	rs12336415	chr9:95195458	G/T	cg14631576	chr9:95140430	CENPP	-0.56	-11.38	-0.48	2.42e-26	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg14345882	chr6:26364793	BTN3A2	0.64	6.44	0.3	3.32e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs73198271	0.515	rs74841285	chr8:8635450	C/T	cg01851573	chr8:8652454	MFHAS1	0.6	8.08	0.37	7.02e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg15208524	chr1:10270712	KIF1B	0.52	7.62	0.35	1.71e-13	Hepatocellular carcinoma;
LUAD	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	6.37	0.3	4.82e-10	Menarche (age at onset);
LUAD	cis	rs3125734	0.633	rs1873685	chr10:64032126	C/T	cg09941381	chr10:64027924	RTKN2	-0.33	-7.69	-0.35	1.05e-13	Rheumatoid arthritis;
LUAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg26338869	chr17:61819248	STRADA	0.38	6.35	0.3	5.52e-10	Prudent dietary pattern;
LUAD	trans	rs71537559	1	rs71537559	chr6:27309779	G/C	cg01620082	chr3:125678407	NA	-0.81	-8.7	-0.39	7.23e-17	Squamous cell lung carcinoma;
LUAD	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg05340658	chr4:99064831	C4orf37	0.52	8.63	0.39	1.28e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910187	0.605	rs2235907	chr20:45809652	A/G	cg27589058	chr20:45804311	EYA2	-0.34	-7.69	-0.35	1.06e-13	Migraine;
LUAD	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-23.49	-0.75	1.05e-78	Height;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07953307	chr16:29000920	LAT	-0.44	-7.21	-0.33	2.68e-12	Cancer;
LUAD	cis	rs7680126	0.596	rs10805364	chr4:10275518	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.8	-0.31	3.54e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg06873352	chr17:61820015	STRADA	0.42	7.01	0.32	9.4e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4953076	0.573	rs2053456	chr2:44448632	G/A	cg04920474	chr2:44395004	PPM1B	0.52	8.07	0.37	7.25e-15	Height;
LUAD	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg18016565	chr1:150552671	MCL1	0.42	7.72	0.35	8.76e-14	Melanoma;
LUAD	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg27068330	chr11:65405492	SIPA1	0.54	8.6	0.39	1.6e-16	Acne (severe);
LUAD	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.67	-10.64	-0.46	1.39e-23	Chronic sinus infection;
LUAD	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg09365446	chr1:150670422	GOLPH3L	0.54	9.4	0.42	3.37e-19	Melanoma;
LUAD	cis	rs1403694	0.515	rs1656925	chr3:186449123	T/C	cg12454167	chr3:186435060	KNG1	0.41	8.5	0.38	3.18e-16	Blood protein levels;
LUAD	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg09365446	chr1:150670422	GOLPH3L	0.66	12.58	0.52	4.9e-31	Tonsillectomy;
LUAD	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg06108461	chr20:60628389	TAF4	-0.91	-13.87	-0.56	2.55e-36	Body mass index;
LUAD	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.07	-14.74	-0.58	5.45e-40	Schizophrenia;
LUAD	cis	rs8044868	0.530	rs12932845	chr16:72122765	G/A	cg23815491	chr16:72088622	HP	0.5	9.28	0.41	9.11e-19	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs863345	0.604	rs11265010	chr1:158498853	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs59698941	0.943	rs66483023	chr5:132257748	A/T	cg14825688	chr5:132208181	LEAP2	-0.47	-6.41	-0.3	3.91e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg01503450	chr10:980765	NA	-0.37	-6.36	-0.3	5.17e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs2282300	0.739	rs1222210	chr11:30362125	A/G	cg25418670	chr11:30344373	C11orf46	0.5	6.87	0.32	2.29e-11	Morning vs. evening chronotype;
LUAD	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.71	-0.35	8.94e-14	Total body bone mineral density;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26726542	chr13:20702031	NA	-0.56	-6.87	-0.32	2.31e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg26769984	chr7:1090371	C7orf50	-0.68	-10.58	-0.46	2.28e-23	Bronchopulmonary dysplasia;
LUAD	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg02733842	chr7:1102375	C7orf50	-0.68	-10.15	-0.44	8.49e-22	Bronchopulmonary dysplasia;
LUAD	cis	rs790123	1.000	rs790125	chr3:122388464	A/G	cg22896480	chr3:122379438	NA	0.41	6.93	0.32	1.58e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.65	-0.42	4.78e-20	Monocyte percentage of white cells;
LUAD	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg11919837	chr8:57350735	NA	-0.43	-6.44	-0.3	3.19e-10	Obesity-related traits;
LUAD	cis	rs9486719	1.000	rs2499816	chr6:96878206	C/T	cg06623918	chr6:96969491	KIAA0776	0.71	10.02	0.44	2.32e-21	Migraine;Coronary artery disease;
LUAD	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg02176678	chr2:219576539	TTLL4	0.74	14.87	0.59	1.63e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs490234	0.702	rs35129945	chr9:128320134	C/T	cg14078157	chr9:128172775	NA	-0.45	-8.09	-0.37	6.57e-15	Mean arterial pressure;
LUAD	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-11.55	-0.49	5.01e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs3857536	0.842	rs2188591	chr6:66939511	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg24801067	chr17:62843696	NA	-0.54	-7.55	-0.34	2.78e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2735413	0.918	rs4888728	chr16:78077199	C/G	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7680126	0.633	rs4697745	chr4:10305081	G/A	cg02734326	chr4:10020555	SLC2A9	-0.5	-6.59	-0.31	1.28e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs986417	0.901	rs713449	chr14:61029084	C/G	cg27398547	chr14:60952738	C14orf39	0.67	7.85	0.36	3.42e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs8017423	0.967	rs61231898	chr14:90691696	G/A	cg14092571	chr14:90743983	NA	-0.49	-8.59	-0.39	1.7e-16	Mortality in heart failure;
LUAD	cis	rs28719689	0.541	rs28376074	chr8:1274394	A/T	cg22761795	chr8:1265118	NA	0.63	7.89	0.36	2.64e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg02375832	chr11:62437615	C11orf48	-0.32	-6.83	-0.32	3.03e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg26384229	chr12:38710491	ALG10B	0.4	6.44	0.3	3.27e-10	Morning vs. evening chronotype;
LUAD	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg08601574	chr20:25228251	PYGB	-0.47	-8.81	-0.39	3.3e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg03948781	chr1:205179583	DSTYK	0.35	6.68	0.31	7.56e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs4604732	0.588	rs7549495	chr1:247627806	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	9.17	0.41	2.14e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg03806693	chr22:41940476	POLR3H	-0.78	-11.01	-0.47	5.6e-25	Vitiligo;
LUAD	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg26513180	chr16:89883248	FANCA	0.47	7.51	0.34	3.5e-13	Vitiligo;
LUAD	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg23260525	chr10:116636907	FAM160B1	0.47	11.0	0.47	6.26e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs60787346	0.883	rs2838334	chr21:45064961	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-7.66	-0.35	1.27e-13	Coronary artery disease;
LUAD	cis	rs7000551	0.751	rs2469770	chr8:22379856	G/A	cg12081754	chr8:22256438	SLC39A14	0.51	8.39	0.38	7.21e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.35	-6.39	-0.3	4.27e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg21963583	chr11:68658836	MRPL21	0.64	11.45	0.49	1.21e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg07636037	chr3:49044803	WDR6	0.57	10.66	0.46	1.16e-23	Parkinson's disease;
LUAD	cis	rs5017598	1.000	rs5017598	chr6:169211494	A/G	cg05672967	chr6:169256475	NA	0.46	9.59	0.42	7.63e-20	Pediatric bone mineral density (femoral neck);Pediatric bone mineral density (hip);
LUAD	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.98	0.36	1.43e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs240764	0.658	rs1336244	chr6:101197953	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-8.38	-0.38	7.87e-16	Neuroticism;
LUAD	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.95	-0.36	1.67e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6076065	1.000	rs2424553	chr20:23403939	A/G	cg11657817	chr20:23433608	CST11	0.45	8.78	0.39	4.22e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs9914988	0.619	rs35477460	chr17:27320276	C/T	cg02049041	chr17:27085579	C17orf63	0.53	6.7	0.31	6.47e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg03806693	chr22:41940476	POLR3H	0.72	9.68	0.43	3.68e-20	Vitiligo;
LUAD	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg23758822	chr17:41437982	NA	0.97	20.73	0.71	2.24e-66	Menopause (age at onset);
LUAD	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	6.7	0.31	6.84e-11	Lung cancer in ever smokers;
LUAD	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg05368731	chr17:41323189	NBR1	0.83	16.4	0.62	3.87e-47	Menopause (age at onset);
LUAD	cis	rs9399401	0.890	rs7755109	chr6:142750392	C/T	cg03128060	chr6:142623767	GPR126	-0.29	-6.47	-0.3	2.68e-10	Chronic obstructive pulmonary disease;
LUAD	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg00277334	chr10:82204260	NA	-0.64	-10.34	-0.45	1.76e-22	Post bronchodilator FEV1;
LUAD	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg12940439	chr1:67600707	NA	0.48	8.85	0.4	2.36e-17	Psoriasis;
LUAD	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg00383909	chr3:49044727	WDR6	0.97	10.36	0.45	1.46e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg11859384	chr17:80120422	CCDC57	-0.5	-9.0	-0.4	7.72e-18	Life satisfaction;
LUAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-9.09	-0.4	3.92e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg07362569	chr17:61921086	SMARCD2	0.39	6.68	0.31	7.64e-11	Prudent dietary pattern;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16239906	chr20:35724590	RBL1	-0.41	-6.4	-0.3	4.1e-10	Height;
LUAD	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg07708487	chr16:89387014	ANKRD11	-0.32	-6.58	-0.3	1.41e-10	Multiple myeloma (IgH translocation);
LUAD	trans	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg04565464	chr8:145669602	NFKBIL2	-0.47	-7.26	-0.33	1.87e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.35	-7.33	-0.34	1.2e-12	Height;
LUAD	cis	rs10811516	0.520	rs4568676	chr9:21184475	C/G	cg23029519	chr9:21187344	IFNA4	0.45	8.42	0.38	5.76e-16	Response to mepolizumab in severe asthma;
LUAD	trans	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.84	-0.32	2.74e-11	Mood instability;
LUAD	cis	rs4700695	0.614	rs153387	chr5:65422236	G/A	cg21114390	chr5:65439923	SFRS12	-0.81	-7.27	-0.33	1.73e-12	Facial morphology (factor 19);
LUAD	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg20607798	chr8:58055168	NA	0.65	8.45	0.38	4.6e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.69	11.9	0.5	2.4e-28	Mean corpuscular volume;
LUAD	cis	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg20368463	chr18:77673604	PQLC1	-0.42	-6.82	-0.31	3.09e-11	Schizophrenia;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg16998327	chr1:184020984	TSEN15	0.4	6.68	0.31	7.51e-11	Optic cup area;
LUAD	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg15557168	chr22:42548783	NA	0.51	9.34	0.41	5.67e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.92	-0.36	2.05e-14	Personality dimensions;
LUAD	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg22618164	chr12:122356400	WDR66	0.75	13.57	0.55	4.54e-35	Mean corpuscular volume;
LUAD	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05901451	chr6:126070800	HEY2	-0.66	-11.14	-0.48	1.91e-25	Brugada syndrome;
LUAD	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg25324976	chr17:61989376	CSHL1	0.36	6.95	0.32	1.43e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4356932	1.000	rs7674409	chr4:76958334	C/G	cg24176760	chr4:76958061	ART3;CXCL11	0.36	6.43	0.3	3.35e-10	Blood protein levels;
LUAD	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.62	-7.44	-0.34	5.8e-13	Body mass index;
LUAD	cis	rs754466	0.651	rs11815015	chr10:79625482	C/T	cg17075019	chr10:79541650	NA	-0.85	-17.56	-0.65	3.08e-52	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg19676328	chr12:49525230	TUBA1B	-0.69	-11.14	-0.48	1.94e-25	Total cholesterol levels;
LUAD	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg12940439	chr1:67600707	NA	0.44	8.36	0.38	9.26e-16	Psoriasis;
LUAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.19	-0.37	3.08e-15	Alzheimer's disease;
LUAD	cis	rs220324	0.688	rs11701681	chr21:43564274	A/G	cg08841829	chr21:43638893	ABCG1	-0.5	-6.79	-0.31	3.8e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.62	8.82	0.39	3.11e-17	Gut microbiome composition (summer);
LUAD	cis	rs72634258	0.945	rs2050198	chr1:8111839	T/G	cg26816564	chr1:7831052	VAMP3	0.57	7.59	0.35	2.04e-13	Inflammatory bowel disease;
LUAD	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg07936489	chr17:37558343	FBXL20	0.48	7.66	0.35	1.25e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg23815491	chr16:72088622	HP	0.48	7.52	0.34	3.33e-13	Blood protein levels;
LUAD	cis	rs7107174	0.901	rs10899494	chr11:78122208	G/T	cg19901956	chr11:77921274	USP35	-0.5	-6.37	-0.3	4.98e-10	Testicular germ cell tumor;
LUAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-9.99	-0.44	3.06e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.62	11.0	0.47	6.4e-25	Birth weight;
LUAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg05434287	chr7:2030229	MAD1L1	0.42	6.9	0.32	1.97e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs747782	0.640	rs11039603	chr11:48256786	G/A	cg03929089	chr4:120376271	NA	0.67	6.74	0.31	5.25e-11	Intraocular pressure;
LUAD	trans	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg13565492	chr6:43139072	SRF	-0.61	-6.47	-0.3	2.76e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg25036284	chr2:26402008	FAM59B	-0.71	-9.5	-0.42	1.56e-19	Gut microbiome composition (summer);
LUAD	cis	rs68170813	0.652	rs75136686	chr7:107180949	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-9.09	-0.4	3.86e-18	Coronary artery disease;
LUAD	cis	rs7945705	0.846	rs4929912	chr11:8816695	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-7.86	-0.36	3.16e-14	Hemoglobin concentration;
LUAD	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg21782813	chr7:2030301	MAD1L1	0.44	7.44	0.34	5.7e-13	Schizophrenia;
LUAD	cis	rs9300255	0.602	rs2695478	chr12:123689521	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-6.7	-0.31	6.64e-11	Neutrophil percentage of white cells;
LUAD	cis	rs9837602	1.000	rs1038294	chr3:99503728	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-8.64	-0.39	1.14e-16	Breast cancer;
LUAD	cis	rs863345	0.548	rs857687	chr1:158577998	T/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.53	-0.3	1.84e-10	Pneumococcal bacteremia;
LUAD	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg15921436	chr17:44337874	NA	-0.73	-10.02	-0.44	2.34e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg08888203	chr3:10149979	C3orf24	0.73	11.17	0.48	1.44e-25	Alzheimer's disease;
LUAD	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	11.94	0.5	1.58e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg02574844	chr11:5959923	NA	-0.42	-7.39	-0.34	7.99e-13	DNA methylation (variation);
LUAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg05896524	chr21:47604654	C21orf56	-0.77	-13.55	-0.55	5.55e-35	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.85e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.66	-0.31	8.3e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg15664640	chr17:80829946	TBCD	0.58	11.27	0.48	6.13e-26	Breast cancer;
LUAD	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg15704280	chr7:45808275	SEPT13	0.9	17.5	0.65	5.41e-52	Coronary artery disease;
LUAD	trans	rs994533	0.928	rs7594625	chr2:218293564	A/C	cg07746351	chr16:89466392	ANKRD11	-0.39	-6.49	-0.3	2.4e-10	Height;
LUAD	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg06558623	chr16:89946397	TCF25	1.16	10.82	0.47	2.89e-24	Skin colour saturation;
LUAD	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.18	-0.33	3.11e-12	Bipolar disorder;
LUAD	trans	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17712092	chr4:129076599	LARP1B	0.86	16.33	0.62	8.07e-47	Eosinophil percentage of white cells;
LUAD	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg06221963	chr1:154839813	KCNN3	-0.85	-19.57	-0.69	3.27e-61	Prostate cancer;
LUAD	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg25173405	chr17:45401733	C17orf57	-0.47	-7.75	-0.35	7.13e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs240764	0.578	rs62422070	chr6:101260827	T/G	cg09795085	chr6:101329169	ASCC3	0.41	7.09	0.33	5.63e-12	Neuroticism;
LUAD	cis	rs6908034	0.556	rs7750703	chr6:19804814	C/G	cg02682789	chr6:19804855	NA	0.91	10.38	0.45	1.26e-22	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs2880765	0.706	rs7172006	chr15:86053359	A/G	cg13263323	chr15:86062960	AKAP13	-0.46	-7.17	-0.33	3.29e-12	Coronary artery disease;
LUAD	cis	rs11696501	0.843	rs6073774	chr20:44150077	C/A	cg11783356	chr20:44313418	WFDC10B	-0.46	-7.18	-0.33	3.12e-12	Brain structure;
LUAD	cis	rs5758659	0.679	rs134870	chr22:42652317	T/C	cg15128208	chr22:42549153	NA	-0.38	-7.71	-0.35	9.31e-14	Cognitive function;
LUAD	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.43e-12	Motion sickness;
LUAD	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg14728415	chr7:32535168	LSM5;AVL9	-0.62	-11.2	-0.48	1.11e-25	Cognitive ability;
LUAD	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg03690763	chr11:133734501	NA	-0.34	-7.81	-0.35	4.7e-14	Childhood ear infection;
LUAD	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg08859206	chr1:53392774	SCP2	-0.72	-13.75	-0.56	7.9e-36	Monocyte count;
LUAD	cis	rs3784262	0.679	rs11071365	chr15:58334126	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.5	-9.76	-0.43	1.92e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	trans	rs10802346	0.545	rs10802345	chr1:246372834	C/T	cg13514129	chr1:39547527	MACF1	0.6	10.57	0.46	2.43e-23	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs10203711	1.000	rs6716457	chr2:239577621	C/T	cg14580085	chr2:239553406	NA	0.42	9.19	0.41	1.74e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg17264618	chr3:40429014	ENTPD3	0.37	7.81	0.36	4.47e-14	Renal cell carcinoma;
LUAD	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg01528321	chr10:82214614	TSPAN14	0.54	8.63	0.39	1.22e-16	Post bronchodilator FEV1;
LUAD	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.94	-0.32	1.5e-11	Crohn's disease;
LUAD	cis	rs938554	0.784	rs7439210	chr4:9971749	C/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-7.83	-0.36	4e-14	Blood metabolite levels;
LUAD	cis	rs1832871	0.541	rs17503148	chr6:158873908	C/T	cg07165851	chr6:158734300	TULP4	0.51	7.34	0.34	1.07e-12	Height;
LUAD	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg14926445	chr8:58193284	C8orf71	-0.47	-6.85	-0.32	2.62e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs59104589	0.521	rs56697150	chr2:242430085	C/A	cg08645257	chr2:242211290	HDLBP	0.38	6.38	0.3	4.66e-10	Fibrinogen levels;
LUAD	cis	rs698833	0.521	rs35627501	chr2:44506971	G/C	cg04920474	chr2:44395004	PPM1B	0.52	9.87	0.43	8.17e-21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs12545109	0.671	rs35500854	chr8:57424303	G/A	cg07776626	chr8:57350775	NA	-0.63	-8.89	-0.4	1.74e-17	Obesity-related traits;
LUAD	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg02782426	chr3:40428986	ENTPD3	-0.39	-8.79	-0.39	3.8e-17	Renal cell carcinoma;
LUAD	cis	rs2075165	0.901	rs7542798	chr1:156224304	A/G	cg20302342	chr1:156215951	PAQR6	0.37	8.35	0.38	9.91e-16	Tonsillectomy;
LUAD	trans	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg01620082	chr3:125678407	NA	-0.71	-7.15	-0.33	3.79e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4700695	0.764	rs152993	chr5:65262968	A/T	cg21114390	chr5:65439923	SFRS12	0.62	7.48	0.34	4.4e-13	Facial morphology (factor 19);
LUAD	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg00129232	chr17:37814104	STARD3	-0.44	-7.3	-0.33	1.44e-12	Asthma;
LUAD	trans	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg01620082	chr3:125678407	NA	-0.44	-6.48	-0.3	2.55e-10	Depression;
LUAD	cis	rs12545109	0.879	rs2576580	chr8:57365828	G/C	cg17761419	chr8:57350749	NA	-0.59	-8.27	-0.37	1.77e-15	Obesity-related traits;
LUAD	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg02931644	chr1:25747376	RHCE	0.43	9.14	0.41	2.73e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18099408	chr3:52552593	STAB1	-0.42	-7.44	-0.34	5.6e-13	Bipolar disorder;
LUAD	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg22823121	chr1:150693482	HORMAD1	-0.38	-7.48	-0.34	4.4e-13	Tonsillectomy;
LUAD	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg20744362	chr22:50050164	C22orf34	0.35	6.69	0.31	7.07e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg22117172	chr7:91764530	CYP51A1	0.37	8.23	0.37	2.4e-15	Breast cancer;
LUAD	cis	rs73198271	0.960	rs73198286	chr8:8612022	C/T	cg01851573	chr8:8652454	MFHAS1	0.51	8.07	0.37	7.28e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs57590327	0.508	rs4605572	chr3:81965751	A/G	cg07356753	chr3:81810745	GBE1	-0.49	-8.28	-0.37	1.66e-15	Extraversion;
LUAD	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	9.86	0.43	8.93e-21	Colorectal cancer;
LUAD	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg10755058	chr3:40428713	ENTPD3	0.38	7.39	0.34	7.8e-13	Renal cell carcinoma;
LUAD	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg19761014	chr17:28927070	LRRC37B2	0.82	8.28	0.37	1.6e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.54	9.46	0.42	2.15e-19	Eosinophil percentage of white cells;
LUAD	cis	rs2046867	0.818	rs6789061	chr3:72888690	C/T	cg04365224	chr3:72788183	NA	-0.44	-6.58	-0.3	1.42e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg05340658	chr4:99064831	C4orf37	0.54	9.14	0.41	2.7e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg11429632	chr9:123964581	RAB14	-0.39	-6.63	-0.31	1.04e-10	Subcortical brain region volumes;
LUAD	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg22532475	chr10:104410764	TRIM8	-0.36	-7.28	-0.33	1.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.42	7.35	0.34	1.05e-12	Lung cancer in ever smokers;
LUAD	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg22823121	chr1:150693482	HORMAD1	0.45	9.17	0.41	2.15e-18	Tonsillectomy;
LUAD	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg00666640	chr1:248458726	OR2T12	0.33	7.83	0.36	3.92e-14	Common traits (Other);
LUAD	cis	rs420259	0.516	rs2369009	chr16:23555726	C/T	cg00143387	chr16:23521605	GGA2	-0.7	-9.72	-0.43	2.68e-20	Bipolar disorder;
LUAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg07217954	chr7:1067459	C7orf50	0.43	6.61	0.31	1.14e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62103177	0.564	rs3930043	chr18:77723832	G/A	cg02751453	chr18:77725136	HSBP1L1	-0.44	-7.53	-0.34	3.05e-13	Opioid sensitivity;
LUAD	cis	rs2108225	0.714	rs929393	chr7:107437048	C/T	cg18560240	chr7:107437656	SLC26A3	-0.42	-7.07	-0.33	6.48e-12	Ulcerative colitis;
LUAD	cis	rs367943	0.688	rs10063452	chr5:112734165	C/T	cg12552261	chr5:112820674	MCC	0.46	8.86	0.4	2.23e-17	Type 2 diabetes;
LUAD	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg00290607	chr11:67383545	NA	0.39	6.52	0.3	1.98e-10	Mean corpuscular volume;
LUAD	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs2535633	0.631	rs2336670	chr3:52998504	T/G	cg18404041	chr3:52824283	ITIH1	0.38	6.58	0.3	1.41e-10	Body mass index;
LUAD	cis	rs6087990	0.735	rs1040555	chr20:31380201	A/T	cg13636640	chr20:31349939	DNMT3B	-0.71	-13.11	-0.54	3.42e-33	Ulcerative colitis;
LUAD	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg13319975	chr6:146136371	FBXO30	0.67	11.45	0.49	1.22e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7674212	0.510	rs6856593	chr4:104177699	T/C	cg16532752	chr4:104119610	CENPE	-0.48	-7.51	-0.34	3.47e-13	Type 2 diabetes;
LUAD	cis	rs1997103	0.954	rs56030000	chr7:55405750	A/G	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-7.82	-0.36	4.26e-14	Neutrophil percentage of white cells;
LUAD	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.07e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-7.35	-0.34	1.06e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1950500	0.617	rs10362	chr14:24846961	G/T	cg07162820	chr14:24837146	NFATC4	0.43	8.28	0.37	1.62e-15	Height;
LUAD	trans	rs75804782	0.641	rs77448526	chr2:239353487	A/C	cg01134436	chr17:81009848	B3GNTL1	0.74	8.1	0.37	6.05e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg10560079	chr2:191398806	TMEM194B	-0.52	-6.41	-0.3	3.8e-10	Diastolic blood pressure;
LUAD	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg15485101	chr11:133734466	NA	0.38	8.48	0.38	3.78e-16	Childhood ear infection;
LUAD	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg07636037	chr3:49044803	WDR6	-0.49	-8.16	-0.37	3.76e-15	Menarche (age at onset);
LUAD	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg23029597	chr12:123009494	RSRC2	-0.57	-9.03	-0.4	6.03e-18	Body mass index;
LUAD	cis	rs3125734	0.633	rs6479792	chr10:63983264	T/G	cg09941381	chr10:64027924	RTKN2	-0.3	-6.92	-0.32	1.72e-11	Rheumatoid arthritis;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg01667350	chr14:21457946	METT11D1	-0.4	-6.39	-0.3	4.36e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs73198271	0.710	rs11779565	chr8:8680020	G/A	cg01851573	chr8:8652454	MFHAS1	0.45	8.24	0.37	2.14e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9287719	0.601	rs62128635	chr2:10725334	G/C	cg02196655	chr2:10830764	NOL10	-0.38	-6.46	-0.3	2.97e-10	Prostate cancer;
LUAD	cis	rs9796	0.689	rs561301	chr15:41444723	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.42	-7.77	-0.35	6.03e-14	Menopause (age at onset);
LUAD	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs10504073	0.647	rs10957357	chr8:49988587	C/A	cg00325661	chr8:49890786	NA	0.44	10.15	0.44	8.55e-22	Blood metabolite ratios;
LUAD	cis	rs62103177	0.564	rs3930043	chr18:77723832	G/A	cg20368463	chr18:77673604	PQLC1	0.52	6.74	0.31	5.23e-11	Opioid sensitivity;
LUAD	cis	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg00071950	chr4:10020882	SLC2A9	0.49	7.02	0.32	8.88e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg16647868	chr5:131706066	SLC22A5	0.49	7.86	0.36	3.3e-14	Breast cancer;
LUAD	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg00106254	chr7:1943704	MAD1L1	-0.54	-7.95	-0.36	1.7e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg22442454	chr1:209979470	IRF6	0.54	7.2	0.33	2.81e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg09367891	chr1:107599246	PRMT6	-0.6	-10.06	-0.44	1.72e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg18129178	chr5:148520854	ABLIM3	0.59	8.49	0.38	3.55e-16	Breast cancer;
LUAD	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg25985355	chr7:65971099	NA	-0.55	-6.74	-0.31	5.36e-11	Diabetic kidney disease;
LUAD	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg00898013	chr13:113819073	PROZ	-0.7	-12.46	-0.52	1.41e-30	Platelet distribution width;
LUAD	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10802521	chr3:52805072	NEK4	-0.48	-8.64	-0.39	1.18e-16	Bipolar disorder;
LUAD	cis	rs7662987	0.527	rs13106879	chr4:100050018	A/G	cg12011299	chr4:100065546	ADH4	-0.67	-6.62	-0.31	1.08e-10	Smoking initiation;
LUAD	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.75	16.02	0.61	1.83e-45	White blood cell count;
LUAD	cis	rs12900413	0.687	rs8034777	chr15:90313057	C/T	cg24249390	chr15:90295951	MESP1	0.33	6.7	0.31	6.53e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	trans	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg18187862	chr3:45730750	SACM1L	0.5	8.03	0.36	9.44e-15	Primary sclerosing cholangitis;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06864046	chr12:89746505	DUSP6	-0.4	-6.54	-0.3	1.73e-10	Cancer;
LUAD	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg22875332	chr1:76189707	ACADM	0.72	10.84	0.47	2.5e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7124681	0.585	rs10838773	chr11:47834346	G/A	cg18512352	chr11:47633146	NA	0.37	6.49	0.3	2.47e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.03	0.32	8.39e-12	Menopause (age at onset);
LUAD	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg19318889	chr4:1322082	MAEA	0.44	6.98	0.32	1.17e-11	Obesity-related traits;
LUAD	trans	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04565464	chr8:145669602	NFKBIL2	0.45	6.73	0.31	5.37e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg06640241	chr16:89574553	SPG7	-0.55	-8.18	-0.37	3.37e-15	Multiple myeloma (IgH translocation);
LUAD	cis	rs9837602	0.748	rs9289985	chr3:99878116	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.59	-7.72	-0.35	8.34e-14	Breast cancer;
LUAD	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.37	0.34	9.11e-13	Tonsillectomy;
LUAD	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg23758822	chr17:41437982	NA	0.89	17.55	0.65	3.46e-52	Menopause (age at onset);
LUAD	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23248424	chr5:179741104	GFPT2	-0.72	-12.08	-0.51	4.42e-29	Height;
LUAD	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg15900387	chr1:150738905	CTSS	-0.36	-6.58	-0.3	1.42e-10	Melanoma;
LUAD	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg25985355	chr7:65971099	NA	-0.51	-6.37	-0.3	5.06e-10	Diabetic kidney disease;
LUAD	cis	rs9393692	0.537	rs9358926	chr6:26323132	C/G	cg13736514	chr6:26305472	NA	-0.52	-8.13	-0.37	4.9e-15	Educational attainment;
LUAD	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg06221963	chr1:154839813	KCNN3	0.85	19.96	0.7	6.1e-63	Prostate cancer;
LUAD	cis	rs642803	0.613	rs565427	chr11:65532825	G/A	cg27068330	chr11:65405492	SIPA1	0.43	6.65	0.31	8.95e-11	Urate levels;
LUAD	cis	rs9399401	0.667	rs11155242	chr6:142691549	A/C	cg04461802	chr6:142623433	GPR126	0.44	8.09	0.37	6.55e-15	Chronic obstructive pulmonary disease;
LUAD	cis	rs13315871	1.000	rs13317835	chr3:58383275	C/T	cg12435725	chr3:58293450	RPP14	-0.67	-7.33	-0.34	1.16e-12	Cholesterol, total;
LUAD	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg19468946	chr17:37922297	IKZF3	-0.42	-6.71	-0.31	6.28e-11	Self-reported allergy;
LUAD	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg13736514	chr6:26305472	NA	-0.69	-12.82	-0.53	5.18e-32	Educational attainment;
LUAD	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.52e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg18944383	chr4:111397179	ENPEP	0.37	7.43	0.34	5.9e-13	Height;
LUAD	cis	rs9896933	0.615	rs2379354	chr17:80704385	G/A	cg20578329	chr17:80767326	TBCD	-0.58	-7.01	-0.32	9.23e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg18811423	chr2:55921094	PNPT1	0.51	8.39	0.38	7.15e-16	Metabolic syndrome;
LUAD	trans	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.7	11.94	0.5	1.6e-28	Mean corpuscular volume;
LUAD	cis	rs13315871	0.790	rs13071148	chr3:58310838	A/C	cg12435725	chr3:58293450	RPP14	-0.71	-7.59	-0.35	2.05e-13	Cholesterol, total;
LUAD	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg17346650	chr17:80929145	B3GNTL1	0.37	6.47	0.3	2.63e-10	Glycated hemoglobin levels;
LUAD	cis	rs1595825	0.891	rs73054867	chr2:198700417	C/G	cg11031976	chr2:198649780	BOLL	-0.47	-7.07	-0.32	6.55e-12	Ulcerative colitis;
LUAD	cis	rs870825	0.655	rs28661636	chr4:185634218	A/C	cg04058563	chr4:185651563	MLF1IP	0.9	14.41	0.57	1.39e-38	Blood protein levels;
LUAD	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18876405	chr7:65276391	NA	-0.4	-6.41	-0.3	3.82e-10	Aortic root size;
LUAD	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg23985595	chr17:80112537	CCDC57	0.47	8.51	0.38	2.99e-16	Life satisfaction;
LUAD	cis	rs912057	0.601	rs1294405	chr6:6737591	A/G	cg06612196	chr6:6737390	NA	0.66	16.3	0.62	1.07e-46	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	trans	rs7395662	0.697	rs11530291	chr11:48764203	C/G	cg15704280	chr7:45808275	SEPT13	0.43	6.66	0.31	8.54e-11	HDL cholesterol;
LUAD	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg14686297	chr22:46650375	NA	0.36	6.44	0.3	3.3e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs68170813	0.559	rs7981	chr7:106843133	G/C	cg02696742	chr7:106810147	HBP1	-0.79	-11.04	-0.47	4.4e-25	Coronary artery disease;
LUAD	cis	rs9467160	0.520	rs2753910	chr6:24442473	C/T	cg20631270	chr6:24437470	GPLD1	-0.42	-7.09	-0.33	5.76e-12	Liver enzyme levels;
LUAD	cis	rs7680126	0.633	rs11735543	chr4:10251652	G/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.36	-0.3	5.12e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.46e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg03929089	chr4:120376271	NA	-0.83	-15.18	-0.59	7.31e-42	Coronary artery disease;
LUAD	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg10556349	chr10:835070	NA	0.68	8.16	0.37	3.91e-15	Eosinophil percentage of granulocytes;
LUAD	cis	rs9902453	0.808	rs10445400	chr17:28183059	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.53	0.42	1.25e-19	Coffee consumption (cups per day);
LUAD	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg20933634	chr6:27740509	NA	0.45	7.12	0.33	4.68e-12	Parkinson's disease;
LUAD	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs2274273	0.624	rs11158034	chr14:55753560	C/T	cg04306507	chr14:55594613	LGALS3	0.42	7.98	0.36	1.34e-14	Protein biomarker;
LUAD	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg12310025	chr6:25882481	NA	0.82	13.69	0.55	1.48e-35	Blood metabolite levels;
LUAD	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg20119798	chr7:94954144	PON1	-0.48	-6.65	-0.31	8.9e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs250677	0.798	rs11168080	chr5:148409821	C/T	cg12140854	chr5:148520817	ABLIM3	-0.63	-9.36	-0.41	4.68e-19	Breast cancer;
LUAD	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07256732	chr16:621771	PIGQ	-0.32	-6.44	-0.3	3.22e-10	Height;
LUAD	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg00310523	chr12:86230176	RASSF9	0.36	7.58	0.35	2.19e-13	Major depressive disorder;
LUAD	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg07305463	chr2:136567211	LCT	-0.38	-7.26	-0.33	1.82e-12	Mosquito bite size;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg16263627	chr15:100339283	C15orf51	-0.35	-6.35	-0.3	5.4e-10	Schizophrenia;
LUAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg22963979	chr7:1858916	MAD1L1	-0.58	-10.06	-0.44	1.77e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs62400317	0.859	rs56357385	chr6:45203591	C/T	cg18551225	chr6:44695536	NA	-0.56	-8.43	-0.38	5.42e-16	Total body bone mineral density;
LUAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg10819733	chr22:24237672	NA	0.35	6.36	0.3	5.39e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7264396	0.563	rs2425146	chr20:34355268	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.97	-0.36	1.45e-14	Total cholesterol levels;
LUAD	cis	rs117623576	0.941	rs7070675	chr10:32407269	G/T	cg03047570	chr10:32398778	NA	-0.9	-10.16	-0.44	7.74e-22	Anti-saccade response;
LUAD	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg07636037	chr3:49044803	WDR6	0.55	8.38	0.38	8.14e-16	Menarche (age at onset);
LUAD	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg25358565	chr5:93447407	FAM172A	0.64	7.66	0.35	1.24e-13	Diabetic retinopathy;
LUAD	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg13319975	chr6:146136371	FBXO30	-0.58	-9.82	-0.43	1.23e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg04663057	chr3:46933782	PTH1R	0.26	6.56	0.3	1.61e-10	Birth weight;
LUAD	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.27e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg16060761	chr17:80687452	NA	-0.54	-7.61	-0.35	1.76e-13	Glycated hemoglobin levels;
LUAD	cis	rs7119	0.651	rs34829483	chr15:77835986	C/T	cg27398640	chr15:77910606	LINGO1	-0.37	-6.73	-0.31	5.45e-11	Type 2 diabetes;
LUAD	cis	rs2262909	0.962	rs73019844	chr19:22249925	T/C	cg11619707	chr19:22235551	ZNF257	0.49	7.57	0.35	2.33e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.55	-0.6	1.9e-43	Chronic sinus infection;
LUAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg24813613	chr7:1882135	MAD1L1	-0.57	-9.34	-0.41	5.48e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg02696790	chr15:75250997	RPP25	0.36	6.9	0.32	1.88e-11	Breast cancer;
LUAD	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg12179176	chr11:130786555	SNX19	0.55	9.27	0.41	9.37e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.27	-0.48	6.22e-26	Type 2 diabetes;
LUAD	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg21433313	chr16:3507492	NAT15	0.76	13.56	0.55	5.15e-35	Tuberculosis;
LUAD	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg14835575	chr10:16859367	RSU1	0.96	13.84	0.56	3.37e-36	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.31e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62400317	0.859	rs1324536	chr6:45116261	C/T	cg18551225	chr6:44695536	NA	0.53	8.35	0.38	9.8e-16	Total body bone mineral density;
LUAD	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg18944383	chr4:111397179	ENPEP	0.42	8.22	0.37	2.45e-15	Height;
LUAD	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.58	-0.35	2.28e-13	HDL cholesterol;
LUAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg27170947	chr2:26402098	FAM59B	-0.63	-8.82	-0.39	2.99e-17	Gut microbiome composition (summer);
LUAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.57	-10.16	-0.44	7.66e-22	Longevity;Endometriosis;
LUAD	cis	rs7172809	0.643	rs16953967	chr15:77836521	C/T	cg11865553	chr15:77376250	NA	-0.38	-6.72	-0.31	5.8e-11	Glucose homeostasis traits;
LUAD	cis	rs2944755	0.919	rs2944754	chr8:141574350	A/G	cg26074100	chr8:141568712	EIF2C2	-0.42	-7.49	-0.34	3.92e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg21385522	chr1:16154831	NA	0.57	9.58	0.42	8.55e-20	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg22244940	chr12:132335942	MMP17	-0.4	-6.85	-0.32	2.61e-11	Migraine;
LUAD	cis	rs7843479	0.601	rs6557712	chr8:21826421	C/T	cg03445287	chr8:21823731	XPO7	-0.47	-8.75	-0.39	4.95e-17	Mean corpuscular volume;
LUAD	cis	rs420259	0.516	rs2239951	chr16:23504993	C/T	cg00143387	chr16:23521605	GGA2	-0.73	-10.12	-0.44	1.08e-21	Bipolar disorder;
LUAD	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg09365446	chr1:150670422	GOLPH3L	-0.56	-9.36	-0.41	4.75e-19	Urate levels;
LUAD	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg17063962	chr7:91808500	NA	-0.61	-10.19	-0.44	6e-22	Breast cancer;
LUAD	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg14345882	chr6:26364793	BTN3A2	0.68	7.11	0.33	4.9e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs933688	0.527	rs1511344	chr5:90582914	G/C	cg17503389	chr5:90575422	NA	-0.54	-7.69	-0.35	1.06e-13	Smoking behavior;
LUAD	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	15.72	0.61	3.51e-44	Smoking behavior;
LUAD	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg13319975	chr6:146136371	FBXO30	-0.64	-11.14	-0.48	1.9e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14829155	chr15:31115871	NA	0.77	13.03	0.54	7.55e-33	Huntington's disease progression;
LUAD	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg13319975	chr6:146136371	FBXO30	-0.55	-9.26	-0.41	1.02e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.58	0.3	1.41e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6754311	0.684	rs11681248	chr2:136820076	C/T	cg05194412	chr2:137003533	NA	0.46	7.1	0.33	5.22e-12	Mosquito bite size;
LUAD	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg04800585	chr6:26043546	HIST1H2BB	-0.47	-8.03	-0.36	9.55e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2735413	0.918	rs4309408	chr16:78071507	G/A	cg04733911	chr16:78082701	NA	-0.35	-8.34	-0.38	1.07e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg01579765	chr21:45077557	HSF2BP	0.66	15.29	0.6	2.39e-42	Mean corpuscular volume;
LUAD	cis	rs78487399	0.808	rs10203174	chr2:43690030	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-6.98	-0.32	1.15e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00769072	chr9:5629304	KIAA1432	-0.43	-6.73	-0.31	5.47e-11	Height;
LUAD	cis	rs11677370	0.603	rs10164826	chr2:3849951	G/C	cg17052675	chr2:3827356	NA	-0.61	-10.35	-0.45	1.52e-22	Type 2 diabetes;
LUAD	cis	rs6066825	0.605	rs761273	chr20:47315488	A/G	cg18078177	chr20:47281410	PREX1	0.41	6.85	0.32	2.58e-11	Colorectal cancer;
LUAD	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	10.8	0.46	3.55e-24	Eosinophil percentage of white cells;
LUAD	cis	rs7851660	0.967	rs907577	chr9:100615117	C/T	cg13688889	chr9:100608707	NA	-0.53	-9.55	-0.42	1.07e-19	Strep throat;
LUAD	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg25358565	chr5:93447407	FAM172A	0.6	7.07	0.33	6.31e-12	Diabetic retinopathy;
LUAD	trans	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.71	-9.88	-0.43	7.5e-21	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs3752645	1.000	rs10261881	chr7:106781650	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-6.42	-0.3	3.62e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs3106136	0.546	rs4693003	chr4:95145469	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.22	-0.44	4.77e-22	Capecitabine sensitivity;
LUAD	cis	rs4954585	0.708	rs10200263	chr2:137007429	C/T	cg05194412	chr2:137003533	NA	0.53	9.53	0.42	1.28e-19	Colorectal cancer;
LUAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg00634984	chr7:65235879	NA	-0.45	-7.33	-0.34	1.14e-12	Calcium levels;
LUAD	cis	rs4853036	0.951	rs10165061	chr2:70146363	C/T	cg02498382	chr2:70120550	SNRNP27	-0.51	-8.3	-0.37	1.42e-15	Colorectal or endometrial cancer;
LUAD	trans	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg19862616	chr7:65841803	NCRNA00174	1.04	25.89	0.78	3.02e-89	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs738322	0.553	rs28565947	chr22:38570775	C/G	cg25457927	chr22:38595422	NA	-0.51	-11.19	-0.48	1.26e-25	Cutaneous nevi;
LUAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg12016809	chr21:47604291	C21orf56	0.65	11.26	0.48	6.47e-26	Testicular germ cell tumor;
LUAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03647317	chr4:187891568	NA	-0.35	-6.48	-0.3	2.5e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.51	7.08	0.33	6.09e-12	Renal function-related traits (BUN);
LUAD	cis	rs600231	0.577	rs12269965	chr11:65232087	C/T	cg17120908	chr11:65337727	SSSCA1	-0.65	-8.59	-0.39	1.66e-16	Bone mineral density;
LUAD	trans	rs2262909	0.962	rs73019842	chr19:22249909	T/G	cg17074339	chr11:11642133	GALNTL4	0.47	7.7	0.35	9.49e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg02423579	chr7:2872169	GNA12	-0.39	-6.37	-0.3	5.01e-10	Plateletcrit;
LUAD	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg20203395	chr5:56204925	C5orf35	-0.39	-6.37	-0.3	4.84e-10	Coronary artery disease;
LUAD	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.0	-0.32	1.02e-11	Height;
LUAD	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg21252483	chr19:49399788	TULP2	-0.68	-10.44	-0.45	7.61e-23	Red cell distribution width;
LUAD	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg24399712	chr22:39784796	NA	0.83	16.87	0.63	3.44e-49	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs1448094	0.872	rs1026085	chr12:86355735	A/G	cg18827107	chr12:86230957	RASSF9	-0.46	-8.34	-0.38	1.04e-15	Major depressive disorder;
LUAD	cis	rs7119038	0.818	rs715412	chr11:118684610	G/A	cg19308663	chr11:118741387	NA	0.45	6.46	0.3	2.81e-10	Sjögren's syndrome;
LUAD	cis	rs225245	0.817	rs225302	chr17:33922396	C/T	cg05299278	chr17:33885742	SLFN14	0.52	11.95	0.5	1.43e-28	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg06387496	chr7:2775674	GNA12	-0.39	-6.5	-0.3	2.24e-10	Height;
LUAD	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg07636037	chr3:49044803	WDR6	0.56	10.82	0.47	2.86e-24	Parkinson's disease;
LUAD	cis	rs1032833	0.732	rs60072979	chr2:180030486	C/T	cg23883738	chr2:179974586	SESTD1	-0.65	-7.31	-0.34	1.32e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs73198271	0.740	rs28521727	chr8:8647217	T/C	cg01851573	chr8:8652454	MFHAS1	0.48	8.54	0.38	2.53e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4900538	0.892	rs4906208	chr14:102956489	G/C	cg18135206	chr14:102964638	TECPR2	1.07	24.36	0.76	1.48e-82	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs10821973	0.527	rs4559572	chr10:63974950	C/G	cg09941381	chr10:64027924	RTKN2	-0.34	-6.74	-0.31	5.22e-11	Hypothyroidism;
LUAD	trans	rs3096299	0.900	rs4785666	chr16:89462771	C/G	cg06774039	chr2:74056087	STAMBP	0.41	6.38	0.3	4.58e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-10.25	-0.45	3.54e-22	Electrocardiographic conduction measures;
LUAD	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg08885076	chr2:99613938	TSGA10	0.4	7.55	0.34	2.78e-13	Chronic sinus infection;
LUAD	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg27432699	chr2:27873401	GPN1	0.56	9.89	0.43	7e-21	Oral cavity cancer;
LUAD	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11890956	chr21:40555474	PSMG1	-0.57	-9.24	-0.41	1.24e-18	Cognitive function;
LUAD	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504073	0.565	rs974780	chr8:49930976	G/A	cg00325661	chr8:49890786	NA	0.48	10.54	0.46	3.16e-23	Blood metabolite ratios;
LUAD	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg08085267	chr17:45401833	C17orf57	-0.53	-8.85	-0.4	2.5e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs10838798	0.607	rs11039537	chr11:48154603	A/G	cg15704280	chr7:45808275	SEPT13	-0.47	-7.25	-0.33	2e-12	Height;
LUAD	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg05925327	chr15:68127851	NA	-0.42	-6.38	-0.3	4.79e-10	Restless legs syndrome;
LUAD	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg03885332	chr11:832357	CD151	-0.43	-8.23	-0.37	2.38e-15	Mean platelet volume;
LUAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14159672	chr1:205819179	PM20D1	0.79	16.01	0.61	1.87e-45	Menarche (age at onset);
LUAD	cis	rs240764	0.817	rs239245	chr6:101090377	C/A	cg09795085	chr6:101329169	ASCC3	0.43	7.48	0.34	4.29e-13	Neuroticism;
LUAD	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.98	-0.4	8.96e-18	Total body bone mineral density;
LUAD	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg27432699	chr2:27873401	GPN1	0.58	10.36	0.45	1.48e-22	Oral cavity cancer;
LUAD	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg18876405	chr7:65276391	NA	-0.42	-6.67	-0.31	7.98e-11	Aortic root size;
LUAD	cis	rs13315871	0.929	rs9811074	chr3:58421846	A/G	cg20936604	chr3:58311152	NA	-0.69	-6.92	-0.32	1.68e-11	Cholesterol, total;
LUAD	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg13732083	chr21:47605072	C21orf56	0.44	6.96	0.32	1.32e-11	Testicular germ cell tumor;
LUAD	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.12	-0.54	3.15e-33	Breast cancer;
LUAD	cis	rs11264213	0.515	rs9660657	chr1:36548941	C/T	cg27506609	chr1:36549197	TEKT2	-0.62	-7.35	-0.34	1.03e-12	Schizophrenia;
LUAD	cis	rs2286503	0.839	rs10276099	chr7:22862950	G/A	cg06496272	chr7:22895283	SNORD93	-0.41	-7.27	-0.33	1.74e-12	Fibrinogen;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21036854	chr14:77506705	NA	-0.41	-6.58	-0.3	1.36e-10	Height;
LUAD	cis	rs6424115	0.790	rs72874118	chr1:24177800	A/G	cg15997130	chr1:24165203	NA	-0.55	-9.44	-0.42	2.57e-19	Immature fraction of reticulocytes;
LUAD	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg24803719	chr17:45855879	NA	-0.32	-6.97	-0.32	1.2e-11	IgG glycosylation;
LUAD	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg15704280	chr7:45808275	SEPT13	-0.52	-8.21	-0.37	2.73e-15	HDL cholesterol;
LUAD	cis	rs490234	0.812	rs4838285	chr9:128446888	C/T	cg14078157	chr9:128172775	NA	-0.45	-8.49	-0.38	3.43e-16	Mean arterial pressure;
LUAD	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg12011299	chr4:100065546	ADH4	0.66	13.53	0.55	6.25e-35	Alcohol dependence;
LUAD	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.54	0.38	2.38e-16	Breast cancer;
LUAD	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.45	-0.89	7.93e-144	Myeloid white cell count;
LUAD	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg26513180	chr16:89883248	FANCA	0.65	6.79	0.31	3.7e-11	Skin colour saturation;
LUAD	cis	rs2735413	0.918	rs11150037	chr16:78075774	A/G	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	6.87	0.32	2.31e-11	Motion sickness;
LUAD	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg08807101	chr21:30365312	RNF160	-0.43	-7.37	-0.34	9.17e-13	Dental caries;
LUAD	cis	rs354225	0.544	rs12713266	chr2:54805443	G/T	cg01766943	chr2:54829624	SPTBN1	0.4	7.5	0.34	3.76e-13	Schizophrenia;
LUAD	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg02493740	chr2:85810744	VAMP5	-0.64	-12.02	-0.5	8.07e-29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs727505	1.000	rs1541416	chr7:124450345	T/C	cg23710748	chr7:124431027	NA	-0.44	-9.52	-0.42	1.4e-19	Lewy body disease;
LUAD	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg25894440	chr7:65020034	NA	-0.62	-6.69	-0.31	6.99e-11	Diabetic kidney disease;
LUAD	cis	rs6499255	0.951	rs12232410	chr16:69736851	G/A	cg15192750	chr16:69999425	NA	0.45	6.83	0.32	3.02e-11	IgE levels;
LUAD	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg14458575	chr2:238380390	NA	0.65	12.23	0.51	1.13e-29	Prostate cancer;
LUAD	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg02038168	chr22:39784481	NA	0.58	10.17	0.44	7.22e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.652	rs77056542	chr7:107089751	G/C	cg02696742	chr7:106810147	HBP1	-0.76	-8.88	-0.4	1.96e-17	Coronary artery disease;
LUAD	trans	rs11039798	0.688	rs12277029	chr11:48852833	G/T	cg03929089	chr4:120376271	NA	0.59	6.8	0.31	3.56e-11	Axial length;
LUAD	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg14092988	chr3:52407081	DNAH1	0.45	9.13	0.41	2.84e-18	Bipolar disorder;
LUAD	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg01528321	chr10:82214614	TSPAN14	0.66	10.56	0.46	2.66e-23	Post bronchodilator FEV1;
LUAD	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg20203395	chr5:56204925	C5orf35	-0.82	-11.97	-0.5	1.2e-28	Initial pursuit acceleration;
LUAD	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg22875332	chr1:76189707	ACADM	-0.85	-15.53	-0.6	2.2e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg16205897	chr5:131564050	P4HA2	-0.41	-9.35	-0.41	5.23e-19	Blood metabolite levels;
LUAD	cis	rs617219	0.889	rs10042338	chr5:78431077	G/C	cg25119155	chr5:78426943	BHMT	0.37	6.49	0.3	2.45e-10	Betaine levels in individuals undergoing cardiac evaluation;
LUAD	cis	rs9341808	0.714	rs9448911	chr6:80913859	A/G	cg08355045	chr6:80787529	NA	0.51	9.14	0.41	2.67e-18	Sitting height ratio;
LUAD	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg24558204	chr6:135376177	HBS1L	0.46	8.56	0.38	2.11e-16	Red blood cell count;
LUAD	cis	rs3815700	0.844	rs444089	chr19:33106991	G/C	cg02997394	chr19:33096574	ANKRD27	0.61	7.74	0.35	7.21e-14	Eosinophilic esophagitis;
LUAD	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg18306943	chr3:40428807	ENTPD3	0.4	7.09	0.33	5.68e-12	Renal cell carcinoma;
LUAD	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg05234568	chr11:5960015	NA	-0.44	-7.89	-0.36	2.6e-14	DNA methylation (variation);
LUAD	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21028142	chr17:79581711	NPLOC4	0.44	9.58	0.42	8.37e-20	Eye color traits;
LUAD	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg26384229	chr12:38710491	ALG10B	-0.41	-6.87	-0.32	2.32e-11	Heart rate;
LUAD	cis	rs1524976	0.738	rs62252647	chr3:65438217	C/T	cg16238336	chr3:65465873	MAGI1	-0.6	-6.85	-0.32	2.64e-11	PR interval;
LUAD	cis	rs9302065	0.565	rs2992910	chr13:95962216	T/A	cg26751094	chr13:95954534	ABCC4	-0.53	-11.28	-0.48	5.79e-26	Blood metabolite levels;
LUAD	cis	rs3784262	0.669	rs4646555	chr15:58355345	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.71	-0.35	9.19e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg27535305	chr1:53392650	SCP2	-0.32	-6.44	-0.3	3.32e-10	Monocyte count;
LUAD	cis	rs1448094	0.645	rs12301701	chr12:86472798	C/T	cg18827107	chr12:86230957	RASSF9	0.48	8.63	0.39	1.28e-16	Major depressive disorder;
LUAD	cis	rs6489882	0.867	rs1154970	chr12:113370427	A/C	cg20102336	chr12:113376681	OAS3	-0.48	-7.45	-0.34	5.36e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs367943	1.000	rs348957	chr5:112821178	C/T	cg12552261	chr5:112820674	MCC	0.59	11.13	0.48	2.02e-25	Type 2 diabetes;
LUAD	cis	rs1395	0.710	rs72817533	chr2:27482612	A/G	cg23587288	chr2:27483067	SLC30A3	-0.41	-7.51	-0.34	3.45e-13	Blood metabolite levels;
LUAD	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg25324976	chr17:61989376	CSHL1	0.39	7.49	0.34	4.17e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg09065629	chr16:1709722	CRAMP1L	0.43	7.4	0.34	7.61e-13	Coronary artery disease;
LUAD	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg27284194	chr4:1044797	NA	0.7	10.13	0.44	9.73e-22	Recombination rate (females);
LUAD	cis	rs877282	0.838	rs11253373	chr10:774857	A/G	cg06581033	chr10:766294	NA	-0.54	-7.29	-0.33	1.56e-12	Uric acid levels;
LUAD	trans	rs6921919	0.673	rs13201681	chr6:28394680	C/T	cg06606381	chr12:133084897	FBRSL1	-1.25	-10.67	-0.46	1.07e-23	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg08761264	chr16:28874980	SH2B1	-0.45	-6.93	-0.32	1.58e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14159672	chr1:205819179	PM20D1	0.91	21.0	0.71	1.37e-67	Menarche (age at onset);
LUAD	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg24920358	chr1:40204285	PPIE	0.7	12.67	0.52	2.04e-31	Blood protein levels;
LUAD	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.4e-12	Lung cancer;
LUAD	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg09537434	chr19:41945824	ATP5SL	-0.54	-8.55	-0.38	2.35e-16	Height;
LUAD	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg15445000	chr17:37608096	MED1	0.44	8.08	0.37	6.77e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	8.38	0.38	8.01e-16	Electroencephalogram traits;
LUAD	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg26384229	chr12:38710491	ALG10B	-0.4	-6.66	-0.31	8.63e-11	Bladder cancer;
LUAD	cis	rs68170813	0.559	rs2395881	chr7:107074323	A/C	cg23024343	chr7:107201750	COG5	0.52	7.2	0.33	2.84e-12	Coronary artery disease;
LUAD	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-6.69	-0.31	7e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg24733560	chr20:60626293	TAF4	0.47	8.42	0.38	5.78e-16	Body mass index;
LUAD	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.58	0.3	1.36e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.652	rs17481621	chr7:107113852	G/C	cg23024343	chr7:107201750	COG5	0.51	6.45	0.3	3.09e-10	Coronary artery disease;
LUAD	cis	rs17867775	0.793	rs17864127	chr7:126730470	C/A	cg02090654	chr7:126698344	MIR592;GRM8	0.73	7.43	0.34	6.04e-13	Anti-saccade response;
LUAD	cis	rs1344694	0.548	rs12468812	chr2:216905867	C/T	cg12620499	chr2:216877984	MREG	0.43	7.54	0.34	2.88e-13	Alcohol dependence;
LUAD	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.37	-0.38	8.25e-16	Schizophrenia;
LUAD	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg09184832	chr6:79620586	NA	-0.51	-9.48	-0.42	1.78e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg09263875	chr16:632152	PIGQ	0.82	17.71	0.65	6.78e-53	Height;
LUAD	cis	rs9393692	0.557	rs9366648	chr6:26306282	T/C	cg00631329	chr6:26305371	NA	-0.57	-9.48	-0.42	1.86e-19	Educational attainment;
LUAD	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg09021430	chr5:549028	NA	-0.69	-13.3	-0.54	5.59e-34	Lung disease severity in cystic fibrosis;
LUAD	trans	rs7395662	0.963	rs4882137	chr11:48615671	A/T	cg00717180	chr2:96193071	NA	-0.39	-7.27	-0.33	1.75e-12	HDL cholesterol;
LUAD	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg22753661	chr15:79092743	ADAMTS7	0.56	8.45	0.38	4.86e-16	Coronary artery disease or large artery stroke;
LUAD	cis	rs4691139	1.000	rs13134489	chr4:165889437	G/A	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.42	-8.12	-0.37	5.27e-15	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14829155	chr15:31115871	NA	0.77	13.03	0.54	7.1e-33	Huntington's disease progression;
LUAD	trans	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00149659	chr3:10157352	C3orf10	0.57	8.06	0.36	7.87e-15	Alzheimer's disease;
LUAD	cis	rs1950626	0.716	rs34572720	chr14:101447150	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.42	7.71	0.35	8.98e-14	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.7e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12545109	0.800	rs2576602	chr8:57394495	C/T	cg19413350	chr8:57351067	NA	-0.46	-7.06	-0.32	6.85e-12	Obesity-related traits;
LUAD	cis	rs11098699	0.821	rs11939262	chr4:124207018	A/G	cg09941581	chr4:124220074	SPATA5	0.49	8.02	0.36	1.05e-14	Mosquito bite size;
LUAD	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg19774624	chr17:42201019	HDAC5	-0.41	-7.11	-0.33	5.01e-12	Total body bone mineral density;
LUAD	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg22598563	chr5:131563921	P4HA2	-0.3	-7.43	-0.34	6.18e-13	Blood metabolite levels;
LUAD	cis	rs12893668	0.703	rs4906338	chr14:104050357	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.49	-7.52	-0.34	3.35e-13	Reticulocyte count;
LUAD	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg03560586	chr2:239334908	ASB1	-0.31	-6.62	-0.31	1.09e-10	Multiple system atrophy;
LUAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.77	-9.43	-0.42	2.82e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23635060	chr16:14379351	NA	0.43	6.62	0.31	1.1e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg21782813	chr7:2030301	MAD1L1	0.52	8.54	0.38	2.45e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg12444411	chr7:2802554	GNA12	-0.36	-6.38	-0.3	4.77e-10	Height;
LUAD	cis	rs877282	1.000	rs877281	chr10:771557	T/G	cg06581033	chr10:766294	NA	-0.56	-7.62	-0.35	1.7e-13	Uric acid levels;
LUAD	cis	rs1018836	0.631	rs9987133	chr8:91470730	T/C	cg16814680	chr8:91681699	NA	-0.56	-9.26	-0.41	1.01e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13315871	1.000	rs13063504	chr3:58409854	A/G	cg12435725	chr3:58293450	RPP14	-0.69	-7.66	-0.35	1.31e-13	Cholesterol, total;
LUAD	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg18944383	chr4:111397179	ENPEP	0.39	7.84	0.36	3.8e-14	Height;
LUAD	cis	rs35883536	1.000	rs9803842	chr1:101134877	G/T	cg06223162	chr1:101003688	GPR88	0.37	6.93	0.32	1.54e-11	Monocyte count;
LUAD	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg24879335	chr3:133465180	TF	0.39	8.03	0.36	9.6e-15	Iron status biomarkers (transferrin levels);
LUAD	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg18811423	chr2:55921094	PNPT1	0.5	8.51	0.38	3.07e-16	Metabolic syndrome;
LUAD	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.21e-16	Prostate cancer;
LUAD	cis	rs6541297	0.941	rs6665258	chr1:230279058	G/A	cg20703242	chr1:230279135	GALNT2	0.66	12.26	0.51	8.85e-30	Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.19	0.33	3.04e-12	Parkinson's disease;
LUAD	cis	rs9972944	0.756	rs8077164	chr17:63764645	C/T	cg07283582	chr17:63770753	CCDC46	-0.5	-11.11	-0.48	2.47e-25	Total body bone mineral density;
LUAD	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg05182265	chr7:156933206	UBE3C	-0.81	-17.37	-0.65	2.13e-51	Body mass index;
LUAD	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg00757033	chr12:89920650	WDR51B	0.7	12.14	0.51	2.6e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg05776053	chr2:74358815	NA	0.46	7.0	0.32	9.98e-12	Gestational age at birth (maternal effect);
LUAD	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg02493740	chr2:85810744	VAMP5	-0.46	-8.51	-0.38	3.07e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.89	0.47	1.68e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg22467129	chr15:76604101	ETFA	-0.49	-8.6	-0.39	1.56e-16	Blood metabolite levels;
LUAD	cis	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg07460842	chr6:66804631	NA	0.74	11.01	0.47	5.89e-25	Exhaled nitric oxide levels;
LUAD	cis	rs3087591	1.000	rs2905870	chr17:29521833	G/A	cg24425628	chr17:29625626	OMG;NF1	0.41	6.63	0.31	1.05e-10	Hip circumference;
LUAD	cis	rs62400317	0.723	rs1329709	chr6:44974956	G/T	cg20913747	chr6:44695427	NA	-0.44	-6.92	-0.32	1.64e-11	Total body bone mineral density;
LUAD	cis	rs829883	0.659	rs11109522	chr12:98930964	C/T	cg25150519	chr12:98850993	NA	-0.5	-7.89	-0.36	2.61e-14	Colorectal adenoma (advanced);
LUAD	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg05044414	chr3:183734942	ABCC5	0.48	10.04	0.44	2.08e-21	Anterior chamber depth;
LUAD	cis	rs9341808	0.590	rs4706841	chr6:81057827	T/A	cg08355045	chr6:80787529	NA	0.48	8.28	0.37	1.59e-15	Sitting height ratio;
LUAD	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11890956	chr21:40555474	PSMG1	0.66	10.44	0.45	7.74e-23	Cognitive function;
LUAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg16606324	chr3:10149918	C3orf24	0.67	10.95	0.47	9.69e-25	Alzheimer's disease;
LUAD	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg26769984	chr7:1090371	C7orf50	0.7	11.24	0.48	7.98e-26	Bronchopulmonary dysplasia;
LUAD	cis	rs17608059	0.566	rs17676459	chr17:13910515	A/G	cg11395062	chr17:14139857	CDRT15	0.46	7.4	0.34	7.26e-13	Temperament;
LUAD	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg12140854	chr5:148520817	ABLIM3	-0.62	-9.83	-0.43	1.14e-20	Breast cancer;
LUAD	trans	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg00953403	chr17:74099816	EXOC7	-0.52	-7.68	-0.35	1.14e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs17197710	0.621	rs12576935	chr11:47246542	G/A	cg13308137	chr11:47528955	CUGBP1	0.46	7.22	0.33	2.5e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2882667	0.898	rs3925110	chr5:138371365	C/G	cg04439458	chr5:138467593	SIL1	-0.38	-6.95	-0.32	1.38e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg02782426	chr3:40428986	ENTPD3	0.38	8.24	0.37	2.17e-15	Renal cell carcinoma;
LUAD	cis	rs910187	0.641	rs6066232	chr20:45818905	C/T	cg27589058	chr20:45804311	EYA2	-0.28	-6.36	-0.3	5.26e-10	Migraine;
LUAD	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg20744362	chr22:50050164	C22orf34	0.4	8.68	0.39	8.64e-17	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.7	-13.71	-0.55	1.13e-35	Ulcerative colitis;
LUAD	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg08508325	chr11:3079039	CARS	-0.61	-13.77	-0.56	6.67e-36	Longevity;
LUAD	cis	rs606458	0.920	rs72643568	chr11:64472977	C/T	cg27243166	chr11:64479496	NRXN2	0.54	6.51	0.3	2.14e-10	Urate levels;
LUAD	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg08807101	chr21:30365312	RNF160	-0.44	-7.64	-0.35	1.46e-13	Dental caries;
LUAD	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg15704280	chr7:45808275	SEPT13	-1.07	-24.16	-0.76	1.14e-81	Height;
LUAD	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg15208524	chr1:10270712	KIF1B	0.46	7.07	0.32	6.62e-12	Hepatocellular carcinoma;
LUAD	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.67	0.35	1.19e-13	Bladder cancer;
LUAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg14926445	chr8:58193284	C8orf71	-0.46	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg05082376	chr22:42548792	NA	-0.42	-6.95	-0.32	1.39e-11	Schizophrenia;
LUAD	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg05887092	chr17:76393375	PGS1	-0.37	-6.74	-0.31	5.32e-11	HDL cholesterol levels;
LUAD	cis	rs11671005	0.735	rs11878198	chr19:58920302	A/G	cg13877915	chr19:58951672	ZNF132	0.55	7.27	0.33	1.75e-12	Mean platelet volume;
LUAD	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg04455712	chr21:45112962	RRP1B	0.52	10.5	0.45	4.44e-23	Mean corpuscular volume;
LUAD	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-7.69	-0.35	1.04e-13	Blood metabolite levels;
LUAD	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg26354017	chr1:205819088	PM20D1	-0.52	-7.98	-0.36	1.37e-14	Menarche (age at onset);
LUAD	cis	rs12681287	0.752	rs4534114	chr8:87271956	A/G	cg00550725	chr8:87521180	FAM82B	0.45	6.57	0.3	1.5e-10	Caudate activity during reward;
LUAD	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	7.67	0.35	1.18e-13	Schizophrenia;
LUAD	cis	rs2485376	1.000	rs2479555	chr10:104025383	A/G	cg20641465	chr10:103991465	PITX3	-0.58	-10.73	-0.46	6.67e-24	QT interval;
LUAD	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg13722127	chr7:150037890	RARRES2	0.48	8.57	0.38	2.02e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg02734326	chr4:10020555	SLC2A9	-0.4	-6.61	-0.31	1.17e-10	Bone mineral density;
LUAD	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg16325326	chr1:53192061	ZYG11B	0.59	10.65	0.46	1.31e-23	Monocyte count;
LUAD	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.45	-0.34	5.19e-13	Heart rate;
LUAD	cis	rs9296092	0.560	rs62407561	chr6:33528103	T/C	cg13560919	chr6:33536144	NA	-0.9	-16.72	-0.63	1.49e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	trans	rs877282	0.682	rs2265092	chr10:780293	C/T	cg22713356	chr15:30763199	NA	-0.86	-12.34	-0.51	4.46e-30	Uric acid levels;
LUAD	cis	rs1232027	0.547	rs1677649	chr5:79966197	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.33	-0.34	1.16e-12	Huntington's disease progression;
LUAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg11062466	chr8:58055876	NA	0.67	8.47	0.38	4.18e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs10254118	0.757	rs7788086	chr7:133135206	C/T	cg10665199	chr7:133106180	EXOC4	0.61	10.29	0.45	2.6e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg22532475	chr10:104410764	TRIM8	-0.5	-9.46	-0.42	2.13e-19	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-7.02	-0.32	8.88e-12	IgG glycosylation;
LUAD	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg22117172	chr7:91764530	CYP51A1	0.36	7.74	0.35	7.58e-14	Breast cancer;
LUAD	cis	rs1894633	0.574	rs61806089	chr1:172338301	A/G	cg13446689	chr1:172328377	DNM3	0.4	6.57	0.3	1.47e-10	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg04944784	chr2:26401820	FAM59B	-0.89	-12.57	-0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg00495681	chr13:53174319	NA	-0.48	-8.87	-0.4	2.06e-17	Lewy body disease;
LUAD	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-7.92	-0.36	2.07e-14	Neutrophil percentage of white cells;
LUAD	cis	rs250677	0.522	rs12523526	chr5:148349107	A/C	cg12140854	chr5:148520817	ABLIM3	0.57	8.9	0.4	1.62e-17	Breast cancer;
LUAD	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg14343924	chr8:8086146	FLJ10661	0.45	7.06	0.32	7.08e-12	Neuroticism;
LUAD	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg07755735	chr2:20870362	GDF7	-0.49	-8.99	-0.4	8.02e-18	Abdominal aortic aneurysm;
LUAD	cis	rs4849845	0.889	rs2278505	chr2:121050560	A/G	cg24070213	chr2:121070622	NA	0.36	6.37	0.3	4.92e-10	Mean platelet volume;
LUAD	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11890956	chr21:40555474	PSMG1	0.78	13.73	0.56	9.48e-36	Cognitive function;
LUAD	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.26e-12	Tonsillectomy;
LUAD	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.74	0.43	2.28e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg09065629	chr16:1709722	CRAMP1L	0.41	7.23	0.33	2.3e-12	Coronary artery disease;
LUAD	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg02527881	chr3:46936655	PTH1R	-0.57	-11.8	-0.5	5.54e-28	Colorectal cancer;
LUAD	cis	rs10992471	0.603	rs10761155	chr9:95153729	C/G	cg14631576	chr9:95140430	CENPP	-0.56	-11.46	-0.49	1.11e-26	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7187994	0.672	rs35307127	chr16:84798089	T/C	cg07647771	chr16:84786436	USP10	-0.31	-8.17	-0.37	3.51e-15	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg00106254	chr7:1943704	MAD1L1	-0.57	-8.85	-0.4	2.38e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2505998	0.843	rs2435344	chr10:43585874	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.35	-6.55	-0.3	1.68e-10	Hirschsprung disease;
LUAD	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg26022315	chr17:47021804	SNF8	0.41	7.33	0.34	1.17e-12	Type 2 diabetes;
LUAD	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg17366294	chr4:99064904	C4orf37	-0.48	-8.35	-0.38	9.53e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1595825	1.000	rs73058821	chr2:198864597	A/G	cg10547527	chr2:198650123	BOLL	-0.49	-6.72	-0.31	5.74e-11	Ulcerative colitis;
LUAD	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg10589385	chr1:150898437	SETDB1	0.39	7.36	0.34	9.7e-13	Tonsillectomy;
LUAD	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg06609049	chr19:2785107	THOP1	1.06	21.11	0.72	4.54e-68	Total cholesterol levels;
LUAD	cis	rs1941023	0.584	rs2241920	chr11:60164204	A/G	cg08716584	chr11:60157161	MS4A7	0.46	8.87	0.4	2.1e-17	Congenital heart disease (maternal effect);
LUAD	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg13770153	chr20:60521292	NA	-0.48	-8.07	-0.37	7.47e-15	Body mass index;
LUAD	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.02	-0.4	6.56e-18	Total body bone mineral density;
LUAD	cis	rs77861329	1.000	rs9857878	chr3:52109668	A/G	cg08692210	chr3:52188851	WDR51A	-0.8	-7.18	-0.33	3.12e-12	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs28595532	0.800	rs111626798	chr4:119352517	C/T	cg21605333	chr4:119757512	SEC24D	0.69	6.8	0.31	3.63e-11	Cannabis dependence symptom count;
LUAD	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg17724175	chr1:150552817	MCL1	0.31	7.16	0.33	3.56e-12	Tonsillectomy;
LUAD	cis	rs654950	0.775	rs28972757	chr1:41993013	T/C	cg06885757	chr1:42089581	HIVEP3	-0.35	-7.45	-0.34	5.27e-13	Airway imaging phenotypes;
LUAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10819733	chr22:24237672	NA	0.36	6.73	0.31	5.38e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18099408	chr3:52552593	STAB1	-0.47	-8.23	-0.37	2.38e-15	Bipolar disorder;
LUAD	cis	rs9487051	0.768	rs445796	chr6:109520145	T/C	cg01475377	chr6:109611718	NA	-0.37	-6.87	-0.32	2.26e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.12e-14	Prostate cancer;
LUAD	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	8.53	0.38	2.66e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs2816062	0.813	rs2745318	chr1:18895844	C/T	cg18795169	chr1:18902165	NA	0.93	22.54	0.74	1.76e-74	Urate levels in lean individuals;
LUAD	cis	rs6750795	0.518	rs1434519	chr2:232433761	A/G	cg19187155	chr2:232395269	NMUR1	0.49	7.57	0.35	2.36e-13	Height;
LUAD	cis	rs657075	0.697	rs2073839	chr5:131650245	C/T	cg21138405	chr5:131827807	IRF1	0.52	6.67	0.31	8.12e-11	Rheumatoid arthritis;
LUAD	cis	rs698833	0.892	rs1085483	chr2:44616047	G/A	cg04920474	chr2:44395004	PPM1B	0.36	6.36	0.3	5.35e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg15181151	chr6:150070149	PCMT1	0.39	7.84	0.36	3.79e-14	Lung cancer;
LUAD	cis	rs4481887	0.927	rs4453081	chr1:248475691	C/G	cg13385794	chr1:248469461	NA	0.25	6.54	0.3	1.75e-10	Common traits (Other);
LUAD	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg04990556	chr1:26633338	UBXN11	0.4	6.66	0.31	8.33e-11	Obesity-related traits;
LUAD	cis	rs7975161	0.832	rs11111955	chr12:104650735	T/C	cg25273343	chr12:104657179	TXNRD1	-0.7	-8.47	-0.38	3.97e-16	Toenail selenium levels;
LUAD	cis	rs11031096	0.738	rs2923950	chr11:4042069	G/C	cg18678763	chr11:4115507	RRM1	0.41	7.34	0.34	1.08e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg09117114	chr16:67998030	SLC12A4	-0.48	-6.81	-0.31	3.33e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg19442545	chr10:75533431	FUT11	-0.49	-8.31	-0.37	1.3e-15	Inflammatory bowel disease;
LUAD	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg10589385	chr1:150898437	SETDB1	-0.4	-7.44	-0.34	5.7e-13	Melanoma;
LUAD	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg22233082	chr15:42492105	MIR627;VPS39	-0.46	-6.4	-0.3	4.16e-10	Hip circumference;
LUAD	cis	rs11811982	0.793	rs78707784	chr1:227286400	T/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.44	0.34	5.54e-13	Optic disc area;
LUAD	cis	rs2985684	0.740	rs2883438	chr14:50044392	T/C	cg04989706	chr14:50066350	PPIL5	-0.51	-7.54	-0.34	2.97e-13	Carotid intima media thickness;
LUAD	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21016266	chr12:122356598	WDR66	0.64	11.77	0.5	7.12e-28	Mean corpuscular volume;
LUAD	trans	rs11039798	1.000	rs11039978	chr11:48760237	A/G	cg03929089	chr4:120376271	NA	0.59	6.8	0.31	3.49e-11	Axial length;
LUAD	cis	rs60154123	0.614	rs661190	chr1:210458697	G/T	cg22029157	chr1:209979665	IRF6	0.49	6.4	0.3	4.14e-10	Coronary artery disease;
LUAD	trans	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17712092	chr4:129076599	LARP1B	0.88	16.54	0.63	9.22e-48	Eosinophil percentage of white cells;
LUAD	cis	rs243505	0.898	rs243541	chr7:148403243	A/T	cg09806900	chr7:148480153	CUL1	-0.42	-7.21	-0.33	2.53e-12	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27286337	chr10:134555280	INPP5A	0.69	10.01	0.44	2.59e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.61	-8.05	-0.36	8.57e-15	Iron status biomarkers;
LUAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.41	-7.07	-0.33	6.31e-12	Longevity;Endometriosis;
LUAD	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg22875332	chr1:76189707	ACADM	0.87	16.41	0.62	3.45e-47	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg04234412	chr22:24373322	LOC391322	0.91	18.05	0.66	1.98e-54	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg20607798	chr8:58055168	NA	0.67	8.74	0.39	5.33e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg03289416	chr15:75166202	SCAMP2	0.51	8.69	0.39	7.81e-17	Breast cancer;
LUAD	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg11707310	chr1:2537719	MMEL1	0.38	7.91	0.36	2.28e-14	Ulcerative colitis;
LUAD	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg05110241	chr16:68378359	PRMT7	-0.81	-8.73	-0.39	5.74e-17	Schizophrenia;
LUAD	cis	rs6960043	0.818	rs10238625	chr7:15054232	A/G	cg19272540	chr7:15055459	NA	0.38	8.78	0.39	4.11e-17	Type 2 diabetes;
LUAD	cis	rs4891159	0.790	rs72975929	chr18:74144630	G/C	cg24786174	chr18:74118243	ZNF516	-0.8	-15.12	-0.59	1.31e-41	Longevity;
LUAD	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg21963583	chr11:68658836	MRPL21	0.62	10.88	0.47	1.76e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2880765	0.835	rs4842886	chr15:86035773	G/A	cg13263323	chr15:86062960	AKAP13	-0.48	-8.91	-0.4	1.5e-17	Coronary artery disease;
LUAD	cis	rs931127	0.658	rs12787843	chr11:65477306	A/C	cg27068330	chr11:65405492	SIPA1	-0.41	-6.7	-0.31	6.75e-11	Systemic lupus erythematosus;
LUAD	trans	rs11039798	1.000	rs115429994	chr11:48761183	C/G	cg02254774	chr11:50257496	LOC441601	0.53	6.61	0.31	1.19e-10	Axial length;
LUAD	trans	rs62458065	0.850	rs7785999	chr7:32461262	G/T	cg00845942	chr12:64062724	DPY19L2	-0.53	-7.23	-0.33	2.24e-12	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2274273	0.905	rs17128183	chr14:55579513	C/T	cg04306507	chr14:55594613	LGALS3	-0.41	-8.52	-0.38	2.78e-16	Protein biomarker;
LUAD	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg24069376	chr3:38537580	EXOG	-0.43	-10.29	-0.45	2.53e-22	Electrocardiographic conduction measures;
LUAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg13560548	chr3:10150139	C3orf24	0.41	6.93	0.32	1.56e-11	Alzheimer's disease;
LUAD	cis	rs2732480	0.500	rs2450986	chr12:48661688	G/A	cg04545296	chr12:48745243	ZNF641	0.39	9.99	0.44	3.02e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg02734326	chr4:10020555	SLC2A9	-0.56	-9.7	-0.43	3.09e-20	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg05340658	chr4:99064831	C4orf37	0.46	6.91	0.32	1.82e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg05342682	chr7:94953680	PON1	-0.48	-6.42	-0.3	3.57e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.84	15.83	0.61	1.14e-44	Lymphocyte counts;
LUAD	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.05	-0.36	8.68e-15	Total body bone mineral density;
LUAD	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg09323728	chr8:95962352	TP53INP1	-0.33	-7.4	-0.34	7.55e-13	Type 2 diabetes;
LUAD	cis	rs2658782	0.789	rs2658775	chr11:93126799	C/T	cg15737290	chr11:93063684	CCDC67	0.48	6.78	0.31	4.07e-11	Pulmonary function decline;
LUAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg01416388	chr22:39784598	NA	-0.54	-9.21	-0.41	1.53e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg07157834	chr1:205819609	PM20D1	-0.46	-6.83	-0.32	2.9100000000000002e-11	Menarche (age at onset);
LUAD	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg15147215	chr3:52552868	STAB1	0.38	6.82	0.31	3.22e-11	Bipolar disorder;
LUAD	cis	rs7246657	0.891	rs2279149	chr19:38024367	T/C	cg23950597	chr19:37808831	NA	-0.58	-7.3	-0.33	1.47e-12	Coronary artery calcification;
LUAD	cis	rs7833986	0.501	rs72653917	chr8:56892844	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.92	14.79	0.58	3.59e-40	Height;
LUAD	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Colorectal cancer;
LUAD	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg09835421	chr16:68378352	PRMT7	-0.84	-9.07	-0.4	4.45e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.76	-0.35	6.46e-14	Blood metabolite levels;
LUAD	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg20119798	chr7:94954144	PON1	-0.48	-6.55	-0.3	1.63e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1816752	0.905	rs9511242	chr13:24993399	G/A	cg02811702	chr13:24901961	NA	0.41	7.06	0.32	6.82e-12	Obesity-related traits;
LUAD	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg08601574	chr20:25228251	PYGB	0.47	8.56	0.38	2.17e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg20703242	chr1:230279135	GALNT2	0.63	10.47	0.45	5.81e-23	Coronary artery disease;
LUAD	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg06713675	chr4:122721982	EXOSC9	-0.59	-11.34	-0.48	3.29e-26	Type 2 diabetes;
LUAD	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg19336497	chr11:14380999	RRAS2	-0.7	-16.18	-0.62	3.43e-46	Sense of smell;
LUAD	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg20019720	chr6:154832845	CNKSR3	0.65	12.67	0.52	2.11e-31	Lipoprotein (a) levels;
LUAD	trans	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.75	0.5	8.76e-28	Mean corpuscular volume;
LUAD	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg06108461	chr20:60628389	TAF4	-0.81	-13.94	-0.56	1.35e-36	Body mass index;
LUAD	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg06808227	chr14:105710500	BRF1	-0.41	-6.57	-0.3	1.5e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg24069376	chr3:38537580	EXOG	-0.34	-7.83	-0.36	3.89e-14	Electrocardiographic conduction measures;
LUAD	cis	rs2294693	0.947	rs9369254	chr6:40989408	T/C	cg14769373	chr6:40998127	UNC5CL	-0.53	-8.14	-0.37	4.51e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg05283184	chr6:79620031	NA	-0.58	-11.68	-0.49	1.58e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.51	-0.42	1.51e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10242455	0.702	rs73401510	chr7:99065812	A/C	cg18809830	chr7:99032528	PTCD1	-0.97	-7.06	-0.32	6.91e-12	Blood metabolite levels;
LUAD	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg05368731	chr17:41323189	NBR1	0.95	19.47	0.69	9.06e-61	Menopause (age at onset);
LUAD	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg25233709	chr10:116636983	FAM160B1	0.42	8.24	0.37	2.12e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs77972916	0.505	rs3851318	chr2:43532808	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-10.35	-0.45	1.54e-22	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.08	26.18	0.79	1.64e-90	Colorectal cancer;
LUAD	trans	rs2665103	0.715	rs11639440	chr15:82571046	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.48	-7.69	-0.35	1.07e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1045714	0.779	rs3735113	chr7:2651563	G/A	cg20813462	chr7:2646259	IQCE	0.65	7.09	0.33	5.78e-12	Urate levels in lean individuals;
LUAD	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg09796270	chr17:17721594	SREBF1	0.36	6.87	0.32	2.29e-11	Total body bone mineral density;
LUAD	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-6.66	-0.31	8.64e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs9929218	0.954	rs9929479	chr16:68821271	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.51	-0.55	7.89e-35	Colorectal cancer;
LUAD	cis	rs89107	1.000	rs283077	chr6:118569679	T/G	cg21191810	chr6:118973309	C6orf204	0.46	8.91	0.4	1.56e-17	Cardiac structure and function;
LUAD	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg10909506	chr17:38081995	ORMDL3	0.41	6.98	0.32	1.15e-11	Self-reported allergy;
LUAD	cis	rs738321	0.671	rs3761446	chr22:38595483	G/A	cg25457927	chr22:38595422	NA	-0.59	-13.33	-0.54	4.18e-34	Breast cancer;
LUAD	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg13385794	chr1:248469461	NA	0.26	7.0	0.32	1.01e-11	Common traits (Other);
LUAD	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg09976142	chr9:130955436	CIZ1	-0.45	-8.31	-0.37	1.33e-15	Attention deficit hyperactivity disorder;
LUAD	trans	rs7395662	1.000	rs4882129	chr11:48588774	T/C	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.76e-10	HDL cholesterol;
LUAD	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-7.68	-0.35	1.11e-13	Longevity;Endometriosis;
LUAD	cis	rs11676348	0.838	rs17844697	chr2:218999255	G/A	cg06547715	chr2:218990976	CXCR2	0.32	7.19	0.33	2.98e-12	Ulcerative colitis;
LUAD	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.39	0.34	7.87e-13	Hypertriglyceridemia;
LUAD	cis	rs3956705	0.966	rs1037324	chr7:32981161	A/C	cg05721444	chr7:32995514	FKBP9	-0.37	-6.47	-0.3	2.65e-10	Red cell distribution width;
LUAD	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.46	0.3	2.97e-10	Depression;
LUAD	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12756686	chr19:29218302	NA	0.73	11.35	0.48	3.13e-26	Methadone dose in opioid dependence;
LUAD	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg19717773	chr7:2847554	GNA12	-0.45	-8.33	-0.38	1.16e-15	Height;
LUAD	cis	rs4925386	0.808	rs1760073	chr20:60926106	A/G	cg24112000	chr20:60950667	NA	0.76	12.83	0.53	4.77e-32	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg14784868	chr12:69753453	YEATS4	0.42	6.89	0.32	2.07e-11	Blood protein levels;
LUAD	cis	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg01251360	chr16:68772225	CDH1	-0.3	-9.12	-0.41	2.99e-18	Colorectal cancer;
LUAD	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg12863693	chr15:85201151	NMB	-0.38	-6.99	-0.32	1.04e-11	Schizophrenia;
LUAD	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg07570687	chr10:102243282	WNT8B	0.45	6.88	0.32	2.22e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.69	13.23	0.54	1.13e-33	Cognitive ability;
LUAD	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg18252515	chr7:66147081	NA	-0.61	-6.76	-0.31	4.72e-11	Diabetic kidney disease;
LUAD	cis	rs877282	0.891	rs11253406	chr10:796297	G/A	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg08472276	chr7:1133186	C7orf50;GPER	0.43	7.86	0.36	3.13e-14	Longevity;Endometriosis;
LUAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg17178900	chr1:205818956	PM20D1	0.74	15.46	0.6	4.86e-43	Menarche (age at onset);
LUAD	cis	rs909002	0.800	rs1061770	chr1:32096265	A/G	cg13919466	chr1:32135498	COL16A1	-0.35	-8.09	-0.37	6.53e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs939658	0.776	rs68147688	chr15:79443848	G/A	cg17916960	chr15:79447300	NA	-0.54	-11.29	-0.48	5.14e-26	Refractive error;
LUAD	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg10876282	chr6:28092338	ZSCAN16	0.43	6.97	0.32	1.26e-11	Parkinson's disease;
LUAD	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg07061783	chr6:25882402	NA	0.51	8.02	0.36	1.04e-14	Blood metabolite levels;
LUAD	cis	rs7216064	1.000	rs7223813	chr17:65945840	A/G	cg08758996	chr17:66097529	LOC651250	0.46	7.03	0.32	8.59e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg10978503	chr1:24200527	CNR2	0.54	11.84	0.5	3.84e-28	Immature fraction of reticulocytes;
LUAD	cis	rs2041840	0.618	rs11124581	chr2:37576638	C/T	cg25727520	chr2:37576821	QPCT	-0.37	-8.04	-0.36	8.93e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs921968	0.565	rs6436072	chr2:219598095	C/T	cg02176678	chr2:219576539	TTLL4	-0.59	-11.89	-0.5	2.42e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.84	-0.32	2.79e-11	Electroencephalogram traits;
LUAD	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg25208724	chr1:156163844	SLC25A44	1.01	18.16	0.66	6.41e-55	Testicular germ cell tumor;
LUAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.64	8.76	0.39	4.6e-17	Renal function-related traits (BUN);
LUAD	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg12292205	chr6:26970375	C6orf41	-0.47	-6.45	-0.3	3.06e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg07741184	chr6:167504864	NA	0.35	8.14	0.37	4.46e-15	Primary biliary cholangitis;
LUAD	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg25554036	chr4:6271136	WFS1	0.68	13.74	0.56	8.84e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1044573	0.514	rs2268879	chr20:25177805	C/T	cg00926318	chr20:25177340	ENTPD6	-0.27	-6.51	-0.3	2.17e-10	Allergic rhinitis;
LUAD	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg08859206	chr1:53392774	SCP2	-0.78	-14.74	-0.58	5.85e-40	Monocyte count;
LUAD	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg02551604	chr5:131831745	NA	-0.61	-10.1	-0.44	1.22e-21	Asthma (sex interaction);
LUAD	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg21231944	chr12:82153410	PPFIA2	-0.36	-6.56	-0.3	1.55e-10	Resting heart rate;
LUAD	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg14829155	chr15:31115871	NA	-0.58	-9.8	-0.43	1.44e-20	Huntington's disease progression;
LUAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.87	-0.32	2.33e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Depression;
LUAD	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg13319975	chr6:146136371	FBXO30	-0.58	-9.9	-0.43	6.25e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg19635926	chr16:89946313	TCF25	0.73	6.44	0.3	3.23e-10	Skin colour saturation;
LUAD	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg27572855	chr1:25598939	RHD	0.54	11.57	0.49	4.48e-27	Erythrocyte sedimentation rate;
LUAD	cis	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.37	-0.34	8.97e-13	Resting heart rate;
LUAD	trans	rs4714291	0.832	rs1524087	chr6:40057504	A/G	cg02267698	chr19:7991119	CTXN1	-0.44	-6.96	-0.32	1.27e-11	Strep throat;
LUAD	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	trans	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg02002194	chr4:3960332	NA	-0.28	-6.78	-0.31	4.15e-11	Mood instability;
LUAD	cis	rs62458065	0.640	rs6950077	chr7:32502895	A/G	cg20159608	chr7:32802032	NA	0.61	8.49	0.38	3.61e-16	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg11494091	chr17:61959527	GH2	0.42	7.96	0.36	1.55e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg08085267	chr17:45401833	C17orf57	0.55	9.41	0.42	3.22e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg08610935	chr16:1836813	NUBP2	0.44	6.88	0.32	2.17e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg24818145	chr4:99064322	C4orf37	0.47	7.88	0.36	2.89e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg19041857	chr6:27730383	NA	-0.39	-6.73	-0.31	5.68e-11	Parkinson's disease;
LUAD	cis	rs7737355	0.853	rs1468453	chr5:130587459	A/C	cg06307176	chr5:131281290	NA	0.43	6.97	0.32	1.23e-11	Life satisfaction;
LUAD	cis	rs250677	0.524	rs183140	chr5:148438803	G/T	cg12140854	chr5:148520817	ABLIM3	-0.51	-8.78	-0.39	4.1e-17	Breast cancer;
LUAD	cis	rs59104589	0.617	rs3771566	chr2:242358299	G/T	cg08645257	chr2:242211290	HDLBP	0.46	7.44	0.34	5.86e-13	Fibrinogen levels;
LUAD	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg13180566	chr4:1052158	NA	-0.38	-6.52	-0.3	1.96e-10	Recombination rate (females);
LUAD	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg22823121	chr1:150693482	HORMAD1	0.4	7.65	0.35	1.33e-13	Melanoma;
LUAD	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg06453172	chr10:134556979	INPP5A	-0.64	-9.67	-0.43	4.21e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg11822812	chr5:140052017	DND1	-0.45	-8.1	-0.37	5.95e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.4	6.97	0.32	1.24e-11	Type 2 diabetes;
LUAD	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg17105886	chr17:28927953	LRRC37B2	0.72	6.57	0.3	1.53e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8177876	0.749	rs2549896	chr16:81087939	C/G	cg08591886	chr16:81111003	C16orf46	0.6	6.58	0.3	1.41e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.84	12.21	0.51	1.38e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg00277334	chr10:82204260	NA	0.71	9.96	0.44	3.91e-21	Post bronchodilator FEV1;
LUAD	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg15506890	chr2:3487001	NA	-0.43	-7.39	-0.34	7.87e-13	Neurofibrillary tangles;
LUAD	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg10523679	chr1:76189770	ACADM	0.91	15.96	0.61	3.12e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg02990361	chr1:107599529	PRMT6	0.49	8.22	0.37	2.61e-15	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg27124370	chr19:33622961	WDR88	0.44	6.7	0.31	6.79e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs593982	1.000	rs72922786	chr11:65562852	G/C	cg08755490	chr11:65554678	OVOL1	-1.16	-13.67	-0.55	1.76e-35	Atopic dermatitis;
LUAD	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9929218	0.501	rs12448999	chr16:68815549	T/A	cg01251360	chr16:68772225	CDH1	-0.27	-8.44	-0.38	5.27e-16	Colorectal cancer;
LUAD	trans	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-10.16	-0.44	7.85e-22	Platelet distribution width;
LUAD	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg04703951	chr17:43578652	NA	0.42	6.74	0.31	5.3e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg27446573	chr6:127587934	RNF146	0.45	6.64	0.31	9.54e-11	Breast cancer;
LUAD	cis	rs1816752	0.819	rs7985478	chr13:24991273	C/T	cg02811702	chr13:24901961	NA	0.44	7.53	0.34	3.13e-13	Obesity-related traits;
LUAD	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg20362242	chr5:692897	TPPP	0.56	6.89	0.32	2.02e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg17644776	chr2:200775616	C2orf69	-0.5	-7.75	-0.35	7.03e-14	Osteoporosis;
LUAD	cis	rs68170813	0.559	rs76299183	chr7:106904859	A/G	cg23024343	chr7:107201750	COG5	0.44	6.45	0.3	3.1e-10	Coronary artery disease;
LUAD	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg00383909	chr3:49044727	WDR6	0.98	10.61	0.46	1.76e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs2041840	0.538	rs6708524	chr2:37572687	C/T	cg25727520	chr2:37576821	QPCT	-0.34	-7.39	-0.34	8.13e-13	Chronic lymphocytic leukemia;
LUAD	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg11262906	chr1:85462892	MCOLN2	-0.5	-7.04	-0.32	7.92e-12	Serum sulfate level;
LUAD	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg15704280	chr7:45808275	SEPT13	-0.69	-11.05	-0.47	4.22e-25	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs1595825	0.679	rs11685247	chr2:198466462	C/A	cg00982548	chr2:198649783	BOLL	-0.49	-6.84	-0.32	2.8e-11	Ulcerative colitis;
LUAD	cis	rs10465746	0.570	rs1886769	chr1:84471134	C/A	cg10977910	chr1:84465055	TTLL7	0.49	7.31	0.34	1.31e-12	Obesity-related traits;
LUAD	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs2735413	0.881	rs11150036	chr16:78075687	C/G	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs13315871	1.000	rs71311864	chr3:58372324	C/T	cg20936604	chr3:58311152	NA	-0.68	-7.09	-0.33	5.62e-12	Cholesterol, total;
LUAD	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	6.7	0.31	6.69e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg06828538	chr7:5463627	TNRC18	0.41	6.62	0.31	1.06e-10	Hepatitis;
LUAD	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	trans	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg03929089	chr4:120376271	NA	-0.55	-6.4	-0.3	4.19e-10	Intraocular pressure;
LUAD	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg00647820	chr17:40259828	DHX58	-0.41	-6.76	-0.31	4.71e-11	Fibrinogen levels;
LUAD	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg22105103	chr4:187893119	NA	0.53	11.32	0.48	4.09e-26	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs7939886	0.920	rs17150096	chr11:55902996	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.38	0.3	4.79e-10	Myopia (pathological);
LUAD	cis	rs6665290	0.669	rs3768423	chr1:227177293	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.12	-30.01	-0.82	7.8e-107	Myeloid white cell count;
LUAD	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg15962314	chr1:44399869	ARTN	0.33	7.16	0.33	3.6e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg26446133	chr18:72167187	CNDP2	-0.82	-12.11	-0.51	3.49e-29	Refractive error;
LUAD	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg08027265	chr7:2291960	NA	-0.42	-7.22	-0.33	2.5e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.24	-0.33	2.19e-12	Neuroticism;
LUAD	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.5	-8.32	-0.37	1.24e-15	Reticulocyte count;
LUAD	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21659725	chr3:3221576	CRBN	0.51	8.3	0.37	1.46e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.95	0.32	1.37e-11	Rheumatoid arthritis;
LUAD	cis	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg01251360	chr16:68772225	CDH1	-0.3	-9.46	-0.42	2.18e-19	Colorectal cancer;
LUAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	12.86	0.53	3.7e-32	Prudent dietary pattern;
LUAD	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-10.5	-0.45	4.5e-23	Gut microbiome composition (summer);
LUAD	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26314531	chr2:26401878	FAM59B	-0.71	-9.84	-0.43	1.01e-20	Gut microbiome composition (summer);
LUAD	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg00933542	chr6:150070202	PCMT1	0.44	9.37	0.41	4.33e-19	Lung cancer;
LUAD	cis	rs11971779	0.680	rs4732369	chr7:139069173	C/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.76	0.31	4.63e-11	Diisocyanate-induced asthma;
LUAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg27454412	chr7:1067447	C7orf50	0.45	7.29	0.33	1.51e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7132746	0.553	rs61928890	chr12:86185637	A/T	cg18827107	chr12:86230957	RASSF9	-0.47	-6.79	-0.31	3.78e-11	Lewy body disease;
LUAD	cis	rs4604732	0.631	rs34330532	chr1:247626844	G/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg22868518	chr11:507468	RNH1	-0.67	-6.48	-0.3	2.6e-10	Body mass index;
LUAD	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg18512352	chr11:47633146	NA	-0.38	-6.84	-0.32	2.73e-11	Subjective well-being;
LUAD	cis	rs62238980	0.614	rs75321866	chr22:32460707	C/T	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	trans	rs75804782	0.572	rs76084375	chr2:239301193	T/C	cg01134436	chr17:81009848	B3GNTL1	0.77	6.82	0.31	3.19e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg25985355	chr7:65971099	NA	-0.38	-6.92	-0.32	1.63e-11	Aortic root size;
LUAD	cis	rs11048434	0.736	rs11048195	chr12:9105923	A/G	cg23795048	chr12:9217529	LOC144571	0.42	7.74	0.35	7.21e-14	Sjögren's syndrome;
LUAD	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-18.45	-0.67	3.31e-56	Coronary artery disease;
LUAD	cis	rs62400317	0.859	rs10456121	chr6:45092545	G/A	cg18551225	chr6:44695536	NA	-0.54	-8.43	-0.38	5.36e-16	Total body bone mineral density;
LUAD	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg18305652	chr10:134549665	INPP5A	0.58	11.77	0.5	7.07e-28	Migraine;
LUAD	trans	rs3219090	0.886	rs2793654	chr1:226601706	T/A	cg27539482	chr13:111589090	NA	0.43	7.18	0.33	3.24e-12	Melanoma;
LUAD	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg01657329	chr11:68192670	LRP5	-0.41	-6.56	-0.3	1.55e-10	Total body bone mineral density;
LUAD	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg27539214	chr16:67997921	SLC12A4	-0.72	-9.19	-0.41	1.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs6828577	0.626	rs17642633	chr4:119412100	A/G	cg26518628	chr1:97050305	NA	-0.41	-6.52	-0.3	1.97e-10	Perioperative myocardial infarction in coronary artery bypass surgery;
LUAD	cis	rs68170813	0.559	rs12540475	chr7:106886295	C/T	cg23024343	chr7:107201750	COG5	0.49	7.19	0.33	2.92e-12	Coronary artery disease;
LUAD	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.59	10.94	0.47	1.06e-24	Eosinophil percentage of white cells;
LUAD	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg00280220	chr17:61926910	NA	0.35	6.74	0.31	5.27e-11	Prudent dietary pattern;
LUAD	cis	rs7336332	0.511	rs7998978	chr13:27999457	T/C	cg22138327	chr13:27999177	GTF3A	0.98	14.32	0.57	3.37e-38	Weight;
LUAD	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg07570687	chr10:102243282	WNT8B	0.45	7.04	0.32	7.59e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs2544390	1.000	rs2673172	chr2:170204800	A/C	cg09226159	chr3:97483488	ARL6	-0.37	-6.42	-0.3	3.68e-10	Urate levels;
LUAD	cis	rs12612619	0.732	rs3806520	chr2:27276202	G/A	cg00617064	chr2:27272375	NA	-0.37	-7.08	-0.33	5.88e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg13511324	chr14:104056883	C14orf153	0.26	6.35	0.3	5.51e-10	Reticulocyte count;
LUAD	cis	rs225245	0.687	rs321614	chr17:33881734	A/G	cg05299278	chr17:33885742	SLFN14	0.47	10.37	0.45	1.37e-22	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs9443645	0.527	rs949846	chr6:79817596	C/T	cg05283184	chr6:79620031	NA	-0.46	-7.95	-0.36	1.75e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs35306767	0.623	rs56201968	chr10:1141666	A/G	cg20503657	chr10:835505	NA	0.58	8.35	0.38	9.82e-16	Eosinophil percentage of granulocytes;
LUAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00149659	chr3:10157352	C3orf10	0.63	8.82	0.39	2.97e-17	Alzheimer's disease;
LUAD	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg02018176	chr4:1364513	KIAA1530	0.55	10.32	0.45	1.96e-22	Longevity;
LUAD	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00166722	chr3:10149974	C3orf24	0.78	13.43	0.55	1.67e-34	Alzheimer's disease;
LUAD	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg08645402	chr16:4508243	NA	0.58	11.29	0.48	5.11e-26	Schizophrenia;
LUAD	cis	rs2625529	0.627	rs12898585	chr15:72473928	T/C	cg16672083	chr15:72433130	SENP8	-0.73	-12.57	-0.52	5.13e-31	Red blood cell count;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg08616760	chr5:178157801	ZNF354A	-0.45	-7.75	-0.35	6.89e-14	Schizophrenia;
LUAD	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg15704280	chr7:45808275	SEPT13	-0.62	-8.34	-0.38	1.07e-15	Axial length;
LUAD	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg15557168	chr22:42548783	NA	-0.5	-9.29	-0.41	8.05e-19	Schizophrenia;
LUAD	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.86	12.37	0.52	3.34e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9837602	1.000	rs10049383	chr3:99748548	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.66	9.55	0.42	1.04e-19	Breast cancer;
LUAD	trans	rs7246760	0.867	rs35416342	chr19:9779058	A/G	cg02900749	chr2:68251473	NA	-0.59	-6.56	-0.3	1.59e-10	Pursuit maintenance gain;
LUAD	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg13770153	chr20:60521292	NA	-1.0	-18.13	-0.66	8.94e-55	Obesity-related traits;
LUAD	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.1	-0.33	5.19e-12	Blood metabolite levels;
LUAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg23283495	chr1:209979779	IRF6	0.7	11.34	0.48	3.35e-26	Cleft lip with or without cleft palate;
LUAD	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.59	-0.42	7.74e-20	Schizophrenia;
LUAD	cis	rs7809615	0.901	rs11973801	chr7:99102911	A/G	cg03133378	chr7:99195931	NA	-0.57	-6.56	-0.3	1.58e-10	Blood metabolite ratios;
LUAD	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg02017074	chr12:117425053	FBXW8	0.68	8.98	0.4	8.99e-18	Subcortical brain region volumes;Hippocampal volume;
LUAD	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg08999081	chr20:33150536	PIGU	0.64	14.11	0.57	2.52e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs675209	0.637	rs665723	chr6:7139064	A/G	cg23726566	chr6:7051754	NA	0.37	6.44	0.3	3.17e-10	Urate levels;
LUAD	cis	rs7712401	0.601	rs246271	chr5:122212822	A/G	cg19077854	chr5:122220652	SNX24	0.34	6.44	0.3	3.19e-10	Mean platelet volume;
LUAD	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg22920501	chr2:26401640	FAM59B	-0.96	-15.53	-0.6	2.43e-43	Gut microbiome composition (summer);
LUAD	cis	rs6906287	0.531	rs72962938	chr6:119016221	T/C	cg21191810	chr6:118973309	C6orf204	0.4	6.97	0.32	1.21e-11	Electrocardiographic conduction measures;
LUAD	cis	rs7582720	0.887	rs72934591	chr2:204019762	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.59	0.42	7.76e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-6.39	-0.3	4.39e-10	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs877282	1.000	rs7100358	chr10:773681	G/A	cg22713356	chr15:30763199	NA	1.17	16.83	0.63	4.95e-49	Uric acid levels;
LUAD	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg10544611	chr16:67998164	SLC12A4	-0.69	-8.27	-0.37	1.75e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1595825	0.732	rs114972685	chr2:198437829	G/A	cg00982548	chr2:198649783	BOLL	-0.51	-6.86	-0.32	2.47e-11	Ulcerative colitis;
LUAD	cis	rs1832871	0.655	rs4292552	chr6:158722888	G/A	cg07165851	chr6:158734300	TULP4	0.7	10.92	0.47	1.23e-24	Height;
LUAD	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg26513180	chr16:89883248	FANCA	0.46	7.24	0.33	2.17e-12	Vitiligo;
LUAD	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg26384229	chr12:38710491	ALG10B	0.47	7.56	0.35	2.46e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg06697600	chr4:7070879	GRPEL1	-0.51	-8.46	-0.38	4.45e-16	Monocyte percentage of white cells;
LUAD	cis	rs6076065	0.683	rs1419010	chr20:23365254	G/C	cg11657817	chr20:23433608	CST11	0.49	9.0	0.4	7.9e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs807669	0.557	rs712958	chr22:19167409	T/C	cg24911827	chr22:19170109	CLTCL1	0.36	7.42	0.34	6.39e-13	Metabolite levels;
LUAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg20607798	chr8:58055168	NA	0.54	6.9	0.32	1.87e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.36	-0.52	3.47e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg15557168	chr22:42548783	NA	0.51	9.41	0.42	3.33e-19	Schizophrenia;
LUAD	cis	rs4722404	0.502	rs13234017	chr7:3110587	C/A	cg19214707	chr7:3157722	NA	-0.44	-6.97	-0.32	1.21e-11	Atopic dermatitis;
LUAD	cis	rs7809615	0.901	rs10235235	chr7:99075831	T/C	cg03133378	chr7:99195931	NA	-0.58	-6.86	-0.32	2.42e-11	Blood metabolite ratios;
LUAD	cis	rs1232027	0.622	rs1650678	chr5:79958711	G/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.0	-0.32	1.04e-11	Huntington's disease progression;
LUAD	cis	rs4077515	0.870	rs11793497	chr9:139271850	A/G	cg14019695	chr9:139328340	INPP5E	0.42	7.9	0.36	2.47e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06544989	chr22:39130855	UNC84B	0.44	8.51	0.38	2.99e-16	Menopause (age at onset);
LUAD	trans	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-16.98	-0.64	1.13e-49	Exhaled nitric oxide output;
LUAD	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg08027265	chr7:2291960	NA	-0.41	-6.9	-0.32	1.95e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs17532515	0.505	rs6829571	chr4:141494927	C/T	cg09181644	chr4:141490428	UCP1	-0.34	-7.0	-0.32	1.01e-11	Select biomarker traits;
LUAD	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg21963583	chr11:68658836	MRPL21	0.66	11.7	0.49	1.43e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg05768032	chr16:30646687	NA	0.45	7.88	0.36	2.82e-14	Multiple myeloma;
LUAD	cis	rs2242073	0.733	rs62194804	chr2:209026780	C/T	cg06181187	chr2:209010896	CRYGB	0.46	7.51	0.34	3.43e-13	Attention deficit hyperactivity disorder;
LUAD	cis	rs4378999	0.800	rs1031925	chr3:51379274	C/T	cg12934382	chr3:51741135	GRM2	-0.42	-6.36	-0.3	5.17e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs6430585	0.528	rs56064699	chr2:136595706	G/A	cg07169764	chr2:136633963	MCM6	0.82	9.4	0.42	3.46e-19	Corneal structure;
LUAD	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.16	-0.37	3.93e-15	Prostate cancer;
LUAD	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08704250	chr15:31115839	NA	0.72	13.22	0.54	1.24e-33	Huntington's disease progression;
LUAD	cis	rs4663969	0.873	rs759174	chr2:234668245	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.46	-0.38	4.54e-16	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg09002919	chr12:50339186	NA	0.62	9.45	0.42	2.29e-19	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs8050260	0.500	rs4783650	chr16:68558528	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-9.43	-0.42	2.74e-19	Plateletcrit;
LUAD	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg06199346	chr11:14280333	SPON1	0.36	7.71	0.35	8.86e-14	Mitochondrial DNA levels;
LUAD	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.68	0.31	7.72e-11	Cardiac Troponin-T levels;
LUAD	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.13	0.37	4.96e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg14092988	chr3:52407081	DNAH1	0.45	9.15	0.41	2.51e-18	Bipolar disorder;
LUAD	cis	rs9581857	0.579	rs9581843	chr13:27980507	T/G	cg22138327	chr13:27999177	GTF3A	0.99	11.51	0.49	7.4e-27	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.64	9.69	0.43	3.36e-20	Alzheimer's disease;
LUAD	trans	rs7395662	0.963	rs7119550	chr11:48927654	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.43	-0.34	5.88e-13	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.62	0.31	1.07e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2046867	0.908	rs67967166	chr3:72794198	A/G	cg25664220	chr3:72788482	NA	-0.64	-11.88	-0.5	2.7e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg25767906	chr1:53392781	SCP2	0.41	7.54	0.34	2.95e-13	Monocyte count;
LUAD	cis	rs1595825	0.891	rs2164070	chr2:198881730	G/C	cg00982548	chr2:198649783	BOLL	-0.68	-9.47	-0.42	1.96e-19	Ulcerative colitis;
LUAD	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.5	0.58	5.66e-39	Schizophrenia;
LUAD	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg22823121	chr1:150693482	HORMAD1	0.45	8.99	0.4	8.07e-18	Tonsillectomy;
LUAD	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	7.52	0.34	3.38e-13	Tonsillectomy;
LUAD	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25427524	chr10:38739819	LOC399744	-0.79	-14.32	-0.57	3.35e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg25985355	chr7:65971099	NA	0.53	6.59	0.31	1.28e-10	Diabetic kidney disease;
LUAD	trans	rs783540	0.500	rs7163840	chr15:83398303	A/G	cg16105309	chr15:79090380	ADAMTS7	0.38	6.37	0.3	4.81e-10	Schizophrenia;
LUAD	cis	rs8060686	0.546	rs7188350	chr16:68149316	T/C	cg09835421	chr16:68378352	PRMT7	-0.52	-6.62	-0.31	1.11e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3018712	0.532	rs2510398	chr11:68421416	G/A	cg16797656	chr11:68205561	LRP5	-0.43	-6.65	-0.31	8.93e-11	Total body bone mineral density;
LUAD	cis	rs887829	0.570	rs6759892	chr2:234601669	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.56	9.67	0.43	4.13e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs6138458	1.000	rs2387362	chr20:24899906	C/T	cg06937882	chr20:24974362	C20orf3	0.34	6.51	0.3	2.16e-10	Blood protein levels;
LUAD	cis	rs4727443	0.899	rs6954978	chr7:99582212	A/G	cg22004693	chr7:99632812	ZKSCAN1	0.4	6.74	0.31	5.26e-11	Interstitial lung disease;
LUAD	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg01528321	chr10:82214614	TSPAN14	0.65	10.41	0.45	9.78e-23	Post bronchodilator FEV1;
LUAD	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg07432352	chr17:45403706	C17orf57	0.39	7.22	0.33	2.36e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.62	-0.39	1.32e-16	Total body bone mineral density;
LUAD	cis	rs7119	0.651	rs12904533	chr15:77845928	G/A	cg27398640	chr15:77910606	LINGO1	-0.36	-6.58	-0.3	1.37e-10	Type 2 diabetes;
LUAD	cis	rs4343996	0.934	rs4320450	chr7:3372308	G/C	cg21248987	chr7:3385318	SDK1	-0.35	-6.64	-0.31	9.94e-11	Motion sickness;
LUAD	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg02753203	chr1:228287806	NA	-0.45	-8.32	-0.38	1.18e-15	Diastolic blood pressure;
LUAD	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.58	10.88	0.47	1.85e-24	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3733418	0.929	rs12507869	chr4:165895674	T/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.48	-6.85	-0.32	2.64e-11	Obesity-related traits;
LUAD	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg08859206	chr1:53392774	SCP2	-0.52	-9.52	-0.42	1.34e-19	Monocyte count;
LUAD	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg09137382	chr11:130731461	NA	0.43	7.95	0.36	1.69e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg08316699	chr6:150357289	NA	0.36	7.55	0.34	2.68e-13	Alopecia areata;
LUAD	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.57	8.34	0.38	1.08e-15	Platelet count;
LUAD	cis	rs6489882	0.966	rs1557866	chr12:113405181	A/C	cg20102336	chr12:113376681	OAS3	-0.48	-6.97	-0.32	1.26e-11	Chronic lymphocytic leukemia;
LUAD	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.87	0.32	2.29e-11	Rheumatoid arthritis;
LUAD	cis	rs870825	0.616	rs4256263	chr4:185622959	C/A	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs28493229	0.708	rs4803352	chr19:41159193	C/T	cg21869046	chr19:41225005	ITPKC	-0.51	-9.11	-0.41	3.25e-18	Kawasaki disease;
LUAD	cis	rs909002	0.759	rs10914454	chr1:32078940	G/A	cg13919466	chr1:32135498	COL16A1	-0.36	-8.32	-0.38	1.2e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7248779	1.000	rs7248779	chr19:2403564	G/T	cg22729335	chr19:2427816	TIMM13	-0.54	-9.59	-0.42	7.57e-20	Cortisol levels (saliva);
LUAD	trans	rs853679	0.546	rs200989	chr6:27816442	A/G	cg06606381	chr12:133084897	FBRSL1	-0.8	-7.98	-0.36	1.4e-14	Depression;
LUAD	cis	rs7173743	0.935	rs12232282	chr15:79136525	T/C	cg00540400	chr15:79124168	NA	-0.35	-6.77	-0.31	4.41e-11	Coronary artery disease;
LUAD	cis	rs12431939	0.598	rs10873047	chr14:51727239	G/T	cg23942311	chr14:51606299	NA	0.46	7.08	0.33	6.04e-12	Cancer;
LUAD	cis	rs2734839	0.964	rs2734833	chr11:113292920	G/A	cg14159747	chr11:113255604	NA	0.53	10.17	0.44	6.88e-22	Information processing speed;
LUAD	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg12432903	chr7:1882776	MAD1L1	-0.41	-6.86	-0.32	2.46e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs977987	0.836	rs7198873	chr16:75474754	G/A	cg03315344	chr16:75512273	CHST6	0.65	14.3	0.57	4.21e-38	Dupuytren's disease;
LUAD	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	6.05e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs875971	1.000	rs778726	chr7:65828731	C/T	cg14917512	chr19:3094685	GNA11	-0.38	-6.61	-0.31	1.18e-10	Aortic root size;
LUAD	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg21862992	chr11:68658383	NA	0.53	9.67	0.43	4.07e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg16797656	chr11:68205561	LRP5	-0.45	-8.99	-0.4	8.34e-18	Total body bone mineral density;
LUAD	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg08085267	chr17:45401833	C17orf57	-0.59	-10.3	-0.45	2.41e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.63	-11.02	-0.47	5.4e-25	Lymphocyte counts;
LUAD	cis	rs796364	0.662	rs11687313	chr2:201146399	G/A	cg23649088	chr2:200775458	C2orf69	-0.62	-6.58	-0.3	1.39e-10	Schizophrenia;
LUAD	cis	rs28785552	0.897	rs34244888	chr19:53242228	T/A	cg10871876	chr19:53194124	ZNF83	0.43	6.87	0.32	2.31e-11	Response to paliperidone in schizophrenia (PANSS score);
LUAD	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	13.06	0.54	5.6e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg25427524	chr10:38739819	LOC399744	-0.63	-9.21	-0.41	1.53e-18	Obesity (extreme);
LUAD	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg27124370	chr19:33622961	WDR88	0.45	7.36	0.34	9.86e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg21798802	chr22:38057573	PDXP	0.35	7.15	0.33	3.75e-12	Fat distribution (HIV);
LUAD	cis	rs8048589	1.000	rs9925009	chr16:12186352	T/A	cg03816625	chr16:12192430	SNX29	0.54	7.97	0.36	1.52e-14	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05487736	chr14:24617114	PSME2;RNF31	-0.4	-6.65	-0.31	9.35e-11	Cancer;
LUAD	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg13385794	chr1:248469461	NA	0.25	6.83	0.32	2.94e-11	Common traits (Other);
LUAD	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.21e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.86	-0.5	3.42e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	10.15	0.44	8.49e-22	Electrocardiographic conduction measures;
LUAD	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg23018236	chr17:30244563	NA	-0.63	-8.21	-0.37	2.66e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg08805041	chr16:621841	PIGQ	-0.32	-6.38	-0.3	4.69e-10	Height;
LUAD	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18876405	chr7:65276391	NA	-0.56	-9.45	-0.42	2.41e-19	Aortic root size;
LUAD	cis	rs5756813	0.661	rs7286550	chr22:38196760	G/A	cg06521852	chr22:38141419	TRIOBP	0.46	8.36	0.38	9.38e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	trans	rs7395662	0.895	rs7924481	chr11:48582457	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.32	-0.34	1.3e-12	HDL cholesterol;
LUAD	cis	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.53	6.49	0.3	2.38e-10	Depression;
LUAD	trans	rs7395662	0.929	rs10838959	chr11:48584732	T/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.76e-10	HDL cholesterol;
LUAD	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg08027265	chr7:2291960	NA	-0.46	-7.89	-0.36	2.67e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg09796270	chr17:17721594	SREBF1	-0.37	-6.94	-0.32	1.47e-11	Total body bone mineral density;
LUAD	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.29	0.51	6.53e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs684232	0.602	rs384628	chr17:554912	G/A	cg15660573	chr17:549704	VPS53	-0.88	-18.35	-0.67	9.45e-56	Prostate cancer;
LUAD	cis	rs2859741	0.935	rs2782410	chr1:37509489	G/C	cg09363841	chr1:37513479	NA	-0.32	-7.98	-0.36	1.36e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg02038168	chr22:39784481	NA	-0.52	-8.31	-0.37	1.33e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs7671266	0.747	rs6827946	chr4:10151335	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.95	-0.32	1.35e-11	Cardiovascular disease risk factors;
LUAD	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg10053473	chr17:62856997	LRRC37A3	0.78	11.09	0.47	2.96e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6993813	0.786	rs7017691	chr8:120023414	G/C	cg01975934	chr8:119970761	NA	-0.37	-7.15	-0.33	3.82e-12	Bone mineral density (hip);
LUAD	cis	rs1595825	1.000	rs1304165	chr2:198877300	G/A	cg11031976	chr2:198649780	BOLL	-0.43	-6.39	-0.3	4.34e-10	Ulcerative colitis;
LUAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg08027265	chr7:2291960	NA	-0.42	-7.22	-0.33	2.5e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2797685	1.000	rs2859390	chr1:7847529	A/G	cg04725166	chr1:7887271	PER3	-0.48	-7.07	-0.32	6.53e-12	Crohn's disease;
LUAD	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg22681709	chr2:178499509	PDE11A	-0.43	-6.75	-0.31	4.98e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg13319975	chr6:146136371	FBXO30	-0.59	-9.83	-0.43	1.1e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-16.21	-0.62	2.57e-46	Headache;
LUAD	trans	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg01620082	chr3:125678407	NA	-0.76	-7.65	-0.35	1.38e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg14983838	chr19:29218262	NA	0.67	9.33	0.41	5.97e-19	Methadone dose in opioid dependence;
LUAD	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg15017067	chr4:17643749	FAM184B	0.34	6.68	0.31	7.58e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7731657	0.537	rs4705924	chr5:130210792	G/A	cg08523029	chr5:130500466	HINT1	-0.57	-7.31	-0.33	1.35e-12	Fasting plasma glucose;
LUAD	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs727505	0.954	rs2239532	chr7:124405676	A/C	cg23710748	chr7:124431027	NA	-0.44	-8.63	-0.39	1.3e-16	Lewy body disease;
LUAD	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.52	-0.38	2.75e-16	Height;
LUAD	cis	rs986417	1.000	rs6573313	chr14:60961299	A/G	cg27398547	chr14:60952738	C14orf39	0.66	7.94	0.36	1.79e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.92	-0.4	1.43e-17	Total body bone mineral density;
LUAD	cis	rs4774899	1.000	rs12910094	chr15:57432559	G/A	cg14026238	chr15:57616123	NA	0.38	7.17	0.33	3.38e-12	Urinary tract infection frequency;
LUAD	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.58	-0.52	4.94e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs556990	0.574	rs473598	chr13:113801189	C/T	cg18105134	chr13:113819100	PROZ	-0.56	-7.81	-0.35	4.66e-14	Blood protein levels;
LUAD	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-12.83	-0.53	4.55e-32	Axial length;
LUAD	trans	rs7916697	0.520	rs10762201	chr10:70040111	A/G	cg04882175	chr6:131122610	NA	0.46	6.36	0.3	5.25e-10	Optic disc area;
LUAD	cis	rs807669	0.524	rs11089258	chr22:19162276	C/T	cg02655711	chr22:19163373	SLC25A1	0.63	12.4	0.52	2.57e-30	Metabolite levels;
LUAD	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.35	-0.38	9.87e-16	Total body bone mineral density;
LUAD	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	8.1	0.37	5.82e-15	Parkinson's disease;
LUAD	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg22875332	chr1:76189707	ACADM	0.83	15.63	0.61	8.66e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg26587870	chr6:27730563	NA	-0.67	-7.2	-0.33	2.68e-12	Depression;
LUAD	cis	rs9807989	0.507	rs4851572	chr2:103019031	G/A	cg03938978	chr2:103052716	IL18RAP	0.45	10.29	0.45	2.54e-22	Asthma;
LUAD	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg11189052	chr15:85197271	WDR73	0.65	8.08	0.37	6.62e-15	Bipolar disorder lithium response (categorical) or schizophrenia;
LUAD	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.0	0.32	1.04e-11	Motion sickness;
LUAD	cis	rs1595825	0.891	rs892513	chr2:198905874	A/G	cg00361562	chr2:198649771	BOLL	0.49	6.93	0.32	1.62e-11	Ulcerative colitis;
LUAD	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg22117172	chr7:91764530	CYP51A1	-0.32	-7.08	-0.33	5.99e-12	Breast cancer;
LUAD	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.63	-0.42	5.56e-20	Life satisfaction;
LUAD	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg14893161	chr1:205819251	PM20D1	-0.53	-8.02	-0.36	1.03e-14	Menarche (age at onset);
LUAD	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg09035930	chr12:129282057	SLC15A4	-0.69	-15.85	-0.61	9.86e-45	Systemic lupus erythematosus;
LUAD	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg14343924	chr8:8086146	FLJ10661	0.4	6.35	0.3	5.51e-10	Retinal vascular caliber;
LUAD	cis	rs1569175	0.522	rs10221945	chr2:200875847	T/C	cg23649088	chr2:200775458	C2orf69	-0.61	-6.71	-0.31	6.2e-11	Response to treatment for acute lymphoblastic leukemia;
LUAD	cis	rs500891	0.525	rs1937783	chr6:84097858	G/C	cg08257003	chr6:84140564	ME1	0.34	6.54	0.3	1.8e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg06784218	chr1:46089804	CCDC17	-0.53	-11.59	-0.49	3.67e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg25358565	chr5:93447407	FAM172A	0.61	7.71	0.35	8.98e-14	Diabetic retinopathy;
LUAD	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg02683114	chr2:24398427	C2orf84	-0.53	-7.85	-0.36	3.47e-14	Asthma;
LUAD	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.51	8.33	0.38	1.13e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-6.73	-0.31	5.55e-11	Bladder cancer;
LUAD	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg15128208	chr22:42549153	NA	0.43	6.76	0.31	4.69e-11	Birth weight;
LUAD	cis	rs2637266	1.000	rs2395385	chr10:78341125	G/A	cg18941641	chr10:78392320	NA	0.32	6.77	0.31	4.45e-11	Pulmonary function;
LUAD	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg05340658	chr4:99064831	C4orf37	0.56	9.63	0.42	5.44e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs813218	0.584	rs793469	chr3:99537305	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	6.77	0.31	4.45e-11	Orofacial clefts;
LUAD	cis	rs7582720	1.000	rs6723704	chr2:203738664	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.45	0.42	2.39e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg08601574	chr20:25228251	PYGB	-0.46	-8.59	-0.39	1.74e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs12367572	0.965	rs1506678	chr12:45249492	A/G	cg04608330	chr12:45269318	NELL2	-0.39	-7.7	-0.35	9.89e-14	Gut microbiome composition (summer);
LUAD	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg23711669	chr6:146136114	FBXO30	0.42	7.2	0.33	2.75e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg08296037	chr16:1584118	IFT140;TMEM204	-0.26	-6.39	-0.3	4.37e-10	Coronary artery disease;
LUAD	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg15445000	chr17:37608096	MED1	0.44	8.23	0.37	2.43e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg02734326	chr4:10020555	SLC2A9	0.56	9.89	0.43	7.08e-21	Bone mineral density;
LUAD	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.55	-0.3	1.72e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg25894440	chr7:65020034	NA	-0.74	-6.7	-0.31	6.87e-11	Diabetic kidney disease;
LUAD	cis	rs4006360	0.646	rs8080164	chr17:39292845	A/G	cg12981595	chr17:39254427	KRTAP4-8	0.32	6.59	0.31	1.28e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-7.69	-0.35	1.01e-13	Neutrophil percentage of white cells;
LUAD	cis	rs11048434	0.736	rs2041625	chr12:9112005	C/T	cg26114124	chr12:9217669	LOC144571	0.36	6.64	0.31	9.81e-11	Sjögren's syndrome;
LUAD	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg05340658	chr4:99064831	C4orf37	0.54	9.15	0.41	2.47e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg24578937	chr1:2090814	PRKCZ	-0.55	-10.93	-0.47	1.17e-24	Height;
LUAD	cis	rs7927771	0.689	rs10734557	chr11:47380061	A/C	cg18512352	chr11:47633146	NA	0.43	7.36	0.34	9.5e-13	Subjective well-being;
LUAD	cis	rs7027203	0.964	rs6479512	chr9:96556985	G/A	cg14396892	chr9:96623032	NA	0.4	7.27	0.33	1.77e-12	DNA methylation (variation);
LUAD	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg02176678	chr2:219576539	TTLL4	0.64	12.44	0.52	1.71e-30	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg21918786	chr6:109611834	NA	-0.56	-10.51	-0.45	4.23e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.78	-0.39	4.19e-17	Total body bone mineral density;
LUAD	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg13180566	chr4:1052158	NA	0.4	6.76	0.31	4.5e-11	Recombination rate (females);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03992926	chr1:186344761	TPR;C1orf27;MIR548F1	-0.55	-6.57	-0.3	1.44e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs144345632	1	rs144345632	chr6:96886894	T/TA	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.04	-0.44	2.05e-21	Facial morphology (factor 17, height of vermillion upper lip);
LUAD	cis	rs897984	0.683	rs9932572	chr16:30841642	A/G	cg02466173	chr16:30829666	NA	-0.84	-17.03	-0.64	6.36e-50	Dementia with Lewy bodies;
LUAD	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03517284	chr6:25882590	NA	0.6	10.02	0.44	2.41e-21	Blood metabolite levels;
LUAD	cis	rs8027181	0.617	rs6495017	chr15:73089625	T/A	cg25632853	chr15:73088954	NA	-0.37	-6.61	-0.31	1.13e-10	Triglyceride levels;
LUAD	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.43	7.67	0.35	1.19e-13	Tonsillectomy;
LUAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00149659	chr3:10157352	C3orf10	0.55	7.77	0.35	5.82e-14	Alzheimer's disease;
LUAD	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg01475377	chr6:109611718	NA	-0.54	-10.42	-0.45	8.98e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg13354988	chr2:263656	ACP1;SH3YL1	0.29	6.36	0.3	5.11e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg25985355	chr7:65971099	NA	0.53	6.72	0.31	6e-11	Diabetic kidney disease;
LUAD	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg08773314	chr2:239334832	ASB1	0.45	10.29	0.45	2.51e-22	Multiple system atrophy;
LUAD	cis	rs12208915	0.731	rs9448581	chr6:79553378	A/G	cg18132916	chr6:79620363	NA	-0.5	-6.74	-0.31	5.13e-11	Left atrial antero-posterior diameter;
LUAD	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg17264618	chr3:40429014	ENTPD3	0.37	8.12	0.37	5.28e-15	Renal cell carcinoma;
LUAD	cis	rs1003719	0.843	rs1003721	chr21:38492657	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.47	7.84	0.36	3.65e-14	Eye color traits;
LUAD	cis	rs10540	0.541	rs7480899	chr11:438459	T/C	cg19913688	chr11:428466	ANO9	0.56	7.58	0.35	2.27e-13	Body mass index;
LUAD	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11644478	chr21:40555479	PSMG1	0.55	7.17	0.33	3.32e-12	Cognitive function;
LUAD	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg11189052	chr15:85197271	WDR73	0.61	7.52	0.34	3.24e-13	Schizophrenia;
LUAD	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg14196790	chr5:131705035	SLC22A5	0.39	6.88	0.32	2.18e-11	Blood metabolite levels;
LUAD	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg02269571	chr22:50332266	NA	-0.68	-9.85	-0.43	9.49e-21	Schizophrenia;
LUAD	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.44	0.38	4.93e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9372498	0.505	rs62422247	chr6:118987559	G/T	cg21191810	chr6:118973309	C6orf204	-0.54	-8.36	-0.38	9.14e-16	Diastolic blood pressure;
LUAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08677398	chr8:58056175	NA	0.53	6.89	0.32	2.06e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9807989	0.773	rs72823661	chr2:102968716	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.05e-10	Asthma;
LUAD	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg19875535	chr5:140030758	IK	0.45	7.42	0.34	6.44e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg25985355	chr7:65971099	NA	-0.38	-6.89	-0.32	2.02e-11	Aortic root size;
LUAD	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17605604	chr5:102612899	C5orf30	-0.45	-6.46	-0.3	2.81e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4900538	0.963	rs1885708	chr14:102960164	A/G	cg18135206	chr14:102964638	TECPR2	1.07	24.06	0.76	3.22e-81	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs10821973	0.527	rs6479795	chr10:64015918	T/C	cg09941381	chr10:64027924	RTKN2	-0.36	-7.17	-0.33	3.39e-12	Hypothyroidism;
LUAD	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg04731861	chr2:219085781	ARPC2	-0.22	-6.91	-0.32	1.85e-11	Colorectal cancer;
LUAD	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg06064525	chr11:970664	AP2A2	-0.54	-11.06	-0.47	3.79e-25	Alzheimer's disease (late onset);
LUAD	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg12193833	chr17:30244370	NA	0.52	6.52	0.3	2.01e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01570182	chr17:44337453	NA	-0.95	-14.02	-0.56	5.84e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4601821	0.895	rs1055075	chr11:113239512	T/C	cg14159747	chr11:113255604	NA	0.48	8.89	0.4	1.75e-17	Alcoholic chronic pancreatitis;
LUAD	trans	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg18187862	chr3:45730750	SACM1L	0.5	7.95	0.36	1.68e-14	Primary sclerosing cholangitis;
LUAD	cis	rs1467026	0.563	rs12629928	chr3:12811796	C/T	cg24848339	chr3:12840334	CAND2	0.34	6.66	0.31	8.57e-11	P wave duration;
LUAD	cis	rs7524258	0.868	rs2157499	chr1:7271472	C/T	cg07173049	chr1:7289937	CAMTA1	0.48	9.28	0.41	9.05e-19	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs4888262	0.545	rs36097721	chr16:74648267	C/G	cg01733217	chr16:74700730	RFWD3	0.51	8.62	0.39	1.4e-16	Testicular germ cell tumor;
LUAD	cis	rs2880765	0.835	rs4536419	chr15:86039471	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.48	-0.3	2.63e-10	Coronary artery disease;
LUAD	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg04352962	chr1:209979756	IRF6	0.51	6.53	0.3	1.89e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs17608059	0.545	rs9944522	chr17:13918783	C/T	cg11395062	chr17:14139857	CDRT15	0.44	6.96	0.32	1.32e-11	Temperament;
LUAD	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg01171360	chr6:293285	DUSP22	-0.54	-9.36	-0.41	4.65e-19	Menopause (age at onset);
LUAD	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg21204522	chr6:27730016	NA	-0.45	-7.22	-0.33	2.4e-12	Parkinson's disease;
LUAD	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg01851573	chr8:8652454	MFHAS1	-0.45	-8.13	-0.37	4.69e-15	Neuroticism;
LUAD	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg08885076	chr2:99613938	TSGA10	-0.4	-7.18	-0.33	3.2e-12	Chronic sinus infection;
LUAD	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg07537917	chr2:241836409	C2orf54	-0.3	-8.43	-0.38	5.59e-16	Urinary metabolites;
LUAD	cis	rs8102476	0.846	rs11083450	chr19:38754239	T/C	cg14131526	chr19:38747285	PPP1R14A	-0.37	-6.88	-0.32	2.15e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7119038	0.774	rs874621	chr11:118655645	G/A	cg19308663	chr11:118741387	NA	0.48	6.65	0.31	9.24e-11	Sjögren's syndrome;
LUAD	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg03929089	chr4:120376271	NA	0.54	7.02	0.32	8.88e-12	Axial length;
LUAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg20607798	chr8:58055168	NA	0.81	9.93	0.43	4.99e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs757647	0.723	rs4835778	chr5:137671026	A/G	cg10676309	chr5:137685565	NA	0.38	6.91	0.32	1.74e-11	Menarche (age at onset);
LUAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13126279	chr21:47581558	C21orf56	0.53	8.9	0.4	1.65e-17	Testicular germ cell tumor;
LUAD	cis	rs7937890	0.559	rs2597221	chr11:14527075	C/T	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.15e-12	Mitochondrial DNA levels;
LUAD	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg02196655	chr2:10830764	NOL10	0.43	7.9	0.36	2.44e-14	Prostate cancer;
LUAD	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg08213375	chr14:104286397	PPP1R13B	0.26	6.85	0.32	2.6e-11	Schizophrenia;
LUAD	trans	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg26043149	chr18:55253948	FECH	-0.42	-6.87	-0.32	2.26e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs54211	0.536	rs470081	chr22:39713105	C/T	cg24399712	chr22:39784796	NA	-0.54	-6.81	-0.31	3.47e-11	Sudden cardiac arrest;
LUAD	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.55	0.52	6.47e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg00922110	chr4:57842668	C4orf14	-0.43	-7.13	-0.33	4.47e-12	Response to bleomycin (chromatid breaks);
LUAD	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg15445000	chr17:37608096	MED1	-0.44	-8.08	-0.37	6.73e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs8017423	0.647	rs4904673	chr14:90817338	G/A	cg14092571	chr14:90743983	NA	0.4	6.75	0.31	4.94e-11	Mortality in heart failure;
LUAD	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg25811766	chr13:21894605	NA	-0.62	-7.54	-0.34	2.91e-13	White matter hyperintensity burden;
LUAD	trans	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg04775059	chr7:64541387	NA	0.52	6.89	0.32	2.04e-11	Aortic root size;
LUAD	cis	rs10489202	1.000	rs275157	chr1:168064178	T/C	cg24449463	chr1:168025552	DCAF6	-0.56	-7.2	-0.33	2.72e-12	Schizophrenia;
LUAD	cis	rs494562	0.730	rs9450271	chr6:86114837	G/A	cg17966619	chr6:86160162	NT5E	0.61	7.68	0.35	1.14e-13	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-11.05	-0.47	4.23e-25	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs10838798	0.517	rs1967210	chr11:48096692	G/T	cg03929089	chr4:120376271	NA	-0.62	-7.74	-0.35	7.57e-14	Height;
LUAD	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg27129171	chr3:47204927	SETD2	0.43	6.96	0.32	1.28e-11	Colorectal cancer;
LUAD	cis	rs1832871	0.711	rs9459826	chr6:158680396	C/G	cg07165851	chr6:158734300	TULP4	-0.69	-11.2	-0.48	1.12e-25	Height;
LUAD	cis	rs3789045	0.774	rs12031912	chr1:204476113	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.43	-7.21	-0.33	2.55e-12	Educational attainment (college completion);
LUAD	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.7	-0.35	9.55e-14	Prostate cancer;
LUAD	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.82	-0.36	4.13e-14	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.85	-11.6	-0.49	3.3e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	8.51	0.38	2.98e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs62400317	0.762	rs12208332	chr6:44903221	C/T	cg20913747	chr6:44695427	NA	-0.44	-6.96	-0.32	1.33e-11	Total body bone mineral density;
LUAD	cis	rs7116495	1.000	rs73539529	chr11:71815596	T/C	cg07596299	chr11:71824057	C11orf51	0.78	6.52	0.3	1.95e-10	Severe influenza A (H1N1) infection;
LUAD	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg20587970	chr11:113659929	NA	-1.16	-17.63	-0.65	1.42e-52	Hip circumference adjusted for BMI;
LUAD	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg18132916	chr6:79620363	NA	-0.46	-7.94	-0.36	1.86e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs78404515	chr7:106909126	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-10.66	-0.46	1.2e-23	Coronary artery disease;
LUAD	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg22598563	chr5:131563921	P4HA2	-0.32	-7.97	-0.36	1.48e-14	Blood metabolite levels;
LUAD	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg04772025	chr11:68637568	NA	0.58	9.3	0.41	7.76e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg09835421	chr16:68378352	PRMT7	-0.73	-8.28	-0.37	1.58e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9473147	0.516	rs7749271	chr6:47485002	T/C	cg20196966	chr6:47445060	CD2AP	0.47	7.34	0.34	1.11e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs6066825	0.555	rs4810849	chr20:47289944	C/T	cg18078177	chr20:47281410	PREX1	0.41	6.75	0.31	4.89e-11	Colorectal cancer;
LUAD	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.5	6.88	0.32	2.22e-11	Platelet count;
LUAD	trans	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg07211511	chr3:129823064	LOC729375	-0.54	-7.15	-0.33	3.96e-12	Blood pressure (smoking interaction);
LUAD	cis	rs7512552	0.839	rs11587116	chr1:150451898	A/T	cg15654264	chr1:150340011	RPRD2	0.55	10.63	0.46	1.5e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs1728785	0.818	rs1728769	chr16:68564186	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.78	0.43	1.69e-20	Ulcerative colitis;
LUAD	cis	rs4285028	0.948	rs34566912	chr3:121679626	G/A	cg11130432	chr3:121712080	ILDR1	-0.6	-8.54	-0.38	2.41e-16	Multiple sclerosis;
LUAD	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27286337	chr10:134555280	INPP5A	0.69	9.93	0.43	4.84e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9902453	0.791	rs3115090	chr17:28035014	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	10.09	0.44	1.3e-21	Coffee consumption (cups per day);
LUAD	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	12.12	0.51	3.3e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg07570687	chr10:102243282	WNT8B	0.44	6.95	0.32	1.41e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg09365446	chr1:150670422	GOLPH3L	0.67	12.01	0.5	8.44e-29	Tonsillectomy;
LUAD	cis	rs62400317	0.859	rs11965520	chr6:45259431	T/A	cg18551225	chr6:44695536	NA	-0.54	-8.42	-0.38	5.77e-16	Total body bone mineral density;
LUAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg24503407	chr1:205819492	PM20D1	0.56	9.98	0.44	3.3e-21	Prostate cancer;
LUAD	trans	rs875971	1.000	rs778685	chr7:65836176	G/T	cg14917512	chr19:3094685	GNA11	-0.38	-6.61	-0.31	1.18e-10	Aortic root size;
LUAD	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05890377	chr2:74357713	NA	0.74	11.59	0.49	3.74e-27	Gestational age at birth (maternal effect);
LUAD	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.48	-8.06	-0.36	8.09e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg24644049	chr4:85504048	CDS1	0.69	6.62	0.31	1.06e-10	Skin colour saturation;
LUAD	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg25427524	chr10:38739819	LOC399744	0.56	9.78	0.43	1.66e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	5.93e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10883723	0.962	rs1056741	chr10:104236640	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	9.44	0.42	2.46e-19	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs11585357	0.501	rs58620951	chr1:17573965	G/A	cg08277548	chr1:17600880	PADI3	-0.66	-7.01	-0.32	9.27e-12	Hair shape;
LUAD	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg04476341	chr5:669733	TPPP	-0.41	-8.24	-0.37	2.23e-15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs2404602	0.647	rs34103231	chr15:76912690	A/G	cg23625390	chr15:77176239	SCAPER	-0.53	-7.95	-0.36	1.75e-14	Blood metabolite levels;
LUAD	cis	rs422249	0.819	rs174605	chr11:61626921	G/T	cg19610905	chr11:61596333	FADS2	-0.49	-7.4	-0.34	7.44e-13	Trans fatty acid levels;
LUAD	cis	rs2057149	0.777	rs7748062	chr6:110701282	A/C	cg01119278	chr6:110721349	DDO	-0.38	-6.45	-0.3	3.03e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs12208915	0.559	rs4706738	chr6:79514153	A/G	cg09184832	chr6:79620586	NA	0.43	7.42	0.34	6.59e-13	Left atrial antero-posterior diameter;
LUAD	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg16387850	chr1:46982889	NA	0.51	7.97	0.36	1.49e-14	Monobrow;
LUAD	cis	rs11600901	0.512	rs2298831	chr11:118068752	T/C	cg15794034	chr11:118095775	AMICA1	-0.46	-8.04	-0.36	9.07e-15	Preeclampsia;
LUAD	cis	rs10489202	0.632	rs3767476	chr1:168066940	C/T	cg24449463	chr1:168025552	DCAF6	-0.66	-10.49	-0.45	4.7e-23	Schizophrenia;
LUAD	cis	rs1728785	1.000	rs12918865	chr16:68566546	G/A	cg02508848	chr16:68573721	ZFP90	-0.43	-6.68	-0.31	7.74e-11	Ulcerative colitis;
LUAD	cis	rs11048434	0.736	rs11048264	chr12:9113581	C/T	cg13575925	chr12:9217583	LOC144571	-0.39	-7.53	-0.34	3.19e-13	Sjögren's syndrome;
LUAD	cis	rs240764	0.817	rs239216	chr6:101147892	T/G	cg09795085	chr6:101329169	ASCC3	0.45	7.81	0.36	4.4e-14	Neuroticism;
LUAD	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg17264618	chr3:40429014	ENTPD3	0.42	8.98	0.4	8.74e-18	Renal cell carcinoma;
LUAD	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.8	-15.51	-0.6	2.84e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg08742575	chr21:47604166	C21orf56	-0.63	-11.28	-0.48	5.68e-26	Testicular germ cell tumor;
LUAD	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-9.0	-0.4	7.76e-18	Bipolar disorder;
LUAD	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg00383909	chr3:49044727	WDR6	-0.44	-6.86	-0.32	2.45e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-7.73	-0.35	7.92e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg25208724	chr1:156163844	SLC25A44	1.1	20.71	0.71	2.63e-66	Testicular germ cell tumor;
LUAD	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-6.37	-0.3	5e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs13082711	0.516	rs1492339	chr3:27371526	A/C	cg02860705	chr3:27208620	NA	-0.56	-9.42	-0.42	3.08e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	trans	rs7395662	1.000	rs2221559	chr11:48707973	A/G	cg15704280	chr7:45808275	SEPT13	0.43	6.75	0.31	5.04e-11	HDL cholesterol;
LUAD	cis	rs31251	1.000	rs32108	chr5:131040552	C/T	cg06307176	chr5:131281290	NA	0.36	6.45	0.3	3.1e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs859767	0.887	rs842348	chr2:135342391	T/G	cg12500956	chr2:135428796	TMEM163	0.33	8.66	0.39	9.74e-17	Neuroticism;
LUAD	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg09184832	chr6:79620586	NA	0.5	9.55	0.42	1.1e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs9408928	0.778	rs9409230	chr9:123967760	A/T	cg00636124	chr16:27215281	JMJD5	0.74	7.24	0.33	2.18e-12	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.75	-0.35	6.69e-14	Breast cancer;
LUAD	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg03467027	chr4:99064603	C4orf37	0.39	6.43	0.3	3.43e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	26.51	0.79	5.76e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.1	0.37	5.83e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg15704280	chr7:45808275	SEPT13	-1.0	-20.03	-0.7	3.06e-63	Height;
LUAD	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg03806693	chr22:41940476	POLR3H	-0.45	-6.88	-0.32	2.14e-11	Neuroticism;
LUAD	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg03929089	chr4:120376271	NA	-0.98	-20.96	-0.71	1.99e-67	Height;
LUAD	cis	rs6445967	0.569	rs67793196	chr3:58290129	T/G	cg13750441	chr3:58318267	PXK	-0.3	-6.4	-0.3	4.19e-10	Platelet count;
LUAD	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg06131755	chr6:160182447	ACAT2	0.43	6.42	0.3	3.77e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg05717871	chr11:638507	DRD4	-0.45	-6.6	-0.31	1.25e-10	Systemic lupus erythematosus;
LUAD	cis	rs6840360	0.571	rs4696098	chr4:152489053	C/T	cg22705602	chr4:152727874	NA	-0.4	-7.01	-0.32	9.72e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg09160332	chr4:120329925	NA	0.37	6.49	0.3	2.47e-10	Corneal astigmatism;
LUAD	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.1	-0.57	2.72e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs2274273	0.901	rs10140801	chr14:55730404	C/T	cg04306507	chr14:55594613	LGALS3	0.37	7.65	0.35	1.4e-13	Protein biomarker;
LUAD	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg18944383	chr4:111397179	ENPEP	0.37	7.63	0.35	1.6e-13	Height;
LUAD	cis	rs9393692	0.557	rs10946810	chr6:26288055	G/A	cg13736514	chr6:26305472	NA	-0.51	-7.97	-0.36	1.47e-14	Educational attainment;
LUAD	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.57	-0.49	4.3e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9902453	0.791	rs3115086	chr17:28025949	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	10.06	0.44	1.74e-21	Coffee consumption (cups per day);
LUAD	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg03874509	chr1:107600012	PRMT6	-0.57	-10.03	-0.44	2.29e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg10523679	chr1:76189770	ACADM	-0.9	-16.25	-0.62	1.66e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg20307385	chr11:47447363	PSMC3	-0.63	-10.03	-0.44	2.13e-21	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9768139	0.658	rs896778	chr7:158113270	A/G	cg24154853	chr7:158122151	PTPRN2	0.56	10.92	0.47	1.25e-24	Calcium levels;
LUAD	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg26924012	chr15:45694286	SPATA5L1	0.89	15.32	0.6	1.89e-42	Homoarginine levels;
LUAD	cis	rs6906287	0.647	rs35962656	chr6:118919593	G/T	cg05564266	chr6:118973597	C6orf204	0.37	7.75	0.35	6.98e-14	Electrocardiographic conduction measures;
LUAD	cis	rs4629710	0.592	rs13195700	chr6:131585299	C/T	cg12606694	chr6:131520996	AKAP7	0.46	6.86	0.32	2.43e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs6554196	0.508	rs981959	chr4:55526962	G/T	cg18836493	chr4:55524333	KIT	-0.39	-7.37	-0.34	8.75e-13	Monocyte count;
LUAD	cis	rs12541635	0.899	rs1429676	chr8:107065790	G/A	cg10147462	chr8:107024639	NA	-0.43	-7.61	-0.35	1.83e-13	Age of smoking initiation;
LUAD	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21659725	chr3:3221576	CRBN	0.86	18.51	0.67	1.87e-56	Intelligence (multi-trait analysis);
LUAD	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg05623727	chr3:50126028	RBM5	-0.34	-7.25	-0.33	1.95e-12	Body mass index;
LUAD	cis	rs6138458	0.743	rs3746330	chr20:24999795	A/G	cg06937882	chr20:24974362	C20orf3	-0.3	-6.42	-0.3	3.66e-10	Blood protein levels;
LUAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg23978390	chr7:1156363	C7orf50	0.43	6.97	0.32	1.19e-11	Longevity;Endometriosis;
LUAD	cis	rs3020333	0.875	rs2982571	chr6:152012739	A/T	cg22157087	chr6:152012887	ESR1	-0.36	-6.41	-0.3	3.83e-10	Total body bone mineral density;
LUAD	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg26513180	chr16:89883248	FANCA	0.7	13.3	0.54	6.03e-34	Vitiligo;
LUAD	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg17105886	chr17:28927953	LRRC37B2	0.83	8.0	0.36	1.18e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	7.11	0.33	4.93e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10924309	0.855	rs2008766	chr1:245860205	C/A	cg00036263	chr1:245852353	KIF26B	-0.48	-7.42	-0.34	6.68e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.45	-0.34	5.47e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.55	-0.6	1.9e-43	Chronic sinus infection;
LUAD	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg12193833	chr17:30244370	NA	-0.58	-6.87	-0.32	2.24e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs7177699	0.557	rs8026598	chr15:79112938	A/G	cg15571903	chr15:79123663	NA	0.37	7.38	0.34	8.64e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27286337	chr10:134555280	INPP5A	0.72	9.52	0.42	1.34e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg17724175	chr1:150552817	MCL1	0.31	7.15	0.33	3.93e-12	Melanoma;
LUAD	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.68	-11.33	-0.48	3.77e-26	Primary sclerosing cholangitis;
LUAD	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg00677455	chr12:58241039	CTDSP2	0.45	7.44	0.34	5.59e-13	Multiple sclerosis;
LUAD	cis	rs1030877	1.000	rs2576743	chr2:105901337	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.59	11.81	0.5	5.26e-28	Obesity-related traits;
LUAD	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg13789015	chr9:136890014	NCRNA00094	0.87	14.5	0.58	5.99e-39	Platelet distribution width;
LUAD	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg09904177	chr6:26538194	HMGN4	0.42	6.93	0.32	1.58e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg11905131	chr22:24372483	LOC391322	-0.64	-11.42	-0.49	1.6e-26	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs910873	0.656	rs62213589	chr20:33219835	A/C	cg16810054	chr20:33298113	TP53INP2	0.59	6.8	0.31	3.57e-11	Melanoma;
LUAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-9.43	-0.42	2.7e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg27446573	chr6:127587934	RNF146	0.46	6.87	0.32	2.28e-11	Breast cancer;
LUAD	cis	rs494562	0.892	rs683218	chr6:86118584	A/G	cg27297263	chr6:86160468	NT5E	0.59	6.55	0.3	1.63e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	8.86	0.4	2.26e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg25482853	chr8:67687455	SGK3	1.12	16.65	0.63	3.25e-48	Obesity-related traits;
LUAD	cis	rs240764	0.658	rs705585	chr6:101262409	A/G	cg09795085	chr6:101329169	ASCC3	0.48	8.41	0.38	6.58e-16	Neuroticism;
LUAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg02951883	chr7:2050386	MAD1L1	-0.95	-18.98	-0.68	1.49e-58	Bipolar disorder and schizophrenia;
LUAD	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg01851573	chr8:8652454	MFHAS1	-0.44	-7.76	-0.35	6.36e-14	Mood instability;
LUAD	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg24596788	chr1:163392923	NA	-0.37	-8.2	-0.37	2.91e-15	Motion sickness;
LUAD	cis	rs240764	0.817	rs240164	chr6:101044487	T/A	cg09795085	chr6:101329169	ASCC3	0.42	6.99	0.32	1.05e-11	Neuroticism;
LUAD	trans	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg26043149	chr18:55253948	FECH	-0.63	-10.46	-0.45	6.4e-23	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.78e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08677398	chr8:58056175	NA	0.53	6.93	0.32	1.57e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9788682	0.633	rs2656070	chr15:78730252	A/G	cg18825076	chr15:78729989	IREB2	-0.53	-7.46	-0.34	5.11e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg12432903	chr7:1882776	MAD1L1	-0.48	-7.9	-0.36	2.52e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg25811766	chr13:21894605	NA	-0.63	-7.62	-0.35	1.67e-13	White matter hyperintensity burden;
LUAD	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg26513180	chr16:89883248	FANCA	0.5	8.33	0.38	1.14e-15	Vitiligo;
LUAD	cis	rs6761276	0.899	rs11677043	chr2:113835520	A/G	cg02343335	chr2:113785852	IL1F8	-0.35	-7.03	-0.32	8.11e-12	Protein quantitative trait loci;
LUAD	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg15962314	chr1:44399869	ARTN	-0.31	-7.02	-0.32	8.9e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs76843318	chr7:106863173	A/G	cg23024343	chr7:107201750	COG5	0.49	7.03	0.32	8.41e-12	Coronary artery disease;
LUAD	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.23	-0.37	2.38e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg07460842	chr6:66804631	NA	-1.06	-16.56	-0.63	7.5e-48	Exhaled nitric oxide output;
LUAD	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg17551891	chr7:1960795	MAD1L1	-0.42	-6.94	-0.32	1.47e-11	Neuroticism;
LUAD	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg20476274	chr7:133979776	SLC35B4	0.86	17.55	0.65	3.47e-52	Mean platelet volume;
LUAD	trans	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg07817883	chr1:32538562	TMEM39B	1.56	13.45	0.55	1.46e-34	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg11235426	chr6:292522	DUSP22	-0.79	-13.55	-0.55	5.48e-35	Menopause (age at onset);
LUAD	cis	rs701145	0.938	rs357504	chr3:153956857	A/C	cg17054900	chr3:154042577	DHX36	0.62	6.8	0.31	3.55e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.38e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg16479474	chr6:28041457	NA	0.39	6.99	0.32	1.1e-11	Parkinson's disease;
LUAD	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg08999081	chr20:33150536	PIGU	0.56	11.77	0.5	7.42e-28	Coronary artery disease;
LUAD	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg22823121	chr1:150693482	HORMAD1	0.4	7.95	0.36	1.72e-14	Melanoma;
LUAD	cis	rs68170813	0.559	rs2107318	chr7:106845969	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-10.87	-0.47	1.86e-24	Coronary artery disease;
LUAD	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg00106254	chr7:1943704	MAD1L1	-0.63	-9.71	-0.43	2.88e-20	Bipolar disorder and schizophrenia;
LUAD	trans	rs1997103	1.000	rs2140915	chr7:55410699	G/C	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg21775007	chr8:11205619	TDH	-0.5	-9.07	-0.4	4.66e-18	Retinal vascular caliber;
LUAD	cis	rs3806843	0.576	rs405192	chr5:140324710	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.33	-6.67	-0.31	7.95e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg07507251	chr3:52567010	NT5DC2	0.34	6.52	0.3	2e-10	Bipolar disorder;
LUAD	cis	rs68170813	0.559	rs10953534	chr7:106913718	A/G	cg23024343	chr7:107201750	COG5	-0.45	-6.41	-0.3	3.79e-10	Coronary artery disease;
LUAD	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg13334819	chr7:99746414	C7orf59	0.63	9.9	0.43	6.48e-21	Coronary artery disease;
LUAD	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg06623918	chr6:96969491	KIAA0776	0.84	16.03	0.61	1.55e-45	Headache;
LUAD	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg01299579	chr2:10830716	NOL10	-0.43	-7.55	-0.34	2.77e-13	Prostate cancer;
LUAD	cis	rs2742234	0.955	rs1800861	chr10:43613843	G/T	cg02780029	chr10:43622663	RET	-0.42	-6.84	-0.32	2.79e-11	Hirschsprung disease;
LUAD	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.28	-0.33	1.66e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg03517284	chr6:25882590	NA	-0.4	-6.53	-0.3	1.91e-10	Height;
LUAD	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg00666640	chr1:248458726	OR2T12	-0.28	-6.79	-0.31	3.87e-11	Common traits (Other);
LUAD	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg06636551	chr8:101224915	SPAG1	-0.38	-6.98	-0.32	1.17e-11	Atrioventricular conduction;
LUAD	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg12623918	chr2:306882	NA	0.36	7.21	0.33	2.62e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg05872129	chr22:39784769	NA	-0.82	-15.65	-0.61	6.93e-44	Intelligence (multi-trait analysis);
LUAD	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.33	-0.34	1.17e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.8	-0.35	4.77e-14	Diabetic kidney disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08877624	chr8:141521446	CHRAC1	-0.57	-7.32	-0.34	1.28e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12655379	chr3:120461794	GTF2E1;RABL3	-0.4	-6.36	-0.3	5.12e-10	Cancer;
LUAD	cis	rs2235649	0.798	rs9932983	chr16:1848184	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.43	-6.95	-0.32	1.42e-11	Blood metabolite levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06178054	chr13:41495913	SUGT1L1	-0.4	-6.37	-0.3	4.91e-10	Height;
LUAD	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.04	-0.32	7.86e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg26354017	chr1:205819088	PM20D1	0.53	8.92	0.4	1.41e-17	Parkinson's disease;
LUAD	cis	rs7274811	0.711	rs184110	chr20:31981432	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.52	7.8	0.35	4.89e-14	Height;
LUAD	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg02176678	chr2:219576539	TTLL4	0.6	11.74	0.5	9.68e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg11707310	chr1:2537719	MMEL1	-0.36	-7.64	-0.35	1.51e-13	Ulcerative colitis;
LUAD	cis	rs9309473	0.583	rs6713196	chr2:73576405	T/C	cg20560298	chr2:73613845	ALMS1	-0.43	-6.66	-0.31	8.58e-11	Metabolite levels;
LUAD	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg05340658	chr4:99064831	C4orf37	0.54	9.17	0.41	2.06e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg27411982	chr8:10470053	RP1L1	0.43	8.13	0.37	4.96e-15	Neuroticism;
LUAD	cis	rs17152411	1.000	rs10901843	chr10:126638020	A/G	cg07906193	chr10:126599966	NA	0.53	7.58	0.35	2.21e-13	Height;
LUAD	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.68	13.33	0.54	4.2e-34	Cognitive ability;
LUAD	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10802521	chr3:52805072	NEK4	-0.62	-11.07	-0.47	3.45e-25	Bipolar disorder;
LUAD	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg23283495	chr1:209979779	IRF6	0.78	9.44	0.42	2.44e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-11.06	-0.47	3.88e-25	Hemoglobin concentration;
LUAD	cis	rs1829883	1.000	rs1403661	chr5:98777056	T/A	cg08333243	chr5:99726346	NA	-0.36	-7.02	-0.32	8.83e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.67	-12.86	-0.53	3.7e-32	Longevity;Endometriosis;
LUAD	cis	rs9322817	0.691	rs4142531	chr6:105324811	G/A	cg02098413	chr6:105308735	HACE1	0.4	8.75	0.39	5.07e-17	Thyroid stimulating hormone;
LUAD	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg17372223	chr3:52568218	NT5DC2	-0.4	-7.16	-0.33	3.6e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2239547	0.522	rs2581780	chr3:53058960	C/T	cg14092988	chr3:52407081	DNAH1	-0.38	-6.5	-0.3	2.29e-10	Schizophrenia;
LUAD	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	10.4	0.45	1e-22	Electrocardiographic conduction measures;
LUAD	cis	rs4481887	0.760	rs4559544	chr1:248412507	T/G	cg00666640	chr1:248458726	OR2T12	0.31	7.51	0.34	3.58e-13	Common traits (Other);
LUAD	cis	rs9341808	0.529	rs9350851	chr6:81059188	A/G	cg08355045	chr6:80787529	NA	0.48	8.1	0.37	5.84e-15	Sitting height ratio;
LUAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08280861	chr8:58055591	NA	0.77	9.5	0.42	1.56e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs11971779	0.680	rs111461944	chr7:139077903	G/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.4	-0.3	4.05e-10	Diisocyanate-induced asthma;
LUAD	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg24634471	chr8:143751801	JRK	0.48	7.84	0.36	3.79e-14	Schizophrenia;
LUAD	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.15	0.33	3.73e-12	Prostate cancer;
LUAD	cis	rs7616330	0.887	rs2100142	chr3:71112560	A/G	cg20891481	chr3:71115714	FOXP1	0.47	7.05	0.32	7.2e-12	QT interval;
LUAD	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg23985595	chr17:80112537	CCDC57	-0.51	-9.21	-0.41	1.56e-18	Life satisfaction;
LUAD	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg08085267	chr17:45401833	C17orf57	-0.5	-8.25	-0.37	1.97e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9341808	0.727	rs9361599	chr6:81025242	C/G	cg08355045	chr6:80787529	NA	0.55	10.08	0.44	1.46e-21	Sitting height ratio;
LUAD	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg05805236	chr11:65401703	PCNXL3	-0.54	-8.92	-0.4	1.43e-17	Acne (severe);
LUAD	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11890956	chr21:40555474	PSMG1	0.82	14.66	0.58	1.25e-39	Cognitive function;
LUAD	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00149659	chr3:10157352	C3orf10	0.6	8.19	0.37	3.2e-15	Alzheimer's disease;
LUAD	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg09904177	chr6:26538194	HMGN4	0.42	6.56	0.3	1.54e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg18180107	chr4:99064573	C4orf37	0.44	7.11	0.33	4.84e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11771526	0.901	rs11760534	chr7:32262966	C/T	cg27532318	chr7:32358331	NA	0.62	7.75	0.35	6.67e-14	Body mass index;
LUAD	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05665937	chr4:1216051	CTBP1	0.47	7.05	0.32	7.17e-12	Longevity;
LUAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg11965913	chr1:205819406	PM20D1	0.9	20.77	0.71	1.46e-66	Menarche (age at onset);
LUAD	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg21204522	chr6:27730016	NA	-0.45	-7.1	-0.33	5.21e-12	Parkinson's disease;
LUAD	cis	rs7851660	0.933	rs894673	chr9:100612270	A/T	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.4	6.69	0.31	6.99e-11	Diastolic blood pressure;
LUAD	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg16989719	chr2:238392110	NA	-0.39	-8.0	-0.36	1.19e-14	Prostate cancer;
LUAD	cis	rs9837602	1.000	rs6790535	chr3:99807735	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-7.58	-0.35	2.2e-13	Breast cancer;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg22969287	chr11:16760677	C11orf58	-0.41	-6.77	-0.31	4.42e-11	Subcortical brain region volumes;
LUAD	cis	rs11229555	0.645	rs12283414	chr11:58176920	C/T	cg15696309	chr11:58395628	NA	-0.73	-10.21	-0.44	5.12e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg02428538	chr16:24856791	SLC5A11	-0.52	-7.18	-0.33	3.18e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs62238980	0.614	rs115866486	chr22:32510228	A/T	cg00543991	chr22:32367038	NA	0.86	8.46	0.38	4.56e-16	Childhood ear infection;
LUAD	cis	rs4660306	0.961	rs12082256	chr1:45951380	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-8.01	-0.36	1.11e-14	Homocysteine levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13686143	chr2:201828163	ORC2L	-0.42	-6.42	-0.3	3.63e-10	Height;
LUAD	cis	rs12208915	0.708	rs9361481	chr6:79726750	T/A	cg11833968	chr6:79620685	NA	0.53	7.76	0.35	6.6e-14	Left atrial antero-posterior diameter;
LUAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-10.0	-0.44	2.93e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg23758822	chr17:41437982	NA	1.01	20.88	0.71	4.44e-67	Menopause (age at onset);
LUAD	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg10909506	chr17:38081995	ORMDL3	0.38	6.87	0.32	2.37e-11	Self-reported allergy;
LUAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg04234412	chr22:24373322	LOC391322	0.75	11.44	0.49	1.41e-26	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs7773004	1.000	rs1155207	chr6:26328365	A/G	cg13736514	chr6:26305472	NA	-0.5	-8.41	-0.38	6.42e-16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg27661571	chr11:113659931	NA	-0.65	-7.63	-0.35	1.5700000000000001e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.83	0.31	3.04e-11	Cognitive test performance;
LUAD	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg02733842	chr7:1102375	C7orf50	-0.68	-10.39	-0.45	1.13e-22	Bronchopulmonary dysplasia;
LUAD	cis	rs7799006	0.606	rs12535174	chr7:2310974	C/T	cg08027265	chr7:2291960	NA	-0.73	-14.81	-0.58	2.74e-40	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.99	11.04	0.47	4.59e-25	Initial pursuit acceleration;
LUAD	cis	rs10504073	0.647	rs12156111	chr8:50017328	G/C	cg00325661	chr8:49890786	NA	0.42	9.6	0.42	7.13e-20	Blood metabolite ratios;
LUAD	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg01765077	chr12:122356316	WDR66	0.59	10.11	0.44	1.17e-21	Mean corpuscular volume;
LUAD	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg00339695	chr16:24857497	SLC5A11	0.53	9.69	0.43	3.56e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg21775007	chr8:11205619	TDH	-0.53	-9.71	-0.43	2.96e-20	Retinal vascular caliber;
LUAD	cis	rs73416724	1.000	rs70953680	chr6:43267831	G/A	cg26312998	chr6:43337775	ZNF318	0.56	6.64	0.31	9.91e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	9.48	0.42	1.8e-19	Lung cancer in ever smokers;
LUAD	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.53	-0.34	3.18e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg18138036	chr10:133769891	PPP2R2D	0.41	6.69	0.31	7.09e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg04450456	chr4:17643702	FAM184B	0.36	6.7	0.31	6.76e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg26168224	chr5:2018326	NA	-0.72	-14.55	-0.58	3.43e-39	Gut microbiome composition (winter);
LUAD	cis	rs4604732	0.631	rs12039642	chr1:247624898	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	9.21	0.41	1.59e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs7395662	1.000	rs7121460	chr11:48545232	C/A	cg00717180	chr2:96193071	NA	-0.4	-7.45	-0.34	5.38e-13	HDL cholesterol;
LUAD	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05901451	chr6:126070800	HEY2	-0.8	-14.71	-0.58	7.44e-40	Brugada syndrome;
LUAD	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.56	0.52	5.93e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs427394	0.802	rs274720	chr5:6719933	A/G	cg10857441	chr5:6722123	POLS	-0.65	-12.78	-0.53	7.75e-32	Menopause (age at onset);
LUAD	cis	rs2109514	0.542	rs1011442	chr7:116088301	G/A	cg04696780	chr7:116139425	CAV2	-0.31	-6.96	-0.32	1.34e-11	Prevalent atrial fibrillation;
LUAD	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.49	-0.34	4.04e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg03714773	chr7:91764589	CYP51A1	0.28	6.67	0.31	8.08e-11	Breast cancer;
LUAD	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg26384229	chr12:38710491	ALG10B	0.51	8.38	0.38	7.67e-16	Heart rate;
LUAD	cis	rs7187994	0.672	rs7185686	chr16:84799013	C/T	cg07647771	chr16:84786436	USP10	-0.3	-7.73	-0.35	8.11e-14	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg13385794	chr1:248469461	NA	0.26	7.04	0.32	7.78e-12	Common traits (Other);
LUAD	cis	rs4523957	0.583	rs2760741	chr17:2020443	C/T	cg16513277	chr17:2031491	SMG6	-0.95	-19.14	-0.68	2.98e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs367943	0.712	rs7731465	chr5:112687385	A/G	cg12552261	chr5:112820674	MCC	-0.46	-8.89	-0.4	1.82e-17	Type 2 diabetes;
LUAD	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	9.54	0.42	1.16e-19	Electrocardiographic conduction measures;
LUAD	cis	rs250585	0.736	rs540719	chr16:23456578	T/C	cg00143387	chr16:23521605	GGA2	0.63	9.08	0.4	4.13e-18	Egg allergy;
LUAD	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg03433033	chr1:76189801	ACADM	0.7	10.05	0.44	1.9e-21	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2154427	0.872	rs76474418	chr21:34050113	A/G	cg21871883	chr21:34145043	C21orf49;C21orf66	0.65	6.7	0.31	6.72e-11	Bilirubin levels;
LUAD	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg05991184	chr2:219186017	PNKD	0.37	7.06	0.32	6.78e-12	Colorectal cancer;
LUAD	cis	rs9796	0.870	rs28581803	chr15:41326513	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.37	-7.02	-0.32	9.02e-12	Menopause (age at onset);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg27127643	chr14:21078142	NA	-0.4	-6.71	-0.31	6.11e-11	Cancer;
LUAD	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg24069376	chr3:38537580	EXOG	0.44	10.58	0.46	2.36e-23	Electrocardiographic conduction measures;
LUAD	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg00310523	chr12:86230176	RASSF9	0.42	8.79	0.39	3.75e-17	Major depressive disorder;
LUAD	cis	rs595982	0.517	rs10404905	chr19:49406175	A/T	cg21252483	chr19:49399788	TULP2	0.48	9.27	0.41	9.92e-19	Red cell distribution width;
LUAD	trans	rs11054731	1.000	rs10845501	chr12:12415697	A/G	cg18844304	chr19:55851052	SUV420H2	0.41	6.45	0.3	3.1e-10	Coronary artery calcification;
LUAD	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg00802000	chr16:706648	WDR90	-0.37	-6.94	-0.32	1.45e-11	Height;
LUAD	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg13319975	chr6:146136371	FBXO30	-0.66	-11.38	-0.48	2.37e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1865721	0.958	rs72977878	chr18:73193037	T/G	cg26385618	chr18:73139727	C18orf62	-0.41	-7.48	-0.34	4.31e-13	Intelligence;
LUAD	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg07153921	chr17:41440717	NA	0.39	6.76	0.31	4.64e-11	Menopause (age at onset);
LUAD	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06544989	chr22:39130855	UNC84B	0.41	7.56	0.34	2.61e-13	Menopause (age at onset);
LUAD	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg22496339	chr2:162101262	NA	-0.46	-7.44	-0.34	5.56e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg00852783	chr1:26633632	UBXN11	0.46	7.56	0.35	2.45e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg22875332	chr1:76189707	ACADM	0.64	10.35	0.45	1.6e-22	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg04287289	chr16:89883240	FANCA	0.8	7.0	0.32	1.01e-11	Skin colour saturation;
LUAD	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg12365402	chr11:9010492	NRIP3	0.48	8.87	0.4	2.04e-17	Hemoglobin concentration;
LUAD	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg07952391	chr2:88470173	THNSL2	-0.4	-6.46	-0.3	2.81e-10	Response to metformin (IC50);
LUAD	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg21385522	chr1:16154831	NA	0.57	9.63	0.42	5.47e-20	Systolic blood pressure;
LUAD	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg11618577	chr2:27665543	KRTCAP3	-0.26	-7.0	-0.32	1.01e-11	Total body bone mineral density;
LUAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	cis	rs2734839	0.964	rs12363125	chr11:113285916	C/T	cg14159747	chr11:113255604	NA	0.53	10.08	0.44	1.45e-21	Information processing speed;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg18652121	chr3:179322868	MRPL47;NDUFB5	0.39	6.36	0.3	5.4e-10	Bilirubin levels;
LUAD	cis	rs9837602	1.000	rs7627991	chr3:99808338	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	9.39	0.42	3.74e-19	Breast cancer;
LUAD	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg05425664	chr17:57184151	TRIM37	-0.41	-6.87	-0.32	2.26e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.01	0.47	5.84e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg01416388	chr22:39784598	NA	-0.53	-8.78	-0.39	4.05e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs988958	0.565	rs4952399	chr2:42289107	A/G	cg12630082	chr2:42275740	PKDCC	0.29	6.4	0.3	4.15e-10	Hypospadias;
LUAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg24813613	chr7:1882135	MAD1L1	-0.44	-6.77	-0.31	4.4e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg18252515	chr7:66147081	NA	-0.62	-6.77	-0.31	4.27e-11	Diabetic kidney disease;
LUAD	cis	rs9902453	0.904	rs7213076	chr17:28419428	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-10.12	-0.44	1.06e-21	Coffee consumption (cups per day);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13104704	chr22:24192004	NA	-0.44	-6.73	-0.31	5.44e-11	Height;
LUAD	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg00147160	chr1:26503991	CNKSR1	0.37	8.74	0.39	5.51e-17	Height;
LUAD	cis	rs4660306	0.961	rs945179	chr1:45992460	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	7.48	0.34	4.37e-13	Homocysteine levels;
LUAD	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg10518543	chr12:38710700	ALG10B	-0.42	-6.8	-0.31	3.6e-11	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05608694	chr5:141303209	KIAA0141	-0.68	-6.53	-0.3	1.94e-10	Type 2 diabetes;
LUAD	trans	rs11700980	0.636	rs115245768	chr21:30256118	T/G	cg14791747	chr16:20752902	THUMPD1	0.62	6.83	0.32	3.04e-11	QRS complex (12-leadsum);
LUAD	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg15900387	chr1:150738905	CTSS	-0.38	-6.85	-0.32	2.62e-11	Melanoma;
LUAD	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg08847533	chr14:75593920	NEK9	0.43	7.43	0.34	6.05e-13	Height;
LUAD	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg18252515	chr7:66147081	NA	-0.61	-6.66	-0.31	8.66e-11	Diabetic kidney disease;
LUAD	cis	rs1461503	0.932	rs7944492	chr11:122838745	G/T	cg27398637	chr11:122830231	C11orf63	-0.37	-7.25	-0.33	2.06e-12	Menarche (age at onset);
LUAD	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg17279839	chr7:150038598	RARRES2	0.43	7.17	0.33	3.34e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs12286929	0.668	rs17304149	chr11:115049180	C/T	cg04055981	chr11:115044050	NA	0.49	8.81	0.39	3.29e-17	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg20701182	chr2:24300061	SF3B14	0.58	6.7	0.31	6.47e-11	Lymphocyte counts;
LUAD	cis	rs9902453	0.679	rs2054847	chr17:28532013	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.44	7.17	0.33	3.45e-12	Coffee consumption (cups per day);
LUAD	trans	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg02002194	chr4:3960332	NA	-0.28	-6.81	-0.31	3.27e-11	Mood instability;
LUAD	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.94	-0.32	1.51e-11	Triglycerides;
LUAD	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-7.63	-0.35	1.53e-13	Platelet count;
LUAD	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg20503657	chr10:835505	NA	1.25	17.91	0.66	8.26e-54	Eosinophil percentage of granulocytes;
LUAD	cis	rs1509123	0.609	rs78727666	chr17:6713108	C/T	cg12642237	chr17:6703447	TEKT1	-0.48	-7.06	-0.32	6.85e-12	Blood metabolite levels;
LUAD	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg11663144	chr21:46675770	NA	-0.61	-11.65	-0.49	2.12e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg21475434	chr5:93447410	FAM172A	0.74	8.33	0.38	1.1e-15	Diabetic retinopathy;
LUAD	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.6	8.33	0.38	1.16e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg22963979	chr7:1858916	MAD1L1	-0.49	-8.45	-0.38	4.76e-16	Bipolar disorder and schizophrenia;
LUAD	trans	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg06774039	chr2:74056087	STAMBP	0.4	6.49	0.3	2.36e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg22442454	chr1:209979470	IRF6	0.56	7.52	0.34	3.39e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs853679	0.699	rs9468318	chr6:28209531	T/A	cg16479474	chr6:28041457	NA	0.41	6.68	0.31	7.73e-11	Depression;
LUAD	cis	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.87	-0.36	3.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg18851521	chr18:268131	THOC1	-0.59	-7.13	-0.33	4.44e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg15467112	chr14:75489610	MLH3	-0.35	-6.44	-0.3	3.24e-10	Height;
LUAD	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-7.86	-0.36	3.21e-14	Total cholesterol levels;
LUAD	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg00530320	chr1:46809349	NSUN4	-0.52	-8.04	-0.36	9.1e-15	Menopause (age at onset);
LUAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg26516362	chr5:178986906	RUFY1	-0.66	-12.28	-0.51	7.62e-30	Lung cancer;
LUAD	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-24.81	-0.77	1.63e-84	Height;
LUAD	cis	rs2046867	0.908	rs9811830	chr3:72809591	A/G	cg25664220	chr3:72788482	NA	-0.65	-12.09	-0.51	4.29e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4700695	0.719	rs153390	chr5:65431087	G/C	cg21114390	chr5:65439923	SFRS12	-0.9	-14.18	-0.57	1.3e-37	Facial morphology (factor 19);
LUAD	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg05340658	chr4:99064831	C4orf37	0.47	7.77	0.35	6.2e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs55665837	0.539	rs731042	chr11:14874975	A/T	cg19336497	chr11:14380999	RRAS2	-0.4	-7.38	-0.34	8.38e-13	Vitamin D levels;
LUAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg06074448	chr4:187884817	NA	-0.36	-7.17	-0.33	3.42e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13315871	1.000	rs71311865	chr3:58372423	G/A	cg12435725	chr3:58293450	RPP14	-0.67	-7.31	-0.33	1.36e-12	Cholesterol, total;
LUAD	cis	rs116095464	1.000	rs62331562	chr5:349298	G/C	cg22496380	chr5:211416	CCDC127	-1.02	-7.79	-0.35	5.22e-14	Breast cancer;
LUAD	cis	rs912057	0.932	rs1294404	chr6:6735022	G/A	cg06612196	chr6:6737390	NA	0.54	11.91	0.5	2.09e-28	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27286337	chr10:134555280	INPP5A	0.69	9.91	0.43	6e-21	Migraine;
LUAD	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg25344623	chr2:136566232	LCT	-0.33	-6.44	-0.3	3.25e-10	Mosquito bite size;
LUAD	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg15704280	chr7:45808275	SEPT13	-0.98	-20.57	-0.71	1.11e-65	Height;
LUAD	cis	rs7107174	1.000	rs10899453	chr11:77997482	A/C	cg19901956	chr11:77921274	USP35	-0.53	-6.83	-0.32	2.92e-11	Testicular germ cell tumor;
LUAD	cis	rs8014204	0.773	rs2241275	chr14:75251440	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.38	-6.82	-0.31	3.09e-11	Caffeine consumption;
LUAD	cis	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg21775007	chr8:11205619	TDH	0.39	6.37	0.3	4.82e-10	Neuroticism;
LUAD	cis	rs2932538	0.961	rs3795820	chr1:113163042	C/A	cg22162597	chr1:113214053	CAPZA1	-0.45	-6.5	-0.3	2.2e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	trans	rs1493916	0.967	rs1389532	chr18:31392323	C/T	cg13755796	chr4:20253514	NA	-0.41	-6.89	-0.32	2.03e-11	Life satisfaction;
LUAD	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg24803719	chr17:45855879	NA	-0.3	-6.45	-0.3	3.02e-10	IgG glycosylation;
LUAD	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg09491104	chr22:46646882	C22orf40	-0.74	-13.49	-0.55	9.76e-35	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2479724	0.818	rs9357369	chr6:41818202	A/C	cg17623882	chr6:41773611	USP49	-0.67	-12.68	-0.52	1.86e-31	Menarche (age at onset);
LUAD	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7582720	1.000	rs114393235	chr2:203795987	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg22705602	chr4:152727874	NA	-0.48	-9.04	-0.4	5.75e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1113500	0.966	rs11185249	chr1:108611646	C/A	cg06207961	chr1:108661230	NA	0.43	8.15	0.37	4.09e-15	Growth-regulated protein alpha levels;
LUAD	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg09509183	chr1:209979624	IRF6	0.62	7.22	0.33	2.48e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg12432903	chr7:1882776	MAD1L1	-0.45	-7.29	-0.33	1.58e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg10435618	chr10:838112	NA	0.47	6.43	0.3	3.54e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs2268241	0.938	rs9974603	chr21:34776300	C/A	cg14850771	chr21:34775459	IFNGR2	0.59	6.96	0.32	1.32e-11	Obesity-related traits;
LUAD	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg23887609	chr12:130822674	PIWIL1	0.45	7.23	0.33	2.3e-12	Menopause (age at onset);
LUAD	cis	rs12681287	0.640	rs4587306	chr8:87385511	T/C	cg27223183	chr8:87520930	FAM82B	0.68	9.52	0.42	1.34e-19	Caudate activity during reward;
LUAD	cis	rs13064411	0.696	rs13325046	chr3:113104444	C/T	cg10517650	chr3:113235015	CCDC52	-0.54	-8.35	-0.38	9.85e-16	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg24101359	chr6:42928495	GNMT	0.54	10.13	0.44	9.56e-22	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg05991184	chr2:219186017	PNKD	-0.36	-7.11	-0.33	5.14e-12	High light scatter reticulocyte percentage of red cells;Plateletcrit;
LUAD	trans	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg01620082	chr3:125678407	NA	-1.01	-10.28	-0.45	2.92e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.9	0.36	2.47e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.45	-7.96	-0.36	1.63e-14	Age at first birth;
LUAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27286337	chr10:134555280	INPP5A	0.73	9.71	0.43	2.92e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	trans	rs2735413	0.875	rs12923229	chr16:78080302	C/A	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg08213375	chr14:104286397	PPP1R13B	0.28	7.4	0.34	7.55e-13	Schizophrenia;
LUAD	cis	rs7191700	0.836	rs10163410	chr16:11430615	G/C	cg00044050	chr16:11439710	C16orf75	0.67	9.54	0.42	1.12e-19	Multiple sclerosis;
LUAD	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg02734326	chr4:10020555	SLC2A9	-0.42	-7.25	-0.33	1.97e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg11062466	chr8:58055876	NA	-0.67	-8.85	-0.4	2.49e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg22467129	chr15:76604101	ETFA	-0.46	-7.59	-0.35	2.01e-13	Blood metabolite levels;
LUAD	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg11766577	chr21:47581405	C21orf56	-0.44	-7.62	-0.35	1.65e-13	Testicular germ cell tumor;
LUAD	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg20487152	chr13:99095054	FARP1	0.55	10.05	0.44	1.9e-21	Neuroticism;
LUAD	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg00074818	chr8:8560427	CLDN23	0.6	9.17	0.41	2.09e-18	Obesity-related traits;
LUAD	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg24838063	chr12:130822603	PIWIL1	0.64	10.68	0.46	9.9899999999999993e-24	Menopause (age at onset);
LUAD	cis	rs13082711	0.911	rs13082777	chr3:27421942	A/G	cg02860705	chr3:27208620	NA	0.57	8.69	0.39	7.85e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs5167	0.750	rs3786505	chr19:45490570	A/G	cg13119609	chr19:45449297	APOC2	0.41	7.53	0.34	3e-13	Blood protein levels;
LUAD	cis	rs6714710	0.580	rs6711101	chr2:98379813	G/A	cg26665480	chr2:98280029	ACTR1B	0.5	8.26	0.37	1.85e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs57590327	0.527	rs7610703	chr3:81613942	G/A	cg07356753	chr3:81810745	GBE1	-0.49	-7.52	-0.34	3.35e-13	Extraversion;
LUAD	trans	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg14917512	chr19:3094685	GNA11	-0.57	-6.86	-0.32	2.49e-11	Diabetic kidney disease;
LUAD	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg00316803	chr15:76480434	C15orf27	-0.44	-7.33	-0.34	1.22e-12	Blood metabolite levels;
LUAD	cis	rs4853036	1.000	rs62134009	chr2:70054296	G/A	cg02498382	chr2:70120550	SNRNP27	-0.51	-8.21	-0.37	2.7e-15	Colorectal or endometrial cancer;
LUAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.83	0.43	1.16e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg03929089	chr4:120376271	NA	-0.45	-6.92	-0.32	1.7e-11	HDL cholesterol;
LUAD	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg26513180	chr16:89883248	FANCA	0.65	6.52	0.3	2.06e-10	Skin colour saturation;
LUAD	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg13319975	chr6:146136371	FBXO30	-0.55	-9.04	-0.4	5.81e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.38	-0.42	3.95e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg22705602	chr4:152727874	NA	-0.4	-7.18	-0.33	3.16e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg11189052	chr15:85197271	WDR73	0.66	8.9	0.4	1.61e-17	Schizophrenia;
LUAD	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.01	0.32	9.65e-12	Prostate cancer;
LUAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg00280220	chr17:61926910	NA	0.37	7.18	0.33	3.23e-12	Prudent dietary pattern;
LUAD	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg11189052	chr15:85197271	WDR73	0.68	9.12	0.41	3.08e-18	Schizophrenia;
LUAD	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg21028142	chr17:79581711	NPLOC4	0.34	6.73	0.31	5.48e-11	Eye color traits;
LUAD	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg00321850	chr1:175162397	KIAA0040	-0.53	-11.37	-0.48	2.55e-26	Alcohol dependence;
LUAD	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg17971929	chr21:40555470	PSMG1	0.57	9.11	0.41	3.25e-18	Cognitive function;
LUAD	cis	rs2274273	1.000	rs7142704	chr14:55630603	C/A	cg04306507	chr14:55594613	LGALS3	0.38	7.83	0.36	3.97e-14	Protein biomarker;
LUAD	trans	rs1941687	0.526	rs9959347	chr18:31316169	C/T	cg27147174	chr7:100797783	AP1S1	-0.56	-9.88	-0.43	7.68e-21	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg09796270	chr17:17721594	SREBF1	-0.39	-7.96	-0.36	1.65e-14	Total body bone mineral density;
LUAD	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.69	-6.44	-0.3	3.22e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.29	0.66	1.79e-55	Prudent dietary pattern;
LUAD	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg10755058	chr3:40428713	ENTPD3	0.39	7.57	0.35	2.33e-13	Renal cell carcinoma;
LUAD	cis	rs12210905	0.541	rs62617138	chr6:27463766	C/A	cg08851530	chr6:28072375	NA	1.03	7.92	0.36	2.19e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg07936489	chr17:37558343	FBXL20	-0.48	-7.58	-0.35	2.26e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs55823223	0.680	rs3744017	chr17:73871467	G/A	cg08125733	chr17:73851984	WBP2	0.66	9.61	0.42	6.63e-20	Psoriasis;
LUAD	cis	rs2651899	0.902	rs1736522	chr1:3080940	C/G	cg22674798	chr1:3096360	PRDM16	0.35	8.83	0.39	2.82e-17	Migraine;
LUAD	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg06002616	chr8:101225028	SPAG1	-0.39	-7.91	-0.36	2.23e-14	Atrioventricular conduction;
LUAD	cis	rs2880765	0.835	rs12708553	chr15:86046833	C/G	cg13263323	chr15:86062960	AKAP13	0.51	9.35	0.41	5.24e-19	Coronary artery disease;
LUAD	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.66	-7.33	-0.34	1.19e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	trans	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs4148883	0.504	rs4147544	chr4:100134514	G/T	cg12011299	chr4:100065546	ADH4	-0.55	-11.43	-0.49	1.47e-26	Alcohol dependence;
LUAD	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg07636037	chr3:49044803	WDR6	0.61	11.9	0.5	2.33e-28	Parkinson's disease;
LUAD	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.43	-0.34	6.14e-13	Bipolar disorder;
LUAD	trans	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg04565464	chr8:145669602	NFKBIL2	0.44	6.53	0.3	1.91e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs17597773	0.527	rs1537806	chr1:221084222	G/A	cg16008148	chr1:221062819	NA	0.43	8.41	0.38	6.53e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg26304593	chr6:42947056	PEX6	-0.46	-7.87	-0.36	3.08e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg17328964	chr8:145687451	CYHR1	-0.66	-11.35	-0.48	3.08e-26	Age at first birth;
LUAD	cis	rs9807989	0.507	rs10204757	chr2:102998974	A/C	cg03938978	chr2:103052716	IL18RAP	0.45	10.24	0.45	3.99e-22	Asthma;
LUAD	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg21475434	chr5:93447410	FAM172A	0.76	8.46	0.38	4.52e-16	Diabetic retinopathy;
LUAD	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.94	0.32	1.44e-11	Cognitive test performance;
LUAD	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg09035930	chr12:129282057	SLC15A4	0.75	17.65	0.65	1.21e-52	Systemic lupus erythematosus;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22522926	chr2:131851181	FAM168B	-0.45	-7.28	-0.33	1.68e-12	Height;
LUAD	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.17	-0.33	3.36e-12	Lung cancer;
LUAD	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg00321850	chr1:175162397	KIAA0040	-0.51	-10.94	-0.47	1.05e-24	Alcohol dependence;
LUAD	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23158103	chr7:148848205	ZNF398	-0.65	-12.24	-0.51	1.05e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs7395662	0.784	rs75694945	chr11:48865463	C/T	cg15704280	chr7:45808275	SEPT13	0.43	6.82	0.31	3.11e-11	HDL cholesterol;
LUAD	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg15428835	chr7:75027521	TRIM73;TRIM74	-0.39	-6.63	-0.31	1.06e-10	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs62229266	0.633	rs34259635	chr21:37403570	T/G	cg08632701	chr21:37451849	NA	-0.39	-6.59	-0.3	1.34e-10	Mitral valve prolapse;
LUAD	cis	rs760794	0.764	rs6904518	chr6:19798704	A/G	cg02404759	chr6:19790362	NA	-0.35	-6.46	-0.3	2.87e-10	Endometriosis;
LUAD	cis	rs6987853	0.814	rs1349471	chr8:42454011	C/T	cg09913449	chr8:42400586	C8orf40	0.46	8.53	0.38	2.65e-16	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg13385794	chr1:248469461	NA	0.26	7.03	0.32	8.12e-12	Common traits (Other);
LUAD	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.1	-0.33	5.4e-12	Height;
LUAD	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg26924012	chr15:45694286	SPATA5L1	1.02	19.46	0.69	1.07e-60	Homoarginine levels;
LUAD	cis	rs4664304	0.966	rs925411	chr2:160745785	G/T	cg23995753	chr2:160760732	LY75	-0.48	-8.62	-0.39	1.37e-16	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs8073060	0.586	rs8074800	chr17:33979148	A/G	cg19694781	chr19:47549865	TMEM160	1.12	18.09	0.66	1.41e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.46	0.3	2.93e-10	Depression;
LUAD	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg24308560	chr3:49941425	MST1R	-0.51	-8.48	-0.38	3.93e-16	Body mass index;
LUAD	cis	rs1816752	0.666	rs7994022	chr13:25017230	A/G	cg02811702	chr13:24901961	NA	0.46	7.89	0.36	2.6e-14	Obesity-related traits;
LUAD	cis	rs701145	0.585	rs357465	chr3:153903095	T/A	cg17054900	chr3:154042577	DHX36	0.61	6.61	0.31	1.18e-10	Coronary artery disease;
LUAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg14820908	chr5:178986412	RUFY1	0.54	8.57	0.38	2.02e-16	Lung cancer;
LUAD	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg23260525	chr10:116636907	FAM160B1	0.53	12.43	0.52	1.84e-30	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4253772	0.626	rs9615960	chr22:46752307	G/A	cg18190219	chr22:46762943	CELSR1	-0.62	-6.53	-0.3	1.89e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.48e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg10523679	chr1:76189770	ACADM	0.9	15.95	0.61	3.64e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12618769	0.625	rs61180742	chr2:99148078	A/G	cg10123293	chr2:99228465	UNC50	0.47	8.2	0.37	2.83e-15	Bipolar disorder;
LUAD	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg22166914	chr1:53195759	ZYG11B	-0.48	-7.9	-0.36	2.51e-14	Monocyte count;
LUAD	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg01528321	chr10:82214614	TSPAN14	0.51	8.45	0.38	4.63e-16	Post bronchodilator FEV1;
LUAD	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg13511324	chr14:104056883	C14orf153	-0.25	-6.47	-0.3	2.75e-10	Coronary artery disease;
LUAD	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg17173187	chr15:85201210	NMB	0.48	8.39	0.38	7.41e-16	Schizophrenia;
LUAD	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg11189052	chr15:85197271	WDR73	0.65	8.08	0.37	6.62e-15	Schizophrenia;
LUAD	cis	rs8077889	0.703	rs231534	chr17:41945564	C/T	cg26893861	chr17:41843967	DUSP3	-0.68	-9.43	-0.42	2.8e-19	Triglycerides;
LUAD	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg16479474	chr6:28041457	NA	0.44	7.44	0.34	5.75e-13	Depression;
LUAD	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg18827107	chr12:86230957	RASSF9	-0.54	-9.47	-0.42	1.97e-19	Major depressive disorder;
LUAD	cis	rs78456975	0.550	rs111467480	chr2:1569154	A/G	cg01028140	chr2:1542097	TPO	-0.43	-7.06	-0.32	6.87e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs9479482	0.967	rs1543547	chr6:150346532	T/C	cg25797454	chr6:150327115	RAET1K	0.33	7.11	0.33	4.88e-12	Alopecia areata;
LUAD	trans	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	8.8	0.39	3.41e-17	Mean corpuscular volume;
LUAD	cis	rs62458065	0.850	rs62458066	chr7:32464484	C/T	cg20159608	chr7:32802032	NA	-0.54	-7.18	-0.33	3.16e-12	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs143626010	1	rs143626010	chr16:28539398	GTGTA/G	cg00204512	chr16:28754710	NA	0.3	6.57	0.3	1.44e-10	Mosquito bite size;
LUAD	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg12334488	chr2:20871173	GDF7	-0.4	-7.11	-0.33	5.12e-12	Abdominal aortic aneurysm;
LUAD	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg12311346	chr5:56204834	C5orf35	-0.83	-12.5	-0.52	1e-30	Initial pursuit acceleration;
LUAD	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg03605463	chr16:89740564	NA	-0.62	-11.6	-0.49	3.21e-27	Hemoglobin concentration;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09604110	chr6:116422028	NT5DC1	-0.67	-6.89	-0.32	1.98e-11	Type 2 diabetes;
LUAD	trans	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg05926928	chr17:57297772	GDPD1	-0.52	-7.84	-0.36	3.6e-14	Schizophrenia;
LUAD	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg25208724	chr1:156163844	SLC25A44	1.19	27.28	0.8	2.87e-95	Testicular germ cell tumor;
LUAD	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg21475434	chr5:93447410	FAM172A	0.74	8.46	0.38	4.26e-16	Diabetic retinopathy;
LUAD	trans	rs1997103	1.000	rs6977292	chr7:55396335	T/C	cg20935933	chr6:143382018	AIG1	0.53	7.46	0.34	4.94e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs17092148	0.945	rs6060034	chr20:33351864	T/C	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.19	-0.37	3.09e-15	Neuroticism;
LUAD	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg05340658	chr4:99064831	C4orf37	0.46	6.99	0.32	1.09e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-7.03	-0.32	8.33e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.5	-7.4	-0.34	7.48e-13	Menarche (age at onset);
LUAD	cis	rs225245	0.817	rs225255	chr17:33955243	A/G	cg05299278	chr17:33885742	SLFN14	-0.5	-11.56	-0.49	4.83e-27	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg18351406	chr4:77819688	ANKRD56	0.62	10.04	0.44	2.06e-21	Emphysema distribution in smoking;
LUAD	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg04455712	chr21:45112962	RRP1B	0.51	10.75	0.46	5.59e-24	Mean corpuscular volume;
LUAD	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg06002616	chr8:101225028	SPAG1	-0.38	-7.78	-0.35	5.51e-14	Atrioventricular conduction;
LUAD	trans	rs564343	0.583	rs2430978	chr11:65816656	G/C	cg26701943	chr11:108369231	KDELC2	-0.5	-8.22	-0.37	2.56e-15	Obesity (early onset extreme);
LUAD	trans	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	17.21	0.64	1.06e-50	Exhaled nitric oxide output;
LUAD	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg08999081	chr20:33150536	PIGU	0.62	13.98	0.56	9.28e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg15017067	chr4:17643749	FAM184B	0.37	7.08	0.33	6.19e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg03388025	chr16:89894329	SPIRE2	0.49	12.61	0.52	3.65e-31	Vitiligo;
LUAD	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg06221963	chr1:154839813	KCNN3	-0.47	-8.44	-0.38	5.24e-16	Schizophrenia;
LUAD	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg20891558	chr2:74357851	NA	0.98	17.42	0.65	1.23e-51	Gestational age at birth (maternal effect);
LUAD	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg16031515	chr1:205743344	RAB7L1	-0.38	-7.52	-0.34	3.35e-13	Menarche (age at onset);
LUAD	cis	rs4523957	0.620	rs9894215	chr17:2070698	G/A	cg16513277	chr17:2031491	SMG6	-0.99	-19.8	-0.69	3.04e-62	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4077468	1.000	rs4077469	chr1:205914885	C/T	cg07167872	chr1:205819463	PM20D1	-0.37	-6.64	-0.31	9.48e-11	Cystic fibrosis-related diabetes;
LUAD	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03264133	chr6:25882463	NA	-0.55	-8.86	-0.4	2.19e-17	Blood metabolite levels;
LUAD	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg22823121	chr1:150693482	HORMAD1	0.45	8.58	0.38	1.84e-16	Melanoma;
LUAD	cis	rs1950626	0.615	rs12893486	chr14:101463800	C/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.42	7.4	0.34	7.42e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg23706161	chr2:109336669	RANBP2	-0.41	-6.64	-0.31	9.89e-11	Mean platelet volume;
LUAD	cis	rs7737355	0.947	rs12656936	chr5:130788642	A/C	cg06307176	chr5:131281290	NA	-0.49	-7.69	-0.35	1.03e-13	Life satisfaction;
LUAD	cis	rs12541635	0.677	rs6997487	chr8:106965511	A/C	cg10147462	chr8:107024639	NA	0.53	9.59	0.42	8.01e-20	Age of smoking initiation;
LUAD	trans	rs4650994	0.789	rs2761471	chr1:178599348	A/C	cg05059571	chr16:84539110	KIAA1609	0.51	8.6	0.39	1.53e-16	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs2274273	0.905	rs4652	chr14:55605036	A/C	cg04306507	chr14:55594613	LGALS3	0.41	8.52	0.38	2.93e-16	Protein biomarker;
LUAD	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.09e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg01475377	chr6:109611718	NA	-0.53	-10.17	-0.44	7.28e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.39	-7.06	-0.32	6.85e-12	Cystic fibrosis severity;
LUAD	cis	rs7267979	0.844	rs6050477	chr20:25221547	C/T	cg08601574	chr20:25228251	PYGB	-0.39	-7.46	-0.34	5.08e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg19862616	chr7:65841803	NCRNA00174	1.05	26.66	0.79	1.38e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg07080864	chr8:57359956	PENK	-0.35	-6.37	-0.3	4.95e-10	Obesity-related traits;
LUAD	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg17644776	chr2:200775616	C2orf69	-0.53	-6.66	-0.31	8.36e-11	Schizophrenia;
LUAD	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24308560	chr3:49941425	MST1R	0.54	9.09	0.4	4.02e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.54	-0.38	2.44e-16	Total body bone mineral density;
LUAD	cis	rs9462027	0.628	rs9469914	chr6:34827693	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.39	-0.38	7.23e-16	Systemic lupus erythematosus;
LUAD	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg11845111	chr2:191398756	TMEM194B	-0.84	-10.68	-0.46	1.02e-23	Diastolic blood pressure;
LUAD	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg10589385	chr1:150898437	SETDB1	0.41	7.68	0.35	1.08e-13	Melanoma;
LUAD	cis	rs11030122	0.673	rs4910590	chr11:4018619	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.21	-0.33	2.56e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg05132306	chr1:1846340	CALML6	0.3	6.4	0.3	4.22e-10	Body mass index;
LUAD	cis	rs9914544	0.545	rs7222748	chr17:18787976	T/C	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.52	-0.3	1.96e-10	Educational attainment (years of education);
LUAD	trans	rs6920965	0.583	rs9388456	chr6:126147197	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-8.02	-0.36	1.04e-14	High light scatter reticulocyte count;
LUAD	cis	rs3823572	0.564	rs2971962	chr7:133639770	G/A	cg03336402	chr7:133662267	EXOC4	0.45	8.07	0.37	7.18e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs75203426	chr7:107017589	G/C	cg23024343	chr7:107201750	COG5	0.51	7.22	0.33	2.44e-12	Coronary artery disease;
LUAD	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg19041857	chr6:27730383	NA	-0.45	-7.64	-0.35	1.51e-13	Parkinson's disease;
LUAD	trans	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.68	-0.39	8.75e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.99	-0.36	1.31e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg26769984	chr7:1090371	C7orf50	0.63	9.64	0.42	5.13e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg11814155	chr7:99998594	ZCWPW1	-0.39	-6.74	-0.31	5.07e-11	Platelet count;
LUAD	trans	rs8002861	0.967	rs7321596	chr13:44472255	G/A	cg17145862	chr1:211918768	LPGAT1	0.76	17.84	0.66	1.7e-53	Leprosy;
LUAD	cis	rs9549328	0.700	rs3011473	chr13:113618096	A/G	cg17524180	chr13:113633600	MCF2L	0.32	6.86	0.32	2.44e-11	Systolic blood pressure;
LUAD	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg00495681	chr13:53174319	NA	-0.49	-8.78	-0.39	4.24e-17	Lewy body disease;
LUAD	trans	rs2665103	0.687	rs11633000	chr15:82561661	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.48	-7.7	-0.35	9.75e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2131877	0.956	rs13315459	chr3:194871995	A/G	cg19760965	chr3:194868843	C3orf21	0.39	6.56	0.3	1.56e-10	Non-small cell lung cancer;
LUAD	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.59	-0.35	2.13e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.41	-0.34	7.09e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11677416	1.000	rs1878320	chr2:113544467	T/C	cg27083787	chr2:113543245	IL1A	0.38	6.61	0.31	1.15e-10	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs864537	0.676	rs2056626	chr1:167420425	T/G	cg22356347	chr1:167427500	CD247	-0.47	-9.53	-0.42	1.27e-19	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs775227	0.574	rs35274817	chr3:113266391	A/G	cg18753928	chr3:113234510	CCDC52	-0.66	-9.08	-0.4	4.15e-18	Dental caries;
LUAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg06074448	chr4:187884817	NA	-0.37	-7.3	-0.33	1.47e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7923837	0.963	rs11187141	chr10:94467145	A/T	cg25093409	chr10:94429542	NA	0.36	6.39	0.3	4.48e-10	Body mass index;Multiple sclerosis;
LUAD	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs1983170	0.673	rs61798836	chr1:92013622	T/C	cg02896835	chr1:92012615	NA	0.58	7.54	0.34	2.82e-13	Eosinophil percentage of white cells;
LUAD	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg00933542	chr6:150070202	PCMT1	0.35	7.41	0.34	6.7e-13	Testicular germ cell tumor;
LUAD	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg07870213	chr5:140052090	DND1	-0.66	-10.01	-0.44	2.6e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg10544611	chr16:67998164	SLC12A4	-0.58	-7.3	-0.33	1.41e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs754466	0.561	rs11002344	chr10:79709725	A/T	cg17075019	chr10:79541650	NA	-0.63	-7.97	-0.36	1.5e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg12756686	chr19:29218302	NA	0.53	6.84	0.32	2.82e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs986417	0.818	rs1950311	chr14:60989604	A/C	cg27398547	chr14:60952738	C14orf39	0.67	8.1	0.37	5.9e-15	Gut microbiota (bacterial taxa);
LUAD	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg03037974	chr15:76606532	NA	0.48	11.35	0.48	3.13e-26	Blood metabolite levels;
LUAD	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg21475434	chr5:93447410	FAM172A	0.77	8.66	0.39	9.72e-17	Diabetic retinopathy;
LUAD	cis	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.44	-0.34	5.76e-13	Triglycerides;
LUAD	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg26763362	chr17:18266135	SHMT1	-0.47	-9.69	-0.43	3.43e-20	Multiple sclerosis;
LUAD	cis	rs6906287	0.647	rs6925641	chr6:118821894	C/T	cg05564266	chr6:118973597	C6orf204	0.36	7.68	0.35	1.08e-13	Electrocardiographic conduction measures;
LUAD	trans	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg04565464	chr8:145669602	NFKBIL2	0.48	7.39	0.34	7.99e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs2072438	0.503	rs4837810	chr9:123881199	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	6.63	0.31	1.05e-10	Rheumatoid arthritis;
LUAD	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg21770322	chr7:97807741	LMTK2	0.33	7.47	0.34	4.57e-13	Breast cancer;
LUAD	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10802521	chr3:52805072	NEK4	-0.62	-11.12	-0.48	2.31e-25	Electroencephalogram traits;
LUAD	cis	rs9473147	0.543	rs9349417	chr6:47580657	A/G	cg20196966	chr6:47445060	CD2AP	0.45	7.01	0.32	9.35e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg15962314	chr1:44399869	ARTN	0.34	7.21	0.33	2.51e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06544989	chr22:39130855	UNC84B	0.47	9.65	0.42	4.75e-20	Menopause (age at onset);
LUAD	cis	rs6998277	0.830	rs7017839	chr8:103610769	G/C	cg10187029	chr8:103597600	NA	0.87	16.06	0.62	1.16e-45	Migraine;
LUAD	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.33	6.64	0.31	9.4e-11	Obesity-related traits;
LUAD	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg06002616	chr8:101225028	SPAG1	-0.38	-7.86	-0.36	3.28e-14	Atrioventricular conduction;
LUAD	cis	rs10203711	0.966	rs4605316	chr2:239595344	C/T	cg14580085	chr2:239553406	NA	0.41	8.75	0.39	5.31e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3790645	1.000	rs35245195	chr1:26884039	C/G	cg23229016	chr1:26872525	RPS6KA1	0.21	6.99	0.32	1.11e-11	Glucose homeostasis traits;
LUAD	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg24801067	chr17:62843696	NA	-0.54	-7.57	-0.35	2.34e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs11696501	0.739	rs6073835	chr20:44286454	C/T	cg11783356	chr20:44313418	WFDC10B	-0.49	-8.09	-0.37	6.42e-15	Brain structure;
LUAD	cis	rs9899728	0.539	rs113775187	chr17:73047290	A/G	cg27626185	chr17:73056755	KCTD2	-0.99	-11.62	-0.49	2.69e-27	Alzheimer's disease or small vessel stroke;
LUAD	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg26304593	chr6:42947056	PEX6	-0.46	-7.81	-0.36	4.47e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7833986	1.000	rs66796428	chr8:57094797	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	10.04	0.44	2.03e-21	Height;
LUAD	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg27124370	chr19:33622961	WDR88	0.46	7.17	0.33	3.44e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs4942242	0.574	rs9533557	chr13:44197487	C/G	cg19169023	chr15:41853346	TYRO3	0.74	12.91	0.53	2.15e-32	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs868036	1.000	rs4776975	chr15:68102220	G/C	cg24579218	chr15:68104479	NA	-0.4	-7.45	-0.34	5.44e-13	Restless legs syndrome;
LUAD	cis	rs73198271	0.562	rs17631052	chr8:8663787	G/A	cg01851573	chr8:8652454	MFHAS1	0.69	10.47	0.45	5.75e-23	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21028142	chr17:79581711	NPLOC4	0.44	9.59	0.42	7.55e-20	Eye color traits;
LUAD	cis	rs899997	0.773	rs11072783	chr15:78965966	G/A	cg04896959	chr15:78267971	NA	0.52	8.32	0.38	1.22e-15	Coronary artery disease or large artery stroke;
LUAD	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-6.66	-0.31	8.64e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7107174	1.000	rs2510045	chr11:77920563	G/T	cg19901956	chr11:77921274	USP35	-0.56	-6.97	-0.32	1.23e-11	Testicular germ cell tumor;
LUAD	cis	rs6500395	1.000	rs9933976	chr16:48590145	A/G	cg04672837	chr16:48644449	N4BP1	0.37	6.44	0.3	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs12554389	0.648	rs1408068	chr9:111256727	C/A	cg23943953	chr10:1514874	ADARB2	0.35	6.55	0.3	1.64e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-7.82	-0.36	4.34e-14	Fear of minor pain;
LUAD	cis	rs910187	0.605	rs6124961	chr20:45804467	G/C	cg27589058	chr20:45804311	EYA2	-0.37	-8.58	-0.38	1.86e-16	Migraine;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg25327839	chr11:73308997	FAM168A	-0.56	-6.64	-0.31	9.9e-11	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg06713675	chr4:122721982	EXOSC9	0.65	11.94	0.5	1.6e-28	Type 2 diabetes;
LUAD	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.83	0.32	2.98e-11	Motion sickness;
LUAD	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg17333051	chr19:2783644	SGTA	-0.43	-6.89	-0.32	2.03e-11	Total cholesterol levels;
LUAD	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg11833968	chr6:79620685	NA	0.41	7.53	0.34	3.02e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs870825	0.929	rs871253	chr4:185589234	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	9.21	0.41	1.52e-18	Blood protein levels;
LUAD	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg26022315	chr17:47021804	SNF8	0.4	7.1	0.33	5.31e-12	Type 2 diabetes;
LUAD	cis	rs1997103	0.906	rs6593231	chr7:55402914	T/A	cg17469321	chr7:55412551	NA	0.67	11.39	0.48	2.05e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06873352	chr17:61820015	STRADA	0.83	18.4	0.67	5.49e-56	Prudent dietary pattern;
LUAD	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg07636037	chr3:49044803	WDR6	0.63	12.11	0.51	3.56e-29	Parkinson's disease;
LUAD	cis	rs1232027	0.656	rs1677642	chr5:79963318	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.15	-0.33	3.76e-12	Huntington's disease progression;
LUAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18402987	chr7:1209562	NA	0.45	7.38	0.34	8.7e-13	Longevity;Endometriosis;
LUAD	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg06713675	chr4:122721982	EXOSC9	-0.83	-17.94	-0.66	6.27e-54	Type 2 diabetes;
LUAD	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg18705301	chr15:41695430	NDUFAF1	0.42	7.68	0.35	1.12e-13	Menopause (age at onset);
LUAD	trans	rs1941687	0.735	rs8085989	chr18:31415929	G/A	cg27147174	chr7:100797783	AP1S1	-0.54	-9.48	-0.42	1.91e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg13877915	chr19:58951672	ZNF132	0.76	14.54	0.58	4e-39	Uric acid clearance;
LUAD	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg11062466	chr8:58055876	NA	0.45	6.44	0.3	3.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg23803603	chr1:2058230	PRKCZ	0.4	6.51	0.3	2.16e-10	Height;
LUAD	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg04450456	chr4:17643702	FAM184B	0.4	7.81	0.36	4.44e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10489202	0.683	rs2294817	chr1:168073601	C/A	cg25738037	chr1:168025549	DCAF6	-0.45	-6.52	-0.3	2.02e-10	Schizophrenia;
LUAD	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg26318627	chr11:63887540	MACROD1	0.36	7.14	0.33	4.06e-12	Platelet count;
LUAD	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-7.06	-0.32	6.74e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg16479474	chr6:28041457	NA	0.48	8.04	0.36	9.29e-15	Depression;
LUAD	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg21226059	chr5:178986404	RUFY1	0.65	9.76	0.43	2.06e-20	Lung cancer;
LUAD	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg14196790	chr5:131705035	SLC22A5	0.36	6.54	0.3	1.77e-10	Blood metabolite levels;
LUAD	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg21709803	chr11:61594965	FADS2	0.34	6.37	0.3	4.96e-10	Trans fatty acid levels;
LUAD	cis	rs7000551	0.527	rs12677619	chr8:22243326	G/A	cg12081754	chr8:22256438	SLC39A14	0.88	14.18	0.57	1.27e-37	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs10203711	1.000	rs4994753	chr2:239567253	T/C	cg14580085	chr2:239553406	NA	0.41	8.9	0.4	1.64e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.54	-0.34	2.91e-13	Blood metabolite levels;
LUAD	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.95	-0.44	4.34e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs6445967	0.545	rs7632862	chr3:58283036	G/A	cg13750441	chr3:58318267	PXK	-0.31	-6.6	-0.31	1.21e-10	Platelet count;
LUAD	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.73	-9.74	-0.43	2.25e-20	Body mass index;
LUAD	cis	rs4711336	0.633	rs9469583	chr6:33717770	T/C	cg13859433	chr6:33739653	LEMD2	-0.3	-7.06	-0.32	6.69e-12	Height;
LUAD	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg10909506	chr17:38081995	ORMDL3	0.4	6.82	0.31	3.22e-11	Self-reported allergy;
LUAD	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.96e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1788820	0.917	rs1788826	chr18:21154024	G/A	cg14672496	chr18:21087552	C18orf8	0.34	6.44	0.3	3.32e-10	Body mass index;
LUAD	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03517284	chr6:25882590	NA	-0.53	-7.67	-0.35	1.21e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7665090	0.967	rs6812747	chr4:103555417	A/C	cg07973026	chr4:103553119	MANBA	0.47	8.43	0.38	5.37e-16	Primary biliary cholangitis;
LUAD	cis	rs593982	0.920	rs563427	chr11:65484569	A/G	cg08755490	chr11:65554678	OVOL1	1.25	15.15	0.59	1.01e-41	Atopic dermatitis;
LUAD	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg14983838	chr19:29218262	NA	0.66	9.7	0.43	3.13e-20	Methadone dose in opioid dependence;
LUAD	cis	rs8014204	0.804	rs2287403	chr14:75259140	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.34	-6.47	-0.3	2.77e-10	Caffeine consumption;
LUAD	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg11833968	chr6:79620685	NA	-0.43	-7.96	-0.36	1.6e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg13319975	chr6:146136371	FBXO30	-0.58	-9.86	-0.43	8.85e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg02990361	chr1:107599529	PRMT6	-0.63	-10.51	-0.46	4.04e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.37	-6.62	-0.31	1.11e-10	Multiple sclerosis;Ankylosing spondylitis;
LUAD	cis	rs59698941	0.943	rs57880964	chr5:132210674	G/C	cg14825688	chr5:132208181	LEAP2	-0.47	-6.67	-0.31	8.01e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13126279	chr21:47581558	C21orf56	-0.62	-11.4	-0.48	1.9e-26	Testicular germ cell tumor;
LUAD	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg14092988	chr3:52407081	DNAH1	0.46	9.18	0.41	1.94e-18	Bipolar disorder;
LUAD	cis	rs6445967	1.000	rs9847151	chr3:58285808	G/A	cg23715586	chr3:58305044	RPP14	0.42	7.63	0.35	1.59e-13	Platelet count;
LUAD	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg07917127	chr4:99064746	C4orf37	0.44	7.21	0.33	2.6e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg18867708	chr6:26865862	GUSBL1	0.42	6.67	0.31	8.13e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg24818145	chr4:99064322	C4orf37	0.47	7.88	0.36	2.89e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg09455208	chr3:40491958	NA	-0.59	-12.63	-0.52	2.93e-31	Renal cell carcinoma;
LUAD	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg25237894	chr2:233734115	C2orf82	-0.57	-10.73	-0.46	6.17e-24	Coronary artery disease;
LUAD	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg10589385	chr1:150898437	SETDB1	0.41	7.95	0.36	1.71e-14	Tonsillectomy;
LUAD	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg00933542	chr6:150070202	PCMT1	0.43	8.96	0.4	1.04e-17	Lung cancer;
LUAD	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06112835	chr11:68658793	MRPL21	0.48	8.62	0.39	1.31e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg04103315	chr3:42642047	NKTR	-0.47	-7.96	-0.36	1.59e-14	Schizophrenia;
LUAD	cis	rs6743376	0.556	rs2441375	chr2:113817268	T/C	cg09040174	chr2:113837401	NA	0.52	8.06	0.37	7.7e-15	Inflammatory biomarkers;
LUAD	cis	rs1595825	0.945	rs6756641	chr2:198849672	T/G	cg00982548	chr2:198649783	BOLL	-0.61	-8.71	-0.39	7.07e-17	Ulcerative colitis;
LUAD	cis	rs6028335	0.610	rs67621213	chr20:37582553	G/A	cg27660920	chr20:37554817	FAM83D	0.55	7.17	0.33	3.34e-12	Alcohol and nicotine co-dependence;
LUAD	cis	rs9297145	0.761	rs12534399	chr7:98746401	A/G	cg05967295	chr7:98741636	SMURF1	0.99	15.5	0.6	3.11e-43	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg18132916	chr6:79620363	NA	-0.45	-7.86	-0.36	3.27e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg00757033	chr12:89920650	WDR51B	0.71	12.25	0.51	1.01e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9329289	0.510	rs12356215	chr10:2545390	C/G	cg15501526	chr10:2543763	NA	0.55	11.85	0.5	3.52e-28	Age-related hearing impairment;
LUAD	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg09835421	chr16:68378352	PRMT7	-1.03	-11.43	-0.49	1.54e-26	Schizophrenia;
LUAD	cis	rs7777754	0.734	rs4947709	chr7:50672907	A/G	cg18232548	chr7:50535776	DDC	-0.4	-6.68	-0.31	7.65e-11	Response to zileuton treatment in asthma (FEV1 change interaction);
LUAD	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs240764	0.604	rs705586	chr6:101268046	C/G	cg09795085	chr6:101329169	ASCC3	0.39	6.71	0.31	6.38e-11	Neuroticism;
LUAD	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg20203395	chr5:56204925	C5orf35	-0.64	-9.97	-0.44	3.64e-21	Initial pursuit acceleration;
LUAD	trans	rs11039798	1.000	rs7479655	chr11:48576714	G/T	cg15704280	chr7:45808275	SEPT13	0.63	7.34	0.34	1.13e-12	Axial length;
LUAD	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.31	0.33	1.33e-12	Morning vs. evening chronotype;
LUAD	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg21238619	chr17:78079768	GAA	-0.33	-6.73	-0.31	5.58e-11	Yeast infection;
LUAD	cis	rs7524258	0.778	rs12028181	chr1:7315085	C/T	cg07173049	chr1:7289937	CAMTA1	-0.46	-8.44	-0.38	5.14e-16	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg08219700	chr8:58056026	NA	0.41	6.39	0.3	4.44e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6558530	0.932	rs7842425	chr8:1706041	G/T	cg17159058	chr8:1704075	NA	-0.38	-6.43	-0.3	3.42e-10	Systolic blood pressure;
LUAD	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg06618935	chr21:46677482	NA	-0.51	-9.81	-0.43	1.31e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs56161922	1.000	rs17045979	chr1:207842704	T/C	cg11752769	chr1:207818423	CR1L	-0.67	-7.0	-0.32	9.84e-12	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg18252515	chr7:66147081	NA	-0.61	-6.79	-0.31	3.86e-11	Diabetic kidney disease;
LUAD	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.61e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg17063962	chr7:91808500	NA	-0.65	-11.14	-0.48	1.89e-25	Breast cancer;
LUAD	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg07169764	chr2:136633963	MCM6	0.77	9.1	0.4	3.56e-18	Corneal structure;
LUAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg15147215	chr3:52552868	STAB1	-0.48	-8.92	-0.4	1.37e-17	Electroencephalogram traits;
LUAD	cis	rs7582720	1.000	rs72934710	chr2:203709776	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.25	0.41	1.14e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.8	-0.31	3.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2651899	0.867	rs2742675	chr1:3079905	A/G	cg22674798	chr1:3096360	PRDM16	0.39	10.0	0.44	2.84e-21	Migraine;
LUAD	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs2806561	0.664	rs55764475	chr1:23318983	C/T	cg12483005	chr1:23474871	LUZP1	0.43	7.03	0.32	8.59e-12	Height;
LUAD	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg20503657	chr10:835505	NA	0.92	13.29	0.54	6.18e-34	Eosinophil percentage of granulocytes;
LUAD	trans	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg14791747	chr16:20752902	THUMPD1	-0.45	-6.9	-0.32	1.87e-11	Dental caries;
LUAD	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg25036284	chr2:26402008	FAM59B	-0.61	-8.43	-0.38	5.33e-16	Gut microbiome composition (summer);
LUAD	cis	rs12753569	0.748	rs1013629	chr1:76513759	A/G	cg00791851	chr1:76518896	NA	0.29	6.59	0.3	1.34e-10	Personality dimensions;
LUAD	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg04287289	chr16:89883240	FANCA	-0.46	-7.64	-0.35	1.45e-13	Vitiligo;
LUAD	cis	rs7107174	0.711	rs66583694	chr11:78037773	C/T	cg19901956	chr11:77921274	USP35	-0.47	-6.69	-0.31	6.88e-11	Testicular germ cell tumor;
LUAD	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg14403583	chr14:105418241	AHNAK2	0.43	8.02	0.36	1.05e-14	Rheumatoid arthritis;
LUAD	cis	rs758324	0.812	rs2159243	chr5:131133900	G/A	cg25547332	chr5:131281432	NA	0.43	6.95	0.32	1.39e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg19622623	chr12:86230825	RASSF9	-0.44	-7.77	-0.35	6.07e-14	Major depressive disorder;
LUAD	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg05368731	chr17:41323189	NBR1	0.95	20.02	0.7	3.33e-63	Menopause (age at onset);
LUAD	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.55e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg06671706	chr8:8559999	CLDN23	0.67	11.55	0.49	5.17e-27	Obesity-related traits;
LUAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg04455712	chr21:45112962	RRP1B	0.42	8.53	0.38	2.69e-16	Mean corpuscular volume;
LUAD	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg19980929	chr12:42632907	YAF2	-0.34	-6.54	-0.3	1.81e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg12179176	chr11:130786555	SNX19	0.54	9.07	0.4	4.68e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.02	0.32	8.9e-12	Hypertriglyceridemia;
LUAD	cis	rs4764487	0.735	rs3782717	chr12:6332310	C/G	cg08284733	chr12:6341482	CD9	0.36	6.47	0.3	2.67e-10	Mean platelet volume;
LUAD	cis	rs11650494	0.908	rs57390430	chr17:47374886	G/A	cg08112188	chr17:47440006	ZNF652	0.93	8.03	0.36	1e-14	Prostate cancer;
LUAD	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg23758822	chr17:41437982	NA	1.01	20.95	0.71	2.33e-67	Menopause (age at onset);
LUAD	cis	rs2445762	0.659	rs12441170	chr15:51653898	G/A	cg20344442	chr15:51633704	GLDN	0.4	6.79	0.31	3.88e-11	Hormone measurements;
LUAD	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg02733842	chr7:1102375	C7orf50	-0.73	-10.84	-0.47	2.6e-24	Bronchopulmonary dysplasia;
LUAD	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg23933602	chr10:16859644	RSU1	0.57	7.64	0.35	1.45e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	trans	rs783540	0.967	rs783529	chr15:83267981	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.45	-7.33	-0.34	1.16e-12	Schizophrenia;
LUAD	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.49	0.3	2.34e-10	Depression;
LUAD	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg12863693	chr15:85201151	NMB	0.37	6.5	0.3	2.28e-10	Schizophrenia;
LUAD	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg26384229	chr12:38710491	ALG10B	0.39	6.44	0.3	3.18e-10	Morning vs. evening chronotype;
LUAD	trans	rs7246760	0.867	rs67539464	chr19:9832424	C/G	cg02900749	chr2:68251473	NA	-0.58	-6.64	-0.31	9.4e-11	Pursuit maintenance gain;
LUAD	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg23029597	chr12:123009494	RSRC2	0.54	8.33	0.38	1.13e-15	Body mass index;
LUAD	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg20276088	chr3:133502917	NA	-0.41	-7.16	-0.33	3.51e-12	Iron status biomarkers;
LUAD	cis	rs6446731	0.593	rs7656026	chr4:3273625	G/C	cg08886695	chr4:3369023	RGS12	-0.5	-8.49	-0.38	3.46e-16	Mean platelet volume;
LUAD	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg05368731	chr17:41323189	NBR1	0.97	20.35	0.7	1.07e-64	Menopause (age at onset);
LUAD	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg19717773	chr7:2847554	GNA12	-0.48	-8.16	-0.37	3.74e-15	Height;
LUAD	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg03929089	chr4:120376271	NA	-0.72	-10.15	-0.44	8.19e-22	Coronary artery disease;
LUAD	cis	rs7617773	0.746	rs4371540	chr3:48353543	G/A	cg11946769	chr3:48343235	NME6	0.44	6.62	0.31	1.07e-10	Coronary artery disease;
LUAD	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.85	-0.32	2.64e-11	Crohn's disease;
LUAD	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.38	-7.08	-0.33	6.14e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg06608945	chr2:219082296	ARPC2	-0.42	-6.91	-0.32	1.75e-11	Colorectal cancer;
LUAD	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg00316803	chr15:76480434	C15orf27	-0.41	-7.97	-0.36	1.53e-14	Blood metabolite levels;
LUAD	cis	rs12568771	0.505	rs2477134	chr1:17633572	A/C	cg08277548	chr1:17600880	PADI3	-0.4	-7.25	-0.33	1.95e-12	IgA nephropathy;
LUAD	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg27170947	chr2:26402098	FAM59B	0.82	11.31	0.48	4.18e-26	Gut microbiome composition (summer);
LUAD	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg17063962	chr7:91808500	NA	0.68	12.12	0.51	3.26e-29	Breast cancer;
LUAD	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.02	0.32	8.9e-12	Hypertriglyceridemia;
LUAD	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12667521	chr19:29218732	NA	0.63	9.62	0.42	6.19e-20	Methadone dose in opioid dependence;
LUAD	cis	rs2625529	0.652	rs8030815	chr15:72403001	T/C	cg16672083	chr15:72433130	SENP8	0.61	11.11	0.48	2.56e-25	Red blood cell count;
LUAD	cis	rs877282	0.741	rs35865720	chr10:753022	G/A	cg06581033	chr10:766294	NA	-0.54	-6.93	-0.32	1.56e-11	Uric acid levels;
LUAD	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-13.7	-0.55	1.26e-35	Monocyte count;
LUAD	cis	rs2275731	0.505	rs7894216	chr10:16479251	C/G	cg04254609	chr10:16479192	PTER	-0.55	-9.21	-0.41	1.58e-18	Bone fracture in osteoporosis;
LUAD	cis	rs733175	0.904	rs3775944	chr4:10019974	G/T	cg02734326	chr4:10020555	SLC2A9	0.45	6.36	0.3	5.14e-10	Psychosis and Alzheimer's disease;
LUAD	cis	rs7394190	0.748	rs11000773	chr10:75534115	G/T	cg02286717	chr10:75415704	SYNPO2L	-0.36	-6.37	-0.3	4.93e-10	Incident atrial fibrillation;
LUAD	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg15992532	chr8:142229932	SLC45A4	0.47	8.21	0.37	2.79e-15	Immature fraction of reticulocytes;
LUAD	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg05727186	chr17:43697356	MGC57346	-0.51	-6.41	-0.3	3.91e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg18138036	chr10:133769891	PPP2R2D	0.42	6.86	0.32	2.43e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs11048434	0.673	rs2159961	chr12:9061456	G/T	cg04155231	chr12:9217510	LOC144571	0.37	6.82	0.31	3.16e-11	Sjögren's syndrome;
LUAD	cis	rs9296092	0.538	rs62407566	chr6:33535786	C/T	cg13560919	chr6:33536144	NA	-0.9	-16.08	-0.62	9.15e-46	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs9399401	0.626	rs13198644	chr6:142783233	A/G	cg04461802	chr6:142623433	GPR126	0.39	7.08	0.33	5.88e-12	Chronic obstructive pulmonary disease;
LUAD	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs2108225	0.872	rs2051954	chr7:107441097	G/C	cg18560240	chr7:107437656	SLC26A3	-0.41	-6.81	-0.31	3.26e-11	Ulcerative colitis;
LUAD	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg17644776	chr2:200775616	C2orf69	-0.5	-7.0	-0.32	1.04e-11	Schizophrenia;
LUAD	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg27068330	chr11:65405492	SIPA1	0.57	9.02	0.4	6.48e-18	Acne (severe);
LUAD	cis	rs9788721	0.836	rs17405217	chr15:78731149	C/T	cg18825076	chr15:78729989	IREB2	-0.59	-10.02	-0.44	2.32e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg22823121	chr1:150693482	HORMAD1	-0.4	-7.89	-0.36	2.63e-14	Tonsillectomy;
LUAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.78	-16.14	-0.62	5.17e-46	Longevity;Endometriosis;
LUAD	cis	rs7173743	0.967	rs28580532	chr15:79134724	C/T	cg00540400	chr15:79124168	NA	-0.34	-6.7	-0.31	6.77e-11	Coronary artery disease;
LUAD	cis	rs116248771	0.690	rs10936149	chr3:158293893	T/G	cg16708174	chr3:158430962	RARRES1	0.48	6.8	0.31	3.49e-11	diarrhoeal disease at age 2;
LUAD	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg02569458	chr12:86230093	RASSF9	0.45	8.07	0.37	7.21e-15	Major depressive disorder;
LUAD	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg27494647	chr7:150038898	RARRES2	0.44	7.17	0.33	3.34e-12	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg21153622	chr11:89784906	NA	-0.36	-7.28	-0.33	1.66e-12	HDL cholesterol;
LUAD	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg07606381	chr6:8435919	SLC35B3	0.42	7.01	0.32	9.22e-12	Motion sickness;
LUAD	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg02527881	chr3:46936655	PTH1R	-0.49	-9.65	-0.42	4.62e-20	Colorectal cancer;
LUAD	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg00757033	chr12:89920650	WDR51B	0.7	12.18	0.51	1.9e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg00898013	chr13:113819073	PROZ	-0.65	-11.66	-0.49	1.97e-27	Platelet distribution width;
LUAD	cis	rs4638749	0.654	rs6761157	chr2:108816885	A/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.39	-0.34	8.1e-13	Blood pressure;
LUAD	cis	rs1160297	0.585	rs2356681	chr2:53097750	C/T	cg07782112	chr2:53107842	NA	0.42	8.9	0.4	1.66e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.64	8.8	0.39	3.48e-17	Renal function-related traits (BUN);
LUAD	trans	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-7.0	-0.32	1.02e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg06784218	chr1:46089804	CCDC17	-0.36	-7.87	-0.36	3.02e-14	Red blood cell count;Reticulocyte count;
LUAD	cis	rs6684514	1.000	rs10908495	chr1:156263940	T/C	cg16558208	chr1:156270281	VHLL	0.53	9.65	0.42	4.74e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.08	-0.44	1.45e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg19622623	chr12:86230825	RASSF9	-0.56	-9.96	-0.44	3.85e-21	Major depressive disorder;
LUAD	trans	rs9929218	1.000	rs12448448	chr16:68802516	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.71	-0.55	1.2e-35	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	1.95e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg23982607	chr1:1823379	GNB1	-0.53	-9.37	-0.41	4.44e-19	Body mass index;
LUAD	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg08645402	chr16:4508243	NA	0.54	9.83	0.43	1.16e-20	Schizophrenia;
LUAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg21782813	chr7:2030301	MAD1L1	0.58	10.33	0.45	1.93e-22	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13012494	chr21:47604986	C21orf56	0.66	11.48	0.49	9.88e-27	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg14847009	chr1:175162515	KIAA0040	0.34	8.82	0.39	2.97e-17	Alcohol dependence;
LUAD	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-15.16	-0.59	8.76e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg18190219	chr22:46762943	CELSR1	-0.47	-6.85	-0.32	2.59e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg20607798	chr8:58055168	NA	0.57	7.3	0.33	1.44e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg11062466	chr8:58055876	NA	0.59	7.65	0.35	1.33e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	5.75e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7692976	0.503	rs9991904	chr4:110922579	A/G	cg06981781	chr4:110842888	EGF	-0.4	-6.83	-0.32	2.87e-11	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08280861	chr8:58055591	NA	0.62	8.04	0.36	9.1e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg25456477	chr12:86230367	RASSF9	0.34	6.55	0.3	1.69e-10	Major depressive disorder;
LUAD	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg15147215	chr3:52552868	STAB1	-0.38	-7.08	-0.33	5.87e-12	Electroencephalogram traits;
LUAD	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg05304507	chr6:116381966	FRK	0.2	6.87	0.32	2.35e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs752010	0.619	rs6702659	chr1:42112236	T/C	cg06885757	chr1:42089581	HIVEP3	0.54	11.96	0.5	1.38e-28	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg07677032	chr17:61819896	STRADA	0.58	10.68	0.46	1e-23	Prudent dietary pattern;
LUAD	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg12311346	chr5:56204834	C5orf35	-0.94	-13.84	-0.56	3.39e-36	Initial pursuit acceleration;
LUAD	cis	rs11031096	0.503	rs67065286	chr11:4105273	A/C	cg18678763	chr11:4115507	RRM1	-0.48	-7.86	-0.36	3.31e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs4243830	0.737	rs925745	chr1:6615690	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.72	-9.38	-0.41	4.17e-19	Body mass index;
LUAD	cis	rs7851660	0.809	rs3808893	chr9:100663745	C/T	cg13688889	chr9:100608707	NA	-0.54	-9.17	-0.41	2.08e-18	Strep throat;
LUAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg08677398	chr8:58056175	NA	0.43	6.61	0.31	1.19e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs790123	0.579	rs1512047	chr3:122398524	C/T	cg15604389	chr3:122379662	NA	0.44	6.58	0.3	1.39e-10	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6748734	1.000	rs6739772	chr2:241840711	A/G	cg07537917	chr2:241836409	C2orf54	-0.3	-8.27	-0.37	1.71e-15	Urinary metabolites;
LUAD	cis	rs7680126	0.596	rs35782983	chr4:10117728	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-7.87	-0.36	3.07e-14	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg09491104	chr22:46646882	C22orf40	-0.71	-12.94	-0.53	1.69e-32	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg17366294	chr4:99064904	C4orf37	0.72	13.24	0.54	1.04e-33	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.812	rs13158215	chr5:130629543	C/A	cg06307176	chr5:131281290	NA	0.39	6.59	0.31	1.33e-10	Life satisfaction;
LUAD	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11890956	chr21:40555474	PSMG1	-0.57	-9.86	-0.43	9.13e-21	Menarche (age at onset);
LUAD	trans	rs11989744	0.500	rs7844903	chr8:23568464	T/C	cg03492747	chr16:86543808	FOXF1	-0.53	-11.25	-0.48	7.37e-26	Waist-hip ratio;
LUAD	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs13064411	0.696	rs1386336	chr3:113144153	C/T	cg18753928	chr3:113234510	CCDC52	-0.72	-11.54	-0.49	5.62e-27	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs1003719	0.680	rs2835630	chr21:38521842	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.33	-0.38	1.16e-15	Eye color traits;
LUAD	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg05890377	chr2:74357713	NA	-0.73	-9.8	-0.43	1.42e-20	Gestational age at birth (maternal effect);
LUAD	cis	rs2625529	0.775	rs4777489	chr15:72430434	C/T	cg16672083	chr15:72433130	SENP8	0.74	12.75	0.53	9.99e-32	Red blood cell count;
LUAD	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg06608945	chr2:219082296	ARPC2	0.52	8.88	0.4	1.86e-17	Colorectal cancer;
LUAD	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06544989	chr22:39130855	UNC84B	0.45	9.01	0.4	7.17e-18	Menopause (age at onset);
LUAD	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.12	-0.37	5.24e-15	Prostate cancer;
LUAD	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07256732	chr16:621771	PIGQ	-0.34	-7.08	-0.33	6.08e-12	Height;
LUAD	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg18854424	chr1:2615690	NA	-0.42	-9.11	-0.41	3.27e-18	Ulcerative colitis;
LUAD	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg05182265	chr7:156933206	UBE3C	-0.8	-17.35	-0.64	2.59e-51	Body mass index;
LUAD	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-9.94	-0.44	4.66e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg07677032	chr17:61819896	STRADA	0.58	10.71	0.46	7.49e-24	Prudent dietary pattern;
LUAD	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg05340658	chr4:99064831	C4orf37	0.45	7.45	0.34	5.14e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg14092988	chr3:52407081	DNAH1	0.33	6.5	0.3	2.22e-10	Bipolar disorder;
LUAD	cis	rs6499255	0.951	rs7200935	chr16:69564497	T/C	cg26679644	chr16:69762563	NA	0.43	6.61	0.31	1.17e-10	IgE levels;
LUAD	cis	rs11153730	0.503	rs283045	chr6:118628476	C/G	cg18833306	chr6:118973337	C6orf204	0.51	9.21	0.41	1.57e-18	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21659725	chr3:3221576	CRBN	-0.87	-18.51	-0.67	1.91e-56	Intelligence (multi-trait analysis);
LUAD	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg04511125	chr2:88470314	THNSL2	-0.51	-8.72	-0.39	6.34e-17	Response to metformin (IC50);
LUAD	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg13073564	chr4:8508604	NA	0.46	7.54	0.34	2.94e-13	Response to antineoplastic agents;
LUAD	cis	rs9868809	0.772	rs9836462	chr3:48712791	C/T	cg00383909	chr3:49044727	WDR6	-0.62	-7.11	-0.33	4.99e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg15468180	chr1:107600409	PRMT6	0.45	7.62	0.35	1.69e-13	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-7.78	-0.35	5.63e-14	Neuroticism;
LUAD	trans	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg00953403	chr17:74099816	EXOC7	0.44	7.0	0.32	1.01e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs8192282	0.739	rs4518898	chr1:154492432	T/C	cg07911225	chr1:154474108	TDRD10;SHE	-0.44	-7.57	-0.35	2.32e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg06484146	chr7:12443880	VWDE	-0.58	-8.54	-0.38	2.37e-16	Coronary artery disease;
LUAD	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg12011299	chr4:100065546	ADH4	0.69	12.45	0.52	1.5e-30	Smoking initiation;
LUAD	cis	rs4588572	0.686	rs116246588	chr5:77683144	T/G	cg11547950	chr5:77652471	NA	0.75	11.81	0.5	5.1e-28	Triglycerides;
LUAD	cis	rs6489882	0.966	rs7311182	chr12:113379123	T/C	cg20102336	chr12:113376681	OAS3	-0.57	-8.89	-0.4	1.76e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg04545296	chr12:48745243	ZNF641	-0.39	-9.76	-0.43	1.93e-20	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs73198271	0.694	rs115037021	chr8:8647080	A/C	cg01851573	chr8:8652454	MFHAS1	0.48	8.49	0.38	3.53e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg20476274	chr7:133979776	SLC35B4	0.81	15.71	0.61	3.81e-44	Mean platelet volume;
LUAD	cis	rs2692947	0.770	rs4527246	chr2:96560303	T/C	cg23100626	chr2:96804247	ASTL	0.3	7.66	0.35	1.31e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg07362569	chr17:61921086	SMARCD2	0.39	6.66	0.31	8.66e-11	Prudent dietary pattern;
LUAD	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.54	-6.91	-0.32	1.78e-11	Body mass index;
LUAD	cis	rs7020830	0.898	rs308492	chr9:37298020	C/T	cg14294708	chr9:37120828	ZCCHC7	0.83	16.2	0.62	2.78e-46	Schizophrenia;
LUAD	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.46	0.3	2.89e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg18944383	chr4:111397179	ENPEP	0.36	6.52	0.3	1.97e-10	Coronary artery disease;
LUAD	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.73	-0.35	7.81e-14	Prostate cancer;
LUAD	cis	rs1524976	0.941	rs9854638	chr3:65477793	C/T	cg16238336	chr3:65465873	MAGI1	-0.62	-7.71	-0.35	9.14e-14	PR interval;
LUAD	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg03983476	chr2:10830698	NOL10	-0.47	-8.26	-0.37	1.86e-15	Prostate cancer;
LUAD	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.71	-12.25	-0.51	9.95e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg08859206	chr1:53392774	SCP2	-0.58	-10.69	-0.46	9.16e-24	Monocyte count;
LUAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg18621852	chr3:10150065	C3orf24	0.46	7.22	0.33	2.44e-12	Alzheimer's disease;
LUAD	cis	rs11771526	0.901	rs62457502	chr7:32330797	C/T	cg13207630	chr7:32358064	NA	0.61	7.66	0.35	1.3e-13	Body mass index;
LUAD	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg15664640	chr17:80829946	TBCD	-0.65	-8.31	-0.37	1.33e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs9287719	0.578	rs62127189	chr2:10761326	T/C	cg03983476	chr2:10830698	NOL10	-0.39	-6.43	-0.3	3.52e-10	Prostate cancer;
LUAD	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.27	0.45	2.99e-22	Lung cancer in ever smokers;
LUAD	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg08236123	chr12:132219811	SFRS8	-0.37	-6.46	-0.3	2.86e-10	Migraine;
LUAD	cis	rs12760731	0.720	rs12048790	chr1:178407906	T/C	cg00404053	chr1:178313656	RASAL2	0.61	7.84	0.36	3.65e-14	Obesity-related traits;
LUAD	cis	rs7402982	0.934	rs6598539	chr15:99204483	T/C	cg03437748	chr15:99193247	IGF1R	0.45	7.93	0.36	1.94e-14	Birth weight;
LUAD	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg10518543	chr12:38710700	ALG10B	-0.45	-7.36	-0.34	9.53e-13	Morning vs. evening chronotype;
LUAD	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.42	-0.38	6.04e-16	Prostate cancer;
LUAD	cis	rs10129255	0.500	rs10143385	chr14:107190796	G/A	cg07958169	chr14:107095056	NA	-0.37	-7.25	-0.33	1.94e-12	Kawasaki disease;
LUAD	cis	rs4786125	0.636	rs11644404	chr16:6904030	C/A	cg03623568	chr16:6915990	A2BP1	-0.49	-10.53	-0.46	3.47e-23	Heart rate variability traits (SDNN);
LUAD	cis	rs863345	0.604	rs11264991	chr1:158472861	T/G	cg12129480	chr1:158549410	OR10X1	-0.24	-6.51	-0.3	2.17e-10	Pneumococcal bacteremia;
LUAD	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg06074448	chr4:187884817	NA	-0.41	-8.15	-0.37	4.3e-15	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13082711	0.911	rs6776318	chr3:27523457	T/C	cg02860705	chr3:27208620	NA	0.6	8.83	0.39	2.91e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6714710	0.603	rs11690687	chr2:98461821	C/T	cg26665480	chr2:98280029	ACTR1B	0.5	8.18	0.37	3.3e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg07636037	chr3:49044803	WDR6	0.64	12.61	0.52	3.44e-31	Parkinson's disease;
LUAD	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg25237894	chr2:233734115	C2orf82	-0.61	-11.42	-0.49	1.69e-26	Coronary artery disease;
LUAD	trans	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg26043149	chr18:55253948	FECH	0.52	8.44	0.38	5.18e-16	Bone mineral density;
LUAD	cis	rs2249625	0.584	rs2496506	chr6:72891324	A/C	cg18830697	chr6:72922368	RIMS1	-0.44	-7.96	-0.36	1.64e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg24813613	chr7:1882135	MAD1L1	-0.53	-8.78	-0.39	4.01e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg07167872	chr1:205819463	PM20D1	-0.53	-8.03	-0.36	9.5e-15	Menarche (age at onset);
LUAD	cis	rs80207740	1.000	rs80207740	chr8:21779937	C/G	cg12468850	chr8:21767224	DOK2	-0.51	-6.44	-0.3	3.2e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs1003719	0.788	rs2835602	chr21:38469069	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.65	0.39	1.11e-16	Eye color traits;
LUAD	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.67	-0.35	1.2e-13	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.17	0.37	3.51e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2235573	0.517	rs4821727	chr22:38393423	C/A	cg19894588	chr14:64061835	NA	0.52	8.13	0.37	4.8e-15	Glioblastoma;Glioma;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg03395511	chr6:291903	DUSP22	-0.75	-12.73	-0.53	1.21e-31	Menopause (age at onset);
LUAD	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-11.87	-0.5	3.03e-28	Bipolar disorder;
LUAD	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg02221422	chr11:68192511	LRP5	-0.41	-6.7	-0.31	6.7e-11	Total body bone mineral density;
LUAD	cis	rs7614311	0.731	rs73130544	chr3:63868596	G/A	cg22134162	chr3:63841271	THOC7	-0.55	-8.91	-0.4	1.54e-17	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg08132940	chr7:1081526	C7orf50	-0.67	-9.25	-0.41	1.11e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2797160	1.000	rs61299898	chr6:126007651	G/C	cg05901451	chr6:126070800	HEY2	0.45	6.61	0.31	1.13e-10	Endometrial cancer;
LUAD	cis	rs2046867	0.908	rs6779684	chr3:72787586	G/A	cg25664220	chr3:72788482	NA	-0.69	-12.09	-0.51	4.15e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg01145583	chr6:160211477	TCP1;MRPL18	-0.44	-6.36	-0.3	5.17e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg24450063	chr1:156163899	SLC25A44	1.03	17.12	0.64	2.56e-50	Testicular germ cell tumor;
LUAD	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg02176678	chr2:219576539	TTLL4	-0.83	-17.47	-0.65	7.58e-52	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs11039798	1.000	rs10838918	chr11:48507449	A/G	cg02254774	chr11:50257496	LOC441601	0.53	6.68	0.31	7.56e-11	Axial length;
LUAD	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12208915	0.848	rs12213359	chr6:79534027	C/A	cg05283184	chr6:79620031	NA	0.49	6.52	0.3	2.06e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs9473147	0.516	rs10456570	chr6:47559451	A/G	cg02130027	chr6:47444894	CD2AP	0.34	6.61	0.31	1.19e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs12579753	0.917	rs12372724	chr12:82193628	C/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.28	-0.33	1.6e-12	Resting heart rate;
LUAD	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg08754654	chr5:154026448	NA	0.47	7.95	0.36	1.76e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg08885076	chr2:99613938	TSGA10	-0.4	-6.98	-0.32	1.16e-11	Chronic sinus infection;
LUAD	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg13298116	chr11:62369859	EML3;MTA2	0.61	11.49	0.49	9.18e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04565464	chr8:145669602	NFKBIL2	0.44	6.77	0.31	4.44e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs113835537	0.529	rs12099041	chr11:66232773	C/T	cg24851651	chr11:66362959	CCS	0.58	10.55	0.46	2.93e-23	Airway imaging phenotypes;
LUAD	cis	rs8112211	0.834	rs11881305	chr19:38804218	A/G	cg14299480	chr19:38876666	GGN	-0.4	-6.88	-0.32	2.14e-11	Blood protein levels;
LUAD	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg03340356	chr1:67600835	NA	0.38	6.7	0.31	6.47e-11	Psoriasis;
LUAD	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19748678	chr4:122722346	EXOSC9	0.43	6.82	0.31	3.18e-11	Type 2 diabetes;
LUAD	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg07570687	chr10:102243282	WNT8B	0.48	7.28	0.33	1.6e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs8112211	0.637	rs2270094	chr19:38840139	T/C	cg14299480	chr19:38876666	GGN	-0.46	-7.43	-0.34	6.11e-13	Blood protein levels;
LUAD	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg03161606	chr19:29218774	NA	0.57	7.83	0.36	4.03e-14	Methadone dose in opioid dependence;
LUAD	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg18827107	chr12:86230957	RASSF9	-0.72	-13.47	-0.55	1.18e-34	Major depressive disorder;
LUAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg18402987	chr7:1209562	NA	0.82	11.09	0.47	2.92e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.15	-0.33	3.89e-12	Glomerular filtration rate;
LUAD	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg07936489	chr17:37558343	FBXL20	-0.45	-7.06	-0.32	6.82e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.08	-0.44	1.51e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.12	-0.37	5e-15	Total body bone mineral density;
LUAD	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg22906224	chr7:99728672	NA	-0.62	-10.86	-0.47	2.08e-24	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg11062466	chr8:58055876	NA	0.58	7.84	0.36	3.57e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg01620082	chr3:125678407	NA	-0.44	-6.48	-0.3	2.55e-10	Depression;
LUAD	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg03467027	chr4:99064603	C4orf37	0.42	6.77	0.31	4.35e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg08807101	chr21:30365312	RNF160	0.39	6.69	0.31	7.09e-11	Dental caries;
LUAD	cis	rs73198271	0.740	rs964771	chr8:8650939	A/G	cg01851573	chr8:8652454	MFHAS1	-0.5	-9.11	-0.41	3.28e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg14396892	chr9:96623032	NA	-0.44	-8.46	-0.38	4.25e-16	DNA methylation (variation);
LUAD	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg00784671	chr22:46762841	CELSR1	-0.43	-6.42	-0.3	3.7e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg21984481	chr17:79567631	NPLOC4	-0.55	-11.63	-0.49	2.6e-27	Eye color traits;
LUAD	cis	rs12431939	1.000	rs67065973	chr14:51656225	T/C	cg23942311	chr14:51606299	NA	-0.56	-7.6	-0.35	1.86e-13	Cancer;
LUAD	cis	rs367943	1.000	rs348962	chr5:112819086	C/T	cg12552261	chr5:112820674	MCC	0.58	11.1	0.47	2.76e-25	Type 2 diabetes;
LUAD	cis	rs2992756	0.663	rs3007734	chr1:18803022	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.56	-9.63	-0.42	5.7e-20	Breast cancer;
LUAD	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg04727924	chr7:799746	HEATR2	-0.53	-7.23	-0.33	2.21e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4588572	0.643	rs10942857	chr5:77760241	A/G	cg11547950	chr5:77652471	NA	-0.77	-12.55	-0.52	6.24e-31	Triglycerides;
LUAD	cis	rs2046867	0.818	rs2208	chr3:72871773	A/G	cg25664220	chr3:72788482	NA	0.64	11.54	0.49	5.63e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs28493229	0.708	rs10407650	chr19:41160970	T/C	cg21869046	chr19:41225005	ITPKC	0.51	8.82	0.39	3.13e-17	Kawasaki disease;
LUAD	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg05368731	chr17:41323189	NBR1	0.98	20.4	0.7	6.3e-65	Menopause (age at onset);
LUAD	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Colorectal cancer;
LUAD	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg21951975	chr1:209979733	IRF6	0.56	8.07	0.37	7.34e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs4888262	0.526	rs8056718	chr16:74612030	G/C	cg01733217	chr16:74700730	RFWD3	0.51	8.65	0.39	1.12e-16	Testicular germ cell tumor;
LUAD	cis	rs7737355	0.812	rs13179482	chr5:130626073	G/A	cg06307176	chr5:131281290	NA	0.39	6.59	0.31	1.33e-10	Life satisfaction;
LUAD	cis	rs78761021	0.867	rs8077150	chr17:9788769	C/T	cg26853458	chr17:9805074	RCVRN	0.32	6.39	0.3	4.51e-10	Type 2 diabetes;
LUAD	cis	rs7607369	0.559	rs13002060	chr2:219660394	G/T	cg02176678	chr2:219576539	TTLL4	-0.54	-10.46	-0.45	6.41e-23	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.06	24.59	0.77	1.42e-83	Chronic sinus infection;
LUAD	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg09021430	chr5:549028	NA	-0.49	-12.39	-0.52	2.64e-30	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg06197492	chr11:2016605	H19	0.34	6.69	0.31	7.1e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs494562	0.892	rs498289	chr6:86116721	A/G	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg17200465	chr3:40428508	ENTPD3	0.27	6.51	0.3	2.1e-10	Renal cell carcinoma;
LUAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00166722	chr3:10149974	C3orf24	0.71	12.36	0.52	3.47e-30	Alzheimer's disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01657511	chr8:142318170	NA	-0.7	-6.6	-0.31	1.26e-10	Type 2 diabetes;
LUAD	cis	rs427394	0.632	rs377137	chr5:6740468	T/G	cg10857441	chr5:6722123	POLS	-0.6	-10.66	-0.46	1.2e-23	Menopause (age at onset);
LUAD	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg09365446	chr1:150670422	GOLPH3L	0.65	12.11	0.51	3.3600000000000003e-29	Tonsillectomy;
LUAD	cis	rs10089	1.000	rs72794401	chr5:127517626	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	9.05	0.4	5.14e-18	Ileal carcinoids;
LUAD	cis	rs72827839	0.516	rs72833458	chr17:45938051	A/G	cg23391107	chr17:45924227	SP6	0.41	6.53	0.3	1.91e-10	Ease of getting up in the morning;
LUAD	trans	rs62103177	0.636	rs9958792	chr18:77627876	T/C	cg05926928	chr17:57297772	GDPD1	-0.7	-9.3	-0.41	7.87e-19	Opioid sensitivity;
LUAD	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.38	0.34	8.52e-13	Bipolar disorder;
LUAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg08132940	chr7:1081526	C7orf50	-0.76	-10.27	-0.45	3.19e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2735413	0.881	rs12919672	chr16:78082760	C/G	cg01028844	chr5:122736986	CEP120	0.41	6.5	0.3	2.24e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	trans	rs2840044	0.963	rs225247	chr17:33944590	T/A	cg19694781	chr19:47549865	TMEM160	-0.63	-10.12	-0.44	1.05e-21	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg19052272	chr2:3704530	ALLC	-0.63	-10.74	-0.46	5.9e-24	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs6960043	0.818	rs4719433	chr7:15065003	A/G	cg19272540	chr7:15055459	NA	-0.37	-8.21	-0.37	2.76e-15	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg11062466	chr8:58055876	NA	0.81	9.86	0.43	9.02e-21	Developmental language disorder (linguistic errors);
LUAD	trans	rs3942852	0.910	rs10742831	chr11:48119691	G/A	cg03929089	chr4:120376271	NA	-0.54	-7.46	-0.34	5.06e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg24829409	chr8:58192753	C8orf71	-0.46	-6.49	-0.3	2.37e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7677751	0.806	rs6850748	chr4:55099164	T/G	cg17187183	chr4:55093834	PDGFRA	0.51	8.63	0.39	1.23e-16	Corneal astigmatism;
LUAD	cis	rs6494488	0.500	rs34758599	chr15:64706332	A/G	cg08069370	chr15:64387884	SNX1	-0.75	-6.65	-0.31	9.29e-11	Coronary artery disease;
LUAD	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg00321850	chr1:175162397	KIAA0040	0.54	11.63	0.49	2.53e-27	Alcohol dependence;
LUAD	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg20476274	chr7:133979776	SLC35B4	0.74	13.98	0.56	8.78e-37	Mean platelet volume;
LUAD	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg17264618	chr3:40429014	ENTPD3	-0.4	-8.87	-0.4	2.04e-17	Renal cell carcinoma;
LUAD	cis	rs9394841	0.692	rs9381094	chr6:41800629	T/C	cg17623882	chr6:41773611	USP49	-0.49	-6.86	-0.32	2.45e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs4638749	0.627	rs1522020	chr2:108833346	C/G	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.3	-0.33	1.48e-12	Blood pressure;
LUAD	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg13319975	chr6:146136371	FBXO30	-0.59	-10.22	-0.45	4.57e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1595825	0.838	rs16823400	chr2:198603229	A/G	cg00982548	chr2:198649783	BOLL	-0.65	-9.25	-0.41	1.13e-18	Ulcerative colitis;
LUAD	trans	rs1997103	0.834	rs10274457	chr7:55390199	G/A	cg20935933	chr6:143382018	AIG1	0.54	7.51	0.34	3.44e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.53	-9.87	-0.43	8.17e-21	Longevity;Endometriosis;
LUAD	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg17509989	chr5:176798049	RGS14	0.77	12.76	0.53	9.33e-32	Urinary electrolytes (magnesium/calcium ratio);
LUAD	cis	rs684232	0.583	rs2657626	chr17:603052	A/G	cg15660573	chr17:549704	VPS53	-0.77	-15.31	-0.6	1.98e-42	Prostate cancer;
LUAD	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.5	6.88	0.32	2.22e-11	Platelet count;
LUAD	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg21709803	chr11:61594965	FADS2	-0.52	-9.25	-0.41	1.11e-18	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg12119029	chr16:89752879	CDK10	-0.31	-6.74	-0.31	5.2e-11	Vitiligo;
LUAD	cis	rs11971779	0.564	rs6467841	chr7:139066092	T/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.76	0.31	4.63e-11	Diisocyanate-induced asthma;
LUAD	cis	rs9604529	0.557	rs74406200	chr13:114741208	C/T	cg24241305	chr13:114826075	RASA3	-0.44	-6.79	-0.31	3.77e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg07256732	chr16:621771	PIGQ	-0.32	-6.54	-0.3	1.8e-10	Height;
LUAD	cis	rs4664304	1.000	rs3806603	chr2:160761808	T/C	cg23995753	chr2:160760732	LY75	-0.48	-8.61	-0.39	1.51e-16	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg22676075	chr6:135203613	NA	-0.52	-9.26	-0.41	1e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	trans	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg18335740	chr13:41363409	SLC25A15	0.57	10.35	0.45	1.6e-22	Lewy body disease;
LUAD	cis	rs1461503	0.934	rs930983	chr11:122834414	A/G	cg27398637	chr11:122830231	C11orf63	-0.35	-6.91	-0.32	1.83e-11	Menarche (age at onset);
LUAD	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg04772025	chr11:68637568	NA	0.55	8.63	0.39	1.3e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg23018236	chr17:30244563	NA	-0.63	-7.9	-0.36	2.41e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs6484504	0.576	rs2616792	chr11:31324298	T/G	cg14844989	chr11:31128820	NA	0.45	8.3	0.37	1.42e-15	Red blood cell count;
LUAD	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg26668828	chr6:292823	DUSP22	-0.59	-9.98	-0.44	3.3e-21	Menopause (age at onset);
LUAD	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.57	8.33	0.38	1.1e-15	Platelet count;
LUAD	cis	rs7814319	0.700	rs11995989	chr8:97264456	C/G	cg20787634	chr8:97240163	UQCRB	-0.36	-6.71	-0.31	6.27e-11	Lung function (FVC);
LUAD	cis	rs9473147	0.543	rs9296558	chr6:47451883	C/T	cg20196966	chr6:47445060	CD2AP	0.41	6.45	0.3	3.06e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06112835	chr11:68658793	MRPL21	0.5	8.81	0.39	3.28e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg08029281	chr1:67600428	NA	-0.33	-6.52	-0.3	2.05e-10	Psoriasis;
LUAD	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg12179176	chr11:130786555	SNX19	0.45	7.24	0.33	2.14e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg13535736	chr9:111863775	C9orf5	-0.43	-6.69	-0.31	7.21e-11	Menarche (age at onset);
LUAD	cis	rs367943	0.672	rs6594712	chr5:112715211	T/G	cg12552261	chr5:112820674	MCC	0.47	9.18	0.41	1.96e-18	Type 2 diabetes;
LUAD	cis	rs9811920	0.809	rs7649349	chr3:99725629	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.62	-11.67	-0.49	1.86e-27	Axial length;
LUAD	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12292205	chr6:26970375	C6orf41	-0.53	-6.92	-0.32	1.66e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg09165964	chr15:75287851	SCAMP5	-0.52	-7.58	-0.35	2.23e-13	Blood trace element (Zn levels);
LUAD	cis	rs1692580	0.807	rs10910036	chr1:2183754	C/G	cg24578937	chr1:2090814	PRKCZ	0.56	11.0	0.47	6.38e-25	Coronary artery disease;
LUAD	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-8.77	-0.39	4.26e-17	Life satisfaction;
LUAD	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg02782426	chr3:40428986	ENTPD3	-0.42	-9.12	-0.41	3.15e-18	Renal cell carcinoma;
LUAD	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg10053473	chr17:62856997	LRRC37A3	0.71	11.44	0.49	1.38e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs16854884	0.558	rs6768153	chr3:143667429	C/A	cg01302019	chr3:143689584	C3orf58	-0.39	-6.64	-0.31	9.5e-11	Economic and political preferences (feminism/equality);
LUAD	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg03714773	chr7:91764589	CYP51A1	-0.31	-7.24	-0.33	2.12e-12	Breast cancer;
LUAD	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg25237894	chr2:233734115	C2orf82	0.6	11.35	0.48	3.04e-26	Coronary artery disease;
LUAD	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg02176678	chr2:219576539	TTLL4	-0.73	-14.63	-0.58	1.64e-39	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg15147215	chr3:52552868	STAB1	-0.4	-7.22	-0.33	2.42e-12	Bipolar disorder;
LUAD	cis	rs7940866	0.738	rs10894308	chr11:130891895	G/A	cg12179176	chr11:130786555	SNX19	0.44	6.95	0.32	1.37e-11	Schizophrenia;
LUAD	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg06627628	chr2:24431161	ITSN2	-0.46	-6.49	-0.3	2.42e-10	Lymphocyte counts;
LUAD	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg13263323	chr15:86062960	AKAP13	0.46	7.58	0.35	2.26e-13	Coronary artery disease;
LUAD	cis	rs790123	0.692	rs796892	chr3:122385402	C/T	cg15604389	chr3:122379662	NA	-0.47	-7.86	-0.36	3.11e-14	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg05082376	chr22:42548792	NA	0.45	7.83	0.36	4.1e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10129255	0.536	rs6576201	chr14:107139713	A/G	cg23076370	chr14:107095027	NA	0.37	7.42	0.34	6.59e-13	Kawasaki disease;
LUAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.47	-0.38	3.96e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg02423579	chr7:2872169	GNA12	-0.77	-13.03	-0.54	7.54e-33	Height;
LUAD	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg04539111	chr16:67997858	SLC12A4	-0.62	-7.53	-0.34	3.15e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11644478	chr21:40555479	PSMG1	-0.4	-6.71	-0.31	6.38e-11	Menarche (age at onset);
LUAD	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.76	-0.31	4.5e-11	Height;
LUAD	trans	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg18335740	chr13:41363409	SLC25A15	0.49	8.6	0.39	1.57e-16	Lewy body disease;
LUAD	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg01874867	chr7:94954059	PON1	-0.48	-6.47	-0.3	2.74e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs2018683	0.523	rs4513881	chr7:29025410	C/T	cg19402173	chr7:128379420	CALU	0.46	7.22	0.33	2.37e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs17683430	0.702	rs75351557	chr22:32416688	A/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LUAD	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg08859206	chr1:53392774	SCP2	0.59	10.6	0.46	1.93e-23	Monocyte count;
LUAD	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg07741184	chr6:167504864	NA	0.31	7.06	0.32	6.7e-12	Crohn's disease;
LUAD	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg09455208	chr3:40491958	NA	0.64	14.25	0.57	6.5e-38	Renal cell carcinoma;
LUAD	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg25036284	chr2:26402008	FAM59B	-0.7	-10.44	-0.45	7.22e-23	Gut microbiome composition (summer);
LUAD	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg15432903	chr11:17409602	KCNJ11	0.55	10.27	0.45	3.03e-22	Type 2 diabetes;
LUAD	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg05340658	chr4:99064831	C4orf37	0.45	7.36	0.34	9.65e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18876405	chr7:65276391	NA	-0.43	-7.01	-0.32	9.55e-12	Aortic root size;
LUAD	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg01849466	chr14:104193079	ZFYVE21	0.45	7.55	0.34	2.62e-13	Body mass index;
LUAD	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.39	-6.95	-0.32	1.42e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg18446336	chr7:2847575	GNA12	-0.32	-6.37	-0.3	4.86e-10	Height;
LUAD	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg02527881	chr3:46936655	PTH1R	-0.49	-9.7	-0.43	3.31e-20	Colorectal cancer;
LUAD	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg08859206	chr1:53392774	SCP2	-0.59	-10.65	-0.46	1.23e-23	Monocyte count;
LUAD	cis	rs62400317	0.821	rs34455867	chr6:45172071	T/C	cg18551225	chr6:44695536	NA	-0.51	-7.76	-0.35	6.29e-14	Total body bone mineral density;
LUAD	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg05872129	chr22:39784769	NA	-0.76	-12.84	-0.53	4.37e-32	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs524023	0.914	rs11231845	chr11:64407419	G/A	cg19131476	chr11:64387923	NRXN2	-0.42	-8.33	-0.38	1.15e-15	Urate levels in obese individuals;
LUAD	cis	rs11048434	0.736	rs1805733	chr12:9089272	A/C	cg13575925	chr12:9217583	LOC144571	0.37	6.84	0.32	2.7e-11	Sjögren's syndrome;
LUAD	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg04287289	chr16:89883240	FANCA	0.82	7.2	0.33	2.72e-12	Skin colour saturation;
LUAD	cis	rs12079745	1.000	rs74967728	chr1:169202731	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-1.1	-8.03	-0.36	9.8e-15	QT interval;
LUAD	cis	rs2274273	0.837	rs6573010	chr14:55721592	T/C	cg04306507	chr14:55594613	LGALS3	0.42	8.72	0.39	6.29e-17	Protein biomarker;
LUAD	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg22467129	chr15:76604101	ETFA	-0.44	-7.06	-0.32	6.78e-12	Blood metabolite levels;
LUAD	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg06671706	chr8:8559999	CLDN23	0.68	11.82	0.5	4.72e-28	Obesity-related traits;
LUAD	cis	rs4243830	1.000	rs58415361	chr1:6592377	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.77	8.29	0.37	1.5e-15	Body mass index;
LUAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-10.22	-0.45	4.59e-22	Electroencephalogram traits;
LUAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg11494091	chr17:61959527	GH2	0.74	18.39	0.67	6.33e-56	Prudent dietary pattern;
LUAD	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg16479474	chr6:28041457	NA	0.35	6.38	0.3	4.6e-10	Cardiac Troponin-T levels;
LUAD	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.75	0.31	4.81e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg17644776	chr2:200775616	C2orf69	0.55	7.32	0.34	1.26e-12	Schizophrenia;
LUAD	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg22906224	chr7:99728672	NA	0.56	9.59	0.42	7.45e-20	Coronary artery disease;
LUAD	cis	rs934734	0.752	rs1039764	chr2:65614613	T/C	cg11674355	chr2:65610261	SPRED2	0.36	6.51	0.3	2.1e-10	Rheumatoid arthritis;
LUAD	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg07599136	chr5:415885	AHRR	0.75	8.43	0.38	5.38e-16	Fat distribution (HIV);
LUAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg10150615	chr22:24372951	LOC391322	-0.48	-7.76	-0.35	6.61e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg01097406	chr16:89675127	NA	0.46	9.85	0.43	9.31e-21	Vitiligo;
LUAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08219700	chr8:58056026	NA	0.6	7.86	0.36	3.13e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9560113	0.881	rs9560111	chr13:112181289	C/T	cg14154082	chr13:112174009	NA	0.36	6.64	0.31	9.5e-11	Menarche (age at onset);
LUAD	cis	rs6761276	0.868	rs13386602	chr2:113834820	A/C	cg10479672	chr2:113810641	IL1F8	-0.38	-7.72	-0.35	8.74e-14	Protein quantitative trait loci;
LUAD	cis	rs9807989	0.839	rs3755276	chr2:102978459	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	6.38	0.3	4.58e-10	Asthma;
LUAD	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg19077165	chr18:44547161	KATNAL2	-0.41	-7.3	-0.33	1.41e-12	Personality dimensions;
LUAD	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg01475377	chr6:109611718	NA	-0.51	-9.48	-0.42	1.86e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg23758822	chr17:41437982	NA	1.01	20.99	0.71	1.52e-67	Menopause (age at onset);
LUAD	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.46	0.3	2.86e-10	Cognitive test performance;
LUAD	cis	rs6714710	0.603	rs6738389	chr2:98386731	A/G	cg26665480	chr2:98280029	ACTR1B	0.5	8.23	0.37	2.39e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg03806693	chr22:41940476	POLR3H	0.73	9.78	0.43	1.7e-20	Vitiligo;
LUAD	cis	rs2041840	0.503	rs10179447	chr2:37578208	C/T	cg25727520	chr2:37576821	QPCT	-0.33	-7.12	-0.33	4.82e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.43	-8.21	-0.37	2.74e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4950928	0.823	rs2494277	chr1:203168092	A/G	cg17014757	chr1:203156097	CHI3L1	-0.61	-8.74	-0.39	5.35e-17	YKL-40 levels;
LUAD	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.8	-0.31	3.54e-11	Retinal vascular caliber;
LUAD	cis	rs2806561	0.929	rs856508	chr1:23532995	A/C	cg19743168	chr1:23544995	NA	0.44	8.06	0.36	7.83e-15	Height;
LUAD	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg22920501	chr2:26401640	FAM59B	-0.76	-10.89	-0.47	1.61e-24	Gut microbiome composition (summer);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20586607	chr14:50235780	KLHDC2	-0.42	-6.61	-0.31	1.13e-10	Height;
LUAD	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg17401720	chr7:158221031	PTPRN2	-0.32	-6.52	-0.3	1.97e-10	Obesity-related traits;
LUAD	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg10518543	chr12:38710700	ALG10B	-0.48	-7.82	-0.36	4.26e-14	Morning vs. evening chronotype;
LUAD	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg15704280	chr7:45808275	SEPT13	-1.0	-20.27	-0.7	2.52e-64	Height;
LUAD	cis	rs938554	0.784	rs7439210	chr4:9971749	C/G	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.27	-0.33	1.71e-12	Blood metabolite levels;
LUAD	cis	rs2235649	0.592	rs7197113	chr16:1969483	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.95	-0.32	1.41e-11	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2810114	0.916	rs2526851	chr14:71416280	G/C	cg15910301	chr14:71632612	NA	-0.41	-6.4	-0.3	4.25e-10	Alcohol dependence;
LUAD	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg03037974	chr15:76606532	NA	0.38	7.9	0.36	2.42e-14	Blood metabolite levels;
LUAD	cis	rs10089	0.552	rs17607942	chr5:127555435	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.47	6.68	0.31	7.72e-11	Ileal carcinoids;
LUAD	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg27432699	chr2:27873401	GPN1	0.57	9.99	0.44	3.13e-21	Oral cavity cancer;
LUAD	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg11494091	chr17:61959527	GH2	0.41	7.7	0.35	9.54e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg09165964	chr15:75287851	SCAMP5	-0.45	-6.79	-0.31	3.77e-11	Blood trace element (Zn levels);
LUAD	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg15997130	chr1:24165203	NA	0.55	9.47	0.42	2.03e-19	Immature fraction of reticulocytes;
LUAD	cis	rs4767364	0.961	rs10850031	chr12:112771063	T/G	cg10833066	chr12:111807467	FAM109A	0.34	6.52	0.3	1.95e-10	Oral cavity and pharyngeal cancer;
LUAD	cis	rs4604732	0.678	rs74154674	chr1:247625685	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7512552	0.698	rs12028001	chr1:150407820	C/T	cg15654264	chr1:150340011	RPRD2	0.58	11.2	0.48	1.09e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg15066416	chr17:45501628	LOC100272146;C17orf57	-0.35	-6.57	-0.3	1.44e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9296092	0.538	rs56199698	chr6:33534505	G/C	cg13560919	chr6:33536144	NA	-0.9	-16.19	-0.62	3.28e-46	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg07917127	chr4:99064746	C4orf37	0.43	6.48	0.3	2.5e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg14917512	chr19:3094685	GNA11	-0.55	-6.51	-0.3	2.14e-10	Diabetic kidney disease;
LUAD	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg24562669	chr7:97807699	LMTK2	0.34	8.25	0.37	2.04e-15	Breast cancer;
LUAD	cis	rs7680126	0.633	rs11728093	chr4:10296407	A/C	cg11266682	chr4:10021025	SLC2A9	-0.48	-7.42	-0.34	6.46e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	trans	rs783540	1.000	rs7496954	chr15:83345536	T/G	cg18393722	chr15:85113863	UBE2QP1	0.46	7.37	0.34	8.78e-13	Schizophrenia;
LUAD	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg26384229	chr12:38710491	ALG10B	-0.46	-7.63	-0.35	1.62e-13	Morning vs. evening chronotype;
LUAD	cis	rs13088645	0.532	rs12695613	chr3:134166572	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	8.62	0.39	1.34e-16	Coronary artery disease;
LUAD	cis	rs1595825	0.891	rs76637837	chr2:198529496	G/A	cg11031976	chr2:198649780	BOLL	-0.46	-6.84	-0.32	2.82e-11	Ulcerative colitis;
LUAD	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg07926092	chr13:79233506	RNF219	-0.6	-8.38	-0.38	7.63e-16	Large artery stroke;
LUAD	cis	rs11958404	0.932	rs6884954	chr5:157436772	C/T	cg05962755	chr5:157440814	NA	0.68	9.59	0.42	7.5599999999999994e-20	IgG glycosylation;
LUAD	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg02269571	chr22:50332266	NA	0.62	9.35	0.41	5.3e-19	Schizophrenia;
LUAD	cis	rs6430585	0.528	rs309113	chr2:136737460	C/A	cg07169764	chr2:136633963	MCM6	0.67	8.4	0.38	7.04e-16	Corneal structure;
LUAD	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.82	0.31	3.12e-11	Depression;
LUAD	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg02569458	chr12:86230093	RASSF9	-0.42	-7.62	-0.35	1.63e-13	Major depressive disorder;
LUAD	cis	rs11030122	0.632	rs10835556	chr11:4083013	A/G	cg18678763	chr11:4115507	RRM1	-0.44	-7.05	-0.32	7.56e-12	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs741677	0.929	rs741678	chr17:464291	T/C	cg06217071	chr17:408420	NA	0.36	7.34	0.34	1.1e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg17177755	chr1:15930204	NA	0.44	7.11	0.33	5.08e-12	Systolic blood pressure;
LUAD	cis	rs2479724	0.905	rs2251274	chr6:41839438	T/G	cg17623882	chr6:41773611	USP49	-0.68	-12.76	-0.53	8.8e-32	Menarche (age at onset);
LUAD	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	18.64	0.67	4.95e-57	Bone mineral density;
LUAD	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg11292332	chr7:45801988	SEPT13	-0.29	-6.56	-0.3	1.54e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1467026	0.691	rs9985266	chr3:12803162	C/T	cg24848339	chr3:12840334	CAND2	-0.35	-6.8	-0.31	3.63e-11	P wave duration;
LUAD	cis	rs68170813	0.523	rs11766131	chr7:107071138	T/C	cg02696742	chr7:106810147	HBP1	-0.8	-10.68	-0.46	9.46e-24	Coronary artery disease;
LUAD	cis	rs13082711	0.834	rs2840088	chr3:27428371	G/A	cg02860705	chr3:27208620	NA	0.59	8.97	0.4	9.69e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg14008862	chr17:28927542	LRRC37B2	0.65	6.47	0.3	2.77e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg06618935	chr21:46677482	NA	-0.47	-9.6	-0.42	7e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs76878669	0.917	rs10444359	chr11:66102807	G/A	cg18002602	chr11:66138449	SLC29A2	-0.4	-6.98	-0.32	1.18e-11	Educational attainment (years of education);
LUAD	cis	rs853679	0.546	rs13195291	chr6:28169241	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.54	6.4	0.3	4.14e-10	Depression;
LUAD	cis	rs11112613	0.713	rs12580741	chr12:105941328	A/G	cg03607813	chr12:105948248	NA	-0.77	-12.89	-0.53	2.66e-32	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs6445967	0.530	rs12486031	chr3:58409679	G/A	cg13750441	chr3:58318267	PXK	-0.33	-6.78	-0.31	4.09e-11	Platelet count;
LUAD	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg03983476	chr2:10830698	NOL10	-0.46	-7.87	-0.36	3.05e-14	Prostate cancer;
LUAD	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg09399716	chr2:46890238	NA	-0.4	-7.75	-0.35	6.84e-14	Height;
LUAD	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9972944	0.756	rs2318869	chr17:63767736	C/G	cg07283582	chr17:63770753	CCDC46	-0.5	-11.38	-0.48	2.38e-26	Total body bone mineral density;
LUAD	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg12935359	chr14:103987150	CKB	-0.49	-7.99	-0.36	1.28e-14	Body mass index;
LUAD	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg09117114	chr16:67998030	SLC12A4	-0.54	-7.19	-0.33	2.99e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2652834	0.718	rs2652839	chr15:63395158	C/T	cg25406657	chr15:63342033	TPM1	-0.39	-6.57	-0.3	1.45e-10	HDL cholesterol;
LUAD	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg27170947	chr2:26402098	FAM59B	-0.8	-11.61	-0.49	3.02e-27	Gut microbiome composition (summer);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21509931	chr17:7218030	GPS2	-0.55	-6.66	-0.31	8.45e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg15605315	chr1:45957053	TESK2	-0.41	-6.4	-0.3	4.04e-10	High light scatter reticulocyte count;
LUAD	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-11.41	-0.49	1.83e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2297441	0.550	rs6011097	chr20:62398825	G/A	cg14758556	chr20:62440591	NA	-0.46	-6.79	-0.31	3.86e-11	Ulcerative colitis;
LUAD	cis	rs11828289	0.660	rs74388652	chr11:23188048	A/G	cg20040320	chr11:23191996	NA	-0.7	-8.11	-0.37	5.7e-15	Cancer;
LUAD	cis	rs3106136	0.967	rs11722476	chr4:95170839	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.43	-0.34	6.06e-13	Capecitabine sensitivity;
LUAD	cis	rs78487399	0.808	rs998768	chr2:43711523	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-7.21	-0.33	2.58e-12	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg12908607	chr1:44402522	ARTN	-0.47	-9.48	-0.42	1.92e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs886126	1.000	rs10082818	chr12:111663177	C/G	cg10833066	chr12:111807467	FAM109A	0.59	10.75	0.46	5.55e-24	Coronary heart disease;
LUAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg24503407	chr1:205819492	PM20D1	0.79	16.07	0.62	1.08e-45	Menarche (age at onset);
LUAD	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22857025	chr5:266934	NA	-1.02	-12.83	-0.53	4.81e-32	Breast cancer;
LUAD	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg01236616	chr12:121019343	POP5	1.2	18.73	0.67	1.94e-57	Type 1 diabetes nephropathy;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15444788	chr1:85666708	SYDE2	-0.42	-6.68	-0.31	7.39e-11	Height;
LUAD	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	13.06	0.54	5.6e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg08470875	chr2:26401718	FAM59B	-0.6	-8.2	-0.37	2.96e-15	Gut microbiome composition (summer);
LUAD	cis	rs7020830	0.931	rs7851239	chr9:37138672	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.74	-13.52	-0.55	6.91e-35	Schizophrenia;
LUAD	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00166722	chr3:10149974	C3orf24	0.75	12.75	0.53	9.7e-32	Alzheimer's disease;
LUAD	trans	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg06606381	chr12:133084897	FBRSL1	-0.54	-6.53	-0.3	1.89e-10	Depression;
LUAD	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg04248312	chr19:17393744	ANKLE1	0.99	18.71	0.67	2.27e-57	Systemic lupus erythematosus;
LUAD	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06544989	chr22:39130855	UNC84B	0.44	7.92	0.36	2.05e-14	Menopause (age at onset);
LUAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg08132940	chr7:1081526	C7orf50	-0.65	-9.05	-0.4	5.17e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11951515	0.966	rs7706402	chr5:43381580	G/A	cg01983248	chr5:43482804	C5orf28	-0.33	-6.76	-0.31	4.62e-11	Metabolite levels  (X-11787);
LUAD	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg08847533	chr14:75593920	NEK9	0.38	6.55	0.3	1.65e-10	Height;
LUAD	cis	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg07460842	chr6:66804631	NA	0.61	9.77	0.43	1.82e-20	Type 2 diabetes;
LUAD	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg05368731	chr17:41323189	NBR1	0.96	19.76	0.69	4.83e-62	Menopause (age at onset);
LUAD	cis	rs6738485	1.000	rs6738485	chr2:106809960	C/T	cg16099169	chr2:106886729	NA	-0.4	-6.76	-0.31	4.7e-11	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs78761021	0.685	rs17744107	chr17:9795735	C/G	cg26853458	chr17:9805074	RCVRN	-0.38	-7.49	-0.34	3.94e-13	Type 2 diabetes;
LUAD	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.05	-0.36	8.68e-15	Total body bone mineral density;
LUAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg05434287	chr7:2030229	MAD1L1	0.38	6.5	0.3	2.29e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9283706	0.513	rs7707409	chr5:66351889	A/G	cg11590213	chr5:66331682	MAST4	0.42	6.88	0.32	2.18e-11	Coronary artery disease;
LUAD	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg22153463	chr1:85462885	MCOLN2	-0.59	-9.03	-0.4	5.94e-18	Serum sulfate level;
LUAD	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg07636037	chr3:49044803	WDR6	0.35	6.48	0.3	2.61e-10	Resting heart rate;
LUAD	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg21862992	chr11:68658383	NA	-0.41	-7.62	-0.35	1.64e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg05434287	chr7:2030229	MAD1L1	0.41	6.74	0.31	5.04e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg02423579	chr7:2872169	GNA12	-0.79	-13.72	-0.55	1.1e-35	Height;
LUAD	cis	rs4713675	0.546	rs10947434	chr6:33691501	G/T	cg14003231	chr6:33640908	ITPR3	0.5	9.61	0.42	6.42e-20	Plateletcrit;
LUAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.45	-8.91	-0.4	1.5e-17	Longevity;Endometriosis;
LUAD	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg09537434	chr19:41945824	ATP5SL	0.5	7.96	0.36	1.58e-14	Height;
LUAD	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg17063962	chr7:91808500	NA	0.67	12.01	0.5	8.3e-29	Breast cancer;
LUAD	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg17724175	chr1:150552817	MCL1	0.37	8.34	0.38	1.05e-15	Melanoma;
LUAD	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg27462398	chr1:86174642	ZNHIT6	-0.39	-7.78	-0.35	5.48e-14	Urate levels in overweight individuals;
LUAD	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg06608945	chr2:219082296	ARPC2	0.42	7.06	0.32	6.91e-12	Colorectal cancer;
LUAD	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.41	6.84	0.32	2.73e-11	Waist circumference;Hip circumference;
LUAD	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg13319975	chr6:146136371	FBXO30	0.63	10.69	0.46	9.01e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.42	0.38	5.75e-16	Platelet count;
LUAD	cis	rs55823223	0.504	rs56098714	chr17:73860303	T/C	cg08125733	chr17:73851984	WBP2	0.57	8.44	0.38	4.93e-16	Psoriasis;
LUAD	trans	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg06606381	chr12:133084897	FBRSL1	-1.13	-10.46	-0.45	6.49e-23	Depression;
LUAD	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg07828340	chr4:882639	GAK	1.06	11.71	0.49	1.24e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	8.06	0.36	8.15e-15	Menarche (age at onset);
LUAD	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg22482690	chr17:47019901	SNF8	0.44	8.37	0.38	8.71e-16	Type 2 diabetes;
LUAD	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.81	-0.31	3.45e-11	Diabetic kidney disease;
LUAD	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg26408565	chr15:76604113	ETFA	-0.55	-9.7	-0.43	3.32e-20	Blood metabolite levels;
LUAD	cis	rs847851	0.612	rs7768189	chr6:34742450	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.78	-0.39	4.09e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg17443473	chr1:3703550	LRRC47	0.47	7.88	0.36	2.74e-14	Red cell distribution width;
LUAD	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-20.46	-0.71	3.39e-65	Height;
LUAD	cis	rs7705042	0.865	rs166079	chr5:141528959	C/T	cg23435118	chr5:141488016	NDFIP1	-0.41	-7.01	-0.32	9.48e-12	Asthma;
LUAD	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg16647868	chr5:131706066	SLC22A5	0.41	7.18	0.33	3.25e-12	Blood metabolite levels;
LUAD	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.35	-6.83	-0.31	3.05e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs62400317	0.762	rs62436375	chr6:44875818	T/C	cg18551225	chr6:44695536	NA	-0.55	-8.52	-0.38	2.8e-16	Total body bone mineral density;
LUAD	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23158103	chr7:148848205	ZNF398	0.49	8.83	0.39	2.74e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg02951883	chr7:2050386	MAD1L1	-0.82	-15.46	-0.6	4.43e-43	Bipolar disorder and schizophrenia;
LUAD	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-8.12	-0.37	5.03e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs76419734	0.510	rs2553461	chr4:106731410	A/G	cg05309399	chr4:106552544	FLJ20184	0.49	6.84	0.32	2.71e-11	Post bronchodilator FEV1;
LUAD	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.36	-0.34	9.76e-13	Resting heart rate;
LUAD	cis	rs4891159	0.505	rs680253	chr18:74167427	A/C	cg24786174	chr18:74118243	ZNF516	-0.84	-19.1	-0.68	4.08e-59	Longevity;
LUAD	cis	rs4812048	0.649	rs3761258	chr20:57618596	C/G	cg14073986	chr20:57617431	SLMO2	-0.79	-9.28	-0.41	9.13e-19	Mean platelet volume;
LUAD	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg08742575	chr21:47604166	C21orf56	0.44	7.28	0.33	1.64e-12	Testicular germ cell tumor;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09378497	chr16:1525169	CLCN7	-0.62	-6.52	-0.3	2.07e-10	Type 2 diabetes;
LUAD	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg11266682	chr4:10021025	SLC2A9	0.65	15.37	0.6	1.18e-42	Bone mineral density;
LUAD	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg18252515	chr7:66147081	NA	-0.62	-6.9	-0.32	1.96e-11	Diabetic kidney disease;
LUAD	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg18404041	chr3:52824283	ITIH1	0.59	12.03	0.5	7.24e-29	Bipolar disorder;
LUAD	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg23533926	chr12:111358616	MYL2	-0.43	-7.35	-0.34	1.03e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs250677	0.522	rs7702695	chr5:148402550	T/A	cg12140854	chr5:148520817	ABLIM3	-0.56	-8.5	-0.38	3.38e-16	Breast cancer;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg25993851	chr11:46722334	ARHGAP1;ZNF408	-0.41	-6.89	-0.32	2.06e-11	Subcortical brain region volumes;
LUAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg11494091	chr17:61959527	GH2	0.74	18.63	0.67	5.61e-57	Prudent dietary pattern;
LUAD	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg05434287	chr7:2030229	MAD1L1	0.41	6.7	0.31	6.5e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1784581	0.588	rs1784606	chr6:162405992	A/T	cg17173639	chr6:162384350	PARK2	-0.4	-6.73	-0.31	5.4e-11	Itch intensity from mosquito bite;
LUAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg06753367	chr22:24256600	NA	0.4	7.2	0.33	2.82e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs427941	0.703	rs201450	chr7:101739441	A/T	cg06246474	chr7:101738831	CUX1	-0.4	-7.14	-0.33	4.06e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10802521	chr3:52805072	NEK4	-0.62	-11.22	-0.48	9.81e-26	Bipolar disorder;
LUAD	cis	rs4713675	0.565	rs4713674	chr6:33708169	C/T	cg13859433	chr6:33739653	LEMD2	0.3	7.17	0.33	3.35e-12	Plateletcrit;
LUAD	trans	rs57046232	0.552	rs6133307	chr20:6333298	C/T	cg21095983	chr6:86352623	SYNCRIP	0.41	6.36	0.3	5.14e-10	Colorectal cancer;
LUAD	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs4523957	0.671	rs12103726	chr17:2192839	C/T	cg16513277	chr17:2031491	SMG6	-0.69	-10.77	-0.46	4.38e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg02158880	chr13:53174818	NA	0.64	11.24	0.48	7.73e-26	Lewy body disease;
LUAD	trans	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.54	0.3	1.82e-10	Neuroticism;
LUAD	cis	rs3784262	0.527	rs4646557	chr15:58354697	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.47	-0.34	4.77e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs10203711	1.000	rs4994756	chr2:239567125	T/C	cg14580085	chr2:239553406	NA	0.41	8.9	0.4	1.64e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-10.65	-0.46	1.31e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg13319975	chr6:146136371	FBXO30	0.63	10.75	0.46	5.51e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg05283184	chr6:79620031	NA	-0.62	-12.3	-0.51	5.91e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs349045	0.560	rs11083725	chr19:44300576	C/T	cg11993925	chr19:44307056	LYPD5	-0.43	-8.66	-0.39	1.04e-16	Reading or mathematical ability;
LUAD	cis	rs420259	0.516	rs1135045	chr16:23489711	C/G	cg00143387	chr16:23521605	GGA2	-0.73	-10.32	-0.45	1.95e-22	Bipolar disorder;
LUAD	cis	rs9469890	0.604	rs11758471	chr6:34503517	A/C	cg17674042	chr6:34482479	PACSIN1	-0.52	-7.26	-0.33	1.93e-12	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg07570687	chr10:102243282	WNT8B	0.45	6.62	0.31	1.06e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg14343924	chr8:8086146	FLJ10661	0.46	7.4	0.34	7.22e-13	Retinal vascular caliber;
LUAD	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg15962314	chr1:44399869	ARTN	0.34	7.73	0.35	8.15e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg04398451	chr17:18023971	MYO15A	-0.65	-11.76	-0.5	7.97e-28	Total body bone mineral density;
LUAD	cis	rs593982	0.920	rs76925283	chr11:65548108	C/T	cg08755490	chr11:65554678	OVOL1	-1.33	-15.35	-0.6	1.37e-42	Atopic dermatitis;
LUAD	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg02569458	chr12:86230093	RASSF9	0.44	8.02	0.36	1.06e-14	Major depressive disorder;
LUAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg11905131	chr22:24372483	LOC391322	-0.56	-9.64	-0.42	5.26e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg19413350	chr8:57351067	NA	-0.41	-6.49	-0.3	2.43e-10	Obesity-related traits;
LUAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg04025307	chr7:1156635	C7orf50	0.56	7.03	0.32	8.54e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs300703	0.654	rs435733	chr2:121222	A/G	cg21211680	chr2:198530	NA	-0.62	-7.96	-0.36	1.6e-14	Blood protein levels;
LUAD	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.39	-0.34	7.8e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2279817	0.954	rs12143113	chr1:18018857	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.57	8.83	0.39	2.81e-17	Neuroticism;
LUAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg12143784	chr7:64541923	NA	-0.44	-7.27	-0.33	1.77e-12	Calcium levels;
LUAD	cis	rs2294693	0.530	rs9381037	chr6:41073638	G/A	cg14769373	chr6:40998127	UNC5CL	-0.6	-8.4	-0.38	6.76e-16	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9473147	0.571	rs9463335	chr6:47479136	G/A	cg20196966	chr6:47445060	CD2AP	0.44	6.83	0.32	3e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg26384229	chr12:38710491	ALG10B	0.51	8.03	0.36	9.76e-15	Bladder cancer;
LUAD	cis	rs3806843	0.576	rs155358	chr5:140297032	A/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.46	-0.3	2.83e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg10518543	chr12:38710700	ALG10B	-0.44	-7.42	-0.34	6.47e-13	Morning vs. evening chronotype;
LUAD	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-8.02	-0.36	1.06e-14	Bipolar disorder;
LUAD	cis	rs4285028	0.696	rs3915060	chr3:121712980	C/T	cg11130432	chr3:121712080	ILDR1	0.57	8.6	0.39	1.62e-16	Multiple sclerosis;
LUAD	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg13902645	chr11:5959945	NA	-0.47	-8.36	-0.38	9.08e-16	DNA methylation (variation);
LUAD	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg02993280	chr1:107599747	PRMT6	0.53	8.66	0.39	1e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs733592	0.560	rs61918773	chr12:48421774	G/A	cg24011408	chr12:48396354	COL2A1	-0.43	-9.11	-0.41	3.24e-18	Plateletcrit;
LUAD	cis	rs1160297	0.609	rs6715847	chr2:53097378	T/G	cg07782112	chr2:53107842	NA	0.37	8.03	0.36	9.56e-15	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs755249	0.529	rs604316	chr1:39879366	T/C	cg27567593	chr1:39956653	BMP8A	-0.35	-7.1	-0.33	5.16e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2230307	0.505	rs571579	chr1:100617372	G/A	cg20868668	chr1:100435035	SLC35A3	-0.5	-7.66	-0.35	1.29e-13	Carotid intima media thickness;
LUAD	cis	rs62400317	0.859	rs72858517	chr6:45223467	A/C	cg20913747	chr6:44695427	NA	-0.4	-6.44	-0.3	3.28e-10	Total body bone mineral density;
LUAD	cis	rs2447097	0.935	rs2447095	chr17:2293420	A/G	cg02569219	chr17:2266849	SGSM2	0.45	8.09	0.37	6.28e-15	Autism spectrum disorder;
LUAD	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg10518543	chr12:38710700	ALG10B	0.44	7.52	0.34	3.32e-13	Heart rate;
LUAD	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg19622623	chr12:86230825	RASSF9	0.37	6.89	0.32	2.04e-11	Major depressive disorder;
LUAD	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg01416388	chr22:39784598	NA	-0.49	-7.58	-0.35	2.22e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs2070677	1.000	rs12263487	chr10:135403585	A/G	cg20169779	chr10:135381914	SYCE1	-0.51	-8.34	-0.38	1.02e-15	Gout;
LUAD	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg22823121	chr1:150693482	HORMAD1	-0.35	-6.8	-0.31	3.53e-11	Tonsillectomy;
LUAD	cis	rs1983170	0.935	rs578155	chr1:91976541	G/A	cg02896835	chr1:92012615	NA	-0.53	-8.23	-0.37	2.26e-15	Eosinophil percentage of white cells;
LUAD	cis	rs1595825	0.891	rs73054825	chr2:198636355	G/C	cg00361562	chr2:198649771	BOLL	-0.46	-6.53	-0.3	1.93e-10	Ulcerative colitis;
LUAD	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg25767906	chr1:53392781	SCP2	0.41	7.43	0.34	5.93e-13	Monocyte count;
LUAD	cis	rs7737355	0.947	rs6596029	chr5:130899079	T/C	cg25547332	chr5:131281432	NA	0.43	6.41	0.3	3.86e-10	Life satisfaction;
LUAD	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg00383909	chr3:49044727	WDR6	0.75	8.6	0.39	1.52e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.54	-0.46	3.26e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg03433033	chr1:76189801	ACADM	-0.7	-11.14	-0.48	1.82e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs193541	0.632	rs154512	chr5:122195040	T/C	cg19077854	chr5:122220652	SNX24	0.35	6.36	0.3	5.13e-10	Glucose homeostasis traits;
LUAD	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg03806693	chr22:41940476	POLR3H	-0.45	-6.92	-0.32	1.66e-11	Neuroticism;
LUAD	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	8.03	0.36	9.83e-15	Breast cancer;
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	ch.5.87268879R	chr5:87233123	NA	-0.45	-6.59	-0.31	1.35e-10	Hepatitis;
LUAD	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg00717180	chr2:96193071	NA	0.37	6.69	0.31	7.2e-11	Coronary artery disease;
LUAD	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg19635926	chr16:89946313	TCF25	0.74	6.53	0.3	1.91e-10	Skin colour saturation;
LUAD	cis	rs4711350	0.765	rs6921772	chr6:33749686	A/G	cg18005901	chr6:33739558	LEMD2	-0.59	-9.48	-0.42	1.8e-19	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08280861	chr8:58055591	NA	0.63	8.18	0.37	3.38e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10150615	chr22:24372951	LOC391322	-0.56	-9.17	-0.41	2.03e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-10.02	-0.44	2.37e-21	Gut microbiome composition (summer);
LUAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg11494091	chr17:61959527	GH2	0.74	18.45	0.67	3.25e-56	Prudent dietary pattern;
LUAD	cis	rs2637266	0.935	rs2583052	chr10:78403288	C/G	cg18941641	chr10:78392320	NA	0.34	7.04	0.32	7.75e-12	Pulmonary function;
LUAD	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.74	13.57	0.55	4.45e-35	Axial length;
LUAD	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg17346650	chr17:80929145	B3GNTL1	0.41	7.62	0.35	1.66e-13	Glycated hemoglobin levels;
LUAD	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg08470875	chr2:26401718	FAM59B	-0.67	-8.95	-0.4	1.1e-17	Gut microbiome composition (summer);
LUAD	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg19193384	chr17:30244184	NA	-0.5	-6.36	-0.3	5.31e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg20607798	chr8:58055168	NA	0.67	8.77	0.39	4.44e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg17366294	chr4:99064904	C4orf37	0.53	9.77	0.43	1.77e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg02551604	chr5:131831745	NA	-0.61	-10.08	-0.44	1.46e-21	Asthma (sex interaction);
LUAD	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.56	-0.34	2.54e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs2580764	0.540	rs2920893	chr2:55270629	C/T	cg09592903	chr2:55203963	RTN4	0.45	10.03	0.44	2.17e-21	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg07917127	chr4:99064746	C4orf37	0.39	6.36	0.3	5.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.744	rs4253760	chr22:46622384	T/G	cg09491104	chr22:46646882	C22orf40	-0.59	-11.43	-0.49	1.47e-26	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg27454412	chr7:1067447	C7orf50	-0.33	-6.54	-0.3	1.79e-10	Bronchopulmonary dysplasia;
LUAD	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg01516881	chr6:292596	DUSP22	-0.55	-9.06	-0.4	4.89e-18	Menopause (age at onset);
LUAD	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg22535103	chr8:58192502	C8orf71	-0.77	-10.85	-0.47	2.3e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg02896835	chr1:92012615	NA	-0.58	-12.05	-0.51	6.16e-29	Breast cancer;
LUAD	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg03806693	chr22:41940476	POLR3H	0.66	9.94	0.44	4.64e-21	Vitiligo;
LUAD	cis	rs7010267	0.935	rs6469789	chr8:119960661	C/G	cg01975934	chr8:119970761	NA	-0.4	-7.57	-0.35	2.29e-13	Total body bone mineral density (age 45-60);
LUAD	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg20607798	chr8:58055168	NA	0.57	7.65	0.35	1.33e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs11255291	1.000	rs10905218	chr10:7733898	C/T	cg13340899	chr10:7670827	ITIH5	0.42	7.12	0.33	4.81e-12	Ovarian reserve;
LUAD	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg24818145	chr4:99064322	C4orf37	0.43	7.18	0.33	3.22e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg13813247	chr22:41461852	NA	-0.49	-7.88	-0.36	2.9e-14	Neuroticism;
LUAD	cis	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg27411982	chr8:10470053	RP1L1	-0.4	-7.25	-0.33	1.99e-12	Triglycerides;
LUAD	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg25894440	chr7:65020034	NA	0.68	7.06	0.32	6.67e-12	Diabetic kidney disease;
LUAD	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg15790184	chr11:494944	RNH1	0.56	6.76	0.31	4.68e-11	Body mass index;
LUAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.49	6.96	0.32	1.32e-11	Renal function-related traits (BUN);
LUAD	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg23029597	chr12:123009494	RSRC2	-0.58	-9.39	-0.42	3.85e-19	Body mass index;
LUAD	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg06636001	chr8:8085503	FLJ10661	0.4	6.38	0.3	4.72e-10	Joint mobility (Beighton score);
LUAD	cis	rs28595532	1.000	rs56225646	chr4:119651217	T/C	cg14228332	chr4:119757509	SEC24D	0.78	7.21	0.33	2.55e-12	Cannabis dependence symptom count;
LUAD	cis	rs7814319	1.000	rs2643338	chr8:97247469	A/G	cg20787634	chr8:97240163	UQCRB	-0.35	-6.64	-0.31	9.93e-11	Lung function (FVC);
LUAD	cis	rs244899	0.967	rs2432642	chr5:167921047	C/G	cg06604206	chr5:167912465	RARS	-0.42	-7.22	-0.33	2.44e-12	Response to platinum-based chemotherapy (carboplatin);
LUAD	cis	rs909002	0.925	rs4949455	chr1:32114793	C/T	cg13919466	chr1:32135498	COL16A1	-0.34	-8.06	-0.36	7.91e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs2735413	0.846	rs12923626	chr16:78080139	A/C	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.82e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg26875233	chr11:93583750	C11orf90	-0.39	-8.86	-0.4	2.23e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs727505	1.000	rs68091803	chr7:124526331	C/T	cg23710748	chr7:124431027	NA	-0.49	-9.82	-0.43	1.18e-20	Lewy body disease;
LUAD	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg27490568	chr2:178487706	NA	0.4	6.47	0.3	2.71e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18876405	chr7:65276391	NA	-0.41	-6.5	-0.3	2.24e-10	Aortic root size;
LUAD	cis	rs6499255	0.951	rs3169315	chr16:69720964	G/A	cg00738113	chr16:70207722	CLEC18C	-0.38	-6.45	-0.3	3.13e-10	IgE levels;
LUAD	cis	rs6696239	0.513	rs2935155	chr1:227773006	C/A	cg12133451	chr1:227746453	NA	0.36	6.54	0.3	1.78e-10	Height;
LUAD	cis	rs6028335	0.577	rs16987738	chr20:37625015	G/T	cg27660920	chr20:37554817	FAM83D	-0.52	-6.75	-0.31	4.97e-11	Alcohol and nicotine co-dependence;
LUAD	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg21798802	chr22:38057573	PDXP	0.47	9.47	0.42	2.07e-19	Fat distribution (HIV);
LUAD	cis	rs17102423	0.602	rs1270073	chr14:65566257	C/A	cg11161011	chr14:65562177	MAX	-0.46	-7.8	-0.35	4.79e-14	Obesity-related traits;
LUAD	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg05182265	chr7:156933206	UBE3C	-0.77	-16.2	-0.62	2.92e-46	Body mass index;
LUAD	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg06873352	chr17:61820015	STRADA	0.42	7.04	0.32	8.02e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg12140854	chr5:148520817	ABLIM3	-0.67	-10.69	-0.46	9.25e-24	Breast cancer;
LUAD	trans	rs2395128	0.510	rs55850531	chr10:76825634	A/T	cg02972559	chr1:45454343	NA	-0.78	-6.42	-0.3	3.61e-10	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg25703541	chr22:24373054	LOC391322	0.89	17.38	0.65	1.83e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg03609598	chr5:56110824	MAP3K1	-0.46	-6.75	-0.31	4.92e-11	Initial pursuit acceleration;
LUAD	cis	rs1692580	0.682	rs12045693	chr1:2205581	A/C	cg21194808	chr1:2205498	SKI	-0.46	-8.2	-0.37	2.85e-15	Coronary artery disease;
LUAD	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	12.73	0.53	1.19e-31	Monocyte percentage of white cells;
LUAD	cis	rs72772090	0.539	rs10515249	chr5:96125259	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-7.02	-0.32	8.82e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs62400317	0.859	rs12205523	chr6:45296618	T/C	cg18551225	chr6:44695536	NA	-0.55	-8.72	-0.39	6.54e-17	Total body bone mineral density;
LUAD	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.55	9.05	0.4	5.12e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7000551	0.751	rs2469768	chr8:22381362	G/A	cg12081754	chr8:22256438	SLC39A14	0.47	7.79	0.35	5.24e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9486719	0.948	rs12203657	chr6:96883285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-9.99	-0.44	2.95e-21	Migraine;Coronary artery disease;
LUAD	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.49	-0.34	3.97e-13	Neutrophil percentage of white cells;
LUAD	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.42	2.49e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg22907277	chr7:1156413	C7orf50	0.68	8.0	0.36	1.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3936840	0.539	rs3742441	chr14:102970581	C/G	cg18135206	chr14:102964638	TECPR2	0.47	6.57	0.3	1.49e-10	Plateletcrit;
LUAD	trans	rs11039798	1.000	rs11530232	chr11:48622376	C/T	cg03929089	chr4:120376271	NA	0.64	6.44	0.3	3.19e-10	Axial length;
LUAD	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg13770153	chr20:60521292	NA	-0.46	-7.81	-0.36	4.42e-14	Body mass index;
LUAD	cis	rs2274273	0.588	rs17675223	chr14:55862236	G/A	cg04306507	chr14:55594613	LGALS3	0.4	7.68	0.35	1.13e-13	Protein biomarker;
LUAD	trans	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg01620082	chr3:125678407	NA	-0.71	-7.31	-0.33	1.38e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs8067545	0.750	rs11871651	chr17:19997425	T/C	cg04132472	chr17:19861366	AKAP10	0.28	6.64	0.31	9.38e-11	Schizophrenia;
LUAD	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg18569988	chr3:195679450	NA	0.4	6.39	0.3	4.3e-10	Pancreatic cancer;
LUAD	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg24558204	chr6:135376177	HBS1L	0.47	8.67	0.39	9.21e-17	Red blood cell count;
LUAD	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg18446336	chr7:2847575	GNA12	-0.38	-7.34	-0.34	1.08e-12	Height;
LUAD	cis	rs2046867	0.818	rs67355490	chr3:72830935	T/C	cg25664220	chr3:72788482	NA	-0.7	-12.36	-0.52	3.61e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg11266682	chr4:10021025	SLC2A9	-0.58	-12.5	-0.52	1.01e-30	Bone mineral density;
LUAD	cis	rs8177876	0.822	rs4324141	chr16:81114825	A/G	cg08591886	chr16:81111003	C16orf46	0.69	6.48	0.3	2.5e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg18944383	chr4:111397179	ENPEP	0.38	7.66	0.35	1.31e-13	Height;
LUAD	cis	rs908922	0.651	rs4845442	chr1:152485545	G/A	cg23254163	chr1:152506842	NA	0.26	7.14	0.33	4.2e-12	Hair morphology;
LUAD	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg26354017	chr1:205819088	PM20D1	-0.52	-7.97	-0.36	1.46e-14	Menarche (age at onset);
LUAD	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg10556349	chr10:835070	NA	0.68	7.97	0.36	1.45e-14	Eosinophil percentage of granulocytes;
LUAD	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg05665937	chr4:1216051	CTBP1	0.47	7.33	0.34	1.16e-12	Longevity;
LUAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg01448562	chr3:133502909	NA	-0.78	-15.72	-0.61	3.63e-44	Iron status biomarkers;
LUAD	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg19193384	chr17:30244184	NA	-0.53	-6.38	-0.3	4.77e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs9814567	0.752	rs13075253	chr3:134329600	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	13.93	0.56	1.38e-36	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7274811	0.652	rs291694	chr20:32000351	A/G	cg14921437	chr20:32255988	NECAB3;C20orf134	0.44	6.63	0.31	1.02e-10	Height;
LUAD	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg13319975	chr6:146136371	FBXO30	0.66	11.4	0.48	2.02e-26	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg18944383	chr4:111397179	ENPEP	0.38	7.6	0.35	1.95e-13	Height;
LUAD	cis	rs12541635	0.677	rs2029879	chr8:107024695	T/A	cg10147462	chr8:107024639	NA	0.56	10.26	0.45	3.35e-22	Age of smoking initiation;
LUAD	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg18240062	chr17:79603768	NPLOC4	0.36	6.35	0.3	5.42e-10	Eye color traits;
LUAD	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg13385794	chr1:248469461	NA	0.26	6.97	0.32	1.23e-11	Common traits (Other);
LUAD	cis	rs7493	0.851	rs11770903	chr7:95026327	A/G	cg19678392	chr7:94953810	PON1	-0.6	-8.47	-0.38	4.08e-16	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg06558623	chr16:89946397	TCF25	1.11	12.32	0.51	5.11e-30	Skin colour saturation;
LUAD	cis	rs4846217	0.920	rs6702280	chr1:10280774	G/A	cg17425144	chr1:10567563	PEX14	-0.54	-7.07	-0.33	6.52e-12	Platelet count;
LUAD	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13732083	chr21:47605072	C21orf56	0.57	9.79	0.43	1.54e-20	Testicular germ cell tumor;
LUAD	cis	rs2692947	0.702	rs4907291	chr2:96654605	T/G	cg23100626	chr2:96804247	ASTL	0.29	7.59	0.35	2.13e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg07570687	chr10:102243282	WNT8B	0.42	6.38	0.3	4.69e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs4660214	0.666	rs663449	chr1:39843958	G/A	cg27567593	chr1:39956653	BMP8A	-0.36	-7.31	-0.34	1.31e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05901451	chr6:126070800	HEY2	-0.44	-6.7	-0.31	6.73e-11	Endometrial cancer;
LUAD	cis	rs1371867	0.810	rs2919470	chr8:101233301	C/A	cg06002616	chr8:101225028	SPAG1	0.44	8.82	0.39	2.97e-17	Atrioventricular conduction;
LUAD	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg06640241	chr16:89574553	SPG7	0.68	12.02	0.5	7.65e-29	Multiple myeloma (IgH translocation);
LUAD	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg14779329	chr11:130786720	SNX19	0.39	6.83	0.32	2.93e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.53	-10.98	-0.47	7.37e-25	Monocyte percentage of white cells;
LUAD	cis	rs7903847	0.642	rs6584127	chr10:99142948	A/C	cg20016023	chr10:99160130	RRP12	-0.3	-7.12	-0.33	4.78e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg13390004	chr1:15929781	NA	0.5	8.89	0.4	1.72e-17	Systolic blood pressure;
LUAD	cis	rs67385638	1.000	rs2855039	chr11:5271671	C/T	cg12559170	chr11:5275217	HBG2	0.32	6.39	0.3	4.34e-10	Hemoglobin levels;
LUAD	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg05182265	chr7:156933206	UBE3C	-0.78	-16.74	-0.63	1.23e-48	Body mass index;
LUAD	cis	rs2985684	0.894	rs6572585	chr14:50021075	A/G	cg04989706	chr14:50066350	PPIL5	-0.5	-7.52	-0.34	3.31e-13	Carotid intima media thickness;
LUAD	cis	rs4343996	0.902	rs4349886	chr7:3370038	C/T	cg21248987	chr7:3385318	SDK1	-0.34	-6.41	-0.3	3.85e-10	Motion sickness;
LUAD	cis	rs3820068	0.871	rs76155024	chr1:15807142	T/C	cg24675056	chr1:15929824	NA	0.44	6.62	0.31	1.12e-10	Systolic blood pressure;
LUAD	cis	rs68170813	0.559	rs7794598	chr7:106826381	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.79	-0.46	3.92e-24	Coronary artery disease;
LUAD	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.96	-23.28	-0.75	9.05e-78	Birth weight;
LUAD	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08109568	chr15:31115862	NA	0.53	9.48	0.42	1.92e-19	Huntington's disease progression;
LUAD	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.76	-0.31	4.74e-11	Diabetic kidney disease;
LUAD	cis	rs2637266	1.000	rs7897348	chr10:78359620	G/A	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.91e-11	Pulmonary function;
LUAD	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg05340658	chr4:99064831	C4orf37	-0.46	-7.62	-0.35	1.63e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs11039798	1.000	rs11039798	chr11:48540223	G/A	cg15704280	chr7:45808275	SEPT13	0.73	7.32	0.34	1.23e-12	Axial length;
LUAD	cis	rs438465	1.000	rs407690	chr6:169826531	A/C	cg11181693	chr6:169825345	NA	-0.64	-8.14	-0.37	4.44e-15	Corneal astigmatism;
LUAD	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.93	13.29	0.54	6.52e-34	Smoking behavior;
LUAD	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06028808	chr11:68637592	NA	0.51	8.57	0.38	2.03e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.41	0.42	3.12e-19	Mean corpuscular volume;
LUAD	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg22166914	chr1:53195759	ZYG11B	0.42	6.84	0.32	2.84e-11	Monocyte count;
LUAD	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg01579765	chr21:45077557	HSF2BP	-0.56	-12.65	-0.52	2.56e-31	Mean corpuscular volume;
LUAD	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg27286337	chr10:134555280	INPP5A	0.69	9.84	0.43	1.03e-20	Migraine;
LUAD	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg09658497	chr7:2847517	GNA12	-0.45	-8.29	-0.37	1.51e-15	Height;
LUAD	cis	rs1829883	0.898	rs13184400	chr5:98784722	G/A	cg08333243	chr5:99726346	NA	-0.36	-6.87	-0.32	2.31e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs4664304	0.802	rs3749114	chr2:160832996	A/T	cg23995753	chr2:160760732	LY75	-0.45	-7.56	-0.34	2.56e-13	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg07256732	chr16:621771	PIGQ	-0.32	-6.5	-0.3	2.31e-10	Height;
LUAD	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg14345882	chr6:26364793	BTN3A2	0.64	6.44	0.3	3.32e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg18305652	chr10:134549665	INPP5A	0.59	12.44	0.52	1.71e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg00316803	chr15:76480434	C15orf27	-0.42	-8.04	-0.36	9.38e-15	Blood metabolite levels;
LUAD	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22496380	chr5:211416	CCDC127	0.88	12.54	0.52	7.14e-31	Breast cancer;
LUAD	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs11214589	0.905	rs12805699	chr11:113241810	T/A	cg14159747	chr11:113255604	NA	0.67	14.44	0.57	1.01e-38	Neuroticism;
LUAD	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg13126279	chr21:47581558	C21orf56	-0.44	-7.54	-0.34	2.9e-13	Testicular germ cell tumor;
LUAD	cis	rs7010267	0.805	rs2062375	chr8:119977792	G/C	cg01975934	chr8:119970761	NA	-0.38	-7.28	-0.33	1.63e-12	Total body bone mineral density (age 45-60);
LUAD	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg14196790	chr5:131705035	SLC22A5	-0.48	-8.51	-0.38	3e-16	Breast cancer;Mosquito bite size;
LUAD	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.82	0.36	4.37e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg02423579	chr7:2872169	GNA12	-0.59	-9.71	-0.43	3.06e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	trans	rs225245	0.817	rs12150359	chr17:34024584	C/T	cg19694781	chr19:47549865	TMEM160	-0.47	-7.8	-0.35	4.73e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	trans	rs1493916	0.905	rs34165207	chr18:31400153	G/A	cg15819921	chr19:927150	ARID3A	-0.44	-7.07	-0.33	6.54e-12	Life satisfaction;
LUAD	trans	rs4650994	0.571	rs6425486	chr1:178528822	G/A	cg05059571	chr16:84539110	KIAA1609	0.41	6.44	0.3	3.16e-10	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs11229555	0.645	rs11229435	chr11:58185796	G/C	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg22906224	chr7:99728672	NA	-0.62	-10.97	-0.47	8.2e-25	Coronary artery disease;
LUAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg11766577	chr21:47581405	C21orf56	-0.56	-9.46	-0.42	2.21e-19	Testicular germ cell tumor;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg02985366	chr16:32360428	NA	-0.41	-7.05	-0.32	7.37e-12	Menopause (age at onset);
LUAD	cis	rs10465746	0.780	rs1871924	chr1:84398466	T/A	cg10977910	chr1:84465055	TTLL7	0.6	9.87	0.43	8.39e-21	Obesity-related traits;
LUAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg15147215	chr3:52552868	STAB1	-0.52	-10.1	-0.44	1.24e-21	Electroencephalogram traits;
LUAD	cis	rs6867032	0.687	rs4998338	chr5:2015910	A/G	cg26168224	chr5:2018326	NA	0.8	18.39	0.67	6.2e-56	Gut microbiome composition (winter);
LUAD	cis	rs367943	0.608	rs6594744	chr5:112990207	T/C	cg12552261	chr5:112820674	MCC	0.42	7.58	0.35	2.16e-13	Type 2 diabetes;
LUAD	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.66	-0.39	9.7e-17	Total body bone mineral density;
LUAD	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg00666640	chr1:248458726	OR2T12	0.32	7.88	0.36	2.71e-14	Common traits (Other);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg12508214	chr8:124553600	FBXO32	-0.63	-6.39	-0.3	4.43e-10	Type 2 diabetes;
LUAD	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.09	0.33	5.75e-12	Menopause (age at onset);
LUAD	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg26924012	chr15:45694286	SPATA5L1	1.02	18.96	0.68	1.76e-58	Homoarginine levels;
LUAD	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg17264618	chr3:40429014	ENTPD3	-0.33	-7.11	-0.33	4.99e-12	Renal cell carcinoma;
LUAD	cis	rs2742234	0.541	rs10793424	chr10:43717116	G/T	cg15436174	chr10:43711423	RASGEF1A	0.55	9.02	0.4	6.55e-18	Hirschsprung disease;
LUAD	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg20933634	chr6:27740509	NA	0.52	8.21	0.37	2.73e-15	Parkinson's disease;
LUAD	cis	rs938554	0.779	rs13106991	chr4:9959011	G/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.04	-0.32	7.69e-12	Blood metabolite levels;
LUAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg22963979	chr7:1858916	MAD1L1	0.58	10.17	0.44	6.91e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg11494091	chr17:61959527	GH2	0.4	7.07	0.33	6.35e-12	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03360920	chr6:159421029	RSPH3	-0.62	-7.66	-0.35	1.32e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3813948	0.818	rs12065624	chr1:207280739	A/T	cg11153969	chr1:207277031	C4BPA	-0.64	-6.87	-0.32	2.3e-11	C4b binding protein levels;
LUAD	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg09323728	chr8:95962352	TP53INP1	-0.35	-8.46	-0.38	4.46e-16	Type 2 diabetes;
LUAD	trans	rs2735413	0.752	rs11642442	chr16:78080800	A/C	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs16910800	0.731	rs56067480	chr11:23190184	C/T	cg20040320	chr11:23191996	NA	-0.74	-9.84	-0.43	1.03e-20	Cancer;
LUAD	trans	rs4650994	0.544	rs4075631	chr1:178506594	C/A	cg05059571	chr16:84539110	KIAA1609	-0.73	-13.31	-0.54	5.41e-34	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.04	-0.32	8.05e-12	Mood instability;
LUAD	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg01119278	chr6:110721349	DDO	0.47	8.84	0.4	2.51e-17	Platelet distribution width;
LUAD	cis	rs977987	0.843	rs2059256	chr16:75395835	G/T	cg03315344	chr16:75512273	CHST6	0.64	13.91	0.56	1.79e-36	Dupuytren's disease;
LUAD	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.04	0.32	7.98e-12	Colorectal cancer;
LUAD	cis	rs11048434	0.736	rs56130437	chr12:9093001	G/A	cg23795048	chr12:9217529	LOC144571	0.41	7.47	0.34	4.58e-13	Sjögren's syndrome;
LUAD	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg13180566	chr4:1052158	NA	-0.39	-6.44	-0.3	3.24e-10	Recombination rate (females);
LUAD	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg02782426	chr3:40428986	ENTPD3	-0.35	-7.75	-0.35	7.09e-14	Renal cell carcinoma;
LUAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11905131	chr22:24372483	LOC391322	-0.57	-9.65	-0.42	4.94e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs58106596	0.747	rs10166046	chr2:232560984	C/T	cg01370599	chr3:116745421	NA	-0.59	-8.74	-0.39	5.49e-17	White blood cell count;Lymphocyte counts;
LUAD	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.48	7.75	0.35	7.06e-14	Personality dimensions;
LUAD	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg12011299	chr4:100065546	ADH4	0.69	12.52	0.52	7.91e-31	Smoking initiation;
LUAD	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg15556689	chr8:8085844	FLJ10661	0.4	6.73	0.31	5.67e-11	Systolic blood pressure;
LUAD	cis	rs68170813	0.559	rs7794965	chr7:106826439	A/G	cg23024343	chr7:107201750	COG5	-0.46	-6.84	-0.32	2.73e-11	Coronary artery disease;
LUAD	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg19077165	chr18:44547161	KATNAL2	-0.4	-6.5	-0.3	2.24e-10	Personality dimensions;
LUAD	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.23	0.48	8.73e-26	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6499255	0.762	rs12325186	chr16:69658807	A/T	cg15192750	chr16:69999425	NA	0.52	7.94	0.36	1.82e-14	IgE levels;
LUAD	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg00647820	chr17:40259828	DHX58	-0.43	-6.72	-0.31	5.98e-11	Fibrinogen levels;
LUAD	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg10589385	chr1:150898437	SETDB1	0.43	8.23	0.37	2.32e-15	Melanoma;
LUAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg10729496	chr3:10149963	C3orf24	0.58	9.43	0.42	2.76e-19	Alzheimer's disease;
LUAD	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg18944383	chr4:111397179	ENPEP	0.42	8.22	0.37	2.45e-15	Height;
LUAD	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.62	0.31	1.09e-10	Cardiac Troponin-T levels;
LUAD	trans	rs9393777	0.668	rs16897515	chr6:27278020	A/C	cg06606381	chr12:133084897	FBRSL1	0.5	6.57	0.3	1.5e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11644478	chr21:40555479	PSMG1	0.69	11.42	0.49	1.63e-26	Cognitive function;
LUAD	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg12667521	chr19:29218732	NA	0.64	7.94	0.36	1.79e-14	Methadone dose in opioid dependence;
LUAD	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	10.4	0.45	1.03e-22	Electrocardiographic conduction measures;
LUAD	cis	rs7809950	1.000	rs7778270	chr7:107224667	A/G	cg23024343	chr7:107201750	COG5	0.71	11.88	0.5	2.77e-28	Coronary artery disease;
LUAD	cis	rs1697139	1.000	rs1697139	chr5:66511535	A/G	cg16691251	chr5:66510806	NA	0.35	6.54	0.3	1.79e-10	Breast cancer;
LUAD	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.51	-0.3	2.17e-10	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.92	0.47	1.29e-24	Mean corpuscular volume;
LUAD	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.45	-6.94	-0.32	1.49e-11	Menarche (age at onset);
LUAD	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg20119798	chr7:94954144	PON1	-0.47	-6.43	-0.3	3.47e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2041840	0.538	rs3770755	chr2:37574134	G/C	cg25727520	chr2:37576821	QPCT	-0.33	-7.16	-0.33	3.63e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.4	-0.34	7.28e-13	Lung cancer;
LUAD	trans	rs9354308	0.868	rs2351729	chr6:66537291	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.8	-0.31	3.49e-11	Metabolite levels;
LUAD	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg05896524	chr21:47604654	C21orf56	0.53	8.94	0.4	1.22e-17	Testicular germ cell tumor;
LUAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg26338869	chr17:61819248	STRADA	0.39	6.56	0.3	1.62e-10	Prudent dietary pattern;
LUAD	cis	rs1816752	0.905	rs7995909	chr13:25013297	T/C	cg02811702	chr13:24901961	NA	0.45	7.88	0.36	2.72e-14	Obesity-related traits;
LUAD	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg13319975	chr6:146136371	FBXO30	-0.58	-9.73	-0.43	2.48e-20	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg06606381	chr12:133084897	FBRSL1	-0.65	-6.62	-0.31	1.07e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg25809561	chr17:30822961	MYO1D	0.5	9.01	0.4	6.91e-18	Schizophrenia;
LUAD	cis	rs8044868	0.530	rs2550868	chr16:72066072	G/A	cg23815491	chr16:72088622	HP	0.53	9.62	0.42	6.27e-20	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.45	0.3	2.98e-10	Depression;
LUAD	cis	rs10089	0.953	rs10463839	chr5:127519675	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.58	8.09	0.37	6.29e-15	Ileal carcinoids;
LUAD	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg18351406	chr4:77819688	ANKRD56	0.62	10.01	0.44	2.71e-21	Emphysema distribution in smoking;
LUAD	cis	rs4372836	0.964	rs56240884	chr2:28940154	C/T	cg09522027	chr2:28974177	PPP1CB	0.59	8.93	0.4	1.32e-17	Body mass index;
LUAD	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg03433033	chr1:76189801	ACADM	0.78	14.06	0.56	4.19e-37	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs41271951	0.512	rs7537292	chr1:151071038	C/G	cg11822372	chr1:151115635	SEMA6C	-0.82	-6.99	-0.32	1.11e-11	Blood protein levels;
LUAD	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg11062466	chr8:58055876	NA	0.67	8.95	0.4	1.14e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.61	-0.55	2.96e-35	Alcohol dependence;
LUAD	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19346786	chr7:2764209	NA	0.59	13.15	0.54	2.38e-33	Height;
LUAD	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg06552810	chr11:31128660	NA	-0.33	-6.53	-0.3	1.89e-10	Red blood cell count;
LUAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg22907277	chr7:1156413	C7orf50	0.79	12.09	0.51	4.14e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-7.81	-0.35	4.71e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg18230493	chr5:56204884	C5orf35	0.7	11.22	0.48	9.18e-26	Initial pursuit acceleration;
LUAD	trans	rs2980436	1	rs2980436	chr8:8092025	A/G	cg02002194	chr4:3960332	NA	0.32	7.69	0.35	1.02e-13	Schizophrenia;
LUAD	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg05340658	chr4:99064831	C4orf37	0.44	7.35	0.34	1.02e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2985684	1.000	rs2985684	chr14:50101682	C/G	cg04989706	chr14:50066350	PPIL5	-0.47	-6.9	-0.32	1.93e-11	Carotid intima media thickness;
LUAD	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg21854759	chr1:92012499	NA	-0.48	-9.07	-0.4	4.42e-18	Breast cancer;
LUAD	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg15704280	chr7:45808275	SEPT13	-0.76	-11.59	-0.49	3.67e-27	Height;
LUAD	cis	rs7123876	0.587	rs11604034	chr11:72364147	G/C	cg03713592	chr11:72463424	ARAP1	0.53	6.46	0.3	2.85e-10	Body mass index;
LUAD	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.54	-7.98	-0.36	1.38e-14	Gut microbiome composition (summer);
LUAD	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg06697600	chr4:7070879	GRPEL1	0.56	7.85	0.36	3.41e-14	Monocyte percentage of white cells;
LUAD	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg05623727	chr3:50126028	RBM5	-0.3	-6.4	-0.3	4.16e-10	Body mass index;
LUAD	cis	rs4853525	0.522	rs62179715	chr2:191570072	C/T	cg11845111	chr2:191398756	TMEM194B	-0.47	-7.58	-0.35	2.24e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	trans	rs412658	0.776	rs12460025	chr19:22318230	A/G	cg17074339	chr11:11642133	GALNTL4	-0.44	-8.38	-0.38	7.73e-16	Telomere length;
LUAD	cis	rs807669	0.903	rs1780640	chr22:19174597	C/T	cg02655711	chr22:19163373	SLC25A1	0.87	19.14	0.68	2.98e-59	Metabolite levels;
LUAD	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.81	-0.39	3.39e-17	Alcohol dependence;
LUAD	trans	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.06	-0.4	4.77e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs796825	0.530	rs4146300	chr3:120000196	A/G	cg21790991	chr3:120137480	FSTL1	-0.46	-7.83	-0.36	3.89e-14	HIV-1 susceptibility;
LUAD	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg23758822	chr17:41437982	NA	0.99	20.82	0.71	8.69e-67	Menopause (age at onset);
LUAD	cis	rs9837602	1.000	rs10212525	chr3:99713377	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.98	-0.32	1.18e-11	Breast cancer;
LUAD	trans	rs6598955	0.671	rs10902735	chr1:26617936	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-10.12	-0.44	1.08e-21	Obesity-related traits;
LUAD	cis	rs7712401	0.601	rs154496	chr5:122221731	A/G	cg19077854	chr5:122220652	SNX24	0.34	6.41	0.3	3.91e-10	Mean platelet volume;
LUAD	cis	rs3739034	0.697	rs76894945	chr2:135491298	T/G	cg12500956	chr2:135428796	TMEM163	0.38	6.8	0.31	3.63e-11	Gut microbiome composition (winter);
LUAD	trans	rs9354308	0.868	rs6923994	chr6:66555665	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.63	-0.31	1.04e-10	Metabolite levels;
LUAD	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg01119278	chr6:110721349	DDO	-0.44	-7.85	-0.36	3.4e-14	Platelet distribution width;
LUAD	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg09537434	chr19:41945824	ATP5SL	-0.53	-8.44	-0.38	5.05e-16	Height;
LUAD	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.64	-0.31	9.63e-11	Total body bone mineral density;
LUAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-7.98	-0.36	1.39e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.56e-12	Crohn's disease;
LUAD	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg19442545	chr10:75533431	FUT11	-0.51	-8.77	-0.39	4.5e-17	Inflammatory bowel disease;
LUAD	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs599083	0.829	rs314751	chr11:68179560	C/T	cg01657329	chr11:68192670	LRP5	0.49	8.03	0.36	9.59e-15	Bone mineral density (spine);
LUAD	cis	rs2046867	0.862	rs62251653	chr3:72811827	C/T	cg04365224	chr3:72788183	NA	-0.48	-6.97	-0.32	1.19e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg07677032	chr17:61819896	STRADA	0.57	10.53	0.46	3.47e-23	Prudent dietary pattern;
LUAD	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg06627628	chr2:24431161	ITSN2	-0.7	-11.05	-0.47	4.27e-25	Asthma;
LUAD	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg07741184	chr6:167504864	NA	0.31	7.46	0.34	4.81e-13	Crohn's disease;
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg10824722	chr1:206506826	NA	-0.39	-6.46	-0.3	2.96e-10	Height;
LUAD	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg16325326	chr1:53192061	ZYG11B	0.67	12.98	0.53	1.14e-32	Monocyte count;
LUAD	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg07305463	chr2:136567211	LCT	0.4	7.56	0.35	2.52e-13	Mosquito bite size;
LUAD	cis	rs2224391	0.955	rs2773322	chr6:5263065	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-9.49	-0.42	1.71e-19	Height;
LUAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg25703541	chr22:24373054	LOC391322	-0.79	-14.27	-0.57	5.49e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.73	-0.35	7.71e-14	Personality dimensions;
LUAD	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03264133	chr6:25882463	NA	-0.52	-7.62	-0.35	1.73e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4660214	0.666	rs10493087	chr1:39717256	C/G	cg27567593	chr1:39956653	BMP8A	0.34	6.76	0.31	4.6e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg25344623	chr2:136566232	LCT	-0.33	-6.42	-0.3	3.71e-10	Mosquito bite size;
LUAD	cis	rs11811982	0.655	rs78384568	chr1:227448375	A/G	cg24860534	chr1:227506868	CDC42BPA	0.69	7.35	0.34	1.07e-12	Optic disc area;
LUAD	cis	rs10489202	1.000	rs34058770	chr1:168057399	C/A	cg24449463	chr1:168025552	DCAF6	-0.58	-7.08	-0.33	6.03e-12	Schizophrenia;
LUAD	cis	rs10751667	0.661	rs6597946	chr11:1037888	A/G	cg06064525	chr11:970664	AP2A2	-0.47	-7.27	-0.33	1.79e-12	Alzheimer's disease (late onset);
LUAD	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg03959625	chr15:84868606	LOC388152	0.41	6.48	0.3	2.55e-10	Schizophrenia;
LUAD	cis	rs4901869	0.966	rs9972206	chr14:59336095	A/G	cg02291164	chr14:59296302	NA	0.65	16.03	0.61	1.65e-45	Panic disorder;
LUAD	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg05110241	chr16:68378359	PRMT7	-0.7	-7.99	-0.36	1.26e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.0	0.32	1.04e-11	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.13	0.37	4.91e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg02018176	chr4:1364513	KIAA1530	-0.38	-7.26	-0.33	1.85e-12	Obesity-related traits;
LUAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg02869364	chr7:1081709	C7orf50	-0.51	-6.57	-0.3	1.48e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.5	-0.38	3.38e-16	Height;
LUAD	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06544989	chr22:39130855	UNC84B	0.45	9.12	0.41	2.99e-18	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg27454412	chr7:1067447	C7orf50	0.44	7.04	0.32	7.84e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg09491104	chr22:46646882	C22orf40	-0.5	-6.76	-0.31	4.47e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03934478	chr11:495069	RNH1	0.76	9.09	0.4	3.8e-18	Body mass index;
LUAD	cis	rs10992471	0.603	rs6479422	chr9:95190694	G/T	cg14631576	chr9:95140430	CENPP	-0.56	-11.38	-0.48	2.42e-26	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs4356932	1.000	rs4859414	chr4:76949997	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.49	-0.3	2.36e-10	Blood protein levels;
LUAD	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg23625390	chr15:77176239	SCAPER	0.4	6.99	0.32	1.08e-11	Blood metabolite levels;
LUAD	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg22823121	chr1:150693482	HORMAD1	0.43	8.64	0.39	1.13e-16	Urate levels;
LUAD	cis	rs1448094	0.872	rs7975457	chr12:86410404	C/T	cg02569458	chr12:86230093	RASSF9	0.4	7.56	0.35	2.51e-13	Major depressive disorder;
LUAD	trans	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg15704280	chr7:45808275	SEPT13	0.64	7.29	0.33	1.58e-12	Intraocular pressure;
LUAD	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg11707310	chr1:2537719	MMEL1	-0.39	-8.45	-0.38	4.79e-16	Ulcerative colitis;
LUAD	trans	rs629535	0.814	rs56301437	chr8:70108518	C/T	cg21567404	chr3:27674614	NA	-0.97	-17.29	-0.64	4.9e-51	Dupuytren's disease;
LUAD	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg17366294	chr4:99064904	C4orf37	0.48	8.44	0.38	5.12e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg24644049	chr4:85504048	CDS1	0.92	7.91	0.36	2.22e-14	Skin colour saturation;
LUAD	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg17971929	chr21:40555470	PSMG1	0.53	7.97	0.36	1.53e-14	Cognitive function;
LUAD	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.55	0.38	2.34e-16	Menopause (age at onset);
LUAD	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg21475434	chr5:93447410	FAM172A	0.73	8.38	0.38	7.71e-16	Diabetic retinopathy;
LUAD	cis	rs300774	0.764	rs300756	chr2:233416	G/A	cg21211680	chr2:198530	NA	0.63	9.11	0.4	3.34e-18	Suicide attempts in bipolar disorder;
LUAD	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg23283495	chr1:209979779	IRF6	0.73	8.78	0.39	4.03e-17	Coronary artery disease;
LUAD	cis	rs7945705	0.875	rs4929914	chr11:8824388	C/T	cg12365402	chr11:9010492	NRIP3	-0.36	-6.58	-0.3	1.36e-10	Hemoglobin concentration;
LUAD	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.4	6.65	0.31	9.03e-11	Total body bone mineral density;
LUAD	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg18446336	chr7:2847575	GNA12	-0.41	-7.53	-0.34	3.02e-13	Height;
LUAD	trans	rs12048904	0.504	rs6678752	chr1:101286949	G/A	cg14530983	chr3:88190749	ZNF654	0.37	6.35	0.3	5.43e-10	Multiple sclerosis;
LUAD	cis	rs7149337	0.836	rs4901087	chr14:51668499	T/C	cg23942311	chr14:51606299	NA	0.85	19.28	0.68	6.48e-60	Cancer;
LUAD	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg12310025	chr6:25882481	NA	-0.64	-9.34	-0.41	5.67e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg01689657	chr7:91764605	CYP51A1	0.32	8.04	0.36	9.26e-15	Breast cancer;
LUAD	cis	rs10203711	1.000	rs907108	chr2:239566285	T/C	cg14580085	chr2:239553406	NA	0.41	8.8	0.39	3.53e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	trans	rs783540	0.656	rs783538	chr15:83253143	C/G	cg16105309	chr15:79090380	ADAMTS7	0.41	7.49	0.34	4.19e-13	Schizophrenia;
LUAD	cis	rs7017914	0.935	rs6981435	chr8:71637148	T/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg12011299	chr4:100065546	ADH4	0.68	12.17	0.51	2.1e-29	Smoking initiation;
LUAD	trans	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.22	0.37	2.6e-15	Rheumatoid arthritis;
LUAD	cis	rs11723261	0.582	rs4634177	chr4:136837	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.42	7.5	0.34	3.75e-13	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg06873352	chr17:61820015	STRADA	-0.72	-14.94	-0.59	7.93e-41	Prudent dietary pattern;
LUAD	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg20587970	chr11:113659929	NA	-1.2	-17.81	-0.65	2.43e-53	Hip circumference adjusted for BMI;
LUAD	trans	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg14791747	chr16:20752902	THUMPD1	0.73	9.94	0.44	4.73e-21	Cognitive test performance;
LUAD	cis	rs12216545	0.737	rs6962143	chr7:150245934	A/G	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.37	-0.3	4.99e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg03467027	chr4:99064603	C4orf37	0.46	7.32	0.34	1.24e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg01579765	chr21:45077557	HSF2BP	-0.59	-13.61	-0.55	3.17e-35	Mean corpuscular volume;
LUAD	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg00814883	chr7:100076585	TSC22D4	-0.87	-13.12	-0.54	3.02e-33	Platelet count;
LUAD	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.36	7.52	0.34	3.24e-13	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01855760	chr4:68567075	LOC550112;UBA6	-0.45	-7.02	-0.32	8.68e-12	Height;
LUAD	cis	rs7809950	0.599	rs2237658	chr7:106837866	T/G	cg23024343	chr7:107201750	COG5	-0.76	-12.58	-0.52	4.95e-31	Coronary artery disease;
LUAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg15117754	chr3:10150083	C3orf24	-0.42	-6.76	-0.31	4.51e-11	Alzheimer's disease;
LUAD	cis	rs12478296	0.786	rs28802397	chr2:243049730	G/A	cg06360820	chr2:242988706	NA	-0.85	-9.85	-0.43	9.87e-21	Obesity-related traits;
LUAD	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg26384229	chr12:38710491	ALG10B	0.46	7.21	0.33	2.57e-12	Bladder cancer;
LUAD	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg24818145	chr4:99064322	C4orf37	0.48	8.21	0.37	2.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg22117172	chr7:91764530	CYP51A1	-0.31	-6.79	-0.31	3.84e-11	Breast cancer;
LUAD	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.94	0.32	1.51e-11	Depression;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg07661849	chr4:146686236	ZNF827	-0.38	-6.42	-0.3	3.58e-10	Schizophrenia;
LUAD	cis	rs7020830	0.571	rs7031314	chr9:37376122	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.6	-9.65	-0.42	4.83e-20	Schizophrenia;
LUAD	cis	rs8192282	0.739	rs6687112	chr1:154497146	C/T	cg07911225	chr1:154474108	TDRD10;SHE	-0.42	-7.14	-0.33	4.04e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg24818145	chr4:99064322	C4orf37	-0.41	-6.65	-0.31	8.95e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg22166914	chr1:53195759	ZYG11B	-0.4	-6.56	-0.3	1.55e-10	Monocyte count;
LUAD	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg05368731	chr17:41323189	NBR1	0.97	19.8	0.69	3.12e-62	Menopause (age at onset);
LUAD	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg02527881	chr3:46936655	PTH1R	-0.66	-14.69	-0.58	9.46e-40	Birth weight;
LUAD	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg18404041	chr3:52824283	ITIH1	-0.41	-7.59	-0.35	2.11e-13	Electroencephalogram traits;
LUAD	cis	rs8130944	0.866	rs1878070	chr21:44123705	A/G	cg16784985	chr21:44105474	PDE9A	-0.38	-6.4	-0.3	4.16e-10	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg27490568	chr2:178487706	NA	0.57	8.56	0.38	2.05e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.75	-0.5	8.51e-28	Mean corpuscular volume;
LUAD	cis	rs9972944	0.729	rs7502798	chr17:63781615	C/T	cg07283582	chr17:63770753	CCDC46	0.48	10.49	0.45	4.8e-23	Total body bone mineral density;
LUAD	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg05182265	chr7:156933206	UBE3C	-0.8	-17.28	-0.64	5.27e-51	Body mass index;
LUAD	cis	rs7180079	1.000	rs12101870	chr15:64526817	A/G	cg08069370	chr15:64387884	SNX1	-0.52	-6.65	-0.31	9.12e-11	Monocyte count;
LUAD	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg14584255	chr6:163149320	PACRG;PARK2	-0.35	-6.94	-0.32	1.45e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg23950597	chr19:37808831	NA	-0.63	-7.45	-0.34	5.28e-13	Coronary artery calcification;
LUAD	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Parkinson's disease;
LUAD	cis	rs12760731	0.720	rs10913535	chr1:178302914	C/A	cg00404053	chr1:178313656	RASAL2	0.65	8.47	0.38	4.11e-16	Obesity-related traits;
LUAD	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.86	12.37	0.52	3.34e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs644148	0.836	rs2686777	chr19:45000386	T/C	cg15540054	chr19:45004280	ZNF180	-0.4	-6.4	-0.3	4.18e-10	Personality dimensions;
LUAD	cis	rs1595825	0.735	rs2164327	chr2:198726773	C/T	cg11031976	chr2:198649780	BOLL	-0.48	-7.25	-0.33	2.03e-12	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	8.93e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg02734326	chr4:10020555	SLC2A9	0.6	10.52	0.46	3.69e-23	Bone mineral density;
LUAD	cis	rs2230307	0.536	rs57637634	chr1:100447467	G/A	cg20868668	chr1:100435035	SLC35A3	0.53	7.87	0.36	3.02e-14	Carotid intima media thickness;
LUAD	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg25985355	chr7:65971099	NA	-0.39	-7.11	-0.33	4.92e-12	Aortic root size;
LUAD	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg00280220	chr17:61926910	NA	0.36	6.97	0.32	1.26e-11	Prudent dietary pattern;
LUAD	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg04545296	chr12:48745243	ZNF641	0.39	10.07	0.44	1.64e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg11344533	chr11:111475393	SIK2	-0.34	-6.47	-0.3	2.68e-10	Primary sclerosing cholangitis;
LUAD	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg27284194	chr4:1044797	NA	0.7	10.12	0.44	1.05e-21	Recombination rate (females);
LUAD	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg00071950	chr4:10020882	SLC2A9	-0.58	-10.51	-0.46	4.11e-23	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg06609049	chr19:2785107	THOP1	0.68	11.28	0.48	5.45e-26	Total cholesterol levels;
LUAD	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg25036284	chr2:26402008	FAM59B	0.64	8.22	0.37	2.48e-15	Gut microbiome composition (summer);
LUAD	cis	rs939658	0.805	rs8024813	chr15:79427260	A/G	cg17916960	chr15:79447300	NA	-0.51	-10.74	-0.46	6.02e-24	Refractive error;
LUAD	cis	rs10504073	0.669	rs341799	chr8:50036574	A/G	cg00325661	chr8:49890786	NA	0.4	9.18	0.41	1.9e-18	Blood metabolite ratios;
LUAD	cis	rs12042938	0.507	rs2570408	chr1:231732934	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.41	-7.37	-0.34	8.82e-13	Neuranatomic and neurocognitive phenotypes;
LUAD	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg19761014	chr17:28927070	LRRC37B2	0.84	8.37	0.38	8.43e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs925255	0.817	rs7606480	chr2:28632377	G/A	cg01273330	chr2:28605224	NA	0.41	8.53	0.38	2.54e-16	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg08470875	chr2:26401718	FAM59B	-0.76	-10.25	-0.45	3.63e-22	Gut microbiome composition (summer);
LUAD	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-6.66	-0.31	8.36e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg12035532	chr1:1886765	KIAA1751	0.42	7.01	0.32	9.75e-12	Body mass index;
LUAD	cis	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg00495681	chr13:53174319	NA	0.43	7.34	0.34	1.07e-12	Lewy body disease;
LUAD	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.4	-7.01	-0.32	9.68e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs17433780	0.504	rs7525985	chr1:89460948	C/T	cg09516651	chr1:89888402	LOC400759	0.39	7.58	0.35	2.18e-13	Carotid intima media thickness;
LUAD	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg26384229	chr12:38710491	ALG10B	0.41	6.81	0.31	3.45e-11	Heart rate;
LUAD	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg06558623	chr16:89946397	TCF25	1.12	9.85	0.43	9.8e-21	Skin colour saturation;
LUAD	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg26597838	chr10:835615	NA	-0.47	-7.72	-0.35	8.56e-14	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs4077468	0.963	rs1342064	chr1:205913073	T/C	cg11965913	chr1:205819406	PM20D1	-0.38	-6.77	-0.31	4.2e-11	Cystic fibrosis-related diabetes;
LUAD	cis	rs41311933	1.000	rs2900181	chr9:123756881	T/A	cg13567360	chr9:123745713	C5	-0.75	-8.78	-0.39	4.24e-17	Coronary artery disease;
LUAD	cis	rs2880765	0.525	rs2062234	chr15:86054490	A/G	cg13263323	chr15:86062960	AKAP13	-0.48	-8.06	-0.36	7.89e-15	Coronary artery disease;
LUAD	cis	rs9902453	0.967	rs4533341	chr17:28495672	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.31	0.37	1.27e-15	Coffee consumption (cups per day);
LUAD	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.37	-6.44	-0.3	3.34e-10	Glaucoma (primary open-angle);
LUAD	cis	rs684232	0.602	rs394747	chr17:562495	C/G	cg12384639	chr17:618140	VPS53	-0.45	-7.86	-0.36	3.22e-14	Prostate cancer;
LUAD	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg00204512	chr16:28754710	NA	0.33	7.25	0.33	2.02e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6554196	0.508	rs6554199	chr4:55522488	G/T	cg18836493	chr4:55524333	KIT	-0.36	-6.6	-0.31	1.23e-10	Monocyte count;
LUAD	trans	rs75804782	0.630	rs56354063	chr2:239253919	A/G	cg01134436	chr17:81009848	B3GNTL1	0.73	6.42	0.3	3.72e-10	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.65	10.41	0.45	9.28e-23	Height;
LUAD	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg21827317	chr3:136751795	NA	0.36	6.58	0.3	1.37e-10	Neuroticism;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg04576684	chr19:17414284	ABHD8	-0.69	-6.5	-0.3	2.32e-10	Type 2 diabetes;
LUAD	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24531977	chr5:56204891	C5orf35	-1.01	-15.24	-0.6	3.9e-42	Type 2 diabetes;
LUAD	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg16205897	chr5:131564050	P4HA2	-0.35	-8.02	-0.36	1.06e-14	Blood metabolite levels;
LUAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg13047869	chr3:10149882	C3orf24	0.65	11.04	0.47	4.37e-25	Alzheimer's disease;
LUAD	cis	rs4900538	0.821	rs12586673	chr14:102827643	C/T	cg18135206	chr14:102964638	TECPR2	-1.0	-19.84	-0.69	2.03e-62	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg13319975	chr6:146136371	FBXO30	-0.57	-9.59	-0.42	7.5e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.85	-0.32	2.63e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg20848291	chr7:100343083	ZAN	-0.58	-7.88	-0.36	2.82e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs13082711	0.513	rs66472045	chr3:27242887	G/A	cg02860705	chr3:27208620	NA	0.62	9.57	0.42	9.37e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg23598886	chr18:12777645	NA	0.64	8.04	0.36	8.85e-15	Inflammatory skin disease;
LUAD	trans	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	11.91	0.5	2.14e-28	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg16606324	chr3:10149918	C3orf24	0.59	9.65	0.42	4.73e-20	Alzheimer's disease;
LUAD	cis	rs6906287	0.631	rs2798321	chr6:118991602	G/T	cg18833306	chr6:118973337	C6orf204	0.45	7.72	0.35	8.44e-14	Electrocardiographic conduction measures;
LUAD	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg14582100	chr15:45693742	SPATA5L1	0.51	9.67	0.43	4.06e-20	Homoarginine levels;
LUAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00149659	chr3:10157352	C3orf10	0.57	8.06	0.36	7.87e-15	Alzheimer's disease;
LUAD	cis	rs758324	0.898	rs10037928	chr5:131142046	T/C	cg06307176	chr5:131281290	NA	0.46	7.49	0.34	4.01e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs623323	1.000	rs623323	chr17:700020	A/G	cg02666820	chr17:700054	NA	0.74	11.13	0.48	2.01e-25	Type 2 diabetes;
LUAD	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg19193384	chr17:30244184	NA	-0.5	-6.43	-0.3	3.42e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs2267137	0.868	rs174770	chr22:29766895	C/T	cg07256473	chr22:29710276	RASL10A	0.42	7.98	0.36	1.36e-14	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2073300	1.000	rs6137976	chr20:23463241	C/T	cg12062639	chr20:23401060	NAPB	0.95	8.87	0.4	2e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg27661571	chr11:113659931	NA	-0.7	-8.14	-0.37	4.58e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs7903847	0.642	rs12359257	chr10:99136359	A/T	cg08345082	chr10:99160200	RRP12	-0.34	-6.72	-0.31	5.97e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg00271210	chr6:167070053	RPS6KA2	0.35	6.71	0.31	6.44e-11	Crohn's disease;
LUAD	cis	rs12286929	0.609	rs11601751	chr11:115094117	C/T	cg04055981	chr11:115044050	NA	0.41	7.14	0.33	4.2e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg14917512	chr19:3094685	GNA11	-0.53	-6.37	-0.3	4.88e-10	Diabetic kidney disease;
LUAD	cis	rs5167	0.781	rs2075619	chr19:45495682	A/G	cg09555818	chr19:45449301	APOC2	0.38	7.23	0.33	2.26e-12	Blood protein levels;
LUAD	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg00129232	chr17:37814104	STARD3	-0.47	-7.37	-0.34	9.32e-13	Asthma;
LUAD	cis	rs13064411	0.597	rs2291905	chr3:113010466	C/T	cg18753928	chr3:113234510	CCDC52	-0.55	-9.28	-0.41	9.2e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs669446	0.528	rs7538463	chr1:44196416	T/A	cg12908607	chr1:44402522	ARTN	-0.35	-7.09	-0.33	5.55e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs2688608	0.623	rs2633317	chr10:75690268	A/G	cg23231163	chr10:75533350	FUT11	-0.37	-6.82	-0.31	3.24e-11	Inflammatory bowel disease;
LUAD	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg13390004	chr1:15929781	NA	0.46	8.13	0.37	4.71e-15	Systolic blood pressure;
LUAD	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.7	11.44	0.49	1.37e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg11062466	chr8:58055876	NA	0.47	6.73	0.31	5.53e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.61	-0.31	1.13e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg20701182	chr2:24300061	SF3B14	0.56	6.65	0.31	8.93e-11	Lymphocyte counts;
LUAD	cis	rs7149337	0.869	rs7159770	chr14:51691835	G/A	cg23942311	chr14:51606299	NA	0.84	19.1	0.68	4.24e-59	Cancer;
LUAD	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	15.15	0.59	9.79e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg14773178	chr5:1868261	NA	0.35	7.04	0.32	7.83e-12	Cardiovascular disease risk factors;
LUAD	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg00522288	chr12:125625016	AACS	-0.4	-6.57	-0.3	1.5e-10	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg18180107	chr4:99064573	C4orf37	0.43	6.79	0.31	3.9e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg03433033	chr1:76189801	ACADM	-0.52	-7.6	-0.35	1.88e-13	Daytime sleep phenotypes;
LUAD	trans	rs2018683	0.584	rs4722880	chr7:28999197	C/T	cg19402173	chr7:128379420	CALU	-0.5	-8.06	-0.36	7.68e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg15691649	chr6:25882328	NA	-0.75	-11.91	-0.5	2.1e-28	Urate levels;
LUAD	cis	rs9341808	0.538	rs7756067	chr6:81019794	C/T	cg08355045	chr6:80787529	NA	-0.4	-7.01	-0.32	9.35e-12	Sitting height ratio;
LUAD	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.28	-0.41	8.54e-19	Life satisfaction;
LUAD	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg16262614	chr3:133464971	TF	0.34	6.39	0.3	4.43e-10	Iron status biomarkers;
LUAD	cis	rs806215	1.000	rs712703	chr7:127257498	C/T	cg25922125	chr7:127225783	GCC1	-0.47	-6.87	-0.32	2.24e-11	Type 2 diabetes;
LUAD	cis	rs13064411	0.696	rs9839921	chr3:113199093	G/C	cg18753928	chr3:113234510	CCDC52	-0.73	-12.47	-0.52	1.34e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg26384229	chr12:38710491	ALG10B	0.45	7.42	0.34	6.6e-13	Bladder cancer;
LUAD	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg19163074	chr7:65112434	INTS4L2	0.45	6.85	0.32	2.68e-11	Aortic root size;
LUAD	cis	rs9611519	0.964	rs2179744	chr22:41621714	G/A	cg13813247	chr22:41461852	NA	-0.41	-6.94	-0.32	1.5e-11	Neuroticism;
LUAD	cis	rs346785	0.965	rs17509527	chr17:74286173	A/G	cg09812376	chr17:74270190	QRICH2	-0.32	-7.7	-0.35	9.44e-14	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02463440	chr8:22132932	PIWIL2	0.54	9.99	0.44	3.16e-21	Hypertriglyceridemia;
LUAD	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg06623918	chr6:96969491	KIAA0776	0.88	17.39	0.65	1.77e-51	Headache;
LUAD	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg14403583	chr14:105418241	AHNAK2	-0.44	-8.14	-0.37	4.36e-15	Rheumatoid arthritis;
LUAD	trans	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg04775059	chr7:64541387	NA	0.5	6.61	0.31	1.18e-10	Aortic root size;
LUAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs3772130	1.000	rs7427165	chr3:121364624	C/T	cg20356878	chr3:121714668	ILDR1	0.47	7.29	0.33	1.49e-12	Cognitive performance;
LUAD	cis	rs908922	0.676	rs498184	chr1:152501423	G/C	cg23254163	chr1:152506842	NA	0.27	7.34	0.34	1.12e-12	Hair morphology;
LUAD	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	8.87	0.4	2.11e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg06606381	chr12:133084897	FBRSL1	-0.89	-9.05	-0.4	5.25e-18	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg21220214	chr8:57350948	NA	-0.6	-8.9	-0.4	1.68e-17	Obesity-related traits;
LUAD	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg12193833	chr17:30244370	NA	-0.58	-6.95	-0.32	1.35e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg20135002	chr11:47629003	NA	-0.4	-7.02	-0.32	8.98e-12	Neuroticism;
LUAD	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs6499255	0.951	rs16959025	chr16:69695589	G/T	cg15192750	chr16:69999425	NA	-0.66	-9.56	-0.42	9.76e-20	IgE levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg25321549	chr5:60629121	ZSWIM6	-0.37	-6.5	-0.3	2.32e-10	Cancer;
LUAD	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg07636037	chr3:49044803	WDR6	0.57	8.87	0.4	2e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg06263672	chr7:65235340	NA	0.51	6.89	0.32	2.05e-11	Aortic root size;
LUAD	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.31	0.45	2.12e-22	Prudent dietary pattern;
LUAD	cis	rs7759001	0.857	rs3734574	chr6:27371193	G/A	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg08085267	chr17:45401833	C17orf57	-0.7	-13.06	-0.54	5.57e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg01874867	chr7:94954059	PON1	-0.52	-6.93	-0.32	1.55e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg02734326	chr4:10020555	SLC2A9	0.54	9.31	0.41	6.88e-19	Bone mineral density;
LUAD	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg11502198	chr6:26597334	ABT1	0.55	9.17	0.41	2.12e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.3	6.59	0.31	1.32e-10	Depression;
LUAD	trans	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg14917512	chr19:3094685	GNA11	-0.59	-6.95	-0.32	1.39e-11	Diabetic kidney disease;
LUAD	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg22862634	chr11:62369728	EML3;MTA2	-0.49	-9.07	-0.4	4.54e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg25985355	chr7:65971099	NA	0.38	6.95	0.32	1.37e-11	Aortic root size;
LUAD	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg09035930	chr12:129282057	SLC15A4	0.71	15.98	0.61	2.56e-45	Systemic lupus erythematosus;
LUAD	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg12311346	chr5:56204834	C5orf35	-0.66	-10.34	-0.45	1.68e-22	Coronary artery disease;
LUAD	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg00204512	chr16:28754710	NA	0.3	6.46	0.3	2.93e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs10411161	0.810	rs59911578	chr19:52385597	G/C	cg22319618	chr22:45562946	NUP50	-0.66	-7.53	-0.34	3.01e-13	Breast cancer;
LUAD	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	8.69	0.39	7.96e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg24531977	chr5:56204891	C5orf35	0.51	8.24	0.37	2.13e-15	Coronary artery disease;
LUAD	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg16479474	chr6:28041457	NA	0.37	6.65	0.31	9.1e-11	Cardiac Troponin-T levels;
LUAD	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg17077180	chr1:38461687	NA	-0.44	-8.07	-0.37	7.14e-15	Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs12541635	0.677	rs1496183	chr8:107024445	C/T	cg10147462	chr8:107024639	NA	0.56	10.26	0.45	3.35e-22	Age of smoking initiation;
LUAD	cis	rs2625529	0.652	rs2957750	chr15:72332258	C/T	cg16672083	chr15:72433130	SENP8	0.66	12.44	0.52	1.75e-30	Red blood cell count;
LUAD	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg18105134	chr13:113819100	PROZ	0.82	14.42	0.57	1.23e-38	Platelet distribution width;
LUAD	cis	rs9462027	0.628	rs2744949	chr6:34633862	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.78	-0.39	4.09e-17	Systemic lupus erythematosus;
LUAD	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-7.55	-0.34	2.72e-13	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg05340658	chr4:99064831	C4orf37	0.53	8.96	0.4	1.04e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.4	6.85	0.32	2.6e-11	Total body bone mineral density;
LUAD	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.49	8.02	0.36	1.06e-14	Lymphocyte percentage of white cells;
LUAD	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg00701064	chr4:6280414	WFS1	0.65	13.92	0.56	1.56e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg23978390	chr7:1156363	C7orf50	0.55	8.63	0.39	1.29e-16	Longevity;Endometriosis;
LUAD	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg01579765	chr21:45077557	HSF2BP	-0.61	-13.66	-0.55	1.84e-35	Mean corpuscular volume;
LUAD	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg12016809	chr21:47604291	C21orf56	0.48	7.47	0.34	4.67e-13	Testicular germ cell tumor;
LUAD	cis	rs4604732	0.631	rs11490199	chr1:247625737	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg19773385	chr1:10388646	KIF1B	-0.42	-6.82	-0.31	3.15e-11	Hepatocellular carcinoma;
LUAD	cis	rs1776421	0.760	rs78493155	chr1:53898195	G/A	cg10892335	chr1:53966318	NA	0.51	7.34	0.34	1.13e-12	PR interval in Tripanosoma cruzi seropositivity;
LUAD	trans	rs2235573	0.527	rs139883	chr22:38369027	C/T	cg19894588	chr14:64061835	NA	0.53	8.29	0.37	1.54e-15	Glioblastoma;Glioma;
LUAD	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11209185	0.602	rs1926285	chr1:68446191	A/T	cg22082780	chr1:68452167	NA	0.38	7.52	0.34	3.31e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg01579765	chr21:45077557	HSF2BP	-0.64	-14.83	-0.58	2.27e-40	Mean corpuscular volume;
LUAD	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26314531	chr2:26401878	FAM59B	-0.53	-7.31	-0.33	1.38e-12	Gut microbiome composition (summer);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg23645831	chr1:15944060	DDI2	-0.67	-6.49	-0.3	2.34e-10	Type 2 diabetes;
LUAD	cis	rs9814567	0.896	rs7653807	chr3:134345724	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.75	-13.71	-0.55	1.22e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg12193833	chr17:30244370	NA	-0.5	-6.54	-0.3	1.82e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs11229555	0.645	rs11560908	chr11:58434545	A/C	cg15696309	chr11:58395628	NA	0.61	7.17	0.33	3.32e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg18132916	chr6:79620363	NA	-0.44	-7.67	-0.35	1.16e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs80319144	1.000	rs80319144	chr2:159199835	C/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.72	0.31	5.73e-11	Restless legs syndrome;
LUAD	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-23.94	-0.76	1.08e-80	Height;
LUAD	cis	rs6906287	0.625	rs11968351	chr6:118901509	G/A	cg21191810	chr6:118973309	C6orf204	0.5	9.56	0.42	9.46e-20	Electrocardiographic conduction measures;
LUAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg18402987	chr7:1209562	NA	0.81	10.97	0.47	8.51e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg18187862	chr3:45730750	SACM1L	-0.54	-7.97	-0.36	1.51e-14	Primary sclerosing cholangitis;
LUAD	cis	rs6445967	0.545	rs7611541	chr3:58283041	C/T	cg13750441	chr3:58318267	PXK	-0.31	-6.6	-0.31	1.21e-10	Platelet count;
LUAD	trans	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.29e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg21970626	chr13:21893289	NA	-0.54	-9.11	-0.41	3.24e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4372836	0.602	rs11685682	chr2:29056801	T/A	cg09522027	chr2:28974177	PPP1CB	0.68	12.15	0.51	2.32e-29	Body mass index;
LUAD	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg07936489	chr17:37558343	FBXL20	-0.46	-7.26	-0.33	1.82e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg24675056	chr1:15929824	NA	0.49	8.5	0.38	3.39e-16	Systolic blood pressure;
LUAD	cis	rs13064411	0.696	rs6768648	chr3:113234141	C/G	cg18753928	chr3:113234510	CCDC52	-0.73	-12.45	-0.52	1.58e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg07917127	chr4:99064746	C4orf37	0.4	6.55	0.3	1.63e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs675209	0.591	rs9405325	chr6:7082633	C/T	cg23726566	chr6:7051754	NA	-0.38	-6.79	-0.31	3.83e-11	Urate levels;
LUAD	cis	rs13315871	1.000	rs9869276	chr3:58401076	G/A	cg20936604	chr3:58311152	NA	-0.67	-6.77	-0.31	4.44e-11	Cholesterol, total;
LUAD	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg26384229	chr12:38710491	ALG10B	-0.44	-7.35	-0.34	1e-12	Morning vs. evening chronotype;
LUAD	cis	rs79349575	0.715	rs1058018	chr17:47000251	C/T	cg22482690	chr17:47019901	SNF8	0.38	7.47	0.34	4.48e-13	Type 2 diabetes;
LUAD	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.44	-0.34	5.69e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7192380	0.893	rs1469908	chr16:69764412	C/T	cg00738113	chr16:70207722	CLEC18C	0.35	6.94	0.32	1.46e-11	Sjögren's syndrome;
LUAD	cis	rs3752645	1.000	rs11509187	chr7:106774453	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-6.7	-0.31	6.6e-11	Bladder cancer (smoking interaction);
LUAD	cis	rs7640424	0.819	rs34154497	chr3:107824222	T/C	cg09227934	chr3:107805635	CD47	-0.57	-9.73	-0.43	2.53e-20	Body mass index;
LUAD	trans	rs1351696	1	rs1351696	chr11:48382471	A/G	cg15704280	chr7:45808275	SEPT13	-0.63	-7.51	-0.34	3.43e-13	D-dimer levels;
LUAD	trans	rs7395662	0.824	rs12787989	chr11:48970887	G/T	cg00717180	chr2:96193071	NA	-0.4	-7.52	-0.34	3.35e-13	HDL cholesterol;
LUAD	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg14196790	chr5:131705035	SLC22A5	0.37	6.48	0.3	2.58e-10	Breast cancer;
LUAD	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg15448220	chr1:150897856	SETDB1	0.57	9.73	0.43	2.61e-20	Melanoma;
LUAD	cis	rs3820068	0.705	rs72643701	chr1:15866219	G/A	cg24675056	chr1:15929824	NA	0.42	6.64	0.31	9.49e-11	Systolic blood pressure;
LUAD	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg03433033	chr1:76189801	ACADM	0.81	14.6	0.58	2.25e-39	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10865541	0.902	rs7593978	chr2:3415544	C/T	cg13173536	chr2:3403300	TTC15	-0.35	-6.49	-0.3	2.35e-10	Obesity-related traits;
LUAD	cis	rs1018836	0.923	rs2213886	chr8:91554163	G/C	cg16814680	chr8:91681699	NA	-0.76	-13.35	-0.54	3.46e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg03037974	chr15:76606532	NA	0.38	8.16	0.37	3.9e-15	Blood metabolite levels;
LUAD	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg12623302	chr6:28058802	ZSCAN12L1	-0.33	-6.55	-0.3	1.64e-10	Depression;
LUAD	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg19622623	chr12:86230825	RASSF9	-0.5	-8.89	-0.4	1.79e-17	Major depressive disorder;
LUAD	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg11502198	chr6:26597334	ABT1	0.54	9.14	0.41	2.56e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24838063	chr12:130822603	PIWIL1	0.63	10.67	0.46	1.06e-23	Menopause (age at onset);
LUAD	cis	rs4253772	0.530	rs28362161	chr22:46807439	C/T	cg00784671	chr22:46762841	CELSR1	-0.58	-6.69	-0.31	7.04e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs367615	0.679	rs4259216	chr5:108841817	A/G	cg17395555	chr5:108820864	NA	0.66	14.25	0.57	6.39e-38	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03168497	chr17:48586147	MYCBPAP	-0.54	-7.87	-0.36	3e-14	Visceral fat;
LUAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg12373951	chr3:133503437	NA	0.35	6.99	0.32	1.09e-11	Iron status biomarkers;
LUAD	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg18446336	chr7:2847575	GNA12	-0.32	-6.51	-0.3	2.17e-10	Height;
LUAD	cis	rs9863	0.861	rs11833002	chr12:124446616	G/A	cg17723958	chr12:124429295	CCDC92	-0.4	-6.64	-0.31	9.48e-11	White blood cell count;
LUAD	cis	rs790123	1.000	rs790115	chr3:122381117	C/T	cg17380795	chr3:122379686	NA	0.45	7.67	0.35	1.21e-13	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg02466173	chr16:30829666	NA	-0.69	-12.45	-0.52	1.63e-30	Multiple myeloma;
LUAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.62	0.55	2.7e-35	Prudent dietary pattern;
LUAD	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02018176	chr4:1364513	KIAA1530	-0.57	-10.19	-0.44	5.98e-22	Obesity-related traits;
LUAD	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.13	-0.41	2.83e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.28	-0.33	1.62e-12	Total body bone mineral density;
LUAD	cis	rs9535307	0.929	rs9535340	chr13:50357873	A/C	cg04663916	chr13:50265991	EBPL	0.62	7.03	0.32	8.33e-12	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg03676636	chr4:99064102	C4orf37	0.32	8.43	0.38	5.49e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9361491	0.510	rs1507151	chr6:79483246	T/C	cg05283184	chr6:79620031	NA	-0.37	-6.5	-0.3	2.27e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg06387496	chr7:2775674	GNA12	-0.38	-6.57	-0.3	1.46e-10	Height;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg24853765	chr1:109584962	WDR47	-0.39	-6.36	-0.3	5.18e-10	Schizophrenia;
LUAD	cis	rs73198271	0.515	rs78790301	chr8:8625786	G/C	cg01851573	chr8:8652454	MFHAS1	0.58	7.8	0.35	4.89e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7215564	0.908	rs35878324	chr17:78677530	C/T	cg09596252	chr17:78655493	RPTOR	0.67	6.73	0.31	5.49e-11	Myopia (pathological);
LUAD	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22968622	chr17:43663579	NA	1.36	25.05	0.77	1.42e-85	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg20476274	chr7:133979776	SLC35B4	0.86	17.73	0.65	5.28e-53	Mean platelet volume;
LUAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18918831	chr3:195489782	MUC4	0.66	7.61	0.35	1.83e-13	Lung disease severity in cystic fibrosis;
LUAD	trans	rs9467711	0.606	rs16891725	chr6:26479150	C/T	cg06606381	chr12:133084897	FBRSL1	-0.58	-6.35	-0.3	5.62e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg22676075	chr6:135203613	NA	0.44	8.15	0.37	4.23e-15	Red blood cell count;
LUAD	cis	rs909002	0.830	rs7542583	chr1:32110813	A/G	cg13919466	chr1:32135498	COL16A1	-0.38	-8.82	-0.39	3e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4804416	1.000	rs4804416	chr19:7223848	G/T	cg00428638	chr19:7224713	INSR	-0.45	-9.01	-0.4	7.17e-18	Thyroid hormone levels;Hypothyroidism;
LUAD	trans	rs7246760	0.867	rs68041339	chr19:9818851	A/G	cg02900749	chr2:68251473	NA	-0.6	-6.64	-0.31	9.52e-11	Pursuit maintenance gain;
LUAD	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg00074818	chr8:8560427	CLDN23	0.67	10.3	0.45	2.42e-22	Obesity-related traits;
LUAD	cis	rs6076065	0.748	rs6048779	chr20:23374709	C/G	cg11657817	chr20:23433608	CST11	0.58	12.12	0.51	3.25e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs12216545	0.737	rs10226860	chr7:150234749	A/G	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.55	-0.3	1.69e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs75920871	0.588	rs688456	chr11:116722551	G/T	cg04087571	chr11:116723030	SIK3	-0.35	-8.07	-0.37	7.39e-15	Subjective well-being;
LUAD	cis	rs2446066	0.520	rs34649330	chr12:53893031	C/T	cg20730629	chr12:53886622	MAP3K12	-0.48	-7.17	-0.33	3.4e-12	Red blood cell count;
LUAD	cis	rs1595825	0.945	rs1850634	chr2:198827896	T/C	cg00361562	chr2:198649771	BOLL	-0.47	-6.72	-0.31	5.79e-11	Ulcerative colitis;
LUAD	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.72	-0.35	8.36e-14	Total body bone mineral density;
LUAD	cis	rs977987	0.806	rs11648176	chr16:75456423	C/G	cg03315344	chr16:75512273	CHST6	0.64	14.06	0.56	4.01e-37	Dupuytren's disease;
LUAD	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03878208	chr11:72483293	STARD10	0.59	7.96	0.36	1.57e-14	Type 2 diabetes;
LUAD	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-13.67	-0.55	1.66e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9914578	1.000	rs8082647	chr17:2010597	C/T	cg16513277	chr17:2031491	SMG6	0.64	9.65	0.42	4.79e-20	Body mass index;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02621020	chr8:145159250	SHARPIN;MAF1	-0.45	-6.96	-0.32	1.31e-11	Height;
LUAD	cis	rs62400317	0.859	rs10948226	chr6:45299174	G/C	cg18551225	chr6:44695536	NA	-0.56	-8.76	-0.39	4.93e-17	Total body bone mineral density;
LUAD	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg13390004	chr1:15929781	NA	0.47	8.34	0.38	1.06e-15	Systolic blood pressure;
LUAD	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg23985595	chr17:80112537	CCDC57	-0.53	-9.66	-0.42	4.55e-20	Life satisfaction;
LUAD	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg08645402	chr16:4508243	NA	-0.52	-9.42	-0.42	3.05e-19	Schizophrenia;
LUAD	cis	rs2012796	0.956	rs56223983	chr14:81814754	G/T	cg02996355	chr14:81879375	NA	0.45	6.49	0.3	2.35e-10	Night sleep phenotypes;
LUAD	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08704250	chr15:31115839	NA	-0.56	-10.15	-0.44	8.52e-22	Huntington's disease progression;
LUAD	cis	rs4764487	0.735	rs11612258	chr12:6360683	G/T	cg08284733	chr12:6341482	CD9	0.36	6.39	0.3	4.39e-10	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4919694	1.000	rs77827514	chr10:104822009	C/T	cg04362960	chr10:104952993	NT5C2	0.73	7.86	0.36	3.28e-14	Arsenic metabolism;
LUAD	cis	rs938554	0.955	rs938564	chr4:9922573	T/G	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.41	-0.34	6.83e-13	Blood metabolite levels;
LUAD	cis	rs7633770	0.735	rs11719679	chr3:46687684	A/G	cg11219411	chr3:46661640	NA	-0.49	-10.35	-0.45	1.55e-22	Coronary artery disease;
LUAD	cis	rs6688613	0.685	rs61815130	chr1:166910465	T/C	cg07049167	chr1:166818506	POGK	0.57	8.54	0.38	2.5e-16	Refractive astigmatism;
LUAD	trans	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg01620082	chr3:125678407	NA	-0.43	-6.62	-0.31	1.08e-10	Parkinson's disease;
LUAD	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg09491104	chr22:46646882	C22orf40	-0.55	-7.65	-0.35	1.34e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs62400317	0.859	rs62400293	chr6:45233580	A/T	cg20913747	chr6:44695427	NA	-0.41	-6.57	-0.3	1.44e-10	Total body bone mineral density;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg04665351	chr12:3000000	TULP3	-0.38	-6.5	-0.3	2.31e-10	Vertical cup-disc ratio;
LUAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg11062466	chr8:58055876	NA	0.68	9.04	0.4	5.7e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg14416269	chr4:6271139	WFS1	0.6	12.46	0.52	1.42e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg05132306	chr1:1846340	CALML6	-0.36	-7.71	-0.35	9.18e-14	Body mass index;
LUAD	cis	rs10489202	0.632	rs6659713	chr1:168072249	G/T	cg25738037	chr1:168025549	DCAF6	0.44	6.7	0.31	6.7e-11	Schizophrenia;
LUAD	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg24578937	chr1:2090814	PRKCZ	-0.5	-9.94	-0.44	4.47e-21	Height;
LUAD	cis	rs11585357	0.709	rs735281	chr1:17616194	T/C	cg08277548	chr1:17600880	PADI3	0.81	12.89	0.53	2.75e-32	Hair shape;
LUAD	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg11965913	chr1:205819406	PM20D1	0.55	8.4	0.38	6.85e-16	Menarche (age at onset);
LUAD	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg09455208	chr3:40491958	NA	-0.59	-12.79	-0.53	6.76e-32	Renal cell carcinoma;
LUAD	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.42	-0.3	3.6e-10	Calcium levels;
LUAD	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg23803603	chr1:2058230	PRKCZ	0.41	6.63	0.31	1.01e-10	Height;
LUAD	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg05457628	chr5:178986728	RUFY1	0.63	9.42	0.42	2.87e-19	Lung cancer;
LUAD	cis	rs7173743	0.756	rs8032771	chr15:79126059	A/G	cg15571903	chr15:79123663	NA	0.44	8.78	0.39	4.24e-17	Coronary artery disease;
LUAD	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs76419734	0.558	rs72669984	chr4:106544702	C/T	cg05309399	chr4:106552544	FLJ20184	-0.56	-6.81	-0.31	3.46e-11	Post bronchodilator FEV1;
LUAD	trans	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg01620082	chr3:125678407	NA	-0.69	-7.61	-0.35	1.86e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	7.47	0.34	4.57e-13	Platelet count;
LUAD	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg00383909	chr3:49044727	WDR6	0.44	6.67	0.31	8.19e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg16850897	chr7:100343110	ZAN	-0.65	-10.55	-0.46	3.04e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs72928364	1.000	rs10511181	chr3:100689862	T/G	cg10123952	chr3:100791384	NA	0.64	7.47	0.34	4.74e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs6076960	0.629	rs6054024	chr20:6229282	A/C	cg21095983	chr6:86352623	SYNCRIP	0.47	7.34	0.34	1.1e-12	Smooth-surface caries;
LUAD	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg21231944	chr12:82153410	PPFIA2	-0.35	-6.48	-0.3	2.53e-10	Resting heart rate;
LUAD	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg11644478	chr21:40555479	PSMG1	-0.4	-6.42	-0.3	3.7e-10	Menarche (age at onset);
LUAD	cis	rs6546550	0.867	rs4852349	chr2:70076954	A/T	cg02498382	chr2:70120550	SNRNP27	-0.56	-10.64	-0.46	1.33e-23	Prevalent atrial fibrillation;
LUAD	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.81	0.31	3.35e-11	Rheumatoid arthritis;
LUAD	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg22963979	chr7:1858916	MAD1L1	-0.5	-8.45	-0.38	4.71e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg17410650	chr12:54324560	NA	-0.55	-12.25	-0.51	1.01e-29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUAD	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.57	-9.78	-0.43	1.69e-20	Menarche (age at onset);
LUAD	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg15448220	chr1:150897856	SETDB1	0.47	8.01	0.36	1.12e-14	Urate levels;
LUAD	cis	rs2242073	0.660	rs4449112	chr2:209000573	T/C	cg06181187	chr2:209010896	CRYGB	-0.34	-6.77	-0.31	4.35e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs943466	1.000	rs6933174	chr6:33751003	G/A	cg16010596	chr6:33739607	LEMD2	-0.4	-7.48	-0.34	4.41e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.78	-0.31	3.96e-11	Post bronchodilator FEV1;
LUAD	cis	rs12681287	0.640	rs12678720	chr8:87457929	T/G	cg27223183	chr8:87520930	FAM82B	-0.68	-9.59	-0.42	7.69e-20	Caudate activity during reward;
LUAD	cis	rs250585	0.850	rs9707	chr16:23534098	G/A	cg00143387	chr16:23521605	GGA2	-0.59	-7.25	-0.33	2.06e-12	Egg allergy;
LUAD	cis	rs12545109	0.800	rs1530218	chr8:57407864	C/G	cg17761419	chr8:57350749	NA	-0.53	-7.58	-0.35	2.26e-13	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg07538946	chr5:131705188	SLC22A5	0.41	6.72	0.31	5.74e-11	Blood metabolite levels;
LUAD	cis	rs1624802	0.841	rs78426981	chr12:130497782	A/G	cg15444478	chr12:130494697	NA	-0.33	-7.15	-0.33	3.85e-12	Obesity-related traits;
LUAD	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	6.83	0.31	3.05e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg00823993	chr13:113535758	ATP11A	0.56	8.54	0.38	2.46e-16	Interstitial lung disease;
LUAD	cis	rs2067615	0.560	rs1882542	chr12:107070049	A/C	cg15890332	chr12:107067104	RFX4	0.42	9.05	0.4	5.39e-18	Heart rate;
LUAD	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg00745463	chr17:30367425	LRRC37B	0.65	7.8	0.35	4.83e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	7.17	0.33	3.32e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg21862992	chr11:68658383	NA	0.5	8.99	0.4	8.23e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3125734	0.633	rs4979772	chr10:63967600	C/T	cg19640130	chr10:64028056	RTKN2	0.34	7.29	0.33	1.56e-12	Rheumatoid arthritis;
LUAD	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg16486109	chr11:613632	IRF7	0.49	8.14	0.37	4.35e-15	Systemic lupus erythematosus;
LUAD	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg03713592	chr11:72463424	ARAP1	0.6	7.6	0.35	1.91e-13	Type 2 diabetes;
LUAD	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg26408565	chr15:76604113	ETFA	-0.45	-7.3	-0.33	1.42e-12	Blood metabolite levels;
LUAD	cis	rs13315871	1.000	rs71311871	chr3:58420613	A/G	cg12435725	chr3:58293450	RPP14	-0.71	-7.37	-0.34	8.8e-13	Cholesterol, total;
LUAD	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06022373	chr22:39101656	GTPBP1	0.44	6.83	0.32	2.89e-11	Menopause (age at onset);
LUAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08219700	chr8:58056026	NA	0.63	8.42	0.38	5.84e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1723838	0.510	rs80217992	chr11:73694260	C/G	cg10064339	chr11:73693792	UCP2	1.3	10.09	0.44	1.37e-21	Obesity-related traits;
LUAD	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg18944383	chr4:111397179	ENPEP	-0.48	-8.62	-0.39	1.38e-16	Coronary artery disease;
LUAD	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg23649088	chr2:200775458	C2orf69	0.52	8.33	0.38	1.14e-15	Osteoporosis;
LUAD	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg08029281	chr1:67600428	NA	0.33	6.37	0.3	4.95e-10	Psoriasis;
LUAD	cis	rs12620999	1.000	rs11689249	chr2:238083542	T/A	cg23555395	chr2:238036564	NA	-0.6	-9.31	-0.41	6.98e-19	Systemic lupus erythematosus;
LUAD	cis	rs6519955	0.860	rs8136098	chr22:46425646	A/G	cg11242978	chr22:46423387	NA	0.36	6.6	0.31	1.23e-10	Dupuytren's disease;
LUAD	cis	rs7100689	0.516	rs3862532	chr10:82015725	A/C	cg01528321	chr10:82214614	TSPAN14	0.49	7.67	0.35	1.17e-13	Post bronchodilator FEV1;
LUAD	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg14196790	chr5:131705035	SLC22A5	0.54	9.5	0.42	1.55e-19	Blood metabolite levels;
LUAD	cis	rs380904	0.519	rs12541790	chr8:144643321	A/G	cg13399544	chr8:144649678	C8orf73	-0.46	-6.61	-0.31	1.16e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs3820068	0.705	rs11589076	chr1:15827027	C/T	cg24675056	chr1:15929824	NA	0.41	6.53	0.3	1.89e-10	Systolic blood pressure;
LUAD	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg01528321	chr10:82214614	TSPAN14	0.66	10.55	0.46	3.07e-23	Post bronchodilator FEV1;
LUAD	trans	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-14.8	-0.58	3.19e-40	Colorectal cancer;
LUAD	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg14196790	chr5:131705035	SLC22A5	0.39	6.78	0.31	3.97e-11	Breast cancer;
LUAD	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg02527881	chr3:46936655	PTH1R	0.42	8.03	0.36	9.68e-15	Colorectal cancer;
LUAD	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg01516881	chr6:292596	DUSP22	-0.52	-8.55	-0.38	2.34e-16	Menopause (age at onset);
LUAD	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg21138405	chr5:131827807	IRF1	0.6	13.77	0.56	6.51e-36	Asthma (sex interaction);
LUAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg25703541	chr22:24373054	LOC391322	0.92	19.06	0.68	6.24e-59	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs500891	0.525	rs1145901	chr6:84038605	T/C	cg08257003	chr6:84140564	ME1	0.34	6.35	0.3	5.43e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.59e-16	Cannabis dependence symptom count;
LUAD	cis	rs60154123	0.730	rs4844989	chr1:210460086	C/T	cg22029157	chr1:209979665	IRF6	0.58	6.82	0.31	3.1e-11	Coronary artery disease;
LUAD	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg04539111	chr16:67997858	SLC12A4	-0.61	-7.54	-0.34	2.83e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.71	-0.35	8.81e-14	Neuroticism;
LUAD	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg18827107	chr12:86230957	RASSF9	-0.54	-9.47	-0.42	1.97e-19	Major depressive disorder;
LUAD	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg26769984	chr7:1090371	C7orf50	0.58	10.09	0.44	1.35e-21	Bronchopulmonary dysplasia;
LUAD	trans	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.4	-0.34	7.32e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs1997103	0.906	rs4618644	chr7:55402037	T/G	cg20935933	chr6:143382018	AIG1	0.53	7.48	0.34	4.32e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg23887609	chr12:130822674	PIWIL1	0.4	6.64	0.31	9.93e-11	Menopause (age at onset);
LUAD	cis	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.87	-0.36	3.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg10053473	chr17:62856997	LRRC37A3	0.76	10.88	0.47	1.78e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06873352	chr17:61820015	STRADA	-0.81	-18.04	-0.66	2.29e-54	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg00933542	chr6:150070202	PCMT1	0.44	9.32	0.41	6.46e-19	Lung cancer;
LUAD	trans	rs3857536	0.813	rs7770349	chr6:66946659	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.54	8.42	0.38	5.72e-16	IgG glycosylation;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11574758	chr20:21107113	PLK1S1	-0.42	-6.58	-0.3	1.36e-10	Height;
LUAD	cis	rs738322	0.511	rs5756947	chr22:38573230	G/A	cg17652424	chr22:38574118	PLA2G6	-0.32	-8.8	-0.39	3.44e-17	Cutaneous nevi;
LUAD	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.62	0.52	3.42e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62400317	0.859	rs12201899	chr6:45298204	C/A	cg18551225	chr6:44695536	NA	-0.56	-8.76	-0.39	4.93e-17	Total body bone mineral density;
LUAD	cis	rs2688608	0.901	rs2664280	chr10:75617344	A/T	cg23231163	chr10:75533350	FUT11	0.44	8.27	0.37	1.7e-15	Inflammatory bowel disease;
LUAD	cis	rs26868	0.766	rs26867	chr16:2249410	T/C	cg25665528	chr16:2260870	C16orf79	-0.35	-7.03	-0.32	8.57e-12	Height;
LUAD	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg26384229	chr12:38710491	ALG10B	0.51	8.33	0.38	1.15e-15	Heart rate;
LUAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg08888203	chr3:10149979	C3orf24	0.74	13.07	0.54	5.1e-33	Alzheimer's disease;
LUAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06873352	chr17:61820015	STRADA	0.83	18.32	0.67	1.32e-55	Prudent dietary pattern;
LUAD	cis	rs12079745	0.793	rs12073439	chr1:169284482	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.94	-6.75	-0.31	4.91e-11	QT interval;
LUAD	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg23422044	chr7:1970798	MAD1L1	0.56	7.05	0.32	7.27e-12	Bipolar disorder;
LUAD	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs41311933	0.656	rs72760209	chr9:123846199	T/C	cg13567360	chr9:123745713	C5	-0.71	-8.05	-0.36	8.57e-15	Coronary artery disease;
LUAD	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg12179176	chr11:130786555	SNX19	-0.65	-11.54	-0.49	5.77e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg11645453	chr3:52864694	ITIH4	0.54	10.03	0.44	2.3e-21	Schizophrenia;
LUAD	trans	rs2262909	1.000	rs2175366	chr19:22128279	C/T	cg17074339	chr11:11642133	GALNTL4	-0.44	-7.08	-0.33	6.22e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.1e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg17173187	chr15:85201210	NMB	0.49	8.52	0.38	2.93e-16	Schizophrenia;
LUAD	cis	rs9341808	0.519	rs3805872	chr6:81035102	G/A	cg08355045	chr6:80787529	NA	-0.41	-6.87	-0.32	2.27e-11	Sitting height ratio;
LUAD	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.99	-0.32	1.07e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg05966235	chr16:28915196	ATP2A1	0.46	7.48	0.34	4.21e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg11189052	chr15:85197271	WDR73	-0.58	-7.58	-0.35	2.19e-13	Schizophrenia;
LUAD	cis	rs6743376	0.556	rs3820738	chr2:113819439	A/G	cg09040174	chr2:113837401	NA	0.48	7.59	0.35	2.06e-13	Inflammatory biomarkers;
LUAD	cis	rs6835098	0.692	rs7657374	chr4:174065756	A/T	cg27433088	chr4:174089019	GALNT7	0.37	7.18	0.33	3.15e-12	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.0	-0.36	1.23e-14	Diabetic kidney disease;
LUAD	trans	rs459571	1.000	rs459571	chr9:136912626	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.71	-10.15	-0.44	8.1e-22	Platelet distribution width;
LUAD	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.72	8.43	0.38	5.46e-16	Body mass index;
LUAD	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.82	0.31	3.12e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg00316803	chr15:76480434	C15orf27	-0.4	-7.44	-0.34	5.86e-13	Blood metabolite levels;
LUAD	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.54	-0.3	1.78e-10	Mood instability;
LUAD	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg14092988	chr3:52407081	DNAH1	0.37	7.49	0.34	4.02e-13	Bipolar disorder;
LUAD	cis	rs6558530	0.965	rs4372027	chr8:1707958	T/C	cg19131313	chr8:1704013	NA	-0.46	-7.43	-0.34	5.88e-13	Systolic blood pressure;
LUAD	cis	rs10744422	0.686	rs4038070	chr12:123299525	C/T	cg16953816	chr12:123349952	VPS37B	0.67	6.39	0.3	4.34e-10	Schizophrenia;
LUAD	cis	rs4523957	0.855	rs7217226	chr17:2136065	A/C	cg16513277	chr17:2031491	SMG6	-0.79	-14.56	-0.58	3.23e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg03233332	chr7:66118400	NA	-0.43	-6.6	-0.31	1.26e-10	Aortic root size;
LUAD	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg02421172	chr7:1938701	MAD1L1	0.41	6.38	0.3	4.74e-10	Bipolar disorder;
LUAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg21280719	chr6:42927975	GNMT	-0.4	-12.32	-0.51	5.11e-30	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19748678	chr4:122722346	EXOSC9	0.43	6.76	0.31	4.64e-11	Type 2 diabetes;
LUAD	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03352830	chr11:487213	PTDSS2	0.83	10.68	0.46	9.98e-24	Body mass index;
LUAD	cis	rs657075	0.697	rs71583480	chr5:131696251	C/G	cg21138405	chr5:131827807	IRF1	0.54	6.58	0.3	1.41e-10	Rheumatoid arthritis;
LUAD	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg06287003	chr12:125626642	AACS	-0.48	-8.53	-0.38	2.68e-16	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg01448562	chr3:133502909	NA	0.67	12.52	0.52	8.61e-31	Iron status biomarkers;
LUAD	trans	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg14343924	chr8:8086146	FLJ10661	0.48	7.37	0.34	9.12e-13	Neuroticism;
LUAD	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg04414720	chr1:150670196	GOLPH3L	0.72	13.36	0.54	3.28e-34	Tonsillectomy;
LUAD	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.43	6.98	0.32	1.15e-11	Lymphocyte counts;
LUAD	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg23283495	chr1:209979779	IRF6	0.72	10.58	0.46	2.32e-23	Cleft lip with or without cleft palate;
LUAD	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg15448220	chr1:150897856	SETDB1	-0.51	-8.9	-0.4	1.6e-17	Melanoma;
LUAD	trans	rs3960554	0.808	rs3779419	chr7:75695081	G/A	cg19862616	chr7:65841803	NCRNA00174	0.83	11.91	0.5	2.17e-28	Eotaxin levels;
LUAD	cis	rs738322	0.600	rs5995542	chr22:38558141	C/T	cg25457927	chr22:38595422	NA	-0.54	-12.8	-0.53	6.38e-32	Cutaneous nevi;
LUAD	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg14196790	chr5:131705035	SLC22A5	-0.46	-8.36	-0.38	9.43e-16	Breast cancer;Mosquito bite size;
LUAD	cis	rs2762353	0.574	rs4419666	chr6:25693274	C/T	cg12310025	chr6:25882481	NA	0.88	14.28	0.57	5.03e-38	Blood metabolite levels;
LUAD	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg12940439	chr1:67600707	NA	-0.48	-8.95	-0.4	1.1e-17	Psoriasis;
LUAD	cis	rs1055129	0.584	rs9895947	chr17:73908566	A/C	cg12407791	chr17:73824354	UNC13D	-0.34	-7.0	-0.32	9.91e-12	White matter hyperintensity burden;
LUAD	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg20673091	chr1:2541236	MMEL1	0.45	9.87	0.43	8.08e-21	Ulcerative colitis;
LUAD	cis	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg27411982	chr8:10470053	RP1L1	-0.39	-7.04	-0.32	7.73e-12	Triglycerides;
LUAD	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	9.86	0.43	8.79e-21	Migraine;Coronary artery disease;
LUAD	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03352830	chr11:487213	PTDSS2	0.68	8.37	0.38	8.44e-16	Body mass index;
LUAD	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg05535760	chr7:792225	HEATR2	0.85	10.95	0.47	1.02e-24	Cerebrospinal P-tau181p levels;
LUAD	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.36	-0.6	1.23e-42	Chronic sinus infection;
LUAD	cis	rs7824557	0.602	rs7816636	chr8:11205654	T/A	cg21775007	chr8:11205619	TDH	0.55	9.82	0.43	1.24e-20	Retinal vascular caliber;
LUAD	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-10.21	-0.44	5.21e-22	Hip circumference adjusted for BMI;
LUAD	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-10.07	-0.44	1.57e-21	Hip circumference adjusted for BMI;
LUAD	cis	rs7927771	0.524	rs10838746	chr11:47706291	A/G	cg18512352	chr11:47633146	NA	0.37	6.63	0.31	9.96e-11	Subjective well-being;
LUAD	trans	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg26043149	chr18:55253948	FECH	0.51	8.32	0.38	1.23e-15	Bone mineral density;
LUAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg08132940	chr7:1081526	C7orf50	-0.77	-10.31	-0.45	2.21e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg10876282	chr6:28092338	ZSCAN16	0.46	7.46	0.34	4.85e-13	Cardiac Troponin-T levels;
LUAD	cis	rs10465746	0.746	rs6663949	chr1:84452853	T/C	cg10977910	chr1:84465055	TTLL7	0.59	9.69	0.43	3.47e-20	Obesity-related traits;
LUAD	cis	rs7187994	0.848	rs16974560	chr16:84788425	A/G	cg07647771	chr16:84786436	USP10	-0.37	-9.5	-0.42	1.53e-19	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg12311346	chr5:56204834	C5orf35	-0.95	-13.99	-0.56	8.27e-37	Initial pursuit acceleration;
LUAD	cis	rs11048434	0.736	rs933462	chr12:9103665	T/G	cg26114124	chr12:9217669	LOC144571	0.37	6.64	0.31	9.58e-11	Sjögren's syndrome;
LUAD	cis	rs35883536	1.000	rs3904672	chr1:101136651	C/T	cg06223162	chr1:101003688	GPR88	0.37	6.93	0.32	1.54e-11	Monocyte count;
LUAD	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg24112000	chr20:60950667	NA	0.71	11.69	0.49	1.55e-27	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg04369109	chr6:150039330	LATS1	-0.44	-7.43	-0.34	5.91e-13	Lung cancer;
LUAD	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg06453172	chr10:134556979	INPP5A	0.44	7.22	0.33	2.39e-12	Migraine;
LUAD	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg11845111	chr2:191398756	TMEM194B	0.79	10.14	0.44	8.63e-22	Diastolic blood pressure;
LUAD	cis	rs2050392	0.894	rs303430	chr10:30706235	C/A	cg18806716	chr10:30721971	MAP3K8	-0.53	-10.6	-0.46	2e-23	Inflammatory bowel disease;
LUAD	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg21028142	chr17:79581711	NPLOC4	0.37	7.44	0.34	5.71e-13	Eye color traits;
LUAD	cis	rs7937890	0.531	rs2597216	chr11:14533916	G/A	cg06199346	chr11:14280333	SPON1	-0.32	-6.42	-0.3	3.58e-10	Mitochondrial DNA levels;
LUAD	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.42	-8.77	-0.39	4.28e-17	Total body bone mineral density;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05663655	chr7:107532014	DLD	-0.44	-6.88	-0.32	2.12e-11	Height;
LUAD	cis	rs11229555	1.000	rs11229555	chr11:58408687	G/T	cg15696309	chr11:58395628	NA	-0.73	-10.96	-0.47	9.05e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg16647868	chr5:131706066	SLC22A5	-0.39	-6.64	-0.31	9.52e-11	Blood metabolite levels;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg13303229	chr5:154136254	LARP1	-0.44	-6.39	-0.3	4.49e-10	Testicular germ cell tumor;
LUAD	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg00316803	chr15:76480434	C15orf27	0.41	6.53	0.3	1.88e-10	Blood metabolite levels;
LUAD	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.18	-0.37	3.39e-15	Bipolar disorder;
LUAD	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg22705602	chr4:152727874	NA	-0.4	-6.95	-0.32	1.38e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs66731853	0.771	rs541244	chr1:20889380	G/A	cg04087271	chr1:20915334	CDA	-0.61	-11.23	-0.48	9e-26	Mean corpuscular volume;
LUAD	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.06	9.22	0.41	1.45e-18	Schizophrenia;
LUAD	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg08085267	chr17:45401833	C17orf57	-0.54	-9.58	-0.42	8.63e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs36051895	0.695	rs10120763	chr9:5002911	C/G	cg02405213	chr9:5042618	JAK2	-0.5	-6.96	-0.32	1.31e-11	Pediatric autoimmune diseases;
LUAD	cis	rs11048434	0.761	rs11494570	chr12:9127147	T/C	cg23795048	chr12:9217529	LOC144571	0.45	8.18	0.37	3.39e-15	Sjögren's syndrome;
LUAD	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg23803603	chr1:2058230	PRKCZ	-0.43	-7.38	-0.34	8.61e-13	Height;
LUAD	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg19774624	chr17:42201019	HDAC5	-0.38	-6.51	-0.3	2.14e-10	Total body bone mineral density;
LUAD	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.47	7.11	0.33	5.11e-12	Total body bone mineral density;
LUAD	cis	rs6424115	0.867	rs10917431	chr1:24174093	T/G	cg15997130	chr1:24165203	NA	-0.55	-9.37	-0.41	4.46e-19	Immature fraction of reticulocytes;
LUAD	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg01299579	chr2:10830716	NOL10	-0.41	-7.17	-0.33	3.3e-12	Prostate cancer;
LUAD	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg26022315	chr17:47021804	SNF8	0.42	7.37	0.34	8.96e-13	Type 2 diabetes;
LUAD	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg22442454	chr1:209979470	IRF6	0.48	6.96	0.32	1.34e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg23950597	chr19:37808831	NA	-0.6	-7.46	-0.34	4.88e-13	Coronary artery calcification;
LUAD	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg21433313	chr16:3507492	NAT15	0.73	9.6	0.42	7.34e-20	Tuberculosis;
LUAD	cis	rs9486719	0.947	rs11757102	chr6:96885073	G/A	cg06623918	chr6:96969491	KIAA0776	-0.71	-9.99	-0.44	2.95e-21	Migraine;Coronary artery disease;
LUAD	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg14092988	chr3:52407081	DNAH1	0.45	9.04	0.4	5.62e-18	Bipolar disorder;
LUAD	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg06608945	chr2:219082296	ARPC2	0.48	8.08	0.37	6.65e-15	Colorectal cancer;
LUAD	cis	rs67072384	1.000	rs72966113	chr11:72450970	C/T	cg04827223	chr11:72435913	ARAP1	-0.61	-7.31	-0.33	1.38e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg22166914	chr1:53195759	ZYG11B	0.45	7.63	0.35	1.52e-13	Monocyte count;
LUAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-6.89	-0.32	2.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg12713893	chr18:19192271	SNRPD1	0.43	6.44	0.3	3.25e-10	QT interval;
LUAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg07167872	chr1:205819463	PM20D1	0.51	8.21	0.37	2.74e-15	Parkinson's disease;
LUAD	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.68	-11.38	-0.48	2.35e-26	Primary sclerosing cholangitis;
LUAD	trans	rs7395662	0.963	rs1588068	chr11:48671745	C/G	cg15704280	chr7:45808275	SEPT13	-0.41	-6.4	-0.3	4.17e-10	HDL cholesterol;
LUAD	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg09491104	chr22:46646882	C22orf40	-0.58	-7.43	-0.34	5.86e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7584330	0.554	rs10178682	chr2:238433818	T/G	cg14458575	chr2:238380390	NA	0.6	9.5	0.42	1.5700000000000001e-19	Prostate cancer;
LUAD	cis	rs12151790	1.000	rs7575512	chr2:235210293	A/G	cg20558320	chr2:235210313	NA	0.58	7.18	0.33	3.2e-12	Osteoporosis-related phenotypes;
LUAD	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg19761014	chr17:28927070	LRRC37B2	0.86	8.36	0.38	9.21e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg09509183	chr1:209979624	IRF6	0.56	7.42	0.34	6.2800000000000005e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg02951883	chr7:2050386	MAD1L1	-0.97	-18.67	-0.67	3.53e-57	Bipolar disorder and schizophrenia;
LUAD	cis	rs7737355	0.812	rs13172003	chr5:131087656	T/C	cg25547332	chr5:131281432	NA	0.43	7.0	0.32	1.01e-11	Life satisfaction;
LUAD	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg03676636	chr4:99064102	C4orf37	0.31	8.13	0.37	4.82e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg07677032	chr17:61819896	STRADA	0.57	10.37	0.45	1.36e-22	Prudent dietary pattern;
LUAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg16606324	chr3:10149918	C3orf24	0.66	9.63	0.42	5.67e-20	Alzheimer's disease;
LUAD	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg27144592	chr16:783916	NARFL	0.35	6.39	0.3	4.27e-10	Height;
LUAD	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg23950597	chr19:37808831	NA	-0.6	-7.57	-0.35	2.4e-13	Coronary artery calcification;
LUAD	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.52	8.09	0.37	6.23e-15	Total body bone mineral density;
LUAD	trans	rs931812	0.757	rs4734014	chr8:101908844	A/G	cg20993868	chr7:22813445	NA	0.53	11.53	0.49	6.4e-27	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs17102423	0.594	rs1998688	chr14:65562306	C/G	cg11161011	chr14:65562177	MAX	0.43	7.17	0.33	3.28e-12	Obesity-related traits;
LUAD	cis	rs420259	0.516	rs10459765	chr16:23467181	T/C	cg00143387	chr16:23521605	GGA2	0.69	9.75	0.43	2.14e-20	Bipolar disorder;
LUAD	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg21782813	chr7:2030301	MAD1L1	0.42	6.98	0.32	1.15e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg06740227	chr12:86229804	RASSF9	0.46	7.94	0.36	1.81e-14	Major depressive disorder;
LUAD	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg00277334	chr10:82204260	NA	-0.62	-8.47	-0.38	4.22e-16	Post bronchodilator FEV1;
LUAD	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg06002616	chr8:101225028	SPAG1	-0.39	-7.89	-0.36	2.56e-14	Atrioventricular conduction;
LUAD	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg10589385	chr1:150898437	SETDB1	0.44	8.22	0.37	2.57e-15	Tonsillectomy;
LUAD	cis	rs7000551	0.715	rs34649162	chr8:22314730	T/C	cg12081754	chr8:22256438	SLC39A14	0.43	7.0	0.32	1.03e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg04398451	chr17:18023971	MYO15A	-0.67	-12.13	-0.51	2.82e-29	Total body bone mineral density;
LUAD	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg06740227	chr12:86229804	RASSF9	0.39	7.07	0.32	6.53e-12	Major depressive disorder;
LUAD	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg07636037	chr3:49044803	WDR6	0.63	12.12	0.51	3.22e-29	Parkinson's disease;
LUAD	cis	rs7827545	0.545	rs6988000	chr8:135559534	C/T	cg17885191	chr8:135476712	NA	0.58	7.9	0.36	2.5e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg07217954	chr7:1067459	C7orf50	-0.37	-6.61	-0.31	1.14e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg11301795	chr4:187892539	NA	-0.77	-15.83	-0.61	1.11e-44	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1509123	0.609	rs7213141	chr17:6711491	A/G	cg12642237	chr17:6703447	TEKT1	-0.48	-7.06	-0.32	6.85e-12	Blood metabolite levels;
LUAD	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.5	8.35	0.38	9.52e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.55	-10.84	-0.47	2.47e-24	Longevity;Endometriosis;
LUAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14893161	chr1:205819251	PM20D1	0.81	17.28	0.64	5.41e-51	Menarche (age at onset);
LUAD	cis	rs12612619	0.732	rs11687536	chr2:27199754	C/T	cg00617064	chr2:27272375	NA	0.37	7.15	0.33	3.89e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.68	-12.07	-0.51	5.1e-29	Menarche (age at onset);
LUAD	cis	rs2882667	0.898	rs4380651	chr5:138391072	A/G	cg04439458	chr5:138467593	SIL1	-0.4	-7.29	-0.33	1.51e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg24768116	chr2:27665128	KRTCAP3	0.26	6.36	0.3	5.3e-10	Oral cavity cancer;
LUAD	cis	rs62238980	0.614	rs976915	chr22:32428445	A/G	cg00543991	chr22:32367038	NA	0.97	9.07	0.4	4.38e-18	Childhood ear infection;
LUAD	cis	rs9473147	0.543	rs9473126	chr6:47481833	C/G	cg20196966	chr6:47445060	CD2AP	0.44	6.8	0.31	3.67e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2235649	0.789	rs9939680	chr16:1852720	C/T	cg08610935	chr16:1836813	NUBP2	-0.48	-7.2	-0.33	2.79e-12	Blood metabolite levels;
LUAD	cis	rs7193541	0.826	rs56143602	chr16:74694692	T/C	cg01733217	chr16:74700730	RFWD3	0.58	10.02	0.44	2.5e-21	Multiple myeloma;
LUAD	cis	rs6840360	0.571	rs17275577	chr4:152519899	G/A	cg22705602	chr4:152727874	NA	-0.43	-7.44	-0.34	5.83e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg03605463	chr16:89740564	NA	0.66	11.23	0.48	8.36e-26	Vitiligo;
LUAD	cis	rs3806843	0.518	rs173471	chr5:140335226	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg20607287	chr7:12443886	VWDE	-0.54	-6.95	-0.32	1.42e-11	Coronary artery disease;
LUAD	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg21918786	chr6:109611834	NA	-0.58	-10.76	-0.46	4.92e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs3806843	0.576	rs265316	chr5:140290843	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.61	-0.31	1.17e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4711350	0.953	rs1547668	chr6:33775446	A/G	cg18005901	chr6:33739558	LEMD2	-0.48	-6.77	-0.31	4.36e-11	Schizophrenia;
LUAD	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7402982	0.934	rs8027457	chr15:99204101	A/G	cg03437748	chr15:99193247	IGF1R	0.46	8.09	0.37	6.36e-15	Birth weight;
LUAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.59	0.31	1.3100000000000001e-10	Prudent dietary pattern;
LUAD	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg06558623	chr16:89946397	TCF25	1.14	9.96	0.44	4.02e-21	Skin colour saturation;
LUAD	cis	rs7779181	0.808	rs10241729	chr7:32289879	A/G	cg27532318	chr7:32358331	NA	0.41	6.66	0.31	8.37e-11	Body mass index;
LUAD	cis	rs4233802	1.000	rs6761697	chr2:151141735	A/G	cg25300694	chr2:151184358	NA	0.8	6.96	0.32	1.26e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	trans	rs9784649	1.000	rs3933895	chr5:25004929	A/T	cg11038491	chr20:34638489	LOC647979	-0.68	-8.39	-0.38	7.43e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg09359103	chr1:154839909	KCNN3	-0.91	-21.33	-0.72	4.35e-69	Prostate cancer;
LUAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.71	13.3	0.54	5.76e-34	Lymphocyte counts;
LUAD	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg26924012	chr15:45694286	SPATA5L1	1.0	18.36	0.67	8.25e-56	Homoarginine levels;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg02820958	chr19:7099040	NA	0.42	7.1	0.33	5.4e-12	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs6758955	0.929	rs73161277	chr2:10480883	A/G	cg15773312	chr2:10472214	HPCAL1	-0.43	-6.91	-0.32	1.81e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12210905	0.688	rs9368509	chr6:27379422	A/G	cg08851530	chr6:28072375	NA	-1.0	-7.7	-0.35	9.96e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg04287289	chr16:89883240	FANCA	-0.56	-9.92	-0.43	5.45e-21	Vitiligo;
LUAD	trans	rs7944735	0.517	rs11039538	chr11:48154990	A/T	cg15704280	chr7:45808275	SEPT13	0.66	7.18	0.33	3.26e-12	Intraocular pressure;
LUAD	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg14541582	chr5:601475	NA	-0.37	-7.94	-0.36	1.79e-14	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.41	-7.06	-0.32	6.91e-12	Platelet count;
LUAD	cis	rs9715521	0.900	rs62301182	chr4:59834267	A/G	cg11281224	chr4:60001000	NA	-0.55	-9.34	-0.41	5.67e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9473147	0.543	rs7738044	chr6:47469273	A/G	cg20196966	chr6:47445060	CD2AP	0.45	7.08	0.33	5.86e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg15997130	chr1:24165203	NA	0.55	9.5	0.42	1.54e-19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
LUAD	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg26769984	chr7:1090371	C7orf50	0.59	9.19	0.41	1.73e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg19635926	chr16:89946313	TCF25	0.75	6.76	0.31	4.56e-11	Skin colour saturation;
LUAD	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg05926928	chr17:57297772	GDPD1	1.39	17.2	0.64	1.21e-50	Opioid sensitivity;
LUAD	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.55	7.81	0.36	4.41e-14	Platelet count;
LUAD	cis	rs3204270	0.810	rs8077959	chr17:79670122	G/A	cg18367735	chr17:79674897	NA	0.54	6.81	0.31	3.43e-11	Dental caries;
LUAD	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg09163369	chr1:210001066	C1orf107	0.5	7.2	0.33	2.79e-12	Orofacial clefts;
LUAD	trans	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg11693508	chr17:37793320	STARD3	0.7	9.32	0.41	6.75e-19	Bipolar disorder;
LUAD	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg27141850	chr2:20869434	GDF7	-0.43	-10.43	-0.45	8.28e-23	Abdominal aortic aneurysm;
LUAD	cis	rs9469890	0.604	rs78871484	chr6:34503677	T/C	cg17674042	chr6:34482479	PACSIN1	-0.53	-7.24	-0.33	2.2e-12	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	10.34	0.45	1.78e-22	Smoking behavior;
LUAD	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg19875535	chr5:140030758	IK	0.44	7.41	0.34	6.93e-13	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.08	0.51	4.71e-29	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg03684893	chr10:554711	DIP2C	0.36	6.44	0.3	3.3e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg22906224	chr7:99728672	NA	0.55	9.5	0.42	1.5700000000000001e-19	Coronary artery disease;
LUAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg18538332	chr22:24372958	LOC391322	-0.54	-9.12	-0.41	3.09e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3806843	0.898	rs3756335	chr5:140213510	A/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.47	8.35	0.38	9.51e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg13453750	chr1:205783389	SLC41A1	-0.38	-6.7	-0.31	6.5e-11	Menarche (age at onset);
LUAD	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg01528321	chr10:82214614	TSPAN14	0.65	9.92	0.43	5.22e-21	Post bronchodilator FEV1;
LUAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg09033563	chr22:24373618	LOC391322	-0.58	-9.55	-0.42	1.07e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg21214613	chr1:16344536	HSPB7	0.35	6.49	0.3	2.46e-10	Systolic blood pressure;
LUAD	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg06718696	chr17:78121285	EIF4A3	0.57	8.58	0.39	1.76e-16	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg21782813	chr7:2030301	MAD1L1	0.51	8.62	0.39	1.31e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg25358565	chr5:93447407	FAM172A	0.59	6.9	0.32	1.97e-11	Diabetic retinopathy;
LUAD	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg10589385	chr1:150898437	SETDB1	0.39	7.39	0.34	8e-13	Tonsillectomy;
LUAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg15112475	chr7:1198522	ZFAND2A	0.36	6.67	0.31	7.83e-11	Longevity;Endometriosis;
LUAD	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.58	-0.3	1.35e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06508976	chr9:131940586	IER5L	-0.41	-6.56	-0.3	1.6e-10	Height;
LUAD	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg02524346	chr8:600233	NA	0.97	10.08	0.44	1.45e-21	IgG glycosylation;
LUAD	cis	rs6906287	0.647	rs10457330	chr6:118731468	A/T	cg21191810	chr6:118973309	C6orf204	0.49	9.53	0.42	1.23e-19	Electrocardiographic conduction measures;
LUAD	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg05991184	chr2:219186017	PNKD	0.37	7.07	0.33	6.39e-12	Colorectal cancer;
LUAD	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-7.59	-0.35	2.05e-13	Tonsillectomy;
LUAD	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg09658497	chr7:2847517	GNA12	-0.47	-8.73	-0.39	6.07e-17	Height;
LUAD	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg07636037	chr3:49044803	WDR6	0.63	12.19	0.51	1.67e-29	Parkinson's disease;
LUAD	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.48e-10	Prostate cancer;
LUAD	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg16850897	chr7:100343110	ZAN	-0.66	-10.84	-0.47	2.42e-24	Other erythrocyte phenotypes;
LUAD	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg12564285	chr5:131593104	PDLIM4	0.37	6.36	0.3	5.16e-10	Breast cancer;
LUAD	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg13685833	chr1:53393034	SCP2	-0.49	-8.1	-0.37	6.06e-15	Monocyte count;
LUAD	cis	rs3743162	0.553	rs4842994	chr15:85415799	A/G	cg12863693	chr15:85201151	NMB	-0.36	-6.48	-0.3	2.54e-10	Alzheimer's disease (age of onset);
LUAD	cis	rs4253772	0.530	rs11090875	chr22:46785301	C/T	cg09491104	chr22:46646882	C22orf40	-0.59	-7.43	-0.34	6.04e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-6.37	-0.3	4.83e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11756438	0.683	rs60497831	chr6:119009327	G/A	cg18833306	chr6:118973337	C6orf204	0.41	6.84	0.32	2.74e-11	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg15790184	chr11:494944	RNH1	0.57	7.06	0.32	6.77e-12	Body mass index;
LUAD	cis	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg26958806	chr6:27640298	NA	0.64	6.35	0.3	5.45e-10	Breast cancer;
LUAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg15117754	chr3:10150083	C3orf24	0.45	7.36	0.34	9.43e-13	Alzheimer's disease;
LUAD	cis	rs7737355	0.947	rs79018835	chr5:130798461	C/A	cg06307176	chr5:131281290	NA	-0.51	-8.07	-0.37	7.57e-15	Life satisfaction;
LUAD	cis	rs7593730	1.000	rs9287795	chr2:161209788	C/G	cg22609984	chr2:161126801	NA	0.43	7.09	0.33	5.72e-12	Type 2 diabetes;
LUAD	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg22681709	chr2:178499509	PDE11A	-0.54	-9.17	-0.41	2.02e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7617773	0.817	rs13059037	chr3:48287879	A/G	cg11946769	chr3:48343235	NME6	0.44	6.75	0.31	4.79e-11	Coronary artery disease;
LUAD	cis	rs9863	0.828	rs75989601	chr12:124466723	C/T	cg17723958	chr12:124429295	CCDC92	-0.41	-6.71	-0.31	6.15e-11	White blood cell count;
LUAD	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg19622623	chr12:86230825	RASSF9	0.43	7.54	0.34	2.89e-13	Major depressive disorder;
LUAD	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg11693508	chr17:37793320	STARD3	0.82	10.41	0.45	9.53e-23	Bipolar disorder;
LUAD	cis	rs6484504	0.553	rs413067	chr11:31223497	T/C	cg06552810	chr11:31128660	NA	-0.32	-6.38	-0.3	4.77e-10	Red blood cell count;
LUAD	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg22117172	chr7:91764530	CYP51A1	-0.34	-7.59	-0.35	2.1e-13	Breast cancer;
LUAD	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.46	7.08	0.33	6.18e-12	Schizophrenia;
LUAD	cis	rs17253792	0.822	rs28513551	chr14:56094993	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs11723261	0.582	rs11248005	chr4:166615	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.41	7.34	0.34	1.1e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.47	-6.5	-0.3	2.25e-10	Iron status biomarkers;
LUAD	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg17063962	chr7:91808500	NA	0.64	10.91	0.47	1.35e-24	Breast cancer;
LUAD	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2652834	0.950	rs2729787	chr15:63401493	G/T	cg25406657	chr15:63342033	TPM1	-0.39	-6.37	-0.3	4.82e-10	HDL cholesterol;
LUAD	cis	rs9948	0.655	rs56913233	chr2:97405896	A/G	cg20312557	chr2:97357134	FER1L5	-0.72	-8.08	-0.37	6.78e-15	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs6458375	1.000	rs62401156	chr6:44203360	G/A	cg04609694	chr6:44204009	NA	0.53	8.46	0.38	4.31e-16	Interleukin-10 levels;
LUAD	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg08601574	chr20:25228251	PYGB	0.46	8.81	0.39	3.18e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs870825	0.655	rs6845058	chr4:185653696	G/A	cg04058563	chr4:185651563	MLF1IP	-0.8	-11.57	-0.49	4.34e-27	Blood protein levels;
LUAD	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg00255919	chr5:131827918	IRF1	-0.28	-6.36	-0.3	5.36e-10	Blood metabolite levels;
LUAD	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg19743168	chr1:23544995	NA	0.36	6.44	0.3	3.23e-10	Height;
LUAD	cis	rs61776719	0.810	rs34655914	chr1:38397341	G/A	cg04673462	chr1:38461896	NA	0.49	10.48	0.45	5.41e-23	Coronary artery disease;
LUAD	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.63	-0.35	1.54e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg06547715	chr2:218990976	CXCR2	-0.28	-6.78	-0.31	4.1e-11	Colorectal cancer;
LUAD	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg16006841	chr5:176797999	RGS14	0.53	9.49	0.42	1.73e-19	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs13064411	0.696	rs7624994	chr3:113228009	T/C	cg10517650	chr3:113235015	CCDC52	-0.55	-9.54	-0.42	1.14e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs4650994	0.816	rs2093770	chr1:178604633	C/A	cg05059571	chr16:84539110	KIAA1609	0.5	8.09	0.37	6.33e-15	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs11671005	0.737	rs11673101	chr19:58995053	G/C	cg13877915	chr19:58951672	ZNF132	0.56	6.89	0.32	2.03e-11	Mean platelet volume;
LUAD	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg14558114	chr2:88469736	THNSL2	0.87	9.0	0.4	7.98e-18	Plasma clusterin levels;
LUAD	cis	rs16958440	0.867	rs12326457	chr18:44678425	A/G	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs738322	0.554	rs6001033	chr22:38557513	T/A	cg17652424	chr22:38574118	PLA2G6	-0.3	-8.22	-0.37	2.58e-15	Cutaneous nevi;
LUAD	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03934478	chr11:495069	RNH1	0.77	9.35	0.41	5.17e-19	Body mass index;
LUAD	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18876405	chr7:65276391	NA	-0.4	-6.46	-0.3	2.94e-10	Aortic root size;
LUAD	cis	rs250585	0.736	rs2040574	chr16:23510326	A/G	cg00143387	chr16:23521605	GGA2	-0.65	-7.47	-0.34	4.53e-13	Egg allergy;
LUAD	cis	rs2262909	0.925	rs73019838	chr19:22247732	T/A	cg11619707	chr19:22235551	ZNF257	0.5	7.74	0.35	7.28e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg17178900	chr1:205818956	PM20D1	-0.62	-12.42	-0.52	2.04e-30	Monocyte percentage of white cells;
LUAD	cis	rs11229555	0.609	rs12270515	chr11:58217945	G/A	cg15696309	chr11:58395628	NA	-0.75	-10.42	-0.45	8.7e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6445967	0.832	rs1055973	chr3:58308960	T/C	cg23715586	chr3:58305044	RPP14	0.46	8.22	0.37	2.6e-15	Platelet count;
LUAD	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg18190219	chr22:46762943	CELSR1	-0.55	-6.81	-0.31	3.26e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg11301795	chr4:187892539	NA	0.74	14.45	0.57	9.36e-39	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7072216	0.922	rs4488133	chr10:100159136	A/T	cg26618903	chr10:100175079	PYROXD2	0.32	7.14	0.33	4.06e-12	Metabolite levels;
LUAD	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.63	0.35	1.5700000000000001e-13	Bladder cancer;
LUAD	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22590775	chr19:49891494	CCDC155	0.68	11.16	0.48	1.64e-25	Multiple sclerosis;
LUAD	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg03188948	chr7:1209495	NA	0.77	7.04	0.32	7.93e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg11084020	chr7:27779567	TAX1BP1	-0.4	-6.73	-0.31	5.71e-11	Subcortical brain region volumes;
LUAD	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg18132916	chr6:79620363	NA	-0.45	-7.66	-0.35	1.29e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1395	0.710	rs11682913	chr2:27473649	G/A	cg23587288	chr2:27483067	SLC30A3	-0.41	-7.48	-0.34	4.33e-13	Blood metabolite levels;
LUAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18099408	chr3:52552593	STAB1	-0.46	-8.03	-0.36	9.96e-15	Bipolar disorder;
LUAD	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg24675658	chr1:53192096	ZYG11B	0.44	7.09	0.33	5.61e-12	Monocyte count;
LUAD	cis	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05901451	chr6:126070800	HEY2	0.44	6.52	0.3	2.05e-10	Endometrial cancer;
LUAD	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg23254163	chr1:152506842	NA	-0.27	-7.33	-0.34	1.15e-12	Hair morphology;
LUAD	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg25237894	chr2:233734115	C2orf82	0.64	12.28	0.51	7.14e-30	Coronary artery disease;
LUAD	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03452623	chr4:187889614	NA	0.82	17.73	0.65	5.19e-53	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg05283184	chr6:79620031	NA	-0.63	-12.53	-0.52	7.52e-31	Intelligence (multi-trait analysis);
LUAD	cis	rs7172809	0.643	rs4243046	chr15:77834746	T/C	cg11865553	chr15:77376250	NA	-0.39	-6.82	-0.31	3.13e-11	Glucose homeostasis traits;
LUAD	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg10909506	chr17:38081995	ORMDL3	0.38	6.64	0.31	9.79e-11	Self-reported allergy;
LUAD	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.6	-0.52	3.83e-31	Monocyte count;
LUAD	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.73	-0.35	7.69e-14	Personality dimensions;
LUAD	cis	rs356992	0.957	rs356979	chr2:60747743	T/C	cg08426369	chr2:60753602	BCL11A	0.45	7.69	0.35	1.03e-13	Educational attainment (years of education);
LUAD	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg26958806	chr6:27640298	NA	0.58	6.45	0.3	3.05e-10	Depression;
LUAD	cis	rs11771526	0.792	rs10249413	chr7:32304259	G/C	cg13207630	chr7:32358064	NA	0.6	7.34	0.34	1.07e-12	Body mass index;
LUAD	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.78e-11	Crohn's disease;
LUAD	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg09998033	chr7:158218633	PTPRN2	-0.42	-7.32	-0.34	1.29e-12	Obesity-related traits;
LUAD	cis	rs6964587	0.647	rs38801	chr7:92046327	G/T	cg17063962	chr7:91808500	NA	-0.61	-9.81	-0.43	1.3e-20	Breast cancer;
LUAD	cis	rs886126	0.627	rs4766559	chr12:111666984	C/T	cg10833066	chr12:111807467	FAM109A	0.53	7.54	0.34	2.89e-13	Coronary heart disease;
LUAD	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg23625390	chr15:77176239	SCAPER	-0.57	-9.19	-0.41	1.73e-18	Blood metabolite levels;
LUAD	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06544989	chr22:39130855	UNC84B	-0.44	-7.98	-0.36	1.35e-14	Menopause (age at onset);
LUAD	cis	rs807669	0.903	rs1780637	chr22:19178250	A/G	cg02655711	chr22:19163373	SLC25A1	0.87	19.03	0.68	9.21e-59	Metabolite levels;
LUAD	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.51	-8.87	-0.4	2.08e-17	Alzheimer's disease (late onset);
LUAD	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg04539111	chr16:67997858	SLC12A4	-0.52	-6.38	-0.3	4.62e-10	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4604732	0.631	rs4436425	chr1:247632323	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.27	0.33	1.74e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7216064	1.000	rs58551145	chr17:65837235	A/G	cg08758996	chr17:66097529	LOC651250	0.46	7.09	0.33	5.82e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg00310523	chr12:86230176	RASSF9	0.35	7.65	0.35	1.38e-13	Major depressive disorder;
LUAD	cis	rs2455799	0.574	rs2455800	chr3:15701589	T/G	cg16303742	chr3:15540471	COLQ	-0.49	-9.23	-0.41	1.33e-18	Mean platelet volume;
LUAD	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24308560	chr3:49941425	MST1R	-0.51	-8.49	-0.38	3.54e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.05	-0.36	8.58e-15	Gout;
LUAD	cis	rs7107174	1.000	rs2256187	chr11:77919768	G/A	cg19901956	chr11:77921274	USP35	-0.56	-6.75	-0.31	5e-11	Testicular germ cell tumor;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04558166	chr1:210001279	C1orf107	-0.54	-6.61	-0.31	1.13e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg07211511	chr3:129823064	LOC729375	-0.58	-7.59	-0.35	2.12e-13	Blood pressure (smoking interaction);
LUAD	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg04896959	chr15:78267971	NA	-0.66	-13.28	-0.54	6.91e-34	Coronary artery disease or large artery stroke;
LUAD	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg11645453	chr3:52864694	ITIH4	-0.39	-7.62	-0.35	1.73e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg18105134	chr13:113819100	PROZ	-1.0	-15.9	-0.61	5.55e-45	Platelet distribution width;
LUAD	cis	rs911186	0.782	rs34569203	chr6:27153984	A/C	cg12292205	chr6:26970375	C6orf41	-0.57	-6.93	-0.32	1.56e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9796	0.558	rs8043253	chr15:41503730	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.5	-9.04	-0.4	5.86e-18	Menopause (age at onset);
LUAD	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05890377	chr2:74357713	NA	0.74	11.56	0.49	4.96e-27	Gestational age at birth (maternal effect);
LUAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg03188948	chr7:1209495	NA	0.64	9.29	0.41	8.14e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2479724	0.569	rs75720073	chr6:41750301	T/A	cg17623882	chr6:41773611	USP49	0.52	7.76	0.35	6.54e-14	Menarche (age at onset);
LUAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg10862848	chr6:42927986	GNMT	-0.31	-8.77	-0.39	4.3e-17	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg03676636	chr4:99064102	C4orf37	0.31	8.08	0.37	6.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg23815491	chr16:72088622	HP	0.48	8.65	0.39	1.09e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	trans	rs8129326	0.664	rs13047294	chr21:35783445	G/A	cg07474852	chr4:123073612	NA	0.51	8.19	0.37	3.1e-15	Cancer;
LUAD	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.33	0.34	1.21e-12	Tonsillectomy;
LUAD	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg17724175	chr1:150552817	MCL1	0.39	9.34	0.41	5.49e-19	Tonsillectomy;
LUAD	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg00316803	chr15:76480434	C15orf27	-0.41	-8.05	-0.36	8.37e-15	Blood metabolite levels;
LUAD	trans	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg01620082	chr3:125678407	NA	-0.44	-6.54	-0.3	1.8e-10	Depression;
LUAD	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	6.52	0.3	2.07e-10	Lung cancer in ever smokers;
LUAD	cis	rs9322817	0.691	rs2499664	chr6:105301484	C/G	cg02098413	chr6:105308735	HACE1	0.41	9.01	0.4	7.23e-18	Thyroid stimulating hormone;
LUAD	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg10909506	chr17:38081995	ORMDL3	0.42	7.24	0.33	2.08e-12	Self-reported allergy;
LUAD	cis	rs2708377	0.789	rs3911150	chr12:11202248	A/G	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	-0.55	-6.87	-0.32	2.32e-11	Bitter taste perception;
LUAD	cis	rs2410601	0.562	rs13275125	chr8:18898352	T/A	cg19414122	chr8:18896631	NA	0.39	7.26	0.33	1.82e-12	Urinary albumin excretion rate in type 1 diabetes;
LUAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00166722	chr3:10149974	C3orf24	0.7	12.22	0.51	1.23e-29	Alzheimer's disease;
LUAD	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg06713675	chr4:122721982	EXOSC9	-0.59	-11.51	-0.49	7.35e-27	Type 2 diabetes;
LUAD	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26314531	chr2:26401878	FAM59B	-0.47	-6.63	-0.31	1.02e-10	Gut microbiome composition (summer);
LUAD	cis	rs11771526	0.892	rs11764802	chr7:32372978	C/T	cg27532318	chr7:32358331	NA	0.69	8.04	0.36	9.23e-15	Body mass index;
LUAD	cis	rs11696501	0.694	rs7266372	chr20:44266635	T/C	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.16	-0.37	3.75e-15	Brain structure;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05733361	chr15:85524456	PDE8A	-0.47	-7.2	-0.33	2.71e-12	Height;
LUAD	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg17063962	chr7:91808500	NA	0.61	10.04	0.44	2.03e-21	Breast cancer;
LUAD	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg05368731	chr17:41323189	NBR1	0.84	16.67	0.63	2.46e-48	Menopause (age at onset);
LUAD	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg11247378	chr22:39784982	NA	0.75	14.3	0.57	3.99e-38	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg23758822	chr17:41437982	NA	1.01	20.82	0.71	8.65e-67	Menopause (age at onset);
LUAD	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.48	-0.38	3.78e-16	Total body bone mineral density;
LUAD	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg00857998	chr1:205179979	DSTYK	0.4	6.55	0.3	1.71e-10	Red blood cell count;
LUAD	cis	rs6087990	0.735	rs6087420	chr20:31359391	G/A	cg13636640	chr20:31349939	DNMT3B	0.76	14.17	0.57	1.44e-37	Ulcerative colitis;
LUAD	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg12310025	chr6:25882481	NA	-0.58	-9.54	-0.42	1.17e-19	Blood metabolite levels;
LUAD	cis	rs829883	0.668	rs829882	chr12:98880099	A/G	cg25150519	chr12:98850993	NA	0.41	6.8	0.31	3.63e-11	Colorectal adenoma (advanced);
LUAD	cis	rs4699052	0.963	rs4699057	chr4:104171123	A/G	cg16532752	chr4:104119610	CENPE	0.42	6.43	0.3	3.46e-10	Testicular germ cell tumor;
LUAD	trans	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg18335740	chr13:41363409	SLC25A15	0.77	14.95	0.59	6.8e-41	Lewy body disease;
LUAD	cis	rs10821973	0.527	rs4322347	chr10:64023097	C/T	cg09941381	chr10:64027924	RTKN2	-0.35	-6.81	-0.31	3.41e-11	Hypothyroidism;
LUAD	cis	rs6674176	0.542	rs803675	chr1:44353237	G/A	cg12908607	chr1:44402522	ARTN	-0.39	-7.01	-0.32	9.58e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg12935359	chr14:103987150	CKB	0.49	7.61	0.35	1.83e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2456568	0.802	rs1395387	chr11:93639307	A/T	cg26875233	chr11:93583750	C11orf90	-0.28	-6.35	-0.3	5.45e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg23954153	chr1:44402353	ARTN	-0.36	-6.68	-0.31	7.6e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg17644776	chr2:200775616	C2orf69	0.6	10.14	0.44	8.94e-22	Osteoporosis;
LUAD	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg17724175	chr1:150552817	MCL1	0.38	8.74	0.39	5.47e-17	Melanoma;
LUAD	cis	rs4594175	0.886	rs11157802	chr14:51622984	C/T	cg23942311	chr14:51606299	NA	0.65	11.43	0.49	1.55e-26	Cancer;
LUAD	cis	rs6906287	0.647	rs13219555	chr6:118816364	G/A	cg05564266	chr6:118973597	C6orf204	0.35	7.42	0.34	6.33e-13	Electrocardiographic conduction measures;
LUAD	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg03526776	chr6:41159608	TREML2	0.33	6.83	0.32	2.88e-11	Alzheimer's disease (late onset);
LUAD	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg21427119	chr20:30132790	HM13	-0.61	-9.25	-0.41	1.09e-18	Mean corpuscular hemoglobin;
LUAD	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11890956	chr21:40555474	PSMG1	-0.58	-9.44	-0.42	2.5e-19	Cognitive function;
LUAD	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg22823121	chr1:150693482	HORMAD1	0.45	9.13	0.41	2.95e-18	Tonsillectomy;
LUAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14159672	chr1:205819179	PM20D1	0.6	10.86	0.47	2.2e-24	Menarche (age at onset);
LUAD	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.49	10.14	0.44	9.13e-22	Monocyte percentage of white cells;
LUAD	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22857025	chr5:266934	NA	-0.99	-14.44	-0.57	1.05e-38	Breast cancer;
LUAD	cis	rs1941023	0.503	rs4528348	chr11:60129505	C/G	cg08716584	chr11:60157161	MS4A7	-0.46	-8.84	-0.39	2.58e-17	Congenital heart disease (maternal effect);
LUAD	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg07570687	chr10:102243282	WNT8B	0.48	7.28	0.33	1.6e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12667521	chr19:29218732	NA	0.6	8.53	0.38	2.65e-16	Methadone dose in opioid dependence;
LUAD	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg24733560	chr20:60626293	TAF4	0.47	8.35	0.38	9.770000000000001e-16	Body mass index;
LUAD	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg09455208	chr3:40491958	NA	0.59	12.44	0.52	1.68e-30	Renal cell carcinoma;
LUAD	cis	rs7487075	0.619	rs12822345	chr12:46834677	G/C	cg23829395	chr12:46796953	NA	0.32	6.96	0.32	1.3e-11	Itch intensity from mosquito bite;
LUAD	cis	rs853679	0.760	rs9368563	chr6:28208558	A/G	cg16479474	chr6:28041457	NA	0.41	6.68	0.31	7.73e-11	Depression;
LUAD	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg24579218	chr15:68104479	NA	-0.62	-9.92	-0.43	5.39e-21	Restless legs syndrome;
LUAD	trans	rs7939886	0.920	rs12224086	chr11:55798259	G/T	cg15704280	chr7:45808275	SEPT13	0.68	6.63	0.31	1.02e-10	Myopia (pathological);
LUAD	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.48	0.3	2.5e-10	Aortic root size;
LUAD	cis	rs714027	0.967	rs4823077	chr22:30545149	A/G	cg11564601	chr22:30592435	NA	-0.39	-8.33	-0.38	1.13e-15	Lymphocyte counts;
LUAD	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg11416102	chr8:651193	ERICH1	0.94	8.99	0.4	8.51e-18	IgG glycosylation;
LUAD	cis	rs6426558	0.537	rs694740	chr1:227293451	A/G	cg10327440	chr1:227177885	CDC42BPA	0.55	8.92	0.4	1.42e-17	Neutrophil percentage of white cells;
LUAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.53	0.3	1.88e-10	Prudent dietary pattern;
LUAD	cis	rs236352	0.576	rs3778016	chr6:36842192	C/T	cg10099585	chr6:36853529	C6orf89	-0.39	-6.38	-0.3	4.55e-10	Heart rate;
LUAD	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg11645453	chr3:52864694	ITIH4	-0.39	-7.71	-0.35	9.09e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs701145	0.537	rs449361	chr3:153922410	T/C	cg17054900	chr3:154042577	DHX36	0.66	7.08	0.33	6.13e-12	Coronary artery disease;
LUAD	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg09455208	chr3:40491958	NA	0.58	12.8	0.53	6.19e-32	Renal cell carcinoma;
LUAD	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg20607798	chr8:58055168	NA	0.67	8.77	0.39	4.44e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg27454412	chr7:1067447	C7orf50	0.41	6.85	0.32	2.56e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.91	12.62	0.52	3.34e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18876405	chr7:65276391	NA	0.41	6.39	0.3	4.42e-10	Aortic root size;
LUAD	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg25817165	chr18:72167213	CNDP2	-0.82	-14.18	-0.57	1.35e-37	Refractive error;
LUAD	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg14092988	chr3:52407081	DNAH1	0.42	8.19	0.37	3.21e-15	Bipolar disorder;
LUAD	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg21153622	chr11:89784906	NA	-0.33	-6.52	-0.3	2.03e-10	Coronary artery disease;
LUAD	cis	rs6062509	0.965	rs6062506	chr20:62352389	T/G	cg01176363	chr20:62369445	LIME1	-0.47	-7.66	-0.35	1.27e-13	Prostate cancer;
LUAD	cis	rs4917300	0.935	rs4917295	chr8:143119810	A/T	cg25363559	chr8:143086065	NA	-0.33	-6.59	-0.31	1.29e-10	Amyotrophic lateral sclerosis;
LUAD	cis	rs239198	0.568	rs34555037	chr6:101327153	G/C	cg09795085	chr6:101329169	ASCC3	0.39	6.63	0.31	1e-10	Menarche (age at onset);
LUAD	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg14345882	chr6:26364793	BTN3A2	0.65	6.49	0.3	2.36e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.43	-0.42	2.82e-19	Life satisfaction;
LUAD	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs4604732	0.589	rs78689516	chr1:247626274	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg11301795	chr4:187892539	NA	-0.76	-15.17	-0.59	8.39e-42	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg11292332	chr7:45801988	SEPT13	-0.31	-6.84	-0.32	2.81e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	6.06e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg10518543	chr12:38710700	ALG10B	0.42	6.44	0.3	3.22e-10	Bladder cancer;
LUAD	cis	rs7833986	1.000	rs13273123	chr8:57100791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	-0.75	-10.11	-0.44	1.11e-21	Height;
LUAD	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg15181151	chr6:150070149	PCMT1	0.39	8.07	0.37	7.15e-15	Lung cancer;
LUAD	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.44	-0.49	1.38e-26	Primary sclerosing cholangitis;
LUAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg07685180	chr8:600429	NA	0.87	8.86	0.4	2.28e-17	IgG glycosylation;
LUAD	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg25809561	chr17:30822961	MYO1D	0.7	14.16	0.57	1.59e-37	Schizophrenia;
LUAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	8.38	0.38	8.08e-16	Electroencephalogram traits;
LUAD	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.43	0.34	6.18e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26314531	chr2:26401878	FAM59B	0.6	8.34	0.38	1.06e-15	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg20503657	chr10:835505	NA	0.96	14.69	0.58	9.35e-40	Eosinophil percentage of granulocytes;
LUAD	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23158103	chr7:148848205	ZNF398	-0.61	-11.21	-0.48	1.05e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg04154034	chr17:28927549	LRRC37B2	0.68	6.74	0.31	5.33e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.44	0.57	1.08e-38	Schizophrenia;
LUAD	cis	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg07460842	chr6:66804631	NA	0.92	14.39	0.57	1.7e-38	Exhaled nitric oxide levels;
LUAD	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg24838063	chr12:130822603	PIWIL1	0.66	11.07	0.47	3.53e-25	Menopause (age at onset);
LUAD	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg13565492	chr6:43139072	SRF	-0.6	-6.35	-0.3	5.72e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg25985355	chr7:65971099	NA	0.39	7.28	0.33	1.6e-12	Aortic root size;
LUAD	trans	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.92	-18.52	-0.67	1.67e-56	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.22	-0.48	9.55e-26	Depression;
LUAD	cis	rs7843479	0.544	rs11135735	chr8:21791557	C/T	cg03445287	chr8:21823731	XPO7	-0.5	-9.37	-0.41	4.38e-19	Mean corpuscular volume;
LUAD	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg17173187	chr15:85201210	NMB	0.39	6.36	0.3	5.2400000000000005e-10	Schizophrenia;
LUAD	trans	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.44	0.42	2.59e-19	Mean corpuscular volume;
LUAD	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg18944383	chr4:111397179	ENPEP	0.39	7.79	0.35	5.19e-14	Height;
LUAD	cis	rs72634258	0.519	rs2071984	chr1:7928656	C/T	cg26816564	chr1:7831052	VAMP3	0.51	7.29	0.33	1.51e-12	Inflammatory bowel disease;
LUAD	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7077164	0.960	rs1227777	chr10:71581131	A/G	cg07630274	chr10:71583235	COL13A1	0.28	6.5	0.3	2.25e-10	Non-alcoholic fatty liver disease histology (lobular);
LUAD	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02018176	chr4:1364513	KIAA1530	0.7	12.15	0.51	2.4e-29	Longevity;
LUAD	cis	rs3733418	1.000	rs3733419	chr4:165878170	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.49	-6.89	-0.32	2.07e-11	Obesity-related traits;
LUAD	cis	rs250677	0.522	rs10038913	chr5:148354224	A/G	cg18129178	chr5:148520854	ABLIM3	0.52	8.12	0.37	5.32e-15	Breast cancer;
LUAD	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg20701182	chr2:24300061	SF3B14	0.65	7.32	0.34	1.25e-12	Lymphocyte counts;
LUAD	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg05110241	chr16:68378359	PRMT7	-0.69	-7.81	-0.35	4.7e-14	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21659725	chr3:3221576	CRBN	-0.64	-10.23	-0.45	4.26e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	9.35	0.41	4.99e-19	Colorectal cancer;
LUAD	cis	rs6547631	0.622	rs1437743	chr2:85924989	A/G	cg21473183	chr2:85925749	GNLY	-0.32	-6.4	-0.3	4.21e-10	Blood protein levels;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg15219393	chr5:149109878	PPARGC1B	-0.41	-6.85	-0.32	2.55e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.4	-7.06	-0.32	6.72e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9487051	0.735	rs351754	chr6:109537553	A/G	cg21918786	chr6:109611834	NA	0.44	7.97	0.36	1.47e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg09365446	chr1:150670422	GOLPH3L	0.66	12.58	0.52	4.9e-31	Tonsillectomy;
LUAD	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg02782426	chr3:40428986	ENTPD3	-0.43	-9.06	-0.4	4.86e-18	Renal cell carcinoma;
LUAD	trans	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg06606381	chr12:133084897	FBRSL1	-0.58	-7.34	-0.34	1.08e-12	Depression;
LUAD	cis	rs9814567	0.762	rs13071253	chr3:134316653	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	12.67	0.52	2.11e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs420259	0.508	rs11074560	chr16:23493356	G/A	cg00143387	chr16:23521605	GGA2	-0.68	-8.96	-0.4	1.08e-17	Bipolar disorder;
LUAD	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.53	-0.34	3.05e-13	Breast cancer;
LUAD	cis	rs7584330	0.554	rs9646716	chr2:238443784	C/T	cg14458575	chr2:238380390	NA	0.6	9.65	0.42	4.63e-20	Prostate cancer;
LUAD	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.6	11.33	0.48	3.69e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12541635	0.966	rs16873989	chr8:106966381	C/T	cg10147462	chr8:107024639	NA	0.47	8.21	0.37	2.68e-15	Age of smoking initiation;
LUAD	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg12564285	chr5:131593104	PDLIM4	0.39	7.39	0.34	7.84e-13	Acylcarnitine levels;
LUAD	cis	rs1018836	0.828	rs7816023	chr8:91567398	T/C	cg16814680	chr8:91681699	NA	-0.6	-9.97	-0.44	3.53e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg25767906	chr1:53392781	SCP2	-0.49	-8.74	-0.39	5.55e-17	Monocyte count;
LUAD	cis	rs57994353	0.897	rs3812595	chr9:139369062	C/T	cg14364472	chr9:139394549	NOTCH1	-0.45	-6.81	-0.31	3.27e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7010267	0.596	rs4354338	chr8:120016060	A/C	cg01975934	chr8:119970761	NA	-0.35	-6.62	-0.31	1.07e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg04944784	chr2:26401820	FAM59B	0.9	12.38	0.52	2.86e-30	Gut microbiome composition (summer);
LUAD	cis	rs7589342	0.839	rs1465641	chr2:106438936	C/T	cg16077055	chr2:106428750	NCK2	0.35	6.41	0.3	3.9e-10	Addiction;
LUAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-8.04	-0.36	9.09e-15	Alzheimer's disease;
LUAD	cis	rs9863	0.694	rs11837287	chr12:124470059	C/T	cg17723958	chr12:124429295	CCDC92	-0.39	-6.47	-0.3	2.78e-10	White blood cell count;
LUAD	cis	rs2617583	0.530	rs10060889	chr5:1456803	A/G	cg13982541	chr5:1466431	LPCAT1	0.54	8.67	0.39	9.44e-17	Breast cancer;
LUAD	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg17264618	chr3:40429014	ENTPD3	0.34	7.2	0.33	2.75e-12	Renal cell carcinoma;
LUAD	cis	rs654950	1.000	rs600401	chr1:41984658	C/T	cg06885757	chr1:42089581	HIVEP3	0.36	8.03	0.36	9.61e-15	Airway imaging phenotypes;
LUAD	cis	rs8027181	0.958	rs4776614	chr15:73082468	C/G	cg25632853	chr15:73088954	NA	0.37	8.17	0.37	3.5e-15	Triglyceride levels;
LUAD	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg06618935	chr21:46677482	NA	0.37	7.64	0.35	1.48e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs2735413	0.918	rs12931394	chr16:78081629	G/A	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg13271783	chr10:134563150	INPP5A	0.39	6.59	0.31	1.28e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg00750074	chr16:89608354	SPG7	-0.57	-9.89	-0.43	6.76e-21	Multiple myeloma (IgH translocation);
LUAD	cis	rs713587	0.563	rs10865315	chr2:25100738	C/A	cg04586622	chr2:25135609	ADCY3	0.38	8.6	0.39	1.6e-16	Body mass index in non-asthmatics;
LUAD	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg10518543	chr12:38710700	ALG10B	0.43	6.52	0.3	2.04e-10	Bladder cancer;
LUAD	cis	rs7809950	0.817	rs4727679	chr7:107085018	T/C	cg23024343	chr7:107201750	COG5	-0.87	-14.53	-0.58	4.32e-39	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg05368731	chr17:41323189	NBR1	0.97	20.35	0.7	1.07e-64	Menopause (age at onset);
LUAD	trans	rs747782	0.582	rs11039571	chr11:48207259	G/A	cg15704280	chr7:45808275	SEPT13	0.67	7.68	0.35	1.09e-13	Intraocular pressure;
LUAD	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg00316803	chr15:76480434	C15orf27	-0.4	-6.8	-0.31	3.68e-11	Blood metabolite levels;
LUAD	cis	rs748404	0.697	rs572959	chr15:43550502	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.52	0.34	3.21e-13	Lung cancer;
LUAD	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg03806693	chr22:41940476	POLR3H	0.54	7.99	0.36	1.29e-14	Vitiligo;
LUAD	cis	rs12545109	0.842	rs2609975	chr8:57401667	T/C	cg09654669	chr8:57350985	NA	-0.64	-9.36	-0.41	4.69e-19	Obesity-related traits;
LUAD	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg21028142	chr17:79581711	NPLOC4	0.42	8.83	0.39	2.71e-17	Eye color traits;
LUAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg08027265	chr7:2291960	NA	-0.4	-6.73	-0.31	5.53e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg18016565	chr1:150552671	MCL1	-0.42	-7.6	-0.35	1.91e-13	Tonsillectomy;
LUAD	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg19700328	chr14:106028568	NA	-0.46	-7.88	-0.36	2.72e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs16867321	0.639	rs12466770	chr2:181441312	C/G	cg23363182	chr2:181467187	NA	0.43	6.99	0.32	1.09e-11	Obesity;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg13053135	chr2:234359932	DGKD	-0.39	-6.44	-0.3	3.32e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg12034118	chr1:209979487	IRF6	0.61	6.89	0.32	2.02e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs6906287	0.647	rs3890198	chr6:118706447	T/C	cg05564266	chr6:118973597	C6orf204	0.33	7.06	0.32	6.82e-12	Electrocardiographic conduction measures;
LUAD	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12756686	chr19:29218302	NA	0.66	9.69	0.43	3.49e-20	Methadone dose in opioid dependence;
LUAD	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg24818145	chr4:99064322	C4orf37	0.46	7.88	0.36	2.74e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg14458575	chr2:238380390	NA	0.65	12.6	0.52	4.05e-31	Prostate cancer;
LUAD	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg16342193	chr10:102329863	NA	0.35	6.35	0.3	5.56e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs12505328	0.966	rs1946968	chr4:174366240	C/A	cg12145043	chr4:174357286	NA	0.56	10.2	0.44	5.65e-22	Chin dimples;
LUAD	cis	rs2554380	0.843	rs2554386	chr15:84403522	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.48	-7.5	-0.34	3.79e-13	Height;
LUAD	cis	rs9479482	0.678	rs3903885	chr6:150364128	G/A	cg08316699	chr6:150357289	NA	0.32	6.55	0.3	1.69e-10	Alopecia areata;
LUAD	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg11814155	chr7:99998594	ZCWPW1	0.42	7.32	0.34	1.25e-12	Platelet count;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg00554614	chr7:127225750	GCC1	0.36	6.36	0.3	5.38e-10	Bipolar disorder;
LUAD	cis	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg27411982	chr8:10470053	RP1L1	0.46	8.27	0.37	1.77e-15	Neuroticism;
LUAD	cis	rs4077515	0.934	rs3829111	chr9:139269483	G/A	cg14019695	chr9:139328340	INPP5E	0.41	7.85	0.36	3.37e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg23018236	chr17:30244563	NA	-0.62	-8.02	-0.36	1.04e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg24818145	chr4:99064322	C4orf37	0.48	8.17	0.37	3.53e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg07776626	chr8:57350775	NA	-0.6	-9.01	-0.4	7.35e-18	Obesity-related traits;
LUAD	cis	rs2387326	0.638	rs75285784	chr10:129940551	A/C	cg16087940	chr10:129947807	NA	-0.62	-8.29	-0.37	1.47e-15	Select biomarker traits;
LUAD	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	9.14	0.41	2.61e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs713587	0.563	rs7591460	chr2:25103967	A/C	cg04586622	chr2:25135609	ADCY3	0.38	8.58	0.39	1.8e-16	Body mass index in non-asthmatics;
LUAD	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-14.21	-0.57	1.01e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.86	0.32	2.46e-11	Obesity-related traits;
LUAD	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg21775007	chr8:11205619	TDH	0.45	8.16	0.37	3.76e-15	Retinal vascular caliber;
LUAD	cis	rs9487051	0.799	rs351724	chr6:109546577	T/C	cg21918786	chr6:109611834	NA	-0.41	-7.25	-0.33	1.96e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg08508325	chr11:3079039	CARS	0.44	8.97	0.4	9.4e-18	Calcium levels;
LUAD	cis	rs17401966	0.965	rs12751375	chr1:10291874	C/G	cg15208524	chr1:10270712	KIF1B	0.54	7.87	0.36	3.1e-14	Hepatocellular carcinoma;
LUAD	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg18196295	chr10:418757	DIP2C	0.46	7.72	0.35	8.75e-14	Psychosis in Alzheimer's disease;
LUAD	cis	rs12541635	0.966	rs4734128	chr8:107026913	G/A	cg10147462	chr8:107024639	NA	0.51	9.21	0.41	1.53e-18	Age of smoking initiation;
LUAD	cis	rs250585	0.920	rs250555	chr16:23444268	T/C	cg00143387	chr16:23521605	GGA2	0.62	7.56	0.34	2.61e-13	Egg allergy;
LUAD	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg02734326	chr4:10020555	SLC2A9	0.57	10.05	0.44	1.84e-21	Bone mineral density;
LUAD	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg06784218	chr1:46089804	CCDC17	0.53	11.22	0.48	9.13e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2249625	0.523	rs2463702	chr6:72853778	A/G	cg18830697	chr6:72922368	RIMS1	0.37	7.2	0.33	2.86e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.5	-8.89	-0.4	1.75e-17	Eosinophil percentage of white cells;
LUAD	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg23978390	chr7:1156363	C7orf50	0.44	6.4	0.3	4.09e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg06740227	chr12:86229804	RASSF9	0.45	7.88	0.36	2.78e-14	Major depressive disorder;
LUAD	cis	rs2535633	0.631	rs2710313	chr3:52969529	T/A	cg11645453	chr3:52864694	ITIH4	-0.38	-6.97	-0.32	1.19e-11	Body mass index;
LUAD	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.41	-0.34	7e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg26354017	chr1:205819088	PM20D1	-0.54	-8.25	-0.37	2.1e-15	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20273774	chr5:180671298	GNB2L1;SNORD95	0.52	6.56	0.3	1.54e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10802521	chr3:52805072	NEK4	-0.62	-11.22	-0.48	9.81e-26	Bipolar disorder;
LUAD	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg17366294	chr4:99064904	C4orf37	0.57	9.73	0.43	2.54e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12681287	0.547	rs35871312	chr8:87543219	T/C	cg27223183	chr8:87520930	FAM82B	0.72	10.23	0.45	4.23e-22	Caudate activity during reward;
LUAD	cis	rs986417	0.786	rs2038277	chr14:61083662	G/A	cg27398547	chr14:60952738	C14orf39	0.69	7.47	0.34	4.79e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg09491104	chr22:46646882	C22orf40	-0.59	-7.73	-0.35	7.88e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg03396347	chr1:1875803	NA	-0.62	-16.03	-0.61	1.59e-45	Body mass index;
LUAD	cis	rs4774899	0.832	rs2703596	chr15:57492360	C/T	cg14026238	chr15:57616123	NA	0.34	6.37	0.3	4.96e-10	Urinary tract infection frequency;
LUAD	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg24558204	chr6:135376177	HBS1L	0.44	7.88	0.36	2.76e-14	Red blood cell count;
LUAD	cis	rs1371614	0.632	rs3739085	chr2:27163044	T/C	cg00617064	chr2:27272375	NA	-0.33	-6.47	-0.3	2.77e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.44	0.57	1.08e-38	Schizophrenia;
LUAD	cis	rs12216545	0.765	rs1916002	chr7:150250894	A/G	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.39	-0.3	4.27e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg07917127	chr4:99064746	C4orf37	0.45	7.35	0.34	1.03e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1003719	0.788	rs2835592	chr21:38464387	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.31e-16	Eye color traits;
LUAD	cis	rs7843479	0.965	rs1484162	chr8:21831385	A/G	cg03445287	chr8:21823731	XPO7	-0.46	-8.35	-0.38	9.78e-16	Mean corpuscular volume;
LUAD	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg03563238	chr19:33554763	RHPN2	-0.37	-8.78	-0.39	4.21e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6484504	0.576	rs158146	chr11:31210433	G/A	cg26647111	chr11:31128758	NA	-0.45	-7.97	-0.36	1.47e-14	Red blood cell count;
LUAD	cis	rs11229555	1.000	rs2276153	chr11:58407740	C/G	cg15696309	chr11:58395628	NA	-0.72	-10.84	-0.47	2.54e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg09455208	chr3:40491958	NA	0.55	12.16	0.51	2.23e-29	Renal cell carcinoma;
LUAD	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg15128208	chr22:42549153	NA	0.4	6.51	0.3	2.17e-10	Birth weight;
LUAD	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg01097406	chr16:89675127	NA	-0.33	-6.64	-0.31	9.86e-11	Vitiligo;
LUAD	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.37	0.38	8.26e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.04e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6489882	0.510	rs61478890	chr12:113364375	A/G	cg20102336	chr12:113376681	OAS3	-0.6	-9.28	-0.41	8.88e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs6484504	0.576	rs438578	chr11:31222579	A/G	cg06552810	chr11:31128660	NA	0.32	6.47	0.3	2.7e-10	Red blood cell count;
LUAD	cis	rs1524976	1.000	rs2037670	chr3:65488142	C/A	cg16238336	chr3:65465873	MAGI1	-0.65	-7.47	-0.34	4.72e-13	PR interval;
LUAD	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg03806693	chr22:41940476	POLR3H	0.73	9.8	0.43	1.39e-20	Vitiligo;
LUAD	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg13119609	chr19:45449297	APOC2	0.61	12.85	0.53	3.94e-32	Blood protein levels;
LUAD	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18099408	chr3:52552593	STAB1	-0.43	-7.7	-0.35	1e-13	Bipolar disorder;
LUAD	trans	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg06606381	chr12:133084897	FBRSL1	-0.72	-8.09	-0.37	6.32e-15	Depression;
LUAD	cis	rs28595532	1.000	rs114778020	chr4:119662584	C/A	cg21605333	chr4:119757512	SEC24D	0.82	7.29	0.33	1.49e-12	Cannabis dependence symptom count;
LUAD	cis	rs864537	0.618	rs2988277	chr1:167431352	A/G	cg22356347	chr1:167427500	CD247	0.47	9.41	0.42	3.13e-19	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs10489202	0.608	rs3753934	chr1:168074677	C/T	cg25738037	chr1:168025549	DCAF6	-0.45	-6.77	-0.31	4.44e-11	Schizophrenia;
LUAD	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.67	-0.35	1.2e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg07988820	chr12:82153109	PPFIA2	0.47	7.39	0.34	7.87e-13	Resting heart rate;
LUAD	cis	rs9309473	0.607	rs1851546	chr2:73591127	C/A	cg20560298	chr2:73613845	ALMS1	-0.43	-6.7	-0.31	6.83e-11	Metabolite levels;
LUAD	cis	rs9462027	0.628	rs9348950	chr6:34673678	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.34	8.65	0.39	1.09e-16	Systemic lupus erythematosus;
LUAD	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg00204512	chr16:28754710	NA	0.33	7.27	0.33	1.79e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7582720	1.000	rs35212307	chr2:203765756	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg10523679	chr1:76189770	ACADM	0.79	11.95	0.5	1.45e-28	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs354225	0.554	rs10166844	chr2:54798272	T/C	cg01766943	chr2:54829624	SPTBN1	0.36	6.42	0.3	3.6e-10	Schizophrenia;
LUAD	cis	rs62400317	0.762	rs62436374	chr6:44874785	C/G	cg18551225	chr6:44695536	NA	-0.58	-8.79	-0.39	3.69e-17	Total body bone mineral density;
LUAD	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg02221422	chr11:68192511	LRP5	-0.4	-6.64	-0.31	9.86e-11	Total body bone mineral density;
LUAD	cis	rs3916	0.911	rs34673751	chr12:121171891	G/A	cg27246729	chr12:121163418	ACADS	0.47	7.38	0.34	8.67e-13	Urinary metabolites (H-NMR features);
LUAD	cis	rs250677	0.522	rs6580589	chr5:148360335	C/G	cg18129178	chr5:148520854	ABLIM3	0.51	7.62	0.35	1.65e-13	Breast cancer;
LUAD	trans	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg04565464	chr8:145669602	NFKBIL2	0.44	6.57	0.3	1.45e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg08132940	chr7:1081526	C7orf50	-0.79	-10.71	-0.46	7.69e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.75	9.11	0.4	3.32e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2882667	0.822	rs11738376	chr5:138398172	G/A	cg04439458	chr5:138467593	SIL1	-0.52	-9.38	-0.42	3.93e-19	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs13418410	0.539	rs1545399	chr2:33843801	A/G	cg04131969	chr2:33951647	MYADML	-0.64	-10.32	-0.45	2.01e-22	Non-response to antidepressants and depression;
LUAD	cis	rs62229266	0.740	rs4817759	chr21:37389559	G/A	cg08632701	chr21:37451849	NA	-0.44	-7.29	-0.33	1.51e-12	Mitral valve prolapse;
LUAD	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg17105886	chr17:28927953	LRRC37B2	0.72	7.05	0.32	7.19e-12	Body mass index;
LUAD	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg04450456	chr4:17643702	FAM184B	0.43	8.49	0.38	3.45e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg22823121	chr1:150693482	HORMAD1	0.42	8.32	0.38	1.19e-15	Tonsillectomy;
LUAD	cis	rs601339	1.000	rs4759361	chr12:123178280	T/A	cg11919336	chr12:123188078	GPR109A	0.45	6.74	0.31	5.32e-11	Adiponectin levels;
LUAD	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg25985355	chr7:65971099	NA	0.53	6.59	0.3	1.34e-10	Diabetic kidney disease;
LUAD	cis	rs2882667	0.931	rs1433009	chr5:138333784	G/A	cg04439458	chr5:138467593	SIL1	-0.41	-7.5	-0.34	3.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1003719	0.762	rs11088381	chr21:38478429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.65	0.39	1.11e-16	Eye color traits;
LUAD	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg21862992	chr11:68658383	NA	0.56	10.16	0.44	7.35e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs12711979	0.509	rs13000873	chr2:3823705	T/C	cg17052675	chr2:3827356	NA	-0.83	-19.35	-0.69	3.11e-60	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg22166914	chr1:53195759	ZYG11B	-0.51	-8.86	-0.4	2.3e-17	Monocyte count;
LUAD	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg20476274	chr7:133979776	SLC35B4	0.71	12.96	0.53	1.38e-32	Mean platelet volume;
LUAD	cis	rs910187	0.678	rs6018328	chr20:45813180	T/C	cg27589058	chr20:45804311	EYA2	-0.31	-6.93	-0.32	1.54e-11	Migraine;
LUAD	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg21285383	chr16:89894308	SPIRE2	0.42	10.3	0.45	2.32e-22	Vitiligo;
LUAD	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg00666640	chr1:248458726	OR2T12	-0.33	-8.37	-0.38	8.73e-16	Common traits (Other);
LUAD	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg27170947	chr2:26402098	FAM59B	0.82	11.32	0.48	3.99e-26	Gut microbiome composition (summer);
LUAD	cis	rs2274273	0.934	rs2341621	chr14:55726425	C/T	cg04306507	chr14:55594613	LGALS3	0.4	8.48	0.38	3.82e-16	Protein biomarker;
LUAD	trans	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg01620082	chr3:125678407	NA	-0.67	-7.94	-0.36	1.84e-14	Depression;
LUAD	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg15962314	chr1:44399869	ARTN	0.34	7.69	0.35	1.02e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg17971929	chr21:40555470	PSMG1	-0.41	-6.39	-0.3	4.26e-10	Cognitive function;
LUAD	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.97	-0.32	1.19e-11	Type 2 diabetes;
LUAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg15147215	chr3:52552868	STAB1	-0.5	-9.47	-0.42	1.96e-19	Electroencephalogram traits;
LUAD	cis	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.96	-0.36	1.62e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg19901468	chr14:105411992	AHNAK2	-0.53	-10.27	-0.45	3.06e-22	Rheumatoid arthritis;
LUAD	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg27170947	chr2:26402098	FAM59B	-0.82	-11.49	-0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg21280719	chr6:42927975	GNMT	-0.41	-12.35	-0.51	4.03e-30	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs684232	0.644	rs1227030	chr17:619882	C/T	cg12384639	chr17:618140	VPS53	0.49	8.59	0.39	1.68e-16	Prostate cancer;
LUAD	cis	rs7680126	0.596	rs17418533	chr4:10316941	T/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-7.96	-0.36	1.56e-14	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg11301795	chr4:187892539	NA	-0.8	-16.53	-0.63	1.06e-47	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg00933542	chr6:150070202	PCMT1	0.43	8.85	0.4	2.47e-17	Lung cancer;
LUAD	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg10556349	chr10:835070	NA	0.59	7.64	0.35	1.48e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg07917127	chr4:99064746	C4orf37	0.42	6.98	0.32	1.14e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg15704280	chr7:45808275	SEPT13	-0.89	-16.44	-0.62	2.7e-47	Height;
LUAD	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg01884057	chr2:25150051	NA	0.32	6.9	0.32	1.95e-11	Body mass index;
LUAD	trans	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg24644049	chr4:85504048	CDS1	0.67	6.39	0.3	4.27e-10	Skin colour saturation;
LUAD	cis	rs4372836	0.729	rs6547873	chr2:28981983	G/A	cg09522027	chr2:28974177	PPP1CB	-0.7	-12.72	-0.53	1.35e-31	Body mass index;
LUAD	cis	rs4846217	1.000	rs6703602	chr1:10378451	C/G	cg17425144	chr1:10567563	PEX14	-0.5	-6.77	-0.31	4.38e-11	Platelet count;
LUAD	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg15557168	chr22:42548783	NA	-0.36	-6.4	-0.3	4.05e-10	Cognitive function;
LUAD	cis	rs2544523	0.511	rs2544535	chr2:15906778	A/G	cg26669897	chr2:15909070	NA	0.48	8.43	0.38	5.46e-16	Asthma or chronic obstructive pulmonary disease;
LUAD	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg18351406	chr4:77819688	ANKRD56	0.62	10.04	0.44	2.06e-21	Emphysema distribution in smoking;
LUAD	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg06618935	chr21:46677482	NA	-0.49	-10.03	-0.44	2.21e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1045714	0.895	rs4721860	chr7:2639994	C/T	cg20813462	chr7:2646259	IQCE	0.67	7.45	0.34	5.28e-13	Urate levels in lean individuals;
LUAD	trans	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg04775059	chr7:64541387	NA	0.5	6.72	0.31	5.9e-11	Aortic root size;
LUAD	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg10518543	chr12:38710700	ALG10B	-0.41	-6.86	-0.32	2.45e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11890956	chr21:40555474	PSMG1	-0.61	-9.93	-0.43	5.02e-21	Cognitive function;
LUAD	cis	rs7809950	0.724	rs1858888	chr7:107046062	T/A	cg23024343	chr7:107201750	COG5	-0.87	-14.65	-0.58	1.38e-39	Coronary artery disease;
LUAD	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06028808	chr11:68637592	NA	0.48	8.08	0.37	6.72e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg22823121	chr1:150693482	HORMAD1	0.43	8.62	0.39	1.33e-16	Tonsillectomy;
LUAD	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.56	-0.3	1.58e-10	Aortic root size;
LUAD	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg15557168	chr22:42548783	NA	-0.45	-8.35	-0.38	9.6e-16	Cognitive function;
LUAD	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23221052	chr5:179740743	GFPT2	-0.7	-11.89	-0.5	2.43e-28	Height;
LUAD	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg04414720	chr1:150670196	GOLPH3L	0.72	13.18	0.54	1.78e-33	Urate levels;
LUAD	trans	rs4714291	0.963	rs1721411	chr6:40102390	T/G	cg02267698	chr19:7991119	CTXN1	0.43	6.44	0.3	3.17e-10	Strep throat;
LUAD	cis	rs2235649	0.833	rs9929185	chr16:1852070	A/G	cg08610935	chr16:1836813	NUBP2	-0.48	-7.41	-0.34	6.77e-13	Blood metabolite levels;
LUAD	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg07617317	chr6:118971624	C6orf204	0.54	8.46	0.38	4.34e-16	Diastolic blood pressure;
LUAD	cis	rs7822232	0.908	rs6558297	chr8:145143934	C/T	cg07195118	chr8:145162905	KIAA1875	-0.67	-6.38	-0.3	4.62e-10	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.97	-0.32	1.23e-11	Bipolar disorder;
LUAD	cis	rs701145	0.640	rs2122365	chr3:153930808	T/G	cg17054900	chr3:154042577	DHX36	0.66	7.56	0.34	2.6e-13	Coronary artery disease;
LUAD	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg25173405	chr17:45401733	C17orf57	-0.46	-7.63	-0.35	1.56e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg19266014	chr7:2183958	MAD1L1	-0.39	-6.7	-0.31	6.59e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg08999081	chr20:33150536	PIGU	-0.62	-13.74	-0.56	8.78e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs595982	0.546	rs12461075	chr19:49399821	G/A	cg21252483	chr19:49399788	TULP2	-0.52	-10.0	-0.44	2.87e-21	Red cell distribution width;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg07332563	chr6:291687	DUSP22	-0.68	-11.81	-0.5	5.37e-28	Menopause (age at onset);
LUAD	cis	rs80319144	1.000	rs6711808	chr2:159267928	A/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.9	0.32	1.92e-11	Restless legs syndrome;
LUAD	cis	rs6987853	0.787	rs2974300	chr8:42440532	C/T	cg09913449	chr8:42400586	C8orf40	0.48	9.3	0.41	7.73e-19	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg17173187	chr15:85201210	NMB	-0.41	-6.66	-0.31	8.68e-11	Schizophrenia;
LUAD	cis	rs1595825	0.838	rs73058878	chr2:198895078	T/G	cg00361562	chr2:198649771	BOLL	-0.47	-6.53	-0.3	1.84e-10	Ulcerative colitis;
LUAD	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg01579765	chr21:45077557	HSF2BP	0.54	11.45	0.49	1.29e-26	Mean corpuscular volume;
LUAD	cis	rs10739663	0.520	rs1566362	chr9:128163132	C/T	cg13590414	chr9:128173245	NA	0.35	6.53	0.3	1.89e-10	Resting heart rate;
LUAD	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.59e-12	Crohn's disease;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg12828819	chr4:126236816	FAT4	-0.38	-6.47	-0.3	2.64e-10	Schizophrenia;
LUAD	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg13606994	chr1:44402422	ARTN	0.36	7.27	0.33	1.77e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs750460	1.000	rs750460	chr15:74241506	G/A	cg01349856	chr15:74220517	LOXL1	-0.38	-6.43	-0.3	3.41e-10	Height;
LUAD	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg06627628	chr2:24431161	ITSN2	-0.7	-11.28	-0.48	5.81e-26	Asthma;
LUAD	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.31	6.49	0.3	2.4e-10	Obesity-related traits;
LUAD	cis	rs12369635	1.000	rs73159540	chr12:129559421	C/T	cg01909103	chr12:129572610	TMEM132D	-0.66	-7.11	-0.33	4.85e-12	Schizophrenia (inflammation and infection response interaction);
LUAD	cis	rs16958440	0.867	rs78854354	chr18:44666924	C/G	cg17192377	chr18:44677553	HDHD2	0.84	7.85	0.36	3.48e-14	Sitting height ratio;
LUAD	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23583168	chr7:148888333	NA	-0.79	-13.44	-0.55	1.52e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg03340356	chr1:67600835	NA	0.41	7.44	0.34	5.69e-13	Psoriasis;
LUAD	trans	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.93	0.43	4.88e-21	Ulcerative colitis;
LUAD	cis	rs2901656	0.640	rs9425316	chr1:172400860	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.54	10.58	0.46	2.25e-23	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs12893668	0.703	rs8017993	chr14:104047734	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.32	-0.34	1.29e-12	Reticulocyte count;
LUAD	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg09367891	chr1:107599246	PRMT6	0.57	9.42	0.42	2.88e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs877282	1.000	rs877281	chr10:771557	T/G	cg22713356	chr15:30763199	NA	1.32	18.8	0.67	9.28e-58	Uric acid levels;
LUAD	cis	rs7507204	0.530	rs4807469	chr19:3443382	G/C	cg08380311	chr19:3435252	NFIC	0.44	7.14	0.33	4.2e-12	Height;
LUAD	cis	rs62238980	0.614	rs55739336	chr22:32505773	C/T	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12993740	chr5:65476531	SFRS12	-0.38	-6.42	-0.3	3.73e-10	Cancer;
LUAD	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg04568274	chr7:158649319	WDR60	0.41	6.68	0.31	7.6e-11	Height;
LUAD	cis	rs2041840	1.000	rs2041840	chr2:37467264	T/C	cg25727520	chr2:37576821	QPCT	-0.36	-7.25	-0.33	1.97e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg24813613	chr7:1882135	MAD1L1	-0.45	-7.15	-0.33	3.82e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	6.78	0.31	3.95e-11	Platelet count;
LUAD	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg23950597	chr19:37808831	NA	-0.63	-7.58	-0.35	2.24e-13	Coronary artery calcification;
LUAD	cis	rs68170813	0.559	rs58663672	chr7:106949444	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.39	-0.45	1.15e-22	Coronary artery disease;
LUAD	cis	rs6558530	0.932	rs10102731	chr8:1709020	A/G	cg19131313	chr8:1704013	NA	-0.46	-7.33	-0.34	1.2e-12	Systolic blood pressure;
LUAD	trans	rs11039798	1.000	rs7928243	chr11:48589192	A/T	cg02254774	chr11:50257496	LOC441601	0.51	6.48	0.3	2.63e-10	Axial length;
LUAD	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.48	-0.38	3.77e-16	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	18.69	0.67	2.76e-57	Bone mineral density;
LUAD	cis	rs2816062	0.813	rs742485	chr1:18900943	A/T	cg18795169	chr1:18902165	NA	-0.94	-22.42	-0.74	6.13e-74	Urate levels in lean individuals;
LUAD	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg15017067	chr4:17643749	FAM184B	0.35	7.0	0.32	1.04e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11958404	0.860	rs72818111	chr5:157438361	A/G	cg05962755	chr5:157440814	NA	0.71	9.95	0.44	4.36e-21	IgG glycosylation;
LUAD	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg26384229	chr12:38710491	ALG10B	0.48	7.77	0.35	5.98e-14	Morning vs. evening chronotype;
LUAD	cis	rs2579500	0.844	rs2579503	chr2:97176634	A/G	cg23100626	chr2:96804247	ASTL	-0.26	-6.51	-0.3	2.07e-10	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs4523957	0.547	rs11078856	chr17:2092064	G/A	cg16513277	chr17:2031491	SMG6	-0.86	-16.45	-0.62	2.4e-47	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs2797160	1.000	rs2747714	chr6:126007620	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.82	0.39	2.93e-17	Endometrial cancer;
LUAD	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg23985595	chr17:80112537	CCDC57	0.52	9.54	0.42	1.11e-19	Life satisfaction;
LUAD	cis	rs123509	0.687	rs17238972	chr3:42819975	C/G	cg12982090	chr3:42733453	KBTBD5	-0.53	-9.02	-0.4	6.71e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg15147215	chr3:52552868	STAB1	-0.43	-8.17	-0.37	3.64e-15	Bipolar disorder;
LUAD	cis	rs7665090	0.967	rs5026470	chr4:103554722	A/G	cg07973026	chr4:103553119	MANBA	0.47	8.43	0.38	5.43e-16	Primary biliary cholangitis;
LUAD	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg18446336	chr7:2847575	GNA12	-0.32	-6.66	-0.31	8.66e-11	Plateletcrit;
LUAD	cis	rs7116495	0.881	rs676721	chr11:71770638	G/A	cg07596299	chr11:71824057	C11orf51	-0.8	-6.79	-0.31	3.74e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs2625529	0.652	rs3759820	chr15:72300031	A/C	cg16672083	chr15:72433130	SENP8	0.66	12.32	0.51	4.95e-30	Red blood cell count;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg09235138	chr15:40987404	RAD51	-0.39	-6.48	-0.3	2.52e-10	Schizophrenia;
LUAD	cis	rs7809950	0.954	rs2894466	chr7:107242909	G/A	cg23024343	chr7:107201750	COG5	0.77	12.62	0.52	3.31e-31	Coronary artery disease;
LUAD	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.32	-0.34	1.3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg14092571	chr14:90743983	NA	0.46	7.85	0.36	3.52e-14	Mortality in heart failure;
LUAD	cis	rs6499255	0.638	rs57824734	chr16:69811995	C/T	cg00738113	chr16:70207722	CLEC18C	-0.37	-6.72	-0.31	5.91e-11	IgE levels;
LUAD	trans	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.48	0.45	5.42e-23	Mean corpuscular volume;
LUAD	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg14343924	chr8:8086146	FLJ10661	0.45	7.24	0.33	2.15e-12	Retinal vascular caliber;
LUAD	cis	rs41271473	0.526	rs10916337	chr1:228714902	C/T	cg10167378	chr1:228756711	NA	0.66	8.87	0.4	2.01e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg21724239	chr8:58056113	NA	0.71	9.43	0.42	2.66e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	ch.11.42038R	chr11:967971	AP2A2	0.4	6.98	0.32	1.18e-11	Alzheimer's disease (late onset);
LUAD	cis	rs9788721	0.836	rs1504550	chr15:78766250	A/G	cg18825076	chr15:78729989	IREB2	-0.58	-9.71	-0.43	2.95e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg17105886	chr17:28927953	LRRC37B2	0.73	6.7	0.31	6.69e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	trans	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg26043149	chr18:55253948	FECH	-0.41	-6.89	-0.32	2.03e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg11189052	chr15:85197271	WDR73	-0.57	-7.57	-0.35	2.4e-13	Schizophrenia;
LUAD	cis	rs6011002	0.614	rs1291208	chr20:62330417	T/C	cg01176363	chr20:62369445	LIME1	-0.74	-6.41	-0.3	3.94e-10	Dental caries;
LUAD	cis	rs7043114	0.525	rs10992374	chr9:95336327	A/C	cg14631576	chr9:95140430	CENPP	-0.39	-8.04	-0.36	9.23e-15	Height;
LUAD	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg27535305	chr1:53392650	SCP2	-0.33	-6.91	-0.32	1.75e-11	Monocyte count;
LUAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg21724239	chr8:58056113	NA	0.6	8.34	0.38	1.03e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg21016266	chr12:122356598	WDR66	0.66	11.99	0.5	1.03e-28	Mean corpuscular volume;
LUAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.16e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg26528668	chr16:1614120	IFT140	0.5	8.92	0.4	1.44e-17	Coronary artery disease;
LUAD	trans	rs236907	0.859	rs6681322	chr1:171773871	A/G	cg13482142	chr2:234261155	NA	-0.5	-6.49	-0.3	2.34e-10	Mean platelet volume;
LUAD	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08280861	chr8:58055591	NA	0.74	8.99	0.4	8.26e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg07636037	chr3:49044803	WDR6	0.45	7.04	0.32	7.69e-12	Menarche (age at onset);
LUAD	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg15147215	chr3:52552868	STAB1	-0.38	-7.3	-0.33	1.45e-12	Cognitive function;
LUAD	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg27432699	chr2:27873401	GPN1	-0.39	-6.58	-0.3	1.4e-10	Total body bone mineral density;
LUAD	cis	rs300774	0.925	rs300740	chr2:164169	G/A	cg21211680	chr2:198530	NA	-0.49	-7.64	-0.35	1.47e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18876405	chr7:65276391	NA	0.56	9.19	0.41	1.77e-18	Aortic root size;
LUAD	cis	rs1595825	0.730	rs1902248	chr2:198492598	C/T	cg10547527	chr2:198650123	BOLL	-0.46	-6.51	-0.3	2.12e-10	Ulcerative colitis;
LUAD	cis	rs9467773	1.000	rs1570060	chr6:26573562	A/G	cg11502198	chr6:26597334	ABT1	0.61	10.06	0.44	1.76e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg12011299	chr4:100065546	ADH4	0.75	15.21	0.59	5.69e-42	Alcohol dependence;
LUAD	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg00106254	chr7:1943704	MAD1L1	-0.57	-8.68	-0.39	8.87e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg20701182	chr2:24300061	SF3B14	0.93	14.05	0.56	4.74e-37	Lymphocyte counts;
LUAD	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg11663144	chr21:46675770	NA	-0.6	-11.78	-0.5	6.56e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg20203395	chr5:56204925	C5orf35	0.47	7.52	0.34	3.31e-13	Coronary artery disease;
LUAD	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg07952391	chr2:88470173	THNSL2	-0.41	-6.82	-0.31	3.19e-11	Response to metformin (IC50);
LUAD	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg00339695	chr16:24857497	SLC5A11	0.52	9.48	0.42	1.86e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.95	-0.36	1.75e-14	Total body bone mineral density;
LUAD	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.58	0.55	3.99e-35	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.51e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg10208301	chr11:6592745	DNHD1	0.5	6.43	0.3	3.53e-10	Coronary artery calcification;
LUAD	cis	rs478304	0.718	rs61744384	chr11:65387378	T/A	cg27068330	chr11:65405492	SIPA1	-0.58	-9.17	-0.41	2.12e-18	Acne (severe);
LUAD	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg18404041	chr3:52824283	ITIH1	-0.41	-7.55	-0.34	2.61e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs11039798	1.000	rs10838918	chr11:48507449	A/G	cg03929089	chr4:120376271	NA	0.57	6.66	0.31	8.65e-11	Axial length;
LUAD	cis	rs698833	0.886	rs4953090	chr2:44565194	C/T	cg04920474	chr2:44395004	PPM1B	0.38	6.65	0.31	9.27e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg01528321	chr10:82214614	TSPAN14	0.52	8.19	0.37	3.07e-15	Post bronchodilator FEV1;
LUAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08280861	chr8:58055591	NA	0.63	8.2	0.37	2.89e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4642101	0.855	rs9836128	chr3:12845426	G/C	cg24848339	chr3:12840334	CAND2	0.39	7.81	0.35	4.65e-14	QRS complex (12-leadsum);
LUAD	cis	rs250677	0.522	rs3763022	chr5:148381078	A/G	cg18129178	chr5:148520854	ABLIM3	-0.5	-8.06	-0.36	8.03e-15	Breast cancer;
LUAD	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-7.28	-0.33	1.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg23301539	chr8:142222248	SLC45A4	0.48	8.78	0.39	4.06e-17	Immature fraction of reticulocytes;
LUAD	cis	rs9322817	0.691	rs2499660	chr6:105285750	T/C	cg02098413	chr6:105308735	HACE1	0.39	8.23	0.37	2.35e-15	Thyroid stimulating hormone;
LUAD	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.22	-0.33	2.43e-12	Height;
LUAD	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.28	-0.33	1.65e-12	Glomerular filtration rate;
LUAD	cis	rs7224737	0.750	rs12325861	chr17:40289412	T/C	cg20291162	chr17:40259547	DHX58	-0.58	-7.8	-0.35	4.77e-14	Fibrinogen levels;
LUAD	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg09455208	chr3:40491958	NA	0.56	12.45	0.52	1.52e-30	Renal cell carcinoma;
LUAD	cis	rs1595825	0.786	rs16826740	chr2:198893927	A/G	cg00361562	chr2:198649771	BOLL	-0.47	-6.52	-0.3	1.96e-10	Ulcerative colitis;
LUAD	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.56	-8.33	-0.38	1.12e-15	Gut microbiome composition (summer);
LUAD	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg26898376	chr11:64110657	CCDC88B	0.37	6.86	0.32	2.52e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg27490568	chr2:178487706	NA	0.4	6.49	0.3	2.47e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.67	0.31	8.11e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.89	0.53	2.7e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.65	0.52	2.46e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12208915	0.848	rs2174740	chr6:79536565	A/G	cg05283184	chr6:79620031	NA	-0.46	-6.36	-0.3	5.18e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-10.94	-0.47	1.1e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs9902453	0.817	rs4794861	chr17:28183174	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.68	0.43	3.79e-20	Coffee consumption (cups per day);
LUAD	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg26384229	chr12:38710491	ALG10B	0.48	7.88	0.36	2.82e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs447921	0.953	rs16968964	chr17:74455272	C/T	cg17201438	chr17:74438067	UBE2O	-0.41	-6.41	-0.3	3.84e-10	Mitochondrial DNA levels;
LUAD	cis	rs1696756	0.877	rs2587500	chr17:77827362	A/T	cg01306824	chr17:77834118	NA	0.44	6.73	0.31	5.65e-11	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs4776059	1.000	rs11858743	chr15:52936330	G/A	cg24008177	chr15:52972085	KIAA1370	0.23	6.46	0.3	2.87e-10	Schizophrenia;
LUAD	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg22166914	chr1:53195759	ZYG11B	-0.45	-7.57	-0.35	2.36e-13	Monocyte count;
LUAD	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg26528668	chr16:1614120	IFT140	0.57	10.22	0.45	4.58e-22	Coronary artery disease;
LUAD	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg22105103	chr4:187893119	NA	0.51	11.03	0.47	4.83e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg00080972	chr5:178986291	RUFY1	0.56	8.77	0.39	4.33e-17	Lung cancer;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg16595484	chr3:122512170	HSPBAP1	0.41	6.53	0.3	1.94e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg18129178	chr5:148520854	ABLIM3	-0.64	-9.72	-0.43	2.68e-20	Breast cancer;
LUAD	cis	rs2953174	0.529	rs3997219	chr2:241541619	T/C	cg07929629	chr2:241523174	NA	0.44	6.71	0.31	6.32e-11	Bipolar disorder;
LUAD	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6701037	1.000	rs1057305	chr1:175126223	T/A	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.09	-0.4	3.74e-18	Alcohol dependence;
LUAD	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03760483	chr17:6899297	ALOX12	0.33	6.37	0.3	4.87e-10	Tonsillectomy;
LUAD	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg03433033	chr1:76189801	ACADM	-0.5	-7.38	-0.34	8.21e-13	Daytime sleep phenotypes;
LUAD	cis	rs4597304	1	rs4597304	chr16:85055741	G/C	cg01715842	chr16:85045600	ZDHHC7	-0.5	-8.39	-0.38	7.59e-16	Dysphagia;
LUAD	cis	rs12819124	0.502	rs10875718	chr12:48411102	G/T	cg04545296	chr12:48745243	ZNF641	0.31	7.73	0.35	7.71e-14	Glycated hemoglobin levels;
LUAD	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg23018236	chr17:30244563	NA	-0.62	-8.02	-0.36	1.04e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs6499255	0.951	rs56282083	chr16:69825728	C/T	cg15192750	chr16:69999425	NA	0.54	8.52	0.38	2.86e-16	IgE levels;
LUAD	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg01475377	chr6:109611718	NA	-0.49	-9.55	-0.42	1.1e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs494562	0.892	rs544403	chr6:86119116	G/T	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs11809207	0.951	rs111772533	chr1:26523404	C/G	cg00147160	chr1:26503991	CNKSR1	0.44	8.81	0.39	3.33e-17	Height;
LUAD	cis	rs59698941	0.550	rs11748063	chr5:132200943	C/T	cg16419906	chr5:132167176	NA	-0.33	-6.55	-0.3	1.67e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.62	-11.27	-0.48	6.17e-26	Urate levels in overweight individuals;
LUAD	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10979	0.651	rs9321921	chr6:143895053	C/T	cg25407410	chr6:143891975	LOC285740	-0.54	-8.0	-0.36	1.19e-14	Hypospadias;
LUAD	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg06671706	chr8:8559999	CLDN23	0.66	11.4	0.48	1.87e-26	Obesity-related traits;
LUAD	trans	rs4650994	1.000	rs12138561	chr1:178518784	G/T	cg05059571	chr16:84539110	KIAA1609	-0.6	-10.27	-0.45	3.04e-22	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg16205897	chr5:131564050	P4HA2	-0.31	-6.87	-0.32	2.25e-11	Blood metabolite levels;
LUAD	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg08470875	chr2:26401718	FAM59B	-0.76	-11.03	-0.47	4.88e-25	Gut microbiome composition (summer);
LUAD	trans	rs9929218	0.861	rs8056206	chr16:68802072	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-13.66	-0.55	1.91e-35	Colorectal cancer;
LUAD	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg24578937	chr1:2090814	PRKCZ	0.79	16.25	0.62	1.81e-46	Height;
LUAD	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg05110241	chr16:68378359	PRMT7	-0.83	-9.16	-0.41	2.3e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.37	0.48	2.6e-26	Height;
LUAD	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg11189052	chr15:85197271	WDR73	0.57	6.79	0.31	3.73e-11	Schizophrenia;
LUAD	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg25036284	chr2:26402008	FAM59B	-0.83	-11.68	-0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs870825	0.655	rs72703561	chr4:185630890	T/C	cg04058563	chr4:185651563	MLF1IP	0.9	14.37	0.57	2.08e-38	Blood protein levels;
LUAD	trans	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg06618935	chr21:46677482	NA	-0.49	-9.99	-0.44	3.09e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg20587970	chr11:113659929	NA	-1.4	-20.93	-0.71	2.68e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs10992471	0.603	rs4744141	chr9:95352140	T/C	cg14631576	chr9:95140430	CENPP	-0.5	-10.28	-0.45	2.83e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.84	-0.36	3.71e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13468249	chr17:7154818	DULLARD;C17orf81	-0.53	-6.59	-0.31	1.35e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg03929089	chr4:120376271	NA	0.55	6.97	0.32	1.2e-11	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs13315871	0.929	rs13322000	chr3:58286929	G/A	cg20936604	chr3:58311152	NA	-0.75	-7.61	-0.35	1.82e-13	Cholesterol, total;
LUAD	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02018176	chr4:1364513	KIAA1530	0.7	12.37	0.52	3.16e-30	Longevity;
LUAD	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg19875535	chr5:140030758	IK	-0.41	-6.85	-0.32	2.7e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg07537917	chr2:241836409	C2orf54	-0.32	-9.11	-0.4	3.33e-18	Urinary metabolites;
LUAD	cis	rs3806843	0.576	rs251368	chr5:140241027	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.31	6.65	0.31	9.12e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg23283495	chr1:209979779	IRF6	0.69	11.22	0.48	9.47e-26	Cleft lip with or without cleft palate;
LUAD	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg17031739	chr1:67600172	NA	0.43	7.75	0.35	6.74e-14	Psoriasis;
LUAD	cis	rs1018836	0.770	rs13266461	chr8:91652817	T/C	cg16814680	chr8:91681699	NA	-0.88	-16.41	-0.62	3.63e-47	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4853036	0.672	rs728128	chr2:70027221	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-6.53	-0.3	1.87e-10	Colorectal or endometrial cancer;
LUAD	cis	rs78487399	0.710	rs72881068	chr2:43690860	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-6.97	-0.32	1.22e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg08508325	chr11:3079039	CARS	0.44	9.12	0.41	3.12e-18	Calcium levels;
LUAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.69	8.91	0.4	1.5e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg00769240	chr8:12517080	NA	-0.39	-6.53	-0.3	1.87e-10	Blood pressure (smoking interaction);
LUAD	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.32	0.37	1.26e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	7.59	0.35	2.07e-13	Tonsillectomy;
LUAD	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg01475377	chr6:109611718	NA	-0.5	-9.26	-0.41	1.05e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg03433033	chr1:76189801	ACADM	-0.45	-6.59	-0.31	1.32e-10	Daytime sleep phenotypes;
LUAD	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg07570687	chr10:102243282	WNT8B	0.47	7.03	0.32	8.48e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg19622623	chr12:86230825	RASSF9	-0.44	-7.76	-0.35	6.54e-14	Major depressive disorder;
LUAD	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	9.29	0.41	7.96e-19	Melanoma;
LUAD	cis	rs6062509	0.895	rs55946717	chr20:62363869	G/A	cg01176363	chr20:62369445	LIME1	-0.47	-7.61	-0.35	1.8e-13	Prostate cancer;
LUAD	cis	rs889398	0.771	rs4985448	chr16:69899395	A/G	cg00738113	chr16:70207722	CLEC18C	-0.35	-7.01	-0.32	9.74e-12	Body mass index;
LUAD	cis	rs911186	0.509	rs6934329	chr6:27158033	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-6.68	-0.31	7.59e-11	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg07817883	chr1:32538562	TMEM39B	0.64	7.84	0.36	3.58e-14	Monocyte percentage of white cells;
LUAD	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg22535103	chr8:58192502	C8orf71	-0.74	-10.68	-0.46	9.9e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs10821973	0.558	rs6479799	chr10:64023166	A/G	cg09941381	chr10:64027924	RTKN2	-0.33	-6.9	-0.32	1.88e-11	Hypothyroidism;
LUAD	cis	rs7680126	0.596	rs4637402	chr4:10045430	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	9.73	0.43	2.55e-20	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs68170813	0.559	rs58319984	chr7:106965794	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-10.28	-0.45	2.81e-22	Coronary artery disease;
LUAD	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg17848003	chr1:3704513	LRRC47	0.53	10.74	0.46	5.7e-24	Red cell distribution width;
LUAD	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg19980929	chr12:42632907	YAF2	-0.35	-6.7	-0.31	6.84e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs921968	0.565	rs6436071	chr2:219598041	A/T	cg02176678	chr2:219576539	TTLL4	-0.59	-11.89	-0.5	2.42e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7000551	0.689	rs4872000	chr8:22337323	G/T	cg12081754	chr8:22256438	SLC39A14	0.46	7.61	0.35	1.77e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs225245	0.782	rs321618	chr17:33912404	A/G	cg05299278	chr17:33885742	SLFN14	0.52	11.95	0.5	1.43e-28	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg06713675	chr4:122721982	EXOSC9	0.56	10.9	0.47	1.5e-24	Type 2 diabetes;
LUAD	cis	rs6435862	0.500	rs12477063	chr2:215673664	C/T	cg04004882	chr2:215674386	BARD1	-0.57	-8.33	-0.38	1.14e-15	Neuroblastoma (high-risk);
LUAD	cis	rs657075	0.697	rs4646204	chr5:131679995	T/A	cg21138405	chr5:131827807	IRF1	0.5	6.36	0.3	5.25e-10	Rheumatoid arthritis;
LUAD	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg09455208	chr3:40491958	NA	0.54	11.12	0.48	2.16e-25	Renal cell carcinoma;
LUAD	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg23758822	chr17:41437982	NA	0.97	19.76	0.69	4.58e-62	Menopause (age at onset);
LUAD	cis	rs757647	0.723	rs4835777	chr5:137670472	G/A	cg10676309	chr5:137685565	NA	0.4	7.12	0.33	4.78e-12	Menarche (age at onset);
LUAD	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg25319279	chr11:5960081	NA	-0.4	-7.31	-0.34	1.3e-12	DNA methylation (variation);
LUAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08219700	chr8:58056026	NA	0.61	8.69	0.39	8.15e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg22920501	chr2:26401640	FAM59B	-0.72	-10.59	-0.46	2.06e-23	Gut microbiome composition (summer);
LUAD	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg23954153	chr1:44402353	ARTN	-0.34	-6.57	-0.3	1.46e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg18016565	chr1:150552671	MCL1	0.37	6.39	0.3	4.36e-10	Melanoma;
LUAD	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg09455208	chr3:40491958	NA	0.52	11.08	0.47	3.26e-25	Renal cell carcinoma;
LUAD	cis	rs17095355	1.000	rs731793	chr10:111716667	C/G	cg00817464	chr10:111662876	XPNPEP1	0.7	9.64	0.42	5.24e-20	Biliary atresia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19826439	chr1:226297528	NA	-0.53	-6.37	-0.3	5.02e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6906287	0.631	rs9320663	chr6:118986172	A/G	cg18833306	chr6:118973337	C6orf204	0.48	8.42	0.38	5.89e-16	Electrocardiographic conduction measures;
LUAD	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.12e-14	Prostate cancer;
LUAD	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg07828340	chr4:882639	GAK	1.05	10.84	0.47	2.47e-24	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	1.000	rs34636547	chr11:48590103	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.76e-10	HDL cholesterol;
LUAD	cis	rs870825	0.616	rs79884757	chr4:185621454	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	trans	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.35	-0.34	1e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg20891283	chr12:69753455	YEATS4	0.46	7.44	0.34	5.68e-13	Blood protein levels;
LUAD	cis	rs3849570	0.576	rs4425286	chr3:81992365	G/A	cg07356753	chr3:81810745	GBE1	-0.5	-8.38	-0.38	7.94e-16	Waist circumference;Body mass index;
LUAD	cis	rs12612619	0.732	rs7560144	chr2:27280460	A/G	cg00617064	chr2:27272375	NA	-0.37	-7.05	-0.32	7.45e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg22244940	chr12:132335942	MMP17	0.48	8.16	0.37	3.97e-15	Migraine;
LUAD	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19717773	chr7:2847554	GNA12	-0.53	-9.27	-0.41	9.36e-19	Height;
LUAD	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-7.06	-0.32	6.83e-12	Height;
LUAD	cis	rs4930561	0.714	rs10896300	chr11:67953772	C/T	cg04465784	chr11:67976953	SUV420H1	0.36	11.34	0.48	3.31e-26	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg02493740	chr2:85810744	VAMP5	-0.39	-7.09	-0.33	5.74e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs4006360	0.547	rs9892487	chr17:39252969	A/C	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.29	0.37	1.48e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs897984	0.542	rs11864839	chr16:31095251	G/C	cg02466173	chr16:30829666	NA	-0.56	-9.69	-0.43	3.38e-20	Dementia with Lewy bodies;
LUAD	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19346786	chr7:2764209	NA	-0.57	-12.22	-0.51	1.31e-29	Height;
LUAD	cis	rs4072705	0.614	rs1570581	chr9:127234059	A/G	cg01786973	chr9:127249749	NR5A1	0.3	6.57	0.3	1.47e-10	Menarche (age at onset);
LUAD	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg06784218	chr1:46089804	CCDC17	-0.53	-11.67	-0.49	1.72e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg23649088	chr2:200775458	C2orf69	-0.62	-9.75	-0.43	2.18e-20	Osteoporosis;
LUAD	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22857025	chr5:266934	NA	-1.02	-13.19	-0.54	1.69e-33	Breast cancer;
LUAD	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg18252515	chr7:66147081	NA	-0.62	-6.81	-0.31	3.45e-11	Diabetic kidney disease;
LUAD	cis	rs9902453	1.000	rs8065059	chr17:28417376	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.15	-0.41	2.4e-18	Coffee consumption (cups per day);
LUAD	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	7.64	0.35	1.45e-13	Breast cancer;
LUAD	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg26384229	chr12:38710491	ALG10B	0.52	8.61	0.39	1.47e-16	Heart rate;
LUAD	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg02734326	chr4:10020555	SLC2A9	0.6	10.44	0.45	7.35e-23	Bone mineral density;
LUAD	cis	rs7671266	0.532	rs28730480	chr4:10048867	C/T	cg11266682	chr4:10021025	SLC2A9	0.43	6.67	0.31	8.25e-11	Cardiovascular disease risk factors;
LUAD	trans	rs9354308	0.903	rs9360158	chr6:66558164	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.44	-0.3	3.33e-10	Metabolite levels;
LUAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg16606324	chr3:10149918	C3orf24	0.56	9.0	0.4	7.99e-18	Alzheimer's disease;
LUAD	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg23544223	chr18:12777786	NA	0.67	8.53	0.38	2.71e-16	Inflammatory skin disease;
LUAD	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg06641503	chr3:48959341	ARIH2	-0.41	-8.11	-0.37	5.45e-15	Menarche (age at onset);
LUAD	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg04450456	chr4:17643702	FAM184B	0.38	7.5	0.34	3.71e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs714027	1.000	rs1003342	chr22:30570022	A/G	cg00539347	chr22:30592296	NA	0.28	6.64	0.31	9.54e-11	Lymphocyte counts;
LUAD	cis	rs10901296	0.660	rs2855197	chr9:133764406	A/G	cg13397898	chr9:133768931	QRFP	0.51	6.8	0.31	3.54e-11	Bilirubin levels;
LUAD	cis	rs1595825	0.891	rs7587716	chr2:198630667	G/T	cg00361562	chr2:198649771	BOLL	-0.48	-6.69	-0.31	7.15e-11	Ulcerative colitis;
LUAD	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.84	0.39	2.55e-17	Parkinson's disease;
LUAD	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.03	-0.44	2.28e-21	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-17.48	-0.65	6.71e-52	Exhaled nitric oxide output;
LUAD	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27286337	chr10:134555280	INPP5A	0.67	9.57	0.42	9.13e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg21918786	chr6:109611834	NA	-0.54	-9.58	-0.42	8.29e-20	Reticulocyte fraction of red cells;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg00116463	chr17:19266443	B9D1	-0.74	-7.16	-0.33	3.52e-12	Type 2 diabetes;
LUAD	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-7.47	-0.34	4.69e-13	Major depressive disorder;
LUAD	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg27489772	chr12:121021490	NA	-0.56	-7.2	-0.33	2.69e-12	Type 1 diabetes nephropathy;
LUAD	cis	rs2455601	0.608	rs1368017	chr11:8867070	A/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.42	-7.87	-0.36	2.97e-14	Schizophrenia;
LUAD	cis	rs3784262	1.000	rs12907038	chr15:58244032	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.43	-8.59	-0.39	1.68e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg12365402	chr11:9010492	NRIP3	0.47	9.1	0.4	3.49e-18	Hemoglobin concentration;
LUAD	cis	rs9473147	0.516	rs7754282	chr6:47502024	C/G	cg02130027	chr6:47444894	CD2AP	-0.35	-6.75	-0.31	4.82e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs4919694	1.000	rs77969925	chr10:104649357	C/T	cg04362960	chr10:104952993	NT5C2	0.75	8.05	0.36	8.67e-15	Arsenic metabolism;
LUAD	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg06713675	chr4:122721982	EXOSC9	-0.84	-18.2	-0.66	4.47e-55	Type 2 diabetes;
LUAD	cis	rs7107174	1.000	rs7116698	chr11:77995191	T/C	cg19901956	chr11:77921274	USP35	-0.53	-6.78	-0.31	4.02e-11	Testicular germ cell tumor;
LUAD	cis	rs6430585	0.583	rs9636213	chr2:136589278	G/A	cg07169764	chr2:136633963	MCM6	-0.63	-7.74	-0.35	7.54e-14	Corneal structure;
LUAD	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.88	-0.36	2.78e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4356932	1.000	rs7665152	chr4:76960205	T/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.52	-0.3	2.05e-10	Blood protein levels;
LUAD	cis	rs11674184	0.525	rs4669755	chr2:11748585	A/C	cg07314298	chr2:11723111	GREB1	0.66	12.48	0.52	1.14e-30	Endometriosis;
LUAD	cis	rs34311866	0.656	rs11731377	chr4:971266	T/G	cg07828340	chr4:882639	GAK	0.66	6.91	0.32	1.81e-11	Parkinson's disease;
LUAD	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg18827107	chr12:86230957	RASSF9	-0.63	-11.52	-0.49	6.82e-27	Major depressive disorder;
LUAD	cis	rs6665290	0.594	rs17592479	chr1:227173892	T/A	cg10327440	chr1:227177885	CDC42BPA	-1.12	-29.62	-0.82	3.3e-105	Myeloid white cell count;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07355551	chr20:2489285	ZNF343	0.41	6.45	0.3	3.12e-10	Gut microbiome composition (summer);
LUAD	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.4	7.96	0.36	1.6e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg21775007	chr8:11205619	TDH	0.47	8.09	0.37	6.19e-15	Retinal vascular caliber;
LUAD	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg10792982	chr14:105748885	BRF1	0.41	9.04	0.4	5.8e-18	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	7.19	0.33	3.04e-12	Tonsillectomy;
LUAD	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg20307385	chr11:47447363	PSMC3	-0.65	-11.08	-0.47	3.21e-25	Diastolic blood pressure;Systolic blood pressure;
LUAD	trans	rs629535	0.773	rs489206	chr8:70064883	T/C	cg21567404	chr3:27674614	NA	1.01	18.48	0.67	2.54e-56	Dupuytren's disease;
LUAD	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg06784218	chr1:46089804	CCDC17	0.51	11.38	0.48	2.39e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg27211696	chr2:191398769	TMEM194B	0.71	9.37	0.41	4.34e-19	Diastolic blood pressure;
LUAD	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg13319975	chr6:146136371	FBXO30	-0.65	-11.11	-0.48	2.41e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg26022315	chr17:47021804	SNF8	0.4	7.29	0.33	1.5e-12	Type 2 diabetes;
LUAD	cis	rs9462027	0.675	rs34657938	chr6:34801631	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.56	-0.38	2.05e-16	Systemic lupus erythematosus;
LUAD	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg15123519	chr2:136567270	LCT	-0.35	-6.39	-0.3	4.4e-10	Mosquito bite size;
LUAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg27454412	chr7:1067447	C7orf50	0.48	7.6	0.35	1.88e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg11584989	chr19:19387371	SF4	-0.61	-9.65	-0.42	4.67e-20	Bipolar disorder;
LUAD	cis	rs12618769	0.594	rs3754876	chr2:99185867	C/T	cg10123293	chr2:99228465	UNC50	0.5	6.59	0.31	1.3100000000000001e-10	Bipolar disorder;
LUAD	cis	rs7193541	0.965	rs8050262	chr16:74661159	T/C	cg01733217	chr16:74700730	RFWD3	0.59	10.32	0.45	2.04e-22	Multiple myeloma;
LUAD	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg10591111	chr5:226296	SDHA	-0.55	-7.14	-0.33	4.05e-12	Breast cancer;
LUAD	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.38	-6.43	-0.3	3.36e-10	Platelet count;
LUAD	cis	rs6543140	0.964	rs13383602	chr2:103085962	C/T	cg04239558	chr2:103089729	SLC9A4	0.36	7.13	0.33	4.32e-12	Blood protein levels;
LUAD	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg04842962	chr6:43655489	MRPS18A	1.06	26.88	0.79	1.57e-93	IgG glycosylation;
LUAD	cis	rs9341808	0.519	rs4446525	chr6:81024053	C/T	cg08355045	chr6:80787529	NA	-0.44	-7.37	-0.34	9.24e-13	Sitting height ratio;
LUAD	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg12623918	chr2:306882	NA	0.34	6.88	0.32	2.19e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg00080972	chr5:178986291	RUFY1	0.64	11.73	0.5	1.03e-27	Lung cancer;
LUAD	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg02569458	chr12:86230093	RASSF9	0.44	8.09	0.37	6.46e-15	Major depressive disorder;
LUAD	cis	rs897984	0.762	rs7206511	chr16:30950352	G/A	cg02466173	chr16:30829666	NA	0.67	12.44	0.52	1.71e-30	Dementia with Lewy bodies;
LUAD	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-6.57	-0.3	1.44e-10	Neutrophil percentage of white cells;
LUAD	trans	rs11039798	0.920	rs11040015	chr11:48783130	G/T	cg02254774	chr11:50257496	LOC441601	0.54	6.78	0.31	4.08e-11	Axial length;
LUAD	cis	rs12200782	0.799	rs72845515	chr6:26646871	A/G	cg11502198	chr6:26597334	ABT1	-0.76	-6.54	-0.3	1.77e-10	Small cell lung carcinoma;
LUAD	cis	rs11771526	0.551	rs1123868	chr7:32251972	C/T	cg27532318	chr7:32358331	NA	0.47	6.8	0.31	3.63e-11	Body mass index;
LUAD	cis	rs8060686	0.516	rs10852439	chr16:68288331	T/C	cg09835421	chr16:68378352	PRMT7	-0.55	-6.94	-0.32	1.45e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.74	-13.58	-0.55	3.91e-35	Menarche (age at onset);
LUAD	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs8060686	0.516	rs7187202	chr16:68273895	T/C	cg05110241	chr16:68378359	PRMT7	-0.58	-7.34	-0.34	1.13e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9467160	1.000	rs9461012	chr6:24441844	A/G	cg16211469	chr6:24423932	MRS2	-0.44	-6.98	-0.32	1.17e-11	Liver enzyme levels;
LUAD	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg00339695	chr16:24857497	SLC5A11	-0.7	-11.14	-0.48	1.83e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs61774743	0.681	rs10749805	chr1:41850182	C/T	cg08462924	chr1:41848221	NA	0.46	8.44	0.38	5.12e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.79	0.53	7.01e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg16329197	chr12:53359506	NA	-0.84	-14.42	-0.57	1.3e-38	Cancer (pleiotropy);
LUAD	trans	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg13698153	chr12:118541722	VSIG10	-0.45	-6.89	-0.32	2.04e-11	Vitiligo;
LUAD	cis	rs7759001	0.803	rs6456775	chr6:27345383	G/T	cg18711553	chr6:27366782	ZNF391	0.39	6.37	0.3	4.86e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg05368731	chr17:41323189	NBR1	0.98	20.21	0.7	4.61e-64	Menopause (age at onset);
LUAD	cis	rs56346965	0.682	rs1155060	chr2:191566439	C/T	cg27211696	chr2:191398769	TMEM194B	-0.43	-7.57	-0.35	2.39e-13	Bone mineral density (Ward's triangle area);
LUAD	cis	rs2625529	0.824	rs4776581	chr15:72207071	G/A	cg16672083	chr15:72433130	SENP8	-0.75	-12.37	-0.52	3.14e-30	Red blood cell count;
LUAD	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.48	0.3	2.58e-10	Depression;
LUAD	cis	rs12545109	0.642	rs2055984	chr8:57418332	A/G	cg17761419	chr8:57350749	NA	-0.54	-6.99	-0.32	1.09e-11	Obesity-related traits;
LUAD	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg02269571	chr22:50332266	NA	-0.86	-9.44	-0.42	2.48e-19	Mean platelet volume;
LUAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg16606324	chr3:10149918	C3orf24	0.68	11.37	0.48	2.59e-26	Alzheimer's disease;
LUAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg07677032	chr17:61819896	STRADA	0.55	10.09	0.44	1.36e-21	Prudent dietary pattern;
LUAD	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg07386859	chr16:1872102	HAGH	0.53	8.33	0.38	1.13e-15	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7799006	0.723	rs12673108	chr7:2286487	C/A	cg08027265	chr7:2291960	NA	-0.75	-14.86	-0.59	1.74e-40	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg08989290	chr16:615782	NHLRC4	0.31	6.6	0.31	1.23e-10	Height;
LUAD	cis	rs3823572	0.564	rs2953619	chr7:133669649	C/G	cg03336402	chr7:133662267	EXOC4	-0.41	-7.34	-0.34	1.07e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.19	-0.33	3.02e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.52	-0.42	1.3e-19	Life satisfaction;
LUAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg22907277	chr7:1156413	C7orf50	0.68	7.98	0.36	1.35e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg11833968	chr6:79620685	NA	-0.44	-8.4	-0.38	6.7e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg27124370	chr19:33622961	WDR88	0.45	7.29	0.33	1.51e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2242073	0.825	rs72968175	chr2:208991128	C/T	cg24664470	chr2:208976933	NA	0.48	6.73	0.31	5.49e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg00701064	chr4:6280414	WFS1	-0.66	-13.64	-0.55	2.22e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.72	8.15	0.37	4.13e-15	Initial pursuit acceleration;
LUAD	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg00933542	chr6:150070202	PCMT1	0.46	9.92	0.43	5.52e-21	Lung cancer;
LUAD	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg00933542	chr6:150070202	PCMT1	0.43	9.18	0.41	1.91e-18	Lung cancer;
LUAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.47	-8.0	-0.36	1.17e-14	Longevity;Endometriosis;
LUAD	cis	rs10193935	0.901	rs12620021	chr2:42477034	T/C	cg27598129	chr2:42591480	NA	-0.78	-9.3	-0.41	7.41e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-6.88	-0.32	2.14e-11	Breast cancer;
LUAD	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg00129232	chr17:37814104	STARD3	-0.46	-7.81	-0.35	4.62e-14	Asthma;
LUAD	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-6.8	-0.31	3.62e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.69	-9.93	-0.43	5.03e-21	Obesity-related traits;
LUAD	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08704250	chr15:31115839	NA	0.71	13.03	0.54	7.21e-33	Huntington's disease progression;
LUAD	trans	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg21659725	chr3:3221576	CRBN	0.39	6.59	0.31	1.32e-10	Resting heart rate;
LUAD	cis	rs7274811	0.711	rs291698	chr20:31982250	A/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.49	7.47	0.34	4.64e-13	Height;
LUAD	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg15128208	chr22:42549153	NA	-0.35	-6.89	-0.32	2.07e-11	Cognitive function;
LUAD	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg18351406	chr4:77819688	ANKRD56	0.59	9.42	0.42	3.05e-19	Emphysema distribution in smoking;
LUAD	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05901451	chr6:126070800	HEY2	0.74	12.97	0.53	1.26e-32	Brugada syndrome;
LUAD	cis	rs2073300	0.793	rs6048814	chr20:23448411	A/C	cg12062639	chr20:23401060	NAPB	0.75	6.96	0.32	1.28e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9837602	0.592	rs1606481	chr3:99427552	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.49	-7.07	-0.33	6.52e-12	Breast cancer;
LUAD	cis	rs4523957	0.579	rs2307143	chr17:2089754	G/A	cg16513277	chr17:2031491	SMG6	-0.87	-16.61	-0.63	4.63e-48	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg09021430	chr5:549028	NA	-0.56	-12.86	-0.53	3.47e-32	Obesity-related traits;
LUAD	trans	rs6678622	1.000	rs6678622	chr1:78092479	C/T	cg20826526	chr3:156266748	SSR3	-0.44	-7.25	-0.33	2.04e-12	Hip circumference;
LUAD	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15320075	chr8:145703422	NA	0.41	6.57	0.3	1.48e-10	Age at first birth;
LUAD	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.3	6.96	0.32	1.32e-11	Prostate cancer;
LUAD	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	24.11	0.76	1.99e-81	Chronic sinus infection;
LUAD	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg06636001	chr8:8085503	FLJ10661	0.44	7.02	0.32	8.97e-12	Mood instability;
LUAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg18538332	chr22:24372958	LOC391322	-0.54	-9.0	-0.4	7.76e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg20607798	chr8:58055168	NA	0.67	8.79	0.39	3.8e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1113500	0.933	rs3893034	chr1:108632178	G/A	cg06207961	chr1:108661230	NA	0.45	8.49	0.38	3.65e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.75	0.31	4.97e-11	Parkinson's disease;
LUAD	cis	rs420259	0.516	rs2106458	chr16:23531431	G/A	cg00143387	chr16:23521605	GGA2	-0.67	-9.24	-0.41	1.17e-18	Bipolar disorder;
LUAD	cis	rs9473147	0.543	rs4711880	chr6:47480676	A/G	cg20196966	chr6:47445060	CD2AP	0.44	6.8	0.31	3.67e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg11645453	chr3:52864694	ITIH4	0.34	6.91	0.32	1.76e-11	Bipolar disorder;
LUAD	cis	rs13082711	0.522	rs537674	chr3:27361901	G/T	cg02860705	chr3:27208620	NA	0.52	8.7	0.39	7.46e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs68170813	0.559	rs2894459	chr7:106960166	C/T	cg02696742	chr7:106810147	HBP1	-0.74	-10.13	-0.44	9.68e-22	Coronary artery disease;
LUAD	cis	rs9394159	0.583	rs6457738	chr6:33617464	C/T	cg14003231	chr6:33640908	ITPR3	-0.52	-10.22	-0.44	4.73e-22	Graves' disease;
LUAD	cis	rs2274273	0.806	rs7146752	chr14:55738907	A/G	cg04306507	chr14:55594613	LGALS3	0.4	8.29	0.37	1.47e-15	Protein biomarker;
LUAD	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg21605333	chr4:119757512	SEC24D	-0.93	-8.74	-0.39	5.62e-17	Cannabis dependence symptom count;
LUAD	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg04398451	chr17:18023971	MYO15A	-0.65	-11.76	-0.5	7.97e-28	Total body bone mineral density;
LUAD	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg05725404	chr16:58534157	NDRG4	-0.7	-7.22	-0.33	2.4e-12	Schizophrenia;
LUAD	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-11.74	-0.5	9.54e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3087591	1.000	rs9902427	chr17:29625430	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.42	-6.88	-0.32	2.14e-11	Hip circumference;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00152838	chr16:24741724	TNRC6A	-0.44	-7.23	-0.33	2.33e-12	Cancer;
LUAD	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg16325326	chr1:53192061	ZYG11B	-0.6	-10.52	-0.46	3.76e-23	Monocyte count;
LUAD	cis	rs16958440	0.609	rs75911383	chr18:44716011	C/T	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03352830	chr11:487213	PTDSS2	0.77	9.49	0.42	1.7e-19	Body mass index;
LUAD	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg22467129	chr15:76604101	ETFA	0.44	7.32	0.34	1.25e-12	Blood metabolite levels;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg09747578	chr1:46769076	LRRC41;UQCRH	-0.4	-6.75	-0.31	4.98e-11	Subcortical brain region volumes;
LUAD	cis	rs10089	0.552	rs58595196	chr5:127558338	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.47	6.44	0.3	3.18e-10	Ileal carcinoids;
LUAD	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg16325326	chr1:53192061	ZYG11B	-0.74	-14.45	-0.57	9.57e-39	Monocyte count;
LUAD	cis	rs9837602	0.938	rs1017968	chr3:99787011	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	9.19	0.41	1.73e-18	Breast cancer;
LUAD	cis	rs2806561	0.780	rs12135629	chr1:23338899	A/G	cg19743168	chr1:23544995	NA	-0.36	-6.52	-0.3	2.02e-10	Height;
LUAD	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.9	0.36	2.43e-14	Breast cancer;
LUAD	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg27170947	chr2:26402098	FAM59B	-0.82	-11.49	-0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg26587870	chr6:27730563	NA	-0.44	-7.09	-0.33	5.59e-12	Parkinson's disease;
LUAD	cis	rs7536201	1.000	rs7550635	chr1:25299637	C/G	cg23273869	chr1:25296894	NA	-0.37	-7.71	-0.35	9.3e-14	Psoriasis vulgaris;
LUAD	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg25753631	chr6:25732923	NA	-0.38	-6.66	-0.31	8.79e-11	Iron status biomarkers;
LUAD	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg11502198	chr6:26597334	ABT1	0.67	11.7	0.49	1.39e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs4523957	0.928	rs216209	chr17:2195130	A/G	cg16513277	chr17:2031491	SMG6	0.75	13.79	0.56	5.55e-36	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.76	12.58	0.52	4.72e-31	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7116495	1.000	rs493065	chr11:71796929	T/C	cg07596299	chr11:71824057	C11orf51	-0.77	-6.53	-0.3	1.86e-10	Severe influenza A (H1N1) infection;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg15672331	chr15:85923765	AKAP13	-0.43	-7.41	-0.34	6.76e-13	Schizophrenia;
LUAD	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg14558114	chr2:88469736	THNSL2	0.86	9.24	0.41	1.18e-18	Plasma clusterin levels;
LUAD	cis	rs12545109	0.800	rs2582404	chr8:57387368	C/T	cg19413350	chr8:57351067	NA	-0.44	-6.72	-0.31	5.87e-11	Obesity-related traits;
LUAD	cis	rs34734847	0.842	rs696337	chr12:121159380	T/C	cg13914990	chr12:121174878	ACADS	0.4	7.68	0.35	1.11e-13	Mean corpuscular volume;
LUAD	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg21016266	chr12:122356598	WDR66	0.69	12.78	0.53	7.39e-32	Mean corpuscular volume;
LUAD	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg13770153	chr20:60521292	NA	-0.58	-9.09	-0.4	3.91e-18	Body mass index;
LUAD	trans	rs12517041	1.000	rs2217309	chr5:23313736	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.48	-6.75	-0.31	4.91e-11	Calcium levels;
LUAD	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg26408565	chr15:76604113	ETFA	-0.45	-7.22	-0.33	2.51e-12	Blood metabolite levels;
LUAD	trans	rs225245	0.687	rs321614	chr17:33881734	A/G	cg19694781	chr19:47549865	TMEM160	-0.45	-7.31	-0.33	1.31e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.4	6.61	0.31	1.14e-10	Systemic lupus erythematosus;
LUAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg16414030	chr3:133502952	NA	-0.66	-12.48	-0.52	1.19e-30	Iron status biomarkers;
LUAD	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg22467129	chr15:76604101	ETFA	0.61	10.7	0.46	8.11e-24	Blood metabolite levels;
LUAD	cis	rs12188164	0.965	rs77101200	chr5:443059	G/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.43	-7.93	-0.36	1.93e-14	Cystic fibrosis severity;
LUAD	cis	rs7598759	0.548	rs11686485	chr2:232360697	C/T	cg19187155	chr2:232395269	NMUR1	0.51	9.63	0.42	5.68e-20	Noise-induced hearing loss;
LUAD	cis	rs2414856	0.504	rs72742986	chr15:64987229	T/C	cg08069370	chr15:64387884	SNX1	-0.74	-6.66	-0.31	8.37e-11	Pulse pressure;Systolic blood pressure;
LUAD	cis	rs55665837	0.961	rs11023237	chr11:14500334	G/A	cg19336497	chr11:14380999	RRAS2	-0.5	-10.09	-0.44	1.39e-21	Vitamin D levels;
LUAD	cis	rs123509	0.913	rs339661	chr3:42753904	G/A	cg10144569	chr3:42726640	KBTBD5	0.49	7.68	0.35	1.14e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg01689657	chr7:91764605	CYP51A1	-0.32	-7.77	-0.35	5.83e-14	Breast cancer;
LUAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22496380	chr5:211416	CCDC127	-1.23	-16.06	-0.62	1.21e-45	Breast cancer;
LUAD	cis	rs6499255	0.951	rs1437136	chr16:69672675	G/C	cg15192750	chr16:69999425	NA	0.55	8.33	0.38	1.15e-15	IgE levels;
LUAD	cis	rs2979489	0.891	rs2915594	chr8:30401367	T/C	cg26383811	chr8:30366931	RBPMS	-0.69	-10.64	-0.46	1.4e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs12134245	0.755	rs11164928	chr1:92012678	G/A	cg02896835	chr1:92012615	NA	-0.63	-13.04	-0.54	6.67e-33	Breast cancer;
LUAD	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.47	-7.37	-0.34	8.8e-13	Tonsillectomy;
LUAD	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg06873352	chr17:61820015	STRADA	0.4	6.5	0.3	2.26e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg05340658	chr4:99064831	C4orf37	0.54	8.8	0.39	3.61e-17	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1493916	0.837	rs10401087	chr18:31320716	A/G	cg15819921	chr19:927150	ARID3A	-0.39	-6.43	-0.3	3.37e-10	Life satisfaction;
LUAD	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg12379764	chr21:47803548	PCNT	-0.38	-6.45	-0.3	3.09e-10	Testicular germ cell tumor;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg08510077	chr3:113666901	ZDHHC23	0.37	6.58	0.3	1.44e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg09184832	chr6:79620586	NA	-0.39	-6.52	-0.3	2.04e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.92	0.43	5.53e-21	Ulcerative colitis;
LUAD	cis	rs17102423	0.594	rs942626	chr14:65550082	C/T	cg11161011	chr14:65562177	MAX	-0.44	-7.42	-0.34	6.52e-13	Obesity-related traits;
LUAD	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg16205897	chr5:131564050	P4HA2	-0.33	-7.17	-0.33	3.32e-12	Breast cancer;Mosquito bite size;
LUAD	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.54	-9.16	-0.41	2.3e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7512552	0.773	rs3737240	chr1:150483355	C/T	cg15654264	chr1:150340011	RPRD2	0.61	11.42	0.49	1.59e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	7.72	0.35	8.73e-14	Menarche (age at onset);
LUAD	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg15557168	chr22:42548783	NA	0.35	6.37	0.3	4.94e-10	Cognitive function;
LUAD	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs497273	0.553	rs508595	chr12:121198891	C/G	cg02419362	chr12:121203948	SPPL3	0.38	7.61	0.35	1.77e-13	Systemic lupus erythematosus;
LUAD	cis	rs6684514	0.961	rs12126696	chr1:156241348	C/T	cg16558208	chr1:156270281	VHLL	0.56	9.96	0.44	4.08e-21	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.1	-0.4	3.7e-18	Alcohol dependence;
LUAD	cis	rs240764	0.578	rs9399688	chr6:101215786	C/T	cg09795085	chr6:101329169	ASCC3	0.4	6.84	0.32	2.84e-11	Neuroticism;
LUAD	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg22117172	chr7:91764530	CYP51A1	-0.32	-6.96	-0.32	1.32e-11	Breast cancer;
LUAD	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg05342682	chr7:94953680	PON1	-0.5	-7.07	-0.33	6.33e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2446066	0.538	rs1485394	chr12:53955485	A/C	cg20730629	chr12:53886622	MAP3K12	-0.46	-6.56	-0.3	1.62e-10	Red blood cell count;
LUAD	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg15147215	chr3:52552868	STAB1	-0.39	-7.17	-0.33	3.31e-12	Bipolar disorder;
LUAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg22907277	chr7:1156413	C7orf50	0.59	7.35	0.34	1.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6062509	0.965	rs6062504	chr20:62348907	A/G	cg21849932	chr20:62369462	LIME1	-0.46	-7.44	-0.34	5.61e-13	Prostate cancer;
LUAD	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg27490568	chr2:178487706	NA	-0.55	-8.41	-0.38	6.41e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg24813613	chr7:1882135	MAD1L1	-0.44	-7.1	-0.33	5.46e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs300703	0.872	rs428697	chr2:213302	G/A	cg24565620	chr2:194026	NA	-0.51	-6.58	-0.3	1.41e-10	Blood protein levels;
LUAD	cis	rs62458065	1.000	rs1450868	chr7:32463666	G/A	cg20159608	chr7:32802032	NA	-0.48	-6.83	-0.32	3.01e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs12618769	0.652	rs7585747	chr2:99219071	T/C	cg10123293	chr2:99228465	UNC50	0.5	8.87	0.4	2.09e-17	Bipolar disorder;
LUAD	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg23029597	chr12:123009494	RSRC2	-0.51	-7.84	-0.36	3.75e-14	Body mass index;
LUAD	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg27532560	chr4:187881888	NA	-0.39	-7.51	-0.34	3.59e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg24578937	chr1:2090814	PRKCZ	-0.77	-15.96	-0.61	3.17e-45	Height;
LUAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.5	-8.99	-0.4	8.19e-18	Lymphocyte counts;
LUAD	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg12458913	chr13:53173898	NA	0.42	7.52	0.34	3.38e-13	Lewy body disease;
LUAD	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg07700843	chr1:2391317	NA	-0.35	-7.27	-0.33	1.74e-12	Schizophrenia;
LUAD	cis	rs11756438	0.572	rs2638544	chr6:119001978	G/A	cg18833306	chr6:118973337	C6orf204	0.54	9.64	0.42	5.02e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.03	-0.44	2.15e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs11622475	1.000	rs10149651	chr14:104394440	A/G	cg12183467	chr14:104352244	NA	0.4	7.09	0.33	5.85e-12	Bipolar disorder;
LUAD	cis	rs57994353	0.897	rs55824202	chr9:139357273	A/T	cg13856295	chr9:139396418	NOTCH1	-0.42	-6.65	-0.31	9.12e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg22875332	chr1:76189707	ACADM	0.9	17.39	0.65	1.66e-51	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg00631329	chr6:26305371	NA	-0.61	-11.4	-0.48	2e-26	Educational attainment;
LUAD	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg22535103	chr8:58192502	C8orf71	-0.67	-7.34	-0.34	1.13e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs494562	0.892	rs573737	chr6:86118233	A/G	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg12953096	chr19:7991105	CTXN1	-0.65	-6.43	-0.3	3.41e-10	Type 2 diabetes;
LUAD	cis	rs977987	0.835	rs3851734	chr16:75371920	T/C	cg03315344	chr16:75512273	CHST6	0.63	13.36	0.54	3.4e-34	Dupuytren's disease;
LUAD	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10802521	chr3:52805072	NEK4	-0.61	-11.07	-0.47	3.56e-25	Bipolar disorder;
LUAD	cis	rs5769707	0.632	rs135872	chr22:50009300	T/C	cg10356904	chr22:49881777	NA	-0.4	-7.66	-0.35	1.24e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg15181151	chr6:150070149	PCMT1	0.39	7.61	0.35	1.78e-13	Lung cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24469923	chr19:11925456	ZNF440	-0.53	-6.53	-0.3	1.91e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6931421	1.000	rs6931421	chr6:80880138	A/C	cg08355045	chr6:80787529	NA	0.53	8.66	0.39	1.04e-16	Sitting height ratio;
LUAD	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg00316803	chr15:76480434	C15orf27	0.42	6.62	0.31	1.07e-10	Blood metabolite levels;
LUAD	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg02951883	chr7:2050386	MAD1L1	-0.82	-14.11	-0.57	2.46e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg05313129	chr8:58192883	C8orf71	-0.57	-8.41	-0.38	6.38e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs637571	0.726	rs526631	chr11:65681965	T/G	cg17712092	chr4:129076599	LARP1B	-0.94	-19.07	-0.68	5.6e-59	Eosinophil percentage of white cells;
LUAD	cis	rs1395	0.778	rs4665960	chr2:27467598	C/T	cg23587288	chr2:27483067	SLC30A3	-0.4	-7.55	-0.34	2.73e-13	Blood metabolite levels;
LUAD	cis	rs7520050	0.966	rs12021587	chr1:46472759	G/T	cg06784218	chr1:46089804	CCDC17	-0.3	-6.47	-0.3	2.69e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg20673091	chr1:2541236	MMEL1	-0.4	-8.44	-0.38	5.08e-16	Ulcerative colitis;
LUAD	cis	rs1232027	0.666	rs34965641	chr5:79942376	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-7.95	-0.36	1.74e-14	Huntington's disease progression;
LUAD	cis	rs11696501	0.694	rs6130870	chr20:44263263	T/C	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.12	-0.37	5.07e-15	Brain structure;
LUAD	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.42	0.34	6.46e-13	Bipolar disorder;
LUAD	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg26597838	chr10:835615	NA	-0.47	-7.32	-0.34	1.22e-12	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7289126	1.000	rs8142686	chr22:38634266	C/T	cg25457927	chr22:38595422	NA	-0.4	-9.22	-0.41	1.47e-18	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs6678622	0.863	rs12742653	chr1:78339481	A/T	cg21968580	chr1:78470640	DNAJB4	0.42	6.83	0.32	2.9e-11	Hip circumference;
LUAD	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg26597838	chr10:835615	NA	0.96	15.02	0.59	3.51e-41	Eosinophil percentage of granulocytes;
LUAD	cis	rs7818345	1.000	rs13278459	chr8:19297583	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.79	0.31	3.82e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.62	-12.88	-0.53	2.92e-32	Hemoglobin concentration;
LUAD	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.33	6.57	0.3	1.53e-10	Obesity-related traits;
LUAD	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg23283495	chr1:209979779	IRF6	0.42	7.42	0.34	6.59e-13	Monobrow;
LUAD	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg13390004	chr1:15929781	NA	0.48	8.45	0.38	4.65e-16	Systolic blood pressure;
LUAD	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03264133	chr6:25882463	NA	-0.55	-8.86	-0.4	2.22e-17	Blood metabolite levels;
LUAD	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg03806693	chr22:41940476	POLR3H	-0.76	-10.8	-0.46	3.64e-24	Vitiligo;
LUAD	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg07828340	chr4:882639	GAK	0.98	10.05	0.44	1.9e-21	Parkinson's disease;
LUAD	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.52	-0.3	2.05e-10	Coronary artery disease;
LUAD	trans	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg07211511	chr3:129823064	LOC729375	0.9	10.42	0.45	8.95e-23	Blood pressure (smoking interaction);
LUAD	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg25324976	chr17:61989376	CSHL1	-0.35	-6.8	-0.31	3.52e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs7916697	0.520	rs12246624	chr10:70036562	C/T	cg04882175	chr6:131122610	NA	-0.49	-6.51	-0.3	2.1e-10	Optic disc area;
LUAD	cis	rs6445967	0.554	rs62259824	chr3:58461665	T/C	cg13750441	chr3:58318267	PXK	-0.33	-6.41	-0.3	3.93e-10	Platelet count;
LUAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs12989701	0.877	rs12994718	chr2:127874226	T/A	cg08168897	chr2:127865431	BIN1	0.44	7.13	0.33	4.35e-12	Alzheimer's disease (late onset);
LUAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg22764044	chr5:178986830	RUFY1	0.64	11.1	0.47	2.72e-25	Lung cancer;
LUAD	cis	rs9487051	0.735	rs351756	chr6:109538773	A/G	cg21918786	chr6:109611834	NA	0.45	8.09	0.37	6.51e-15	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10788264	0.504	rs4751885	chr10:124020305	G/T	cg09507567	chr10:124027408	NA	0.54	12.29	0.51	6.98e-30	Total body bone mineral density;
LUAD	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.96	0.53	1.4e-32	Cognitive ability;
LUAD	trans	rs4714291	0.963	rs1923489	chr6:40023088	T/C	cg02267698	chr19:7991119	CTXN1	0.43	6.49	0.3	2.38e-10	Strep throat;
LUAD	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg00255919	chr5:131827918	IRF1	0.5	11.92	0.5	1.97e-28	Asthma (sex interaction);
LUAD	cis	rs41311933	0.803	rs41258306	chr9:123716103	T/C	cg13567360	chr9:123745713	C5	-0.73	-6.71	-0.31	6.31e-11	Coronary artery disease;
LUAD	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs11098699	0.821	rs7665617	chr4:124201196	C/G	cg09941581	chr4:124220074	SPATA5	0.44	7.09	0.33	5.64e-12	Mosquito bite size;
LUAD	cis	rs11112613	0.713	rs11112589	chr12:105951226	C/G	cg03607813	chr12:105948248	NA	-0.72	-12.39	-0.52	2.74e-30	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs1784581	0.761	rs7741581	chr6:162435250	C/T	cg17173639	chr6:162384350	PARK2	0.49	8.95	0.4	1.15e-17	Itch intensity from mosquito bite;
LUAD	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg23625390	chr15:77176239	SCAPER	-0.55	-8.88	-0.4	1.91e-17	Blood metabolite levels;
LUAD	cis	rs4601821	0.858	rs7945132	chr11:113262473	A/T	cg14159747	chr11:113255604	NA	0.47	8.76	0.39	4.67e-17	Alcoholic chronic pancreatitis;
LUAD	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.41e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7843479	0.965	rs2291317	chr8:21827162	C/T	cg03445287	chr8:21823731	XPO7	-0.45	-8.24	-0.37	2.19e-15	Mean corpuscular volume;
LUAD	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.67	-10.39	-0.45	1.13e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs9788721	0.902	rs951266	chr15:78878541	C/T	cg18825076	chr15:78729989	IREB2	-0.54	-8.82	-0.39	2.92e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs231513	0.954	rs231497	chr17:41975947	A/G	cg26893861	chr17:41843967	DUSP3	-0.54	-6.6	-0.31	1.22e-10	Cognitive function;
LUAD	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg09537434	chr19:41945824	ATP5SL	-0.42	-6.73	-0.31	5.62e-11	Height;
LUAD	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg23625390	chr15:77176239	SCAPER	0.43	7.62	0.35	1.66e-13	Blood metabolite levels;
LUAD	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.43	-7.68	-0.35	1.14e-13	Age at first birth;
LUAD	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg24069376	chr3:38537580	EXOG	0.45	11.0	0.47	6.63e-25	Electrocardiographic conduction measures;
LUAD	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg05110241	chr16:68378359	PRMT7	-0.68	-7.69	-0.35	1.01e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg23978390	chr7:1156363	C7orf50	0.56	8.79	0.39	3.71e-17	Longevity;Endometriosis;
LUAD	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg06064525	chr11:970664	AP2A2	-0.53	-10.86	-0.47	2.05e-24	Alzheimer's disease (late onset);
LUAD	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg11494091	chr17:61959527	GH2	0.74	18.42	0.67	4.77e-56	Prudent dietary pattern;
LUAD	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-7.12	-0.33	4.77e-12	Morning vs. evening chronotype;
LUAD	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.84	-14.75	-0.58	4.9e-40	IgG glycosylation;
LUAD	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg13722127	chr7:150037890	RARRES2	0.5	8.65	0.39	1.08e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4409675	0.576	rs10751725	chr1:28216191	A/C	cg23691781	chr1:28212827	C1orf38	-0.39	-11.48	-0.49	9.57e-27	Corneal astigmatism;
LUAD	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg15226275	chr6:116381976	FRK	0.24	7.67	0.35	1.2e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg11859384	chr17:80120422	CCDC57	-0.52	-9.35	-0.41	5.05e-19	Life satisfaction;
LUAD	cis	rs9811920	0.809	rs793437	chr3:99559854	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	7.08	0.33	5.96e-12	Axial length;
LUAD	cis	rs11811982	0.793	rs75261338	chr1:227510379	A/C	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg10792982	chr14:105748885	BRF1	0.41	8.86	0.4	2.25e-17	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs7395662	1.000	rs7482176	chr11:48604620	C/G	cg00717180	chr2:96193071	NA	-0.38	-7.04	-0.32	7.7e-12	HDL cholesterol;
LUAD	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg01579765	chr21:45077557	HSF2BP	-0.57	-12.76	-0.53	8.95e-32	Mean corpuscular volume;
LUAD	cis	rs78761021	0.867	rs17743194	chr17:9788251	A/G	cg26853458	chr17:9805074	RCVRN	-0.33	-6.66	-0.31	8.64e-11	Type 2 diabetes;
LUAD	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg05714579	chr10:131428358	MGMT	-0.43	-6.88	-0.32	2.11e-11	Response to temozolomide;
LUAD	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg07305463	chr2:136567211	LCT	0.39	7.39	0.34	8.14e-13	Mosquito bite size;
LUAD	cis	rs10979	1.000	rs6905264	chr6:143894378	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.28	-0.45	2.77e-22	Hypospadias;
LUAD	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg25985355	chr7:65971099	NA	0.54	6.8	0.31	3.56e-11	Diabetic kidney disease;
LUAD	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.93	0.76	1.24e-80	Chronic sinus infection;
LUAD	cis	rs17253792	0.822	rs17683728	chr14:56060389	C/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs1723838	0.590	rs7396121	chr11:73402070	G/A	cg10064339	chr11:73693792	UCP2	0.84	6.62	0.31	1.08e-10	Obesity-related traits;
LUAD	cis	rs12618769	0.597	rs17504774	chr2:99135627	A/G	cg10123293	chr2:99228465	UNC50	-0.46	-8.12	-0.37	5.01e-15	Bipolar disorder;
LUAD	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg16988262	chr1:15930761	NA	0.4	6.81	0.31	3.37e-11	Systolic blood pressure;
LUAD	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg21862992	chr11:68658383	NA	0.53	9.73	0.43	2.5e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg21545522	chr1:205238299	TMCC2	0.38	7.02	0.32	9.15e-12	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg03714773	chr7:91764589	CYP51A1	0.27	6.48	0.3	2.55e-10	Breast cancer;
LUAD	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg07741184	chr6:167504864	NA	0.39	8.82	0.39	3.14e-17	Primary biliary cholangitis;
LUAD	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-6.5	-0.3	2.31e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg15181151	chr6:150070149	PCMT1	0.41	8.53	0.38	2.66e-16	Lung cancer;
LUAD	cis	rs2637266	0.935	rs2583050	chr10:78403615	C/T	cg18941641	chr10:78392320	NA	0.34	7.04	0.32	7.75e-12	Pulmonary function;
LUAD	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-7.79	-0.35	5.41e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs12681287	0.547	rs11992656	chr8:87534869	T/A	cg27223183	chr8:87520930	FAM82B	0.72	10.25	0.45	3.68e-22	Caudate activity during reward;
LUAD	cis	rs7040024	0.754	rs10815893	chr9:859409	A/G	cg14021170	chr9:826657	NA	-0.43	-6.61	-0.31	1.17e-10	Testicular germ cell tumor;Testicular cancer;
LUAD	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg26408565	chr15:76604113	ETFA	-0.44	-7.09	-0.33	5.74e-12	Blood metabolite levels;
LUAD	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg08470875	chr2:26401718	FAM59B	-0.63	-8.54	-0.38	2.44e-16	Gut microbiome composition (summer);
LUAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg15117754	chr3:10150083	C3orf24	0.42	7.0	0.32	1.03e-11	Alzheimer's disease;
LUAD	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18099408	chr3:52552593	STAB1	0.47	8.25	0.37	2.05e-15	Bipolar disorder;
LUAD	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-10.68	-0.46	9.9e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22496380	chr5:211416	CCDC127	-0.89	-11.37	-0.48	2.61e-26	Breast cancer;
LUAD	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg16850897	chr7:100343110	ZAN	0.38	6.76	0.31	4.68e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs220324	0.688	rs11701681	chr21:43564274	A/G	cg09727148	chr21:43560719	UMODL1	0.57	8.58	0.39	1.79e-16	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg02221422	chr11:68192511	LRP5	-0.41	-6.78	-0.31	3.98e-11	Total body bone mineral density;
LUAD	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg17911788	chr17:44343683	NA	0.44	6.66	0.31	8.52e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7267979	1.000	rs6107047	chr20:25442097	G/A	cg08601574	chr20:25228251	PYGB	0.43	7.95	0.36	1.72e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25427524	chr10:38739819	LOC399744	-0.76	-13.67	-0.55	1.66e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg12179176	chr11:130786555	SNX19	0.47	7.54	0.34	2.94e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg08280861	chr8:58055591	NA	0.62	8.17	0.37	3.49e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs78761021	0.720	rs55740146	chr17:9796599	G/A	cg26853458	chr17:9805074	RCVRN	0.41	7.9	0.36	2.49e-14	Type 2 diabetes;
LUAD	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg00631329	chr6:26305371	NA	-0.7	-13.53	-0.55	6.38e-35	Educational attainment;
LUAD	cis	rs9392556	0.510	rs613028	chr6:4102139	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.57	-8.6	-0.39	1.6e-16	Blood metabolite levels;
LUAD	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg08885076	chr2:99613938	TSGA10	0.4	7.55	0.34	2.79e-13	Chronic sinus infection;
LUAD	cis	rs12079745	0.590	rs7544446	chr1:169256524	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-1.02	-7.75	-0.35	6.91e-14	QT interval;
LUAD	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg02196655	chr2:10830764	NOL10	-0.43	-7.66	-0.35	1.31e-13	Prostate cancer;
LUAD	cis	rs9394841	0.667	rs3827633	chr6:41759846	A/C	cg25600774	chr6:41776562	USP49	-0.44	-6.7	-0.31	6.63e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs2692947	0.740	rs11695514	chr2:96548068	C/T	cg23100626	chr2:96804247	ASTL	0.31	7.57	0.35	2.32e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs8044868	0.586	rs2070937	chr16:72089740	A/G	cg23815491	chr16:72088622	HP	0.56	10.61	0.46	1.76e-23	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg09253696	chr17:73873529	TRIM47	-0.69	-8.89	-0.4	1.78e-17	Psoriasis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10517474	chr16:31470676	ARMC5	-0.58	-7.02	-0.32	8.79e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10901296	0.660	rs2772033	chr9:133757080	G/A	cg01000188	chr9:133769184	QRFP	0.55	6.47	0.3	2.71e-10	Bilirubin levels;
LUAD	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg23649088	chr2:200775458	C2orf69	-0.64	-9.45	-0.42	2.38e-19	Bipolar disorder lithium response (continuous) or schizophrenia;
LUAD	trans	rs8073060	0.586	rs225286	chr17:33930458	G/A	cg19694781	chr19:47549865	TMEM160	-1.26	-19.81	-0.69	3.02e-62	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs12618769	0.597	rs3769738	chr2:99078367	T/C	cg10123293	chr2:99228465	UNC50	0.47	8.65	0.39	1.11e-16	Bipolar disorder;
LUAD	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg07967210	chr17:47022446	SNF8	0.35	6.4	0.3	4.22e-10	Type 2 diabetes;
LUAD	cis	rs68170813	0.559	rs76646886	chr7:107034328	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-10.37	-0.45	1.35e-22	Coronary artery disease;
LUAD	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg27489772	chr12:121021490	NA	0.56	7.04	0.32	7.9e-12	Type 1 diabetes nephropathy;
LUAD	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg22823121	chr1:150693482	HORMAD1	0.43	8.21	0.37	2.79e-15	Melanoma;
LUAD	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.49	0.3	2.39e-10	Cardiac Troponin-T levels;
LUAD	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg25173405	chr17:45401733	C17orf57	-0.57	-9.77	-0.43	1.83e-20	Glaucoma (primary open-angle);
LUAD	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.94	-0.4	1.17e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3125734	0.633	rs10821968	chr10:63993905	C/T	cg09941381	chr10:64027924	RTKN2	0.31	7.12	0.33	4.74e-12	Rheumatoid arthritis;
LUAD	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg21963583	chr11:68658836	MRPL21	0.66	11.63	0.49	2.59e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2455799	0.613	rs4685258	chr3:15792315	G/A	cg16303742	chr3:15540471	COLQ	-0.52	-9.72	-0.43	2.83e-20	Mean platelet volume;
LUAD	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg05110241	chr16:68378359	PRMT7	-0.84	-9.13	-0.41	2.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg05887092	chr17:76393375	PGS1	0.42	7.42	0.34	6.3e-13	HDL cholesterol levels;
LUAD	trans	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg03886242	chr7:26192032	NFE2L3	-0.44	-7.74	-0.35	7.52e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg14844989	chr11:31128820	NA	-0.46	-8.33	-0.38	1.17e-15	Red blood cell count;
LUAD	cis	rs10089	0.953	rs10045113	chr5:127386631	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	10.66	0.46	1.14e-23	Ileal carcinoids;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg20257096	chr14:21851954	SUPT16H	-0.38	-6.45	-0.3	3.12e-10	Subcortical brain region volumes;
LUAD	cis	rs367943	0.666	rs7700413	chr5:112704435	T/C	cg12552261	chr5:112820674	MCC	0.44	8.88	0.4	1.95e-17	Type 2 diabetes;
LUAD	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg23815491	chr16:72088622	HP	0.52	9.68	0.43	3.73e-20	Fibrinogen levels;
LUAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg08132940	chr7:1081526	C7orf50	-0.71	-10.09	-0.44	1.36e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12545109	0.800	rs1440763	chr8:57410481	C/A	cg09654669	chr8:57350985	NA	-0.65	-9.15	-0.41	2.44e-18	Obesity-related traits;
LUAD	cis	rs6906287	0.669	rs6913012	chr6:118973137	G/A	cg18833306	chr6:118973337	C6orf204	0.48	8.43	0.38	5.49e-16	Electrocardiographic conduction measures;
LUAD	trans	rs7944735	0.767	rs1017875	chr11:47999218	C/T	cg03929089	chr4:120376271	NA	0.63	7.94	0.36	1.83e-14	Intraocular pressure;
LUAD	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg22823121	chr1:150693482	HORMAD1	-0.36	-7.01	-0.32	9.66e-12	Tonsillectomy;
LUAD	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7395662	0.926	rs11039893	chr11:48657754	G/A	cg15704280	chr7:45808275	SEPT13	-0.44	-7.04	-0.32	7.82e-12	HDL cholesterol;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg12393697	chr2:187558983	FAM171B	-0.63	-6.43	-0.3	3.45e-10	Type 2 diabetes;
LUAD	cis	rs12618769	0.625	rs3820945	chr2:99105156	G/A	cg10123293	chr2:99228465	UNC50	0.46	8.12	0.37	5.1e-15	Bipolar disorder;
LUAD	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg07402062	chr16:89894098	SPIRE2	0.46	11.72	0.5	1.13e-27	Vitiligo;
LUAD	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.61	-0.31	1.18e-10	Prostate cancer;
LUAD	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.59	9.48	0.42	1.81e-19	Cognitive ability;
LUAD	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg02423579	chr7:2872169	GNA12	-0.89	-16.01	-0.61	2.02e-45	Height;
LUAD	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg09117114	chr16:67998030	SLC12A4	0.6	8.06	0.36	8.07e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs731174	0.797	rs565316	chr1:38157624	T/C	cg22449745	chr1:38156939	CDCA8;C1orf109	-0.3	-6.51	-0.3	2.13e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg22496339	chr2:162101262	NA	0.52	8.52	0.38	2.75e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg08219700	chr8:58056026	NA	0.5	7.7	0.35	9.58e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15664640	chr17:80829946	TBCD	-0.55	-10.47	-0.45	5.71e-23	Breast cancer;
LUAD	cis	rs1953600	0.870	rs2789695	chr10:81946840	C/T	cg00277334	chr10:82204260	NA	0.42	7.18	0.33	3.19e-12	Sarcoidosis;
LUAD	cis	rs2742234	0.590	rs2435376	chr10:43684963	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.52	-8.87	-0.4	2.13e-17	Hirschsprung disease;
LUAD	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	10.39	0.45	1.12e-22	Bone mineral density;
LUAD	cis	rs17094222	0.504	rs4917904	chr10:102447292	G/A	cg26540559	chr10:102447443	NA	0.44	8.87	0.4	2.13e-17	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.25	6.56	0.3	1.58e-10	Parkinson's disease;
LUAD	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg18131467	chr2:239335373	ASB1	0.59	9.1	0.4	3.46e-18	Multiple system atrophy;
LUAD	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg10645314	chr2:3704589	ALLC	-0.88	-12.94	-0.53	1.76e-32	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04565464	chr8:145669602	NFKBIL2	0.44	6.9	0.32	1.88e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs236907	0.812	rs2232807	chr1:171750095	T/C	cg13482142	chr2:234261155	NA	0.5	6.51	0.3	2.12e-10	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.98	0.53	1.18e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg23978390	chr7:1156363	C7orf50	0.53	7.34	0.34	1.09e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg12444411	chr7:2802554	GNA12	-0.36	-6.54	-0.3	1.77e-10	Height;
LUAD	cis	rs55823223	0.618	rs72860390	chr17:73869914	A/G	cg14955151	chr17:73874635	TRIM47	-0.43	-6.65	-0.31	9.21e-11	Psoriasis;
LUAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg15117754	chr3:10150083	C3orf24	0.38	6.41	0.3	3.84e-10	Alzheimer's disease;
LUAD	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg26384229	chr12:38710491	ALG10B	0.48	7.69	0.35	1.01e-13	Bladder cancer;
LUAD	cis	rs3087591	1.000	rs7220483	chr17:29577248	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.43	-7.0	-0.32	9.88e-12	Hip circumference;
LUAD	cis	rs3916	0.662	rs2138249	chr12:121124142	A/C	cg13914990	chr12:121174878	ACADS	0.38	7.19	0.33	2.94e-12	Urinary metabolites (H-NMR features);
LUAD	cis	rs367943	0.698	rs2217296	chr5:112973829	A/T	cg12552261	chr5:112820674	MCC	0.47	8.41	0.38	6.39e-16	Type 2 diabetes;
LUAD	cis	rs1595825	0.945	rs6736825	chr2:198854224	C/T	cg00361562	chr2:198649771	BOLL	-0.48	-6.76	-0.31	4.47e-11	Ulcerative colitis;
LUAD	cis	rs1595825	0.891	rs59990242	chr2:198895868	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-7.0	-0.32	1.02e-11	Ulcerative colitis;
LUAD	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10802521	chr3:52805072	NEK4	-0.53	-8.99	-0.4	8.43e-18	Bipolar disorder;
LUAD	cis	rs4481887	0.800	rs10888342	chr1:248441999	A/G	cg00666640	chr1:248458726	OR2T12	0.3	7.41	0.34	6.89e-13	Common traits (Other);
LUAD	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.67	9.47	0.42	2.04e-19	Lymphocyte percentage of white cells;
LUAD	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-6.85	-0.32	2.7e-11	IgG glycosylation;
LUAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9522267	0.535	rs9522286	chr13:112230909	A/G	cg10483660	chr13:112241077	NA	-0.32	-6.79	-0.31	3.7e-11	Hepatitis;
LUAD	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs9393692	0.557	rs1883213	chr6:26303178	A/C	cg00631329	chr6:26305371	NA	-0.56	-9.49	-0.42	1.68e-19	Educational attainment;
LUAD	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg12573674	chr2:1569213	NA	0.61	6.88	0.32	2.22e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg18755752	chr8:142205143	DENND3	-0.56	-10.24	-0.45	4.05e-22	Immature fraction of reticulocytes;
LUAD	cis	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	8.11	0.37	5.68e-15	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg14664628	chr15:75095509	CSK	-0.43	-6.84	-0.32	2.76e-11	Breast cancer;
LUAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.62	-11.7	-0.49	1.39e-27	Longevity;Endometriosis;
LUAD	cis	rs250585	0.688	rs30017	chr16:23412310	G/A	cg00143387	chr16:23521605	GGA2	0.58	8.28	0.37	1.67e-15	Egg allergy;
LUAD	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg21775979	chr11:780331	NA	0.44	8.23	0.37	2.29e-15	Breast cancer;
LUAD	trans	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg01620082	chr3:125678407	NA	-0.71	-7.15	-0.33	3.79e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg19163074	chr7:65112434	INTS4L2	0.42	6.38	0.3	4.72e-10	Aortic root size;
LUAD	trans	rs1997103	1.000	rs2331068	chr7:55408220	G/A	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg05084668	chr3:125655381	ALG1L	-0.86	-11.32	-0.48	3.89e-26	Blood pressure (smoking interaction);
LUAD	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg08807101	chr21:30365312	RNF160	-0.41	-7.12	-0.33	4.81e-12	Dental caries;
LUAD	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg06623918	chr6:96969491	KIAA0776	-0.77	-12.43	-0.52	1.96e-30	Migraine;Coronary artery disease;
LUAD	cis	rs73206853	0.841	rs28772589	chr12:110845040	C/T	cg12870014	chr12:110450643	ANKRD13A	0.61	6.73	0.31	5.38e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg02176678	chr2:219576539	TTLL4	0.68	13.66	0.55	1.94e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9394841	0.692	rs9381095	chr6:41806708	T/A	cg17623882	chr6:41773611	USP49	-0.49	-6.86	-0.32	2.45e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19263974	chr12:3103878	TEAD4	0.48	6.36	0.3	5.11e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11958404	0.932	rs12514557	chr5:157418954	T/C	cg05962755	chr5:157440814	NA	0.53	7.66	0.35	1.29e-13	IgG glycosylation;
LUAD	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg02569458	chr12:86230093	RASSF9	0.41	7.42	0.34	6.57e-13	Major depressive disorder;
LUAD	cis	rs57920188	0.535	rs4295856	chr1:4094842	C/T	cg10510935	chr1:4059661	NA	0.45	6.87	0.32	2.31e-11	Interleukin-17 levels;
LUAD	cis	rs7737355	0.773	rs4705895	chr5:131102194	T/C	cg06307176	chr5:131281290	NA	0.44	7.39	0.34	8.04e-13	Life satisfaction;
LUAD	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.79	-10.36	-0.45	1.41e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs62400317	0.826	rs10807321	chr6:45330974	T/C	cg18551225	chr6:44695536	NA	-0.52	-8.16	-0.37	3.95e-15	Total body bone mineral density;
LUAD	cis	rs4523957	0.928	rs4790325	chr17:2192085	C/T	cg16513277	chr17:2031491	SMG6	-0.77	-14.42	-0.57	1.26e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg12064134	chr16:90016061	DEF8	0.36	6.49	0.3	2.46e-10	Squamous cell carcinoma;
LUAD	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg05665937	chr4:1216051	CTBP1	0.43	7.78	0.35	5.43e-14	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.38e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg04287289	chr16:89883240	FANCA	0.74	6.5	0.3	2.27e-10	Skin colour saturation;
LUAD	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg13180566	chr4:1052158	NA	-0.39	-6.56	-0.3	1.6e-10	Recombination rate (females);
LUAD	cis	rs6988985	0.533	rs6391	chr8:143956965	A/G	cg10324643	chr8:143916377	GML	0.3	6.36	0.3	5.18e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs2425143	1.000	rs11696947	chr20:34312658	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.43	-0.34	6.01e-13	Blood protein levels;
LUAD	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg09455208	chr3:40491958	NA	-0.58	-12.63	-0.52	3.09e-31	Renal cell carcinoma;
LUAD	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg20362242	chr5:692897	TPPP	0.5	6.8	0.31	3.51e-11	Ulcerative colitis;
LUAD	trans	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	6.07e-11	Depression;
LUAD	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	12.24	0.51	1.1e-29	Monocyte percentage of white cells;
LUAD	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg11494091	chr17:61959527	GH2	0.45	8.57	0.38	2.03e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-6.61	-0.31	1.14e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg01620082	chr3:125678407	NA	-0.72	-7.28	-0.33	1.62e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg06784218	chr1:46089804	CCDC17	0.51	11.23	0.48	8.7e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.43	-0.52	1.89e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-11.03	-0.47	5.12e-25	Monocyte percentage of white cells;
LUAD	cis	rs758324	0.812	rs13165154	chr5:131155020	C/T	cg25547332	chr5:131281432	NA	0.41	6.63	0.31	1.01e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs28655083	1.000	rs7197078	chr16:77072735	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-7.14	-0.33	4.13e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06873352	chr17:61820015	STRADA	0.53	8.72	0.39	6.32e-17	Height;
LUAD	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg13736514	chr6:26305472	NA	-0.67	-12.81	-0.53	5.57e-32	Educational attainment;
LUAD	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18876405	chr7:65276391	NA	0.41	6.62	0.31	1.06e-10	Aortic root size;
LUAD	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18404041	chr3:52824283	ITIH1	-0.61	-12.36	-0.52	3.51e-30	Bipolar disorder;
LUAD	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11644478	chr21:40555479	PSMG1	0.67	11.26	0.48	6.75e-26	Cognitive function;
LUAD	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg01868782	chr6:126071099	HEY2	0.32	6.8	0.31	3.49e-11	Brugada syndrome;
LUAD	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.37	0.38	8.27e-16	Platelet count;
LUAD	cis	rs6684514	1.000	rs12038203	chr1:156248265	C/T	cg16558208	chr1:156270281	VHLL	0.52	9.49	0.42	1.75e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg02993280	chr1:107599747	PRMT6	0.52	8.59	0.39	1.72e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	6.7	0.31	6.69e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.43	-0.34	6.08e-13	Bipolar disorder;
LUAD	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg19163074	chr7:65112434	INTS4L2	0.42	6.38	0.3	4.66e-10	Aortic root size;
LUAD	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg09796270	chr17:17721594	SREBF1	0.37	6.95	0.32	1.35e-11	Total body bone mineral density;
LUAD	cis	rs1595825	0.891	rs7584475	chr2:198577424	A/C	cg10547527	chr2:198650123	BOLL	-0.51	-7.2	-0.33	2.7e-12	Ulcerative colitis;
LUAD	cis	rs4253772	0.938	rs45550937	chr22:46638128	C/G	cg09491104	chr22:46646882	C22orf40	-0.54	-7.83	-0.36	4.09e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9875589	0.509	rs2733556	chr3:14100172	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.35	6.45	0.3	3.05e-10	Ovarian reserve;
LUAD	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg02176678	chr2:219576539	TTLL4	0.61	11.71	0.49	1.22e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg04234412	chr22:24373322	LOC391322	-0.87	-16.53	-0.63	1.08e-47	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg02423579	chr7:2872169	GNA12	0.48	7.79	0.35	5.35e-14	Loneliness (linear analysis);
LUAD	cis	rs2880765	0.743	rs6497191	chr15:86011501	T/C	cg13263323	chr15:86062960	AKAP13	-0.48	-8.64	-0.39	1.14e-16	Coronary artery disease;
LUAD	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg16325326	chr1:53192061	ZYG11B	-0.64	-11.99	-0.5	1.04e-28	Monocyte count;
LUAD	cis	rs877282	0.755	rs2486579	chr10:785647	G/A	cg17470449	chr10:769945	NA	0.48	7.45	0.34	5.32e-13	Uric acid levels;
LUAD	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg14343924	chr8:8086146	FLJ10661	0.48	7.25	0.33	1.94e-12	Neuroticism;
LUAD	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg27426351	chr10:43362370	NA	0.56	8.92	0.4	1.38e-17	Blood protein levels;
LUAD	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg00129232	chr17:37814104	STARD3	-0.43	-6.85	-0.32	2.62e-11	Asthma;
LUAD	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg21823605	chr1:152486609	CRCT1	0.29	6.68	0.31	7.5e-11	Hair morphology;
LUAD	cis	rs4006360	0.588	rs2001523	chr17:39262814	C/T	cg20663846	chr17:39254439	KRTAP4-8	0.35	7.42	0.34	6.46e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg07460842	chr6:66804631	NA	0.83	9.8	0.43	1.43e-20	Exhaled nitric oxide output;
LUAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-7.95	-0.36	1.74e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg22482690	chr17:47019901	SNF8	0.44	8.31	0.37	1.32e-15	Type 2 diabetes;
LUAD	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg11915388	chr22:42470451	FAM109B	-0.42	-7.59	-0.35	2.08e-13	Schizophrenia;
LUAD	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg21475434	chr5:93447410	FAM172A	0.71	8.32	0.38	1.22e-15	Diabetic retinopathy;
LUAD	cis	rs7940866	0.774	rs7480903	chr11:130832276	A/G	cg12179176	chr11:130786555	SNX19	0.41	6.5	0.3	2.24e-10	Schizophrenia;
LUAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.64	11.58	0.49	3.96e-27	Lymphocyte counts;
LUAD	cis	rs732716	0.853	rs62129349	chr19:4385659	A/G	cg21934504	chr19:4445085	UBXN6	0.46	7.71	0.35	9.19e-14	Mean corpuscular volume;
LUAD	cis	rs2581828	0.541	rs2115781	chr3:53131829	T/C	cg24530246	chr3:53118167	NA	0.31	6.57	0.3	1.53e-10	Crohn's disease;
LUAD	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/A	cg13877915	chr19:58951672	ZNF132	0.55	7.32	0.34	1.22e-12	Mean platelet volume;
LUAD	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.34	-7.26	-0.33	1.9e-12	Hemoglobin concentration;
LUAD	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg01851573	chr8:8652454	MFHAS1	-0.39	-6.77	-0.31	4.22e-11	Mood instability;
LUAD	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.94e-11	Hepatitis;
LUAD	cis	rs1595825	0.891	rs7585709	chr2:198883682	C/T	cg00361562	chr2:198649771	BOLL	-0.46	-6.49	-0.3	2.43e-10	Ulcerative colitis;
LUAD	cis	rs2046867	0.862	rs6549483	chr3:72805316	T/G	cg27402429	chr3:72788294	NA	-0.4	-6.36	-0.3	5.37e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg12863693	chr15:85201151	NMB	0.39	7.2	0.33	2.78e-12	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	8.88e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg02428538	chr16:24856791	SLC5A11	-0.55	-7.76	-0.35	6.52e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg21248554	chr2:27665150	KRTCAP3	0.33	8.88	0.4	1.87e-17	Total body bone mineral density;
LUAD	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg14019146	chr3:50243930	SLC38A3	-0.35	-6.43	-0.3	3.52e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs4130548	0.577	rs12730346	chr1:78687156	C/T	cg20826526	chr3:156266748	SSR3	-0.48	-7.76	-0.35	6.49e-14	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Waist circumference;
LUAD	cis	rs7759001	0.857	rs4713092	chr6:27363898	T/C	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg10729496	chr3:10149963	C3orf24	0.47	7.0	0.32	1.02e-11	Alzheimer's disease;
LUAD	cis	rs6761276	0.649	rs12711751	chr2:113837765	T/G	cg09040174	chr2:113837401	NA	0.74	13.47	0.55	1.15e-34	Protein quantitative trait loci;
LUAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg05434287	chr7:2030229	MAD1L1	-0.39	-6.56	-0.3	1.54e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs8068544	0.818	rs78333491	chr17:40163138	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.2	-12.25	-0.51	9.73e-30	Reticulocyte fraction of red cells;Reticulocyte count;
LUAD	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs9652601	0.779	rs11648679	chr16:11175984	A/G	cg04616529	chr16:11181986	CLEC16A	0.38	6.77	0.31	4.45e-11	Systemic lupus erythematosus;
LUAD	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18099408	chr3:52552593	STAB1	-0.53	-9.6	-0.42	7.07e-20	Electroencephalogram traits;
LUAD	trans	rs747782	0.583	rs11039666	chr11:48324841	C/G	cg15704280	chr7:45808275	SEPT13	0.75	7.78	0.35	5.75e-14	Intraocular pressure;
LUAD	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg06108461	chr20:60628389	TAF4	-0.74	-12.67	-0.52	2.11e-31	Body mass index;
LUAD	cis	rs7843479	1.000	rs13276082	chr8:21823184	A/G	cg03445287	chr8:21823731	XPO7	-0.46	-8.52	-0.38	2.74e-16	Mean corpuscular volume;
LUAD	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.39	-0.34	7.99e-13	Bipolar disorder;
LUAD	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	7.89	0.36	2.57e-14	Menarche (age at onset);
LUAD	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg17372223	chr3:52568218	NT5DC2	0.4	7.27	0.33	1.77e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11756438	0.683	rs57237379	chr6:119018319	G/A	cg18833306	chr6:118973337	C6orf204	0.39	6.49	0.3	2.41e-10	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg08807101	chr21:30365312	RNF160	-0.44	-7.67	-0.35	1.22e-13	Dental caries;
LUAD	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg18490616	chr2:88469792	THNSL2	-0.41	-6.42	-0.3	3.56e-10	Response to metformin (IC50);
LUAD	trans	rs11039798	0.623	rs584851	chr11:48416321	A/G	cg15704280	chr7:45808275	SEPT13	-0.63	-7.5	-0.34	3.88e-13	Axial length;
LUAD	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03934478	chr11:495069	RNH1	0.76	9.18	0.41	1.97e-18	Body mass index;
LUAD	cis	rs968567	0.689	rs61897795	chr11:61618169	A/G	cg11250194	chr11:61601937	FADS2	-0.57	-7.01	-0.32	9.51e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs7705042	0.865	rs7723666	chr5:141513966	C/T	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.75	-0.31	4.87e-11	Asthma;
LUAD	cis	rs1869026	0.621	rs3860374	chr2:121348224	C/T	cg03661458	chr2:121334411	NA	-0.35	-6.51	-0.3	2.07e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg10978503	chr1:24200527	CNR2	-0.43	-7.97	-0.36	1.54e-14	Immature fraction of reticulocytes;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg05698098	chr11:61595494	FADS2	-0.49	-6.37	-0.3	4.87e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg11494091	chr17:61959527	GH2	0.45	8.58	0.39	1.76e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs11696501	0.688	rs6073833	chr20:44279894	T/G	cg11783356	chr20:44313418	WFDC10B	-0.49	-8.22	-0.37	2.53e-15	Brain structure;
LUAD	cis	rs986417	1.000	rs2093212	chr14:60843322	G/A	cg27398547	chr14:60952738	C14orf39	-0.61	-7.3	-0.33	1.43e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.91	0.36	2.31e-14	Parkinson's disease;
LUAD	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24308560	chr3:49941425	MST1R	-0.57	-9.61	-0.42	6.39e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs9302690	0.557	rs223869	chr16:57494992	C/A	cg16753122	chr16:57506917	DOK4	0.56	6.37	0.3	5.05e-10	Blood protein levels;
LUAD	cis	rs943466	1.000	rs943462	chr6:33769578	G/A	cg16010596	chr6:33739607	LEMD2	-0.43	-7.98	-0.36	1.38e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs6835098	1.000	rs1054496	chr4:174089080	A/G	cg27433088	chr4:174089019	GALNT7	0.36	6.76	0.31	4.57e-11	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs4730250	0.708	rs4730242	chr7:107057373	G/C	cg02696742	chr7:106810147	HBP1	-0.79	-10.37	-0.45	1.35e-22	Osteoarthritis;
LUAD	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg26597838	chr10:835615	NA	0.85	12.95	0.53	1.55e-32	Eosinophil percentage of granulocytes;
LUAD	cis	rs986417	1.000	rs1955686	chr14:61093560	C/T	cg27398547	chr14:60952738	C14orf39	0.65	7.32	0.34	1.28e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.25	0.41	1.08e-18	Alzheimer's disease;
LUAD	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg04450456	chr4:17643702	FAM184B	0.37	6.89	0.32	1.97e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.32	-0.34	1.22e-12	Coronary artery disease;
LUAD	cis	rs10203711	1.000	rs6731675	chr2:239566943	T/C	cg14580085	chr2:239553406	NA	0.41	8.9	0.4	1.64e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1595825	0.836	rs79748557	chr2:198567912	G/T	cg10547527	chr2:198650123	BOLL	-0.52	-7.28	-0.33	1.69e-12	Ulcerative colitis;
LUAD	cis	rs9900497	0.504	rs2228100	chr17:19642952	C/G	cg22552966	chr17:19620595	SLC47A2	0.34	7.55	0.34	2.67e-13	Response to paliperidone in schizophrenia (CGI-S score);
LUAD	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg00634984	chr7:65235879	NA	0.49	6.51	0.3	2.15e-10	Aortic root size;
LUAD	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg15208524	chr1:10270712	KIF1B	0.55	8.12	0.37	5.25e-15	Hepatocellular carcinoma;
LUAD	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg22079354	chr11:130786696	SNX19	0.39	6.41	0.3	3.91e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs28830936	0.510	rs7175346	chr15:42100674	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.57	-14.21	-0.57	9.68e-38	Diastolic blood pressure;
LUAD	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg23260525	chr10:116636907	FAM160B1	0.53	12.59	0.52	4.52e-31	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26314531	chr2:26401878	FAM59B	-0.52	-7.2	-0.33	2.73e-12	Gut microbiome composition (summer);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg19763809	chr2:98703475	VWA3B	-0.61	-6.49	-0.3	2.42e-10	Type 2 diabetes;
LUAD	trans	rs208520	0.661	rs851466	chr6:66840476	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-17.37	-0.65	2.04e-51	Exhaled nitric oxide output;
LUAD	trans	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg01620082	chr3:125678407	NA	-0.44	-6.69	-0.31	7.18e-11	Parkinson's disease;
LUAD	cis	rs12620999	0.941	rs4408676	chr2:238085280	C/T	cg23555395	chr2:238036564	NA	-0.58	-8.8	-0.39	3.63e-17	Systemic lupus erythematosus;
LUAD	cis	rs2734839	0.964	rs1116313	chr11:113296107	A/G	cg14159747	chr11:113255604	NA	0.53	10.35	0.45	1.6400000000000001e-22	Information processing speed;
LUAD	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs2979489	0.891	rs2979498	chr8:30375251	T/A	cg26383811	chr8:30366931	RBPMS	-0.69	-10.47	-0.45	5.95e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06873352	chr17:61820015	STRADA	0.83	18.6	0.67	7.24e-57	Prudent dietary pattern;
LUAD	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg15991700	chr5:179719416	MAPK9	-0.63	-6.43	-0.3	3.37e-10	Type 2 diabetes;
LUAD	cis	rs7809950	1.000	rs2712200	chr7:107142435	G/T	cg23024343	chr7:107201750	COG5	-0.73	-12.35	-0.51	3.95e-30	Coronary artery disease;
LUAD	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg16414030	chr3:133502952	NA	-0.54	-9.56	-0.42	1.02e-19	Iron status biomarkers;
LUAD	cis	rs73086581	1.000	rs6052220	chr20:3970594	C/T	cg02187196	chr20:3869020	PANK2	0.42	6.43	0.3	3.36e-10	Response to antidepressants in depression;
LUAD	cis	rs7107174	1.000	rs1893447	chr11:77973182	A/G	cg02023728	chr11:77925099	USP35	0.43	7.24	0.33	2.07e-12	Testicular germ cell tumor;
LUAD	cis	rs7100689	0.580	rs7083519	chr10:82207524	C/G	cg00277334	chr10:82204260	NA	-0.83	-15.83	-0.61	1.14e-44	Post bronchodilator FEV1;
LUAD	cis	rs11724804	0.532	rs62295557	chr4:855708	G/A	cg20916646	chr4:852691	GAK	0.61	8.54	0.38	2.38e-16	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg10518543	chr12:38710700	ALG10B	-0.42	-6.83	-0.32	3.03e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs17095355	0.605	rs2274978	chr10:111631665	C/G	cg00817464	chr10:111662876	XPNPEP1	0.58	7.3	0.33	1.46e-12	Biliary atresia;
LUAD	cis	rs6906287	0.573	rs6928210	chr6:118699394	C/G	cg21191810	chr6:118973309	C6orf204	0.49	9.54	0.42	1.17e-19	Electrocardiographic conduction measures;
LUAD	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.28	6.35	0.3	5.56e-10	Parkinson's disease;
LUAD	cis	rs6761276	0.727	rs6743376	chr2:113832333	C/A	cg09040174	chr2:113837401	NA	0.73	12.02	0.5	7.92e-29	Protein quantitative trait loci;
LUAD	trans	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.73	0.35	7.68e-14	Resting heart rate;
LUAD	cis	rs8044868	0.530	rs7201866	chr16:72086534	A/T	cg23815491	chr16:72088622	HP	0.51	9.34	0.41	5.49e-19	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg02527881	chr3:46936655	PTH1R	-0.6	-11.03	-0.47	4.79e-25	Birth weight;
LUAD	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.09	-0.33	5.65e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg17366294	chr4:99064904	C4orf37	0.7	13.2	0.54	1.41e-33	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2637266	1.000	rs1907314	chr10:78337948	G/A	cg18941641	chr10:78392320	NA	0.32	6.61	0.31	1.15e-10	Pulmonary function;
LUAD	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg18190219	chr22:46762943	CELSR1	-0.55	-6.82	-0.31	3.08e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg15358701	chr1:161410459	NA	-0.68	-6.93	-0.32	1.58e-11	Rheumatoid arthritis;
LUAD	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg02782426	chr3:40428986	ENTPD3	0.35	7.51	0.34	3.61e-13	Renal cell carcinoma;
LUAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg12432903	chr7:1882776	MAD1L1	0.43	7.01	0.32	9.55e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs990171	0.538	rs4851017	chr2:103120769	C/A	cg03938978	chr2:103052716	IL18RAP	0.33	6.54	0.3	1.83e-10	Lymphocyte counts;
LUAD	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg01236616	chr12:121019343	POP5	1.29	19.06	0.68	6.42e-59	Type 1 diabetes nephropathy;
LUAD	cis	rs9341808	0.718	rs9448893	chr6:80837239	A/G	cg08355045	chr6:80787529	NA	0.56	10.09	0.44	1.38e-21	Sitting height ratio;
LUAD	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg14092988	chr3:52407081	DNAH1	0.37	7.48	0.34	4.47e-13	Bipolar disorder;
LUAD	trans	rs6074578	0.902	rs6033484	chr20:185926	A/G	cg13035437	chr7:30634158	GARS	-0.35	-6.46	-0.3	2.81e-10	Hirschsprung disease;
LUAD	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg19418458	chr7:158789849	NA	0.52	9.46	0.42	2.15e-19	Facial morphology (factor 20);
LUAD	cis	rs12210905	1.000	rs12209456	chr6:27085225	C/T	cg11502198	chr6:26597334	ABT1	-0.78	-6.36	-0.3	5.22e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg27129171	chr3:47204927	SETD2	-0.45	-7.16	-0.33	3.51e-12	Colorectal cancer;
LUAD	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.59e-12	Breast cancer;
LUAD	cis	rs427394	1.000	rs427394	chr5:6745875	A/G	cg10857441	chr5:6722123	POLS	-0.62	-11.84	-0.5	4.01e-28	Menopause (age at onset);
LUAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.47	-7.89	-0.36	2.61e-14	Longevity;Endometriosis;
LUAD	trans	rs9929218	0.953	rs3118227	chr16:68734855	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-16.49	-0.63	1.52e-47	Colorectal cancer;
LUAD	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.75e-11	Crohn's disease;
LUAD	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg10589385	chr1:150898437	SETDB1	0.39	7.39	0.34	8e-13	Tonsillectomy;
LUAD	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg27535305	chr1:53392650	SCP2	0.32	6.52	0.3	1.98e-10	Monocyte count;
LUAD	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg00166722	chr3:10149974	C3orf24	0.64	10.65	0.46	1.3e-23	Alzheimer's disease;
LUAD	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg19041857	chr6:27730383	NA	-0.44	-7.61	-0.35	1.82e-13	Parkinson's disease;
LUAD	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg14671364	chr1:107599128	PRMT6	-0.54	-9.34	-0.41	5.43e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg19418458	chr7:158789849	NA	-0.61	-10.64	-0.46	1.37e-23	Facial morphology (factor 20);
LUAD	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.52	-8.41	-0.38	6.3e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg23277830	chr1:3704460	LRRC47	0.46	9.47	0.42	2.04e-19	Red cell distribution width;
LUAD	trans	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.41	-6.91	-0.32	1.81e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs3784262	0.867	rs8036453	chr15:58371635	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.41	-8.0	-0.36	1.19e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs11771526	0.901	rs41519845	chr7:32315443	A/T	cg13207630	chr7:32358064	NA	0.6	7.43	0.34	6.24e-13	Body mass index;
LUAD	cis	rs9487051	0.708	rs378447	chr6:109526823	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.08	-0.33	6.07e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs67981189	0.634	rs221900	chr14:71604354	C/T	cg15816911	chr14:71606274	NA	0.38	7.21	0.33	2.58e-12	Schizophrenia;
LUAD	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-20.58	-0.71	1.06e-65	Height;
LUAD	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg02038168	chr22:39784481	NA	-0.57	-9.37	-0.41	4.38e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg05283184	chr6:79620031	NA	-0.58	-11.68	-0.49	1.62e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs6494488	0.500	rs72742943	chr15:64889463	G/A	cg08069370	chr15:64387884	SNX1	-0.75	-6.59	-0.3	1.34e-10	Coronary artery disease;
LUAD	cis	rs6545883	1.000	rs6545883	chr2:61772257	A/G	cg15711740	chr2:61764176	XPO1	-0.42	-7.05	-0.32	7.31e-12	Tuberculosis;
LUAD	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg18180107	chr4:99064573	C4orf37	-0.43	-6.9	-0.32	1.86e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12893668	0.667	rs71417869	chr14:104077434	A/G	cg13511324	chr14:104056883	C14orf153	0.26	6.49	0.3	2.38e-10	Reticulocyte count;
LUAD	cis	rs807669	0.742	rs1206544	chr22:19215039	C/T	cg02655711	chr22:19163373	SLC25A1	0.7	14.91	0.59	1.11e-40	Metabolite levels;
LUAD	cis	rs17433780	0.504	rs1409150	chr1:89473175	A/G	cg09516651	chr1:89888402	LOC400759	0.4	7.57	0.35	2.29e-13	Carotid intima media thickness;
LUAD	cis	rs7737355	0.947	rs6879005	chr5:130615445	C/T	cg06307176	chr5:131281290	NA	0.46	7.33	0.34	1.21e-12	Life satisfaction;
LUAD	trans	rs6076960	0.622	rs6054063	chr20:6262992	C/A	cg21095983	chr6:86352623	SYNCRIP	0.4	6.37	0.3	4.81e-10	Smooth-surface caries;
LUAD	cis	rs344364	0.576	rs238677	chr16:1883279	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.87	-0.32	2.28e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.1	-0.51	3.76e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg04539111	chr16:67997858	SLC12A4	0.59	7.33	0.34	1.16e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg00300879	chr1:26503847	CNKSR1	-0.29	-8.48	-0.38	3.9e-16	Height;
LUAD	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.41	-0.34	6.98e-13	Coronary artery disease;
LUAD	cis	rs7264396	0.836	rs6088880	chr20:34165582	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.42	6.66	0.31	8.74e-11	Total cholesterol levels;
LUAD	cis	rs41311933	0.562	rs72760240	chr9:123914606	G/A	cg13567360	chr9:123745713	C5	-0.7	-8.3	-0.37	1.38e-15	Coronary artery disease;
LUAD	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg09654669	chr8:57350985	NA	-0.66	-9.52	-0.42	1.31e-19	Obesity-related traits;
LUAD	cis	rs9837602	0.507	rs1059905	chr3:99516879	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	6.54	0.3	1.79e-10	Breast cancer;
LUAD	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-8.53	-0.38	2.62e-16	Monocyte percentage of white cells;
LUAD	cis	rs59104589	0.550	rs62193172	chr2:242277715	G/C	cg08645257	chr2:242211290	HDLBP	0.46	7.3	0.33	1.45e-12	Fibrinogen levels;
LUAD	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg06112835	chr11:68658793	MRPL21	-0.35	-6.44	-0.3	3.33e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1385374	0.858	rs11059928	chr12:129296103	A/T	cg09035930	chr12:129282057	SLC15A4	-0.65	-6.91	-0.32	1.8e-11	Systemic lupus erythematosus;
LUAD	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06544989	chr22:39130855	UNC84B	0.38	7.68	0.35	1.13e-13	Menopause (age at onset);
LUAD	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg13319975	chr6:146136371	FBXO30	-0.61	-10.26	-0.45	3.26e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg01475377	chr6:109611718	NA	-0.54	-10.28	-0.45	2.73e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-7.33	-0.34	1.17e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg05044414	chr3:183734942	ABCC5	0.46	9.51	0.42	1.48e-19	Anterior chamber depth;
LUAD	trans	rs11039798	0.764	rs76882342	chr11:48939091	A/T	cg02254774	chr11:50257496	LOC441601	0.52	6.56	0.3	1.62e-10	Axial length;
LUAD	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.38	-6.79	-0.31	3.79e-11	Alzheimer's disease (late onset);
LUAD	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.62	7.38	0.34	8.48e-13	Lung cancer in ever smokers;
LUAD	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-7.23	-0.33	2.22e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7177699	0.557	rs8035093	chr15:79120670	T/C	cg15571903	chr15:79123663	NA	0.38	7.57	0.35	2.43e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11890956	chr21:40555474	PSMG1	0.82	14.66	0.58	1.25e-39	Cognitive function;
LUAD	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg11344533	chr11:111475393	SIK2	-0.37	-6.8	-0.31	3.52e-11	Primary sclerosing cholangitis;
LUAD	cis	rs3784262	0.669	rs4646603	chr15:58290024	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.69	-0.35	1.02e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg14582100	chr15:45693742	SPATA5L1	0.42	8.23	0.37	2.27e-15	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs8192282	0.739	rs6662503	chr1:154477069	T/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.31	-0.33	1.33e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	trans	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg07211511	chr3:129823064	LOC729375	-0.83	-9.02	-0.4	6.42e-18	Blood pressure (smoking interaction);
LUAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08280861	chr8:58055591	NA	0.63	8.28	0.37	1.69e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18876405	chr7:65276391	NA	-0.43	-7.08	-0.33	6.16e-12	Aortic root size;
LUAD	cis	rs3931020	0.548	rs2134836	chr1:75271646	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.42	6.62	0.31	1.11e-10	Resistin levels;
LUAD	trans	rs7395662	1.000	rs11039820	chr11:48562252	A/G	cg00717180	chr2:96193071	NA	-0.38	-7.18	-0.33	3.13e-12	HDL cholesterol;
LUAD	cis	rs7584330	0.704	rs11884395	chr2:238359366	C/T	cg14458575	chr2:238380390	NA	0.85	16.12	0.62	6.41e-46	Prostate cancer;
LUAD	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg02371401	chr5:676784	TPPP	-0.47	-7.68	-0.35	1.12e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg00750074	chr16:89608354	SPG7	-0.55	-9.59	-0.42	7.87e-20	Multiple myeloma (IgH translocation);
LUAD	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg18016565	chr1:150552671	MCL1	0.41	7.52	0.34	3.34e-13	Tonsillectomy;
LUAD	cis	rs9341808	0.718	rs7740627	chr6:80916347	A/G	cg08355045	chr6:80787529	NA	0.59	10.55	0.46	3.02e-23	Sitting height ratio;
LUAD	cis	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg08601574	chr20:25228251	PYGB	-0.45	-8.23	-0.37	2.35e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg13379983	chr2:198649727	BOLL	-0.46	-6.48	-0.3	2.52e-10	Ulcerative colitis;
LUAD	cis	rs4604732	0.631	rs10925044	chr1:247627071	A/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7107174	1.000	rs2511190	chr11:77988310	T/C	cg02023728	chr11:77925099	USP35	0.47	7.26	0.33	1.89e-12	Testicular germ cell tumor;
LUAD	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs68170813	0.559	rs6964798	chr7:106933013	C/G	cg23024343	chr7:107201750	COG5	0.51	7.4	0.34	7.21e-13	Coronary artery disease;
LUAD	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg02734326	chr4:10020555	SLC2A9	0.56	9.77	0.43	1.78e-20	Bone mineral density;
LUAD	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg06108461	chr20:60628389	TAF4	-0.97	-17.64	-0.65	1.33e-52	Body mass index;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11843700	chr19:1490497	REEP6;PCSK4	-0.42	-6.41	-0.3	3.86e-10	Height;
LUAD	cis	rs2625529	0.730	rs1481861	chr15:72240129	A/G	cg16672083	chr15:72433130	SENP8	0.67	12.15	0.51	2.42e-29	Red blood cell count;
LUAD	cis	rs3772130	0.545	rs7340674	chr3:121574215	T/C	cg20356878	chr3:121714668	ILDR1	0.68	13.98	0.56	9.13e-37	Cognitive performance;
LUAD	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.46	-0.34	4.94e-13	Resting heart rate;
LUAD	cis	rs7833986	1.000	rs35883156	chr8:57078933	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.79	10.14	0.44	8.94e-22	Height;
LUAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg24829409	chr8:58192753	C8orf71	-0.61	-7.97	-0.36	1.48e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg02176678	chr2:219576539	TTLL4	-0.82	-17.41	-0.65	1.35e-51	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.66	0.39	9.68e-17	Rheumatoid arthritis;
LUAD	trans	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg27411982	chr8:10470053	RP1L1	0.43	7.98	0.36	1.43e-14	Mood instability;
LUAD	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg18898632	chr2:242989856	NA	-0.51	-6.36	-0.3	5.15e-10	Obesity-related traits;
LUAD	cis	rs7809950	0.678	rs7788271	chr7:106985873	A/G	cg23024343	chr7:107201750	COG5	-0.82	-13.89	-0.56	2.07e-36	Coronary artery disease;
LUAD	cis	rs870825	0.932	rs28594349	chr4:185574415	G/A	cg04058563	chr4:185651563	MLF1IP	0.69	8.56	0.38	2.18e-16	Blood protein levels;
LUAD	cis	rs938554	1.000	rs6832456	chr4:9924336	A/C	cg11266682	chr4:10021025	SLC2A9	0.44	7.63	0.35	1.62e-13	Blood metabolite levels;
LUAD	cis	rs7705042	0.865	rs4912623	chr5:141505462	T/A	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.59	-0.31	1.29e-10	Asthma;
LUAD	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg01657329	chr11:68192670	LRP5	0.4	6.6	0.31	1.23e-10	Total body bone mineral density;
LUAD	cis	rs89107	0.576	rs17227124	chr6:118741382	T/C	cg21191810	chr6:118973309	C6orf204	0.41	7.67	0.35	1.18e-13	Cardiac structure and function;
LUAD	cis	rs9811920	0.809	rs4928235	chr3:99706870	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	7.1	0.33	5.47e-12	Axial length;
LUAD	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.76	10.35	0.45	1.52e-22	Smoking behavior;
LUAD	cis	rs10979	0.931	rs9484771	chr6:143896897	T/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.28	-0.45	2.77e-22	Hypospadias;
LUAD	cis	rs912330	0.529	rs4772100	chr13:99196573	G/T	cg20487152	chr13:99095054	FARP1	-0.34	-6.42	-0.3	3.73e-10	Alzheimer's disease;
LUAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg05434287	chr7:2030229	MAD1L1	0.39	6.44	0.3	3.27e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs909002	0.830	rs10914460	chr1:32113216	T/C	cg13919466	chr1:32135498	COL16A1	-0.39	-9.05	-0.4	5.41e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs432925	0.600	rs379056	chr16:339291	G/C	cg06233593	chr16:337645	AXIN1	0.3	6.73	0.31	5.51e-11	Morning vs. evening chronotype;
LUAD	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg07741184	chr6:167504864	NA	0.31	7.06	0.32	6.7e-12	Crohn's disease;
LUAD	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21659725	chr3:3221576	CRBN	-0.52	-8.33	-0.38	1.14e-15	Body mass index;
LUAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs652260	1.000	rs590394	chr19:7902505	C/T	cg26014689	chr19:7917955	EVI5L	-0.43	-8.1	-0.37	5.97e-15	Menarche (age at onset);
LUAD	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18404041	chr3:52824283	ITIH1	-0.6	-12.47	-0.52	1.32e-30	Electroencephalogram traits;
LUAD	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg19773385	chr1:10388646	KIF1B	0.42	6.47	0.3	2.73e-10	Hepatocellular carcinoma;
LUAD	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg04414720	chr1:150670196	GOLPH3L	0.73	13.64	0.55	2.2e-35	Tonsillectomy;
LUAD	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg24733560	chr20:60626293	TAF4	0.47	9.31	0.41	6.8e-19	Body mass index;
LUAD	trans	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg06606381	chr12:133084897	FBRSL1	-0.81	-6.77	-0.31	4.41e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg02527881	chr3:46936655	PTH1R	0.43	8.33	0.38	1.17e-15	Colorectal cancer;
LUAD	cis	rs10129255	0.518	rs8009594	chr14:107185733	G/T	cg07958169	chr14:107095056	NA	-0.37	-7.43	-0.34	6.19e-13	Kawasaki disease;
LUAD	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02788857	chr8:22132959	PIWIL2	0.57	10.45	0.45	7.08e-23	Hypertriglyceridemia;
LUAD	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg18016565	chr1:150552671	MCL1	0.41	7.58	0.35	2.14e-13	Tonsillectomy;
LUAD	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg19875535	chr5:140030758	IK	0.47	7.71	0.35	8.78e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg27284194	chr4:1044797	NA	0.67	8.97	0.4	9.37e-18	Recombination rate (females);
LUAD	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg20503657	chr10:835505	NA	0.65	8.4	0.38	6.75e-16	Eosinophil percentage of granulocytes;
LUAD	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg03340356	chr1:67600835	NA	-0.44	-7.56	-0.34	2.57e-13	Psoriasis;
LUAD	cis	rs7809950	1.000	rs2712191	chr7:107182724	C/G	cg23024343	chr7:107201750	COG5	-0.72	-11.97	-0.5	1.23e-28	Coronary artery disease;
LUAD	cis	rs4332037	0.722	rs28705934	chr7:1916116	T/A	cg02421172	chr7:1938701	MAD1L1	0.4	6.36	0.3	5.21e-10	Bipolar disorder;
LUAD	cis	rs16958440	0.867	rs12386092	chr18:44672058	C/T	cg17192377	chr18:44677553	HDHD2	0.84	7.85	0.36	3.48e-14	Sitting height ratio;
LUAD	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.37	-6.57	-0.3	1.5e-10	Caffeine consumption;
LUAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg08132940	chr7:1081526	C7orf50	-0.77	-10.36	-0.45	1.49e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg09455208	chr3:40491958	NA	0.55	12.15	0.51	2.32e-29	Renal cell carcinoma;
LUAD	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg09365446	chr1:150670422	GOLPH3L	0.4	6.95	0.32	1.35e-11	Tonsillectomy;
LUAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg00024416	chr22:24240387	NA	0.44	7.85	0.36	3.47e-14	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs3845702	0.736	rs72960660	chr2:180832482	A/G	cg01881094	chr2:180872142	CWC22	0.78	8.16	0.37	4.01e-15	Schizophrenia;
LUAD	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg27284194	chr4:1044797	NA	0.7	10.2	0.44	5.31e-22	Recombination rate (females);
LUAD	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg02734326	chr4:10020555	SLC2A9	0.43	7.44	0.34	5.71e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs11771526	0.901	rs10244622	chr7:32302960	C/T	cg27532318	chr7:32358331	NA	0.59	7.42	0.34	6.66e-13	Body mass index;
LUAD	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg05340658	chr4:99064831	C4orf37	-0.45	-7.37	-0.34	9.16e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.49	-7.85	-0.36	3.53e-14	Tonsillectomy;
LUAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg03188948	chr7:1209495	NA	0.8	9.76	0.43	2.04e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg22681709	chr2:178499509	PDE11A	-0.49	-8.16	-0.37	3.79e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	9.03	0.4	5.91e-18	Alzheimer's disease;
LUAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg06074448	chr4:187884817	NA	-0.36	-7.19	-0.33	3.03e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6500395	0.962	rs868792	chr16:48640632	T/C	cg04672837	chr16:48644449	N4BP1	0.39	6.7	0.31	6.62e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs738322	0.511	rs2267370	chr22:38576826	G/A	cg17652424	chr22:38574118	PLA2G6	-0.32	-8.8	-0.39	3.49e-17	Cutaneous nevi;
LUAD	cis	rs2996428	0.629	rs12135894	chr1:3728061	C/T	cg13057898	chr1:3703894	LRRC47	0.63	10.83	0.47	2.7e-24	Red cell distribution width;
LUAD	trans	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg00769240	chr8:12517080	NA	-0.43	-7.32	-0.34	1.26e-12	Blood pressure (smoking interaction);
LUAD	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg07138768	chr7:917805	C7orf20	0.37	7.42	0.34	6.34e-13	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg02569458	chr12:86230093	RASSF9	0.44	8.09	0.37	6.27e-15	Major depressive disorder;
LUAD	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10802521	chr3:52805072	NEK4	-0.61	-11.07	-0.47	3.56e-25	Bipolar disorder;
LUAD	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs738322	0.600	rs7286105	chr22:38557821	A/G	cg17652424	chr22:38574118	PLA2G6	-0.3	-8.22	-0.37	2.58e-15	Cutaneous nevi;
LUAD	trans	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg00953403	chr17:74099816	EXOC7	0.47	7.5	0.34	3.75e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs7267979	0.718	rs2983489	chr20:25244120	C/A	cg08601574	chr20:25228251	PYGB	0.42	7.88	0.36	2.87e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs859767	0.501	rs6745983	chr2:135430709	C/T	cg12500956	chr2:135428796	TMEM163	-0.28	-7.66	-0.35	1.28e-13	Neuroticism;
LUAD	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg22442454	chr1:209979470	IRF6	0.5	6.66	0.31	8.51e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg02423579	chr7:2872169	GNA12	-0.76	-12.91	-0.53	2.2e-32	Height;
LUAD	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg02176678	chr2:219576539	TTLL4	0.7	13.94	0.56	1.37e-36	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-24.12	-0.76	1.69e-81	Height;
LUAD	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg27446573	chr6:127587934	RNF146	0.43	6.39	0.3	4.35e-10	Breast cancer;
LUAD	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg12311346	chr5:56204834	C5orf35	-0.65	-10.28	-0.45	2.78e-22	Coronary artery disease;
LUAD	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg26384229	chr12:38710491	ALG10B	-0.4	-6.75	-0.31	4.83e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1003719	0.715	rs2835667	chr21:38579914	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.14	-0.37	4.54e-15	Eye color traits;
LUAD	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg20203395	chr5:56204925	C5orf35	0.59	9.12	0.41	3.02e-18	Initial pursuit acceleration;
LUAD	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg17644776	chr2:200775616	C2orf69	-0.53	-6.66	-0.31	8.36e-11	Schizophrenia;
LUAD	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg18827107	chr12:86230957	RASSF9	-0.54	-9.54	-0.42	1.12e-19	Major depressive disorder;
LUAD	cis	rs6840360	1.000	rs10049991	chr4:152664163	A/T	cg22705602	chr4:152727874	NA	-0.32	-6.36	-0.3	5.1e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7274811	0.652	rs158672	chr20:32023286	T/C	cg13403462	chr20:32256071	NECAB3;C20orf134	0.44	6.6	0.31	1.26e-10	Height;
LUAD	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg06221963	chr1:154839813	KCNN3	-0.83	-19.22	-0.68	1.22e-59	Prostate cancer;
LUAD	cis	rs113835537	0.877	rs2229456	chr11:66328741	A/C	cg24851651	chr11:66362959	CCS	0.55	8.03	0.36	9.78e-15	Airway imaging phenotypes;
LUAD	cis	rs4901869	1.000	rs4901869	chr14:59334128	A/G	cg02291164	chr14:59296302	NA	0.64	15.65	0.61	6.93e-44	Panic disorder;
LUAD	cis	rs9807989	0.507	rs1420097	chr2:103009354	C/G	cg03938978	chr2:103052716	IL18RAP	-0.44	-10.13	-0.44	9.96e-22	Asthma;
LUAD	cis	rs790123	0.553	rs7612991	chr3:122351791	T/C	cg24850323	chr3:122379709	NA	0.36	6.71	0.31	6.2e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg09509183	chr1:209979624	IRF6	-0.49	-7.15	-0.33	3.95e-12	Cleft lip with or without cleft palate;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02002494	chr3:119013045	CDGAP	-0.42	-6.81	-0.31	3.4e-11	Height;
LUAD	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg13180566	chr4:1052158	NA	-0.39	-6.66	-0.31	8.6e-11	Recombination rate (females);
LUAD	cis	rs7267979	0.816	rs1044573	chr20:25206654	A/G	cg08601574	chr20:25228251	PYGB	0.44	8.08	0.37	6.7e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg11766577	chr21:47581405	C21orf56	-0.46	-7.83	-0.36	3.89e-14	Testicular germ cell tumor;
LUAD	cis	rs748404	0.697	rs524547	chr15:43551023	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.19	0.37	3.03e-15	Lung cancer;
LUAD	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg07211511	chr3:129823064	LOC729375	0.8	11.74	0.5	9.93e-28	Blood pressure (smoking interaction);
LUAD	cis	rs155076	0.666	rs4770128	chr13:21881922	A/G	cg11317459	chr13:21872234	NA	1.17	20.27	0.7	2.54e-64	White matter hyperintensity burden;
LUAD	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.41	-8.09	-0.37	6.58e-15	Glomerular filtration rate;
LUAD	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg24154853	chr7:158122151	PTPRN2	-0.53	-10.51	-0.46	4.04e-23	Calcium levels;
LUAD	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.58	-0.42	8.21e-20	Schizophrenia;
LUAD	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg00321850	chr1:175162397	KIAA0040	0.55	11.9	0.5	2.33e-28	Alcohol dependence;
LUAD	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg03929089	chr4:120376271	NA	-0.92	-17.61	-0.65	1.82e-52	Height;
LUAD	cis	rs2235649	0.704	rs1742425	chr16:1904524	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.46	-7.2	-0.33	2.78e-12	Blood metabolite levels;
LUAD	cis	rs9378688	0.654	rs6596879	chr6:2364847	T/C	cg12303981	chr6:2244766	GMDS	0.44	6.6	0.31	1.2e-10	Caudate nucleus volume;
LUAD	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg24801067	chr17:62843696	NA	-0.53	-8.74	-0.39	5.52e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg18138036	chr10:133769891	PPP2R2D	0.4	6.41	0.3	3.96e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg20290983	chr6:43655470	MRPS18A	0.92	17.21	0.64	1.12e-50	IgG glycosylation;
LUAD	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg00814883	chr7:100076585	TSC22D4	-0.85	-12.48	-0.52	1.24e-30	Platelet count;
LUAD	trans	rs2262909	0.962	rs55728714	chr19:22262899	A/G	cg17074339	chr11:11642133	GALNTL4	0.48	7.75	0.35	7.12e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg00310523	chr12:86230176	RASSF9	0.36	7.27	0.33	1.73e-12	Major depressive disorder;
LUAD	trans	rs783540	0.935	rs2278355	chr15:83331155	C/T	cg18393722	chr15:85113863	UBE2QP1	0.42	6.82	0.31	3.22e-11	Schizophrenia;
LUAD	cis	rs7524258	0.868	rs916393	chr1:7272250	T/C	cg04342483	chr1:7259290	CAMTA1	-0.27	-6.5	-0.3	2.24e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg25173405	chr17:45401733	C17orf57	0.52	9.05	0.4	5.1e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2652834	0.718	rs2652836	chr15:63396301	A/G	cg25406657	chr15:63342033	TPM1	0.38	6.7	0.31	6.86e-11	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg17366294	chr4:99064904	C4orf37	0.66	12.51	0.52	9.18e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4774899	0.752	rs2733332	chr15:57388349	C/T	cg14026238	chr15:57616123	NA	0.42	8.06	0.36	8.06e-15	Urinary tract infection frequency;
LUAD	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg22532475	chr10:104410764	TRIM8	-0.45	-8.78	-0.39	4.07e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11644478	chr21:40555479	PSMG1	0.69	11.45	0.49	1.23e-26	Cognitive function;
LUAD	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg22875332	chr1:76189707	ACADM	-0.72	-10.87	-0.47	1.86e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg10434728	chr15:90938212	IQGAP1	-0.35	-7.12	-0.33	4.77e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs55665837	1.000	rs2305305	chr11:14540942	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-10.14	-0.44	8.76e-22	Vitamin D levels;
LUAD	cis	rs68170813	0.559	rs17428071	chr7:106878200	C/G	cg23024343	chr7:107201750	COG5	0.5	7.36	0.34	9.41e-13	Coronary artery disease;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg01021488	chr15:99395581	IGF1R	-0.4	-7.18	-0.33	3.11e-12	Vertical cup-disc ratio;
LUAD	cis	rs754466	0.580	rs1058198	chr10:79566632	G/A	cg17075019	chr10:79541650	NA	-0.89	-18.85	-0.68	5.44e-58	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3087591	0.922	rs2905805	chr17:29502856	C/A	cg24425628	chr17:29625626	OMG;NF1	0.41	6.66	0.31	8.3e-11	Hip circumference;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08413565	chr3:129035733	H1FX;C3orf47	-0.45	-7.23	-0.33	2.35e-12	Height;
LUAD	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg09826364	chr7:158789723	NA	-0.41	-7.28	-0.33	1.68e-12	Facial morphology (factor 20);
LUAD	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06544989	chr22:39130855	UNC84B	0.45	9.02	0.4	6.41e-18	Menopause (age at onset);
LUAD	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	7.98	0.36	1.36e-14	Breast cancer;
LUAD	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.77	0.46	4.7e-24	Colorectal cancer;
LUAD	cis	rs7020830	0.825	rs13297152	chr9:37075623	C/T	cg14294708	chr9:37120828	ZCCHC7	0.85	16.0	0.61	2.19e-45	Schizophrenia;
LUAD	cis	rs9399137	0.507	rs7772031	chr6:135259734	G/A	cg22676075	chr6:135203613	NA	-0.56	-9.99	-0.44	2.97e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs56283067	0.847	rs12198153	chr6:44691878	T/C	cg18551225	chr6:44695536	NA	-0.61	-10.15	-0.44	8.03e-22	Total body bone mineral density;
LUAD	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg06784218	chr1:46089804	CCDC17	0.6	13.33	0.54	4.38e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18099408	chr3:52552593	STAB1	-0.53	-9.59	-0.42	7.61e-20	Electroencephalogram traits;
LUAD	cis	rs7202877	0.706	rs467780	chr16:75437138	A/G	cg03315344	chr16:75512273	CHST6	-0.47	-6.55	-0.3	1.7e-10	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10802521	chr3:52805072	NEK4	-0.54	-9.17	-0.41	2.16e-18	Bipolar disorder;
LUAD	cis	rs2278491	0.557	rs4876679	chr8:117763873	A/G	cg23513447	chr8:117778558	UTP23	-0.55	-7.7	-0.35	9.58e-14	Body mass index;
LUAD	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg06618935	chr21:46677482	NA	-0.42	-8.5	-0.38	3.17e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg04455712	chr21:45112962	RRP1B	-0.4	-8.16	-0.37	3.84e-15	Mean corpuscular volume;
LUAD	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.45	-0.3	3.13e-10	Triglycerides;
LUAD	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg17200465	chr3:40428508	ENTPD3	0.27	6.46	0.3	2.86e-10	Renal cell carcinoma;
LUAD	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg17200465	chr3:40428508	ENTPD3	0.27	6.47	0.3	2.68e-10	Renal cell carcinoma;
LUAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.84	0.43	1.07e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28655083	0.956	rs11863953	chr16:77065710	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.41	-6.88	-0.32	2.22e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7191700	0.578	rs243324	chr16:11354970	A/G	cg00044050	chr16:11439710	C16orf75	0.66	10.69	0.46	9.36e-24	Multiple sclerosis;
LUAD	cis	rs6460942	0.915	rs17324858	chr7:12305792	G/T	cg20607287	chr7:12443886	VWDE	-0.43	-6.52	-0.3	2.03e-10	Coronary artery disease;
LUAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg24829409	chr8:58192753	C8orf71	-0.53	-6.86	-0.32	2.48e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9900062	0.546	rs2676294	chr17:62710764	A/G	cg02097616	chr17:62675921	NA	-0.69	-11.78	-0.5	6.8e-28	QT interval;
LUAD	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg02891314	chr5:179741120	GFPT2	-0.7	-11.29	-0.48	5.2e-26	Height;
LUAD	cis	rs4849845	0.653	rs34874174	chr2:121011980	A/C	cg24070213	chr2:121070622	NA	0.39	7.39	0.34	7.95e-13	Mean platelet volume;
LUAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg13560548	chr3:10150139	C3orf24	0.45	7.66	0.35	1.27e-13	Alzheimer's disease;
LUAD	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.86	0.32	2.51e-11	Blood metabolite levels;
LUAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.12	0.41	3.07e-18	Alzheimer's disease;
LUAD	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg04369109	chr6:150039330	LATS1	-0.42	-6.89	-0.32	1.99e-11	Lung cancer;
LUAD	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9462027	0.628	rs9462019	chr6:34748730	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.91	-0.4	1.57e-17	Systemic lupus erythematosus;
LUAD	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg03859395	chr2:55845619	SMEK2	0.75	13.87	0.56	2.59e-36	Metabolic syndrome;
LUAD	trans	rs7939886	0.920	rs12417606	chr11:55750479	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.74	0.31	5.23e-11	Myopia (pathological);
LUAD	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg11766577	chr21:47581405	C21orf56	-0.45	-7.73	-0.35	7.82e-14	Testicular germ cell tumor;
LUAD	cis	rs11955175	0.850	rs111959286	chr5:40704141	A/T	cg04002187	chr5:40835754	RPL37	0.76	6.53	0.3	1.93e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg24154853	chr7:158122151	PTPRN2	0.58	11.52	0.49	7.04e-27	Calcium levels;
LUAD	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg03929089	chr4:120376271	NA	-0.44	-6.8	-0.31	3.65e-11	Height;
LUAD	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg00784671	chr22:46762841	CELSR1	-0.45	-7.22	-0.33	2.39e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs698833	0.892	rs1067371	chr2:44651982	A/G	cg04920474	chr2:44395004	PPM1B	0.4	7.1	0.33	5.18e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg00071950	chr4:10020882	SLC2A9	0.76	15.34	0.6	1.48e-42	Bone mineral density;
LUAD	cis	rs250585	1.000	rs152457	chr16:23581678	A/G	cg00143387	chr16:23521605	GGA2	0.67	7.93	0.36	1.92e-14	Egg allergy;
LUAD	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg16797656	chr11:68205561	LRP5	-0.47	-10.21	-0.44	4.83e-22	Total body bone mineral density;
LUAD	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg11707310	chr1:2537719	MMEL1	0.36	7.44	0.34	5.52e-13	Ulcerative colitis;
LUAD	cis	rs1957429	0.901	rs3813423	chr14:65347475	C/A	cg23373153	chr14:65346875	NA	0.55	6.45	0.3	2.99e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg04414720	chr1:150670196	GOLPH3L	0.58	9.97	0.44	3.69e-21	Melanoma;
LUAD	cis	rs367615	0.918	rs17161895	chr5:108855831	T/G	cg17395555	chr5:108820864	NA	0.54	9.21	0.41	1.5e-18	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs6499255	0.903	rs1800566	chr16:69745145	C/T	cg15192750	chr16:69999425	NA	0.55	8.2	0.37	3e-15	IgE levels;
LUAD	trans	rs800082	0.668	rs9821986	chr3:144292701	T/G	cg24215973	chr2:240111563	HDAC4	-0.6	-9.92	-0.43	5.57e-21	Smoking behavior;
LUAD	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18876405	chr7:65276391	NA	-0.43	-6.85	-0.32	2.58e-11	Aortic root size;
LUAD	cis	rs9443645	0.527	rs12527806	chr6:79507667	A/T	cg05283184	chr6:79620031	NA	-0.42	-7.42	-0.34	6.62e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4664308	0.967	rs17831329	chr2:160915819	T/C	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.81	-0.31	3.29e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs62238980	0.614	rs116888565	chr22:32419164	C/A	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg08999081	chr20:33150536	PIGU	-0.63	-13.67	-0.55	1.75e-35	Glomerular filtration rate (creatinine);
LUAD	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.75	0.31	4.93e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg19700328	chr14:106028568	NA	-0.46	-7.82	-0.36	4.26e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg25703541	chr22:24373054	LOC391322	-0.83	-15.27	-0.6	3.01e-42	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg11062466	chr8:58055876	NA	0.67	9.02	0.4	6.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-7.98	-0.36	1.4e-14	Total body bone mineral density;
LUAD	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11644478	chr21:40555479	PSMG1	0.6	10.21	0.44	5.11e-22	Cognitive function;
LUAD	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg20291162	chr17:40259547	DHX58	-0.69	-10.6	-0.46	1.94e-23	Fibrinogen levels;
LUAD	trans	rs853679	0.607	rs13207345	chr6:28265572	C/T	cg01620082	chr3:125678407	NA	-1.07	-10.43	-0.45	8.25e-23	Depression;
LUAD	trans	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg24644049	chr4:85504048	CDS1	0.85	7.7	0.35	9.77e-14	Skin colour saturation;
LUAD	cis	rs295140	0.546	rs842830	chr2:201131124	C/T	cg23649088	chr2:200775458	C2orf69	-0.48	-8.44	-0.38	5.06e-16	QT interval;
LUAD	cis	rs4849845	0.637	rs62168279	chr2:121026771	T/C	cg24070213	chr2:121070622	NA	0.39	7.39	0.34	7.95e-13	Mean platelet volume;
LUAD	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12588279	chr6:26043732	HIST1H2BB	0.4	6.67	0.31	8.1e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg10356904	chr22:49881777	NA	-0.36	-7.2	-0.33	2.79e-12	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7737355	0.947	rs10067982	chr5:130835940	C/G	cg25547332	chr5:131281432	NA	0.42	6.46	0.3	2.82e-10	Life satisfaction;
LUAD	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg02951883	chr7:2050386	MAD1L1	-0.85	-14.65	-0.58	1.38e-39	Bipolar disorder and schizophrenia;
LUAD	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.46	6.99	0.32	1.1e-11	Total cholesterol levels;
LUAD	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg21153622	chr11:89784906	NA	0.33	6.71	0.31	6.23e-11	Coronary artery disease;
LUAD	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg00495681	chr13:53174319	NA	0.77	15.48	0.6	3.64e-43	Lewy body disease;
LUAD	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.74	-12.36	-0.52	3.61e-30	Primary sclerosing cholangitis;
LUAD	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.3	-7.58	-0.35	2.18e-13	Total body bone mineral density;
LUAD	cis	rs2742417	0.603	rs2742395	chr3:45758595	A/G	cg10512202	chr3:45649293	LIMD1	0.46	8.64	0.39	1.21e-16	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02353165	chr6:42928485	GNMT	0.41	7.26	0.33	1.85e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs853679	0.546	rs35016036	chr6:28314880	C/T	cg01620082	chr3:125678407	NA	-1.11	-10.37	-0.45	1.37e-22	Depression;
LUAD	cis	rs6087990	0.735	rs6058892	chr20:31388461	C/T	cg13636640	chr20:31349939	DNMT3B	0.73	13.11	0.54	3.53e-33	Ulcerative colitis;
LUAD	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg22875332	chr1:76189707	ACADM	0.86	15.44	0.6	5.89e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg22535103	chr8:58192502	C8orf71	-0.62	-6.68	-0.31	7.64e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1044826	0.642	rs6439860	chr3:139175797	A/G	cg00490450	chr3:139108681	COPB2	0.43	6.98	0.32	1.12e-11	Obesity-related traits;
LUAD	cis	rs6684514	0.922	rs11264475	chr1:156306918	G/A	cg16558208	chr1:156270281	VHLL	0.53	9.64	0.42	5e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg02002194	chr4:3960332	NA	-0.27	-6.74	-0.31	5.31e-11	Neuroticism;
LUAD	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg25324976	chr17:61989376	CSHL1	0.34	6.6	0.31	1.24e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg06210147	chr17:40428290	STAT5B	-0.41	-6.8	-0.31	3.51e-11	Schizophrenia;
LUAD	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	8.77	0.39	4.5e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7937890	0.559	rs2575829	chr11:14485021	C/T	cg06199346	chr11:14280333	SPON1	-0.33	-6.53	-0.3	1.94e-10	Mitochondrial DNA levels;
LUAD	cis	rs10392	0.543	rs3752290	chr20:37555116	G/C	cg27552599	chr20:37590471	DHX35	0.4	6.87	0.32	2.33e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18404041	chr3:52824283	ITIH1	0.51	10.23	0.45	4.11e-22	Electroencephalogram traits;
LUAD	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02018176	chr4:1364513	KIAA1530	0.7	12.15	0.51	2.33e-29	Longevity;
LUAD	cis	rs6831352	0.879	rs1984364	chr4:100070783	A/C	cg12011299	chr4:100065546	ADH4	-0.74	-13.43	-0.55	1.72e-34	Alcohol dependence;
LUAD	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg15704280	chr7:45808275	SEPT13	-1.0	-20.54	-0.71	1.61e-65	Coronary artery disease;
LUAD	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg06618935	chr21:46677482	NA	-0.5	-10.02	-0.44	2.32e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs727505	1.000	rs10228201	chr7:124449895	A/G	cg23710748	chr7:124431027	NA	-0.45	-9.45	-0.42	2.27e-19	Lewy body disease;
LUAD	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg22920501	chr2:26401640	FAM59B	-0.76	-10.89	-0.47	1.61e-24	Gut microbiome composition (summer);
LUAD	trans	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg07393940	chr7:158741817	NA	-0.67	-11.45	-0.49	1.21e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg17971929	chr21:40555470	PSMG1	-0.43	-6.98	-0.32	1.17e-11	Cognitive function;
LUAD	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.53	-8.81	-0.39	3.32e-17	Glomerular filtration rate;
LUAD	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg18252515	chr7:66147081	NA	-0.63	-6.99	-0.32	1.1e-11	Diabetic kidney disease;
LUAD	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg17063962	chr7:91808500	NA	0.67	11.83	0.5	4.27e-28	Breast cancer;
LUAD	cis	rs71403859	0.730	rs12931191	chr16:71621373	A/T	cg08717414	chr16:71523259	ZNF19	0.6	7.12	0.33	4.81e-12	Post bronchodilator FEV1;
LUAD	cis	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg07460842	chr6:66804631	NA	0.97	13.16	0.54	2.25e-33	Exhaled nitric oxide output;
LUAD	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	9.13	0.41	2.95e-18	Urate levels;
LUAD	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08280861	chr8:58055591	NA	0.8	9.65	0.42	4.69e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg02269571	chr22:50332266	NA	0.59	8.91	0.4	1.49e-17	Schizophrenia;
LUAD	cis	rs6424115	0.708	rs34570472	chr1:24191720	A/G	cg10978503	chr1:24200527	CNR2	-0.48	-8.92	-0.4	1.41e-17	Immature fraction of reticulocytes;
LUAD	trans	rs853679	0.607	rs13199906	chr6:27834139	C/G	cg06606381	chr12:133084897	FBRSL1	-1.13	-10.46	-0.45	6.49e-23	Depression;
LUAD	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg16342193	chr10:102329863	NA	-0.35	-6.36	-0.3	5.23e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg03289416	chr15:75166202	SCAMP2	0.5	8.57	0.38	1.96e-16	Breast cancer;
LUAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg24101359	chr6:42928495	GNMT	0.46	8.45	0.38	4.83e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	11.83	0.5	4.13e-28	Exhaled nitric oxide levels;
LUAD	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg11909912	chr17:43974919	MAPT;LOC100130148	0.41	6.88	0.32	2.19e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	7.25	0.33	2.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg14926445	chr8:58193284	C8orf71	-0.48	-7.01	-0.32	9.25e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg27490568	chr2:178487706	NA	0.58	8.46	0.38	4.43e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2882667	0.931	rs10075893	chr5:138355871	A/G	cg04439458	chr5:138467593	SIL1	0.39	7.11	0.33	5.09e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg06108461	chr20:60628389	TAF4	-0.7	-9.39	-0.42	3.7e-19	Obesity-related traits;
LUAD	cis	rs870825	0.616	rs36022027	chr4:185639192	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.97	0.56	9.31e-37	Blood protein levels;
LUAD	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25427524	chr10:38739819	LOC399744	-0.75	-13.59	-0.55	3.56e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs17154702	0.510	rs7831224	chr8:8656647	C/T	cg01851573	chr8:8652454	MFHAS1	0.63	10.05	0.44	1.95e-21	Neurocognitive impairment in HIV-1 infection (continuous);
LUAD	cis	rs4711336	1.000	rs11759396	chr6:33656654	C/G	cg14003231	chr6:33640908	ITPR3	0.53	10.03	0.44	2.14e-21	Height;
LUAD	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21659725	chr3:3221576	CRBN	-0.84	-17.88	-0.66	1.17e-53	Intelligence (multi-trait analysis);
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg25428156	chr4:119556601	NA	-0.32	-6.35	-0.3	5.49e-10	Height;
LUAD	cis	rs35771425	1.000	rs12569232	chr1:211553064	G/C	cg25617285	chr1:211431773	RCOR3	-0.44	-6.47	-0.3	2.66e-10	Educational attainment (years of education);
LUAD	trans	rs7395662	0.927	rs12793888	chr11:48488056	A/G	cg00717180	chr2:96193071	NA	-0.4	-7.38	-0.34	8.67e-13	HDL cholesterol;
LUAD	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06022373	chr22:39101656	GTPBP1	0.45	7.56	0.34	2.6e-13	Menopause (age at onset);
LUAD	cis	rs9341808	0.754	rs3793000	chr6:80995137	G/A	cg08355045	chr6:80787529	NA	0.52	9.31	0.41	7.24e-19	Sitting height ratio;
LUAD	cis	rs11169225	0.756	rs3759124	chr12:50343166	G/A	cg09002919	chr12:50339186	NA	0.61	8.14	0.37	4.38e-15	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg12140854	chr5:148520817	ABLIM3	-0.67	-10.77	-0.46	4.43e-24	Breast cancer;
LUAD	cis	rs7731657	0.537	rs1989052	chr5:130347413	T/C	cg08523029	chr5:130500466	HINT1	0.61	8.24	0.37	2.19e-15	Fasting plasma glucose;
LUAD	trans	rs3942852	0.868	rs10769315	chr11:48110367	A/G	cg03929089	chr4:120376271	NA	-0.53	-7.13	-0.33	4.27e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg27446573	chr6:127587934	RNF146	0.45	6.61	0.31	1.18e-10	Breast cancer;
LUAD	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg27170947	chr2:26402098	FAM59B	-0.63	-8.78	-0.39	3.98e-17	Gut microbiome composition (summer);
LUAD	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg15445000	chr17:37608096	MED1	0.44	8.24	0.37	2.18e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg00684032	chr4:1343700	KIAA1530	-0.4	-6.9	-0.32	1.88e-11	Obesity-related traits;
LUAD	cis	rs35123781	0.654	rs356443	chr5:139077829	G/C	cg10513866	chr5:139070639	NA	0.54	8.6	0.39	1.59e-16	Schizophrenia;
LUAD	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24531977	chr5:56204891	C5orf35	-0.97	-15.04	-0.59	2.8e-41	Initial pursuit acceleration;
LUAD	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg17724175	chr1:150552817	MCL1	0.4	9.7	0.43	3.13e-20	Tonsillectomy;
LUAD	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg08999081	chr20:33150536	PIGU	0.63	14.12	0.57	2.27e-37	Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg11494091	chr17:61959527	GH2	0.74	18.62	0.67	6.03e-57	Prudent dietary pattern;
LUAD	cis	rs12431939	1.000	rs67628731	chr14:51662708	C/G	cg23942311	chr14:51606299	NA	-0.48	-6.71	-0.31	6.13e-11	Cancer;
LUAD	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg08645402	chr16:4508243	NA	0.53	9.62	0.42	5.99e-20	Schizophrenia;
LUAD	cis	rs1018836	0.544	rs10112371	chr8:91457626	C/T	cg16814680	chr8:91681699	NA	0.5	8.01	0.36	1.1e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg09998033	chr7:158218633	PTPRN2	-0.42	-7.51	-0.34	3.65e-13	Obesity-related traits;
LUAD	cis	rs4372836	0.964	rs2045884	chr2:28964355	C/T	cg09522027	chr2:28974177	PPP1CB	-0.63	-9.91	-0.43	5.76e-21	Body mass index;
LUAD	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg24558204	chr6:135376177	HBS1L	0.46	8.41	0.38	6.52e-16	Red blood cell count;
LUAD	cis	rs6993813	0.837	rs4495461	chr8:120019317	A/T	cg01975934	chr8:119970761	NA	-0.37	-7.26	-0.33	1.87e-12	Bone mineral density (hip);
LUAD	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg00074818	chr8:8560427	CLDN23	0.64	9.95	0.44	4.13e-21	Obesity-related traits;
LUAD	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg20991723	chr1:152506922	NA	0.32	6.43	0.3	3.42e-10	Hair morphology;
LUAD	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg15664640	chr17:80829946	TBCD	0.6	11.58	0.49	4e-27	Breast cancer;
LUAD	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.74	-9.99	-0.44	3.13e-21	Glomerular filtration rate in chronic kidney disease;
LUAD	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg26384229	chr12:38710491	ALG10B	0.49	7.88	0.36	2.76e-14	Morning vs. evening chronotype;
LUAD	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg04267008	chr7:1944627	MAD1L1	0.51	7.74	0.35	7.2e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs7731657	0.537	rs12332151	chr5:130344771	T/C	cg08523029	chr5:130500466	HINT1	-0.6	-7.75	-0.35	6.72e-14	Fasting plasma glucose;
LUAD	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg15691649	chr6:25882328	NA	0.46	7.39	0.34	8e-13	Blood metabolite levels;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg23627909	chr14:60337760	RTN1	0.38	6.4	0.3	4.2e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9394841	0.667	rs10807268	chr6:41777591	A/T	cg25600774	chr6:41776562	USP49	-0.43	-6.56	-0.3	1.55e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	trans	rs7781370	1.000	rs7781370	chr7:96133531	A/G	cg00529697	chr5:75013131	C5orf37	-0.41	-7.02	-0.32	8.73e-12	Bone mineral density (hip);
LUAD	trans	rs11989744	0.957	rs57291069	chr8:23570211	G/T	cg03492747	chr16:86543808	FOXF1	0.41	6.88	0.32	2.18e-11	Waist-hip ratio;
LUAD	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.02e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg09650180	chr20:62225654	GMEB2	-0.46	-6.69	-0.31	7.03e-11	Glioblastoma;
LUAD	cis	rs7119	0.689	rs12907630	chr15:77812906	G/T	cg27398640	chr15:77910606	LINGO1	-0.34	-6.52	-0.3	2.06e-10	Type 2 diabetes;
LUAD	cis	rs9902453	0.904	rs55633288	chr17:28368196	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.53	-0.46	3.46e-23	Coffee consumption (cups per day);
LUAD	cis	rs7833986	0.501	rs2719255	chr8:57036658	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.97	17.01	0.64	8.45e-50	Height;
LUAD	cis	rs73206853	0.764	rs73205079	chr12:110599953	C/T	cg12870014	chr12:110450643	ANKRD13A	0.64	7.98	0.36	1.41e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg04775059	chr7:64541387	NA	-0.52	-6.97	-0.32	1.21e-11	Aortic root size;
LUAD	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg26384229	chr12:38710491	ALG10B	0.46	7.49	0.34	4.04e-13	Bladder cancer;
LUAD	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg19678392	chr7:94953810	PON1	-0.57	-7.73	-0.35	7.93e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.85	16.85	0.63	3.93e-49	Birth weight;
LUAD	cis	rs6867913	0.709	rs891987	chr5:141467196	A/T	cg23435118	chr5:141488016	NDFIP1	0.44	7.25	0.33	2e-12	Asthma;
LUAD	cis	rs11640533	1.000	rs11640533	chr16:53412862	A/G	cg10144400	chr16:53407678	NA	-0.37	-6.36	-0.3	5.17e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs8008758	0.517	rs1620117	chr14:101696931	C/A	cg26224664	chr14:101693935	NA	-0.43	-10.92	-0.47	1.29e-24	Body mass index (alcohol intake interaction);
LUAD	cis	rs28374715	0.662	rs16971558	chr15:41458619	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.9	-16.44	-0.62	2.53e-47	Ulcerative colitis;
LUAD	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg02493740	chr2:85810744	VAMP5	-0.61	-11.38	-0.48	2.39e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg03037974	chr15:76606532	NA	0.47	11.08	0.47	3.1e-25	Blood metabolite levels;
LUAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.16	-0.41	2.27e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	6.51	0.3	2.08e-10	Prudent dietary pattern;
LUAD	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg25767906	chr1:53392781	SCP2	-0.41	-7.32	-0.34	1.25e-12	Monocyte count;
LUAD	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg13334819	chr7:99746414	C7orf59	-0.65	-10.47	-0.45	5.66e-23	Coronary artery disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07956936	chr16:72127419	TXNL4B;DHX38	-0.42	-6.43	-0.3	3.36e-10	Height;
LUAD	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg14092988	chr3:52407081	DNAH1	-0.39	-7.84	-0.36	3.72e-14	Bipolar disorder;
LUAD	trans	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg06606381	chr12:133084897	FBRSL1	-1.13	-10.53	-0.46	3.64e-23	Depression;
LUAD	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg06074448	chr4:187884817	NA	-0.43	-8.82	-0.39	3.02e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.42	-0.34	6.4e-13	Glomerular filtration rate;
LUAD	trans	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg19862616	chr7:65841803	NCRNA00174	1.06	27.31	0.8	2.21e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4268898	0.552	rs7560342	chr2:24371691	T/C	cg06627628	chr2:24431161	ITSN2	0.44	7.52	0.34	3.4e-13	Asthma;
LUAD	cis	rs1595825	0.891	rs10497810	chr2:198895732	C/T	cg00982548	chr2:198649783	BOLL	-0.65	-9.18	-0.41	1.88e-18	Ulcerative colitis;
LUAD	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg12179176	chr11:130786555	SNX19	0.47	7.76	0.35	6.34e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18404041	chr3:52824283	ITIH1	-0.59	-12.0	-0.5	9.27e-29	Bipolar disorder;
LUAD	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg24558204	chr6:135376177	HBS1L	0.46	8.44	0.38	5.09e-16	Red blood cell count;
LUAD	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg04568274	chr7:158649319	WDR60	0.44	7.08	0.33	5.93e-12	Height;
LUAD	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg09021430	chr5:549028	NA	0.48	12.12	0.51	3.1e-29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg00383909	chr3:49044727	WDR6	0.88	9.82	0.43	1.18e-20	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.47	0.52	1.27e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12681287	0.608	rs13272148	chr8:87481853	T/C	cg27223183	chr8:87520930	FAM82B	-0.67	-9.61	-0.42	6.38e-20	Caudate activity during reward;
LUAD	trans	rs1973993	0.745	rs9437743	chr1:96961723	C/T	cg10631902	chr5:14652156	NA	0.47	8.06	0.36	7.63e-15	Weight;
LUAD	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg16325326	chr1:53192061	ZYG11B	-0.73	-14.21	-0.57	9.36e-38	Monocyte count;
LUAD	cis	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg27411982	chr8:10470053	RP1L1	-0.37	-6.56	-0.3	1.54e-10	Retinal vascular caliber;
LUAD	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg06552810	chr11:31128660	NA	0.32	6.35	0.3	5.45e-10	Red blood cell count;
LUAD	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.46	0.3	2.97e-10	Depression;
LUAD	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg20135002	chr11:47629003	NA	-0.41	-7.19	-0.33	3.02e-12	Subjective well-being;
LUAD	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-7.45	-0.34	5.41e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg11062466	chr8:58055876	NA	0.73	8.85	0.4	2.36e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg09904177	chr6:26538194	HMGN4	0.44	7.4	0.34	7.22e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-9.98	-0.44	3.35e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7903847	0.642	rs12359257	chr10:99136359	A/T	cg20016023	chr10:99160130	RRP12	-0.34	-8.14	-0.37	4.5e-15	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg25173405	chr17:45401733	C17orf57	-0.46	-7.54	-0.34	2.84e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg25838465	chr1:92012736	NA	-0.7	-15.05	-0.59	2.61e-41	Breast cancer;
LUAD	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.6	-0.42	7.19e-20	Life satisfaction;
LUAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg00383909	chr3:49044727	WDR6	0.75	8.62	0.39	1.37e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs375066	0.620	rs10401170	chr19:44299623	C/T	cg12072164	chr19:44306565	LYPD5	-0.39	-8.01	-0.36	1.15e-14	Breast cancer;
LUAD	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg13535736	chr9:111863775	C9orf5	-0.42	-6.57	-0.3	1.53e-10	Menarche (age at onset);
LUAD	cis	rs3820068	0.705	rs74054769	chr1:15860147	A/C	cg13390004	chr1:15929781	NA	0.41	6.62	0.31	1.08e-10	Systolic blood pressure;
LUAD	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg07570687	chr10:102243282	WNT8B	0.48	7.4	0.34	7.49e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs8027181	0.682	rs4777546	chr15:73104435	C/T	cg25632853	chr15:73088954	NA	-0.33	-7.22	-0.33	2.44e-12	Triglyceride levels;
LUAD	cis	rs2652834	1.000	rs2652834	chr15:63396867	A/G	cg25406657	chr15:63342033	TPM1	-0.43	-6.85	-0.32	2.68e-11	HDL cholesterol;
LUAD	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg21724239	chr8:58056113	NA	0.76	9.02	0.4	6.76e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs427394	0.582	rs274662	chr5:6704860	G/A	cg12316010	chr5:6737918	POLS	0.36	7.0	0.32	1.04e-11	Menopause (age at onset);
LUAD	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-8.69	-0.39	7.98e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg22676075	chr6:135203613	NA	0.57	10.11	0.44	1.14e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg17366294	chr4:99064904	C4orf37	0.47	8.38	0.38	8.17e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg18252515	chr7:66147081	NA	-0.62	-6.9	-0.32	1.96e-11	Diabetic kidney disease;
LUAD	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg16479474	chr6:28041457	NA	0.48	8.18	0.37	3.31e-15	Depression;
LUAD	cis	rs6430585	0.527	rs62168836	chr2:136463117	G/A	cg07169764	chr2:136633963	MCM6	0.59	6.97	0.32	1.21e-11	Corneal structure;
LUAD	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg17724175	chr1:150552817	MCL1	0.35	8.22	0.37	2.52e-15	Melanoma;
LUAD	cis	rs813218	0.527	rs793450	chr3:99532532	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.41	-7.44	-0.34	5.7e-13	Orofacial clefts;
LUAD	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg15017067	chr4:17643749	FAM184B	0.35	6.9	0.32	1.97e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg00634984	chr7:65235879	NA	0.45	7.26	0.33	1.82e-12	Calcium levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg21798447	chr4:85504053	CDS1	-0.4	-6.56	-0.3	1.55e-10	Schizophrenia;
LUAD	cis	rs7107174	1.000	rs10899454	chr11:77997513	T/C	cg02023728	chr11:77925099	USP35	0.46	7.22	0.33	2.46e-12	Testicular germ cell tumor;
LUAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg10862848	chr6:42927986	GNMT	-0.33	-9.47	-0.42	2.03e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.44	0.3	3.25e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.87	-0.36	3.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg18016565	chr1:150552671	MCL1	0.42	7.8	0.35	5.01e-14	Tonsillectomy;
LUAD	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg08999081	chr20:33150536	PIGU	0.6	13.03	0.54	7.26e-33	Glomerular filtration rate (creatinine);
LUAD	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.03	-0.44	2.15e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs2041840	0.847	rs12611683	chr2:37503938	C/T	cg25727520	chr2:37576821	QPCT	-0.33	-6.75	-0.31	4.9e-11	Chronic lymphocytic leukemia;
LUAD	cis	rs713587	0.525	rs11687089	chr2:25082926	T/C	cg01884057	chr2:25150051	NA	0.33	6.97	0.32	1.19e-11	Body mass index in non-asthmatics;
LUAD	cis	rs7119	0.667	rs907393	chr15:77903447	T/C	cg27398640	chr15:77910606	LINGO1	0.39	7.46	0.34	5.05e-13	Type 2 diabetes;
LUAD	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg05234568	chr11:5960015	NA	-0.57	-11.02	-0.47	5.32e-25	DNA methylation (variation);
LUAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg24813613	chr7:1882135	MAD1L1	-0.42	-6.64	-0.31	9.68e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs4588572	0.570	rs2115433	chr5:77700363	C/T	cg11547950	chr5:77652471	NA	-0.63	-10.56	-0.46	2.79e-23	Triglycerides;
LUAD	trans	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg01620082	chr3:125678407	NA	-1.03	-10.19	-0.44	6.11e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12618769	0.543	rs2278211	chr2:99149946	G/A	cg10123293	chr2:99228465	UNC50	0.48	8.2	0.37	2.98e-15	Bipolar disorder;
LUAD	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg15704280	chr7:45808275	SEPT13	0.63	8.08	0.37	6.77e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg20476274	chr7:133979776	SLC35B4	0.84	17.14	0.64	2.21e-50	Mean platelet volume;
LUAD	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg06046430	chr4:77819534	ANKRD56	0.55	8.87	0.4	2.12e-17	Emphysema distribution in smoking;
LUAD	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg22467129	chr15:76604101	ETFA	-0.48	-7.75	-0.35	6.68e-14	Blood metabolite levels;
LUAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg02869364	chr7:1081709	C7orf50	-0.5	-6.43	-0.3	3.45e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg00290607	chr11:67383545	NA	0.4	6.58	0.3	1.38e-10	Mean corpuscular volume;
LUAD	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg10053473	chr17:62856997	LRRC37A3	0.79	11.2	0.48	1.1e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7680126	0.500	rs11735668	chr4:10148655	C/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-8.13	-0.37	4.81e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12530845	1.000	rs73721606	chr7:135335678	C/T	cg23117316	chr7:135346802	PL-5283	-0.49	-9.1	-0.4	3.53e-18	Red blood cell traits;
LUAD	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18876405	chr7:65276391	NA	-0.45	-7.26	-0.33	1.87e-12	Aortic root size;
LUAD	cis	rs9581857	0.579	rs1759861	chr13:27996406	A/C	cg22138327	chr13:27999177	GTF3A	-0.95	-11.65	-0.49	2.07e-27	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg13679303	chr9:96623674	NA	-0.37	-7.35	-0.34	1e-12	DNA methylation (variation);
LUAD	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg00204512	chr16:28754710	NA	0.35	7.49	0.34	4.06e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg13319975	chr6:146136371	FBXO30	-0.57	-9.59	-0.42	7.84e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03452623	chr4:187889614	NA	-0.83	-17.3	-0.64	4.07e-51	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg00310523	chr12:86230176	RASSF9	0.34	6.89	0.32	2.05e-11	Major depressive disorder;
LUAD	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg00666640	chr1:248458726	OR2T12	0.32	7.84	0.36	3.83e-14	Common traits (Other);
LUAD	cis	rs4638749	0.677	rs13414687	chr2:108806245	A/G	cg25838818	chr2:108905173	SULT1C2	-0.39	-6.96	-0.32	1.31e-11	Blood pressure;
LUAD	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22857025	chr5:266934	NA	-0.97	-14.68	-0.58	1.01e-39	Breast cancer;
LUAD	cis	rs938554	0.915	rs4697913	chr4:9941262	C/T	cg00071950	chr4:10020882	SLC2A9	-0.43	-6.71	-0.31	6.17e-11	Blood metabolite levels;
LUAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.67	-12.16	-0.51	2.21e-29	Longevity;Endometriosis;
LUAD	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg09359103	chr1:154839909	KCNN3	-0.9	-19.91	-0.7	1.06e-62	Prostate cancer;
LUAD	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg20703242	chr1:230279135	GALNT2	0.68	12.73	0.53	1.17e-31	Coronary artery disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06130371	chr15:65578830	PARP16	-0.75	-7.46	-0.34	4.82e-13	Type 2 diabetes;
LUAD	trans	rs11039798	1.000	rs12280020	chr11:48618844	G/C	cg15704280	chr7:45808275	SEPT13	0.64	7.65	0.35	1.4e-13	Axial length;
LUAD	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg07153921	chr17:41440717	NA	-0.41	-6.92	-0.32	1.68e-11	Menopause (age at onset);
LUAD	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg04539111	chr16:67997858	SLC12A4	-0.62	-7.86	-0.36	3.14e-14	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg09997638	chr19:17530742	FAM125A	-0.42	-7.13	-0.33	4.49e-12	Schizophrenia;
LUAD	cis	rs4253772	0.515	rs7287164	chr22:46781008	T/C	cg00784671	chr22:46762841	CELSR1	-0.6	-7.29	-0.33	1.52e-12	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.87	-0.32	2.28e-11	Neuroticism;
LUAD	cis	rs7843479	0.601	rs3824338	chr8:21864540	A/C	cg03445287	chr8:21823731	XPO7	-0.5	-9.32	-0.41	6.31e-19	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg21204522	chr6:27730016	NA	-0.44	-6.97	-0.32	1.22e-11	Parkinson's disease;
LUAD	cis	rs1018836	0.923	rs6986088	chr8:91538474	A/C	cg16814680	chr8:91681699	NA	-0.71	-12.38	-0.52	3.05e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10207060	0.500	rs62183161	chr2:240699856	C/T	cg07506560	chr2:240697449	NA	0.41	6.81	0.31	3.37e-11	Obesity-related traits;
LUAD	cis	rs7301016	0.802	rs73139054	chr12:62842227	T/C	cg11441379	chr12:63026424	NA	0.54	6.44	0.3	3.16e-10	IgG glycosylation;
LUAD	cis	rs870825	0.655	rs28555435	chr4:185647300	C/A	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs6906287	0.647	rs2077162	chr6:118687469	G/A	cg21191810	chr6:118973309	C6orf204	0.49	9.25	0.41	1.1e-18	Electrocardiographic conduction measures;
LUAD	trans	rs783540	1.000	rs803688	chr15:83216793	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.43	-6.79	-0.31	3.81e-11	Schizophrenia;
LUAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-7.97	-0.36	1.51e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg24675056	chr1:15929824	NA	0.49	8.5	0.38	3.39e-16	Systolic blood pressure;
LUAD	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.42	-8.09	-0.37	6.29e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs7395662	0.745	rs10838830	chr11:48233932	A/G	cg00717180	chr2:96193071	NA	0.39	7.16	0.33	3.6e-12	HDL cholesterol;
LUAD	cis	rs7524258	0.868	rs4908610	chr1:7311260	C/A	cg07173049	chr1:7289937	CAMTA1	0.45	8.2	0.37	2.93e-15	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs863345	0.604	rs12122663	chr1:158506724	A/G	cg12129480	chr1:158549410	OR10X1	-0.24	-6.6	-0.31	1.21e-10	Pneumococcal bacteremia;
LUAD	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg08085267	chr17:45401833	C17orf57	-0.59	-10.32	-0.45	1.96e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4409675	0.576	rs7520860	chr1:28232952	C/A	cg23691781	chr1:28212827	C1orf38	0.39	11.38	0.48	2.42e-26	Corneal astigmatism;
LUAD	trans	rs1493916	0.870	rs7235698	chr18:31382486	A/G	cg15819921	chr19:927150	ARID3A	-0.46	-7.64	-0.35	1.47e-13	Life satisfaction;
LUAD	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg07599136	chr5:415885	AHRR	0.79	8.72	0.39	6.59e-17	Fat distribution (HIV);
LUAD	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg19635926	chr16:89946313	TCF25	0.78	6.86	0.32	2.44e-11	Skin colour saturation;
LUAD	cis	rs2235649	0.833	rs4335769	chr16:1849376	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-6.72	-0.31	6.01e-11	Blood metabolite levels;
LUAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.61	-9.71	-0.43	2.86e-20	Renal function-related traits (BUN);
LUAD	cis	rs9581857	0.579	rs9581846	chr13:27987953	A/G	cg22138327	chr13:27999177	GTF3A	0.97	11.55	0.49	5.4e-27	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs938554	1.000	rs16890979	chr4:9922167	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.43	-0.38	5.57e-16	Blood metabolite levels;
LUAD	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg09365446	chr1:150670422	GOLPH3L	-0.49	-8.43	-0.38	5.59e-16	Tonsillectomy;
LUAD	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg18446336	chr7:2847575	GNA12	-0.32	-6.42	-0.3	3.64e-10	Height;
LUAD	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9784649	0.891	rs57762467	chr5:25025700	C/T	cg08600765	chr20:34638493	LOC647979	-0.65	-7.62	-0.35	1.64e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs11771526	0.901	rs7791914	chr7:32296754	A/G	cg13207630	chr7:32358064	NA	0.58	7.16	0.33	3.49e-12	Body mass index;
LUAD	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg00495681	chr13:53174319	NA	0.5	9.11	0.4	3.4e-18	Lewy body disease;
LUAD	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg00684032	chr4:1343700	KIAA1530	0.46	7.42	0.34	6.6e-13	Obesity-related traits;
LUAD	cis	rs4594175	0.926	rs4131365	chr14:51622444	C/T	cg23942311	chr14:51606299	NA	0.64	10.98	0.47	7.84e-25	Cancer;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26402253	chr7:87849886	SRI	0.44	6.57	0.3	1.5e-10	Gut microbiome composition (summer);
LUAD	cis	rs10992471	0.580	rs724102	chr9:95383290	T/C	cg14631576	chr9:95140430	CENPP	-0.46	-8.79	-0.39	3.66e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg11645453	chr3:52864694	ITIH4	0.54	10.04	0.44	2.08e-21	Schizophrenia;
LUAD	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg23533926	chr12:111358616	MYL2	-0.4	-6.79	-0.31	3.7e-11	Extrinsic epigenetic age acceleration;
LUAD	trans	rs1493916	0.748	rs1389535	chr18:31310416	A/G	cg15819921	chr19:927150	ARID3A	0.4	6.59	0.31	1.27e-10	Life satisfaction;
LUAD	cis	rs9473147	0.516	rs13212790	chr6:47576367	T/C	cg12968598	chr6:47444699	CD2AP	0.35	6.39	0.3	4.37e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg26408565	chr15:76604113	ETFA	-0.55	-9.69	-0.43	3.51e-20	Blood metabolite levels;
LUAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg19678392	chr7:94953810	PON1	-0.59	-10.91	-0.47	1.4e-24	Paraoxonase activity;
LUAD	cis	rs3815700	1.000	rs7248273	chr19:33096816	C/T	cg02997394	chr19:33096574	ANKRD27	0.61	7.74	0.35	7.55e-14	Eosinophilic esophagitis;
LUAD	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg15105011	chr4:940614	TMEM175	0.5	7.24	0.33	2.16e-12	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	trans	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg15962314	chr1:44399869	ARTN	0.3	6.87	0.32	2.36e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg15242686	chr22:24348715	GSTTP1	-0.49	-8.85	-0.4	2.44e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6490294	0.659	rs7133964	chr12:112198021	C/G	cg10833066	chr12:111807467	FAM109A	0.36	6.56	0.3	1.56e-10	Mean platelet volume;
LUAD	cis	rs6494488	0.500	rs72758943	chr15:64678701	G/A	cg08069370	chr15:64387884	SNX1	-0.75	-6.73	-0.31	5.5e-11	Coronary artery disease;
LUAD	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.91	0.76	1.53e-80	Chronic sinus infection;
LUAD	cis	rs9467160	0.734	rs9467170	chr6:24452754	G/A	cg20631270	chr6:24437470	GPLD1	0.41	6.42	0.3	3.61e-10	Liver enzyme levels;
LUAD	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg06641503	chr3:48959341	ARIH2	-0.4	-7.84	-0.36	3.58e-14	Parkinson's disease;
LUAD	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg21775007	chr8:11205619	TDH	0.47	8.49	0.38	3.58e-16	Retinal vascular caliber;
LUAD	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg03806693	chr22:41940476	POLR3H	-0.62	-9.34	-0.41	5.52e-19	Vitiligo;
LUAD	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg00666640	chr1:248458726	OR2T12	0.31	7.45	0.34	5.41e-13	Common traits (Other);
LUAD	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg04414720	chr1:150670196	GOLPH3L	0.72	12.52	0.52	8.12e-31	Melanoma;
LUAD	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg02527881	chr3:46936655	PTH1R	0.44	8.41	0.38	6.51e-16	Colorectal cancer;
LUAD	cis	rs6138458	1.000	rs227618	chr20:24909472	T/C	cg06937882	chr20:24974362	C20orf3	-0.33	-6.36	-0.3	5.17e-10	Blood protein levels;
LUAD	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg09359103	chr1:154839909	KCNN3	-0.89	-20.08	-0.7	1.82e-63	Prostate cancer;
LUAD	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg20673091	chr1:2541236	MMEL1	0.46	10.01	0.44	2.68e-21	Ulcerative colitis;
LUAD	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18876405	chr7:65276391	NA	0.44	6.98	0.32	1.15e-11	Aortic root size;
LUAD	cis	rs67478160	0.634	rs2144080	chr14:104258761	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.62	-11.45	-0.49	1.29e-26	Schizophrenia;
LUAD	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg25985355	chr7:65971099	NA	-0.54	-6.7	-0.31	6.48e-11	Diabetic kidney disease;
LUAD	trans	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg27411982	chr8:10470053	RP1L1	0.43	8.18	0.37	3.34e-15	Mood instability;
LUAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg27454412	chr7:1067447	C7orf50	0.42	7.39	0.34	7.81e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg23018236	chr17:30244563	NA	-0.59	-7.46	-0.34	4.93e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg26304593	chr6:42947056	PEX6	-0.45	-7.49	-0.34	4.07e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6988985	0.765	rs7824229	chr8:143984064	A/C	cg10324643	chr8:143916377	GML	0.31	6.43	0.3	3.37e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05890377	chr2:74357713	NA	0.61	8.2	0.37	2.94e-15	Gestational age at birth (maternal effect);
LUAD	cis	rs7659604	0.502	rs10212738	chr4:122675724	G/A	cg06713675	chr4:122721982	EXOSC9	0.42	7.68	0.35	1.11e-13	Type 2 diabetes;
LUAD	cis	rs6442522	0.768	rs3821638	chr3:15511044	A/G	cg16303742	chr3:15540471	COLQ	0.38	6.62	0.31	1.08e-10	Uric acid levels;
LUAD	cis	rs4594175	0.926	rs9323207	chr14:51621908	A/G	cg23942311	chr14:51606299	NA	-0.62	-10.68	-0.46	1.02e-23	Cancer;
LUAD	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.41	0.38	6.2e-16	Platelet count;
LUAD	cis	rs12620999	0.555	rs4078064	chr2:238110296	C/T	cg23555395	chr2:238036564	NA	-0.48	-7.08	-0.33	6.12e-12	Systemic lupus erythematosus;
LUAD	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	6.48	0.3	2.51e-10	Menarche (age at onset);
LUAD	cis	rs2274273	0.837	rs56949365	chr14:55790078	T/C	cg04306507	chr14:55594613	LGALS3	0.44	9.18	0.41	1.99e-18	Protein biomarker;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg11235426	chr6:292522	DUSP22	-0.81	-13.96	-0.56	1.06e-36	Menopause (age at onset);
LUAD	trans	rs5756813	0.530	rs5756822	chr22:38196474	C/T	cg19894588	chr14:64061835	NA	0.78	13.62	0.55	2.74e-35	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg26924012	chr15:45694286	SPATA5L1	0.53	8.88	0.4	1.94e-17	Glomerular filtration rate;
LUAD	cis	rs7107174	0.892	rs10793310	chr11:78099014	T/G	cg02023728	chr11:77925099	USP35	0.47	7.26	0.33	1.86e-12	Testicular germ cell tumor;
LUAD	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg00106254	chr7:1943704	MAD1L1	-0.6	-8.85	-0.4	2.33e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs73206853	0.563	rs9706438	chr12:111195158	A/G	cg12870014	chr12:110450643	ANKRD13A	0.57	6.46	0.3	2.96e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs1594829	0.500	rs4871973	chr8:26199883	A/G	cg13160058	chr8:26243215	BNIP3L	-0.36	-7.61	-0.35	1.76e-13	Height;
LUAD	cis	rs3772130	0.583	rs12695415	chr3:121398853	C/T	cg20356878	chr3:121714668	ILDR1	0.59	11.1	0.47	2.69e-25	Cognitive performance;
LUAD	cis	rs72634258	0.519	rs4908708	chr1:7938113	G/C	cg26816564	chr1:7831052	VAMP3	0.52	7.36	0.34	9.73e-13	Inflammatory bowel disease;
LUAD	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg27494647	chr7:150038898	RARRES2	0.42	6.98	0.32	1.14e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg26893861	chr17:41843967	DUSP3	0.9	14.25	0.57	6.83e-38	Triglycerides;
LUAD	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg12016809	chr21:47604291	C21orf56	0.45	7.51	0.34	3.64e-13	Testicular germ cell tumor;
LUAD	trans	rs7395662	1.000	rs11039854	chr11:48607688	G/A	cg00717180	chr2:96193071	NA	-0.38	-7.14	-0.33	4e-12	HDL cholesterol;
LUAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg00280220	chr17:61926910	NA	-0.36	-6.92	-0.32	1.65e-11	Prudent dietary pattern;
LUAD	cis	rs11893307	0.507	rs1465305	chr2:191585392	C/G	cg27211696	chr2:191398769	TMEM194B	-0.41	-6.87	-0.32	2.36e-11	Mean platelet volume;
LUAD	cis	rs3772130	1.000	rs34086988	chr3:121352745	G/C	cg20356878	chr3:121714668	ILDR1	0.47	7.28	0.33	1.59e-12	Cognitive performance;
LUAD	cis	rs7107174	0.786	rs4945262	chr11:77990831	T/C	cg19901956	chr11:77921274	USP35	-0.51	-6.42	-0.3	3.73e-10	Testicular germ cell tumor;
LUAD	cis	rs2932538	0.922	rs12125361	chr1:113144779	C/T	cg22162597	chr1:113214053	CAPZA1	0.46	6.99	0.32	1.1e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg26408565	chr15:76604113	ETFA	-0.45	-7.31	-0.33	1.38e-12	Blood metabolite levels;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg23556447	chr6:90529595	MDN1	-0.57	-8.0	-0.36	1.2e-14	Testicular germ cell tumor;
LUAD	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg25036284	chr2:26402008	FAM59B	-0.83	-12.35	-0.51	4.08e-30	Gut microbiome composition (summer);
LUAD	cis	rs698833	0.886	rs786654	chr2:44581007	A/G	cg04920474	chr2:44395004	PPM1B	0.43	7.75	0.35	7.05e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs7903847	0.642	rs11189159	chr10:99113964	G/A	cg20016023	chr10:99160130	RRP12	-0.31	-6.95	-0.32	1.37e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs73086581	1.000	rs3746665	chr20:3910406	C/T	cg02187196	chr20:3869020	PANK2	-0.42	-6.43	-0.3	3.36e-10	Response to antidepressants in depression;
LUAD	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg27284194	chr4:1044797	NA	0.44	6.85	0.32	2.66e-11	Obesity-related traits;
LUAD	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.49	7.01	0.32	9.55e-12	Cognitive test performance;
LUAD	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-9.63	-0.42	5.76e-20	Gut microbiome composition (summer);
LUAD	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.83	-10.92	-0.47	1.28e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg02487331	chr1:146550467	NA	-0.33	-6.39	-0.3	4.28e-10	HIV-1 control;
LUAD	trans	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg18876405	chr7:65276391	NA	-0.52	-8.72	-0.39	6.18e-17	Aortic root size;
LUAD	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg11584989	chr19:19387371	SF4	-0.36	-6.48	-0.3	2.55e-10	Tonsillectomy;
LUAD	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg15383120	chr6:291909	DUSP22	-0.46	-7.45	-0.34	5.24e-13	Menopause (age at onset);
LUAD	cis	rs8040855	0.599	rs8037195	chr15:85724686	G/A	cg04831495	chr15:85060580	GOLGA6L5	0.46	7.87	0.36	3.05e-14	Bulimia nervosa;
LUAD	cis	rs11971779	0.680	rs6467840	chr7:139065401	A/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.46	-0.3	2.86e-10	Diisocyanate-induced asthma;
LUAD	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg08048268	chr3:133502702	NA	0.42	8.31	0.37	1.29e-15	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg23625390	chr15:77176239	SCAPER	-0.57	-9.15	-0.41	2.49e-18	Blood metabolite levels;
LUAD	cis	rs1595825	0.891	rs1440086	chr2:198906354	A/G	cg00982548	chr2:198649783	BOLL	-0.6	-8.46	-0.38	4.25e-16	Ulcerative colitis;
LUAD	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.77e-11	Depression;
LUAD	trans	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg04775059	chr7:64541387	NA	0.5	6.79	0.31	3.75e-11	Aortic root size;
LUAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.47	-8.62	-0.39	1.32e-16	Longevity;Endometriosis;
LUAD	cis	rs4919694	1.000	rs12245779	chr10:104645944	C/A	cg04362960	chr10:104952993	NT5C2	0.77	8.23	0.37	2.36e-15	Arsenic metabolism;
LUAD	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg27170947	chr2:26402098	FAM59B	-0.63	-9.15	-0.41	2.44e-18	Gut microbiome composition (summer);
LUAD	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg18230493	chr5:56204884	C5orf35	-0.57	-9.44	-0.42	2.51e-19	Coronary artery disease;
LUAD	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg08773314	chr2:239334832	ASB1	0.43	9.88	0.43	7.25e-21	Multiple system atrophy;
LUAD	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg22535103	chr8:58192502	C8orf71	-0.71	-10.36	-0.45	1.5e-22	Developmental language disorder (linguistic errors);
LUAD	trans	rs9929218	1.000	rs4500718	chr16:68754312	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-14.42	-0.57	1.21e-38	Colorectal cancer;
LUAD	cis	rs10504073	0.545	rs4406405	chr8:49957261	G/C	cg00325661	chr8:49890786	NA	0.48	10.55	0.46	2.86e-23	Blood metabolite ratios;
LUAD	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg25452165	chr22:42524984	CYP2D6	-0.38	-6.35	-0.3	5.57e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1044573	0.526	rs6050422	chr20:25177920	A/G	cg08601574	chr20:25228251	PYGB	0.34	6.35	0.3	5.43e-10	Allergic rhinitis;
LUAD	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg23985595	chr17:80112537	CCDC57	-0.51	-9.26	-0.41	1.01e-18	Life satisfaction;
LUAD	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg25809561	chr17:30822961	MYO1D	0.63	12.01	0.5	8.27e-29	Schizophrenia;
LUAD	cis	rs10504073	0.647	rs12546839	chr8:50009020	C/T	cg00325661	chr8:49890786	NA	0.46	10.3	0.45	2.29e-22	Blood metabolite ratios;
LUAD	cis	rs9419702	0.538	rs9419628	chr10:133539299	A/C	cg04492858	chr10:133558786	NA	0.37	6.86	0.32	2.46e-11	Survival in rectal cancer;
LUAD	cis	rs12681287	0.640	rs7841690	chr8:87365359	T/C	cg00550725	chr8:87521180	FAM82B	-0.46	-6.72	-0.31	5.81e-11	Caudate activity during reward;
LUAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg07217954	chr7:1067459	C7orf50	0.43	6.63	0.31	1.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.75	0.31	4.93e-11	Colorectal cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg24641829	chr4:126662821	NA	0.35	6.59	0.31	1.34e-10	Schizophrenia;
LUAD	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg24634471	chr8:143751801	JRK	0.48	7.84	0.36	3.79e-14	Schizophrenia;
LUAD	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	6.68	0.31	7.55e-11	Obesity-related traits;
LUAD	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg20476274	chr7:133979776	SLC35B4	0.86	17.25	0.64	7.03e-51	Mean platelet volume;
LUAD	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg09137382	chr11:130731461	NA	0.4	7.43	0.34	6.19e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg24596788	chr1:163392923	NA	-0.36	-7.56	-0.34	2.61e-13	Motion sickness;
LUAD	cis	rs2421770	0.530	rs4756217	chr11:35366733	C/T	cg13971030	chr11:35366721	SLC1A2	-0.46	-8.06	-0.36	8.07e-15	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg24324837	chr19:49891574	CCDC155	0.46	6.43	0.3	3.46e-10	Multiple sclerosis;
LUAD	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg17971929	chr21:40555470	PSMG1	0.5	7.6	0.35	1.89e-13	Cognitive function;
LUAD	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg26536354	chr8:144654954	C8orf73	0.59	6.52	0.3	2.03e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg05084668	chr3:125655381	ALG1L	-0.66	-10.62	-0.46	1.61e-23	Blood pressure (smoking interaction);
LUAD	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg09359103	chr1:154839909	KCNN3	-0.9	-20.66	-0.71	4.71e-66	Prostate cancer;
LUAD	trans	rs9951602	0.512	rs1903722	chr18:76646539	G/A	cg02800362	chr5:177631904	HNRNPAB	0.92	14.5	0.58	5.54e-39	Obesity-related traits;
LUAD	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-13.33	-0.54	4.25e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg00634984	chr7:65235879	NA	0.51	6.8	0.31	3.65e-11	Aortic root size;
LUAD	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg19622623	chr12:86230825	RASSF9	-0.36	-6.57	-0.3	1.47e-10	Major depressive disorder;
LUAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.55	-10.1	-0.44	1.21e-21	Longevity;Endometriosis;
LUAD	cis	rs12681287	0.640	rs13253515	chr8:87458596	T/A	cg27223183	chr8:87520930	FAM82B	-0.68	-9.59	-0.42	7.69e-20	Caudate activity during reward;
LUAD	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg13798912	chr7:905769	UNC84A	-0.63	-7.2	-0.33	2.75e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7923837	0.687	rs10882101	chr10:94462427	T/C	cg25093409	chr10:94429542	NA	0.36	6.46	0.3	2.89e-10	Body mass index;Multiple sclerosis;
LUAD	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg22705602	chr4:152727874	NA	-0.4	-7.18	-0.33	3.16e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.61	-8.87	-0.4	2.09e-17	Gut microbiome composition (summer);
LUAD	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg20476274	chr7:133979776	SLC35B4	0.84	16.59	0.63	5.64e-48	Mean platelet volume;
LUAD	cis	rs13315871	0.929	rs71311854	chr3:58319159	G/A	cg12435725	chr3:58293450	RPP14	-0.73	-7.72	-0.35	8.35e-14	Cholesterol, total;
LUAD	cis	rs6426558	0.537	rs12039370	chr1:227326472	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.55	-8.94	-0.4	1.24e-17	Neutrophil percentage of white cells;
LUAD	cis	rs80319144	0.535	rs78501515	chr2:159401009	G/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	7.51	0.34	3.49e-13	Restless legs syndrome;
LUAD	cis	rs2797160	1.000	rs926853	chr6:126021435	A/T	cg05901451	chr6:126070800	HEY2	0.43	6.44	0.3	3.19e-10	Endometrial cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27109030	chr19:2702898	GNG7	-0.51	-6.4	-0.3	4.17e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg14893161	chr1:205819251	PM20D1	-0.52	-7.93	-0.36	1.92e-14	Menarche (age at onset);
LUAD	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg19875535	chr5:140030758	IK	-0.41	-6.99	-0.32	1.06e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00753739	chr10:11653489	USP6NL	-0.41	-6.44	-0.3	3.17e-10	Height;
LUAD	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg13319975	chr6:146136371	FBXO30	-0.65	-11.09	-0.47	2.95e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg03433033	chr1:76189801	ACADM	0.86	17.38	0.65	1.99e-51	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.5	0.3	2.24e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9393692	0.557	rs61324092	chr6:26297392	G/A	cg00631329	chr6:26305371	NA	-0.57	-9.54	-0.42	1.11e-19	Educational attainment;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg12220178	chr1:156721612	HDGF	-0.66	-6.74	-0.31	5.24e-11	Type 2 diabetes;
LUAD	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg21191810	chr6:118973309	C6orf204	-0.53	-8.03	-0.36	9.72e-15	Diastolic blood pressure;
LUAD	cis	rs6840360	0.593	rs4696107	chr4:152606823	G/A	cg22705602	chr4:152727874	NA	-0.47	-8.6	-0.39	1.58e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs354225	0.615	rs12713274	chr2:54848728	C/T	cg26097391	chr2:54893211	SPTBN1	-0.43	-6.74	-0.31	5.29e-11	Schizophrenia;
LUAD	trans	rs9784649	1.000	rs1493479	chr5:24987768	A/G	cg11038491	chr20:34638489	LOC647979	-0.59	-7.88	-0.36	2.76e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7107174	1.000	rs2512535	chr11:77971468	C/T	cg19901956	chr11:77921274	USP35	-0.47	-6.64	-0.31	9.46e-11	Testicular germ cell tumor;
LUAD	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.38	0.34	8.74e-13	Menopause (age at onset);
LUAD	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg09509183	chr1:209979624	IRF6	0.51	6.58	0.3	1.4e-10	Cleft lip with or without cleft palate;
LUAD	trans	rs7939886	0.920	rs10792448	chr11:55804542	C/G	cg15704280	chr7:45808275	SEPT13	0.68	6.58	0.3	1.39e-10	Myopia (pathological);
LUAD	cis	rs12681287	0.640	rs4490816	chr8:87384938	T/C	cg00550725	chr8:87521180	FAM82B	-0.47	-6.73	-0.31	5.71e-11	Caudate activity during reward;
LUAD	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.72	-13.3	-0.54	5.77e-34	Menarche (age at onset);
LUAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08439880	chr3:133502540	NA	-0.46	-9.08	-0.4	4.19e-18	Iron status biomarkers;
LUAD	cis	rs12367572	1.000	rs7304472	chr12:45262324	A/G	cg04608330	chr12:45269318	NELL2	-0.4	-7.46	-0.34	4.84e-13	Gut microbiome composition (summer);
LUAD	cis	rs11229555	1.000	rs2298608	chr11:58404467	A/G	cg15696309	chr11:58395628	NA	0.7	10.47	0.45	5.76e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs3806843	0.576	rs155363	chr5:140301543	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.58	-0.3	1.42e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg15147215	chr3:52552868	STAB1	-0.4	-7.24	-0.33	2.2e-12	Bipolar disorder;
LUAD	cis	rs1003719	0.762	rs4399800	chr21:38489478	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.47	0.38	4.04e-16	Eye color traits;
LUAD	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg01097406	chr16:89675127	NA	0.33	7.05	0.32	7.18e-12	Vitiligo;
LUAD	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg26513180	chr16:89883248	FANCA	0.68	12.64	0.52	2.84e-31	Vitiligo;
LUAD	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs60154123	0.615	rs701943	chr1:210425727	A/G	cg22029157	chr1:209979665	IRF6	-0.55	-6.59	-0.31	1.3100000000000001e-10	Coronary artery disease;
LUAD	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg03676636	chr4:99064102	C4orf37	0.3	7.25	0.33	1.96e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg07167872	chr1:205819463	PM20D1	-0.53	-8.06	-0.36	8.17e-15	Menarche (age at onset);
LUAD	cis	rs6761276	0.899	rs13389457	chr2:113834885	T/C	cg10479672	chr2:113810641	IL1F8	-0.38	-7.72	-0.35	8.74e-14	Protein quantitative trait loci;
LUAD	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	9.19	0.41	1.74e-18	Platelet count;
LUAD	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg22963979	chr7:1858916	MAD1L1	-0.57	-9.68	-0.43	3.74e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs7474896	0.537	rs1208683	chr10:38093723	A/G	cg25427524	chr10:38739819	LOC399744	0.58	8.29	0.37	1.51e-15	Obesity (extreme);
LUAD	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg14092988	chr3:52407081	DNAH1	0.45	9.09	0.4	3.91e-18	Bipolar disorder;
LUAD	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg24803719	chr17:45855879	NA	-0.33	-7.26	-0.33	1.85e-12	IgG glycosylation;
LUAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg12373951	chr3:133503437	NA	0.37	7.32	0.34	1.29e-12	Iron status biomarkers;
LUAD	trans	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg11292332	chr7:45801988	SEPT13	-0.28	-6.5	-0.3	2.26e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6066825	0.555	rs6019378	chr20:47309716	C/T	cg18078177	chr20:47281410	PREX1	0.42	7.07	0.33	6.44e-12	Colorectal cancer;
LUAD	trans	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.85	-0.32	2.54e-11	Diabetic kidney disease;
LUAD	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg08742575	chr21:47604166	C21orf56	0.43	7.26	0.33	1.93e-12	Testicular germ cell tumor;
LUAD	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg11645453	chr3:52864694	ITIH4	0.33	6.45	0.3	3.15e-10	Bipolar disorder;
LUAD	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg17105886	chr17:28927953	LRRC37B2	0.82	7.87	0.36	2.9e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs12681287	0.752	rs10111095	chr8:87250984	T/C	cg27223183	chr8:87520930	FAM82B	-0.59	-8.21	-0.37	2.75e-15	Caudate activity during reward;
LUAD	cis	rs7582720	1.000	rs72928605	chr2:203832120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	9.69	0.43	3.37e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs757647	1.000	rs17171820	chr5:137761832	A/G	cg10676309	chr5:137685565	NA	0.37	7.08	0.33	5.87e-12	Menarche (age at onset);
LUAD	cis	rs28830936	1.000	rs2577960	chr15:42028354	C/A	cg17847044	chr15:42102381	MAPKBP1	0.33	6.58	0.3	1.39e-10	Diastolic blood pressure;
LUAD	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg24397884	chr7:158709396	WDR60	0.57	10.32	0.45	2.09e-22	Height;
LUAD	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg19077165	chr18:44547161	KATNAL2	0.42	7.49	0.34	4.14e-13	Personality dimensions;
LUAD	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg09184832	chr6:79620586	NA	-0.5	-9.44	-0.42	2.49e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg04450456	chr4:17643702	FAM184B	-0.42	-8.42	-0.38	6.05e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7584330	0.554	rs74001383	chr2:238424418	T/C	cg14458575	chr2:238380390	NA	0.6	9.85	0.43	9.28e-21	Prostate cancer;
LUAD	cis	rs9914988	0.943	rs3181215	chr17:27077331	C/T	cg20469991	chr17:27169893	C17orf63	0.49	6.49	0.3	2.43e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.76	0.35	6.46e-14	Platelet count;
LUAD	cis	rs4774899	0.966	rs11071305	chr15:57371178	A/G	cg14026238	chr15:57616123	NA	0.37	6.89	0.32	2.06e-11	Urinary tract infection frequency;
LUAD	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg19636519	chr7:99541626	NA	0.39	7.0	0.32	1.03e-11	Coronary artery disease;
LUAD	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg10434728	chr15:90938212	IQGAP1	0.38	7.54	0.34	2.92e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg06221963	chr1:154839813	KCNN3	-0.85	-20.1	-0.7	1.48e-63	Prostate cancer;
LUAD	cis	rs7180079	1.000	rs6494469	chr15:64551279	C/T	cg08069370	chr15:64387884	SNX1	-0.51	-6.56	-0.3	1.6e-10	Monocyte count;
LUAD	cis	rs1215050	0.904	rs165246	chr4:98688541	C/T	cg05340658	chr4:99064831	C4orf37	0.4	6.38	0.3	4.55e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs17767294	0.708	rs6908688	chr6:27886051	A/G	cg08851530	chr6:28072375	NA	0.92	6.73	0.31	5.48e-11	Parkinson's disease;
LUAD	trans	rs1997103	1.000	rs4947504	chr7:55409428	T/C	cg20935933	chr6:143382018	AIG1	0.48	6.77	0.31	4.43e-11	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.22e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.698	rs9374081	chr6:109631782	A/G	cg21918786	chr6:109611834	NA	-0.42	-6.71	-0.31	6.15e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs239198	0.534	rs1813223	chr6:101331909	C/T	cg09795085	chr6:101329169	ASCC3	0.39	6.9	0.32	1.93e-11	Menarche (age at onset);
LUAD	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06022373	chr22:39101656	GTPBP1	0.46	7.13	0.33	4.42e-12	Menopause (age at onset);
LUAD	cis	rs738321	0.757	rs5750546	chr22:38542499	C/T	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.91	-0.32	1.78e-11	Breast cancer;
LUAD	cis	rs1696756	1.000	rs1696756	chr17:77827973	C/T	cg02876276	chr17:77834299	NA	0.4	6.43	0.3	3.49e-10	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg09365446	chr1:150670422	GOLPH3L	0.63	11.15	0.48	1.79e-25	Melanoma;
LUAD	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg20503657	chr10:835505	NA	1.01	14.78	0.58	3.74e-40	Eosinophil percentage of granulocytes;
LUAD	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20916646	chr4:852691	GAK	0.54	7.52	0.34	3.24e-13	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.55	-0.34	2.63e-13	Lung cancer;
LUAD	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.4	7.02	0.32	8.69e-12	Menarche (age at onset);
LUAD	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg25237894	chr2:233734115	C2orf82	0.61	12.56	0.52	5.86e-31	Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs2857891	1.000	rs2595500	chr11:6963165	C/T	cg04053776	chr11:6947353	ZNF215	-0.49	-7.25	-0.33	1.96e-12	Response to cytadine analogues (cytosine arabinoside);
LUAD	cis	rs208520	0.690	rs207118	chr6:66788948	T/A	cg07460842	chr6:66804631	NA	-1.06	-16.63	-0.63	3.97e-48	Exhaled nitric oxide output;
LUAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.4	-0.45	1.06e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg25344623	chr2:136566232	LCT	0.33	6.41	0.3	3.98e-10	Mosquito bite size;
LUAD	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg03563238	chr19:33554763	RHPN2	-0.39	-9.17	-0.41	2.14e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4849845	0.598	rs3933620	chr2:121034936	A/T	cg24070213	chr2:121070622	NA	0.41	7.81	0.36	4.42e-14	Mean platelet volume;
LUAD	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg23173402	chr1:227635558	NA	0.8	6.92	0.32	1.72e-11	Major depressive disorder;
LUAD	cis	rs6028335	0.674	rs68173814	chr20:37621180	A/G	cg27660920	chr20:37554817	FAM83D	0.52	6.53	0.3	1.91e-10	Alcohol and nicotine co-dependence;
LUAD	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg05805236	chr11:65401703	PCNXL3	0.42	7.28	0.33	1.66e-12	Acne (severe);
LUAD	cis	rs7737355	0.947	rs31253	chr5:130833011	A/C	cg06307176	chr5:131281290	NA	0.48	7.72	0.35	8.34e-14	Life satisfaction;
LUAD	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg11266682	chr4:10021025	SLC2A9	0.69	15.79	0.61	1.72e-44	Bone mineral density;
LUAD	cis	rs9902453	0.740	rs2244247	chr17:28110174	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.61	-0.46	1.8e-23	Coffee consumption (cups per day);
LUAD	cis	rs62458065	0.568	rs62466415	chr7:32518254	C/T	cg20159608	chr7:32802032	NA	-0.59	-7.8	-0.35	4.83e-14	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs1032833	0.732	rs79717491	chr2:180033844	T/C	cg23883738	chr2:179974586	SESTD1	-0.65	-7.32	-0.34	1.28e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg03161606	chr19:29218774	NA	0.52	7.17	0.33	3.37e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	trans	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg18187862	chr3:45730750	SACM1L	-0.53	-8.39	-0.38	7.17e-16	Primary sclerosing cholangitis;
LUAD	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg13535736	chr9:111863775	C9orf5	-0.42	-6.39	-0.3	4.4e-10	Menarche (age at onset);
LUAD	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg22535103	chr8:58192502	C8orf71	-0.66	-7.27	-0.33	1.77e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6586163	0.527	rs3740286	chr10:90751340	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.69	11.6	0.49	3.25e-27	Chronic lymphocytic leukemia;
LUAD	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg10518543	chr12:38710700	ALG10B	-0.42	-6.99	-0.32	1.05e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg04539111	chr16:67997858	SLC12A4	-0.5	-6.55	-0.3	1.68e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg00784671	chr22:46762841	CELSR1	-0.6	-7.74	-0.35	7.19e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7274811	0.681	rs293733	chr20:31975976	C/T	cg13403462	chr20:32256071	NECAB3;C20orf134	0.45	6.97	0.32	1.2e-11	Height;
LUAD	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.98	-0.4	8.9e-18	Total body bone mineral density;
LUAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg07362569	chr17:61921086	SMARCD2	0.37	6.5	0.3	2.29e-10	Prudent dietary pattern;
LUAD	cis	rs9581857	0.547	rs9579095	chr13:28082555	C/T	cg22138327	chr13:27999177	GTF3A	0.85	9.02	0.4	6.56e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs113835537	0.529	rs2305535	chr11:66272237	A/G	cg24851651	chr11:66362959	CCS	-0.52	-9.38	-0.41	4.11e-19	Airway imaging phenotypes;
LUAD	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg13906792	chr15:75199810	C15orf17	-0.34	-6.38	-0.3	4.61e-10	Caffeine consumption;
LUAD	cis	rs1816752	0.819	rs4769349	chr13:24982832	A/G	cg02811702	chr13:24901961	NA	-0.4	-7.02	-0.32	8.94e-12	Obesity-related traits;
LUAD	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg23758822	chr17:41437982	NA	1.01	21.18	0.72	2.19e-68	Menopause (age at onset);
LUAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg23958373	chr8:599963	NA	1.07	10.45	0.45	6.76e-23	IgG glycosylation;
LUAD	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg09359103	chr1:154839909	KCNN3	-0.9	-20.46	-0.71	3.48e-65	Prostate cancer;
LUAD	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg03714773	chr7:91764589	CYP51A1	-0.27	-6.5	-0.3	2.21e-10	Breast cancer;
LUAD	cis	rs12681287	0.640	rs12550142	chr8:87471861	C/A	cg00550725	chr8:87521180	FAM82B	0.45	6.52	0.3	1.98e-10	Caudate activity during reward;
LUAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.47	0.3	2.7e-10	Prudent dietary pattern;
LUAD	cis	rs6445967	0.569	rs2885868	chr3:58284692	G/A	cg13750441	chr3:58318267	PXK	-0.3	-6.42	-0.3	3.77e-10	Platelet count;
LUAD	cis	rs1816752	0.683	rs7330532	chr13:25017591	C/T	cg02811702	chr13:24901961	NA	0.46	7.89	0.36	2.6e-14	Obesity-related traits;
LUAD	cis	rs2046867	0.818	rs60228315	chr3:72805034	C/A	cg25664220	chr3:72788482	NA	-0.69	-12.15	-0.51	2.5e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg22189786	chr22:42395067	WBP2NL	0.46	6.56	0.3	1.58e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs9462027	0.651	rs7769820	chr6:34760228	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.91	-0.4	1.58e-17	Systemic lupus erythematosus;
LUAD	cis	rs56283067	0.504	rs62436021	chr6:44705375	C/A	cg18551225	chr6:44695536	NA	-0.57	-8.85	-0.4	2.35e-17	Total body bone mineral density;
LUAD	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.82	9.08	0.4	4.27e-18	Initial pursuit acceleration;
LUAD	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg09365446	chr1:150670422	GOLPH3L	0.65	12.18	0.51	1.81e-29	Melanoma;
LUAD	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg10468373	chr11:64009913	FKBP2	0.54	6.8	0.31	3.62e-11	Mean platelet volume;
LUAD	trans	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg01620082	chr3:125678407	NA	-0.43	-6.51	-0.3	2.11e-10	Parkinson's disease;
LUAD	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg03714773	chr7:91764589	CYP51A1	-0.27	-6.54	-0.3	1.82e-10	Breast cancer;
LUAD	cis	rs2386661	0.591	rs11255051	chr10:5653450	A/G	cg26603656	chr10:5671107	NA	0.36	6.38	0.3	4.64e-10	Breast cancer;
LUAD	cis	rs12612619	0.732	rs1440044	chr2:27226954	A/G	cg00617064	chr2:27272375	NA	-0.38	-7.28	-0.33	1.62e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs10392	0.850	rs74272986	chr20:37558270	A/G	cg27660920	chr20:37554817	FAM83D	0.58	7.47	0.34	4.64e-13	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.64	-0.31	9.9e-11	Coronary artery disease;
LUAD	cis	rs7267979	0.789	rs9927	chr20:25277244	A/G	cg08601574	chr20:25228251	PYGB	0.42	7.76	0.35	6.44e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg23649088	chr2:200775458	C2orf69	0.58	8.25	0.37	1.97e-15	Schizophrenia;
LUAD	cis	rs9296092	0.521	rs56332659	chr6:33537887	T/C	cg13560919	chr6:33536144	NA	-0.85	-14.74	-0.58	5.62e-40	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg11494091	chr17:61959527	GH2	0.43	8.11	0.37	5.45e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6690583	0.623	rs1371141	chr1:85455372	C/A	cg22153463	chr1:85462885	MCOLN2	0.55	6.37	0.3	4.97e-10	Serum sulfate level;
LUAD	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg13902645	chr11:5959945	NA	0.54	10.09	0.44	1.37e-21	DNA methylation (variation);
LUAD	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-14.23	-0.57	8.3e-38	Headache;
LUAD	cis	rs11867934	0.577	rs9893676	chr17:17054951	C/G	cg26176665	chr17:16994978	MPRIP	0.41	6.91	0.32	1.8e-11	Diabetic retinopathy;
LUAD	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg00071950	chr4:10020882	SLC2A9	0.63	12.07	0.51	5.03e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-11.18	-0.48	1.31e-25	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs8073060	0.544	rs225283	chr17:33934912	A/G	cg19694781	chr19:47549865	TMEM160	-1.25	-19.7	-0.69	8.62e-62	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.24	0.48	7.87e-26	Height;
LUAD	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg00129232	chr17:37814104	STARD3	-0.45	-7.43	-0.34	6.19e-13	Asthma;
LUAD	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg04727924	chr7:799746	HEATR2	-0.55	-7.46	-0.34	5.03e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs12900413	0.603	rs7177841	chr15:90302117	C/A	cg24249390	chr15:90295951	MESP1	-0.35	-6.97	-0.32	1.23e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.21	0.33	2.67e-12	Motion sickness;
LUAD	cis	rs524023	0.958	rs2021860	chr11:64361384	G/T	cg19131476	chr11:64387923	NRXN2	-0.37	-7.11	-0.33	5.05e-12	Urate levels in obese individuals;
LUAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-9.2	-0.41	1.69e-18	Alzheimer's disease;
LUAD	cis	rs929596	0.755	rs4148325	chr2:234673309	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.73	-12.78	-0.53	7.43e-32	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg02176678	chr2:219576539	TTLL4	-0.81	-16.65	-0.63	3.13e-48	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9302065	0.529	rs2992904	chr13:95958173	A/C	cg26751094	chr13:95954534	ABCC4	-0.54	-11.38	-0.48	2.29e-26	Blood metabolite levels;
LUAD	trans	rs1973993	0.745	rs7512263	chr1:96941158	C/A	cg10631902	chr5:14652156	NA	-0.51	-8.57	-0.38	1.92e-16	Weight;
LUAD	cis	rs356992	0.767	rs1896297	chr2:60738227	A/G	cg08426369	chr2:60753602	BCL11A	-0.42	-7.26	-0.33	1.91e-12	Educational attainment (years of education);
LUAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.76e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg27432699	chr2:27873401	GPN1	-0.38	-6.47	-0.3	2.77e-10	Total body bone mineral density;
LUAD	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg26384229	chr12:38710491	ALG10B	-0.42	-7.28	-0.33	1.63e-12	Morning vs. evening chronotype;
LUAD	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg07570687	chr10:102243282	WNT8B	0.42	6.42	0.3	3.65e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg01689657	chr7:91764605	CYP51A1	0.34	8.51	0.38	2.96e-16	Breast cancer;
LUAD	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg05665937	chr4:1216051	CTBP1	0.42	7.04	0.32	7.61e-12	Obesity-related traits;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg02796970	chr10:39023768	NA	-0.49	-7.82	-0.36	4.37e-14	Menopause (age at onset);
LUAD	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg25828334	chr19:18545568	ISYNA1	0.37	7.46	0.34	5.11e-13	Breast cancer;
LUAD	cis	rs4660214	0.666	rs2490946	chr1:39837627	G/A	cg27567593	chr1:39956653	BMP8A	-0.37	-7.38	-0.34	8.61e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg05368731	chr17:41323189	NBR1	0.98	20.4	0.7	6.3e-65	Menopause (age at onset);
LUAD	cis	rs1448094	0.842	rs7309725	chr12:86440612	T/C	cg06740227	chr12:86229804	RASSF9	0.35	6.42	0.3	3.67e-10	Major depressive disorder;
LUAD	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg27432699	chr2:27873401	GPN1	-0.39	-6.38	-0.3	4.73e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg19041857	chr6:27730383	NA	-0.43	-7.28	-0.33	1.6e-12	Parkinson's disease;
LUAD	cis	rs13082711	0.954	rs34348584	chr3:27532704	T/C	cg02860705	chr3:27208620	NA	0.63	8.9	0.4	1.6e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg02574844	chr11:5959923	NA	-0.38	-6.68	-0.31	7.38e-11	DNA methylation (variation);
LUAD	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg08999081	chr20:33150536	PIGU	-0.57	-12.59	-0.52	4.51e-31	Glomerular filtration rate (creatinine);
LUAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg11494091	chr17:61959527	GH2	0.74	18.58	0.67	8.68e-57	Prudent dietary pattern;
LUAD	cis	rs13315871	0.929	rs11715290	chr3:58298413	C/T	cg12435725	chr3:58293450	RPP14	-0.74	-7.88	-0.36	2.86e-14	Cholesterol, total;
LUAD	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.53	0.38	2.62e-16	Parkinson's disease;
LUAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08677398	chr8:58056175	NA	0.47	6.55	0.3	1.69e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9972944	0.902	rs9972885	chr17:63771264	G/T	cg07283582	chr17:63770753	CCDC46	0.51	11.68	0.49	1.64e-27	Total body bone mineral density;
LUAD	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg04727924	chr7:799746	HEATR2	-0.52	-7.04	-0.32	7.9e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.51	7.79	0.35	5.35e-14	Alzheimer's disease (late onset);
LUAD	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg25753631	chr6:25732923	NA	-0.38	-6.52	-0.3	1.95e-10	Iron status biomarkers;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg03395511	chr6:291903	DUSP22	-0.78	-13.4	-0.55	2.3e-34	Menopause (age at onset);
LUAD	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg14583973	chr4:3374767	RGS12	0.29	7.24	0.33	2.08e-12	Serum sulfate level;
LUAD	cis	rs642803	0.591	rs620088	chr11:65508986	G/A	cg27068330	chr11:65405492	SIPA1	0.43	6.68	0.31	7.34e-11	Urate levels;
LUAD	trans	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	8.71	0.39	7e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg03929089	chr4:120376271	NA	-0.45	-6.91	-0.32	1.78e-11	HDL cholesterol;
LUAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.22	0.54	1.26e-33	Prudent dietary pattern;
LUAD	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg18105134	chr13:113819100	PROZ	-0.8	-14.09	-0.57	3.1e-37	Platelet distribution width;
LUAD	cis	rs870825	0.549	rs7699919	chr4:185648610	A/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg20283391	chr11:68216788	NA	-0.42	-6.56	-0.3	1.56e-10	Total body bone mineral density;
LUAD	cis	rs6005807	0.843	rs9620799	chr22:28895412	T/G	cg12565055	chr22:29076175	TTC28	0.66	6.36	0.3	5.12e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs2274273	0.870	rs4366639	chr14:55790516	T/G	cg04306507	chr14:55594613	LGALS3	0.44	9.18	0.41	1.99e-18	Protein biomarker;
LUAD	cis	rs9914988	1.000	rs9895443	chr17:27182944	A/G	cg02049041	chr17:27085579	C17orf63	0.57	7.76	0.35	6.23e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg05313129	chr8:58192883	C8orf71	-0.54	-8.01	-0.36	1.14e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg15448220	chr1:150897856	SETDB1	0.5	8.61	0.39	1.48e-16	Tonsillectomy;
LUAD	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg01191920	chr7:158217561	PTPRN2	0.73	16.26	0.62	1.52e-46	Obesity-related traits;
LUAD	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg05368731	chr17:41323189	NBR1	0.96	19.98	0.7	5.14e-63	Menopause (age at onset);
LUAD	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg12935359	chr14:103987150	CKB	-0.47	-7.43	-0.34	6.16e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	7.46	0.34	5.09e-13	Platelet count;
LUAD	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg06108461	chr20:60628389	TAF4	-0.94	-16.76	-0.63	9.8e-49	Body mass index;
LUAD	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.67	-11.15	-0.48	1.72e-25	Primary sclerosing cholangitis;
LUAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg24813613	chr7:1882135	MAD1L1	-0.55	-8.8	-0.39	3.44e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs7395662	0.571	rs1605358	chr11:48689318	T/A	cg15704280	chr7:45808275	SEPT13	-0.45	-7.12	-0.33	4.68e-12	HDL cholesterol;
LUAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00149659	chr3:10157352	C3orf10	0.62	8.52	0.38	2.91e-16	Alzheimer's disease;
LUAD	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	10.25	0.45	3.58e-22	Total body bone mineral density;
LUAD	cis	rs11112613	0.713	rs11112592	chr12:105951702	C/T	cg03607813	chr12:105948248	NA	-0.7	-12.14	-0.51	2.59e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.05	0.32	7.2e-12	Menopause (age at onset);
LUAD	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-9.58	-0.42	8.67e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg19635926	chr16:89946313	TCF25	0.74	6.97	0.32	1.22e-11	Skin colour saturation;
LUAD	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg00634984	chr7:65235879	NA	0.47	6.44	0.3	3.28e-10	Aortic root size;
LUAD	cis	rs6484504	0.576	rs208072	chr11:31141288	A/G	cg26647111	chr11:31128758	NA	0.46	8.2	0.37	2.85e-15	Red blood cell count;
LUAD	cis	rs9826463	0.527	rs73238170	chr3:142100311	T/A	cg20824294	chr3:142316082	PLS1	0.41	7.19	0.33	3.01e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg24829409	chr8:58192753	C8orf71	-0.61	-7.66	-0.35	1.28e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs8027181	0.839	rs2277598	chr15:73027478	T/C	cg25632853	chr15:73088954	NA	0.31	6.67	0.31	8.04e-11	Triglyceride levels;
LUAD	cis	rs17539620	0.624	rs62432752	chr6:154841074	A/G	cg20019720	chr6:154832845	CNKSR3	0.63	11.46	0.49	1.17e-26	Lipoprotein (a) levels;
LUAD	cis	rs4072705	0.616	rs915033	chr9:127245558	C/G	cg14219918	chr9:127249562	NR5A1	0.28	6.44	0.3	3.22e-10	Menarche (age at onset);
LUAD	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-11.58	-0.49	4.03e-27	Bone mineral density;
LUAD	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg01475377	chr6:109611718	NA	-0.51	-9.49	-0.42	1.75e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs12200560	0.524	rs1413525	chr6:97073096	C/T	cg06623918	chr6:96969491	KIAA0776	0.5	7.66	0.35	1.32e-13	Coronary heart disease;
LUAD	cis	rs6076065	0.723	rs2275788	chr20:23338694	G/A	cg11657817	chr20:23433608	CST11	0.5	9.18	0.41	1.93e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs3806843	0.576	rs246049	chr5:140327590	T/G	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs113835537	0.529	rs11227501	chr11:66274072	T/C	cg24851651	chr11:66362959	CCS	0.56	9.98	0.44	3.25e-21	Airway imaging phenotypes;
LUAD	cis	rs12765878	1.000	rs11191847	chr10:105650626	G/C	cg11005552	chr10:105648138	OBFC1	0.44	8.34	0.38	1.04e-15	Coronary artery disease;
LUAD	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-10.92	-0.47	1.24e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1160297	0.576	rs74181216	chr2:53093194	G/C	cg07782112	chr2:53107842	NA	0.39	8.23	0.37	2.32e-15	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.66	0.31	8.38e-11	Parkinson's disease;
LUAD	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg16049864	chr8:95962084	TP53INP1	-0.55	-12.07	-0.51	4.96e-29	Type 2 diabetes;
LUAD	cis	rs7937890	0.531	rs2575859	chr11:14510736	C/T	cg06199346	chr11:14280333	SPON1	-0.32	-6.42	-0.3	3.58e-10	Mitochondrial DNA levels;
LUAD	cis	rs62400317	0.859	rs17209741	chr6:45292438	A/T	cg20913747	chr6:44695427	NA	-0.4	-6.55	-0.3	1.68e-10	Total body bone mineral density;
LUAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg00776166	chr8:613548	NA	0.54	6.7	0.31	6.68e-11	IgG glycosylation;
LUAD	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg08807101	chr21:30365312	RNF160	-0.43	-7.51	-0.34	3.48e-13	Dental caries;
LUAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.5	-8.4	-0.38	6.91e-16	Longevity;Endometriosis;
LUAD	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs7274811	0.846	rs57668191	chr20:32289763	A/G	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.46	-6.63	-0.31	1.05e-10	Height;
LUAD	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-7.98	-0.36	1.36e-14	Diabetic kidney disease;
LUAD	cis	rs6665290	0.904	rs1343744	chr1:227183022	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.2	-36.16	-0.87	1.7e-131	Myeloid white cell count;
LUAD	cis	rs1448094	0.872	rs4919777	chr12:86358491	C/T	cg06740227	chr12:86229804	RASSF9	0.35	6.42	0.3	3.59e-10	Major depressive disorder;
LUAD	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.43	0.3	3.5e-10	Depression;
LUAD	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg24069376	chr3:38537580	EXOG	-0.3	-7.05	-0.32	7.27e-12	Electrocardiographic conduction measures;
LUAD	cis	rs877282	0.891	rs12357999	chr10:796468	A/C	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13268671	chr2:166810585	TTC21B	-0.41	-6.53	-0.3	1.88e-10	Height;
LUAD	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.73	-8.62	-0.39	1.39e-16	Body mass index;
LUAD	cis	rs7149242	0.696	rs7141210	chr14:101182470	T/C	cg10189261	chr14:101176105	NA	0.39	7.38	0.34	8.26e-13	Platelet count;
LUAD	cis	rs12519773	0.526	rs4869415	chr5:92522764	A/G	cg18783429	chr5:92414398	NA	0.44	7.95	0.36	1.72e-14	Migraine;
LUAD	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg14582100	chr15:45693742	SPATA5L1	0.64	12.5	0.52	9.64e-31	Homoarginine levels;
LUAD	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg27171569	chr16:83987465	OSGIN1	0.66	15.43	0.6	6.38e-43	Pursuit maintenance gain;
LUAD	cis	rs250677	0.522	rs6875902	chr5:148407893	C/A	cg12140854	chr5:148520817	ABLIM3	-0.58	-8.51	-0.38	2.95e-16	Breast cancer;
LUAD	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg19622623	chr12:86230825	RASSF9	-0.55	-9.84	-0.43	1.02e-20	Major depressive disorder;
LUAD	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06558623	chr16:89946397	TCF25	0.82	8.34	0.38	1.04e-15	Skin colour saturation;
LUAD	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg07305463	chr2:136567211	LCT	0.39	7.34	0.34	1.07e-12	Mosquito bite size;
LUAD	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6840360	0.571	rs62327271	chr4:152535916	A/G	cg22705602	chr4:152727874	NA	-0.4	-7.08	-0.33	5.85e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs9951602	0.920	rs3859334	chr18:76684193	G/A	cg02800362	chr5:177631904	HNRNPAB	0.69	8.87	0.4	2.15e-17	Obesity-related traits;
LUAD	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg06766960	chr11:133703094	NA	-0.45	-8.45	-0.38	4.78e-16	Childhood ear infection;
LUAD	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.73	-0.31	5.59e-11	Morning vs. evening chronotype;
LUAD	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg25358565	chr5:93447407	FAM172A	-0.58	-7.29	-0.33	1.59e-12	Diabetic retinopathy;
LUAD	cis	rs240764	0.746	rs240153	chr6:101067135	A/C	cg09795085	chr6:101329169	ASCC3	0.43	7.35	0.34	1e-12	Neuroticism;
LUAD	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg05368731	chr17:41323189	NBR1	0.98	20.4	0.7	6.3e-65	Menopause (age at onset);
LUAD	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg02734326	chr4:10020555	SLC2A9	0.49	7.62	0.35	1.65e-13	Blood metabolite levels;
LUAD	cis	rs10924309	0.889	rs10802246	chr1:245858493	T/G	cg00036263	chr1:245852353	KIF26B	-0.48	-7.49	-0.34	4.11e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs17095355	0.792	rs61881587	chr10:111759710	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.61	-8.26	-0.37	1.95e-15	Biliary atresia;
LUAD	cis	rs9341808	0.754	rs9341810	chr6:80974838	G/A	cg08355045	chr6:80787529	NA	0.57	10.44	0.45	7.34e-23	Sitting height ratio;
LUAD	cis	rs72928364	0.860	rs16843225	chr3:100801257	A/C	cg10123952	chr3:100791384	NA	0.65	7.54	0.34	2.91e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11112613	0.775	rs12371537	chr12:105971425	T/C	cg03607813	chr12:105948248	NA	0.77	12.06	0.51	5.55e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg08885076	chr2:99613938	TSGA10	0.36	6.65	0.31	9.14e-11	Chronic sinus infection;
LUAD	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18876405	chr7:65276391	NA	-0.42	-6.58	-0.3	1.38e-10	Aortic root size;
LUAD	trans	rs9991328	0.782	rs6532080	chr4:89731745	A/C	cg07140885	chr10:99495859	ZFYVE27	0.34	6.38	0.3	4.54e-10	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg06064525	chr11:970664	AP2A2	0.53	10.94	0.47	1.06e-24	Alzheimer's disease (late onset);
LUAD	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg14582100	chr15:45693742	SPATA5L1	0.64	12.62	0.52	3.31e-31	Homoarginine levels;
LUAD	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.33	6.77	0.31	4.32e-11	Obesity-related traits;
LUAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg22663859	chr13:21900854	NA	0.48	7.69	0.35	1.01e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs7017914	1.000	rs7017914	chr8:71591203	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.66	-0.31	8.78e-11	Bone mineral density;
LUAD	cis	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg25834613	chr7:1915315	MAD1L1	-0.41	-6.53	-0.3	1.87e-10	Bipolar disorder;
LUAD	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg18306943	chr3:40428807	ENTPD3	0.42	7.07	0.32	6.56e-12	Renal cell carcinoma;
LUAD	cis	rs12413816	0.963	rs12359348	chr10:13765950	C/T	cg16485048	chr10:13749193	FRMD4A	-0.45	-8.03	-0.36	1e-14	Red cell distribution width;
LUAD	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg09117114	chr16:67998030	SLC12A4	-0.48	-7.19	-0.33	2.97e-12	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01973771	chr19:2740143	SLC39A3	0.42	6.59	0.31	1.33e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg21153622	chr11:89784906	NA	-0.34	-6.79	-0.31	3.83e-11	Height;
LUAD	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg18833306	chr6:118973337	C6orf204	-0.54	-7.64	-0.35	1.44e-13	Diastolic blood pressure;
LUAD	cis	rs7814319	1.000	rs6468495	chr8:97259953	C/A	cg20787634	chr8:97240163	UQCRB	-0.34	-6.48	-0.3	2.55e-10	Lung function (FVC);
LUAD	cis	rs13064411	0.696	rs6783965	chr3:113198722	C/T	cg18753928	chr3:113234510	CCDC52	-0.73	-12.27	-0.51	8.25e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg25427524	chr10:38739819	LOC399744	-0.64	-9.26	-0.41	1.01e-18	Obesity (extreme);
LUAD	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg24154853	chr7:158122151	PTPRN2	0.57	11.37	0.48	2.59e-26	Calcium levels;
LUAD	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg08885076	chr2:99613938	TSGA10	0.36	6.46	0.3	2.91e-10	Chronic sinus infection;
LUAD	cis	rs813218	0.523	rs669676	chr3:99448852	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.42	-7.93	-0.36	1.93e-14	Orofacial clefts;
LUAD	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg22920501	chr2:26401640	FAM59B	0.98	15.44	0.6	5.42e-43	Gut microbiome composition (summer);
LUAD	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg16342193	chr10:102329863	NA	-0.38	-6.62	-0.31	1.06e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs3733585	0.683	rs3796839	chr4:10009917	G/A	cg26043149	chr18:55253948	FECH	0.51	8.19	0.37	3.12e-15	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7010267	0.668	rs4563920	chr8:119993689	A/G	cg01975934	chr8:119970761	NA	-0.34	-6.58	-0.3	1.35e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg05084668	chr3:125655381	ALG1L	-0.65	-10.41	-0.45	9.71e-23	Blood pressure (smoking interaction);
LUAD	cis	rs6445967	0.579	rs11130640	chr3:58414908	C/G	cg23715586	chr3:58305044	RPP14	0.4	6.61	0.31	1.17e-10	Platelet count;
LUAD	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg20891283	chr12:69753455	YEATS4	0.44	7.08	0.33	6.17e-12	Blood protein levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg16688232	chr8:126010694	SQLE	-0.64	-6.69	-0.31	7.13e-11	Type 2 diabetes;
LUAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg24642844	chr7:1081250	C7orf50	-0.98	-14.73	-0.58	5.99e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-7.01	-0.32	9.64e-12	Neuroticism;
LUAD	cis	rs2004318	1.000	rs4097296	chr19:55141019	G/A	cg03320607	chr19:54800032	LILRA3	-0.68	-7.19	-0.33	3.01e-12	Blood protein levels;
LUAD	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05901451	chr6:126070800	HEY2	0.84	16.68	0.63	2.22e-48	Brugada syndrome;
LUAD	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg12940439	chr1:67600707	NA	0.42	8.13	0.37	4.94e-15	Psoriasis;
LUAD	cis	rs6005807	0.719	rs12165715	chr22:29005595	T/C	cg12565055	chr22:29076175	TTC28	0.74	8.39	0.38	7.2e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg02269571	chr22:50332266	NA	0.87	8.62	0.39	1.33e-16	Schizophrenia;
LUAD	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.55	7.82	0.36	4.12e-14	Platelet count;
LUAD	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg08280861	chr8:58055591	NA	0.55	7.05	0.32	7.49e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.79e-18	Life satisfaction;
LUAD	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7659604	0.689	rs4283687	chr4:122663460	A/G	cg06713675	chr4:122721982	EXOSC9	-0.57	-10.7	-0.46	8.1e-24	Type 2 diabetes;
LUAD	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	6.44	0.3	3.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg27661571	chr11:113659931	NA	-0.71	-8.27	-0.37	1.77e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs2067615	0.524	rs7309351	chr12:107077432	C/T	cg15890332	chr12:107067104	RFX4	-0.42	-8.82	-0.39	3.01e-17	Heart rate;
LUAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg11494091	chr17:61959527	GH2	0.74	18.17	0.66	6.22e-55	Prudent dietary pattern;
LUAD	cis	rs2274273	0.868	rs6573007	chr14:55625938	T/G	cg04306507	chr14:55594613	LGALS3	0.41	8.4	0.38	7e-16	Protein biomarker;
LUAD	cis	rs1003719	0.737	rs2835587	chr21:38461795	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.63	0.39	1.29e-16	Eye color traits;
LUAD	trans	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg06606381	chr12:133084897	FBRSL1	-0.8	-6.73	-0.31	5.41e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-13.38	-0.55	2.64e-34	Exhaled nitric oxide output;
LUAD	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg22961513	chr11:14280813	SPON1	0.44	9.29	0.41	8.27e-19	Mitochondrial DNA levels;
LUAD	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-10.47	-0.45	5.66e-23	Electroencephalogram traits;
LUAD	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg02371401	chr5:676784	TPPP	-0.47	-7.68	-0.35	1.12e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg13319975	chr6:146136371	FBXO30	-0.58	-9.74	-0.43	2.4e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg07741184	chr6:167504864	NA	0.31	7.37	0.34	9.25e-13	Crohn's disease;
LUAD	cis	rs6785206	0.803	rs6774512	chr3:128415868	C/T	cg16766828	chr3:128327626	NA	-0.85	-9.04	-0.4	5.57e-18	Lymphocyte percentage of white cells;
LUAD	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg05283184	chr6:79620031	NA	-0.43	-7.66	-0.35	1.28e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg17063962	chr7:91808500	NA	-0.67	-11.89	-0.5	2.47e-28	Breast cancer;
LUAD	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg02176678	chr2:219576539	TTLL4	0.68	13.71	0.55	1.17e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg19500851	chr17:37840957	PGAP3	-0.33	-6.44	-0.3	3.29e-10	Asthma;
LUAD	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.39	0.45	1.09e-22	Post bronchodilator FEV1;
LUAD	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg07404485	chr7:94953653	PON1	-0.5	-7.31	-0.33	1.34e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-14.98	-0.59	5.41e-41	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg18200150	chr17:30822561	MYO1D	0.42	7.71	0.35	9.03e-14	Schizophrenia;
LUAD	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg20307385	chr11:47447363	PSMC3	0.65	11.09	0.47	2.92e-25	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs17197710	0.673	rs41301449	chr11:47303821	C/T	cg13308137	chr11:47528955	CUGBP1	0.45	7.11	0.33	4.83e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg27535305	chr1:53392650	SCP2	-0.32	-6.56	-0.3	1.62e-10	Monocyte count;
LUAD	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg26408565	chr15:76604113	ETFA	-0.45	-7.71	-0.35	9.22e-14	Blood metabolite levels;
LUAD	cis	rs12681287	0.752	rs10085920	chr8:87252666	C/T	cg00550725	chr8:87521180	FAM82B	0.44	6.39	0.3	4.38e-10	Caudate activity during reward;
LUAD	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg03354898	chr7:1950403	MAD1L1	-0.39	-7.26	-0.33	1.89e-12	Schizophrenia;
LUAD	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03264133	chr6:25882463	NA	0.5	8.42	0.38	5.8e-16	Blood metabolite levels;
LUAD	cis	rs9535307	0.858	rs2025263	chr13:50308847	C/T	cg04663916	chr13:50265991	EBPL	0.58	6.89	0.32	2.03e-11	Obesity-related traits;
LUAD	cis	rs7731657	0.537	rs3981333	chr5:130375045	A/T	cg08523029	chr5:130500466	HINT1	-0.56	-7.29	-0.33	1.49e-12	Fasting plasma glucose;
LUAD	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg09184832	chr6:79620586	NA	-0.51	-9.57	-0.42	9.14e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg05579598	chr16:88989069	CBFA2T3	0.31	6.51	0.3	2.07e-10	Social autistic-like traits;
LUAD	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg07570687	chr10:102243282	WNT8B	0.44	6.5	0.3	2.22e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs977987	0.843	rs59155720	chr16:75483806	A/G	cg03315344	chr16:75512273	CHST6	0.64	14.03	0.56	5.48e-37	Dupuytren's disease;
LUAD	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.41	0.34	6.78e-13	Tonsillectomy;
LUAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.25	-0.37	2.05e-15	Alzheimer's disease;
LUAD	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg20090143	chr19:45452003	APOC2	0.39	8.93	0.4	1.3e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.05	0.54	6.28e-33	Prudent dietary pattern;
LUAD	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg21782813	chr7:2030301	MAD1L1	0.43	7.12	0.33	4.71e-12	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.89	0.36	2.69e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg07606381	chr6:8435919	SLC35B3	0.41	6.74	0.31	5.16e-11	Motion sickness;
LUAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08439880	chr3:133502540	NA	-0.46	-9.19	-0.41	1.81e-18	Iron status biomarkers;
LUAD	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg24818145	chr4:99064322	C4orf37	0.46	7.8	0.35	4.86e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg06064525	chr11:970664	AP2A2	-0.53	-10.79	-0.46	3.81e-24	Alzheimer's disease (late onset);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07363239	chr6:135502390	MYB	-0.39	-6.61	-0.31	1.17e-10	Cancer;
LUAD	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg03929089	chr4:120376271	NA	-0.98	-20.22	-0.7	4.42e-64	Height;
LUAD	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg18876405	chr7:65276391	NA	-0.61	-10.64	-0.46	1.4e-23	Aortic root size;
LUAD	cis	rs10540	0.541	rs7480899	chr11:438459	T/C	cg03934478	chr11:495069	RNH1	-0.5	-6.82	-0.31	3.07e-11	Body mass index;
LUAD	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg10523679	chr1:76189770	ACADM	0.76	10.92	0.47	1.29e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg11494091	chr17:61959527	GH2	0.45	8.58	0.39	1.76e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs9314614	0.901	rs2978902	chr8:6690173	C/G	cg11829072	chr8:125463024	TRMT12	0.44	7.57	0.35	2.4e-13	IgA nephropathy;White blood cell count (basophil);
LUAD	trans	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.66	-0.35	1.26e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg06618935	chr21:46677482	NA	-0.46	-8.45	-0.38	4.8e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11633958	1	rs11633958	chr15:78862064	C/T	cg18825076	chr15:78729989	IREB2	-0.55	-8.88	-0.4	1.95e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg13180566	chr4:1052158	NA	-0.4	-7.06	-0.32	6.91e-12	Recombination rate (females);
LUAD	cis	rs28830936	0.528	rs11630242	chr15:42124643	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.54	-12.79	-0.53	6.63e-32	Diastolic blood pressure;
LUAD	cis	rs1448094	0.872	rs7300073	chr12:86393513	A/C	cg18827107	chr12:86230957	RASSF9	-0.48	-8.65	-0.39	1.07e-16	Major depressive disorder;
LUAD	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.49	7.5	0.34	3.77e-13	Schizophrenia;
LUAD	cis	rs11229555	1.000	rs12799215	chr11:58405674	C/T	cg15696309	chr11:58395628	NA	-0.72	-10.88	-0.47	1.72e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs752010	0.714	rs7552928	chr1:42086664	C/T	cg06885757	chr1:42089581	HIVEP3	0.48	11.06	0.47	3.88e-25	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs7524102	0.561	rs7550872	chr1:22711378	A/G	cg18560010	chr1:22690912	NA	0.49	6.43	0.3	3.55e-10	Bone mineral density;Bone mineral density (spine);Ulcerative colitis;Bone mineral density (hip);Dupuytren's disease;
LUAD	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23158103	chr7:148848205	ZNF398	-0.67	-12.51	-0.52	9.4e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg27411982	chr8:10470053	RP1L1	0.36	6.48	0.3	2.54e-10	Mood instability;
LUAD	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg03611598	chr17:48586076	MYCBPAP	0.69	9.5	0.42	1.62e-19	Visceral fat;
LUAD	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18404041	chr3:52824283	ITIH1	-0.6	-12.04	-0.51	6.26e-29	Bipolar disorder;
LUAD	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.67	-0.35	1.19e-13	Lung cancer;
LUAD	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg03874509	chr1:107600012	PRMT6	-0.57	-9.97	-0.44	3.48e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.71e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg06641503	chr3:48959341	ARIH2	-0.39	-7.72	-0.35	8.68e-14	Parkinson's disease;
LUAD	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg11062466	chr8:58055876	NA	0.45	6.41	0.3	3.85e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg00666640	chr1:248458726	OR2T12	-0.31	-7.43	-0.34	6.25e-13	Common traits (Other);
LUAD	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg23982607	chr1:1823379	GNB1	0.43	7.12	0.33	4.6e-12	Body mass index;
LUAD	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg21194808	chr1:2205498	SKI	0.41	6.5	0.3	2.33e-10	Height;
LUAD	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg17105886	chr17:28927953	LRRC37B2	0.77	7.72	0.35	8.51e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg18721089	chr20:30220636	NA	-0.45	-6.49	-0.3	2.44e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg02807482	chr3:125708958	NA	-0.66	-8.74	-0.39	5.32e-17	Blood pressure (smoking interaction);
LUAD	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg21427119	chr20:30132790	HM13	-0.5	-7.98	-0.36	1.4e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg11645453	chr3:52864694	ITIH4	-0.39	-7.62	-0.35	1.7e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07167872	chr1:205819463	PM20D1	0.84	18.32	0.67	1.32e-55	Menarche (age at onset);
LUAD	cis	rs17152411	0.817	rs4478950	chr10:126596425	T/C	cg07906193	chr10:126599966	NA	0.49	7.14	0.33	3.98e-12	Height;
LUAD	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg23625390	chr15:77176239	SCAPER	0.39	6.94	0.32	1.47e-11	Blood metabolite levels;
LUAD	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg11707310	chr1:2537719	MMEL1	0.37	7.85	0.36	3.39e-14	Ulcerative colitis;
LUAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg00634984	chr7:65235879	NA	-0.44	-7.11	-0.33	4.96e-12	Calcium levels;
LUAD	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg25358565	chr5:93447407	FAM172A	0.61	7.26	0.33	1.85e-12	Diabetic retinopathy;
LUAD	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg13319975	chr6:146136371	FBXO30	-0.59	-9.96	-0.44	3.97e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.15	0.33	3.78e-12	Motion sickness;
LUAD	cis	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg23950597	chr19:37808831	NA	-0.64	-7.57	-0.35	2.43e-13	Coronary artery calcification;
LUAD	cis	rs2282300	0.739	rs10835647	chr11:30313268	A/G	cg06241208	chr11:30344200	C11orf46	-0.58	-7.68	-0.35	1.12e-13	Morning vs. evening chronotype;
LUAD	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg14828511	chr1:107599125	PRMT6	0.59	10.37	0.45	1.3e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4372836	0.504	rs7597048	chr2:29066756	A/G	cg09522027	chr2:28974177	PPP1CB	0.49	8.77	0.39	4.49e-17	Body mass index;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24908708	chr8:95835570	INTS8	-0.58	-6.91	-0.32	1.74e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg21782813	chr7:2030301	MAD1L1	-0.48	-8.3	-0.37	1.38e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg25817165	chr18:72167213	CNDP2	-0.8	-14.05	-0.56	4.57e-37	Refractive error;
LUAD	cis	rs1595825	0.891	rs73054808	chr2:198602283	C/T	cg00361562	chr2:198649771	BOLL	-0.47	-6.58	-0.3	1.37e-10	Ulcerative colitis;
LUAD	cis	rs34638657	0.732	rs11866711	chr16:82201038	A/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.95	-0.32	1.43e-11	Lung adenocarcinoma;
LUAD	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg11822812	chr5:140052017	DND1	-0.44	-7.9	-0.36	2.49e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs829883	0.902	rs829884	chr12:98879500	C/G	cg25150519	chr12:98850993	NA	0.66	10.96	0.47	8.67e-25	Colorectal adenoma (advanced);
LUAD	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg06618935	chr21:46677482	NA	-0.5	-10.01	-0.44	2.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg15133208	chr4:90757351	SNCA	-0.47	-7.23	-0.33	2.23e-12	Neuroticism;
LUAD	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg21775007	chr8:11205619	TDH	0.48	8.25	0.37	2.05e-15	Retinal vascular caliber;
LUAD	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg24450063	chr1:156163899	SLC25A44	1.05	16.88	0.63	3.18e-49	Testicular germ cell tumor;
LUAD	cis	rs2932538	0.961	rs4240534	chr1:113175429	T/A	cg22162597	chr1:113214053	CAPZA1	-0.45	-6.71	-0.31	6.41e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg07570687	chr10:102243282	WNT8B	0.46	7.09	0.33	5.53e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg06873352	chr17:61820015	STRADA	0.53	8.64	0.39	1.15e-16	Height;
LUAD	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg12011299	chr4:100065546	ADH4	-0.71	-13.17	-0.54	1.94e-33	Alcohol dependence;
LUAD	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg06873352	chr17:61820015	STRADA	0.4	6.77	0.31	4.26e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg24579218	chr15:68104479	NA	-0.54	-9.33	-0.41	6.09e-19	Restless legs syndrome;
LUAD	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg09491104	chr22:46646882	C22orf40	-0.74	-13.44	-0.55	1.6e-34	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg27490568	chr2:178487706	NA	0.4	6.68	0.31	7.67e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.55	10.24	0.45	3.98e-22	Axial length;
LUAD	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.5	-0.34	3.79e-13	Type 2 diabetes;
LUAD	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.53e-11	Depression;
LUAD	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03934478	chr11:495069	RNH1	0.76	9.7	0.43	3.33e-20	Body mass index;
LUAD	cis	rs4889855	0.530	rs4890052	chr17:78564245	G/T	cg16591659	chr17:78472290	NA	0.44	7.83	0.36	3.91e-14	Fractional excretion of uric acid;
LUAD	cis	rs367615	0.512	rs246104	chr5:108700982	A/C	cg17395555	chr5:108820864	NA	-0.5	-9.3	-0.41	7.63e-19	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg23260525	chr10:116636907	FAM160B1	0.52	12.16	0.51	2.29e-29	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg13722127	chr7:150037890	RARRES2	0.41	6.64	0.31	9.66e-11	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07989796	chr19:41082579	SHKBP1	-0.67	-6.64	-0.31	9.9e-11	Type 2 diabetes;
LUAD	trans	rs2018683	0.523	rs1499227	chr7:29025615	C/T	cg19402173	chr7:128379420	CALU	-0.43	-6.86	-0.32	2.39e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.57	-10.24	-0.45	4e-22	Longevity;Endometriosis;
LUAD	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg21194808	chr1:2205498	SKI	0.4	6.42	0.3	3.77e-10	Height;
LUAD	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg26769984	chr7:1090371	C7orf50	0.58	9.54	0.42	1.16e-19	Bronchopulmonary dysplasia;
LUAD	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg06608945	chr2:219082296	ARPC2	0.47	8.03	0.36	9.94e-15	Colorectal cancer;
LUAD	trans	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg18335740	chr13:41363409	SLC25A15	0.51	8.49	0.38	3.49e-16	Lewy body disease;
LUAD	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg27219399	chr15:67835830	MAP2K5	-0.39	-6.72	-0.31	6.07e-11	Obesity;
LUAD	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg11344533	chr11:111475393	SIK2	-0.38	-7.0	-0.32	9.89e-12	Primary sclerosing cholangitis;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02235289	chr2:27852069	GPN1;CCDC121	-0.44	-7.52	-0.34	3.34e-13	Cancer;
LUAD	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-12.39	-0.52	2.63e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg18190219	chr22:46762943	CELSR1	-0.59	-6.43	-0.3	3.46e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7937890	0.531	rs2575859	chr11:14510736	C/T	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.25e-11	Mitochondrial DNA levels;
LUAD	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg22753661	chr15:79092743	ADAMTS7	0.52	7.96	0.36	1.62e-14	Coronary artery disease or large artery stroke;
LUAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.9	-0.4	1.6e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.31	6.51	0.3	2.11e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg14345882	chr6:26364793	BTN3A2	0.7	7.17	0.33	3.35e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1509123	0.609	rs75742091	chr17:6703870	C/T	cg12642237	chr17:6703447	TEKT1	-0.51	-7.62	-0.35	1.68e-13	Blood metabolite levels;
LUAD	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg19302996	chr17:73780495	UNK	-0.4	-6.76	-0.31	4.66e-11	White matter hyperintensity burden;
LUAD	trans	rs5756813	0.661	rs7286550	chr22:38196760	G/A	cg19894588	chr14:64061835	NA	-0.54	-7.74	-0.35	7.56e-14	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg21823605	chr1:152486609	CRCT1	0.28	6.42	0.3	3.66e-10	Hair morphology;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23300289	chr9:132146083	NA	-0.46	-7.56	-0.35	2.55e-13	Height;
LUAD	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg12193833	chr17:30244370	NA	-0.58	-7.0	-0.32	1.03e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs2657888	0.593	rs2638318	chr12:56857422	C/T	cg23002907	chr12:56915593	RBMS2	0.42	7.57	0.35	2.39e-13	Adiponectin levels;
LUAD	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg10755058	chr3:40428713	ENTPD3	0.38	7.37	0.34	8.91e-13	Renal cell carcinoma;
LUAD	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg11707310	chr1:2537719	MMEL1	0.4	8.55	0.38	2.24e-16	Ulcerative colitis;
LUAD	cis	rs9972944	0.902	rs9972883	chr17:63771316	C/A	cg07283582	chr17:63770753	CCDC46	0.53	12.07	0.51	4.89e-29	Total body bone mineral density;
LUAD	trans	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg25894440	chr7:65020034	NA	-0.62	-6.56	-0.3	1.58e-10	Diabetic kidney disease;
LUAD	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg08999081	chr20:33150536	PIGU	0.63	14.41	0.57	1.46e-38	Coronary artery disease;
LUAD	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg27661571	chr11:113659931	NA	-0.7	-8.14	-0.37	4.58e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg04414720	chr1:150670196	GOLPH3L	-0.52	-8.11	-0.37	5.43e-15	Tonsillectomy;
LUAD	cis	rs9863	0.898	rs11057400	chr12:124425149	C/T	cg17723958	chr12:124429295	CCDC92	-0.44	-6.99	-0.32	1.09e-11	White blood cell count;
LUAD	trans	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.84	-0.32	2.82e-11	Diabetic kidney disease;
LUAD	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg09835421	chr16:68378352	PRMT7	-0.82	-8.83	-0.39	2.73e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg21775007	chr8:11205619	TDH	0.48	8.6	0.39	1.6e-16	Retinal vascular caliber;
LUAD	cis	rs3760982	0.626	rs12463370	chr19:44292166	G/A	cg11993925	chr19:44307056	LYPD5	0.42	8.16	0.37	3.86e-15	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg02734326	chr4:10020555	SLC2A9	0.63	11.4	0.48	2.02e-26	Bone mineral density;
LUAD	cis	rs420259	0.516	rs120961	chr16:23590302	C/T	cg00143387	chr16:23521605	GGA2	0.7	9.84	0.43	1.08e-20	Bipolar disorder;
LUAD	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg02038168	chr22:39784481	NA	-0.59	-10.28	-0.45	2.74e-22	Intelligence (multi-trait analysis);
LUAD	trans	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg27411982	chr8:10470053	RP1L1	0.39	6.85	0.32	2.69e-11	Morning vs. evening chronotype;
LUAD	cis	rs775227	0.574	rs3732809	chr3:113045561	A/G	cg18753928	chr3:113234510	CCDC52	-0.62	-8.0	-0.36	1.17e-14	Dental caries;
LUAD	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg07606381	chr6:8435919	SLC35B3	0.42	6.78	0.31	3.97e-11	Motion sickness;
LUAD	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-9.1	-0.4	3.69e-18	Bipolar disorder;
LUAD	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg20701182	chr2:24300061	SF3B14	0.89	13.3	0.54	5.5e-34	Lymphocyte counts;
LUAD	trans	rs1941687	0.764	rs1493918	chr18:31381845	C/G	cg27147174	chr7:100797783	AP1S1	-0.51	-8.82	-0.39	3.09e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs11126435	0.858	rs363630	chr2:74933811	T/G	cg19285774	chr2:74907978	SEMA4F	0.37	6.41	0.3	3.79e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1497828	1.000	rs2815225	chr1:217529336	C/T	cg04411442	chr1:217543379	NA	-0.35	-6.53	-0.3	1.91e-10	Dialysis-related mortality;
LUAD	trans	rs9503551	0.584	rs9328160	chr6:3325158	A/G	cg13915676	chr9:139305538	SDCCAG3;PMPCA	0.49	6.6	0.31	1.2e-10	Nicotine dependence;
LUAD	cis	rs220324	0.688	rs915840	chr21:43560871	T/C	cg09727148	chr21:43560719	UMODL1	0.58	8.78	0.39	4.05e-17	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03452623	chr4:187889614	NA	-0.81	-16.45	-0.62	2.42e-47	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18402987	chr7:1209562	NA	0.45	7.43	0.34	6.14e-13	Longevity;Endometriosis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07610776	chr16:1832675	SPSB3;NUBP2	-0.49	-7.57	-0.35	2.41e-13	Height;
LUAD	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg05368731	chr17:41323189	NBR1	0.95	19.3	0.68	5.6899999999999994e-60	Menopause (age at onset);
LUAD	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg22947322	chr17:47091978	IGF2BP1	0.34	6.43	0.3	3.54e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg08885076	chr2:99613938	TSGA10	0.4	7.55	0.34	2.79e-13	Chronic sinus infection;
LUAD	cis	rs13040088	1.000	rs10854167	chr20:61533039	G/C	cg23096297	chr20:61557774	DIDO1	0.74	10.47	0.45	5.56e-23	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.34e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg19302996	chr17:73780495	UNK	-0.4	-6.72	-0.31	6.06e-11	White matter hyperintensity burden;
LUAD	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg21724239	chr8:58056113	NA	0.63	7.99	0.36	1.33e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg12568669	chr8:11666485	FDFT1	-0.24	-6.59	-0.31	1.32e-10	Morning vs. evening chronotype;
LUAD	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg26384229	chr12:38710491	ALG10B	0.49	7.99	0.36	1.33e-14	Bladder cancer;
LUAD	cis	rs10129255	0.556	rs6576224	chr14:107186236	G/A	cg23076370	chr14:107095027	NA	-0.44	-8.68	-0.39	8.54e-17	Kawasaki disease;
LUAD	trans	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg07211511	chr3:129823064	LOC729375	-0.56	-7.62	-0.35	1.69e-13	Blood pressure (smoking interaction);
LUAD	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg02423579	chr7:2872169	GNA12	-0.83	-14.62	-0.58	1.83e-39	Height;
LUAD	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-9.95	-0.44	4.42e-21	Schizophrenia;
LUAD	cis	rs16921914	0.559	rs2985140	chr11:31315886	C/T	cg26647111	chr11:31128758	NA	0.46	8.01	0.36	1.15e-14	Bone mineral density (spine);
LUAD	cis	rs2692947	0.770	rs72492163	chr2:96417816	G/A	cg23100626	chr2:96804247	ASTL	0.32	7.7	0.35	9.56e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg19163074	chr7:65112434	INTS4L2	0.44	6.73	0.31	5.45e-11	Aortic root size;
LUAD	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg11965913	chr1:205819406	PM20D1	-0.41	-6.57	-0.3	1.46e-10	Prostate-specific antigen levels;
LUAD	cis	rs7474896	0.537	rs2749589	chr10:38266870	C/T	cg25427524	chr10:38739819	LOC399744	0.62	8.86	0.4	2.28e-17	Obesity (extreme);
LUAD	cis	rs490234	0.702	rs7864945	chr9:128373469	C/T	cg14078157	chr9:128172775	NA	-0.47	-8.36	-0.38	9.4e-16	Mean arterial pressure;
LUAD	trans	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg07211511	chr3:129823064	LOC729375	-0.49	-6.38	-0.3	4.58e-10	Blood pressure (smoking interaction);
LUAD	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg11845111	chr2:191398756	TMEM194B	-0.87	-10.96	-0.47	8.87e-25	Diastolic blood pressure;
LUAD	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg18225595	chr11:63971243	STIP1	0.46	7.83	0.36	3.88e-14	Platelet count;
LUAD	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12756686	chr19:29218302	NA	0.67	9.8	0.43	1.39e-20	Methadone dose in opioid dependence;
LUAD	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg03929089	chr4:120376271	NA	-0.74	-12.14	-0.51	2.62e-29	Coronary artery disease;
LUAD	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21659725	chr3:3221576	CRBN	0.63	10.85	0.47	2.32e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.7	0.31	6.54e-11	Platelet count;
LUAD	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg10792982	chr14:105748885	BRF1	0.42	9.24	0.41	1.22e-18	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg10591111	chr5:226296	SDHA	-0.55	-7.14	-0.33	4.05e-12	Breast cancer;
LUAD	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg10295955	chr4:187884368	NA	-1.14	-28.09	-0.81	9.64e-99	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg00666640	chr1:248458726	OR2T12	0.31	7.6	0.35	1.94e-13	Common traits (Other);
LUAD	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.39	0.34	7.92e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg24818145	chr4:99064322	C4orf37	0.47	7.99	0.36	1.29e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs938554	0.876	rs10017945	chr4:9937852	A/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-7.13	-0.33	4.25e-12	Blood metabolite levels;
LUAD	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg24558204	chr6:135376177	HBS1L	0.49	9.08	0.4	4.18e-18	Red blood cell count;
LUAD	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg07776626	chr8:57350775	NA	-0.61	-9.04	-0.4	5.77e-18	Obesity-related traits;
LUAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.91e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.65	0.35	1.37e-13	Resting heart rate;
LUAD	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg06640241	chr16:89574553	SPG7	0.48	7.8	0.35	4.88e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs7814319	0.933	rs7002575	chr8:97242124	G/A	cg20787634	chr8:97240163	UQCRB	-0.39	-7.65	-0.35	1.35e-13	Lung function (FVC);
LUAD	cis	rs7289126	1.000	rs7289126	chr22:38628306	A/C	cg17652424	chr22:38574118	PLA2G6	0.25	7.14	0.33	4.11e-12	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.9	-0.32	1.96e-11	Bipolar disorder;
LUAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg17328964	chr8:145687451	CYHR1	0.41	6.88	0.32	2.23e-11	Age at first birth;
LUAD	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.84e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs870825	0.616	rs1401360	chr4:185643571	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.03	0.56	5.61e-37	Blood protein levels;
LUAD	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg19635926	chr16:89946313	TCF25	0.74	6.53	0.3	1.91e-10	Skin colour saturation;
LUAD	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg05865280	chr17:75406074	SEPT9	0.62	19.84	0.69	2.07e-62	Airflow obstruction;
LUAD	cis	rs7771547	0.519	rs9654588	chr6:36363923	A/C	cg02952361	chr6:36355661	ETV7	0.46	6.69	0.31	7.23e-11	Platelet distribution width;
LUAD	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg24803719	chr17:45855879	NA	0.33	7.4	0.34	7.27e-13	IgG glycosylation;
LUAD	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg26384229	chr12:38710491	ALG10B	0.42	6.98	0.32	1.14e-11	Morning vs. evening chronotype;
LUAD	cis	rs9807989	0.507	rs1035129	chr2:103019785	T/C	cg03938978	chr2:103052716	IL18RAP	0.45	10.29	0.45	2.54e-22	Asthma;
LUAD	cis	rs735539	0.521	rs2762989	chr13:21392521	C/G	cg27499820	chr13:21296301	IL17D	0.51	7.55	0.34	2.72e-13	Dental caries;
LUAD	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg09835421	chr16:68378352	PRMT7	-1.01	-11.37	-0.48	2.47e-26	Schizophrenia;
LUAD	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg14092988	chr3:52407081	DNAH1	0.44	8.97	0.4	9.48e-18	Bipolar disorder;
LUAD	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg16647868	chr5:131706066	SLC22A5	-0.51	-8.14	-0.37	4.5e-15	Blood metabolite levels;
LUAD	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06112835	chr11:68658793	MRPL21	0.51	9.09	0.4	4e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.6	0.35	1.93e-13	Cannabis dependence symptom count;
LUAD	cis	rs11166629	0.883	rs11778878	chr8:135599220	C/T	cg27224718	chr8:135614730	ZFAT	-0.45	-7.61	-0.35	1.82e-13	Smoking quantity;
LUAD	cis	rs6484504	0.576	rs9971609	chr11:31434104	C/T	cg14844989	chr11:31128820	NA	0.45	8.05	0.36	8.51e-15	Red blood cell count;
LUAD	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	9.92	0.43	5.4e-21	Electrocardiographic conduction measures;
LUAD	cis	rs13315871	1.000	rs4367085	chr3:58389235	A/G	cg12435725	chr3:58293450	RPP14	-0.67	-7.36	-0.34	9.57e-13	Cholesterol, total;
LUAD	trans	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.5	-8.0	-0.36	1.18e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs2270927	1.000	rs13174383	chr5:75580416	T/G	cg13563193	chr19:33072644	PDCD5	0.92	9.19	0.41	1.73e-18	Mean corpuscular volume;
LUAD	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg21191810	chr6:118973309	C6orf204	-0.52	-8.17	-0.37	3.68e-15	Diastolic blood pressure;
LUAD	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6445967	0.530	rs12497256	chr3:58408353	G/A	cg23715586	chr3:58305044	RPP14	0.41	6.75	0.31	5.04e-11	Platelet count;
LUAD	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg00129232	chr17:37814104	STARD3	-0.45	-7.49	-0.34	3.99e-13	Asthma;
LUAD	cis	rs16850073	0.524	rs2367289	chr4:74715281	A/T	cg01447579	chr4:74847100	PF4	0.37	6.36	0.3	5.22e-10	Granulocyte percentage of myeloid white cells;Blood protein levels;Monocyte percentage of white cells;Sum neutrophil eosinophil counts;White blood cell count;
LUAD	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg11050988	chr7:1952600	MAD1L1	-0.38	-7.77	-0.35	6.01e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs67981189	0.896	rs2158997	chr14:71497794	C/G	cg15816911	chr14:71606274	NA	-0.36	-6.56	-0.3	1.58e-10	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg05340658	chr4:99064831	C4orf37	0.53	9.07	0.4	4.46e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3956705	1.000	rs2392158	chr7:32980203	G/A	cg05721444	chr7:32995514	FKBP9	-0.37	-6.45	-0.3	3e-10	Red cell distribution width;
LUAD	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg00784671	chr22:46762841	CELSR1	-0.43	-6.69	-0.31	7.18e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs55788414	0.725	rs55634380	chr16:81188793	T/G	cg06400318	chr16:81190750	PKD1L2	-0.76	-10.06	-0.44	1.67e-21	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg23625390	chr15:77176239	SCAPER	-0.56	-9.07	-0.4	4.62e-18	Blood metabolite levels;
LUAD	cis	rs6496044	0.548	rs7163032	chr15:86072419	T/A	cg13263323	chr15:86062960	AKAP13	-0.57	-10.72	-0.46	7.08e-24	Interstitial lung disease;
LUAD	trans	rs75804782	0.630	rs55762325	chr2:239250723	A/G	cg01134436	chr17:81009848	B3GNTL1	0.77	6.81	0.31	3.43e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg02782426	chr3:40428986	ENTPD3	0.35	7.5	0.34	3.66e-13	Renal cell carcinoma;
LUAD	cis	rs6138458	1.000	rs2387361	chr20:24899905	C/T	cg26195577	chr20:24973756	C20orf3	-0.96	-16.03	-0.61	1.65e-45	Blood protein levels;
LUAD	cis	rs9972944	0.651	rs7221371	chr17:63765174	C/A	cg07283582	chr17:63770753	CCDC46	-0.5	-11.18	-0.48	1.28e-25	Total body bone mineral density;
LUAD	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg12119029	chr16:89752879	CDK10	0.34	7.49	0.34	3.99e-13	Hemoglobin concentration;
LUAD	cis	rs59918340	0.509	rs11784862	chr8:142203452	T/C	cg23750338	chr8:142222470	SLC45A4	0.51	9.99	0.44	3.17e-21	Immature fraction of reticulocytes;
LUAD	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg00277334	chr10:82204260	NA	-0.44	-7.33	-0.34	1.16e-12	Post bronchodilator FEV1;
LUAD	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg17063962	chr7:91808500	NA	0.64	10.93	0.47	1.12e-24	Breast cancer;
LUAD	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg24733560	chr20:60626293	TAF4	0.45	8.63	0.39	1.21e-16	Body mass index;
LUAD	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg17372223	chr3:52568218	NT5DC2	0.39	7.07	0.33	6.44e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg08632164	chr7:65971372	NA	-0.54	-6.42	-0.3	3.69e-10	Diabetic kidney disease;
LUAD	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.26	-6.7	-0.31	6.77e-11	Total body bone mineral density;
LUAD	cis	rs4660214	0.666	rs950805	chr1:39705458	A/C	cg27567593	chr1:39956653	BMP8A	0.35	6.86	0.32	2.46e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg26384229	chr12:38710491	ALG10B	-0.41	-7.05	-0.32	7.11e-12	Heart rate;
LUAD	cis	rs6076065	0.723	rs2253924	chr20:23388020	G/A	cg11657817	chr20:23433608	CST11	0.46	8.78	0.39	3.94e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg06064525	chr11:970664	AP2A2	0.54	11.19	0.48	1.28e-25	Alzheimer's disease (late onset);
LUAD	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.61	0.35	1.81e-13	Breast cancer;
LUAD	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg07343612	chr16:622815	PIGQ	-0.79	-15.58	-0.6	1.46e-43	Height;
LUAD	cis	rs877282	0.853	rs10904545	chr10:757100	G/A	cg06581033	chr10:766294	NA	-0.56	-7.21	-0.33	2.57e-12	Uric acid levels;
LUAD	cis	rs4698036	0.601	rs4698050	chr4:10410748	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.24	-0.33	2.13e-12	Cardiovascular disease risk factors;
LUAD	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg18171855	chr10:2543474	NA	0.45	8.33	0.38	1.1e-15	Age-related hearing impairment;
LUAD	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	7.44	0.34	5.75e-13	Schizophrenia;
LUAD	trans	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg02030672	chr11:45687055	CHST1	-0.37	-6.58	-0.3	1.36e-10	Obesity-related traits;
LUAD	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg02569458	chr12:86230093	RASSF9	-0.42	-7.72	-0.35	8.32e-14	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg02931644	chr1:25747376	RHCE	0.42	8.53	0.38	2.69e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg06784218	chr1:46089804	CCDC17	0.59	13.23	0.54	1.08e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg18477163	chr1:228402036	OBSCN	0.38	7.02	0.32	9.09e-12	Diastolic blood pressure;
LUAD	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg07936489	chr17:37558343	FBXL20	-0.46	-6.95	-0.32	1.43e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg04731861	chr2:219085781	ARPC2	-0.24	-7.31	-0.33	1.34e-12	Colorectal cancer;
LUAD	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg16479474	chr6:28041457	NA	0.44	7.45	0.34	5.43e-13	Depression;
LUAD	cis	rs8060686	0.516	rs8048365	chr16:68253326	T/A	cg09835421	chr16:68378352	PRMT7	-0.52	-6.57	-0.3	1.5e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg18252515	chr7:66147081	NA	-0.61	-6.75	-0.31	4.99e-11	Diabetic kidney disease;
LUAD	cis	rs698833	0.501	rs35347977	chr2:44506921	C/T	cg04920474	chr2:44395004	PPM1B	0.53	10.06	0.44	1.75e-21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg03676636	chr4:99064102	C4orf37	0.32	8.39	0.38	7.2e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg03526776	chr6:41159608	TREML2	0.34	7.25	0.33	1.94e-12	Alzheimer's disease (late onset);
LUAD	cis	rs727505	1.000	rs10240673	chr7:124513050	A/G	cg23710748	chr7:124431027	NA	-0.47	-9.56	-0.42	9.77e-20	Lewy body disease;
LUAD	cis	rs1011018	0.628	rs1015121	chr7:139455384	T/C	cg26515926	chr7:139453581	HIPK2	-0.49	-6.39	-0.3	4.45e-10	Systolic blood pressure;
LUAD	cis	rs9430161	0.644	rs6685766	chr1:11037051	T/C	cg02454025	chr1:11042201	C1orf127	0.98	16.69	0.63	2.13e-48	Ewing sarcoma;
LUAD	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs56283067	0.887	rs12198016	chr6:44771708	C/T	cg18551225	chr6:44695536	NA	-0.57	-8.55	-0.38	2.34e-16	Total body bone mineral density;
LUAD	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg08798685	chr6:27730294	NA	-0.69	-7.3	-0.33	1.46e-12	Depression;
LUAD	cis	rs11811982	0.793	rs116657151	chr1:227530925	A/G	cg24860534	chr1:227506868	CDC42BPA	0.7	7.61	0.35	1.79e-13	Optic disc area;
LUAD	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg20503657	chr10:835505	NA	1.24	18.15	0.66	7.7e-55	Eosinophil percentage of granulocytes;
LUAD	cis	rs7582720	1.000	rs72932558	chr2:203847325	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.64	0.42	5.27e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg05865280	chr17:75406074	SEPT9	0.61	19.3	0.68	5.44e-60	Airflow obstruction;
LUAD	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg21856205	chr7:94953877	PON1	-0.55	-7.87	-0.36	3.04e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg13319975	chr6:146136371	FBXO30	-0.59	-9.91	-0.43	5.68e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg10518543	chr12:38710700	ALG10B	0.44	7.41	0.34	6.73e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs807669	0.548	rs885979	chr22:19198375	T/C	cg24911827	chr22:19170109	CLTCL1	0.33	6.94	0.32	1.49e-11	Metabolite levels;
LUAD	cis	rs3772130	0.583	rs11710169	chr3:121426655	A/G	cg20356878	chr3:121714668	ILDR1	0.6	11.37	0.48	2.61e-26	Cognitive performance;
LUAD	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg26384229	chr12:38710491	ALG10B	0.41	6.51	0.3	2.16e-10	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.23e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg16797656	chr11:68205561	LRP5	-0.38	-7.11	-0.33	4.84e-12	Bone mineral density (spine);
LUAD	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.82e-23	Post bronchodilator FEV1;
LUAD	cis	rs9486719	0.894	rs34826652	chr6:96899085	A/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.14	-0.44	8.67e-22	Migraine;Coronary artery disease;
LUAD	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg01416388	chr22:39784598	NA	-0.53	-9.02	-0.4	6.61e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7274811	0.554	rs35556109	chr20:32133489	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.48	-7.02	-0.32	9.05e-12	Height;
LUAD	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg00316803	chr15:76480434	C15orf27	0.41	6.49	0.3	2.41e-10	Blood metabolite levels;
LUAD	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg21862992	chr11:68658383	NA	0.52	9.42	0.42	2.94e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg17366294	chr4:99064904	C4orf37	0.65	12.64	0.52	2.71e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.33	-0.45	1.8e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg06627628	chr2:24431161	ITSN2	-0.7	-11.09	-0.47	2.84e-25	Asthma;
LUAD	cis	rs89107	0.688	rs283091	chr6:118588684	A/G	cg18833306	chr6:118973337	C6orf204	-0.51	-9.42	-0.42	2.88e-19	Cardiac structure and function;
LUAD	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.42	0.52	1.99e-30	Tonsillectomy;
LUAD	cis	rs17655565	1.000	rs73309373	chr12:52701409	C/T	cg08257133	chr12:52711352	KRT83	0.4	6.96	0.32	1.31e-11	Plasma amyloid beta peptide concentrations (ABx-42);
LUAD	trans	rs264537	0.565	rs1816957	chr3:76703866	G/T	cg18884271	chr12:65641969	LEMD3	0.4	6.54	0.3	1.76e-10	Periodontitis (PAL4Q3);
LUAD	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg11909912	chr17:43974919	MAPT;LOC100130148	0.39	6.62	0.31	1.1e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg16325326	chr1:53192061	ZYG11B	-0.51	-7.89	-0.36	2.62e-14	Monocyte count;
LUAD	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs684232	0.644	rs2543781	chr17:602469	C/G	cg12384639	chr17:618140	VPS53	0.49	8.7	0.39	7.34e-17	Prostate cancer;
LUAD	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg09021430	chr5:549028	NA	0.48	12.13	0.51	2.92e-29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg05132306	chr1:1846340	CALML6	-0.35	-7.27	-0.33	1.72e-12	Body mass index;
LUAD	cis	rs12368653	0.583	rs7952989	chr12:58095989	T/C	cg12615879	chr12:58013172	SLC26A10	0.52	11.06	0.47	3.93e-25	Multiple sclerosis;
LUAD	trans	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg06606381	chr12:133084897	FBRSL1	-1.15	-9.48	-0.42	1.85e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs250677	0.522	rs919730	chr5:148352401	T/C	cg12140854	chr5:148520817	ABLIM3	0.56	8.43	0.38	5.55e-16	Breast cancer;
LUAD	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg25208724	chr1:156163844	SLC25A44	0.98	15.05	0.59	2.61e-41	Testicular germ cell tumor;
LUAD	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg14664628	chr15:75095509	CSK	0.59	9.52	0.42	1.36e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg09911534	chr15:67153556	NA	0.46	6.75	0.31	4.89e-11	Lung cancer (smoking interaction);
LUAD	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg02975922	chr3:195473998	MUC4	-0.46	-7.4	-0.34	7.19e-13	Pancreatic cancer;
LUAD	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.72	-8.76	-0.39	4.86e-17	Ankle injury;
LUAD	cis	rs9768139	0.658	rs73746486	chr7:158113191	A/G	cg25566285	chr7:158114605	PTPRN2	0.49	10.23	0.45	4.44e-22	Calcium levels;
LUAD	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg21823605	chr1:152486609	CRCT1	0.29	6.66	0.31	8.42e-11	Hair morphology;
LUAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06873352	chr17:61820015	STRADA	0.82	18.34	0.67	1.09e-55	Prudent dietary pattern;
LUAD	trans	rs12517041	1.000	rs71611220	chr5:23281005	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.46	-0.3	2.82e-10	Calcium levels;
LUAD	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10802521	chr3:52805072	NEK4	-0.61	-11.16	-0.48	1.59e-25	Bipolar disorder;
LUAD	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg08029281	chr1:67600428	NA	0.37	7.41	0.34	6.76e-13	Psoriasis;
LUAD	cis	rs68170813	0.521	rs75035695	chr7:106818731	T/C	cg23024343	chr7:107201750	COG5	0.49	7.09	0.33	5.65e-12	Coronary artery disease;
LUAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg07157834	chr1:205819609	PM20D1	-0.47	-7.63	-0.35	1.54e-13	Parkinson's disease;
LUAD	cis	rs4790333	0.537	rs2447106	chr17:2257819	A/T	cg02569219	chr17:2266849	SGSM2	-0.52	-10.01	-0.44	2.66e-21	Proinsulin levels;
LUAD	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg05966235	chr16:28915196	ATP2A1	0.46	7.48	0.34	4.21e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg08508325	chr11:3079039	CARS	0.44	9.16	0.41	2.3e-18	Calcium levels;
LUAD	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg13699009	chr12:122356056	WDR66	-0.3	-6.64	-0.31	9.53e-11	Mean corpuscular volume;
LUAD	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	7.34	0.34	1.1e-12	Platelet count;
LUAD	cis	rs10203711	1.000	rs907113	chr2:239567724	T/C	cg14580085	chr2:239553406	NA	0.41	8.9	0.4	1.64e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg24733560	chr20:60626293	TAF4	0.39	7.54	0.34	2.99e-13	Body mass index;
LUAD	cis	rs9902453	0.874	rs11653805	chr17:28378276	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.53	-0.46	3.46e-23	Coffee consumption (cups per day);
LUAD	cis	rs7084921	0.608	rs2862950	chr10:101844785	A/G	cg19754520	chr10:101825118	CPN1	-0.35	-7.08	-0.33	5.91e-12	Bone mineral density;
LUAD	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg06740227	chr12:86229804	RASSF9	0.47	8.25	0.37	2.09e-15	Major depressive disorder;
LUAD	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg00074818	chr8:8560427	CLDN23	0.66	10.13	0.44	9.68e-22	Obesity-related traits;
LUAD	cis	rs6842047	0.563	rs10025990	chr4:187146258	T/C	cg23442198	chr4:187126114	CYP4V2	0.96	9.43	0.42	2.79e-19	Blood protein levels;
LUAD	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg05616858	chr17:37843591	ERBB2;PGAP3	0.34	6.7	0.31	6.82e-11	Asthma;
LUAD	cis	rs1865721	1.000	rs17283454	chr18:73186619	G/A	cg26385618	chr18:73139727	C18orf62	-0.42	-7.74	-0.35	7.17e-14	Intelligence;
LUAD	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg10591111	chr5:226296	SDHA	0.57	7.16	0.33	3.7e-12	Breast cancer;
LUAD	trans	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg26811252	chr16:29126840	RRN3P2	0.6	10.29	0.45	2.64e-22	Menopause (age at onset);
LUAD	cis	rs240764	0.604	rs9373590	chr6:101212001	A/T	cg09795085	chr6:101329169	ASCC3	0.4	6.87	0.32	2.37e-11	Neuroticism;
LUAD	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg07570687	chr10:102243282	WNT8B	0.45	7.04	0.32	7.59e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs12579753	0.917	rs11115032	chr12:82205073	T/C	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.29	-0.33	1.59e-12	Resting heart rate;
LUAD	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg26384229	chr12:38710491	ALG10B	-0.47	-8.0	-0.36	1.22e-14	Morning vs. evening chronotype;
LUAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg26516362	chr5:178986906	RUFY1	-0.68	-12.1	-0.51	3.93e-29	Lung cancer;
LUAD	cis	rs7582720	1.000	rs72936304	chr2:204036357	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.44	0.42	2.48e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6005807	0.719	rs2881496	chr22:28921265	C/G	cg12565055	chr22:29076175	TTC28	-0.72	-8.42	-0.38	6e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs1215050	0.791	rs684210	chr4:98678740	G/C	cg24818145	chr4:99064322	C4orf37	0.41	6.77	0.31	4.2e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg09796270	chr17:17721594	SREBF1	0.37	7.53	0.34	3.2e-13	Total body bone mineral density;
LUAD	cis	rs501916	0.796	rs628501	chr15:48027328	C/G	cg16110827	chr15:48056943	SEMA6D	-0.37	-6.66	-0.31	8.42e-11	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg23229984	chr5:148520753	ABLIM3	0.47	6.72	0.31	6.01e-11	Breast cancer;
LUAD	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26314531	chr2:26401878	FAM59B	-0.64	-8.69	-0.39	8.09e-17	Gut microbiome composition (summer);
LUAD	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg15704280	chr7:45808275	SEPT13	-0.91	-16.7	-0.63	1.9e-48	Height;
LUAD	cis	rs12541635	0.902	rs13277300	chr8:107062819	C/T	cg10147462	chr8:107024639	NA	-0.45	-8.08	-0.37	6.64e-15	Age of smoking initiation;
LUAD	cis	rs89107	0.576	rs78757409	chr6:118789259	C/T	cg21191810	chr6:118973309	C6orf204	0.41	7.55	0.34	2.7e-13	Cardiac structure and function;
LUAD	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg02782426	chr3:40428986	ENTPD3	0.43	9.26	0.41	1.02e-18	Renal cell carcinoma;
LUAD	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg21775007	chr8:11205619	TDH	-0.51	-9.19	-0.41	1.75e-18	Retinal vascular caliber;
LUAD	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02018176	chr4:1364513	KIAA1530	0.7	12.29	0.51	6.55e-30	Longevity;
LUAD	cis	rs1865721	1.000	rs17284077	chr18:73204128	C/T	cg26385618	chr18:73139727	C18orf62	-0.4	-7.32	-0.34	1.3e-12	Intelligence;
LUAD	cis	rs7193541	0.684	rs9931225	chr16:74699293	T/C	cg01733217	chr16:74700730	RFWD3	0.69	13.24	0.54	9.74e-34	Multiple myeloma;
LUAD	cis	rs35883536	1.000	rs3861733	chr1:101111807	G/A	cg06223162	chr1:101003688	GPR88	0.35	6.57	0.3	1.52e-10	Monocyte count;
LUAD	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg14668632	chr7:2872130	GNA12	-0.49	-8.78	-0.39	4.11e-17	Height;
LUAD	cis	rs9512730	0.911	rs4142420	chr13:28068442	A/G	cg04070771	chr13:27998621	GTF3A	0.45	6.65	0.31	9.16e-11	Schizophrenia;
LUAD	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.41	6.67	0.31	7.85e-11	Multiple sclerosis;
LUAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg05434287	chr7:2030229	MAD1L1	0.4	6.67	0.31	8.04e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg18876405	chr7:65276391	NA	0.44	7.37	0.34	9.26e-13	Calcium levels;
LUAD	cis	rs11214589	0.651	rs12360992	chr11:113262900	A/C	cg14159747	chr11:113255604	NA	0.66	13.77	0.56	6.41e-36	Neuroticism;
LUAD	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg11266682	chr4:10021025	SLC2A9	0.69	15.76	0.61	2.29e-44	Bone mineral density;
LUAD	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg07636037	chr3:49044803	WDR6	-0.36	-6.43	-0.3	3.54e-10	Resting heart rate;
LUAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg26338869	chr17:61819248	STRADA	-0.39	-6.46	-0.3	2.86e-10	Prudent dietary pattern;
LUAD	cis	rs9653442	0.675	rs961788	chr2:100641459	T/C	cg22139774	chr2:100720529	AFF3	-0.35	-6.8	-0.31	3.69e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	12.64	0.52	2.73e-31	Monocyte percentage of white cells;
LUAD	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg22868518	chr11:507468	RNH1	-0.65	-6.42	-0.3	3.77e-10	Body mass index;
LUAD	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg13319975	chr6:146136371	FBXO30	0.56	9.37	0.41	4.26e-19	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.47	0.34	4.76e-13	Resting heart rate;
LUAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg27094323	chr7:1216898	NA	-0.37	-6.72	-0.31	5.89e-11	Longevity;Endometriosis;
LUAD	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.87	-0.36	2.91e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs731174	0.802	rs631102	chr1:38178836	C/T	cg06917450	chr1:38156652	C1orf109	-0.41	-6.4	-0.3	4.18e-10	Prostate cancer (SNP x SNP interaction);
LUAD	trans	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg21659725	chr3:3221576	CRBN	0.4	6.71	0.31	6.2e-11	Resting heart rate;
LUAD	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg09455208	chr3:40491958	NA	0.65	13.94	0.56	1.35e-36	Renal cell carcinoma;
LUAD	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg22029157	chr1:209979665	IRF6	0.78	11.53	0.49	5.97e-27	Cleft lip with or without cleft palate;
LUAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg24101359	chr6:42928495	GNMT	0.47	8.67	0.39	9.11e-17	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26314531	chr2:26401878	FAM59B	0.73	9.78	0.43	1.66e-20	Gut microbiome composition (summer);
LUAD	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.16	-0.37	3.93e-15	Prostate cancer;
LUAD	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg19875535	chr5:140030758	IK	0.45	7.45	0.34	5.43e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg10589385	chr1:150898437	SETDB1	0.45	8.44	0.38	5.11e-16	Melanoma;
LUAD	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg06697600	chr4:7070879	GRPEL1	-0.54	-8.89	-0.4	1.83e-17	Monocyte percentage of white cells;
LUAD	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg22491629	chr6:157744540	C6orf35	-0.81	-9.37	-0.41	4.22e-19	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.61	-11.53	-0.49	6e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.59	0.52	4.48e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs78049276	0.688	rs73855809	chr4:148380348	G/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.62	-7.19	-0.33	3.03e-12	Pulse pressure;
LUAD	cis	rs72928364	1.000	rs62273925	chr3:100641795	T/C	cg10123952	chr3:100791384	NA	0.64	7.28	0.33	1.63e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg00530320	chr1:46809349	NSUN4	0.51	7.86	0.36	3.16e-14	Menopause (age at onset);
LUAD	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg22875332	chr1:76189707	ACADM	0.84	16.83	0.63	4.9e-49	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	7.36	0.34	9.69e-13	Parkinson's disease;
LUAD	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.37	0.38	8.27e-16	Platelet count;
LUAD	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg08422745	chr4:174089978	GALNT7	-0.96	-18.05	-0.66	2.05e-54	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg03188948	chr7:1209495	NA	0.66	9.71	0.43	2.97e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg22875332	chr1:76189707	ACADM	0.8	14.75	0.58	5.12e-40	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs35883536	1.000	rs1610387	chr1:101123943	T/G	cg06223162	chr1:101003688	GPR88	0.37	6.84	0.32	2.83e-11	Monocyte count;
LUAD	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg26677194	chr12:130822605	PIWIL1	0.55	9.04	0.4	5.6e-18	Menopause (age at onset);
LUAD	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg23229984	chr5:148520753	ABLIM3	0.5	7.85	0.36	3.45e-14	Breast cancer;
LUAD	cis	rs12472274	0.536	rs12619455	chr2:239080149	A/C	cg17459225	chr2:239074497	NA	0.61	6.89	0.32	2.05e-11	Phospholipid levels (plasma);
LUAD	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg27494647	chr7:150038898	RARRES2	0.43	7.26	0.33	1.89e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg09201001	chr11:18656081	SPTY2D1	0.37	6.36	0.3	5.19e-10	Breast cancer;
LUAD	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg11502198	chr6:26597334	ABT1	0.56	9.32	0.41	6.74e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs2548003	0.518	rs2554904	chr5:28726189	T/A	cg22863700	chr5:28928346	NA	0.44	6.54	0.3	1.81e-10	Hip geometry;
LUAD	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg11062466	chr8:58055876	NA	0.65	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg06636551	chr8:101224915	SPAG1	-0.37	-6.68	-0.31	7.67e-11	Atrioventricular conduction;
LUAD	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg06484146	chr7:12443880	VWDE	-0.59	-7.62	-0.35	1.72e-13	Coronary artery disease;
LUAD	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg02038168	chr22:39784481	NA	-0.54	-8.52	-0.38	2.74e-16	Post bronchodilator FEV1;
LUAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg19626725	chr5:178986131	RUFY1	-0.48	-8.82	-0.39	3e-17	Lung cancer;
LUAD	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg10253484	chr15:75165896	SCAMP2	-0.41	-6.46	-0.3	2.85e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs28595532	0.920	rs115317002	chr4:119722809	T/C	cg14228332	chr4:119757509	SEC24D	0.91	8.44	0.38	5.18e-16	Cannabis dependence symptom count;
LUAD	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg11247378	chr22:39784982	NA	-0.74	-13.9	-0.56	1.94e-36	Intelligence (multi-trait analysis);
LUAD	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18099408	chr3:52552593	STAB1	-0.39	-7.03	-0.32	8.58e-12	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg21214613	chr1:16344536	HSPB7	0.62	11.96	0.5	1.37e-28	Systolic blood pressure;
LUAD	cis	rs7246657	0.943	rs2045908	chr19:37979768	C/G	cg23950597	chr19:37808831	NA	-0.59	-7.38	-0.34	8.43e-13	Coronary artery calcification;
LUAD	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26314531	chr2:26401878	FAM59B	-0.59	-8.21	-0.37	2.66e-15	Gut microbiome composition (summer);
LUAD	cis	rs4888262	0.508	rs6564153	chr16:74658723	A/C	cg01733217	chr16:74700730	RFWD3	0.49	7.92	0.36	2.08e-14	Testicular germ cell tumor;
LUAD	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg03859395	chr2:55845619	SMEK2	0.75	13.89	0.56	2.02e-36	Metabolic syndrome;
LUAD	cis	rs1957429	0.901	rs1467570	chr14:65347858	A/G	cg23373153	chr14:65346875	NA	0.55	6.45	0.3	2.99e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg11266682	chr4:10021025	SLC2A9	-0.6	-12.99	-0.53	1.04e-32	Bone mineral density;
LUAD	cis	rs62400317	0.859	rs1324536	chr6:45116261	C/T	cg20913747	chr6:44695427	NA	0.41	6.77	0.31	4.43e-11	Total body bone mineral density;
LUAD	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg04369109	chr6:150039330	LATS1	-0.44	-7.21	-0.33	2.67e-12	Lung cancer;
LUAD	cis	rs3736594	0.918	rs12471347	chr2:27981655	G/C	cg27432699	chr2:27873401	GPN1	0.44	6.66	0.31	8.49e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg01579765	chr21:45077557	HSF2BP	-0.59	-13.39	-0.55	2.57e-34	Mean corpuscular volume;
LUAD	cis	rs3806843	0.548	rs246055	chr5:140325662	C/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs863345	0.565	rs59188837	chr1:158500636	C/G	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg14558114	chr2:88469736	THNSL2	-0.41	-6.48	-0.3	2.55e-10	Response to metformin (IC50);
LUAD	cis	rs4493873	0.840	rs11786324	chr8:92090573	G/C	cg16814680	chr8:91681699	NA	0.41	6.62	0.31	1.12e-10	Migraine - clinic-based;
LUAD	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg12445461	chr9:6681608	NA	0.41	6.41	0.3	3.79e-10	Bilirubin levels;
LUAD	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.74	-0.31	5.24e-11	Diabetic kidney disease;
LUAD	trans	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg16011800	chr17:1958478	HIC1	-0.57	-7.84	-0.36	3.68e-14	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg04727924	chr7:799746	HEATR2	-0.53	-7.19	-0.33	2.93e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs2286885	1.000	rs10733679	chr9:129242416	C/T	cg15282417	chr9:129245246	FAM125B	0.43	8.79	0.39	3.71e-17	Intraocular pressure;
LUAD	cis	rs10489202	0.632	rs202259	chr1:167962072	G/A	cg25738037	chr1:168025549	DCAF6	-0.5	-7.45	-0.34	5.33e-13	Schizophrenia;
LUAD	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg09222892	chr1:25734099	RHCE	-0.5	-9.17	-0.41	2.15e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg18138036	chr10:133769891	PPP2R2D	0.42	6.82	0.31	3.25e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg07217954	chr7:1067459	C7orf50	0.39	6.47	0.3	2.66e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg11693508	chr17:37793320	STARD3	0.72	9.39	0.42	3.83e-19	Bipolar disorder;
LUAD	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.63	8.71	0.39	6.7e-17	Renal function-related traits (BUN);
LUAD	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg09455208	chr3:40491958	NA	0.52	10.85	0.47	2.22e-24	Renal cell carcinoma;
LUAD	trans	rs3857536	0.813	rs6903411	chr6:66938288	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg03188948	chr7:1209495	NA	0.39	6.37	0.3	4.88e-10	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.06	-26.88	-0.79	1.5e-93	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs991427	1.000	rs17018691	chr12:91473900	A/C	cg11428724	chr1:18957632	PAX7	0.42	6.49	0.3	2.37e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.98	0.53	1.11e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12210905	0.688	rs72845031	chr6:27535404	C/T	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg01324343	chr3:183735012	ABCC5	0.63	12.23	0.51	1.12e-29	Anterior chamber depth;
LUAD	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg02221422	chr11:68192511	LRP5	0.39	6.56	0.3	1.59e-10	Total body bone mineral density;
LUAD	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg18230493	chr5:56204884	C5orf35	-0.57	-9.39	-0.42	3.65e-19	Coronary artery disease;
LUAD	trans	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg07393940	chr7:158741817	NA	-0.68	-11.71	-0.49	1.29e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4372836	0.504	rs6547881	chr2:29032746	C/T	cg09522027	chr2:28974177	PPP1CB	0.6	10.51	0.46	3.96e-23	Body mass index;
LUAD	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg11822812	chr5:140052017	DND1	0.36	6.47	0.3	2.7e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09991975	chr22:39096760	JOSD1	-0.66	-6.8	-0.31	3.68e-11	Type 2 diabetes;
LUAD	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg09399716	chr2:46890238	NA	-0.38	-6.68	-0.31	7.61e-11	Height;
LUAD	cis	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg07460842	chr6:66804631	NA	1.16	27.67	0.8	6.22e-97	Exhaled nitric oxide output;
LUAD	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg18944383	chr4:111397179	ENPEP	-0.46	-8.57	-0.38	1.94e-16	Coronary artery disease;
LUAD	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg08885076	chr2:99613938	TSGA10	-0.39	-6.89	-0.32	2.06e-11	Chronic sinus infection;
LUAD	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg07685180	chr8:600429	NA	0.87	8.71	0.39	6.87e-17	IgG glycosylation;
LUAD	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg20701182	chr2:24300061	SF3B14	0.53	6.48	0.3	2.6e-10	Lymphocyte counts;
LUAD	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24531977	chr5:56204891	C5orf35	0.78	12.56	0.52	5.76e-31	Initial pursuit acceleration;
LUAD	trans	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg25482853	chr8:67687455	SGK3	1.13	16.62	0.63	4.13e-48	Obesity-related traits;
LUAD	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.58	-0.35	2.22e-13	Lung cancer;
LUAD	cis	rs9902453	0.765	rs6505143	chr17:28150585	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	10.68	0.46	1.01e-23	Coffee consumption (cups per day);
LUAD	cis	rs13315871	1.000	rs12330157	chr3:58364562	C/T	cg20936604	chr3:58311152	NA	-0.68	-7.01	-0.32	9.24e-12	Cholesterol, total;
LUAD	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	8.7	0.39	7.32e-17	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-7.02	-0.32	8.97e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg15445000	chr17:37608096	MED1	0.44	8.23	0.37	2.26e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs7584330	0.554	rs57140815	chr2:238428330	A/G	cg14458575	chr2:238380390	NA	0.54	8.68	0.39	8.36e-17	Prostate cancer;
LUAD	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg22029157	chr1:209979665	IRF6	0.71	9.45	0.42	2.33e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs142958719	1	rs142958719	chr5:131232959	G/A	cg25547332	chr5:131281432	NA	-0.45	-6.67	-0.31	8.19e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs367943	0.965	rs458044	chr5:112797779	A/G	cg12552261	chr5:112820674	MCC	-0.59	-11.07	-0.47	3.5e-25	Type 2 diabetes;
LUAD	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg03433033	chr1:76189801	ACADM	0.87	17.68	0.65	9.15e-53	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs3818285	0.885	rs10787217	chr10:111621103	A/T	cg00817464	chr10:111662876	XPNPEP1	0.55	7.9	0.36	2.46e-14	Superior crus of antihelix expression;
LUAD	trans	rs7200543	1.000	rs4985124	chr16:15125441	A/C	cg24683922	chr1:11983373	KIAA2013	-0.48	-8.25	-0.37	1.96e-15	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	trans	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg14791747	chr16:20752902	THUMPD1	0.49	7.29	0.33	1.57e-12	Pancreatic cancer;
LUAD	cis	rs7000551	0.532	rs55726237	chr8:22252985	C/T	cg12081754	chr8:22256438	SLC39A14	0.9	14.85	0.59	1.99e-40	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-14.49	-0.58	6.57e-39	Exhaled nitric oxide output;
LUAD	trans	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.08	-0.33	6.07e-12	Dental caries;
LUAD	cis	rs7904368	0.754	rs11254231	chr10:16870246	A/G	cg14835575	chr10:16859367	RSU1	0.92	13.01	0.53	8.43e-33	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg04414720	chr1:150670196	GOLPH3L	0.67	11.79	0.5	6.3e-28	Melanoma;
LUAD	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg17105886	chr17:28927953	LRRC37B2	0.68	7.74	0.35	7.17e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs62238980	0.521	rs78578916	chr22:32456881	G/A	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg04842962	chr6:43655489	MRPS18A	0.91	16.8	0.63	6.83e-49	IgG glycosylation;
LUAD	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg11845111	chr2:191398756	TMEM194B	-0.86	-11.29	-0.48	5.18e-26	Diastolic blood pressure;
LUAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg25703541	chr22:24373054	LOC391322	0.85	15.55	0.6	1.83e-43	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg25828334	chr19:18545568	ISYNA1	-0.36	-7.19	-0.33	2.97e-12	Breast cancer;
LUAD	cis	rs4691139	0.658	rs4690798	chr4:165926586	C/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.41	-7.78	-0.35	5.64e-14	Ovarian cancer in BRCA1 mutation carriers;
LUAD	trans	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg18187862	chr3:45730750	SACM1L	0.56	8.78	0.39	4.02e-17	Primary sclerosing cholangitis;
LUAD	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg12444411	chr7:2802554	GNA12	-0.36	-6.37	-0.3	4.93e-10	Height;
LUAD	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg02631126	chr6:28058918	ZSCAN12L1	-0.37	-7.79	-0.35	5.3e-14	Parkinson's disease;
LUAD	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg03714773	chr7:91764589	CYP51A1	0.27	6.37	0.3	4.88e-10	Breast cancer;
LUAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg12432903	chr7:1882776	MAD1L1	-0.49	-8.05	-0.36	8.63e-15	Testicular germ cell tumor;
LUAD	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg23229984	chr5:148520753	ABLIM3	0.49	7.68	0.35	1.14e-13	Breast cancer;
LUAD	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg13468214	chr4:1046988	NA	0.39	9.06	0.4	4.78e-18	Recombination rate (males);
LUAD	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.559	rs77013162	chr7:107071674	A/C	cg02696742	chr7:106810147	HBP1	-0.79	-10.38	-0.45	1.22e-22	Coronary artery disease;
LUAD	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg15790184	chr11:494944	RNH1	0.56	6.96	0.32	1.28e-11	Body mass index;
LUAD	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg19717773	chr7:2847554	GNA12	-0.56	-10.56	-0.46	2.78e-23	Height;
LUAD	cis	rs738322	0.574	rs738323	chr22:38569527	C/T	cg17652424	chr22:38574118	PLA2G6	-0.3	-7.98	-0.36	1.37e-14	Cutaneous nevi;
LUAD	trans	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg07211511	chr3:129823064	LOC729375	-0.91	-12.47	-0.52	1.32e-30	Blood pressure (smoking interaction);
LUAD	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg12034118	chr1:209979487	IRF6	0.55	7.32	0.34	1.26e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs9392556	0.829	rs634698	chr6:4114247	T/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.4	-6.92	-0.32	1.69e-11	Blood metabolite levels;
LUAD	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-7.41	-0.34	6.71e-13	Morning vs. evening chronotype;
LUAD	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg12193833	chr17:30244370	NA	-0.58	-7.08	-0.33	6.03e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs9811920	0.965	rs10222474	chr3:99862551	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.62	11.42	0.49	1.61e-26	Axial length;
LUAD	cis	rs7107174	0.901	rs2512525	chr11:77923019	T/C	cg02023728	chr11:77925099	USP35	0.53	8.08	0.37	6.77e-15	Testicular germ cell tumor;
LUAD	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06112835	chr11:68658793	MRPL21	0.52	9.37	0.41	4.41e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs62238980	0.522	rs2413065	chr22:32458608	C/A	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.85	-0.32	2.63e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg25985355	chr7:65971099	NA	-0.54	-6.73	-0.31	5.5e-11	Diabetic kidney disease;
LUAD	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg03948781	chr1:205179583	DSTYK	0.34	6.4	0.3	4.01e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg13575925	chr12:9217583	LOC144571	0.39	7.26	0.33	1.92e-12	Sjögren's syndrome;
LUAD	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg14092988	chr3:52407081	DNAH1	0.45	8.98	0.4	8.87e-18	Bipolar disorder;
LUAD	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg09165964	chr15:75287851	SCAMP5	-0.53	-7.65	-0.35	1.37e-13	Blood trace element (Zn levels);
LUAD	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg26384229	chr12:38710491	ALG10B	0.45	7.31	0.33	1.39e-12	Bladder cancer;
LUAD	cis	rs6688613	1.000	rs11578336	chr1:166958710	T/G	cg07049167	chr1:166818506	POGK	0.4	6.45	0.3	3.15e-10	Refractive astigmatism;
LUAD	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg12927641	chr6:109611667	NA	-0.51	-8.81	-0.39	3.15e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs9326248	0.581	rs4938331	chr11:116930682	C/A	cg20608306	chr11:116969690	SIK3	0.31	6.84	0.32	2.87e-11	Blood protein levels;
LUAD	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg11070056	chr1:107600091	PRMT6	-0.64	-11.27	-0.48	6.35e-26	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4774899	0.800	rs2169466	chr15:57417471	T/A	cg14026238	chr15:57616123	NA	0.36	6.67	0.31	7.85e-11	Urinary tract infection frequency;
LUAD	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg26408565	chr15:76604113	ETFA	-0.44	-7.17	-0.33	3.3e-12	Blood metabolite levels;
LUAD	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg23029597	chr12:123009494	RSRC2	-0.6	-9.51	-0.42	1.42e-19	Body mass index;
LUAD	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg18252515	chr7:66147081	NA	-0.62	-6.76	-0.31	4.63e-11	Diabetic kidney disease;
LUAD	cis	rs7647973	0.922	rs56049603	chr3:49585243	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-9.14	-0.41	2.71e-18	Menarche (age at onset);
LUAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg21724239	chr8:58056113	NA	0.65	8.35	0.38	9.78e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg10755058	chr3:40428713	ENTPD3	-0.39	-7.59	-0.35	2.09e-13	Renal cell carcinoma;
LUAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.46	-7.81	-0.36	4.55e-14	Longevity;Endometriosis;
LUAD	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg09509183	chr1:209979624	IRF6	0.52	6.63	0.31	1.04e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg05872129	chr22:39784769	NA	-0.8	-14.87	-0.59	1.54e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg13699009	chr12:122356056	WDR66	0.3	6.46	0.3	2.83e-10	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.705	rs4646072	chr1:15827711	G/A	cg24675056	chr1:15929824	NA	0.41	6.53	0.3	1.89e-10	Systolic blood pressure;
LUAD	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.99	-0.4	8.44e-18	Total body bone mineral density;
LUAD	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg01851573	chr8:8652454	MFHAS1	-0.39	-6.82	-0.31	3.11e-11	Mood instability;
LUAD	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg04398451	chr17:18023971	MYO15A	0.69	12.54	0.52	6.96e-31	Total body bone mineral density;
LUAD	cis	rs2354432	1.000	rs6680778	chr1:146747153	T/C	cg25205988	chr1:146714368	CHD1L	0.6	7.56	0.35	2.47e-13	Mitochondrial DNA levels;
LUAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg08219700	chr8:58056026	NA	0.59	7.91	0.36	2.2e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08708735	chr7:1609515	KIAA1908;PSMG3	-0.57	-7.01	-0.32	9.74e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.76	-0.35	6.63e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg09359103	chr1:154839909	KCNN3	-0.93	-21.48	-0.72	9.52e-70	Prostate cancer;
LUAD	cis	rs7524258	0.868	rs11120885	chr1:7306755	C/G	cg07173049	chr1:7289937	CAMTA1	0.43	8.16	0.37	3.98e-15	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg21138405	chr5:131827807	IRF1	0.56	13.0	0.53	9.78e-33	Asthma (sex interaction);
LUAD	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg09455208	chr3:40491958	NA	-0.6	-13.3	-0.54	5.61e-34	Renal cell carcinoma;
LUAD	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg09222892	chr1:25734099	RHCE	0.5	9.31	0.41	7.01e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.5	6.71	0.31	6.42e-11	Platelet count;
LUAD	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.68	-11.27	-0.48	6.14e-26	Primary sclerosing cholangitis;
LUAD	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.62	8.87	0.4	2.08e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg11502198	chr6:26597334	ABT1	0.55	9.17	0.41	2.12e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs55788414	0.932	rs9929253	chr16:81181641	C/T	cg06400318	chr16:81190750	PKD1L2	-0.56	-7.34	-0.34	1.12e-12	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg13385794	chr1:248469461	NA	0.25	6.83	0.32	2.99e-11	Common traits (Other);
LUAD	cis	rs758324	0.648	rs31474	chr5:131405027	A/G	cg06307176	chr5:131281290	NA	-0.39	-6.77	-0.31	4.25e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg27124370	chr19:33622961	WDR88	-0.44	-6.96	-0.32	1.33e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs12711979	0.765	rs881852	chr2:3821508	A/G	cg17052675	chr2:3827356	NA	-0.52	-10.38	-0.45	1.23e-22	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs75920871	1.000	rs79974099	chr11:116802581	T/A	cg04087571	chr11:116723030	SIK3	-0.32	-6.46	-0.3	2.86e-10	Subjective well-being;
LUAD	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg12432903	chr7:1882776	MAD1L1	-0.52	-8.87	-0.4	2.08e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg03037974	chr15:76606532	NA	0.38	8.21	0.37	2.79e-15	Blood metabolite levels;
LUAD	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg21963583	chr11:68658836	MRPL21	0.64	11.45	0.49	1.21e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs1973993	0.691	rs2985636	chr1:96889884	T/A	cg10631902	chr5:14652156	NA	0.68	14.03	0.56	5.67e-37	Weight;
LUAD	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg05340658	chr4:99064831	C4orf37	0.53	8.94	0.4	1.25e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg06740227	chr12:86229804	RASSF9	0.36	6.53	0.3	1.91e-10	Major depressive disorder;
LUAD	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg15704280	chr7:45808275	SEPT13	-1.07	-25.01	-0.77	2.01e-85	Height;
LUAD	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg11766577	chr21:47581405	C21orf56	-0.46	-7.97	-0.36	1.46e-14	Testicular germ cell tumor;
LUAD	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg17788362	chr6:86352627	SYNCRIP	0.43	6.69	0.31	6.91e-11	Smooth-surface caries;
LUAD	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.48	6.36	0.3	5.3e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg12193833	chr17:30244370	NA	-0.58	-6.99	-0.32	1.07e-11	Hip circumference adjusted for BMI;
LUAD	trans	rs7395662	0.889	rs1848158	chr11:48697294	C/T	cg15704280	chr7:45808275	SEPT13	-0.41	-6.35	-0.3	5.43e-10	HDL cholesterol;
LUAD	cis	rs2302190	0.882	rs9903050	chr17:56636908	T/C	cg25885038	chr17:56607967	SEPT4	-0.52	-8.28	-0.37	1.66e-15	Vitamin D levels;
LUAD	trans	rs853679	0.546	rs2232429	chr6:28359632	T/G	cg01620082	chr3:125678407	NA	-1.08	-9.99	-0.44	3.19e-21	Depression;
LUAD	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg02782426	chr3:40428986	ENTPD3	0.43	9.13	0.41	2.85e-18	Renal cell carcinoma;
LUAD	cis	rs62400317	0.859	rs4443508	chr6:45235952	C/T	cg18551225	chr6:44695536	NA	-0.56	-8.7	-0.39	7.44e-17	Total body bone mineral density;
LUAD	cis	rs11958404	0.932	rs11949394	chr5:157425198	A/G	cg05962755	chr5:157440814	NA	0.61	8.91	0.4	1.54e-17	IgG glycosylation;
LUAD	cis	rs4073416	0.542	rs6573616	chr14:66046816	A/G	cg10998611	chr14:65879393	FUT8;LOC645431	-0.42	-6.37	-0.3	4.92e-10	N-glycan levels;
LUAD	cis	rs739496	0.546	rs12426493	chr12:112344756	T/C	cg10833066	chr12:111807467	FAM109A	0.43	7.11	0.33	4.85e-12	Platelet count;
LUAD	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg24818145	chr4:99064322	C4orf37	0.51	7.58	0.35	2.27e-13	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg21153622	chr11:89784906	NA	-0.33	-6.52	-0.3	2e-10	HDL cholesterol;
LUAD	cis	rs75229567	0.618	rs11177819	chr12:70134836	T/G	cg10114359	chr12:70132523	RAB3IP	0.87	7.21	0.33	2.6e-12	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg11189052	chr15:85197271	WDR73	0.61	7.61	0.35	1.75e-13	Schizophrenia;
LUAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg14789911	chr21:47582049	C21orf56	-0.4	-7.0	-0.32	1.01e-11	Testicular germ cell tumor;
LUAD	cis	rs2816062	0.747	rs2816049	chr1:18893768	A/G	cg18795169	chr1:18902165	NA	-0.94	-22.53	-0.74	2.02e-74	Urate levels in lean individuals;
LUAD	cis	rs7274811	0.779	rs34145153	chr20:32159067	C/T	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.44	-6.61	-0.31	1.19e-10	Height;
LUAD	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg12935359	chr14:103987150	CKB	0.49	7.52	0.34	3.21e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7100689	0.646	rs10736356	chr10:82148325	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	10.5	0.45	4.39e-23	Post bronchodilator FEV1;
LUAD	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.61	-0.55	2.97e-35	Alcohol dependence;
LUAD	cis	rs7017914	0.967	rs6472538	chr8:71586971	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.58	-0.3	1.44e-10	Bone mineral density;
LUAD	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg27068330	chr11:65405492	SIPA1	-0.82	-13.08	-0.54	4.36e-33	Acne (severe);
LUAD	cis	rs9811920	0.535	rs792835	chr3:99476295	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.76	-0.39	4.64e-17	Axial length;
LUAD	trans	rs1422110	0.681	rs35625401	chr5:85465408	G/A	cg01787110	chr1:109008453	NBPF6	0.67	10.78	0.46	4.36e-24	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	9.39	0.42	3.73e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg04036182	chr15:45458818	NA	0.38	6.78	0.31	3.97e-11	Glomerular filtration rate;
LUAD	cis	rs2554380	0.891	rs1155070	chr15:84303084	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.51	-7.17	-0.33	3.43e-12	Height;
LUAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs714515	0.586	rs4916264	chr1:172450760	C/T	cg13446689	chr1:172328377	DNM3	-0.33	-6.41	-0.3	3.89e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg06697600	chr4:7070879	GRPEL1	-0.51	-7.54	-0.34	2.88e-13	Monocyte percentage of white cells;
LUAD	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg17264618	chr3:40429014	ENTPD3	-0.39	-8.58	-0.39	1.77e-16	Renal cell carcinoma;
LUAD	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg15181151	chr6:150070149	PCMT1	0.41	8.55	0.38	2.19e-16	Lung cancer;
LUAD	trans	rs372883	0.648	rs15092	chr21:30718201	G/A	cg14791747	chr16:20752902	THUMPD1	0.49	7.22	0.33	2.47e-12	Pancreatic cancer;
LUAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg11062466	chr8:58055876	NA	0.67	8.77	0.39	4.3e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.67	0.35	1.19e-13	Bladder cancer;
LUAD	cis	rs9469890	0.604	rs11758426	chr6:34503338	A/G	cg17674042	chr6:34482479	PACSIN1	-0.46	-6.63	-0.31	1.03e-10	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg03467027	chr4:99064603	C4orf37	0.39	6.37	0.3	5.05e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg18138036	chr10:133769891	PPP2R2D	0.41	6.61	0.31	1.19e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg22676075	chr6:135203613	NA	0.39	6.89	0.32	2.05e-11	Red blood cell count;
LUAD	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg00316803	chr15:76480434	C15orf27	0.4	6.72	0.31	5.84e-11	Blood metabolite levels;
LUAD	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg05697835	chr1:2722811	NA	0.31	6.46	0.3	2.89e-10	Ulcerative colitis;
LUAD	cis	rs7932354	0.528	rs7125807	chr11:47041163	G/T	cg19486271	chr11:47235900	DDB2	0.45	7.2	0.33	2.81e-12	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg23758822	chr17:41437982	NA	0.87	13.95	0.56	1.14e-36	Menopause (age at onset);
LUAD	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.53	0.3	1.87e-10	Platelet count;
LUAD	cis	rs2731664	0.792	rs335435	chr5:176867943	A/G	cg23176889	chr5:176863531	GRK6	-0.7	-13.24	-0.54	9.86e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs3784262	0.528	rs10518961	chr15:58334345	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-7.12	-0.33	4.53e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs28830936	1.000	rs17678138	chr15:42043067	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.35	-7.37	-0.34	8.91e-13	Diastolic blood pressure;
LUAD	cis	rs7937890	0.559	rs1548074	chr11:14534825	A/G	cg06199346	chr11:14280333	SPON1	-0.32	-6.42	-0.3	3.58e-10	Mitochondrial DNA levels;
LUAD	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg00071950	chr4:10020882	SLC2A9	0.72	14.84	0.59	2.08e-40	Bone mineral density;
LUAD	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg19875535	chr5:140030758	IK	0.41	6.98	0.32	1.15e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25789201	chr7:72395803	POM121	0.4	6.48	0.3	2.58e-10	Bilirubin levels;
LUAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg21724239	chr8:58056113	NA	0.89	10.73	0.46	6.28e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.61	0.31	1.15e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg16325326	chr1:53192061	ZYG11B	-0.61	-10.92	-0.47	1.24e-24	Monocyte count;
LUAD	cis	rs7833986	0.501	rs2719257	chr8:56940173	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.99	17.46	0.65	8.55e-52	Height;
LUAD	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg18512352	chr11:47633146	NA	-0.48	-8.42	-0.38	5.96e-16	Subjective well-being;
LUAD	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.07	-0.33	6.37e-12	Height;
LUAD	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.61	11.91	0.5	2.13e-28	Hemoglobin concentration;
LUAD	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.79e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg01868782	chr6:126071099	HEY2	0.33	6.85	0.32	2.69e-11	Brugada syndrome;
LUAD	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg13877915	chr19:58951672	ZNF132	0.74	14.27	0.57	5.38e-38	Uric acid clearance;
LUAD	trans	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg02002194	chr4:3960332	NA	-0.29	-7.14	-0.33	3.98e-12	Mood instability;
LUAD	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg13514129	chr1:39547527	MACF1	0.67	12.41	0.52	2.32e-30	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.66	-0.31	8.61e-11	Mood instability;
LUAD	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-7.48	-0.34	4.3e-13	Coronary artery disease;
LUAD	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg27454412	chr7:1067447	C7orf50	-0.35	-6.59	-0.31	1.29e-10	Bronchopulmonary dysplasia;
LUAD	trans	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg18187862	chr3:45730750	SACM1L	0.55	8.87	0.4	2.07e-17	Primary sclerosing cholangitis;
LUAD	trans	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg26043149	chr18:55253948	FECH	1.05	17.66	0.65	1.05e-52	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg24818145	chr4:99064322	C4orf37	-0.42	-6.88	-0.32	2.22e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg06627628	chr2:24431161	ITSN2	-0.54	-6.65	-0.31	8.85e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs17095355	1.000	rs7906904	chr10:111708193	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.77	-11.13	-0.48	1.98e-25	Biliary atresia;
LUAD	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	9.23	0.41	1.27e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19717773	chr7:2847554	GNA12	-0.58	-9.9	-0.43	6.53e-21	Height;
LUAD	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg10591111	chr5:226296	SDHA	-0.54	-7.01	-0.32	9.49e-12	Breast cancer;
LUAD	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-7.29	-0.33	1.49e-12	Glaucoma (primary open-angle);
LUAD	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.67	0.43	4.1e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg01849466	chr14:104193079	ZFYVE21	0.46	7.69	0.35	1.04e-13	Body mass index;
LUAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg20607798	chr8:58055168	NA	0.72	9.44	0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs654950	0.776	rs2759252	chr1:42021854	G/A	cg06885757	chr1:42089581	HIVEP3	-0.48	-10.66	-0.46	1.15e-23	Airway imaging phenotypes;
LUAD	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg27432699	chr2:27873401	GPN1	0.57	9.96	0.44	3.86e-21	Oral cavity cancer;
LUAD	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg15128208	chr22:42549153	NA	0.43	6.69	0.31	6.91e-11	Birth weight;
LUAD	trans	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.94	-16.59	-0.63	5.89e-48	Colorectal cancer;
LUAD	trans	rs11088226	0.645	rs11702343	chr21:33937888	C/A	cg09050820	chr6:167586206	TCP10L2	0.89	12.44	0.52	1.76e-30	Gastritis;
LUAD	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11890956	chr21:40555474	PSMG1	-0.64	-11.07	-0.47	3.4e-25	Cognitive function;
LUAD	cis	rs1595825	1.000	rs61605589	chr2:198876532	T/C	cg10547527	chr2:198650123	BOLL	-0.49	-6.75	-0.31	4.76e-11	Ulcerative colitis;
LUAD	trans	rs1422110	0.519	rs12055343	chr5:85437684	T/C	cg01787110	chr1:109008453	NBPF6	0.61	10.16	0.44	7.32e-22	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg06671706	chr8:8559999	CLDN23	0.64	11.22	0.48	9.53e-26	Obesity-related traits;
LUAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg06453172	chr10:134556979	INPP5A	-0.77	-10.93	-0.47	1.16e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg14828511	chr1:107599125	PRMT6	-0.61	-10.68	-0.46	9.61e-24	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg06697600	chr4:7070879	GRPEL1	-0.49	-8.14	-0.37	4.44e-15	Monocyte percentage of white cells;
LUAD	cis	rs986417	0.892	rs57925468	chr14:60816129	G/A	cg27398547	chr14:60952738	C14orf39	-0.62	-7.37	-0.34	8.82e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	cis	rs1965732	0.588	rs11682334	chr2:3716780	G/T	cg10645314	chr2:3704589	ALLC	-0.4	-7.08	-0.33	6.14e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg00933542	chr6:150070202	PCMT1	0.42	8.27	0.37	1.77e-15	Lung cancer;
LUAD	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg17063962	chr7:91808500	NA	0.68	12.05	0.51	5.84e-29	Breast cancer;
LUAD	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg02269571	chr22:50332266	NA	-0.65	-9.92	-0.43	5.47e-21	Schizophrenia;
LUAD	cis	rs7224737	0.673	rs11079035	chr17:40289012	C/T	cg20291162	chr17:40259547	DHX58	-0.56	-7.58	-0.35	2.16e-13	Fibrinogen levels;
LUAD	cis	rs17362650	0.921	rs10495565	chr2:9686440	A/G	cg12832956	chr2:9616023	IAH1	-0.47	-7.4	-0.34	7.6e-13	Alcohol dependence (age at onset);
LUAD	trans	rs2797160	1.000	rs6904992	chr6:126016003	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.58e-17	Endometrial cancer;
LUAD	trans	rs1997103	1.000	rs11238364	chr7:55407632	G/T	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg23173402	chr1:227635558	NA	-0.67	-7.41	-0.34	6.82e-13	Major depressive disorder;
LUAD	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg01475377	chr6:109611718	NA	-0.47	-8.55	-0.38	2.26e-16	Reticulocyte fraction of red cells;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg05833251	chr14:23938784	NGDN	-0.4	-6.48	-0.3	2.5e-10	Subcortical brain region volumes;
LUAD	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg24818145	chr4:99064322	C4orf37	0.45	7.68	0.35	1.12e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	1.000	rs59274738	chr17:28437635	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	9.2	0.41	1.62e-18	Coffee consumption (cups per day);
LUAD	trans	rs564343	0.966	rs537497	chr11:65866187	G/A	cg26701943	chr11:108369231	KDELC2	-0.45	-7.55	-0.34	2.78e-13	Obesity (early onset extreme);
LUAD	cis	rs4523957	0.671	rs216205	chr17:2196150	C/T	cg16513277	chr17:2031491	SMG6	0.68	10.44	0.45	7.21e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08439880	chr3:133502540	NA	-0.45	-8.98	-0.4	8.92e-18	Iron status biomarkers;
LUAD	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg19622623	chr12:86230825	RASSF9	-0.55	-9.8	-0.43	1.42e-20	Major depressive disorder;
LUAD	cis	rs6987853	0.933	rs2923401	chr8:42442208	T/C	cg09913449	chr8:42400586	C8orf40	0.42	7.59	0.35	2.06e-13	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg00255919	chr5:131827918	IRF1	0.49	11.85	0.5	3.74e-28	Asthma (sex interaction);
LUAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.25	-0.37	2.05e-15	Alzheimer's disease;
LUAD	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg07936489	chr17:37558343	FBXL20	0.44	6.82	0.31	3.08e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.65	12.03	0.5	6.93e-29	Lymphocyte counts;
LUAD	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg00255919	chr5:131827918	IRF1	0.49	11.74	0.5	9.7e-28	Asthma (sex interaction);
LUAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg21724239	chr8:58056113	NA	0.75	9.8	0.43	1.48e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs929596	0.667	rs7567229	chr2:234612539	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-11.72	-0.5	1.16e-27	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-9.02	-0.4	6.56e-18	Alzheimer's disease;
LUAD	cis	rs9462027	0.562	rs2814946	chr6:34651180	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-8.58	-0.39	1.8e-16	Systemic lupus erythematosus;
LUAD	cis	rs1865721	0.804	rs719179	chr18:73146396	A/G	cg26385618	chr18:73139727	C18orf62	-0.51	-10.07	-0.44	1.63e-21	Intelligence;
LUAD	cis	rs56283067	0.577	rs114009236	chr6:44897517	T/C	cg18551225	chr6:44695536	NA	-0.59	-8.96	-0.4	1.06e-17	Total body bone mineral density;
LUAD	cis	rs2455601	0.744	rs2163626	chr11:8983547	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-7.49	-0.34	4.03e-13	Schizophrenia;
LUAD	cis	rs11650494	0.901	rs117087923	chr17:47364913	G/A	cg08112188	chr17:47440006	ZNF652	0.97	8.03	0.36	9.84e-15	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.53	0.42	1.28e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9560113	0.843	rs9555808	chr13:112181284	A/T	cg14154082	chr13:112174009	NA	0.36	6.64	0.31	9.5e-11	Menarche (age at onset);
LUAD	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg11663144	chr21:46675770	NA	-0.57	-11.43	-0.49	1.55e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs57994353	0.802	rs12002854	chr9:139377499	G/A	cg14364472	chr9:139394549	NOTCH1	-0.45	-6.87	-0.32	2.24e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg24397884	chr7:158709396	WDR60	-0.74	-13.61	-0.55	2.94e-35	Height;
LUAD	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg26769984	chr7:1090371	C7orf50	0.57	9.6	0.42	7.15e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg00071950	chr4:10020882	SLC2A9	-0.59	-11.16	-0.48	1.6e-25	Bone mineral density;
LUAD	cis	rs89107	0.603	rs399844	chr6:118613435	A/G	cg18833306	chr6:118973337	C6orf204	0.56	10.39	0.45	1.16e-22	Cardiac structure and function;
LUAD	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg18512352	chr11:47633146	NA	-0.55	-9.75	-0.43	2.16e-20	Subjective well-being;
LUAD	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg25838465	chr1:92012736	NA	-0.73	-16.1	-0.62	8.14e-46	Breast cancer;
LUAD	cis	rs34366173	1	rs34366173	chr15:63998914	CTT/C	cg14776518	chr15:63892607	FBXL22	0.36	6.69	0.31	6.94e-11	Reticulocyte fraction of red cells;
LUAD	trans	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg05926928	chr17:57297772	GDPD1	-0.49	-7.32	-0.34	1.29e-12	Schizophrenia;
LUAD	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg21285383	chr16:89894308	SPIRE2	0.4	9.51	0.42	1.48e-19	Vitiligo;
LUAD	cis	rs909002	0.849	rs2280386	chr1:32086912	A/C	cg13919466	chr1:32135498	COL16A1	-0.34	-7.87	-0.36	3.05e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs7712671	0.840	rs11241418	chr5:116527405	C/T	cg21909475	chr1:169764459	C1orf156;C1orf112	0.42	6.63	0.31	1.01e-10	Schizophrenia;
LUAD	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg13319975	chr6:146136371	FBXO30	0.67	11.46	0.49	1.18e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.62e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg25457927	chr22:38595422	NA	-0.59	-15.54	-0.6	2.16e-43	Cutaneous nevi;
LUAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10819733	chr22:24237672	NA	0.4	7.62	0.35	1.68e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08219700	chr8:58056026	NA	0.63	8.82	0.39	2.92e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg00277334	chr10:82204260	NA	-0.96	-22.03	-0.73	3.49e-72	Post bronchodilator FEV1;
LUAD	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg23625390	chr15:77176239	SCAPER	-0.54	-8.61	-0.39	1.42e-16	Blood metabolite levels;
LUAD	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.23	0.48	8.73e-26	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9560113	0.509	rs28608633	chr13:112206880	G/A	cg10483660	chr13:112241077	NA	0.49	9.62	0.42	6.29e-20	Menarche (age at onset);
LUAD	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg13397359	chr6:42928475	GNMT	0.65	13.45	0.55	1.38e-34	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4743820	0.651	rs4744036	chr9:93932466	G/A	cg14446406	chr9:93919335	NA	-0.48	-8.24	-0.37	2.24e-15	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg00255919	chr5:131827918	IRF1	0.46	11.17	0.48	1.5e-25	Asthma (sex interaction);
LUAD	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg07138768	chr7:917805	C7orf20	0.38	7.57	0.35	2.29e-13	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs9399401	0.667	rs6900233	chr6:142717283	C/G	cg04461802	chr6:142623433	GPR126	0.47	8.88	0.4	1.89e-17	Chronic obstructive pulmonary disease;
LUAD	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg22875332	chr1:76189707	ACADM	-0.69	-11.09	-0.47	2.88e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2485376	1.000	rs733283	chr10:103996576	A/T	cg20641465	chr10:103991465	PITX3	-0.55	-10.02	-0.44	2.49e-21	QT interval;
LUAD	cis	rs2004318	1.000	rs7246195	chr19:55080842	T/G	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.96e-13	Blood protein levels;
LUAD	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg16797656	chr11:68205561	LRP5	0.44	8.41	0.38	6.4e-16	Total body bone mineral density;
LUAD	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg22906224	chr7:99728672	NA	0.6	10.36	0.45	1.43e-22	Coronary artery disease;
LUAD	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg13944838	chr5:179740914	GFPT2	-0.78	-12.63	-0.52	3.13e-31	Height;
LUAD	trans	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg01620082	chr3:125678407	NA	-0.69	-7.1	-0.33	5.37e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03264133	chr6:25882463	NA	-0.56	-8.23	-0.37	2.27e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs629535	0.821	rs660144	chr8:70035629	T/C	cg21567404	chr3:27674614	NA	1.01	18.57	0.67	9.52e-57	Dupuytren's disease;
LUAD	cis	rs7911264	0.967	rs2497318	chr10:94432000	C/T	cg25093409	chr10:94429542	NA	-0.36	-6.61	-0.31	1.13e-10	Inflammatory bowel disease;
LUAD	cis	rs41311933	0.803	rs62578383	chr9:123690582	C/G	cg13567360	chr9:123745713	C5	-0.83	-7.22	-0.33	2.36e-12	Coronary artery disease;
LUAD	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg21856205	chr7:94953877	PON1	-0.54	-7.42	-0.34	6.56e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs11098699	0.784	rs12506890	chr4:124240982	T/C	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg17366294	chr4:99064904	C4orf37	0.72	13.45	0.55	1.46e-34	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2274273	0.662	rs67588230	chr14:55667030	C/T	cg04306507	chr14:55594613	LGALS3	0.44	8.18	0.37	3.41e-15	Protein biomarker;
LUAD	cis	rs6494488	0.500	rs72744763	chr15:65076652	C/T	cg08069370	chr15:64387884	SNX1	-0.74	-6.64	-0.31	9.68e-11	Coronary artery disease;
LUAD	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg20673091	chr1:2541236	MMEL1	-0.39	-8.17	-0.37	3.69e-15	Ulcerative colitis;
LUAD	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg05872129	chr22:39784769	NA	-0.74	-12.38	-0.52	2.88e-30	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg02158880	chr13:53174818	NA	-0.44	-7.32	-0.34	1.26e-12	Lewy body disease;
LUAD	trans	rs853679	0.607	rs34243448	chr6:28193102	C/A	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.13	-0.48	1.99e-25	Depression;
LUAD	trans	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.11	-0.4	3.41e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg24818145	chr4:99064322	C4orf37	0.47	7.95	0.36	1.71e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4409675	0.576	rs2474470	chr1:28234999	C/T	cg23691781	chr1:28212827	C1orf38	0.38	11.13	0.48	1.99e-25	Corneal astigmatism;
LUAD	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg05313129	chr8:58192883	C8orf71	-0.55	-7.1	-0.33	5.45e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg05295671	chr13:79234353	RNF219	0.52	7.58	0.35	2.21e-13	Large artery stroke;
LUAD	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4660214	0.666	rs3116387	chr1:39742869	T/G	cg27567593	chr1:39956653	BMP8A	0.33	6.7	0.31	6.57e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs12049351	0.719	rs10916499	chr1:229641078	T/G	cg11742688	chr1:229674241	ABCB10	-0.4	-6.39	-0.3	4.27e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg11266682	chr4:10021025	SLC2A9	0.67	15.52	0.6	2.67e-43	Bone mineral density;
LUAD	cis	rs904251	0.600	rs1874736	chr6:37447994	C/G	cg25019722	chr6:37503610	NA	-0.3	-6.86	-0.32	2.51e-11	Cognitive performance;
LUAD	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg02175503	chr12:58329896	NA	-0.38	-6.6	-0.31	1.26e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg08997352	chr12:9597637	DDX12	-0.63	-10.78	-0.46	4.04e-24	Breast size;
LUAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg08132940	chr7:1081526	C7orf50	-0.68	-9.61	-0.42	6.7e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg12373951	chr3:133503437	NA	0.37	7.23	0.33	2.24e-12	Iron status biomarkers;
LUAD	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg06138931	chr13:21896616	NA	0.46	6.69	0.31	7.12e-11	White matter hyperintensity burden;
LUAD	cis	rs59698941	0.943	rs73271090	chr5:132313550	G/A	cg14825688	chr5:132208181	LEAP2	-0.49	-6.54	-0.3	1.73e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg18131467	chr2:239335373	ASB1	0.7	12.3	0.51	6.41e-30	Multiple system atrophy;
LUAD	cis	rs897984	0.568	rs11862962	chr16:30909706	C/G	cg05768032	chr16:30646687	NA	0.42	6.55	0.3	1.66e-10	Dementia with Lewy bodies;
LUAD	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.61	-0.31	1.13e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-6.41	-0.3	3.88e-10	Neutrophil percentage of white cells;
LUAD	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.85	0.36	3.45e-14	Breast cancer;
LUAD	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg22442454	chr1:209979470	IRF6	0.58	6.49	0.3	2.45e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18404041	chr3:52824283	ITIH1	-0.6	-11.87	-0.5	3e-28	Bipolar disorder;
LUAD	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg00316803	chr15:76480434	C15orf27	0.4	6.64	0.31	9.48e-11	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg03929089	chr4:120376271	NA	0.6	9.34	0.41	5.52e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg23277830	chr1:3704460	LRRC47	0.41	8.36	0.38	9.13e-16	Red cell distribution width;
LUAD	cis	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg27411982	chr8:10470053	RP1L1	0.37	6.38	0.3	4.75e-10	Neuroticism;
LUAD	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg06060754	chr5:176797920	RGS14	-0.55	-8.7	-0.39	7.53e-17	Urate levels in lean individuals;
LUAD	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg22852734	chr6:133119734	C6orf192	0.79	9.98	0.44	3.43e-21	Type 2 diabetes nephropathy;
LUAD	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg10591111	chr5:226296	SDHA	-0.56	-7.24	-0.33	2.14e-12	Breast cancer;
LUAD	cis	rs8099014	1.000	rs4384676	chr18:56125973	T/A	cg12907477	chr18:56117327	MIR122	0.38	6.45	0.3	2.98e-10	Platelet count;
LUAD	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg08997352	chr12:9597637	DDX12	-0.45	-6.97	-0.32	1.21e-11	IgG glycosylation;
LUAD	cis	rs7851660	0.874	rs1443436	chr9:100631298	T/A	cg13688889	chr9:100608707	NA	-0.48	-8.27	-0.37	1.72e-15	Strep throat;
LUAD	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg15181151	chr6:150070149	PCMT1	0.33	6.44	0.3	3.17e-10	Lung cancer;
LUAD	trans	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg11693508	chr17:37793320	STARD3	0.71	9.09	0.4	3.78e-18	Bipolar disorder;
LUAD	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg16205897	chr5:131564050	P4HA2	-0.31	-6.84	-0.32	2.74e-11	Acylcarnitine levels;
LUAD	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-8.43	-0.38	5.33e-16	Gut microbiome composition (summer);
LUAD	cis	rs2637266	1.000	rs2637268	chr10:78332213	G/T	cg18941641	chr10:78392320	NA	0.31	6.47	0.3	2.64e-10	Pulmonary function;
LUAD	cis	rs4730250	0.655	rs4727671	chr7:106876045	A/G	cg02696742	chr7:106810147	HBP1	-0.74	-10.35	-0.45	1.6e-22	Osteoarthritis;
LUAD	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.33	6.58	0.3	1.39e-10	Parkinson's disease;
LUAD	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg17346650	chr17:80929145	B3GNTL1	0.41	7.1	0.33	5.34e-12	Glycated hemoglobin levels;
LUAD	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg10435618	chr10:838112	NA	0.47	6.43	0.3	3.54e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg03354898	chr7:1950403	MAD1L1	-0.43	-8.14	-0.37	4.51e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs494562	0.892	rs520090	chr6:86116635	G/A	cg13315970	chr6:86159197	NT5E	0.73	8.27	0.37	1.81e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.61	-11.48	-0.49	1.01e-26	Schizophrenia;
LUAD	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg15556689	chr8:8085844	FLJ10661	0.41	7.1	0.33	5.23e-12	Mood instability;
LUAD	cis	rs758324	0.947	rs28537859	chr5:131237277	C/G	cg06307176	chr5:131281290	NA	-0.53	-8.35	-0.38	9.75e-16	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.59	-10.77	-0.46	4.67e-24	Longevity;Endometriosis;
LUAD	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.55	-0.34	2.68e-13	Bipolar disorder and schizophrenia;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg05010219	chr10:134210111	PWWP2B	-0.35	-6.49	-0.3	2.35e-10	Schizophrenia;
LUAD	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg18512352	chr11:47633146	NA	0.41	7.16	0.33	3.54e-12	Subjective well-being;
LUAD	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.38	6.67	0.31	8.07e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-6.68	-0.31	7.63e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg00666640	chr1:248458726	OR2T12	0.33	8.05	0.36	8.2e-15	Common traits (Other);
LUAD	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18876405	chr7:65276391	NA	-0.42	-6.68	-0.31	7.59e-11	Aortic root size;
LUAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs57590327	0.555	rs3772909	chr3:81707264	T/C	cg07356753	chr3:81810745	GBE1	-0.64	-10.03	-0.44	2.18e-21	Extraversion;
LUAD	cis	rs9487051	0.735	rs459956	chr6:109524760	A/G	cg01475377	chr6:109611718	NA	-0.38	-6.88	-0.32	2.21e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg15557168	chr22:42548783	NA	0.51	9.44	0.42	2.62e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9287719	0.674	rs6432130	chr2:10821557	T/C	cg02196655	chr2:10830764	NOL10	0.45	8.14	0.37	4.62e-15	Prostate cancer;
LUAD	cis	rs6541297	0.645	rs638112	chr1:230310736	C/A	cg20703242	chr1:230279135	GALNT2	-0.48	-6.99	-0.32	1.08e-11	Coronary artery disease;
LUAD	cis	rs11098699	0.784	rs12510460	chr4:124240937	A/G	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	cis	rs3087591	1.000	rs2057769	chr17:29691368	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.4	-6.52	-0.3	1.99e-10	Hip circumference;
LUAD	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg23758822	chr17:41437982	NA	1.01	20.57	0.71	1.2e-65	Menopause (age at onset);
LUAD	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg10518543	chr12:38710700	ALG10B	0.41	6.38	0.3	4.74e-10	Bladder cancer;
LUAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.48	-8.78	-0.39	4.16e-17	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg05340658	chr4:99064831	C4orf37	0.53	9.01	0.4	7.15e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg03929089	chr4:120376271	NA	-0.97	-19.77	-0.69	4.53e-62	Height;
LUAD	trans	rs1997103	1.000	rs4590393	chr7:55408990	C/T	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg17724175	chr1:150552817	MCL1	0.36	8.24	0.37	2.14e-15	Melanoma;
LUAD	cis	rs7640424	0.649	rs35876429	chr3:107928557	C/T	cg09227934	chr3:107805635	CD47	-0.47	-8.51	-0.38	3.12e-16	Body mass index;
LUAD	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg06532163	chr17:45867833	NA	0.48	7.68	0.35	1.13e-13	IgG glycosylation;
LUAD	cis	rs9616064	0.557	rs9615397	chr22:47049086	C/T	cg05621596	chr22:47072043	GRAMD4	-0.65	-10.81	-0.47	3.33e-24	Urate levels in obese individuals;
LUAD	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg18867708	chr6:26865862	GUSBL1	0.47	7.64	0.35	1.44e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg20203395	chr5:56204925	C5orf35	0.94	12.71	0.53	1.42e-31	Initial pursuit acceleration;
LUAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-7.57	-0.35	2.31e-13	Longevity;Endometriosis;
LUAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg07677032	chr17:61819896	STRADA	0.57	10.39	0.45	1.09e-22	Prudent dietary pattern;
LUAD	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-15.21	-0.59	5.52e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg01620082	chr3:125678407	NA	-0.77	-6.74	-0.31	5.27e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.1	-0.4	3.69e-18	Bipolar disorder;
LUAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg11494091	chr17:61959527	GH2	0.74	18.63	0.67	5.61e-57	Prudent dietary pattern;
LUAD	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg02569458	chr12:86230093	RASSF9	0.42	7.63	0.35	1.54e-13	Major depressive disorder;
LUAD	cis	rs3845702	1.000	rs9989852	chr2:180839707	G/A	cg01881094	chr2:180872142	CWC22	-0.62	-7.74	-0.35	7.52e-14	Schizophrenia;
LUAD	cis	rs17253792	0.908	rs9972177	chr14:56073206	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.62	0.55	2.87e-35	Tonsillectomy;
LUAD	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg06784218	chr1:46089804	CCDC17	0.51	11.25	0.48	7.47e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.81	0.31	3.41e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6960043	0.818	rs6967891	chr7:15065074	T/C	cg19272540	chr7:15055459	NA	-0.36	-7.95	-0.36	1.75e-14	Type 2 diabetes;
LUAD	cis	rs6005807	0.719	rs9625514	chr22:29022188	T/C	cg12565055	chr22:29076175	TTC28	0.75	8.76	0.39	4.71e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg02951883	chr7:2050386	MAD1L1	-0.82	-14.17	-0.57	1.47e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg08508325	chr11:3079039	CARS	-0.61	-13.39	-0.55	2.48e-34	Longevity;
LUAD	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg09163369	chr1:210001066	C1orf107	0.44	6.42	0.3	3.64e-10	Orofacial clefts;
LUAD	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg02574844	chr11:5959923	NA	-0.43	-8.21	-0.37	2.78e-15	DNA methylation (variation);
LUAD	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg13385794	chr1:248469461	NA	0.25	6.77	0.31	4.29e-11	Common traits (Other);
LUAD	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg23029597	chr12:123009494	RSRC2	-0.57	-8.96	-0.4	1.08e-17	Body mass index;
LUAD	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.42	-7.03	-0.32	8.09e-12	Tonsillectomy;
LUAD	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg09021430	chr5:549028	NA	-0.69	-14.5	-0.58	5.84e-39	Obesity-related traits;
LUAD	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg17264618	chr3:40429014	ENTPD3	0.37	8.16	0.37	3.86e-15	Renal cell carcinoma;
LUAD	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.49	-0.3	2.38e-10	Prostate cancer;
LUAD	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg03233332	chr7:66118400	NA	-0.44	-6.69	-0.31	6.95e-11	Aortic root size;
LUAD	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	11.84	0.5	3.95e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs7020830	0.858	rs7856690	chr9:37127545	A/T	cg14294708	chr9:37120828	ZCCHC7	0.8	14.95	0.59	6.85e-41	Schizophrenia;
LUAD	cis	rs7903847	0.646	rs10882924	chr10:99159304	T/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.66	-0.35	1.24e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7737355	0.947	rs31257	chr5:130828715	C/G	cg06307176	chr5:131281290	NA	0.48	7.72	0.35	8.34e-14	Life satisfaction;
LUAD	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.87	-0.36	3.05e-14	Neutrophil percentage of white cells;
LUAD	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg24803719	chr17:45855879	NA	-0.34	-6.86	-0.32	2.51e-11	IgG glycosylation;
LUAD	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg10169327	chr19:45448959	APOC2	0.38	7.56	0.34	2.58e-13	Blood protein levels;
LUAD	trans	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	10.57	0.46	2.59e-23	Type 2 diabetes;
LUAD	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg24558204	chr6:135376177	HBS1L	0.46	8.44	0.38	5.09e-16	Red blood cell count;
LUAD	cis	rs7737355	0.738	rs7710364	chr5:130842724	T/C	cg06307176	chr5:131281290	NA	0.42	6.93	0.32	1.62e-11	Life satisfaction;
LUAD	cis	rs11741688	0.631	rs4444956	chr5:178325515	A/G	cg20935368	chr5:178288625	ZNF354B	0.4	7.15	0.33	3.95e-12	Sleep duration;
LUAD	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg16060761	chr17:80687452	NA	-0.57	-8.16	-0.37	3.89e-15	Glycated hemoglobin levels;
LUAD	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg11707310	chr1:2537719	MMEL1	0.39	8.42	0.38	5.78e-16	Ulcerative colitis;
LUAD	cis	rs7264396	0.623	rs2425127	chr20:34332037	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.97	-0.36	1.49e-14	Total cholesterol levels;
LUAD	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.49	-6.72	-0.31	5.9e-11	Iron status biomarkers;
LUAD	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12756686	chr19:29218302	NA	0.66	10.16	0.44	7.65e-22	Methadone dose in opioid dependence;
LUAD	trans	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg07211511	chr3:129823064	LOC729375	-0.55	-7.0	-0.32	1e-11	Blood pressure (smoking interaction);
LUAD	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.3	-0.45	2.46e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs1448094	1.000	rs7305284	chr12:86343786	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-8.05	-0.36	8.48e-15	Major depressive disorder;
LUAD	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg15557168	chr22:42548783	NA	-0.38	-6.72	-0.31	5.79e-11	Cognitive function;
LUAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg21782813	chr7:2030301	MAD1L1	0.57	10.09	0.44	1.36e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs1003719	0.715	rs35199609	chr21:38510262	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-8.99	-0.4	8.43e-18	Eye color traits;
LUAD	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg03859395	chr2:55845619	SMEK2	0.66	11.62	0.49	2.91e-27	Metabolic syndrome;
LUAD	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg05805236	chr11:65401703	PCNXL3	0.39	6.6	0.31	1.27e-10	Acne (severe);
LUAD	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.6	-0.42	7.05e-20	Life satisfaction;
LUAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-10.06	-0.44	1.77e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg08999081	chr20:33150536	PIGU	0.62	13.72	0.55	1.08e-35	Glomerular filtration rate (creatinine);
LUAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg10802521	chr3:52805072	NEK4	-0.52	-8.71	-0.39	6.87e-17	Bipolar disorder;
LUAD	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-6.68	-0.31	7.38e-11	Tonsillectomy;
LUAD	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg07570687	chr10:102243282	WNT8B	0.46	7.09	0.33	5.59e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	15.8	0.61	1.55e-44	Bone mineral density;
LUAD	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg20933634	chr6:27740509	NA	0.44	6.97	0.32	1.2e-11	Parkinson's disease;
LUAD	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.21e-16	Prostate cancer;
LUAD	cis	rs7215564	0.908	rs34084509	chr17:78696577	C/A	cg16980736	chr17:78789706	RPTOR	-0.63	-6.61	-0.31	1.18e-10	Myopia (pathological);
LUAD	cis	rs887829	0.569	rs4124874	chr2:234665659	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.28	-0.37	1.68e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs1832871	0.711	rs12527510	chr6:158657299	T/G	cg07165851	chr6:158734300	TULP4	0.69	10.21	0.44	5.22e-22	Height;
LUAD	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg18306943	chr3:40428807	ENTPD3	0.41	7.22	0.33	2.39e-12	Renal cell carcinoma;
LUAD	cis	rs8017423	0.967	rs4904656	chr14:90721442	G/T	cg14092571	chr14:90743983	NA	-0.5	-8.82	-0.39	3.06e-17	Mortality in heart failure;
LUAD	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.6	-12.56	-0.52	5.83e-31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6546550	0.935	rs10865380	chr2:70091246	T/C	cg02498382	chr2:70120550	SNRNP27	-0.54	-10.45	-0.45	6.84e-23	Prevalent atrial fibrillation;
LUAD	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg24642844	chr7:1081250	C7orf50	-0.97	-14.58	-0.58	2.57e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs17169635	0.840	rs3800746	chr7:134550086	G/C	cg07876788	chr7:134849633	TMEM140	-0.44	-6.56	-0.3	1.54e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg27490568	chr2:178487706	NA	-0.4	-6.63	-0.31	1.06e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6489882	0.934	rs10850103	chr12:113385000	A/T	cg20102336	chr12:113376681	OAS3	-0.48	-7.11	-0.33	5.07e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg24848339	chr3:12840334	CAND2	0.44	9.1	0.4	3.65e-18	P wave duration;
LUAD	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg11062466	chr8:58055876	NA	0.54	7.38	0.34	8.52e-13	Developmental language disorder (linguistic errors);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg19233923	chr11:63753598	OTUB1	0.39	6.53	0.3	1.91e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg13390004	chr1:15929781	NA	0.46	8.14	0.37	4.33e-15	Systolic blood pressure;
LUAD	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs231513	0.911	rs231527	chr17:41951228	T/C	cg26893861	chr17:41843967	DUSP3	-0.54	-6.52	-0.3	2.04e-10	Cognitive function;
LUAD	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-9.67	-0.43	4.18e-20	Gut microbiome composition (summer);
LUAD	cis	rs12478296	0.591	rs6746311	chr2:243001279	A/G	cg06360820	chr2:242988706	NA	-0.65	-9.61	-0.42	6.49e-20	Obesity-related traits;
LUAD	cis	rs12079745	0.623	rs2982468	chr1:169090971	A/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.92	-7.32	-0.34	1.23e-12	QT interval;
LUAD	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg06784218	chr1:46089804	CCDC17	0.57	12.4	0.52	2.4e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-10.75	-0.46	5.3e-24	Bipolar disorder;
LUAD	cis	rs67696533	1.000	rs6141319	chr20:31144807	A/G	cg13636640	chr20:31349939	DNMT3B	0.44	6.71	0.31	6.16e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs2932538	0.744	rs6537742	chr1:113085197	G/T	cg22162597	chr1:113214053	CAPZA1	0.47	6.52	0.3	2.05e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg24642844	chr7:1081250	C7orf50	-0.98	-14.82	-0.58	2.67e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.74	0.31	5.29e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.46	-0.42	2.09e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg23958373	chr8:599963	NA	1.1	11.23	0.48	8.42e-26	IgG glycosylation;
LUAD	cis	rs735539	1.000	rs6490606	chr13:21285096	C/G	cg04906043	chr13:21280425	IL17D	0.37	6.73	0.31	5.39e-11	Dental caries;
LUAD	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg27661571	chr11:113659931	NA	-0.56	-6.9	-0.32	1.9e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs1816752	0.905	rs11839006	chr13:25010031	T/C	cg02811702	chr13:24901961	NA	0.45	7.62	0.35	1.63e-13	Obesity-related traits;
LUAD	cis	rs62400317	0.859	rs11966878	chr6:45328265	C/T	cg18551225	chr6:44695536	NA	0.51	8.13	0.37	4.92e-15	Total body bone mineral density;
LUAD	cis	rs4604732	0.631	rs12036460	chr1:247626928	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.34	0.41	5.7e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg25767906	chr1:53392781	SCP2	0.42	7.89	0.36	2.53e-14	Monocyte count;
LUAD	cis	rs6696239	0.513	rs4653848	chr1:227728911	C/T	cg12133451	chr1:227746453	NA	0.35	6.44	0.3	3.29e-10	Height;
LUAD	cis	rs4846217	1.000	rs6693965	chr1:10378416	G/T	cg17425144	chr1:10567563	PEX14	-0.5	-6.77	-0.31	4.38e-11	Platelet count;
LUAD	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg09796270	chr17:17721594	SREBF1	0.4	7.9	0.36	2.44e-14	Total body bone mineral density;
LUAD	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg11502198	chr6:26597334	ABT1	0.84	11.98	0.5	1.1e-28	Small cell lung carcinoma;
LUAD	cis	rs7580658	0.509	rs12477653	chr2:127952081	C/T	cg16751203	chr2:127950803	CYP27C1	0.4	6.73	0.31	5.63e-11	Protein C levels;
LUAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg13560548	chr3:10150139	C3orf24	0.45	7.03	0.32	8.11e-12	Alzheimer's disease;
LUAD	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg08999081	chr20:33150536	PIGU	-0.37	-7.45	-0.34	5.48e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs68170813	0.559	rs17429146	chr7:106964281	A/G	cg23024343	chr7:107201750	COG5	0.45	6.45	0.3	3.02e-10	Coronary artery disease;
LUAD	cis	rs877282	0.891	rs12767062	chr10:797961	C/T	cg17470449	chr10:769945	NA	0.63	9.55	0.42	1.05e-19	Uric acid levels;
LUAD	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg17425144	chr1:10567563	PEX14	0.59	12.31	0.51	5.7e-30	Prostate cancer;
LUAD	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.55	0.38	2.23e-16	Menopause (age at onset);
LUAD	cis	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg25834613	chr7:1915315	MAD1L1	-0.41	-6.53	-0.3	1.87e-10	Bipolar disorder;
LUAD	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg15448220	chr1:150897856	SETDB1	0.46	7.81	0.36	4.47e-14	Tonsillectomy;
LUAD	trans	rs459571	0.959	rs410876	chr9:136893867	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.63	-9.18	-0.41	1.99e-18	Platelet distribution width;
LUAD	cis	rs11030122	0.661	rs12290747	chr11:3939650	T/C	cg18678763	chr11:4115507	RRM1	-0.45	-7.36	-0.34	9.42e-13	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs6490294	0.861	rs2106956	chr12:112418918	C/T	cg10833066	chr12:111807467	FAM109A	0.42	6.79	0.31	3.87e-11	Mean platelet volume;
LUAD	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.36	-7.07	-0.33	6.41e-12	Crohn's disease;
LUAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg13047869	chr3:10149882	C3orf24	0.59	10.0	0.44	2.77e-21	Alzheimer's disease;
LUAD	cis	rs427941	0.655	rs201472	chr7:101744428	C/T	cg06246474	chr7:101738831	CUX1	0.39	6.83	0.32	2.88e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg23029597	chr12:123009494	RSRC2	-0.47	-7.29	-0.33	1.56e-12	Body mass index;
LUAD	cis	rs4588572	0.686	rs2362823	chr5:77693623	A/G	cg11547950	chr5:77652471	NA	0.77	12.61	0.52	3.75e-31	Triglycerides;
LUAD	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg04703951	chr17:43578652	NA	0.61	8.66	0.39	1e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.96	0.32	1.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9888739	0.920	rs12920597	chr16:31304382	C/T	cg15817542	chr16:31343056	ITGAM	-0.47	-6.5	-0.3	2.2e-10	Systemic lupus erythematosus;
LUAD	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	0.64	7.15	0.33	3.78e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg26924012	chr15:45694286	SPATA5L1	0.99	18.3	0.66	1.64e-55	Homoarginine levels;
LUAD	cis	rs6782228	0.675	rs2253151	chr3:128330137	T/C	cg16766828	chr3:128327626	NA	-0.38	-7.11	-0.33	4.87e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg15704280	chr7:45808275	SEPT13	-0.51	-8.06	-0.36	8.02e-15	Height;
LUAD	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg14844989	chr11:31128820	NA	-0.46	-8.45	-0.38	4.81e-16	Red blood cell count;
LUAD	cis	rs193541	0.555	rs2438151	chr5:122199197	A/G	cg19077854	chr5:122220652	SNX24	0.35	6.38	0.3	4.6e-10	Glucose homeostasis traits;
LUAD	cis	rs11112613	0.609	rs7966960	chr12:106032152	G/A	cg03607813	chr12:105948248	NA	0.53	6.88	0.32	2.19e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg27494647	chr7:150038898	RARRES2	0.52	9.56	0.42	9.59e-20	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.83	0.31	3.04e-11	Cognitive test performance;
LUAD	cis	rs3733418	0.929	rs13149062	chr4:165905360	T/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-7.16	-0.33	3.49e-12	Obesity-related traits;
LUAD	cis	rs4523957	0.890	rs8076939	chr17:2099931	C/A	cg16513277	chr17:2031491	SMG6	-0.8	-15.12	-0.59	1.33e-41	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6426558	0.572	rs2670471	chr1:227454328	T/C	cg10327440	chr1:227177885	CDC42BPA	0.56	9.07	0.4	4.36e-18	Neutrophil percentage of white cells;
LUAD	cis	rs9462027	0.539	rs9469883	chr6:34758627	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.91	-0.4	1.53e-17	Systemic lupus erythematosus;
LUAD	cis	rs7665090	1.000	rs3194585	chr4:103553090	A/G	cg07973026	chr4:103553119	MANBA	0.48	8.52	0.38	2.74e-16	Primary biliary cholangitis;
LUAD	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg11915388	chr22:42470451	FAM109B	-0.41	-7.32	-0.34	1.26e-12	Schizophrenia;
LUAD	cis	rs4901869	0.966	rs9972208	chr14:59336116	C/T	cg02291164	chr14:59296302	NA	0.65	16.03	0.61	1.65e-45	Panic disorder;
LUAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg07677032	chr17:61819896	STRADA	0.57	10.54	0.46	3.21e-23	Prudent dietary pattern;
LUAD	cis	rs3750965	0.839	rs921670	chr11:68871639	C/T	cg06818126	chr11:68850279	TPCN2	-0.43	-6.56	-0.3	1.61e-10	Hair color;
LUAD	cis	rs7586879	0.828	rs1077641	chr2:25123665	G/A	cg04586622	chr2:25135609	ADCY3	0.36	7.28	0.33	1.68e-12	Body mass index;
LUAD	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	8.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg24818145	chr4:99064322	C4orf37	0.47	7.97	0.36	1.44e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg10589385	chr1:150898437	SETDB1	0.42	7.76	0.35	6.39e-14	Melanoma;
LUAD	cis	rs2050392	0.929	rs10826798	chr10:30700904	G/A	cg18806716	chr10:30721971	MAP3K8	0.52	10.46	0.45	6.04e-23	Inflammatory bowel disease;
LUAD	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg24578937	chr1:2090814	PRKCZ	0.78	16.35	0.62	6.3e-47	Height;
LUAD	cis	rs7119	0.635	rs2667764	chr15:77881239	C/T	cg27398640	chr15:77910606	LINGO1	0.42	8.27	0.37	1.73e-15	Type 2 diabetes;
LUAD	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg00316803	chr15:76480434	C15orf27	-0.43	-8.65	-0.39	1.1e-16	Blood metabolite levels;
LUAD	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg21171335	chr12:122356390	WDR66	0.75	13.87	0.56	2.56e-36	Mean platelet volume;
LUAD	cis	rs427394	0.664	rs274722	chr5:6718668	C/T	cg10857441	chr5:6722123	POLS	-0.59	-11.85	-0.5	3.59e-28	Menopause (age at onset);
LUAD	cis	rs12540874	0.965	rs9791887	chr7:50661170	A/C	cg18232548	chr7:50535776	DDC	-0.53	-8.8	-0.39	3.59e-17	Systemic sclerosis;
LUAD	cis	rs2485376	0.842	rs11191283	chr10:104163569	G/A	cg20641465	chr10:103991465	PITX3	-0.53	-9.03	-0.4	6.15e-18	QT interval;
LUAD	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg03684893	chr10:554711	DIP2C	-0.36	-6.43	-0.3	3.38e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg02931644	chr1:25747376	RHCE	0.44	9.36	0.41	4.68e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg19901468	chr14:105411992	AHNAK2	-0.53	-10.26	-0.45	3.24e-22	Rheumatoid arthritis;
LUAD	cis	rs11696501	0.637	rs6130865	chr20:44211845	C/T	cg11783356	chr20:44313418	WFDC10B	-0.46	-7.07	-0.33	6.24e-12	Brain structure;
LUAD	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg00204512	chr16:28754710	NA	0.3	6.48	0.3	2.58e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.47	-8.66	-0.39	9.78e-17	Longevity;Endometriosis;
LUAD	cis	rs7680126	0.585	rs34768406	chr4:10118350	C/A	cg11266682	chr4:10021025	SLC2A9	-0.45	-6.81	-0.31	3.46e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs6740322	0.748	rs6544635	chr2:43486704	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-11.0	-0.47	6.47e-25	Coronary artery disease;
LUAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg10819733	chr22:24237672	NA	-0.4	-7.33	-0.34	1.17e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg27286337	chr10:134555280	INPP5A	0.73	11.24	0.48	7.81e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1953600	0.818	rs2152546	chr10:81906384	G/T	cg00277334	chr10:82204260	NA	-0.36	-6.36	-0.3	5.22e-10	Sarcoidosis;
LUAD	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg15704280	chr7:45808275	SEPT13	-0.91	-17.34	-0.64	2.89e-51	Coronary artery disease;
LUAD	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg23649088	chr2:200775458	C2orf69	0.61	7.74	0.35	7.36e-14	Schizophrenia;
LUAD	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg14008862	chr17:28927542	LRRC37B2	0.75	7.45	0.34	5.13e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg09033563	chr22:24373618	LOC391322	0.51	7.11	0.33	4.92e-12	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg13319975	chr6:146136371	FBXO30	0.56	9.4	0.42	3.43e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4664304	0.789	rs7595388	chr2:160756345	G/A	cg23995753	chr2:160760732	LY75	-0.41	-7.37	-0.34	9.21e-13	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1997103	1.000	rs4590393	chr7:55408990	C/T	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg16205897	chr5:131564050	P4HA2	-0.34	-7.42	-0.34	6.27e-13	Breast cancer;
LUAD	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg19717773	chr7:2847554	GNA12	-0.54	-10.22	-0.44	4.8e-22	Height;
LUAD	cis	rs375066	0.620	rs10401170	chr19:44299623	C/T	cg11993925	chr19:44307056	LYPD5	-0.37	-7.19	-0.33	2.94e-12	Breast cancer;
LUAD	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg10755058	chr3:40428713	ENTPD3	0.37	7.06	0.32	6.95e-12	Renal cell carcinoma;
LUAD	cis	rs1044826	0.642	rs407958	chr3:139213632	T/C	cg00490450	chr3:139108681	COPB2	0.41	6.48	0.3	2.49e-10	Obesity-related traits;
LUAD	cis	rs1232027	0.700	rs1643636	chr5:79928767	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg00074818	chr8:8560427	CLDN23	0.69	10.55	0.46	2.99e-23	Obesity-related traits;
LUAD	cis	rs6138458	1.000	rs6138458	chr20:24973769	C/T	cg26195577	chr20:24973756	C20orf3	0.97	17.03	0.64	6.78e-50	Blood protein levels;
LUAD	cis	rs1595825	0.735	rs113834557	chr2:198611624	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-7.15	-0.33	3.77e-12	Ulcerative colitis;
LUAD	trans	rs4799710	0.620	rs12454561	chr18:31272238	C/T	cg27147174	chr7:100797783	AP1S1	-0.4	-6.39	-0.3	4.41e-10	Pulmonary function;
LUAD	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.49	-0.42	1.75e-19	Life satisfaction;
LUAD	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg20203395	chr5:56204925	C5orf35	0.41	6.44	0.3	3.35e-10	Coronary artery disease;
LUAD	cis	rs9914544	0.524	rs7209853	chr17:18798600	G/A	cg25390199	chr17:18761479	PRPSAP2	-0.37	-6.44	-0.3	3.29e-10	Educational attainment (years of education);
LUAD	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg23649088	chr2:200775458	C2orf69	-0.57	-6.48	-0.3	2.57e-10	Schizophrenia;
LUAD	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg07636037	chr3:49044803	WDR6	0.62	10.4	0.45	9.98e-23	Menarche (age at onset);
LUAD	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06544989	chr22:39130855	UNC84B	0.42	7.88	0.36	2.89e-14	Menopause (age at onset);
LUAD	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg13722127	chr7:150037890	RARRES2	0.5	8.84	0.39	2.63e-17	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg04850017	chr11:63683019	RCOR2	0.37	8.04	0.36	8.78e-15	Pulse pressure;
LUAD	cis	rs6665290	0.904	rs12409428	chr1:227189969	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.45	-0.89	7.93e-144	Myeloid white cell count;
LUAD	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg14582100	chr15:45693742	SPATA5L1	0.63	12.53	0.52	7.51e-31	Homoarginine levels;
LUAD	cis	rs7945705	0.875	rs10769955	chr11:8784647	G/C	cg12365402	chr11:9010492	NRIP3	0.39	6.81	0.31	3.44e-11	Hemoglobin concentration;
LUAD	trans	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg26043149	chr18:55253948	FECH	-0.44	-7.04	-0.32	7.58e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-7.36	-0.34	9.88e-13	Systolic blood pressure;
LUAD	cis	rs2663905	0.706	rs7162859	chr15:81360038	C/T	cg09888468	chr15:81410853	NA	0.53	8.02	0.36	1.07e-14	QT interval (drug interaction);
LUAD	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg19318889	chr4:1322082	MAEA	-0.73	-12.56	-0.52	5.44e-31	Obesity-related traits;
LUAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27286337	chr10:134555280	INPP5A	-0.68	-9.26	-0.41	1.07e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg25554036	chr4:6271136	WFS1	0.69	13.72	0.55	1.11e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs9796	0.505	rs28665387	chr15:41532869	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.46	-8.42	-0.38	5.97e-16	Menopause (age at onset);
LUAD	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg00784671	chr22:46762841	CELSR1	-0.44	-6.76	-0.31	4.48e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2274273	1.000	rs3825613	chr14:55593172	A/C	cg04306507	chr14:55594613	LGALS3	0.38	7.69	0.35	1.07e-13	Protein biomarker;
LUAD	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg25173405	chr17:45401733	C17orf57	0.45	7.49	0.34	4.13e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7020830	0.898	rs7857936	chr9:37078491	T/C	cg14294708	chr9:37120828	ZCCHC7	0.83	16.11	0.62	7.19e-46	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg04398451	chr17:18023971	MYO15A	0.63	10.89	0.47	1.7e-24	Total body bone mineral density;
LUAD	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	cis	rs2485376	0.967	rs772025	chr10:104075721	T/C	cg20641465	chr10:103991465	PITX3	-0.56	-10.29	-0.45	2.68e-22	QT interval;
LUAD	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.8	0.35	4.99e-14	Bladder cancer;
LUAD	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg16647868	chr5:131706066	SLC22A5	-0.38	-6.38	-0.3	4.59e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.55	9.7	0.43	3.32e-20	Lymphocyte counts;
LUAD	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg14343924	chr8:8086146	FLJ10661	0.55	8.49	0.38	3.54e-16	Neuroticism;
LUAD	trans	rs1268789	0.571	rs949507	chr4:79394086	C/T	cg02784696	chr2:24270586	C2orf44	-0.46	-7.09	-0.33	5.55e-12	Hair shape;Hair morphology;
LUAD	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg21285383	chr16:89894308	SPIRE2	0.42	9.16	0.41	2.27e-18	Vitiligo;
LUAD	cis	rs7524258	0.903	rs4908609	chr1:7292910	G/A	cg07173049	chr1:7289937	CAMTA1	0.55	10.37	0.45	1.34e-22	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs977987	0.778	rs11149825	chr16:75434878	C/T	cg03315344	chr16:75512273	CHST6	0.64	14.16	0.57	1.63e-37	Dupuytren's disease;
LUAD	cis	rs9625935	0.700	rs9625921	chr22:30508275	C/G	cg11564601	chr22:30592435	NA	-0.31	-6.56	-0.3	1.54e-10	Tonsillectomy;
LUAD	cis	rs7709909	0.553	rs6151653	chr5:79971612	A/G	cg24059623	chr5:79951536	MSH3;DHFR	0.47	6.97	0.32	1.22e-11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs2294693	0.530	rs2076472	chr6:41029342	C/T	cg14769373	chr6:40998127	UNC5CL	0.56	7.9	0.36	2.39e-14	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs9443645	0.527	rs949846	chr6:79817596	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-6.77	-0.31	4.41e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	15.35	0.6	1.35e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg12940439	chr1:67600707	NA	0.48	9.21	0.41	1.57e-18	Psoriasis;
LUAD	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg21016266	chr12:122356598	WDR66	-0.68	-12.31	-0.51	5.58e-30	Mean corpuscular volume;
LUAD	cis	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05901451	chr6:126070800	HEY2	-0.46	-7.13	-0.33	4.44e-12	Endometrial cancer;
LUAD	cis	rs2455799	0.613	rs2470537	chr3:15716898	C/T	cg16303742	chr3:15540471	COLQ	-0.46	-8.64	-0.39	1.19e-16	Mean platelet volume;
LUAD	cis	rs140330585	1	rs140330585	chr15:78866445	G/A	cg18825076	chr15:78729989	IREB2	-0.56	-9.1	-0.4	3.54e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg09509183	chr1:209979624	IRF6	0.36	6.38	0.3	4.73e-10	Monobrow;
LUAD	cis	rs1448094	0.935	rs4919775	chr12:86339985	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-8.04	-0.36	8.89e-15	Major depressive disorder;
LUAD	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg05313129	chr8:58192883	C8orf71	-0.5	-7.57	-0.35	2.42e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg21782813	chr7:2030301	MAD1L1	0.52	8.87	0.4	2.09e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs4462272	0.503	rs12774352	chr10:101840960	A/G	cg19754520	chr10:101825118	CPN1	-0.34	-7.42	-0.34	6.67e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg07951810	chr12:65153561	GNS	-0.43	-7.14	-0.33	4.23e-12	Subcortical brain region volumes;
LUAD	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg05082376	chr22:42548792	NA	-0.38	-6.68	-0.31	7.61e-11	Cognitive function;
LUAD	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg11344533	chr11:111475393	SIK2	-0.35	-6.68	-0.31	7.77e-11	Primary sclerosing cholangitis;
LUAD	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg06671706	chr8:8559999	CLDN23	0.65	11.29	0.48	5.18e-26	Obesity-related traits;
LUAD	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg00530320	chr1:46809349	NSUN4	0.53	8.01	0.36	1.09e-14	Menopause (age at onset);
LUAD	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg26587870	chr6:27730563	NA	0.52	8.7	0.39	7.52e-17	Parkinson's disease;
LUAD	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg12908607	chr1:44402522	ARTN	-0.54	-10.96	-0.47	8.77e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs12791968	0.527	rs4755924	chr11:45013328	A/G	cg11846598	chr11:44996168	LOC221122	-0.58	-7.7	-0.35	9.92e-14	Inhibitory control;
LUAD	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.58	-0.39	1.8e-16	Neutrophil percentage of white cells;
LUAD	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg25173405	chr17:45401733	C17orf57	-0.55	-9.34	-0.41	5.34e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.6	-11.09	-0.47	2.8e-25	Homoarginine levels;
LUAD	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2797160	1.000	rs1418639	chr6:125999940	C/T	cg05901451	chr6:126070800	HEY2	-0.45	-6.73	-0.31	5.6e-11	Endometrial cancer;
LUAD	cis	rs10791323	0.517	rs1120245	chr11:133745290	A/G	cg03690763	chr11:133734501	NA	-0.27	-6.41	-0.3	3.86e-10	Childhood ear infection;
LUAD	trans	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg04775059	chr7:64541387	NA	0.51	6.96	0.32	1.33e-11	Aortic root size;
LUAD	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg18827107	chr12:86230957	RASSF9	-0.53	-9.21	-0.41	1.54e-18	Major depressive disorder;
LUAD	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg17105886	chr17:28927953	LRRC37B2	0.77	7.67	0.35	1.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs713477	0.845	rs4898863	chr14:55910284	T/A	cg13175173	chr14:55914753	NA	-0.33	-6.97	-0.32	1.22e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg14092988	chr3:52407081	DNAH1	0.37	7.53	0.34	3.17e-13	Bipolar disorder;
LUAD	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.52	0.34	3.34e-13	Tonsillectomy;
LUAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg24642844	chr7:1081250	C7orf50	-0.93	-13.9	-0.56	1.94e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.87	0.36	2.95e-14	Morning vs. evening chronotype;
LUAD	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg03388025	chr16:89894329	SPIRE2	0.33	7.14	0.33	4.22e-12	Vitiligo;
LUAD	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	trans	rs62103177	0.683	rs62101232	chr18:77722454	T/C	cg05926928	chr17:57297772	GDPD1	1.02	11.33	0.48	3.51e-26	Opioid sensitivity;
LUAD	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.36	0.45	1.44e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg18755752	chr8:142205143	DENND3	-0.44	-7.61	-0.35	1.79e-13	Immature fraction of reticulocytes;
LUAD	cis	rs75920871	0.858	rs17120280	chr11:116942132	G/A	cg04087571	chr11:116723030	SIK3	-0.33	-6.73	-0.31	5.61e-11	Subjective well-being;
LUAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg10150615	chr22:24372951	LOC391322	-0.56	-9.08	-0.4	4.3e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.42	-0.34	6.4e-13	Glomerular filtration rate;
LUAD	cis	rs494562	1.000	rs495469	chr6:86117025	C/T	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1232027	0.622	rs1650676	chr5:79959398	C/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.02	-0.32	8.63e-12	Huntington's disease progression;
LUAD	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg13679303	chr9:96623674	NA	-0.37	-7.49	-0.34	3.98e-13	DNA methylation (variation);
LUAD	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg07537917	chr2:241836409	C2orf54	-0.32	-9.18	-0.41	1.92e-18	Urinary metabolites;
LUAD	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg17063962	chr7:91808500	NA	-0.62	-10.69	-0.46	9.4e-24	Breast cancer;
LUAD	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg18240062	chr17:79603768	NPLOC4	-0.36	-6.35	-0.3	5.42e-10	Eye color traits;
LUAD	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg12458913	chr13:53173898	NA	-0.39	-7.03	-0.32	8.23e-12	Lewy body disease;
LUAD	cis	rs4588572	0.686	rs67689570	chr5:77676843	T/C	cg11547950	chr5:77652471	NA	0.75	11.75	0.5	9.04e-28	Triglycerides;
LUAD	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg21724239	chr8:58056113	NA	0.62	7.69	0.35	1.01e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg08645402	chr16:4508243	NA	-0.47	-8.44	-0.38	5e-16	Schizophrenia;
LUAD	cis	rs2444217	0.872	rs2531977	chr16:4043701	C/G	cg09300795	chr16:4042428	ADCY9	0.52	8.97	0.4	1e-17	Body mass index;
LUAD	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg17063962	chr7:91808500	NA	0.7	12.5	0.52	9.93e-31	Breast cancer;
LUAD	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg10523679	chr1:76189770	ACADM	0.95	18.66	0.67	4.06e-57	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7617773	0.817	rs6791930	chr3:48329900	A/G	cg11946769	chr3:48343235	NME6	0.43	6.65	0.31	8.89e-11	Coronary artery disease;
LUAD	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg15549821	chr19:49342101	PLEKHA4	-0.77	-10.11	-0.44	1.1e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.0	10.53	0.46	3.59e-23	Lung cancer in ever smokers;
LUAD	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.89	0.4	1.76e-17	Cognitive ability;
LUAD	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.68e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg04455712	chr21:45112962	RRP1B	0.47	9.34	0.41	5.43e-19	Mean corpuscular volume;
LUAD	cis	rs6684428	1.000	rs10888948	chr1:56382722	G/A	cg11651538	chr1:56320950	NA	-0.41	-6.58	-0.3	1.38e-10	Airflow obstruction;
LUAD	cis	rs62238980	0.614	rs117826138	chr22:32398149	T/C	cg00543991	chr22:32367038	NA	0.95	8.87	0.4	2.05e-17	Childhood ear infection;
LUAD	cis	rs7737355	0.898	rs4706025	chr5:130913788	T/A	cg06307176	chr5:131281290	NA	0.49	7.59	0.35	2.07e-13	Life satisfaction;
LUAD	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg19318889	chr4:1322082	MAEA	-0.42	-7.33	-0.34	1.18e-12	Obesity-related traits;
LUAD	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg13319975	chr6:146136371	FBXO30	-0.58	-9.9	-0.43	6.61e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg15448220	chr1:150897856	SETDB1	0.46	7.97	0.36	1.54e-14	Tonsillectomy;
LUAD	trans	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg14917512	chr19:3094685	GNA11	-0.54	-6.52	-0.3	2.03e-10	Diabetic kidney disease;
LUAD	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23248424	chr5:179741104	GFPT2	0.65	10.77	0.46	4.62e-24	Height;
LUAD	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg06808227	chr14:105710500	BRF1	-0.41	-6.37	-0.3	4.83e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg02569458	chr12:86230093	RASSF9	0.41	7.77	0.35	5.92e-14	Major depressive disorder;
LUAD	cis	rs7709909	0.553	rs245014	chr5:80024434	T/C	cg24059623	chr5:79951536	MSH3;DHFR	0.49	7.44	0.34	5.8e-13	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs10992471	0.702	rs10120915	chr9:95547725	A/C	cg14631576	chr9:95140430	CENPP	-0.38	-7.56	-0.34	2.56e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11644478	chr21:40555479	PSMG1	-0.42	-7.03	-0.32	8.09e-12	Menarche (age at onset);
LUAD	cis	rs7943203	0.524	rs227060	chr11:108204881	C/T	cg04873221	chr11:107992290	ACAT1	-0.48	-7.29	-0.33	1.59e-12	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg11062466	chr8:58055876	NA	0.54	7.41	0.34	6.98e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs11756438	0.547	rs1343287	chr6:119001805	T/C	cg18833306	chr6:118973337	C6orf204	0.54	9.64	0.42	5.02e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg13565492	chr6:43139072	SRF	-0.58	-6.41	-0.3	3.97e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg01145583	chr6:160211477	TCP1;MRPL18	-0.44	-6.36	-0.3	5.17e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.88	-0.32	2.16e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.87	0.32	2.27e-11	Obesity-related traits;
LUAD	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg19761014	chr17:28927070	LRRC37B2	0.74	8.62	0.39	1.38e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg12011299	chr4:100065546	ADH4	0.71	12.93	0.53	1.8e-32	Smoking initiation;
LUAD	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg18196295	chr10:418757	DIP2C	-0.42	-6.4	-0.3	4.03e-10	Psychosis in Alzheimer's disease;
LUAD	trans	rs7944735	0.690	rs7927682	chr11:47947658	T/C	cg03929089	chr4:120376271	NA	0.59	7.42	0.34	6.35e-13	Intraocular pressure;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13986503	chr11:126152983	TIRAP	-0.52	-6.4	-0.3	4.05e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg11344533	chr11:111475393	SIK2	-0.37	-6.64	-0.31	9.55e-11	Primary sclerosing cholangitis;
LUAD	cis	rs738321	0.701	rs11703601	chr22:38598041	C/T	cg25457927	chr22:38595422	NA	-0.58	-12.73	-0.53	1.21e-31	Breast cancer;
LUAD	cis	rs8051149	0.688	rs55776570	chr16:87869516	C/G	cg09285525	chr16:87869786	SLC7A5	0.39	6.42	0.3	3.66e-10	Blood metabolite levels;
LUAD	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg27539214	chr16:67997921	SLC12A4	-0.68	-8.09	-0.37	6.58e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg07460842	chr6:66804631	NA	-1.04	-16.24	-0.62	1.97e-46	Exhaled nitric oxide output;
LUAD	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg03859395	chr2:55845619	SMEK2	0.75	13.99	0.56	7.83e-37	Metabolic syndrome;
LUAD	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg16479474	chr6:28041457	NA	0.41	7.22	0.33	2.47e-12	Parkinson's disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06432538	chr5:67512385	NA	-0.4	-6.49	-0.3	2.37e-10	Cancer;
LUAD	cis	rs7107174	1.000	rs11237460	chr11:78056274	G/A	cg19901956	chr11:77921274	USP35	-0.49	-7.1	-0.33	5.14e-12	Testicular germ cell tumor;
LUAD	cis	rs7192380	1.000	rs2161630	chr16:69606461	C/T	cg00738113	chr16:70207722	CLEC18C	-0.33	-6.65	-0.31	9.29e-11	Sjögren's syndrome;
LUAD	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg09835421	chr16:68378352	PRMT7	-1.08	-12.61	-0.52	3.43e-31	Schizophrenia;
LUAD	trans	rs7395662	0.597	rs2135684	chr11:48748469	G/A	cg00717180	chr2:96193071	NA	-0.38	-7.09	-0.33	5.69e-12	HDL cholesterol;
LUAD	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg18811423	chr2:55921094	PNPT1	0.51	8.37	0.38	8.76e-16	Metabolic syndrome;
LUAD	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-7.97	-0.36	1.53e-14	Multiple myeloma (hyperdiploidy);
LUAD	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs17532515	0.505	rs2043125	chr4:141494104	A/G	cg09181644	chr4:141490428	UCP1	0.36	7.35	0.34	1.04e-12	Select biomarker traits;
LUAD	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.62e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg08847533	chr14:75593920	NEK9	0.39	6.68	0.31	7.43e-11	Height;
LUAD	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	6.76	0.31	4.58e-11	Lung cancer in ever smokers;
LUAD	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg13813247	chr22:41461852	NA	0.41	6.76	0.31	4.7e-11	Neuroticism;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10891259	chr1:116943802	C1orf203;ATP1A1	0.48	6.96	0.32	1.34e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg25324976	chr17:61989376	CSHL1	0.38	7.39	0.34	7.68e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15664640	chr17:80829946	TBCD	0.56	10.74	0.46	5.69e-24	Breast cancer;
LUAD	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg03929089	chr4:120376271	NA	-0.97	-20.33	-0.7	1.38e-64	Height;
LUAD	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg08807101	chr21:30365312	RNF160	-0.43	-7.32	-0.34	1.24e-12	Dental caries;
LUAD	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.65	-0.31	9.09e-11	Mood instability;
LUAD	cis	rs7945718	0.839	rs11022512	chr11:12835952	G/A	cg25843174	chr11:12811716	TEAD1	0.22	6.75	0.31	4.86e-11	Educational attainment (years of education);
LUAD	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1030877	1.000	rs2254301	chr2:105880734	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.6	11.75	0.5	8.91e-28	Obesity-related traits;
LUAD	cis	rs13064411	0.696	rs7624994	chr3:113228009	T/C	cg18753928	chr3:113234510	CCDC52	-0.73	-12.4	-0.52	2.56e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs8073060	1.000	rs8073060	chr17:33875262	T/A	cg19694781	chr19:47549865	TMEM160	0.71	11.14	0.48	1.83e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg20790798	chr5:1857306	NA	-0.47	-8.22	-0.37	2.43e-15	Cardiovascular disease risk factors;
LUAD	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg26587870	chr6:27730563	NA	-0.48	-7.81	-0.35	4.59e-14	Parkinson's disease;
LUAD	cis	rs11676348	0.901	rs7562334	chr2:219003360	G/A	cg06547715	chr2:218990976	CXCR2	0.39	9.22	0.41	1.43e-18	Ulcerative colitis;
LUAD	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg16102102	chr5:83017553	HAPLN1	-0.74	-12.44	-0.52	1.77e-30	Prostate cancer;
LUAD	cis	rs1385374	0.858	rs34888374	chr12:129296536	G/A	cg09035930	chr12:129282057	SLC15A4	-0.65	-6.91	-0.32	1.79e-11	Systemic lupus erythematosus;
LUAD	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg17971929	chr21:40555470	PSMG1	0.56	8.87	0.4	2.04e-17	Cognitive function;
LUAD	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg08798685	chr6:27730294	NA	-0.64	-7.08	-0.33	6.04e-12	Breast cancer;
LUAD	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	ch.11.42038R	chr11:967971	AP2A2	0.39	6.86	0.32	2.41e-11	Alzheimer's disease (late onset);
LUAD	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg14926445	chr8:58193284	C8orf71	-0.47	-6.85	-0.32	2.62e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg13010199	chr12:38710504	ALG10B	0.39	6.38	0.3	4.65e-10	Bladder cancer;
LUAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-9.14	-0.41	2.6e-18	Alzheimer's disease;
LUAD	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.47	-0.3	2.64e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs13315871	1.000	rs9819072	chr3:58353647	A/C	cg20936604	chr3:58311152	NA	-0.69	-7.12	-0.33	4.52e-12	Cholesterol, total;
LUAD	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg22961513	chr11:14280813	SPON1	0.41	8.59	0.39	1.66e-16	Mitochondrial DNA levels;
LUAD	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.31	-6.89	-0.32	2.09e-11	Dupuytren's disease;
LUAD	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.84	-0.32	2.78e-11	Neuroticism;
LUAD	cis	rs1595825	0.891	rs57990618	chr2:198660838	C/T	cg11031976	chr2:198649780	BOLL	-0.49	-6.89	-0.32	2.06e-11	Ulcerative colitis;
LUAD	cis	rs12208915	0.709	rs12663824	chr6:79483130	A/C	cg05283184	chr6:79620031	NA	0.5	6.89	0.32	2.04e-11	Left atrial antero-posterior diameter;
LUAD	cis	rs13315871	0.929	rs17059171	chr3:58302586	A/G	cg20936604	chr3:58311152	NA	-0.77	-8.41	-0.38	6.3e-16	Cholesterol, total;
LUAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08219700	chr8:58056026	NA	0.55	7.5	0.34	3.72e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	2.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4604732	0.536	rs12049066	chr1:247642655	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.43	7.33	0.34	1.15e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg26384229	chr12:38710491	ALG10B	-0.46	-7.89	-0.36	2.68e-14	Heart rate;
LUAD	cis	rs35883536	0.647	rs17402665	chr1:101046940	C/T	cg06223162	chr1:101003688	GPR88	-0.48	-9.31	-0.41	7.1e-19	Monocyte count;
LUAD	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.65	0.42	4.68e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	trans	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg26043149	chr18:55253948	FECH	0.44	7.31	0.33	1.34e-12	Bone mineral density;
LUAD	cis	rs7584330	0.554	rs7558685	chr2:238434943	A/G	cg14458575	chr2:238380390	NA	0.6	9.62	0.42	6.18e-20	Prostate cancer;
LUAD	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.8	0.39	3.42e-17	Menopause (age at onset);
LUAD	trans	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg14917512	chr19:3094685	GNA11	-0.55	-6.51	-0.3	2.14e-10	Diabetic kidney disease;
LUAD	cis	rs8192282	0.690	rs7543174	chr1:154527672	C/T	cg07911225	chr1:154474108	TDRD10;SHE	-0.38	-6.86	-0.32	2.5e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7084921	0.608	rs12773948	chr10:101865115	T/A	cg19754520	chr10:101825118	CPN1	-0.34	-6.68	-0.31	7.77e-11	Bone mineral density;
LUAD	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg01017244	chr2:74357527	NA	0.83	12.09	0.51	4.16e-29	Gestational age at birth (maternal effect);
LUAD	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg15448220	chr1:150897856	SETDB1	0.47	8.02	0.36	1.07e-14	Tonsillectomy;
LUAD	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.79	0.31	3.77e-11	Motion sickness;
LUAD	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.05	0.36	8.77e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2455799	0.573	rs2470539	chr3:15717844	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-9.22	-0.41	1.4e-18	Mean platelet volume;
LUAD	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg13514129	chr1:39547527	MACF1	0.67	12.32	0.51	4.99e-30	Fractional exhaled nitric oxide (childhood);
LUAD	trans	rs9951602	0.512	rs9946123	chr18:76654557	A/G	cg02800362	chr5:177631904	HNRNPAB	0.92	14.62	0.58	1.88e-39	Obesity-related traits;
LUAD	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.72	-0.43	2.63e-20	Bipolar disorder and schizophrenia;
LUAD	trans	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.93	0.4	1.35e-17	Endometrial cancer;
LUAD	trans	rs877282	0.735	rs111609055	chr10:826539	A/G	cg22713356	chr15:30763199	NA	0.87	10.81	0.47	3.14e-24	Uric acid levels;
LUAD	cis	rs921968	0.565	rs2272191	chr2:219609776	G/A	cg02176678	chr2:219576539	TTLL4	-0.59	-12.08	-0.51	4.49e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.51e-15	Bipolar disorder;
LUAD	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg23933602	chr10:16859644	RSU1	0.98	21.28	0.72	7.6e-69	Platelet distribution width;
LUAD	cis	rs3820068	0.705	rs11587541	chr1:15899478	T/C	cg13390004	chr1:15929781	NA	0.42	6.66	0.31	8.64e-11	Systolic blood pressure;
LUAD	cis	rs5758511	0.573	rs1569451	chr22:42232291	C/T	cg03131358	chr22:42195972	CCDC134	-0.38	-6.51	-0.3	2.07e-10	Birth weight;
LUAD	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.44	-7.4	-0.34	7.59e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg13319975	chr6:146136371	FBXO30	-0.59	-9.97	-0.44	3.49e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14240646	chr10:27532245	ACBD5	-0.99	-11.97	-0.5	1.24e-28	Breast cancer;
LUAD	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg10518543	chr12:38710700	ALG10B	-0.43	-7.27	-0.33	1.8e-12	Morning vs. evening chronotype;
LUAD	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.78	-0.43	1.63e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7851660	0.844	rs12342417	chr9:100639065	G/A	cg13688889	chr9:100608707	NA	-0.51	-8.75	-0.39	5.3e-17	Strep throat;
LUAD	cis	rs1215050	0.904	rs890469	chr4:98923293	T/C	cg17366294	chr4:99064904	C4orf37	-0.42	-7.24	-0.33	2.17e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.75	-0.31	5e-11	Mood instability;
LUAD	cis	rs73058052	0.597	rs11083979	chr19:50096144	T/C	cg21913888	chr19:50084626	PRRG2;NOSIP	0.33	8.58	0.38	1.88e-16	Fibrinogen levels;
LUAD	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg14668632	chr7:2872130	GNA12	-0.76	-13.76	-0.56	7.07e-36	Height;
LUAD	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg19318889	chr4:1322082	MAEA	0.85	13.81	0.56	4.43e-36	Longevity;
LUAD	cis	rs12200560	0.505	rs4240555	chr6:97076274	T/C	cg06623918	chr6:96969491	KIAA0776	0.47	7.3	0.33	1.44e-12	Coronary heart disease;
LUAD	cis	rs11893307	0.509	rs2109958	chr2:191533114	T/C	cg11845111	chr2:191398756	TMEM194B	-0.48	-6.94	-0.32	1.51e-11	Mean platelet volume;
LUAD	cis	rs3800461	0.544	rs41312309	chr6:34498328	C/T	cg17674042	chr6:34482479	PACSIN1	-0.77	-9.77	-0.43	1.77e-20	Chronic lymphocytic leukemia;
LUAD	cis	rs4006360	0.606	rs11657468	chr17:39233876	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.06	0.36	7.88e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs612683	0.824	rs17454919	chr1:100830370	A/G	cg06223162	chr1:101003688	GPR88	0.41	7.76	0.35	6.41e-14	Breast cancer;
LUAD	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg00757033	chr12:89920650	WDR51B	0.7	12.2	0.51	1.47e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs4356932	0.967	rs6532103	chr4:76953885	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.37	-6.71	-0.31	6.28e-11	Blood protein levels;
LUAD	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg01851573	chr8:8652454	MFHAS1	0.38	6.64	0.31	9.95e-11	Neuroticism;
LUAD	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.15	-0.33	3.89e-12	Breast cancer;
LUAD	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg23260525	chr10:116636907	FAM160B1	0.46	10.54	0.46	3.11e-23	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg15468180	chr1:107600409	PRMT6	-0.45	-7.71	-0.35	9.11e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.92	-0.36	2.08e-14	Prostate cancer;
LUAD	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg24130564	chr14:104152367	KLC1	-0.53	-9.4	-0.42	3.54e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs877282	0.853	rs11595510	chr10:756757	C/G	cg22713356	chr15:30763199	NA	1.21	16.41	0.62	3.54e-47	Uric acid levels;
LUAD	cis	rs6993813	0.967	rs1872422	chr8:120048305	A/C	cg01975934	chr8:119970761	NA	-0.37	-7.17	-0.33	3.34e-12	Bone mineral density (hip);
LUAD	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg02569458	chr12:86230093	RASSF9	0.45	8.1	0.37	6.02e-15	Major depressive disorder;
LUAD	cis	rs13315871	0.929	rs13080508	chr3:58300116	G/A	cg20936604	chr3:58311152	NA	-0.77	-8.41	-0.38	6.3e-16	Cholesterol, total;
LUAD	cis	rs6500395	1.000	rs9933329	chr16:48646572	T/C	cg04672837	chr16:48644449	N4BP1	0.39	6.82	0.31	3.1e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs877282	0.583	rs10904566	chr10:821662	C/G	cg22713356	chr15:30763199	NA	0.9	11.18	0.48	1.35e-25	Uric acid levels;
LUAD	cis	rs7582720	1.000	rs72932781	chr2:203697278	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.41	0.42	3.29e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.35	0.34	9.99e-13	Menopause (age at onset);
LUAD	cis	rs754466	1.000	rs56256440	chr10:79698207	A/G	cg17075019	chr10:79541650	NA	-0.81	-13.26	-0.54	8.27e-34	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg08213375	chr14:104286397	PPP1R13B	0.27	7.12	0.33	4.78e-12	Schizophrenia;
LUAD	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg01256987	chr12:42539512	GXYLT1	-0.34	-6.7	-0.31	6.74e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg17105886	chr17:28927953	LRRC37B2	0.8	7.82	0.36	4.29e-14	Body mass index;
LUAD	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg09904177	chr6:26538194	HMGN4	0.43	7.24	0.33	2.2e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.26	-6.48	-0.3	2.51e-10	Coronary artery disease;
LUAD	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg01191920	chr7:158217561	PTPRN2	-0.69	-15.17	-0.59	8.55e-42	Obesity-related traits;
LUAD	cis	rs2239547	0.522	rs9846976	chr3:53007995	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-8.78	-0.39	4.05e-17	Schizophrenia;
LUAD	cis	rs1816752	0.806	rs3816218	chr13:25017171	A/G	cg02811702	chr13:24901961	NA	0.46	7.89	0.36	2.6e-14	Obesity-related traits;
LUAD	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs999943	0.774	rs10947421	chr6:33611278	G/T	cg14003231	chr6:33640908	ITPR3	0.84	16.98	0.64	1.08e-49	Obesity (extreme);
LUAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07362569	chr17:61921086	SMARCD2	-0.38	-6.54	-0.3	1.74e-10	Prudent dietary pattern;
LUAD	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg02454025	chr1:11042201	C1orf127	1.04	17.76	0.65	3.83e-53	Ewing sarcoma;
LUAD	cis	rs7586879	0.521	rs1865689	chr2:25108197	C/T	cg01884057	chr2:25150051	NA	-0.34	-7.39	-0.34	7.67e-13	Body mass index;
LUAD	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg13180566	chr4:1052158	NA	-0.39	-6.71	-0.31	6.2e-11	Recombination rate (females);
LUAD	cis	rs790123	1.000	rs790117	chr3:122380888	C/T	cg22896480	chr3:122379438	NA	0.41	6.73	0.31	5.44e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg04287289	chr16:89883240	FANCA	0.74	7.46	0.34	4.93e-13	Skin colour saturation;
LUAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg01101876	chr2:183580910	DNAJC10	-0.51	-6.62	-0.31	1.08e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs929596	0.574	rs75444879	chr2:234587848	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-10.22	-0.44	4.71e-22	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs684232	0.666	rs461521	chr17:622497	G/T	cg15660573	chr17:549704	VPS53	-0.67	-12.54	-0.52	7.1e-31	Prostate cancer;
LUAD	cis	rs4845570	1.000	rs17568246	chr1:151736456	A/G	cg07092448	chr1:151763213	TDRKH	-0.72	-8.04	-0.36	8.86e-15	Coronary artery disease;
LUAD	trans	rs208520	0.661	rs704519	chr6:66801136	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-17.5	-0.65	5.51e-52	Exhaled nitric oxide output;
LUAD	cis	rs6489882	0.671	rs4767024	chr12:113358791	T/C	cg20102336	chr12:113376681	OAS3	-0.54	-8.13	-0.37	4.95e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg08601574	chr20:25228251	PYGB	0.46	8.55	0.38	2.35e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-11.14	-0.48	1.96e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs9796	0.870	rs10851402	chr15:41263438	C/T	cg18705301	chr15:41695430	NDUFAF1	0.37	7.1	0.33	5.45e-12	Menopause (age at onset);
LUAD	cis	rs10207060	0.778	rs6543581	chr2:240702308	C/T	cg07506560	chr2:240697449	NA	-0.41	-8.16	-0.37	3.76e-15	Obesity-related traits;
LUAD	trans	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg16006296	chr10:38738647	LOC399744	0.35	6.4	0.3	4.06e-10	Diastolic blood pressure;
LUAD	cis	rs2290402	0.536	rs2061846	chr4:852484	A/G	cg23939001	chr4:940644	TMEM175	-0.44	-6.58	-0.3	1.39e-10	Type 2 diabetes;
LUAD	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg26898376	chr11:64110657	CCDC88B	-0.37	-7.11	-0.33	4.91e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg27170947	chr2:26402098	FAM59B	-0.81	-11.51	-0.49	7.14e-27	Gut microbiome composition (summer);
LUAD	cis	rs4790333	0.715	rs2447110	chr17:2261677	A/G	cg27406664	chr17:2294951	MNT	0.41	7.93	0.36	2.01e-14	Proinsulin levels;
LUAD	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg04455712	chr21:45112962	RRP1B	0.39	7.96	0.36	1.64e-14	Mean corpuscular volume;
LUAD	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08219700	chr8:58056026	NA	0.61	8.05	0.36	8.74e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.8	-0.35	4.83e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2735413	0.958	rs2735401	chr16:78057103	A/C	cg04733911	chr16:78082701	NA	0.32	7.54	0.34	2.9e-13	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg22676075	chr6:135203613	NA	0.48	8.48	0.38	3.85e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg16405210	chr4:1374714	KIAA1530	-0.61	-9.53	-0.42	1.25e-19	Longevity;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg02048674	chr19:49991517	RPL13AP5;RPL13A	0.43	6.79	0.31	3.74e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg02753203	chr1:228287806	NA	-0.65	-12.78	-0.53	7.8e-32	Diastolic blood pressure;
LUAD	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.52	-0.42	1.37e-19	Life satisfaction;
LUAD	cis	rs4664304	0.739	rs66814375	chr2:160716059	C/T	cg23995753	chr2:160760732	LY75	-0.41	-6.88	-0.32	2.18e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg19418458	chr7:158789849	NA	0.51	8.04	0.36	9.15e-15	Facial morphology (factor 20);
LUAD	cis	rs7786808	0.579	rs12669482	chr7:158188813	G/A	cg01191920	chr7:158217561	PTPRN2	-0.62	-12.81	-0.53	5.53e-32	Obesity-related traits;
LUAD	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	6.39	0.3	4.41e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8038465	0.622	rs2509	chr15:73859488	A/T	cg15420318	chr15:73925796	NPTN	-0.47	-7.68	-0.35	1.11e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1044826	0.642	rs167187	chr3:139237008	C/T	cg00490450	chr3:139108681	COPB2	-0.42	-6.7	-0.31	6.71e-11	Obesity-related traits;
LUAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg20849893	chr7:64541193	NA	-0.45	-7.21	-0.33	2.53e-12	Calcium levels;
LUAD	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.34	7.09	0.33	5.49e-12	Depression;
LUAD	cis	rs6499255	1.000	rs60231938	chr16:69830415	G/A	cg15192750	chr16:69999425	NA	0.54	8.51	0.38	3.16e-16	IgE levels;
LUAD	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg03929089	chr4:120376271	NA	-0.92	-17.83	-0.66	2.01e-53	Height;
LUAD	trans	rs2018683	0.707	rs1021689	chr7:28974223	G/T	cg19402173	chr7:128379420	CALU	-0.52	-8.44	-0.38	5.15e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.72	-0.35	8.21e-14	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs78049276	0.512	rs6820938	chr4:148395903	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.62	-8.7	-0.39	7.48e-17	Pulse pressure;
LUAD	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.4	-0.34	7.33e-13	Bipolar disorder;
LUAD	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg03433033	chr1:76189801	ACADM	0.85	15.12	0.59	1.3e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs943466	1.000	rs4711346	chr6:33730996	C/G	cg16010596	chr6:33739607	LEMD2	-0.34	-6.42	-0.3	3.77e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs12545109	0.879	rs1975285	chr8:57358682	G/C	cg19413350	chr8:57351067	NA	-0.47	-6.93	-0.32	1.55e-11	Obesity-related traits;
LUAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00166722	chr3:10149974	C3orf24	0.73	12.41	0.52	2.18e-30	Alzheimer's disease;
LUAD	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg18016565	chr1:150552671	MCL1	0.41	7.55	0.34	2.78e-13	Tonsillectomy;
LUAD	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg26168224	chr5:2018326	NA	-0.58	-9.88	-0.43	7.28e-21	Gut microbiome composition (winter);
LUAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08048268	chr3:133502702	NA	-0.51	-10.46	-0.45	6.22e-23	Iron status biomarkers;
LUAD	cis	rs7809950	0.861	rs2701682	chr7:107295835	G/A	cg23024343	chr7:107201750	COG5	0.84	13.09	0.54	3.98e-33	Coronary artery disease;
LUAD	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg18252515	chr7:66147081	NA	0.6	6.62	0.31	1.08e-10	Diabetic kidney disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03734322	chr17:1532856	SLC43A2	-0.46	-7.17	-0.33	3.29e-12	Height;
LUAD	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg25535316	chr11:579198	PHRF1	-0.4	-6.4	-0.3	4.17e-10	Systemic lupus erythematosus;
LUAD	cis	rs877282	1.000	rs34257857	chr10:772993	C/A	cg17470449	chr10:769945	NA	0.68	10.67	0.46	1.06e-23	Uric acid levels;
LUAD	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg17366294	chr4:99064904	C4orf37	0.53	9.77	0.43	1.77e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg08470875	chr2:26401718	FAM59B	-0.76	-11.0	-0.47	6.2e-25	Gut microbiome composition (summer);
LUAD	trans	rs4942242	0.640	rs9533563	chr13:44212127	A/G	cg19169023	chr15:41853346	TYRO3	-0.68	-11.76	-0.5	7.75e-28	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg26924012	chr15:45694286	SPATA5L1	1.03	19.34	0.68	3.82e-60	Homoarginine levels;
LUAD	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg17845761	chr1:175162550	KIAA0040	0.34	9.12	0.41	3.17e-18	Alcohol dependence;
LUAD	trans	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg18876405	chr7:65276391	NA	0.48	7.78	0.35	5.47e-14	Corneal structure;
LUAD	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg03605463	chr16:89740564	NA	0.58	10.77	0.46	4.48e-24	Hemoglobin concentration;
LUAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.48	0.45	5.49e-23	Prudent dietary pattern;
LUAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.51	-9.36	-0.41	4.8e-19	Longevity;Endometriosis;
LUAD	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg11502198	chr6:26597334	ABT1	0.66	11.38	0.48	2.33e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg08888203	chr3:10149979	C3orf24	0.72	11.26	0.48	6.58e-26	Alzheimer's disease;
LUAD	cis	rs7712401	0.601	rs144597	chr5:122223232	A/C	cg19077854	chr5:122220652	SNX24	0.35	6.53	0.3	1.95e-10	Mean platelet volume;
LUAD	cis	rs7582720	1.000	rs72934729	chr2:203737770	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.45	0.42	2.39e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg25753631	chr6:25732923	NA	-0.37	-6.43	-0.3	3.49e-10	Iron status biomarkers;
LUAD	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg00310523	chr12:86230176	RASSF9	0.4	7.98	0.36	1.4e-14	Major depressive disorder;
LUAD	cis	rs1881797	0.527	rs78486847	chr1:247638515	C/T	cg21399703	chr1:247681439	NA	0.46	6.38	0.3	4.58e-10	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2637266	0.783	rs720249	chr10:78476143	T/C	cg18941641	chr10:78392320	NA	0.33	6.92	0.32	1.7e-11	Pulmonary function;
LUAD	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg08493051	chr2:3487164	NA	-0.45	-7.81	-0.35	4.63e-14	Neurofibrillary tangles;
LUAD	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg14671364	chr1:107599128	PRMT6	0.6	10.11	0.44	1.19e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs8002861	0.935	rs7319725	chr13:44445421	T/C	cg17145862	chr1:211918768	LPGAT1	0.78	18.54	0.67	1.35e-56	Leprosy;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11582133	chr15:41576691	LOC729082	0.42	6.43	0.3	3.49e-10	Gut microbiome composition (summer);
LUAD	cis	rs758324	0.853	rs1604082	chr5:131176917	A/G	cg06307176	chr5:131281290	NA	0.43	7.25	0.33	2e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg13385794	chr1:248469461	NA	0.26	7.14	0.33	4.05e-12	Common traits (Other);
LUAD	cis	rs6684514	1.000	rs11264462	chr1:156241728	G/A	cg16558208	chr1:156270281	VHLL	0.53	9.5	0.42	1.58e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs13190036	1.000	rs13175695	chr5:176699811	A/G	cg06733329	chr5:176740039	MXD3	-0.51	-7.0	-0.32	1.03e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	cis	rs12791968	0.527	rs4755300	chr11:45013421	C/T	cg11846598	chr11:44996168	LOC221122	0.59	7.88	0.36	2.88e-14	Inhibitory control;
LUAD	trans	rs2797160	1.000	rs9401843	chr6:126004124	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.65	-0.39	1.08e-16	Endometrial cancer;
LUAD	trans	rs877282	0.853	rs11596346	chr10:756673	A/T	cg22713356	chr15:30763199	NA	1.24	16.27	0.62	1.44e-46	Uric acid levels;
LUAD	cis	rs11771526	0.681	rs79578813	chr7:32308867	G/T	cg27511599	chr7:32358540	NA	0.51	6.51	0.3	2.08e-10	Body mass index;
LUAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg22907277	chr7:1156413	C7orf50	0.67	8.46	0.38	4.34e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.22	-0.41	1.46e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg23982607	chr1:1823379	GNB1	-0.9	-18.84	-0.68	6.51e-58	Body mass index;
LUAD	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg00757033	chr12:89920650	WDR51B	0.69	12.2	0.51	1.54e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7737355	0.898	rs4706030	chr5:130957486	A/G	cg06307176	chr5:131281290	NA	0.5	7.68	0.35	1.11e-13	Life satisfaction;
LUAD	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg02018176	chr4:1364513	KIAA1530	0.37	6.95	0.32	1.43e-11	Obesity-related traits;
LUAD	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg09873201	chr16:3507582	NAT15	-0.53	-8.04	-0.36	9.04e-15	Tuberculosis;
LUAD	cis	rs471144	0.881	rs12089980	chr1:152431931	C/T	cg23107878	chr1:152161397	NA	0.66	6.6	0.31	1.26e-10	Inflammatory skin disease;
LUAD	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg05717871	chr11:638507	DRD4	-0.41	-6.46	-0.3	2.85e-10	Systemic lupus erythematosus;
LUAD	cis	rs757647	0.723	rs59023560	chr5:137736998	T/A	cg10676309	chr5:137685565	NA	0.42	7.52	0.34	3.22e-13	Menarche (age at onset);
LUAD	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg08999081	chr20:33150536	PIGU	0.48	9.11	0.4	3.43e-18	Coronary artery disease;
LUAD	trans	rs1493916	0.748	rs4799355	chr18:31313124	G/T	cg15819921	chr19:927150	ARID3A	-0.4	-6.5	-0.3	2.2e-10	Life satisfaction;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12641047	chr11:75110500	SNORD15A;RPS3	-0.4	-6.62	-0.31	1.07e-10	Cancer;
LUAD	trans	rs853679	0.607	rs34691223	chr6:28258208	C/A	cg01620082	chr3:125678407	NA	-1.05	-10.62	-0.46	1.58e-23	Depression;
LUAD	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg09263875	chr16:632152	PIGQ	0.81	17.48	0.65	7.12e-52	Height;
LUAD	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.22	-0.37	2.55e-15	Total body bone mineral density;
LUAD	trans	rs8073060	0.586	rs6505484	chr17:33993152	G/A	cg19694781	chr19:47549865	TMEM160	-1.22	-19.18	-0.68	1.92e-59	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg04000281	chr11:63949212	NA	-0.29	-6.7	-0.31	6.84e-11	Platelet count;
LUAD	cis	rs2742234	0.666	rs715106	chr10:43616751	C/A	cg15436174	chr10:43711423	RASGEF1A	-0.52	-8.7	-0.39	7.65e-17	Hirschsprung disease;
LUAD	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg04944784	chr2:26401820	FAM59B	-0.84	-11.27	-0.48	6.21e-26	Gut microbiome composition (summer);
LUAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg27532560	chr4:187881888	NA	-0.36	-6.86	-0.32	2.42e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17401966	0.898	rs12122107	chr1:10251449	C/T	cg15208524	chr1:10270712	KIF1B	0.53	7.48	0.34	4.47e-13	Hepatocellular carcinoma;
LUAD	cis	rs427394	0.582	rs274662	chr5:6704860	G/A	cg10857441	chr5:6722123	POLS	-0.57	-10.1	-0.44	1.23e-21	Menopause (age at onset);
LUAD	cis	rs34311866	0.808	rs748483	chr4:952409	A/G	cg14530993	chr4:882597	GAK	0.71	6.73	0.31	5.37e-11	Parkinson's disease;
LUAD	cis	rs7193541	0.929	rs12933037	chr16:74660174	G/A	cg01733217	chr16:74700730	RFWD3	0.57	9.62	0.42	5.89e-20	Multiple myeloma;
LUAD	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg05340658	chr4:99064831	C4orf37	-0.55	-9.35	-0.41	5.28e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	6.6	0.31	1.21e-10	Rheumatoid arthritis;
LUAD	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg02683114	chr2:24398427	C2orf84	-0.4	-6.38	-0.3	4.57e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg01788221	chr16:89496183	ANKRD11	-0.35	-6.71	-0.31	6.28e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg24675658	chr1:53192096	ZYG11B	0.44	7.09	0.33	5.61e-12	Monocyte count;
LUAD	cis	rs35740288	0.770	rs11630968	chr15:86118001	C/T	cg13263323	chr15:86062960	AKAP13	-0.43	-6.77	-0.31	4.39e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	trans	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.29	0.54	6.55e-34	Exhaled nitric oxide output;
LUAD	cis	rs1003719	0.788	rs4817843	chr21:38447040	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.44	0.38	5.28e-16	Eye color traits;
LUAD	cis	rs11048434	0.736	rs7957321	chr12:9120154	C/T	cg04155231	chr12:9217510	LOC144571	0.38	7.05	0.32	7.26e-12	Sjögren's syndrome;
LUAD	cis	rs12347191	0.500	rs1912998	chr9:100621386	T/C	cg13688889	chr9:100608707	NA	-0.63	-10.21	-0.44	4.95e-22	Orofacial clefts;
LUAD	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg25985355	chr7:65971099	NA	-0.53	-6.62	-0.31	1.09e-10	Diabetic kidney disease;
LUAD	cis	rs9473147	0.516	rs9296564	chr6:47494759	A/G	cg02130027	chr6:47444894	CD2AP	0.37	7.06	0.32	6.69e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg08859206	chr1:53392774	SCP2	-0.57	-10.72	-0.46	7.25e-24	Monocyte count;
LUAD	cis	rs10916814	0.588	rs4571937	chr1:20897033	G/A	cg24502330	chr1:20914028	CDA	-0.36	-7.11	-0.33	4.91e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg19318889	chr4:1322082	MAEA	0.46	7.63	0.35	1.61e-13	Obesity-related traits;
LUAD	cis	rs138544659	1	rs138544659	chr15:78900701	T/G	cg18825076	chr15:78729989	IREB2	-0.58	-9.46	-0.42	2.23e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	trans	rs75804782	0.572	rs77008212	chr2:239307113	A/G	cg01134436	chr17:81009848	B3GNTL1	0.77	6.82	0.31	3.14e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs57994353	0.793	rs33982662	chr9:139324737	C/A	cg14169450	chr9:139327907	INPP5E	0.41	6.67	0.31	7.86e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg00677455	chr12:58241039	CTDSP2	0.43	7.41	0.34	7.08e-13	Multiple sclerosis;
LUAD	trans	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg14917512	chr19:3094685	GNA11	0.58	6.84	0.32	2.72e-11	Diabetic kidney disease;
LUAD	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg11189052	chr15:85197271	WDR73	0.65	8.87	0.4	2.1e-17	Schizophrenia;
LUAD	cis	rs6024905	0.783	rs6069757	chr20:36956516	G/A	cg07053727	chr20:36965646	BPI	0.35	6.39	0.3	4.39e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg25173405	chr17:45401733	C17orf57	-0.53	-9.09	-0.4	3.97e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27286337	chr10:134555280	INPP5A	0.72	9.72	0.43	2.76e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg17097710	chr5:1061055	SLC12A7	-0.41	-7.38	-0.34	8.22e-13	QT interval;
LUAD	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg13393036	chr8:95962371	TP53INP1	0.33	7.01	0.32	9.66e-12	Type 2 diabetes;
LUAD	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg24733560	chr20:60626293	TAF4	0.48	9.45	0.42	2.39e-19	Body mass index;
LUAD	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg03388025	chr16:89894329	SPIRE2	0.32	6.85	0.32	2.56e-11	Vitiligo;
LUAD	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg03929089	chr4:120376271	NA	-0.46	-7.11	-0.33	5.09e-12	Height;
LUAD	cis	rs4692589	0.606	rs11943813	chr4:170938243	T/C	cg19918862	chr4:170955249	NA	0.33	6.81	0.31	3.46e-11	Anxiety disorder;
LUAD	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg17633681	chr16:88106987	BANP	0.38	6.75	0.31	4.76e-11	Menopause (age at onset);
LUAD	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs2279817	0.691	rs7543007	chr1:17990475	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.42	-6.36	-0.3	5.37e-10	Neuroticism;
LUAD	cis	rs6684514	1.000	rs2296375	chr1:156309372	G/C	cg16558208	chr1:156270281	VHLL	0.52	9.25	0.41	1.13e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg11301795	chr4:187892539	NA	-0.77	-15.69	-0.61	4.73e-44	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs73206853	0.563	rs73194032	chr12:111162182	G/A	cg12870014	chr12:110450643	ANKRD13A	0.6	7.08	0.33	5.94e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.66	0.31	8.34e-11	Depression;
LUAD	cis	rs3820068	0.871	rs76155024	chr1:15807142	T/C	cg17177755	chr1:15930204	NA	0.46	6.55	0.3	1.69e-10	Systolic blood pressure;
LUAD	trans	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg27411982	chr8:10470053	RP1L1	0.43	7.64	0.35	1.43e-13	Mood instability;
LUAD	cis	rs3820068	0.705	rs11584398	chr1:15880275	G/A	cg13390004	chr1:15929781	NA	0.43	6.8	0.31	3.67e-11	Systolic blood pressure;
LUAD	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg07432352	chr17:45403706	C17orf57	0.34	6.5	0.3	2.31e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg23711669	chr6:146136114	FBXO30	0.4	6.78	0.31	3.97e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg05283184	chr6:79620031	NA	-0.62	-12.45	-0.52	1.51e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11890956	chr21:40555474	PSMG1	0.82	14.73	0.58	6.31e-40	Cognitive function;
LUAD	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg22681709	chr2:178499509	PDE11A	-0.47	-7.76	-0.35	6.59e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg11301795	chr4:187892539	NA	-0.77	-15.69	-0.61	4.73e-44	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg08601574	chr20:25228251	PYGB	0.47	8.56	0.38	2.17e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs13082711	0.911	rs923940	chr3:27459341	C/G	cg02860705	chr3:27208620	NA	0.57	8.8	0.39	3.48e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg07157834	chr1:205819609	PM20D1	-0.46	-6.88	-0.32	2.19e-11	Menarche (age at onset);
LUAD	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg20933634	chr6:27740509	NA	0.47	7.0	0.32	9.82e-12	Breast cancer;
LUAD	cis	rs56104184	0.830	rs73061622	chr19:49358111	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.21	-17.38	-0.65	1.85e-51	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg05754148	chr16:3507555	NAT15	-0.42	-6.45	-0.3	2.99e-10	Body mass index (adult);
LUAD	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg26384229	chr12:38710491	ALG10B	0.39	6.79	0.31	3.84e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg06484146	chr7:12443880	VWDE	-0.58	-7.35	-0.34	1.01e-12	Coronary artery disease;
LUAD	cis	rs6500395	1.000	rs12934126	chr16:48705951	C/G	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg17749961	chr2:30669863	LCLAT1	0.55	6.64	0.31	9.86e-11	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg26898376	chr11:64110657	CCDC88B	0.37	6.86	0.32	2.52e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg08027265	chr7:2291960	NA	-0.47	-8.1	-0.37	5.95e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs17445774	0.857	rs6435043	chr2:200900974	C/G	cg23649088	chr2:200775458	C2orf69	0.73	11.49	0.49	8.61e-27	LDL cholesterol to HDL cholesterol ratio;
LUAD	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg23815491	chr16:72088622	HP	0.55	9.92	0.43	5.42e-21	Fibrinogen levels;
LUAD	cis	rs4954585	0.683	rs4072434	chr2:137014023	C/G	cg05194412	chr2:137003533	NA	0.62	11.2	0.48	1.12e-25	Colorectal cancer;
LUAD	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg02551604	chr5:131831745	NA	0.62	9.9	0.43	6.43e-21	Asthma (sex interaction);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg04515913	chr15:89182103	ISG20	0.42	6.74	0.31	5.3e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg15123519	chr2:136567270	LCT	0.36	6.51	0.3	2.13e-10	Mosquito bite size;
LUAD	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	8.07	0.37	7.13e-15	Rheumatoid arthritis;
LUAD	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.1	-0.57	2.78e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs1950626	0.623	rs35947256	chr14:101460366	G/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.36	6.73	0.31	5.54e-11	Pelvic organ prolapse (moderate/severe);
LUAD	trans	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	6.07e-11	Depression;
LUAD	cis	rs7917772	0.582	rs7922780	chr10:104401203	G/A	cg22532475	chr10:104410764	TRIM8	0.4	8.18	0.37	3.45e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-7.04	-0.32	7.65e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs220324	0.738	rs9975104	chr21:43579344	G/T	cg08841829	chr21:43638893	ABCG1	-0.52	-6.9	-0.32	1.88e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs208520	0.661	rs207079	chr6:66770462	C/T	cg07460842	chr6:66804631	NA	-1.06	-16.52	-0.63	1.12e-47	Exhaled nitric oxide output;
LUAD	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg06623918	chr6:96969491	KIAA0776	0.89	17.63	0.65	1.47e-52	Headache;
LUAD	cis	rs7043114	0.544	rs12335553	chr9:95297871	A/C	cg14631576	chr9:95140430	CENPP	-0.4	-8.04	-0.36	9.07e-15	Height;
LUAD	cis	rs250585	1.000	rs2073951	chr16:23546561	G/C	cg00143387	chr16:23521605	GGA2	-0.68	-8.1	-0.37	6.11e-15	Egg allergy;
LUAD	cis	rs9796	0.621	rs7170049	chr15:41484287	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.45	-7.99	-0.36	1.26e-14	Menopause (age at onset);
LUAD	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg08859206	chr1:53392774	SCP2	-0.78	-14.8	-0.58	3.05e-40	Monocyte count;
LUAD	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg20701182	chr2:24300061	SF3B14	0.56	6.65	0.31	8.93e-11	Lymphocyte counts;
LUAD	cis	rs7043114	0.507	rs10992340	chr9:95209693	T/C	cg14631576	chr9:95140430	CENPP	-0.39	-7.93	-0.36	1.97e-14	Height;
LUAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg24813613	chr7:1882135	MAD1L1	-0.5	-8.33	-0.38	1.12e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1034435	0.755	rs713923	chr22:48891519	C/T	cg05992904	chr22:48892994	FAM19A5	0.72	15.67	0.61	5.86e-44	Late-onset Alzheimer's disease;
LUAD	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg09455208	chr3:40491958	NA	0.57	12.58	0.52	4.94e-31	Renal cell carcinoma;
LUAD	cis	rs7737355	0.947	rs39600	chr5:130828649	A/T	cg25547332	chr5:131281432	NA	0.43	6.64	0.31	9.7e-11	Life satisfaction;
LUAD	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg06781209	chr11:61594997	FADS2	-0.39	-7.44	-0.34	5.71e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.54	0.3	1.75e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7799006	0.929	rs35791351	chr7:2269248	C/T	cg08027265	chr7:2291960	NA	-0.57	-10.58	-0.46	2.37e-23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg17063962	chr7:91808500	NA	0.71	12.53	0.52	7.17e-31	Breast cancer;
LUAD	cis	rs490234	0.966	rs509753	chr9:128303518	G/A	cg14078157	chr9:128172775	NA	0.38	7.09	0.33	5.68e-12	Mean arterial pressure;
LUAD	trans	rs7395662	1.000	rs10838944	chr11:48559571	T/C	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.75e-10	HDL cholesterol;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08721347	chr1:95538652	ALG14	-0.46	-7.02	-0.32	8.76e-12	Height;
LUAD	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg22166914	chr1:53195759	ZYG11B	0.4	6.6	0.31	1.26e-10	Monocyte count;
LUAD	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg10053473	chr17:62856997	LRRC37A3	0.79	11.18	0.48	1.29e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.08	-0.37	6.68e-15	Total body bone mineral density;
LUAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00149659	chr3:10157352	C3orf10	0.57	8.06	0.36	7.87e-15	Alzheimer's disease;
LUAD	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg09904177	chr6:26538194	HMGN4	0.44	7.36	0.34	9.71e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg25358565	chr5:93447407	FAM172A	0.64	7.62	0.35	1.63e-13	Diabetic retinopathy;
LUAD	cis	rs68170813	0.652	rs76742243	chr7:107144202	G/A	cg23024343	chr7:107201750	COG5	0.52	6.59	0.31	1.32e-10	Coronary artery disease;
LUAD	cis	rs4774899	1.000	rs12900986	chr15:57258736	C/G	cg14026238	chr15:57616123	NA	-0.35	-6.77	-0.31	4.3e-11	Urinary tract infection frequency;
LUAD	cis	rs9972944	0.702	rs987931	chr17:63765911	T/G	cg07283582	chr17:63770753	CCDC46	-0.5	-11.22	-0.48	9.47e-26	Total body bone mineral density;
LUAD	cis	rs28595532	0.841	rs115233595	chr4:119744214	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg05182265	chr7:156933206	UBE3C	0.68	13.15	0.54	2.44e-33	Body mass index;
LUAD	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg27490568	chr2:178487706	NA	0.4	6.78	0.31	3.95e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg01689657	chr7:91764605	CYP51A1	-0.36	-8.86	-0.4	2.22e-17	Breast cancer;
LUAD	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.69	11.28	0.48	5.42e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg27535305	chr1:53392650	SCP2	0.31	6.59	0.31	1.33e-10	Monocyte count;
LUAD	cis	rs4253772	0.872	rs45552534	chr22:46638171	G/A	cg09491104	chr22:46646882	C22orf40	-0.54	-7.83	-0.36	4.09e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg00271210	chr6:167070053	RPS6KA2	0.35	6.71	0.31	6.44e-11	Crohn's disease;
LUAD	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg08085267	chr17:45401833	C17orf57	-0.49	-8.27	-0.37	1.81e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-6.68	-0.31	7.38e-11	Tonsillectomy;
LUAD	cis	rs367943	0.966	rs348932	chr5:112812457	G/A	cg12552261	chr5:112820674	MCC	-0.58	-11.04	-0.47	4.66e-25	Type 2 diabetes;
LUAD	cis	rs9323205	0.906	rs11629336	chr14:51686620	A/C	cg23942311	chr14:51606299	NA	0.61	9.87	0.43	7.88e-21	Cancer;
LUAD	cis	rs2063714	0.532	rs2063713	chr6:157196299	G/T	cg23222435	chr6:157204239	ARID1B	-0.44	-7.43	-0.34	6.1e-13	Sitting height ratio;
LUAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg18402987	chr7:1209562	NA	0.77	9.45	0.42	2.3e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg18811423	chr2:55921094	PNPT1	0.55	9.21	0.41	1.58e-18	Metabolic syndrome;
LUAD	cis	rs62064224	0.553	rs9896320	chr17:30689814	G/A	cg25809561	chr17:30822961	MYO1D	0.48	8.71	0.39	6.78e-17	Schizophrenia;
LUAD	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.84e-26	Alzheimer's disease (late onset);
LUAD	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg00852783	chr1:26633632	UBXN11	0.45	7.28	0.33	1.68e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg00922110	chr4:57842668	C4orf14	-0.44	-8.43	-0.38	5.53e-16	Response to bleomycin (chromatid breaks);
LUAD	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg13789015	chr9:136890014	NCRNA00094	0.87	14.5	0.58	5.64e-39	Platelet distribution width;
LUAD	cis	rs2692947	0.696	rs1724121	chr2:96808549	T/C	cg23100626	chr2:96804247	ASTL	0.36	9.74	0.43	2.41e-20	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2742234	1.000	rs1864395	chr10:43655697	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.45	-8.11	-0.37	5.44e-15	Hirschsprung disease;
LUAD	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg27144592	chr16:783916	NARFL	0.71	12.47	0.52	1.35e-30	Height;
LUAD	cis	rs3750965	1.000	rs731974	chr11:68847156	C/T	cg06818126	chr11:68850279	TPCN2	-0.48	-7.04	-0.32	7.63e-12	Hair color;
LUAD	cis	rs863345	0.625	rs10752626	chr1:158528118	G/A	cg12129480	chr1:158549410	OR10X1	-0.25	-6.7	-0.31	6.5500000000000006e-11	Pneumococcal bacteremia;
LUAD	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs897984	0.762	rs1870293	chr16:30970941	T/C	cg02466173	chr16:30829666	NA	0.61	11.12	0.48	2.19e-25	Dementia with Lewy bodies;
LUAD	cis	rs7737355	0.812	rs8180462	chr5:130907189	A/G	cg25547332	chr5:131281432	NA	0.4	6.64	0.31	9.83e-11	Life satisfaction;
LUAD	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg18827107	chr12:86230957	RASSF9	-0.69	-12.71	-0.53	1.37e-31	Major depressive disorder;
LUAD	cis	rs67311347	0.544	rs12635762	chr3:40332759	C/T	cg02782426	chr3:40428986	ENTPD3	-0.3	-6.49	-0.3	2.4e-10	Renal cell carcinoma;
LUAD	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg18944383	chr4:111397179	ENPEP	0.38	7.69	0.35	1.05e-13	Height;
LUAD	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.42	-0.42	3.07e-19	Dilated cardiomyopathy;
LUAD	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg18512352	chr11:47633146	NA	-0.56	-10.02	-0.44	2.34e-21	Subjective well-being;
LUAD	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg00530320	chr1:46809349	NSUN4	0.53	7.97	0.36	1.45e-14	Menopause (age at onset);
LUAD	cis	rs300774	0.841	rs453447	chr2:205446	G/T	cg21211680	chr2:198530	NA	0.59	8.65	0.39	1.09e-16	Suicide attempts in bipolar disorder;
LUAD	cis	rs62238980	0.614	rs2413064	chr22:32458536	G/T	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg00321850	chr1:175162397	KIAA0040	-0.51	-10.8	-0.46	3.6e-24	Alcohol dependence;
LUAD	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg03467027	chr4:99064603	C4orf37	0.42	6.83	0.32	2.88e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6076065	0.748	rs6048781	chr20:23380027	T/C	cg11657817	chr20:23433608	CST11	0.57	12.04	0.51	6.46e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg26343298	chr8:95960752	TP53INP1	0.33	6.43	0.3	3.49e-10	Type 2 diabetes;
LUAD	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg23758822	chr17:41437982	NA	0.99	19.88	0.7	1.35e-62	Menopause (age at onset);
LUAD	trans	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg21659725	chr3:3221576	CRBN	-0.58	-9.2	-0.41	1.6e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7937890	0.532	rs2575833	chr11:14492505	A/C	cg23387056	chr11:14280742	SPON1	-0.36	-6.93	-0.32	1.61e-11	Mitochondrial DNA levels;
LUAD	cis	rs10979	0.597	rs9496685	chr6:143908690	G/A	cg25407410	chr6:143891975	LOC285740	-0.54	-7.66	-0.35	1.31e-13	Hypospadias;
LUAD	cis	rs7975161	0.638	rs10861170	chr12:104615957	A/G	cg04063896	chr12:104565784	NA	-0.36	-6.64	-0.31	9.67e-11	Toenail selenium levels;
LUAD	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg00316803	chr15:76480434	C15orf27	-0.41	-8.0	-0.36	1.21e-14	Blood metabolite levels;
LUAD	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22857025	chr5:266934	NA	0.97	14.49	0.58	6.38e-39	Breast cancer;
LUAD	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.18	-0.37	3.44e-15	Bone mineral density (spine);
LUAD	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg16989719	chr2:238392110	NA	-0.38	-7.88	-0.36	2.73e-14	Prostate cancer;
LUAD	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg09359103	chr1:154839909	KCNN3	-0.5	-8.88	-0.4	1.92e-17	Schizophrenia;
LUAD	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg07917127	chr4:99064746	C4orf37	0.42	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4006360	0.520	rs4986664	chr17:39250248	C/T	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.3	0.37	1.43e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7084921	0.608	rs7474634	chr10:101863410	A/C	cg19754520	chr10:101825118	CPN1	0.35	7.13	0.33	4.37e-12	Bone mineral density;
LUAD	cis	rs4888262	0.508	rs12598701	chr16:74539904	G/A	cg01733217	chr16:74700730	RFWD3	0.48	8.15	0.37	4.06e-15	Testicular germ cell tumor;
LUAD	cis	rs4713675	0.565	rs9366828	chr6:33672798	G/A	cg13859433	chr6:33739653	LEMD2	-0.3	-7.06	-0.32	6.95e-12	Plateletcrit;
LUAD	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg12623918	chr2:306882	NA	0.36	7.27	0.33	1.72e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.85	-0.36	3.56e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg06753367	chr22:24256600	NA	-0.38	-6.61	-0.31	1.13e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg02782426	chr3:40428986	ENTPD3	0.43	9.58	0.42	8.59e-20	Renal cell carcinoma;
LUAD	cis	rs4072705	0.614	rs1570581	chr9:127234059	A/G	cg13476313	chr9:127244764	NR5A1	0.34	8.34	0.38	1.05e-15	Menarche (age at onset);
LUAD	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg19077165	chr18:44547161	KATNAL2	-0.43	-7.37	-0.34	8.87e-13	Personality dimensions;
LUAD	cis	rs60871478	1.000	rs62432223	chr7:787959	A/G	cg04727924	chr7:799746	HEATR2	-0.52	-6.73	-0.31	5.39e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7833986	0.501	rs2719226	chr8:57044066	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.97	16.98	0.64	1.07e-49	Height;
LUAD	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg16006841	chr5:176797999	RGS14	-0.69	-12.68	-0.52	1.91e-31	Urinary electrolytes (magnesium/calcium ratio);
LUAD	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.38	-0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg13319975	chr6:146136371	FBXO30	-0.61	-10.41	-0.45	9.87e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7107174	0.901	rs2450133	chr11:77925759	A/C	cg19901956	chr11:77921274	USP35	-0.54	-6.72	-0.31	5.73e-11	Testicular germ cell tumor;
LUAD	cis	rs7870753	0.578	rs2145985	chr9:99174531	C/T	cg13563390	chr9:99253610	HABP4	-0.38	-6.43	-0.3	3.36e-10	Height;
LUAD	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24308560	chr3:49941425	MST1R	0.6	10.31	0.45	2.29e-22	Intelligence (multi-trait analysis);
LUAD	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg05727186	chr17:43697356	MGC57346	-0.55	-6.83	-0.32	3e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg14820908	chr5:178986412	RUFY1	-0.69	-12.4	-0.52	2.52e-30	Lung cancer;
LUAD	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-7.34	-0.34	1.08e-12	Morning vs. evening chronotype;
LUAD	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00934597	chr7:893267	UNC84A	-0.53	-8.74	-0.39	5.7e-17	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs977987	0.771	rs8048527	chr16:75422054	C/A	cg03315344	chr16:75512273	CHST6	0.64	14.09	0.57	3.09e-37	Dupuytren's disease;
LUAD	cis	rs8017423	0.967	rs17188605	chr14:90722579	C/T	cg14092571	chr14:90743983	NA	-0.5	-8.89	-0.4	1.76e-17	Mortality in heart failure;
LUAD	cis	rs7731657	0.510	rs986496	chr5:130282172	C/T	cg08523029	chr5:130500466	HINT1	0.57	7.43	0.34	5.98e-13	Fasting plasma glucose;
LUAD	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12667521	chr19:29218732	NA	0.59	8.42	0.38	6.1e-16	Methadone dose in opioid dependence;
LUAD	cis	rs2115630	0.764	rs11073716	chr15:85335774	C/T	cg11189052	chr15:85197271	WDR73	-0.46	-7.29	-0.33	1.52e-12	P wave terminal force;
LUAD	cis	rs208520	0.909	rs62414639	chr6:67023706	G/A	cg07460842	chr6:66804631	NA	0.82	9.61	0.42	6.36e-20	Exhaled nitric oxide output;
LUAD	cis	rs7911264	0.905	rs7918084	chr10:94429467	C/T	cg25093409	chr10:94429542	NA	0.38	6.96	0.32	1.31e-11	Inflammatory bowel disease;
LUAD	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg06627628	chr2:24431161	ITSN2	-0.48	-6.66	-0.31	8.58e-11	Lymphocyte counts;
LUAD	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg07685180	chr8:600429	NA	0.78	7.65	0.35	1.35e-13	IgG glycosylation;
LUAD	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg16049864	chr8:95962084	TP53INP1	-0.54	-11.64	-0.49	2.29e-27	Type 2 diabetes;
LUAD	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg07917127	chr4:99064746	C4orf37	0.44	6.76	0.31	4.71e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg00316803	chr15:76480434	C15orf27	0.41	6.55	0.3	1.64e-10	Blood metabolite levels;
LUAD	cis	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg24308560	chr3:49941425	MST1R	0.39	6.52	0.3	1.97e-10	Body mass index;
LUAD	cis	rs6960043	0.818	rs10228796	chr7:15064190	C/G	cg19272540	chr7:15055459	NA	-0.36	-7.89	-0.36	2.56e-14	Type 2 diabetes;
LUAD	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg21918786	chr6:109611834	NA	-0.61	-11.41	-0.48	1.85e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs2625529	0.652	rs8027164	chr15:72407733	A/T	cg16672083	chr15:72433130	SENP8	0.65	12.17	0.51	1.98e-29	Red blood cell count;
LUAD	cis	rs7319311	0.965	rs9583488	chr13:111031352	G/A	cg05272587	chr13:111038400	COL4A2	0.39	7.04	0.32	7.97e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs9796	0.870	rs3101436	chr15:41287689	A/G	cg18705301	chr15:41695430	NDUFAF1	0.39	7.38	0.34	8.68e-13	Menopause (age at onset);
LUAD	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg07741184	chr6:167504864	NA	0.36	8.43	0.38	5.38e-16	Crohn's disease;
LUAD	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg03289416	chr15:75166202	SCAMP2	0.45	7.52	0.34	3.28e-13	Breast cancer;
LUAD	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg03929089	chr4:120376271	NA	-0.97	-19.76	-0.69	5e-62	Height;
LUAD	cis	rs2425143	1.000	rs6058303	chr20:34290281	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.31	-0.34	1.32e-12	Blood protein levels;
LUAD	trans	rs11039798	0.841	rs11500573	chr11:48713900	T/G	cg15704280	chr7:45808275	SEPT13	0.67	7.89	0.36	2.62e-14	Axial length;
LUAD	cis	rs2282300	0.739	rs1765139	chr11:30353725	T/C	cg06241208	chr11:30344200	C11orf46	-0.52	-6.61	-0.31	1.19e-10	Morning vs. evening chronotype;
LUAD	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-9.0	-0.4	7.89e-18	Bipolar disorder;
LUAD	trans	rs1493916	0.905	rs4799727	chr18:31393095	T/G	cg15819921	chr19:927150	ARID3A	-0.48	-8.04	-0.36	9.03e-15	Life satisfaction;
LUAD	cis	rs713587	0.563	rs2033655	chr2:25101092	C/T	cg04586622	chr2:25135609	ADCY3	0.37	8.44	0.38	5e-16	Body mass index in non-asthmatics;
LUAD	cis	rs758324	0.681	rs25879	chr5:131407044	A/G	cg06307176	chr5:131281290	NA	-0.41	-6.71	-0.31	6.3e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg03340356	chr1:67600835	NA	0.42	7.05	0.32	7.44e-12	Psoriasis;
LUAD	cis	rs2637266	1.000	rs12260379	chr10:78365036	C/T	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.72e-11	Pulmonary function;
LUAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg15117754	chr3:10150083	C3orf24	-0.45	-7.39	-0.34	7.8e-13	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg02049041	chr17:27085579	C17orf63	0.66	8.78	0.39	4.2e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg27411982	chr8:10470053	RP1L1	0.39	6.72	0.31	5.83e-11	Joint mobility (Beighton score);
LUAD	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.22	-0.33	2.51e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7582720	1.000	rs72936852	chr2:203775475	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22496380	chr5:211416	CCDC127	-0.95	-13.32	-0.54	4.88e-34	Breast cancer;
LUAD	cis	rs8017423	0.967	rs2282030	chr14:90730265	G/A	cg14092571	chr14:90743983	NA	-0.48	-8.38	-0.38	7.73e-16	Mortality in heart failure;
LUAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg16031515	chr1:205743344	RAB7L1	-0.38	-7.59	-0.35	2.12e-13	Menarche (age at onset);
LUAD	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg21399703	chr1:247681439	NA	0.43	7.77	0.35	5.82e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg02269571	chr22:50332266	NA	-0.67	-9.73	-0.43	2.56e-20	Schizophrenia;
LUAD	cis	rs6594713	0.533	rs67589221	chr5:112980860	G/T	cg12552261	chr5:112820674	MCC	0.52	6.66	0.31	8.69e-11	Brain cytoarchitecture;
LUAD	cis	rs9462027	0.606	rs2815001	chr6:34634353	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.78	-0.39	4.09e-17	Systemic lupus erythematosus;
LUAD	cis	rs2131877	1.000	rs2131877	chr3:194858374	C/T	cg19760965	chr3:194868843	C3orf21	0.39	6.39	0.3	4.4e-10	Non-small cell lung cancer;
LUAD	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg00106254	chr7:1943704	MAD1L1	-0.5	-7.33	-0.34	1.17e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs2735413	0.918	rs12918409	chr16:78082681	G/A	cg01028844	chr5:122736986	CEP120	0.41	6.5	0.3	2.24e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs754466	0.914	rs12219971	chr10:79701526	T/C	cg17075019	chr10:79541650	NA	-0.81	-13.17	-0.54	2.05e-33	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1957429	0.901	rs8008745	chr14:65351593	C/G	cg23373153	chr14:65346875	NA	0.57	6.75	0.31	4.75e-11	Pediatric areal bone mineral density (radius);
LUAD	trans	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Parkinson's disease;
LUAD	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-8.83	-0.39	2.81e-17	Life satisfaction;
LUAD	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg27284194	chr4:1044797	NA	0.71	10.27	0.45	2.96e-22	Recombination rate (females);
LUAD	cis	rs11811982	0.793	rs74683900	chr1:227226260	C/T	cg24860534	chr1:227506868	CDC42BPA	0.68	7.12	0.33	4.56e-12	Optic disc area;
LUAD	cis	rs6594713	0.717	rs10056194	chr5:112857862	T/G	cg12552261	chr5:112820674	MCC	0.61	9.44	0.42	2.52e-19	Brain cytoarchitecture;
LUAD	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg17971929	chr21:40555470	PSMG1	0.52	8.01	0.36	1.15e-14	Cognitive function;
LUAD	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg23231163	chr10:75533350	FUT11	-0.52	-9.86	-0.43	9.15e-21	Inflammatory bowel disease;
LUAD	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg02527881	chr3:46936655	PTH1R	0.5	9.84	0.43	1.05e-20	Colorectal cancer;
LUAD	cis	rs4481887	0.861	rs4309013	chr1:248480768	C/T	cg00666640	chr1:248458726	OR2T12	0.31	7.6	0.35	1.96e-13	Common traits (Other);
LUAD	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg22875332	chr1:76189707	ACADM	0.76	12.46	0.52	1.42e-30	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg11416102	chr8:651193	ERICH1	0.84	7.81	0.36	4.55e-14	IgG glycosylation;
LUAD	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs853679	0.607	rs34788973	chr6:27879200	C/A	cg06606381	chr12:133084897	FBRSL1	-1.24	-10.91	-0.47	1.36e-24	Depression;
LUAD	cis	rs2274273	0.870	rs3783650	chr14:55848972	A/C	cg04306507	chr14:55594613	LGALS3	0.4	8.51	0.38	3.14e-16	Protein biomarker;
LUAD	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg02782426	chr3:40428986	ENTPD3	0.34	7.13	0.33	4.43e-12	Renal cell carcinoma;
LUAD	cis	rs7640424	0.826	rs7635063	chr3:107818777	C/T	cg09227934	chr3:107805635	CD47	-0.67	-12.1	-0.51	3.78e-29	Body mass index;
LUAD	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11809207	0.719	rs4659415	chr1:26580790	C/T	cg00300879	chr1:26503847	CNKSR1	0.3	6.74	0.31	5.18e-11	Height;
LUAD	cis	rs1881797	1.000	rs55852476	chr1:247696173	G/A	cg11166453	chr1:247681781	NA	0.42	7.9	0.36	2.4e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs1160297	0.585	rs12713229	chr2:53090105	T/C	cg07782112	chr2:53107842	NA	0.36	7.61	0.35	1.82e-13	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs41311933	0.656	rs72760225	chr9:123885930	G/A	cg13567360	chr9:123745713	C5	-0.73	-8.43	-0.38	5.36e-16	Coronary artery disease;
LUAD	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.54	0.3	1.77e-10	Depression;
LUAD	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21582582	chr3:182698605	DCUN1D1	0.43	7.16	0.33	3.6e-12	Body mass index;
LUAD	cis	rs11031096	0.727	rs2056853	chr11:4142172	C/T	cg18678763	chr11:4115507	RRM1	-0.42	-7.23	-0.33	2.23e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.45	-8.06	-0.36	7.94e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg05110241	chr16:68378359	PRMT7	-0.7	-9.15	-0.41	2.39e-18	Schizophrenia;
LUAD	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	13.06	0.54	5.6e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg08885076	chr2:99613938	TSGA10	0.4	7.55	0.34	2.79e-13	Chronic sinus infection;
LUAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08677398	chr8:58056175	NA	0.54	7.08	0.33	6.02e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7523050	0.643	rs35665867	chr1:109395436	G/A	cg08274380	chr1:109419600	GPSM2	0.79	6.8	0.31	3.65e-11	Fat distribution (HIV);
LUAD	cis	rs748404	0.697	rs473016	chr15:43558823	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.14	0.37	4.58e-15	Lung cancer;
LUAD	cis	rs220324	0.738	rs28655628	chr21:43578317	C/T	cg09727148	chr21:43560719	UMODL1	0.54	7.79	0.35	5.15e-14	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg20503657	chr10:835505	NA	-0.43	-6.86	-0.32	2.41e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.81	-0.36	4.44e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04565464	chr8:145669602	NFKBIL2	0.47	7.01	0.32	9.2e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7512552	0.780	rs2794681	chr1:150321951	C/T	cg15654264	chr1:150340011	RPRD2	0.61	11.6	0.49	3.48e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg21153622	chr11:89784906	NA	-0.34	-6.76	-0.31	4.6e-11	HDL cholesterol;
LUAD	cis	rs7582720	1.000	rs76890136	chr2:203850011	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.64	0.42	5.27e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg05340658	chr4:99064831	C4orf37	0.44	6.76	0.31	4.58e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9462027	0.628	rs2814992	chr6:34617144	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.76	-0.39	4.79e-17	Systemic lupus erythematosus;
LUAD	cis	rs68170813	0.523	rs3757713	chr7:107042750	A/C	cg02696742	chr7:106810147	HBP1	-0.79	-10.6	-0.46	1.93e-23	Coronary artery disease;
LUAD	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg04450456	chr4:17643702	FAM184B	0.37	6.83	0.32	2.98e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg12334488	chr2:20871173	GDF7	-0.42	-7.3	-0.33	1.48e-12	Abdominal aortic aneurysm;
LUAD	cis	rs6696239	0.513	rs1021554	chr1:227743951	C/T	cg12133451	chr1:227746453	NA	0.37	6.69	0.31	7.07e-11	Height;
LUAD	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg18306943	chr3:40428807	ENTPD3	0.39	6.92	0.32	1.68e-11	Renal cell carcinoma;
LUAD	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg16953816	chr12:123349952	VPS37B	0.62	6.92	0.32	1.68e-11	Schizophrenia;
LUAD	cis	rs73206853	0.841	rs73206886	chr12:110851190	T/G	cg12870014	chr12:110450643	ANKRD13A	0.64	7.25	0.33	2e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg27170947	chr2:26402098	FAM59B	0.85	11.7	0.49	1.4e-27	Gut microbiome composition (summer);
LUAD	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26314531	chr2:26401878	FAM59B	-0.58	-7.99	-0.36	1.33e-14	Gut microbiome composition (summer);
LUAD	cis	rs62229266	0.625	rs2051395	chr21:37431265	A/C	cg12218747	chr21:37451666	NA	0.41	7.13	0.33	4.24e-12	Mitral valve prolapse;
LUAD	cis	rs9837602	1.000	rs71313585	chr3:99770696	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.83	-0.32	2.99e-11	Breast cancer;
LUAD	cis	rs1448094	0.802	rs7487591	chr12:86434112	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-8.23	-0.37	2.32e-15	Major depressive disorder;
LUAD	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07157834	chr1:205819609	PM20D1	0.72	13.85	0.56	3.06e-36	Menarche (age at onset);
LUAD	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg00784671	chr22:46762841	CELSR1	-0.55	-7.18	-0.33	3.1e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg23758822	chr17:41437982	NA	1.01	20.98	0.71	1.71e-67	Menopause (age at onset);
LUAD	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg21427119	chr20:30132790	HM13	-0.49	-7.72	-0.35	8.73e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26314531	chr2:26401878	FAM59B	-0.71	-10.42	-0.45	8.83e-23	Gut microbiome composition (summer);
LUAD	cis	rs2806561	0.929	rs6669568	chr1:23540469	G/A	cg19743168	chr1:23544995	NA	-0.45	-8.39	-0.38	7.17e-16	Height;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	ch.10.2196322F	chr10:104248062	ACTR1A	-0.37	-6.39	-0.3	4.3e-10	Cancer;
LUAD	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg07507251	chr3:52567010	NT5DC2	0.38	7.49	0.34	3.94e-13	Bipolar disorder;
LUAD	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg18446336	chr7:2847575	GNA12	-0.33	-6.69	-0.31	6.9e-11	Height;
LUAD	cis	rs4604732	0.588	rs74154678	chr1:247626202	A/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs3820068	0.734	rs6669156	chr1:15905206	T/A	cg24675056	chr1:15929824	NA	0.42	6.69	0.31	6.95e-11	Systolic blood pressure;
LUAD	cis	rs73198271	0.595	rs117424193	chr8:8591377	T/C	cg01851573	chr8:8652454	MFHAS1	0.47	6.8	0.31	3.6e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4660306	1.000	rs7522705	chr1:45992300	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.41	6.79	0.31	3.77e-11	Homocysteine levels;
LUAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.33	-0.41	5.78e-19	Alzheimer's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20490126	chr1:25870007	LDLRAP1	-0.55	-7.02	-0.32	8.88e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1448094	0.872	rs7975457	chr12:86410404	C/T	cg00310523	chr12:86230176	RASSF9	0.38	7.9	0.36	2.43e-14	Major depressive disorder;
LUAD	cis	rs7192380	0.928	rs12933210	chr16:69742048	A/T	cg00738113	chr16:70207722	CLEC18C	0.36	7.33	0.34	1.16e-12	Sjögren's syndrome;
LUAD	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg21775007	chr8:11205619	TDH	0.53	9.67	0.43	3.97e-20	Retinal vascular caliber;
LUAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg08132940	chr7:1081526	C7orf50	-0.79	-10.66	-0.46	1.16e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.38e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs701145	0.878	rs355760	chr3:154009933	T/C	cg17054900	chr3:154042577	DHX36	0.65	7.17	0.33	3.4e-12	Coronary artery disease;
LUAD	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg20476274	chr7:133979776	SLC35B4	0.77	13.68	0.55	1.59e-35	Mean platelet volume;
LUAD	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg18512352	chr11:47633146	NA	-0.47	-8.19	-0.37	3.14e-15	Subjective well-being;
LUAD	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg17063962	chr7:91808500	NA	-0.68	-12.23	-0.51	1.19e-29	Breast cancer;
LUAD	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg11502198	chr6:26597334	ABT1	0.55	9.27	0.41	9.37e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs616402	0.564	rs602601	chr1:10567058	C/T	cg17425144	chr1:10567563	PEX14	0.61	12.78	0.53	7.72e-32	Breast size;
LUAD	cis	rs9487051	0.704	rs1741930	chr6:109519797	T/A	cg01475377	chr6:109611718	NA	-0.38	-7.31	-0.33	1.36e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg06641503	chr3:48959341	ARIH2	-0.4	-7.71	-0.35	9.03e-14	Parkinson's disease;
LUAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-8.07	-0.37	7.12e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg11707310	chr1:2537719	MMEL1	0.4	8.37	0.38	8.29e-16	Ulcerative colitis;
LUAD	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg05754148	chr16:3507555	NAT15	-0.65	-11.45	-0.49	1.26e-26	Tuberculosis;
LUAD	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.38	0.55	2.81e-34	Tonsillectomy;
LUAD	cis	rs986417	1.000	rs1254292	chr14:60863636	T/C	cg27398547	chr14:60952738	C14orf39	-0.59	-7.53	-0.34	3.01e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg17757837	chr7:157058334	UBE3C	-0.47	-8.27	-0.37	1.71e-15	Body mass index;
LUAD	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.44	0.38	4.93e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg08280861	chr8:58055591	NA	0.65	8.38	0.38	7.96e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.77	-0.53	8.14e-32	Monocyte count;
LUAD	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg15467112	chr14:75489610	MLH3	-0.36	-6.57	-0.3	1.5e-10	Height;
LUAD	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.45	-9.06	-0.4	4.96e-18	Glomerular filtration rate;
LUAD	trans	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg19862616	chr7:65841803	NCRNA00174	1.06	27.22	0.8	5.27e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2242073	0.733	rs10206080	chr2:209024195	G/T	cg06181187	chr2:209010896	CRYGB	0.45	7.12	0.33	4.78e-12	Attention deficit hyperactivity disorder;
LUAD	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.92	0.36	2.07e-14	Depression;
LUAD	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg22482690	chr17:47019901	SNF8	0.45	8.58	0.38	1.86e-16	Type 2 diabetes;
LUAD	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.17e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.1	-0.4	3.47e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg05304507	chr6:116381966	FRK	0.2	6.75	0.31	4.86e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs9796	0.870	rs28501589	chr15:41282534	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.38	-7.21	-0.33	2.63e-12	Menopause (age at onset);
LUAD	trans	rs853679	0.505	rs200992	chr6:27814677	A/G	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.63	-0.35	1.58e-13	Depression;
LUAD	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg00933542	chr6:150070202	PCMT1	0.45	9.97	0.44	3.47e-21	Lung cancer;
LUAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg01475377	chr6:109611718	NA	0.56	10.86	0.47	2.13e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg02551604	chr5:131831745	NA	-0.61	-10.08	-0.44	1.46e-21	Asthma (sex interaction);
LUAD	cis	rs4409675	0.871	rs10902678	chr1:28268573	C/T	cg23691781	chr1:28212827	C1orf38	-0.28	-7.01	-0.32	9.25e-12	Corneal astigmatism;
LUAD	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg09658497	chr7:2847517	GNA12	-0.56	-9.55	-0.42	1.06e-19	Height;
LUAD	cis	rs17021463	0.966	rs7657789	chr4:95178589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.09	-0.44	1.4e-21	Testicular germ cell tumor;
LUAD	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.79	0.76	5.02e-80	Chronic sinus infection;
LUAD	cis	rs11209185	0.563	rs4655763	chr1:68438400	G/A	cg22082780	chr1:68452167	NA	-0.39	-7.6	-0.35	1.92e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs9837602	0.688	rs793488	chr3:99495567	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-8.12	-0.37	5.01e-15	Breast cancer;
LUAD	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg16060761	chr17:80687452	NA	-0.59	-8.5	-0.38	3.34e-16	Glycated hemoglobin levels;
LUAD	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg14196790	chr5:131705035	SLC22A5	0.47	8.51	0.38	3.06e-16	Blood metabolite levels;
LUAD	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg19622623	chr12:86230825	RASSF9	-0.54	-9.48	-0.42	1.79e-19	Major depressive disorder;
LUAD	trans	rs78049276	0.736	rs10305838	chr4:148400256	T/C	cg13149281	chr14:23389818	RBM23;PRMT5	-0.58	-6.64	-0.31	9.38e-11	Pulse pressure;
LUAD	cis	rs12049351	0.774	rs4148757	chr1:229693846	A/C	cg11742688	chr1:229674241	ABCB10	-0.42	-6.96	-0.32	1.28e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs9644630	0.841	rs4922035	chr8:19328174	C/T	cg06562184	chr8:19319451	CSGALNACT1	0.36	6.73	0.31	5.61e-11	Oropharynx cancer;
LUAD	cis	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.53	-7.5	-0.34	3.81e-13	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg22535103	chr8:58192502	C8orf71	-0.78	-11.06	-0.47	3.66e-25	Developmental language disorder (linguistic errors);
LUAD	cis	rs7187994	0.848	rs12933308	chr16:84770973	A/G	cg07647771	chr16:84786436	USP10	-0.37	-9.08	-0.4	4.25e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg07460842	chr6:66804631	NA	1.08	16.91	0.63	2.34e-49	Exhaled nitric oxide output;
LUAD	trans	rs4650994	0.544	rs2811306	chr1:178599248	C/G	cg05059571	chr16:84539110	KIAA1609	0.68	11.95	0.5	1.44e-28	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs732716	0.889	rs55637375	chr19:4386845	A/G	cg21934504	chr19:4445085	UBXN6	0.46	7.7	0.35	9.4e-14	Mean corpuscular volume;
LUAD	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.28	-7.23	-0.33	2.22e-12	Schizophrenia;
LUAD	cis	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.42	8.11	0.37	5.36e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg19500851	chr17:37840957	PGAP3	-0.35	-6.98	-0.32	1.12e-11	Asthma;
LUAD	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-7.05	-0.32	7.19e-12	Blood metabolite levels;
LUAD	cis	rs3733418	0.929	rs4691138	chr4:165908641	A/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-6.99	-0.32	1.08e-11	Obesity-related traits;
LUAD	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02463440	chr8:22132932	PIWIL2	0.55	10.03	0.44	2.26e-21	Hypertriglyceridemia;
LUAD	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg23254163	chr1:152506842	NA	0.25	6.95	0.32	1.38e-11	Hair morphology;
LUAD	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.56	-0.3	1.56e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg18834416	chr8:37888184	EIF4EBP1	0.42	6.92	0.32	1.65e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg03948781	chr1:205179583	DSTYK	0.35	6.4	0.3	4.17e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs4594175	0.926	rs4901083	chr14:51604998	C/A	cg23942311	chr14:51606299	NA	0.64	11.13	0.48	2.02e-25	Cancer;
LUAD	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.39	7.41	0.34	7e-13	IgG glycosylation;
LUAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg00450029	chr8:599525	NA	0.83	8.15	0.37	4.17e-15	IgG glycosylation;
LUAD	cis	rs11640533	0.901	rs11862250	chr16:53415038	C/A	cg09744766	chr16:53407421	NA	0.41	6.96	0.32	1.26e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-10.49	-0.45	4.75e-23	Bone mineral density;
LUAD	cis	rs6577655	0.547	rs7841171	chr8:135591699	G/A	cg17885191	chr8:135476712	NA	0.63	8.34	0.38	1.05e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg07708487	chr16:89387014	ANKRD11	-0.35	-6.87	-0.32	2.32e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs7903847	0.642	rs61863816	chr10:99128503	G/A	cg20016023	chr10:99160130	RRP12	-0.32	-6.99	-0.32	1.09e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2992756	0.519	rs2992740	chr1:18810344	G/T	cg14356550	chr1:18808102	KLHDC7A	-0.41	-7.1	-0.33	5.17e-12	Breast cancer;
LUAD	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg26513180	chr16:89883248	FANCA	0.78	7.09	0.33	5.78e-12	Skin colour saturation;
LUAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg11494091	chr17:61959527	GH2	0.74	18.44	0.67	3.58e-56	Prudent dietary pattern;
LUAD	cis	rs4711350	0.765	rs6921772	chr6:33749686	A/G	cg16010596	chr6:33739607	LEMD2	-0.42	-7.76	-0.35	6.49e-14	Schizophrenia;
LUAD	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg11189052	chr15:85197271	WDR73	0.67	8.92	0.4	1.47e-17	Schizophrenia;
LUAD	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	7.96	0.36	1.56e-14	Menopause (age at onset);
LUAD	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg18944383	chr4:111397179	ENPEP	0.48	8.56	0.38	2.08e-16	Coronary artery disease;
LUAD	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.7	-0.35	9.55e-14	Prostate cancer;
LUAD	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18876405	chr7:65276391	NA	0.4	6.49	0.3	2.45e-10	Aortic root size;
LUAD	trans	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg11693508	chr17:37793320	STARD3	0.79	9.93	0.43	5.13e-21	Bipolar disorder;
LUAD	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.04	0.32	7.86e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9296092	0.538	rs75501442	chr6:33519493	A/G	cg13560919	chr6:33536144	NA	-0.88	-16.13	-0.62	5.99e-46	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg18105134	chr13:113819100	PROZ	0.9	16.1	0.62	7.59e-46	Platelet distribution width;
LUAD	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg06784218	chr1:46089804	CCDC17	-0.59	-13.5	-0.55	8.81e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg25767906	chr1:53392781	SCP2	-0.44	-8.13	-0.37	4.76e-15	Monocyte count;
LUAD	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg00361562	chr2:198649771	BOLL	0.47	6.78	0.31	4.14e-11	Ulcerative colitis;
LUAD	cis	rs6669119	0.668	rs75088145	chr1:19092368	G/A	cg19637330	chr1:19110922	NA	0.62	7.37	0.34	8.81e-13	Percentage gas trapping;
LUAD	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg23587288	chr2:27483067	SLC30A3	-0.43	-8.45	-0.38	4.69e-16	Blood metabolite levels;
LUAD	cis	rs1448094	0.802	rs7397730	chr12:86416212	T/C	cg00310523	chr12:86230176	RASSF9	0.38	8.05	0.36	8.58e-15	Major depressive disorder;
LUAD	cis	rs4774899	0.966	rs7161965	chr15:57485620	G/A	cg14026238	chr15:57616123	NA	0.35	6.47	0.3	2.69e-10	Urinary tract infection frequency;
LUAD	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.43	-8.59	-0.39	1.75e-16	Total body bone mineral density;
LUAD	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.7	13.06	0.54	5.44e-33	Axial length;
LUAD	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg19224673	chr16:74330485	PSMD7	-0.42	-6.71	-0.31	6.08e-11	Brain structure;
LUAD	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.3	-0.33	1.42e-12	Total body bone mineral density;
LUAD	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg15790184	chr11:494944	RNH1	0.42	6.83	0.32	2.9100000000000002e-11	Systemic lupus erythematosus;
LUAD	cis	rs4888262	0.526	rs6564142	chr16:74590047	T/C	cg01733217	chr16:74700730	RFWD3	0.47	8.03	0.36	1e-14	Testicular germ cell tumor;
LUAD	cis	rs2070488	0.662	rs7375040	chr3:38469116	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.49	7.68	0.35	1.13e-13	Electrocardiographic conduction measures;
LUAD	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg12444411	chr7:2802554	GNA12	-0.36	-6.38	-0.3	4.54e-10	Height;
LUAD	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg16322792	chr1:120165303	ZNF697	0.71	19.01	0.68	1.1e-58	Systemic lupus erythematosus;
LUAD	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg17366294	chr4:99064904	C4orf37	0.66	12.83	0.53	4.8e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	3.96e-11	Depression;
LUAD	cis	rs4356932	1.000	rs10014049	chr4:76953532	C/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.5	-0.3	2.22e-10	Blood protein levels;
LUAD	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	9.37	0.41	4.47e-19	Total body bone mineral density;
LUAD	cis	rs7527798	0.592	rs12144801	chr1:207857773	A/G	cg09232269	chr1:207846808	CR1L	-0.37	-7.14	-0.33	4.07e-12	Erythrocyte sedimentation rate;
LUAD	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg18827107	chr12:86230957	RASSF9	0.45	8.27	0.37	1.77e-15	Major depressive disorder;
LUAD	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.46	8.22	0.37	2.52e-15	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg18944383	chr4:111397179	ENPEP	0.38	7.55	0.34	2.66e-13	Height;
LUAD	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg09835421	chr16:68378352	PRMT7	-0.77	-8.18	-0.37	3.36e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7512552	0.839	rs696616	chr1:150336173	G/A	cg15654264	chr1:150340011	RPRD2	0.61	11.66	0.49	1.96e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg26384229	chr12:38710491	ALG10B	0.46	7.45	0.34	5.26e-13	Bladder cancer;
LUAD	cis	rs5756813	0.635	rs6000899	chr22:38203796	C/T	cg06521852	chr22:38141419	TRIOBP	0.47	8.54	0.38	2.38e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs10206020	0.836	rs10202105	chr2:1553301	C/T	cg01028140	chr2:1542097	TPO	-0.47	-7.67	-0.35	1.18e-13	IgG glycosylation;
LUAD	cis	rs72901758	0.700	rs34219567	chr17:76248036	A/G	cg26068271	chr17:76253126	NA	0.42	7.13	0.33	4.38e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7809950	0.773	rs62483722	chr7:107186349	C/T	cg23024343	chr7:107201750	COG5	-0.71	-11.96	-0.5	1.39e-28	Coronary artery disease;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16189954	chr22:29138267	HSCB;CHEK2	0.45	6.91	0.32	1.77e-11	Gut microbiome composition (summer);
LUAD	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg18230493	chr5:56204884	C5orf35	-0.42	-6.8	-0.31	3.57e-11	Coronary artery disease;
LUAD	cis	rs758324	0.947	rs2404778	chr5:131172886	T/C	cg25547332	chr5:131281432	NA	0.44	6.71	0.31	6.3e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg07527032	chr15:84868466	LOC388152	0.44	6.65	0.31	9.36e-11	Schizophrenia;
LUAD	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg07636037	chr3:49044803	WDR6	0.6	11.34	0.48	3.29e-26	Parkinson's disease;
LUAD	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg08213375	chr14:104286397	PPP1R13B	0.26	6.9	0.32	1.92e-11	Schizophrenia;
LUAD	cis	rs7107174	0.901	rs10899473	chr11:78042983	A/C	cg02023728	chr11:77925099	USP35	0.4	6.77	0.31	4.35e-11	Testicular germ cell tumor;
LUAD	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg17063962	chr7:91808500	NA	0.73	13.25	0.54	9.24e-34	Breast cancer;
LUAD	cis	rs3800461	0.544	rs76990047	chr6:34504042	T/G	cg17674042	chr6:34482479	PACSIN1	-0.8	-9.8	-0.43	1.44e-20	Chronic lymphocytic leukemia;
LUAD	cis	rs7465272	1.000	rs35868630	chr8:143685933	G/A	cg10104451	chr8:143696006	ARC	-0.58	-7.9	-0.36	2.51e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg25358565	chr5:93447407	FAM172A	0.6	7.52	0.34	3.31e-13	Diabetic retinopathy;
LUAD	cis	rs2004318	1.000	rs78389389	chr19:55071704	T/C	cg03320607	chr19:54800032	LILRA3	-0.73	-7.77	-0.35	5.93e-14	Blood protein levels;
LUAD	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg00316803	chr15:76480434	C15orf27	0.39	6.47	0.3	2.79e-10	Blood metabolite levels;
LUAD	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg20991723	chr1:152506922	NA	0.35	6.91	0.32	1.77e-11	Hair morphology;
LUAD	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.1	0.33	5.14e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg15997130	chr1:24165203	NA	0.56	9.51	0.42	1.43e-19	Immature fraction of reticulocytes;
LUAD	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg23950597	chr19:37808831	NA	-0.62	-7.32	-0.34	1.23e-12	Coronary artery calcification;
LUAD	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs9826463	0.757	rs2229032	chr3:142178144	A/G	cg20824294	chr3:142316082	PLS1	-0.41	-7.12	-0.33	4.78e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9513627	0.833	rs4605005	chr13:100132471	T/C	cg25919922	chr13:100150906	NA	0.75	8.03	0.36	9.56e-15	Obesity-related traits;
LUAD	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg09092052	chr15:45571596	NA	0.41	6.44	0.3	3.33e-10	Glomerular filtration rate;
LUAD	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.62	0.31	1.09e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10950821	0.770	rs2893006	chr7:20687181	C/T	cg02470904	chr7:20686108	ABCB5	0.38	6.42	0.3	3.62e-10	Response to statin therapy;
LUAD	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg11707310	chr1:2537719	MMEL1	0.4	8.52	0.38	2.82e-16	Multiple sclerosis;
LUAD	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg02782426	chr3:40428986	ENTPD3	0.42	8.88	0.4	1.94e-17	Renal cell carcinoma;
LUAD	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18099408	chr3:52552593	STAB1	-0.46	-8.07	-0.37	7.55e-15	Bipolar disorder;
LUAD	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg12311346	chr5:56204834	C5orf35	-0.47	-7.76	-0.35	6.64e-14	Coronary artery disease;
LUAD	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg01200585	chr1:228362443	C1orf69	-0.41	-7.37	-0.34	9.13e-13	Diastolic blood pressure;
LUAD	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg04414720	chr1:150670196	GOLPH3L	-0.49	-8.17	-0.37	3.6e-15	Tonsillectomy;
LUAD	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg00495681	chr13:53174319	NA	0.5	9.09	0.4	3.91e-18	Lewy body disease;
LUAD	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.12	0.33	4.7e-12	Motion sickness;
LUAD	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg18132916	chr6:79620363	NA	-0.45	-7.84	-0.36	3.67e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg02951883	chr7:2050386	MAD1L1	-0.81	-14.01	-0.56	6.44e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.68	-0.31	7.72e-11	Bladder cancer;
LUAD	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs7737355	0.898	rs3775999	chr5:130970090	T/C	cg06307176	chr5:131281290	NA	0.52	7.84	0.36	3.64e-14	Life satisfaction;
LUAD	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.38	0.34	8.6e-13	Blood metabolite levels;
LUAD	cis	rs317689	1.000	rs317689	chr12:69727190	G/A	cg11871910	chr12:69753446	YEATS4	0.5	7.21	0.33	2.68e-12	Response to diuretic therapy;
LUAD	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg08742575	chr21:47604166	C21orf56	0.43	7.14	0.33	4.08e-12	Testicular germ cell tumor;
LUAD	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg07404485	chr7:94953653	PON1	0.48	6.92	0.32	1.65e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.95e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs354225	0.544	rs13403284	chr2:54805749	A/G	cg01766943	chr2:54829624	SPTBN1	0.4	7.5	0.34	3.76e-13	Schizophrenia;
LUAD	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg02951883	chr7:2050386	MAD1L1	-0.79	-13.39	-0.55	2.47e-34	Bipolar disorder and schizophrenia;
LUAD	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.38	-8.14	-0.37	4.44e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg15128208	chr22:42549153	NA	0.43	6.73	0.31	5.5e-11	Birth weight;
LUAD	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg08916839	chr5:415575	AHRR	0.86	10.01	0.44	2.53e-21	Fat distribution (HIV);
LUAD	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg13319975	chr6:146136371	FBXO30	0.67	11.6	0.49	3.45e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4072705	0.586	rs7855247	chr9:127246644	T/C	cg13476313	chr9:127244764	NR5A1	-0.36	-8.67	-0.39	9.62e-17	Menarche (age at onset);
LUAD	cis	rs12760731	0.720	rs2175254	chr1:178319105	G/A	cg00404053	chr1:178313656	RASAL2	0.74	9.42	0.42	2.91e-19	Obesity-related traits;
LUAD	cis	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg27411982	chr8:10470053	RP1L1	0.39	6.63	0.31	1.04e-10	Neuroticism;
LUAD	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg09658497	chr7:2847517	GNA12	-0.46	-8.53	-0.38	2.66e-16	Height;
LUAD	cis	rs57590327	0.583	rs13062245	chr3:81833718	G/T	cg07356753	chr3:81810745	GBE1	-0.64	-10.47	-0.45	5.89e-23	Extraversion;
LUAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06873352	chr17:61820015	STRADA	0.81	18.16	0.66	6.8e-55	Prudent dietary pattern;
LUAD	cis	rs2281845	0.859	rs58364051	chr1:201077667	A/G	cg22815214	chr1:201083145	CACNA1S	0.56	9.47	0.42	2.06e-19	Permanent tooth development;
LUAD	trans	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg00953403	chr17:74099816	EXOC7	0.47	7.47	0.34	4.73e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg02931644	chr1:25747376	RHCE	-0.42	-8.58	-0.39	1.81e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg08514558	chr10:81106712	PPIF	0.5	9.61	0.42	6.63e-20	Height;
LUAD	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg20673091	chr1:2541236	MMEL1	0.39	8.16	0.37	3.74e-15	Ulcerative colitis;
LUAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06873352	chr17:61820015	STRADA	0.82	18.31	0.67	1.36e-55	Prudent dietary pattern;
LUAD	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg08997352	chr12:9597637	DDX12	-0.7	-12.67	-0.52	2e-31	Breast size;
LUAD	cis	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05901451	chr6:126070800	HEY2	0.45	6.65	0.31	9.09e-11	Endometrial cancer;
LUAD	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg21823605	chr1:152486609	CRCT1	0.3	6.9	0.32	1.92e-11	Hair morphology;
LUAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.87	16.78	0.63	8.23e-49	Lymphocyte counts;
LUAD	cis	rs736408	0.812	rs9881468	chr3:52828628	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-6.86	-0.32	2.42e-11	Bipolar disorder;
LUAD	cis	rs12824058	0.737	rs2398508	chr12:130816460	G/A	cg26677194	chr12:130822605	PIWIL1	0.55	8.9	0.4	1.65e-17	Menopause (age at onset);
LUAD	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.83	0.31	3.04e-11	Cognitive test performance;
LUAD	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg01299579	chr2:10830716	NOL10	-0.42	-7.27	-0.33	1.73e-12	Prostate cancer;
LUAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg11301795	chr4:187892539	NA	-0.76	-14.99	-0.59	4.86e-41	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26314531	chr2:26401878	FAM59B	-0.62	-8.92	-0.4	1.37e-17	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg22535103	chr8:58192502	C8orf71	-0.77	-10.85	-0.47	2.3e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg19318889	chr4:1322082	MAEA	0.47	7.78	0.35	5.45e-14	Obesity-related traits;
LUAD	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.57	-0.3	1.5e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg05132306	chr1:1846340	CALML6	-0.36	-7.63	-0.35	1.56e-13	Body mass index;
LUAD	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.82	0.31	3.11e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2932538	0.922	rs6659677	chr1:113087076	G/C	cg22162597	chr1:113214053	CAPZA1	0.45	6.87	0.32	2.31e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	trans	rs28735056	0.660	rs12454454	chr18:77674634	C/T	cg05926928	chr17:57297772	GDPD1	-0.5	-7.61	-0.35	1.75e-13	Schizophrenia;
LUAD	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg26384229	chr12:38710491	ALG10B	0.46	7.49	0.34	4.17e-13	Bladder cancer;
LUAD	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg13722127	chr7:150037890	RARRES2	0.45	7.42	0.34	6.32e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1997103	1.000	rs4947500	chr7:55407270	C/A	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs11718455	0.960	rs13065591	chr3:43996585	T/C	cg08738300	chr3:44038990	NA	0.43	6.55	0.3	1.67e-10	Coronary artery disease;
LUAD	cis	rs7945718	0.967	rs11826129	chr11:12768883	G/A	cg25843174	chr11:12811716	TEAD1	0.23	6.93	0.32	1.6e-11	Educational attainment (years of education);
LUAD	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg04703951	chr17:43578652	NA	-0.44	-7.0	-0.32	1.03e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1461503	0.966	rs10892939	chr11:122841959	T/C	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg23625390	chr15:77176239	SCAPER	-0.46	-7.42	-0.34	6.44e-13	Blood metabolite levels;
LUAD	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg17761419	chr8:57350749	NA	-0.51	-7.67	-0.35	1.17e-13	Obesity-related traits;
LUAD	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg19418458	chr7:158789849	NA	0.64	11.6	0.49	3.34e-27	Facial morphology (factor 20);
LUAD	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg23758822	chr17:41437982	NA	1.02	21.04	0.72	8.57e-68	Menopause (age at onset);
LUAD	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.72	-0.5	1.18e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.66	10.77	0.46	4.69e-24	Height;
LUAD	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg03474202	chr17:45855739	NA	-0.41	-8.67	-0.39	9.02e-17	IgG glycosylation;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03024183	chr8:37963317	ASH2L	-0.55	-6.7	-0.31	6.48e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1595825	0.945	rs6756641	chr2:198849672	T/G	cg00361562	chr2:198649771	BOLL	-0.45	-6.43	-0.3	3.4e-10	Ulcerative colitis;
LUAD	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg14784868	chr12:69753453	YEATS4	0.45	7.38	0.34	8.38e-13	Blood protein levels;
LUAD	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg02551604	chr5:131831745	NA	0.6	9.56	0.42	9.43e-20	Asthma (sex interaction);
LUAD	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg05340658	chr4:99064831	C4orf37	-0.55	-9.55	-0.42	1.1e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg13877915	chr19:58951672	ZNF132	0.73	13.96	0.56	1.12e-36	Uric acid clearance;
LUAD	cis	rs2412208	0.582	rs7536178	chr1:7128056	G/A	cg20434152	chr1:7120926	CAMTA1	-0.35	-7.55	-0.34	2.71e-13	Survival in sporadic amyotrophic lateral sclerosis;
LUAD	cis	rs4454254	1.000	rs4454254	chr8:141060027	C/T	cg06693505	chr8:141057453	TRAPPC9	-0.31	-6.36	-0.3	5.09e-10	Pulse pressure;
LUAD	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg19875535	chr5:140030758	IK	-0.44	-7.45	-0.34	5.22e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg17366294	chr4:99064904	C4orf37	0.71	13.37	0.54	3.03e-34	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7192380	0.965	rs3848278	chr16:69640867	T/C	cg00738113	chr16:70207722	CLEC18C	-0.34	-6.95	-0.32	1.42e-11	Sjögren's syndrome;
LUAD	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs847577	0.609	rs11765552	chr7:97822115	T/A	cg21770322	chr7:97807741	LMTK2	0.35	8.33	0.38	1.16e-15	Breast cancer;
LUAD	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg11871910	chr12:69753446	YEATS4	0.7	12.08	0.51	4.52e-29	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.35	-0.34	1.06e-12	Triglycerides;
LUAD	cis	rs10979	1.000	rs9496673	chr6:143885393	C/G	cg25407410	chr6:143891975	LOC285740	-0.61	-9.65	-0.42	4.73e-20	Hypospadias;
LUAD	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.63	-0.52	2.96e-31	Monocyte count;
LUAD	cis	rs934734	0.752	rs1876518	chr2:65608909	C/T	cg11674355	chr2:65610261	SPRED2	0.37	6.52	0.3	1.95e-10	Rheumatoid arthritis;
LUAD	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg23649088	chr2:200775458	C2orf69	-0.63	-8.15	-0.37	4.31e-15	Schizophrenia;
LUAD	cis	rs2997447	0.846	rs3008230	chr1:26401331	A/G	cg00147160	chr1:26503991	CNKSR1	0.35	6.51	0.3	2.1e-10	QRS complex (12-leadsum);
LUAD	cis	rs17102423	0.594	rs2781373	chr14:65568215	G/A	cg11161011	chr14:65562177	MAX	-0.46	-7.84	-0.36	3.67e-14	Obesity-related traits;
LUAD	cis	rs13064411	0.627	rs9872168	chr3:113233132	A/C	cg18753928	chr3:113234510	CCDC52	-0.73	-12.33	-0.51	4.52e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-8.46	-0.38	4.39e-16	Alzheimer's disease (late onset);
LUAD	cis	rs986417	0.901	rs1950316	chr14:61018305	T/C	cg27398547	chr14:60952738	C14orf39	0.64	7.62	0.35	1.68e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg06641503	chr3:48959341	ARIH2	-0.4	-7.81	-0.35	4.71e-14	Parkinson's disease;
LUAD	trans	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg26384229	chr12:38710491	ALG10B	0.38	6.35	0.3	5.56e-10	Morning vs. evening chronotype;
LUAD	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27286337	chr10:134555280	INPP5A	0.72	9.67	0.43	4.1e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg22906224	chr7:99728672	NA	0.66	11.07	0.47	3.36e-25	Coronary artery disease;
LUAD	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.59	-0.49	3.54e-27	Primary sclerosing cholangitis;
LUAD	cis	rs11690462	0.528	rs11691698	chr2:26642190	A/G	cg22920501	chr2:26401640	FAM59B	0.52	7.4	0.34	7.46e-13	Coronary artery disease;
LUAD	cis	rs2485376	0.813	rs56238324	chr10:104149814	C/G	cg20641465	chr10:103991465	PITX3	-0.52	-9.07	-0.4	4.41e-18	QT interval;
LUAD	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg18306943	chr3:40428807	ENTPD3	0.42	7.04	0.32	7.93e-12	Renal cell carcinoma;
LUAD	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg24112000	chr20:60950667	NA	-0.63	-9.15	-0.41	2.42e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg00071950	chr4:10020882	SLC2A9	-0.62	-11.71	-0.49	1.3e-27	Bone mineral density;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25833238	chr6:153304325	FBXO5	-0.59	-7.06	-0.32	6.83e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.6	0.39	1.62e-16	Menopause (age at onset);
LUAD	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg13870426	chr17:30244630	NA	-0.55	-6.36	-0.3	5.35e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg24813613	chr7:1882135	MAD1L1	-0.4	-6.43	-0.3	3.46e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs3125734	0.671	rs3852406	chr10:64015162	T/C	cg19640130	chr10:64028056	RTKN2	-0.35	-7.44	-0.34	5.68e-13	Rheumatoid arthritis;
LUAD	cis	rs240764	0.717	rs13208757	chr6:101175014	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-7.23	-0.33	2.25e-12	Neuroticism;
LUAD	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg08847533	chr14:75593920	NEK9	0.43	7.24	0.33	2.09e-12	Height;
LUAD	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg15181151	chr6:150070149	PCMT1	0.39	7.9	0.36	2.38e-14	Lung cancer;
LUAD	cis	rs3812049	0.737	rs1993878	chr5:127476971	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	7.84	0.36	3.67e-14	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs7474896	0.559	rs1024202	chr10:38278977	A/C	cg25427524	chr10:38739819	LOC399744	0.6	8.52	0.38	2.75e-16	Obesity (extreme);
LUAD	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg24829409	chr8:58192753	C8orf71	-0.53	-6.88	-0.32	2.16e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6906287	0.573	rs6928210	chr6:118699394	C/G	cg18833306	chr6:118973337	C6orf204	0.46	8.31	0.37	1.28e-15	Electrocardiographic conduction measures;
LUAD	cis	rs2281845	0.507	rs7547762	chr1:201088245	A/G	cg06714761	chr1:201096289	NA	0.34	7.37	0.34	8.75e-13	Permanent tooth development;
LUAD	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg01324343	chr3:183735012	ABCC5	0.64	12.27	0.51	7.91e-30	Anterior chamber depth;
LUAD	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg22105103	chr4:187893119	NA	0.58	12.84	0.53	4.32e-32	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3761847	0.593	rs10985140	chr9:123822837	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	6.49	0.3	2.38e-10	Rheumatoid arthritis;
LUAD	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg18016565	chr1:150552671	MCL1	0.37	6.39	0.3	4.44e-10	Melanoma;
LUAD	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.4	7.27	0.33	1.8e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1692580	0.807	rs4648818	chr1:2178999	C/T	cg24578937	chr1:2090814	PRKCZ	0.54	10.34	0.45	1.65e-22	Coronary artery disease;
LUAD	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg23992470	chr4:843637	GAK	0.67	7.35	0.34	1.04e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.33	-0.45	1.83e-22	Monocyte percentage of white cells;
LUAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.67	-0.31	7.97e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12760731	0.565	rs77024410	chr1:178164121	A/C	cg00404053	chr1:178313656	RASAL2	0.73	9.11	0.41	3.27e-18	Obesity-related traits;
LUAD	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg00684032	chr4:1343700	KIAA1530	0.42	6.96	0.32	1.34e-11	Obesity-related traits;
LUAD	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg16447950	chr5:562315	NA	-0.41	-6.41	-0.3	3.89e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs600626	0.947	rs644361	chr11:75452392	C/T	cg24262691	chr11:75473276	NA	-0.4	-6.36	-0.3	5.29e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg05805236	chr11:65401703	PCNXL3	-0.52	-8.68	-0.39	8.46e-17	Acne (severe);
LUAD	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg18180107	chr4:99064573	C4orf37	0.42	6.75	0.31	4.94e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6665290	0.836	rs12593	chr1:227172290	A/G	cg10327440	chr1:227177885	CDC42BPA	1.15	32.13	0.84	1.43e-115	Myeloid white cell count;
LUAD	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg14583973	chr4:3374767	RGS12	0.29	7.12	0.33	4.57e-12	Serum sulfate level;
LUAD	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg00666640	chr1:248458726	OR2T12	-0.33	-8.16	-0.37	3.77e-15	Common traits (Other);
LUAD	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg27494647	chr7:150038898	RARRES2	0.43	7.07	0.33	6.48e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg15744005	chr10:104629667	AS3MT	-0.32	-6.39	-0.3	4.43e-10	Immature fraction of reticulocytes;Schizophrenia;
LUAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg11965913	chr1:205819406	PM20D1	-0.77	-15.65	-0.61	6.83e-44	Monocyte percentage of white cells;
LUAD	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.56	9.83	0.43	1.08e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg11502198	chr6:26597334	ABT1	0.54	9.08	0.4	4.13e-18	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04153114	chr8:99129570	POP1;HRSP12	-0.56	-7.09	-0.33	5.58e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg17063962	chr7:91808500	NA	-0.63	-11.03	-0.47	4.87e-25	Breast cancer;
LUAD	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.25	-0.33	2.06e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs11088226	0.801	rs2833886	chr21:33923872	C/A	cg09050820	chr6:167586206	TCP10L2	0.64	9.74	0.43	2.41e-20	Gastritis;
LUAD	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg06740227	chr12:86229804	RASSF9	0.47	8.27	0.37	1.75e-15	Major depressive disorder;
LUAD	cis	rs2742234	0.955	rs2503841	chr10:43675721	C/T	cg02780029	chr10:43622663	RET	-0.43	-6.97	-0.32	1.19e-11	Hirschsprung disease;
LUAD	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	6.57	0.3	1.5e-10	Tonsillectomy;
LUAD	trans	rs801193	0.591	rs721717	chr7:66130292	G/T	cg19163074	chr7:65112434	INTS4L2	0.42	6.43	0.3	3.38e-10	Aortic root size;
LUAD	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.31	-6.9	-0.32	1.85e-11	Dupuytren's disease;
LUAD	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg09537434	chr19:41945824	ATP5SL	-0.45	-6.96	-0.32	1.32e-11	Height;
LUAD	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg02782426	chr3:40428986	ENTPD3	0.34	7.47	0.34	4.79e-13	Renal cell carcinoma;
LUAD	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-9.17	-0.41	2.16e-18	Bipolar disorder;
LUAD	cis	rs6500395	1.000	rs2354578	chr16:48593298	T/C	cg04672837	chr16:48644449	N4BP1	0.37	6.37	0.3	4.93e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1997103	0.822	rs10273426	chr7:55417857	G/A	cg17469321	chr7:55412551	NA	0.64	10.72	0.46	6.98e-24	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26314531	chr2:26401878	FAM59B	-0.64	-8.7	-0.39	7.27e-17	Gut microbiome composition (summer);
LUAD	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.53	-0.34	3.18e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1692580	0.840	rs696094	chr1:2169215	G/A	cg24578937	chr1:2090814	PRKCZ	0.53	10.19	0.44	5.86e-22	Coronary artery disease;
LUAD	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6808694	0.568	rs6550401	chr3:20219694	A/C	cg00235661	chr3:20228976	SGOL1	0.44	7.29	0.33	1.52e-12	Ischemic stroke;
LUAD	trans	rs4650994	0.525	rs2493860	chr1:178541492	A/G	cg05059571	chr16:84539110	KIAA1609	-0.73	-13.01	-0.53	8.56e-33	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg03034668	chr16:1723424	CRAMP1L	-0.4	-6.84	-0.32	2.86e-11	Coronary artery disease;
LUAD	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.52	-0.42	1.3e-19	Life satisfaction;
LUAD	cis	rs262150	0.659	rs73167293	chr7:158772638	C/T	cg09640425	chr7:158790006	NA	0.51	6.93	0.32	1.59e-11	Facial morphology (factor 20);
LUAD	cis	rs73198271	0.515	rs76653757	chr8:8624901	C/A	cg01851573	chr8:8652454	MFHAS1	0.54	7.01	0.32	9.6e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs7395662	0.817	rs1848151	chr11:48692658	G/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.43	-0.3	3.53e-10	HDL cholesterol;
LUAD	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	8.38	0.38	7.9e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg07917127	chr4:99064746	C4orf37	0.45	7.26	0.33	1.93e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg24733560	chr20:60626293	TAF4	0.48	9.34	0.41	5.58e-19	Body mass index;
LUAD	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg20203395	chr5:56204925	C5orf35	0.64	9.84	0.43	1.02e-20	Initial pursuit acceleration;
LUAD	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.68e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4853525	0.522	rs62179717	chr2:191590813	T/G	cg11845111	chr2:191398756	TMEM194B	-0.43	-6.84	-0.32	2.74e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs713587	0.521	rs6545766	chr2:25077856	C/T	cg01884057	chr2:25150051	NA	0.31	6.46	0.3	2.8e-10	Body mass index in non-asthmatics;
LUAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.63	-11.04	-0.47	4.59e-25	Lymphocyte counts;
LUAD	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg13393036	chr8:95962371	TP53INP1	-0.41	-9.96	-0.44	3.93e-21	Type 2 diabetes;
LUAD	cis	rs977987	0.843	rs62062568	chr16:75445324	T/C	cg03315344	chr16:75512273	CHST6	0.64	13.94	0.56	1.35e-36	Dupuytren's disease;
LUAD	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg18232548	chr7:50535776	DDC	-0.72	-13.61	-0.55	3.02e-35	Systemic sclerosis;
LUAD	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg18105134	chr13:113819100	PROZ	-0.87	-15.14	-0.59	1.08e-41	Platelet distribution width;
LUAD	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg15448220	chr1:150897856	SETDB1	-0.44	-7.47	-0.34	4.57e-13	Tonsillectomy;
LUAD	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg02734326	chr4:10020555	SLC2A9	-0.49	-8.47	-0.38	4.07e-16	Bone mineral density;
LUAD	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg05368731	chr17:41323189	NBR1	0.95	20.15	0.7	8.25e-64	Menopause (age at onset);
LUAD	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg15921436	chr17:44337874	NA	-0.72	-9.58	-0.42	8.12e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg20503657	chr10:835505	NA	-0.88	-13.73	-0.56	9.84e-36	Eosinophil percentage of granulocytes;
LUAD	cis	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg21775007	chr8:11205619	TDH	0.37	6.37	0.3	4.97e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs6076065	0.692	rs6083092	chr20:23348836	T/C	cg11657817	chr20:23433608	CST11	0.5	9.12	0.41	3.15e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg26924012	chr15:45694286	SPATA5L1	-1.0	-18.54	-0.67	1.34e-56	Homoarginine levels;
LUAD	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg03676636	chr4:99064102	C4orf37	-0.31	-8.25	-0.37	1.96e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.01	-0.36	1.11e-14	Total body bone mineral density;
LUAD	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24308560	chr3:49941425	MST1R	0.56	9.54	0.42	1.19e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs300774	0.925	rs300708	chr2:140449	A/G	cg21211680	chr2:198530	NA	-0.46	-7.29	-0.33	1.57e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs3862030	0.720	rs2025713	chr10:104230156	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-8.02	-0.36	1.06e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs7737355	0.738	rs10051609	chr5:130877080	G/C	cg25547332	chr5:131281432	NA	0.43	6.9	0.32	1.91e-11	Life satisfaction;
LUAD	cis	rs41311933	0.656	rs2230214	chr9:123782299	G/A	cg13567360	chr9:123745713	C5	-0.69	-8.29	-0.37	1.56e-15	Coronary artery disease;
LUAD	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg00981070	chr1:2046702	PRKCZ	0.36	6.96	0.32	1.28e-11	Height;
LUAD	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg10578991	chr7:12443926	VWDE	-0.49	-7.06	-0.32	6.86e-12	Coronary artery disease;
LUAD	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg22029157	chr1:209979665	IRF6	0.82	10.25	0.45	3.62e-22	Cleft lip with or without cleft palate;
LUAD	trans	rs9929218	0.817	rs3114404	chr16:68722096	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.96	-16.73	-0.63	1.45e-48	Colorectal cancer;
LUAD	cis	rs4691139	1.000	rs12512283	chr4:165908927	G/A	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.46	-9.07	-0.4	4.57e-18	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg22963979	chr7:1858916	MAD1L1	-0.54	-9.2	-0.41	1.65e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg01528321	chr10:82214614	TSPAN14	0.64	10.17	0.44	6.82e-22	Post bronchodilator FEV1;
LUAD	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.02	-0.44	2.34e-21	Migraine;Coronary artery disease;
LUAD	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg24450063	chr1:156163899	SLC25A44	1.19	23.61	0.75	3.22e-79	Testicular germ cell tumor;
LUAD	cis	rs17433780	0.666	rs2624	chr1:89518623	C/T	cg09516651	chr1:89888402	LOC400759	-0.52	-10.11	-0.44	1.15e-21	Carotid intima media thickness;
LUAD	cis	rs7336332	0.598	rs74563672	chr13:28010660	A/G	cg22138327	chr13:27999177	GTF3A	0.77	10.1	0.44	1.22e-21	Weight;
LUAD	cis	rs11585357	0.895	rs72633828	chr1:17632251	G/A	cg08277548	chr1:17600880	PADI3	-0.97	-14.21	-0.57	9.94e-38	Hair shape;
LUAD	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19346786	chr7:2764209	NA	0.54	11.8	0.5	5.72e-28	Height;
LUAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg11494091	chr17:61959527	GH2	0.74	18.37	0.67	7.81e-56	Prudent dietary pattern;
LUAD	cis	rs3789045	0.729	rs16853822	chr1:204450341	C/G	cg17419461	chr1:204415978	PIK3C2B	-0.43	-7.32	-0.34	1.27e-12	Educational attainment (college completion);
LUAD	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	1.03	17.89	0.66	1.04e-53	IgG glycosylation;
LUAD	cis	rs7551222	0.749	rs6594018	chr1:204568152	A/G	cg20240347	chr1:204465584	NA	-0.33	-6.45	-0.3	3.15e-10	Schizophrenia;
LUAD	cis	rs11958404	0.932	rs6859470	chr5:157429505	T/G	cg05962755	chr5:157440814	NA	0.69	9.52	0.42	1.31e-19	IgG glycosylation;
LUAD	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg15133208	chr4:90757351	SNCA	-0.47	-7.46	-0.34	5.04e-13	Neuroticism;
LUAD	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18404041	chr3:52824283	ITIH1	-0.59	-11.89	-0.5	2.54e-28	Bipolar disorder;
LUAD	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.21	-0.48	1.07e-25	Type 2 diabetes;
LUAD	cis	rs4730250	0.707	rs3729877	chr7:106787065	T/G	cg02696742	chr7:106810147	HBP1	0.81	10.75	0.46	5.27e-24	Osteoarthritis;
LUAD	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg25324976	chr17:61989376	CSHL1	0.38	7.41	0.34	7.14e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs78761021	0.867	rs62067560	chr17:9785427	G/A	cg26853458	chr17:9805074	RCVRN	0.37	7.36	0.34	9.97e-13	Type 2 diabetes;
LUAD	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg25767906	chr1:53392781	SCP2	-0.48	-8.62	-0.39	1.33e-16	Monocyte count;
LUAD	cis	rs1448094	0.836	rs7484454	chr12:86425576	A/G	cg19622623	chr12:86230825	RASSF9	-0.37	-6.7	-0.31	6.76e-11	Major depressive disorder;
LUAD	cis	rs4253772	0.591	rs9615348	chr22:46729338	C/G	cg09491104	chr22:46646882	C22orf40	-0.55	-6.91	-0.32	1.79e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg09998033	chr7:158218633	PTPRN2	0.43	7.75	0.35	6.66e-14	Obesity-related traits;
LUAD	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-11.75	-0.5	8.58e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.41	0.3	3.89e-10	Cognitive test performance;
LUAD	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08109568	chr15:31115862	NA	-0.61	-10.23	-0.45	4.27e-22	Huntington's disease progression;
LUAD	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg13390004	chr1:15929781	NA	0.47	8.41	0.38	6.16e-16	Systolic blood pressure;
LUAD	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10802521	chr3:52805072	NEK4	-0.55	-9.09	-0.4	3.98e-18	Bipolar disorder;
LUAD	cis	rs977987	0.902	rs4888430	chr16:75494424	T/C	cg03315344	chr16:75512273	CHST6	0.66	14.74	0.58	5.52e-40	Dupuytren's disease;
LUAD	cis	rs6594713	0.756	rs10053341	chr5:112784007	G/T	cg12552261	chr5:112820674	MCC	0.63	9.41	0.42	3.08e-19	Brain cytoarchitecture;
LUAD	cis	rs7107174	1.000	rs10899458	chr11:78007451	A/T	cg02023728	chr11:77925099	USP35	0.49	7.24	0.33	2.14e-12	Testicular germ cell tumor;
LUAD	cis	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg06360820	chr2:242988706	NA	-0.97	-13.11	-0.54	3.57e-33	Obesity-related traits;
LUAD	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg04546413	chr19:29218101	NA	0.7	10.37	0.45	1.3e-22	Methadone dose in opioid dependence;
LUAD	cis	rs11771526	0.579	rs77818421	chr7:32375129	G/T	cg13207630	chr7:32358064	NA	0.74	7.68	0.35	1.12e-13	Body mass index;
LUAD	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg05340658	chr4:99064831	C4orf37	-0.52	-8.32	-0.37	1.26e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg16354688	chr1:16370265	CLCNKB	0.27	6.43	0.3	3.46e-10	Systolic blood pressure;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg22037798	chr1:231473786	C1orf124;EXOC8	-0.47	-6.63	-0.31	1.02e-10	Testicular germ cell tumor;
LUAD	cis	rs11771526	0.901	rs78065961	chr7:32300967	C/T	cg13207630	chr7:32358064	NA	0.58	7.23	0.33	2.21e-12	Body mass index;
LUAD	cis	rs4409675	0.576	rs6662916	chr1:28219873	G/T	cg23691781	chr1:28212827	C1orf38	0.39	11.33	0.48	3.76e-26	Corneal astigmatism;
LUAD	cis	rs6558530	0.897	rs7838456	chr8:1707591	T/G	cg17159058	chr8:1704075	NA	-0.4	-6.57	-0.3	1.5e-10	Systolic blood pressure;
LUAD	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg22508957	chr16:3507546	NAT15	0.79	13.34	0.54	4.12e-34	Tuberculosis;
LUAD	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21659725	chr3:3221576	CRBN	0.66	11.38	0.48	2.25e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.56	8.11	0.37	5.72e-15	Platelet count;
LUAD	cis	rs16910800	1.000	rs16910794	chr11:23202631	A/T	cg20040320	chr11:23191996	NA	-0.48	-7.21	-0.33	2.66e-12	Cancer;
LUAD	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.47	7.46	0.34	5.08e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg17652424	chr22:38574118	PLA2G6	-0.33	-10.13	-0.44	9.75e-22	Cutaneous nevi;
LUAD	cis	rs7289126	0.966	rs4820329	chr22:38646063	G/A	cg17652424	chr22:38574118	PLA2G6	-0.24	-6.68	-0.31	7.36e-11	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs7744392	0.557	rs9296148	chr6:35337467	G/A	cg03355690	chr6:35265616	DEF6	0.63	6.36	0.3	5.32e-10	Cataracts in type 2 diabetes;
LUAD	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg16680214	chr1:154839983	KCNN3	-0.63	-13.26	-0.54	8.05e-34	Prostate cancer;
LUAD	cis	rs9341808	0.690	rs6930534	chr6:80896050	C/T	cg08355045	chr6:80787529	NA	0.58	10.49	0.45	4.9e-23	Sitting height ratio;
LUAD	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11890956	chr21:40555474	PSMG1	-0.6	-9.72	-0.43	2.73e-20	Cognitive function;
LUAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg11494091	chr17:61959527	GH2	0.74	18.32	0.67	1.27e-55	Prudent dietary pattern;
LUAD	trans	rs7395662	1.000	rs4882123	chr11:48575739	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.36	-0.34	9.81e-13	HDL cholesterol;
LUAD	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg14458575	chr2:238380390	NA	0.65	12.09	0.51	3.98e-29	Prostate cancer;
LUAD	cis	rs739496	0.895	rs7965040	chr12:111920295	A/C	cg10833066	chr12:111807467	FAM109A	0.39	6.68	0.31	7.73e-11	Platelet count;
LUAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7911264	0.967	rs9419741	chr10:94430525	A/G	cg25093409	chr10:94429542	NA	-0.38	-6.86	-0.32	2.39e-11	Inflammatory bowel disease;
LUAD	cis	rs739496	0.579	rs2285695	chr12:112375308	T/G	cg10833066	chr12:111807467	FAM109A	0.42	6.87	0.32	2.33e-11	Platelet count;
LUAD	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg22166914	chr1:53195759	ZYG11B	0.46	7.56	0.34	2.55e-13	Monocyte count;
LUAD	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg27661571	chr11:113659931	NA	-0.73	-8.28	-0.37	1.6e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08048268	chr3:133502702	NA	-0.56	-11.28	-0.48	5.74e-26	Iron status biomarkers;
LUAD	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.62e-18	Life satisfaction;
LUAD	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg08798685	chr6:27730294	NA	-0.64	-6.9	-0.32	1.87e-11	Breast cancer;
LUAD	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg00310523	chr12:86230176	RASSF9	0.41	8.71	0.39	6.76e-17	Major depressive disorder;
LUAD	cis	rs3821902	0.646	rs55955229	chr3:64015425	T/C	cg22134162	chr3:63841271	THOC7	-0.4	-6.74	-0.31	5.35e-11	Breast cancer;
LUAD	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg02569458	chr12:86230093	RASSF9	-0.41	-7.6	-0.35	1.95e-13	Major depressive disorder;
LUAD	cis	rs1524976	0.943	rs11711510	chr3:65524312	C/T	cg16238336	chr3:65465873	MAGI1	-0.65	-7.01	-0.32	9.6e-12	PR interval;
LUAD	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg06608945	chr2:219082296	ARPC2	-0.42	-6.9	-0.32	1.85e-11	Colorectal cancer;
LUAD	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg15181151	chr6:150070149	PCMT1	0.34	6.87	0.32	2.25e-11	Lung cancer;
LUAD	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.04e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg27266060	chr8:22091797	NA	0.48	8.73	0.39	5.9e-17	Hypertriglyceridemia;
LUAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg05313129	chr8:58192883	C8orf71	-0.55	-7.09	-0.33	5.61e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9393692	0.620	rs9357005	chr6:26336838	C/A	cg00631329	chr6:26305371	NA	-0.52	-9.11	-0.41	3.2e-18	Educational attainment;
LUAD	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg11814155	chr7:99998594	ZCWPW1	0.4	6.53	0.3	1.88e-10	Platelet count;
LUAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg07677032	chr17:61819896	STRADA	0.58	10.65	0.46	1.23e-23	Prudent dietary pattern;
LUAD	cis	rs6714710	0.603	rs956039	chr2:98416848	C/A	cg26665480	chr2:98280029	ACTR1B	0.55	8.98	0.4	8.82e-18	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs3862030	0.720	rs12569526	chr10:104237007	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-8.19	-0.37	3.03e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg13385794	chr1:248469461	NA	0.26	7.08	0.33	5.93e-12	Common traits (Other);
LUAD	cis	rs6499255	0.904	rs7194753	chr16:69564364	A/G	cg15192750	chr16:69999425	NA	-0.47	-7.28	-0.33	1.67e-12	IgE levels;
LUAD	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg00495681	chr13:53174319	NA	0.51	9.16	0.41	2.19e-18	Lewy body disease;
LUAD	cis	rs4343996	0.807	rs6964838	chr7:3509969	A/G	cg21248987	chr7:3385318	SDK1	-0.37	-6.91	-0.32	1.76e-11	Motion sickness;
LUAD	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg05425664	chr17:57184151	TRIM37	0.43	7.66	0.35	1.24e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.48	-7.75	-0.35	6.82e-14	Alzheimer's disease (late onset);
LUAD	cis	rs1595825	0.891	rs76450397	chr2:198786112	T/C	cg10547527	chr2:198650123	BOLL	-0.53	-7.64	-0.35	1.45e-13	Ulcerative colitis;
LUAD	cis	rs999943	0.846	rs9357162	chr6:33613344	G/A	cg14003231	chr6:33640908	ITPR3	0.88	17.95	0.66	5.54e-54	Obesity (extreme);
LUAD	cis	rs4409675	0.913	rs11587731	chr1:28263750	T/C	cg23691781	chr1:28212827	C1orf38	-0.32	-8.13	-0.37	4.85e-15	Corneal astigmatism;
LUAD	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.46	0.3	2.89e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg02493798	chr17:6899577	ALOX12	-0.35	-6.79	-0.31	3.76e-11	Tonsillectomy;
LUAD	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg25894440	chr7:65020034	NA	-0.62	-6.77	-0.31	4.3e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg17366294	chr4:99064904	C4orf37	0.53	9.69	0.43	3.43e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg05283184	chr6:79620031	NA	-0.61	-12.35	-0.51	3.84e-30	Intelligence (multi-trait analysis);
LUAD	trans	rs8002861	0.935	rs1819595	chr13:44429716	T/A	cg17145862	chr1:211918768	LPGAT1	0.77	18.25	0.66	2.72e-55	Leprosy;
LUAD	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06028808	chr11:68637592	NA	0.44	7.41	0.34	6.98e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg24644049	chr4:85504048	CDS1	0.86	7.02	0.32	8.92e-12	Skin colour saturation;
LUAD	cis	rs28595532	1.000	rs28600971	chr4:119712728	G/T	cg02775129	chr4:119771670	NA	-0.87	-8.35	-0.38	9.98e-16	Cannabis dependence symptom count;
LUAD	cis	rs7731657	0.518	rs7706328	chr5:130218943	G/C	cg08523029	chr5:130500466	HINT1	-0.59	-7.58	-0.35	2.24e-13	Fasting plasma glucose;
LUAD	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg26384229	chr12:38710491	ALG10B	0.42	6.9	0.32	1.95e-11	Morning vs. evening chronotype;
LUAD	cis	rs2933343	0.951	rs7648327	chr3:128570708	A/G	cg11901034	chr3:128598214	ACAD9	-0.47	-6.43	-0.3	3.38e-10	IgG glycosylation;
LUAD	cis	rs7119	0.667	rs907390	chr15:77902419	T/C	cg27398640	chr15:77910606	LINGO1	0.39	7.68	0.35	1.13e-13	Type 2 diabetes;
LUAD	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.68	-0.35	1.08e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg04155289	chr7:94953770	PON1	-0.54	-7.39	-0.34	7.69e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4285028	0.747	rs10049060	chr3:121358448	C/T	cg11130432	chr3:121712080	ILDR1	0.46	6.75	0.31	4.99e-11	Multiple sclerosis;
LUAD	cis	rs1232027	0.656	rs1650655	chr5:79964808	A/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.45	-7.39	-0.34	7.89e-13	Huntington's disease progression;
LUAD	cis	rs7709909	1.000	rs7709909	chr5:80001170	C/T	cg24059623	chr5:79951536	MSH3;DHFR	0.4	6.83	0.32	2.96e-11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg08027265	chr7:2291960	NA	-0.42	-7.36	-0.34	9.44e-13	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg17063962	chr7:91808500	NA	0.71	12.79	0.53	6.97e-32	Breast cancer;
LUAD	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg15017067	chr4:17643749	FAM184B	0.35	6.87	0.32	2.37e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg15147215	chr3:52552868	STAB1	-0.4	-7.18	-0.33	3.23e-12	Bipolar disorder;
LUAD	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg10589385	chr1:150898437	SETDB1	0.45	8.2	0.37	3.01e-15	Melanoma;
LUAD	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg03676636	chr4:99064102	C4orf37	0.32	8.42	0.38	5.87e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg02775129	chr4:119771670	NA	0.88	8.05	0.36	8.44e-15	Cannabis dependence symptom count;
LUAD	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg02753203	chr1:228287806	NA	-0.49	-9.02	-0.4	6.58e-18	Diastolic blood pressure;
LUAD	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.98	-0.32	1.14e-11	Height;
LUAD	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg11822812	chr5:140052017	DND1	-0.38	-7.03	-0.32	8.08e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg10589385	chr1:150898437	SETDB1	0.44	8.25	0.37	2.04e-15	Melanoma;
LUAD	cis	rs1232027	0.700	rs1382543	chr5:79960955	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	trans	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg06606381	chr12:133084897	FBRSL1	-0.88	-8.43	-0.38	5.63e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7274811	0.744	rs209677	chr20:32140287	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.52	7.92	0.36	2.15e-14	Height;
LUAD	cis	rs35883536	0.967	rs2050471	chr1:101175651	C/T	cg06223162	chr1:101003688	GPR88	0.36	6.7	0.31	6.82e-11	Monocyte count;
LUAD	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg10755058	chr3:40428713	ENTPD3	0.39	7.03	0.32	8.11e-12	Renal cell carcinoma;
LUAD	trans	rs4942242	0.640	rs9533571	chr13:44230136	C/T	cg19169023	chr15:41853346	TYRO3	-0.67	-11.52	-0.49	6.65e-27	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg11344533	chr11:111475393	SIK2	-0.34	-6.49	-0.3	2.44e-10	Primary sclerosing cholangitis;
LUAD	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.23	0.33	2.34e-12	Breast cancer;
LUAD	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg09491104	chr22:46646882	C22orf40	-0.58	-11.38	-0.48	2.37e-26	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4849845	0.637	rs11688038	chr2:121026582	A/G	cg24070213	chr2:121070622	NA	0.4	7.58	0.35	2.15e-13	Mean platelet volume;
LUAD	cis	rs7762018	0.556	rs78233989	chr6:170102041	C/G	cg24289452	chr6:170231220	NA	-0.6	-6.7	-0.31	6.87e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs3812049	0.784	rs7734927	chr5:127453735	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	7.62	0.35	1.62e-13	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs4604732	0.631	rs1106720	chr1:247624681	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.45	7.26	0.33	1.85e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg06271696	chr7:157225062	NA	-0.52	-10.72	-0.46	7.28e-24	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs6987853	0.749	rs13250124	chr8:42404737	G/A	cg09913449	chr8:42400586	C8orf40	0.52	10.42	0.45	8.89e-23	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg04775059	chr7:64541387	NA	0.51	6.85	0.32	2.66e-11	Aortic root size;
LUAD	trans	rs6601327	0.736	rs4840426	chr8:9408978	G/T	cg27411982	chr8:10470053	RP1L1	0.39	7.37	0.34	9.11e-13	Multiple myeloma (hyperdiploidy);
LUAD	trans	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg06606381	chr12:133084897	FBRSL1	-1.12	-9.62	-0.42	6.28e-20	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	trans	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg04565464	chr8:145669602	NFKBIL2	-0.43	-6.74	-0.31	5.14e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg10729496	chr3:10149963	C3orf24	0.45	6.63	0.31	1.02e-10	Alzheimer's disease;
LUAD	cis	rs8177876	0.749	rs79834398	chr16:81090638	G/A	cg08591886	chr16:81111003	C16orf46	-0.71	-6.36	-0.3	5.18e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg01579765	chr21:45077557	HSF2BP	0.61	13.42	0.55	1.91e-34	Mean corpuscular volume;
LUAD	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg13319975	chr6:146136371	FBXO30	0.68	11.78	0.5	6.62e-28	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg15462221	chr8:8086144	FLJ10661	0.39	6.55	0.3	1.69e-10	Neuroticism;
LUAD	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg27489772	chr12:121021490	NA	0.55	6.94	0.32	1.48e-11	Type 1 diabetes nephropathy;
LUAD	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg02880119	chr16:3481970	NA	-0.52	-7.83	-0.36	3.89e-14	Body mass index (adult);
LUAD	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg15147215	chr3:52552868	STAB1	-0.38	-7.13	-0.33	4.3e-12	Electroencephalogram traits;
LUAD	cis	rs11048434	0.636	rs12815310	chr12:9059934	A/G	cg04155231	chr12:9217510	LOC144571	0.36	6.7	0.31	6.48e-11	Sjögren's syndrome;
LUAD	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.09	0.33	5.58e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs999943	0.846	rs1570760	chr6:33622933	C/T	cg14003231	chr6:33640908	ITPR3	0.92	18.66	0.67	3.84e-57	Obesity (extreme);
LUAD	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg22482690	chr17:47019901	SNF8	0.44	8.41	0.38	6.57e-16	Type 2 diabetes;
LUAD	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg05754148	chr16:3507555	NAT15	0.66	11.13	0.48	2.11e-25	Tuberculosis;
LUAD	cis	rs9837602	1.000	rs793496	chr3:99507254	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.6	-8.59	-0.39	1.71e-16	Breast cancer;
LUAD	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.67	-11.85	-0.5	3.68e-28	Melanoma;
LUAD	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg07432352	chr17:45403706	C17orf57	0.34	6.5	0.3	2.31e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg00958927	chr1:175162553	KIAA0040	0.25	6.4	0.3	4.12e-10	Alcohol dependence;
LUAD	cis	rs9341808	0.621	rs2322627	chr6:80806341	T/A	cg08355045	chr6:80787529	NA	0.63	11.82	0.5	4.67e-28	Sitting height ratio;
LUAD	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg17279839	chr7:150038598	RARRES2	0.44	7.2	0.33	2.69e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.53	-0.34	3.11e-13	Resting heart rate;
LUAD	cis	rs77972916	0.561	rs4372955	chr2:43566146	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-7.98	-0.36	1.38e-14	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg20701182	chr2:24300061	SF3B14	0.62	7.02	0.32	8.9e-12	Lymphocyte counts;
LUAD	cis	rs6906287	0.625	rs7757892	chr6:118844221	G/A	cg18833306	chr6:118973337	C6orf204	0.46	8.11	0.37	5.44e-15	Electrocardiographic conduction measures;
LUAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08219700	chr8:58056026	NA	0.62	8.74	0.39	5.72e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs11048434	0.761	rs10842660	chr12:9138897	G/A	cg04155231	chr12:9217510	LOC144571	0.41	7.69	0.35	1.01e-13	Sjögren's syndrome;
LUAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.18	0.54	1.79e-33	Prudent dietary pattern;
LUAD	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.76	0.31	4.48e-11	Platelet count;
LUAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-8.24	-0.37	2.1e-15	Alzheimer's disease;
LUAD	cis	rs6060717	0.528	rs73905955	chr20:34332938	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.14	-0.33	4.06e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.55	-9.71	-0.43	2.85e-20	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg05340658	chr4:99064831	C4orf37	0.53	9.02	0.4	6.77e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg23544223	chr18:12777786	NA	0.68	8.63	0.39	1.25e-16	Inflammatory skin disease;
LUAD	cis	rs3806843	0.576	rs246045	chr5:140329884	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.66	-0.31	8.76e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg26384229	chr12:38710491	ALG10B	0.44	7.31	0.33	1.37e-12	Morning vs. evening chronotype;
LUAD	cis	rs1018836	0.923	rs12545726	chr8:91532087	T/A	cg16814680	chr8:91681699	NA	-0.76	-12.94	-0.53	1.73e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg12400702	chr3:12838781	CAND2	0.31	6.36	0.3	5.19e-10	Parkinson's disease;
LUAD	cis	rs6087990	0.806	rs875041	chr20:31383530	C/T	cg13636640	chr20:31349939	DNMT3B	0.79	13.93	0.56	1.5e-36	Ulcerative colitis;
LUAD	cis	rs9296092	0.517	rs56043172	chr6:33522363	T/G	cg13560919	chr6:33536144	NA	-0.88	-16.8	-0.63	6.99e-49	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg13560548	chr3:10150139	C3orf24	-0.42	-6.99	-0.32	1.08e-11	Alzheimer's disease;
LUAD	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg09137382	chr11:130731461	NA	0.44	8.17	0.37	3.53e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7737355	0.947	rs39600	chr5:130828649	A/T	cg06307176	chr5:131281290	NA	0.48	7.72	0.35	8.34e-14	Life satisfaction;
LUAD	cis	rs77741769	0.529	rs12579868	chr12:121207147	C/T	cg02419362	chr12:121203948	SPPL3	0.41	8.51	0.38	2.95e-16	Mean corpuscular volume;
LUAD	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg12016809	chr21:47604291	C21orf56	0.45	7.51	0.34	3.64e-13	Testicular germ cell tumor;
LUAD	cis	rs73195822	0.667	rs7967408	chr12:111164408	A/C	cg12870014	chr12:110450643	ANKRD13A	0.6	7.0	0.32	1.02e-11	Itch intensity from mosquito bite;
LUAD	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg25237894	chr2:233734115	C2orf82	0.48	9.36	0.41	4.83e-19	Coronary artery disease;
LUAD	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg03676636	chr4:99064102	C4orf37	0.35	8.98	0.4	9.32e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2797160	1.000	rs4895798	chr6:126000162	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.79	-0.39	3.9e-17	Endometrial cancer;
LUAD	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg22431228	chr1:16359049	CLCNKA	-0.37	-7.2	-0.33	2.83e-12	Systolic blood pressure;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21913454	chr19:35454891	ZNF792	-0.4	-6.59	-0.31	1.3e-10	Cancer;
LUAD	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg06784218	chr1:46089804	CCDC17	0.5	11.05	0.47	4.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9503598	1.000	rs9503598	chr6:3446263	A/G	cg00476032	chr6:3446245	SLC22A23	-0.37	-8.2	-0.37	2.97e-15	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg07402062	chr16:89894098	SPIRE2	0.44	11.26	0.48	6.81e-26	Vitiligo;
LUAD	cis	rs13064411	0.660	rs3829889	chr3:113015464	G/A	cg10517650	chr3:113235015	CCDC52	-0.45	-7.39	-0.34	7.97e-13	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.57	-9.44	-0.42	2.61e-19	Renal function-related traits (BUN);
LUAD	cis	rs2274273	1.000	rs1009977	chr14:55603002	T/G	cg04306507	chr14:55594613	LGALS3	0.38	7.95	0.36	1.7e-14	Protein biomarker;
LUAD	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg00933542	chr6:150070202	PCMT1	0.43	9.17	0.41	2.07e-18	Lung cancer;
LUAD	cis	rs813218	0.584	rs11711935	chr3:99808804	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.44	8.17	0.37	3.61e-15	Orofacial clefts;
LUAD	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.79	-10.36	-0.45	1.41e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs6708413	0.520	rs6543151	chr2:103114041	A/G	cg03938978	chr2:103052716	IL18RAP	0.34	6.69	0.31	7.24e-11	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9372498	0.536	rs9489460	chr6:118925754	C/T	cg07617317	chr6:118971624	C6orf204	0.55	8.33	0.38	1.11e-15	Diastolic blood pressure;
LUAD	cis	rs870825	0.616	rs4443323	chr4:185629805	C/A	cg04058563	chr4:185651563	MLF1IP	0.85	12.46	0.52	1.43e-30	Blood protein levels;
LUAD	cis	rs13064411	0.735	rs13098166	chr3:113210038	A/G	cg10517650	chr3:113235015	CCDC52	-0.56	-9.63	-0.42	5.58e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg00316803	chr15:76480434	C15orf27	-0.4	-7.59	-0.35	2e-13	Blood metabolite levels;
LUAD	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg03909863	chr11:638404	DRD4	-0.48	-6.54	-0.3	1.75e-10	Systemic lupus erythematosus;
LUAD	cis	rs7617773	0.780	rs13079728	chr3:48339360	A/G	cg11946769	chr3:48343235	NME6	0.44	6.71	0.31	6.35e-11	Coronary artery disease;
LUAD	cis	rs4853036	0.859	rs10196546	chr2:70157158	T/C	cg02498382	chr2:70120550	SNRNP27	-0.52	-8.52	-0.38	2.74e-16	Colorectal or endometrial cancer;
LUAD	cis	rs7680126	0.633	rs2868937	chr4:10303081	C/T	cg00071950	chr4:10020882	SLC2A9	-0.59	-8.03	-0.36	9.49e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs62238980	0.614	rs4821025	chr22:32416892	C/T	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06544989	chr22:39130855	UNC84B	0.39	8.03	0.36	9.43e-15	Menopause (age at onset);
LUAD	trans	rs34816374	1	rs34816374	chr6:26949672	A/G	cg01620082	chr3:125678407	NA	-0.99	-9.58	-0.42	8.69e-20	Lung cancer in ever smokers;
LUAD	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg19761014	chr17:28927070	LRRC37B2	0.86	8.36	0.38	9.21e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7617773	0.780	rs11718350	chr3:48360992	T/G	cg11946769	chr3:48343235	NME6	0.44	6.7	0.31	6.73e-11	Coronary artery disease;
LUAD	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg12140854	chr5:148520817	ABLIM3	0.68	11.18	0.48	1.36e-25	Breast cancer;
LUAD	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg27284194	chr4:1044797	NA	0.69	9.96	0.44	3.84e-21	Recombination rate (females);
LUAD	cis	rs6484504	0.576	rs158139	chr11:31216076	C/T	cg26647111	chr11:31128758	NA	-0.46	-8.24	-0.37	2.13e-15	Red blood cell count;
LUAD	trans	rs208520	0.955	rs12216176	chr6:67005130	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	10.59	0.46	2.08e-23	Exhaled nitric oxide output;
LUAD	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg11502198	chr6:26597334	ABT1	0.55	9.17	0.41	2.12e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7043114	0.525	rs6479417	chr9:95064562	G/C	cg14631576	chr9:95140430	CENPP	-0.41	-8.39	-0.38	7.2e-16	Height;
LUAD	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg14789911	chr21:47582049	C21orf56	0.42	7.06	0.32	6.7e-12	Testicular germ cell tumor;
LUAD	cis	rs1475718	0.526	rs10785876	chr9:137122767	C/G	cg21243944	chr9:137118148	NA	-0.33	-6.97	-0.32	1.25e-11	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg17063962	chr7:91808500	NA	-0.65	-11.09	-0.47	2.8e-25	Breast cancer;
LUAD	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg17757837	chr7:157058334	UBE3C	-0.47	-8.26	-0.37	1.82e-15	Body mass index;
LUAD	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg00717180	chr2:96193071	NA	-0.4	-7.4	-0.34	7.24e-13	HDL cholesterol;
LUAD	cis	rs7617773	0.780	rs11716848	chr3:48378500	G/A	cg11946769	chr3:48343235	NME6	0.44	6.7	0.31	6.73e-11	Coronary artery disease;
LUAD	trans	rs867371	0.519	rs1566560	chr15:82524457	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.41	-6.89	-0.32	2.07e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LUAD	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.72	-0.31	5.95e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg09491104	chr22:46646882	C22orf40	-0.51	-7.06	-0.32	7.02e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4604732	0.631	rs1106721	chr1:247624676	A/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.45	7.26	0.33	1.85e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1691799	0.867	rs1168338	chr12:66759369	T/C	cg16791601	chr12:66731901	HELB	-0.37	-6.68	-0.31	7.39e-11	White blood cell count (basophil);
LUAD	trans	rs11638815	0.520	rs4779032	chr15:83245326	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.43	-7.25	-0.33	2.06e-12	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	cis	rs1232027	0.700	rs1478834	chr5:79949575	C/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-8.09	-0.37	6.53e-15	Huntington's disease progression;
LUAD	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg25358565	chr5:93447407	FAM172A	0.58	7.2	0.33	2.69e-12	Diabetic retinopathy;
LUAD	cis	rs1127311	0.905	rs6702449	chr1:154583210	A/C	cg17218026	chr1:154582156	ADAR	0.5	10.0	0.44	2.89e-21	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg18225595	chr11:63971243	STIP1	0.53	8.8	0.39	3.55e-17	Platelet count;
LUAD	trans	rs57046232	0.552	rs6038449	chr20:6337980	C/T	cg21095983	chr6:86352623	SYNCRIP	0.41	6.47	0.3	2.67e-10	Colorectal cancer;
LUAD	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11645453	chr3:52864694	ITIH4	0.33	6.57	0.3	1.46e-10	Bipolar disorder;
LUAD	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg20891558	chr2:74357851	NA	0.97	16.03	0.61	1.58e-45	Gestational age at birth (maternal effect);
LUAD	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg20744362	chr22:50050164	C22orf34	0.43	9.48	0.42	1.87e-19	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7851660	0.935	rs12347191	chr9:100619719	C/T	cg13688889	chr9:100608707	NA	-0.52	-9.44	-0.42	2.47e-19	Strep throat;
LUAD	cis	rs35771425	1.000	rs35771425	chr1:211609768	T/C	cg25617285	chr1:211431773	RCOR3	-0.44	-6.36	-0.3	5.16e-10	Educational attainment (years of education);
LUAD	cis	rs7680126	0.596	rs4698009	chr4:10284993	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-6.96	-0.32	1.34e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg24399712	chr22:39784796	NA	-0.78	-14.99	-0.59	4.78e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs9837602	0.551	rs1630555	chr3:99423273	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.49	-6.97	-0.32	1.21e-11	Breast cancer;
LUAD	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg06108461	chr20:60628389	TAF4	-0.81	-14.11	-0.57	2.53e-37	Body mass index;
LUAD	trans	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg19862616	chr7:65841803	NCRNA00174	1.03	25.27	0.78	1.46e-86	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg14558114	chr2:88469736	THNSL2	0.87	9.31	0.41	6.92e-19	Plasma clusterin levels;
LUAD	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Depression;
LUAD	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg15448220	chr1:150897856	SETDB1	-0.46	-7.98	-0.36	1.43e-14	Tonsillectomy;
LUAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.51	9.21	0.41	1.56e-18	Lymphocyte counts;
LUAD	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.78	10.98	0.47	7.54e-25	Smoking behavior;
LUAD	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22590775	chr19:49891494	CCDC155	0.54	7.7	0.35	9.62e-14	Multiple sclerosis;
LUAD	trans	rs4650994	1.000	rs10798615	chr1:178513895	T/G	cg05059571	chr16:84539110	KIAA1609	-0.63	-10.71	-0.46	7.74e-24	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg26384229	chr12:38710491	ALG10B	-0.46	-7.76	-0.35	6.51e-14	Bladder cancer;
LUAD	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg11814155	chr7:99998594	ZCWPW1	0.43	7.32	0.34	1.26e-12	Platelet count;
LUAD	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.32	6.7	0.31	6.51e-11	Parkinson's disease;
LUAD	cis	rs1595825	0.838	rs73058883	chr2:198896255	C/T	cg10547527	chr2:198650123	BOLL	-0.51	-7.0	-0.32	1.02e-11	Ulcerative colitis;
LUAD	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg15448220	chr1:150897856	SETDB1	0.56	9.56	0.42	9.56e-20	Melanoma;
LUAD	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg02423579	chr7:2872169	GNA12	-0.83	-14.82	-0.58	2.49e-40	Height;
LUAD	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg00784671	chr22:46762841	CELSR1	-0.48	-7.01	-0.32	9.36e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg22532475	chr10:104410764	TRIM8	-0.42	-8.3	-0.37	1.37e-15	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs12893668	0.667	rs71417869	chr14:104077434	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.49	-0.38	3.46e-16	Reticulocyte count;
LUAD	cis	rs2262909	0.745	rs1989120	chr19:22205528	T/C	cg11619707	chr19:22235551	ZNF257	-0.42	-6.39	-0.3	4.34e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs684232	0.666	rs423887	chr17:593600	A/G	cg12384639	chr17:618140	VPS53	0.47	7.72	0.35	8.56e-14	Prostate cancer;
LUAD	cis	rs12681287	0.752	rs10104242	chr8:87247714	G/C	cg27223183	chr8:87520930	FAM82B	-0.59	-8.28	-0.37	1.58e-15	Caudate activity during reward;
LUAD	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg04414720	chr1:150670196	GOLPH3L	-0.71	-13.26	-0.54	8.75e-34	Tonsillectomy;
LUAD	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.46	-0.34	5.04e-13	Bipolar disorder;
LUAD	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg27284194	chr4:1044797	NA	0.7	10.18	0.44	6.52e-22	Recombination rate (females);
LUAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08439880	chr3:133502540	NA	-0.45	-8.85	-0.4	2.36e-17	Iron status biomarkers;
LUAD	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-8.99	-0.4	8.48e-18	Blood metabolite levels;
LUAD	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg21545522	chr1:205238299	TMCC2	0.39	7.25	0.33	1.94e-12	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg06453172	chr10:134556979	INPP5A	-0.66	-9.9	-0.43	6.49e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21582582	chr3:182698605	DCUN1D1	0.72	14.09	0.57	3.19e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.802	rs11117146	chr12:86382870	C/T	cg02569458	chr12:86230093	RASSF9	-0.36	-6.87	-0.32	2.27e-11	Major depressive disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25563616	chr16:8962190	CARHSP1	-0.42	-6.56	-0.3	1.61e-10	Height;
LUAD	cis	rs10489202	0.632	rs203779	chr1:167877647	T/G	cg24449463	chr1:168025552	DCAF6	-0.74	-12.12	-0.51	3.11e-29	Schizophrenia;
LUAD	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg06740227	chr12:86229804	RASSF9	0.44	7.57	0.35	2.34e-13	Major depressive disorder;
LUAD	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg17264618	chr3:40429014	ENTPD3	0.38	7.81	0.36	4.49e-14	Renal cell carcinoma;
LUAD	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg18196295	chr10:418757	DIP2C	0.5	8.41	0.38	6.37e-16	Psychosis in Alzheimer's disease;
LUAD	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg00147160	chr1:26503991	CNKSR1	0.37	8.77	0.39	4.53e-17	Height;
LUAD	cis	rs4767364	0.796	rs4767293	chr12:112463296	A/G	cg10833066	chr12:111807467	FAM109A	0.35	6.69	0.31	7.07e-11	Oral cavity and pharyngeal cancer;
LUAD	trans	rs87938	1.000	rs417052	chr3:41125962	A/G	cg11224624	chr8:145049280	PLEC1	0.4	6.47	0.3	2.77e-10	Bone mineral density (hip);
LUAD	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg14668632	chr7:2872130	GNA12	-0.47	-8.42	-0.38	5.93e-16	Height;
LUAD	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg13736514	chr6:26305472	NA	-0.5	-8.95	-0.4	1.09e-17	Educational attainment;
LUAD	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg25036284	chr2:26402008	FAM59B	0.82	10.87	0.47	1.92e-24	Gut microbiome composition (summer);
LUAD	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg20991723	chr1:152506922	NA	0.32	6.39	0.3	4.44e-10	Hair morphology;
LUAD	cis	rs4730250	0.640	rs7783562	chr7:106917438	G/T	cg02696742	chr7:106810147	HBP1	-0.67	-7.65	-0.35	1.38e-13	Osteoarthritis;
LUAD	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg00933542	chr6:150070202	PCMT1	0.35	7.31	0.33	1.34e-12	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08677398	chr8:58056175	NA	0.47	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03517284	chr6:25882590	NA	0.85	14.33	0.57	3.09e-38	Blood metabolite levels;
LUAD	cis	rs4891159	0.548	rs654754	chr18:74143695	T/C	cg24786174	chr18:74118243	ZNF516	0.88	21.31	0.72	5.46e-69	Longevity;
LUAD	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg02734326	chr4:10020555	SLC2A9	-0.45	-8.07	-0.37	7.3e-15	Bone mineral density;
LUAD	trans	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg13565492	chr6:43139072	SRF	-0.6	-6.4	-0.3	4.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg22535103	chr8:58192502	C8orf71	-0.75	-9.17	-0.41	2.16e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs735539	0.521	rs1348370	chr13:21404658	A/C	cg27499820	chr13:21296301	IL17D	0.43	7.26	0.33	1.93e-12	Dental caries;
LUAD	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg06784218	chr1:46089804	CCDC17	-0.6	-13.5	-0.55	8.61e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03517284	chr6:25882590	NA	-0.57	-9.19	-0.41	1.75e-18	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02081018	chr21:38445169	PIGP;TTC3	-0.46	-6.46	-0.3	2.88e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg02176678	chr2:219576539	TTLL4	0.6	11.61	0.49	3.1e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg03037974	chr15:76606532	NA	-0.39	-8.58	-0.38	1.88e-16	Blood metabolite levels;
LUAD	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21659725	chr3:3221576	CRBN	-0.5	-8.3	-0.37	1.39e-15	Body mass index;
LUAD	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.48	-0.45	5.41e-23	Total body bone mineral density;
LUAD	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg27490568	chr2:178487706	NA	0.5	8.52	0.38	2.94e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4006360	0.503	rs1848808	chr17:39249321	T/C	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.25	0.37	2e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg00802000	chr16:706648	WDR90	-0.38	-7.14	-0.33	4.15e-12	Height;
LUAD	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg10729496	chr3:10149963	C3orf24	0.58	9.38	0.42	3.91e-19	Alzheimer's disease;
LUAD	cis	rs11585357	0.947	rs11585119	chr1:17605792	C/A	cg08277548	chr1:17600880	PADI3	-0.96	-14.01	-0.56	6.58e-37	Hair shape;
LUAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12016809	chr21:47604291	C21orf56	-0.65	-10.97	-0.47	8.13e-25	Testicular germ cell tumor;
LUAD	cis	rs7607369	0.559	rs4674341	chr2:219659911	A/G	cg02176678	chr2:219576539	TTLL4	-0.54	-10.46	-0.45	6.41e-23	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg11502198	chr6:26597334	ABT1	0.73	12.5	0.52	1.02e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg21475434	chr5:93447410	FAM172A	0.75	8.29	0.37	1.48e-15	Diabetic retinopathy;
LUAD	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg08470875	chr2:26401718	FAM59B	-0.77	-10.37	-0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.62	-0.31	1.09e-10	Height;
LUAD	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg21153622	chr11:89784906	NA	0.33	6.7	0.31	6.6e-11	Coronary artery disease;
LUAD	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg12573674	chr2:1569213	NA	-0.6	-6.7	-0.31	6.54e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg02683114	chr2:24398427	C2orf84	0.41	6.9	0.32	1.94e-11	Asthma;
LUAD	cis	rs10916814	1.000	rs12145351	chr1:20901181	C/A	cg24502330	chr1:20914028	CDA	-0.38	-7.12	-0.33	4.7e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15369054	chr17:80825471	TBCD	0.65	10.82	0.47	2.88e-24	Breast cancer;
LUAD	cis	rs367943	0.698	rs4336355	chr5:113000368	C/T	cg12552261	chr5:112820674	MCC	0.51	9.15	0.41	2.45e-18	Type 2 diabetes;
LUAD	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg19767477	chr5:127420684	SLC12A2	-0.44	-6.75	-0.31	4.94e-11	Ileal carcinoids;
LUAD	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg26446133	chr18:72167187	CNDP2	-0.89	-15.48	-0.6	3.75e-43	Refractive error;
LUAD	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08109568	chr15:31115862	NA	-0.61	-10.2	-0.44	5.56e-22	Huntington's disease progression;
LUAD	trans	rs877282	0.755	rs2790388	chr10:786084	T/C	cg22713356	chr15:30763199	NA	1.06	15.5	0.6	3.11e-43	Uric acid levels;
LUAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg26338869	chr17:61819248	STRADA	-0.38	-6.43	-0.3	3.45e-10	Prudent dietary pattern;
LUAD	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg07741184	chr6:167504864	NA	0.36	8.17	0.37	3.66e-15	Primary biliary cholangitis;
LUAD	trans	rs1422110	0.879	rs1363268	chr5:85469695	C/T	cg01787110	chr1:109008453	NBPF6	-0.66	-10.66	-0.46	1.15e-23	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg20203395	chr5:56204925	C5orf35	0.51	8.07	0.37	7.42e-15	Type 2 diabetes;
LUAD	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg10523679	chr1:76189770	ACADM	0.97	19.51	0.69	6.37e-61	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg03983476	chr2:10830698	NOL10	0.4	6.81	0.31	3.36e-11	Prostate cancer;
LUAD	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg04034577	chr2:241836375	C2orf54	-0.47	-10.24	-0.45	3.79e-22	Urinary metabolites;
LUAD	trans	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-16.11	-0.62	6.99e-46	Exhaled nitric oxide output;
LUAD	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.79	-0.35	5.18e-14	Type 2 diabetes;
LUAD	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg05110241	chr16:68378359	PRMT7	-0.81	-8.73	-0.39	5.85e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12681287	0.752	rs2917557	chr8:87314071	C/T	cg27223183	chr8:87520930	FAM82B	-0.63	-8.68	-0.39	8.43e-17	Caudate activity during reward;
LUAD	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg00106254	chr7:1943704	MAD1L1	-0.6	-8.9	-0.4	1.61e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg03929089	chr4:120376271	NA	-0.84	-14.71	-0.58	7.64e-40	Height;
LUAD	cis	rs9462027	0.606	rs2744941	chr6:34646917	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-8.58	-0.38	1.86e-16	Systemic lupus erythematosus;
LUAD	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg13679303	chr9:96623674	NA	-0.37	-7.39	-0.34	7.99e-13	DNA methylation (variation);
LUAD	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg06547715	chr2:218990976	CXCR2	-0.27	-6.39	-0.3	4.29e-10	Colorectal cancer;
LUAD	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg08470875	chr2:26401718	FAM59B	-0.62	-8.45	-0.38	4.6e-16	Gut microbiome composition (summer);
LUAD	cis	rs10821973	0.527	rs4246940	chr10:64021586	G/C	cg09941381	chr10:64027924	RTKN2	-0.36	-7.11	-0.33	4.96e-12	Hypothyroidism;
LUAD	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg20476274	chr7:133979776	SLC35B4	0.75	13.06	0.54	5.72e-33	Mean platelet volume;
LUAD	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg17724175	chr1:150552817	MCL1	0.33	7.64	0.35	1.47e-13	Melanoma;
LUAD	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg21427119	chr20:30132790	HM13	-0.62	-9.46	-0.42	2.24e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg07617317	chr6:118971624	C6orf204	0.55	8.02	0.36	1.08e-14	Diastolic blood pressure;
LUAD	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg02733842	chr7:1102375	C7orf50	-0.65	-9.86	-0.43	8.99e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg18198730	chr1:247681584	NA	0.44	7.62	0.35	1.71e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs447921	0.861	rs4789301	chr17:74454212	A/C	cg17201438	chr17:74438067	UBE2O	-0.64	-8.59	-0.39	1.73e-16	Mitochondrial DNA levels;
LUAD	cis	rs3772130	0.962	rs9839617	chr3:121516577	A/G	cg20356878	chr3:121714668	ILDR1	0.53	8.6	0.39	1.59e-16	Cognitive performance;
LUAD	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.91	13.16	0.54	2.11e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1997103	0.954	rs2030807	chr7:55378485	A/G	cg17469321	chr7:55412551	NA	0.66	11.17	0.48	1.42e-25	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg20203395	chr5:56204925	C5orf35	-0.51	-8.33	-0.38	1.12e-15	Coronary artery disease;
LUAD	cis	rs6684514	0.922	rs12022657	chr1:156314147	A/G	cg16558208	chr1:156270281	VHLL	0.52	9.47	0.42	1.97e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.21e-16	Prostate cancer;
LUAD	cis	rs4692589	0.606	rs13127322	chr4:170935169	C/T	cg19918862	chr4:170955249	NA	0.33	6.93	0.32	1.62e-11	Anxiety disorder;
LUAD	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg25457927	chr22:38595422	NA	-0.53	-13.87	-0.56	2.48e-36	Cutaneous nevi;
LUAD	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg11517269	chr6:28058789	ZSCAN12L1	0.38	7.34	0.34	1.09e-12	Lung cancer in ever smokers;
LUAD	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg00277334	chr10:82204260	NA	-0.46	-7.72	-0.35	8.26e-14	Post bronchodilator FEV1;
LUAD	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	8.98	0.4	9.27e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.4	-0.38	7.05e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg10589385	chr1:150898437	SETDB1	0.39	7.2	0.33	2.71e-12	Melanoma;
LUAD	cis	rs7107174	1.000	rs7119933	chr11:78049750	A/C	cg19901956	chr11:77921274	USP35	-0.47	-6.79	-0.31	3.93e-11	Testicular germ cell tumor;
LUAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	cis	rs1018836	0.608	rs2142147	chr8:91468200	A/G	cg16814680	chr8:91681699	NA	-0.54	-8.83	-0.39	2.73e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.35	-6.57	-0.3	1.51e-10	Caffeine consumption;
LUAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg04025307	chr7:1156635	C7orf50	0.6	6.78	0.31	4.07e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs78761021	0.755	rs17681812	chr17:9794540	C/T	cg26853458	chr17:9805074	RCVRN	0.38	7.02	0.32	9.07e-12	Type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.08	-0.4	4.08e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.31	-7.15	-0.33	3.96e-12	Lymphocyte counts;
LUAD	cis	rs10821973	0.527	rs4115469	chr10:64018865	T/C	cg09941381	chr10:64027924	RTKN2	-0.36	-7.18	-0.33	3.15e-12	Hypothyroidism;
LUAD	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg04944784	chr2:26401820	FAM59B	0.91	13.67	0.55	1.81e-35	Gut microbiome composition (summer);
LUAD	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg05590025	chr7:65112418	INTS4L2	0.74	7.8	0.35	5.02e-14	Diabetic kidney disease;
LUAD	cis	rs2046867	0.862	rs67961837	chr3:72840877	T/G	cg04365224	chr3:72788183	NA	-0.48	-7.08	-0.33	6.21e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs758324	0.580	rs35566767	chr5:131606049	C/G	cg21138405	chr5:131827807	IRF1	0.52	6.74	0.31	5.35e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg23262351	chr6:79576851	IRAK1BP1	0.43	7.23	0.33	2.23e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg00129232	chr17:37814104	STARD3	-0.45	-7.7	-0.35	9.43e-14	Asthma;
LUAD	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.15	-0.33	3.88e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7084921	0.608	rs11598979	chr10:101833720	C/T	cg02250046	chr10:101825185	CPN1	-0.34	-6.49	-0.3	2.43e-10	Bone mineral density;
LUAD	cis	rs9902453	0.934	rs7223645	chr17:28491029	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	8.41	0.38	6.35e-16	Coffee consumption (cups per day);
LUAD	cis	rs2629540	0.889	rs4962696	chr10:126445630	A/G	cg08799069	chr10:126477246	METTL10	-0.5	-7.36	-0.34	9.36e-13	Cocaine dependence;
LUAD	cis	rs41311933	1.000	rs41311897	chr9:123745816	T/C	cg13567360	chr9:123745713	C5	-0.84	-9.46	-0.42	2.12e-19	Coronary artery disease;
LUAD	cis	rs4072705	1.000	rs4838201	chr9:127460617	C/T	cg01786973	chr9:127249749	NR5A1	0.3	6.52	0.3	2e-10	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.93	0.32	1.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg11502198	chr6:26597334	ABT1	0.66	11.48	0.49	9.8e-27	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg18944383	chr4:111397179	ENPEP	0.38	7.76	0.35	6.25e-14	Height;
LUAD	cis	rs89107	0.603	rs399844	chr6:118613435	A/G	cg21191810	chr6:118973309	C6orf204	0.54	10.98	0.47	7.78e-25	Cardiac structure and function;
LUAD	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.63	-0.31	1.04e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.49	0.34	3.92e-13	Tonsillectomy;
LUAD	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg22532475	chr10:104410764	TRIM8	-0.36	-7.28	-0.33	1.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs77972916	0.519	rs13411327	chr2:43515483	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-7.69	-0.35	1.01e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg05665937	chr4:1216051	CTBP1	0.42	7.23	0.33	2.21e-12	Obesity-related traits;
LUAD	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg02733842	chr7:1102375	C7orf50	-0.67	-10.25	-0.45	3.58e-22	Bronchopulmonary dysplasia;
LUAD	cis	rs4319547	0.695	rs11058034	chr12:122894936	G/T	cg23029597	chr12:123009494	RSRC2	0.52	7.66	0.35	1.25e-13	Body mass index;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg00566492	chr22:39096679	JOSD1	-0.39	-6.95	-0.32	1.36e-11	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg13560548	chr3:10150139	C3orf24	0.44	7.33	0.34	1.15e-12	Alzheimer's disease;
LUAD	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.09	0.37	6.52e-15	Breast cancer;
LUAD	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg22920501	chr2:26401640	FAM59B	-0.96	-14.18	-0.57	1.34e-37	Gut microbiome composition (summer);
LUAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.78	14.59	0.58	2.44e-39	Lymphocyte counts;
LUAD	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg27588902	chr6:42928151	GNMT	-0.37	-9.7	-0.43	3.32e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg23978390	chr7:1156363	C7orf50	0.45	7.07	0.33	6.28e-12	Longevity;Endometriosis;
LUAD	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	12.64	0.52	2.63e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.18	-0.41	1.88e-18	Life satisfaction;
LUAD	cis	rs10129255	0.500	rs6576232	chr14:107195328	A/G	cg07958169	chr14:107095056	NA	-0.37	-7.36	-0.34	9.87e-13	Kawasaki disease;
LUAD	cis	rs2274273	0.624	rs7150763	chr14:55839801	A/G	cg04306507	chr14:55594613	LGALS3	0.4	7.77	0.35	6.14e-14	Protein biomarker;
LUAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18099408	chr3:52552593	STAB1	-0.54	-9.67	-0.43	4e-20	Electroencephalogram traits;
LUAD	trans	rs11088226	0.681	rs2833891	chr21:33928821	A/G	cg09050820	chr6:167586206	TCP10L2	0.89	13.15	0.54	2.26e-33	Gastritis;
LUAD	cis	rs67072384	0.818	rs12284245	chr11:72477668	C/T	cg04827223	chr11:72435913	ARAP1	-0.63	-6.61	-0.31	1.13e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21496518	chr3:15374154	SH3BP5	0.33	6.4	0.3	4.11e-10	Cancer;
LUAD	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-13.61	-0.55	3.15e-35	Chronic sinus infection;
LUAD	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.5	0.3	2.33e-10	Depression;
LUAD	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg15704280	chr7:45808275	SEPT13	-0.93	-18.2	-0.66	4.29e-55	Coronary artery disease;
LUAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg21724239	chr8:58056113	NA	0.6	8.48	0.38	3.71e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs59698941	0.943	rs79586717	chr5:132251790	T/C	cg14825688	chr5:132208181	LEAP2	-0.47	-6.41	-0.3	3.91e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg18305652	chr10:134549665	INPP5A	0.61	11.82	0.5	4.88e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.33e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs4953404	0.613	rs897532	chr2:46893225	G/A	cg09399716	chr2:46890238	NA	-0.34	-6.68	-0.31	7.36e-11	Pulse pressure (alcohol consumption interaction);
LUAD	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg13319975	chr6:146136371	FBXO30	0.59	9.96	0.44	4.05e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg05890377	chr2:74357713	NA	0.82	11.86	0.5	3.37e-28	Gestational age at birth (maternal effect);
LUAD	cis	rs4664304	1.000	rs57771571	chr2:160767804	G/C	cg06573604	chr2:160760825	LY75	-0.4	-6.77	-0.31	4.24e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg18833306	chr6:118973337	C6orf204	-0.54	-7.61	-0.35	1.81e-13	Diastolic blood pressure;
LUAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.61	8.07	0.37	7.25e-15	Renal function-related traits (BUN);
LUAD	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg25804541	chr17:80189381	SLC16A3	0.3	6.4	0.3	4.11e-10	Life satisfaction;
LUAD	cis	rs6542838	0.641	rs6757098	chr2:99471399	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.32	-0.34	1.28e-12	Fear of minor pain;
LUAD	cis	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg07460842	chr6:66804631	NA	-1.05	-16.3	-0.62	1.04e-46	Exhaled nitric oxide output;
LUAD	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg06775570	chr1:201857621	SHISA4	0.27	6.78	0.31	4.04e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUAD	cis	rs863345	0.625	rs7534112	chr1:158532065	G/A	cg12129480	chr1:158549410	OR10X1	-0.25	-6.63	-0.31	1.01e-10	Pneumococcal bacteremia;
LUAD	cis	rs36051895	0.659	rs10974935	chr9:5050307	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-6.43	-0.3	3.41e-10	Pediatric autoimmune diseases;
LUAD	cis	rs2279817	0.955	rs2270977	chr1:18023509	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.59	9.67	0.43	4.19e-20	Neuroticism;
LUAD	cis	rs7095607	0.560	rs2673794	chr10:69926097	T/C	cg18986048	chr10:69913749	MYPN	0.48	8.19	0.37	3.13e-15	Lung function (FVC);
LUAD	cis	rs73206853	0.841	rs28480627	chr12:110834659	T/C	cg12870014	chr12:110450643	ANKRD13A	0.64	7.17	0.33	3.47e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg26384229	chr12:38710491	ALG10B	0.49	7.85	0.36	3.37e-14	Morning vs. evening chronotype;
LUAD	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg24768116	chr2:27665128	KRTCAP3	0.26	6.44	0.3	3.29e-10	Oral cavity cancer;
LUAD	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg07256732	chr16:621771	PIGQ	-0.32	-6.54	-0.3	1.8e-10	Height;
LUAD	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg21220214	chr8:57350948	NA	-0.65	-9.24	-0.41	1.22e-18	Obesity-related traits;
LUAD	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg01299579	chr2:10830716	NOL10	-0.43	-7.65	-0.35	1.38e-13	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg03467027	chr4:99064603	C4orf37	0.42	6.84	0.32	2.78e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs367943	0.712	rs10042223	chr5:112712832	C/T	cg12552261	chr5:112820674	MCC	0.47	9.26	0.41	1.05e-18	Type 2 diabetes;
LUAD	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs77505915	0.512	rs12921808	chr16:75383984	T/C	cg03315344	chr16:75512273	CHST6	-0.43	-7.72	-0.35	8.57e-14	Migraine;
LUAD	cis	rs7727544	0.582	rs3749756	chr5:131534499	C/T	cg14196790	chr5:131705035	SLC22A5	0.42	7.27	0.33	1.72e-12	Blood metabolite levels;
LUAD	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg11915388	chr22:42470451	FAM109B	0.41	7.29	0.33	1.51e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg27211696	chr2:191398769	TMEM194B	-0.71	-14.77	-0.58	4e-40	Pulse pressure;
LUAD	trans	rs9929218	0.954	rs17715799	chr16:68830511	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.6	-0.52	3.93e-31	Colorectal cancer;
LUAD	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg03983476	chr2:10830698	NOL10	0.4	6.78	0.31	3.99e-11	Prostate cancer;
LUAD	cis	rs9902453	1.000	rs6505152	chr17:28331466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-8.99	-0.4	8.33e-18	Coffee consumption (cups per day);
LUAD	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-7.01	-0.32	9.7e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	trans	rs9467711	0.790	rs17598658	chr6:26175866	A/C	cg01620082	chr3:125678407	NA	-1.09	-9.32	-0.41	6.48e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7737355	0.812	rs13173941	chr5:130623232	T/A	cg06307176	chr5:131281290	NA	0.39	6.59	0.31	1.33e-10	Life satisfaction;
LUAD	cis	rs11971779	0.680	rs4732376	chr7:139098024	G/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg19413350	chr8:57351067	NA	-0.41	-6.54	-0.3	1.75e-10	Obesity-related traits;
LUAD	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg08645402	chr16:4508243	NA	0.52	9.0	0.4	7.75e-18	Schizophrenia;
LUAD	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg17200465	chr3:40428508	ENTPD3	-0.27	-6.94	-0.32	1.49e-11	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg07917127	chr4:99064746	C4orf37	0.42	7.01	0.32	9.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg07636037	chr3:49044803	WDR6	0.54	10.22	0.44	4.78e-22	Menarche (age at onset);
LUAD	cis	rs12681287	0.640	rs12550142	chr8:87471861	C/A	cg27223183	chr8:87520930	FAM82B	-0.67	-9.54	-0.42	1.12e-19	Caudate activity during reward;
LUAD	cis	rs7524258	0.900	rs2412151	chr1:7303216	G/C	cg07173049	chr1:7289937	CAMTA1	0.38	7.0	0.32	1.03e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs2274273	0.967	rs10137409	chr14:55611441	A/C	cg04306507	chr14:55594613	LGALS3	0.37	7.52	0.34	3.26e-13	Protein biomarker;
LUAD	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg11189052	chr15:85197271	WDR73	0.61	7.56	0.34	2.57e-13	Schizophrenia;
LUAD	cis	rs4242434	0.597	rs876714	chr8:22482799	A/G	cg03733263	chr8:22462867	KIAA1967	0.61	10.34	0.45	1.68e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg15557168	chr22:42548783	NA	-0.35	-6.5	-0.3	2.22e-10	Cognitive function;
LUAD	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg16049864	chr8:95962084	TP53INP1	-0.54	-11.59	-0.49	3.81e-27	Type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg08888203	chr3:10149979	C3orf24	0.74	12.91	0.53	2.26e-32	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg07917127	chr4:99064746	C4orf37	0.42	7.03	0.32	8.11e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg18404041	chr3:52824283	ITIH1	0.52	8.77	0.39	4.42e-17	Schizophrenia;
LUAD	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg06640241	chr16:89574553	SPG7	0.5	8.3	0.37	1.38e-15	Multiple myeloma (IgH translocation);
LUAD	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg16414030	chr3:133502952	NA	0.42	7.68	0.35	1.15e-13	Iron status biomarkers;
LUAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14159672	chr1:205819179	PM20D1	0.78	15.49	0.6	3.4e-43	Menarche (age at onset);
LUAD	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs4891159	0.570	rs690132	chr18:74117261	T/C	cg24786174	chr18:74118243	ZNF516	0.9	22.51	0.74	2.36e-74	Longevity;
LUAD	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-8.69	-0.39	7.82e-17	Schizophrenia;
LUAD	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg26750617	chr12:132293702	NA	0.38	6.39	0.3	4.39e-10	Migraine;
LUAD	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-15.16	-0.59	8.76e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs7010267	0.740	rs1872426	chr8:119949756	A/C	cg01975934	chr8:119970761	NA	0.35	6.75	0.31	4.98e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs62400317	0.859	rs58769170	chr6:45298531	C/T	cg18551225	chr6:44695536	NA	-0.55	-8.72	-0.39	6.54e-17	Total body bone mineral density;
LUAD	cis	rs68170813	0.599	rs12533516	chr7:106937135	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.4	-0.45	1.03e-22	Coronary artery disease;
LUAD	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg18306943	chr3:40428807	ENTPD3	0.42	6.99	0.32	1.07e-11	Renal cell carcinoma;
LUAD	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg05865280	chr17:75406074	SEPT9	0.61	19.16	0.68	2.4e-59	Airflow obstruction;
LUAD	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg22166914	chr1:53195759	ZYG11B	-0.45	-7.62	-0.35	1.66e-13	Monocyte count;
LUAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg08132940	chr7:1081526	C7orf50	-0.76	-10.29	-0.45	2.63e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg02551604	chr5:131831745	NA	-0.61	-10.02	-0.44	2.39e-21	Asthma (sex interaction);
LUAD	cis	rs9807989	0.501	rs11903946	chr2:103005330	A/G	cg03938978	chr2:103052716	IL18RAP	0.45	10.24	0.45	3.99e-22	Asthma;
LUAD	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15664640	chr17:80829946	TBCD	0.73	13.53	0.55	6.39e-35	Breast cancer;
LUAD	cis	rs7705042	0.828	rs1036209	chr5:141498632	T/A	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.78	-0.31	3.98e-11	Asthma;
LUAD	cis	rs742132	0.545	rs11969981	chr6:25650817	T/A	cg03517284	chr6:25882590	NA	0.56	6.44	0.3	3.22e-10	Uric acid levels;
LUAD	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.09	-0.33	5.49e-12	Total body bone mineral density;
LUAD	cis	rs12519773	0.576	rs1496337	chr5:92411293	C/T	cg18783429	chr5:92414398	NA	0.51	8.69	0.39	8.2e-17	Migraine;
LUAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg18402987	chr7:1209562	NA	0.79	9.77	0.43	1.84e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg06387496	chr7:2775674	GNA12	0.38	6.44	0.3	3.21e-10	Height;
LUAD	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14240646	chr10:27532245	ACBD5	-0.91	-12.1	-0.51	3.91e-29	Breast cancer;
LUAD	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18876405	chr7:65276391	NA	-0.57	-9.56	-0.42	9.81e-20	Aortic root size;
LUAD	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg18129178	chr5:148520854	ABLIM3	0.66	10.03	0.44	2.25e-21	Breast cancer;
LUAD	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg14343924	chr8:8086146	FLJ10661	-0.4	-6.38	-0.3	4.63e-10	Neuroticism;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg13196216	chr6:34231128	NA	-0.43	-6.95	-0.32	1.36e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.48e-10	Prostate cancer;
LUAD	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg03609598	chr5:56110824	MAP3K1	-0.46	-6.75	-0.31	4.92e-11	Initial pursuit acceleration;
LUAD	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg03929089	chr4:120376271	NA	-0.98	-20.96	-0.71	1.99e-67	Height;
LUAD	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg08798685	chr6:27730294	NA	-0.43	-7.01	-0.32	9.19e-12	Parkinson's disease;
LUAD	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg06263672	chr7:65235340	NA	-0.47	-7.59	-0.35	2.01e-13	Calcium levels;
LUAD	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg03289416	chr15:75166202	SCAMP2	0.42	7.27	0.33	1.73e-12	Caffeine consumption;
LUAD	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.41	-7.3	-0.33	1.47e-12	Platelet count;
LUAD	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg10755058	chr3:40428713	ENTPD3	0.38	6.96	0.32	1.29e-11	Renal cell carcinoma;
LUAD	cis	rs7107174	1.000	rs10899481	chr11:78058721	A/T	cg19901956	chr11:77921274	USP35	0.5	7.1	0.33	5.14e-12	Testicular germ cell tumor;
LUAD	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.77	-10.12	-0.44	1.06e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg05043794	chr9:111880884	C9orf5	-0.43	-6.71	-0.31	6.22e-11	Menarche (age at onset);
LUAD	cis	rs9462027	0.651	rs1543559	chr6:34784104	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.77	-0.39	4.4e-17	Systemic lupus erythematosus;
LUAD	cis	rs6591341	0.515	rs599301	chr11:68189945	G/C	cg02221422	chr11:68192511	LRP5	-0.45	-7.17	-0.33	3.41e-12	Lean body mass;
LUAD	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg21862992	chr11:68658383	NA	0.52	9.59	0.42	7.47e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg15017067	chr4:17643749	FAM184B	0.36	6.92	0.32	1.65e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10489202	0.608	rs7533646	chr1:168077593	A/C	cg25738037	chr1:168025549	DCAF6	-0.45	-6.55	-0.3	1.69e-10	Schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15257096	chr17:80010266	GPS1;RFNG	-0.41	-6.53	-0.3	1.86e-10	Height;
LUAD	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg04546413	chr19:29218101	NA	0.58	8.27	0.37	1.73e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg06387496	chr7:2775674	GNA12	-0.4	-6.67	-0.31	7.94e-11	Height;
LUAD	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg10523679	chr1:76189770	ACADM	-0.46	-6.45	-0.3	3e-10	Daytime sleep phenotypes;
LUAD	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg17344932	chr17:38183730	MED24;SNORD124	0.75	16.02	0.61	1.83e-45	White blood cell count;
LUAD	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg10523679	chr1:76189770	ACADM	0.89	15.6	0.6	1.15e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-7.79	-0.35	5.25e-14	Heart rate;
LUAD	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg12863693	chr15:85201151	NMB	0.39	7.23	0.33	2.23e-12	Schizophrenia;
LUAD	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg22532475	chr10:104410764	TRIM8	-0.43	-8.53	-0.38	2.67e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs62400317	0.826	rs62400330	chr6:45321455	G/A	cg20913747	chr6:44695427	NA	-0.41	-6.66	-0.31	8.71e-11	Total body bone mineral density;
LUAD	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.09	0.37	6.18e-15	Menopause (age at onset);
LUAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg16414030	chr3:133502952	NA	-0.69	-13.59	-0.55	3.76e-35	Iron status biomarkers;
LUAD	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg18196295	chr10:418757	DIP2C	0.41	6.74	0.31	5.3e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs4891159	0.513	rs2554831	chr18:74113513	C/G	cg24786174	chr18:74118243	ZNF516	0.85	19.65	0.69	1.46e-61	Longevity;
LUAD	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg21191810	chr6:118973309	C6orf204	-0.52	-8.14	-0.37	4.53e-15	Diastolic blood pressure;
LUAD	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg22029157	chr1:209979665	IRF6	0.78	10.01	0.44	2.56e-21	Cleft lip with or without cleft palate;
LUAD	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg25554036	chr4:6271136	WFS1	-0.62	-11.71	-0.49	1.24e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-7.75	-0.35	6.73e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.53	-0.34	3.18e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg26924012	chr15:45694286	SPATA5L1	0.94	15.54	0.6	2.16e-43	Homoarginine levels;
LUAD	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg03806693	chr22:41940476	POLR3H	0.55	7.98	0.36	1.4e-14	Vitiligo;
LUAD	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.75	-0.35	6.69e-14	Personality dimensions;
LUAD	cis	rs17641971	0.684	rs11990854	chr8:49992048	T/C	cg00325661	chr8:49890786	NA	0.3	6.8	0.31	3.68e-11	Blood metabolite levels;
LUAD	cis	rs3818285	1.000	rs10787218	chr10:111621456	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.44	-0.38	4.96e-16	Superior crus of antihelix expression;
LUAD	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg16479474	chr6:28041457	NA	0.45	7.73	0.35	7.89e-14	Depression;
LUAD	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg11339718	chr16:89000225	CBFA2T3	-0.31	-6.37	-0.3	5.07e-10	Social autistic-like traits;
LUAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg18402987	chr7:1209562	NA	0.83	11.43	0.49	1.47e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg09796270	chr17:17721594	SREBF1	0.37	7.51	0.34	3.65e-13	Total body bone mineral density;
LUAD	cis	rs9462027	0.628	rs2814971	chr6:34714209	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.36	9.07	0.4	4.36e-18	Systemic lupus erythematosus;
LUAD	cis	rs2742417	1.000	rs17328701	chr3:45734258	A/G	cg10512202	chr3:45649293	LIMD1	0.37	6.45	0.3	3.05e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg05340658	chr4:99064831	C4orf37	0.53	9.01	0.4	7.25e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg02569458	chr12:86230093	RASSF9	-0.41	-7.98	-0.36	1.41e-14	Major depressive disorder;
LUAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg11062466	chr8:58055876	NA	-0.67	-9.09	-0.4	3.99e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6545883	0.929	rs10190332	chr2:61619267	T/G	cg15711740	chr2:61764176	XPO1	0.41	6.45	0.3	2.97e-10	Tuberculosis;
LUAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.39	-0.34	7.9e-13	Electroencephalogram traits;
LUAD	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	13.06	0.54	5.6e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.77e-11	Depression;
LUAD	cis	rs6496044	0.568	rs2880765	chr15:86056462	A/T	cg13263323	chr15:86062960	AKAP13	0.54	10.09	0.44	1.38e-21	Interstitial lung disease;
LUAD	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg09537434	chr19:41945824	ATP5SL	-0.51	-8.1	-0.37	6.01e-15	Height;
LUAD	cis	rs6665290	0.935	rs6704144	chr1:227201030	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.13	-31.47	-0.84	6.99e-113	Myeloid white cell count;
LUAD	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.25	-0.37	2.03e-15	Total body bone mineral density;
LUAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00149659	chr3:10157352	C3orf10	0.6	8.64	0.39	1.17e-16	Alzheimer's disease;
LUAD	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	9.17	0.41	2.12e-18	Hip circumference adjusted for BMI;
LUAD	cis	rs4523957	0.928	rs216190	chr17:2187457	C/T	cg16513277	chr17:2031491	SMG6	0.77	14.38	0.57	1.84e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg08645402	chr16:4508243	NA	0.56	9.92	0.43	5.56e-21	Schizophrenia;
LUAD	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg25554036	chr4:6271136	WFS1	0.68	13.23	0.54	1.11e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs12541635	0.677	rs2163124	chr8:107058862	G/T	cg10147462	chr8:107024639	NA	0.52	9.27	0.41	9.89e-19	Age of smoking initiation;
LUAD	cis	rs17532515	0.505	rs7692084	chr4:141497900	A/G	cg09181644	chr4:141490428	UCP1	0.36	7.17	0.33	3.3e-12	Select biomarker traits;
LUAD	cis	rs2797160	1.000	rs4897153	chr6:126003403	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.6	-0.31	1.23e-10	Endometrial cancer;
LUAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg10862848	chr6:42927986	GNMT	0.29	8.4	0.38	6.76e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7584330	0.554	rs1343768	chr2:238444881	G/A	cg14458575	chr2:238380390	NA	0.6	9.63	0.42	5.71e-20	Prostate cancer;
LUAD	cis	rs9581857	0.556	rs9579085	chr13:28041039	G/A	cg22138327	chr13:27999177	GTF3A	0.78	11.2	0.48	1.11e-25	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs12216545	0.737	rs1916007	chr7:150240289	A/G	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.38	-0.3	4.64e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg13073564	chr4:8508604	NA	-0.63	-11.68	-0.49	1.57e-27	Response to antineoplastic agents;
LUAD	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.97	-0.4	9.69e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg18827107	chr12:86230957	RASSF9	-0.67	-12.11	-0.51	3.37e-29	Major depressive disorder;
LUAD	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.27	-6.49	-0.3	2.45e-10	Prostate cancer;
LUAD	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg14668632	chr7:2872130	GNA12	-0.68	-12.02	-0.5	7.54e-29	Height;
LUAD	cis	rs7119	0.651	rs12917431	chr15:77850184	C/G	cg27398640	chr15:77910606	LINGO1	-0.34	-6.41	-0.3	3.83e-10	Type 2 diabetes;
LUAD	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg04492858	chr10:133558786	NA	0.39	7.97	0.36	1.49e-14	Survival in rectal cancer;
LUAD	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18876405	chr7:65276391	NA	-0.42	-6.72	-0.31	5.87e-11	Aortic root size;
LUAD	cis	rs9372498	0.536	rs62422189	chr6:118907053	C/T	cg18833306	chr6:118973337	C6orf204	-0.54	-7.61	-0.35	1.86e-13	Diastolic blood pressure;
LUAD	cis	rs910187	0.538	rs2868849	chr20:45802273	G/A	cg27589058	chr20:45804311	EYA2	-0.37	-8.41	-0.38	6.51e-16	Migraine;
LUAD	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg12407791	chr17:73824354	UNC13D	-0.31	-6.57	-0.3	1.45e-10	White matter hyperintensity burden;
LUAD	cis	rs12286929	0.687	rs6589487	chr11:115089927	T/C	cg04055981	chr11:115044050	NA	-0.44	-7.74	-0.35	7.14e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs61931739	0.513	rs4931760	chr12:33898361	T/C	cg10518543	chr12:38710700	ALG10B	0.41	6.47	0.3	2.69e-10	Morning vs. evening chronotype;
LUAD	cis	rs1788820	0.957	rs1652375	chr18:21109269	T/C	cg14672496	chr18:21087552	C18orf8	0.34	6.36	0.3	5.1e-10	Body mass index;
LUAD	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg20487152	chr13:99095054	FARP1	-0.43	-7.17	-0.33	3.37e-12	Longevity;
LUAD	cis	rs733175	0.857	rs3796838	chr4:10011030	C/T	cg11266682	chr4:10021025	SLC2A9	0.44	7.11	0.33	4.89e-12	Psychosis and Alzheimer's disease;
LUAD	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.4	6.66	0.31	8.47e-11	Type 2 diabetes;
LUAD	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg00204512	chr16:28754710	NA	0.33	7.11	0.33	4.84e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs747782	0.639	rs17198985	chr11:48183565	T/C	cg15704280	chr7:45808275	SEPT13	0.68	7.63	0.35	1.56e-13	Intraocular pressure;
LUAD	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg04369109	chr6:150039330	LATS1	-0.48	-7.87	-0.36	3.1e-14	Lung cancer;
LUAD	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	7.37	0.34	8.94e-13	Platelet count;
LUAD	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.62	-0.39	1.34e-16	Total body bone mineral density;
LUAD	cis	rs4372836	0.504	rs13024443	chr2:29046185	C/T	cg09522027	chr2:28974177	PPP1CB	-0.6	-10.74	-0.46	5.69e-24	Body mass index;
LUAD	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg02428538	chr16:24856791	SLC5A11	-0.48	-7.04	-0.32	7.76e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs4767631	0.666	rs10850917	chr12:118316834	A/G	cg16351957	chr6:71874784	NA	0.41	6.59	0.31	1.35e-10	Biochemical measures;
LUAD	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg20487152	chr13:99095054	FARP1	-0.5	-8.48	-0.38	3.83e-16	Neuroticism;
LUAD	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg14668632	chr7:2872130	GNA12	-0.68	-12.18	-0.51	1.76e-29	Height;
LUAD	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11650494	0.908	rs77488129	chr17:47448970	G/A	cg11430096	chr6:110968061	CDK19	0.89	6.74	0.31	5.17e-11	Prostate cancer;
LUAD	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg15128208	chr22:42549153	NA	0.36	7.44	0.34	5.81e-13	Cognitive function;
LUAD	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg26818010	chr10:134567672	INPP5A	-0.89	-15.27	-0.6	3.07e-42	Migraine;
LUAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg18402987	chr7:1209562	NA	0.81	9.98	0.44	3.44e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7705042	0.828	rs249638	chr5:141530696	G/C	cg08523384	chr5:141488047	NDFIP1	-0.4	-6.85	-0.32	2.58e-11	Asthma;
LUAD	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg14686297	chr22:46650375	NA	-0.38	-6.57	-0.3	1.44e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6752107	0.791	rs3792106	chr2:234190740	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.53	9.25	0.41	1.11e-18	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg16205897	chr5:131564050	P4HA2	-0.34	-7.52	-0.34	3.35e-13	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs727505	0.954	rs66691367	chr7:124654217	G/T	cg23710748	chr7:124431027	NA	-0.42	-8.32	-0.38	1.2e-15	Lewy body disease;
LUAD	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg23758822	chr17:41437982	NA	1.01	20.84	0.71	6.8e-67	Menopause (age at onset);
LUAD	cis	rs3106136	0.934	rs4693004	chr4:95168456	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.44	-0.34	5.56e-13	Capecitabine sensitivity;
LUAD	cis	rs8064299	0.597	rs2016126	chr17:72784932	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.42	6.74	0.31	5.14e-11	Monocyte count;
LUAD	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.89	-0.5	2.44e-28	Bipolar disorder;
LUAD	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg13385794	chr1:248469461	NA	0.26	6.97	0.32	1.25e-11	Common traits (Other);
LUAD	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg20476274	chr7:133979776	SLC35B4	0.56	9.44	0.42	2.56e-19	Mean platelet volume;
LUAD	cis	rs494562	1.000	rs495472	chr6:86117021	C/T	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg07010633	chr17:73824396	UNC13D	-0.33	-6.63	-0.31	1e-10	White matter hyperintensity burden;
LUAD	cis	rs1003719	0.742	rs8129231	chr21:38501034	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.53	-8.93	-0.4	1.28e-17	Eye color traits;
LUAD	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg17145862	chr1:211918768	LPGAT1	-0.69	-13.54	-0.55	6.22e-35	Leprosy;
LUAD	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.74	10.29	0.45	2.57e-22	Smoking behavior;
LUAD	cis	rs7503807	1.000	rs8079537	chr17:78600818	A/G	cg09596252	chr17:78655493	RPTOR	0.41	7.93	0.36	2e-14	Obesity;
LUAD	trans	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg24644049	chr4:85504048	CDS1	0.91	7.72	0.35	8.48e-14	Skin colour saturation;
LUAD	cis	rs2274471	0.680	rs10974996	chr9:5192082	C/G	cg03390472	chr9:5043263	JAK2	0.55	7.37	0.34	9.11e-13	Crohn's disease;
LUAD	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg09904177	chr6:26538194	HMGN4	0.42	6.85	0.32	2.6e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg21191810	chr6:118973309	C6orf204	0.47	6.81	0.31	3.33e-11	Diastolic blood pressure;
LUAD	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.73	-14.15	-0.57	1.74e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg10560079	chr2:191398806	TMEM194B	-0.54	-7.07	-0.33	6.28e-12	Diastolic blood pressure;
LUAD	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	ch.11.42038R	chr11:967971	AP2A2	0.41	7.21	0.33	2.59e-12	Alzheimer's disease (late onset);
LUAD	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg17807903	chr1:86174739	ZNHIT6	-0.73	-14.96	-0.59	6.39e-41	Urate levels in overweight individuals;
LUAD	cis	rs4073416	0.542	rs1953415	chr14:65988034	A/G	cg10998611	chr14:65879393	FUT8;LOC645431	-0.43	-6.5	-0.3	2.27e-10	N-glycan levels;
LUAD	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.55	-12.09	-0.51	4.19e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg18446336	chr7:2847575	GNA12	-0.37	-6.94	-0.32	1.46e-11	Height;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16208240	chr11:16627650	NA	0.44	6.8	0.31	3.48e-11	Gut microbiome composition (summer);
LUAD	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg16797656	chr11:68205561	LRP5	0.45	8.47	0.38	4.1e-16	Total body bone mineral density;
LUAD	cis	rs62064224	0.589	rs9903650	chr17:30689370	T/A	cg25809561	chr17:30822961	MYO1D	0.47	8.62	0.39	1.37e-16	Schizophrenia;
LUAD	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg07362569	chr17:61921086	SMARCD2	0.4	6.93	0.32	1.61e-11	Prudent dietary pattern;
LUAD	cis	rs11195062	0.766	rs4918489	chr10:112034446	A/G	cg19214408	chr10:111981687	MXI1	-0.41	-6.88	-0.32	2.11e-11	Multiple myeloma;
LUAD	cis	rs1595825	0.838	rs7603283	chr2:198517592	A/G	cg11031976	chr2:198649780	BOLL	-0.45	-6.72	-0.31	5.83e-11	Ulcerative colitis;
LUAD	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg15445000	chr17:37608096	MED1	0.44	7.95	0.36	1.68e-14	Glomerular filtration rate (creatinine);
LUAD	trans	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.59	10.82	0.47	2.86e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg12292205	chr6:26970375	C6orf41	-0.53	-9.33	-0.41	5.93e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs68170813	0.559	rs17427123	chr7:106823661	G/A	cg23024343	chr7:107201750	COG5	0.5	7.26	0.33	1.92e-12	Coronary artery disease;
LUAD	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06022373	chr22:39101656	GTPBP1	0.48	7.97	0.36	1.45e-14	Menopause (age at onset);
LUAD	cis	rs9811920	0.838	rs12488245	chr3:99835254	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.08	0.47	3.15e-25	Axial length;
LUAD	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg25319279	chr11:5960081	NA	0.5	9.79	0.43	1.58e-20	DNA methylation (variation);
LUAD	cis	rs12049351	0.719	rs3818237	chr1:229631193	A/G	cg11742688	chr1:229674241	ABCB10	-0.4	-6.59	-0.31	1.28e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg26513180	chr16:89883248	FANCA	-0.44	-7.42	-0.34	6.36e-13	Vitiligo;
LUAD	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.78	0.35	5.45e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08219700	chr8:58056026	NA	0.63	8.82	0.39	2.92e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg06753367	chr22:24256600	NA	-0.39	-7.04	-0.32	7.64e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.33	6.42	0.3	3.57e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.73e-16	Neutrophil percentage of white cells;
LUAD	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg24308560	chr3:49941425	MST1R	-0.52	-8.72	-0.39	6.52e-17	Body mass index;
LUAD	trans	rs8002861	0.619	rs1337203	chr13:44423621	T/G	cg12856521	chr11:46389249	DGKZ	0.47	7.94	0.36	1.8e-14	Leprosy;
LUAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2230307	0.536	rs522696	chr1:100476662	G/A	cg20868668	chr1:100435035	SLC35A3	0.54	7.78	0.35	5.7e-14	Carotid intima media thickness;
LUAD	cis	rs231513	0.954	rs231493	chr17:41976998	G/C	cg26893861	chr17:41843967	DUSP3	-0.54	-6.55	-0.3	1.69e-10	Cognitive function;
LUAD	cis	rs3750082	0.889	rs7785065	chr7:32915204	C/A	cg05721444	chr7:32995514	FKBP9	0.37	6.75	0.31	4.79e-11	Glomerular filtration rate (creatinine);
LUAD	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg26384229	chr12:38710491	ALG10B	0.47	7.62	0.35	1.66e-13	Morning vs. evening chronotype;
LUAD	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg03714773	chr7:91764589	CYP51A1	0.29	6.77	0.31	4.35e-11	Breast cancer;
LUAD	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg13126279	chr21:47581558	C21orf56	-0.44	-7.39	-0.34	7.73e-13	Testicular germ cell tumor;
LUAD	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg01579765	chr21:45077557	HSF2BP	0.55	12.01	0.5	8.21e-29	Mean corpuscular volume;
LUAD	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg03929089	chr4:120376271	NA	-0.99	-20.65	-0.71	4.76e-66	Height;
LUAD	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-7.84	-0.36	3.64e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg21016266	chr12:122356598	WDR66	0.62	10.92	0.47	1.23e-24	Mean corpuscular volume;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg17271592	chr1:149821902	HIST2H2AA4;HIST2H2AA3	0.39	6.58	0.3	1.38e-10	Bipolar disorder;
LUAD	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg22920501	chr2:26401640	FAM59B	-0.98	-15.18	-0.59	7.06e-42	Gut microbiome composition (summer);
LUAD	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg21231944	chr12:82153410	PPFIA2	-0.37	-6.69	-0.31	7.14e-11	Resting heart rate;
LUAD	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg25894440	chr7:65020034	NA	-0.67	-7.22	-0.33	2.47e-12	Diabetic kidney disease;
LUAD	trans	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	11.74	0.5	9.92e-28	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs4072705	0.967	rs4838208	chr9:127528035	C/A	cg01786973	chr9:127249749	NR5A1	0.29	6.37	0.3	4.92e-10	Menarche (age at onset);
LUAD	trans	rs28735056	0.904	rs12953738	chr18:77627877	A/G	cg05926928	chr17:57297772	GDPD1	0.5	7.37	0.34	8.96e-13	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9878978	0.964	rs62233799	chr3:2465761	G/T	cg21928760	chr3:2462534	CNTN4	-0.34	-6.64	-0.31	9.48e-11	Blood pressure (smoking interaction);
LUAD	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.53	0.38	2.62e-16	Parkinson's disease;
LUAD	cis	rs7044106	0.791	rs4836831	chr9:123496570	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	9.08	0.4	4.08e-18	Hip circumference adjusted for BMI;
LUAD	cis	rs731174	1.000	rs731174	chr1:38196841	C/T	cg12339802	chr1:38156545	C1orf109	0.44	6.63	0.31	1.03e-10	Prostate cancer (SNP x SNP interaction);
LUAD	trans	rs1493916	0.870	rs1389531	chr18:31386616	C/T	cg27147174	chr7:100797783	AP1S1	-0.68	-12.33	-0.51	4.58e-30	Life satisfaction;
LUAD	cis	rs4285028	0.948	rs2877560	chr3:121699238	C/A	cg20356878	chr3:121714668	ILDR1	-0.49	-6.55	-0.3	1.7e-10	Multiple sclerosis;
LUAD	cis	rs77741769	0.571	rs12580949	chr12:121298164	A/G	cg02419362	chr12:121203948	SPPL3	0.43	8.76	0.39	4.59e-17	Mean corpuscular volume;
LUAD	cis	rs2016266	0.859	rs10876433	chr12:53734114	G/A	cg26875137	chr12:53738046	NA	-0.37	-7.26	-0.33	1.89e-12	Bone mineral density (spine);Bone mineral density;
LUAD	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg04703951	chr17:43578652	NA	-0.46	-7.41	-0.34	6.9e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg02002194	chr4:3960332	NA	-0.27	-6.84	-0.32	2.73e-11	Mood instability;
LUAD	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg02569458	chr12:86230093	RASSF9	0.39	7.25	0.33	2.05e-12	Major depressive disorder;
LUAD	trans	rs208520	0.874	rs208469	chr6:66915891	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-14.27	-0.57	5.29e-38	Exhaled nitric oxide output;
LUAD	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg09796270	chr17:17721594	SREBF1	0.37	6.94	0.32	1.45e-11	Total body bone mineral density;
LUAD	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg23231163	chr10:75533350	FUT11	-0.51	-9.41	-0.42	3.19e-19	Inflammatory bowel disease;
LUAD	cis	rs2357013	0.725	rs12052462	chr2:53228940	A/G	cg07782112	chr2:53107842	NA	-0.36	-7.12	-0.33	4.78e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg27494647	chr7:150038898	RARRES2	-0.52	-9.42	-0.42	2.99e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs62400317	0.859	rs12205379	chr6:45215074	G/A	cg18551225	chr6:44695536	NA	-0.55	-8.39	-0.38	7.19e-16	Total body bone mineral density;
LUAD	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg23649088	chr2:200775458	C2orf69	0.52	8.29	0.37	1.53e-15	Osteoporosis;
LUAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.21	0.44	5.2e-22	Prudent dietary pattern;
LUAD	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg19717773	chr7:2847554	GNA12	-0.48	-7.92	-0.36	2.15e-14	Height;
LUAD	cis	rs494562	0.892	rs9294335	chr6:86126680	C/T	cg21730993	chr6:86159210	NT5E	0.71	7.75	0.35	6.84e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.78	14.68	0.58	9.91e-40	Lymphocyte counts;
LUAD	cis	rs1160297	0.609	rs2356680	chr2:53095313	T/C	cg07782112	chr2:53107842	NA	0.42	8.98	0.4	8.9e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg14530993	chr4:882597	GAK	0.75	7.04	0.32	7.72e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg09436375	chr6:42928200	GNMT	-0.29	-8.23	-0.37	2.35e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg12599982	chr1:44399894	ARTN	0.33	6.46	0.3	2.94e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.98	-0.36	1.41e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.61	0.31	1.14e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg05368731	chr17:41323189	NBR1	0.97	20.35	0.7	1.07e-64	Menopause (age at onset);
LUAD	cis	rs10992471	0.729	rs13284038	chr9:95555488	A/G	cg14631576	chr9:95140430	CENPP	-0.39	-7.79	-0.35	5.1e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg04455712	chr21:45112962	RRP1B	0.44	8.84	0.39	2.62e-17	Mean corpuscular volume;
LUAD	cis	rs7520050	0.933	rs9787208	chr1:46314616	C/A	cg06784218	chr1:46089804	CCDC17	-0.3	-6.39	-0.3	4.32e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg13012494	chr21:47604986	C21orf56	0.47	7.79	0.35	5.28e-14	Testicular germ cell tumor;
LUAD	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg12573674	chr2:1569213	NA	-0.6	-7.03	-0.32	8.31e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg17800788	chr1:21766015	NBPF3	0.35	6.92	0.32	1.68e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26314531	chr2:26401878	FAM59B	-0.55	-7.81	-0.36	4.42e-14	Gut microbiome composition (summer);
LUAD	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg13010199	chr12:38710504	ALG10B	0.38	6.35	0.3	5.45e-10	Bladder cancer;
LUAD	cis	rs6546550	0.901	rs6716937	chr2:70127229	G/A	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.97	-0.47	8.27e-25	Prevalent atrial fibrillation;
LUAD	cis	rs986417	1.000	rs12587609	chr14:60928850	C/G	cg27398547	chr14:60952738	C14orf39	0.63	7.72	0.35	8.34e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs4631830	0.900	rs11006274	chr10:51540291	C/T	cg20129853	chr10:51489980	NA	0.31	6.4	0.3	4.17e-10	Prostate-specific antigen levels;
LUAD	cis	rs57502260	0.679	rs72936524	chr11:68275898	G/A	cg16797656	chr11:68205561	LRP5	0.45	6.52	0.3	1.95e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs3820068	0.705	rs4645983	chr1:15850603	G/A	cg24675056	chr1:15929824	NA	0.42	6.79	0.31	3.84e-11	Systolic blood pressure;
LUAD	cis	rs4891159	0.527	rs689642	chr18:74119120	A/C	cg24786174	chr18:74118243	ZNF516	0.93	23.83	0.76	3.49e-80	Longevity;
LUAD	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg24818145	chr4:99064322	C4orf37	0.41	6.79	0.31	3.85e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.54	-9.07	-0.4	4.41e-18	Electrocardiographic conduction measures;
LUAD	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg06064525	chr11:970664	AP2A2	-0.56	-11.48	-0.49	1.01e-26	Alzheimer's disease (late onset);
LUAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg05564831	chr3:52568323	NT5DC2	0.35	6.49	0.3	2.42e-10	Electroencephalogram traits;
LUAD	cis	rs2067615	0.579	rs6539283	chr12:107222989	C/T	cg15890332	chr12:107067104	RFX4	0.41	8.8	0.39	3.64e-17	Heart rate;
LUAD	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg14598338	chr9:96623480	NA	-0.45	-9.57	-0.42	8.89e-20	DNA methylation (variation);
LUAD	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg12935359	chr14:103987150	CKB	0.48	7.57	0.35	2.32e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs11039798	1.000	rs10838942	chr11:48557163	C/G	cg02254774	chr11:50257496	LOC441601	0.53	6.57	0.3	1.5e-10	Axial length;
LUAD	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.2	-0.41	1.59e-18	Alcohol dependence;
LUAD	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.56	8.11	0.37	5.72e-15	Platelet count;
LUAD	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.22	15.72	0.61	3.61e-44	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs3936840	1.000	rs3936840	chr14:102984274	G/C	cg18135206	chr14:102964638	TECPR2	0.53	8.5	0.38	3.27e-16	Plateletcrit;
LUAD	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg03388025	chr16:89894329	SPIRE2	0.52	13.64	0.55	2.23e-35	Vitiligo;
LUAD	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg25894440	chr7:65020034	NA	-0.68	-7.36	-0.34	9.49e-13	Diabetic kidney disease;
LUAD	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg15992532	chr8:142229932	SLC45A4	0.47	8.25	0.37	2e-15	Immature fraction of reticulocytes;
LUAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00166722	chr3:10149974	C3orf24	0.73	10.94	0.47	1.1e-24	Alzheimer's disease;
LUAD	cis	rs2267137	0.903	rs5752903	chr22:29769306	G/T	cg07256473	chr22:29710276	RASL10A	0.39	7.25	0.33	1.96e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.75	0.31	4.84e-11	Breast cancer;
LUAD	cis	rs2979489	0.786	rs2979514	chr8:30399461	A/C	cg26383811	chr8:30366931	RBPMS	-0.69	-10.64	-0.46	1.4e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg12432903	chr7:1882776	MAD1L1	-0.53	-8.66	-0.39	1.01e-16	Bipolar disorder and schizophrenia;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg05064044	chr6:292385	DUSP22	-0.8	-13.57	-0.55	4.27e-35	Menopause (age at onset);
LUAD	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg02569458	chr12:86230093	RASSF9	-0.42	-7.76	-0.35	6.58e-14	Major depressive disorder;
LUAD	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg08125733	chr17:73851984	WBP2	-0.51	-7.69	-0.35	1.05e-13	Psoriasis;
LUAD	cis	rs4072980	0.545	rs7519947	chr1:38447725	T/C	cg18451016	chr1:38461880	NA	-0.46	-8.05	-0.36	8.25e-15	Coronary artery disease;
LUAD	cis	rs807669	0.903	rs807667	chr22:19161327	A/G	cg02655711	chr22:19163373	SLC25A1	-0.86	-19.42	-0.69	1.59e-60	Metabolite levels;
LUAD	cis	rs6005807	0.719	rs12169071	chr22:29033210	C/G	cg12565055	chr22:29076175	TTC28	0.74	8.71	0.39	6.98e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg18446336	chr7:2847575	GNA12	-0.37	-6.89	-0.32	2.08e-11	Height;
LUAD	cis	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg00071950	chr4:10020882	SLC2A9	0.49	7.02	0.32	8.88e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs9535307	0.929	rs4942863	chr13:50314408	T/C	cg04663916	chr13:50265991	EBPL	0.58	6.89	0.32	2.03e-11	Obesity-related traits;
LUAD	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg01849466	chr14:104193079	ZFYVE21	0.5	8.19	0.37	3.22e-15	Body mass index;
LUAD	trans	rs11039798	0.841	rs7294179	chr11:48765408	G/A	cg15704280	chr7:45808275	SEPT13	0.76	7.75	0.35	7.08e-14	Axial length;
LUAD	cis	rs11971779	0.616	rs10278377	chr7:139103071	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	7.16e-11	Diisocyanate-induced asthma;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg27149388	chr12:47473796	AMIGO2	-0.7	-6.58	-0.3	1.38e-10	Type 2 diabetes;
LUAD	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg01851573	chr8:8652454	MFHAS1	-0.41	-7.5	-0.34	3.71e-13	Mood instability;
LUAD	cis	rs9522267	0.708	rs914032	chr13:112241019	G/A	cg10483660	chr13:112241077	NA	0.31	6.49	0.3	2.38e-10	Hepatitis;
LUAD	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg23758822	chr17:41437982	NA	1.02	20.75	0.71	1.76e-66	Menopause (age at onset);
LUAD	trans	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg07211511	chr3:129823064	LOC729375	-0.54	-6.98	-0.32	1.14e-11	Blood pressure (smoking interaction);
LUAD	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg02753203	chr1:228287806	NA	-0.46	-8.5	-0.38	3.21e-16	Diastolic blood pressure;
LUAD	cis	rs3784262	0.669	rs7171261	chr15:58356855	C/G	cg12031962	chr15:58353849	ALDH1A2	0.39	7.58	0.35	2.18e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg11859384	chr17:80120422	CCDC57	0.43	7.53	0.34	3.18e-13	Life satisfaction;
LUAD	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.7	-12.93	-0.53	1.8e-32	Axial length;
LUAD	cis	rs6076065	0.722	rs6048760	chr20:23345844	G/T	cg11657817	chr20:23433608	CST11	-0.54	-11.21	-0.48	1.06e-25	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs897984	0.647	rs8060857	chr16:31002720	G/A	cg02466173	chr16:30829666	NA	0.64	11.41	0.49	1.73e-26	Dementia with Lewy bodies;
LUAD	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg27432699	chr2:27873401	GPN1	0.58	10.28	0.45	2.92e-22	Oral cavity cancer;
LUAD	cis	rs904251	0.522	rs882322	chr6:37484103	A/G	cg25019722	chr6:37503610	NA	-0.32	-7.53	-0.34	3.07e-13	Cognitive performance;
LUAD	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg23231163	chr10:75533350	FUT11	-0.51	-9.46	-0.42	2.22e-19	Inflammatory bowel disease;
LUAD	cis	rs1915146	0.546	rs9422857	chr10:126861278	C/G	cg23000734	chr10:126850823	CTBP2	0.55	10.85	0.47	2.37e-24	Menarche (age at onset);
LUAD	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg23992470	chr4:843637	GAK	0.7	7.51	0.34	3.61e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg26924012	chr15:45694286	SPATA5L1	0.64	10.92	0.47	1.27e-24	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg27454412	chr7:1067447	C7orf50	0.44	7.01	0.32	9.47e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg15082635	chr5:180670110	GNB2L1;SNORD96A	-0.39	-6.6	-0.31	1.27e-10	Subcortical brain region volumes;
LUAD	trans	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg08071915	chr8:12219732	FAM66A	-0.4	-6.6	-0.31	1.24e-10	Mood instability;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04661747	chr11:46264818	NA	-0.45	-7.21	-0.33	2.65e-12	Height;
LUAD	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.41	-0.52	2.17e-30	Bone mineral density;
LUAD	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg03037974	chr15:76606532	NA	0.38	8.06	0.36	7.95e-15	Blood metabolite levels;
LUAD	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg03806693	chr22:41940476	POLR3H	0.58	8.35	0.38	9.57e-16	Vitiligo;
LUAD	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23583168	chr7:148888333	NA	-0.93	-19.33	-0.68	4.08e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg16606324	chr3:10149918	C3orf24	0.55	8.15	0.37	4.27e-15	Alzheimer's disease;
LUAD	cis	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg02807482	chr3:125708958	NA	-0.62	-6.41	-0.3	3.99e-10	Blood pressure (smoking interaction);
LUAD	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg00321850	chr1:175162397	KIAA0040	-0.51	-10.71	-0.46	7.9e-24	Alcohol dependence;
LUAD	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.3e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg11494091	chr17:61959527	GH2	0.74	18.42	0.67	4.62e-56	Prudent dietary pattern;
LUAD	cis	rs2386661	0.826	rs11255996	chr10:5670832	G/A	cg26603656	chr10:5671107	NA	0.42	7.18	0.33	3.16e-12	Breast cancer;
LUAD	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	7.55	0.34	2.62e-13	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs2944755	1.000	rs2944755	chr8:141574194	A/G	cg26074100	chr8:141568712	EIF2C2	-0.42	-7.5	-0.34	3.75e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg15117754	chr3:10150083	C3orf24	-0.42	-6.89	-0.32	2.02e-11	Alzheimer's disease;
LUAD	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9427116	0.502	rs9426827	chr1:154589965	T/C	cg17218026	chr1:154582156	ADAR	0.49	9.66	0.43	4.51e-20	Blood protein levels;
LUAD	cis	rs11178918	0.505	rs76503339	chr12:72154154	T/A	cg10168894	chr12:72148281	RAB21	-0.53	-6.58	-0.3	1.39e-10	Economic and political preferences (time);
LUAD	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.63	-0.31	1e-10	Coronary artery disease;
LUAD	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.57	-0.3	1.46e-10	Aortic root size;
LUAD	cis	rs72928364	1.000	rs34719725	chr3:100677492	T/A	cg10123952	chr3:100791384	NA	0.61	7.32	0.34	1.27e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg21028142	chr17:79581711	NPLOC4	0.38	7.62	0.35	1.63e-13	Eye color traits;
LUAD	cis	rs1595825	0.945	rs61184128	chr2:198843659	C/T	cg00982548	chr2:198649783	BOLL	-0.63	-8.96	-0.4	1.05e-17	Ulcerative colitis;
LUAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg13047869	chr3:10149882	C3orf24	0.63	10.8	0.46	3.58e-24	Alzheimer's disease;
LUAD	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg22875332	chr1:76189707	ACADM	0.85	15.32	0.6	1.82e-42	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg26022315	chr17:47021804	SNF8	0.4	7.13	0.33	4.46e-12	Type 2 diabetes;
LUAD	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24308560	chr3:49941425	MST1R	-0.56	-9.47	-0.42	2.07e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21659725	chr3:3221576	CRBN	0.5	8.29	0.37	1.57e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs13315871	1.000	rs74834816	chr3:58321828	G/A	cg20936604	chr3:58311152	NA	-0.75	-7.33	-0.34	1.17e-12	Cholesterol, total;
LUAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg12373951	chr3:133503437	NA	0.35	6.83	0.32	3.01e-11	Iron status biomarkers;
LUAD	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg17200465	chr3:40428508	ENTPD3	0.29	6.78	0.31	4.03e-11	Renal cell carcinoma;
LUAD	cis	rs494562	0.730	rs9362209	chr6:86114491	C/T	cg13315970	chr6:86159197	NT5E	0.59	6.65	0.31	8.89e-11	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg23950597	chr19:37808831	NA	-0.64	-7.57	-0.35	2.43e-13	Coronary artery calcification;
LUAD	cis	rs9314323	0.767	rs13271042	chr8:26190212	T/G	cg13160058	chr8:26243215	BNIP3L	-0.48	-9.76	-0.43	2.02e-20	Red cell distribution width;
LUAD	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg04369109	chr6:150039330	LATS1	-0.48	-7.7	-0.35	9.76e-14	Lung cancer;
LUAD	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.67	-0.31	7.96e-11	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.44	0.38	5.18e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7177699	0.526	rs7165733	chr15:79123505	G/A	cg00540400	chr15:79124168	NA	0.44	9.73	0.43	2.48e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg21220214	chr8:57350948	NA	-0.59	-8.73	-0.39	6.17e-17	Obesity-related traits;
LUAD	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg17264618	chr3:40429014	ENTPD3	0.36	7.64	0.35	1.49e-13	Renal cell carcinoma;
LUAD	cis	rs7833986	0.941	rs13249175	chr8:57058706	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.87	11.39	0.48	2.22e-26	Height;
LUAD	cis	rs3087591	1.000	rs2952980	chr17:29473353	G/A	cg24425628	chr17:29625626	OMG;NF1	0.4	6.45	0.3	2.98e-10	Hip circumference;
LUAD	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-6.38	-0.3	4.61e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs12530845	1.000	rs60179239	chr7:135333028	A/G	cg23117316	chr7:135346802	PL-5283	-0.49	-9.13	-0.41	2.92e-18	Red blood cell traits;
LUAD	cis	rs2235649	0.592	rs8051883	chr16:1958978	G/A	cg08610935	chr16:1836813	NUBP2	-0.51	-7.48	-0.34	4.38e-13	Blood metabolite levels;
LUAD	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.41	7.33	0.34	1.15e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs62238980	0.614	rs76142630	chr22:32392177	A/T	cg00543991	chr22:32367038	NA	0.92	8.16	0.37	3.95e-15	Childhood ear infection;
LUAD	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg01616529	chr11:638424	DRD4	-0.44	-6.43	-0.3	3.42e-10	Systemic lupus erythematosus;
LUAD	cis	rs7814319	0.933	rs13261690	chr8:97238661	C/A	cg20787634	chr8:97240163	UQCRB	-0.38	-7.52	-0.34	3.35e-13	Lung function (FVC);
LUAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg12373951	chr3:133503437	NA	0.35	6.88	0.32	2.16e-11	Iron status biomarkers;
LUAD	cis	rs11756438	0.572	rs2798326	chr6:119005226	C/T	cg18833306	chr6:118973337	C6orf204	0.51	9.31	0.41	7.21e-19	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.43	-0.34	5.88e-13	Morning vs. evening chronotype;
LUAD	cis	rs11078597	0.731	rs34962442	chr17:1640529	C/T	cg18436246	chr17:1640651	WDR81	0.78	12.1	0.51	3.69e-29	Serum albumin level;
LUAD	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg21475434	chr5:93447410	FAM172A	0.77	8.48	0.38	3.85e-16	Diabetic retinopathy;
LUAD	cis	rs600231	0.665	rs1784858	chr11:65222952	T/C	cg17120908	chr11:65337727	SSSCA1	-0.59	-9.12	-0.41	3.12e-18	Bone mineral density;
LUAD	cis	rs77741769	0.571	rs12822123	chr12:121298644	C/T	cg02419362	chr12:121203948	SPPL3	0.41	8.29	0.37	1.53e-15	Mean corpuscular volume;
LUAD	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg13319975	chr6:146136371	FBXO30	0.64	11.11	0.48	2.38e-25	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs2262909	0.962	rs409835	chr19:22230671	T/C	cg17074339	chr11:11642133	GALNTL4	-0.46	-7.54	-0.34	2.93e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.7e-32	Immature fraction of reticulocytes;
LUAD	cis	rs56283067	0.887	rs10948172	chr6:44777691	A/G	cg18551225	chr6:44695536	NA	-0.5	-7.64	-0.35	1.51e-13	Total body bone mineral density;
LUAD	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg05434287	chr7:2030229	MAD1L1	0.39	6.54	0.3	1.74e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs2735413	0.813	rs11644471	chr16:78077237	A/T	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.9	-0.32	1.95e-11	Retinal vascular caliber;
LUAD	cis	rs427394	0.802	rs274721	chr5:6719164	C/T	cg10857441	chr5:6722123	POLS	-0.65	-12.78	-0.53	7.75e-32	Menopause (age at onset);
LUAD	cis	rs7119038	0.731	rs10892283	chr11:118636980	A/G	cg19308663	chr11:118741387	NA	0.48	6.69	0.31	7.14e-11	Sjögren's syndrome;
LUAD	trans	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg06606381	chr12:133084897	FBRSL1	-1.11	-10.33	-0.45	1.84e-22	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3849570	0.961	rs3821548	chr3:81758728	C/G	cg07356753	chr3:81810745	GBE1	-0.71	-12.83	-0.53	4.55e-32	Waist circumference;Body mass index;
LUAD	trans	rs4714291	0.963	rs1721412	chr6:40100606	T/G	cg02267698	chr19:7991119	CTXN1	0.42	6.37	0.3	4.95e-10	Strep throat;
LUAD	cis	rs12541635	0.677	rs13439705	chr8:106967268	T/C	cg10147462	chr8:107024639	NA	0.53	9.32	0.41	6.49e-19	Age of smoking initiation;
LUAD	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg02775129	chr4:119771670	NA	-0.79	-7.63	-0.35	1.53e-13	Cannabis dependence symptom count;
LUAD	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg03433033	chr1:76189801	ACADM	-0.48	-6.84	-0.32	2.72e-11	Daytime sleep phenotypes;
LUAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07167872	chr1:205819463	PM20D1	0.78	15.86	0.61	8.37e-45	Menarche (age at onset);
LUAD	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg18277682	chr1:228362509	C1orf69	-0.4	-6.72	-0.31	6.01e-11	Diastolic blood pressure;
LUAD	cis	rs1127311	0.901	rs11264223	chr1:154565519	G/A	cg17218026	chr1:154582156	ADAR	0.49	9.5	0.42	1.54e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs912057	0.582	rs1294412	chr6:6739854	A/G	cg06612196	chr6:6737390	NA	0.66	16.48	0.63	1.67e-47	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg25767906	chr1:53392781	SCP2	0.39	7.09	0.33	5.52e-12	Monocyte count;
LUAD	trans	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg21051086	chr3:73046214	PPP4R2	0.39	6.55	0.3	1.64e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs733175	0.855	rs9291640	chr4:10007086	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	9.76	0.43	1.92e-20	Psychosis and Alzheimer's disease;
LUAD	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg08601574	chr20:25228251	PYGB	0.47	8.8	0.39	3.44e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg02269571	chr22:50332266	NA	-0.68	-9.9	-0.43	6.32e-21	Schizophrenia;
LUAD	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg00383909	chr3:49044727	WDR6	0.98	9.18	0.41	1.98e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs7759001	0.857	rs4711147	chr6:27344496	A/G	cg18711553	chr6:27366782	ZNF391	0.39	6.37	0.3	4.86e-10	Glomerular filtration rate (creatinine);
LUAD	trans	rs7246760	0.867	rs2287843	chr19:9769913	G/A	cg02900749	chr2:68251473	NA	-0.59	-6.42	-0.3	3.63e-10	Pursuit maintenance gain;
LUAD	cis	rs1483890	0.723	rs13075664	chr3:69411365	G/A	cg22125112	chr3:69402811	FRMD4B	0.45	7.66	0.35	1.31e-13	Resting heart rate;
LUAD	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs6546550	0.901	rs1979214	chr2:70137498	G/C	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.0	-0.47	6.47e-25	Prevalent atrial fibrillation;
LUAD	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24531977	chr5:56204891	C5orf35	-0.99	-15.17	-0.59	8.56e-42	Initial pursuit acceleration;
LUAD	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.7e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg09455208	chr3:40491958	NA	0.56	12.54	0.52	6.8e-31	Renal cell carcinoma;
LUAD	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg12863693	chr15:85201151	NMB	0.37	6.46	0.3	2.89e-10	Schizophrenia;
LUAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.5e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg26384229	chr12:38710491	ALG10B	0.43	6.52	0.3	2.03e-10	Heart rate;
LUAD	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.45	-6.85	-0.32	2.6e-11	Schizophrenia;
LUAD	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg15921436	chr17:44337874	NA	0.86	11.52	0.49	6.55e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg22676075	chr6:135203613	NA	0.37	6.76	0.31	4.51e-11	Red blood cell count;
LUAD	cis	rs6489882	0.703	rs11066451	chr12:113361443	G/A	cg20102336	chr12:113376681	OAS3	-0.58	-8.88	-0.4	1.88e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg23950597	chr19:37808831	NA	-0.64	-7.74	-0.35	7.52e-14	Coronary artery calcification;
LUAD	cis	rs7551222	0.752	rs12039454	chr1:204542580	C/T	cg20240347	chr1:204465584	NA	0.33	6.41	0.3	3.99e-10	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg12034118	chr1:209979487	IRF6	0.52	7.53	0.34	3.1400000000000003e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg13642260	chr9:130955380	CIZ1	-0.6	-10.94	-0.47	1.02e-24	Attention deficit hyperactivity disorder;
LUAD	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg04842962	chr6:43655489	MRPS18A	1.05	27.44	0.8	5.75e-96	IgG glycosylation;
LUAD	cis	rs9427116	0.531	rs35504625	chr1:154599778	C/G	cg17218026	chr1:154582156	ADAR	0.48	9.29	0.41	8.34e-19	Blood protein levels;
LUAD	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.99	0.36	1.29e-14	Depression;
LUAD	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-8.26	-0.37	1.9e-15	HDL cholesterol;
LUAD	cis	rs4006360	0.554	rs1848810	chr17:39236025	A/G	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.12	0.37	5.21e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg02869364	chr7:1081709	C7orf50	-0.51	-6.57	-0.3	1.48e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19653117	chr2:32502924	YIPF4	-0.4	-6.78	-0.31	3.93e-11	Cancer;
LUAD	cis	rs16958440	0.867	rs16949275	chr18:44700703	A/G	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12756686	chr19:29218302	NA	0.66	9.71	0.43	2.87e-20	Methadone dose in opioid dependence;
LUAD	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs7827545	0.644	rs3739427	chr8:135524938	T/C	cg17885191	chr8:135476712	NA	-0.59	-9.18	-0.41	1.9e-18	Hypertension (SNP x SNP interaction);
LUAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg05896524	chr21:47604654	C21orf56	0.73	13.02	0.53	8.21e-33	Testicular germ cell tumor;
LUAD	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg13184886	chr1:27153565	ZDHHC18	-0.7	-7.43	-0.34	5.92e-13	Type 2 diabetes;
LUAD	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg17810781	chr1:201082982	CACNA1S	-0.37	-6.69	-0.31	7.03e-11	Permanent tooth development;
LUAD	cis	rs7614311	0.636	rs66490742	chr3:63913653	G/A	cg22134162	chr3:63841271	THOC7	-0.46	-7.79	-0.35	5.15e-14	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg17264618	chr3:40429014	ENTPD3	0.41	8.83	0.39	2.84e-17	Renal cell carcinoma;
LUAD	cis	rs9796	0.870	rs4923890	chr15:41258990	T/C	cg18705301	chr15:41695430	NDUFAF1	0.38	7.18	0.33	3.16e-12	Menopause (age at onset);
LUAD	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.76	0.31	4.45e-11	Parkinson's disease;
LUAD	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs11229555	0.609	rs12289198	chr11:58175057	T/C	cg15696309	chr11:58395628	NA	-0.73	-10.3	-0.45	2.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg23283495	chr1:209979779	IRF6	0.68	10.82	0.47	3.1e-24	Cleft lip with or without cleft palate;
LUAD	cis	rs68170813	0.559	rs2249043	chr7:106960515	C/T	cg23024343	chr7:107201750	COG5	0.51	7.36	0.34	9.92e-13	Coronary artery disease;
LUAD	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg22906224	chr7:99728672	NA	-0.58	-9.95	-0.44	4.09e-21	Coronary artery disease;
LUAD	cis	rs870825	0.616	rs2090589	chr4:185647731	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg23625390	chr15:77176239	SCAPER	-0.46	-7.27	-0.33	1.7e-12	Blood metabolite levels;
LUAD	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.76	0.35	6.46e-14	Platelet count;
LUAD	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03647317	chr4:187891568	NA	-0.36	-6.78	-0.31	4.02e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs735539	0.609	rs7332034	chr13:21214943	T/C	cg27499820	chr13:21296301	IL17D	0.55	9.03	0.4	5.96e-18	Dental caries;
LUAD	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6867913	0.709	rs2338874	chr5:141466926	G/A	cg23435118	chr5:141488016	NDFIP1	-0.44	-7.16	-0.33	3.51e-12	Asthma;
LUAD	cis	rs13631	0.894	rs7856589	chr9:140003921	A/G	cg14289826	chr9:140003911	NA	-0.43	-9.04	-0.4	5.79e-18	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg02221750	chr19:17393354	ANKLE1	-0.75	-12.37	-0.52	3.19e-30	Systemic lupus erythematosus;
LUAD	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.79	-10.36	-0.45	1.41e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg02734326	chr4:10020555	SLC2A9	-0.45	-7.19	-0.33	2.87e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg07741184	chr6:167504864	NA	0.31	7.13	0.33	4.32e-12	Crohn's disease;
LUAD	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg03676636	chr4:99064102	C4orf37	0.3	7.05	0.32	7.2e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg21605333	chr4:119757512	SEC24D	0.69	6.85	0.32	2.67e-11	Cannabis dependence symptom count;
LUAD	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg05368731	chr17:41323189	NBR1	0.97	20.35	0.7	1.07e-64	Menopause (age at onset);
LUAD	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs28595532	0.545	rs13132957	chr4:119250841	G/C	cg02775129	chr4:119771670	NA	-0.58	-6.47	-0.3	2.67e-10	Cannabis dependence symptom count;
LUAD	cis	rs698833	0.828	rs6706053	chr2:44517662	C/T	cg04920474	chr2:44395004	PPM1B	-0.36	-6.44	-0.3	3.34e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.7	-11.86	-0.5	3.16e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs2882667	0.822	rs13187096	chr5:138404088	C/A	cg04439458	chr5:138467593	SIL1	-0.52	-9.25	-0.41	1.12e-18	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg11584989	chr19:19387371	SF4	-0.36	-6.52	-0.3	1.95e-10	Tonsillectomy;
LUAD	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03264133	chr6:25882463	NA	0.89	14.73	0.58	6.19e-40	Blood metabolite levels;
LUAD	cis	rs67366981	1.000	rs57178676	chr14:77704595	A/C	cg22824376	chr14:77648248	TMEM63C	0.61	6.65	0.31	9.04e-11	Obsessive-compulsive symptoms;
LUAD	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.31	7.68	0.35	1.15e-13	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	10.53	0.46	3.36e-23	Type 2 diabetes;
LUAD	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg26566898	chr11:117069891	TAGLN	0.35	6.77	0.31	4.34e-11	Blood protein levels;
LUAD	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg05966235	chr16:28915196	ATP2A1	0.51	8.12	0.37	5.11e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg13606994	chr1:44402422	ARTN	-0.39	-7.33	-0.34	1.21e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg15208524	chr1:10270712	KIF1B	0.44	6.74	0.31	5.33e-11	Hepatocellular carcinoma;
LUAD	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg03684893	chr10:554711	DIP2C	-0.37	-6.45	-0.3	3.14e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg12311346	chr5:56204834	C5orf35	-0.51	-8.15	-0.37	4.01e-15	Coronary artery disease;
LUAD	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg20933634	chr6:27740509	NA	0.45	7.12	0.33	4.68e-12	Parkinson's disease;
LUAD	cis	rs2235649	0.583	rs3760038	chr16:1874717	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.51	-7.45	-0.34	5.17e-13	Blood metabolite levels;
LUAD	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.47	7.79	0.35	5.37e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs3960554	1.000	rs2097947	chr7:75836382	A/T	cg19862616	chr7:65841803	NCRNA00174	0.79	11.24	0.48	7.64e-26	Eotaxin levels;
LUAD	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18876405	chr7:65276391	NA	-0.43	-6.8	-0.31	3.59e-11	Aortic root size;
LUAD	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg26924012	chr15:45694286	SPATA5L1	0.97	17.41	0.65	1.44e-51	Homoarginine levels;
LUAD	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg04800585	chr6:26043546	HIST1H2BB	0.43	7.3	0.33	1.43e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg22482690	chr17:47019901	SNF8	0.46	8.88	0.4	1.87e-17	Type 2 diabetes;
LUAD	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg11814155	chr7:99998594	ZCWPW1	0.42	7.21	0.33	2.59e-12	Platelet count;
LUAD	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21659725	chr3:3221576	CRBN	-0.87	-18.5	-0.67	2.08e-56	Intelligence (multi-trait analysis);
LUAD	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg12483005	chr1:23474871	LUZP1	0.52	9.0	0.4	7.99e-18	Height;
LUAD	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg11915388	chr22:42470451	FAM109B	-0.4	-7.35	-0.34	1.06e-12	Schizophrenia;
LUAD	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg04450456	chr4:17643702	FAM184B	0.42	8.21	0.37	2.61e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11048434	0.736	rs12821842	chr12:9108984	G/A	cg13575925	chr12:9217583	LOC144571	0.37	7.03	0.32	8.36e-12	Sjögren's syndrome;
LUAD	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg17863274	chr19:49399704	TULP2	-0.66	-10.02	-0.44	2.43e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg05896524	chr21:47604654	C21orf56	-0.73	-13.17	-0.54	2e-33	Testicular germ cell tumor;
LUAD	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg17200465	chr3:40428508	ENTPD3	0.28	7.09	0.33	5.6e-12	Renal cell carcinoma;
LUAD	cis	rs877282	0.898	rs11253349	chr10:765897	C/G	cg06581033	chr10:766294	NA	-0.62	-8.35	-0.38	1.02e-15	Uric acid levels;
LUAD	trans	rs7395662	0.624	rs11040162	chr11:48959991	C/T	cg00717180	chr2:96193071	NA	0.39	7.47	0.34	4.7e-13	HDL cholesterol;
LUAD	cis	rs9863	0.931	rs11057401	chr12:124427306	A/T	cg17723958	chr12:124429295	CCDC92	-0.42	-6.78	-0.31	4.09e-11	White blood cell count;
LUAD	cis	rs62064224	0.614	rs11656445	chr17:30694164	T/C	cg18200150	chr17:30822561	MYO1D	0.41	7.56	0.35	2.49e-13	Schizophrenia;
LUAD	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg26343298	chr8:95960752	TP53INP1	0.35	7.39	0.34	8.17e-13	Type 2 diabetes;
LUAD	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.23	-0.41	1.3e-18	Type 2 diabetes;
LUAD	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-7.86	-0.36	3.27e-14	Total cholesterol levels;
LUAD	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-9.75	-0.43	2.16e-20	Lymphocyte counts;
LUAD	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg02454025	chr1:11042201	C1orf127	0.99	17.13	0.64	2.49e-50	Ewing sarcoma;
LUAD	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg03037974	chr15:76606532	NA	-0.38	-8.2	-0.37	3e-15	Blood metabolite levels;
LUAD	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg13722127	chr7:150037890	RARRES2	0.43	7.3	0.33	1.39e-12	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg15704280	chr7:45808275	SEPT13	0.64	8.17	0.37	3.52e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7633770	0.769	rs2385858	chr3:46660436	T/C	cg11219411	chr3:46661640	NA	0.61	14.2	0.57	1.09e-37	Coronary artery disease;
LUAD	cis	rs28595532	1.000	rs115004746	chr4:119642137	C/T	cg02775129	chr4:119771670	NA	-0.82	-7.63	-0.35	1.59e-13	Cannabis dependence symptom count;
LUAD	cis	rs428668	0.681	rs428064	chr5:150696498	G/A	cg11125805	chr5:150678162	SLC36A3	0.48	8.98	0.4	9.01e-18	Skin aging (microtopography measurement);
LUAD	cis	rs1045714	0.895	rs4721866	chr7:2643341	G/A	cg20813462	chr7:2646259	IQCE	0.67	7.52	0.34	3.4e-13	Urate levels in lean individuals;
LUAD	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg14092988	chr3:52407081	DNAH1	0.43	8.51	0.38	3.03e-16	Bipolar disorder;
LUAD	cis	rs240764	0.583	rs11155638	chr6:101203801	T/A	cg09795085	chr6:101329169	ASCC3	-0.47	-8.29	-0.37	1.51e-15	Neuroticism;
LUAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg15117754	chr3:10150083	C3orf24	0.44	7.09	0.33	5.76e-12	Alzheimer's disease;
LUAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg27454412	chr7:1067447	C7orf50	0.44	7.02	0.32	8.94e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs875971	1.000	rs778696	chr7:65870813	C/G	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs1595825	0.627	rs76341431	chr2:198379118	G/A	cg00982548	chr2:198649783	BOLL	-0.5	-6.57	-0.3	1.51e-10	Ulcerative colitis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26574964	chr11:117049906	SIDT2	-0.66	-8.14	-0.37	4.55e-15	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs72928364	0.929	rs13065684	chr3:100773738	T/C	cg10123952	chr3:100791384	NA	0.76	8.69	0.39	7.85e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg01884057	chr2:25150051	NA	0.33	6.92	0.32	1.65e-11	Body mass index;
LUAD	cis	rs2404602	0.735	rs4886800	chr15:76678692	A/G	cg23625390	chr15:77176239	SCAPER	-0.4	-6.56	-0.3	1.59e-10	Blood metabolite levels;
LUAD	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg06611532	chr13:114900021	NA	0.38	8.96	0.4	1.04e-17	Schizophrenia;
LUAD	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.58	8.22	0.37	2.54e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg19635926	chr16:89946313	TCF25	0.78	6.89	0.32	2.01e-11	Skin colour saturation;
LUAD	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.31	-8.22	-0.37	2.6e-15	Total body bone mineral density;
LUAD	cis	rs7524258	0.868	rs4908607	chr1:7269323	A/G	cg07173049	chr1:7289937	CAMTA1	0.51	9.82	0.43	1.22e-20	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg15017067	chr4:17643749	FAM184B	0.36	7.24	0.33	2.09e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7503807	0.837	rs9915667	chr17:78754340	A/G	cg09596252	chr17:78655493	RPTOR	-0.42	-8.24	-0.37	2.14e-15	Obesity;
LUAD	cis	rs4786125	0.665	rs7201025	chr16:6920592	C/T	cg03623568	chr16:6915990	A2BP1	-0.48	-10.27	-0.45	2.95e-22	Heart rate variability traits (SDNN);
LUAD	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg05187965	chr10:45406764	TMEM72	-0.42	-8.25	-0.37	2.1e-15	Mean corpuscular volume;
LUAD	cis	rs2235642	0.533	rs17135391	chr16:1605606	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.51	-8.05	-0.36	8.42e-15	Coronary artery disease;
LUAD	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15664640	chr17:80829946	TBCD	-0.85	-17.56	-0.65	3.19e-52	Breast cancer;
LUAD	cis	rs2067615	0.579	rs10861655	chr12:107129419	A/G	cg15890332	chr12:107067104	RFX4	-0.38	-8.4	-0.38	6.62e-16	Heart rate;
LUAD	cis	rs7512552	0.839	rs1097070	chr1:150332955	A/T	cg15654264	chr1:150340011	RPRD2	0.58	11.1	0.47	2.73e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.93e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.18	-0.33	3.09e-12	Glomerular filtration rate;
LUAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08219700	chr8:58056026	NA	0.63	8.82	0.39	2.92e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02432532	chr2:37898366	CDC42EP3	-0.4	-6.51	-0.3	2.07e-10	Cancer;
LUAD	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.41	-0.34	7.13e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg26513180	chr16:89883248	FANCA	0.78	7.17	0.33	3.36e-12	Skin colour saturation;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg11310629	chr13:45991975	SLC25A30	0.44	6.66	0.31	8.37e-11	Monocyte percentage of white cells;
LUAD	cis	rs4285028	0.948	rs13089878	chr3:121703895	T/C	cg11130432	chr3:121712080	ILDR1	-0.58	-8.2	-0.37	2.81e-15	Multiple sclerosis;
LUAD	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg19318889	chr4:1322082	MAEA	0.48	8.44	0.38	5.27e-16	Obesity-related traits;
LUAD	cis	rs6424115	1.000	rs7515969	chr1:24158398	G/A	cg10978503	chr1:24200527	CNR2	-0.56	-12.2	-0.51	1.52e-29	Immature fraction of reticulocytes;
LUAD	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.73	0.31	5.49e-11	Aortic root size;
LUAD	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.38	-6.75	-0.31	4.87e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg15921436	chr17:44337874	NA	0.63	9.42	0.42	2.9e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg10755058	chr3:40428713	ENTPD3	0.45	8.46	0.38	4.46e-16	Renal cell carcinoma;
LUAD	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg18404041	chr3:52824283	ITIH1	0.45	8.3	0.37	1.46e-15	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.73	-13.38	-0.55	2.82e-34	Axial length;
LUAD	cis	rs5771069	0.931	rs137864	chr22:50446988	C/T	cg27068297	chr22:50451975	IL17REL	0.33	6.59	0.31	1.29e-10	Ulcerative colitis;
LUAD	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg06627628	chr2:24431161	ITSN2	-0.68	-10.79	-0.46	3.9e-24	Asthma;
LUAD	cis	rs7705042	0.865	rs6874308	chr5:141506911	C/T	cg08523384	chr5:141488047	NDFIP1	-0.38	-6.58	-0.3	1.35e-10	Asthma;
LUAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg11494091	chr17:61959527	GH2	0.74	18.58	0.67	9.11e-57	Prudent dietary pattern;
LUAD	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg06064525	chr11:970664	AP2A2	-0.42	-8.15	-0.37	4.24e-15	Alzheimer's disease (late onset);
LUAD	cis	rs2274471	0.699	rs10758672	chr9:5116369	T/C	cg03390472	chr9:5043263	JAK2	-0.56	-8.58	-0.39	1.78e-16	Crohn's disease;
LUAD	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg13126279	chr21:47581558	C21orf56	0.42	6.62	0.31	1.12e-10	Testicular germ cell tumor;
LUAD	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.86	-11.77	-0.5	7.51e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs113835537	0.529	rs11227510	chr11:66281220	T/C	cg24851651	chr11:66362959	CCS	0.57	10.1	0.44	1.25e-21	Airway imaging phenotypes;
LUAD	cis	rs7605378	0.688	rs769961	chr2:200712141	C/A	cg23649088	chr2:200775458	C2orf69	0.68	10.67	0.46	1.1e-23	Osteoporosis;
LUAD	cis	rs28595532	0.545	rs17516526	chr4:119259199	C/G	cg02775129	chr4:119771670	NA	-0.58	-6.44	-0.3	3.23e-10	Cannabis dependence symptom count;
LUAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg12419862	chr22:24373484	LOC391322	-0.68	-11.68	-0.49	1.62e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10908458	0.584	rs10908455	chr1:155067283	C/T	cg00103785	chr1:155043322	NA	0.31	6.4	0.3	4.16e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9837602	1.000	rs6802422	chr3:99778655	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.63	-9.24	-0.41	1.25e-18	Breast cancer;
LUAD	cis	rs9287719	0.639	rs2357650	chr2:10696877	C/T	cg02196655	chr2:10830764	NOL10	-0.39	-6.54	-0.3	1.79e-10	Prostate cancer;
LUAD	cis	rs886126	0.950	rs2078851	chr12:111690579	C/T	cg10833066	chr12:111807467	FAM109A	-0.54	-10.02	-0.44	2.34e-21	Coronary heart disease;
LUAD	cis	rs1535500	0.967	rs11756091	chr6:39282806	G/T	cg06347083	chr6:39282316	KCNK17	-0.37	-7.88	-0.36	2.75e-14	Type 2 diabetes;
LUAD	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg23711669	chr6:146136114	FBXO30	0.39	6.66	0.31	8.51e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12949688	0.967	rs9905938	chr17:55824351	G/A	cg12582317	chr17:55822272	NA	0.36	7.18	0.33	3.1e-12	Schizophrenia;
LUAD	cis	rs7771547	0.603	rs10947615	chr6:36599596	T/C	cg02952361	chr6:36355661	ETV7	0.47	6.4	0.3	4.24e-10	Platelet distribution width;
LUAD	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.5	-8.43	-0.38	5.43e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg15128208	chr22:42549153	NA	-0.37	-7.03	-0.32	8.55e-12	Cognitive function;
LUAD	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg24803719	chr17:45855879	NA	-0.34	-7.52	-0.34	3.27e-13	IgG glycosylation;
LUAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg01577475	chr2:114033581	PAX8;LOC440839	-0.31	-7.03	-0.32	8.22e-12	Lymphocyte counts;
LUAD	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg00634984	chr7:65235879	NA	0.48	6.5	0.3	2.24e-10	Aortic root size;
LUAD	trans	rs8073060	0.586	rs225305	chr17:33921160	C/T	cg19694781	chr19:47549865	TMEM160	-1.24	-19.82	-0.69	2.46e-62	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg10556349	chr10:835070	NA	0.51	6.94	0.32	1.47e-11	Eosinophil percentage of granulocytes;
LUAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.52	-8.85	-0.4	2.43e-17	Longevity;Endometriosis;
LUAD	cis	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.96	-0.36	1.63e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs742132	0.520	rs2294344	chr6:25652225	C/A	cg03517284	chr6:25882590	NA	0.56	6.44	0.3	3.22e-10	Uric acid levels;
LUAD	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg19418458	chr7:158789849	NA	0.65	8.67	0.39	9.59e-17	Facial morphology (factor 20);
LUAD	cis	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg06609049	chr19:2785107	THOP1	0.71	11.87	0.5	3.07e-28	Total cholesterol levels;
LUAD	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg11833968	chr6:79620685	NA	-0.43	-8.08	-0.37	6.94e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg18200150	chr17:30822561	MYO1D	0.62	12.21	0.51	1.37e-29	Schizophrenia;
LUAD	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.39	-6.95	-0.32	1.42e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2274471	0.645	rs73395330	chr9:5082839	C/T	cg03390472	chr9:5043263	JAK2	-0.56	-8.14	-0.37	4.54e-15	Crohn's disease;
LUAD	cis	rs35883536	0.611	rs72977390	chr1:101107147	C/T	cg06223162	chr1:101003688	GPR88	0.37	6.68	0.31	7.4e-11	Monocyte count;
LUAD	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg21475434	chr5:93447410	FAM172A	0.74	8.77	0.39	4.57e-17	Diabetic retinopathy;
LUAD	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.98	0.36	1.42e-14	Parkinson's disease;
LUAD	trans	rs9951602	0.512	rs1599634	chr18:76643645	T/C	cg02800362	chr5:177631904	HNRNPAB	0.92	14.18	0.57	1.25e-37	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.8	0.35	4.86e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg17264618	chr3:40429014	ENTPD3	0.38	8.64	0.39	1.18e-16	Renal cell carcinoma;
LUAD	cis	rs6541297	0.757	rs2760537	chr1:230326412	C/T	cg20703242	chr1:230279135	GALNT2	-0.43	-6.81	-0.31	3.39e-11	Coronary artery disease;
LUAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.53	-7.38	-0.34	8.36e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05901451	chr6:126070800	HEY2	0.59	9.23	0.41	1.34e-18	Endometrial cancer;
LUAD	cis	rs12286929	0.669	rs11606837	chr11:115042837	C/T	cg04055981	chr11:115044050	NA	0.46	8.4	0.38	6.85e-16	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2067615	0.579	rs10861665	chr12:107193836	T/C	cg15890332	chr12:107067104	RFX4	0.39	8.42	0.38	5.76e-16	Heart rate;
LUAD	cis	rs7215564	0.908	rs7503757	chr17:78685599	A/G	cg16980736	chr17:78789706	RPTOR	-0.61	-6.55	-0.3	1.65e-10	Myopia (pathological);
LUAD	cis	rs2011503	0.941	rs17751061	chr19:19413092	C/T	cg11584989	chr19:19387371	SF4	0.5	7.4	0.34	7.58e-13	Bipolar disorder;
LUAD	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg06002616	chr8:101225028	SPAG1	0.4	7.98	0.36	1.36e-14	Atrioventricular conduction;
LUAD	cis	rs7932354	0.528	rs1060573	chr11:47179829	A/G	cg19486271	chr11:47235900	DDB2	-0.44	-7.06	-0.32	7.05e-12	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg05966235	chr16:28915196	ATP2A1	0.47	7.56	0.35	2.49e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs877282	0.842	rs35872126	chr10:764545	G/A	cg22713356	chr15:30763199	NA	1.26	17.41	0.65	1.4e-51	Uric acid levels;
LUAD	cis	rs9644630	0.696	rs35736969	chr8:19319620	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.29	-6.83	-0.32	3.01e-11	Oropharynx cancer;
LUAD	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg25566285	chr7:158114605	PTPRN2	0.51	10.82	0.47	2.96e-24	Calcium levels;
LUAD	cis	rs11681884	1.000	rs11684289	chr2:113845038	T/G	cg12858261	chr2:113808755	IL1F8	0.51	6.42	0.3	3.6e-10	Stroke;
LUAD	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg09650180	chr20:62225654	GMEB2	-0.48	-6.9	-0.32	1.93e-11	Glioblastoma;
LUAD	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg02782426	chr3:40428986	ENTPD3	-0.4	-8.65	-0.39	1.06e-16	Renal cell carcinoma;
LUAD	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg00530320	chr1:46809349	NSUN4	-0.47	-7.49	-0.34	3.97e-13	Menopause (age at onset);
LUAD	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg06387496	chr7:2775674	GNA12	-0.38	-6.53	-0.3	1.87e-10	Height;
LUAD	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.47	-7.75	-0.35	7.06e-14	Diastolic blood pressure;
LUAD	cis	rs208520	0.661	rs207111	chr6:66792513	C/T	cg07460842	chr6:66804631	NA	-1.06	-16.63	-0.63	3.97e-48	Exhaled nitric oxide output;
LUAD	cis	rs5758511	0.514	rs9607882	chr22:42567451	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.66	11.45	0.49	1.21e-26	Birth weight;
LUAD	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.85	15.22	0.59	4.75e-42	Chronic sinus infection;
LUAD	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg04450456	chr4:17643702	FAM184B	-0.4	-7.88	-0.36	2.88e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg11693508	chr17:37793320	STARD3	0.48	6.81	0.31	3.37e-11	Neuroticism;
LUAD	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24531977	chr5:56204891	C5orf35	0.8	12.96	0.53	1.35e-32	Initial pursuit acceleration;
LUAD	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg04842962	chr6:43655489	MRPS18A	0.94	17.9	0.66	9.08e-54	IgG glycosylation;
LUAD	trans	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg14917512	chr19:3094685	GNA11	0.57	6.87	0.32	2.28e-11	Diabetic kidney disease;
LUAD	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26314531	chr2:26401878	FAM59B	0.54	7.83	0.36	3.89e-14	Gut microbiome composition (summer);
LUAD	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg19729930	chr2:74357872	NA	0.99	17.64	0.65	1.28e-52	Gestational age at birth (maternal effect);
LUAD	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg05805236	chr11:65401703	PCNXL3	0.4	6.67	0.31	7.88e-11	Acne (severe);
LUAD	cis	rs78487399	0.808	rs1388387	chr2:43736969	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-6.8	-0.31	3.61e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg15208524	chr1:10270712	KIF1B	0.46	7.21	0.33	2.52e-12	Hepatocellular carcinoma;
LUAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10819733	chr22:24237672	NA	0.38	7.11	0.33	4.84e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg09658497	chr7:2847517	GNA12	0.54	9.23	0.41	1.36e-18	Height;
LUAD	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg00080972	chr5:178986291	RUFY1	0.56	9.15	0.41	2.41e-18	Lung cancer;
LUAD	cis	rs6500395	0.963	rs2111242	chr16:48708300	T/C	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg02569458	chr12:86230093	RASSF9	0.42	7.99	0.36	1.29e-14	Major depressive disorder;
LUAD	cis	rs12912251	1.000	rs12916379	chr15:38991520	A/G	cg01338139	chr15:38987640	C15orf53	-0.58	-9.14	-0.41	2.59e-18	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs4889855	0.530	rs4890048	chr17:78549602	G/A	cg16591659	chr17:78472290	NA	0.37	6.61	0.31	1.17e-10	Fractional excretion of uric acid;
LUAD	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg03388025	chr16:89894329	SPIRE2	-0.32	-7.83	-0.36	4.1e-14	Vitiligo;
LUAD	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg07507251	chr3:52567010	NT5DC2	0.39	7.48	0.34	4.4e-13	Bipolar disorder;
LUAD	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03517284	chr6:25882590	NA	-0.56	-8.16	-0.37	3.83e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26688472	chr2:203638928	ICA1L	-0.48	-6.36	-0.3	5.35e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs2735413	0.881	rs11150036	chr16:78075687	C/G	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs9560113	0.960	rs61967677	chr13:112174044	A/G	cg14154082	chr13:112174009	NA	0.37	6.83	0.32	3.01e-11	Menarche (age at onset);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05800758	chr8:101225800	SPAG1	-0.42	-6.59	-0.31	1.3100000000000001e-10	Height;
LUAD	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg22676075	chr6:135203613	NA	0.43	8.07	0.37	7.35e-15	Red blood cell count;
LUAD	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg08999081	chr20:33150536	PIGU	0.47	9.13	0.41	2.95e-18	Coronary artery disease;
LUAD	cis	rs2239547	0.522	rs2564947	chr3:53046216	C/T	cg18404041	chr3:52824283	ITIH1	0.52	9.13	0.41	2.76e-18	Schizophrenia;
LUAD	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg10518543	chr12:38710700	ALG10B	-0.43	-7.1	-0.33	5.36e-12	Bladder cancer;
LUAD	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.77	-0.31	4.39e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg02734326	chr4:10020555	SLC2A9	0.62	11.05	0.47	4.04e-25	Bone mineral density;
LUAD	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg26597838	chr10:835615	NA	0.84	11.61	0.49	3.06e-27	Eosinophil percentage of granulocytes;
LUAD	trans	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17712092	chr4:129076599	LARP1B	0.85	16.0	0.61	2.05e-45	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg22467129	chr15:76604101	ETFA	-0.6	-11.07	-0.47	3.4e-25	Blood metabolite levels;
LUAD	trans	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg03886242	chr7:26192032	NFE2L3	0.36	6.49	0.3	2.4e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg15445000	chr17:37608096	MED1	0.44	8.23	0.37	2.26e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs3125734	0.633	rs7088891	chr10:64034019	G/T	cg09941381	chr10:64027924	RTKN2	-0.33	-7.76	-0.35	6.46e-14	Rheumatoid arthritis;
LUAD	cis	rs6063312	0.935	rs6095256	chr20:47340806	C/T	cg18078177	chr20:47281410	PREX1	0.65	8.29	0.37	1.55e-15	Tonometry;
LUAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg14789911	chr21:47582049	C21orf56	-0.42	-7.21	-0.33	2.62e-12	Testicular germ cell tumor;
LUAD	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg25324976	chr17:61989376	CSHL1	0.37	7.02	0.32	8.72e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.12	0.41	3.07e-18	Alzheimer's disease;
LUAD	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg15921436	chr17:44337874	NA	0.87	11.55	0.49	5.36e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg17757837	chr7:157058334	UBE3C	-0.46	-8.24	-0.37	2.11e-15	Body mass index;
LUAD	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg00898013	chr13:113819073	PROZ	0.79	14.26	0.57	5.85e-38	Platelet distribution width;
LUAD	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.8	-10.21	-0.44	4.9e-22	Body mass index;
LUAD	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18876405	chr7:65276391	NA	-0.6	-10.1	-0.44	1.25e-21	Aortic root size;
LUAD	cis	rs10210302	0.504	rs1000141	chr2:234242347	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.43	7.14	0.33	4.1e-12	Crohn's disease;
LUAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.33	0.41	6.2e-19	Alzheimer's disease;
LUAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.62	-10.8	-0.46	3.55e-24	Lymphocyte counts;
LUAD	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg22868518	chr11:507468	RNH1	-0.68	-6.83	-0.32	3.02e-11	Body mass index;
LUAD	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg05425664	chr17:57184151	TRIM37	0.44	7.73	0.35	7.81e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7267979	0.932	rs13040655	chr20:25582197	C/T	cg08601574	chr20:25228251	PYGB	0.4	7.26	0.33	1.93e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.11	-25.4	-0.78	3.98e-87	Ulcerative colitis;
LUAD	cis	rs986417	1.000	rs1254286	chr14:60858300	T/C	cg27398547	chr14:60952738	C14orf39	-0.64	-7.79	-0.35	5.1e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg04455712	chr21:45112962	RRP1B	-0.46	-9.11	-0.4	3.42e-18	Mean corpuscular volume;
LUAD	cis	rs1997103	1.000	rs2877284	chr7:55408778	A/G	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06544989	chr22:39130855	UNC84B	0.45	8.98	0.4	9.14e-18	Menopause (age at onset);
LUAD	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg09184832	chr6:79620586	NA	-0.51	-9.57	-0.42	9.14e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg04267008	chr7:1944627	MAD1L1	-0.65	-9.89	-0.43	6.75e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs28595532	0.920	rs115317002	chr4:119722809	T/C	cg02775129	chr4:119771670	NA	-0.84	-7.67	-0.35	1.17e-13	Cannabis dependence symptom count;
LUAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg08888203	chr3:10149979	C3orf24	0.74	13.07	0.54	5.1e-33	Alzheimer's disease;
LUAD	cis	rs1298908	1.000	rs1298908	chr10:82013134	A/G	cg01528321	chr10:82214614	TSPAN14	-0.41	-6.58	-0.3	1.43e-10	Diabetic kidney disease;
LUAD	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg17366294	chr4:99064904	C4orf37	0.65	12.41	0.52	2.19e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg15181151	chr6:150070149	PCMT1	0.4	8.19	0.37	3.06e-15	Lung cancer;
LUAD	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg03433033	chr1:76189801	ACADM	0.91	18.19	0.66	5.1e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs877282	1.000	rs112522746	chr10:772288	T/C	cg22713356	chr15:30763199	NA	1.17	16.73	0.63	1.35e-48	Uric acid levels;
LUAD	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg01475377	chr6:109611718	NA	-0.51	-9.43	-0.42	2.74e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg15448220	chr1:150897856	SETDB1	0.54	9.15	0.41	2.36e-18	Melanoma;
LUAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg18621852	chr3:10150065	C3orf24	0.48	8.45	0.38	4.89e-16	Alzheimer's disease;
LUAD	trans	rs8002861	0.870	rs4942255	chr13:44451844	A/T	cg17145862	chr1:211918768	LPGAT1	-0.76	-17.57	-0.65	2.63e-52	Leprosy;
LUAD	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.42	6.39	0.3	4.29e-10	Height;
LUAD	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.95	-0.36	1.76e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs62400317	0.762	rs17423748	chr6:44943982	T/C	cg18551225	chr6:44695536	NA	-0.57	-8.58	-0.39	1.8e-16	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.845	rs12601963	chr17:28246358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.26	0.41	1.08e-18	Coffee consumption (cups per day);
LUAD	cis	rs4930561	0.690	rs6591334	chr11:67924559	A/G	cg04465784	chr11:67976953	SUV420H1	-0.34	-10.56	-0.46	2.73e-23	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg14416269	chr4:6271139	WFS1	0.63	12.22	0.51	1.24e-29	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg01620082	chr3:125678407	NA	-0.64	-7.68	-0.35	1.15e-13	Depression;
LUAD	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25427524	chr10:38739819	LOC399744	-0.74	-13.14	-0.54	2.5e-33	Extrinsic epigenetic age acceleration;
LUAD	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06873352	chr17:61820015	STRADA	0.82	18.45	0.67	3.55e-56	Prudent dietary pattern;
LUAD	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg02176678	chr2:219576539	TTLL4	0.68	13.63	0.55	2.41e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg05887092	chr17:76393375	PGS1	0.42	7.45	0.34	5.18e-13	HDL cholesterol levels;
LUAD	cis	rs3736594	0.759	rs6753736	chr2:27958855	C/G	cg27432699	chr2:27873401	GPN1	-0.44	-6.74	-0.31	5.2e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg08798685	chr6:27730294	NA	-0.7	-7.44	-0.34	5.48e-13	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg23887609	chr12:130822674	PIWIL1	0.41	6.7	0.31	6.58e-11	Menopause (age at onset);
LUAD	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg18944383	chr4:111397179	ENPEP	0.41	8.27	0.37	1.7e-15	Height;
LUAD	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.88	-0.36	2.85e-14	Type 2 diabetes;
LUAD	cis	rs74417235	0.684	rs71590150	chr5:154060512	A/T	cg08893839	chr5:154027129	NA	0.55	7.24	0.33	2.1e-12	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-7.7	-0.35	9.61e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg23173402	chr1:227635558	NA	0.69	6.56	0.3	1.57e-10	Major depressive disorder;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09272667	chr5:157285937	CLINT1	-0.4	-6.69	-0.31	6.9e-11	Cancer;
LUAD	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg17644776	chr2:200775616	C2orf69	0.47	8.03	0.36	9.71e-15	Systolic blood pressure;
LUAD	cis	rs10992471	0.603	rs968040	chr9:95279985	C/A	cg14631576	chr9:95140430	CENPP	-0.51	-10.22	-0.45	4.58e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-12.13	-0.51	2.77e-29	Mean corpuscular volume;
LUAD	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg23985595	chr17:80112537	CCDC57	0.53	9.6	0.42	7.27e-20	Life satisfaction;
LUAD	cis	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg07460842	chr6:66804631	NA	0.71	12.74	0.53	1.1e-31	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs500891	0.574	rs13214484	chr6:84133338	T/C	cg08257003	chr6:84140564	ME1	0.34	6.42	0.3	3.66e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg16797656	chr11:68205561	LRP5	-0.48	-9.27	-0.41	9.75e-19	Total body bone mineral density;
LUAD	trans	rs853679	0.546	rs200954	chr6:27838764	C/G	cg01620082	chr3:125678407	NA	-0.83	-9.09	-0.4	3.8e-18	Depression;
LUAD	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg01579765	chr21:45077557	HSF2BP	-0.65	-15.17	-0.59	8.3e-42	Mean corpuscular volume;
LUAD	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	6.97	0.32	1.2e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs938554	0.826	rs7376960	chr4:9970570	A/G	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.1	-0.33	5.37e-12	Blood metabolite levels;
LUAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg08280861	chr8:58055591	NA	0.5	6.98	0.32	1.15e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6546550	0.901	rs34586537	chr2:70163316	G/T	cg02498382	chr2:70120550	SNRNP27	0.58	11.21	0.48	1.06e-25	Prevalent atrial fibrillation;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg23143603	chr11:82783581	RAB30	-0.38	-6.36	-0.3	5.13e-10	Subcortical brain region volumes;
LUAD	cis	rs654950	0.875	rs632166	chr1:41995681	T/C	cg06885757	chr1:42089581	HIVEP3	-0.32	-6.75	-0.31	5.03e-11	Airway imaging phenotypes;
LUAD	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg09796270	chr17:17721594	SREBF1	0.35	6.72	0.31	5.81e-11	Total body bone mineral density;
LUAD	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04876069	chr12:132293656	NA	-0.44	-8.26	-0.37	1.83e-15	Migraine;
LUAD	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.43	0.55	1.69e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15369054	chr17:80825471	TBCD	0.39	6.59	0.31	1.3100000000000001e-10	Breast cancer;
LUAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg01620082	chr3:125678407	NA	-0.77	-8.27	-0.37	1.79e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg18129178	chr5:148520854	ABLIM3	-0.54	-8.54	-0.38	2.42e-16	Breast cancer;
LUAD	cis	rs734999	0.869	rs1555791	chr1:2498862	G/C	cg18854424	chr1:2615690	NA	0.34	7.81	0.35	4.58e-14	Ulcerative colitis;
LUAD	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg12310025	chr6:25882481	NA	0.59	9.85	0.43	9.5e-21	Blood metabolite levels;
LUAD	cis	rs1832871	0.672	rs12529235	chr6:158766950	A/G	cg07165851	chr6:158734300	TULP4	0.72	10.98	0.47	7.47e-25	Height;
LUAD	cis	rs6687430	0.526	rs12117392	chr1:10608583	T/C	cg17425144	chr1:10567563	PEX14	0.54	10.47	0.45	5.71e-23	Hand grip strength;
LUAD	cis	rs2230307	0.536	rs2893426	chr1:100528200	G/T	cg20868668	chr1:100435035	SLC35A3	0.52	7.55	0.34	2.73e-13	Carotid intima media thickness;
LUAD	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.44	0.3	3.23e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4942242	1.000	rs4942242	chr13:44217064	A/G	cg19169023	chr15:41853346	TYRO3	0.53	9.25	0.41	1.15e-18	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg06453172	chr10:134556979	INPP5A	-0.76	-10.85	-0.47	2.37e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6432018	0.927	rs6734469	chr2:9735900	G/A	cg12832956	chr2:9616023	IAH1	-0.36	-6.48	-0.3	2.55e-10	Heart rate variability traits;
LUAD	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg27411982	chr8:10470053	RP1L1	0.41	7.57	0.35	2.43e-13	Neuroticism;
LUAD	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg27068330	chr11:65405492	SIPA1	-0.74	-11.86	-0.5	3.16e-28	Acne (severe);
LUAD	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg12034118	chr1:209979487	IRF6	0.54	6.6	0.31	1.2e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs6761276	0.649	rs10169599	chr2:113838652	A/G	cg09040174	chr2:113837401	NA	-0.7	-12.58	-0.52	4.66e-31	Protein quantitative trait loci;
LUAD	cis	rs757081	0.667	rs60173525	chr11:17259967	A/G	cg15432903	chr11:17409602	KCNJ11	-0.4	-6.39	-0.3	4.26e-10	Systolic blood pressure;
LUAD	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05926928	chr17:57297772	GDPD1	1.39	17.62	0.65	1.57e-52	Opioid sensitivity;
LUAD	cis	rs13315871	1.000	rs9869576	chr3:58401262	G/A	cg12435725	chr3:58293450	RPP14	-0.69	-7.35	-0.34	1.05e-12	Cholesterol, total;
LUAD	cis	rs1160297	0.552	rs6545313	chr2:53222840	A/G	cg07782112	chr2:53107842	NA	-0.34	-6.77	-0.31	4.4e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs17818399	0.815	rs17768018	chr2:46862011	A/G	cg09399716	chr2:46890238	NA	-0.41	-7.81	-0.35	4.7e-14	Height;
LUAD	trans	rs11165623	0.602	rs7521690	chr1:97015761	A/C	cg10631902	chr5:14652156	NA	-0.42	-7.41	-0.34	6.96e-13	Hip circumference;Waist circumference;
LUAD	cis	rs7677751	0.806	rs7673984	chr4:55088761	C/T	cg00691999	chr4:55094011	PDGFRA	0.34	6.49	0.3	2.39e-10	Corneal astigmatism;
LUAD	cis	rs11971779	0.553	rs10228643	chr7:139115420	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.85	0.32	2.66e-11	Diisocyanate-induced asthma;
LUAD	cis	rs9811920	0.535	rs704571	chr3:99481946	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.76	-0.39	4.77e-17	Axial length;
LUAD	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg03690763	chr11:133734501	NA	-0.36	-8.27	-0.37	1.79e-15	Childhood ear infection;
LUAD	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg06046430	chr4:77819534	ANKRD56	0.46	7.33	0.34	1.21e-12	Emphysema distribution in smoking;
LUAD	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs4900538	0.855	rs72698602	chr14:102880454	T/C	cg18135206	chr14:102964638	TECPR2	-1.02	-21.2	-0.72	1.77e-68	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg08508325	chr11:3079039	CARS	-0.58	-12.74	-0.53	1.1e-31	Longevity;
LUAD	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg23625390	chr15:77176239	SCAPER	0.4	6.91	0.32	1.75e-11	Blood metabolite levels;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg14929913	chr10:1147979	WDR37	-0.42	-7.07	-0.33	6.39e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9807989	0.773	rs5010059	chr2:102968826	C/G	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.05e-10	Asthma;
LUAD	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06112835	chr11:68658793	MRPL21	0.51	9.3	0.41	7.78e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg07599136	chr5:415885	AHRR	0.7	7.79	0.35	5.32e-14	Fat distribution (HIV);
LUAD	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg24801067	chr17:62843696	NA	-0.54	-7.5	-0.34	3.86e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg10556349	chr10:835070	NA	0.6	7.63	0.35	1.55e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg14582100	chr15:45693742	SPATA5L1	0.63	11.92	0.5	1.87e-28	Homoarginine levels;
LUAD	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg26446133	chr18:72167187	CNDP2	-0.88	-15.94	-0.61	4.01e-45	Refractive error;
LUAD	cis	rs6542838	0.641	rs1581249	chr2:99500630	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.47	-0.3	2.73e-10	Fear of minor pain;
LUAD	cis	rs7599312	0.534	rs7596285	chr2:213406961	G/A	cg16329650	chr2:213403929	ERBB4	0.61	10.88	0.47	1.72e-24	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06394585	chr2:148777915	ORC4L	-0.43	-6.7	-0.31	6.7e-11	Height;
LUAD	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02475777	chr4:1388615	CRIPAK	0.59	8.43	0.38	5.38e-16	Longevity;
LUAD	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg24399712	chr22:39784796	NA	-0.55	-8.18	-0.37	3.44e-15	IgG glycosylation;
LUAD	cis	rs6087990	0.735	rs2889703	chr20:31379184	C/A	cg13636640	chr20:31349939	DNMT3B	0.7	12.61	0.52	3.43e-31	Ulcerative colitis;
LUAD	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05901451	chr6:126070800	HEY2	-0.67	-11.23	-0.48	8.65e-26	Brugada syndrome;
LUAD	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg04398451	chr17:18023971	MYO15A	-0.92	-18.47	-0.67	2.76e-56	Total body bone mineral density;
LUAD	trans	rs877282	0.945	rs11253398	chr10:790012	T/C	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00802000	chr16:706648	WDR90	-0.4	-7.48	-0.34	4.23e-13	Height;
LUAD	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06873352	chr17:61820015	STRADA	0.56	9.08	0.4	4.2e-18	Height;
LUAD	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	9.77	0.43	1.83e-20	Ileal carcinoids;
LUAD	cis	rs701145	0.585	rs357466	chr3:153902868	A/G	cg17054900	chr3:154042577	DHX36	0.59	6.54	0.3	1.81e-10	Coronary artery disease;
LUAD	cis	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg26587870	chr6:27730563	NA	-0.55	-8.45	-0.38	4.63e-16	Parkinson's disease;
LUAD	cis	rs8060686	0.623	rs28700885	chr16:68154544	A/G	cg26727032	chr16:67993705	SLC12A4	-0.46	-7.69	-0.35	1.01e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg01689657	chr7:91764605	CYP51A1	-0.3	-7.19	-0.33	2.99e-12	Breast cancer;
LUAD	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg25208724	chr1:156163844	SLC25A44	0.98	15.05	0.59	2.71e-41	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg16988262	chr1:15930761	NA	0.42	7.06	0.32	6.73e-12	Systolic blood pressure;
LUAD	trans	rs637571	0.544	rs500161	chr11:65695438	C/T	cg17712092	chr4:129076599	LARP1B	1.0	20.39	0.7	7.05e-65	Eosinophil percentage of white cells;
LUAD	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg01802117	chr1:53393560	SCP2	0.43	8.07	0.37	7.39e-15	Monocyte count;
LUAD	cis	rs2535633	0.602	rs6801235	chr3:53009595	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.49	-0.3	2.44e-10	Body mass index;
LUAD	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg05110241	chr16:68378359	PRMT7	-0.94	-10.63	-0.46	1.44e-23	Magnesium levels;
LUAD	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg07905965	chr19:39260460	NA	0.46	8.53	0.38	2.7e-16	Heart rate;
LUAD	cis	rs4372836	0.681	rs13394863	chr2:28956684	C/A	cg09522027	chr2:28974177	PPP1CB	-0.47	-7.9	-0.36	2.51e-14	Body mass index;
LUAD	cis	rs9868809	0.881	rs3821876	chr3:48668394	G/T	cg00383909	chr3:49044727	WDR6	0.66	7.2	0.33	2.73e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg21770322	chr7:97807741	LMTK2	0.35	8.3	0.37	1.42e-15	Prostate cancer (SNP x SNP interaction);Prostate cancer;
LUAD	trans	rs1973993	1.000	rs1973993	chr1:96943994	A/G	cg10631902	chr5:14652156	NA	0.55	10.54	0.46	3.15e-23	Weight;
LUAD	cis	rs7107174	1.000	rs1893447	chr11:77973182	A/G	cg19901956	chr11:77921274	USP35	-0.48	-6.59	-0.31	1.32e-10	Testicular germ cell tumor;
LUAD	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg03948781	chr1:205179583	DSTYK	0.33	6.43	0.3	3.45e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.87	0.36	3.06e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03517284	chr6:25882590	NA	-0.58	-9.54	-0.42	1.16e-19	Blood metabolite levels;
LUAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg00280220	chr17:61926910	NA	0.37	7.1	0.33	5.47e-12	Prudent dietary pattern;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04844971	chr15:50979486	TRPM7	-0.4	-6.43	-0.3	3.55e-10	Height;
LUAD	cis	rs6906287	0.573	rs7757943	chr6:118697981	C/G	cg21191810	chr6:118973309	C6orf204	0.48	9.45	0.42	2.32e-19	Electrocardiographic conduction measures;
LUAD	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg02660097	chr11:68866761	NA	0.47	6.52	0.3	1.96e-10	Blond vs. brown hair color;
LUAD	trans	rs2262909	0.962	rs55728714	chr19:22262899	A/G	cg05197062	chr11:11642011	GALNTL4	0.6	9.18	0.41	1.96e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs524023	1.000	rs3825018	chr11:64358809	G/A	cg19131476	chr11:64387923	NRXN2	-0.36	-6.77	-0.31	4.39e-11	Urate levels in obese individuals;
LUAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg18621852	chr3:10150065	C3orf24	0.49	8.44	0.38	5.14e-16	Alzheimer's disease;
LUAD	cis	rs986417	0.748	rs1955691	chr14:61004128	G/A	cg27398547	chr14:60952738	C14orf39	0.66	7.85	0.36	3.45e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg23985595	chr17:80112537	CCDC57	0.52	9.57	0.42	8.96e-20	Life satisfaction;
LUAD	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg17177755	chr1:15930204	NA	0.49	7.55	0.34	2.67e-13	Systolic blood pressure;
LUAD	cis	rs4888262	0.564	rs6564147	chr16:74622586	G/A	cg01733217	chr16:74700730	RFWD3	0.51	8.57	0.38	1.95e-16	Testicular germ cell tumor;
LUAD	cis	rs716316	0.590	rs6135309	chr20:14902522	C/T	cg04470754	chr20:14904432	MACROD2	-0.6	-9.67	-0.43	4.09e-20	Advanced glycation end-product levels;
LUAD	cis	rs1160297	0.609	rs17504530	chr2:53092800	C/G	cg07782112	chr2:53107842	NA	0.34	7.13	0.33	4.39e-12	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg07596845	chr6:82957841	IBTK	0.43	6.83	0.32	2.9e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs151234	0.741	rs10521145	chr16:28596884	A/G	cg04643524	chr16:28609220	SULT1A2	-0.6	-9.09	-0.4	3.78e-18	Platelet distribution width;
LUAD	cis	rs7789940	0.951	rs7787526	chr7:75947553	C/T	cg10167463	chr7:75959203	YWHAG	-0.71	-12.53	-0.52	7.58e-31	Multiple sclerosis;
LUAD	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg11266682	chr4:10021025	SLC2A9	0.41	6.86	0.32	2.44e-11	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg21016266	chr12:122356598	WDR66	0.64	11.52	0.49	6.65e-27	Mean corpuscular volume;
LUAD	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-11.14	-0.48	1.88e-25	Hemoglobin concentration;
LUAD	cis	rs7177699	0.557	rs6495333	chr15:79113215	G/A	cg15571903	chr15:79123663	NA	0.37	7.45	0.34	5.31e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs6005807	0.546	rs1297607	chr22:28719656	G/A	cg12565055	chr22:29076175	TTC28	-0.73	-8.36	-0.38	8.88e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.22	0.37	2.47e-15	Breast cancer;
LUAD	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg07538946	chr5:131705188	SLC22A5	0.42	6.83	0.32	3e-11	Blood metabolite levels;
LUAD	cis	rs853679	0.585	rs201000	chr6:27809159	C/T	cg26587870	chr6:27730563	NA	-0.51	-7.97	-0.36	1.48e-14	Depression;
LUAD	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg16342193	chr10:102329863	NA	-0.38	-6.54	-0.3	1.76e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs3806843	0.576	rs246017	chr5:140335060	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg00603274	chr11:61596626	FADS2	-0.51	-7.82	-0.36	4.31e-14	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg18833306	chr6:118973337	C6orf204	-0.52	-7.5	-0.34	3.77e-13	Diastolic blood pressure;
LUAD	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg04731861	chr2:219085781	ARPC2	-0.22	-6.75	-0.31	4.83e-11	Colorectal cancer;
LUAD	cis	rs2880765	0.835	rs4340287	chr15:86043737	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.4	-0.3	4.17e-10	Coronary artery disease;
LUAD	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.82	-0.36	4.23e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs67072384	1.000	rs56693670	chr11:72445143	G/T	cg04827223	chr11:72435913	ARAP1	-0.62	-7.6	-0.35	1.96e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg00634984	chr7:65235879	NA	0.47	7.63	0.35	1.56e-13	Calcium levels;
LUAD	cis	rs9948	1.000	rs72811623	chr2:97496473	C/T	cg20312557	chr2:97357134	FER1L5	-0.6	-6.91	-0.32	1.75e-11	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs10392	0.543	rs58414555	chr20:37554152	A/C	cg27552599	chr20:37590471	DHX35	0.38	6.5	0.3	2.24e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg07212818	chr11:638076	DRD4	-0.45	-6.73	-0.31	5.64e-11	Systemic lupus erythematosus;
LUAD	trans	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.81	-0.31	3.33e-11	Diabetic kidney disease;
LUAD	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg19077165	chr18:44547161	KATNAL2	0.39	6.83	0.32	2.89e-11	Personality dimensions;
LUAD	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg23933602	chr10:16859644	RSU1	0.6	8.36	0.38	9.32e-16	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs3106136	0.967	rs35670996	chr4:95199479	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.78	-0.35	5.47e-14	Capecitabine sensitivity;
LUAD	cis	rs12765878	0.729	rs12573103	chr10:105639241	A/G	cg11005552	chr10:105648138	OBFC1	0.44	8.26	0.37	1.82e-15	Coronary artery disease;
LUAD	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg00684032	chr4:1343700	KIAA1530	0.41	6.8	0.31	3.54e-11	Obesity-related traits;
LUAD	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg09640425	chr7:158790006	NA	0.52	6.71	0.31	6.24e-11	Facial morphology (factor 20);
LUAD	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg15133208	chr4:90757351	SNCA	-0.46	-6.81	-0.31	3.26e-11	Neuroticism;
LUAD	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.04	0.32	7.98e-12	Colorectal cancer;
LUAD	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg26384229	chr12:38710491	ALG10B	0.48	7.8	0.35	4.88e-14	Bladder cancer;
LUAD	cis	rs7264396	0.836	rs41293080	chr20:34187697	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-6.7	-0.31	6.76e-11	Total cholesterol levels;
LUAD	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg13334819	chr7:99746414	C7orf59	-0.67	-10.35	-0.45	1.58e-22	Coronary artery disease;
LUAD	trans	rs6897795	0.680	rs9329137	chr5:177616370	C/T	cg19598605	chr2:70056955	GMCL1	-0.59	-7.95	-0.36	1.67e-14	Plateletcrit;
LUAD	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg04450456	chr4:17643702	FAM184B	0.41	8.19	0.37	3.16e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg27068330	chr11:65405492	SIPA1	0.54	8.6	0.39	1.6e-16	Acne (severe);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16756419	chr11:6704627	MRPL17	-0.55	-6.73	-0.31	5.66e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg08280861	chr8:58055591	NA	0.55	7.1	0.33	5.42e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6684514	1.000	rs12023438	chr1:156254358	A/G	cg16558208	chr1:156270281	VHLL	0.53	9.58	0.42	8.12e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg11189052	chr15:85197271	WDR73	-0.62	-10.4	-0.45	1.01e-22	P wave terminal force;
LUAD	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg19163074	chr7:65112434	INTS4L2	0.44	6.75	0.31	5.04e-11	Aortic root size;
LUAD	trans	rs12517041	1.000	rs10074124	chr5:23318235	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.73	-0.31	5.37e-11	Calcium levels;
LUAD	cis	rs739496	0.579	rs4767068	chr12:112281013	A/G	cg10833066	chr12:111807467	FAM109A	0.44	7.32	0.34	1.27e-12	Platelet count;
LUAD	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg07169764	chr2:136633963	MCM6	0.8	9.06	0.4	4.9e-18	Corneal structure;
LUAD	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.56	0.3	1.55e-10	Menarche (age at onset);
LUAD	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg00634984	chr7:65235879	NA	-0.47	-6.46	-0.3	2.81e-10	Aortic root size;
LUAD	cis	rs3806933	0.522	rs12521169	chr5:110448313	G/A	cg04450332	chr5:110408780	TSLP	0.35	6.71	0.31	6.22e-11	Eosinophilic esophagitis;
LUAD	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg11166453	chr1:247681781	NA	0.41	8.36	0.38	9.04e-16	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs897984	0.762	rs2305880	chr16:30999462	T/C	cg02466173	chr16:30829666	NA	0.66	12.07	0.51	5.01e-29	Dementia with Lewy bodies;
LUAD	cis	rs1232027	0.656	rs1650682	chr5:79957931	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.01	-0.32	9.29e-12	Huntington's disease progression;
LUAD	cis	rs6474412	1.000	rs4736835	chr8:42547033	T/C	cg25026480	chr8:42547641	NA	0.36	6.37	0.3	4.83e-10	Smoking behavior;
LUAD	cis	rs2242073	0.668	rs111279488	chr2:209026022	A/C	cg06181187	chr2:209010896	CRYGB	0.45	7.12	0.33	4.78e-12	Attention deficit hyperactivity disorder;
LUAD	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	10.12	0.44	1.09e-21	Breast cancer;
LUAD	cis	rs7617773	0.743	rs13071960	chr3:48367537	A/G	cg11946769	chr3:48343235	NME6	0.45	6.89	0.32	2.05e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg07917127	chr4:99064746	C4orf37	0.41	6.84	0.32	2.87e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg05805236	chr11:65401703	PCNXL3	-0.61	-9.8	-0.43	1.48e-20	Acne (severe);
LUAD	cis	rs4588572	0.644	rs10942856	chr5:77746199	A/G	cg11547950	chr5:77652471	NA	0.62	10.52	0.46	3.88e-23	Triglycerides;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg25649203	chr7:42971699	MRPL32;PSMA2	0.43	6.85	0.32	2.58e-11	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.54	-9.34	-0.41	5.38e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06873352	chr17:61820015	STRADA	0.83	18.53	0.67	1.56e-56	Prudent dietary pattern;
LUAD	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg01299579	chr2:10830716	NOL10	0.44	7.87	0.36	3.01e-14	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.46	0.3	2.97e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg08859206	chr1:53392774	SCP2	0.63	11.73	0.5	1.01e-27	Monocyte count;
LUAD	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg06505273	chr16:24850292	NA	-0.44	-6.47	-0.3	2.69e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.65	-0.31	9.09e-11	Mood instability;
LUAD	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg26022315	chr17:47021804	SNF8	0.4	7.27	0.33	1.77e-12	Type 2 diabetes;
LUAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg13047869	chr3:10149882	C3orf24	0.6	10.03	0.44	2.24e-21	Alzheimer's disease;
LUAD	trans	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg21659725	chr3:3221576	CRBN	-0.61	-9.94	-0.44	4.52e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05901451	chr6:126070800	HEY2	-0.44	-6.63	-0.31	1.03e-10	Endometrial cancer;
LUAD	trans	rs9951602	0.512	rs8084836	chr18:76647841	A/G	cg02800362	chr5:177631904	HNRNPAB	0.9	13.8	0.56	4.93e-36	Obesity-related traits;
LUAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg21427119	chr20:30132790	HM13	-0.5	-7.8	-0.35	4.72e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs10193935	1.000	rs13391906	chr2:42538617	C/G	cg27598129	chr2:42591480	NA	-0.81	-9.97	-0.44	3.48e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-7.45	-0.34	5.2e-13	Alzheimer's disease (late onset);
LUAD	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg06138931	chr13:21896616	NA	0.49	6.75	0.31	4.84e-11	White matter hyperintensity burden;
LUAD	cis	rs10911363	0.573	rs2702181	chr1:183516985	T/A	cg09173681	chr1:183549694	NCF2	0.58	10.86	0.47	2.14e-24	Systemic lupus erythematosus;
LUAD	cis	rs877282	0.898	rs11253344	chr10:765162	C/T	cg17470449	chr10:769945	NA	0.63	9.0	0.4	7.54e-18	Uric acid levels;
LUAD	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg00631329	chr6:26305371	NA	0.45	7.57	0.35	2.32e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg21775007	chr8:11205619	TDH	0.37	6.42	0.3	3.6e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	trans	rs1493916	0.870	rs8097667	chr18:31387003	C/T	cg27147174	chr7:100797783	AP1S1	-0.69	-12.46	-0.52	1.39e-30	Life satisfaction;
LUAD	cis	rs7043114	0.525	rs10739927	chr9:95052081	G/T	cg14631576	chr9:95140430	CENPP	-0.42	-8.45	-0.38	4.8e-16	Height;
LUAD	cis	rs9283706	0.608	rs1991492	chr5:66328309	A/G	cg11590213	chr5:66331682	MAST4	0.41	6.73	0.31	5.54e-11	Coronary artery disease;
LUAD	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg03806693	chr22:41940476	POLR3H	-0.78	-11.01	-0.47	5.6e-25	Vitiligo;
LUAD	cis	rs8077889	0.956	rs116979403	chr17:41849105	G/A	cg26893861	chr17:41843967	DUSP3	0.95	14.39	0.57	1.68e-38	Triglycerides;
LUAD	cis	rs4774899	0.752	rs7168387	chr15:57398934	C/T	cg14026238	chr15:57616123	NA	-0.43	-8.12	-0.37	5.22e-15	Urinary tract infection frequency;
LUAD	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg04450456	chr4:17643702	FAM184B	0.42	8.31	0.37	1.28e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg24558204	chr6:135376177	HBS1L	0.46	8.18	0.37	3.31e-15	Red blood cell count;
LUAD	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.5	-7.95	-0.36	1.72e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg12564285	chr5:131593104	PDLIM4	0.39	7.39	0.34	7.84e-13	Acylcarnitine levels;
LUAD	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg17761419	chr8:57350749	NA	-0.52	-7.86	-0.36	3.16e-14	Obesity-related traits;
LUAD	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg22676075	chr6:135203613	NA	0.42	7.79	0.35	5.41e-14	Reticulocyte count;High light scatter reticulocyte count;
LUAD	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg09365446	chr1:150670422	GOLPH3L	0.54	9.57	0.42	8.7e-20	Melanoma;
LUAD	cis	rs939658	1.000	rs4778935	chr15:79453282	T/C	cg17916960	chr15:79447300	NA	0.46	9.35	0.41	5.3e-19	Refractive error;
LUAD	cis	rs10979	0.964	rs9321922	chr6:143895231	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.28	-0.45	2.77e-22	Hypospadias;
LUAD	cis	rs12949688	0.870	rs9906591	chr17:55816832	T/C	cg12582317	chr17:55822272	NA	0.36	7.33	0.34	1.18e-12	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg18932078	chr1:2524107	MMEL1	0.39	7.22	0.33	2.41e-12	Ulcerative colitis;
LUAD	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg02428538	chr16:24856791	SLC5A11	0.62	9.0	0.4	7.76e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs240764	0.658	rs35967345	chr6:101187858	T/G	cg09795085	chr6:101329169	ASCC3	-0.48	-8.55	-0.38	2.24e-16	Neuroticism;
LUAD	cis	rs10499694	0.933	rs11575334	chr7:50597301	G/A	cg18232548	chr7:50535776	DDC	-0.44	-7.48	-0.34	4.48e-13	Body mass index;
LUAD	cis	rs7771547	0.573	rs9470274	chr6:36397229	G/A	cg07856975	chr6:36356162	ETV7	0.49	7.77	0.35	6.21e-14	Platelet distribution width;
LUAD	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg21427119	chr20:30132790	HM13	-0.59	-8.73	-0.39	5.84e-17	Mean corpuscular hemoglobin;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11058696	chr20:16711094	SNRPB2	-0.41	-6.72	-0.31	5.81e-11	Cancer;
LUAD	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.37	7.57	0.35	2.33e-13	Obesity-related traits;
LUAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg10729496	chr3:10149963	C3orf24	0.6	10.05	0.44	1.82e-21	Alzheimer's disease;
LUAD	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg03560586	chr2:239334908	ASB1	-0.31	-6.62	-0.31	1.06e-10	Multiple system atrophy;
LUAD	cis	rs9487051	0.735	rs419106	chr6:109520067	C/G	cg12927641	chr6:109611667	NA	-0.36	-6.36	-0.3	5.16e-10	Reticulocyte fraction of red cells;
LUAD	trans	rs2898857	0.545	rs12602382	chr17:47356805	C/A	cg11430096	chr6:110968061	CDK19	0.53	8.19	0.37	3.04e-15	Cancer;
LUAD	trans	rs11039798	0.610	rs11530356	chr11:48836290	C/A	cg03929089	chr4:120376271	NA	0.6	6.83	0.32	2.88e-11	Axial length;
LUAD	cis	rs208520	0.837	rs208488	chr6:66926902	C/T	cg07460842	chr6:66804631	NA	-0.96	-13.69	-0.55	1.4e-35	Exhaled nitric oxide output;
LUAD	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg10802521	chr3:52805072	NEK4	-0.48	-8.11	-0.37	5.36e-15	Bipolar disorder;
LUAD	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21385522	chr1:16154831	NA	-0.58	-8.88	-0.4	1.93e-17	Dilated cardiomyopathy;
LUAD	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg13319975	chr6:146136371	FBXO30	0.83	14.11	0.57	2.59e-37	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg25767906	chr1:53392781	SCP2	-0.42	-7.6	-0.35	1.93e-13	Monocyte count;
LUAD	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg00933542	chr6:150070202	PCMT1	0.43	9.18	0.41	1.91e-18	Lung cancer;
LUAD	cis	rs367943	0.666	rs6594703	chr5:112691999	A/G	cg12552261	chr5:112820674	MCC	0.47	9.26	0.41	1.01e-18	Type 2 diabetes;
LUAD	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg02527881	chr3:46936655	PTH1R	-0.54	-11.18	-0.48	1.34e-25	Colorectal cancer;
LUAD	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg17173187	chr15:85201210	NMB	0.48	8.42	0.38	6.05e-16	Schizophrenia;
LUAD	trans	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.47	-0.3	2.7e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.57	-0.49	4.54e-27	Primary sclerosing cholangitis;
LUAD	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg18230493	chr5:56204884	C5orf35	-0.85	-12.54	-0.52	6.65e-31	Initial pursuit acceleration;
LUAD	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.98	0.36	1.42e-14	Parkinson's disease;
LUAD	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg04111992	chr7:158790115	NA	0.5	8.7	0.39	7.34e-17	Facial morphology (factor 20);
LUAD	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.32	6.94	0.32	1.47e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6484504	0.512	rs7940020	chr11:31366453	T/G	cg06552810	chr11:31128660	NA	0.32	6.37	0.3	4.81e-10	Red blood cell count;
LUAD	cis	rs6456156	0.875	rs55802221	chr6:167517320	G/A	cg07741184	chr6:167504864	NA	-0.28	-6.41	-0.3	3.83e-10	Primary biliary cholangitis;
LUAD	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg06387496	chr7:2775674	GNA12	-0.38	-6.53	-0.3	1.89e-10	Height;
LUAD	trans	rs11039798	0.920	rs11500574	chr11:48713986	A/T	cg03929089	chr4:120376271	NA	0.6	6.9	0.32	1.89e-11	Axial length;
LUAD	cis	rs72928364	0.932	rs2595894	chr3:100677882	G/C	cg10123952	chr3:100791384	NA	-0.54	-6.74	-0.31	5.33e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg22963979	chr7:1858916	MAD1L1	-0.64	-10.9	-0.47	1.46e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25427524	chr10:38739819	LOC399744	-0.72	-13.32	-0.54	4.61e-34	Extrinsic epigenetic age acceleration;
LUAD	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg15704280	chr7:45808275	SEPT13	0.64	8.59	0.39	1.7e-16	Axial length;
LUAD	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.44	-8.05	-0.36	8.53e-15	Cystic fibrosis severity;
LUAD	cis	rs367615	0.552	rs2963025	chr5:108733256	A/C	cg17395555	chr5:108820864	NA	-0.47	-9.01	-0.4	7.1e-18	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg07936489	chr17:37558343	FBXL20	0.45	7.15	0.33	3.88e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs11809207	0.723	rs57653638	chr1:26524401	A/G	cg00300879	chr1:26503847	CNKSR1	0.28	6.94	0.32	1.49e-11	Height;
LUAD	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg14186256	chr22:23484241	RTDR1	0.46	7.88	0.36	2.71e-14	Bone mineral density;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11053546	chr10:12110665	DHTKD1	-0.43	-7.14	-0.33	4.06e-12	Cancer;
LUAD	cis	rs11971779	0.680	rs11760420	chr7:139114768	C/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.35	-0.3	5.53e-10	Diisocyanate-induced asthma;
LUAD	trans	rs58106596	0.800	rs28883318	chr2:232562935	G/A	cg01370599	chr3:116745421	NA	0.59	8.54	0.38	2.37e-16	White blood cell count;Lymphocyte counts;
LUAD	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.57	-9.78	-0.43	1.69e-20	Menarche (age at onset);
LUAD	cis	rs72949976	0.584	rs13001511	chr2:214025262	G/A	cg08319019	chr2:214017104	IKZF2	0.58	9.03	0.4	6.34e-18	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs67311347	1.000	rs67311347	chr3:40533243	G/A	cg09455208	chr3:40491958	NA	0.53	10.92	0.47	1.32e-24	Renal cell carcinoma;
LUAD	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg21427119	chr20:30132790	HM13	-0.49	-7.41	-0.34	7.06e-13	Mean corpuscular hemoglobin;
LUAD	trans	rs2262909	1.000	rs2078089	chr19:22209753	A/T	cg17074339	chr11:11642133	GALNTL4	-0.43	-6.81	-0.31	3.42e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.55	0.3	1.7e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.53	-0.34	3.11e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg12656391	chr1:43425156	SLC2A1	-0.31	-6.47	-0.3	2.76e-10	Red cell distribution width;
LUAD	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg22532475	chr10:104410764	TRIM8	-0.45	-8.83	-0.39	2.7e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg00484396	chr16:3507460	NAT15	-0.71	-13.12	-0.54	3.24e-33	Tuberculosis;
LUAD	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg16647868	chr5:131706066	SLC22A5	-0.41	-6.84	-0.32	2.86e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg06713675	chr4:122721982	EXOSC9	0.46	8.45	0.38	4.71e-16	Type 2 diabetes;
LUAD	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg21385522	chr1:16154831	NA	0.56	8.97	0.4	9.87e-18	Systolic blood pressure;
LUAD	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg23992470	chr4:843637	GAK	0.67	7.36	0.34	9.39e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg15110403	chr19:17392923	ANKLE1	-0.48	-7.82	-0.36	4.26e-14	Systemic lupus erythematosus;
LUAD	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg11416102	chr8:651193	ERICH1	0.78	7.95	0.36	1.69e-14	IgG glycosylation;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26141063	chr18:32870200	ZNF271;ZNF397OS	-0.66	-6.52	-0.3	1.98e-10	Type 2 diabetes;
LUAD	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg20891283	chr12:69753455	YEATS4	0.46	7.44	0.34	5.68e-13	Blood protein levels;
LUAD	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg14834391	chr1:2537342	MMEL1	-0.31	-6.46	-0.3	2.83e-10	Ulcerative colitis;
LUAD	cis	rs11756438	0.572	rs2638544	chr6:119001978	G/A	cg21191810	chr6:118973309	C6orf204	0.5	9.59	0.42	7.77e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg25251562	chr2:3704773	ALLC	0.57	9.68	0.43	3.62e-20	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs3087591	0.960	rs12943508	chr17:29599954	C/G	cg24425628	chr17:29625626	OMG;NF1	0.42	6.76	0.31	4.55e-11	Hip circumference;
LUAD	trans	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg16724585	chr3:197361211	NA	-0.52	-7.8	-0.35	4.93e-14	Pancreatic cancer;
LUAD	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg22823121	chr1:150693482	HORMAD1	0.41	7.97	0.36	1.48e-14	Melanoma;
LUAD	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg01324343	chr3:183735012	ABCC5	0.64	12.03	0.5	7.16e-29	Anterior chamber depth;
LUAD	trans	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21659725	chr3:3221576	CRBN	-0.5	-8.35	-0.38	1e-15	Body mass index;
LUAD	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	9.05	0.4	5.42e-18	Hip circumference adjusted for BMI;
LUAD	cis	rs1448094	0.617	rs4842569	chr12:86468609	T/G	cg19622623	chr12:86230825	RASSF9	0.4	7.2	0.33	2.7e-12	Major depressive disorder;
LUAD	trans	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.16	0.54	2.23e-33	Exhaled nitric oxide output;
LUAD	cis	rs62103177	0.525	rs1835410	chr18:77702025	T/C	cg20368463	chr18:77673604	PQLC1	-0.53	-6.72	-0.31	5.99e-11	Opioid sensitivity;
LUAD	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg20675196	chr20:2854059	PTPRA	-0.38	-6.52	-0.3	2.03e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg02782426	chr3:40428986	ENTPD3	0.43	9.15	0.41	2.39e-18	Renal cell carcinoma;
LUAD	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg12034118	chr1:209979487	IRF6	0.56	7.46	0.34	4.87e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs11971779	0.590	rs6944104	chr7:139051120	T/A	cg23387468	chr7:139079360	LUC7L2	0.28	6.49	0.3	2.47e-10	Diisocyanate-induced asthma;
LUAD	cis	rs7107174	1.000	rs1485483	chr11:77930138	T/C	cg02023728	chr11:77925099	USP35	0.59	8.78	0.39	4.16e-17	Testicular germ cell tumor;
LUAD	cis	rs2386661	0.826	rs2386651	chr10:5678031	C/A	cg26603656	chr10:5671107	NA	0.43	7.22	0.33	2.44e-12	Breast cancer;
LUAD	cis	rs72772090	0.634	rs12186366	chr5:96088850	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-7.99	-0.36	1.27e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg15468180	chr1:107600409	PRMT6	0.41	6.64	0.31	9.82e-11	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	11.79	0.5	6.08e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02895995	chr19:7554069	PEX11G	0.39	6.57	0.3	1.5e-10	Bilirubin levels;
LUAD	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg10560079	chr2:191398806	TMEM194B	0.44	8.0	0.36	1.21e-14	Pulse pressure;
LUAD	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg06532163	chr17:45867833	NA	0.47	8.52	0.38	2.87e-16	IgG glycosylation;
LUAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg18402987	chr7:1209562	NA	0.64	9.29	0.41	7.98e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13315871	1.000	rs28417694	chr3:58373939	A/G	cg12435725	chr3:58293450	RPP14	-0.67	-7.31	-0.33	1.36e-12	Cholesterol, total;
LUAD	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.55	0.3	1.63e-10	Depression;
LUAD	cis	rs13315871	1.000	rs13060489	chr3:58339287	G/A	cg12435725	chr3:58293450	RPP14	-0.71	-7.71	-0.35	9.08e-14	Cholesterol, total;
LUAD	cis	rs7000551	0.689	rs2469753	chr8:22383225	T/C	cg12081754	chr8:22256438	SLC39A14	0.42	6.82	0.31	3.12e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg02428538	chr16:24856791	SLC5A11	-0.51	-7.15	-0.33	3.75e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25427524	chr10:38739819	LOC399744	-0.7	-12.55	-0.52	6.5e-31	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2425143	1.000	rs6060578	chr20:34305445	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.36	-0.34	9.53e-13	Blood protein levels;
LUAD	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4900538	0.927	rs8005804	chr14:102957803	A/G	cg18135206	chr14:102964638	TECPR2	1.07	24.36	0.76	1.48e-82	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg07460842	chr6:66804631	NA	1.06	16.76	0.63	1.03e-48	Exhaled nitric oxide output;
LUAD	cis	rs2629540	0.737	rs10901821	chr10:126480556	T/C	cg08799069	chr10:126477246	METTL10	-0.41	-6.57	-0.3	1.51e-10	Cocaine dependence;
LUAD	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg15704280	chr7:45808275	SEPT13	-0.69	-11.05	-0.47	4.28e-25	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	8.37	0.38	8.78e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11644478	chr21:40555479	PSMG1	-0.54	-8.74	-0.39	5.4e-17	Cognitive function;
LUAD	cis	rs2425143	0.643	rs6058324	chr20:34388789	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.06	-0.32	6.65e-12	Blood protein levels;
LUAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg00280220	chr17:61926910	NA	0.37	7.21	0.33	2.62e-12	Prudent dietary pattern;
LUAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg12419862	chr22:24373484	LOC391322	0.67	11.38	0.48	2.32e-26	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg11584989	chr19:19387371	SF4	0.36	6.61	0.31	1.17e-10	Tonsillectomy;
LUAD	cis	rs4953076	0.573	rs7595470	chr2:44402467	A/G	cg04920474	chr2:44395004	PPM1B	0.54	8.5	0.38	3.26e-16	Height;
LUAD	trans	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.58	-0.35	2.14e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.09e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg05434287	chr7:2030229	MAD1L1	0.43	6.98	0.32	1.12e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15541040	chr2:3486749	NA	-0.44	-7.86	-0.36	3.13e-14	Neurofibrillary tangles;
LUAD	cis	rs977987	0.843	rs4888415	chr16:75448921	C/T	cg03315344	chr16:75512273	CHST6	0.62	13.6	0.55	3.21e-35	Dupuytren's disease;
LUAD	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg12140854	chr5:148520817	ABLIM3	-0.6	-10.09	-0.44	1.32e-21	Breast cancer;
LUAD	cis	rs7107174	1.000	rs10899476	chr11:78051794	A/G	cg02023728	chr11:77925099	USP35	0.43	6.76	0.31	4.53e-11	Testicular germ cell tumor;
LUAD	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg06108461	chr20:60628389	TAF4	-1.11	-20.19	-0.7	5.7e-64	Body mass index;
LUAD	cis	rs13223928	0.572	rs12538887	chr7:3134821	G/A	cg19214707	chr7:3157722	NA	-0.46	-7.94	-0.36	1.8e-14	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg24818145	chr4:99064322	C4orf37	0.47	7.91	0.36	2.32e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	11.54	0.49	5.56e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7818345	0.967	rs6992893	chr8:19287504	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.84	0.32	2.78e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg07741184	chr6:167504864	NA	-0.3	-7.12	-0.33	4.53e-12	Crohn's disease;
LUAD	trans	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg21582582	chr3:182698605	DCUN1D1	0.39	6.48	0.3	2.54e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg15181151	chr6:150070149	PCMT1	0.4	8.24	0.37	2.12e-15	Lung cancer;
LUAD	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg17264618	chr3:40429014	ENTPD3	-0.39	-8.58	-0.39	1.79e-16	Renal cell carcinoma;
LUAD	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg07828340	chr4:882639	GAK	0.98	10.01	0.44	2.6e-21	Parkinson's disease;
LUAD	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg10589385	chr1:150898437	SETDB1	0.45	8.44	0.38	5.11e-16	Melanoma;
LUAD	trans	rs1864729	1.000	rs1835743	chr8:98282643	T/C	cg08679828	chr8:102218111	ZNF706	-0.83	-8.79	-0.39	3.88e-17	Estradiol plasma levels (breast cancer);
LUAD	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg15448220	chr1:150897856	SETDB1	0.46	7.97	0.36	1.47e-14	Tonsillectomy;
LUAD	cis	rs7187994	0.848	rs7498516	chr16:84774452	A/G	cg07647771	chr16:84786436	USP10	0.35	7.83	0.36	3.88e-14	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg09436375	chr6:42928200	GNMT	-0.28	-7.98	-0.36	1.43e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.1	0.33	5.39e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs9341808	0.667	rs7746917	chr6:80931503	T/C	cg08355045	chr6:80787529	NA	0.48	8.61	0.39	1.5e-16	Sitting height ratio;
LUAD	cis	rs13064411	0.735	rs7631138	chr3:113231925	A/T	cg10517650	chr3:113235015	CCDC52	-0.56	-9.65	-0.42	4.76e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg08601574	chr20:25228251	PYGB	-0.43	-8.09	-0.37	6.56e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg21450137	chr2:25016479	C2orf79;CENPO	-0.42	-6.43	-0.3	3.37e-10	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg05717871	chr11:638507	DRD4	-0.41	-6.45	-0.3	3.12e-10	Systemic lupus erythematosus;
LUAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14159672	chr1:205819179	PM20D1	0.78	15.61	0.6	1.02e-43	Menarche (age at onset);
LUAD	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg26513180	chr16:89883248	FANCA	0.49	8.38	0.38	7.75e-16	Vitiligo;
LUAD	cis	rs2637266	1.000	rs1907298	chr10:78329928	A/T	cg18941641	chr10:78392320	NA	0.32	6.6	0.31	1.25e-10	Pulmonary function;
LUAD	cis	rs1953600	0.837	rs3098105	chr10:81953266	C/T	cg00277334	chr10:82204260	NA	0.42	7.18	0.33	3.19e-12	Sarcoidosis;
LUAD	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg09904177	chr6:26538194	HMGN4	0.44	7.31	0.34	1.31e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg08132940	chr7:1081526	C7orf50	-0.62	-6.51	-0.3	2.07e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg17173187	chr15:85201210	NMB	0.48	8.52	0.38	2.92e-16	Schizophrenia;
LUAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg24813613	chr7:1882135	MAD1L1	-0.55	-8.59	-0.39	1.65e-16	Bipolar disorder and schizophrenia;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg20684973	chr10:105127632	TAF5	-0.38	-6.57	-0.3	1.53e-10	Subcortical brain region volumes;
LUAD	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg06191203	chr2:152266755	RIF1	-0.57	-8.37	-0.38	8.72e-16	Lung cancer;
LUAD	trans	rs9467711	1.000	rs1883215	chr6:26314233	G/C	cg06606381	chr12:133084897	FBRSL1	-0.61	-6.42	-0.3	3.74e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg18512352	chr11:47633146	NA	-0.47	-8.03	-0.36	9.8e-15	Subjective well-being;
LUAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg05457628	chr5:178986728	RUFY1	0.67	11.74	0.5	9.47e-28	Lung cancer;
LUAD	cis	rs78707713	0.512	rs35793747	chr10:71182165	A/G	cg12610070	chr10:71211762	TSPAN15	-0.4	-10.05	-0.44	1.89e-21	Venous thromboembolism;
LUAD	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.62	-0.39	1.31e-16	Alzheimer's disease (late onset);
LUAD	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18876405	chr7:65276391	NA	0.44	6.94	0.32	1.47e-11	Aortic root size;
LUAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg11766577	chr21:47581405	C21orf56	0.64	11.71	0.49	1.28e-27	Testicular germ cell tumor;
LUAD	cis	rs6445967	0.569	rs12054183	chr3:58287533	C/T	cg13750441	chr3:58318267	PXK	-0.3	-6.4	-0.3	4.19e-10	Platelet count;
LUAD	cis	rs4321325	0.733	rs75834205	chr2:127947237	G/T	cg11380483	chr2:127933992	NA	0.5	6.49	0.3	2.45e-10	Protein C levels;
LUAD	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg08798685	chr6:27730294	NA	-0.66	-7.1	-0.33	5.26e-12	Breast cancer;
LUAD	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg00310523	chr12:86230176	RASSF9	-0.39	-7.98	-0.36	1.43e-14	Major depressive disorder;
LUAD	cis	rs887829	0.569	rs10179091	chr2:234657983	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-9.41	-0.42	3.24e-19	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.37	-6.74	-0.31	5.3e-11	Parkinson's disease;
LUAD	cis	rs4243830	1.000	rs11809957	chr1:6584420	C/A	cg04093404	chr1:6614507	TAS1R1;NOL9	0.73	8.17	0.37	3.71e-15	Body mass index;
LUAD	cis	rs7084921	0.549	rs9888058	chr10:101859205	C/T	cg02250046	chr10:101825185	CPN1	-0.34	-6.71	-0.31	6.08e-11	Bone mineral density;
LUAD	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.38	6.65	0.31	9.14e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.64	-11.8	-0.5	5.81e-28	Prudent dietary pattern;
LUAD	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg13722127	chr7:150037890	RARRES2	0.44	7.64	0.35	1.43e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6087990	0.735	rs6119946	chr20:31329704	A/G	cg13636640	chr20:31349939	DNMT3B	-0.73	-12.73	-0.53	1.19e-31	Ulcerative colitis;
LUAD	cis	rs8067287	0.595	rs62065423	chr17:16828571	C/T	cg26910001	chr17:16838321	NA	-0.49	-6.9	-0.32	1.91e-11	Diabetic kidney disease;
LUAD	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.61	-10.48	-0.45	5.34e-23	Cognitive ability;
LUAD	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg27284194	chr4:1044797	NA	0.67	9.73	0.43	2.62e-20	Recombination rate (females);
LUAD	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg17191109	chr10:126851326	NA	0.33	6.43	0.3	3.51e-10	Menarche (age at onset);
LUAD	cis	rs7264396	0.790	rs8125090	chr20:34360015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-7.66	-0.35	1.28e-13	Total cholesterol levels;
LUAD	cis	rs7301016	0.846	rs11174575	chr12:63026392	G/A	cg11441379	chr12:63026424	NA	0.62	7.41	0.34	6.8e-13	IgG glycosylation;
LUAD	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	6.36	0.3	5.3e-10	Menarche (age at onset);
LUAD	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg10356904	chr22:49881777	NA	0.33	6.93	0.32	1.59e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg26554054	chr8:600488	NA	0.79	7.5	0.34	3.83e-13	IgG glycosylation;
LUAD	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.33	0.34	1.18e-12	Menopause (age at onset);
LUAD	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg17810781	chr1:201082982	CACNA1S	-0.36	-6.59	-0.31	1.28e-10	Permanent tooth development;
LUAD	cis	rs11229555	0.609	rs7128459	chr11:58179291	C/T	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg22907277	chr7:1156413	C7orf50	0.68	7.97	0.36	1.49e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs868036	0.645	rs4492996	chr15:68113240	A/G	cg24579218	chr15:68104479	NA	-0.56	-9.73	-0.43	2.53e-20	Restless legs syndrome;
LUAD	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg04756594	chr16:24857601	SLC5A11	-0.73	-12.56	-0.52	5.85e-31	Intelligence (multi-trait analysis);
LUAD	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg06766960	chr11:133703094	NA	-0.45	-8.47	-0.38	4.09e-16	Childhood ear infection;
LUAD	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg25456477	chr12:86230367	RASSF9	0.33	6.86	0.32	2.44e-11	Major depressive disorder;
LUAD	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-9.6	-0.42	7.04e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7572644	0.699	rs1458396	chr2:28136351	A/G	cg27432699	chr2:27873401	GPN1	-0.42	-6.54	-0.3	1.73e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUAD	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg26898376	chr11:64110657	CCDC88B	0.38	7.14	0.33	3.98e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.48	-9.76	-0.43	1.97e-20	Monocyte percentage of white cells;
LUAD	cis	rs7680126	0.632	rs6834645	chr4:10150174	G/A	cg02734326	chr4:10020555	SLC2A9	-0.5	-6.69	-0.31	6.93e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	trans	rs225245	0.791	rs2285742	chr17:34018682	C/T	cg19694781	chr19:47549865	TMEM160	-0.47	-7.74	-0.35	7.51e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg26597838	chr10:835615	NA	0.97	15.33	0.6	1.6e-42	Eosinophil percentage of granulocytes;
LUAD	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs428668	0.681	rs192193	chr5:150692590	A/G	cg14086364	chr5:150678334	SLC36A3	0.35	6.63	0.31	1.05e-10	Skin aging (microtopography measurement);
LUAD	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg12698349	chr2:225449008	CUL3	0.85	16.95	0.64	1.53e-49	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs7771547	0.603	rs10947615	chr6:36599596	T/C	cg04289385	chr6:36355825	ETV7	0.49	6.54	0.3	1.74e-10	Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.6	0.52	4.03e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6076065	0.748	rs4142246	chr20:23388975	A/G	cg11657817	chr20:23433608	CST11	0.57	11.92	0.5	1.99e-28	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg26022315	chr17:47021804	SNF8	0.4	7.29	0.33	1.57e-12	Type 2 diabetes;
LUAD	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg08213375	chr14:104286397	PPP1R13B	0.26	6.84	0.32	2.82e-11	Schizophrenia;
LUAD	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg22823121	chr1:150693482	HORMAD1	-0.36	-6.91	-0.32	1.83e-11	Tonsillectomy;
LUAD	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg10556349	chr10:835070	NA	0.58	7.44	0.34	5.71e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.4	-0.3	4.09e-10	Alzheimer's disease (late onset);
LUAD	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg07741184	chr6:167504864	NA	-0.3	-7.14	-0.33	4.02e-12	Crohn's disease;
LUAD	cis	rs853679	0.585	rs201000	chr6:27809159	C/T	cg20933634	chr6:27740509	NA	0.51	7.6	0.35	1.96e-13	Depression;
LUAD	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg11266682	chr4:10021025	SLC2A9	0.44	8.2	0.37	2.94e-15	Blood metabolite levels;
LUAD	trans	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg04565464	chr8:145669602	NFKBIL2	0.44	6.64	0.31	9.41e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg08470875	chr2:26401718	FAM59B	-0.77	-10.37	-0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg17863274	chr19:49399704	TULP2	-0.53	-7.56	-0.35	2.51e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7192380	0.965	rs7205551	chr16:69605968	G/A	cg26679644	chr16:69762563	NA	0.49	9.42	0.42	2.97e-19	Sjögren's syndrome;
LUAD	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg20848291	chr7:100343083	ZAN	-0.58	-7.88	-0.36	2.82e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7192380	0.895	rs2917670	chr16:69758963	T/C	cg00738113	chr16:70207722	CLEC18C	0.35	6.94	0.32	1.49e-11	Sjögren's syndrome;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25201980	chr8:146127417	ZNF250	-0.45	-7.09	-0.33	5.76e-12	Height;
LUAD	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs2692947	0.732	rs56847058	chr2:96406893	C/T	cg23100626	chr2:96804247	ASTL	0.32	7.71	0.35	9.34e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22307029	chr19:49891270	CCDC155	0.69	9.88	0.43	7.42e-21	Multiple sclerosis;
LUAD	cis	rs6669919	0.967	rs11119752	chr1:211675765	A/G	cg10512769	chr1:211675356	NA	-0.34	-7.37	-0.34	8.93e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs494562	0.892	rs575477	chr6:86118064	A/G	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg02951883	chr7:2050386	MAD1L1	-0.81	-14.05	-0.56	4.44e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23583168	chr7:148888333	NA	-0.93	-19.3	-0.68	5.26e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg12160578	chr15:63334699	TPM1	0.36	6.67	0.31	7.78e-11	Platelet count;
LUAD	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg10792982	chr14:105748885	BRF1	0.4	8.71	0.39	7.17e-17	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg11214544	chr1:2391121	NA	-0.57	-11.1	-0.47	2.74e-25	Non-obstructive azoospermia;
LUAD	cis	rs1476679	0.962	rs34995835	chr7:99990364	T/G	cg19116668	chr7:99932089	PMS2L1	0.33	7.0	0.32	1.03e-11	Alzheimer's disease (late onset);
LUAD	cis	rs11195062	0.693	rs950232	chr10:111988373	C/T	cg19214408	chr10:111981687	MXI1	-0.45	-7.36	-0.34	9.7e-13	Multiple myeloma;
LUAD	trans	rs2262909	0.962	rs11667209	chr19:22259467	A/G	cg05197062	chr11:11642011	GALNTL4	0.59	9.14	0.41	2.61e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	trans	rs1493916	0.967	rs34341086	chr18:31400141	C/T	cg15819921	chr19:927150	ARID3A	-0.44	-7.07	-0.33	6.54e-12	Life satisfaction;
LUAD	cis	rs3125734	0.660	rs4979780	chr10:63992740	A/C	cg09941381	chr10:64027924	RTKN2	-0.3	-6.93	-0.32	1.53e-11	Rheumatoid arthritis;
LUAD	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.55	-0.3	1.72e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg13685833	chr1:53393034	SCP2	0.49	7.43	0.34	6.26e-13	Monocyte count;
LUAD	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg09491104	chr22:46646882	C22orf40	-0.5	-7.4	-0.34	7.26e-13	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01974100	chr14:45431075	FAM179B;KLHL28	-0.42	-7.02	-0.32	9.06e-12	Cancer;
LUAD	cis	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg07460842	chr6:66804631	NA	0.96	12.75	0.53	9.7e-32	Exhaled nitric oxide output;
LUAD	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg07404485	chr7:94953653	PON1	-0.51	-7.58	-0.35	2.27e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2573652	0.755	rs1469830	chr15:100517403	G/T	cg09918751	chr15:100517450	ADAMTS17	0.65	12.77	0.53	8.29e-32	Height;
LUAD	cis	rs56346965	0.967	rs11900804	chr2:191533767	T/C	cg11845111	chr2:191398756	TMEM194B	-0.46	-7.85	-0.36	3.45e-14	Bone mineral density (Ward's triangle area);
LUAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg24579218	chr15:68104479	NA	-0.56	-9.84	-0.43	1.01e-20	Restless legs syndrome;
LUAD	cis	rs7605378	1.000	rs2689766	chr2:200697539	A/T	cg17644776	chr2:200775616	C2orf69	0.48	7.49	0.34	4.18e-13	Osteoporosis;
LUAD	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg22535103	chr8:58192502	C8orf71	-0.59	-7.72	-0.35	8.2e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg26384229	chr12:38710491	ALG10B	0.39	6.64	0.31	9.56e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg01657329	chr11:68192670	LRP5	-0.44	-6.64	-0.31	9.78e-11	Total body bone mineral density;
LUAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11905131	chr22:24372483	LOC391322	-0.57	-9.67	-0.43	4.23e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.34e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21582582	chr3:182698605	DCUN1D1	0.6	9.7	0.43	3.32e-20	Resting heart rate;
LUAD	cis	rs4906332	1.000	rs4906332	chr14:103980134	A/T	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.0	-0.32	9.96e-12	Coronary artery disease;
LUAD	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg10591111	chr5:226296	SDHA	-0.55	-7.0	-0.32	1.04e-11	Breast cancer;
LUAD	trans	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg07817883	chr1:32538562	TMEM39B	1.38	12.0	0.5	9.11e-29	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17327406	chr4:6303265	WFS1	0.55	6.96	0.32	1.31e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7927771	0.524	rs3758655	chr11:47703943	T/C	cg18512352	chr11:47633146	NA	0.37	6.63	0.31	9.96e-11	Subjective well-being;
LUAD	cis	rs16866061	0.962	rs16825685	chr2:225434256	C/G	cg12698349	chr2:225449008	CUL3	0.78	13.83	0.56	3.78e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg21782813	chr7:2030301	MAD1L1	0.57	10.0	0.44	2.88e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg08999081	chr20:33150536	PIGU	-0.63	-14.31	-0.57	3.69e-38	Glomerular filtration rate (creatinine);
LUAD	cis	rs2040771	0.711	rs361639	chr22:19268024	A/G	cg02655711	chr22:19163373	SLC25A1	0.54	10.07	0.44	1.6e-21	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.76	16.32	0.62	8.8e-47	White blood cell count;
LUAD	trans	rs7246760	0.867	rs56307296	chr19:9744099	G/T	cg02900749	chr2:68251473	NA	-0.61	-6.62	-0.31	1.07e-10	Pursuit maintenance gain;
LUAD	trans	rs7899719	1.000	rs7073851	chr10:77417967	A/G	cg24786579	chr12:32832461	DNM1L	0.62	6.59	0.31	1.3100000000000001e-10	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length);
LUAD	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg11530693	chr1:120165357	ZNF697	0.86	18.75	0.67	1.62e-57	Systemic lupus erythematosus;
LUAD	cis	rs427941	0.632	rs201493	chr7:101754865	T/C	cg06246474	chr7:101738831	CUX1	0.38	6.64	0.31	9.76e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs12210905	0.614	rs72845006	chr6:27492958	G/A	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs10489202	0.632	rs202273	chr1:167919963	A/G	cg25738037	chr1:168025549	DCAF6	-0.46	-7.03	-0.32	8.45e-12	Schizophrenia;
LUAD	cis	rs9914544	0.545	rs9898426	chr17:18794071	A/G	cg25390199	chr17:18761479	PRPSAP2	-0.37	-6.43	-0.3	3.39e-10	Educational attainment (years of education);
LUAD	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.27	0.33	1.79e-12	Menopause (age at onset);
LUAD	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg16342193	chr10:102329863	NA	-0.36	-6.39	-0.3	4.28e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06028605	chr16:24865363	SLC5A11	0.52	7.93	0.36	1.99e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.21	0.33	2.6e-12	Menopause (age at onset);
LUAD	cis	rs6484504	0.553	rs413067	chr11:31223497	T/C	cg26647111	chr11:31128758	NA	-0.46	-8.24	-0.37	2.13e-15	Red blood cell count;
LUAD	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg13722127	chr7:150037890	RARRES2	0.47	8.38	0.38	7.87e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4389656	0.740	rs412643	chr5:6720715	A/G	cg10857441	chr5:6722123	POLS	-0.47	-8.1	-0.37	6e-15	Coronary artery disease;
LUAD	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.48	-0.38	3.82e-16	Height;
LUAD	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg24829409	chr8:58192753	C8orf71	-0.55	-6.53	-0.3	1.84e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4974559	0.947	rs10000797	chr4:1345647	G/A	cg07757535	chr4:1339547	NA	0.39	6.38	0.3	4.57e-10	Systolic blood pressure;
LUAD	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg26022315	chr17:47021804	SNF8	0.41	7.43	0.34	6.03e-13	Type 2 diabetes;
LUAD	cis	rs10504073	0.584	rs4873300	chr8:49902201	C/G	cg00325661	chr8:49890786	NA	0.48	10.54	0.46	3.16e-23	Blood metabolite ratios;
LUAD	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.57	-0.58	2.84e-39	Schizophrenia;
LUAD	cis	rs11169225	0.590	rs7305534	chr12:50341610	T/C	cg09002919	chr12:50339186	NA	0.44	7.04	0.32	7.85e-12	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg07404485	chr7:94953653	PON1	-0.5	-7.31	-0.33	1.36e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4853525	0.859	rs1894775	chr2:191716706	T/C	cg11845111	chr2:191398756	TMEM194B	-0.38	-6.47	-0.3	2.75e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg00814883	chr7:100076585	TSC22D4	-0.87	-13.12	-0.54	3.02e-33	Platelet count;
LUAD	cis	rs73198271	0.515	rs76620708	chr8:8619083	C/T	cg01851573	chr8:8652454	MFHAS1	0.59	7.44	0.34	5.82e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4919694	1.000	rs11191545	chr10:104829793	C/T	cg04362960	chr10:104952993	NT5C2	0.73	7.87	0.36	3.07e-14	Arsenic metabolism;
LUAD	cis	rs12579753	0.872	rs7956132	chr12:82178709	A/G	cg07988820	chr12:82153109	PPFIA2	-0.41	-6.72	-0.31	5.83e-11	Resting heart rate;
LUAD	cis	rs3781426	0.824	rs10901850	chr10:126707881	C/T	cg04494136	chr10:126703576	CTBP2	-0.33	-6.44	-0.3	3.23e-10	Height;
LUAD	cis	rs2239547	0.603	rs12489490	chr3:53064022	C/A	cg14092988	chr3:52407081	DNAH1	0.42	6.82	0.31	3.15e-11	Schizophrenia;
LUAD	cis	rs9972944	0.756	rs6416945	chr17:63763942	G/A	cg07283582	chr17:63770753	CCDC46	-0.5	-11.17	-0.48	1.48e-25	Total body bone mineral density;
LUAD	cis	rs2625529	0.730	rs2957368	chr15:72329906	C/T	cg16672083	chr15:72433130	SENP8	-0.66	-12.13	-0.51	2.96e-29	Red blood cell count;
LUAD	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg08999081	chr20:33150536	PIGU	0.62	13.72	0.55	1.08e-35	Glomerular filtration rate (creatinine);
LUAD	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg25324976	chr17:61989376	CSHL1	0.38	7.41	0.34	7.08e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg06641503	chr3:48959341	ARIH2	0.35	6.7	0.31	6.64e-11	Menarche (age at onset);
LUAD	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23221052	chr5:179740743	GFPT2	-0.72	-12.0	-0.5	9.33e-29	Height;
LUAD	cis	rs2224391	0.911	rs6925249	chr6:5262510	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-9.85	-0.43	9.37e-21	Height;
LUAD	cis	rs9308433	0.529	rs59864830	chr1:214474889	A/G	cg06198575	chr1:214491504	SMYD2	0.47	7.64	0.35	1.47e-13	IgG glycosylation;
LUAD	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.55	0.42	1.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs16958440	0.867	rs12326412	chr18:44683594	A/C	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg08601574	chr20:25228251	PYGB	0.46	8.55	0.38	2.35e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg11301795	chr4:187892539	NA	0.73	14.86	0.59	1.64e-40	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.62	-0.35	1.7e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-11.49	-0.49	8.67e-27	Migraine;Coronary artery disease;
LUAD	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg09029085	chr17:47094198	IGF2BP1	0.3	6.74	0.31	5.07e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	trans	rs1493916	0.967	rs9953768	chr18:31399468	A/G	cg13755796	chr4:20253514	NA	-0.41	-6.85	-0.32	2.7e-11	Life satisfaction;
LUAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg13560548	chr3:10150139	C3orf24	0.42	6.9	0.32	1.95e-11	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.786	rs116046984	chr2:198884413	G/A	cg11031976	chr2:198649780	BOLL	-0.45	-6.51	-0.3	2.12e-10	Ulcerative colitis;
LUAD	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg08859206	chr1:53392774	SCP2	-0.58	-10.64	-0.46	1.43e-23	Monocyte count;
LUAD	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-8.67	-0.39	9.24e-17	Platelet count;
LUAD	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg10792982	chr14:105748885	BRF1	0.46	10.02	0.44	2.49e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-8.14	-0.37	4.56e-15	Alzheimer's disease;
LUAD	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg15017067	chr4:17643749	FAM184B	0.36	7.08	0.33	6.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	11.49	0.49	8.5e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs12760731	0.565	rs11580064	chr1:178226520	A/G	cg00404053	chr1:178313656	RASAL2	0.7	9.01	0.4	7.34e-18	Obesity-related traits;
LUAD	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg00316803	chr15:76480434	C15orf27	-0.42	-8.18	-0.37	3.31e-15	Blood metabolite levels;
LUAD	cis	rs939658	1.000	rs34286854	chr15:79454374	C/T	cg17916960	chr15:79447300	NA	-0.48	-9.7	-0.43	3.22e-20	Refractive error;
LUAD	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12292205	chr6:26970375	C6orf41	-0.48	-6.71	-0.31	6.2e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.51	-0.38	3.12e-16	Gut microbiome composition (summer);
LUAD	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg13393036	chr8:95962371	TP53INP1	-0.35	-8.3	-0.37	1.45e-15	Type 2 diabetes;
LUAD	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg10523679	chr1:76189770	ACADM	-0.83	-13.17	-0.54	2.01e-33	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.03	0.32	8.56e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg00802000	chr16:706648	WDR90	-0.37	-6.94	-0.32	1.45e-11	Height;
LUAD	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg18404041	chr3:52824283	ITIH1	0.56	9.33	0.41	6.18e-19	Schizophrenia;
LUAD	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg09323728	chr8:95962352	TP53INP1	-0.35	-8.63	-0.39	1.28e-16	Type 2 diabetes;
LUAD	trans	rs3960554	0.610	rs11971800	chr7:75731608	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	11.88	0.5	2.81e-28	Eotaxin levels;
LUAD	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg08085267	chr17:45401833	C17orf57	-0.53	-9.4	-0.42	3.46e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2840044	0.517	rs2124247	chr17:33885468	G/A	cg05299278	chr17:33885742	SLFN14	0.54	12.85	0.53	3.8e-32	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs6987853	0.814	rs2923415	chr8:42455577	A/G	cg09913449	chr8:42400586	C8orf40	0.41	7.44	0.34	5.5e-13	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.46	-0.49	1.2e-26	Primary sclerosing cholangitis;
LUAD	cis	rs758324	0.773	rs608834	chr5:131271528	G/C	cg06307176	chr5:131281290	NA	-0.45	-7.51	-0.34	3.65e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9473147	0.543	rs4711878	chr6:47456118	A/G	cg02130027	chr6:47444894	CD2AP	0.36	6.87	0.32	2.33e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs6906287	0.669	rs2356491	chr6:118806564	A/G	cg05564266	chr6:118973597	C6orf204	0.34	7.35	0.34	1.03e-12	Electrocardiographic conduction measures;
LUAD	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg01884057	chr2:25150051	NA	0.34	7.19	0.33	3.04e-12	Body mass index;
LUAD	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg22823121	chr1:150693482	HORMAD1	0.41	7.88	0.36	2.81e-14	Melanoma;
LUAD	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg00757033	chr12:89920650	WDR51B	0.69	12.09	0.51	3.99e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs12618769	0.625	rs17034241	chr2:99224998	C/G	cg10123293	chr2:99228465	UNC50	0.5	8.71	0.39	7.07e-17	Bipolar disorder;
LUAD	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg10468373	chr11:64009913	FKBP2	0.55	6.89	0.32	2e-11	Mean platelet volume;
LUAD	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg14582100	chr15:45693742	SPATA5L1	0.62	11.79	0.5	6.0500000000000004e-28	Homoarginine levels;
LUAD	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg19912559	chr1:40204330	PPIE	0.56	9.52	0.42	1.29e-19	Blood protein levels;
LUAD	cis	rs6960043	0.818	rs10267273	chr7:15053589	A/G	cg19272540	chr7:15055459	NA	-0.35	-7.82	-0.36	4.16e-14	Type 2 diabetes;
LUAD	cis	rs4523957	0.719	rs1532292	chr17:2097483	T/G	cg16513277	chr17:2031491	SMG6	-0.75	-14.15	-0.57	1.79e-37	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7551222	0.752	rs10793766	chr1:204549496	C/T	cg20240347	chr1:204465584	NA	-0.35	-6.72	-0.31	6.07e-11	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.68	-9.95	-0.44	4.35e-21	Alzheimer's disease;
LUAD	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg22823121	chr1:150693482	HORMAD1	0.37	7.25	0.33	1.95e-12	Melanoma;
LUAD	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg07507251	chr3:52567010	NT5DC2	0.37	7.31	0.34	1.31e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2387326	0.767	rs11016098	chr10:129942982	A/G	cg16087940	chr10:129947807	NA	-0.65	-8.9	-0.4	1.63e-17	Select biomarker traits;
LUAD	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg13856295	chr9:139396418	NOTCH1	-0.42	-6.62	-0.31	1.09e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.3	-0.33	1.42e-12	Height;
LUAD	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg05590025	chr7:65112418	INTS4L2	-0.72	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs12422267	0.536	rs11246933	chr12:132610314	G/A	cg09764611	chr12:132620959	NA	-0.66	-11.03	-0.47	4.93e-25	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs698833	0.798	rs4953082	chr2:44524064	G/A	cg04920474	chr2:44395004	PPM1B	0.41	7.43	0.34	6.12e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03517284	chr6:25882590	NA	-0.53	-8.81	-0.39	3.27e-17	Blood metabolite levels;
LUAD	cis	rs7215564	0.908	rs4969411	chr17:78747982	T/C	cg09596252	chr17:78655493	RPTOR	-0.49	-6.37	-0.3	4.91e-10	Myopia (pathological);
LUAD	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg23758822	chr17:41437982	NA	-0.88	-18.28	-0.66	2e-55	Menopause (age at onset);
LUAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00166722	chr3:10149974	C3orf24	0.7	12.15	0.51	2.46e-29	Alzheimer's disease;
LUAD	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.78e-11	Crohn's disease;
LUAD	cis	rs986417	1.000	rs1254255	chr14:60831342	G/A	cg27398547	chr14:60952738	C14orf39	-0.61	-7.25	-0.33	1.95e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg13319975	chr6:146136371	FBXO30	0.65	11.34	0.48	3.42e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8192282	0.584	rs6427724	chr1:154502499	T/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.46	-7.08	-0.33	6.18e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7089973	0.564	rs55671354	chr10:116571281	T/C	cg23260525	chr10:116636907	FAM160B1	0.49	11.46	0.49	1.11e-26	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10911363	0.550	rs10911353	chr1:183489203	G/A	cg09173681	chr1:183549694	NCF2	0.54	10.01	0.44	2.52e-21	Systemic lupus erythematosus;
LUAD	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg03433033	chr1:76189801	ACADM	0.45	6.64	0.31	9.95e-11	Daytime sleep phenotypes;
LUAD	cis	rs7903847	0.620	rs7923385	chr10:99117097	T/A	cg20016023	chr10:99160130	RRP12	-0.29	-6.89	-0.32	2.05e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs55665837	1.000	rs10832276	chr11:14483274	C/T	cg19336497	chr11:14380999	RRAS2	-0.49	-9.73	-0.43	2.6e-20	Vitamin D levels;
LUAD	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg12311346	chr5:56204834	C5orf35	-0.56	-8.99	-0.4	8.58e-18	Coronary artery disease;
LUAD	trans	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.72	13.06	0.54	5.44e-33	Mean corpuscular volume;
LUAD	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg00484396	chr16:3507460	NAT15	0.71	12.01	0.5	8.56e-29	Tuberculosis;
LUAD	cis	rs7180079	0.925	rs72756918	chr15:64478079	G/A	cg08069370	chr15:64387884	SNX1	-0.52	-6.63	-0.31	1.01e-10	Monocyte count;
LUAD	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-9.44	-0.42	2.52e-19	Educational attainment;
LUAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.29	0.41	8.5e-19	Alzheimer's disease;
LUAD	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg07870213	chr5:140052090	DND1	1.03	14.52	0.58	4.7e-39	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg21427119	chr20:30132790	HM13	-0.52	-8.39	-0.38	7.42e-16	Mean corpuscular hemoglobin;
LUAD	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg18016565	chr1:150552671	MCL1	0.41	7.58	0.35	2.14e-13	Tonsillectomy;
LUAD	cis	rs6543140	0.964	rs6543138	chr2:103066132	G/A	cg04239558	chr2:103089729	SLC9A4	0.36	7.34	0.34	1.09e-12	Blood protein levels;
LUAD	cis	rs240764	0.610	rs41288423	chr6:101166095	G/A	cg09795085	chr6:101329169	ASCC3	-0.4	-6.97	-0.32	1.21e-11	Neuroticism;
LUAD	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg05535760	chr7:792225	HEATR2	-0.76	-8.88	-0.4	1.91e-17	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7009516	0.819	rs13257101	chr8:24223583	A/T	cg01759110	chr8:24241694	ADAMDEC1	-0.44	-8.78	-0.39	4.08e-17	Hair greying;
LUAD	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg08805041	chr16:621841	PIGQ	-0.31	-6.47	-0.3	2.74e-10	Height;
LUAD	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	9.43	0.42	2.69e-19	Melanoma;
LUAD	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg07636037	chr3:49044803	WDR6	-0.44	-7.26	-0.33	1.86e-12	Menarche (age at onset);
LUAD	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.69	-10.82	-0.47	3.02e-24	Ileal carcinoids;
LUAD	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg02782426	chr3:40428986	ENTPD3	0.32	6.78	0.31	4.05e-11	Renal cell carcinoma;
LUAD	trans	rs931812	0.858	rs4734017	chr8:101912073	C/T	cg20993868	chr7:22813445	NA	0.58	11.74	0.5	9.91e-28	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg21204522	chr6:27730016	NA	-0.47	-7.48	-0.34	4.41e-13	Parkinson's disease;
LUAD	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg09035930	chr12:129282057	SLC15A4	0.69	15.27	0.6	3.18e-42	Systemic lupus erythematosus;
LUAD	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg03605463	chr16:89740564	NA	-0.42	-6.46	-0.3	2.87e-10	Vitiligo;
LUAD	cis	rs1003719	0.680	rs7276569	chr21:38578207	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.2	-0.37	2.89e-15	Eye color traits;
LUAD	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg11057378	chr10:81107060	PPIF	0.39	7.1	0.33	5.38e-12	Height;
LUAD	cis	rs9715521	1.000	rs9715521	chr4:59824487	G/A	cg11281224	chr4:60001000	NA	-0.56	-9.51	-0.42	1.5e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs1945213	0.694	rs67394518	chr11:55855303	G/A	cg03929089	chr4:120376271	NA	0.6	7.2	0.33	2.84e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs806794	1.000	rs806794	chr6:26200677	A/G	cg00631329	chr6:26305371	NA	-0.46	-7.52	-0.34	3.24e-13	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUAD	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg11247378	chr22:39784982	NA	-0.74	-13.57	-0.55	4.56e-35	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg18196295	chr10:418757	DIP2C	0.47	7.96	0.36	1.61e-14	Psychosis in Alzheimer's disease;
LUAD	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg03714773	chr7:91764589	CYP51A1	0.27	6.45	0.3	3.05e-10	Breast cancer;
LUAD	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg19318889	chr4:1322082	MAEA	0.45	7.59	0.35	2.09e-13	Obesity-related traits;
LUAD	cis	rs1461503	0.966	rs10892938	chr11:122841921	A/C	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.17e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg04369109	chr6:150039330	LATS1	-0.46	-7.31	-0.33	1.34e-12	Lung cancer;
LUAD	cis	rs738322	0.775	rs13056506	chr22:38580917	G/T	cg25457927	chr22:38595422	NA	0.64	17.01	0.64	8.42e-50	Cutaneous nevi;
LUAD	cis	rs9522267	0.502	rs9522297	chr13:112234419	C/T	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.93e-11	Hepatitis;
LUAD	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg23254163	chr1:152506842	NA	0.26	7.14	0.33	4.21e-12	Hair morphology;
LUAD	trans	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg02030672	chr11:45687055	CHST1	0.46	8.39	0.38	7.54e-16	Obesity-related traits;
LUAD	trans	rs87938	1.000	rs401680	chr3:41127094	A/T	cg11224624	chr8:145049280	PLEC1	0.38	6.41	0.3	3.87e-10	Bone mineral density (hip);
LUAD	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06022373	chr22:39101656	GTPBP1	0.44	6.58	0.3	1.38e-10	Menopause (age at onset);
LUAD	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	9.23	0.41	1.34e-18	Melanoma;
LUAD	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg21775007	chr8:11205619	TDH	-0.5	-9.01	-0.4	7.37e-18	Retinal vascular caliber;
LUAD	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg02428538	chr16:24856791	SLC5A11	-0.48	-6.7	-0.31	6.81e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg25208724	chr1:156163844	SLC25A44	1.19	27.18	0.8	7.73e-95	Testicular germ cell tumor;
LUAD	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.87	-0.43	8.13e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg05368731	chr17:41323189	NBR1	0.95	20.02	0.7	3.33e-63	Menopause (age at onset);
LUAD	cis	rs6430585	0.591	rs61187091	chr2:136468238	G/A	cg07169764	chr2:136633963	MCM6	0.68	7.64	0.35	1.47e-13	Corneal structure;
LUAD	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.44	6.72	0.31	6.05e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs494562	0.892	rs520090	chr6:86116635	G/A	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg27102117	chr16:15229624	NA	0.58	10.47	0.45	5.58e-23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg00933542	chr6:150070202	PCMT1	0.45	9.52	0.42	1.34e-19	Lung cancer;
LUAD	cis	rs6445967	1.000	rs13082844	chr3:58318261	G/A	cg23715586	chr3:58305044	RPP14	0.43	7.67	0.35	1.2e-13	Platelet count;
LUAD	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.73	-0.31	5.59e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs796364	0.525	rs10931895	chr2:201143242	C/T	cg23649088	chr2:200775458	C2orf69	0.53	7.65	0.35	1.39e-13	Schizophrenia;
LUAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg10687131	chr2:20871002	GDF7	-0.49	-9.21	-0.41	1.59e-18	Abdominal aortic aneurysm;
LUAD	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg22029157	chr1:209979665	IRF6	0.8	11.78	0.5	6.74e-28	Cleft lip with or without cleft palate;
LUAD	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg06484146	chr7:12443880	VWDE	-0.59	-7.48	-0.34	4.21e-13	Coronary artery disease;
LUAD	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg08773314	chr2:239334832	ASB1	0.41	9.46	0.42	2.15e-19	Multiple system atrophy;
LUAD	trans	rs3960554	0.808	rs13438599	chr7:75768022	G/A	cg19862616	chr7:65841803	NCRNA00174	0.81	10.9	0.47	1.46e-24	Eotaxin levels;
LUAD	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-8.17	-0.37	3.62e-15	Alzheimer's disease (late onset);
LUAD	cis	rs953387	1.000	rs2056297	chr2:136899116	G/T	cg05194412	chr2:137003533	NA	-0.4	-6.58	-0.3	1.43e-10	Arthritis (juvenile idiopathic);
LUAD	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg15181151	chr6:150070149	PCMT1	0.41	8.55	0.38	2.2e-16	Lung cancer;
LUAD	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08219700	chr8:58056026	NA	0.61	8.65	0.39	1.12e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg06074448	chr4:187884817	NA	-0.36	-6.99	-0.32	1.1e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.58	-10.69	-0.46	9.23e-24	Longevity;Endometriosis;
LUAD	cis	rs1595825	0.891	rs7580003	chr2:198517893	C/T	cg00982548	chr2:198649783	BOLL	-0.62	-8.81	-0.39	3.37e-17	Ulcerative colitis;
LUAD	cis	rs7107174	1.000	rs948662	chr11:77979829	A/G	cg02023728	chr11:77925099	USP35	0.48	7.27	0.33	1.77e-12	Testicular germ cell tumor;
LUAD	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg09365446	chr1:150670422	GOLPH3L	0.63	10.99	0.47	6.79e-25	Melanoma;
LUAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg04025307	chr7:1156635	C7orf50	0.72	12.93	0.53	1.81e-32	Longevity;Endometriosis;
LUAD	cis	rs1847202	0.826	rs1979884	chr3:72948515	T/C	cg25664220	chr3:72788482	NA	-0.43	-7.56	-0.35	2.48e-13	Motion sickness;
LUAD	cis	rs56283067	0.847	rs60328783	chr6:44693099	C/G	cg18551225	chr6:44695536	NA	-0.61	-10.16	-0.44	7.59e-22	Total body bone mineral density;
LUAD	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.23	-0.41	1.35e-18	Alcohol dependence;
LUAD	cis	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg08601574	chr20:25228251	PYGB	0.47	8.88	0.4	1.86e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg25753631	chr6:25732923	NA	-0.37	-6.48	-0.3	2.53e-10	Iron status biomarkers;
LUAD	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.18	-0.41	1.96e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-7.06	-0.32	6.74e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg06221963	chr1:154839813	KCNN3	0.66	14.07	0.56	3.58e-37	Prostate cancer;
LUAD	cis	rs1044826	0.597	rs6772199	chr3:139178133	C/T	cg00490450	chr3:139108681	COPB2	0.41	6.46	0.3	2.9e-10	Obesity-related traits;
LUAD	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg18105134	chr13:113819100	PROZ	-0.86	-15.11	-0.59	1.5e-41	Platelet distribution width;
LUAD	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.51	10.54	0.46	3.22e-23	Monocyte percentage of white cells;
LUAD	trans	rs1406428	0.573	rs12613632	chr2:51705755	C/G	cg07192821	chr15:45003560	B2M	0.45	6.44	0.3	3.34e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs57590327	0.503	rs9866374	chr3:81615311	T/C	cg07356753	chr3:81810745	GBE1	-0.51	-7.72	-0.35	8.26e-14	Extraversion;
LUAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg14820908	chr5:178986412	RUFY1	-0.59	-10.41	-0.45	9.34e-23	Lung cancer;
LUAD	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg02158880	chr13:53174818	NA	0.4	6.6	0.31	1.22e-10	Lewy body disease;
LUAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.56	7.91	0.36	2.2e-14	Renal function-related traits (BUN);
LUAD	cis	rs2692947	0.726	rs13009727	chr2:96769883	C/G	cg23100626	chr2:96804247	ASTL	-0.34	-9.22	-0.41	1.4e-18	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg13126279	chr21:47581558	C21orf56	-0.44	-7.56	-0.35	2.46e-13	Testicular germ cell tumor;
LUAD	cis	rs6076065	0.723	rs6083095	chr20:23354090	C/T	cg11657817	chr20:23433608	CST11	0.47	8.84	0.39	2.63e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs3784262	0.669	rs4646592	chr15:58302557	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.66	-0.35	1.24e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05835761	chr10:73648991	NA	-0.45	-7.19	-0.33	2.9e-12	Height;
LUAD	cis	rs10129255	0.536	rs8004835	chr14:107142378	A/C	cg23076370	chr14:107095027	NA	-0.41	-8.12	-0.37	5.26e-15	Kawasaki disease;
LUAD	cis	rs701145	0.938	rs355747	chr3:153962973	T/C	cg17054900	chr3:154042577	DHX36	0.66	7.1	0.33	5.4e-12	Coronary artery disease;
LUAD	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg26597838	chr10:835615	NA	0.76	10.29	0.45	2.61e-22	Eosinophil percentage of granulocytes;
LUAD	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg14196790	chr5:131705035	SLC22A5	0.48	8.41	0.38	6.35e-16	Breast cancer;Mosquito bite size;
LUAD	cis	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg07460842	chr6:66804631	NA	0.95	12.61	0.52	3.58e-31	Exhaled nitric oxide output;
LUAD	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.02	0.32	8.93e-12	Motion sickness;
LUAD	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg25894440	chr7:65020034	NA	0.61	6.58	0.3	1.37e-10	Diabetic kidney disease;
LUAD	cis	rs2040771	0.770	rs2518840	chr22:19255856	A/C	cg02655711	chr22:19163373	SLC25A1	0.58	10.78	0.46	4.03e-24	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg11050988	chr7:1952600	MAD1L1	-0.38	-7.77	-0.35	6.01e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs4378999	0.800	rs1383251	chr3:51366840	G/A	cg12934382	chr3:51741135	GRM2	0.4	6.43	0.3	3.46e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg00316803	chr15:76480434	C15orf27	0.4	6.57	0.3	1.44e-10	Blood metabolite levels;
LUAD	cis	rs3784262	1.000	rs4646627	chr15:58255305	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.46	-9.55	-0.42	1.04e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7737355	0.773	rs28852	chr5:131027842	A/C	cg06307176	chr5:131281290	NA	0.46	7.52	0.34	3.42e-13	Life satisfaction;
LUAD	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-16.12	-0.62	6.61e-46	Schizophrenia;
LUAD	trans	rs853679	0.556	rs67297533	chr6:28141253	G/T	cg06606381	chr12:133084897	FBRSL1	-1.22	-10.86	-0.47	2.15e-24	Depression;
LUAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg24829409	chr8:58192753	C8orf71	0.59	7.99	0.36	1.3e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs2544390	1.000	rs2673172	chr2:170204800	A/C	cg17607973	chr7:100027408	MEPCE;ZCWPW1	0.37	6.37	0.3	5.06e-10	Urate levels;
LUAD	cis	rs4077515	0.874	rs10781505	chr9:139271355	C/T	cg14169450	chr9:139327907	INPP5E	-0.37	-6.59	-0.31	1.3100000000000001e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6445967	0.530	rs57925583	chr3:58393153	T/G	cg13750441	chr3:58318267	PXK	-0.33	-6.81	-0.31	3.43e-11	Platelet count;
LUAD	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg26528668	chr16:1614120	IFT140	0.57	10.28	0.45	2.83e-22	Coronary artery disease;
LUAD	cis	rs853679	0.546	rs35017208	chr6:28345282	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.59	6.83	0.32	2.96e-11	Depression;
LUAD	cis	rs1032833	0.732	rs112452546	chr2:179958681	T/A	cg23883738	chr2:179974586	SESTD1	-0.72	-8.26	-0.37	1.9e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.53	-8.87	-0.4	2.05e-17	Electrocardiographic conduction measures;
LUAD	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.23	-0.33	2.34e-12	Height;
LUAD	trans	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg21051086	chr3:73046214	PPP4R2	-0.46	-7.42	-0.34	6.61e-13	Pancreatic cancer;
LUAD	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg24801067	chr17:62843696	NA	0.62	8.35	0.38	1.01e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg15181151	chr6:150070149	PCMT1	0.41	8.39	0.38	7.38e-16	Lung cancer;
LUAD	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg23985595	chr17:80112537	CCDC57	0.53	9.67	0.43	3.95e-20	Life satisfaction;
LUAD	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg18854424	chr1:2615690	NA	0.42	9.16	0.41	2.21e-18	Ulcerative colitis;
LUAD	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg11859384	chr17:80120422	CCDC57	0.42	7.45	0.34	5.35e-13	Life satisfaction;
LUAD	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg05425664	chr17:57184151	TRIM37	0.43	7.66	0.35	1.24e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs3219090	0.705	rs2695237	chr1:226603635	T/C	cg27539482	chr13:111589090	NA	0.43	7.26	0.33	1.85e-12	Melanoma;
LUAD	cis	rs7474896	0.515	rs594594	chr10:38307723	A/G	cg25427524	chr10:38739819	LOC399744	0.57	8.1	0.37	5.78e-15	Obesity (extreme);
LUAD	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.86	0.43	8.58e-21	Monocyte percentage of white cells;
LUAD	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg10755058	chr3:40428713	ENTPD3	0.37	7.27	0.33	1.78e-12	Renal cell carcinoma;
LUAD	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg25456477	chr12:86230367	RASSF9	-0.33	-6.42	-0.3	3.63e-10	Major depressive disorder;
LUAD	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.22	0.33	2.38e-12	Tonsillectomy;
LUAD	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg22535103	chr8:58192502	C8orf71	-0.64	-9.1	-0.4	3.59e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg19774624	chr17:42201019	HDAC5	-0.41	-7.19	-0.33	2.96e-12	Total body bone mineral density;
LUAD	cis	rs9457247	0.508	rs7760495	chr6:167506795	C/T	cg07741184	chr6:167504864	NA	0.32	7.38	0.34	8.39e-13	Crohn's disease;
LUAD	trans	rs7404843	0.852	rs111259294	chr16:15511930	C/T	cg02716450	chr16:28638775	NA	0.78	8.35	0.38	9.95e-16	Testicular germ cell tumor;
LUAD	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.42	-7.67	-0.35	1.2e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	8.0	0.36	1.17e-14	Rheumatoid arthritis;
LUAD	trans	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.72	-10.07	-0.44	1.64e-21	Obesity-related traits;
LUAD	trans	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	7.66	0.35	1.26e-13	Resting heart rate;
LUAD	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg11070056	chr1:107600091	PRMT6	0.52	9.1	0.4	3.55e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg22920501	chr2:26401640	FAM59B	-0.73	-10.4	-0.45	1.08e-22	Gut microbiome composition (summer);
LUAD	cis	rs9972944	0.756	rs6504344	chr17:63756668	C/T	cg07283582	chr17:63770753	CCDC46	-0.52	-11.68	-0.49	1.63e-27	Total body bone mineral density;
LUAD	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg11859384	chr17:80120422	CCDC57	-0.48	-8.67	-0.39	9.17e-17	Life satisfaction;
LUAD	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.46	-6.98	-0.32	1.16e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs1483890	1.000	rs900671	chr3:69406527	C/A	cg22125112	chr3:69402811	FRMD4B	0.4	7.17	0.33	3.31e-12	Resting heart rate;
LUAD	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg14343924	chr8:8086146	FLJ10661	-0.45	-7.16	-0.33	3.5e-12	Joint mobility (Beighton score);
LUAD	cis	rs9462027	0.628	rs2814991	chr6:34615443	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.74	-0.39	5.36e-17	Systemic lupus erythematosus;
LUAD	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg05865280	chr17:75406074	SEPT9	0.62	19.62	0.69	2.12e-61	Airflow obstruction;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17994390	chr8:95565953	KIAA1429	-0.42	-6.39	-0.3	4.51e-10	Height;
LUAD	trans	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg07817883	chr1:32538562	TMEM39B	1.34	12.95	0.53	1.47e-32	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs829661	0.532	rs9789517	chr2:30785824	C/G	cg12454169	chr2:30669597	LCLAT1	0.43	6.73	0.31	5.67e-11	Midgestational circulating levels of PBDEs (fetal genetic effect);
LUAD	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg17178900	chr1:205818956	PM20D1	0.55	10.39	0.45	1.14e-22	Menarche (age at onset);
LUAD	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg20701182	chr2:24300061	SF3B14	0.61	6.74	0.31	5.22e-11	Lymphocyte counts;
LUAD	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg23758822	chr17:41437982	NA	1.02	20.75	0.71	1.76e-66	Menopause (age at onset);
LUAD	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg08125733	chr17:73851984	WBP2	0.61	8.96	0.4	1.07e-17	Psoriasis;
LUAD	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg21963583	chr11:68658836	MRPL21	0.62	10.77	0.46	4.68e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.83	-11.44	-0.49	1.43e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs938554	0.612	rs9991278	chr4:10002665	A/G	cg00071950	chr4:10020882	SLC2A9	0.54	8.45	0.38	4.71e-16	Blood metabolite levels;
LUAD	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg27490568	chr2:178487706	NA	0.4	6.66	0.31	8.5e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.53	1.39e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg27490568	chr2:178487706	NA	0.39	6.51	0.3	2.08e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs13063635	0.915	rs1994491	chr3:45960420	G/C	cg16320329	chr3:45981161	FYCO1	-0.51	-6.41	-0.3	3.93e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg08805041	chr16:621841	PIGQ	-0.32	-6.4	-0.3	4.24e-10	Height;
LUAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22442454	chr1:209979470	IRF6	0.53	7.69	0.35	1.02e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg25985355	chr7:65971099	NA	-0.51	-6.37	-0.3	4.89e-10	Diabetic kidney disease;
LUAD	trans	rs75804782	0.581	rs72987336	chr2:239365345	T/C	cg01134436	chr17:81009848	B3GNTL1	0.76	8.47	0.38	4.1e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08219700	chr8:58056026	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg12311346	chr5:56204834	C5orf35	-0.74	-11.81	-0.5	5.05e-28	Initial pursuit acceleration;
LUAD	cis	rs11893307	0.537	rs7571572	chr2:191553637	C/G	cg11845111	chr2:191398756	TMEM194B	-0.44	-6.56	-0.3	1.55e-10	Mean platelet volume;
LUAD	cis	rs3862260	0.905	rs3850870	chr1:120161037	C/T	cg16322792	chr1:120165303	ZNF697	0.61	15.06	0.59	2.54e-41	Systemic lupus erythematosus;
LUAD	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg17971929	chr21:40555470	PSMG1	0.55	8.71	0.39	6.67e-17	Cognitive function;
LUAD	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg09462578	chr12:12878428	APOLD1	-0.53	-8.37	-0.38	8.42e-16	Lymphocyte counts;
LUAD	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg12140854	chr5:148520817	ABLIM3	-0.7	-10.55	-0.46	2.9e-23	Breast cancer;
LUAD	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg20503657	chr10:835505	NA	0.93	14.08	0.56	3.38e-37	Eosinophil percentage of granulocytes;
LUAD	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	6.64	0.31	9.39e-11	Schizophrenia;
LUAD	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg02993280	chr1:107599747	PRMT6	-0.57	-9.24	-0.41	1.19e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.53	-0.34	3.1400000000000003e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg12034118	chr1:209979487	IRF6	0.52	7.55	0.34	2.77e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21545522	chr1:205238299	TMCC2	0.38	7.12	0.33	4.54e-12	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.38	-0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.48	-8.05	-0.36	8.66e-15	Body mass index;
LUAD	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.31	0.34	1.32e-12	Tonsillectomy;
LUAD	cis	rs55665837	0.539	rs10832311	chr11:14881926	T/G	cg19336497	chr11:14380999	RRAS2	-0.39	-7.37	-0.34	8.8e-13	Vitamin D levels;
LUAD	cis	rs7177699	0.550	rs7182103	chr15:79123946	G/T	cg00540400	chr15:79124168	NA	0.44	9.73	0.43	2.48e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs3750082	0.780	rs9638884	chr7:32913612	T/C	cg05721444	chr7:32995514	FKBP9	0.37	6.75	0.31	4.77e-11	Glomerular filtration rate (creatinine);
LUAD	trans	rs853679	0.607	rs201002	chr6:27808192	A/G	cg01620082	chr3:125678407	NA	-0.74	-8.63	-0.39	1.25e-16	Depression;
LUAD	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg15017067	chr4:17643749	FAM184B	0.37	7.06	0.32	6.69e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg12062639	chr20:23401060	NAPB	1.09	11.27	0.48	6.09e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.42	-6.74	-0.31	5.19e-11	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34421088	0.585	rs1390950	chr8:11595829	C/T	cg13293535	chr8:11597251	GATA4	0.3	7.07	0.33	6.36e-12	Neuroticism;
LUAD	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.44	-0.38	5.08e-16	Prostate cancer;
LUAD	cis	rs6907340	0.517	rs9465531	chr6:19798649	A/T	cg02682789	chr6:19804855	NA	0.44	6.63	0.31	1.01e-10	Endometriosis;
LUAD	cis	rs11893307	0.509	rs62179690	chr2:191529873	T/C	cg27211696	chr2:191398769	TMEM194B	-0.43	-6.5	-0.3	2.31e-10	Mean platelet volume;
LUAD	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg09137382	chr11:130731461	NA	0.41	7.5	0.34	3.81e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs597583	0.664	rs4936384	chr11:117398591	C/T	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.53	-0.38	2.61e-16	Putamen volume;
LUAD	cis	rs6545883	0.868	rs28749199	chr2:61827052	A/G	cg15711740	chr2:61764176	XPO1	-0.42	-6.6	-0.31	1.26e-10	Tuberculosis;
LUAD	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg00933542	chr6:150070202	PCMT1	0.38	7.97	0.36	1.5e-14	Lung cancer;
LUAD	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.4e-15	Prostate cancer;
LUAD	cis	rs7582720	1.000	rs72936842	chr2:203773686	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.79	11.01	0.47	5.93e-25	Smoking behavior;
LUAD	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg05132306	chr1:1846340	CALML6	-0.35	-7.62	-0.35	1.73e-13	Body mass index;
LUAD	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg22029157	chr1:209979665	IRF6	-0.36	-6.44	-0.3	3.29e-10	Monobrow;
LUAD	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg09455208	chr3:40491958	NA	0.55	12.05	0.51	6.1e-29	Renal cell carcinoma;
LUAD	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg21399703	chr1:247681439	NA	-0.43	-8.2	-0.37	2.85e-15	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs9951602	0.512	rs6506872	chr18:76649695	T/C	cg02800362	chr5:177631904	HNRNPAB	0.92	14.03	0.56	5.64e-37	Obesity-related traits;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg02993250	chr10:5726650	C10orf18	-0.65	-6.6	-0.31	1.23e-10	Type 2 diabetes;
LUAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.67	-8.44	-0.38	4.93e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg12615879	chr12:58013172	SLC26A10	0.61	13.27	0.54	7.87e-34	Multiple sclerosis;
LUAD	cis	rs757081	0.667	rs1987694	chr11:17107648	G/C	cg15432903	chr11:17409602	KCNJ11	-0.4	-6.49	-0.3	2.45e-10	Systolic blood pressure;
LUAD	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg13010199	chr12:38710504	ALG10B	0.4	6.68	0.31	7.59e-11	Bladder cancer;
LUAD	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg05709478	chr1:6581295	PLEKHG5	0.55	6.95	0.32	1.38e-11	Body mass index;
LUAD	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg26898376	chr11:64110657	CCDC88B	0.38	7.11	0.33	5.04e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg04234412	chr22:24373322	LOC391322	-0.83	-15.26	-0.6	3.42e-42	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs9467711	0.651	rs9467623	chr6:25860580	G/A	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.52	-0.3	2.06e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11676348	0.772	rs6738953	chr2:218950036	C/A	cg06547715	chr2:218990976	CXCR2	0.32	7.18	0.33	3.21e-12	Ulcerative colitis;
LUAD	cis	rs2997447	0.761	rs2783670	chr1:26455182	A/G	cg00147160	chr1:26503991	CNKSR1	0.34	6.36	0.3	5.25e-10	QRS complex (12-leadsum);
LUAD	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg00071950	chr4:10020882	SLC2A9	0.75	15.27	0.6	2.96e-42	Bone mineral density;
LUAD	cis	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg07460842	chr6:66804631	NA	-1.02	-15.41	-0.6	7.61e-43	Exhaled nitric oxide output;
LUAD	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg00383909	chr3:49044727	WDR6	0.99	10.63	0.46	1.45e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs477895	0.838	rs2001003	chr11:64018687	C/A	cg23719950	chr11:63933701	MACROD1	-0.58	-6.86	-0.32	2.4e-11	Mean platelet volume;
LUAD	cis	rs7833986	1.000	rs4263734	chr8:57099931	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.76	10.2	0.44	5.57e-22	Height;
LUAD	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.89	0.32	2.07e-11	Rheumatoid arthritis;
LUAD	cis	rs11153730	0.503	rs283049	chr6:118635122	G/C	cg21191810	chr6:118973309	C6orf204	0.52	10.3	0.45	2.35e-22	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08677398	chr8:58056175	NA	0.47	6.57	0.3	1.52e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7809950	0.637	rs3801964	chr7:106836242	T/C	cg23024343	chr7:107201750	COG5	-0.83	-13.54	-0.55	5.89e-35	Coronary artery disease;
LUAD	cis	rs9826463	0.702	rs56397702	chr3:142304764	C/T	cg20824294	chr3:142316082	PLS1	0.48	8.0	0.36	1.18e-14	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	7.08	0.33	6.22e-12	Parkinson's disease;
LUAD	cis	rs76878669	0.606	rs2282531	chr11:66099494	C/T	cg18002602	chr11:66138449	SLC29A2	-0.46	-9.77	-0.43	1.88e-20	Educational attainment (years of education);
LUAD	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.23	-0.45	4.31e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs929596	0.728	rs6744284	chr2:234625297	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-11.97	-0.5	1.2e-28	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	8.13	0.37	4.65e-15	Blood metabolite levels;
LUAD	cis	rs11864453	1.000	rs1035559	chr16:72031860	A/G	cg23815491	chr16:72088622	HP	0.51	9.06	0.4	4.72e-18	Fibrinogen levels;
LUAD	cis	rs2235649	0.623	rs8048162	chr16:1848918	C/T	cg08610935	chr16:1836813	NUBP2	-0.5	-7.71	-0.35	8.96e-14	Blood metabolite levels;
LUAD	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg23283495	chr1:209979779	IRF6	0.74	10.9	0.47	1.5e-24	Cleft lip with or without cleft palate;
LUAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.64	-0.46	1.42e-23	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg27384769	chr19:14142958	IL27RA	-0.66	-6.85	-0.32	2.66e-11	Type 2 diabetes;
LUAD	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg03806693	chr22:41940476	POLR3H	-0.58	-8.25	-0.37	1.97e-15	Vitiligo;
LUAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg24846343	chr22:24311635	DDTL	0.75	16.31	0.62	9.26e-47	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg25036284	chr2:26402008	FAM59B	-0.61	-8.38	-0.38	7.68e-16	Gut microbiome composition (summer);
LUAD	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg02903104	chr8:1507517	DLGAP2	0.38	8.38	0.38	7.83e-16	Lung cancer;
LUAD	cis	rs7843479	0.965	rs11784535	chr8:21857787	G/A	cg03445287	chr8:21823731	XPO7	-0.44	-8.02	-0.36	1.06e-14	Mean corpuscular volume;
LUAD	cis	rs9652601	0.959	rs2041670	chr16:11174652	G/A	cg04616529	chr16:11181986	CLEC16A	0.37	6.52	0.3	2.02e-10	Systemic lupus erythematosus;
LUAD	cis	rs62400317	1.000	rs62400317	chr6:45284923	C/T	cg18551225	chr6:44695536	NA	-0.53	-8.35	-0.38	1e-15	Total body bone mineral density;
LUAD	cis	rs4523957	0.583	rs2760743	chr17:2017079	A/C	cg16513277	chr17:2031491	SMG6	0.96	18.86	0.68	4.83e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7089973	0.872	rs7909657	chr10:116629096	C/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.68	0.43	3.68e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg08071915	chr8:12219732	FAM66A	-0.42	-6.52	-0.3	1.95e-10	Mood instability;
LUAD	trans	rs8002861	0.641	rs6561148	chr13:44426269	C/T	cg17145862	chr1:211918768	LPGAT1	0.66	12.96	0.53	1.45e-32	Leprosy;
LUAD	cis	rs11585357	0.843	rs72646796	chr1:17612503	T/C	cg08277548	chr1:17600880	PADI3	-0.95	-13.92	-0.56	1.61e-36	Hair shape;
LUAD	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg17633681	chr16:88106987	BANP	0.39	6.57	0.3	1.47e-10	Menopause (age at onset);
LUAD	trans	rs62458065	0.640	rs10274556	chr7:32513947	A/G	cg00845942	chr12:64062724	DPY19L2	-0.58	-7.84	-0.36	3.71e-14	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg19041857	chr6:27730383	NA	-0.46	-7.32	-0.34	1.29e-12	Breast cancer;
LUAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg07677032	chr17:61819896	STRADA	0.56	10.18	0.44	6.31e-22	Prudent dietary pattern;
LUAD	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.18	-0.41	1.88e-18	Life satisfaction;
LUAD	trans	rs1493916	0.777	rs1845385	chr18:31318336	T/C	cg27147174	chr7:100797783	AP1S1	-0.64	-11.3	-0.48	4.67e-26	Life satisfaction;
LUAD	cis	rs1190552	0.846	rs12883789	chr14:102954621	G/A	cg18135206	chr14:102964638	TECPR2	0.47	6.53	0.3	1.94e-10	Blood protein levels;
LUAD	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713675	0.505	rs753890	chr6:33652880	G/A	cg13859433	chr6:33739653	LEMD2	-0.29	-6.65	-0.31	9.08e-11	Plateletcrit;
LUAD	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg04192923	chr4:3473232	DOK7	0.36	6.53	0.3	1.88e-10	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LUAD	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg17366294	chr4:99064904	C4orf37	0.63	12.0	0.5	9.53e-29	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg09491104	chr22:46646882	C22orf40	0.7	12.82	0.53	5.2e-32	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.31	0.33	1.37e-12	Tonsillectomy;
LUAD	cis	rs4711350	0.862	rs570749	chr6:33710229	C/T	cg18005901	chr6:33739558	LEMD2	0.51	7.13	0.33	4.42e-12	Schizophrenia;
LUAD	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.61	0.35	1.84e-13	Lung cancer;
LUAD	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg20302342	chr1:156215951	PAQR6	0.38	8.64	0.39	1.13e-16	Tonsillectomy;
LUAD	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg06028605	chr16:24865363	SLC5A11	0.43	7.34	0.34	1.07e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg07741184	chr6:167504864	NA	0.36	8.27	0.37	1.76e-15	Crohn's disease;
LUAD	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg15962314	chr1:44399869	ARTN	-0.32	-7.16	-0.33	3.71e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg02896835	chr1:92012615	NA	-0.58	-11.93	-0.5	1.69e-28	Breast cancer;
LUAD	trans	rs8129326	0.718	rs2834481	chr21:35795370	C/T	cg07474852	chr4:123073612	NA	0.45	7.62	0.35	1.66e-13	Cancer;
LUAD	cis	rs1451375	0.698	rs11489734	chr7:50635730	A/T	cg18232548	chr7:50535776	DDC	0.49	8.12	0.37	5.23e-15	Malaria;
LUAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs5756813	0.754	rs3788529	chr22:38158709	A/G	cg06521852	chr22:38141419	TRIOBP	0.5	9.2	0.41	1.65e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11644478	chr21:40555479	PSMG1	-0.58	-9.11	-0.41	3.26e-18	Cognitive function;
LUAD	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg10755058	chr3:40428713	ENTPD3	0.37	7.06	0.32	6.95e-12	Renal cell carcinoma;
LUAD	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg06002616	chr8:101225028	SPAG1	-0.39	-8.04	-0.36	8.81e-15	Atrioventricular conduction;
LUAD	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg13319975	chr6:146136371	FBXO30	0.59	9.97	0.44	3.59e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17095355	1.000	rs11194940	chr10:111742223	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.67	-9.08	-0.4	4.09e-18	Biliary atresia;
LUAD	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg02782426	chr3:40428986	ENTPD3	0.44	9.51	0.42	1.41e-19	Renal cell carcinoma;
LUAD	cis	rs6669119	0.668	rs17354622	chr1:19087996	G/T	cg26220594	chr1:19110978	NA	0.59	7.35	0.34	1.03e-12	Percentage gas trapping;
LUAD	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg00321850	chr1:175162397	KIAA0040	-0.52	-11.04	-0.47	4.57e-25	Alcohol dependence;
LUAD	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg11822812	chr5:140052017	DND1	-0.38	-6.85	-0.32	2.57e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7523050	0.730	rs34254854	chr1:109419875	C/T	cg08274380	chr1:109419600	GPSM2	0.7	6.49	0.3	2.4e-10	Fat distribution (HIV);
LUAD	cis	rs1401999	0.898	rs6443928	chr3:183729487	C/T	cg05044414	chr3:183734942	ABCC5	0.47	9.95	0.44	4.43e-21	Anterior chamber depth;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg22777949	chr11:810211	SNORA52;RPLP2	-0.41	-6.55	-0.3	1.7e-10	Schizophrenia;
LUAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg21970626	chr13:21893289	NA	-0.55	-9.42	-0.42	2.87e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.28	-6.77	-0.31	4.26e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg16060761	chr17:80687452	NA	-0.61	-8.83	-0.39	2.83e-17	Glycated hemoglobin levels;
LUAD	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.44	0.3	3.28e-10	Depression;
LUAD	trans	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg15704280	chr7:45808275	SEPT13	-0.58	-7.82	-0.36	4.16e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg26528668	chr16:1614120	IFT140	0.54	9.55	0.42	1.04e-19	Coronary artery disease;
LUAD	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.33	0.54	4.38e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6456156	0.766	rs150112	chr6:167509878	C/T	cg07741184	chr6:167504864	NA	-0.31	-7.19	-0.33	3.01e-12	Primary biliary cholangitis;
LUAD	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg03213289	chr20:61660250	NA	-0.62	-12.83	-0.53	4.55e-32	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs1371614	0.588	rs11126784	chr2:27169842	C/A	cg00617064	chr2:27272375	NA	-0.37	-7.23	-0.33	2.3e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	trans	rs12200782	1.000	rs72843802	chr6:26517515	C/T	cg08851530	chr6:28072375	NA	0.72	6.69	0.31	7.12e-11	Small cell lung carcinoma;
LUAD	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg24101359	chr6:42928495	GNMT	0.52	10.03	0.44	2.27e-21	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9807989	0.839	rs10204837	chr2:102977730	C/A	cg03938978	chr2:103052716	IL18RAP	0.31	6.38	0.3	4.58e-10	Asthma;
LUAD	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg03806693	chr22:41940476	POLR3H	0.75	9.8	0.43	1.49e-20	Vitiligo;
LUAD	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg06191203	chr2:152266755	RIF1	0.46	7.23	0.33	2.31e-12	Lung cancer;
LUAD	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg10356904	chr22:49881777	NA	-0.4	-7.48	-0.34	4.39e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2455601	0.671	rs2568091	chr11:8986048	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-7.56	-0.35	2.5e-13	Schizophrenia;
LUAD	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg15962314	chr1:44399869	ARTN	0.33	7.25	0.33	2.04e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs12681288	0.523	rs112307130	chr8:962483	G/A	cg04851639	chr8:1020857	NA	-0.33	-7.67	-0.35	1.23e-13	Schizophrenia;
LUAD	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	0.58	6.57	0.3	1.52e-10	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs3741798	0.908	rs61922046	chr12:12495675	A/T	cg08615371	chr12:12503544	MANSC1	0.74	6.72	0.31	6.03e-11	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10802521	chr3:52805072	NEK4	-0.54	-9.17	-0.41	2.16e-18	Bipolar disorder;
LUAD	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg08645402	chr16:4508243	NA	0.52	9.49	0.42	1.77e-19	Schizophrenia;
LUAD	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.61	11.8	0.5	5.88e-28	Hemoglobin concentration;
LUAD	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.1	-0.33	5.27e-12	Breast cancer;
LUAD	cis	rs4604732	0.631	rs12091081	chr1:247623064	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.43	6.77	0.31	4.42e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-6.72	-0.31	5.87e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg26043149	chr18:55253948	FECH	-0.46	-7.42	-0.34	6.51e-13	Bone mineral density;
LUAD	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg23711669	chr6:146136114	FBXO30	0.39	6.74	0.31	5.36e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.86	-0.36	3.15e-14	Diabetic kidney disease;
LUAD	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg07741184	chr6:167504864	NA	-0.31	-7.34	-0.34	1.14e-12	Crohn's disease;
LUAD	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-7.24	-0.33	2.1e-12	Blood metabolite levels;
LUAD	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg19875535	chr5:140030758	IK	0.45	7.49	0.34	3.96e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg13918804	chr1:2043761	PRKCZ	0.41	7.0	0.32	1.01e-11	Height;
LUAD	cis	rs4699052	0.893	rs4699058	chr4:104171321	T/A	cg16532752	chr4:104119610	CENPE	-0.46	-7.11	-0.33	4.82e-12	Testicular germ cell tumor;
LUAD	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg06060754	chr5:176797920	RGS14	0.55	10.52	0.46	3.94e-23	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg06627628	chr2:24431161	ITSN2	-0.56	-6.55	-0.3	1.63e-10	Lymphocyte counts;
LUAD	cis	rs9487051	0.724	rs11966072	chr6:109634828	A/G	cg21918786	chr6:109611834	NA	-0.43	-6.83	-0.32	2.99e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg06640241	chr16:89574553	SPG7	-0.43	-6.99	-0.32	1.07e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs10097731	0.901	rs10464891	chr8:82042900	C/A	cg25230327	chr8:82042993	NA	-0.66	-11.5	-0.49	7.85e-27	Serum total protein level;
LUAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg11416102	chr8:651193	ERICH1	0.96	9.22	0.41	1.43e-18	IgG glycosylation;
LUAD	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03452623	chr4:187889614	NA	-0.84	-18.07	-0.66	1.58e-54	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1941687	0.702	rs10460050	chr18:31413671	G/T	cg27147174	chr7:100797783	AP1S1	-0.54	-9.6	-0.42	6.85e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs1941184	0.526	rs16961940	chr18:29031909	A/G	cg03238162	chr18:29027701	DSG3	0.36	6.39	0.3	4.33e-10	Parkinson's disease (age of onset);
LUAD	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	9.64	0.42	5.33e-20	Ileal carcinoids;
LUAD	cis	rs9314323	1.000	rs9314323	chr8:26243136	A/G	cg13160058	chr8:26243215	BNIP3L	-0.47	-9.87	-0.43	7.99e-21	Red cell distribution width;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07136949	chr6:7986672	MGC26597	0.53	6.42	0.3	3.76e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg20503657	chr10:835505	NA	-0.46	-7.19	-0.33	2.93e-12	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.3	-6.46	-0.3	2.82e-10	Height;
LUAD	cis	rs62229266	0.659	rs7275820	chr21:37409414	G/A	cg08632701	chr21:37451849	NA	-0.39	-6.6	-0.31	1.25e-10	Mitral valve prolapse;
LUAD	cis	rs11958404	0.615	rs10475649	chr5:157447301	T/C	cg05962755	chr5:157440814	NA	0.44	8.43	0.38	5.43e-16	IgG glycosylation;
LUAD	cis	rs9814567	0.727	rs4245908	chr3:134349205	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-12.52	-0.52	8.49e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg20933634	chr6:27740509	NA	0.47	7.32	0.34	1.22e-12	Parkinson's disease;
LUAD	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg03354898	chr7:1950403	MAD1L1	-0.39	-7.41	-0.34	7.15e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg06608945	chr2:219082296	ARPC2	-0.42	-7.0	-0.32	9.91e-12	Colorectal cancer;
LUAD	cis	rs12711979	0.765	rs13028529	chr2:3825467	C/T	cg17052675	chr2:3827356	NA	-0.52	-10.55	-0.46	2.93e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg16205897	chr5:131564050	P4HA2	-0.34	-7.43	-0.34	5.97e-13	Breast cancer;
LUAD	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg12011299	chr4:100065546	ADH4	0.7	13.54	0.55	5.95e-35	Alcohol dependence;
LUAD	cis	rs1395	1.000	rs1395	chr2:27424636	G/A	cg23587288	chr2:27483067	SLC30A3	0.39	7.85	0.36	3.57e-14	Blood metabolite levels;
LUAD	cis	rs1451375	0.617	rs2329366	chr7:50544966	G/A	cg18232548	chr7:50535776	DDC	-0.65	-9.02	-0.4	6.8e-18	Malaria;
LUAD	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.61	-0.31	1.13e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg04944784	chr2:26401820	FAM59B	-0.76	-10.48	-0.45	5.47e-23	Gut microbiome composition (summer);
LUAD	cis	rs12122100	0.774	rs12723253	chr1:146523303	C/T	cg03526459	chr1:146549940	NA	-0.36	-6.54	-0.3	1.73e-10	HIV-1 control;
LUAD	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.18	0.54	1.78e-33	Prudent dietary pattern;
LUAD	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06505273	chr16:24850292	NA	0.47	6.83	0.32	2.98e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4692589	1.000	rs7688417	chr4:170938732	C/T	cg19918862	chr4:170955249	NA	0.29	6.95	0.32	1.41e-11	Anxiety disorder;
LUAD	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg04731861	chr2:219085781	ARPC2	0.21	6.52	0.3	2.01e-10	Colorectal cancer;
LUAD	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg17644776	chr2:200775616	C2orf69	0.56	7.49	0.34	4.16e-13	Schizophrenia;
LUAD	trans	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.75	-0.31	4.82e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7020830	0.898	rs13289199	chr9:37278064	A/T	cg14294708	chr9:37120828	ZCCHC7	0.87	17.48	0.65	7.2e-52	Schizophrenia;
LUAD	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg04455712	chr21:45112962	RRP1B	-0.46	-9.14	-0.41	2.73e-18	Mean corpuscular volume;
LUAD	cis	rs7216064	1.000	rs4569324	chr17:65872750	C/T	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg14711859	chr11:8959438	ASCL3	0.37	6.96	0.32	1.31e-11	Hematocrit;
LUAD	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	7.46	0.34	5.11e-13	Tonsillectomy;
LUAD	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg02683114	chr2:24398427	C2orf84	0.47	7.13	0.33	4.29e-12	Asthma;
LUAD	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg05966235	chr16:28915196	ATP2A1	0.47	7.61	0.35	1.75e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.96	-0.36	1.6e-14	Diabetic kidney disease;
LUAD	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg25456477	chr12:86230367	RASSF9	0.33	6.65	0.31	9.32e-11	Major depressive disorder;
LUAD	cis	rs116248771	0.739	rs4334688	chr3:158358666	C/G	cg16708174	chr3:158430962	RARRES1	0.47	6.82	0.31	3.07e-11	diarrhoeal disease at age 2;
LUAD	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.47e-10	Depression;
LUAD	cis	rs7903847	0.642	rs7078004	chr10:99140511	A/G	cg20016023	chr10:99160130	RRP12	-0.29	-7.15	-0.33	3.82e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg26924012	chr15:45694286	SPATA5L1	0.8	13.08	0.54	4.53e-33	Homoarginine levels;
LUAD	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg03433033	chr1:76189801	ACADM	-0.44	-6.46	-0.3	2.92e-10	Daytime sleep phenotypes;
LUAD	cis	rs977987	0.778	rs4888400	chr16:75425596	G/C	cg03315344	chr16:75512273	CHST6	0.64	13.98	0.56	9.24e-37	Dupuytren's disease;
LUAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-7.84	-0.36	3.71e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg05082376	chr22:42548792	NA	0.42	7.31	0.33	1.33e-12	Schizophrenia;
LUAD	cis	rs12210905	0.688	rs12189640	chr6:27474657	T/C	cg08851530	chr6:28072375	NA	1.03	7.92	0.36	2.19e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs12618769	0.652	rs1062847	chr2:99226173	T/A	cg10123293	chr2:99228465	UNC50	0.5	8.97	0.4	9.88e-18	Bipolar disorder;
LUAD	cis	rs2742234	0.590	rs2435338	chr10:43642115	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.5	-8.69	-0.39	7.96e-17	Hirschsprung disease;
LUAD	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg12062639	chr20:23401060	NAPB	1.08	11.35	0.48	2.96e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3752645	1.000	rs8180787	chr7:106773312	A/G	cg02696742	chr7:106810147	HBP1	-0.7	-6.56	-0.3	1.62e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg05991184	chr2:219186017	PNKD	-0.35	-6.74	-0.31	5.33e-11	Colorectal cancer;
LUAD	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	7.98	0.36	1.4e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg14847009	chr1:175162515	KIAA0040	0.3	7.69	0.35	1.05e-13	Alcohol dependence;
LUAD	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg13944838	chr5:179740914	GFPT2	-0.81	-13.72	-0.55	1.06e-35	Height;
LUAD	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg00280220	chr17:61926910	NA	0.36	7.0	0.32	1.04e-11	Prudent dietary pattern;
LUAD	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg26384229	chr12:38710491	ALG10B	0.46	7.82	0.36	4.23e-14	Bladder cancer;
LUAD	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg17366294	chr4:99064904	C4orf37	0.65	12.62	0.52	3.18e-31	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg01620082	chr3:125678407	NA	-0.44	-6.67	-0.31	7.84e-11	Parkinson's disease;
LUAD	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15664640	chr17:80829946	TBCD	0.69	13.6	0.55	3.38e-35	Breast cancer;
LUAD	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg04025307	chr7:1156635	C7orf50	0.58	8.58	0.39	1.82e-16	Bronchopulmonary dysplasia;
LUAD	cis	rs1448094	0.935	rs10746355	chr12:86330227	A/T	cg00310523	chr12:86230176	RASSF9	0.34	7.21	0.33	2.64e-12	Major depressive disorder;
LUAD	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg12257156	chr7:158823799	VIPR2	0.47	7.16	0.33	3.51e-12	Facial morphology (factor 20);
LUAD	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg03929089	chr4:120376271	NA	-0.65	-9.44	-0.42	2.54e-19	Height;
LUAD	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg15383120	chr6:291909	DUSP22	-0.49	-8.19	-0.37	3.05e-15	Menopause (age at onset);
LUAD	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg22535103	chr8:58192502	C8orf71	-0.61	-6.85	-0.32	2.56e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7709909	0.532	rs26781	chr5:80052766	A/G	cg24059623	chr5:79951536	MSH3;DHFR	0.48	7.19	0.33	2.89e-12	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	trans	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg20587970	chr11:113659929	NA	0.89	11.79	0.5	6.14e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs3925075	0.500	rs11641624	chr16:31268985	C/T	cg10451425	chr16:31478370	ARMC5	0.39	6.37	0.3	5.07e-10	IgA nephropathy;
LUAD	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg05340658	chr4:99064831	C4orf37	0.53	8.91	0.4	1.53e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg09117114	chr16:67998030	SLC12A4	-0.52	-6.64	-0.31	9.7e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg01579765	chr21:45077557	HSF2BP	-0.53	-12.08	-0.51	4.43e-29	Mean corpuscular volume;
LUAD	cis	rs4273100	1.000	rs4924986	chr17:19242467	C/T	cg03910582	chr17:19030146	GRAPL	-0.57	-7.49	-0.34	4.05e-13	Schizophrenia;
LUAD	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg19052272	chr2:3704530	ALLC	0.39	6.98	0.32	1.11e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg11062466	chr8:58055876	NA	0.45	6.47	0.3	2.66e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg02683114	chr2:24398427	C2orf84	-0.54	-8.03	-0.36	9.62e-15	Asthma;
LUAD	cis	rs17152411	0.895	rs7900929	chr10:126584999	A/C	cg07906193	chr10:126599966	NA	0.52	7.4	0.34	7.21e-13	Height;
LUAD	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg03676636	chr4:99064102	C4orf37	0.35	8.97	0.4	9.49e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg02985366	chr16:32360428	NA	-0.41	-7.13	-0.33	4.39e-12	Menopause (age at onset);
LUAD	cis	rs123509	0.687	rs6865	chr3:42826041	A/C	cg10144569	chr3:42726640	KBTBD5	-0.47	-7.29	-0.33	1.52e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg05283184	chr6:79620031	NA	0.6	11.98	0.5	1.12e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg11845111	chr2:191398756	TMEM194B	-0.6	-11.09	-0.47	2.93e-25	Pulse pressure;
LUAD	cis	rs806794	0.804	rs9379833	chr6:26207175	C/A	cg00631329	chr6:26305371	NA	-0.48	-7.3	-0.33	1.39e-12	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg08888203	chr3:10149979	C3orf24	0.74	13.07	0.54	5.1e-33	Alzheimer's disease;
LUAD	trans	rs2665103	0.610	rs56398167	chr15:82529823	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.4	-6.7	-0.31	6.79e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg01299579	chr2:10830716	NOL10	0.44	7.69	0.35	1.07e-13	Prostate cancer;
LUAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg15117754	chr3:10150083	C3orf24	0.44	7.09	0.33	5.76e-12	Alzheimer's disease;
LUAD	trans	rs8002861	0.664	rs4941474	chr13:44450289	C/T	cg12856521	chr11:46389249	DGKZ	0.47	8.05	0.36	8.54e-15	Leprosy;
LUAD	cis	rs7903847	0.642	rs7924254	chr10:99120925	C/T	cg20016023	chr10:99160130	RRP12	-0.32	-6.99	-0.32	1.08e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg10589385	chr1:150898437	SETDB1	0.44	7.96	0.36	1.59e-14	Melanoma;
LUAD	cis	rs1461503	0.966	rs1461501	chr11:122844416	A/G	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg23422044	chr7:1970798	MAD1L1	-0.55	-7.02	-0.32	8.64e-12	Bipolar disorder;
LUAD	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg18811423	chr2:55921094	PNPT1	0.51	8.4	0.38	6.94e-16	Metabolic syndrome;
LUAD	cis	rs41311933	0.611	rs72760215	chr9:123859665	T/A	cg13567360	chr9:123745713	C5	-0.72	-8.29	-0.37	1.5e-15	Coronary artery disease;
LUAD	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg02269571	chr22:50332266	NA	0.6	9.15	0.41	2.47e-18	Schizophrenia;
LUAD	cis	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg21775007	chr8:11205619	TDH	0.55	10.04	0.44	2.09e-21	Retinal vascular caliber;
LUAD	cis	rs9914544	0.545	rs12452289	chr17:18781809	T/G	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.49	-0.3	2.45e-10	Educational attainment (years of education);
LUAD	trans	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg06606381	chr12:133084897	FBRSL1	0.6	6.77	0.31	4.35e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg16479474	chr6:28041457	NA	0.34	6.37	0.3	5.07e-10	Parkinson's disease;
LUAD	cis	rs13095912	0.752	rs9758141	chr3:185315085	A/T	cg11274856	chr3:185301563	NA	0.49	9.32	0.41	6.64e-19	Systolic blood pressure;
LUAD	cis	rs75920871	0.841	rs112151056	chr11:116919368	G/A	cg04087571	chr11:116723030	SIK3	-0.33	-6.75	-0.31	4.79e-11	Subjective well-being;
LUAD	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg00634984	chr7:65235879	NA	0.48	6.52	0.3	2e-10	Aortic root size;
LUAD	cis	rs1031391	0.716	rs10772416	chr12:11170087	T/A	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	0.62	8.6	0.39	1.55e-16	Bitter taste perception;
LUAD	trans	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg06606381	chr12:133084897	FBRSL1	-0.81	-6.77	-0.31	4.41e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21582582	chr3:182698605	DCUN1D1	0.72	14.11	0.57	2.63e-37	Intelligence (multi-trait analysis);
LUAD	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21659725	chr3:3221576	CRBN	0.67	11.43	0.49	1.46e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg08470875	chr2:26401718	FAM59B	-0.62	-8.45	-0.38	4.88e-16	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg20607798	chr8:58055168	NA	0.58	7.54	0.34	2.94e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs4006360	0.522	rs72625953	chr17:39237157	A/C	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.37	0.38	8.48e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs12545109	0.800	rs1467125	chr8:57418638	C/T	cg19413350	chr8:57351067	NA	-0.45	-6.89	-0.32	2.09e-11	Obesity-related traits;
LUAD	cis	rs7072216	0.763	rs10883091	chr10:100167239	C/T	cg26618903	chr10:100175079	PYROXD2	-0.37	-7.98	-0.36	1.34e-14	Metabolite levels;
LUAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg16606324	chr3:10149918	C3orf24	-0.54	-7.54	-0.34	2.84e-13	Alzheimer's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11343086	chr1:202113710	ARL8A	-0.45	-6.96	-0.32	1.29e-11	Height;
LUAD	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg26924012	chr15:45694286	SPATA5L1	1.02	18.92	0.68	2.86e-58	Homoarginine levels;
LUAD	trans	rs62103177	0.714	rs12607447	chr18:77605212	A/G	cg05926928	chr17:57297772	GDPD1	0.82	11.65	0.49	2.11e-27	Opioid sensitivity;
LUAD	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg07967210	chr17:47022446	SNF8	0.35	6.38	0.3	4.54e-10	Type 2 diabetes;
LUAD	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg25753631	chr6:25732923	NA	-0.39	-6.44	-0.3	3.25e-10	Iron status biomarkers;
LUAD	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-7.41	-0.34	6.96e-13	Morning vs. evening chronotype;
LUAD	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg03929089	chr4:120376271	NA	-0.92	-17.27	-0.64	5.85e-51	Height;
LUAD	cis	rs10065203	0.527	rs152177	chr5:14354270	G/A	cg26595256	chr5:14380529	TRIO	-0.41	-7.04	-0.32	8.04e-12	Paclitaxel-induced neuropathy;
LUAD	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg23978390	chr7:1156363	C7orf50	0.57	7.78	0.35	5.6e-14	Bronchopulmonary dysplasia;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg04783966	chr14:21152735	RNASE4;ANG	-0.36	-6.52	-0.3	2.03e-10	Schizophrenia;
LUAD	cis	rs9788721	0.933	rs72738786	chr15:78828086	G/T	cg18825076	chr15:78729989	IREB2	-0.56	-8.99	-0.4	8.29e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	trans	rs3903072	0.528	rs7928652	chr11:65580228	A/C	cg17712092	chr4:129076599	LARP1B	0.61	9.34	0.41	5.55e-19	Breast cancer;
LUAD	cis	rs2070488	0.662	rs6599202	chr3:38480651	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.49	7.68	0.35	1.13e-13	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.88	0.36	2.78e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg16797656	chr11:68205561	LRP5	0.46	8.98	0.4	8.96e-18	Total body bone mineral density;
LUAD	cis	rs1395	0.922	rs6547521	chr2:27488432	G/C	cg23587288	chr2:27483067	SLC30A3	-0.4	-8.08	-0.37	6.72e-15	Blood metabolite levels;
LUAD	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.56	-10.4	-0.45	1.06e-22	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg22167660	chr19:40885241	HIPK4	-0.45	-7.14	-0.33	4.07e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1953600	0.870	rs12770550	chr10:81953451	G/T	cg04850286	chr10:81895943	PLAC9	0.36	6.52	0.3	1.98e-10	Sarcoidosis;
LUAD	cis	rs11716531	0.573	rs642570	chr3:27342595	C/G	cg02860705	chr3:27208620	NA	0.51	8.51	0.38	3.01e-16	Diastolic blood pressure;
LUAD	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.26	-0.37	1.83e-15	Bipolar disorder;
LUAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg04546413	chr19:29218101	NA	0.68	10.13	0.44	9.56e-22	Methadone dose in opioid dependence;
LUAD	cis	rs1451375	0.698	rs68143668	chr7:50638110	C/T	cg18232548	chr7:50535776	DDC	0.49	7.98	0.36	1.35e-14	Malaria;
LUAD	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21582582	chr3:182698605	DCUN1D1	0.6	10.15	0.44	8.01e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs13427251	0.653	rs11123787	chr2:100156940	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.4	-6.47	-0.3	2.68e-10	Chronic sinus infection;
LUAD	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg25985355	chr7:65971099	NA	-0.38	-6.89	-0.32	2.02e-11	Aortic root size;
LUAD	cis	rs9644630	0.965	rs10105097	chr8:19364883	A/C	cg06699216	chr8:19333253	CSGALNACT1	0.33	8.16	0.37	3.77e-15	Oropharynx cancer;
LUAD	cis	rs1371614	0.545	rs12105356	chr2:27175570	T/C	cg00617064	chr2:27272375	NA	-0.36	-6.75	-0.31	5.01e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs9902453	0.904	rs12103671	chr17:28408217	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-9.81	-0.43	1.28e-20	Coffee consumption (cups per day);
LUAD	cis	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-7.62	-0.35	1.7e-13	Neuroticism;
LUAD	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg13902645	chr11:5959945	NA	-0.51	-8.83	-0.39	2.75e-17	DNA methylation (variation);
LUAD	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg08999081	chr20:33150536	PIGU	0.62	13.95	0.56	1.24e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.68	-0.35	1.15e-13	Alzheimer's disease (late onset);
LUAD	trans	rs3960554	0.569	rs10464565	chr7:75869526	T/G	cg19862616	chr7:65841803	NCRNA00174	0.57	8.8	0.39	3.51e-17	Eotaxin levels;
LUAD	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.71	-14.65	-0.58	1.31e-39	Urate levels in overweight individuals;
LUAD	cis	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg21775007	chr8:11205619	TDH	-0.37	-6.38	-0.3	4.59e-10	Systolic blood pressure;
LUAD	cis	rs6545883	0.929	rs10173974	chr2:61748900	C/G	cg15711740	chr2:61764176	XPO1	-0.39	-6.38	-0.3	4.53e-10	Tuberculosis;
LUAD	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	15.71	0.61	3.97e-44	Bone mineral density;
LUAD	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg21854759	chr1:92012499	NA	-0.47	-6.82	-0.31	3.1e-11	Eosinophil percentage of white cells;
LUAD	cis	rs35883536	0.647	rs2783693	chr1:101045040	C/T	cg06223162	chr1:101003688	GPR88	0.49	9.68	0.43	3.64e-20	Monocyte count;
LUAD	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06544989	chr22:39130855	UNC84B	0.42	7.63	0.35	1.58e-13	Menopause (age at onset);
LUAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg02725872	chr8:58115012	NA	-0.33	-6.46	-0.3	2.9e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg00981070	chr1:2046702	PRKCZ	0.36	6.88	0.32	2.1e-11	Height;
LUAD	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	8.4	0.38	6.97e-16	Breast cancer;
LUAD	cis	rs12760731	0.720	rs12035174	chr1:178314311	A/T	cg00404053	chr1:178313656	RASAL2	0.65	8.49	0.38	3.47e-16	Obesity-related traits;
LUAD	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg17971929	chr21:40555470	PSMG1	0.39	6.43	0.3	3.51e-10	Cognitive function;
LUAD	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	14.33	0.57	3.02e-38	Lung cancer in ever smokers;
LUAD	cis	rs11723261	0.621	rs6599307	chr4:143777	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	8.25	0.37	2.1e-15	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg01868782	chr6:126071099	HEY2	0.3	6.35	0.3	5.48e-10	Brugada syndrome;
LUAD	cis	rs2019216	0.934	rs7405575	chr17:21936954	T/C	cg05591447	chr17:21909280	FLJ36000	-0.3	-7.74	-0.35	7.59e-14	Pelvic organ prolapse;
LUAD	trans	rs1728785	1.000	rs7205960	chr16:68565604	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.79	0.43	1.59e-20	Ulcerative colitis;
LUAD	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg16479474	chr6:28041457	NA	0.42	7.42	0.34	6.35e-13	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13082711	0.906	rs34775440	chr3:27447333	G/T	cg02860705	chr3:27208620	NA	0.61	9.21	0.41	1.55e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs684232	0.602	rs331014	chr17:532103	C/T	cg12384639	chr17:618140	VPS53	0.48	8.12	0.37	5.21e-15	Prostate cancer;
LUAD	cis	rs1232027	0.622	rs1628627	chr5:79967262	A/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.34	-0.34	1.13e-12	Huntington's disease progression;
LUAD	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23158103	chr7:148848205	ZNF398	-0.65	-12.12	-0.51	3.28e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg05887092	chr17:76393375	PGS1	0.42	7.42	0.34	6.29e-13	HDL cholesterol levels;
LUAD	cis	rs4988958	0.565	rs10206291	chr2:103038863	T/C	cg03938978	chr2:103052716	IL18RAP	0.45	10.37	0.45	1.29e-22	Asthma (childhood onset);
LUAD	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.38	-8.12	-0.37	5.05e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2230307	0.536	rs7518943	chr1:100463422	G/T	cg20868668	chr1:100435035	SLC35A3	0.5	7.33	0.34	1.16e-12	Carotid intima media thickness;
LUAD	cis	rs4285028	0.603	rs79312528	chr3:121608997	T/C	cg11130432	chr3:121712080	ILDR1	-0.6	-8.37	-0.38	8.21e-16	Multiple sclerosis;
LUAD	cis	rs7084416	0.517	rs75453629	chr10:82010658	C/T	cg00277334	chr10:82204260	NA	0.47	7.8	0.35	4.85e-14	Post bronchodilator FEV1;
LUAD	cis	rs2233152	0.610	rs10416308	chr19:41312261	G/A	cg21869046	chr19:41225005	ITPKC	0.44	7.97	0.36	1.52e-14	Kawasaki disease;
LUAD	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06028808	chr11:68637592	NA	0.49	8.14	0.37	4.35e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg07870213	chr5:140052090	DND1	0.88	12.71	0.53	1.41e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg11901034	chr3:128598214	ACAD9	-0.55	-8.75	-0.39	5.24e-17	IgG glycosylation;
LUAD	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg26384229	chr12:38710491	ALG10B	0.47	7.51	0.34	3.49e-13	Heart rate;
LUAD	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg26384229	chr12:38710491	ALG10B	0.44	7.51	0.34	3.55e-13	Heart rate;
LUAD	cis	rs4343996	0.720	rs10250421	chr7:3458288	A/T	cg21248987	chr7:3385318	SDK1	0.37	7.0	0.32	1e-11	Motion sickness;
LUAD	cis	rs9902453	0.934	rs8079028	chr17:28484234	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.8	0.43	1.44e-20	Coffee consumption (cups per day);
LUAD	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg18252515	chr7:66147081	NA	-0.6	-6.59	-0.31	1.33e-10	Diabetic kidney disease;
LUAD	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg23887609	chr12:130822674	PIWIL1	0.41	6.92	0.32	1.68e-11	Menopause (age at onset);
LUAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg09367891	chr1:107599246	PRMT6	-0.58	-9.66	-0.42	4.56e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg00271210	chr6:167070053	RPS6KA2	0.34	6.6	0.31	1.27e-10	Crohn's disease;
LUAD	cis	rs9905704	0.681	rs887206	chr17:56575084	G/C	cg19466818	chr17:56409534	MIR142	0.34	6.8	0.31	3.51e-11	Testicular germ cell tumor;
LUAD	cis	rs1160297	0.601	rs1828337	chr2:53096942	G/T	cg07782112	chr2:53107842	NA	0.37	7.81	0.36	4.45e-14	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs8073060	0.519	rs8065286	chr17:33864479	A/G	cg05299278	chr17:33885742	SLFN14	-0.36	-7.33	-0.34	1.2e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg05665937	chr4:1216051	CTBP1	-0.46	-6.82	-0.31	3.25e-11	Longevity;
LUAD	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg03037974	chr15:76606532	NA	0.38	8.06	0.36	7.89e-15	Blood metabolite levels;
LUAD	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22590775	chr19:49891494	CCDC155	-0.62	-8.85	-0.4	2.33e-17	Multiple sclerosis;
LUAD	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg16414030	chr3:133502952	NA	0.39	6.9	0.32	1.89e-11	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg10645314	chr2:3704589	ALLC	0.66	10.4	0.45	1.03e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs35771425	1.000	rs11580728	chr1:211614280	C/T	cg25617285	chr1:211431773	RCOR3	-0.42	-6.38	-0.3	4.56e-10	Educational attainment (years of education);
LUAD	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg15147215	chr3:52552868	STAB1	-0.41	-7.52	-0.34	3.41e-13	Bipolar disorder;
LUAD	cis	rs7771547	0.603	rs10947614	chr6:36573822	G/C	cg02952361	chr6:36355661	ETV7	0.48	6.47	0.3	2.68e-10	Platelet distribution width;
LUAD	cis	rs11971779	0.715	rs7779390	chr7:139112953	C/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.38	-0.3	4.74e-10	Diisocyanate-induced asthma;
LUAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs4942242	0.512	rs9533552	chr13:44187194	C/T	cg19169023	chr15:41853346	TYRO3	-0.75	-12.81	-0.53	5.4e-32	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs10821973	0.527	rs7078397	chr10:63984649	C/T	cg09941381	chr10:64027924	RTKN2	-0.34	-6.77	-0.31	4.23e-11	Hypothyroidism;
LUAD	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg24733560	chr20:60626293	TAF4	0.47	9.19	0.41	1.73e-18	Body mass index;
LUAD	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg17757837	chr7:157058334	UBE3C	-0.51	-9.17	-0.41	2.07e-18	Body mass index;
LUAD	cis	rs2625529	0.761	rs8028532	chr15:72348054	G/A	cg16672083	chr15:72433130	SENP8	-0.74	-12.52	-0.52	8.6e-31	Red blood cell count;
LUAD	cis	rs4253772	0.530	rs9615362	chr22:46795141	A/C	cg00784671	chr22:46762841	CELSR1	0.48	6.69	0.31	7.01e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg27411982	chr8:10470053	RP1L1	0.37	6.54	0.3	1.79e-10	Systolic blood pressure;
LUAD	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	7.6	0.35	1.92e-13	Tonsillectomy;
LUAD	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01570182	chr17:44337453	NA	1.12	17.17	0.64	1.59e-50	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg00530320	chr1:46809349	NSUN4	0.52	7.94	0.36	1.89e-14	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.27e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg22079354	chr11:130786696	SNX19	0.41	7.1	0.33	5.38e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2425143	0.730	rs6060624	chr20:34413663	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.85	-0.32	2.62e-11	Blood protein levels;
LUAD	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg11189052	chr15:85197271	WDR73	0.68	8.96	0.4	1.06e-17	Schizophrenia;
LUAD	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg27170947	chr2:26402098	FAM59B	-0.62	-8.7	-0.39	7.22e-17	Gut microbiome composition (summer);
LUAD	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg08847533	chr14:75593920	NEK9	0.39	6.57	0.3	1.46e-10	Height;
LUAD	cis	rs7017914	0.967	rs56112621	chr8:71588394	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.58	-0.3	1.44e-10	Bone mineral density;
LUAD	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg17509989	chr5:176798049	RGS14	0.58	10.35	0.45	1.52e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.54	-0.38	2.4e-16	Alzheimer's disease (late onset);
LUAD	cis	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg07460842	chr6:66804631	NA	0.59	9.1	0.4	3.47e-18	Type 2 diabetes;
LUAD	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg03609598	chr5:56110824	MAP3K1	0.48	7.11	0.33	4.92e-12	Initial pursuit acceleration;
LUAD	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg02160872	chr5:212506	CCDC127	-0.51	-6.61	-0.31	1.16e-10	Breast cancer;
LUAD	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.65	-9.31	-0.41	6.86e-19	Height;
LUAD	cis	rs89107	0.688	rs283086	chr6:118596941	C/T	cg21191810	chr6:118973309	C6orf204	0.49	9.58	0.42	8.23e-20	Cardiac structure and function;
LUAD	cis	rs7705042	0.861	rs6860138	chr5:141509985	G/A	cg08523384	chr5:141488047	NDFIP1	-0.38	-6.48	-0.3	2.55e-10	Asthma;
LUAD	cis	rs4711336	0.809	rs749338	chr6:33653448	A/G	cg14003231	chr6:33640908	ITPR3	-0.51	-9.85	-0.43	9.21e-21	Height;
LUAD	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg03859395	chr2:55845619	SMEK2	0.74	13.8	0.56	5.19e-36	Metabolic syndrome;
LUAD	cis	rs2377058	0.803	rs13332439	chr16:89730479	A/T	cg12119029	chr16:89752879	CDK10	-0.36	-7.57	-0.35	2.36e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.8	-17.2	-0.64	1.15e-50	Longevity;Endometriosis;
LUAD	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg25985355	chr7:65971099	NA	0.37	6.98	0.32	1.16e-11	Aortic root size;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19978540	chr12:3409405	NA	-0.43	-7.1	-0.33	5.37e-12	Height;
LUAD	cis	rs4604732	0.536	rs4925674	chr1:247636906	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.43	7.44	0.34	5.62e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg06636001	chr8:8085503	FLJ10661	0.44	7.02	0.32	9.12e-12	Systolic blood pressure;
LUAD	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.55	-0.89	3.42e-144	Myeloid white cell count;
LUAD	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg03233332	chr7:66118400	NA	-0.43	-6.43	-0.3	3.38e-10	Aortic root size;
LUAD	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07930192	chr7:1003750	NA	0.39	7.48	0.34	4.42e-13	Longevity;Endometriosis;
LUAD	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg04025307	chr7:1156635	C7orf50	0.66	9.42	0.42	2.99e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg07169764	chr2:136633963	MCM6	0.64	7.69	0.35	1.05e-13	Corneal structure;
LUAD	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg00864171	chr11:67383662	NA	0.36	6.37	0.3	4.98e-10	Mean corpuscular volume;
LUAD	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.67	-11.33	-0.48	3.61e-26	Primary sclerosing cholangitis;
LUAD	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs72772090	0.710	rs17400741	chr5:96066576	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-6.74	-0.31	5.07e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs8099014	0.816	rs8099343	chr18:56110071	C/T	cg12907477	chr18:56117327	MIR122	0.39	6.66	0.31	8.43e-11	Platelet count;
LUAD	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg04398451	chr17:18023971	MYO15A	0.64	11.43	0.49	1.45e-26	Total body bone mineral density;
LUAD	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.9	-0.36	2.43e-14	Menopause (age at onset);
LUAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg08027265	chr7:2291960	NA	-0.41	-6.76	-0.31	4.54e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-10.29	-0.45	2.64e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg21918786	chr6:109611834	NA	-0.62	-11.37	-0.48	2.56e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg19635926	chr16:89946313	TCF25	0.73	6.44	0.3	3.23e-10	Skin colour saturation;
LUAD	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg06618935	chr21:46677482	NA	-0.51	-10.35	-0.45	1.58e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg21775007	chr8:11205619	TDH	0.47	8.11	0.37	5.36e-15	Retinal vascular caliber;
LUAD	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11890956	chr21:40555474	PSMG1	0.81	14.59	0.58	2.52e-39	Cognitive function;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09242721	chr3:3168535	TRNT1	-0.53	-6.56	-0.3	1.54e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg11502198	chr6:26597334	ABT1	0.68	11.85	0.5	3.69e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs3823572	0.564	rs3735050	chr7:133682181	T/C	cg03336402	chr7:133662267	EXOC4	-0.43	-7.52	-0.34	3.26e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7809950	0.678	rs17153981	chr7:106922106	A/G	cg23024343	chr7:107201750	COG5	-0.8	-13.32	-0.54	4.98e-34	Coronary artery disease;
LUAD	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg21724239	chr8:58056113	NA	0.8	9.72	0.43	2.8e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs8017423	0.967	rs8016385	chr14:90721946	G/A	cg14092571	chr14:90743983	NA	-0.5	-8.8	-0.39	3.61e-17	Mortality in heart failure;
LUAD	cis	rs6993813	0.872	rs4615609	chr8:120035493	A/G	cg01975934	chr8:119970761	NA	-0.37	-7.23	-0.33	2.26e-12	Bone mineral density (hip);
LUAD	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg27170947	chr2:26402098	FAM59B	0.8	10.65	0.46	1.3e-23	Gut microbiome composition (summer);
LUAD	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg26816564	chr1:7831052	VAMP3	0.68	9.32	0.41	6.48e-19	Inflammatory bowel disease;
LUAD	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18099408	chr3:52552593	STAB1	-0.42	-7.44	-0.34	5.6e-13	Bipolar disorder;
LUAD	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	6.94	0.32	1.44e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12049351	0.774	rs754022	chr1:229637645	C/A	cg11742688	chr1:229674241	ABCB10	-0.42	-6.74	-0.31	5.32e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg09796270	chr17:17721594	SREBF1	0.38	7.79	0.35	5.3e-14	Total body bone mineral density;
LUAD	cis	rs67981189	0.513	rs221893	chr14:71611414	G/A	cg15816911	chr14:71606274	NA	-0.36	-6.71	-0.31	6.37e-11	Schizophrenia;
LUAD	cis	rs1215050	0.791	rs684210	chr4:98678740	G/C	cg05340658	chr4:99064831	C4orf37	0.43	7.01	0.32	9.19e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg27279351	chr12:120934652	DYNLL1	0.44	6.68	0.31	7.71e-11	High light scatter reticulocyte count;
LUAD	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg07305463	chr2:136567211	LCT	0.38	7.1	0.33	5.38e-12	Mosquito bite size;
LUAD	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg06641503	chr3:48959341	ARIH2	-0.41	-7.9	-0.36	2.41e-14	Parkinson's disease;
LUAD	cis	rs4280164	0.887	rs11158634	chr14:24776457	C/G	cg07162820	chr14:24837146	NFATC4	0.33	6.56	0.3	1.58e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs2735413	0.881	rs12920025	chr16:78083005	C/T	cg04733911	chr16:78082701	NA	-0.35	-8.21	-0.37	2.74e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs2996428	0.561	rs12134919	chr1:3744641	G/A	cg10555106	chr1:3691387	LOC388588	0.4	6.46	0.3	2.87e-10	Red cell distribution width;
LUAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg03188948	chr7:1209495	NA	0.72	9.12	0.41	2.97e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.26	0.33	1.91e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs1595825	0.891	rs16823385	chr2:198602101	G/A	cg00982548	chr2:198649783	BOLL	-0.66	-8.91	-0.4	1.49e-17	Ulcerative colitis;
LUAD	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.03	-0.32	8.29e-12	Total body bone mineral density;
LUAD	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-7.33	-0.34	1.17e-12	Coronary artery disease;
LUAD	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg26022315	chr17:47021804	SNF8	0.4	7.3	0.33	1.45e-12	Type 2 diabetes;
LUAD	cis	rs11971779	0.680	rs7801613	chr7:139039927	A/G	cg23387468	chr7:139079360	LUC7L2	-0.29	-6.68	-0.31	7.49e-11	Diisocyanate-induced asthma;
LUAD	trans	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg21582582	chr3:182698605	DCUN1D1	0.4	6.67	0.31	8.17e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs62400317	0.762	rs12190313	chr6:44903902	T/G	cg18551225	chr6:44695536	NA	-0.59	-8.89	-0.4	1.85e-17	Total body bone mineral density;
LUAD	cis	rs11229555	0.645	rs12785578	chr11:58206432	C/T	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg27102117	chr16:15229624	NA	0.73	13.04	0.54	6.71e-33	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg13606994	chr1:44402422	ARTN	-0.36	-7.29	-0.33	1.56e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs11039798	0.844	rs41431447	chr11:48983199	A/G	cg15704280	chr7:45808275	SEPT13	0.75	7.53	0.34	2.99e-13	Axial length;
LUAD	cis	rs1595825	0.891	rs1440086	chr2:198906354	A/G	cg10547527	chr2:198650123	BOLL	-0.47	-6.55	-0.3	1.68e-10	Ulcerative colitis;
LUAD	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-10.21	-0.44	5.21e-22	Hip circumference adjusted for BMI;
LUAD	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03264133	chr6:25882463	NA	-0.55	-8.86	-0.4	2.19e-17	Blood metabolite levels;
LUAD	cis	rs2996428	0.709	rs6667255	chr1:3711689	T/C	cg18436788	chr1:3704244	LRRC47	0.33	6.72	0.31	5.74e-11	Red cell distribution width;
LUAD	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg22117172	chr7:91764530	CYP51A1	0.3	6.63	0.31	1.03e-10	Breast cancer;
LUAD	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.3	-0.45	2.31e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.39	0.55	2.41e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg07217954	chr7:1067459	C7orf50	0.4	6.56	0.3	1.54e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg06618935	chr21:46677482	NA	0.48	9.63	0.42	5.81e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs35995292	0.926	rs10259755	chr7:38897012	A/C	cg19327137	chr7:38886074	VPS41	0.5	8.29	0.37	1.55e-15	Subjective well-being (multi-trait analysis);
LUAD	cis	rs2289700	0.518	rs77362013	chr15:79167260	T/C	cg04896959	chr15:78267971	NA	-0.6	-7.18	-0.33	3.25e-12	Bipolar disorder;
LUAD	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg10057126	chr4:77819792	ANKRD56	0.55	9.62	0.42	6.09e-20	Emphysema distribution in smoking;
LUAD	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg09117114	chr16:67998030	SLC12A4	-0.61	-8.24	-0.37	2.13e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.6	-0.31	1.26e-10	Morning vs. evening chronotype;
LUAD	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg04455712	chr21:45112962	RRP1B	0.42	8.48	0.38	3.71e-16	Mean corpuscular volume;
LUAD	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg11833968	chr6:79620685	NA	0.42	7.88	0.36	2.73e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg05283184	chr6:79620031	NA	-0.6	-12.21	-0.51	1.37e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg07741184	chr6:167504864	NA	0.4	9.25	0.41	1.15e-18	Crohn's disease;
LUAD	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg15123519	chr2:136567270	LCT	0.39	7.11	0.33	4.99e-12	Mosquito bite size;
LUAD	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg03467027	chr4:99064603	C4orf37	0.41	6.61	0.31	1.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg18180107	chr4:99064573	C4orf37	0.43	6.96	0.32	1.27e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg05425664	chr17:57184151	TRIM37	0.43	7.66	0.35	1.28e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg10295955	chr4:187884368	NA	-1.17	-30.52	-0.83	6e-109	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25427524	chr10:38739819	LOC399744	-0.79	-14.22	-0.57	8.83e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg11070056	chr1:107600091	PRMT6	0.58	9.8	0.43	1.41e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg14039649	chr22:38352398	POLR2F	0.36	6.4	0.3	4.21e-10	Glioblastoma;Glioma;
LUAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg11494091	chr17:61959527	GH2	0.74	18.24	0.66	3.05e-55	Prudent dietary pattern;
LUAD	cis	rs2996428	0.709	rs6424052	chr1:3713746	A/G	cg17443473	chr1:3703550	LRRC47	0.45	7.55	0.34	2.77e-13	Red cell distribution width;
LUAD	cis	rs7224314	1.000	rs7224314	chr17:65386214	A/C	cg01507342	chr17:65387096	PITPNC1	-0.53	-9.02	-0.4	6.63e-18	Diisocyanate-induced asthma;
LUAD	cis	rs1882538	0.564	rs10488164	chr7:133106199	A/G	cg10665199	chr7:133106180	EXOC4	0.62	10.9	0.47	1.56e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.5	0.3	2.33e-10	Depression;
LUAD	cis	rs6906287	0.647	rs67832971	chr6:118832205	C/T	cg21191810	chr6:118973309	C6orf204	0.5	9.77	0.43	1.85e-20	Electrocardiographic conduction measures;
LUAD	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg12908607	chr1:44402522	ARTN	-0.52	-9.95	-0.44	4.2e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	9.8	0.43	1.41e-20	Colorectal cancer;
LUAD	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg04369109	chr6:150039330	LATS1	-0.44	-6.88	-0.32	2.12e-11	Lung cancer;
LUAD	cis	rs1032833	0.732	rs17454108	chr2:179987043	T/G	cg23883738	chr2:179974586	SESTD1	-0.7	-7.73	-0.35	8.12e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg03929089	chr4:120376271	NA	-0.82	-15.03	-0.59	3.2e-41	Coronary artery disease;
LUAD	cis	rs7010267	0.596	rs7010043	chr8:120011331	G/T	cg01975934	chr8:119970761	NA	-0.35	-6.53	-0.3	1.87e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg20380214	chr12:9217688	LOC144571	-0.36	-6.88	-0.32	2.16e-11	Sjögren's syndrome;
LUAD	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg18132916	chr6:79620363	NA	-0.46	-7.97	-0.36	1.44e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9394152	0.810	rs9380364	chr6:33471721	T/C	cg13560919	chr6:33536144	NA	0.51	8.64	0.39	1.17e-16	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs1723838	0.510	rs2735572	chr11:73688492	C/T	cg10064339	chr11:73693792	UCP2	1.33	10.84	0.47	2.58e-24	Obesity-related traits;
LUAD	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg02371401	chr5:676784	TPPP	-0.36	-6.56	-0.3	1.61e-10	Ulcerative colitis;
LUAD	cis	rs8025790	0.508	rs12441823	chr15:67912977	C/T	cg24579218	chr15:68104479	NA	-0.46	-7.3	-0.33	1.47e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.79	-15.26	-0.6	3.22e-42	Intelligence (multi-trait analysis);
LUAD	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg26384229	chr12:38710491	ALG10B	0.41	6.51	0.3	2.16e-10	Morning vs. evening chronotype;
LUAD	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-11.93	-0.5	1.77e-28	Monocyte percentage of white cells;
LUAD	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg13390004	chr1:15929781	NA	0.48	8.45	0.38	4.82e-16	Systolic blood pressure;
LUAD	trans	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg01620082	chr3:125678407	NA	-0.78	-7.91	-0.36	2.22e-14	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs7395662	1.000	rs7938880	chr11:48642154	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.24	-0.33	2.12e-12	HDL cholesterol;
LUAD	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg25324976	chr17:61989376	CSHL1	0.38	7.39	0.34	7.83e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg18180107	chr4:99064573	C4orf37	0.4	6.45	0.3	3.04e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.3	0.51	6.1e-30	Tonsillectomy;
LUAD	trans	rs7395662	0.929	rs7952580	chr11:48595206	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.33	-0.34	1.14e-12	HDL cholesterol;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17649588	chr1:117602748	TTF2	-0.45	-6.81	-0.31	3.42e-11	Height;
LUAD	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg13770153	chr20:60521292	NA	-0.58	-9.07	-0.4	4.6e-18	Body mass index;
LUAD	trans	rs564343	0.966	rs527962	chr11:65884718	G/A	cg26701943	chr11:108369231	KDELC2	-0.45	-7.5	-0.34	3.87e-13	Obesity (early onset extreme);
LUAD	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg15445000	chr17:37608096	MED1	-0.44	-8.07	-0.37	7.45e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13012494	chr21:47604986	C21orf56	-0.7	-12.15	-0.51	2.44e-29	Testicular germ cell tumor;
LUAD	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg03037974	chr15:76606532	NA	0.38	7.97	0.36	1.5e-14	Blood metabolite levels;
LUAD	trans	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg27411982	chr8:10470053	RP1L1	-0.4	-6.96	-0.32	1.29e-11	Mood instability;
LUAD	cis	rs2262909	0.889	rs61268244	chr19:22310130	C/T	cg11619707	chr19:22235551	ZNF257	0.49	7.52	0.34	3.33e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2070677	0.935	rs2070676	chr10:135351137	C/G	cg20169779	chr10:135381914	SYCE1	0.49	7.6	0.35	1.93e-13	Gout;
LUAD	cis	rs34638657	0.732	rs12597010	chr16:82199971	G/A	cg09439754	chr16:82129088	HSD17B2	-0.37	-7.07	-0.33	6.52e-12	Lung adenocarcinoma;
LUAD	cis	rs13144136	0.687	rs11737643	chr4:10658199	T/A	cg10242279	chr4:10666415	CLNK	-0.3	-6.39	-0.3	4.46e-10	Resistance to antihypertensive treatment in hypertension;
LUAD	cis	rs11650494	0.908	rs79768864	chr17:47446968	C/A	cg08112188	chr17:47440006	ZNF652	0.98	8.22	0.37	2.52e-15	Prostate cancer;
LUAD	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg12935359	chr14:103987150	CKB	-0.49	-7.85	-0.36	3.52e-14	Body mass index;
LUAD	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.48	0.42	1.89e-19	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg01616529	chr11:638424	DRD4	-0.44	-6.47	-0.3	2.66e-10	Systemic lupus erythematosus;
LUAD	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg04539111	chr16:67997858	SLC12A4	-0.63	-7.79	-0.35	5.32e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg08632164	chr7:65971372	NA	0.36	6.38	0.3	4.77e-10	Aortic root size;
LUAD	cis	rs6424115	1.000	rs12121387	chr1:24166536	T/G	cg15997130	chr1:24165203	NA	-0.57	-9.92	-0.43	5.56e-21	Immature fraction of reticulocytes;
LUAD	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg25894440	chr7:65020034	NA	-0.62	-6.63	-0.31	1.05e-10	Diabetic kidney disease;
LUAD	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg00981070	chr1:2046702	PRKCZ	-0.35	-7.61	-0.35	1.85e-13	Height;
LUAD	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg18277682	chr1:228362509	C1orf69	-0.39	-6.53	-0.3	1.92e-10	Diastolic blood pressure;
LUAD	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.49	-0.34	3.99e-13	Type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.77	-0.46	4.63e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs4481887	0.893	rs11204632	chr1:248479532	G/A	cg00666640	chr1:248458726	OR2T12	0.31	7.46	0.34	4.85e-13	Common traits (Other);
LUAD	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	12.56	0.52	5.89e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg00953403	chr17:74099816	EXOC7	0.41	6.36	0.3	5.37e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs2242663	0.529	rs1785640	chr11:66223158	C/T	cg18002602	chr11:66138449	SLC29A2	-0.33	-6.73	-0.31	5.52e-11	Bipolar disorder;
LUAD	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg06544989	chr22:39130855	UNC84B	0.42	8.04	0.36	9.18e-15	Menopause (age at onset);
LUAD	cis	rs11971779	0.715	rs7781459	chr7:139093882	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.75	0.31	4.97e-11	Diisocyanate-induced asthma;
LUAD	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg25233709	chr10:116636983	FAM160B1	0.39	7.55	0.34	2.63e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg07217954	chr7:1067459	C7orf50	-0.43	-7.47	-0.34	4.76e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs2289328	1.000	rs2289328	chr15:40705417	G/A	cg08996748	chr15:40651036	DISP2	-0.51	-7.29	-0.33	1.5e-12	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LUAD	cis	rs62238980	0.614	rs116941748	chr22:32404361	C/T	cg00543991	chr22:32367038	NA	0.95	9.02	0.4	6.52e-18	Childhood ear infection;
LUAD	cis	rs12760731	0.565	rs6701848	chr1:178156816	A/C	cg00404053	chr1:178313656	RASAL2	0.66	8.47	0.38	4.1e-16	Obesity-related traits;
LUAD	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.54	-0.34	2.95e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6684428	1.000	rs12145137	chr1:56370557	A/T	cg11651538	chr1:56320950	NA	-0.4	-6.39	-0.3	4.39e-10	Airflow obstruction;
LUAD	cis	rs6546550	0.933	rs6546555	chr2:70135760	A/G	cg02498382	chr2:70120550	SNRNP27	-0.58	-11.0	-0.47	6.47e-25	Prevalent atrial fibrillation;
LUAD	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg23625390	chr15:77176239	SCAPER	0.5	7.71	0.35	8.99e-14	Blood metabolite levels;
LUAD	cis	rs1003719	0.715	rs2835644	chr21:38545610	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.43	-0.38	5.42e-16	Eye color traits;
LUAD	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	9.13	0.41	2.83e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.77e-11	Depression;
LUAD	trans	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg17712092	chr4:129076599	LARP1B	-0.65	-10.15	-0.44	8.61e-22	Eosinophil percentage of white cells;
LUAD	cis	rs2637266	0.783	rs7898786	chr10:78481338	T/C	cg18941641	chr10:78392320	NA	0.32	6.83	0.32	2.98e-11	Pulmonary function;
LUAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg20607798	chr8:58055168	NA	0.56	6.88	0.32	2.17e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg13390004	chr1:15929781	NA	0.48	8.48	0.38	3.74e-16	Systolic blood pressure;
LUAD	cis	rs295140	0.605	rs3739119	chr2:201194279	C/A	cg23649088	chr2:200775458	C2orf69	-0.43	-7.33	-0.34	1.15e-12	QT interval;
LUAD	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.57	-0.35	2.34e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21483842	chr13:49821938	CDADC1	-0.46	-6.97	-0.32	1.2e-11	Height;
LUAD	trans	rs2735413	0.918	rs56397244	chr16:78081366	A/T	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg07061783	chr6:25882402	NA	0.53	8.16	0.37	3.75e-15	Blood metabolite levels;
LUAD	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg19418458	chr7:158789849	NA	-0.57	-10.02	-0.44	2.49e-21	Facial morphology (factor 20);
LUAD	trans	rs12310956	0.531	rs10772110	chr12:33841755	A/G	cg10518543	chr12:38710700	ALG10B	0.41	6.56	0.3	1.54e-10	Morning vs. evening chronotype;
LUAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg16606324	chr3:10149918	C3orf24	0.65	10.77	0.46	4.51e-24	Alzheimer's disease;
LUAD	cis	rs1003719	0.788	rs1155785	chr21:38447939	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.52	0.38	2.94e-16	Eye color traits;
LUAD	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg27490568	chr2:178487706	NA	0.58	9.42	0.42	2.88e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg26354017	chr1:205819088	PM20D1	-0.43	-6.89	-0.32	2.08e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg06636551	chr8:101224915	SPAG1	-0.37	-6.67	-0.31	8.12e-11	Atrioventricular conduction;
LUAD	cis	rs5167	0.677	rs2238682	chr19:45458593	C/T	cg09555818	chr19:45449301	APOC2	0.37	6.75	0.31	4.79e-11	Blood protein levels;
LUAD	cis	rs3087591	0.920	rs7225014	chr17:29572973	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.7	-0.31	6.65e-11	Hip circumference;
LUAD	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg15247329	chr7:2764246	NA	-0.35	-6.44	-0.3	3.2e-10	Height;
LUAD	cis	rs79243044	0.695	rs7945471	chr11:5543803	T/C	cg24229750	chr11:5531283	UBQLN3	0.29	6.41	0.3	3.88e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.23	-0.37	2.38e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs6708413	0.501	rs2075189	chr2:103118689	C/G	cg03938978	chr2:103052716	IL18RAP	0.33	6.55	0.3	1.71e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9560113	0.550	rs1163633	chr13:112231561	G/T	cg10483660	chr13:112241077	NA	-0.47	-9.87	-0.43	8.05e-21	Menarche (age at onset);
LUAD	cis	rs7607369	0.648	rs55983650	chr2:219654932	T/C	cg02176678	chr2:219576539	TTLL4	-0.75	-15.29	-0.6	2.43e-42	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11636702	chr4:11370466	MIR572	0.43	6.48	0.3	2.49e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg15147215	chr3:52552868	STAB1	-0.38	-7.06	-0.32	7.06e-12	Bipolar disorder;
LUAD	cis	rs2658782	0.789	rs3020073	chr11:93103830	T/C	cg15737290	chr11:93063684	CCDC67	0.49	7.04	0.32	7.94e-12	Pulmonary function decline;
LUAD	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg10909506	chr17:38081995	ORMDL3	0.4	7.2	0.33	2.71e-12	Self-reported allergy;
LUAD	cis	rs12144309	0.554	rs2476602	chr1:114396955	C/T	cg03325407	chr1:114423726	BCL2L15	0.4	7.04	0.32	8.07e-12	Coronary artery disease;
LUAD	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg05665937	chr4:1216051	CTBP1	0.44	7.7	0.35	9.54e-14	Obesity-related traits;
LUAD	cis	rs4660214	0.694	rs16866216	chr1:39674588	A/G	cg27567593	chr1:39956653	BMP8A	0.38	7.39	0.34	8.12e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25427524	chr10:38739819	LOC399744	0.77	14.8	0.58	3.09e-40	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg12599982	chr1:44399894	ARTN	-0.33	-6.68	-0.31	7.75e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg23262073	chr20:60523788	NA	-0.37	-6.45	-0.3	3.02e-10	Body mass index;
LUAD	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.47	0.3	2.64e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg13390004	chr1:15929781	NA	0.48	8.5	0.38	3.18e-16	Systolic blood pressure;
LUAD	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg12143784	chr7:64541923	NA	-0.51	-8.36	-0.38	9.47e-16	Calcium levels;
LUAD	cis	rs72928364	0.929	rs62275826	chr3:100762644	G/A	cg10123952	chr3:100791384	NA	0.76	8.5	0.38	3.18e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs116248771	0.739	rs2082159	chr3:158359667	C/T	cg16708174	chr3:158430962	RARRES1	0.47	6.82	0.31	3.07e-11	diarrhoeal disease at age 2;
LUAD	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.58	0.35	2.26e-13	Bladder cancer;
LUAD	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	24.27	0.76	3.88e-82	Chronic sinus infection;
LUAD	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg19318889	chr4:1322082	MAEA	0.46	7.18	0.33	3.24e-12	Obesity-related traits;
LUAD	cis	rs7264396	0.563	rs7268195	chr20:34339854	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.0	-0.36	1.2e-14	Total cholesterol levels;
LUAD	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg03474202	chr17:45855739	NA	-0.38	-8.75	-0.39	5.11e-17	IgG glycosylation;
LUAD	cis	rs68092024	0.704	rs793487	chr3:99495422	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-9.31	-0.41	7.17e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs13223928	0.592	rs4722439	chr7:3155858	C/T	cg19214707	chr7:3157722	NA	0.51	9.35	0.41	5.02e-19	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs4713118	0.619	rs200486	chr6:27779506	C/T	cg26587870	chr6:27730563	NA	-0.51	-7.91	-0.36	2.31e-14	Parkinson's disease;
LUAD	cis	rs68170813	0.559	rs2023892	chr7:106847686	C/T	cg02696742	chr7:106810147	HBP1	0.79	11.21	0.48	1.06e-25	Coronary artery disease;
LUAD	trans	rs4131805	0.642	rs4800307	chr18:26074141	T/A	cg26154937	chr10:49674883	ARHGAP22	0.3	6.54	0.3	1.76e-10	Hip geometry;
LUAD	cis	rs1003719	0.591	rs2835618	chr21:38503126	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.34	-0.38	1.09e-15	Eye color traits;
LUAD	cis	rs9549367	0.569	rs3024738	chr13:113819921	T/A	cg00898013	chr13:113819073	PROZ	0.76	13.58	0.55	4.24e-35	Platelet distribution width;
LUAD	cis	rs41278232	1.000	rs41278232	chr20:62606617	G/A	cg03065311	chr20:62601662	ZNF512B	0.54	7.17	0.33	3.32e-12	Tonsillectomy;
LUAD	cis	rs897984	0.568	rs72799330	chr16:30893555	C/A	cg02466173	chr16:30829666	NA	-0.67	-10.52	-0.46	3.74e-23	Dementia with Lewy bodies;
LUAD	cis	rs240764	0.658	rs35168784	chr6:101183499	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.55	-0.38	2.34e-16	Neuroticism;
LUAD	cis	rs9341808	0.538	rs667097	chr6:80978943	G/A	cg08355045	chr6:80787529	NA	-0.44	-7.5	-0.34	3.78e-13	Sitting height ratio;
LUAD	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg18404041	chr3:52824283	ITIH1	-0.54	-9.14	-0.41	2.65e-18	Schizophrenia;
LUAD	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg19635926	chr16:89946313	TCF25	-0.63	-6.54	-0.3	1.82e-10	Skin colour saturation;
LUAD	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg26677194	chr12:130822605	PIWIL1	0.62	9.92	0.43	5.43e-21	Menopause (age at onset);
LUAD	cis	rs2407156	0.861	rs17790303	chr5:81690042	C/G	cg15871215	chr5:81402204	ATG10	-0.49	-6.72	-0.31	5.98e-11	Breast cancer;
LUAD	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg17063962	chr7:91808500	NA	0.7	12.02	0.5	7.51e-29	Breast cancer;
LUAD	cis	rs3806843	0.548	rs246052	chr5:140326413	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.59	-0.31	1.33e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg14582100	chr15:45693742	SPATA5L1	0.5	9.36	0.41	4.73e-19	Homoarginine levels;
LUAD	cis	rs4290604	0.679	rs73083545	chr2:237983894	C/G	cg23555395	chr2:238036564	NA	0.5	6.88	0.32	2.2e-11	Asthma;
LUAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.29	0.37	1.55e-15	Alzheimer's disease;
LUAD	trans	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg07393940	chr7:158741817	NA	0.66	11.29	0.48	5.31e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10979	0.597	rs9496684	chr6:143908687	C/A	cg25407410	chr6:143891975	LOC285740	-0.54	-7.66	-0.35	1.31e-13	Hypospadias;
LUAD	cis	rs6545883	0.868	rs7594191	chr2:61840018	A/G	cg15711740	chr2:61764176	XPO1	0.41	6.44	0.3	3.21e-10	Tuberculosis;
LUAD	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg09998033	chr7:158218633	PTPRN2	0.39	6.73	0.31	5.63e-11	Obesity-related traits;
LUAD	cis	rs907683	0.546	rs1058261	chr2:220285309	C/T	cg15015639	chr2:220282977	DES	-0.49	-9.02	-0.4	6.54e-18	Resting heart rate;
LUAD	trans	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg07817883	chr1:32538562	TMEM39B	-0.52	-7.15	-0.33	3.94e-12	Monocyte percentage of white cells;
LUAD	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg24675056	chr1:15929824	NA	0.46	7.92	0.36	2.09e-14	Systolic blood pressure;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12572545	chr4:166248219	SC4MOL	-0.39	-6.52	-0.3	2.01e-10	Cancer;
LUAD	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg23254163	chr1:152506842	NA	0.27	7.33	0.34	1.14e-12	Hair morphology;
LUAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07167872	chr1:205819463	PM20D1	0.88	19.74	0.69	6.07e-62	Menarche (age at onset);
LUAD	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg27661571	chr11:113659931	NA	-0.68	-7.92	-0.36	2.05e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg05754148	chr16:3507555	NAT15	0.81	10.12	0.44	1.05e-21	Tuberculosis;
LUAD	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.27	0.37	1.7e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg00300879	chr1:26503847	CNKSR1	0.29	8.4	0.38	6.97e-16	Height;
LUAD	cis	rs250585	0.736	rs250579	chr16:23425585	A/G	cg00143387	chr16:23521605	GGA2	0.62	8.99	0.4	8.07e-18	Egg allergy;
LUAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg15147215	chr3:52552868	STAB1	-0.49	-9.23	-0.41	1.35e-18	Electroencephalogram traits;
LUAD	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg10518543	chr12:38710700	ALG10B	-0.52	-8.45	-0.38	4.61e-16	Morning vs. evening chronotype;
LUAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-7.2	-0.33	2.72e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg00933542	chr6:150070202	PCMT1	0.34	6.85	0.32	2.54e-11	Testicular germ cell tumor;
LUAD	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22857025	chr5:266934	NA	-1.06	-13.35	-0.54	3.53e-34	Breast cancer;
LUAD	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.01	-0.44	2.52e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	6.38	0.3	4.69e-10	Cognitive test performance;
LUAD	cis	rs28595532	1.000	rs114682099	chr4:119702004	C/T	cg21605333	chr4:119757512	SEC24D	0.83	7.78	0.35	5.59e-14	Cannabis dependence symptom count;
LUAD	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg19318889	chr4:1322082	MAEA	0.47	7.8	0.35	4.92e-14	Obesity-related traits;
LUAD	cis	rs713587	0.713	rs12618252	chr2:25207950	G/A	cg01884057	chr2:25150051	NA	-0.33	-6.86	-0.32	2.48e-11	Body mass index in non-asthmatics;
LUAD	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg22920501	chr2:26401640	FAM59B	0.86	10.98	0.47	7.74e-25	Gut microbiome composition (summer);
LUAD	cis	rs12681287	0.752	rs10103229	chr8:87248954	C/T	cg27223183	chr8:87520930	FAM82B	0.59	8.11	0.37	5.51e-15	Caudate activity during reward;
LUAD	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg07741184	chr6:167504864	NA	0.31	7.47	0.34	4.74e-13	Crohn's disease;
LUAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg02951883	chr7:2050386	MAD1L1	-0.97	-19.42	-0.69	1.58e-60	Bipolar disorder and schizophrenia;
LUAD	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg16479474	chr6:28041457	NA	0.39	7.01	0.32	9.18e-12	Parkinson's disease;
LUAD	cis	rs6543140	0.964	rs1523205	chr2:103070176	G/T	cg03938978	chr2:103052716	IL18RAP	0.35	6.7	0.31	6.76e-11	Blood protein levels;
LUAD	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg09835421	chr16:68378352	PRMT7	-0.81	-8.86	-0.4	2.2e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11622475	1.000	rs8021692	chr14:104428576	C/G	cg12183467	chr14:104352244	NA	-0.4	-6.78	-0.31	4.12e-11	Bipolar disorder;
LUAD	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg06453172	chr10:134556979	INPP5A	-0.67	-10.08	-0.44	1.42e-21	Migraine;
LUAD	cis	rs6586111	1.000	rs7093787	chr10:82371127	C/T	cg03086067	chr10:82368399	SH2D4B	-0.26	-6.35	-0.3	5.56e-10	Capecitabine sensitivity;
LUAD	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg17628894	chr11:804452	LRDD	0.31	6.52	0.3	2.02e-10	Breast cancer;
LUAD	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg05368731	chr17:41323189	NBR1	0.95	19.1	0.68	4.31e-59	Menopause (age at onset);
LUAD	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg26022315	chr17:47021804	SNF8	0.4	7.21	0.33	2.63e-12	Type 2 diabetes;
LUAD	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg11494091	chr17:61959527	GH2	0.4	6.99	0.32	1.1e-11	Height;
LUAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg03188948	chr7:1209495	NA	0.66	8.65	0.39	1.1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg11189052	chr15:85197271	WDR73	0.58	7.47	0.34	4.68e-13	Schizophrenia;
LUAD	cis	rs9807989	0.507	rs2160201	chr2:103033961	T/C	cg03938978	chr2:103052716	IL18RAP	0.44	10.14	0.44	8.64e-22	Asthma;
LUAD	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18404041	chr3:52824283	ITIH1	-0.59	-11.92	-0.5	1.99e-28	Bipolar disorder;
LUAD	cis	rs1018836	0.828	rs7006279	chr8:91605364	A/G	cg16814680	chr8:91681699	NA	-0.6	-10.08	-0.44	1.49e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs367943	0.665	rs11950173	chr5:112960995	C/T	cg12552261	chr5:112820674	MCC	0.37	6.51	0.3	2.1e-10	Type 2 diabetes;
LUAD	trans	rs1973993	0.689	rs17115225	chr1:96884330	C/T	cg10631902	chr5:14652156	NA	-0.47	-7.97	-0.36	1.45e-14	Weight;
LUAD	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg05623727	chr3:50126028	RBM5	-0.31	-6.75	-0.31	4.91e-11	Body mass index;
LUAD	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg05590025	chr7:65112418	INTS4L2	-0.76	-7.97	-0.36	1.5e-14	Diabetic kidney disease;
LUAD	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.18e-13	Morning vs. evening chronotype;
LUAD	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21659725	chr3:3221576	CRBN	-0.64	-11.14	-0.48	1.97e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.83	0.53	4.8e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg23625390	chr15:77176239	SCAPER	0.39	7.16	0.33	3.7e-12	Blood metabolite levels;
LUAD	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg23029597	chr12:123009494	RSRC2	-0.53	-8.29	-0.37	1.54e-15	Body mass index;
LUAD	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.45	8.94	0.4	1.22e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg11494091	chr17:61959527	GH2	0.74	18.42	0.67	4.62e-56	Prudent dietary pattern;
LUAD	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg09365446	chr1:150670422	GOLPH3L	0.59	10.73	0.46	6.57e-24	Tonsillectomy;
LUAD	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg05283184	chr6:79620031	NA	0.45	8.08	0.37	6.78e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg05872129	chr22:39784769	NA	-0.76	-12.86	-0.53	3.58e-32	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	trans	rs62458065	0.850	rs7808992	chr7:32470677	C/T	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.43	-0.34	5.99e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs13315871	1.000	rs13096020	chr3:58367771	G/A	cg12435725	chr3:58293450	RPP14	-0.67	-7.26	-0.33	1.93e-12	Cholesterol, total;
LUAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9522267	0.737	rs7330902	chr13:112227599	C/T	cg10483660	chr13:112241077	NA	-0.32	-6.73	-0.31	5.56e-11	Hepatitis;
LUAD	cis	rs76878669	0.561	rs6591215	chr11:66170611	A/C	cg10616300	chr11:66138557	SLC29A2	-0.34	-7.25	-0.33	1.95e-12	Educational attainment (years of education);
LUAD	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg25838465	chr1:92012736	NA	-0.63	-12.39	-0.52	2.61e-30	Breast cancer;
LUAD	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23157637	chr14:20881440	TEP1	-0.4	-6.37	-0.3	5.01e-10	Cancer;
LUAD	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg06784218	chr1:46089804	CCDC17	0.6	13.39	0.55	2.41e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7009516	0.716	rs371439	chr8:24225477	T/A	cg01759110	chr8:24241694	ADAMDEC1	0.35	7.03	0.32	8.09e-12	Hair greying;
LUAD	cis	rs3806843	0.576	rs246046	chr5:140329264	T/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg13319975	chr6:146136371	FBXO30	-0.58	-9.83	-0.43	1.17e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg14834391	chr1:2537342	MMEL1	-0.31	-6.53	-0.3	1.83e-10	Ulcerative colitis;
LUAD	cis	rs2486012	1.000	rs1636879	chr1:44428680	G/C	cg12908607	chr1:44402522	ARTN	0.51	6.52	0.3	1.97e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg03929089	chr4:120376271	NA	-0.98	-20.33	-0.7	1.4e-64	Height;
LUAD	cis	rs7213347	0.780	rs9892016	chr17:2146422	A/G	cg02569219	chr17:2266849	SGSM2	-0.45	-7.51	-0.34	3.48e-13	Total body bone mineral density;
LUAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	6.54	0.3	1.74e-10	Electroencephalogram traits;
LUAD	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03264133	chr6:25882463	NA	0.58	9.68	0.43	3.8e-20	Blood metabolite levels;
LUAD	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.76	-14.72	-0.58	7.05e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs7568458	0.905	rs10172544	chr2:85788270	C/A	cg02493740	chr2:85810744	VAMP5	-0.43	-7.71	-0.35	8.9e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg14668632	chr7:2872130	GNA12	-0.46	-7.89	-0.36	2.69e-14	Height;
LUAD	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg26384229	chr12:38710491	ALG10B	0.48	7.8	0.35	4.88e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs55728055	0.661	rs62237775	chr22:31965401	A/G	cg01338084	chr22:32026380	PISD	0.9	6.84	0.32	2.75e-11	Age-related hearing impairment;
LUAD	cis	rs6499255	1.000	rs1139178	chr16:69781468	T/C	cg15192750	chr16:69999425	NA	0.56	8.71	0.39	7.07e-17	IgE levels;
LUAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg04025307	chr7:1156635	C7orf50	0.6	6.77	0.31	4.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg17063962	chr7:91808500	NA	-0.63	-10.7	-0.46	8.63e-24	Breast cancer;
LUAD	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs7395662	0.963	rs6485889	chr11:48608785	C/T	cg15704280	chr7:45808275	SEPT13	-0.41	-6.47	-0.3	2.64e-10	HDL cholesterol;
LUAD	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg08132940	chr7:1081526	C7orf50	-0.77	-10.31	-0.45	2.21e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg06484146	chr7:12443880	VWDE	-0.52	-6.62	-0.31	1.11e-10	Coronary artery disease;
LUAD	cis	rs714027	1.000	rs6006356	chr22:30503171	G/A	cg11564601	chr22:30592435	NA	-0.4	-8.7	-0.39	7.26e-17	Lymphocyte counts;
LUAD	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.1	-0.33	5.17e-12	Blood metabolite levels;
LUAD	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg06873352	chr17:61820015	STRADA	0.42	7.01	0.32	9.4e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg00784671	chr22:46762841	CELSR1	-0.41	-6.35	-0.3	5.42e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs10170310	0.938	rs11680891	chr2:139264454	T/G	cg03782584	chr2:139258740	SPOPL	0.31	6.44	0.3	3.16e-10	Response to antipsychotic treatment;
LUAD	cis	rs6738485	0.567	rs7598745	chr2:106848216	A/T	cg16099169	chr2:106886729	NA	0.37	6.47	0.3	2.78e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.87	-0.43	8.36e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs1957429	0.808	rs4899150	chr14:65344400	A/G	cg23373153	chr14:65346875	NA	0.61	6.52	0.3	1.95e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg05901451	chr6:126070800	HEY2	-0.43	-6.43	-0.3	3.53e-10	Endometrial cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10989441	chr1:231347308	TRIM67	-0.42	-6.48	-0.3	2.63e-10	Height;
LUAD	cis	rs7089973	0.934	rs68085797	chr10:116632130	A/T	cg25233709	chr10:116636983	FAM160B1	0.36	6.75	0.31	5.04e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg05110241	chr16:68378359	PRMT7	-0.93	-10.7	-0.46	8.36e-24	Schizophrenia;
LUAD	cis	rs73086581	0.947	rs56123574	chr20:3878081	C/G	cg02187196	chr20:3869020	PANK2	0.46	6.51	0.3	2.17e-10	Response to antidepressants in depression;
LUAD	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg15017067	chr4:17643749	FAM184B	0.37	7.2	0.33	2.74e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9972944	0.902	rs59009755	chr17:63772263	C/T	cg07283582	chr17:63770753	CCDC46	0.52	11.68	0.49	1.63e-27	Total body bone mineral density;
LUAD	cis	rs3820068	0.705	rs58424111	chr1:15868470	A/C	cg13390004	chr1:15929781	NA	0.41	6.48	0.3	2.54e-10	Systolic blood pressure;
LUAD	trans	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg20849893	chr7:64541193	NA	0.49	6.44	0.3	3.17e-10	Aortic root size;
LUAD	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg08999081	chr20:33150536	PIGU	0.6	13.37	0.54	3.02e-34	Glomerular filtration rate (creatinine);
LUAD	cis	rs12142240	1.000	rs12146051	chr1:46742952	G/C	cg00530320	chr1:46809349	NSUN4	0.45	6.93	0.32	1.63e-11	Menopause (age at onset);
LUAD	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg25024717	chr12:54324583	NA	-0.33	-6.72	-0.31	5.73e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs11229555	0.645	rs11601296	chr11:58423297	A/G	cg15696309	chr11:58395628	NA	-0.61	-7.21	-0.33	2.57e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs4771122	0.596	rs7334690	chr13:28081535	C/T	cg22138327	chr13:27999177	GTF3A	0.53	7.98	0.36	1.43e-14	Body mass index;
LUAD	cis	rs7301826	0.651	rs1554807	chr12:131280417	C/T	cg11011512	chr12:131303247	STX2	-0.44	-7.46	-0.34	4.87e-13	Plasma plasminogen activator levels;
LUAD	cis	rs76878669	0.561	rs4930362	chr11:66154360	T/C	cg10616300	chr11:66138557	SLC29A2	0.36	7.61	0.35	1.83e-13	Educational attainment (years of education);
LUAD	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22496380	chr5:211416	CCDC127	-0.93	-13.14	-0.54	2.51e-33	Breast cancer;
LUAD	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	11.61	0.49	3.09e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs7607369	0.637	rs3888879	chr2:219290676	C/T	cg02176678	chr2:219576539	TTLL4	-0.79	-15.14	-0.59	1.08e-41	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs2075371	0.501	rs1613152	chr7:134019837	A/G	cg20476274	chr7:133979776	SLC35B4	0.56	9.7	0.43	3.14e-20	Mean platelet volume;
LUAD	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg22875332	chr1:76189707	ACADM	0.87	16.23	0.62	2.2e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.79	-0.35	5.18e-14	Type 2 diabetes;
LUAD	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg08601574	chr20:25228251	PYGB	0.47	8.88	0.4	1.93e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg00106254	chr7:1943704	MAD1L1	-0.55	-7.94	-0.36	1.86e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs6011002	0.745	rs4809331	chr20:62370890	A/G	cg21849932	chr20:62369462	LIME1	-0.78	-6.44	-0.3	3.34e-10	Dental caries;
LUAD	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.3	-0.33	1.45e-12	Schizophrenia;
LUAD	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.37	6.53	0.3	1.86e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	7.46	0.34	5.09e-13	Platelet count;
LUAD	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg08645402	chr16:4508243	NA	0.52	8.98	0.4	8.66e-18	Schizophrenia;
LUAD	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg00074818	chr8:8560427	CLDN23	0.58	8.86	0.4	2.27e-17	Obesity-related traits;
LUAD	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg09658497	chr7:2847517	GNA12	-0.54	-9.1	-0.4	3.66e-18	Height;
LUAD	trans	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg07211511	chr3:129823064	LOC729375	-0.92	-12.5	-0.52	9.99e-31	Blood pressure (smoking interaction);
LUAD	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg19761014	chr17:28927070	LRRC37B2	0.69	6.75	0.31	4.76e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg26597838	chr10:835615	NA	0.99	15.69	0.61	4.7e-44	Eosinophil percentage of granulocytes;
LUAD	trans	rs2797160	1.000	rs6933471	chr6:126017029	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.48e-17	Endometrial cancer;
LUAD	cis	rs28595532	0.920	rs56303276	chr4:119723514	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.45	0.38	4.86e-16	Cannabis dependence symptom count;
LUAD	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.78	-0.43	1.63e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs10924309	0.924	rs10802245	chr1:245858321	G/A	cg00036263	chr1:245852353	KIF26B	-0.48	-7.41	-0.34	7.12e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg05132306	chr1:1846340	CALML6	-0.36	-7.71	-0.35	9.18e-14	Body mass index;
LUAD	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg13180566	chr4:1052158	NA	-0.4	-6.68	-0.31	7.67e-11	Recombination rate (females);
LUAD	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.56	-8.16	-0.37	3.84e-15	Gut microbiome composition (summer);
LUAD	cis	rs9905704	0.671	rs2531737	chr17:56554357	A/G	cg19466818	chr17:56409534	MIR142	0.34	6.82	0.31	3.06e-11	Testicular germ cell tumor;
LUAD	cis	rs62229266	0.609	rs2835253	chr21:37419745	T/C	cg12218747	chr21:37451666	NA	-0.43	-7.39	-0.34	7.79e-13	Mitral valve prolapse;
LUAD	trans	rs1493916	1.000	rs4393645	chr18:31394407	C/T	cg13755796	chr4:20253514	NA	-0.42	-7.0	-0.32	1e-11	Life satisfaction;
LUAD	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.43	-0.34	5.94e-13	Type 2 diabetes;
LUAD	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg10792982	chr14:105748885	BRF1	0.45	9.42	0.42	2.87e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9652601	0.779	rs725613	chr16:11169683	T/G	cg04616529	chr16:11181986	CLEC16A	0.4	7.25	0.33	1.96e-12	Systemic lupus erythematosus;
LUAD	cis	rs11167764	0.895	rs13189044	chr5:141471431	A/C	cg23435118	chr5:141488016	NDFIP1	-0.48	-7.26	-0.33	1.84e-12	Crohn's disease;
LUAD	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg21475434	chr5:93447410	FAM172A	0.75	8.47	0.38	4.15e-16	Diabetic retinopathy;
LUAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg05434287	chr7:2030229	MAD1L1	0.43	7.2	0.33	2.82e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg05434287	chr7:2030229	MAD1L1	0.4	6.68	0.31	7.4e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs12912251	1.000	rs2172835	chr15:38990171	C/T	cg01338139	chr15:38987640	C15orf53	-0.57	-9.14	-0.41	2.55e-18	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.74	-8.83	-0.39	2.82e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg06074448	chr4:187884817	NA	-0.37	-7.18	-0.33	3.24e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg08508325	chr11:3079039	CARS	-0.45	-9.86	-0.43	9.01e-21	Longevity;
LUAD	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg04155289	chr7:94953770	PON1	-0.52	-6.89	-0.32	2.09e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg18132916	chr6:79620363	NA	-0.46	-7.85	-0.36	3.47e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08608800	chr13:46626937	ZC3H13	-0.44	-7.48	-0.34	4.35e-13	Cancer;
LUAD	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg26384229	chr12:38710491	ALG10B	0.4	6.38	0.3	4.65e-10	Morning vs. evening chronotype;
LUAD	cis	rs12989701	0.877	rs13029812	chr2:127872622	A/G	cg08168897	chr2:127865431	BIN1	0.44	7.08	0.33	5.93e-12	Alzheimer's disease (late onset);
LUAD	cis	rs7213347	0.707	rs216182	chr17:2173063	A/G	cg16513277	chr17:2031491	SMG6	0.43	6.39	0.3	4.45e-10	Total body bone mineral density;
LUAD	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg18252515	chr7:66147081	NA	0.59	6.49	0.3	2.42e-10	Diabetic kidney disease;
LUAD	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg11871910	chr12:69753446	YEATS4	0.71	12.0	0.5	9.02e-29	Blood protein levels;
LUAD	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.51e-15	Bipolar disorder;
LUAD	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg11166453	chr1:247681781	NA	0.35	7.05	0.32	7.21e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg23625390	chr15:77176239	SCAPER	-0.54	-8.19	-0.37	3.04e-15	Blood metabolite levels;
LUAD	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7119	0.604	rs2271396	chr15:77907535	C/G	cg27398640	chr15:77910606	LINGO1	0.41	8.17	0.37	3.63e-15	Type 2 diabetes;
LUAD	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.35	-0.41	4.99e-19	Life satisfaction;
LUAD	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg04414720	chr1:150670196	GOLPH3L	0.74	12.94	0.53	1.7e-32	Melanoma;
LUAD	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.13	-0.33	4.32e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-10.02	-0.44	2.48e-21	Lymphocyte counts;
LUAD	trans	rs1728785	1.000	rs4783653	chr16:68562815	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	9.51	0.42	1.44e-19	Ulcerative colitis;
LUAD	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg23933602	chr10:16859644	RSU1	0.93	19.7	0.69	8.85e-62	Platelet distribution width;
LUAD	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-8.5	-0.38	3.2e-16	Gut microbiome composition (summer);
LUAD	cis	rs7586879	0.796	rs36071142	chr2:25080570	C/T	cg04586622	chr2:25135609	ADCY3	0.35	7.12	0.33	4.77e-12	Body mass index;
LUAD	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.47	9.16	0.41	2.34e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3760982	0.585	rs1386502	chr19:44293356	T/C	cg11993925	chr19:44307056	LYPD5	0.55	11.36	0.48	2.83e-26	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.89e-14	Depression;
LUAD	cis	rs870825	0.549	rs28579266	chr4:185627262	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg02018176	chr4:1364513	KIAA1530	-0.56	-9.98	-0.44	3.41e-21	Obesity-related traits;
LUAD	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg00383909	chr3:49044727	WDR6	0.43	6.6	0.31	1.26e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs240110	0.515	rs12530388	chr6:101329173	A/C	cg09795085	chr6:101329169	ASCC3	0.51	8.96	0.4	1.05e-17	Neuroticism;
LUAD	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg21724239	chr8:58056113	NA	0.68	8.58	0.38	1.86e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-7.24	-0.33	2.07e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg11871910	chr12:69753446	YEATS4	-0.69	-12.18	-0.51	1.76e-29	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs4911259	0.552	rs11697394	chr20:31460076	G/A	cg13636640	chr20:31349939	DNMT3B	-0.59	-9.73	-0.43	2.58e-20	Inflammatory bowel disease;
LUAD	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg12310025	chr6:25882481	NA	-0.57	-9.18	-0.41	1.98e-18	Blood metabolite levels;
LUAD	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg13685833	chr1:53393034	SCP2	-0.4	-6.66	-0.31	8.28e-11	Monocyte count;
LUAD	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.85	-0.32	2.69e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg04398451	chr17:18023971	MYO15A	0.78	14.15	0.57	1.76e-37	Total body bone mineral density;
LUAD	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg09365446	chr1:150670422	GOLPH3L	-0.39	-6.37	-0.3	4.9e-10	Tonsillectomy;
LUAD	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg09796270	chr17:17721594	SREBF1	0.34	6.38	0.3	4.79e-10	Total body bone mineral density;
LUAD	trans	rs629535	0.814	rs56326813	chr8:70107736	T/A	cg21567404	chr3:27674614	NA	-0.97	-17.34	-0.64	2.81e-51	Dupuytren's disease;
LUAD	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg10518543	chr12:38710700	ALG10B	-0.43	-7.21	-0.33	2.62e-12	Heart rate;
LUAD	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg05368731	chr17:41323189	NBR1	0.98	20.96	0.71	2.08e-67	Menopause (age at onset);
LUAD	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg24399712	chr22:39784796	NA	-0.82	-15.86	-0.61	8.65e-45	Intelligence (multi-trait analysis);
LUAD	trans	rs11039798	0.841	rs11500573	chr11:48713900	T/G	cg03929089	chr4:120376271	NA	0.6	6.9	0.32	1.89e-11	Axial length;
LUAD	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg20587970	chr11:113659929	NA	-1.41	-20.86	-0.71	5.65e-67	Hip circumference adjusted for BMI;
LUAD	trans	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg11693508	chr17:37793320	STARD3	0.81	10.52	0.46	3.8e-23	Bipolar disorder;
LUAD	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.51	0.3	2.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26314531	chr2:26401878	FAM59B	-0.72	-9.77	-0.43	1.88e-20	Gut microbiome composition (summer);
LUAD	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg05283184	chr6:79620031	NA	-0.61	-12.21	-0.51	1.42e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs4986172	0.539	rs3744760	chr17:43195981	C/T	cg10701640	chr17:43249399	NA	-0.4	-7.5	-0.34	3.68e-13	Height;
LUAD	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg00666640	chr1:248458726	OR2T12	0.32	7.85	0.36	3.42e-14	Common traits (Other);
LUAD	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg20556744	chr2:9614537	IAH1	0.66	6.56	0.3	1.55e-10	Opioid sensitivity;
LUAD	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.38	0.38	7.67e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.48	-0.3	2.63e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6684514	1.000	rs2277870	chr1:156246792	C/T	cg16558208	chr1:156270281	VHLL	0.53	9.58	0.42	8.12e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs78456975	0.699	rs17091772	chr2:1519679	A/C	cg12573674	chr2:1569213	NA	-0.6	-7.11	-0.33	5.07e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21582582	chr3:182698605	DCUN1D1	0.61	9.8	0.43	1.44e-20	Resting heart rate;
LUAD	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg09835421	chr16:68378352	PRMT7	-1.05	-12.18	-0.51	1.86e-29	Magnesium levels;
LUAD	cis	rs7607369	0.559	rs4674340	chr2:219659799	A/G	cg02176678	chr2:219576539	TTLL4	-0.54	-10.53	-0.46	3.62e-23	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs28595532	0.702	rs72670256	chr4:119391043	G/A	cg21605333	chr4:119757512	SEC24D	0.67	6.63	0.31	1.06e-10	Cannabis dependence symptom count;
LUAD	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg02931644	chr1:25747376	RHCE	-0.43	-9.19	-0.41	1.78e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg00204512	chr16:28754710	NA	0.33	7.13	0.33	4.27e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6835098	0.692	rs6822683	chr4:174063974	G/A	cg08422745	chr4:174089978	GALNT7	-0.85	-15.04	-0.59	3.06e-41	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg18105134	chr13:113819100	PROZ	0.95	15.83	0.61	1.22e-44	Platelet distribution width;
LUAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.62	-9.82	-0.43	1.18e-20	Renal function-related traits (BUN);
LUAD	cis	rs10733682	0.659	rs3906146	chr9:129463613	C/T	cg00232160	chr9:129468157	NA	0.48	8.6	0.39	1.58e-16	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs3960554	0.610	rs10265696	chr7:75766712	G/A	cg19862616	chr7:65841803	NCRNA00174	0.82	10.99	0.47	6.7e-25	Eotaxin levels;
LUAD	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg07636037	chr3:49044803	WDR6	0.56	8.68	0.39	8.76e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.37	-6.48	-0.3	2.53e-10	Glaucoma (primary open-angle);
LUAD	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg10435618	chr10:838112	NA	0.47	6.41	0.3	3.95e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs10899021	0.790	rs11236180	chr11:74342928	A/G	cg25880958	chr11:74394337	NA	-0.59	-8.04	-0.36	8.92e-15	Response to metformin (IC50);
LUAD	cis	rs4073416	0.542	rs6573614	chr14:65958703	G/A	cg10998611	chr14:65879393	FUT8;LOC645431	-0.42	-6.45	-0.3	3.01e-10	N-glycan levels;
LUAD	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.86	-0.36	3.12e-14	Diabetic kidney disease;
LUAD	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg02527881	chr3:46936655	PTH1R	0.44	8.93	0.4	1.36e-17	Colorectal cancer;
LUAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg20276088	chr3:133502917	NA	-0.38	-6.66	-0.31	8.37e-11	Iron status biomarkers;
LUAD	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg06671706	chr8:8559999	CLDN23	0.61	10.9	0.47	1.51e-24	Obesity-related traits;
LUAD	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg09184832	chr6:79620586	NA	-0.52	-9.82	-0.43	1.17e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs11677370	0.574	rs11686118	chr2:3854938	C/T	cg17052675	chr2:3827356	NA	-0.63	-10.58	-0.46	2.31e-23	Type 2 diabetes;
LUAD	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	13.63	0.55	2.48e-35	Lung cancer in ever smokers;
LUAD	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-8.12	-0.37	5e-15	Bipolar disorder;
LUAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.59	-7.56	-0.35	2.45e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.1	-23.79	-0.76	5.24e-80	Ulcerative colitis;
LUAD	cis	rs904251	0.504	rs1757188	chr6:37483808	A/G	cg25019722	chr6:37503610	NA	-0.32	-7.48	-0.34	4.26e-13	Cognitive performance;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg23666278	chr2:171785822	GORASP2	-0.4	-6.46	-0.3	2.94e-10	Vertical cup-disc ratio;
LUAD	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg00666640	chr1:248458726	OR2T12	0.32	7.65	0.35	1.4e-13	Common traits (Other);
LUAD	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg24955955	chr5:415729	AHRR	0.78	8.86	0.4	2.22e-17	Fat distribution (HIV);
LUAD	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg18180107	chr4:99064573	C4orf37	0.4	6.46	0.3	2.87e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.49	0.6	3.51e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs17532515	0.652	rs6836265	chr4:141379314	T/C	cg03645522	chr4:141391200	NA	0.4	6.43	0.3	3.46e-10	Select biomarker traits;
LUAD	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-11.05	-0.47	4.13e-25	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg07817883	chr1:32538562	TMEM39B	1.38	12.14	0.51	2.74e-29	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg21385522	chr1:16154831	NA	0.44	6.65	0.31	9.07e-11	Dilated cardiomyopathy;
LUAD	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg23229984	chr5:148520753	ABLIM3	0.49	7.63	0.35	1.62e-13	Breast cancer;
LUAD	cis	rs2070677	0.799	rs11101854	chr10:135394430	G/A	cg20169779	chr10:135381914	SYCE1	-0.52	-8.27	-0.37	1.81e-15	Gout;
LUAD	cis	rs1832871	0.672	rs56115227	chr6:158773884	G/A	cg07165851	chr6:158734300	TULP4	0.72	11.32	0.48	3.97e-26	Height;
LUAD	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg06028605	chr16:24865363	SLC5A11	0.39	6.82	0.31	3.12e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg19318889	chr4:1322082	MAEA	-0.86	-14.46	-0.58	8.19e-39	Longevity;
LUAD	cis	rs143111788	1	rs143111788	chr6:41919175	CCAGCTACT/C	cg17623882	chr6:41773611	USP49	-0.57	-10.07	-0.44	1.63e-21	Red cell distribution width;
LUAD	trans	rs62458065	0.513	rs9655340	chr7:32535920	A/G	cg00845942	chr12:64062724	DPY19L2	0.57	8.24	0.37	2.13e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2816062	0.813	rs2816057	chr1:18902257	G/C	cg18795169	chr1:18902165	NA	-0.96	-23.09	-0.75	6.36e-77	Urate levels in lean individuals;
LUAD	cis	rs6005807	0.843	rs55738739	chr22:28798655	C/G	cg12565055	chr22:29076175	TTC28	0.69	6.76	0.31	4.66e-11	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg06064525	chr11:970664	AP2A2	-0.55	-11.33	-0.48	3.62e-26	Alzheimer's disease (late onset);
LUAD	cis	rs57502260	0.573	rs12291008	chr11:68389072	T/C	cg16797656	chr11:68205561	LRP5	0.41	7.52	0.34	3.4e-13	Total body bone mineral density (age 45-60);
LUAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg18402987	chr7:1209562	NA	0.79	9.77	0.43	1.84e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21659725	chr3:3221576	CRBN	-0.63	-11.06	-0.47	3.94e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg08439880	chr3:133502540	NA	-0.34	-6.86	-0.32	2.42e-11	Ankle injury;
LUAD	cis	rs2554380	0.943	rs2401128	chr15:84347178	C/A	cg14598478	chr15:84363061	ADAMTSL3	-0.58	-8.95	-0.4	1.1e-17	Height;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg00785783	chr3:112280577	ATG3;SLC35A5	-0.69	-7.11	-0.33	4.97e-12	Type 2 diabetes;
LUAD	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg25036284	chr2:26402008	FAM59B	-0.83	-11.76	-0.5	8.27e-28	Gut microbiome composition (summer);
LUAD	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg03161606	chr19:29218774	NA	0.61	8.68	0.39	8.9e-17	Methadone dose in opioid dependence;
LUAD	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg20701182	chr2:24300061	SF3B14	0.88	13.43	0.55	1.71e-34	Lymphocyte counts;
LUAD	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg14343924	chr8:8086146	FLJ10661	0.48	7.41	0.34	7.12e-13	Neuroticism;
LUAD	cis	rs2692947	0.800	rs61409777	chr2:96581373	C/A	cg23100626	chr2:96804247	ASTL	0.3	7.72	0.35	8.29e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg26597838	chr10:835615	NA	0.96	15.02	0.59	3.51e-41	Eosinophil percentage of granulocytes;
LUAD	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg26513180	chr16:89883248	FANCA	0.75	6.76	0.31	4.55e-11	Skin colour saturation;
LUAD	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg15704280	chr7:45808275	SEPT13	-0.66	-10.04	-0.44	2.1e-21	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg15485101	chr11:133734466	NA	0.33	7.53	0.34	3.03e-13	Childhood ear infection;
LUAD	cis	rs17155006	0.746	rs430628	chr7:107746214	T/G	cg05962710	chr7:107745446	LAMB4	-0.34	-7.31	-0.33	1.37e-12	Pneumococcal bacteremia;
LUAD	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.65	9.01	0.4	6.98e-18	Gut microbiome composition (summer);
LUAD	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg03714773	chr7:91764589	CYP51A1	0.28	6.59	0.3	1.34e-10	Breast cancer;
LUAD	trans	rs7487075	0.786	rs7966288	chr12:46674970	C/T	cg17341174	chr7:97923834	BAIAP2L1	-0.34	-6.37	-0.3	4.86e-10	Itch intensity from mosquito bite;
LUAD	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg27210415	chr4:713949	PCGF3	0.62	9.29	0.41	8.31e-19	White blood cell count;
LUAD	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg03806693	chr22:41940476	POLR3H	0.78	10.44	0.45	7.3e-23	Cannabis dependence symptom count;
LUAD	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg01851573	chr8:8652454	MFHAS1	-0.44	-8.02	-0.36	1.08e-14	Mood instability;
LUAD	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.86	0.32	2.49e-11	Depression;
LUAD	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg11645453	chr3:52864694	ITIH4	0.33	6.44	0.3	3.24e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-7.68	-0.35	1.14e-13	Schizophrenia;
LUAD	cis	rs4700695	0.719	rs27087	chr5:65453050	G/A	cg21114390	chr5:65439923	SFRS12	-0.93	-14.49	-0.58	6.17e-39	Facial morphology (factor 19);
LUAD	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg19413350	chr8:57351067	NA	-0.42	-6.7	-0.31	6.48e-11	Obesity-related traits;
LUAD	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg23018236	chr17:30244563	NA	-0.62	-8.1	-0.37	5.99e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00166722	chr3:10149974	C3orf24	0.63	10.42	0.45	8.88e-23	Alzheimer's disease;
LUAD	cis	rs9392556	0.796	rs6597031	chr6:4106370	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.43	-7.46	-0.34	5.12e-13	Blood metabolite levels;
LUAD	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-12.17	-0.51	2.1e-29	Schizophrenia;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22276571	chr20:17549599	DSTN	0.42	6.35	0.3	5.58e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg18132916	chr6:79620363	NA	-0.45	-7.66	-0.35	1.24e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.25	-0.51	9.53e-30	Platelet count;
LUAD	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg11845111	chr2:191398756	TMEM194B	-0.6	-11.03	-0.47	4.79e-25	Pulse pressure;
LUAD	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg12908607	chr1:44402522	ARTN	-0.47	-9.39	-0.42	3.77e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs494562	0.892	rs619299	chr6:86121482	A/T	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs354225	0.532	rs354211	chr2:54932516	C/T	cg26097391	chr2:54893211	SPTBN1	0.45	7.43	0.34	6.04e-13	Schizophrenia;
LUAD	cis	rs11030122	0.702	rs10835399	chr11:3989182	G/A	cg18678763	chr11:4115507	RRM1	-0.44	-7.25	-0.33	2.04e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.58	-0.46	2.2e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg09658497	chr7:2847517	GNA12	-0.47	-8.05	-0.36	8.23e-15	Height;
LUAD	cis	rs6961069	0.713	rs3211821	chr7:80278563	A/G	cg04458919	chr7:80252533	CD36	0.37	7.14	0.33	4.01e-12	Platelet count;
LUAD	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg22442454	chr1:209979470	IRF6	0.57	6.37	0.3	5.03e-10	Coronary artery disease;
LUAD	cis	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg06191203	chr2:152266755	RIF1	-0.44	-6.85	-0.32	2.62e-11	Lung cancer;
LUAD	cis	rs12530845	0.673	rs73721607	chr7:135335822	C/T	cg23117316	chr7:135346802	PL-5283	-0.57	-8.73	-0.39	5.78e-17	Red blood cell traits;
LUAD	cis	rs870825	0.616	rs28608669	chr4:185632890	T/C	cg04058563	chr4:185651563	MLF1IP	0.89	14.06	0.56	4e-37	Blood protein levels;
LUAD	cis	rs67311347	0.544	rs2278930	chr3:40351092	C/T	cg09455208	chr3:40491958	NA	0.51	10.78	0.46	4.03e-24	Renal cell carcinoma;
LUAD	cis	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg05084668	chr3:125655381	ALG1L	-0.45	-6.52	-0.3	1.98e-10	Blood pressure (smoking interaction);
LUAD	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08280861	chr8:58055591	NA	0.63	8.2	0.37	2.89e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg06671706	chr8:8559999	CLDN23	0.65	11.28	0.48	5.66e-26	Obesity-related traits;
LUAD	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	8.49	0.38	3.54e-16	Breast cancer;
LUAD	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg15997130	chr1:24165203	NA	-0.53	-9.36	-0.41	4.75e-19	Immature fraction of reticulocytes;
LUAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg11941060	chr3:133502564	NA	-0.66	-11.94	-0.5	1.59e-28	Iron status biomarkers;
LUAD	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.62	-7.04	-0.32	7.84e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg18200150	chr17:30822561	MYO1D	0.41	7.49	0.34	3.98e-13	Schizophrenia;
LUAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08048268	chr3:133502702	NA	0.49	9.95	0.44	4.39e-21	Iron status biomarkers;
LUAD	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	8.77	0.39	4.27e-17	Rheumatoid arthritis;
LUAD	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg27532758	chr8:7812741	FAM66E	-0.39	-6.52	-0.3	2.03e-10	Neuroticism;
LUAD	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.62	-0.31	1.09e-10	Prostate cancer;
LUAD	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg16479474	chr6:28041457	NA	0.45	7.99	0.36	1.27e-14	Depression;
LUAD	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg12034118	chr1:209979487	IRF6	0.56	7.38	0.34	8.23e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg18854424	chr1:2615690	NA	0.42	9.1	0.4	3.72e-18	Ulcerative colitis;
LUAD	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21659725	chr3:3221576	CRBN	0.66	11.36	0.48	2.77e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg13010199	chr12:38710504	ALG10B	0.39	6.35	0.3	5.46e-10	Bladder cancer;
LUAD	cis	rs62400317	0.723	rs1329709	chr6:44974956	G/T	cg18551225	chr6:44695536	NA	-0.59	-8.97	-0.4	1e-17	Total body bone mineral density;
LUAD	cis	rs6701037	0.967	rs1057302	chr1:175126423	A/G	cg14847009	chr1:175162515	KIAA0040	-0.33	-8.54	-0.38	2.37e-16	Alcohol dependence;
LUAD	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg02493740	chr2:85810744	VAMP5	-0.61	-11.25	-0.48	7.25e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg11345693	chr17:79170810	AZI1	0.3	6.67	0.31	7.88e-11	Frontotemporal dementia;
LUAD	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg20607798	chr8:58055168	NA	0.57	7.89	0.36	2.56e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg14582100	chr15:45693742	SPATA5L1	0.55	10.04	0.44	2.04e-21	Homoarginine levels;
LUAD	cis	rs10504073	0.647	rs4493918	chr8:50015937	C/G	cg00325661	chr8:49890786	NA	0.44	9.99	0.44	3.13e-21	Blood metabolite ratios;
LUAD	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg02018176	chr4:1364513	KIAA1530	0.37	6.45	0.3	3.02e-10	Obesity-related traits;
LUAD	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg01528321	chr10:82214614	TSPAN14	0.45	7.01	0.32	9.34e-12	Post bronchodilator FEV1;
LUAD	cis	rs6831352	0.729	rs4699718	chr4:100067791	G/A	cg12011299	chr4:100065546	ADH4	-0.74	-13.43	-0.55	1.72e-34	Alcohol dependence;
LUAD	cis	rs7192380	1.000	rs11647110	chr16:69589363	G/A	cg26679644	chr16:69762563	NA	0.48	9.14	0.41	2.64e-18	Sjögren's syndrome;
LUAD	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg19622623	chr12:86230825	RASSF9	-0.43	-7.42	-0.34	6.52e-13	Major depressive disorder;
LUAD	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg07741184	chr6:167504864	NA	0.42	9.92	0.43	5.42e-21	Primary biliary cholangitis;
LUAD	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg14582100	chr15:45693742	SPATA5L1	0.64	12.57	0.52	5.2500000000000004e-31	Homoarginine levels;
LUAD	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07343612	chr16:622815	PIGQ	-0.84	-16.84	-0.63	4.37e-49	Height;
LUAD	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21659725	chr3:3221576	CRBN	-0.64	-10.89	-0.47	1.66e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	9.04	0.4	5.53e-18	Breast cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14225481	chr14:64855023	MTHFD1	-0.4	-6.35	-0.3	5.48e-10	Cancer;
LUAD	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg26314531	chr2:26401878	FAM59B	-0.7	-9.61	-0.42	6.5e-20	Gut microbiome composition (summer);
LUAD	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00149659	chr3:10157352	C3orf10	0.86	11.57	0.49	4.56e-27	Alzheimer's disease;
LUAD	cis	rs17092148	1.000	rs6058117	chr20:33366905	A/G	cg16810054	chr20:33298113	TP53INP2	-0.52	-8.11	-0.37	5.7e-15	Neuroticism;
LUAD	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	9.63	0.42	5.43e-20	Lung cancer in ever smokers;
LUAD	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg23254163	chr1:152506842	NA	0.24	6.62	0.31	1.11e-10	Hair morphology;
LUAD	cis	rs2070433	0.539	rs2070432	chr21:47957332	G/A	cg12379764	chr21:47803548	PCNT	0.47	6.79	0.31	3.75e-11	Lymphocyte counts;
LUAD	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg08280861	chr8:58055591	NA	0.56	7.53	0.34	3.1e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg11707310	chr1:2537719	MMEL1	0.41	8.78	0.39	4.15e-17	Ulcerative colitis;
LUAD	cis	rs2292884	0.505	rs77856818	chr2:238402830	G/A	cg14458575	chr2:238380390	NA	0.78	11.37	0.48	2.55e-26	Prostate cancer;
LUAD	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg10356904	chr22:49881777	NA	-0.38	-7.43	-0.34	5.89e-13	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg22532475	chr10:104410764	TRIM8	-0.49	-9.72	-0.43	2.75e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.69	-0.31	7.12e-11	Height;
LUAD	trans	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg01620082	chr3:125678407	NA	-0.71	-7.18	-0.33	3.14e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.95	0.36	1.74e-14	Depression;
LUAD	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg24069376	chr3:38537580	EXOG	0.37	8.51	0.38	3.16e-16	Electrocardiographic conduction measures;
LUAD	cis	rs1784581	0.588	rs9295178	chr6:162419226	T/A	cg17173639	chr6:162384350	PARK2	0.44	7.85	0.36	3.5e-14	Itch intensity from mosquito bite;
LUAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg08132940	chr7:1081526	C7orf50	-0.77	-10.31	-0.45	2.21e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg05665937	chr4:1216051	CTBP1	0.38	6.4	0.3	4.03e-10	Obesity-related traits;
LUAD	cis	rs3821902	0.646	rs17344570	chr3:64014239	A/C	cg22134162	chr3:63841271	THOC7	0.37	6.72	0.31	5.9e-11	Breast cancer;
LUAD	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg06618935	chr21:46677482	NA	-0.49	-10.03	-0.44	2.19e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1448094	0.836	rs7484454	chr12:86425576	A/G	cg02569458	chr12:86230093	RASSF9	0.36	6.94	0.32	1.52e-11	Major depressive disorder;
LUAD	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg07169764	chr2:136633963	MCM6	-0.78	-9.33	-0.41	6.06e-19	Corneal structure;
LUAD	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg12140854	chr5:148520817	ABLIM3	0.63	9.93	0.43	4.9e-21	Breast cancer;
LUAD	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg18099408	chr3:52552593	STAB1	0.4	7.34	0.34	1.1e-12	Bipolar disorder;
LUAD	cis	rs2230307	0.656	rs6699449	chr1:100542638	G/A	cg20868668	chr1:100435035	SLC35A3	0.61	7.13	0.33	4.25e-12	Carotid intima media thickness;
LUAD	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg16479474	chr6:28041457	NA	0.46	7.67	0.35	1.2e-13	Depression;
LUAD	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg02782426	chr3:40428986	ENTPD3	0.35	7.71	0.35	9.11e-14	Renal cell carcinoma;
LUAD	cis	rs12545109	0.800	rs2609978	chr8:57394467	T/C	cg21220214	chr8:57350948	NA	-0.66	-9.25	-0.41	1.12e-18	Obesity-related traits;
LUAD	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-7.98	-0.36	1.43e-14	Alzheimer's disease;
LUAD	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.71	-12.22	-0.51	1.27e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg11707310	chr1:2537719	MMEL1	0.38	7.98	0.36	1.37e-14	Ulcerative colitis;
LUAD	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg17264618	chr3:40429014	ENTPD3	0.42	8.99	0.4	8.15e-18	Renal cell carcinoma;
LUAD	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.61	0.35	1.81e-13	Breast cancer;
LUAD	cis	rs2019216	0.502	rs1842113	chr17:21872137	G/A	cg22648282	chr17:21454238	C17orf51	-0.46	-8.0	-0.36	1.21e-14	Pelvic organ prolapse;
LUAD	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg03929089	chr4:120376271	NA	0.84	15.25	0.6	3.57e-42	Coronary artery disease;
LUAD	cis	rs7236492	0.683	rs79747802	chr18:77198964	C/T	cg15644404	chr18:77186268	NFATC1	-0.61	-6.9	-0.32	1.9e-11	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6714710	0.580	rs11690737	chr2:98461953	C/T	cg26665480	chr2:98280029	ACTR1B	0.5	8.29	0.37	1.47e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs17095355	1.000	rs12570612	chr10:111717685	C/T	cg00817464	chr10:111662876	XPNPEP1	0.68	9.54	0.42	1.14e-19	Biliary atresia;
LUAD	cis	rs77106637	0.929	rs74333814	chr11:72457487	C/T	cg03713592	chr11:72463424	ARAP1	0.92	11.19	0.48	1.25e-25	Type 2 diabetes;
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg25694218	chr21:27106793	ATP5J;GABPA	-0.38	-6.55	-0.3	1.62e-10	Migraine with aura;
LUAD	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg00049323	chr5:472564	LOC25845	0.45	7.43	0.34	5.9e-13	Cystic fibrosis severity;
LUAD	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-9.11	-0.4	3.42e-18	Hemoglobin concentration;
LUAD	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.64e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg24848339	chr3:12840334	CAND2	0.44	9.2	0.41	1.7e-18	QRS complex (12-leadsum);
LUAD	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg17644776	chr2:200775616	C2orf69	0.52	6.54	0.3	1.83e-10	Schizophrenia;
LUAD	cis	rs7187994	0.790	rs12922301	chr16:84794870	A/G	cg07647771	chr16:84786436	USP10	-0.38	-9.87	-0.43	8.44e-21	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg24768116	chr2:27665128	KRTCAP3	0.26	6.46	0.3	2.92e-10	Oral cavity cancer;
LUAD	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg24818145	chr4:99064322	C4orf37	0.43	7.24	0.33	2.14e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg26597838	chr10:835615	NA	1.29	19.5	0.69	6.85e-61	Eosinophil percentage of granulocytes;
LUAD	cis	rs4268898	0.965	rs4665673	chr2:24459737	A/T	cg06627628	chr2:24431161	ITSN2	0.46	7.78	0.35	5.67e-14	Asthma;
LUAD	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-7.41	-0.34	6.97e-13	Alzheimer's disease (late onset);
LUAD	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.95	-0.53	1.47e-32	Dilated cardiomyopathy;
LUAD	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.4	6.96	0.32	1.32e-11	Body mass index (adult);
LUAD	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs990171	0.538	rs2075192	chr2:103118228	A/G	cg03938978	chr2:103052716	IL18RAP	0.33	6.55	0.3	1.71e-10	Lymphocyte counts;
LUAD	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg02903104	chr8:1507517	DLGAP2	0.31	6.81	0.31	3.4e-11	Lung cancer;
LUAD	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.26e-12	Tonsillectomy;
LUAD	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg20503657	chr10:835505	NA	-0.67	-10.13	-0.44	9.52e-22	Eosinophil percentage of granulocytes;
LUAD	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg24308560	chr3:49941425	MST1R	0.49	8.09	0.37	6.19e-15	Body mass index;
LUAD	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg24399712	chr22:39784796	NA	-0.74	-12.25	-0.51	1.01e-29	Post bronchodilator FEV1;
LUAD	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg21427119	chr20:30132790	HM13	-0.57	-8.79	-0.39	3.87e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg20362242	chr5:692897	TPPP	0.63	7.93	0.36	2e-14	Obesity-related traits;
LUAD	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg02733842	chr7:1102375	C7orf50	-0.82	-11.79	-0.5	6.14e-28	Bronchopulmonary dysplasia;
LUAD	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg21427119	chr20:30132790	HM13	-0.61	-8.97	-0.4	1e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg18876405	chr7:65276391	NA	0.62	10.44	0.45	7.2e-23	Aortic root size;
LUAD	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg20307385	chr11:47447363	PSMC3	0.67	11.26	0.48	6.81e-26	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12292205	chr6:26970375	C6orf41	-0.47	-6.57	-0.3	1.47e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11406300	chr15:69687028	PAQR5	0.43	6.91	0.32	1.84e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs10489202	0.608	rs6659593	chr1:168072152	A/T	cg25738037	chr1:168025549	DCAF6	-0.47	-7.01	-0.32	9.67e-12	Schizophrenia;
LUAD	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.81	-0.36	4.44e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3736594	0.546	rs7571558	chr2:27839832	C/G	cg27432699	chr2:27873401	GPN1	0.45	6.61	0.31	1.13e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18789337	chr6:114180353	MARCKS	-0.41	-6.51	-0.3	2.17e-10	Height;
LUAD	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg25985355	chr7:65971099	NA	-0.52	-6.56	-0.3	1.57e-10	Diabetic kidney disease;
LUAD	cis	rs7586879	0.765	rs10171663	chr2:25086431	T/C	cg04586622	chr2:25135609	ADCY3	0.37	7.83	0.36	4.02e-14	Body mass index;
LUAD	cis	rs7301016	0.846	rs11174569	chr12:63021161	A/C	cg11441379	chr12:63026424	NA	0.64	7.84	0.36	3.57e-14	IgG glycosylation;
LUAD	cis	rs6906287	0.647	rs7772921	chr6:118964623	C/G	cg05564266	chr6:118973597	C6orf204	0.36	7.61	0.35	1.78e-13	Electrocardiographic conduction measures;
LUAD	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg03388025	chr16:89894329	SPIRE2	0.49	12.74	0.53	1.05e-31	Vitiligo;
LUAD	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg19980929	chr12:42632907	YAF2	0.33	6.41	0.3	4e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.86	0.32	2.49e-11	Depression;
LUAD	cis	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg00071950	chr4:10020882	SLC2A9	0.47	6.74	0.31	5.33e-11	Gout;Urate levels;Serum uric acid levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07972541	chr16:28961971	NFATC2IP	-0.56	-6.76	-0.31	4.53e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg27170947	chr2:26402098	FAM59B	0.8	11.88	0.5	2.87e-28	Gut microbiome composition (summer);
LUAD	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg00316803	chr15:76480434	C15orf27	0.4	6.38	0.3	4.55e-10	Blood metabolite levels;
LUAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg18621852	chr3:10150065	C3orf24	0.43	6.92	0.32	1.69e-11	Alzheimer's disease;
LUAD	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg18932078	chr1:2524107	MMEL1	0.37	7.01	0.32	9.72e-12	Ulcerative colitis;
LUAD	cis	rs79996792	0.736	rs79299044	chr2:162494182	T/A	cg22496339	chr2:162101262	NA	0.52	6.66	0.31	8.6e-11	Neuroticism;
LUAD	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg05110241	chr16:68378359	PRMT7	-0.8	-8.78	-0.39	4.06e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg25358565	chr5:93447407	FAM172A	0.65	7.74	0.35	7.18e-14	Diabetic retinopathy;
LUAD	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg16647868	chr5:131706066	SLC22A5	-0.41	-7.04	-0.32	7.86e-12	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg08601574	chr20:25228251	PYGB	-0.47	-8.74	-0.39	5.56e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg04511125	chr2:88470314	THNSL2	1.0	11.56	0.49	4.73e-27	Plasma clusterin levels;
LUAD	cis	rs174775	0.513	rs3788411	chr22:29728783	T/C	cg07256473	chr22:29710276	RASL10A	-0.54	-10.31	-0.45	2.23e-22	Immature fraction of reticulocytes;
LUAD	cis	rs7640424	0.649	rs13082569	chr3:107870835	A/C	cg09227934	chr3:107805635	CD47	0.5	9.04	0.4	5.6e-18	Body mass index;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg13742182	chr4:126236674	FAT4	0.42	6.64	0.31	9.9e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg03467027	chr4:99064603	C4orf37	0.44	7.17	0.33	3.42e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12711979	0.509	rs1031478	chr2:3827425	G/A	cg17052675	chr2:3827356	NA	-0.85	-20.56	-0.71	1.25e-65	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg05872129	chr22:39784769	NA	-0.77	-12.83	-0.53	4.68e-32	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg06608945	chr2:219082296	ARPC2	0.41	6.84	0.32	2.7e-11	Colorectal cancer;
LUAD	cis	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg02508848	chr16:68573721	ZFP90	-0.42	-6.55	-0.3	1.72e-10	Ulcerative colitis;
LUAD	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg22535103	chr8:58192502	C8orf71	-0.75	-10.57	-0.46	2.46e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs13064411	0.696	rs869343	chr3:113226705	C/T	cg18753928	chr3:113234510	CCDC52	-0.73	-12.41	-0.52	2.31e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	11.66	0.49	2.02e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs3087591	0.960	rs8080679	chr17:29602610	A/G	cg24425628	chr17:29625626	OMG;NF1	0.41	6.68	0.31	7.36e-11	Hip circumference;
LUAD	cis	rs868943	0.743	rs11153591	chr6:116328533	A/T	cg15226275	chr6:116381976	FRK	0.23	6.46	0.3	2.86e-10	Total cholesterol levels;
LUAD	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg10909506	chr17:38081995	ORMDL3	0.37	6.52	0.3	1.96e-10	Self-reported allergy;
LUAD	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg04545296	chr12:48745243	ZNF641	0.42	10.59	0.46	2.06e-23	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg11494091	chr17:61959527	GH2	-0.43	-8.52	-0.38	2.89e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10821973	0.527	rs7089059	chr10:64034274	C/T	cg09941381	chr10:64027924	RTKN2	-0.36	-7.15	-0.33	3.87e-12	Hypothyroidism;
LUAD	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15506890	chr2:3487001	NA	-0.45	-7.79	-0.35	5.07e-14	Neurofibrillary tangles;
LUAD	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg13859433	chr6:33739653	LEMD2	-0.36	-8.24	-0.37	2.22e-15	Crohn's disease;
LUAD	cis	rs79349575	0.756	rs62078385	chr17:47045009	C/T	cg22482690	chr17:47019901	SNF8	0.46	8.79	0.39	3.77e-17	Type 2 diabetes;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg09947615	chr4:42659549	ATP8A1	-0.46	-6.45	-0.3	2.98e-10	Testicular germ cell tumor;
LUAD	cis	rs494562	0.892	rs632163	chr6:86122062	C/T	cg17966619	chr6:86160162	NT5E	0.58	7.3	0.33	1.41e-12	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs6688613	1.000	rs6427049	chr1:166956593	C/T	cg07049167	chr1:166818506	POGK	0.41	6.9	0.32	1.92e-11	Refractive astigmatism;
LUAD	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.32	0.34	1.3e-12	Obesity-related traits;
LUAD	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg13877915	chr19:58951672	ZNF132	0.76	14.71	0.58	7.36e-40	Uric acid clearance;
LUAD	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg15704280	chr7:45808275	SEPT13	-0.61	-9.26	-0.41	1.01e-18	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg18806716	chr10:30721971	MAP3K8	0.79	16.62	0.63	4.26e-48	Inflammatory bowel disease;
LUAD	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00802000	chr16:706648	WDR90	-0.41	-7.77	-0.35	6.07e-14	Height;
LUAD	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg24818145	chr4:99064322	C4orf37	0.46	7.83	0.36	4.1e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7216064	0.817	rs28609796	chr17:65855104	T/A	cg08758996	chr17:66097529	LOC651250	0.47	7.17	0.33	3.32e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg09835421	chr16:68378352	PRMT7	-0.84	-9.09	-0.4	3.9e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.45	0.52	1.56e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1983170	0.673	rs11164934	chr1:92015267	C/T	cg02896835	chr1:92012615	NA	0.55	7.18	0.33	3.25e-12	Eosinophil percentage of white cells;
LUAD	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-8.77	-0.39	4.28e-17	Chronic sinus infection;
LUAD	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg17279839	chr7:150038598	RARRES2	0.43	7.5	0.34	3.83e-13	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg07393940	chr7:158741817	NA	-0.7	-11.83	-0.5	4.26e-28	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs6940638	1.000	rs12215773	chr6:27039233	T/C	cg01620082	chr3:125678407	NA	-0.51	-6.64	-0.31	9.73e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	8.38	0.38	8.17e-16	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27353979	chr11:66445383	RBM4B	-0.44	-6.93	-0.32	1.61e-11	Height;
LUAD	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg11502198	chr6:26597334	ABT1	-0.46	-7.27	-0.33	1.77e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2019216	0.542	rs12450889	chr17:21889379	A/G	cg05591447	chr17:21909280	FLJ36000	-0.27	-6.57	-0.3	1.49e-10	Pelvic organ prolapse;
LUAD	cis	rs2901656	1.000	rs6699095	chr1:172429245	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.38	7.6	0.35	1.91e-13	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs12681287	0.752	rs4389908	chr8:87274852	A/G	cg00550725	chr8:87521180	FAM82B	0.46	6.6	0.31	1.2e-10	Caudate activity during reward;
LUAD	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.52	-8.75	-0.39	5.07e-17	Electrocardiographic conduction measures;
LUAD	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.43	-0.34	5.93e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg16989719	chr2:238392110	NA	-0.31	-6.75	-0.31	4.87e-11	Prostate cancer;
LUAD	trans	rs264537	0.565	rs1816957	chr3:76703866	G/T	cg26146184	chr11:124637008	C11orf61	-0.42	-6.49	-0.3	2.45e-10	Periodontitis (PAL4Q3);
LUAD	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg04944784	chr2:26401820	FAM59B	-0.89	-12.69	-0.53	1.67e-31	Gut microbiome composition (summer);
LUAD	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg01689657	chr7:91764605	CYP51A1	0.32	7.72	0.35	8.49e-14	Breast cancer;
LUAD	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg10544611	chr16:67998164	SLC12A4	-0.68	-7.9	-0.36	2.5e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg27535305	chr1:53392650	SCP2	0.31	6.59	0.31	1.33e-10	Monocyte count;
LUAD	cis	rs7799006	0.722	rs33981648	chr7:2288669	T/C	cg02951883	chr7:2050386	MAD1L1	-0.46	-7.2	-0.33	2.77e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg17063962	chr7:91808500	NA	-0.69	-12.55	-0.52	6.2e-31	Breast cancer;
LUAD	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.15e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg14983838	chr19:29218262	NA	-0.57	-7.3	-0.33	1.44e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.47	0.3	2.76e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg17279839	chr7:150038598	RARRES2	0.44	7.46	0.34	4.98e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg15445000	chr17:37608096	MED1	0.42	7.76	0.35	6.55e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg22029157	chr1:209979665	IRF6	0.47	8.39	0.38	7.36e-16	Monobrow;
LUAD	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg16205897	chr5:131564050	P4HA2	-0.44	-10.16	-0.44	7.79e-22	Blood metabolite levels;
LUAD	cis	rs4072705	0.646	rs10120967	chr9:127244134	C/T	cg13476313	chr9:127244764	NR5A1	0.36	9.22	0.41	1.37e-18	Menarche (age at onset);
LUAD	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg02493740	chr2:85810744	VAMP5	-0.4	-7.31	-0.33	1.35e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs1816752	0.875	rs7993132	chr13:24987041	C/T	cg02811702	chr13:24901961	NA	0.43	7.37	0.34	9.06e-13	Obesity-related traits;
LUAD	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.77	0.31	4.29e-11	Parkinson's disease;
LUAD	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg08885076	chr2:99613938	TSGA10	0.36	6.51	0.3	2.12e-10	Chronic sinus infection;
LUAD	cis	rs10203711	1.000	rs10207724	chr2:239566705	G/C	cg14580085	chr2:239553406	NA	0.41	8.9	0.4	1.64e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg13047869	chr3:10149882	C3orf24	0.64	9.6	0.42	6.98e-20	Alzheimer's disease;
LUAD	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg01324343	chr3:183735012	ABCC5	0.9	18.85	0.68	5.59e-58	Anterior chamber depth;
LUAD	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg18016565	chr1:150552671	MCL1	-0.4	-7.31	-0.33	1.33e-12	Tonsillectomy;
LUAD	cis	rs6445967	0.530	rs12492472	chr3:58409972	A/C	cg13750441	chr3:58318267	PXK	-0.33	-6.75	-0.31	4.86e-11	Platelet count;
LUAD	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg09365446	chr1:150670422	GOLPH3L	0.61	10.91	0.47	1.43e-24	Melanoma;
LUAD	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg04989706	chr14:50066350	PPIL5	-0.53	-7.72	-0.35	8.41e-14	Carotid intima media thickness;
LUAD	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg15485101	chr11:133734466	NA	0.37	8.3	0.37	1.38e-15	Childhood ear infection;
LUAD	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg03714773	chr7:91764589	CYP51A1	0.29	6.5	0.3	2.29e-10	Breast cancer;
LUAD	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg24069376	chr3:38537580	EXOG	-0.43	-10.28	-0.45	2.72e-22	Electrocardiographic conduction measures;
LUAD	cis	rs4700695	0.668	rs153393	chr5:65428707	A/G	cg21114390	chr5:65439923	SFRS12	-0.89	-13.82	-0.56	3.98e-36	Facial morphology (factor 19);
LUAD	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.36e-12	Lung cancer;
LUAD	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03264133	chr6:25882463	NA	0.54	9.16	0.41	2.19e-18	Blood metabolite levels;
LUAD	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg03929089	chr4:120376271	NA	-0.51	-6.69	-0.31	7.26e-11	Axial length;
LUAD	cis	rs877282	0.898	rs12356709	chr10:763365	A/G	cg17470449	chr10:769945	NA	0.62	8.83	0.39	2.91e-17	Uric acid levels;
LUAD	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg14829155	chr15:31115871	NA	-0.58	-9.69	-0.43	3.38e-20	Huntington's disease progression;
LUAD	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.59e-12	Breast cancer;
LUAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg26338869	chr17:61819248	STRADA	-0.38	-6.35	-0.3	5.48e-10	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.13e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2882667	0.858	rs11951899	chr5:138374310	A/G	cg04439458	chr5:138467593	SIL1	-0.52	-9.25	-0.41	1.13e-18	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs738322	0.555	rs5750548	chr22:38547016	C/A	cg17652424	chr22:38574118	PLA2G6	-0.26	-6.9	-0.32	1.89e-11	Cutaneous nevi;
LUAD	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg11502198	chr6:26597334	ABT1	-0.52	-8.8	-0.39	3.46e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg23758822	chr17:41437982	NA	1.01	20.56	0.71	1.26e-65	Menopause (age at onset);
LUAD	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19346786	chr7:2764209	NA	-0.59	-12.8	-0.53	6.2e-32	Height;
LUAD	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg13902645	chr11:5959945	NA	-0.52	-8.84	-0.39	2.55e-17	DNA methylation (variation);
LUAD	cis	rs494562	0.892	rs547052	chr6:86118840	G/A	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs11048434	0.736	rs1805733	chr12:9089272	A/C	cg23795048	chr12:9217529	LOC144571	0.41	7.43	0.34	6.22e-13	Sjögren's syndrome;
LUAD	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg18230493	chr5:56204884	C5orf35	0.71	11.26	0.48	6.79e-26	Initial pursuit acceleration;
LUAD	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg04455712	chr21:45112962	RRP1B	0.41	8.19	0.37	3.13e-15	Mean corpuscular volume;
LUAD	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	6.48	0.3	2.58e-10	Schizophrenia;
LUAD	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.11e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg20476274	chr7:133979776	SLC35B4	0.84	16.59	0.63	5.64e-48	Mean platelet volume;
LUAD	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg11189052	chr15:85197271	WDR73	0.6	7.45	0.34	5.25e-13	Schizophrenia;
LUAD	cis	rs11811982	0.793	rs114006056	chr1:227537248	C/G	cg24860534	chr1:227506868	CDC42BPA	0.68	7.35	0.34	1.05e-12	Optic disc area;
LUAD	cis	rs17152411	1.000	rs7077936	chr10:126650065	C/T	cg07906193	chr10:126599966	NA	0.55	7.78	0.35	5.76e-14	Height;
LUAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg08888203	chr3:10149979	C3orf24	0.74	12.98	0.53	1.18e-32	Alzheimer's disease;
LUAD	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg21138405	chr5:131827807	IRF1	0.6	13.89	0.56	2.17e-36	Asthma (sex interaction);
LUAD	cis	rs1595825	1.000	rs74935794	chr2:198871195	T/G	cg00982548	chr2:198649783	BOLL	-0.6	-8.64	-0.39	1.14e-16	Ulcerative colitis;
LUAD	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.43	0.55	1.69e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10802521	chr3:52805072	NEK4	-0.52	-8.98	-0.4	9.02e-18	Bipolar disorder;
LUAD	cis	rs12618769	0.597	rs72821956	chr2:99159966	G/T	cg10123293	chr2:99228465	UNC50	0.5	8.68	0.39	8.52e-17	Bipolar disorder;
LUAD	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.67	0.31	8.23e-11	Menarche (age at onset);
LUAD	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-8.69	-0.39	7.98e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg19717773	chr7:2847554	GNA12	-0.55	-10.25	-0.45	3.73e-22	Height;
LUAD	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	8.12	0.37	4.98e-15	Breast cancer;
LUAD	cis	rs7551222	0.752	rs10900596	chr1:204522457	T/C	cg20240347	chr1:204465584	NA	-0.33	-6.36	-0.3	5.09e-10	Schizophrenia;
LUAD	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg26022315	chr17:47021804	SNF8	-0.42	-7.25	-0.33	1.96e-12	Type 2 diabetes;
LUAD	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06221963	chr1:154839813	KCNN3	-0.87	-21.0	-0.71	1.32e-67	Prostate cancer;
LUAD	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg25233709	chr10:116636983	FAM160B1	0.39	7.65	0.35	1.39e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg18755752	chr8:142205143	DENND3	-0.44	-7.61	-0.35	1.79e-13	Immature fraction of reticulocytes;
LUAD	cis	rs4343996	0.902	rs4719894	chr7:3381789	C/T	cg21248987	chr7:3385318	SDK1	-0.35	-6.53	-0.3	1.83e-10	Motion sickness;
LUAD	cis	rs57502260	0.764	rs3867143	chr11:68223074	A/G	cg16797656	chr11:68205561	LRP5	0.49	7.45	0.34	5.41e-13	Total body bone mineral density (age 45-60);
LUAD	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg24813613	chr7:1882135	MAD1L1	-0.43	-6.82	-0.31	3.12e-11	Testicular germ cell tumor;
LUAD	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	8.67	0.39	9.29e-17	Breast cancer;
LUAD	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg05697835	chr1:2722811	NA	0.32	6.65	0.31	9.1e-11	Ulcerative colitis;
LUAD	cis	rs3784262	0.528	rs6493979	chr15:58338052	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.34	-0.34	1.08e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23158103	chr7:148848205	ZNF398	-0.67	-12.49	-0.52	1.13e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg16649755	chr6:88412160	NCRNA00120;AKIRIN2	-0.38	-6.54	-0.3	1.78e-10	Subcortical brain region volumes;
LUAD	cis	rs1018836	0.892	rs4735210	chr8:91549399	G/T	cg16814680	chr8:91681699	NA	-0.62	-10.64	-0.46	1.33e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12365397	0.526	rs11607331	chr11:43157244	T/C	cg03447554	chr11:43094025	NA	0.42	7.58	0.35	2.23e-13	Migraine;
LUAD	cis	rs6087990	1.000	rs2424900	chr20:31344342	G/C	cg13636640	chr20:31349939	DNMT3B	0.84	15.94	0.61	3.95e-45	Ulcerative colitis;
LUAD	trans	rs877282	0.583	rs12356155	chr10:823940	C/T	cg22713356	chr15:30763199	NA	0.87	10.77	0.46	4.59e-24	Uric acid levels;
LUAD	cis	rs754466	0.958	rs11002341	chr10:79701363	A/C	cg17075019	chr10:79541650	NA	-0.81	-13.17	-0.54	2.05e-33	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2505998	0.833	rs1800858	chr10:43595968	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.35	-6.46	-0.3	2.83e-10	Hirschsprung disease;
LUAD	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.74	-10.08	-0.44	1.43e-21	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg04287289	chr16:89883240	FANCA	0.78	6.92	0.32	1.73e-11	Skin colour saturation;
LUAD	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg18135555	chr8:22132992	PIWIL2	0.44	7.79	0.35	5.33e-14	Hypertriglyceridemia;
LUAD	cis	rs78366141	0.649	rs77135481	chr4:89689680	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.92	6.38	0.3	4.74e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs11971779	0.680	rs2355785	chr7:139070983	C/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.76	0.31	4.63e-11	Diisocyanate-induced asthma;
LUAD	cis	rs61008539	1.000	rs61008539	chr7:858506	C/G	cg15782153	chr7:917662	C7orf20	0.56	10.31	0.45	2.2e-22	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg25894440	chr7:65020034	NA	0.64	6.95	0.32	1.41e-11	Diabetic kidney disease;
LUAD	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg17724175	chr1:150552817	MCL1	0.31	7.11	0.33	5e-12	Melanoma;
LUAD	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg22117172	chr7:91764530	CYP51A1	0.33	7.1	0.33	5.27e-12	Breast cancer;
LUAD	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-6.56	-0.3	1.59e-10	Lung cancer;
LUAD	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	8.48	0.38	3.94e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg08989290	chr16:615782	NHLRC4	0.31	6.67	0.31	7.94e-11	Height;
LUAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6546550	0.867	rs7592647	chr2:70139134	C/T	cg02498382	chr2:70120550	SNRNP27	-0.57	-10.9	-0.47	1.54e-24	Prevalent atrial fibrillation;
LUAD	cis	rs7089973	0.610	rs17721905	chr10:116731596	A/G	cg23260525	chr10:116636907	FAM160B1	0.34	6.38	0.3	4.54e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.68	-0.31	7.6e-11	Breast cancer;
LUAD	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg14728415	chr7:32535168	LSM5;AVL9	0.69	12.46	0.52	1.37e-30	Cognitive ability;
LUAD	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg10589385	chr1:150898437	SETDB1	0.42	7.71	0.35	8.82e-14	Blood protein levels;
LUAD	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg27661460	chr16:88844969	FAM38A	0.62	10.08	0.44	1.42e-21	Glycated hemoglobin levels;
LUAD	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg05865280	chr17:75406074	SEPT9	0.61	19.3	0.68	5.44e-60	Airflow obstruction;
LUAD	cis	rs6489882	0.966	rs10744791	chr12:113410316	C/T	cg20102336	chr12:113376681	OAS3	-0.44	-6.55	-0.3	1.71e-10	Chronic lymphocytic leukemia;
LUAD	trans	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg14917512	chr19:3094685	GNA11	0.56	6.69	0.31	7e-11	Diabetic kidney disease;
LUAD	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg23018236	chr17:30244563	NA	-0.68	-8.23	-0.37	2.42e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg23950597	chr19:37808831	NA	0.58	7.05	0.32	7.26e-12	Coronary artery calcification;
LUAD	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg02574844	chr11:5959923	NA	-0.42	-7.32	-0.34	1.23e-12	DNA methylation (variation);
LUAD	trans	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.67	11.3	0.48	4.62e-26	Mean corpuscular volume;
LUAD	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg18016565	chr1:150552671	MCL1	0.41	7.5	0.34	3.86e-13	Tonsillectomy;
LUAD	trans	rs587242	1.000	rs61786492	chr1:96904739	A/C	cg10631902	chr5:14652156	NA	0.44	7.23	0.33	2.23e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg18944383	chr4:111397179	ENPEP	0.47	8.28	0.37	1.69e-15	Coronary artery disease;
LUAD	cis	rs17154702	0.524	rs2664041	chr8:8593144	A/G	cg01851573	chr8:8652454	MFHAS1	0.44	8.04	0.36	9.06e-15	Neurocognitive impairment in HIV-1 infection (continuous);
LUAD	cis	rs6906287	0.647	rs35962656	chr6:118919593	G/T	cg21191810	chr6:118973309	C6orf204	0.5	9.67	0.43	4.11e-20	Electrocardiographic conduction measures;
LUAD	cis	rs62238980	0.614	rs74611447	chr22:32417612	T/A	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg09796270	chr17:17721594	SREBF1	0.37	6.94	0.32	1.43e-11	Total body bone mineral density;
LUAD	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg13012494	chr21:47604986	C21orf56	0.48	7.89	0.36	2.65e-14	Testicular germ cell tumor;
LUAD	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25427524	chr10:38739819	LOC399744	-0.74	-13.54	-0.55	6.04e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs354225	0.544	rs10208225	chr2:54806049	G/A	cg01766943	chr2:54829624	SPTBN1	0.4	7.44	0.34	5.71e-13	Schizophrenia;
LUAD	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.44	-0.34	5.5e-13	Bipolar disorder;
LUAD	cis	rs7274811	0.744	rs6120309	chr20:32169600	A/G	cg12710480	chr20:32254216	NECAB3;C20orf134	-0.32	-6.35	-0.3	5.44e-10	Height;
LUAD	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg22681709	chr2:178499509	PDE11A	0.47	7.84	0.36	3.76e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08280861	chr8:58055591	NA	0.53	6.61	0.31	1.18e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs12618769	0.597	rs3729568	chr2:99100196	T/G	cg10123293	chr2:99228465	UNC50	0.42	7.85	0.36	3.37e-14	Bipolar disorder;
LUAD	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-9.11	-0.4	3.38e-18	Life satisfaction;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24079997	chr4:52709183	DCUN1D4	-0.39	-6.45	-0.3	3.03e-10	Cancer;
LUAD	cis	rs12618769	0.652	rs3820941	chr2:99233781	C/T	cg10123293	chr2:99228465	UNC50	0.5	8.72	0.39	6.24e-17	Bipolar disorder;
LUAD	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.52	-0.38	2.76e-16	Alzheimer's disease (late onset);
LUAD	cis	rs4774899	0.966	rs12898327	chr15:57363937	G/T	cg14026238	chr15:57616123	NA	0.36	6.77	0.31	4.41e-11	Urinary tract infection frequency;
LUAD	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg00316803	chr15:76480434	C15orf27	-0.38	-7.11	-0.33	4.84e-12	Blood metabolite levels;
LUAD	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg21775007	chr8:11205619	TDH	-0.51	-9.3	-0.41	7.38e-19	Retinal vascular caliber;
LUAD	cis	rs727505	0.607	rs67680878	chr7:124787381	G/A	cg23710748	chr7:124431027	NA	-0.38	-7.72	-0.35	8.31e-14	Lewy body disease;
LUAD	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05901451	chr6:126070800	HEY2	-0.84	-16.32	-0.62	8.45e-47	Brugada syndrome;
LUAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg14092988	chr3:52407081	DNAH1	0.35	7.05	0.32	7.42e-12	Hemoglobin concentration;
LUAD	cis	rs752010	0.967	rs6675999	chr1:42099024	T/G	cg06885757	chr1:42089581	HIVEP3	0.45	9.65	0.42	4.79e-20	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.59	-9.92	-0.43	5.32e-21	Menarche (age at onset);
LUAD	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg11494091	chr17:61959527	GH2	0.75	18.54	0.67	1.39e-56	Prudent dietary pattern;
LUAD	trans	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg06606381	chr12:133084897	FBRSL1	-0.9	-8.61	-0.39	1.42e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg11266682	chr4:10021025	SLC2A9	0.68	15.82	0.61	1.35e-44	Bone mineral density;
LUAD	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.78	0.31	4.11e-11	Schizophrenia;
LUAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg22535103	chr8:58192502	C8orf71	-0.74	-9.2	-0.41	1.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7759001	0.857	rs2143061	chr6:27353705	T/C	cg18711553	chr6:27366782	ZNF391	0.39	6.43	0.3	3.36e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg02569458	chr12:86230093	RASSF9	0.43	7.85	0.36	3.46e-14	Major depressive disorder;
LUAD	trans	rs9467711	0.720	rs1417998	chr6:26162019	T/A	cg06606381	chr12:133084897	FBRSL1	-0.62	-6.45	-0.3	3.01e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg04287289	chr16:89883240	FANCA	0.42	6.55	0.3	1.71e-10	Vitiligo;
LUAD	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg03340356	chr1:67600835	NA	0.44	7.51	0.34	3.62e-13	Psoriasis;
LUAD	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg20673091	chr1:2541236	MMEL1	0.34	7.27	0.33	1.75e-12	Multiple sclerosis;
LUAD	cis	rs354225	0.565	rs2971880	chr2:54885640	A/T	cg26097391	chr2:54893211	SPTBN1	0.45	7.97	0.36	1.53e-14	Schizophrenia;
LUAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg02869364	chr7:1081709	C7orf50	-0.5	-6.43	-0.3	3.45e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23732368	chr3:48936262	SLC25A20	-0.53	-6.41	-0.3	3.87e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg15704280	chr7:45808275	SEPT13	0.65	7.64	0.35	1.48e-13	Axial length;
LUAD	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg04703951	chr17:43578652	NA	-0.54	-8.02	-0.36	1.03e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.95	-0.36	1.77e-14	Monocyte percentage of white cells;
LUAD	cis	rs1461503	0.966	rs11218907	chr11:122841562	A/G	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs9908158	1	rs9908158	chr17:33890083	T/C	cg05299278	chr17:33885742	SLFN14	-0.46	-9.43	-0.42	2.84e-19	Platelet count;Platelet distribution width;
LUAD	cis	rs7274811	0.901	rs17404047	chr20:32305781	A/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.5	-6.79	-0.31	3.69e-11	Height;
LUAD	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11644478	chr21:40555479	PSMG1	-0.4	-6.65	-0.31	8.87e-11	Menarche (age at onset);
LUAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg11766577	chr21:47581405	C21orf56	-0.6	-10.73	-0.46	6.23e-24	Testicular germ cell tumor;
LUAD	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg00634984	chr7:65235879	NA	-0.47	-6.46	-0.3	2.81e-10	Aortic root size;
LUAD	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03517284	chr6:25882590	NA	-0.64	-9.45	-0.42	2.38e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs4356932	1.000	rs7683657	chr4:76962643	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.48	-0.3	2.48e-10	Blood protein levels;
LUAD	cis	rs1448094	0.813	rs6539942	chr12:86452969	T/C	cg06740227	chr12:86229804	RASSF9	-0.36	-6.53	-0.3	1.87e-10	Major depressive disorder;
LUAD	cis	rs12936587	0.535	rs6502615	chr17:17612023	C/T	cg01246520	chr17:17644344	RAI1	0.39	6.56	0.3	1.61e-10	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LUAD	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg11266682	chr4:10021025	SLC2A9	0.55	12.03	0.5	7.27e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3761847	0.622	rs10818498	chr9:123787566	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	6.53	0.3	1.86e-10	Rheumatoid arthritis;
LUAD	cis	rs2046867	0.818	rs7620212	chr3:72778610	C/T	cg04365224	chr3:72788183	NA	-0.49	-7.32	-0.34	1.26e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12711979	0.904	rs12329356	chr2:3868533	G/C	cg17052675	chr2:3827356	NA	-0.48	-8.75	-0.39	5.2e-17	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03647317	chr4:187891568	NA	-0.36	-6.79	-0.31	3.84e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7512552	0.809	rs698923	chr1:150379159	G/A	cg15654264	chr1:150340011	RPRD2	0.62	11.72	0.5	1.12e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg02421172	chr7:1938701	MAD1L1	0.46	6.67	0.31	7.89e-11	Bipolar disorder;
LUAD	cis	rs7809615	0.901	rs10226310	chr7:99118320	G/A	cg03133378	chr7:99195931	NA	-0.56	-6.54	-0.3	1.83e-10	Blood metabolite ratios;
LUAD	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg09184832	chr6:79620586	NA	-0.53	-9.85	-0.43	9.54e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-10.85	-0.47	2.4e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11048434	0.736	rs12833375	chr12:9112018	A/T	cg26114124	chr12:9217669	LOC144571	0.36	6.63	0.31	1.01e-10	Sjögren's syndrome;
LUAD	cis	rs4812048	0.649	rs6070705	chr20:57625231	A/C	cg14073986	chr20:57617431	SLMO2	0.82	9.89	0.43	6.7e-21	Mean platelet volume;
LUAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg27532560	chr4:187881888	NA	-0.34	-6.41	-0.3	3.8e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg16797656	chr11:68205561	LRP5	0.47	9.25	0.41	1.1e-18	Total body bone mineral density;
LUAD	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg24069376	chr3:38537580	EXOG	0.37	8.39	0.38	7.29e-16	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.5	0.42	1.62e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6761276	0.899	rs11693750	chr2:113835602	C/T	cg02343335	chr2:113785852	IL1F8	-0.35	-7.01	-0.32	9.26e-12	Protein quantitative trait loci;
LUAD	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg20291162	chr17:40259547	DHX58	-0.68	-10.52	-0.46	3.77e-23	Fibrinogen levels;
LUAD	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg17372223	chr3:52568218	NT5DC2	-0.39	-7.2	-0.33	2.8e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg00857998	chr1:205179979	DSTYK	0.41	6.82	0.31	3.22e-11	Red blood cell count;
LUAD	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.41	-0.34	7.07e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11958404	0.932	rs6865373	chr5:157436728	A/G	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg25237894	chr2:233734115	C2orf82	-0.6	-11.9	-0.5	2.4e-28	Coronary artery disease;
LUAD	cis	rs713477	0.935	rs10144034	chr14:55914273	C/A	cg13175173	chr14:55914753	NA	-0.35	-7.4	-0.34	7.41e-13	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg22535103	chr8:58192502	C8orf71	-0.6	-6.5	-0.3	2.23e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg18240062	chr17:79603768	NPLOC4	0.46	8.11	0.37	5.34e-15	Eye color traits;
LUAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs11039798	0.778	rs7944523	chr11:48911019	G/A	cg02254774	chr11:50257496	LOC441601	0.52	6.56	0.3	1.62e-10	Axial length;
LUAD	trans	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg19894588	chr14:64061835	NA	0.53	8.33	0.38	1.13e-15	Glioblastoma;Glioma;
LUAD	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg06618935	chr21:46677482	NA	-0.51	-10.29	-0.45	2.56e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg02450064	chr17:40260053	DHX58	-0.43	-7.24	-0.33	2.16e-12	Fibrinogen levels;
LUAD	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg17105886	chr17:28927953	LRRC37B2	0.81	7.87	0.36	3.06e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg09835421	chr16:68378352	PRMT7	-0.84	-9.07	-0.4	4.45e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.62	-10.36	-0.45	1.49e-22	Longevity;Endometriosis;
LUAD	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.79	0.35	5.13e-14	Morning vs. evening chronotype;
LUAD	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-14.35	-0.57	2.58e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2835872	0.861	rs8126563	chr21:39052624	C/T	cg06728970	chr21:39037746	KCNJ6	-0.41	-7.26	-0.33	1.88e-12	Electroencephalographic traits in alcoholism;
LUAD	cis	rs986417	0.818	rs1998189	chr14:60974987	A/T	cg27398547	chr14:60952738	C14orf39	0.67	8.03	0.36	9.45e-15	Gut microbiota (bacterial taxa);
LUAD	cis	rs12545109	0.800	rs1913278	chr8:57403725	T/C	cg09654669	chr8:57350985	NA	-0.64	-9.39	-0.42	3.74e-19	Obesity-related traits;
LUAD	cis	rs13315871	0.858	rs78946071	chr3:58318523	G/T	cg12435725	chr3:58293450	RPP14	-0.73	-7.69	-0.35	1.08e-13	Cholesterol, total;
LUAD	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg24642844	chr7:1081250	C7orf50	-0.96	-10.45	-0.45	6.88e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg05283184	chr6:79620031	NA	-0.61	-12.41	-0.52	2.33e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg07080864	chr8:57359956	PENK	-0.38	-6.53	-0.3	1.84e-10	Obesity-related traits;
LUAD	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg10518543	chr12:38710700	ALG10B	-0.42	-6.9	-0.32	1.86e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg11859384	chr17:80120422	CCDC57	0.5	9.04	0.4	5.52e-18	Life satisfaction;
LUAD	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18876405	chr7:65276391	NA	0.42	6.5	0.3	2.21e-10	Aortic root size;
LUAD	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg10755058	chr3:40428713	ENTPD3	0.47	8.68	0.39	8.54e-17	Renal cell carcinoma;
LUAD	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg03929089	chr4:120376271	NA	-0.52	-7.64	-0.35	1.47e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs494562	0.892	rs640093	chr6:86115866	C/T	cg13315970	chr6:86159197	NT5E	0.62	7.18	0.33	3.19e-12	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs8068544	0.748	rs75881902	chr17:40156612	C/A	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.2	-12.25	-0.51	9.73e-30	Reticulocyte fraction of red cells;Reticulocyte count;
LUAD	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.8	0.31	3.54e-11	Depression;
LUAD	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06873352	chr17:61820015	STRADA	0.81	18.3	0.66	1.61e-55	Prudent dietary pattern;
LUAD	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg05110241	chr16:68378359	PRMT7	-0.84	-9.17	-0.41	2.07e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg07404485	chr7:94953653	PON1	-0.49	-7.08	-0.33	5.93e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs8062405	0.723	rs762633	chr16:28608341	T/C	cg00204512	chr16:28754710	NA	0.32	6.81	0.31	3.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg17807903	chr1:86174739	ZNHIT6	-0.69	-15.07	-0.59	2.09e-41	Urate levels in overweight individuals;
LUAD	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg26384229	chr12:38710491	ALG10B	0.4	6.41	0.3	3.95e-10	Morning vs. evening chronotype;
LUAD	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.68e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3087591	1.000	rs2012988	chr17:29547296	T/C	cg24425628	chr17:29625626	OMG;NF1	0.41	6.75	0.31	4.76e-11	Hip circumference;
LUAD	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg01579765	chr21:45077557	HSF2BP	-0.58	-13.4	-0.55	2.32e-34	Mean corpuscular volume;
LUAD	cis	rs3739034	0.938	rs17733977	chr2:135470056	G/A	cg12500956	chr2:135428796	TMEM163	0.37	6.78	0.31	4.16e-11	Gut microbiome composition (winter);
LUAD	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.99	-0.4	8.54e-18	Total body bone mineral density;
LUAD	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg03433033	chr1:76189801	ACADM	-0.71	-11.56	-0.49	4.64e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg26516362	chr5:178986906	RUFY1	0.59	10.19	0.44	6.03e-22	Lung cancer;
LUAD	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.47	-7.82	-0.36	4.24e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg00255919	chr5:131827918	IRF1	0.5	11.9	0.5	2.21e-28	Asthma (sex interaction);
LUAD	cis	rs9902453	1.000	rs12600993	chr17:28291222	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	8.79	0.39	3.69e-17	Coffee consumption (cups per day);
LUAD	cis	rs6087990	0.735	rs6058883	chr20:31365719	C/T	cg13636640	chr20:31349939	DNMT3B	-0.74	-13.57	-0.55	4.33e-35	Ulcerative colitis;
LUAD	cis	rs11098699	0.821	rs11098703	chr4:124218462	C/G	cg09941581	chr4:124220074	SPATA5	0.48	7.94	0.36	1.84e-14	Mosquito bite size;
LUAD	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg04539111	chr16:67997858	SLC12A4	-0.59	-6.92	-0.32	1.67e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.36	0.48	2.77e-26	Height;
LUAD	cis	rs2404602	0.622	rs9635380	chr15:77103479	A/G	cg23625390	chr15:77176239	SCAPER	-0.52	-7.72	-0.35	8.54e-14	Blood metabolite levels;
LUAD	cis	rs1595825	0.891	rs16826873	chr2:198898222	A/C	cg00982548	chr2:198649783	BOLL	0.65	9.11	0.41	3.24e-18	Ulcerative colitis;
LUAD	cis	rs6743376	0.556	rs3180235	chr2:113820672	C/T	cg09040174	chr2:113837401	NA	-0.45	-7.05	-0.32	7.38e-12	Inflammatory biomarkers;
LUAD	cis	rs2235642	0.525	rs8048290	chr16:1562026	T/C	cg03034668	chr16:1723424	CRAMP1L	-0.41	-6.54	-0.3	1.73e-10	Coronary artery disease;
LUAD	trans	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.4	-0.42	3.56e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg01620082	chr3:125678407	NA	-0.74	-7.6	-0.35	1.89e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs36051895	0.659	rs4495487	chr9:5072798	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-6.37	-0.3	5.06e-10	Pediatric autoimmune diseases;
LUAD	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18876405	chr7:65276391	NA	-0.58	-9.91	-0.43	5.83e-21	Aortic root size;
LUAD	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg09184832	chr6:79620586	NA	-0.5	-9.41	-0.42	3.15e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg14343924	chr8:8086146	FLJ10661	-0.4	-6.37	-0.3	4.92e-10	Neuroticism;
LUAD	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	8.76	0.39	4.61e-17	Total body bone mineral density;
LUAD	cis	rs758324	0.812	rs6893957	chr5:131198780	T/C	cg06307176	chr5:131281290	NA	0.45	7.55	0.34	2.74e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs2625529	0.824	rs12903484	chr15:72299481	G/A	cg16672083	chr15:72433130	SENP8	-0.77	-13.0	-0.53	9.5e-33	Red blood cell count;
LUAD	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg27129171	chr3:47204927	SETD2	0.4	6.52	0.3	2.04e-10	Colorectal cancer;
LUAD	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg05340658	chr4:99064831	C4orf37	0.42	6.97	0.32	1.21e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg18230493	chr5:56204884	C5orf35	-0.48	-7.89	-0.36	2.54e-14	Coronary artery disease;
LUAD	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg06611532	chr13:114900021	NA	0.37	8.6	0.39	1.6e-16	Schizophrenia;
LUAD	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg03929089	chr4:120376271	NA	-0.69	-9.94	-0.44	4.5e-21	Coronary artery disease;
LUAD	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.34	-7.6	-0.35	1.89e-13	Blood metabolite levels;
LUAD	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg11494091	chr17:61959527	GH2	0.45	8.45	0.38	4.61e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg26384229	chr12:38710491	ALG10B	-0.4	-6.74	-0.31	5.13e-11	Morning vs. evening chronotype;
LUAD	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg17420585	chr12:42539391	GXYLT1	-0.38	-6.67	-0.31	7.93e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg10018233	chr7:150070692	REPIN1	0.54	9.58	0.42	8.06e-20	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg26408565	chr15:76604113	ETFA	-0.44	-7.05	-0.32	7.19e-12	Blood metabolite levels;
LUAD	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.38e-13	Menopause (age at onset);
LUAD	cis	rs9326248	0.581	rs11216242	chr11:116901549	G/A	cg20608306	chr11:116969690	SIK3	0.32	7.11	0.33	5.12e-12	Blood protein levels;
LUAD	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg21475434	chr5:93447410	FAM172A	0.76	8.29	0.37	1.5e-15	Diabetic retinopathy;
LUAD	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg24578937	chr1:2090814	PRKCZ	0.55	11.51	0.49	7.35e-27	Height;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04849788	chr3:160283695	KPNA4	0.43	6.62	0.31	1.1e-10	Gut microbiome composition (summer);
LUAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-9.6	-0.42	7.23e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg23750338	chr8:142222470	SLC45A4	0.62	14.15	0.57	1.77e-37	Immature fraction of reticulocytes;
LUAD	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg08085267	chr17:45401833	C17orf57	-0.64	-11.37	-0.48	2.58e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg19761014	chr17:28927070	LRRC37B2	0.67	7.46	0.34	5.03e-13	Body mass index;
LUAD	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.6	-0.31	1.23e-10	Coronary artery disease;
LUAD	cis	rs1040555	0.516	rs242547	chr20:31418581	T/C	cg13636640	chr20:31349939	DNMT3B	0.61	10.29	0.45	2.5e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg16797656	chr11:68205561	LRP5	0.45	9.4	0.42	3.4e-19	Total body bone mineral density;
LUAD	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg00484396	chr16:3507460	NAT15	-0.69	-11.66	-0.49	1.99e-27	Tuberculosis;
LUAD	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg25767906	chr1:53392781	SCP2	-0.48	-8.62	-0.39	1.36e-16	Monocyte count;
LUAD	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg15921436	chr17:44337874	NA	0.63	9.36	0.41	4.86e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.68	-10.38	-0.45	1.22e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs9427116	0.502	rs9427104	chr1:154589232	C/T	cg17218026	chr1:154582156	ADAR	0.5	9.91	0.43	5.79e-21	Blood protein levels;
LUAD	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg21951975	chr1:209979733	IRF6	0.58	6.99	0.32	1.06e-11	Coronary artery disease;
LUAD	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.92	0.36	2.07e-14	Depression;
LUAD	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg12940439	chr1:67600707	NA	0.45	8.84	0.39	2.58e-17	Psoriasis;
LUAD	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg17644776	chr2:200775616	C2orf69	0.54	8.1	0.37	6.08e-15	LDL cholesterol to HDL cholesterol ratio;
LUAD	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg25233709	chr10:116636983	FAM160B1	0.41	8.26	0.37	1.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg12483005	chr1:23474871	LUZP1	0.52	9.0	0.4	7.99e-18	Height;
LUAD	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg21862992	chr11:68658383	NA	0.52	9.59	0.42	7.47e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg08742575	chr21:47604166	C21orf56	0.5	8.12	0.37	5.23e-15	Testicular germ cell tumor;
LUAD	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg13073564	chr4:8508604	NA	0.46	8.54	0.38	2.51e-16	Response to antineoplastic agents;
LUAD	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.87	0.32	2.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg02461776	chr11:598696	PHRF1	0.47	6.87	0.32	2.31e-11	Systemic lupus erythematosus;
LUAD	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg19875535	chr5:140030758	IK	0.44	7.41	0.34	6.93e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9341808	0.727	rs10943697	chr6:80931506	A/C	cg08355045	chr6:80787529	NA	0.58	10.47	0.45	5.61e-23	Sitting height ratio;
LUAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg24642844	chr7:1081250	C7orf50	-0.98	-14.8	-0.58	2.97e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6445967	0.569	rs12493748	chr3:58311282	A/G	cg23715586	chr3:58305044	RPP14	0.4	6.46	0.3	2.84e-10	Platelet count;
LUAD	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg16049864	chr8:95962084	TP53INP1	-0.55	-12.0	-0.5	9.76e-29	Type 2 diabetes;
LUAD	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg02975922	chr3:195473998	MUC4	-0.44	-7.22	-0.33	2.43e-12	Pancreatic cancer;
LUAD	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg00339695	chr16:24857497	SLC5A11	0.46	8.49	0.38	3.52e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg08422745	chr4:174089978	GALNT7	-0.95	-18.45	-0.67	3.38e-56	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs4674676	1	rs4674676	chr2:223529112	A/G	cg25565276	chr2:223520875	FARSB	0.56	7.15	0.33	3.96e-12	Chin dimples;
LUAD	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.59e-12	Breast cancer;
LUAD	trans	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17712092	chr4:129076599	LARP1B	0.94	18.01	0.66	3.14e-54	Eosinophil percentage of white cells;
LUAD	cis	rs7010267	0.570	rs6469798	chr8:120018291	C/T	cg01975934	chr8:119970761	NA	-0.35	-6.58	-0.3	1.43e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18099408	chr3:52552593	STAB1	-0.46	-7.89	-0.36	2.59e-14	Bipolar disorder;
LUAD	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg07870213	chr5:140052090	DND1	0.98	13.57	0.55	4.36e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg04248312	chr19:17393744	ANKLE1	-0.99	-18.52	-0.67	1.58e-56	Systemic lupus erythematosus;
LUAD	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg08213375	chr14:104286397	PPP1R13B	0.28	7.22	0.33	2.41e-12	Schizophrenia;
LUAD	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg15181151	chr6:150070149	PCMT1	0.34	6.43	0.3	3.44e-10	Lung cancer;
LUAD	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs3849570	0.695	rs9830445	chr3:81508063	T/G	cg07356753	chr3:81810745	GBE1	0.48	7.59	0.35	2e-13	Waist circumference;Body mass index;
LUAD	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08109568	chr15:31115862	NA	0.54	9.58	0.42	8.24e-20	Huntington's disease progression;
LUAD	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg25173405	chr17:45401733	C17orf57	0.51	8.65	0.39	1.1e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg02221422	chr11:68192511	LRP5	0.4	6.73	0.31	5.5e-11	Total body bone mineral density;
LUAD	cis	rs6445967	1.000	rs9846885	chr3:58285789	C/T	cg23715586	chr3:58305044	RPP14	0.42	7.63	0.35	1.59e-13	Platelet count;
LUAD	cis	rs3784262	1.000	rs4646619	chr15:58258342	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.46	-9.59	-0.42	7.64e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.6	-0.35	1.95e-13	Blood trace element (Zn levels);
LUAD	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg08610063	chr20:61569321	C20orf11;DIDO1	-0.41	-6.66	-0.31	8.4e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg27284194	chr4:1044797	NA	0.7	10.18	0.44	6.52e-22	Recombination rate (females);
LUAD	cis	rs11229555	0.645	rs10896814	chr11:58430699	T/C	cg15696309	chr11:58395628	NA	-0.58	-7.13	-0.33	4.26e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg21775007	chr8:11205619	TDH	0.49	8.76	0.39	4.75e-17	Retinal vascular caliber;
LUAD	trans	rs7395662	0.929	rs7108559	chr11:48619151	G/T	cg00717180	chr2:96193071	NA	-0.4	-7.43	-0.34	6.13e-13	HDL cholesterol;
LUAD	cis	rs2625529	0.938	rs4777464	chr15:72131763	C/T	cg16672083	chr15:72433130	SENP8	-0.68	-11.41	-0.49	1.74e-26	Red blood cell count;
LUAD	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg10556349	chr10:835070	NA	0.53	7.07	0.32	6.55e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs2880765	0.835	rs4281668	chr15:86047286	C/T	cg13263323	chr15:86062960	AKAP13	-0.5	-8.89	-0.4	1.82e-17	Coronary artery disease;
LUAD	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg21963583	chr11:68658836	MRPL21	0.65	11.57	0.49	4.37e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.38	0.34	8.64e-13	Menopause (age at onset);
LUAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg24829409	chr8:58192753	C8orf71	-0.62	-9.29	-0.41	7.92e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg08916839	chr5:415575	AHRR	0.9	9.87	0.43	8.3e-21	Fat distribution (HIV);
LUAD	cis	rs8099014	1.000	rs7243073	chr18:56130293	A/C	cg12907477	chr18:56117327	MIR122	0.38	6.42	0.3	3.73e-10	Platelet count;
LUAD	cis	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.87	-7.49	-0.34	3.97e-13	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs2806561	1.000	rs1571466	chr1:23449183	T/C	cg19743168	chr1:23544995	NA	0.38	6.97	0.32	1.25e-11	Height;
LUAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.6	8.12	0.37	5.11e-15	Renal function-related traits (BUN);
LUAD	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg03929089	chr4:120376271	NA	-0.66	-10.66	-0.46	1.21e-23	Coronary artery disease;
LUAD	cis	rs909341	0.537	rs6089971	chr20:62385846	G/A	cg14758556	chr20:62440591	NA	0.44	6.46	0.3	2.86e-10	Atopic dermatitis;
LUAD	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg10544611	chr16:67998164	SLC12A4	-0.63	-7.35	-0.34	1.06e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs847851	0.630	rs9462021	chr6:34758640	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.91	-0.4	1.53e-17	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13236679	chr6:37467396	C6orf129	-0.43	-6.59	-0.31	1.29e-10	Height;
LUAD	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg26924012	chr15:45694286	SPATA5L1	1.0	18.37	0.67	7.73e-56	Homoarginine levels;
LUAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02359409	chr6:42947317	PEX6	-0.37	-6.38	-0.3	4.75e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	1.04e-10	Diabetic kidney disease;
LUAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg25703541	chr22:24373054	LOC391322	-0.9	-17.64	-0.65	1.35e-52	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.42	-0.38	6.04e-16	Prostate cancer;
LUAD	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.41	0.3	3.89e-10	Cognitive test performance;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg08914844	chr7:86688919	KIAA1324L	-0.49	-6.44	-0.3	3.2e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.42	0.34	6.39e-13	Bipolar disorder;
LUAD	trans	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg18335740	chr13:41363409	SLC25A15	0.78	15.05	0.59	2.78e-41	Lewy body disease;
LUAD	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg00255919	chr5:131827918	IRF1	0.5	11.9	0.5	2.21e-28	Asthma (sex interaction);
LUAD	cis	rs35883536	0.647	rs10875328	chr1:101169328	C/T	cg06223162	chr1:101003688	GPR88	-0.41	-7.46	-0.34	4.81e-13	Monocyte count;
LUAD	trans	rs459571	0.916	rs467303	chr9:136904835	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-10.02	-0.44	2.32e-21	Platelet distribution width;
LUAD	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg14345882	chr6:26364793	BTN3A2	0.66	6.81	0.31	3.39e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11126435	0.858	rs60935309	chr2:74933398	C/T	cg19285774	chr2:74907978	SEMA4F	0.37	6.41	0.3	3.79e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs225245	0.791	rs8067294	chr17:34027964	T/C	cg19694781	chr19:47549865	TMEM160	-0.48	-7.93	-0.36	2.03e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs9303280	0.747	rs1453559	chr17:38020419	T/C	cg10909506	chr17:38081995	ORMDL3	0.38	7.01	0.32	9.5e-12	Self-reported allergy;
LUAD	cis	rs3784262	0.669	rs12905608	chr15:58314139	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.49	-0.34	4.08e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15664640	chr17:80829946	TBCD	0.79	15.6	0.6	1.14e-43	Breast cancer;
LUAD	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	9.77	0.43	1.8e-20	Lung cancer in ever smokers;
LUAD	cis	rs727505	1.000	rs7795943	chr7:124483796	C/A	cg23710748	chr7:124431027	NA	-0.46	-9.44	-0.42	2.62e-19	Lewy body disease;
LUAD	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg18131467	chr2:239335373	ASB1	0.68	11.94	0.5	1.63e-28	Multiple system atrophy;
LUAD	trans	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.46	0.34	4.99e-13	Resting heart rate;
LUAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg18621852	chr3:10150065	C3orf24	0.47	7.18	0.33	3.19e-12	Alzheimer's disease;
LUAD	cis	rs7665090	0.936	rs5026474	chr4:103554810	C/A	cg07973026	chr4:103553119	MANBA	0.48	8.45	0.38	4.89e-16	Primary biliary cholangitis;
LUAD	trans	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-9.11	-0.4	3.22e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-6.95	-0.32	1.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg08807101	chr21:30365312	RNF160	-0.43	-7.41	-0.34	7.05e-13	Dental caries;
LUAD	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg03467027	chr4:99064603	C4orf37	0.46	7.32	0.34	1.24e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs870825	0.616	rs7658186	chr4:185622509	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.91	0.56	1.71e-36	Blood protein levels;
LUAD	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg27433088	chr4:174089019	GALNT7	0.4	7.67	0.35	1.22e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg08712631	chr7:1960676	MAD1L1	-0.41	-6.66	-0.31	8.56e-11	Neuroticism;
LUAD	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg04539111	chr16:67997858	SLC12A4	-0.5	-6.82	-0.31	3.14e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg11050988	chr7:1952600	MAD1L1	0.32	6.56	0.3	1.62e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs3845702	0.736	rs6433821	chr2:180837806	T/A	cg01881094	chr2:180872142	CWC22	-0.82	-8.78	-0.39	3.98e-17	Schizophrenia;
LUAD	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg13319975	chr6:146136371	FBXO30	-0.64	-11.03	-0.47	5.03e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.61	8.23	0.37	2.41e-15	Gut microbiome composition (summer);
LUAD	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg19635926	chr16:89946313	TCF25	0.77	7.27	0.33	1.78e-12	Skin colour saturation;
LUAD	trans	rs6810798	0.520	rs57997710	chr4:148329382	G/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.47	-7.12	-0.33	4.59e-12	Coronary artery disease;
LUAD	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg27068330	chr11:65405492	SIPA1	0.73	11.88	0.5	2.8e-28	Acne (severe);
LUAD	cis	rs4853525	0.859	rs6434424	chr2:191722126	A/C	cg11845111	chr2:191398756	TMEM194B	-0.38	-6.48	-0.3	2.53e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg11057378	chr10:81107060	PPIF	0.37	6.95	0.32	1.43e-11	Height;
LUAD	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg14582100	chr15:45693742	SPATA5L1	0.64	12.49	0.52	1.11e-30	Homoarginine levels;
LUAD	cis	rs4147929	0.532	rs2242437	chr19:1065563	G/C	cg26576206	chr19:1064938	ABCA7	0.47	7.25	0.33	1.97e-12	Alzheimer's disease (late onset);
LUAD	cis	rs67072384	0.901	rs11235585	chr11:72476007	G/A	cg04827223	chr11:72435913	ARAP1	-0.63	-6.6	-0.31	1.23e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg10876282	chr6:28092338	ZSCAN16	0.42	6.65	0.31	8.99e-11	Cardiac Troponin-T levels;
LUAD	cis	rs10821973	0.527	rs7076775	chr10:64019606	C/T	cg09941381	chr10:64027924	RTKN2	-0.36	-7.18	-0.33	3.15e-12	Hypothyroidism;
LUAD	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.35	-6.55	-0.3	1.62e-10	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg20607798	chr8:58055168	NA	0.58	7.84	0.36	3.62e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg11427898	chr15:38544983	SPRED1	-0.51	-6.49	-0.3	2.44e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg19875535	chr5:140030758	IK	0.45	7.45	0.34	5.38e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs17102423	0.602	rs1007914	chr14:65566261	C/A	cg11161011	chr14:65562177	MAX	-0.51	-8.35	-0.38	9.76e-16	Obesity-related traits;
LUAD	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg18721089	chr20:30220636	NA	-0.49	-7.07	-0.33	6.49e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs4743820	0.651	rs73494914	chr9:93923108	G/A	cg14446406	chr9:93919335	NA	0.5	8.35	0.38	9.92e-16	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg21475434	chr5:93447410	FAM172A	0.72	8.12	0.37	5.13e-15	Diabetic retinopathy;
LUAD	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.18	-0.33	3.1e-12	Coronary artery disease;
LUAD	cis	rs6687430	0.526	rs7555790	chr1:10613167	A/G	cg17425144	chr1:10567563	PEX14	-0.54	-10.57	-0.46	2.4e-23	Hand grip strength;
LUAD	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg00934597	chr7:893267	UNC84A	-0.49	-6.49	-0.3	2.44e-10	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg11814155	chr7:99998594	ZCWPW1	0.42	7.32	0.34	1.22e-12	Platelet count;
LUAD	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg22920501	chr2:26401640	FAM59B	-0.96	-14.19	-0.57	1.13e-37	Gut microbiome composition (summer);
LUAD	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg18105134	chr13:113819100	PROZ	-0.85	-14.85	-0.59	1.95e-40	Platelet distribution width;
LUAD	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg26677194	chr12:130822605	PIWIL1	0.56	9.12	0.41	3.15e-18	Menopause (age at onset);
LUAD	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg11494091	chr17:61959527	GH2	0.73	17.78	0.65	3.29e-53	Prudent dietary pattern;
LUAD	cis	rs9863	0.861	rs11057396	chr12:124419062	A/C	cg17723958	chr12:124429295	CCDC92	-0.41	-6.58	-0.3	1.4e-10	White blood cell count;
LUAD	trans	rs10411161	0.702	rs10420224	chr19:52398955	A/G	cg22319618	chr22:45562946	NUP50	-0.66	-9.44	-0.42	2.52e-19	Breast cancer;
LUAD	cis	rs7587476	0.784	rs13026390	chr2:215687075	C/T	cg04004882	chr2:215674386	BARD1	-0.51	-6.51	-0.3	2.18e-10	Neuroblastoma;
LUAD	cis	rs7202877	0.706	rs247425	chr16:75460402	C/T	cg03315344	chr16:75512273	CHST6	-0.47	-6.36	-0.3	5.31e-10	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs4824093	0.610	rs73443986	chr22:50321193	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-7.05	-0.32	7.25e-12	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg06611532	chr13:114900021	NA	0.38	8.98	0.4	9.08e-18	Schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14457132	chr6:7389888	CAGE1;RIOK1	-0.56	-6.76	-0.31	4.54e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7607369	0.719	rs7567622	chr2:219624549	A/T	cg02176678	chr2:219576539	TTLL4	-0.59	-12.09	-0.51	4.12e-29	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs13144136	0.687	rs11725559	chr4:10654270	A/G	cg10242279	chr4:10666415	CLNK	0.3	6.49	0.3	2.34e-10	Resistance to antihypertensive treatment in hypertension;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13593297	chr4:123844277	SPATA5;NUDT6	-0.38	-6.35	-0.3	5.45e-10	Cancer;
LUAD	cis	rs2290402	0.505	rs17165087	chr4:845841	C/T	cg23939001	chr4:940644	TMEM175	-0.44	-6.48	-0.3	2.58e-10	Type 2 diabetes;
LUAD	cis	rs10242455	0.717	rs72494455	chr7:99336777	C/G	cg18809830	chr7:99032528	PTCD1	-0.81	-7.3	-0.33	1.4e-12	Blood metabolite levels;
LUAD	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg06640241	chr16:89574553	SPG7	0.71	12.71	0.53	1.45e-31	Multiple myeloma (IgH translocation);
LUAD	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg00383909	chr3:49044727	WDR6	0.99	10.63	0.46	1.45e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-7.46	-0.34	4.85e-13	Total cholesterol levels;
LUAD	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg00631329	chr6:26305371	NA	-0.69	-12.85	-0.53	3.84e-32	Educational attainment;
LUAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg11494091	chr17:61959527	GH2	0.74	18.35	0.67	9.02e-56	Prudent dietary pattern;
LUAD	cis	rs524023	1.000	rs10897518	chr11:64360705	A/G	cg19131476	chr11:64387923	NRXN2	0.37	7.06	0.32	7.04e-12	Urate levels in obese individuals;
LUAD	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.37	6.64	0.31	9.74e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg22029157	chr1:209979665	IRF6	0.47	8.46	0.38	4.35e-16	Monobrow;
LUAD	cis	rs6545883	0.929	rs12612982	chr2:61747355	G/A	cg15711740	chr2:61764176	XPO1	-0.4	-6.48	-0.3	2.58e-10	Tuberculosis;
LUAD	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg11905131	chr22:24372483	LOC391322	0.56	9.74	0.43	2.28e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg04414720	chr1:150670196	GOLPH3L	0.6	10.36	0.45	1.43e-22	Melanoma;
LUAD	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg02423579	chr7:2872169	GNA12	0.83	14.29	0.57	4.62e-38	Height;
LUAD	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg07570687	chr10:102243282	WNT8B	0.46	6.96	0.32	1.27e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg18131467	chr2:239335373	ASB1	-0.72	-12.73	-0.53	1.19e-31	Multiple system atrophy;
LUAD	cis	rs78487399	0.808	rs6746632	chr2:43712163	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-6.47	-0.3	2.8e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg10295955	chr4:187884368	NA	-1.16	-30.66	-0.83	1.5e-109	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4891159	0.790	rs7241485	chr18:74122325	C/T	cg24786174	chr18:74118243	ZNF516	-0.8	-15.14	-0.59	1.09e-41	Longevity;
LUAD	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg06558623	chr16:89946397	TCF25	1.15	10.14	0.44	9.29e-22	Skin colour saturation;
LUAD	cis	rs10782582	0.569	rs2131557	chr1:76388589	A/C	cg03433033	chr1:76189801	ACADM	0.46	6.72	0.31	5.85e-11	Daytime sleep phenotypes;
LUAD	trans	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.42	-0.34	6.68e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg14396892	chr9:96623032	NA	-0.45	-8.68	-0.39	8.85e-17	DNA methylation (variation);
LUAD	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.22	-0.37	2.55e-15	Bipolar disorder;
LUAD	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18876405	chr7:65276391	NA	-0.58	-9.91	-0.43	5.74e-21	Aortic root size;
LUAD	cis	rs12545109	0.732	rs1973629	chr8:57429583	A/G	cg21220214	chr8:57350948	NA	-0.65	-8.65	-0.39	1.06e-16	Obesity-related traits;
LUAD	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg13385794	chr1:248469461	NA	0.25	6.63	0.31	1.01e-10	Common traits (Other);
LUAD	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg18252515	chr7:66147081	NA	0.61	6.73	0.31	5.65e-11	Diabetic kidney disease;
LUAD	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg06618935	chr21:46677482	NA	-0.47	-9.27	-0.41	9.45e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg12400702	chr3:12838781	CAND2	0.31	6.45	0.3	3.15e-10	Parkinson's disease;
LUAD	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-7.98	-0.36	1.38e-14	Electroencephalogram traits;
LUAD	cis	rs71478720	0.953	rs7131094	chr11:112044917	C/T	cg09122223	chr11:112035175	IL18	0.41	6.48	0.3	2.59e-10	Interleukin-18 levels;
LUAD	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg24578937	chr1:2090814	PRKCZ	0.59	12.36	0.52	3.65e-30	Height;
LUAD	cis	rs11098699	0.784	rs4833270	chr4:124242562	T/A	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.98	-0.36	1.38e-14	Diabetic kidney disease;
LUAD	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg02527881	chr3:46936655	PTH1R	-0.51	-10.39	-0.45	1.11e-22	Colorectal cancer;
LUAD	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.4	0.38	6.99e-16	Platelet count;
LUAD	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg21475434	chr5:93447410	FAM172A	0.74	8.32	0.37	1.26e-15	Diabetic retinopathy;
LUAD	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg15181151	chr6:150070149	PCMT1	0.39	7.84	0.36	3.65e-14	Lung cancer;
LUAD	trans	rs11088226	0.681	rs2833901	chr21:33939318	T/C	cg09050820	chr6:167586206	TCP10L2	0.91	12.43	0.52	1.85e-30	Gastritis;
LUAD	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12667521	chr19:29218732	NA	0.6	8.56	0.38	2.18e-16	Methadone dose in opioid dependence;
LUAD	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg14343924	chr8:8086146	FLJ10661	0.47	7.41	0.34	7.07e-13	Mood instability;
LUAD	cis	rs9902453	0.904	rs12948898	chr17:28410324	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.27	-0.45	3.14e-22	Coffee consumption (cups per day);
LUAD	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg13722127	chr7:150037890	RARRES2	0.45	8.09	0.37	6.57e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg17173187	chr15:85201210	NMB	0.39	6.51	0.3	2.15e-10	Schizophrenia;
LUAD	cis	rs7020830	0.931	rs1388978	chr9:37144062	G/T	cg14294708	chr9:37120828	ZCCHC7	0.79	14.95	0.59	7.39e-41	Schizophrenia;
LUAD	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.89	0.53	2.7e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg02423579	chr7:2872169	GNA12	-0.57	-9.64	-0.42	5.05e-20	Height;
LUAD	cis	rs9393692	0.557	rs989133	chr6:26336300	T/C	cg13736514	chr6:26305472	NA	-0.5	-7.7	-0.35	9.71e-14	Educational attainment;
LUAD	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg18944383	chr4:111397179	ENPEP	0.4	7.96	0.36	1.63e-14	Height;
LUAD	cis	rs7592578	0.508	rs10931451	chr2:191270888	G/A	cg11845111	chr2:191398756	TMEM194B	-0.57	-7.52	-0.34	3.21e-13	Diastolic blood pressure;
LUAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg10729496	chr3:10149963	C3orf24	0.64	9.56	0.42	9.9e-20	Alzheimer's disease;
LUAD	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg00634984	chr7:65235879	NA	0.49	6.85	0.32	2.62e-11	Aortic root size;
LUAD	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.43	0.34	6.06e-13	Tonsillectomy;
LUAD	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg13334819	chr7:99746414	C7orf59	0.63	9.9	0.43	6.48e-21	Coronary artery disease;
LUAD	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.62	-8.15	-0.37	4.22e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg13271783	chr10:134563150	INPP5A	-0.45	-7.85	-0.36	3.53e-14	Migraine;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg02798066	chr3:66551530	LRIG1	-0.37	-6.66	-0.31	8.53e-11	Schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09547032	chr19:13906148	ZSWIM4	-0.69	-7.06	-0.32	6.68e-12	Type 2 diabetes;
LUAD	cis	rs7010267	0.596	rs13262276	chr8:120033918	A/T	cg01975934	chr8:119970761	NA	-0.34	-6.59	-0.31	1.29e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.82	0.36	4.26e-14	Bladder cancer;
LUAD	cis	rs78487399	0.808	rs7601093	chr2:43710807	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-7.16	-0.33	3.56e-12	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg06532163	chr17:45867833	NA	0.48	7.37	0.34	9.15e-13	IgG glycosylation;
LUAD	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.46	7.2	0.33	2.81e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs367943	0.698	rs13167361	chr5:112961789	C/G	cg12552261	chr5:112820674	MCC	0.44	7.94	0.36	1.82e-14	Type 2 diabetes;
LUAD	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg04025307	chr7:1156635	C7orf50	0.56	8.23	0.37	2.34e-15	Bronchopulmonary dysplasia;
LUAD	cis	rs2658782	0.950	rs2446061	chr11:93149277	C/T	cg15737290	chr11:93063684	CCDC67	0.53	7.35	0.34	1.01e-12	Pulmonary function decline;
LUAD	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg15181151	chr6:150070149	PCMT1	0.33	6.49	0.3	2.43e-10	Testicular germ cell tumor;
LUAD	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.74	-0.61	2.73e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9486719	1.000	rs2205755	chr6:96864704	A/G	cg06623918	chr6:96969491	KIAA0776	0.71	9.96	0.44	3.8e-21	Migraine;Coronary artery disease;
LUAD	cis	rs2455826	0.834	rs2470530	chr3:15688758	C/T	cg16303742	chr3:15540471	COLQ	-0.42	-7.05	-0.32	7.53e-12	Inflammatory skin disease;
LUAD	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg11814155	chr7:99998594	ZCWPW1	0.43	7.37	0.34	9.23e-13	Platelet count;
LUAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg16031515	chr1:205743344	RAB7L1	-0.36	-7.3	-0.33	1.45e-12	Menarche (age at onset);
LUAD	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg04944784	chr2:26401820	FAM59B	0.88	12.15	0.51	2.37e-29	Gut microbiome composition (summer);
LUAD	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg25985355	chr7:65971099	NA	-0.55	-6.85	-0.32	2.54e-11	Gout;
LUAD	cis	rs673604	1.000	rs673604	chr1:35687815	T/C	cg12633102	chr1:35676489	NA	-0.62	-8.83	-0.39	2.8e-17	Endometrial cancer;
LUAD	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.56	-0.34	2.56e-13	Lung cancer;
LUAD	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg02734326	chr4:10020555	SLC2A9	-0.45	-7.48	-0.34	4.32e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs11247915	0.561	rs12750420	chr1:26608649	G/A	cg01568347	chr1:26488053	GRRP1	0.34	6.49	0.3	2.38e-10	Obesity-related traits;
LUAD	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg04727924	chr7:799746	HEATR2	-0.55	-7.4	-0.34	7.51e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs9560113	0.960	rs953260	chr13:112173685	C/T	cg14154082	chr13:112174009	NA	0.36	6.61	0.31	1.14e-10	Menarche (age at onset);
LUAD	trans	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg18335740	chr13:41363409	SLC25A15	0.75	15.03	0.59	3.11e-41	Lewy body disease;
LUAD	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg05082376	chr22:42548792	NA	0.43	7.63	0.35	1.61e-13	Schizophrenia;
LUAD	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg26566898	chr11:117069891	TAGLN	0.34	6.6	0.31	1.23e-10	Blood protein levels;
LUAD	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg22491629	chr6:157744540	C6orf35	-0.69	-8.39	-0.38	7.41e-16	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9972944	0.756	rs7222229	chr17:63765025	T/G	cg07283582	chr17:63770753	CCDC46	-0.5	-11.18	-0.48	1.28e-25	Total body bone mineral density;
LUAD	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.41	7.52	0.34	3.21e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-6.78	-0.31	4.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg14159672	chr1:205819179	PM20D1	-0.52	-7.75	-0.35	7.08e-14	Menarche (age at onset);
LUAD	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg18755752	chr8:142205143	DENND3	0.44	7.82	0.36	4.15e-14	Immature fraction of reticulocytes;
LUAD	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg00310523	chr12:86230176	RASSF9	-0.35	-7.18	-0.33	3.18e-12	Major depressive disorder;
LUAD	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg26587870	chr6:27730563	NA	-0.69	-6.96	-0.32	1.34e-11	Depression;
LUAD	cis	rs4660306	0.961	rs2991966	chr1:45999503	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.52	-8.26	-0.37	1.86e-15	Homocysteine levels;
LUAD	cis	rs7258465	1.000	rs34746918	chr19:18539744	C/T	cg25828334	chr19:18545568	ISYNA1	-0.38	-7.68	-0.35	1.09e-13	Breast cancer;
LUAD	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg20673091	chr1:2541236	MMEL1	0.36	7.56	0.34	2.61e-13	Ulcerative colitis;
LUAD	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.35	-0.34	1e-12	Breast cancer;
LUAD	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	9.15	0.41	2.48e-18	Total body bone mineral density;
LUAD	trans	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg21051086	chr3:73046214	PPP4R2	-0.45	-7.34	-0.34	1.09e-12	Pancreatic cancer;
LUAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.67	-7.76	-0.35	6.33e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4321325	0.546	rs11886766	chr2:127948621	G/A	cg11380483	chr2:127933992	NA	0.48	6.69	0.31	7.31e-11	Protein C levels;
LUAD	cis	rs6445967	0.530	rs12497256	chr3:58408353	G/A	cg13750441	chr3:58318267	PXK	-0.33	-6.78	-0.31	4.04e-11	Platelet count;
LUAD	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11890956	chr21:40555474	PSMG1	0.79	13.63	0.55	2.64e-35	Cognitive function;
LUAD	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.06e-11	Parkinson's disease;
LUAD	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg04731861	chr2:219085781	ARPC2	0.24	7.25	0.33	2e-12	Colorectal cancer;
LUAD	cis	rs790123	0.842	rs796889	chr3:122398461	T/C	cg17380795	chr3:122379686	NA	0.44	7.09	0.33	5.5e-12	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg05368731	chr17:41323189	NBR1	0.98	20.49	0.71	2.59e-65	Menopause (age at onset);
LUAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg07217954	chr7:1067459	C7orf50	0.39	6.56	0.3	1.58e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg25809561	chr17:30822961	MYO1D	-0.47	-8.67	-0.39	9.07e-17	Schizophrenia;
LUAD	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg06400119	chr7:158046222	PTPRN2	0.34	6.85	0.32	2.69e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4481887	0.800	rs28680862	chr1:248515419	T/C	cg00666640	chr1:248458726	OR2T12	0.28	7.04	0.32	7.73e-12	Common traits (Other);
LUAD	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg14092988	chr3:52407081	DNAH1	0.45	9.15	0.41	2.51e-18	Bipolar disorder;
LUAD	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06022373	chr22:39101656	GTPBP1	0.43	6.49	0.3	2.35e-10	Menopause (age at onset);
LUAD	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	8.75e-12	Aortic root size;
LUAD	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.45	-0.52	1.54e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs3754214	0.857	rs488271	chr1:150284534	A/G	cg15654264	chr1:150340011	RPRD2	-0.35	-6.36	-0.3	5.3e-10	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7202877	0.610	rs7202284	chr16:75374346	A/T	cg03315344	chr16:75512273	CHST6	0.53	7.35	0.34	1e-12	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg27068330	chr11:65405492	SIPA1	0.55	8.57	0.38	2.02e-16	Acne (severe);
LUAD	cis	rs66731853	0.769	rs530104	chr1:20895721	A/G	cg04087271	chr1:20915334	CDA	-0.52	-8.76	-0.39	4.87e-17	Mean corpuscular volume;
LUAD	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.36	0.34	9.58e-13	Tonsillectomy;
LUAD	trans	rs4883201	0.706	rs10771185	chr12:9056410	C/T	cg07302910	chr10:118891355	VAX1	0.36	6.37	0.3	4.97e-10	Cholesterol, total;Total cholesterol levels;
LUAD	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg26818010	chr10:134567672	INPP5A	-0.84	-14.61	-0.58	2e-39	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg22963979	chr7:1858916	MAD1L1	-0.54	-9.44	-0.42	2.6e-19	Bipolar disorder and schizophrenia;
LUAD	trans	rs208520	0.754	rs851593	chr6:66875783	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.02	15.45	0.6	5.19e-43	Exhaled nitric oxide output;
LUAD	cis	rs1997103	0.954	rs4947505	chr7:55409448	T/C	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg00981070	chr1:2046702	PRKCZ	0.37	6.74	0.31	5.04e-11	Height;
LUAD	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg20607798	chr8:58055168	NA	0.57	7.73	0.35	7.98e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-15.36	-0.6	1.3e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs877282	0.797	rs35927768	chr10:753095	T/C	cg22713356	chr15:30763199	NA	1.22	15.45	0.6	5.21e-43	Uric acid levels;
LUAD	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg26384229	chr12:38710491	ALG10B	0.46	7.49	0.34	4.19e-13	Bladder cancer;
LUAD	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg18180107	chr4:99064573	C4orf37	0.43	6.93	0.32	1.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs708547	0.647	rs781666	chr4:57830981	A/G	cg00922110	chr4:57842668	C4orf14	-0.39	-7.19	-0.33	2.87e-12	Response to bleomycin (chromatid breaks);
LUAD	cis	rs354225	0.544	rs4455200	chr2:54801591	T/A	cg01766943	chr2:54829624	SPTBN1	0.37	6.8	0.31	3.6e-11	Schizophrenia;
LUAD	cis	rs490234	0.702	rs4838279	chr9:128411726	G/A	cg14078157	chr9:128172775	NA	-0.44	-7.91	-0.36	2.35e-14	Mean arterial pressure;
LUAD	trans	rs9951602	0.512	rs9953258	chr18:76651199	A/C	cg02800362	chr5:177631904	HNRNPAB	0.92	14.03	0.56	5.64e-37	Obesity-related traits;
LUAD	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2692947	0.800	rs2692936	chr2:96745729	G/A	cg23100626	chr2:96804247	ASTL	0.36	8.92	0.4	1.38e-17	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg22166914	chr1:53195759	ZYG11B	-0.52	-9.0	-0.4	7.84e-18	Monocyte count;
LUAD	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.63	-0.31	1.04e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.11	0.44	1.11e-21	Lymphocyte percentage of white cells;
LUAD	trans	rs4942242	1.000	rs7335094	chr13:44223936	T/C	cg19169023	chr15:41853346	TYRO3	-0.49	-8.42	-0.38	5.94e-16	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.29	-0.45	2.59e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.52	-0.34	3.39e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg21963583	chr11:68658836	MRPL21	0.65	11.58	0.49	3.97e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08280861	chr8:58055591	NA	0.63	8.2	0.37	2.89e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg13180566	chr4:1052158	NA	-0.39	-6.56	-0.3	1.6e-10	Recombination rate (females);
LUAD	cis	rs10992471	0.603	rs4743873	chr9:95270781	C/T	cg14631576	chr9:95140430	CENPP	0.55	11.31	0.48	4.44e-26	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-9.23	-0.41	1.35e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg00083206	chr6:110721305	DDO	-0.36	-6.41	-0.3	3.86e-10	Platelet distribution width;
LUAD	cis	rs4253772	0.530	rs28528366	chr22:46680696	G/A	cg09491104	chr22:46646882	C22orf40	-0.59	-7.44	-0.34	5.59e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9921222	0.509	rs2301522	chr16:359953	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.5	8.47	0.38	4.15e-16	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg24579218	chr15:68104479	NA	0.54	8.92	0.4	1.38e-17	Obesity;
LUAD	cis	rs7903847	0.642	rs7074511	chr10:99140177	G/A	cg20016023	chr10:99160130	RRP12	-0.29	-7.17	-0.33	3.41e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg23281280	chr6:28129359	ZNF389	0.45	6.56	0.3	1.62e-10	Depression;
LUAD	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9297145	0.761	rs28545226	chr7:98732472	A/T	cg05967295	chr7:98741636	SMURF1	0.97	14.58	0.58	2.73e-39	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg08888203	chr3:10149979	C3orf24	0.77	13.54	0.55	6.14e-35	Alzheimer's disease;
LUAD	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06022373	chr22:39101656	GTPBP1	0.46	7.13	0.33	4.42e-12	Menopause (age at onset);
LUAD	trans	rs853679	0.607	rs35030260	chr6:28305508	G/A	cg01620082	chr3:125678407	NA	-1.11	-10.41	-0.45	9.45e-23	Depression;
LUAD	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg03806693	chr22:41940476	POLR3H	0.52	7.66	0.35	1.31e-13	Vitiligo;
LUAD	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg27494647	chr7:150038898	RARRES2	0.51	9.33	0.41	5.88e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg01689657	chr7:91764605	CYP51A1	-0.3	-7.29	-0.33	1.58e-12	Breast cancer;
LUAD	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg24579218	chr15:68104479	NA	-0.62	-9.55	-0.42	1.06e-19	Restless legs syndrome;
LUAD	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	8.98	0.4	9e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg00310523	chr12:86230176	RASSF9	0.41	8.09	0.37	6.17e-15	Major depressive disorder;
LUAD	trans	rs225245	0.755	rs6505491	chr17:34026335	A/G	cg19694781	chr19:47549865	TMEM160	-0.48	-7.93	-0.36	2.03e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs10927875	0.526	rs2179615	chr1:16282426	G/A	cg21385522	chr1:16154831	NA	-0.93	-13.46	-0.55	1.33e-34	Dilated cardiomyopathy;
LUAD	cis	rs4660214	0.615	rs597708	chr1:39820963	G/C	cg27567593	chr1:39956653	BMP8A	-0.36	-7.25	-0.33	1.95e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4601821	0.522	rs754672	chr11:113249136	C/T	cg14159747	chr11:113255604	NA	0.69	14.87	0.59	1.61e-40	Alcoholic chronic pancreatitis;
LUAD	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg00071950	chr4:10020882	SLC2A9	-0.73	-14.77	-0.58	4.32e-40	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11479843	chr12:15941373	EPS8	0.38	6.35	0.3	5.49e-10	Survival in pancreatic cancer;
LUAD	trans	rs6076960	0.564	rs3852935	chr20:6143180	C/G	cg17788362	chr6:86352627	SYNCRIP	0.42	7.01	0.32	9.7e-12	Smooth-surface caries;
LUAD	cis	rs6445967	0.530	rs12629939	chr3:58396163	T/C	cg23715586	chr3:58305044	RPP14	0.41	6.75	0.31	5e-11	Platelet count;
LUAD	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg02782426	chr3:40428986	ENTPD3	0.35	7.7	0.35	9.47e-14	Renal cell carcinoma;
LUAD	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg18131467	chr2:239335373	ASB1	0.59	9.1	0.4	3.46e-18	Multiple system atrophy;
LUAD	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.58	-11.18	-0.48	1.28e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs208520	0.837	rs208486	chr6:66926255	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-13.97	-0.56	1.02e-36	Exhaled nitric oxide output;
LUAD	cis	rs13064411	0.627	rs9872168	chr3:113233132	A/C	cg10517650	chr3:113235015	CCDC52	-0.55	-9.42	-0.42	2.93e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs9469913	0.799	rs3800457	chr6:34663598	C/T	cg14254433	chr6:34482411	PACSIN1	0.43	6.81	0.31	3.29e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg27286337	chr10:134555280	INPP5A	0.69	10.0	0.44	2.76e-21	Migraine;
LUAD	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.52	0.3	2.02e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg17105886	chr17:28927953	LRRC37B2	0.73	7.15	0.33	3.9e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg05425664	chr17:57184151	TRIM37	-0.43	-7.66	-0.35	1.29e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2840044	1.000	rs10068	chr17:33901965	C/G	cg05299278	chr17:33885742	SLFN14	-0.44	-8.89	-0.4	1.73e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs2985684	1.000	rs56098064	chr14:50105849	T/C	cg04989706	chr14:50066350	PPIL5	-0.47	-6.92	-0.32	1.66e-11	Carotid intima media thickness;
LUAD	cis	rs911186	0.509	rs6934329	chr6:27158033	A/G	cg12292205	chr6:26970375	C6orf41	-0.57	-7.23	-0.33	2.33e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21659725	chr3:3221576	CRBN	0.86	18.67	0.67	3.5e-57	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9658691	0.646	rs2862834	chr10:90741374	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.8	9.67	0.43	3.97e-20	Mosquito bite size;
LUAD	cis	rs7737355	0.898	rs6864413	chr5:130637868	G/T	cg06307176	chr5:131281290	NA	0.46	7.32	0.34	1.25e-12	Life satisfaction;
LUAD	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg11125805	chr5:150678162	SLC36A3	0.76	17.76	0.65	3.86e-53	Skin aging (microtopography measurement);
LUAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg04267008	chr7:1944627	MAD1L1	0.68	10.79	0.46	3.76e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.6	-0.52	3.83e-31	Monocyte count;
LUAD	cis	rs10489202	0.608	rs16828093	chr1:168078384	C/T	cg24449463	chr1:168025552	DCAF6	-0.63	-9.9	-0.43	6.23e-21	Schizophrenia;
LUAD	cis	rs8177876	0.822	rs1414	chr16:81115857	A/G	cg08591886	chr16:81111003	C16orf46	-0.79	-7.37	-0.34	8.94e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg22906224	chr7:99728672	NA	0.66	11.09	0.47	2.99e-25	Coronary artery disease;
LUAD	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg00310523	chr12:86230176	RASSF9	0.39	7.84	0.36	3.8e-14	Major depressive disorder;
LUAD	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.36	-6.75	-0.31	4.76e-11	Caffeine consumption;
LUAD	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg22732515	chr19:44031385	ETHE1	0.58	9.53	0.42	1.25e-19	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs775227	0.574	rs66866534	chr3:113147315	T/C	cg18753928	chr3:113234510	CCDC52	-0.67	-8.71	-0.39	6.99e-17	Dental caries;
LUAD	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.1	-0.33	5.39e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08677398	chr8:58056175	NA	0.49	7.0	0.32	1.02e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7000551	0.606	rs13256933	chr8:22267199	T/G	cg12081754	chr8:22256438	SLC39A14	0.89	13.72	0.55	1.11e-35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2797160	0.874	rs58305111	chr6:126008386	G/T	cg05901451	chr6:126070800	HEY2	0.45	6.58	0.3	1.38e-10	Endometrial cancer;
LUAD	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	cis	rs4889855	0.530	rs12946972	chr17:78618922	A/G	cg16591659	chr17:78472290	NA	-0.43	-7.56	-0.35	2.47e-13	Fractional excretion of uric acid;
LUAD	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg11814155	chr7:99998594	ZCWPW1	0.43	7.48	0.34	4.27e-13	Platelet count;
LUAD	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	8.75e-12	Aortic root size;
LUAD	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg26597838	chr10:835615	NA	0.99	15.03	0.59	3.29e-41	Eosinophil percentage of granulocytes;
LUAD	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.71	-0.31	6.18e-11	Waist circumference;Hip circumference;
LUAD	cis	rs12368653	0.651	rs2307097	chr12:58195801	T/C	cg12615879	chr12:58013172	SLC26A10	0.44	8.99	0.4	8.32e-18	Multiple sclerosis;
LUAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	cis	rs904251	0.523	rs2797796	chr6:37480886	T/C	cg25019722	chr6:37503610	NA	-0.33	-7.54	-0.34	2.95e-13	Cognitive performance;
LUAD	cis	rs57590327	0.503	rs7426937	chr3:81881360	T/C	cg07356753	chr3:81810745	GBE1	-0.54	-8.54	-0.38	2.5e-16	Extraversion;
LUAD	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg14895029	chr7:2775587	GNA12	-0.43	-6.92	-0.32	1.72e-11	Height;
LUAD	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	cis	rs8192282	0.739	rs6662503	chr1:154477069	T/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.44	-6.77	-0.31	4.36e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg25358565	chr5:93447407	FAM172A	0.65	7.76	0.35	6.38e-14	Diabetic retinopathy;
LUAD	trans	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.42	0.55	1.77e-34	Exhaled nitric oxide output;
LUAD	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg17330251	chr7:94953956	PON1	-0.52	-6.84	-0.32	2.84e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg10729496	chr3:10149963	C3orf24	0.58	9.4	0.42	3.55e-19	Alzheimer's disease;
LUAD	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg26384229	chr12:38710491	ALG10B	0.52	8.6	0.39	1.6e-16	Heart rate;
LUAD	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18876405	chr7:65276391	NA	0.56	9.37	0.41	4.28e-19	Aortic root size;
LUAD	cis	rs4713675	0.546	rs10947430	chr6:33658534	G/A	cg14003231	chr6:33640908	ITPR3	0.5	9.62	0.42	6.05e-20	Plateletcrit;
LUAD	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg01579765	chr21:45077557	HSF2BP	-0.56	-12.06	-0.51	5.38e-29	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.85e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.74	-0.35	7.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6701037	0.522	rs7521981	chr1:175091151	C/T	cg00321850	chr1:175162397	KIAA0040	-0.36	-7.24	-0.33	2.1e-12	Alcohol dependence;
LUAD	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg17633681	chr16:88106987	BANP	0.4	7.01	0.32	9.61e-12	Menopause (age at onset);
LUAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg13397359	chr6:42928475	GNMT	0.62	11.67	0.49	1.86e-27	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs743757	1.000	rs2236957	chr3:50440426	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	7.22	0.33	2.37e-12	Diastolic blood pressure;
LUAD	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.24	0.33	2.13e-12	Blood metabolite levels;
LUAD	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg27490568	chr2:178487706	NA	-0.38	-6.4	-0.3	4.25e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7523050	0.730	rs67312582	chr1:109423976	A/G	cg08274380	chr1:109419600	GPSM2	0.71	6.57	0.3	1.49e-10	Fat distribution (HIV);
LUAD	cis	rs55823223	0.648	rs72860389	chr17:73866071	C/T	cg14955151	chr17:73874635	TRIM47	-0.42	-6.5	-0.3	2.31e-10	Psoriasis;
LUAD	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg05623727	chr3:50126028	RBM5	0.3	6.54	0.3	1.79e-10	Body mass index;
LUAD	cis	rs12208915	0.945	rs12201183	chr6:79570120	A/G	cg11833968	chr6:79620685	NA	0.52	6.39	0.3	4.37e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs4722585	0.764	rs4259314	chr7:26182214	A/G	cg07876897	chr7:26191696	NFE2L3	-0.44	-6.93	-0.32	1.59e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg17105886	chr17:28927953	LRRC37B2	0.77	7.72	0.35	8.51e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7584330	0.518	rs6715245	chr2:238445803	C/T	cg14458575	chr2:238380390	NA	0.84	13.23	0.54	1.16e-33	Prostate cancer;
LUAD	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg10792982	chr14:105748885	BRF1	0.44	9.63	0.42	5.49e-20	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg11663144	chr21:46675770	NA	-0.57	-10.54	-0.46	3.09e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg05665937	chr4:1216051	CTBP1	-0.4	-7.23	-0.33	2.32e-12	Obesity-related traits;
LUAD	cis	rs7216064	0.532	rs3890640	chr17:66053028	C/T	cg08758996	chr17:66097529	LOC651250	-0.4	-6.52	-0.3	1.96e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22590775	chr19:49891494	CCDC155	0.6	8.67	0.39	9.37e-17	Multiple sclerosis;
LUAD	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.7	-11.39	-0.48	2.09e-26	Resting heart rate;
LUAD	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.78	0.43	1.66e-20	Monocyte percentage of white cells;
LUAD	cis	rs9372498	0.536	rs25422	chr6:118807847	A/G	cg07617317	chr6:118971624	C6orf204	-0.5	-7.15	-0.33	3.74e-12	Diastolic blood pressure;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg05332869	chr20:39658073	TOP1	0.41	6.42	0.3	3.68e-10	Diastolic blood pressure;
LUAD	cis	rs55788414	0.932	rs8048115	chr16:81182554	T/C	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.99	-0.36	1.34e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs3026401	0.562	rs2863231	chr11:31796560	C/T	cg14844989	chr11:31128820	NA	-0.38	-6.73	-0.31	5.62e-11	Body mass index;
LUAD	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg03709012	chr19:19516395	GATAD2A	0.53	7.07	0.32	6.62e-12	Nonalcoholic fatty liver disease;
LUAD	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg23711669	chr6:146136114	FBXO30	0.38	6.43	0.3	3.36e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg03433033	chr1:76189801	ACADM	0.71	10.64	0.46	1.42e-23	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg27490568	chr2:178487706	NA	0.45	7.48	0.34	4.38e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg17063962	chr7:91808500	NA	-0.66	-11.62	-0.49	2.73e-27	Breast cancer;
LUAD	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg08632164	chr7:65971372	NA	-0.38	-6.62	-0.31	1.09e-10	Aortic root size;
LUAD	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg12623918	chr2:306882	NA	0.35	7.03	0.32	8.29e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg14917512	chr19:3094685	GNA11	-0.57	-6.81	-0.31	3.33e-11	Diabetic kidney disease;
LUAD	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg15704280	chr7:45808275	SEPT13	0.91	17.39	0.65	1.68e-51	Coronary artery disease;
LUAD	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg02493740	chr2:85810744	VAMP5	0.39	7.14	0.33	3.97e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg00852783	chr1:26633632	UBXN11	0.42	7.36	0.34	9.71e-13	Obesity-related traits;
LUAD	cis	rs1997103	0.863	rs4480062	chr7:55401299	T/C	cg17469321	chr7:55412551	NA	0.67	11.39	0.48	2.05e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg03477792	chr4:77819574	ANKRD56	0.48	7.18	0.33	3.2e-12	Emphysema distribution in smoking;
LUAD	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.85	0.32	2.61e-11	Cardiac Troponin-T levels;
LUAD	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg01788221	chr16:89496183	ANKRD11	-0.34	-6.43	-0.3	3.41e-10	Multiple myeloma (IgH translocation);
LUAD	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg23533926	chr12:111358616	MYL2	-0.42	-7.21	-0.33	2.63e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg18402987	chr7:1209562	NA	0.41	6.86	0.32	2.38e-11	Longevity;Endometriosis;
LUAD	cis	rs13315871	1.000	rs11709976	chr3:58325347	A/G	cg20936604	chr3:58311152	NA	-0.78	-8.27	-0.37	1.76e-15	Cholesterol, total;
LUAD	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg04772025	chr11:68637568	NA	0.57	9.07	0.4	4.47e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.36	0.34	9.98e-13	Tonsillectomy;
LUAD	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg06627628	chr2:24431161	ITSN2	-0.69	-11.0	-0.47	6.25e-25	Asthma;
LUAD	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg19622623	chr12:86230825	RASSF9	-0.42	-7.44	-0.34	5.78e-13	Major depressive disorder;
LUAD	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg00074818	chr8:8560427	CLDN23	0.67	10.19	0.44	6.11e-22	Obesity-related traits;
LUAD	trans	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg27600084	chr12:12264075	NA	0.38	7.07	0.33	6.32e-12	Breast size;
LUAD	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg00769240	chr8:12517080	NA	-0.39	-6.54	-0.3	1.77e-10	Blood pressure (smoking interaction);
LUAD	cis	rs6499255	0.904	rs7194753	chr16:69564364	A/G	cg26679644	chr16:69762563	NA	-0.43	-6.7	-0.31	6.6e-11	IgE levels;
LUAD	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-6.77	-0.31	4.37e-11	Neuroticism;
LUAD	cis	rs7903847	0.642	rs2275090	chr10:99148151	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-7.16	-0.33	3.5e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs992157	0.730	rs4280446	chr2:219184721	T/C	cg05991184	chr2:219186017	PNKD	-0.41	-7.75	-0.35	6.75e-14	Colorectal cancer;
LUAD	cis	rs9649213	0.533	rs1541409	chr7:98027580	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.77	-11.09	-0.47	2.84e-25	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg09835421	chr16:68378352	PRMT7	-0.83	-8.82	-0.39	2.95e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg20307385	chr11:47447363	PSMC3	0.68	11.69	0.49	1.45e-27	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg23254163	chr1:152506842	NA	0.26	7.15	0.33	3.9e-12	Hair morphology;
LUAD	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg06547715	chr2:218990976	CXCR2	0.29	7.25	0.33	2.05e-12	Colorectal cancer;
LUAD	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg00383909	chr3:49044727	WDR6	0.58	6.82	0.31	3.09e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7107174	1.000	rs114142124	chr11:78047537	T/C	cg02023728	chr11:77925099	USP35	0.45	7.09	0.33	5.68e-12	Testicular germ cell tumor;
LUAD	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg15208524	chr1:10270712	KIF1B	0.43	6.49	0.3	2.44e-10	Hepatocellular carcinoma;
LUAD	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg14396892	chr9:96623032	NA	-0.42	-8.12	-0.37	5.11e-15	DNA methylation (variation);
LUAD	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg25024717	chr12:54324583	NA	-0.33	-6.66	-0.31	8.49e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs9616064	0.704	rs41346347	chr22:46958507	A/C	cg05621596	chr22:47072043	GRAMD4	-0.44	-7.02	-0.32	8.73e-12	Urate levels in obese individuals;
LUAD	cis	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.66	-0.31	8.57e-11	Neuroticism;
LUAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg21782813	chr7:2030301	MAD1L1	0.42	6.98	0.32	1.14e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.15	-0.33	3.79e-12	Total cholesterol levels;
LUAD	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.3	-0.33	1.45e-12	Morning vs. evening chronotype;
LUAD	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg25753631	chr6:25732923	NA	-0.47	-8.27	-0.37	1.73e-15	Iron status biomarkers;
LUAD	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg02269571	chr22:50332266	NA	0.59	8.99	0.4	8.24e-18	Schizophrenia;
LUAD	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg21100191	chr22:23484243	RTDR1	0.73	13.32	0.54	4.65e-34	Bone mineral density;
LUAD	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.37	-0.3	4.81e-10	Neuroticism;
LUAD	cis	rs240764	0.619	rs9403962	chr6:101129997	T/A	cg09795085	chr6:101329169	ASCC3	0.39	6.38	0.3	4.77e-10	Neuroticism;
LUAD	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg01256987	chr12:42539512	GXYLT1	-0.32	-6.41	-0.3	4e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs7274811	0.652	rs291686	chr20:32010851	T/C	cg14921437	chr20:32255988	NECAB3;C20orf134	0.47	7.19	0.33	3e-12	Height;
LUAD	cis	rs2932538	0.922	rs6698030	chr1:113138318	G/A	cg22162597	chr1:113214053	CAPZA1	0.45	6.7	0.31	6.52e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg23262073	chr20:60523788	NA	-0.37	-6.45	-0.3	3.02e-10	Body mass index;
LUAD	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg10426581	chr7:100472382	SRRT	0.77	10.26	0.45	3.32e-22	Resting heart rate;
LUAD	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg04450456	chr4:17643702	FAM184B	0.37	7.33	0.34	1.21e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4523957	0.855	rs216172	chr17:2126504	G/C	cg16513277	chr17:2031491	SMG6	-0.81	-14.96	-0.59	6.27e-41	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg10518543	chr12:38710700	ALG10B	0.43	6.42	0.3	3.59e-10	Bladder cancer;
LUAD	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.82	-14.34	-0.57	2.86e-38	Chronic sinus infection;
LUAD	trans	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg07393940	chr7:158741817	NA	0.66	11.29	0.48	5.31e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4150161	0.656	rs2288025	chr16:84211735	A/C	cg10106505	chr16:84220380	TAF1C	-0.83	-7.97	-0.36	1.47e-14	Systolic blood pressure response to hydrochlorothiazide in hypertension;
LUAD	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg02696790	chr15:75250997	RPP25	-0.34	-6.91	-0.32	1.84e-11	Systemic lupus erythematosus;
LUAD	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg17509989	chr5:176798049	RGS14	0.58	9.15	0.41	2.5e-18	Urate levels in lean individuals;
LUAD	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg09117114	chr16:67998030	SLC12A4	-0.57	-7.44	-0.34	5.56e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg14092988	chr3:52407081	DNAH1	0.33	6.49	0.3	2.38e-10	Bipolar disorder;
LUAD	cis	rs7524258	0.835	rs7543228	chr1:7306538	G/C	cg07173049	chr1:7289937	CAMTA1	0.4	7.56	0.34	2.59e-13	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs10799445	0.550	rs7512348	chr1:227740272	C/T	cg12133451	chr1:227746453	NA	0.37	6.76	0.31	4.65e-11	Height;
LUAD	trans	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg04775059	chr7:64541387	NA	0.5	6.82	0.31	3.24e-11	Aortic root size;
LUAD	cis	rs68170813	0.559	rs74584447	chr7:106944755	T/C	cg23024343	chr7:107201750	COG5	0.5	7.24	0.33	2.07e-12	Coronary artery disease;
LUAD	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	8.47	0.38	4.02e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs12545109	0.837	rs4738500	chr8:57356193	G/A	cg21220214	chr8:57350948	NA	-0.67	-9.22	-0.41	1.44e-18	Obesity-related traits;
LUAD	trans	rs7395662	0.963	rs4882002	chr11:48546731	A/C	cg15704280	chr7:45808275	SEPT13	-0.41	-6.37	-0.3	4.81e-10	HDL cholesterol;
LUAD	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg08470875	chr2:26401718	FAM59B	-0.6	-8.2	-0.37	2.96e-15	Gut microbiome composition (summer);
LUAD	cis	rs72720396	1.000	rs72720396	chr1:91191582	A/G	cg13456504	chr1:91191583	NA	0.63	10.76	0.46	4.92e-24	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2816062	1.000	rs2816062	chr1:18903902	G/A	cg18795169	chr1:18902165	NA	-0.82	-17.71	-0.65	6.37e-53	Urate levels in lean individuals;
LUAD	cis	rs2274273	0.934	rs10144418	chr14:55817708	T/C	cg04306507	chr14:55594613	LGALS3	0.43	9.06	0.4	4.74e-18	Protein biomarker;
LUAD	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg25324976	chr17:61989376	CSHL1	0.38	7.52	0.34	3.36e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg01206211	chr2:36825736	FEZ2	0.52	9.67	0.43	4.02e-20	Height;
LUAD	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg14186256	chr22:23484241	RTDR1	0.42	7.37	0.34	8.99e-13	Bone mineral density;
LUAD	cis	rs9549328	0.565	rs35371379	chr13:113616715	T/C	cg17524180	chr13:113633600	MCF2L	0.3	6.41	0.3	3.88e-10	Systolic blood pressure;
LUAD	trans	rs7615952	0.546	rs11717632	chr3:125321130	G/C	cg17147758	chr8:6949321	NA	-0.47	-7.17	-0.33	3.4e-12	Blood pressure (smoking interaction);
LUAD	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg17105886	chr17:28927953	LRRC37B2	0.84	8.11	0.37	5.73e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs13315871	0.929	rs77825960	chr3:58318677	A/G	cg20936604	chr3:58311152	NA	-0.79	-8.38	-0.38	7.68e-16	Cholesterol, total;
LUAD	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22496380	chr5:211416	CCDC127	-1.22	-16.07	-0.62	1.07e-45	Breast cancer;
LUAD	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg15704280	chr7:45808275	SEPT13	-0.97	-20.27	-0.7	2.41e-64	Height;
LUAD	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg24558204	chr6:135376177	HBS1L	0.42	7.08	0.33	6.1e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs2235649	0.833	rs9922139	chr16:1848329	G/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-6.72	-0.31	6.01e-11	Blood metabolite levels;
LUAD	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg27588902	chr6:42928151	GNMT	-0.37	-9.82	-0.43	1.24e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg03467027	chr4:99064603	C4orf37	-0.44	-7.22	-0.33	2.39e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs79349575	0.756	rs62078385	chr17:47045009	C/T	cg26022315	chr17:47021804	SNF8	0.41	7.32	0.34	1.25e-12	Type 2 diabetes;
LUAD	cis	rs11811982	0.793	rs79608947	chr1:227508929	G/C	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg04282206	chr17:62833786	PLEKHM1P	-0.54	-8.26	-0.37	1.89e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg08807101	chr21:30365312	RNF160	0.51	8.84	0.4	2.53e-17	Dental caries;
LUAD	cis	rs921968	0.607	rs2465100	chr2:219551044	A/T	cg02176678	chr2:219576539	TTLL4	-0.59	-11.83	-0.5	4.21e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9972944	0.756	rs2024273	chr17:63768972	A/G	cg07283582	chr17:63770753	CCDC46	-0.51	-11.6	-0.49	3.32e-27	Total body bone mineral density;
LUAD	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg12940439	chr1:67600707	NA	0.49	9.12	0.41	3.06e-18	Psoriasis;
LUAD	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg25036284	chr2:26402008	FAM59B	-0.67	-9.17	-0.41	2.13e-18	Gut microbiome composition (summer);
LUAD	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg21862992	chr11:68658383	NA	0.53	9.67	0.43	4.05e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs8013055	0.796	rs4075104	chr14:106000214	C/A	cg19700328	chr14:106028568	NA	-0.45	-7.64	-0.35	1.46e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	trans	rs8073060	0.544	rs225268	chr17:33966224	A/C	cg19694781	chr19:47549865	TMEM160	-1.24	-19.59	-0.69	2.7e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs9462027	0.727	rs3798352	chr6:34734809	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.84	-0.39	2.55e-17	Systemic lupus erythematosus;
LUAD	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	cis	rs1079204	1.000	rs13423003	chr2:219111341	G/C	cg05728596	chr2:219128475	GPBAR1	1.04	9.77	0.43	1.88e-20	Smooth-surface caries;
LUAD	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg09509183	chr1:209979624	IRF6	0.58	7.21	0.33	2.57e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs41311933	0.656	rs72758170	chr9:123773376	T/A	cg13567360	chr9:123745713	C5	-0.68	-8.11	-0.37	5.39e-15	Coronary artery disease;
LUAD	cis	rs1816752	0.837	rs7324645	chr13:25000855	A/G	cg02811702	chr13:24901961	NA	0.38	6.6	0.31	1.27e-10	Obesity-related traits;
LUAD	trans	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg11693508	chr17:37793320	STARD3	0.51	7.6	0.35	1.97e-13	Neuroticism;
LUAD	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg25173405	chr17:45401733	C17orf57	-0.45	-7.74	-0.35	7.64e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	9.82	0.43	1.26e-20	Breast cancer;
LUAD	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg26924012	chr15:45694286	SPATA5L1	0.59	9.14	0.41	2.69e-18	Glomerular filtration rate;
LUAD	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg10792982	chr14:105748885	BRF1	0.42	9.27	0.41	9.93e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg22431228	chr1:16359049	CLCNKA	-0.63	-12.69	-0.53	1.68e-31	Dilated cardiomyopathy;
LUAD	trans	rs87938	0.931	rs436792	chr3:41153124	A/C	cg11224624	chr8:145049280	PLEC1	-0.41	-6.55	-0.3	1.72e-10	Bone mineral density (hip);
LUAD	cis	rs12900413	0.631	rs62023455	chr15:90301999	G/A	cg24249390	chr15:90295951	MESP1	-0.35	-6.83	-0.32	3.03e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08280861	chr8:58055591	NA	0.63	8.3	0.37	1.42e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg02269571	chr22:50332266	NA	-0.68	-9.9	-0.43	6.32e-21	Schizophrenia;
LUAD	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg11822812	chr5:140052017	DND1	-0.45	-8.2	-0.37	3e-15	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg03929089	chr4:120376271	NA	-0.99	-20.65	-0.71	4.76e-66	Height;
LUAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg08888203	chr3:10149979	C3orf24	0.74	13.07	0.54	5.1e-33	Alzheimer's disease;
LUAD	cis	rs11078597	0.731	rs12944946	chr17:1649486	C/G	cg18436246	chr17:1640651	WDR81	0.78	12.27	0.51	8e-30	Serum albumin level;
LUAD	cis	rs314370	0.570	rs314313	chr7:100423365	C/T	cg10426581	chr7:100472382	SRRT	-0.43	-6.92	-0.32	1.66e-11	Resting heart rate;
LUAD	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.47	-7.4	-0.34	7.48e-13	Tonsillectomy;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg04990056	chr1:28099876	STX12	-0.69	-6.58	-0.3	1.39e-10	Type 2 diabetes;
LUAD	cis	rs7542375	0.524	rs2807869	chr1:221094068	A/G	cg16008148	chr1:221062819	NA	0.42	8.37	0.38	8.77e-16	Obesity-related traits;
LUAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.36	-6.85	-0.32	2.64e-11	Longevity;Endometriosis;
LUAD	cis	rs4906332	0.840	rs34161327	chr14:103857325	G/A	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.24	-0.33	2.16e-12	Coronary artery disease;
LUAD	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg00933542	chr6:150070202	PCMT1	0.43	9.26	0.41	1.03e-18	Lung cancer;
LUAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg17063962	chr7:91808500	NA	0.73	13.25	0.54	9.24e-34	Breast cancer;
LUAD	cis	rs2625529	0.689	rs2957742	chr15:72302894	C/G	cg16672083	chr15:72433130	SENP8	0.62	11.38	0.48	2.26e-26	Red blood cell count;
LUAD	cis	rs1595825	0.945	rs2139050	chr2:198852636	A/G	cg00361562	chr2:198649771	BOLL	-0.48	-6.76	-0.31	4.47e-11	Ulcerative colitis;
LUAD	cis	rs727505	0.551	rs2293346	chr7:124783849	C/T	cg23710748	chr7:124431027	NA	-0.35	-7.33	-0.34	1.18e-12	Lewy body disease;
LUAD	trans	rs75804782	0.641	rs3769123	chr2:239349328	C/G	cg01134436	chr17:81009848	B3GNTL1	0.73	8.02	0.36	1.02e-14	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg00701064	chr4:6280414	WFS1	0.61	12.85	0.53	3.76e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg04455712	chr21:45112962	RRP1B	0.51	10.55	0.46	2.97e-23	Mean corpuscular volume;
LUAD	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.38	6.85	0.32	2.59e-11	Systemic lupus erythematosus;
LUAD	cis	rs4589502	0.800	rs1498499	chr15:67202620	C/T	cg09911534	chr15:67153556	NA	0.41	7.1	0.33	5.19e-12	Lung cancer (smoking interaction);
LUAD	cis	rs11153730	0.503	rs283057	chr6:118625734	T/C	cg05564266	chr6:118973597	C6orf204	0.3	6.43	0.3	3.46e-10	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18876405	chr7:65276391	NA	0.6	10.14	0.44	8.74e-22	Aortic root size;
LUAD	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg23758822	chr17:41437982	NA	1.02	20.96	0.71	1.99e-67	Menopause (age at onset);
LUAD	trans	rs7200543	1.000	rs4500751	chr16:15140211	C/T	cg24683922	chr1:11983373	KIAA2013	-0.46	-7.55	-0.34	2.76e-13	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs10203711	0.600	rs1810138	chr2:239561888	T/C	cg14580085	chr2:239553406	NA	0.4	8.43	0.38	5.62e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504073	0.647	rs55920380	chr8:50026353	G/A	cg00325661	chr8:49890786	NA	0.43	9.5	0.42	1.5700000000000001e-19	Blood metabolite ratios;
LUAD	cis	rs733175	0.951	rs7669090	chr4:10028131	C/T	cg00071950	chr4:10020882	SLC2A9	0.57	8.54	0.38	2.44e-16	Psychosis and Alzheimer's disease;
LUAD	cis	rs9811920	0.625	rs7631174	chr3:99913902	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.64	0.39	1.15e-16	Axial length;
LUAD	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg07266350	chr3:49460521	AMT;NICN1	-0.36	-6.56	-0.3	1.6e-10	Menarche (age at onset);
LUAD	cis	rs684232	0.666	rs423887	chr17:593600	A/G	cg15660573	chr17:549704	VPS53	-0.78	-14.1	-0.57	2.85e-37	Prostate cancer;
LUAD	cis	rs10465746	0.775	rs4907186	chr1:84340753	G/T	cg10977910	chr1:84465055	TTLL7	0.6	9.61	0.42	6.46e-20	Obesity-related traits;
LUAD	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08439880	chr3:133502540	NA	-0.49	-9.67	-0.43	3.93e-20	Iron status biomarkers;
LUAD	cis	rs892961	0.932	rs55661113	chr17:75408386	A/C	cg05865280	chr17:75406074	SEPT9	0.61	18.43	0.67	4.11e-56	Airflow obstruction;
LUAD	cis	rs12545109	0.876	rs4738494	chr8:57327438	G/T	cg17761419	chr8:57350749	NA	-0.56	-7.83	-0.36	3.99e-14	Obesity-related traits;
LUAD	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg12119029	chr16:89752879	CDK10	0.35	7.24	0.33	2.16e-12	Vitiligo;
LUAD	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg15664640	chr17:80829946	TBCD	-0.66	-8.34	-0.38	1.1e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg20673091	chr1:2541236	MMEL1	-0.44	-9.49	-0.42	1.67e-19	Ulcerative colitis;
LUAD	cis	rs806794	0.804	rs9393688	chr6:26207174	A/T	cg13736514	chr6:26305472	NA	-0.48	-7.19	-0.33	3e-12	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUAD	trans	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg06606381	chr12:133084897	FBRSL1	0.82	8.3	0.37	1.44e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg02018176	chr4:1364513	KIAA1530	-0.38	-7.06	-0.32	6.71e-12	Obesity-related traits;
LUAD	cis	rs8077889	0.703	rs72836567	chr17:41945776	G/A	cg26893861	chr17:41843967	DUSP3	0.86	10.64	0.46	1.37e-23	Triglycerides;
LUAD	cis	rs73198271	1.000	rs11775821	chr8:8609153	A/G	cg01851573	chr8:8652454	MFHAS1	0.52	8.39	0.38	7.3e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg15147215	chr3:52552868	STAB1	-0.42	-7.48	-0.34	4.2e-13	Bipolar disorder;
LUAD	cis	rs599083	0.590	rs661988	chr11:68189251	T/G	cg02221422	chr11:68192511	LRP5	-0.46	-6.7	-0.31	6.65e-11	Bone mineral density (spine);
LUAD	cis	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg14039649	chr22:38352398	POLR2F	0.38	6.86	0.32	2.39e-11	Glioblastoma;Glioma;
LUAD	trans	rs3960554	0.529	rs6465049	chr7:75874489	A/G	cg19862616	chr7:65841803	NCRNA00174	0.51	7.81	0.36	4.53e-14	Eotaxin levels;
LUAD	cis	rs7771547	0.723	rs9366908	chr6:36550488	G/A	cg07856975	chr6:36356162	ETV7	0.45	6.37	0.3	4.89e-10	Platelet distribution width;
LUAD	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg03806693	chr22:41940476	POLR3H	0.55	8.01	0.36	1.13e-14	Vitiligo;
LUAD	cis	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.87	-0.4	2.13e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg07432352	chr17:45403706	C17orf57	-0.42	-8.28	-0.37	1.58e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg05283184	chr6:79620031	NA	-0.45	-8.02	-0.36	1.04e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1160297	0.585	rs12713228	chr2:53090032	T/C	cg07782112	chr2:53107842	NA	0.41	8.67	0.39	9.42e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs8192282	0.739	rs7539745	chr1:154526414	C/G	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.36	-0.34	9.48e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg21733973	chr7:65235735	NA	0.46	7.42	0.34	6.2800000000000005e-13	Calcium levels;
LUAD	cis	rs7487075	0.619	rs4768725	chr12:46848478	T/C	cg23829395	chr12:46796953	NA	0.32	6.99	0.32	1.08e-11	Itch intensity from mosquito bite;
LUAD	cis	rs9346649	0.616	rs7740995	chr6:168492221	G/A	cg02770688	chr6:168491649	NA	0.52	9.73	0.43	2.47e-20	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg09796270	chr17:17721594	SREBF1	-0.37	-7.29	-0.33	1.54e-12	Total body bone mineral density;
LUAD	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg20487152	chr13:99095054	FARP1	-0.49	-8.3	-0.37	1.44e-15	Longevity;
LUAD	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg05340658	chr4:99064831	C4orf37	0.55	9.45	0.42	2.4e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg27446573	chr6:127587934	RNF146	0.41	6.38	0.3	4.63e-10	Breast cancer;
LUAD	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	cis	rs7771547	0.521	rs2180929	chr6:36394087	G/A	cg04289385	chr6:36355825	ETV7	0.48	6.91	0.32	1.77e-11	Platelet distribution width;
LUAD	cis	rs3823572	0.564	rs4728305	chr7:133666949	C/T	cg03336402	chr7:133662267	EXOC4	-0.42	-7.65	-0.35	1.39e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7937890	0.505	rs4403769	chr11:14450176	C/T	cg22961513	chr11:14280813	SPON1	-0.37	-7.08	-0.33	6.01e-12	Mitochondrial DNA levels;
LUAD	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg16325326	chr1:53192061	ZYG11B	0.7	13.45	0.55	1.43e-34	Monocyte count;
LUAD	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg04851639	chr8:1020857	NA	-0.42	-10.67	-0.46	1.06e-23	Schizophrenia;
LUAD	cis	rs5167	0.781	rs11672748	chr19:45490192	A/G	cg09555818	chr19:45449301	APOC2	0.39	7.35	0.34	1.05e-12	Blood protein levels;
LUAD	cis	rs698833	0.886	rs6721675	chr2:44566027	G/A	cg04920474	chr2:44395004	PPM1B	0.38	6.72	0.31	5.95e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg02176678	chr2:219576539	TTLL4	-0.68	-14.06	-0.56	4.17e-37	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs7833986	0.534	rs72653924	chr8:56906088	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	14.5	0.58	5.81e-39	Height;
LUAD	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.45	-0.3	3.12e-10	Triglycerides;
LUAD	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg11822812	chr5:140052017	DND1	-0.37	-6.73	-0.31	5.62e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12986413	0.624	rs12460763	chr19:2138507	A/G	cg09261902	chr19:2140048	AP3D1	0.34	6.79	0.31	3.9e-11	Height;
LUAD	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg20933634	chr6:27740509	NA	0.47	7.32	0.34	1.22e-12	Parkinson's disease;
LUAD	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg05896524	chr21:47604654	C21orf56	0.54	9.05	0.4	5.18e-18	Testicular germ cell tumor;
LUAD	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg20744362	chr22:50050164	C22orf34	0.42	9.18	0.41	1.9e-18	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg17480646	chr11:65405466	SIPA1	-0.45	-6.79	-0.31	3.91e-11	Acne (severe);
LUAD	cis	rs873917	0.620	rs784595	chr1:40135017	C/T	cg00990022	chr1:40138052	NT5C1A	-0.43	-6.79	-0.31	3.79e-11	Amyotrophic lateral sclerosis;
LUAD	cis	rs4378999	0.748	rs1480353	chr3:51383144	A/G	cg12934382	chr3:51741135	GRM2	0.38	6.85	0.32	2.66e-11	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg19442545	chr10:75533431	FUT11	-0.47	-7.7	-0.35	1e-13	Inflammatory bowel disease;
LUAD	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg26384229	chr12:38710491	ALG10B	0.48	7.83	0.36	3.83e-14	Morning vs. evening chronotype;
LUAD	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg23625390	chr15:77176239	SCAPER	0.37	6.56	0.3	1.56e-10	Blood metabolite levels;
LUAD	cis	rs736801	0.704	rs56399423	chr5:131672657	T/C	cg16205897	chr5:131564050	P4HA2	-0.37	-7.89	-0.36	2.68e-14	Breast cancer;Mosquito bite size;
LUAD	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg08029281	chr1:67600428	NA	0.36	6.62	0.31	1.1e-10	Psoriasis;
LUAD	cis	rs12545109	0.800	rs1837617	chr8:57417592	C/T	cg19413350	chr8:57351067	NA	-0.43	-6.65	-0.31	8.9e-11	Obesity-related traits;
LUAD	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.91	0.76	1.53e-80	Chronic sinus infection;
LUAD	cis	rs6445967	0.569	rs2280166	chr3:58309602	C/T	cg13750441	chr3:58318267	PXK	-0.31	-6.39	-0.3	4.48e-10	Platelet count;
LUAD	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg02049041	chr17:27085579	C17orf63	0.63	8.3	0.37	1.37e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs67981189	0.529	rs61990387	chr14:71491567	A/G	cg15910301	chr14:71632612	NA	0.41	6.52	0.3	2.04e-10	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10189230	0.935	rs3770146	chr2:222344196	G/A	cg14652038	chr2:222343519	EPHA4	0.43	8.5	0.38	3.36e-16	Urate levels in lean individuals;
LUAD	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg05304507	chr6:116381966	FRK	-0.2	-6.96	-0.32	1.31e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg25036284	chr2:26402008	FAM59B	-0.66	-9.07	-0.4	4.42e-18	Gut microbiome composition (summer);
LUAD	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.43	-6.94	-0.32	1.52e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg06608945	chr2:219082296	ARPC2	-0.42	-6.95	-0.32	1.38e-11	Colorectal cancer;
LUAD	cis	rs9341808	0.519	rs676311	chr6:80989750	T/G	cg08355045	chr6:80787529	NA	-0.43	-7.26	-0.33	1.87e-12	Sitting height ratio;
LUAD	trans	rs1941687	0.797	rs8098255	chr18:31401850	A/G	cg27147174	chr7:100797783	AP1S1	0.49	8.0	0.36	1.2e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs752010	0.574	rs12130138	chr1:42117792	A/C	cg06885757	chr1:42089581	HIVEP3	0.42	8.91	0.4	1.53e-17	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs1395	0.767	rs1821986	chr2:27405835	A/G	cg23587288	chr2:27483067	SLC30A3	0.41	8.27	0.37	1.75e-15	Blood metabolite levels;
LUAD	trans	rs225245	0.541	rs321612	chr17:33881631	T/C	cg19694781	chr19:47549865	TMEM160	-0.6	-9.67	-0.43	4.05e-20	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.56	-0.3	1.59e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg23758822	chr17:41437982	NA	1.0	20.98	0.71	1.68e-67	Menopause (age at onset);
LUAD	cis	rs2637266	0.935	rs2579719	chr10:78400026	A/G	cg18941641	chr10:78392320	NA	0.34	7.04	0.32	7.75e-12	Pulmonary function;
LUAD	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg18230493	chr5:56204884	C5orf35	0.44	7.42	0.34	6.34e-13	Coronary artery disease;
LUAD	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg20503657	chr10:835505	NA	0.83	12.69	0.53	1.64e-31	Eosinophil percentage of granulocytes;
LUAD	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg12623302	chr6:28058802	ZSCAN12L1	0.3	6.61	0.31	1.14e-10	Parkinson's disease;
LUAD	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.47	0.38	4.01e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg06808227	chr14:105710500	BRF1	-0.43	-6.6	-0.31	1.21e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs8060686	0.623	rs58388686	chr16:68075439	A/G	cg05110241	chr16:68378359	PRMT7	-0.53	-6.9	-0.32	1.95e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg22029157	chr1:209979665	IRF6	0.84	10.14	0.44	9.26e-22	Cleft lip with or without cleft palate;
LUAD	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.54	9.21	0.41	1.56e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg06263672	chr7:65235340	NA	0.49	6.73	0.31	5.47e-11	Aortic root size;
LUAD	cis	rs16910800	0.953	rs73481422	chr11:23205174	T/C	cg20040320	chr11:23191996	NA	-0.5	-7.44	-0.34	5.5e-13	Cancer;
LUAD	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg04398451	chr17:18023971	MYO15A	0.78	14.11	0.57	2.51e-37	Total body bone mineral density;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11954230	chr10:105677556	OBFC1	-0.43	-6.55	-0.3	1.68e-10	Height;
LUAD	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	9.39	0.42	3.66e-19	Colorectal cancer;
LUAD	trans	rs8073060	0.521	rs225254	chr17:33953384	G/A	cg19694781	chr19:47549865	TMEM160	-0.63	-10.19	-0.44	5.74e-22	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg26513180	chr16:89883248	FANCA	0.82	7.4	0.34	7.56e-13	Skin colour saturation;
LUAD	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.58	8.2	0.37	2.93e-15	Platelet count;
LUAD	trans	rs564343	1.000	rs564343	chr11:65895166	C/T	cg26701943	chr11:108369231	KDELC2	0.45	7.5	0.34	3.78e-13	Obesity (early onset extreme);
LUAD	trans	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.74	0.46	5.74e-24	Exhaled nitric oxide output;
LUAD	trans	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	9.97e-11	Diabetic kidney disease;
LUAD	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg17633681	chr16:88106987	BANP	0.4	6.82	0.31	3.13e-11	Menopause (age at onset);
LUAD	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg19622623	chr12:86230825	RASSF9	-0.45	-7.81	-0.35	4.68e-14	Major depressive disorder;
LUAD	cis	rs6489882	0.867	rs7972033	chr12:113363283	C/T	cg20102336	chr12:113376681	OAS3	-0.6	-9.14	-0.41	2.59e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs1003719	0.788	rs9974286	chr21:38456832	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.51	-8.67	-0.39	9.31e-17	Eye color traits;
LUAD	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg26597838	chr10:835615	NA	1.04	15.53	0.6	2.36e-43	Eosinophil percentage of granulocytes;
LUAD	cis	rs644148	0.836	rs2686774	chr19:44999827	T/C	cg15540054	chr19:45004280	ZNF180	-0.41	-6.7	-0.31	6.61e-11	Personality dimensions;
LUAD	cis	rs300774	0.800	rs300716	chr2:136844	G/A	cg21211680	chr2:198530	NA	-0.45	-7.14	-0.33	3.98e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.74	-13.45	-0.55	1.43e-34	Axial length;
LUAD	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg19622623	chr12:86230825	RASSF9	0.4	7.12	0.33	4.55e-12	Major depressive disorder;
LUAD	cis	rs6541297	0.703	rs637180	chr1:230311677	G/A	cg20703242	chr1:230279135	GALNT2	-0.47	-6.93	-0.32	1.6e-11	Coronary artery disease;
LUAD	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg09915433	chr19:53449742	NA	-0.54	-9.27	-0.41	9.25e-19	Psoriasis;
LUAD	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.37	6.66	0.31	8.32e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg10729496	chr3:10149963	C3orf24	0.66	9.63	0.42	5.82e-20	Alzheimer's disease;
LUAD	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg25324976	chr17:61989376	CSHL1	0.38	7.31	0.33	1.35e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg07870213	chr5:140052090	DND1	-0.62	-9.48	-0.42	1.92e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00974835	chr14:74960278	NPC2;ISCA2	-0.55	-6.64	-0.31	9.81e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg17063962	chr7:91808500	NA	0.7	12.51	0.52	8.87e-31	Breast cancer;
LUAD	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg06532163	chr17:45867833	NA	0.47	8.35	0.38	9.57e-16	IgG glycosylation;
LUAD	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg21918786	chr6:109611834	NA	-0.56	-10.52	-0.46	3.72e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2455799	0.593	rs13085352	chr3:15914845	T/C	cg16303742	chr3:15540471	COLQ	-0.5	-9.01	-0.4	7.11e-18	Mean platelet volume;
LUAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg22907277	chr7:1156413	C7orf50	0.67	8.22	0.37	2.47e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg06618935	chr21:46677482	NA	-0.5	-9.99	-0.44	3.18e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.55	-0.3	1.65e-10	Joint mobility (Beighton score);
LUAD	cis	rs9581857	0.547	rs75783371	chr13:28109961	T/C	cg22138327	chr13:27999177	GTF3A	0.81	8.47	0.38	4.13e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs2274273	0.870	rs6573009	chr14:55682324	A/C	cg04306507	chr14:55594613	LGALS3	0.41	8.5	0.38	3.25e-16	Protein biomarker;
LUAD	cis	rs2425143	1.000	rs7267759	chr20:34257284	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.25	-0.33	2.05e-12	Blood protein levels;
LUAD	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg05665937	chr4:1216051	CTBP1	0.41	7.45	0.34	5.26e-13	Obesity-related traits;
LUAD	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg15181151	chr6:150070149	PCMT1	0.41	8.53	0.38	2.66e-16	Lung cancer;
LUAD	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg09117114	chr16:67998030	SLC12A4	-0.51	-7.25	-0.33	2.04e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg24558204	chr6:135376177	HBS1L	0.45	7.64	0.35	1.51e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs68170813	0.562	rs78181351	chr7:106999301	A/G	cg23024343	chr7:107201750	COG5	0.52	7.35	0.34	1.03e-12	Coronary artery disease;
LUAD	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Body mass index;
LUAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06873352	chr17:61820015	STRADA	0.83	18.59	0.67	8.47e-57	Prudent dietary pattern;
LUAD	cis	rs12210905	1.000	rs9348756	chr6:27228259	G/A	cg11502198	chr6:26597334	ABT1	-0.81	-6.51	-0.3	2.19e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg03289416	chr15:75166202	SCAMP2	0.59	10.16	0.44	7.52e-22	Breast cancer;
LUAD	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25427524	chr10:38739819	LOC399744	-0.76	-13.63	-0.55	2.62e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs56046484	0.620	rs34585903	chr15:85528124	G/T	cg08123816	chr15:85640762	PDE8A	-0.44	-6.49	-0.3	2.39e-10	Testicular germ cell tumor;
LUAD	cis	rs10203711	1.000	rs1810140	chr2:239568163	T/C	cg14580085	chr2:239553406	NA	0.42	8.95	0.4	1.12e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7000551	0.751	rs2449340	chr8:22389900	T/G	cg12081754	chr8:22256438	SLC39A14	0.43	7.06	0.32	6.82e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.9	9.43	0.42	2.65e-19	Initial pursuit acceleration;
LUAD	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7705042	0.828	rs6580224	chr5:141489306	A/G	cg23435118	chr5:141488016	NDFIP1	-0.38	-6.48	-0.3	2.59e-10	Asthma;
LUAD	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg03396347	chr1:1875803	NA	-0.6	-15.56	-0.6	1.6700000000000001e-43	Body mass index;
LUAD	cis	rs62400317	0.859	rs4498350	chr6:45268438	C/T	cg18551225	chr6:44695536	NA	-0.53	-8.36	-0.38	9.31e-16	Total body bone mineral density;
LUAD	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg21248554	chr2:27665150	KRTCAP3	0.32	8.81	0.39	3.28e-17	Total body bone mineral density;
LUAD	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg21226059	chr5:178986404	RUFY1	0.62	9.47	0.42	2.08e-19	Lung cancer;
LUAD	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg10426581	chr7:100472382	SRRT	0.76	9.98	0.44	3.41e-21	Resting heart rate;
LUAD	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg09263875	chr16:632152	PIGQ	0.81	16.99	0.64	9.51e-50	Height;
LUAD	cis	rs741677	0.826	rs12938729	chr17:475780	T/C	cg13332499	chr17:408570	NA	0.34	6.81	0.31	3.37e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs867371	0.519	rs1566559	chr15:82524461	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.41	-6.89	-0.32	2.07e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LUAD	cis	rs2732480	0.577	rs1489109	chr12:48738780	C/A	cg04545296	chr12:48745243	ZNF641	0.38	9.55	0.42	1.07e-19	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg11845111	chr2:191398756	TMEM194B	0.68	12.56	0.52	5.88e-31	Pulse pressure;
LUAD	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14829155	chr15:31115871	NA	0.75	12.46	0.52	1.39e-30	Huntington's disease progression;
LUAD	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg25427524	chr10:38739819	LOC399744	0.71	11.92	0.5	1.89e-28	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2902440	0.502	rs4655527	chr1:67664491	G/A	cg17031739	chr1:67600172	NA	0.39	7.18	0.33	3.2e-12	Crohn's disease;
LUAD	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg01097406	chr16:89675127	NA	-0.31	-6.67	-0.31	8.19e-11	Vitiligo;
LUAD	cis	rs3027234	0.734	rs11650309	chr17:8129538	C/G	cg08322244	chr17:8066669	VAMP2	-0.45	-6.65	-0.31	9.1e-11	Telomere length;
LUAD	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12379764	chr21:47803548	PCNT	-0.6	-9.48	-0.42	1.87e-19	Testicular germ cell tumor;
LUAD	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg06766960	chr11:133703094	NA	-0.37	-6.89	-0.32	2.01e-11	Childhood ear infection;
LUAD	cis	rs877282	0.898	rs11253347	chr10:765769	A/G	cg06581033	chr10:766294	NA	-0.62	-8.35	-0.38	1.02e-15	Uric acid levels;
LUAD	cis	rs524023	0.874	rs7102344	chr11:64396569	A/T	cg19131476	chr11:64387923	NRXN2	-0.41	-7.94	-0.36	1.87e-14	Urate levels in obese individuals;
LUAD	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.36	7.33	0.34	1.14e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg04455712	chr21:45112962	RRP1B	0.43	8.45	0.38	4.74e-16	Mean corpuscular volume;
LUAD	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg11301795	chr4:187892539	NA	-0.77	-15.68	-0.61	5.23e-44	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23442477	chr15:85258977	SEC11A	-0.44	-7.35	-0.34	1.06e-12	Cancer;
LUAD	cis	rs1232027	0.656	rs1650749	chr5:79981544	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.41	-6.38	-0.3	4.54e-10	Huntington's disease progression;
LUAD	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg04944784	chr2:26401820	FAM59B	-0.66	-9.51	-0.42	1.44e-19	Gut microbiome composition (summer);
LUAD	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg17105886	chr17:28927953	LRRC37B2	-0.79	-7.61	-0.35	1.84e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs9951602	0.512	rs4799249	chr18:76654370	A/G	cg02800362	chr5:177631904	HNRNPAB	0.91	14.57	0.58	3.06e-39	Obesity-related traits;
LUAD	cis	rs62400317	0.859	rs6919813	chr6:45159177	C/T	cg20913747	chr6:44695427	NA	-0.43	-6.75	-0.31	4.97e-11	Total body bone mineral density;
LUAD	cis	rs7809950	1.000	rs10267907	chr7:107184466	C/T	cg23024343	chr7:107201750	COG5	-0.74	-12.38	-0.52	2.86e-30	Coronary artery disease;
LUAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00149659	chr3:10157352	C3orf10	0.61	8.49	0.38	3.41e-16	Alzheimer's disease;
LUAD	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg07806771	chr7:64541737	NA	0.54	8.69	0.39	7.77e-17	Calcium levels;
LUAD	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg25173405	chr17:45401733	C17orf57	-0.52	-8.76	-0.39	4.79e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg16060761	chr17:80687452	NA	-0.57	-7.98	-0.36	1.39e-14	Glycated hemoglobin levels;
LUAD	cis	rs72928364	0.860	rs13085636	chr3:100797104	G/A	cg10123952	chr3:100791384	NA	0.73	8.37	0.38	8.49e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg03929089	chr4:120376271	NA	0.8	14.34	0.57	2.75e-38	Height;
LUAD	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	9.18	0.41	1.93e-18	Tonsillectomy;
LUAD	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg18944383	chr4:111397179	ENPEP	-0.38	-6.97	-0.32	1.21e-11	Coronary artery disease;
LUAD	cis	rs743757	1.000	rs743756	chr3:50481717	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.44	6.97	0.32	1.24e-11	Diastolic blood pressure;
LUAD	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg01874867	chr7:94954059	PON1	-0.5	-6.88	-0.32	2.18e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.35	-0.38	9.63e-16	Prostate cancer;
LUAD	trans	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg14917512	chr19:3094685	GNA11	-0.37	-6.38	-0.3	4.56e-10	Aortic root size;
LUAD	trans	rs7395662	0.681	rs2865641	chr11:48941099	A/C	cg15704280	chr7:45808275	SEPT13	-0.44	-6.97	-0.32	1.22e-11	HDL cholesterol;
LUAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg11062466	chr8:58055876	NA	0.67	8.84	0.39	2.69e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17712092	chr4:129076599	LARP1B	0.85	15.68	0.61	5.01e-44	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.66	-0.39	1e-16	Total body bone mineral density;
LUAD	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg08885076	chr2:99613938	TSGA10	0.39	7.3	0.33	1.48e-12	Chronic sinus infection;
LUAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg26818010	chr10:134567672	INPP5A	1.0	16.88	0.63	3.09e-49	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg03690763	chr11:133734501	NA	-0.29	-7.04	-0.32	7.7e-12	Childhood ear infection;
LUAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg26818010	chr10:134567672	INPP5A	-0.51	-7.04	-0.32	7.6e-12	Primary sclerosing cholangitis;
LUAD	cis	rs922692	0.744	rs12899147	chr15:79079512	A/G	cg22753661	chr15:79092743	ADAMTS7	0.5	8.09	0.37	6.33e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg13685833	chr1:53393034	SCP2	0.48	7.36	0.34	9.7e-13	Monocyte count;
LUAD	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg26924012	chr15:45694286	SPATA5L1	0.86	14.67	0.58	1.07e-39	Homoarginine levels;
LUAD	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg20469991	chr17:27169893	C17orf63	-0.52	-6.58	-0.3	1.37e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7336332	0.598	rs1885988	chr13:28010262	C/T	cg22138327	chr13:27999177	GTF3A	-0.75	-10.36	-0.45	1.4e-22	Weight;
LUAD	cis	rs300774	1.000	rs2015419	chr2:118385	A/G	cg21211680	chr2:198530	NA	-0.46	-6.76	-0.31	4.61e-11	Suicide attempts in bipolar disorder;
LUAD	trans	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg15655154	chr3:113604241	GRAMD1C	0.55	9.96	0.44	3.86e-21	Diastolic blood pressure;
LUAD	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg22875332	chr1:76189707	ACADM	0.74	11.27	0.48	6.08e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.62	-11.65	-0.49	2.08e-27	Schizophrenia;
LUAD	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg00717180	chr2:96193071	NA	-0.48	-9.03	-0.4	6.15e-18	Height;
LUAD	cis	rs62238980	0.522	rs62238974	chr22:32568024	A/G	cg00543991	chr22:32367038	NA	0.82	7.22	0.33	2.37e-12	Childhood ear infection;
LUAD	cis	rs1232027	0.700	rs2560424	chr5:79925305	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg21724239	chr8:58056113	NA	0.72	9.56	0.42	1.01e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.23	0.54	1.13e-33	Prudent dietary pattern;
LUAD	cis	rs62025270	0.547	rs416916	chr15:86192416	G/A	cg13263323	chr15:86062960	AKAP13	0.47	7.4	0.34	7.63e-13	Idiopathic pulmonary fibrosis;
LUAD	trans	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.67	12.18	0.51	1.79e-29	Mean corpuscular volume;
LUAD	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg06552810	chr11:31128660	NA	-0.34	-6.6	-0.31	1.2e-10	Red blood cell count;
LUAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg23131131	chr22:24373011	LOC391322	-0.6	-10.08	-0.44	1.52e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs933688	0.527	rs1511344	chr5:90582914	G/C	cg00335715	chr5:90575459	NA	-0.55	-8.07	-0.37	7.37e-15	Smoking behavior;
LUAD	cis	rs2249625	0.874	rs2463747	chr6:72878113	T/A	cg18830697	chr6:72922368	RIMS1	-0.36	-6.79	-0.31	3.88e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs9560113	1.000	rs11069895	chr13:112178824	C/T	cg14154082	chr13:112174009	NA	0.37	6.85	0.32	2.62e-11	Menarche (age at onset);
LUAD	cis	rs1595825	0.891	rs10497810	chr2:198895732	C/T	cg10547527	chr2:198650123	BOLL	-0.51	-7.0	-0.32	1.02e-11	Ulcerative colitis;
LUAD	cis	rs2274273	0.870	rs10139083	chr14:55782735	C/A	cg04306507	chr14:55594613	LGALS3	0.43	8.8	0.39	3.52e-17	Protein biomarker;
LUAD	cis	rs11048434	0.736	rs11048195	chr12:9105923	A/G	cg26114124	chr12:9217669	LOC144571	0.36	6.75	0.31	4.88e-11	Sjögren's syndrome;
LUAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg22764044	chr5:178986830	RUFY1	0.67	11.86	0.5	3.16e-28	Lung cancer;
LUAD	cis	rs7937682	0.562	rs10891276	chr11:111370415	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.42	-7.07	-0.33	6.39e-12	Primary sclerosing cholangitis;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg13099847	chr1:33546750	ADC	0.4	6.4	0.3	4.08e-10	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg18335740	chr13:41363409	SLC25A15	0.56	9.87	0.43	8.05e-21	Lewy body disease;
LUAD	cis	rs6754311	0.593	rs4954279	chr2:136409073	G/A	cg07305463	chr2:136567211	LCT	-0.33	-6.37	-0.3	4.82e-10	Mosquito bite size;
LUAD	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg17372223	chr3:52568218	NT5DC2	-0.36	-6.52	-0.3	1.97e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.16	0.37	4e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6987853	0.901	rs2974344	chr8:42400732	T/G	cg09913449	chr8:42400586	C8orf40	0.43	8.13	0.37	4.63e-15	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.52	0.3	2.03e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs1865721	0.771	rs62092763	chr18:73128623	T/G	cg26385618	chr18:73139727	C18orf62	-0.51	-10.1	-0.44	1.25e-21	Intelligence;
LUAD	trans	rs2665103	0.589	rs3858953	chr15:82530390	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.41	-6.9	-0.32	1.88e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.85	16.26	0.62	1.62e-46	Lymphocyte counts;
LUAD	trans	rs2735413	0.918	rs34094825	chr16:78081392	G/C	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs354225	0.544	rs7340302	chr2:54803671	A/C	cg01766943	chr2:54829624	SPTBN1	0.38	6.9	0.32	1.88e-11	Schizophrenia;
LUAD	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg22467129	chr15:76604101	ETFA	-0.59	-10.86	-0.47	2.09e-24	Blood metabolite levels;
LUAD	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg00383909	chr3:49044727	WDR6	0.83	9.07	0.4	4.64e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs9768139	0.658	rs73746486	chr7:158113191	A/G	cg24154853	chr7:158122151	PTPRN2	0.56	11.01	0.47	5.65e-25	Calcium levels;
LUAD	cis	rs6906287	0.609	rs6938041	chr6:118852468	C/A	cg21191810	chr6:118973309	C6orf204	0.49	9.47	0.42	1.96e-19	Electrocardiographic conduction measures;
LUAD	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg08213375	chr14:104286397	PPP1R13B	0.27	6.94	0.32	1.47e-11	Schizophrenia;
LUAD	cis	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg02966332	chr20:62369605	LIME1	-0.48	-7.7	-0.35	9.87e-14	Prostate cancer;
LUAD	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg08316699	chr6:150357289	NA	0.32	6.71	0.31	6.13e-11	Alopecia areata;
LUAD	cis	rs1865721	0.848	rs12966327	chr18:73208445	C/T	cg26385618	chr18:73139727	C18orf62	-0.39	-7.11	-0.33	4.94e-12	Intelligence;
LUAD	cis	rs9469890	0.604	rs11758471	chr6:34503517	A/C	cg14254433	chr6:34482411	PACSIN1	-0.58	-8.36	-0.38	8.99e-16	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.48	7.77	0.35	6.21e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs11690462	0.750	rs12470259	chr2:26611034	C/G	cg13255216	chr2:26625047	C2orf39	-0.35	-6.51	-0.3	2.13e-10	Coronary artery disease;
LUAD	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg02269571	chr22:50332266	NA	-0.67	-9.57	-0.42	9.14e-20	Schizophrenia;
LUAD	cis	rs7107174	1.000	rs7128666	chr11:78102363	A/T	cg02023728	chr11:77925099	USP35	0.47	7.25	0.33	1.95e-12	Testicular germ cell tumor;
LUAD	cis	rs8192282	0.739	rs6697103	chr1:154499926	C/T	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.37	-0.34	8.86e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7809950	0.953	rs2520263	chr7:107179119	T/C	cg23024343	chr7:107201750	COG5	-0.74	-12.49	-0.52	1.06e-30	Coronary artery disease;
LUAD	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg00316803	chr15:76480434	C15orf27	-0.43	-8.42	-0.38	5.72e-16	Blood metabolite levels;
LUAD	cis	rs1965732	0.563	rs13409104	chr2:3718692	C/T	cg25251562	chr2:3704773	ALLC	-0.36	-6.8	-0.31	3.63e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	11.57	0.49	4.27e-27	Bone mineral density;
LUAD	cis	rs2224391	0.822	rs2773321	chr6:5262220	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-9.82	-0.43	1.22e-20	Height;
LUAD	cis	rs55823223	0.648	rs66584478	chr17:73870203	G/A	cg09253696	chr17:73873529	TRIM47	-0.43	-7.27	-0.33	1.8e-12	Psoriasis;
LUAD	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.02	0.32	9.12e-12	Parkinson's disease;
LUAD	cis	rs68170813	0.559	rs77422419	chr7:106957932	A/G	cg23024343	chr7:107201750	COG5	0.5	7.2	0.33	2.84e-12	Coronary artery disease;
LUAD	cis	rs59104589	0.583	rs62186377	chr2:242211450	A/G	cg08645257	chr2:242211290	HDLBP	0.51	8.03	0.36	9.52e-15	Fibrinogen levels;
LUAD	cis	rs10193935	0.901	rs7601905	chr2:42494144	A/G	cg27598129	chr2:42591480	NA	-0.61	-8.12	-0.37	5e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs76878669	0.561	rs7125752	chr11:66162419	C/T	cg10616300	chr11:66138557	SLC29A2	-0.37	-7.73	-0.35	7.95e-14	Educational attainment (years of education);
LUAD	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg08754478	chr10:133766260	PPP2R2D	0.69	12.24	0.51	1.08e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18876405	chr7:65276391	NA	-0.58	-9.91	-0.43	5.83e-21	Aortic root size;
LUAD	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.74	10.53	0.46	3.43e-23	Smoking behavior;
LUAD	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg22676075	chr6:135203613	NA	0.41	7.45	0.34	5.15e-13	Red blood cell count;
LUAD	cis	rs113835537	0.529	rs11227514	chr11:66286627	G/A	cg26679405	chr11:66247800	DPP3	-0.44	-6.4	-0.3	4.08e-10	Airway imaging phenotypes;
LUAD	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg16325326	chr1:53192061	ZYG11B	0.67	13.02	0.54	7.64e-33	Monocyte count;
LUAD	cis	rs79839061	0.732	rs56852661	chr4:826257	G/A	cg14530993	chr4:882597	GAK	0.76	6.67	0.31	7.79e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9297145	0.761	rs62473005	chr7:98742510	G/C	cg05967295	chr7:98741636	SMURF1	0.99	15.56	0.6	1.71e-43	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	7.28	0.33	1.66e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg03188948	chr7:1209495	NA	0.83	10.1	0.44	1.29e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg12483801	chr4:183727862	NA	0.62	7.41	0.34	6.94e-13	Pediatric autoimmune diseases;
LUAD	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg03433033	chr1:76189801	ACADM	-0.67	-10.83	-0.47	2.8e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg07952391	chr2:88470173	THNSL2	-0.42	-6.92	-0.32	1.72e-11	Response to metformin (IC50);
LUAD	cis	rs1006703	0.544	rs8082265	chr17:3838761	C/T	cg06463185	chr17:3833770	ATP2A3	-0.78	-8.6	-0.39	1.58e-16	Glucose homeostasis traits;
LUAD	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00166722	chr3:10149974	C3orf24	0.73	12.65	0.52	2.57e-31	Alzheimer's disease;
LUAD	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg03676636	chr4:99064102	C4orf37	0.3	7.23	0.33	2.26e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg12458913	chr13:53173898	NA	0.46	8.4	0.38	6.76e-16	Lewy body disease;
LUAD	cis	rs11229555	1.000	rs11603890	chr11:58402251	T/C	cg15696309	chr11:58395628	NA	-0.72	-10.9	-0.47	1.54e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg17366294	chr4:99064904	C4orf37	0.64	10.26	0.45	3.34e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs225245	0.791	rs720774	chr17:34017453	T/G	cg05299278	chr17:33885742	SLFN14	0.5	11.32	0.48	3.96e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg10356904	chr22:49881777	NA	-0.4	-8.53	-0.38	2.54e-16	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg21475434	chr5:93447410	FAM172A	0.78	8.67	0.39	9.01e-17	Diabetic retinopathy;
LUAD	cis	rs4891159	0.790	rs11150953	chr18:74145491	G/A	cg24786174	chr18:74118243	ZNF516	-0.79	-14.61	-0.58	2.01e-39	Longevity;
LUAD	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg00484396	chr16:3507460	NAT15	-0.72	-8.4	-0.38	6.61e-16	Tuberculosis;
LUAD	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg05481257	chr2:20870211	GDF7	-0.6	-12.24	-0.51	1.07e-29	Abdominal aortic aneurysm;
LUAD	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg03806693	chr22:41940476	POLR3H	-0.45	-6.97	-0.32	1.22e-11	Neuroticism;
LUAD	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg08999081	chr20:33150536	PIGU	-0.63	-13.96	-0.56	1.06e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg09537434	chr19:41945824	ATP5SL	-0.52	-8.13	-0.37	4.67e-15	Height;
LUAD	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg00631329	chr6:26305371	NA	-0.69	-13.31	-0.54	5.33e-34	Educational attainment;
LUAD	cis	rs59698941	0.943	rs12513758	chr5:132239939	C/G	cg14825688	chr5:132208181	LEAP2	-0.48	-6.49	-0.3	2.48e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg21709803	chr11:61594965	FADS2	0.39	7.12	0.33	4.73e-12	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs12530845	0.887	rs59400686	chr7:135360029	A/G	cg23117316	chr7:135346802	PL-5283	-0.49	-8.26	-0.37	1.85e-15	Red blood cell traits;
LUAD	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.62	-0.42	6.01e-20	Life satisfaction;
LUAD	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg08508325	chr11:3079039	CARS	-0.62	-13.53	-0.55	6.48e-35	Longevity;
LUAD	cis	rs6732160	1.000	rs6732160	chr2:73387228	A/G	cg01422370	chr2:73384389	NA	0.33	6.65	0.31	9.09e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs782590	0.875	rs62165175	chr2:55745810	T/A	cg03859395	chr2:55845619	SMEK2	0.64	11.44	0.49	1.4e-26	Metabolic syndrome;
LUAD	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg05731713	chr7:157510257	PTPRN2	0.45	10.49	0.45	5.01e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7009516	0.669	rs13270982	chr8:24248552	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.43	-8.64	-0.39	1.2e-16	Hair greying;
LUAD	trans	rs783540	0.934	rs8043401	chr15:83356259	A/G	cg18393722	chr15:85113863	UBE2QP1	0.47	7.6	0.35	1.87e-13	Schizophrenia;
LUAD	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg20701182	chr2:24300061	SF3B14	0.64	7.4	0.34	7.23e-13	Lymphocyte counts;
LUAD	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg16414030	chr3:133502952	NA	-0.69	-13.45	-0.55	1.34e-34	Iron status biomarkers;
LUAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg02951883	chr7:2050386	MAD1L1	0.72	11.56	0.49	4.74e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg17063962	chr7:91808500	NA	0.68	12.15	0.51	2.4e-29	Breast cancer;
LUAD	cis	rs7789940	0.904	rs12531348	chr7:75937191	G/C	cg10167463	chr7:75959203	YWHAG	-0.69	-12.03	-0.5	7.08e-29	Multiple sclerosis;
LUAD	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	7.38	0.34	8.42e-13	Mood instability;
LUAD	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg04218760	chr10:45406644	TMEM72	-0.31	-7.58	-0.35	2.24e-13	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.68e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg17063962	chr7:91808500	NA	0.71	12.45	0.52	1.53e-30	Breast cancer;
LUAD	trans	rs75804782	0.521	rs72993033	chr2:239382882	A/G	cg01134436	chr17:81009848	B3GNTL1	0.8	8.77	0.39	4.27e-17	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg19413350	chr8:57351067	NA	-0.41	-6.54	-0.3	1.75e-10	Obesity-related traits;
LUAD	cis	rs704	0.605	rs2227736	chr17:26693231	G/C	cg10342447	chr17:26645325	TMEM97	-0.4	-7.98	-0.36	1.41e-14	Osteoprotegerin levels;
LUAD	trans	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.34	0.51	4.46e-30	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg20307385	chr11:47447363	PSMC3	0.52	7.71	0.35	9.11e-14	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.03	-15.38	-0.6	1.01e-42	Schizophrenia;
LUAD	cis	rs8030485	0.536	rs1915724	chr15:79441027	A/G	cg17916960	chr15:79447300	NA	0.41	8.04	0.36	9.42e-15	Left ventricle wall thickness;
LUAD	cis	rs1461503	0.966	rs1461502	chr11:122844927	C/G	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs6424115	1.000	rs12121387	chr1:24166536	T/G	cg10978503	chr1:24200527	CNR2	-0.56	-12.01	-0.5	8.86e-29	Immature fraction of reticulocytes;
LUAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.79	-0.43	1.6e-20	Alzheimer's disease;
LUAD	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-9.12	-0.41	3.15e-18	Life satisfaction;
LUAD	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03517284	chr6:25882590	NA	-0.54	-8.89	-0.4	1.74e-17	Blood metabolite levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg04100724	chr12:92539208	BTG1	0.4	6.82	0.31	3.23e-11	Schizophrenia;
LUAD	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg11707310	chr1:2537719	MMEL1	0.37	7.76	0.35	6.58e-14	Ulcerative colitis;
LUAD	trans	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.59	-11.08	-0.47	3.18e-25	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.92	-0.53	2.07e-32	Dilated cardiomyopathy;
LUAD	cis	rs7593730	0.832	rs2925757	chr2:161101169	C/T	cg22609984	chr2:161126801	NA	0.45	6.51	0.3	2.1e-10	Type 2 diabetes;
LUAD	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg06641503	chr3:48959341	ARIH2	-0.37	-7.05	-0.32	7.42e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg26587870	chr6:27730563	NA	-0.67	-7.21	-0.33	2.68e-12	Depression;
LUAD	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg10589385	chr1:150898437	SETDB1	-0.34	-6.43	-0.3	3.49e-10	Tonsillectomy;
LUAD	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg15017067	chr4:17643749	FAM184B	0.38	7.42	0.34	6.2800000000000005e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10129255	0.500	rs10143385	chr14:107190796	G/A	cg23076370	chr14:107095027	NA	-0.43	-8.61	-0.39	1.41e-16	Kawasaki disease;
LUAD	cis	rs9952991	0.941	rs60735058	chr18:12795470	T/A	cg23598886	chr18:12777645	NA	-0.68	-8.16	-0.37	3.82e-15	Inflammatory skin disease;
LUAD	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg18827107	chr12:86230957	RASSF9	-0.7	-13.06	-0.54	5.27e-33	Major depressive disorder;
LUAD	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg26597838	chr10:835615	NA	1.31	20.55	0.71	1.41e-65	Eosinophil percentage of granulocytes;
LUAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg09436375	chr6:42928200	GNMT	-0.29	-8.19	-0.37	3.21e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9473147	0.516	rs2151974	chr6:47515630	G/A	cg02130027	chr6:47444894	CD2AP	0.36	6.97	0.32	1.2e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs66731853	0.769	rs477679	chr1:20894618	A/G	cg04087271	chr1:20915334	CDA	0.57	9.31	0.41	7.15e-19	Mean corpuscular volume;
LUAD	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg18436788	chr1:3704244	LRRC47	0.31	6.44	0.3	3.26e-10	Red cell distribution width;
LUAD	cis	rs13064411	0.696	rs11921931	chr3:113015091	G/A	cg10517650	chr3:113235015	CCDC52	-0.42	-6.61	-0.31	1.15e-10	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7336332	0.662	rs9581862	chr13:28039993	T/G	cg22138327	chr13:27999177	GTF3A	0.77	11.02	0.47	5.19e-25	Weight;
LUAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg23131131	chr22:24373011	LOC391322	-0.52	-8.5	-0.38	3.21e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg20607287	chr7:12443886	VWDE	-0.53	-6.65	-0.31	9.19e-11	Coronary artery disease;
LUAD	cis	rs8017423	0.967	rs12589808	chr14:90719236	C/T	cg14092571	chr14:90743983	NA	0.45	7.77	0.35	6.1e-14	Mortality in heart failure;
LUAD	cis	rs3784262	0.528	rs1994926	chr15:58334587	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.25	-0.33	1.94e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.44	0.42	2.52e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg20848291	chr7:100343083	ZAN	-0.64	-10.02	-0.44	2.32e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg19318889	chr4:1322082	MAEA	0.5	6.49	0.3	2.42e-10	Recombination rate (females);
LUAD	cis	rs35883536	0.935	rs12409832	chr1:101107725	A/G	cg06223162	chr1:101003688	GPR88	0.35	6.57	0.3	1.53e-10	Monocyte count;
LUAD	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.4	-11.08	-0.47	3.11e-25	Total body bone mineral density;
LUAD	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg26597838	chr10:835615	NA	-0.68	-10.41	-0.45	9.25e-23	Eosinophil percentage of granulocytes;
LUAD	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-9.92	-0.43	5.51e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9863	0.827	rs12823740	chr12:124458002	C/A	cg17723958	chr12:124429295	CCDC92	-0.4	-6.67	-0.31	8.12e-11	White blood cell count;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg26187342	chr17:65713858	NOL11	-0.41	-6.84	-0.32	2.72e-11	Schizophrenia;
LUAD	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg27535305	chr1:53392650	SCP2	0.35	7.34	0.34	1.12e-12	Monocyte count;
LUAD	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.08e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg09526685	chr4:187126073	CYP4V2	-0.92	-9.9	-0.43	6.47e-21	Blood protein levels;
LUAD	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg13385794	chr1:248469461	NA	0.25	6.78	0.31	3.99e-11	Common traits (Other);
LUAD	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg11822812	chr5:140052017	DND1	0.37	6.45	0.3	3.11e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9911578	0.681	rs8070135	chr17:56459063	G/A	cg05425664	chr17:57184151	TRIM37	0.41	6.77	0.31	4.36e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03352830	chr11:487213	PTDSS2	0.82	10.79	0.46	3.87e-24	Body mass index;
LUAD	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg08999081	chr20:33150536	PIGU	-0.62	-13.96	-0.56	1.08e-36	Glomerular filtration rate (creatinine);
LUAD	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs4906332	1.000	rs8004501	chr14:103981662	G/A	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.08	-0.33	5.97e-12	Coronary artery disease;
LUAD	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06505273	chr16:24850292	NA	0.48	6.75	0.31	4.95e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6500395	1.000	rs1420704	chr16:48716902	C/T	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg23625390	chr15:77176239	SCAPER	0.38	6.7	0.31	6.88e-11	Blood metabolite levels;
LUAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08219700	chr8:58056026	NA	0.57	8.08	0.37	6.8e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs208515	0.560	rs207084	chr6:66776966	T/C	cg07460842	chr6:66804631	NA	-1.13	-26.39	-0.79	2.07e-91	Exhaled nitric oxide levels;
LUAD	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg13271783	chr10:134563150	INPP5A	-0.41	-7.39	-0.34	7.83e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg26384229	chr12:38710491	ALG10B	0.5	8.12	0.37	5.2e-15	Heart rate;
LUAD	cis	rs11958404	0.932	rs76601259	chr5:157430337	C/T	cg05962755	chr5:157440814	NA	0.66	8.83	0.39	2.82e-17	IgG glycosylation;
LUAD	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.45	7.81	0.35	4.66e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg14835575	chr10:16859367	RSU1	0.85	13.34	0.54	3.98e-34	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs6840360	0.615	rs4696268	chr4:152464723	G/A	cg22705602	chr4:152727874	NA	-0.37	-6.71	-0.31	6.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7584330	0.780	rs2292884	chr2:238443226	A/G	cg14458575	chr2:238380390	NA	0.61	11.46	0.49	1.11e-26	Prostate cancer;
LUAD	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.41	6.42	0.3	3.6e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.99	-0.36	1.34e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg00318621	chr2:106887213	NA	-0.49	-8.56	-0.38	2.14e-16	Facial morphology (factor 23);
LUAD	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg20503657	chr10:835505	NA	0.81	10.57	0.46	2.6e-23	Eosinophil percentage of granulocytes;
LUAD	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg16447950	chr5:562315	NA	0.43	6.96	0.32	1.28e-11	Obesity-related traits;
LUAD	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg26384229	chr12:38710491	ALG10B	0.5	8.22	0.37	2.6e-15	Heart rate;
LUAD	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.31	0.37	1.36e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg13271783	chr10:134563150	INPP5A	0.41	6.74	0.31	5.13e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg06621757	chr12:54674353	HNRPA1L-2;HNRNPA1;CBX5	0.39	6.79	0.31	3.76e-11	Bipolar disorder;
LUAD	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg18932078	chr1:2524107	MMEL1	0.37	6.89	0.32	1.98e-11	Ulcerative colitis;
LUAD	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg22117172	chr7:91764530	CYP51A1	-0.35	-7.59	-0.35	2.08e-13	Breast cancer;
LUAD	trans	rs11083241	0.570	rs7243677	chr18:25558198	C/T	cg15286784	chr20:47895175	C20orf199;SNORD12C;ZNFX1	-0.43	-7.43	-0.34	6.09e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg25358565	chr5:93447407	FAM172A	0.61	7.12	0.33	4.79e-12	Diabetic retinopathy;
LUAD	cis	rs11153730	0.503	rs283046	chr6:118627503	T/C	cg18833306	chr6:118973337	C6orf204	0.51	9.22	0.41	1.43e-18	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs7107174	0.901	rs4944199	chr11:78122779	A/G	cg19901956	chr11:77921274	USP35	-0.49	-6.65	-0.31	9.15e-11	Testicular germ cell tumor;
LUAD	cis	rs4786125	0.573	rs7201500	chr16:6897659	A/G	cg03623568	chr16:6915990	A2BP1	-0.33	-7.32	-0.34	1.23e-12	Heart rate variability traits (SDNN);
LUAD	trans	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg01620082	chr3:125678407	NA	-1.04	-10.31	-0.45	2.26e-22	Depression;
LUAD	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg02880119	chr16:3481970	NA	-0.52	-7.81	-0.35	4.57e-14	Body mass index (adult);
LUAD	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg11822812	chr5:140052017	DND1	-0.44	-8.14	-0.37	4.36e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.65	-10.39	-0.45	1.16e-22	Menarche (age at onset);
LUAD	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg21427119	chr20:30132790	HM13	-0.62	-9.46	-0.42	2.24e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs12042938	0.507	rs1765778	chr1:231732356	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.41	-7.27	-0.33	1.81e-12	Neuranatomic and neurocognitive phenotypes;
LUAD	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg03929089	chr4:120376271	NA	0.57	7.41	0.34	6.73e-13	Axial length;
LUAD	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-7.68	-0.35	1.09e-13	Total body bone mineral density;
LUAD	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg00784671	chr22:46762841	CELSR1	-0.61	-7.56	-0.34	2.55e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.62	11.0	0.47	6.4e-25	Birth weight;
LUAD	cis	rs4900538	0.787	rs11704	chr14:102808655	C/G	cg18135206	chr14:102964638	TECPR2	0.93	18.01	0.66	2.93e-54	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg18252515	chr7:66147081	NA	0.62	6.85	0.32	2.68e-11	Diabetic kidney disease;
LUAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg11416102	chr8:651193	ERICH1	0.93	8.66	0.39	1.01e-16	IgG glycosylation;
LUAD	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg13798912	chr7:905769	UNC84A	-0.58	-6.94	-0.32	1.45e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg24578937	chr1:2090814	PRKCZ	-0.55	-10.96	-0.47	8.79e-25	Height;
LUAD	cis	rs2235649	0.798	rs9932875	chr16:1848012	A/G	cg08610935	chr16:1836813	NUBP2	-0.5	-7.8	-0.35	4.87e-14	Blood metabolite levels;
LUAD	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg14092988	chr3:52407081	DNAH1	0.45	9.03	0.4	6.01e-18	Bipolar disorder;
LUAD	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.63	-11.81	-0.5	5.06e-28	Schizophrenia;
LUAD	cis	rs738322	0.753	rs2267372	chr22:38598234	A/G	cg03162506	chr22:38580953	NA	-0.32	-6.53	-0.3	1.93e-10	Cutaneous nevi;
LUAD	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg19196401	chr6:110721138	DDO	-0.47	-9.17	-0.41	2.05e-18	Platelet distribution width;
LUAD	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg12599982	chr1:44399894	ARTN	0.35	6.75	0.31	5.02e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.85	12.05	0.51	5.82e-29	Smoking behavior;
LUAD	cis	rs4692589	0.802	rs1480542	chr4:170953614	C/T	cg19918862	chr4:170955249	NA	0.33	7.53	0.34	3.1400000000000003e-13	Anxiety disorder;
LUAD	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg02951883	chr7:2050386	MAD1L1	-0.82	-13.89	-0.56	2.17e-36	Bipolar disorder and schizophrenia;
LUAD	cis	rs17095355	0.539	rs3890722	chr10:111925233	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.93	-0.36	1.97e-14	Biliary atresia;
LUAD	cis	rs7551222	0.752	rs6594016	chr1:204539462	G/A	cg20240347	chr1:204465584	NA	-0.33	-6.38	-0.3	4.6e-10	Schizophrenia;
LUAD	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.32	6.46	0.3	2.86e-10	Menopause (age at onset);
LUAD	cis	rs62025270	0.522	rs338519	chr15:86214879	T/C	cg13263323	chr15:86062960	AKAP13	0.43	6.73	0.31	5.44e-11	Idiopathic pulmonary fibrosis;
LUAD	cis	rs8014204	0.804	rs35769520	chr14:75255115	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.34	-6.45	-0.3	3.03e-10	Caffeine consumption;
LUAD	cis	rs7000551	0.689	rs2449339	chr8:22387981	G/A	cg12081754	chr8:22256438	SLC39A14	0.42	6.9	0.32	1.86e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs1003719	0.788	rs13050757	chr21:38465345	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.31e-16	Eye color traits;
LUAD	cis	rs1595825	0.891	rs7573687	chr2:198893376	A/G	cg00361562	chr2:198649771	BOLL	-0.47	-6.53	-0.3	1.84e-10	Ulcerative colitis;
LUAD	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg16701003	chr16:89028210	CBFA2T3	0.55	10.49	0.45	4.79e-23	Social autistic-like traits;
LUAD	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.68	-0.35	1.12e-13	Breast cancer;
LUAD	cis	rs1215050	0.791	rs13107606	chr4:98823187	C/A	cg05340658	chr4:99064831	C4orf37	0.47	7.82	0.36	4.17e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1395	0.571	rs114507490	chr2:27527246	T/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.46	7.75	0.35	7.07e-14	Blood metabolite levels;
LUAD	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22496380	chr5:211416	CCDC127	-1.12	-14.95	-0.59	6.8e-41	Breast cancer;
LUAD	cis	rs2282300	0.739	rs7942129	chr11:30224692	G/A	cg06241208	chr11:30344200	C11orf46	-0.56	-7.34	-0.34	1.13e-12	Morning vs. evening chronotype;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg01854420	chr3:99536702	MIR548G;C3orf26	-0.34	-6.77	-0.31	4.4e-11	Schizophrenia;
LUAD	trans	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg04995722	chr7:26192034	NFE2L3	0.41	7.05	0.32	7.18e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg22482690	chr17:47019901	SNF8	0.44	8.39	0.38	7.54e-16	Type 2 diabetes;
LUAD	cis	rs55665837	1.000	rs3923294	chr11:14441402	T/G	cg19336497	chr11:14380999	RRAS2	-0.51	-10.27	-0.45	3.17e-22	Vitamin D levels;
LUAD	cis	rs250585	1.000	rs538023	chr16:23462501	G/A	cg00143387	chr16:23521605	GGA2	0.67	8.0	0.36	1.17e-14	Egg allergy;
LUAD	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg26850624	chr5:429559	AHRR	-0.42	-6.65	-0.31	9.24e-11	Cystic fibrosis severity;
LUAD	trans	rs3960554	0.800	rs112463197	chr7:75622912	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	10.95	0.47	9.48e-25	Eotaxin levels;
LUAD	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg25809561	chr17:30822961	MYO1D	0.49	8.96	0.4	1.08e-17	Schizophrenia;
LUAD	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg02269571	chr22:50332266	NA	0.58	8.56	0.38	2.13e-16	Schizophrenia;
LUAD	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.61	0.31	1.19e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs17362650	0.694	rs4496315	chr2:9568445	G/A	cg12832956	chr2:9616023	IAH1	-0.5	-8.64	-0.39	1.13e-16	Alcohol dependence (age at onset);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24059404	chr4:184580366	C4orf41;RWDD4A	-0.41	-6.82	-0.31	3.22e-11	Cancer;
LUAD	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg07389463	chr12:132296394	NA	0.49	8.8	0.39	3.54e-17	Migraine;
LUAD	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg05342682	chr7:94953680	PON1	-0.48	-6.46	-0.3	2.87e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg20135002	chr11:47629003	NA	-0.41	-7.18	-0.33	3.08e-12	Subjective well-being;
LUAD	cis	rs4604732	0.631	rs76761880	chr1:247626377	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg09796270	chr17:17721594	SREBF1	0.38	7.56	0.34	2.61e-13	Total body bone mineral density;
LUAD	cis	rs6835098	1.000	rs4561909	chr4:174086937	A/T	cg27433088	chr4:174089019	GALNT7	0.4	7.39	0.34	7.7e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg19610905	chr11:61596333	FADS2	-0.63	-10.03	-0.44	2.23e-21	Trans fatty acid levels;
LUAD	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg05754148	chr16:3507555	NAT15	0.68	11.08	0.47	3.09e-25	Tuberculosis;
LUAD	trans	rs7395662	1.000	rs7949554	chr11:48581992	C/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.76e-10	HDL cholesterol;
LUAD	cis	rs9902453	0.765	rs2874505	chr17:28037923	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	10.26	0.45	3.26e-22	Coffee consumption (cups per day);
LUAD	cis	rs1137	0.857	rs205637	chr2:74951106	C/T	cg19285774	chr2:74907978	SEMA4F	-0.35	-6.67	-0.31	7.79e-11	Myopia (pathological);
LUAD	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.35	6.73	0.31	5.7e-11	Lung cancer in ever smokers;
LUAD	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg23109721	chr2:106886537	NA	-0.62	-10.15	-0.44	8.11e-22	Facial morphology (factor 23);
LUAD	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg06547715	chr2:218990976	CXCR2	0.28	6.66	0.31	8.71e-11	Colorectal cancer;
LUAD	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg14895029	chr7:2775587	GNA12	0.44	7.33	0.34	1.19e-12	Height;
LUAD	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg05368731	chr17:41323189	NBR1	0.86	13.58	0.55	4e-35	Menopause (age at onset);
LUAD	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg13319975	chr6:146136371	FBXO30	-0.58	-9.77	-0.43	1.88e-20	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg07817883	chr1:32538562	TMEM39B	-0.54	-7.46	-0.34	4.98e-13	Monocyte percentage of white cells;
LUAD	cis	rs4285028	0.948	rs71329247	chr3:121681523	C/T	cg11130432	chr3:121712080	ILDR1	-0.61	-8.53	-0.38	2.59e-16	Multiple sclerosis;
LUAD	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg04727924	chr7:799746	HEATR2	-0.59	-7.47	-0.34	4.6e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg18490616	chr2:88469792	THNSL2	0.8	8.39	0.38	7.12e-16	Plasma clusterin levels;
LUAD	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21659725	chr3:3221576	CRBN	-0.61	-9.76	-0.43	2.03e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs8017423	0.904	rs11621127	chr14:90802050	G/A	cg14092571	chr14:90743983	NA	0.47	8.28	0.37	1.67e-15	Mortality in heart failure;
LUAD	trans	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	13.08	0.54	4.68e-33	Exhaled nitric oxide output;
LUAD	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg18854424	chr1:2615690	NA	0.43	9.54	0.42	1.14e-19	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg09640425	chr7:158790006	NA	-0.46	-7.84	-0.36	3.63e-14	Facial morphology (factor 20);
LUAD	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg17105886	chr17:28927953	LRRC37B2	0.65	7.6	0.35	1.95e-13	Body mass index;
LUAD	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-9.12	-0.41	3.17e-18	Life satisfaction;
LUAD	cis	rs62238980	0.521	rs733907	chr22:32462564	T/C	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs9633740	1.000	rs9633740	chr10:82265271	A/G	cg00277334	chr10:82204260	NA	-0.65	-8.9	-0.4	1.67e-17	Post bronchodilator FEV1;
LUAD	cis	rs9633740	1.000	rs10749609	chr10:82249752	G/A	cg00277334	chr10:82204260	NA	-0.58	-8.08	-0.37	6.87e-15	Post bronchodilator FEV1;
LUAD	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg21963583	chr11:68658836	MRPL21	-0.62	-11.05	-0.47	4.04e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7737355	1.000	rs9327608	chr5:130650134	G/A	cg06307176	chr5:131281290	NA	0.46	7.29	0.33	1.52e-12	Life satisfaction;
LUAD	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg02527881	chr3:46936655	PTH1R	-0.73	-17.67	-0.65	9.42e-53	Birth weight;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21594567	chr8:146228379	ZNF252;C8orf77	-0.54	-6.5	-0.3	2.27e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg00383909	chr3:49044727	WDR6	-0.89	-9.52	-0.42	1.38e-19	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs9584850	0.834	rs3783005	chr13:99111337	A/T	cg17380943	chr13:99100506	FARP1	0.34	6.59	0.31	1.27e-10	Neuroticism;
LUAD	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg17063962	chr7:91808500	NA	-0.61	-10.49	-0.45	4.95e-23	Breast cancer;
LUAD	cis	rs55788414	0.505	rs7190949	chr16:81189583	C/T	cg06400318	chr16:81190750	PKD1L2	0.59	9.04	0.4	5.85e-18	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.63	11.83	0.5	4.16e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2996428	0.561	rs2275827	chr1:3746585	T/G	cg17443473	chr1:3703550	LRRC47	0.44	7.54	0.34	2.95e-13	Red cell distribution width;
LUAD	cis	rs16910800	0.731	rs55908012	chr11:23191640	G/A	cg20040320	chr11:23191996	NA	-0.73	-9.89	-0.43	7.04e-21	Cancer;
LUAD	cis	rs1371867	0.810	rs3020182	chr8:101233008	T/C	cg06636551	chr8:101224915	SPAG1	0.41	7.37	0.34	9.22e-13	Atrioventricular conduction;
LUAD	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.25	0.37	2.07e-15	Breast cancer;
LUAD	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg24579218	chr15:68104479	NA	-0.56	-9.74	-0.43	2.35e-20	Restless legs syndrome;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02289200	chr1:156085197	LMNA	-0.42	-7.07	-0.33	6.36e-12	Cancer;
LUAD	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg18351406	chr4:77819688	ANKRD56	0.63	10.07	0.44	1.6e-21	Emphysema distribution in smoking;
LUAD	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	9.83	0.43	1.13e-20	Lymphocyte percentage of white cells;
LUAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.55	-9.66	-0.43	4.27e-20	Longevity;Endometriosis;
LUAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg03354898	chr7:1950403	MAD1L1	0.43	8.18	0.37	3.34e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs1190545	0.588	rs4906213	chr14:102991021	C/T	cg18135206	chr14:102964638	TECPR2	0.48	7.34	0.34	1.11e-12	Platelet count;
LUAD	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg03289416	chr15:75166202	SCAMP2	0.42	7.13	0.33	4.51e-12	Caffeine consumption;
LUAD	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg03676636	chr4:99064102	C4orf37	0.29	6.94	0.32	1.5e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9581857	0.615	rs3759435	chr13:27996813	T/G	cg22138327	chr13:27999177	GTF3A	0.95	12.7	0.53	1.63e-31	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg10560079	chr2:191398806	TMEM194B	0.46	8.32	0.37	1.27e-15	Pulse pressure;
LUAD	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1829883	1.000	rs2461971	chr5:98777650	A/G	cg08333243	chr5:99726346	NA	-0.36	-7.02	-0.32	8.83e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9868809	0.772	rs9812977	chr3:48720303	G/A	cg00383909	chr3:49044727	WDR6	0.81	8.38	0.38	7.63e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.1	-0.57	2.78e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-6.49	-0.3	2.47e-10	Height;
LUAD	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg13263323	chr15:86062960	AKAP13	-0.45	-7.46	-0.34	5e-13	Coronary artery disease;
LUAD	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg00802000	chr16:706648	WDR90	-0.43	-6.83	-0.32	2.99e-11	Height;
LUAD	trans	rs1973993	0.708	rs6593605	chr1:96956775	A/G	cg10631902	chr5:14652156	NA	-0.48	-8.12	-0.37	5.01e-15	Weight;
LUAD	cis	rs3784262	0.669	rs1061278	chr15:58246029	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.34	-0.34	1.12e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.45	0.55	1.38e-34	Prudent dietary pattern;
LUAD	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg07636037	chr3:49044803	WDR6	0.5	8.28	0.37	1.68e-15	Menarche (age at onset);
LUAD	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg18230493	chr5:56204884	C5orf35	0.42	7.11	0.33	4.95e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs2224391	0.704	rs17139985	chr6:5261603	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-9.76	-0.43	2.05e-20	Height;
LUAD	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.38e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2732480	0.577	rs1489108	chr12:48738781	G/A	cg04545296	chr12:48745243	ZNF641	0.38	9.55	0.42	1.07e-19	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg06608945	chr2:219082296	ARPC2	0.5	8.63	0.39	1.25e-16	Colorectal cancer;
LUAD	cis	rs877282	0.891	rs11253393	chr10:788824	G/T	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg00933542	chr6:150070202	PCMT1	0.43	9.07	0.4	4.64e-18	Lung cancer;
LUAD	cis	rs17152411	0.895	rs7906592	chr10:126627861	C/G	cg07906193	chr10:126599966	NA	0.56	7.84	0.36	3.69e-14	Height;
LUAD	cis	rs4604732	0.527	rs79329288	chr1:247626513	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg10755058	chr3:40428713	ENTPD3	0.39	7.13	0.33	4.36e-12	Renal cell carcinoma;
LUAD	cis	rs59918340	1.000	rs59918340	chr8:142232256	A/G	cg23750338	chr8:142222470	SLC45A4	0.43	9.08	0.4	4.27e-18	Immature fraction of reticulocytes;
LUAD	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg19041857	chr6:27730383	NA	-0.43	-7.36	-0.34	9.93e-13	Parkinson's disease;
LUAD	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg15145296	chr3:125709740	NA	-0.52	-6.4	-0.3	4.24e-10	Blood pressure (smoking interaction);
LUAD	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg02038168	chr22:39784481	NA	-0.6	-10.94	-0.47	1.08e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs9323205	0.765	rs2999387	chr14:51652986	C/G	cg23942311	chr14:51606299	NA	-0.53	-9.65	-0.42	4.96e-20	Cancer;
LUAD	cis	rs74181299	0.784	rs2723082	chr2:65289623	C/T	cg05010058	chr2:65284262	CEP68	0.3	6.62	0.31	1.06e-10	Pulse pressure;
LUAD	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg25173405	chr17:45401733	C17orf57	-0.53	-8.98	-0.4	8.99e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg07917127	chr4:99064746	C4orf37	0.43	6.5	0.3	2.26e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg26354017	chr1:205819088	PM20D1	0.92	21.65	0.73	1.64e-70	Menarche (age at onset);
LUAD	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.35	-0.45	1.56e-22	Monocyte percentage of white cells;
LUAD	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg07930192	chr7:1003750	NA	0.36	6.87	0.32	2.34e-11	Longevity;Endometriosis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01379158	chr17:17206552	NT5M	-0.45	-7.07	-0.33	6.45e-12	Height;
LUAD	cis	rs12545109	0.842	rs2609975	chr8:57401667	T/C	cg19413350	chr8:57351067	NA	-0.43	-6.58	-0.3	1.38e-10	Obesity-related traits;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg12362060	chr15:41575950	LOC729082	-0.4	-6.61	-0.31	1.17e-10	Subcortical brain region volumes;
LUAD	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg11189052	chr15:85197271	WDR73	0.61	8.11	0.37	5.68e-15	Schizophrenia;
LUAD	cis	rs600231	0.571	rs10896000	chr11:65218018	A/G	cg21890820	chr11:65308645	LTBP3	0.46	7.11	0.33	5.06e-12	Bone mineral density;
LUAD	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg26769984	chr7:1090371	C7orf50	0.58	9.5	0.42	1.52e-19	Bronchopulmonary dysplasia;
LUAD	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg12623918	chr2:306882	NA	0.34	6.88	0.32	2.14e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs10504073	0.584	rs1511365	chr8:49975321	A/T	cg00325661	chr8:49890786	NA	0.48	10.57	0.46	2.59e-23	Blood metabolite ratios;
LUAD	cis	rs6545883	0.868	rs7574631	chr2:61825142	T/G	cg15711740	chr2:61764176	XPO1	-0.42	-6.58	-0.3	1.43e-10	Tuberculosis;
LUAD	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg25811766	chr13:21894605	NA	-0.62	-7.35	-0.34	1.04e-12	White matter hyperintensity burden;
LUAD	cis	rs73198271	0.653	rs10087633	chr8:8660444	A/G	cg01851573	chr8:8652454	MFHAS1	0.46	8.19	0.37	3.1e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg00745463	chr17:30367425	LRRC37B	-0.82	-9.78	-0.43	1.75e-20	Hip circumference adjusted for BMI;
LUAD	cis	rs11677416	1.000	rs2856837	chr2:113541925	G/A	cg27083787	chr2:113543245	IL1A	0.4	6.78	0.31	3.96e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs2806561	0.929	rs6669568	chr1:23540469	G/A	cg12483005	chr1:23474871	LUZP1	-0.38	-6.39	-0.3	4.28e-10	Height;
LUAD	cis	rs4692589	1.000	rs17546378	chr4:170935854	G/A	cg19918862	chr4:170955249	NA	0.29	6.95	0.32	1.36e-11	Anxiety disorder;
LUAD	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.54	7.37	0.34	8.77e-13	Platelet count;
LUAD	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg10018233	chr7:150070692	REPIN1	0.49	7.66	0.35	1.27e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs929596	0.597	rs10173355	chr2:234597321	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.64	-10.88	-0.47	1.78e-24	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg26343298	chr8:95960752	TP53INP1	0.38	8.08	0.37	7.06e-15	Type 2 diabetes;
LUAD	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg27494647	chr7:150038898	RARRES2	0.5	8.61	0.39	1.48e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs889398	0.771	rs8048550	chr16:69891759	T/G	cg00738113	chr16:70207722	CLEC18C	-0.35	-6.89	-0.32	2.02e-11	Body mass index;
LUAD	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg23933602	chr10:16859644	RSU1	0.61	8.31	0.37	1.34e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs62064224	0.589	rs2041306	chr17:30665675	T/C	cg18200150	chr17:30822561	MYO1D	0.42	7.55	0.34	2.7e-13	Schizophrenia;
LUAD	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.56	0.3	1.55e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg14092988	chr3:52407081	DNAH1	0.45	9.04	0.4	5.62e-18	Bipolar disorder;
LUAD	trans	rs459571	0.920	rs460154	chr9:136909309	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.62	-9.21	-0.41	1.51e-18	Platelet distribution width;
LUAD	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg10909506	chr17:38081995	ORMDL3	0.39	6.72	0.31	5.84e-11	Self-reported allergy;
LUAD	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg02018176	chr4:1364513	KIAA1530	0.48	9.13	0.41	2.89e-18	Longevity;
LUAD	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-6.91	-0.32	1.84e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg21475434	chr5:93447410	FAM172A	-0.57	-7.54	-0.34	2.82e-13	Diabetic retinopathy;
LUAD	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.74	0.43	2.28e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg14784868	chr12:69753453	YEATS4	0.45	7.38	0.34	8.38e-13	Blood protein levels;
LUAD	trans	rs7181230	0.922	rs4924410	chr15:40339494	A/C	cg22705835	chr10:65332833	REEP3	0.34	6.47	0.3	2.71e-10	Dehydroepiandrosterone sulphate levels;
LUAD	cis	rs6445967	0.530	rs12631656	chr3:58409063	T/C	cg23715586	chr3:58305044	RPP14	0.41	6.75	0.31	4.8e-11	Platelet count;
LUAD	cis	rs4711350	1.000	rs10947436	chr6:33739960	A/G	cg18005901	chr6:33739558	LEMD2	-0.52	-7.61	-0.35	1.84e-13	Schizophrenia;
LUAD	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg21385522	chr1:16154831	NA	-0.63	-11.3	-0.48	4.67e-26	Dilated cardiomyopathy;
LUAD	cis	rs17154702	0.506	rs74525088	chr8:8628413	A/T	cg01851573	chr8:8652454	MFHAS1	0.55	7.46	0.34	4.82e-13	Neurocognitive impairment in HIV-1 infection (continuous);
LUAD	cis	rs6761276	0.868	rs12468224	chr2:113834434	G/C	cg02343335	chr2:113785852	IL1F8	-0.35	-7.01	-0.32	9.57e-12	Protein quantitative trait loci;
LUAD	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07266350	chr3:49460521	AMT;NICN1	0.38	6.63	0.31	1.02e-10	Menarche (age at onset);
LUAD	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg24596788	chr1:163392923	NA	-0.35	-7.47	-0.34	4.6e-13	Motion sickness;
LUAD	cis	rs9296092	0.538	rs78061112	chr6:33526587	T/G	cg13560919	chr6:33536144	NA	-0.9	-16.72	-0.63	1.49e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg08219700	chr8:58056026	NA	0.41	6.39	0.3	4.44e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	8.18	0.37	3.24e-15	Tonsillectomy;
LUAD	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg02734326	chr4:10020555	SLC2A9	0.54	9.63	0.42	5.62e-20	Bone mineral density;
LUAD	cis	rs829880	0.558	rs249821	chr12:98897811	T/C	cg25150519	chr12:98850993	NA	0.42	6.8	0.31	3.61e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.4	6.55	0.3	1.71e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg13535736	chr9:111863775	C9orf5	-0.43	-6.58	-0.3	1.41e-10	Menarche (age at onset);
LUAD	trans	rs7939886	0.920	rs17149859	chr11:55795356	G/A	cg15704280	chr7:45808275	SEPT13	0.67	6.51	0.3	2.08e-10	Myopia (pathological);
LUAD	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg10755058	chr3:40428713	ENTPD3	-0.4	-7.79	-0.35	5.31e-14	Renal cell carcinoma;
LUAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg22535103	chr8:58192502	C8orf71	-0.59	-6.91	-0.32	1.77e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs62400317	0.859	rs10456122	chr6:45163057	C/G	cg18551225	chr6:44695536	NA	-0.55	-8.43	-0.38	5.56e-16	Total body bone mineral density;
LUAD	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg06623918	chr6:96969491	KIAA0776	0.7	10.13	0.44	9.56e-22	Migraine;Coronary artery disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12738264	chr7:148725795	PDIA4	-0.41	-6.36	-0.3	5.38e-10	Height;
LUAD	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg14834391	chr1:2537342	MMEL1	0.31	6.4	0.3	4.1e-10	Ulcerative colitis;
LUAD	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg15208524	chr1:10270712	KIF1B	0.43	6.49	0.3	2.44e-10	Hepatocellular carcinoma;
LUAD	cis	rs6808694	0.568	rs17006711	chr3:20228005	C/T	cg00235661	chr3:20228976	SGOL1	0.45	7.4	0.34	7.59e-13	Ischemic stroke;
LUAD	cis	rs295140	0.506	rs295136	chr2:201141002	G/C	cg17644776	chr2:200775616	C2orf69	0.39	6.53	0.3	1.88e-10	QT interval;
LUAD	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs3820068	0.705	rs4646087	chr1:15822404	A/G	cg13390004	chr1:15929781	NA	0.4	6.41	0.3	3.8e-10	Systolic blood pressure;
LUAD	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.57e-13	Tonsillectomy;
LUAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg06453172	chr10:134556979	INPP5A	-0.77	-10.93	-0.47	1.16e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01585723	chr16:33734837	NA	0.36	6.69	0.31	7.3e-11	Menopause (age at onset);
LUAD	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg24558204	chr6:135376177	HBS1L	0.49	8.33	0.38	1.11e-15	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.87	-0.36	3.09e-14	Total body bone mineral density;
LUAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg14789911	chr21:47582049	C21orf56	-0.49	-8.72	-0.39	6.36e-17	Testicular germ cell tumor;
LUAD	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg10876282	chr6:28092338	ZSCAN16	0.47	7.42	0.34	6.4e-13	Cardiac Troponin-T levels;
LUAD	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg04369109	chr6:150039330	LATS1	-0.44	-7.11	-0.33	4.97e-12	Lung cancer;
LUAD	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg07169764	chr2:136633963	MCM6	0.66	8.13	0.37	4.81e-15	Corneal structure;
LUAD	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg01528321	chr10:82214614	TSPAN14	0.7	10.74	0.46	5.95e-24	Post bronchodilator FEV1;
LUAD	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg04117972	chr1:227635322	NA	0.65	6.6	0.31	1.24e-10	Major depressive disorder;
LUAD	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg24531977	chr5:56204891	C5orf35	-0.58	-9.26	-0.41	1.05e-18	Coronary artery disease;
LUAD	cis	rs829883	0.659	rs12366275	chr12:98920276	G/C	cg25150519	chr12:98850993	NA	-0.52	-8.14	-0.37	4.49e-15	Colorectal adenoma (advanced);
LUAD	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg10589385	chr1:150898437	SETDB1	0.41	7.69	0.35	1.06e-13	Melanoma;
LUAD	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.34e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs240764	0.817	rs239207	chr6:101137765	A/C	cg09795085	chr6:101329169	ASCC3	0.45	7.86	0.36	3.22e-14	Neuroticism;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22833807	chr22:36925177	EIF3D	-0.43	-6.58	-0.3	1.43e-10	Height;
LUAD	cis	rs236352	0.576	rs6914008	chr6:36853037	T/A	cg10099585	chr6:36853529	C6orf89	-0.39	-6.36	-0.3	5.35e-10	Heart rate;
LUAD	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg04414720	chr1:150670196	GOLPH3L	0.73	13.63	0.55	2.53e-35	Tonsillectomy;
LUAD	cis	rs3743104	0.534	rs11854391	chr15:33022582	A/T	cg07179000	chr15:33023586	GREM1	-0.37	-6.75	-0.31	4.94e-11	Hypospadias;
LUAD	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg17063962	chr7:91808500	NA	-0.68	-12.1	-0.51	3.7e-29	Breast cancer;
LUAD	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	9.24	0.41	1.22e-18	Colorectal cancer;
LUAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg26354017	chr1:205819088	PM20D1	0.81	17.06	0.64	5.12e-50	Menarche (age at onset);
LUAD	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg05340658	chr4:99064831	C4orf37	0.42	7.11	0.33	4.84e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg27572855	chr1:25598939	RHD	0.55	11.75	0.5	8.88e-28	Erythrocyte sedimentation rate;
LUAD	cis	rs4435501	1.000	rs4435501	chr2:96981369	G/T	cg23100626	chr2:96804247	ASTL	-0.44	-6.44	-0.3	3.25e-10	Major depressive disorder;
LUAD	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11890956	chr21:40555474	PSMG1	0.78	13.22	0.54	1.22e-33	Cognitive function;
LUAD	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg11530693	chr1:120165357	ZNF697	0.86	18.58	0.67	9.09e-57	Systemic lupus erythematosus;
LUAD	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.44	-0.3	3.26e-10	Morning vs. evening chronotype;
LUAD	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg01657329	chr11:68192670	LRP5	-0.41	-6.56	-0.3	1.58e-10	Total body bone mineral density;
LUAD	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg12179176	chr11:130786555	SNX19	-0.45	-7.25	-0.33	2.01e-12	Schizophrenia;
LUAD	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg14345882	chr6:26364793	BTN3A2	0.7	7.1	0.33	5.18e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg02951883	chr7:2050386	MAD1L1	-0.76	-13.16	-0.54	2.07e-33	Bipolar disorder and schizophrenia;
LUAD	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg12863693	chr15:85201151	NMB	0.42	7.7	0.35	9.43e-14	Schizophrenia;
LUAD	cis	rs17401966	1.000	rs17401924	chr1:10384439	A/G	cg15208524	chr1:10270712	KIF1B	0.54	7.97	0.36	1.48e-14	Hepatocellular carcinoma;
LUAD	cis	rs9469913	0.740	rs2814977	chr6:34576433	G/A	cg14254433	chr6:34482411	PACSIN1	-0.43	-6.67	-0.31	7.91e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg18876405	chr7:65276391	NA	0.4	6.36	0.3	5.4e-10	Aortic root size;
LUAD	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg04398451	chr17:18023971	MYO15A	-0.63	-11.45	-0.49	1.22e-26	Total body bone mineral density;
LUAD	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg21775007	chr8:11205619	TDH	-0.51	-9.17	-0.41	2.04e-18	Retinal vascular caliber;
LUAD	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg01097406	chr16:89675127	NA	0.45	9.66	0.43	4.31e-20	Vitiligo;
LUAD	cis	rs6594713	0.921	rs7725712	chr5:112744642	T/C	cg12552261	chr5:112820674	MCC	0.55	8.56	0.38	2.09e-16	Brain cytoarchitecture;
LUAD	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.34	-9.22	-0.41	1.38e-18	Total body bone mineral density;
LUAD	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg03929089	chr4:120376271	NA	0.55	7.21	0.33	2.53e-12	Axial length;
LUAD	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg00277334	chr10:82204260	NA	-0.96	-23.14	-0.75	3.96e-77	Post bronchodilator FEV1;
LUAD	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06022373	chr22:39101656	GTPBP1	0.46	7.3	0.33	1.43e-12	Menopause (age at onset);
LUAD	cis	rs6964587	0.708	rs38800	chr7:92046191	C/G	cg17063962	chr7:91808500	NA	-0.59	-9.29	-0.41	7.93e-19	Breast cancer;
LUAD	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.78	10.68	0.46	9.83e-24	Smoking behavior;
LUAD	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22496380	chr5:211416	CCDC127	-0.94	-13.19	-0.54	1.7e-33	Breast cancer;
LUAD	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4812048	0.696	rs6070694	chr20:57591126	G/A	cg14073986	chr20:57617431	SLMO2	0.86	9.48	0.42	1.78e-19	Mean platelet volume;
LUAD	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.53	-0.3	1.87e-10	Total body bone mineral density;
LUAD	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg16325326	chr1:53192061	ZYG11B	-0.67	-12.26	-0.51	8.9e-30	Monocyte count;
LUAD	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg02228675	chr17:40259724	DHX58	-0.45	-7.41	-0.34	7.15e-13	Fibrinogen levels;
LUAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg10411590	chr13:21900810	NA	0.46	7.49	0.34	4.11e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs2581828	0.656	rs2581786	chr3:53126143	G/A	cg24530246	chr3:53118167	NA	0.3	6.55	0.3	1.63e-10	Crohn's disease;
LUAD	cis	rs877282	0.891	rs11253355	chr10:768367	C/G	cg06581033	chr10:766294	NA	-0.62	-8.37	-0.38	8.8e-16	Uric acid levels;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg04228104	chr1:150551925	MCL1	-0.47	-6.48	-0.3	2.51e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg26597838	chr10:835615	NA	0.83	11.24	0.48	8.04e-26	Eosinophil percentage of granulocytes;
LUAD	cis	rs9796	0.553	rs1869908	chr15:41257224	C/A	cg18705301	chr15:41695430	NDUFAF1	0.52	9.52	0.42	1.34e-19	Menopause (age at onset);
LUAD	cis	rs4971059	0.507	rs11264321	chr1:155085898	C/A	cg23973274	chr1:155060172	NA	-0.46	-7.94	-0.36	1.78e-14	Breast cancer;
LUAD	trans	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg23815491	chr16:72088622	HP	-0.53	-9.79	-0.43	1.53e-20	Fibrinogen levels;
LUAD	trans	rs1997103	1.000	rs2177803	chr7:55410773	A/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg03806693	chr22:41940476	POLR3H	-0.81	-11.46	-0.49	1.15e-26	Vitiligo;
LUAD	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06544989	chr22:39130855	UNC84B	0.44	8.16	0.37	3.77e-15	Menopause (age at onset);
LUAD	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.42	-0.38	5.93e-16	Total cholesterol levels;
LUAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.84	0.43	1.07e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05901451	chr6:126070800	HEY2	-0.84	-16.01	-0.61	1.89e-45	Brugada syndrome;
LUAD	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.94	0.36	1.86e-14	Morning vs. evening chronotype;
LUAD	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	9.63	0.42	5.79e-20	Electrocardiographic conduction measures;
LUAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg18621852	chr3:10150065	C3orf24	0.42	7.5	0.34	3.87e-13	Alzheimer's disease;
LUAD	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.74	-13.62	-0.55	2.73e-35	Menarche (age at onset);
LUAD	cis	rs8060686	0.623	rs6499162	chr16:68239460	T/C	cg09835421	chr16:68378352	PRMT7	-0.51	-6.44	-0.3	3.26e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	12.46	0.52	1.37e-30	Bone mineral density;
LUAD	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs714027	1.000	rs5763767	chr22:30493882	G/A	cg11564601	chr22:30592435	NA	-0.4	-8.76	-0.39	4.85e-17	Lymphocyte counts;
LUAD	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.71	0.35	9.15e-14	Breast cancer;
LUAD	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg23029597	chr12:123009494	RSRC2	-0.51	-7.87	-0.36	3.05e-14	Body mass index;
LUAD	cis	rs807669	0.868	rs2800973	chr22:19168616	A/G	cg24911827	chr22:19170109	CLTCL1	0.49	10.13	0.44	9.59e-22	Metabolite levels;
LUAD	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg11822812	chr5:140052017	DND1	-0.41	-7.48	-0.34	4.24e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg15117754	chr3:10150083	C3orf24	0.44	7.13	0.33	4.51e-12	Alzheimer's disease;
LUAD	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg14416269	chr4:6271139	WFS1	0.62	10.74	0.46	5.98e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs62238980	0.614	rs17683704	chr22:32506041	A/G	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg26587870	chr6:27730563	NA	-0.53	-8.07	-0.37	7.35e-15	Breast cancer;
LUAD	cis	rs10392	0.543	rs2867240	chr20:37538354	C/T	cg27552599	chr20:37590471	DHX35	0.39	6.73	0.31	5.45e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-9.17	-0.41	2.03e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs356992	0.957	rs356993	chr2:60750560	C/T	cg08426369	chr2:60753602	BCL11A	-0.47	-7.99	-0.36	1.34e-14	Educational attainment (years of education);
LUAD	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg12062639	chr20:23401060	NAPB	1.1	11.43	0.49	1.54e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg03806693	chr22:41940476	POLR3H	-0.53	-7.99	-0.36	1.25e-14	Vitiligo;
LUAD	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg15704280	chr7:45808275	SEPT13	-0.65	-9.96	-0.44	3.97e-21	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg22920501	chr2:26401640	FAM59B	-0.64	-9.29	-0.41	8e-19	Gut microbiome composition (summer);
LUAD	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg02428538	chr16:24856791	SLC5A11	-0.56	-7.55	-0.34	2.79e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.46e-11	Parkinson's disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07907534	chr15:75745703	SIN3A	-0.41	-6.74	-0.31	5.29e-11	Cancer;
LUAD	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4906332	1.000	rs35771849	chr14:103981942	A/G	cg13511324	chr14:104056883	C14orf153	0.26	6.55	0.3	1.67e-10	Coronary artery disease;
LUAD	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg22875332	chr1:76189707	ACADM	0.89	18.16	0.66	6.95e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.66	-0.35	1.26e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg21775007	chr8:11205619	TDH	0.47	8.49	0.38	3.66e-16	Retinal vascular caliber;
LUAD	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg23029597	chr12:123009494	RSRC2	-0.56	-8.95	-0.4	1.13e-17	Body mass index;
LUAD	cis	rs7759001	0.857	rs4455661	chr6:27373130	C/T	cg18711553	chr6:27366782	ZNF391	-0.39	-6.47	-0.3	2.78e-10	Glomerular filtration rate (creatinine);
LUAD	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg18944383	chr4:111397179	ENPEP	0.4	7.66	0.35	1.3e-13	Height;
LUAD	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.21	-0.48	1.07e-25	Type 2 diabetes;
LUAD	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg19875535	chr5:140030758	IK	-0.41	-6.83	-0.32	2.99e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs13315871	0.929	rs9857333	chr3:58293551	G/C	cg12435725	chr3:58293450	RPP14	-0.75	-8.52	-0.38	2.81e-16	Cholesterol, total;
LUAD	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.53	-0.3	1.92e-10	Prostate cancer;
LUAD	cis	rs8008758	1.000	rs12435364	chr14:101690209	G/A	cg26224664	chr14:101693935	NA	-0.37	-7.54	-0.34	2.84e-13	Body mass index (alcohol intake interaction);
LUAD	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg18129178	chr5:148520854	ABLIM3	-0.63	-9.66	-0.42	4.55e-20	Breast cancer;
LUAD	cis	rs5758265	1	rs5758265	chr22:41617897	G/A	cg13813247	chr22:41461852	NA	-0.39	-6.44	-0.3	3.29e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg24644049	chr4:85504048	CDS1	0.92	7.94	0.36	1.78e-14	Skin colour saturation;
LUAD	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg14835575	chr10:16859367	RSU1	0.49	7.6	0.35	1.89e-13	Platelet distribution width;
LUAD	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg19761014	chr17:28927070	LRRC37B2	0.94	9.4	0.42	3.59e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6906287	0.625	rs7764280	chr6:118692514	A/G	cg18833306	chr6:118973337	C6orf204	0.53	9.89	0.43	7.2e-21	Electrocardiographic conduction measures;
LUAD	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg23018236	chr17:30244563	NA	0.48	6.62	0.31	1.11e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.42	6.57	0.3	1.52e-10	Alzheimer's disease (late onset);
LUAD	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.5	-0.3	2.31e-10	Breast cancer;
LUAD	cis	rs250677	0.522	rs4431331	chr5:148353574	A/C	cg18129178	chr5:148520854	ABLIM3	-0.5	-7.49	-0.34	4.11e-13	Breast cancer;
LUAD	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg00321850	chr1:175162397	KIAA0040	0.55	11.7	0.49	1.38e-27	Diastolic blood pressure;
LUAD	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg13390004	chr1:15929781	NA	0.49	8.58	0.39	1.77e-16	Systolic blood pressure;
LUAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03647317	chr4:187891568	NA	-0.34	-6.39	-0.3	4.39e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg12856521	chr11:46389249	DGKZ	-0.46	-7.71	-0.35	9.24e-14	Leprosy;
LUAD	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.73	-0.39	6.11e-17	Alzheimer's disease (late onset);
LUAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg08888203	chr3:10149979	C3orf24	0.63	10.75	0.46	5.31e-24	Alzheimer's disease;
LUAD	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg15962314	chr1:44399869	ARTN	0.3	6.87	0.32	2.36e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg05313129	chr8:58192883	C8orf71	-0.57	-8.41	-0.38	6.38e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.44	0.3	3.28e-10	Depression;
LUAD	trans	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.38	-0.38	7.69e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.72	-0.61	3.57e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs986417	0.901	rs4901989	chr14:61014743	G/C	cg27398547	chr14:60952738	C14orf39	0.66	7.65	0.35	1.38e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg06740227	chr12:86229804	RASSF9	0.45	7.73	0.35	7.89e-14	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg07917127	chr4:99064746	C4orf37	0.4	6.56	0.3	1.54e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35306767	0.579	rs7091502	chr10:1154979	C/T	cg20503657	chr10:835505	NA	0.69	8.6	0.39	1.55e-16	Eosinophil percentage of granulocytes;
LUAD	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23158103	chr7:148848205	ZNF398	-0.65	-12.35	-0.51	3.78e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg25358565	chr5:93447407	FAM172A	0.63	7.71	0.35	8.8e-14	Diabetic retinopathy;
LUAD	trans	rs10411161	0.702	rs7251571	chr19:52389057	A/G	cg22319618	chr22:45562946	NUP50	-0.62	-9.05	-0.4	5.42e-18	Breast cancer;
LUAD	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg02807482	chr3:125708958	NA	-0.66	-8.76	-0.39	4.84e-17	Blood pressure (smoking interaction);
LUAD	trans	rs1464500	0.584	rs7298723	chr12:24408228	T/C	cg10556349	chr10:835070	NA	-0.48	-6.52	-0.3	1.99e-10	Juvenile osteochondritis dissecans;Response to antipsychotic treatment;
LUAD	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg04756594	chr16:24857601	SLC5A11	0.73	11.78	0.5	6.9e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg08632164	chr7:65971372	NA	-0.38	-6.51	-0.3	2.16e-10	Aortic root size;
LUAD	cis	rs2625529	0.775	rs12913042	chr15:72202309	C/T	cg16672083	chr15:72433130	SENP8	-0.75	-12.38	-0.52	2.88e-30	Red blood cell count;
LUAD	cis	rs12618769	0.597	rs2309390	chr2:99114310	T/C	cg10123293	chr2:99228465	UNC50	0.47	8.47	0.38	4.18e-16	Bipolar disorder;
LUAD	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.38	-0.6	9.91e-43	Eye color traits;
LUAD	cis	rs2992756	0.663	rs2992762	chr1:18804609	A/G	cg24076588	chr1:18808559	KLHDC7A	-0.45	-7.6	-0.35	1.95e-13	Breast cancer;
LUAD	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03264133	chr6:25882463	NA	-0.48	-7.75	-0.35	6.71e-14	Blood metabolite levels;
LUAD	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg27535305	chr1:53392650	SCP2	-0.38	-7.99	-0.36	1.29e-14	Monocyte count;
LUAD	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg02734326	chr4:10020555	SLC2A9	0.62	11.27	0.48	6.32e-26	Bone mineral density;
LUAD	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg23533926	chr12:111358616	MYL2	-0.4	-6.91	-0.32	1.76e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18099408	chr3:52552593	STAB1	-0.52	-9.54	-0.42	1.13e-19	Electroencephalogram traits;
LUAD	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg02696790	chr15:75250997	RPP25	0.36	6.73	0.31	5.65e-11	Breast cancer;
LUAD	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-7.48	-0.34	4.35e-13	Morning vs. evening chronotype;
LUAD	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs746627	0.583	rs10512506	chr17:63809889	G/C	cg07283582	chr17:63770753	CCDC46	-0.49	-8.28	-0.37	1.63e-15	Total body bone mineral density;
LUAD	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg22963979	chr7:1858916	MAD1L1	-0.56	-9.72	-0.43	2.69e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg11266682	chr4:10021025	SLC2A9	0.69	15.76	0.61	2.27e-44	Bone mineral density;
LUAD	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg17063962	chr7:91808500	NA	0.71	12.79	0.53	6.97e-32	Breast cancer;
LUAD	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18404041	chr3:52824283	ITIH1	-0.59	-12.0	-0.5	9.05e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs4986172	0.700	rs71373536	chr17:43221808	G/A	cg10701640	chr17:43249399	NA	0.57	9.9	0.43	6.54e-21	Height;
LUAD	cis	rs9948	0.655	rs3731940	chr2:97377883	A/G	cg20312557	chr2:97357134	FER1L5	0.5	6.65	0.31	8.96e-11	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg02782426	chr3:40428986	ENTPD3	0.43	9.0	0.4	7.49e-18	Renal cell carcinoma;
LUAD	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.6	8.5	0.38	3.33e-16	Gut microbiome composition (summer);
LUAD	cis	rs1405069	0.809	rs1063021	chr6:36932327	A/G	cg26433444	chr6:36932349	PI16	0.43	8.57	0.38	1.95e-16	Chemerin levels;
LUAD	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg04539111	chr16:67997858	SLC12A4	-0.63	-7.69	-0.35	1.03e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs7615952	0.546	rs2979340	chr3:125341384	C/T	cg17147758	chr8:6949321	NA	-0.49	-7.45	-0.34	5.27e-13	Blood pressure (smoking interaction);
LUAD	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-6.96	-0.32	1.32e-11	Lung cancer;
LUAD	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg02493740	chr2:85810744	VAMP5	-0.61	-11.23	-0.48	8.33e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.43	-8.31	-0.37	1.34e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg25418748	chr5:178977236	RUFY1	-0.42	-7.13	-0.33	4.24e-12	Subcortical brain region volumes;
LUAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.65	-12.13	-0.51	2.85e-29	Longevity;Endometriosis;
LUAD	trans	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg19862616	chr7:65841803	NCRNA00174	1.06	27.53	0.8	2.32e-96	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg21475434	chr5:93447410	FAM172A	0.78	8.63	0.39	1.23e-16	Diabetic retinopathy;
LUAD	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg14668632	chr7:2872130	GNA12	-0.46	-7.98	-0.36	1.39e-14	Height;
LUAD	trans	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg27411982	chr8:10470053	RP1L1	0.45	7.96	0.36	1.64e-14	Mood instability;
LUAD	cis	rs977987	0.806	rs4888425	chr16:75476363	T/C	cg03315344	chr16:75512273	CHST6	0.65	14.37	0.57	2.04e-38	Dupuytren's disease;
LUAD	cis	rs62400317	0.821	rs12202232	chr6:45208345	G/A	cg18551225	chr6:44695536	NA	-0.57	-8.63	-0.39	1.22e-16	Total body bone mineral density;
LUAD	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg01528321	chr10:82214614	TSPAN14	0.65	10.39	0.45	1.09e-22	Post bronchodilator FEV1;
LUAD	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.14	-0.33	4.03e-12	Height;
LUAD	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.48	7.46	0.34	4.87e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg15181151	chr6:150070149	PCMT1	-0.41	-8.61	-0.39	1.48e-16	Lung cancer;
LUAD	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg15467112	chr14:75489610	MLH3	0.35	6.36	0.3	5.33e-10	Height;
LUAD	cis	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg05084668	chr3:125655381	ALG1L	-0.86	-11.3	-0.48	4.85e-26	Blood pressure (smoking interaction);
LUAD	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg17724175	chr1:150552817	MCL1	-0.39	-9.19	-0.41	1.76e-18	Urate levels;
LUAD	cis	rs524023	0.958	rs11231825	chr11:64360274	T/C	cg19131476	chr11:64387923	NRXN2	-0.36	-6.94	-0.32	1.44e-11	Urate levels in obese individuals;
LUAD	cis	rs2840044	1.000	rs8073935	chr17:33985849	C/T	cg05299278	chr17:33885742	SLFN14	0.43	8.68	0.39	8.59e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg14582100	chr15:45693742	SPATA5L1	0.63	12.48	0.52	1.21e-30	Homoarginine levels;
LUAD	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg05425664	chr17:57184151	TRIM37	-0.42	-7.53	-0.34	3.12e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg21548813	chr6:291882	DUSP22	-0.8	-13.75	-0.56	8.27e-36	Menopause (age at onset);
LUAD	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg00898013	chr13:113819073	PROZ	-0.84	-15.19	-0.59	6.39e-42	Platelet distribution width;
LUAD	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg10755058	chr3:40428713	ENTPD3	0.45	8.44	0.38	5.23e-16	Renal cell carcinoma;
LUAD	cis	rs17362650	0.653	rs12474647	chr2:9554280	A/T	cg12832956	chr2:9616023	IAH1	-0.47	-8.25	-0.37	2.06e-15	Alcohol dependence (age at onset);
LUAD	cis	rs4774899	1.000	rs12916958	chr15:57267365	A/G	cg14026238	chr15:57616123	NA	0.33	6.37	0.3	4.86e-10	Urinary tract infection frequency;
LUAD	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg06608945	chr2:219082296	ARPC2	0.44	7.41	0.34	7.14e-13	Colorectal cancer;
LUAD	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg11317459	chr13:21872234	NA	-1.09	-14.71	-0.58	7.3e-40	White matter hyperintensity burden;
LUAD	cis	rs4481887	0.927	rs9651177	chr1:248445702	A/G	cg00666640	chr1:248458726	OR2T12	0.3	7.35	0.34	1.04e-12	Common traits (Other);
LUAD	cis	rs4706831	0.663	rs1984242	chr6:81051245	A/G	cg08355045	chr6:80787529	NA	0.46	7.88	0.36	2.79e-14	Joint mobility (Beighton score);
LUAD	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	7.08	0.33	5.9e-12	Lung cancer in ever smokers;
LUAD	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.75	0.39	5.1e-17	Lung cancer in ever smokers;
LUAD	cis	rs9430161	0.579	rs6696575	chr1:11037136	G/A	cg02454025	chr1:11042201	C1orf127	1.0	16.95	0.64	1.45e-49	Ewing sarcoma;
LUAD	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.04	-0.4	5.49e-18	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg18187862	chr3:45730750	SACM1L	0.56	8.78	0.39	4.02e-17	Primary sclerosing cholangitis;
LUAD	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg18209359	chr17:80159595	CCDC57	0.38	6.49	0.3	2.44e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4409675	0.576	rs2749110	chr1:28235010	T/C	cg23691781	chr1:28212827	C1orf38	0.38	11.08	0.47	3.31e-25	Corneal astigmatism;
LUAD	cis	rs2242073	0.660	rs11679743	chr2:209004632	C/T	cg06181187	chr2:209010896	CRYGB	-0.35	-6.88	-0.32	2.11e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg21280719	chr6:42927975	GNMT	-0.39	-11.97	-0.5	1.18e-28	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs758324	0.812	rs10045303	chr5:131202801	C/T	cg06307176	chr5:131281290	NA	-0.46	-7.72	-0.35	8.25e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg12927641	chr6:109611667	NA	-0.49	-8.63	-0.39	1.28e-16	Reticulocyte fraction of red cells;
LUAD	cis	rs6484504	0.761	rs10835747	chr11:31170095	G/A	cg26647111	chr11:31128758	NA	-0.43	-6.66	-0.31	8.79e-11	Red blood cell count;
LUAD	cis	rs941764	1.000	rs941764	chr14:91841069	C/T	cg10511902	chr14:91842949	CCDC88C	-0.45	-10.84	-0.47	2.58e-24	Breast cancer;
LUAD	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg26688816	chr2:46740690	ATP6V1E2	0.5	8.31	0.37	1.3e-15	HDL cholesterol;
LUAD	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg03959625	chr15:84868606	LOC388152	0.4	6.4	0.3	4.1e-10	Schizophrenia;
LUAD	cis	rs2731664	0.756	rs2545796	chr5:176864269	T/C	cg23176889	chr5:176863531	GRK6	-0.74	-14.5	-0.58	5.68e-39	Intelligence (multi-trait analysis);
LUAD	cis	rs9473147	0.516	rs7767350	chr6:47485126	C/T	cg20196966	chr6:47445060	CD2AP	0.44	6.8	0.31	3.67e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs68170813	0.599	rs77878465	chr7:106890996	G/A	cg23024343	chr7:107201750	COG5	0.45	6.6	0.31	1.24e-10	Coronary artery disease;
LUAD	cis	rs3789045	0.774	rs4252697	chr1:204501383	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.44	-7.32	-0.34	1.24e-12	Educational attainment (college completion);
LUAD	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg22529645	chr1:3704559	LRRC47	0.52	9.75	0.43	2.18e-20	Red cell distribution width;
LUAD	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.14	-0.54	2.51e-33	Breast cancer;
LUAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.45	6.47	0.3	2.73e-10	Renal function-related traits (BUN);
LUAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg04025307	chr7:1156635	C7orf50	0.65	7.4	0.34	7.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg04034577	chr2:241836375	C2orf54	-0.5	-11.14	-0.48	1.96e-25	Urinary metabolites;
LUAD	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg01874867	chr7:94954059	PON1	0.45	6.58	0.3	1.42e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6545883	0.895	rs2442029	chr2:61679552	G/T	cg15711740	chr2:61764176	XPO1	-0.41	-6.53	-0.3	1.94e-10	Tuberculosis;
LUAD	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg23992470	chr4:843637	GAK	0.7	7.28	0.33	1.65e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg06740227	chr12:86229804	RASSF9	0.45	8.24	0.37	2.22e-15	Major depressive disorder;
LUAD	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg09359103	chr1:154839909	KCNN3	-0.91	-21.24	-0.72	1.09e-68	Prostate cancer;
LUAD	cis	rs4462272	0.557	rs17668357	chr10:102003906	G/C	cg19754520	chr10:101825118	CPN1	-0.3	-6.39	-0.3	4.37e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.51	8.76	0.39	4.66e-17	Electrocardiographic conduction measures;
LUAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22338127	chr1:209979572	IRF6	0.49	6.73	0.31	5.5e-11	Cleft lip with or without cleft palate;
LUAD	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.41	-19.61	-0.69	2.25e-61	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg03609598	chr5:56110824	MAP3K1	0.47	6.99	0.32	1.08e-11	Initial pursuit acceleration;
LUAD	cis	rs2286885	1.000	rs741025	chr9:129251792	C/T	cg15282417	chr9:129245246	FAM125B	0.47	9.74	0.43	2.32e-20	Intraocular pressure;
LUAD	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg02773041	chr1:40204384	PPIE	0.52	8.48	0.38	3.9e-16	Blood protein levels;
LUAD	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13012494	chr21:47604986	C21orf56	-0.66	-11.71	-0.49	1.29e-27	Testicular germ cell tumor;
LUAD	cis	rs13112683	0.638	rs2667365	chr4:140781918	T/C	cg02876341	chr4:140783585	MAML3	0.3	6.5	0.3	2.33e-10	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LUAD	cis	rs7759001	0.857	rs9468115	chr6:27363587	T/C	cg18711553	chr6:27366782	ZNF391	0.39	6.52	0.3	2.05e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg12935359	chr14:103987150	CKB	0.46	7.6	0.35	1.93e-13	Body mass index;
LUAD	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg22117172	chr7:91764530	CYP51A1	-0.32	-6.98	-0.32	1.11e-11	Breast cancer;
LUAD	cis	rs13064411	0.518	rs2399480	chr3:113228599	T/C	cg18753928	chr3:113234510	CCDC52	-0.55	-9.72	-0.43	2.66e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.58	-0.3	1.41e-10	Aortic root size;
LUAD	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg02527881	chr3:46936655	PTH1R	0.68	15.09	0.59	1.82e-41	Birth weight;
LUAD	cis	rs13082711	0.595	rs6783818	chr3:27361988	C/G	cg02860705	chr3:27208620	NA	0.78	12.26	0.51	9.27e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg21252483	chr19:49399788	TULP2	-0.88	-14.31	-0.57	3.61e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg03806693	chr22:41940476	POLR3H	0.77	10.28	0.45	2.78e-22	Vitiligo;
LUAD	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg22166914	chr1:53195759	ZYG11B	0.4	6.6	0.31	1.24e-10	Monocyte count;
LUAD	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.79	14.74	0.58	5.39e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg07167872	chr1:205819463	PM20D1	0.58	10.42	0.45	8.55e-23	Prostate cancer;
LUAD	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg23018236	chr17:30244563	NA	-0.59	-7.86	-0.36	3.18e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg11822812	chr5:140052017	DND1	0.37	6.48	0.3	2.5e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs806215	0.950	rs3735642	chr7:127224286	A/G	cg25922125	chr7:127225783	GCC1	-0.47	-6.63	-0.31	1e-10	Type 2 diabetes;
LUAD	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg16479474	chr6:28041457	NA	0.41	7.14	0.33	4.11e-12	Parkinson's disease;
LUAD	cis	rs62229266	0.804	rs2835263	chr21:37430245	A/G	cg08632701	chr21:37451849	NA	0.42	6.97	0.32	1.19e-11	Mitral valve prolapse;
LUAD	cis	rs727505	1.000	rs67084428	chr7:124499388	G/T	cg23710748	chr7:124431027	NA	-0.47	-9.56	-0.42	9.77e-20	Lewy body disease;
LUAD	cis	rs9788682	0.747	rs2656069	chr15:78745707	C/T	cg18825076	chr15:78729989	IREB2	-0.54	-7.62	-0.35	1.69e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs9394169	0.613	rs2395399	chr6:33777432	T/C	cg16010596	chr6:33739607	LEMD2	-0.34	-6.52	-0.3	2.02e-10	Essential tremor;
LUAD	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg25237894	chr2:233734115	C2orf82	-0.62	-11.67	-0.49	1.87e-27	Coronary artery disease;
LUAD	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg19622623	chr12:86230825	RASSF9	-0.43	-7.47	-0.34	4.69e-13	Major depressive disorder;
LUAD	cis	rs7116495	1.000	rs7948821	chr11:71652485	G/A	cg07596299	chr11:71824057	C11orf51	-0.76	-6.69	-0.31	6.89e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg04414720	chr1:150670196	GOLPH3L	0.74	13.81	0.56	4.54e-36	Tonsillectomy;
LUAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg17178900	chr1:205818956	PM20D1	-0.66	-12.94	-0.53	1.72e-32	Menarche (age at onset);
LUAD	cis	rs11809207	1.000	rs4659412	chr1:26518470	C/T	cg00300879	chr1:26503847	CNKSR1	0.28	6.93	0.32	1.61e-11	Height;
LUAD	cis	rs3820068	0.705	rs4646075	chr1:15827461	T/C	cg24675056	chr1:15929824	NA	0.41	6.58	0.3	1.39e-10	Systolic blood pressure;
LUAD	cis	rs4409675	0.576	rs2815707	chr1:28238880	T/C	cg23691781	chr1:28212827	C1orf38	0.38	11.08	0.47	3.13e-25	Corneal astigmatism;
LUAD	cis	rs73086581	1.000	rs73086510	chr20:3922131	T/C	cg02187196	chr20:3869020	PANK2	0.49	6.78	0.31	4.14e-11	Response to antidepressants in depression;
LUAD	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg27286337	chr10:134555280	INPP5A	0.72	11.02	0.47	5.21e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg01416388	chr22:39784598	NA	-0.55	-9.37	-0.41	4.43e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg22907277	chr7:1156413	C7orf50	0.71	8.31	0.37	1.29e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1784581	0.894	rs1784594	chr6:162382734	A/G	cg17173639	chr6:162384350	PARK2	-0.58	-10.63	-0.46	1.53e-23	Itch intensity from mosquito bite;
LUAD	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg01741372	chr11:783889	NA	-0.52	-11.45	-0.49	1.21e-26	Breast cancer;
LUAD	cis	rs6688613	0.694	rs3820387	chr1:166820284	A/T	cg07049167	chr1:166818506	POGK	0.61	10.06	0.44	1.7e-21	Refractive astigmatism;
LUAD	trans	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg02002194	chr4:3960332	NA	-0.29	-7.0	-0.32	9.97e-12	Mood instability;
LUAD	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg19041857	chr6:27730383	NA	-0.43	-7.44	-0.34	5.75e-13	Parkinson's disease;
LUAD	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg26354017	chr1:205819088	PM20D1	-0.53	-8.21	-0.37	2.8e-15	Menarche (age at onset);
LUAD	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg02734326	chr4:10020555	SLC2A9	0.42	7.3	0.33	1.47e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-7.01	-0.32	9.56e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.6	8.21	0.37	2.72e-15	Renal function-related traits (BUN);
LUAD	cis	rs10129255	0.500	rs11627315	chr14:107210420	T/C	cg07958169	chr14:107095056	NA	-0.36	-7.2	-0.33	2.71e-12	Kawasaki disease;
LUAD	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03517284	chr6:25882590	NA	-0.57	-9.19	-0.41	1.75e-18	Blood metabolite levels;
LUAD	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.45	-0.42	2.41e-19	Life satisfaction;
LUAD	cis	rs4409675	0.576	rs2749119	chr1:28236248	G/A	cg23691781	chr1:28212827	C1orf38	0.38	11.08	0.47	3.32e-25	Corneal astigmatism;
LUAD	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg23281280	chr6:28129359	ZNF389	0.46	6.58	0.3	1.39e-10	Depression;
LUAD	cis	rs6748734	0.857	rs4675857	chr2:241842326	T/C	cg07537917	chr2:241836409	C2orf54	-0.31	-8.6	-0.39	1.58e-16	Urinary metabolites;
LUAD	trans	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg19862616	chr7:65841803	NCRNA00174	1.06	26.71	0.79	7.98e-93	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg21475434	chr5:93447410	FAM172A	-0.57	-7.36	-0.34	9.38e-13	Diabetic retinopathy;
LUAD	cis	rs2996428	0.643	rs6424056	chr1:3722486	G/A	cg17848003	chr1:3704513	LRRC47	0.51	10.46	0.45	6.18e-23	Red cell distribution width;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10542027	chr5:78532229	JMY	-0.45	-7.04	-0.32	7.97e-12	Height;
LUAD	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg23262073	chr20:60523788	NA	-0.37	-6.65	-0.31	9.19e-11	Body mass index;
LUAD	cis	rs904251	0.861	rs2776877	chr6:37487135	G/A	cg25019722	chr6:37503610	NA	-0.3	-6.62	-0.31	1.12e-10	Cognitive performance;
LUAD	cis	rs71636778	0.509	rs71636795	chr1:27241025	A/G	cg12203394	chr1:27248618	NUDC	0.52	6.56	0.3	1.57e-10	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg05896524	chr21:47604654	C21orf56	0.54	9.09	0.4	3.91e-18	Testicular germ cell tumor;
LUAD	cis	rs9296095	0.948	rs75080135	chr6:33552707	A/C	cg14003231	chr6:33640908	ITPR3	0.6	10.3	0.45	2.34e-22	Platelet count;
LUAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg02869364	chr7:1081709	C7orf50	-0.52	-6.71	-0.31	6.11e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg01884057	chr2:25150051	NA	-0.33	-7.08	-0.33	5.9e-12	Body mass index;
LUAD	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	3.01e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg25894440	chr7:65020034	NA	-0.68	-7.32	-0.34	1.29e-12	Diabetic kidney disease;
LUAD	cis	rs7582720	1.000	rs79642273	chr2:203830851	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg00310523	chr12:86230176	RASSF9	0.42	8.87	0.4	2.05e-17	Major depressive disorder;
LUAD	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs11585357	0.895	rs72633808	chr1:17618665	A/G	cg08277548	chr1:17600880	PADI3	-0.95	-13.88	-0.56	2.3e-36	Hair shape;
LUAD	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg04287289	chr16:89883240	FANCA	0.75	6.36	0.3	5.13e-10	Skin colour saturation;
LUAD	trans	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg27411982	chr8:10470053	RP1L1	-0.36	-6.45	-0.3	3.03e-10	Mood instability;
LUAD	cis	rs17376456	0.825	rs17314074	chr5:93161467	T/C	cg21475434	chr5:93447410	FAM172A	0.73	7.33	0.34	1.16e-12	Diabetic retinopathy;
LUAD	cis	rs494562	0.892	rs522129	chr6:86116381	A/G	cg17966619	chr6:86160162	NT5E	0.66	8.01	0.36	1.14e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs593982	0.843	rs680948	chr11:65472394	C/G	cg08755490	chr11:65554678	OVOL1	1.24	14.7	0.58	8.39e-40	Atopic dermatitis;
LUAD	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg18230493	chr5:56204884	C5orf35	0.65	10.42	0.45	8.88e-23	Initial pursuit acceleration;
LUAD	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg12884169	chr21:40033163	ERG	0.5	10.76	0.46	4.86e-24	Coronary artery disease;
LUAD	cis	rs55665837	1.000	rs11023215	chr11:14436970	C/T	cg19336497	chr11:14380999	RRAS2	-0.47	-9.2	-0.41	1.66e-18	Vitamin D levels;
LUAD	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg27068330	chr11:65405492	SIPA1	-0.75	-11.32	-0.48	3.97e-26	Acne (severe);
LUAD	cis	rs6011002	0.550	rs6010634	chr20:62363838	T/C	cg21849932	chr20:62369462	LIME1	-0.78	-6.45	-0.3	3.09e-10	Dental caries;
LUAD	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg18016565	chr1:150552671	MCL1	-0.4	-7.03	-0.32	8.56e-12	Tonsillectomy;
LUAD	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg10556349	chr10:835070	NA	0.46	6.98	0.32	1.13e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg25457927	chr22:38595422	NA	-0.53	-13.59	-0.55	3.7e-35	Cutaneous nevi;
LUAD	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg09904177	chr6:26538194	HMGN4	0.43	7.26	0.33	1.87e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1692580	0.840	rs263526	chr1:2173504	T/C	cg21194808	chr1:2205498	SKI	0.39	6.49	0.3	2.47e-10	Coronary artery disease;
LUAD	cis	rs12912251	1.000	rs7163869	chr15:38988391	G/C	cg01338139	chr15:38987640	C15orf53	-0.6	-9.37	-0.41	4.42e-19	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs71403859	0.502	rs34015581	chr16:71508229	T/A	cg08717414	chr16:71523259	ZNF19	-0.62	-7.66	-0.35	1.26e-13	Post bronchodilator FEV1;
LUAD	cis	rs7937682	0.562	rs7938620	chr11:111366844	G/A	cg09085632	chr11:111637200	PPP2R1B	0.43	7.26	0.33	1.93e-12	Primary sclerosing cholangitis;
LUAD	cis	rs67072384	1.000	rs7128364	chr11:72451941	A/C	cg04827223	chr11:72435913	ARAP1	-0.62	-7.61	-0.35	1.8e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs10504073	0.584	rs62507210	chr8:49946601	C/T	cg00325661	chr8:49890786	NA	0.45	10.11	0.44	1.19e-21	Blood metabolite ratios;
LUAD	trans	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.73	12.33	0.51	4.86e-30	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs4372836	0.636	rs4665434	chr2:28976403	A/G	cg09522027	chr2:28974177	PPP1CB	-0.45	-7.53	-0.34	3.19e-13	Body mass index;
LUAD	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg00745463	chr17:30367425	LRRC37B	0.74	8.79	0.39	3.75e-17	Hip circumference adjusted for BMI;
LUAD	trans	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	10.17	0.44	7.15e-22	Type 2 diabetes;
LUAD	cis	rs6489882	0.902	rs1981557	chr12:113372866	G/C	cg20102336	chr12:113376681	OAS3	-0.61	-9.51	-0.42	1.51e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.74	-8.83	-0.39	2.86e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7089973	0.872	rs36036948	chr10:116631649	A/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.54	0.42	1.15e-19	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs9929218	0.953	rs12920562	chr16:68737512	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-16.47	-0.63	1.89e-47	Colorectal cancer;
LUAD	cis	rs7043114	0.525	rs1053446	chr9:95146761	T/A	cg14631576	chr9:95140430	CENPP	-0.42	-8.55	-0.38	2.28e-16	Height;
LUAD	cis	rs7705042	0.826	rs11749731	chr5:141500436	A/C	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.78	-0.31	3.98e-11	Asthma;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05041382	chr13:50366546	KPNA3	-0.66	-6.68	-0.31	7.76e-11	Type 2 diabetes;
LUAD	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg25894440	chr7:65020034	NA	-0.63	-6.67	-0.31	8.15e-11	Diabetic kidney disease;
LUAD	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg00999904	chr2:3704751	ALLC	0.51	8.87	0.4	2.02e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg16262614	chr3:133464971	TF	0.42	8.34	0.38	1.05e-15	Iron status biomarkers (transferrin levels);
LUAD	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg06784218	chr1:46089804	CCDC17	-0.6	-13.55	-0.55	5.61e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg05182265	chr7:156933206	UBE3C	-0.8	-17.24	-0.64	8.1e-51	Body mass index;
LUAD	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg08085267	chr17:45401833	C17orf57	-0.49	-8.13	-0.37	4.74e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg27068330	chr11:65405492	SIPA1	-0.81	-13.01	-0.53	8.9e-33	Acne (severe);
LUAD	cis	rs12711979	0.528	rs1823860	chr2:3867013	A/G	cg17052675	chr2:3827356	NA	-0.42	-7.33	-0.34	1.18e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.46e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg12935359	chr14:103987150	CKB	-0.48	-7.46	-0.34	4.81e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs12541635	0.966	rs12680670	chr8:107006811	T/G	cg10147462	chr8:107024639	NA	0.51	9.21	0.41	1.48e-18	Age of smoking initiation;
LUAD	trans	rs783540	0.934	rs4779050	chr15:83368738	T/G	cg18393722	chr15:85113863	UBE2QP1	0.44	7.07	0.33	6.38e-12	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg02527881	chr3:46936655	PTH1R	0.45	8.61	0.39	1.47e-16	Colorectal cancer;
LUAD	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg10819733	chr22:24237672	NA	-0.42	-7.73	-0.35	7.67e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg05896524	chr21:47604654	C21orf56	-0.74	-13.22	-0.54	1.27e-33	Testicular germ cell tumor;
LUAD	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.41	7.14	0.33	4.16e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg02683114	chr2:24398427	C2orf84	-0.43	-6.56	-0.3	1.6e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs478304	0.718	rs1151490	chr11:65390485	A/C	cg05805236	chr11:65401703	PCNXL3	0.47	7.89	0.36	2.62e-14	Acne (severe);
LUAD	cis	rs6709815	0.841	rs12694442	chr2:219663599	T/C	cg02176678	chr2:219576539	TTLL4	-0.54	-10.56	-0.46	2.61e-23	Reticulocyte count;High light scatter reticulocyte count;
LUAD	cis	rs7147624	1.000	rs11848209	chr14:66022832	T/A	cg03016385	chr14:66212404	NA	-0.59	-7.2	-0.33	2.86e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg19875535	chr5:140030758	IK	-0.44	-7.42	-0.34	6.64e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg23711669	chr6:146136114	FBXO30	-0.39	-6.52	-0.3	2.05e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg00071950	chr4:10020882	SLC2A9	0.83	17.17	0.64	1.67e-50	Bone mineral density;
LUAD	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg20135002	chr11:47629003	NA	-0.41	-7.16	-0.33	3.69e-12	Subjective well-being;
LUAD	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.45	8.06	0.36	7.91e-15	Systemic lupus erythematosus;
LUAD	cis	rs9522267	0.535	rs914031	chr13:112240176	C/A	cg10483660	chr13:112241077	NA	-0.33	-7.07	-0.33	6.48e-12	Hepatitis;
LUAD	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00684032	chr4:1343700	KIAA1530	0.49	7.94	0.36	1.86e-14	Obesity-related traits;
LUAD	trans	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.92	-0.32	1.66e-11	Gout;
LUAD	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg09658497	chr7:2847517	GNA12	-0.49	-9.33	-0.41	6.15e-19	Height;
LUAD	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg04414720	chr1:150670196	GOLPH3L	0.73	13.42	0.55	1.78e-34	Tonsillectomy;
LUAD	trans	rs7944735	0.567	rs76477746	chr11:48103368	G/C	cg15704280	chr7:45808275	SEPT13	0.71	6.99	0.32	1.06e-11	Intraocular pressure;
LUAD	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14019695	chr9:139328340	INPP5E	-0.48	-9.62	-0.42	6.1e-20	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg05727186	chr17:43697356	MGC57346	-0.51	-6.36	-0.3	5.32e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.36e-12	Lung cancer;
LUAD	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg17724175	chr1:150552817	MCL1	0.36	8.14	0.37	4.6e-15	Melanoma;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg21400344	chr1:25870172	LDLRAP1	-0.44	-6.89	-0.32	2.03e-11	Vertical cup-disc ratio;
LUAD	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg15744005	chr10:104629667	AS3MT	-0.44	-7.75	-0.35	6.72e-14	Arsenic metabolism;
LUAD	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg22920501	chr2:26401640	FAM59B	-0.96	-14.64	-0.58	1.49e-39	Gut microbiome composition (summer);
LUAD	cis	rs7953508	0.711	rs11107116	chr12:93978504	G/T	cg18151635	chr12:93972918	NA	-0.73	-11.41	-0.49	1.75e-26	Pubertal anthropometrics;
LUAD	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.65	-0.31	8.88e-11	Total body bone mineral density;
LUAD	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg00981070	chr1:2046702	PRKCZ	0.36	6.97	0.32	1.25e-11	Height;
LUAD	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg19302996	chr17:73780495	UNK	0.39	6.64	0.31	9.89e-11	White matter hyperintensity burden;
LUAD	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg16006841	chr5:176797999	RGS14	-0.59	-8.94	-0.4	1.22e-17	Urate levels in lean individuals;
LUAD	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg04455712	chr21:45112962	RRP1B	0.45	8.77	0.39	4.42e-17	Mean corpuscular volume;
LUAD	cis	rs4711336	1.000	rs2296741	chr6:33659557	C/T	cg14003231	chr6:33640908	ITPR3	0.51	9.73	0.43	2.42e-20	Height;
LUAD	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg26384229	chr12:38710491	ALG10B	0.44	7.21	0.33	2.66e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs11971779	0.590	rs59602547	chr7:139117023	G/A	cg23387468	chr7:139079360	LUC7L2	0.3	6.98	0.32	1.17e-11	Diisocyanate-induced asthma;
LUAD	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg11663144	chr21:46675770	NA	-0.5	-9.11	-0.4	3.43e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-6.8	-0.31	3.6e-11	Glaucoma (primary open-angle);
LUAD	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg25985355	chr7:65971099	NA	-0.55	-6.74	-0.31	5.26e-11	Gout;
LUAD	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-9.52	-0.42	1.35e-19	Life satisfaction;
LUAD	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg06074448	chr4:187884817	NA	-0.36	-7.19	-0.33	3.03e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs7737355	0.812	rs2549011	chr5:130657418	G/C	cg06307176	chr5:131281290	NA	-0.39	-6.61	-0.31	1.16e-10	Life satisfaction;
LUAD	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg23992470	chr4:843637	GAK	-0.64	-6.82	-0.31	3.14e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg04267008	chr7:1944627	MAD1L1	0.48	7.58	0.35	2.19e-13	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg16606324	chr3:10149918	C3orf24	0.59	9.65	0.42	4.73e-20	Alzheimer's disease;
LUAD	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.4	-6.72	-0.31	6.04e-11	Total body bone mineral density;
LUAD	trans	rs7395662	0.892	rs11040014	chr11:48783057	G/A	cg00717180	chr2:96193071	NA	0.36	6.71	0.31	6.13e-11	HDL cholesterol;
LUAD	cis	rs9517320	0.517	rs4772097	chr13:99194652	C/A	cg20487152	chr13:99095054	FARP1	-0.46	-7.66	-0.35	1.26e-13	Longevity;
LUAD	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg20701182	chr2:24300061	SF3B14	0.56	6.71	0.31	6.14e-11	Lymphocyte counts;
LUAD	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg11822812	chr5:140052017	DND1	0.38	6.96	0.32	1.28e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1997103	1.000	rs2177804	chr7:55410302	G/A	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.34e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg08514558	chr10:81106712	PPIF	0.49	9.35	0.41	5.26e-19	Height;
LUAD	cis	rs8049603	0.812	rs13306657	chr16:23197302	C/T	cg09552652	chr16:23197569	SCNN1G	0.39	6.8	0.31	3.62e-11	Multiple sclerosis;
LUAD	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.49	-0.42	1.66e-19	Life satisfaction;
LUAD	cis	rs13088645	0.683	rs9790169	chr3:134151959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-6.97	-0.32	1.2e-11	Coronary artery disease;
LUAD	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg05966235	chr16:28915196	ATP2A1	0.51	8.14	0.37	4.34e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs62064224	0.589	rs4132610	chr17:30801441	C/T	cg25809561	chr17:30822961	MYO1D	0.49	8.97	0.4	9.57e-18	Schizophrenia;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg13916990	chr9:34048851	UBAP2	-0.35	-6.39	-0.3	4.27e-10	Schizophrenia;
LUAD	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg17366294	chr4:99064904	C4orf37	0.45	8.06	0.36	7.87e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg25811766	chr13:21894605	NA	0.69	9.23	0.41	1.32e-18	White matter hyperintensity burden;
LUAD	trans	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.85	-0.32	2.58e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg00339695	chr16:24857497	SLC5A11	-0.56	-8.92	-0.4	1.43e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg10560079	chr2:191398806	TMEM194B	-0.48	-6.47	-0.3	2.72e-10	Diastolic blood pressure;
LUAD	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	6.98	0.32	1.12e-11	Motion sickness;
LUAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00166722	chr3:10149974	C3orf24	0.63	10.43	0.45	8.13e-23	Alzheimer's disease;
LUAD	cis	rs12548874	0.607	rs12543492	chr8:95891843	C/A	cg26343298	chr8:95960752	TP53INP1	0.34	6.77	0.31	4.26e-11	Hemoglobin concentration;
LUAD	cis	rs6906287	0.647	rs7772921	chr6:118964623	C/G	cg21191810	chr6:118973309	C6orf204	0.49	9.35	0.41	5.07e-19	Electrocardiographic conduction measures;
LUAD	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg00277334	chr10:82204260	NA	-0.47	-7.74	-0.35	7.43e-14	Post bronchodilator FEV1;
LUAD	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg12599982	chr1:44399894	ARTN	0.34	6.85	0.32	2.57e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg03445287	chr8:21823731	XPO7	-0.46	-8.62	-0.39	1.3e-16	Mean corpuscular volume;
LUAD	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg02807482	chr3:125708958	NA	-0.66	-8.85	-0.4	2.44e-17	Blood pressure (smoking interaction);
LUAD	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11644478	chr21:40555479	PSMG1	-0.67	-11.08	-0.47	3.31e-25	Cognitive function;
LUAD	trans	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg11693508	chr17:37793320	STARD3	0.77	10.03	0.44	2.22e-21	Bipolar disorder;
LUAD	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg00933542	chr6:150070202	PCMT1	0.45	9.85	0.43	9.36e-21	Lung cancer;
LUAD	cis	rs60733400	0.644	rs28774982	chr1:2621352	C/G	cg20673091	chr1:2541236	MMEL1	-0.37	-7.79	-0.35	5.29e-14	Multiple sclerosis;
LUAD	cis	rs1904096	0.506	rs6823404	chr4:95197520	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.51	-9.76	-0.43	2.04e-20	Type 2 diabetes;
LUAD	cis	rs6484504	0.532	rs1475558	chr11:31263428	A/G	cg26647111	chr11:31128758	NA	-0.42	-7.45	-0.34	5.3e-13	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg24920358	chr1:40204285	PPIE	0.7	12.47	0.52	1.29e-30	Blood protein levels;
LUAD	cis	rs877282	0.853	rs11253332	chr10:755262	G/C	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg20307385	chr11:47447363	PSMC3	0.53	7.75	0.35	6.84e-14	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg14530993	chr4:882597	GAK	0.8	7.92	0.36	2.16e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg20476274	chr7:133979776	SLC35B4	0.83	16.66	0.63	2.87e-48	Mean platelet volume;
LUAD	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg17644776	chr2:200775616	C2orf69	0.55	7.44	0.34	5.68e-13	Schizophrenia;
LUAD	cis	rs4280164	0.945	rs4981503	chr14:24786293	T/G	cg22990158	chr14:24802150	ADCY4	-0.46	-6.67	-0.31	7.99e-11	Parent of origin effect on language impairment (paternal);
LUAD	trans	rs853679	0.607	rs13205911	chr6:28124114	C/T	cg01620082	chr3:125678407	NA	-1.1	-10.38	-0.45	1.25e-22	Depression;
LUAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg24503407	chr1:205819492	PM20D1	0.44	7.06	0.32	6.78e-12	Parkinson's disease;
LUAD	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-8.92	-0.4	1.46e-17	Gut microbiome composition (summer);
LUAD	cis	rs748404	0.697	rs546722	chr15:43580819	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.5	8.12	0.37	5.3e-15	Lung cancer;
LUAD	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.06	-0.32	6.83e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg22920501	chr2:26401640	FAM59B	-0.76	-10.97	-0.47	8.37e-25	Gut microbiome composition (summer);
LUAD	cis	rs9341808	0.718	rs6910201	chr6:80904938	G/C	cg08355045	chr6:80787529	NA	0.58	10.52	0.46	3.89e-23	Sitting height ratio;
LUAD	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg17177755	chr1:15930204	NA	0.45	7.26	0.33	1.82e-12	Systolic blood pressure;
LUAD	cis	rs977987	0.872	rs3743609	chr16:75467021	G/C	cg03315344	chr16:75512273	CHST6	0.64	13.79	0.56	5.63e-36	Dupuytren's disease;
LUAD	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg18512352	chr11:47633146	NA	-0.56	-10.08	-0.44	1.43e-21	Subjective well-being;
LUAD	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01570182	chr17:44337453	NA	-0.94	-13.85	-0.56	3.18e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg19761014	chr17:28927070	LRRC37B2	0.82	8.34	0.38	1.09e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.43	-7.67	-0.35	1.2e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg26384229	chr12:38710491	ALG10B	0.49	7.87	0.36	2.95e-14	Morning vs. evening chronotype;
LUAD	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	10.43	0.45	8.34e-23	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg03388025	chr16:89894329	SPIRE2	0.48	12.48	0.52	1.23e-30	Vitiligo;
LUAD	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.83	0.31	3.04e-11	Cognitive test performance;
LUAD	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg26924012	chr15:45694286	SPATA5L1	1.03	19.22	0.68	1.28e-59	Homoarginine levels;
LUAD	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg06713675	chr4:122721982	EXOSC9	-0.76	-15.05	-0.59	2.63e-41	Type 2 diabetes;
LUAD	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26314531	chr2:26401878	FAM59B	-0.58	-8.03	-0.36	9.92e-15	Gut microbiome composition (summer);
LUAD	cis	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg07460842	chr6:66804631	NA	1.07	16.65	0.63	3.04e-48	Exhaled nitric oxide output;
LUAD	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg08514558	chr10:81106712	PPIF	0.47	9.2	0.41	1.65e-18	Height;
LUAD	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg17509989	chr5:176798049	RGS14	-0.6	-9.31	-0.41	7.06e-19	Urate levels in lean individuals;
LUAD	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg26513180	chr16:89883248	FANCA	0.79	7.19	0.33	2.92e-12	Skin colour saturation;
LUAD	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.41	-0.42	3.33e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg23229984	chr5:148520753	ABLIM3	0.49	7.68	0.35	1.13e-13	Breast cancer;
LUAD	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	8.37	0.38	8.35e-16	Schizophrenia;
LUAD	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.61	11.82	0.5	4.65e-28	Hemoglobin concentration;
LUAD	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg22166914	chr1:53195759	ZYG11B	0.47	7.86	0.36	3.26e-14	Monocyte count;
LUAD	cis	rs9427116	0.702	rs9427109	chr1:154609009	A/G	cg17218026	chr1:154582156	ADAR	0.51	9.88	0.43	7.53e-21	Blood protein levels;
LUAD	cis	rs4853525	0.859	rs1882397	chr2:191720132	A/C	cg11845111	chr2:191398756	TMEM194B	-0.39	-6.44	-0.3	3.22e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs3849570	0.565	rs1851926	chr3:81977231	A/C	cg07356753	chr3:81810745	GBE1	-0.5	-8.35	-0.38	9.55e-16	Waist circumference;Body mass index;
LUAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg12432903	chr7:1882776	MAD1L1	-0.51	-8.51	-0.38	2.96e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg21775007	chr8:11205619	TDH	0.37	6.44	0.3	3.16e-10	Neuroticism;
LUAD	cis	rs57994353	0.897	rs55824202	chr9:139357273	A/T	cg14019695	chr9:139328340	INPP5E	0.42	6.78	0.31	4.11e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs7617773	0.817	rs9830016	chr3:48282494	A/G	cg11946769	chr3:48343235	NME6	0.39	6.42	0.3	3.67e-10	Coronary artery disease;
LUAD	cis	rs977987	0.778	rs4887821	chr16:75398574	G/A	cg03315344	chr16:75512273	CHST6	0.64	13.98	0.56	9.05e-37	Dupuytren's disease;
LUAD	cis	rs11771526	0.792	rs11770580	chr7:32305009	T/C	cg13207630	chr7:32358064	NA	0.61	7.56	0.35	2.47e-13	Body mass index;
LUAD	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg26384229	chr12:38710491	ALG10B	0.44	7.36	0.34	9.65e-13	Morning vs. evening chronotype;
LUAD	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs734999	0.549	rs867436	chr1:2523723	C/T	cg11707310	chr1:2537719	MMEL1	0.37	7.69	0.35	1.01e-13	Ulcerative colitis;
LUAD	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg08610935	chr16:1836813	NUBP2	-0.64	-11.86	-0.5	3.36e-28	Insulin-like growth factors;
LUAD	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg04586622	chr2:25135609	ADCY3	-0.36	-8.39	-0.38	7.53e-16	Body mass index;
LUAD	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg25985355	chr7:65971099	NA	0.38	7.02	0.32	8.92e-12	Aortic root size;
LUAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13732083	chr21:47605072	C21orf56	0.61	10.39	0.45	1.13e-22	Testicular germ cell tumor;
LUAD	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg02683114	chr2:24398427	C2orf84	0.43	7.14	0.33	4.05e-12	Asthma;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg09315468	chr8:38089562	DDHD2	0.4	6.48	0.3	2.53e-10	Diastolic blood pressure;
LUAD	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg25319279	chr11:5960081	NA	-0.41	-7.23	-0.33	2.21e-12	DNA methylation (variation);
LUAD	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.66	0.35	1.27e-13	Depression;
LUAD	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg01181863	chr3:195395398	SDHAP2	-0.65	-10.71	-0.46	7.87e-24	Bronchopulmonary dysplasia;
LUAD	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg01579765	chr21:45077557	HSF2BP	-0.56	-12.78	-0.53	7.29e-32	Mean corpuscular volume;
LUAD	cis	rs62238980	0.614	rs76474221	chr22:32415212	C/G	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg08213375	chr14:104286397	PPP1R13B	0.26	6.85	0.32	2.6e-11	Schizophrenia;
LUAD	cis	rs3760982	0.585	rs67648499	chr19:44294055	G/A	cg21496419	chr19:44306685	LYPD5	0.33	7.35	0.34	1.01e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	trans	rs629535	0.773	rs681534	chr8:70056964	A/C	cg21567404	chr3:27674614	NA	1.01	18.45	0.67	3.38e-56	Dupuytren's disease;
LUAD	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg22875332	chr1:76189707	ACADM	0.68	10.83	0.47	2.86e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9302065	0.565	rs2993584	chr13:95961678	C/A	cg26751094	chr13:95954534	ABCC4	-0.52	-10.97	-0.47	8.35e-25	Blood metabolite levels;
LUAD	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg00204512	chr16:28754710	NA	0.3	6.4	0.3	4.22e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4812048	1.000	rs6070696	chr20:57597645	A/G	cg14073986	chr20:57617431	SLMO2	0.55	7.15	0.33	3.9e-12	Mean platelet volume;
LUAD	cis	rs1403694	0.695	rs3806689	chr3:186435077	A/G	cg12454167	chr3:186435060	KNG1	0.5	10.5	0.45	4.58e-23	Blood protein levels;
LUAD	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg18138036	chr10:133769891	PPP2R2D	0.4	6.45	0.3	3.01e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-8.07	-0.37	7.21e-15	Total body bone mineral density;
LUAD	cis	rs863345	0.564	rs11265014	chr1:158503221	T/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.46	-0.3	2.84e-10	Pneumococcal bacteremia;
LUAD	cis	rs12472274	0.941	rs4663861	chr2:239105203	C/T	cg17459225	chr2:239074497	NA	0.71	9.6	0.42	7.36e-20	Phospholipid levels (plasma);
LUAD	cis	rs1045714	0.895	rs73043182	chr7:2646005	C/T	cg24848437	chr7:2645542	IQCE	0.73	8.51	0.38	3.02e-16	Urate levels in lean individuals;
LUAD	cis	rs13315871	1.000	rs9869576	chr3:58401262	G/A	cg20936604	chr3:58311152	NA	-0.69	-6.9	-0.32	1.86e-11	Cholesterol, total;
LUAD	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg02450064	chr17:40260053	DHX58	-0.42	-7.29	-0.33	1.5e-12	Fibrinogen levels;
LUAD	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18876405	chr7:65276391	NA	0.44	6.94	0.32	1.47e-11	Aortic root size;
LUAD	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.0	0.36	1.25e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62238980	0.614	rs77034034	chr22:32466661	G/A	cg00543991	chr22:32367038	NA	0.92	8.7	0.39	7.27e-17	Childhood ear infection;
LUAD	cis	rs1595825	0.735	rs2053394	chr2:198946335	C/T	cg00361562	chr2:198649771	BOLL	-0.52	-7.01	-0.32	9.48e-12	Ulcerative colitis;
LUAD	cis	rs6835098	1.000	rs1054497	chr4:174089048	A/T	cg27433088	chr4:174089019	GALNT7	-0.38	-7.42	-0.34	6.51e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg20891558	chr2:74357851	NA	0.97	16.56	0.63	7.93e-48	Gestational age at birth (maternal effect);
LUAD	cis	rs929596	0.606	rs10178992	chr2:234657877	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.64	-11.1	-0.48	2.63e-25	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-12.01	-0.5	8.63e-29	Bipolar disorder;
LUAD	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.91	0.36	2.31e-14	Bladder cancer;
LUAD	cis	rs9644630	0.658	rs4427190	chr8:19321385	C/T	cg06699216	chr8:19333253	CSGALNACT1	0.27	6.47	0.3	2.76e-10	Oropharynx cancer;
LUAD	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg07917127	chr4:99064746	C4orf37	0.38	6.35	0.3	5.44e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg03886242	chr7:26192032	NFE2L3	-0.39	-6.72	-0.31	5.91e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg21385522	chr1:16154831	NA	0.44	6.67	0.31	8.08e-11	Dilated cardiomyopathy;
LUAD	trans	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg01620082	chr3:125678407	NA	-0.72	-7.28	-0.33	1.62e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9354308	1.000	rs9360161	chr6:66565457	C/T	cg07460842	chr6:66804631	NA	0.41	6.49	0.3	2.37e-10	Metabolite levels;
LUAD	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg06873352	chr17:61820015	STRADA	0.39	6.41	0.3	3.9e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg18402987	chr7:1209562	NA	0.88	12.01	0.5	8.9e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs72928364	1.000	rs13088524	chr3:100688082	A/C	cg10123952	chr3:100791384	NA	0.64	7.47	0.34	4.74e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg18827107	chr12:86230957	RASSF9	-0.46	-8.32	-0.38	1.2e-15	Major depressive disorder;
LUAD	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg19622623	chr12:86230825	RASSF9	-0.45	-7.74	-0.35	7.39e-14	Major depressive disorder;
LUAD	cis	rs240764	0.817	rs240147	chr6:101078300	G/A	cg09795085	chr6:101329169	ASCC3	0.43	7.52	0.34	3.23e-13	Neuroticism;
LUAD	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg16405210	chr4:1374714	KIAA1530	0.48	7.79	0.35	5.09e-14	Obesity-related traits;
LUAD	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg06197492	chr11:2016605	H19	0.36	7.35	0.34	1.04e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg16049864	chr8:95962084	TP53INP1	-0.6	-13.11	-0.54	3.38e-33	Type 2 diabetes;
LUAD	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.59	0.42	7.97e-20	Cognitive ability;
LUAD	trans	rs7395662	0.853	rs10838885	chr11:48398806	A/G	cg00717180	chr2:96193071	NA	-0.38	-7.09	-0.33	5.66e-12	HDL cholesterol;
LUAD	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg22875332	chr1:76189707	ACADM	0.79	13.09	0.54	4e-33	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg04450456	chr4:17643702	FAM184B	0.43	8.45	0.38	4.86e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	8.98	0.4	9.27e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg17147758	chr8:6949321	NA	-0.5	-8.97	-0.4	9.59e-18	Blood pressure (smoking interaction);
LUAD	cis	rs7940866	0.803	rs10894307	chr11:130876350	G/A	cg12179176	chr11:130786555	SNX19	0.42	6.6	0.31	1.22e-10	Schizophrenia;
LUAD	cis	rs239198	0.602	rs4840157	chr6:101326375	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-7.09	-0.33	5.66e-12	Menarche (age at onset);
LUAD	cis	rs4824093	0.610	rs7410773	chr22:50313727	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.87	-7.71	-0.35	9.29e-14	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg17264618	chr3:40429014	ENTPD3	0.43	9.12	0.41	3.06e-18	Renal cell carcinoma;
LUAD	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.85	-0.36	3.56e-14	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06649899	chr16:67261154	TMEM208;LRRC29	0.44	7.06	0.32	7.06e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg08085267	chr17:45401833	C17orf57	-0.54	-9.41	-0.42	3.28e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg01579765	chr21:45077557	HSF2BP	-0.58	-13.75	-0.56	7.77e-36	Mean corpuscular volume;
LUAD	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg09399716	chr2:46890238	NA	-0.46	-9.16	-0.41	2.21e-18	Height;
LUAD	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg14829155	chr15:31115871	NA	-0.59	-9.76	-0.43	2.02e-20	Huntington's disease progression;
LUAD	cis	rs68170813	0.559	rs4515482	chr7:107072681	A/C	cg02696742	chr7:106810147	HBP1	-0.78	-10.91	-0.47	1.42e-24	Coronary artery disease;
LUAD	cis	rs7665090	0.528	rs3774968	chr4:103531112	A/G	cg07973026	chr4:103553119	MANBA	0.41	6.58	0.3	1.37e-10	Primary biliary cholangitis;
LUAD	trans	rs11039798	0.920	rs11040013	chr11:48782862	G/A	cg15704280	chr7:45808275	SEPT13	0.66	7.53	0.34	3.18e-13	Axial length;
LUAD	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg08632164	chr7:65971372	NA	-0.55	-6.42	-0.3	3.67e-10	Diabetic kidney disease;
LUAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg22535103	chr8:58192502	C8orf71	-0.72	-8.94	-0.4	1.24e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.1	-0.57	2.7e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg21433313	chr16:3507492	NAT15	0.74	9.65	0.42	4.61e-20	Tuberculosis;
LUAD	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg15147215	chr3:52552868	STAB1	-0.41	-7.41	-0.34	7.02e-13	Bipolar disorder;
LUAD	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.39	-6.38	-0.3	4.78e-10	Tonsillectomy;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09529537	chr5:78531947	JMY	0.42	6.62	0.31	1.09e-10	Monocyte percentage of white cells;
LUAD	cis	rs9914544	0.545	rs8067882	chr17:18807131	A/G	cg25390199	chr17:18761479	PRPSAP2	-0.39	-6.38	-0.3	4.62e-10	Educational attainment (years of education);
LUAD	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg25894440	chr7:65020034	NA	-0.62	-6.69	-0.31	6.99e-11	Diabetic kidney disease;
LUAD	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg08798685	chr6:27730294	NA	-0.67	-7.09	-0.33	5.83e-12	Breast cancer;
LUAD	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.5	8.4	0.38	6.61e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs9902453	0.967	rs8067576	chr17:28444254	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.53	0.38	2.56e-16	Coffee consumption (cups per day);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09158336	chr17:76338205	NA	-0.54	-6.51	-0.3	2.13e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg06627628	chr2:24431161	ITSN2	-0.5	-8.71	-0.39	7.03e-17	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg19622623	chr12:86230825	RASSF9	-0.45	-7.92	-0.36	2.19e-14	Major depressive disorder;
LUAD	cis	rs62238980	0.614	rs743763	chr22:32458861	C/T	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs1448094	0.967	rs7312144	chr12:86328256	T/C	cg00310523	chr12:86230176	RASSF9	0.35	7.56	0.34	2.58e-13	Major depressive disorder;
LUAD	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg14458575	chr2:238380390	NA	0.7	12.87	0.53	3.38e-32	Prostate cancer;
LUAD	cis	rs9875589	0.509	rs7648345	chr3:14039901	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	7.23	0.33	2.3e-12	Ovarian reserve;
LUAD	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg10556349	chr10:835070	NA	0.67	7.97	0.36	1.48e-14	Eosinophil percentage of granulocytes;
LUAD	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg22920501	chr2:26401640	FAM59B	0.7	10.41	0.45	9.67e-23	Gut microbiome composition (summer);
LUAD	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg13319975	chr6:146136371	FBXO30	0.82	14.28	0.57	4.93e-38	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg09253696	chr17:73873529	TRIM47	-0.45	-7.53	-0.34	3.09e-13	Psoriasis;
LUAD	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg07828340	chr4:882639	GAK	1.07	10.86	0.47	2.18e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg03474202	chr17:45855739	NA	0.39	9.51	0.42	1.43e-19	IgG glycosylation;
LUAD	cis	rs68170813	0.641	rs34084719	chr7:107095227	A/G	cg02696742	chr7:106810147	HBP1	-0.8	-9.97	-0.44	3.47e-21	Coronary artery disease;
LUAD	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg08632164	chr7:65971372	NA	-0.37	-6.45	-0.3	2.98e-10	Aortic root size;
LUAD	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.8	0.53	6.31e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg10556349	chr10:835070	NA	-0.43	-6.59	-0.31	1.3100000000000001e-10	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg18876405	chr7:65276391	NA	0.44	7.37	0.34	9.1e-13	Calcium levels;
LUAD	cis	rs870825	0.616	rs2003994	chr4:185636568	G/T	cg04058563	chr4:185651563	MLF1IP	0.88	14.04	0.56	4.87e-37	Blood protein levels;
LUAD	cis	rs367943	0.666	rs10041899	chr5:112724742	A/T	cg12552261	chr5:112820674	MCC	0.48	9.32	0.41	6.67e-19	Type 2 diabetes;
LUAD	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg00933542	chr6:150070202	PCMT1	0.4	7.9	0.36	2.4e-14	Lung cancer;
LUAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg00080972	chr5:178986291	RUFY1	0.59	9.12	0.41	3.16e-18	Lung cancer;
LUAD	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg19862616	chr7:65841803	NCRNA00174	1.05	26.51	0.79	5.76e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.67	0.31	8.08e-11	Prudent dietary pattern;
LUAD	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg25208724	chr1:156163844	SLC25A44	1.18	26.35	0.79	3.05e-91	Testicular germ cell tumor;
LUAD	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg19610905	chr11:61596333	FADS2	0.6	10.44	0.45	7.52e-23	Trans fatty acid levels;
LUAD	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg21699342	chr2:239360505	ASB1	0.56	10.85	0.47	2.37e-24	Multiple system atrophy;
LUAD	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.5	0.3	2.31e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg14686297	chr22:46650375	NA	-0.38	-6.57	-0.3	1.44e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.51	0.55	7.95e-35	Prudent dietary pattern;
LUAD	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg26022315	chr17:47021804	SNF8	0.4	7.27	0.33	1.77e-12	Type 2 diabetes;
LUAD	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	6.65	0.31	8.97e-11	Personality dimensions;
LUAD	cis	rs8170	0.603	rs10259	chr19:17430915	G/A	cg04749549	chr19:17459798	NA	-0.37	-6.89	-0.32	1.99e-11	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUAD	cis	rs231513	0.769	rs537169	chr17:41976740	G/A	cg26893861	chr17:41843967	DUSP3	-0.54	-6.55	-0.3	1.69e-10	Cognitive function;
LUAD	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg00080972	chr5:178986291	RUFY1	0.58	8.84	0.39	2.68e-17	Lung cancer;
LUAD	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21016266	chr12:122356598	WDR66	0.63	11.44	0.49	1.34e-26	Mean corpuscular volume;
LUAD	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg08999081	chr20:33150536	PIGU	0.63	14.53	0.58	4.13e-39	Coronary artery disease;
LUAD	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.72	-12.34	-0.51	4.14e-30	Breast cancer;
LUAD	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23583168	chr7:148888333	NA	-0.81	-13.76	-0.56	7.54e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg03609598	chr5:56110824	MAP3K1	-0.68	-9.21	-0.41	1.59e-18	Initial pursuit acceleration;
LUAD	cis	rs7588746	0.521	rs73054585	chr2:201144386	T/A	cg17644776	chr2:200775616	C2orf69	-0.45	-6.56	-0.3	1.61e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LUAD	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg20503657	chr10:835505	NA	1.24	18.49	0.67	2.18e-56	Eosinophil percentage of granulocytes;
LUAD	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg05044414	chr3:183734942	ABCC5	0.48	10.01	0.44	2.6e-21	Anterior chamber depth;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01484320	chr1:109757057	SARS	-0.43	-6.62	-0.31	1.08e-10	Height;
LUAD	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg05805236	chr11:65401703	PCNXL3	-0.54	-8.98	-0.4	8.86e-18	Acne (severe);
LUAD	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg01191920	chr7:158217561	PTPRN2	0.62	13.06	0.54	5.3e-33	Obesity-related traits;
LUAD	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg03714773	chr7:91764589	CYP51A1	0.27	6.51	0.3	2.18e-10	Breast cancer;
LUAD	cis	rs62458065	0.640	rs10241303	chr7:32534203	T/G	cg20159608	chr7:32802032	NA	-0.64	-8.74	-0.39	5.68e-17	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs8072100	0.537	rs9912450	chr17:45402208	C/T	cg25173405	chr17:45401733	C17orf57	-0.66	-10.74	-0.46	5.76e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg25358565	chr5:93447407	FAM172A	0.63	7.4	0.34	7.42e-13	Diabetic retinopathy;
LUAD	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg13319975	chr6:146136371	FBXO30	0.66	11.42	0.49	1.67e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17539620	0.519	rs12665532	chr6:154835182	C/G	cg20019720	chr6:154832845	CNKSR3	0.64	14.2	0.57	1.11e-37	Lipoprotein (a) levels;
LUAD	trans	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.75	11.08	0.47	3.15e-25	Ulcerative colitis;
LUAD	trans	rs8002861	0.875	rs12872943	chr13:44410553	G/A	cg17145862	chr1:211918768	LPGAT1	-0.66	-14.28	-0.57	5.03e-38	Leprosy;
LUAD	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg15448220	chr1:150897856	SETDB1	0.48	8.27	0.37	1.81e-15	Melanoma;
LUAD	cis	rs9863	0.828	rs4765541	chr12:124465995	T/C	cg17723958	chr12:124429295	CCDC92	-0.39	-6.56	-0.3	1.6e-10	White blood cell count;
LUAD	trans	rs3219090	1.000	rs1341336	chr1:226596389	A/G	cg27539482	chr13:111589090	NA	0.43	7.22	0.33	2.49e-12	Melanoma;
LUAD	cis	rs17767294	0.541	rs72845050	chr6:27610070	A/C	cg08851530	chr6:28072375	NA	1.02	7.58	0.35	2.2e-13	Parkinson's disease;
LUAD	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg07211511	chr3:129823064	LOC729375	-0.84	-12.25	-0.51	9.76e-30	Blood pressure (smoking interaction);
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08812504	chr1:180123798	QSOX1	-0.39	-6.57	-0.3	1.5e-10	Schizophrenia;
LUAD	cis	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg01251360	chr16:68772225	CDH1	0.27	8.62	0.39	1.32e-16	Colorectal cancer;
LUAD	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg24768116	chr2:27665128	KRTCAP3	0.27	6.56	0.3	1.58e-10	Oral cavity cancer;
LUAD	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg13736514	chr6:26305472	NA	-0.76	-13.87	-0.56	2.6e-36	Educational attainment;
LUAD	cis	rs704	0.585	rs1007398	chr17:26665648	A/G	cg10342447	chr17:26645325	TMEM97	-0.4	-8.02	-0.36	1.08e-14	Osteoprotegerin levels;
LUAD	cis	rs8099014	1.000	rs7238962	chr18:56130112	A/G	cg12907477	chr18:56117327	MIR122	0.38	6.42	0.3	3.76e-10	Platelet count;
LUAD	trans	rs11039798	1.000	rs8188963	chr11:48685693	C/A	cg02254774	chr11:50257496	LOC441601	0.53	6.61	0.31	1.19e-10	Axial length;
LUAD	cis	rs3803170	0.513	rs11065888	chr12:111828663	G/C	cg10833066	chr12:111807467	FAM109A	0.47	8.71	0.39	6.67e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg21963583	chr11:68658836	MRPL21	0.67	11.74	0.5	9.42e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs12760731	0.565	rs116253445	chr1:178216962	C/T	cg00404053	chr1:178313656	RASAL2	0.72	9.09	0.4	4.02e-18	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs526821	0.553	rs519637	chr11:55295935	A/T	cg04317927	chr11:55418816	OR4S2	0.39	7.29	0.33	1.52e-12	Pediatric bone mineral density (spine);
LUAD	trans	rs8073060	0.544	rs7211724	chr17:33993414	C/G	cg19694781	chr19:47549865	TMEM160	-1.23	-19.69	-0.69	1.02e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03352830	chr11:487213	PTDSS2	0.81	10.46	0.45	6.49e-23	Body mass index;
LUAD	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.53	-0.38	2.66e-16	Alzheimer's disease (late onset);
LUAD	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg18129748	chr3:49941408	MST1R	-0.4	-6.56	-0.3	1.56e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg26384229	chr12:38710491	ALG10B	0.38	6.48	0.3	2.48e-10	Bladder cancer;
LUAD	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg13560548	chr3:10150139	C3orf24	0.39	6.5	0.3	2.22e-10	Alzheimer's disease;
LUAD	cis	rs9486719	0.749	rs1009596	chr6:96843688	A/G	cg06623918	chr6:96969491	KIAA0776	0.71	9.3	0.41	7.58e-19	Migraine;Coronary artery disease;
LUAD	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg10645314	chr2:3704589	ALLC	-0.42	-7.33	-0.34	1.18e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg14019146	chr3:50243930	SLC38A3	-0.39	-7.62	-0.35	1.74e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg13685833	chr1:53393034	SCP2	-0.4	-6.66	-0.31	8.28e-11	Monocyte count;
LUAD	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg06636001	chr8:8085503	FLJ10661	0.43	6.86	0.32	2.39e-11	Mood instability;
LUAD	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg00321850	chr1:175162397	KIAA0040	0.54	11.67	0.49	1.82e-27	Alcohol dependence;
LUAD	trans	rs28735056	0.904	rs12962619	chr18:77628832	T/C	cg05926928	chr17:57297772	GDPD1	0.5	7.37	0.34	8.96e-13	Schizophrenia;
LUAD	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg04673462	chr1:38461896	NA	0.41	8.36	0.38	9.31e-16	Coronary artery disease;
LUAD	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg08847533	chr14:75593920	NEK9	-0.39	-6.74	-0.31	5.06e-11	Height;
LUAD	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18404041	chr3:52824283	ITIH1	-0.67	-14.46	-0.58	8.82e-39	Bipolar disorder;
LUAD	cis	rs4268898	0.760	rs7597919	chr2:24563646	A/G	cg06627628	chr2:24431161	ITSN2	0.39	6.86	0.32	2.49e-11	Asthma;
LUAD	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg24801067	chr17:62843696	NA	-0.56	-7.69	-0.35	1.01e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg06640241	chr16:89574553	SPG7	0.48	8.01	0.36	1.16e-14	Multiple myeloma (IgH translocation);
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg05370988	chr3:186500739	EIF4A2	0.42	7.19	0.33	2.98e-12	Anger;
LUAD	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg04586622	chr2:25135609	ADCY3	0.36	8.31	0.37	1.34e-15	Body mass index;
LUAD	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg17724175	chr1:150552817	MCL1	-0.41	-9.31	-0.41	6.76e-19	Blood protein levels;
LUAD	cis	rs7975161	0.515	rs7299866	chr12:104576197	C/T	cg25273343	chr12:104657179	TXNRD1	-0.55	-6.88	-0.32	2.17e-11	Toenail selenium levels;
LUAD	cis	rs747650	0.892	rs7111764	chr11:47233209	G/A	cg19486271	chr11:47235900	DDB2	-0.44	-7.33	-0.34	1.15e-12	Acne (severe);
LUAD	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.45	-7.97	-0.36	1.53e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg23625390	chr15:77176239	SCAPER	-0.53	-8.05	-0.36	8.19e-15	Blood metabolite levels;
LUAD	cis	rs10744422	0.925	rs2292132	chr12:123332834	T/C	cg16953816	chr12:123349952	VPS37B	0.59	6.64	0.31	9.46e-11	Schizophrenia;
LUAD	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg26384229	chr12:38710491	ALG10B	0.48	7.83	0.36	3.98e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg22920501	chr2:26401640	FAM59B	0.78	11.26	0.48	6.46e-26	Gut microbiome composition (summer);
LUAD	cis	rs7089973	0.934	rs12771956	chr10:116576228	C/G	cg23260525	chr10:116636907	FAM160B1	0.42	8.5	0.38	3.17e-16	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg03300805	chr3:127266751	NA	-0.68	-6.58	-0.3	1.36e-10	Type 2 diabetes;
LUAD	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.33	-9.12	-0.41	3.05e-18	Total body bone mineral density;
LUAD	cis	rs2637266	0.935	rs1907323	chr10:78336015	C/T	cg18941641	chr10:78392320	NA	0.32	6.7	0.31	6.87e-11	Pulmonary function;
LUAD	cis	rs7089973	0.872	rs11818115	chr10:116634891	G/A	cg25233709	chr10:116636983	FAM160B1	0.39	7.55	0.34	2.67e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.9	0.36	2.43e-14	Breast cancer;
LUAD	cis	rs2244613	0.832	rs7187684	chr16:55794951	C/T	cg27396498	chr16:55794478	CES4	-0.5	-7.27	-0.33	1.79e-12	Response to dabigatran etexilate treatment;
LUAD	cis	rs3823572	0.504	rs2346266	chr7:133639533	A/G	cg03336402	chr7:133662267	EXOC4	0.41	7.5	0.34	3.8e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg00450029	chr8:599525	NA	0.83	8.34	0.38	1.08e-15	IgG glycosylation;
LUAD	trans	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg11693508	chr17:37793320	STARD3	0.56	8.06	0.36	7.99e-15	Neuroticism;
LUAD	trans	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.36	-0.3	5.32e-10	Systolic blood pressure;
LUAD	cis	rs3845702	0.668	rs6759271	chr2:180844303	T/C	cg01881094	chr2:180872142	CWC22	-0.82	-8.72	-0.39	6.23e-17	Schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg15718162	chr19:47551509	TMEM160	-0.63	-6.7	-0.31	6.87e-11	Type 2 diabetes;
LUAD	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg08601574	chr20:25228251	PYGB	-0.47	-8.82	-0.39	2.94e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14240646	chr10:27532245	ACBD5	0.92	12.09	0.51	4.17e-29	Breast cancer;
LUAD	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.13	-30.96	-0.83	8.62e-111	Myeloid white cell count;
LUAD	cis	rs1691799	0.899	rs1183272	chr12:66735421	T/C	cg16791601	chr12:66731901	HELB	-0.36	-6.57	-0.3	1.49e-10	White blood cell count (basophil);
LUAD	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.78e-11	Crohn's disease;
LUAD	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg03354898	chr7:1950403	MAD1L1	-0.39	-7.43	-0.34	6.03e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg16989719	chr2:238392110	NA	-0.35	-6.38	-0.3	4.64e-10	Prostate cancer;
LUAD	cis	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg11143507	chr3:125485238	NA	-0.44	-7.39	-0.34	7.83e-13	Blood pressure (smoking interaction);
LUAD	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg22920501	chr2:26401640	FAM59B	-0.82	-11.54	-0.49	5.88e-27	Gut microbiome composition (summer);
LUAD	cis	rs889398	0.774	rs6499263	chr16:69890149	T/C	cg00738113	chr16:70207722	CLEC18C	-0.35	-6.89	-0.32	1.99e-11	Body mass index;
LUAD	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg00495681	chr13:53174319	NA	0.68	13.68	0.55	1.61e-35	Lewy body disease;
LUAD	cis	rs17401966	1.000	rs4845934	chr1:10468946	G/A	cg15208524	chr1:10270712	KIF1B	0.51	7.45	0.34	5.25e-13	Hepatocellular carcinoma;
LUAD	cis	rs11971779	0.617	rs66652773	chr7:139109573	C/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	7.16e-11	Diisocyanate-induced asthma;
LUAD	trans	rs1459104	0.636	rs559362	chr11:55275456	T/G	cg15704280	chr7:45808275	SEPT13	0.63	7.22	0.33	2.37e-12	Body mass index;
LUAD	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	6.45	0.3	3.05e-10	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg03467027	chr4:99064603	C4orf37	0.41	6.75	0.31	4.81e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg13870426	chr17:30244630	NA	-0.56	-6.62	-0.31	1.1e-10	Hip circumference adjusted for BMI;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16242888	chr9:34179479	UBAP1	-0.43	-6.62	-0.31	1.12e-10	Height;
LUAD	trans	rs853679	0.546	rs13213152	chr6:28349698	A/G	cg06606381	chr12:133084897	FBRSL1	-1.25	-10.76	-0.46	5.08e-24	Depression;
LUAD	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg05182265	chr7:156933206	UBE3C	0.81	17.09	0.64	3.51e-50	Body mass index;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg00779477	chr16:89787489	ZNF276;C16orf7	-0.41	-7.17	-0.33	3.38e-12	Schizophrenia;
LUAD	cis	rs11971779	0.680	rs7805767	chr7:139111415	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	7.16e-11	Diisocyanate-induced asthma;
LUAD	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.52	-0.38	2.93e-16	Total body bone mineral density;
LUAD	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg15017067	chr4:17643749	FAM184B	0.35	7.0	0.32	1.04e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg11494091	chr17:61959527	GH2	0.74	18.57	0.67	1.04e-56	Prudent dietary pattern;
LUAD	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg07570687	chr10:102243282	WNT8B	0.46	7.28	0.33	1.66e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06544989	chr22:39130855	UNC84B	0.42	7.75	0.35	6.82e-14	Menopause (age at onset);
LUAD	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg01765077	chr12:122356316	WDR66	0.58	10.24	0.45	4.04e-22	Mean platelet volume;
LUAD	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg06064525	chr11:970664	AP2A2	-0.43	-8.38	-0.38	7.77e-16	Alzheimer's disease (late onset);
LUAD	trans	rs1493916	1.000	rs4393645	chr18:31394407	C/T	cg27147174	chr7:100797783	AP1S1	-0.68	-11.96	-0.5	1.35e-28	Life satisfaction;
LUAD	cis	rs6430585	0.640	rs58301703	chr2:136532225	G/A	cg07169764	chr2:136633963	MCM6	0.79	8.99	0.4	8.54e-18	Corneal structure;
LUAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg22907277	chr7:1156413	C7orf50	0.51	8.47	0.38	4.16e-16	Longevity;Endometriosis;
LUAD	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.92	0.36	2.15e-14	Bladder cancer;
LUAD	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg15790184	chr11:494944	RNH1	0.4	6.64	0.31	9.47e-11	Systemic lupus erythematosus;
LUAD	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg04756594	chr16:24857601	SLC5A11	0.51	10.05	0.44	1.85e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg17724175	chr1:150552817	MCL1	0.38	8.69	0.39	8.21e-17	Melanoma;
LUAD	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg18876405	chr7:65276391	NA	0.47	7.6	0.35	1.99e-13	Aortic root size;
LUAD	cis	rs4642101	0.793	rs13086170	chr3:12832604	G/C	cg24848339	chr3:12840334	CAND2	0.41	8.19	0.37	3.11e-15	QRS complex (12-leadsum);
LUAD	cis	rs6460942	1.000	rs79964328	chr7:12319392	A/C	cg06484146	chr7:12443880	VWDE	-0.54	-6.44	-0.3	3.32e-10	Coronary artery disease;
LUAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.22	-0.41	1.38e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-12.89	-0.53	2.75e-32	Breast cancer;
LUAD	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg16479474	chr6:28041457	NA	0.45	7.73	0.35	7.89e-14	Parkinson's disease;
LUAD	cis	rs4888262	0.526	rs4887777	chr16:74637821	A/G	cg01733217	chr16:74700730	RFWD3	0.51	8.53	0.38	2.57e-16	Testicular germ cell tumor;
LUAD	trans	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.05e-19	Life satisfaction;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg04249066	chr8:144680433	EEF1D;TIGD5	0.39	6.38	0.3	4.7e-10	Optic cup area;
LUAD	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg26304593	chr6:42947056	PEX6	-0.44	-7.41	-0.34	7.03e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs11677416	1.000	rs3783555	chr2:113531093	T/C	cg27083787	chr2:113543245	IL1A	0.38	6.46	0.3	2.8e-10	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.53	0.34	3.03e-13	Bipolar disorder;
LUAD	cis	rs220324	0.738	rs9984830	chr21:43570705	A/G	cg09727148	chr21:43560719	UMODL1	0.48	7.42	0.34	6.54e-13	Idiopathic osteonecrosis of the femoral head;
LUAD	trans	rs28735056	0.508	rs67651675	chr18:77673562	A/G	cg05926928	chr17:57297772	GDPD1	-0.43	-6.45	-0.3	2.99e-10	Schizophrenia;
LUAD	cis	rs4594175	0.926	rs12434681	chr14:51595335	A/G	cg23942311	chr14:51606299	NA	0.65	10.78	0.46	4.36e-24	Cancer;
LUAD	cis	rs7089973	0.836	rs1966384	chr10:116627910	G/T	cg25233709	chr10:116636983	FAM160B1	0.39	7.47	0.34	4.68e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs807669	0.777	rs9605972	chr22:19253274	C/T	cg02655711	chr22:19163373	SLC25A1	0.67	14.51	0.58	5.49e-39	Metabolite levels;
LUAD	cis	rs853679	0.527	rs9461443	chr6:28194629	A/T	cg16479474	chr6:28041457	NA	0.4	6.99	0.32	1.1e-11	Depression;
LUAD	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.69	-12.75	-0.53	1e-31	Ulcerative colitis;
LUAD	trans	rs75804782	0.521	rs2117691	chr2:239414734	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	8.06	0.36	7.81e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs4523957	0.548	rs7225623	chr17:2089548	T/C	cg16513277	chr17:2031491	SMG6	-0.87	-16.6	-0.63	5.24e-48	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20149956	chr1:249132233	ZNF672	-0.59	-7.23	-0.33	2.28e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg12119029	chr16:89752879	CDK10	0.32	6.56	0.3	1.54e-10	Vitiligo;
LUAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg07677032	chr17:61819896	STRADA	0.57	10.26	0.45	3.23e-22	Prudent dietary pattern;
LUAD	cis	rs7474896	0.559	rs1735629	chr10:38178309	C/T	cg25427524	chr10:38739819	LOC399744	0.6	8.46	0.38	4.25e-16	Obesity (extreme);
LUAD	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg27624424	chr6:160112604	SOD2	0.45	6.46	0.3	2.83e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.88	-0.36	2.8e-14	Neutrophil percentage of white cells;
LUAD	cis	rs4072705	1.000	rs10818983	chr9:127411577	T/A	cg13476313	chr9:127244764	NR5A1	0.3	7.35	0.34	1.02e-12	Menarche (age at onset);
LUAD	cis	rs938554	0.784	rs4481233	chr4:9956079	A/G	cg00071950	chr4:10020882	SLC2A9	0.57	8.38	0.38	7.97e-16	Blood metabolite levels;
LUAD	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg26408565	chr15:76604113	ETFA	-0.48	-7.48	-0.34	4.47e-13	Blood metabolite levels;
LUAD	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg06740227	chr12:86229804	RASSF9	0.39	7.03	0.32	8.28e-12	Major depressive disorder;
LUAD	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg07167872	chr1:205819463	PM20D1	-0.41	-6.84	-0.32	2.76e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg17330251	chr7:94953956	PON1	-0.53	-7.17	-0.33	3.36e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg23254163	chr1:152506842	NA	0.25	7.08	0.33	6.14e-12	Hair morphology;
LUAD	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg05082376	chr22:42548792	NA	0.45	7.85	0.36	3.38e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1448094	0.872	rs1026085	chr12:86355735	A/G	cg00310523	chr12:86230176	RASSF9	0.35	7.4	0.34	7.34e-13	Major depressive disorder;
LUAD	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.74e-12	Breast cancer;
LUAD	cis	rs2224391	0.628	rs2753230	chr6:5248538	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	0.61	9.68	0.43	3.84e-20	Height;
LUAD	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.6	8.45	0.38	4.59e-16	Gut microbiome composition (summer);
LUAD	cis	rs490234	0.966	rs542974	chr9:128373218	G/A	cg14078157	chr9:128172775	NA	0.37	6.87	0.32	2.26e-11	Mean arterial pressure;
LUAD	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg26373071	chr5:1325741	CLPTM1L	0.35	7.11	0.33	5.05e-12	Lung cancer;
LUAD	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg07606381	chr6:8435919	SLC35B3	0.41	6.88	0.32	2.13e-11	Motion sickness;
LUAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.47	-0.38	3.96e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2485376	0.967	rs2485375	chr10:104049966	C/T	cg20641465	chr10:103991465	PITX3	-0.58	-10.7	-0.46	8.59e-24	QT interval;
LUAD	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg25173405	chr17:45401733	C17orf57	0.45	7.83	0.36	4.03e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.57	-0.35	2.38e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3760982	0.585	rs1386502	chr19:44293356	T/C	cg12072164	chr19:44306565	LYPD5	0.42	8.49	0.38	3.57e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg10518543	chr12:38710700	ALG10B	-0.49	-8.19	-0.37	3.21e-15	Morning vs. evening chronotype;
LUAD	trans	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg17712092	chr4:129076599	LARP1B	-0.77	-11.86	-0.5	3.29e-28	Breast cancer;
LUAD	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.62	0.55	2.78e-35	Urate levels;
LUAD	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7607369	0.559	rs4674339	chr2:219659787	C/G	cg02176678	chr2:219576539	TTLL4	-0.54	-10.53	-0.46	3.62e-23	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg06873352	chr17:61820015	STRADA	-0.51	-7.41	-0.34	6.84e-13	Height;
LUAD	cis	rs701145	0.585	rs436852	chr3:153913403	G/A	cg17054900	chr3:154042577	DHX36	0.65	7.28	0.33	1.63e-12	Coronary artery disease;
LUAD	cis	rs4589502	1.000	rs80263963	chr15:67127228	C/T	cg09911534	chr15:67153556	NA	-0.52	-6.69	-0.31	7.03e-11	Lung cancer (smoking interaction);
LUAD	cis	rs2692947	0.702	rs7604842	chr2:96777340	C/T	cg23100626	chr2:96804247	ASTL	-0.34	-8.85	-0.4	2.48e-17	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2004318	1.000	rs78747672	chr19:55077875	A/G	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.93e-13	Blood protein levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg18297491	chr5:180670388	GNB2L1;SNORD96A;SNORD95	-0.42	-6.76	-0.31	4.73e-11	Cancer;
LUAD	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.44e-10	Prostate cancer;
LUAD	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg08798685	chr6:27730294	NA	-0.43	-6.99	-0.32	1.09e-11	Parkinson's disease;
LUAD	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg10518543	chr12:38710700	ALG10B	-0.5	-8.19	-0.37	3.08e-15	Morning vs. evening chronotype;
LUAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg22764044	chr5:178986830	RUFY1	0.64	11.13	0.48	2.08e-25	Lung cancer;
LUAD	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg24596788	chr1:163392923	NA	-0.35	-7.8	-0.35	5e-14	Motion sickness;
LUAD	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg14092988	chr3:52407081	DNAH1	0.41	8.06	0.36	7.97e-15	Bipolar disorder;
LUAD	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg20203395	chr5:56204925	C5orf35	-0.7	-10.05	-0.44	1.88e-21	Initial pursuit acceleration;
LUAD	cis	rs758324	0.947	rs13154286	chr5:131160189	A/G	cg25547332	chr5:131281432	NA	0.42	6.51	0.3	2.18e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26314531	chr2:26401878	FAM59B	-0.56	-7.78	-0.35	5.77e-14	Gut microbiome composition (summer);
LUAD	cis	rs1478897	0.898	rs2249040	chr8:11390779	A/T	cg27411982	chr8:10470053	RP1L1	-0.36	-6.36	-0.3	5.21e-10	Systemic lupus erythematosus;
LUAD	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs62238980	0.614	rs7289853	chr22:32427773	C/G	cg00543991	chr22:32367038	NA	0.81	7.87	0.36	2.91e-14	Childhood ear infection;
LUAD	cis	rs10992471	0.528	rs10761158	chr9:95205322	T/G	cg14631576	chr9:95140430	CENPP	-0.49	-9.99	-0.44	3.18e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-16.28	-0.62	1.23e-46	Schizophrenia;
LUAD	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg13390004	chr1:15929781	NA	-0.47	-8.42	-0.38	5.92e-16	Systolic blood pressure;
LUAD	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06022373	chr22:39101656	GTPBP1	0.48	7.86	0.36	3.31e-14	Menopause (age at onset);
LUAD	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg20587970	chr11:113659929	NA	-1.39	-20.52	-0.71	1.95e-65	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg23840854	chr1:161414152	NA	-0.86	-11.14	-0.48	1.95e-25	Rheumatoid arthritis;
LUAD	cis	rs12976411	0.575	rs35798291	chr19:32826264	T/C	cg02282382	chr19:32836354	ZNF507	0.71	6.44	0.3	3.24e-10	Coronary artery disease;
LUAD	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg18944383	chr4:111397179	ENPEP	0.48	9.12	0.41	3.18e-18	Coronary artery disease;
LUAD	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg24818145	chr4:99064322	C4orf37	-0.49	-8.49	-0.38	3.66e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg23992470	chr4:843637	GAK	0.72	7.48	0.34	4.34e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg07741184	chr6:167504864	NA	0.3	7.24	0.33	2.14e-12	Crohn's disease;
LUAD	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.5	6.62	0.31	1.08e-10	Platelet count;
LUAD	cis	rs243505	0.898	rs243536	chr7:148409941	C/T	cg09806900	chr7:148480153	CUL1	0.39	6.56	0.3	1.55e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs10799445	0.569	rs2999745	chr1:227792539	C/T	cg12133451	chr1:227746453	NA	-0.36	-6.39	-0.3	4.32e-10	Height;
LUAD	cis	rs870825	0.616	rs56232457	chr4:185628153	T/G	cg04058563	chr4:185651563	MLF1IP	0.84	13.85	0.56	3.03e-36	Blood protein levels;
LUAD	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.55	-0.6	1.9e-43	Chronic sinus infection;
LUAD	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.44	0.34	5.55e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg08888203	chr3:10149979	C3orf24	0.63	10.73	0.46	6.56e-24	Alzheimer's disease;
LUAD	trans	rs72766638	1.000	rs72766638	chr9:136931778	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.54	-6.48	-0.3	2.58e-10	Mosquito bite size;
LUAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.67	-12.78	-0.53	7.48e-32	Prudent dietary pattern;
LUAD	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg06263672	chr7:65235340	NA	0.48	6.46	0.3	2.93e-10	Aortic root size;
LUAD	cis	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg07460842	chr6:66804631	NA	0.91	14.35	0.57	2.47e-38	Exhaled nitric oxide levels;
LUAD	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.45	0.34	5.29e-13	Bipolar disorder;
LUAD	cis	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg07460842	chr6:66804631	NA	0.83	9.8	0.43	1.43e-20	Exhaled nitric oxide output;
LUAD	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-11.35	-0.48	3.07e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg25554036	chr4:6271136	WFS1	0.69	13.84	0.56	3.36e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg27490568	chr2:178487706	NA	-0.61	-8.79	-0.39	3.77e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23300289	chr9:132146083	NA	0.4	6.37	0.3	4.88e-10	Gut microbiome composition (summer);
LUAD	cis	rs2554380	0.843	rs1426162	chr15:84386003	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.48	-7.45	-0.34	5.45e-13	Height;
LUAD	cis	rs7215564	0.908	rs34547024	chr17:78661373	C/G	cg09596252	chr17:78655493	RPTOR	0.53	6.49	0.3	2.36e-10	Myopia (pathological);
LUAD	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg26168224	chr5:2018326	NA	-0.57	-9.64	-0.42	5.34e-20	Gut microbiome composition (winter);
LUAD	cis	rs3760982	0.585	rs11673534	chr19:44298884	G/A	cg21496419	chr19:44306685	LYPD5	0.34	7.59	0.35	2.1e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs1832871	0.672	rs9457362	chr6:158772052	C/T	cg07165851	chr6:158734300	TULP4	0.72	11.32	0.48	4.12e-26	Height;
LUAD	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.72	0.31	5.95e-11	Menarche (age at onset);
LUAD	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg25985355	chr7:65971099	NA	-0.51	-6.41	-0.3	3.8e-10	Diabetic kidney disease;
LUAD	cis	rs9560113	0.573	rs7988040	chr13:112226534	C/G	cg10483660	chr13:112241077	NA	0.47	9.75	0.43	2.18e-20	Menarche (age at onset);
LUAD	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg15704280	chr7:45808275	SEPT13	-0.69	-11.05	-0.47	4.22e-25	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg23254163	chr1:152506842	NA	0.25	7.07	0.33	6.24e-12	Hair morphology;
LUAD	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg07870213	chr5:140052090	DND1	1.04	14.61	0.58	2.06e-39	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7493	0.901	rs17882539	chr7:95026408	G/A	cg21856205	chr7:94953877	PON1	-0.55	-7.89	-0.36	2.53e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.24	0.45	3.97e-22	Mean corpuscular volume;
LUAD	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.56	-0.38	2.16e-16	Total body bone mineral density;
LUAD	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg21385522	chr1:16154831	NA	-0.57	-9.1	-0.4	3.67e-18	Systolic blood pressure;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg22265110	chr17:4871194	SPAG7	-0.67	-6.81	-0.31	3.41e-11	Type 2 diabetes;
LUAD	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg07677032	chr17:61819896	STRADA	0.51	9.18	0.41	1.91e-18	Prudent dietary pattern;
LUAD	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.46	0.34	5.03e-13	Bipolar disorder;
LUAD	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg06108461	chr20:60628389	TAF4	-0.82	-14.18	-0.57	1.32e-37	Body mass index;
LUAD	cis	rs2227564	0.794	rs2688620	chr10:75684532	A/G	cg23231163	chr10:75533350	FUT11	-0.42	-6.41	-0.3	3.87e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7677751	0.767	rs890204	chr4:55064439	C/G	cg17187183	chr4:55093834	PDGFRA	0.44	7.29	0.33	1.51e-12	Corneal astigmatism;
LUAD	trans	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg26811252	chr16:29126840	RRN3P2	0.61	10.35	0.45	1.63e-22	Menopause (age at onset);
LUAD	trans	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg18512352	chr11:47633146	NA	-0.57	-10.14	-0.44	8.77e-22	Subjective well-being;
LUAD	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg19163074	chr7:65112434	INTS4L2	0.43	6.61	0.31	1.18e-10	Aortic root size;
LUAD	cis	rs758324	0.812	rs10045303	chr5:131202801	C/T	cg25547332	chr5:131281432	NA	-0.43	-7.12	-0.33	4.79e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg13859433	chr6:33739653	LEMD2	-0.36	-7.49	-0.34	3.99e-13	Schizophrenia;
LUAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg24846343	chr22:24311635	DDTL	0.78	17.83	0.65	1.99e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7119	0.635	rs2682910	chr15:77880114	C/A	cg27398640	chr15:77910606	LINGO1	0.42	8.16	0.37	4e-15	Type 2 diabetes;
LUAD	cis	rs72772090	0.539	rs72775810	chr5:96185307	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-6.76	-0.31	4.7e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25887236	chr18:74844781	MBP	-0.54	-6.66	-0.31	8.62e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg08601574	chr20:25228251	PYGB	-0.47	-8.9	-0.4	1.66e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs13082711	0.911	rs6797389	chr3:27502070	G/T	cg02860705	chr3:27208620	NA	0.61	9.35	0.41	5.18e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg17551891	chr7:1960795	MAD1L1	-0.38	-6.38	-0.3	4.69e-10	Neuroticism;
LUAD	cis	rs9811920	0.809	rs4928150	chr3:99685991	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.19	0.48	1.22e-25	Axial length;
LUAD	cis	rs68170813	0.559	rs6947675	chr7:106817184	T/C	cg23024343	chr7:107201750	COG5	0.5	7.26	0.33	1.92e-12	Coronary artery disease;
LUAD	cis	rs12620999	0.887	rs6723783	chr2:237963572	C/A	cg23555395	chr2:238036564	NA	0.48	7.08	0.33	6.07e-12	Systemic lupus erythematosus;
LUAD	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg08422745	chr4:174089978	GALNT7	-0.93	-16.53	-0.63	1.05e-47	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	trans	rs62103177	0.673	rs7242867	chr18:77603270	A/T	cg05926928	chr17:57297772	GDPD1	0.82	11.65	0.49	2.11e-27	Opioid sensitivity;
LUAD	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.9	-0.32	1.95e-11	Retinal vascular caliber;
LUAD	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg03874509	chr1:107600012	PRMT6	-0.57	-9.93	-0.43	4.87e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.33	-7.17	-0.33	3.28e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg22823121	chr1:150693482	HORMAD1	-0.4	-7.86	-0.36	3.2e-14	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504073	0.584	rs4873307	chr8:49950417	C/T	cg00325661	chr8:49890786	NA	0.46	10.34	0.45	1.73e-22	Blood metabolite ratios;
LUAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-7.15	-0.33	3.91e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs739496	0.947	rs12580300	chr12:111849271	G/A	cg10833066	chr12:111807467	FAM109A	0.42	6.65	0.31	9.18e-11	Platelet count;
LUAD	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg17264618	chr3:40429014	ENTPD3	0.37	7.81	0.36	4.47e-14	Renal cell carcinoma;
LUAD	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg06263672	chr7:65235340	NA	0.48	6.53	0.3	1.84e-10	Aortic root size;
LUAD	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg02012338	chr4:187126139	CYP4V2	1.07	10.58	0.46	2.35e-23	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg03467027	chr4:99064603	C4orf37	0.39	6.45	0.3	3.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg04995722	chr7:26192034	NFE2L3	0.43	7.3	0.33	1.44e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg04414720	chr1:150670196	GOLPH3L	0.71	12.42	0.52	2.12e-30	Melanoma;
LUAD	cis	rs12618769	0.597	rs2278214	chr2:99135738	A/G	cg10123293	chr2:99228465	UNC50	-0.47	-8.22	-0.37	2.46e-15	Bipolar disorder;
LUAD	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg16205897	chr5:131564050	P4HA2	0.3	6.57	0.3	1.51e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-10.49	-0.45	4.71e-23	Gut microbiome composition (summer);
LUAD	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg13798912	chr7:905769	UNC84A	-0.63	-7.21	-0.33	2.6e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg19442545	chr10:75533431	FUT11	-0.47	-7.89	-0.36	2.63e-14	Inflammatory bowel disease;
LUAD	cis	rs73198271	0.562	rs17698256	chr8:8659613	C/T	cg01851573	chr8:8652454	MFHAS1	0.71	10.83	0.47	2.65e-24	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs68170813	0.641	rs79434636	chr7:107105656	A/C	cg23024343	chr7:107201750	COG5	0.5	6.96	0.32	1.32e-11	Coronary artery disease;
LUAD	cis	rs2046867	0.862	rs11922180	chr3:72836119	A/G	cg25664220	chr3:72788482	NA	0.68	12.3	0.51	5.94e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.32	7.48	0.34	4.43e-13	Prostate cancer;
LUAD	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg16988262	chr1:15930761	NA	0.44	7.4	0.34	7.63e-13	Systolic blood pressure;
LUAD	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.61	0.39	1.49e-16	Parkinson's disease;
LUAD	cis	rs1448094	0.872	rs7300073	chr12:86393513	A/C	cg00310523	chr12:86230176	RASSF9	0.37	7.87	0.36	3.09e-14	Major depressive disorder;
LUAD	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg01528321	chr10:82214614	TSPAN14	0.64	10.49	0.45	4.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs11077998	0.840	rs9894993	chr17:80481088	T/C	cg10255544	chr17:80519551	FOXK2	0.33	6.58	0.3	1.43e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03264133	chr6:25882463	NA	0.5	8.46	0.38	4.43e-16	Blood metabolite levels;
LUAD	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-7.78	-0.35	5.61e-14	Breast cancer;
LUAD	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg14835575	chr10:16859367	RSU1	0.98	14.18	0.57	1.25e-37	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs4077515	0.901	rs3812573	chr9:139276680	C/T	cg14019695	chr9:139328340	INPP5E	0.41	7.54	0.34	2.95e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.44e-10	Prostate cancer;
LUAD	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg23254163	chr1:152506842	NA	0.24	6.62	0.31	1.11e-10	Hair morphology;
LUAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg11494091	chr17:61959527	GH2	0.74	18.75	0.67	1.61e-57	Prudent dietary pattern;
LUAD	cis	rs9902453	0.967	rs56326816	chr17:28492805	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.31	0.37	1.27e-15	Coffee consumption (cups per day);
LUAD	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg18131467	chr2:239335373	ASB1	0.72	12.65	0.52	2.59e-31	Multiple system atrophy;
LUAD	cis	rs863345	0.547	rs10908675	chr1:158504129	A/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.99	17.25	0.64	6.77e-51	IgG glycosylation;
LUAD	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.44	-0.34	5.5e-13	Electroencephalogram traits;
LUAD	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg25985355	chr7:65971099	NA	0.53	6.72	0.31	6e-11	Diabetic kidney disease;
LUAD	cis	rs3818285	0.556	rs3758409	chr10:111669239	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.7	-10.53	-0.46	3.61e-23	Superior crus of antihelix expression;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12877462	chr4:100484858	RG9MTD2;MTTP	-0.43	-6.72	-0.31	5.8200000000000003e-11	Height;
LUAD	trans	rs12200782	0.799	rs72845515	chr6:26646871	A/G	cg08851530	chr6:28072375	NA	0.71	6.46	0.3	2.85e-10	Small cell lung carcinoma;
LUAD	cis	rs6138458	0.962	rs6036976	chr20:24901567	T/G	cg26195577	chr20:24973756	C20orf3	-0.95	-16.29	-0.62	1.18e-46	Blood protein levels;
LUAD	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg18252515	chr7:66147081	NA	0.59	6.49	0.3	2.42e-10	Diabetic kidney disease;
LUAD	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg11901034	chr3:128598214	ACAD9	-0.5	-7.86	-0.36	3.19e-14	IgG glycosylation;
LUAD	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg17279839	chr7:150038598	RARRES2	0.45	7.72	0.35	8.76e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs2274273	0.967	rs11622740	chr14:55617844	G/A	cg04306507	chr14:55594613	LGALS3	0.37	7.49	0.34	4.04e-13	Protein biomarker;
LUAD	cis	rs9581857	0.556	rs9581861	chr13:28039991	C/T	cg22138327	chr13:27999177	GTF3A	0.77	11.02	0.47	5.19e-25	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg16325326	chr1:53192061	ZYG11B	0.59	10.44	0.45	7.5e-23	Monocyte count;
LUAD	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg00857998	chr1:205179979	DSTYK	0.41	6.82	0.31	3.22e-11	Red blood cell count;
LUAD	cis	rs3813948	0.543	rs2808466	chr1:207273751	T/C	cg11153969	chr1:207277031	C4BPA	-0.69	-9.13	-0.41	2.88e-18	C4b binding protein levels;
LUAD	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08704250	chr15:31115839	NA	-0.7	-12.51	-0.52	8.84e-31	Huntington's disease progression;
LUAD	cis	rs315934	0.664	rs315924	chr2:113864514	G/A	cg09040174	chr2:113837401	NA	-0.61	-7.4	-0.34	7.6e-13	Dysmenorrheic pain;
LUAD	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg26597838	chr10:835615	NA	0.99	15.6	0.6	1.17e-43	Eosinophil percentage of granulocytes;
LUAD	cis	rs7258465	1.000	rs10413237	chr19:18548249	A/C	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.62	-0.31	1.12e-10	Breast cancer;
LUAD	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs4253772	0.872	rs78864133	chr22:46638486	C/T	cg09491104	chr22:46646882	C22orf40	-0.54	-7.83	-0.36	4.09e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.61	-0.42	6.55e-20	Alzheimer's disease;
LUAD	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg13057898	chr1:3703894	LRRC47	0.62	10.62	0.46	1.66e-23	Red cell distribution width;
LUAD	cis	rs8177876	0.822	rs9925940	chr16:81110984	T/G	cg08591886	chr16:81111003	C16orf46	-0.76	-7.09	-0.33	5.65e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg03467027	chr4:99064603	C4orf37	0.44	7.12	0.33	4.72e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg07507251	chr3:52567010	NT5DC2	-0.37	-7.23	-0.33	2.27e-12	Bipolar disorder;
LUAD	cis	rs4849845	0.777	rs3931841	chr2:121041314	A/G	cg24070213	chr2:121070622	NA	0.36	6.46	0.3	2.91e-10	Mean platelet volume;
LUAD	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg27394845	chr17:28928406	LRRC37B2	0.5	6.37	0.3	4.96e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.96	-0.4	1.07e-17	Bipolar disorder;
LUAD	cis	rs908922	0.651	rs1337341	chr1:152508259	A/C	cg23254163	chr1:152506842	NA	0.25	6.8	0.31	3.49e-11	Hair morphology;
LUAD	cis	rs89107	0.576	rs4307206	chr6:118813320	A/C	cg21191810	chr6:118973309	C6orf204	-0.38	-7.16	-0.33	3.6e-12	Cardiac structure and function;
LUAD	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25427524	chr10:38739819	LOC399744	0.77	14.73	0.58	6.31e-40	Extrinsic epigenetic age acceleration;
LUAD	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.73	0.31	5.49e-11	Colorectal cancer;
LUAD	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg27535305	chr1:53392650	SCP2	-0.33	-6.67	-0.31	8.06e-11	Monocyte count;
LUAD	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg07917127	chr4:99064746	C4orf37	0.4	6.63	0.31	1.04e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.7	-0.35	9.5e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg06641503	chr3:48959341	ARIH2	-0.37	-7.3	-0.33	1.4e-12	Menarche (age at onset);
LUAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg03188948	chr7:1209495	NA	0.8	9.83	0.43	1.16e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07402800	chr8:145582003	FBXL6;GPR172A	-0.47	-8.62	-0.39	1.31e-16	Cancer;
LUAD	cis	rs6906287	0.669	rs6913012	chr6:118973137	G/A	cg05564266	chr6:118973597	C6orf204	0.36	7.61	0.35	1.81e-13	Electrocardiographic conduction measures;
LUAD	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08219700	chr8:58056026	NA	0.63	8.86	0.4	2.2e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs427394	0.659	rs274693	chr5:6734162	G/A	cg10857441	chr5:6722123	POLS	-0.61	-10.89	-0.47	1.57e-24	Menopause (age at onset);
LUAD	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg12311346	chr5:56204834	C5orf35	-0.83	-12.5	-0.52	1e-30	Initial pursuit acceleration;
LUAD	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.75	0.31	5.04e-11	Aortic root size;
LUAD	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg02743256	chr7:2109353	MAD1L1	-0.48	-6.62	-0.31	1.12e-10	Bipolar disorder;
LUAD	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg00277334	chr10:82204260	NA	-0.55	-8.74	-0.39	5.7e-17	Post bronchodilator FEV1;
LUAD	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg09365446	chr1:150670422	GOLPH3L	0.67	12.69	0.53	1.67e-31	Tonsillectomy;
LUAD	cis	rs679087	1.000	rs679087	chr12:29917265	C/A	cg14258853	chr12:29935411	TMTC1	-0.6	-10.36	-0.45	1.44e-22	Schizophrenia;
LUAD	cis	rs7072216	0.763	rs6584202	chr10:100170383	G/A	cg26618903	chr10:100175079	PYROXD2	-0.4	-8.77	-0.39	4.38e-17	Metabolite levels;
LUAD	trans	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg04775059	chr7:64541387	NA	-0.52	-6.95	-0.32	1.38e-11	Aortic root size;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01990225	chr2:97406019	LMAN2L	-0.42	-7.28	-0.33	1.6e-12	Cancer;
LUAD	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23583168	chr7:148888333	NA	-0.94	-19.29	-0.68	5.95e-60	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.39	-0.38	7.48e-16	Total body bone mineral density;
LUAD	cis	rs4953404	0.588	rs1319499	chr2:46894846	T/A	cg09399716	chr2:46890238	NA	-0.34	-6.56	-0.3	1.62e-10	Pulse pressure (alcohol consumption interaction);
LUAD	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg23625390	chr15:77176239	SCAPER	-0.38	-6.8	-0.31	3.63e-11	Blood metabolite levels;
LUAD	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg17366294	chr4:99064904	C4orf37	-0.51	-9.13	-0.41	2.88e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg13126279	chr21:47581558	C21orf56	-0.48	-7.93	-0.36	1.93e-14	Testicular germ cell tumor;
LUAD	trans	rs7395662	0.963	rs11039950	chr11:48737471	G/A	cg00717180	chr2:96193071	NA	0.39	7.17	0.33	3.29e-12	HDL cholesterol;
LUAD	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.39e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg06627628	chr2:24431161	ITSN2	-0.47	-6.61	-0.31	1.17e-10	Lymphocyte counts;
LUAD	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24531977	chr5:56204891	C5orf35	1.15	18.2	0.66	4.47e-55	Initial pursuit acceleration;
LUAD	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg13319975	chr6:146136371	FBXO30	0.62	10.24	0.45	3.81e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.66	-0.39	1e-16	Total body bone mineral density;
LUAD	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.53	8.91	0.4	1.48e-17	Electrocardiographic conduction measures;
LUAD	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.1	0.33	5.41e-12	Motion sickness;
LUAD	trans	rs1997103	0.954	rs2030807	chr7:55378485	A/G	cg20935933	chr6:143382018	AIG1	0.56	7.78	0.35	5.68e-14	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg04414720	chr1:150670196	GOLPH3L	0.66	11.36	0.48	2.68e-26	Melanoma;
LUAD	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg00383909	chr3:49044727	WDR6	0.92	10.2	0.44	5.62e-22	Cognitive function;
LUAD	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg17480646	chr11:65405466	SIPA1	-0.45	-6.76	-0.31	4.6e-11	Acne (severe);
LUAD	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg26384229	chr12:38710491	ALG10B	0.43	7.14	0.33	4.02e-12	Morning vs. evening chronotype;
LUAD	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg15147215	chr3:52552868	STAB1	-0.4	-7.43	-0.34	6.13e-13	Electroencephalogram traits;
LUAD	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.53	-10.98	-0.47	7.27e-25	Monocyte percentage of white cells;
LUAD	cis	rs1018836	0.923	rs6988733	chr8:91535686	C/T	cg16814680	chr8:91681699	NA	-0.77	-13.37	-0.55	2.89e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7615952	0.605	rs11708269	chr3:125332150	C/T	cg05084668	chr3:125655381	ALG1L	-0.53	-6.39	-0.3	4.33e-10	Blood pressure (smoking interaction);
LUAD	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg18190219	chr22:46762943	CELSR1	-0.55	-6.71	-0.31	6.21e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg17105886	chr17:28927953	LRRC37B2	0.83	8.16	0.37	3.87e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg11905131	chr22:24372483	LOC391322	-0.63	-11.24	-0.48	7.9e-26	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs11700980	0.636	rs17797032	chr21:30265585	G/A	cg14791747	chr16:20752902	THUMPD1	0.62	6.77	0.31	4.39e-11	QRS complex (12-leadsum);
LUAD	cis	rs757081	0.667	rs615424	chr11:17210481	G/A	cg15432903	chr11:17409602	KCNJ11	-0.4	-6.41	-0.3	3.95e-10	Systolic blood pressure;
LUAD	cis	rs8060686	0.668	rs2418739	chr16:68092850	G/C	cg26727032	chr16:67993705	SLC12A4	-0.46	-7.75	-0.35	7.07e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23158103	chr7:148848205	ZNF398	-0.57	-9.63	-0.42	5.4e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg03609598	chr5:56110824	MAP3K1	-0.48	-7.59	-0.35	2.07e-13	Coronary artery disease;
LUAD	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06873352	chr17:61820015	STRADA	0.54	9.01	0.4	7.42e-18	Height;
LUAD	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg13385794	chr1:248469461	NA	0.27	7.19	0.33	2.95e-12	Common traits (Other);
LUAD	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg26597838	chr10:835615	NA	0.83	11.24	0.48	8.04e-26	Eosinophil percentage of granulocytes;
LUAD	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-7.08	-0.33	5.91e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs17401966	0.838	rs12120191	chr1:10345772	A/G	cg15208524	chr1:10270712	KIF1B	0.42	6.51	0.3	2.19e-10	Hepatocellular carcinoma;
LUAD	trans	rs3812049	0.784	rs7734927	chr5:127453735	T/A	cg16011800	chr17:1958478	HIC1	-0.57	-8.13	-0.37	4.83e-15	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.45	-8.16	-0.37	3.78e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18404041	chr3:52824283	ITIH1	-0.61	-13.05	-0.54	5.84e-33	Bipolar disorder;
LUAD	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg03929089	chr4:120376271	NA	-0.98	-20.34	-0.7	1.25e-64	Height;
LUAD	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg01475377	chr6:109611718	NA	-0.48	-8.81	-0.39	3.25e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg10556349	chr10:835070	NA	0.58	6.77	0.31	4.23e-11	Eosinophil percentage of granulocytes;
LUAD	cis	rs4006360	0.646	rs11868364	chr17:39236968	G/A	cg16090541	chr17:39240343	KRTAP4-7	-0.37	-6.51	-0.3	2.07e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg03714773	chr7:91764589	CYP51A1	0.31	7.29	0.33	1.54e-12	Breast cancer;
LUAD	cis	rs68170813	0.559	rs74774133	chr7:106941449	T/C	cg23024343	chr7:107201750	COG5	0.44	6.47	0.3	2.71e-10	Coronary artery disease;
LUAD	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg11502198	chr6:26597334	ABT1	0.67	11.83	0.5	4.41e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg02176678	chr2:219576539	TTLL4	-0.75	-14.98	-0.59	5.39e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs17102423	0.594	rs1271582	chr14:65564703	T/G	cg16583315	chr14:65563665	MAX	-0.38	-7.3	-0.33	1.47e-12	Obesity-related traits;
LUAD	cis	rs11741688	0.631	rs4444956	chr5:178325515	A/G	cg21944022	chr5:178288650	ZNF354B	0.54	9.98	0.44	3.2e-21	Sleep duration;
LUAD	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg26384229	chr12:38710491	ALG10B	0.48	7.72	0.35	8.7e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg20848291	chr7:100343083	ZAN	0.4	6.88	0.32	2.1e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs727505	1.000	rs10264060	chr7:124486413	C/A	cg23710748	chr7:124431027	NA	-0.45	-9.32	-0.41	6.67e-19	Lewy body disease;
LUAD	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg19610905	chr11:61596333	FADS2	-0.67	-10.94	-0.47	1.03e-24	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs7336332	0.941	rs9579097	chr13:28084337	C/T	cg22138327	chr13:27999177	GTF3A	0.85	9.02	0.4	6.56e-18	Weight;
LUAD	cis	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg06360820	chr2:242988706	NA	-0.89	-9.58	-0.42	8.22e-20	Obesity-related traits;
LUAD	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg02574844	chr11:5959923	NA	-0.45	-8.19	-0.37	3.12e-15	DNA methylation (variation);
LUAD	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	7.55	0.34	2.77e-13	Menopause (age at onset);
LUAD	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03264133	chr6:25882463	NA	-0.57	-9.39	-0.42	3.71e-19	Blood metabolite levels;
LUAD	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg07432352	chr17:45403706	C17orf57	-0.4	-7.41	-0.34	6.97e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs587242	0.515	rs12741065	chr1:97169877	A/G	cg10631902	chr5:14652156	NA	0.38	6.42	0.3	3.68e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg25838465	chr1:92012736	NA	-0.72	-16.1	-0.62	7.89e-46	Breast cancer;
LUAD	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg24690094	chr11:67383802	NA	0.4	7.12	0.33	4.63e-12	Mean corpuscular volume;
LUAD	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg14196790	chr5:131705035	SLC22A5	0.54	9.86	0.43	9.01e-21	Blood metabolite levels;
LUAD	cis	rs13064411	0.735	rs7636128	chr3:113133701	A/T	cg10517650	chr3:113235015	CCDC52	-0.48	-8.04	-0.36	8.96e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg02560186	chr11:3602584	NA	-0.34	-6.52	-0.3	2.07e-10	Blood pressure (smoking interaction);
LUAD	cis	rs2016266	0.855	rs930900	chr12:53727545	T/C	cg26875137	chr12:53738046	NA	0.34	7.11	0.33	5.05e-12	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs9462027	0.628	rs1543558	chr6:34784371	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.84	-0.4	2.52e-17	Systemic lupus erythematosus;
LUAD	cis	rs7731657	0.537	rs3981875	chr5:130226055	G/C	cg08523029	chr5:130500466	HINT1	-0.59	-7.71	-0.35	9e-14	Fasting plasma glucose;
LUAD	trans	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg01620082	chr3:125678407	NA	-0.8	-8.08	-0.37	6.7e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg27446573	chr6:127587934	RNF146	0.45	6.6	0.31	1.24e-10	Breast cancer;
LUAD	cis	rs10392	0.543	rs16987679	chr20:37557185	G/C	cg27552599	chr20:37590471	DHX35	0.41	6.9	0.32	1.91e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg19622623	chr12:86230825	RASSF9	-0.46	-8.05	-0.36	8.23e-15	Major depressive disorder;
LUAD	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.62	0.55	2.78e-35	Tonsillectomy;
LUAD	cis	rs1030877	0.515	rs2679895	chr2:105906480	C/G	cg02079111	chr2:105885981	TGFBRAP1	0.4	6.39	0.3	4.3e-10	Obesity-related traits;
LUAD	cis	rs10489202	0.632	rs202268	chr1:167927339	T/C	cg25738037	chr1:168025549	DCAF6	-0.48	-7.22	-0.33	2.39e-12	Schizophrenia;
LUAD	cis	rs12545109	0.723	rs2610045	chr8:57413439	A/G	cg17761419	chr8:57350749	NA	0.52	7.88	0.36	2.78e-14	Obesity-related traits;
LUAD	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08704250	chr15:31115839	NA	-0.73	-13.42	-0.55	1.81e-34	Huntington's disease progression;
LUAD	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg03676636	chr4:99064102	C4orf37	0.32	8.31	0.37	1.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg18944383	chr4:111397179	ENPEP	-0.37	-7.07	-0.33	6.63e-12	Coronary artery disease;
LUAD	trans	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.42	-0.3	3.58e-10	Systemic lupus erythematosus;
LUAD	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg06606381	chr12:133084897	FBRSL1	-1.21	-11.4	-0.48	1.89e-26	Depression;
LUAD	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg14530993	chr4:882597	GAK	0.73	6.9	0.32	1.89e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg13047869	chr3:10149882	C3orf24	0.65	11.01	0.47	5.64e-25	Alzheimer's disease;
LUAD	cis	rs4523957	0.928	rs10852932	chr17:2143460	G/T	cg16513277	chr17:2031491	SMG6	-0.74	-13.71	-0.55	1.23e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg07305463	chr2:136567211	LCT	0.38	6.85	0.32	2.54e-11	Mosquito bite size;
LUAD	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.68	-0.35	1.08e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.42	-7.57	-0.35	2.35e-13	Tonsillectomy;
LUAD	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg23172400	chr8:95962367	TP53INP1	-0.34	-8.0	-0.36	1.19e-14	Type 2 diabetes;
LUAD	cis	rs2456568	0.741	rs10831137	chr11:93636912	C/T	cg26875233	chr11:93583750	C11orf90	-0.29	-6.36	-0.3	5.33e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06022373	chr22:39101656	GTPBP1	0.44	6.76	0.31	4.65e-11	Menopause (age at onset);
LUAD	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg00999904	chr2:3704751	ALLC	-0.39	-7.19	-0.33	2.91e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs847577	0.569	rs2394817	chr7:97690438	C/T	cg21770322	chr7:97807741	LMTK2	0.3	7.1	0.33	5.23e-12	Breast cancer;
LUAD	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	4.04e-11	Depression;
LUAD	cis	rs868036	1.000	rs1471460	chr15:68089299	G/A	cg08079166	chr15:68083412	MAP2K5	0.3	6.44	0.3	3.27e-10	Restless legs syndrome;
LUAD	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg03676636	chr4:99064102	C4orf37	0.34	8.89	0.4	1.83e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg11062466	chr8:58055876	NA	0.51	7.09	0.33	5.72e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs3733585	0.566	rs35955619	chr4:9918986	T/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-10.58	-0.46	2.25e-23	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2067615	0.542	rs7133161	chr12:107139540	A/G	cg15890332	chr12:107067104	RFX4	0.39	8.38	0.38	7.79e-16	Heart rate;
LUAD	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg14092988	chr3:52407081	DNAH1	0.36	7.21	0.33	2.62e-12	Electroencephalogram traits;
LUAD	cis	rs11671005	0.735	rs11670871	chr19:58940514	C/T	cg13877915	chr19:58951672	ZNF132	-0.54	-7.51	-0.34	3.64e-13	Mean platelet volume;
LUAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.56e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg06453172	chr10:134556979	INPP5A	-0.79	-11.08	-0.47	3.28e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9878978	1.000	rs62233805	chr3:2474385	T/G	cg21928760	chr3:2462534	CNTN4	-0.35	-6.86	-0.32	2.43e-11	Blood pressure (smoking interaction);
LUAD	cis	rs999943	0.846	rs999942	chr6:33624902	G/C	cg14003231	chr6:33640908	ITPR3	0.92	18.93	0.68	2.44e-58	Obesity (extreme);
LUAD	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg09658497	chr7:2847517	GNA12	-0.41	-7.34	-0.34	1.08e-12	Height;
LUAD	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14240646	chr10:27532245	ACBD5	0.95	12.33	0.51	4.83e-30	Breast cancer;
LUAD	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg05535760	chr7:792225	HEATR2	0.99	12.33	0.51	4.83e-30	Cerebrospinal P-tau181p levels;
LUAD	cis	rs1965732	0.588	rs4849976	chr2:3717567	A/C	cg19052272	chr2:3704530	ALLC	-0.42	-7.94	-0.36	1.78e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs12216545	0.737	rs1916006	chr7:150240556	T/C	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.38	-0.3	4.64e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs208520	0.874	rs208491	chr6:66928459	C/G	cg07460842	chr6:66804631	NA	-0.96	-13.64	-0.55	2.33e-35	Exhaled nitric oxide output;
LUAD	cis	rs8177876	0.822	rs7204040	chr16:81113493	G/A	cg08591886	chr16:81111003	C16orf46	-0.76	-7.01	-0.32	9.76e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-7.25	-0.33	2.05e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg03209412	chr4:183728196	NA	0.8	11.26	0.48	6.74e-26	Pediatric autoimmune diseases;
LUAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.14	-0.37	4.47e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7665090	1.000	rs1077358	chr4:103553926	C/T	cg07973026	chr4:103553119	MANBA	0.47	8.43	0.38	5.53e-16	Primary biliary cholangitis;
LUAD	cis	rs3806843	0.576	rs246074	chr5:140307969	C/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.33	-6.73	-0.31	5.54e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11048434	0.723	rs2080117	chr12:9138341	C/T	cg13575925	chr12:9217583	LOC144571	0.38	7.04	0.32	7.72e-12	Sjögren's syndrome;
LUAD	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg22920501	chr2:26401640	FAM59B	-0.93	-15.18	-0.59	7.12e-42	Gut microbiome composition (summer);
LUAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.55	-9.71	-0.43	2.85e-20	Lymphocyte counts;
LUAD	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-7.05	-0.32	7.36e-12	Mood instability;
LUAD	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg01884057	chr2:25150051	NA	0.34	7.13	0.33	4.26e-12	Body mass index;
LUAD	cis	rs7512552	0.803	rs9436127	chr1:150490565	G/A	cg15654264	chr1:150340011	RPRD2	0.6	11.48	0.49	9.28e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg02269571	chr22:50332266	NA	-0.61	-9.39	-0.42	3.69e-19	Schizophrenia;
LUAD	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10802521	chr3:52805072	NEK4	-0.52	-9.09	-0.4	3.91e-18	Bipolar disorder;
LUAD	cis	rs12216545	0.737	rs10238055	chr7:150249729	G/A	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.37	-0.3	5.02e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	7.94e-19	Tonsillectomy;
LUAD	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg14458575	chr2:238380390	NA	0.71	13.08	0.54	4.63e-33	Prostate cancer;
LUAD	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg14582100	chr15:45693742	SPATA5L1	0.64	12.65	0.52	2.43e-31	Homoarginine levels;
LUAD	cis	rs7809950	1.000	rs10273733	chr7:107258121	A/G	cg23024343	chr7:107201750	COG5	0.61	9.16	0.41	2.2e-18	Coronary artery disease;
LUAD	cis	rs9354308	0.899	rs2802056	chr6:66546219	C/A	cg07460842	chr6:66804631	NA	0.49	7.47	0.34	4.73e-13	Metabolite levels;
LUAD	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg16512390	chr1:228756714	NA	0.72	10.26	0.45	3.24e-22	Chronic lymphocytic leukemia;
LUAD	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg22482690	chr17:47019901	SNF8	0.45	8.66	0.39	1.03e-16	Type 2 diabetes;
LUAD	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg27411982	chr8:10470053	RP1L1	0.42	7.29	0.33	1.51e-12	Retinal vascular caliber;
LUAD	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg18350739	chr11:68623251	NA	-0.37	-6.35	-0.3	5.4e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg03690763	chr11:133734501	NA	-0.29	-7.05	-0.32	7.35e-12	Childhood ear infection;
LUAD	cis	rs9287719	0.625	rs7567304	chr2:10790029	T/C	cg02196655	chr2:10830764	NOL10	0.46	8.1	0.37	5.95e-15	Prostate cancer;
LUAD	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg09537434	chr19:41945824	ATP5SL	0.52	7.93	0.36	1.96e-14	Height;
LUAD	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.48	8.07	0.37	7.36e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg06453172	chr10:134556979	INPP5A	-0.66	-9.81	-0.43	1.33e-20	Migraine;
LUAD	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00166722	chr3:10149974	C3orf24	0.73	10.94	0.47	1.1e-24	Alzheimer's disease;
LUAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.55	8.48	0.38	3.69e-16	Renal function-related traits (BUN);
LUAD	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg05887092	chr17:76393375	PGS1	0.55	11.37	0.48	2.53e-26	HDL cholesterol levels;
LUAD	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11890956	chr21:40555474	PSMG1	-0.51	-8.65	-0.39	1.08e-16	Menarche (age at onset);
LUAD	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg01802117	chr1:53393560	SCP2	0.34	6.83	0.32	2.93e-11	Monocyte count;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg20150972	chr6:13574573	SIRT5	-0.63	-6.39	-0.3	4.33e-10	Type 2 diabetes;
LUAD	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg06060754	chr5:176797920	RGS14	-0.66	-12.65	-0.52	2.4e-31	Urinary electrolytes (magnesium/calcium ratio);
LUAD	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg12564285	chr5:131593104	PDLIM4	0.34	6.52	0.3	2.07e-10	Breast cancer;
LUAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg13560548	chr3:10150139	C3orf24	0.42	6.85	0.32	2.65e-11	Alzheimer's disease;
LUAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.58	-0.38	1.84e-16	Bipolar disorder and schizophrenia;
LUAD	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs72799341	0.706	rs11865499	chr16:31132250	A/G	cg05768032	chr16:30646687	NA	0.38	6.58	0.3	1.43e-10	Diastolic blood pressure;
LUAD	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg08847533	chr14:75593920	NEK9	-0.4	-6.72	-0.31	6.04e-11	Height;
LUAD	cis	rs2485376	1.000	rs1854291	chr10:103992122	T/C	cg20641465	chr10:103991465	PITX3	0.56	10.3	0.45	2.45e-22	QT interval;
LUAD	cis	rs2455799	0.573	rs2455793	chr3:15743844	A/G	cg16303742	chr3:15540471	COLQ	-0.46	-8.58	-0.39	1.76e-16	Mean platelet volume;
LUAD	cis	rs11785400	0.928	rs2280878	chr8:143722366	G/A	cg10596483	chr8:143751796	JRK	0.44	6.97	0.32	1.19e-11	Schizophrenia;
LUAD	cis	rs4588572	0.643	rs10474555	chr5:77799193	A/G	cg11547950	chr5:77652471	NA	0.72	11.17	0.48	1.5e-25	Triglycerides;
LUAD	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg17063962	chr7:91808500	NA	0.73	13.26	0.54	8.27e-34	Breast cancer;
LUAD	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg15358701	chr1:161410459	NA	-0.68	-6.86	-0.32	2.52e-11	Rheumatoid arthritis;
LUAD	cis	rs6489882	0.902	rs1981556	chr12:113372961	C/G	cg20102336	chr12:113376681	OAS3	-0.61	-9.51	-0.42	1.44e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs6500395	1.000	rs11644518	chr16:48616789	A/G	cg04672837	chr16:48644449	N4BP1	0.39	6.7	0.31	6.59e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg06640241	chr16:89574553	SPG7	0.65	11.12	0.48	2.18e-25	Multiple myeloma (IgH translocation);
LUAD	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.8	-0.31	3.66e-11	Schizophrenia;
LUAD	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg18811423	chr2:55921094	PNPT1	0.55	9.37	0.41	4.27e-19	Metabolic syndrome;
LUAD	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg02807482	chr3:125708958	NA	-0.65	-8.49	-0.38	3.45e-16	Blood pressure (smoking interaction);
LUAD	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg13319975	chr6:146136371	FBXO30	0.63	10.67	0.46	1.1e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg12419862	chr22:24373484	LOC391322	-0.72	-13.12	-0.54	3.2e-33	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs250677	0.522	rs4705301	chr5:148354902	C/G	cg12140854	chr5:148520817	ABLIM3	-0.55	-9.03	-0.4	6.34e-18	Breast cancer;
LUAD	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.68	-13.19	-0.54	1.59e-33	Cognitive ability;
LUAD	trans	rs1941687	0.563	rs1586987	chr18:31338661	A/G	cg13755796	chr4:20253514	NA	-0.39	-6.69	-0.31	7.1e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg21918786	chr6:109611834	NA	0.55	10.14	0.44	8.65e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg12365402	chr11:9010492	NRIP3	0.35	6.42	0.3	3.62e-10	Hemoglobin concentration;
LUAD	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg24675056	chr1:15929824	NA	0.48	8.33	0.38	1.13e-15	Systolic blood pressure;
LUAD	cis	rs4713675	0.584	rs749847	chr6:33665001	G/C	cg13859433	chr6:33739653	LEMD2	-0.3	-7.04	-0.32	7.94e-12	Plateletcrit;
LUAD	cis	rs12286929	0.637	rs34138164	chr11:115050127	A/G	cg04055981	chr11:115044050	NA	0.48	8.67	0.39	9.27e-17	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg17031739	chr1:67600172	NA	0.56	9.92	0.43	5.44e-21	Psoriasis;
LUAD	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22496380	chr5:211416	CCDC127	-1.21	-16.3	-0.62	1.06e-46	Breast cancer;
LUAD	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg21984481	chr17:79567631	NPLOC4	-0.6	-12.89	-0.53	2.65e-32	Eye color traits;
LUAD	cis	rs12541635	0.677	rs6469026	chr8:107006356	T/C	cg10147462	chr8:107024639	NA	0.55	9.7	0.43	3.14e-20	Age of smoking initiation;
LUAD	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg03388025	chr16:89894329	SPIRE2	-0.33	-7.53	-0.34	3.13e-13	Vitiligo;
LUAD	cis	rs12541635	0.934	rs57715289	chr8:106967124	A/T	cg10147462	chr8:107024639	NA	0.47	8.17	0.37	3.52e-15	Age of smoking initiation;
LUAD	cis	rs13315871	1.000	rs74834816	chr3:58321828	G/A	cg12435725	chr3:58293450	RPP14	-0.75	-7.77	-0.35	6.07e-14	Cholesterol, total;
LUAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.58e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12936587	0.536	rs8075153	chr17:17622666	C/T	cg04398451	chr17:18023971	MYO15A	0.45	7.34	0.34	1.14e-12	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LUAD	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg13732083	chr21:47605072	C21orf56	0.42	6.97	0.32	1.2e-11	Testicular germ cell tumor;
LUAD	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg15962314	chr1:44399869	ARTN	0.27	6.41	0.3	3.78e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6430585	0.527	rs62168830	chr2:136443900	A/T	cg07169764	chr2:136633963	MCM6	0.59	6.92	0.32	1.66e-11	Corneal structure;
LUAD	cis	rs1997103	1.000	rs9649851	chr7:55398692	C/A	cg17469321	chr7:55412551	NA	0.67	11.41	0.49	1.73e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7617773	0.780	rs13081169	chr3:48356797	G/A	cg11946769	chr3:48343235	NME6	0.44	6.79	0.31	3.79e-11	Coronary artery disease;
LUAD	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg06784218	chr1:46089804	CCDC17	-0.54	-11.63	-0.49	2.61e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg25344623	chr2:136566232	LCT	0.34	6.67	0.31	7.91e-11	Mosquito bite size;
LUAD	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg12016809	chr21:47604291	C21orf56	0.45	7.51	0.34	3.64e-13	Testicular germ cell tumor;
LUAD	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg17105886	chr17:28927953	LRRC37B2	0.8	7.82	0.36	4.29e-14	Body mass index;
LUAD	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg12310025	chr6:25882481	NA	-0.56	-9.01	-0.4	7.22e-18	Blood metabolite levels;
LUAD	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg00255919	chr5:131827918	IRF1	-0.51	-11.99	-0.5	1.06e-28	Asthma (sex interaction);
LUAD	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg27068330	chr11:65405492	SIPA1	0.77	12.77	0.53	8.35e-32	Acne (severe);
LUAD	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg25237894	chr2:233734115	C2orf82	0.62	11.89	0.5	2.48e-28	Coronary artery disease;
LUAD	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg25894440	chr7:65020034	NA	0.64	6.92	0.32	1.65e-11	Diabetic kidney disease;
LUAD	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg16205897	chr5:131564050	P4HA2	0.31	6.71	0.31	6.38e-11	Blood metabolite levels;
LUAD	cis	rs6987853	0.933	rs2974339	chr8:42397529	T/C	cg09913449	chr8:42400586	C8orf40	0.43	7.93	0.36	2.03e-14	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg25985355	chr7:65971099	NA	-0.39	-7.2	-0.33	2.8e-12	Aortic root size;
LUAD	cis	rs2066819	1.000	rs77768890	chr12:56725121	A/G	cg26714650	chr12:56694279	CS	-0.85	-7.1	-0.33	5.17e-12	Psoriasis vulgaris;
LUAD	cis	rs6479527	0.840	rs987511	chr9:96757868	C/T	cg14459158	chr9:96720562	NA	0.38	6.65	0.31	9.34e-11	Esophageal adenocarcinoma;
LUAD	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.26	-0.54	8.48e-34	Chronic sinus infection;
LUAD	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	6.72	0.31	5.91e-11	Cognitive test performance;
LUAD	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg09365446	chr1:150670422	GOLPH3L	-0.62	-12.0	-0.5	9.03e-29	Tonsillectomy;
LUAD	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg23260525	chr10:116636907	FAM160B1	0.47	10.79	0.46	3.99e-24	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-9.7	-0.43	3.1e-20	Schizophrenia;
LUAD	cis	rs9560113	1.000	rs9560113	chr13:112183348	A/G	cg14154082	chr13:112174009	NA	0.36	6.72	0.31	5.91e-11	Menarche (age at onset);
LUAD	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg25019722	chr6:37503610	NA	-0.3	-6.69	-0.31	7.16e-11	Cognitive performance;
LUAD	cis	rs556990	0.760	rs3024739	chr13:113819948	G/A	cg18105134	chr13:113819100	PROZ	-1.07	-19.53	-0.69	5.37e-61	Blood protein levels;
LUAD	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg00376283	chr12:123451042	ABCB9	0.41	6.61	0.31	1.18e-10	Platelet count;
LUAD	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg07636037	chr3:49044803	WDR6	0.54	10.28	0.45	2.87e-22	Menarche (age at onset);
LUAD	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.52	-0.42	1.29e-19	Life satisfaction;
LUAD	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg08355456	chr11:67383691	NA	0.37	6.39	0.3	4.45e-10	Mean corpuscular volume;
LUAD	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.47	-0.3	2.66e-10	Bladder cancer;
LUAD	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg26384229	chr12:38710491	ALG10B	0.49	7.96	0.36	1.55e-14	Heart rate;
LUAD	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg04703951	chr17:43578652	NA	0.45	7.31	0.33	1.34e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg18132916	chr6:79620363	NA	-0.45	-7.77	-0.35	5.94e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.06e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg17063962	chr7:91808500	NA	0.67	11.92	0.5	1.89e-28	Breast cancer;
LUAD	cis	rs7584330	0.784	rs1463795	chr2:238412392	C/G	cg14458575	chr2:238380390	NA	-0.68	-13.09	-0.54	4.29e-33	Prostate cancer;
LUAD	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg01528321	chr10:82214614	TSPAN14	0.63	9.91	0.43	5.83e-21	Post bronchodilator FEV1;
LUAD	cis	rs599083	0.590	rs10791984	chr11:68407835	T/G	cg01657329	chr11:68192670	LRP5	0.42	7.1	0.33	5.15e-12	Bone mineral density (spine);
LUAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg08888203	chr3:10149979	C3orf24	0.69	12.44	0.52	1.77e-30	Alzheimer's disease;
LUAD	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg13607699	chr17:42295918	UBTF	-0.56	-9.05	-0.4	5.15e-18	Total body bone mineral density;
LUAD	trans	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg26043149	chr18:55253948	FECH	-0.41	-6.7	-0.31	6.67e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg04225089	chr17:73874465	TRIM47	0.38	7.0	0.32	1.03e-11	Psoriasis;
LUAD	cis	rs7705042	0.897	rs249681	chr5:141538017	G/C	cg08523384	chr5:141488047	NDFIP1	-0.41	-6.91	-0.32	1.77e-11	Asthma;
LUAD	cis	rs56283067	0.847	rs56300373	chr6:44690904	C/T	cg18551225	chr6:44695536	NA	-0.62	-10.34	-0.45	1.75e-22	Total body bone mineral density;
LUAD	cis	rs56161922	0.818	rs4437879	chr1:207875977	G/A	cg11752769	chr1:207818423	CR1L	-0.63	-6.43	-0.3	3.4e-10	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg03806693	chr22:41940476	POLR3H	-0.6	-8.47	-0.38	3.99e-16	Vitiligo;
LUAD	cis	rs6723108	0.651	rs6724866	chr2:135407310	C/A	cg12500956	chr2:135428796	TMEM163	-0.29	-7.6	-0.35	1.87e-13	Type 2 diabetes;
LUAD	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg11494091	chr17:61959527	GH2	-0.51	-8.49	-0.38	3.42e-16	Height;
LUAD	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.27	-0.33	1.72e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4478137	0.824	rs10857353	chr4:164215835	A/G	cg06758707	chr4:164254230	NPY1R	-0.42	-6.72	-0.31	5.73e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs735539	1.000	rs735539	chr13:21280034	A/G	cg04906043	chr13:21280425	IL17D	0.4	7.18	0.33	3.24e-12	Dental caries;
LUAD	trans	rs75804782	0.641	rs72987321	chr2:239352765	T/G	cg01134436	chr17:81009848	B3GNTL1	0.74	8.1	0.37	5.86e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg23711669	chr6:146136114	FBXO30	0.4	6.81	0.31	3.4e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg00071950	chr4:10020882	SLC2A9	0.65	10.72	0.46	6.76e-24	Blood metabolite levels;
LUAD	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg26566898	chr11:117069891	TAGLN	0.35	6.75	0.31	4.8e-11	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.16e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6087990	0.735	rs2424921	chr20:31385814	C/T	cg13636640	chr20:31349939	DNMT3B	0.74	13.13	0.54	2.75e-33	Ulcerative colitis;
LUAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg13560548	chr3:10150139	C3orf24	0.49	7.87	0.36	3.1e-14	Alzheimer's disease;
LUAD	cis	rs4689388	0.609	rs4234729	chr4:6286087	T/C	cg00701064	chr4:6280414	WFS1	0.55	9.45	0.42	2.35e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg25767906	chr1:53392781	SCP2	-0.42	-7.87	-0.36	2.96e-14	Monocyte count;
LUAD	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg18099408	chr3:52552593	STAB1	-0.45	-7.95	-0.36	1.72e-14	Bipolar disorder;
LUAD	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg03983476	chr2:10830698	NOL10	-0.47	-8.19	-0.37	3.04e-15	Prostate cancer;
LUAD	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg02569458	chr12:86230093	RASSF9	0.45	8.21	0.37	2.64e-15	Major depressive disorder;
LUAD	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg27600084	chr12:12264075	NA	0.35	6.43	0.3	3.38e-10	Breast size;
LUAD	cis	rs597583	0.715	rs4938400	chr11:117399604	C/A	cg27161313	chr11:117392002	DSCAML1	-0.59	-9.16	-0.41	2.23e-18	Putamen volume;
LUAD	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg11645453	chr3:52864694	ITIH4	0.51	10.06	0.44	1.68e-21	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.55	0.42	1.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4730250	0.707	rs78472146	chr7:106967491	C/A	cg23024343	chr7:107201750	COG5	0.49	6.96	0.32	1.33e-11	Osteoarthritis;
LUAD	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg10589385	chr1:150898437	SETDB1	0.43	7.9	0.36	2.5e-14	Melanoma;
LUAD	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg26597838	chr10:835615	NA	0.77	10.01	0.44	2.65e-21	Eosinophil percentage of granulocytes;
LUAD	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg22431228	chr1:16359049	CLCNKA	-0.47	-8.48	-0.38	3.71e-16	Dilated cardiomyopathy;
LUAD	cis	rs863345	0.584	rs6657638	chr1:158497184	C/G	cg12129480	chr1:158549410	OR10X1	-0.24	-6.39	-0.3	4.26e-10	Pneumococcal bacteremia;
LUAD	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	15.07	0.59	2.18e-41	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg12863693	chr15:85201151	NMB	0.45	8.19	0.37	3.08e-15	Schizophrenia;
LUAD	cis	rs2797160	1.000	rs1739367	chr6:126004720	G/T	cg05901451	chr6:126070800	HEY2	-0.45	-6.66	-0.31	8.37e-11	Endometrial cancer;
LUAD	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.68	12.03	0.5	7.44e-29	Cognitive ability;
LUAD	cis	rs6961069	0.777	rs1761667	chr7:80244939	G/A	cg04458919	chr7:80252533	CD36	0.36	6.93	0.32	1.62e-11	Platelet count;
LUAD	cis	rs7192380	0.630	rs2965749	chr16:69771914	C/T	cg26679644	chr16:69762563	NA	-0.47	-8.88	-0.4	1.94e-17	Sjögren's syndrome;
LUAD	cis	rs7010267	0.503	rs13264172	chr8:120012861	T/A	cg01975934	chr8:119970761	NA	-0.37	-6.97	-0.32	1.22e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg13319975	chr6:146136371	FBXO30	0.66	11.42	0.49	1.59e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7709909	0.553	rs17205503	chr5:79982839	C/T	cg24059623	chr5:79951536	MSH3;DHFR	0.5	7.32	0.34	1.29e-12	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg12310025	chr6:25882481	NA	-0.73	-10.54	-0.46	3.27e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs7737355	0.812	rs11242083	chr5:130927526	A/T	cg06307176	chr5:131281290	NA	0.42	6.73	0.31	5.41e-11	Life satisfaction;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04317366	chr17:1588445	PRPF8	-0.39	-6.83	-0.32	2.9e-11	Cancer;
LUAD	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg05110241	chr16:68378359	PRMT7	-0.81	-8.75	-0.39	5.05e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.58e-11	Parkinson's disease;
LUAD	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg05283184	chr6:79620031	NA	-0.61	-12.18	-0.51	1.9e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs12545109	0.800	rs1467125	chr8:57418638	C/T	cg09654669	chr8:57350985	NA	-0.67	-9.65	-0.42	4.76e-20	Obesity-related traits;
LUAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-9.04	-0.4	5.69e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6484504	0.600	rs2761593	chr11:31326752	G/T	cg14844989	chr11:31128820	NA	0.43	7.98	0.36	1.4e-14	Red blood cell count;
LUAD	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg17724175	chr1:150552817	MCL1	0.31	7.16	0.33	3.56e-12	Tonsillectomy;
LUAD	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg11919837	chr8:57350735	NA	-0.43	-6.44	-0.3	3.19e-10	Obesity-related traits;
LUAD	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.66	9.28	0.41	9.09e-19	Lymphocyte percentage of white cells;
LUAD	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg05966235	chr16:28915196	ATP2A1	0.42	6.76	0.31	4.68e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs713587	0.713	rs12466350	chr2:25239969	A/G	cg04586622	chr2:25135609	ADCY3	0.32	7.05	0.32	7.31e-12	Body mass index in non-asthmatics;
LUAD	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg03676636	chr4:99064102	C4orf37	0.37	9.49	0.42	1.73e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg17177755	chr1:15930204	NA	0.44	7.17	0.33	3.32e-12	Systolic blood pressure;
LUAD	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg05368731	chr17:41323189	NBR1	0.95	19.19	0.68	1.76e-59	Menopause (age at onset);
LUAD	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg05872129	chr22:39784769	NA	-0.81	-15.19	-0.59	6.54e-42	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21582582	chr3:182698605	DCUN1D1	0.46	7.71	0.35	9.29e-14	Body mass index;
LUAD	cis	rs3931020	0.626	rs277402	chr1:75188321	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	-0.49	-6.4	-0.3	4.06e-10	Resistin levels;
LUAD	cis	rs13064411	0.518	rs7646188	chr3:113219272	C/T	cg10517650	chr3:113235015	CCDC52	-0.38	-7.21	-0.33	2.52e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg17724175	chr1:150552817	MCL1	-0.36	-8.59	-0.39	1.73e-16	Melanoma;
LUAD	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg01028140	chr2:1542097	TPO	-0.54	-7.52	-0.34	3.22e-13	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs758324	0.783	rs253941	chr5:131320293	C/T	cg06307176	chr5:131281290	NA	-0.5	-7.74	-0.35	7.65e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9644630	0.897	rs4921654	chr8:19359974	G/T	cg06699216	chr8:19333253	CSGALNACT1	0.3	7.31	0.33	1.34e-12	Oropharynx cancer;
LUAD	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg22823121	chr1:150693482	HORMAD1	0.45	8.65	0.39	1.07e-16	Melanoma;
LUAD	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.41	-6.63	-0.31	1.01e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg19320564	chr1:40157253	HPCAL4	-0.4	-6.93	-0.32	1.53e-11	Schizophrenia;
LUAD	trans	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg14791747	chr16:20752902	THUMPD1	0.74	9.96	0.44	4.03e-21	Cognitive test performance;
LUAD	trans	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg19894588	chr14:64061835	NA	0.52	8.21	0.37	2.77e-15	Glioblastoma;Glioma;
LUAD	cis	rs3816788	0.792	rs7013323	chr8:21869024	C/G	cg03445287	chr8:21823731	XPO7	-0.48	-8.48	-0.38	3.86e-16	Lung cancer in ever smokers;
LUAD	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.3	-7.22	-0.33	2.5e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg21475434	chr5:93447410	FAM172A	-0.8	-8.98	-0.4	9.19e-18	Diabetic retinopathy;
LUAD	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg13770153	chr20:60521292	NA	-0.59	-9.21	-0.41	1.5e-18	Body mass index;
LUAD	cis	rs9393692	0.620	rs9366650	chr6:26335997	G/A	cg00631329	chr6:26305371	NA	-0.52	-9.11	-0.4	3.37e-18	Educational attainment;
LUAD	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg25237894	chr2:233734115	C2orf82	0.63	11.98	0.5	1.16e-28	Coronary artery disease;
LUAD	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg04772025	chr11:68637568	NA	0.56	9.01	0.4	7.03e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg11909912	chr17:43974919	MAPT;LOC100130148	0.4	6.73	0.31	5.69e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs11771526	0.901	rs11767695	chr7:32315960	G/A	cg27511599	chr7:32358540	NA	0.52	6.51	0.3	2.12e-10	Body mass index;
LUAD	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg05887092	chr17:76393375	PGS1	0.41	7.28	0.33	1.65e-12	HDL cholesterol levels;
LUAD	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.9	-0.36	2.43e-14	Total body bone mineral density;
LUAD	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg08508325	chr11:3079039	CARS	0.43	8.77	0.39	4.27e-17	Calcium levels;
LUAD	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg17971929	chr21:40555470	PSMG1	0.52	8.11	0.37	5.73e-15	Cognitive function;
LUAD	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg23442198	chr4:187126114	CYP4V2	1.11	11.16	0.48	1.57e-25	Blood protein levels;
LUAD	cis	rs2625529	0.775	rs62023342	chr15:72161305	A/C	cg16672083	chr15:72433130	SENP8	-0.76	-12.84	-0.53	4.18e-32	Red blood cell count;
LUAD	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11118844	0.739	rs10863653	chr1:221943926	T/C	cg04222084	chr1:221915650	DUSP10	-0.61	-7.09	-0.33	5.85e-12	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg06108461	chr20:60628389	TAF4	-1.12	-20.48	-0.71	2.9e-65	Body mass index;
LUAD	cis	rs1691799	0.867	rs1168316	chr12:66746239	A/G	cg16791601	chr12:66731901	HELB	-0.36	-6.47	-0.3	2.78e-10	White blood cell count (basophil);
LUAD	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg05872129	chr22:39784769	NA	-0.75	-12.19	-0.51	1.62e-29	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs3800461	0.544	rs6919434	chr6:34498923	C/T	cg14254433	chr6:34482411	PACSIN1	-0.76	-9.94	-0.44	4.76e-21	Chronic lymphocytic leukemia;
LUAD	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg18404041	chr3:52824283	ITIH1	-0.39	-7.0	-0.32	1.02e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg26384229	chr12:38710491	ALG10B	0.48	7.67	0.35	1.19e-13	Bladder cancer;
LUAD	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg06606381	chr12:133084897	FBRSL1	-0.51	-6.74	-0.31	5.27e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.58	0.3	1.36e-10	Cardiac Troponin-T levels;
LUAD	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg21204522	chr6:27730016	NA	-0.47	-7.5	-0.34	3.72e-13	Parkinson's disease;
LUAD	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg07570687	chr10:102243282	WNT8B	0.48	7.28	0.33	1.6e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs4853036	0.672	rs6546549	chr2:70030469	C/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-6.36	-0.3	5.14e-10	Colorectal or endometrial cancer;
LUAD	cis	rs1869026	0.621	rs6746992	chr2:121348472	A/G	cg03661458	chr2:121334411	NA	0.36	6.64	0.31	9.73e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.54	0.3	1.75e-10	Aortic root size;
LUAD	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	7.45	0.34	5.16e-13	Tonsillectomy;
LUAD	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg03929089	chr4:120376271	NA	-0.92	-17.46	-0.65	8.02e-52	Coronary artery disease;
LUAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.99	0.47	7.04e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12232852	chr3:69129018	UBA3	-0.41	-6.44	-0.3	3.33e-10	Height;
LUAD	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg17849569	chr6:28058911	ZSCAN12L1	-0.32	-7.0	-0.32	1.03e-11	Depression;
LUAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg21385606	chr21:47601150	C21orf56	-0.35	-6.46	-0.3	2.96e-10	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs2230307	0.536	rs640030	chr1:100574992	C/T	cg20868668	chr1:100435035	SLC35A3	-0.54	-7.76	-0.35	6.63e-14	Carotid intima media thickness;
LUAD	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg21220214	chr8:57350948	NA	-0.59	-8.73	-0.39	6.17e-17	Obesity-related traits;
LUAD	cis	rs68170813	0.559	rs4730223	chr7:106814234	A/T	cg02696742	chr7:106810147	HBP1	0.76	10.72	0.46	6.87e-24	Coronary artery disease;
LUAD	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg27129171	chr3:47204927	SETD2	0.43	6.96	0.32	1.28e-11	Colorectal cancer;
LUAD	cis	rs11078597	0.731	rs4790285	chr17:1651697	C/T	cg18436246	chr17:1640651	WDR81	-0.76	-12.41	-0.52	2.31e-30	Serum albumin level;
LUAD	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg22431228	chr1:16359049	CLCNKA	-0.54	-10.4	-0.45	1.05e-22	Dilated cardiomyopathy;
LUAD	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-11.99	-0.5	1.07e-28	Migraine;Coronary artery disease;
LUAD	cis	rs2041840	1.000	rs13409250	chr2:37463642	A/G	cg25727520	chr2:37576821	QPCT	-0.35	-7.05	-0.32	7.4e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	10.14	0.44	8.77e-22	Migraine;Coronary artery disease;
LUAD	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg07527032	chr15:84868466	LOC388152	0.44	6.68	0.31	7.49e-11	Schizophrenia;
LUAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg07677032	chr17:61819896	STRADA	-0.52	-9.12	-0.41	3.16e-18	Prudent dietary pattern;
LUAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg07414643	chr4:187882934	NA	0.32	6.64	0.31	9.74e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1003719	0.788	rs2835586	chr21:38461326	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.63	0.39	1.29e-16	Eye color traits;
LUAD	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.5e-19	Life satisfaction;
LUAD	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg20701182	chr2:24300061	SF3B14	0.9	13.41	0.55	1.99e-34	Lymphocyte counts;
LUAD	cis	rs12210905	0.688	rs12209174	chr6:27443952	G/A	cg08851530	chr6:28072375	NA	1.03	7.92	0.36	2.19e-14	Hip circumference adjusted for BMI;
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01516881	chr6:292596	DUSP22	-0.77	-13.33	-0.54	4.52e-34	Menopause (age at onset);
LUAD	cis	rs6960043	0.818	rs10487796	chr7:15063430	T/A	cg19272540	chr7:15055459	NA	0.38	8.38	0.38	7.99e-16	Type 2 diabetes;
LUAD	trans	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg07393940	chr7:158741817	NA	0.69	11.46	0.49	1.12e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg18402987	chr7:1209562	NA	0.78	9.48	0.42	1.89e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg08132940	chr7:1081526	C7orf50	-0.79	-10.71	-0.46	7.69e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg20290983	chr6:43655470	MRPS18A	1.06	26.46	0.79	1.03e-91	IgG glycosylation;
LUAD	cis	rs4604732	0.588	rs7552461	chr1:247628644	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.1	0.33	5.32e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs4664304	0.629	rs955388	chr2:160837921	A/G	cg23995753	chr2:160760732	LY75	-0.38	-6.67	-0.31	8.04e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg09704166	chr2:114031854	PAX8;LOC440839	-0.48	-9.09	-0.4	3.95e-18	Lymphocyte counts;
LUAD	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg16479474	chr6:28041457	NA	0.44	7.44	0.34	5.75e-13	Depression;
LUAD	cis	rs7119	0.717	rs8032405	chr15:77825344	A/G	cg27398640	chr15:77910606	LINGO1	-0.36	-6.64	-0.31	9.57e-11	Type 2 diabetes;
LUAD	trans	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg01620082	chr3:125678407	NA	-0.89	-9.11	-0.4	3.23e-18	Depression;
LUAD	cis	rs8044868	0.530	rs8060770	chr16:72155694	C/A	cg23815491	chr16:72088622	HP	0.5	9.34	0.41	5.62e-19	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.5	-8.12	-0.37	5.13e-15	Renal function-related traits (BUN);
LUAD	cis	rs367943	0.501	rs960691	chr5:112971654	G/C	cg12552261	chr5:112820674	MCC	0.45	8.06	0.36	7.8e-15	Type 2 diabetes;
LUAD	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg02038168	chr22:39784481	NA	-0.59	-10.34	-0.45	1.71e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs4713675	0.584	rs942643	chr6:33668370	A/G	cg14003231	chr6:33640908	ITPR3	0.49	9.49	0.42	1.67e-19	Plateletcrit;
LUAD	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg18944383	chr4:111397179	ENPEP	0.48	8.51	0.38	3e-16	Coronary artery disease;
LUAD	cis	rs12210905	0.688	rs12202956	chr6:27356476	T/C	cg08851530	chr6:28072375	NA	1.09	7.95	0.36	1.69e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg25358565	chr5:93447407	FAM172A	-0.49	-6.36	-0.3	5.3e-10	Diabetic retinopathy;
LUAD	cis	rs1595825	0.891	rs77032596	chr2:198603185	T/G	cg11031976	chr2:198649780	BOLL	-0.48	-6.8	-0.31	3.53e-11	Ulcerative colitis;
LUAD	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg18721089	chr20:30220636	NA	-0.49	-7.04	-0.32	7.57e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs6076065	0.723	rs2424545	chr20:23390876	A/G	cg11657817	chr20:23433608	CST11	-0.49	-9.23	-0.41	1.33e-18	Facial morphology (factor 15, philtrum width);
LUAD	trans	rs3960554	0.808	rs112372188	chr7:75723376	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	11.17	0.48	1.48e-25	Eotaxin levels;
LUAD	cis	rs1949733	0.582	rs61258495	chr4:8534017	G/A	cg13073564	chr4:8508604	NA	0.41	7.17	0.33	3.47e-12	Response to antineoplastic agents;
LUAD	cis	rs11083475	0.714	rs7248584	chr19:39258110	C/T	cg07905965	chr19:39260460	NA	0.44	8.16	0.37	3.91e-15	Heart rate;
LUAD	cis	rs6688613	0.840	rs6660048	chr1:166954186	C/T	cg07049167	chr1:166818506	POGK	-0.43	-6.7	-0.31	6.67e-11	Refractive astigmatism;
LUAD	cis	rs41271473	0.526	rs12353961	chr1:228738252	G/C	cg10167378	chr1:228756711	NA	0.66	8.9	0.4	1.59e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg05425664	chr17:57184151	TRIM37	-0.43	-7.51	-0.34	3.5e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg09165964	chr15:75287851	SCAMP5	-0.47	-7.06	-0.32	7.01e-12	Blood trace element (Zn levels);
LUAD	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg07677032	chr17:61819896	STRADA	0.58	10.68	0.46	1e-23	Prudent dietary pattern;
LUAD	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg23649088	chr2:200775458	C2orf69	-0.57	-6.71	-0.31	6.25e-11	Schizophrenia;
LUAD	cis	rs7590720	1.000	rs7592663	chr2:216894978	T/C	cg12620499	chr2:216877984	MREG	0.55	8.64	0.39	1.13e-16	Alcohol dependence;
LUAD	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg00933542	chr6:150070202	PCMT1	0.46	9.54	0.42	1.15e-19	Lung cancer;
LUAD	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg09835421	chr16:68378352	PRMT7	-0.74	-8.32	-0.37	1.26e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2637266	1.000	rs10824431	chr10:78356622	C/A	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.18	0.54	1.83e-33	Prudent dietary pattern;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg02878701	chr21:47706221	MCM3AP;C21orf57	-0.4	-6.48	-0.3	2.52e-10	Vertical cup-disc ratio;
LUAD	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24531977	chr5:56204891	C5orf35	-0.85	-12.89	-0.53	2.69e-32	Initial pursuit acceleration;
LUAD	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg18252515	chr7:66147081	NA	0.62	6.77	0.31	4.25e-11	Diabetic kidney disease;
LUAD	cis	rs4144027	0.791	rs66473563	chr14:104361871	C/T	cg12183467	chr14:104352244	NA	0.35	6.81	0.31	3.41e-11	Blood metabolite levels;
LUAD	cis	rs1691799	0.899	rs1168320	chr12:66744849	C/T	cg16791601	chr12:66731901	HELB	-0.35	-6.42	-0.3	3.68e-10	White blood cell count (basophil);
LUAD	trans	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg01620082	chr3:125678407	NA	0.43	6.65	0.31	9.08e-11	Parkinson's disease;
LUAD	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg27068330	chr11:65405492	SIPA1	-0.78	-12.68	-0.52	1.89e-31	Acne (severe);
LUAD	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg22496339	chr2:162101262	NA	0.73	13.42	0.55	1.77e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg04234412	chr22:24373322	LOC391322	-0.82	-15.02	-0.59	3.44e-41	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg02371401	chr5:676784	TPPP	-0.48	-7.81	-0.36	4.42e-14	Lung disease severity in cystic fibrosis;
LUAD	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg13393036	chr8:95962371	TP53INP1	0.35	7.66	0.35	1.32e-13	Type 2 diabetes;
LUAD	cis	rs3845702	0.736	rs115569960	chr2:180848214	C/T	cg01881094	chr2:180872142	CWC22	0.81	8.62	0.39	1.31e-16	Schizophrenia;
LUAD	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg15704280	chr7:45808275	SEPT13	-0.58	-9.55	-0.42	1.08e-19	HDL cholesterol;
LUAD	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg20701182	chr2:24300061	SF3B14	0.65	7.32	0.34	1.25e-12	Lymphocyte counts;
LUAD	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg07606381	chr6:8435919	SLC35B3	0.42	6.82	0.31	3.13e-11	Motion sickness;
LUAD	trans	rs9929218	0.906	rs4783571	chr16:68806778	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.93	-0.56	1.47e-36	Colorectal cancer;
LUAD	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg27535305	chr1:53392650	SCP2	0.35	7.27	0.33	1.81e-12	Monocyte count;
LUAD	trans	rs877282	0.891	rs12767062	chr10:797961	C/T	cg22713356	chr15:30763199	NA	1.29	19.16	0.68	2.3e-59	Uric acid levels;
LUAD	trans	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg03859395	chr2:55845619	SMEK2	-0.45	-6.81	-0.31	3.47e-11	Metabolic syndrome;
LUAD	cis	rs9549367	0.588	rs9549360	chr13:113893032	C/G	cg18105134	chr13:113819100	PROZ	-0.73	-9.16	-0.41	2.27e-18	Platelet distribution width;
LUAD	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.83	-0.32	2.98e-11	Joint mobility (Beighton score);
LUAD	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg06873352	chr17:61820015	STRADA	0.42	7.07	0.32	6.63e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs11811982	0.793	rs11812048	chr1:227511074	C/T	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	trans	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg01620082	chr3:125678407	NA	-0.89	-6.99	-0.32	1.08e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg25894440	chr7:65020034	NA	0.62	6.63	0.31	1.03e-10	Diabetic kidney disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20566420	chr12:122327043	PSMD9	-0.41	-6.62	-0.31	1.06e-10	Height;
LUAD	cis	rs760805	0.932	rs742232	chr1:25251706	T/C	cg22509179	chr1:25234806	RUNX3	-0.76	-13.51	-0.55	8.12e-35	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23583168	chr7:148888333	NA	-1.05	-25.97	-0.78	1.34e-89	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg06608945	chr2:219082296	ARPC2	-0.45	-7.47	-0.34	4.49e-13	Colorectal cancer;
LUAD	cis	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg08601574	chr20:25228251	PYGB	0.47	8.88	0.4	1.93e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg11301795	chr4:187892539	NA	-0.76	-15.61	-0.6	1.04e-43	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.24	-0.33	2.13e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg07460842	chr6:66804631	NA	-1.06	-16.72	-0.63	1.47e-48	Exhaled nitric oxide output;
LUAD	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg04218760	chr10:45406644	TMEM72	-0.31	-7.84	-0.36	3.63e-14	Mean corpuscular volume;
LUAD	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.37	6.36	0.3	5.35e-10	Bone mineral density (spine);Bone mineral density;
LUAD	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg02002194	chr4:3960332	NA	-0.28	-6.71	-0.31	6.46e-11	Mood instability;
LUAD	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg16797656	chr11:68205561	LRP5	-0.47	-10.25	-0.45	3.73e-22	Total body bone mineral density;
LUAD	cis	rs9976767	0.608	rs3746923	chr21:43826344	C/T	cg23042151	chr21:43824109	UBASH3A	-0.3	-6.54	-0.3	1.79e-10	Type 1 diabetes;
LUAD	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg16647868	chr5:131706066	SLC22A5	-0.4	-7.02	-0.32	8.7e-12	Blood metabolite levels;
LUAD	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.93	0.36	2e-14	Bladder cancer;
LUAD	trans	rs853679	1.000	rs1778511	chr6:28229411	G/A	cg01620082	chr3:125678407	NA	0.49	6.69	0.31	7.05e-11	Depression;
LUAD	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg05313129	chr8:58192883	C8orf71	-0.57	-8.5	-0.38	3.25e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg26597838	chr10:835615	NA	0.83	11.28	0.48	5.7e-26	Eosinophil percentage of granulocytes;
LUAD	cis	rs4481887	0.830	rs6686474	chr1:248477116	A/C	cg00666640	chr1:248458726	OR2T12	0.31	7.6	0.35	1.96e-13	Common traits (Other);
LUAD	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-8.92	-0.4	1.39e-17	Gut microbiome composition (summer);
LUAD	cis	rs3091242	0.933	rs9645452	chr1:25668326	C/T	cg09222892	chr1:25734099	RHCE	0.51	9.51	0.42	1.51e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg14784868	chr12:69753453	YEATS4	-0.4	-6.49	-0.3	2.45e-10	Blood protein levels;
LUAD	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg10792982	chr14:105748885	BRF1	0.46	10.08	0.44	1.51e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg07617317	chr6:118971624	C6orf204	0.56	8.38	0.38	7.73e-16	Diastolic blood pressure;
LUAD	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg05393297	chr12:53359155	NA	-0.95	-17.37	-0.65	2.06e-51	Cancer (pleiotropy);
LUAD	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6761276	0.899	rs12711750	chr2:113835380	C/A	cg10479672	chr2:113810641	IL1F8	-0.38	-7.65	-0.35	1.39e-13	Protein quantitative trait loci;
LUAD	cis	rs7487075	0.619	rs12824565	chr12:46834693	A/G	cg23829395	chr12:46796953	NA	0.32	6.96	0.32	1.3e-11	Itch intensity from mosquito bite;
LUAD	trans	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.63	10.38	0.45	1.2e-22	Endometrial cancer;
LUAD	cis	rs1595825	0.891	rs7573687	chr2:198893376	A/G	cg11031976	chr2:198649780	BOLL	-0.45	-6.58	-0.3	1.4e-10	Ulcerative colitis;
LUAD	cis	rs7709909	0.532	rs6151670	chr5:79983215	C/G	cg24059623	chr5:79951536	MSH3;DHFR	0.48	7.17	0.33	3.29e-12	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg08280861	chr8:58055591	NA	0.7	7.61	0.35	1.79e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg20476274	chr7:133979776	SLC35B4	0.74	13.14	0.54	2.56e-33	Mean platelet volume;
LUAD	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11644478	chr21:40555479	PSMG1	0.68	10.84	0.47	2.5e-24	Cognitive function;
LUAD	cis	rs2073300	1.000	rs34449811	chr20:23443771	T/C	cg12062639	chr20:23401060	NAPB	0.98	8.35	0.38	9.91e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7945705	0.875	rs4929914	chr11:8824388	C/T	cg10639395	chr11:8710044	RPL27A	0.32	6.39	0.3	4.47e-10	Hemoglobin concentration;
LUAD	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg00321850	chr1:175162397	KIAA0040	-0.51	-10.93	-0.47	1.15e-24	Alcohol dependence;
LUAD	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg26384229	chr12:38710491	ALG10B	0.47	7.78	0.35	5.79e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg17847044	chr15:42102381	MAPKBP1	0.57	14.3	0.57	4.06e-38	Diastolic blood pressure;
LUAD	trans	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg02030672	chr11:45687055	CHST1	-0.38	-6.87	-0.32	2.38e-11	Obesity-related traits;
LUAD	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg23950597	chr19:37808831	NA	-0.6	-7.46	-0.34	4.88e-13	Coronary artery calcification;
LUAD	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.71	0.39	7.09e-17	Menopause (age at onset);
LUAD	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.11	-0.37	5.52e-15	Diabetic kidney disease;
LUAD	trans	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.89	-0.36	2.65e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg04450456	chr4:17643702	FAM184B	0.4	7.85	0.36	3.35e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2249625	0.545	rs2249021	chr6:72889472	A/G	cg18830697	chr6:72922368	RIMS1	-0.44	-7.96	-0.36	1.55e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-6.38	-0.3	4.52e-10	Height;
LUAD	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg06108461	chr20:60628389	TAF4	-0.86	-15.12	-0.59	1.36e-41	Body mass index;
LUAD	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg04036182	chr15:45458818	NA	0.4	6.5	0.3	2.27e-10	Glomerular filtration rate;
LUAD	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg00530320	chr1:46809349	NSUN4	0.53	7.97	0.36	1.45e-14	Menopause (age at onset);
LUAD	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg05425664	chr17:57184151	TRIM37	0.42	7.53	0.34	3.17e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg07538946	chr5:131705188	SLC22A5	0.41	6.72	0.31	5.91e-11	Blood metabolite levels;
LUAD	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg08470875	chr2:26401718	FAM59B	0.77	10.11	0.44	1.11e-21	Gut microbiome composition (summer);
LUAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06873352	chr17:61820015	STRADA	0.83	18.31	0.66	1.45e-55	Prudent dietary pattern;
LUAD	cis	rs77861329	1.000	rs164639	chr3:52210872	A/G	cg08692210	chr3:52188851	WDR51A	-0.8	-8.26	-0.37	1.84e-15	Macrophage inflammatory protein 1b levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04174070	chr7:75624163	TMEM120A	-0.41	-6.36	-0.3	5.31e-10	Height;
LUAD	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg18944383	chr4:111397179	ENPEP	0.38	7.68	0.35	1.09e-13	Height;
LUAD	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg08470875	chr2:26401718	FAM59B	-0.74	-10.19	-0.44	6.05e-22	Gut microbiome composition (summer);
LUAD	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg07305463	chr2:136567211	LCT	0.37	7.2	0.33	2.71e-12	Mosquito bite size;
LUAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg06092702	chr1:163392909	NA	-0.39	-8.44	-0.38	5.02e-16	Motion sickness;
LUAD	cis	rs6756513	0.501	rs7581977	chr2:70174054	C/T	cg02498382	chr2:70120550	SNRNP27	0.53	9.89	0.43	7e-21	Breast cancer;Platelet count;
LUAD	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg06784218	chr1:46089804	CCDC17	0.51	11.23	0.48	8.7e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01171360	chr6:293285	DUSP22	-0.75	-13.39	-0.55	2.46e-34	Menopause (age at onset);
LUAD	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg02423579	chr7:2872169	GNA12	0.89	16.21	0.62	2.59e-46	Height;
LUAD	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg11915388	chr22:42470451	FAM109B	-0.39	-7.15	-0.33	3.8e-12	Schizophrenia;
LUAD	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg01528321	chr10:82214614	TSPAN14	0.66	10.56	0.46	2.66e-23	Post bronchodilator FEV1;
LUAD	cis	rs7614311	0.681	rs6801346	chr3:63947128	A/G	cg22134162	chr3:63841271	THOC7	0.54	9.39	0.42	3.65e-19	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.28	0.66	1.99e-55	Prudent dietary pattern;
LUAD	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.55	8.34	0.38	1.03e-15	Total cholesterol levels;
LUAD	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg08805041	chr16:621841	PIGQ	-0.32	-6.45	-0.3	3.08e-10	Height;
LUAD	cis	rs6717918	0.816	rs11901692	chr2:233149739	A/G	ch.2.233013039R	chr2:233304795	NA	-0.45	-6.51	-0.3	2.17e-10	Height;
LUAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.81	0.43	1.28e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg17063962	chr7:91808500	NA	0.66	11.31	0.48	4.3e-26	Breast cancer;
LUAD	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg12310025	chr6:25882481	NA	-0.51	-7.41	-0.34	6.86e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	6.97	0.32	1.25e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg18621852	chr3:10150065	C3orf24	0.48	8.45	0.38	4.89e-16	Alzheimer's disease;
LUAD	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg00769240	chr8:12517080	NA	-0.39	-6.64	-0.31	9.43e-11	Blood pressure (smoking interaction);
LUAD	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-11.35	-0.48	3.07e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg08219700	chr8:58056026	NA	0.57	7.93	0.36	1.94e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1003719	0.788	rs4411798	chr21:38453183	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.47	8.16	0.37	3.74e-15	Eye color traits;
LUAD	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg22535103	chr8:58192502	C8orf71	-0.68	-7.24	-0.33	2.2e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7122539	0.646	rs543191	chr11:66583779	T/G	cg24851651	chr11:66362959	CCS	0.37	6.75	0.31	4.99e-11	HIV-1 susceptibility;
LUAD	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.51	-0.34	3.49e-13	Breast cancer;
LUAD	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg21475434	chr5:93447410	FAM172A	0.73	8.11	0.37	5.5e-15	Diabetic retinopathy;
LUAD	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg11822812	chr5:140052017	DND1	0.36	6.41	0.3	3.79e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs62064224	0.614	rs2286645	chr17:30696292	C/T	cg25809561	chr17:30822961	MYO1D	0.48	8.61	0.39	1.41e-16	Schizophrenia;
LUAD	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg24642844	chr7:1081250	C7orf50	-0.98	-14.87	-0.59	1.54e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.3	0.51	6.42e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs240764	0.621	rs12175456	chr6:101219511	A/T	cg09795085	chr6:101329169	ASCC3	-0.43	-7.6	-0.35	1.96e-13	Neuroticism;
LUAD	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg21252483	chr19:49399788	TULP2	-0.89	-14.65	-0.58	1.34e-39	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs2718058	0.519	rs2722243	chr7:37873467	A/C	cg15028436	chr7:37888078	TXNDC3	0.34	7.13	0.33	4.27e-12	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg24829409	chr8:58192753	C8orf71	-0.62	-7.2	-0.33	2.8e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg24818145	chr4:99064322	C4orf37	0.47	7.98	0.36	1.37e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg21545522	chr1:205238299	TMCC2	0.36	6.61	0.31	1.14e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg18105134	chr13:113819100	PROZ	-0.85	-14.92	-0.59	9.31e-41	Platelet distribution width;
LUAD	cis	rs4713675	0.709	rs626156	chr6:33670482	A/G	cg13859433	chr6:33739653	LEMD2	0.31	7.14	0.33	4.04e-12	Plateletcrit;
LUAD	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg22906224	chr7:99728672	NA	0.64	10.81	0.47	3.28e-24	Coronary artery disease;
LUAD	cis	rs17336368	1.000	rs17336368	chr6:44751668	G/A	cg18551225	chr6:44695536	NA	-0.59	-9.72	-0.43	2.82e-20	Chin dimples;
LUAD	cis	rs28735056	0.620	rs12456484	chr18:77677315	C/G	cg20368463	chr18:77673604	PQLC1	0.51	8.53	0.38	2.61e-16	Schizophrenia;
LUAD	trans	rs9314614	0.933	rs2741098	chr8:6690276	C/T	cg11829072	chr8:125463024	TRMT12	0.44	7.65	0.35	1.39e-13	IgA nephropathy;White blood cell count (basophil);
LUAD	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg11502198	chr6:26597334	ABT1	0.56	9.3	0.41	7.51e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs1018946	chr7:106851754	T/C	cg23024343	chr7:107201750	COG5	0.49	7.03	0.32	8.41e-12	Coronary artery disease;
LUAD	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.89	-0.32	2.06e-11	Retinal vascular caliber;
LUAD	cis	rs9837602	1.000	rs704582	chr3:99571926	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.57	8.1	0.37	5.9e-15	Breast cancer;
LUAD	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs1232027	0.700	rs1643635	chr5:79928216	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.66	-0.35	1.3e-13	Huntington's disease progression;
LUAD	cis	rs6867032	1.000	rs7729761	chr5:2015783	G/T	cg26168224	chr5:2018326	NA	0.8	18.39	0.67	6.2e-56	Gut microbiome composition (winter);
LUAD	cis	rs9392556	0.829	rs7744628	chr6:4119996	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	0.42	7.37	0.34	9.24e-13	Blood metabolite levels;
LUAD	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg20628663	chr10:43360327	NA	-0.74	-11.25	-0.48	7.59e-26	Blood protein levels;
LUAD	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg24503407	chr1:205819492	PM20D1	0.52	9.47	0.42	1.95e-19	Menarche (age at onset);
LUAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg11050988	chr7:1952600	MAD1L1	-0.37	-7.54	-0.34	2.94e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7677751	0.806	rs890203	chr4:55097405	A/C	cg17187183	chr4:55093834	PDGFRA	0.51	8.63	0.39	1.23e-16	Corneal astigmatism;
LUAD	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg12311346	chr5:56204834	C5orf35	-0.43	-7.09	-0.33	5.5e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs12900413	0.687	rs12906905	chr15:90315399	A/G	cg24249390	chr15:90295951	MESP1	-0.34	-6.83	-0.32	2.94e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg18515171	chr17:58156344	HEATR6	-0.4	-6.86	-0.32	2.53e-11	Subcortical brain region volumes;
LUAD	cis	rs11112613	0.713	rs12321309	chr12:105943263	T/G	cg03607813	chr12:105948248	NA	0.88	13.97	0.56	1.02e-36	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg05368731	chr17:41323189	NBR1	0.95	20.02	0.7	3.33e-63	Menopause (age at onset);
LUAD	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg05082376	chr22:42548792	NA	0.45	7.8	0.35	4.73e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.82	0.53	5.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg11822812	chr5:140052017	DND1	0.38	6.8	0.31	3.53e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs9467711	0.606	rs9393735	chr6:26582327	A/G	cg01620082	chr3:125678407	NA	-0.63	-7.31	-0.33	1.34e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg21605333	chr4:119757512	SEC24D	0.93	8.76	0.39	4.9e-17	Cannabis dependence symptom count;
LUAD	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg04414720	chr1:150670196	GOLPH3L	0.57	9.61	0.42	6.48e-20	Tonsillectomy;
LUAD	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg21775007	chr8:11205619	TDH	-0.5	-9.05	-0.4	5.27e-18	Retinal vascular caliber;
LUAD	cis	rs12760731	0.720	rs12022185	chr1:178279653	A/G	cg00404053	chr1:178313656	RASAL2	0.75	9.48	0.42	1.85e-19	Obesity-related traits;
LUAD	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.19	15.75	0.61	2.5e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4692589	1.000	rs11732126	chr4:170937416	A/G	cg19918862	chr4:170955249	NA	0.29	6.95	0.32	1.38e-11	Anxiety disorder;
LUAD	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.4	7.06	0.32	6.8e-12	Systemic lupus erythematosus;
LUAD	cis	rs7107174	1.000	rs10899475	chr11:78051610	T/C	cg19901956	chr11:77921274	USP35	-0.52	-7.35	-0.34	1.06e-12	Testicular germ cell tumor;
LUAD	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg03714773	chr7:91764589	CYP51A1	0.28	6.6	0.31	1.24e-10	Breast cancer;
LUAD	cis	rs12210905	0.688	rs72845012	chr6:27501986	C/A	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs2479724	0.613	rs9367113	chr6:41809801	T/G	cg17623882	chr6:41773611	USP49	-0.54	-7.97	-0.36	1.45e-14	Menarche (age at onset);
LUAD	cis	rs599083	0.590	rs661988	chr11:68189251	T/G	cg16797656	chr11:68205561	LRP5	0.4	7.11	0.33	5.13e-12	Bone mineral density (spine);
LUAD	cis	rs701145	0.585	rs2689330	chr3:153929990	T/C	cg17054900	chr3:154042577	DHX36	0.65	7.0	0.32	1.03e-11	Coronary artery disease;
LUAD	cis	rs2485376	1.000	rs7080055	chr10:104008280	A/C	cg20641465	chr10:103991465	PITX3	0.58	10.7	0.46	8.59e-24	QT interval;
LUAD	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg18252515	chr7:66147081	NA	-0.63	-6.96	-0.32	1.34e-11	Diabetic kidney disease;
LUAD	cis	rs6908034	0.607	rs77791009	chr6:19812602	A/G	cg02682789	chr6:19804855	NA	0.91	9.09	0.4	3.9e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg18230493	chr5:56204884	C5orf35	-0.45	-7.53	-0.34	3.1e-13	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg26384229	chr12:38710491	ALG10B	0.48	7.66	0.35	1.31e-13	Bladder cancer;
LUAD	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg04727924	chr7:799746	HEATR2	-0.53	-7.2	-0.33	2.72e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg12011299	chr4:100065546	ADH4	0.63	12.99	0.53	1.04e-32	Alcohol dependence;
LUAD	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.88	-0.36	2.77e-14	Diabetic kidney disease;
LUAD	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg07708487	chr16:89387014	ANKRD11	-0.33	-6.68	-0.31	7.7e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg02176678	chr2:219576539	TTLL4	0.75	15.06	0.59	2.35e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1509123	0.702	rs117094755	chr17:6720746	A/T	cg12642237	chr17:6703447	TEKT1	-0.46	-6.78	-0.31	4.05e-11	Blood metabolite levels;
LUAD	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.53	-9.47	-0.42	1.98e-19	Axial length;
LUAD	cis	rs7561273	0.586	rs7589717	chr2:24357463	G/A	cg20701182	chr2:24300061	SF3B14	0.46	7.52	0.34	3.31e-13	Quantitative traits;
LUAD	cis	rs12505328	0.966	rs10023094	chr4:174356664	C/T	cg12145043	chr4:174357286	NA	-0.57	-10.21	-0.44	4.98e-22	Chin dimples;
LUAD	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg14343924	chr8:8086146	FLJ10661	-0.49	-7.95	-0.36	1.77e-14	Mood instability;
LUAD	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg07936489	chr17:37558343	FBXL20	0.46	7.21	0.33	2.62e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg00857998	chr1:205179979	DSTYK	0.4	6.62	0.31	1.11e-10	Red blood cell count;
LUAD	cis	rs7590720	0.788	rs4674050	chr2:216907322	G/T	cg12620499	chr2:216877984	MREG	0.59	9.95	0.44	4.26e-21	Alcohol dependence;
LUAD	cis	rs9430161	0.644	rs6685766	chr1:11037051	T/C	cg27631724	chr1:11040367	C1orf127	0.55	9.6	0.42	7.01e-20	Ewing sarcoma;
LUAD	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.58	-0.35	2.13e-13	Lung cancer;
LUAD	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg24733560	chr20:60626293	TAF4	0.48	8.42	0.38	5.79e-16	Body mass index;
LUAD	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg06627628	chr2:24431161	ITSN2	-0.69	-10.79	-0.46	3.89e-24	Asthma;
LUAD	cis	rs1018836	0.786	rs10956736	chr8:91602067	C/T	cg16814680	chr8:91681699	NA	-0.59	-9.86	-0.43	8.73e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs657075	0.697	rs34757387	chr5:131652677	G/T	cg21138405	chr5:131827807	IRF1	0.5	6.42	0.3	3.76e-10	Rheumatoid arthritis;
LUAD	cis	rs4523957	0.583	rs1565763	chr17:2055300	T/C	cg16513277	chr17:2031491	SMG6	-0.98	-19.26	-0.68	8.26e-60	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg02454025	chr1:11042201	C1orf127	0.99	17.13	0.64	2.49e-50	Ewing sarcoma;
LUAD	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg04990556	chr1:26633338	UBXN11	0.44	6.86	0.32	2.46e-11	Obesity-related traits;
LUAD	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg17724175	chr1:150552817	MCL1	0.31	7.11	0.33	4.93e-12	Melanoma;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg05360265	chr6:147525477	STXBP5	-0.42	-7.37	-0.34	9.22e-13	Schizophrenia;
LUAD	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.52	0.52	8.06e-31	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg04775059	chr7:64541387	NA	0.51	6.76	0.31	4.5e-11	Aortic root size;
LUAD	cis	rs9875589	0.509	rs9824910	chr3:14040136	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.37	6.7	0.31	6.74e-11	Ovarian reserve;
LUAD	cis	rs7799006	0.964	rs3757440	chr7:2272936	A/G	cg02951883	chr7:2050386	MAD1L1	-0.46	-7.69	-0.35	1.05e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2625529	0.775	rs4777477	chr15:72269612	G/A	cg16672083	chr15:72433130	SENP8	-0.76	-12.67	-0.52	1.99e-31	Red blood cell count;
LUAD	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.79	-0.35	5.18e-14	Type 2 diabetes;
LUAD	cis	rs6499255	0.953	rs3811349	chr16:69791266	T/G	cg26679644	chr16:69762563	NA	0.42	6.58	0.3	1.43e-10	IgE levels;
LUAD	cis	rs11696845	0.604	rs1980577	chr20:43382112	A/G	cg25301532	chr20:43378953	KCNK15	0.48	8.13	0.37	4.91e-15	Obesity-related traits;
LUAD	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg15557168	chr22:42548783	NA	0.51	9.41	0.42	3.33e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs36715	0.909	rs152906	chr5:127551840	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.47	6.49	0.3	2.46e-10	Breast cancer;
LUAD	trans	rs225245	0.791	rs3890901	chr17:34011322	A/C	cg19694781	chr19:47549865	TMEM160	-0.47	-7.79	-0.35	5.17e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg08847533	chr14:75593920	NEK9	0.39	6.72	0.31	5.97e-11	Height;
LUAD	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-7.07	-0.33	6.43e-12	Schizophrenia;
LUAD	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg14582100	chr15:45693742	SPATA5L1	0.62	12.07	0.51	5.11e-29	Homoarginine levels;
LUAD	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg11645453	chr3:52864694	ITIH4	-0.54	-9.72	-0.43	2.81e-20	Schizophrenia;
LUAD	trans	rs629535	0.773	rs630235	chr8:70033529	T/G	cg21567404	chr3:27674614	NA	1.01	18.29	0.66	1.7e-55	Dupuytren's disease;
LUAD	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg20556744	chr2:9614537	IAH1	0.65	6.56	0.3	1.54e-10	Opioid sensitivity;
LUAD	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg11814155	chr7:99998594	ZCWPW1	0.44	7.41	0.34	7.05e-13	Platelet count;
LUAD	cis	rs739496	0.579	rs4766705	chr12:112333660	C/A	cg10833066	chr12:111807467	FAM109A	0.42	6.95	0.32	1.38e-11	Platelet count;
LUAD	cis	rs10499694	0.933	rs12718583	chr7:50582631	T/C	cg18232548	chr7:50535776	DDC	-0.44	-7.44	-0.34	5.65e-13	Body mass index;
LUAD	cis	rs7818345	0.935	rs6983973	chr8:19287867	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.84	0.32	2.85e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	trans	rs1178968	0.901	rs9784947	chr7:72748888	C/G	cg15428835	chr7:75027521	TRIM73;TRIM74	0.5	6.38	0.3	4.77e-10	Triglyceride levels;
LUAD	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11890956	chr21:40555474	PSMG1	-0.58	-10.3	-0.45	2.48e-22	Menarche (age at onset);
LUAD	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.75	0.53	9.73e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs747782	0.583	rs11039666	chr11:48324841	C/G	cg03929089	chr4:120376271	NA	0.66	6.66	0.31	8.32e-11	Intraocular pressure;
LUAD	cis	rs1691799	0.899	rs1168299	chr12:66736074	C/G	cg16791601	chr12:66731901	HELB	-0.36	-6.46	-0.3	2.85e-10	White blood cell count (basophil);
LUAD	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg14583973	chr4:3374767	RGS12	-0.3	-7.66	-0.35	1.27e-13	Serum sulfate level;
LUAD	cis	rs1232027	0.700	rs73765839	chr5:79947823	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-8.03	-0.36	1.01e-14	Huntington's disease progression;
LUAD	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg04365224	chr3:72788183	NA	-0.44	-6.56	-0.3	1.55e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg15181151	chr6:150070149	PCMT1	-0.43	-8.53	-0.38	2.59e-16	Lung cancer;
LUAD	cis	rs12541635	0.801	rs12155862	chr8:107105243	G/A	cg10147462	chr8:107024639	NA	-0.42	-7.34	-0.34	1.11e-12	Age of smoking initiation;
LUAD	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg24112000	chr20:60950667	NA	-0.89	-13.99	-0.56	7.68e-37	Colorectal cancer;
LUAD	cis	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg02751453	chr18:77725136	HSBP1L1	0.36	6.83	0.32	3e-11	Opioid sensitivity;
LUAD	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9283706	0.689	rs6889240	chr5:66320940	A/G	cg11590213	chr5:66331682	MAST4	0.4	6.57	0.3	1.5e-10	Coronary artery disease;
LUAD	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3106136	0.546	rs2276910	chr4:95129238	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-8.98	-0.4	8.92e-18	Capecitabine sensitivity;
LUAD	cis	rs354225	0.544	rs10183867	chr2:54812722	C/G	cg01766943	chr2:54829624	SPTBN1	0.38	7.12	0.33	4.75e-12	Schizophrenia;
LUAD	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-7.07	-0.33	6.28e-12	Waist circumference;Hip circumference;
LUAD	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.17	-0.33	3.4e-12	Total body bone mineral density;
LUAD	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg25894440	chr7:65020034	NA	0.61	6.5	0.3	2.29e-10	Diabetic kidney disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg25307593	chr12:40499811	SLC2A13	-0.64	-6.48	-0.3	2.54e-10	Type 2 diabetes;
LUAD	trans	rs78049276	0.736	rs6841473	chr4:148407652	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.59	-6.7	-0.31	6.47e-11	Pulse pressure;
LUAD	cis	rs6688613	0.694	rs2075946	chr1:166818566	A/G	cg07049167	chr1:166818506	POGK	0.64	10.22	0.44	4.66e-22	Refractive astigmatism;
LUAD	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg19773385	chr1:10388646	KIF1B	-0.42	-6.82	-0.31	3.24e-11	Hepatocellular carcinoma;
LUAD	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg09658497	chr7:2847517	GNA12	-0.49	-8.41	-0.38	6.27e-16	Height;
LUAD	cis	rs10799445	0.568	rs3010190	chr1:227804310	T/C	cg12133451	chr1:227746453	NA	-0.38	-6.64	-0.31	9.53e-11	Height;
LUAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg06453172	chr10:134556979	INPP5A	-0.76	-10.99	-0.47	7.11e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	7.64	0.35	1.44e-13	Schizophrenia;
LUAD	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg25036284	chr2:26402008	FAM59B	-0.58	-8.17	-0.37	3.48e-15	Gut microbiome composition (summer);
LUAD	cis	rs644148	0.803	rs2686771	chr19:44999494	T/C	cg15540054	chr19:45004280	ZNF180	-0.41	-6.7	-0.31	6.67e-11	Personality dimensions;
LUAD	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00149659	chr3:10157352	C3orf10	0.55	6.96	0.32	1.32e-11	Alzheimer's disease;
LUAD	cis	rs7940866	0.774	rs10466547	chr11:130823576	T/C	cg12179176	chr11:130786555	SNX19	0.41	6.46	0.3	2.81e-10	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08280861	chr8:58055591	NA	0.63	8.31	0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg18512352	chr11:47633146	NA	-0.54	-9.64	-0.42	5.21e-20	Subjective well-being;
LUAD	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.29	0.33	1.49e-12	Tonsillectomy;
LUAD	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg17063962	chr7:91808500	NA	0.59	9.82	0.43	1.26e-20	Breast cancer;
LUAD	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg13385794	chr1:248469461	NA	0.26	6.97	0.32	1.23e-11	Common traits (Other);
LUAD	trans	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	17.1	0.64	3.24e-50	Exhaled nitric oxide output;
LUAD	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg09658497	chr7:2847517	GNA12	-0.53	-8.8	-0.39	3.4e-17	Height;
LUAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg16606324	chr3:10149918	C3orf24	0.68	11.35	0.48	3.15e-26	Alzheimer's disease;
LUAD	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg03806693	chr22:41940476	POLR3H	-0.62	-8.81	-0.39	3.32e-17	Vitiligo;
LUAD	cis	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg02508848	chr16:68573721	ZFP90	0.41	6.52	0.3	2.02e-10	Ulcerative colitis;
LUAD	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg09796270	chr17:17721594	SREBF1	-0.37	-6.94	-0.32	1.44e-11	Total body bone mineral density;
LUAD	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.8	11.49	0.49	8.75e-27	Smoking behavior;
LUAD	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg04036182	chr15:45458818	NA	-0.38	-6.52	-0.3	2.01e-10	Glomerular filtration rate;
LUAD	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg22117172	chr7:91764530	CYP51A1	-0.31	-6.78	-0.31	3.99e-11	Breast cancer;
LUAD	trans	rs9949291	0.565	rs1581426	chr18:61375519	C/T	cg01416111	chr7:120590947	ING3	-0.37	-6.35	-0.3	5.69e-10	Eosinophil percentage of white cells;
LUAD	cis	rs7809950	0.817	rs2253833	chr7:107205669	A/G	cg23024343	chr7:107201750	COG5	0.82	13.96	0.56	1.03e-36	Coronary artery disease;
LUAD	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.83	0.32	2.93e-11	Colorectal cancer;
LUAD	cis	rs4006360	0.604	rs1976318	chr17:39250906	A/G	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.27	0.37	1.75e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs7250872	0.647	rs2304615	chr19:1826112	A/G	cg10370574	chr19:1840461	REXO1	-0.64	-10.59	-0.46	2.14e-23	Bipolar disorder;
LUAD	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg19743168	chr1:23544995	NA	0.39	6.84	0.32	2.72e-11	Height;
LUAD	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg25985355	chr7:65971099	NA	-0.4	-7.38	-0.34	8.44e-13	Aortic root size;
LUAD	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg03563238	chr19:33554763	RHPN2	-0.35	-8.28	-0.37	1.58e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg03929089	chr4:120376271	NA	-0.56	-8.27	-0.37	1.77e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg01097406	chr16:89675127	NA	-0.31	-6.36	-0.3	5.19e-10	Vitiligo;
LUAD	cis	rs10203711	0.966	rs4998692	chr2:239564772	T/G	cg14580085	chr2:239553406	NA	0.41	8.63	0.39	1.26e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00166722	chr3:10149974	C3orf24	0.74	12.64	0.52	2.68e-31	Alzheimer's disease;
LUAD	cis	rs12893668	0.628	rs57072546	chr14:104063723	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.92	-0.36	2.16e-14	Reticulocyte count;
LUAD	cis	rs4642101	0.537	rs4997708	chr3:12839603	G/A	cg24848339	chr3:12840334	CAND2	0.43	8.46	0.38	4.35e-16	QRS complex (12-leadsum);
LUAD	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg11166453	chr1:247681781	NA	-0.39	-7.45	-0.34	5.17e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.82	-0.39	3.12e-17	Bone mineral density;
LUAD	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg06263672	chr7:65235340	NA	0.49	6.8	0.31	3.61e-11	Aortic root size;
LUAD	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg13010199	chr12:38710504	ALG10B	0.4	6.6	0.31	1.25e-10	Bladder cancer;
LUAD	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg19622623	chr12:86230825	RASSF9	-0.55	-9.79	-0.43	1.53e-20	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.0	0.36	1.25e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg27284194	chr4:1044797	NA	0.69	10.11	0.44	1.17e-21	Recombination rate (females);
LUAD	cis	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg05084668	chr3:125655381	ALG1L	-0.59	-9.27	-0.41	9.67e-19	Blood pressure (smoking interaction);
LUAD	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg05090351	chr10:126851162	NA	-0.59	-11.87	-0.5	2.94e-28	Menarche (age at onset);
LUAD	cis	rs7582720	1.000	rs72932573	chr2:203861113	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.64	0.42	5.27e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.51	0.34	3.46e-13	Breast cancer;
LUAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg22907277	chr7:1156413	C7orf50	0.67	7.9	0.36	2.46e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg10518543	chr12:38710700	ALG10B	0.43	6.54	0.3	1.75e-10	Bladder cancer;
LUAD	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg26384229	chr12:38710491	ALG10B	-0.38	-6.54	-0.3	1.8e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9296092	0.538	rs76589475	chr6:33519517	G/C	cg13560919	chr6:33536144	NA	-0.88	-16.13	-0.62	5.99e-46	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg00255919	chr5:131827918	IRF1	-0.46	-10.35	-0.45	1.51e-22	Asthma (sex interaction);
LUAD	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg19610905	chr11:61596333	FADS2	-0.6	-10.11	-0.44	1.11e-21	Trans fatty acid levels;
LUAD	trans	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	26.51	0.79	5.76e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs243505	0.762	rs3779036	chr7:148488507	C/T	cg09806900	chr7:148480153	CUL1	0.47	8.08	0.37	7.06e-15	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7010267	0.570	rs10090576	chr8:120037816	T/C	cg01975934	chr8:119970761	NA	-0.34	-6.43	-0.3	3.5e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg09117114	chr16:67998030	SLC12A4	-0.6	-7.42	-0.34	6.48e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3760982	0.935	rs10422990	chr19:44295273	C/T	cg12072164	chr19:44306565	LYPD5	0.38	7.75	0.35	6.95e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs250677	1.000	rs40525	chr5:148432932	G/T	cg12140854	chr5:148520817	ABLIM3	0.57	9.61	0.42	6.46e-20	Breast cancer;
LUAD	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.44	-0.49	1.35e-26	Type 2 diabetes;
LUAD	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg07952391	chr2:88470173	THNSL2	0.78	8.41	0.38	6.13e-16	Plasma clusterin levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24351649	chr7:5463456	TNRC18	-0.45	-6.9	-0.32	1.93e-11	Height;
LUAD	cis	rs7107174	0.892	rs11601195	chr11:78073501	A/G	cg02023728	chr11:77925099	USP35	0.46	7.33	0.34	1.2e-12	Testicular germ cell tumor;
LUAD	cis	rs1003719	0.715	rs4261789	chr21:38503762	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-9.03	-0.4	5.91e-18	Eye color traits;
LUAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.53	-7.35	-0.34	1.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs367943	1.000	rs2248930	chr5:112811119	G/T	cg12552261	chr5:112820674	MCC	-0.58	-11.04	-0.47	4.66e-25	Type 2 diabetes;
LUAD	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.52e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs478304	0.530	rs11568300	chr11:65425167	C/G	cg05805236	chr11:65401703	PCNXL3	-0.56	-9.34	-0.41	5.58e-19	Acne (severe);
LUAD	cis	rs7625357	0.718	rs933604	chr3:169326445	C/G	cg14572252	chr3:169309425	MECOM	-0.49	-8.31	-0.37	1.31e-15	Childhood and early adolescence aggressive behavior;
LUAD	cis	rs922182	0.557	rs4776662	chr15:64203562	G/A	cg02919090	chr15:64263738	DAPK2	-0.35	-6.62	-0.31	1.12e-10	Blood protein levels;
LUAD	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg20587970	chr11:113659929	NA	-1.06	-16.09	-0.62	9.08e-46	Hip circumference adjusted for BMI;
LUAD	trans	rs12517041	1.000	rs2099090	chr5:23287823	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.45	-0.3	3.1e-10	Calcium levels;
LUAD	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg06484146	chr7:12443880	VWDE	-0.57	-7.49	-0.34	4.15e-13	Coronary artery disease;
LUAD	cis	rs1595825	0.735	rs57603546	chr2:198918524	C/A	cg00982548	chr2:198649783	BOLL	-0.64	-8.82	-0.39	3.05e-17	Ulcerative colitis;
LUAD	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg18811423	chr2:55921094	PNPT1	0.51	8.52	0.38	2.89e-16	Metabolic syndrome;
LUAD	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg07549590	chr16:15018862	NA	0.57	10.74	0.46	5.71e-24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs6484504	0.532	rs10835757	chr11:31281902	C/T	cg26647111	chr11:31128758	NA	-0.42	-7.62	-0.35	1.73e-13	Red blood cell count;
LUAD	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg19761014	chr17:28927070	LRRC37B2	0.69	6.75	0.31	4.76e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2836633	0.859	rs8132069	chr21:40032611	T/C	cg12884169	chr21:40033163	ERG	0.45	9.42	0.42	2.9e-19	Coronary artery disease;
LUAD	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.53	-6.41	-0.3	3.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg20503657	chr10:835505	NA	0.96	14.22	0.57	8.75e-38	Eosinophil percentage of granulocytes;
LUAD	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg02240030	chr7:2089880	MAD1L1	0.33	6.48	0.3	2.49e-10	Neuroticism;
LUAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg00431813	chr7:1051703	C7orf50	-0.45	-8.45	-0.38	4.68e-16	Longevity;Endometriosis;
LUAD	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg17971929	chr21:40555470	PSMG1	0.54	8.45	0.38	4.58e-16	Cognitive function;
LUAD	cis	rs896543	0.702	rs6715324	chr2:237495510	C/T	cg25295825	chr2:237489920	CXCR7	0.47	8.68	0.39	8.63e-17	Alcohol dependence (age at onset);
LUAD	trans	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.73	0.35	8.15e-14	Resting heart rate;
LUAD	cis	rs1595825	0.945	rs16826320	chr2:198845623	T/C	cg00982548	chr2:198649783	BOLL	-0.63	-8.96	-0.4	1.05e-17	Ulcerative colitis;
LUAD	cis	rs7072216	0.763	rs2147901	chr10:100165496	A/C	cg26618903	chr10:100175079	PYROXD2	0.37	8.07	0.37	7.32e-15	Metabolite levels;
LUAD	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.9	12.92	0.53	2.11e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg11845111	chr2:191398756	TMEM194B	0.69	12.75	0.53	9.54e-32	Pulse pressure;
LUAD	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg04944784	chr2:26401820	FAM59B	0.73	9.39	0.42	3.75e-19	Gut microbiome composition (summer);
LUAD	cis	rs1385374	0.858	rs11059926	chr12:129294244	A/T	cg09035930	chr12:129282057	SLC15A4	-0.65	-6.91	-0.32	1.79e-11	Systemic lupus erythematosus;
LUAD	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg15128208	chr22:42549153	NA	0.42	6.72	0.31	5.78e-11	Birth weight;
LUAD	cis	rs4919694	0.808	rs112574306	chr10:104971159	C/T	cg04362960	chr10:104952993	NT5C2	0.77	7.69	0.35	1.04e-13	Arsenic metabolism;
LUAD	cis	rs11893307	0.509	rs6726273	chr2:191529696	T/C	cg11845111	chr2:191398756	TMEM194B	-0.48	-6.94	-0.32	1.51e-11	Mean platelet volume;
LUAD	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg17031739	chr1:67600172	NA	0.5	8.84	0.39	2.7e-17	Psoriasis;
LUAD	cis	rs7665090	1.000	rs2125211	chr4:103559876	C/T	cg07973026	chr4:103553119	MANBA	-0.45	-7.84	-0.36	3.72e-14	Primary biliary cholangitis;
LUAD	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-12.43	-0.52	1.96e-30	Migraine;Coronary artery disease;
LUAD	cis	rs4308124	0.708	rs10178095	chr2:111972516	C/T	cg04571233	chr2:111982156	NA	-0.46	-6.53	-0.3	1.84e-10	Vitiligo;
LUAD	cis	rs17155006	0.664	rs411396	chr7:107744759	A/G	cg05962710	chr7:107745446	LAMB4	-0.32	-6.91	-0.32	1.75e-11	Pneumococcal bacteremia;
LUAD	cis	rs8051149	0.688	rs12444670	chr16:87870312	C/T	cg10099957	chr16:87869757	SLC7A5	0.48	8.5	0.38	3.23e-16	Blood metabolite levels;
LUAD	cis	rs367943	1.000	rs348952	chr5:112821990	G/T	cg12552261	chr5:112820674	MCC	-0.59	-11.17	-0.48	1.49e-25	Type 2 diabetes;
LUAD	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	12.47	0.52	1.25e-30	Lung cancer in ever smokers;
LUAD	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.48	-8.05	-0.36	8.66e-15	Body mass index;
LUAD	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg24818145	chr4:99064322	C4orf37	-0.41	-6.84	-0.32	2.75e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.0	0.44	2.81e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg05313129	chr8:58192883	C8orf71	0.52	6.7	0.31	6.78e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2235649	0.798	rs78540053	chr16:1853275	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.5	-8.19	-0.37	3.1e-15	Blood metabolite levels;
LUAD	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg14092988	chr3:52407081	DNAH1	0.45	8.98	0.4	9.3e-18	Bipolar disorder;
LUAD	cis	rs752010	0.530	rs10789401	chr1:42081111	A/G	cg06885757	chr1:42089581	HIVEP3	0.63	14.29	0.57	4.5e-38	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.69	10.49	0.45	5.04e-23	Renal function-related traits (BUN);
LUAD	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03264133	chr6:25882463	NA	-0.57	-9.39	-0.42	3.69e-19	Blood metabolite levels;
LUAD	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg17724175	chr1:150552817	MCL1	0.34	7.87	0.36	3.01e-14	Melanoma;
LUAD	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg25554036	chr4:6271136	WFS1	0.68	12.49	0.52	1.04e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg08219700	chr8:58056026	NA	0.47	6.95	0.32	1.4e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg17063962	chr7:91808500	NA	0.72	12.75	0.53	9.92e-32	Breast cancer;
LUAD	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.04e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.66	-0.61	6.36e-44	Eye color traits;
LUAD	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	7.74	0.35	7.63e-14	Tonsillectomy;
LUAD	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg22676075	chr6:135203613	NA	0.42	7.56	0.35	2.52e-13	Red blood cell count;
LUAD	cis	rs9900062	0.586	rs35018407	chr17:62690181	A/C	cg02097616	chr17:62675921	NA	0.56	9.37	0.41	4.51e-19	QT interval;
LUAD	trans	rs3942852	0.868	rs7122335	chr11:48106486	C/T	cg15704280	chr7:45808275	SEPT13	-0.58	-7.73	-0.35	7.93e-14	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs853679	0.546	rs200490	chr6:27796935	G/T	cg01620082	chr3:125678407	NA	-0.81	-8.71	-0.39	7.07e-17	Depression;
LUAD	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg00666640	chr1:248458726	OR2T12	0.32	7.76	0.35	6.59e-14	Common traits (Other);
LUAD	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg00129232	chr17:37814104	STARD3	-0.43	-6.85	-0.32	2.57e-11	Asthma;
LUAD	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg27284194	chr4:1044797	NA	0.7	10.18	0.44	6.52e-22	Recombination rate (females);
LUAD	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg11845111	chr2:191398756	TMEM194B	-0.73	-9.77	-0.43	1.84e-20	Diastolic blood pressure;
LUAD	cis	rs6489882	0.867	rs7304898	chr12:113365667	T/C	cg20102336	chr12:113376681	OAS3	-0.6	-9.41	-0.42	3.32e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg00814883	chr7:100076585	TSC22D4	-0.77	-10.8	-0.46	3.67e-24	Platelet count;
LUAD	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg27490568	chr2:178487706	NA	-0.57	-8.29	-0.37	1.56e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18403220	chr7:56019978	MRPS17	0.4	6.77	0.31	4.27e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg11645453	chr3:52864694	ITIH4	-0.35	-6.91	-0.32	1.8e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg10150615	chr22:24372951	LOC391322	-0.58	-9.68	-0.43	3.63e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2274273	0.840	rs6573013	chr14:55735873	A/C	cg04306507	chr14:55594613	LGALS3	0.41	8.5	0.38	3.24e-16	Protein biomarker;
LUAD	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg13390004	chr1:15929781	NA	0.48	7.97	0.36	1.47e-14	Systolic blood pressure;
LUAD	cis	rs1609391	0.543	rs9859810	chr3:136629986	A/G	cg15507776	chr3:136538369	TMEM22	0.5	8.96	0.4	1.08e-17	Neuroticism;
LUAD	cis	rs7917772	0.582	rs3977756	chr10:104398582	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.66	-0.31	8.49e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg15501526	chr10:2543763	NA	-0.69	-15.73	-0.61	3.05e-44	Age-related hearing impairment;
LUAD	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg23172400	chr8:95962367	TP53INP1	-0.32	-6.96	-0.32	1.32e-11	Type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg17063962	chr7:91808500	NA	0.68	12.08	0.51	4.7e-29	Breast cancer;
LUAD	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg06191203	chr2:152266755	RIF1	-0.53	-8.05	-0.36	8.7e-15	Lung cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06867113	chr7:23636910	CCDC126	-0.42	-7.07	-0.33	6.32e-12	Cancer;
LUAD	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg25817165	chr18:72167213	CNDP2	-0.69	-10.4	-0.45	1.04e-22	Refractive error;
LUAD	cis	rs868036	1.000	rs1026734	chr15:68100950	T/C	cg08079166	chr15:68083412	MAP2K5	0.3	6.49	0.3	2.39e-10	Restless legs syndrome;
LUAD	cis	rs990171	0.511	rs4851013	chr2:103116135	C/T	cg03938978	chr2:103052716	IL18RAP	0.33	6.5	0.3	2.28e-10	Lymphocyte counts;
LUAD	cis	rs4919694	0.615	rs78384860	chr10:105003019	G/T	cg04362960	chr10:104952993	NT5C2	0.71	7.39	0.34	7.76e-13	Arsenic metabolism;
LUAD	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg06618935	chr21:46677482	NA	-0.41	-8.17	-0.37	3.7e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg12310025	chr6:25882481	NA	0.55	9.06	0.4	4.99e-18	Blood metabolite levels;
LUAD	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg09835421	chr16:68378352	PRMT7	-0.77	-8.86	-0.4	2.2e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg24818145	chr4:99064322	C4orf37	0.45	7.7	0.35	9.53e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg20307385	chr11:47447363	PSMC3	0.7	11.65	0.49	2.06e-27	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg17366294	chr4:99064904	C4orf37	0.71	13.37	0.55	2.86e-34	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.37	6.47	0.3	2.65e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg07538946	chr5:131705188	SLC22A5	0.54	9.08	0.4	4.19e-18	Blood metabolite levels;
LUAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg05313129	chr8:58192883	C8orf71	-0.54	-7.04	-0.32	7.65e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9796	0.621	rs691702	chr15:41474399	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.49	-0.38	3.46e-16	Menopause (age at onset);
LUAD	cis	rs1451375	0.617	rs7790758	chr7:50561544	G/A	cg18232548	chr7:50535776	DDC	-0.66	-9.16	-0.41	2.29e-18	Malaria;
LUAD	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24838063	chr12:130822603	PIWIL1	0.64	10.8	0.47	3.41e-24	Menopause (age at onset);
LUAD	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.8	0.35	5e-14	Lung cancer;
LUAD	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg18404041	chr3:52824283	ITIH1	-0.61	-12.67	-0.52	2.13e-31	Bipolar disorder;
LUAD	trans	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg26043149	chr18:55253948	FECH	-0.41	-6.79	-0.31	3.84e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg18131467	chr2:239335373	ASB1	0.73	12.68	0.52	1.85e-31	Multiple system atrophy;
LUAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02353165	chr6:42928485	GNMT	0.5	9.33	0.41	6.22e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7020830	0.894	rs13300951	chr9:37146627	A/G	cg14294708	chr9:37120828	ZCCHC7	0.86	17.21	0.64	1.05e-50	Schizophrenia;
LUAD	trans	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg06606381	chr12:133084897	FBRSL1	-1.14	-9.86	-0.43	8.79e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7009516	0.669	rs4872231	chr8:24247556	A/G	cg01759110	chr8:24241694	ADAMDEC1	-0.43	-8.65	-0.39	1.08e-16	Hair greying;
LUAD	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg06064525	chr11:970664	AP2A2	-0.55	-11.22	-0.48	9.56e-26	Alzheimer's disease (late onset);
LUAD	cis	rs829883	0.646	rs4762494	chr12:98933834	T/G	cg25150519	chr12:98850993	NA	-0.5	-7.9	-0.36	2.44e-14	Colorectal adenoma (advanced);
LUAD	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg01528321	chr10:82214614	TSPAN14	0.46	7.29	0.33	1.53e-12	Post bronchodilator FEV1;
LUAD	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg08219700	chr8:58056026	NA	0.45	6.54	0.3	1.73e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06022373	chr22:39101656	GTPBP1	0.46	7.21	0.33	2.6e-12	Menopause (age at onset);
LUAD	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.59	0.42	7.72e-20	Monocyte percentage of white cells;
LUAD	cis	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg27411982	chr8:10470053	RP1L1	-0.42	-7.54	-0.34	2.93e-13	Neuroticism;
LUAD	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg04414720	chr1:150670196	GOLPH3L	0.73	12.89	0.53	2.64e-32	Melanoma;
LUAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg18538332	chr22:24372958	LOC391322	-0.55	-9.14	-0.41	2.57e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.53	9.05	0.4	5.46e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6920965	0.507	rs9385388	chr6:126215296	C/T	cg05901451	chr6:126070800	HEY2	-0.47	-7.23	-0.33	2.21e-12	High light scatter reticulocyte count;
LUAD	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	6.36	0.3	5.3e-10	Menarche (age at onset);
LUAD	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg23018236	chr17:30244563	NA	-0.57	-7.58	-0.35	2.14e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs757647	0.723	rs12657315	chr5:137770961	C/T	cg10676309	chr5:137685565	NA	0.42	7.49	0.34	3.97e-13	Menarche (age at onset);
LUAD	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg11098525	chr4:1320231	MAEA	-0.39	-6.51	-0.3	2.12e-10	Obesity-related traits;
LUAD	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg24596788	chr1:163392923	NA	-0.38	-8.12	-0.37	5.26e-15	Motion sickness;
LUAD	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs4409675	0.576	rs7535816	chr1:28234054	A/G	cg23691781	chr1:28212827	C1orf38	0.39	11.06	0.47	3.78e-25	Corneal astigmatism;
LUAD	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg09491104	chr22:46646882	C22orf40	-0.58	-7.64	-0.35	1.47e-13	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs11895698	1	rs11895698	chr2:239338495	C/T	cg01134436	chr17:81009848	B3GNTL1	0.55	6.44	0.3	3.16e-10	Chronotype;
LUAD	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg12908607	chr1:44402522	ARTN	-0.52	-9.63	-0.42	5.72e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg00933542	chr6:150070202	PCMT1	0.47	9.84	0.43	1.03e-20	Lung cancer;
LUAD	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.31	7.69	0.35	1.03e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs494562	0.892	rs567686	chr6:86124164	A/T	cg17966619	chr6:86160162	NT5E	0.65	7.73	0.35	7.8e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg08027265	chr7:2291960	NA	-0.41	-6.85	-0.32	2.59e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg13047869	chr3:10149882	C3orf24	0.66	9.99	0.44	2.97e-21	Alzheimer's disease;
LUAD	cis	rs6445967	0.579	rs11130640	chr3:58414908	C/G	cg13750441	chr3:58318267	PXK	-0.31	-6.48	-0.3	2.55e-10	Platelet count;
LUAD	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg26513180	chr16:89883248	FANCA	0.69	12.92	0.53	2.08e-32	Vitiligo;
LUAD	cis	rs12946454	0.521	rs66827053	chr17:43250653	A/G	cg10701640	chr17:43249399	NA	0.58	11.03	0.47	5.08e-25	Systolic blood pressure;
LUAD	trans	rs208520	0.955	rs208532	chr6:66961280	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-13.5	-0.55	8.62e-35	Exhaled nitric oxide output;
LUAD	cis	rs6987853	0.966	rs1901282	chr8:42392942	C/G	cg09913449	chr8:42400586	C8orf40	0.43	7.92	0.36	2.14e-14	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg09253696	chr17:73873529	TRIM47	-0.45	-7.58	-0.35	2.18e-13	Psoriasis;
LUAD	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg04282206	chr17:62833786	PLEKHM1P	0.61	9.17	0.41	2.05e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3733418	0.929	rs2280325	chr4:165928254	C/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.45	-6.39	-0.3	4.29e-10	Obesity-related traits;
LUAD	cis	rs673604	1.000	rs7512578	chr1:35677847	T/C	cg12633102	chr1:35676489	NA	-0.72	-9.88	-0.43	7.62e-21	Endometrial cancer;
LUAD	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg05665937	chr4:1216051	CTBP1	0.49	7.45	0.34	5.19e-13	Longevity;
LUAD	cis	rs7584330	0.780	rs9973650	chr2:238380266	G/A	cg16989719	chr2:238392110	NA	-0.33	-6.56	-0.3	1.59e-10	Prostate cancer;
LUAD	cis	rs7010267	0.740	rs1905786	chr8:119951692	T/C	cg01975934	chr8:119970761	NA	-0.36	-6.94	-0.32	1.52e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.33	7.19	0.33	2.92e-12	Cardiac Troponin-T levels;
LUAD	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.73e-16	Neutrophil percentage of white cells;
LUAD	cis	rs6906287	0.647	rs11753128	chr6:118853514	C/T	cg21191810	chr6:118973309	C6orf204	0.49	9.47	0.42	1.96e-19	Electrocardiographic conduction measures;
LUAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg14926445	chr8:58193284	C8orf71	-0.47	-6.85	-0.32	2.54e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.37	0.3	4.93e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg12257156	chr7:158823799	VIPR2	0.5	7.38	0.34	8.52e-13	Facial morphology (factor 20);
LUAD	cis	rs6669072	0.590	rs10922922	chr1:91237055	G/A	cg08895590	chr1:91227319	NA	0.31	6.49	0.3	2.46e-10	Cognitive function;
LUAD	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg26384229	chr12:38710491	ALG10B	-0.42	-6.8	-0.31	3.53e-11	Morning vs. evening chronotype;
LUAD	cis	rs938554	0.956	rs13115469	chr4:9925145	T/C	cg11266682	chr4:10021025	SLC2A9	0.43	7.58	0.35	2.28e-13	Blood metabolite levels;
LUAD	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.45	0.55	1.37e-34	Prudent dietary pattern;
LUAD	cis	rs6942407	0.546	rs10257953	chr7:86799726	C/T	cg02420886	chr7:86849541	C7orf23	0.64	7.36	0.34	9.79e-13	Food allergy;
LUAD	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg17264618	chr3:40429014	ENTPD3	0.4	8.63	0.39	1.22e-16	Renal cell carcinoma;
LUAD	trans	rs1178968	1.000	rs4717756	chr7:72765458	C/G	cg15428835	chr7:75027521	TRIM73;TRIM74	-0.51	-6.45	-0.3	2.99e-10	Triglyceride levels;
LUAD	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg21475434	chr5:93447410	FAM172A	0.74	8.22	0.37	2.58e-15	Diabetic retinopathy;
LUAD	trans	rs12310956	0.510	rs1565026	chr12:33887499	A/G	cg10518543	chr12:38710700	ALG10B	0.41	6.79	0.31	3.93e-11	Morning vs. evening chronotype;
LUAD	cis	rs28735056	0.660	rs12454454	chr18:77674634	C/T	cg20368463	chr18:77673604	PQLC1	-0.56	-9.52	-0.42	1.34e-19	Schizophrenia;
LUAD	cis	rs3791556	0.898	rs3791549	chr2:240109024	A/G	cg03281426	chr2:240109471	HDAC4	-0.49	-9.38	-0.41	4.22e-19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg18721089	chr20:30220636	NA	-0.45	-6.49	-0.3	2.44e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs1448094	0.842	rs10779231	chr12:86462237	T/C	cg06740227	chr12:86229804	RASSF9	-0.36	-6.5	-0.3	2.28e-10	Major depressive disorder;
LUAD	trans	rs78049276	0.688	rs75697049	chr4:148375242	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.62	-7.17	-0.33	3.33e-12	Pulse pressure;
LUAD	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg24675056	chr1:15929824	NA	0.48	8.35	0.38	9.85e-16	Systolic blood pressure;
LUAD	cis	rs12210905	0.688	rs12209905	chr6:27404592	C/G	cg08851530	chr6:28072375	NA	1.03	7.52	0.34	3.3e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs6708413	0.528	rs7567885	chr2:103108852	G/T	cg03938978	chr2:103052716	IL18RAP	-0.35	-7.11	-0.33	4.96e-12	Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.32	0.34	1.28e-12	Morning vs. evening chronotype;
LUAD	cis	rs12612619	0.732	rs11126857	chr2:27297757	G/A	cg00617064	chr2:27272375	NA	0.36	6.85	0.32	2.55e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs12760731	0.720	rs2862379	chr1:178442906	T/A	cg00404053	chr1:178313656	RASAL2	0.65	8.3	0.37	1.43e-15	Obesity-related traits;
LUAD	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg23992470	chr4:843637	GAK	0.71	7.36	0.34	9.62e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg16479474	chr6:28041457	NA	-0.46	-8.15	-0.37	4.23e-15	Depression;
LUAD	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg11859384	chr17:80120422	CCDC57	0.43	7.62	0.35	1.66e-13	Life satisfaction;
LUAD	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03264133	chr6:25882463	NA	-0.57	-9.39	-0.42	3.71e-19	Blood metabolite levels;
LUAD	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-7.66	-0.35	1.28e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs57590327	0.504	rs4856349	chr3:81502928	C/T	cg07356753	chr3:81810745	GBE1	0.48	7.56	0.35	2.45e-13	Extraversion;
LUAD	cis	rs12681287	0.640	rs12549332	chr8:87353392	G/A	cg27223183	chr8:87520930	FAM82B	-0.69	-9.59	-0.42	8.02e-20	Caudate activity during reward;
LUAD	cis	rs9308433	0.529	rs4655244	chr1:214497580	A/G	cg06198575	chr1:214491504	SMYD2	0.46	7.86	0.36	3.21e-14	IgG glycosylation;
LUAD	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg02176678	chr2:219576539	TTLL4	0.62	12.13	0.51	2.94e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs13315871	1.000	rs9824965	chr3:58433505	T/A	cg12435725	chr3:58293450	RPP14	-0.67	-7.44	-0.34	5.6e-13	Cholesterol, total;
LUAD	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	6.99	0.32	1.06e-11	Motion sickness;
LUAD	trans	rs66573146	1.000	rs67405518	chr4:6965930	C/T	cg07817883	chr1:32538562	TMEM39B	1.56	13.45	0.55	1.46e-34	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg17863274	chr19:49399704	TULP2	0.44	6.7	0.31	6.86e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg23649088	chr2:200775458	C2orf69	-0.64	-8.92	-0.4	1.37e-17	Schizophrenia;
LUAD	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg06608945	chr2:219082296	ARPC2	-0.45	-7.41	-0.34	6.77e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg26384229	chr12:38710491	ALG10B	0.42	7.31	0.33	1.35e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg13319975	chr6:146136371	FBXO30	-0.58	-9.73	-0.43	2.44e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6688613	1.000	rs10918606	chr1:166957249	A/G	cg07049167	chr1:166818506	POGK	0.41	6.9	0.32	1.92e-11	Refractive astigmatism;
LUAD	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg14668632	chr7:2872130	GNA12	-0.76	-13.93	-0.56	1.4e-36	Height;
LUAD	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg06697600	chr4:7070879	GRPEL1	0.56	7.91	0.36	2.28e-14	Monocyte percentage of white cells;
LUAD	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg00495681	chr13:53174319	NA	0.49	8.7	0.39	7.38e-17	Lewy body disease;
LUAD	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg23229984	chr5:148520753	ABLIM3	0.48	6.89	0.32	2.06e-11	Breast cancer;
LUAD	cis	rs6545883	0.931	rs778765	chr2:61786385	A/T	cg15711740	chr2:61764176	XPO1	-0.44	-6.94	-0.32	1.44e-11	Tuberculosis;
LUAD	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg26513180	chr16:89883248	FANCA	0.68	6.45	0.3	3.01e-10	Skin colour saturation;
LUAD	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg00383909	chr3:49044727	WDR6	0.73	7.63	0.35	1.61e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg22732515	chr19:44031385	ETHE1	0.59	9.55	0.42	1.06e-19	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.12	0.66	9.48e-55	Prudent dietary pattern;
LUAD	cis	rs12681287	0.752	rs12681438	chr8:87293089	G/A	cg27223183	chr8:87520930	FAM82B	-0.6	-8.22	-0.37	2.45e-15	Caudate activity during reward;
LUAD	cis	rs1816752	0.716	rs9553289	chr13:24974778	T/A	cg02811702	chr13:24901961	NA	-0.37	-6.44	-0.3	3.3e-10	Obesity-related traits;
LUAD	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-9.24	-0.41	1.23e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg17724175	chr1:150552817	MCL1	0.35	7.93	0.36	2.02e-14	Urate levels;
LUAD	trans	rs931812	0.825	rs13271753	chr8:101895491	T/C	cg20993868	chr7:22813445	NA	0.63	12.43	0.52	1.88e-30	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg21385522	chr1:16154831	NA	0.62	9.47	0.42	1.96e-19	Dilated cardiomyopathy;
LUAD	trans	rs7042889	1.000	rs7042889	chr9:131795361	A/C	cg18136963	chr6:139013146	NA	-0.67	-6.54	-0.3	1.76e-10	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;
LUAD	cis	rs669446	0.561	rs1143701	chr1:44084739	C/T	cg12908607	chr1:44402522	ARTN	-0.36	-6.71	-0.31	6.46e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg04800585	chr6:26043546	HIST1H2BB	0.48	8.36	0.38	9.08e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg17264618	chr3:40429014	ENTPD3	0.35	7.41	0.34	6.79e-13	Renal cell carcinoma;
LUAD	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03264133	chr6:25882463	NA	-0.57	-9.39	-0.42	3.71e-19	Blood metabolite levels;
LUAD	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg20673091	chr1:2541236	MMEL1	-0.4	-8.47	-0.38	4.05e-16	Ulcerative colitis;
LUAD	trans	rs4650994	0.525	rs10913567	chr1:178511941	A/C	cg05059571	chr16:84539110	KIAA1609	-0.74	-13.22	-0.54	1.24e-33	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs559928	0.576	rs750832	chr11:64163302	C/T	cg05555928	chr11:63887634	MACROD1	0.47	7.62	0.35	1.74e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUAD	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg00701064	chr4:6280414	WFS1	0.63	13.14	0.54	2.63e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg07570687	chr10:102243282	WNT8B	0.48	7.37	0.34	9.16e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg02569458	chr12:86230093	RASSF9	0.42	7.6	0.35	1.87e-13	Major depressive disorder;
LUAD	cis	rs7659604	0.517	rs6856996	chr4:122671271	C/T	cg06713675	chr4:122721982	EXOSC9	-0.73	-12.99	-0.53	1.06e-32	Type 2 diabetes;
LUAD	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg04036182	chr15:45458818	NA	-0.4	-7.06	-0.32	6.85e-12	Glomerular filtration rate;
LUAD	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg18180107	chr4:99064573	C4orf37	0.42	6.8	0.31	3.49e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10128251	0.962	rs10752281	chr10:5711220	C/T	cg24097872	chr10:5724021	NA	-0.42	-7.71	-0.35	9.38e-14	Childhood ear infection;
LUAD	cis	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg26958806	chr6:27640298	NA	0.65	6.38	0.3	4.73e-10	Depression;
LUAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11905131	chr22:24372483	LOC391322	-0.54	-9.36	-0.41	4.94e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9308433	0.733	rs11120300	chr1:214509499	A/T	cg06198575	chr1:214491504	SMYD2	-0.36	-6.38	-0.3	4.58e-10	IgG glycosylation;
LUAD	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg12140854	chr5:148520817	ABLIM3	-0.67	-10.69	-0.46	9.25e-24	Breast cancer;
LUAD	trans	rs800082	1.000	rs4681378	chr3:144308005	C/T	cg24215973	chr2:240111563	HDAC4	-0.42	-6.6	-0.31	1.23e-10	Smoking behavior;
LUAD	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10802521	chr3:52805072	NEK4	-0.61	-10.99	-0.47	7.01e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg15557168	chr22:42548783	NA	-0.56	-10.82	-0.47	3.08e-24	Schizophrenia;
LUAD	cis	rs612683	0.735	rs3754131	chr1:100931073	A/C	cg06223162	chr1:101003688	GPR88	0.48	9.48	0.42	1.8e-19	Breast cancer;
LUAD	cis	rs1832871	0.672	rs62437159	chr6:158697705	C/T	cg07165851	chr6:158734300	TULP4	0.7	10.9	0.47	1.52e-24	Height;
LUAD	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg11344533	chr11:111475393	SIK2	-0.34	-6.44	-0.3	3.24e-10	Primary sclerosing cholangitis;
LUAD	cis	rs7827545	1.000	rs2119879	chr8:135549042	T/C	cg17885191	chr8:135476712	NA	0.52	8.22	0.37	2.57e-15	Hypertension (SNP x SNP interaction);
LUAD	cis	rs10129255	0.500	rs8006888	chr14:107190456	A/C	cg07958169	chr14:107095056	NA	-0.37	-7.36	-0.34	9.55e-13	Kawasaki disease;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg14264489	chr6:43018788	CUL7	0.43	6.93	0.32	1.6e-11	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg06640241	chr16:89574553	SPG7	0.49	8.09	0.37	6.38e-15	Multiple myeloma (IgH translocation);
LUAD	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg07432352	chr17:45403706	C17orf57	-0.41	-7.99	-0.36	1.26e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs17401966	1.000	rs12407992	chr1:10311983	A/C	cg15208524	chr1:10270712	KIF1B	0.54	8.2	0.37	2.92e-15	Hepatocellular carcinoma;
LUAD	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg07936489	chr17:37558343	FBXL20	-0.46	-7.31	-0.33	1.38e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg18230493	chr5:56204884	C5orf35	-0.87	-13.06	-0.54	5.37e-33	Type 2 diabetes;
LUAD	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg04398451	chr17:18023971	MYO15A	-0.91	-18.46	-0.67	3.06e-56	Total body bone mineral density;
LUAD	cis	rs17433780	0.860	rs10922545	chr1:89492201	C/T	cg09516651	chr1:89888402	LOC400759	0.54	9.63	0.42	5.65e-20	Carotid intima media thickness;
LUAD	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg09658497	chr7:2847517	GNA12	-0.53	-9.61	-0.42	6.73e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs804292	1.000	rs804292	chr8:11643915	C/T	cg26752888	chr8:11627280	NEIL2	-0.47	-6.7	-0.31	6.86e-11	Alcohol dependence;Nicotine use;
LUAD	cis	rs13631	0.728	rs10118245	chr9:139979592	C/T	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.38	6.39	0.3	4.33e-10	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.57	-9.82	-0.43	1.2e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs240110	0.548	rs12190574	chr6:101173842	T/G	cg09795085	chr6:101329169	ASCC3	-0.39	-6.57	-0.3	1.5e-10	Neuroticism;
LUAD	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg00776166	chr8:613548	NA	0.58	6.44	0.3	3.29e-10	IgG glycosylation;
LUAD	cis	rs9308433	0.529	rs55760458	chr1:214491536	G/C	cg06198575	chr1:214491504	SMYD2	0.46	7.79	0.35	5.08e-14	IgG glycosylation;
LUAD	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg01256987	chr12:42539512	GXYLT1	-0.33	-6.43	-0.3	3.45e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg24503407	chr1:205819492	PM20D1	-0.52	-7.82	-0.36	4.33e-14	Menarche (age at onset);
LUAD	cis	rs7809615	0.901	rs6947941	chr7:99156446	G/T	cg03133378	chr7:99195931	NA	-0.58	-6.55	-0.3	1.65e-10	Blood metabolite ratios;
LUAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg18402987	chr7:1209562	NA	0.78	9.6	0.42	7.29e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg09365446	chr1:150670422	GOLPH3L	0.61	10.91	0.47	1.39e-24	Melanoma;
LUAD	cis	rs4900538	0.855	rs1210074	chr14:102889098	G/A	cg18135206	chr14:102964638	TECPR2	-1.01	-20.98	-0.71	1.6e-67	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	trans	rs6561151	0.681	rs17571812	chr13:44472462	G/A	cg17145862	chr1:211918768	LPGAT1	0.54	6.82	0.31	3.11e-11	Crohn's disease;
LUAD	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg12193833	chr17:30244370	NA	-0.58	-7.04	-0.32	7.63e-12	Hip circumference adjusted for BMI;
LUAD	trans	rs4714291	0.862	rs2984445	chr6:40069935	C/T	cg02267698	chr19:7991119	CTXN1	-0.44	-6.9	-0.32	1.93e-11	Strep throat;
LUAD	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg22532475	chr10:104410764	TRIM8	0.43	8.26	0.37	1.83e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg04990556	chr1:26633338	UBXN11	-0.43	-6.91	-0.32	1.77e-11	Obesity-related traits;
LUAD	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08045932	chr20:61659980	NA	0.51	9.67	0.43	4.09e-20	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.41	6.87	0.32	2.35e-11	Total body bone mineral density;
LUAD	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	6.98	0.32	1.12e-11	Menopause (age at onset);
LUAD	cis	rs7216064	1.000	rs62084214	chr17:65843325	C/G	cg08758996	chr17:66097529	LOC651250	0.46	6.98	0.32	1.15e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs7119	0.678	rs12914098	chr15:77823013	C/T	cg27398640	chr15:77910606	LINGO1	-0.35	-6.46	-0.3	2.84e-10	Type 2 diabetes;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg08875094	chr6:100016130	CCNC	0.46	7.17	0.33	3.35e-12	Immune response to smallpox vaccine (IL-6);
LUAD	trans	rs225245	0.817	rs1476553	chr17:33994566	C/T	cg19694781	chr19:47549865	TMEM160	-0.46	-7.53	-0.34	3.03e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg02018176	chr4:1364513	KIAA1530	0.37	7.0	0.32	1e-11	Obesity-related traits;
LUAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg13047869	chr3:10149882	C3orf24	0.67	11.48	0.49	9.3e-27	Alzheimer's disease;
LUAD	cis	rs6665290	0.839	rs6699400	chr1:227190497	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-41.29	-0.9	1.7e-150	Myeloid white cell count;
LUAD	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21582582	chr3:182698605	DCUN1D1	0.6	9.53	0.42	1.25e-19	Resting heart rate;
LUAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.64	-0.42	4.99e-20	Alzheimer's disease;
LUAD	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg04450456	chr4:17643702	FAM184B	-0.38	-7.79	-0.35	5.15e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4790333	0.537	rs898750	chr17:2255193	A/G	cg27406664	chr17:2294951	MNT	0.42	8.3	0.37	1.39e-15	Proinsulin levels;
LUAD	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg10544611	chr16:67998164	SLC12A4	-0.69	-8.05	-0.36	8.2e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg25173405	chr17:45401733	C17orf57	-0.46	-7.62	-0.35	1.72e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg03806693	chr22:41940476	POLR3H	0.53	7.89	0.36	2.54e-14	Vitiligo;
LUAD	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg16647868	chr5:131706066	SLC22A5	0.37	6.36	0.3	5.27e-10	Blood metabolite levels;
LUAD	cis	rs9394438	0.628	rs804843	chr6:37545923	A/G	cg00985040	chr6:37553208	NA	-0.41	-8.78	-0.39	4.16e-17	IgG glycosylation;
LUAD	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.86	0.4	2.24e-17	Parkinson's disease;
LUAD	cis	rs9287719	0.614	rs10929678	chr2:10723095	T/C	cg02196655	chr2:10830764	NOL10	-0.39	-6.79	-0.31	3.85e-11	Prostate cancer;
LUAD	trans	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21582582	chr3:182698605	DCUN1D1	0.48	8.08	0.37	6.92e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg08758996	chr17:66097529	LOC651250	-0.42	-6.97	-0.32	1.23e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24029414	chr10:128075852	ADAM12	0.37	6.46	0.3	2.87e-10	Gut microbiome composition (summer);
LUAD	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg11871910	chr12:69753446	YEATS4	0.47	7.45	0.34	5.26e-13	Response to diuretic therapy;
LUAD	trans	rs12517041	1.000	rs35411935	chr5:23282784	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.47	-0.3	2.73e-10	Calcium levels;
LUAD	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg00933542	chr6:150070202	PCMT1	0.43	9.18	0.41	1.95e-18	Lung cancer;
LUAD	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.98	0.53	1.2e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs28493229	0.708	rs80003555	chr19:41160612	C/G	cg21869046	chr19:41225005	ITPKC	0.52	9.04	0.4	5.57e-18	Kawasaki disease;
LUAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg10729496	chr3:10149963	C3orf24	0.57	9.47	0.42	1.95e-19	Alzheimer's disease;
LUAD	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.87	-0.32	2.31e-11	Crohn's disease;
LUAD	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg17644776	chr2:200775616	C2orf69	0.55	7.29	0.33	1.57e-12	Schizophrenia;
LUAD	cis	rs722864	0.744	rs1809139	chr2:173982876	C/T	cg09210666	chr2:173941575	ZAK	0.54	7.26	0.33	1.84e-12	Lung cancer;
LUAD	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg26587870	chr6:27730563	NA	-0.43	-7.13	-0.33	4.41e-12	Parkinson's disease;
LUAD	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg14784868	chr12:69753453	YEATS4	0.44	7.18	0.33	3.26e-12	Blood protein levels;
LUAD	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg12573674	chr2:1569213	NA	-0.56	-8.43	-0.38	5.31e-16	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.49	-0.38	3.5e-16	Total body bone mineral density;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23168483	chr15:65669821	IGDCC3	-0.37	-6.38	-0.3	4.55e-10	Cancer;
LUAD	cis	rs1953600	0.837	rs2573352	chr10:81939813	T/C	cg00277334	chr10:82204260	NA	0.42	7.09	0.33	5.6e-12	Sarcoidosis;
LUAD	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25427524	chr10:38739819	LOC399744	0.74	13.5	0.55	8.9e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg15997130	chr1:24165203	NA	0.54	9.45	0.42	2.4e-19	Immature fraction of reticulocytes;
LUAD	cis	rs10129255	0.536	rs3944157	chr14:107138303	C/T	cg07958169	chr14:107095056	NA	-0.33	-6.46	-0.3	2.85e-10	Kawasaki disease;
LUAD	cis	rs9287719	0.674	rs6432130	chr2:10821557	T/C	cg01299579	chr2:10830716	NOL10	0.39	6.84	0.32	2.81e-11	Prostate cancer;
LUAD	cis	rs12900413	0.603	rs12906832	chr15:90301314	C/G	cg24249390	chr15:90295951	MESP1	-0.35	-6.97	-0.32	1.23e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg06609049	chr19:2785107	THOP1	1.16	23.36	0.75	4.2e-78	Total cholesterol levels;
LUAD	cis	rs7932354	0.528	rs7479189	chr11:47057009	T/A	cg19486271	chr11:47235900	DDB2	-0.43	-6.83	-0.32	2.99e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg05535760	chr7:792225	HEATR2	0.85	11.34	0.48	3.26e-26	Cerebrospinal P-tau181p levels;
LUAD	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg22482690	chr17:47019901	SNF8	0.44	8.31	0.37	1.32e-15	Type 2 diabetes;
LUAD	cis	rs877282	0.682	rs2265092	chr10:780293	C/T	cg06581033	chr10:766294	NA	0.41	6.42	0.3	3.67e-10	Uric acid levels;
LUAD	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg25237894	chr2:233734115	C2orf82	-0.5	-9.61	-0.42	6.82e-20	Coronary artery disease;
LUAD	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg03806693	chr22:41940476	POLR3H	-0.61	-8.7	-0.39	7.4e-17	Vitiligo;
LUAD	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg07570687	chr10:102243282	WNT8B	0.48	7.37	0.34	9.16e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs7746199	0.736	rs34038546	chr6:27607660	C/A	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.65	-0.46	1.24e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg01299579	chr2:10830716	NOL10	-0.43	-7.67	-0.35	1.17e-13	Prostate cancer;
LUAD	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg06608945	chr2:219082296	ARPC2	0.47	7.8	0.35	4.82e-14	Colorectal cancer;
LUAD	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.39	-7.15	-0.33	3.96e-12	Urate levels in overweight individuals;
LUAD	cis	rs4372836	0.729	rs10198789	chr2:28968811	C/T	cg09522027	chr2:28974177	PPP1CB	-0.69	-12.77	-0.53	8.17e-32	Body mass index;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15609812	chr20:47281632	PREX1	0.41	6.36	0.3	5.09e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg14917512	chr19:3094685	GNA11	0.58	6.91	0.32	1.77e-11	Diabetic kidney disease;
LUAD	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg00129232	chr17:37814104	STARD3	-0.46	-7.29	-0.33	1.54e-12	Asthma;
LUAD	cis	rs2160860	0.965	rs7013824	chr8:39808425	A/G	cg25981315	chr8:39806701	IDO2	0.34	6.38	0.3	4.54e-10	Blood metabolite levels;
LUAD	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg05304507	chr6:116381966	FRK	0.2	6.79	0.31	3.7e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg08999081	chr20:33150536	PIGU	-0.58	-12.69	-0.53	1.73e-31	Glomerular filtration rate (creatinine);
LUAD	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg02931644	chr1:25747376	RHCE	0.42	8.74	0.39	5.63e-17	Erythrocyte sedimentation rate;
LUAD	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg00277334	chr10:82204260	NA	0.46	7.45	0.34	5.46e-13	Post bronchodilator FEV1;
LUAD	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg03563238	chr19:33554763	RHPN2	-0.39	-9.17	-0.41	2.14e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs877282	0.891	rs34652870	chr10:772218	T/C	cg06581033	chr10:766294	NA	-0.55	-7.44	-0.34	5.75e-13	Uric acid levels;
LUAD	cis	rs501916	1.000	rs648627	chr15:48055738	C/T	cg16110827	chr15:48056943	SEMA6D	-0.35	-7.02	-0.32	9.16e-12	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.13	-31.15	-0.83	1.5e-111	Myeloid white cell count;
LUAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00149659	chr3:10157352	C3orf10	0.57	7.3	0.33	1.41e-12	Alzheimer's disease;
LUAD	cis	rs17155006	0.664	rs405869	chr7:107742609	T/C	cg05962710	chr7:107745446	LAMB4	-0.35	-7.3	-0.33	1.42e-12	Pneumococcal bacteremia;
LUAD	cis	rs4604732	0.578	rs79203328	chr1:247626581	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs11690462	0.963	rs7603413	chr2:26561117	C/A	cg13255216	chr2:26625047	C2orf39	0.38	6.49	0.3	2.42e-10	Coronary artery disease;
LUAD	cis	rs698833	0.501	rs12473699	chr2:44507673	G/A	cg04920474	chr2:44395004	PPM1B	0.54	10.45	0.45	6.77e-23	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	trans	rs8023401	0.938	rs8029557	chr15:48732692	A/G	cg01054110	chr12:125002332	NCOR2	-0.43	-6.51	-0.3	2.12e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18876405	chr7:65276391	NA	-0.46	-7.41	-0.34	6.92e-13	Aortic root size;
LUAD	cis	rs7178572	1.000	rs6495240	chr15:77766556	T/C	cg15453836	chr15:77711506	NA	-0.35	-6.41	-0.3	3.78e-10	Type 2 diabetes;
LUAD	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg25767906	chr1:53392781	SCP2	-0.47	-8.81	-0.39	3.37e-17	Monocyte count;
LUAD	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs7809799	0.571	rs11977673	chr7:98893935	C/G	cg12290671	chr7:99195819	NA	0.71	6.7	0.31	6.65e-11	Ulcerative colitis;
LUAD	cis	rs943466	0.955	rs3763253	chr6:33772761	C/T	cg16010596	chr6:33739607	LEMD2	0.36	6.97	0.32	1.2e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg21951975	chr1:209979733	IRF6	-0.53	-7.07	-0.32	6.59e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs4906332	1.000	rs35862113	chr14:103857229	G/T	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.24	-0.33	2.16e-12	Coronary artery disease;
LUAD	cis	rs7000551	0.715	rs7828610	chr8:22307326	C/T	cg12081754	chr8:22256438	SLC39A14	0.5	8.61	0.39	1.5e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.41	-8.44	-0.38	4.94e-16	Height;
LUAD	trans	rs4714291	0.802	rs2983140	chr6:40017224	A/G	cg02267698	chr19:7991119	CTXN1	-0.45	-7.13	-0.33	4.27e-12	Strep throat;
LUAD	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.92	-0.47	1.26e-24	Total body bone mineral density;
LUAD	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg18446336	chr7:2847575	GNA12	-0.38	-7.02	-0.32	8.91e-12	Height;
LUAD	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg00074818	chr8:8560427	CLDN23	0.66	10.24	0.45	3.78e-22	Obesity-related traits;
LUAD	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg17177755	chr1:15930204	NA	0.46	7.41	0.34	6.87e-13	Systolic blood pressure;
LUAD	trans	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.57	-9.19	-0.41	1.84e-18	Mean corpuscular volume;
LUAD	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg03477792	chr4:77819574	ANKRD56	0.48	7.3	0.33	1.45e-12	Emphysema distribution in smoking;
LUAD	cis	rs13040088	0.872	rs13039291	chr20:61572760	C/T	cg23096297	chr20:61557774	DIDO1	0.74	9.83	0.43	1.13e-20	Menopause (age at onset);
LUAD	cis	rs13315871	0.929	rs11130627	chr3:58315749	G/A	cg12435725	chr3:58293450	RPP14	-0.73	-7.69	-0.35	1.08e-13	Cholesterol, total;
LUAD	cis	rs220324	0.688	rs9637294	chr21:43571540	G/A	cg09727148	chr21:43560719	UMODL1	0.56	8.22	0.37	2.53e-15	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs938554	0.876	rs6855911	chr4:9935910	A/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-7.05	-0.32	7.41e-12	Blood metabolite levels;
LUAD	cis	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-7.28	-0.33	1.6e-12	Neuroticism;
LUAD	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22455342	chr2:225449267	CUL3	0.68	10.51	0.46	3.99e-23	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg20701182	chr2:24300061	SF3B14	0.56	6.71	0.31	6.14e-11	Lymphocyte counts;
LUAD	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg04225089	chr17:73874465	TRIM47	-0.38	-6.79	-0.31	3.84e-11	Psoriasis;
LUAD	cis	rs7793919	0.726	rs10232008	chr7:4783206	T/G	cg09789173	chr7:4769017	FOXK1	0.73	14.88	0.59	1.4e-40	Mosquito bite size;
LUAD	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg11645453	chr3:52864694	ITIH4	-0.54	-10.11	-0.44	1.11e-21	Schizophrenia;
LUAD	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg08213375	chr14:104286397	PPP1R13B	0.25	6.38	0.3	4.6e-10	Schizophrenia;
LUAD	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23158103	chr7:148848205	ZNF398	-0.65	-12.24	-0.51	1.05e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg17971929	chr21:40555470	PSMG1	-0.43	-6.98	-0.32	1.17e-11	Cognitive function;
LUAD	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg17105886	chr17:28927953	LRRC37B2	0.79	7.79	0.35	5.16e-14	Body mass index;
LUAD	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg07741184	chr6:167504864	NA	0.4	9.15	0.41	2.42e-18	Crohn's disease;
LUAD	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg03651054	chr13:50194643	NA	0.4	8.08	0.37	7.06e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.74	-14.81	-0.58	2.75e-40	Lung cancer;
LUAD	cis	rs727505	1.000	rs67939974	chr7:124554364	C/T	cg23710748	chr7:124431027	NA	-0.49	-9.82	-0.43	1.24e-20	Lewy body disease;
LUAD	trans	rs11039798	0.920	rs12292685	chr11:48571032	G/T	cg02254774	chr11:50257496	LOC441601	0.52	6.62	0.31	1.08e-10	Axial length;
LUAD	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg02886208	chr11:14281011	SPON1	0.4	8.17	0.37	3.5e-15	Mitochondrial DNA levels;
LUAD	cis	rs73198271	0.515	rs78890841	chr8:8637018	G/A	cg01851573	chr8:8652454	MFHAS1	0.6	8.02	0.36	1.06e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg16989719	chr2:238392110	NA	-0.34	-6.79	-0.31	3.78e-11	Prostate cancer;
LUAD	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg08989290	chr16:615782	NHLRC4	0.31	6.72	0.31	5.75e-11	Height;
LUAD	cis	rs4664304	0.802	rs17830307	chr2:160871799	T/C	cg23995753	chr2:160760732	LY75	-0.43	-7.38	-0.34	8.34e-13	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg15921436	chr17:44337874	NA	0.83	10.66	0.46	1.13e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00475322	chr7:917719	C7orf20	0.59	10.69	0.46	9.01e-24	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg09165964	chr15:75287851	SCAMP5	0.48	7.09	0.33	5.61e-12	Blood trace element (Zn levels);
LUAD	cis	rs7043114	0.525	rs10820964	chr9:95041636	G/A	cg14631576	chr9:95140430	CENPP	-0.42	-8.45	-0.38	4.8e-16	Height;
LUAD	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg17264618	chr3:40429014	ENTPD3	0.43	9.06	0.4	4.91e-18	Renal cell carcinoma;
LUAD	cis	rs8017423	0.647	rs12590712	chr14:90822481	T/C	cg14092571	chr14:90743983	NA	0.39	6.54	0.3	1.81e-10	Mortality in heart failure;
LUAD	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14240646	chr10:27532245	ACBD5	-0.84	-11.78	-0.5	6.85e-28	Breast cancer;
LUAD	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.79	-0.35	5.2e-14	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg24829409	chr8:58192753	C8orf71	-0.53	-6.88	-0.32	2.16e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.47	-0.34	4.58e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg21659725	chr3:3221576	CRBN	-0.6	-9.65	-0.42	4.96e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg24562669	chr7:97807699	LMTK2	0.31	7.44	0.34	5.81e-13	Breast cancer;
LUAD	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg10802521	chr3:52805072	NEK4	-0.46	-6.51	-0.3	2.09e-10	Schizophrenia;
LUAD	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg21984481	chr17:79567631	NPLOC4	-0.57	-11.96	-0.5	1.32e-28	Eye color traits;
LUAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-9.2	-0.41	1.69e-18	Alzheimer's disease;
LUAD	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg19052272	chr2:3704530	ALLC	0.53	8.62	0.39	1.4e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs1018836	0.545	rs7840203	chr8:91701223	A/G	cg16814680	chr8:91681699	NA	-1.02	-22.68	-0.74	4.3e-75	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg10556349	chr10:835070	NA	0.68	8.13	0.37	4.75e-15	Eosinophil percentage of granulocytes;
LUAD	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg19302996	chr17:73780495	UNK	-0.47	-7.89	-0.36	2.58e-14	White matter hyperintensity burden;
LUAD	cis	rs28830936	1.000	rs11070343	chr15:41940146	T/A	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.59	-0.3	1.35e-10	Diastolic blood pressure;
LUAD	cis	rs7665090	1.000	rs5026473	chr4:103554793	A/G	cg07973026	chr4:103553119	MANBA	0.48	8.5	0.38	3.38e-16	Primary biliary cholangitis;
LUAD	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11890956	chr21:40555474	PSMG1	0.79	14.07	0.56	3.89e-37	Cognitive function;
LUAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.56	8.25	0.37	1.96e-15	Alzheimer's disease;
LUAD	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg05872129	chr22:39784769	NA	-0.8	-15.27	-0.6	2.97e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.34	-7.41	-0.34	6.79e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg20283391	chr11:68216788	NA	-0.42	-6.8	-0.31	3.61e-11	Total body bone mineral density;
LUAD	cis	rs6494488	0.500	rs72742934	chr15:64875723	T/C	cg08069370	chr15:64387884	SNX1	-0.75	-6.59	-0.3	1.34e-10	Coronary artery disease;
LUAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg22764044	chr5:178986830	RUFY1	-0.62	-10.65	-0.46	1.32e-23	Lung cancer;
LUAD	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg00255919	chr5:131827918	IRF1	-0.29	-6.61	-0.31	1.14e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs1113500	0.814	rs12039712	chr1:108641199	A/G	cg06207961	chr1:108661230	NA	0.34	6.38	0.3	4.72e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg10645314	chr2:3704589	ALLC	-0.57	-9.12	-0.41	3.12e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07032473	chr8:95274411	GEM	-0.42	-6.47	-0.3	2.69e-10	Height;
LUAD	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg20135002	chr11:47629003	NA	-0.42	-7.32	-0.34	1.22e-12	Subjective well-being;
LUAD	cis	rs427941	0.632	rs201503	chr7:101759595	C/G	cg06246474	chr7:101738831	CUX1	0.36	6.36	0.3	5.13e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg25452165	chr22:42524984	CYP2D6	-0.38	-6.35	-0.3	5.57e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4917300	0.647	rs13272465	chr8:143120934	C/T	cg25363559	chr8:143086065	NA	-0.38	-7.62	-0.35	1.69e-13	Amyotrophic lateral sclerosis;
LUAD	cis	rs752010	0.838	rs11210505	chr1:42104731	G/C	cg06885757	chr1:42089581	HIVEP3	0.39	8.31	0.37	1.36e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg21782813	chr7:2030301	MAD1L1	-0.44	-7.06	-0.32	6.92e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2479724	0.935	rs7753507	chr6:41784094	C/T	cg17623882	chr6:41773611	USP49	0.69	13.02	0.53	7.72e-33	Menarche (age at onset);
LUAD	trans	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg20587970	chr11:113659929	NA	0.88	11.25	0.48	7.45e-26	Hip circumference adjusted for BMI;
LUAD	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.29	6.76	0.31	4.57e-11	Prostate cancer;
LUAD	cis	rs9462027	0.583	rs912716	chr6:34715761	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.88	-0.4	1.86e-17	Systemic lupus erythematosus;
LUAD	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	8.53	0.38	2.57e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg23533926	chr12:111358616	MYL2	-0.43	-7.34	-0.34	1.07e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14240646	chr10:27532245	ACBD5	-0.89	-12.01	-0.5	8.41e-29	Breast cancer;
LUAD	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg18105134	chr13:113819100	PROZ	-0.81	-14.51	-0.58	5.21e-39	Platelet distribution width;
LUAD	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg02269571	chr22:50332266	NA	-0.68	-9.85	-0.43	9.49e-21	Schizophrenia;
LUAD	cis	rs4308124	0.708	rs56693625	chr2:111965155	G/A	cg04571233	chr2:111982156	NA	-0.45	-6.42	-0.3	3.76e-10	Vitiligo;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04971418	chr5:93954596	C5orf36;ANKRD32	-0.54	-6.91	-0.32	1.74e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14537243	chr17:66193605	LOC440461	-0.47	-7.58	-0.35	2.16e-13	Height;
LUAD	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg19761014	chr17:28927070	LRRC37B2	0.93	9.19	0.41	1.82e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2479724	0.870	rs3747753	chr6:41753380	G/T	cg17623882	chr6:41773611	USP49	0.71	13.35	0.54	3.44e-34	Menarche (age at onset);
LUAD	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.46	8.12	0.37	5.16e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg11211951	chr8:145729740	GPT	-0.33	-6.38	-0.3	4.65e-10	Age at first birth;
LUAD	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg05340658	chr4:99064831	C4orf37	0.51	7.2	0.33	2.8e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg01620082	chr3:125678407	NA	-1.0	-10.13	-0.44	1.01e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.65	-9.69	-0.43	3.49e-20	Alzheimer's disease;
LUAD	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg15485101	chr11:133734466	NA	0.36	7.85	0.36	3.52e-14	Childhood ear infection;
LUAD	cis	rs1823874	0.581	rs11855419	chr15:100327480	A/G	cg16400843	chr15:100339927	C15orf51	-0.33	-6.99	-0.32	1.1e-11	IgG glycosylation;
LUAD	cis	rs968567	0.705	rs174575	chr11:61602003	C/G	cg00603274	chr11:61596626	FADS2	-0.46	-8.13	-0.37	4.74e-15	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg02160872	chr5:212506	CCDC127	-0.51	-6.61	-0.31	1.16e-10	Breast cancer;
LUAD	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg05890377	chr2:74357713	NA	0.84	12.12	0.51	3.13e-29	Gestational age at birth (maternal effect);
LUAD	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg14396892	chr9:96623032	NA	-0.45	-8.82	-0.39	3.12e-17	DNA methylation (variation);
LUAD	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg13385794	chr1:248469461	NA	0.26	6.88	0.32	2.12e-11	Common traits (Other);
LUAD	cis	rs68170813	0.559	rs74745121	chr7:106958037	T/C	cg23024343	chr7:107201750	COG5	0.5	7.2	0.33	2.84e-12	Coronary artery disease;
LUAD	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg03929089	chr4:120376271	NA	-0.82	-15.03	-0.59	3.2e-41	Coronary artery disease;
LUAD	cis	rs2485376	1.000	rs772029	chr10:104072327	T/C	cg20641465	chr10:103991465	PITX3	-0.58	-10.64	-0.46	1.43e-23	QT interval;
LUAD	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg20487152	chr13:99095054	FARP1	-0.46	-7.9	-0.36	2.37e-14	Longevity;
LUAD	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11890956	chr21:40555474	PSMG1	-0.59	-9.65	-0.42	4.71e-20	Cognitive function;
LUAD	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg00310523	chr12:86230176	RASSF9	0.4	7.92	0.36	2.08e-14	Major depressive disorder;
LUAD	cis	rs7095607	0.654	rs7081017	chr10:69954451	A/G	cg18986048	chr10:69913749	MYPN	0.41	7.2	0.33	2.82e-12	Lung function (FVC);
LUAD	cis	rs1524976	1.000	rs1554664	chr3:65501649	A/G	cg16238336	chr3:65465873	MAGI1	0.65	7.55	0.34	2.73e-13	PR interval;
LUAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg10729496	chr3:10149963	C3orf24	0.61	10.07	0.44	1.56e-21	Alzheimer's disease;
LUAD	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg20503657	chr10:835505	NA	0.84	12.63	0.52	3.09e-31	Eosinophil percentage of granulocytes;
LUAD	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg11822812	chr5:140052017	DND1	-0.38	-7.07	-0.32	6.63e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs751728	1.000	rs4342423	chr6:33732679	C/T	cg13859433	chr6:33739653	LEMD2	-0.41	-9.56	-0.42	9.64e-20	Crohn's disease;
LUAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg03188948	chr7:1209495	NA	0.81	9.86	0.43	9.06e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2274273	0.805	rs60972460	chr14:55571773	A/T	cg04306507	chr14:55594613	LGALS3	0.39	8.11	0.37	5.46e-15	Protein biomarker;
LUAD	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg04989706	chr14:50066350	PPIL5	-0.51	-7.37	-0.34	9e-13	Carotid intima media thickness;
LUAD	cis	rs250585	0.790	rs181835	chr16:23397113	T/C	cg00143387	chr16:23521605	GGA2	0.52	7.2	0.33	2.81e-12	Egg allergy;
LUAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg10729496	chr3:10149963	C3orf24	0.57	9.51	0.42	1.49e-19	Alzheimer's disease;
LUAD	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.5	-8.31	-0.37	1.28e-15	Tonsillectomy;
LUAD	cis	rs7241530	0.717	rs28445036	chr18:75889191	G/A	cg14642773	chr18:75888474	NA	0.32	6.56	0.3	1.55e-10	Educational attainment (years of education);
LUAD	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21659725	chr3:3221576	CRBN	-0.63	-10.29	-0.45	2.65e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7089973	0.872	rs35628210	chr10:116630031	G/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.66	0.43	4.27e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg27266060	chr8:22091797	NA	0.41	7.63	0.35	1.54e-13	Hypertriglyceridemia;
LUAD	cis	rs7178572	0.568	rs1191196	chr15:77646504	C/T	cg15453836	chr15:77711506	NA	0.38	6.6	0.31	1.22e-10	Type 2 diabetes;
LUAD	cis	rs8112211	0.911	rs2286476	chr19:38850759	G/A	cg14299480	chr19:38876666	GGN	-0.45	-7.92	-0.36	2.05e-14	Blood protein levels;
LUAD	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27297192	chr10:134578999	INPP5A	0.39	6.91	0.32	1.74e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1997103	0.954	rs9649854	chr7:55410213	G/A	cg17469321	chr7:55412551	NA	0.65	11.08	0.47	3.29e-25	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg03233332	chr7:66118400	NA	-0.43	-6.48	-0.3	2.56e-10	Aortic root size;
LUAD	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg26893861	chr17:41843967	DUSP3	0.94	14.52	0.58	5.01e-39	Triglycerides;
LUAD	cis	rs7149337	0.805	rs3007164	chr14:51646935	A/G	cg23942311	chr14:51606299	NA	0.85	20.07	0.7	1.99e-63	Cancer;
LUAD	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg02782426	chr3:40428986	ENTPD3	0.43	9.26	0.41	1.02e-18	Renal cell carcinoma;
LUAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg00106254	chr7:1943704	MAD1L1	-0.54	-7.74	-0.35	7.41e-14	Bipolar disorder and schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25341937	chr6:17706893	NUP153	-0.6	-7.29	-0.33	1.49e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2294693	0.679	rs1534995	chr6:40960731	G/A	cg14769373	chr6:40998127	UNC5CL	-0.52	-7.36	-0.34	9.36e-13	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg19761014	chr17:28927070	LRRC37B2	0.83	8.19	0.37	3.03e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg15993354	chr19:12912590	PRDX2	-0.41	-6.53	-0.3	1.91e-10	Vertical cup-disc ratio;
LUAD	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg05368731	chr17:41323189	NBR1	0.83	16.89	0.63	2.61e-49	Menopause (age at onset);
LUAD	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.95	13.05	0.54	6.31e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg14668632	chr7:2872130	GNA12	-0.72	-13.0	-0.53	9.7e-33	Height;
LUAD	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg12564285	chr5:131593104	PDLIM4	0.37	6.96	0.32	1.33e-11	Acylcarnitine levels;
LUAD	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg20673091	chr1:2541236	MMEL1	-0.4	-8.39	-0.38	7.42e-16	Ulcerative colitis;
LUAD	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg07305463	chr2:136567211	LCT	0.36	6.53	0.3	1.87e-10	Mosquito bite size;
LUAD	cis	rs2859741	1.000	rs2795009	chr1:37509494	C/T	cg09363841	chr1:37513479	NA	-0.32	-7.94	-0.36	1.81e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs78761021	0.755	rs17744048	chr17:9794996	A/G	cg26853458	chr17:9805074	RCVRN	0.38	7.02	0.32	9.07e-12	Type 2 diabetes;
LUAD	cis	rs1983170	0.668	rs17131491	chr1:92017649	A/C	cg02896835	chr1:92012615	NA	0.47	6.71	0.31	6.27e-11	Eosinophil percentage of white cells;
LUAD	cis	rs367615	0.879	rs56689485	chr5:108879828	A/T	cg17395555	chr5:108820864	NA	0.54	8.81	0.39	3.32e-17	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg27144592	chr16:783916	NARFL	0.36	6.45	0.3	3.01e-10	Height;
LUAD	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.09	-0.44	1.33e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3750082	0.692	rs10248993	chr7:32927147	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.47	-6.67	-0.31	8.25e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs2882667	0.627	rs1549203	chr5:138468344	A/G	cg04439458	chr5:138467593	SIL1	0.45	8.78	0.39	4.05e-17	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg05592363	chr5:78908495	PAPD4	0.42	6.72	0.31	5.85e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs76878669	0.561	rs4630308	chr11:66162587	G/A	cg10616300	chr11:66138557	SLC29A2	0.36	7.63	0.35	1.58e-13	Educational attainment (years of education);
LUAD	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.56e-12	Crohn's disease;
LUAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg21782813	chr7:2030301	MAD1L1	0.53	8.99	0.4	8.12e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.67	-10.96	-0.47	9.06e-25	Primary sclerosing cholangitis;
LUAD	trans	rs1997103	1.000	rs6958664	chr7:55404958	T/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.43	7.29	0.33	1.51e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs16866061	1.000	rs72974203	chr2:225408430	G/A	cg12698349	chr2:225449008	CUL3	0.77	13.43	0.55	1.67e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg12432903	chr7:1882776	MAD1L1	-0.44	-7.08	-0.33	5.87e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg07917127	chr4:99064746	C4orf37	-0.44	-7.21	-0.33	2.62e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg02549819	chr16:58548995	SETD6	0.79	6.48	0.3	2.59e-10	Schizophrenia;
LUAD	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg25208724	chr1:156163844	SLC25A44	1.0	16.15	0.62	4.63e-46	Testicular germ cell tumor;
LUAD	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg04511125	chr2:88470314	THNSL2	0.99	11.45	0.49	1.28e-26	Plasma clusterin levels;
LUAD	cis	rs9584850	0.834	rs12463	chr13:99105302	G/A	cg17380943	chr13:99100506	FARP1	-0.35	-6.59	-0.31	1.3e-10	Neuroticism;
LUAD	cis	rs2637266	0.967	rs7477607	chr10:78358768	G/T	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.33e-11	Pulmonary function;
LUAD	cis	rs7633770	0.710	rs4683259	chr3:46698538	A/G	cg11219411	chr3:46661640	NA	-0.46	-9.87	-0.43	8.37e-21	Coronary artery disease;
LUAD	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.72	-0.61	3.37e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg10792982	chr14:105748885	BRF1	0.46	9.93	0.43	4.92e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg10876282	chr6:28092338	ZSCAN16	0.41	6.6	0.31	1.25e-10	Cardiac Troponin-T levels;
LUAD	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	6.82	0.31	3.13e-11	Motion sickness;
LUAD	cis	rs12995491	1.000	rs12995491	chr2:88527414	C/T	cg07952391	chr2:88470173	THNSL2	0.39	6.43	0.3	3.38e-10	Response to metformin (IC50);
LUAD	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.35	-7.58	-0.35	2.21e-13	Hemoglobin concentration;
LUAD	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg15181151	chr6:150070149	PCMT1	0.4	8.3	0.37	1.4e-15	Lung cancer;
LUAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg24846343	chr22:24311635	DDTL	0.74	15.46	0.6	4.78e-43	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg19901468	chr14:105411992	AHNAK2	-0.51	-9.96	-0.44	3.96e-21	Rheumatoid arthritis;
LUAD	cis	rs892961	0.931	rs2411110	chr17:75400143	A/C	cg05865280	chr17:75406074	SEPT9	0.55	12.06	0.51	5.33e-29	Airflow obstruction;
LUAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg27532560	chr4:187881888	NA	-0.36	-6.86	-0.32	2.42e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg16989719	chr2:238392110	NA	-0.39	-8.0	-0.36	1.19e-14	Prostate cancer;
LUAD	cis	rs4072705	0.967	rs4838209	chr9:127528842	C/T	cg01786973	chr9:127249749	NR5A1	0.29	6.37	0.3	4.92e-10	Menarche (age at onset);
LUAD	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg20673091	chr1:2541236	MMEL1	0.44	9.61	0.42	6.53e-20	Ulcerative colitis;
LUAD	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg11859384	chr17:80120422	CCDC57	-0.47	-8.47	-0.38	3.96e-16	Life satisfaction;
LUAD	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg18512352	chr11:47633146	NA	-0.43	-7.5	-0.34	3.83e-13	Subjective well-being;
LUAD	trans	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04565464	chr8:145669602	NFKBIL2	0.42	6.46	0.3	2.88e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg05966235	chr16:28915196	ATP2A1	0.42	6.84	0.32	2.78e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs3760982	0.585	rs11673490	chr19:44298885	C/A	cg11993925	chr19:44307056	LYPD5	0.54	11.3	0.48	4.71e-26	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22590775	chr19:49891494	CCDC155	0.59	8.37	0.38	8.74e-16	Multiple sclerosis;
LUAD	cis	rs2857891	1.000	rs2595501	chr11:6955340	G/A	cg04053776	chr11:6947353	ZNF215	0.48	6.77	0.31	4.3e-11	Response to cytadine analogues (cytosine arabinoside);
LUAD	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg07917127	chr4:99064746	C4orf37	0.44	7.25	0.33	2.06e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12681287	0.547	rs6985066	chr8:87526439	A/C	cg27223183	chr8:87520930	FAM82B	-0.73	-10.4	-0.45	1.03e-22	Caudate activity during reward;
LUAD	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg06671706	chr8:8559999	CLDN23	0.65	11.33	0.48	3.77e-26	Obesity-related traits;
LUAD	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg09263875	chr16:632152	PIGQ	0.81	17.48	0.65	7.12e-52	Height;
LUAD	cis	rs17095355	1.000	rs12246851	chr10:111726340	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.69	-9.35	-0.41	5.32e-19	Biliary atresia;
LUAD	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg22029157	chr1:209979665	IRF6	0.46	8.32	0.38	1.18e-15	Monobrow;
LUAD	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg00631329	chr6:26305371	NA	0.46	7.68	0.35	1.08e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg10729496	chr3:10149963	C3orf24	0.64	9.56	0.42	9.9e-20	Alzheimer's disease;
LUAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg20607798	chr8:58055168	NA	0.67	8.73	0.39	5.82e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg17264618	chr3:40429014	ENTPD3	0.37	8.17	0.37	3.66e-15	Renal cell carcinoma;
LUAD	trans	rs1728785	0.901	rs7194664	chr16:68643313	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.3	0.45	2.48e-22	Ulcerative colitis;
LUAD	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg25985355	chr7:65971099	NA	-0.55	-6.75	-0.31	4.77e-11	Diabetic kidney disease;
LUAD	trans	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg26043149	chr18:55253948	FECH	-0.42	-6.87	-0.32	2.35e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.53	-0.3	1.94e-10	Joint mobility (Beighton score);
LUAD	cis	rs7909074	0.509	rs2183994	chr10:45389940	T/C	cg05187965	chr10:45406764	TMEM72	-0.41	-7.48	-0.34	4.35e-13	Mean corpuscular volume;
LUAD	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg22753661	chr15:79092743	ADAMTS7	0.57	8.59	0.39	1.69e-16	Coronary artery disease or large artery stroke;
LUAD	cis	rs853679	0.546	rs13213986	chr6:28358009	T/A	cg12623302	chr6:28058802	ZSCAN12L1	0.6	6.85	0.32	2.57e-11	Depression;
LUAD	cis	rs9807989	0.839	rs6543123	chr2:102977196	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	6.38	0.3	4.76e-10	Asthma;
LUAD	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	10.52	0.46	3.91e-23	Resting heart rate;
LUAD	cis	rs4930561	0.714	rs11228151	chr11:67949371	C/G	cg04465784	chr11:67976953	SUV420H1	-0.35	-11.0	-0.47	6.2e-25	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs68170813	0.652	rs17403088	chr7:107111373	C/A	cg02696742	chr7:106810147	HBP1	-0.76	-8.99	-0.4	8.04e-18	Coronary artery disease;
LUAD	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.13	0.33	4.46e-12	Menopause (age at onset);
LUAD	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg17063962	chr7:91808500	NA	-0.67	-11.59	-0.49	3.71e-27	Breast cancer;
LUAD	cis	rs7487075	0.619	rs9669404	chr12:46798963	A/G	cg23829395	chr12:46796953	NA	-0.29	-6.75	-0.31	4.76e-11	Itch intensity from mosquito bite;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03555433	chr16:67753508	GFOD2	-0.49	-7.75	-0.35	6.8e-14	Height;
LUAD	cis	rs2230307	0.536	rs580611	chr1:100622925	G/A	cg20868668	chr1:100435035	SLC35A3	-0.51	-7.69	-0.35	1.06e-13	Carotid intima media thickness;
LUAD	cis	rs7000551	0.689	rs7007673	chr8:22316687	G/T	cg12081754	chr8:22256438	SLC39A14	0.45	7.38	0.34	8.21e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg05373962	chr22:49881684	NA	-0.52	-10.9	-0.47	1.57e-24	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2625529	0.824	rs12916951	chr15:72252498	C/T	cg16672083	chr15:72433130	SENP8	-0.71	-11.98	-0.5	1.09e-28	Red blood cell count;
LUAD	cis	rs752010	0.644	rs6700390	chr1:42112554	A/G	cg06885757	chr1:42089581	HIVEP3	0.46	10.2	0.44	5.36e-22	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg02574844	chr11:5959923	NA	-0.38	-6.56	-0.3	1.54e-10	DNA methylation (variation);
LUAD	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg05887092	chr17:76393375	PGS1	0.42	7.42	0.34	6.31e-13	HDL cholesterol levels;
LUAD	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg02527881	chr3:46936655	PTH1R	0.4	7.61	0.35	1.76e-13	Colorectal cancer;
LUAD	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg14552801	chr7:65878734	NA	0.38	6.48	0.3	2.48e-10	Aortic root size;
LUAD	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.75	-0.39	5.27e-17	Breast cancer;
LUAD	cis	rs3784262	0.669	rs17820990	chr15:58349568	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.71	-0.35	9.17e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg02549819	chr16:58548995	SETD6	0.82	6.85	0.32	2.62e-11	Schizophrenia;
LUAD	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg01065977	chr19:18549689	ISYNA1	-0.39	-7.26	-0.33	1.86e-12	Breast cancer;
LUAD	cis	rs6484504	0.600	rs7122895	chr11:31346620	G/C	cg14844989	chr11:31128820	NA	0.45	8.26	0.37	1.86e-15	Red blood cell count;
LUAD	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg16342193	chr10:102329863	NA	-0.38	-6.85	-0.32	2.58e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg08132940	chr7:1081526	C7orf50	-0.77	-10.36	-0.45	1.49e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg23260525	chr10:116636907	FAM160B1	0.46	10.45	0.45	6.78e-23	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4889855	0.530	rs7209279	chr17:78598055	T/A	cg16591659	chr17:78472290	NA	-0.43	-7.48	-0.34	4.38e-13	Fractional excretion of uric acid;
LUAD	trans	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg14343924	chr8:8086146	FLJ10661	-0.4	-6.36	-0.3	5.23e-10	Systolic blood pressure;
LUAD	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg03709012	chr19:19516395	GATAD2A	0.53	7.03	0.32	8.31e-12	Nonalcoholic fatty liver disease;
LUAD	cis	rs36051895	0.659	rs12337134	chr9:5061578	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-7.21	-0.33	2.65e-12	Pediatric autoimmune diseases;
LUAD	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg26597838	chr10:835615	NA	1.3	20.44	0.7	4.34e-65	Eosinophil percentage of granulocytes;
LUAD	cis	rs698833	0.926	rs1067394	chr2:44638123	A/C	cg04920474	chr2:44395004	PPM1B	0.38	6.72	0.31	5.97e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs3820068	0.705	rs4646085	chr1:15825411	A/T	cg24675056	chr1:15929824	NA	0.41	6.37	0.3	4.82e-10	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.36e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7582720	1.000	rs72934751	chr2:203747522	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg13732083	chr21:47605072	C21orf56	0.41	6.79	0.31	3.88e-11	Testicular germ cell tumor;
LUAD	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.74	15.95	0.61	3.47e-45	White blood cell count (basophil);White blood cell count;
LUAD	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg10523679	chr1:76189770	ACADM	0.83	14.73	0.58	6.07e-40	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg24154853	chr7:158122151	PTPRN2	0.58	11.48	0.49	9.87e-27	Calcium levels;
LUAD	cis	rs380904	0.517	rs11775744	chr8:144649192	A/G	cg13399544	chr8:144649678	C8orf73	-0.51	-7.33	-0.34	1.15e-12	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.23	0.45	4.13e-22	Ileal carcinoids;
LUAD	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg05754148	chr16:3507555	NAT15	0.81	8.23	0.37	2.36e-15	Tuberculosis;
LUAD	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg02018176	chr4:1364513	KIAA1530	-0.39	-7.19	-0.33	2.88e-12	Obesity-related traits;
LUAD	cis	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg17551891	chr7:1960795	MAD1L1	-0.42	-7.01	-0.32	9.31e-12	Bipolar disorder;
LUAD	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg24069376	chr3:38537580	EXOG	0.43	10.21	0.44	4.91e-22	Electrocardiographic conduction measures;
LUAD	cis	rs2274273	1.000	rs67805055	chr14:55587552	C/T	cg04306507	chr14:55594613	LGALS3	0.37	7.53	0.34	3.19e-13	Protein biomarker;
LUAD	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg25319279	chr11:5960081	NA	-0.4	-7.59	-0.35	2.08e-13	DNA methylation (variation);
LUAD	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.39	0.45	1.09e-22	Post bronchodilator FEV1;
LUAD	cis	rs11112613	0.713	rs55646142	chr12:105949557	G/A	cg03607813	chr12:105948248	NA	0.81	13.83	0.56	3.89e-36	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg10518543	chr12:38710700	ALG10B	-0.41	-6.67	-0.31	8.14e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.46	6.92	0.32	1.72e-11	Schizophrenia;
LUAD	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg05425664	chr17:57184151	TRIM37	-0.45	-7.99	-0.36	1.33e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg04455712	chr21:45112962	RRP1B	0.44	8.93	0.4	1.36e-17	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg17366294	chr4:99064904	C4orf37	0.63	12.2	0.51	1.59e-29	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg17063962	chr7:91808500	NA	0.69	11.85	0.5	3.46e-28	Breast cancer;
LUAD	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg08632164	chr7:65971372	NA	-0.37	-6.48	-0.3	2.61e-10	Aortic root size;
LUAD	cis	rs68170813	0.652	rs7784906	chr7:107148386	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-8.98	-0.4	8.67e-18	Coronary artery disease;
LUAD	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg10792982	chr14:105748885	BRF1	0.44	9.72	0.43	2.74e-20	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg13870426	chr17:30244630	NA	-0.55	-6.51	-0.3	2.17e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs16958440	0.867	rs75901436	chr18:44689644	C/T	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg27454412	chr7:1067447	C7orf50	-0.45	-7.8	-0.35	4.9e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.87	-0.36	2.99e-14	Diabetic kidney disease;
LUAD	cis	rs72799341	0.706	rs1060506	chr16:31133449	C/T	cg05768032	chr16:30646687	NA	0.4	7.15	0.33	3.74e-12	Diastolic blood pressure;
LUAD	cis	rs76878669	0.561	rs2279861	chr11:66133336	A/G	cg10616300	chr11:66138557	SLC29A2	0.34	7.29	0.33	1.56e-12	Educational attainment (years of education);
LUAD	cis	rs10207060	0.500	rs10181238	chr2:240709496	G/A	cg07506560	chr2:240697449	NA	0.39	6.5	0.3	2.22e-10	Obesity-related traits;
LUAD	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg27494647	chr7:150038898	RARRES2	0.51	8.87	0.4	2.06e-17	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs11178918	0.585	rs7308477	chr12:72145486	G/A	cg10168894	chr12:72148281	RAB21	-0.53	-6.46	-0.3	2.87e-10	Economic and political preferences (time);
LUAD	cis	rs2742234	0.504	rs7093409	chr10:43740067	A/G	cg15436174	chr10:43711423	RASGEF1A	0.5	8.63	0.39	1.3e-16	Hirschsprung disease;
LUAD	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21659725	chr3:3221576	CRBN	-0.5	-8.14	-0.37	4.33e-15	Body mass index;
LUAD	cis	rs6025261	0.761	rs6099359	chr20:55509896	G/T	cg04763273	chr20:55502381	NA	-0.31	-6.36	-0.3	5.17e-10	Verbal memory performance (delayed recall level);
LUAD	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg10169327	chr19:45448959	APOC2	0.37	7.31	0.34	1.31e-12	Blood protein levels;
LUAD	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg05110241	chr16:68378359	PRMT7	-0.87	-9.29	-0.41	7.97e-19	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg04025307	chr7:1156635	C7orf50	0.59	6.72	0.31	5.99e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg00666640	chr1:248458726	OR2T12	0.32	7.65	0.35	1.34e-13	Common traits (Other);
LUAD	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.86	12.37	0.52	3.34e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs853679	0.505	rs35781323	chr6:28144832	T/C	cg01620082	chr3:125678407	NA	-1.1	-10.38	-0.45	1.25e-22	Depression;
LUAD	cis	rs9462027	0.606	rs7756009	chr6:34715395	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.76	-0.39	4.62e-17	Systemic lupus erythematosus;
LUAD	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.68	-8.17	-0.37	3.56e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.52	8.24	0.37	2.21e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg00784671	chr22:46762841	CELSR1	-0.43	-6.69	-0.31	7.18e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg13385794	chr1:248469461	NA	-0.24	-6.58	-0.3	1.42e-10	Common traits (Other);
LUAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-7.24	-0.33	2.07e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg01528321	chr10:82214614	TSPAN14	0.54	8.61	0.39	1.45e-16	Post bronchodilator FEV1;
LUAD	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg01765077	chr12:122356316	WDR66	-0.46	-7.68	-0.35	1.08e-13	Mean corpuscular volume;
LUAD	cis	rs250585	0.920	rs30019	chr16:23408427	C/G	cg00143387	chr16:23521605	GGA2	0.55	6.92	0.32	1.72e-11	Egg allergy;
LUAD	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg18132916	chr6:79620363	NA	-0.45	-7.72	-0.35	8.48e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg13354988	chr2:263656	ACP1;SH3YL1	0.3	6.56	0.3	1.61e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg16405210	chr4:1374714	KIAA1530	-0.51	-8.81	-0.39	3.21e-17	Longevity;
LUAD	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg02450064	chr17:40260053	DHX58	0.45	7.73	0.35	7.99e-14	Fibrinogen levels;
LUAD	cis	rs2840044	1.000	rs225243	chr17:33947212	A/G	cg05299278	chr17:33885742	SLFN14	0.43	8.72	0.39	6.54e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg20469991	chr17:27169893	C17orf63	-0.52	-6.57	-0.3	1.45e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg10518543	chr12:38710700	ALG10B	0.42	6.44	0.3	3.26e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs12681287	0.640	rs7830480	chr8:87403137	T/C	cg27223183	chr8:87520930	FAM82B	0.67	9.53	0.42	1.22e-19	Caudate activity during reward;
LUAD	cis	rs9287719	0.649	rs58633964	chr2:10736382	T/G	cg05042697	chr2:10830656	NOL10	-0.37	-6.35	-0.3	5.41e-10	Prostate cancer;
LUAD	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg16647868	chr5:131706066	SLC22A5	0.39	6.6	0.31	1.23e-10	Acylcarnitine levels;
LUAD	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg07828340	chr4:882639	GAK	1.08	11.65	0.49	2.12e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.24	0.37	2.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg17264618	chr3:40429014	ENTPD3	0.4	8.93	0.4	1.36e-17	Renal cell carcinoma;
LUAD	cis	rs72772090	0.539	rs114006288	chr5:96118004	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-7.18	-0.33	3.2e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.26	-0.45	3.23e-22	Total body bone mineral density;
LUAD	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.4	-6.61	-0.31	1.13e-10	Schizophrenia;
LUAD	cis	rs17767294	0.572	rs11965137	chr6:27624749	G/A	cg08851530	chr6:28072375	NA	0.8	6.39	0.3	4.39e-10	Parkinson's disease;
LUAD	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg16988262	chr1:15930761	NA	0.42	6.95	0.32	1.37e-11	Systolic blood pressure;
LUAD	trans	rs11039798	1.000	rs3902928	chr11:48581458	A/T	cg15704280	chr7:45808275	SEPT13	0.64	7.58	0.35	2.27e-13	Axial length;
LUAD	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg12016809	chr21:47604291	C21orf56	-0.41	-6.97	-0.32	1.26e-11	Testicular germ cell tumor;
LUAD	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg21191810	chr6:118973309	C6orf204	-0.48	-7.67	-0.35	1.23e-13	Diastolic blood pressure;
LUAD	cis	rs78487399	0.808	rs6737882	chr2:43731908	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.45	-0.3	3.02e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg01324343	chr3:183735012	ABCC5	-0.8	-17.59	-0.65	2.35e-52	Anterior chamber depth;
LUAD	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs3806843	0.548	rs246052	chr5:140326413	G/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.41	-0.3	4e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg03714773	chr7:91764589	CYP51A1	0.27	6.53	0.3	1.94e-10	Breast cancer;
LUAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00149659	chr3:10157352	C3orf10	0.6	8.34	0.38	1.05e-15	Alzheimer's disease;
LUAD	trans	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg24644049	chr4:85504048	CDS1	0.9	7.58	0.35	2.22e-13	Skin colour saturation;
LUAD	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg08999081	chr20:33150536	PIGU	0.46	8.97	0.4	9.4e-18	Coronary artery disease;
LUAD	cis	rs9503598	0.636	rs7745968	chr6:3467745	G/T	cg00476032	chr6:3446245	SLC22A23	0.32	6.78	0.31	4.13e-11	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	trans	rs4653425	1.000	rs6694288	chr1:225884588	G/C	cg09308580	chr2:43405947	NA	0.38	6.56	0.3	1.61e-10	Neuroticism;
LUAD	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg06015036	chr11:32914618	QSER1	-0.39	-6.61	-0.31	1.16e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18876405	chr7:65276391	NA	-0.44	-6.95	-0.32	1.35e-11	Aortic root size;
LUAD	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg10053473	chr17:62856997	LRRC37A3	0.73	11.46	0.49	1.19e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	8.94	0.4	1.18e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg14582100	chr15:45693742	SPATA5L1	0.64	12.5	0.52	1e-30	Homoarginine levels;
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg18000306	chr6:288505	NA	0.41	7.62	0.35	1.71e-13	Menopause (age at onset);
LUAD	cis	rs72634258	0.945	rs4908724	chr1:8119251	G/T	cg26816564	chr1:7831052	VAMP3	0.55	7.09	0.33	5.77e-12	Inflammatory bowel disease;
LUAD	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg15704280	chr7:45808275	SEPT13	-0.81	-13.39	-0.55	2.5e-34	Coronary artery disease;
LUAD	cis	rs4917300	0.586	rs1352949	chr8:143096253	G/C	cg25363559	chr8:143086065	NA	-0.47	-9.35	-0.41	4.95e-19	Amyotrophic lateral sclerosis;
LUAD	cis	rs7903847	0.642	rs7092350	chr10:99140218	A/T	cg20016023	chr10:99160130	RRP12	-0.29	-7.14	-0.33	4.02e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg02660097	chr11:68866761	NA	0.5	6.97	0.32	1.22e-11	Blond vs. brown hair color;
LUAD	cis	rs2816062	0.735	rs2816054	chr1:18896431	C/T	cg18795169	chr1:18902165	NA	-0.93	-22.42	-0.74	6.42e-74	Urate levels in lean individuals;
LUAD	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.06	-0.32	6.83e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	trans	rs11039798	1.000	rs7942042	chr11:48520270	A/G	cg15704280	chr7:45808275	SEPT13	0.64	7.39	0.34	7.73e-13	Axial length;
LUAD	cis	rs56283067	0.847	rs10456536	chr6:44692995	G/C	cg20913747	chr6:44695427	NA	-0.44	-7.54	-0.34	2.83e-13	Total body bone mineral density;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg05389560	chr12:21654664	RECQL;GOLT1B	0.39	6.5	0.3	2.3e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg18833306	chr6:118973337	C6orf204	-0.54	-7.7	-0.35	9.53e-14	Diastolic blood pressure;
LUAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg13560548	chr3:10150139	C3orf24	-0.39	-6.44	-0.3	3.29e-10	Alzheimer's disease;
LUAD	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg13385794	chr1:248469461	NA	0.26	7.04	0.32	7.92e-12	Common traits (Other);
LUAD	cis	rs73198271	0.960	rs73198287	chr8:8612786	C/T	cg01851573	chr8:8652454	MFHAS1	0.51	8.07	0.37	7.28e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs8060686	0.668	rs9932414	chr16:68219969	A/G	cg05110241	chr16:68378359	PRMT7	-0.55	-7.14	-0.33	4e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg03037974	chr15:76606532	NA	0.38	8.03	0.36	1.01e-14	Blood metabolite levels;
LUAD	cis	rs10203711	0.966	rs6713626	chr2:239566896	C/T	cg14580085	chr2:239553406	NA	0.41	8.9	0.4	1.64e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18402987	chr7:1209562	NA	0.46	7.82	0.36	4.33e-14	Longevity;Endometriosis;
LUAD	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03934478	chr11:495069	RNH1	0.79	9.93	0.43	5.15e-21	Body mass index;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17059624	chr11:85358760	TMEM126A	-0.43	-6.66	-0.31	8.77e-11	Height;
LUAD	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg07217954	chr7:1067459	C7orf50	0.41	6.38	0.3	4.58e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg08999081	chr20:33150536	PIGU	-0.46	-9.48	-0.42	1.86e-19	Coronary artery disease;
LUAD	cis	rs12545109	0.800	rs2609979	chr8:57390066	G/A	cg21220214	chr8:57350948	NA	-0.63	-9.08	-0.4	4.27e-18	Obesity-related traits;
LUAD	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.02e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg17346650	chr17:80929145	B3GNTL1	-0.4	-7.49	-0.34	3.93e-13	Glycated hemoglobin levels;
LUAD	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	11.3	0.48	4.74e-26	Resting heart rate;
LUAD	cis	rs4285028	0.747	rs4048699	chr3:121404483	A/G	cg11130432	chr3:121712080	ILDR1	0.46	6.55	0.3	1.65e-10	Multiple sclerosis;
LUAD	cis	rs2692947	0.696	rs2969490	chr2:96803904	A/G	cg23100626	chr2:96804247	ASTL	0.35	9.49	0.42	1.77e-19	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.27	0.37	1.73e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs79976124	0.837	rs10498840	chr6:66658513	A/G	cg07460842	chr6:66804631	NA	0.64	10.21	0.44	5.12e-22	Type 2 diabetes;
LUAD	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg20290983	chr6:43655470	MRPS18A	0.96	18.32	0.67	1.35e-55	IgG glycosylation;
LUAD	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg06064525	chr11:970664	AP2A2	-0.54	-11.11	-0.48	2.46e-25	Alzheimer's disease (late onset);
LUAD	trans	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg04565464	chr8:145669602	NFKBIL2	0.43	6.41	0.3	3.97e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg04450456	chr4:17643702	FAM184B	0.39	7.85	0.36	3.54e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7818345	1.000	rs4392916	chr8:19309355	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.33	7.15	0.33	3.93e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs7084921	0.579	rs2862951	chr10:101844948	A/C	cg19754520	chr10:101825118	CPN1	-0.34	-6.93	-0.32	1.6e-11	Bone mineral density;
LUAD	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg02951883	chr7:2050386	MAD1L1	-0.8	-13.42	-0.55	1.84e-34	Bipolar disorder and schizophrenia;
LUAD	cis	rs17253792	0.822	rs79618862	chr14:56093971	C/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg04248312	chr19:17393744	ANKLE1	-1.01	-18.67	-0.67	3.55e-57	Systemic lupus erythematosus;
LUAD	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.61	0.35	1.8e-13	Cannabis dependence symptom count;
LUAD	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg05665937	chr4:1216051	CTBP1	0.41	6.73	0.31	5.7e-11	Obesity-related traits;
LUAD	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg17063962	chr7:91808500	NA	0.6	9.84	0.43	1.08e-20	Breast cancer;
LUAD	trans	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg04775059	chr7:64541387	NA	-0.5	-6.95	-0.32	1.41e-11	Aortic root size;
LUAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg18402987	chr7:1209562	NA	0.78	9.54	0.42	1.19e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg06740227	chr12:86229804	RASSF9	0.48	8.29	0.37	1.49e-15	Major depressive disorder;
LUAD	cis	rs12681288	0.676	rs34435811	chr8:990630	T/A	cg04851639	chr8:1020857	NA	-0.4	-9.38	-0.42	3.92e-19	Schizophrenia;
LUAD	trans	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg18335740	chr13:41363409	SLC25A15	-0.53	-9.55	-0.42	1.06e-19	Lewy body disease;
LUAD	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg11645453	chr3:52864694	ITIH4	0.32	6.73	0.31	5.67e-11	Bipolar disorder;
LUAD	cis	rs7107174	1.000	rs2256464	chr11:77917305	C/A	cg19901956	chr11:77921274	USP35	-0.48	-6.37	-0.3	4.99e-10	Testicular germ cell tumor;
LUAD	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg18944383	chr4:111397179	ENPEP	0.37	7.43	0.34	6.25e-13	Height;
LUAD	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg12310025	chr6:25882481	NA	-0.58	-8.29	-0.37	1.52e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg05805236	chr11:65401703	PCNXL3	0.41	6.96	0.32	1.34e-11	Acne (severe);
LUAD	cis	rs1965732	0.588	rs11682334	chr2:3716780	G/T	cg19052272	chr2:3704530	ALLC	-0.37	-7.04	-0.32	7.69e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg02527881	chr3:46936655	PTH1R	-0.45	-8.85	-0.4	2.38e-17	Colorectal cancer;
LUAD	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg00933542	chr6:150070202	PCMT1	0.37	7.75	0.35	6.92e-14	Lung cancer;
LUAD	cis	rs7107174	0.901	rs11237459	chr11:78056273	A/C	cg19901956	chr11:77921274	USP35	-0.49	-7.1	-0.33	5.14e-12	Testicular germ cell tumor;
LUAD	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg15790184	chr11:494944	RNH1	0.55	6.83	0.32	2.96e-11	Body mass index;
LUAD	trans	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg22153745	chr1:153894579	GATAD2B	-0.55	-8.08	-0.37	6.8e-15	Total cholesterol levels;
LUAD	cis	rs9512730	0.553	rs6491213	chr13:28049822	T/C	cg04070771	chr13:27998621	GTF3A	0.51	7.43	0.34	6.25e-13	Schizophrenia;
LUAD	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg15557168	chr22:42548783	NA	-0.55	-10.85	-0.47	2.4e-24	Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg25810927	chr2:84686638	SUCLG1	-0.44	-7.34	-0.34	1.13e-12	Cancer;
LUAD	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	7.88	0.36	2.75e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg09323728	chr8:95962352	TP53INP1	-0.34	-8.14	-0.37	4.6e-15	Type 2 diabetes;
LUAD	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg14784868	chr12:69753453	YEATS4	0.42	6.63	0.31	1.03e-10	Blood protein levels;
LUAD	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg18854424	chr1:2615690	NA	0.41	9.09	0.4	3.77e-18	Ulcerative colitis;
LUAD	cis	rs7614311	0.681	rs3774708	chr3:63881549	A/C	cg22134162	chr3:63841271	THOC7	-0.46	-8.05	-0.36	8.69e-15	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg09796270	chr17:17721594	SREBF1	-0.38	-7.58	-0.35	2.19e-13	Total body bone mineral density;
LUAD	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.33	0.34	1.21e-12	Tonsillectomy;
LUAD	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg10556349	chr10:835070	NA	0.52	6.79	0.31	3.81e-11	Eosinophil percentage of granulocytes;
LUAD	cis	rs9902453	0.933	rs7225462	chr17:28321226	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	10.17	0.44	7.12e-22	Coffee consumption (cups per day);
LUAD	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.88	-0.36	2.86e-14	Monocyte percentage of white cells;
LUAD	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg07741184	chr6:167504864	NA	0.36	8.11	0.37	5.42e-15	Primary biliary cholangitis;
LUAD	cis	rs10489202	0.683	rs202260	chr1:167956167	G/T	cg25738037	chr1:168025549	DCAF6	-0.49	-7.32	-0.34	1.27e-12	Schizophrenia;
LUAD	cis	rs6594713	0.679	rs71577448	chr5:112768874	C/T	cg12552261	chr5:112820674	MCC	0.53	7.35	0.34	1.01e-12	Brain cytoarchitecture;
LUAD	cis	rs6761276	0.780	rs12477867	chr2:113835919	C/A	cg02343335	chr2:113785852	IL1F8	-0.35	-7.01	-0.32	9.26e-12	Protein quantitative trait loci;
LUAD	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg04944784	chr2:26401820	FAM59B	-0.69	-9.74	-0.43	2.36e-20	Gut microbiome composition (summer);
LUAD	cis	rs2806561	0.929	rs641452	chr1:23538386	A/G	cg12483005	chr1:23474871	LUZP1	0.39	6.48	0.3	2.51e-10	Height;
LUAD	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg08085267	chr17:45401833	C17orf57	-0.61	-10.76	-0.46	4.86e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3849570	0.961	rs10154945	chr3:81833766	A/C	cg07356753	chr3:81810745	GBE1	-0.71	-12.52	-0.52	8.53e-31	Waist circumference;Body mass index;
LUAD	cis	rs1113500	0.565	rs1777455	chr1:108590288	C/A	cg06207961	chr1:108661230	NA	-0.4	-6.5	-0.3	2.22e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs240764	0.621	rs11752659	chr6:101212241	A/G	cg09795085	chr6:101329169	ASCC3	-0.48	-8.35	-0.38	1.01e-15	Neuroticism;
LUAD	trans	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.95	0.47	9.41e-25	Mean corpuscular volume;
LUAD	cis	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg21775007	chr8:11205619	TDH	0.57	10.4	0.45	1.02e-22	Retinal vascular caliber;
LUAD	cis	rs999737	0.922	rs2158357	chr14:69029203	C/T	cg04147497	chr14:69052728	RAD51L1	-0.45	-6.99	-0.32	1.04e-11	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg17443473	chr1:3703550	LRRC47	0.4	7.06	0.32	6.69e-12	Red cell distribution width;
LUAD	cis	rs9906944	0.641	rs11655587	chr17:47140794	C/T	cg14634687	chr17:47094252	IGF2BP1	0.26	6.62	0.31	1.09e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs735539	1.000	rs6490604	chr13:21284828	A/G	cg04906043	chr13:21280425	IL17D	-0.38	-6.59	-0.31	1.33e-10	Dental caries;
LUAD	cis	rs11229555	0.645	rs12269928	chr11:58184358	T/C	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.4e-15	Prostate cancer;
LUAD	cis	rs62238980	0.614	rs117338064	chr22:32447147	A/C	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.66	12.15	0.51	2.32e-29	Lymphocyte counts;
LUAD	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg01028140	chr2:1542097	TPO	-0.57	-7.52	-0.34	3.41e-13	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs738322	0.511	rs5756947	chr22:38573230	G/A	cg25457927	chr22:38595422	NA	-0.49	-10.77	-0.46	4.58e-24	Cutaneous nevi;
LUAD	cis	rs9653442	0.648	rs11123805	chr2:100643464	A/G	cg22139774	chr2:100720529	AFF3	-0.35	-6.85	-0.32	2.56e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg18621852	chr3:10150065	C3orf24	-0.49	-8.52	-0.38	2.85e-16	Alzheimer's disease;
LUAD	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg24634471	chr8:143751801	JRK	0.48	7.6	0.35	1.86e-13	Schizophrenia;
LUAD	cis	rs4730250	0.707	rs257386	chr7:106807783	C/G	cg02696742	chr7:106810147	HBP1	-0.88	-11.56	-0.49	4.81e-27	Osteoarthritis;
LUAD	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg13770153	chr20:60521292	NA	-0.57	-9.59	-0.42	7.53e-20	Body mass index;
LUAD	cis	rs7027203	1.000	rs7864114	chr9:96551954	A/G	cg14396892	chr9:96623032	NA	0.4	7.22	0.33	2.41e-12	DNA methylation (variation);
LUAD	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg09117114	chr16:67998030	SLC12A4	-0.53	-7.0	-0.32	1.01e-11	Schizophrenia;
LUAD	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg19436804	chr8:8560866	CLDN23	0.42	6.4	0.3	4.01e-10	Obesity-related traits;
LUAD	cis	rs2857891	1.000	rs2638090	chr11:6955142	A/G	cg04053776	chr11:6947353	ZNF215	0.49	6.89	0.32	2.08e-11	Response to cytadine analogues (cytosine arabinoside);
LUAD	cis	rs9811920	0.641	rs58704213	chr3:99690331	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	7.16	0.33	3.62e-12	Axial length;
LUAD	cis	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.87	-0.36	3e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg12863693	chr15:85201151	NMB	0.37	6.35	0.3	5.41e-10	Schizophrenia;
LUAD	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.44	-0.3	3.21e-10	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.83	-11.18	-0.48	1.33e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7809950	0.655	rs4730220	chr7:106809056	A/G	cg23024343	chr7:107201750	COG5	-0.59	-10.1	-0.44	1.24e-21	Coronary artery disease;
LUAD	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg18016565	chr1:150552671	MCL1	0.41	7.55	0.34	2.78e-13	Tonsillectomy;
LUAD	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11890956	chr21:40555474	PSMG1	0.8	13.53	0.55	6.63e-35	Cognitive function;
LUAD	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.16e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg12011299	chr4:100065546	ADH4	0.66	12.17	0.51	2.06e-29	Alcohol dependence;
LUAD	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg25036284	chr2:26402008	FAM59B	-0.67	-9.17	-0.41	2.13e-18	Gut microbiome composition (summer);
LUAD	cis	rs2839627	0.561	rs6586250	chr21:44270229	C/T	cg03543861	chr21:44258195	NA	0.65	9.44	0.42	2.59e-19	Information processing speed;
LUAD	cis	rs3125734	0.660	rs4979780	chr10:63992740	A/C	cg19640130	chr10:64028056	RTKN2	-0.34	-7.21	-0.33	2.66e-12	Rheumatoid arthritis;
LUAD	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg22920501	chr2:26401640	FAM59B	-0.96	-14.21	-0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg22823121	chr1:150693482	HORMAD1	0.44	8.91	0.4	1.55e-17	Tonsillectomy;
LUAD	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg12863693	chr15:85201151	NMB	0.38	6.63	0.31	1.04e-10	Schizophrenia;
LUAD	cis	rs10465746	0.935	rs12133778	chr1:84367626	A/G	cg10977910	chr1:84465055	TTLL7	0.49	7.86	0.36	3.22e-14	Obesity-related traits;
LUAD	cis	rs1595825	0.891	rs74265511	chr2:198494782	C/T	cg10547527	chr2:198650123	BOLL	-0.54	-7.55	-0.34	2.64e-13	Ulcerative colitis;
LUAD	cis	rs1395	0.778	rs6709602	chr2:27405497	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.5	8.85	0.4	2.49e-17	Blood metabolite levels;
LUAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg03188948	chr7:1209495	NA	0.48	7.69	0.35	1.05e-13	Longevity;Endometriosis;
LUAD	cis	rs10992471	0.603	rs2094281	chr9:95290654	C/G	cg14631576	chr9:95140430	CENPP	0.47	9.54	0.42	1.19e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg22920501	chr2:26401640	FAM59B	0.96	14.01	0.56	6.6e-37	Gut microbiome composition (summer);
LUAD	trans	rs62458065	0.513	rs10245103	chr7:32534829	T/G	cg00845942	chr12:64062724	DPY19L2	-0.52	-7.73	-0.35	7.99e-14	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg21856205	chr7:94953877	PON1	0.51	7.0	0.32	1.02e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23583168	chr7:148888333	NA	-0.91	-18.89	-0.68	3.84e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs10812641	0.875	rs7032942	chr9:2792552	A/C	cg21442773	chr1:236029828	LYST	-0.35	-6.42	-0.3	3.63e-10	Blood trace element (Se levels);
LUAD	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg17330251	chr7:94953956	PON1	-0.53	-7.17	-0.33	3.36e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg03161606	chr19:29218774	NA	0.54	8.08	0.37	7.03e-15	Methadone dose in opioid dependence;
LUAD	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg19748678	chr4:122722346	EXOSC9	0.45	7.03	0.32	8.19e-12	Type 2 diabetes;
LUAD	cis	rs2235649	0.592	rs8051883	chr16:1958978	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.46	-7.14	-0.33	4.17e-12	Blood metabolite levels;
LUAD	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg27426351	chr10:43362370	NA	0.52	8.47	0.38	3.99e-16	Blood protein levels;
LUAD	cis	rs6060717	0.536	rs2425104	chr20:34312346	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.43	-0.34	6.01e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs9322817	0.691	rs9391241	chr6:105223663	T/C	cg02098413	chr6:105308735	HACE1	-0.43	-9.22	-0.41	1.45e-18	Thyroid stimulating hormone;
LUAD	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25427524	chr10:38739819	LOC399744	-0.8	-14.35	-0.57	2.58e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2742417	0.603	rs1019129	chr3:45780780	T/C	cg10512202	chr3:45649293	LIMD1	0.48	8.95	0.4	1.16e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs13257813	0.727	rs691605	chr8:19028649	A/G	cg15587955	chr8:19026658	NA	0.39	6.63	0.31	1.01e-10	Mean platelet volume;
LUAD	cis	rs9473147	0.602	rs9296567	chr6:47553402	G/A	cg20196966	chr6:47445060	CD2AP	0.43	6.64	0.31	9.38e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg07685180	chr8:600429	NA	0.88	8.7	0.39	7.28e-17	IgG glycosylation;
LUAD	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg10426581	chr7:100472382	SRRT	0.73	9.47	0.42	2.05e-19	Resting heart rate;
LUAD	cis	rs2066819	1.000	rs79101914	chr12:56729739	A/G	cg26714650	chr12:56694279	CS	-0.86	-7.09	-0.33	5.59e-12	Psoriasis vulgaris;
LUAD	cis	rs1950626	0.623	rs34448411	chr14:101429287	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.37	7.41	0.34	7.14e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg05340658	chr4:99064831	C4orf37	0.54	9.15	0.41	2.47e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg23000734	chr10:126850823	CTBP2	0.55	11.0	0.47	6.51e-25	Menarche (age at onset);
LUAD	trans	rs11088226	0.681	rs1015048	chr21:33949306	T/C	cg09050820	chr6:167586206	TCP10L2	0.93	14.01	0.56	6.34e-37	Gastritis;
LUAD	cis	rs738322	0.901	rs132941	chr22:38545942	T/C	cg17652424	chr22:38574118	PLA2G6	-0.29	-8.39	-0.38	7.57e-16	Cutaneous nevi;
LUAD	cis	rs10992471	0.603	rs10116813	chr9:95090360	C/T	cg14631576	chr9:95140430	CENPP	-0.57	-11.64	-0.49	2.4e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs12711979	0.509	rs10191674	chr2:3827891	C/T	cg17052675	chr2:3827356	NA	-0.84	-20.1	-0.7	1.42e-63	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.8	0.35	4.88e-14	Bladder cancer;
LUAD	trans	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg25894440	chr7:65020034	NA	-0.64	-6.83	-0.32	2.97e-11	Gout;
LUAD	trans	rs9503551	0.642	rs56786893	chr6:3333876	A/G	cg13915676	chr9:139305538	SDCCAG3;PMPCA	0.49	6.48	0.3	2.52e-10	Nicotine dependence;
LUAD	cis	rs2651899	0.902	rs1798246	chr1:3080855	A/C	cg22396632	chr1:3079212	PRDM16	-0.35	-7.91	-0.36	2.29e-14	Migraine;
LUAD	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg07636037	chr3:49044803	WDR6	0.48	8.05	0.36	8.37e-15	Menarche (age at onset);
LUAD	trans	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg13565492	chr6:43139072	SRF	-0.67	-9.26	-0.41	1.03e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg02931644	chr1:25747376	RHCE	0.52	11.38	0.48	2.37e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg00255919	chr5:131827918	IRF1	-0.29	-6.51	-0.3	2.15e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs7119	0.604	rs2667783	chr15:77862529	G/A	cg27398640	chr15:77910606	LINGO1	0.36	6.75	0.31	4.76e-11	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.84e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg08470875	chr2:26401718	FAM59B	0.77	9.28	0.41	8.64e-19	Gut microbiome composition (summer);
LUAD	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.59	11.4	0.48	1.88e-26	Hemoglobin concentration;
LUAD	cis	rs752010	1.000	rs4999015	chr1:42093547	G/A	cg06885757	chr1:42089581	HIVEP3	0.44	9.51	0.42	1.5e-19	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs4713675	0.565	rs3818530	chr6:33661222	C/G	cg14003231	chr6:33640908	ITPR3	0.49	9.36	0.41	4.63e-19	Plateletcrit;
LUAD	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg15105011	chr4:940614	TMEM175	0.52	8.15	0.37	4.28e-15	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs939658	0.805	rs34478496	chr15:79440997	C/A	cg17916960	chr15:79447300	NA	-0.53	-11.26	-0.48	6.91e-26	Refractive error;
LUAD	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7166081	0.738	rs2286664	chr15:67701495	A/G	cg27219399	chr15:67835830	MAP2K5	0.4	7.37	0.34	9.21e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08280861	chr8:58055591	NA	0.67	8.72	0.39	6.27e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1451375	0.550	rs10239830	chr7:50603829	A/G	cg18232548	chr7:50535776	DDC	0.63	8.55	0.38	2.25e-16	Malaria;
LUAD	trans	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg27411982	chr8:10470053	RP1L1	0.39	7.08	0.33	6.11e-12	Systolic blood pressure;
LUAD	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg04398451	chr17:18023971	MYO15A	-0.65	-11.71	-0.49	1.3e-27	Total body bone mineral density;
LUAD	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg18129178	chr5:148520854	ABLIM3	-0.65	-9.88	-0.43	7.61e-21	Breast cancer;
LUAD	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg07341007	chr3:195489909	MUC4	-0.58	-6.85	-0.32	2.68e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg12483005	chr1:23474871	LUZP1	0.4	6.71	0.31	6.45e-11	Height;
LUAD	cis	rs2742417	1.000	rs2673035	chr3:45753665	C/G	cg10512202	chr3:45649293	LIMD1	0.37	6.54	0.3	1.78e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg01475377	chr6:109611718	NA	-0.52	-9.93	-0.43	5.01e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs1232027	0.656	rs844369	chr5:79993502	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.41	-6.47	-0.3	2.79e-10	Huntington's disease progression;
LUAD	cis	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg08071915	chr8:12219732	FAM66A	-0.42	-7.21	-0.33	2.59e-12	Neuroticism;
LUAD	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg07917127	chr4:99064746	C4orf37	0.41	6.72	0.31	5.72e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10465746	0.780	rs2389649	chr1:84379449	C/T	cg10977910	chr1:84465055	TTLL7	0.6	9.77	0.43	1.79e-20	Obesity-related traits;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg14526892	chr3:33839911	PDCD6IP	0.38	6.39	0.3	4.4e-10	Optic cup area;
LUAD	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.42e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg09085632	chr11:111637200	PPP2R1B	0.61	9.65	0.42	4.8e-20	Primary sclerosing cholangitis;
LUAD	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg16447950	chr5:562315	NA	-0.38	-7.24	-0.33	2.1e-12	Obesity-related traits;
LUAD	cis	rs1113500	0.933	rs10785833	chr1:108639082	A/G	cg06207961	chr1:108661230	NA	0.45	8.45	0.38	4.75e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg11189052	chr15:85197271	WDR73	0.68	9.24	0.41	1.17e-18	Schizophrenia;
LUAD	cis	rs7017914	0.967	rs59992214	chr8:71599545	C/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.61	-0.31	1.13e-10	Bone mineral density;
LUAD	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.38	-7.36	-0.34	9.61e-13	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs7236492	0.688	rs9709477	chr18:77202786	C/A	cg15644404	chr18:77186268	NFATC1	-0.61	-6.9	-0.32	1.9e-11	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg02753203	chr1:228287806	NA	0.77	14.07	0.56	3.73e-37	Diastolic blood pressure;
LUAD	cis	rs11948739	0.610	rs2419754	chr5:130252688	T/C	cg08523029	chr5:130500466	HINT1	0.58	7.52	0.34	3.34e-13	Pediatric bone mineral content (hip);
LUAD	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg12062639	chr20:23401060	NAPB	1.08	11.35	0.48	2.96e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg12940439	chr1:67600707	NA	0.45	8.37	0.38	8.35e-16	Psoriasis;
LUAD	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg09650180	chr20:62225654	GMEB2	-0.48	-6.9	-0.32	1.85e-11	Glioblastoma;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg05881034	chr3:42623675	SEC22C	-0.53	-6.87	-0.32	2.23e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.64	-0.31	9.84e-11	Coronary artery disease;
LUAD	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.49	7.72	0.35	8.42e-14	Alzheimer's disease (late onset);
LUAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11905131	chr22:24372483	LOC391322	-0.53	-8.99	-0.4	8.02e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4604732	0.631	rs56704806	chr1:247626148	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg01579765	chr21:45077557	HSF2BP	-0.58	-13.43	-0.55	1.71e-34	Mean corpuscular volume;
LUAD	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg26647111	chr11:31128758	NA	-0.45	-7.9	-0.36	2.39e-14	Red blood cell count;
LUAD	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg17845761	chr1:175162550	KIAA0040	-0.34	-8.98	-0.4	8.89e-18	Alcohol dependence;
LUAD	cis	rs597583	0.575	rs35200015	chr11:117383215	G/A	cg27161313	chr11:117392002	DSCAML1	-0.52	-7.89	-0.36	2.67e-14	Putamen volume;
LUAD	cis	rs6669119	0.668	rs79187116	chr1:19091297	G/A	cg26220594	chr1:19110978	NA	0.57	7.24	0.33	2.16e-12	Percentage gas trapping;
LUAD	trans	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.74	11.15	0.48	1.79e-25	Ulcerative colitis;
LUAD	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11890956	chr21:40555474	PSMG1	0.67	11.59	0.49	3.76e-27	Cognitive function;
LUAD	trans	rs2544390	1.000	rs2673172	chr2:170204800	A/C	cg05569124	chr11:125495582	CHEK1	-0.36	-6.59	-0.31	1.3100000000000001e-10	Urate levels;
LUAD	cis	rs939658	0.776	rs4778925	chr15:79443791	C/T	cg17916960	chr15:79447300	NA	-0.51	-10.6	-0.46	2e-23	Refractive error;
LUAD	trans	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg01620082	chr3:125678407	NA	-1.09	-10.7	-0.46	8.55e-24	Depression;
LUAD	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg11663144	chr21:46675770	NA	-0.6	-11.72	-0.5	1.12e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg00852783	chr1:26633632	UBXN11	0.43	6.7	0.31	6.83e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg08999081	chr20:33150536	PIGU	-0.37	-7.27	-0.33	1.78e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg15133208	chr4:90757351	SNCA	-0.48	-7.07	-0.33	6.36e-12	Neuroticism;
LUAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7762018	0.556	rs80250989	chr6:170105553	T/C	cg24289452	chr6:170231220	NA	-0.59	-6.59	-0.31	1.29e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs12579753	0.871	rs10862363	chr12:82201254	T/A	cg07988820	chr12:82153109	PPFIA2	-0.45	-7.06	-0.32	6.8e-12	Resting heart rate;
LUAD	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg24069376	chr3:38537580	EXOG	0.45	10.95	0.47	9.48e-25	Electrocardiographic conduction measures;
LUAD	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg03037974	chr15:76606532	NA	0.37	7.7	0.35	9.89e-14	Blood metabolite levels;
LUAD	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg01868782	chr6:126071099	HEY2	0.32	6.88	0.32	2.11e-11	Brugada syndrome;
LUAD	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg14671364	chr1:107599128	PRMT6	0.56	9.35	0.41	5.26e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25427524	chr10:38739819	LOC399744	-0.79	-14.22	-0.57	8.83e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2131877	0.956	rs2279634	chr3:194868944	G/T	cg19760965	chr3:194868843	C3orf21	0.43	7.12	0.33	4.68e-12	Non-small cell lung cancer;
LUAD	cis	rs10489202	0.608	rs4657733	chr1:168086434	G/A	cg24449463	chr1:168025552	DCAF6	-0.64	-10.01	-0.44	2.56e-21	Schizophrenia;
LUAD	cis	rs11771526	0.901	rs10282699	chr7:32297967	C/T	cg13207630	chr7:32358064	NA	0.57	7.18	0.33	3.14e-12	Body mass index;
LUAD	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg16950941	chr11:66035639	RAB1B	0.43	7.25	0.33	2e-12	Gout;
LUAD	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg04414720	chr1:150670196	GOLPH3L	0.6	10.27	0.45	2.97e-22	Tonsillectomy;
LUAD	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	6.43	0.3	3.37e-10	Personality dimensions;
LUAD	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg11859384	chr17:80120422	CCDC57	0.49	8.88	0.4	1.9e-17	Life satisfaction;
LUAD	cis	rs7216064	1.000	rs2365764	chr17:65857714	G/A	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg26384229	chr12:38710491	ALG10B	-0.4	-6.67	-0.31	8.05e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	14.0	0.56	7.42e-37	Prudent dietary pattern;
LUAD	trans	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.4	-0.38	7.05e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs250677	0.522	rs10042466	chr5:148393634	T/C	cg12140854	chr5:148520817	ABLIM3	-0.56	-8.66	-0.39	1.02e-16	Breast cancer;
LUAD	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg06713675	chr4:122721982	EXOSC9	-0.83	-17.82	-0.65	2.07e-53	Type 2 diabetes;
LUAD	trans	rs78049276	0.512	rs7659823	chr4:148398877	C/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.65	-9.36	-0.41	4.82e-19	Pulse pressure;
LUAD	cis	rs4713118	0.619	rs200486	chr6:27779506	C/T	cg19041857	chr6:27730383	NA	-0.43	-6.86	-0.32	2.44e-11	Parkinson's disease;
LUAD	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg21153622	chr11:89784906	NA	-0.33	-6.52	-0.3	1.99e-10	HDL cholesterol;
LUAD	cis	rs2742234	0.910	rs2505513	chr10:43633537	C/G	cg02780029	chr10:43622663	RET	-0.42	-6.95	-0.32	1.36e-11	Hirschsprung disease;
LUAD	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg16797656	chr11:68205561	LRP5	0.45	8.48	0.38	3.83e-16	Total body bone mineral density;
LUAD	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg00204512	chr16:28754710	NA	0.34	7.28	0.33	1.66e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21582582	chr3:182698605	DCUN1D1	0.43	7.11	0.33	4.85e-12	Body mass index;
LUAD	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg23978390	chr7:1156363	C7orf50	0.57	7.98	0.36	1.38e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg18404041	chr3:52824283	ITIH1	-0.36	-6.79	-0.31	3.77e-11	Electroencephalogram traits;
LUAD	cis	rs778371	0.723	rs6710294	chr2:233579634	T/C	cg08000102	chr2:233561755	GIGYF2	0.4	6.53	0.3	1.9e-10	Schizophrenia;
LUAD	cis	rs9322817	0.593	rs9404579	chr6:105229807	T/C	cg02098413	chr6:105308735	HACE1	-0.44	-9.25	-0.41	1.17e-18	Thyroid stimulating hormone;
LUAD	cis	rs3784262	0.669	rs4646559	chr15:58354258	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.69	-0.35	1.07e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.85	-16.24	-0.62	1.98e-46	Lymphocyte counts;
LUAD	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.31e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg25251562	chr2:3704773	ALLC	-0.5	-8.3	-0.37	1.46e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs12365397	0.552	rs7122200	chr11:43163328	C/G	cg03447554	chr11:43094025	NA	0.43	7.63	0.35	1.53e-13	Migraine;
LUAD	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg24675056	chr1:15929824	NA	0.48	8.0	0.36	1.18e-14	Systolic blood pressure;
LUAD	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg22681709	chr2:178499509	PDE11A	-0.44	-7.51	-0.34	3.53e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg13334819	chr7:99746414	C7orf59	0.66	10.57	0.46	2.57e-23	Coronary artery disease;
LUAD	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg06671706	chr8:8559999	CLDN23	0.67	11.8	0.5	5.68e-28	Obesity-related traits;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05605996	chr19:3185677	NCLN	-0.42	-7.09	-0.33	5.79e-12	Cancer;
LUAD	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg21214613	chr1:16344536	HSPB7	0.6	11.52	0.49	7e-27	Dilated cardiomyopathy;
LUAD	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.31	-6.73	-0.31	5.41e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg14789911	chr21:47582049	C21orf56	-0.42	-7.29	-0.33	1.53e-12	Testicular germ cell tumor;
LUAD	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg03714773	chr7:91764589	CYP51A1	-0.27	-6.49	-0.3	2.38e-10	Breast cancer;
LUAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg11062466	chr8:58055876	NA	0.45	6.38	0.3	4.74e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.49	-8.05	-0.36	8.26e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg04565464	chr8:145669602	NFKBIL2	0.48	7.34	0.34	1.09e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg18105134	chr13:113819100	PROZ	-1.05	-19.41	-0.69	1.85e-60	Platelet distribution width;
LUAD	cis	rs2535633	0.602	rs2581816	chr3:53014657	C/T	cg11645453	chr3:52864694	ITIH4	0.39	7.37	0.34	9.31e-13	Body mass index;
LUAD	cis	rs910187	0.641	rs6124966	chr20:45813099	T/G	cg27589058	chr20:45804311	EYA2	-0.32	-7.36	-0.34	9.78e-13	Migraine;
LUAD	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.28	-0.51	7.65e-30	Platelet count;
LUAD	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg00717180	chr2:96193071	NA	-0.45	-8.39	-0.38	7.39e-16	Coronary artery disease;
LUAD	cis	rs36715	1.000	rs251386	chr5:127547298	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	6.8	0.31	3.47e-11	Breast cancer;
LUAD	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.71	0.31	6.39e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs459571	0.635	rs379471	chr9:136890649	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.64	-9.39	-0.42	3.61e-19	Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs559928	0.502	rs7127926	chr11:64190767	G/T	cg05555928	chr11:63887634	MACROD1	-0.46	-7.23	-0.33	2.26e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUAD	cis	rs1018836	0.631	rs61276517	chr8:91474406	A/G	cg16814680	chr8:91681699	NA	-0.54	-8.86	-0.4	2.25e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg19743168	chr1:23544995	NA	0.36	6.44	0.3	3.23e-10	Height;
LUAD	cis	rs8064299	1.000	rs8064299	chr17:72762646	C/A	cg21922841	chr17:72744131	SLC9A3R1	0.25	6.38	0.3	4.75e-10	Monocyte count;
LUAD	cis	rs3849570	1.000	rs13088000	chr3:81839404	T/C	cg07356753	chr3:81810745	GBE1	-0.71	-12.53	-0.52	7.36e-31	Waist circumference;Body mass index;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg08120389	chr17:19881268	AKAP10	-0.5	-6.35	-0.3	5.57e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs28655083	0.843	rs1502433	chr16:77087101	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.4	6.94	0.32	1.49e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10193935	0.901	rs12615383	chr2:42610551	A/G	cg27598129	chr2:42591480	NA	0.75	9.42	0.42	2.92e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg16680214	chr1:154839983	KCNN3	0.49	9.75	0.43	2.08e-20	Prostate cancer;
LUAD	cis	rs12545109	0.837	rs6474063	chr8:57355545	C/T	cg07776626	chr8:57350775	NA	-0.68	-9.66	-0.43	4.28e-20	Obesity-related traits;
LUAD	cis	rs2742417	0.935	rs1468543	chr3:45776900	A/G	cg10512202	chr3:45649293	LIMD1	0.39	6.98	0.32	1.17e-11	Response to anti-depressant treatment in major depressive disorder;
LUAD	trans	rs1728785	0.892	rs1170427	chr16:68603852	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.34	0.45	1.73e-22	Ulcerative colitis;
LUAD	cis	rs236352	0.557	rs9368966	chr6:36825430	A/G	cg10099585	chr6:36853529	C6orf89	-0.4	-6.6	-0.31	1.27e-10	Heart rate;
LUAD	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg15557168	chr22:42548783	NA	0.51	9.41	0.42	3.33e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg08219700	chr8:58056026	NA	0.55	7.9	0.36	2.44e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg20503657	chr10:835505	NA	1.22	17.93	0.66	6.75e-54	Eosinophil percentage of granulocytes;
LUAD	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.37	-0.3	4.97e-10	Coronary artery disease;
LUAD	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-8.27	-0.37	1.78e-15	Platelet count;
LUAD	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg13180566	chr4:1052158	NA	-0.4	-6.72	-0.31	5.87e-11	Recombination rate (females);
LUAD	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg11584989	chr19:19387371	SF4	0.56	8.82	0.39	3.07e-17	Bipolar disorder;
LUAD	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	9.18	0.41	1.99e-18	Melanoma;
LUAD	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg04772025	chr11:68637568	NA	0.54	8.45	0.38	4.72e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg22875332	chr1:76189707	ACADM	0.92	19.15	0.68	2.6e-59	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02463440	chr8:22132932	PIWIL2	0.56	10.59	0.46	2.15e-23	Hypertriglyceridemia;
LUAD	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg22535103	chr8:58192502	C8orf71	-0.75	-10.64	-0.46	1.35e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs5756813	0.754	rs13057133	chr22:38179473	C/T	cg06521852	chr22:38141419	TRIOBP	0.49	9.19	0.41	1.85e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs7072216	0.763	rs733345	chr10:100164215	G/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-8.39	-0.38	7.15e-16	Metabolite levels;
LUAD	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg05044414	chr3:183734942	ABCC5	-0.46	-8.55	-0.38	2.29e-16	Anterior chamber depth;
LUAD	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg27068330	chr11:65405492	SIPA1	-0.79	-12.23	-0.51	1.17e-29	Acne (severe);
LUAD	cis	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05901451	chr6:126070800	HEY2	-0.55	-8.6	-0.39	1.62e-16	Endometrial cancer;
LUAD	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg23815491	chr16:72088622	HP	0.55	10.06	0.44	1.76e-21	Fibrinogen levels;
LUAD	cis	rs12216545	0.765	rs1851435	chr7:150228785	A/T	cg08960815	chr7:150264767	GIMAP4	-0.31	-6.72	-0.31	5.98e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs870825	0.549	rs10015956	chr4:185614705	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.09	0.57	3.19e-37	Blood protein levels;
LUAD	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg02527881	chr3:46936655	PTH1R	-0.51	-10.39	-0.45	1.11e-22	Colorectal cancer;
LUAD	cis	rs4268898	0.722	rs34565113	chr2:24423076	G/T	cg06627628	chr2:24431161	ITSN2	0.4	6.86	0.32	2.43e-11	Asthma;
LUAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.22	-0.41	1.38e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg04756594	chr16:24857601	SLC5A11	-0.58	-9.71	-0.43	2.96e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22857025	chr5:266934	NA	-0.97	-14.68	-0.58	1.01e-39	Breast cancer;
LUAD	trans	rs3960554	0.932	rs4728614	chr7:75841589	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.79	-10.24	-0.45	3.89e-22	Eotaxin levels;
LUAD	cis	rs10193935	0.901	rs10174872	chr2:42459807	T/G	cg27598129	chr2:42591480	NA	-0.8	-9.61	-0.42	6.48e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02047359	chr10:75174015	ANXA7	0.45	7.36	0.34	9.41e-13	Bilirubin levels;
LUAD	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.36	-0.34	9.67e-13	Bipolar disorder;
LUAD	cis	rs9902453	1.000	rs7222308	chr17:28277041	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.22	0.41	1.37e-18	Coffee consumption (cups per day);
LUAD	cis	rs62064224	0.512	rs9912766	chr17:30712780	A/G	cg25809561	chr17:30822961	MYO1D	0.48	8.64	0.39	1.17e-16	Schizophrenia;
LUAD	cis	rs8060686	0.516	rs7197756	chr16:68275516	A/C	cg05110241	chr16:68378359	PRMT7	-0.61	-7.87	-0.36	3e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1847202	0.927	rs13081361	chr3:72947895	T/C	cg25664220	chr3:72788482	NA	-0.43	-7.52	-0.34	3.35e-13	Motion sickness;
LUAD	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg09835421	chr16:68378352	PRMT7	-0.85	-9.1	-0.4	3.55e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg23950597	chr19:37808831	NA	-0.61	-7.51	-0.34	3.54e-13	Coronary artery calcification;
LUAD	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg25456477	chr12:86230367	RASSF9	0.33	6.68	0.31	7.67e-11	Major depressive disorder;
LUAD	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg12011299	chr4:100065546	ADH4	0.69	12.43	0.52	1.82e-30	Smoking initiation;
LUAD	cis	rs2735413	0.918	rs12918409	chr16:78082681	G/A	cg04733911	chr16:78082701	NA	-0.35	-8.21	-0.37	2.74e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg13798912	chr7:905769	UNC84A	-0.63	-7.21	-0.33	2.55e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs62400317	0.859	rs12201555	chr6:45294400	T/A	cg20913747	chr6:44695427	NA	-0.41	-6.66	-0.31	8.77e-11	Total body bone mineral density;
LUAD	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg06873352	chr17:61820015	STRADA	-0.43	-7.24	-0.33	2.13e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg02176678	chr2:219576539	TTLL4	0.74	14.93	0.59	8.76e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6840360	0.571	rs2406976	chr4:152541056	G/C	cg22705602	chr4:152727874	NA	-0.38	-6.72	-0.31	6.06e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs16958440	0.867	rs77149690	chr18:44697143	T/C	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	trans	rs3857536	0.740	rs9360191	chr6:66942454	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.42	-0.3	3.59e-10	Blood trace element (Cu levels);
LUAD	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-7.95	-0.36	1.71e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg00757033	chr12:89920650	WDR51B	0.69	12.15	0.51	2.5e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.38	-0.38	7.66e-16	Prostate cancer;
LUAD	trans	rs2797160	1.000	rs9321050	chr6:126001568	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-8.59	-0.39	1.73e-16	Endometrial cancer;
LUAD	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg07936489	chr17:37558343	FBXL20	-0.47	-7.48	-0.34	4.41e-13	Glomerular filtration rate (creatinine);
LUAD	trans	rs2735413	0.918	rs1922621	chr16:78075015	A/G	cg01028844	chr5:122736986	CEP120	0.4	6.37	0.3	4.93e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg03388025	chr16:89894329	SPIRE2	0.34	7.77	0.35	6.18e-14	Vitiligo;
LUAD	cis	rs13095912	1.000	rs13072061	chr3:185326023	G/T	cg11274856	chr3:185301563	NA	0.39	7.85	0.36	3.44e-14	Systolic blood pressure;
LUAD	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.59	0.31	1.29e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg02389323	chr16:88786976	FAM38A	0.96	9.7	0.43	3.09e-20	Plateletcrit;
LUAD	cis	rs7737355	0.812	rs181738	chr5:130820451	T/C	cg06307176	chr5:131281290	NA	0.42	6.86	0.32	2.52e-11	Life satisfaction;
LUAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg08558340	chr7:100472263	SRRT	0.51	6.39	0.3	4.38e-10	Resting heart rate;
LUAD	cis	rs6714710	0.603	rs2278700	chr2:98427382	T/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.19	0.37	3.04e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs2425143	1.000	rs2378409	chr20:34392464	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.09	-0.33	5.5e-12	Blood protein levels;
LUAD	cis	rs1003719	0.715	rs2156077	chr21:38539357	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.43	-0.38	5.44e-16	Eye color traits;
LUAD	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg20503657	chr10:835505	NA	0.99	15.53	0.6	2.26e-43	Eosinophil percentage of granulocytes;
LUAD	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg00495681	chr13:53174319	NA	0.71	14.43	0.57	1.19e-38	Lewy body disease;
LUAD	cis	rs600626	0.529	rs10899115	chr11:75471849	A/G	cg24262691	chr11:75473276	NA	0.55	7.85	0.36	3.54e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7561273	0.609	rs10189243	chr2:24293756	C/T	cg20701182	chr2:24300061	SF3B14	0.41	6.85	0.32	2.59e-11	Quantitative traits;
LUAD	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg12923728	chr3:195709715	SDHAP1	0.44	6.72	0.31	5.9e-11	Mean corpuscular volume;
LUAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.39	-0.38	7.4e-16	Alzheimer's disease;
LUAD	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.92	-0.36	2.08e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg06547715	chr2:218990976	CXCR2	-0.28	-6.77	-0.31	4.35e-11	Colorectal cancer;
LUAD	trans	rs9354308	0.933	rs2022856	chr6:66568235	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.51	7.6	0.35	1.91e-13	Metabolite levels;
LUAD	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg14668632	chr7:2872130	GNA12	-0.74	-13.61	-0.55	2.91e-35	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00140813	chr16:28857836	TUFM	-0.58	-7.08	-0.33	5.9e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-11.18	-0.48	1.31e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg02269571	chr22:50332266	NA	-0.61	-9.22	-0.41	1.46e-18	Schizophrenia;
LUAD	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg04827223	chr11:72435913	ARAP1	-0.5	-7.42	-0.34	6.34e-13	Type 2 diabetes;
LUAD	cis	rs3087591	0.960	rs2066736	chr17:29559932	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.42	-6.7	-0.31	6.72e-11	Hip circumference;
LUAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg18621852	chr3:10150065	C3orf24	-0.48	-8.34	-0.38	1.03e-15	Alzheimer's disease;
LUAD	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg04731861	chr2:219085781	ARPC2	0.27	8.3	0.37	1.4e-15	Colorectal cancer;
LUAD	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg27454412	chr7:1067447	C7orf50	-0.45	-7.77	-0.35	5.88e-14	Bronchopulmonary dysplasia;
LUAD	trans	rs9784649	0.760	rs72755820	chr5:25066181	G/A	cg11038491	chr20:34638489	LOC647979	-0.82	-10.82	-0.47	2.97e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22307029	chr19:49891270	CCDC155	0.76	12.34	0.51	4.11e-30	Multiple sclerosis;
LUAD	cis	rs11048434	0.698	rs10842537	chr12:9066158	T/C	cg04155231	chr12:9217510	LOC144571	0.38	6.96	0.32	1.29e-11	Sjögren's syndrome;
LUAD	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg01579765	chr21:45077557	HSF2BP	-0.57	-12.74	-0.53	1.03e-31	Mean corpuscular volume;
LUAD	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg23649088	chr2:200775458	C2orf69	0.6	7.94	0.36	1.88e-14	Schizophrenia;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25654697	chr7:7680075	RPA3	0.43	6.6	0.31	1.26e-10	Gut microbiome composition (summer);
LUAD	cis	rs9902453	0.967	rs1906450	chr17:28515744	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.33	0.38	1.17e-15	Coffee consumption (cups per day);
LUAD	cis	rs7771547	0.723	rs56144242	chr6:36553209	G/T	cg07856975	chr6:36356162	ETV7	0.45	6.39	0.3	4.41e-10	Platelet distribution width;
LUAD	cis	rs11828289	0.660	rs17306433	chr11:23223034	C/G	cg20040320	chr11:23191996	NA	-0.69	-7.98	-0.36	1.4e-14	Cancer;
LUAD	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg05373962	chr22:49881684	NA	-0.51	-10.63	-0.46	1.56e-23	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.18	-0.37	3.36e-15	Total body bone mineral density;
LUAD	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg11494091	chr17:61959527	GH2	0.44	8.2	0.37	2.89e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg18105134	chr13:113819100	PROZ	0.91	16.49	0.63	1.5e-47	Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17095355	1.000	rs12259261	chr10:111725145	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.69	-9.35	-0.41	5.32e-19	Biliary atresia;
LUAD	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg27432699	chr2:27873401	GPN1	-0.38	-6.44	-0.3	3.21e-10	Total body bone mineral density;
LUAD	cis	rs6678622	0.931	rs9729667	chr1:78349214	C/T	cg21968580	chr1:78470640	DNAJB4	0.43	7.08	0.33	5.89e-12	Hip circumference;
LUAD	cis	rs9972944	0.902	rs9972956	chr17:63771092	T/C	cg07283582	chr17:63770753	CCDC46	0.53	11.91	0.5	2.08e-28	Total body bone mineral density;
LUAD	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg06627628	chr2:24431161	ITSN2	-0.54	-6.42	-0.3	3.57e-10	Lymphocyte counts;
LUAD	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg22508957	chr16:3507546	NAT15	-0.48	-7.86	-0.36	3.27e-14	Body mass index (adult);
LUAD	cis	rs2274273	0.840	rs7144737	chr14:55822946	C/T	cg04306507	chr14:55594613	LGALS3	0.46	9.79	0.43	1.52e-20	Protein biomarker;
LUAD	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg21699342	chr2:239360505	ASB1	0.56	10.87	0.47	1.94e-24	Multiple system atrophy;
LUAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg13047869	chr3:10149882	C3orf24	0.66	11.09	0.47	2.88e-25	Alzheimer's disease;
LUAD	cis	rs244731	1.000	rs244729	chr5:176539018	C/G	cg06060754	chr5:176797920	RGS14	0.51	8.68	0.39	8.63e-17	Urate levels in lean individuals;
LUAD	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg12599982	chr1:44399894	ARTN	0.35	7.23	0.33	2.33e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg18016565	chr1:150552671	MCL1	0.41	7.58	0.35	2.14e-13	Tonsillectomy;
LUAD	cis	rs11112613	0.713	rs58066965	chr12:105952505	C/G	cg03607813	chr12:105948248	NA	0.74	12.78	0.53	7.56e-32	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs9462027	0.606	rs2814987	chr6:34605145	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.83	-0.39	2.83e-17	Systemic lupus erythematosus;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg22199615	chr2:167233070	SCN9A	-0.37	-6.63	-0.31	1.01e-10	Schizophrenia;
LUAD	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg16479474	chr6:28041457	NA	0.37	6.68	0.31	7.51e-11	Cardiac Troponin-T levels;
LUAD	trans	rs9467711	0.651	rs13210041	chr6:26037601	G/A	cg01620082	chr3:125678407	NA	-1.02	-8.07	-0.37	7.29e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg05991184	chr2:219186017	PNKD	0.37	6.94	0.32	1.48e-11	Colorectal cancer;
LUAD	cis	rs1595825	0.891	rs7580003	chr2:198517893	C/T	cg11031976	chr2:198649780	BOLL	-0.46	-6.77	-0.31	4.3e-11	Ulcerative colitis;
LUAD	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg03690763	chr11:133734501	NA	-0.34	-7.73	-0.35	7.89e-14	Childhood ear infection;
LUAD	trans	rs2797160	1.000	rs1739380	chr6:126012858	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.54	8.7	0.39	7.72e-17	Endometrial cancer;
LUAD	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg17105886	chr17:28927953	LRRC37B2	-0.65	-7.39	-0.34	7.9e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg15445000	chr17:37608096	MED1	0.44	8.19	0.37	3.14e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs684232	0.602	rs8064796	chr17:525937	A/C	cg15660573	chr17:549704	VPS53	-0.87	-18.09	-0.66	1.3e-54	Prostate cancer;
LUAD	cis	rs62027291	0.654	rs62028181	chr15:77006293	A/G	cg22467129	chr15:76604101	ETFA	0.71	6.54	0.3	1.74e-10	Plateletcrit;
LUAD	cis	rs2652834	0.808	rs28583444	chr15:63357852	T/G	cg25406657	chr15:63342033	TPM1	-0.45	-7.23	-0.33	2.32e-12	HDL cholesterol;
LUAD	cis	rs12760731	0.720	rs12755909	chr1:178305298	G/A	cg00404053	chr1:178313656	RASAL2	0.74	9.39	0.42	3.84e-19	Obesity-related traits;
LUAD	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg21545522	chr1:205238299	TMCC2	0.35	6.7	0.31	6.73e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg08219700	chr8:58056026	NA	0.71	9.14	0.41	2.7e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs34734847	0.814	rs17847	chr12:121149475	A/G	cg27246729	chr12:121163418	ACADS	0.37	6.9	0.32	1.86e-11	Mean corpuscular volume;
LUAD	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg15083037	chr5:83017644	HAPLN1	-0.52	-7.96	-0.36	1.61e-14	Prostate cancer;
LUAD	cis	rs6854137	0.758	rs35114118	chr4:169731095	G/A	cg20607169	chr4:169750834	PALLD	0.4	7.12	0.33	4.67e-12	Vein graft stenosis in coronary artery bypass grafting;
LUAD	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg16405210	chr4:1374714	KIAA1530	-0.59	-9.04	-0.4	5.86e-18	Longevity;
LUAD	cis	rs7107174	0.901	rs2511159	chr11:77974193	G/T	cg02023728	chr11:77925099	USP35	-0.39	-6.65	-0.31	8.99e-11	Testicular germ cell tumor;
LUAD	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02475777	chr4:1388615	CRIPAK	-0.68	-9.82	-0.43	1.2e-20	Longevity;
LUAD	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.43	-6.81	-0.31	3.47e-11	Ulcerative colitis;Inflammatory bowel disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg26035463	chr12:117627651	FBXO21	-0.44	-7.05	-0.32	7.49e-12	Height;
LUAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.8	-0.39	3.6e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs9581857	0.556	rs1885990	chr13:28040502	C/T	cg22138327	chr13:27999177	GTF3A	0.75	10.69	0.46	8.73e-24	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs454510	0.726	rs838989	chr1:120182906	G/A	cg16322792	chr1:120165303	ZNF697	0.37	6.9	0.32	1.91e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg02931644	chr1:25747376	RHCE	-0.42	-8.54	-0.38	2.45e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg18827107	chr12:86230957	RASSF9	0.54	9.64	0.42	5.29e-20	Major depressive disorder;
LUAD	cis	rs7107174	0.681	rs11237443	chr11:78005089	C/A	cg02023728	chr11:77925099	USP35	0.46	7.12	0.33	4.55e-12	Testicular germ cell tumor;
LUAD	cis	rs727505	1.000	rs9655845	chr7:124513355	G/C	cg23710748	chr7:124431027	NA	-0.46	-9.43	-0.42	2.67e-19	Lewy body disease;
LUAD	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg15556689	chr8:8085844	FLJ10661	0.41	6.45	0.3	3.05e-10	Mood instability;
LUAD	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg03714773	chr7:91764589	CYP51A1	0.29	6.52	0.3	1.98e-10	Breast cancer;
LUAD	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.21	0.33	2.67e-12	Motion sickness;
LUAD	trans	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg14917512	chr19:3094685	GNA11	0.36	6.43	0.3	3.46e-10	Aortic root size;
LUAD	cis	rs4253772	0.938	rs78336060	chr22:46641597	C/T	cg09491104	chr22:46646882	C22orf40	-0.51	-6.98	-0.32	1.12e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg13789015	chr9:136890014	NCRNA00094	0.75	12.69	0.53	1.64e-31	Platelet distribution width;
LUAD	cis	rs7590720	1.000	rs4674058	chr2:216909368	A/G	cg12620499	chr2:216877984	MREG	0.57	8.94	0.4	1.26e-17	Alcohol dependence;
LUAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.57	-9.83	-0.43	1.08e-20	Longevity;Endometriosis;
LUAD	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg11707310	chr1:2537719	MMEL1	-0.38	-7.93	-0.36	2.04e-14	Ulcerative colitis;
LUAD	cis	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.42	7.99	0.36	1.26e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs10501293	0.529	rs2902301	chr11:43093159	A/T	cg03447554	chr11:43094025	NA	-0.38	-7.76	-0.35	6.25e-14	Cognitive performance;
LUAD	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg09184832	chr6:79620586	NA	-0.53	-9.84	-0.43	1.07e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs72720396	0.789	rs12048450	chr1:91199660	G/A	cg13456504	chr1:91191583	NA	0.57	10.1	0.44	1.3e-21	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg02466173	chr16:30829666	NA	-0.71	-12.59	-0.52	4.39e-31	Multiple myeloma;
LUAD	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg13319975	chr6:146136371	FBXO30	-0.58	-9.67	-0.43	3.99e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg15605315	chr1:45957053	TESK2	-0.41	-6.43	-0.3	3.54e-10	High light scatter reticulocyte count;
LUAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg00280220	chr17:61926910	NA	0.36	6.9	0.32	1.9e-11	Prudent dietary pattern;
LUAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg27588902	chr6:42928151	GNMT	-0.35	-9.18	-0.41	1.9e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.51	-0.34	3.62e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg16031515	chr1:205743344	RAB7L1	-0.34	-6.79	-0.31	3.79e-11	Menarche (age at onset);
LUAD	cis	rs758324	0.853	rs4705902	chr5:131150267	C/G	cg06307176	chr5:131281290	NA	0.49	7.79	0.35	5.32e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg16205897	chr5:131564050	P4HA2	0.3	6.56	0.3	1.58e-10	Blood metabolite levels;
LUAD	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.44	-0.57	1e-38	Schizophrenia;
LUAD	cis	rs208520	0.802	rs208516	chr6:66946119	T/C	cg07460842	chr6:66804631	NA	-1.0	-14.54	-0.58	4.06e-39	Exhaled nitric oxide output;
LUAD	cis	rs10465746	0.935	rs2389647	chr1:84403041	C/T	cg10977910	chr1:84465055	TTLL7	0.49	7.84	0.36	3.62e-14	Obesity-related traits;
LUAD	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.43	7.57	0.35	2.32e-13	Type 2 diabetes;
LUAD	cis	rs11640533	0.901	rs2908790	chr16:53412161	T/C	cg04653913	chr16:53407753	NA	0.5	8.94	0.4	1.2e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7000551	0.725	rs2461489	chr8:22370253	G/A	cg12081754	chr8:22256438	SLC39A14	0.48	7.9	0.36	2.49e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg11062466	chr8:58055876	NA	0.67	9.01	0.4	7.2e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.33	6.58	0.3	1.39e-10	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.65	0.31	9.11e-11	Depression;
LUAD	cis	rs12505328	0.514	rs7673260	chr4:174390296	A/T	cg12145043	chr4:174357286	NA	0.42	6.7	0.31	6.53e-11	Chin dimples;
LUAD	cis	rs1215050	0.782	rs6532693	chr4:98655815	T/C	cg17366294	chr4:99064904	C4orf37	-0.45	-7.94	-0.36	1.86e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7814319	0.840	rs10504961	chr8:97240129	C/T	cg20787634	chr8:97240163	UQCRB	-0.39	-7.65	-0.35	1.35e-13	Lung function (FVC);
LUAD	cis	rs1395	0.961	rs4665963	chr2:27528692	T/C	cg23587288	chr2:27483067	SLC30A3	-0.38	-7.2	-0.33	2.7e-12	Blood metabolite levels;
LUAD	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg08645402	chr16:4508243	NA	0.58	10.04	0.44	1.96e-21	Schizophrenia;
LUAD	cis	rs7000551	0.715	rs12544074	chr8:22338378	A/G	cg12081754	chr8:22256438	SLC39A14	0.51	8.45	0.38	4.68e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg22079354	chr11:130786696	SNX19	-0.38	-6.58	-0.3	1.36e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg23029597	chr12:123009494	RSRC2	-0.5	-7.83	-0.36	3.88e-14	Body mass index;
LUAD	trans	rs3942852	0.869	rs4752806	chr11:48118199	G/C	cg15704280	chr7:45808275	SEPT13	-0.59	-8.01	-0.36	1.14e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.56	8.06	0.36	7.96e-15	Platelet count;
LUAD	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.19	0.37	3.05e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs79839061	0.732	rs11734742	chr4:821565	C/T	cg07828340	chr4:882639	GAK	0.99	9.21	0.41	1.48e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7737355	0.898	rs3775998	chr5:130979332	A/G	cg25547332	chr5:131281432	NA	0.44	6.61	0.31	1.16e-10	Life satisfaction;
LUAD	trans	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg20542592	chr8:11973495	FAM66D	-0.4	-6.39	-0.3	4.27e-10	Mood instability;
LUAD	cis	rs17092148	1.000	rs60789653	chr20:33447162	G/A	cg16810054	chr20:33298113	TP53INP2	0.52	8.09	0.37	6.49e-15	Neuroticism;
LUAD	cis	rs4478037	0.749	rs9311003	chr3:33131070	A/G	cg19404215	chr3:33155277	CRTAP	-0.59	-7.41	-0.34	6.9e-13	Major depressive disorder;
LUAD	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg01017244	chr2:74357527	NA	0.9	14.57	0.58	2.93e-39	Gestational age at birth (maternal effect);
LUAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.73	-0.35	8.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg01689657	chr7:91764605	CYP51A1	0.32	7.96	0.36	1.63e-14	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09273779	chr9:35605990	TESK1	-0.41	-6.56	-0.3	1.53e-10	Height;
LUAD	cis	rs6076065	0.723	rs2424541	chr20:23386776	T/C	cg11657817	chr20:23433608	CST11	0.46	8.78	0.39	3.99e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg13385794	chr1:248469461	NA	0.27	7.35	0.34	1.05e-12	Common traits (Other);
LUAD	cis	rs11031096	0.868	rs2304891	chr11:4103524	A/G	cg18678763	chr11:4115507	RRM1	0.38	6.69	0.31	7.03e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg23625390	chr15:77176239	SCAPER	-0.46	-7.26	-0.33	1.82e-12	Blood metabolite levels;
LUAD	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg12311346	chr5:56204834	C5orf35	-0.44	-7.2	-0.33	2.79e-12	Coronary artery disease;
LUAD	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg10589385	chr1:150898437	SETDB1	-0.4	-7.72	-0.35	8.24e-14	Tonsillectomy;
LUAD	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg14343924	chr8:8086146	FLJ10661	0.51	8.06	0.36	8.03e-15	Mood instability;
LUAD	cis	rs698833	0.852	rs4953089	chr2:44565024	G/A	cg04920474	chr2:44395004	PPM1B	0.38	6.67	0.31	8.1e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg13385794	chr1:248469461	NA	0.24	6.35	0.3	5.48e-10	Common traits (Other);
LUAD	cis	rs500891	0.525	rs12190282	chr6:84056328	A/G	cg08257003	chr6:84140564	ME1	0.34	6.68	0.31	7.45e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg26338869	chr17:61819248	STRADA	-0.39	-6.58	-0.3	1.37e-10	Prudent dietary pattern;
LUAD	cis	rs68170813	0.641	rs1978085	chr7:107095216	T/C	cg23024343	chr7:107201750	COG5	0.5	7.0	0.32	9.81e-12	Coronary artery disease;
LUAD	cis	rs16958440	0.867	rs80006910	chr18:44696382	C/G	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg09085632	chr11:111637200	PPP2R1B	0.75	11.78	0.5	6.62e-28	Primary sclerosing cholangitis;
LUAD	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg06808227	chr14:105710500	BRF1	-0.43	-6.86	-0.32	2.38e-11	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg26513180	chr16:89883248	FANCA	0.82	7.41	0.34	6.77e-13	Skin colour saturation;
LUAD	trans	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	12.92	0.53	2.02e-32	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg06641503	chr3:48959341	ARIH2	-0.38	-7.51	-0.34	3.65e-13	Menarche (age at onset);
LUAD	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg15017067	chr4:17643749	FAM184B	0.34	6.64	0.31	9.46e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs859767	0.501	rs6705916	chr2:135397569	C/T	cg12500956	chr2:135428796	TMEM163	-0.27	-7.14	-0.33	4.02e-12	Neuroticism;
LUAD	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg17177755	chr1:15930204	NA	0.45	7.32	0.34	1.28e-12	Systolic blood pressure;
LUAD	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg21775007	chr8:11205619	TDH	0.54	9.73	0.43	2.48e-20	Retinal vascular caliber;
LUAD	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg14558114	chr2:88469736	THNSL2	0.86	9.25	0.41	1.14e-18	Plasma clusterin levels;
LUAD	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg26384229	chr12:38710491	ALG10B	0.43	7.34	0.34	1.1e-12	Heart rate;
LUAD	cis	rs10911363	0.615	rs12024309	chr1:183419981	A/G	cg09173681	chr1:183549694	NCF2	-0.55	-10.04	-0.44	2.02e-21	Systemic lupus erythematosus;
LUAD	cis	rs17095355	1.000	rs6584962	chr10:111689904	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.77	-10.86	-0.47	2.03e-24	Biliary atresia;
LUAD	cis	rs2230307	0.572	rs512999	chr1:100563330	A/G	cg20868668	chr1:100435035	SLC35A3	0.53	7.69	0.35	1.01e-13	Carotid intima media thickness;
LUAD	trans	rs4130548	0.554	rs12732514	chr1:78640339	C/T	cg20826526	chr3:156266748	SSR3	-0.49	-8.02	-0.36	1.04e-14	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Waist circumference;
LUAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00149659	chr3:10157352	C3orf10	0.53	7.35	0.34	1.06e-12	Alzheimer's disease;
LUAD	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	8.03e-16	Body mass index;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04236901	chr4:175204805	KIAA1712;FBXO8	-0.38	-6.39	-0.3	4.44e-10	Cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09378111	chr2:211036309	C2orf67	-0.43	-6.62	-0.31	1.09e-10	Height;
LUAD	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg19980929	chr12:42632907	YAF2	-0.34	-6.54	-0.3	1.8e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs4460629	0.742	rs11264312	chr1:155075888	T/C	cg23973274	chr1:155060172	NA	-0.37	-6.38	-0.3	4.52e-10	Serum magnesium levels;
LUAD	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.46	0.52	1.4e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg22676075	chr6:135203613	NA	0.41	7.59	0.35	2.13e-13	Red blood cell count;
LUAD	cis	rs10129255	0.500	rs2105989	chr14:107138216	C/T	cg23076370	chr14:107095027	NA	-0.44	-8.84	-0.39	2.69e-17	Kawasaki disease;
LUAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg23978390	chr7:1156363	C7orf50	0.46	7.45	0.34	5.45e-13	Longevity;Endometriosis;
LUAD	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg14196790	chr5:131705035	SLC22A5	0.37	6.56	0.3	1.58e-10	Breast cancer;
LUAD	cis	rs9902453	0.753	rs7226121	chr17:28208125	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	9.79	0.43	1.56e-20	Coffee consumption (cups per day);
LUAD	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg24801067	chr17:62843696	NA	-0.54	-8.67	-0.39	9.11e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.41	7.34	0.34	1.08e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.61	0.31	1.14e-10	Prudent dietary pattern;
LUAD	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg05182265	chr7:156933206	UBE3C	-0.78	-16.69	-0.63	2e-48	Body mass index;
LUAD	cis	rs10129255	0.500	rs988132	chr14:107184997	C/T	cg23076370	chr14:107095027	NA	-0.44	-8.64	-0.39	1.2e-16	Kawasaki disease;
LUAD	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg25208724	chr1:156163844	SLC25A44	0.97	15.19	0.59	6.54e-42	Testicular germ cell tumor;
LUAD	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg27279351	chr12:120934652	DYNLL1	0.44	6.66	0.31	8.45e-11	High light scatter reticulocyte count;
LUAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6840360	0.868	rs6823462	chr4:152708740	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.65	-0.31	8.95e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2932538	0.922	rs12406906	chr1:113117900	G/T	cg22162597	chr1:113214053	CAPZA1	-0.47	-7.04	-0.32	7.99e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	trans	rs7615952	0.546	rs11718647	chr3:125352022	G/A	cg17147758	chr8:6949321	NA	-0.51	-8.14	-0.37	4.37e-15	Blood pressure (smoking interaction);
LUAD	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg13385794	chr1:248469461	NA	0.25	6.85	0.32	2.55e-11	Common traits (Other);
LUAD	trans	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg14791747	chr16:20752902	THUMPD1	0.71	10.15	0.44	8.32e-22	Cognitive test performance;
LUAD	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24308560	chr3:49941425	MST1R	0.52	8.63	0.39	1.27e-16	Body mass index;
LUAD	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.42	0.34	6.2800000000000005e-13	Menopause (age at onset);
LUAD	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg06784218	chr1:46089804	CCDC17	0.5	10.92	0.47	1.22e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg08357012	chr13:99090919	FARP1	0.34	6.37	0.3	4.87e-10	Neuroticism;
LUAD	cis	rs4601821	0.635	rs2303380	chr11:113200709	G/A	cg14159747	chr11:113255604	NA	0.37	6.74	0.31	5.07e-11	Alcoholic chronic pancreatitis;
LUAD	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg03037974	chr15:76606532	NA	0.4	8.64	0.39	1.21e-16	Blood metabolite levels;
LUAD	cis	rs9633740	1.000	rs9633740	chr10:82265271	A/G	cg01528321	chr10:82214614	TSPAN14	0.76	10.03	0.44	2.27e-21	Post bronchodilator FEV1;
LUAD	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg02993280	chr1:107599747	PRMT6	-0.56	-9.12	-0.41	3.09e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9902453	0.704	rs2617874	chr17:28085172	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.15	0.37	4.06e-15	Coffee consumption (cups per day);
LUAD	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg17063962	chr7:91808500	NA	0.72	12.75	0.53	9.92e-32	Breast cancer;
LUAD	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.93	11.73	0.5	1.03e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7107174	1.000	rs10899470	chr11:78020052	C/T	cg02023728	chr11:77925099	USP35	0.52	7.85	0.36	3.49e-14	Testicular germ cell tumor;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09190325	chr6:26539014	HMGN4	-0.41	-6.58	-0.3	1.43e-10	Cancer;
LUAD	cis	rs2286885	1.000	rs1537989	chr9:129241824	C/T	cg15282417	chr9:129245246	FAM125B	0.43	8.63	0.39	1.22e-16	Intraocular pressure;
LUAD	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg06641503	chr3:48959341	ARIH2	-0.4	-7.69	-0.35	1.06e-13	Parkinson's disease;
LUAD	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg22823121	chr1:150693482	HORMAD1	0.45	9.17	0.41	2.15e-18	Tonsillectomy;
LUAD	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.12	-0.44	1.06e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg03959625	chr15:84868606	LOC388152	0.42	6.76	0.31	4.72e-11	Schizophrenia;
LUAD	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg22431228	chr1:16359049	CLCNKA	-0.53	-9.6	-0.42	7.14e-20	Dilated cardiomyopathy;
LUAD	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg11247378	chr22:39784982	NA	-0.67	-11.15	-0.48	1.73e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg07741184	chr6:167504864	NA	0.36	8.24	0.37	2.11e-15	Primary biliary cholangitis;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg22114827	chr17:4852349	PFN1	-0.68	-6.77	-0.31	4.41e-11	Type 2 diabetes;
LUAD	cis	rs2652834	0.851	rs11071721	chr15:63350218	T/C	cg25406657	chr15:63342033	TPM1	-0.43	-6.8	-0.31	3.69e-11	HDL cholesterol;
LUAD	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg15605315	chr1:45957053	TESK2	0.49	7.74	0.35	7.49e-14	High light scatter reticulocyte count;
LUAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg04025307	chr7:1156635	C7orf50	0.66	12.36	0.52	3.44e-30	Longevity;Endometriosis;
LUAD	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg21475434	chr5:93447410	FAM172A	0.74	8.1	0.37	5.73e-15	Diabetic retinopathy;
LUAD	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg06740227	chr12:86229804	RASSF9	0.46	8.21	0.37	2.72e-15	Major depressive disorder;
LUAD	cis	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.98	-0.32	1.13e-11	Morning vs. evening chronotype;
LUAD	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg08807101	chr21:30365312	RNF160	0.43	6.36	0.3	5.17e-10	Selective IgA deficiency;
LUAD	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg00898013	chr13:113819073	PROZ	-0.64	-11.5	-0.49	7.92e-27	Platelet distribution width;
LUAD	cis	rs11958404	0.932	rs72816566	chr5:157427613	G/A	cg05962755	chr5:157440814	NA	0.5	7.74	0.35	7.22e-14	IgG glycosylation;
LUAD	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg00277334	chr10:82204260	NA	-0.63	-9.91	-0.43	5.81e-21	Post bronchodilator FEV1;
LUAD	cis	rs5756813	0.635	rs11089856	chr22:38205784	A/C	cg06521852	chr22:38141419	TRIOBP	0.47	8.62	0.39	1.37e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg10978503	chr1:24200527	CNR2	0.46	9.3	0.41	7.59e-19	Immature fraction of reticulocytes;
LUAD	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.34	-0.41	5.69e-19	Schizophrenia;
LUAD	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg22117172	chr7:91764530	CYP51A1	0.35	7.6	0.35	1.94e-13	Breast cancer;
LUAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg06753367	chr22:24256600	NA	-0.39	-6.9	-0.32	1.94e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg12927641	chr6:109611667	NA	-0.51	-8.95	-0.4	1.16e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs11585357	0.947	rs6666990	chr1:17611520	G/A	cg08277548	chr1:17600880	PADI3	0.84	12.79	0.53	7.02e-32	Hair shape;
LUAD	cis	rs4638749	0.677	rs7595399	chr2:108835943	C/G	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.38	-0.34	8.25e-13	Blood pressure;
LUAD	cis	rs3862030	0.720	rs11191295	chr10:104231054	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-8.02	-0.36	1.06e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	trans	rs7395662	0.929	rs7946248	chr11:48613516	T/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.48	-0.3	2.57e-10	HDL cholesterol;
LUAD	cis	rs2996428	0.709	rs7527973	chr1:3704041	C/T	cg17848003	chr1:3704513	LRRC47	0.56	11.28	0.48	5.37e-26	Red cell distribution width;
LUAD	cis	rs6496044	0.568	rs4842888	chr15:86063133	C/T	cg13263323	chr15:86062960	AKAP13	0.57	10.62	0.46	1.66e-23	Interstitial lung disease;
LUAD	cis	rs7523050	0.730	rs12729728	chr1:109431110	C/A	cg08274380	chr1:109419600	GPSM2	0.75	6.74	0.31	5.3e-11	Fat distribution (HIV);
LUAD	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg18944383	chr4:111397179	ENPEP	-0.5	-9.08	-0.4	4.21e-18	Coronary artery disease;
LUAD	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg03929089	chr4:120376271	NA	-0.44	-6.76	-0.31	4.55e-11	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg00745463	chr17:30367425	LRRC37B	-0.82	-9.78	-0.43	1.75e-20	Hip circumference adjusted for BMI;
LUAD	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg22166914	chr1:53195759	ZYG11B	0.44	7.6	0.35	1.99e-13	Monocyte count;
LUAD	cis	rs4072705	0.967	rs4838210	chr9:127546183	A/G	cg13476313	chr9:127244764	NR5A1	-0.27	-6.59	-0.3	1.35e-10	Menarche (age at onset);
LUAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg27286337	chr10:134555280	INPP5A	0.73	9.58	0.42	8.09e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-8.21	-0.37	2.68e-15	Menarche (age at onset);
LUAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg16606324	chr3:10149918	C3orf24	-0.67	-9.79	-0.43	1.62e-20	Alzheimer's disease;
LUAD	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg15900387	chr1:150738905	CTSS	-0.38	-6.85	-0.32	2.62e-11	Melanoma;
LUAD	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg08999081	chr20:33150536	PIGU	0.49	9.34	0.41	5.75e-19	Coronary artery disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17561891	chr7:86849173	C7orf23	-0.5	-6.56	-0.3	1.57e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs4698048	0.506	rs6833292	chr4:10272429	C/T	cg26043149	chr18:55253948	FECH	-0.49	-7.96	-0.36	1.59e-14	Skin aging (microtopography measurement);
LUAD	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg21918786	chr6:109611834	NA	-0.58	-10.65	-0.46	1.24e-23	Reticulocyte fraction of red cells;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02548606	chr15:77363299	TSPAN3	-0.46	-7.13	-0.33	4.24e-12	Height;
LUAD	cis	rs6961069	0.773	rs1761661	chr7:80238041	A/C	cg04458919	chr7:80252533	CD36	-0.35	-6.7	-0.31	6.51e-11	Platelet count;
LUAD	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg12035532	chr1:1886765	KIAA1751	0.41	7.02	0.32	8.76e-12	Body mass index;
LUAD	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg03714773	chr7:91764589	CYP51A1	0.31	7.14	0.33	4.12e-12	Breast cancer;
LUAD	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg10518543	chr12:38710700	ALG10B	0.42	6.44	0.3	3.26e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs698833	0.926	rs786622	chr2:44606598	C/T	cg04920474	chr2:44395004	PPM1B	0.4	7.12	0.33	4.75e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-7.12	-0.33	4.55e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg17366294	chr4:99064904	C4orf37	0.67	12.4	0.52	2.38e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs12612619	0.704	rs11680633	chr2:27224209	T/C	cg00617064	chr2:27272375	NA	-0.36	-6.96	-0.32	1.3e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00149659	chr3:10157352	C3orf10	0.57	7.95	0.36	1.67e-14	Alzheimer's disease;
LUAD	cis	rs2806561	0.695	rs66592286	chr1:23333649	G/C	cg19743168	chr1:23544995	NA	0.37	6.46	0.3	2.96e-10	Height;
LUAD	cis	rs7180079	0.925	rs56246583	chr15:64534123	A/T	cg08069370	chr15:64387884	SNX1	-0.53	-6.53	-0.3	1.95e-10	Monocyte count;
LUAD	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg02038168	chr22:39784481	NA	-0.52	-8.93	-0.4	1.31e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.98	-0.36	1.42e-14	Mood instability;
LUAD	cis	rs2742234	0.541	rs61845684	chr10:43744983	T/C	cg15436174	chr10:43711423	RASGEF1A	0.52	8.66	0.39	1.03e-16	Hirschsprung disease;
LUAD	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg13047869	chr3:10149882	C3orf24	0.65	11.01	0.47	5.64e-25	Alzheimer's disease;
LUAD	cis	rs12618769	0.652	rs2276603	chr2:99205962	C/T	cg10123293	chr2:99228465	UNC50	-0.52	-9.03	-0.4	5.91e-18	Bipolar disorder;
LUAD	trans	rs783540	0.967	rs1145173	chr15:83223425	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.76	-0.31	4.47e-11	Schizophrenia;
LUAD	cis	rs12431939	0.947	rs59298295	chr14:51659047	T/G	cg23942311	chr14:51606299	NA	-0.62	-8.0	-0.36	1.22e-14	Cancer;
LUAD	cis	rs12545109	0.679	rs1973628	chr8:57429360	T/C	cg17761419	chr8:57350749	NA	-0.61	-7.34	-0.34	1.13e-12	Obesity-related traits;
LUAD	trans	rs11039798	1.000	rs7102865	chr11:48458361	A/C	cg15704280	chr7:45808275	SEPT13	0.65	7.66	0.35	1.29e-13	Axial length;
LUAD	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg20307385	chr11:47447363	PSMC3	0.68	11.69	0.49	1.45e-27	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg08645402	chr16:4508243	NA	0.52	9.11	0.4	3.42e-18	Schizophrenia;
LUAD	cis	rs12210905	0.688	rs60888769	chr6:27490922	A/G	cg08851530	chr6:28072375	NA	0.94	6.85	0.32	2.58e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs4911259	0.513	rs6057665	chr20:31463460	A/G	cg13636640	chr20:31349939	DNMT3B	-0.57	-9.37	-0.41	4.5e-19	Inflammatory bowel disease;
LUAD	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg04450456	chr4:17643702	FAM184B	0.39	7.74	0.35	7.5e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg24818145	chr4:99064322	C4orf37	0.41	6.83	0.32	2.9100000000000002e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg26769984	chr7:1090371	C7orf50	0.69	10.24	0.45	4e-22	Bronchopulmonary dysplasia;
LUAD	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg10164272	chr16:89456328	ANKRD11	0.41	6.58	0.3	1.36e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-11.5	-0.49	8.41e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs13064411	0.696	rs36054418	chr3:113204762	G/T	cg18753928	chr3:113234510	CCDC52	-0.73	-12.47	-0.52	1.34e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg16647868	chr5:131706066	SLC22A5	0.38	6.55	0.3	1.7e-10	Acylcarnitine levels;
LUAD	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg07870213	chr5:140052090	DND1	0.98	13.31	0.54	5.39e-34	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs68170813	0.559	rs7804979	chr7:106999453	C/G	cg23024343	chr7:107201750	COG5	0.46	6.7	0.31	6.86e-11	Coronary artery disease;
LUAD	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg20701182	chr2:24300061	SF3B14	0.91	13.81	0.56	4.56e-36	Lymphocyte counts;
LUAD	trans	rs7395662	1.000	rs7479134	chr11:48625409	A/C	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	1.99e-12	HDL cholesterol;
LUAD	cis	rs3736594	0.879	rs77154381	chr2:27982119	A/G	cg25309888	chr2:27988724	NA	0.3	6.78	0.31	4.14e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg22906224	chr7:99728672	NA	-0.56	-9.68	-0.43	3.82e-20	Coronary artery disease;
LUAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg16606324	chr3:10149918	C3orf24	-0.69	-11.43	-0.49	1.54e-26	Alzheimer's disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07398558	chr1:28879201	TRNAU1AP	-0.41	-6.92	-0.32	1.63e-11	Cancer;
LUAD	cis	rs7818345	0.845	rs11782540	chr8:19268251	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.34	7.2	0.33	2.76e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg25482853	chr8:67687455	SGK3	1.18	18.25	0.66	2.68e-55	Lung disease severity in cystic fibrosis;
LUAD	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.9	-0.36	2.51e-14	Neuroticism;
LUAD	cis	rs870825	0.550	rs57301026	chr4:185646505	C/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.85	-0.36	3.57e-14	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg17466768	chr2:25194156	DNAJC27	-0.37	-6.4	-0.3	4.1e-10	Subcortical brain region volumes;
LUAD	cis	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg05084668	chr3:125655381	ALG1L	-0.68	-9.05	-0.4	5.06e-18	Blood pressure (smoking interaction);
LUAD	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg05714579	chr10:131428358	MGMT	0.41	6.76	0.31	4.7e-11	Response to temozolomide;
LUAD	cis	rs12545109	0.800	rs1837617	chr8:57417592	C/T	cg17761419	chr8:57350749	NA	-0.53	-7.64	-0.35	1.44e-13	Obesity-related traits;
LUAD	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg21153622	chr11:89784906	NA	-0.34	-6.54	-0.3	1.77e-10	Coronary artery disease;
LUAD	cis	rs7192380	0.737	rs7204433	chr16:69589924	A/G	cg26679644	chr16:69762563	NA	0.42	7.96	0.36	1.58e-14	Sjögren's syndrome;
LUAD	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg04727924	chr7:799746	HEATR2	-0.55	-7.24	-0.33	2.1e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs2046867	0.908	rs62251654	chr3:72816488	C/T	cg25664220	chr3:72788482	NA	-0.7	-12.57	-0.52	5.28e-31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg27535305	chr1:53392650	SCP2	-0.38	-7.96	-0.36	1.6e-14	Monocyte count;
LUAD	cis	rs7584330	0.504	rs11890255	chr2:238434605	A/G	cg14458575	chr2:238380390	NA	0.57	9.06	0.4	4.8e-18	Prostate cancer;
LUAD	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg23602478	chr1:26503979	CNKSR1	0.28	7.03	0.32	8.36e-12	Height;
LUAD	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg16479474	chr6:28041457	NA	0.36	6.84	0.32	2.71e-11	Parkinson's disease;
LUAD	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	9.47	0.42	2.07e-19	Electrocardiographic conduction measures;
LUAD	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg03477792	chr4:77819574	ANKRD56	0.49	7.53	0.34	3.15e-13	Emphysema distribution in smoking;
LUAD	trans	rs4714291	0.802	rs2983143	chr6:40044850	G/T	cg02267698	chr19:7991119	CTXN1	-0.46	-7.23	-0.33	2.35e-12	Strep throat;
LUAD	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg07432352	chr17:45403706	C17orf57	-0.42	-8.08	-0.37	6.74e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs758324	0.812	rs2088718	chr5:131179189	C/T	cg25547332	chr5:131281432	NA	0.42	6.8	0.31	3.54e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg05283184	chr6:79620031	NA	-0.6	-11.96	-0.5	1.4e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg16647868	chr5:131706066	SLC22A5	0.39	6.47	0.3	2.64e-10	Breast cancer;Mosquito bite size;
LUAD	trans	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg01620082	chr3:125678407	NA	-0.9	-8.66	-0.39	1.04e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg24069376	chr3:38537580	EXOG	-0.31	-7.17	-0.33	3.35e-12	Electrocardiographic conduction measures;
LUAD	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg13319975	chr6:146136371	FBXO30	-0.58	-9.84	-0.43	1.04e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8040855	0.579	rs4843029	chr15:85725395	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.46	7.85	0.36	3.35e-14	Bulimia nervosa;
LUAD	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg19302996	chr17:73780495	UNK	-0.46	-7.71	-0.35	8.95e-14	White matter hyperintensity burden;
LUAD	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26314531	chr2:26401878	FAM59B	-0.58	-7.96	-0.36	1.56e-14	Gut microbiome composition (summer);
LUAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00166722	chr3:10149974	C3orf24	0.71	12.36	0.52	3.47e-30	Alzheimer's disease;
LUAD	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-9.62	-0.42	5.91e-20	Life satisfaction;
LUAD	cis	rs78761021	0.867	rs17676067	chr17:9791375	C/T	cg26853458	chr17:9805074	RCVRN	-0.35	-6.63	-0.31	1.03e-10	Type 2 diabetes;
LUAD	cis	rs3750965	0.959	rs3376	chr11:68856680	G/A	cg06818126	chr11:68850279	TPCN2	-0.49	-7.31	-0.33	1.37e-12	Hair color;
LUAD	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg11494091	chr17:61959527	GH2	0.43	8.23	0.37	2.31e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg16797656	chr11:68205561	LRP5	0.48	9.33	0.41	6.11e-19	Total body bone mineral density;
LUAD	trans	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg27411982	chr8:10470053	RP1L1	0.39	6.89	0.32	2.05e-11	Neuroticism;
LUAD	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg26958806	chr6:27640298	NA	0.57	6.36	0.3	5.16e-10	Depression;
LUAD	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg20701182	chr2:24300061	SF3B14	0.64	7.21	0.33	2.68e-12	Lymphocyte counts;
LUAD	trans	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg09872104	chr7:134855509	C7orf49	-0.88	-7.49	-0.34	4.04e-13	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-11.41	-0.48	1.85e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg17264618	chr3:40429014	ENTPD3	0.44	9.28	0.41	9.04e-19	Renal cell carcinoma;
LUAD	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.37	-6.6	-0.31	1.21e-10	Caffeine consumption;
LUAD	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg12908607	chr1:44402522	ARTN	-0.51	-9.79	-0.43	1.58e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg01528321	chr10:82214614	TSPAN14	-0.7	-9.23	-0.41	1.33e-18	Post bronchodilator FEV1;
LUAD	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg20290983	chr6:43655470	MRPS18A	0.88	13.74	0.56	8.88e-36	IgG glycosylation;
LUAD	cis	rs7116495	1.000	rs2511114	chr11:71792147	T/C	cg07596299	chr11:71824057	C11orf51	-0.77	-6.53	-0.3	1.86e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.62	0.31	1.12e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg23625390	chr15:77176239	SCAPER	-0.47	-7.26	-0.33	1.86e-12	Blood metabolite levels;
LUAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-10.75	-0.46	5.43e-24	Lymphocyte counts;
LUAD	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg19163074	chr7:65112434	INTS4L2	0.45	6.75	0.31	4.83e-11	Aortic root size;
LUAD	cis	rs11958404	0.932	rs72818109	chr5:157438340	A/T	cg05962755	chr5:157440814	NA	0.71	9.95	0.44	4.36e-21	IgG glycosylation;
LUAD	cis	rs17433780	1.000	rs17433780	chr1:89474818	C/T	cg09516651	chr1:89888402	LOC400759	-0.46	-8.61	-0.39	1.43e-16	Carotid intima media thickness;
LUAD	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg25173405	chr17:45401733	C17orf57	0.56	9.5	0.42	1.55e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs2018683	1.000	rs160837	chr7:29012732	C/G	cg19402173	chr7:128379420	CALU	-0.65	-11.19	-0.48	1.23e-25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3125734	0.719	rs3852410	chr10:64037563	A/G	cg19640130	chr10:64028056	RTKN2	0.34	7.27	0.33	1.79e-12	Rheumatoid arthritis;
LUAD	cis	rs8192282	0.739	rs11265627	chr1:154496286	A/C	cg16683920	chr1:154474344	TDRD10;SHE	0.41	6.93	0.32	1.57e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7843479	0.930	rs2054713	chr8:21840534	A/G	cg03445287	chr8:21823731	XPO7	-0.46	-8.55	-0.38	2.19e-16	Mean corpuscular volume;
LUAD	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg20673091	chr1:2541236	MMEL1	-0.38	-8.09	-0.37	6.18e-15	Ulcerative colitis;
LUAD	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.39	0.34	8e-13	Tonsillectomy;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13920768	chr9:133557644	PRDM12	-0.61	-7.56	-0.35	2.59e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7903847	0.642	rs11189204	chr10:99164394	C/T	cg20016023	chr10:99160130	RRP12	-0.27	-6.59	-0.31	1.32e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.59	-7.79	-0.35	5.27e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	8.59	0.39	1.67e-16	Bipolar disorder and schizophrenia;
LUAD	trans	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg07817883	chr1:32538562	TMEM39B	1.11	11.79	0.5	6.44e-28	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg10523679	chr1:76189770	ACADM	-0.9	-15.9	-0.61	5.92e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08677398	chr8:58056175	NA	0.54	6.94	0.32	1.52e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11195062	0.766	rs1935465	chr10:112029300	G/A	cg19214408	chr10:111981687	MXI1	-0.4	-6.66	-0.31	8.6e-11	Multiple myeloma;
LUAD	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg25753631	chr6:25732923	NA	-0.37	-6.43	-0.3	3.49e-10	Iron status biomarkers;
LUAD	cis	rs1950626	0.750	rs34228453	chr14:101440321	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.56	0.34	2.6e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg17105886	chr17:28927953	LRRC37B2	0.76	7.49	0.34	4.05e-13	Body mass index;
LUAD	cis	rs4919694	1.000	rs80327774	chr10:104656671	T/C	cg04362960	chr10:104952993	NT5C2	0.74	7.94	0.36	1.84e-14	Arsenic metabolism;
LUAD	cis	rs9457247	0.508	rs6941355	chr6:167506238	A/G	cg07741184	chr6:167504864	NA	0.31	7.05	0.32	7.36e-12	Crohn's disease;
LUAD	cis	rs1215050	0.782	rs6853916	chr4:98653387	C/T	cg17366294	chr4:99064904	C4orf37	-0.45	-7.94	-0.36	1.86e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7582720	1.000	rs72934554	chr2:203987806	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.69	0.43	3.45e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg15448220	chr1:150897856	SETDB1	0.46	7.98	0.36	1.42e-14	Tonsillectomy;
LUAD	cis	rs4588572	0.643	rs11744479	chr5:77729220	T/G	cg11547950	chr5:77652471	NA	-0.78	-12.73	-0.53	1.23e-31	Triglycerides;
LUAD	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08677398	chr8:58056175	NA	0.53	6.93	0.32	1.57e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1784581	0.588	rs6415086	chr6:162418147	C/T	cg17173639	chr6:162384350	PARK2	0.43	7.73	0.35	7.74e-14	Itch intensity from mosquito bite;
LUAD	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg09222892	chr1:25734099	RHCE	-0.48	-8.92	-0.4	1.42e-17	Plateletcrit;Mean corpuscular volume;
LUAD	trans	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-9.67	-0.43	3.94e-20	Brugada syndrome;
LUAD	trans	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg12400702	chr3:12838781	CAND2	0.31	6.43	0.3	3.54e-10	Parkinson's disease;
LUAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.14	-0.44	8.71e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs4683142	0.518	rs6802312	chr3:46025941	T/C	cg11211486	chr3:46033800	FYCO1	-0.4	-6.65	-0.31	9.17e-11	Methadone dose in opioid dependence;
LUAD	cis	rs15676	0.783	rs10988120	chr9:131564695	G/C	cg00228799	chr9:131580591	ENDOG	-0.47	-7.34	-0.34	1.07e-12	Blood metabolite levels;
LUAD	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg01028140	chr2:1542097	TPO	-0.49	-6.81	-0.31	3.38e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs11622475	0.953	rs6576012	chr14:104400159	T/C	cg12183467	chr14:104352244	NA	0.41	7.2	0.33	2.79e-12	Bipolar disorder;
LUAD	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	6.39	0.3	4.33e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs4662945	0.525	rs10174479	chr2:130296287	A/C	cg05962382	chr2:130345044	NA	-0.37	-6.9	-0.32	1.9e-11	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs910187	0.678	rs7352690	chr20:45815352	C/G	cg27589058	chr20:45804311	EYA2	-0.33	-7.6	-0.35	1.97e-13	Migraine;
LUAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	8.99	0.4	8.62e-18	Lymphocyte counts;
LUAD	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg06636551	chr8:101224915	SPAG1	-0.37	-6.67	-0.31	8.11e-11	Atrioventricular conduction;
LUAD	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg10589385	chr1:150898437	SETDB1	0.41	7.73	0.35	7.73e-14	Tonsillectomy;
LUAD	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.12	0.33	4.7e-12	Motion sickness;
LUAD	cis	rs11102986	0.607	rs10776909	chr9:137288746	T/C	cg00753924	chr9:137298813	RXRA	-0.69	-10.04	-0.44	2.12e-21	Intelligence;
LUAD	trans	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg07211511	chr3:129823064	LOC729375	-0.57	-7.54	-0.34	2.93e-13	Blood pressure (smoking interaction);
LUAD	trans	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg01620082	chr3:125678407	NA	-0.72	-7.28	-0.33	1.62e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg26384229	chr12:38710491	ALG10B	0.47	7.56	0.35	2.48e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg04517722	chr19:17905589	B3GNT3	0.46	8.61	0.39	1.41e-16	Tumor biomarkers;
LUAD	cis	rs806215	0.826	rs712699	chr7:127250597	G/A	cg25922125	chr7:127225783	GCC1	0.49	7.1	0.33	5.32e-12	Type 2 diabetes;
LUAD	cis	rs11153730	0.503	rs12212582	chr6:118626480	A/G	cg18833306	chr6:118973337	C6orf204	0.46	8.48	0.38	3.74e-16	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg06547715	chr2:218990976	CXCR2	-0.27	-6.43	-0.3	3.48e-10	Colorectal cancer;
LUAD	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg11766577	chr21:47581405	C21orf56	-0.52	-8.63	-0.39	1.3e-16	Testicular germ cell tumor;
LUAD	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18876405	chr7:65276391	NA	-0.46	-7.41	-0.34	6.92e-13	Aortic root size;
LUAD	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03264133	chr6:25882463	NA	-0.58	-9.5	-0.42	1.61e-19	Blood metabolite levels;
LUAD	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.56	-0.3	1.56e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6076065	0.723	rs6083087	chr20:23341529	C/T	cg11657817	chr20:23433608	CST11	0.47	8.91	0.4	1.5e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs11756438	0.572	rs2798326	chr6:119005226	C/T	cg21191810	chr6:118973309	C6orf204	0.48	9.38	0.41	4.09e-19	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12843872	chr7:90894352	FZD1	-0.43	-6.95	-0.32	1.36e-11	Height;
LUAD	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-6.75	-0.31	4.93e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg16060761	chr17:80687452	NA	0.45	6.84	0.32	2.74e-11	Breast cancer;
LUAD	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.5	-8.35	-0.38	9.63e-16	Electrocardiographic conduction measures;
LUAD	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg02493740	chr2:85810744	VAMP5	-0.53	-9.62	-0.42	5.99e-20	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg14345882	chr6:26364793	BTN3A2	0.7	7.1	0.33	5.18e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8064299	0.597	rs3785539	chr17:72775099	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.4	6.51	0.3	2.19e-10	Monocyte count;
LUAD	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs13112683	0.638	rs2667364	chr4:140782082	C/T	cg02876341	chr4:140783585	MAML3	0.31	6.69	0.31	7.05e-11	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LUAD	cis	rs654950	0.934	rs638859	chr1:42001444	A/G	cg06885757	chr1:42089581	HIVEP3	0.44	9.55	0.42	1.09e-19	Airway imaging phenotypes;
LUAD	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03517284	chr6:25882590	NA	0.59	9.82	0.43	1.25e-20	Blood metabolite levels;
LUAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg02869364	chr7:1081709	C7orf50	-0.36	-6.61	-0.31	1.17e-10	Longevity;Endometriosis;
LUAD	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.66	-0.35	1.25e-13	Monocyte percentage of white cells;
LUAD	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg18230493	chr5:56204884	C5orf35	-0.86	-12.47	-0.52	1.26e-30	Initial pursuit acceleration;
LUAD	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.17	-0.37	3.67e-15	Bipolar disorder;
LUAD	trans	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg22153745	chr1:153894579	GATAD2B	-0.51	-7.36	-0.34	9.95e-13	Total cholesterol levels;
LUAD	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg27490568	chr2:178487706	NA	0.52	8.09	0.37	6.41e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.3	6.43	0.3	3.53e-10	Parkinson's disease;
LUAD	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg06808227	chr14:105710500	BRF1	-0.44	-6.88	-0.32	2.11e-11	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.3	6.42	0.3	3.67e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7932354	0.528	rs4752962	chr11:47141670	C/G	cg19486271	chr11:47235900	DDB2	0.43	6.85	0.32	2.6e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg23172400	chr8:95962367	TP53INP1	-0.35	-8.24	-0.37	2.13e-15	Type 2 diabetes;
LUAD	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg19413350	chr8:57351067	NA	-0.41	-6.49	-0.3	2.43e-10	Obesity-related traits;
LUAD	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg27454412	chr7:1067447	C7orf50	0.48	7.76	0.35	6.64e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3820068	0.705	rs4646091	chr1:15822043	T/C	cg24675056	chr1:15929824	NA	0.41	6.58	0.3	1.39e-10	Systolic blood pressure;
LUAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg13560548	chr3:10150139	C3orf24	0.42	6.89	0.32	2.02e-11	Alzheimer's disease;
LUAD	cis	rs9581857	0.579	rs76657892	chr13:27997604	A/G	cg22138327	chr13:27999177	GTF3A	0.94	11.44	0.49	1.41e-26	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs6445967	0.530	rs4420888	chr3:58392817	C/T	cg13750441	chr3:58318267	PXK	-0.33	-6.81	-0.31	3.43e-11	Platelet count;
LUAD	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg11814155	chr7:99998594	ZCWPW1	0.44	7.49	0.34	4.15e-13	Platelet count;
LUAD	cis	rs698833	0.828	rs786623	chr2:44606171	C/T	cg04920474	chr2:44395004	PPM1B	0.39	7.08	0.33	6.05e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg00750074	chr16:89608354	SPG7	-0.58	-10.02	-0.44	2.41e-21	Multiple myeloma (IgH translocation);
LUAD	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg21782813	chr7:2030301	MAD1L1	0.48	8.33	0.38	1.13e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg26587870	chr6:27730563	NA	-0.59	-6.56	-0.3	1.54e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2797685	1.000	rs2797685	chr1:7879063	C/T	cg04725166	chr1:7887271	PER3	-0.47	-6.88	-0.32	2.21e-11	Crohn's disease;
LUAD	cis	rs13315871	1.000	rs13071688	chr3:58398730	G/A	cg20936604	chr3:58311152	NA	-0.69	-6.9	-0.32	1.86e-11	Cholesterol, total;
LUAD	cis	rs9322817	0.691	rs2499659	chr6:105286124	A/T	cg02098413	chr6:105308735	HACE1	0.41	8.96	0.4	1.06e-17	Thyroid stimulating hormone;
LUAD	cis	rs17152411	0.895	rs7079153	chr10:126587146	C/G	cg07906193	chr10:126599966	NA	0.54	7.58	0.35	2.28e-13	Height;
LUAD	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg02683114	chr2:24398427	C2orf84	0.43	7.16	0.33	3.54e-12	Asthma;
LUAD	cis	rs4474465	0.607	rs4945303	chr11:78283803	A/G	cg19901956	chr11:77921274	USP35	0.46	6.37	0.3	4.85e-10	Alzheimer's disease (survival time);
LUAD	trans	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.39	-0.3	4.45e-10	Aortic root size;
LUAD	cis	rs2742234	0.541	rs1317214	chr10:43733531	C/G	cg15436174	chr10:43711423	RASGEF1A	0.52	8.7	0.39	7.19e-17	Hirschsprung disease;
LUAD	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-6.96	-0.32	1.27e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg04455712	chr21:45112962	RRP1B	0.44	8.96	0.4	1.01e-17	Mean corpuscular volume;
LUAD	cis	rs169797	0.748	rs372769	chr20:31938224	A/C	cg03904042	chr20:32255491	NECAB3;C20orf134	0.49	7.07	0.32	6.61e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.52	-0.3	1.96e-10	Breast cancer;
LUAD	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg27284194	chr4:1044797	NA	0.69	9.91	0.43	5.79e-21	Recombination rate (females);
LUAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg08742575	chr21:47604166	C21orf56	0.63	11.2	0.48	1.09e-25	Testicular germ cell tumor;
LUAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00166722	chr3:10149974	C3orf24	0.72	10.68	0.46	9.55e-24	Alzheimer's disease;
LUAD	cis	rs9581857	0.547	rs9581871	chr13:28085767	G/A	cg22138327	chr13:27999177	GTF3A	0.8	8.6	0.39	1.58e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs4700695	0.614	rs251285	chr5:65211137	A/T	cg21114390	chr5:65439923	SFRS12	0.64	7.98	0.36	1.4e-14	Facial morphology (factor 19);
LUAD	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg06671706	chr8:8559999	CLDN23	0.64	10.93	0.47	1.13e-24	Obesity-related traits;
LUAD	cis	rs12545109	0.959	rs12547974	chr8:57314785	G/T	cg21220214	chr8:57350948	NA	-0.61	-8.62	-0.39	1.36e-16	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg23281280	chr6:28129359	ZNF389	0.46	6.59	0.31	1.29e-10	Depression;
LUAD	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg05340658	chr4:99064831	C4orf37	0.54	9.17	0.41	2.02e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg05535760	chr7:792225	HEATR2	0.84	11.27	0.48	6e-26	Cerebrospinal P-tau181p levels;
LUAD	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg03609598	chr5:56110824	MAP3K1	-0.55	-7.58	-0.35	2.14e-13	Initial pursuit acceleration;
LUAD	cis	rs7731657	0.537	rs1010208	chr5:130325939	T/C	cg08523029	chr5:130500466	HINT1	0.56	7.36	0.34	9.74e-13	Fasting plasma glucose;
LUAD	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg00530320	chr1:46809349	NSUN4	0.52	7.98	0.36	1.43e-14	Menopause (age at onset);
LUAD	cis	rs9462027	0.628	rs2296360	chr6:34803558	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.68	-0.39	8.66e-17	Systemic lupus erythematosus;
LUAD	cis	rs2455826	0.520	rs2455839	chr3:15760462	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.66	-0.31	8.77e-11	Inflammatory skin disease;
LUAD	cis	rs8077889	0.956	rs4793025	chr17:41841621	T/C	cg26893861	chr17:41843967	DUSP3	0.95	14.54	0.58	3.77e-39	Triglycerides;
LUAD	cis	rs2067615	0.579	rs10507214	chr12:107194461	G/A	cg15890332	chr12:107067104	RFX4	0.39	8.42	0.38	5.76e-16	Heart rate;
LUAD	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg02466173	chr16:30829666	NA	-0.85	-17.44	-0.65	9.92e-52	Dementia with Lewy bodies;
LUAD	cis	rs123509	0.687	rs73077208	chr3:42835205	G/A	cg10144569	chr3:42726640	KBTBD5	-0.48	-7.19	-0.33	3.04e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg03948781	chr1:205179583	DSTYK	0.33	6.45	0.3	3.09e-10	Red blood cell count;
LUAD	cis	rs713587	0.563	rs2384057	chr2:25100167	C/G	cg04586622	chr2:25135609	ADCY3	0.37	8.41	0.38	6.45e-16	Body mass index in non-asthmatics;
LUAD	cis	rs9400271	0.527	rs9400274	chr6:109639876	G/A	cg21918786	chr6:109611834	NA	0.41	6.84	0.32	2.74e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs13095912	0.638	rs6791369	chr3:185289989	C/A	cg11274856	chr3:185301563	NA	0.48	8.84	0.39	2.62e-17	Systolic blood pressure;
LUAD	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg16479474	chr6:28041457	NA	0.37	6.45	0.3	3.12e-10	Parkinson's disease;
LUAD	trans	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.28	0.48	5.39e-26	Mean corpuscular volume;
LUAD	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg15128208	chr22:42549153	NA	0.43	6.73	0.31	5.5e-11	Birth weight;
LUAD	cis	rs68170813	0.559	rs78079372	chr7:106934548	T/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.48	-0.45	5.22e-23	Coronary artery disease;
LUAD	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg01689657	chr7:91764605	CYP51A1	0.36	8.95	0.4	1.15e-17	Breast cancer;
LUAD	cis	rs41311933	0.706	rs72760212	chr9:123851778	A/G	cg13567360	chr9:123745713	C5	-0.71	-8.19	-0.37	3.07e-15	Coronary artery disease;
LUAD	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1595825	0.891	rs57340905	chr2:198565823	C/T	cg00982548	chr2:198649783	BOLL	-0.61	-8.55	-0.38	2.19e-16	Ulcerative colitis;
LUAD	cis	rs6901004	0.570	rs783084	chr6:111477887	T/C	cg15721981	chr6:111408429	SLC16A10	0.57	8.89	0.4	1.81e-17	Blood metabolite levels;
LUAD	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg17633681	chr16:88106987	BANP	0.4	6.94	0.32	1.51e-11	Menopause (age at onset);
LUAD	cis	rs2282300	0.739	rs1717775	chr11:30350254	T/G	cg06241208	chr11:30344200	C11orf46	-0.54	-6.94	-0.32	1.49e-11	Morning vs. evening chronotype;
LUAD	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg15147215	chr3:52552868	STAB1	-0.4	-7.24	-0.33	2.2e-12	Bipolar disorder;
LUAD	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg06108461	chr20:60628389	TAF4	-1.12	-20.44	-0.7	4.17e-65	Body mass index;
LUAD	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg06618935	chr21:46677482	NA	-0.46	-9.34	-0.41	5.35e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7095607	0.704	rs34869044	chr10:69953763	C/T	cg18986048	chr10:69913749	MYPN	0.42	7.42	0.34	6.49e-13	Lung function (FVC);
LUAD	cis	rs17021463	0.872	rs11097417	chr4:95268071	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.15	-0.33	3.77e-12	Testicular germ cell tumor;
LUAD	cis	rs6594713	0.642	rs13171630	chr5:112837037	C/T	cg12552261	chr5:112820674	MCC	0.53	7.38	0.34	8.32e-13	Brain cytoarchitecture;
LUAD	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.27	-0.33	1.77e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1403694	0.515	rs1648722	chr3:186448989	C/T	cg12454167	chr3:186435060	KNG1	0.41	8.55	0.38	2.21e-16	Blood protein levels;
LUAD	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06544989	chr22:39130855	UNC84B	0.44	8.88	0.4	1.86e-17	Menopause (age at onset);
LUAD	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.2	-37.91	-0.88	4.11e-138	Myeloid white cell count;
LUAD	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg03806693	chr22:41940476	POLR3H	0.54	8.0	0.36	1.23e-14	Vitiligo;
LUAD	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg13698168	chr13:111522651	C13orf29	-0.44	-6.6	-0.31	1.26e-10	Sitting height ratio;
LUAD	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg17971929	chr21:40555470	PSMG1	0.55	8.7	0.39	7.3e-17	Cognitive function;
LUAD	cis	rs6960043	0.905	rs10264723	chr7:15054370	T/C	cg19272540	chr7:15055459	NA	0.36	8.15	0.37	4.22e-15	Type 2 diabetes;
LUAD	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg06784218	chr1:46089804	CCDC17	0.59	13.28	0.54	7.08e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10802521	chr3:52805072	NEK4	0.54	9.72	0.43	2.79e-20	Bipolar disorder;
LUAD	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg00631329	chr6:26305371	NA	-0.68	-13.21	-0.54	1.41e-33	Educational attainment;
LUAD	cis	rs35740288	0.770	rs12898597	chr15:86189919	T/C	cg13263323	chr15:86062960	AKAP13	-0.44	-7.1	-0.33	5.14e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg04455712	chr21:45112962	RRP1B	0.48	9.41	0.42	3.28e-19	Mean corpuscular volume;
LUAD	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.5	0.49	8.44e-27	Mean corpuscular volume;
LUAD	cis	rs9462027	0.628	rs9462006	chr6:34710327	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.02	-0.4	6.62e-18	Systemic lupus erythematosus;
LUAD	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg21153622	chr11:89784906	NA	-0.33	-6.56	-0.3	1.61e-10	Coronary artery disease;
LUAD	cis	rs7089973	0.872	rs7075888	chr10:116627117	C/T	cg25233709	chr10:116636983	FAM160B1	0.39	7.56	0.35	2.48e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs300774	0.925	rs300721	chr2:134436	A/T	cg21211680	chr2:198530	NA	-0.47	-7.38	-0.34	8.37e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg11301795	chr4:187892539	NA	-0.76	-15.36	-0.6	1.28e-42	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg05709478	chr1:6581295	PLEKHG5	0.57	7.49	0.34	3.99e-13	Body mass index;
LUAD	cis	rs57920188	0.640	rs4378174	chr1:4080885	C/T	cg10510935	chr1:4059661	NA	0.47	7.27	0.33	1.76e-12	Interleukin-17 levels;
LUAD	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg16205897	chr5:131564050	P4HA2	-0.46	-10.79	-0.46	3.87e-24	Blood metabolite levels;
LUAD	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg07741184	chr6:167504864	NA	-0.3	-7.21	-0.33	2.62e-12	Crohn's disease;
LUAD	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-7.81	-0.36	4.42e-14	Blood metabolite levels;
LUAD	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg21028142	chr17:79581711	NPLOC4	0.37	7.6	0.35	1.91e-13	Eye color traits;
LUAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg25703541	chr22:24373054	LOC391322	-0.86	-15.81	-0.61	1.45e-44	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs11039798	1.000	rs7131020	chr11:48642132	A/G	cg02254774	chr11:50257496	LOC441601	0.54	6.69	0.31	7e-11	Axial length;
LUAD	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11644478	chr21:40555479	PSMG1	-0.54	-8.69	-0.39	7.78e-17	Cognitive function;
LUAD	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg17509989	chr5:176798049	RGS14	0.58	10.24	0.45	3.84e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg25894440	chr7:65020034	NA	-0.64	-6.89	-0.32	2.03e-11	Diabetic kidney disease;
LUAD	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg03806693	chr22:41940476	POLR3H	0.69	9.73	0.43	2.44e-20	Vitiligo;
LUAD	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.51	-0.34	3.62e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.85	-15.25	-0.6	3.7e-42	Menarche (age at onset);
LUAD	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg03709012	chr19:19516395	GATAD2A	0.52	6.94	0.32	1.5e-11	Nonalcoholic fatty liver disease;
LUAD	cis	rs2073300	1.000	rs78000067	chr20:23439507	A/G	cg09953122	chr20:23471693	CST8	-0.65	-6.37	-0.3	4.9e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg08885076	chr2:99613938	TSGA10	0.36	6.53	0.3	1.85e-10	Chronic sinus infection;
LUAD	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25427524	chr10:38739819	LOC399744	-0.74	-13.14	-0.54	2.5e-33	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg23950597	chr19:37808831	NA	-0.61	-7.55	-0.34	2.74e-13	Coronary artery calcification;
LUAD	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg17178900	chr1:205818956	PM20D1	0.84	19.25	0.68	9.65e-60	Menarche (age at onset);
LUAD	cis	rs28374715	0.532	rs11854820	chr15:41676526	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.12	-23.63	-0.75	2.58e-79	Ulcerative colitis;
LUAD	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg12193833	chr17:30244370	NA	-0.58	-6.95	-0.32	1.35e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.96	0.32	1.34e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1598856	1.000	rs1598856	chr4:103446115	A/G	cg07973026	chr4:103553119	MANBA	0.4	6.56	0.3	1.57e-10	Primary biliary cholangitis;
LUAD	trans	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg18187862	chr3:45730750	SACM1L	-0.55	-7.87	-0.36	2.97e-14	Primary sclerosing cholangitis;
LUAD	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg13736514	chr6:26305472	NA	-0.69	-12.82	-0.53	5.18e-32	Educational attainment;
LUAD	cis	rs11031096	0.502	rs4910875	chr11:4047855	C/G	cg18678763	chr11:4115507	RRM1	-0.46	-7.55	-0.34	2.7e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg00933542	chr6:150070202	PCMT1	0.44	9.6	0.42	6.92e-20	Lung cancer;
LUAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14893161	chr1:205819251	PM20D1	0.95	23.31	0.75	6.76e-78	Menarche (age at onset);
LUAD	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg00745463	chr17:30367425	LRRC37B	0.62	7.98	0.36	1.38e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs4853036	1.000	rs3732269	chr2:70046255	G/C	cg02498382	chr2:70120550	SNRNP27	-0.51	-8.15	-0.37	4.14e-15	Colorectal or endometrial cancer;
LUAD	cis	rs727505	1.000	rs28702851	chr7:124442991	G/A	cg23710748	chr7:124431027	NA	-0.49	-9.9	-0.43	6.2e-21	Lewy body disease;
LUAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg18621852	chr3:10150065	C3orf24	0.42	7.46	0.34	5.08e-13	Alzheimer's disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03072229	chr16:8715850	C16orf68	-0.4	-6.47	-0.3	2.78e-10	Cancer;
LUAD	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg19773385	chr1:10388646	KIF1B	-0.42	-6.96	-0.32	1.27e-11	Hepatocellular carcinoma;
LUAD	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11644478	chr21:40555479	PSMG1	0.66	10.98	0.47	7.67e-25	Cognitive function;
LUAD	cis	rs612683	0.658	rs12407689	chr1:100999585	C/G	cg09408571	chr1:101003634	GPR88	0.33	6.51	0.3	2.08e-10	Breast cancer;
LUAD	cis	rs727505	0.954	rs58618031	chr7:124583896	T/C	cg23710748	chr7:124431027	NA	-0.41	-8.6	-0.39	1.6e-16	Lewy body disease;
LUAD	trans	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg01620082	chr3:125678407	NA	-0.64	-7.68	-0.35	1.15e-13	Depression;
LUAD	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.43	-0.34	5.94e-13	Type 2 diabetes;
LUAD	cis	rs6484504	0.600	rs942272	chr11:31364368	C/T	cg06552810	chr11:31128660	NA	0.32	6.37	0.3	4.81e-10	Red blood cell count;
LUAD	cis	rs68170813	0.559	rs75672288	chr7:107031549	G/C	cg23024343	chr7:107201750	COG5	0.52	7.33	0.34	1.16e-12	Coronary artery disease;
LUAD	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg18827107	chr12:86230957	RASSF9	-0.68	-12.46	-0.52	1.37e-30	Major depressive disorder;
LUAD	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.4	7.06	0.32	6.78e-12	Systemic lupus erythematosus;
LUAD	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg21427119	chr20:30132790	HM13	-0.59	-8.73	-0.39	5.84e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg04756594	chr16:24857601	SLC5A11	0.73	12.67	0.52	2.05e-31	Intelligence (multi-trait analysis);
LUAD	cis	rs117623576	0.941	rs211409	chr10:32393213	T/C	cg03047570	chr10:32398778	NA	0.91	11.24	0.48	8.05e-26	Anti-saccade response;
LUAD	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.59	7.39	0.34	7.83e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg17173187	chr15:85201210	NMB	0.41	6.61	0.31	1.14e-10	Schizophrenia;
LUAD	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg01206211	chr2:36825736	FEZ2	-0.58	-11.96	-0.5	1.4e-28	Height;
LUAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg04025307	chr7:1156635	C7orf50	0.65	7.38	0.34	8.34e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.3	-0.37	1.38e-15	Height;
LUAD	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg17063962	chr7:91808500	NA	0.68	12.35	0.51	4.05e-30	Breast cancer;
LUAD	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg12193833	chr17:30244370	NA	-0.55	-7.14	-0.33	4.2e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.69	-11.92	-0.5	1.92e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg09537434	chr19:41945824	ATP5SL	-0.54	-8.5	-0.38	3.34e-16	Height;
LUAD	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg21385522	chr1:16154831	NA	-1.06	-22.59	-0.74	1.08e-74	Dilated cardiomyopathy;
LUAD	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg05754148	chr16:3507555	NAT15	0.81	10.11	0.44	1.11e-21	Tuberculosis;
LUAD	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg08085267	chr17:45401833	C17orf57	0.65	11.82	0.5	4.81e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs75804782	0.641	rs3769125	chr2:239349562	A/G	cg01134436	chr17:81009848	B3GNTL1	0.73	8.02	0.36	1.02e-14	Morning vs. evening chronotype;Chronotype;
LUAD	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg05926928	chr17:57297772	GDPD1	1.39	17.2	0.64	1.21e-50	Opioid sensitivity;
LUAD	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg12011299	chr4:100065546	ADH4	0.69	12.43	0.52	1.8e-30	Alcohol dependence;
LUAD	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.42	0.52	2.08e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.29	-0.33	1.5e-12	Lung cancer;
LUAD	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15541040	chr2:3486749	NA	-0.43	-7.44	-0.34	5.56e-13	Neurofibrillary tangles;
LUAD	cis	rs10465746	0.935	rs6687372	chr1:84447634	C/T	cg10977910	chr1:84465055	TTLL7	0.52	8.49	0.38	3.56e-16	Obesity-related traits;
LUAD	trans	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg07817883	chr1:32538562	TMEM39B	-0.51	-6.87	-0.32	2.29e-11	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg15997130	chr1:24165203	NA	0.54	9.28	0.41	9.02e-19	Immature fraction of reticulocytes;
LUAD	cis	rs4711350	0.954	rs943464	chr6:33731469	A/G	cg18005901	chr6:33739558	LEMD2	0.5	7.5	0.34	3.79e-13	Schizophrenia;
LUAD	cis	rs12024301	0.557	rs16861243	chr1:183589382	A/G	cg19264170	chr1:183622470	APOBEC4;RGL1	-0.68	-7.08	-0.33	5.88e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg18490616	chr2:88469792	THNSL2	0.8	8.0	0.36	1.17e-14	Plasma clusterin levels;
LUAD	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg12011299	chr4:100065546	ADH4	-0.72	-13.46	-0.55	1.22e-34	Alcohol dependence;
LUAD	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-6.52	-0.3	2.06e-10	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs10979	1.000	rs9390112	chr6:143896147	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.22	-0.44	4.82e-22	Hypospadias;
LUAD	cis	rs907683	0.583	rs10932803	chr2:220292739	A/T	cg15015639	chr2:220282977	DES	0.48	8.98	0.4	9.01e-18	Resting heart rate;
LUAD	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg14779329	chr11:130786720	SNX19	0.42	7.54	0.34	2.81e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24333813	chr2:71296102	NAGK	-0.4	-6.37	-0.3	4.8e-10	Cancer;
LUAD	cis	rs1957429	0.901	rs1467571	chr14:65347682	C/T	cg23373153	chr14:65346875	NA	0.55	6.45	0.3	2.99e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs344364	0.602	rs8044343	chr16:1881145	G/C	cg07386859	chr16:1872102	HAGH	0.52	7.86	0.36	3.3e-14	Glomerular filtration rate in chronic kidney disease;
LUAD	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg07870213	chr5:140052090	DND1	1.03	14.5	0.58	5.71e-39	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg20701182	chr2:24300061	SF3B14	0.56	6.79	0.31	3.82e-11	Lymphocyte counts;
LUAD	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg02734326	chr4:10020555	SLC2A9	0.5	8.62	0.39	1.32e-16	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9287719	0.578	rs10168852	chr2:10746323	C/A	cg02196655	chr2:10830764	NOL10	-0.38	-6.73	-0.31	5.61e-11	Prostate cancer;
LUAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg08888203	chr3:10149979	C3orf24	0.73	11.21	0.48	1.01e-25	Alzheimer's disease;
LUAD	cis	rs7705042	0.828	rs249638	chr5:141530696	G/C	cg23435118	chr5:141488016	NDFIP1	-0.41	-7.01	-0.32	9.48e-12	Asthma;
LUAD	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg18180107	chr4:99064573	C4orf37	0.46	7.22	0.33	2.39e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2067615	0.507	rs10746064	chr12:107086245	G/T	cg15890332	chr12:107067104	RFX4	0.41	8.59	0.39	1.63e-16	Heart rate;
LUAD	trans	rs7395662	0.963	rs6485889	chr11:48608785	C/T	cg00717180	chr2:96193071	NA	-0.38	-7.14	-0.33	4e-12	HDL cholesterol;
LUAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg22907277	chr7:1156413	C7orf50	0.46	7.87	0.36	2.96e-14	Longevity;Endometriosis;
LUAD	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg04546413	chr19:29218101	NA	-0.5	-6.41	-0.3	3.96e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs35849525	0.633	rs62263602	chr3:50152491	C/T	cg14019146	chr3:50243930	SLC38A3	-0.41	-6.68	-0.31	7.67e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.66	-0.35	1.24e-13	Reticulocyte count;
LUAD	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg26677194	chr12:130822605	PIWIL1	0.56	9.18	0.41	1.91e-18	Menopause (age at onset);
LUAD	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg10589385	chr1:150898437	SETDB1	0.43	8.23	0.37	2.32e-15	Melanoma;
LUAD	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg06640241	chr16:89574553	SPG7	-0.66	-11.78	-0.5	6.91e-28	Multiple myeloma (IgH translocation);
LUAD	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg09537434	chr19:41945824	ATP5SL	-0.44	-6.89	-0.32	2.08e-11	Height;
LUAD	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg00383909	chr3:49044727	WDR6	0.71	7.46	0.34	4.9e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs72901758	0.700	rs56245572	chr17:76248064	G/C	cg26068271	chr17:76253126	NA	0.42	7.21	0.33	2.58e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg26818010	chr10:134567672	INPP5A	-0.98	-15.96	-0.61	3.12e-45	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg27494647	chr7:150038898	RARRES2	0.54	9.4	0.42	3.61e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.61	0.31	1.14e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs1829883	1.000	rs1523381	chr5:98773754	T/C	cg08333243	chr5:99726346	NA	-0.36	-6.86	-0.32	2.42e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg09509183	chr1:209979624	IRF6	0.37	6.52	0.3	1.96e-10	Monobrow;
LUAD	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg26384229	chr12:38710491	ALG10B	0.51	8.34	0.38	1.08e-15	Heart rate;
LUAD	cis	rs807669	0.807	rs698422	chr22:19205826	A/T	cg02655711	chr22:19163373	SLC25A1	0.7	14.94	0.59	7.99e-41	Metabolite levels;
LUAD	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg05966235	chr16:28915196	ATP2A1	0.47	7.71	0.35	8.82e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs35995292	0.534	rs2392604	chr7:38918012	C/T	cg19327137	chr7:38886074	VPS41	0.76	15.92	0.61	4.74e-45	Subjective well-being (multi-trait analysis);
LUAD	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg15181151	chr6:150070149	PCMT1	0.41	8.31	0.37	1.27e-15	Lung cancer;
LUAD	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg22676075	chr6:135203613	NA	0.41	7.69	0.35	1.08e-13	Red blood cell count;
LUAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg08219700	chr8:58056026	NA	0.42	6.39	0.3	4.45e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg13334819	chr7:99746414	C7orf59	-0.66	-10.54	-0.46	3.19e-23	Coronary artery disease;
LUAD	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-9.1	-0.4	3.59e-18	Hemoglobin concentration;
LUAD	cis	rs7937890	0.559	rs6486197	chr11:14529874	C/G	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.15e-12	Mitochondrial DNA levels;
LUAD	cis	rs12618769	0.597	rs4851136	chr2:99060873	A/T	cg10123293	chr2:99228465	UNC50	0.46	8.11	0.37	5.48e-15	Bipolar disorder;
LUAD	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg00431813	chr7:1051703	C7orf50	-0.53	-10.45	-0.45	6.67e-23	Longevity;Endometriosis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17533455	chr5:130599827	CDC42SE2	-0.53	-6.59	-0.31	1.33e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg19912559	chr1:40204330	PPIE	0.57	9.94	0.44	4.64e-21	Blood protein levels;
LUAD	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg11247378	chr22:39784982	NA	0.64	11.77	0.5	7.4e-28	IgG glycosylation;
LUAD	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg00717180	chr2:96193071	NA	-0.44	-8.38	-0.38	8.02e-16	Coronary artery disease;
LUAD	cis	rs4481887	0.893	rs10888337	chr1:248428227	A/G	cg00666640	chr1:248458726	OR2T12	-0.32	-8.0	-0.36	1.18e-14	Common traits (Other);
LUAD	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-7.45	-0.34	5.21e-13	Morning vs. evening chronotype;
LUAD	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg13334819	chr7:99746414	C7orf59	0.65	10.36	0.45	1.43e-22	Coronary artery disease;
LUAD	cis	rs7737355	0.947	rs13174006	chr5:130963473	A/G	cg06307176	chr5:131281290	NA	0.5	7.63	0.35	1.5700000000000001e-13	Life satisfaction;
LUAD	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-9.4	-0.42	3.35e-19	Height;
LUAD	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.19	-0.33	2.93e-12	Bipolar disorder;
LUAD	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06022373	chr22:39101656	GTPBP1	0.48	8.03	0.36	9.45e-15	Menopause (age at onset);
LUAD	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.1	-0.4	3.7e-18	Alcohol dependence;
LUAD	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg20607798	chr8:58055168	NA	0.73	9.15	0.41	2.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6987853	0.966	rs2974359	chr8:42434194	T/C	cg09913449	chr8:42400586	C8orf40	0.42	7.7	0.35	9.99e-14	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	10.07	0.44	1.66e-21	Axial length;
LUAD	cis	rs11771526	0.892	rs62457541	chr7:32372566	G/A	cg27511599	chr7:32358540	NA	0.61	7.06	0.32	6.68e-12	Body mass index;
LUAD	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.88	-9.34	-0.41	5.53e-19	Initial pursuit acceleration;
LUAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.9	0.47	1.51e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg22823121	chr1:150693482	HORMAD1	-0.45	-8.85	-0.4	2.41e-17	Melanoma;
LUAD	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg18876405	chr7:65276391	NA	0.62	10.91	0.47	1.33e-24	Calcium levels;
LUAD	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg18755752	chr8:142205143	DENND3	-0.8	-16.28	-0.62	1.3e-46	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7241530	0.662	rs4799261	chr18:75889293	G/A	cg14642773	chr18:75888474	NA	0.32	6.53	0.3	1.94e-10	Educational attainment (years of education);
LUAD	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg18230493	chr5:56204884	C5orf35	-0.44	-7.38	-0.34	8.23e-13	Coronary artery disease;
LUAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg04352962	chr1:209979756	IRF6	0.52	7.36	0.34	9.51e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs6543140	0.964	rs4851589	chr2:103077145	A/G	cg04239558	chr2:103089729	SLC9A4	0.34	7.0	0.32	9.99e-12	Blood protein levels;
LUAD	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	6.89	0.32	2.07e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg26554054	chr8:600488	NA	-0.79	-6.78	-0.31	4.06e-11	IgG glycosylation;
LUAD	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.38	6.55	0.3	1.71e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs9814567	0.727	rs4543053	chr3:134351724	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-12.52	-0.52	8.49e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.51e-10	Prudent dietary pattern;
LUAD	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.44	-7.17	-0.33	3.42e-12	Tonsillectomy;
LUAD	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.43	-7.61	-0.35	1.75e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg11941060	chr3:133502564	NA	-0.65	-11.58	-0.49	3.87e-27	Iron status biomarkers;
LUAD	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg17366294	chr4:99064904	C4orf37	0.65	10.31	0.45	2.13e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg12310025	chr6:25882481	NA	0.59	9.81	0.43	1.35e-20	Blood metabolite levels;
LUAD	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg04842962	chr6:43655489	MRPS18A	1.06	27.46	0.8	4.78e-96	IgG glycosylation;
LUAD	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.49	-0.34	4.19e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg20291162	chr17:40259547	DHX58	-0.7	-10.99	-0.47	6.82e-25	Fibrinogen levels;
LUAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14893161	chr1:205819251	PM20D1	0.94	23.24	0.75	1.32e-77	Menarche (age at onset);
LUAD	cis	rs57994353	0.897	rs67220311	chr9:139376668	T/C	cg13856295	chr9:139396418	NOTCH1	-0.42	-6.62	-0.31	1.08e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs7932354	0.502	rs57323109	chr11:47193367	T/G	cg19486271	chr11:47235900	DDB2	0.43	6.78	0.31	4.02e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg00280220	chr17:61926910	NA	0.36	6.98	0.32	1.12e-11	Prudent dietary pattern;
LUAD	cis	rs12681287	0.640	rs7846090	chr8:87467724	A/T	cg00550725	chr8:87521180	FAM82B	0.44	6.46	0.3	2.93e-10	Caudate activity during reward;
LUAD	cis	rs17401966	0.798	rs12408435	chr1:10323342	T/A	cg15208524	chr1:10270712	KIF1B	0.56	8.37	0.38	8.64e-16	Hepatocellular carcinoma;
LUAD	cis	rs1564271	0.553	rs1616702	chr10:26989529	G/C	cg13837822	chr10:26931731	LOC731789	0.44	9.0	0.4	8e-18	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUAD	cis	rs12530845	0.943	rs11984203	chr7:135325947	C/T	cg23117316	chr7:135346802	PL-5283	0.48	8.66	0.39	9.88e-17	Red blood cell traits;
LUAD	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg23985595	chr17:80112537	CCDC57	0.44	7.86	0.36	3.25e-14	Life satisfaction;
LUAD	cis	rs4523957	0.819	rs12450354	chr17:2159982	C/T	cg16513277	chr17:2031491	SMG6	0.76	14.65	0.58	1.29e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs600626	0.636	rs11236514	chr11:75451343	A/C	cg24262691	chr11:75473276	NA	-0.5	-6.6	-0.31	1.21e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg19413350	chr8:57351067	NA	-0.42	-6.7	-0.31	6.48e-11	Obesity-related traits;
LUAD	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg18105134	chr13:113819100	PROZ	0.91	16.43	0.62	2.83e-47	Platelet distribution width;
LUAD	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	17.05	0.64	5.29e-50	Homoarginine levels;
LUAD	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg26924012	chr15:45694286	SPATA5L1	0.85	14.61	0.58	2.08e-39	Homoarginine levels;
LUAD	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg03049243	chr19:54619116	PRPF31;TFPT	0.4	6.58	0.3	1.37e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg14779329	chr11:130786720	SNX19	0.39	6.84	0.32	2.74e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9896933	0.614	rs3785511	chr17:80886316	G/T	cg20578329	chr17:80767326	TBCD	0.57	6.82	0.31	3.16e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg13047869	chr3:10149882	C3orf24	0.64	9.6	0.42	6.98e-20	Alzheimer's disease;
LUAD	cis	rs7584330	0.554	rs6744807	chr2:238424684	A/G	cg14458575	chr2:238380390	NA	0.53	8.6	0.39	1.58e-16	Prostate cancer;
LUAD	cis	rs8099014	1.000	rs4940698	chr18:56108914	G/A	cg12907477	chr18:56117327	MIR122	0.39	6.71	0.31	6.24e-11	Platelet count;
LUAD	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.05	-13.82	-0.56	3.99e-36	Schizophrenia;
LUAD	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.46	0.3	2.97e-10	Parkinson's disease;
LUAD	trans	rs8073060	0.586	rs4796101	chr17:33998593	C/T	cg19694781	chr19:47549865	TMEM160	-1.23	-19.4	-0.69	1.92e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs10751667	0.677	rs11246386	chr11:1044938	C/T	cg06064525	chr11:970664	AP2A2	0.44	7.18	0.33	3.08e-12	Alzheimer's disease (late onset);
LUAD	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18876405	chr7:65276391	NA	-0.44	-6.91	-0.32	1.83e-11	Aortic root size;
LUAD	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs17362650	1.000	rs13032363	chr2:9620740	T/C	cg12832956	chr2:9616023	IAH1	-0.48	-7.53	-0.34	3.11e-13	Alcohol dependence (age at onset);
LUAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.91e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg08999081	chr20:33150536	PIGU	0.63	14.12	0.57	2.27e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.4	7.87	0.36	2.97e-14	Depression;
LUAD	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg02527881	chr3:46936655	PTH1R	-0.69	-15.98	-0.61	2.73e-45	Birth weight;
LUAD	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg05368731	chr17:41323189	NBR1	0.98	20.99	0.71	1.56e-67	Menopause (age at onset);
LUAD	cis	rs10992471	0.603	rs1121978	chr9:95140351	T/G	cg14631576	chr9:95140430	CENPP	-0.56	-11.5	-0.49	8.43e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg03609598	chr5:56110824	MAP3K1	-0.47	-7.37	-0.34	8.94e-13	Coronary artery disease;
LUAD	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg10978503	chr1:24200527	CNR2	-0.47	-8.76	-0.39	4.82e-17	Immature fraction of reticulocytes;
LUAD	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg26384229	chr12:38710491	ALG10B	-0.43	-7.2	-0.33	2.71e-12	Morning vs. evening chronotype;
LUAD	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg00020340	chr7:910388	UNC84A	0.66	7.12	0.33	4.72e-12	Initial pursuit acceleration;
LUAD	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg25358565	chr5:93447407	FAM172A	0.57	6.86	0.32	2.44e-11	Diabetic retinopathy;
LUAD	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg03433033	chr1:76189801	ACADM	0.9	18.08	0.66	1.48e-54	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6076065	0.723	rs2251145	chr20:23399998	G/A	cg11657817	chr20:23433608	CST11	0.46	8.51	0.38	3.06e-16	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg18827107	chr12:86230957	RASSF9	-0.62	-10.97	-0.47	8.2e-25	Major depressive disorder;
LUAD	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg06221963	chr1:154839813	KCNN3	-0.82	-18.62	-0.67	5.79e-57	Prostate cancer;
LUAD	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.71	-0.55	1.2e-35	Alcohol dependence;
LUAD	trans	rs7395662	0.553	rs11040122	chr11:48901038	A/G	cg15704280	chr7:45808275	SEPT13	0.43	6.88	0.32	2.17e-11	HDL cholesterol;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg27196102	chr16:23464713	COG7	-0.39	-6.6	-0.31	1.24e-10	Cancer;
LUAD	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.5	-0.3	2.21e-10	Prostate cancer;
LUAD	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg13870426	chr17:30244630	NA	-0.57	-6.63	-0.31	1.05e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg20019720	chr6:154832845	CNKSR3	0.65	12.84	0.53	4.41e-32	Lipoprotein (a) levels;
LUAD	cis	rs7582720	1.000	rs72936323	chr2:204050474	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.58	0.42	8.55e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg16325326	chr1:53192061	ZYG11B	-0.7	-12.82	-0.53	4.93e-32	Monocyte count;
LUAD	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg19610905	chr11:61596333	FADS2	-0.66	-11.28	-0.48	5.78e-26	LDL cholesterol;
LUAD	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg15226275	chr6:116381976	FRK	0.23	7.64	0.35	1.44e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs11893307	0.509	rs11895262	chr2:191533862	C/T	cg27211696	chr2:191398769	TMEM194B	-0.43	-6.5	-0.3	2.31e-10	Mean platelet volume;
LUAD	cis	rs10170310	1.000	rs12691947	chr2:139264471	A/G	cg10095539	chr2:139258744	SPOPL	0.32	6.43	0.3	3.36e-10	Response to antipsychotic treatment;
LUAD	cis	rs68170813	0.559	rs6971675	chr7:106833797	G/A	cg02696742	chr7:106810147	HBP1	-0.8	-11.12	-0.48	2.18e-25	Coronary artery disease;
LUAD	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg22189786	chr22:42395067	WBP2NL	0.45	6.48	0.3	2.49e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs4713675	0.565	rs4711341	chr6:33690797	A/G	cg13859433	chr6:33739653	LEMD2	-0.3	-7.15	-0.33	3.93e-12	Plateletcrit;
LUAD	cis	rs2274273	0.870	rs10134339	chr14:55814380	T/C	cg04306507	chr14:55594613	LGALS3	0.41	8.68	0.39	8.93e-17	Protein biomarker;
LUAD	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs864537	0.622	rs1214598	chr1:167426424	C/T	cg22356347	chr1:167427500	CD247	-0.49	-9.58	-0.42	8.64e-20	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs7737355	0.812	rs11746227	chr5:130961236	C/T	cg25547332	chr5:131281432	NA	0.41	6.45	0.3	3e-10	Life satisfaction;
LUAD	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg12884169	chr21:40033163	ERG	-0.48	-10.4	-0.45	1.06e-22	Coronary artery disease;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg05772935	chr16:1790400	MAPK8IP3	0.42	6.67	0.31	8.13e-11	Vertical cup-disc ratio;
LUAD	cis	rs1443512	0.947	rs1822438	chr12:54342326	A/C	cg17410650	chr12:54324560	NA	-0.45	-8.33	-0.38	1.12e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg27446573	chr6:127587934	RNF146	0.44	6.62	0.31	1.06e-10	Breast cancer;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg23260799	chr11:451101	PTDSS2	0.4	6.36	0.3	5.09e-10	Bilirubin levels;
LUAD	trans	rs8002861	0.846	rs12869355	chr13:44478193	A/C	cg17145862	chr1:211918768	LPGAT1	0.66	13.79	0.56	5.59e-36	Leprosy;
LUAD	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg27211696	chr2:191398769	TMEM194B	0.75	15.71	0.61	3.83e-44	Pulse pressure;
LUAD	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.63	0.31	1.05e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.866	rs4795529	chr17:28443549	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.63	0.42	5.71e-20	Coffee consumption (cups per day);
LUAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg04025307	chr7:1156635	C7orf50	0.66	7.49	0.34	4.17e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.84	0.36	3.79e-14	Lung cancer;
LUAD	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg06108461	chr20:60628389	TAF4	-0.77	-13.43	-0.55	1.67e-34	Body mass index;
LUAD	cis	rs7584330	0.554	rs113271883	chr2:238425594	A/G	cg14458575	chr2:238380390	NA	0.61	9.83	0.43	1.1e-20	Prostate cancer;
LUAD	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg01200585	chr1:228362443	C1orf69	-0.41	-7.52	-0.34	3.29e-13	Diastolic blood pressure;
LUAD	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.91	-0.32	1.74e-11	Lung cancer;
LUAD	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg06618935	chr21:46677482	NA	-0.5	-10.01	-0.44	2.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg26513180	chr16:89883248	FANCA	0.82	7.4	0.34	7.56e-13	Skin colour saturation;
LUAD	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22307029	chr19:49891270	CCDC155	0.74	10.47	0.45	5.82e-23	Multiple sclerosis;
LUAD	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23583168	chr7:148888333	NA	-0.89	-17.6	-0.65	1.93e-52	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg18129178	chr5:148520854	ABLIM3	-0.63	-9.61	-0.42	6.34e-20	Breast cancer;
LUAD	cis	rs7084921	0.549	rs9888058	chr10:101859205	C/T	cg19754520	chr10:101825118	CPN1	-0.36	-7.68	-0.35	1.14e-13	Bone mineral density;
LUAD	cis	rs1497828	0.956	rs1497834	chr1:217535731	G/T	cg04411442	chr1:217543379	NA	-0.35	-6.52	-0.3	2.02e-10	Dialysis-related mortality;
LUAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.77	14.36	0.57	2.32e-38	Lymphocyte counts;
LUAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg07217954	chr7:1067459	C7orf50	0.46	7.16	0.33	3.62e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	12.05	0.51	5.79e-29	Hip circumference adjusted for BMI;
LUAD	trans	rs1864585	0.520	rs7838335	chr8:10589913	C/T	cg26278703	chr11:58910052	FAM111A	0.48	6.39	0.3	4.33e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	trans	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg18335740	chr13:41363409	SLC25A15	0.57	10.51	0.46	4.24e-23	Lewy body disease;
LUAD	cis	rs9462027	0.628	rs11757370	chr6:34760736	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.91	-0.4	1.53e-17	Systemic lupus erythematosus;
LUAD	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.6	10.28	0.45	2.78e-22	Electrocardiographic conduction measures;
LUAD	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg22823121	chr1:150693482	HORMAD1	-0.39	-7.62	-0.35	1.63e-13	Tonsillectomy;
LUAD	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg14092571	chr14:90743983	NA	0.47	8.06	0.37	7.66e-15	Mortality in heart failure;
LUAD	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg27284194	chr4:1044797	NA	0.7	9.99	0.44	3.08e-21	Recombination rate (females);
LUAD	cis	rs7172809	0.573	rs4886864	chr15:77674022	C/T	cg11865553	chr15:77376250	NA	-0.39	-6.46	-0.3	2.91e-10	Glucose homeostasis traits;
LUAD	cis	rs13315871	0.929	rs73835170	chr3:58318448	A/G	cg20936604	chr3:58311152	NA	-0.79	-8.34	-0.38	1.05e-15	Cholesterol, total;
LUAD	trans	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg26043149	chr18:55253948	FECH	-0.39	-6.36	-0.3	5.31e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg04369109	chr6:150039330	LATS1	-0.51	-6.37	-0.3	4.98e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs367943	0.698	rs10050530	chr5:112971042	A/C	cg12552261	chr5:112820674	MCC	0.45	8.06	0.36	7.8e-15	Type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg01689657	chr7:91764605	CYP51A1	-0.38	-9.54	-0.42	1.18e-19	Breast cancer;
LUAD	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg26384229	chr12:38710491	ALG10B	-0.43	-7.27	-0.33	1.76e-12	Morning vs. evening chronotype;
LUAD	cis	rs4629710	0.645	rs34601891	chr6:131551238	C/T	cg12606694	chr6:131520996	AKAP7	0.48	7.04	0.32	7.65e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg11919837	chr8:57350735	NA	-0.43	-6.44	-0.3	3.19e-10	Obesity-related traits;
LUAD	cis	rs7187994	0.895	rs7184644	chr16:84786460	C/A	cg07647771	chr16:84786436	USP10	-0.37	-9.43	-0.42	2.79e-19	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs2294693	0.947	rs9349176	chr6:40989525	C/T	cg14769373	chr6:40998127	UNC5CL	-0.53	-8.1	-0.37	5.79e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22496380	chr5:211416	CCDC127	-0.95	-13.32	-0.54	4.88e-34	Breast cancer;
LUAD	trans	rs9784649	1.000	rs56205870	chr5:24958870	A/G	cg11038491	chr20:34638489	LOC647979	-0.62	-8.03	-0.36	1.01e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6445967	0.531	rs62259315	chr3:58284508	T/C	cg13750441	chr3:58318267	PXK	-0.3	-6.42	-0.3	3.77e-10	Platelet count;
LUAD	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg04369109	chr6:150039330	LATS1	-0.44	-7.29	-0.33	1.54e-12	Lung cancer;
LUAD	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg12311346	chr5:56204834	C5orf35	-0.91	-13.39	-0.55	2.46e-34	Initial pursuit acceleration;
LUAD	trans	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg07817883	chr1:32538562	TMEM39B	1.59	13.76	0.56	7.11e-36	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.96	20.72	0.71	2.41e-66	Chronic sinus infection;
LUAD	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg01299579	chr2:10830716	NOL10	-0.42	-7.42	-0.34	6.53e-13	Prostate cancer;
LUAD	cis	rs16910800	0.731	rs1871953	chr11:23192677	G/A	cg20040320	chr11:23191996	NA	-0.73	-9.72	-0.43	2.81e-20	Cancer;
LUAD	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg05590025	chr7:65112418	INTS4L2	-0.76	-7.97	-0.36	1.5e-14	Diabetic kidney disease;
LUAD	cis	rs2637266	1.000	rs10824425	chr10:78340310	C/G	cg18941641	chr10:78392320	NA	0.32	6.76	0.31	4.47e-11	Pulmonary function;
LUAD	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg02049041	chr17:27085579	C17orf63	0.65	8.59	0.39	1.65e-16	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs853679	0.546	rs2232423	chr6:28366151	A/G	cg01620082	chr3:125678407	NA	-1.08	-9.99	-0.44	3.19e-21	Depression;
LUAD	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg06873352	chr17:61820015	STRADA	0.41	6.91	0.32	1.81e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg01528321	chr10:82214614	TSPAN14	0.46	7.29	0.33	1.53e-12	Post bronchodilator FEV1;
LUAD	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg06064525	chr11:970664	AP2A2	-0.53	-10.86	-0.47	2.05e-24	Alzheimer's disease (late onset);
LUAD	cis	rs7503807	0.967	rs12940622	chr17:78615571	G/A	cg09596252	chr17:78655493	RPTOR	0.4	7.84	0.36	3.8e-14	Obesity;
LUAD	cis	rs2066819	1.000	rs77032009	chr12:56679971	A/G	cg26714650	chr12:56694279	CS	-0.86	-7.23	-0.33	2.25e-12	Psoriasis vulgaris;
LUAD	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg20503657	chr10:835505	NA	1.0	14.67	0.58	1.11e-39	Eosinophil percentage of granulocytes;
LUAD	cis	rs2882667	0.898	rs2043272	chr5:138390631	A/C	cg04439458	chr5:138467593	SIL1	-0.42	-7.62	-0.35	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs11971779	0.715	rs7781459	chr7:139093882	A/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs2070997	0.617	rs7848941	chr9:133744672	G/A	cg03924115	chr9:133768966	QRFP	0.49	6.52	0.3	2.07e-10	Response to amphetamines;
LUAD	cis	rs77741769	0.529	rs909053	chr12:121237668	G/A	cg02419362	chr12:121203948	SPPL3	0.39	7.91	0.36	2.23e-14	Mean corpuscular volume;
LUAD	trans	rs459571	0.959	rs392134	chr9:136909008	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-10.04	-0.44	2.1e-21	Platelet distribution width;
LUAD	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg05283184	chr6:79620031	NA	-0.56	-11.26	-0.48	6.71e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs67072384	1.000	rs67075228	chr11:72450775	C/T	cg04827223	chr11:72435913	ARAP1	-0.63	-7.29	-0.33	1.54e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	12.54	0.52	7.14e-31	Monocyte percentage of white cells;
LUAD	cis	rs2882667	0.898	rs10038121	chr5:138389602	A/G	cg04439458	chr5:138467593	SIL1	-0.4	-7.35	-0.34	1.02e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg06060754	chr5:176797920	RGS14	-0.56	-9.32	-0.41	6.36e-19	Urate levels in lean individuals;
LUAD	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.54	7.57	0.35	2.36e-13	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.56	0.3	1.56e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg25985355	chr7:65971099	NA	-0.39	-7.21	-0.33	2.59e-12	Aortic root size;
LUAD	trans	rs4714291	0.802	rs3008833	chr6:39986303	G/A	cg02267698	chr19:7991119	CTXN1	-0.45	-7.15	-0.33	3.82e-12	Strep throat;
LUAD	cis	rs8040855	0.599	rs6496792	chr15:85725745	T/A	cg04831495	chr15:85060580	GOLGA6L5	0.45	7.8	0.35	5.05e-14	Bulimia nervosa;
LUAD	trans	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg18187862	chr3:45730750	SACM1L	0.56	8.25	0.37	1.97e-15	Primary sclerosing cholangitis;
LUAD	cis	rs9875589	0.509	rs4685058	chr3:14030384	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.38	7.09	0.33	5.79e-12	Ovarian reserve;
LUAD	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.86	0.32	2.43e-11	Lung cancer;
LUAD	cis	rs6430585	0.591	rs1374330	chr2:136420908	A/C	cg07169764	chr2:136633963	MCM6	0.63	7.08	0.33	6.2e-12	Corneal structure;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg03826601	chr12:9102508	M6PR	-0.43	-7.18	-0.33	3.26e-12	Subcortical brain region volumes;
LUAD	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg01579765	chr21:45077557	HSF2BP	-0.57	-12.35	-0.51	4.08e-30	Mean corpuscular volume;
LUAD	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg15921436	chr17:44337874	NA	0.64	9.49	0.42	1.76e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.56	-0.34	2.57e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg02421172	chr7:1938701	MAD1L1	0.48	6.76	0.31	4.63e-11	Bipolar disorder;
LUAD	cis	rs6604026	0.666	rs11164830	chr1:93356823	C/A	cg17283838	chr1:93427260	FAM69A	-0.42	-6.6	-0.31	1.22e-10	Multiple sclerosis;
LUAD	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.22	-0.37	2.52e-15	Bipolar disorder;
LUAD	cis	rs6545883	0.965	rs11887205	chr2:61774473	T/G	cg15711740	chr2:61764176	XPO1	-0.43	-6.88	-0.32	2.16e-11	Tuberculosis;
LUAD	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg01097406	chr16:89675127	NA	0.32	6.7	0.31	6.59e-11	Vitiligo;
LUAD	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg10556349	chr10:835070	NA	0.58	7.26	0.33	1.82e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs9952991	0.941	rs60735058	chr18:12795470	T/A	cg23544223	chr18:12777786	NA	-0.71	-8.65	-0.39	1.09e-16	Inflammatory skin disease;
LUAD	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.53	14.39	0.57	1.75e-38	Schizophrenia;
LUAD	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg02734326	chr4:10020555	SLC2A9	0.63	11.28	0.48	5.67e-26	Bone mineral density;
LUAD	cis	rs7301016	0.948	rs10877870	chr12:62923955	A/G	cg11441379	chr12:63026424	NA	0.56	7.07	0.32	6.57e-12	IgG glycosylation;
LUAD	cis	rs397969	0.646	rs1638526	chr17:19848450	T/C	cg04132472	chr17:19861366	AKAP10	0.35	7.44	0.34	5.66e-13	Platelet count;
LUAD	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg13319975	chr6:146136371	FBXO30	-0.62	-10.6	-0.46	1.98e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs56046484	0.711	rs71397835	chr15:85530771	C/T	cg08123816	chr15:85640762	PDE8A	-0.44	-6.55	-0.3	1.63e-10	Testicular germ cell tumor;
LUAD	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg27490568	chr2:178487706	NA	0.58	8.58	0.39	1.78e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg21280719	chr6:42927975	GNMT	-0.38	-11.65	-0.49	2.05e-27	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05383670	chr11:64879206	TM7SF2	-0.54	-6.58	-0.3	1.35e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9837602	1.000	rs9878931	chr3:99712634	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	9.02	0.4	6.64e-18	Breast cancer;
LUAD	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg08999081	chr20:33150536	PIGU	0.63	13.91	0.56	1.68e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg20701182	chr2:24300061	SF3B14	0.89	13.24	0.54	1.04e-33	Lymphocyte counts;
LUAD	cis	rs9388451	0.531	rs9401850	chr6:126151000	T/G	cg05901451	chr6:126070800	HEY2	-0.58	-9.27	-0.41	9.79e-19	Brugada syndrome;
LUAD	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	8.8	0.39	3.53e-17	Colorectal cancer;
LUAD	cis	rs11958404	0.932	rs6894528	chr5:157434788	A/G	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.44	-0.49	1.38e-26	Primary sclerosing cholangitis;
LUAD	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg07538946	chr5:131705188	SLC22A5	0.53	8.69	0.39	8.25e-17	Blood metabolite levels;
LUAD	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg14458575	chr2:238380390	NA	0.65	12.0	0.5	9.46e-29	Prostate cancer;
LUAD	cis	rs68170813	0.652	rs77056542	chr7:107089751	G/C	cg23024343	chr7:107201750	COG5	0.53	6.59	0.31	1.33e-10	Coronary artery disease;
LUAD	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg11070056	chr1:107600091	PRMT6	0.64	10.97	0.47	8.55e-25	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1448094	0.967	rs10047659	chr12:86338278	C/A	cg18827107	chr12:86230957	RASSF9	-0.45	-8.04	-0.36	8.89e-15	Major depressive disorder;
LUAD	cis	rs74181299	0.890	rs2540950	chr2:65279223	C/T	cg05010058	chr2:65284262	CEP68	0.3	6.5	0.3	2.33e-10	Pulse pressure;
LUAD	cis	rs6138458	1.000	rs6106984	chr20:24977006	T/C	cg26195577	chr20:24973756	C20orf3	0.98	17.44	0.65	9.94e-52	Blood protein levels;
LUAD	cis	rs6881634	0.501	rs10942852	chr5:77698582	G/T	cg11547950	chr5:77652471	NA	-0.36	-6.51	-0.3	2.19e-10	Hippocampal atrophy;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg24043887	chr11:695896	TMEM80;DEAF1	-0.41	-6.73	-0.31	5.52e-11	Vertical cup-disc ratio;
LUAD	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.22	-0.37	2.45e-15	Bipolar disorder;
LUAD	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg15485101	chr11:133734466	NA	-0.32	-7.3	-0.33	1.42e-12	Childhood ear infection;
LUAD	cis	rs722864	0.627	rs61151985	chr2:173930266	G/A	cg09210666	chr2:173941575	ZAK	0.53	6.92	0.32	1.64e-11	Lung cancer;
LUAD	cis	rs887829	0.570	rs10445704	chr2:234600274	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.69	-0.43	3.53e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg17173187	chr15:85201210	NMB	0.51	9.11	0.41	3.29e-18	Schizophrenia;
LUAD	cis	rs713477	0.901	rs7146306	chr14:55905853	C/T	cg13175173	chr14:55914753	NA	-0.33	-6.94	-0.32	1.49e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	13.23	0.54	1.07e-33	Lymphocyte counts;
LUAD	trans	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.7	-0.31	6.5500000000000006e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg01689657	chr7:91764605	CYP51A1	0.33	8.28	0.37	1.62e-15	Breast cancer;
LUAD	cis	rs9826463	0.582	rs11707154	chr3:142077131	A/T	cg20824294	chr3:142316082	PLS1	0.42	7.3	0.33	1.39e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10193935	0.901	rs10490552	chr2:42559947	C/T	cg27598129	chr2:42591480	NA	0.69	8.96	0.4	1.06e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg09835421	chr16:68378352	PRMT7	-0.77	-8.82	-0.39	2.95e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11958404	0.932	rs72816556	chr5:157424412	C/G	cg05962755	chr5:157440814	NA	0.5	7.8	0.35	4.85e-14	IgG glycosylation;
LUAD	cis	rs4638749	0.677	rs1563112	chr2:108850579	C/T	cg25838818	chr2:108905173	SULT1C2	-0.43	-7.59	-0.35	2.05e-13	Blood pressure;
LUAD	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg09936400	chr10:82049201	MAT1A	0.37	6.6	0.31	1.21e-10	Post bronchodilator FEV1;
LUAD	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg00310523	chr12:86230176	RASSF9	0.4	7.92	0.36	2.13e-14	Major depressive disorder;
LUAD	cis	rs6782228	0.585	rs6774515	chr3:128415878	C/T	cg16766828	chr3:128327626	NA	-0.39	-7.3	-0.33	1.43e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg15485101	chr11:133734466	NA	0.38	8.61	0.39	1.5e-16	Childhood ear infection;
LUAD	cis	rs1595825	0.891	rs16826791	chr2:198895133	C/G	cg11031976	chr2:198649780	BOLL	-0.45	-6.58	-0.3	1.4e-10	Ulcerative colitis;
LUAD	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg00316803	chr15:76480434	C15orf27	-0.41	-7.65	-0.35	1.35e-13	Blood metabolite levels;
LUAD	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg03690763	chr11:133734501	NA	-0.34	-7.84	-0.36	3.67e-14	Childhood ear infection;
LUAD	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg12310025	chr6:25882481	NA	-0.41	-6.7	-0.31	6.66e-11	Height;
LUAD	trans	rs2840044	0.534	rs2124246	chr17:33885431	G/A	cg19694781	chr19:47549865	TMEM160	-0.43	-7.12	-0.33	4.64e-12	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg23954153	chr1:44402353	ARTN	-0.33	-6.36	-0.3	5.26e-10	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs2688608	0.967	rs9971038	chr10:75661149	C/T	cg19442545	chr10:75533431	FUT11	-0.4	-6.87	-0.32	2.33e-11	Inflammatory bowel disease;
LUAD	cis	rs9837602	1.000	rs9873878	chr3:99711816	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	9.02	0.4	6.64e-18	Breast cancer;
LUAD	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg07741184	chr6:167504864	NA	0.31	7.37	0.34	9.33e-13	Crohn's disease;
LUAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg14820908	chr5:178986412	RUFY1	0.58	9.64	0.42	5.31e-20	Lung cancer;
LUAD	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg00933542	chr6:150070202	PCMT1	0.43	9.22	0.41	1.44e-18	Lung cancer;
LUAD	cis	rs4253772	1.000	rs4253766	chr22:46623905	C/T	cg09491104	chr22:46646882	C22orf40	-0.55	-8.04	-0.36	9.38e-15	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs17102423	0.594	rs10151162	chr14:65566695	T/C	cg11161011	chr14:65562177	MAX	-0.47	-7.84	-0.36	3.7e-14	Obesity-related traits;
LUAD	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg05874882	chr4:1763078	NA	-0.35	-6.41	-0.3	3.83e-10	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs926938	0.584	rs1299780	chr1:115366014	G/A	cg12756093	chr1:115239321	AMPD1	0.36	6.45	0.3	3.02e-10	Autism;
LUAD	cis	rs4845570	0.834	rs1196467	chr1:151710038	T/C	cg07092448	chr1:151763213	TDRKH	0.69	7.83	0.36	3.97e-14	Coronary artery disease;
LUAD	cis	rs72928364	0.932	rs2245266	chr3:100618773	T/C	cg10123952	chr3:100791384	NA	-0.54	-6.76	-0.31	4.69e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12210905	0.688	rs12215353	chr6:27407022	C/T	cg08851530	chr6:28072375	NA	1.03	7.52	0.34	3.3e-13	Hip circumference adjusted for BMI;
LUAD	trans	rs2735413	0.918	rs4888733	chr16:78080523	C/T	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg01065977	chr19:18549689	ISYNA1	-0.38	-7.37	-0.34	9.33e-13	Breast cancer;
LUAD	cis	rs35883536	0.566	rs4908086	chr1:101088124	C/T	cg06223162	chr1:101003688	GPR88	0.4	7.25	0.33	1.96e-12	Monocyte count;
LUAD	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg08027265	chr7:2291960	NA	-0.46	-8.17	-0.37	3.67e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg08132940	chr7:1081526	C7orf50	-0.57	-6.65	-0.31	9.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg08645402	chr16:4508243	NA	-0.51	-9.11	-0.41	3.26e-18	Schizophrenia;
LUAD	trans	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg01620082	chr3:125678407	NA	-1.0	-9.42	-0.42	3.03e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7737355	0.812	rs10041712	chr5:130765670	C/G	cg06307176	chr5:131281290	NA	-0.42	-7.06	-0.32	6.99e-12	Life satisfaction;
LUAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg12016809	chr21:47604291	C21orf56	-0.66	-11.67	-0.49	1.77e-27	Testicular germ cell tumor;
LUAD	cis	rs1696756	0.877	rs2587500	chr17:77827362	A/T	cg02876276	chr17:77834299	NA	0.48	7.17	0.33	3.31e-12	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01435196	chr19:46009946	VASP	-0.69	-6.62	-0.31	1.08e-10	Type 2 diabetes;
LUAD	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg06636551	chr8:101224915	SPAG1	0.35	6.36	0.3	5.29e-10	Atrioventricular conduction;
LUAD	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg15017067	chr4:17643749	FAM184B	0.36	7.03	0.32	8.42e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg00080972	chr5:178986291	RUFY1	0.64	11.57	0.49	4.35e-27	Lung cancer;
LUAD	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg06873352	chr17:61820015	STRADA	0.8	17.64	0.65	1.38e-52	Prudent dietary pattern;
LUAD	cis	rs497273	0.534	rs13746	chr12:121201167	C/T	cg02419362	chr12:121203948	SPPL3	0.37	7.54	0.34	2.88e-13	Systemic lupus erythematosus;
LUAD	cis	rs9283706	0.608	rs12523505	chr5:66334631	C/T	cg11590213	chr5:66331682	MAST4	0.41	6.64	0.31	9.84e-11	Coronary artery disease;
LUAD	cis	rs748404	0.697	rs493444	chr15:43566470	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	7.37	0.34	8.97e-13	Lung cancer;
LUAD	cis	rs796825	0.586	rs2030413	chr3:120082782	A/G	cg21790991	chr3:120137480	FSTL1	0.4	6.85	0.32	2.59e-11	HIV-1 susceptibility;
LUAD	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg09904177	chr6:26538194	HMGN4	0.44	7.4	0.34	7.22e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs78049276	0.562	rs55965782	chr4:148378442	T/C	cg13149281	chr14:23389818	RBM23;PRMT5	-0.64	-7.98	-0.36	1.41e-14	Pulse pressure;
LUAD	cis	rs11958404	0.932	rs6859826	chr5:157429710	T/C	cg05962755	chr5:157440814	NA	0.69	9.52	0.42	1.31e-19	IgG glycosylation;
LUAD	cis	rs4786125	0.920	rs6500849	chr16:6895246	C/T	cg03623568	chr16:6915990	A2BP1	-0.41	-8.41	-0.38	6.36e-16	Heart rate variability traits (SDNN);
LUAD	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg15997130	chr1:24165203	NA	-0.57	-10.23	-0.45	4.19e-22	Immature fraction of reticulocytes;
LUAD	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg08085267	chr17:45401833	C17orf57	0.57	10.18	0.44	6.24e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2835872	0.758	rs1709817	chr21:39036349	T/A	cg06728970	chr21:39037746	KCNJ6	0.41	7.77	0.35	5.86e-14	Electroencephalographic traits in alcoholism;
LUAD	cis	rs12681287	0.752	rs13256500	chr8:87247063	G/A	cg00550725	chr8:87521180	FAM82B	0.43	6.36	0.3	5.17e-10	Caudate activity during reward;
LUAD	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg13319975	chr6:146136371	FBXO30	-0.6	-9.72	-0.43	2.65e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.79	8.88	0.4	1.9e-17	Initial pursuit acceleration;
LUAD	trans	rs10802346	0.545	rs4607841	chr1:246373295	T/C	cg22732515	chr19:44031385	ETHE1	0.59	9.5	0.42	1.58e-19	Fractional exhaled nitric oxide (childhood);
LUAD	trans	rs9914544	0.583	rs11078422	chr17:18804413	C/T	cg21372672	chr17:16614065	CCDC144A	-0.37	-6.58	-0.3	1.38e-10	Educational attainment (years of education);
LUAD	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.31	6.37	0.3	4.95e-10	Obesity-related traits;
LUAD	cis	rs4268898	0.552	rs11125455	chr2:24374557	C/G	cg20701182	chr2:24300061	SF3B14	-0.4	-6.35	-0.3	5.54e-10	Asthma;
LUAD	cis	rs1595825	0.891	rs73056823	chr2:198769788	T/C	cg00361562	chr2:198649771	BOLL	-0.47	-6.73	-0.31	5.53e-11	Ulcerative colitis;
LUAD	cis	rs4481887	0.741	rs28589987	chr1:248564785	T/C	cg13385794	chr1:248469461	NA	0.24	6.37	0.3	4.88e-10	Common traits (Other);
LUAD	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg17845761	chr1:175162550	KIAA0040	0.38	10.0	0.44	2.85e-21	Alcohol dependence;
LUAD	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg10978503	chr1:24200527	CNR2	0.47	9.59	0.42	7.78e-20	Immature fraction of reticulocytes;
LUAD	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg00310523	chr12:86230176	RASSF9	0.34	7.37	0.34	9.34e-13	Major depressive disorder;
LUAD	cis	rs7107174	1.000	rs6592772	chr11:78015563	A/C	cg19901956	chr11:77921274	USP35	-0.53	-6.54	-0.3	1.79e-10	Testicular germ cell tumor;
LUAD	cis	rs11214589	0.905	rs12804573	chr11:113241726	G/A	cg14159747	chr11:113255604	NA	0.67	14.44	0.57	1.01e-38	Neuroticism;
LUAD	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg08601574	chr20:25228251	PYGB	0.47	8.89	0.4	1.77e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs28493229	0.708	rs10425069	chr19:41152847	C/T	cg21869046	chr19:41225005	ITPKC	0.55	9.22	0.41	1.36e-18	Kawasaki disease;
LUAD	cis	rs12050794	0.636	rs3759902	chr15:72525274	C/G	cg16672083	chr15:72433130	SENP8	0.65	12.19	0.51	1.72e-29	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg25358565	chr5:93447407	FAM172A	0.6	7.02	0.32	9.01e-12	Diabetic retinopathy;
LUAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg10729496	chr3:10149963	C3orf24	0.49	7.88	0.36	2.73e-14	Alzheimer's disease;
LUAD	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs950027	1.000	rs950027	chr15:45801035	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.49	-8.25	-0.37	1.98e-15	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs1757171	0.542	rs3818985	chr6:37484214	G/T	cg25019722	chr6:37503610	NA	-0.33	-7.6	-0.35	1.94e-13	Cognitive performance;
LUAD	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-14.78	-0.58	3.82e-40	Schizophrenia;
LUAD	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg17105886	chr17:28927953	LRRC37B2	0.77	7.72	0.35	8.51e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg16405210	chr4:1374714	KIAA1530	-0.38	-6.41	-0.3	3.97e-10	Obesity-related traits;
LUAD	cis	rs977987	0.815	rs11861810	chr16:75461829	A/G	cg03315344	chr16:75512273	CHST6	0.64	14.04	0.56	5.11e-37	Dupuytren's disease;
LUAD	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg06028605	chr16:24865363	SLC5A11	0.38	6.73	0.31	5.7e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2658782	0.547	rs3133454	chr11:93059019	A/C	cg15737290	chr11:93063684	CCDC67	0.58	9.78	0.43	1.74e-20	Pulmonary function decline;
LUAD	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg00999904	chr2:3704751	ALLC	-0.4	-7.28	-0.33	1.69e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg20848291	chr7:100343083	ZAN	-0.57	-7.77	-0.35	6.12e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2797160	0.967	rs2747715	chr6:126007719	A/T	cg05901451	chr6:126070800	HEY2	0.45	6.56	0.3	1.58e-10	Endometrial cancer;
LUAD	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg11494091	chr17:61959527	GH2	0.46	8.57	0.38	1.96e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06022373	chr22:39101656	GTPBP1	0.46	7.21	0.33	2.6e-12	Menopause (age at onset);
LUAD	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg08316699	chr6:150357289	NA	0.35	7.65	0.35	1.41e-13	Alopecia areata;
LUAD	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg01689657	chr7:91764605	CYP51A1	0.27	6.43	0.3	3.48e-10	Breast cancer;
LUAD	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg13319975	chr6:146136371	FBXO30	0.68	11.63	0.49	2.67e-27	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg14917512	chr19:3094685	GNA11	-0.56	-6.52	-0.3	2.06e-10	Diabetic kidney disease;
LUAD	cis	rs2731664	0.792	rs335420	chr5:176898619	C/T	cg23176889	chr5:176863531	GRK6	0.72	14.26	0.57	6.03e-38	Intelligence (multi-trait analysis);
LUAD	cis	rs11048434	0.736	rs1805724	chr12:9104609	T/C	cg04155231	chr12:9217510	LOC144571	0.4	7.52	0.34	3.22e-13	Sjögren's syndrome;
LUAD	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg09658497	chr7:2847517	GNA12	-0.54	-9.18	-0.41	1.89e-18	Height;
LUAD	trans	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.68	-10.03	-0.44	2.27e-21	Platelet distribution width;
LUAD	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.81	11.67	0.49	1.73e-27	Smoking behavior;
LUAD	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg24531977	chr5:56204891	C5orf35	-0.5	-7.98	-0.36	1.41e-14	Coronary artery disease;
LUAD	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg17330251	chr7:94953956	PON1	-0.53	-7.24	-0.33	2.19e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg11901034	chr3:128598214	ACAD9	-0.5	-7.55	-0.34	2.77e-13	IgG glycosylation;
LUAD	cis	rs12711979	0.765	rs897069	chr2:3818947	C/T	cg17052675	chr2:3827356	NA	0.51	10.36	0.45	1.51e-22	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs2742234	0.541	rs1059484	chr10:43679800	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.52	-8.9	-0.4	1.67e-17	Hirschsprung disease;
LUAD	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	8.07	0.37	7.21e-15	Breast cancer;
LUAD	cis	rs931127	0.505	rs746429	chr11:65417434	G/A	cg05805236	chr11:65401703	PCNXL3	-0.59	-9.57	-0.42	8.73e-20	Systemic lupus erythematosus;
LUAD	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg00684032	chr4:1343700	KIAA1530	0.4	6.85	0.32	2.58e-11	Obesity-related traits;
LUAD	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.03	-0.4	6.21e-18	Alcohol dependence;
LUAD	cis	rs701145	0.537	rs437396	chr3:153923273	A/G	cg17054900	chr3:154042577	DHX36	0.66	7.08	0.33	6.13e-12	Coronary artery disease;
LUAD	cis	rs73416724	1.000	rs70953686	chr6:43269516	G/A	cg26312998	chr6:43337775	ZNF318	0.56	6.64	0.31	9.91e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg26022315	chr17:47021804	SNF8	0.41	7.36	0.34	9.46e-13	Type 2 diabetes;
LUAD	cis	rs1018836	1.000	rs1018836	chr8:91570362	A/G	cg16814680	chr8:91681699	NA	-0.57	-9.54	-0.42	1.12e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg27284194	chr4:1044797	NA	0.69	9.96	0.44	4.02e-21	Recombination rate (females);
LUAD	cis	rs897984	0.568	rs67264578	chr16:30879395	G/A	cg02466173	chr16:30829666	NA	-0.66	-10.56	-0.46	2.8e-23	Dementia with Lewy bodies;
LUAD	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.55	-9.19	-0.41	1.84e-18	Glomerular filtration rate;
LUAD	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg20933634	chr6:27740509	NA	-0.49	-7.84	-0.36	3.62e-14	Parkinson's disease;
LUAD	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg09365446	chr1:150670422	GOLPH3L	0.61	10.49	0.45	4.69e-23	Melanoma;
LUAD	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg07741184	chr6:167504864	NA	0.31	7.47	0.34	4.74e-13	Crohn's disease;
LUAD	trans	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg24644049	chr4:85504048	CDS1	0.92	8.03	0.36	9.44e-15	Skin colour saturation;
LUAD	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-9.99	-0.44	3.11e-21	Migraine;Coronary artery disease;
LUAD	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg22467129	chr15:76604101	ETFA	-0.46	-7.63	-0.35	1.54e-13	Blood metabolite levels;
LUAD	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg02782426	chr3:40428986	ENTPD3	0.42	8.88	0.4	1.94e-17	Renal cell carcinoma;
LUAD	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg19761014	chr17:28927070	LRRC37B2	0.76	8.91	0.4	1.52e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs73198271	0.599	rs10103169	chr8:8650698	T/A	cg01851573	chr8:8652454	MFHAS1	0.52	9.2	0.41	1.67e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23158103	chr7:148848205	ZNF398	-0.57	-9.74	-0.43	2.41e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-6.38	-0.3	4.64e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg03605463	chr16:89740564	NA	0.67	11.56	0.49	4.66e-27	Vitiligo;
LUAD	cis	rs1034435	0.755	rs5768681	chr22:48894501	C/T	cg05992904	chr22:48892994	FAM19A5	-0.74	-16.41	-0.62	3.5e-47	Late-onset Alzheimer's disease;
LUAD	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg07757535	chr4:1339547	NA	0.29	6.39	0.3	4.46e-10	Longevity;
LUAD	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg11871910	chr12:69753446	YEATS4	0.7	12.08	0.51	4.53e-29	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs2425143	1.000	rs11696369	chr20:34378629	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.44	-0.34	5.51e-13	Blood protein levels;
LUAD	cis	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg05084668	chr3:125655381	ALG1L	-0.49	-7.56	-0.34	2.57e-13	Blood pressure (smoking interaction);
LUAD	cis	rs11771526	1.000	rs11764617	chr7:32339102	T/C	cg13207630	chr7:32358064	NA	0.69	7.92	0.36	2.08e-14	Body mass index;
LUAD	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg06627628	chr2:24431161	ITSN2	-0.56	-9.33	-0.41	6.08e-19	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs7192380	1.000	rs7191292	chr16:69669427	G/A	cg26679644	chr16:69762563	NA	0.5	9.63	0.42	5.56e-20	Sjögren's syndrome;
LUAD	cis	rs73198271	0.515	rs11774722	chr8:8642448	T/C	cg01851573	chr8:8652454	MFHAS1	0.61	7.69	0.35	1.06e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-9.24	-0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg13385794	chr1:248469461	NA	0.26	7.07	0.33	6.48e-12	Common traits (Other);
LUAD	cis	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg08601574	chr20:25228251	PYGB	0.41	7.58	0.35	2.26e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs73206853	0.764	rs55913108	chr12:110816507	T/C	cg12870014	chr12:110450643	ANKRD13A	0.63	7.15	0.33	3.92e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg02683114	chr2:24398427	C2orf84	-0.5	-7.79	-0.35	5.22e-14	Asthma;
LUAD	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg14834391	chr1:2537342	MMEL1	-0.31	-6.51	-0.3	2.11e-10	Ulcerative colitis;
LUAD	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg23262073	chr20:60523788	NA	-0.48	-7.66	-0.35	1.24e-13	Body mass index;
LUAD	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-7.25	-0.33	1.95e-12	Body mass index;
LUAD	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg24690094	chr11:67383802	NA	0.4	7.29	0.33	1.52e-12	Mean corpuscular volume;
LUAD	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg26384229	chr12:38710491	ALG10B	-0.44	-7.45	-0.34	5.19e-13	Heart rate;
LUAD	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg08773314	chr2:239334832	ASB1	0.45	10.23	0.45	4.24e-22	Multiple system atrophy;
LUAD	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg26727032	chr16:67993705	SLC12A4	0.5	6.67	0.31	7.8e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg04565464	chr8:145669602	NFKBIL2	0.45	6.5	0.3	2.22e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2286885	1.000	rs10819171	chr9:129253074	G/A	cg15282417	chr9:129245246	FAM125B	0.43	8.83	0.39	2.9e-17	Intraocular pressure;
LUAD	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg24818145	chr4:99064322	C4orf37	-0.42	-6.88	-0.32	2.22e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.47	-0.3	2.64e-10	Schizophrenia;
LUAD	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg17366294	chr4:99064904	C4orf37	0.58	9.74	0.43	2.4e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg06713675	chr4:122721982	EXOSC9	-0.6	-11.58	-0.49	4.05e-27	Type 2 diabetes;
LUAD	cis	rs1832871	0.683	rs9457224	chr6:158666139	C/T	cg07165851	chr6:158734300	TULP4	0.7	10.57	0.46	2.44e-23	Height;
LUAD	cis	rs10203711	1.000	rs10187717	chr2:239558168	T/C	cg14580085	chr2:239553406	NA	0.4	8.48	0.38	3.77e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg23231163	chr10:75533350	FUT11	-0.51	-9.4	-0.42	3.52e-19	Inflammatory bowel disease;
LUAD	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg15704280	chr7:45808275	SEPT13	-1.06	-24.5	-0.77	3.71e-83	Height;
LUAD	cis	rs7680126	0.596	rs12510549	chr4:10276467	A/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-7.63	-0.35	1.56e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg26597838	chr10:835615	NA	0.99	15.39	0.6	9e-43	Eosinophil percentage of granulocytes;
LUAD	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg10518543	chr12:38710700	ALG10B	-0.42	-6.39	-0.3	4.49e-10	Heart rate;
LUAD	cis	rs1595825	0.891	rs73061069	chr2:198908825	A/G	cg00361562	chr2:198649771	BOLL	-0.49	-6.86	-0.32	2.44e-11	Ulcerative colitis;
LUAD	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg11266682	chr4:10021025	SLC2A9	0.65	15.35	0.6	1.39e-42	Bone mineral density;
LUAD	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg00316803	chr15:76480434	C15orf27	-0.39	-7.38	-0.34	8.47e-13	Blood metabolite levels;
LUAD	cis	rs6672530	0.518	rs10916169	chr1:227764857	T/C	cg12133451	chr1:227746453	NA	0.36	6.52	0.3	1.95e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg09835421	chr16:68378352	PRMT7	-0.85	-9.1	-0.4	3.55e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg08219700	chr8:58056026	NA	0.42	6.37	0.3	4.85e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.6	11.48	0.49	9.94e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.3	-6.61	-0.31	1.17e-10	Blood metabolite levels;
LUAD	cis	rs7493	0.950	rs11977702	chr7:95029767	C/T	cg20119798	chr7:94954144	PON1	-0.48	-6.53	-0.3	1.88e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.61	7.54	0.34	2.83e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg14893161	chr1:205819251	PM20D1	0.48	7.83	0.36	4.04e-14	Parkinson's disease;
LUAD	cis	rs2286885	0.965	rs4837092	chr9:129250251	T/C	cg15282417	chr9:129245246	FAM125B	0.44	8.96	0.4	1.02e-17	Intraocular pressure;
LUAD	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg19875535	chr5:140030758	IK	-0.39	-6.61	-0.31	1.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.76	-14.14	-0.57	1.88e-37	Brugada syndrome;
LUAD	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg11822812	chr5:140052017	DND1	-0.41	-7.48	-0.34	4.24e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg08436684	chr16:88034427	BANP	-0.49	-6.37	-0.3	4.82e-10	Menopause (age at onset);
LUAD	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg18827107	chr12:86230957	RASSF9	-0.56	-9.88	-0.43	7.31e-21	Major depressive disorder;
LUAD	cis	rs7903847	0.667	rs11189181	chr10:99144154	A/G	cg08345082	chr10:99160200	RRP12	-0.36	-7.09	-0.33	5.63e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1018836	0.923	rs13268594	chr8:91588545	G/T	cg16814680	chr8:91681699	NA	-0.68	-11.47	-0.49	1.05e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12545109	0.613	rs4541914	chr8:57254555	T/G	cg17761419	chr8:57350749	NA	-0.58	-7.78	-0.35	5.63e-14	Obesity-related traits;
LUAD	cis	rs877282	0.842	rs35117541	chr10:764683	C/T	cg17470449	chr10:769945	NA	0.62	8.83	0.39	2.91e-17	Uric acid levels;
LUAD	trans	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg14791747	chr16:20752902	THUMPD1	0.74	10.02	0.44	2.33e-21	Cognitive test performance;
LUAD	cis	rs1784581	0.674	rs1789996	chr6:162391895	T/C	cg17173639	chr6:162384350	PARK2	-0.51	-9.26	-0.41	1.03e-18	Itch intensity from mosquito bite;
LUAD	cis	rs739496	1.000	rs7296313	chr12:111878526	T/C	cg10833066	chr12:111807467	FAM109A	0.45	8.28	0.37	1.59e-15	Platelet count;
LUAD	cis	rs490234	0.841	rs521119	chr9:128314394	T/C	cg14078157	chr9:128172775	NA	0.43	8.02	0.36	1.07e-14	Mean arterial pressure;
LUAD	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg17264618	chr3:40429014	ENTPD3	0.4	8.8	0.39	3.49e-17	Renal cell carcinoma;
LUAD	cis	rs10193935	1.000	rs4494804	chr2:42395946	A/T	cg27598129	chr2:42591480	NA	-0.77	-10.03	-0.44	2.15e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs593982	0.920	rs488170	chr11:65481544	T/C	cg08755490	chr11:65554678	OVOL1	1.23	14.66	0.58	1.2e-39	Atopic dermatitis;
LUAD	cis	rs7677751	0.806	rs4864863	chr4:55100831	A/G	cg17187183	chr4:55093834	PDGFRA	0.51	8.63	0.39	1.23e-16	Corneal astigmatism;
LUAD	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg08847533	chr14:75593920	NEK9	0.39	6.67	0.31	8.02e-11	Height;
LUAD	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	15.8	0.61	1.55e-44	Bone mineral density;
LUAD	trans	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg21659725	chr3:3221576	CRBN	-0.57	-9.17	-0.41	2.12e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg08470875	chr2:26401718	FAM59B	-0.67	-8.95	-0.4	1.1e-17	Gut microbiome composition (summer);
LUAD	trans	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg25482853	chr8:67687455	SGK3	1.03	16.44	0.62	2.46e-47	Obesity-related traits;
LUAD	cis	rs6761276	0.649	rs10184259	chr2:113838628	T/C	cg10479672	chr2:113810641	IL1F8	-0.36	-7.1	-0.33	5.39e-12	Protein quantitative trait loci;
LUAD	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg04414720	chr1:150670196	GOLPH3L	0.68	11.88	0.5	2.73e-28	Melanoma;
LUAD	cis	rs1448094	0.872	rs10863147	chr12:86408441	G/C	cg18827107	chr12:86230957	RASSF9	-0.46	-8.29	-0.37	1.5e-15	Major depressive disorder;
LUAD	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg14789911	chr21:47582049	C21orf56	-0.48	-8.52	-0.38	2.88e-16	Testicular germ cell tumor;
LUAD	cis	rs11166629	1.000	rs1036820	chr8:135646571	C/T	cg27224718	chr8:135614730	ZFAT	-0.56	-10.15	-0.44	8.18e-22	Smoking quantity;
LUAD	cis	rs10504073	0.506	rs7007271	chr8:49941897	T/C	cg00325661	chr8:49890786	NA	0.44	10.16	0.44	7.89e-22	Blood metabolite ratios;
LUAD	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.38	6.4	0.3	4.1e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg21770322	chr7:97807741	LMTK2	0.32	7.63	0.35	1.59e-13	Breast cancer;
LUAD	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg10755058	chr3:40428713	ENTPD3	0.39	7.03	0.32	8.11e-12	Renal cell carcinoma;
LUAD	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg06713675	chr4:122721982	EXOSC9	-0.84	-18.16	-0.66	6.49e-55	Type 2 diabetes;
LUAD	cis	rs13333054	1.000	rs12232384	chr16:86009760	A/C	cg08215318	chr16:86016387	NA	-0.47	-7.8	-0.35	4.72e-14	Multiple sclerosis;
LUAD	cis	rs12893668	0.663	rs12889731	chr14:104087482	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-8.06	-0.36	8.16e-15	Reticulocyte count;
LUAD	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg08773314	chr2:239334832	ASB1	0.45	10.49	0.45	4.74e-23	Multiple system atrophy;
LUAD	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg18512352	chr11:47633146	NA	-0.56	-10.04	-0.44	2.02e-21	Subjective well-being;
LUAD	cis	rs9837602	0.938	rs10511177	chr3:99724873	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.6	-9.13	-0.41	2.78e-18	Breast cancer;
LUAD	cis	rs1832871	0.672	rs6933928	chr6:158747071	C/T	cg07165851	chr6:158734300	TULP4	0.73	11.15	0.48	1.7e-25	Height;
LUAD	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg13393036	chr8:95962371	TP53INP1	0.37	8.08	0.37	7.01e-15	Type 2 diabetes;
LUAD	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.66	-0.39	9.95e-17	Total body bone mineral density;
LUAD	cis	rs1448094	0.967	rs11117116	chr12:86331087	A/T	cg00310523	chr12:86230176	RASSF9	0.35	7.56	0.34	2.58e-13	Major depressive disorder;
LUAD	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	12.16	0.51	2.29e-29	Hip circumference adjusted for BMI;
LUAD	trans	rs931812	0.964	rs2102290	chr8:101919844	G/C	cg20993868	chr7:22813445	NA	0.58	11.44	0.49	1.36e-26	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg13385794	chr1:248469461	NA	0.26	6.97	0.32	1.23e-11	Common traits (Other);
LUAD	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg21775007	chr8:11205619	TDH	-0.5	-9.09	-0.4	3.95e-18	Retinal vascular caliber;
LUAD	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg07936489	chr17:37558343	FBXL20	0.51	6.91	0.32	1.82e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg00071950	chr4:10020882	SLC2A9	-0.65	-12.63	-0.52	3.08e-31	Bone mineral density;
LUAD	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18876405	chr7:65276391	NA	-0.43	-6.77	-0.31	4.24e-11	Aortic root size;
LUAD	trans	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg14917512	chr19:3094685	GNA11	-0.56	-6.58	-0.3	1.39e-10	Diabetic kidney disease;
LUAD	cis	rs490234	0.702	rs10120000	chr9:128288428	C/T	cg14078157	chr9:128172775	NA	-0.46	-8.3	-0.37	1.46e-15	Mean arterial pressure;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04730925	chr18:51795821	POLI	-0.42	-6.39	-0.3	4.47e-10	Height;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg26668828	chr6:292823	DUSP22	-0.8	-14.36	-0.57	2.16e-38	Menopause (age at onset);
LUAD	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg23758822	chr17:41437982	NA	1.02	20.93	0.71	2.75e-67	Menopause (age at onset);
LUAD	cis	rs2046867	0.818	rs7637138	chr3:72910886	A/G	cg25664220	chr3:72788482	NA	-0.6	-10.48	-0.45	5.51e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg05621596	chr22:47072043	GRAMD4	-0.66	-10.96	-0.47	9.25e-25	Urate levels in obese individuals;
LUAD	trans	rs8002861	0.713	rs7339417	chr13:44413496	A/T	cg17145862	chr1:211918768	LPGAT1	0.65	13.06	0.54	5.38e-33	Leprosy;
LUAD	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg16342193	chr10:102329863	NA	-0.41	-6.85	-0.32	2.55e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg14824382	chr8:144680115	EEF1D;TIGD5	-0.48	-6.69	-0.31	7.3e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs6840360	0.571	rs1822347	chr4:152525319	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.68	-0.31	7.66e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg18132916	chr6:79620363	NA	-0.45	-7.64	-0.35	1.44e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg14300568	chr18:57567149	PMAIP1	-0.61	-6.36	-0.3	5.21e-10	Type 2 diabetes;
LUAD	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg09222892	chr1:25734099	RHCE	-0.47	-8.83	-0.39	2.71e-17	Erythrocyte sedimentation rate;
LUAD	cis	rs735539	0.517	rs9552241	chr13:21127569	C/G	cg27499820	chr13:21296301	IL17D	-0.5	-8.54	-0.38	2.46e-16	Dental caries;
LUAD	cis	rs12545109	0.700	rs2670045	chr8:57393695	A/G	cg11919837	chr8:57350735	NA	-0.44	-6.44	-0.3	3.18e-10	Obesity-related traits;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03432151	chr15:89745000	ABHD2	-0.52	-7.1	-0.33	5.47e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg10589385	chr1:150898437	SETDB1	0.41	7.68	0.35	1.09e-13	Melanoma;
LUAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03647317	chr4:187891568	NA	-0.35	-6.47	-0.3	2.79e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg18187862	chr3:45730750	SACM1L	-0.57	-8.81	-0.39	3.16e-17	Primary sclerosing cholangitis;
LUAD	trans	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg25482853	chr8:67687455	SGK3	0.64	10.35	0.45	1.57e-22	Obesity-related traits;
LUAD	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	7.83	0.36	4.09e-14	Menarche (age at onset);
LUAD	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.69	0.31	7.09e-11	Aortic root size;
LUAD	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.8	0.76	4.34e-80	Chronic sinus infection;
LUAD	cis	rs4072705	0.835	rs7855360	chr9:127556704	C/T	cg13476313	chr9:127244764	NR5A1	0.33	7.71	0.35	9.24e-14	Menarche (age at onset);
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg08651674	chr6:7108441	RREB1	0.5	7.73	0.35	8.1e-14	Monocyte percentage of white cells;
LUAD	cis	rs71403859	0.803	rs8063455	chr16:71599977	G/A	cg08717414	chr16:71523259	ZNF19	-0.54	-6.42	-0.3	3.71e-10	Post bronchodilator FEV1;
LUAD	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg09824328	chr1:43425412	SLC2A1	-0.78	-10.33	-0.45	1.81e-22	Monocyte count;
LUAD	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg00933542	chr6:150070202	PCMT1	0.41	8.69	0.39	8.27e-17	Lung cancer;
LUAD	cis	rs2485376	1.000	rs2246775	chr10:104057251	A/C	cg20641465	chr10:103991465	PITX3	-0.56	-10.35	-0.45	1.56e-22	QT interval;
LUAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08280861	chr8:58055591	NA	0.75	9.28	0.41	8.96e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg09517075	chr8:22133004	PIWIL2	0.5	9.23	0.41	1.34e-18	Hypertriglyceridemia;
LUAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.17	-0.37	3.56e-15	Alzheimer's disease;
LUAD	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08564027	chr20:61660810	NA	-0.78	-15.63	-0.61	8.27e-44	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg11833968	chr6:79620685	NA	-0.43	-8.15	-0.37	4.3e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.68	0.31	7.6e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg08999081	chr20:33150536	PIGU	0.47	9.15	0.41	2.47e-18	Coronary artery disease;
LUAD	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg01256987	chr12:42539512	GXYLT1	0.36	7.1	0.33	5.27e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg07343612	chr16:622815	PIGQ	-0.79	-15.62	-0.6	9.55e-44	Height;
LUAD	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.71	0.49	1.31e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	9.4	0.42	3.48e-19	Melanoma;
LUAD	cis	rs2692947	0.711	rs34639392	chr2:96508976	T/C	cg23100626	chr2:96804247	ASTL	0.31	7.72	0.35	8.22e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7107174	1.000	rs11237456	chr11:78040780	C/G	cg19901956	chr11:77921274	USP35	-0.47	-6.7	-0.31	6.84e-11	Testicular germ cell tumor;
LUAD	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg00933542	chr6:150070202	PCMT1	0.46	10.0	0.44	2.73e-21	Lung cancer;
LUAD	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6087990	0.735	rs910083	chr20:31378690	A/C	cg13636640	chr20:31349939	DNMT3B	0.76	13.75	0.56	8.07e-36	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg05340658	chr4:99064831	C4orf37	0.53	9.0	0.4	7.76e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg00684032	chr4:1343700	KIAA1530	0.41	7.03	0.32	8.18e-12	Obesity-related traits;
LUAD	cis	rs12618769	0.652	rs4851144	chr2:99220707	T/C	cg10123293	chr2:99228465	UNC50	0.5	8.68	0.39	8.69e-17	Bipolar disorder;
LUAD	cis	rs7824557	0.569	rs7816601	chr8:11205593	T/C	cg21775007	chr8:11205619	TDH	0.55	9.82	0.43	1.24e-20	Retinal vascular caliber;
LUAD	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg19413350	chr8:57351067	NA	-0.41	-6.52	-0.3	1.95e-10	Obesity-related traits;
LUAD	cis	rs938554	0.513	rs3733588	chr4:9997303	A/G	cg02734326	chr4:10020555	SLC2A9	-0.46	-7.06	-0.32	6.98e-12	Blood metabolite levels;
LUAD	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg12311346	chr5:56204834	C5orf35	-0.43	-7.09	-0.33	5.77e-12	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs1232027	0.700	rs836823	chr5:79943714	A/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.47	-7.48	-0.34	4.21e-13	Huntington's disease progression;
LUAD	cis	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg21775007	chr8:11205619	TDH	0.57	10.13	0.44	9.44e-22	Retinal vascular caliber;
LUAD	cis	rs367943	0.665	rs4401566	chr5:112963356	A/G	cg12552261	chr5:112820674	MCC	0.43	7.7	0.35	9.83e-14	Type 2 diabetes;
LUAD	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg04287289	chr16:89883240	FANCA	0.66	6.84	0.32	2.87e-11	Skin colour saturation;
LUAD	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg17063962	chr7:91808500	NA	0.7	12.76	0.53	8.88e-32	Breast cancer;
LUAD	trans	rs7395662	1.000	rs7478900	chr11:48544003	T/C	cg00717180	chr2:96193071	NA	-0.39	-7.36	-0.34	9.52e-13	HDL cholesterol;
LUAD	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg09835421	chr16:68378352	PRMT7	-0.66	-8.37	-0.38	8.64e-16	Schizophrenia;
LUAD	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg08085267	chr17:45401833	C17orf57	0.6	10.63	0.46	1.52e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4711350	1.000	rs10947436	chr6:33739960	A/G	cg13859433	chr6:33739653	LEMD2	-0.36	-6.89	-0.32	2.02e-11	Schizophrenia;
LUAD	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg03714773	chr7:91764589	CYP51A1	0.29	6.82	0.31	3.18e-11	Breast cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg19977964	chr5:56206213	C5orf35	-0.39	-6.7	-0.31	6.64e-11	Schizophrenia;
LUAD	cis	rs7172809	0.573	rs2137977	chr15:77575505	T/C	cg11865553	chr15:77376250	NA	-0.39	-6.38	-0.3	4.66e-10	Glucose homeostasis traits;
LUAD	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg02551604	chr5:131831745	NA	-0.61	-10.1	-0.44	1.22e-21	Asthma (sex interaction);
LUAD	cis	rs7000551	0.751	rs2100291	chr8:22374551	C/T	cg12081754	chr8:22256438	SLC39A14	0.47	7.81	0.35	4.71e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg16006841	chr5:176797999	RGS14	0.55	10.05	0.44	1.88e-21	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs8099014	1.000	rs9319930	chr18:56123799	C/T	cg12907477	chr18:56117327	MIR122	0.4	6.77	0.31	4.3e-11	Platelet count;
LUAD	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2262909	0.962	rs409835	chr19:22230671	T/C	cg11619707	chr19:22235551	ZNF257	-0.48	-7.46	-0.34	4.98e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg23950597	chr19:37808831	NA	-0.6	-7.44	-0.34	5.68e-13	Coronary artery calcification;
LUAD	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg17366294	chr4:99064904	C4orf37	0.48	8.45	0.38	4.74e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs760805	0.965	rs11249203	chr1:25258585	G/C	cg22509179	chr1:25234806	RUNX3	-0.75	-13.51	-0.55	8.17e-35	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.85	-14.87	-0.59	1.5e-40	IgG glycosylation;
LUAD	cis	rs11971779	0.680	rs7804388	chr7:139086413	A/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs4073416	0.518	rs2149839	chr14:65983448	G/A	cg10998611	chr14:65879393	FUT8;LOC645431	-0.43	-6.48	-0.3	2.56e-10	N-glycan levels;
LUAD	cis	rs926938	0.583	rs12401670	chr1:115244337	C/T	cg12756093	chr1:115239321	AMPD1	-0.42	-6.75	-0.31	5.01e-11	Autism;
LUAD	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.49	6.42	0.3	3.56e-10	Platelet count;
LUAD	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06873352	chr17:61820015	STRADA	0.56	9.07	0.4	4.54e-18	Height;
LUAD	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg15123519	chr2:136567270	LCT	0.39	7.26	0.33	1.89e-12	Mosquito bite size;
LUAD	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg17757837	chr7:157058334	UBE3C	0.46	8.26	0.37	1.86e-15	Body mass index;
LUAD	trans	rs9467711	0.790	rs17598658	chr6:26175866	A/C	cg06606381	chr12:133084897	FBRSL1	-1.23	-9.97	-0.44	3.73e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg05340658	chr4:99064831	C4orf37	0.56	9.45	0.42	2.3e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7395662	0.895	rs11039869	chr11:48622312	C/G	cg00717180	chr2:96193071	NA	-0.39	-7.27	-0.33	1.72e-12	HDL cholesterol;
LUAD	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22857025	chr5:266934	NA	-0.97	-13.27	-0.54	7.57e-34	Breast cancer;
LUAD	cis	rs438465	1.000	rs2997885	chr6:169868587	C/A	cg11181693	chr6:169825345	NA	-0.63	-7.89	-0.36	2.62e-14	Corneal astigmatism;
LUAD	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg02423579	chr7:2872169	GNA12	-0.55	-9.32	-0.41	6.57e-19	Height;
LUAD	cis	rs231513	0.822	rs231520	chr17:41956983	T/C	cg26893861	chr17:41843967	DUSP3	-0.54	-6.58	-0.3	1.4e-10	Cognitive function;
LUAD	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.59	-0.31	1.3100000000000001e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1942	0.837	rs12440045	chr15:41782684	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.41	-7.05	-0.32	7.34e-12	Eosinophil percentage of granulocytes;
LUAD	trans	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg18335740	chr13:41363409	SLC25A15	0.49	8.76	0.39	4.7e-17	Lewy body disease;
LUAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23066280	chr7:158032496	PTPRN2	0.33	6.4	0.3	4.05e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg16680214	chr1:154839983	KCNN3	-0.62	-12.8	-0.53	6.13e-32	Prostate cancer;
LUAD	cis	rs6028335	0.674	rs61213966	chr20:37621906	A/G	cg27660920	chr20:37554817	FAM83D	0.52	6.54	0.3	1.79e-10	Alcohol and nicotine co-dependence;
LUAD	cis	rs34734847	0.871	rs2239760	chr12:121163518	C/A	cg21892295	chr12:121157589	UNC119B	-0.45	-8.4	-0.38	7.04e-16	Mean corpuscular volume;
LUAD	cis	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg02508848	chr16:68573721	ZFP90	-0.42	-6.55	-0.3	1.72e-10	Ulcerative colitis;
LUAD	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg10589385	chr1:150898437	SETDB1	0.44	7.96	0.36	1.59e-14	Melanoma;
LUAD	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg01802117	chr1:53393560	SCP2	-0.4	-8.01	-0.36	1.09e-14	Monocyte count;
LUAD	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg24803719	chr17:45855879	NA	-0.33	-7.34	-0.34	1.07e-12	IgG glycosylation;
LUAD	cis	rs4077515	0.967	rs4567159	chr9:139277059	G/A	cg14019695	chr9:139328340	INPP5E	0.4	7.56	0.34	2.61e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs887829	0.570	rs10168155	chr2:234596836	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.67	-0.43	4e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs151234	0.741	rs151227	chr16:28549508	C/T	cg04643524	chr16:28609220	SULT1A2	0.59	8.51	0.38	2.97e-16	Platelet distribution width;
LUAD	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg20607798	chr8:58055168	NA	0.67	8.73	0.39	5.82e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg22875332	chr1:76189707	ACADM	0.9	18.28	0.66	1.87e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12618769	0.597	rs4850876	chr2:99112069	C/T	cg10123293	chr2:99228465	UNC50	0.46	8.12	0.37	5.1e-15	Bipolar disorder;
LUAD	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg07917127	chr4:99064746	C4orf37	-0.43	-6.69	-0.31	7.16e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6906287	0.669	rs2356491	chr6:118806564	A/G	cg21191810	chr6:118973309	C6orf204	0.48	9.48	0.42	1.89e-19	Electrocardiographic conduction measures;
LUAD	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.18	0.54	1.83e-33	Prudent dietary pattern;
LUAD	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg20701182	chr2:24300061	SF3B14	0.64	7.16	0.33	3.54e-12	Lymphocyte counts;
LUAD	cis	rs3784262	0.631	rs4646625	chr15:58256296	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.4	-8.08	-0.37	6.85e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg18252515	chr7:66147081	NA	-0.62	-6.9	-0.32	1.96e-11	Diabetic kidney disease;
LUAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.07e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg17724175	chr1:150552817	MCL1	0.39	9.43	0.42	2.64e-19	Tonsillectomy;
LUAD	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.31	-0.33	1.36e-12	Lung cancer;
LUAD	cis	rs9443645	0.527	rs12194642	chr6:79538791	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.05	-0.32	7.33e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.576	rs251370	chr5:140246287	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.33	7.02	0.32	8.68e-12	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg19862616	chr7:65841803	NCRNA00174	1.01	23.8	0.76	4.33e-80	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs34375054	0.660	rs57031290	chr12:125593053	A/G	cg06287003	chr12:125626642	AACS	-0.43	-6.4	-0.3	4.08e-10	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg03676636	chr4:99064102	C4orf37	0.32	8.42	0.38	5.87e-16	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.7	-0.46	8.37e-24	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs494562	0.892	rs619299	chr6:86121482	A/T	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg22618164	chr12:122356400	WDR66	0.65	11.2	0.48	1.14e-25	Mean corpuscular volume;
LUAD	cis	rs7640424	0.728	rs326338	chr3:107843004	T/C	cg09227934	chr3:107805635	CD47	0.35	6.5	0.3	2.2e-10	Body mass index;
LUAD	trans	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg06606381	chr12:133084897	FBRSL1	-0.85	-8.23	-0.37	2.33e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg02450064	chr17:40260053	DHX58	-0.45	-7.5	-0.34	3.78e-13	Fibrinogen levels;
LUAD	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	14.94	0.59	7.9e-41	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs295137	0.799	rs4145969	chr2:201139961	C/T	cg23649088	chr2:200775458	C2orf69	-0.49	-8.38	-0.38	7.73e-16	Asthma (bronchodilator response);
LUAD	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg18854424	chr1:2615690	NA	0.43	9.4	0.42	3.47e-19	Ulcerative colitis;
LUAD	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg25358565	chr5:93447407	FAM172A	-0.56	-6.81	-0.31	3.4e-11	Diabetic retinopathy;
LUAD	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg03433033	chr1:76189801	ACADM	-0.71	-11.38	-0.48	2.35e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4954585	0.683	rs4452212	chr2:137015991	G/A	cg05194412	chr2:137003533	NA	0.62	11.2	0.48	1.12e-25	Colorectal cancer;
LUAD	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg20203395	chr5:56204925	C5orf35	-0.52	-8.3	-0.37	1.39e-15	Coronary artery disease;
LUAD	cis	rs12760731	0.720	rs12072124	chr1:178366990	G/A	cg00404053	chr1:178313656	RASAL2	0.56	7.82	0.36	4.27e-14	Obesity-related traits;
LUAD	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg15123519	chr2:136567270	LCT	0.38	7.0	0.32	9.89e-12	Mosquito bite size;
LUAD	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg04414720	chr1:150670196	GOLPH3L	0.73	13.62	0.55	2.78e-35	Tonsillectomy;
LUAD	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg10518543	chr12:38710700	ALG10B	-0.47	-7.68	-0.35	1.08e-13	Morning vs. evening chronotype;
LUAD	cis	rs2742417	0.603	rs2673055	chr3:45772772	G/A	cg10512202	chr3:45649293	LIMD1	0.47	8.85	0.4	2.46e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs4713675	0.565	rs3818530	chr6:33661222	C/G	cg13859433	chr6:33739653	LEMD2	-0.3	-7.05	-0.32	7.48e-12	Plateletcrit;
LUAD	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg26384229	chr12:38710491	ALG10B	0.49	7.91	0.36	2.25e-14	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg15704280	chr7:45808275	SEPT13	0.66	8.86	0.4	2.21e-17	Axial length;
LUAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs2735413	0.875	rs4888737	chr16:78083819	A/G	cg01028844	chr5:122736986	CEP120	0.41	6.46	0.3	2.87e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg10978503	chr1:24200527	CNR2	0.59	12.81	0.53	5.88e-32	Immature fraction of reticulocytes;
LUAD	cis	rs986417	1.000	rs1268621	chr14:60921571	G/A	cg27398547	chr14:60952738	C14orf39	-0.63	-7.71	-0.35	9.21e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.46	0.55	1.24e-34	Prudent dietary pattern;
LUAD	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg10523679	chr1:76189770	ACADM	-0.73	-11.4	-0.48	1.92e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21659725	chr3:3221576	CRBN	-0.63	-10.9	-0.47	1.53e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs17092148	1.000	rs7271289	chr20:33397303	C/T	cg16810054	chr20:33298113	TP53INP2	0.53	8.3	0.37	1.44e-15	Neuroticism;
LUAD	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.99	-0.4	8.34e-18	Bipolar disorder;
LUAD	cis	rs7789940	0.810	rs12533978	chr7:75943352	T/C	cg10167463	chr7:75959203	YWHAG	-0.7	-12.39	-0.52	2.61e-30	Multiple sclerosis;
LUAD	cis	rs13095912	0.785	rs6800725	chr3:185298156	C/A	cg11274856	chr3:185301563	NA	0.5	9.18	0.41	1.9e-18	Systolic blood pressure;
LUAD	cis	rs1018836	0.923	rs2105967	chr8:91587522	A/G	cg16814680	chr8:91681699	NA	-0.7	-11.73	-0.5	1.03e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg16479474	chr6:28041457	NA	-0.43	-7.36	-0.34	9.58e-13	Depression;
LUAD	cis	rs2282300	0.739	rs1222219	chr11:30344345	G/C	cg06241208	chr11:30344200	C11orf46	-0.54	-6.77	-0.31	4.45e-11	Morning vs. evening chronotype;
LUAD	trans	rs1420585	1.000	rs12597905	chr16:49002003	A/C	cg23586138	chr2:27719544	FNDC4;GCKR	-0.39	-6.57	-0.3	1.45e-10	Pursuit maintenance gain;
LUAD	cis	rs35740288	0.770	rs10520592	chr15:86114142	G/C	cg13263323	chr15:86062960	AKAP13	-0.43	-6.91	-0.32	1.74e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg26958806	chr6:27640298	NA	0.56	6.35	0.3	5.49e-10	Breast cancer;
LUAD	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg05313129	chr8:58192883	C8orf71	-0.5	-7.57	-0.35	2.42e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs977987	0.806	rs35787595	chr16:75466847	G/C	cg03315344	chr16:75512273	CHST6	0.65	14.2	0.57	1.1e-37	Dupuytren's disease;
LUAD	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg03676636	chr4:99064102	C4orf37	0.37	9.45	0.42	2.41e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg16031515	chr1:205743344	RAB7L1	0.32	6.48	0.3	2.63e-10	Monocyte percentage of white cells;
LUAD	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg02389323	chr16:88786976	FAM38A	0.9	10.44	0.45	7.33e-23	Plateletcrit;
LUAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg15117754	chr3:10150083	C3orf24	0.46	7.67	0.35	1.23e-13	Alzheimer's disease;
LUAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg09033563	chr22:24373618	LOC391322	-0.51	-7.92	-0.36	2.13e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.55	-0.34	2.78e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.06e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.812	rs7731773	chr5:130973943	A/G	cg25547332	chr5:131281432	NA	0.44	6.95	0.32	1.36e-11	Life satisfaction;
LUAD	trans	rs587242	0.528	rs7541317	chr1:97193145	A/G	cg10631902	chr5:14652156	NA	0.4	6.76	0.31	4.72e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg23029597	chr12:123009494	RSRC2	-0.54	-8.29	-0.37	1.54e-15	Body mass index;
LUAD	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9314323	0.624	rs117982737	chr8:26241010	C/T	cg13160058	chr8:26243215	BNIP3L	0.44	7.29	0.33	1.57e-12	Red cell distribution width;
LUAD	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg25894440	chr7:65020034	NA	-0.68	-7.18	-0.33	3.16e-12	Diabetic kidney disease;
LUAD	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg09222892	chr1:25734099	RHCE	0.47	8.92	0.4	1.43e-17	Plateletcrit;Mean corpuscular volume;
LUAD	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg03929089	chr4:120376271	NA	-0.92	-17.08	-0.64	3.99e-50	Height;
LUAD	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg06637938	chr14:75390232	RPS6KL1	0.48	8.07	0.37	7.43e-15	Caffeine consumption;
LUAD	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg04398451	chr17:18023971	MYO15A	-0.77	-14.07	-0.56	3.7e-37	Total body bone mineral density;
LUAD	trans	rs3857536	0.813	rs7769683	chr6:66946256	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg07432352	chr17:45403706	C17orf57	0.4	7.46	0.34	5.11e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg04111992	chr7:158790115	NA	-0.49	-8.37	-0.38	8.37e-16	Facial morphology (factor 20);
LUAD	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg10518543	chr12:38710700	ALG10B	0.53	8.6	0.39	1.56e-16	Morning vs. evening chronotype;
LUAD	cis	rs10129255	0.500	rs4774189	chr14:107176517	G/T	cg23076370	chr14:107095027	NA	-0.43	-8.51	-0.38	3.11e-16	Kawasaki disease;
LUAD	cis	rs9807989	0.507	rs10200952	chr2:103027651	A/C	cg03938978	chr2:103052716	IL18RAP	0.45	10.33	0.45	1.82e-22	Asthma;
LUAD	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg24558204	chr6:135376177	HBS1L	0.47	8.59	0.39	1.65e-16	Red blood cell count;
LUAD	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10802521	chr3:52805072	NEK4	-0.53	-9.01	-0.4	7.2e-18	Bipolar disorder;
LUAD	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg10589385	chr1:150898437	SETDB1	0.41	7.75	0.35	7.13e-14	Tonsillectomy;
LUAD	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg13263323	chr15:86062960	AKAP13	-0.43	-7.26	-0.33	1.91e-12	Coronary artery disease;
LUAD	cis	rs9807989	0.811	rs4485585	chr2:102970759	T/C	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.05e-10	Asthma;
LUAD	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg03676636	chr4:99064102	C4orf37	0.29	7.34	0.34	1.07e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg06623918	chr6:96969491	KIAA0776	-0.88	-17.35	-0.64	2.47e-51	Headache;
LUAD	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.38	-0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.65	-0.31	9.33e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1595825	1.000	rs1440087	chr2:198871476	G/C	cg11031976	chr2:198649780	BOLL	-0.46	-6.77	-0.31	4.41e-11	Ulcerative colitis;
LUAD	cis	rs10746514	0.833	rs867844	chr1:232266278	A/T	cg09506761	chr1:232265262	NA	0.39	7.43	0.34	5.88e-13	Response to statin therapy;
LUAD	cis	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-7.41	-0.34	6.86e-13	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg09858108	chr8:58055024	NA	0.59	10.04	0.44	2e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs17095355	1.000	rs72828245	chr10:111746596	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.67	-8.8	-0.39	3.4e-17	Biliary atresia;
LUAD	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07054040	chr15:37393282	MEIS2	-0.65	-6.46	-0.3	2.86e-10	Type 2 diabetes;
LUAD	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg07828340	chr4:882639	GAK	1.05	10.73	0.46	6.2e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs10489202	0.608	rs6657019	chr1:168079669	T/C	cg25738037	chr1:168025549	DCAF6	-0.45	-6.78	-0.31	4.01e-11	Schizophrenia;
LUAD	cis	rs2777491	0.507	rs11854081	chr15:41646398	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.11	-25.06	-0.77	1.26e-85	Ulcerative colitis;
LUAD	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg00701064	chr4:6280414	WFS1	0.67	14.78	0.58	3.95e-40	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.75	9.38	0.42	3.98e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs798766	0.953	rs13123646	chr4:1740539	T/C	cg05874882	chr4:1763078	NA	-0.36	-6.4	-0.3	4.17e-10	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08280861	chr8:58055591	NA	0.57	7.34	0.34	1.13e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg26354017	chr1:205819088	PM20D1	0.49	8.16	0.37	3.81e-15	Parkinson's disease;
LUAD	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.33	0.38	1.1e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7000551	0.779	rs2443507	chr8:22373231	G/A	cg12081754	chr8:22256438	SLC39A14	0.48	8.01	0.36	1.1e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.76	-0.43	1.99e-20	Schizophrenia;
LUAD	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg06221963	chr1:154839813	KCNN3	-0.85	-20.05	-0.7	2.36e-63	Prostate cancer;
LUAD	cis	rs6669119	0.668	rs75509607	chr1:19093763	C/T	cg26220594	chr1:19110978	NA	0.58	7.5	0.34	3.92e-13	Percentage gas trapping;
LUAD	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.7	0.31	6.68e-11	Colorectal cancer;
LUAD	trans	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04565464	chr8:145669602	NFKBIL2	0.46	6.8	0.31	3.69e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1595825	0.891	rs10497810	chr2:198895732	C/T	cg11031976	chr2:198649780	BOLL	-0.45	-6.53	-0.3	1.84e-10	Ulcerative colitis;
LUAD	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg25237894	chr2:233734115	C2orf82	0.56	10.74	0.46	5.87e-24	Coronary artery disease;
LUAD	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg09998033	chr7:158218633	PTPRN2	-0.43	-7.63	-0.35	1.5700000000000001e-13	Obesity-related traits;
LUAD	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg01689657	chr7:91764605	CYP51A1	0.29	7.11	0.33	4.83e-12	Breast cancer;
LUAD	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg07570687	chr10:102243282	WNT8B	0.48	7.31	0.33	1.34e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-11.65	-0.49	2.23e-27	Bone mineral density;
LUAD	trans	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.75	0.35	7e-14	Resting heart rate;
LUAD	cis	rs7274811	0.625	rs293707	chr20:31937048	T/G	cg14921437	chr20:32255988	NECAB3;C20orf134	0.45	6.53	0.3	1.86e-10	Height;
LUAD	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg06953865	chr19:18549723	ISYNA1	-0.36	-6.72	-0.31	5.99e-11	Breast cancer;
LUAD	cis	rs8018808	0.935	rs4223	chr14:77893276	A/G	cg20045696	chr14:77926864	AHSA1	-0.38	-6.8	-0.31	3.53e-11	Myeloid white cell count;
LUAD	cis	rs10193935	1.000	rs10173107	chr2:42420302	A/T	cg27598129	chr2:42591480	NA	-0.8	-9.85	-0.43	9.83e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	0.947	rs11744232	chr5:130911732	A/G	cg25547332	chr5:131281432	NA	0.4	6.44	0.3	3.31e-10	Life satisfaction;
LUAD	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg04034577	chr2:241836375	C2orf54	-0.51	-11.37	-0.48	2.51e-26	Urinary metabolites;
LUAD	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg08885076	chr2:99613938	TSGA10	0.41	7.76	0.35	6.48e-14	Chronic sinus infection;
LUAD	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg09835421	chr16:68378352	PRMT7	-1.02	-11.51	-0.49	7.59e-27	Schizophrenia;
LUAD	trans	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg24644049	chr4:85504048	CDS1	0.88	7.59	0.35	2.1e-13	Skin colour saturation;
LUAD	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg12623302	chr6:28058802	ZSCAN12L1	-0.32	-6.54	-0.3	1.75e-10	Depression;
LUAD	trans	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg06606381	chr12:133084897	FBRSL1	-0.49	-6.6	-0.31	1.2e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.42	8.1	0.37	5.91e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs89107	0.675	rs283080	chr6:118606000	C/A	cg21191810	chr6:118973309	C6orf204	0.48	9.32	0.41	6.61e-19	Cardiac structure and function;
LUAD	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-16.22	-0.62	2.41e-46	Schizophrenia;
LUAD	cis	rs11676348	0.808	rs4674267	chr2:219046437	C/T	cg06547715	chr2:218990976	CXCR2	0.29	6.58	0.3	1.38e-10	Ulcerative colitis;
LUAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg12143784	chr7:64541923	NA	-0.44	-7.29	-0.33	1.56e-12	Calcium levels;
LUAD	cis	rs17152411	1.000	rs12573033	chr10:126607803	T/G	cg07906193	chr10:126599966	NA	0.54	7.7	0.35	9.58e-14	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg07269724	chr19:12904655	NA	-0.41	-6.35	-0.3	5.58e-10	Height;
LUAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg07234876	chr8:600039	NA	-0.93	-10.07	-0.44	1.6e-21	IgG glycosylation;
LUAD	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg04450456	chr4:17643702	FAM184B	0.41	7.88	0.36	2.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6998277	1.000	rs16869658	chr8:103633762	C/T	cg10187029	chr8:103597600	NA	0.77	12.47	0.52	1.35e-30	Migraine;
LUAD	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3942852	0.712	rs2174129	chr11:48108557	A/C	cg03929089	chr4:120376271	NA	-0.52	-7.59	-0.35	2.12e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg04673462	chr1:38461896	NA	0.42	8.12	0.37	4.98e-15	Coronary artery disease;
LUAD	cis	rs1476679	0.927	rs2405442	chr7:99971313	T/C	cg19116668	chr7:99932089	PMS2L1	0.32	6.55	0.3	1.7e-10	Alzheimer's disease (late onset);
LUAD	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg00310523	chr12:86230176	RASSF9	0.4	7.97	0.36	1.53e-14	Major depressive disorder;
LUAD	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11890956	chr21:40555474	PSMG1	-0.61	-10.0	-0.44	2.83e-21	Cognitive function;
LUAD	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg00814883	chr7:100076585	TSC22D4	-0.77	-10.33	-0.45	1.88e-22	Platelet count;
LUAD	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg14092571	chr14:90743983	NA	-0.49	-8.62	-0.39	1.36e-16	Mortality in heart failure;
LUAD	cis	rs9341808	0.718	rs12203867	chr6:80820833	G/T	cg08355045	chr6:80787529	NA	0.56	10.11	0.44	1.17e-21	Sitting height ratio;
LUAD	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg13010199	chr12:38710504	ALG10B	0.4	6.57	0.3	1.47e-10	Bladder cancer;
LUAD	cis	rs7680126	0.500	rs4697717	chr4:10149784	C/G	cg00071950	chr4:10020882	SLC2A9	-0.57	-8.22	-0.37	2.6e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	trans	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.23	0.48	8.94e-26	Mean corpuscular volume;
LUAD	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.46	7.72	0.35	8.29e-14	Body mass index (adult);
LUAD	cis	rs57502260	0.573	rs11228294	chr11:68388567	C/T	cg16797656	chr11:68205561	LRP5	0.44	8.17	0.37	3.69e-15	Total body bone mineral density (age 45-60);
LUAD	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.81e-12	Colorectal cancer;
LUAD	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg17366294	chr4:99064904	C4orf37	0.52	9.53	0.42	1.25e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg25894440	chr7:65020034	NA	-0.69	-7.35	-0.34	1.02e-12	Diabetic kidney disease;
LUAD	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg26384229	chr12:38710491	ALG10B	0.4	6.41	0.3	3.95e-10	Morning vs. evening chronotype;
LUAD	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg13870426	chr17:30244630	NA	-0.59	-6.98	-0.32	1.16e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs9463078	0.683	rs227850	chr6:44699068	C/T	cg25276700	chr6:44698697	NA	0.36	6.67	0.31	8.17e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUAD	cis	rs6005807	0.843	rs9620797	chr22:28895265	C/A	cg12565055	chr22:29076175	TTC28	0.67	6.52	0.3	1.99e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs75920871	0.841	rs61905709	chr11:116897834	C/T	cg04087571	chr11:116723030	SIK3	-0.32	-6.48	-0.3	2.63e-10	Subjective well-being;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09560365	chr7:152373463	XRCC2	-0.39	-6.47	-0.3	2.64e-10	Cancer;
LUAD	cis	rs2274273	0.870	rs946059	chr14:55847466	A/G	cg04306507	chr14:55594613	LGALS3	0.4	8.58	0.38	1.88e-16	Protein biomarker;
LUAD	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg06784218	chr1:46089804	CCDC17	0.59	13.21	0.54	1.38e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9296095	1.000	rs5745568	chr6:33548394	G/T	cg24505687	chr6:33548425	BAK1	0.46	7.49	0.34	4.08e-13	Platelet count;
LUAD	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg20542592	chr8:11973495	FAM66D	0.41	6.41	0.3	3.86e-10	Joint mobility (Beighton score);
LUAD	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg24829409	chr8:58192753	C8orf71	-0.55	-8.05	-0.36	8.4e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-8.78	-0.39	3.98e-17	Gut microbiome composition (summer);
LUAD	cis	rs193541	0.632	rs6595413	chr5:122156949	G/A	cg19077854	chr5:122220652	SNX24	0.37	6.45	0.3	2.99e-10	Glucose homeostasis traits;
LUAD	cis	rs4006360	0.546	rs1846043	chr17:39265300	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.39	8.38	0.38	8.04e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg05425664	chr17:57184151	TRIM37	-0.43	-7.66	-0.35	1.29e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs806215	1.000	rs712700	chr7:127250907	T/C	cg25922125	chr7:127225783	GCC1	0.49	7.15	0.33	3.77e-12	Type 2 diabetes;
LUAD	cis	rs7809950	0.678	rs2301801	chr7:106870746	T/C	cg23024343	chr7:107201750	COG5	-0.82	-13.52	-0.55	7.34e-35	Coronary artery disease;
LUAD	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.54	-9.65	-0.42	4.62e-20	Lymphocyte counts;
LUAD	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg20701182	chr2:24300061	SF3B14	0.56	6.7	0.31	6.56e-11	Lymphocyte counts;
LUAD	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-7.58	-0.35	2.19e-13	Lung cancer;
LUAD	cis	rs7651039	1.000	rs7651039	chr3:15648004	C/T	cg16303742	chr3:15540471	COLQ	-0.46	-8.38	-0.38	7.67e-16	Coronary heart disease;
LUAD	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18876405	chr7:65276391	NA	0.44	6.88	0.32	2.13e-11	Aortic root size;
LUAD	cis	rs4790333	0.571	rs2012068	chr17:2255351	C/T	cg02569219	chr17:2266849	SGSM2	0.53	9.92	0.43	5.36e-21	Proinsulin levels;
LUAD	cis	rs908922	0.676	rs2105117	chr1:152484129	G/A	cg23254163	chr1:152506842	NA	0.24	6.57	0.3	1.5e-10	Hair morphology;
LUAD	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg17063962	chr7:91808500	NA	0.7	12.44	0.52	1.65e-30	Breast cancer;
LUAD	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	8.72	0.39	6.45e-17	Ileal carcinoids;
LUAD	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg15704280	chr7:45808275	SEPT13	0.66	8.88	0.4	1.94e-17	Axial length;
LUAD	cis	rs62238980	0.614	rs116982428	chr22:32381272	G/C	cg00543991	chr22:32367038	NA	0.94	8.78	0.39	4.09e-17	Childhood ear infection;
LUAD	cis	rs1371614	0.545	rs3769137	chr2:27169490	C/T	cg00617064	chr2:27272375	NA	0.35	6.75	0.31	4.88e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg13010199	chr12:38710504	ALG10B	0.39	6.35	0.3	5.46e-10	Bladder cancer;
LUAD	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.08	-0.33	6.17e-12	Total cholesterol levels;
LUAD	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08704250	chr15:31115839	NA	-0.48	-8.68	-0.39	8.94e-17	Huntington's disease progression;
LUAD	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg06547715	chr2:218990976	CXCR2	-0.3	-7.13	-0.33	4.44e-12	Colorectal cancer;
LUAD	cis	rs4774899	0.869	rs2585102	chr15:57331821	G/A	cg14026238	chr15:57616123	NA	-0.34	-6.39	-0.3	4.28e-10	Urinary tract infection frequency;
LUAD	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.33	0.38	1.1e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.87	0.36	2.95e-14	Morning vs. evening chronotype;
LUAD	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg25358565	chr5:93447407	FAM172A	0.6	7.48	0.34	4.4e-13	Diabetic retinopathy;
LUAD	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg02196655	chr2:10830764	NOL10	-0.44	-8.1	-0.37	6.01e-15	Prostate cancer;
LUAD	cis	rs13064411	0.542	rs13082603	chr3:113223362	T/C	cg10517650	chr3:113235015	CCDC52	-0.45	-8.28	-0.37	1.61e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs10916814	0.959	rs2101731	chr1:20901922	G/A	cg24502330	chr1:20914028	CDA	-0.38	-7.1	-0.33	5.31e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26314531	chr2:26401878	FAM59B	-0.55	-7.72	-0.35	8.65e-14	Gut microbiome composition (summer);
LUAD	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11644478	chr21:40555479	PSMG1	0.47	7.89	0.36	2.54e-14	Cognitive function;
LUAD	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg14196790	chr5:131705035	SLC22A5	-0.49	-8.88	-0.4	1.9e-17	Blood metabolite levels;
LUAD	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.89	-0.36	2.58e-14	Blood metabolite levels;
LUAD	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg18827107	chr12:86230957	RASSF9	-0.53	-9.44	-0.42	2.62e-19	Major depressive disorder;
LUAD	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.41	-8.94	-0.4	1.26e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.37	0.55	2.89e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs62238980	0.614	rs4820061	chr22:32378359	G/T	cg00543991	chr22:32367038	NA	0.94	8.78	0.39	4.09e-17	Childhood ear infection;
LUAD	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg15445000	chr17:37608096	MED1	-0.45	-8.35	-0.38	9.73e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg05340658	chr4:99064831	C4orf37	-0.44	-7.33	-0.34	1.14e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg19862616	chr7:65841803	NCRNA00174	1.04	25.7	0.78	2.02e-88	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg14631576	chr9:95140430	CENPP	-0.48	-9.66	-0.43	4.27e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg20340149	chr2:122407145	CLASP1	0.4	6.5	0.3	2.23e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs8112211	0.731	rs11673222	chr19:38824344	G/A	cg14299480	chr19:38876666	GGN	-0.44	-6.39	-0.3	4.38e-10	Blood protein levels;
LUAD	cis	rs9814567	0.806	rs2293294	chr3:134322814	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.75	13.8	0.56	5.22e-36	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2688608	0.901	rs2664280	chr10:75617344	A/T	cg19442545	chr10:75533431	FUT11	0.43	7.33	0.34	1.2e-12	Inflammatory bowel disease;
LUAD	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg27454412	chr7:1067447	C7orf50	-0.43	-8.02	-0.36	1.06e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs4148087	1.000	rs4148087	chr21:43622267	C/T	cg08841829	chr21:43638893	ABCG1	-0.53	-7.45	-0.34	5.2e-13	Eating disorder in bipolar disorder;
LUAD	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg13390004	chr1:15929781	NA	0.49	8.61	0.39	1.49e-16	Systolic blood pressure;
LUAD	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg12311346	chr5:56204834	C5orf35	0.74	11.81	0.5	5.39e-28	Initial pursuit acceleration;
LUAD	cis	rs1232027	0.656	rs1677625	chr5:79960448	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.02	-0.32	8.96e-12	Huntington's disease progression;
LUAD	cis	rs12545109	0.842	rs2670050	chr8:57402914	T/G	cg07776626	chr8:57350775	NA	-0.59	-8.72	-0.39	6.63e-17	Obesity-related traits;
LUAD	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg05304507	chr6:116381966	FRK	0.2	6.79	0.31	3.75e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg12935359	chr14:103987150	CKB	-0.49	-7.85	-0.36	3.52e-14	Body mass index;
LUAD	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg03467027	chr4:99064603	C4orf37	0.41	6.46	0.3	2.95e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs986417	1.000	rs10148202	chr14:61055940	C/T	cg27398547	chr14:60952738	C14orf39	-0.58	-6.52	-0.3	2.02e-10	Gut microbiota (bacterial taxa);
LUAD	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg01689657	chr7:91764605	CYP51A1	-0.28	-6.69	-0.31	7.04e-11	Breast cancer;
LUAD	cis	rs12519773	0.526	rs4285204	chr5:92528272	C/T	cg18783429	chr5:92414398	NA	0.44	7.78	0.35	5.47e-14	Migraine;
LUAD	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg27661571	chr11:113659931	NA	-0.69	-8.01	-0.36	1.1e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg27170947	chr2:26402098	FAM59B	-0.79	-11.04	-0.47	4.52e-25	Gut microbiome composition (summer);
LUAD	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg14458575	chr2:238380390	NA	0.65	12.44	0.52	1.69e-30	Prostate cancer;
LUAD	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg21918786	chr6:109611834	NA	-0.59	-10.85	-0.47	2.29e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg23029597	chr12:123009494	RSRC2	-0.58	-9.2	-0.41	1.69e-18	Body mass index;
LUAD	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.63	0.31	1e-10	Depression;
LUAD	cis	rs62238980	0.614	rs78247456	chr22:32442531	G/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg17200465	chr3:40428508	ENTPD3	0.27	6.51	0.3	2.18e-10	Renal cell carcinoma;
LUAD	cis	rs1595825	0.891	rs1016883	chr2:198881668	A/G	cg10547527	chr2:198650123	BOLL	0.5	6.9	0.32	1.9e-11	Ulcerative colitis;
LUAD	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg05283184	chr6:79620031	NA	-0.59	-11.9	-0.5	2.38e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs7010267	0.508	rs1385500	chr8:119976186	A/T	cg01975934	chr8:119970761	NA	-0.36	-6.97	-0.32	1.25e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-9.33	-0.41	6.07e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs9715521	0.775	rs11723682	chr4:59851969	C/T	cg11281224	chr4:60001000	NA	-0.6	-10.19	-0.44	5.7e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs57994353	0.793	rs12552167	chr9:139322927	C/T	cg14019695	chr9:139328340	INPP5E	0.42	6.97	0.32	1.25e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg14773178	chr5:1868261	NA	0.34	6.63	0.31	1.03e-10	Cardiovascular disease risk factors;
LUAD	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg11057378	chr10:81107060	PPIF	0.38	7.19	0.33	2.95e-12	Height;
LUAD	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg02782426	chr3:40428986	ENTPD3	0.41	8.57	0.38	1.97e-16	Renal cell carcinoma;
LUAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg10295955	chr4:187884368	NA	-1.17	-30.84	-0.83	2.83e-110	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.68	12.9	0.53	2.35e-32	Cognitive ability;
LUAD	cis	rs8060686	0.858	rs10468274	chr16:67922342	C/T	cg26727032	chr16:67993705	SLC12A4	-0.55	-9.14	-0.41	2.6e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4315565	0.688	rs11887395	chr2:69270926	A/G	cg13358873	chr2:69271042	ANTXR1	-0.48	-6.85	-0.32	2.59e-11	Height;
LUAD	trans	rs11992162	0.967	rs4841661	chr8:11832769	T/C	cg27411982	chr8:10470053	RP1L1	0.35	6.36	0.3	5.37e-10	Monocyte count;
LUAD	trans	rs2840044	1.000	rs225243	chr17:33947212	A/G	cg19694781	chr19:47549865	TMEM160	-0.63	-10.19	-0.44	5.72e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs4280164	0.551	rs2295300	chr14:24805117	C/T	cg22990158	chr14:24802150	ADCY4	0.59	9.21	0.41	1.56e-18	Parent of origin effect on language impairment (paternal);
LUAD	trans	rs12517041	1.000	rs35561495	chr5:23309925	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg05468064	chr22:46423449	NA	-0.55	-11.99	-0.5	9.93e-29	Dupuytren's disease;
LUAD	cis	rs877282	0.898	rs11253340	chr10:764786	G/T	cg06581033	chr10:766294	NA	-0.58	-7.95	-0.36	1.74e-14	Uric acid levels;
LUAD	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg16797656	chr11:68205561	LRP5	0.45	8.71	0.39	6.92e-17	Total body bone mineral density;
LUAD	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg25985355	chr7:65971099	NA	-0.51	-6.41	-0.3	3.8e-10	Diabetic kidney disease;
LUAD	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22455342	chr2:225449267	CUL3	-0.44	-6.66	-0.31	8.64e-11	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs4790333	1.000	rs4790333	chr17:2262703	A/G	cg02569219	chr17:2266849	SGSM2	-0.71	-14.74	-0.58	5.69e-40	Proinsulin levels;
LUAD	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg17173187	chr15:85201210	NMB	0.5	8.49	0.38	3.52e-16	Schizophrenia;
LUAD	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg23758822	chr17:41437982	NA	0.99	20.03	0.7	3.12e-63	Menopause (age at onset);
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg27387226	chr11:6704760	MRPL17	0.38	6.41	0.3	3.88e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg11062466	chr8:58055876	NA	0.54	7.41	0.34	6.86e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg20701182	chr2:24300061	SF3B14	0.53	6.49	0.3	2.44e-10	Lymphocyte counts;
LUAD	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg23815491	chr16:72088622	HP	0.51	9.16	0.41	2.21e-18	Fibrinogen levels;
LUAD	cis	rs986417	0.551	rs4901991	chr14:61065025	T/C	cg27398547	chr14:60952738	C14orf39	0.64	7.12	0.33	4.64e-12	Gut microbiota (bacterial taxa);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg16206743	chr13:37633760	FAM48A	-0.69	-6.8	-0.31	3.59e-11	Type 2 diabetes;
LUAD	cis	rs7827545	0.545	rs4909477	chr8:135562976	A/G	cg17885191	chr8:135476712	NA	0.53	7.4	0.34	7.17e-13	Hypertension (SNP x SNP interaction);
LUAD	cis	rs13064411	0.696	rs6773497	chr3:113186514	T/C	cg18753928	chr3:113234510	CCDC52	-0.69	-11.86	-0.5	3.16e-28	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg22875332	chr1:76189707	ACADM	0.84	16.81	0.63	5.93e-49	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg11301795	chr4:187892539	NA	-0.76	-14.78	-0.58	3.66e-40	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3845702	0.736	rs2367990	chr2:180843126	C/T	cg01881094	chr2:180872142	CWC22	-0.76	-8.42	-0.38	5.86e-16	Schizophrenia;
LUAD	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg00898013	chr13:113819073	PROZ	-0.69	-12.17	-0.51	2.05e-29	Platelet distribution width;
LUAD	cis	rs4072705	0.967	rs10120039	chr9:127406961	A/G	cg13476313	chr9:127244764	NR5A1	0.3	7.26	0.33	1.88e-12	Menarche (age at onset);
LUAD	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06505273	chr16:24850292	NA	-0.44	-6.44	-0.3	3.29e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06873352	chr17:61820015	STRADA	0.83	18.53	0.67	1.56e-56	Prudent dietary pattern;
LUAD	trans	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg11887960	chr12:57824829	NA	0.55	6.91	0.32	1.82e-11	Obesity-related traits;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg27417846	chr2:88927289	EIF2AK3	-0.46	-6.4	-0.3	4.16e-10	Testicular germ cell tumor;
LUAD	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.78	-13.3	-0.54	5.74e-34	Chronic sinus infection;
LUAD	cis	rs9535307	0.929	rs3851162	chr13:50354150	T/G	cg04663916	chr13:50265991	EBPL	0.59	6.94	0.32	1.52e-11	Obesity-related traits;
LUAD	trans	rs9951602	0.512	rs77157626	chr18:76644771	C/T	cg02800362	chr5:177631904	HNRNPAB	0.91	14.15	0.57	1.73e-37	Obesity-related traits;
LUAD	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg16049864	chr8:95962084	TP53INP1	-0.5	-10.47	-0.45	5.97e-23	Type 2 diabetes;
LUAD	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg18209359	chr17:80159595	CCDC57	0.39	6.49	0.3	2.36e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs67311347	1.000	rs67311347	chr3:40533243	G/A	cg17264618	chr3:40429014	ENTPD3	0.39	8.31	0.37	1.32e-15	Renal cell carcinoma;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08615371	chr12:12503544	MANSC1	-0.39	-6.41	-0.3	3.93e-10	Cancer;
LUAD	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg05896524	chr21:47604654	C21orf56	0.54	8.87	0.4	2.13e-17	Testicular germ cell tumor;
LUAD	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg04248312	chr19:17393744	ANKLE1	-1.0	-18.47	-0.67	2.7e-56	Systemic lupus erythematosus;
LUAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.2	-0.41	1.61e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10802521	chr3:52805072	NEK4	-0.5	-8.91	-0.4	1.58e-17	Cognitive function;
LUAD	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-9.71	-0.43	2.94e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6782228	0.606	rs2811497	chr3:128363332	C/T	cg16766828	chr3:128327626	NA	-0.38	-7.2	-0.33	2.78e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg16988262	chr1:15930761	NA	0.43	7.26	0.33	1.87e-12	Systolic blood pressure;
LUAD	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg07984980	chr16:89898383	SPIRE2	0.36	6.41	0.3	3.96e-10	Vitiligo;
LUAD	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg25233709	chr10:116636983	FAM160B1	0.41	8.11	0.37	5.39e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.49	7.82	0.36	4.3e-14	Total body bone mineral density;
LUAD	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg04851639	chr8:1020857	NA	0.38	9.57	0.42	8.87e-20	Schizophrenia;
LUAD	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.73	-0.31	5.49e-11	Height;
LUAD	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.55e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9658691	0.607	rs9658750	chr10:90766596	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.62	-7.6	-0.35	1.9e-13	Mosquito bite size;
LUAD	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg05425664	chr17:57184151	TRIM37	0.41	7.38	0.34	8.59e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4268898	0.552	rs11125454	chr2:24373669	T/C	cg06627628	chr2:24431161	ITSN2	0.44	7.44	0.34	5.51e-13	Asthma;
LUAD	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg11814155	chr7:99998594	ZCWPW1	0.43	7.57	0.35	2.38e-13	Platelet count;
LUAD	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg26384229	chr12:38710491	ALG10B	0.44	7.37	0.34	9.1e-13	Morning vs. evening chronotype;
LUAD	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02372712	chr7:149470295	ZNF467	-0.46	-7.21	-0.33	2.52e-12	Height;
LUAD	cis	rs9948	0.867	rs17119598	chr2:97486315	A/G	cg20312557	chr2:97357134	FER1L5	0.54	6.62	0.31	1.06e-10	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg18446336	chr7:2847575	GNA12	-0.32	-6.53	-0.3	1.9e-10	Height;
LUAD	cis	rs4072705	1.000	rs4240487	chr9:127370307	C/T	cg13476313	chr9:127244764	NR5A1	0.29	7.08	0.33	6.15e-12	Menarche (age at onset);
LUAD	cis	rs7428	0.545	rs4832163	chr2:85541083	T/C	cg24342717	chr2:85555507	TGOLN2	-0.48	-7.95	-0.36	1.67e-14	Ear protrusion;
LUAD	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg11887960	chr12:57824829	NA	0.59	7.3	0.33	1.46e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.71	-9.31	-0.41	6.92e-19	Body mass index;
LUAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg04025307	chr7:1156635	C7orf50	0.66	7.49	0.34	4.17e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs921968	0.565	rs6708192	chr2:219592227	A/G	cg02176678	chr2:219576539	TTLL4	-0.57	-11.42	-0.49	1.59e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs3816788	0.837	rs6557640	chr8:21771731	A/T	cg03445287	chr8:21823731	XPO7	-0.44	-8.08	-0.37	6.76e-15	Lung cancer in ever smokers;
LUAD	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg04267008	chr7:1944627	MAD1L1	-0.79	-13.23	-0.54	1.15e-33	Bipolar disorder and schizophrenia;
LUAD	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg25204440	chr1:209979598	IRF6	0.47	6.36	0.3	5.17e-10	Cleft lip with or without cleft palate;
LUAD	trans	rs6561151	0.681	rs17653353	chr13:44421746	A/G	cg12856521	chr11:46389249	DGKZ	0.93	12.83	0.53	4.81e-32	Crohn's disease;
LUAD	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg14671364	chr1:107599128	PRMT6	-0.62	-10.63	-0.46	1.5e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs11168351	1.000	rs11168351	chr12:48403765	C/T	cg04545296	chr12:48745243	ZNF641	0.32	8.04	0.36	9.25e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.38e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11971779	0.584	rs6962029	chr7:139034719	T/C	cg23387468	chr7:139079360	LUC7L2	0.28	6.42	0.3	3.57e-10	Diisocyanate-induced asthma;
LUAD	trans	rs225245	0.755	rs226432	chr17:34043825	G/A	cg19694781	chr19:47549865	TMEM160	0.46	7.52	0.34	3.37e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs59104589	0.521	rs2240482	chr2:242405021	C/T	cg08645257	chr2:242211290	HDLBP	0.39	6.54	0.3	1.76e-10	Fibrinogen levels;
LUAD	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.58	-8.41	-0.38	6.18e-16	Gut microbiome composition (summer);
LUAD	cis	rs36051895	0.664	rs10974960	chr9:5095842	G/A	cg02405213	chr9:5042618	JAK2	-0.44	-6.6	-0.31	1.23e-10	Pediatric autoimmune diseases;
LUAD	cis	rs7937890	0.559	rs2597200	chr11:14485600	A/G	cg02886208	chr11:14281011	SPON1	-0.34	-6.52	-0.3	2.05e-10	Mitochondrial DNA levels;
LUAD	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg05590025	chr7:65112418	INTS4L2	0.74	8.05	0.36	8.39e-15	Diabetic kidney disease;
LUAD	cis	rs12144309	0.608	rs1217417	chr1:114400904	C/G	cg03325407	chr1:114423726	BCL2L15	0.4	6.88	0.32	2.15e-11	Coronary artery disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24371152	chr4:159592377	C4orf46;ETFDH	-0.39	-6.43	-0.3	3.46e-10	Cancer;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg12960782	chr5:59996455	DEPDC1B	-0.39	-6.44	-0.3	3.21e-10	Subcortical brain region volumes;
LUAD	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg06925179	chr17:43578568	NA	0.45	6.42	0.3	3.59e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg16988262	chr1:15930761	NA	0.41	6.82	0.31	3.07e-11	Systolic blood pressure;
LUAD	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg26384229	chr12:38710491	ALG10B	0.42	7.04	0.32	7.83e-12	Morning vs. evening chronotype;
LUAD	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg06697600	chr4:7070879	GRPEL1	-0.52	-8.68	-0.39	8.48e-17	Monocyte percentage of white cells;
LUAD	cis	rs1215050	0.791	rs4699318	chr4:98664370	T/G	cg24818145	chr4:99064322	C4orf37	-0.41	-6.77	-0.31	4.2e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg27411982	chr8:10470053	RP1L1	0.4	7.09	0.33	5.79e-12	Retinal vascular caliber;
LUAD	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg11189052	chr15:85197271	WDR73	0.62	8.17	0.37	3.69e-15	Schizophrenia;
LUAD	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg06784218	chr1:46089804	CCDC17	0.6	13.33	0.54	4.38e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg03983476	chr2:10830698	NOL10	-0.46	-7.88	-0.36	2.87e-14	Prostate cancer;
LUAD	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg14828511	chr1:107599125	PRMT6	-0.51	-9.2	-0.41	1.7e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6993813	0.758	rs7013731	chr8:120038365	T/C	cg01975934	chr8:119970761	NA	-0.37	-7.22	-0.33	2.41e-12	Bone mineral density (hip);
LUAD	cis	rs13064411	0.696	rs6808394	chr3:113122524	T/G	cg10517650	chr3:113235015	CCDC52	-0.54	-8.87	-0.4	2.04e-17	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.72	-0.35	8.21e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7219021	0.961	rs7209108	chr17:46863898	C/T	cg14634687	chr17:47094252	IGF2BP1	0.3	6.48	0.3	2.61e-10	Schizophrenia or bipolar disorder;
LUAD	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg13271783	chr10:134563150	INPP5A	-0.41	-7.12	-0.33	4.8e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06028605	chr16:24865363	SLC5A11	0.59	9.1	0.4	3.54e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg03859395	chr2:55845619	SMEK2	0.75	14.03	0.56	5.73e-37	Metabolic syndrome;
LUAD	cis	rs939658	0.683	rs1560895	chr15:79468082	A/G	cg17916960	chr15:79447300	NA	-0.34	-6.45	-0.3	3.02e-10	Refractive error;
LUAD	cis	rs7512552	0.966	rs1122967	chr1:150258838	C/G	cg15654264	chr1:150340011	RPRD2	-0.46	-8.5	-0.38	3.37e-16	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg15147215	chr3:52552868	STAB1	-0.38	-7.15	-0.33	3.74e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg03526776	chr6:41159608	TREML2	0.32	6.55	0.3	1.71e-10	Alzheimer's disease (late onset);
LUAD	cis	rs113835537	0.529	rs80100524	chr11:66245936	C/T	cg26679405	chr11:66247800	DPP3	-0.45	-6.56	-0.3	1.55e-10	Airway imaging phenotypes;
LUAD	cis	rs7737355	0.773	rs3776006	chr5:130875538	C/T	cg06307176	chr5:131281290	NA	0.43	7.11	0.33	4.87e-12	Life satisfaction;
LUAD	cis	rs459571	0.959	rs465724	chr9:136910097	C/T	cg13789015	chr9:136890014	NCRNA00094	0.74	12.4	0.52	2.56e-30	Platelet distribution width;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14018420	chr1:21766356	NBPF3	-0.52	-6.46	-0.3	2.95e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg14416269	chr4:6271139	WFS1	0.62	10.87	0.47	1.93e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg09222892	chr1:25734099	RHCE	-0.5	-9.19	-0.41	1.74e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs9308433	0.529	rs9430133	chr1:214496313	C/T	cg06198575	chr1:214491504	SMYD2	0.46	7.86	0.36	3.21e-14	IgG glycosylation;
LUAD	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.39	8.25	0.37	2.03e-15	Hemoglobin concentration;
LUAD	cis	rs67311347	0.594	rs12629111	chr3:40285351	T/C	cg17264618	chr3:40429014	ENTPD3	0.35	7.41	0.34	7.01e-13	Renal cell carcinoma;
LUAD	cis	rs6835098	0.828	rs28612521	chr4:174085294	G/A	cg27433088	chr4:174089019	GALNT7	0.39	7.5	0.34	3.85e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.63	8.33	0.38	1.14e-15	Gut microbiome composition (summer);
LUAD	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg15226275	chr6:116381976	FRK	0.23	7.63	0.35	1.5700000000000001e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-13.58	-0.55	3.96e-35	Chronic sinus infection;
LUAD	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.55	0.34	2.78e-13	Tonsillectomy;
LUAD	cis	rs2880765	0.835	rs12324277	chr15:86041735	G/A	cg13263323	chr15:86062960	AKAP13	-0.51	-9.37	-0.41	4.26e-19	Coronary artery disease;
LUAD	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.02e-13	Morning vs. evening chronotype;
LUAD	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22857025	chr5:266934	NA	-0.97	-14.37	-0.57	1.96e-38	Breast cancer;
LUAD	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg17724175	chr1:150552817	MCL1	0.36	8.42	0.38	5.98e-16	Melanoma;
LUAD	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-7.45	-0.34	5.23e-13	Menarche (age at onset);
LUAD	cis	rs2067615	0.579	rs12424114	chr12:107144328	A/G	cg15890332	chr12:107067104	RFX4	0.39	8.22	0.37	2.48e-15	Heart rate;
LUAD	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg02734326	chr4:10020555	SLC2A9	0.54	9.72	0.43	2.73e-20	Bone mineral density;
LUAD	trans	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg01620082	chr3:125678407	NA	-0.45	-6.71	-0.31	6.45e-11	Depression;
LUAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg12745145	chr7:2261452	MAD1L1	0.34	6.41	0.3	3.99e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg00495681	chr13:53174319	NA	-0.49	-9.13	-0.41	2.91e-18	Lewy body disease;
LUAD	cis	rs78707713	0.560	rs61848397	chr10:71225584	C/A	cg12610070	chr10:71211762	TSPAN15	-0.38	-9.19	-0.41	1.82e-18	Venous thromboembolism;
LUAD	cis	rs7809950	0.678	rs2237660	chr7:106862963	T/A	cg23024343	chr7:107201750	COG5	-0.8	-12.72	-0.53	1.28e-31	Coronary artery disease;
LUAD	cis	rs62400317	0.859	rs10948213	chr6:45158515	T/C	cg20913747	chr6:44695427	NA	-0.43	-6.71	-0.31	6.21e-11	Total body bone mineral density;
LUAD	cis	rs4523957	0.820	rs57307236	chr17:2159502	A/G	cg16513277	chr17:2031491	SMG6	-0.62	-11.05	-0.47	3.97e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs863345	0.604	rs11265021	chr1:158511810	A/T	cg12129480	chr1:158549410	OR10X1	0.24	6.57	0.3	1.49e-10	Pneumococcal bacteremia;
LUAD	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg14092988	chr3:52407081	DNAH1	0.44	8.97	0.4	9.48e-18	Bipolar disorder;
LUAD	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg18512352	chr11:47633146	NA	0.43	7.59	0.35	2.11e-13	Subjective well-being;
LUAD	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.64	7.23	0.33	2.31e-12	Lung cancer in ever smokers;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg07157506	chr18:12883603	PTPN2	0.38	6.38	0.3	4.75e-10	Bilirubin levels;
LUAD	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11890956	chr21:40555474	PSMG1	-0.58	-9.41	-0.42	3.2e-19	Cognitive function;
LUAD	trans	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.15	-0.41	2.45e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2249625	0.545	rs2463746	chr6:72876954	C/G	cg18830697	chr6:72922368	RIMS1	-0.44	-8.07	-0.37	7.58e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs758324	0.947	rs13154286	chr5:131160189	A/G	cg06307176	chr5:131281290	NA	0.49	7.77	0.35	5.88e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs12208915	0.720	rs9352655	chr6:79503423	T/A	cg05283184	chr6:79620031	NA	0.52	6.53	0.3	1.87e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.73	-0.39	5.9e-17	Total body bone mineral density;
LUAD	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg10518543	chr12:38710700	ALG10B	0.42	6.42	0.3	3.68e-10	Bladder cancer;
LUAD	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg00814883	chr7:100076585	TSC22D4	-0.82	-11.41	-0.49	1.75e-26	Platelet count;
LUAD	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg25767906	chr1:53392781	SCP2	0.4	7.3	0.33	1.44e-12	Monocyte count;
LUAD	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06544989	chr22:39130855	UNC84B	0.44	8.07	0.37	7.45e-15	Menopause (age at onset);
LUAD	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg09835421	chr16:68378352	PRMT7	-0.84	-9.09	-0.4	3.93e-18	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs78049276	0.651	rs59415853	chr4:148378225	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.64	-7.98	-0.36	1.35e-14	Pulse pressure;
LUAD	cis	rs921968	0.565	rs3770219	chr2:219619766	T/C	cg02176678	chr2:219576539	TTLL4	-0.59	-12.0	-0.5	9.65e-29	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg01620082	chr3:125678407	NA	-0.44	-6.67	-0.31	7.84e-11	Depression;
LUAD	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg12407791	chr17:73824354	UNC13D	0.35	7.26	0.33	1.83e-12	White matter hyperintensity burden;
LUAD	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.65	0.35	1.37e-13	Breast cancer;
LUAD	cis	rs1448094	0.706	rs10863149	chr12:86425498	A/T	cg02569458	chr12:86230093	RASSF9	0.38	7.18	0.33	3.25e-12	Major depressive disorder;
LUAD	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg01874867	chr7:94954059	PON1	0.49	6.83	0.31	3.06e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg27170947	chr2:26402098	FAM59B	-0.83	-12.27	-0.51	8.38e-30	Gut microbiome composition (summer);
LUAD	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.32	0.38	1.19e-15	Rheumatoid arthritis;
LUAD	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg18932078	chr1:2524107	MMEL1	-0.36	-6.66	-0.31	8.47e-11	Ulcerative colitis;
LUAD	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg11189052	chr15:85197271	WDR73	0.57	6.87	0.32	2.26e-11	Schizophrenia;
LUAD	cis	rs1775715	0.707	rs2808088	chr10:32146150	A/G	cg04359828	chr10:32216031	ARHGAP12	0.31	6.48	0.3	2.54e-10	Bipolar disorder with mood-incongruent psychosis;
LUAD	cis	rs2070997	0.715	rs11244164	chr9:133736116	A/G	cg13397898	chr9:133768931	QRFP	0.46	6.67	0.31	8.04e-11	Response to amphetamines;
LUAD	cis	rs12681287	0.547	rs66808088	chr8:87521212	C/T	cg27223183	chr8:87520930	FAM82B	-0.73	-10.24	-0.45	3.93e-22	Caudate activity during reward;
LUAD	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg15133208	chr4:90757351	SNCA	-0.46	-6.81	-0.31	3.26e-11	Neuroticism;
LUAD	cis	rs8038465	0.622	rs710086	chr15:73877001	C/T	cg15420318	chr15:73925796	NPTN	0.44	7.31	0.34	1.31e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	2.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg27490568	chr2:178487706	NA	0.58	8.48	0.38	3.89e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2046867	0.908	rs62251655	chr3:72821708	T/C	cg25664220	chr3:72788482	NA	-0.7	-12.68	-0.52	1.87e-31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg10755058	chr3:40428713	ENTPD3	0.44	8.35	0.38	1.01e-15	Renal cell carcinoma;
LUAD	cis	rs1595825	0.891	rs77706948	chr2:198608441	T/G	cg10547527	chr2:198650123	BOLL	-0.53	-7.08	-0.33	6.15e-12	Ulcerative colitis;
LUAD	cis	rs7937890	0.559	rs2575825	chr11:14472096	T/C	cg23387056	chr11:14280742	SPON1	-0.34	-6.57	-0.3	1.5e-10	Mitochondrial DNA levels;
LUAD	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg22307029	chr19:49891270	CCDC155	0.69	7.61	0.35	1.79e-13	Multiple sclerosis;
LUAD	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg18132916	chr6:79620363	NA	-0.45	-7.8	-0.35	4.84e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.6	-0.31	1.24e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03517284	chr6:25882590	NA	-0.93	-16.7	-0.63	1.89e-48	Uric acid levels;
LUAD	cis	rs7274811	0.681	rs158676	chr20:31974395	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	0.47	7.19	0.33	2.91e-12	Height;
LUAD	trans	rs12210905	1.000	rs12209429	chr6:27054867	G/A	cg08851530	chr6:28072375	NA	0.73	6.43	0.3	3.39e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs68170813	1.000	rs35024078	chr7:107245468	A/G	cg02696742	chr7:106810147	HBP1	-0.51	-6.83	-0.32	2.89e-11	Coronary artery disease;
LUAD	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg16414030	chr3:133502952	NA	-0.69	-13.43	-0.55	1.67e-34	Iron status biomarkers;
LUAD	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-7.73	-0.35	7.94e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs4692589	0.581	rs6821231	chr4:170959988	C/T	cg19918862	chr4:170955249	NA	0.31	6.44	0.3	3.31e-10	Anxiety disorder;
LUAD	cis	rs9372498	0.536	rs62422224	chr6:118941116	G/A	cg18833306	chr6:118973337	C6orf204	-0.55	-7.75	-0.35	7.07e-14	Diastolic blood pressure;
LUAD	cis	rs9863	0.828	rs4765562	chr12:124472571	T/C	cg17723958	chr12:124429295	CCDC92	-0.38	-6.41	-0.3	3.97e-10	White blood cell count;
LUAD	cis	rs6087990	0.842	rs6119279	chr20:31330612	A/G	cg13636640	chr20:31349939	DNMT3B	0.77	14.14	0.57	1.87e-37	Ulcerative colitis;
LUAD	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg07080864	chr8:57359956	PENK	-0.37	-6.61	-0.31	1.14e-10	Obesity-related traits;
LUAD	cis	rs2046867	0.908	rs4677206	chr3:72780052	A/T	cg25664220	chr3:72788482	NA	0.65	12.05	0.51	6.02e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	7.02	0.32	8.99e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs684232	0.897	rs1237094	chr17:619842	C/T	cg12384639	chr17:618140	VPS53	-0.39	-6.48	-0.3	2.61e-10	Prostate cancer;
LUAD	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs10489202	0.632	rs275143	chr1:168056724	A/G	cg24449463	chr1:168025552	DCAF6	-0.77	-12.46	-0.52	1.49e-30	Schizophrenia;
LUAD	trans	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg26043149	chr18:55253948	FECH	-0.42	-6.93	-0.32	1.56e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	7.57	0.35	2.32e-13	Tonsillectomy;
LUAD	trans	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg14917512	chr19:3094685	GNA11	-0.56	-6.66	-0.31	8.45e-11	Diabetic kidney disease;
LUAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg16606324	chr3:10149918	C3orf24	0.64	10.16	0.44	7.92e-22	Alzheimer's disease;
LUAD	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg00784671	chr22:46762841	CELSR1	-0.53	-7.29	-0.33	1.52e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9929218	0.581	rs4783676	chr16:68801077	A/C	cg01251360	chr16:68772225	CDH1	-0.25	-7.83	-0.36	3.9e-14	Colorectal cancer;
LUAD	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg16479474	chr6:28041457	NA	0.47	8.01	0.36	1.12e-14	Depression;
LUAD	cis	rs939658	0.626	rs11631406	chr15:79445789	C/T	cg17916960	chr15:79447300	NA	-0.42	-8.66	-0.39	9.83e-17	Refractive error;
LUAD	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg10950924	chr17:47092072	IGF2BP1	-0.4	-7.6	-0.35	1.93e-13	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs5756391	0.546	rs4821565	chr22:37314415	C/T	cg16356956	chr22:37317934	CSF2RB	-0.35	-7.66	-0.35	1.3e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs943466	1.000	rs11755593	chr6:33740325	G/C	cg07979401	chr6:33739406	LEMD2	-0.37	-6.38	-0.3	4.62e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	11.63	0.49	2.51e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg12292205	chr6:26970375	C6orf41	-0.36	-6.39	-0.3	4.47e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg19046167	chr17:80928561	B3GNTL1	0.44	6.4	0.3	4.01e-10	Glycated hemoglobin levels;
LUAD	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23158103	chr7:148848205	ZNF398	-0.49	-8.62	-0.39	1.37e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7301016	1.000	rs7962519	chr12:62868885	T/G	cg11441379	chr12:63026424	NA	0.52	6.39	0.3	4.45e-10	IgG glycosylation;
LUAD	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg02734326	chr4:10020555	SLC2A9	0.65	11.46	0.49	1.2e-26	Bone mineral density;
LUAD	cis	rs1003719	0.715	rs2835657	chr21:38565064	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-8.16	-0.37	3.87e-15	Eye color traits;
LUAD	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg13319975	chr6:146136371	FBXO30	0.59	9.9	0.43	6.15e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg06521852	chr22:38141419	TRIOBP	0.49	9.43	0.42	2.79e-19	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.81	-0.43	1.37e-20	Schizophrenia;
LUAD	cis	rs3008870	0.755	rs2065002	chr1:67487119	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.48	-7.95	-0.36	1.66e-14	Lymphocyte percentage of white cells;
LUAD	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg10876282	chr6:28092338	ZSCAN16	0.45	7.23	0.33	2.28e-12	Parkinson's disease;
LUAD	cis	rs6665290	0.904	rs1045290	chr1:227178700	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.9	-0.89	4.52e-149	Myeloid white cell count;
LUAD	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg03859395	chr2:55845619	SMEK2	0.74	13.8	0.56	5.19e-36	Metabolic syndrome;
LUAD	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg19773385	chr1:10388646	KIF1B	-0.43	-7.07	-0.33	6.37e-12	Hepatocellular carcinoma;
LUAD	cis	rs62400317	0.859	rs12196217	chr6:45204921	C/T	cg18551225	chr6:44695536	NA	-0.56	-8.51	-0.38	3.02e-16	Total body bone mineral density;
LUAD	cis	rs2535633	0.631	rs2581827	chr3:52966558	C/T	cg18404041	chr3:52824283	ITIH1	0.4	6.88	0.32	2.15e-11	Body mass index;
LUAD	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-11.31	-0.48	4.12e-26	Bone mineral density;
LUAD	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg26597838	chr10:835615	NA	0.84	11.56	0.49	4.78e-27	Eosinophil percentage of granulocytes;
LUAD	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg10556349	chr10:835070	NA	0.58	7.55	0.34	2.76e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg01236616	chr12:121019343	POP5	1.29	19.06	0.68	6.42e-59	Type 1 diabetes nephropathy;
LUAD	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg26597838	chr10:835615	NA	0.78	12.4	0.52	2.51e-30	Eosinophil percentage of granulocytes;
LUAD	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg08213375	chr14:104286397	PPP1R13B	0.26	6.65	0.31	9.24e-11	Schizophrenia;
LUAD	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg21775007	chr8:11205619	TDH	0.37	6.49	0.3	2.34e-10	Neuroticism;
LUAD	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-14.19	-0.57	1.2e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg09491104	chr22:46646882	C22orf40	-0.55	-8.38	-0.38	7.79e-16	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg09509183	chr1:209979624	IRF6	0.37	6.52	0.3	2e-10	Monobrow;
LUAD	trans	rs79911532	0.515	rs10226745	chr7:75843603	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	8.85	0.4	2.45e-17	Mononucleosis;
LUAD	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg05340658	chr4:99064831	C4orf37	0.54	9.23	0.41	1.32e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.768	rs399561	chr6:109524979	G/A	cg21918786	chr6:109611834	NA	-0.42	-7.32	-0.34	1.29e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg17724175	chr1:150552817	MCL1	0.35	7.96	0.36	1.57e-14	Melanoma;
LUAD	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	8.51	0.38	3.05e-16	Eosinophil percentage of white cells;
LUAD	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg24818145	chr4:99064322	C4orf37	0.49	8.03	0.36	1.01e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6484504	0.576	rs208088	chr11:31192686	T/C	cg14844989	chr11:31128820	NA	-0.44	-8.05	-0.36	8.6e-15	Red blood cell count;
LUAD	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg13902645	chr11:5959945	NA	-0.58	-10.08	-0.44	1.41e-21	DNA methylation (variation);
LUAD	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06112835	chr11:68658793	MRPL21	0.5	9.17	0.41	2.06e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg19610905	chr11:61596333	FADS2	-0.58	-9.84	-0.43	1.03e-20	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06873352	chr17:61820015	STRADA	0.56	9.17	0.41	2.1e-18	Height;
LUAD	cis	rs17253792	0.558	rs10083353	chr14:56066370	G/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.43	-0.3	3.43e-10	Putamen volume;
LUAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg02869364	chr7:1081709	C7orf50	-0.5	-6.46	-0.3	2.91e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg24644049	chr4:85504048	CDS1	0.87	6.99	0.32	1.05e-11	Skin colour saturation;
LUAD	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg00784671	chr22:46762841	CELSR1	-0.62	-7.64	-0.35	1.46e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2637266	0.783	rs846585	chr10:78494466	T/G	cg18941641	chr10:78392320	NA	0.32	6.64	0.31	9.42e-11	Pulmonary function;
LUAD	cis	rs7927592	0.513	rs556442	chr11:68192690	G/A	cg16797656	chr11:68205561	LRP5	-0.52	-10.95	-0.47	9.37e-25	Total body bone mineral density;
LUAD	trans	rs12517041	1.000	rs34515966	chr5:23310388	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.49	-6.96	-0.32	1.32e-11	Calcium levels;
LUAD	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.73	0.39	6.05e-17	Menopause (age at onset);
LUAD	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.17	-0.48	1.5e-25	Type 2 diabetes;
LUAD	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg18944383	chr4:111397179	ENPEP	0.42	8.31	0.37	1.3e-15	Height;
LUAD	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.73	0.35	7.65e-14	Breast cancer;
LUAD	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg25237894	chr2:233734115	C2orf82	-0.6	-11.92	-0.5	1.96e-28	Coronary artery disease;
LUAD	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.84	-0.32	2.71e-11	Mood instability;
LUAD	cis	rs1448094	0.813	rs6539942	chr12:86452969	T/C	cg02569458	chr12:86230093	RASSF9	-0.37	-7.04	-0.32	8.03e-12	Major depressive disorder;
LUAD	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62400317	0.762	rs10484625	chr6:44823449	G/A	cg18551225	chr6:44695536	NA	-0.59	-8.79	-0.39	3.79e-17	Total body bone mineral density;
LUAD	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.54	-0.42	1.12e-19	Schizophrenia;
LUAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg22907277	chr7:1156413	C7orf50	0.68	8.01	0.36	1.12e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6496044	0.963	rs6496050	chr15:86069250	A/G	cg13263323	chr15:86062960	AKAP13	-0.53	-9.25	-0.41	1.14e-18	Interstitial lung disease;
LUAD	cis	rs11214589	0.651	rs11214595	chr11:113259658	G/T	cg14159747	chr11:113255604	NA	0.65	13.54	0.55	5.91e-35	Neuroticism;
LUAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg03188948	chr7:1209495	NA	0.39	6.63	0.31	1.03e-10	Longevity;Endometriosis;
LUAD	cis	rs17818399	0.888	rs2346419	chr2:46845069	G/C	cg21681030	chr2:46777652	RHOQ	0.36	6.67	0.31	8.16e-11	Height;
LUAD	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg16479474	chr6:28041457	NA	0.39	6.69	0.31	7.24e-11	Parkinson's disease;
LUAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg10411590	chr13:21900810	NA	0.46	7.68	0.35	1.1e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg00129232	chr17:37814104	STARD3	-0.45	-7.63	-0.35	1.55e-13	Asthma;
LUAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg05896524	chr21:47604654	C21orf56	0.76	12.76	0.53	8.63e-32	Testicular germ cell tumor;
LUAD	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg03714773	chr7:91764589	CYP51A1	-0.27	-6.54	-0.3	1.82e-10	Breast cancer;
LUAD	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg01065977	chr19:18549689	ISYNA1	-0.35	-6.65	-0.31	8.93e-11	Breast cancer;
LUAD	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg13385794	chr1:248469461	NA	-0.25	-6.78	-0.31	4.18e-11	Common traits (Other);
LUAD	cis	rs62238980	0.614	rs4821016	chr22:32402598	T/C	cg00543991	chr22:32367038	NA	0.96	9.05	0.4	5.32e-18	Childhood ear infection;
LUAD	cis	rs4903604	0.581	rs12879719	chr14:78035253	C/A	cg18872420	chr14:78023429	SPTLC2	0.47	8.47	0.38	4e-16	Gut microbiome composition (winter);
LUAD	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg16145915	chr7:1198662	ZFAND2A	0.41	6.5	0.3	2.3e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg00495681	chr13:53174319	NA	0.72	14.41	0.57	1.35e-38	Lewy body disease;
LUAD	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg21775007	chr8:11205619	TDH	0.55	9.97	0.44	3.61e-21	Retinal vascular caliber;
LUAD	cis	rs910187	0.641	rs3818010	chr20:45816562	A/G	cg27589058	chr20:45804311	EYA2	-0.31	-7.07	-0.33	6.44e-12	Migraine;
LUAD	trans	rs8073060	0.586	rs225288	chr17:33929291	G/A	cg19694781	chr19:47549865	TMEM160	-1.26	-19.81	-0.69	3.02e-62	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs6547631	0.622	rs1437744	chr2:85925084	G/A	cg21473183	chr2:85925749	GNLY	0.35	7.48	0.34	4.44e-13	Blood protein levels;
LUAD	cis	rs2692947	0.770	rs11689832	chr2:96554851	A/C	cg23100626	chr2:96804247	ASTL	0.31	7.6	0.35	1.96e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg15704280	chr7:45808275	SEPT13	-0.59	-9.67	-0.43	4.12e-20	HDL cholesterol;
LUAD	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.49	-9.75	-0.43	2.06e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg21823605	chr1:152486609	CRCT1	0.28	6.37	0.3	5.08e-10	Hair morphology;
LUAD	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	9.89	0.43	6.86e-21	Total body bone mineral density;
LUAD	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg13126279	chr21:47581558	C21orf56	-0.45	-7.7	-0.35	9.44e-14	Testicular germ cell tumor;
LUAD	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.46	-7.9	-0.36	2.43e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7481584	0.962	rs2071110	chr11:2991219	C/G	cg11201177	chr11:2961805	NA	0.38	6.51	0.3	2.13e-10	Calcium levels;
LUAD	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11890956	chr21:40555474	PSMG1	0.81	14.33	0.57	3.06e-38	Cognitive function;
LUAD	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg19767477	chr5:127420684	SLC12A2	-0.43	-6.66	-0.31	8.78e-11	Ileal carcinoids;
LUAD	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.48	-0.3	2.55e-10	Parkinson's disease;
LUAD	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1395	1.000	rs6717980	chr2:27452784	T/C	cg23587288	chr2:27483067	SLC30A3	-0.38	-7.69	-0.35	1.03e-13	Blood metabolite levels;
LUAD	cis	rs4629710	0.592	rs4310080	chr6:131538377	T/G	cg12606694	chr6:131520996	AKAP7	0.49	7.14	0.33	4.01e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg04731861	chr2:219085781	ARPC2	-0.22	-6.88	-0.32	2.22e-11	Colorectal cancer;
LUAD	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg27494647	chr7:150038898	RARRES2	0.51	9.33	0.41	5.88e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.27e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.18	-0.33	3.09e-12	Glomerular filtration rate;
LUAD	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg05110241	chr16:68378359	PRMT7	-0.68	-7.69	-0.35	1.01e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.53	0.3	1.83e-10	Platelet count;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg25177113	chr1:955463	AGRN	-0.74	-7.36	-0.34	9.87e-13	Type 2 diabetes;
LUAD	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg23758822	chr17:41437982	NA	1.02	21.24	0.72	1.15e-68	Menopause (age at onset);
LUAD	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg13073564	chr4:8508604	NA	-0.54	-9.96	-0.44	3.99e-21	Response to antineoplastic agents;
LUAD	cis	rs9322817	0.691	rs9377679	chr6:105345036	C/T	cg02098413	chr6:105308735	HACE1	0.42	9.19	0.41	1.82e-18	Thyroid stimulating hormone;
LUAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg05434287	chr7:2030229	MAD1L1	0.41	6.85	0.32	2.6e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg11766577	chr21:47581405	C21orf56	-0.55	-9.71	-0.43	3.01e-20	Testicular germ cell tumor;
LUAD	cis	rs208520	0.837	rs208509	chr6:66941706	A/G	cg07460842	chr6:66804631	NA	-0.97	-13.96	-0.56	1.11e-36	Exhaled nitric oxide output;
LUAD	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg19622623	chr12:86230825	RASSF9	-0.47	-8.08	-0.37	6.84e-15	Major depressive disorder;
LUAD	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg06808227	chr14:105710500	BRF1	-0.43	-6.72	-0.31	5.71e-11	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg17252645	chr8:143867129	LY6D	-0.35	-6.45	-0.3	2.98e-10	Urinary tract infection frequency;
LUAD	cis	rs2637266	1.000	rs7897061	chr10:78366776	C/T	cg18941641	chr10:78392320	NA	0.32	6.7	0.31	6.59e-11	Pulmonary function;
LUAD	cis	rs7516138	1.000	rs4240895	chr1:9713386	C/T	cg26573321	chr1:9711663	PIK3CD	0.8	15.17	0.59	8.41e-42	Monocyte count;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08467299	chr10:112678755	NCRNA00081;SHOC2	-0.42	-6.41	-0.3	3.89e-10	Height;
LUAD	cis	rs151234	0.741	rs56236750	chr16:28594711	C/T	cg04609801	chr16:28609176	SULT1A2	0.61	8.66	0.39	9.7e-17	Platelet distribution width;
LUAD	cis	rs2224391	1.000	rs2224391	chr6:5260936	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.66	-10.89	-0.47	1.64e-24	Height;
LUAD	cis	rs16866061	1.000	rs10498163	chr2:225434445	A/G	cg12698349	chr2:225449008	CUL3	0.77	13.5	0.55	8.79e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs752010	0.746	rs11210499	chr1:42089703	C/T	cg06885757	chr1:42089581	HIVEP3	-0.5	-11.76	-0.5	8.04e-28	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg18446336	chr7:2847575	GNA12	-0.39	-7.34	-0.34	1.08e-12	Height;
LUAD	cis	rs1387259	0.758	rs2634670	chr12:48771877	G/A	cg04545296	chr12:48745243	ZNF641	0.39	9.96	0.44	3.8e-21	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs1832871	0.505	rs11757895	chr6:158812456	G/T	cg07165851	chr6:158734300	TULP4	0.63	8.83	0.39	2.89e-17	Height;
LUAD	cis	rs2979489	0.580	rs73245347	chr8:30448213	T/G	cg26383811	chr8:30366931	RBPMS	-0.57	-8.62	-0.39	1.38e-16	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs13315871	1.000	rs11706420	chr3:58392411	C/T	cg20936604	chr3:58311152	NA	0.63	6.73	0.31	5.48e-11	Cholesterol, total;
LUAD	trans	rs75804782	0.515	rs79557340	chr2:239297952	G/A	cg01134436	chr17:81009848	B3GNTL1	0.77	6.84	0.32	2.75e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs4285028	0.948	rs71329247	chr3:121681523	C/T	cg20356878	chr3:121714668	ILDR1	-0.5	-6.67	-0.31	8.17e-11	Multiple sclerosis;
LUAD	cis	rs68170813	0.559	rs2395881	chr7:107074323	A/C	cg02696742	chr7:106810147	HBP1	-0.8	-10.68	-0.46	9.46e-24	Coronary artery disease;
LUAD	cis	rs10916814	0.632	rs7545313	chr1:20902728	C/T	cg24502330	chr1:20914028	CDA	-0.36	-7.15	-0.33	3.88e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg06784218	chr1:46089804	CCDC17	0.56	12.27	0.51	8.47e-30	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.72	-0.31	5.75e-11	Endometrial cancer;
LUAD	trans	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg21659725	chr3:3221576	CRBN	-0.59	-9.58	-0.42	8.49e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs78707713	0.592	rs3829182	chr10:71251384	A/G	cg12610070	chr10:71211762	TSPAN15	-0.37	-9.08	-0.4	4.28e-18	Venous thromboembolism;
LUAD	cis	rs758324	0.812	rs6893070	chr5:131237599	A/G	cg25547332	chr5:131281432	NA	-0.42	-6.75	-0.31	4.82e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs10746514	0.833	rs12039526	chr1:232272599	C/T	cg09506761	chr1:232265262	NA	-0.41	-7.6	-0.35	1.94e-13	Response to statin therapy;
LUAD	cis	rs7937890	0.559	rs2575830	chr11:14485602	C/A	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.44e-11	Mitochondrial DNA levels;
LUAD	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09263875	chr16:632152	PIGQ	0.82	17.71	0.65	6.71e-53	Height;
LUAD	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.43	0.3	3.48e-10	Cognitive test performance;
LUAD	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	6.5	0.3	2.33e-10	Tonsillectomy;
LUAD	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg03209412	chr4:183728196	NA	0.8	11.02	0.47	5.42e-25	Pediatric autoimmune diseases;
LUAD	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-8.03	-0.36	9.63e-15	Total cholesterol levels;
LUAD	trans	rs7944735	0.517	rs11039520	chr11:48130794	A/G	cg15704280	chr7:45808275	SEPT13	0.68	7.34	0.34	1.13e-12	Intraocular pressure;
LUAD	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg03690763	chr11:133734501	NA	-0.29	-7.04	-0.32	7.7e-12	Childhood ear infection;
LUAD	cis	rs4594175	0.926	rs4414399	chr14:51596929	G/T	cg23942311	chr14:51606299	NA	0.65	10.78	0.46	4.36e-24	Cancer;
LUAD	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.4	7.99	0.36	1.31e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.27	-0.33	1.71e-12	Lung cancer;
LUAD	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg08885076	chr2:99613938	TSGA10	-0.4	-6.97	-0.32	1.26e-11	Chronic sinus infection;
LUAD	cis	rs77972916	0.505	rs1322	chr2:43521167	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-10.17	-0.44	6.96e-22	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg22535103	chr8:58192502	C8orf71	-0.75	-9.0	-0.4	7.73e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg03188948	chr7:1209495	NA	0.83	10.1	0.44	1.29e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg20607798	chr8:58055168	NA	0.78	9.18	0.41	1.97e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.7e-32	Immature fraction of reticulocytes;
LUAD	cis	rs4786125	0.920	rs7194057	chr16:6895960	T/C	cg03623568	chr16:6915990	A2BP1	-0.42	-8.53	-0.38	2.73e-16	Heart rate variability traits (SDNN);
LUAD	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg17644776	chr2:200775616	C2orf69	0.55	7.38	0.34	8.48e-13	Schizophrenia;
LUAD	cis	rs72634258	0.945	rs7517357	chr1:8025275	C/T	cg26816564	chr1:7831052	VAMP3	0.52	6.69	0.31	7.2e-11	Inflammatory bowel disease;
LUAD	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg18252515	chr7:66147081	NA	-0.61	-6.6	-0.31	1.2e-10	Diabetic kidney disease;
LUAD	cis	rs7737355	0.947	rs12659474	chr5:130801304	T/C	cg25547332	chr5:131281432	NA	-0.42	-6.39	-0.3	4.35e-10	Life satisfaction;
LUAD	trans	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg19862616	chr7:65841803	NCRNA00174	1.04	25.7	0.78	2.02e-88	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg06618935	chr21:46677482	NA	-0.5	-10.01	-0.44	2.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg13859433	chr6:33739653	LEMD2	-0.34	-7.03	-0.32	8.49e-12	Schizophrenia;
LUAD	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg14668632	chr7:2872130	GNA12	-0.46	-8.17	-0.37	3.62e-15	Height;
LUAD	cis	rs9650315	0.530	rs7830138	chr8:57084125	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.55	7.77	0.35	6.07e-14	Height;
LUAD	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg18876405	chr7:65276391	NA	0.43	7.19	0.33	2.89e-12	Calcium levels;
LUAD	trans	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg06606381	chr12:133084897	FBRSL1	-0.94	-8.96	-0.4	1.05e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-9.74	-0.43	2.36e-20	Gut microbiome composition (summer);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg22718914	chr6:147525462	STXBP5	-0.4	-6.78	-0.31	4.15e-11	Schizophrenia;
LUAD	cis	rs8051149	0.793	rs12448415	chr16:87871096	A/G	cg01412419	chr16:87856264	NA	0.4	6.48	0.3	2.52e-10	Blood metabolite levels;
LUAD	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg02038168	chr22:39784481	NA	-0.52	-8.93	-0.4	1.31e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg01620082	chr3:125678407	NA	-0.46	-6.64	-0.31	9.91e-11	Depression;
LUAD	cis	rs10504073	0.669	rs4493917	chr8:50015846	C/T	cg00325661	chr8:49890786	NA	0.44	9.99	0.44	3.13e-21	Blood metabolite ratios;
LUAD	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg14631576	chr9:95140430	CENPP	-0.48	-9.63	-0.42	5.4e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.35	-18.12	-0.66	9.73e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg09263875	chr16:632152	PIGQ	0.82	18.13	0.66	8.66e-55	Height;
LUAD	cis	rs11166629	1.000	rs6992668	chr8:135645129	T/C	cg27224718	chr8:135614730	ZFAT	0.61	10.91	0.47	1.39e-24	Smoking quantity;
LUAD	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg05717871	chr11:638507	DRD4	-0.41	-6.45	-0.3	3.12e-10	Systemic lupus erythematosus;
LUAD	cis	rs6688613	0.694	rs12562794	chr1:166828957	A/G	cg07049167	chr1:166818506	POGK	0.56	8.93	0.4	1.32e-17	Refractive astigmatism;
LUAD	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg11062466	chr8:58055876	NA	0.45	6.46	0.3	2.86e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.49	0.38	3.54e-16	Parkinson's disease;
LUAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7809950	0.678	rs7788330	chr7:106985648	G/T	cg23024343	chr7:107201750	COG5	-0.82	-13.89	-0.56	2.07e-36	Coronary artery disease;
LUAD	cis	rs59698941	0.943	rs4705980	chr5:132286084	T/C	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg17177755	chr1:15930204	NA	0.46	7.41	0.34	6.87e-13	Systolic blood pressure;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg04305134	chr10:75173374	ANXA7	0.46	7.43	0.34	5.99e-13	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg24568646	chr21:30446238	CCT8	-0.38	-6.41	-0.3	3.83e-10	Subcortical brain region volumes;
LUAD	cis	rs7177699	0.557	rs12442476	chr15:79117856	G/A	cg15571903	chr15:79123663	NA	0.38	7.6	0.35	1.87e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7827545	1.000	rs7008121	chr8:135565904	T/C	cg17885191	chr8:135476712	NA	0.5	7.98	0.36	1.42e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.5	-9.09	-0.4	3.83e-18	Longevity;Endometriosis;
LUAD	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.8	11.17	0.48	1.42e-25	Smoking behavior;
LUAD	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg21153622	chr11:89784906	NA	-0.35	-6.86	-0.32	2.43e-11	HDL cholesterol;
LUAD	cis	rs2213920	0.516	rs34302658	chr9:118168158	T/A	cg13918206	chr9:118159781	DEC1	-0.59	-6.87	-0.32	2.27e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LUAD	cis	rs4523957	0.928	rs7213232	chr17:2165340	A/G	cg16513277	chr17:2031491	SMG6	-0.73	-14.17	-0.57	1.48e-37	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs57590327	0.503	rs7631052	chr3:81866235	C/A	cg07356753	chr3:81810745	GBE1	-0.61	-9.96	-0.44	3.85e-21	Extraversion;
LUAD	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg14835575	chr10:16859367	RSU1	0.98	14.24	0.57	7.19e-38	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg27572855	chr1:25598939	RHD	0.54	12.05	0.51	6.23e-29	Erythrocyte sedimentation rate;
LUAD	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg00204512	chr16:28754710	NA	0.33	7.11	0.33	4.84e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-6.56	-0.3	1.55e-10	IgG glycosylation;
LUAD	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg09658497	chr7:2847517	GNA12	-0.55	-9.56	-0.42	9.88e-20	Height;
LUAD	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg08601574	chr20:25228251	PYGB	-0.47	-8.81	-0.39	3.23e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4604732	0.631	rs11490200	chr1:247625915	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18404041	chr3:52824283	ITIH1	-0.6	-12.1	-0.51	3.65e-29	Bipolar disorder;
LUAD	cis	rs7408868	1.000	rs1548554	chr19:15277938	C/T	cg14696996	chr19:15285081	NOTCH3	0.82	10.59	0.46	2.07e-23	Pulse pressure;
LUAD	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18876405	chr7:65276391	NA	0.44	6.94	0.32	1.47e-11	Aortic root size;
LUAD	cis	rs9487051	0.768	rs351742	chr6:109527325	C/T	cg01475377	chr6:109611718	NA	0.38	6.87	0.32	2.38e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg13126279	chr21:47581558	C21orf56	-0.43	-7.38	-0.34	8.49e-13	Testicular germ cell tumor;
LUAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg07677032	chr17:61819896	STRADA	0.56	10.09	0.44	1.34e-21	Prudent dietary pattern;
LUAD	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg12714757	chr17:73874637	TRIM47	-0.43	-6.69	-0.31	7.14e-11	Psoriasis;
LUAD	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg05373962	chr22:49881684	NA	-0.55	-13.02	-0.53	7.8e-33	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg05064044	chr6:292385	DUSP22	-0.8	-13.62	-0.55	2.65e-35	Menopause (age at onset);
LUAD	trans	rs1941687	0.797	rs9954214	chr18:31390754	T/C	cg27147174	chr7:100797783	AP1S1	-0.5	-8.26	-0.37	1.93e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.67	0.39	9.26e-17	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6754311	0.510	rs1374329	chr2:136421323	A/G	cg07305463	chr2:136567211	LCT	-0.38	-7.08	-0.33	6.19e-12	Mosquito bite size;
LUAD	cis	rs4006360	0.531	rs4544293	chr17:39241359	T/C	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.28	0.37	1.66e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22307029	chr19:49891270	CCDC155	0.66	9.51	0.42	1.41e-19	Multiple sclerosis;
LUAD	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg18944383	chr4:111397179	ENPEP	0.38	7.62	0.35	1.66e-13	Height;
LUAD	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg15691649	chr6:25882328	NA	0.68	10.36	0.45	1.48e-22	Blood metabolite levels;
LUAD	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg08048268	chr3:133502702	NA	-0.34	-6.6	-0.31	1.24e-10	Iron status biomarkers;
LUAD	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg24803719	chr17:45855879	NA	-0.33	-7.23	-0.33	2.25e-12	IgG glycosylation;
LUAD	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.56	-0.35	2.48e-13	Lung cancer;
LUAD	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg16102102	chr5:83017553	HAPLN1	-0.77	-12.62	-0.52	3.25e-31	Prostate cancer;
LUAD	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg05340658	chr4:99064831	C4orf37	0.49	8.19	0.37	3.08e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs75804782	0.572	rs74979875	chr2:239302568	G/A	cg01134436	chr17:81009848	B3GNTL1	0.77	6.82	0.31	3.14e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg23815491	chr16:72088622	HP	0.54	9.89	0.43	7e-21	Fibrinogen levels;
LUAD	cis	rs612683	0.518	rs10875287	chr1:100812908	T/C	cg06223162	chr1:101003688	GPR88	-0.36	-6.95	-0.32	1.36e-11	Breast cancer;
LUAD	cis	rs7779181	0.508	rs12534148	chr7:32248311	G/A	cg27511599	chr7:32358540	NA	0.38	6.44	0.3	3.19e-10	Body mass index;
LUAD	cis	rs11048434	0.673	rs11611106	chr12:9060204	A/C	cg04155231	chr12:9217510	LOC144571	-0.37	-6.7	-0.31	6.69e-11	Sjögren's syndrome;
LUAD	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.86	0.32	2.46e-11	Obesity-related traits;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09592155	chr17:8029700	NA	-0.62	-6.43	-0.3	3.52e-10	Type 2 diabetes;
LUAD	cis	rs2220004	0.559	rs77199005	chr11:55738602	G/A	cg22937354	chr11:55606216	OR5D16	-0.38	-6.87	-0.32	2.37e-11	Odorant perception (&beta-damascenone);
LUAD	cis	rs3806843	0.548	rs246058	chr5:140325134	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg20607798	chr8:58055168	NA	0.66	8.7	0.39	7.67e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9560113	1.000	rs9555812	chr13:112181535	A/G	cg14154082	chr13:112174009	NA	0.35	6.56	0.3	1.6e-10	Menarche (age at onset);
LUAD	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg25566285	chr7:158114605	PTPRN2	0.42	7.34	0.34	1.07e-12	Response to amphetamines;
LUAD	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg15790184	chr11:494944	RNH1	0.56	6.73	0.31	5.62e-11	Body mass index;
LUAD	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg04989706	chr14:50066350	PPIL5	-0.54	-7.79	-0.35	5.09e-14	Carotid intima media thickness;
LUAD	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	6.92	0.32	1.64e-11	Platelet count;
LUAD	cis	rs1776421	0.760	rs61768413	chr1:53904746	C/T	cg10892335	chr1:53966318	NA	0.5	7.24	0.33	2.14e-12	PR interval in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4642101	0.883	rs11718898	chr3:12848822	T/C	cg24848339	chr3:12840334	CAND2	0.35	6.8	0.31	3.6e-11	QRS complex (12-leadsum);
LUAD	cis	rs1032833	0.732	rs74367571	chr2:179959890	T/C	cg23883738	chr2:179974586	SESTD1	-0.72	-8.26	-0.37	1.86e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg07817883	chr1:32538562	TMEM39B	1.62	13.92	0.56	1.57e-36	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs123509	0.913	rs339682	chr3:42791123	A/G	cg12982090	chr3:42733453	KBTBD5	0.55	9.67	0.43	4.23e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg10792982	chr14:105748885	BRF1	0.4	8.71	0.39	6.88e-17	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs7395662	0.819	rs12269855	chr11:48778652	C/G	cg00717180	chr2:96193071	NA	-0.38	-7.13	-0.33	4.51e-12	HDL cholesterol;
LUAD	cis	rs57920188	0.568	rs12137595	chr1:4094068	C/T	cg20703997	chr1:4087676	NA	0.51	7.68	0.35	1.13e-13	Interleukin-17 levels;
LUAD	cis	rs7187994	0.790	rs62048856	chr16:84764491	C/A	cg07647771	chr16:84786436	USP10	-0.37	-9.32	-0.41	6.38e-19	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11890956	chr21:40555474	PSMG1	-0.62	-10.45	-0.45	6.61e-23	Cognitive function;
LUAD	cis	rs117623576	0.941	rs211422	chr10:32398589	A/G	cg03047570	chr10:32398778	NA	0.87	10.89	0.47	1.6e-24	Anti-saccade response;
LUAD	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg18180107	chr4:99064573	C4orf37	0.42	6.81	0.31	3.47e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6906287	0.647	rs12207209	chr6:118850375	T/G	cg21191810	chr6:118973309	C6orf204	0.49	9.47	0.42	1.96e-19	Electrocardiographic conduction measures;
LUAD	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.56	-0.42	9.94e-20	Schizophrenia;
LUAD	cis	rs3790645	1.000	rs1064196	chr1:26887592	C/T	cg23229016	chr1:26872525	RPS6KA1	-0.21	-7.0	-0.32	1.03e-11	Glucose homeostasis traits;
LUAD	cis	rs1691799	0.899	rs1168317	chr12:66746225	C/T	cg16791601	chr12:66731901	HELB	-0.36	-6.47	-0.3	2.78e-10	White blood cell count (basophil);
LUAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	trans	rs587242	1.000	rs509770	chr1:96891615	G/A	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs10193935	1.000	rs13421289	chr2:42412808	T/C	cg27598129	chr2:42591480	NA	-0.76	-9.98	-0.44	3.21e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.49	-7.85	-0.36	3.53e-14	Tonsillectomy;
LUAD	cis	rs684232	0.602	rs35206514	chr17:519859	T/C	cg12384639	chr17:618140	VPS53	0.49	8.24	0.37	2.17e-15	Prostate cancer;
LUAD	trans	rs783540	0.809	rs3970696	chr15:83263756	A/T	cg18393722	chr15:85113863	UBE2QP1	0.41	6.72	0.31	6.06e-11	Schizophrenia;
LUAD	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg06028605	chr16:24865363	SLC5A11	-0.39	-6.86	-0.32	2.46e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg07266350	chr3:49460521	AMT;NICN1	-0.36	-6.47	-0.3	2.73e-10	Menarche (age at onset);
LUAD	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg03806693	chr22:41940476	POLR3H	-0.77	-10.07	-0.44	1.64e-21	Vitiligo;
LUAD	cis	rs6961069	0.774	rs1413661	chr7:80243003	G/C	cg04458919	chr7:80252533	CD36	-0.36	-6.84	-0.32	2.87e-11	Platelet count;
LUAD	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.56	9.6	0.42	6.93e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg01448562	chr3:133502909	NA	-0.66	-12.07	-0.51	5.1e-29	Iron status biomarkers;
LUAD	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg06641503	chr3:48959341	ARIH2	-0.39	-7.75	-0.35	6.89e-14	Parkinson's disease;
LUAD	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg25985355	chr7:65971099	NA	0.55	6.9	0.32	1.91e-11	Gout;
LUAD	cis	rs2625529	0.652	rs9302260	chr15:72174611	T/C	cg16672083	chr15:72433130	SENP8	0.63	11.78	0.5	6.83e-28	Red blood cell count;
LUAD	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg22676075	chr6:135203613	NA	0.42	7.79	0.35	5.41e-14	Red blood cell count;
LUAD	cis	rs7932354	0.528	rs11039107	chr11:47157866	G/A	cg19486271	chr11:47235900	DDB2	0.43	6.74	0.31	5.31e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg05665937	chr4:1216051	CTBP1	0.39	6.73	0.31	5.52e-11	Obesity-related traits;
LUAD	cis	rs26868	0.766	rs27556	chr16:2249325	T/C	cg25665528	chr16:2260870	C16orf79	-0.35	-7.03	-0.32	8.5e-12	Height;
LUAD	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg08645402	chr16:4508243	NA	0.54	9.92	0.43	5.31e-21	Schizophrenia;
LUAD	trans	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.67	-0.31	8.17e-11	Neuroticism;
LUAD	cis	rs4006360	0.575	rs6416909	chr17:39235389	A/G	cg20663846	chr17:39254439	KRTAP4-8	-0.37	-8.12	-0.37	5.3e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.97	0.32	1.21e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg23625390	chr15:77176239	SCAPER	-0.54	-8.34	-0.38	1.02e-15	Blood metabolite levels;
LUAD	cis	rs17253792	0.822	rs74824071	chr14:56095142	T/G	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg18827107	chr12:86230957	RASSF9	0.53	9.6	0.42	7.2e-20	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.16e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.92	0.36	2.07e-14	Depression;
LUAD	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg14828511	chr1:107599125	PRMT6	0.6	10.55	0.46	2.86e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs17102423	0.896	rs8004805	chr14:65579720	T/C	cg11161011	chr14:65562177	MAX	-0.41	-6.68	-0.31	7.51e-11	Obesity-related traits;
LUAD	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.76e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg06547715	chr2:218990976	CXCR2	0.28	6.62	0.31	1.1e-10	Colorectal cancer;
LUAD	cis	rs68170813	0.559	rs74906766	chr7:106885236	T/A	cg23024343	chr7:107201750	COG5	0.5	7.3	0.33	1.43e-12	Coronary artery disease;
LUAD	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg04944784	chr2:26401820	FAM59B	-0.89	-12.57	-0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs35123781	0.696	rs356429	chr5:139073143	C/T	cg10513866	chr5:139070639	NA	0.54	8.73	0.39	5.96e-17	Schizophrenia;
LUAD	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21659725	chr3:3221576	CRBN	-0.87	-18.36	-0.67	8.22e-56	Intelligence (multi-trait analysis);
LUAD	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs12545109	0.879	rs2609994	chr8:57365844	A/G	cg21220214	chr8:57350948	NA	-0.66	-9.13	-0.41	2.8e-18	Obesity-related traits;
LUAD	cis	rs4713675	0.584	rs6916949	chr6:33678290	C/G	cg13859433	chr6:33739653	LEMD2	-0.3	-7.11	-0.33	5.14e-12	Plateletcrit;
LUAD	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg00316803	chr15:76480434	C15orf27	-0.4	-7.53	-0.34	3.15e-13	Blood metabolite levels;
LUAD	cis	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg27411982	chr8:10470053	RP1L1	0.41	7.97	0.36	1.54e-14	Neuroticism;
LUAD	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg04063615	chr12:132293388	NA	-0.36	-6.38	-0.3	4.55e-10	Migraine;
LUAD	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg25427524	chr10:38739819	LOC399744	-0.62	-9.31	-0.41	6.95e-19	Obesity (extreme);
LUAD	cis	rs12541635	0.966	rs2059943	chr8:107071607	G/T	cg10147462	chr8:107024639	NA	0.48	8.54	0.38	2.5e-16	Age of smoking initiation;
LUAD	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg18198730	chr1:247681584	NA	0.43	7.41	0.34	6.86e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2688608	0.901	rs2459446	chr10:75601596	C/T	cg23231163	chr10:75533350	FUT11	0.47	8.76	0.39	4.76e-17	Inflammatory bowel disease;
LUAD	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg04756594	chr16:24857601	SLC5A11	0.74	13.08	0.54	4.49e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs1941687	0.831	rs12954615	chr18:31384449	G/T	cg27147174	chr7:100797783	AP1S1	-0.5	-8.61	-0.39	1.49e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg19077165	chr18:44547161	KATNAL2	-0.44	-7.67	-0.35	1.2e-13	Personality dimensions;
LUAD	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.47	-0.52	1.3e-30	Bone mineral density;
LUAD	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg15181151	chr6:150070149	PCMT1	0.38	7.07	0.33	6.24e-12	Lung cancer;
LUAD	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-7.4	-0.34	7.59e-13	Personality dimensions;
LUAD	cis	rs1011018	0.628	rs7798740	chr7:139462162	T/C	cg26515926	chr7:139453581	HIPK2	-0.49	-6.38	-0.3	4.56e-10	Systolic blood pressure;
LUAD	cis	rs11771526	0.892	rs62457540	chr7:32372199	A/G	cg27532318	chr7:32358331	NA	0.68	7.97	0.36	1.44e-14	Body mass index;
LUAD	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06112835	chr11:68658793	MRPL21	0.52	9.47	0.42	2.08e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.5	0.58	5.66e-39	Schizophrenia;
LUAD	cis	rs7147624	1.000	rs2411349	chr14:66214426	T/C	cg03016385	chr14:66212404	NA	-0.58	-6.96	-0.32	1.31e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	trans	rs2270927	0.510	rs6453213	chr5:75579518	A/G	cg13563193	chr19:33072644	PDCD5	0.97	9.36	0.41	4.91e-19	Mean corpuscular volume;
LUAD	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg03690763	chr11:133734501	NA	-0.29	-7.04	-0.32	7.7e-12	Childhood ear infection;
LUAD	cis	rs1595825	0.891	rs73056823	chr2:198769788	T/C	cg00982548	chr2:198649783	BOLL	-0.63	-9.1	-0.4	3.47e-18	Ulcerative colitis;
LUAD	cis	rs12681287	0.605	rs2976181	chr8:87344470	C/T	cg27223183	chr8:87520930	FAM82B	-0.63	-9.03	-0.4	6.32e-18	Caudate activity during reward;
LUAD	trans	rs12517041	0.872	rs28839222	chr5:23312044	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs1564271	0.528	rs2209350	chr10:26987779	A/G	cg13837822	chr10:26931731	LOC731789	0.47	10.05	0.44	1.88e-21	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUAD	cis	rs1232027	0.622	rs857016	chr5:79975981	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.77	-0.31	4.44e-11	Huntington's disease progression;
LUAD	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg12193833	chr17:30244370	NA	-0.57	-6.85	-0.32	2.68e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg24531977	chr5:56204891	C5orf35	-0.48	-7.94	-0.36	1.88e-14	Coronary artery disease;
LUAD	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg15664640	chr17:80829946	TBCD	0.5	9.46	0.42	2.22e-19	Breast cancer;
LUAD	cis	rs11696501	0.694	rs2171371	chr20:44273482	T/C	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.16	-0.37	3.75e-15	Brain structure;
LUAD	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg23815491	chr16:72088622	HP	-0.57	-10.65	-0.46	1.25e-23	Fibrinogen levels;
LUAD	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	6.71	0.31	6.45e-11	Lung cancer in ever smokers;
LUAD	cis	rs8017423	0.845	rs8005870	chr14:90723172	A/C	cg14092571	chr14:90743983	NA	-0.5	-8.87	-0.4	2.07e-17	Mortality in heart failure;
LUAD	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg25753631	chr6:25732923	NA	-0.45	-7.9	-0.36	2.47e-14	Iron status biomarkers;
LUAD	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg04990556	chr1:26633338	UBXN11	-0.4	-6.69	-0.31	7.23e-11	Obesity-related traits;
LUAD	cis	rs8177876	0.822	rs74437879	chr16:81112592	A/G	cg08591886	chr16:81111003	C16orf46	-0.76	-7.01	-0.32	9.76e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.5	-8.0	-0.36	1.18e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-11.78	-0.5	6.48e-28	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.89	0.53	2.58e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg20503657	chr10:835505	NA	0.75	9.88	0.43	7.23e-21	Eosinophil percentage of granulocytes;
LUAD	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg21016266	chr12:122356598	WDR66	0.69	12.89	0.53	2.57e-32	Mean corpuscular volume;
LUAD	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg07930552	chr6:133119739	C6orf192	0.56	6.55	0.3	1.71e-10	Type 2 diabetes nephropathy;
LUAD	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg01097406	chr16:89675127	NA	0.34	6.95	0.32	1.35e-11	Vitiligo;
LUAD	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg11266682	chr4:10021025	SLC2A9	0.5	10.15	0.44	8.25e-22	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs12579753	0.917	rs6539580	chr12:82184765	T/C	cg07988820	chr12:82153109	PPFIA2	-0.45	-7.21	-0.33	2.55e-12	Resting heart rate;
LUAD	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg22823121	chr1:150693482	HORMAD1	0.4	7.58	0.35	2.18e-13	Melanoma;
LUAD	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg08798685	chr6:27730294	NA	-0.64	-6.82	-0.31	3.14e-11	Breast cancer;
LUAD	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg15704280	chr7:45808275	SEPT13	0.59	8.93	0.4	1.27e-17	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg09367891	chr1:107599246	PRMT6	0.55	9.23	0.41	1.33e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14829155	chr15:31115871	NA	-0.66	-11.19	-0.48	1.23e-25	Huntington's disease progression;
LUAD	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg13012494	chr21:47604986	C21orf56	0.43	6.61	0.31	1.14e-10	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.26	0.37	1.92e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.3	-6.61	-0.31	1.17e-10	Blood metabolite levels;
LUAD	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.35	-6.47	-0.3	2.67e-10	Caffeine consumption;
LUAD	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg17911788	chr17:44343683	NA	-0.5	-7.05	-0.32	7.29e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs78456975	1.000	rs10208449	chr2:1563257	G/A	cg01028140	chr2:1542097	TPO	-0.59	-7.05	-0.32	7.3e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg14008862	chr17:28927542	LRRC37B2	0.75	7.32	0.34	1.23e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg11502198	chr6:26597334	ABT1	0.48	7.59	0.35	2.06e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9948	0.655	rs17119564	chr2:97384728	G/A	cg20312557	chr2:97357134	FER1L5	-0.65	-7.42	-0.34	6.6e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs4285028	0.796	rs12638492	chr3:121711763	G/A	cg11130432	chr3:121712080	ILDR1	-0.6	-8.4	-0.38	6.87e-16	Multiple sclerosis;
LUAD	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg03474202	chr17:45855739	NA	-0.41	-9.62	-0.42	5.97e-20	IgG glycosylation;
LUAD	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg02951883	chr7:2050386	MAD1L1	-0.75	-12.58	-0.52	4.63e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs4791641	1.000	rs4791641	chr17:8161149	C/T	cg08322244	chr17:8066669	VAMP2	0.37	7.01	0.32	9.23e-12	LDL cholesterol levels;Hematocrit;Hemoglobin concentration;Red blood cell count;LDL cholesterol;
LUAD	cis	rs4689388	0.609	rs4234729	chr4:6286087	T/C	cg25554036	chr4:6271136	WFS1	0.64	10.4	0.45	1.06e-22	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg01579765	chr21:45077557	HSF2BP	-0.56	-11.75	-0.5	8.78e-28	Mean corpuscular volume;
LUAD	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg18099408	chr3:52552593	STAB1	-0.42	-7.12	-0.33	4.6e-12	Bipolar disorder;
LUAD	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg08071915	chr8:12219732	FAM66A	0.37	6.35	0.3	5.58e-10	Neuroticism;
LUAD	cis	rs10823500	0.777	rs7919014	chr10:71944577	T/C	cg02100629	chr10:71892760	AIFM2	-0.38	-7.59	-0.35	2.08e-13	Blood protein levels;
LUAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg25703541	chr22:24373054	LOC391322	-0.81	-15.53	-0.6	2.31e-43	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6960043	0.748	rs10228561	chr7:15063961	C/T	cg19272540	chr7:15055459	NA	-0.36	-7.98	-0.36	1.43e-14	Type 2 diabetes;
LUAD	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg23260525	chr10:116636907	FAM160B1	0.49	11.58	0.49	4.17e-27	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg02016892	chr7:22122612	NA	-0.64	-6.77	-0.31	4.32e-11	Type 2 diabetes;
LUAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg08132940	chr7:1081526	C7orf50	-0.67	-9.75	-0.43	2.19e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.59	8.67	0.39	9.11e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg11070056	chr1:107600091	PRMT6	-0.53	-9.24	-0.41	1.17e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.44	8.18	0.37	3.26e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg20607798	chr8:58055168	NA	0.81	9.93	0.43	5.04e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg05110241	chr16:68378359	PRMT7	-0.8	-8.77	-0.39	4.56e-17	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs75804782	0.625	rs59039294	chr2:239470654	G/A	cg01134436	chr17:81009848	B3GNTL1	0.71	7.25	0.33	1.94e-12	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.44	-0.42	2.55e-19	Schizophrenia;
LUAD	cis	rs62238980	0.614	rs17683011	chr22:32445946	A/G	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs7809950	0.678	rs13230144	chr7:106909172	T/C	cg23024343	chr7:107201750	COG5	-0.81	-13.93	-0.56	1.39e-36	Coronary artery disease;
LUAD	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg22875332	chr1:76189707	ACADM	-0.43	-6.37	-0.3	4.82e-10	Daytime sleep phenotypes;
LUAD	cis	rs4776059	1.000	rs2288271	chr15:52886466	A/G	cg24008177	chr15:52972085	KIAA1370	0.25	6.86	0.32	2.41e-11	Schizophrenia;
LUAD	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.53	-9.69	-0.43	3.57e-20	Schizophrenia;
LUAD	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg26769984	chr7:1090371	C7orf50	0.66	9.58	0.42	8.11e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.8	-0.43	1.38e-20	Schizophrenia;
LUAD	cis	rs6665290	0.904	rs2297418	chr1:227192579	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.45	-0.89	7.93e-144	Myeloid white cell count;
LUAD	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg18252515	chr7:66147081	NA	-0.63	-6.94	-0.32	1.5e-11	Gout;
LUAD	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.35	7.08	0.33	5.89e-12	IgG glycosylation;
LUAD	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg26769984	chr7:1090371	C7orf50	0.7	11.03	0.47	4.75e-25	Bronchopulmonary dysplasia;
LUAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg21724239	chr8:58056113	NA	0.67	8.55	0.38	2.23e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg00814883	chr7:100076585	TSC22D4	-0.8	-11.68	-0.49	1.64e-27	Platelet count;
LUAD	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg26597838	chr10:835615	NA	0.8	10.96	0.47	9.29e-25	Eosinophil percentage of granulocytes;
LUAD	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg11822812	chr5:140052017	DND1	0.38	6.66	0.31	8.67e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg27124370	chr19:33622961	WDR88	0.45	6.88	0.32	2.12e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg05991184	chr2:219186017	PNKD	-0.38	-7.39	-0.34	8.12e-13	Colorectal cancer;
LUAD	cis	rs10865541	0.806	rs4971503	chr2:3417221	G/A	cg22182287	chr2:3452347	TTC15	0.46	8.04	0.36	9.09e-15	Obesity-related traits;
LUAD	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg15226275	chr6:116381976	FRK	0.23	7.58	0.35	2.19e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs6669072	0.669	rs814545	chr1:91240551	C/G	cg08895590	chr1:91227319	NA	-0.32	-6.64	-0.31	9.82e-11	Cognitive function;
LUAD	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg19729930	chr2:74357872	NA	1.04	16.75	0.63	1.11e-48	Gestational age at birth (maternal effect);
LUAD	cis	rs1448094	0.874	rs10779219	chr12:86322643	T/G	cg00310523	chr12:86230176	RASSF9	0.35	7.56	0.34	2.58e-13	Major depressive disorder;
LUAD	cis	rs8048589	0.642	rs8062015	chr16:12176879	G/A	cg03816625	chr16:12192430	SNX29	0.48	7.28	0.33	1.69e-12	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg14024328	chr4:719362	PCGF3	-0.54	-8.76	-0.39	4.67e-17	White blood cell count;
LUAD	cis	rs12912251	0.947	rs7165988	chr15:38988815	C/G	cg01338139	chr15:38987640	C15orf53	-0.59	-9.29	-0.41	7.95e-19	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.49	-8.94	-0.4	1.26e-17	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08109568	chr15:31115862	NA	0.78	13.45	0.55	1.37e-34	Huntington's disease progression;
LUAD	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg21285383	chr16:89894308	SPIRE2	0.41	9.96	0.44	3.82e-21	Vitiligo;
LUAD	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg19622623	chr12:86230825	RASSF9	0.42	7.49	0.34	3.93e-13	Major depressive disorder;
LUAD	cis	rs6076065	0.723	rs6132604	chr20:23342226	G/A	cg11657817	chr20:23433608	CST11	0.49	9.1	0.4	3.64e-18	Facial morphology (factor 15, philtrum width);
LUAD	trans	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg13565492	chr6:43139072	SRF	-0.62	-7.08	-0.33	5.96e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs16858210	0.874	rs7618182	chr3:183607003	T/A	cg01324343	chr3:183735012	ABCC5	0.43	6.73	0.31	5.53e-11	Menopause (age at onset);
LUAD	cis	rs2294693	0.947	rs742492	chr6:40996381	G/A	cg14769373	chr6:40998127	UNC5CL	-0.54	-8.36	-0.38	8.97e-16	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs7274811	0.711	rs293713	chr20:31942247	A/G	cg13403462	chr20:32256071	NECAB3;C20orf134	0.46	7.11	0.33	5.13e-12	Height;
LUAD	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg17200465	chr3:40428508	ENTPD3	0.27	6.42	0.3	3.68e-10	Renal cell carcinoma;
LUAD	trans	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.7	-9.62	-0.42	5.94e-20	Obesity-related traits;
LUAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08439880	chr3:133502540	NA	-0.5	-10.3	-0.45	2.44e-22	Iron status biomarkers;
LUAD	cis	rs9611519	1.000	rs4820433	chr22:41607065	C/G	cg13813247	chr22:41461852	NA	-0.44	-7.52	-0.34	3.27e-13	Neuroticism;
LUAD	trans	rs61332075	0.540	rs55986470	chr2:239363773	A/G	cg01134436	chr17:81009848	B3GNTL1	0.58	7.01	0.32	9.39e-12	Lung function (FEV1/FVC);
LUAD	cis	rs12681287	0.640	rs13253261	chr8:87458500	T/C	cg27223183	chr8:87520930	FAM82B	-0.68	-9.59	-0.42	7.69e-20	Caudate activity during reward;
LUAD	cis	rs921968	0.565	rs4672897	chr2:219588134	A/G	cg02176678	chr2:219576539	TTLL4	-0.59	-12.08	-0.51	4.68e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs999737	1.000	rs11628293	chr14:69037320	A/G	cg04147497	chr14:69052728	RAD51L1	-0.46	-7.08	-0.33	5.93e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs73198271	0.740	rs10092720	chr8:8649117	A/C	cg01851573	chr8:8652454	MFHAS1	0.49	8.62	0.39	1.32e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg07538946	chr5:131705188	SLC22A5	0.48	7.82	0.36	4.25e-14	Breast cancer;Mosquito bite size;
LUAD	cis	rs12681287	0.752	rs13262673	chr8:87293600	G/A	cg00550725	chr8:87521180	FAM82B	0.46	6.63	0.31	1.05e-10	Caudate activity during reward;
LUAD	cis	rs10540	0.541	rs7480899	chr11:438459	T/C	cg08200582	chr11:442649	ANO9	0.57	8.08	0.37	7.01e-15	Body mass index;
LUAD	trans	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg21153622	chr11:89784906	NA	-0.34	-6.75	-0.31	5e-11	HDL cholesterol;
LUAD	cis	rs34734847	0.965	rs2005455	chr12:121128699	A/G	cg21892295	chr12:121157589	UNC119B	-0.46	-8.5	-0.38	3.22e-16	Mean corpuscular volume;
LUAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg04025307	chr7:1156635	C7orf50	0.52	7.51	0.34	3.53e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs13082711	0.911	rs2172298	chr3:27425611	T/C	cg02860705	chr3:27208620	NA	0.55	8.45	0.38	4.87e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs62238980	0.614	rs75805646	chr22:32441396	A/G	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg25894440	chr7:65020034	NA	-0.64	-6.89	-0.32	2.03e-11	Diabetic kidney disease;
LUAD	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg16060761	chr17:80687452	NA	-0.59	-8.43	-0.38	5.63e-16	Glycated hemoglobin levels;
LUAD	cis	rs4006360	0.579	rs2132841	chr17:39234970	T/C	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.02	0.36	1.04e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg06740227	chr12:86229804	RASSF9	0.36	6.36	0.3	5.27e-10	Major depressive disorder;
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18110333	chr6:292329	DUSP22	0.75	12.89	0.53	2.64e-32	Menopause (age at onset);
LUAD	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg04944784	chr2:26401820	FAM59B	0.64	9.03	0.4	6.34e-18	Gut microbiome composition (summer);
LUAD	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg14779329	chr11:130786720	SNX19	-0.39	-6.99	-0.32	1.05e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7903847	0.642	rs10882922	chr10:99158537	C/T	cg20016023	chr10:99160130	RRP12	-0.32	-7.81	-0.36	4.51e-14	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7000551	0.689	rs6993341	chr8:22310933	T/C	cg12081754	chr8:22256438	SLC39A14	0.45	7.52	0.34	3.24e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2242073	0.597	rs3820906	chr2:208993830	A/G	cg24664470	chr2:208976933	NA	0.43	7.18	0.33	3.08e-12	Attention deficit hyperactivity disorder;
LUAD	trans	rs9929218	0.608	rs35158985	chr16:68796746	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-13.0	-0.53	9.74e-33	Colorectal cancer;
LUAD	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.14	-0.33	4.01e-12	Height;
LUAD	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg00802000	chr16:706648	WDR90	-0.37	-6.94	-0.32	1.45e-11	Height;
LUAD	cis	rs1018836	0.798	rs4735295	chr8:91671608	C/A	cg16814680	chr8:91681699	NA	-0.89	-16.44	-0.62	2.63e-47	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg27094323	chr7:1216898	NA	-0.37	-6.56	-0.3	1.55e-10	Longevity;Endometriosis;
LUAD	trans	rs11088226	1.000	rs2833889	chr21:33927768	G/T	cg09050820	chr6:167586206	TCP10L2	-0.58	-8.13	-0.37	4.68e-15	Gastritis;
LUAD	trans	rs7395662	0.736	rs4882036	chr11:48749384	A/G	cg15704280	chr7:45808275	SEPT13	-0.45	-7.09	-0.33	5.81e-12	HDL cholesterol;
LUAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg13047869	chr3:10149882	C3orf24	0.65	10.97	0.47	8.01e-25	Alzheimer's disease;
LUAD	trans	rs877282	1.000	rs11253367	chr10:773389	G/A	cg22713356	chr15:30763199	NA	1.19	17.09	0.64	3.65e-50	Uric acid levels;
LUAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00166722	chr3:10149974	C3orf24	0.71	12.36	0.52	3.47e-30	Alzheimer's disease;
LUAD	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg08508325	chr11:3079039	CARS	0.42	8.75	0.39	5.2e-17	Calcium levels;
LUAD	cis	rs873917	0.577	rs784611	chr1:40125988	T/A	cg00990022	chr1:40138052	NT5C1A	-0.44	-6.61	-0.31	1.14e-10	Amyotrophic lateral sclerosis;
LUAD	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.45	-8.08	-0.37	6.86e-15	Menarche (age at onset);
LUAD	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg03609598	chr5:56110824	MAP3K1	-0.45	-7.02	-0.32	9.16e-12	Coronary artery disease;
LUAD	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg06784218	chr1:46089804	CCDC17	-0.6	-13.5	-0.55	8.61e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.47	8.85	0.4	2.49e-17	Hemoglobin concentration;
LUAD	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-8.36	-0.38	9.22e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg18944383	chr4:111397179	ENPEP	-0.38	-7.03	-0.32	8.24e-12	Coronary artery disease;
LUAD	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg21605333	chr4:119757512	SEC24D	-0.85	-7.65	-0.35	1.34e-13	Cannabis dependence symptom count;
LUAD	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.6e-19	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.42	-0.38	5.94e-16	Height;
LUAD	cis	rs11167764	0.895	rs7734160	chr5:141473144	G/T	cg23435118	chr5:141488016	NDFIP1	-0.48	-7.25	-0.33	2.06e-12	Crohn's disease;
LUAD	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg19622623	chr12:86230825	RASSF9	-0.54	-9.54	-0.42	1.16e-19	Major depressive disorder;
LUAD	trans	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg01620082	chr3:125678407	NA	-1.03	-10.19	-0.44	5.95e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	-0.45	-8.35	-0.38	1.01e-15	Menopause (age at onset);
LUAD	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg04990556	chr1:26633338	UBXN11	-0.4	-6.56	-0.3	1.54e-10	Obesity-related traits;
LUAD	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg06641503	chr3:48959341	ARIH2	-0.37	-7.15	-0.33	3.73e-12	Parkinson's disease;
LUAD	cis	rs6688613	1.000	rs6665341	chr1:166947018	A/G	cg07049167	chr1:166818506	POGK	0.38	6.37	0.3	4.82e-10	Refractive astigmatism;
LUAD	cis	rs1034435	0.755	rs5767173	chr22:48892473	T/C	cg05992904	chr22:48892994	FAM19A5	-0.76	-17.16	-0.64	1.77e-50	Late-onset Alzheimer's disease;
LUAD	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg18252515	chr7:66147081	NA	-0.6	-6.73	-0.31	5.43e-11	Diabetic kidney disease;
LUAD	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg23649088	chr2:200775458	C2orf69	-0.61	-8.55	-0.38	2.35e-16	Schizophrenia;
LUAD	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg02807482	chr3:125708958	NA	-0.66	-8.85	-0.4	2.44e-17	Blood pressure (smoking interaction);
LUAD	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-7.59	-0.35	2.06e-13	Fear of minor pain;
LUAD	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	9.77	0.43	1.83e-20	Ileal carcinoids;
LUAD	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg05283184	chr6:79620031	NA	-0.61	-12.47	-0.52	1.28e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	13.23	0.54	1.13e-33	Lymphocyte counts;
LUAD	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg08000102	chr2:233561755	GIGYF2	0.42	6.54	0.3	1.83e-10	Coronary artery disease;
LUAD	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg12365402	chr11:9010492	NRIP3	0.53	10.84	0.47	2.43e-24	Hemoglobin concentration;
LUAD	cis	rs1953600	1.000	rs1953600	chr10:81911725	A/G	cg00277334	chr10:82204260	NA	0.4	6.91	0.32	1.82e-11	Sarcoidosis;
LUAD	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.64	-7.34	-0.34	1.13e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	8.98	0.4	9.27e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg11344533	chr11:111475393	SIK2	-0.37	-6.82	-0.31	3.23e-11	Primary sclerosing cholangitis;
LUAD	cis	rs8060686	0.516	rs7189794	chr16:68277727	T/C	cg05110241	chr16:68378359	PRMT7	-0.58	-7.34	-0.34	1.13e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs938554	0.779	rs9998811	chr4:9966477	G/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-7.89	-0.36	2.52e-14	Blood metabolite levels;
LUAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg12432903	chr7:1882776	MAD1L1	-0.53	-8.65	-0.39	1.1e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg14779329	chr11:130786720	SNX19	0.39	6.84	0.32	2.74e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg08645402	chr16:4508243	NA	-0.51	-9.11	-0.41	3.26e-18	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2274273	0.967	rs67756714	chr14:55589823	G/A	cg04306507	chr14:55594613	LGALS3	0.37	7.46	0.34	4.96e-13	Protein biomarker;
LUAD	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9650657	0.655	rs1991651	chr8:10706411	C/G	cg27411982	chr8:10470053	RP1L1	0.37	6.38	0.3	4.74e-10	Neuroticism;
LUAD	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg10518543	chr12:38710700	ALG10B	0.42	6.41	0.3	3.84e-10	Heart rate;
LUAD	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg05805236	chr11:65401703	PCNXL3	-0.4	-6.73	-0.31	5.56e-11	Acne (severe);
LUAD	cis	rs8044868	0.530	rs8059437	chr16:72116467	A/G	cg23815491	chr16:72088622	HP	0.5	9.32	0.41	6.53e-19	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.34	0.38	1.06e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4664308	0.935	rs4665148	chr2:160917901	A/G	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.79	-0.31	3.88e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg18621852	chr3:10150065	C3orf24	0.51	9.11	0.4	3.39e-18	Alzheimer's disease;
LUAD	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg15208524	chr1:10270712	KIF1B	0.52	7.62	0.35	1.71e-13	Hepatocellular carcinoma;
LUAD	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.95	-14.54	-0.58	3.82e-39	Schizophrenia;
LUAD	cis	rs13064411	0.542	rs7631335	chr3:113209166	C/T	cg18753928	chr3:113234510	CCDC52	-0.55	-9.73	-0.43	2.58e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs73206853	0.764	rs17682012	chr12:111094454	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.61	-6.7	-0.31	6.59e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs78472555	0.954	rs2123926	chr15:100264518	T/C	cg18869061	chr15:100272053	LYSMD4	-0.43	-6.7	-0.31	6.65e-11	Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg15181151	chr6:150070149	PCMT1	0.41	8.53	0.38	2.66e-16	Lung cancer;
LUAD	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg18811423	chr2:55921094	PNPT1	0.51	8.46	0.38	4.28e-16	Metabolic syndrome;
LUAD	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg24399712	chr22:39784796	NA	-0.82	-15.86	-0.61	8.77e-45	Intelligence (multi-trait analysis);
LUAD	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg18811423	chr2:55921094	PNPT1	0.57	9.66	0.43	4.27e-20	Metabolic syndrome;
LUAD	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg14008862	chr17:28927542	LRRC37B2	0.78	7.77	0.35	6.16e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.33	-9.11	-0.41	3.25e-18	Total body bone mineral density;
LUAD	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg22552966	chr17:19620595	SLC47A2	-0.39	-8.43	-0.38	5.54e-16	Response to paliperidone in schizophrenia (CGI-S score);
LUAD	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-8.32	-0.38	1.18e-15	Alzheimer's disease (late onset);
LUAD	cis	rs11229555	0.645	rs4506677	chr11:58213852	T/C	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	8.19	0.37	3.09e-15	Parkinson's disease;
LUAD	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg19163074	chr7:65112434	INTS4L2	0.44	6.75	0.31	4.89e-11	Aortic root size;
LUAD	cis	rs7937890	0.559	rs1116739	chr11:14489182	G/C	cg02251663	chr11:14281053	SPON1	-0.34	-6.5	-0.3	2.33e-10	Mitochondrial DNA levels;
LUAD	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11890956	chr21:40555474	PSMG1	-0.74	-12.92	-0.53	2e-32	Cognitive function;
LUAD	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg04025307	chr7:1156635	C7orf50	0.55	7.57	0.35	2.43e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs7224314	1.000	rs7226214	chr17:65383323	C/T	cg01507342	chr17:65387096	PITPNC1	-0.53	-8.69	-0.39	8.12e-17	Diisocyanate-induced asthma;
LUAD	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg18538332	chr22:24372958	LOC391322	-0.49	-8.15	-0.37	4.1e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	cis	rs11756438	0.572	rs2638541	chr6:119003743	A/T	cg18833306	chr6:118973337	C6orf204	0.5	9.06	0.4	4.78e-18	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs57994353	0.897	rs11999532	chr9:139371405	G/C	cg13856295	chr9:139396418	NOTCH1	-0.43	-6.83	-0.32	3.01e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.79	-0.31	3.84e-11	Height;
LUAD	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg20203395	chr5:56204925	C5orf35	-0.79	-11.63	-0.49	2.48e-27	Initial pursuit acceleration;
LUAD	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg25173405	chr17:45401733	C17orf57	0.46	7.9	0.36	2.39e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21659725	chr3:3221576	CRBN	-0.86	-18.3	-0.66	1.52e-55	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg11814155	chr7:99998594	ZCWPW1	0.4	6.5	0.3	2.31e-10	Platelet count;
LUAD	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.45	0.34	5.32e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs2455601	0.638	rs2248245	chr11:8988350	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.43	-7.8	-0.35	4.75e-14	Schizophrenia;
LUAD	cis	rs300774	0.925	rs300707	chr2:141324	G/T	cg21211680	chr2:198530	NA	-0.46	-7.29	-0.33	1.57e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.54	0.3	1.79e-10	Cardiac Troponin-T levels;
LUAD	cis	rs3204270	0.639	rs62080213	chr17:79642531	C/T	cg09655341	chr17:79618100	PDE6G	0.52	6.61	0.31	1.18e-10	Dental caries;
LUAD	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03878208	chr11:72483293	STARD10	0.61	8.07	0.37	7.46e-15	Type 2 diabetes;
LUAD	trans	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg18335740	chr13:41363409	SLC25A15	0.73	13.94	0.56	1.28e-36	Lewy body disease;
LUAD	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg13560548	chr3:10150139	C3orf24	0.41	6.74	0.31	5.15e-11	Alzheimer's disease;
LUAD	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10802521	chr3:52805072	NEK4	-0.59	-10.38	-0.45	1.2e-22	Electroencephalogram traits;
LUAD	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.14	0.48	1.9e-25	Eosinophil percentage of white cells;
LUAD	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg03676636	chr4:99064102	C4orf37	0.32	8.31	0.37	1.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6424115	1.000	rs58035855	chr1:24165248	G/C	cg10978503	chr1:24200527	CNR2	-0.55	-11.85	-0.5	3.56e-28	Immature fraction of reticulocytes;
LUAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg22907277	chr7:1156413	C7orf50	0.71	8.26	0.37	1.84e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7246760	0.867	rs34648216	chr19:9850690	T/A	cg02900749	chr2:68251473	NA	-0.67	-7.07	-0.33	6.36e-12	Pursuit maintenance gain;
LUAD	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg21775007	chr8:11205619	TDH	0.46	8.31	0.37	1.27e-15	Retinal vascular caliber;
LUAD	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg00634984	chr7:65235879	NA	0.52	6.97	0.32	1.21e-11	Aortic root size;
LUAD	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg23950597	chr19:37808831	NA	-0.64	-7.69	-0.35	1.07e-13	Coronary artery calcification;
LUAD	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22307029	chr19:49891270	CCDC155	0.78	12.52	0.52	8.17e-31	Multiple sclerosis;
LUAD	cis	rs1997103	1.000	rs6958022	chr7:55397389	G/A	cg17469321	chr7:55412551	NA	0.67	11.41	0.49	1.73e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg14196790	chr5:131705035	SLC22A5	0.36	6.35	0.3	5.53e-10	Blood metabolite levels;
LUAD	cis	rs7633770	0.786	rs6442012	chr3:46686346	A/G	cg11219411	chr3:46661640	NA	0.59	13.09	0.54	4.01e-33	Coronary artery disease;
LUAD	trans	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg14343924	chr8:8086146	FLJ10661	-0.4	-6.36	-0.3	5.12e-10	Neuroticism;
LUAD	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.39	-7.44	-0.34	5.69e-13	Menarche (age at onset);
LUAD	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.53	-0.34	3.18e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg01802117	chr1:53393560	SCP2	0.37	7.08	0.33	6.03e-12	Monocyte count;
LUAD	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.82e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2455799	1.000	rs2166758	chr3:15856233	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-6.68	-0.31	7.53e-11	Mean platelet volume;
LUAD	cis	rs2294693	0.945	rs9381023	chr6:40983281	C/T	cg14769373	chr6:40998127	UNC5CL	0.54	8.19	0.37	3.23e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg09904177	chr6:26538194	HMGN4	0.44	7.41	0.34	6.96e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg11062466	chr8:58055876	NA	0.7	8.65	0.39	1.08e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg24558204	chr6:135376177	HBS1L	0.46	8.58	0.38	1.83e-16	Red blood cell count;
LUAD	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg16342193	chr10:102329863	NA	-0.37	-6.67	-0.31	7.96e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1448094	0.842	rs10863155	chr12:86446416	T/C	cg19622623	chr12:86230825	RASSF9	0.36	6.69	0.31	6.94e-11	Major depressive disorder;
LUAD	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.6	-0.52	3.83e-31	Monocyte count;
LUAD	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	11.15	0.48	1.67e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg09365446	chr1:150670422	GOLPH3L	0.65	12.17	0.51	1.94e-29	Tonsillectomy;
LUAD	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg19163074	chr7:65112434	INTS4L2	-0.45	-6.87	-0.32	2.37e-11	Aortic root size;
LUAD	cis	rs17152411	1.000	rs733401	chr10:126594158	A/T	cg07906193	chr10:126599966	NA	0.53	7.6	0.35	1.95e-13	Height;
LUAD	cis	rs9914988	0.673	rs12325788	chr17:27080049	G/A	cg02049041	chr17:27085579	C17orf63	0.6	8.14	0.37	4.33e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs68170813	0.521	rs61673847	chr7:106892431	A/G	cg02696742	chr7:106810147	HBP1	-0.78	-10.85	-0.47	2.34e-24	Coronary artery disease;
LUAD	cis	rs11811982	0.793	rs35601687	chr1:227510995	G/A	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.77	0.31	4.36e-11	Rheumatoid arthritis;
LUAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg07677032	chr17:61819896	STRADA	0.57	10.37	0.45	1.36e-22	Prudent dietary pattern;
LUAD	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg10978503	chr1:24200527	CNR2	-0.45	-8.43	-0.38	5.54e-16	Immature fraction of reticulocytes;
LUAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.4	-6.53	-0.3	1.94e-10	Longevity;Endometriosis;
LUAD	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg08645402	chr16:4508243	NA	0.58	11.32	0.48	3.81e-26	Schizophrenia;
LUAD	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22857025	chr5:266934	NA	-0.95	-14.28	-0.57	5.15e-38	Breast cancer;
LUAD	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg21854759	chr1:92012499	NA	0.5	9.38	0.41	4.06e-19	Breast cancer;
LUAD	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg26114124	chr12:9217669	LOC144571	0.4	7.22	0.33	2.48e-12	Sjögren's syndrome;
LUAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg21970626	chr13:21893289	NA	-0.48	-8.37	-0.38	8.4e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs9715521	0.677	rs4490528	chr4:59854572	T/G	cg11281224	chr4:60001000	NA	-0.59	-10.73	-0.46	6.38e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.29	0.66	1.79e-55	Prudent dietary pattern;
LUAD	cis	rs16866061	1.000	rs7588380	chr2:225341304	A/T	cg12698349	chr2:225449008	CUL3	-0.76	-13.17	-0.54	2.01e-33	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.51e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09578018	chr15:60883649	RORA	-0.42	-7.03	-0.32	8.12e-12	Height;
LUAD	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.13	-0.41	2.85e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.23e-12	Tonsillectomy;
LUAD	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.54	-9.1	-0.4	3.65e-18	Glomerular filtration rate;
LUAD	cis	rs10899021	0.915	rs11236198	chr11:74372200	G/T	cg25880958	chr11:74394337	NA	-0.62	-8.06	-0.36	7.76e-15	Response to metformin (IC50);
LUAD	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg19875535	chr5:140030758	IK	-0.42	-7.21	-0.33	2.53e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg01528321	chr10:82214614	TSPAN14	0.55	8.73	0.39	5.76e-17	Post bronchodilator FEV1;
LUAD	cis	rs7705042	0.793	rs7705547	chr5:141514027	A/G	cg08523384	chr5:141488047	NDFIP1	-0.39	-6.67	-0.31	8.02e-11	Asthma;
LUAD	cis	rs6076065	0.755	rs6076071	chr20:23406380	A/C	cg11657817	chr20:23433608	CST11	0.48	8.77	0.39	4.42e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg18138036	chr10:133769891	PPP2R2D	0.42	6.72	0.31	5.95e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs7017914	0.934	rs6992879	chr8:71699283	A/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.43	-0.3	3.46e-10	Bone mineral density;
LUAD	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg09085632	chr11:111637200	PPP2R1B	0.64	9.85	0.43	9.28e-21	Primary sclerosing cholangitis;
LUAD	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg04025307	chr7:1156635	C7orf50	0.65	7.41	0.34	7.09e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs3219090	0.962	rs3754376	chr1:226561064	C/A	cg27539482	chr13:111589090	NA	-0.41	-7.0	-0.32	9.96e-12	Melanoma;
LUAD	trans	rs9929218	0.954	rs9925923	chr16:68819614	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.64	-0.55	2.34e-35	Colorectal cancer;
LUAD	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg03732007	chr1:2071316	PRKCZ	-0.34	-6.65	-0.31	8.93e-11	Height;
LUAD	cis	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg21775007	chr8:11205619	TDH	0.38	6.64	0.31	9.92e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg27490568	chr2:178487706	NA	0.58	8.58	0.39	1.81e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg01621132	chr19:10221146	PPAN-P2RY11;P2RY11;PPAN	-0.34	-7.69	-0.35	1.02e-13	Narcolepsy;
LUAD	cis	rs10170310	1.000	rs6720716	chr2:139268802	A/G	cg10095539	chr2:139258744	SPOPL	0.32	6.44	0.3	3.29e-10	Response to antipsychotic treatment;
LUAD	cis	rs4964805	0.626	rs11111767	chr12:104176246	A/G	cg02344784	chr12:104178138	NT5DC3	-0.37	-6.36	-0.3	5.12e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg22467129	chr15:76604101	ETFA	-0.48	-7.87	-0.36	3.02e-14	Blood metabolite levels;
LUAD	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg16325326	chr1:53192061	ZYG11B	0.59	10.65	0.46	1.31e-23	Monocyte count;
LUAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg25703541	chr22:24373054	LOC391322	-0.9	-17.7	-0.65	6.97e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg26587870	chr6:27730563	NA	-0.48	-7.99	-0.36	1.29e-14	Parkinson's disease;
LUAD	cis	rs17102423	0.755	rs884683	chr14:65574482	C/T	cg11161011	chr14:65562177	MAX	-0.53	-8.31	-0.37	1.28e-15	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.48	-0.3	2.55e-10	Depression;
LUAD	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08677398	chr8:58056175	NA	0.55	7.08	0.33	6.06e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg24801067	chr17:62843696	NA	0.53	8.4	0.38	6.98e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg10434728	chr15:90938212	IQGAP1	0.38	7.49	0.34	3.94e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg02574844	chr11:5959923	NA	-0.44	-8.1	-0.37	6.03e-15	DNA methylation (variation);
LUAD	trans	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg04565464	chr8:145669602	NFKBIL2	0.45	6.58	0.3	1.36e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg03188948	chr7:1209495	NA	0.4	6.5	0.3	2.21e-10	Longevity;Endometriosis;
LUAD	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg24803719	chr17:45855879	NA	-0.34	-7.52	-0.34	3.27e-13	IgG glycosylation;
LUAD	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg09359103	chr1:154839909	KCNN3	-0.95	-22.27	-0.73	2.87e-73	Prostate cancer;
LUAD	cis	rs758324	0.898	rs10037928	chr5:131142046	T/C	cg25547332	chr5:131281432	NA	0.43	6.95	0.32	1.39e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg14917512	chr19:3094685	GNA11	-0.37	-6.37	-0.3	4.98e-10	Aortic root size;
LUAD	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg18451016	chr1:38461880	NA	-0.45	-8.25	-0.37	1.97e-15	Coronary artery disease;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg04520396	chr17:1585312	PRPF8	-0.44	-7.48	-0.34	4.45e-13	Diastolic blood pressure;
LUAD	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg15997130	chr1:24165203	NA	-0.49	-7.73	-0.35	7.73e-14	Immature fraction of reticulocytes;
LUAD	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg15557168	chr22:42548783	NA	-0.5	-8.91	-0.4	1.55e-17	Schizophrenia;
LUAD	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.69	-9.16	-0.41	2.31e-18	Yeast infection;
LUAD	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg18016565	chr1:150552671	MCL1	0.42	7.83	0.36	4.05e-14	Tonsillectomy;
LUAD	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg19318889	chr4:1322082	MAEA	0.52	8.51	0.38	2.97e-16	Longevity;
LUAD	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg24578937	chr1:2090814	PRKCZ	0.79	16.49	0.63	1.56e-47	Height;
LUAD	cis	rs9897596	1	rs9897596	chr17:17593453	T/C	cg01246520	chr17:17644344	RAI1	0.38	6.41	0.3	3.96e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg02079420	chr8:82753780	SNX16	0.39	7.59	0.35	2.09e-13	Diastolic blood pressure;
LUAD	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg21775007	chr8:11205619	TDH	0.53	9.62	0.42	6.07e-20	Retinal vascular caliber;
LUAD	cis	rs3823572	0.564	rs10272509	chr7:133636302	A/G	cg03336402	chr7:133662267	EXOC4	0.42	7.63	0.35	1.56e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03452623	chr4:187889614	NA	-0.82	-17.0	-0.64	9.23e-50	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs735539	0.555	rs2818987	chr13:21304911	C/T	cg27499820	chr13:21296301	IL17D	0.5	7.51	0.34	3.57e-13	Dental caries;
LUAD	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg15181151	chr6:150070149	PCMT1	0.41	8.31	0.37	1.29e-15	Lung cancer;
LUAD	cis	rs524023	0.957	rs12365089	chr11:64364735	A/T	cg19131476	chr11:64387923	NRXN2	-0.39	-7.39	-0.34	7.74e-13	Urate levels in obese individuals;
LUAD	cis	rs7089973	0.872	rs60820172	chr10:116625891	C/T	cg23260525	chr10:116636907	FAM160B1	0.43	9.68	0.43	3.68e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg24737193	chr18:12778029	NA	-0.51	-6.45	-0.3	3.15e-10	Inflammatory skin disease;
LUAD	cis	rs4774899	0.934	rs12904561	chr15:57510974	G/A	cg14026238	chr15:57616123	NA	0.37	6.85	0.32	2.55e-11	Urinary tract infection frequency;
LUAD	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg00129232	chr17:37814104	STARD3	-0.44	-7.57	-0.35	2.32e-13	Asthma;
LUAD	cis	rs10979	1.000	rs9403504	chr6:143885430	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-9.65	-0.42	4.73e-20	Hypospadias;
LUAD	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg22618164	chr12:122356400	WDR66	0.65	11.13	0.48	2.08e-25	Mean corpuscular volume;
LUAD	cis	rs13315871	1.000	rs9862969	chr3:58341917	A/G	cg20936604	chr3:58311152	NA	-0.69	-7.31	-0.33	1.35e-12	Cholesterol, total;
LUAD	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg20628663	chr10:43360327	NA	-0.73	-11.33	-0.48	3.61e-26	Blood protein levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26532042	chr19:49468557	FTL	-0.68	-6.74	-0.31	5.22e-11	Type 2 diabetes;
LUAD	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg23887609	chr12:130822674	PIWIL1	0.4	6.66	0.31	8.62e-11	Menopause (age at onset);
LUAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg08888203	chr3:10149979	C3orf24	0.64	9.93	0.43	4.86e-21	Alzheimer's disease;
LUAD	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg24531977	chr5:56204891	C5orf35	-0.42	-6.77	-0.31	4.3e-11	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs57920188	0.568	rs10915665	chr1:4093717	G/T	cg20703997	chr1:4087676	NA	0.49	8.69	0.39	8e-17	Interleukin-17 levels;
LUAD	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg03354898	chr7:1950403	MAD1L1	0.34	6.53	0.3	1.86e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg18230493	chr5:56204884	C5orf35	-0.54	-8.64	-0.39	1.18e-16	Coronary artery disease;
LUAD	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg13390004	chr1:15929781	NA	0.5	8.89	0.4	1.72e-17	Systolic blood pressure;
LUAD	cis	rs2109514	0.840	rs13223362	chr7:116137006	G/A	cg12739419	chr7:116140593	CAV2	-0.33	-6.88	-0.32	2.16e-11	Prevalent atrial fibrillation;
LUAD	cis	rs12478296	0.591	rs12719765	chr2:242997202	C/G	cg06360820	chr2:242988706	NA	-0.68	-9.91	-0.43	5.69e-21	Obesity-related traits;
LUAD	cis	rs11893307	0.537	rs57780226	chr2:191547865	C/G	cg11845111	chr2:191398756	TMEM194B	-0.45	-6.74	-0.31	5.24e-11	Mean platelet volume;
LUAD	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg00933542	chr6:150070202	PCMT1	0.43	8.8	0.39	3.54e-17	Lung cancer;
LUAD	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06022373	chr22:39101656	GTPBP1	0.48	8.18	0.37	3.43e-15	Menopause (age at onset);
LUAD	cis	rs8060686	0.623	rs6499162	chr16:68239460	T/C	cg26727032	chr16:67993705	SLC12A4	-0.46	-7.6	-0.35	1.95e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg20607798	chr8:58055168	NA	-0.81	-10.04	-0.44	2.05e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs6840360	0.967	rs6535817	chr4:152641941	G/C	cg22705602	chr4:152727874	NA	-0.32	-6.38	-0.3	4.68e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg11707310	chr1:2537719	MMEL1	-0.41	-8.62	-0.39	1.34e-16	Ulcerative colitis;
LUAD	trans	rs3942852	0.955	rs1532754	chr11:48115279	A/T	cg15704280	chr7:45808275	SEPT13	-0.62	-8.59	-0.39	1.71e-16	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	ch.12.31424680R	chr12:31533413	NA	-0.39	-6.87	-0.32	2.34e-11	Subcortical brain region volumes;
LUAD	cis	rs4660214	0.666	rs6600290	chr1:39622823	G/A	cg27567593	chr1:39956653	BMP8A	0.33	6.44	0.3	3.32e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4409675	0.913	rs61789696	chr1:28258905	G/A	cg23691781	chr1:28212827	C1orf38	0.28	6.67	0.31	8.19e-11	Corneal astigmatism;
LUAD	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg02951883	chr7:2050386	MAD1L1	-0.75	-11.8	-0.5	5.54e-28	Bipolar disorder and schizophrenia;
LUAD	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs6424115	1.000	rs58035855	chr1:24165248	G/C	cg15997130	chr1:24165203	NA	-0.55	-9.58	-0.42	8.24e-20	Immature fraction of reticulocytes;
LUAD	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg22823121	chr1:150693482	HORMAD1	-0.47	-9.46	-0.42	2.17e-19	Melanoma;
LUAD	cis	rs12618769	0.597	rs72819987	chr2:99046253	A/G	cg10123293	chr2:99228465	UNC50	0.45	8.1	0.37	5.85e-15	Bipolar disorder;
LUAD	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg04731861	chr2:219085781	ARPC2	-0.21	-6.38	-0.3	4.69e-10	Colorectal cancer;
LUAD	cis	rs11471957	1	rs11471957	chr20:57598332	C/CAA	cg14073986	chr20:57617431	SLMO2	0.55	7.11	0.33	5.06e-12	Platelet count;Mean platelet volume;
LUAD	cis	rs11072804	1	rs11072804	chr15:79078486	T/G	cg12645284	chr15:79092878	ADAMTS7	0.43	7.31	0.33	1.36e-12	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.98	0.32	1.12e-11	Hypertriglyceridemia;
LUAD	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg12035532	chr1:1886765	KIAA1751	0.42	7.01	0.32	9.18e-12	Body mass index;
LUAD	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg08742575	chr21:47604166	C21orf56	0.44	7.35	0.34	1.05e-12	Testicular germ cell tumor;
LUAD	cis	rs1448094	0.967	rs10746357	chr12:86341044	A/T	cg00310523	chr12:86230176	RASSF9	0.36	7.73	0.35	7.83e-14	Major depressive disorder;
LUAD	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24308560	chr3:49941425	MST1R	-0.53	-8.98	-0.4	8.92e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg01475377	chr6:109611718	NA	-0.47	-8.66	-0.39	1.01e-16	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
LUAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg27588902	chr6:42928151	GNMT	-0.36	-9.7	-0.43	3.09e-20	Plasma homocysteine levels (post-methionine load test);
LUAD	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.4	-6.57	-0.3	1.51e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.4	6.58	0.3	1.36e-10	Total body bone mineral density;
LUAD	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.32	0.41	6.52e-19	Colorectal cancer;
LUAD	cis	rs2019216	0.564	rs907707	chr17:21910083	G/C	cg22648282	chr17:21454238	C17orf51	-0.43	-7.73	-0.35	7.92e-14	Pelvic organ prolapse;
LUAD	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg09491104	chr22:46646882	C22orf40	-0.62	-10.72	-0.46	6.89e-24	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs13064411	0.542	rs4396864	chr3:113212562	C/T	cg18753928	chr3:113234510	CCDC52	-0.55	-9.73	-0.43	2.58e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg09455208	chr3:40491958	NA	0.53	11.75	0.5	8.76e-28	Renal cell carcinoma;
LUAD	trans	rs911186	0.509	rs6934329	chr6:27158033	A/G	cg06606381	chr12:133084897	FBRSL1	-0.62	-7.52	-0.34	3.24e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs657075	0.640	rs2073838	chr5:131649222	G/A	cg21138405	chr5:131827807	IRF1	0.53	6.73	0.31	5.64e-11	Rheumatoid arthritis;
LUAD	cis	rs4711336	0.664	rs4713662	chr6:33674188	A/G	cg13859433	chr6:33739653	LEMD2	-0.29	-6.93	-0.32	1.6e-11	Height;
LUAD	cis	rs9811920	0.809	rs793437	chr3:99559854	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.56	-10.64	-0.46	1.38e-23	Axial length;
LUAD	cis	rs796364	0.616	rs1523818	chr2:200684704	G/T	cg23649088	chr2:200775458	C2orf69	0.52	6.49	0.3	2.4e-10	Schizophrenia;
LUAD	cis	rs8025790	0.508	rs4776370	chr15:67904511	T/C	cg27219399	chr15:67835830	MAP2K5	0.43	7.61	0.35	1.76e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs4285028	0.948	rs12493952	chr3:121708497	C/T	cg20356878	chr3:121714668	ILDR1	-0.5	-6.79	-0.31	3.75e-11	Multiple sclerosis;
LUAD	cis	rs11622475	1.000	rs12889168	chr14:104481957	A/T	cg12183467	chr14:104352244	NA	-0.42	-7.57	-0.35	2.38e-13	Bipolar disorder;
LUAD	cis	rs8062405	0.721	rs151303	chr16:28492510	C/A	cg00204512	chr16:28754710	NA	0.32	6.65	0.31	9.33e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg26384229	chr12:38710491	ALG10B	0.49	7.89	0.36	2.62e-14	Bladder cancer;
LUAD	cis	rs775227	0.574	rs55693215	chr3:113064094	T/C	cg18753928	chr3:113234510	CCDC52	-0.71	-9.25	-0.41	1.16e-18	Dental caries;
LUAD	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18876405	chr7:65276391	NA	0.57	9.53	0.42	1.22e-19	Aortic root size;
LUAD	trans	rs629535	0.773	rs686683	chr8:70070364	G/A	cg21567404	chr3:27674614	NA	1.0	18.36	0.67	8.53e-56	Dupuytren's disease;
LUAD	cis	rs7020830	0.861	rs2291589	chr9:37079661	T/G	cg14294708	chr9:37120828	ZCCHC7	0.83	16.3	0.62	1.07e-46	Schizophrenia;
LUAD	cis	rs9902453	0.845	rs3102558	chr17:28023142	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.32	0.41	6.74e-19	Coffee consumption (cups per day);
LUAD	cis	rs72928364	1.000	rs2595893	chr3:100677842	C/T	cg10123952	chr3:100791384	NA	-0.54	-6.74	-0.31	5.28e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg01657329	chr11:68192670	LRP5	-0.4	-6.38	-0.3	4.67e-10	Total body bone mineral density;
LUAD	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg06609049	chr19:2785107	THOP1	0.66	11.2	0.48	1.1e-25	Total cholesterol levels;
LUAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg08219700	chr8:58056026	NA	0.51	7.69	0.35	1.07e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg10645314	chr2:3704589	ALLC	-0.88	-12.94	-0.53	1.76e-32	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs2274471	0.699	rs7033053	chr9:5042987	G/A	cg03390472	chr9:5043263	JAK2	-0.62	-9.39	-0.42	3.86e-19	Crohn's disease;
LUAD	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg21823605	chr1:152486609	CRCT1	0.28	6.52	0.3	2.01e-10	Hair morphology;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg26574964	chr11:117049906	SIDT2	-0.46	-7.25	-0.33	1.95e-12	Vertical cup-disc ratio;
LUAD	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg15017067	chr4:17643749	FAM184B	0.36	7.17	0.33	3.41e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.6	-0.52	3.97e-31	Monocyte count;
LUAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.5e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg22442454	chr1:209979470	IRF6	0.55	7.33	0.34	1.16e-12	Cleft lip with or without cleft palate;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03993171	chr6:86388501	SNORD50B;SNORD50A;SNHG5	-0.55	-6.79	-0.31	3.81e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4889855	0.578	rs7216808	chr17:78484187	A/G	cg16591659	chr17:78472290	NA	-0.56	-8.74	-0.39	5.49e-17	Fractional excretion of uric acid;
LUAD	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg04036182	chr15:45458818	NA	-0.39	-6.82	-0.31	3.26e-11	Glomerular filtration rate;
LUAD	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.4e-15	Prostate cancer;
LUAD	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg06618935	chr21:46677482	NA	-0.51	-10.35	-0.45	1.55e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg16486109	chr11:613632	IRF7	0.53	7.87	0.36	3.07e-14	Systemic lupus erythematosus;
LUAD	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.68	-10.38	-0.45	1.2e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg20476274	chr7:133979776	SLC35B4	0.86	17.56	0.65	3.17e-52	Mean platelet volume;
LUAD	cis	rs427394	0.659	rs274674	chr5:6755460	C/T	cg14682080	chr5:6737778	POLS	0.34	7.49	0.34	4.06e-13	Menopause (age at onset);
LUAD	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg08632164	chr7:65971372	NA	-0.54	-6.42	-0.3	3.69e-10	Diabetic kidney disease;
LUAD	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg25894440	chr7:65020034	NA	0.61	6.61	0.31	1.15e-10	Diabetic kidney disease;
LUAD	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg18944383	chr4:111397179	ENPEP	0.38	7.62	0.35	1.66e-13	Height;
LUAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg01874867	chr7:94954059	PON1	-0.68	-12.5	-0.52	9.57e-31	Paraoxonase activity;
LUAD	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg00316803	chr15:76480434	C15orf27	-0.43	-8.47	-0.38	4.06e-16	Blood metabolite levels;
LUAD	cis	rs929596	0.517	rs3806592	chr2:234625936	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-10.89	-0.47	1.6e-24	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg20607798	chr8:58055168	NA	0.67	8.71	0.39	7.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.17	0.33	3.28e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	6.64	0.31	9.48e-11	Electroencephalogram traits;
LUAD	cis	rs2637266	0.935	rs4520537	chr10:78392978	C/T	cg18941641	chr10:78392320	NA	0.35	7.26	0.33	1.85e-12	Pulmonary function;
LUAD	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03264133	chr6:25882463	NA	0.59	9.8	0.43	1.41e-20	Blood metabolite levels;
LUAD	cis	rs113835537	0.529	rs10501397	chr11:66272976	G/T	cg24851651	chr11:66362959	CCS	0.53	9.7	0.43	3.32e-20	Airway imaging phenotypes;
LUAD	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg11517269	chr6:28058789	ZSCAN12L1	0.27	6.5	0.3	2.3e-10	Cardiac Troponin-T levels;
LUAD	cis	rs5839475	1	rs5839475	chr2:234188015	A/AG	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.45	6.91	0.32	1.74e-11	Strep throat;
LUAD	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg04287289	chr16:89883240	FANCA	0.44	6.68	0.31	7.33e-11	Vitiligo;
LUAD	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg08999081	chr20:33150536	PIGU	-0.62	-13.96	-0.56	1.08e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.47	-6.91	-0.32	1.76e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7395662	1.000	rs11039779	chr11:48517895	G/A	cg00717180	chr2:96193071	NA	-0.4	-7.54	-0.34	2.92e-13	HDL cholesterol;
LUAD	cis	rs938554	0.744	rs938558	chr4:9939205	G/A	cg00071950	chr4:10020882	SLC2A9	0.51	8.74	0.39	5.39e-17	Blood metabolite levels;
LUAD	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg22105103	chr4:187893119	NA	0.5	10.57	0.46	2.46e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg18621852	chr3:10150065	C3orf24	0.45	7.0	0.32	9.95e-12	Alzheimer's disease;
LUAD	cis	rs11811982	0.793	rs74433506	chr1:227426502	T/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.34	0.34	1.13e-12	Optic disc area;
LUAD	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg09263875	chr16:632152	PIGQ	0.84	18.34	0.67	1.04e-55	Height;
LUAD	trans	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-9.27	-0.41	9.98e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-7.58	-0.35	2.16e-13	Lung cancer;
LUAD	cis	rs4660306	0.961	rs4660868	chr1:45986497	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.5	-7.98	-0.36	1.36e-14	Homocysteine levels;
LUAD	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg00634984	chr7:65235879	NA	0.47	6.37	0.3	4.91e-10	Aortic root size;
LUAD	cis	rs7593730	0.848	rs6432614	chr2:161208537	C/T	cg22609984	chr2:161126801	NA	0.44	7.12	0.33	4.78e-12	Type 2 diabetes;
LUAD	cis	rs11048434	0.761	rs12824380	chr12:9132017	A/G	cg13575925	chr12:9217583	LOC144571	0.4	7.33	0.34	1.21e-12	Sjögren's syndrome;
LUAD	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.58	-0.42	8.57e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs698833	0.892	rs698797	chr2:44689905	G/C	cg04920474	chr2:44395004	PPM1B	0.4	7.08	0.33	6.13e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg27529037	chr20:44575021	PCIF1	0.46	8.09	0.37	6.49e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs62064224	0.614	rs728718	chr17:30708960	T/G	cg18200150	chr17:30822561	MYO1D	0.41	7.59	0.35	2.11e-13	Schizophrenia;
LUAD	cis	rs8017423	0.967	rs59006192	chr14:90706456	C/T	cg14092571	chr14:90743983	NA	-0.49	-8.75	-0.39	5.11e-17	Mortality in heart failure;
LUAD	trans	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg14343924	chr8:8086146	FLJ10661	0.44	6.56	0.3	1.57e-10	Neuroticism;
LUAD	trans	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.85	0.43	9.44e-21	Ulcerative colitis;
LUAD	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	6.63	0.31	1.02e-10	Electroencephalogram traits;
LUAD	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg16989719	chr2:238392110	NA	-0.37	-7.88	-0.36	2.89e-14	Prostate cancer;
LUAD	trans	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.32	0.45	2.03e-22	Mean corpuscular volume;
LUAD	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.49	-0.3	2.47e-10	Aortic root size;
LUAD	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg10518543	chr12:38710700	ALG10B	-0.45	-7.3	-0.33	1.46e-12	Morning vs. evening chronotype;
LUAD	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg25036284	chr2:26402008	FAM59B	-0.68	-9.24	-0.41	1.26e-18	Gut microbiome composition (summer);
LUAD	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg19875535	chr5:140030758	IK	-0.39	-6.56	-0.3	1.56e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg00277334	chr10:82204260	NA	-0.63	-10.52	-0.46	3.81e-23	Post bronchodilator FEV1;
LUAD	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg22532475	chr10:104410764	TRIM8	-0.48	-9.47	-0.42	1.96e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg00204512	chr16:28754710	NA	0.36	7.8	0.35	4.72e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg10820262	chr4:111866929	NA	0.4	6.8	0.31	3.59e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg02753203	chr1:228287806	NA	-0.46	-8.29	-0.37	1.48e-15	Diastolic blood pressure;
LUAD	cis	rs28735056	0.933	rs499472	chr18:77589759	C/T	cg20368463	chr18:77673604	PQLC1	-0.41	-6.43	-0.3	3.43e-10	Schizophrenia;
LUAD	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg12011299	chr4:100065546	ADH4	0.75	14.9	0.59	1.15e-40	Alcohol dependence;
LUAD	cis	rs12681287	0.640	rs12541793	chr8:87462558	G/A	cg27223183	chr8:87520930	FAM82B	-0.68	-9.59	-0.42	7.69e-20	Caudate activity during reward;
LUAD	cis	rs2581828	0.656	rs891368	chr3:53123273	A/G	cg24530246	chr3:53118167	NA	0.3	6.39	0.3	4.4e-10	Crohn's disease;
LUAD	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg19635926	chr16:89946313	TCF25	0.7	6.57	0.3	1.47e-10	Skin colour saturation;
LUAD	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg18252515	chr7:66147081	NA	-0.63	-6.89	-0.32	2.01e-11	Diabetic kidney disease;
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg05064044	chr6:292385	DUSP22	-0.8	-13.67	-0.55	1.7000000000000001e-35	Menopause (age at onset);
LUAD	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg23933602	chr10:16859644	RSU1	0.56	7.64	0.35	1.47e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg26677194	chr12:130822605	PIWIL1	0.53	8.82	0.39	3.08e-17	Menopause (age at onset);
LUAD	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.44	-0.34	5.74e-13	Electroencephalogram traits;
LUAD	cis	rs62400317	0.762	rs72865924	chr6:44878943	G/A	cg20913747	chr6:44695427	NA	-0.41	-6.42	-0.3	3.76e-10	Total body bone mineral density;
LUAD	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg02410480	chr12:132819930	GALNT9	-0.29	-6.51	-0.3	2.19e-10	Anti-saccade response;
LUAD	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg18827107	chr12:86230957	RASSF9	-0.48	-8.67	-0.39	9.58e-17	Major depressive disorder;
LUAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.49	0.34	4.14e-13	Electroencephalogram traits;
LUAD	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg19635926	chr16:89946313	TCF25	0.73	6.44	0.3	3.23e-10	Skin colour saturation;
LUAD	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg06641503	chr3:48959341	ARIH2	-0.4	-7.81	-0.35	4.63e-14	Parkinson's disease;
LUAD	cis	rs3739034	0.877	rs13033373	chr2:135520534	T/C	cg12500956	chr2:135428796	TMEM163	0.38	6.8	0.31	3.63e-11	Gut microbiome composition (winter);
LUAD	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg27494647	chr7:150038898	RARRES2	0.48	8.48	0.38	3.87e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs870825	0.616	rs4437295	chr4:185643336	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.03	0.56	5.61e-37	Blood protein levels;
LUAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08219700	chr8:58056026	NA	0.56	7.71	0.35	8.86e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg24503407	chr1:205819492	PM20D1	0.5	8.46	0.38	4.27e-16	Menarche (age at onset);
LUAD	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg10755058	chr3:40428713	ENTPD3	0.43	8.13	0.37	4.84e-15	Renal cell carcinoma;
LUAD	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg20848291	chr7:100343083	ZAN	0.39	6.76	0.31	4.47e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg18755752	chr8:142205143	DENND3	-0.45	-7.84	-0.36	3.63e-14	Immature fraction of reticulocytes;
LUAD	cis	rs11971779	0.680	rs17613690	chr7:139088401	C/T	cg24109934	chr7:139138155	KLRG2	0.32	6.69	0.31	7.2e-11	Diisocyanate-induced asthma;
LUAD	trans	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	15.41	0.6	7.3e-43	Exhaled nitric oxide levels;
LUAD	cis	rs853679	0.607	rs34505829	chr6:28133239	A/T	cg12623302	chr6:28058802	ZSCAN12L1	0.56	6.53	0.3	1.91e-10	Depression;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01311654	chr14:90864090	CALM1	-0.39	-6.39	-0.3	4.37e-10	Cancer;
LUAD	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg24596788	chr1:163392923	NA	-0.37	-8.08	-0.37	6.82e-15	Motion sickness;
LUAD	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg09796270	chr17:17721594	SREBF1	0.38	7.39	0.34	7.84e-13	Total body bone mineral density;
LUAD	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg20476274	chr7:133979776	SLC35B4	0.85	17.28	0.64	5.44e-51	Mean platelet volume;
LUAD	trans	rs629535	0.911	rs490165	chr8:70014976	A/G	cg21567404	chr3:27674614	NA	-0.97	-18.3	-0.66	1.62e-55	Dupuytren's disease;
LUAD	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	ch.11.42038R	chr11:967971	AP2A2	0.39	6.88	0.32	2.19e-11	Alzheimer's disease (late onset);
LUAD	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg20290983	chr6:43655470	MRPS18A	1.08	27.77	0.8	2.21e-97	IgG glycosylation;
LUAD	cis	rs12681288	0.748	rs2123054	chr8:1028227	C/G	cg04851639	chr8:1020857	NA	-0.45	-10.53	-0.46	3.51e-23	Schizophrenia;
LUAD	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg00071950	chr4:10020882	SLC2A9	0.6	11.8	0.5	5.77e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg01874867	chr7:94954059	PON1	-0.52	-7.12	-0.33	4.65e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02065704	chr22:37172029	RABL4	-0.38	-6.51	-0.3	2.18e-10	Cancer;
LUAD	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg03467027	chr4:99064603	C4orf37	0.39	6.45	0.3	3.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs28735056	0.591	rs62101204	chr18:77712832	G/A	cg05926928	chr17:57297772	GDPD1	0.53	8.12	0.37	5.32e-15	Schizophrenia;
LUAD	cis	rs67072384	1.000	rs12289259	chr11:72446731	A/C	cg04827223	chr11:72435913	ARAP1	-0.62	-7.63	-0.35	1.56e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.75	-0.39	5.25e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs7289126	1.000	rs5750571	chr22:38640312	A/G	cg25457927	chr22:38595422	NA	-0.44	-10.18	-0.44	6.19e-22	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg15445000	chr17:37608096	MED1	-0.44	-8.21	-0.37	2.74e-15	Glomerular filtration rate (creatinine);
LUAD	trans	rs877282	1.000	rs12763443	chr10:771941	G/A	cg22713356	chr15:30763199	NA	1.34	19.16	0.68	2.24e-59	Uric acid levels;
LUAD	trans	rs4650994	0.593	rs6676155	chr1:178508360	C/A	cg05059571	chr16:84539110	KIAA1609	0.43	6.45	0.3	3.15e-10	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg26587870	chr6:27730563	NA	-0.66	-7.01	-0.32	9.66e-12	Breast cancer;
LUAD	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26314531	chr2:26401878	FAM59B	-0.58	-7.99	-0.36	1.33e-14	Gut microbiome composition (summer);
LUAD	cis	rs116248771	0.739	rs12488447	chr3:158421824	T/C	cg16708174	chr3:158430962	RARRES1	0.47	6.85	0.32	2.68e-11	diarrhoeal disease at age 2;
LUAD	cis	rs2932538	0.922	rs12048528	chr1:113210534	A/C	cg22162597	chr1:113214053	CAPZA1	-0.45	-6.8	-0.31	3.6e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs2996428	0.643	rs6424056	chr1:3722486	G/A	cg22529645	chr1:3704559	LRRC47	0.54	10.36	0.45	1.5e-22	Red cell distribution width;
LUAD	cis	rs6993813	0.872	rs7018198	chr8:120048033	A/G	cg01975934	chr8:119970761	NA	-0.35	-6.94	-0.32	1.45e-11	Bone mineral density (hip);
LUAD	cis	rs1997103	1.000	rs6949222	chr7:55411264	C/T	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg12311346	chr5:56204834	C5orf35	-0.92	-14.06	-0.56	4.27e-37	Initial pursuit acceleration;
LUAD	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg23029597	chr12:123009494	RSRC2	-0.5	-7.65	-0.35	1.36e-13	Body mass index;
LUAD	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg13732083	chr21:47605072	C21orf56	0.51	8.56	0.38	2.12e-16	Testicular germ cell tumor;
LUAD	cis	rs73198271	0.515	rs78922347	chr8:8627916	G/C	cg01851573	chr8:8652454	MFHAS1	0.58	7.8	0.35	4.89e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06544989	chr22:39130855	UNC84B	0.44	8.27	0.37	1.7e-15	Menopause (age at onset);
LUAD	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg20587970	chr11:113659929	NA	-1.38	-20.5	-0.71	2.42e-65	Hip circumference adjusted for BMI;
LUAD	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg26384229	chr12:38710491	ALG10B	-0.44	-7.53	-0.34	3.07e-13	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.33e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	13.98	0.56	9.2e-37	Exhaled nitric oxide output;
LUAD	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	7.4	0.34	7.46e-13	Platelet count;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09514589	chr15:76603992	ETFA	-0.48	-7.51	-0.34	3.51e-13	Height;
LUAD	cis	rs4900538	0.821	rs7012	chr14:102814945	C/T	cg18135206	chr14:102964638	TECPR2	-0.94	-19.53	-0.69	5.09e-61	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg12655452	chr1:77685094	PIGK	-0.77	-7.49	-0.34	4.14e-13	Type 2 diabetes;
LUAD	cis	rs12928939	0.517	rs9940234	chr16:71964805	C/T	cg03805757	chr16:71968109	PKD1L3	-0.54	-8.76	-0.39	4.77e-17	Post bronchodilator FEV1;
LUAD	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg25036284	chr2:26402008	FAM59B	-0.58	-8.17	-0.37	3.48e-15	Gut microbiome composition (summer);
LUAD	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg17264618	chr3:40429014	ENTPD3	0.39	8.73	0.39	6.13e-17	Renal cell carcinoma;
LUAD	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg09491104	chr22:46646882	C22orf40	-0.6	-7.88	-0.36	2.86e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg25736982	chr6:160182554	ACAT2	0.78	11.47	0.49	1.08e-26	Iron status biomarkers;
LUAD	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.12	15.14	0.59	1.13e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg07936489	chr17:37558343	FBXL20	-0.43	-6.66	-0.31	8.46e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs2224391	1.000	rs2753249	chr6:5263475	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-9.49	-0.42	1.71e-19	Height;
LUAD	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg01689657	chr7:91764605	CYP51A1	-0.35	-8.68	-0.39	8.39e-17	Breast cancer;
LUAD	cis	rs6500395	1.000	rs1386040	chr16:48631207	A/G	cg04672837	chr16:48644449	N4BP1	0.38	6.57	0.3	1.46e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7707921	0.752	rs2406910	chr5:81308719	C/T	cg15871215	chr5:81402204	ATG10	0.67	11.02	0.47	5.26e-25	Breast cancer;
LUAD	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg23803603	chr1:2058230	PRKCZ	0.41	6.58	0.3	1.41e-10	Height;
LUAD	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg13902645	chr11:5959945	NA	-0.59	-10.22	-0.45	4.57e-22	DNA methylation (variation);
LUAD	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg21475434	chr5:93447410	FAM172A	0.71	8.44	0.38	4.95e-16	Diabetic retinopathy;
LUAD	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg05110241	chr16:68378359	PRMT7	-0.56	-6.4	-0.3	4.02e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg06002616	chr8:101225028	SPAG1	-0.41	-8.27	-0.37	1.71e-15	Atrioventricular conduction;
LUAD	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23583168	chr7:148888333	NA	-1.05	-25.83	-0.78	5.45e-89	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg02423579	chr7:2872169	GNA12	-0.89	-15.91	-0.61	5.26e-45	Height;
LUAD	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg24818145	chr4:99064322	C4orf37	-0.41	-6.76	-0.31	4.45e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.45	-0.3	3.12e-10	Triglycerides;
LUAD	cis	rs10484885	0.878	rs72921959	chr6:90591326	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.69	-6.79	-0.31	3.74e-11	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg04455712	chr21:45112962	RRP1B	0.42	8.48	0.38	3.71e-16	Mean corpuscular volume;
LUAD	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg17366294	chr4:99064904	C4orf37	0.48	8.38	0.38	7.88e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7119	0.604	rs2682924	chr15:77863720	C/T	cg27398640	chr15:77910606	LINGO1	-0.36	-6.88	-0.32	2.12e-11	Type 2 diabetes;
LUAD	cis	rs17095355	1.000	rs11194922	chr10:111695656	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.72	-9.69	-0.43	3.51e-20	Biliary atresia;
LUAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.52	7.96	0.36	1.54e-14	Renal function-related traits (BUN);
LUAD	cis	rs2455826	0.521	rs2455805	chr3:15704873	T/C	cg16303742	chr3:15540471	COLQ	-0.39	-6.49	-0.3	2.44e-10	Inflammatory skin disease;
LUAD	cis	rs7809950	1.000	rs2712189	chr7:107195747	G/A	cg23024343	chr7:107201750	COG5	-0.72	-12.24	-0.51	1.08e-29	Coronary artery disease;
LUAD	cis	rs4072705	0.646	rs4838187	chr9:127242076	G/C	cg13476313	chr9:127244764	NR5A1	0.37	9.11	0.4	3.4e-18	Menarche (age at onset);
LUAD	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg19318889	chr4:1322082	MAEA	0.44	7.08	0.33	5.92e-12	Obesity-related traits;
LUAD	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg08514558	chr10:81106712	PPIF	0.52	10.08	0.44	1.46e-21	Height;
LUAD	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg08773314	chr2:239334832	ASB1	0.45	10.3	0.45	2.29e-22	Multiple system atrophy;
LUAD	trans	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg05926928	chr17:57297772	GDPD1	-0.64	-8.61	-0.39	1.47e-16	Opioid sensitivity;
LUAD	cis	rs7799006	0.606	rs4721527	chr7:2306655	G/A	cg08027265	chr7:2291960	NA	-0.73	-14.58	-0.58	2.55e-39	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg05922057	chr17:4047571	ZZEF1;CYB5D2	-0.39	-6.76	-0.31	4.68e-11	Type 2 diabetes;
LUAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg04025307	chr7:1156635	C7orf50	0.86	16.72	0.63	1.49e-48	Longevity;Endometriosis;
LUAD	cis	rs775227	1.000	rs13094203	chr3:112993367	G/A	cg18753928	chr3:113234510	CCDC52	-0.45	-6.42	-0.3	3.61e-10	Dental caries;
LUAD	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg27432699	chr2:27873401	GPN1	0.59	10.37	0.45	1.36e-22	Oral cavity cancer;
LUAD	cis	rs11167764	0.945	rs13161849	chr5:141473395	A/G	cg08523384	chr5:141488047	NDFIP1	-0.47	-7.08	-0.33	6.04e-12	Crohn's disease;
LUAD	cis	rs7149242	1.000	rs11620937	chr14:101151012	C/G	cg18089426	chr14:101175970	NA	0.37	6.55	0.3	1.62e-10	Platelet count;
LUAD	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg00310523	chr12:86230176	RASSF9	0.4	8.01	0.36	1.15e-14	Major depressive disorder;
LUAD	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.58	-7.63	-0.35	1.5700000000000001e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg00933542	chr6:150070202	PCMT1	0.43	9.24	0.41	1.26e-18	Lung cancer;
LUAD	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg10802521	chr3:52805072	NEK4	-0.42	-6.38	-0.3	4.62e-10	Bipolar disorder;
LUAD	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg24675658	chr1:53192096	ZYG11B	0.44	7.09	0.33	5.61e-12	Monocyte count;
LUAD	cis	rs870825	0.929	rs56106324	chr4:185589901	C/A	cg04058563	chr4:185651563	MLF1IP	0.74	9.41	0.42	3.18e-19	Blood protein levels;
LUAD	cis	rs881375	0.967	rs1548783	chr9:123658639	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	6.69	0.31	7.02e-11	Rheumatoid arthritis;
LUAD	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.99	0.32	1.08e-11	Depression;
LUAD	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg02527881	chr3:46936655	PTH1R	0.68	15.09	0.59	1.82e-41	Birth weight;
LUAD	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg25358565	chr5:93447407	FAM172A	0.55	6.68	0.31	7.63e-11	Diabetic retinopathy;
LUAD	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg15445000	chr17:37608096	MED1	0.44	8.2	0.37	3e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg05368731	chr17:41323189	NBR1	0.98	20.41	0.7	5.67e-65	Menopause (age at onset);
LUAD	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg12432903	chr7:1882776	MAD1L1	-0.41	-6.77	-0.31	4.22e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg04586622	chr2:25135609	ADCY3	0.38	8.47	0.38	4.16e-16	Body mass index;
LUAD	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg06131755	chr6:160182447	ACAT2	0.43	6.48	0.3	2.57e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg26384229	chr12:38710491	ALG10B	0.49	7.87	0.36	3.1e-14	Heart rate;
LUAD	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg21433313	chr16:3507492	NAT15	0.76	14.21	0.57	9.91e-38	Tuberculosis;
LUAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg26513180	chr16:89883248	FANCA	0.79	7.27	0.33	1.76e-12	Skin colour saturation;
LUAD	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg15448220	chr1:150897856	SETDB1	-0.46	-7.98	-0.36	1.34e-14	Tonsillectomy;
LUAD	cis	rs59104589	0.535	rs73002160	chr2:242321707	A/C	cg08645257	chr2:242211290	HDLBP	0.47	7.48	0.34	4.4e-13	Fibrinogen levels;
LUAD	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg02423579	chr7:2872169	GNA12	-0.73	-12.35	-0.51	4.05e-30	Height;
LUAD	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg26384229	chr12:38710491	ALG10B	0.41	7.01	0.32	9.45e-12	Morning vs. evening chronotype;
LUAD	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg10435618	chr10:838112	NA	0.47	6.43	0.3	3.54e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.68	0.31	7.6e-11	Prudent dietary pattern;
LUAD	cis	rs1569328	0.752	rs741847	chr14:75722496	C/T	cg18117039	chr14:75741733	NA	-0.51	-8.5	-0.38	3.23e-16	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2387326	0.638	rs76288438	chr10:129940554	A/C	cg16087940	chr10:129947807	NA	-0.62	-8.29	-0.37	1.47e-15	Select biomarker traits;
LUAD	cis	rs1448094	0.802	rs12369634	chr12:86406792	C/G	cg25456477	chr12:86230367	RASSF9	0.33	6.67	0.31	8e-11	Major depressive disorder;
LUAD	cis	rs877282	0.945	rs877280	chr10:771599	C/T	cg17470449	chr10:769945	NA	0.69	9.98	0.44	3.39e-21	Uric acid levels;
LUAD	cis	rs9487051	0.676	rs9386775	chr6:109561779	T/C	cg21918786	chr6:109611834	NA	-0.42	-7.2	-0.33	2.71e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg02683114	chr2:24398427	C2orf84	-0.54	-7.81	-0.35	4.61e-14	Asthma;
LUAD	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg22467129	chr15:76604101	ETFA	-0.47	-7.69	-0.35	1.07e-13	Blood metabolite levels;
LUAD	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg11266682	chr4:10021025	SLC2A9	0.69	15.97	0.61	2.74e-45	Bone mineral density;
LUAD	trans	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg03929089	chr4:120376271	NA	0.57	6.56	0.3	1.54e-10	Axial length;
LUAD	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.08	15.37	0.6	1.14e-42	Lung cancer in ever smokers;
LUAD	trans	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg26811252	chr16:29126840	RRN3P2	0.59	10.39	0.45	1.15e-22	Menopause (age at onset);
LUAD	cis	rs757081	0.867	rs2521999	chr11:17333183	G/A	cg15432903	chr11:17409602	KCNJ11	-0.43	-6.78	-0.31	4.17e-11	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg00814883	chr7:100076585	TSC22D4	-0.8	-11.19	-0.48	1.2e-25	Platelet count;
LUAD	trans	rs853679	0.546	rs200948	chr6:27835272	T/C	cg01620082	chr3:125678407	NA	-0.83	-8.92	-0.4	1.44e-17	Depression;
LUAD	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg01657329	chr11:68192670	LRP5	0.47	8.51	0.38	3.04e-16	Total body bone mineral density;
LUAD	cis	rs13082711	0.911	rs923941	chr3:27458914	A/G	cg02860705	chr3:27208620	NA	0.61	9.38	0.41	4.18e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs877282	0.898	rs11253356	chr10:768604	G/A	cg17470449	chr10:769945	NA	0.56	8.0	0.36	1.22e-14	Uric acid levels;
LUAD	trans	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg14917512	chr19:3094685	GNA11	0.38	6.7	0.31	6.82e-11	Aortic root size;
LUAD	cis	rs8060686	0.516	rs7197756	chr16:68275516	A/C	cg09835421	chr16:68378352	PRMT7	-0.56	-7.03	-0.32	8.08e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.44	-0.42	2.63e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18099408	chr3:52552593	STAB1	-0.46	-8.17	-0.37	3.58e-15	Bipolar disorder;
LUAD	trans	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg14917512	chr19:3094685	GNA11	-0.57	-6.79	-0.31	3.92e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.4e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11811982	0.793	rs79655227	chr1:227285708	T/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.44	0.34	5.54e-13	Optic disc area;
LUAD	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg27124370	chr19:33622961	WDR88	0.46	7.15	0.33	3.92e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	7.76	0.35	6.61e-14	Rheumatoid arthritis;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg01171360	chr6:293285	DUSP22	-0.74	-13.14	-0.54	2.64e-33	Menopause (age at onset);
LUAD	trans	rs7246760	0.867	rs66927855	chr19:9811728	C/T	cg02900749	chr2:68251473	NA	-0.6	-6.64	-0.31	9.81e-11	Pursuit maintenance gain;
LUAD	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.97	0.4	9.92e-18	Parkinson's disease;
LUAD	cis	rs7665090	1.000	rs5026476	chr4:103554910	A/C	cg07973026	chr4:103553119	MANBA	0.47	8.43	0.38	5.37e-16	Primary biliary cholangitis;
LUAD	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg01802117	chr1:53393560	SCP2	-0.35	-6.79	-0.31	3.89e-11	Monocyte count;
LUAD	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg17724175	chr1:150552817	MCL1	-0.35	-8.01	-0.36	1.1e-14	Melanoma;
LUAD	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg03714773	chr7:91764589	CYP51A1	-0.3	-7.24	-0.33	2.13e-12	Breast cancer;
LUAD	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-6.93	-0.32	1.58e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs3960554	0.673	rs112680895	chr7:75623520	G/A	cg19862616	chr7:65841803	NCRNA00174	0.83	11.16	0.48	1.65e-25	Eotaxin levels;
LUAD	cis	rs9826463	0.582	rs73238187	chr3:142143674	T/C	cg20824294	chr3:142316082	PLS1	0.36	6.42	0.3	3.58e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs367943	0.649	rs255866	chr5:112748532	A/T	cg12552261	chr5:112820674	MCC	0.5	9.77	0.43	1.88e-20	Type 2 diabetes;
LUAD	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg25173405	chr17:45401733	C17orf57	-0.53	-8.99	-0.4	8.22e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9394152	0.845	rs9366823	chr6:33471059	C/T	cg13560919	chr6:33536144	NA	0.51	8.64	0.39	1.17e-16	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg02221422	chr11:68192511	LRP5	0.39	6.57	0.3	1.44e-10	Total body bone mineral density;
LUAD	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg04036182	chr15:45458818	NA	0.39	6.65	0.31	8.95e-11	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg11915388	chr22:42470451	FAM109B	-0.42	-7.44	-0.34	5.67e-13	Schizophrenia;
LUAD	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg11901034	chr3:128598214	ACAD9	-0.55	-8.75	-0.39	5.24e-17	IgG glycosylation;
LUAD	trans	rs637571	0.584	rs659824	chr11:65636509	A/G	cg17712092	chr4:129076599	LARP1B	-0.76	-13.42	-0.55	1.88e-34	Eosinophil percentage of white cells;
LUAD	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.45	0.45	6.61e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs72928364	1.000	rs2713789	chr3:100623404	G/A	cg10123952	chr3:100791384	NA	-0.54	-6.74	-0.31	5.11e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs68170813	0.559	rs76859341	chr7:107070146	C/G	cg23024343	chr7:107201750	COG5	0.5	7.2	0.33	2.75e-12	Coronary artery disease;
LUAD	trans	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg14917512	chr19:3094685	GNA11	-0.37	-6.37	-0.3	4.98e-10	Aortic root size;
LUAD	cis	rs7107174	1.000	rs11602622	chr11:78010830	A/G	cg02023728	chr11:77925099	USP35	0.51	7.92	0.36	2.16e-14	Testicular germ cell tumor;
LUAD	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-8.25	-0.37	1.96e-15	Blood metabolite levels;
LUAD	cis	rs7394190	0.748	rs3740293	chr10:75406141	A/C	cg02286717	chr10:75415704	SYNPO2L	-0.39	-7.53	-0.34	3.03e-13	Incident atrial fibrillation;
LUAD	cis	rs7617773	0.780	rs35778847	chr3:48346985	G/T	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	trans	rs6076960	0.684	rs6054055	chr20:6257517	C/G	cg17788362	chr6:86352627	SYNCRIP	0.42	6.61	0.31	1.16e-10	Smooth-surface caries;
LUAD	cis	rs9972944	0.756	rs9894298	chr17:63769225	G/A	cg07283582	chr17:63770753	CCDC46	-0.51	-11.6	-0.49	3.32e-27	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9522267	0.535	rs7323631	chr13:112232269	A/G	cg10483660	chr13:112241077	NA	-0.32	-6.84	-0.32	2.79e-11	Hepatitis;
LUAD	cis	rs10896135	0.526	rs1987169	chr11:66448044	A/G	cg24851651	chr11:66362959	CCS	-0.51	-8.09	-0.37	6.2e-15	Bipolar disorder;
LUAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.4	-6.38	-0.3	4.68e-10	Longevity;Endometriosis;
LUAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg03188948	chr7:1209495	NA	0.83	10.17	0.44	6.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03517284	chr6:25882590	NA	-0.59	-9.61	-0.42	6.44e-20	Blood metabolite levels;
LUAD	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	7.34	0.34	1.11e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9487051	0.702	rs368467	chr6:109519451	T/C	cg21918786	chr6:109611834	NA	-0.41	-7.55	-0.34	2.75e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg08773314	chr2:239334832	ASB1	0.47	10.86	0.47	2.05e-24	Multiple system atrophy;
LUAD	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg06808227	chr14:105710500	BRF1	-0.42	-6.52	-0.3	2.06e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs6499255	1.000	rs73579497	chr16:69824150	C/G	cg15192750	chr16:69999425	NA	0.54	8.56	0.38	2.13e-16	IgE levels;
LUAD	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg25036284	chr2:26402008	FAM59B	-0.54	-7.77	-0.35	6.12e-14	Gut microbiome composition (summer);
LUAD	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg04414720	chr1:150670196	GOLPH3L	0.72	13.17	0.54	1.95e-33	Tonsillectomy;
LUAD	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg00071950	chr4:10020882	SLC2A9	-0.59	-10.81	-0.47	3.12e-24	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs870825	1.000	rs870821	chr4:185587377	T/C	cg04058563	chr4:185651563	MLF1IP	0.74	10.06	0.44	1.67e-21	Blood protein levels;
LUAD	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg07212818	chr11:638076	DRD4	-0.47	-6.81	-0.31	3.36e-11	Systemic lupus erythematosus;
LUAD	trans	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg16011800	chr17:1958478	HIC1	-0.57	-8.02	-0.36	1.04e-14	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11644478	chr21:40555479	PSMG1	-0.41	-6.73	-0.31	5.41e-11	Menarche (age at onset);
LUAD	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg04827223	chr11:72435913	ARAP1	-0.49	-6.74	-0.31	5.05e-11	Type 2 diabetes;
LUAD	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg15083037	chr5:83017644	HAPLN1	-0.51	-7.6	-0.35	1.97e-13	Prostate cancer;
LUAD	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg18827107	chr12:86230957	RASSF9	-0.53	-9.34	-0.41	5.41e-19	Major depressive disorder;
LUAD	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4273100	1.000	rs12602286	chr17:19236954	G/T	cg03910582	chr17:19030146	GRAPL	-0.55	-7.42	-0.34	6.58e-13	Schizophrenia;
LUAD	cis	rs10979	0.964	rs35205240	chr6:143898676	T/C	cg25407410	chr6:143891975	LOC285740	-0.65	-10.27	-0.45	3.18e-22	Hypospadias;
LUAD	cis	rs12618769	0.597	rs17032870	chr2:99132786	C/T	cg10123293	chr2:99228465	UNC50	0.47	8.47	0.38	4.2e-16	Bipolar disorder;
LUAD	cis	rs9811920	0.715	rs6776886	chr3:99906270	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.47	8.95	0.4	1.13e-17	Axial length;
LUAD	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg14983838	chr19:29218262	NA	0.67	9.86	0.43	9.04e-21	Methadone dose in opioid dependence;
LUAD	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.44	-7.33	-0.34	1.17e-12	Tonsillectomy;
LUAD	cis	rs4664308	1.000	rs6759836	chr2:160912802	C/T	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.73	-0.31	5.56e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg15997130	chr1:24165203	NA	0.54	9.28	0.41	9.02e-19	Immature fraction of reticulocytes;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg02698600	chr1:201450009	NA	0.38	6.59	0.31	1.3e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs240764	0.781	rs239227	chr6:101107089	C/G	cg09795085	chr6:101329169	ASCC3	0.44	7.51	0.34	3.56e-13	Neuroticism;
LUAD	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg01516881	chr6:292596	DUSP22	-0.52	-8.47	-0.38	3.96e-16	Menopause (age at onset);
LUAD	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg23254163	chr1:152506842	NA	0.25	7.13	0.33	4.3e-12	Hair morphology;
LUAD	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg20607287	chr7:12443886	VWDE	-0.54	-6.85	-0.32	2.59e-11	Coronary artery disease;
LUAD	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg22823121	chr1:150693482	HORMAD1	0.43	8.85	0.4	2.44e-17	Tonsillectomy;
LUAD	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg24558204	chr6:135376177	HBS1L	0.47	8.64	0.39	1.14e-16	Red blood cell count;
LUAD	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6445967	0.569	rs67471622	chr3:58320918	T/C	cg23715586	chr3:58305044	RPP14	0.41	6.61	0.31	1.14e-10	Platelet count;
LUAD	cis	rs78761021	0.720	rs7220089	chr17:9796985	G/A	cg26853458	chr17:9805074	RCVRN	0.41	7.9	0.36	2.49e-14	Type 2 diabetes;
LUAD	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg09359103	chr1:154839909	KCNN3	-0.86	-17.96	-0.66	4.99e-54	Prostate cancer;
LUAD	cis	rs262150	0.592	rs56062559	chr7:158769109	T/C	cg09640425	chr7:158790006	NA	0.54	6.63	0.31	1.03e-10	Facial morphology (factor 20);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg26689765	chr5:52083512	ITGA1;PELO	-0.41	-6.8	-0.31	3.49e-11	Subcortical brain region volumes;
LUAD	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg02569458	chr12:86230093	RASSF9	-0.41	-7.64	-0.35	1.48e-13	Major depressive disorder;
LUAD	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg25324976	chr17:61989376	CSHL1	0.34	6.6	0.31	1.23e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg18335740	chr13:41363409	SLC25A15	0.6	11.06	0.47	3.87e-25	Lewy body disease;
LUAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg24829409	chr8:58192753	C8orf71	-0.53	-6.88	-0.32	2.16e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs62400317	0.859	rs12201005	chr6:45136922	A/T	cg18551225	chr6:44695536	NA	-0.52	-8.19	-0.37	3.03e-15	Total body bone mineral density;
LUAD	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg24818145	chr4:99064322	C4orf37	0.47	7.94	0.36	1.86e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg04450456	chr4:17643702	FAM184B	0.39	7.83	0.36	4.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg26384229	chr12:38710491	ALG10B	-0.38	-6.4	-0.3	4.05e-10	Morning vs. evening chronotype;
LUAD	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg00933542	chr6:150070202	PCMT1	0.45	9.52	0.42	1.34e-19	Lung cancer;
LUAD	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00475322	chr7:917719	C7orf20	0.58	10.57	0.46	2.53e-23	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.36	7.34	0.34	1.09e-12	Hemoglobin concentration;
LUAD	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg19678392	chr7:94953810	PON1	-0.58	-8.33	-0.38	1.1e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg04248312	chr19:17393744	ANKLE1	-1.01	-18.67	-0.67	3.74e-57	Systemic lupus erythematosus;
LUAD	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26314531	chr2:26401878	FAM59B	-0.64	-8.71	-0.39	6.83e-17	Gut microbiome composition (summer);
LUAD	cis	rs66731853	0.769	rs657624	chr1:20888348	C/T	cg04087271	chr1:20915334	CDA	-0.59	-10.96	-0.47	9.16e-25	Mean corpuscular volume;
LUAD	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.25	-0.45	3.49e-22	Total body bone mineral density;
LUAD	trans	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.02	21.24	0.72	1.13e-68	Colorectal cancer;
LUAD	cis	rs490234	0.702	rs13284551	chr9:128411969	C/T	cg14078157	chr9:128172775	NA	-0.44	-7.91	-0.36	2.35e-14	Mean arterial pressure;
LUAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg26516362	chr5:178986906	RUFY1	-0.47	-8.08	-0.37	6.93e-15	Lung cancer;
LUAD	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg22920501	chr2:26401640	FAM59B	0.91	14.03	0.56	5.61e-37	Gut microbiome composition (summer);
LUAD	cis	rs7481584	0.926	rs12806061	chr11:3008404	G/A	cg11201177	chr11:2961805	NA	0.39	6.62	0.31	1.08e-10	Calcium levels;
LUAD	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg07917127	chr4:99064746	C4orf37	0.4	6.51	0.3	2.13e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs877282	1.000	rs12779159	chr10:772143	T/C	cg06581033	chr10:766294	NA	-0.53	-7.02	-0.32	8.81e-12	Uric acid levels;
LUAD	cis	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg07460842	chr6:66804631	NA	0.95	12.61	0.52	3.58e-31	Exhaled nitric oxide output;
LUAD	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg09253696	chr17:73873529	TRIM47	-0.41	-7.2	-0.33	2.8e-12	Psoriasis;
LUAD	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg18944383	chr4:111397179	ENPEP	0.37	7.42	0.34	6.65e-13	Height;
LUAD	cis	rs6987853	0.931	rs2923399	chr8:42439509	G/A	cg09913449	chr8:42400586	C8orf40	0.42	7.68	0.35	1.09e-13	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1784581	0.569	rs9364629	chr6:162416831	T/G	cg17173639	chr6:162384350	PARK2	0.44	7.94	0.36	1.79e-14	Itch intensity from mosquito bite;
LUAD	cis	rs7927592	0.513	rs630225	chr11:68194611	A/C	cg02221422	chr11:68192511	LRP5	-0.43	-7.11	-0.33	4.94e-12	Total body bone mineral density;
LUAD	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22307029	chr19:49891270	CCDC155	0.7	10.31	0.45	2.28e-22	Multiple sclerosis;
LUAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.56	0.3	1.61e-10	Prudent dietary pattern;
LUAD	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg03733263	chr8:22462867	KIAA1967	0.73	12.65	0.52	2.4e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs4700695	0.841	rs428880	chr5:65245133	C/A	cg21114390	chr5:65439923	SFRS12	0.62	7.49	0.34	4.12e-13	Facial morphology (factor 19);
LUAD	cis	rs1595825	0.891	rs16823385	chr2:198602101	G/A	cg00361562	chr2:198649771	BOLL	-0.49	-6.64	-0.31	9.9e-11	Ulcerative colitis;
LUAD	cis	rs4948275	0.550	rs7082786	chr10:63176990	C/A	cg02461363	chr10:63212496	TMEM26	-0.35	-7.47	-0.34	4.7e-13	Night sleep phenotypes;
LUAD	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg20991723	chr1:152506922	NA	0.35	6.99	0.32	1.05e-11	Hair morphology;
LUAD	trans	rs1493916	0.967	rs9953765	chr18:31399464	A/G	cg27147174	chr7:100797783	AP1S1	-0.67	-11.7	-0.49	1.36e-27	Life satisfaction;
LUAD	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg16099169	chr2:106886729	NA	-0.62	-9.57	-0.42	9.12e-20	Facial morphology (factor 23);
LUAD	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg19761014	chr17:28927070	LRRC37B2	0.93	9.0	0.4	7.52e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12868349	chr11:71639594	RNF121;LOC100133315	-0.41	-6.64	-0.31	9.66e-11	Height;
LUAD	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27286337	chr10:134555280	INPP5A	0.69	10.05	0.44	1.83e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-6.91	-0.32	1.83e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.43	-6.75	-0.31	4.91e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg02569458	chr12:86230093	RASSF9	0.44	8.02	0.36	1.06e-14	Major depressive disorder;
LUAD	cis	rs10838532	0.591	rs1996573	chr11:45974643	C/G	cg24204282	chr11:45944920	GYLTL1B	0.41	6.59	0.3	1.34e-10	Axial length;
LUAD	trans	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg18187862	chr3:45730750	SACM1L	0.4	6.45	0.3	3.05e-10	Primary sclerosing cholangitis;
LUAD	cis	rs6684514	1.000	rs2241106	chr1:156218910	C/G	cg16558208	chr1:156270281	VHLL	0.51	9.05	0.4	5.1e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg21890820	chr11:65308645	LTBP3	1.17	10.12	0.44	1.03e-21	Height;
LUAD	cis	rs6456156	0.716	rs6905876	chr6:167521562	C/T	cg07741184	chr6:167504864	NA	0.28	6.64	0.31	9.58e-11	Primary biliary cholangitis;
LUAD	cis	rs344364	0.602	rs7188401	chr16:1876949	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.56	-0.3	1.59e-10	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg07153921	chr17:41440717	NA	0.39	6.49	0.3	2.43e-10	Menopause (age at onset);
LUAD	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg02079420	chr8:82753780	SNX16	-0.43	-8.69	-0.39	7.83e-17	Diastolic blood pressure;
LUAD	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.12	-0.44	1.05e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs220324	0.738	rs9984830	chr21:43570705	A/G	cg08841829	chr21:43638893	ABCG1	-0.48	-6.91	-0.32	1.74e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg01657329	chr11:68192670	LRP5	-0.55	-9.77	-0.43	1.81e-20	Total body bone mineral density;
LUAD	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg13319975	chr6:146136371	FBXO30	-0.6	-10.27	-0.45	2.97e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg02505535	chr3:195703920	SDHAP1	-0.34	-7.18	-0.33	3.23e-12	Pancreatic cancer;
LUAD	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-8.31	-0.37	1.36e-15	Type 2 diabetes;
LUAD	cis	rs4964805	0.954	rs11111785	chr12:104189056	A/G	cg02344784	chr12:104178138	NT5DC3	0.37	6.4	0.3	4.15e-10	Attention deficit hyperactivity disorder;
LUAD	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg26818010	chr10:134567672	INPP5A	-0.99	-15.61	-0.6	1.04e-43	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs62064224	0.614	rs6505294	chr17:30687415	C/T	cg18200150	chr17:30822561	MYO1D	0.41	7.42	0.34	6.2800000000000005e-13	Schizophrenia;
LUAD	cis	rs2233152	0.611	rs28660501	chr19:41300277	G/T	cg21869046	chr19:41225005	ITPKC	0.41	7.44	0.34	5.62e-13	Kawasaki disease;
LUAD	trans	rs11039798	0.764	rs11040208	chr11:49012509	A/G	cg15704280	chr7:45808275	SEPT13	0.74	7.43	0.34	6.17e-13	Axial length;
LUAD	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.06	0.32	6.99e-12	Menopause (age at onset);
LUAD	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.34	0.48	3.43e-26	Height;
LUAD	trans	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg26043149	chr18:55253948	FECH	-0.41	-6.79	-0.31	3.84e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg21775007	chr8:11205619	TDH	-0.49	-8.5	-0.38	3.22e-16	Retinal vascular caliber;
LUAD	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg01689657	chr7:91764605	CYP51A1	0.34	8.51	0.38	2.96e-16	Breast cancer;
LUAD	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.53	-8.87	-0.4	2e-17	Electrocardiographic conduction measures;
LUAD	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg11915388	chr22:42470451	FAM109B	-0.43	-7.77	-0.35	5.9e-14	Schizophrenia;
LUAD	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg09835421	chr16:68378352	PRMT7	-0.81	-8.86	-0.4	2.2e-17	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15423197	chr18:32870352	ZNF271;ZNF397OS	-0.54	-7.62	-0.35	1.64e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11644478	chr21:40555479	PSMG1	-0.41	-6.73	-0.31	5.41e-11	Menarche (age at onset);
LUAD	cis	rs73206853	0.841	rs55972509	chr12:110992755	T/C	cg12870014	chr12:110450643	ANKRD13A	0.61	6.8	0.31	3.59e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg15900387	chr1:150738905	CTSS	-0.37	-6.71	-0.31	6.41e-11	Melanoma;
LUAD	cis	rs34734847	0.787	rs658521	chr12:121162414	G/T	cg13914990	chr12:121174878	ACADS	0.4	7.69	0.35	1.07e-13	Mean corpuscular volume;
LUAD	cis	rs62238980	0.614	rs2413063	chr22:32458252	A/C	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs4077515	0.839	rs10781518	chr9:139300547	C/T	cg14169450	chr9:139327907	INPP5E	-0.36	-6.39	-0.3	4.29e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg02733842	chr7:1102375	C7orf50	-0.43	-7.38	-0.34	8.42e-13	Longevity;Endometriosis;
LUAD	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg10518543	chr12:38710700	ALG10B	-0.44	-7.09	-0.33	5.59e-12	Morning vs. evening chronotype;
LUAD	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg08859206	chr1:53392774	SCP2	0.56	10.11	0.44	1.19e-21	Monocyte count;
LUAD	cis	rs11051970	0.611	rs56146365	chr12:32529634	A/G	cg24626660	chr12:32551988	NA	0.32	6.7	0.31	6.81e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg09509183	chr1:209979624	IRF6	0.56	7.78	0.35	5.74e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg11663144	chr21:46675770	NA	-0.62	-12.36	-0.52	3.67e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.58	0.35	2.23e-13	Morning vs. evening chronotype;
LUAD	cis	rs2839186	0.584	rs2032111	chr21:47904569	G/A	cg13126279	chr21:47581558	C21orf56	-0.44	-7.1	-0.33	5.31e-12	Testicular germ cell tumor;
LUAD	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg22676075	chr6:135203613	NA	0.41	7.48	0.34	4.45e-13	Red blood cell count;
LUAD	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg07741184	chr6:167504864	NA	0.36	8.15	0.37	4.15e-15	Primary biliary cholangitis;
LUAD	cis	rs35883536	0.545	rs115017855	chr1:101101830	T/A	cg06223162	chr1:101003688	GPR88	0.39	7.26	0.33	1.87e-12	Monocyte count;
LUAD	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg00666640	chr1:248458726	OR2T12	0.34	8.26	0.37	1.91e-15	Common traits (Other);
LUAD	cis	rs10504073	0.647	rs7817571	chr8:50003218	T/C	cg00325661	chr8:49890786	NA	0.45	10.04	0.44	2e-21	Blood metabolite ratios;
LUAD	cis	rs62400317	0.859	rs55964727	chr6:45259079	A/C	cg18551225	chr6:44695536	NA	-0.53	-8.4	-0.38	7.09e-16	Total body bone mineral density;
LUAD	trans	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.69	11.55	0.49	5.25e-27	Mean corpuscular volume;
LUAD	cis	rs2859741	0.967	rs534131	chr1:37484237	T/C	cg09363841	chr1:37513479	NA	-0.31	-7.69	-0.35	1.06e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg22963979	chr7:1858916	MAD1L1	-0.56	-9.77	-0.43	1.84e-20	Bipolar disorder and schizophrenia;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg06522063	chr2:190306158	WDR75	-0.39	-6.64	-0.31	9.39e-11	Subcortical brain region volumes;
LUAD	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs716316	1.000	rs716316	chr20:14908741	C/T	cg04470754	chr20:14904432	MACROD2	0.6	10.76	0.46	5.02e-24	Advanced glycation end-product levels;
LUAD	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.64	-0.31	9.64e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg01579765	chr21:45077557	HSF2BP	-0.59	-12.41	-0.52	2.36e-30	Mean corpuscular volume;
LUAD	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg22681709	chr2:178499509	PDE11A	-0.42	-7.05	-0.32	7.26e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg07507251	chr3:52567010	NT5DC2	0.32	6.59	0.31	1.33e-10	Cognitive function;
LUAD	cis	rs1816752	0.774	rs7986162	chr13:25000079	C/T	cg02811702	chr13:24901961	NA	0.39	6.72	0.31	5.98e-11	Obesity-related traits;
LUAD	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg11822812	chr5:140052017	DND1	0.39	7.0	0.32	9.79e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg11189052	chr15:85197271	WDR73	0.7	9.49	0.42	1.76e-19	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg10729496	chr3:10149963	C3orf24	0.58	9.45	0.42	2.41e-19	Alzheimer's disease;
LUAD	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18099408	chr3:52552593	STAB1	-0.53	-9.6	-0.42	7.2e-20	Electroencephalogram traits;
LUAD	cis	rs2625529	0.824	rs4777471	chr15:72207804	A/G	cg16672083	chr15:72433130	SENP8	-0.75	-12.4	-0.52	2.54e-30	Red blood cell count;
LUAD	cis	rs11681884	1.000	rs11677407	chr2:113845029	C/T	cg12858261	chr2:113808755	IL1F8	0.51	6.42	0.3	3.6e-10	Stroke;
LUAD	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg22920501	chr2:26401640	FAM59B	0.96	13.88	0.56	2.24e-36	Gut microbiome composition (summer);
LUAD	cis	rs10037055	1.000	rs6886255	chr5:176718361	A/G	cg06733329	chr5:176740039	MXD3	-0.44	-7.37	-0.34	9.3e-13	Migraine without aura;
LUAD	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg26384229	chr12:38710491	ALG10B	0.44	7.36	0.34	9.87e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs62400317	0.762	rs62436376	chr6:44885817	C/T	cg18551225	chr6:44695536	NA	-0.59	-8.89	-0.4	1.75e-17	Total body bone mineral density;
LUAD	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg08859206	chr1:53392774	SCP2	0.63	11.73	0.5	1.01e-27	Monocyte count;
LUAD	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.43	6.69	0.31	7.25e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7274811	0.711	rs291689	chr20:32003974	A/G	cg14921437	chr20:32255988	NECAB3;C20orf134	0.45	6.84	0.32	2.87e-11	Height;
LUAD	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg17063962	chr7:91808500	NA	0.7	12.68	0.52	1.9e-31	Breast cancer;
LUAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.65	12.02	0.5	7.74e-29	Lymphocyte counts;
LUAD	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg15017067	chr4:17643749	FAM184B	0.35	6.99	0.32	1.08e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg05887092	chr17:76393375	PGS1	-0.39	-6.86	-0.32	2.48e-11	HDL cholesterol levels;
LUAD	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg06197492	chr11:2016605	H19	0.42	8.63	0.39	1.27e-16	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg05872129	chr22:39784769	NA	-0.82	-15.49	-0.6	3.32e-43	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg25535316	chr11:579198	PHRF1	-0.4	-6.54	-0.3	1.77e-10	Systemic lupus erythematosus;
LUAD	cis	rs62229266	0.740	rs4817759	chr21:37389559	G/A	cg12218747	chr21:37451666	NA	-0.47	-8.1	-0.37	5.89e-15	Mitral valve prolapse;
LUAD	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg12292205	chr6:26970375	C6orf41	-0.58	-7.12	-0.33	4.64e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	7.75	0.35	7.09e-14	Parkinson's disease;
LUAD	cis	rs17092148	0.636	rs59030726	chr20:33454117	G/A	cg16810054	chr20:33298113	TP53INP2	0.43	7.57	0.35	2.43e-13	Neuroticism;
LUAD	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg01324343	chr3:183735012	ABCC5	0.93	25.1	0.77	8.39e-86	Anterior chamber depth;
LUAD	cis	rs7833986	0.534	rs10504198	chr8:57006254	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	1.02	18.03	0.66	2.59e-54	Height;
LUAD	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.34	6.47	0.3	2.72e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg19610905	chr11:61596333	FADS2	-0.65	-11.11	-0.48	2.49e-25	Trans fatty acid levels;
LUAD	cis	rs2425143	0.687	rs6119649	chr20:34369596	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	7.44	0.34	5.54e-13	Blood protein levels;
LUAD	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg25894440	chr7:65020034	NA	0.64	6.95	0.32	1.41e-11	Diabetic kidney disease;
LUAD	trans	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg11693508	chr17:37793320	STARD3	0.68	8.95	0.4	1.17e-17	Bipolar disorder;
LUAD	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg26384229	chr12:38710491	ALG10B	0.5	8.25	0.37	2.07e-15	Heart rate;
LUAD	cis	rs13315871	0.929	rs9871725	chr3:58292525	T/G	cg12435725	chr3:58293450	RPP14	-0.74	-7.88	-0.36	2.86e-14	Cholesterol, total;
LUAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.23	0.41	1.36e-18	Alzheimer's disease;
LUAD	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg02423579	chr7:2872169	GNA12	-0.77	-13.01	-0.53	9.03e-33	Height;
LUAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.59	-10.78	-0.46	4.36e-24	Longevity;Endometriosis;
LUAD	cis	rs9811920	0.660	rs7619512	chr3:99729132	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.52	-9.86	-0.43	8.87e-21	Axial length;
LUAD	cis	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.93	-0.32	1.62e-11	Neuroticism;
LUAD	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg00071950	chr4:10020882	SLC2A9	0.73	15.18	0.59	7.04e-42	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.89	-0.43	6.79e-21	Hip circumference adjusted for BMI;
LUAD	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg16479474	chr6:28041457	NA	0.46	7.81	0.36	4.47e-14	Depression;
LUAD	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg25985355	chr7:65971099	NA	-0.38	-6.89	-0.32	2.02e-11	Aortic root size;
LUAD	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.6	-0.52	3.83e-31	Monocyte count;
LUAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.91e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg25621096	chr1:151032116	CDC42SE1;MLLT11	-0.54	-6.42	-0.3	3.58e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-8.0	-0.36	1.18e-14	Neuroticism;
LUAD	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg03714773	chr7:91764589	CYP51A1	0.31	7.09	0.33	5.75e-12	Breast cancer;
LUAD	trans	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg14917512	chr19:3094685	GNA11	-0.54	-6.36	-0.3	5.37e-10	Diabetic kidney disease;
LUAD	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg09323728	chr8:95962352	TP53INP1	-0.35	-8.47	-0.38	4.12e-16	Type 2 diabetes;
LUAD	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg07636037	chr3:49044803	WDR6	0.54	8.48	0.38	3.84e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg21153622	chr11:89784906	NA	-0.33	-6.46	-0.3	2.95e-10	Coronary artery disease;
LUAD	cis	rs62238980	0.614	rs55695217	chr22:32463135	C/G	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg27490568	chr2:178487706	NA	0.4	6.65	0.31	9.21e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.78	0.31	4.16e-11	Cardiac Troponin-T levels;
LUAD	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg14092988	chr3:52407081	DNAH1	0.57	11.28	0.48	5.76e-26	Bipolar disorder;
LUAD	cis	rs12472274	0.617	rs7568705	chr2:239081808	C/T	cg17459225	chr2:239074497	NA	0.51	7.46	0.34	4.81e-13	Phospholipid levels (plasma);
LUAD	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.43	0.34	5.94e-13	Morning vs. evening chronotype;
LUAD	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg02493740	chr2:85810744	VAMP5	-0.45	-8.27	-0.37	1.78e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg00280220	chr17:61926910	NA	0.36	6.8	0.31	3.5e-11	Prudent dietary pattern;
LUAD	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg03609598	chr5:56110824	MAP3K1	0.64	8.76	0.39	4.61e-17	Initial pursuit acceleration;
LUAD	cis	rs2652834	1.000	rs8032104	chr15:63400584	A/G	cg25406657	chr15:63342033	TPM1	-0.42	-6.73	-0.31	5.38e-11	HDL cholesterol;
LUAD	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg06509362	chr16:69970511	WWP2	0.48	6.67	0.31	7.84e-11	Menarche (age at onset);
LUAD	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.8	0.39	3.42e-17	Menopause (age at onset);
LUAD	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.76	8.45	0.38	4.6e-16	Yeast infection;
LUAD	trans	rs11039798	0.764	rs11039771	chr11:48513273	C/T	cg02254774	chr11:50257496	LOC441601	0.53	6.78	0.31	4.16e-11	Axial length;
LUAD	cis	rs68170813	0.559	rs9641378	chr7:106868003	T/C	cg23024343	chr7:107201750	COG5	0.49	7.22	0.33	2.5e-12	Coronary artery disease;
LUAD	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg15485101	chr11:133734466	NA	0.38	8.34	0.38	1.05e-15	Childhood ear infection;
LUAD	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg04117972	chr1:227635322	NA	0.84	7.61	0.35	1.83e-13	Major depressive disorder;
LUAD	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg11062466	chr8:58055876	NA	0.68	8.94	0.4	1.25e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg08888203	chr3:10149979	C3orf24	0.74	12.83	0.53	4.77e-32	Alzheimer's disease;
LUAD	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg18129178	chr5:148520854	ABLIM3	0.6	9.26	0.41	1.05e-18	Breast cancer;
LUAD	trans	rs7939886	0.841	rs11231800	chr11:55770930	A/G	cg15704280	chr7:45808275	SEPT13	0.69	6.75	0.31	4.74e-11	Myopia (pathological);
LUAD	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg17264618	chr3:40429014	ENTPD3	0.43	9.16	0.41	2.25e-18	Renal cell carcinoma;
LUAD	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.51	-6.46	-0.3	2.93e-10	Iron status biomarkers;
LUAD	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg04586622	chr2:25135609	ADCY3	-0.33	-7.36	-0.34	9.41e-13	Body mass index in non-asthmatics;
LUAD	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg24324837	chr19:49891574	CCDC155	0.48	7.68	0.35	1.12e-13	Multiple sclerosis;
LUAD	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.35	-6.92	-0.32	1.69e-11	Glomerular filtration rate;
LUAD	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg10596483	chr8:143751796	JRK	0.46	7.34	0.34	1.08e-12	Schizophrenia;
LUAD	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg08048268	chr3:133502702	NA	0.41	8.13	0.37	4.72e-15	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg14789911	chr21:47582049	C21orf56	-0.48	-8.4	-0.38	6.8e-16	Testicular germ cell tumor;
LUAD	cis	rs2455799	0.613	rs1393969	chr3:15730257	G/A	cg16303742	chr3:15540471	COLQ	-0.52	-9.69	-0.43	3.38e-20	Mean platelet volume;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg02985366	chr16:32360428	NA	-0.42	-7.27	-0.33	1.74e-12	Menopause (age at onset);
LUAD	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg00071950	chr4:10020882	SLC2A9	-0.62	-11.9	-0.5	2.4e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg23283495	chr1:209979779	IRF6	0.74	10.84	0.47	2.58e-24	Cleft lip with or without cleft palate;
LUAD	cis	rs2070677	0.935	rs13376793	chr10:135421344	C/G	cg20169779	chr10:135381914	SYCE1	-0.51	-8.03	-0.36	9.61e-15	Gout;
LUAD	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18099408	chr3:52552593	STAB1	0.42	7.39	0.34	8.12e-13	Bipolar disorder;
LUAD	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg19717773	chr7:2847554	GNA12	-0.49	-9.18	-0.41	1.99e-18	Height;
LUAD	cis	rs7845219	0.555	rs1129152	chr8:95888307	C/T	cg13393036	chr8:95962371	TP53INP1	-0.33	-7.42	-0.34	6.2800000000000005e-13	Type 2 diabetes;
LUAD	cis	rs35883536	0.647	rs10875316	chr1:101044150	G/A	cg06223162	chr1:101003688	GPR88	-0.47	-9.21	-0.41	1.51e-18	Monocyte count;
LUAD	trans	rs629535	0.862	rs654604	chr8:70048939	C/A	cg21567404	chr3:27674614	NA	1.01	18.57	0.67	9.52e-57	Dupuytren's disease;
LUAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg00634984	chr7:65235879	NA	0.54	8.82	0.39	3.07e-17	Calcium levels;
LUAD	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-10.5	-0.45	4.64e-23	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg10591111	chr5:226296	SDHA	-0.55	-7.0	-0.32	1.04e-11	Breast cancer;
LUAD	cis	rs3125734	0.719	rs4529854	chr10:64043975	C/T	cg19640130	chr10:64028056	RTKN2	-0.34	-7.12	-0.33	4.74e-12	Rheumatoid arthritis;
LUAD	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg18180107	chr4:99064573	C4orf37	0.42	6.71	0.31	6.45e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg02951883	chr7:2050386	MAD1L1	-0.72	-11.44	-0.49	1.33e-26	Bipolar disorder and schizophrenia;
LUAD	trans	rs7395662	1.000	rs6485907	chr11:48651695	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.21	-0.33	2.52e-12	HDL cholesterol;
LUAD	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg23283495	chr1:209979779	IRF6	0.7	10.02	0.44	2.37e-21	Cleft lip with or without cleft palate;
LUAD	cis	rs7614311	0.681	rs57766205	chr3:63895303	G/C	cg22134162	chr3:63841271	THOC7	-0.39	-7.07	-0.32	6.54e-12	Lung function (FVC);Lung function (FEV1);
LUAD	trans	rs2018683	0.899	rs10479817	chr7:28978148	A/C	cg19402173	chr7:128379420	CALU	-0.62	-10.19	-0.44	5.97e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10823500	0.636	rs7082396	chr10:71945511	C/A	cg02100629	chr10:71892760	AIFM2	-0.38	-7.99	-0.36	1.31e-14	Blood protein levels;
LUAD	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.47	-0.42	2.05e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1451375	1.000	rs2329340	chr7:50620229	C/T	cg18232548	chr7:50535776	DDC	0.61	10.03	0.44	2.14e-21	Malaria;
LUAD	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg12935359	chr14:103987150	CKB	0.48	8.01	0.36	1.09e-14	Body mass index;
LUAD	cis	rs72772090	0.539	rs11738115	chr5:96113072	A/T	cg17330273	chr5:96107758	CAST;ERAP1	0.62	7.29	0.33	1.5e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg10208301	chr11:6592745	DNHD1	0.48	6.35	0.3	5.63e-10	Coronary artery calcification;
LUAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.6	0.31	1.26e-10	Prudent dietary pattern;
LUAD	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg07507251	chr3:52567010	NT5DC2	0.37	7.34	0.34	1.09e-12	Bipolar disorder;
LUAD	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18876405	chr7:65276391	NA	-0.44	-6.98	-0.32	1.18e-11	Aortic root size;
LUAD	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg21775007	chr8:11205619	TDH	0.48	8.25	0.37	2.05e-15	Retinal vascular caliber;
LUAD	trans	rs7939886	0.920	rs11227145	chr11:55839278	C/A	cg15704280	chr7:45808275	SEPT13	0.66	6.47	0.3	2.67e-10	Myopia (pathological);
LUAD	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-15.16	-0.59	9.2e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg02725872	chr8:58115012	NA	-0.33	-6.46	-0.3	2.9e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs16854884	0.586	rs6782789	chr3:143746691	G/A	cg01302019	chr3:143689584	C3orf58	-0.37	-6.65	-0.31	9.18e-11	Economic and political preferences (feminism/equality);
LUAD	trans	rs11650494	0.908	rs118099826	chr17:47447836	G/T	cg11430096	chr6:110968061	CDK19	0.89	6.74	0.31	5.21e-11	Prostate cancer;
LUAD	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.5e-19	Life satisfaction;
LUAD	cis	rs2816062	0.775	rs2745315	chr1:18897118	G/A	cg18795169	chr1:18902165	NA	-0.93	-21.9	-0.73	1.25e-71	Urate levels in lean individuals;
LUAD	trans	rs13090388	1	rs13090388	chr3:49391082	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.17	-0.41	2.11e-18	Intelligence (multi-trait analysis);Educational attainment (years of education);
LUAD	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg21963583	chr11:68658836	MRPL21	0.68	12.1	0.51	3.68e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg21475434	chr5:93447410	FAM172A	0.77	8.25	0.37	2.02e-15	Diabetic retinopathy;
LUAD	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg03929089	chr4:120376271	NA	-0.46	-7.12	-0.33	4.65e-12	Height;
LUAD	cis	rs2625529	0.730	rs6494990	chr15:72401074	T/A	cg16672083	chr15:72433130	SENP8	0.67	12.09	0.51	4.09e-29	Red blood cell count;
LUAD	cis	rs938554	0.612	rs28592748	chr4:9998605	T/C	cg11266682	chr4:10021025	SLC2A9	0.52	9.11	0.4	3.35e-18	Blood metabolite levels;
LUAD	cis	rs4006360	0.522	rs11871050	chr17:39236997	A/T	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.2	0.37	2.94e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs4372836	1.000	rs55835850	chr2:28949296	T/C	cg09522027	chr2:28974177	PPP1CB	0.62	9.78	0.43	1.63e-20	Body mass index;
LUAD	cis	rs7474896	0.515	rs624359	chr10:38299132	T/C	cg25427524	chr10:38739819	LOC399744	0.58	8.33	0.38	1.16e-15	Obesity (extreme);
LUAD	cis	rs1232027	0.656	rs1677709	chr5:79980729	A/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.42	-6.5	-0.3	2.27e-10	Huntington's disease progression;
LUAD	cis	rs7937890	0.559	rs6486197	chr11:14529874	C/G	cg06199346	chr11:14280333	SPON1	-0.32	-6.42	-0.3	3.58e-10	Mitochondrial DNA levels;
LUAD	cis	rs73206853	0.764	rs56127909	chr12:110833763	G/A	cg12870014	chr12:110450643	ANKRD13A	0.61	6.73	0.31	5.38e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg24829409	chr8:58192753	C8orf71	0.52	6.76	0.31	4.47e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21659725	chr3:3221576	CRBN	-0.86	-18.32	-0.67	1.29e-55	Intelligence (multi-trait analysis);
LUAD	cis	rs11756438	0.683	rs11754023	chr6:119005785	A/G	cg21191810	chr6:118973309	C6orf204	0.39	7.02	0.32	8.94e-12	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg10578991	chr7:12443926	VWDE	-0.49	-7.04	-0.32	7.96e-12	Coronary artery disease;
LUAD	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg11494091	chr17:61959527	GH2	0.74	18.29	0.66	1.81e-55	Prudent dietary pattern;
LUAD	cis	rs4378999	0.748	rs6445628	chr3:51370933	C/T	cg12934382	chr3:51741135	GRM2	-0.43	-6.89	-0.32	2.08e-11	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21028142	chr17:79581711	NPLOC4	0.45	9.79	0.43	1.54e-20	Eye color traits;
LUAD	cis	rs9902453	0.933	rs7216494	chr17:28502651	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	8.75	0.39	5.11e-17	Coffee consumption (cups per day);
LUAD	cis	rs11771526	1.000	rs6462350	chr7:32342000	G/A	cg27532318	chr7:32358331	NA	0.69	8.24	0.37	2.21e-15	Body mass index;
LUAD	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.42	0.57	1.29e-38	Schizophrenia;
LUAD	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg20556744	chr2:9614537	IAH1	0.66	6.54	0.3	1.81e-10	Opioid sensitivity;
LUAD	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg09029085	chr17:47094198	IGF2BP1	0.29	6.62	0.31	1.06e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg27394845	chr17:28928406	LRRC37B2	0.51	6.46	0.3	2.86e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg18110333	chr6:292329	DUSP22	-0.77	-12.9	-0.53	2.49e-32	Menopause (age at onset);
LUAD	cis	rs12505328	0.514	rs7673462	chr4:174390414	A/C	cg12145043	chr4:174357286	NA	0.42	6.7	0.31	6.53e-11	Chin dimples;
LUAD	cis	rs2806561	0.734	rs7548692	chr1:23354877	T/A	cg12483005	chr1:23474871	LUZP1	0.42	6.89	0.32	1.97e-11	Height;
LUAD	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg18350739	chr11:68623251	NA	-0.37	-6.38	-0.3	4.69e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg05283184	chr6:79620031	NA	-0.62	-12.45	-0.52	1.52e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg08219700	chr8:58056026	NA	0.42	6.4	0.3	4.22e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs367615	0.704	rs55956735	chr5:108845042	A/G	cg17395555	chr5:108820864	NA	0.66	14.14	0.57	1.89e-37	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg22598563	chr5:131563921	P4HA2	-0.34	-8.76	-0.39	4.76e-17	Blood metabolite levels;
LUAD	cis	rs367943	0.665	rs10061922	chr5:112969775	G/T	cg12552261	chr5:112820674	MCC	0.41	7.15	0.33	3.81e-12	Type 2 diabetes;
LUAD	cis	rs870825	0.872	rs12507711	chr4:185571776	C/T	cg04058563	chr4:185651563	MLF1IP	0.67	8.98	0.4	9.1e-18	Blood protein levels;
LUAD	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.31	-0.41	6.84e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg02569458	chr12:86230093	RASSF9	0.45	8.21	0.37	2.72e-15	Major depressive disorder;
LUAD	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg12863693	chr15:85201151	NMB	0.36	6.39	0.3	4.44e-10	Schizophrenia;
LUAD	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg13902645	chr11:5959945	NA	-0.51	-8.9	-0.4	1.66e-17	DNA methylation (variation);
LUAD	cis	rs4343996	0.692	rs1546742	chr7:3456210	C/A	cg21248987	chr7:3385318	SDK1	0.35	6.4	0.3	4.08e-10	Motion sickness;
LUAD	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs1044826	0.667	rs295471	chr3:139213922	G/C	cg00490450	chr3:139108681	COPB2	0.41	6.5	0.3	2.2e-10	Obesity-related traits;
LUAD	trans	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg01620082	chr3:125678407	NA	-0.46	-6.76	-0.31	4.61e-11	Depression;
LUAD	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg25811766	chr13:21894605	NA	0.75	9.64	0.42	5.21e-20	White matter hyperintensity burden;
LUAD	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg18252515	chr7:66147081	NA	-0.63	-6.97	-0.32	1.22e-11	Gout;
LUAD	cis	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg07460842	chr6:66804631	NA	1.06	16.52	0.63	1.1e-47	Exhaled nitric oxide output;
LUAD	trans	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg26043149	chr18:55253948	FECH	0.4	6.61	0.31	1.17e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg07677032	chr17:61819896	STRADA	0.56	10.14	0.44	9.26e-22	Prudent dietary pattern;
LUAD	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg15448220	chr1:150897856	SETDB1	-0.41	-6.93	-0.32	1.61e-11	Tonsillectomy;
LUAD	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg09365446	chr1:150670422	GOLPH3L	0.55	9.46	0.42	2.18e-19	Melanoma;
LUAD	cis	rs4481887	0.927	rs4534422	chr1:248479482	A/G	cg13385794	chr1:248469461	NA	0.26	6.96	0.32	1.31e-11	Common traits (Other);
LUAD	cis	rs9902453	0.817	rs67206808	chr17:28190096	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.43	0.42	2.72e-19	Coffee consumption (cups per day);
LUAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg03188948	chr7:1209495	NA	0.74	9.58	0.42	8.61e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg23533926	chr12:111358616	MYL2	-0.4	-6.91	-0.32	1.76e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18876405	chr7:65276391	NA	-0.43	-6.91	-0.32	1.8e-11	Aortic root size;
LUAD	trans	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg01620082	chr3:125678407	NA	-0.81	-7.83	-0.36	4.01e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg13319975	chr6:146136371	FBXO30	-0.65	-11.3	-0.48	4.52e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg00814883	chr7:100076585	TSC22D4	-0.87	-13.12	-0.54	3.02e-33	Platelet count;
LUAD	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg02421172	chr7:1938701	MAD1L1	0.48	7.09	0.33	5.75e-12	Bipolar disorder;
LUAD	cis	rs9430161	0.579	rs6696575	chr1:11037136	G/A	cg27631724	chr1:11040367	C1orf127	0.56	9.82	0.43	1.18e-20	Ewing sarcoma;
LUAD	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs2018683	0.899	rs10479816	chr7:28978021	G/A	cg19402173	chr7:128379420	CALU	-0.62	-10.43	-0.45	7.77e-23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9788721	0.967	rs2036527	chr15:78851615	G/A	cg18825076	chr15:78729989	IREB2	-0.53	-8.71	-0.39	7.09e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs7633770	0.786	rs6808214	chr3:46682746	T/C	cg11219411	chr3:46661640	NA	0.58	12.86	0.53	3.49e-32	Coronary artery disease;
LUAD	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03352830	chr11:487213	PTDSS2	0.81	10.53	0.46	3.59e-23	Body mass index;
LUAD	cis	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg21775007	chr8:11205619	TDH	-0.4	-7.07	-0.32	6.56e-12	Retinal vascular caliber;
LUAD	cis	rs12545109	0.879	rs1581129	chr8:57377476	T/C	cg19413350	chr8:57351067	NA	-0.47	-7.07	-0.33	6.31e-12	Obesity-related traits;
LUAD	cis	rs28830936	1.000	rs17734856	chr15:42045160	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.54	-0.3	1.76e-10	Diastolic blood pressure;
LUAD	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.39	7.1	0.33	5.14e-12	Systemic lupus erythematosus;
LUAD	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg13180566	chr4:1052158	NA	-0.4	-6.72	-0.31	5.87e-11	Recombination rate (females);
LUAD	cis	rs1997103	1.000	rs9649781	chr7:55411809	A/G	cg17469321	chr7:55412551	NA	0.7	11.79	0.5	5.98e-28	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.35	0.45	1.62e-22	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg03467027	chr4:99064603	C4orf37	0.42	6.94	0.32	1.5e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg22705602	chr4:152727874	NA	-0.4	-6.95	-0.32	1.38e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg03948781	chr1:205179583	DSTYK	-0.35	-6.59	-0.31	1.3e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg18876405	chr7:65276391	NA	-0.42	-6.71	-0.31	6.18e-11	Aortic root size;
LUAD	cis	rs4268898	0.932	rs7577964	chr2:24598279	A/G	cg02683114	chr2:24398427	C2orf84	0.39	6.44	0.3	3.16e-10	Asthma;
LUAD	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg11859384	chr17:80120422	CCDC57	-0.5	-8.94	-0.4	1.19e-17	Life satisfaction;
LUAD	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.73	0.31	5.55e-11	Colorectal cancer;
LUAD	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.47	0.45	5.72e-23	Prudent dietary pattern;
LUAD	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg13870426	chr17:30244630	NA	-0.56	-6.52	-0.3	2.06e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg20701182	chr2:24300061	SF3B14	0.53	6.49	0.3	2.44e-10	Lymphocyte counts;
LUAD	cis	rs17102423	0.594	rs1957948	chr14:65542629	A/G	cg16583315	chr14:65563665	MAX	0.35	6.4	0.3	4.06e-10	Obesity-related traits;
LUAD	cis	rs2882667	0.628	rs13167462	chr5:138177261	G/A	cg04439458	chr5:138467593	SIL1	-0.44	-7.17	-0.33	3.45e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg02782426	chr3:40428986	ENTPD3	0.36	7.81	0.35	4.59e-14	Renal cell carcinoma;
LUAD	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg04282206	chr17:62833786	PLEKHM1P	0.42	6.98	0.32	1.11e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.63	8.44	0.38	5.24e-16	Renal function-related traits (BUN);
LUAD	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	8.58	0.38	1.87e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg05434287	chr7:2030229	MAD1L1	0.39	6.6	0.31	1.23e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.9	0.36	2.38e-14	Lung cancer;
LUAD	trans	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg11887960	chr12:57824829	NA	0.5	6.57	0.3	1.49e-10	Obesity-related traits;
LUAD	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg09359103	chr1:154839909	KCNN3	-0.89	-20.01	-0.7	3.61e-63	Prostate cancer;
LUAD	cis	rs78707713	0.560	rs61848398	chr10:71226103	G/A	cg12610070	chr10:71211762	TSPAN15	-0.38	-9.31	-0.41	6.8e-19	Venous thromboembolism;
LUAD	cis	rs7107174	0.901	rs2450137	chr11:77925233	C/G	cg19901956	chr11:77921274	USP35	-0.49	-6.36	-0.3	5.33e-10	Testicular germ cell tumor;
LUAD	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg06618935	chr21:46677482	NA	-0.4	-8.05	-0.36	8.56e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11890956	chr21:40555474	PSMG1	0.76	13.47	0.55	1.14e-34	Cognitive function;
LUAD	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg04842962	chr6:43655489	MRPS18A	1.07	27.19	0.8	7e-95	IgG glycosylation;
LUAD	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07343612	chr16:622815	PIGQ	-0.83	-16.78	-0.63	7.93e-49	Height;
LUAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.76e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg12927641	chr6:109611667	NA	-0.48	-8.02	-0.36	1.07e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs758324	0.891	rs491624	chr5:131270222	A/T	cg25547332	chr5:131281432	NA	-0.44	-6.67	-0.31	7.91e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs9811920	0.809	rs6802817	chr3:99779264	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	7.74	0.35	7.53e-14	Axial length;
LUAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg27588902	chr6:42928151	GNMT	-0.35	-9.24	-0.41	1.25e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08219700	chr8:58056026	NA	0.63	8.82	0.39	2.92e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7737355	0.842	rs30733	chr5:130704956	T/A	cg06307176	chr5:131281290	NA	-0.39	-6.59	-0.31	1.29e-10	Life satisfaction;
LUAD	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg04450456	chr4:17643702	FAM184B	0.38	7.34	0.34	1.08e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg19678392	chr7:94953810	PON1	-0.59	-8.04	-0.36	8.95e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7617773	0.780	rs34589064	chr3:48339549	G/A	cg11946769	chr3:48343235	NME6	0.44	6.8	0.31	3.52e-11	Coronary artery disease;
LUAD	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg11494091	chr17:61959527	GH2	0.42	7.69	0.35	1.07e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs1268789	0.571	rs949507	chr4:79394086	C/T	cg02410754	chr1:32410520	NA	-0.43	-7.21	-0.33	2.56e-12	Hair shape;Hair morphology;
LUAD	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg06784218	chr1:46089804	CCDC17	-0.53	-11.67	-0.49	1.72e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg04117972	chr1:227635322	NA	0.65	6.6	0.31	1.24e-10	Major depressive disorder;
LUAD	cis	rs6496044	0.568	rs10468112	chr15:86073424	G/C	cg13263323	chr15:86062960	AKAP13	-0.57	-10.71	-0.46	7.6e-24	Interstitial lung disease;
LUAD	cis	rs2386661	1.000	rs2386661	chr10:5670275	A/G	cg26603656	chr10:5671107	NA	0.35	6.52	0.3	2.05e-10	Breast cancer;
LUAD	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg03929089	chr4:120376271	NA	-0.98	-20.38	-0.7	8.23e-65	Height;
LUAD	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg00071950	chr4:10020882	SLC2A9	0.86	18.78	0.67	1.11e-57	Bone mineral density;
LUAD	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg02951883	chr7:2050386	MAD1L1	-0.61	-9.65	-0.42	4.78e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs2421770	0.504	rs4756213	chr11:35363566	T/C	cg13971030	chr11:35366721	SLC1A2	-0.46	-7.98	-0.36	1.36e-14	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs600231	0.665	rs1621277	chr11:65221954	A/G	cg17120908	chr11:65337727	SSSCA1	0.54	8.48	0.38	3.86e-16	Bone mineral density;
LUAD	cis	rs1800682	0.528	rs11202918	chr10:90742008	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.65	11.1	0.47	2.79e-25	Chronic lymphocytic leukemia;
LUAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg25985355	chr7:65971099	NA	0.53	6.7	0.31	6.87e-11	Diabetic kidney disease;
LUAD	trans	rs208520	0.874	rs208485	chr6:66925654	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-14.0	-0.56	7.08e-37	Exhaled nitric oxide output;
LUAD	cis	rs6429082	0.518	rs1812350	chr1:235659920	C/A	cg26050004	chr1:235667680	B3GALNT2	0.38	6.43	0.3	3.37e-10	Adiposity;
LUAD	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg08601574	chr20:25228251	PYGB	-0.46	-8.66	-0.39	1.02e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg01416388	chr22:39784598	NA	-0.52	-8.69	-0.39	7.9e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-14.47	-0.58	8.07e-39	Headache;
LUAD	trans	rs62103177	0.565	rs473119	chr18:77849459	T/G	cg05926928	chr17:57297772	GDPD1	-0.83	-10.31	-0.45	2.18e-22	Opioid sensitivity;
LUAD	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg03467027	chr4:99064603	C4orf37	0.4	6.4	0.3	4.24e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9283706	0.594	rs7735834	chr5:66337444	A/G	cg11590213	chr5:66331682	MAST4	-0.4	-6.61	-0.31	1.17e-10	Coronary artery disease;
LUAD	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg10518543	chr12:38710700	ALG10B	0.41	6.39	0.3	4.29e-10	Bladder cancer;
LUAD	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg16797656	chr11:68205561	LRP5	0.45	8.68	0.39	8.8e-17	Total body bone mineral density;
LUAD	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg04455712	chr21:45112962	RRP1B	0.52	10.51	0.45	4.25e-23	Coronary artery disease;
LUAD	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg09936400	chr10:82049201	MAT1A	0.37	6.71	0.31	6.1e-11	Post bronchodilator FEV1;
LUAD	cis	rs727505	0.521	rs66787780	chr7:124791849	G/A	cg23710748	chr7:124431027	NA	-0.38	-7.72	-0.35	8.31e-14	Lewy body disease;
LUAD	cis	rs8027181	0.839	rs2304597	chr15:73052431	A/G	cg25632853	chr15:73088954	NA	0.31	6.85	0.32	2.68e-11	Triglyceride levels;
LUAD	cis	rs10129255	0.556	rs9324093	chr14:107139910	C/T	cg23076370	chr14:107095027	NA	-0.4	-8.02	-0.36	1.05e-14	Kawasaki disease;
LUAD	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.48	-0.38	3.78e-16	Total body bone mineral density;
LUAD	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.27	0.33	1.79e-12	Menopause (age at onset);
LUAD	trans	rs4714291	1.000	rs6925661	chr6:39995063	T/C	cg02267698	chr19:7991119	CTXN1	0.45	6.36	0.3	5.31e-10	Strep throat;
LUAD	cis	rs12612619	0.732	rs11679069	chr2:27270311	G/A	cg00617064	chr2:27272375	NA	-0.38	-7.08	-0.33	5.99e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.79	-0.35	5.2e-14	Type 2 diabetes;
LUAD	cis	rs11030122	0.632	rs4910596	chr11:4084604	A/G	cg18678763	chr11:4115507	RRM1	-0.45	-7.1	-0.33	5.17e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg21252483	chr19:49399788	TULP2	-0.68	-10.44	-0.45	7.61e-23	Red cell distribution width;
LUAD	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.55	0.52	6.54e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs3823572	0.504	rs10255763	chr7:133632286	A/G	cg03336402	chr7:133662267	EXOC4	0.39	7.09	0.33	5.68e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg07708487	chr16:89387014	ANKRD11	-0.34	-6.72	-0.31	6.03e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg17120908	chr11:65337727	SSSCA1	-0.59	-9.12	-0.41	3.12e-18	Bone mineral density;
LUAD	cis	rs3916	0.641	rs2393749	chr12:121131891	C/T	cg13914990	chr12:121174878	ACADS	0.37	7.07	0.33	6.27e-12	Urinary metabolites (H-NMR features);
LUAD	cis	rs25422	0.887	rs9320666	chr6:118989181	C/T	cg07617317	chr6:118971624	C6orf204	0.51	7.67	0.35	1.16e-13	Renal cell carcinoma;
LUAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg21782813	chr7:2030301	MAD1L1	0.41	6.95	0.32	1.36e-11	Schizophrenia;
LUAD	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg01579765	chr21:45077557	HSF2BP	-0.63	-15.1	-0.59	1.71e-41	Mean corpuscular volume;
LUAD	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg00631329	chr6:26305371	NA	-0.69	-13.12	-0.54	3.11e-33	Educational attainment;
LUAD	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg14186256	chr22:23484241	RTDR1	0.46	7.72	0.35	8.25e-14	Bone mineral density;
LUAD	cis	rs870825	0.616	rs10013562	chr4:185610486	A/G	cg04058563	chr4:185651563	MLF1IP	0.78	12.51	0.52	9.14e-31	Blood protein levels;
LUAD	trans	rs587242	1.000	rs662450	chr1:96891547	C/G	cg10631902	chr5:14652156	NA	0.44	7.19	0.33	2.96e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	trans	rs6540	1.000	rs540078	chr11:254256	C/T	cg01239928	chr8:8748536	MFHAS1	0.69	6.35	0.3	5.5e-10	Endometriosis;
LUAD	cis	rs1707322	1.000	rs1613296	chr1:46546852	A/C	cg06784218	chr1:46089804	CCDC17	-0.5	-10.76	-0.46	4.94e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg03538708	chr1:25844672	NA	-0.37	-6.39	-0.3	4.42e-10	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg18132916	chr6:79620363	NA	-0.46	-7.95	-0.36	1.68e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg23231163	chr10:75533350	FUT11	-0.51	-9.33	-0.41	5.87e-19	Inflammatory bowel disease;
LUAD	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg00933542	chr6:150070202	PCMT1	0.45	10.0	0.44	2.78e-21	Lung cancer;
LUAD	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg14598338	chr9:96623480	NA	-0.4	-8.43	-0.38	5.48e-16	DNA methylation (variation);
LUAD	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.46	-0.52	1.39e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg04398451	chr17:18023971	MYO15A	-0.62	-11.27	-0.48	5.95e-26	Total body bone mineral density;
LUAD	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-6.49	-0.3	2.35e-10	Personality dimensions;
LUAD	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg04155289	chr7:94953770	PON1	-0.56	-7.58	-0.35	2.24e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.27	0.48	6.09e-26	Height;
LUAD	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg02990361	chr1:107599529	PRMT6	0.61	10.23	0.45	4.45e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg16205897	chr5:131564050	P4HA2	-0.44	-10.13	-0.44	9.92e-22	Blood metabolite levels;
LUAD	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg27124370	chr19:33622961	WDR88	0.45	6.88	0.32	2.12e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1595825	0.891	rs75946628	chr2:198546239	C/T	cg00361562	chr2:198649771	BOLL	-0.48	-6.64	-0.31	9.69e-11	Ulcerative colitis;
LUAD	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg04450456	chr4:17643702	FAM184B	0.41	7.88	0.36	2.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	10.15	0.44	8.27e-22	Total body bone mineral density;
LUAD	cis	rs250585	0.850	rs152460	chr16:23573833	A/C	cg00143387	chr16:23521605	GGA2	0.7	9.91	0.43	6.05e-21	Egg allergy;
LUAD	trans	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg06606381	chr12:133084897	FBRSL1	-0.65	-7.19	-0.33	2.98e-12	Depression;
LUAD	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg23758822	chr17:41437982	NA	1.01	20.7	0.71	2.92e-66	Menopause (age at onset);
LUAD	cis	rs938554	0.779	rs7442295	chr4:9966380	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.32	-0.34	1.27e-12	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg19678392	chr7:94953810	PON1	-0.59	-8.23	-0.37	2.41e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg10426581	chr7:100472382	SRRT	0.78	10.34	0.45	1.73e-22	Resting heart rate;
LUAD	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06665799	chr5:177019313	TMED9	-0.4	-6.59	-0.31	1.28e-10	Cancer;
LUAD	cis	rs9283706	0.608	rs1428407	chr5:66330416	C/T	cg11590213	chr5:66331682	MAST4	0.4	6.58	0.3	1.41e-10	Coronary artery disease;
LUAD	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg26513180	chr16:89883248	FANCA	0.47	7.51	0.34	3.5e-13	Vitiligo;
LUAD	cis	rs6840360	0.554	rs4643789	chr4:152726691	C/T	cg22705602	chr4:152727874	NA	-0.44	-8.56	-0.38	2.18e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg22482690	chr17:47019901	SNF8	0.45	8.44	0.38	4.97e-16	Type 2 diabetes;
LUAD	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg00647820	chr17:40259828	DHX58	-0.43	-6.84	-0.32	2.75e-11	Fibrinogen levels;
LUAD	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.51	8.4	0.38	7.01e-16	Lymphocyte percentage of white cells;
LUAD	cis	rs7789940	0.857	rs12532935	chr7:75939698	G/C	cg10167463	chr7:75959203	YWHAG	-0.65	-11.22	-0.48	9.26e-26	Multiple sclerosis;
LUAD	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg15123519	chr2:136567270	LCT	0.38	6.85	0.32	2.6e-11	Mosquito bite size;
LUAD	cis	rs367615	0.552	rs10042721	chr5:108713970	C/T	cg17395555	chr5:108820864	NA	-0.48	-9.02	-0.4	6.52e-18	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg24818145	chr4:99064322	C4orf37	0.47	8.0	0.36	1.25e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8099014	0.954	rs4294895	chr18:56126867	T/C	cg12907477	chr18:56117327	MIR122	0.41	7.05	0.32	7.17e-12	Platelet count;
LUAD	cis	rs7586879	0.964	rs4077680	chr2:25122942	A/G	cg04586622	chr2:25135609	ADCY3	0.34	7.36	0.34	9.36e-13	Body mass index;
LUAD	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg14092571	chr14:90743983	NA	-0.49	-8.53	-0.38	2.69e-16	Mortality in heart failure;
LUAD	cis	rs7607369	0.648	rs7582193	chr2:219652532	T/C	cg02176678	chr2:219576539	TTLL4	-0.69	-14.08	-0.56	3.54e-37	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg22875332	chr1:76189707	ACADM	0.9	18.28	0.66	1.87e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs240764	0.584	rs11155653	chr6:101217123	G/A	cg09795085	chr6:101329169	ASCC3	-0.46	-7.98	-0.36	1.39e-14	Neuroticism;
LUAD	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.43	-7.08	-0.33	6.09e-12	Tonsillectomy;
LUAD	cis	rs2637266	0.905	rs1978925	chr10:78399879	C/T	cg18941641	chr10:78392320	NA	0.34	7.04	0.32	7.75e-12	Pulmonary function;
LUAD	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg11062466	chr8:58055876	NA	0.54	7.43	0.34	6.13e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10802521	chr3:52805072	NEK4	-0.53	-9.07	-0.4	4.38e-18	Bipolar disorder;
LUAD	cis	rs72634258	0.945	rs1883679	chr1:8100451	T/G	cg26816564	chr1:7831052	VAMP3	0.57	7.59	0.35	2.02e-13	Inflammatory bowel disease;
LUAD	cis	rs12216545	0.765	rs1879865	chr7:150258423	A/C	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.4	-0.3	4.11e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg21724239	chr8:58056113	NA	0.71	9.11	0.4	3.34e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	8.42	0.38	5.95e-16	Menarche (age at onset);
LUAD	cis	rs3806843	0.576	rs246024	chr5:140333952	C/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.74e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7680126	0.596	rs12510549	chr4:10276467	A/G	cg00071950	chr4:10020882	SLC2A9	-0.58	-8.23	-0.37	2.35e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg16060761	chr17:80687452	NA	-0.53	-7.67	-0.35	1.19e-13	Glycated hemoglobin levels;
LUAD	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.67	0.31	8.13e-11	Menarche (age at onset);
LUAD	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg14668632	chr7:2872130	GNA12	-0.47	-8.36	-0.38	8.82e-16	Height;
LUAD	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg17063962	chr7:91808500	NA	-0.67	-11.71	-0.49	1.27e-27	Breast cancer;
LUAD	trans	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg01620082	chr3:125678407	NA	-0.74	-7.62	-0.35	1.71e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3849570	0.883	rs28435942	chr3:81679692	C/T	cg07356753	chr3:81810745	GBE1	-0.7	-11.96	-0.5	1.3e-28	Waist circumference;Body mass index;
LUAD	trans	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs6484504	0.779	rs16921914	chr11:31210771	G/A	cg26647111	chr11:31128758	NA	-0.42	-6.5	-0.3	2.29e-10	Red blood cell count;
LUAD	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg20607798	chr8:58055168	NA	0.44	6.36	0.3	5.11e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs17092148	0.579	rs62212082	chr20:33454241	T/A	cg16810054	chr20:33298113	TP53INP2	0.39	7.03	0.32	8.14e-12	Neuroticism;
LUAD	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg18230493	chr5:56204884	C5orf35	-0.45	-7.6	-0.35	1.91e-13	Coronary artery disease;
LUAD	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg25324976	chr17:61989376	CSHL1	0.38	7.41	0.34	7.1e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.47	0.45	5.72e-23	Prudent dietary pattern;
LUAD	cis	rs7771547	0.603	rs9357218	chr6:36549858	G/A	cg12173498	chr6:36355764	ETV7	0.47	6.36	0.3	5.18e-10	Platelet distribution width;
LUAD	trans	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg19862616	chr7:65841803	NCRNA00174	1.06	27.31	0.8	2.21e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1784581	0.722	rs1789993	chr6:162398976	T/C	cg17173639	chr6:162384350	PARK2	-0.52	-9.39	-0.42	3.78e-19	Itch intensity from mosquito bite;
LUAD	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg11344533	chr11:111475393	SIK2	-0.36	-6.69	-0.31	7.26e-11	Primary sclerosing cholangitis;
LUAD	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.32e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9462027	0.628	rs6929567	chr6:34692735	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.35	9.0	0.4	7.61e-18	Systemic lupus erythematosus;
LUAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.75	9.19	0.41	1.76e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08859206	chr1:53392774	SCP2	0.83	15.64	0.61	7.89e-44	Monocyte count;
LUAD	cis	rs10821973	0.527	rs6479797	chr10:64016463	C/G	cg09941381	chr10:64027924	RTKN2	-0.36	-7.17	-0.33	3.39e-12	Hypothyroidism;
LUAD	cis	rs11771526	0.901	rs7357136	chr7:32302338	G/T	cg13207630	chr7:32358064	NA	0.6	7.32	0.34	1.27e-12	Body mass index;
LUAD	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.97	20.95	0.71	2.26e-67	Chronic sinus infection;
LUAD	trans	rs1959947	0.585	rs8008487	chr14:41534471	A/C	cg17076397	chr5:10353763	MARCH6	0.38	6.44	0.3	3.21e-10	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06022373	chr22:39101656	GTPBP1	0.45	6.95	0.32	1.42e-11	Menopause (age at onset);
LUAD	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg03188948	chr7:1209495	NA	0.88	11.79	0.5	6.43e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg26022315	chr17:47021804	SNF8	0.4	7.18	0.33	3.19e-12	Type 2 diabetes;
LUAD	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg11833968	chr6:79620685	NA	-0.42	-7.87	-0.36	2.92e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs68170813	0.559	rs59782202	chr7:107032766	G/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.36	-0.45	1.42e-22	Coronary artery disease;
LUAD	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg08280861	chr8:58055591	NA	0.58	7.27	0.33	1.73e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10715287	chr14:77648040	TMEM63C	-0.44	-7.05	-0.32	7.17e-12	Height;
LUAD	cis	rs758324	0.947	rs6596041	chr5:131198860	C/T	cg25547332	chr5:131281432	NA	0.43	6.62	0.31	1.07e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg12419862	chr22:24373484	LOC391322	-0.65	-10.91	-0.47	1.39e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg00074818	chr8:8560427	CLDN23	0.65	9.94	0.44	4.43e-21	Obesity-related traits;
LUAD	cis	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.43	8.26	0.37	1.82e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7771547	0.573	rs546353	chr6:36398597	C/A	cg07856975	chr6:36356162	ETV7	0.48	7.39	0.34	8.01e-13	Platelet distribution width;
LUAD	cis	rs4891159	0.548	rs690414	chr18:74117840	T/C	cg24786174	chr18:74118243	ZNF516	0.9	22.51	0.74	2.36e-74	Longevity;
LUAD	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-9.41	-0.42	3.16e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.48	6.93	0.32	1.55e-11	Renal function-related traits (BUN);
LUAD	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg09021430	chr5:549028	NA	-0.5	-12.86	-0.53	3.52e-32	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.61	-0.35	1.77e-13	Bone mineral density;
LUAD	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.56	0.52	5.93e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs239198	0.568	rs979122	chr6:101332215	C/T	cg09795085	chr6:101329169	ASCC3	-0.38	-6.68	-0.31	7.65e-11	Menarche (age at onset);
LUAD	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.35	6.89	0.32	2.08e-11	Lung cancer in ever smokers;
LUAD	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg14202850	chr17:43974869	MAPT;LOC100130148	0.38	6.41	0.3	3.9e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7186908	0.793	rs7191623	chr16:72212044	G/A	cg23815491	chr16:72088622	HP	0.48	7.52	0.34	3.28e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg26554054	chr8:600488	NA	-0.7	-7.57	-0.35	2.29e-13	IgG glycosylation;
LUAD	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg13010199	chr12:38710504	ALG10B	0.4	6.39	0.3	4.41e-10	Bladder cancer;
LUAD	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg25535316	chr11:579198	PHRF1	-0.41	-6.51	-0.3	2.19e-10	Systemic lupus erythematosus;
LUAD	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg13877915	chr19:58951672	ZNF132	0.73	13.82	0.56	4.13e-36	Uric acid clearance;
LUAD	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg05283184	chr6:79620031	NA	0.61	12.31	0.51	5.38e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg08873628	chr1:175162347	KIAA0040	0.39	6.54	0.3	1.8e-10	Diastolic blood pressure;
LUAD	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg21545522	chr1:205238299	TMCC2	0.37	6.8	0.31	3.64e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg03806693	chr22:41940476	POLR3H	-0.62	-8.74	-0.39	5.43e-17	Vitiligo;
LUAD	cis	rs9652601	0.919	rs12924729	chr16:11187783	C/T	cg04616529	chr16:11181986	CLEC16A	0.37	6.53	0.3	1.93e-10	Systemic lupus erythematosus;
LUAD	cis	rs6961069	0.749	rs1537477	chr7:80251202	A/C	cg04458919	chr7:80252533	CD36	0.38	7.26	0.33	1.91e-12	Platelet count;
LUAD	cis	rs6087990	0.735	rs4911260	chr20:31376490	T/C	cg13636640	chr20:31349939	DNMT3B	0.75	13.54	0.55	5.81e-35	Ulcerative colitis;
LUAD	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg22598563	chr5:131563921	P4HA2	-0.29	-6.88	-0.32	2.17e-11	Blood metabolite levels;
LUAD	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg02269571	chr22:50332266	NA	0.59	8.96	0.4	1.05e-17	Schizophrenia;
LUAD	cis	rs7737355	0.812	rs8180462	chr5:130907189	A/G	cg06307176	chr5:131281290	NA	0.42	7.03	0.32	8.54e-12	Life satisfaction;
LUAD	cis	rs2658782	0.789	rs3020057	chr11:93118515	C/T	cg15737290	chr11:93063684	CCDC67	0.48	7.22	0.33	2.45e-12	Pulmonary function decline;
LUAD	cis	rs1723838	0.826	rs77411374	chr11:73496290	C/T	cg10064339	chr11:73693792	UCP2	0.86	6.77	0.31	4.23e-11	Obesity-related traits;
LUAD	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg15147215	chr3:52552868	STAB1	-0.37	-6.9	-0.32	1.96e-11	Bipolar disorder;
LUAD	cis	rs9595066	0.667	rs3809350	chr13:44736179	T/C	cg04068111	chr13:44716778	NA	-0.56	-9.25	-0.41	1.1e-18	Schizophrenia;
LUAD	cis	rs7147624	0.573	rs10148699	chr14:66199662	G/A	cg03016385	chr14:66212404	NA	-0.58	-6.94	-0.32	1.49e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs208520	0.706	rs851601	chr6:66893853	G/A	cg07460842	chr6:66804631	NA	-0.98	-14.59	-0.58	2.37e-39	Exhaled nitric oxide output;
LUAD	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg25036284	chr2:26402008	FAM59B	-0.62	-8.43	-0.38	5.53e-16	Gut microbiome composition (summer);
LUAD	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg01028140	chr2:1542097	TPO	-0.5	-6.86	-0.32	2.52e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg10434728	chr15:90938212	IQGAP1	-0.37	-7.18	-0.33	3.09e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg10523679	chr1:76189770	ACADM	-0.74	-11.41	-0.49	1.84e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg26384229	chr12:38710491	ALG10B	-0.43	-7.27	-0.33	1.7e-12	Morning vs. evening chronotype;
LUAD	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg06558623	chr16:89946397	TCF25	1.17	10.91	0.47	1.4e-24	Skin colour saturation;
LUAD	cis	rs1113500	0.933	rs61797345	chr1:108623728	G/A	cg06207961	chr1:108661230	NA	0.45	8.52	0.38	2.83e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs7264396	0.513	rs3787169	chr20:34419884	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-7.47	-0.34	4.63e-13	Total cholesterol levels;
LUAD	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg23625390	chr15:77176239	SCAPER	-0.48	-7.76	-0.35	6.44e-14	Blood metabolite levels;
LUAD	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-6.6	-0.31	1.21e-10	Height;
LUAD	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg10636054	chr15:40330586	SRP14	1.03	11.69	0.49	1.46e-27	Corneal curvature;
LUAD	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	9.7	0.43	3.23e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10979	1.000	rs12212011	chr6:143894694	C/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.28	-0.45	2.77e-22	Hypospadias;
LUAD	trans	rs11039798	0.920	rs11039940	chr11:48716316	C/T	cg02254774	chr11:50257496	LOC441601	0.52	6.58	0.3	1.4e-10	Axial length;
LUAD	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg11189052	chr15:85197271	WDR73	0.59	7.48	0.34	4.22e-13	Schizophrenia;
LUAD	cis	rs2455601	0.529	rs2653569	chr11:8986978	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-8.01	-0.36	1.12e-14	Schizophrenia;
LUAD	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg07332563	chr6:291687	DUSP22	-0.47	-7.97	-0.36	1.49e-14	Menopause (age at onset);
LUAD	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg21984481	chr17:79567631	NPLOC4	-0.71	-17.22	-0.64	1e-50	Eye color traits;
LUAD	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg22189786	chr22:42395067	WBP2NL	0.46	6.57	0.3	1.53e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg15445000	chr17:37608096	MED1	-0.43	-7.98	-0.36	1.41e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg17105886	chr17:28927953	LRRC37B2	0.83	8.0	0.36	1.18e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.96	0.32	1.28e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs28655083	0.956	rs7184198	chr16:77069490	T/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-7.51	-0.34	3.44e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg05368731	chr17:41323189	NBR1	0.95	19.45	0.69	1.22e-60	Menopause (age at onset);
LUAD	cis	rs9394169	0.592	rs4304152	chr6:33723290	C/T	cg13859433	chr6:33739653	LEMD2	-0.35	-8.49	-0.38	3.6e-16	Essential tremor;
LUAD	cis	rs6547631	0.592	rs13408224	chr2:85923936	C/T	cg21473183	chr2:85925749	GNLY	0.35	7.58	0.35	2.25e-13	Blood protein levels;
LUAD	cis	rs11048434	0.723	rs1805737	chr12:9084670	A/T	cg04155231	chr12:9217510	LOC144571	0.39	7.26	0.33	1.93e-12	Sjögren's syndrome;
LUAD	cis	rs1873147	1.000	rs12443295	chr15:63313666	C/T	cg12160578	chr15:63334699	TPM1	-0.35	-6.51	-0.3	2.19e-10	Orofacial clefts;
LUAD	trans	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg25482853	chr8:67687455	SGK3	1.12	17.13	0.64	2.44e-50	Obesity-related traits;
LUAD	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg06636551	chr8:101224915	SPAG1	0.37	6.75	0.31	4.9e-11	Atrioventricular conduction;
LUAD	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg00277334	chr10:82204260	NA	-0.63	-10.52	-0.46	3.81e-23	Post bronchodilator FEV1;
LUAD	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg07570687	chr10:102243282	WNT8B	0.46	7.04	0.32	8.05e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg15468180	chr1:107600409	PRMT6	-0.45	-7.69	-0.35	1.03e-13	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg15704280	chr7:45808275	SEPT13	-0.59	-9.66	-0.43	4.3e-20	HDL cholesterol;
LUAD	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs7072216	0.763	rs942804	chr10:100168499	C/A	cg26618903	chr10:100175079	PYROXD2	-0.36	-7.89	-0.36	2.67e-14	Metabolite levels;
LUAD	cis	rs490234	0.934	rs13293237	chr9:128430966	T/C	cg14078157	chr9:128172775	NA	-0.38	-6.79	-0.31	3.92e-11	Mean arterial pressure;
LUAD	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg15181151	chr6:150070149	PCMT1	0.32	6.36	0.3	5.29e-10	Testicular germ cell tumor;
LUAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg10295955	chr4:187884368	NA	-1.09	-25.63	-0.78	4.22e-88	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg10518543	chr12:38710700	ALG10B	0.4	6.43	0.3	3.47e-10	Morning vs. evening chronotype;
LUAD	cis	rs2486288	0.656	rs1706767	chr15:45569099	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.44	-6.82	-0.31	3.16e-11	Glomerular filtration rate;
LUAD	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg12863693	chr15:85201151	NMB	0.4	7.34	0.34	1.09e-12	Schizophrenia;
LUAD	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg19163074	chr7:65112434	INTS4L2	0.45	6.87	0.32	2.34e-11	Aortic root size;
LUAD	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg25358565	chr5:93447407	FAM172A	0.62	7.22	0.33	2.46e-12	Diabetic retinopathy;
LUAD	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.33	-7.55	-0.34	2.73e-13	Lung cancer;
LUAD	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg07217954	chr7:1067459	C7orf50	-0.38	-6.84	-0.32	2.73e-11	Bronchopulmonary dysplasia;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg06908895	chr20:25038786	ACSS1	0.4	6.48	0.3	2.54e-10	Diastolic blood pressure;
LUAD	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg08761264	chr16:28874980	SH2B1	-0.46	-7.07	-0.33	6.45e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg24818145	chr4:99064322	C4orf37	0.46	7.21	0.33	2.65e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg04155231	chr12:9217510	LOC144571	0.42	7.96	0.36	1.59e-14	Sjögren's syndrome;
LUAD	cis	rs877282	0.838	rs34778553	chr10:796865	T/C	cg06581033	chr10:766294	NA	-0.57	-7.97	-0.36	1.54e-14	Uric acid levels;
LUAD	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg09835421	chr16:68378352	PRMT7	-0.83	-8.99	-0.4	8.54e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs57994353	0.598	rs72775768	chr9:139324574	C/T	cg14169450	chr9:139327907	INPP5E	0.44	7.61	0.35	1.82e-13	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs656900	0.715	rs673079	chr15:80115406	G/A	cg02196730	chr15:80188777	MTHFS	-0.4	-6.83	-0.32	3e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	7.89	0.36	2.57e-14	Breast cancer;
LUAD	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg19717773	chr7:2847554	GNA12	-0.5	-8.51	-0.38	3.04e-16	Height;
LUAD	cis	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg07460842	chr6:66804631	NA	-1.12	-26.2	-0.79	1.3e-90	Exhaled nitric oxide output;
LUAD	cis	rs78487399	0.808	rs6544666	chr2:43732234	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.52	-0.3	1.98e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg23803603	chr1:2058230	PRKCZ	-0.39	-6.97	-0.32	1.21e-11	Height;
LUAD	cis	rs7937890	0.561	rs2575849	chr11:14539639	T/A	cg06199346	chr11:14280333	SPON1	-0.32	-6.42	-0.3	3.58e-10	Mitochondrial DNA levels;
LUAD	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.59	-10.11	-0.44	1.11e-21	Electrocardiographic conduction measures;
LUAD	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg21475434	chr5:93447410	FAM172A	-0.49	-6.82	-0.31	3.24e-11	Diabetic retinopathy;
LUAD	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg26384229	chr12:38710491	ALG10B	-0.41	-7.05	-0.32	7.1e-12	Heart rate;
LUAD	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg00530320	chr1:46809349	NSUN4	-0.52	-8.08	-0.37	6.81e-15	Menopause (age at onset);
LUAD	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg24818145	chr4:99064322	C4orf37	-0.42	-6.84	-0.32	2.72e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg17652424	chr22:38574118	PLA2G6	-0.32	-9.55	-0.42	1.06e-19	Cutaneous nevi;
LUAD	trans	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg26043149	chr18:55253948	FECH	-0.48	-8.06	-0.36	7.93e-15	Bone mineral density;
LUAD	cis	rs9581857	0.685	rs9319367	chr13:28042197	T/C	cg22138327	chr13:27999177	GTF3A	0.84	9.65	0.42	4.63e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg07741184	chr6:167504864	NA	0.4	9.19	0.41	1.73e-18	Crohn's disease;
LUAD	cis	rs9837602	1.000	rs9878931	chr3:99712634	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.98	-0.32	1.18e-11	Breast cancer;
LUAD	cis	rs1595825	0.891	rs1016883	chr2:198881668	A/G	cg11031976	chr2:198649780	BOLL	0.45	6.49	0.3	2.37e-10	Ulcerative colitis;
LUAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.82	-18.19	-0.66	4.82e-55	Longevity;Endometriosis;
LUAD	cis	rs7536201	1.000	rs7528484	chr1:25292668	C/T	cg23273869	chr1:25296894	NA	-0.34	-6.83	-0.32	3.02e-11	Psoriasis vulgaris;
LUAD	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg11344533	chr11:111475393	SIK2	-0.35	-6.68	-0.31	7.77e-11	Primary sclerosing cholangitis;
LUAD	cis	rs10821973	0.527	rs4586044	chr10:63979074	A/G	cg09941381	chr10:64027924	RTKN2	-0.34	-6.75	-0.31	4.95e-11	Hypothyroidism;
LUAD	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg13736514	chr6:26305472	NA	-0.72	-13.51	-0.55	8.24e-35	Educational attainment;
LUAD	cis	rs886126	0.901	rs4766557	chr12:111664044	G/C	cg10833066	chr12:111807467	FAM109A	0.58	10.67	0.46	1.09e-23	Coronary heart disease;
LUAD	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg08470875	chr2:26401718	FAM59B	-0.74	-9.99	-0.44	2.97e-21	Gut microbiome composition (summer);
LUAD	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg04450456	chr4:17643702	FAM184B	0.37	6.99	0.32	1.08e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs367943	0.672	rs1517207	chr5:112717245	G/A	cg12552261	chr5:112820674	MCC	0.47	9.3	0.41	7.76e-19	Type 2 diabetes;
LUAD	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg02493740	chr2:85810744	VAMP5	0.45	8.13	0.37	4.9e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs11078597	0.671	rs1045806	chr17:1641806	G/A	cg18436246	chr17:1640651	WDR81	0.79	12.3	0.51	6.14e-30	Serum albumin level;
LUAD	cis	rs6005807	0.920	rs73437900	chr22:28757306	C/T	cg12565055	chr22:29076175	TTC28	0.67	6.61	0.31	1.19e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9314323	0.767	rs6557915	chr8:26209062	C/A	cg13160058	chr8:26243215	BNIP3L	-0.48	-9.87	-0.43	8.21e-21	Red cell distribution width;
LUAD	cis	rs1448094	0.617	rs1502800	chr12:86476255	A/G	cg18827107	chr12:86230957	RASSF9	-0.46	-8.28	-0.37	1.66e-15	Major depressive disorder;
LUAD	cis	rs4774899	1.000	rs2116065	chr15:57254593	T/A	cg14026238	chr15:57616123	NA	0.34	6.54	0.3	1.75e-10	Urinary tract infection frequency;
LUAD	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg07967210	chr17:47022446	SNF8	0.37	6.64	0.31	9.6e-11	Type 2 diabetes;
LUAD	cis	rs6942407	0.546	rs6465093	chr7:86764877	G/A	cg02420886	chr7:86849541	C7orf23	0.64	7.26	0.33	1.88e-12	Food allergy;
LUAD	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg04287289	chr16:89883240	FANCA	-0.41	-6.65	-0.31	9.03e-11	Vitiligo;
LUAD	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg23625390	chr15:77176239	SCAPER	0.4	7.25	0.33	1.97e-12	Blood metabolite levels;
LUAD	cis	rs4699052	0.963	rs6849319	chr4:104192742	G/C	cg16532752	chr4:104119610	CENPE	-0.49	-7.32	-0.34	1.3e-12	Testicular germ cell tumor;
LUAD	trans	rs10411161	0.702	rs6509592	chr19:52393150	G/A	cg22319618	chr22:45562946	NUP50	-0.7	-9.88	-0.43	7.71e-21	Breast cancer;
LUAD	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg25894440	chr7:65020034	NA	-0.62	-6.63	-0.31	1.05e-10	Diabetic kidney disease;
LUAD	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg11833968	chr6:79620685	NA	-0.43	-8.2	-0.37	3.01e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg17644776	chr2:200775616	C2orf69	0.53	7.58	0.35	2.27e-13	Schizophrenia;
LUAD	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg00277334	chr10:82204260	NA	-0.62	-10.36	-0.45	1.49e-22	Post bronchodilator FEV1;
LUAD	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg12935359	chr14:103987150	CKB	-0.48	-7.5	-0.34	3.8e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg05043794	chr9:111880884	C9orf5	-0.34	-6.47	-0.3	2.71e-10	Menarche (age at onset);
LUAD	trans	rs360929	0.935	rs360926	chr4:152905470	T/C	cg22822647	chr19:16771056	TMEM38A;C19orf42	-0.53	-6.58	-0.3	1.42e-10	Volumetric brain MRI;
LUAD	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg17366294	chr4:99064904	C4orf37	0.47	8.21	0.37	2.76e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10128251	0.847	rs12777965	chr10:5724297	T/C	cg24097872	chr10:5724021	NA	-0.51	-9.42	-0.42	3.03e-19	Childhood ear infection;
LUAD	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg20607287	chr7:12443886	VWDE	-0.56	-6.9	-0.32	1.9e-11	Coronary artery disease;
LUAD	cis	rs7671266	0.668	rs6834055	chr4:10158511	A/T	cg00071950	chr4:10020882	SLC2A9	-0.62	-8.81	-0.39	3.15e-17	Cardiovascular disease risk factors;
LUAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07167872	chr1:205819463	PM20D1	0.78	15.77	0.61	2.14e-44	Menarche (age at onset);
LUAD	cis	rs3026401	0.562	rs2863231	chr11:31796560	C/T	cg26647111	chr11:31128758	NA	-0.38	-6.43	-0.3	3.4e-10	Body mass index;
LUAD	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.19	-0.54	1.66e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.22e-32	Immature fraction of reticulocytes;
LUAD	cis	rs1997103	1.000	rs4948011	chr7:55403859	A/G	cg17469321	chr7:55412551	NA	0.65	11.12	0.48	2.16e-25	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg23985595	chr17:80112537	CCDC57	0.52	9.41	0.42	3.25e-19	Life satisfaction;
LUAD	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg17031739	chr1:67600172	NA	0.44	8.1	0.37	5.97e-15	Psoriasis;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg24465118	chr20:47895107	C20orf199;SNORD12C;ZNFX1	-0.39	-6.52	-0.3	2.06e-10	Subcortical brain region volumes;
LUAD	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	trans	rs1973993	0.967	rs10875017	chr1:96949526	C/T	cg10631902	chr5:14652156	NA	0.53	9.99	0.44	3.07e-21	Weight;
LUAD	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg23758822	chr17:41437982	NA	1.01	21.23	0.72	1.26e-68	Menopause (age at onset);
LUAD	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06873352	chr17:61820015	STRADA	0.77	16.64	0.63	3.41e-48	Prudent dietary pattern;
LUAD	trans	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	5.94e-11	Depression;
LUAD	cis	rs897984	0.568	rs4889653	chr16:30895713	C/T	cg02466173	chr16:30829666	NA	0.64	10.24	0.45	4.05e-22	Dementia with Lewy bodies;
LUAD	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14240646	chr10:27532245	ACBD5	-1.01	-12.01	-0.5	8.35e-29	Breast cancer;
LUAD	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg07870213	chr5:140052090	DND1	1.03	14.56	0.58	3.14e-39	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg06484146	chr7:12443880	VWDE	-0.6	-7.49	-0.34	4.15e-13	Coronary artery disease;
LUAD	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg00495681	chr13:53174319	NA	0.48	8.61	0.39	1.42e-16	Lewy body disease;
LUAD	cis	rs7789940	1.000	rs2072435	chr7:75959188	G/A	cg10167463	chr7:75959203	YWHAG	-0.71	-12.89	-0.53	2.6e-32	Multiple sclerosis;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01885050	chr13:41240761	FOXO1	-0.62	-6.73	-0.31	5.37e-11	Type 2 diabetes;
LUAD	trans	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.85	0.43	9.44e-21	Ulcerative colitis;
LUAD	cis	rs7020830	0.516	rs36047049	chr9:37375472	G/T	cg14294708	chr9:37120828	ZCCHC7	0.65	9.86	0.43	8.72e-21	Schizophrenia;
LUAD	trans	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg25482853	chr8:67687455	SGK3	0.66	10.15	0.44	8.43e-22	Obesity-related traits;
LUAD	cis	rs4889911	0.544	rs1285273	chr17:77830885	A/G	cg00646381	chr17:77835854	NA	0.53	9.12	0.41	2.98e-18	Electroencephalogram traits;
LUAD	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg00277334	chr10:82204260	NA	-0.64	-10.33	-0.45	1.83e-22	Post bronchodilator FEV1;
LUAD	cis	rs4974559	0.947	rs10018627	chr4:1356358	G/A	cg07757535	chr4:1339547	NA	0.4	6.57	0.3	1.47e-10	Systolic blood pressure;
LUAD	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg24450063	chr1:156163899	SLC25A44	1.03	18.86	0.68	5.05e-58	Testicular germ cell tumor;
LUAD	cis	rs7107174	0.901	rs2511162	chr11:77927101	A/G	cg02023728	chr11:77925099	USP35	0.45	7.58	0.35	2.27e-13	Testicular germ cell tumor;
LUAD	cis	rs9900062	0.586	rs6504249	chr17:62676149	A/G	cg02097616	chr17:62675921	NA	0.74	12.44	0.52	1.66e-30	QT interval;
LUAD	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg11859384	chr17:80120422	CCDC57	0.48	8.51	0.38	3.02e-16	Life satisfaction;
LUAD	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg09835421	chr16:68378352	PRMT7	-0.82	-8.78	-0.39	4.06e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.39	-6.77	-0.31	4.3e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.3	-0.45	2.44e-22	Platelet count;
LUAD	cis	rs17152411	0.895	rs3940439	chr10:126584531	C/G	cg07906193	chr10:126599966	NA	0.55	7.71	0.35	9.13e-14	Height;
LUAD	cis	rs1448094	0.836	rs7484454	chr12:86425576	A/G	cg06740227	chr12:86229804	RASSF9	0.36	6.6	0.31	1.24e-10	Major depressive disorder;
LUAD	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.42	-0.57	1.25e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg13736514	chr6:26305472	NA	-0.55	-10.15	-0.44	8.42e-22	Educational attainment;
LUAD	cis	rs910187	0.571	rs6512428	chr20:45807822	T/C	cg27589058	chr20:45804311	EYA2	-0.37	-8.32	-0.37	1.23e-15	Migraine;
LUAD	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg00852783	chr1:26633632	UBXN11	0.46	7.61	0.35	1.83e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg16479474	chr6:28041457	NA	0.41	6.96	0.32	1.28e-11	Parkinson's disease;
LUAD	cis	rs2235649	0.833	rs9929264	chr16:1851934	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.48	-7.89	-0.36	2.58e-14	Blood metabolite levels;
LUAD	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg01416388	chr22:39784598	NA	-0.53	-8.77	-0.39	4.25e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs2046867	0.908	rs62251636	chr3:72792650	A/G	cg25664220	chr3:72788482	NA	-0.68	-12.3	-0.51	6.06e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs13064411	0.627	rs28536176	chr3:113143625	T/C	cg18753928	chr3:113234510	CCDC52	-0.71	-11.37	-0.48	2.59e-26	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg22963979	chr7:1858916	MAD1L1	-0.58	-10.06	-0.44	1.77e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg09184832	chr6:79620586	NA	-0.4	-6.82	-0.31	3.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6500602	0.584	rs11646063	chr16:4439209	A/G	cg08645402	chr16:4508243	NA	-0.4	-7.34	-0.34	1.09e-12	Schizophrenia;
LUAD	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.16	0.48	1.59e-25	Height;
LUAD	cis	rs72901758	0.696	rs72909029	chr17:76249451	A/G	cg25512537	chr17:76250053	NA	0.38	7.53	0.34	3.1400000000000003e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg25358565	chr5:93447407	FAM172A	0.63	7.75	0.35	6.78e-14	Diabetic retinopathy;
LUAD	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg14345882	chr6:26364793	BTN3A2	0.7	7.1	0.33	5.18e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.7	0.31	6.68e-11	Breast cancer;
LUAD	cis	rs3925075	0.531	rs4261553	chr16:31349164	T/C	cg10451425	chr16:31478370	ARMC5	0.4	6.49	0.3	2.47e-10	IgA nephropathy;
LUAD	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg02176678	chr2:219576539	TTLL4	0.74	14.93	0.59	8.76e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-10.55	-0.46	3.02e-23	Asthma;
LUAD	cis	rs1595825	0.891	rs57990618	chr2:198660838	C/T	cg00361562	chr2:198649771	BOLL	-0.5	-6.74	-0.31	5.06e-11	Ulcerative colitis;
LUAD	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.47	2.77e-24	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg07266350	chr3:49460521	AMT;NICN1	-0.36	-6.51	-0.3	2.19e-10	Menarche (age at onset);
LUAD	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg19717773	chr7:2847554	GNA12	-0.51	-9.69	-0.43	3.42e-20	Height;
LUAD	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg24531977	chr5:56204891	C5orf35	-0.48	-8.0	-0.36	1.18e-14	Coronary artery disease;
LUAD	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg04287289	chr16:89883240	FANCA	0.78	6.62	0.31	1.08e-10	Skin colour saturation;
LUAD	cis	rs6076065	0.963	rs999072	chr20:23347553	C/T	cg11657817	chr20:23433608	CST11	0.49	9.7	0.43	3.17e-20	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg21775007	chr8:11205619	TDH	-0.4	-6.99	-0.32	1.05e-11	Retinal vascular caliber;
LUAD	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.04	-15.1	-0.59	1.56e-41	Schizophrenia;
LUAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.4	-6.9	-0.32	1.95e-11	Longevity;Endometriosis;
LUAD	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.73	0.31	5.45e-11	Cognitive test performance;
LUAD	cis	rs12579753	0.917	rs7132465	chr12:82205840	C/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.29	-0.33	1.59e-12	Resting heart rate;
LUAD	cis	rs943466	0.537	rs2296329	chr6:33650743	A/G	cg14003231	chr6:33640908	ITPR3	0.51	7.53	0.34	3.13e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs7937890	0.869	rs2915404	chr11:14404825	A/G	cg22961513	chr11:14280813	SPON1	-0.4	-8.06	-0.37	7.65e-15	Mitochondrial DNA levels;
LUAD	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg00071950	chr4:10020882	SLC2A9	0.85	17.56	0.65	3.18e-52	Bone mineral density;
LUAD	cis	rs4804416	1.000	rs4804414	chr19:7223785	C/T	cg09779027	chr19:7224513	INSR	0.53	10.79	0.46	4e-24	Thyroid hormone levels;Hypothyroidism;
LUAD	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg15704280	chr7:45808275	SEPT13	0.64	8.68	0.39	8.81e-17	Axial length;
LUAD	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22590775	chr19:49891494	CCDC155	0.59	8.45	0.38	4.63e-16	Multiple sclerosis;
LUAD	trans	rs2262909	0.962	rs11673195	chr19:22313814	T/C	cg17074339	chr11:11642133	GALNTL4	0.46	7.55	0.34	2.8e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12893668	0.663	rs12889731	chr14:104087482	C/T	cg13511324	chr14:104056883	C14orf153	0.26	6.39	0.3	4.48e-10	Reticulocyte count;
LUAD	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.14	-0.33	4.01e-12	Lung cancer;
LUAD	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg05340658	chr4:99064831	C4orf37	0.53	8.96	0.4	1.07e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-7.06	-0.32	6.76e-12	Blood metabolite levels;
LUAD	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg20587970	chr11:113659929	NA	-1.17	-18.24	-0.66	2.83e-55	Hip circumference adjusted for BMI;
LUAD	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg25753631	chr6:25732923	NA	-0.46	-8.04	-0.36	8.79e-15	Iron status biomarkers;
LUAD	cis	rs7149337	0.805	rs2999357	chr14:51606001	C/G	cg23942311	chr14:51606299	NA	0.88	20.43	0.7	4.83e-65	Cancer;
LUAD	cis	rs7274811	0.681	rs291674	chr20:31954890	C/G	cg14921437	chr20:32255988	NECAB3;C20orf134	0.47	7.14	0.33	4.06e-12	Height;
LUAD	trans	rs11650494	0.908	rs11650087	chr17:47362923	T/A	cg11430096	chr6:110968061	CDK19	0.9	6.86	0.32	2.43e-11	Prostate cancer;
LUAD	cis	rs7177699	0.525	rs7166770	chr15:79113568	A/G	cg15571903	chr15:79123663	NA	0.37	7.44	0.34	5.5e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg00852783	chr1:26633632	UBXN11	0.46	7.61	0.35	1.83e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg10356904	chr22:49881777	NA	-0.43	-8.51	-0.38	2.99e-16	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg08645402	chr16:4508243	NA	-0.51	-8.94	-0.4	1.18e-17	Schizophrenia;
LUAD	cis	rs375066	0.592	rs10401203	chr19:44299666	C/T	cg12072164	chr19:44306565	LYPD5	-0.39	-8.05	-0.36	8.41e-15	Breast cancer;
LUAD	cis	rs240764	0.658	rs4571568	chr6:101223955	T/A	cg09795085	chr6:101329169	ASCC3	-0.47	-8.27	-0.37	1.71e-15	Neuroticism;
LUAD	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg03037974	chr15:76606532	NA	0.4	8.81	0.39	3.27e-17	Blood metabolite levels;
LUAD	cis	rs11800820	0.555	rs12565947	chr1:246650225	T/C	cg16700716	chr1:246684329	NA	-0.37	-6.96	-0.32	1.31e-11	Obesity-related traits;
LUAD	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg25894440	chr7:65020034	NA	-0.62	-6.61	-0.31	1.13e-10	Diabetic kidney disease;
LUAD	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg03433033	chr1:76189801	ACADM	0.78	12.7	0.53	1.62e-31	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs231513	0.906	rs1642611	chr17:41997712	T/C	cg26893861	chr17:41843967	DUSP3	-0.68	-7.62	-0.35	1.67e-13	Cognitive function;
LUAD	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg00339695	chr16:24857497	SLC5A11	-0.7	-11.25	-0.48	7.08e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs9513627	0.573	rs7325697	chr13:100117793	A/G	cg25919922	chr13:100150906	NA	0.66	8.05	0.36	8.53e-15	Obesity-related traits;
LUAD	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg16606324	chr3:10149918	C3orf24	0.58	8.48	0.38	3.77e-16	Alzheimer's disease;
LUAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12379764	chr21:47803548	PCNT	0.39	6.43	0.3	3.51e-10	Testicular germ cell tumor;
LUAD	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg14092988	chr3:52407081	DNAH1	0.39	7.9	0.36	2.5e-14	Electroencephalogram traits;
LUAD	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.53	-8.61	-0.39	1.45e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg24578937	chr1:2090814	PRKCZ	0.79	16.54	0.63	9.74e-48	Height;
LUAD	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg05342682	chr7:94953680	PON1	-0.5	-7.02	-0.32	9.01e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg11822812	chr5:140052017	DND1	0.38	6.99	0.32	1.07e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.57	-7.36	-0.34	9.77e-13	Body mass index;
LUAD	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.54	-0.34	2.94e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12681287	0.571	rs10097450	chr8:87358677	G/A	cg00550725	chr8:87521180	FAM82B	-0.46	-6.72	-0.31	5.81e-11	Caudate activity during reward;
LUAD	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg08645402	chr16:4508243	NA	-0.52	-9.1	-0.4	3.48e-18	Schizophrenia;
LUAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg22681709	chr2:178499509	PDE11A	-0.51	-8.71	-0.39	6.73e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.63	-11.88	-0.5	2.78e-28	Longevity;Endometriosis;
LUAD	cis	rs2302190	0.882	rs9903173	chr17:56607358	C/T	cg25885038	chr17:56607967	SEPT4	-0.5	-8.16	-0.37	3.87e-15	Vitamin D levels;
LUAD	cis	rs738322	0.555	rs5750549	chr22:38547172	C/T	cg25457927	chr22:38595422	NA	-0.57	-13.37	-0.55	2.91e-34	Cutaneous nevi;
LUAD	cis	rs2859741	0.967	rs507460	chr1:37493206	C/G	cg09363841	chr1:37513479	NA	0.33	8.0	0.36	1.18e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.06	0.32	6.7e-12	Platelet count;
LUAD	cis	rs4891159	0.548	rs660342	chr18:74130896	C/G	cg24786174	chr18:74118243	ZNF516	0.9	22.63	0.74	6.83e-75	Longevity;
LUAD	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg02753203	chr1:228287806	NA	0.56	10.18	0.44	6.46e-22	Diastolic blood pressure;
LUAD	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	9.13	0.41	2.95e-18	Tonsillectomy;
LUAD	cis	rs9487051	0.734	rs56214745	chr6:109536748	G/T	cg01475377	chr6:109611718	NA	-0.38	-6.84	-0.32	2.81e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.83	0.31	3.04e-11	Cognitive test performance;
LUAD	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg14784868	chr12:69753453	YEATS4	0.44	7.17	0.33	3.41e-12	Blood protein levels;
LUAD	cis	rs9652601	1.000	rs9652601	chr16:11174365	G/A	cg04616529	chr16:11181986	CLEC16A	0.36	6.36	0.3	5.37e-10	Systemic lupus erythematosus;
LUAD	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg11871910	chr12:69753446	YEATS4	-0.5	-7.52	-0.34	3.35e-13	Response to diuretic therapy;
LUAD	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg17105886	chr17:28927953	LRRC37B2	0.83	8.0	0.36	1.18e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg25566285	chr7:158114605	PTPRN2	0.53	11.36	0.48	2.74e-26	Calcium levels;
LUAD	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg12458913	chr13:53173898	NA	0.36	6.62	0.31	1.08e-10	Lewy body disease;
LUAD	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg07402062	chr16:89894098	SPIRE2	0.46	11.77	0.5	7.53e-28	Vitiligo;
LUAD	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg25036284	chr2:26402008	FAM59B	-0.55	-7.8	-0.35	4.95e-14	Gut microbiome composition (summer);
LUAD	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	8.37	0.38	8.57e-16	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg09796270	chr17:17721594	SREBF1	0.37	7.58	0.35	2.28e-13	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg11062466	chr8:58055876	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg06784218	chr1:46089804	CCDC17	0.54	11.61	0.49	3.16e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs13190036	0.901	rs10072499	chr5:176655237	T/G	cg06733329	chr5:176740039	MXD3	0.51	7.03	0.32	8.22e-12	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	cis	rs62400317	0.762	rs10484625	chr6:44823449	G/A	cg20913747	chr6:44695427	NA	-0.46	-7.07	-0.33	6.27e-12	Total body bone mineral density;
LUAD	cis	rs8017423	0.630	rs4904678	chr14:90821670	T/C	cg14092571	chr14:90743983	NA	0.39	6.54	0.3	1.77e-10	Mortality in heart failure;
LUAD	cis	rs2455799	0.552	rs2470540	chr3:15718652	T/A	cg16303742	chr3:15540471	COLQ	-0.44	-8.05	-0.36	8.44e-15	Mean platelet volume;
LUAD	cis	rs4698790	0.635	rs11734208	chr4:110690128	C/G	cg07850274	chr4:110748770	RRH	0.42	6.98	0.32	1.11e-11	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUAD	cis	rs4285028	0.747	rs9808981	chr3:121429561	G/A	cg11130432	chr3:121712080	ILDR1	-0.47	-6.82	-0.31	3.11e-11	Multiple sclerosis;
LUAD	cis	rs2275731	0.506	rs7905643	chr10:16521007	T/G	cg04254609	chr10:16479192	PTER	-0.46	-7.47	-0.34	4.77e-13	Bone fracture in osteoporosis;
LUAD	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg27535305	chr1:53392650	SCP2	-0.38	-7.88	-0.36	2.85e-14	Monocyte count;
LUAD	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.33	7.19	0.33	2.98e-12	Cardiac Troponin-T levels;
LUAD	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg06618935	chr21:46677482	NA	-0.5	-10.12	-0.44	1.03e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg18135555	chr8:22132992	PIWIL2	0.41	7.53	0.34	3.17e-13	Hypertriglyceridemia;
LUAD	trans	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg04775059	chr7:64541387	NA	0.5	6.72	0.31	5.94e-11	Aortic root size;
LUAD	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs877282	0.898	rs11253356	chr10:768604	G/A	cg06581033	chr10:766294	NA	-0.6	-8.16	-0.37	3.77e-15	Uric acid levels;
LUAD	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg15123519	chr2:136567270	LCT	0.38	7.0	0.32	9.89e-12	Mosquito bite size;
LUAD	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg17971929	chr21:40555470	PSMG1	-0.41	-6.56	-0.3	1.54e-10	Cognitive function;
LUAD	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg14530993	chr4:882597	GAK	0.79	7.95	0.36	1.66e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7084921	0.578	rs12776318	chr10:101868677	T/G	cg19754520	chr10:101825118	CPN1	-0.35	-6.99	-0.32	1.08e-11	Bone mineral density;
LUAD	cis	rs6906287	0.631	rs9320665	chr6:118986309	G/A	cg21191810	chr6:118973309	C6orf204	0.5	9.63	0.42	5.73e-20	Electrocardiographic conduction measures;
LUAD	cis	rs1018836	0.828	rs9297871	chr8:91572731	G/A	cg16814680	chr8:91681699	NA	-0.6	-9.97	-0.44	3.69e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg07741184	chr6:167504864	NA	0.35	8.24	0.37	2.23e-15	Crohn's disease;
LUAD	cis	rs250585	0.920	rs11074563	chr16:23523293	G/C	cg00143387	chr16:23521605	GGA2	-0.66	-8.02	-0.36	1.04e-14	Egg allergy;
LUAD	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg24399712	chr22:39784796	NA	-0.76	-12.97	-0.53	1.25e-32	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	trans	rs8002861	0.935	rs4942256	chr13:44455920	A/T	cg17145862	chr1:211918768	LPGAT1	0.77	18.33	0.67	1.18e-55	Leprosy;
LUAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg24829409	chr8:58192753	C8orf71	0.51	6.44	0.3	3.18e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg19717773	chr7:2847554	GNA12	-0.52	-9.91	-0.43	6.12e-21	Height;
LUAD	cis	rs9297145	0.565	rs12705030	chr7:98765041	A/G	cg05967295	chr7:98741636	SMURF1	-0.74	-13.4	-0.55	2.16e-34	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg08885076	chr2:99613938	TSGA10	-0.41	-7.21	-0.33	2.65e-12	Chronic sinus infection;
LUAD	cis	rs7712401	0.601	rs154501	chr5:122211594	T/C	cg19077854	chr5:122220652	SNX24	0.34	6.44	0.3	3.19e-10	Mean platelet volume;
LUAD	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg08859206	chr1:53392774	SCP2	0.59	10.66	0.46	1.19e-23	Monocyte count;
LUAD	cis	rs11650494	0.710	rs11654557	chr17:47390136	A/G	cg08112188	chr17:47440006	ZNF652	0.96	7.93	0.36	2.03e-14	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03517284	chr6:25882590	NA	-0.5	-7.44	-0.34	5.51e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg11266682	chr4:10021025	SLC2A9	0.69	15.76	0.61	2.29e-44	Bone mineral density;
LUAD	cis	rs6484504	0.652	rs674035	chr11:31399014	G/A	cg14844989	chr11:31128820	NA	0.45	8.13	0.37	4.71e-15	Red blood cell count;
LUAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg21724239	chr8:58056113	NA	0.65	8.41	0.38	6.32e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg13126279	chr21:47581558	C21orf56	-0.44	-7.59	-0.35	2.01e-13	Testicular germ cell tumor;
LUAD	cis	rs62238980	0.614	rs76363976	chr22:32383968	C/T	cg02631450	chr22:32366979	NA	0.81	6.56	0.3	1.61e-10	Childhood ear infection;
LUAD	cis	rs4356932	1.000	rs4859415	chr4:76956528	A/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.54	-0.3	1.78e-10	Blood protein levels;
LUAD	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg12599982	chr1:44399894	ARTN	0.34	6.58	0.3	1.42e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.65	-9.73	-0.43	2.54e-20	IgG glycosylation;
LUAD	cis	rs752010	0.714	rs2148635	chr1:42082452	C/T	cg06885757	chr1:42089581	HIVEP3	-0.48	-11.33	-0.48	3.65e-26	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs3862260	0.967	rs3862261	chr1:120160822	G/A	cg11530693	chr1:120165357	ZNF697	0.68	13.29	0.54	6.06e-34	Systemic lupus erythematosus;
LUAD	cis	rs7799006	0.895	rs3757437	chr7:2271980	C/T	cg02951883	chr7:2050386	MAD1L1	-0.52	-7.98	-0.36	1.44e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg05926928	chr17:57297772	GDPD1	1.38	17.68	0.65	9.22e-53	Opioid sensitivity;
LUAD	cis	rs1691799	0.899	rs1168307	chr12:66739539	A/G	cg16791601	chr12:66731901	HELB	-0.36	-6.54	-0.3	1.76e-10	White blood cell count (basophil);
LUAD	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg27068330	chr11:65405492	SIPA1	-0.76	-11.67	-0.49	1.86e-27	Acne (severe);
LUAD	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.21	0.33	2.62e-12	Parkinson's disease;
LUAD	cis	rs1298062	0.861	rs2431827	chr19:50994214	C/G	cg11430371	chr19:50961752	MYBPC2	0.32	6.57	0.3	1.52e-10	Age of smoking initiation;
LUAD	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg16647868	chr5:131706066	SLC22A5	0.41	6.74	0.31	5.26e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-6.68	-0.31	7.64e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6543140	0.929	rs7602207	chr2:103032366	C/G	cg04239558	chr2:103089729	SLC9A4	0.35	7.01	0.32	9.26e-12	Blood protein levels;
LUAD	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg08213375	chr14:104286397	PPP1R13B	0.27	7.14	0.33	4.14e-12	Schizophrenia;
LUAD	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg26022315	chr17:47021804	SNF8	0.4	7.27	0.33	1.77e-12	Type 2 diabetes;
LUAD	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg02753203	chr1:228287806	NA	0.68	12.63	0.52	2.92e-31	Diastolic blood pressure;
LUAD	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg00666640	chr1:248458726	OR2T12	0.32	7.88	0.36	2.71e-14	Common traits (Other);
LUAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg00280220	chr17:61926910	NA	0.36	6.92	0.32	1.72e-11	Prudent dietary pattern;
LUAD	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-7.5	-0.34	3.76e-13	Tonsillectomy;
LUAD	cis	rs4930561	1.000	rs4930561	chr11:67931761	C/T	cg04465784	chr11:67976953	SUV420H1	-0.31	-9.81	-0.43	1.34e-20	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	trans	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg07211511	chr3:129823064	LOC729375	-0.53	-6.73	-0.31	5.7e-11	Blood pressure (smoking interaction);
LUAD	cis	rs1371614	0.566	rs10184824	chr2:27177952	C/A	cg00617064	chr2:27272375	NA	0.35	6.45	0.3	3.03e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs1003719	0.788	rs59637309	chr21:38475398	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.64	0.39	1.13e-16	Eye color traits;
LUAD	cis	rs7809950	1.000	rs2712215	chr7:107188207	A/G	cg23024343	chr7:107201750	COG5	-0.73	-12.3	-0.51	5.99e-30	Coronary artery disease;
LUAD	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg13770153	chr20:60521292	NA	-0.48	-8.08	-0.37	6.98e-15	Body mass index;
LUAD	cis	rs12545109	0.800	rs2576591	chr8:57423606	A/G	cg21220214	chr8:57350948	NA	-0.6	-8.31	-0.37	1.29e-15	Obesity-related traits;
LUAD	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.48	-8.05	-0.36	8.66e-15	Body mass index;
LUAD	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-9.03	-0.4	6.31e-18	Life satisfaction;
LUAD	cis	rs1045714	0.895	rs4721867	chr7:2643352	A/G	cg20813462	chr7:2646259	IQCE	-0.68	-7.88	-0.36	2.77e-14	Urate levels in lean individuals;
LUAD	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg09365446	chr1:150670422	GOLPH3L	0.67	12.58	0.52	4.67e-31	Tonsillectomy;
LUAD	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	9.36	0.41	4.66e-19	Electrocardiographic conduction measures;
LUAD	trans	rs3219090	0.861	rs2570370	chr1:226607385	T/C	cg27539482	chr13:111589090	NA	0.41	6.77	0.31	4.3e-11	Melanoma;
LUAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-12.65	-0.52	2.45e-31	Chronic sinus infection;
LUAD	cis	rs6494488	0.500	rs72742927	chr15:64866305	G/T	cg08069370	chr15:64387884	SNX1	-0.75	-6.59	-0.3	1.34e-10	Coronary artery disease;
LUAD	cis	rs11249608	0.636	rs6888539	chr5:178449010	T/A	cg01312482	chr5:178451176	ZNF879	-0.45	-7.0	-0.32	1.03e-11	Pubertal anthropometrics;
LUAD	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg08085267	chr17:45401833	C17orf57	0.58	10.24	0.45	3.9e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg20283391	chr11:68216788	NA	-0.41	-6.6	-0.31	1.21e-10	Total body bone mineral density;
LUAD	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg04455712	chr21:45112962	RRP1B	-0.37	-6.71	-0.31	6.38e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg13334819	chr7:99746414	C7orf59	0.63	9.9	0.43	6.48e-21	Coronary artery disease;
LUAD	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg08999081	chr20:33150536	PIGU	0.51	9.9	0.43	6.4e-21	Coronary artery disease;
LUAD	cis	rs62229266	0.804	rs880221	chr21:37420785	C/T	cg12218747	chr21:37451666	NA	-0.48	-8.26	-0.37	1.92e-15	Mitral valve prolapse;
LUAD	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg06784218	chr1:46089804	CCDC17	0.51	11.15	0.48	1.71e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg06558623	chr16:89946397	TCF25	1.23	12.4	0.52	2.47e-30	Skin colour saturation;
LUAD	cis	rs743757	1.000	rs1107265	chr3:50431995	A/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	7.22	0.33	2.37e-12	Diastolic blood pressure;
LUAD	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-9.0	-0.4	8e-18	Hemoglobin concentration;
LUAD	cis	rs3818285	0.655	rs2475277	chr10:111639730	C/T	cg00817464	chr10:111662876	XPNPEP1	0.83	16.09	0.62	8.33e-46	Superior crus of antihelix expression;
LUAD	cis	rs9473147	0.516	rs9381579	chr6:47556680	C/T	cg20196966	chr6:47445060	CD2AP	0.43	6.86	0.32	2.39e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg01176363	chr20:62369445	LIME1	0.48	7.95	0.36	1.67e-14	Prostate cancer;
LUAD	trans	rs11039798	0.778	rs7944523	chr11:48911019	G/A	cg03929089	chr4:120376271	NA	0.59	6.79	0.31	3.9e-11	Axial length;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg04364504	chr16:58035198	C16orf57;ZNF319	0.42	6.65	0.31	8.87e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg09365446	chr1:150670422	GOLPH3L	0.63	11.12	0.48	2.34e-25	Melanoma;
LUAD	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg17987982	chr7:158820591	NA	-0.39	-6.52	-0.3	2.04e-10	Facial morphology (factor 20);
LUAD	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.58	0.3	1.43e-10	Parkinson's disease;
LUAD	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.69	0.31	7.25e-11	Colorectal cancer;
LUAD	cis	rs8067287	1.000	rs4318250	chr17:16817593	A/T	cg26910001	chr17:16838321	NA	-0.49	-6.54	-0.3	1.8e-10	Diabetic kidney disease;
LUAD	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg27490568	chr2:178487706	NA	0.4	6.82	0.31	3.1e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15369054	chr17:80825471	TBCD	0.66	10.8	0.46	3.46e-24	Breast cancer;
LUAD	cis	rs1965732	0.563	rs13390724	chr2:3721632	G/A	cg00999904	chr2:3704751	ALLC	-0.38	-7.25	-0.33	2e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg24675056	chr1:15929824	NA	0.43	6.89	0.32	2.03e-11	Systolic blood pressure;
LUAD	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg21699342	chr2:239360505	ASB1	0.54	10.73	0.46	6.57e-24	Multiple system atrophy;
LUAD	cis	rs11650175	0.796	rs67460273	chr17:63757188	G/A	cg07283582	chr17:63770753	CCDC46	0.39	7.82	0.36	4.22e-14	Chin dimples;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23330034	chr19:41770021	HNRNPUL1	-0.45	-7.12	-0.33	4.61e-12	Height;
LUAD	cis	rs2882667	0.931	rs10075951	chr5:138355963	G/T	cg04439458	chr5:138467593	SIL1	-0.39	-7.03	-0.32	8.24e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg11693508	chr17:37793320	STARD3	-0.73	-9.62	-0.42	6.16e-20	Bipolar disorder;
LUAD	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-7.21	-0.33	2.59e-12	Obesity-related traits;
LUAD	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg06608945	chr2:219082296	ARPC2	0.43	7.26	0.33	1.84e-12	Colorectal cancer;
LUAD	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg12940439	chr1:67600707	NA	0.48	9.08	0.4	4.13e-18	Psoriasis;
LUAD	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg26384229	chr12:38710491	ALG10B	0.45	7.29	0.33	1.58e-12	Heart rate;
LUAD	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.03	0.32	8.47e-12	Motion sickness;
LUAD	cis	rs7216064	0.954	rs4790973	chr17:65951133	C/T	cg08758996	chr17:66097529	LOC651250	0.47	7.11	0.33	4.88e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs1595825	0.786	rs74484541	chr2:198894223	T/C	cg10547527	chr2:198650123	BOLL	-0.51	-7.0	-0.32	1.02e-11	Ulcerative colitis;
LUAD	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.71	-12.2	-0.51	1.51e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.68e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg07936489	chr17:37558343	FBXL20	0.43	6.86	0.32	2.4e-11	Glomerular filtration rate (creatinine);
LUAD	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg18944383	chr4:111397179	ENPEP	-0.5	-9.08	-0.4	4.21e-18	Coronary artery disease;
LUAD	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.91	0.4	1.48e-17	Cognitive ability;
LUAD	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg03929089	chr4:120376271	NA	-0.97	-19.76	-0.69	5e-62	Height;
LUAD	cis	rs7746082	0.627	rs12216416	chr6:106473270	C/T	cg02270332	chr6:106475062	NA	0.4	6.83	0.32	3.02e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg04450456	chr4:17643702	FAM184B	0.36	6.93	0.32	1.58e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1595825	0.891	rs2293255	chr2:198621506	T/C	cg11031976	chr2:198649780	BOLL	-0.48	-7.17	-0.33	3.34e-12	Ulcerative colitis;
LUAD	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg07217954	chr7:1067459	C7orf50	-0.43	-7.31	-0.33	1.32e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg04727924	chr7:799746	HEATR2	-0.55	-7.48	-0.34	4.29e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg10589385	chr1:150898437	SETDB1	0.42	7.75	0.35	6.81e-14	Melanoma;
LUAD	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg04287289	chr16:89883240	FANCA	0.65	6.64	0.31	9.54e-11	Skin colour saturation;
LUAD	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg00701064	chr4:6280414	WFS1	-0.62	-13.47	-0.55	1.17e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs12618769	0.597	rs17446058	chr2:99164160	A/G	cg10123293	chr2:99228465	UNC50	0.49	8.67	0.39	9.35e-17	Bipolar disorder;
LUAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg02951883	chr7:2050386	MAD1L1	-0.73	-11.56	-0.49	4.7e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg24642844	chr7:1081250	C7orf50	-0.97	-14.91	-0.59	1.1e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg10978503	chr1:24200527	CNR2	0.59	12.65	0.52	2.41e-31	Immature fraction of reticulocytes;
LUAD	cis	rs2742417	1.000	rs2742432	chr3:45737467	G/T	cg10512202	chr3:45649293	LIMD1	0.36	6.49	0.3	2.34e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-7.75	-0.35	7.05e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs4604732	0.631	rs12080860	chr1:247623053	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	9.37	0.41	4.47e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2554380	0.943	rs4843152	chr15:84363542	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.61	-9.16	-0.41	2.21e-18	Height;
LUAD	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg08213375	chr14:104286397	PPP1R13B	-0.27	-6.94	-0.32	1.45e-11	Schizophrenia;
LUAD	cis	rs60154123	0.614	rs4844988	chr1:210459888	C/T	cg22029157	chr1:209979665	IRF6	0.49	6.37	0.3	4.93e-10	Coronary artery disease;
LUAD	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg19318889	chr4:1322082	MAEA	0.46	7.56	0.35	2.48e-13	Obesity-related traits;
LUAD	cis	rs2882667	0.931	rs11955952	chr5:138329119	A/G	cg04439458	chr5:138467593	SIL1	-0.38	-7.12	-0.33	4.78e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs11771526	0.901	rs62457471	chr7:32306737	A/C	cg27511599	chr7:32358540	NA	0.51	6.45	0.3	2.99e-10	Body mass index;
LUAD	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg05283184	chr6:79620031	NA	-0.61	-12.38	-0.52	3.02e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	24.27	0.76	3.88e-82	Chronic sinus infection;
LUAD	cis	rs986417	1.000	rs3931460	chr14:60939101	A/C	cg27398547	chr14:60952738	C14orf39	0.58	6.89	0.32	2.08e-11	Gut microbiota (bacterial taxa);
LUAD	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg16647868	chr5:131706066	SLC22A5	-0.5	-7.8	-0.35	4.99e-14	Breast cancer;
LUAD	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg11859384	chr17:80120422	CCDC57	0.51	9.2	0.41	1.67e-18	Life satisfaction;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18574395	chr18:9102960	NDUFV2	-0.43	-6.72	-0.31	5.96e-11	Height;
LUAD	cis	rs1816752	0.819	rs9511240	chr13:24985906	G/A	cg02811702	chr13:24901961	NA	0.43	7.37	0.34	9.06e-13	Obesity-related traits;
LUAD	cis	rs12368653	0.641	rs11172300	chr12:58076515	C/T	cg12615879	chr12:58013172	SLC26A10	0.52	10.8	0.47	3.4e-24	Multiple sclerosis;
LUAD	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg10207240	chr12:122356781	WDR66	0.43	7.38	0.34	8.6e-13	Mean platelet volume;
LUAD	cis	rs4774899	0.752	rs2470079	chr15:57322099	G/C	cg14026238	chr15:57616123	NA	-0.39	-7.48	-0.34	4.33e-13	Urinary tract infection frequency;
LUAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg18402987	chr7:1209562	NA	0.77	9.45	0.42	2.3e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs986417	1.000	rs4901994	chr14:61090202	C/T	cg27398547	chr14:60952738	C14orf39	0.64	7.09	0.33	5.66e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg18180107	chr4:99064573	C4orf37	0.41	6.62	0.31	1.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08677398	chr8:58056175	NA	0.53	6.67	0.31	7.86e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs6445967	1.000	rs1913715	chr3:58308214	G/A	cg23715586	chr3:58305044	RPP14	0.42	7.59	0.35	2.05e-13	Platelet count;
LUAD	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg00745463	chr17:30367425	LRRC37B	-1.07	-12.36	-0.52	3.46e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs12760731	0.565	rs12732507	chr1:178098296	A/G	cg00404053	chr1:178313656	RASAL2	0.72	9.2	0.41	1.59e-18	Obesity-related traits;
LUAD	cis	rs59698941	0.891	rs72799497	chr5:132291148	T/C	cg14825688	chr5:132208181	LEAP2	-0.48	-6.46	-0.3	2.82e-10	Apolipoprotein A-IV levels;
LUAD	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg03929089	chr4:120376271	NA	-0.6	-9.48	-0.42	1.81e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg15181151	chr6:150070149	PCMT1	0.42	8.59	0.39	1.74e-16	Lung cancer;
LUAD	trans	rs2262909	0.962	rs422344	chr19:22230956	C/G	cg05197062	chr11:11642011	GALNTL4	0.57	8.82	0.39	2.93e-17	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg10560079	chr2:191398806	TMEM194B	-0.54	-7.08	-0.33	5.86e-12	Diastolic blood pressure;
LUAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg03188948	chr7:1209495	NA	0.81	9.78	0.43	1.65e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10950821	0.770	rs73688305	chr7:20682189	A/G	cg02470904	chr7:20686108	ABCB5	0.39	6.47	0.3	2.78e-10	Response to statin therapy;
LUAD	cis	rs2230307	0.572	rs514090	chr1:100563186	C/G	cg20868668	chr1:100435035	SLC35A3	0.53	7.69	0.35	1.01e-13	Carotid intima media thickness;
LUAD	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg25036284	chr2:26402008	FAM59B	0.84	12.45	0.52	1.59e-30	Gut microbiome composition (summer);
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg11235426	chr6:292522	DUSP22	-0.79	-13.59	-0.55	3.58e-35	Menopause (age at onset);
LUAD	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg22907277	chr7:1156413	C7orf50	0.49	8.22	0.37	2.47e-15	Longevity;Endometriosis;
LUAD	cis	rs4268898	0.552	rs12620938	chr2:24367122	C/A	cg06627628	chr2:24431161	ITSN2	0.43	7.45	0.34	5.26e-13	Asthma;
LUAD	cis	rs10504073	0.584	rs11778863	chr8:49954893	C/T	cg00325661	chr8:49890786	NA	0.48	10.56	0.46	2.75e-23	Blood metabolite ratios;
LUAD	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.0	0.32	1.01e-11	Motion sickness;
LUAD	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.54	7.74	0.35	7.4e-14	Platelet count;
LUAD	cis	rs3733418	0.929	rs17623445	chr4:165894658	C/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.48	-6.82	-0.31	3.2e-11	Obesity-related traits;
LUAD	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg23018236	chr17:30244563	NA	-0.69	-8.3	-0.37	1.46e-15	Hip circumference adjusted for BMI;
LUAD	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.67	-0.31	8.15e-11	Triglycerides;
LUAD	cis	rs7107174	1.000	rs7112234	chr11:78102470	G/A	cg19901956	chr11:77921274	USP35	-0.48	-6.81	-0.31	3.36e-11	Testicular germ cell tumor;
LUAD	cis	rs2880765	0.743	rs8039049	chr15:86007629	A/G	cg13263323	chr15:86062960	AKAP13	-0.48	-8.66	-0.39	9.83e-17	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.53	0.3	1.89e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg08219700	chr8:58056026	NA	0.43	6.51	0.3	2.19e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg08798685	chr6:27730294	NA	-0.44	-7.07	-0.32	6.57e-12	Parkinson's disease;
LUAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.7	-13.03	-0.54	7.39e-33	Lymphocyte counts;
LUAD	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg06074448	chr4:187884817	NA	-0.36	-7.06	-0.32	6.92e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg07423050	chr13:99094983	FARP1	0.7	13.87	0.56	2.65e-36	Educational attainment (years of education);
LUAD	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	6.88	0.32	2.23e-11	Motion sickness;
LUAD	cis	rs10901296	0.660	rs2772033	chr9:133757080	G/A	cg03924115	chr9:133768966	QRFP	0.52	6.41	0.3	3.81e-10	Bilirubin levels;
LUAD	cis	rs4711350	0.765	rs2395446	chr6:33743264	C/T	cg07979401	chr6:33739406	LEMD2	-0.54	-10.02	-0.44	2.46e-21	Schizophrenia;
LUAD	cis	rs62400317	0.793	rs12210230	chr6:45344854	T/A	cg20913747	chr6:44695427	NA	-0.4	-6.44	-0.3	3.34e-10	Total body bone mineral density;
LUAD	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22496380	chr5:211416	CCDC127	-0.94	-12.48	-0.52	1.19e-30	Breast cancer;
LUAD	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg24818145	chr4:99064322	C4orf37	0.42	7.03	0.32	8.35e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs367615	0.679	rs11241021	chr5:108812090	T/G	cg17395555	chr5:108820864	NA	0.68	14.17	0.57	1.36e-37	Colorectal cancer (SNP x SNP interaction);
LUAD	trans	rs629535	0.748	rs689410	chr8:70037558	G/A	cg21567404	chr3:27674614	NA	1.01	18.57	0.67	9.52e-57	Dupuytren's disease;
LUAD	cis	rs9486719	1.000	rs2472889	chr6:96866803	T/G	cg06623918	chr6:96969491	KIAA0776	0.71	9.98	0.44	3.33e-21	Migraine;Coronary artery disease;
LUAD	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg08859206	chr1:53392774	SCP2	-0.58	-10.64	-0.46	1.43e-23	Monocyte count;
LUAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg00431813	chr7:1051703	C7orf50	-0.37	-6.69	-0.31	6.89e-11	Longevity;Endometriosis;
LUAD	trans	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg11693508	chr17:37793320	STARD3	0.71	9.34	0.41	5.49e-19	Bipolar disorder;
LUAD	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg05082376	chr22:42548792	NA	-0.49	-9.01	-0.4	7.12e-18	Schizophrenia;
LUAD	trans	rs10838798	0.563	rs2870080	chr11:48144224	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.16	-0.33	3.58e-12	Height;
LUAD	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg09035930	chr12:129282057	SLC15A4	-0.55	-10.2	-0.44	5.37e-22	Systemic lupus erythematosus;
LUAD	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.67	0.35	1.24e-13	Platelet count;
LUAD	cis	rs7107174	1.000	rs2511155	chr11:77969223	G/A	cg19901956	chr11:77921274	USP35	-0.52	-6.66	-0.31	8.78e-11	Testicular germ cell tumor;
LUAD	trans	rs28551159	1	rs28551159	chr6:26376368	A/G	cg01620082	chr3:125678407	NA	-0.72	-7.28	-0.33	1.62e-12	Urinary tract infection frequency;
LUAD	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.99	-0.4	8.39e-18	Bipolar disorder;
LUAD	cis	rs9394169	0.709	rs6919321	chr6:33724004	G/A	cg13859433	chr6:33739653	LEMD2	-0.35	-8.41	-0.38	6.4e-16	Essential tremor;
LUAD	cis	rs10392	0.543	rs62204117	chr20:37565335	T/C	cg27552599	chr20:37590471	DHX35	0.41	6.96	0.32	1.34e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg04703951	chr17:43578652	NA	0.52	7.37	0.34	8.94e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg03526776	chr6:41159608	TREML2	0.54	11.2	0.48	1.1e-25	Alzheimer's disease (late onset);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg16599698	chr5:77590670	AP3B1	-0.65	-6.4	-0.3	4.05e-10	Type 2 diabetes;
LUAD	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.68	-0.31	7.47e-11	Mood instability;
LUAD	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7771547	0.607	rs9348997	chr6:36430560	A/G	cg07856975	chr6:36356162	ETV7	-0.43	-6.56	-0.3	1.62e-10	Platelet distribution width;
LUAD	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg22963979	chr7:1858916	MAD1L1	0.66	11.6	0.49	3.26e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs4006360	0.505	rs8067313	chr17:39290306	G/T	cg20663846	chr17:39254439	KRTAP4-8	0.34	7.21	0.33	2.57e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	8.46	0.38	4.25e-16	Electroencephalogram traits;
LUAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.66	-12.07	-0.51	4.99e-29	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.81	0.35	4.68e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8099014	0.861	rs4940703	chr18:56115386	A/G	cg12907477	chr18:56117327	MIR122	0.49	8.08	0.37	6.96e-15	Platelet count;
LUAD	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg08885076	chr2:99613938	TSGA10	0.36	6.52	0.3	1.98e-10	Chronic sinus infection;
LUAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg05215272	chr17:6899095	ALOX12	0.44	8.46	0.38	4.48e-16	Tonsillectomy;
LUAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg13560548	chr3:10150139	C3orf24	0.45	7.51	0.34	3.43e-13	Alzheimer's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01398415	chr1:226309536	NA	-0.4	-6.47	-0.3	2.64e-10	Height;
LUAD	trans	rs343496	0.877	rs340925	chr9:6088398	T/G	cg16665231	chr1:245741199	KIF26B	-0.41	-6.35	-0.3	5.44e-10	Asthma and hay fever;
LUAD	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg22117172	chr7:91764530	CYP51A1	0.33	7.3	0.33	1.41e-12	Breast cancer;
LUAD	trans	rs1973993	0.934	rs588660	chr1:96886604	G/A	cg10631902	chr5:14652156	NA	0.54	9.97	0.44	3.47e-21	Weight;
LUAD	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg03161606	chr19:29218774	NA	0.55	7.32	0.34	1.23e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs877282	0.898	rs10904547	chr10:766283	C/T	cg06581033	chr10:766294	NA	-0.58	-7.94	-0.36	1.8e-14	Uric acid levels;
LUAD	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-7.48	-0.34	4.31e-13	Morning vs. evening chronotype;
LUAD	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg23625390	chr15:77176239	SCAPER	0.4	7.3	0.33	1.41e-12	Blood metabolite levels;
LUAD	cis	rs7727544	0.582	rs3805683	chr5:131535125	T/G	cg07538946	chr5:131705188	SLC22A5	0.4	6.43	0.3	3.41e-10	Blood metabolite levels;
LUAD	cis	rs7254114	0.578	rs3745682	chr19:11313256	C/T	cg02815516	chr19:11306319	KANK2	-0.32	-6.92	-0.32	1.64e-11	Immature fraction of reticulocytes;
LUAD	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	7.39	0.34	7.78e-13	Platelet count;
LUAD	cis	rs15676	0.783	rs4837316	chr9:131577450	A/G	cg00228799	chr9:131580591	ENDOG	0.5	7.84	0.36	3.74e-14	Blood metabolite levels;
LUAD	trans	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg02002194	chr4:3960332	NA	0.28	6.41	0.3	3.86e-10	Mood instability;
LUAD	cis	rs6500395	1.000	rs8058362	chr16:48645316	T/C	cg04672837	chr16:48644449	N4BP1	0.39	6.82	0.31	3.1e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg26446133	chr18:72167187	CNDP2	-0.79	-11.32	-0.48	4.11e-26	Refractive error;
LUAD	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.26e-12	Tonsillectomy;
LUAD	cis	rs2735413	0.846	rs12923626	chr16:78080139	A/C	cg04733911	chr16:78082701	NA	-0.35	-8.3	-0.37	1.37e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	trans	rs800082	0.690	rs800081	chr3:144339980	C/T	cg24215973	chr2:240111563	HDAC4	0.59	9.54	0.42	1.16e-19	Smoking behavior;
LUAD	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.71	-14.74	-0.58	5.82e-40	Lung cancer;
LUAD	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.67	-8.51	-0.38	3.14e-16	Yeast infection;
LUAD	cis	rs12549902	0.966	rs6990613	chr8:41515130	A/G	cg17182837	chr8:41585554	ANK1	-0.36	-7.49	-0.34	4.16e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUAD	cis	rs6076065	0.723	rs6083110	chr20:23373674	C/T	cg11657817	chr20:23433608	CST11	0.48	8.95	0.4	1.12e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg02176678	chr2:219576539	TTLL4	0.58	10.99	0.47	6.95e-25	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4664308	0.935	rs4292050	chr2:160940899	G/T	cg03641300	chr2:160917029	PLA2R1	-0.37	-6.43	-0.3	3.54e-10	Idiopathic membranous nephropathy;
LUAD	cis	rs7771547	0.519	rs9654588	chr6:36363923	A/C	cg07856975	chr6:36356162	ETV7	0.56	8.29	0.37	1.47e-15	Platelet distribution width;
LUAD	cis	rs3760982	0.813	rs10426528	chr19:44299298	A/G	cg12072164	chr19:44306565	LYPD5	0.39	7.86	0.36	3.13e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	7.04	0.32	7.65e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg20701182	chr2:24300061	SF3B14	0.57	6.88	0.32	2.14e-11	Lymphocyte counts;
LUAD	cis	rs17054265	1.000	rs28399804	chr9:91260386	T/G	cg14112041	chr9:91262358	LOC286238	0.34	6.35	0.3	5.4e-10	Obesity-related traits;
LUAD	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg03609598	chr5:56110824	MAP3K1	-0.65	-8.82	-0.39	3.1e-17	Initial pursuit acceleration;
LUAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg00080972	chr5:178986291	RUFY1	0.64	11.61	0.49	3.11e-27	Lung cancer;
LUAD	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg06784218	chr1:46089804	CCDC17	0.55	12.13	0.51	2.81e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg07870213	chr5:140052090	DND1	-0.72	-11.07	-0.47	3.39e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg07570687	chr10:102243282	WNT8B	0.45	6.88	0.32	2.19e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg16615211	chr3:44902933	MIR564;TMEM42	0.38	7.11	0.33	4.96e-12	Depressive symptoms;
LUAD	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.59	-9.08	-0.4	4.22e-18	IgG glycosylation;
LUAD	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.86	-12.08	-0.51	4.63e-29	Red cell distribution width;
LUAD	cis	rs2806561	0.929	rs2867315	chr1:23541286	C/T	cg12483005	chr1:23474871	LUZP1	-0.38	-6.39	-0.3	4.28e-10	Height;
LUAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10819733	chr22:24237672	NA	-0.46	-8.66	-0.39	1.02e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01622965	chr7:98476371	TRRAP	-0.44	-6.93	-0.32	1.61e-11	Height;
LUAD	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg26446133	chr18:72167187	CNDP2	-0.57	-8.86	-0.4	2.22e-17	Mononucleosis;
LUAD	cis	rs4604732	0.631	rs4436425	chr1:247632323	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.45	7.27	0.33	1.74e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7020830	0.931	rs7027473	chr9:37132462	A/G	cg14294708	chr9:37120828	ZCCHC7	0.85	16.86	0.63	3.59e-49	Schizophrenia;
LUAD	cis	rs11696501	0.947	rs11696176	chr20:44115425	G/C	cg11783356	chr20:44313418	WFDC10B	-0.47	-7.13	-0.33	4.28e-12	Brain structure;
LUAD	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg03213289	chr20:61660250	NA	0.64	13.65	0.55	2.03e-35	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg06002616	chr8:101225028	SPAG1	0.38	7.82	0.36	4.3e-14	Atrioventricular conduction;
LUAD	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg06740227	chr12:86229804	RASSF9	0.4	7.09	0.33	5.5e-12	Major depressive disorder;
LUAD	cis	rs2688608	0.725	rs2633314	chr10:75683590	C/T	cg23231163	chr10:75533350	FUT11	-0.37	-6.91	-0.32	1.84e-11	Inflammatory bowel disease;
LUAD	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg02734326	chr4:10020555	SLC2A9	-0.42	-7.32	-0.34	1.24e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg13770153	chr20:60521292	NA	-0.46	-7.7	-0.35	9.92e-14	Body mass index;
LUAD	cis	rs4604732	0.631	rs12031721	chr1:247623773	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.1	0.33	5.32e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.7e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2455826	0.520	rs2654649	chr3:15776684	A/G	cg16303742	chr3:15540471	COLQ	-0.38	-6.54	-0.3	1.82e-10	Inflammatory skin disease;
LUAD	cis	rs6906287	0.647	rs13220480	chr6:118916627	G/A	cg21191810	chr6:118973309	C6orf204	0.5	9.69	0.43	3.54e-20	Electrocardiographic conduction measures;
LUAD	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg12927641	chr6:109611667	NA	-0.51	-8.81	-0.39	3.15e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs2235544	0.579	rs1537321	chr1:54482236	C/A	cg25741118	chr1:54482237	LDLRAD1	-0.25	-7.04	-0.32	7.78e-12	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUAD	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg08999081	chr20:33150536	PIGU	-0.62	-13.96	-0.56	1.08e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08704250	chr15:31115839	NA	-0.56	-10.0	-0.44	2.94e-21	Huntington's disease progression;
LUAD	cis	rs17253792	0.730	rs77079997	chr14:56155250	A/G	cg01858014	chr14:56050164	KTN1	-0.58	-6.37	-0.3	4.99e-10	Putamen volume;
LUAD	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg11871910	chr12:69753446	YEATS4	0.55	8.46	0.38	4.55e-16	Blood protein levels;
LUAD	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg23029597	chr12:123009494	RSRC2	-0.59	-9.48	-0.42	1.81e-19	Body mass index;
LUAD	cis	rs7074356	0.569	rs7090863	chr10:82021393	C/A	cg27171509	chr10:82033454	MAT1A	-0.49	-6.86	-0.32	2.41e-11	Borderline personality disorder;
LUAD	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg22491629	chr6:157744540	C6orf35	-0.82	-9.51	-0.42	1.46e-19	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg07917127	chr4:99064746	C4orf37	0.41	6.89	0.32	2.01e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.16	0.33	3.58e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4889855	0.556	rs4890043	chr17:78526831	C/T	cg16591659	chr17:78472290	NA	0.37	6.55	0.3	1.66e-10	Fractional excretion of uric acid;
LUAD	cis	rs7481584	1.000	rs7481584	chr11:3029089	G/A	cg11201177	chr11:2961805	NA	0.39	6.61	0.31	1.2e-10	Calcium levels;
LUAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg11494091	chr17:61959527	GH2	0.74	18.45	0.67	3.25e-56	Prudent dietary pattern;
LUAD	cis	rs17102423	0.755	rs4902358	chr14:65542477	A/G	cg11161011	chr14:65562177	MAX	-0.48	-7.72	-0.35	8.45e-14	Obesity-related traits;
LUAD	cis	rs78761021	0.792	rs62064479	chr17:9794101	G/C	cg26853458	chr17:9805074	RCVRN	0.37	7.02	0.32	9.12e-12	Type 2 diabetes;
LUAD	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.92	0.32	1.71e-11	Rheumatoid arthritis;
LUAD	trans	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.29e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg26875233	chr11:93583750	C11orf90	-0.39	-8.85	-0.4	2.36e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs7665090	0.870	rs228627	chr4:103573082	C/T	cg07973026	chr4:103553119	MANBA	-0.41	-7.12	-0.33	4.58e-12	Primary biliary cholangitis;
LUAD	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg23758822	chr17:41437982	NA	0.99	20.3	0.7	1.77e-64	Menopause (age at onset);
LUAD	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-9.24	-0.41	1.24e-18	Platelet count;
LUAD	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg06002616	chr8:101225028	SPAG1	-0.39	-8.04	-0.36	8.81e-15	Atrioventricular conduction;
LUAD	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.42	6.94	0.32	1.48e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg23018236	chr17:30244563	NA	0.63	7.93	0.36	2.04e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg25208724	chr1:156163844	SLC25A44	1.1	20.71	0.71	2.63e-66	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.41	0.42	3.22e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg15117754	chr3:10150083	C3orf24	0.4	6.66	0.31	8.79e-11	Alzheimer's disease;
LUAD	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg21475434	chr5:93447410	FAM172A	-0.48	-6.55	-0.3	1.63e-10	Diabetic retinopathy;
LUAD	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg04944784	chr2:26401820	FAM59B	-0.89	-12.57	-0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs72845660	1.000	rs17780667	chr10:104076231	C/T	cg20641465	chr10:103991465	PITX3	-0.47	-6.73	-0.31	5.55e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg20290983	chr6:43655470	MRPS18A	1.08	27.63	0.8	8.57e-97	IgG glycosylation;
LUAD	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg22920501	chr2:26401640	FAM59B	-0.81	-11.43	-0.49	1.48e-26	Gut microbiome composition (summer);
LUAD	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg06766960	chr11:133703094	NA	-0.38	-7.18	-0.33	3.07e-12	Childhood ear infection;
LUAD	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg15704280	chr7:45808275	SEPT13	-0.87	-16.21	-0.62	2.62e-46	Coronary artery disease;
LUAD	cis	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg21775007	chr8:11205619	TDH	0.57	10.4	0.45	1.07e-22	Retinal vascular caliber;
LUAD	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg03806693	chr22:41940476	POLR3H	-0.75	-9.79	-0.43	1.54e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06505273	chr16:24850292	NA	0.51	7.58	0.35	2.14e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs977987	0.843	rs28655617	chr16:75489642	G/A	cg03315344	chr16:75512273	CHST6	0.65	14.08	0.57	3.24e-37	Dupuytren's disease;
LUAD	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg10544611	chr16:67998164	SLC12A4	-0.69	-8.27	-0.37	1.75e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg05717871	chr11:638507	DRD4	-0.45	-6.53	-0.3	1.94e-10	Systemic lupus erythematosus;
LUAD	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg02931644	chr1:25747376	RHCE	0.42	8.73	0.39	5.89e-17	Erythrocyte sedimentation rate;
LUAD	cis	rs8017423	0.933	rs7150378	chr14:90724566	G/A	cg14092571	chr14:90743983	NA	-0.49	-8.63	-0.39	1.23e-16	Mortality in heart failure;
LUAD	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg01416388	chr22:39784598	NA	-0.53	-8.95	-0.4	1.17e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg04234412	chr22:24373322	LOC391322	-0.83	-15.26	-0.6	3.42e-42	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6005807	0.719	rs7289625	chr22:28896546	G/A	cg12565055	chr22:29076175	TTC28	0.71	7.86	0.36	3.28e-14	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-9.2	-0.41	1.69e-18	Alzheimer's disease;
LUAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg17178900	chr1:205818956	PM20D1	0.4	6.64	0.31	9.88e-11	Parkinson's disease;
LUAD	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg18811423	chr2:55921094	PNPT1	0.47	7.58	0.35	2.21e-13	Metabolic syndrome;
LUAD	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg21605333	chr4:119757512	SEC24D	0.81	7.78	0.35	5.59e-14	Cannabis dependence symptom count;
LUAD	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg11833968	chr6:79620685	NA	-0.44	-8.25	-0.37	1.97e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs3761168	0.590	rs6140787	chr20:8873576	C/T	cg24570042	chr15:51634583	GLDN	0.64	6.39	0.3	4.4e-10	Social communication problems;
LUAD	cis	rs12474201	0.894	rs4952842	chr2:46925730	C/A	cg09399716	chr2:46890238	NA	-0.37	-6.87	-0.32	2.31e-11	Height;
LUAD	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg23950597	chr19:37808831	NA	-0.62	-7.42	-0.34	6.54e-13	Coronary artery calcification;
LUAD	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.84e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1448094	0.802	rs11117146	chr12:86382870	C/T	cg19622623	chr12:86230825	RASSF9	0.39	7.09	0.33	5.5e-12	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1395	0.848	rs6716850	chr2:27525350	G/A	cg23587288	chr2:27483067	SLC30A3	-0.37	-7.13	-0.33	4.29e-12	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg18811423	chr2:55921094	PNPT1	0.55	9.31	0.41	6.8e-19	Metabolic syndrome;
LUAD	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.86	-0.5	3.42e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs887829	0.667	rs7577677	chr2:234590616	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-9.76	-0.43	1.97e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg09835421	chr16:68378352	PRMT7	-0.72	-8.16	-0.37	4.01e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg05887092	chr17:76393375	PGS1	0.41	7.28	0.33	1.65e-12	HDL cholesterol levels;
LUAD	cis	rs4243830	1.000	rs12046884	chr1:6594561	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	0.77	8.42	0.38	6.09e-16	Body mass index;
LUAD	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg09491104	chr22:46646882	C22orf40	-0.69	-12.92	-0.53	2.03e-32	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg15704280	chr7:45808275	SEPT13	-0.53	-8.37	-0.38	8.75e-16	HDL cholesterol;
LUAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg09436375	chr6:42928200	GNMT	-0.29	-8.28	-0.37	1.69e-15	Plasma homocysteine levels (post-methionine load test);
LUAD	cis	rs2531992	0.800	rs2907272	chr16:4019350	C/T	cg08098950	chr16:4033226	ADCY9	-0.45	-6.42	-0.3	3.68e-10	Waist circumference;
LUAD	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06544989	chr22:39130855	UNC84B	0.44	8.23	0.37	2.29e-15	Menopause (age at onset);
LUAD	cis	rs2455799	0.613	rs11128760	chr3:15873407	A/G	cg16303742	chr3:15540471	COLQ	-0.52	-9.56	-0.42	9.56e-20	Mean platelet volume;
LUAD	cis	rs2663905	0.611	rs2663924	chr15:81392903	T/G	cg09888468	chr15:81410853	NA	-0.55	-9.71	-0.43	3.05e-20	QT interval (drug interaction);
LUAD	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg21724239	chr8:58056113	NA	0.57	7.39	0.34	7.94e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg18252515	chr7:66147081	NA	0.61	6.67	0.31	7.98e-11	Diabetic kidney disease;
LUAD	cis	rs4691139	1.000	rs12498808	chr4:165906905	T/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.44	-8.74	-0.39	5.52e-17	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9914988	0.945	rs9279	chr17:27187636	G/T	cg20469991	chr17:27169893	C17orf63	0.51	6.61	0.31	1.2e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg02018176	chr4:1364513	KIAA1530	0.37	7.07	0.32	6.59e-12	Obesity-related traits;
LUAD	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.27	-6.84	-0.32	2.85e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg24503407	chr1:205819492	PM20D1	0.78	15.79	0.61	1.68e-44	Menarche (age at onset);
LUAD	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg13385794	chr1:248469461	NA	0.26	6.78	0.31	4.11e-11	Common traits (Other);
LUAD	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.98	0.53	1.2e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg04944784	chr2:26401820	FAM59B	-0.72	-10.14	-0.44	9.13e-22	Gut microbiome composition (summer);
LUAD	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg05834845	chr3:195489306	MUC4	0.63	7.6	0.35	1.9e-13	Lung disease severity in cystic fibrosis;
LUAD	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg20587970	chr11:113659929	NA	-1.38	-20.5	-0.71	2.42e-65	Hip circumference adjusted for BMI;
LUAD	cis	rs9443645	0.611	rs10943616	chr6:79823541	G/A	cg09184832	chr6:79620586	NA	-0.4	-6.55	-0.3	1.72e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs16910800	0.953	rs77585463	chr11:23205379	T/C	cg20040320	chr11:23191996	NA	-0.5	-7.38	-0.34	8.25e-13	Cancer;
LUAD	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg23018236	chr17:30244563	NA	-0.61	-7.88	-0.36	2.85e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08280861	chr8:58055591	NA	0.68	8.39	0.38	7.28e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs2294693	0.530	rs9381034	chr6:41049508	T/C	cg14769373	chr6:40998127	UNC5CL	-0.6	-8.4	-0.38	6.75e-16	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg27170947	chr2:26402098	FAM59B	-0.69	-9.5	-0.42	1.62e-19	Gut microbiome composition (summer);
LUAD	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg04756594	chr16:24857601	SLC5A11	0.53	10.22	0.45	4.54e-22	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06640728	chr7:1512940	INTS1	0.49	6.37	0.3	5.08e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg06558623	chr16:89946397	TCF25	1.15	10.72	0.46	7.17e-24	Skin colour saturation;
LUAD	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg26022315	chr17:47021804	SNF8	0.4	7.29	0.33	1.5e-12	Type 2 diabetes;
LUAD	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.57	-8.46	-0.38	4.55e-16	Alzheimer's disease (late onset);
LUAD	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg09365446	chr1:150670422	GOLPH3L	0.54	9.57	0.42	9.3e-20	Melanoma;
LUAD	cis	rs78456975	0.699	rs17091772	chr2:1519679	A/C	cg01028140	chr2:1542097	TPO	-0.49	-6.76	-0.31	4.65e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg20744362	chr22:50050164	C22orf34	0.43	9.49	0.42	1.73e-19	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg18306943	chr3:40428807	ENTPD3	0.41	7.38	0.34	8.62e-13	Renal cell carcinoma;
LUAD	trans	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg13698153	chr12:118541722	VSIG10	0.42	6.57	0.3	1.46e-10	Vitiligo;
LUAD	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-6.96	-0.32	1.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4072705	1.000	rs10818987	chr9:127520729	T/C	cg13476313	chr9:127244764	NR5A1	0.29	6.99	0.32	1.07e-11	Menarche (age at onset);
LUAD	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg00074818	chr8:8560427	CLDN23	0.66	10.19	0.44	6.13e-22	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.7	0.31	6.74e-11	Depression;
LUAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg13047869	chr3:10149882	C3orf24	0.67	10.02	0.44	2.37e-21	Alzheimer's disease;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg14668821	chr17:77704760	ENPP7	0.32	6.47	0.3	2.75e-10	Menopause (age at onset);
LUAD	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg03037974	chr15:76606532	NA	0.48	11.25	0.48	7.43e-26	Blood metabolite levels;
LUAD	trans	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.63	0.46	1.52e-23	Mean corpuscular volume;
LUAD	cis	rs3916	0.955	rs35525135	chr12:121140064	T/C	cg27246729	chr12:121163418	ACADS	0.47	7.67	0.35	1.18e-13	Urinary metabolites (H-NMR features);
LUAD	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg03477792	chr4:77819574	ANKRD56	0.48	7.3	0.33	1.45e-12	Emphysema distribution in smoking;
LUAD	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg12863693	chr15:85201151	NMB	0.44	8.17	0.37	3.6e-15	Schizophrenia;
LUAD	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03517284	chr6:25882590	NA	-0.58	-9.56	-0.42	1.02e-19	Blood metabolite levels;
LUAD	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19717773	chr7:2847554	GNA12	-0.58	-9.97	-0.44	3.62e-21	Height;
LUAD	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg14949292	chr17:78079608	GAA	-0.34	-6.36	-0.3	5.13e-10	Yeast infection;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17417054	chr1:36235406	CLSPN	-0.42	-6.81	-0.31	3.39e-11	Cancer;
LUAD	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg15309053	chr8:964076	NA	0.34	7.57	0.35	2.33e-13	Schizophrenia;
LUAD	cis	rs7944584	0.552	rs12361415	chr11:47474146	T/G	cg20307385	chr11:47447363	PSMC3	0.53	7.79	0.35	5.38e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs1448094	0.967	rs10779222	chr12:86330775	G/A	cg02569458	chr12:86230093	RASSF9	0.37	7.07	0.33	6.27e-12	Major depressive disorder;
LUAD	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg03959625	chr15:84868606	LOC388152	0.4	6.37	0.3	4.98e-10	Schizophrenia;
LUAD	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg16850897	chr7:100343110	ZAN	-0.59	-8.17	-0.37	3.56e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs476633	0.708	rs9888708	chr15:41446030	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.6	-10.78	-0.46	4.17e-24	Glomerular filtration rate (creatinine);
LUAD	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg18230493	chr5:56204884	C5orf35	-0.72	-10.58	-0.46	2.26e-23	Initial pursuit acceleration;
LUAD	cis	rs12545109	0.842	rs2609975	chr8:57401667	T/C	cg17761419	chr8:57350749	NA	-0.54	-7.93	-0.36	1.98e-14	Obesity-related traits;
LUAD	cis	rs1032833	0.732	rs79640162	chr2:180005464	T/C	cg23883738	chr2:179974586	SESTD1	-0.68	-7.64	-0.35	1.5e-13	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg08859206	chr1:53392774	SCP2	-0.6	-10.85	-0.47	2.35e-24	Monocyte count;
LUAD	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg02018176	chr4:1364513	KIAA1530	0.37	6.4	0.3	4.09e-10	Obesity-related traits;
LUAD	cis	rs6547631	0.622	rs34943381	chr2:85923997	A/G	cg21473183	chr2:85925749	GNLY	0.35	7.59	0.35	2.1e-13	Blood protein levels;
LUAD	cis	rs11048434	0.736	rs2377672	chr12:9112414	A/G	cg04155231	chr12:9217510	LOC144571	0.4	7.51	0.34	3.49e-13	Sjögren's syndrome;
LUAD	cis	rs7809950	0.954	rs2712229	chr7:107295326	T/A	cg23024343	chr7:107201750	COG5	0.64	10.59	0.46	2.08e-23	Coronary artery disease;
LUAD	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg03676636	chr4:99064102	C4orf37	0.29	6.95	0.32	1.35e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13064411	0.518	rs2669909	chr3:113265727	A/G	cg18753928	chr3:113234510	CCDC52	0.44	7.98	0.36	1.36e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg00745463	chr17:30367425	LRRC37B	-0.83	-10.11	-0.44	1.15e-21	Hip circumference adjusted for BMI;
LUAD	cis	rs77972916	0.561	rs13411629	chr2:43566990	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-6.82	-0.31	3.2e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	6.73	0.31	5.57e-11	Mood instability;
LUAD	cis	rs8077889	0.750	rs34462326	chr17:41932210	T/C	cg26893861	chr17:41843967	DUSP3	0.88	11.38	0.48	2.36e-26	Triglycerides;
LUAD	cis	rs61990749	0.597	rs10136053	chr14:78155205	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.48	-6.39	-0.3	4.31e-10	Fibroblast growth factor basic levels;
LUAD	cis	rs2046867	0.862	rs11922180	chr3:72836119	A/G	cg04365224	chr3:72788183	NA	0.48	7.29	0.33	1.51e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1448094	0.933	rs10779218	chr12:86320053	A/G	cg18827107	chr12:86230957	RASSF9	-0.43	-7.87	-0.36	3.04e-14	Major depressive disorder;
LUAD	cis	rs73086581	0.787	rs68127408	chr20:3868447	T/C	cg02187196	chr20:3869020	PANK2	0.54	7.64	0.35	1.44e-13	Response to antidepressants in depression;
LUAD	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg17074396	chr22:49843754	NA	-0.31	-6.5	-0.3	2.26e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg25173405	chr17:45401733	C17orf57	0.45	7.7	0.35	9.47e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4604732	0.589	rs78689516	chr1:247626274	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs1728785	1.000	rs1069288	chr16:68585285	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.85	0.43	9.79e-21	Ulcerative colitis;
LUAD	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg25894440	chr7:65020034	NA	-0.61	-6.5	-0.3	2.26e-10	Diabetic kidney disease;
LUAD	cis	rs6541297	1.000	rs6665260	chr1:230279067	G/T	cg20703242	chr1:230279135	GALNT2	0.66	12.26	0.51	8.85e-30	Coronary artery disease;
LUAD	cis	rs77861329	0.670	rs9828327	chr3:52120209	T/C	cg08692210	chr3:52188851	WDR51A	0.55	6.95	0.32	1.36e-11	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.24	0.37	2.17e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg27432699	chr2:27873401	GPN1	0.57	9.91	0.43	5.94e-21	Oral cavity cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22776125	chr6:167041314	RPS6KA2	-0.45	-7.09	-0.33	5.77e-12	Height;
LUAD	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06028808	chr11:68637592	NA	0.49	8.34	0.38	1.06e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.16	0.41	2.24e-18	Alzheimer's disease;
LUAD	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	8.2	0.37	2.97e-15	Colorectal cancer;
LUAD	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg13126279	chr21:47581558	C21orf56	-0.44	-7.54	-0.34	2.94e-13	Testicular germ cell tumor;
LUAD	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.61	8.54	0.38	2.38e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs3812049	0.506	rs36694	chr5:127548955	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.48	6.74	0.31	5.13e-11	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg21798802	chr22:38057573	PDXP	0.49	9.94	0.44	4.69e-21	Fat distribution (HIV);
LUAD	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg03037974	chr15:76606532	NA	0.37	7.89	0.36	2.58e-14	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.01	0.32	9.52e-12	Motion sickness;
LUAD	cis	rs12545109	0.800	rs1968551	chr8:57407760	T/C	cg17761419	chr8:57350749	NA	-0.53	-7.58	-0.35	2.26e-13	Obesity-related traits;
LUAD	cis	rs68170813	0.559	rs77605964	chr7:106962948	G/A	cg23024343	chr7:107201750	COG5	0.49	6.95	0.32	1.38e-11	Coronary artery disease;
LUAD	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs35883536	0.647	rs10875313	chr1:101043057	T/C	cg06223162	chr1:101003688	GPR88	-0.47	-8.99	-0.4	8.64e-18	Monocyte count;
LUAD	cis	rs12912251	1.000	rs12901215	chr15:38992893	G/A	cg01338139	chr15:38987640	C15orf53	-0.58	-9.13	-0.41	2.75e-18	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs4493873	1.000	rs4568579	chr8:92072144	T/C	cg16814680	chr8:91681699	NA	0.43	6.82	0.31	3.07e-11	Migraine - clinic-based;
LUAD	cis	rs7903847	0.620	rs954149	chr10:99122936	G/A	cg20016023	chr10:99160130	RRP12	-0.28	-6.81	-0.31	3.41e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg05434287	chr7:2030229	MAD1L1	0.42	6.88	0.32	2.23e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs7395662	1.000	rs4882096	chr11:48534102	T/G	cg00717180	chr2:96193071	NA	-0.4	-7.48	-0.34	4.34e-13	HDL cholesterol;
LUAD	cis	rs1595825	0.945	rs2139050	chr2:198852636	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-7.28	-0.33	1.65e-12	Ulcerative colitis;
LUAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg07685180	chr8:600429	NA	0.86	8.61	0.39	1.41e-16	IgG glycosylation;
LUAD	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg27572855	chr1:25598939	RHD	0.55	11.6	0.49	3.42e-27	Erythrocyte sedimentation rate;
LUAD	cis	rs13064411	0.696	rs1552432	chr3:113225660	G/C	cg10517650	chr3:113235015	CCDC52	-0.56	-9.59	-0.42	7.81e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs13088645	0.729	rs7620040	chr3:134163082	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-8.4	-0.38	6.82e-16	Coronary artery disease;
LUAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg23958373	chr8:599963	NA	1.1	10.72	0.46	6.92e-24	IgG glycosylation;
LUAD	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg13390004	chr1:15929781	NA	-0.49	-8.22	-0.37	2.58e-15	Systolic blood pressure;
LUAD	cis	rs427394	0.582	rs4701751	chr5:6704137	C/T	cg14682080	chr5:6737778	POLS	0.34	7.32	0.34	1.28e-12	Menopause (age at onset);
LUAD	cis	rs62400317	0.859	rs12212745	chr6:45166258	C/T	cg18551225	chr6:44695536	NA	-0.55	-8.4	-0.38	6.63e-16	Total body bone mineral density;
LUAD	cis	rs169797	0.748	rs372769	chr20:31938224	A/C	cg13403462	chr20:32256071	NECAB3;C20orf134	0.43	6.4	0.3	4.17e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11644478	chr21:40555479	PSMG1	0.4	6.54	0.3	1.77e-10	Cognitive function;
LUAD	cis	rs2797685	0.898	rs3753503	chr1:7841971	G/A	cg04725166	chr1:7887271	PER3	-0.5	-7.3	-0.33	1.48e-12	Crohn's disease;
LUAD	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg04944784	chr2:26401820	FAM59B	-0.71	-10.03	-0.44	2.15e-21	Gut microbiome composition (summer);
LUAD	trans	rs1493916	0.905	rs12455290	chr18:31398778	A/G	cg27147174	chr7:100797783	AP1S1	-0.72	-13.0	-0.53	9.84e-33	Life satisfaction;
LUAD	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06544989	chr22:39130855	UNC84B	0.45	8.46	0.38	4.49e-16	Menopause (age at onset);
LUAD	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg05342682	chr7:94953680	PON1	-0.5	-7.01	-0.32	9.29e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg23231163	chr10:75533350	FUT11	-0.51	-9.37	-0.41	4.29e-19	Inflammatory bowel disease;
LUAD	cis	rs7010267	0.544	rs6984287	chr8:120054122	C/G	cg01975934	chr8:119970761	NA	-0.33	-6.4	-0.3	4.14e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.34	-9.11	-0.4	3.35e-18	Total body bone mineral density;
LUAD	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg07343612	chr16:622815	PIGQ	-0.82	-15.59	-0.6	1.29e-43	Height;
LUAD	cis	rs921968	0.565	rs6436081	chr2:219637884	A/G	cg02176678	chr2:219576539	TTLL4	-0.57	-11.29	-0.48	5.24e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.8	0.56	4.76e-36	Prudent dietary pattern;
LUAD	cis	rs2742234	0.541	rs7096500	chr10:43712095	C/T	cg15436174	chr10:43711423	RASGEF1A	0.55	9.02	0.4	6.55e-18	Hirschsprung disease;
LUAD	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg00383909	chr3:49044727	WDR6	0.82	8.1	0.37	6.09e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs72928364	1.000	rs41273557	chr3:100621683	T/A	cg10123952	chr3:100791384	NA	0.63	7.24	0.33	2.2e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg17724175	chr1:150552817	MCL1	0.37	8.37	0.38	8.58e-16	Melanoma;
LUAD	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg04287289	chr16:89883240	FANCA	0.43	6.49	0.3	2.45e-10	Vitiligo;
LUAD	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg00981070	chr1:2046702	PRKCZ	0.37	6.97	0.32	1.23e-11	Height;
LUAD	cis	rs12216545	0.765	rs12538768	chr7:150250000	A/G	cg08960815	chr7:150264767	GIMAP4	-0.29	-6.39	-0.3	4.27e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2579500	0.807	rs6576978	chr2:97285852	C/T	cg23100626	chr2:96804247	ASTL	-0.29	-7.18	-0.33	3.11e-12	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs2652834	0.851	rs4468558	chr15:63346681	T/C	cg25406657	chr15:63342033	TPM1	-0.42	-6.71	-0.31	6.14e-11	HDL cholesterol;
LUAD	cis	rs3106136	0.967	rs2664892	chr4:95154186	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.59	-0.35	2.08e-13	Capecitabine sensitivity;
LUAD	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg22105103	chr4:187893119	NA	0.54	11.49	0.49	8.62e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg13263323	chr15:86062960	AKAP13	-0.51	-9.26	-0.41	1.03e-18	Coronary artery disease;
LUAD	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg01200585	chr1:228362443	C1orf69	0.45	7.34	0.34	1.13e-12	Diastolic blood pressure;
LUAD	cis	rs4631830	0.863	rs4554834	chr10:51530146	A/C	cg20129853	chr10:51489980	NA	-0.32	-6.39	-0.3	4.35e-10	Prostate-specific antigen levels;
LUAD	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg27432699	chr2:27873401	GPN1	0.58	10.24	0.45	3.81e-22	Oral cavity cancer;
LUAD	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg10057126	chr4:77819792	ANKRD56	0.55	9.65	0.42	4.94e-20	Emphysema distribution in smoking;
LUAD	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg11822812	chr5:140052017	DND1	0.42	7.72	0.35	8.51e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg10802521	chr3:52805072	NEK4	0.46	6.57	0.3	1.5e-10	Schizophrenia;
LUAD	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg21770322	chr7:97807741	LMTK2	0.35	8.24	0.37	2.13e-15	Breast cancer;
LUAD	cis	rs13315871	1.000	rs9844128	chr3:58391127	C/T	cg20936604	chr3:58311152	NA	-0.67	-6.77	-0.31	4.23e-11	Cholesterol, total;
LUAD	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.14	-0.54	2.51e-33	Breast cancer;
LUAD	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg00684032	chr4:1343700	KIAA1530	0.38	6.4	0.3	4.08e-10	Obesity-related traits;
LUAD	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg22532475	chr10:104410764	TRIM8	-0.36	-7.29	-0.33	1.58e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2286503	0.839	rs4722189	chr7:22860474	G/A	cg06496272	chr7:22895283	SNORD93	-0.41	-7.25	-0.33	1.99e-12	Fibrinogen;
LUAD	trans	rs1904173	0.866	rs10069227	chr5:25355273	G/C	cg08850729	chr1:60036715	FGGY	0.63	6.73	0.31	5.59e-11	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg03929089	chr4:120376271	NA	-0.98	-19.94	-0.7	7.25e-63	Height;
LUAD	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg12564285	chr5:131593104	PDLIM4	0.37	6.9	0.32	1.86e-11	Acylcarnitine levels;
LUAD	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg21724239	chr8:58056113	NA	0.71	9.3	0.41	7.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.7	0.35	9.77e-14	Breast cancer;
LUAD	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg03609598	chr5:56110824	MAP3K1	0.53	6.66	0.31	8.5e-11	Initial pursuit acceleration;
LUAD	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg17173187	chr15:85201210	NMB	-0.32	-6.41	-0.3	3.91e-10	P wave terminal force;
LUAD	cis	rs62238980	0.614	rs117959136	chr22:32373225	T/C	cg00543991	chr22:32367038	NA	0.91	8.21	0.37	2.8e-15	Childhood ear infection;
LUAD	cis	rs10193935	0.901	rs10169411	chr2:42637749	G/A	cg27598129	chr2:42591480	NA	-0.7	-8.93	-0.4	1.34e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9517320	0.517	rs4772097	chr13:99194652	C/A	cg07423050	chr13:99094983	FARP1	-0.52	-8.69	-0.39	7.74e-17	Longevity;
LUAD	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs11811982	0.793	rs77168416	chr1:227321838	T/G	cg24860534	chr1:227506868	CDC42BPA	0.66	7.22	0.33	2.41e-12	Optic disc area;
LUAD	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg00310523	chr12:86230176	RASSF9	0.38	7.8	0.35	5.05e-14	Major depressive disorder;
LUAD	cis	rs2404602	0.530	rs11072614	chr15:76967205	G/A	cg00316803	chr15:76480434	C15orf27	0.46	7.0	0.32	9.92e-12	Blood metabolite levels;
LUAD	cis	rs73416724	1.000	rs79329802	chr6:43387332	G/A	cg26312998	chr6:43337775	ZNF318	0.56	6.82	0.31	3.14e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg06552810	chr11:31128660	NA	-0.33	-6.49	-0.3	2.36e-10	Red blood cell count;
LUAD	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.17	0.37	3.58e-15	Menopause (age at onset);
LUAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.64	-9.37	-0.41	4.54e-19	Alzheimer's disease;
LUAD	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg00277334	chr10:82204260	NA	0.6	10.03	0.44	2.17e-21	Post bronchodilator FEV1;
LUAD	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg05805236	chr11:65401703	PCNXL3	-0.54	-8.98	-0.4	8.86e-18	Acne (severe);
LUAD	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg08085267	chr17:45401833	C17orf57	-0.51	-8.53	-0.38	2.62e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs859767	0.704	rs9287437	chr2:135357502	C/T	cg12500956	chr2:135428796	TMEM163	-0.3	-7.88	-0.36	2.88e-14	Neuroticism;
LUAD	trans	rs9393777	0.778	rs13219354	chr6:27185664	T/C	cg01620082	chr3:125678407	NA	-0.84	-8.87	-0.4	2.15e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.42	-7.63	-0.35	1.58e-13	Longevity;Endometriosis;
LUAD	cis	rs9581857	0.725	rs1924074	chr13:28015387	C/G	cg22138327	chr13:27999177	GTF3A	-0.91	-10.59	-0.46	2.1e-23	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg24675658	chr1:53192096	ZYG11B	-0.39	-6.56	-0.3	1.58e-10	Monocyte count;
LUAD	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg06640241	chr16:89574553	SPG7	0.44	6.96	0.32	1.29e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg05340658	chr4:99064831	C4orf37	0.54	9.18	0.41	1.91e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62238980	0.614	rs117721418	chr22:32394519	C/T	cg00543991	chr22:32367038	NA	0.92	8.16	0.37	3.95e-15	Childhood ear infection;
LUAD	cis	rs7186908	1.000	rs7186908	chr16:72220373	G/C	cg23815491	chr16:72088622	HP	0.53	8.15	0.37	4.26e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg17264618	chr3:40429014	ENTPD3	0.42	8.86	0.4	2.29e-17	Renal cell carcinoma;
LUAD	trans	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.65	-0.46	1.24e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg05425664	chr17:57184151	TRIM37	0.43	7.68	0.35	1.12e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg05922057	chr17:4047571	ZZEF1;CYB5D2	-0.39	-6.76	-0.31	4.68e-11	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg18187862	chr3:45730750	SACM1L	0.5	7.76	0.35	6.57e-14	Primary sclerosing cholangitis;
LUAD	cis	rs4711336	0.935	rs754404	chr6:33664730	T/C	cg14003231	chr6:33640908	ITPR3	0.49	9.49	0.42	1.7e-19	Height;
LUAD	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg12311346	chr5:56204834	C5orf35	0.46	7.55	0.34	2.75e-13	Coronary artery disease;
LUAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg13560548	chr3:10150139	C3orf24	0.44	7.22	0.33	2.47e-12	Alzheimer's disease;
LUAD	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg06608945	chr2:219082296	ARPC2	-0.39	-6.41	-0.3	3.85e-10	Colorectal cancer;
LUAD	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg03859395	chr2:55845619	SMEK2	0.75	14.14	0.57	1.83e-37	Metabolic syndrome;
LUAD	cis	rs4919694	1.000	rs12241091	chr10:104808997	G/A	cg04362960	chr10:104952993	NT5C2	0.73	7.86	0.36	3.28e-14	Arsenic metabolism;
LUAD	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg20290983	chr6:43655470	MRPS18A	1.06	26.75	0.79	5.33e-93	IgG glycosylation;
LUAD	cis	rs250677	0.687	rs2963485	chr5:148452043	A/G	cg18129178	chr5:148520854	ABLIM3	0.54	8.43	0.38	5.55e-16	Breast cancer;
LUAD	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg08999081	chr20:33150536	PIGU	0.44	8.73	0.39	5.89e-17	Coronary artery disease;
LUAD	cis	rs6430585	0.591	rs12475553	chr2:136483355	G/T	cg07169764	chr2:136633963	MCM6	0.71	7.87	0.36	3.09e-14	Corneal structure;
LUAD	cis	rs7680126	0.536	rs7661701	chr4:10064098	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	7.64	0.35	1.48e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.63	0.31	1.04e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13315871	0.929	rs2056120	chr3:58309436	A/T	cg20936604	chr3:58311152	NA	-0.77	-8.41	-0.38	6.4e-16	Cholesterol, total;
LUAD	cis	rs490234	0.783	rs4838278	chr9:128403509	T/C	cg14078157	chr9:128172775	NA	-0.39	-6.83	-0.32	2.88e-11	Mean arterial pressure;
LUAD	trans	rs2270927	0.510	rs2358712	chr5:75580687	A/G	cg13563193	chr19:33072644	PDCD5	0.97	9.05	0.4	5.13e-18	Mean corpuscular volume;
LUAD	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg23301539	chr8:142222248	SLC45A4	0.5	9.02	0.4	6.39e-18	Immature fraction of reticulocytes;
LUAD	cis	rs300774	1.000	rs146562	chr2:119663	T/G	cg21211680	chr2:198530	NA	-0.49	-7.05	-0.32	7.44e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.6	10.39	0.45	1.15e-22	Lymphocyte counts;
LUAD	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg15790184	chr11:494944	RNH1	0.4	6.6	0.31	1.24e-10	Systemic lupus erythematosus;
LUAD	cis	rs1062746	1.000	rs1062746	chr16:87364650	A/G	cg02258303	chr16:87377426	FBXO31	-0.43	-7.41	-0.34	6.86e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg05425664	chr17:57184151	TRIM37	-0.43	-7.76	-0.35	6.53e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs62238980	0.614	rs117581209	chr22:32420212	T/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.02	-0.36	1.02e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg09033563	chr22:24373618	LOC391322	0.56	8.85	0.4	2.35e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg13722127	chr7:150037890	RARRES2	0.44	7.24	0.33	2.18e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1448094	0.617	rs1393612	chr12:86474576	T/C	cg18827107	chr12:86230957	RASSF9	0.5	8.92	0.4	1.43e-17	Major depressive disorder;
LUAD	cis	rs10916814	0.632	rs4655224	chr1:20902195	A/C	cg24502330	chr1:20914028	CDA	-0.36	-7.1	-0.33	5.32e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg17644776	chr2:200775616	C2orf69	0.48	7.54	0.34	2.95e-13	Osteoporosis;
LUAD	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg19767477	chr5:127420684	SLC12A2	-0.42	-6.52	-0.3	1.99e-10	Ileal carcinoids;
LUAD	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg21862992	chr11:68658383	NA	0.53	9.67	0.43	4.07e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg23625390	chr15:77176239	SCAPER	0.39	6.89	0.32	2.03e-11	Blood metabolite levels;
LUAD	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg26513180	chr16:89883248	FANCA	0.73	13.92	0.56	1.51e-36	Vitiligo;
LUAD	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg07217954	chr7:1067459	C7orf50	-0.38	-6.91	-0.32	1.79e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs7527798	0.592	rs6684643	chr1:207846242	A/T	cg09232269	chr1:207846808	CR1L	-0.37	-6.96	-0.32	1.28e-11	Erythrocyte sedimentation rate;
LUAD	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg15147215	chr3:52552868	STAB1	-0.4	-7.18	-0.33	3.23e-12	Bipolar disorder;
LUAD	cis	rs600231	0.542	rs10896009	chr11:65246054	A/G	cg17120908	chr11:65337727	SSSCA1	0.57	7.62	0.35	1.65e-13	Bone mineral density;
LUAD	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg00922110	chr4:57842668	C4orf14	-0.42	-7.21	-0.33	2.56e-12	Response to bleomycin (chromatid breaks);
LUAD	trans	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg06606381	chr12:133084897	FBRSL1	-0.88	-8.43	-0.38	5.63e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3204270	0.810	rs62077191	chr17:79678063	A/G	cg18367735	chr17:79674897	NA	0.59	6.92	0.32	1.66e-11	Dental caries;
LUAD	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.94	-0.32	1.52e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg05872129	chr22:39784769	NA	0.47	6.72	0.31	5.95e-11	IgG glycosylation;
LUAD	cis	rs9535307	0.719	rs1198319	chr13:50376858	T/C	cg04663916	chr13:50265991	EBPL	-0.6	-6.82	-0.31	3.13e-11	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.53e-11	Depression;
LUAD	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg09060608	chr5:178986726	RUFY1	-0.66	-11.91	-0.5	2.14e-28	Lung cancer;
LUAD	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.16	0.33	3.63e-12	Prostate cancer;
LUAD	trans	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg26811252	chr16:29126840	RRN3P2	0.6	10.02	0.44	2.4e-21	Menopause (age at onset);
LUAD	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg15147215	chr3:52552868	STAB1	-0.41	-7.43	-0.34	6.14e-13	Bipolar disorder;
LUAD	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg18827107	chr12:86230957	RASSF9	-0.67	-12.4	-0.52	2.53e-30	Major depressive disorder;
LUAD	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Depression;
LUAD	cis	rs13315871	0.929	rs13101057	chr3:58291467	A/G	cg20936604	chr3:58311152	NA	-0.75	-7.61	-0.35	1.82e-13	Cholesterol, total;
LUAD	cis	rs62400317	0.859	rs17209741	chr6:45292438	A/T	cg18551225	chr6:44695536	NA	-0.53	-8.39	-0.38	7.2e-16	Total body bone mineral density;
LUAD	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg06131755	chr6:160182447	ACAT2	0.43	6.4	0.3	4.18e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg10792982	chr14:105748885	BRF1	0.44	9.34	0.41	5.5e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7809950	0.678	rs2237665	chr7:106906998	T/C	cg23024343	chr7:107201750	COG5	-0.81	-13.81	-0.56	4.5e-36	Coronary artery disease;
LUAD	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg12011299	chr4:100065546	ADH4	-0.73	-13.69	-0.55	1.47e-35	Alcohol dependence;
LUAD	cis	rs73416724	1.000	rs112870457	chr6:43280714	T/G	cg26312998	chr6:43337775	ZNF318	0.55	6.58	0.3	1.36e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg00495681	chr13:53174319	NA	0.71	14.11	0.57	2.6e-37	Lewy body disease;
LUAD	cis	rs7927592	0.830	rs11228240	chr11:68218290	C/T	cg20283391	chr11:68216788	NA	-0.44	-6.75	-0.31	5e-11	Total body bone mineral density;
LUAD	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.52	-8.98	-0.4	9.24e-18	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg20587970	chr11:113659929	NA	-1.42	-21.6	-0.72	2.9e-70	Hip circumference adjusted for BMI;
LUAD	cis	rs9556958	0.708	rs4772092	chr13:99166614	A/G	cg07423050	chr13:99094983	FARP1	-0.39	-6.97	-0.32	1.2e-11	Educational attainment (years of education);
LUAD	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.09	0.33	5.52e-12	Parkinson's disease;
LUAD	cis	rs597583	0.715	rs4938399	chr11:117398399	C/T	cg27161313	chr11:117392002	DSCAML1	-0.58	-9.04	-0.4	5.51e-18	Putamen volume;
LUAD	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18404041	chr3:52824283	ITIH1	0.61	12.32	0.51	4.99e-30	Bipolar disorder;
LUAD	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg01733217	chr16:74700730	RFWD3	0.54	8.53	0.38	2.55e-16	Testicular germ cell tumor;
LUAD	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg23758822	chr17:41437982	NA	1.01	21.18	0.72	2.04e-68	Menopause (age at onset);
LUAD	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.65	9.17	0.41	2.12e-18	Gut microbiome composition (summer);
LUAD	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.33	6.49	0.3	2.48e-10	Obesity-related traits;
LUAD	cis	rs13095912	1.000	rs9714158	chr3:185328780	C/T	cg11274856	chr3:185301563	NA	0.39	7.79	0.35	5.08e-14	Systolic blood pressure;
LUAD	cis	rs1953600	0.870	rs2789690	chr10:81938204	G/T	cg00277334	chr10:82204260	NA	0.42	7.09	0.33	5.6e-12	Sarcoidosis;
LUAD	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg22681709	chr2:178499509	PDE11A	-0.44	-7.05	-0.32	7.22e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00149659	chr3:10157352	C3orf10	-0.57	-7.9	-0.36	2.44e-14	Alzheimer's disease;
LUAD	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.43	-8.57	-0.38	2.03e-16	Glomerular filtration rate;
LUAD	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg17074396	chr22:49843754	NA	-0.29	-6.36	-0.3	5.33e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg00431813	chr7:1051703	C7orf50	-0.35	-6.38	-0.3	4.71e-10	Longevity;Endometriosis;
LUAD	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg23254163	chr1:152506842	NA	0.25	6.71	0.31	6.14e-11	Hair morphology;
LUAD	cis	rs76878669	0.561	rs12420203	chr11:66163794	T/C	cg10616300	chr11:66138557	SLC29A2	0.36	7.63	0.35	1.58e-13	Educational attainment (years of education);
LUAD	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg18944383	chr4:111397179	ENPEP	0.41	7.98	0.36	1.37e-14	Height;
LUAD	cis	rs9487051	0.702	rs670414	chr6:109529912	A/G	cg01475377	chr6:109611718	NA	0.41	7.49	0.34	3.97e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg02158880	chr13:53174818	NA	0.41	6.97	0.32	1.2e-11	Lewy body disease;
LUAD	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.7e-32	Immature fraction of reticulocytes;
LUAD	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg09555818	chr19:45449301	APOC2	-0.62	-13.05	-0.54	5.99e-33	Blood protein levels;
LUAD	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.41	-7.83	-0.36	3.89e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-13.33	-0.54	4.25e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg05425664	chr17:57184151	TRIM37	-0.43	-7.72	-0.35	8.56e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	7.55	0.34	2.71e-13	Platelet count;
LUAD	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg22875332	chr1:76189707	ACADM	0.75	11.83	0.5	4.34e-28	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg07741184	chr6:167504864	NA	-0.33	-7.78	-0.35	5.71e-14	Crohn's disease;
LUAD	cis	rs3803170	0.513	rs10849946	chr12:111830485	C/G	cg10833066	chr12:111807467	FAM109A	-0.48	-8.96	-0.4	1.05e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg00922110	chr4:57842668	C4orf14	-0.41	-6.92	-0.32	1.68e-11	Response to bleomycin (chromatid breaks);
LUAD	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg06547715	chr2:218990976	CXCR2	0.28	6.7	0.31	6.53e-11	Colorectal cancer;
LUAD	cis	rs250677	0.522	rs2217638	chr5:148364355	A/G	cg12140854	chr5:148520817	ABLIM3	0.57	8.93	0.4	1.27e-17	Breast cancer;
LUAD	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg16479474	chr6:28041457	NA	0.37	6.97	0.32	1.25e-11	Parkinson's disease;
LUAD	trans	rs11039798	1.000	rs7104642	chr11:48588534	C/T	cg15704280	chr7:45808275	SEPT13	0.65	7.68	0.35	1.13e-13	Axial length;
LUAD	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.31	0.41	6.89e-19	Colorectal cancer;
LUAD	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg15704280	chr7:45808275	SEPT13	-0.52	-8.32	-0.38	1.26e-15	Height;
LUAD	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6761276	0.899	rs12466799	chr2:113835999	T/C	cg10479672	chr2:113810641	IL1F8	-0.38	-7.65	-0.35	1.39e-13	Protein quantitative trait loci;
LUAD	cis	rs943466	1.000	rs751096	chr6:33742838	C/T	cg16010596	chr6:33739607	LEMD2	0.37	6.47	0.3	2.67e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg05872129	chr22:39784769	NA	-0.75	-12.6	-0.52	3.8e-31	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	trans	rs8073060	0.586	rs6505486	chr17:33996776	G/A	cg19694781	chr19:47549865	TMEM160	-1.22	-19.03	-0.68	8.46e-59	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	trans	rs11039798	1.000	rs12225599	chr11:48755868	T/C	cg03929089	chr4:120376271	NA	0.59	6.8	0.31	3.49e-11	Axial length;
LUAD	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg11494091	chr17:61959527	GH2	0.41	7.8	0.35	4.81e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9522267	0.535	rs11069897	chr13:112231319	A/G	cg10483660	chr13:112241077	NA	-0.31	-6.61	-0.31	1.15e-10	Hepatitis;
LUAD	cis	rs204247	0.565	rs411094	chr6:13718264	C/A	cg02206980	chr6:13574034	SIRT5	-0.41	-8.23	-0.37	2.4e-15	Breast cancer;
LUAD	cis	rs1371614	0.635	rs9309559	chr2:27141515	G/T	cg00617064	chr2:27272375	NA	-0.34	-6.39	-0.3	4.28e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg03714773	chr7:91764589	CYP51A1	0.29	6.48	0.3	2.53e-10	Breast cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12378831	chr13:46626792	ZC3H13	-0.42	-7.0	-0.32	9.9e-12	Cancer;
LUAD	cis	rs7326068	0.524	rs7998500	chr13:21159000	A/G	cg27499820	chr13:21296301	IL17D	0.44	7.96	0.36	1.55e-14	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg07741184	chr6:167504864	NA	0.33	7.77	0.35	6.15e-14	Crohn's disease;
LUAD	cis	rs7487075	0.619	rs10880973	chr12:46853209	C/A	cg23829395	chr12:46796953	NA	0.31	6.89	0.32	2.03e-11	Itch intensity from mosquito bite;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg08811588	chr7:100473311	SRRT	0.42	6.85	0.32	2.68e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg25985355	chr7:65971099	NA	0.38	7.08	0.33	5.94e-12	Aortic root size;
LUAD	cis	rs11622475	1.000	rs2236246	chr14:104379206	A/C	cg12183467	chr14:104352244	NA	0.4	7.28	0.33	1.66e-12	Bipolar disorder;
LUAD	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.46	-7.07	-0.32	6.54e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg13736514	chr6:26305472	NA	-0.67	-12.81	-0.53	5.57e-32	Educational attainment;
LUAD	trans	rs7395662	1.000	rs11039779	chr11:48517895	G/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.65	-0.31	9.19e-11	HDL cholesterol;
LUAD	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg14343924	chr8:8086146	FLJ10661	-0.48	-7.87	-0.36	2.9e-14	Systolic blood pressure;
LUAD	cis	rs73206853	0.764	rs56123836	chr12:110999032	G/A	cg12870014	chr12:110450643	ANKRD13A	0.64	7.18	0.33	3.19e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs7395662	1.000	rs7483920	chr11:48599969	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.33	-0.34	1.14e-12	HDL cholesterol;
LUAD	cis	rs2046867	0.908	rs68142603	chr3:72790220	A/C	cg04365224	chr3:72788183	NA	-0.47	-7.13	-0.33	4.38e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg05697835	chr1:2722811	NA	0.32	6.59	0.31	1.29e-10	Ulcerative colitis;
LUAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-10.13	-0.44	1.01e-21	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04595323	chr17:78400892	FLJ35220	-0.41	-6.52	-0.3	1.96e-10	Height;
LUAD	cis	rs9811920	0.809	rs793443	chr3:99573547	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	6.65	0.31	8.92e-11	Axial length;
LUAD	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg22079354	chr11:130786696	SNX19	0.37	6.35	0.3	5.44e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg03733263	chr8:22462867	KIAA1967	0.75	13.17	0.54	1.9e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg02357741	chr19:55813339	BRSK1	0.39	6.56	0.3	1.54e-10	Bipolar disorder;
LUAD	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg04842962	chr6:43655489	MRPS18A	-0.9	-17.46	-0.65	8.1e-52	IgG glycosylation;
LUAD	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg23352942	chr3:46931381	PTH1R	0.41	8.41	0.38	6.26e-16	Birth weight;
LUAD	cis	rs11951515	0.508	rs7706431	chr5:43582423	C/T	cg01983248	chr5:43482804	C5orf28	-0.38	-8.25	-0.37	2.09e-15	Metabolite levels  (X-11787);
LUAD	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg23950597	chr19:37808831	NA	-0.6	-7.47	-0.34	4.67e-13	Coronary artery calcification;
LUAD	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-9.21	-0.41	1.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg07606381	chr6:8435919	SLC35B3	-0.41	-6.89	-0.32	1.97e-11	Motion sickness;
LUAD	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg00316803	chr15:76480434	C15orf27	-0.4	-7.58	-0.35	2.19e-13	Blood metabolite levels;
LUAD	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg25985355	chr7:65971099	NA	-0.38	-6.89	-0.32	2.02e-11	Aortic root size;
LUAD	cis	rs78456975	0.739	rs11896906	chr2:1519550	A/G	cg01028140	chr2:1542097	TPO	-0.49	-6.79	-0.31	3.89e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg21659725	chr3:3221576	CRBN	0.38	6.53	0.3	1.85e-10	Resting heart rate;
LUAD	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.58	-10.38	-0.45	1.21e-22	Melanoma;
LUAD	cis	rs490234	0.966	rs829312	chr9:128377873	C/T	cg14078157	chr9:128172775	NA	-0.37	-6.95	-0.32	1.38e-11	Mean arterial pressure;
LUAD	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg00933542	chr6:150070202	PCMT1	0.41	8.19	0.37	3.02e-15	Lung cancer;
LUAD	cis	rs10744422	1.000	rs921808	chr12:123323135	A/G	cg16953816	chr12:123349952	VPS37B	-0.64	-7.27	-0.33	1.74e-12	Schizophrenia;
LUAD	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg27494647	chr7:150038898	RARRES2	0.43	7.24	0.33	2.12e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7586879	0.639	rs6722022	chr2:25098859	A/G	cg04586622	chr2:25135609	ADCY3	0.38	8.56	0.38	2.06e-16	Body mass index;
LUAD	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg21016266	chr12:122356598	WDR66	0.7	12.94	0.53	1.72e-32	Mean corpuscular volume;
LUAD	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg24838063	chr12:130822603	PIWIL1	0.64	10.8	0.46	3.49e-24	Menopause (age at onset);
LUAD	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg15395560	chr15:45543142	SLC28A2	0.37	6.36	0.3	5.22e-10	Uric acid levels;
LUAD	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg12257156	chr7:158823799	VIPR2	0.5	7.38	0.34	8.52e-13	Facial morphology (factor 20);
LUAD	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg21475434	chr5:93447410	FAM172A	-0.61	-7.78	-0.35	5.57e-14	Diabetic retinopathy;
LUAD	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg11915388	chr22:42470451	FAM109B	-0.42	-7.33	-0.34	1.14e-12	Schizophrenia;
LUAD	cis	rs7107174	1.000	rs11601590	chr11:78073288	T/G	cg19901956	chr11:77921274	USP35	-0.48	-6.86	-0.32	2.41e-11	Testicular germ cell tumor;
LUAD	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11905131	chr22:24372483	LOC391322	-0.5	-8.67	-0.39	9.4e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.79	-0.31	3.76e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg17911788	chr17:44343683	NA	-0.49	-6.8	-0.31	3.57e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs2018683	0.677	rs2057956	chr7:28973460	G/A	cg19402173	chr7:128379420	CALU	-0.52	-8.38	-0.38	7.8e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.27	-6.81	-0.31	3.44e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs4853036	0.951	rs61422548	chr2:70110249	G/T	cg02498382	chr2:70120550	SNRNP27	-0.53	-8.47	-0.38	3.96e-16	Colorectal or endometrial cancer;
LUAD	cis	rs7843479	1.000	rs13248727	chr8:21842063	T/C	cg03445287	chr8:21823731	XPO7	-0.46	-8.46	-0.38	4.46e-16	Mean corpuscular volume;
LUAD	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg16680214	chr1:154839983	KCNN3	-0.63	-13.16	-0.54	2.08e-33	Prostate cancer;
LUAD	cis	rs7945718	0.934	rs10831909	chr11:12817182	C/G	cg25843174	chr11:12811716	TEAD1	0.25	7.62	0.35	1.65e-13	Educational attainment (years of education);
LUAD	cis	rs698833	0.886	rs2289463	chr2:44565447	A/T	cg04920474	chr2:44395004	PPM1B	0.37	6.46	0.3	2.84e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.81	0.31	3.35e-11	Rheumatoid arthritis;
LUAD	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg02753203	chr1:228287806	NA	-0.47	-8.53	-0.38	2.63e-16	Diastolic blood pressure;
LUAD	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg10645314	chr2:3704589	ALLC	-0.45	-7.55	-0.34	2.64e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg22862634	chr11:62369728	EML3;MTA2	-0.5	-9.13	-0.41	2.85e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2625529	0.761	rs16956444	chr15:72271235	C/T	cg16672083	chr15:72433130	SENP8	-0.76	-12.74	-0.53	1.1e-31	Red blood cell count;
LUAD	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg22875332	chr1:76189707	ACADM	0.92	19.17	0.68	1.99e-59	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg19336497	chr11:14380999	RRAS2	-0.33	-6.65	-0.31	9.04e-11	Mitochondrial DNA levels;
LUAD	cis	rs500891	0.525	rs2324416	chr6:84074210	A/G	cg08257003	chr6:84140564	ME1	0.35	6.74	0.31	5.28e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.5	-10.79	-0.46	3.93e-24	Longevity;Endometriosis;
LUAD	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-11.79	-0.5	5.97e-28	Bipolar disorder;
LUAD	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	10.93	0.47	1.15e-24	Hip circumference adjusted for BMI;
LUAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.69	-8.61	-0.39	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.63	-10.58	-0.46	2.33e-23	Glomerular filtration rate;
LUAD	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg09658497	chr7:2847517	GNA12	-0.53	-9.01	-0.4	7.09e-18	Height;
LUAD	cis	rs12681287	0.608	rs1135451	chr8:87483608	T/C	cg27223183	chr8:87520930	FAM82B	-0.67	-9.61	-0.42	6.38e-20	Caudate activity during reward;
LUAD	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg21214613	chr1:16344536	HSPB7	0.57	10.26	0.45	3.41e-22	Dilated cardiomyopathy;
LUAD	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg20933634	chr6:27740509	NA	0.52	8.21	0.37	2.73e-15	Parkinson's disease;
LUAD	trans	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg14917512	chr19:3094685	GNA11	-0.57	-6.8	-0.31	3.69e-11	Diabetic kidney disease;
LUAD	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-6.67	-0.31	8.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg06641503	chr3:48959341	ARIH2	-0.41	-8.16	-0.37	3.98e-15	Parkinson's disease;
LUAD	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg05340658	chr4:99064831	C4orf37	0.45	7.36	0.34	9.65e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs8192282	0.739	rs6691727	chr1:154497005	C/T	cg16683920	chr1:154474344	TDRD10;SHE	0.45	6.98	0.32	1.16e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22968622	chr17:43663579	NA	-1.17	-19.66	-0.69	1.36e-61	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.24	-0.45	3.99e-22	Migraine;Coronary artery disease;
LUAD	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.59	10.88	0.47	1.71e-24	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg09021430	chr5:549028	NA	-0.71	-13.59	-0.55	3.71e-35	Obesity-related traits;
LUAD	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg17264618	chr3:40429014	ENTPD3	0.39	8.36	0.38	9.02e-16	Renal cell carcinoma;
LUAD	trans	rs4714291	0.832	rs6917417	chr6:40104628	T/C	cg02267698	chr19:7991119	CTXN1	-0.45	-7.09	-0.33	5.64e-12	Strep throat;
LUAD	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg03929089	chr4:120376271	NA	-0.93	-17.31	-0.64	3.84e-51	Height;
LUAD	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.25	-0.45	3.48e-22	Bipolar disorder;
LUAD	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg08470875	chr2:26401718	FAM59B	-0.79	-11.13	-0.48	2.11e-25	Gut microbiome composition (summer);
LUAD	cis	rs9788721	0.836	rs2009746	chr15:78754102	A/G	cg18825076	chr15:78729989	IREB2	-0.55	-9.38	-0.42	3.92e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs1953600	0.870	rs2573370	chr10:81951366	C/T	cg04850286	chr10:81895943	PLAC9	0.36	6.48	0.3	2.6e-10	Sarcoidosis;
LUAD	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg14092988	chr3:52407081	DNAH1	-0.37	-7.64	-0.35	1.5e-13	Electroencephalogram traits;
LUAD	cis	rs73086581	1.000	rs73086508	chr20:3921715	C/T	cg02187196	chr20:3869020	PANK2	0.49	6.78	0.31	4.14e-11	Response to antidepressants in depression;
LUAD	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg23954153	chr1:44402353	ARTN	-0.34	-6.73	-0.31	5.62e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg24642844	chr7:1081250	C7orf50	-0.98	-14.8	-0.58	2.97e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg07741184	chr6:167504864	NA	0.36	8.11	0.37	5.42e-15	Primary biliary cholangitis;
LUAD	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg18132916	chr6:79620363	NA	-0.45	-7.81	-0.36	4.49e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg02574844	chr11:5959923	NA	-0.43	-7.36	-0.34	9.66e-13	DNA methylation (variation);
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg20762182	chr15:69727293	KIF23	-0.43	-7.05	-0.32	7.32e-12	Schizophrenia;
LUAD	trans	rs2262909	1.000	rs2017962	chr19:22208751	T/C	cg05197062	chr11:11642011	GALNTL4	-0.54	-8.09	-0.37	6.21e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg25324976	chr17:61989376	CSHL1	0.37	7.25	0.33	2.05e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg01868782	chr6:126071099	HEY2	0.3	6.35	0.3	5.48e-10	Brugada syndrome;
LUAD	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg23260525	chr10:116636907	FAM160B1	0.53	12.49	0.52	1.07e-30	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg10729496	chr3:10149963	C3orf24	0.57	9.52	0.42	1.35e-19	Alzheimer's disease;
LUAD	cis	rs6906287	0.647	rs11153767	chr6:118960519	C/T	cg05564266	chr6:118973597	C6orf204	0.37	7.65	0.35	1.41e-13	Electrocardiographic conduction measures;
LUAD	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.51	10.47	0.45	5.74e-23	Monocyte percentage of white cells;
LUAD	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg26343298	chr8:95960752	TP53INP1	0.35	7.38	0.34	8.73e-13	Type 2 diabetes;
LUAD	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-9.79	-0.43	1.5e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg12599982	chr1:44399894	ARTN	0.32	6.53	0.3	1.92e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg27411982	chr8:10470053	RP1L1	0.42	7.59	0.35	2.09e-13	Retinal vascular caliber;
LUAD	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg24562669	chr7:97807699	LMTK2	0.32	7.48	0.34	4.25e-13	Breast cancer;
LUAD	trans	rs87938	1.000	rs87938	chr3:41137672	A/G	cg11224624	chr8:145049280	PLEC1	0.4	6.5	0.3	2.29e-10	Bone mineral density (hip);
LUAD	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.56	8.18	0.37	3.4e-15	Platelet count;
LUAD	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs2274273	0.712	rs9806049	chr14:55525589	C/A	cg04306507	chr14:55594613	LGALS3	0.32	6.53	0.3	1.84e-10	Protein biomarker;
LUAD	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.3	-0.33	1.47e-12	Reticulocyte count;
LUAD	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg18225595	chr11:63971243	STIP1	0.39	6.92	0.32	1.71e-11	Platelet count;
LUAD	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg13606994	chr1:44402422	ARTN	-0.37	-7.33	-0.34	1.18e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2688608	0.839	rs2675662	chr10:75599127	A/G	cg19442545	chr10:75533431	FUT11	0.43	7.25	0.33	1.96e-12	Inflammatory bowel disease;
LUAD	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.66	9.16	0.41	2.24e-18	Lymphocyte percentage of white cells;
LUAD	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg13073564	chr4:8508604	NA	0.61	11.22	0.48	9.55e-26	Response to antineoplastic agents;
LUAD	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg25809561	chr17:30822961	MYO1D	0.74	15.63	0.61	8.69e-44	Schizophrenia;
LUAD	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-6.66	-0.31	8.64e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg05991184	chr2:219186017	PNKD	0.39	7.36	0.34	9.64e-13	Colorectal cancer;
LUAD	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg02018176	chr4:1364513	KIAA1530	-0.58	-10.44	-0.45	7.59e-23	Obesity-related traits;
LUAD	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg18131467	chr2:239335373	ASB1	0.71	12.02	0.5	7.66e-29	Multiple system atrophy;
LUAD	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg25456477	chr12:86230367	RASSF9	0.33	6.37	0.3	5e-10	Major depressive disorder;
LUAD	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg25173405	chr17:45401733	C17orf57	-0.46	-7.51	-0.34	3.53e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7527798	0.592	rs11118359	chr1:207858546	T/C	cg09232269	chr1:207846808	CR1L	-0.38	-7.2	-0.33	2.7e-12	Erythrocyte sedimentation rate;
LUAD	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg05064044	chr6:292385	DUSP22	-0.56	-9.02	-0.4	6.49e-18	Menopause (age at onset);
LUAD	cis	rs4917300	0.626	rs902821	chr8:143100074	G/A	cg26003909	chr8:143102224	NA	-0.3	-6.37	-0.3	4.93e-10	Amyotrophic lateral sclerosis;
LUAD	cis	rs863345	0.608	rs11265013	chr1:158499625	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.52	-0.3	2.01e-10	Pneumococcal bacteremia;
LUAD	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg12140854	chr5:148520817	ABLIM3	-0.62	-9.75	-0.43	2.17e-20	Breast cancer;
LUAD	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg11266682	chr4:10021025	SLC2A9	0.63	14.73	0.58	5.89e-40	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6087990	0.806	rs992472	chr20:31385269	G/T	cg13636640	chr20:31349939	DNMT3B	0.79	14.01	0.56	6.64e-37	Ulcerative colitis;
LUAD	trans	rs10838798	0.523	rs11039593	chr11:48240112	A/G	cg03929089	chr4:120376271	NA	-0.43	-6.51	-0.3	2.17e-10	Height;
LUAD	cis	rs739496	0.563	rs7484754	chr12:112047296	T/A	cg10833066	chr12:111807467	FAM109A	0.44	7.1	0.33	5.23e-12	Platelet count;
LUAD	trans	rs11039798	0.623	rs584851	chr11:48416321	A/G	cg03929089	chr4:120376271	NA	-0.55	-6.4	-0.3	4.22e-10	Axial length;
LUAD	cis	rs2455799	0.634	rs6771390	chr3:15906637	C/G	cg16303742	chr3:15540471	COLQ	-0.5	-9.02	-0.4	6.45e-18	Mean platelet volume;
LUAD	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.52	-0.3	2.05e-10	Coronary artery disease;
LUAD	cis	rs2625529	0.652	rs2957740	chr15:72307691	A/G	cg16672083	chr15:72433130	SENP8	0.65	12.4	0.52	2.51e-30	Red blood cell count;
LUAD	cis	rs36051895	0.659	rs12343867	chr9:5074189	T/C	cg02405213	chr9:5042618	JAK2	-0.51	-7.06	-0.32	6.92e-12	Pediatric autoimmune diseases;
LUAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.79	-0.39	3.73e-17	Lymphocyte counts;
LUAD	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg06781209	chr11:61594997	FADS2	-0.4	-7.18	-0.33	3.19e-12	Bipolar disorder;
LUAD	cis	rs877282	0.629	rs78997110	chr10:764388	A/G	cg06581033	chr10:766294	NA	-0.6	-7.87	-0.36	3.11e-14	Uric acid levels;
LUAD	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13174863	1.000	rs13174863	chr5:139080745	C/T	cg10513866	chr5:139070639	NA	-0.5	-6.74	-0.31	5.12e-11	Body mass index;
LUAD	cis	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.61	-0.35	1.85e-13	Neuroticism;
LUAD	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg20119798	chr7:94954144	PON1	-0.49	-6.5	-0.3	2.28e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs300703	0.935	rs300749	chr2:208143	G/T	cg21211680	chr2:198530	NA	0.59	6.54	0.3	1.81e-10	Blood protein levels;
LUAD	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg25894440	chr7:65020034	NA	-0.66	-7.14	-0.33	4.06e-12	Diabetic kidney disease;
LUAD	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg05425664	chr17:57184151	TRIM37	-0.43	-7.66	-0.35	1.27e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1003719	0.715	rs7282195	chr21:38508619	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-9.06	-0.4	4.94e-18	Eye color traits;
LUAD	cis	rs6906287	0.647	rs12206329	chr6:118863789	G/T	cg21191810	chr6:118973309	C6orf204	0.5	9.77	0.43	1.85e-20	Electrocardiographic conduction measures;
LUAD	cis	rs741677	1.000	rs9911960	chr17:466598	T/C	cg13332499	chr17:408570	NA	0.35	6.94	0.32	1.44e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg10729496	chr3:10149963	C3orf24	-0.64	-9.58	-0.42	8.37e-20	Alzheimer's disease;
LUAD	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg15051221	chr5:177434457	FAM153C	0.44	8.05	0.36	8.62e-15	Methadone dose in opioid dependence;
LUAD	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg00495681	chr13:53174319	NA	0.48	8.65	0.39	1.07e-16	Lewy body disease;
LUAD	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg08859206	chr1:53392774	SCP2	-0.48	-8.59	-0.39	1.69e-16	Monocyte count;
LUAD	cis	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg07460842	chr6:66804631	NA	0.93	14.97	0.59	5.58e-41	Exhaled nitric oxide levels;
LUAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.84	-0.32	2.83e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg04703951	chr17:43578652	NA	0.62	8.58	0.39	1.79e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg21100191	chr22:23484243	RTDR1	0.66	11.26	0.48	6.42e-26	Bone mineral density;
LUAD	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg25319279	chr11:5960081	NA	-0.41	-7.55	-0.34	2.7e-13	DNA methylation (variation);
LUAD	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg19610905	chr11:61596333	FADS2	-0.65	-11.15	-0.48	1.66e-25	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
LUAD	cis	rs7274811	0.744	rs209677	chr20:32140287	C/T	cg14921437	chr20:32255988	NECAB3;C20orf134	0.5	7.79	0.35	5.23e-14	Height;
LUAD	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06112835	chr11:68658793	MRPL21	0.51	9.31	0.41	6.9e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg25319279	chr11:5960081	NA	-0.4	-7.53	-0.34	3.13e-13	DNA methylation (variation);
LUAD	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg17971929	chr21:40555470	PSMG1	0.54	8.42	0.38	6e-16	Cognitive function;
LUAD	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg08885076	chr2:99613938	TSGA10	0.36	6.5	0.3	2.27e-10	Chronic sinus infection;
LUAD	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg17105886	chr17:28927953	LRRC37B2	0.66	7.66	0.35	1.25e-13	Body mass index;
LUAD	trans	rs7395662	1.000	rs11039777	chr11:48517049	T/G	cg00717180	chr2:96193071	NA	-0.4	-7.53	-0.34	3.16e-13	HDL cholesterol;
LUAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg10150615	chr22:24372951	LOC391322	-0.55	-8.76	-0.39	4.69e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg14820908	chr5:178986412	RUFY1	-0.59	-9.62	-0.42	6.16e-20	Lung cancer;
LUAD	cis	rs1957429	0.808	rs1467573	chr14:65347583	T/C	cg23373153	chr14:65346875	NA	0.56	6.55	0.3	1.67e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg03467027	chr4:99064603	C4orf37	0.42	6.88	0.32	2.14e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.523	rs7781947	chr7:106902219	A/G	cg02696742	chr7:106810147	HBP1	-0.78	-10.87	-0.47	1.93e-24	Coronary artery disease;
LUAD	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg22907277	chr7:1156413	C7orf50	0.79	11.01	0.47	5.99e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6987853	0.527	rs2974298	chr8:42376477	T/C	cg09913449	chr8:42400586	C8orf40	-0.35	-6.56	-0.3	1.61e-10	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4389656	0.767	rs369769	chr5:6720712	T/C	cg10857441	chr5:6722123	POLS	-0.47	-8.1	-0.37	6e-15	Coronary artery disease;
LUAD	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg25566285	chr7:158114605	PTPRN2	0.51	10.89	0.47	1.66e-24	Calcium levels;
LUAD	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11890956	chr21:40555474	PSMG1	0.79	14.14	0.57	1.92e-37	Cognitive function;
LUAD	cis	rs17401966	0.838	rs10864449	chr1:10296922	A/T	cg15208524	chr1:10270712	KIF1B	0.42	6.46	0.3	2.9e-10	Hepatocellular carcinoma;
LUAD	cis	rs2109514	0.967	rs55883210	chr7:116160524	G/A	cg12739419	chr7:116140593	CAV2	-0.37	-7.95	-0.36	1.74e-14	Prevalent atrial fibrillation;
LUAD	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.27	-0.45	3.01e-22	Total body bone mineral density;
LUAD	cis	rs7173743	1.000	rs4420501	chr15:79138478	A/T	cg15571903	chr15:79123663	NA	-0.36	-6.85	-0.32	2.66e-11	Coronary artery disease;
LUAD	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs1595825	0.891	rs2164070	chr2:198881730	G/C	cg10547527	chr2:198650123	BOLL	-0.52	-7.06	-0.32	6.86e-12	Ulcerative colitis;
LUAD	trans	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	15.95	0.61	3.53e-45	Exhaled nitric oxide levels;
LUAD	cis	rs10992471	0.603	rs11792019	chr9:95195229	C/T	cg14631576	chr9:95140430	CENPP	-0.56	-11.38	-0.48	2.42e-26	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs2404602	0.591	rs11635162	chr15:76951105	C/T	cg00316803	chr15:76480434	C15orf27	0.44	6.51	0.3	2.13e-10	Blood metabolite levels;
LUAD	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg18944383	chr4:111397179	ENPEP	0.4	8.16	0.37	3.75e-15	Height;
LUAD	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg10518543	chr12:38710700	ALG10B	-0.48	-8.15	-0.37	4.17e-15	Morning vs. evening chronotype;
LUAD	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg00321850	chr1:175162397	KIAA0040	0.55	11.9	0.5	2.32e-28	Alcohol dependence;
LUAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14159672	chr1:205819179	PM20D1	0.79	15.7	0.61	4.19e-44	Menarche (age at onset);
LUAD	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.48	-0.3	2.5e-10	Alzheimer's disease (late onset);
LUAD	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06873352	chr17:61820015	STRADA	0.51	8.4	0.38	7.04e-16	Height;
LUAD	cis	rs9354308	0.933	rs55672811	chr6:66571730	G/A	cg07460842	chr6:66804631	NA	0.48	7.1	0.33	5.25e-12	Metabolite levels;
LUAD	cis	rs35883536	1.000	rs12239531	chr1:101085661	A/G	cg06223162	chr1:101003688	GPR88	0.35	6.38	0.3	4.67e-10	Monocyte count;
LUAD	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg22852734	chr6:133119734	C6orf192	0.8	9.86	0.43	8.98e-21	Type 2 diabetes nephropathy;
LUAD	cis	rs6484504	0.576	rs158144	chr11:31211795	A/C	cg14844989	chr11:31128820	NA	-0.44	-8.1	-0.37	5.8e-15	Red blood cell count;
LUAD	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg20673091	chr1:2541236	MMEL1	-0.38	-8.09	-0.37	6.18e-15	Ulcerative colitis;
LUAD	cis	rs6474412	1.000	rs9792277	chr8:42545827	G/A	cg25026480	chr8:42547641	NA	0.36	6.37	0.3	4.83e-10	Smoking behavior;
LUAD	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.32	-7.2	-0.33	2.72e-12	Dupuytren's disease;
LUAD	cis	rs55665837	0.701	rs11023278	chr11:14641184	G/T	cg19336497	chr11:14380999	RRAS2	-0.4	-7.1	-0.33	5.38e-12	Vitamin D levels;
LUAD	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg26677194	chr12:130822605	PIWIL1	0.55	9.07	0.4	4.52e-18	Menopause (age at onset);
LUAD	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg22532475	chr10:104410764	TRIM8	0.44	8.46	0.38	4.3e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4743820	0.651	rs10991797	chr9:93930671	A/G	cg14446406	chr9:93919335	NA	-0.51	-8.49	-0.38	3.6e-16	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-6.48	-0.3	2.49e-10	Gut microbiome composition (summer);
LUAD	trans	rs1941687	0.764	rs1493915	chr18:31377582	G/T	cg27147174	chr7:100797783	AP1S1	-0.53	-9.39	-0.42	3.7e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg12365402	chr11:9010492	NRIP3	-0.5	-9.4	-0.42	3.46e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.46e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg06640241	chr16:89574553	SPG7	0.49	8.07	0.37	7.53e-15	Multiple myeloma (IgH translocation);
LUAD	cis	rs10193935	0.901	rs10200000	chr2:42442212	A/G	cg27598129	chr2:42591480	NA	-0.79	-10.59	-0.46	2.07e-23	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13315871	0.790	rs9825431	chr3:58406694	G/C	cg12435725	chr3:58293450	RPP14	-0.69	-7.35	-0.34	1.05e-12	Cholesterol, total;
LUAD	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg01017244	chr2:74357527	NA	0.88	14.46	0.58	8.74e-39	Gestational age at birth (maternal effect);
LUAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7089973	0.872	rs35010779	chr10:116631816	A/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.53	0.42	1.25e-19	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg17105886	chr17:28927953	LRRC37B2	0.72	7.05	0.32	7.19e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8170	0.603	rs8109328	chr19:17417955	C/T	cg04749549	chr19:17459798	NA	-0.34	-6.38	-0.3	4.62e-10	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg07217954	chr7:1067459	C7orf50	0.43	6.63	0.31	1.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg26384229	chr12:38710491	ALG10B	0.42	6.98	0.32	1.15e-11	Morning vs. evening chronotype;
LUAD	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg23887609	chr12:130822674	PIWIL1	0.41	6.92	0.32	1.64e-11	Menopause (age at onset);
LUAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03407747	chr17:6899364	ALOX12	-0.42	-7.95	-0.36	1.68e-14	Tonsillectomy;
LUAD	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg26384229	chr12:38710491	ALG10B	0.44	7.18	0.33	3.19e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.53e-11	Depression;
LUAD	cis	rs243505	0.762	rs10225300	chr7:148502007	G/C	cg09806900	chr7:148480153	CUL1	0.45	7.8	0.35	4.82e-14	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg15556689	chr8:8085844	FLJ10661	0.41	6.72	0.31	5.85e-11	Systolic blood pressure;
LUAD	cis	rs10865541	0.902	rs6739163	chr2:3419011	G/A	cg13173536	chr2:3403300	TTC15	-0.34	-6.61	-0.31	1.16e-10	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg09365446	chr1:150670422	GOLPH3L	0.61	10.88	0.47	1.74e-24	Melanoma;
LUAD	trans	rs6561151	0.957	rs9316058	chr13:44485076	G/C	cg17145862	chr1:211918768	LPGAT1	0.55	9.23	0.41	1.29e-18	Crohn's disease;
LUAD	cis	rs4372836	0.504	rs2045886	chr2:29010517	A/G	cg09522027	chr2:28974177	PPP1CB	-0.61	-10.9	-0.47	1.49e-24	Body mass index;
LUAD	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.8	-0.31	3.56e-11	Personality dimensions;
LUAD	cis	rs9443645	0.527	rs7756996	chr6:79509367	A/C	cg05283184	chr6:79620031	NA	-0.42	-7.32	-0.34	1.22e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs12200560	0.505	rs211166	chr6:97068598	T/C	cg06623918	chr6:96969491	KIAA0776	0.46	6.98	0.32	1.14e-11	Coronary heart disease;
LUAD	cis	rs12545109	0.842	rs10958482	chr8:57389331	G/T	cg07080864	chr8:57359956	PENK	-0.38	-6.44	-0.3	3.34e-10	Obesity-related traits;
LUAD	cis	rs240764	0.621	rs6925316	chr6:101209137	C/G	cg09795085	chr6:101329169	ASCC3	-0.42	-7.38	-0.34	8.74e-13	Neuroticism;
LUAD	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg04568274	chr7:158649319	WDR60	0.43	6.69	0.31	6.94e-11	Height;
LUAD	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg03929089	chr4:120376271	NA	-0.76	-12.63	-0.52	2.98e-31	Height;
LUAD	cis	rs12618769	0.597	rs17505326	chr2:99156807	T/A	cg10123293	chr2:99228465	UNC50	0.5	8.72	0.39	6.32e-17	Bipolar disorder;
LUAD	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg27170947	chr2:26402098	FAM59B	-0.65	-9.1	-0.4	3.49e-18	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg03289416	chr15:75166202	SCAMP2	0.45	7.76	0.35	6.23e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg17105886	chr17:28927953	LRRC37B2	0.71	6.49	0.3	2.4e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9902453	0.845	rs7501472	chr17:28010628	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.25	0.41	1.08e-18	Coffee consumption (cups per day);
LUAD	cis	rs4604732	0.631	rs60311891	chr1:247623127	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	9.26	0.41	1.06e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs3750965	1.000	rs7937006	chr11:68843932	C/T	cg06818126	chr11:68850279	TPCN2	-0.49	-7.16	-0.33	3.49e-12	Hair color;
LUAD	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg11814155	chr7:99998594	ZCWPW1	0.45	7.63	0.35	1.53e-13	Platelet count;
LUAD	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg18129748	chr3:49941408	MST1R	-0.44	-7.14	-0.33	4.2e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg17063962	chr7:91808500	NA	0.72	12.75	0.53	9.92e-32	Breast cancer;
LUAD	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg13126279	chr21:47581558	C21orf56	-0.44	-6.41	-0.3	3.84e-10	Testicular germ cell tumor;
LUAD	cis	rs16958440	0.867	rs75808931	chr18:44693042	C/T	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg16049864	chr8:95962084	TP53INP1	-0.4	-7.65	-0.35	1.4e-13	Type 2 diabetes;
LUAD	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.38	7.9	0.36	2.5e-14	Hemoglobin concentration;
LUAD	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg21724239	chr8:58056113	NA	0.57	7.56	0.35	2.45e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7536201	0.967	rs11249212	chr1:25293201	A/G	cg23273869	chr1:25296894	NA	-0.35	-7.0	-0.32	9.8e-12	Psoriasis vulgaris;
LUAD	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	cg06064525	chr11:970664	AP2A2	-0.45	-8.91	-0.4	1.51e-17	Alzheimer's disease (late onset);
LUAD	cis	rs7187994	0.636	rs36081182	chr16:84772534	G/A	cg07647771	chr16:84786436	USP10	-0.28	-7.53	-0.34	3.04e-13	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg07917127	chr4:99064746	C4orf37	0.42	7.02	0.32	9.09e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg04135861	chr2:62115680	CCT4	-0.68	-7.02	-0.32	9.08e-12	Type 2 diabetes;
LUAD	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg23815491	chr16:72088622	HP	0.59	11.17	0.48	1.4e-25	Fibrinogen levels;
LUAD	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.51	6.96	0.32	1.32e-11	Platelet count;
LUAD	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg10591111	chr5:226296	SDHA	-0.56	-6.84	-0.32	2.72e-11	Breast cancer;
LUAD	trans	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg06437703	chr8:37914619	EIF4EBP1	-0.59	-10.77	-0.46	4.52e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9810890	0.850	rs73198884	chr3:128543424	T/C	cg15033153	chr3:128514015	RAB7A	0.7	6.39	0.3	4.29e-10	Dental caries;
LUAD	cis	rs7147624	1.000	rs7160390	chr14:66052460	G/A	cg03016385	chr14:66212404	NA	-0.59	-7.09	-0.33	5.74e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.85	-0.32	2.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11229555	0.645	rs12797488	chr11:58174653	A/T	cg15696309	chr11:58395628	NA	-0.78	-10.55	-0.46	2.97e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.5	-7.74	-0.35	7.59e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg16342193	chr10:102329863	NA	-0.41	-7.28	-0.33	1.6e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg22166914	chr1:53195759	ZYG11B	0.44	7.58	0.35	2.23e-13	Monocyte count;
LUAD	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg03289416	chr15:75166202	SCAMP2	0.45	7.76	0.35	6.26e-14	Breast cancer;
LUAD	cis	rs1950626	0.743	rs12884454	chr14:101465627	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.42	7.35	0.34	1.01e-12	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	15.84	0.61	1.1e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs875971	0.895	rs778700	chr7:65866450	C/T	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs11696845	0.649	rs6031782	chr20:43383832	A/G	cg25301532	chr20:43378953	KCNK15	-0.46	-8.22	-0.37	2.44e-15	Obesity-related traits;
LUAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg15242686	chr22:24348715	GSTTP1	0.43	7.24	0.33	2.09e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08024127	chr15:55611607	PIGB	-0.41	-6.68	-0.31	7.72e-11	Cancer;
LUAD	cis	rs9486719	0.741	rs976356	chr6:96849437	T/A	cg06623918	chr6:96969491	KIAA0776	0.73	9.62	0.42	5.97e-20	Migraine;Coronary artery disease;
LUAD	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg01324343	chr3:183735012	ABCC5	0.94	25.01	0.77	2.01e-85	Anterior chamber depth;
LUAD	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7516138	1.000	rs4240896	chr1:9713500	A/G	cg26573321	chr1:9711663	PIK3CD	-0.77	-14.6	-0.58	2.11e-39	Monocyte count;
LUAD	cis	rs59698941	0.943	rs60042606	chr5:132248170	G/T	cg14825688	chr5:132208181	LEAP2	-0.47	-6.41	-0.3	3.91e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs6490294	0.529	rs7137386	chr12:112283914	T/G	cg10833066	chr12:111807467	FAM109A	0.36	6.82	0.31	3.18e-11	Mean platelet volume;
LUAD	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-9.91	-0.43	5.96e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs2066819	1.000	rs59811639	chr12:56695954	C/T	cg26714650	chr12:56694279	CS	-0.86	-7.23	-0.33	2.25e-12	Psoriasis vulgaris;
LUAD	trans	rs7246760	1.000	rs73507215	chr19:9887312	C/T	cg02900749	chr2:68251473	NA	-0.63	-6.87	-0.32	2.25e-11	Pursuit maintenance gain;
LUAD	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg11247378	chr22:39784982	NA	-0.75	-14.13	-0.57	2.12e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg07936489	chr17:37558343	FBXL20	-0.42	-6.79	-0.31	3.91e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs8017423	1.000	rs2184281	chr14:90685923	A/G	cg14092571	chr14:90743983	NA	0.46	7.87	0.36	3.03e-14	Mortality in heart failure;
LUAD	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg26875233	chr11:93583750	C11orf90	-0.39	-8.88	-0.4	1.98e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.35	-6.95	-0.32	1.38e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs965604	1.000	rs4887057	chr15:78760918	G/A	cg18825076	chr15:78729989	IREB2	0.43	7.31	0.33	1.38e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg15147215	chr3:52552868	STAB1	0.46	8.78	0.39	4.18e-17	Electroencephalogram traits;
LUAD	cis	rs77972916	0.536	rs62137421	chr2:43594091	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-7.03	-0.32	8.22e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs35771425	0.600	rs6667063	chr1:211660746	G/A	cg10512769	chr1:211675356	NA	-0.39	-7.05	-0.32	7.42e-12	Educational attainment (years of education);
LUAD	cis	rs2302190	0.769	rs7215531	chr17:56493374	A/T	cg25885038	chr17:56607967	SEPT4	-0.5	-7.63	-0.35	1.55e-13	Vitamin D levels;
LUAD	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.09	0.33	5.82e-12	Depression;
LUAD	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg01028140	chr2:1542097	TPO	-0.41	-6.89	-0.32	2.09e-11	IgG glycosylation;
LUAD	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg24675658	chr1:53192096	ZYG11B	-0.4	-6.74	-0.31	5.35e-11	Monocyte count;
LUAD	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06112835	chr11:68658793	MRPL21	0.51	9.28	0.41	9.08e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9896933	0.614	rs3785511	chr17:80886316	G/T	cg15664640	chr17:80829946	TBCD	0.65	8.31	0.37	1.29e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg01181863	chr3:195395398	SDHAP2	-0.67	-10.7	-0.46	8.4e-24	Pancreatic cancer;
LUAD	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg18944383	chr4:111397179	ENPEP	0.38	7.62	0.35	1.66e-13	Height;
LUAD	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg12483005	chr1:23474871	LUZP1	0.52	9.0	0.4	7.99e-18	Height;
LUAD	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg03605463	chr16:89740564	NA	0.66	11.45	0.49	1.23e-26	Vitiligo;
LUAD	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg08280861	chr8:58055591	NA	0.57	7.54	0.34	2.91e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg19052272	chr2:3704530	ALLC	-0.89	-14.14	-0.57	1.9e-37	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs2235649	0.746	rs113666107	chr16:1848642	C/A	cg08610935	chr16:1836813	NUBP2	-0.5	-7.64	-0.35	1.49e-13	Blood metabolite levels;
LUAD	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg10755058	chr3:40428713	ENTPD3	0.43	8.44	0.38	5.28e-16	Renal cell carcinoma;
LUAD	cis	rs6087990	0.871	rs1007122	chr20:31346001	C/T	cg13636640	chr20:31349939	DNMT3B	0.77	14.07	0.56	3.63e-37	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.08	0.33	6.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg21475434	chr5:93447410	FAM172A	-0.66	-7.92	-0.36	2.08e-14	Diabetic retinopathy;
LUAD	cis	rs1997103	1.000	rs10270618	chr7:55396712	T/A	cg17469321	chr7:55412551	NA	0.67	11.41	0.49	1.73e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg18446336	chr7:2847575	GNA12	0.32	6.58	0.3	1.42e-10	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27338377	chr3:5068433	NA	-0.43	-6.44	-0.3	3.27e-10	Height;
LUAD	trans	rs9929218	0.954	rs12928043	chr16:68828885	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-12.67	-0.52	1.99e-31	Colorectal cancer;
LUAD	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg02275930	chr1:2372054	NA	-0.36	-7.16	-0.33	3.7e-12	Non-obstructive azoospermia;
LUAD	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg13722127	chr7:150037890	RARRES2	0.43	7.16	0.33	3.55e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg21724239	chr8:58056113	NA	0.8	9.71	0.43	2.89e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10802521	chr3:52805072	NEK4	-0.62	-11.2	-0.48	1.1e-25	Bipolar disorder;
LUAD	cis	rs10540	0.584	rs10751659	chr11:437559	C/T	cg19913688	chr11:428466	ANO9	0.56	7.55	0.34	2.7e-13	Body mass index;
LUAD	cis	rs6840360	0.554	rs62329088	chr4:152471289	C/T	cg22705602	chr4:152727874	NA	-0.37	-6.71	-0.31	6.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.31	7.17	0.33	3.27e-12	Prostate cancer;
LUAD	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg08645402	chr16:4508243	NA	0.53	9.62	0.42	6.05e-20	Schizophrenia;
LUAD	trans	rs2832077	0.505	rs9305386	chr21:30386751	A/G	cg14791747	chr16:20752902	THUMPD1	-0.7	-7.67	-0.35	1.18e-13	Cognitive test performance;
LUAD	cis	rs89107	0.651	rs283084	chr6:118603999	G/A	cg18833306	chr6:118973337	C6orf204	0.53	9.69	0.43	3.52e-20	Cardiac structure and function;
LUAD	cis	rs4523957	0.928	rs12938295	chr17:2160854	A/G	cg16513277	chr17:2031491	SMG6	0.76	14.68	0.58	1.05e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg10518543	chr12:38710700	ALG10B	-0.45	-7.36	-0.34	9.93e-13	Morning vs. evening chronotype;
LUAD	cis	rs13333054	1.000	rs12232384	chr16:86009760	A/C	cg04454285	chr16:86016317	NA	-0.41	-6.62	-0.31	1.07e-10	Multiple sclerosis;
LUAD	cis	rs117623576	0.941	rs7911845	chr10:32441827	T/C	cg03047570	chr10:32398778	NA	-0.79	-9.31	-0.41	6.85e-19	Anti-saccade response;
LUAD	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08109568	chr15:31115862	NA	0.59	10.01	0.44	2.71e-21	Huntington's disease progression;
LUAD	cis	rs2554380	0.760	rs1946367	chr15:84425263	G/T	cg14598478	chr15:84363061	ADAMTSL3	-0.51	-8.16	-0.37	3.87e-15	Height;
LUAD	cis	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg02751453	chr18:77725136	HSBP1L1	0.36	6.77	0.31	4.29e-11	Opioid sensitivity;
LUAD	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08219700	chr8:58056026	NA	0.77	9.98	0.44	3.39e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs7818345	0.904	rs11780388	chr8:19271554	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.3	6.51	0.3	2.17e-10	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg04545296	chr12:48745243	ZNF641	0.4	10.23	0.45	4.37e-22	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs240764	0.583	rs6905113	chr6:101209368	A/G	cg09795085	chr6:101329169	ASCC3	-0.42	-7.38	-0.34	8.74e-13	Neuroticism;
LUAD	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg11062466	chr8:58055876	NA	0.67	9.02	0.4	6.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg06608945	chr2:219082296	ARPC2	0.48	8.12	0.37	5.22e-15	Colorectal cancer;
LUAD	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg14847009	chr1:175162515	KIAA0040	0.32	8.51	0.38	3.12e-16	Alcohol dependence;
LUAD	cis	rs1816752	0.905	rs6490929	chr13:25014252	G/A	cg02811702	chr13:24901961	NA	0.45	7.88	0.36	2.72e-14	Obesity-related traits;
LUAD	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg15704280	chr7:45808275	SEPT13	-0.93	-18.24	-0.66	3.04e-55	Coronary artery disease;
LUAD	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg02734326	chr4:10020555	SLC2A9	0.64	11.33	0.48	3.73e-26	Bone mineral density;
LUAD	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg24503407	chr1:205819492	PM20D1	-0.52	-7.86	-0.36	3.11e-14	Menarche (age at onset);
LUAD	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.19	0.54	1.61e-33	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg03467027	chr4:99064603	C4orf37	0.4	6.47	0.3	2.77e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6460942	0.915	rs17444044	chr7:12458736	A/G	cg06484146	chr7:12443880	VWDE	-0.58	-7.26	-0.33	1.9e-12	Coronary artery disease;
LUAD	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.56	0.55	4.79e-35	Prudent dietary pattern;
LUAD	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg23029597	chr12:123009494	RSRC2	0.55	8.54	0.38	2.47e-16	Body mass index;
LUAD	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg17173187	chr15:85201210	NMB	0.42	6.84	0.32	2.77e-11	Schizophrenia;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22685446	chr4:142142014	ZNF330	-0.52	-6.51	-0.3	2.1e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4730250	0.707	rs10253291	chr7:106786550	C/A	cg02696742	chr7:106810147	HBP1	0.82	10.96	0.47	8.98e-25	Osteoarthritis;
LUAD	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg17810781	chr1:201082982	CACNA1S	0.37	6.75	0.31	4.82e-11	Permanent tooth development;
LUAD	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.34	-7.65	-0.35	1.37e-13	Lung cancer;
LUAD	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg26384229	chr12:38710491	ALG10B	0.47	7.65	0.35	1.4e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2797160	1.000	rs1739377	chr6:126012236	T/C	cg05901451	chr6:126070800	HEY2	0.46	7.02	0.32	9.11e-12	Endometrial cancer;
LUAD	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg17644776	chr2:200775616	C2orf69	-0.52	-6.53	-0.3	1.9e-10	Schizophrenia;
LUAD	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg17105886	chr17:28927953	LRRC37B2	-0.67	-7.67	-0.35	1.21e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg27588902	chr6:42928151	GNMT	-0.37	-9.79	-0.43	1.59e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg18477163	chr1:228402036	OBSCN	0.43	7.65	0.35	1.41e-13	Diastolic blood pressure;
LUAD	cis	rs41311933	0.656	rs41273412	chr9:123880570	T/C	cg13567360	chr9:123745713	C5	-0.73	-8.46	-0.38	4.36e-16	Coronary artery disease;
LUAD	cis	rs4006360	0.632	rs4986668	chr17:39250408	T/G	cg16090541	chr17:39240343	KRTAP4-7	-0.36	-6.44	-0.3	3.32e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.55	-9.48	-0.42	1.88e-19	Urate levels;
LUAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg02951883	chr7:2050386	MAD1L1	0.71	11.71	0.49	1.28e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg12927641	chr6:109611667	NA	-0.48	-8.07	-0.37	7.15e-15	Reticulocyte fraction of red cells;
LUAD	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg04450456	chr4:17643702	FAM184B	0.37	7.26	0.33	1.9e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7811528	0.591	rs11770552	chr7:2709471	C/T	cg11411865	chr7:2701802	TTYH3	0.57	7.31	0.33	1.35e-12	Schizophrenia;
LUAD	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg03161606	chr19:29218774	NA	0.6	7.48	0.34	4.42e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs6906287	0.647	rs973944	chr6:118850956	T/G	cg18833306	chr6:118973337	C6orf204	0.47	8.43	0.38	5.36e-16	Electrocardiographic conduction measures;
LUAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg24642844	chr7:1081250	C7orf50	-0.93	-13.8	-0.56	4.79e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2882667	0.898	rs2116789	chr5:138394262	G/T	cg04439458	chr5:138467593	SIL1	-0.4	-7.23	-0.33	2.29e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs3806843	0.576	rs246027	chr5:140333601	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1864400	0.645	rs2249005	chr10:43627280	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.51	-8.52	-0.38	2.93e-16	Hirschsprung disease;
LUAD	cis	rs3772130	0.923	rs13434284	chr3:121482842	C/A	cg20356878	chr3:121714668	ILDR1	0.52	8.17	0.37	3.58e-15	Cognitive performance;
LUAD	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg17971929	chr21:40555470	PSMG1	0.53	8.19	0.37	3.06e-15	Cognitive function;
LUAD	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg26384229	chr12:38710491	ALG10B	0.41	7.09	0.33	5.63e-12	Morning vs. evening chronotype;
LUAD	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg13722127	chr7:150037890	RARRES2	0.45	7.69	0.35	1.01e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg15691649	chr6:25882328	NA	0.4	6.43	0.3	3.37e-10	Blood metabolite levels;
LUAD	cis	rs4917300	0.626	rs1388796	chr8:143096437	A/G	cg25363559	chr8:143086065	NA	-0.47	-9.4	-0.42	3.58e-19	Amyotrophic lateral sclerosis;
LUAD	cis	rs9914544	0.545	rs8077775	chr17:18809543	A/G	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.5	-0.3	2.33e-10	Educational attainment (years of education);
LUAD	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.71	-0.31	6.35e-11	Triglycerides;
LUAD	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg17761419	chr8:57350749	NA	-0.52	-7.89	-0.36	2.69e-14	Obesity-related traits;
LUAD	cis	rs8060686	0.516	rs10852439	chr16:68288331	T/C	cg26727032	chr16:67993705	SLC12A4	-0.51	-8.42	-0.38	5.85e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg00933542	chr6:150070202	PCMT1	0.43	9.24	0.41	1.26e-18	Lung cancer;
LUAD	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg04727924	chr7:799746	HEATR2	-0.53	-7.19	-0.33	2.93e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.92	0.36	2.07e-14	Depression;
LUAD	cis	rs877282	0.945	rs11253390	chr10:788678	A/G	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	cis	rs1594829	0.535	rs17055121	chr8:26170975	C/T	cg13160058	chr8:26243215	BNIP3L	-0.35	-7.83	-0.36	3.91e-14	Height;
LUAD	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg20991723	chr1:152506922	NA	0.35	6.94	0.32	1.45e-11	Hair morphology;
LUAD	cis	rs9329289	0.851	rs9732077	chr10:2539925	A/T	cg18171855	chr10:2543474	NA	0.34	6.63	0.31	9.96e-11	Age-related hearing impairment;
LUAD	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21028142	chr17:79581711	NPLOC4	0.45	9.82	0.43	1.21e-20	Eye color traits;
LUAD	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg22496339	chr2:162101262	NA	0.42	6.7	0.31	6.84e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.52	0.3	1.99e-10	Menarche (age at onset);
LUAD	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg10518543	chr12:38710700	ALG10B	-0.43	-7.01	-0.32	9.31e-12	Heart rate;
LUAD	cis	rs67073037	0.956	rs4666125	chr2:29112923	T/C	cg09522027	chr2:28974177	PPP1CB	0.47	6.67	0.31	8.13e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
LUAD	cis	rs4356932	0.967	rs6835736	chr4:76962494	A/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.52	-0.3	2.05e-10	Blood protein levels;
LUAD	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.46	0.3	2.86e-10	Cognitive test performance;
LUAD	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg13010199	chr12:38710504	ALG10B	0.4	6.65	0.31	9.13e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg12373951	chr3:133503437	NA	0.37	7.41	0.34	6.94e-13	Iron status biomarkers;
LUAD	cis	rs807669	0.933	rs712959	chr22:19159015	C/T	cg24911827	chr22:19170109	CLTCL1	0.33	6.89	0.32	2.01e-11	Metabolite levels;
LUAD	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg20701182	chr2:24300061	SF3B14	0.58	6.66	0.31	8.55e-11	Lymphocyte counts;
LUAD	trans	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg04565464	chr8:145669602	NFKBIL2	0.45	6.67	0.31	7.93e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg05340658	chr4:99064831	C4orf37	0.46	7.56	0.34	2.56e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.17	-0.33	3.32e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.3	0.37	1.41e-15	Rheumatoid arthritis;
LUAD	cis	rs909341	0.710	rs6089953	chr20:62291008	C/T	cg04115418	chr20:62273971	STMN3	0.34	6.45	0.3	3.01e-10	Atopic dermatitis;
LUAD	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg22676075	chr6:135203613	NA	0.42	7.58	0.35	2.24e-13	Red blood cell count;
LUAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg11941060	chr3:133502564	NA	-0.63	-11.32	-0.48	3.79e-26	Iron status biomarkers;
LUAD	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18876405	chr7:65276391	NA	0.57	9.38	0.42	3.98e-19	Aortic root size;
LUAD	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg11859384	chr17:80120422	CCDC57	0.48	8.67	0.39	9.09e-17	Life satisfaction;
LUAD	cis	rs494562	0.892	rs683218	chr6:86118584	A/G	cg13315970	chr6:86159197	NT5E	0.74	8.34	0.38	1.04e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg14582100	chr15:45693742	SPATA5L1	0.5	9.36	0.41	4.73e-19	Homoarginine levels;
LUAD	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg17173187	chr15:85201210	NMB	0.49	8.4	0.38	7.07e-16	Schizophrenia;
LUAD	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg00310523	chr12:86230176	RASSF9	0.4	7.97	0.36	1.53e-14	Major depressive disorder;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg15362363	chr18:268256	THOC1	-0.42	-7.01	-0.32	9.76e-12	Cancer;
LUAD	cis	rs739496	0.843	rs598710	chr12:111973141	A/C	cg10833066	chr12:111807467	FAM109A	0.43	6.67	0.31	8.22e-11	Platelet count;
LUAD	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg18811423	chr2:55921094	PNPT1	-0.44	-7.17	-0.33	3.28e-12	Metabolic syndrome;
LUAD	cis	rs2580764	0.566	rs2972072	chr2:55295370	G/T	cg09592903	chr2:55203963	RTN4	0.42	9.41	0.42	3.09e-19	Mean platelet volume;
LUAD	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg24450063	chr1:156163899	SLC25A44	1.17	27.96	0.81	3.41e-98	Testicular germ cell tumor;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12889510	chr2:204399188	RAPH1	-0.46	-7.06	-0.32	6.98e-12	Height;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08576197	chr17:80170622	CCDC57	-0.41	-6.96	-0.32	1.26e-11	Cancer;
LUAD	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg19077165	chr18:44547161	KATNAL2	0.43	7.51	0.34	3.63e-13	Personality dimensions;
LUAD	trans	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.64	0.49	2.27e-27	Mean corpuscular volume;
LUAD	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg14582100	chr15:45693742	SPATA5L1	0.43	8.59	0.39	1.63e-16	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.7	0.39	7.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs739496	0.843	rs583140	chr12:111985954	G/A	cg10833066	chr12:111807467	FAM109A	0.41	6.5	0.3	2.22e-10	Platelet count;
LUAD	cis	rs1448094	0.967	rs7313443	chr12:86332940	G/A	cg00310523	chr12:86230176	RASSF9	0.35	7.56	0.34	2.58e-13	Major depressive disorder;
LUAD	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg01324343	chr3:183735012	ABCC5	0.96	25.62	0.78	4.64e-88	Anterior chamber depth;
LUAD	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg23283495	chr1:209979779	IRF6	0.72	9.17	0.41	2.14e-18	Cleft lip with or without cleft palate;
LUAD	trans	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg02002194	chr4:3960332	NA	-0.27	-6.4	-0.3	4.07e-10	Retinal vascular caliber;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg27620946	chr8:42011116	AP3M2	0.41	6.54	0.3	1.8e-10	Diastolic blood pressure;
LUAD	cis	rs752010	0.631	rs4660549	chr1:42088102	A/G	cg06885757	chr1:42089581	HIVEP3	0.65	14.29	0.57	4.61e-38	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22496380	chr5:211416	CCDC127	-0.95	-13.32	-0.54	4.88e-34	Breast cancer;
LUAD	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg25456477	chr12:86230367	RASSF9	0.32	6.5	0.3	2.23e-10	Major depressive disorder;
LUAD	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg08601574	chr20:25228251	PYGB	-0.47	-8.91	-0.4	1.53e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg07936489	chr17:37558343	FBXL20	-0.48	-7.58	-0.35	2.26e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg21280719	chr6:42927975	GNMT	-0.38	-11.75	-0.5	8.81e-28	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs17490626	0.533	rs12771890	chr10:71189483	T/A	cg12610070	chr10:71211762	TSPAN15	-0.4	-10.14	-0.44	9.32e-22	Thrombosis;
LUAD	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg23262073	chr20:60523788	NA	-0.46	-7.41	-0.34	7.12e-13	Body mass index;
LUAD	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.766	rs351748	chr6:109532296	C/T	cg21918786	chr6:109611834	NA	0.44	8.01	0.36	1.1e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.77	-0.31	4.31e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2239547	0.522	rs2581823	chr3:53022076	C/G	cg11645453	chr3:52864694	ITIH4	-0.57	-11.03	-0.47	5.02e-25	Schizophrenia;
LUAD	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg10589385	chr1:150898437	SETDB1	0.39	7.42	0.34	6.51e-13	Tonsillectomy;
LUAD	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg03233332	chr7:66118400	NA	-0.45	-6.89	-0.32	2.07e-11	Aortic root size;
LUAD	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg07423050	chr13:99094983	FARP1	0.62	11.53	0.49	6.26e-27	Neuroticism;
LUAD	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg02880119	chr16:3481970	NA	0.55	8.21	0.37	2.64e-15	Body mass index (adult);
LUAD	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.44	-7.31	-0.33	1.35e-12	Insulin-like growth factors;
LUAD	cis	rs13315871	0.929	rs11717700	chr3:58250876	T/A	cg20936604	chr3:58311152	NA	-0.76	-7.48	-0.34	4.24e-13	Cholesterol, total;
LUAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg09436375	chr6:42928200	GNMT	-0.3	-8.67	-0.39	9.24e-17	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs17152411	0.901	rs7098050	chr10:126657015	G/T	cg07906193	chr10:126599966	NA	0.53	7.31	0.33	1.35e-12	Height;
LUAD	cis	rs7107174	0.901	rs7110387	chr11:78117875	A/G	cg02023728	chr11:77925099	USP35	0.42	6.4	0.3	4.09e-10	Testicular germ cell tumor;
LUAD	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg09509183	chr1:209979624	IRF6	0.58	8.88	0.4	1.99e-17	Cleft lip with or without cleft palate;
LUAD	cis	rs62400317	0.793	rs6924185	chr6:45017228	C/A	cg18551225	chr6:44695536	NA	-0.55	-8.57	-0.38	2.02e-16	Total body bone mineral density;
LUAD	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg12199221	chr5:83017078	HAPLN1	-0.4	-6.37	-0.3	5.07e-10	Prostate cancer;
LUAD	cis	rs4343996	0.719	rs10254665	chr7:3483504	T/G	cg21248987	chr7:3385318	SDK1	0.35	6.5	0.3	2.24e-10	Motion sickness;
LUAD	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg00634984	chr7:65235879	NA	0.48	6.74	0.31	5.29e-11	Aortic root size;
LUAD	cis	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg07460842	chr6:66804631	NA	1.17	27.35	0.8	1.48e-95	Exhaled nitric oxide output;
LUAD	cis	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg02508848	chr16:68573721	ZFP90	-0.42	-6.55	-0.3	1.72e-10	Ulcerative colitis;
LUAD	trans	rs587242	1.000	rs2968487	chr1:96887370	C/T	cg10631902	chr5:14652156	NA	0.43	7.17	0.33	3.28e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs877282	0.838	rs11253408	chr10:796374	T/C	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	cis	rs7607369	0.559	rs13027908	chr2:219660374	T/C	cg02176678	chr2:219576539	TTLL4	-0.54	-10.46	-0.45	6.41e-23	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs2797160	1.000	rs1739357	chr6:126019655	T/G	cg05901451	chr6:126070800	HEY2	0.45	6.67	0.31	8.11e-11	Endometrial cancer;
LUAD	cis	rs12579753	0.917	rs12366599	chr12:82212112	C/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-7.76	-0.35	6.44e-14	Resting heart rate;
LUAD	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg19041857	chr6:27730383	NA	-0.37	-6.39	-0.3	4.33e-10	Parkinson's disease;
LUAD	cis	rs9473147	0.543	rs1004173	chr6:47445017	C/T	cg12968598	chr6:47444699	CD2AP	0.36	6.35	0.3	5.41e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2274273	0.840	rs11547116	chr14:55738165	T/C	cg04306507	chr14:55594613	LGALS3	0.41	8.5	0.38	3.3e-16	Protein biomarker;
LUAD	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg05754148	chr16:3507555	NAT15	0.5	7.22	0.33	2.44e-12	Body mass index (adult);
LUAD	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg04546413	chr19:29218101	NA	0.57	7.39	0.34	8e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs698833	0.892	rs698801	chr2:44691662	G/C	cg04920474	chr2:44395004	PPM1B	0.41	7.45	0.34	5.44e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg23950597	chr19:37808831	NA	-0.63	-7.58	-0.35	2.24e-13	Coronary artery calcification;
LUAD	cis	rs6554196	0.525	rs12499367	chr4:55505911	C/T	cg18836493	chr4:55524333	KIT	-0.35	-6.47	-0.3	2.69e-10	Monocyte count;
LUAD	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg00898013	chr13:113819073	PROZ	0.72	12.96	0.53	1.34e-32	Platelet distribution width;
LUAD	cis	rs11893307	0.509	rs62179690	chr2:191529873	T/C	cg11845111	chr2:191398756	TMEM194B	-0.48	-6.94	-0.32	1.51e-11	Mean platelet volume;
LUAD	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.54	-0.52	6.67e-31	Hip circumference adjusted for BMI;
LUAD	trans	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg26043149	chr18:55253948	FECH	-0.41	-6.71	-0.31	6.24e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg14558114	chr2:88469736	THNSL2	0.69	7.06	0.32	6.94e-12	Plasma clusterin levels;
LUAD	cis	rs9393692	0.557	rs12660432	chr6:26317384	C/T	cg13736514	chr6:26305472	NA	-0.53	-8.63	-0.39	1.23e-16	Educational attainment;
LUAD	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.75	8.27	0.37	1.75e-15	Initial pursuit acceleration;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12019576	chr4:154388535	KIAA0922	-0.45	-7.14	-0.33	4.08e-12	Height;
LUAD	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-8.02	-0.36	1.05e-14	Total body bone mineral density;
LUAD	cis	rs3752645	1.000	rs17341680	chr7:106782397	G/T	cg02696742	chr7:106810147	HBP1	-0.69	-6.46	-0.3	2.88e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg26597838	chr10:835615	NA	0.85	13.3	0.54	5.98e-34	Eosinophil percentage of granulocytes;
LUAD	cis	rs7731657	0.537	rs2189509	chr5:130316093	A/G	cg08523029	chr5:130500466	HINT1	-0.57	-7.33	-0.34	1.2e-12	Fasting plasma glucose;
LUAD	trans	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg06606381	chr12:133084897	FBRSL1	-0.49	-6.39	-0.3	4.26e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7119038	0.818	rs10892288	chr11:118644694	A/G	cg19308663	chr11:118741387	NA	0.48	6.75	0.31	4.95e-11	Sjögren's syndrome;
LUAD	cis	rs7274811	0.723	rs6120329	chr20:32210238	T/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.46	-6.93	-0.32	1.63e-11	Height;
LUAD	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12310025	chr6:25882481	NA	-0.56	-8.13	-0.37	4.71e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	9.9	0.43	6.34e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4389656	0.767	rs274704	chr5:6728340	A/G	cg10857441	chr5:6722123	POLS	-0.47	-7.94	-0.36	1.87e-14	Coronary artery disease;
LUAD	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg01689657	chr7:91764605	CYP51A1	0.35	8.77	0.39	4.54e-17	Breast cancer;
LUAD	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-8.74	-0.39	5.56e-17	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg07917127	chr4:99064746	C4orf37	0.42	6.97	0.32	1.24e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.87	-16.74	-0.63	1.21e-48	Menarche (age at onset);
LUAD	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.39	-6.36	-0.3	5.1e-10	Multiple sclerosis;
LUAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14159672	chr1:205819179	PM20D1	0.46	7.58	0.35	2.21e-13	Parkinson's disease;
LUAD	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg15704280	chr7:45808275	SEPT13	-0.5	-7.93	-0.36	2e-14	HDL cholesterol;
LUAD	cis	rs2637266	0.663	rs846581	chr10:78497984	C/T	cg18941641	chr10:78392320	NA	0.31	6.59	0.31	1.29e-10	Pulmonary function;
LUAD	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.39	0.34	7.96e-13	Tonsillectomy;
LUAD	cis	rs3106136	0.967	rs72665658	chr4:95144761	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.6	-0.35	1.89e-13	Capecitabine sensitivity;
LUAD	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg06221963	chr1:154839813	KCNN3	0.84	19.84	0.69	2.18e-62	Prostate cancer;
LUAD	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg19336497	chr11:14380999	RRAS2	-0.67	-14.38	-0.57	1.89e-38	Sense of smell;
LUAD	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg02251663	chr11:14281053	SPON1	-0.35	-6.79	-0.31	3.75e-11	Mitochondrial DNA levels;
LUAD	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.6	11.47	0.49	1.06e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4713675	0.565	rs4713659	chr6:33667839	A/G	cg13859433	chr6:33739653	LEMD2	-0.28	-6.78	-0.31	4.06e-11	Plateletcrit;
LUAD	cis	rs7009516	0.716	rs4559243	chr8:24221015	A/G	cg01759110	chr8:24241694	ADAMDEC1	0.33	6.52	0.3	2.06e-10	Hair greying;
LUAD	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg10755058	chr3:40428713	ENTPD3	0.46	8.5	0.38	3.35e-16	Renal cell carcinoma;
LUAD	cis	rs7523050	0.643	rs12725689	chr1:109405151	T/C	cg08274380	chr1:109419600	GPSM2	0.77	6.7	0.31	6.54e-11	Fat distribution (HIV);
LUAD	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg08885076	chr2:99613938	TSGA10	-0.41	-7.21	-0.33	2.63e-12	Chronic sinus infection;
LUAD	cis	rs9341808	0.718	rs9343971	chr6:80882056	C/T	cg08355045	chr6:80787529	NA	0.58	10.5	0.45	4.44e-23	Sitting height ratio;
LUAD	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg11189052	chr15:85197271	WDR73	0.64	8.22	0.37	2.57e-15	Schizophrenia;
LUAD	cis	rs758324	0.947	rs72793242	chr5:131242506	A/T	cg25547332	chr5:131281432	NA	-0.45	-6.87	-0.32	2.27e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7264396	0.563	rs73902913	chr20:34432784	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-7.46	-0.34	5.05e-13	Total cholesterol levels;
LUAD	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg05340658	chr4:99064831	C4orf37	0.55	9.5	0.42	1.62e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg03467027	chr4:99064603	C4orf37	0.43	7.02	0.32	8.86e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6060717	0.529	rs6060535	chr20:34235522	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.2	-0.33	2.78e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg21433313	chr16:3507492	NAT15	0.75	12.63	0.52	3.04e-31	Tuberculosis;
LUAD	cis	rs7274811	0.681	rs186026	chr20:31951993	G/T	cg13403462	chr20:32256071	NECAB3;C20orf134	0.47	7.22	0.33	2.46e-12	Height;
LUAD	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg06074448	chr4:187884817	NA	-0.36	-7.09	-0.33	5.68e-12	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg24801067	chr17:62843696	NA	-0.54	-7.57	-0.35	2.34e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg01448562	chr3:133502909	NA	-0.67	-12.49	-0.52	1.09e-30	Iron status biomarkers;
LUAD	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg05805236	chr11:65401703	PCNXL3	-0.52	-8.64	-0.39	1.19e-16	Acne (severe);
LUAD	cis	rs593982	0.920	rs4930298	chr11:65448108	T/A	cg08755490	chr11:65554678	OVOL1	-1.23	-12.58	-0.52	4.56e-31	Atopic dermatitis;
LUAD	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.4	6.62	0.31	1.08e-10	Lymphocyte counts;
LUAD	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg14159672	chr1:205819179	PM20D1	0.74	14.87	0.59	1.63e-40	Menarche (age at onset);
LUAD	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg02221422	chr11:68192511	LRP5	-0.41	-6.67	-0.31	7.91e-11	Total body bone mineral density;
LUAD	cis	rs2579500	0.807	rs6753926	chr2:97298949	T/C	cg23100626	chr2:96804247	ASTL	-0.29	-7.38	-0.34	8.41e-13	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs7503807	0.935	rs62068348	chr17:78608575	T/C	cg09596252	chr17:78655493	RPTOR	0.41	7.9	0.36	2.49e-14	Obesity;
LUAD	trans	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg19862616	chr7:65841803	NCRNA00174	1.04	25.82	0.78	6.23e-89	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg07404485	chr7:94953653	PON1	-0.48	-6.94	-0.32	1.48e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7072216	0.881	rs2182169	chr10:100148004	T/C	cg26618903	chr10:100175079	PYROXD2	-0.3	-6.47	-0.3	2.66e-10	Metabolite levels;
LUAD	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg05590025	chr7:65112418	INTS4L2	-0.78	-8.26	-0.37	1.9e-15	Diabetic kidney disease;
LUAD	cis	rs6005807	0.719	rs58049055	chr22:29007850	A/G	cg12565055	chr22:29076175	TTC28	0.75	8.76	0.39	4.71e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs9796	0.866	rs516156	chr15:41381257	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.38	-7.22	-0.33	2.5e-12	Menopause (age at onset);
LUAD	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.34	-0.34	1.08e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs72928364	0.929	rs10511182	chr3:100772835	C/G	cg10123952	chr3:100791384	NA	0.7	8.02	0.36	1.05e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.11	-0.4	3.38e-18	Bipolar disorder and schizophrenia;
LUAD	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg00769240	chr8:12517080	NA	-0.43	-8.36	-0.38	9.09e-16	Blood pressure (smoking interaction);
LUAD	cis	rs62238980	0.614	rs117432936	chr22:32382309	G/T	cg00543991	chr22:32367038	NA	0.92	8.48	0.38	3.7e-16	Childhood ear infection;
LUAD	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg13180566	chr4:1052158	NA	-0.39	-6.78	-0.31	4.17e-11	Recombination rate (females);
LUAD	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.4	-7.62	-0.35	1.66e-13	Menopause (age at onset);
LUAD	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg10518543	chr12:38710700	ALG10B	-0.43	-7.05	-0.32	7.16e-12	Morning vs. evening chronotype;
LUAD	cis	rs56046484	0.750	rs12900078	chr15:85523969	G/A	cg08123816	chr15:85640762	PDE8A	-0.44	-6.38	-0.3	4.64e-10	Testicular germ cell tumor;
LUAD	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg05805236	chr11:65401703	PCNXL3	-0.56	-9.36	-0.41	4.69e-19	Acne (severe);
LUAD	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Body mass index;
LUAD	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg04034577	chr2:241836375	C2orf54	-0.52	-11.58	-0.49	4.12e-27	Urinary metabolites;
LUAD	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg06221963	chr1:154839813	KCNN3	-0.84	-19.89	-0.7	1.25e-62	Prostate cancer;
LUAD	cis	rs8017423	0.647	rs4904679	chr14:90821801	C/T	cg14092571	chr14:90743983	NA	0.39	6.54	0.3	1.77e-10	Mortality in heart failure;
LUAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg22105103	chr4:187893119	NA	0.54	11.55	0.49	5.37e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg18854424	chr1:2615690	NA	0.43	9.38	0.41	4.03e-19	Ulcerative colitis;
LUAD	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg14728415	chr7:32535168	LSM5;AVL9	0.7	12.75	0.53	9.8e-32	Cognitive ability;
LUAD	cis	rs4268898	0.552	rs35331966	chr2:24367828	C/T	cg06627628	chr2:24431161	ITSN2	0.43	7.45	0.34	5.26e-13	Asthma;
LUAD	cis	rs6499255	0.951	rs12232410	chr16:69736851	G/A	cg00738113	chr16:70207722	CLEC18C	-0.38	-6.43	-0.3	3.48e-10	IgE levels;
LUAD	cis	rs7107174	1.000	rs10793309	chr11:78093799	G/A	cg19901956	chr11:77921274	USP35	-0.48	-6.75	-0.31	4.94e-11	Testicular germ cell tumor;
LUAD	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg09455208	chr3:40491958	NA	0.65	14.16	0.57	1.5e-37	Renal cell carcinoma;
LUAD	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg03690763	chr11:133734501	NA	-0.35	-8.36	-0.38	9.03e-16	Childhood ear infection;
LUAD	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg11707310	chr1:2537719	MMEL1	0.37	7.85	0.36	3.39e-14	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg08219700	chr8:58056026	NA	0.49	7.17	0.33	3.48e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs76878669	0.561	rs4930363	chr11:66169676	C/T	cg18002602	chr11:66138449	SLC29A2	0.46	9.88	0.43	7.69e-21	Educational attainment (years of education);
LUAD	cis	rs2996428	0.709	rs12127399	chr1:3721609	G/A	cg17848003	chr1:3704513	LRRC47	0.51	10.1	0.44	1.25e-21	Red cell distribution width;
LUAD	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg19610905	chr11:61596333	FADS2	-0.69	-9.75	-0.43	2.2e-20	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg16606324	chr3:10149918	C3orf24	0.67	9.77	0.43	1.76e-20	Alzheimer's disease;
LUAD	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.14	0.37	4.52e-15	Menopause (age at onset);
LUAD	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.46	7.44	0.34	5.76e-13	Lung cancer in ever smokers;
LUAD	cis	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg07460842	chr6:66804631	NA	-0.7	-12.83	-0.53	4.53e-32	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs10979	0.964	rs9496683	chr6:143898845	G/A	cg25407410	chr6:143891975	LOC285740	-0.65	-10.28	-0.45	2.91e-22	Hypospadias;
LUAD	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.51	-8.11	-0.37	5.55e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg06547715	chr2:218990976	CXCR2	-0.3	-7.19	-0.33	3.02e-12	Colorectal cancer;
LUAD	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg24818145	chr4:99064322	C4orf37	0.5	8.11	0.37	5.69e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.08	0.33	5.99e-12	Platelet count;
LUAD	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21659725	chr3:3221576	CRBN	-0.5	-8.3	-0.37	1.38e-15	Body mass index;
LUAD	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg25767906	chr1:53392781	SCP2	0.42	7.62	0.35	1.64e-13	Monocyte count;
LUAD	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg11859384	chr17:80120422	CCDC57	0.52	9.27	0.41	9.34e-19	Life satisfaction;
LUAD	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg26384229	chr12:38710491	ALG10B	0.47	7.59	0.35	2.05e-13	Bladder cancer;
LUAD	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg10555106	chr1:3691387	LOC388588	0.4	6.41	0.3	3.83e-10	Red cell distribution width;
LUAD	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg06641503	chr3:48959341	ARIH2	-0.41	-7.98	-0.36	1.35e-14	Parkinson's disease;
LUAD	cis	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg07460842	chr6:66804631	NA	0.93	14.85	0.59	1.95e-40	Exhaled nitric oxide levels;
LUAD	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg10589385	chr1:150898437	SETDB1	0.45	8.26	0.37	1.91e-15	Melanoma;
LUAD	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg07570687	chr10:102243282	WNT8B	0.44	6.8	0.31	3.5e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg17724175	chr1:150552817	MCL1	0.39	9.28	0.41	9.17e-19	Tonsillectomy;
LUAD	cis	rs7072216	0.763	rs6584201	chr10:100170209	T/C	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.68	-0.39	8.56e-17	Metabolite levels;
LUAD	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg18404041	chr3:52824283	ITIH1	0.42	7.67	0.35	1.19e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12681287	0.604	rs7017716	chr8:87429001	A/C	cg27223183	chr8:87520930	FAM82B	-0.64	-9.49	-0.42	1.71e-19	Caudate activity during reward;
LUAD	cis	rs7132746	0.553	rs7399276	chr12:86189219	A/G	cg18827107	chr12:86230957	RASSF9	-0.46	-6.5	-0.3	2.25e-10	Lewy body disease;
LUAD	cis	rs1457451	0.688	rs7589055	chr2:65862734	G/A	cg16240816	chr2:65861662	NA	0.41	6.5	0.3	2.28e-10	Iron status biomarkers;
LUAD	cis	rs2412208	0.816	rs7525119	chr1:7061430	C/T	cg20434152	chr1:7120926	CAMTA1	-0.3	-6.53	-0.3	1.87e-10	Survival in sporadic amyotrophic lateral sclerosis;
LUAD	cis	rs10821973	0.527	rs55832840	chr10:64026314	G/A	cg09941381	chr10:64027924	RTKN2	-0.35	-6.85	-0.32	2.64e-11	Hypothyroidism;
LUAD	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.41	6.98	0.32	1.15e-11	Total body bone mineral density;
LUAD	cis	rs13315871	0.929	rs7643185	chr3:58311158	A/C	cg20936604	chr3:58311152	NA	0.74	8.09	0.37	6.26e-15	Cholesterol, total;
LUAD	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg11645453	chr3:52864694	ITIH4	-0.36	-6.79	-0.31	3.84e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11098699	0.784	rs11098701	chr4:124216461	C/G	cg09941581	chr4:124220074	SPATA5	0.49	8.01	0.36	1.1e-14	Mosquito bite size;
LUAD	cis	rs731174	0.921	rs6686264	chr1:38192337	A/T	cg12339802	chr1:38156545	C1orf109	-0.43	-6.81	-0.31	3.36e-11	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg23625390	chr15:77176239	SCAPER	0.39	6.91	0.32	1.77e-11	Blood metabolite levels;
LUAD	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg26587870	chr6:27730563	NA	-0.44	-7.15	-0.33	3.76e-12	Parkinson's disease;
LUAD	cis	rs1461503	0.932	rs11218909	chr11:122842613	C/T	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.13	15.22	0.59	4.98e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg05368731	chr17:41323189	NBR1	0.87	14.5	0.58	6e-39	Menopause (age at onset);
LUAD	cis	rs6432018	1.000	rs10210225	chr2:9739225	A/G	cg12832956	chr2:9616023	IAH1	-0.37	-6.6	-0.31	1.26e-10	Heart rate variability traits;
LUAD	cis	rs4356932	1.000	rs8878	chr4:76942300	C/T	cg24176760	chr4:76958061	ART3;CXCL11	0.36	6.56	0.3	1.61e-10	Blood protein levels;
LUAD	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg07930552	chr6:133119739	C6orf192	0.59	7.06	0.32	7.05e-12	Type 2 diabetes nephropathy;
LUAD	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg23109721	chr2:106886537	NA	-0.48	-6.79	-0.31	3.8e-11	Facial morphology (factor 23);
LUAD	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg03806693	chr22:41940476	POLR3H	-0.76	-10.78	-0.46	4.37e-24	Vitiligo;
LUAD	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg25767906	chr1:53392781	SCP2	-0.55	-10.21	-0.44	4.87e-22	Monocyte count;
LUAD	cis	rs6121246	0.609	rs4453755	chr20:30331047	G/A	cg21427119	chr20:30132790	HM13	-0.35	-6.44	-0.3	3.34e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg18129748	chr3:49941408	MST1R	-0.4	-6.56	-0.3	1.56e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg24558204	chr6:135376177	HBS1L	0.45	8.37	0.38	8.58e-16	Red blood cell count;
LUAD	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg15485101	chr11:133734466	NA	0.34	7.81	0.36	4.43e-14	Childhood ear infection;
LUAD	cis	rs7727544	0.647	rs6898270	chr5:131421190	C/T	cg14196790	chr5:131705035	SLC22A5	0.49	8.66	0.39	9.79e-17	Blood metabolite levels;
LUAD	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.34	0.38	1.03e-15	Menopause (age at onset);
LUAD	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-9.73	-0.43	2.58e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3862260	0.905	rs3850870	chr1:120161037	C/T	cg11530693	chr1:120165357	ZNF697	0.68	13.29	0.54	6.06e-34	Systemic lupus erythematosus;
LUAD	cis	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg05084668	chr3:125655381	ALG1L	-0.63	-10.1	-0.44	1.2e-21	Blood pressure (smoking interaction);
LUAD	cis	rs7274811	0.846	rs57668191	chr20:32289763	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.5	-7.06	-0.32	6.78e-12	Height;
LUAD	cis	rs4604732	0.588	rs12045675	chr1:247623915	C/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.17	0.33	3.31e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg01620082	chr3:125678407	NA	-0.44	-6.7	-0.31	6.82e-11	Depression;
LUAD	cis	rs12545109	0.765	rs2576594	chr8:57412126	T/G	cg19413350	chr8:57351067	NA	-0.44	-6.5	-0.3	2.24e-10	Obesity-related traits;
LUAD	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg00898013	chr13:113819073	PROZ	-0.84	-15.04	-0.59	2.87e-41	Platelet distribution width;
LUAD	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg25838465	chr1:92012736	NA	0.7	15.13	0.59	1.2e-41	Breast cancer;
LUAD	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg00784671	chr22:46762841	CELSR1	-0.65	-7.82	-0.36	4.3e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs77861329	0.920	rs9846049	chr3:52120214	A/G	cg08692210	chr3:52188851	WDR51A	0.87	8.66	0.39	1.04e-16	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8051149	0.688	rs12444533	chr16:87869711	C/T	cg10099957	chr16:87869757	SLC7A5	0.49	8.53	0.38	2.64e-16	Blood metabolite levels;
LUAD	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.52	7.05	0.32	7.28e-12	Platelet count;
LUAD	cis	rs7178572	0.568	rs12911371	chr15:77689050	C/T	cg15453836	chr15:77711506	NA	-0.36	-6.42	-0.3	3.59e-10	Type 2 diabetes;
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01171360	chr6:293285	DUSP22	-0.73	-12.95	-0.53	1.53e-32	Menopause (age at onset);
LUAD	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.06e-19	Life satisfaction;
LUAD	cis	rs11178918	0.585	rs10879336	chr12:72174070	C/G	cg10168894	chr12:72148281	RAB21	-0.53	-6.58	-0.3	1.39e-10	Economic and political preferences (time);
LUAD	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.87	0.36	2.95e-14	Morning vs. evening chronotype;
LUAD	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg08085267	chr17:45401833	C17orf57	0.66	12.18	0.51	1.9e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs887829	0.569	rs2008595	chr2:234637192	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-8.75	-0.39	5.13e-17	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	trans	rs10411161	0.808	rs892040	chr19:52396645	A/G	cg22319618	chr22:45562946	NUP50	-0.68	-7.45	-0.34	5.24e-13	Breast cancer;
LUAD	cis	rs1079204	1.000	rs10178462	chr2:219083353	G/T	cg05728596	chr2:219128475	GPBAR1	1.04	9.98	0.44	3.44e-21	Smooth-surface caries;
LUAD	trans	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg26043149	chr18:55253948	FECH	0.51	8.09	0.37	6.29e-15	Bone mineral density;
LUAD	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg24531977	chr5:56204891	C5orf35	-0.4	-6.5	-0.3	2.26e-10	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg06221963	chr1:154839813	KCNN3	-0.85	-20.1	-0.7	1.48e-63	Prostate cancer;
LUAD	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg21475434	chr5:93447410	FAM172A	0.73	8.51	0.38	2.97e-16	Diabetic retinopathy;
LUAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08280861	chr8:58055591	NA	-0.55	-6.94	-0.32	1.44e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9905704	0.633	rs2018966	chr17:56477565	C/T	cg19466818	chr17:56409534	MIR142	0.34	6.9	0.32	1.95e-11	Testicular germ cell tumor;
LUAD	cis	rs2235649	0.833	rs7190337	chr16:1850469	A/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.4	-6.44	-0.3	3.26e-10	Blood metabolite levels;
LUAD	cis	rs11771526	0.901	rs62456038	chr7:32288663	G/A	cg27511599	chr7:32358540	NA	0.54	6.57	0.3	1.45e-10	Body mass index;
LUAD	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg11663144	chr21:46675770	NA	-0.59	-11.76	-0.5	7.73e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6906287	0.559	rs7751467	chr6:118893861	T/A	cg18833306	chr6:118973337	C6orf204	0.47	8.27	0.37	1.75e-15	Electrocardiographic conduction measures;
LUAD	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg19622623	chr12:86230825	RASSF9	-0.55	-9.77	-0.43	1.76e-20	Major depressive disorder;
LUAD	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg06630425	chr16:818451	MSLN	-0.44	-7.4	-0.34	7.56e-13	Mean corpuscular volume;
LUAD	cis	rs7100689	0.556	rs10788541	chr10:82016530	T/G	cg00277334	chr10:82204260	NA	-0.45	-7.36	-0.34	9.88e-13	Post bronchodilator FEV1;
LUAD	trans	rs7395662	0.777	rs7114291	chr11:48608251	A/G	cg15704280	chr7:45808275	SEPT13	-0.41	-6.47	-0.3	2.64e-10	HDL cholesterol;
LUAD	cis	rs757081	0.667	rs12420958	chr11:17100432	G/T	cg15432903	chr11:17409602	KCNJ11	-0.4	-6.49	-0.3	2.45e-10	Systolic blood pressure;
LUAD	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg23625390	chr15:77176239	SCAPER	0.39	7.1	0.33	5.32e-12	Blood metabolite levels;
LUAD	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg27170947	chr2:26402098	FAM59B	-0.69	-9.41	-0.42	3.19e-19	Gut microbiome composition (summer);
LUAD	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg24803719	chr17:45855879	NA	-0.33	-7.26	-0.33	1.85e-12	IgG glycosylation;
LUAD	cis	rs7593730	0.551	rs6706685	chr2:161151559	T/C	cg22609984	chr2:161126801	NA	0.57	10.09	0.44	1.35e-21	Type 2 diabetes;
LUAD	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-10.4	-0.45	1.05e-22	Lymphocyte counts;
LUAD	cis	rs977987	0.806	rs6564252	chr16:75388940	C/T	cg03315344	chr16:75512273	CHST6	0.65	14.12	0.57	2.29e-37	Dupuytren's disease;
LUAD	cis	rs367943	0.637	rs6891711	chr5:113009026	G/T	cg12552261	chr5:112820674	MCC	-0.42	-7.35	-0.34	1.04e-12	Type 2 diabetes;
LUAD	cis	rs2235544	0.554	rs7540270	chr1:54484682	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.25	-6.74	-0.31	5.35e-11	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUAD	cis	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg22729335	chr19:2427816	TIMM13	0.87	17.81	0.65	2.36e-53	Cortisol levels (saliva);
LUAD	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg17279839	chr7:150038598	RARRES2	0.46	7.58	0.35	2.15e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs10911363	0.509	rs10911339	chr1:183442097	C/T	cg09173681	chr1:183549694	NCF2	0.57	10.45	0.45	6.94e-23	Systemic lupus erythematosus;
LUAD	cis	rs2485376	1.000	rs2993089	chr10:104078760	G/C	cg20641465	chr10:103991465	PITX3	-0.58	-10.64	-0.46	1.43e-23	QT interval;
LUAD	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.41	-11.05	-0.47	4.14e-25	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.47	0.38	4.11e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10802521	chr3:52805072	NEK4	-0.62	-11.07	-0.47	3.45e-25	Bipolar disorder;
LUAD	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg10523679	chr1:76189770	ACADM	0.89	15.74	0.61	2.8e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg04775059	chr7:64541387	NA	0.5	6.82	0.31	3.07e-11	Aortic root size;
LUAD	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26314531	chr2:26401878	FAM59B	0.73	9.91	0.43	6.1e-21	Gut microbiome composition (summer);
LUAD	cis	rs6840360	0.550	rs7689266	chr4:152561048	T/C	cg22705602	chr4:152727874	NA	-0.4	-6.94	-0.32	1.52e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs490234	0.702	rs1891035	chr9:128258684	T/C	cg14078157	chr9:128172775	NA	-0.46	-8.13	-0.37	4.75e-15	Mean arterial pressure;
LUAD	cis	rs3916	0.794	rs10431386	chr12:121128926	A/G	cg27246729	chr12:121163418	ACADS	-0.38	-6.78	-0.31	4.17e-11	Urinary metabolites (H-NMR features);
LUAD	cis	rs11811982	0.793	rs80297171	chr1:227516320	A/G	cg24860534	chr1:227506868	CDC42BPA	0.65	7.18	0.33	3.17e-12	Optic disc area;
LUAD	cis	rs4853525	0.522	rs7574840	chr2:191584236	C/G	cg27211696	chr2:191398769	TMEM194B	-0.4	-6.71	-0.31	6.14e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-8.04	-0.36	9.25e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.42e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.51	-8.07	-0.37	7.14e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6988985	0.560	rs4418320	chr8:143944138	G/A	cg10324643	chr8:143916377	GML	0.3	6.41	0.3	3.94e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg17644776	chr2:200775616	C2orf69	-0.52	-6.53	-0.3	1.9e-10	Schizophrenia;
LUAD	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg09222892	chr1:25734099	RHCE	-0.49	-8.98	-0.4	9.17e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs4653767	1.000	rs708774	chr1:226921530	C/G	cg05049329	chr1:226924846	ITPKB	0.46	8.22	0.37	2.55e-15	Parkinson's disease;
LUAD	cis	rs354225	0.584	rs6739140	chr2:54823502	C/G	cg01766943	chr2:54829624	SPTBN1	0.39	7.24	0.33	2.12e-12	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg13047869	chr3:10149882	C3orf24	-0.68	-11.61	-0.49	3.07e-27	Alzheimer's disease;
LUAD	trans	rs10805346	0.531	rs12498927	chr4:10115523	C/T	cg26043149	chr18:55253948	FECH	-0.49	-8.18	-0.37	3.31e-15	Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg06547715	chr2:218990976	CXCR2	0.28	6.64	0.31	9.55e-11	Colorectal cancer;
LUAD	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg11214544	chr1:2391121	NA	-0.59	-11.36	-0.48	2.87e-26	Non-obstructive azoospermia;
LUAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08280861	chr8:58055591	NA	0.54	6.91	0.32	1.79e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg13319975	chr6:146136371	FBXO30	0.64	10.96	0.47	9.13e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg04000281	chr11:63949212	NA	-0.26	-6.46	-0.3	2.86e-10	Platelet count;
LUAD	cis	rs11112613	0.775	rs61200462	chr12:105969271	G/A	cg03607813	chr12:105948248	NA	0.77	11.96	0.5	1.38e-28	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg16647868	chr5:131706066	SLC22A5	0.41	7.05	0.32	7.4e-12	Blood metabolite levels;
LUAD	cis	rs300774	0.925	rs300737	chr2:170576	A/G	cg21211680	chr2:198530	NA	-0.5	-7.91	-0.36	2.29e-14	Suicide attempts in bipolar disorder;
LUAD	cis	rs1461503	0.934	rs7119533	chr11:122832683	A/T	cg27398637	chr11:122830231	C11orf63	-0.32	-6.42	-0.3	3.74e-10	Menarche (age at onset);
LUAD	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg10356904	chr22:49881777	NA	-0.39	-7.17	-0.33	3.42e-12	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg07967210	chr17:47022446	SNF8	0.35	6.38	0.3	4.54e-10	Type 2 diabetes;
LUAD	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg00666640	chr1:248458726	OR2T12	0.3	7.24	0.33	2.14e-12	Common traits (Other);
LUAD	cis	rs68170813	0.559	rs6951639	chr7:106817639	A/G	cg23024343	chr7:107201750	COG5	0.49	7.09	0.33	5.65e-12	Coronary artery disease;
LUAD	trans	rs1728785	1.000	rs1170439	chr16:68608511	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	11.54	0.49	5.91e-27	Ulcerative colitis;
LUAD	cis	rs72634258	0.554	rs17374292	chr1:7881234	C/T	cg26816564	chr1:7831052	VAMP3	0.66	9.09	0.4	3.87e-18	Inflammatory bowel disease;
LUAD	trans	rs9393777	0.777	rs35984974	chr6:27410422	G/A	cg06606381	chr12:133084897	FBRSL1	-0.79	-8.51	-0.38	3.15e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs11229555	0.645	rs34350060	chr11:58184902	T/C	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs3784262	0.643	rs8030766	chr15:58369209	A/G	cg12031962	chr15:58353849	ALDH1A2	0.39	7.83	0.36	4.02e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs16867321	0.639	rs13028421	chr2:181444035	G/T	cg23363182	chr2:181467187	NA	0.43	7.04	0.32	7.82e-12	Obesity;
LUAD	trans	rs11885103	0.791	rs28698506	chr2:584970	T/C	cg12228919	chr15:44955936	SPG11	-0.44	-6.67	-0.31	7.89e-11	Heschl's gyrus morphology;
LUAD	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg14416269	chr4:6271139	WFS1	0.61	12.61	0.52	3.65e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg06740227	chr12:86229804	RASSF9	-0.41	-7.36	-0.34	9.88e-13	Major depressive disorder;
LUAD	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06873352	chr17:61820015	STRADA	0.82	18.17	0.66	5.72e-55	Prudent dietary pattern;
LUAD	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18876405	chr7:65276391	NA	0.42	6.68	0.31	7.53e-11	Aortic root size;
LUAD	cis	rs9826463	0.757	rs60001529	chr3:142282717	G/A	cg20824294	chr3:142316082	PLS1	0.44	7.77	0.35	6.2e-14	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg27068330	chr11:65405492	SIPA1	0.57	9.08	0.4	4.24e-18	Acne (severe);
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg14016074	chr11:809449	RPLP2	0.42	6.69	0.31	6.96e-11	Diastolic blood pressure;
LUAD	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg04234412	chr22:24373322	LOC391322	0.78	15.29	0.6	2.44e-42	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs870825	0.616	rs4444872	chr4:185628405	A/G	cg04058563	chr4:185651563	MLF1IP	0.84	13.72	0.55	1.09e-35	Blood protein levels;
LUAD	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg24801067	chr17:62843696	NA	0.59	8.19	0.37	3.09e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg18306943	chr3:40428807	ENTPD3	0.42	7.02	0.32	9.01e-12	Renal cell carcinoma;
LUAD	cis	rs62005083	0.500	rs10135300	chr14:74574561	G/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.57	7.84	0.36	3.73e-14	Mean corpuscular volume;
LUAD	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg12908607	chr1:44402522	ARTN	0.45	8.81	0.39	3.18e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7737355	1.000	rs7719126	chr5:130613749	T/C	cg06307176	chr5:131281290	NA	0.46	7.36	0.34	9.6e-13	Life satisfaction;
LUAD	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg22496339	chr2:162101262	NA	0.73	13.52	0.55	7.32e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07167872	chr1:205819463	PM20D1	0.89	19.82	0.69	2.61e-62	Menarche (age at onset);
LUAD	cis	rs4664304	0.754	rs17829052	chr2:160821067	G/A	cg23995753	chr2:160760732	LY75	-0.39	-7.01	-0.32	9.37e-12	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg14863489	chr8:121457196	MTBP;MRPL13	-0.37	-6.35	-0.3	5.65e-10	Schizophrenia;
LUAD	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18876405	chr7:65276391	NA	-0.6	-10.26	-0.45	3.25e-22	Cotinine glucuronidation;
LUAD	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg03885332	chr11:832357	CD151	-0.42	-7.99	-0.36	1.29e-14	Mean platelet volume;
LUAD	cis	rs2882667	0.861	rs10037106	chr5:138365490	G/T	cg04439458	chr5:138467593	SIL1	-0.39	-7.12	-0.33	4.76e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06590470	chr9:34523253	ENHO	0.42	6.36	0.3	5.11e-10	Gut microbiome composition (summer);
LUAD	cis	rs7814319	0.838	rs10955067	chr8:97230982	C/T	cg20787634	chr8:97240163	UQCRB	-0.39	-7.57	-0.35	2.29e-13	Lung function (FVC);
LUAD	cis	rs12618769	0.625	rs2278207	chr2:99163261	T/A	cg10123293	chr2:99228465	UNC50	0.5	8.7	0.39	7.25e-17	Bipolar disorder;
LUAD	cis	rs11077998	0.967	rs7350963	chr17:80491067	G/A	cg10255544	chr17:80519551	FOXK2	0.35	7.0	0.32	9.8e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg06028605	chr16:24865363	SLC5A11	-0.53	-8.15	-0.37	4.18e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg02269571	chr22:50332266	NA	0.59	8.93	0.4	1.36e-17	Schizophrenia;
LUAD	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg24308560	chr3:49941425	MST1R	-0.48	-8.03	-0.36	9.65e-15	Body mass index;
LUAD	cis	rs11811982	0.793	rs77317375	chr1:227511926	A/G	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs7680126	0.536	rs3796841	chr4:10007904	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	8.54	0.38	2.38e-16	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg16680214	chr1:154839983	KCNN3	-0.63	-13.16	-0.54	2.08e-33	Prostate cancer;
LUAD	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg07570687	chr10:102243282	WNT8B	0.48	7.39	0.34	8.08e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.25	0.33	1.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg00310523	chr12:86230176	RASSF9	0.37	7.61	0.35	1.74e-13	Major depressive disorder;
LUAD	cis	rs1448094	0.842	rs7309725	chr12:86440612	T/C	cg00310523	chr12:86230176	RASSF9	0.34	7.19	0.33	2.88e-12	Major depressive disorder;
LUAD	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg21153622	chr11:89784906	NA	-0.33	-6.44	-0.3	3.19e-10	HDL cholesterol;
LUAD	trans	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg06606381	chr12:133084897	FBRSL1	-0.62	-7.37	-0.34	9.02e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.45	-7.89	-0.36	2.6e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/G	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.57	7.61	0.35	1.86e-13	Type 2 diabetes;
LUAD	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg00666640	chr1:248458726	OR2T12	0.3	7.22	0.33	2.5e-12	Common traits (Other);
LUAD	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg15028436	chr7:37888078	TXNDC3	0.36	7.38	0.34	8.36e-13	Alzheimer's disease (late onset);
LUAD	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg15445000	chr17:37608096	MED1	0.44	8.14	0.37	4.49e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg22442454	chr1:209979470	IRF6	0.53	7.08	0.33	6.12e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg27494647	chr7:150038898	RARRES2	0.55	9.35	0.41	5.3e-19	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs7584330	0.504	rs61213635	chr2:238428132	A/G	cg14458575	chr2:238380390	NA	0.54	8.68	0.39	8.36e-17	Prostate cancer;
LUAD	cis	rs9467773	1.000	rs1977201	chr6:26573674	T/C	cg11502198	chr6:26597334	ABT1	0.61	10.06	0.44	1.76e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs9462027	1.000	rs9462027	chr6:34797241	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.3	-6.84	-0.32	2.77e-11	Systemic lupus erythematosus;
LUAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg26354017	chr1:205819088	PM20D1	0.61	11.58	0.49	4.05e-27	Menarche (age at onset);
LUAD	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg25358565	chr5:93447407	FAM172A	0.66	7.75	0.35	6.74e-14	Diabetic retinopathy;
LUAD	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg04772025	chr11:68637568	NA	0.57	9.14	0.41	2.7e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11030122	0.702	rs10500590	chr11:3964724	T/C	cg18678763	chr11:4115507	RRM1	-0.44	-7.35	-0.34	1.05e-12	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs853679	0.546	rs35656932	chr6:28191288	G/T	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.13	-0.48	1.99e-25	Depression;
LUAD	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg22875332	chr1:76189707	ACADM	0.74	11.04	0.47	4.5e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs11039798	1.000	rs11039904	chr11:48682597	T/A	cg02254774	chr11:50257496	LOC441601	0.53	6.68	0.31	7.68e-11	Axial length;
LUAD	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg22535103	chr8:58192502	C8orf71	-0.69	-7.5	-0.34	3.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg05182265	chr7:156933206	UBE3C	-0.78	-16.6	-0.63	5.04e-48	Body mass index;
LUAD	cis	rs10392	0.516	rs4141892	chr20:37590758	T/C	cg27552599	chr20:37590471	DHX35	0.38	6.35	0.3	5.56e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg07636037	chr3:49044803	WDR6	0.35	6.48	0.3	2.61e-10	Resting heart rate;
LUAD	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg15962314	chr1:44399869	ARTN	0.36	8.17	0.37	3.6e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs78761021	0.685	rs62064483	chr17:9796862	C/T	cg26853458	chr17:9805074	RCVRN	0.41	7.9	0.36	2.49e-14	Type 2 diabetes;
LUAD	cis	rs6785206	0.772	rs2811493	chr3:128357299	C/G	cg16766828	chr3:128327626	NA	-0.87	-8.97	-0.4	1e-17	Lymphocyte percentage of white cells;
LUAD	cis	rs4888262	0.508	rs4544266	chr16:74660993	C/A	cg01733217	chr16:74700730	RFWD3	0.5	8.13	0.37	4.71e-15	Testicular germ cell tumor;
LUAD	cis	rs9503598	0.636	rs6596974	chr6:3465833	C/T	cg00476032	chr6:3446245	SLC22A23	0.32	6.77	0.31	4.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.37	6.52	0.3	2.04e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.36	0.38	9.25e-16	Lymphocyte percentage of white cells;
LUAD	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg02549819	chr16:58548995	SETD6	0.83	6.93	0.32	1.59e-11	Schizophrenia;
LUAD	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg20307385	chr11:47447363	PSMC3	0.65	11.15	0.48	1.73e-25	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg20307385	chr11:47447363	PSMC3	0.66	11.13	0.48	2.12e-25	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.66	0.31	8.67e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-17.14	-0.64	2.24e-50	Exhaled nitric oxide output;
LUAD	cis	rs6543140	0.964	rs4851010	chr2:103056127	A/T	cg04239558	chr2:103089729	SLC9A4	-0.34	-6.96	-0.32	1.34e-11	Blood protein levels;
LUAD	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg03609598	chr5:56110824	MAP3K1	-0.61	-8.2	-0.37	2.92e-15	Initial pursuit acceleration;
LUAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07167872	chr1:205819463	PM20D1	0.88	19.74	0.69	6.07e-62	Menarche (age at onset);
LUAD	trans	rs10802346	0.545	rs2362253	chr1:246371676	G/A	cg13514129	chr1:39547527	MACF1	0.62	11.17	0.48	1.52e-25	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg07757535	chr4:1339547	NA	0.31	6.36	0.3	5.32e-10	Longevity;
LUAD	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg18252515	chr7:66147081	NA	-0.62	-6.72	-0.31	5.75e-11	Diabetic kidney disease;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg27656398	chr12:123451108	ABCB9	0.4	6.4	0.3	4.05e-10	Optic cup area;
LUAD	cis	rs59104589	0.521	rs3771584	chr2:242399493	C/G	cg08645257	chr2:242211290	HDLBP	0.39	6.66	0.31	8.71e-11	Fibrinogen levels;
LUAD	cis	rs6732160	0.932	rs6546803	chr2:73381315	C/G	cg01422370	chr2:73384389	NA	0.34	6.7	0.31	6.68e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg13390004	chr1:15929781	NA	0.48	8.5	0.38	3.18e-16	Systolic blood pressure;
LUAD	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg05368731	chr17:41323189	NBR1	0.97	20.69	0.71	3.2e-66	Menopause (age at onset);
LUAD	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg17063962	chr7:91808500	NA	-0.63	-10.74	-0.46	5.78e-24	Breast cancer;
LUAD	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg26513180	chr16:89883248	FANCA	0.78	7.09	0.33	5.51e-12	Skin colour saturation;
LUAD	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg21862992	chr11:68658383	NA	0.52	9.62	0.42	5.84e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7586879	0.796	rs10187348	chr2:25078415	G/C	cg04586622	chr2:25135609	ADCY3	0.35	7.12	0.33	4.63e-12	Body mass index;
LUAD	cis	rs13315871	0.929	rs76226186	chr3:58318499	C/T	cg12435725	chr3:58293450	RPP14	-0.73	-7.69	-0.35	1.08e-13	Cholesterol, total;
LUAD	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-10.73	-0.46	6.25e-24	Schizophrenia;
LUAD	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg14844989	chr11:31128820	NA	-0.45	-8.33	-0.38	1.15e-15	Red blood cell count;
LUAD	trans	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg14917512	chr19:3094685	GNA11	-0.58	-6.88	-0.32	2.19e-11	Diabetic kidney disease;
LUAD	trans	rs28735056	0.967	rs498541	chr18:77589655	G/A	cg05926928	chr17:57297772	GDPD1	-0.48	-6.89	-0.32	2.04e-11	Schizophrenia;
LUAD	cis	rs6743376	0.554	rs11123160	chr2:113836165	A/T	cg09040174	chr2:113837401	NA	0.65	8.69	0.39	7.9e-17	Inflammatory biomarkers;
LUAD	trans	rs2262909	0.962	rs436662	chr19:22232107	C/T	cg05197062	chr11:11642011	GALNTL4	-0.58	-9.0	-0.4	7.43e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11716531	0.574	rs62256311	chr3:27271505	G/A	cg02860705	chr3:27208620	NA	0.65	10.04	0.44	2e-21	Diastolic blood pressure;
LUAD	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg15147215	chr3:52552868	STAB1	0.41	7.48	0.34	4.3e-13	Bipolar disorder;
LUAD	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg09359103	chr1:154839909	KCNN3	-0.9	-19.24	-0.68	1.05e-59	Prostate cancer;
LUAD	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.89	0.32	2.09e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs991427	1.000	rs11105973	chr12:91472347	A/T	cg11428724	chr1:18957632	PAX7	0.42	6.49	0.3	2.37e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg22444338	chr7:1054449	C7orf50	0.41	6.96	0.32	1.32e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs4664304	0.772	rs12692572	chr2:160743793	G/A	cg23995753	chr2:160760732	LY75	0.36	6.5	0.3	2.23e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08280861	chr8:58055591	NA	0.55	7.16	0.33	3.53e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg02990361	chr1:107599529	PRMT6	-0.56	-9.3	-0.41	7.81e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg17724175	chr1:150552817	MCL1	0.4	9.73	0.43	2.44e-20	Melanoma;
LUAD	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.33	-6.48	-0.3	2.59e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg04546413	chr19:29218101	NA	0.7	10.3	0.45	2.36e-22	Methadone dose in opioid dependence;
LUAD	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.66	-11.64	-0.49	2.4200000000000002e-27	Breast cancer;
LUAD	cis	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.53	6.48	0.3	2.51e-10	Depression;
LUAD	cis	rs3823572	0.564	rs2346275	chr7:133662166	G/A	cg03336402	chr7:133662267	EXOC4	-0.41	-7.59	-0.35	2.08e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.77	-0.46	4.38e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg23752985	chr2:85803571	VAMP8	0.34	6.71	0.31	6.35e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	trans	rs10802346	0.545	rs1770003	chr1:246408356	A/G	cg13514129	chr1:39547527	MACF1	0.61	10.87	0.47	1.88e-24	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs9650657	0.769	rs6601527	chr8:10665444	C/A	cg27411982	chr8:10470053	RP1L1	-0.4	-6.91	-0.32	1.75e-11	Neuroticism;
LUAD	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg06618935	chr21:46677482	NA	-0.46	-9.3	-0.41	7.88e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg05082376	chr22:42548792	NA	-0.38	-6.69	-0.31	7.22e-11	Cognitive function;
LUAD	cis	rs9902453	0.967	rs1042173	chr17:28525011	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.48	8.16	0.37	3.82e-15	Coffee consumption (cups per day);
LUAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.51	-9.11	-0.4	3.38e-18	Lymphocyte counts;
LUAD	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1728785	0.818	rs1170430	chr16:68604954	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.34	0.45	1.73e-22	Ulcerative colitis;
LUAD	cis	rs9399401	0.710	rs12190271	chr6:142681409	A/G	cg04461802	chr6:142623433	GPR126	-0.4	-7.52	-0.34	3.37e-13	Chronic obstructive pulmonary disease;
LUAD	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg16405210	chr4:1374714	KIAA1530	-0.61	-9.33	-0.41	6.01e-19	Longevity;
LUAD	cis	rs751728	1.000	rs2395449	chr6:33728755	T/A	cg13859433	chr6:33739653	LEMD2	-0.38	-8.84	-0.39	2.64e-17	Crohn's disease;
LUAD	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg10755058	chr3:40428713	ENTPD3	0.35	6.66	0.31	8.76e-11	Renal cell carcinoma;
LUAD	cis	rs4523957	0.559	rs216174	chr17:2164898	A/G	cg16513277	chr17:2031491	SMG6	0.68	9.87	0.43	8.42e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg11062466	chr8:58055876	NA	0.65	8.47	0.38	4.22e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg03388025	chr16:89894329	SPIRE2	-0.32	-7.51	-0.34	3.46e-13	Vitiligo;
LUAD	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21659725	chr3:3221576	CRBN	-0.86	-18.3	-0.66	1.52e-55	Intelligence (multi-trait analysis);
LUAD	cis	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg23950597	chr19:37808831	NA	-0.55	-7.0	-0.32	1e-11	Coronary artery calcification;
LUAD	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg00071950	chr4:10020882	SLC2A9	0.85	18.69	0.67	2.77e-57	Bone mineral density;
LUAD	cis	rs7267979	0.844	rs6083824	chr20:25363057	G/A	cg08601574	chr20:25228251	PYGB	-0.41	-7.69	-0.35	1.07e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg10909506	chr17:38081995	ORMDL3	0.38	6.56	0.3	1.59e-10	Self-reported allergy;
LUAD	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg25358565	chr5:93447407	FAM172A	0.64	7.66	0.35	1.24e-13	Diabetic retinopathy;
LUAD	trans	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg01620082	chr3:125678407	NA	-0.82	-8.39	-0.38	7.49e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg20701182	chr2:24300061	SF3B14	0.64	7.21	0.33	2.61e-12	Lymphocyte counts;
LUAD	cis	rs7072216	0.763	rs12259939	chr10:100169021	T/C	cg26618903	chr10:100175079	PYROXD2	-0.38	-8.29	-0.37	1.5e-15	Metabolite levels;
LUAD	cis	rs11696501	0.688	rs6094197	chr20:44316492	C/T	cg11783356	chr20:44313418	WFDC10B	-0.51	-8.36	-0.38	9.42e-16	Brain structure;
LUAD	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg21782813	chr7:2030301	MAD1L1	0.4	6.56	0.3	1.55e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg02428538	chr16:24856791	SLC5A11	0.5	6.95	0.32	1.4e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg07211511	chr3:129823064	LOC729375	-0.58	-7.64	-0.35	1.51e-13	Blood pressure (smoking interaction);
LUAD	trans	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-10.92	-0.47	1.25e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2235642	0.859	rs9927529	chr16:1619488	C/T	cg26528668	chr16:1614120	IFT140	0.54	9.73	0.43	2.56e-20	Coronary artery disease;
LUAD	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg10755058	chr3:40428713	ENTPD3	0.47	8.68	0.39	8.54e-17	Renal cell carcinoma;
LUAD	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg20290983	chr6:43655470	MRPS18A	1.06	27.23	0.8	4.61e-95	IgG glycosylation;
LUAD	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg20135002	chr11:47629003	NA	-0.42	-7.45	-0.34	5.46e-13	Subjective well-being;
LUAD	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.43	-0.3	3.48e-10	Schizophrenia;
LUAD	cis	rs9329221	0.655	rs4292737	chr8:10259115	A/G	cg21775007	chr8:11205619	TDH	-0.37	-6.44	-0.3	3.3e-10	Neuroticism;
LUAD	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg13319975	chr6:146136371	FBXO30	0.59	9.9	0.43	6.15e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.47	-0.3	2.8e-10	Coronary artery disease;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg24947615	chr21:44515479	U2AF1	-0.4	-6.37	-0.3	4.95e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	7.19	0.33	2.98e-12	Platelet count;
LUAD	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg03388025	chr16:89894329	SPIRE2	0.5	13.01	0.53	8.8e-33	Vitiligo;
LUAD	cis	rs12545109	0.571	rs7002482	chr8:57295200	C/T	cg21220214	chr8:57350948	NA	-0.64	-8.86	-0.4	2.32e-17	Obesity-related traits;
LUAD	cis	rs2839627	0.561	rs4148970	chr21:44313293	A/G	cg03543861	chr21:44258195	NA	0.66	9.22	0.41	1.41e-18	Information processing speed;
LUAD	cis	rs71403859	0.803	rs10500562	chr16:71627731	A/C	cg08717414	chr16:71523259	ZNF19	-0.57	-6.71	-0.31	6.2e-11	Post bronchodilator FEV1;
LUAD	cis	rs2279817	0.780	rs11585339	chr1:18000120	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-7.79	-0.35	5.11e-14	Neuroticism;
LUAD	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg02975922	chr3:195473998	MUC4	-0.42	-7.05	-0.32	7.22e-12	Pancreatic cancer;
LUAD	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg15181151	chr6:150070149	PCMT1	0.39	7.8	0.35	5e-14	Lung cancer;
LUAD	trans	rs2898857	0.524	rs11652146	chr17:47422363	G/A	cg11430096	chr6:110968061	CDK19	-0.49	-7.41	-0.34	6.9e-13	Cancer;
LUAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06873352	chr17:61820015	STRADA	0.81	17.7	0.65	7.06e-53	Prudent dietary pattern;
LUAD	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg20701182	chr2:24300061	SF3B14	0.54	6.51	0.3	2.18e-10	Lymphocyte counts;
LUAD	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg00083206	chr6:110721305	DDO	-0.44	-8.11	-0.37	5.64e-15	Platelet distribution width;
LUAD	cis	rs7173743	1.000	rs4567668	chr15:79140692	T/C	cg15571903	chr15:79123663	NA	-0.36	-6.85	-0.32	2.66e-11	Coronary artery disease;
LUAD	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	9.43	0.42	2.81e-19	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg07917127	chr4:99064746	C4orf37	0.45	7.5	0.34	3.8e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg09654669	chr8:57350985	NA	-0.65	-9.79	-0.43	1.53e-20	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg16479474	chr6:28041457	NA	0.44	7.4	0.34	7.22e-13	Depression;
LUAD	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg09455208	chr3:40491958	NA	0.51	10.87	0.47	2.01e-24	Renal cell carcinoma;
LUAD	cis	rs9768139	0.708	rs35057023	chr7:158114748	G/A	cg24154853	chr7:158122151	PTPRN2	0.55	10.91	0.47	1.38e-24	Calcium levels;
LUAD	cis	rs6543140	0.964	rs62154972	chr2:103048738	G/A	cg03938978	chr2:103052716	IL18RAP	0.36	6.93	0.32	1.59e-11	Blood protein levels;
LUAD	cis	rs4601821	0.895	rs7130431	chr11:113238223	A/C	cg14159747	chr11:113255604	NA	0.44	8.18	0.37	3.45e-15	Alcoholic chronic pancreatitis;
LUAD	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg12292205	chr6:26970375	C6orf41	0.38	6.73	0.31	5.43e-11	Schizophrenia;
LUAD	trans	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg01620082	chr3:125678407	NA	-0.44	-6.67	-0.31	7.84e-11	Depression;
LUAD	cis	rs16866061	1.000	rs34345163	chr2:225459080	A/G	cg12698349	chr2:225449008	CUL3	0.77	13.38	0.55	2.71e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs9560113	0.959	rs9555802	chr13:112179504	T/C	cg14154082	chr13:112174009	NA	0.36	6.75	0.31	4.77e-11	Menarche (age at onset);
LUAD	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00149659	chr3:10157352	C3orf10	0.6	8.3	0.37	1.46e-15	Alzheimer's disease;
LUAD	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg09491104	chr22:46646882	C22orf40	-0.68	-12.27	-0.51	7.99e-30	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9902453	0.868	rs9902340	chr17:28476458	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.59	-0.42	7.79e-20	Coffee consumption (cups per day);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26947572	chr2:10442852	HPCAL1	-0.65	-6.55	-0.3	1.69e-10	Type 2 diabetes;
LUAD	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-6.36	-0.3	5.22e-10	Body mass index;
LUAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg15117754	chr3:10150083	C3orf24	0.41	6.66	0.31	8.38e-11	Alzheimer's disease;
LUAD	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg21475434	chr5:93447410	FAM172A	0.72	8.1	0.37	6.1e-15	Diabetic retinopathy;
LUAD	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg23029597	chr12:123009494	RSRC2	-0.54	-8.2	-0.37	2.98e-15	Body mass index;
LUAD	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg18105139	chr6:28058856	ZSCAN12L1	0.25	6.5	0.3	2.24e-10	Parkinson's disease;
LUAD	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg10518543	chr12:38710700	ALG10B	0.41	6.38	0.3	4.54e-10	Bladder cancer;
LUAD	trans	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	16.81	0.63	6.47e-49	Exhaled nitric oxide output;
LUAD	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg10518543	chr12:38710700	ALG10B	-0.44	-7.24	-0.33	2.19e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11644478	chr21:40555479	PSMG1	0.71	11.96	0.5	1.29e-28	Cognitive function;
LUAD	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg02176678	chr2:219576539	TTLL4	-0.69	-14.08	-0.56	3.54e-37	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs977987	0.806	rs4146809	chr16:75415775	A/G	cg03315344	chr16:75512273	CHST6	-0.64	-14.0	-0.56	7.48e-37	Dupuytren's disease;
LUAD	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg22117172	chr7:91764530	CYP51A1	-0.4	-8.82	-0.39	3.13e-17	Breast cancer;
LUAD	trans	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.15	26.91	0.79	1.07e-93	Exhaled nitric oxide output;
LUAD	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg09085632	chr11:111637200	PPP2R1B	0.69	10.44	0.45	7.51e-23	Primary sclerosing cholangitis;
LUAD	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg18446336	chr7:2847575	GNA12	-0.32	-6.52	-0.3	1.95e-10	Height;
LUAD	cis	rs34638657	0.732	rs62045962	chr16:82200604	T/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.89	-0.32	2.07e-11	Lung adenocarcinoma;
LUAD	cis	rs1953600	0.729	rs2819872	chr10:81906269	A/G	cg00277334	chr10:82204260	NA	0.37	6.59	0.31	1.33e-10	Sarcoidosis;
LUAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg02869364	chr7:1081709	C7orf50	-0.52	-6.75	-0.31	4.98e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21659725	chr3:3221576	CRBN	0.63	10.85	0.47	2.32e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg04398451	chr17:18023971	MYO15A	-0.65	-11.76	-0.5	7.97e-28	Total body bone mineral density;
LUAD	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.79	-0.35	5.18e-14	Type 2 diabetes;
LUAD	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.08	13.48	0.55	1.06e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg14343924	chr8:8086146	FLJ10661	-0.49	-7.94	-0.36	1.79e-14	Mood instability;
LUAD	cis	rs300774	0.841	rs410690	chr2:203346	G/A	cg21211680	chr2:198530	NA	0.62	8.81	0.39	3.33e-17	Suicide attempts in bipolar disorder;
LUAD	cis	rs4409675	0.597	rs1000431	chr1:28225114	C/T	cg23691781	chr1:28212827	C1orf38	0.38	11.0	0.47	6.6e-25	Corneal astigmatism;
LUAD	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg26924012	chr15:45694286	SPATA5L1	1.02	19.07	0.68	5.59e-59	Homoarginine levels;
LUAD	trans	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg21659725	chr3:3221576	CRBN	-0.57	-9.07	-0.4	4.35e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg01620082	chr3:125678407	NA	-0.44	-6.66	-0.31	8.39e-11	Depression;
LUAD	cis	rs11031096	0.899	rs2412344	chr11:4107584	T/C	cg18678763	chr11:4115507	RRM1	0.37	6.48	0.3	2.6e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg09537434	chr19:41945824	ATP5SL	-0.51	-8.19	-0.37	3.11e-15	Height;
LUAD	cis	rs8051149	0.688	rs16943320	chr16:87870379	A/G	cg10099957	chr16:87869757	SLC7A5	0.47	8.33	0.38	1.16e-15	Blood metabolite levels;
LUAD	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg18402987	chr7:1209562	NA	0.63	9.11	0.41	3.21e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg16850897	chr7:100343110	ZAN	0.65	10.69	0.46	9e-24	Other erythrocyte phenotypes;
LUAD	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg05805236	chr11:65401703	PCNXL3	-0.55	-8.76	-0.39	4.7e-17	Acne (severe);
LUAD	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg13319975	chr6:146136371	FBXO30	-0.66	-11.52	-0.49	6.99e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg25894440	chr7:65020034	NA	-0.59	-6.43	-0.3	3.45e-10	Diabetic kidney disease;
LUAD	cis	rs748404	0.697	rs530683	chr15:43568999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.49	-8.12	-0.37	5e-15	Lung cancer;
LUAD	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2625529	0.713	rs16956634	chr15:72552243	C/G	cg16672083	chr15:72433130	SENP8	0.77	13.19	0.54	1.7e-33	Red blood cell count;
LUAD	cis	rs4594175	0.926	rs11624975	chr14:51628347	T/C	cg23942311	chr14:51606299	NA	0.65	11.11	0.48	2.38e-25	Cancer;
LUAD	cis	rs17095355	1.000	rs12247564	chr10:111721400	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.69	-9.35	-0.41	5.32e-19	Biliary atresia;
LUAD	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg03467027	chr4:99064603	C4orf37	-0.42	-6.9	-0.32	1.85e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23535768	chr15:68570349	FEM1B	-0.53	-6.41	-0.3	3.87e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.71e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg08470875	chr2:26401718	FAM59B	-0.68	-9.14	-0.41	2.66e-18	Gut microbiome composition (summer);
LUAD	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg25894440	chr7:65020034	NA	0.61	6.58	0.3	1.37e-10	Diabetic kidney disease;
LUAD	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg24801067	chr17:62843696	NA	-0.51	-8.17	-0.37	3.49e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg07930552	chr6:133119739	C6orf192	0.86	6.59	0.3	1.35e-10	Type 2 diabetes nephropathy;
LUAD	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg22139774	chr2:100720529	AFF3	-0.39	-7.66	-0.35	1.27e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg27087555	chr16:88793112	FAM38A	-1.15	-14.18	-0.57	1.32e-37	Plateletcrit;
LUAD	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg15147215	chr3:52552868	STAB1	-0.42	-7.54	-0.34	2.85e-13	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.59	0.52	4.33e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6669119	0.668	rs75509607	chr1:19093763	C/T	cg19637330	chr1:19110922	NA	0.62	7.4	0.34	7.6e-13	Percentage gas trapping;
LUAD	cis	rs6543140	0.964	rs10196334	chr2:103090041	T/C	cg03938978	chr2:103052716	IL18RAP	0.35	6.72	0.31	6.04e-11	Blood protein levels;
LUAD	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg12444411	chr7:2802554	GNA12	-0.35	-6.46	-0.3	2.85e-10	Height;
LUAD	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-12.01	-0.5	8.63e-29	Bipolar disorder;
LUAD	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg26587870	chr6:27730563	NA	-0.48	-7.99	-0.36	1.29e-14	Parkinson's disease;
LUAD	cis	rs17270561	0.541	rs2009610	chr6:25967068	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.59	-7.52	-0.34	3.26e-13	Iron status biomarkers;
LUAD	trans	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg06606381	chr12:133084897	FBRSL1	-1.1	-10.02	-0.44	2.46e-21	Intelligence (multi-trait analysis);
LUAD	trans	rs853679	0.546	rs200954	chr6:27838764	C/G	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.4	-0.38	6.84e-16	Depression;
LUAD	cis	rs62400317	0.859	rs62438877	chr6:45089064	A/G	cg18551225	chr6:44695536	NA	-0.54	-8.48	-0.38	3.84e-16	Total body bone mineral density;
LUAD	cis	rs1045714	1.000	rs1045713	chr7:2653579	G/A	cg20813462	chr7:2646259	IQCE	0.67	7.13	0.33	4.32e-12	Urate levels in lean individuals;
LUAD	cis	rs9487051	0.735	rs1761608	chr6:109517706	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.55	-0.34	2.62e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg04989706	chr14:50066350	PPIL5	-0.51	-7.56	-0.35	2.51e-13	Carotid intima media thickness;
LUAD	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg01579765	chr21:45077557	HSF2BP	-0.59	-13.69	-0.55	1.44e-35	Mean corpuscular volume;
LUAD	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg24069376	chr3:38537580	EXOG	0.45	10.93	0.47	1.2e-24	Electrocardiographic conduction measures;
LUAD	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg03929089	chr4:120376271	NA	-0.97	-19.69	-0.69	9.73e-62	Height;
LUAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg07677032	chr17:61819896	STRADA	0.57	10.3	0.45	2.42e-22	Prudent dietary pattern;
LUAD	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg21775007	chr8:11205619	TDH	-0.5	-9.08	-0.4	4.26e-18	Retinal vascular caliber;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg14611774	chr19:9929570	FBXL12	-0.65	-6.37	-0.3	5.04e-10	Type 2 diabetes;
LUAD	cis	rs7120118	0.517	rs56177220	chr11:47328377	C/T	cg13308137	chr11:47528955	CUGBP1	0.37	6.57	0.3	1.51e-10	HDL cholesterol;
LUAD	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.55e-11	Crohn's disease;
LUAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg20302342	chr1:156215951	PAQR6	0.38	8.64	0.39	1.2e-16	Tonsillectomy;
LUAD	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg04450456	chr4:17643702	FAM184B	0.4	7.96	0.36	1.6e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg12179176	chr11:130786555	SNX19	0.48	7.66	0.35	1.27e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs12431939	1.000	rs66806841	chr14:51670524	G/C	cg23942311	chr14:51606299	NA	-0.55	-7.79	-0.35	5.26e-14	Cancer;
LUAD	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs600626	0.588	rs10793124	chr11:75452267	C/G	cg24262691	chr11:75473276	NA	0.55	6.99	0.32	1.06e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg00684032	chr4:1343700	KIAA1530	0.41	6.77	0.31	4.32e-11	Obesity-related traits;
LUAD	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg22683308	chr4:1340831	KIAA1530	-0.48	-7.73	-0.35	7.86e-14	Longevity;
LUAD	cis	rs354225	0.584	rs13432302	chr2:54813938	A/C	cg01766943	chr2:54829624	SPTBN1	0.38	7.0	0.32	1.01e-11	Schizophrenia;
LUAD	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21659725	chr3:3221576	CRBN	0.66	11.38	0.48	2.25e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg19875535	chr5:140030758	IK	-0.44	-7.42	-0.34	6.64e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg13870426	chr17:30244630	NA	-0.56	-6.64	-0.31	9.38e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg15117754	chr3:10150083	C3orf24	0.44	7.05	0.32	7.29e-12	Alzheimer's disease;
LUAD	trans	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	8.8	0.39	3.41e-17	Mean corpuscular volume;
LUAD	trans	rs1728785	1.000	rs7202306	chr16:68587684	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.3	0.45	2.33e-22	Ulcerative colitis;
LUAD	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	7.67	0.35	1.18e-13	Menarche (age at onset);
LUAD	cis	rs17067123	0.614	rs2383271	chr4:180071469	G/A	cg26610307	chr4:180072759	NA	-0.52	-6.74	-0.31	5.24e-11	Response to hepatitis C treatment;
LUAD	trans	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.62	10.24	0.45	3.81e-22	Endometrial cancer;
LUAD	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg02683114	chr2:24398427	C2orf84	0.41	6.91	0.32	1.81e-11	Asthma;
LUAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.81	0.43	1.28e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1697139	0.935	rs1625369	chr5:66513022	C/T	cg16691251	chr5:66510806	NA	0.34	6.44	0.3	3.28e-10	Breast cancer;
LUAD	trans	rs1941687	0.563	rs2032189	chr18:31332200	T/A	cg15819921	chr19:927150	ARID3A	-0.49	-8.38	-0.38	8.06e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs1696756	0.638	rs1285274	chr17:77829907	G/A	cg02876276	chr17:77834299	NA	0.52	7.81	0.36	4.53e-14	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg19743168	chr1:23544995	NA	0.36	6.42	0.3	3.62e-10	Height;
LUAD	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg24818145	chr4:99064322	C4orf37	-0.42	-6.88	-0.32	2.22e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	18.34	0.67	1.09e-55	Bone mineral density;
LUAD	cis	rs9807989	0.801	rs72823663	chr2:102968738	G/C	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.05e-10	Asthma;
LUAD	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg03929089	chr4:120376271	NA	0.59	7.64	0.35	1.46e-13	Axial length;
LUAD	cis	rs12474201	0.928	rs12999586	chr2:46938736	C/T	cg09399716	chr2:46890238	NA	-0.35	-6.42	-0.3	3.59e-10	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg22438603	chr5:127418940	SLC12A2;FLJ33630	-0.53	-6.36	-0.3	5.09e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00166722	chr3:10149974	C3orf24	-0.64	-9.23	-0.41	1.3e-18	Alzheimer's disease;
LUAD	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg12935359	chr14:103987150	CKB	-0.46	-8.04	-0.36	8.96e-15	Body mass index;
LUAD	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg23387056	chr11:14280742	SPON1	0.44	9.41	0.42	3.12e-19	Mitochondrial DNA levels;
LUAD	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg16325326	chr1:53192061	ZYG11B	0.73	14.17	0.57	1.47e-37	Monocyte count;
LUAD	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06544989	chr22:39130855	UNC84B	0.43	7.96	0.36	1.62e-14	Menopause (age at onset);
LUAD	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg26924012	chr15:45694286	SPATA5L1	0.64	10.99	0.47	6.81e-25	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs12541635	0.966	rs7839239	chr8:107020406	C/T	cg10147462	chr8:107024639	NA	0.51	9.25	0.41	1.13e-18	Age of smoking initiation;
LUAD	cis	rs6684514	1.000	rs12024813	chr1:156224529	C/A	cg16558208	chr1:156270281	VHLL	0.5	9.04	0.4	5.9e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg03433033	chr1:76189801	ACADM	-0.7	-11.16	-0.48	1.62e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.39	-0.3	4.33e-10	Aortic root size;
LUAD	cis	rs10979	1.000	rs13197332	chr6:143888095	T/A	cg25407410	chr6:143891975	LOC285740	-0.63	-10.01	-0.44	2.54e-21	Hypospadias;
LUAD	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg04586622	chr2:25135609	ADCY3	0.37	8.54	0.38	2.41e-16	Body mass index;
LUAD	cis	rs500891	0.574	rs3798891	chr6:84117293	C/A	cg08257003	chr6:84140564	ME1	0.34	6.52	0.3	2.01e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	7.6	0.35	1.91e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs7937890	0.810	rs10734224	chr11:14424124	G/T	cg23387056	chr11:14280742	SPON1	-0.4	-8.2	-0.37	2.88e-15	Mitochondrial DNA levels;
LUAD	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.37	0.38	8.27e-16	Platelet count;
LUAD	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg23649088	chr2:200775458	C2orf69	0.6	7.91	0.36	2.29e-14	Schizophrenia;
LUAD	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg17077180	chr1:38461687	NA	-0.48	-9.88	-0.43	7.5e-21	Coronary artery disease;
LUAD	cis	rs367615	0.918	rs4270746	chr5:108876839	T/C	cg17395555	chr5:108820864	NA	0.53	8.63	0.39	1.28e-16	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.72	-0.35	8.41e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg15181151	chr6:150070149	PCMT1	0.32	6.48	0.3	2.63e-10	Testicular germ cell tumor;
LUAD	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg23985595	chr17:80112537	CCDC57	0.42	7.55	0.34	2.67e-13	Life satisfaction;
LUAD	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg08999081	chr20:33150536	PIGU	0.62	13.94	0.56	1.28e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg22532475	chr10:104410764	TRIM8	-0.45	-8.83	-0.39	2.7e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.62	10.73	0.46	6.69e-24	Lymphocyte counts;
LUAD	cis	rs7584330	0.504	rs6742601	chr2:238427940	C/G	cg14458575	chr2:238380390	NA	0.5	8.02	0.36	1.02e-14	Prostate cancer;
LUAD	cis	rs7241530	0.717	rs9949518	chr18:75889092	C/A	cg14642773	chr18:75888474	NA	0.33	6.63	0.31	1.02e-10	Educational attainment (years of education);
LUAD	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg00277334	chr10:82204260	NA	-0.64	-8.75	-0.39	5.28e-17	Post bronchodilator FEV1;
LUAD	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs2235649	0.833	rs9929264	chr16:1851934	T/C	cg08610935	chr16:1836813	NUBP2	-0.48	-7.41	-0.34	6.77e-13	Blood metabolite levels;
LUAD	cis	rs7254827	0.826	rs62127867	chr19:17223260	C/T	cg19418318	chr19:17219073	MYO9B	-0.56	-6.45	-0.3	3.12e-10	Mean platelet volume;
LUAD	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg24644049	chr4:85504048	CDS1	0.88	7.16	0.33	3.55e-12	Skin colour saturation;
LUAD	cis	rs7828089	0.875	rs6998575	chr8:22254499	C/T	cg12081754	chr8:22256438	SLC39A14	0.62	11.44	0.49	1.37e-26	Verbal declarative memory;
LUAD	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg13679303	chr9:96623674	NA	-0.36	-7.36	-0.34	9.98e-13	DNA methylation (variation);
LUAD	cis	rs9469890	0.604	rs78121911	chr6:34503739	T/C	cg17674042	chr6:34482479	PACSIN1	-0.61	-8.13	-0.37	4.87e-15	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs4845570	0.831	rs11588258	chr1:151780728	A/T	cg07092448	chr1:151763213	TDRKH	-0.71	-7.83	-0.36	3.99e-14	Coronary artery disease;
LUAD	cis	rs36096196	0.945	rs12080256	chr1:2251357	C/A	cg06784691	chr1:2245988	NA	-0.33	-6.77	-0.31	4.2e-11	Coronary artery disease;
LUAD	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg01689657	chr7:91764605	CYP51A1	0.38	9.42	0.42	3.02e-19	Breast cancer;
LUAD	trans	rs5756813	0.700	rs1894525	chr22:38186400	G/A	cg19894588	chr14:64061835	NA	-0.46	-6.57	-0.3	1.45e-10	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02359409	chr6:42947317	PEX6	-0.38	-6.77	-0.31	4.36e-11	Plasma homocysteine levels (post-methionine load test);
LUAD	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg02734326	chr4:10020555	SLC2A9	0.64	11.35	0.48	3.04e-26	Bone mineral density;
LUAD	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg03929089	chr4:120376271	NA	-0.96	-19.52	-0.69	5.88e-61	Height;
LUAD	cis	rs713477	1.000	rs7142204	chr14:55908436	G/T	cg13175173	chr14:55914753	NA	0.34	7.12	0.33	4.58e-12	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg11766577	chr21:47581405	C21orf56	-0.46	-7.88	-0.36	2.83e-14	Testicular germ cell tumor;
LUAD	cis	rs9362426	0.887	rs1209113	chr6:88079456	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	6.58	0.3	1.35e-10	Depressive episodes in bipolar disorder;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14516552	chr9:96213518	FAM120AOS;FAM120A	-0.6	-7.39	-0.34	8.13e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01081069	chr19:19643269	YJEFN3	-0.38	-6.62	-0.31	1.07e-10	Height;
LUAD	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-7.99	-0.36	1.29e-14	Total body bone mineral density;
LUAD	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg11871910	chr12:69753446	YEATS4	0.49	7.67	0.35	1.22e-13	Blood protein levels;
LUAD	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg22482690	chr17:47019901	SNF8	0.44	8.37	0.38	8.71e-16	Type 2 diabetes;
LUAD	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg12365402	chr11:9010492	NRIP3	-0.52	-10.55	-0.46	2.87e-23	Hemoglobin concentration;
LUAD	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg06873352	chr17:61820015	STRADA	0.43	7.24	0.33	2.2e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg17724175	chr1:150552817	MCL1	0.39	9.25	0.41	1.08e-18	Tonsillectomy;
LUAD	cis	rs2882667	1.000	rs10064130	chr5:138309307	C/T	cg04439458	chr5:138467593	SIL1	-0.43	-7.81	-0.36	4.54e-14	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.23	-0.41	1.3e-18	Type 2 diabetes;
LUAD	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.79	0.31	3.74e-11	Parkinson's disease;
LUAD	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg07636037	chr3:49044803	WDR6	0.64	12.52	0.52	8.46e-31	Parkinson's disease;
LUAD	cis	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg08601574	chr20:25228251	PYGB	-0.44	-8.05	-0.36	8.28e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1003719	0.788	rs2835595	chr21:38466203	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.31e-16	Eye color traits;
LUAD	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg10591111	chr5:226296	SDHA	0.55	7.12	0.33	4.58e-12	Breast cancer;
LUAD	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.74	13.61	0.55	2.92e-35	Axial length;
LUAD	trans	rs1406428	0.573	rs12613632	chr2:51705755	C/G	cg22798821	chr11:11864085	USP47	0.44	6.36	0.3	5.35e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs71403859	0.730	rs17347255	chr16:71587225	C/T	cg08717414	chr16:71523259	ZNF19	-0.63	-7.5	-0.34	3.85e-13	Post bronchodilator FEV1;
LUAD	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg00666640	chr1:248458726	OR2T12	0.31	7.62	0.35	1.64e-13	Common traits (Other);
LUAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg02524346	chr8:600233	NA	1.07	10.01	0.44	2.53e-21	IgG glycosylation;
LUAD	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg02527881	chr3:46936655	PTH1R	-0.45	-8.73	-0.39	5.87e-17	Colorectal cancer;
LUAD	cis	rs240110	0.539	rs6934256	chr6:101338728	G/A	cg09795085	chr6:101329169	ASCC3	0.49	8.8	0.39	3.52e-17	Neuroticism;
LUAD	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.9	-0.36	2.52e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg01884057	chr2:25150051	NA	0.31	6.41	0.3	3.82e-10	Body mass index;
LUAD	cis	rs750460	0.816	rs4337252	chr15:74226765	G/C	cg23484268	chr15:74220776	LOXL1	0.38	7.52	0.34	3.22e-13	Height;
LUAD	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg11502198	chr6:26597334	ABT1	0.45	7.25	0.33	1.94e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11644478	chr21:40555479	PSMG1	0.71	11.88	0.5	2.7e-28	Cognitive function;
LUAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-7.25	-0.33	2.05e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs78761021	0.867	rs7222664	chr17:9785283	G/C	cg26853458	chr17:9805074	RCVRN	0.34	6.95	0.32	1.41e-11	Type 2 diabetes;
LUAD	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08677398	chr8:58056175	NA	0.53	6.67	0.31	7.86e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12900413	0.687	rs13343248	chr15:90311226	A/T	cg24249390	chr15:90295951	MESP1	-0.34	-6.64	-0.31	9.46e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	trans	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg24644049	chr4:85504048	CDS1	0.89	7.59	0.35	2.05e-13	Skin colour saturation;
LUAD	cis	rs57590327	0.528	rs2229519	chr3:81698130	T/C	cg07356753	chr3:81810745	GBE1	-0.65	-10.28	-0.45	2.78e-22	Extraversion;
LUAD	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg17724175	chr1:150552817	MCL1	0.31	7.14	0.33	3.97e-12	Melanoma;
LUAD	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	7.82	0.36	4.31e-14	Multiple sclerosis;
LUAD	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg22868518	chr11:507468	RNH1	-0.63	-6.45	-0.3	3.15e-10	Body mass index;
LUAD	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg20587970	chr11:113659929	NA	-1.12	-13.27	-0.54	7.43e-34	Hip circumference adjusted for BMI;
LUAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg10150615	chr22:24372951	LOC391322	-0.52	-8.26	-0.37	1.91e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4638749	1.000	rs2198463	chr2:108875093	T/A	cg25838818	chr2:108905173	SULT1C2	-0.54	-8.65	-0.39	1.1e-16	Blood pressure;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04574383	chr2:47169026	MCFD2;TTC7A	0.53	6.56	0.3	1.6e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg19717773	chr7:2847554	GNA12	-0.56	-10.44	-0.45	7.58e-23	Height;
LUAD	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.74	-0.31	5.28e-11	Type 2 diabetes;
LUAD	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg00852783	chr1:26633632	UBXN11	0.44	6.97	0.32	1.26e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg07936489	chr17:37558343	FBXL20	0.46	7.15	0.33	3.91e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg23262073	chr20:60523788	NA	-0.37	-6.43	-0.3	3.54e-10	Body mass index;
LUAD	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg26513180	chr16:89883248	FANCA	0.49	8.26	0.37	1.92e-15	Vitiligo;
LUAD	trans	rs12439619	0.921	rs4778672	chr15:82537354	G/T	cg04831495	chr15:85060580	GOLGA6L5	0.55	8.7	0.39	7.27e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06834434	chr14:75079333	LTBP2	-0.52	-6.65	-0.31	8.99e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10802521	chr3:52805072	NEK4	-0.55	-9.5	-0.42	1.56e-19	Bipolar disorder;
LUAD	cis	rs28655083	0.912	rs2171097	chr16:77085037	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.39	-6.52	-0.3	2.01e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23158103	chr7:148848205	ZNF398	-0.61	-11.18	-0.48	1.35e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg14671364	chr1:107599128	PRMT6	-0.59	-10.36	-0.45	1.49e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg11189052	chr15:85197271	WDR73	0.62	7.85	0.36	3.45e-14	Schizophrenia;
LUAD	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg14396892	chr9:96623032	NA	-0.44	-8.39	-0.38	7.47e-16	DNA methylation (variation);
LUAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg18621852	chr3:10150065	C3orf24	0.42	7.46	0.34	5.08e-13	Alzheimer's disease;
LUAD	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.31	-0.41	7.07e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08280861	chr8:58055591	NA	0.55	7.16	0.33	3.53e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg13319975	chr6:146136371	FBXO30	-0.59	-10.09	-0.44	1.4e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg23711669	chr6:146136114	FBXO30	0.38	6.44	0.3	3.18e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg21659725	chr3:3221576	CRBN	0.4	6.68	0.31	7.75e-11	Resting heart rate;
LUAD	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-14.51	-0.58	5.36e-39	Schizophrenia;
LUAD	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg05890377	chr2:74357713	NA	0.84	12.07	0.51	5.04e-29	Gestational age at birth (maternal effect);
LUAD	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg26597838	chr10:835615	NA	1.01	15.73	0.61	3.14e-44	Eosinophil percentage of granulocytes;
LUAD	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg00750074	chr16:89608354	SPG7	-0.57	-9.97	-0.44	3.72e-21	Multiple myeloma (IgH translocation);
LUAD	cis	rs67311347	0.544	rs6787516	chr3:40355616	C/T	cg09455208	chr3:40491958	NA	0.5	10.61	0.46	1.79e-23	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62238980	0.614	rs4289286	chr22:32458612	G/A	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg11062466	chr8:58055876	NA	0.77	9.39	0.42	3.86e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs28374715	0.662	rs8038983	chr15:41473316	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.9	-16.8	-0.63	6.97e-49	Ulcerative colitis;
LUAD	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.76	-9.68	-0.43	3.83e-20	Body mass index;
LUAD	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg05564831	chr3:52568323	NT5DC2	0.38	6.88	0.32	2.16e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg06263672	chr7:65235340	NA	0.48	6.44	0.3	3.19e-10	Aortic root size;
LUAD	cis	rs7394190	0.748	rs4746146	chr10:75527197	C/T	cg02286717	chr10:75415704	SYNPO2L	-0.36	-6.43	-0.3	3.52e-10	Incident atrial fibrillation;
LUAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg04234412	chr22:24373322	LOC391322	-0.81	-15.58	-0.6	1.46e-43	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg07685180	chr8:600429	NA	-0.95	-8.3	-0.37	1.43e-15	IgG glycosylation;
LUAD	cis	rs7614311	0.594	rs58473894	chr3:63857208	G/C	cg22134162	chr3:63841271	THOC7	-0.38	-6.97	-0.32	1.2e-11	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs9888739	0.858	rs60312440	chr16:31340086	C/T	cg15817542	chr16:31343056	ITGAM	-0.45	-7.52	-0.34	3.28e-13	Systemic lupus erythematosus;
LUAD	cis	rs220324	0.688	rs715744	chr21:43565503	G/C	cg08841829	chr21:43638893	ABCG1	-0.5	-6.72	-0.31	5.79e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs2019216	0.521	rs9807074	chr17:21930856	T/C	cg22648282	chr17:21454238	C17orf51	-0.48	-8.4	-0.38	7.06e-16	Pelvic organ prolapse;
LUAD	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.11	0.48	2.38e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg23978390	chr7:1156363	C7orf50	0.53	8.33	0.38	1.14e-15	Longevity;Endometriosis;
LUAD	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg11822812	chr5:140052017	DND1	-0.41	-7.58	-0.35	2.14e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg26597838	chr10:835615	NA	0.99	15.71	0.61	3.88e-44	Eosinophil percentage of granulocytes;
LUAD	cis	rs1832871	0.711	rs56043101	chr6:158682277	A/G	cg07165851	chr6:158734300	TULP4	0.72	11.09	0.47	2.89e-25	Height;
LUAD	cis	rs9399401	0.601	rs9321870	chr6:142800758	A/T	cg04461802	chr6:142623433	GPR126	0.36	6.53	0.3	1.84e-10	Chronic obstructive pulmonary disease;
LUAD	cis	rs3784262	0.669	rs34226780	chr15:58280168	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.27	-0.33	1.72e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7843479	0.601	rs11780532	chr8:21838670	T/A	cg03445287	chr8:21823731	XPO7	-0.49	-9.12	-0.41	2.96e-18	Mean corpuscular volume;
LUAD	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-24.59	-0.77	1.45e-83	Height;
LUAD	cis	rs41271473	0.526	rs12094319	chr1:228717836	G/C	cg16512390	chr1:228756714	NA	0.69	9.12	0.41	3e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.41	0.34	6.92e-13	Menopause (age at onset);
LUAD	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg02251663	chr11:14281053	SPON1	0.38	7.6	0.35	1.96e-13	Mitochondrial DNA levels;
LUAD	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg07395648	chr5:131743802	NA	0.39	6.56	0.3	1.6e-10	Breast cancer;
LUAD	cis	rs2249625	0.874	rs1819067	chr6:72849139	A/C	cg18830697	chr6:72922368	RIMS1	-0.36	-6.84	-0.32	2.81e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg01884057	chr2:25150051	NA	0.32	6.81	0.31	3.36e-11	Body mass index;
LUAD	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg05368731	chr17:41323189	NBR1	0.96	20.41	0.7	6.12e-65	Menopause (age at onset);
LUAD	cis	rs1003719	0.715	rs2835653	chr21:38558636	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.22	-0.37	2.56e-15	Eye color traits;
LUAD	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg26384229	chr12:38710491	ALG10B	0.43	7.31	0.33	1.36e-12	Morning vs. evening chronotype;
LUAD	trans	rs11039798	0.610	rs11530356	chr11:48836290	C/A	cg02254774	chr11:50257496	LOC441601	0.54	6.74	0.31	5.12e-11	Axial length;
LUAD	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26314531	chr2:26401878	FAM59B	0.72	9.18	0.41	1.96e-18	Gut microbiome composition (summer);
LUAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.62	9.16	0.41	2.27e-18	Alzheimer's disease;
LUAD	trans	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg11693508	chr17:37793320	STARD3	0.55	7.82	0.36	4.18e-14	Neuroticism;
LUAD	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg26384229	chr12:38710491	ALG10B	-0.46	-7.72	-0.35	8.46e-14	Bladder cancer;
LUAD	trans	rs8073060	0.586	rs225280	chr17:33976296	C/T	cg19694781	chr19:47549865	TMEM160	-1.24	-19.47	-0.69	9.31e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs4930561	0.765	rs7931502	chr11:67959607	A/C	cg04465784	chr11:67976953	SUV420H1	0.28	8.27	0.37	1.77e-15	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs7264396	0.635	rs6058363	chr20:34505054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-7.08	-0.33	6.15e-12	Total cholesterol levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg10324096	chr14:92587714	CPSF2;NDUFB1	-0.68	-6.52	-0.3	2.03e-10	Type 2 diabetes;
LUAD	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg00071950	chr4:10020882	SLC2A9	-0.75	-15.14	-0.59	1.12e-41	Bone mineral density;
LUAD	cis	rs2455799	0.613	rs13080234	chr3:15852492	C/T	cg16303742	chr3:15540471	COLQ	-0.53	-9.8	-0.43	1.45e-20	Mean platelet volume;
LUAD	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg18305652	chr10:134549665	INPP5A	0.58	12.0	0.5	9.29e-29	Migraine;
LUAD	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs72627123	0.500	rs7359018	chr14:74521008	T/C	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.57	7.95	0.36	1.75e-14	Morning vs. evening chronotype;
LUAD	trans	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs7147624	1.000	rs1009465	chr14:65970370	G/C	cg03016385	chr14:66212404	NA	-0.57	-6.81	-0.31	3.26e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03533382	chr5:126853128	PRRC1	-0.44	-6.94	-0.32	1.45e-11	Height;
LUAD	cis	rs7737355	0.947	rs12659474	chr5:130801304	T/C	cg06307176	chr5:131281290	NA	-0.51	-8.02	-0.36	1.03e-14	Life satisfaction;
LUAD	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.61	-0.31	1.18e-10	Prostate cancer;
LUAD	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg16414030	chr3:133502952	NA	-0.67	-12.62	-0.52	3.26e-31	Iron status biomarkers;
LUAD	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.61	-8.02	-0.36	1.02e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs4523957	0.552	rs923862	chr17:2031382	A/C	cg16513277	chr17:2031491	SMG6	-0.98	-20.08	-0.7	1.79e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg24101359	chr6:42928495	GNMT	0.46	8.6	0.39	1.53e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg18230493	chr5:56204884	C5orf35	-0.85	-12.28	-0.51	7.56e-30	Initial pursuit acceleration;
LUAD	cis	rs7178572	0.568	rs12910480	chr15:77664212	G/C	cg15453836	chr15:77711506	NA	-0.36	-6.44	-0.3	3.15e-10	Type 2 diabetes;
LUAD	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg18132916	chr6:79620363	NA	-0.45	-7.69	-0.35	1.02e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg08999081	chr20:33150536	PIGU	-0.59	-12.85	-0.53	3.75e-32	Glomerular filtration rate (creatinine);
LUAD	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.54	9.44	0.42	2.48e-19	Eosinophil percentage of white cells;
LUAD	trans	rs11039798	0.688	rs8188953	chr11:48749201	A/T	cg15704280	chr7:45808275	SEPT13	0.67	7.85	0.36	3.53e-14	Axial length;
LUAD	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-15.36	-0.6	1.3e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg04756594	chr16:24857601	SLC5A11	0.77	13.34	0.54	3.93e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg18932078	chr1:2524107	MMEL1	-0.36	-6.68	-0.31	7.55e-11	Ulcerative colitis;
LUAD	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-9.01	-0.4	7.28e-18	Schizophrenia;
LUAD	cis	rs7000551	0.751	rs1482337	chr8:22395509	A/G	cg12081754	chr8:22256438	SLC39A14	-0.42	-7.09	-0.33	5.57e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs12431939	0.762	rs60225624	chr14:51704366	C/T	cg23942311	chr14:51606299	NA	-0.56	-7.7	-0.35	9.85e-14	Cancer;
LUAD	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg02734326	chr4:10020555	SLC2A9	0.62	11.27	0.48	6.32e-26	Bone mineral density;
LUAD	cis	rs332507	0.830	rs3772781	chr3:124387439	G/T	cg05980111	chr3:124395277	KALRN	0.44	6.94	0.32	1.52e-11	Plateletcrit;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01956158	chr8:132916947	EFR3A	-0.4	-6.39	-0.3	4.28e-10	Height;
LUAD	cis	rs669446	0.533	rs28833034	chr1:44212942	A/G	cg12908607	chr1:44402522	ARTN	-0.36	-7.04	-0.32	7.77e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg07741184	chr6:167504864	NA	0.31	7.16	0.33	3.5e-12	Crohn's disease;
LUAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg27532560	chr4:187881888	NA	-0.36	-6.89	-0.32	2.08e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg01475377	chr6:109611718	NA	-0.48	-8.64	-0.39	1.19e-16	Reticulocyte fraction of red cells;
LUAD	cis	rs11945232	1.000	rs28630962	chr4:88336386	C/T	cg23841344	chr4:88312519	HSD17B11	-0.57	-8.74	-0.39	5.39e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6952808	0.964	rs10950407	chr7:1895666	T/G	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.34	-0.34	1.14e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg07917127	chr4:99064746	C4orf37	0.4	6.61	0.31	1.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08677398	chr8:58056175	NA	0.46	6.54	0.3	1.76e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6005807	0.719	rs73430189	chr22:29004881	C/A	cg12565055	chr22:29076175	TTC28	0.74	8.39	0.38	7.2e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs1045714	0.895	rs4719602	chr7:2647800	G/A	cg24848437	chr7:2645542	IQCE	0.74	8.6	0.39	1.54e-16	Urate levels in lean individuals;
LUAD	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06873352	chr17:61820015	STRADA	0.57	9.22	0.41	1.37e-18	Height;
LUAD	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg22117172	chr7:91764530	CYP51A1	0.33	7.33	0.34	1.21e-12	Breast cancer;
LUAD	cis	rs6429082	0.811	rs291348	chr1:235667690	A/G	cg26050004	chr1:235667680	B3GALNT2	0.4	6.72	0.31	5.86e-11	Adiposity;
LUAD	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg02158880	chr13:53174818	NA	0.5	8.7	0.39	7.53e-17	Lewy body disease;
LUAD	cis	rs420259	0.516	rs428438	chr16:23461754	A/C	cg00143387	chr16:23521605	GGA2	0.69	9.73	0.43	2.62e-20	Bipolar disorder;
LUAD	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg03340356	chr1:67600835	NA	0.44	7.45	0.34	5.25e-13	Psoriasis;
LUAD	cis	rs7771547	0.519	rs7773253	chr6:36373451	T/A	cg04289385	chr6:36355825	ETV7	0.48	7.09	0.33	5.7e-12	Platelet distribution width;
LUAD	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14495033	chr9:140707378	EHMT1	-0.47	-6.76	-0.31	4.71e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6088590	0.748	rs6142206	chr20:33212055	G/A	cg08999081	chr20:33150536	PIGU	0.51	9.98	0.44	3.3e-21	Coronary artery disease;
LUAD	cis	rs13315871	0.929	rs13322156	chr3:58287620	C/T	cg12435725	chr3:58293450	RPP14	-0.74	-7.88	-0.36	2.86e-14	Cholesterol, total;
LUAD	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg24578937	chr1:2090814	PRKCZ	0.77	15.71	0.61	3.86e-44	Height;
LUAD	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg14983838	chr19:29218262	NA	0.6	7.67	0.35	1.22e-13	Methadone dose in opioid dependence;
LUAD	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.49	7.33	0.34	1.17e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10744422	0.925	rs3825143	chr12:123352179	C/T	cg16953816	chr12:123349952	VPS37B	0.64	7.39	0.34	7.82e-13	Schizophrenia;
LUAD	cis	rs438465	1.000	rs745398	chr6:169854753	A/G	cg11181693	chr6:169825345	NA	-0.61	-7.9	-0.36	2.39e-14	Corneal astigmatism;
LUAD	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg11707310	chr1:2537719	MMEL1	-0.37	-7.87	-0.36	2.95e-14	Multiple sclerosis;
LUAD	trans	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg14791747	chr16:20752902	THUMPD1	-0.49	-7.23	-0.33	2.33e-12	Pancreatic cancer;
LUAD	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg19622623	chr12:86230825	RASSF9	0.42	7.49	0.34	3.93e-13	Major depressive disorder;
LUAD	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg26384229	chr12:38710491	ALG10B	0.47	7.66	0.35	1.29e-13	Morning vs. evening chronotype;
LUAD	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg01475377	chr6:109611718	NA	-0.52	-10.02	-0.44	2.46e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg08859206	chr1:53392774	SCP2	0.57	10.27	0.45	3.07e-22	Monocyte count;
LUAD	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg24397884	chr7:158709396	WDR60	0.59	10.72	0.46	6.71e-24	Height;
LUAD	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg21963583	chr11:68658836	MRPL21	0.65	11.6	0.49	3.41e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg25517755	chr10:38738941	LOC399744	-0.42	-6.61	-0.31	1.17e-10	Corneal astigmatism;
LUAD	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg24768116	chr2:27665128	KRTCAP3	0.26	6.46	0.3	2.93e-10	Oral cavity cancer;
LUAD	cis	rs863345	0.604	rs4584390	chr1:158505975	T/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.58	-0.3	1.38e-10	Pneumococcal bacteremia;
LUAD	cis	rs7712401	0.601	rs154506	chr5:122202781	A/G	cg19077854	chr5:122220652	SNX24	0.36	6.75	0.31	4.8e-11	Mean platelet volume;
LUAD	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg02018176	chr4:1364513	KIAA1530	0.56	10.67	0.46	1.03e-23	Longevity;
LUAD	cis	rs10102274	1.000	rs7013400	chr8:91775846	G/T	cg16814680	chr8:91681699	NA	-0.81	-6.35	-0.3	5.42e-10	Cerebrospinal fluid clusterin levels;
LUAD	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg27068330	chr11:65405492	SIPA1	-0.75	-11.14	-0.48	1.82e-25	Acne (severe);
LUAD	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-10.25	-0.45	3.54e-22	Electrocardiographic conduction measures;
LUAD	cis	rs76419734	0.510	rs2216515	chr4:106750214	C/T	cg05309399	chr4:106552544	FLJ20184	0.52	7.57	0.35	2.34e-13	Post bronchodilator FEV1;
LUAD	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.67	-12.87	-0.53	3.21e-32	Ulcerative colitis;
LUAD	cis	rs7937890	0.559	rs4369365	chr11:14444515	C/G	cg06199346	chr11:14280333	SPON1	-0.32	-6.38	-0.3	4.78e-10	Mitochondrial DNA levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05545111	chr9:6758140	KDM4C	-0.43	-6.56	-0.3	1.53e-10	Height;
LUAD	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg08798685	chr6:27730294	NA	-0.71	-7.61	-0.35	1.82e-13	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1595825	0.891	rs73054825	chr2:198636355	G/C	cg10547527	chr2:198650123	BOLL	-0.57	-8.09	-0.37	6.29e-15	Ulcerative colitis;
LUAD	cis	rs4389656	0.826	rs395939	chr5:6734245	T/C	cg10857441	chr5:6722123	POLS	-0.46	-7.81	-0.35	4.61e-14	Coronary artery disease;
LUAD	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg09658497	chr7:2847517	GNA12	-0.47	-8.45	-0.38	4.67e-16	Height;
LUAD	cis	rs7584330	0.554	rs76519914	chr2:238429818	G/A	cg14458575	chr2:238380390	NA	0.65	10.25	0.45	3.6e-22	Prostate cancer;
LUAD	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg18854424	chr1:2615690	NA	0.43	9.43	0.42	2.73e-19	Ulcerative colitis;
LUAD	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg12379764	chr21:47803548	PCNT	-0.39	-6.75	-0.31	5.01e-11	Testicular germ cell tumor;
LUAD	cis	rs1696756	0.638	rs1285274	chr17:77829907	G/A	cg00646381	chr17:77835854	NA	0.52	8.62	0.39	1.31e-16	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.2	-0.37	2.81e-15	Breast cancer;
LUAD	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs7793919	0.726	rs10261971	chr7:4776547	A/G	cg00064840	chr7:4784485	FOXK1	0.34	6.55	0.3	1.68e-10	Mosquito bite size;
LUAD	trans	rs867371	0.502	rs2047679	chr15:82531881	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.41	-6.88	-0.32	2.15e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LUAD	cis	rs72627123	0.500	rs68148895	chr14:74529523	C/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.57	7.95	0.36	1.75e-14	Morning vs. evening chronotype;
LUAD	cis	rs2996428	0.709	rs12127399	chr1:3721609	G/A	cg23277830	chr1:3704460	LRRC47	0.46	9.37	0.41	4.41e-19	Red cell distribution width;
LUAD	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23158103	chr7:148848205	ZNF398	-0.66	-12.59	-0.52	4.25e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2797160	1.000	rs6904992	chr6:126016003	G/A	cg05901451	chr6:126070800	HEY2	0.45	6.71	0.31	6.22e-11	Endometrial cancer;
LUAD	cis	rs4911259	0.507	rs8118663	chr20:31398876	A/G	cg13636640	chr20:31349939	DNMT3B	0.62	8.65	0.39	1.05e-16	Inflammatory bowel disease;
LUAD	cis	rs2019216	0.967	rs2342216	chr17:21910379	A/C	cg05591447	chr17:21909280	FLJ36000	-0.29	-7.73	-0.35	7.83e-14	Pelvic organ prolapse;
LUAD	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18876405	chr7:65276391	NA	0.58	9.58	0.42	8.43e-20	Aortic root size;
LUAD	cis	rs7527798	0.592	rs6667238	chr1:207822856	G/A	cg09232269	chr1:207846808	CR1L	-0.36	-6.84	-0.32	2.87e-11	Erythrocyte sedimentation rate;
LUAD	cis	rs7707921	0.881	rs2629744	chr5:81381997	A/T	cg15871215	chr5:81402204	ATG10	-0.68	-9.86	-0.43	8.82e-21	Breast cancer;
LUAD	cis	rs8017423	0.967	rs11623275	chr14:90721335	C/T	cg14092571	chr14:90743983	NA	-0.5	-8.82	-0.39	3.06e-17	Mortality in heart failure;
LUAD	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.44	0.45	7.31e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg03467027	chr4:99064603	C4orf37	0.4	6.49	0.3	2.41e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg19894588	chr14:64061835	NA	0.53	8.12	0.37	5.01e-15	Glioblastoma;Glioma;
LUAD	cis	rs10189230	0.967	rs13012429	chr2:222350788	C/T	cg14652038	chr2:222343519	EPHA4	0.44	8.79	0.39	3.74e-17	Urate levels in lean individuals;
LUAD	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg10978503	chr1:24200527	CNR2	-0.53	-11.25	-0.48	7.09e-26	Immature fraction of reticulocytes;
LUAD	cis	rs7524258	0.868	rs10779678	chr1:7300573	A/G	cg07173049	chr1:7289937	CAMTA1	0.52	9.9	0.43	6.36e-21	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	trans	rs9929218	0.954	rs34530130	chr16:68827620	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.76	-0.53	8.79e-32	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg09654669	chr8:57350985	NA	-0.65	-9.79	-0.43	1.53e-20	Obesity-related traits;
LUAD	cis	rs1595825	0.891	rs74265511	chr2:198494782	C/T	cg11031976	chr2:198649780	BOLL	-0.45	-6.64	-0.31	9.81e-11	Ulcerative colitis;
LUAD	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.5	-8.3	-0.37	1.37e-15	Reticulocyte count;
LUAD	cis	rs12711979	0.509	rs13021385	chr2:3826387	T/C	cg17052675	chr2:3827356	NA	-0.84	-19.76	-0.69	4.64e-62	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.36	-0.57	2.19e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg25036284	chr2:26402008	FAM59B	-0.62	-8.66	-0.39	9.71e-17	Gut microbiome composition (summer);
LUAD	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg11235426	chr6:292522	DUSP22	-0.59	-9.93	-0.43	5.12e-21	Menopause (age at onset);
LUAD	cis	rs1997103	1.000	rs4947501	chr7:55407342	C/T	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg08888203	chr3:10149979	C3orf24	0.74	12.97	0.53	1.25e-32	Alzheimer's disease;
LUAD	cis	rs438034	1.000	rs376776	chr1:214830142	A/T	cg16144317	chr1:214725524	PTPN14	-0.36	-6.78	-0.31	4.05e-11	Response to antineoplastic agents;
LUAD	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg26446133	chr18:72167187	CNDP2	-0.92	-16.19	-0.62	3.3e-46	Refractive error;
LUAD	cis	rs7107174	1.000	rs7107174	chr11:77997936	C/T	cg02023728	chr11:77925099	USP35	0.5	7.53	0.34	3.12e-13	Testicular germ cell tumor;
LUAD	cis	rs240764	0.680	rs239234	chr6:101101234	G/A	cg09795085	chr6:101329169	ASCC3	0.4	6.91	0.32	1.78e-11	Neuroticism;
LUAD	cis	rs13064411	0.696	rs9869318	chr3:113146271	T/C	cg18753928	chr3:113234510	CCDC52	-0.71	-11.54	-0.49	5.65e-27	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.61	8.85	0.4	2.39e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg15017067	chr4:17643749	FAM184B	-0.35	-6.94	-0.32	1.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg24450063	chr1:156163899	SLC25A44	1.15	26.88	0.79	1.54e-93	Testicular germ cell tumor;
LUAD	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	9.08	0.4	4.09e-18	Electrocardiographic conduction measures;
LUAD	cis	rs2742417	0.967	rs2742419	chr3:45731929	G/A	cg10512202	chr3:45649293	LIMD1	0.36	6.41	0.3	3.92e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg15448220	chr1:150897856	SETDB1	-0.46	-7.95	-0.36	1.72e-14	Tonsillectomy;
LUAD	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg22529645	chr1:3704559	LRRC47	0.57	10.67	0.46	1.07e-23	Red cell distribution width;
LUAD	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-7.25	-0.33	2e-12	Blood metabolite levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27221266	chr10:96122679	NOC3L	-0.42	-6.53	-0.3	1.95e-10	Height;
LUAD	cis	rs8112211	0.561	rs117234139	chr19:38808504	A/G	cg14299480	chr19:38876666	GGN	-0.4	-6.83	-0.32	2.9100000000000002e-11	Blood protein levels;
LUAD	cis	rs3916	0.955	rs35771722	chr12:121154000	A/G	cg27246729	chr12:121163418	ACADS	0.46	7.51	0.34	3.49e-13	Urinary metabolites (H-NMR features);
LUAD	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	6.44	0.3	3.17e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6906287	0.647	rs6902812	chr6:118936294	A/G	cg05564266	chr6:118973597	C6orf204	0.38	7.9	0.36	2.46e-14	Electrocardiographic conduction measures;
LUAD	cis	rs9535307	0.615	rs3736830	chr13:50306221	G/C	cg04663916	chr13:50265991	EBPL	0.64	8.77	0.39	4.34e-17	Obesity-related traits;
LUAD	cis	rs501916	0.932	rs483656	chr15:48055932	T/C	cg16110827	chr15:48056943	SEMA6D	-0.35	-6.89	-0.32	1.97e-11	Inflammatory bowel disease;Ulcerative colitis;
LUAD	trans	rs62458065	0.640	rs28587905	chr7:32533054	C/T	cg00845942	chr12:64062724	DPY19L2	-0.57	-7.57	-0.35	2.4e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7568458	0.840	rs2886722	chr2:85742297	C/T	cg02493740	chr2:85810744	VAMP5	0.38	6.89	0.32	1.99e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg03388025	chr16:89894329	SPIRE2	0.31	6.95	0.32	1.42e-11	Vitiligo;
LUAD	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7923837	0.687	rs1977833	chr10:94463945	G/A	cg25093409	chr10:94429542	NA	0.38	6.78	0.31	4e-11	Body mass index;Multiple sclerosis;
LUAD	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-9.46	-0.42	2.13e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg09184832	chr6:79620586	NA	0.52	9.8	0.43	1.47e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg13390004	chr1:15929781	NA	0.49	8.6	0.39	1.6e-16	Systolic blood pressure;
LUAD	cis	rs9462027	0.606	rs2814984	chr6:34597513	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.59	-0.39	1.71e-16	Systemic lupus erythematosus;
LUAD	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24308560	chr3:49941425	MST1R	0.55	9.37	0.41	4.35e-19	Body mass index;
LUAD	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg14689365	chr7:158441557	NCAPG2	-0.4	-6.37	-0.3	5.07e-10	Height;
LUAD	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg21475434	chr5:93447410	FAM172A	-0.6	-7.69	-0.35	1.06e-13	Diabetic retinopathy;
LUAD	cis	rs6076065	0.723	rs2249943	chr20:23378098	A/G	cg11657817	chr20:23433608	CST11	0.48	8.9	0.4	1.6e-17	Facial morphology (factor 15, philtrum width);
LUAD	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-24.69	-0.77	5.58e-84	Height;
LUAD	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.29	-6.62	-0.31	1.08e-10	Lymphocyte counts;
LUAD	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg18240062	chr17:79603768	NPLOC4	0.46	8.12	0.37	5.26e-15	Eye color traits;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg07151637	chr22:32149913	DEPDC5	0.37	6.56	0.3	1.61e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg03684893	chr10:554711	DIP2C	0.37	6.57	0.3	1.5e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs11671005	0.570	rs73062110	chr19:58936642	G/T	cg13877915	chr19:58951672	ZNF132	0.55	7.4	0.34	7.57e-13	Mean platelet volume;
LUAD	cis	rs7173743	0.756	rs7169511	chr15:79128665	T/C	cg00540400	chr15:79124168	NA	0.42	8.56	0.38	2.04e-16	Coronary artery disease;
LUAD	cis	rs10744422	0.858	rs2292136	chr12:123339344	A/G	cg16953816	chr12:123349952	VPS37B	0.59	6.54	0.3	1.75e-10	Schizophrenia;
LUAD	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03352830	chr11:487213	PTDSS2	0.82	10.88	0.47	1.75e-24	Body mass index;
LUAD	cis	rs13082711	0.595	rs4973762	chr3:27364789	A/T	cg02860705	chr3:27208620	NA	0.71	11.39	0.48	2.05e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg25834613	chr7:1915315	MAD1L1	-0.41	-6.54	-0.3	1.78e-10	Bipolar disorder;
LUAD	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg14664628	chr15:75095509	CSK	-0.6	-9.65	-0.42	4.85e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	trans	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg01620082	chr3:125678407	NA	-0.43	-6.65	-0.31	8.96e-11	Parkinson's disease;
LUAD	cis	rs2735413	0.881	rs12919818	chr16:78082862	C/T	cg04733911	chr16:78082701	NA	-0.34	-8.13	-0.37	4.86e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs250585	1.000	rs1557686	chr16:23558751	G/A	cg00143387	chr16:23521605	GGA2	-0.69	-8.13	-0.37	4.95e-15	Egg allergy;
LUAD	cis	rs367943	0.665	rs4705560	chr5:112977073	T/G	cg12552261	chr5:112820674	MCC	0.46	8.18	0.37	3.33e-15	Type 2 diabetes;
LUAD	cis	rs7707921	1.000	rs891159	chr5:81491087	A/G	cg15871215	chr5:81402204	ATG10	-0.73	-10.58	-0.46	2.36e-23	Breast cancer;
LUAD	cis	rs977987	0.966	rs62060551	chr16:75502312	A/C	cg03315344	chr16:75512273	CHST6	0.66	14.42	0.57	1.22e-38	Dupuytren's disease;
LUAD	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs6489882	0.867	rs4766674	chr12:113365201	A/C	cg20102336	chr12:113376681	OAS3	0.59	9.05	0.4	5.28e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs3750965	0.920	rs10896421	chr11:68863048	T/C	cg06818126	chr11:68850279	TPCN2	-0.45	-6.68	-0.31	7.78e-11	Hair color;
LUAD	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg07685180	chr8:600429	NA	0.92	9.17	0.41	2.09e-18	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2075371	0.547	rs12666682	chr7:134021784	C/A	cg20476274	chr7:133979776	SLC35B4	0.5	8.34	0.38	1.09e-15	Mean platelet volume;
LUAD	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg02990361	chr1:107599529	PRMT6	0.59	9.9	0.43	6.22e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg00784671	chr22:46762841	CELSR1	-0.58	-7.74	-0.35	7.22e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11890956	chr21:40555474	PSMG1	0.82	14.83	0.58	2.32e-40	Cognitive function;
LUAD	cis	rs6076065	0.723	rs2424534	chr20:23378866	A/G	cg11657817	chr20:23433608	CST11	-0.46	-8.71	-0.39	6.69e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	8.57	0.38	1.91e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4942783	0.647	rs9590972	chr13:31583488	A/G	cg22761482	chr13:31579400	NA	-0.35	-6.55	-0.3	1.71e-10	Subjective well-being;
LUAD	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.79e-18	Life satisfaction;
LUAD	cis	rs2387326	0.680	rs954650	chr10:129941513	C/A	cg16087940	chr10:129947807	NA	-0.62	-8.35	-0.38	9.73e-16	Select biomarker traits;
LUAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg18621852	chr3:10150065	C3orf24	0.47	7.82	0.36	4.15e-14	Alzheimer's disease;
LUAD	cis	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.53	6.52	0.3	1.99e-10	Depression;
LUAD	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg09835421	chr16:68378352	PRMT7	-1.08	-12.61	-0.52	3.43e-31	Schizophrenia;
LUAD	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg00647820	chr17:40259828	DHX58	-0.44	-6.96	-0.32	1.27e-11	Fibrinogen levels;
LUAD	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg21138405	chr5:131827807	IRF1	0.6	13.88	0.56	2.35e-36	Asthma (sex interaction);
LUAD	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg09222892	chr1:25734099	RHCE	-0.46	-8.54	-0.38	2.5e-16	Plateletcrit;Mean corpuscular volume;
LUAD	trans	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg27411982	chr8:10470053	RP1L1	0.37	6.79	0.31	3.74e-11	Monocyte count;
LUAD	cis	rs829883	0.934	rs1641642	chr12:98898726	A/G	cg25150519	chr12:98850993	NA	0.67	11.16	0.48	1.54e-25	Colorectal adenoma (advanced);
LUAD	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg07169764	chr2:136633963	MCM6	0.78	9.16	0.41	2.24e-18	Corneal structure;
LUAD	cis	rs9462027	0.628	rs7776219	chr6:34784667	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.77	-0.39	4.4e-17	Systemic lupus erythematosus;
LUAD	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg21856205	chr7:94953877	PON1	-0.56	-7.98	-0.36	1.39e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg14668632	chr7:2872130	GNA12	-0.74	-13.22	-0.54	1.18e-33	Height;
LUAD	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg03929089	chr4:120376271	NA	-0.92	-17.08	-0.64	3.89e-50	Height;
LUAD	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg10518543	chr12:38710700	ALG10B	-0.43	-7.08	-0.33	5.88e-12	Bladder cancer;
LUAD	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11890956	chr21:40555474	PSMG1	0.79	13.87	0.56	2.54e-36	Cognitive function;
LUAD	cis	rs9473147	0.516	rs2171089	chr6:47515811	A/G	cg12968598	chr6:47444699	CD2AP	0.35	6.36	0.3	5.2400000000000005e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2455799	1.000	rs9859622	chr3:15828264	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.7	-0.31	6.6e-11	Mean platelet volume;
LUAD	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg22532475	chr10:104410764	TRIM8	0.44	8.46	0.38	4.3e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg21775007	chr8:11205619	TDH	-0.5	-9.01	-0.4	7.37e-18	Retinal vascular caliber;
LUAD	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg01579765	chr21:45077557	HSF2BP	-0.64	-15.28	-0.6	2.85e-42	Mean corpuscular volume;
LUAD	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg05590025	chr7:65112418	INTS4L2	-0.78	-8.26	-0.37	1.9e-15	Diabetic kidney disease;
LUAD	cis	rs9914988	0.943	rs7215310	chr17:27088626	G/T	cg02049041	chr17:27085579	C17orf63	0.65	8.79	0.39	3.8e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.84	0.47	2.51e-24	Smoking behavior;
LUAD	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg06108461	chr20:60628389	TAF4	-0.95	-16.98	-0.64	1.14e-49	Body mass index;
LUAD	cis	rs6489882	0.867	rs6489868	chr12:113363692	C/G	cg20102336	chr12:113376681	OAS3	0.55	8.62	0.39	1.34e-16	Chronic lymphocytic leukemia;
LUAD	trans	rs7246760	1.000	rs7246772	chr19:9886283	C/T	cg02900749	chr2:68251473	NA	-0.63	-6.87	-0.32	2.25e-11	Pursuit maintenance gain;
LUAD	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21659725	chr3:3221576	CRBN	-0.65	-11.29	-0.48	4.94e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg06618935	chr21:46677482	NA	-0.5	-10.01	-0.44	2.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg26528668	chr16:1614120	IFT140	0.57	10.41	0.45	9.2e-23	Coronary artery disease;
LUAD	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg26924012	chr15:45694286	SPATA5L1	1.0	18.37	0.67	7.73e-56	Homoarginine levels;
LUAD	trans	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg18335740	chr13:41363409	SLC25A15	-0.73	-14.09	-0.57	3.07e-37	Lewy body disease;
LUAD	trans	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg21659725	chr3:3221576	CRBN	-0.58	-9.2	-0.41	1.6e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg11292332	chr7:45801988	SEPT13	-0.3	-6.63	-0.31	1.05e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg17330251	chr7:94953956	PON1	-0.55	-7.66	-0.35	1.27e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg05044414	chr3:183734942	ABCC5	0.4	8.07	0.37	7.41e-15	Anterior chamber depth;
LUAD	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg11502198	chr6:26597334	ABT1	0.67	11.79	0.5	6.23e-28	Intelligence (multi-trait analysis);
LUAD	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg20542592	chr8:11973495	FAM66D	0.42	6.51	0.3	2.08e-10	Joint mobility (Beighton score);
LUAD	cis	rs68170813	0.652	rs4730250	chr7:107207695	A/G	cg23024343	chr7:107201750	COG5	0.52	6.62	0.31	1.11e-10	Coronary artery disease;
LUAD	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg07402062	chr16:89894098	SPIRE2	-0.46	-11.51	-0.49	7.5e-27	Vitiligo;
LUAD	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg04800585	chr6:26043546	HIST1H2BB	0.5	8.59	0.39	1.68e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs35146811	0.844	rs12705071	chr7:99682026	T/C	cg13334819	chr7:99746414	C7orf59	-0.65	-9.31	-0.41	7.25e-19	Coronary artery disease;
LUAD	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg03340356	chr1:67600835	NA	0.44	7.61	0.35	1.84e-13	Psoriasis;
LUAD	cis	rs2735413	0.881	rs12918547	chr16:78082746	G/A	cg04733911	chr16:78082701	NA	-0.35	-8.21	-0.37	2.74e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg05555928	chr11:63887634	MACROD1	0.34	6.41	0.3	3.98e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs4280164	0.551	rs882726	chr14:24797997	C/A	cg22990158	chr14:24802150	ADCY4	0.58	8.73	0.39	6.01e-17	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.56e-11	Depression;
LUAD	cis	rs601339	1.000	rs509548	chr12:123181855	T/A	cg11919336	chr12:123188078	GPR109A	0.47	7.25	0.33	2.02e-12	Adiponectin levels;
LUAD	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg06873352	chr17:61820015	STRADA	0.42	7.08	0.33	5.93e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.42	-6.63	-0.31	1.01e-10	Schizophrenia;
LUAD	cis	rs7177699	0.557	rs10083697	chr15:79124039	G/A	cg00540400	chr15:79124168	NA	-0.47	-9.92	-0.43	5.54e-21	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg12698349	chr2:225449008	CUL3	0.84	16.65	0.63	3.13e-48	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg17173187	chr15:85201210	NMB	0.54	9.44	0.42	2.54e-19	Schizophrenia;
LUAD	cis	rs6087990	0.806	rs4911258	chr20:31369479	G/A	cg13636640	chr20:31349939	DNMT3B	0.75	13.63	0.55	2.5e-35	Ulcerative colitis;
LUAD	trans	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg01620082	chr3:125678407	NA	-0.45	-6.71	-0.31	6.31e-11	Depression;
LUAD	trans	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg13565492	chr6:43139072	SRF	-0.73	-9.06	-0.4	4.79e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2274273	0.870	rs4597235	chr14:55851987	A/G	cg04306507	chr14:55594613	LGALS3	0.41	8.77	0.39	4.47e-17	Protein biomarker;
LUAD	cis	rs72949976	0.934	rs1922794	chr2:214026181	G/A	cg08319019	chr2:214017104	IKZF2	-0.5	-7.54	-0.34	2.98e-13	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs7000551	0.751	rs2461481	chr8:22382780	A/G	cg12081754	chr8:22256438	SLC39A14	-0.4	-6.54	-0.3	1.78e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg22920501	chr2:26401640	FAM59B	-0.82	-11.51	-0.49	7.66e-27	Gut microbiome composition (summer);
LUAD	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg03878208	chr11:72483293	STARD10	0.4	6.47	0.3	2.7e-10	Body mass index;
LUAD	cis	rs7818345	0.534	rs34221121	chr8:19319625	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.32	-7.28	-0.33	1.64e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg07341007	chr3:195489909	MUC4	0.54	6.64	0.31	9.8e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg18252515	chr7:66147081	NA	-0.61	-6.66	-0.31	8.66e-11	Diabetic kidney disease;
LUAD	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg00814883	chr7:100076585	TSC22D4	-0.8	-11.59	-0.49	3.55e-27	Platelet count;
LUAD	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg09021430	chr5:549028	NA	-0.69	-13.3	-0.54	5.59e-34	Lung disease severity in cystic fibrosis;
LUAD	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	12.49	0.52	1.0500000000000001e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg22166914	chr1:53195759	ZYG11B	0.46	7.52	0.34	3.3e-13	Monocyte count;
LUAD	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg24578937	chr1:2090814	PRKCZ	-0.55	-10.93	-0.47	1.17e-24	Height;
LUAD	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.26	-0.37	1.93e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg04856117	chr22:19949901	COMT	-0.29	-6.65	-0.31	9.03e-11	Blood metabolite levels;
LUAD	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg02423579	chr7:2872169	GNA12	-0.53	-8.75	-0.39	5.31e-17	Height;
LUAD	cis	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.43	8.24	0.37	2.23e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2625529	0.824	rs4445848	chr15:72354598	C/T	cg16672083	chr15:72433130	SENP8	-0.74	-12.57	-0.52	5.03e-31	Red blood cell count;
LUAD	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg18138036	chr10:133769891	PPP2R2D	0.41	6.69	0.31	7.09e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg03477792	chr4:77819574	ANKRD56	0.48	7.22	0.33	2.45e-12	Emphysema distribution in smoking;
LUAD	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg15704280	chr7:45808275	SEPT13	-0.53	-8.5	-0.38	3.38e-16	HDL cholesterol;
LUAD	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg10556349	chr10:835070	NA	0.68	7.97	0.36	1.45e-14	Eosinophil percentage of granulocytes;
LUAD	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg12062639	chr20:23401060	NAPB	1.09	11.26	0.48	6.95e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg13319975	chr6:146136371	FBXO30	-0.57	-9.51	-0.42	1.49e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg02696790	chr15:75250997	RPP25	0.38	7.09	0.33	5.57e-12	Breast cancer;
LUAD	trans	rs13128441	0.528	rs4689200	chr4:5189645	G/A	cg26099876	chr8:141644609	EIF2C2	-0.49	-6.94	-0.32	1.52e-11	Celiac disease;
LUAD	trans	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg01620082	chr3:125678407	NA	-1.04	-10.21	-0.44	4.98e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg06640241	chr16:89574553	SPG7	0.48	7.94	0.36	1.81e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs2070997	0.617	rs3808816	chr9:133746117	C/T	cg03924115	chr9:133768966	QRFP	-0.51	-7.02	-0.32	8.95e-12	Response to amphetamines;
LUAD	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.53	0.42	1.28e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12950390	0.548	rs7215477	chr17:45858117	A/C	cg03474202	chr17:45855739	NA	-0.31	-7.43	-0.34	6.24e-13	IgG glycosylation;
LUAD	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.22	0.33	2.45e-12	Blood metabolite levels;
LUAD	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.33	6.49	0.3	2.34e-10	Obesity-related traits;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg06988368	chr1:147142773	ACP6	0.43	6.81	0.31	3.35e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg12011299	chr4:100065546	ADH4	0.76	15.55	0.6	1.92e-43	Alcohol dependence;
LUAD	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg21770322	chr7:97807741	LMTK2	0.34	7.84	0.36	3.67e-14	Breast cancer;
LUAD	cis	rs34638657	0.702	rs35865749	chr16:82199677	T/C	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.96	-0.32	1.29e-11	Lung adenocarcinoma;
LUAD	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.56	-0.42	9.62e-20	Schizophrenia;
LUAD	trans	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.63	10.51	0.46	4.1000000000000003e-23	Endometrial cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09410845	chr2:203241870	BMPR2	-0.39	-6.36	-0.3	5.23e-10	Cancer;
LUAD	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg03733263	chr8:22462867	KIAA1967	0.63	10.77	0.46	4.56e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg22598563	chr5:131563921	P4HA2	-0.34	-8.74	-0.39	5.36e-17	Blood metabolite levels;
LUAD	cis	rs4072705	1.000	rs10760373	chr9:127485445	T/A	cg13476313	chr9:127244764	NR5A1	0.29	7.02	0.32	9.05e-12	Menarche (age at onset);
LUAD	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.48	-7.26	-0.33	1.83e-12	Alzheimer's disease (late onset);
LUAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-7.97	-0.36	1.48e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg27284194	chr4:1044797	NA	0.64	9.57	0.42	9.3e-20	Recombination rate (females);
LUAD	cis	rs10744422	1.000	rs2292135	chr12:123334075	G/A	cg16953816	chr12:123349952	VPS37B	0.59	6.56	0.3	1.6e-10	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg24829409	chr8:58192753	C8orf71	-0.5	-6.48	-0.3	2.5e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs10838798	0.501	rs2270994	chr11:48157869	T/C	cg15704280	chr7:45808275	SEPT13	-0.45	-6.8	-0.31	3.65e-11	Height;
LUAD	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg18252515	chr7:66147081	NA	0.6	6.68	0.31	7.56e-11	Diabetic kidney disease;
LUAD	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.54	8.12	0.37	5.28e-15	Total cholesterol levels;
LUAD	trans	rs1997103	1.000	rs10228182	chr7:55406695	A/T	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs11771526	0.681	rs117788703	chr7:32411009	T/C	cg13207630	chr7:32358064	NA	0.66	6.81	0.31	3.46e-11	Body mass index;
LUAD	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg18721089	chr20:30220636	NA	-0.49	-7.03	-0.32	8.37e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs1843834	0.624	rs2396110	chr2:225560219	A/G	cg22455342	chr2:225449267	CUL3	0.47	6.9	0.32	1.94e-11	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.54	-8.86	-0.4	2.17e-17	Primary sclerosing cholangitis;
LUAD	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg14345882	chr6:26364793	BTN3A2	0.67	6.83	0.32	2.88e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs151234	0.741	rs3194168	chr16:28603012	A/G	cg04643524	chr16:28609220	SULT1A2	0.64	8.99	0.4	8.25e-18	Platelet distribution width;
LUAD	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg01657329	chr11:68192670	LRP5	-0.42	-6.64	-0.31	9.55e-11	Total body bone mineral density;
LUAD	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg03609598	chr5:56110824	MAP3K1	-0.49	-7.78	-0.35	5.51e-14	Coronary artery disease;
LUAD	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.6	11.57	0.49	4.2e-27	Hemoglobin concentration;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22716488	chr6:35995431	MAPK14	-0.43	-6.7	-0.31	6.51e-11	Height;
LUAD	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.4	-0.42	3.45e-19	Life satisfaction;
LUAD	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg06627628	chr2:24431161	ITSN2	0.58	9.58	0.42	8.56e-20	Asthma;
LUAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg11766577	chr21:47581405	C21orf56	0.56	9.45	0.42	2.26e-19	Testicular germ cell tumor;
LUAD	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg11502198	chr6:26597334	ABT1	0.55	9.09	0.4	3.73e-18	Intelligence (multi-trait analysis);
LUAD	trans	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg01620082	chr3:125678407	NA	-0.72	-7.28	-0.33	1.62e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg10518543	chr12:38710700	ALG10B	0.41	6.37	0.3	4.9e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs62064224	0.614	rs9916114	chr17:30766950	T/C	cg18200150	chr17:30822561	MYO1D	0.41	7.5	0.34	3.7e-13	Schizophrenia;
LUAD	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-23.94	-0.76	1.08e-80	Height;
LUAD	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg21605333	chr4:119757512	SEC24D	0.8	7.7	0.35	9.49e-14	Cannabis dependence symptom count;
LUAD	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg10518543	chr12:38710700	ALG10B	-0.5	-8.34	-0.38	1.09e-15	Morning vs. evening chronotype;
LUAD	cis	rs698833	0.506	rs4952705	chr2:44499867	T/C	cg00619915	chr2:44497795	NA	-0.43	-6.43	-0.3	3.51e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg12160578	chr15:63334699	TPM1	-0.36	-6.68	-0.31	7.66e-11	Platelet count;
LUAD	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg11301795	chr4:187892539	NA	-0.77	-15.71	-0.61	3.69e-44	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg01657329	chr11:68192670	LRP5	0.47	8.53	0.38	2.73e-16	Total body bone mineral density;
LUAD	trans	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg14791747	chr16:20752902	THUMPD1	-0.51	-6.99	-0.32	1.09e-11	Selective IgA deficiency;
LUAD	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg22431228	chr1:16359049	CLCNKA	0.41	8.05	0.36	8.36e-15	Systolic blood pressure;
LUAD	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg12365402	chr11:9010492	NRIP3	-0.47	-8.99	-0.4	8.2e-18	Hemoglobin concentration;
LUAD	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.63	-0.31	1.04e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg01620082	chr3:125678407	NA	-0.82	-8.32	-0.38	1.24e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg27631724	chr1:11040367	C1orf127	0.53	8.98	0.4	8.82e-18	Ewing sarcoma;
LUAD	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg07708487	chr16:89387014	ANKRD11	-0.33	-6.52	-0.3	2.03e-10	Multiple myeloma (IgH translocation);
LUAD	trans	rs875971	0.545	rs316324	chr7:65610614	A/G	cg04775059	chr7:64541387	NA	-0.49	-6.73	-0.31	5.69e-11	Aortic root size;
LUAD	cis	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg27411982	chr8:10470053	RP1L1	0.43	8.17	0.37	3.6e-15	Neuroticism;
LUAD	cis	rs11098699	0.687	rs4833903	chr4:124245631	G/T	cg09941581	chr4:124220074	SPATA5	0.42	6.66	0.31	8.48e-11	Mosquito bite size;
LUAD	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg25036284	chr2:26402008	FAM59B	-0.62	-8.47	-0.38	3.96e-16	Gut microbiome composition (summer);
LUAD	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06873352	chr17:61820015	STRADA	0.8	17.69	0.65	8.16e-53	Prudent dietary pattern;
LUAD	cis	rs7527798	0.592	rs12025522	chr1:207854355	A/C	cg09232269	chr1:207846808	CR1L	0.35	6.66	0.31	8.72e-11	Erythrocyte sedimentation rate;
LUAD	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10802521	chr3:52805072	NEK4	-0.62	-11.07	-0.47	3.45e-25	Bipolar disorder;
LUAD	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.08	-0.33	6.01e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9473147	0.571	rs9395285	chr6:47554177	G/A	cg02130027	chr6:47444894	CD2AP	0.37	6.99	0.32	1.06e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg07917127	chr4:99064746	C4orf37	0.43	7.09	0.33	5.6e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg25036284	chr2:26402008	FAM59B	0.82	11.63	0.49	2.65e-27	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg11062466	chr8:58055876	NA	0.74	8.74	0.39	5.34e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg17063962	chr7:91808500	NA	0.71	12.44	0.52	1.68e-30	Breast cancer;
LUAD	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.92	0.32	1.65e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg18132916	chr6:79620363	NA	-0.46	-7.89	-0.36	2.66e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs8177876	0.749	rs78707250	chr16:81080362	G/A	cg08591886	chr16:81111003	C16orf46	-0.84	-7.43	-0.34	6.08e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg26043149	chr18:55253948	FECH	0.43	7.03	0.32	8.56e-12	Bone mineral density;
LUAD	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg14345882	chr6:26364793	BTN3A2	0.66	7.08	0.33	6.08e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg05872129	chr22:39784769	NA	0.79	14.83	0.58	2.28e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs9341808	0.714	rs4256394	chr6:80882142	C/T	cg08355045	chr6:80787529	NA	0.47	8.43	0.38	5.6e-16	Sitting height ratio;
LUAD	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg07332563	chr6:291687	DUSP22	-0.48	-8.27	-0.37	1.7e-15	Menopause (age at onset);
LUAD	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.02	0.32	8.64e-12	Parkinson's disease;
LUAD	cis	rs1971256	0.500	rs9479050	chr6:151806338	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.66	-7.0	-0.32	1.02e-11	Endometriosis;
LUAD	cis	rs9326248	0.581	rs10892072	chr11:116960313	G/A	cg20608306	chr11:116969690	SIK3	0.3	6.81	0.31	3.4e-11	Blood protein levels;
LUAD	cis	rs1215050	0.874	rs2167893	chr4:99048464	A/T	cg17366294	chr4:99064904	C4orf37	0.42	7.23	0.33	2.21e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg00020340	chr7:910388	UNC84A	0.65	7.05	0.32	7.43e-12	Initial pursuit acceleration;
LUAD	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg16680214	chr1:154839983	KCNN3	-0.67	-14.59	-0.58	2.48e-39	Prostate cancer;
LUAD	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg26384229	chr12:38710491	ALG10B	0.42	7.12	0.33	4.78e-12	Morning vs. evening chronotype;
LUAD	cis	rs300703	0.719	rs400040	chr2:199422	G/T	cg24565620	chr2:194026	NA	-0.41	-6.44	-0.3	3.27e-10	Blood protein levels;
LUAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg27454412	chr7:1067447	C7orf50	0.44	6.98	0.32	1.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.66	0.39	9.7e-17	Menarche (age at onset);
LUAD	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.28	-0.33	1.62e-12	Total body bone mineral density;
LUAD	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg06671706	chr8:8559999	CLDN23	0.66	11.38	0.48	2.41e-26	Obesity-related traits;
LUAD	cis	rs4604732	0.578	rs112449432	chr1:247624180	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	9.05	0.4	5.38e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6733011	0.582	rs6757099	chr2:99415235	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.68	-0.31	7.37e-11	Bipolar disorder;
LUAD	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	trans	rs3812049	0.784	rs3749748	chr5:127350549	C/T	cg16011800	chr17:1958478	HIC1	0.56	7.58	0.35	2.15e-13	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-7.18	-0.33	3.25e-12	Bladder cancer;
LUAD	cis	rs859767	0.741	rs11684785	chr2:135393110	C/T	cg12500956	chr2:135428796	TMEM163	-0.31	-8.22	-0.37	2.51e-15	Neuroticism;
LUAD	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.57	0.35	2.31e-13	Breast cancer;
LUAD	cis	rs7799006	0.593	rs12531150	chr7:2289888	C/T	cg08027265	chr7:2291960	NA	-0.73	-14.86	-0.59	1.8e-40	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg10544611	chr16:67998164	SLC12A4	-0.57	-7.01	-0.32	9.19e-12	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg01506766	chr13:46626746	ZC3H13	-0.43	-7.33	-0.34	1.21e-12	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg24011408	chr12:48396354	COL2A1	-0.43	-9.56	-0.42	9.84e-20	Plateletcrit;
LUAD	cis	rs6961069	0.713	rs1049654	chr7:80275455	A/C	cg04458919	chr7:80252533	CD36	0.35	6.69	0.31	6.96e-11	Platelet count;
LUAD	trans	rs2840044	1.000	rs9891800	chr17:33895015	G/C	cg19694781	chr19:47549865	TMEM160	0.64	10.32	0.45	2.01e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg15242686	chr22:24348715	GSTTP1	0.43	7.23	0.33	2.27e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4280164	0.578	rs17184689	chr14:24794440	A/C	cg22990158	chr14:24802150	ADCY4	0.54	8.45	0.38	4.62e-16	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.39	-0.38	7.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7818345	0.935	rs4633071	chr8:19275852	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.64	0.31	9.67e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs1881797	0.527	rs78486847	chr1:247638515	C/T	cg14830002	chr1:247616686	OR2B11	0.51	6.98	0.32	1.12e-11	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs89107	0.551	rs2078383	chr6:118706643	C/T	cg18833306	chr6:118973337	C6orf204	0.38	6.41	0.3	3.85e-10	Cardiac structure and function;
LUAD	trans	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.03	21.36	0.72	3.34e-69	Colorectal cancer;
LUAD	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg03714773	chr7:91764589	CYP51A1	0.29	6.76	0.31	4.57e-11	Breast cancer;
LUAD	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg04154034	chr17:28927549	LRRC37B2	0.58	6.86	0.32	2.51e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg13390004	chr1:15929781	NA	0.49	8.6	0.39	1.6e-16	Systolic blood pressure;
LUAD	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg06552810	chr11:31128660	NA	-0.35	-6.89	-0.32	1.97e-11	Red blood cell count;
LUAD	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg12311346	chr5:56204834	C5orf35	-0.93	-13.95	-0.56	1.23e-36	Initial pursuit acceleration;
LUAD	cis	rs6564851	1.000	rs6564851	chr16:81264597	A/C	cg00908271	chr16:81254010	PKD1L2	-0.29	-6.59	-0.3	1.35e-10	Carotenoid and tocopherol levels;
LUAD	cis	rs12545109	0.800	rs2582401	chr8:57401656	A/G	cg07776626	chr8:57350775	NA	-0.62	-8.64	-0.39	1.13e-16	Obesity-related traits;
LUAD	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.32e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg04025307	chr7:1156635	C7orf50	0.73	13.25	0.54	9.48e-34	Longevity;Endometriosis;
LUAD	trans	rs10838798	0.504	rs7121133	chr11:48156131	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.3	-0.33	1.42e-12	Height;
LUAD	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg00339695	chr16:24857497	SLC5A11	0.7	11.16	0.48	1.58e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.61	-7.17	-0.33	3.29e-12	Body mass index;
LUAD	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg21252483	chr19:49399788	TULP2	-0.68	-10.44	-0.45	7.61e-23	Red cell distribution width;
LUAD	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg18252515	chr7:66147081	NA	-0.62	-6.89	-0.32	2.03e-11	Diabetic kidney disease;
LUAD	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg12863693	chr15:85201151	NMB	0.4	7.38	0.34	8.52e-13	Schizophrenia;
LUAD	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg14092988	chr3:52407081	DNAH1	0.45	9.04	0.4	5.62e-18	Bipolar disorder;
LUAD	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg23803603	chr1:2058230	PRKCZ	-0.42	-7.4	-0.34	7.3e-13	Height;
LUAD	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg26727032	chr16:67993705	SLC12A4	-0.53	-7.0	-0.32	1.04e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9341808	0.667	rs2490244	chr6:80891112	A/T	cg08355045	chr6:80787529	NA	0.53	9.48	0.42	1.82e-19	Sitting height ratio;
LUAD	trans	rs7395662	1.000	rs10769371	chr11:48531184	G/A	cg00717180	chr2:96193071	NA	-0.4	-7.48	-0.34	4.34e-13	HDL cholesterol;
LUAD	trans	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg17712092	chr4:129076599	LARP1B	-0.77	-11.88	-0.5	2.85e-28	Breast cancer;
LUAD	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg21951975	chr1:209979733	IRF6	0.55	7.18	0.33	3.11e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg24818145	chr4:99064322	C4orf37	-0.42	-6.93	-0.32	1.56e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg04511125	chr2:88470314	THNSL2	0.87	9.44	0.42	2.49e-19	Plasma clusterin levels;
LUAD	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg07917127	chr4:99064746	C4orf37	0.41	6.89	0.32	2.01e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4900538	0.963	rs1190554	chr14:102918686	T/C	cg18135206	chr14:102964638	TECPR2	1.04	23.58	0.75	4.45e-79	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	trans	rs629535	0.773	rs569064	chr8:70065967	A/G	cg21567404	chr3:27674614	NA	1.01	18.42	0.67	4.82e-56	Dupuytren's disease;
LUAD	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg01765077	chr12:122356316	WDR66	0.56	9.56	0.42	9.91e-20	Mean corpuscular volume;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20317180	chr19:56111252	FIZ1;ZNF524	-0.48	-7.43	-0.34	6.22e-13	Height;
LUAD	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg22823121	chr1:150693482	HORMAD1	0.46	9.01	0.4	7.39e-18	Melanoma;
LUAD	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg10518543	chr12:38710700	ALG10B	-0.46	-7.43	-0.34	6.18e-13	Morning vs. evening chronotype;
LUAD	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-10.02	-0.44	2.37e-21	Gut microbiome composition (summer);
LUAD	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg25817165	chr18:72167213	CNDP2	-0.69	-9.97	-0.44	3.5e-21	Refractive error;
LUAD	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg03948781	chr1:205179583	DSTYK	0.33	6.43	0.3	3.45e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs34286592	0.929	rs35901559	chr16:29829615	T/C	cg08218971	chr16:29826754	C16orf53;PRRT2	0.4	6.44	0.3	3.26e-10	Multiple sclerosis;
LUAD	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-20.31	-0.7	1.58e-64	Height;
LUAD	cis	rs4698036	0.586	rs7672759	chr4:10285015	G/A	cg11266682	chr4:10021025	SLC2A9	0.36	6.73	0.31	5.54e-11	Cardiovascular disease risk factors;
LUAD	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.51	-10.65	-0.46	1.3e-23	Monocyte percentage of white cells;
LUAD	cis	rs13095912	0.752	rs62291883	chr3:185313842	T/C	cg11274856	chr3:185301563	NA	0.49	9.3	0.41	7.49e-19	Systolic blood pressure;
LUAD	cis	rs6554196	0.525	rs2192159	chr4:55505529	C/G	cg18836493	chr4:55524333	KIT	-0.35	-6.36	-0.3	5.38e-10	Monocyte count;
LUAD	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg12908607	chr1:44402522	ARTN	-0.45	-8.95	-0.4	1.1e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs6499129	0.558	rs7203742	chr16:67605794	A/G	cg26727032	chr16:67993705	SLC12A4	0.39	6.65	0.31	9.29e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg11494091	chr17:61959527	GH2	0.74	18.57	0.67	1.04e-56	Prudent dietary pattern;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24611962	chr5:162887527	HMMR;NUDCD2	-0.4	-6.65	-0.31	9e-11	Cancer;
LUAD	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg23758822	chr17:41437982	NA	-0.92	-18.84	-0.68	6.09e-58	Menopause (age at onset);
LUAD	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.3	6.35	0.3	5.54e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg25767906	chr1:53392781	SCP2	-0.53	-9.95	-0.44	4.17e-21	Monocyte count;
LUAD	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg06671706	chr8:8559999	CLDN23	0.66	11.37	0.48	2.49e-26	Obesity-related traits;
LUAD	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg21475434	chr5:93447410	FAM172A	-0.72	-8.32	-0.38	1.22e-15	Diabetic retinopathy;
LUAD	cis	rs7191439	0.583	rs9935872	chr16:88788477	A/G	cg02389323	chr16:88786976	FAM38A	0.87	8.91	0.4	1.48e-17	Plateletcrit;
LUAD	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg07636037	chr3:49044803	WDR6	0.48	8.17	0.37	3.61e-15	Menarche (age at onset);
LUAD	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg20891283	chr12:69753455	YEATS4	0.45	7.35	0.34	1.06e-12	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg08645402	chr16:4508243	NA	0.59	10.24	0.45	3.87e-22	Schizophrenia;
LUAD	cis	rs807669	0.802	rs762528	chr22:19166680	A/G	cg24911827	chr22:19170109	CLTCL1	0.47	9.72	0.43	2.71e-20	Metabolite levels;
LUAD	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	10.06	0.44	1.77e-21	Colorectal cancer;
LUAD	cis	rs9283706	0.595	rs6866433	chr5:66324152	A/G	cg11590213	chr5:66331682	MAST4	0.37	6.46	0.3	2.86e-10	Coronary artery disease;
LUAD	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg17105886	chr17:28927953	LRRC37B2	0.84	8.04	0.36	9.01e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4889855	0.530	rs62068346	chr17:78608052	A/G	cg16591659	chr17:78472290	NA	-0.43	-7.48	-0.34	4.39e-13	Fractional excretion of uric acid;
LUAD	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.49	-10.03	-0.44	2.22e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg16506072	chr16:85833520	COX4NB;COX4I1	-0.68	-6.69	-0.31	7.09e-11	Type 2 diabetes;
LUAD	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg14779329	chr11:130786720	SNX19	0.39	6.83	0.32	2.93e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg02733842	chr7:1102375	C7orf50	-0.7	-10.27	-0.45	3.07e-22	Bronchopulmonary dysplasia;
LUAD	trans	rs11671005	0.568	rs73068329	chr19:59080325	C/T	cg22037779	chr5:139682734	PFDN1	-0.67	-8.76	-0.39	4.78e-17	Mean platelet volume;
LUAD	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg16479474	chr6:28041457	NA	0.48	7.88	0.36	2.73e-14	Depression;
LUAD	cis	rs17102423	0.594	rs1124752	chr14:65567515	G/T	cg16583315	chr14:65563665	MAX	-0.35	-6.55	-0.3	1.7e-10	Obesity-related traits;
LUAD	cis	rs558133	0.896	rs478667	chr5:78424154	G/A	cg25119155	chr5:78426943	BHMT	0.53	9.55	0.42	1.08e-19	Blood and toenail selenium levels;
LUAD	cis	rs62238980	0.614	rs55695217	chr22:32463135	C/G	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs2425143	1.000	rs733609	chr20:34393074	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.01	-0.32	9.69e-12	Blood protein levels;
LUAD	cis	rs7107174	1.000	rs7941617	chr11:78021146	C/T	cg02023728	chr11:77925099	USP35	0.39	6.39	0.3	4.31e-10	Testicular germ cell tumor;
LUAD	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg12564285	chr5:131593104	PDLIM4	0.37	6.96	0.32	1.33e-11	Acylcarnitine levels;
LUAD	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.69	-0.31	7.2e-11	Neuroticism;
LUAD	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.85	0.53	3.81e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.617	rs76923959	chr7:107182915	T/C	cg23024343	chr7:107201750	COG5	0.53	6.68	0.31	7.62e-11	Coronary artery disease;
LUAD	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg22467129	chr15:76604101	ETFA	-0.59	-10.76	-0.46	4.92e-24	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg03037974	chr15:76606532	NA	0.37	7.97	0.36	1.5e-14	Blood metabolite levels;
LUAD	cis	rs11971779	0.680	rs9683	chr7:139107739	T/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.69	0.31	7.16e-11	Diisocyanate-induced asthma;
LUAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg11301795	chr4:187892539	NA	-0.77	-15.58	-0.6	1.42e-43	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg07606381	chr6:8435919	SLC35B3	0.4	6.65	0.31	9.07e-11	Motion sickness;
LUAD	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.15	-0.41	2.44e-18	Total body bone mineral density;
LUAD	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg15921436	chr17:44337874	NA	0.87	11.46	0.49	1.13e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg08632164	chr7:65971372	NA	-0.55	-6.37	-0.3	4.93e-10	Diabetic kidney disease;
LUAD	cis	rs7107174	1.000	rs10899465	chr11:78013588	G/A	cg19901956	chr11:77921274	USP35	-0.53	-6.55	-0.3	1.66e-10	Testicular germ cell tumor;
LUAD	cis	rs6840360	0.901	rs4696293	chr4:152707380	C/T	cg22705602	chr4:152727874	NA	0.34	6.93	0.32	1.63e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg23649088	chr2:200775458	C2orf69	-0.57	-6.71	-0.31	6.25e-11	Schizophrenia;
LUAD	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg13180566	chr4:1052158	NA	0.38	6.57	0.3	1.51e-10	Recombination rate (females);
LUAD	cis	rs17092148	0.887	rs2378199	chr20:33186480	T/C	cg16810054	chr20:33298113	TP53INP2	-0.49	-7.52	-0.34	3.31e-13	Neuroticism;
LUAD	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg04586622	chr2:25135609	ADCY3	0.37	8.36	0.38	9.08e-16	Body mass index;
LUAD	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg15181151	chr6:150070149	PCMT1	0.41	8.54	0.38	2.45e-16	Lung cancer;
LUAD	cis	rs2120019	0.608	rs8042558	chr15:75320433	G/T	cg09165964	chr15:75287851	SCAMP5	-0.48	-7.71	-0.35	9.17e-14	Blood trace element (Zn levels);
LUAD	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg18252515	chr7:66147081	NA	-0.63	-6.85	-0.32	2.58e-11	Diabetic kidney disease;
LUAD	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg12935359	chr14:103987150	CKB	-0.48	-7.45	-0.34	5.36e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg03467027	chr4:99064603	C4orf37	0.41	6.71	0.31	6.16e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg22852734	chr6:133119734	C6orf192	0.79	9.98	0.44	3.43e-21	Type 2 diabetes nephropathy;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg02368765	chr17:38219085	THRA	-0.67	-6.7	-0.31	6.81e-11	Type 2 diabetes;
LUAD	cis	rs6992820	0.933	rs35193637	chr8:56741274	A/C	cg06880721	chr8:56792545	LYN	-0.45	-7.37	-0.34	9e-13	Mean platelet volume;
LUAD	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg18277682	chr1:228362509	C1orf69	-0.38	-6.44	-0.3	3.25e-10	Diastolic blood pressure;
LUAD	cis	rs977987	0.742	rs34624768	chr16:75331572	G/A	cg03315344	chr16:75512273	CHST6	0.63	13.75	0.56	7.95e-36	Dupuytren's disease;
LUAD	cis	rs13315871	0.929	rs9818581	chr3:58293101	A/G	cg20936604	chr3:58311152	NA	-0.75	-7.61	-0.35	1.82e-13	Cholesterol, total;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg00529697	chr5:75013131	C5orf37	-0.39	-6.58	-0.3	1.38e-10	Schizophrenia;
LUAD	cis	rs354225	0.544	rs10169954	chr2:54808117	C/G	cg01766943	chr2:54829624	SPTBN1	0.39	7.34	0.34	1.1e-12	Schizophrenia;
LUAD	cis	rs6005807	0.668	rs9620808	chr22:28993331	A/C	cg12565055	chr22:29076175	TTC28	0.75	8.76	0.39	4.71e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18876405	chr7:65276391	NA	0.42	6.7	0.31	6.8e-11	Aortic root size;
LUAD	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg26384229	chr12:38710491	ALG10B	-0.38	-6.52	-0.3	2.03e-10	Heart rate;
LUAD	cis	rs8044868	0.512	rs12935266	chr16:72157000	C/G	cg23815491	chr16:72088622	HP	0.48	8.84	0.4	2.52e-17	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg26022315	chr17:47021804	SNF8	0.41	7.3	0.33	1.47e-12	Type 2 diabetes;
LUAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.41	0.55	2.11e-34	Prudent dietary pattern;
LUAD	cis	rs7177699	0.557	rs7403593	chr15:79111962	A/G	cg15571903	chr15:79123663	NA	-0.38	-7.6	-0.35	1.91e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg01528321	chr10:82214614	TSPAN14	-0.89	-12.52	-0.52	7.93e-31	Post bronchodilator FEV1;
LUAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.85	0.56	3.1e-36	Prudent dietary pattern;
LUAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27297192	chr10:134578999	INPP5A	0.38	6.7	0.31	6.64e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg10518543	chr12:38710700	ALG10B	-0.47	-7.78	-0.35	5.71e-14	Morning vs. evening chronotype;
LUAD	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg02269571	chr22:50332266	NA	-0.88	-9.68	-0.43	3.76e-20	Schizophrenia;
LUAD	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-8.55	-0.38	2.25e-16	Neutrophil percentage of white cells;
LUAD	cis	rs7017914	0.967	rs13274381	chr8:71765094	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.5	-0.3	2.33e-10	Bone mineral density;
LUAD	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg25237894	chr2:233734115	C2orf82	-0.63	-12.03	-0.5	7.44e-29	Coronary artery disease;
LUAD	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg08219700	chr8:58056026	NA	0.66	8.49	0.38	3.45e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg21191810	chr6:118973309	C6orf204	-0.53	-8.18	-0.37	3.32e-15	Diastolic blood pressure;
LUAD	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg11901034	chr3:128598214	ACAD9	-0.55	-8.75	-0.39	5.24e-17	IgG glycosylation;
LUAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg13271783	chr10:134563150	INPP5A	-0.41	-6.57	-0.3	1.49e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs57920188	0.640	rs4478781	chr1:4086827	C/T	cg20703997	chr1:4087676	NA	0.5	8.61	0.39	1.42e-16	Interleukin-17 levels;
LUAD	cis	rs2554380	0.891	rs2562781	chr15:84312568	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.54	-8.42	-0.38	5.71e-16	Height;
LUAD	trans	rs56133113	0.710	rs77154202	chr11:72814580	T/G	cg01847441	chr14:69431073	ACTN1	-0.6	-6.65	-0.31	9.02e-11	Mean platelet volume;
LUAD	cis	rs4268898	0.862	rs11125549	chr2:24576240	C/T	cg02683114	chr2:24398427	C2orf84	0.41	6.77	0.31	4.34e-11	Asthma;
LUAD	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg05340658	chr4:99064831	C4orf37	0.46	7.59	0.35	2.1e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4713675	0.565	rs4711343	chr6:33714548	G/A	cg14003231	chr6:33640908	ITPR3	0.4	7.53	0.34	3.04e-13	Plateletcrit;
LUAD	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg25703541	chr22:24373054	LOC391322	-0.79	-13.84	-0.56	3.39e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs55788414	0.932	rs35424543	chr16:81181983	G/A	cg06400318	chr16:81190750	PKD1L2	-0.75	-8.83	-0.39	2.7e-17	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg25233709	chr10:116636983	FAM160B1	0.41	8.26	0.37	1.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs4650994	1.000	rs10913568	chr1:178513411	C/T	cg05059571	chr16:84539110	KIAA1609	-0.62	-10.55	-0.46	2.83e-23	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg10729496	chr3:10149963	C3orf24	0.49	7.88	0.36	2.73e-14	Alzheimer's disease;
LUAD	cis	rs68170813	0.559	rs7807648	chr7:106965091	C/T	cg23024343	chr7:107201750	COG5	0.45	6.43	0.3	3.5e-10	Coronary artery disease;
LUAD	cis	rs9905704	0.681	rs1860262	chr17:56580997	T/C	cg19466818	chr17:56409534	MIR142	0.35	6.81	0.31	3.46e-11	Testicular germ cell tumor;
LUAD	cis	rs9837602	1.000	rs1021103	chr3:99603230	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.61	9.07	0.4	4.67e-18	Breast cancer;
LUAD	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg06064525	chr11:970664	AP2A2	-0.56	-11.58	-0.49	3.87e-27	Alzheimer's disease (late onset);
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg11235426	chr6:292522	DUSP22	-0.81	-13.99	-0.56	7.96e-37	Menopause (age at onset);
LUAD	cis	rs1232027	0.700	rs1623489	chr5:79926115	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.78	-0.35	5.66e-14	Huntington's disease progression;
LUAD	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.11	-0.37	5.46e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs738322	0.772	rs9619724	chr22:38517880	T/G	cg25457927	chr22:38595422	NA	-0.45	-10.81	-0.47	3.13e-24	Cutaneous nevi;
LUAD	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg02158880	chr13:53174818	NA	0.55	9.59	0.42	7.73e-20	Lewy body disease;
LUAD	cis	rs7614311	0.731	rs56263032	chr3:63863022	G/A	cg22134162	chr3:63841271	THOC7	-0.54	-9.02	-0.4	6.67e-18	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs791888	0.965	rs791877	chr10:89406863	A/G	cg13926569	chr10:89418898	PAPSS2	0.45	8.38	0.38	7.82e-16	Magnesium levels;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg22868346	chr14:67826966	EIF2S1;ATP6V1D	0.39	6.62	0.31	1.07e-10	Bipolar disorder;
LUAD	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg04398451	chr17:18023971	MYO15A	-0.71	-12.77	-0.53	7.96e-32	Total body bone mineral density;
LUAD	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg07507251	chr3:52567010	NT5DC2	0.38	7.39	0.34	7.75e-13	Bipolar disorder;
LUAD	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg25817165	chr18:72167213	CNDP2	-0.72	-10.76	-0.46	4.9e-24	Refractive error;
LUAD	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.86	-0.36	3.11e-14	Menopause (age at onset);
LUAD	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg18827107	chr12:86230957	RASSF9	-0.5	-8.85	-0.4	2.37e-17	Major depressive disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16092991	chr4:15004611	CPEB2	-0.42	-6.56	-0.3	1.57e-10	Height;
LUAD	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg16205897	chr5:131564050	P4HA2	-0.34	-7.54	-0.34	2.95e-13	Blood metabolite levels;
LUAD	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg25985355	chr7:65971099	NA	-0.53	-6.56	-0.3	1.58e-10	Diabetic kidney disease;
LUAD	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg11915388	chr22:42470451	FAM109B	-0.43	-7.75	-0.35	6.73e-14	Schizophrenia;
LUAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg06138931	chr13:21896616	NA	0.43	7.38	0.34	8.74e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg08847533	chr14:75593920	NEK9	0.38	6.47	0.3	2.66e-10	Height;
LUAD	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg10755058	chr3:40428713	ENTPD3	-0.39	-7.38	-0.34	8.57e-13	Renal cell carcinoma;
LUAD	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg16479474	chr6:28041457	NA	0.45	7.66	0.35	1.27e-13	Depression;
LUAD	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg17724175	chr1:150552817	MCL1	0.37	8.47	0.38	4.04e-16	Melanoma;
LUAD	trans	rs9929218	0.529	rs17715450	chr16:68729785	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	24.45	0.77	6.01e-83	Colorectal cancer;
LUAD	cis	rs943466	1.000	rs6933568	chr6:33751261	G/A	cg16010596	chr6:33739607	LEMD2	-0.4	-7.53	-0.34	3.18e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg13319975	chr6:146136371	FBXO30	-0.6	-10.09	-0.44	1.4e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg09835421	chr16:68378352	PRMT7	-0.84	-8.89	-0.4	1.74e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs807669	0.903	rs1771540	chr22:19173933	T/A	cg24911827	chr22:19170109	CLTCL1	0.45	9.27	0.41	9.71e-19	Metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04414295	chr14:102606318	WDR20;HSP90AA1	-0.55	-6.66	-0.31	8.7e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs61990749	0.597	rs72685264	chr14:78152998	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.51	-6.43	-0.3	3.55e-10	Fibroblast growth factor basic levels;
LUAD	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg21724239	chr8:58056113	NA	0.78	9.27	0.41	9.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg21724239	chr8:58056113	NA	0.82	9.87	0.43	7.95e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs6740322	0.748	rs6727631	chr2:43470408	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-11.05	-0.47	4e-25	Coronary artery disease;
LUAD	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21659725	chr3:3221576	CRBN	0.64	11.06	0.47	3.75e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs13082711	1.000	rs6791212	chr3:27507179	C/A	cg02860705	chr3:27208620	NA	0.61	9.26	0.41	1.05e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs4713675	0.525	rs622917	chr6:33702869	C/T	cg13859433	chr6:33739653	LEMD2	0.27	6.38	0.3	4.78e-10	Plateletcrit;
LUAD	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg22676075	chr6:135203613	NA	-0.6	-11.36	-0.48	2.76e-26	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg12419862	chr22:24373484	LOC391322	-0.66	-10.91	-0.47	1.41e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg18105134	chr13:113819100	PROZ	-0.81	-14.59	-0.58	2.35e-39	Platelet distribution width;
LUAD	cis	rs9394841	0.667	rs71558769	chr6:41782107	T/C	cg17623882	chr6:41773611	USP49	-0.51	-7.23	-0.33	2.35e-12	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg08470875	chr2:26401718	FAM59B	-0.64	-8.68	-0.39	8.69e-17	Gut microbiome composition (summer);
LUAD	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg26384229	chr12:38710491	ALG10B	0.44	7.3	0.33	1.4e-12	Bladder cancer;
LUAD	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg17264618	chr3:40429014	ENTPD3	-0.42	-9.01	-0.4	6.99e-18	Renal cell carcinoma;
LUAD	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.33	-0.34	1.16e-12	Reticulocyte count;
LUAD	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg08085267	chr17:45401833	C17orf57	0.65	12.06	0.51	5.52e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11971779	0.584	rs7786469	chr7:139094621	G/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	trans	rs516805	0.748	rs11154070	chr6:122684031	C/T	cg09232021	chr16:79630003	MAF	-0.42	-6.42	-0.3	3.76e-10	Lymphocyte counts;
LUAD	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg03289416	chr15:75166202	SCAMP2	0.49	8.33	0.38	1.11e-15	Breast cancer;
LUAD	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.38	-0.38	7.71e-16	Bipolar disorder;
LUAD	cis	rs62238980	0.614	rs734092	chr22:32462167	C/G	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg13902645	chr11:5959945	NA	-0.53	-9.91	-0.43	5.97e-21	DNA methylation (variation);
LUAD	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg27446573	chr6:127587934	RNF146	0.45	6.61	0.31	1.18e-10	Breast cancer;
LUAD	cis	rs977987	0.843	rs12149063	chr16:75451758	G/A	cg03315344	chr16:75512273	CHST6	0.64	14.06	0.56	4.12e-37	Dupuytren's disease;
LUAD	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg11062466	chr8:58055876	NA	0.45	6.47	0.3	2.66e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs354225	0.544	rs10170355	chr2:54808322	G/A	cg01766943	chr2:54829624	SPTBN1	0.38	7.21	0.33	2.56e-12	Schizophrenia;
LUAD	cis	rs714515	0.900	rs9425291	chr1:172312769	A/G	cg14508705	chr1:172360182	DNM3	-0.36	-6.43	-0.3	3.45e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs8192282	0.739	rs6697115	chr1:154499947	C/T	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.37	-0.34	8.86e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg01884057	chr2:25150051	NA	0.31	6.74	0.31	5.3e-11	Body mass index;
LUAD	cis	rs7809950	0.817	rs2807	chr7:107260778	G/A	cg23024343	chr7:107201750	COG5	0.87	14.25	0.57	6.78e-38	Coronary artery disease;
LUAD	trans	rs4650994	0.593	rs12040058	chr1:178503557	C/G	cg05059571	chr16:84539110	KIAA1609	0.44	6.5	0.3	2.27e-10	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs4700695	0.925	rs10069614	chr5:65396530	A/C	cg21114390	chr5:65439923	SFRS12	-0.59	-7.23	-0.33	2.23e-12	Facial morphology (factor 19);
LUAD	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg05887092	chr17:76393375	PGS1	0.41	7.28	0.33	1.65e-12	HDL cholesterol levels;
LUAD	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg24690094	chr11:67383802	NA	0.45	7.24	0.33	2.07e-12	Mean corpuscular volume;
LUAD	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg02951883	chr7:2050386	MAD1L1	-0.82	-14.19	-0.57	1.14e-37	Bipolar disorder and schizophrenia;
LUAD	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-10.03	-0.44	2.29e-21	Coronary artery disease;
LUAD	cis	rs4604732	0.631	rs10925043	chr1:247627001	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	10.26	0.45	3.37e-22	Birth weight;
LUAD	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg04154034	chr17:28927549	LRRC37B2	0.56	6.67	0.31	8.13e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg20487152	chr13:99095054	FARP1	-0.48	-8.36	-0.38	8.99e-16	Longevity;
LUAD	trans	rs11885103	0.543	rs1320364	chr2:563219	A/G	cg12228919	chr15:44955936	SPG11	-0.41	-6.35	-0.3	5.55e-10	Heschl's gyrus morphology;
LUAD	cis	rs9837602	0.745	rs792834	chr3:99476121	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-8.16	-0.37	3.91e-15	Breast cancer;
LUAD	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg15147215	chr3:52552868	STAB1	-0.4	-7.18	-0.33	3.18e-12	Bipolar disorder;
LUAD	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22857025	chr5:266934	NA	-1.06	-11.95	-0.5	1.45e-28	Breast cancer;
LUAD	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg24733560	chr20:60626293	TAF4	0.41	6.92	0.32	1.68e-11	Body mass index;
LUAD	cis	rs12612619	0.732	rs714513	chr2:27206474	T/C	cg00617064	chr2:27272375	NA	-0.37	-7.28	-0.33	1.69e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg25173405	chr17:45401733	C17orf57	0.45	7.81	0.36	4.4e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	10.66	0.46	1.19e-23	Hip circumference adjusted for BMI;
LUAD	cis	rs6714710	0.603	rs11681535	chr2:98488949	G/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.19	0.37	3.16e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	trans	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg16011800	chr17:1958478	HIC1	0.61	8.87	0.4	2.04e-17	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs4409675	0.597	rs1467464	chr1:28211650	T/C	cg23691781	chr1:28212827	C1orf38	0.39	11.32	0.48	3.92e-26	Corneal astigmatism;
LUAD	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11741688	0.557	rs6897783	chr5:178330574	G/A	cg09339527	chr5:178322752	ZFP2	-0.35	-7.37	-0.34	8.84e-13	Sleep duration;
LUAD	cis	rs6545883	0.929	rs6545873	chr2:61733012	T/C	cg15711740	chr2:61764176	XPO1	-0.4	-6.37	-0.3	4.92e-10	Tuberculosis;
LUAD	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg04450456	chr4:17643702	FAM184B	0.36	6.83	0.32	2.98e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs807669	0.903	rs807668	chr22:19162686	A/G	cg02655711	chr22:19163373	SLC25A1	0.88	19.66	0.69	1.3e-61	Metabolite levels;
LUAD	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg23758822	chr17:41437982	NA	0.91	18.19	0.66	5.03e-55	Menopause (age at onset);
LUAD	cis	rs62400317	0.826	rs11970496	chr6:45125833	A/G	cg20913747	chr6:44695427	NA	-0.4	-6.42	-0.3	3.73e-10	Total body bone mineral density;
LUAD	cis	rs2041840	0.961	rs4670687	chr2:37536513	C/T	cg25727520	chr2:37576821	QPCT	-0.36	-7.59	-0.35	2.09e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg08027265	chr7:2291960	NA	-0.49	-8.43	-0.38	5.42e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg26384229	chr12:38710491	ALG10B	0.5	8.01	0.36	1.09e-14	Heart rate;
LUAD	cis	rs354225	0.608	rs168505	chr2:54920968	C/T	cg26097391	chr2:54893211	SPTBN1	0.5	8.93	0.4	1.31e-17	Schizophrenia;
LUAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg05457628	chr5:178986728	RUFY1	0.57	9.61	0.42	6.65e-20	Lung cancer;
LUAD	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg07636037	chr3:49044803	WDR6	0.48	8.06	0.36	8.15e-15	Menarche (age at onset);
LUAD	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg14159672	chr1:205819179	PM20D1	0.44	7.08	0.33	5.87e-12	Parkinson's disease;
LUAD	cis	rs11771526	0.686	rs28399034	chr7:32272898	A/G	cg13207630	chr7:32358064	NA	0.54	7.0	0.32	1.01e-11	Body mass index;
LUAD	cis	rs6546550	0.935	rs3214007	chr2:70098808	A/G	cg02498382	chr2:70120550	SNRNP27	-0.57	-10.82	-0.47	2.94e-24	Prevalent atrial fibrillation;
LUAD	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg20673091	chr1:2541236	MMEL1	0.39	8.16	0.37	3.74e-15	Ulcerative colitis;
LUAD	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.49	0.34	3.94e-13	Bipolar disorder;
LUAD	cis	rs2985684	1.000	rs7142457	chr14:50097862	C/T	cg04989706	chr14:50066350	PPIL5	-0.46	-6.72	-0.31	5.79e-11	Carotid intima media thickness;
LUAD	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg23625390	chr15:77176239	SCAPER	0.39	7.15	0.33	3.83e-12	Blood metabolite levels;
LUAD	trans	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg13565492	chr6:43139072	SRF	-0.74	-10.08	-0.44	1.42e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg08280861	chr8:58055591	NA	0.72	8.44	0.38	4.98e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg12648201	chr2:27665141	KRTCAP3	0.32	7.98	0.36	1.43e-14	Total body bone mineral density;
LUAD	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg07677032	chr17:61819896	STRADA	0.55	9.94	0.44	4.74e-21	Prudent dietary pattern;
LUAD	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Body mass index;
LUAD	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg25208724	chr1:156163844	SLC25A44	1.15	21.65	0.72	1.72e-70	Testicular germ cell tumor;
LUAD	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg07741184	chr6:167504864	NA	0.31	7.47	0.34	4.74e-13	Crohn's disease;
LUAD	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg02782426	chr3:40428986	ENTPD3	0.36	7.52	0.34	3.35e-13	Renal cell carcinoma;
LUAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg04025307	chr7:1156635	C7orf50	0.65	7.4	0.34	7.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12545109	0.732	rs1973629	chr8:57429583	A/G	cg11919837	chr8:57350735	NA	-0.47	-6.36	-0.3	5.35e-10	Obesity-related traits;
LUAD	cis	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg07460842	chr6:66804631	NA	-1.06	-16.77	-0.63	9.09e-49	Exhaled nitric oxide output;
LUAD	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg10755058	chr3:40428713	ENTPD3	0.45	8.41	0.38	6.43e-16	Renal cell carcinoma;
LUAD	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg07870213	chr5:140052090	DND1	1.01	14.29	0.57	4.28e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3784262	1.000	rs4646593	chr15:58302467	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.48	-9.73	-0.43	2.52e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg25804541	chr17:80189381	SLC16A3	0.32	6.92	0.32	1.71e-11	Life satisfaction;
LUAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg10411590	chr13:21900810	NA	0.45	7.04	0.32	7.83e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg08029281	chr1:67600428	NA	0.35	6.66	0.31	8.38e-11	Psoriasis;
LUAD	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg01028140	chr2:1542097	TPO	-0.48	-7.78	-0.35	5.73e-14	IgG glycosylation;
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01585723	chr16:33734837	NA	0.35	6.38	0.3	4.6e-10	Menopause (age at onset);
LUAD	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg02574844	chr11:5959923	NA	-0.45	-8.23	-0.37	2.39e-15	DNA methylation (variation);
LUAD	cis	rs943466	1.000	rs61394483	chr6:33751945	G/A	cg16010596	chr6:33739607	LEMD2	-0.41	-7.66	-0.35	1.26e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg14092988	chr3:52407081	DNAH1	0.44	8.95	0.4	1.15e-17	Bipolar disorder;
LUAD	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg03929089	chr4:120376271	NA	-0.97	-20.33	-0.7	1.38e-64	Height;
LUAD	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg03714773	chr7:91764589	CYP51A1	0.31	7.34	0.34	1.1e-12	Breast cancer;
LUAD	cis	rs4460629	0.804	rs56112907	chr1:155070862	C/A	cg23973274	chr1:155060172	NA	-0.37	-6.35	-0.3	5.46e-10	Serum magnesium levels;
LUAD	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg09365446	chr1:150670422	GOLPH3L	0.67	12.61	0.52	3.58e-31	Tonsillectomy;
LUAD	cis	rs10129255	0.556	rs8010005	chr14:107186226	A/G	cg07958169	chr14:107095056	NA	-0.37	-7.26	-0.33	1.89e-12	Kawasaki disease;
LUAD	cis	rs7739264	0.564	rs760796	chr6:19790387	C/T	cg02404759	chr6:19790362	NA	-0.35	-6.7	-0.31	6.84e-11	Endometriosis;
LUAD	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg25817165	chr18:72167213	CNDP2	-0.66	-9.9	-0.43	6.13e-21	Refractive error;
LUAD	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.29	0.51	6.53e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs679087	0.932	rs10843506	chr12:29930883	G/A	cg14258853	chr12:29935411	TMTC1	0.62	11.84	0.5	3.99e-28	Schizophrenia;
LUAD	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg22508957	chr16:3507546	NAT15	-0.43	-6.65	-0.31	9.1e-11	Body mass index (adult);
LUAD	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg23954153	chr1:44402353	ARTN	-0.34	-6.73	-0.31	5.62e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs25645	0.800	rs34003767	chr17:38194296	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.68	13.66	0.55	1.93e-35	Myeloid white cell count;
LUAD	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg14343924	chr8:8086146	FLJ10661	0.43	6.91	0.32	1.8e-11	Neuroticism;
LUAD	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg16060761	chr17:80687452	NA	0.7	11.54	0.49	5.77e-27	Glycated hemoglobin levels;
LUAD	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg00310523	chr12:86230176	RASSF9	0.41	8.17	0.37	3.51e-15	Major depressive disorder;
LUAD	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg19318889	chr4:1322082	MAEA	0.91	15.61	0.6	1.02e-43	Longevity;
LUAD	cis	rs8028313	0.630	rs7169086	chr15:67934454	C/T	cg24579218	chr15:68104479	NA	-0.52	-8.33	-0.38	1.1e-15	Obesity;
LUAD	cis	rs1020064	0.945	rs1030878	chr2:105910598	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.42	6.66	0.31	8.75e-11	AIDS;
LUAD	cis	rs11696501	0.792	rs2235584	chr20:44172436	C/T	cg11783356	chr20:44313418	WFDC10B	-0.39	-6.84	-0.32	2.73e-11	Brain structure;
LUAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg21782813	chr7:2030301	MAD1L1	0.53	8.94	0.4	1.23e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06873352	chr17:61820015	STRADA	0.83	18.59	0.67	8.47e-57	Prudent dietary pattern;
LUAD	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.3	-0.33	1.41e-12	Morning vs. evening chronotype;
LUAD	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg18306943	chr3:40428807	ENTPD3	0.42	7.0	0.32	1.01e-11	Renal cell carcinoma;
LUAD	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.52	-0.3	1.96e-10	Breast cancer;
LUAD	cis	rs4072705	0.646	rs915032	chr9:127245682	G/C	cg13476313	chr9:127244764	NR5A1	0.36	9.03	0.4	5.94e-18	Menarche (age at onset);
LUAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-10.65	-0.46	1.23e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.57	-0.3	1.44e-10	Breast cancer;
LUAD	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.55	0.3	1.71e-10	Lung cancer in ever smokers;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09901735	chr16:19729769	C16orf88;IQCK	-0.49	-7.89	-0.36	2.53e-14	Height;
LUAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg04234412	chr22:24373322	LOC391322	0.82	14.98	0.59	5.21e-41	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	0.7	11.29	0.48	5.14e-26	Menarche (age at onset);
LUAD	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg07936489	chr17:37558343	FBXL20	0.46	7.34	0.34	1.13e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs3087591	0.960	rs8067021	chr17:29555078	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.62	-0.31	1.08e-10	Hip circumference;
LUAD	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg27211696	chr2:191398769	TMEM194B	-0.65	-8.34	-0.38	1.05e-15	Diastolic blood pressure;
LUAD	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg11859384	chr17:80120422	CCDC57	-0.49	-8.71	-0.39	7.15e-17	Life satisfaction;
LUAD	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg13319975	chr6:146136371	FBXO30	0.58	9.73	0.43	2.62e-20	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs4650994	0.525	rs10913574	chr1:178536482	G/C	cg05059571	chr16:84539110	KIAA1609	-0.7	-12.64	-0.52	2.63e-31	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs1198430	1.000	rs946268	chr1:23747766	A/G	cg12023170	chr1:23751761	TCEA3	-0.47	-6.5	-0.3	2.27e-10	Total cholesterol levels;
LUAD	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg08742575	chr21:47604166	C21orf56	0.44	7.34	0.34	1.09e-12	Testicular germ cell tumor;
LUAD	cis	rs4919694	0.808	rs77521106	chr10:104980726	G/T	cg04362960	chr10:104952993	NT5C2	0.79	7.96	0.36	1.65e-14	Arsenic metabolism;
LUAD	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg01802117	chr1:53393560	SCP2	0.37	7.2	0.33	2.8e-12	Monocyte count;
LUAD	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg20476274	chr7:133979776	SLC35B4	0.84	17.14	0.64	2.21e-50	Mean platelet volume;
LUAD	cis	rs6987853	0.933	rs2974352	chr8:42408483	C/T	cg09913449	chr8:42400586	C8orf40	0.43	8.08	0.37	6.69e-15	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg18129748	chr3:49941408	MST1R	0.42	6.99	0.32	1.1e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.33	-9.22	-0.41	1.37e-18	Total body bone mineral density;
LUAD	cis	rs6854137	0.758	rs12641770	chr4:169736989	C/T	cg20607169	chr4:169750834	PALLD	0.42	7.6	0.35	1.89e-13	Vein graft stenosis in coronary artery bypass grafting;
LUAD	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg09658497	chr7:2847517	GNA12	-0.42	-7.36	-0.34	9.6e-13	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg02084811	chr12:49524778	TUBA1B	-0.54	-6.59	-0.31	1.29e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg09835421	chr16:68378352	PRMT7	-0.83	-8.99	-0.4	8.54e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg16850897	chr7:100343110	ZAN	0.4	7.03	0.32	8.37e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73206853	0.925	rs12310834	chr12:110762756	A/G	cg12870014	chr12:110450643	ANKRD13A	0.55	7.48	0.34	4.47e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg15147215	chr3:52552868	STAB1	-0.39	-6.98	-0.32	1.18e-11	Electroencephalogram traits;
LUAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg26818010	chr10:134567672	INPP5A	-0.93	-15.41	-0.6	7.68e-43	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg15557168	chr22:42548783	NA	-0.43	-7.83	-0.36	4.06e-14	Cognitive function;
LUAD	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.9	0.36	2.47e-14	Morning vs. evening chronotype;
LUAD	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg19678392	chr7:94953810	PON1	-0.59	-8.27	-0.37	1.72e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg02683114	chr2:24398427	C2orf84	-0.43	-6.69	-0.31	6.9e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs7274811	0.744	rs2071056	chr20:32265513	A/G	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.45	-6.83	-0.32	2.95e-11	Height;
LUAD	cis	rs4523957	0.583	rs2641437	chr17:2019158	G/A	cg16513277	chr17:2031491	SMG6	-0.96	-19.57	-0.69	3.56e-61	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs113835537	0.529	rs2305532	chr11:66298594	C/T	cg24851651	chr11:66362959	CCS	0.57	10.01	0.44	2.64e-21	Airway imaging phenotypes;
LUAD	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg02176678	chr2:219576539	TTLL4	0.68	13.71	0.55	1.17e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg06623918	chr6:96969491	KIAA0776	0.88	17.5	0.65	5.43e-52	Headache;
LUAD	trans	rs7395662	1.000	rs11039819	chr11:48562181	G/T	cg00717180	chr2:96193071	NA	-0.38	-7.09	-0.33	5.74e-12	HDL cholesterol;
LUAD	cis	rs1816752	0.777	rs6490915	chr13:24987862	G/C	cg02811702	chr13:24901961	NA	0.43	7.36	0.34	9.81e-13	Obesity-related traits;
LUAD	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg18827107	chr12:86230957	RASSF9	0.6	10.82	0.47	2.94e-24	Major depressive disorder;
LUAD	cis	rs35995292	0.500	rs1019065	chr7:38939775	C/T	cg19327137	chr7:38886074	VPS41	0.71	14.57	0.58	2.85e-39	Subjective well-being (multi-trait analysis);
LUAD	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg11859384	chr17:80120422	CCDC57	-0.52	-9.35	-0.41	5.05e-19	Life satisfaction;
LUAD	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg27433088	chr4:174089019	GALNT7	0.38	7.5	0.34	3.81e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08834631	chr3:197687333	LMLN;IQCG	-0.44	-7.46	-0.34	5.06e-13	Cancer;
LUAD	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.97	0.4	1.01e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06028808	chr11:68637592	NA	0.42	7.0	0.32	1.02e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg20701182	chr2:24300061	SF3B14	0.56	6.71	0.31	6.14e-11	Lymphocyte counts;
LUAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg11941060	chr3:133502564	NA	-0.71	-13.34	-0.54	3.77e-34	Iron status biomarkers;
LUAD	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.17	0.37	3.53e-15	Rheumatoid arthritis;
LUAD	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg12935359	chr14:103987150	CKB	-0.49	-8.23	-0.37	2.41e-15	Body mass index;
LUAD	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg18944383	chr4:111397179	ENPEP	0.5	9.13	0.41	2.87e-18	Height;
LUAD	cis	rs9308433	0.529	rs10465697	chr1:214499948	T/C	cg06198575	chr1:214491504	SMYD2	0.45	7.62	0.35	1.65e-13	IgG glycosylation;
LUAD	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg23758822	chr17:41437982	NA	1.01	21.18	0.72	2.04e-68	Menopause (age at onset);
LUAD	cis	rs10193935	0.901	rs1390609	chr2:42666230	G/T	cg27598129	chr2:42591480	NA	0.64	8.48	0.38	3.87e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-8.37	-0.38	8.32e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg16647868	chr5:131706066	SLC22A5	0.38	6.44	0.3	3.33e-10	Blood metabolite levels;
LUAD	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg03929089	chr4:120376271	NA	-0.74	-12.12	-0.51	3.08e-29	Coronary artery disease;
LUAD	cis	rs10992471	0.651	rs2296669	chr9:95373790	A/G	cg14631576	chr9:95140430	CENPP	0.49	10.04	0.44	2.04e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs4268898	0.896	rs2702042	chr2:24546542	C/T	cg06627628	chr2:24431161	ITSN2	-0.5	-8.52	-0.38	2.93e-16	Asthma;
LUAD	cis	rs2882667	0.628	rs13154573	chr5:138148064	T/C	cg04439458	chr5:138467593	SIL1	-0.38	-6.37	-0.3	5.04e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg15117754	chr3:10150083	C3orf24	0.42	6.75	0.31	4.97e-11	Alzheimer's disease;
LUAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg11062466	chr8:58055876	NA	0.81	9.84	0.43	1.05e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs1113500	0.787	rs10881501	chr1:108641745	C/T	cg06207961	chr1:108661230	NA	0.34	6.51	0.3	2.18e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.04	-0.4	5.49e-18	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs564343	0.765	rs1558974	chr11:65877774	T/A	cg26701943	chr11:108369231	KDELC2	0.41	6.43	0.3	3.37e-10	Obesity (early onset extreme);
LUAD	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.59	0.55	3.63e-35	Tonsillectomy;
LUAD	cis	rs7224314	1.000	rs62085810	chr17:65372855	G/A	cg01507342	chr17:65387096	PITPNC1	-0.51	-7.82	-0.36	4.22e-14	Diisocyanate-induced asthma;
LUAD	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg22907277	chr7:1156413	C7orf50	0.59	9.96	0.44	4.05e-21	Longevity;Endometriosis;
LUAD	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs4523957	0.928	rs216183	chr17:2173923	A/G	cg16513277	chr17:2031491	SMG6	0.77	14.63	0.58	1.66e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7084921	0.552	rs2862991	chr10:101876736	C/G	cg19754520	chr10:101825118	CPN1	-0.32	-6.65	-0.31	9.34e-11	Bone mineral density;
LUAD	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs6665290	0.904	rs9727512	chr1:227185375	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-37.84	-0.88	7.51e-138	Myeloid white cell count;
LUAD	cis	rs116248771	0.690	rs16829314	chr3:158416409	C/T	cg16708174	chr3:158430962	RARRES1	0.43	6.47	0.3	2.68e-10	diarrhoeal disease at age 2;
LUAD	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62238980	0.614	rs79065504	chr22:32486442	A/G	cg00543991	chr22:32367038	NA	0.88	8.53	0.38	2.57e-16	Childhood ear infection;
LUAD	cis	rs7937890	0.559	rs2575838	chr11:14498221	C/G	cg23387056	chr11:14280742	SPON1	-0.34	-6.67	-0.31	8.19e-11	Mitochondrial DNA levels;
LUAD	cis	rs4523957	0.818	rs4790887	chr17:2130592	C/A	cg16513277	chr17:2031491	SMG6	0.81	15.0	0.59	4.17e-41	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg15448220	chr1:150897856	SETDB1	0.51	8.65	0.39	1.1e-16	Melanoma;
LUAD	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs4642101	0.511	rs9809596	chr3:12840513	C/G	cg24848339	chr3:12840334	CAND2	0.52	10.97	0.47	8.34e-25	QRS complex (12-leadsum);
LUAD	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg26394196	chr10:1453818	ADARB2	-0.33	-6.46	-0.3	2.88e-10	Radiation response;
LUAD	cis	rs16910800	1.000	rs1531809	chr11:23194373	A/T	cg20040320	chr11:23191996	NA	-0.49	-7.19	-0.33	2.97e-12	Cancer;
LUAD	cis	rs6496044	0.591	rs979825	chr15:86080625	A/T	cg13263323	chr15:86062960	AKAP13	-0.52	-9.37	-0.41	4.34e-19	Interstitial lung disease;
LUAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08048268	chr3:133502702	NA	0.51	10.09	0.44	1.3e-21	Iron status biomarkers;
LUAD	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg01579765	chr21:45077557	HSF2BP	0.65	14.63	0.58	1.66e-39	Mean corpuscular volume;
LUAD	cis	rs1497828	0.956	rs2818975	chr1:217550732	T/G	cg04411442	chr1:217543379	NA	0.38	6.84	0.32	2.79e-11	Dialysis-related mortality;
LUAD	trans	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg26043149	chr18:55253948	FECH	-0.4	-6.69	-0.31	6.98e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4006360	0.646	rs9902561	chr17:39295384	G/A	cg12981595	chr17:39254427	KRTAP4-8	0.32	6.56	0.3	1.58e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6688613	1.000	rs7518155	chr1:166954896	G/T	cg07049167	chr1:166818506	POGK	-0.4	-6.89	-0.32	2.1e-11	Refractive astigmatism;
LUAD	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.7	0.31	6.86e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-10.69	-0.46	9.29e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg26384229	chr12:38710491	ALG10B	0.5	8.31	0.37	1.33e-15	Heart rate;
LUAD	cis	rs67981189	0.529	rs8010063	chr14:71510125	T/A	cg15910301	chr14:71632612	NA	0.41	6.43	0.3	3.44e-10	Schizophrenia;
LUAD	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.36e-12	Lung cancer;
LUAD	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.11	0.33	5.08e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg13334819	chr7:99746414	C7orf59	0.65	10.36	0.45	1.43e-22	Coronary artery disease;
LUAD	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06873352	chr17:61820015	STRADA	-0.8	-17.52	-0.65	4.68e-52	Prudent dietary pattern;
LUAD	cis	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg21775007	chr8:11205619	TDH	0.55	9.81	0.43	1.36e-20	Retinal vascular caliber;
LUAD	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.85	0.4	2.4e-17	Cognitive ability;
LUAD	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.8	-0.35	4.77e-14	Diabetic kidney disease;
LUAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg10729496	chr3:10149963	C3orf24	0.58	9.47	0.42	2.05e-19	Alzheimer's disease;
LUAD	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.49	-0.42	1.75e-19	Type 2 diabetes;
LUAD	cis	rs10203711	0.966	rs4998693	chr2:239564753	G/T	cg14580085	chr2:239553406	NA	0.41	8.63	0.39	1.26e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8017423	0.967	rs11845329	chr14:90727749	C/T	cg14092571	chr14:90743983	NA	-0.48	-8.29	-0.37	1.48e-15	Mortality in heart failure;
LUAD	cis	rs7683537	0.554	rs55830081	chr4:185666477	A/C	cg04058563	chr4:185651563	MLF1IP	0.72	9.72	0.43	2.81e-20	Systemic lupus erythematosus;
LUAD	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04921814	chr1:145575587	PIAS3	0.41	6.81	0.31	3.37e-11	Survival in pancreatic cancer;
LUAD	cis	rs6761276	0.899	rs13398125	chr2:113834835	G/A	cg06383401	chr2:113825234	IL1F10	-0.3	-6.48	-0.3	2.6200000000000003e-10	Protein quantitative trait loci;
LUAD	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.66	-0.39	9.69e-17	Total body bone mineral density;
LUAD	cis	rs11214589	0.774	rs7116782	chr11:113250938	A/G	cg14159747	chr11:113255604	NA	0.7	15.06	0.59	2.46e-41	Neuroticism;
LUAD	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.39	-0.34	7.98e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg00757033	chr12:89920650	WDR51B	0.7	12.3	0.51	6.22e-30	NT-proBNP levels in acute coronary syndrome;
LUAD	trans	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.78	-0.31	4.08e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg05044414	chr3:183734942	ABCC5	0.35	6.85	0.32	2.7e-11	Anterior chamber depth;
LUAD	cis	rs938554	0.744	rs13129697	chr4:9926967	T/G	cg00071950	chr4:10020882	SLC2A9	-0.57	-9.69	-0.43	3.47e-20	Blood metabolite levels;
LUAD	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg13732083	chr21:47605072	C21orf56	0.42	6.95	0.32	1.39e-11	Testicular germ cell tumor;
LUAD	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.34	-0.34	1.1e-12	Lung cancer;
LUAD	cis	rs870825	0.616	rs67409049	chr4:185623989	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.69	-13.54	-0.55	5.83e-35	Ulcerative colitis;
LUAD	cis	rs5758511	0.773	rs10154700	chr22:42365073	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.39	6.77	0.31	4.45e-11	Birth weight;
LUAD	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg13385794	chr1:248469461	NA	0.26	7.11	0.33	5.13e-12	Common traits (Other);
LUAD	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg15557168	chr22:42548783	NA	-0.48	-8.55	-0.38	2.27e-16	Schizophrenia;
LUAD	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg24558204	chr6:135376177	HBS1L	0.46	8.56	0.38	2.1e-16	Red blood cell count;
LUAD	trans	rs637571	0.565	rs633800	chr11:65638719	G/A	cg17712092	chr4:129076599	LARP1B	-0.79	-13.68	-0.55	1.53e-35	Eosinophil percentage of white cells;
LUAD	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg16205897	chr5:131564050	P4HA2	-0.43	-10.15	-0.44	8.07e-22	Blood metabolite levels;
LUAD	cis	rs4072705	0.967	rs10760369	chr9:127397400	A/G	cg01786973	chr9:127249749	NR5A1	0.3	6.65	0.31	9.01e-11	Menarche (age at onset);
LUAD	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg00495681	chr13:53174319	NA	0.77	15.82	0.61	1.33e-44	Lewy body disease;
LUAD	cis	rs2456568	0.741	rs2102332	chr11:93635281	G/T	cg26875233	chr11:93583750	C11orf90	-0.29	-6.39	-0.3	4.35e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.33e-10	Ulcerative colitis;
LUAD	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg15181151	chr6:150070149	PCMT1	0.33	6.56	0.3	1.62e-10	Testicular germ cell tumor;
LUAD	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.13	14.79	0.58	3.33e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg17366294	chr4:99064904	C4orf37	0.52	9.35	0.41	5.01e-19	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.55	-9.25	-0.41	1.12e-18	Mean corpuscular volume;
LUAD	cis	rs2425143	0.730	rs7263640	chr20:34314725	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.43	-0.34	6.03e-13	Blood protein levels;
LUAD	cis	rs9837602	1.000	rs923471	chr3:99757853	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	8.72	0.39	6.44e-17	Breast cancer;
LUAD	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg07636037	chr3:49044803	WDR6	0.64	12.6	0.52	4.11e-31	Parkinson's disease;
LUAD	trans	rs11039798	1.000	rs9667626	chr11:48485877	T/C	cg15704280	chr7:45808275	SEPT13	0.65	7.62	0.35	1.63e-13	Axial length;
LUAD	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.9	-0.36	2.43e-14	Total body bone mineral density;
LUAD	cis	rs9972944	0.756	rs7218844	chr17:63768289	G/A	cg07283582	chr17:63770753	CCDC46	-0.51	-11.6	-0.49	3.32e-27	Total body bone mineral density;
LUAD	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.63	9.73	0.43	2.47e-20	Alzheimer's disease;
LUAD	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg00339695	chr16:24857497	SLC5A11	0.73	11.72	0.5	1.18e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs892961	0.899	rs3650	chr17:75415835	T/C	cg05865280	chr17:75406074	SEPT9	0.63	20.11	0.7	1.27e-63	Airflow obstruction;
LUAD	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg19163074	chr7:65112434	INTS4L2	0.44	6.6	0.31	1.21e-10	Aortic root size;
LUAD	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg11292332	chr7:45801988	SEPT13	-0.28	-6.36	-0.3	5.26e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	7.64	0.35	1.44e-13	Schizophrenia;
LUAD	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg03037974	chr15:76606532	NA	0.38	8.02	0.36	1.01e-14	Blood metabolite levels;
LUAD	trans	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg01620082	chr3:125678407	NA	-0.81	-8.1	-0.37	6.15e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1997103	0.871	rs1997100	chr7:55399656	C/G	cg17469321	chr7:55412551	NA	0.67	11.41	0.49	1.73e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg12419862	chr22:24373484	LOC391322	-0.64	-10.76	-0.46	5.11e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27297192	chr10:134578999	INPP5A	0.34	6.37	0.3	5.01e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9341808	0.519	rs3805878	chr6:81013855	A/G	cg08355045	chr6:80787529	NA	0.38	6.56	0.3	1.53e-10	Sitting height ratio;
LUAD	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg22491629	chr6:157744540	C6orf35	-0.8	-8.91	-0.4	1.53e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg13271783	chr10:134563150	INPP5A	0.43	7.12	0.33	4.53e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1712517	0.771	rs2292807	chr10:105155645	T/C	cg05636881	chr10:105038444	INA	0.32	6.38	0.3	4.71e-10	Migraine;
LUAD	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg06671706	chr8:8559999	CLDN23	0.66	11.43	0.49	1.52e-26	Obesity-related traits;
LUAD	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg07507251	chr3:52567010	NT5DC2	0.39	7.57	0.35	2.31e-13	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.4	0.38	6.77e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-6.77	-0.31	4.35e-11	Alzheimer's disease (late onset);
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23995395	chr4:83821786	THAP9	0.45	7.05	0.32	7.47e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs1045714	0.895	rs4719594	chr7:2639790	G/A	cg24848437	chr7:2645542	IQCE	0.69	8.0	0.36	1.24e-14	Urate levels in lean individuals;
LUAD	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg00074818	chr8:8560427	CLDN23	0.69	10.64	0.46	1.44e-23	Obesity-related traits;
LUAD	trans	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg01620082	chr3:125678407	NA	-0.9	-8.66	-0.39	1.04e-16	Intelligence (multi-trait analysis);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04206329	chr16:30597253	ZNF785	0.43	6.44	0.3	3.3e-10	Gut microbiome composition (summer);
LUAD	cis	rs240764	0.711	rs240112	chr6:101059253	C/A	cg09795085	chr6:101329169	ASCC3	0.43	7.29	0.33	1.55e-12	Neuroticism;
LUAD	cis	rs11741688	0.557	rs6600994	chr5:178336005	T/A	cg09339527	chr5:178322752	ZFP2	-0.35	-7.34	-0.34	1.12e-12	Sleep duration;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg21008684	chr2:157198370	NA	-0.38	-6.41	-0.3	3.78e-10	Subcortical brain region volumes;
LUAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.07e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs59918340	0.509	rs11784862	chr8:142203452	T/C	cg18755752	chr8:142205143	DENND3	-0.46	-7.41	-0.34	6.76e-13	Immature fraction of reticulocytes;
LUAD	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg03477792	chr4:77819574	ANKRD56	0.49	7.31	0.33	1.32e-12	Emphysema distribution in smoking;
LUAD	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35995292	0.500	rs2392606	chr7:38926955	C/A	cg19327137	chr7:38886074	VPS41	0.72	14.58	0.58	2.61e-39	Subjective well-being (multi-trait analysis);
LUAD	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg07936489	chr17:37558343	FBXL20	-0.49	-6.43	-0.3	3.42e-10	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
LUAD	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.39	-6.41	-0.3	3.81e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs11676855	1.000	rs11676855	chr2:235900171	C/T	cg14917874	chr2:235941519	SH3BP4	-0.4	-6.84	-0.32	2.83e-11	Dialysis-related mortality;
LUAD	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13126279	chr21:47581558	C21orf56	0.61	11.26	0.48	6.9e-26	Testicular germ cell tumor;
LUAD	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.57	-8.93	-0.4	1.28e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg05590025	chr7:65112418	INTS4L2	0.74	8.06	0.36	8.13e-15	Diabetic kidney disease;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg21951070	chr3:185826924	ETV5	-0.55	-6.64	-0.31	9.94e-11	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg22117172	chr7:91764530	CYP51A1	0.33	7.35	0.34	1.05e-12	Breast cancer;
LUAD	cis	rs1113500	0.933	rs11185256	chr1:108633957	C/T	cg06207961	chr1:108661230	NA	0.45	8.49	0.38	3.65e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.48	8.68	0.39	8.47e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7843479	1.000	rs1032094	chr8:21820479	A/T	cg03445287	chr8:21823731	XPO7	-0.46	-8.62	-0.39	1.31e-16	Mean corpuscular volume;
LUAD	cis	rs10465746	0.967	rs12140068	chr1:84394286	A/C	cg10977910	chr1:84465055	TTLL7	0.5	8.09	0.37	6.55e-15	Obesity-related traits;
LUAD	cis	rs6494488	0.500	rs111858590	chr15:65063622	C/A	cg08069370	chr15:64387884	SNX1	-0.72	-6.64	-0.31	9.61e-11	Coronary artery disease;
LUAD	cis	rs12681287	0.640	rs6992944	chr8:87419308	G/T	cg00550725	chr8:87521180	FAM82B	-0.44	-6.42	-0.3	3.69e-10	Caudate activity during reward;
LUAD	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	7.3	0.33	1.48e-12	Schizophrenia;
LUAD	cis	rs804280	0.662	rs804283	chr8:11611043	G/A	cg23972785	chr8:11611189	GATA4	0.45	7.41	0.34	6.7e-13	Myopia (pathological);
LUAD	trans	rs5756813	0.754	rs13057133	chr22:38179473	C/T	cg19894588	chr14:64061835	NA	-0.46	-6.55	-0.3	1.72e-10	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.56	0.3	1.55e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.41	8.02	0.36	1.08e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	8.74	0.39	5.32e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg15432903	chr11:17409602	KCNJ11	0.54	10.23	0.45	4.3e-22	Type 2 diabetes;
LUAD	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg09117114	chr16:67998030	SLC12A4	-0.51	-7.47	-0.34	4.65e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.1	0.33	5.4e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.5	-0.42	1.5700000000000001e-19	Life satisfaction;
LUAD	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	9.24	0.41	1.25e-18	Colorectal cancer;
LUAD	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg22920501	chr2:26401640	FAM59B	-0.76	-10.89	-0.47	1.61e-24	Gut microbiome composition (summer);
LUAD	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg05368731	chr17:41323189	NBR1	0.97	19.8	0.69	3.12e-62	Menopause (age at onset);
LUAD	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.0	22.16	0.73	8.56e-73	Chronic sinus infection;
LUAD	cis	rs73198271	0.737	rs535094	chr8:8633928	A/G	cg01851573	chr8:8652454	MFHAS1	0.41	7.25	0.33	1.99e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9768139	0.708	rs34267680	chr7:158115084	C/T	cg24154853	chr7:158122151	PTPRN2	0.56	10.94	0.47	1.1e-24	Calcium levels;
LUAD	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg24846343	chr22:24311635	DDTL	0.74	16.58	0.63	6.5e-48	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12753569	0.748	rs1013630	chr1:76513819	G/T	cg00791851	chr1:76518896	NA	0.29	6.46	0.3	2.8e-10	Personality dimensions;
LUAD	cis	rs853679	0.556	rs67297533	chr6:28141253	G/T	cg12623302	chr6:28058802	ZSCAN12L1	0.56	6.53	0.3	1.91e-10	Depression;
LUAD	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg16606324	chr3:10149918	C3orf24	0.7	11.51	0.49	7.19e-27	Alzheimer's disease;
LUAD	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg26022315	chr17:47021804	SNF8	0.4	7.21	0.33	2.63e-12	Type 2 diabetes;
LUAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg18402987	chr7:1209562	NA	0.81	9.91	0.43	6.12e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11585357	0.947	rs11585118	chr1:17605774	C/A	cg08277548	chr1:17600880	PADI3	-0.96	-14.01	-0.56	6.58e-37	Hair shape;
LUAD	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-13.39	-0.55	2.38e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg05043794	chr9:111880884	C9orf5	0.39	6.75	0.31	4.8e-11	Menarche (age at onset);
LUAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg00080972	chr5:178986291	RUFY1	-0.57	-9.96	-0.44	3.78e-21	Lung cancer;
LUAD	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03517284	chr6:25882590	NA	0.85	14.41	0.57	1.36e-38	Blood metabolite levels;
LUAD	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.86	0.47	2.08e-24	Smoking behavior;
LUAD	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg00277334	chr10:82204260	NA	-0.52	-8.55	-0.38	2.26e-16	Post bronchodilator FEV1;
LUAD	trans	rs1941687	0.702	rs8090097	chr18:31413448	A/C	cg27147174	chr7:100797783	AP1S1	-0.5	-8.88	-0.4	1.85e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs59698941	0.527	rs1557852	chr5:132181800	G/A	cg16419906	chr5:132167176	NA	-0.32	-6.37	-0.3	4.91e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg03609598	chr5:56110824	MAP3K1	-0.42	-6.72	-0.31	5.83e-11	Coronary artery disease;
LUAD	cis	rs8058578	0.945	rs34480360	chr16:30798689	G/A	cg02466173	chr16:30829666	NA	-0.72	-12.64	-0.52	2.82e-31	Multiple myeloma;
LUAD	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg21475434	chr5:93447410	FAM172A	0.75	8.38	0.38	8.01e-16	Diabetic retinopathy;
LUAD	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg21724239	chr8:58056113	NA	0.54	7.26	0.33	1.89e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1395	0.778	rs6709602	chr2:27405497	C/T	cg23587288	chr2:27483067	SLC30A3	-0.41	-7.72	-0.35	8.24e-14	Blood metabolite levels;
LUAD	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27297192	chr10:134578999	INPP5A	0.37	6.35	0.3	5.4e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7512552	0.809	rs696618	chr1:150376139	T/G	cg15654264	chr1:150340011	RPRD2	0.59	11.29	0.48	4.91e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg04111992	chr7:158790115	NA	-0.48	-8.15	-0.37	4.17e-15	Facial morphology (factor 20);
LUAD	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg20607798	chr8:58055168	NA	0.77	9.27	0.41	9.7e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg03806693	chr22:41940476	POLR3H	-0.7	-9.49	-0.42	1.73e-19	Vitiligo;
LUAD	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.58	-0.3	1.38e-10	Breast cancer;
LUAD	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.83	0.53	4.8e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1882538	0.512	rs13241734	chr7:133122742	C/G	cg10665199	chr7:133106180	EXOC4	0.61	10.26	0.45	3.21e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg14092988	chr3:52407081	DNAH1	0.45	9.15	0.41	2.51e-18	Bipolar disorder;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg10950113	chr16:69166907	CHTF8;CIRH1A	-0.38	-6.41	-0.3	3.95e-10	Cancer;
LUAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.51	-0.38	3.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg16325326	chr1:53192061	ZYG11B	0.65	11.2	0.48	1.08e-25	Monocyte count;
LUAD	cis	rs757647	0.723	rs75313335	chr5:137751128	A/T	cg10676309	chr5:137685565	NA	0.41	7.15	0.33	3.86e-12	Menarche (age at onset);
LUAD	cis	rs17095355	1.000	rs17126886	chr10:111695257	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.72	-9.69	-0.43	3.51e-20	Biliary atresia;
LUAD	cis	rs2734839	0.537	rs1554929	chr11:113278764	C/T	cg14159747	chr11:113255604	NA	0.65	13.57	0.55	4.59e-35	Information processing speed;
LUAD	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg19743168	chr1:23544995	NA	0.39	6.84	0.32	2.72e-11	Height;
LUAD	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg05340658	chr4:99064831	C4orf37	0.53	9.05	0.4	5.17e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg15704280	chr7:45808275	SEPT13	-1.0	-20.04	-0.7	2.63e-63	Height;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg09392819	chr2:26568944	SELI;GPR113	-0.45	-7.01	-0.32	9.29e-12	Vertical cup-disc ratio;
LUAD	cis	rs9972944	0.756	rs7222190	chr17:63764953	T/C	cg07283582	chr17:63770753	CCDC46	-0.49	-11.07	-0.47	3.37e-25	Total body bone mineral density;
LUAD	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg09160332	chr4:120329925	NA	-0.36	-6.38	-0.3	4.65e-10	Corneal astigmatism;
LUAD	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg24308560	chr3:49941425	MST1R	-0.5	-8.03	-0.36	1e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs2262909	0.849	rs2666447	chr19:22132868	T/A	cg17074339	chr11:11642133	GALNTL4	-0.43	-7.05	-0.32	7.49e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4964805	0.683	rs12424737	chr12:104196221	A/C	cg02344784	chr12:104178138	NT5DC3	0.45	9.15	0.41	2.53e-18	Attention deficit hyperactivity disorder;
LUAD	cis	rs6975373	0.730	rs1009528	chr7:4456304	G/T	cg10785373	chr7:4456119	NA	-0.51	-6.39	-0.3	4.49e-10	Borderline personality disorder;
LUAD	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg21191810	chr6:118973309	C6orf204	-0.52	-8.14	-0.37	4.53e-15	Diastolic blood pressure;
LUAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.61	-8.76	-0.39	4.71e-17	Alzheimer's disease;
LUAD	cis	rs1832871	0.541	rs62438578	chr6:158871624	C/T	cg07165851	chr6:158734300	TULP4	0.52	7.42	0.34	6.68e-13	Height;
LUAD	cis	rs10979	0.965	rs34373782	chr6:143888258	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.3	-0.45	2.33e-22	Hypospadias;
LUAD	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.68	-0.35	1.08e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.74	-12.43	-0.52	1.91e-30	Primary sclerosing cholangitis;
LUAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg24642844	chr7:1081250	C7orf50	-0.96	-14.28	-0.57	5.05e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.39	6.7	0.31	6.81e-11	Total body bone mineral density;
LUAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg27454412	chr7:1067447	C7orf50	0.48	7.74	0.35	7.28e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-10.06	-0.44	1.72e-21	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02179112	chr5:10354198	MARCH6	0.43	6.55	0.3	1.7e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg06640241	chr16:89574553	SPG7	0.49	8.16	0.37	3.88e-15	Multiple myeloma (IgH translocation);
LUAD	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg07606381	chr6:8435919	SLC35B3	0.4	6.65	0.31	9.07e-11	Motion sickness;
LUAD	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg02896835	chr1:92012615	NA	0.55	8.3	0.37	1.41e-15	Eosinophil percentage of white cells;
LUAD	cis	rs11031096	0.899	rs7124301	chr11:4105270	T/C	cg18678763	chr11:4115507	RRM1	0.38	6.71	0.31	6.34e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.71	0.31	6.25e-11	Breast cancer;
LUAD	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg08601574	chr20:25228251	PYGB	-0.47	-8.81	-0.39	3.3e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg04455712	chr21:45112962	RRP1B	0.47	9.22	0.41	1.37e-18	Mean corpuscular volume;
LUAD	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg09455208	chr3:40491958	NA	0.56	12.31	0.51	5.81e-30	Renal cell carcinoma;
LUAD	cis	rs7250872	0.606	rs2304616	chr19:1826164	G/T	cg10370574	chr19:1840461	REXO1	-0.65	-10.65	-0.46	1.28e-23	Bipolar disorder;
LUAD	cis	rs6717918	1.000	rs6717918	chr2:233155110	T/C	ch.2.233013039R	chr2:233304795	NA	0.47	7.09	0.33	5.62e-12	Height;
LUAD	cis	rs738322	0.553	rs28718653	chr22:38570698	C/A	cg17652424	chr22:38574118	PLA2G6	-0.3	-7.98	-0.36	1.38e-14	Cutaneous nevi;
LUAD	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.11	-24.77	-0.77	2.39e-84	Ulcerative colitis;
LUAD	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg07636037	chr3:49044803	WDR6	0.48	8.2	0.37	2.85e-15	Menarche (age at onset);
LUAD	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.87	-0.61	7.81e-45	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg12927641	chr6:109611667	NA	-0.54	-9.64	-0.42	5.28e-20	Reticulocyte fraction of red cells;
LUAD	trans	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg18187862	chr3:45730750	SACM1L	0.54	8.3	0.37	1.43e-15	Primary sclerosing cholangitis;
LUAD	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.23	0.33	2.33e-12	Lung cancer;
LUAD	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg05564831	chr3:52568323	NT5DC2	0.36	6.89	0.32	2.05e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7833986	0.501	rs2976036	chr8:57031721	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.99	17.76	0.65	4.05e-53	Height;
LUAD	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg02423579	chr7:2872169	GNA12	-0.91	-16.52	-0.63	1.19e-47	Height;
LUAD	cis	rs12431939	0.947	rs66478864	chr14:51597265	T/G	cg23942311	chr14:51606299	NA	-0.64	-8.59	-0.39	1.72e-16	Cancer;
LUAD	cis	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.98	-0.36	1.37e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs7395662	1.000	rs10769390	chr11:48618222	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.48	-0.3	2.57e-10	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg18180107	chr4:99064573	C4orf37	0.43	6.82	0.31	3.15e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg22442454	chr1:209979470	IRF6	0.48	7.15	0.33	3.84e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs1003719	0.715	rs2835647	chr21:38546773	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.43	-0.38	5.42e-16	Eye color traits;
LUAD	cis	rs757647	0.723	rs61315180	chr5:137749294	A/G	cg10676309	chr5:137685565	NA	0.42	7.49	0.34	4.12e-13	Menarche (age at onset);
LUAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg07677032	chr17:61819896	STRADA	0.56	10.11	0.44	1.15e-21	Prudent dietary pattern;
LUAD	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg18404041	chr3:52824283	ITIH1	-0.4	-7.27	-0.33	1.74e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg17105886	chr17:28927953	LRRC37B2	0.83	8.0	0.36	1.18e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg05283184	chr6:79620031	NA	-0.63	-12.53	-0.52	7.52e-31	Intelligence (multi-trait analysis);
LUAD	cis	rs7586879	0.559	rs13387729	chr2:25076126	A/G	cg04586622	chr2:25135609	ADCY3	0.37	8.45	0.38	4.6e-16	Body mass index;
LUAD	cis	rs732716	0.785	rs62129354	chr19:4396505	G/A	cg21934504	chr19:4445085	UBXN6	0.45	7.46	0.34	5e-13	Mean corpuscular volume;
LUAD	cis	rs10744422	0.925	rs897391	chr12:123326374	G/A	cg16953816	chr12:123349952	VPS37B	0.62	7.17	0.33	3.34e-12	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg00898013	chr13:113819073	PROZ	0.73	13.12	0.54	3.18e-33	Platelet distribution width;
LUAD	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	8.71	0.39	6.68e-17	Alzheimer's disease;
LUAD	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg10589385	chr1:150898437	SETDB1	0.44	8.0	0.36	1.19e-14	Melanoma;
LUAD	cis	rs7833986	0.501	rs72653978	chr8:57018393	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	1.02	18.03	0.66	2.59e-54	Height;
LUAD	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20997463	chr12:53689079	PFDN5	0.4	6.5	0.3	2.25e-10	Survival in pancreatic cancer;
LUAD	cis	rs2235649	0.789	rs4567715	chr16:1849363	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-8.15	-0.37	4.02e-15	Blood metabolite levels;
LUAD	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.31	6.37	0.3	4.89e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg09826364	chr7:158789723	NA	-0.38	-6.82	-0.31	3.1e-11	Facial morphology (factor 20);
LUAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg06753367	chr22:24256600	NA	-0.42	-7.61	-0.35	1.84e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4588572	0.643	rs35299318	chr5:77668322	A/C	cg11547950	chr5:77652471	NA	0.78	11.81	0.5	4.99e-28	Triglycerides;
LUAD	cis	rs10979	0.571	rs9386039	chr6:143916992	A/T	cg25407410	chr6:143891975	LOC285740	0.48	6.57	0.3	1.47e-10	Hypospadias;
LUAD	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg00316803	chr15:76480434	C15orf27	-0.41	-7.77	-0.35	5.83e-14	Blood metabolite levels;
LUAD	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg01028140	chr2:1542097	TPO	-0.48	-6.75	-0.31	4.9e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2882667	0.788	rs11959691	chr5:138481088	C/T	cg04439458	chr5:138467593	SIL1	-0.56	-10.04	-0.44	2.08e-21	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg10544611	chr16:67998164	SLC12A4	-0.54	-6.87	-0.32	2.38e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs72772090	0.710	rs17400685	chr5:96066366	A/C	cg17330273	chr5:96107758	CAST;ERAP1	0.56	6.71	0.31	6.3e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg07677032	chr17:61819896	STRADA	0.55	10.09	0.44	1.41e-21	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg18016565	chr1:150552671	MCL1	0.41	7.55	0.34	2.78e-13	Tonsillectomy;
LUAD	cis	rs1265507	0.559	rs2551388	chr12:114858247	G/A	cg12437821	chr12:114852027	NA	-0.35	-6.58	-0.3	1.44e-10	Percent mammographic density;
LUAD	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg21191810	chr6:118973309	C6orf204	-0.53	-8.04	-0.36	9.31e-15	Diastolic blood pressure;
LUAD	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg18200150	chr17:30822561	MYO1D	0.44	8.23	0.37	2.39e-15	Schizophrenia;
LUAD	cis	rs12681287	0.752	rs4534114	chr8:87271956	A/G	cg27223183	chr8:87520930	FAM82B	-0.61	-8.45	-0.38	4.88e-16	Caudate activity during reward;
LUAD	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg04282206	chr17:62833786	PLEKHM1P	-0.38	-6.37	-0.3	4.84e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1882538	0.901	rs35284403	chr7:132948884	T/C	cg10665199	chr7:133106180	EXOC4	0.4	6.51	0.3	2.11e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg11915388	chr22:42470451	FAM109B	0.41	7.28	0.33	1.64e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg08885076	chr2:99613938	TSGA10	0.36	6.46	0.3	2.91e-10	Chronic sinus infection;
LUAD	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg17330251	chr7:94953956	PON1	-0.57	-7.89	-0.36	2.67e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg00280220	chr17:61926910	NA	0.37	7.06	0.32	7.05e-12	Prudent dietary pattern;
LUAD	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.47	-6.75	-0.31	4.91e-11	Schizophrenia;
LUAD	cis	rs2455601	0.608	rs59025804	chr11:8870301	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-8.49	-0.38	3.62e-16	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg13047869	chr3:10149882	C3orf24	0.64	11.02	0.47	5.16e-25	Alzheimer's disease;
LUAD	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg26408565	chr15:76604113	ETFA	-0.56	-9.77	-0.43	1.78e-20	Blood metabolite levels;
LUAD	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg01689657	chr7:91764605	CYP51A1	0.31	7.49	0.34	4.16e-13	Breast cancer;
LUAD	trans	rs75804782	0.625	rs10929277	chr2:239468639	T/G	cg01134436	chr17:81009848	B3GNTL1	0.71	7.28	0.33	1.64e-12	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs10129255	0.500	rs7161740	chr14:107184358	G/T	cg07958169	chr14:107095056	NA	-0.37	-7.24	-0.33	2.07e-12	Kawasaki disease;
LUAD	cis	rs10489202	0.657	rs201540	chr1:167992883	G/A	cg25738037	chr1:168025549	DCAF6	-0.5	-7.44	-0.34	5.79e-13	Schizophrenia;
LUAD	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg21699342	chr2:239360505	ASB1	0.6	11.7	0.49	1.41e-27	Multiple system atrophy;
LUAD	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11644478	chr21:40555479	PSMG1	-0.41	-6.88	-0.32	2.23e-11	Menarche (age at onset);
LUAD	cis	rs8130944	0.859	rs11700836	chr21:44112463	A/G	cg16784985	chr21:44105474	PDE9A	-0.39	-6.67	-0.31	8.15e-11	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs317865	0.748	rs73234656	chr4:16212702	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.9	8.88	0.4	1.93e-17	Kidney disease (early stage) in type 1 diabetes;
LUAD	cis	rs10129255	0.530	rs11624912	chr14:107129907	A/G	cg23076370	chr14:107095027	NA	-0.43	-8.51	-0.38	3.07e-16	Kawasaki disease;
LUAD	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg01475377	chr6:109611718	NA	0.53	10.23	0.45	4.32e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg23352942	chr3:46931381	PTH1R	-0.37	-7.47	-0.34	4.62e-13	Birth weight;
LUAD	cis	rs28595532	0.920	rs56303276	chr4:119723514	C/T	cg02775129	chr4:119771670	NA	-0.87	-7.97	-0.36	1.54e-14	Cannabis dependence symptom count;
LUAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs240764	0.817	rs239239	chr6:101094554	A/G	cg09795085	chr6:101329169	ASCC3	0.43	7.48	0.34	4.29e-13	Neuroticism;
LUAD	cis	rs2932538	0.883	rs6696991	chr1:113095661	C/T	cg22162597	chr1:113214053	CAPZA1	0.41	6.49	0.3	2.37e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg09796270	chr17:17721594	SREBF1	-0.38	-7.56	-0.34	2.57e-13	Body mass index;
LUAD	cis	rs6445967	0.554	rs10866017	chr3:58445757	A/C	cg13750441	chr3:58318267	PXK	-0.32	-6.56	-0.3	1.54e-10	Platelet count;
LUAD	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg03609598	chr5:56110824	MAP3K1	-0.66	-8.8	-0.39	3.51e-17	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg06873352	chr17:61820015	STRADA	0.43	7.1	0.33	5.3e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg19635926	chr16:89946313	TCF25	0.74	6.47	0.3	2.79e-10	Skin colour saturation;
LUAD	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs10100465	0.961	rs13439042	chr8:118634613	A/T	cg09430518	chr8:118662568	NA	0.33	6.69	0.31	7.26e-11	Leprosy;
LUAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.81	-0.31	3.33e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs412658	0.504	rs17769372	chr19:22114704	T/C	cg05197062	chr11:11642011	GALNTL4	-0.41	-7.1	-0.33	5.18e-12	Telomere length;
LUAD	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg22705602	chr4:152727874	NA	-0.48	-9.07	-0.4	4.69e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg06611532	chr13:114900021	NA	0.38	9.03	0.4	6.31e-18	Schizophrenia;
LUAD	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg15921436	chr17:44337874	NA	0.87	11.52	0.49	6.94e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg09365446	chr1:150670422	GOLPH3L	0.66	12.34	0.51	4.22e-30	Tonsillectomy;
LUAD	cis	rs3087591	0.920	rs4795592	chr17:29612620	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.63	-0.31	1e-10	Hip circumference;
LUAD	cis	rs708547	0.647	rs1718830	chr4:57888510	T/C	cg00922110	chr4:57842668	C4orf14	-0.44	-8.13	-0.37	4.7e-15	Response to bleomycin (chromatid breaks);
LUAD	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg06609049	chr19:2785107	THOP1	-1.06	-21.3	-0.72	6.26e-69	Total cholesterol levels;
LUAD	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg12193833	chr17:30244370	NA	-0.56	-7.27	-0.33	1.71e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs7937890	0.531	rs2597216	chr11:14533916	G/A	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.15e-12	Mitochondrial DNA levels;
LUAD	trans	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg04995722	chr7:26192034	NFE2L3	0.36	6.44	0.3	3.17e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2928148	0.522	rs11858278	chr15:41416276	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.71	-12.66	-0.52	2.35e-31	Glomerular filtration rate in non diabetics (creatinine);
LUAD	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg25427524	chr10:38739819	LOC399744	-0.58	-6.63	-0.31	1.01e-10	Obesity (extreme);
LUAD	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg03806693	chr22:41940476	POLR3H	-0.8	-11.23	-0.48	8.97e-26	Vitiligo;
LUAD	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7301826	0.651	rs7968675	chr12:131303377	C/T	cg11011512	chr12:131303247	STX2	0.43	7.27	0.33	1.75e-12	Plasma plasminogen activator levels;
LUAD	cis	rs10979	1.000	rs12203151	chr6:143884856	C/T	cg25407410	chr6:143891975	LOC285740	-0.6	-9.22	-0.41	1.39e-18	Hypospadias;
LUAD	cis	rs790123	1.000	rs790125	chr3:122388464	A/G	cg24850323	chr3:122379709	NA	0.39	7.2	0.33	2.76e-12	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg04995722	chr7:26192034	NFE2L3	0.45	7.82	0.36	4.3e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg20607798	chr8:58055168	NA	0.58	7.95	0.36	1.75e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7737355	0.947	rs6864173	chr5:130871822	T/C	cg25547332	chr5:131281432	NA	0.43	6.5	0.3	2.28e-10	Life satisfaction;
LUAD	cis	rs3823572	0.504	rs2971968	chr7:133642599	C/A	cg03336402	chr7:133662267	EXOC4	-0.43	-7.74	-0.35	7.14e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs11756438	0.572	rs1771755	chr6:119018877	A/T	cg21191810	chr6:118973309	C6orf204	-0.47	-9.26	-0.41	1e-18	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4372836	1.000	rs4666119	chr2:28975690	C/G	cg09522027	chr2:28974177	PPP1CB	-0.61	-9.67	-0.43	3.92e-20	Body mass index;
LUAD	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg05805236	chr11:65401703	PCNXL3	-0.55	-8.77	-0.39	4.4e-17	Acne (severe);
LUAD	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27286337	chr10:134555280	INPP5A	0.73	9.71	0.43	2.92e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs3784262	0.565	rs8041644	chr15:58266833	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.34	-6.54	-0.3	1.79e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg27087555	chr16:88793112	FAM38A	-0.85	-7.84	-0.36	3.64e-14	Plateletcrit;
LUAD	cis	rs427941	0.632	rs201526	chr7:101774333	T/G	cg06246474	chr7:101738831	CUX1	0.37	6.46	0.3	2.93e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.4	-7.1	-0.33	5.32e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12681287	0.604	rs13279589	chr8:87477723	C/T	cg27223183	chr8:87520930	FAM82B	-0.67	-9.61	-0.42	6.38e-20	Caudate activity during reward;
LUAD	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg05425664	chr17:57184151	TRIM37	0.43	7.66	0.35	1.28e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg00106254	chr7:1943704	MAD1L1	-0.6	-9.02	-0.4	6.53e-18	Bipolar disorder and schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03157738	chr19:11308118	KANK2	-0.42	-6.96	-0.32	1.32e-11	Height;
LUAD	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-19.11	-0.68	3.68e-59	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg24675056	chr1:15929824	NA	0.48	8.44	0.38	5.23e-16	Systolic blood pressure;
LUAD	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21659725	chr3:3221576	CRBN	-0.65	-10.4	-0.45	1.01e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6062509	0.929	rs55791529	chr20:62363858	C/T	cg21849932	chr20:62369462	LIME1	-0.46	-7.29	-0.33	1.54e-12	Prostate cancer;
LUAD	trans	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg25894440	chr7:65020034	NA	-0.64	-6.78	-0.31	4e-11	Gout;
LUAD	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.5	-0.38	3.38e-16	Height;
LUAD	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.78	-0.35	5.7e-14	Blood metabolite levels;
LUAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg03188948	chr7:1209495	NA	0.84	11.39	0.48	2.2e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg02551604	chr5:131831745	NA	-0.64	-10.27	-0.45	3.17e-22	Asthma (sex interaction);
LUAD	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24308560	chr3:49941425	MST1R	0.54	9.11	0.41	3.2e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18876405	chr7:65276391	NA	0.61	10.26	0.45	3.39e-22	Aortic root size;
LUAD	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg04455712	chr21:45112962	RRP1B	-0.47	-9.2	-0.41	1.61e-18	Mean corpuscular volume;
LUAD	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.28	-0.45	2.81e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg11645453	chr3:52864694	ITIH4	0.57	10.76	0.46	4.9e-24	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg07748719	chr16:1272498	TPSG1	0.72	13.76	0.56	7.65e-36	Blood protein levels;
LUAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.57	0.3	1.44e-10	Prudent dietary pattern;
LUAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg24101359	chr6:42928495	GNMT	0.48	8.99	0.4	8.18e-18	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7107174	1.000	rs10899454	chr11:77997513	T/C	cg19901956	chr11:77921274	USP35	-0.53	-6.86	-0.32	2.5e-11	Testicular germ cell tumor;
LUAD	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg00204512	chr16:28754710	NA	0.32	6.88	0.32	2.15e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs62238980	0.614	rs78443579	chr22:32449283	A/G	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	trans	rs8073060	0.504	rs225271	chr17:33969836	C/T	cg19694781	chr19:47549865	TMEM160	-1.23	-19.49	-0.69	7.55e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg25358565	chr5:93447407	FAM172A	0.56	6.78	0.31	3.96e-11	Diabetic retinopathy;
LUAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.63	8.32	0.37	1.23e-15	Renal function-related traits (BUN);
LUAD	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-10.93	-0.47	1.18e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.25e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg22117172	chr7:91764530	CYP51A1	-0.32	-6.78	-0.31	4.16e-11	Breast cancer;
LUAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg03188948	chr7:1209495	NA	0.85	11.4	0.48	1.87e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6474412	0.700	rs7017612	chr8:42599245	A/C	cg25026480	chr8:42547641	NA	-0.36	-6.46	-0.3	2.92e-10	Smoking behavior;
LUAD	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22857025	chr5:266934	NA	0.94	14.39	0.57	1.64e-38	Breast cancer;
LUAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg24642844	chr7:1081250	C7orf50	-0.95	-14.09	-0.57	3.22e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.52	-0.3	2.06e-10	Neuroticism;
LUAD	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg23262073	chr20:60523788	NA	0.62	9.97	0.44	3.7e-21	Obesity-related traits;
LUAD	cis	rs2046867	0.818	rs17010133	chr3:72827987	T/C	cg04365224	chr3:72788183	NA	-0.46	-6.68	-0.31	7.32e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg11645453	chr3:52864694	ITIH4	0.39	7.65	0.35	1.33e-13	Bipolar disorder;
LUAD	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg04369109	chr6:150039330	LATS1	-0.44	-7.4	-0.34	7.63e-13	Lung cancer;
LUAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg08742575	chr21:47604166	C21orf56	0.48	7.97	0.36	1.45e-14	Testicular germ cell tumor;
LUAD	cis	rs921968	0.565	rs6723334	chr2:219629303	C/T	cg02176678	chr2:219576539	TTLL4	0.59	12.06	0.51	5.51e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg13319975	chr6:146136371	FBXO30	-0.8	-13.69	-0.55	1.48e-35	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg26043149	chr18:55253948	FECH	-0.41	-6.39	-0.3	4.42e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7215564	0.818	rs36034584	chr17:78671478	A/G	cg09596252	chr17:78655493	RPTOR	0.56	6.85	0.32	2.57e-11	Myopia (pathological);
LUAD	cis	rs1034435	0.755	rs6007869	chr22:48894213	A/G	cg05992904	chr22:48892994	FAM19A5	-0.74	-16.55	-0.63	8.19e-48	Late-onset Alzheimer's disease;
LUAD	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg09222892	chr1:25734099	RHCE	-0.46	-8.47	-0.38	4e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.43	0.34	5.99e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg04450456	chr4:17643702	FAM184B	-0.41	-7.99	-0.36	1.28e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7072216	0.922	rs59667296	chr10:100146313	A/T	cg26618903	chr10:100175079	PYROXD2	-0.33	-7.25	-0.33	2.01e-12	Metabolite levels;
LUAD	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.86	0.4	2.19e-17	Parkinson's disease;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg21186779	chr16:46462885	NA	-0.39	-6.63	-0.31	1e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg24450063	chr1:156163899	SLC25A44	1.15	22.7	0.74	3.44e-75	Testicular germ cell tumor;
LUAD	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-7.21	-0.33	2.53e-12	Personality dimensions;
LUAD	cis	rs938554	0.829	rs5028843	chr4:9940806	G/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-7.14	-0.33	4.18e-12	Blood metabolite levels;
LUAD	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg06784218	chr1:46089804	CCDC17	-0.6	-13.41	-0.55	2.12e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg27490568	chr2:178487706	NA	0.38	6.42	0.3	3.59e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-10.96	-0.47	9.35e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg00316803	chr15:76480434	C15orf27	-0.42	-6.82	-0.31	3.25e-11	Blood metabolite levels;
LUAD	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg15147215	chr3:52552868	STAB1	-0.39	-7.19	-0.33	2.99e-12	Bipolar disorder;
LUAD	cis	rs807669	0.903	rs756651	chr22:19179367	T/C	cg02655711	chr22:19163373	SLC25A1	0.87	18.96	0.68	1.73e-58	Metabolite levels;
LUAD	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg17366294	chr4:99064904	C4orf37	-0.49	-8.6	-0.39	1.62e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg00310523	chr12:86230176	RASSF9	0.4	8.01	0.36	1.13e-14	Major depressive disorder;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08663936	chr19:50093678	PRR12;PRRG2	-0.67	-6.39	-0.3	4.36e-10	Type 2 diabetes;
LUAD	cis	rs9535307	0.929	rs7984061	chr13:50337340	G/A	cg04663916	chr13:50265991	EBPL	0.58	6.9	0.32	1.93e-11	Obesity-related traits;
LUAD	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.5	0.38	3.17e-16	Parkinson's disease;
LUAD	cis	rs1385374	0.858	rs10847697	chr12:129299385	C/T	cg09035930	chr12:129282057	SLC15A4	-0.62	-6.95	-0.32	1.42e-11	Systemic lupus erythematosus;
LUAD	trans	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg14917512	chr19:3094685	GNA11	0.58	6.9	0.32	1.86e-11	Gout;
LUAD	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	11.63	0.49	2.51e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg06606381	chr12:133084897	FBRSL1	0.8	7.98	0.36	1.38e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1395	0.778	rs724311	chr2:27441645	A/G	cg23587288	chr2:27483067	SLC30A3	-0.39	-7.52	-0.34	3.38e-13	Blood metabolite levels;
LUAD	cis	rs2154319	0.887	rs6696524	chr1:41539494	A/G	cg02290550	chr1:41487317	SLFNL1	-0.38	-6.46	-0.3	2.96e-10	Height;
LUAD	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg02423579	chr7:2872169	GNA12	-0.91	-16.31	-0.62	9.81e-47	Height;
LUAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08677398	chr8:58056175	NA	0.48	6.77	0.31	4.3e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs8060686	0.516	rs2290700	chr16:68288983	T/G	cg05110241	chr16:68378359	PRMT7	-0.58	-7.41	-0.34	6.73e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9902453	0.542	rs3809789	chr17:27955761	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	8.62	0.39	1.39e-16	Coffee consumption (cups per day);
LUAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11905131	chr22:24372483	LOC391322	0.53	8.97	0.4	9.82e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg22676075	chr6:135203613	NA	0.4	7.49	0.34	4.11e-13	Red blood cell count;
LUAD	trans	rs7395662	0.963	rs10769382	chr11:48590415	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.76e-10	HDL cholesterol;
LUAD	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	6.93	0.32	1.62e-11	Cognitive test performance;
LUAD	cis	rs7586879	1.000	rs11683212	chr2:25120196	T/C	cg04586622	chr2:25135609	ADCY3	0.34	7.37	0.34	8.82e-13	Body mass index;
LUAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.22	-0.41	1.38e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7107174	0.786	rs2450134	chr11:77925778	A/G	cg02023728	chr11:77925099	USP35	0.49	7.94	0.36	1.9e-14	Testicular germ cell tumor;
LUAD	cis	rs9394841	0.667	rs71558769	chr6:41782107	T/C	cg25600774	chr6:41776562	USP49	-0.43	-6.56	-0.3	1.55e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg27539214	chr16:67997921	SLC12A4	-0.7	-8.94	-0.4	1.26e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg00049323	chr5:472564	LOC25845	0.46	7.69	0.35	1.01e-13	Cystic fibrosis severity;
LUAD	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	9.02	0.4	6.75e-18	Hip circumference adjusted for BMI;
LUAD	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.3	-0.33	1.41e-12	Morning vs. evening chronotype;
LUAD	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg17644776	chr2:200775616	C2orf69	-0.55	-6.66	-0.31	8.72e-11	Schizophrenia;
LUAD	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg04365224	chr3:72788183	NA	-0.44	-6.43	-0.3	3.35e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21932983	chr1:6321378	GPR153	-0.54	-6.7	-0.31	6.75e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.18	-0.33	3.12e-12	Height;
LUAD	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg27124370	chr19:33622961	WDR88	0.47	7.33	0.34	1.21e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs11077998	0.903	rs8064554	chr17:80501093	A/G	cg10255544	chr17:80519551	FOXK2	0.36	7.1	0.33	5.32e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg03433033	chr1:76189801	ACADM	-0.48	-7.02	-0.32	8.81e-12	Daytime sleep phenotypes;
LUAD	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.44e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg10560079	chr2:191398806	TMEM194B	-0.4	-7.18	-0.33	3.19e-12	Pulse pressure;
LUAD	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg11941060	chr3:133502564	NA	-0.49	-7.99	-0.36	1.34e-14	Iron status biomarkers;
LUAD	cis	rs12618769	0.625	rs72819970	chr2:99034554	C/G	cg10123293	chr2:99228465	UNC50	0.46	8.35	0.38	9.92e-16	Bipolar disorder;
LUAD	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.55	-0.42	1.09e-19	Life satisfaction;
LUAD	cis	rs72949976	0.966	rs6752061	chr2:214027818	C/T	cg08319019	chr2:214017104	IKZF2	-0.5	-7.5	-0.34	3.71e-13	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg15147215	chr3:52552868	STAB1	-0.52	-10.08	-0.44	1.48e-21	Electroencephalogram traits;
LUAD	cis	rs2637266	1.000	rs7475686	chr10:78358761	T/C	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.33e-11	Pulmonary function;
LUAD	cis	rs3784262	0.740	rs8032572	chr15:58311280	A/G	cg12031962	chr15:58353849	ALDH1A2	0.4	7.86	0.36	3.29e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg00757033	chr12:89920650	WDR51B	0.7	12.14	0.51	2.6e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg02136620	chr5:178986620	RUFY1	-0.48	-7.73	-0.35	7.65e-14	Lung cancer;
LUAD	cis	rs8060686	0.858	rs13334918	chr16:67901343	A/G	cg26727032	chr16:67993705	SLC12A4	-0.52	-8.74	-0.39	5.67e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11048434	0.736	rs11048337	chr12:9121330	C/A	cg04155231	chr12:9217510	LOC144571	0.38	7.37	0.34	9.22e-13	Sjögren's syndrome;
LUAD	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg05110241	chr16:68378359	PRMT7	-0.68	-7.6	-0.35	1.94e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg24558204	chr6:135376177	HBS1L	0.47	8.67	0.39	9.04e-17	Red blood cell count;
LUAD	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg15358701	chr1:161410459	NA	-0.68	-6.93	-0.32	1.58e-11	Rheumatoid arthritis;
LUAD	cis	rs11677416	1.000	rs4848300	chr2:113527906	T/C	cg27083787	chr2:113543245	IL1A	0.38	6.64	0.31	9.56e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs75920871	0.925	rs61903417	chr11:116956157	T/G	cg04087571	chr11:116723030	SIK3	-0.33	-6.69	-0.31	7.14e-11	Subjective well-being;
LUAD	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg06784218	chr1:46089804	CCDC17	0.51	11.23	0.48	8.7e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9715521	0.900	rs62299249	chr4:59824174	G/A	cg11281224	chr4:60001000	NA	-0.56	-9.51	-0.42	1.5e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg18016565	chr1:150552671	MCL1	0.41	7.55	0.34	2.78e-13	Tonsillectomy;
LUAD	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg21782813	chr7:2030301	MAD1L1	0.61	10.48	0.45	5.39e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg26384229	chr12:38710491	ALG10B	0.44	7.21	0.33	2.63e-12	Bladder cancer;
LUAD	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg21775007	chr8:11205619	TDH	0.39	6.56	0.3	1.55e-10	Mood instability;
LUAD	trans	rs10411161	0.671	rs10412377	chr19:52350672	C/G	cg22319618	chr22:45562946	NUP50	0.45	6.75	0.31	4.82e-11	Breast cancer;
LUAD	cis	rs3806843	0.548	rs246058	chr5:140325134	G/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg02869364	chr7:1081709	C7orf50	-0.52	-6.71	-0.31	6.11e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg05110241	chr16:68378359	PRMT7	-0.81	-8.63	-0.39	1.24e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs123509	0.913	rs339661	chr3:42753904	G/A	cg12982090	chr3:42733453	KBTBD5	0.54	9.58	0.42	8.13e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg02782426	chr3:40428986	ENTPD3	-0.39	-8.76	-0.39	4.92e-17	Renal cell carcinoma;
LUAD	cis	rs73416724	1.000	rs111882537	chr6:43366075	C/A	cg26312998	chr6:43337775	ZNF318	0.54	6.42	0.3	3.63e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3750965	1.000	rs7950657	chr11:68834831	G/A	cg06818126	chr11:68850279	TPCN2	-0.47	-6.9	-0.32	1.94e-11	Hair color;
LUAD	cis	rs142958719	1	rs142958719	chr5:131232959	G/A	cg06307176	chr5:131281290	NA	-0.55	-8.54	-0.38	2.45e-16	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	cis	rs6545883	0.929	rs2256615	chr2:61679894	C/G	cg15711740	chr2:61764176	XPO1	-0.41	-6.53	-0.3	1.94e-10	Tuberculosis;
LUAD	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg12667521	chr19:29218732	NA	0.61	7.66	0.35	1.3e-13	Methadone dose in opioid dependence;
LUAD	cis	rs2742417	0.603	rs2742448	chr3:45764246	C/T	cg10512202	chr3:45649293	LIMD1	-0.48	-8.21	-0.37	2.65e-15	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs13315871	1.000	rs9819072	chr3:58353647	A/C	cg12435725	chr3:58293450	RPP14	-0.69	-7.53	-0.34	3.08e-13	Cholesterol, total;
LUAD	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg27432699	chr2:27873401	GPN1	0.58	10.36	0.45	1.48e-22	Oral cavity cancer;
LUAD	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.6	11.34	0.48	3.24e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7737355	0.812	rs32106	chr5:131038940	A/G	cg25547332	chr5:131281432	NA	0.42	6.82	0.31	3.14e-11	Life satisfaction;
LUAD	cis	rs12348691	0.503	rs7848950	chr9:100612774	T/C	cg13688889	chr9:100608707	NA	-0.63	-10.2	-0.44	5.33e-22	Alopecia areata;
LUAD	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg19622623	chr12:86230825	RASSF9	-0.53	-9.35	-0.41	5.22e-19	Major depressive disorder;
LUAD	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg03396347	chr1:1875803	NA	0.3	6.72	0.31	5.79e-11	Body mass index;
LUAD	cis	rs6906287	0.647	rs34479834	chr6:118826244	T/A	cg18833306	chr6:118973337	C6orf204	0.48	8.53	0.38	2.56e-16	Electrocardiographic conduction measures;
LUAD	cis	rs10489202	0.608	rs3753934	chr1:168074677	C/T	cg24449463	chr1:168025552	DCAF6	-0.64	-10.24	-0.45	3.94e-22	Schizophrenia;
LUAD	trans	rs6920965	0.561	rs9401851	chr6:126181956	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-8.45	-0.38	4.59e-16	High light scatter reticulocyte count;
LUAD	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg05234568	chr11:5960015	NA	-0.5	-9.02	-0.4	6.77e-18	DNA methylation (variation);
LUAD	cis	rs11051970	0.879	rs10844201	chr12:32575029	A/G	cg24626660	chr12:32551988	NA	0.33	6.6	0.31	1.21e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg27490568	chr2:178487706	NA	0.54	8.96	0.4	1.04e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg19041857	chr6:27730383	NA	-0.43	-7.14	-0.33	4e-12	Parkinson's disease;
LUAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg03354898	chr7:1950403	MAD1L1	-0.45	-8.75	-0.39	5.05e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-6.65	-0.31	9.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs714027	1.000	rs4823073	chr22:30512258	G/A	cg00539347	chr22:30592296	NA	-0.28	-6.6	-0.31	1.26e-10	Lymphocyte counts;
LUAD	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg06671706	chr8:8559999	CLDN23	-0.37	-6.45	-0.3	2.98e-10	Mood instability;
LUAD	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.91	0.36	2.29e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg00701064	chr4:6280414	WFS1	0.65	13.78	0.56	6.18e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs41311933	0.901	rs41312877	chr9:123733171	T/C	cg13567360	chr9:123745713	C5	-0.76	-8.88	-0.4	1.95e-17	Coronary artery disease;
LUAD	trans	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg06606381	chr12:133084897	FBRSL1	-0.77	-7.81	-0.36	4.45e-14	Breast cancer;
LUAD	cis	rs10089	0.953	rs758179	chr5:127354424	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	10.03	0.44	2.19e-21	Ileal carcinoids;
LUAD	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg01017244	chr2:74357527	NA	0.67	9.35	0.41	5.06e-19	Gestational age at birth (maternal effect);
LUAD	cis	rs524023	0.874	rs492175	chr11:64433078	A/G	cg19131476	chr11:64387923	NRXN2	0.42	8.31	0.37	1.3e-15	Urate levels in obese individuals;
LUAD	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.3	-6.69	-0.31	7.01e-11	Systemic lupus erythematosus;
LUAD	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg06641503	chr3:48959341	ARIH2	-0.36	-6.75	-0.31	4.79e-11	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg07917127	chr4:99064746	C4orf37	0.42	7.03	0.32	8.37e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7617773	0.780	rs13084616	chr3:48339699	A/G	cg11946769	chr3:48343235	NME6	-0.44	-6.9	-0.32	1.87e-11	Coronary artery disease;
LUAD	cis	rs7027203	0.964	rs7853688	chr9:96523254	C/A	cg14396892	chr9:96623032	NA	0.39	7.05	0.32	7.55e-12	DNA methylation (variation);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15716185	chr18:60190644	ZCCHC2	-0.42	-6.6	-0.31	1.22e-10	Height;
LUAD	cis	rs977987	0.585	rs62059845	chr16:75430713	A/G	cg03315344	chr16:75512273	CHST6	0.64	14.04	0.56	5.18e-37	Dupuytren's disease;
LUAD	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg26818010	chr10:134567672	INPP5A	-0.76	-13.23	-0.54	1.09e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg00757033	chr12:89920650	WDR51B	0.71	12.35	0.51	4.05e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg05623727	chr3:50126028	RBM5	0.3	6.39	0.3	4.35e-10	Body mass index;
LUAD	cis	rs7677751	0.806	rs7681399	chr4:55090886	T/G	cg17187183	chr4:55093834	PDGFRA	0.52	8.77	0.39	4.57e-17	Corneal astigmatism;
LUAD	trans	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg19894588	chr14:64061835	NA	-0.45	-6.62	-0.31	1.1e-10	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs7799006	1.000	rs7799006	chr7:2278226	C/T	cg08027265	chr7:2291960	NA	-0.61	-11.35	-0.48	2.91e-26	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg19622623	chr12:86230825	RASSF9	-0.43	-7.65	-0.35	1.37e-13	Major depressive disorder;
LUAD	cis	rs7760535	0.656	rs1883136	chr6:111907023	G/T	cg22127309	chr6:111907043	TRAF3IP2	-0.43	-7.9	-0.36	2.36e-14	Metabolic traits;
LUAD	cis	rs1232027	0.666	rs1677636	chr5:79926126	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.81	-0.36	4.46e-14	Huntington's disease progression;
LUAD	cis	rs12618769	0.652	rs17513468	chr2:99235169	T/G	cg10123293	chr2:99228465	UNC50	0.49	8.74	0.39	5.53e-17	Bipolar disorder;
LUAD	cis	rs55665837	0.540	rs7938266	chr11:14709324	A/G	cg19336497	chr11:14380999	RRAS2	-0.41	-7.91	-0.36	2.21e-14	Vitamin D levels;
LUAD	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg26597838	chr10:835615	NA	1.29	19.4	0.69	1.86e-60	Eosinophil percentage of granulocytes;
LUAD	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.35	0.38	1.02e-15	Platelet count;
LUAD	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg03929089	chr4:120376271	NA	0.64	8.86	0.4	2.19e-17	Coronary artery disease;
LUAD	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg06544989	chr22:39130855	UNC84B	0.46	8.84	0.39	2.61e-17	Menopause (age at onset);
LUAD	cis	rs17789174	0.855	rs57997696	chr16:85082468	C/G	cg27466129	chr16:85060822	KIAA0513	0.36	7.95	0.36	1.73e-14	Dysphagia;
LUAD	cis	rs4242434	0.819	rs7826059	chr8:22512068	T/C	cg03733263	chr8:22462867	KIAA1967	-0.68	-11.74	-0.5	9.22e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs6005807	0.843	rs738627	chr22:28857340	C/T	cg12565055	chr22:29076175	TTC28	0.67	6.48	0.3	2.57e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg09117114	chr16:67998030	SLC12A4	-0.48	-6.78	-0.31	4.12e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg08847533	chr14:75593920	NEK9	0.39	6.57	0.3	1.47e-10	Height;
LUAD	cis	rs17789174	0.903	rs12597107	chr16:85070381	G/T	cg27466129	chr16:85060822	KIAA0513	0.36	7.69	0.35	1.07e-13	Dysphagia;
LUAD	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg11502198	chr6:26597334	ABT1	0.88	12.43	0.52	1.85e-30	Small cell lung carcinoma;
LUAD	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg06641503	chr3:48959341	ARIH2	0.36	6.75	0.31	4.89e-11	Parkinson's disease;
LUAD	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg09222892	chr1:25734099	RHCE	-0.45	-8.31	-0.37	1.33e-15	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg19318889	chr4:1322082	MAEA	0.53	8.8	0.39	3.46e-17	Obesity-related traits;
LUAD	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg11965913	chr1:205819406	PM20D1	0.6	10.61	0.46	1.77e-23	Prostate cancer;
LUAD	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg25427524	chr10:38739819	LOC399744	-0.66	-9.43	-0.42	2.66e-19	Obesity (extreme);
LUAD	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg04455712	chr21:45112962	RRP1B	0.47	9.31	0.41	7.21e-19	Mean corpuscular volume;
LUAD	cis	rs4660306	0.961	rs2152077	chr1:45986670	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-6.64	-0.31	9.36e-11	Homocysteine levels;
LUAD	trans	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg07817883	chr1:32538562	TMEM39B	1.16	12.15	0.51	2.43e-29	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg20476274	chr7:133979776	SLC35B4	0.82	15.98	0.61	2.5e-45	Mean platelet volume;
LUAD	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg17063962	chr7:91808500	NA	0.71	12.47	0.52	1.35e-30	Breast cancer;
LUAD	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg11833968	chr6:79620685	NA	-0.45	-8.32	-0.38	1.22e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg02176678	chr2:219576539	TTLL4	0.59	11.28	0.48	5.49e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg12573674	chr2:1569213	NA	-0.64	-9.28	-0.41	8.57e-19	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	10.06	0.44	1.69e-21	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg14847009	chr1:175162515	KIAA0040	-0.34	-8.8	-0.39	3.43e-17	Alcohol dependence;
LUAD	cis	rs7524258	0.868	rs4243825	chr1:7308264	T/C	cg07173049	chr1:7289937	CAMTA1	0.54	10.15	0.44	8.43e-22	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs12519773	0.597	rs4342312	chr5:92477890	C/A	cg18783429	chr5:92414398	NA	0.49	8.74	0.39	5.58e-17	Migraine;
LUAD	cis	rs1395	0.744	rs3739092	chr2:27462076	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.49	8.7	0.39	7.49e-17	Blood metabolite levels;
LUAD	cis	rs2742417	0.603	rs9826208	chr3:45773991	C/T	cg10512202	chr3:45649293	LIMD1	0.48	8.92	0.4	1.42e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg05340658	chr4:99064831	C4orf37	0.44	7.42	0.34	6.37e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg11915388	chr22:42470451	FAM109B	-0.39	-7.03	-0.32	8.33e-12	Schizophrenia;
LUAD	cis	rs990171	0.538	rs4851016	chr2:103120400	C/T	cg03938978	chr2:103052716	IL18RAP	0.33	6.48	0.3	2.49e-10	Lymphocyte counts;
LUAD	cis	rs798766	1.000	rs1374469	chr4:1724799	C/T	cg05874882	chr4:1763078	NA	-0.37	-6.43	-0.3	3.42e-10	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg08999081	chr20:33150536	PIGU	-0.59	-12.96	-0.53	1.44e-32	Glomerular filtration rate (creatinine);
LUAD	cis	rs6738485	0.601	rs7566680	chr2:106851657	G/A	cg16099169	chr2:106886729	NA	-0.41	-7.19	-0.33	3e-12	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg18016565	chr1:150552671	MCL1	0.41	7.64	0.35	1.51e-13	Urate levels;
LUAD	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg14634687	chr17:47094252	IGF2BP1	0.26	6.55	0.3	1.68e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg01802117	chr1:53393560	SCP2	-0.34	-6.59	-0.31	1.28e-10	Monocyte count;
LUAD	cis	rs4919694	0.901	rs79331374	chr10:104882913	G/A	cg04362960	chr10:104952993	NT5C2	0.75	7.96	0.36	1.58e-14	Arsenic metabolism;
LUAD	cis	rs9322817	0.583	rs10782363	chr6:105149713	C/G	cg02098413	chr6:105308735	HACE1	0.37	7.9	0.36	2.4e-14	Thyroid stimulating hormone;
LUAD	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14240646	chr10:27532245	ACBD5	-0.89	-12.01	-0.5	8.41e-29	Breast cancer;
LUAD	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg11919837	chr8:57350735	NA	-0.47	-6.7	-0.31	6.7e-11	Obesity-related traits;
LUAD	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg10729496	chr3:10149963	C3orf24	0.57	9.46	0.42	2.24e-19	Alzheimer's disease;
LUAD	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg18876405	chr7:65276391	NA	0.67	11.53	0.49	6.15e-27	Aortic root size;
LUAD	cis	rs6066835	1.000	rs2223684	chr20:47354880	A/C	cg18078177	chr20:47281410	PREX1	0.65	6.51	0.3	2.1e-10	Multiple myeloma;
LUAD	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg02807482	chr3:125708958	NA	-0.65	-9.37	-0.41	4.52e-19	Blood pressure (smoking interaction);
LUAD	cis	rs7095607	0.785	rs10823142	chr10:69921335	T/A	cg18986048	chr10:69913749	MYPN	0.38	6.5	0.3	2.21e-10	Lung function (FVC);
LUAD	cis	rs1497406	0.744	rs6677710	chr1:16507618	A/G	cg02998240	chr1:16508668	NA	-0.25	-7.51	-0.34	3.52e-13	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg04398451	chr17:18023971	MYO15A	-0.65	-11.71	-0.49	1.3e-27	Total body bone mineral density;
LUAD	cis	rs11958404	0.860	rs11135023	chr5:157420082	G/T	cg05962755	chr5:157440814	NA	0.47	8.0	0.36	1.22e-14	IgG glycosylation;
LUAD	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg15962314	chr1:44399869	ARTN	0.32	7.5	0.34	3.67e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs35883536	0.647	rs10493929	chr1:101043928	A/C	cg06223162	chr1:101003688	GPR88	-0.46	-8.98	-0.4	9.27e-18	Monocyte count;
LUAD	cis	rs8112211	0.731	rs931749	chr19:38818925	C/T	cg01275006	chr19:38876250	GGN	-0.5	-6.44	-0.3	3.3e-10	Blood protein levels;
LUAD	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.82	9.5	0.42	1.52e-19	Initial pursuit acceleration;
LUAD	trans	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg19862616	chr7:65841803	NCRNA00174	1.05	25.07	0.77	1.11e-85	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg22920501	chr2:26401640	FAM59B	-0.74	-10.7	-0.46	8.57e-24	Gut microbiome composition (summer);
LUAD	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg16797656	chr11:68205561	LRP5	0.46	8.75	0.39	5.29e-17	Total body bone mineral density;
LUAD	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg04756594	chr16:24857601	SLC5A11	0.78	13.6	0.55	3.48e-35	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg18180107	chr4:99064573	C4orf37	0.42	6.74	0.31	5.2e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1965732	0.588	rs4849976	chr2:3717567	A/C	cg25251562	chr2:3704773	ALLC	-0.37	-7.03	-0.32	8.09e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg22920501	chr2:26401640	FAM59B	-0.83	-11.51	-0.49	7.15e-27	Gut microbiome composition (summer);
LUAD	cis	rs9902453	0.967	rs11080121	chr17:28528842	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.48	7.96	0.36	1.59e-14	Coffee consumption (cups per day);
LUAD	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg02683114	chr2:24398427	C2orf84	0.53	8.19	0.37	3.04e-15	Asthma;
LUAD	cis	rs7640424	0.819	rs179046	chr3:107840773	A/C	cg09227934	chr3:107805635	CD47	-0.47	-8.2	-0.37	2.86e-15	Body mass index;
LUAD	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg07606381	chr6:8435919	SLC35B3	0.4	6.59	0.31	1.3100000000000001e-10	Motion sickness;
LUAD	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg08798685	chr6:27730294	NA	0.46	7.04	0.32	7.95e-12	Parkinson's disease;
LUAD	cis	rs138341189	1	rs138341189	chr11:68224411	GATTGTGCCAAT/G	cg16797656	chr11:68205561	LRP5	0.49	7.47	0.34	4.69e-13	Monobrow;
LUAD	cis	rs31251	0.782	rs2108450	chr5:131271022	T/G	cg06307176	chr5:131281290	NA	0.4	7.12	0.33	4.65e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg11915388	chr22:42470451	FAM109B	0.41	7.28	0.33	1.64e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.58	-0.42	8.2e-20	Schizophrenia;
LUAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.29	0.37	1.55e-15	Alzheimer's disease;
LUAD	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg02269571	chr22:50332266	NA	0.62	9.41	0.42	3.2e-19	Schizophrenia;
LUAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg05313129	chr8:58192883	C8orf71	-0.54	-7.06	-0.32	6.9e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1003719	0.646	rs2835672	chr21:38581234	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.14	-0.37	4.54e-15	Eye color traits;
LUAD	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg12310025	chr6:25882481	NA	-0.56	-8.14	-0.37	4.49e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs56346965	0.788	rs1468685	chr2:191565771	A/T	cg27211696	chr2:191398769	TMEM194B	0.43	7.53	0.34	2.99e-13	Bone mineral density (Ward's triangle area);
LUAD	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg03929089	chr4:120376271	NA	-0.99	-20.58	-0.71	9.86e-66	Height;
LUAD	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg22029157	chr1:209979665	IRF6	0.81	11.88	0.5	2.75e-28	Cleft lip with or without cleft palate;
LUAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08280861	chr8:58055591	NA	0.63	8.24	0.37	2.25e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs6499255	1.000	rs7189424	chr16:69782746	G/A	cg15192750	chr16:69999425	NA	0.54	8.52	0.38	2.91e-16	IgE levels;
LUAD	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg25767906	chr1:53392781	SCP2	-0.44	-8.13	-0.37	4.76e-15	Monocyte count;
LUAD	cis	rs11696845	0.776	rs6073538	chr20:43379264	A/C	cg25301532	chr20:43378953	KCNK15	0.46	7.88	0.36	2.73e-14	Obesity-related traits;
LUAD	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg02569458	chr12:86230093	RASSF9	-0.41	-7.6	-0.35	1.95e-13	Major depressive disorder;
LUAD	cis	rs2286885	0.965	rs10987301	chr9:129250688	T/C	cg15282417	chr9:129245246	FAM125B	-0.45	-9.2	-0.41	1.64e-18	Intraocular pressure;
LUAD	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg05754148	chr16:3507555	NAT15	-0.48	-7.92	-0.36	2.15e-14	Body mass index (adult);
LUAD	cis	rs427941	0.632	rs201480	chr7:101747575	A/G	cg06246474	chr7:101738831	CUX1	0.39	6.8	0.31	3.59e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7617773	0.743	rs13081633	chr3:48357281	A/G	cg11946769	chr3:48343235	NME6	0.44	6.7	0.31	6.86e-11	Coronary artery disease;
LUAD	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.58	0.3	1.43e-10	Cardiac Troponin-T levels;
LUAD	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg23262073	chr20:60523788	NA	-0.48	-7.66	-0.35	1.24e-13	Body mass index;
LUAD	cis	rs56161922	1.000	rs41274776	chr1:207812791	A/G	cg11752769	chr1:207818423	CR1L	-0.62	-6.38	-0.3	4.69e-10	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg00129232	chr17:37814104	STARD3	-0.45	-7.37	-0.34	8.95e-13	Asthma;
LUAD	cis	rs897984	0.542	rs6565217	chr16:31083324	C/T	cg02466173	chr16:30829666	NA	-0.55	-9.45	-0.42	2.28e-19	Dementia with Lewy bodies;
LUAD	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg25358565	chr5:93447407	FAM172A	0.58	6.77	0.31	4.31e-11	Diabetic retinopathy;
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg13214185	chr14:107219616	NA	0.39	6.88	0.32	2.13e-11	Menopause (age at onset);
LUAD	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.44	0.57	1.08e-38	Schizophrenia;
LUAD	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg14582100	chr15:45693742	SPATA5L1	0.63	12.41	0.52	2.26e-30	Homoarginine levels;
LUAD	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg13535736	chr9:111863775	C9orf5	-0.42	-6.42	-0.3	3.68e-10	Menarche (age at onset);
LUAD	cis	rs6460942	1.000	rs62448562	chr7:12398785	T/C	cg06484146	chr7:12443880	VWDE	-0.6	-7.47	-0.34	4.7e-13	Coronary artery disease;
LUAD	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg12483801	chr4:183727862	NA	0.55	6.72	0.31	6.02e-11	Pediatric autoimmune diseases;
LUAD	cis	rs7267979	0.789	rs62213729	chr20:25363426	C/T	cg08601574	chr20:25228251	PYGB	-0.38	-7.16	-0.33	3.56e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-9.59	-0.42	7.63e-20	Migraine;Coronary artery disease;
LUAD	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg10909506	chr17:38081995	ORMDL3	0.37	6.76	0.31	4.7e-11	Asthma;
LUAD	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg25256661	chr17:7137939	DVL2	0.75	14.86	0.59	1.8e-40	Diastolic blood pressure;
LUAD	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05535760	chr7:792225	HEATR2	1.0	12.52	0.52	8.33e-31	Cerebrospinal P-tau181p levels;
LUAD	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.22e-19	Life satisfaction;
LUAD	trans	rs8002861	0.713	rs7339417	chr13:44413496	A/T	cg12856521	chr11:46389249	DGKZ	0.47	7.87	0.36	3e-14	Leprosy;
LUAD	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg18876405	chr7:65276391	NA	-0.61	-10.64	-0.46	1.34e-23	Aortic root size;
LUAD	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg07677032	chr17:61819896	STRADA	0.57	10.27	0.45	3.15e-22	Prudent dietary pattern;
LUAD	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg11663144	chr21:46675770	NA	-0.58	-11.3	-0.48	4.9e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.44	-7.8	-0.35	4.9e-14	Longevity;Endometriosis;
LUAD	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg21399703	chr1:247681439	NA	0.45	8.07	0.37	7.29e-15	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.84	-0.32	2.72e-11	Neuroticism;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14806418	chr10:131904271	NA	0.4	6.46	0.3	2.93e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg04565464	chr8:145669602	NFKBIL2	0.43	6.57	0.3	1.52e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs494562	1.000	rs494562	chr6:86117129	A/G	cg27297263	chr6:86160468	NT5E	0.6	6.77	0.31	4.41e-11	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg00310523	chr12:86230176	RASSF9	0.4	8.23	0.37	2.42e-15	Major depressive disorder;
LUAD	cis	rs10992471	0.518	rs4743876	chr9:95512216	C/G	cg14631576	chr9:95140430	CENPP	-0.44	-8.46	-0.38	4.27e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7818345	0.687	rs13275706	chr8:19327151	C/G	cg06699216	chr8:19333253	CSGALNACT1	-0.31	-7.46	-0.34	5.11e-13	Language performance in older adults (adjusted for episodic memory);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05135523	chr16:31085704	ZNF668;ZNF646	-0.39	-6.56	-0.3	1.55e-10	Cancer;
LUAD	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg22823121	chr1:150693482	HORMAD1	0.48	9.32	0.41	6.7e-19	Melanoma;
LUAD	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.49	7.79	0.35	5.16e-14	Total body bone mineral density;
LUAD	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg14092988	chr3:52407081	DNAH1	0.37	7.48	0.34	4.47e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs11126435	0.858	rs12621560	chr2:74934367	G/T	cg19285774	chr2:74907978	SEMA4F	0.37	6.41	0.3	3.79e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg08316699	chr6:150357289	NA	-0.34	-7.13	-0.33	4.31e-12	Alopecia areata;
LUAD	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	8.31	0.37	1.29e-15	Breast cancer;
LUAD	trans	rs7246760	1.000	rs73014068	chr19:9922783	T/C	cg02900749	chr2:68251473	NA	-0.63	-6.83	-0.32	3.03e-11	Pursuit maintenance gain;
LUAD	cis	rs2652834	1.000	rs68088462	chr15:63397617	T/C	cg25406657	chr15:63342033	TPM1	-0.43	-6.89	-0.32	2.09e-11	HDL cholesterol;
LUAD	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg05340658	chr4:99064831	C4orf37	-0.44	-7.25	-0.33	2.02e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg14926445	chr8:58193284	C8orf71	-0.48	-6.65	-0.31	9.27e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1639906	0.965	rs1637750	chr7:2227811	A/G	cg18044113	chr7:2236405	MAD1L1	0.34	6.54	0.3	1.75e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg08280861	chr8:58055591	NA	0.55	7.6	0.35	1.86e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs16958440	0.867	rs28578518	chr18:44687548	A/C	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg09658497	chr7:2847517	GNA12	0.47	9.19	0.41	1.74e-18	Height;
LUAD	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg13319975	chr6:146136371	FBXO30	-0.64	-10.92	-0.47	1.25e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg02773041	chr1:40204384	PPIE	0.52	8.48	0.38	3.9e-16	Blood protein levels;
LUAD	trans	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg26043149	chr18:55253948	FECH	1.04	17.66	0.65	1.12e-52	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs17092148	0.887	rs6058077	chr20:33140999	G/A	cg16810054	chr20:33298113	TP53INP2	-0.48	-7.2	-0.33	2.82e-12	Neuroticism;
LUAD	cis	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.88	-0.36	2.84e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg27124370	chr19:33622961	WDR88	0.42	6.81	0.31	3.42e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg04989706	chr14:50066350	PPIL5	-0.51	-7.57	-0.35	2.3e-13	Carotid intima media thickness;
LUAD	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg24450063	chr1:156163899	SLC25A44	1.03	18.84	0.68	6.22e-58	Testicular germ cell tumor;
LUAD	cis	rs1728785	0.901	rs698711	chr16:68561955	C/T	cg02508848	chr16:68573721	ZFP90	-0.41	-6.55	-0.3	1.66e-10	Ulcerative colitis;
LUAD	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg23803603	chr1:2058230	PRKCZ	0.41	6.71	0.31	6.35e-11	Height;
LUAD	cis	rs8038465	0.516	rs8037836	chr15:73859855	G/A	cg15420318	chr15:73925796	NPTN	0.37	6.44	0.3	3.25e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.77	-10.12	-0.44	1.06e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg03690763	chr11:133734501	NA	-0.34	-7.67	-0.35	1.18e-13	Childhood ear infection;
LUAD	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg12573674	chr2:1569213	NA	-0.61	-7.2	-0.33	2.74e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs2019216	0.521	rs2175657	chr17:21908494	T/G	cg22648282	chr17:21454238	C17orf51	-0.46	-8.13	-0.37	4.9e-15	Pelvic organ prolapse;
LUAD	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg09117114	chr16:67998030	SLC12A4	-0.53	-6.98	-0.32	1.12e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9399401	0.601	rs643975	chr6:142844251	C/G	cg03128060	chr6:142623767	GPR126	-0.42	-7.91	-0.36	2.25e-14	Chronic obstructive pulmonary disease;
LUAD	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg04827223	chr11:72435913	ARAP1	-0.52	-7.62	-0.35	1.71e-13	Type 2 diabetes;
LUAD	trans	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.7	12.13	0.51	2.79e-29	Mean corpuscular volume;
LUAD	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg06191203	chr2:152266755	RIF1	-0.6	-8.98	-0.4	9.23e-18	Lung cancer;
LUAD	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg13902645	chr11:5959945	NA	0.59	11.48	0.49	9.5e-27	DNA methylation (variation);
LUAD	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg23018236	chr17:30244563	NA	-0.7	-8.68	-0.39	8.97e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs62400317	0.701	rs12194924	chr6:44961513	T/C	cg20913747	chr6:44695427	NA	-0.45	-6.99	-0.32	1.09e-11	Total body bone mineral density;
LUAD	cis	rs870825	0.556	rs6552811	chr4:185653351	T/A	cg04058563	chr4:185651563	MLF1IP	-0.85	-13.44	-0.55	1.6e-34	Blood protein levels;
LUAD	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg08999081	chr20:33150536	PIGU	0.6	13.33	0.54	4.48e-34	Glomerular filtration rate (creatinine);
LUAD	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg15704280	chr7:45808275	SEPT13	-0.9	-17.64	-0.65	1.29e-52	Coronary artery disease;
LUAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.87	16.74	0.63	1.25e-48	Lymphocyte counts;
LUAD	cis	rs6546550	0.935	rs60207187	chr2:70093910	G/A	cg02498382	chr2:70120550	SNRNP27	-0.56	-11.09	-0.47	2.86e-25	Prevalent atrial fibrillation;
LUAD	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4919694	1.000	rs78214351	chr10:104822688	A/G	cg04362960	chr10:104952993	NT5C2	0.73	7.86	0.36	3.28e-14	Arsenic metabolism;
LUAD	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-7.06	-0.32	6.78e-12	Blood metabolite levels;
LUAD	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-7.48	-0.34	4.35e-13	Tonsillectomy;
LUAD	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-8.93	-0.4	1.3e-17	Bipolar disorder;
LUAD	cis	rs713477	0.967	rs4901565	chr14:55912508	T/G	cg13175173	chr14:55914753	NA	-0.35	-7.2	-0.33	2.78e-12	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg25894440	chr7:65020034	NA	0.63	6.74	0.31	5.21e-11	Diabetic kidney disease;
LUAD	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.33e-13	Menopause (age at onset);
LUAD	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg20290983	chr6:43655470	MRPS18A	-0.85	-17.33	-0.64	3.07e-51	IgG glycosylation;
LUAD	cis	rs2274273	1.000	rs67098772	chr14:55595242	G/A	cg04306507	chr14:55594613	LGALS3	0.38	7.69	0.35	1.07e-13	Protein biomarker;
LUAD	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg10433463	chr1:1889099	KIAA1751	0.33	6.91	0.32	1.84e-11	Body mass index;
LUAD	trans	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg03929089	chr4:120376271	NA	-0.55	-7.35	-0.34	1.02e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs469568	0.543	rs4700789	chr5:178669361	A/G	cg08999896	chr5:178685787	ADAMTS2	0.31	6.53	0.3	1.89e-10	Stroke (pediatric);
LUAD	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg15557168	chr22:42548783	NA	0.51	9.31	0.41	6.84e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7851660	0.809	rs7034249	chr9:100653821	C/T	cg13688889	chr9:100608707	NA	-0.54	-9.08	-0.4	4.17e-18	Strep throat;
LUAD	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg20891283	chr12:69753455	YEATS4	0.45	7.28	0.33	1.69e-12	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg00717180	chr2:96193071	NA	-0.46	-8.4	-0.38	6.61e-16	Coronary artery disease;
LUAD	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg06627628	chr2:24431161	ITSN2	-0.56	-9.49	-0.42	1.76e-19	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg11887960	chr12:57824829	NA	0.59	7.3	0.33	1.46e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs4523957	0.963	rs216178	chr17:2168840	T/C	cg16513277	chr17:2031491	SMG6	0.77	14.68	0.58	1.02e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-14.76	-0.58	4.43e-40	Bone mineral density;
LUAD	cis	rs7187994	1.000	rs7187994	chr16:84753453	A/G	cg07647771	chr16:84786436	USP10	-0.38	-9.77	-0.43	1.84e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.09	-0.33	5.49e-12	Total body bone mineral density;
LUAD	cis	rs897984	0.806	rs1458202	chr16:30953202	A/G	cg02466173	chr16:30829666	NA	-0.67	-12.68	-0.52	1.89e-31	Dementia with Lewy bodies;
LUAD	cis	rs80319144	1.000	rs77748196	chr2:159302112	C/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.9	0.32	1.88e-11	Restless legs syndrome;
LUAD	cis	rs10979	0.679	rs9496680	chr6:143896915	G/A	cg25407410	chr6:143891975	LOC285740	-0.57	-8.57	-0.38	1.96e-16	Hypospadias;
LUAD	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04004882	chr2:215674386	BARD1	-0.65	-9.59	-0.42	7.64e-20	Neuroblastoma (high-risk);
LUAD	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg12011299	chr4:100065546	ADH4	0.68	12.19	0.51	1.62e-29	Alcohol dependence;
LUAD	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg13918804	chr1:2043761	PRKCZ	0.41	6.97	0.32	1.24e-11	Height;
LUAD	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg12908607	chr1:44402522	ARTN	0.53	10.61	0.46	1.81e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs9393777	0.778	rs67457459	chr6:27198343	T/G	cg01620082	chr3:125678407	NA	-0.84	-9.04	-0.4	5.71e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.95	0.36	1.74e-14	Parkinson's disease;
LUAD	cis	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg05901451	chr6:126070800	HEY2	-0.51	-7.73	-0.35	7.72e-14	Endometrial cancer;
LUAD	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg12179176	chr11:130786555	SNX19	0.55	9.27	0.41	9.37e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.36	7.01	0.32	9.58e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg24399712	chr22:39784796	NA	-0.73	-12.49	-0.52	1.13e-30	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg12011299	chr4:100065546	ADH4	0.66	13.81	0.56	4.38e-36	Alcohol dependence;
LUAD	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg13047869	chr3:10149882	C3orf24	0.59	9.99	0.44	2.95e-21	Alzheimer's disease;
LUAD	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg25036284	chr2:26402008	FAM59B	-0.63	-8.72	-0.39	6.6e-17	Gut microbiome composition (summer);
LUAD	trans	rs1728785	0.688	rs698718	chr16:68560185	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.78	0.43	1.69e-20	Ulcerative colitis;
LUAD	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg06060754	chr5:176797920	RGS14	0.53	8.98	0.4	8.87e-18	Urate levels in lean individuals;
LUAD	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg22532475	chr10:104410764	TRIM8	-0.45	-8.83	-0.39	2.7e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg15017067	chr4:17643749	FAM184B	0.34	6.4	0.3	4.13e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8014204	0.804	rs2241274	chr14:75251331	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.35	-6.5	-0.3	2.23e-10	Caffeine consumption;
LUAD	cis	rs9296095	1.000	rs5745568	chr6:33548394	G/T	cg07679836	chr6:33548423	BAK1	0.4	6.37	0.3	4.91e-10	Platelet count;
LUAD	cis	rs7731657	0.537	rs7725020	chr5:130285115	C/G	cg08523029	chr5:130500466	HINT1	0.57	7.43	0.34	5.98e-13	Fasting plasma glucose;
LUAD	cis	rs10992471	0.580	rs12341093	chr9:95234182	G/T	cg14631576	chr9:95140430	CENPP	-0.56	-11.52	-0.49	7.08e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs2046867	0.818	rs62249874	chr3:72911202	G/C	cg25664220	chr3:72788482	NA	-0.61	-10.57	-0.46	2.49e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs8170	0.603	rs7249329	chr19:17423373	G/T	cg04749549	chr19:17459798	NA	-0.35	-6.46	-0.3	2.81e-10	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUAD	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg08773314	chr2:239334832	ASB1	0.44	9.54	0.42	1.19e-19	Multiple system atrophy;
LUAD	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg23887609	chr12:130822674	PIWIL1	0.4	6.66	0.31	8.62e-11	Menopause (age at onset);
LUAD	cis	rs17095355	0.605	rs2274979	chr10:111631781	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.5	-0.34	3.87e-13	Biliary atresia;
LUAD	cis	rs943466	1.000	rs11753083	chr6:33761111	C/G	cg16010596	chr6:33739607	LEMD2	-0.39	-7.23	-0.33	2.24e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs1595825	0.891	rs73058867	chr2:198891568	A/G	cg00982548	chr2:198649783	BOLL	-0.65	-9.16	-0.41	2.31e-18	Ulcerative colitis;
LUAD	cis	rs11971779	0.584	rs6942519	chr7:139070090	A/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.46	-0.3	2.86e-10	Diisocyanate-induced asthma;
LUAD	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.8	0.35	4.88e-14	Bladder cancer;
LUAD	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10802521	chr3:52805072	NEK4	-0.54	-9.1	-0.4	3.51e-18	Bipolar disorder;
LUAD	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg26924012	chr15:45694286	SPATA5L1	0.64	11.01	0.47	5.78e-25	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg12179176	chr11:130786555	SNX19	0.51	8.55	0.38	2.29e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.6	8.45	0.38	4.59e-16	Gut microbiome composition (summer);
LUAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg04025307	chr7:1156635	C7orf50	0.51	8.84	0.39	2.55e-17	Longevity;Endometriosis;
LUAD	cis	rs36051895	0.659	rs11999076	chr9:5037694	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-6.39	-0.3	4.45e-10	Pediatric autoimmune diseases;
LUAD	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg07570687	chr10:102243282	WNT8B	0.44	6.72	0.31	5.75e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-10.93	-0.47	1.21e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2357013	0.746	rs1160297	chr2:53237320	G/C	cg07782112	chr2:53107842	NA	-0.34	-6.72	-0.31	5.93e-11	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.21	0.44	5.05e-22	Ileal carcinoids;
LUAD	trans	rs6561151	0.681	rs17571812	chr13:44472462	G/A	cg12856521	chr11:46389249	DGKZ	0.98	12.7	0.53	1.5e-31	Crohn's disease;
LUAD	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg00316803	chr15:76480434	C15orf27	-0.43	-8.65	-0.39	1.1e-16	Blood metabolite levels;
LUAD	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg25838465	chr1:92012736	NA	-0.7	-15.0	-0.59	4.3e-41	Breast cancer;
LUAD	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.08	0.54	4.6e-33	Prudent dietary pattern;
LUAD	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg09537434	chr19:41945824	ATP5SL	-0.47	-7.35	-0.34	1.05e-12	Height;
LUAD	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg04155289	chr7:94953770	PON1	-0.5	-6.44	-0.3	3.22e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs59104589	0.517	rs15129	chr2:242168976	T/C	cg08645257	chr2:242211290	HDLBP	0.4	6.56	0.3	1.58e-10	Fibrinogen levels;
LUAD	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg22117172	chr7:91764530	CYP51A1	-0.35	-7.53	-0.34	3.02e-13	Breast cancer;
LUAD	cis	rs7903847	0.642	rs2297667	chr10:99145492	A/T	cg20016023	chr10:99160130	RRP12	-0.28	-6.73	-0.31	5.52e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs758324	0.755	rs578637	chr5:131267609	G/A	cg06307176	chr5:131281290	NA	-0.46	-7.71	-0.35	9e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs61897795	0.657	rs174587	chr11:61612830	C/T	cg19610905	chr11:61596333	FADS2	-0.71	-9.97	-0.44	3.7e-21	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12756686	chr19:29218302	NA	0.65	9.53	0.42	1.24e-19	Methadone dose in opioid dependence;
LUAD	cis	rs9902453	1.000	rs4239227	chr17:28389103	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.23	-0.41	1.27e-18	Coffee consumption (cups per day);
LUAD	cis	rs738321	0.757	rs6001020	chr22:38538246	C/G	cg17652424	chr22:38574118	PLA2G6	-0.27	-7.26	-0.33	1.83e-12	Breast cancer;
LUAD	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg27572855	chr1:25598939	RHD	0.59	13.33	0.54	4.16e-34	Erythrocyte sedimentation rate;
LUAD	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg09137382	chr11:130731461	NA	0.43	8.15	0.37	4.22e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7833986	0.501	rs2667983	chr8:56894087	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.92	14.81	0.58	2.78e-40	Height;
LUAD	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg11235426	chr6:292522	DUSP22	-0.57	-9.44	-0.42	2.52e-19	Menopause (age at onset);
LUAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06873352	chr17:61820015	STRADA	0.81	18.27	0.66	2.08e-55	Prudent dietary pattern;
LUAD	cis	rs347685	0.871	rs7644383	chr3:141743951	C/T	cg02222454	chr3:141762828	NA	0.46	6.44	0.3	3.19e-10	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine);
LUAD	trans	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg26043149	chr18:55253948	FECH	0.5	7.99	0.36	1.31e-14	Bone mineral density;
LUAD	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.54	-0.34	2.94e-13	Fear of minor pain;
LUAD	trans	rs2262909	0.962	rs7255049	chr19:22213111	A/G	cg05197062	chr11:11642011	GALNTL4	-0.45	-7.13	-0.33	4.3e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg07930552	chr6:133119739	C6orf192	0.6	7.41	0.34	7.03e-13	Type 2 diabetes nephropathy;
LUAD	trans	rs9995821	0.713	rs4315762	chr4:154863425	C/G	cg26525076	chr1:4749249	AJAP1	0.32	6.36	0.3	5.27e-10	facial morphology traits (multivariate analysis);
LUAD	cis	rs6489882	0.867	rs6489867	chr12:113363550	C/T	cg20102336	chr12:113376681	OAS3	-0.54	-8.39	-0.38	7.47e-16	Chronic lymphocytic leukemia;
LUAD	cis	rs1595825	0.732	rs79207930	chr2:198423111	G/T	cg00982548	chr2:198649783	BOLL	-0.5	-6.74	-0.31	5.36e-11	Ulcerative colitis;
LUAD	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg04944784	chr2:26401820	FAM59B	-0.76	-10.5	-0.45	4.4e-23	Gut microbiome composition (summer);
LUAD	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg10589385	chr1:150898437	SETDB1	0.4	7.5	0.34	3.69e-13	Tonsillectomy;
LUAD	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg15704280	chr7:45808275	SEPT13	0.92	17.68	0.65	8.62e-53	Coronary artery disease;
LUAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07157834	chr1:205819609	PM20D1	0.83	17.58	0.65	2.4e-52	Menarche (age at onset);
LUAD	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg13319975	chr6:146136371	FBXO30	0.69	12.0	0.5	9.75e-29	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg20203395	chr5:56204925	C5orf35	-0.49	-7.65	-0.35	1.36e-13	Coronary artery disease;
LUAD	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg26513180	chr16:89883248	FANCA	0.66	12.28	0.51	7.28e-30	Vitiligo;
LUAD	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg21984481	chr17:79567631	NPLOC4	-0.55	-11.51	-0.49	7.63e-27	Eye color traits;
LUAD	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.34	6.8	0.31	3.57e-11	Obesity-related traits;
LUAD	cis	rs76878669	0.917	rs10896110	chr11:66101978	G/A	cg18002602	chr11:66138449	SLC29A2	-0.4	-6.98	-0.32	1.18e-11	Educational attainment (years of education);
LUAD	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg03690763	chr11:133734501	NA	0.32	7.3	0.33	1.44e-12	Childhood ear infection;
LUAD	cis	rs57994353	0.659	rs76259794	chr9:139377405	C/A	cg14169450	chr9:139327907	INPP5E	0.41	6.51	0.3	2.19e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	trans	rs11989744	1.000	rs34389484	chr8:23572963	T/G	cg03492747	chr16:86543808	FOXF1	0.4	6.54	0.3	1.77e-10	Waist-hip ratio;
LUAD	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.56	0.3	1.61e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs57920188	0.535	rs12129515	chr1:4094101	G/A	cg20703997	chr1:4087676	NA	0.48	9.01	0.4	7.04e-18	Interleukin-17 levels;
LUAD	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg15412446	chr2:106886593	NA	-0.63	-9.67	-0.43	4.16e-20	Facial morphology (factor 23);
LUAD	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg14186256	chr22:23484241	RTDR1	0.46	8.01	0.36	1.1e-14	Bone mineral density;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg03688707	chr13:76124424	UCHL3	-0.4	-6.88	-0.32	2.14e-11	Subcortical brain region volumes;
LUAD	cis	rs11671005	0.693	rs11668757	chr19:58928299	A/T	cg13877915	chr19:58951672	ZNF132	0.56	7.42	0.34	6.66e-13	Mean platelet volume;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13265914	chr8:21999630	REEP4	0.42	6.78	0.31	3.93e-11	Monocyte percentage of white cells;
LUAD	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg06547715	chr2:218990976	CXCR2	-0.27	-6.41	-0.3	3.81e-10	Colorectal cancer;
LUAD	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg00814883	chr7:100076585	TSC22D4	-0.82	-11.99	-0.5	1.02e-28	Platelet count;
LUAD	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg18180107	chr4:99064573	C4orf37	0.4	6.44	0.3	3.25e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg13319975	chr6:146136371	FBXO30	-0.55	-9.04	-0.4	5.59e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14893161	chr1:205819251	PM20D1	0.62	11.63	0.49	2.51e-27	Menarche (age at onset);
LUAD	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg08219700	chr8:58056026	NA	0.66	8.44	0.38	4.97e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg06753367	chr22:24256600	NA	-0.39	-6.86	-0.32	2.5e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg17105886	chr17:28927953	LRRC37B2	0.83	7.92	0.36	2.14e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7584330	0.518	rs11884238	chr2:238424671	T/G	cg14458575	chr2:238380390	NA	0.6	9.75	0.43	2.21e-20	Prostate cancer;
LUAD	cis	rs6740322	0.895	rs6710656	chr2:43566941	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.78	-11.37	-0.48	2.62e-26	Coronary artery disease;
LUAD	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg08470875	chr2:26401718	FAM59B	-0.77	-10.45	-0.45	7e-23	Gut microbiome composition (summer);
LUAD	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg09658497	chr7:2847517	GNA12	-0.55	-9.18	-0.41	1.99e-18	Height;
LUAD	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg05425664	chr17:57184151	TRIM37	0.44	7.74	0.35	7.17e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.3	6.66	0.31	8.75e-11	Systemic lupus erythematosus;
LUAD	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg01475377	chr6:109611718	NA	-0.55	-10.6	-0.46	1.93e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg04539111	chr16:67997858	SLC12A4	-0.5	-6.82	-0.31	3.14e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg18404041	chr3:52824283	ITIH1	-0.35	-6.8	-0.31	3.57e-11	Electroencephalogram traits;
LUAD	cis	rs7107174	1.000	rs731600	chr11:77963133	A/G	cg02023728	chr11:77925099	USP35	0.38	6.46	0.3	2.84e-10	Testicular germ cell tumor;
LUAD	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs701145	0.640	rs357497	chr3:153943068	C/A	cg17054900	chr3:154042577	DHX36	0.66	6.8	0.31	3.64e-11	Coronary artery disease;
LUAD	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg23649088	chr2:200775458	C2orf69	0.47	8.38	0.38	7.68e-16	Asthma (bronchodilator response);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg10048961	chr12:123459168	OGFOD2;ABCB9	-0.48	-8.37	-0.38	8.4e-16	Cancer;
LUAD	cis	rs4460629	0.742	rs6693477	chr1:155081940	A/G	cg23973274	chr1:155060172	NA	-0.36	-6.49	-0.3	2.44e-10	Serum magnesium levels;
LUAD	cis	rs364477	0.762	rs9299104	chr9:1001254	C/T	cg13952963	chr9:998547	NA	-0.52	-7.33	-0.34	1.2e-12	Major depressive disorder;
LUAD	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg16479474	chr6:28041457	NA	0.36	6.43	0.3	3.53e-10	Parkinson's disease;
LUAD	cis	rs11971779	0.616	rs6974907	chr7:139068729	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.76	0.31	4.63e-11	Diisocyanate-induced asthma;
LUAD	cis	rs669446	0.562	rs3791036	chr1:44155383	A/G	cg12908607	chr1:44402522	ARTN	-0.34	-6.78	-0.31	4.07e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg11062466	chr8:58055876	NA	0.54	7.38	0.34	8.52e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs79839061	0.520	rs2279187	chr4:875529	C/T	cg23992470	chr4:843637	GAK	0.79	8.12	0.37	5.05e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg02176678	chr2:219576539	TTLL4	0.63	12.33	0.51	4.51e-30	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs875971	0.660	rs2191268	chr7:66110224	C/T	cg18876405	chr7:65276391	NA	0.39	6.65	0.31	8.88e-11	Aortic root size;
LUAD	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg15181151	chr6:150070149	PCMT1	0.39	7.91	0.36	2.31e-14	Lung cancer;
LUAD	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg03037974	chr15:76606532	NA	0.48	11.04	0.47	4.64e-25	Blood metabolite levels;
LUAD	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg16479474	chr6:28041457	NA	0.44	7.46	0.34	4.87e-13	Depression;
LUAD	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.19	-0.37	3.18e-15	Total cholesterol levels;
LUAD	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg07305463	chr2:136567211	LCT	-0.37	-7.02	-0.32	8.95e-12	Mosquito bite size;
LUAD	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.23	0.37	2.35e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg25173405	chr17:45401733	C17orf57	0.52	8.75	0.39	5.23e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg07414643	chr4:187882934	NA	0.33	6.72	0.31	5.77e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs240764	0.658	rs7740006	chr6:101220432	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-7.48	-0.34	4.29e-13	Neuroticism;
LUAD	cis	rs62238980	0.614	rs117486425	chr22:32441850	A/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	trans	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg04775059	chr7:64541387	NA	0.5	6.72	0.31	5.94e-11	Aortic root size;
LUAD	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg18252515	chr7:66147081	NA	-0.58	-6.43	-0.3	3.52e-10	Diabetic kidney disease;
LUAD	cis	rs2377058	0.882	rs11646741	chr16:89730084	G/C	cg12119029	chr16:89752879	CDK10	-0.36	-7.55	-0.34	2.77e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs870825	0.860	rs60523653	chr4:185604676	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	10.21	0.44	4.85e-22	Blood protein levels;
LUAD	trans	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg04775059	chr7:64541387	NA	-0.51	-6.99	-0.32	1.07e-11	Aortic root size;
LUAD	cis	rs1997103	0.822	rs940878	chr7:55419663	A/G	cg17469321	chr7:55412551	NA	0.64	10.51	0.46	3.99e-23	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs10821973	0.527	rs7092870	chr10:63971272	T/C	cg09941381	chr10:64027924	RTKN2	-0.35	-6.83	-0.32	3.03e-11	Hypothyroidism;
LUAD	cis	rs2573652	1.000	rs1469829	chr15:100517332	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.56	-10.6	-0.46	1.95e-23	Height;
LUAD	cis	rs1395	0.778	rs724311	chr2:27441645	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	8.61	0.39	1.46e-16	Blood metabolite levels;
LUAD	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg18138036	chr10:133769891	PPP2R2D	0.42	6.74	0.31	5.28e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg22244940	chr12:132335942	MMP17	0.41	7.01	0.32	9.43e-12	Migraine;
LUAD	trans	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg24644049	chr4:85504048	CDS1	0.85	6.92	0.32	1.67e-11	Skin colour saturation;
LUAD	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg19418458	chr7:158789849	NA	0.65	8.71	0.39	6.78e-17	Facial morphology (factor 20);
LUAD	cis	rs7773004	0.905	rs6932727	chr6:26327087	C/A	cg13736514	chr6:26305472	NA	-0.49	-8.15	-0.37	4.06e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg25344623	chr2:136566232	LCT	0.35	6.8	0.31	3.64e-11	Mosquito bite size;
LUAD	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg26384229	chr12:38710491	ALG10B	-0.42	-7.15	-0.33	3.89e-12	Morning vs. evening chronotype;
LUAD	trans	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg18335740	chr13:41363409	SLC25A15	0.82	15.7	0.61	4.43e-44	Lewy body disease;
LUAD	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg03929089	chr4:120376271	NA	-0.46	-7.12	-0.33	4.65e-12	Height;
LUAD	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.04	23.44	0.75	1.77e-78	Chronic sinus infection;
LUAD	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg09796270	chr17:17721594	SREBF1	-0.37	-6.94	-0.32	1.47e-11	Total body bone mineral density;
LUAD	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg23262073	chr20:60523788	NA	-0.45	-7.68	-0.35	1.13e-13	Body mass index;
LUAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg13047869	chr3:10149882	C3orf24	0.58	9.88	0.43	7.49e-21	Alzheimer's disease;
LUAD	cis	rs4372836	0.930	rs7607844	chr2:28971738	T/A	cg09522027	chr2:28974177	PPP1CB	-0.61	-9.48	-0.42	1.81e-19	Body mass index;
LUAD	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg12310025	chr6:25882481	NA	0.83	13.9	0.56	1.85e-36	Blood metabolite levels;
LUAD	cis	rs597583	0.806	rs1941390	chr11:117396991	G/A	cg27161313	chr11:117392002	DSCAML1	-0.49	-8.17	-0.37	3.66e-15	Putamen volume;
LUAD	cis	rs986417	0.901	rs10134736	chr14:60998540	A/T	cg27398547	chr14:60952738	C14orf39	0.67	8.02	0.36	1.06e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg05340658	chr4:99064831	C4orf37	0.53	8.91	0.4	1.53e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg00999904	chr2:3704751	ALLC	-0.4	-7.42	-0.34	6.55e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg10523679	chr1:76189770	ACADM	0.81	12.95	0.53	1.5e-32	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs981844	0.753	rs62325149	chr4:154728006	G/C	cg10279832	chr4:154682576	RNF175	-0.34	-6.38	-0.3	4.53e-10	Response to statins (LDL cholesterol change);
LUAD	trans	rs6076960	0.598	rs3905168	chr20:6226752	C/T	cg21095983	chr6:86352623	SYNCRIP	0.47	7.34	0.34	1.1e-12	Smooth-surface caries;
LUAD	trans	rs877282	0.583	rs10904564	chr10:819459	C/G	cg22713356	chr15:30763199	NA	0.9	11.32	0.48	4.1e-26	Uric acid levels;
LUAD	cis	rs2731664	0.792	rs335467	chr5:176890642	A/G	cg23176889	chr5:176863531	GRK6	-0.73	-14.39	-0.57	1.71e-38	Intelligence (multi-trait analysis);
LUAD	cis	rs76878669	0.561	rs55998145	chr11:66152586	A/G	cg10616300	chr11:66138557	SLC29A2	0.36	7.65	0.35	1.38e-13	Educational attainment (years of education);
LUAD	cis	rs904251	0.525	rs12200378	chr6:37425304	A/G	cg25019722	chr6:37503610	NA	-0.31	-6.94	-0.32	1.48e-11	Cognitive performance;
LUAD	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg17724175	chr1:150552817	MCL1	0.39	9.28	0.41	9.17e-19	Tonsillectomy;
LUAD	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg08885076	chr2:99613938	TSGA10	0.37	6.65	0.31	9.32e-11	Chronic sinus infection;
LUAD	cis	rs11696501	0.688	rs6073861	chr20:44325708	G/A	cg11783356	chr20:44313418	WFDC10B	-0.51	-8.34	-0.38	1.09e-15	Brain structure;
LUAD	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg11292332	chr7:45801988	SEPT13	-0.28	-6.35	-0.3	5.54e-10	Extrinsic epigenetic age acceleration;
LUAD	trans	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg01620082	chr3:125678407	NA	-1.02	-9.91	-0.43	6e-21	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs208520	0.661	rs207079	chr6:66770462	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-17.08	-0.64	4.03e-50	Exhaled nitric oxide output;
LUAD	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg11502198	chr6:26597334	ABT1	0.73	12.5	0.52	1.02e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg06873352	chr17:61820015	STRADA	0.41	6.91	0.32	1.84e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-7.54	-0.34	2.81e-13	Personality dimensions;
LUAD	cis	rs2806561	0.704	rs6680974	chr1:23376233	A/G	cg12483005	chr1:23474871	LUZP1	0.43	6.91	0.32	1.78e-11	Height;
LUAD	cis	rs17152411	0.895	rs11245420	chr10:126586469	T/C	cg07906193	chr10:126599966	NA	0.54	7.65	0.35	1.34e-13	Height;
LUAD	cis	rs673604	0.536	rs41267245	chr1:35648492	G/A	cg12633102	chr1:35676489	NA	-0.77	-7.32	-0.34	1.25e-12	Endometrial cancer;
LUAD	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg07217954	chr7:1067459	C7orf50	0.46	7.13	0.33	4.48e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs886126	0.950	rs2097658	chr12:111690466	C/T	cg10833066	chr12:111807467	FAM109A	0.55	9.97	0.44	3.61e-21	Coronary heart disease;
LUAD	cis	rs11771526	0.901	rs17161137	chr7:32323799	G/T	cg27511599	chr7:32358540	NA	0.53	6.6	0.31	1.22e-10	Body mass index;
LUAD	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg08470875	chr2:26401718	FAM59B	-0.57	-7.85	-0.36	3.5e-14	Gut microbiome composition (summer);
LUAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-9.81	-0.43	1.31e-20	Alzheimer's disease;
LUAD	cis	rs6696239	0.513	rs4653853	chr1:227751602	C/A	cg12133451	chr1:227746453	NA	0.36	6.5	0.3	2.28e-10	Height;
LUAD	cis	rs10504073	0.584	rs17642664	chr8:49942945	A/G	cg00325661	chr8:49890786	NA	0.45	10.11	0.44	1.19e-21	Blood metabolite ratios;
LUAD	cis	rs367943	0.712	rs9326889	chr5:112731438	A/G	cg12552261	chr5:112820674	MCC	0.48	9.29	0.41	8.52e-19	Type 2 diabetes;
LUAD	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-8.82	-0.39	3.06e-17	Gut microbiome composition (summer);
LUAD	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg09184832	chr6:79620586	NA	-0.47	-8.24	-0.37	2.11e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.17	0.37	3.49e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg07343612	chr16:622815	PIGQ	-0.83	-16.06	-0.62	1.13e-45	Height;
LUAD	cis	rs10242455	0.717	rs4646461	chr7:99331473	C/T	cg18809830	chr7:99032528	PTCD1	-0.81	-7.52	-0.34	3.24e-13	Blood metabolite levels;
LUAD	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg20933634	chr6:27740509	NA	0.52	8.05	0.36	8.44e-15	Parkinson's disease;
LUAD	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg05342682	chr7:94953680	PON1	-0.48	-6.87	-0.32	2.36e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg24675056	chr1:15929824	NA	0.49	8.43	0.38	5.55e-16	Systolic blood pressure;
LUAD	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg17328964	chr8:145687451	CYHR1	0.66	11.45	0.49	1.27e-26	Age at first birth;
LUAD	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg13180566	chr4:1052158	NA	-0.39	-6.66	-0.31	8.6e-11	Recombination rate (females);
LUAD	cis	rs4638749	0.734	rs35184015	chr2:108870540	C/T	cg25838818	chr2:108905173	SULT1C2	-0.38	-6.63	-0.31	1e-10	Blood pressure;
LUAD	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg13319975	chr6:146136371	FBXO30	-0.59	-9.9	-0.43	6.35e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg19346786	chr7:2764209	NA	-0.49	-10.49	-0.45	4.78e-23	Height;
LUAD	trans	rs7712671	0.840	rs11241418	chr5:116527405	C/T	cg21930229	chr1:32758033	HDAC1	0.41	6.38	0.3	4.73e-10	Schizophrenia;
LUAD	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.85e-14	Depression;
LUAD	trans	rs11885103	0.543	rs2685227	chr2:561099	T/C	cg12228919	chr15:44955936	SPG11	-0.41	-6.35	-0.3	5.55e-10	Heschl's gyrus morphology;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05964953	chr2:73114371	SPR	-0.37	-6.35	-0.3	5.49e-10	Height;
LUAD	cis	rs9302690	1.000	rs74809791	chr16:57472860	G/T	cg27017172	chr16:57497170	POLR2C	1.2	9.47	0.42	2.03e-19	Blood protein levels;
LUAD	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg22535103	chr8:58192502	C8orf71	-0.61	-6.64	-0.31	9.85e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9715521	0.803	rs28676590	chr4:59808524	T/C	cg11281224	chr4:60001000	NA	-0.46	-7.66	-0.35	1.27e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg09060608	chr5:178986726	RUFY1	0.76	13.48	0.55	1.07e-34	Lung cancer;
LUAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg16606324	chr3:10149918	C3orf24	-0.71	-11.74	-0.5	9.48e-28	Alzheimer's disease;
LUAD	trans	rs10802346	0.545	rs1770003	chr1:246408356	A/G	cg22732515	chr19:44031385	ETHE1	0.55	8.9	0.4	1.63e-17	Fractional exhaled nitric oxide (childhood);
LUAD	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-20.04	-0.7	2.63e-63	Height;
LUAD	cis	rs3806843	0.546	rs246023	chr5:140333990	G/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.74e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11118844	0.793	rs4433402	chr1:221946172	A/G	cg04222084	chr1:221915650	DUSP10	-0.65	-7.6	-0.35	1.98e-13	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	cis	rs2580764	0.517	rs2972070	chr2:55301691	G/A	cg09592903	chr2:55203963	RTN4	0.4	8.79	0.39	3.75e-17	Mean platelet volume;
LUAD	cis	rs2019216	0.500	rs12938673	chr17:21941987	C/G	cg22648282	chr17:21454238	C17orf51	-0.41	-6.38	-0.3	4.65e-10	Pelvic organ prolapse;
LUAD	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg10802521	chr3:52805072	NEK4	-0.47	-7.69	-0.35	1.07e-13	Electroencephalogram traits;
LUAD	trans	rs2806561	1.000	rs2776822	chr1:23492782	A/G	cg17059624	chr11:85358760	TMEM126A	0.4	6.43	0.3	3.36e-10	Height;
LUAD	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg24675056	chr1:15929824	NA	0.47	8.22	0.37	2.46e-15	Systolic blood pressure;
LUAD	trans	rs11039798	0.920	rs12417899	chr11:49017552	G/A	cg03929089	chr4:120376271	NA	0.66	6.52	0.3	2.05e-10	Axial length;
LUAD	trans	rs11039798	0.688	rs8188953	chr11:48749201	A/T	cg02254774	chr11:50257496	LOC441601	0.53	6.6	0.31	1.24e-10	Axial length;
LUAD	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.27e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs58106596	0.660	rs13398149	chr2:232564881	A/C	cg01370599	chr3:116745421	NA	0.6	7.75	0.35	6.97e-14	White blood cell count;Lymphocyte counts;
LUAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg03188948	chr7:1209495	NA	0.81	9.85	0.43	9.21e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg07423050	chr13:99094983	FARP1	-0.55	-9.21	-0.41	1.58e-18	Longevity;
LUAD	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.38	0.34	8.64e-13	Menopause (age at onset);
LUAD	cis	rs2274273	0.638	rs17672364	chr14:55705904	G/T	cg04306507	chr14:55594613	LGALS3	0.44	8.13	0.37	4.83e-15	Protein biomarker;
LUAD	cis	rs239198	0.578	rs13193416	chr6:101299602	A/T	cg09795085	chr6:101329169	ASCC3	0.41	6.99	0.32	1.05e-11	Menarche (age at onset);
LUAD	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg03733263	chr8:22462867	KIAA1967	0.74	12.99	0.53	1.06e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs2795502	0.938	rs3121281	chr10:43400753	A/G	cg20628663	chr10:43360327	NA	0.7	11.19	0.48	1.26e-25	Blood protein levels;
LUAD	cis	rs7607369	0.566	rs55658481	chr2:219284215	G/A	cg02176678	chr2:219576539	TTLL4	-0.76	-14.58	-0.58	2.69e-39	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg13319975	chr6:146136371	FBXO30	0.57	9.61	0.42	6.51e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg10434728	chr15:90938212	IQGAP1	-0.33	-6.48	-0.3	2.55e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg24642844	chr7:1081250	C7orf50	-0.92	-13.73	-0.56	9.37e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2073300	1.000	rs6106655	chr20:23441982	C/G	cg12062639	chr20:23401060	NAPB	0.91	8.63	0.39	1.28e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs11958404	0.929	rs60700182	chr5:157438376	A/G	cg05962755	chr5:157440814	NA	0.55	8.28	0.37	1.65e-15	IgG glycosylation;
LUAD	cis	rs2985684	0.846	rs4476096	chr14:50019391	A/C	cg04989706	chr14:50066350	PPIL5	-0.48	-7.23	-0.33	2.29e-12	Carotid intima media thickness;
LUAD	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg12623918	chr2:306882	NA	0.35	7.1	0.33	5.47e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg05373962	chr22:49881684	NA	-0.54	-12.85	-0.53	4.03e-32	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9296095	0.632	rs6914422	chr6:33534880	A/G	cg14003231	chr6:33640908	ITPR3	-0.47	-8.82	-0.39	3.06e-17	Platelet count;
LUAD	cis	rs2070677	1.000	rs743534	chr10:135349226	G/T	cg20169779	chr10:135381914	SYCE1	0.51	7.96	0.36	1.55e-14	Gout;
LUAD	cis	rs12545109	0.571	rs4237014	chr8:57284479	C/A	cg09654669	chr8:57350985	NA	-0.72	-10.05	-0.44	1.84e-21	Obesity-related traits;
LUAD	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.59	7.08	0.33	5.97e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg14581129	chr12:53358946	NA	-0.88	-16.24	-0.62	1.85e-46	Cancer (pleiotropy);
LUAD	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg03609598	chr5:56110824	MAP3K1	-0.47	-7.35	-0.34	1.05e-12	Coronary artery disease;
LUAD	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg17366294	chr4:99064904	C4orf37	0.59	9.94	0.44	4.75e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1395	0.925	rs1659696	chr2:27407831	G/A	cg23587288	chr2:27483067	SLC30A3	0.4	8.12	0.37	5.07e-15	Blood metabolite levels;
LUAD	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18404041	chr3:52824283	ITIH1	-0.63	-12.68	-0.52	1.85e-31	Bipolar disorder;
LUAD	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg17747265	chr1:1875780	NA	-0.75	-18.71	-0.67	2.38e-57	Body mass index;
LUAD	trans	rs3219090	0.861	rs2136875	chr1:226606536	G/A	cg27539482	chr13:111589090	NA	0.43	7.14	0.33	4.04e-12	Melanoma;
LUAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.33	6.7	0.31	6.87e-11	Obesity-related traits;
LUAD	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg27144592	chr16:783916	NARFL	0.35	6.39	0.3	4.37e-10	Height;
LUAD	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg06484146	chr7:12443880	VWDE	-0.49	-6.92	-0.32	1.67e-11	Coronary artery disease;
LUAD	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.81	-0.47	3.26e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg10556349	chr10:835070	NA	0.68	8.14	0.37	4.52e-15	Eosinophil percentage of granulocytes;
LUAD	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs738322	0.726	rs5750561	chr22:38595260	A/T	cg25457927	chr22:38595422	NA	0.69	20.37	0.7	9.15e-65	Cutaneous nevi;
LUAD	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg08712631	chr7:1960676	MAD1L1	-0.4	-6.51	-0.3	2.09e-10	Neuroticism;
LUAD	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.88	-0.36	2.89e-14	Blood metabolite levels;
LUAD	cis	rs17102423	0.755	rs12880781	chr14:65576257	C/T	cg11161011	chr14:65562177	MAX	-0.52	-8.24	-0.37	2.22e-15	Obesity-related traits;
LUAD	trans	rs2898857	0.524	rs2119931	chr17:47429834	A/G	cg11430096	chr6:110968061	CDK19	-0.49	-7.38	-0.34	8.72e-13	Cancer;
LUAD	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg07266350	chr3:49460521	AMT;NICN1	-0.36	-6.38	-0.3	4.75e-10	Menarche (age at onset);
LUAD	cis	rs9535307	0.584	rs61961502	chr13:50393700	G/A	cg04663916	chr13:50265991	EBPL	-0.63	-6.49	-0.3	2.41e-10	Obesity-related traits;
LUAD	cis	rs9287719	0.639	rs2357649	chr2:10696788	C/T	cg02196655	chr2:10830764	NOL10	0.4	7.0	0.32	9.9e-12	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg03467027	chr4:99064603	C4orf37	0.42	6.79	0.31	3.9e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62238980	0.614	rs77630998	chr22:32452744	T/C	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg13896783	chr2:159313876	CCDC148;PKP4	-0.41	-6.6	-0.31	1.23e-10	Vertical cup-disc ratio;
LUAD	cis	rs6028335	0.610	rs67882716	chr20:37573239	T/C	cg27660920	chr20:37554817	FAM83D	0.53	7.02	0.32	8.64e-12	Alcohol and nicotine co-dependence;
LUAD	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg19912559	chr1:40204330	PPIE	0.55	9.45	0.42	2.4e-19	Blood protein levels;
LUAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg02869364	chr7:1081709	C7orf50	-0.38	-7.06	-0.32	6.86e-12	Longevity;Endometriosis;
LUAD	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg03037974	chr15:76606532	NA	0.37	7.78	0.35	5.68e-14	Blood metabolite levels;
LUAD	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11890956	chr21:40555474	PSMG1	0.78	13.39	0.55	2.37e-34	Cognitive function;
LUAD	cis	rs36051895	0.632	rs10118789	chr9:5141178	G/A	cg02405213	chr9:5042618	JAK2	-0.48	-6.6	-0.31	1.27e-10	Pediatric autoimmune diseases;
LUAD	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg00933542	chr6:150070202	PCMT1	0.44	9.05	0.4	5.44e-18	Lung cancer;
LUAD	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg12615879	chr12:58013172	SLC26A10	0.51	10.88	0.47	1.75e-24	Multiple sclerosis;
LUAD	cis	rs10924309	0.924	rs2008747	chr1:245860418	C/A	cg00036263	chr1:245852353	KIF26B	-0.47	-6.95	-0.32	1.42e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs8017423	0.967	rs7142513	chr14:90705182	T/C	cg14092571	chr14:90743983	NA	-0.45	-7.83	-0.36	3.85e-14	Mortality in heart failure;
LUAD	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg23625390	chr15:77176239	SCAPER	-0.39	-6.88	-0.32	2.23e-11	Blood metabolite levels;
LUAD	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg05535760	chr7:792225	HEATR2	-0.88	-11.6	-0.49	3.21e-27	Cerebrospinal P-tau181p levels;
LUAD	trans	rs75804782	1.000	rs75804782	chr2:239316043	T/C	cg01134436	chr17:81009848	B3GNTL1	0.8	8.58	0.39	1.84e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.33	-7.55	-0.34	2.73e-13	Lung cancer;
LUAD	cis	rs7737355	0.947	rs58895212	chr5:130797057	C/A	cg06307176	chr5:131281290	NA	-0.49	-7.69	-0.35	1.03e-13	Life satisfaction;
LUAD	cis	rs2901656	0.677	rs1063412	chr1:172410967	G/A	cg03748243	chr1:172413542	C1orf105;PIGC	0.52	10.01	0.44	2.56e-21	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg27411982	chr8:10470053	RP1L1	0.42	7.98	0.36	1.42e-14	Neuroticism;
LUAD	cis	rs225245	0.755	rs6505493	chr17:34028901	A/G	cg05299278	chr17:33885742	SLFN14	0.5	11.35	0.48	2.94e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.41	6.49	0.3	2.36e-10	Platelet count;
LUAD	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg15017067	chr4:17643749	FAM184B	0.34	6.4	0.3	4.13e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs5167	0.743	rs8111069	chr19:45483438	A/C	cg13119609	chr19:45449297	APOC2	0.41	7.54	0.34	2.92e-13	Blood protein levels;
LUAD	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg24397884	chr7:158709396	WDR60	0.65	8.94	0.4	1.18e-17	Height;
LUAD	cis	rs41311933	0.656	rs41309040	chr9:123781763	C/G	cg13567360	chr9:123745713	C5	-0.68	-8.12	-0.37	5.12e-15	Coronary artery disease;
LUAD	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg04267008	chr7:1944627	MAD1L1	-0.73	-11.51	-0.49	7.58e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.87	-12.67	-0.52	2.07e-31	Red cell distribution width;
LUAD	cis	rs7739264	0.564	rs1155100	chr6:19804365	C/T	cg02404759	chr6:19790362	NA	-0.35	-6.53	-0.3	1.84e-10	Endometriosis;
LUAD	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg12458913	chr13:53173898	NA	-0.36	-6.64	-0.31	9.41e-11	Lewy body disease;
LUAD	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg14159672	chr1:205819179	PM20D1	-0.45	-7.04	-0.32	7.63e-12	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg15147215	chr3:52552868	STAB1	-0.36	-6.41	-0.3	3.91e-10	Bipolar disorder;
LUAD	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.54	0.38	2.46e-16	Platelet count;
LUAD	cis	rs17826219	0.789	rs4794873	chr17:28748352	C/T	cg17105886	chr17:28927953	LRRC37B2	0.68	6.78	0.31	3.97e-11	Body mass index;
LUAD	trans	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg06606381	chr12:133084897	FBRSL1	-1.13	-10.46	-0.45	6.49e-23	Depression;
LUAD	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg17063962	chr7:91808500	NA	0.7	12.6	0.52	4.02e-31	Breast cancer;
LUAD	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg01200585	chr1:228362443	C1orf69	0.42	6.82	0.31	3.17e-11	Diastolic blood pressure;
LUAD	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.19	-0.41	1.79e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg22508957	chr16:3507546	NAT15	0.75	13.48	0.55	1.09e-34	Tuberculosis;
LUAD	cis	rs12155623	0.668	rs6472114	chr8:49789561	T/C	cg22283653	chr8:49824208	NA	-0.53	-11.01	-0.47	6.03e-25	Sudden cardiac arrest;
LUAD	trans	rs11039798	0.920	rs12292685	chr11:48571032	G/T	cg15704280	chr7:45808275	SEPT13	0.63	7.45	0.34	5.19e-13	Axial length;
LUAD	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg03563238	chr19:33554763	RHPN2	-0.37	-8.56	-0.38	2.12e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.59	11.47	0.49	1.1e-26	Birth weight;
LUAD	cis	rs701145	0.586	rs355785	chr3:153990251	T/G	cg17054900	chr3:154042577	DHX36	0.64	7.07	0.33	6.28e-12	Coronary artery disease;
LUAD	cis	rs2742417	0.603	rs2064062	chr3:45761115	G/C	cg10512202	chr3:45649293	LIMD1	0.47	8.81	0.39	3.19e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs1865721	0.771	rs724764	chr18:73139742	C/T	cg26385618	chr18:73139727	C18orf62	-0.51	-10.45	-0.45	7.02e-23	Intelligence;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02099313	chr1:231114956	TTC13;ARV1	0.41	6.4	0.3	4.13e-10	Bilirubin levels;
LUAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg10295955	chr4:187884368	NA	-1.17	-30.81	-0.83	3.81e-110	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11771526	0.551	rs1008652	chr7:32254403	A/G	cg13207630	chr7:32358064	NA	-0.49	-6.89	-0.32	1.98e-11	Body mass index;
LUAD	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg21475434	chr5:93447410	FAM172A	0.74	8.22	0.37	2.58e-15	Diabetic retinopathy;
LUAD	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg11189052	chr15:85197271	WDR73	0.68	8.91	0.4	1.57e-17	Schizophrenia;
LUAD	cis	rs735539	1.000	rs6490606	chr13:21285096	C/G	cg27499820	chr13:21296301	IL17D	-0.41	-7.2	-0.33	2.74e-12	Dental caries;
LUAD	cis	rs12042938	0.507	rs1655299	chr1:231732161	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.41	-7.27	-0.33	1.81e-12	Neuranatomic and neurocognitive phenotypes;
LUAD	cis	rs7192380	0.651	rs61460899	chr16:69682780	T/A	cg15192750	chr16:69999425	NA	0.42	6.71	0.31	6.31e-11	Sjögren's syndrome;
LUAD	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg17366294	chr4:99064904	C4orf37	0.48	8.43	0.38	5.53e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-6.63	-0.31	1.05e-10	Schizophrenia;
LUAD	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.55	-0.3	1.65e-10	Breast cancer;
LUAD	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg17644776	chr2:200775616	C2orf69	-0.55	-6.54	-0.3	1.81e-10	Schizophrenia;
LUAD	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg03733263	chr8:22462867	KIAA1967	0.64	10.94	0.47	1.05e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg02775129	chr4:119771670	NA	-0.87	-7.95	-0.36	1.72e-14	Cannabis dependence symptom count;
LUAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg12373951	chr3:133503437	NA	0.33	6.55	0.3	1.64e-10	Iron status biomarkers;
LUAD	cis	rs1788820	0.957	rs1652342	chr18:21099583	C/T	cg14672496	chr18:21087552	C18orf8	0.35	6.69	0.31	7.29e-11	Body mass index;
LUAD	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-7.04	-0.32	7.75e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3772130	0.924	rs55643643	chr3:121440197	A/C	cg20356878	chr3:121714668	ILDR1	0.51	7.87	0.36	3.04e-14	Cognitive performance;
LUAD	cis	rs4356932	1.000	rs7699624	chr4:76962631	G/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.48	-0.3	2.48e-10	Blood protein levels;
LUAD	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	9.4	0.42	3.45e-19	Colorectal cancer;
LUAD	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg14186256	chr22:23484241	RTDR1	0.49	8.17	0.37	3.52e-15	Bone mineral density;
LUAD	cis	rs4774899	0.932	rs17239431	chr15:57526756	C/T	cg14026238	chr15:57616123	NA	0.35	6.56	0.3	1.6e-10	Urinary tract infection frequency;
LUAD	cis	rs4930561	0.714	rs7122250	chr11:67946472	T/C	cg04465784	chr11:67976953	SUV420H1	-0.35	-10.91	-0.47	1.42e-24	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	trans	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg21659725	chr3:3221576	CRBN	-0.39	-6.64	-0.31	9.56e-11	Resting heart rate;
LUAD	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg21699342	chr2:239360505	ASB1	0.58	11.41	0.49	1.79e-26	Multiple system atrophy;
LUAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg21385606	chr21:47601150	C21orf56	0.36	6.43	0.3	3.37e-10	Testicular germ cell tumor;
LUAD	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg07936489	chr17:37558343	FBXL20	-0.47	-7.5	-0.34	3.76e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg24818145	chr4:99064322	C4orf37	0.48	8.32	0.37	1.26e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs113835537	0.529	rs3741360	chr11:66300348	A/G	cg24851651	chr11:66362959	CCS	0.58	10.15	0.44	8.23e-22	Airway imaging phenotypes;
LUAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg22907277	chr7:1156413	C7orf50	0.55	9.47	0.42	1.93e-19	Longevity;Endometriosis;
LUAD	cis	rs62400317	0.859	rs62436780	chr6:45128261	A/T	cg20913747	chr6:44695427	NA	-0.4	-6.48	-0.3	2.52e-10	Total body bone mineral density;
LUAD	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg01851573	chr8:8652454	MFHAS1	-0.43	-7.73	-0.35	7.73e-14	Mood instability;
LUAD	trans	rs7944735	1.000	rs7944735	chr11:47955608	G/C	cg15704280	chr7:45808275	SEPT13	0.67	8.62	0.39	1.33e-16	Intraocular pressure;
LUAD	cis	rs490234	0.841	rs490333	chr9:128354569	T/C	cg14078157	chr9:128172775	NA	0.4	7.65	0.35	1.37e-13	Mean arterial pressure;
LUAD	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg20283391	chr11:68216788	NA	-0.4	-6.38	-0.3	4.54e-10	Total body bone mineral density;
LUAD	cis	rs2235649	0.833	rs9933168	chr16:1848361	A/G	cg08610935	chr16:1836813	NUBP2	-0.5	-7.64	-0.35	1.49e-13	Blood metabolite levels;
LUAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg09060608	chr5:178986726	RUFY1	0.6	10.33	0.45	1.92e-22	Lung cancer;
LUAD	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg13319975	chr6:146136371	FBXO30	-0.59	-9.91	-0.43	5.83e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6691722	0.506	rs1016209	chr1:24745615	A/G	cg18323236	chr1:24743029	NIPAL3	-0.45	-7.93	-0.36	1.97e-14	Response to interferon beta in multiple sclerosis;
LUAD	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg06784218	chr1:46089804	CCDC17	0.5	10.99	0.47	6.85e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg26384229	chr12:38710491	ALG10B	0.48	7.69	0.35	1.01e-13	Bladder cancer;
LUAD	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.22	-0.41	1.46e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11644478	chr21:40555479	PSMG1	-0.51	-8.11	-0.37	5.69e-15	Cognitive function;
LUAD	cis	rs17532515	0.652	rs67255527	chr4:141385671	C/G	cg03645522	chr4:141391200	NA	0.39	6.35	0.3	5.46e-10	Select biomarker traits;
LUAD	cis	rs10838532	0.515	rs10838541	chr11:46043747	T/C	cg24204282	chr11:45944920	GYLTL1B	0.4	6.49	0.3	2.43e-10	Axial length;
LUAD	cis	rs754466	0.606	rs11002308	chr10:79594796	A/T	cg17075019	chr10:79541650	NA	-0.89	-18.68	-0.67	3.37e-57	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg08316699	chr6:150357289	NA	0.32	6.76	0.31	4.5e-11	Alopecia areata;
LUAD	cis	rs6060717	0.536	rs11699899	chr20:34525646	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.2	-0.33	2.74e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs9902453	0.904	rs12952179	chr17:28412687	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-10.12	-0.44	1.07e-21	Coffee consumption (cups per day);
LUAD	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.84	-0.36	3.71e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg25566285	chr7:158114605	PTPRN2	0.5	10.52	0.46	3.82e-23	Calcium levels;
LUAD	cis	rs4700695	0.925	rs12657113	chr5:65396959	A/C	cg21114390	chr5:65439923	SFRS12	-0.63	-8.65	-0.39	1.08e-16	Facial morphology (factor 19);
LUAD	cis	rs2224391	0.911	rs9504368	chr6:5261460	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-9.87	-0.43	8.47e-21	Height;
LUAD	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg16205897	chr5:131564050	P4HA2	-0.33	-7.3	-0.33	1.43e-12	Breast cancer;
LUAD	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg11317459	chr13:21872234	NA	-1.09	-14.71	-0.58	7.3e-40	White matter hyperintensity burden;
LUAD	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.6	0.31	1.25e-10	Cardiac Troponin-T levels;
LUAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg22907277	chr7:1156413	C7orf50	-0.56	-9.34	-0.41	5.54e-19	Longevity;Endometriosis;
LUAD	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg18252515	chr7:66147081	NA	-0.6	-6.61	-0.31	1.17e-10	Diabetic kidney disease;
LUAD	cis	rs7223966	0.729	rs2003549	chr17:62008437	C/T	cg06873352	chr17:61820015	STRADA	0.42	6.53	0.3	1.91e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg19163074	chr7:65112434	INTS4L2	-0.44	-6.76	-0.31	4.62e-11	Aortic root size;
LUAD	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg04703951	chr17:43578652	NA	0.56	7.91	0.36	2.22e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.92	-0.36	2.08e-14	Prostate cancer;
LUAD	cis	rs11098699	0.821	rs2047201	chr4:124233384	A/G	cg09941581	chr4:124220074	SPATA5	-0.4	-6.42	-0.3	3.73e-10	Mosquito bite size;
LUAD	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg09998033	chr7:158218633	PTPRN2	0.49	8.87	0.4	2.12e-17	Obesity-related traits;
LUAD	trans	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg14917512	chr19:3094685	GNA11	0.57	6.77	0.31	4.22e-11	Diabetic kidney disease;
LUAD	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg19622623	chr12:86230825	RASSF9	-0.39	-6.93	-0.32	1.58e-11	Major depressive disorder;
LUAD	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg18944383	chr4:111397179	ENPEP	0.37	7.43	0.34	5.94e-13	Height;
LUAD	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg23743428	chr13:21893420	NA	-0.5	-9.14	-0.41	2.66e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg14847009	chr1:175162515	KIAA0040	0.3	7.75	0.35	6.86e-14	Alcohol dependence;
LUAD	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.49	9.98	0.44	3.33e-21	Monocyte percentage of white cells;
LUAD	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.68	-11.27	-0.48	6.14e-26	Primary sclerosing cholangitis;
LUAD	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.88	-0.5	2.81e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg07211511	chr3:129823064	LOC729375	0.79	11.79	0.5	6.36e-28	Blood pressure (smoking interaction);
LUAD	cis	rs2997447	0.739	rs60141220	chr1:26395741	G/A	cg00147160	chr1:26503991	CNKSR1	0.35	6.43	0.3	3.38e-10	QRS complex (12-leadsum);
LUAD	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs7975161	0.671	rs4475991	chr12:104596756	A/G	cg25273343	chr12:104657179	TXNRD1	0.49	7.44	0.34	5.51e-13	Toenail selenium levels;
LUAD	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg00280220	chr17:61926910	NA	0.36	6.99	0.32	1.08e-11	Prudent dietary pattern;
LUAD	cis	rs4730250	0.802	rs77936580	chr7:106946343	G/A	cg02696742	chr7:106810147	HBP1	-0.78	-10.63	-0.46	1.49e-23	Osteoarthritis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04381393	chr17:80545636	FOXK2	0.49	6.37	0.3	4.93e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg14582100	chr15:45693742	SPATA5L1	0.64	12.48	0.52	1.23e-30	Homoarginine levels;
LUAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg11062466	chr8:58055876	NA	0.67	9.01	0.4	7.2e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg08885076	chr2:99613938	TSGA10	0.38	6.84	0.32	2.82e-11	Chronic sinus infection;
LUAD	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-6.94	-0.32	1.47e-11	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUAD	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03517284	chr6:25882590	NA	-0.58	-8.48	-0.38	3.9e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg02240030	chr7:2089880	MAD1L1	0.34	6.78	0.31	3.96e-11	Neuroticism;
LUAD	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg17443473	chr1:3703550	LRRC47	-0.46	-7.8	-0.35	4.97e-14	Red cell distribution width;
LUAD	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg10589385	chr1:150898437	SETDB1	0.44	8.32	0.38	1.18e-15	Melanoma;
LUAD	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg19622623	chr12:86230825	RASSF9	0.42	7.51	0.34	3.49e-13	Major depressive disorder;
LUAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg27094323	chr7:1216898	NA	-0.36	-6.43	-0.3	3.36e-10	Longevity;Endometriosis;
LUAD	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.5	-0.34	3.89e-13	Coronary artery disease;
LUAD	cis	rs1448094	0.967	rs10746357	chr12:86341044	A/T	cg18827107	chr12:86230957	RASSF9	-0.45	-8.11	-0.37	5.37e-15	Major depressive disorder;
LUAD	cis	rs977987	0.806	rs8050769	chr16:75388434	C/T	cg03315344	chr16:75512273	CHST6	0.65	14.12	0.57	2.29e-37	Dupuytren's disease;
LUAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg07021052	chr2:20871279	NA	-0.47	-8.39	-0.38	7.15e-16	Abdominal aortic aneurysm;
LUAD	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg03929089	chr4:120376271	NA	0.53	7.01	0.32	9.25e-12	Axial length;
LUAD	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg18404041	chr3:52824283	ITIH1	-0.53	-8.89	-0.4	1.82e-17	Schizophrenia;
LUAD	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg25985355	chr7:65971099	NA	0.38	7.0	0.32	1.03e-11	Aortic root size;
LUAD	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15664640	chr17:80829946	TBCD	0.69	13.61	0.55	3.18e-35	Breast cancer;
LUAD	cis	rs9549328	0.565	rs35988856	chr13:113617427	T/C	cg17524180	chr13:113633600	MCF2L	0.31	6.61	0.31	1.16e-10	Systolic blood pressure;
LUAD	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg22467129	chr15:76604101	ETFA	-0.48	-8.01	-0.36	1.13e-14	Blood metabolite levels;
LUAD	cis	rs12681288	0.644	rs2600494	chr8:1025517	C/T	cg15309053	chr8:964076	NA	0.4	8.58	0.39	1.79e-16	Schizophrenia;
LUAD	cis	rs1728785	0.818	rs1728769	chr16:68564186	C/T	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.3100000000000001e-10	Ulcerative colitis;
LUAD	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg10909506	chr17:38081995	ORMDL3	0.41	7.4	0.34	7.57e-13	Self-reported allergy;
LUAD	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24838063	chr12:130822603	PIWIL1	0.64	10.7	0.46	8.19e-24	Menopause (age at onset);
LUAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg10729496	chr3:10149963	C3orf24	0.53	8.48	0.38	3.83e-16	Alzheimer's disease;
LUAD	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg07169764	chr2:136633963	MCM6	0.81	9.42	0.42	2.98e-19	Corneal structure;
LUAD	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg02527881	chr3:46936655	PTH1R	-0.53	-10.78	-0.46	4.34e-24	Colorectal cancer;
LUAD	cis	rs7843479	0.582	rs11779655	chr8:21794041	A/G	cg03445287	chr8:21823731	XPO7	0.48	9.23	0.41	1.29e-18	Mean corpuscular volume;
LUAD	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg18827107	chr12:86230957	RASSF9	-0.54	-9.5	-0.42	1.55e-19	Major depressive disorder;
LUAD	trans	rs11165623	0.792	rs1931180	chr1:96914049	C/T	cg10631902	chr5:14652156	NA	-0.63	-12.31	-0.51	5.6e-30	Hip circumference;Waist circumference;
LUAD	cis	rs773506	0.628	rs4743820	chr9:93928416	C/T	cg14446406	chr9:93919335	NA	-0.37	-6.64	-0.31	9.53e-11	Type 2 diabetes nephropathy;
LUAD	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg27102117	chr16:15229624	NA	-0.56	-10.19	-0.44	6.1e-22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg22535103	chr8:58192502	C8orf71	-0.72	-8.94	-0.4	1.24e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1215050	0.791	rs7681599	chr4:98664109	C/T	cg05340658	chr4:99064831	C4orf37	-0.43	-7.01	-0.32	9.19e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10905065	0.827	rs10752111	chr10:5837286	T/C	cg11519256	chr10:5708881	ASB13	0.42	6.99	0.32	1.09e-11	Menopause (age at onset);
LUAD	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg12311346	chr5:56204834	C5orf35	-0.43	-7.15	-0.33	3.96e-12	Coronary artery disease;
LUAD	trans	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg08071915	chr8:12219732	FAM66A	-0.4	-6.49	-0.3	2.34e-10	Parkinson's disease;
LUAD	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg05393297	chr12:53359155	NA	-0.94	-18.14	-0.66	8.08e-55	Cancer (pleiotropy);
LUAD	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.51	0.34	3.58e-13	Morning vs. evening chronotype;
LUAD	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg03733263	chr8:22462867	KIAA1967	0.56	9.75	0.43	2.19e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg18854424	chr1:2615690	NA	0.4	8.59	0.39	1.74e-16	Ulcerative colitis;
LUAD	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg07757535	chr4:1339547	NA	0.28	6.51	0.3	2.08e-10	Longevity;
LUAD	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg15017067	chr4:17643749	FAM184B	0.35	6.88	0.32	2.22e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg21385522	chr1:16154831	NA	-0.59	-9.92	-0.43	5.25e-21	Systolic blood pressure;
LUAD	cis	rs3820068	0.705	rs72645804	chr1:15868387	A/C	cg13390004	chr1:15929781	NA	0.4	6.4	0.3	4.17e-10	Systolic blood pressure;
LUAD	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg17105886	chr17:28927953	LRRC37B2	0.69	7.71	0.35	9.2e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg02951883	chr7:2050386	MAD1L1	-0.97	-18.32	-0.67	1.3e-55	Bipolar disorder and schizophrenia;
LUAD	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.36	0.34	9.7e-13	Menopause (age at onset);
LUAD	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs6543140	0.929	rs6742530	chr2:103082280	G/A	cg03938978	chr2:103052716	IL18RAP	0.35	6.82	0.31	3.26e-11	Blood protein levels;
LUAD	cis	rs2274273	0.624	rs3783651	chr14:55850973	G/C	cg04306507	chr14:55594613	LGALS3	0.41	7.87	0.36	2.94e-14	Protein biomarker;
LUAD	trans	rs1493916	0.905	rs10460051	chr18:31413679	C/T	cg27147174	chr7:100797783	AP1S1	-0.7	-12.7	-0.53	1.64e-31	Life satisfaction;
LUAD	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg02421172	chr7:1938701	MAD1L1	-0.48	-6.67	-0.31	7.97e-11	Bipolar disorder;
LUAD	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg03709012	chr19:19516395	GATAD2A	0.51	6.8	0.31	3.56e-11	Nonalcoholic fatty liver disease;
LUAD	cis	rs10189230	0.967	rs10498113	chr2:222352629	C/T	cg14652038	chr2:222343519	EPHA4	0.44	8.91	0.4	1.49e-17	Urate levels in lean individuals;
LUAD	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg00339695	chr16:24857497	SLC5A11	-0.7	-11.3	-0.48	4.76e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg05340658	chr4:99064831	C4orf37	-0.44	-7.21	-0.33	2.52e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg09137382	chr11:130731461	NA	0.4	7.42	0.34	6.48e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg11822812	chr5:140052017	DND1	0.38	6.73	0.31	5.4e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg05434287	chr7:2030229	MAD1L1	0.41	6.69	0.31	7.24e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg19678392	chr7:94953810	PON1	-0.58	-8.17	-0.37	3.63e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg09184832	chr6:79620586	NA	-0.39	-6.58	-0.3	1.36e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg10729496	chr3:10149963	C3orf24	0.55	9.29	0.41	8.33e-19	Alzheimer's disease;
LUAD	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg21214613	chr1:16344536	HSPB7	0.61	12.08	0.51	4.35e-29	Systolic blood pressure;
LUAD	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.55e-11	Crohn's disease;
LUAD	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg07432352	chr17:45403706	C17orf57	-0.43	-8.3	-0.37	1.38e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-8.56	-0.38	2.14e-16	Endometrial cancer;
LUAD	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg18129748	chr3:49941408	MST1R	-0.4	-6.53	-0.3	1.86e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1816752	0.805	rs61614647	chr13:25015967	C/T	cg02811702	chr13:24901961	NA	0.46	8.05	0.36	8.26e-15	Obesity-related traits;
LUAD	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.36e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	17.08	0.64	3.89e-50	Exhaled nitric oxide output;
LUAD	cis	rs240764	0.619	rs9399656	chr6:101127124	C/T	cg09795085	chr6:101329169	ASCC3	0.39	6.36	0.3	5.4e-10	Neuroticism;
LUAD	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg11494091	chr17:61959527	GH2	0.75	18.53	0.67	1.57e-56	Prudent dietary pattern;
LUAD	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg12311346	chr5:56204834	C5orf35	-0.93	-13.82	-0.56	4.05e-36	Initial pursuit acceleration;
LUAD	cis	rs701145	0.878	rs433903	chr3:153980130	A/G	cg17054900	chr3:154042577	DHX36	0.63	6.88	0.32	2.11e-11	Coronary artery disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08369580	chr5:149828673	RPS14	-0.39	-6.62	-0.31	1.09e-10	Cancer;
LUAD	cis	rs4148087	0.860	rs9976024	chr21:43641657	A/G	cg08841829	chr21:43638893	ABCG1	0.56	7.72	0.35	8.3e-14	Eating disorder in bipolar disorder;
LUAD	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg19077165	chr18:44547161	KATNAL2	-0.42	-7.33	-0.34	1.15e-12	Personality dimensions;
LUAD	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg04586622	chr2:25135609	ADCY3	0.38	8.57	0.38	1.92e-16	Body mass index in non-asthmatics;
LUAD	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg18138036	chr10:133769891	PPP2R2D	0.41	6.47	0.3	2.65e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg24733560	chr20:60626293	TAF4	-0.43	-7.25	-0.33	1.97e-12	Body mass index;
LUAD	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg10802521	chr3:52805072	NEK4	-0.47	-7.96	-0.36	1.65e-14	Bipolar disorder;
LUAD	cis	rs2999052	0.526	rs2075402	chr3:127784262	C/T	cg00340326	chr3:127988088	EEFSEC	0.3	6.38	0.3	4.69e-10	Hypospadias;
LUAD	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.39	-6.72	-0.31	5.91e-11	Longevity;Endometriosis;
LUAD	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg26384229	chr12:38710491	ALG10B	0.45	7.31	0.33	1.36e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7107174	1.000	rs9651769	chr11:77996166	T/C	cg19901956	chr11:77921274	USP35	-0.53	-6.82	-0.31	3.1e-11	Testicular germ cell tumor;
LUAD	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg08514558	chr10:81106712	PPIF	0.51	10.15	0.44	8.59e-22	Height;
LUAD	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.05	0.36	8.26e-15	Breast cancer;
LUAD	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg20607287	chr7:12443886	VWDE	-0.54	-6.83	-0.32	3.03e-11	Coronary artery disease;
LUAD	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg19077165	chr18:44547161	KATNAL2	0.47	8.16	0.37	3.74e-15	Personality dimensions;
LUAD	cis	rs4006360	0.525	rs72625956	chr17:39237517	T/C	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.14	0.37	4.35e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg27432699	chr2:27873401	GPN1	0.56	9.94	0.44	4.53e-21	Oral cavity cancer;
LUAD	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg00757033	chr12:89920650	WDR51B	0.69	12.14	0.51	2.56e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg11062466	chr8:58055876	NA	0.45	6.43	0.3	3.52e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg23281280	chr6:28129359	ZNF389	0.46	6.57	0.3	1.45e-10	Depression;
LUAD	cis	rs17152411	1.000	rs17152433	chr10:126670356	G/A	cg07906193	chr10:126599966	NA	0.44	6.53	0.3	1.95e-10	Height;
LUAD	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg14582100	chr15:45693742	SPATA5L1	0.64	12.48	0.52	1.23e-30	Homoarginine levels;
LUAD	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-11.78	-0.5	6.48e-28	Bipolar disorder;
LUAD	cis	rs1983170	0.736	rs13447479	chr1:91970464	T/G	cg25838465	chr1:92012736	NA	0.52	6.59	0.3	1.35e-10	Eosinophil percentage of white cells;
LUAD	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg21385522	chr1:16154831	NA	-0.95	-15.48	-0.6	3.69e-43	Dilated cardiomyopathy;
LUAD	cis	rs2131877	0.573	rs58370605	chr3:194842877	A/G	cg25921813	chr3:194797138	C3orf21	0.35	6.51	0.3	2.19e-10	Non-small cell lung cancer;
LUAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg08027265	chr7:2291960	NA	-0.43	-7.21	-0.33	2.54e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg12935359	chr14:103987150	CKB	-0.46	-7.41	-0.34	6.86e-13	Body mass index;
LUAD	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg00666640	chr1:248458726	OR2T12	0.31	7.6	0.35	1.94e-13	Common traits (Other);
LUAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg13397359	chr6:42928475	GNMT	0.6	11.14	0.48	1.91e-25	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg02951883	chr7:2050386	MAD1L1	0.84	15.42	0.6	7.17e-43	Bipolar disorder and schizophrenia;
LUAD	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg22166914	chr1:53195759	ZYG11B	0.4	6.66	0.31	8.55e-11	Monocyte count;
LUAD	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg23172400	chr8:95962367	TP53INP1	-0.37	-8.69	-0.39	8.27e-17	Type 2 diabetes;
LUAD	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg20307385	chr11:47447363	PSMC3	0.65	11.06	0.47	3.93e-25	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg08132940	chr7:1081526	C7orf50	-0.69	-9.67	-0.43	4.01e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg00933542	chr6:150070202	PCMT1	0.45	9.52	0.42	1.34e-19	Lung cancer;
LUAD	cis	rs250585	1.000	rs3785408	chr16:23519986	T/C	cg00143387	chr16:23521605	GGA2	-0.69	-8.07	-0.37	7.61e-15	Egg allergy;
LUAD	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg01802117	chr1:53393560	SCP2	0.33	6.47	0.3	2.68e-10	Monocyte count;
LUAD	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4523957	0.928	rs6502155	chr17:2176964	A/G	cg16513277	chr17:2031491	SMG6	-0.77	-14.53	-0.58	4.36e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-8.16	-0.37	3.79e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6494488	0.500	rs72741373	chr15:64800861	C/T	cg08069370	chr15:64387884	SNX1	-0.75	-6.73	-0.31	5.69e-11	Coronary artery disease;
LUAD	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg09365446	chr1:150670422	GOLPH3L	0.64	11.28	0.48	5.37e-26	Melanoma;
LUAD	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg26597838	chr10:835615	NA	1.05	15.98	0.61	2.69e-45	Eosinophil percentage of granulocytes;
LUAD	trans	rs2735413	0.918	rs36068555	chr16:78077082	G/A	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg22166914	chr1:53195759	ZYG11B	0.45	7.63	0.35	1.52e-13	Monocyte count;
LUAD	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs612683	0.664	rs6702766	chr1:100997635	A/G	cg09408571	chr1:101003634	GPR88	-0.32	-6.36	-0.3	5.32e-10	Breast cancer;
LUAD	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg11578532	chr1:161008127	TSTD1	0.42	8.98	0.4	8.99e-18	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg00280220	chr17:61926910	NA	-0.35	-6.67	-0.31	7.87e-11	Prudent dietary pattern;
LUAD	cis	rs11048434	0.736	rs12812913	chr12:9110836	C/G	cg23795048	chr12:9217529	LOC144571	0.42	7.77	0.35	5.88e-14	Sjögren's syndrome;
LUAD	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg19318889	chr4:1322082	MAEA	0.57	9.71	0.43	3.01e-20	Longevity;
LUAD	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg18477163	chr1:228402036	OBSCN	-0.36	-7.27	-0.33	1.74e-12	Diastolic blood pressure;
LUAD	cis	rs4604732	0.631	rs34330532	chr1:247626844	G/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg08132940	chr7:1081526	C7orf50	-0.76	-10.14	-0.44	9.04e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg09904177	chr6:26538194	HMGN4	-0.43	-7.19	-0.33	3.05e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg24324837	chr19:49891574	CCDC155	0.55	8.18	0.37	3.3e-15	Multiple sclerosis;
LUAD	cis	rs3761847	0.651	rs1323472	chr9:123826335	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	6.45	0.3	3.06e-10	Rheumatoid arthritis;
LUAD	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg09998033	chr7:158218633	PTPRN2	-0.48	-8.56	-0.38	2.08e-16	Obesity-related traits;
LUAD	cis	rs7582720	1.000	rs72928613	chr2:203839628	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.56	0.42	9.63e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg08501292	chr6:25962987	TRIM38	0.71	6.47	0.3	2.66e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg02269571	chr22:50332266	NA	0.59	8.96	0.4	1.05e-17	Schizophrenia;
LUAD	cis	rs4862307	0.688	rs6552741	chr4:184990335	A/G	cg06737308	chr4:185021514	ENPP6	-0.55	-8.94	-0.4	1.2e-17	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs12049351	0.613	rs12037690	chr1:229642385	G/A	cg11742688	chr1:229674241	ABCB10	-0.41	-6.5	-0.3	2.32e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg16060761	chr17:80687452	NA	-0.57	-8.07	-0.37	7.28e-15	Glycated hemoglobin levels;
LUAD	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-7.32	-0.34	1.22e-12	Longevity;Endometriosis;
LUAD	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg01324343	chr3:183735012	ABCC5	0.91	24.4	0.76	1.04e-82	Anterior chamber depth;
LUAD	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg17724175	chr1:150552817	MCL1	-0.37	-9.38	-0.41	4.13e-19	Tonsillectomy;
LUAD	cis	rs2425143	1.000	rs17093027	chr20:34319118	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.43	-0.34	6.03e-13	Blood protein levels;
LUAD	cis	rs12612619	0.724	rs7355650	chr2:27245475	T/C	cg00617064	chr2:27272375	NA	0.35	6.5	0.3	2.21e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs35205176	0.644	rs13224372	chr7:51578207	A/G	cg20478239	chr7:51544475	NA	-0.34	-6.58	-0.3	1.36e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9863	0.828	rs952632	chr12:124469738	A/G	cg17723958	chr12:124429295	CCDC92	-0.39	-6.47	-0.3	2.78e-10	White blood cell count;
LUAD	cis	rs6969780	0.915	rs12666926	chr7:27189561	A/G	cg05579037	chr7:27184853	NA	0.51	6.79	0.31	3.79e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg02927949	chr13:103426033	C13orf27	-0.71	-6.64	-0.31	9.67e-11	Type 2 diabetes;
LUAD	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg25985355	chr7:65971099	NA	-0.51	-6.41	-0.3	3.8e-10	Diabetic kidney disease;
LUAD	cis	rs2456568	0.503	rs11020603	chr11:93667439	A/G	cg26875233	chr11:93583750	C11orf90	0.41	8.77	0.39	4.46e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs4343996	0.870	rs6974075	chr7:3392071	A/G	cg21248987	chr7:3385318	SDK1	-0.37	-6.91	-0.32	1.75e-11	Motion sickness;
LUAD	trans	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg18187862	chr3:45730750	SACM1L	-0.5	-7.44	-0.34	5.83e-13	Primary sclerosing cholangitis;
LUAD	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg05425664	chr17:57184151	TRIM37	-0.43	-7.64	-0.35	1.43e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg26384229	chr12:38710491	ALG10B	0.48	7.83	0.36	3.83e-14	Morning vs. evening chronotype;
LUAD	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg26513180	chr16:89883248	FANCA	0.69	12.88	0.53	3.04e-32	Vitiligo;
LUAD	cis	rs11098699	0.769	rs11726870	chr4:124229175	A/G	cg09941581	chr4:124220074	SPATA5	0.46	7.31	0.33	1.33e-12	Mosquito bite size;
LUAD	trans	rs12517041	0.935	rs13152937	chr5:23304368	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.57	-0.3	1.47e-10	Calcium levels;
LUAD	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg07212818	chr11:638076	DRD4	-0.45	-6.79	-0.31	3.82e-11	Systemic lupus erythematosus;
LUAD	cis	rs4243830	0.677	rs1556035	chr1:6579607	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.51	-6.39	-0.3	4.32e-10	Body mass index;
LUAD	cis	rs9469913	0.799	rs2492859	chr6:34645266	A/G	cg14254433	chr6:34482411	PACSIN1	-0.43	-6.83	-0.32	2.93e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs732716	0.819	rs12459919	chr19:4434503	C/T	cg21934504	chr19:4445085	UBXN6	0.44	7.25	0.33	1.96e-12	Mean corpuscular volume;
LUAD	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg12935359	chr14:103987150	CKB	-0.48	-8.57	-0.38	1.89e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06873352	chr17:61820015	STRADA	0.81	17.69	0.65	7.7e-53	Prudent dietary pattern;
LUAD	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg23750338	chr8:142222470	SLC45A4	0.61	13.74	0.56	9.16e-36	Immature fraction of reticulocytes;
LUAD	cis	rs1832871	0.672	rs9456289	chr6:158740347	G/A	cg07165851	chr6:158734300	TULP4	0.72	11.08	0.47	3.21e-25	Height;
LUAD	cis	rs4006360	0.551	rs2320193	chr17:39243414	T/C	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.27	0.37	1.75e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg09436375	chr6:42928200	GNMT	-0.3	-8.55	-0.38	2.35e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02048674	chr19:49991517	RPL13AP5;RPL13A	0.58	7.26	0.33	1.81e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg02228675	chr17:40259724	DHX58	-0.42	-6.98	-0.32	1.15e-11	Fibrinogen levels;
LUAD	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg00717180	chr2:96193071	NA	-0.44	-8.38	-0.38	7.78e-16	HDL cholesterol;
LUAD	cis	rs938554	0.577	rs4591605	chr4:10002719	T/C	cg02734326	chr4:10020555	SLC2A9	0.47	6.65	0.31	9.15e-11	Blood metabolite levels;
LUAD	cis	rs9473147	0.516	rs7749167	chr6:47493940	G/A	cg20196966	chr6:47445060	CD2AP	0.45	7.08	0.33	6.11e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs758324	0.947	rs559971	chr5:131316164	A/G	cg06307176	chr5:131281290	NA	0.49	7.83	0.36	3.86e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.92	-0.5	1.99e-28	Bipolar disorder;
LUAD	cis	rs12545109	0.800	rs2118261	chr8:57393286	A/G	cg21220214	chr8:57350948	NA	0.59	8.7	0.39	7.56e-17	Obesity-related traits;
LUAD	cis	rs72928364	1.000	rs2576387	chr3:100629426	C/T	cg10123952	chr3:100791384	NA	-0.56	-7.09	-0.33	5.6e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1953600	0.870	rs2236557	chr10:81923961	A/G	cg00277334	chr10:82204260	NA	0.4	6.82	0.31	3.12e-11	Sarcoidosis;
LUAD	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11644478	chr21:40555479	PSMG1	-0.4	-6.61	-0.31	1.13e-10	Menarche (age at onset);
LUAD	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.6	-0.52	3.83e-31	Monocyte count;
LUAD	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg03983476	chr2:10830698	NOL10	-0.47	-8.19	-0.37	3.04e-15	Prostate cancer;
LUAD	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg26958806	chr6:27640298	NA	0.6	7.02	0.32	8.85e-12	Depression;
LUAD	cis	rs10781543	0.817	rs1128874	chr9:139323424	T/C	cg14019695	chr9:139328340	INPP5E	0.55	10.77	0.46	4.74e-24	Monocyte percentage of white cells;
LUAD	cis	rs240764	0.658	rs9322181	chr6:101221630	C/A	cg09795085	chr6:101329169	ASCC3	-0.43	-7.48	-0.34	4.29e-13	Neuroticism;
LUAD	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.72	-0.31	5.85e-11	Joint mobility (Beighton score);
LUAD	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18876405	chr7:65276391	NA	-0.44	-7.06	-0.32	7.09e-12	Aortic root size;
LUAD	cis	rs7707921	0.881	rs112413913	chr5:81359709	A/G	cg15871215	chr5:81402204	ATG10	-0.7	-9.99	-0.44	3.1e-21	Breast cancer;
LUAD	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg18240062	chr17:79603768	NPLOC4	-0.36	-6.35	-0.3	5.42e-10	Eye color traits;
LUAD	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg17147758	chr8:6949321	NA	-0.5	-8.74	-0.39	5.42e-17	Blood pressure (smoking interaction);
LUAD	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg09365446	chr1:150670422	GOLPH3L	-0.43	-7.24	-0.33	2.14e-12	Tonsillectomy;
LUAD	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg08859206	chr1:53392774	SCP2	-0.6	-10.79	-0.46	3.96e-24	Monocyte count;
LUAD	cis	rs7809799	0.826	rs73159509	chr7:98885462	C/T	cg12290671	chr7:99195819	NA	-0.79	-6.53	-0.3	1.87e-10	Ulcerative colitis;
LUAD	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg19678392	chr7:94953810	PON1	-0.59	-8.3	-0.37	1.38e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg02508848	chr16:68573721	ZFP90	-0.42	-6.57	-0.3	1.44e-10	Ulcerative colitis;
LUAD	cis	rs7187994	0.609	rs7197496	chr16:84742830	C/T	cg07647771	chr16:84786436	USP10	0.27	7.57	0.35	2.32e-13	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs67311347	0.544	rs1454492	chr3:40352884	C/T	cg09455208	chr3:40491958	NA	0.51	10.81	0.47	3.22e-24	Renal cell carcinoma;
LUAD	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	12.45	0.52	1.63e-30	Monocyte percentage of white cells;
LUAD	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg18811423	chr2:55921094	PNPT1	0.55	9.21	0.41	1.58e-18	Metabolic syndrome;
LUAD	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg15017067	chr4:17643749	FAM184B	-0.37	-6.98	-0.32	1.12e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9322817	0.691	rs2486138	chr6:105290223	G/A	cg02098413	chr6:105308735	HACE1	0.42	9.01	0.4	7.42e-18	Thyroid stimulating hormone;
LUAD	cis	rs654950	0.776	rs2759254	chr1:42035683	G/C	cg06885757	chr1:42089581	HIVEP3	-0.49	-10.87	-0.47	1.9e-24	Airway imaging phenotypes;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg14826764	chr17:37729812	NA	-0.39	-6.64	-0.31	9.61e-11	Schizophrenia;
LUAD	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg06453172	chr10:134556979	INPP5A	-0.68	-9.95	-0.44	4.28e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.88	13.33	0.54	4.17e-34	Chronic sinus infection;
LUAD	cis	rs9296092	0.538	rs62405942	chr6:33517346	G/A	cg13560919	chr6:33536144	NA	-0.88	-16.45	-0.62	2.23e-47	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	trans	rs4650994	0.525	rs4316329	chr1:178509333	C/T	cg05059571	chr16:84539110	KIAA1609	-0.73	-13.28	-0.54	6.97e-34	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs7394190	1.000	rs7394190	chr10:75421648	G/A	cg04833713	chr10:74871078	NUDT13	0.36	6.58	0.3	1.4e-10	Incident atrial fibrillation;
LUAD	cis	rs9878978	0.964	rs11707598	chr3:2478957	T/C	cg21928760	chr3:2462534	CNTN4	-0.35	-6.98	-0.32	1.14e-11	Blood pressure (smoking interaction);
LUAD	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg15704280	chr7:45808275	SEPT13	0.64	8.17	0.37	3.52e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg26304593	chr6:42947056	PEX6	-0.46	-7.67	-0.35	1.22e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs713587	0.875	rs6746013	chr2:25143649	C/G	cg04586622	chr2:25135609	ADCY3	0.32	7.04	0.32	7.89e-12	Body mass index in non-asthmatics;
LUAD	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg14345882	chr6:26364793	BTN3A2	0.7	7.09	0.33	5.67e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11771526	0.681	rs78534662	chr7:32406022	A/T	cg27532318	chr7:32358331	NA	0.67	7.09	0.33	5.51e-12	Body mass index;
LUAD	cis	rs12681287	1.000	rs7833786	chr8:87271374	C/T	cg27223183	chr8:87520930	FAM82B	0.59	8.51	0.38	2.96e-16	Caudate activity during reward;
LUAD	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.42	-7.36	-0.34	9.93e-13	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg05313129	chr8:58192883	C8orf71	-0.57	-8.5	-0.38	3.25e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs758324	0.947	rs476428	chr5:131301615	G/A	cg06307176	chr5:131281290	NA	-0.51	-7.9	-0.36	2.39e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7474896	0.537	rs2749588	chr10:38269457	C/G	cg25427524	chr10:38739819	LOC399744	-0.6	-8.57	-0.38	1.96e-16	Obesity (extreme);
LUAD	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg02782426	chr3:40428986	ENTPD3	-0.31	-6.64	-0.31	9.88e-11	Renal cell carcinoma;
LUAD	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg24733560	chr20:60626293	TAF4	0.47	8.31	0.37	1.28e-15	Body mass index;
LUAD	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg13511324	chr14:104056883	C14orf153	0.26	6.59	0.31	1.29e-10	Reticulocyte count;
LUAD	cis	rs2235649	0.592	rs7197113	chr16:1969483	G/A	cg08610935	chr16:1836813	NUBP2	-0.5	-7.38	-0.34	8.25e-13	Blood metabolite levels;
LUAD	cis	rs10992471	0.603	rs10118939	chr9:95293641	C/G	cg14631576	chr9:95140430	CENPP	-0.51	-10.23	-0.45	4.16e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs5756813	0.754	rs8136757	chr22:38185971	A/G	cg06521852	chr22:38141419	TRIOBP	0.47	9.05	0.4	5.34e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg07936489	chr17:37558343	FBXL20	0.45	7.15	0.33	3.8e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs6484504	0.576	rs176373	chr11:31136026	G/T	cg14844989	chr11:31128820	NA	-0.45	-8.21	-0.37	2.72e-15	Red blood cell count;
LUAD	cis	rs877282	0.853	rs7079299	chr10:756455	A/G	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-12.68	-0.52	1.89e-31	Mean corpuscular volume;
LUAD	cis	rs11958404	0.932	rs112993559	chr5:157414712	A/C	cg05962755	chr5:157440814	NA	0.53	7.63	0.35	1.5700000000000001e-13	IgG glycosylation;
LUAD	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.73	-0.58	6.05e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2274273	0.774	rs17128440	chr14:55861912	C/T	cg04306507	chr14:55594613	LGALS3	0.42	8.88	0.4	1.92e-17	Protein biomarker;
LUAD	cis	rs4911259	0.533	rs6058931	chr20:31471012	C/T	cg13636640	chr20:31349939	DNMT3B	-0.58	-9.39	-0.42	3.63e-19	Inflammatory bowel disease;
LUAD	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg17410650	chr12:54324560	NA	-0.53	-10.43	-0.45	7.99e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs12893668	0.628	rs57072546	chr14:104063723	T/C	cg13511324	chr14:104056883	C14orf153	0.27	6.67	0.31	8.23e-11	Reticulocyte count;
LUAD	cis	rs1595825	0.945	rs73058818	chr2:198862600	C/T	cg11031976	chr2:198649780	BOLL	-0.45	-6.8	-0.31	3.61e-11	Ulcerative colitis;
LUAD	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.76	0.31	4.45e-11	Parkinson's disease;
LUAD	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11644478	chr21:40555479	PSMG1	0.69	11.36	0.48	2.69e-26	Cognitive function;
LUAD	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06028808	chr11:68637592	NA	0.49	8.06	0.36	8.15e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24531977	chr5:56204891	C5orf35	-0.98	-15.14	-0.59	1.06e-41	Initial pursuit acceleration;
LUAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg16031515	chr1:205743344	RAB7L1	-0.37	-7.28	-0.33	1.6e-12	Menarche (age at onset);
LUAD	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.45	0.34	5.16e-13	Bipolar disorder;
LUAD	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg14345882	chr6:26364793	BTN3A2	-0.53	-6.36	-0.3	5.32e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg04944784	chr2:26401820	FAM59B	0.89	13.09	0.54	4.34e-33	Gut microbiome composition (summer);
LUAD	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg08132940	chr7:1081526	C7orf50	-0.78	-10.58	-0.46	2.29e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg03929089	chr4:120376271	NA	-0.98	-19.69	-0.69	9.88e-62	Height;
LUAD	cis	rs73206853	0.841	rs57726737	chr12:110843701	A/G	cg12870014	chr12:110450643	ANKRD13A	0.63	6.82	0.31	3.22e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg08280861	chr8:58055591	NA	0.71	8.58	0.39	1.81e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6066835	1.000	rs6095270	chr20:47356062	T/C	cg18078177	chr20:47281410	PREX1	0.72	6.57	0.3	1.51e-10	Multiple myeloma;
LUAD	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg00898013	chr13:113819073	PROZ	-0.62	-11.35	-0.48	3.01e-26	Platelet distribution width;
LUAD	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg12573674	chr2:1569213	NA	-0.56	-8.3	-0.37	1.39e-15	IgG glycosylation;
LUAD	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg05754148	chr16:3507555	NAT15	0.81	10.72	0.46	6.8e-24	Tuberculosis;
LUAD	cis	rs13315871	0.929	rs9871725	chr3:58292525	T/G	cg20936604	chr3:58311152	NA	-0.75	-7.61	-0.35	1.82e-13	Cholesterol, total;
LUAD	cis	rs7107174	1.000	rs10899456	chr11:78000155	C/G	cg02023728	chr11:77925099	USP35	0.47	7.46	0.34	4.8e-13	Testicular germ cell tumor;
LUAD	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg17724175	chr1:150552817	MCL1	0.39	9.43	0.42	2.64e-19	Tonsillectomy;
LUAD	cis	rs6594713	0.819	rs13180522	chr5:112726022	A/G	cg12552261	chr5:112820674	MCC	0.52	8.12	0.37	5.31e-15	Brain cytoarchitecture;
LUAD	cis	rs1232027	0.656	rs836806	chr5:79974983	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.77	-0.31	4.44e-11	Huntington's disease progression;
LUAD	cis	rs1639906	0.965	rs1639908	chr7:2230644	C/G	cg18044113	chr7:2236405	MAD1L1	0.39	7.63	0.35	1.62e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8044868	1.000	rs8044868	chr16:72162102	C/T	cg23815491	chr16:72088622	HP	0.41	7.43	0.34	5.96e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs10465746	0.967	rs12748268	chr1:84374438	T/C	cg10977910	chr1:84465055	TTLL7	0.49	8.02	0.36	1.06e-14	Obesity-related traits;
LUAD	cis	rs870825	0.860	rs62339895	chr4:185598681	A/G	cg04058563	chr4:185651563	MLF1IP	-0.8	-11.54	-0.49	5.92e-27	Blood protein levels;
LUAD	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg07537917	chr2:241836409	C2orf54	-0.3	-8.47	-0.38	4.01e-16	Urinary metabolites;
LUAD	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg12310025	chr6:25882481	NA	-0.59	-9.64	-0.42	5.14e-20	Blood metabolite levels;
LUAD	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg03609598	chr5:56110824	MAP3K1	-0.67	-8.93	-0.4	1.35e-17	Type 2 diabetes;
LUAD	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg15467112	chr14:75489610	MLH3	-0.35	-6.4	-0.3	4.14e-10	Height;
LUAD	trans	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.38	-0.38	7.69e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3849570	1.000	rs2290081	chr3:81810725	C/T	cg07356753	chr3:81810745	GBE1	-0.7	-12.36	-0.52	3.65e-30	Waist circumference;Body mass index;
LUAD	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg11707310	chr1:2537719	MMEL1	0.4	8.48	0.38	3.84e-16	Ulcerative colitis;
LUAD	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg15704280	chr7:45808275	SEPT13	-0.65	-9.97	-0.44	3.52e-21	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg11814155	chr7:99998594	ZCWPW1	0.42	7.21	0.33	2.59e-12	Platelet count;
LUAD	cis	rs7927771	0.524	rs12785949	chr11:47729770	C/T	cg18512352	chr11:47633146	NA	0.37	6.52	0.3	1.98e-10	Subjective well-being;
LUAD	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg03929089	chr4:120376271	NA	-0.85	-15.41	-0.6	7.68e-43	Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg08213375	chr14:104286397	PPP1R13B	0.28	7.22	0.33	2.41e-12	Schizophrenia;
LUAD	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg04455712	chr21:45112962	RRP1B	0.48	9.81	0.43	1.34e-20	Mean corpuscular volume;
LUAD	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.9	9.55	0.42	1.06e-19	Initial pursuit acceleration;
LUAD	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg01028140	chr2:1542097	TPO	-0.42	-6.99	-0.32	1.08e-11	IgG glycosylation;
LUAD	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg09184832	chr6:79620586	NA	-0.52	-9.72	-0.43	2.78e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg02527881	chr3:46936655	PTH1R	0.35	6.37	0.3	4.99e-10	Colorectal cancer;
LUAD	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg13393036	chr8:95962371	TP53INP1	-0.33	-7.51	-0.34	3.44e-13	Type 2 diabetes;
LUAD	cis	rs6494488	0.500	rs72742928	chr15:64868480	T/A	cg08069370	chr15:64387884	SNX1	-0.75	-6.59	-0.3	1.34e-10	Coronary artery disease;
LUAD	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg06873352	chr17:61820015	STRADA	0.43	7.2	0.33	2.8e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4908760	0.811	rs301802	chr1:8497307	A/T	cg01447281	chr1:8482689	RERE	-0.39	-8.1	-0.37	6.01e-15	Vitiligo;
LUAD	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg15485101	chr11:133734466	NA	0.37	7.96	0.36	1.62e-14	Childhood ear infection;
LUAD	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg05991184	chr2:219186017	PNKD	0.37	7.01	0.32	9.56e-12	Colorectal cancer;
LUAD	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg25457927	chr22:38595422	NA	-0.53	-13.87	-0.56	2.48e-36	Cutaneous nevi;
LUAD	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.63	-0.42	5.64e-20	Schizophrenia;
LUAD	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg18404041	chr3:52824283	ITIH1	0.43	7.95	0.36	1.74e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11650175	1.000	rs11650175	chr17:63743650	T/C	cg07283582	chr17:63770753	CCDC46	0.39	7.37	0.34	8.78e-13	Chin dimples;
LUAD	cis	rs68170813	0.559	rs11761181	chr7:106954879	T/C	cg23024343	chr7:107201750	COG5	0.48	6.9	0.32	1.9e-11	Coronary artery disease;
LUAD	trans	rs11039798	1.000	rs10769383	chr11:48592510	C/G	cg15704280	chr7:45808275	SEPT13	0.58	7.08	0.33	5.99e-12	Axial length;
LUAD	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg04756594	chr16:24857601	SLC5A11	0.51	10.1	0.44	1.25e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs7903847	0.642	rs11189163	chr10:99121361	C/T	cg20016023	chr10:99160130	RRP12	-0.32	-6.99	-0.32	1.08e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7587476	0.682	rs13009646	chr2:215691259	T/A	cg04004882	chr2:215674386	BARD1	0.52	6.61	0.31	1.17e-10	Neuroblastoma;
LUAD	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg23815491	chr16:72088622	HP	0.59	11.16	0.48	1.61e-25	Fibrinogen levels;
LUAD	cis	rs1448094	0.836	rs7484454	chr12:86425576	A/G	cg18827107	chr12:86230957	RASSF9	-0.45	-8.23	-0.37	2.32e-15	Major depressive disorder;
LUAD	cis	rs10193935	0.786	rs10178087	chr2:42409631	C/A	cg27598129	chr2:42591480	NA	-0.76	-10.02	-0.44	2.5e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11890956	chr21:40555474	PSMG1	0.79	13.76	0.56	7.13e-36	Cognitive function;
LUAD	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.55	9.8	0.43	1.46e-20	Eosinophil percentage of white cells;
LUAD	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg09835421	chr16:68378352	PRMT7	-0.56	-6.98	-0.32	1.16e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg18016565	chr1:150552671	MCL1	0.41	7.55	0.34	2.78e-13	Tonsillectomy;
LUAD	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg13010199	chr12:38710504	ALG10B	0.38	6.35	0.3	5.51e-10	Bladder cancer;
LUAD	cis	rs7100689	0.826	rs7098414	chr10:82214586	A/C	cg01528321	chr10:82214614	TSPAN14	0.91	13.86	0.56	2.67e-36	Post bronchodilator FEV1;
LUAD	cis	rs8077889	0.719	rs4793033	chr17:41879627	C/T	cg26893861	chr17:41843967	DUSP3	1.11	23.72	0.76	1e-79	Triglycerides;
LUAD	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	10.06	0.44	1.69e-21	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-9.11	-0.41	3.21e-18	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg18180107	chr4:99064573	C4orf37	-0.41	-6.67	-0.31	8.09e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg13319975	chr6:146136371	FBXO30	-0.62	-10.98	-0.47	7.85e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.61	6.9	0.32	1.96e-11	Crohn's disease;
LUAD	cis	rs9902453	0.967	rs9900911	chr17:28330280	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-9.05	-0.4	5.28e-18	Coffee consumption (cups per day);
LUAD	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg21475434	chr5:93447410	FAM172A	0.58	7.29	0.33	1.58e-12	Diabetic retinopathy;
LUAD	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg09455208	chr3:40491958	NA	-0.63	-13.53	-0.55	6.56e-35	Renal cell carcinoma;
LUAD	trans	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.46	-0.34	4.98e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs7395662	1.000	rs1605364	chr11:48684843	G/T	cg00717180	chr2:96193071	NA	-0.35	-6.49	-0.3	2.47e-10	HDL cholesterol;
LUAD	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg19635926	chr16:89946313	TCF25	0.74	6.93	0.32	1.62e-11	Skin colour saturation;
LUAD	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-9.66	-0.43	4.4e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7789940	0.904	rs6948661	chr7:75961647	T/C	cg10167463	chr7:75959203	YWHAG	-0.71	-12.89	-0.53	2.6e-32	Multiple sclerosis;
LUAD	cis	rs4919694	1.000	rs12252500	chr10:104794984	G/C	cg04362960	chr10:104952993	NT5C2	0.76	8.04	0.36	8.8e-15	Arsenic metabolism;
LUAD	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs45430	1.000	rs408825	chr21:42743496	A/G	cg06102954	chr21:42741788	MX2	-0.31	-6.55	-0.3	1.62e-10	Melanoma;
LUAD	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg03684893	chr10:554711	DIP2C	-0.52	-9.6	-0.42	7.17e-20	Psychosis in Alzheimer's disease;
LUAD	cis	rs7010267	0.740	rs11573885	chr8:119949165	T/C	cg01975934	chr8:119970761	NA	0.36	6.91	0.32	1.82e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.66	-0.31	8.51e-11	Crohn's disease;
LUAD	cis	rs6840360	0.571	rs1822346	chr4:152525303	G/C	cg22705602	chr4:152727874	NA	-0.38	-6.68	-0.31	7.66e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg21963583	chr11:68658836	MRPL21	0.65	11.64	0.49	2.34e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs12545109	0.800	rs1837620	chr8:57399473	C/A	cg09654669	chr8:57350985	NA	-0.66	-9.7	-0.43	3.08e-20	Obesity-related traits;
LUAD	trans	rs2544390	1.000	rs2673172	chr2:170204800	A/C	cg17397028	chr4:91048584	FAM190A	-0.36	-6.35	-0.3	5.43e-10	Urate levels;
LUAD	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg04225089	chr17:73874465	TRIM47	-0.51	-6.44	-0.3	3.25e-10	Psoriasis;
LUAD	cis	rs367943	0.698	rs2195373	chr5:112998798	G/C	cg12552261	chr5:112820674	MCC	0.5	9.0	0.4	7.43e-18	Type 2 diabetes;
LUAD	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg00316803	chr15:76480434	C15orf27	-0.36	-6.5	-0.3	2.2e-10	Blood metabolite levels;
LUAD	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg23583168	chr7:148888333	NA	-1.04	-24.48	-0.77	4.51e-83	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg19717773	chr7:2847554	GNA12	-0.46	-7.75	-0.35	6.71e-14	Height;
LUAD	trans	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg07817883	chr1:32538562	TMEM39B	1.49	12.49	0.52	1.1e-30	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg15485101	chr11:133734466	NA	0.34	7.58	0.35	2.15e-13	Childhood ear infection;
LUAD	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.8	-0.31	3.68e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6906287	0.647	rs6938226	chr6:118852561	C/A	cg21191810	chr6:118973309	C6orf204	0.49	9.47	0.42	1.96e-19	Electrocardiographic conduction measures;
LUAD	cis	rs6840360	0.571	rs2165789	chr4:152510130	A/T	cg22705602	chr4:152727874	NA	-0.43	-7.39	-0.34	7.68e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg00757033	chr12:89920650	WDR51B	0.71	12.27	0.51	8.07e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg11494091	chr17:61959527	GH2	0.45	8.72	0.39	6.5e-17	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg06608945	chr2:219082296	ARPC2	0.47	8.03	0.36	9.94e-15	Colorectal cancer;
LUAD	cis	rs7213347	0.707	rs216196	chr17:2202943	T/C	cg02569219	chr17:2266849	SGSM2	0.45	7.25	0.33	2.06e-12	Total body bone mineral density;
LUAD	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-10.64	-0.46	1.43e-23	Gut microbiome composition (summer);
LUAD	cis	rs889398	0.742	rs12446197	chr16:69854869	A/G	cg00738113	chr16:70207722	CLEC18C	0.36	7.16	0.33	3.5e-12	Body mass index;
LUAD	cis	rs3806843	0.547	rs246065	chr5:140323638	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.67	-0.31	8.11e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs225245	0.791	rs8067294	chr17:34027964	T/C	cg05299278	chr17:33885742	SLFN14	0.5	11.24	0.48	7.65e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg27494647	chr7:150038898	RARRES2	0.53	9.1	0.4	3.69e-18	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs208520	0.690	rs207094	chr6:66799009	G/A	cg07460842	chr6:66804631	NA	-1.09	-17.03	-0.64	6.56e-50	Exhaled nitric oxide output;
LUAD	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg18132916	chr6:79620363	NA	-0.45	-7.92	-0.36	2.15e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg22491629	chr6:157744540	C6orf35	-0.82	-9.53	-0.42	1.21e-19	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.49	10.2	0.44	5.25e-22	Monocyte percentage of white cells;
LUAD	cis	rs478304	0.593	rs12576766	chr11:65488556	C/T	cg17480646	chr11:65405466	SIPA1	-0.44	-6.43	-0.3	3.48e-10	Acne (severe);
LUAD	trans	rs17689437	0.671	rs1728790	chr16:68596308	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.44	-7.12	-0.33	4.66e-12	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LUAD	cis	rs1509123	0.609	rs117349613	chr17:6719666	T/C	cg12642237	chr17:6703447	TEKT1	-0.46	-6.68	-0.31	7.65e-11	Blood metabolite levels;
LUAD	cis	rs62229266	0.804	rs2255858	chr21:37412752	T/C	cg12218747	chr21:37451666	NA	-0.48	-8.25	-0.37	2.01e-15	Mitral valve prolapse;
LUAD	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg01236616	chr12:121019343	POP5	1.29	19.09	0.68	4.89e-59	Type 1 diabetes nephropathy;
LUAD	cis	rs1232027	0.666	rs1650710	chr5:79936161	T/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs9826463	0.527	rs6780665	chr3:142063689	G/A	cg20824294	chr3:142316082	PLS1	0.41	7.08	0.33	5.96e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg00204512	chr16:28754710	NA	0.31	6.55	0.3	1.7e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg23000734	chr10:126850823	CTBP2	-0.59	-12.41	-0.52	2.25e-30	Menarche (age at onset);
LUAD	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg10544611	chr16:67998164	SLC12A4	-0.63	-7.37	-0.34	9.29e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10802521	chr3:52805072	NEK4	-0.62	-11.08	-0.47	3.05e-25	Electroencephalogram traits;
LUAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	0.4	6.97	0.32	1.19e-11	Renal function-related traits (BUN);
LUAD	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs4713675	0.584	rs749847	chr6:33665001	G/C	cg14003231	chr6:33640908	ITPR3	0.48	9.32	0.41	6.49e-19	Plateletcrit;
LUAD	cis	rs6969780	0.915	rs4722659	chr7:27166750	C/T	cg05579037	chr7:27184853	NA	0.46	6.65	0.31	8.84e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg17940805	chr19:7595268	MCOLN1	0.5	6.66	0.31	8.67e-11	Venous thromboembolism (SNP x SNP interaction);
LUAD	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21659725	chr3:3221576	CRBN	-0.63	-11.0	-0.47	6.22e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.88	-0.32	2.21e-11	Type 2 diabetes;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg08893449	chr6:35310274	PPARD	-0.35	-6.45	-0.3	3.15e-10	Schizophrenia;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg11309891	chr11:73388802	RAB6A	0.4	6.4	0.3	4.2e-10	Prostate cancer (SNP x SNP interaction);
LUAD	trans	rs7712671	0.840	rs11241418	chr5:116527405	C/T	cg22023770	chr6:13486545	C6orf114;GFOD1	0.37	6.36	0.3	5.13e-10	Schizophrenia;
LUAD	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg25427524	chr10:38739819	LOC399744	0.52	7.75	0.35	6.97e-14	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.43	6.98	0.32	1.16e-11	Lymphocyte counts;
LUAD	cis	rs8040855	0.542	rs2342122	chr15:85728535	C/G	cg04831495	chr15:85060580	GOLGA6L5	0.42	6.87	0.32	2.3e-11	Bulimia nervosa;
LUAD	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.48	-0.3	2.61e-10	Prostate cancer;
LUAD	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg13319975	chr6:146136371	FBXO30	-0.55	-9.25	-0.41	1.08e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4243830	0.737	rs4908923	chr1:6614535	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.54	-7.04	-0.32	7.58e-12	Body mass index;
LUAD	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg03526776	chr6:41159608	TREML2	0.33	6.9	0.32	1.86e-11	Alzheimer's disease (late onset);
LUAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14159672	chr1:205819179	PM20D1	-0.7	-13.21	-0.54	1.36e-33	Menarche (age at onset);
LUAD	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg08999081	chr20:33150536	PIGU	-0.37	-7.06	-0.32	7.07e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-8.96	-0.4	1.02e-17	Lymphocyte counts;
LUAD	cis	rs7680126	0.596	rs17198547	chr4:10141419	A/G	cg00071950	chr4:10020882	SLC2A9	0.61	9.01	0.4	6.88e-18	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-7.15	-0.33	3.91e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg06671706	chr8:8559999	CLDN23	0.67	11.51	0.49	7.38e-27	Obesity-related traits;
LUAD	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg06873352	chr17:61820015	STRADA	0.41	6.85	0.32	2.64e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21659725	chr3:3221576	CRBN	-0.52	-8.33	-0.38	1.14e-15	Body mass index;
LUAD	cis	rs4243830	1.000	rs12401795	chr1:6594773	A/G	cg05709478	chr1:6581295	PLEKHG5	0.58	6.53	0.3	1.84e-10	Body mass index;
LUAD	cis	rs2067615	0.524	rs754184	chr12:107117521	A/G	cg15890332	chr12:107067104	RFX4	0.4	8.51	0.38	3.11e-16	Heart rate;
LUAD	cis	rs9796	0.700	rs2305656	chr15:41279519	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-9.58	-0.42	8.66e-20	Menopause (age at onset);
LUAD	cis	rs7843479	0.601	rs10866837	chr8:21861663	G/C	cg03445287	chr8:21823731	XPO7	-0.48	-9.21	-0.41	1.5e-18	Mean corpuscular volume;
LUAD	cis	rs11030122	0.592	rs4910880	chr11:4084630	C/G	cg18678763	chr11:4115507	RRM1	-0.41	-6.64	-0.31	9.74e-11	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs79911532	0.515	rs8509	chr7:75616577	G/A	cg19862616	chr7:65841803	NCRNA00174	0.83	8.4	0.38	6.86e-16	Mononucleosis;
LUAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.84	-15.12	-0.59	1.33e-41	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.71e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs875971	1.000	rs709597	chr7:65825983	A/G	cg14917512	chr19:3094685	GNA11	0.37	6.47	0.3	2.68e-10	Aortic root size;
LUAD	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg27102117	chr16:15229624	NA	-0.72	-12.91	-0.53	2.13e-32	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg23231163	chr10:75533350	FUT11	-0.52	-9.58	-0.42	8.47e-20	Inflammatory bowel disease;
LUAD	cis	rs9837602	0.938	rs9815439	chr3:99785206	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-7.66	-0.35	1.25e-13	Breast cancer;
LUAD	cis	rs9811920	0.893	rs6798114	chr3:99892825	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.59	10.62	0.46	1.62e-23	Axial length;
LUAD	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.35	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs6076065	0.723	rs6083119	chr20:23390923	T/G	cg11657817	chr20:23433608	CST11	0.49	9.11	0.4	3.32e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg19318889	chr4:1322082	MAEA	0.46	7.45	0.34	5.27e-13	Obesity-related traits;
LUAD	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg06784218	chr1:46089804	CCDC17	0.6	13.45	0.55	1.43e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg08989290	chr16:615782	NHLRC4	0.31	6.75	0.31	4.82e-11	Height;
LUAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg27454412	chr7:1067447	C7orf50	0.44	7.0	0.32	9.96e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs877282	0.898	rs12354872	chr10:763362	G/A	cg17470449	chr10:769945	NA	0.62	8.83	0.39	2.91e-17	Uric acid levels;
LUAD	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg03474202	chr17:45855739	NA	-0.38	-9.33	-0.41	6.2e-19	IgG glycosylation;
LUAD	cis	rs6011002	0.590	rs1298721	chr20:62352319	T/C	cg21849932	chr20:62369462	LIME1	-0.78	-6.47	-0.3	2.78e-10	Dental caries;
LUAD	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg17848003	chr1:3704513	LRRC47	0.53	10.67	0.46	1.09e-23	Red cell distribution width;
LUAD	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.87	16.74	0.63	1.25e-48	Lymphocyte counts;
LUAD	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg15704280	chr7:45808275	SEPT13	-1.07	-25.01	-0.77	2.01e-85	Height;
LUAD	cis	rs73198271	0.515	rs76224322	chr8:8635841	C/G	cg01851573	chr8:8652454	MFHAS1	0.6	8.03	0.36	9.74e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg23649088	chr2:200775458	C2orf69	-0.57	-6.44	-0.3	3.21e-10	Schizophrenia;
LUAD	cis	rs9341808	1.000	rs9341808	chr6:80953257	C/A	cg08355045	chr6:80787529	NA	0.55	10.24	0.45	3.78e-22	Sitting height ratio;
LUAD	cis	rs7621025	0.500	rs9845460	chr3:136587117	A/G	cg15507776	chr3:136538369	TMEM22	0.62	10.05	0.44	1.85e-21	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUAD	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg00271210	chr6:167070053	RPS6KA2	0.35	6.65	0.31	9.31e-11	Crohn's disease;
LUAD	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg04025307	chr7:1156635	C7orf50	0.52	7.14	0.33	3.97e-12	Bronchopulmonary dysplasia;
LUAD	cis	rs72949976	0.584	rs12471432	chr2:214022893	A/T	cg08319019	chr2:214017104	IKZF2	0.57	8.8	0.39	3.58e-17	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg17264618	chr3:40429014	ENTPD3	0.38	8.55	0.38	2.29e-16	Renal cell carcinoma;
LUAD	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg03929089	chr4:120376271	NA	-0.97	-19.75	-0.69	5.18e-62	Height;
LUAD	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg02734326	chr4:10020555	SLC2A9	-0.41	-6.61	-0.31	1.17e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg09033563	chr22:24373618	LOC391322	0.53	8.4	0.38	6.96e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg24644049	chr4:85504048	CDS1	0.84	7.01	0.32	9.44e-12	Skin colour saturation;
LUAD	cis	rs250585	1.000	rs6497666	chr16:23495677	C/T	cg00143387	chr16:23521605	GGA2	-0.69	-8.22	-0.37	2.6e-15	Egg allergy;
LUAD	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg16405210	chr4:1374714	KIAA1530	-0.44	-7.26	-0.33	1.93e-12	Longevity;
LUAD	trans	rs783540	1.000	rs1259180	chr15:83244680	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.71	-0.31	6.31e-11	Schizophrenia;
LUAD	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21659725	chr3:3221576	CRBN	-0.62	-10.84	-0.47	2.51e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg00310523	chr12:86230176	RASSF9	0.37	7.32	0.34	1.25e-12	Major depressive disorder;
LUAD	cis	rs11048434	0.736	rs1476911	chr12:9090859	C/T	cg13575925	chr12:9217583	LOC144571	0.39	7.29	0.33	1.49e-12	Sjögren's syndrome;
LUAD	cis	rs2262909	0.962	rs401424	chr19:22232023	A/G	cg11619707	chr19:22235551	ZNF257	-0.44	-6.99	-0.32	1.07e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg09184832	chr6:79620586	NA	-0.52	-9.75	-0.43	2.07e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2274273	0.682	rs1187876	chr14:55495199	A/T	cg04306507	chr14:55594613	LGALS3	-0.33	-6.87	-0.32	2.28e-11	Protein biomarker;
LUAD	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg17264618	chr3:40429014	ENTPD3	-0.39	-8.53	-0.38	2.58e-16	Renal cell carcinoma;
LUAD	trans	rs853679	0.607	rs200489	chr6:27798257	T/C	cg06606381	chr12:133084897	FBRSL1	-0.81	-8.05	-0.36	8.5e-15	Depression;
LUAD	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.38	0.34	8.33e-13	Morning vs. evening chronotype;
LUAD	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.87	0.36	2.92e-14	Depression;
LUAD	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg00901687	chr17:48585270	MYCBPAP	-0.48	-7.13	-0.33	4.49e-12	Visceral fat;
LUAD	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.42	-0.34	6.62e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs908922	0.676	rs477621	chr1:152486252	T/C	cg20991723	chr1:152506922	NA	0.34	6.57	0.3	1.5e-10	Hair morphology;
LUAD	cis	rs12791968	0.527	rs12285862	chr11:45014326	T/G	cg11846598	chr11:44996168	LOC221122	-0.59	-7.84	-0.36	3.67e-14	Inhibitory control;
LUAD	cis	rs6543140	0.964	rs4851592	chr2:103087641	C/T	cg04239558	chr2:103089729	SLC9A4	0.36	7.1	0.33	5.23e-12	Blood protein levels;
LUAD	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24531977	chr5:56204891	C5orf35	-1.0	-15.36	-0.6	1.21e-42	Initial pursuit acceleration;
LUAD	trans	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg26043149	chr18:55253948	FECH	-0.44	-6.61	-0.31	1.14e-10	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3736594	0.959	rs6547796	chr2:27975394	T/C	cg27432699	chr2:27873401	GPN1	-0.47	-7.4	-0.34	7.23e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-8.12	-0.37	5.09e-15	Alzheimer's disease;
LUAD	cis	rs2249625	1.000	rs55970804	chr6:72923351	G/A	cg18830697	chr6:72922368	RIMS1	0.35	6.36	0.3	5.32e-10	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg01191920	chr7:158217561	PTPRN2	-0.66	-14.17	-0.57	1.4e-37	Obesity-related traits;
LUAD	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg00431813	chr7:1051703	C7orf50	-0.46	-9.08	-0.4	4.08e-18	Longevity;Endometriosis;
LUAD	cis	rs2066819	1.000	rs74673257	chr12:56638077	T/C	cg26714650	chr12:56694279	CS	-0.83	-6.99	-0.32	1.05e-11	Psoriasis vulgaris;
LUAD	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg11062466	chr8:58055876	NA	0.45	6.48	0.3	2.49e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg24838063	chr12:130822603	PIWIL1	-0.71	-11.77	-0.5	7.33e-28	Menopause (age at onset);
LUAD	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg14530993	chr4:882597	GAK	0.71	6.84	0.32	2.76e-11	Parkinson's disease;
LUAD	cis	rs89107	0.688	rs281867	chr6:118575808	C/T	cg21191810	chr6:118973309	C6orf204	0.48	9.23	0.41	1.31e-18	Cardiac structure and function;
LUAD	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-7.65	-0.35	1.41e-13	Blood metabolite levels;
LUAD	cis	rs10193935	0.901	rs10189710	chr2:42573102	C/G	cg27598129	chr2:42591480	NA	-0.73	-9.58	-0.42	8.29e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21271452	chr8:141522359	CHRAC1	-0.42	-6.82	-0.31	3.15e-11	Height;
LUAD	cis	rs4321325	0.733	rs13389505	chr2:127934888	T/C	cg11380483	chr2:127933992	NA	0.5	7.23	0.33	2.21e-12	Protein C levels;
LUAD	cis	rs8067545	0.750	rs4924803	chr17:19991806	C/T	cg04132472	chr17:19861366	AKAP10	0.3	7.11	0.33	4.93e-12	Schizophrenia;
LUAD	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg14926445	chr8:58193284	C8orf71	-0.44	-6.55	-0.3	1.68e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04175292	chr6:44187226	SLC29A1	-0.43	-6.65	-0.31	9.04e-11	Height;
LUAD	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.7	0.39	7.31e-17	Menarche (age at onset);
LUAD	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg18827107	chr12:86230957	RASSF9	-0.48	-8.52	-0.38	2.83e-16	Major depressive disorder;
LUAD	trans	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg18335740	chr13:41363409	SLC25A15	0.73	14.03	0.56	5.48e-37	Lewy body disease;
LUAD	cis	rs1215050	0.791	rs165239	chr4:98682549	C/T	cg24818145	chr4:99064322	C4orf37	0.41	6.72	0.31	5.8e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg27411982	chr8:10470053	RP1L1	-0.39	-7.26	-0.33	1.86e-12	Triglycerides;
LUAD	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg17971929	chr21:40555470	PSMG1	0.55	8.64	0.39	1.14e-16	Cognitive function;
LUAD	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.71	0.35	9.24e-14	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs7746199	0.736	rs35848276	chr6:27521096	C/T	cg06606381	chr12:133084897	FBRSL1	-1.18	-10.49	-0.45	4.93e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.62	12.05	0.51	5.75e-29	Hemoglobin concentration;
LUAD	trans	rs7395662	0.926	rs7122869	chr11:48727999	G/T	cg15704280	chr7:45808275	SEPT13	0.43	6.75	0.31	5.04e-11	HDL cholesterol;
LUAD	cis	rs7593730	1.000	rs6727751	chr2:161220275	C/T	cg22609984	chr2:161126801	NA	0.43	6.97	0.32	1.2e-11	Type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26383454	chr6:11104957	HERV-FRD;LOC221710	0.54	6.88	0.32	2.19e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.39	8.28	0.37	1.58e-15	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg18721089	chr20:30220636	NA	-0.47	-6.72	-0.31	5.96e-11	Mean corpuscular hemoglobin;
LUAD	trans	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg12400702	chr3:12838781	CAND2	0.31	6.41	0.3	3.87e-10	Parkinson's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25409748	chr1:205744748	RAB7L1	-0.41	-6.41	-0.3	3.87e-10	Height;
LUAD	cis	rs4243830	1.000	rs41278016	chr1:6584045	C/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.81	8.34	0.38	1.03e-15	Body mass index;
LUAD	trans	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg18834416	chr8:37888184	EIF4EBP1	0.42	7.12	0.33	4.67e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2455799	0.573	rs2455836	chr3:15754538	A/G	cg16303742	chr3:15540471	COLQ	-0.5	-9.14	-0.41	2.64e-18	Mean platelet volume;
LUAD	trans	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.03	-0.32	8.35e-12	Dental caries;
LUAD	cis	rs10782582	0.609	rs5745543	chr1:76365111	A/T	cg03433033	chr1:76189801	ACADM	-0.44	-6.39	-0.3	4.35e-10	Daytime sleep phenotypes;
LUAD	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg15962314	chr1:44399869	ARTN	0.3	6.87	0.32	2.36e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs7945705	0.782	rs3763918	chr11:8819683	T/A	cg09997546	chr11:8931473	C11orf17;ST5	0.34	7.02	0.32	9.02e-12	Hemoglobin concentration;
LUAD	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.81	-0.35	4.6e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9811920	0.809	rs4928151	chr3:99767553	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-11.39	-0.48	2.22e-26	Axial length;
LUAD	trans	rs4650994	0.935	rs4652306	chr1:178528206	T/C	cg05059571	chr16:84539110	KIAA1609	-0.59	-10.06	-0.44	1.73e-21	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs4774899	1.000	rs12901780	chr15:57258531	T/A	cg14026238	chr15:57616123	NA	0.35	6.64	0.31	9.78e-11	Urinary tract infection frequency;
LUAD	cis	rs6688613	1.000	rs6695162	chr1:166953455	C/G	cg07049167	chr1:166818506	POGK	0.4	6.81	0.31	3.3e-11	Refractive astigmatism;
LUAD	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg22875332	chr1:76189707	ACADM	0.86	16.01	0.61	2.02e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.98	0.32	1.14e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg09658497	chr7:2847517	GNA12	0.42	7.69	0.35	1.04e-13	Height;
LUAD	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.12	-0.37	5.33e-15	Prostate cancer;
LUAD	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg09658497	chr7:2847517	GNA12	-0.47	-7.88	-0.36	2.79e-14	Height;
LUAD	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg00717180	chr2:96193071	NA	-0.39	-6.84	-0.32	2.86e-11	Height;
LUAD	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg23758822	chr17:41437982	NA	0.99	20.95	0.71	2.25e-67	Menopause (age at onset);
LUAD	cis	rs494562	0.892	rs618448	chr6:86121324	G/A	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24531977	chr5:56204891	C5orf35	-1.0	-15.31	-0.6	1.95e-42	Initial pursuit acceleration;
LUAD	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.5	-0.42	1.53e-19	Life satisfaction;
LUAD	cis	rs7095607	0.560	rs2634709	chr10:69925789	C/T	cg18986048	chr10:69913749	MYPN	0.48	8.19	0.37	3.13e-15	Lung function (FVC);
LUAD	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg02975922	chr3:195473998	MUC4	0.44	7.4	0.34	7.62e-13	Pancreatic cancer;
LUAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg16606324	chr3:10149918	C3orf24	0.62	9.35	0.41	5.26e-19	Alzheimer's disease;
LUAD	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg18190219	chr22:46762943	CELSR1	-0.58	-6.37	-0.3	5.08e-10	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs7395662	1.000	rs55834832	chr11:48562583	T/G	cg00717180	chr2:96193071	NA	-0.39	-7.31	-0.33	1.32e-12	HDL cholesterol;
LUAD	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg00745463	chr17:30367425	LRRC37B	-0.82	-9.97	-0.44	3.57e-21	Hip circumference adjusted for BMI;
LUAD	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg08027265	chr7:2291960	NA	-0.41	-6.91	-0.32	1.81e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6582630	0.562	rs35080195	chr12:38310866	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.66	-0.31	8.35e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg04352962	chr1:209979756	IRF6	0.5	6.56	0.3	1.6e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg09365446	chr1:150670422	GOLPH3L	0.6	10.75	0.46	5.22e-24	Melanoma;
LUAD	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26314531	chr2:26401878	FAM59B	-0.7	-9.53	-0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	6.73	0.31	5.71e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.38	6.75	0.31	4.8e-11	Systemic lupus erythematosus;
LUAD	cis	rs6066835	1.000	rs73138221	chr20:47349525	T/C	cg18078177	chr20:47281410	PREX1	0.76	6.61	0.31	1.13e-10	Multiple myeloma;
LUAD	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg18944383	chr4:111397179	ENPEP	0.38	7.62	0.35	1.73e-13	Height;
LUAD	cis	rs881375	0.526	rs1930785	chr9:123691237	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	6.78	0.31	3.95e-11	Rheumatoid arthritis;
LUAD	cis	rs5756813	0.584	rs12484820	chr22:38207556	A/G	cg06521852	chr22:38141419	TRIOBP	0.47	8.38	0.38	7.95e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs7107174	1.000	rs7939352	chr11:78003151	G/A	cg02023728	chr11:77925099	USP35	0.39	6.43	0.3	3.41e-10	Testicular germ cell tumor;
LUAD	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16723738	chr1:3371586	ARHGEF16	-0.4	-6.53	-0.3	1.93e-10	Cancer;
LUAD	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg03037974	chr15:76606532	NA	-0.42	-9.52	-0.42	1.32e-19	Blood metabolite levels;
LUAD	cis	rs7737355	0.853	rs11745955	chr5:130605143	C/T	cg06307176	chr5:131281290	NA	0.38	6.45	0.3	2.98e-10	Life satisfaction;
LUAD	cis	rs2625529	0.557	rs1000281	chr15:72553422	A/G	cg16672083	chr15:72433130	SENP8	0.62	11.68	0.49	1.71e-27	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8044868	0.541	rs7202268	chr16:72086746	A/G	cg23815491	chr16:72088622	HP	0.56	10.63	0.46	1.54e-23	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg21231944	chr12:82153410	PPFIA2	-0.35	-6.49	-0.3	2.35e-10	Resting heart rate;
LUAD	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg07414643	chr4:187882934	NA	0.33	6.76	0.31	4.57e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03264133	chr6:25882463	NA	-0.57	-9.39	-0.42	3.69e-19	Blood metabolite levels;
LUAD	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.92	-0.5	1.99e-28	Bipolar disorder;
LUAD	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg22753661	chr15:79092743	ADAMTS7	-0.55	-8.49	-0.38	3.56e-16	Coronary artery disease or large artery stroke;
LUAD	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg22535103	chr8:58192502	C8orf71	-0.75	-9.16	-0.41	2.19e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg03188948	chr7:1209495	NA	0.85	11.44	0.49	1.43e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg04455712	chr21:45112962	RRP1B	0.43	8.84	0.4	2.54e-17	Mean corpuscular volume;
LUAD	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05901451	chr6:126070800	HEY2	-0.79	-15.1	-0.59	1.65e-41	Brugada syndrome;
LUAD	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg11871910	chr12:69753446	YEATS4	0.7	12.04	0.51	6.75e-29	Blood protein levels;
LUAD	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg02493740	chr2:85810744	VAMP5	-0.42	-7.62	-0.35	1.63e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg13511324	chr14:104056883	C14orf153	0.26	6.5	0.3	2.29e-10	Reticulocyte count;
LUAD	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg22532475	chr10:104410764	TRIM8	-0.45	-8.78	-0.39	4.05e-17	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg06740227	chr12:86229804	RASSF9	0.38	6.74	0.31	5.19e-11	Major depressive disorder;
LUAD	cis	rs977987	0.778	rs4243112	chr16:75321031	T/C	cg03315344	chr16:75512273	CHST6	0.64	13.7	0.55	1.32e-35	Dupuytren's disease;
LUAD	cis	rs6906287	0.647	rs11153734	chr6:118726220	A/G	cg05564266	chr6:118973597	C6orf204	0.33	6.82	0.31	3.06e-11	Electrocardiographic conduction measures;
LUAD	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg08684580	chr7:98029266	BAIAP2L1	0.35	6.57	0.3	1.52e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg09658497	chr7:2847517	GNA12	-0.47	-7.97	-0.36	1.5e-14	Height;
LUAD	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg19041857	chr6:27730383	NA	-0.35	-6.39	-0.3	4.46e-10	Hepatitis A;
LUAD	cis	rs500891	0.525	rs1144179	chr6:84026572	C/G	cg08257003	chr6:84140564	ME1	0.34	6.38	0.3	4.57e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	7.47	0.34	4.55e-13	Menarche (age at onset);
LUAD	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg24531977	chr5:56204891	C5orf35	-0.57	-9.22	-0.41	1.43e-18	Coronary artery disease;
LUAD	cis	rs597539	0.690	rs7104351	chr11:68617886	A/G	cg04772025	chr11:68637568	NA	0.59	9.35	0.41	4.95e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4774899	0.752	rs2470082	chr15:57337093	C/T	cg14026238	chr15:57616123	NA	0.41	7.95	0.36	1.74e-14	Urinary tract infection frequency;
LUAD	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg23625390	chr15:77176239	SCAPER	0.37	6.38	0.3	4.53e-10	Blood metabolite levels;
LUAD	cis	rs1997103	1.000	rs6968966	chr7:55411356	A/G	cg17469321	chr7:55412551	NA	0.66	11.37	0.48	2.65e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg01528321	chr10:82214614	TSPAN14	0.55	8.65	0.39	1.07e-16	Post bronchodilator FEV1;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02189121	chr6:79943796	HMGN3	-0.38	-6.62	-0.31	1.1e-10	Cancer;
LUAD	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg14228332	chr4:119757509	SEC24D	0.8	7.37	0.34	9.34e-13	Cannabis dependence symptom count;
LUAD	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg03929089	chr4:120376271	NA	0.66	10.03	0.44	2.21e-21	Coronary artery disease;
LUAD	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg06618935	chr21:46677482	NA	-0.44	-7.9	-0.36	2.45e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7805747	1.000	rs10480299	chr7:151405818	A/G	cg17611936	chr7:151411526	PRKAG2	0.44	6.52	0.3	1.96e-10	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LUAD	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg26752003	chr8:145688521	CYHR1	0.56	9.87	0.43	8.02e-21	Age at first birth;
LUAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg11062466	chr8:58055876	NA	0.67	9.02	0.4	6.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg21475434	chr5:93447410	FAM172A	0.75	8.68	0.39	8.38e-17	Diabetic retinopathy;
LUAD	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg26384229	chr12:38710491	ALG10B	-0.38	-6.42	-0.3	3.65e-10	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs8073060	0.586	rs225291	chr17:33927126	A/G	cg19694781	chr19:47549865	TMEM160	-0.96	-15.26	-0.6	3.49e-42	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg01065977	chr19:18549689	ISYNA1	-0.41	-7.86	-0.36	3.16e-14	Breast cancer;
LUAD	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg15448220	chr1:150897856	SETDB1	0.57	9.88	0.43	7.45e-21	Melanoma;
LUAD	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg24920358	chr1:40204285	PPIE	0.72	12.85	0.53	3.96e-32	Blood protein levels;
LUAD	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03517284	chr6:25882590	NA	-0.56	-8.25	-0.37	1.97e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg03037974	chr15:76606532	NA	0.38	8.18	0.37	3.28e-15	Blood metabolite levels;
LUAD	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.83	-11.44	-0.49	1.43e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs12791968	0.765	rs12794751	chr11:44998769	C/G	cg11846598	chr11:44996168	LOC221122	-0.61	-9.24	-0.41	1.2e-18	Inhibitory control;
LUAD	cis	rs7617773	0.817	rs9847953	chr3:48282695	A/G	cg11946769	chr3:48343235	NME6	0.42	6.69	0.31	7.3e-11	Coronary artery disease;
LUAD	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.94	-0.36	1.87e-14	Diabetic kidney disease;
LUAD	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.63	-0.31	1.05e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.9	-0.4	1.67e-17	Lymphocyte counts;
LUAD	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg18811423	chr2:55921094	PNPT1	0.51	8.63	0.39	1.23e-16	Metabolic syndrome;
LUAD	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.59	-0.52	4.41e-31	Monocyte count;
LUAD	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.88	-0.32	2.16e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg14196790	chr5:131705035	SLC22A5	0.39	6.87	0.32	2.24e-11	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs6867032	0.527	rs4975790	chr5:2010376	C/T	cg26168224	chr5:2018326	NA	0.48	9.35	0.41	5.31e-19	Gut microbiome composition (winter);
LUAD	cis	rs10426930	0.671	rs57900491	chr19:4995295	A/T	cg25246084	chr19:4971487	KDM4B	-0.46	-8.0	-0.36	1.19e-14	Monocyte percentage of white cells;
LUAD	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg26752003	chr8:145688521	CYHR1	-0.54	-9.46	-0.42	2.1e-19	Age at first birth;
LUAD	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg25767906	chr1:53392781	SCP2	0.41	7.43	0.34	5.93e-13	Monocyte count;
LUAD	cis	rs80319144	1.000	rs2356091	chr2:159239443	A/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.83	0.32	2.95e-11	Restless legs syndrome;
LUAD	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg01200585	chr1:228362443	C1orf69	0.4	6.88	0.32	2.17e-11	Diastolic blood pressure;
LUAD	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg10556349	chr10:835070	NA	0.68	8.22	0.37	2.57e-15	Eosinophil percentage of granulocytes;
LUAD	trans	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg21582582	chr3:182698605	DCUN1D1	0.49	8.02	0.36	1.07e-14	Body mass index;
LUAD	trans	rs12517041	1.000	rs6879916	chr5:23312603	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg04851639	chr8:1020857	NA	-0.43	-10.58	-0.46	2.22e-23	Schizophrenia;
LUAD	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg15704280	chr7:45808275	SEPT13	-0.62	-8.4	-0.38	6.9e-16	Axial length;
LUAD	cis	rs317865	0.529	rs28487914	chr4:16191303	T/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.6	6.57	0.3	1.49e-10	Kidney disease (early stage) in type 1 diabetes;
LUAD	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg03289416	chr15:75166202	SCAMP2	0.43	7.2	0.33	2.76e-12	Caffeine consumption;
LUAD	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg22117172	chr7:91764530	CYP51A1	-0.32	-6.99	-0.32	1.06e-11	Breast cancer;
LUAD	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg25985355	chr7:65971099	NA	-0.36	-6.52	-0.3	1.99e-10	Aortic root size;
LUAD	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.98	-0.32	1.12e-11	Retinal vascular caliber;
LUAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg04025307	chr7:1156635	C7orf50	0.65	7.86	0.36	3.2e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg05697835	chr1:2722811	NA	0.31	6.56	0.3	1.6e-10	Ulcerative colitis;
LUAD	cis	rs9393692	0.620	rs9393696	chr6:26291591	T/C	cg00631329	chr6:26305371	NA	-0.54	-9.4	-0.42	3.58e-19	Educational attainment;
LUAD	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg17480646	chr11:65405466	SIPA1	-0.45	-6.87	-0.32	2.37e-11	Acne (severe);
LUAD	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg26893861	chr17:41843967	DUSP3	-1.19	-28.2	-0.81	3.43e-99	Triglycerides;
LUAD	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.12e-14	Prostate cancer;
LUAD	trans	rs11039798	0.920	rs61448762	chr11:48923756	G/A	cg03929089	chr4:120376271	NA	0.68	6.78	0.31	4.18e-11	Axial length;
LUAD	cis	rs4711336	1.000	rs2296742	chr6:33659793	G/A	cg14003231	chr6:33640908	ITPR3	0.5	9.54	0.42	1.13e-19	Height;
LUAD	cis	rs3760982	1.000	rs3760983	chr19:44286660	C/T	cg12072164	chr19:44306565	LYPD5	-0.38	-7.59	-0.35	2.03e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs7100689	0.784	rs4934139	chr10:82177023	C/A	cg01528321	chr10:82214614	TSPAN14	0.71	10.71	0.46	7.47e-24	Post bronchodilator FEV1;
LUAD	trans	rs7395662	0.786	rs12791074	chr11:49005023	G/A	cg00717180	chr2:96193071	NA	-0.44	-8.61	-0.39	1.46e-16	HDL cholesterol;
LUAD	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg07936489	chr17:37558343	FBXL20	-0.44	-6.88	-0.32	2.14e-11	Glomerular filtration rate (creatinine);
LUAD	trans	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.92	0.47	1.29e-24	Mean corpuscular volume;
LUAD	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg19346786	chr7:2764209	NA	-0.3	-6.44	-0.3	3.27e-10	Height;
LUAD	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg18477163	chr1:228402036	OBSCN	0.43	8.52	0.38	2.75e-16	Diastolic blood pressure;
LUAD	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg23758822	chr17:41437982	NA	1.0	20.98	0.71	1.6e-67	Menopause (age at onset);
LUAD	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	6.81	0.31	3.27e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg14196790	chr5:131705035	SLC22A5	0.39	6.88	0.32	2.18e-11	Blood metabolite levels;
LUAD	cis	rs6952808	0.771	rs11762834	chr7:1895641	C/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-8.94	-0.4	1.23e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs490234	0.702	rs13302549	chr9:128284775	T/C	cg14078157	chr9:128172775	NA	-0.45	-7.94	-0.36	1.8e-14	Mean arterial pressure;
LUAD	cis	rs7744392	1.000	rs7744392	chr6:35322763	C/T	cg03355690	chr6:35265616	DEF6	-0.78	-6.54	-0.3	1.73e-10	Cataracts in type 2 diabetes;
LUAD	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg07153921	chr17:41440717	NA	-0.4	-6.6	-0.31	1.23e-10	Menopause (age at onset);
LUAD	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg18944383	chr4:111397179	ENPEP	0.41	7.97	0.36	1.44e-14	Height;
LUAD	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg06060754	chr5:176797920	RGS14	0.52	9.76	0.43	1.91e-20	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg11062466	chr8:58055876	NA	0.45	6.37	0.3	4.87e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9560113	0.959	rs9560108	chr13:112180303	A/C	cg14154082	chr13:112174009	NA	0.36	6.75	0.31	4.77e-11	Menarche (age at onset);
LUAD	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg22681709	chr2:178499509	PDE11A	0.41	6.91	0.32	1.74e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4604732	0.589	rs78689516	chr1:247626274	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg04450456	chr4:17643702	FAM184B	0.41	8.17	0.37	3.49e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3820068	0.705	rs7533125	chr1:15883744	T/C	cg13390004	chr1:15929781	NA	0.43	6.78	0.31	4.09e-11	Systolic blood pressure;
LUAD	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg26528668	chr16:1614120	IFT140	0.57	10.26	0.45	3.27e-22	Coronary artery disease;
LUAD	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11644478	chr21:40555479	PSMG1	0.68	11.1	0.48	2.63e-25	Cognitive function;
LUAD	cis	rs6665290	0.904	rs3768425	chr1:227178127	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.9	-0.89	4.52e-149	Myeloid white cell count;
LUAD	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10802521	chr3:52805072	NEK4	-0.6	-10.97	-0.47	8.5e-25	Electroencephalogram traits;
LUAD	cis	rs7607369	0.559	rs4674343	chr2:219660346	C/T	cg02176678	chr2:219576539	TTLL4	0.53	10.45	0.45	6.9e-23	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs4523957	0.651	rs9906705	chr17:2063714	T/G	cg16513277	chr17:2031491	SMG6	-0.96	-18.89	-0.68	3.82e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg02773041	chr1:40204384	PPIE	0.53	8.81	0.39	3.29e-17	Blood protein levels;
LUAD	cis	rs35771425	1.000	rs11579557	chr1:211619703	A/G	cg25617285	chr1:211431773	RCOR3	0.47	6.93	0.32	1.54e-11	Educational attainment (years of education);
LUAD	trans	rs9929218	0.508	rs1559366	chr16:68799611	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.99	20.69	0.71	3.24e-66	Colorectal cancer;
LUAD	cis	rs7737355	0.812	rs2158294	chr5:130878215	A/G	cg06307176	chr5:131281290	NA	0.44	7.14	0.33	4.19e-12	Life satisfaction;
LUAD	cis	rs494562	0.892	rs1322403	chr6:86127162	A/G	cg17966619	chr6:86160162	NT5E	0.66	7.83	0.36	4.05e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs2072438	0.503	rs10739590	chr9:123871481	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	6.57	0.3	1.48e-10	Rheumatoid arthritis;
LUAD	cis	rs7582720	1.000	rs72932791	chr2:203700870	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.39	0.42	3.83e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg06060754	chr5:176797920	RGS14	-0.49	-9.21	-0.41	1.59e-18	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg00603274	chr11:61596626	FADS2	-0.37	-6.4	-0.3	4.11e-10	Trans fatty acid levels;
LUAD	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg15181151	chr6:150070149	PCMT1	0.41	8.43	0.38	5.35e-16	Lung cancer;
LUAD	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00149659	chr3:10157352	C3orf10	0.61	8.68	0.39	8.54e-17	Alzheimer's disease;
LUAD	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg27087555	chr16:88793112	FAM38A	-0.85	-7.95	-0.36	1.66e-14	Plateletcrit;
LUAD	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg06784218	chr1:46089804	CCDC17	-0.51	-11.18	-0.48	1.3e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg21475434	chr5:93447410	FAM172A	0.77	8.58	0.38	1.84e-16	Diabetic retinopathy;
LUAD	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg26513180	chr16:89883248	FANCA	0.69	12.97	0.53	1.28e-32	Vitiligo;
LUAD	cis	rs6688613	0.694	rs11576455	chr1:166811970	G/A	cg07049167	chr1:166818506	POGK	0.64	9.83	0.43	1.13e-20	Refractive astigmatism;
LUAD	cis	rs11958404	0.615	rs7704746	chr5:157450601	C/G	cg05962755	chr5:157440814	NA	0.44	8.46	0.38	4.4e-16	IgG glycosylation;
LUAD	trans	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg05926928	chr17:57297772	GDPD1	-0.76	-9.29	-0.41	8.12e-19	Opioid sensitivity;
LUAD	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg21862992	chr11:68658383	NA	0.54	9.67	0.43	3.99e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15506890	chr2:3487001	NA	-0.42	-7.03	-0.32	8.18e-12	Neurofibrillary tangles;
LUAD	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg05340658	chr4:99064831	C4orf37	0.43	7.11	0.33	4.99e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11958404	0.932	rs72818113	chr5:157439825	G/T	cg05962755	chr5:157440814	NA	0.71	9.95	0.44	4.36e-21	IgG glycosylation;
LUAD	trans	rs7246760	1.000	rs67509260	chr19:9864321	C/T	cg02900749	chr2:68251473	NA	-0.64	-7.04	-0.32	7.78e-12	Pursuit maintenance gain;
LUAD	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg15147215	chr3:52552868	STAB1	-0.4	-7.15	-0.33	3.75e-12	Bipolar disorder;
LUAD	cis	rs9807989	0.507	rs2293224	chr2:103035779	T/C	cg03938978	chr2:103052716	IL18RAP	0.45	10.33	0.45	1.82e-22	Asthma;
LUAD	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg08048268	chr3:133502702	NA	-0.49	-8.9	-0.4	1.63e-17	Iron status biomarkers;
LUAD	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg07501729	chr16:846077	CHTF18	0.4	7.44	0.34	5.82e-13	Mean corpuscular volume;
LUAD	cis	rs597583	0.951	rs579239	chr11:117425009	T/C	cg27161313	chr11:117392002	DSCAML1	-0.4	-6.89	-0.32	2.04e-11	Putamen volume;
LUAD	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg21017887	chr14:105400489	NA	0.76	14.6	0.58	2.18e-39	Rheumatoid arthritis;
LUAD	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.46	-7.49	-0.34	4.11e-13	Tonsillectomy;
LUAD	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.8	-13.77	-0.56	6.43e-36	Chronic sinus infection;
LUAD	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg13319975	chr6:146136371	FBXO30	-0.61	-10.43	-0.45	7.75e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg10639395	chr11:8710044	RPL27A	-0.32	-6.4	-0.3	4.14e-10	Hemoglobin concentration;
LUAD	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg26924012	chr15:45694286	SPATA5L1	1.02	19.01	0.68	1.09e-58	Homoarginine levels;
LUAD	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg24069376	chr3:38537580	EXOG	-0.31	-6.97	-0.32	1.25e-11	Electrocardiographic conduction measures;
LUAD	cis	rs1443512	1.000	rs1443512	chr12:54342684	A/C	cg17410650	chr12:54324560	NA	-0.44	-8.08	-0.37	6.93e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs7586879	0.828	rs4077677	chr2:25122798	G/C	cg04586622	chr2:25135609	ADCY3	0.36	7.28	0.33	1.68e-12	Body mass index;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg11192808	chr8:101170185	SPAG1	-0.54	-6.45	-0.3	3.12e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg08470875	chr2:26401718	FAM59B	-0.58	-8.09	-0.37	6.37e-15	Gut microbiome composition (summer);
LUAD	cis	rs2404602	0.647	rs7181506	chr15:76935677	G/T	cg23625390	chr15:77176239	SCAPER	0.42	6.57	0.3	1.46e-10	Blood metabolite levels;
LUAD	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.38	-6.74	-0.31	5.29e-11	Age at first birth;
LUAD	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg23750338	chr8:142222470	SLC45A4	0.61	13.93	0.56	1.39e-36	Immature fraction of reticulocytes;
LUAD	trans	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg19862616	chr7:65841803	NCRNA00174	1.07	27.3	0.8	2.24e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7394190	0.748	rs11000772	chr10:75533988	T/G	cg02286717	chr10:75415704	SYNPO2L	-0.36	-6.37	-0.3	4.93e-10	Incident atrial fibrillation;
LUAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg15083037	chr5:83017644	HAPLN1	0.47	7.4	0.34	7.44e-13	Prostate cancer;
LUAD	cis	rs9372498	0.732	rs17080124	chr6:118717814	A/G	cg07617317	chr6:118971624	C6orf204	0.63	6.89	0.32	1.99e-11	Diastolic blood pressure;
LUAD	cis	rs13112683	0.638	rs11100314	chr4:140783603	A/G	cg02876341	chr4:140783585	MAML3	0.32	7.1	0.33	5.28e-12	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LUAD	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg18758796	chr5:131593413	PDLIM4	0.37	6.44	0.3	3.29e-10	Acylcarnitine levels;
LUAD	cis	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg27411982	chr8:10470053	RP1L1	0.39	7.13	0.33	4.27e-12	Neuroticism;
LUAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg22105103	chr4:187893119	NA	0.57	12.61	0.52	3.6e-31	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg03929089	chr4:120376271	NA	-0.77	-12.19	-0.51	1.62e-29	Coronary artery disease;
LUAD	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg02569458	chr12:86230093	RASSF9	0.43	7.86	0.36	3.32e-14	Major depressive disorder;
LUAD	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25427524	chr10:38739819	LOC399744	-0.8	-14.51	-0.58	5.23e-39	Extrinsic epigenetic age acceleration;
LUAD	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21659725	chr3:3221576	CRBN	-0.51	-8.28	-0.37	1.6e-15	Body mass index;
LUAD	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg02049041	chr17:27085579	C17orf63	0.66	8.72	0.39	6.31e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9399401	0.626	rs7756434	chr6:142775295	A/G	cg03128060	chr6:142623767	GPR126	0.44	8.62	0.39	1.38e-16	Chronic obstructive pulmonary disease;
LUAD	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	7.29	0.33	1.51e-12	Neuroticism;
LUAD	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg09835421	chr16:68378352	PRMT7	-1.04	-12.15	-0.51	2.41e-29	Schizophrenia;
LUAD	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg10523679	chr1:76189770	ACADM	0.62	9.64	0.42	5.3e-20	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg03188948	chr7:1209495	NA	0.81	9.78	0.43	1.65e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg14668632	chr7:2872130	GNA12	-0.75	-13.17	-0.54	2.01e-33	Height;
LUAD	cis	rs4444235	0.761	rs12898159	chr14:54415291	C/T	cg16720578	chr14:54410717	NA	0.5	8.64	0.39	1.14e-16	Colorectal cancer;
LUAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg16606324	chr3:10149918	C3orf24	0.67	11.2	0.48	1.15e-25	Alzheimer's disease;
LUAD	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12923728	chr3:195709715	SDHAP1	-0.76	-12.73	-0.53	1.17e-31	Pancreatic cancer;
LUAD	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg02931644	chr1:25747376	RHCE	0.48	10.4	0.45	1.05e-22	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg03467027	chr4:99064603	C4orf37	0.41	6.65	0.31	8.93e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.74	-0.35	7.45e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2274273	0.662	rs66476033	chr14:55660863	C/A	cg04306507	chr14:55594613	LGALS3	0.42	7.82	0.36	4.39e-14	Protein biomarker;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25696485	chr21:38445943	PIGP;TTC3	-0.51	-6.37	-0.3	4.86e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9826463	0.582	rs73238155	chr3:142073145	G/A	cg20824294	chr3:142316082	PLS1	0.4	6.99	0.32	1.11e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg19743168	chr1:23544995	NA	0.39	6.84	0.32	2.72e-11	Height;
LUAD	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg21984481	chr17:79567631	NPLOC4	-0.55	-11.61	-0.49	3.09e-27	Eye color traits;
LUAD	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18876405	chr7:65276391	NA	-0.42	-6.68	-0.31	7.32e-11	Aortic root size;
LUAD	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.57	-9.86	-0.43	8.78e-21	Electrocardiographic conduction measures;
LUAD	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg18230493	chr5:56204884	C5orf35	-0.57	-9.45	-0.42	2.37e-19	Coronary artery disease;
LUAD	cis	rs870825	0.655	rs10033035	chr4:185630880	T/C	cg04058563	chr4:185651563	MLF1IP	0.9	14.37	0.57	2.08e-38	Blood protein levels;
LUAD	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg07926092	chr13:79233506	RNF219	0.75	10.35	0.45	1.57e-22	Large artery stroke;
LUAD	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg24690094	chr11:67383802	NA	0.41	7.26	0.33	1.82e-12	Mean corpuscular volume;
LUAD	cis	rs597583	0.950	rs473343	chr11:117408156	G/C	cg27161313	chr11:117392002	DSCAML1	-0.41	-6.98	-0.32	1.13e-11	Putamen volume;
LUAD	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg04455712	chr21:45112962	RRP1B	0.51	10.75	0.46	5.59e-24	Mean corpuscular volume;
LUAD	trans	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.38	-0.3	4.78e-10	Depression;
LUAD	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	cis	rs9914544	0.545	rs8071783	chr17:18807939	C/G	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.5	-0.3	2.26e-10	Educational attainment (years of education);
LUAD	trans	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg17712092	chr4:129076599	LARP1B	-0.93	-18.6	-0.67	7.66e-57	Eosinophil percentage of white cells;
LUAD	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.1	-0.57	2.78e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-6.59	-0.3	1.34e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs11771526	0.681	rs62457535	chr7:32358710	C/G	cg27511599	chr7:32358540	NA	0.62	7.01	0.32	9.72e-12	Body mass index;
LUAD	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.58	0.3	1.39e-10	Parkinson's disease;
LUAD	cis	rs7903847	0.642	rs11189172	chr10:99135215	T/C	cg08345082	chr10:99160200	RRP12	-0.34	-6.71	-0.31	6.45e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs8018808	1.000	rs4899652	chr14:77848972	A/G	cg20045696	chr14:77926864	AHSA1	-0.37	-6.74	-0.31	5.07e-11	Myeloid white cell count;
LUAD	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg24308560	chr3:49941425	MST1R	0.42	6.87	0.32	2.36e-11	Menarche (age at onset);
LUAD	cis	rs11771526	0.681	rs117559022	chr7:32405120	C/T	cg27532318	chr7:32358331	NA	0.67	7.09	0.33	5.51e-12	Body mass index;
LUAD	trans	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg18187862	chr3:45730750	SACM1L	-0.54	-7.97	-0.36	1.51e-14	Primary sclerosing cholangitis;
LUAD	cis	rs1595825	0.945	rs73058813	chr2:198858268	A/G	cg00361562	chr2:198649771	BOLL	-0.45	-6.47	-0.3	2.71e-10	Ulcerative colitis;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg14660007	chr13:78271894	SLAIN1	-0.37	-6.38	-0.3	4.73e-10	Schizophrenia;
LUAD	cis	rs9486719	0.948	rs2499817	chr6:96878321	C/T	cg06623918	chr6:96969491	KIAA0776	0.71	10.02	0.44	2.32e-21	Migraine;Coronary artery disease;
LUAD	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg07169764	chr2:136633963	MCM6	0.82	9.73	0.43	2.45e-20	Corneal structure;
LUAD	cis	rs62238980	0.614	rs4820062	chr22:32392437	T/C	cg00543991	chr22:32367038	NA	0.92	8.16	0.37	3.95e-15	Childhood ear infection;
LUAD	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.39	8.28	0.37	1.64e-15	Hemoglobin concentration;
LUAD	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.81	-12.48	-0.52	1.22e-30	Chronic sinus infection;
LUAD	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg00071950	chr4:10020882	SLC2A9	0.76	15.47	0.6	4.22e-43	Bone mineral density;
LUAD	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg07538946	chr5:131705188	SLC22A5	0.53	8.59	0.39	1.74e-16	Blood metabolite levels;
LUAD	cis	rs9346649	0.654	rs12527055	chr6:168492655	C/T	cg02770688	chr6:168491649	NA	0.53	9.9	0.43	6.35e-21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs6445967	0.593	rs7644457	chr3:58417190	G/C	cg23715586	chr3:58305044	RPP14	0.4	6.61	0.31	1.17e-10	Platelet count;
LUAD	cis	rs4664308	0.905	rs62175518	chr2:160915149	C/T	cg03641300	chr2:160917029	PLA2R1	-0.4	-7.11	-0.33	4.88e-12	Idiopathic membranous nephropathy;
LUAD	cis	rs12545109	0.765	rs2438063	chr8:57384360	A/G	cg17761419	chr8:57350749	NA	0.55	8.12	0.37	5.21e-15	Obesity-related traits;
LUAD	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg21204522	chr6:27730016	NA	0.49	7.99	0.36	1.28e-14	Parkinson's disease;
LUAD	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg15997130	chr1:24165203	NA	0.57	10.17	0.44	7.27e-22	Immature fraction of reticulocytes;
LUAD	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-7.06	-0.32	6.71e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.79	-0.31	3.92e-11	Height;
LUAD	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.62	0.31	1.12e-10	Schizophrenia;
LUAD	trans	rs7200543	1.000	rs34614532	chr16:15132908	T/C	cg24683922	chr1:11983373	KIAA2013	-0.49	-8.24	-0.37	2.15e-15	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg05373962	chr22:49881684	NA	-0.48	-9.99	-0.44	3.08e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs2224391	0.628	rs2753223	chr6:5244317	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-8.68	-0.39	8.61e-17	Height;
LUAD	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg21100191	chr22:23484243	RTDR1	0.73	12.77	0.53	8.53e-32	Bone mineral density;
LUAD	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg05434287	chr7:2030229	MAD1L1	0.43	7.19	0.33	2.99e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.15	-0.37	4.24e-15	Cannabis dependence symptom count;
LUAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg22535103	chr8:58192502	C8orf71	-0.68	-7.31	-0.34	1.3e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2041840	0.521	rs4670193	chr2:37536488	G/A	cg25727520	chr2:37576821	QPCT	-0.36	-7.57	-0.35	2.29e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg20203395	chr5:56204925	C5orf35	-0.63	-9.62	-0.42	5.99e-20	Initial pursuit acceleration;
LUAD	cis	rs7945705	0.791	rs7944560	chr11:8817276	A/T	cg10639395	chr11:8710044	RPL27A	-0.33	-6.37	-0.3	4.84e-10	Hemoglobin concentration;
LUAD	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg09796270	chr17:17721594	SREBF1	0.36	6.92	0.32	1.69e-11	Total body bone mineral density;
LUAD	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg15117754	chr3:10150083	C3orf24	0.45	7.46	0.34	4.87e-13	Alzheimer's disease;
LUAD	cis	rs4523957	0.855	rs1231206	chr17:2125605	G/A	cg16513277	chr17:2031491	SMG6	-0.8	-14.85	-0.59	1.95e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg07917127	chr4:99064746	C4orf37	0.45	7.27	0.33	1.71e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9309473	0.687	rs12465867	chr2:73612102	C/T	cg20560298	chr2:73613845	ALMS1	-0.42	-6.53	-0.3	1.91e-10	Metabolite levels;
LUAD	trans	rs1493916	0.870	rs7239173	chr18:31395534	A/T	cg27147174	chr7:100797783	AP1S1	-0.69	-12.54	-0.52	7.11e-31	Life satisfaction;
LUAD	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg23950597	chr19:37808831	NA	-0.65	-7.71	-0.35	9.3e-14	Coronary artery calcification;
LUAD	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.86	-0.32	2.45e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs7944735	0.671	rs7106731	chr11:48003392	T/G	cg15704280	chr7:45808275	SEPT13	0.64	9.06	0.4	4.83e-18	Intraocular pressure;
LUAD	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg11502198	chr6:26597334	ABT1	0.54	9.14	0.41	2.56e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs4285028	0.948	rs7651226	chr3:121670802	G/T	cg11130432	chr3:121712080	ILDR1	-0.59	-8.33	-0.38	1.1e-15	Multiple sclerosis;
LUAD	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg03213289	chr20:61660250	NA	0.69	14.76	0.58	4.6e-40	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg05665937	chr4:1216051	CTBP1	0.44	7.45	0.34	5.17e-13	Obesity-related traits;
LUAD	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg12310025	chr6:25882481	NA	0.5	8.03	0.36	9.68e-15	Blood metabolite levels;
LUAD	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg17757837	chr7:157058334	UBE3C	0.49	8.66	0.39	9.83e-17	Body mass index;
LUAD	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-9.25	-0.41	1.16e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16015499	chr1:159888603	TAGLN2	0.46	7.43	0.34	6.21e-13	Height;
LUAD	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg11845111	chr2:191398756	TMEM194B	-0.84	-11.11	-0.48	2.36e-25	Diastolic blood pressure;
LUAD	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg18446336	chr7:2847575	GNA12	-0.36	-6.77	-0.31	4.36e-11	Height;
LUAD	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg18105134	chr13:113819100	PROZ	-0.83	-14.78	-0.58	3.88e-40	Platelet distribution width;
LUAD	cis	rs4253772	0.530	rs9615980	chr22:46791143	A/T	cg00784671	chr22:46762841	CELSR1	-0.61	-7.38	-0.34	8.66e-13	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.7	11.97	0.5	1.22e-28	Mean corpuscular volume;
LUAD	cis	rs4523957	0.620	rs898749	chr17:2085185	G/A	cg16513277	chr17:2031491	SMG6	-0.95	-18.95	-0.68	2.08e-58	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	8.36	0.38	9.4e-16	Schizophrenia;
LUAD	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg04539111	chr16:67997858	SLC12A4	-0.5	-6.72	-0.31	5.99e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg22676075	chr6:135203613	NA	0.39	7.17	0.33	3.47e-12	Red blood cell count;
LUAD	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg25324976	chr17:61989376	CSHL1	0.36	6.99	0.32	1.06e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg27284194	chr4:1044797	NA	0.67	8.99	0.4	8.09e-18	Recombination rate (females);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21038964	chr1:155113214	DPM3	-0.4	-6.37	-0.3	5.02e-10	Cancer;
LUAD	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.75	0.31	4.93e-11	Colorectal cancer;
LUAD	cis	rs6998277	0.830	rs12543046	chr8:103603809	A/G	cg10187029	chr8:103597600	NA	-0.86	-16.61	-0.63	4.65e-48	Migraine;
LUAD	cis	rs3772130	0.583	rs34051021	chr3:121433005	C/A	cg20356878	chr3:121714668	ILDR1	0.6	11.32	0.48	3.83e-26	Cognitive performance;
LUAD	trans	rs2262909	0.962	rs11667209	chr19:22259467	A/G	cg17074339	chr11:11642133	GALNTL4	0.47	7.7	0.35	9.49e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1816752	0.783	rs7317712	chr13:24985503	C/T	cg02811702	chr13:24901961	NA	0.43	7.38	0.34	8.61e-13	Obesity-related traits;
LUAD	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg26513180	chr16:89883248	FANCA	0.78	7.09	0.33	5.51e-12	Skin colour saturation;
LUAD	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg05234568	chr11:5960015	NA	-0.55	-9.91	-0.43	6.02e-21	DNA methylation (variation);
LUAD	cis	rs9462027	0.628	rs7771778	chr6:34660324	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.33	8.58	0.38	1.86e-16	Systemic lupus erythematosus;
LUAD	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.61	-0.31	1.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg24846343	chr22:24311635	DDTL	0.76	17.13	0.64	2.37e-50	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg05313129	chr8:58192883	C8orf71	-0.55	-7.15	-0.33	3.91e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs62400317	0.859	rs62438863	chr6:45040592	C/T	cg18551225	chr6:44695536	NA	-0.58	-8.88	-0.4	1.88e-17	Total body bone mineral density;
LUAD	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg07810366	chr2:100720526	AFF3	-0.35	-7.11	-0.33	4.92e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg23996000	chr6:157721067	C6orf35	0.7	6.82	0.31	3.22e-11	Type 2 diabetes;
LUAD	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.33	-6.48	-0.3	2.59e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	10.28	0.45	2.73e-22	Axial length;
LUAD	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg20701182	chr2:24300061	SF3B14	0.91	13.54	0.55	6.17e-35	Lymphocyte counts;
LUAD	cis	rs73072330	1.000	rs17729010	chr3:47912703	A/G	cg09665691	chr3:47563885	NA	-0.91	-7.1	-0.33	5.35e-12	Stem cell growth factor beta levels;
LUAD	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7274811	0.901	rs55990870	chr20:32302908	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.51	-6.91	-0.32	1.78e-11	Height;
LUAD	trans	rs587242	1.000	rs661573	chr1:96891371	G/A	cg10631902	chr5:14652156	NA	0.44	7.22	0.33	2.4e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg07538946	chr5:131705188	SLC22A5	-0.54	-9.16	-0.41	2.21e-18	Blood metabolite levels;
LUAD	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg17689763	chr4:710664	PCGF3	-0.59	-10.0	-0.44	2.83e-21	White blood cell count;
LUAD	cis	rs4713675	0.565	rs2281829	chr6:33675642	A/G	cg13859433	chr6:33739653	LEMD2	-0.29	-6.88	-0.32	2.11e-11	Plateletcrit;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06589161	chr5:180618230	NA	-0.52	-6.35	-0.3	5.62e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg18825076	chr15:78729989	IREB2	0.46	6.4	0.3	4.1e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs4332037	0.722	rs4721140	chr7:1917635	A/T	cg02421172	chr7:1938701	MAD1L1	0.41	6.46	0.3	2.97e-10	Bipolar disorder;
LUAD	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21582582	chr3:182698605	DCUN1D1	0.72	14.04	0.56	4.91e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24308560	chr3:49941425	MST1R	-0.57	-9.53	-0.42	1.24e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg18230493	chr5:56204884	C5orf35	-0.84	-12.35	-0.51	4.05e-30	Initial pursuit acceleration;
LUAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13126279	chr21:47581558	C21orf56	-0.61	-10.9	-0.47	1.46e-24	Testicular germ cell tumor;
LUAD	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg21918786	chr6:109611834	NA	-0.58	-11.03	-0.47	4.88e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-9.2	-0.41	1.68e-18	Life satisfaction;
LUAD	cis	rs9522267	0.535	rs11069900	chr13:112233285	G/A	cg10483660	chr13:112241077	NA	-0.32	-6.93	-0.32	1.55e-11	Hepatitis;
LUAD	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg00310523	chr12:86230176	RASSF9	0.39	8.07	0.37	7.24e-15	Major depressive disorder;
LUAD	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg08632164	chr7:65971372	NA	-0.38	-6.56	-0.3	1.56e-10	Aortic root size;
LUAD	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-15.24	-0.6	4.28e-42	Schizophrenia;
LUAD	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg17757837	chr7:157058334	UBE3C	-0.51	-9.11	-0.4	3.35e-18	Body mass index;
LUAD	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg04287289	chr16:89883240	FANCA	0.7	12.84	0.53	4.09e-32	Vitiligo;
LUAD	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35883536	0.611	rs61070860	chr1:101097628	G/A	cg06223162	chr1:101003688	GPR88	0.39	7.15	0.33	3.79e-12	Monocyte count;
LUAD	cis	rs7851660	0.679	rs7033765	chr9:100591705	A/T	cg13688889	chr9:100608707	NA	0.4	7.59	0.35	2.11e-13	Strep throat;
LUAD	cis	rs9362426	1.000	rs173334	chr6:88080223	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	6.58	0.3	1.4e-10	Depressive episodes in bipolar disorder;
LUAD	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.44	-0.34	5.63e-13	Menopause (age at onset);
LUAD	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg23172400	chr8:95962367	TP53INP1	0.3	6.49	0.3	2.46e-10	Type 2 diabetes;
LUAD	cis	rs807669	0.934	rs762523	chr22:19180589	A/G	cg02655711	chr22:19163373	SLC25A1	0.87	19.03	0.68	9.21e-59	Metabolite levels;
LUAD	cis	rs3106136	0.967	rs12643901	chr4:95145132	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.6	-0.35	1.89e-13	Capecitabine sensitivity;
LUAD	trans	rs11039798	1.000	rs11039904	chr11:48682597	T/A	cg03929089	chr4:120376271	NA	0.6	6.86	0.32	2.45e-11	Axial length;
LUAD	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg14552801	chr7:65878734	NA	-0.37	-6.37	-0.3	4.8e-10	Aortic root size;
LUAD	cis	rs68170813	0.559	rs12537785	chr7:107050221	T/C	cg23024343	chr7:107201750	COG5	0.5	7.2	0.33	2.75e-12	Coronary artery disease;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg15985338	chr7:6048868	PMS2;AIMP2	0.42	6.71	0.31	6.26e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.35	7.01	0.32	9.51e-12	Depression;
LUAD	cis	rs11677370	0.561	rs4849990	chr2:3819558	A/G	cg17052675	chr2:3827356	NA	-0.57	-9.54	-0.42	1.17e-19	Type 2 diabetes;
LUAD	cis	rs28655083	1.000	rs1875582	chr16:77063147	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.4	6.73	0.31	5.68e-11	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9329221	0.655	rs4316191	chr8:10259229	G/A	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.71	-0.31	6.17e-11	Neuroticism;
LUAD	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg10876282	chr6:28092338	ZSCAN16	0.45	7.31	0.33	1.39e-12	Parkinson's disease;
LUAD	trans	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg27411982	chr8:10470053	RP1L1	0.42	7.68	0.35	1.1e-13	Joint mobility (Beighton score);
LUAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08280861	chr8:58055591	NA	0.54	6.47	0.3	2.64e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs12545109	0.765	rs2438063	chr8:57384360	A/G	cg09654669	chr8:57350985	NA	0.67	9.8	0.43	1.4e-20	Obesity-related traits;
LUAD	cis	rs2554380	0.943	rs11636516	chr15:84361773	A/T	cg14598478	chr15:84363061	ADAMTSL3	-0.59	-8.92	-0.4	1.42e-17	Height;
LUAD	cis	rs7671266	0.532	rs7349721	chr4:10042562	A/T	cg00071950	chr4:10020882	SLC2A9	0.53	7.85	0.36	3.42e-14	Cardiovascular disease risk factors;
LUAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.6	-0.31	1.21e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4711350	0.954	rs1536501	chr6:33727885	C/T	cg18005901	chr6:33739558	LEMD2	0.51	7.46	0.34	5.06e-13	Schizophrenia;
LUAD	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg08999081	chr20:33150536	PIGU	-0.63	-13.85	-0.56	3.21e-36	Glomerular filtration rate (creatinine);
LUAD	trans	rs2184971	0.522	rs9518030	chr13:100902925	A/G	cg06556929	chr8:142368169	GPR20	0.32	6.42	0.3	3.75e-10	Refractive error;
LUAD	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg13385794	chr1:248469461	NA	0.24	6.4	0.3	4.07e-10	Common traits (Other);
LUAD	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.67	12.58	0.52	4.58e-31	Cognitive ability;
LUAD	cis	rs1595825	0.891	rs16866980	chr2:198513009	A/C	cg10547527	chr2:198650123	BOLL	-0.54	-7.74	-0.35	7.64e-14	Ulcerative colitis;
LUAD	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg03340356	chr1:67600835	NA	0.39	6.89	0.32	2.01e-11	Psoriasis;
LUAD	cis	rs4588572	0.537	rs7702000	chr5:77730556	A/G	cg11547950	chr5:77652471	NA	-0.62	-10.68	-0.46	1e-23	Triglycerides;
LUAD	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg21385522	chr1:16154831	NA	0.58	8.61	0.39	1.51e-16	Dilated cardiomyopathy;
LUAD	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg25036284	chr2:26402008	FAM59B	-0.83	-11.78	-0.5	6.58e-28	Gut microbiome composition (summer);
LUAD	cis	rs3774830	0.748	rs7698146	chr4:5465476	G/A	cg26943120	chr4:5472116	STK32B	0.38	7.85	0.36	3.55e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg04398451	chr17:18023971	MYO15A	-0.65	-11.74	-0.5	1e-27	Total body bone mineral density;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04151384	chr11:10315732	SBF2	-0.52	-6.55	-0.3	1.72e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4713675	0.584	rs4713661	chr6:33674174	C/A	cg14003231	chr6:33640908	ITPR3	0.5	9.55	0.42	1.04e-19	Plateletcrit;
LUAD	cis	rs2046867	0.862	rs62251657	chr3:72832076	C/T	cg04365224	chr3:72788183	NA	-0.47	-6.86	-0.32	2.39e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg05132306	chr1:1846340	CALML6	-0.35	-7.57	-0.35	2.41e-13	Body mass index;
LUAD	cis	rs62400317	0.762	rs6909047	chr6:44998915	C/G	cg18551225	chr6:44695536	NA	-0.5	-7.33	-0.34	1.15e-12	Total body bone mineral density;
LUAD	cis	rs1210638	0.575	rs11703200	chr22:18959169	G/A	cg14259594	chr22:18958660	DGCR5	0.74	10.76	0.46	5.12e-24	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs12711979	0.512	rs1466227	chr2:3832358	T/C	cg17052675	chr2:3827356	NA	-0.37	-6.62	-0.31	1.12e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg26384229	chr12:38710491	ALG10B	0.48	7.82	0.36	4.31e-14	Bladder cancer;
LUAD	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg24733560	chr20:60626293	TAF4	0.46	8.04	0.36	9.3e-15	Body mass index;
LUAD	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11644478	chr21:40555479	PSMG1	0.57	8.49	0.38	3.58e-16	Cognitive function;
LUAD	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg20135002	chr11:47629003	NA	-0.42	-7.27	-0.33	1.72e-12	Subjective well-being;
LUAD	cis	rs16910800	1.000	rs2449442	chr11:23197362	C/T	cg20040320	chr11:23191996	NA	0.47	7.3	0.33	1.41e-12	Cancer;
LUAD	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24531977	chr5:56204891	C5orf35	-1.0	-15.19	-0.59	6.67e-42	Initial pursuit acceleration;
LUAD	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg14671364	chr1:107599128	PRMT6	0.56	9.35	0.41	5.26e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9972944	0.702	rs6416946	chr17:63763967	C/T	cg07283582	chr17:63770753	CCDC46	-0.5	-11.17	-0.48	1.48e-25	Total body bone mineral density;
LUAD	cis	rs938554	0.784	rs11726102	chr4:9951664	T/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-7.97	-0.36	1.51e-14	Blood metabolite levels;
LUAD	cis	rs3096299	0.900	rs4785666	chr16:89462771	C/G	cg06640241	chr16:89574553	SPG7	0.49	8.02	0.36	1.06e-14	Multiple myeloma (IgH translocation);
LUAD	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg13390004	chr1:15929781	NA	0.48	8.51	0.38	3.05e-16	Systolic blood pressure;
LUAD	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg02569458	chr12:86230093	RASSF9	0.43	7.89	0.36	2.61e-14	Major depressive disorder;
LUAD	cis	rs1160297	0.576	rs6746666	chr2:53089346	C/T	cg07782112	chr2:53107842	NA	0.34	7.35	0.34	1.04e-12	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.28	0.54	7.04e-34	Prudent dietary pattern;
LUAD	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg10544611	chr16:67998164	SLC12A4	-0.63	-7.4	-0.34	7.62e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7680126	0.596	rs10020887	chr4:10140751	C/G	cg02734326	chr4:10020555	SLC2A9	-0.48	-6.64	-0.31	9.72e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.47	-0.3	2.65e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	6.92	0.32	1.64e-11	Platelet count;
LUAD	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg06608945	chr2:219082296	ARPC2	0.44	7.41	0.34	6.84e-13	Colorectal cancer;
LUAD	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg26597838	chr10:835615	NA	0.72	9.14	0.41	2.59e-18	Eosinophil percentage of granulocytes;
LUAD	cis	rs870825	0.929	rs55746424	chr4:185589603	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	10.36	0.45	1.44e-22	Blood protein levels;
LUAD	cis	rs2625529	0.668	rs72733369	chr15:72567260	G/A	cg16672083	chr15:72433130	SENP8	-0.77	-12.99	-0.53	1.09e-32	Red blood cell count;
LUAD	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.1	-0.57	2.72e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg13385794	chr1:248469461	NA	0.27	7.17	0.33	3.46e-12	Common traits (Other);
LUAD	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.64	11.24	0.48	8.16e-26	Birth weight;
LUAD	cis	rs6499188	0.571	rs1645975	chr16:68564448	C/T	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.3100000000000001e-10	Ulcerative colitis;
LUAD	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg09737314	chr17:6899359	ALOX12	-0.36	-7.0	-0.32	1.03e-11	Tonsillectomy;
LUAD	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-6.59	-0.31	1.33e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26314531	chr2:26401878	FAM59B	-0.64	-8.7	-0.39	7.27e-17	Gut microbiome composition (summer);
LUAD	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg07256732	chr16:621771	PIGQ	-0.32	-6.5	-0.3	2.31e-10	Height;
LUAD	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.61	-0.35	1.82e-13	Blood metabolite levels;
LUAD	cis	rs2797685	1.000	rs707466	chr1:7861600	C/A	cg04725166	chr1:7887271	PER3	-0.47	-6.86	-0.32	2.38e-11	Crohn's disease;
LUAD	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.67	0.35	1.19e-13	Bladder cancer;
LUAD	cis	rs250677	0.522	rs2895837	chr5:148357535	C/T	cg12140854	chr5:148520817	ABLIM3	0.57	9.03	0.4	6.04e-18	Breast cancer;
LUAD	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg05805236	chr11:65401703	PCNXL3	-0.54	-8.9	-0.4	1.65e-17	Acne (severe);
LUAD	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg13271783	chr10:134563150	INPP5A	-0.41	-7.11	-0.33	5.11e-12	Migraine;
LUAD	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg27490568	chr2:178487706	NA	0.39	6.43	0.3	3.44e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs459571	0.804	rs448918	chr9:136885979	G/A	cg13789015	chr9:136890014	NCRNA00094	0.84	14.18	0.57	1.31e-37	Platelet distribution width;
LUAD	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg01206211	chr2:36825736	FEZ2	-0.49	-9.5	-0.42	1.54e-19	Height;
LUAD	cis	rs151234	0.676	rs231970	chr16:28567004	A/G	cg04609801	chr16:28609176	SULT1A2	0.62	8.88	0.4	1.97e-17	Platelet distribution width;
LUAD	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg23649088	chr2:200775458	C2orf69	-0.62	-7.8	-0.35	4.98e-14	Schizophrenia;
LUAD	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg10518543	chr12:38710700	ALG10B	0.41	6.37	0.3	4.83e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7799006	0.723	rs33922585	chr7:2285178	C/T	cg08027265	chr7:2291960	NA	-0.75	-14.77	-0.58	4.11e-40	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03517284	chr6:25882590	NA	-0.55	-9.34	-0.41	5.34e-19	Blood metabolite levels;
LUAD	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05665937	chr4:1216051	CTBP1	0.45	6.8	0.31	3.68e-11	Longevity;
LUAD	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg20701182	chr2:24300061	SF3B14	0.89	13.24	0.54	1.04e-33	Lymphocyte counts;
LUAD	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs9902453	1.000	rs28664971	chr17:28437410	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.14	0.44	8.82e-22	Coffee consumption (cups per day);
LUAD	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.66	-0.31	8.4e-11	Schizophrenia;
LUAD	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg22431228	chr1:16359049	CLCNKA	-0.42	-8.27	-0.37	1.71e-15	Systolic blood pressure;
LUAD	cis	rs2625529	0.556	rs35603965	chr15:72523043	C/T	cg16672083	chr15:72433130	SENP8	0.66	12.01	0.5	8.42e-29	Red blood cell count;
LUAD	trans	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg14791747	chr16:20752902	THUMPD1	-0.49	-7.57	-0.35	2.3e-13	Dental caries;
LUAD	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg00129232	chr17:37814104	STARD3	-0.45	-7.67	-0.35	1.21e-13	Asthma;
LUAD	cis	rs2880765	0.835	rs12910373	chr15:86046802	G/C	cg04831495	chr15:85060580	GOLGA6L5	-0.37	-6.35	-0.3	5.56e-10	Coronary artery disease;
LUAD	cis	rs1395	0.922	rs1561535	chr2:27471025	C/T	cg23587288	chr2:27483067	SLC30A3	-0.39	-7.8	-0.35	5.05e-14	Blood metabolite levels;
LUAD	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg06753367	chr22:24256600	NA	-0.36	-6.61	-0.31	1.19e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7107174	0.892	rs2510042	chr11:77923665	C/T	cg19901956	chr11:77921274	USP35	-0.51	-6.52	-0.3	2.07e-10	Testicular germ cell tumor;
LUAD	cis	rs6993813	0.872	rs4424291	chr8:120018735	A/G	cg01975934	chr8:119970761	NA	-0.37	-7.32	-0.34	1.29e-12	Bone mineral density (hip);
LUAD	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.61	-0.31	1.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg06618935	chr21:46677482	NA	-0.45	-8.13	-0.37	4.65e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11677416	1.000	rs1040193	chr2:113530099	C/T	cg27083787	chr2:113543245	IL1A	0.4	6.79	0.31	3.84e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs7394190	0.748	rs3781216	chr10:75522404	G/A	cg02286717	chr10:75415704	SYNPO2L	-0.37	-6.52	-0.3	2e-10	Incident atrial fibrillation;
LUAD	cis	rs8044868	0.521	rs7203821	chr16:72101165	T/C	cg23815491	chr16:72088622	HP	0.54	10.24	0.45	4.05e-22	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg14668632	chr7:2872130	GNA12	-0.73	-13.22	-0.54	1.18e-33	Height;
LUAD	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg10435618	chr10:838112	NA	0.47	6.42	0.3	3.63e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg24154853	chr7:158122151	PTPRN2	0.56	11.21	0.48	1.02e-25	Calcium levels;
LUAD	cis	rs9462027	0.628	rs9469887	chr6:34758940	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.0	-0.4	7.78e-18	Systemic lupus erythematosus;
LUAD	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg18827107	chr12:86230957	RASSF9	0.54	9.74	0.43	2.24e-20	Major depressive disorder;
LUAD	cis	rs6456156	1.000	rs7761159	chr6:167519907	T/A	cg07741184	chr6:167504864	NA	0.3	6.8	0.31	3.61e-11	Primary biliary cholangitis;
LUAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.19	-0.44	5.9e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs11167764	0.638	rs7729747	chr5:141478055	C/A	cg23435118	chr5:141488016	NDFIP1	-0.49	-7.16	-0.33	3.54e-12	Crohn's disease;
LUAD	cis	rs1030268	0.505	rs77112963	chr7:133259399	G/A	cg10665199	chr7:133106180	EXOC4	0.47	6.52	0.3	1.99e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.74	0.39	5.6e-17	Menopause (age at onset);
LUAD	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-8.22	-0.37	2.5e-15	Hemoglobin concentration;
LUAD	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg25036284	chr2:26402008	FAM59B	-0.83	-11.68	-0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs7107174	0.892	rs11601866	chr11:78011153	G/A	cg19901956	chr11:77921274	USP35	-0.55	-6.8	-0.31	3.66e-11	Testicular germ cell tumor;
LUAD	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg08470875	chr2:26401718	FAM59B	-0.77	-10.38	-0.45	1.18e-22	Gut microbiome composition (summer);
LUAD	cis	rs2282300	0.739	rs1222210	chr11:30362125	A/G	cg06241208	chr11:30344200	C11orf46	0.62	8.2	0.37	2.92e-15	Morning vs. evening chronotype;
LUAD	cis	rs13082711	0.596	rs683503	chr3:27348094	C/T	cg02860705	chr3:27208620	NA	0.59	9.8	0.43	1.43e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08048268	chr3:133502702	NA	-0.52	-10.35	-0.45	1.51e-22	Iron status biomarkers;
LUAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg13047869	chr3:10149882	C3orf24	0.62	10.46	0.45	6.42e-23	Alzheimer's disease;
LUAD	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg13560548	chr3:10150139	C3orf24	0.42	7.05	0.32	7.39e-12	Alzheimer's disease;
LUAD	cis	rs1595825	0.891	rs16825917	chr2:198805185	C/T	cg11031976	chr2:198649780	BOLL	-0.49	-7.13	-0.33	4.41e-12	Ulcerative colitis;
LUAD	cis	rs863345	0.647	rs923663	chr1:158507732	A/T	cg12129480	chr1:158549410	OR10X1	0.25	6.8	0.31	3.55e-11	Pneumococcal bacteremia;
LUAD	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.69	-0.35	1.05e-13	Bipolar disorder;
LUAD	cis	rs7149337	0.869	rs10137481	chr14:51694614	C/T	cg23942311	chr14:51606299	NA	0.83	18.71	0.67	2.47e-57	Cancer;
LUAD	cis	rs760805	1.000	rs11249204	chr1:25261740	C/T	cg22509179	chr1:25234806	RUNX3	0.74	13.44	0.55	1.47e-34	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg10518543	chr12:38710700	ALG10B	-0.47	-7.69	-0.35	1.01e-13	Morning vs. evening chronotype;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg23627909	chr14:60337760	RTN1	-0.38	-6.8	-0.31	3.65e-11	Subcortical brain region volumes;
LUAD	trans	rs853679	0.607	rs35749575	chr6:28114818	G/T	cg01620082	chr3:125678407	NA	-1.1	-10.38	-0.45	1.25e-22	Depression;
LUAD	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22496380	chr5:211416	CCDC127	-0.94	-13.19	-0.54	1.7e-33	Breast cancer;
LUAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg05313129	chr8:58192883	C8orf71	-0.57	-8.38	-0.38	7.67e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6541297	1.000	rs6674744	chr1:230279011	C/T	cg20703242	chr1:230279135	GALNT2	0.66	12.03	0.5	7.15e-29	Coronary artery disease;
LUAD	cis	rs6445967	0.569	rs12495873	chr3:58322118	T/G	cg23715586	chr3:58305044	RPP14	0.4	6.35	0.3	5.5e-10	Platelet count;
LUAD	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg14092988	chr3:52407081	DNAH1	0.41	8.26	0.37	1.88e-15	Bipolar disorder;
LUAD	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.64	11.93	0.5	1.78e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg18252515	chr7:66147081	NA	-0.6	-6.73	-0.31	5.43e-11	Diabetic kidney disease;
LUAD	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg11494091	chr17:61959527	GH2	0.4	7.04	0.32	7.97e-12	Height;
LUAD	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg02733842	chr7:1102375	C7orf50	-0.62	-9.93	-0.43	5.05e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg27471124	chr11:109292789	C11orf87	0.35	6.89	0.32	2.05e-11	Schizophrenia;
LUAD	cis	rs2629540	0.855	rs12776722	chr10:126469833	G/A	cg08799069	chr10:126477246	METTL10	0.5	7.21	0.33	2.54e-12	Cocaine dependence;
LUAD	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-7.86	-0.36	3.22e-14	Tonsillectomy;
LUAD	cis	rs317865	0.737	rs16893097	chr4:16156964	G/T	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.7	6.84	0.32	2.84e-11	Kidney disease (early stage) in type 1 diabetes;
LUAD	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg19875535	chr5:140030758	IK	-0.44	-7.45	-0.34	5.22e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg16486109	chr11:613632	IRF7	0.5	7.66	0.35	1.32e-13	Systemic lupus erythematosus;
LUAD	cis	rs12200560	0.505	rs2387378	chr6:97077504	C/A	cg06623918	chr6:96969491	KIAA0776	0.47	7.35	0.34	1.01e-12	Coronary heart disease;
LUAD	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg26769984	chr7:1090371	C7orf50	0.58	9.34	0.41	5.6e-19	Bronchopulmonary dysplasia;
LUAD	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg26818010	chr10:134567672	INPP5A	-0.99	-16.26	-0.62	1.62e-46	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7009516	0.792	rs13265142	chr8:24229709	T/A	cg01759110	chr8:24241694	ADAMDEC1	-0.44	-8.84	-0.39	2.62e-17	Hair greying;
LUAD	cis	rs4730250	0.634	rs11767623	chr7:106792332	C/T	cg02696742	chr7:106810147	HBP1	0.82	10.81	0.47	3.2e-24	Osteoarthritis;
LUAD	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg24399712	chr22:39784796	NA	0.69	12.07	0.51	5.18e-29	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg05283184	chr6:79620031	NA	-0.62	-12.39	-0.52	2.61e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9837602	0.592	rs629120	chr3:99425767	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	6.38	0.3	4.58e-10	Breast cancer;
LUAD	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg24818145	chr4:99064322	C4orf37	0.41	6.92	0.32	1.7e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs2018683	1.000	rs2018683	chr7:29014195	G/T	cg19402173	chr7:128379420	CALU	-0.61	-10.7	-0.46	8.05e-24	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.4	6.82	0.31	3.18e-11	Menarche (age at onset);
LUAD	cis	rs1062753	0.771	rs932376	chr22:42614362	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.38	6.85	0.32	2.55e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs1065852	0.906	rs5751232	chr22:42564304	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.66	11.45	0.49	1.21e-26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg17063962	chr7:91808500	NA	0.68	12.19	0.51	1.65e-29	Breast cancer;
LUAD	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg19729930	chr2:74357872	NA	1.01	18.79	0.67	9.91e-58	Gestational age at birth (maternal effect);
LUAD	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg04455712	chr21:45112962	RRP1B	0.43	8.62	0.39	1.38e-16	Mean corpuscular volume;
LUAD	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg02683114	chr2:24398427	C2orf84	-0.52	-7.72	-0.35	8.48e-14	Asthma;
LUAD	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.59	9.71	0.43	3.02e-20	Birth weight;
LUAD	cis	rs9300255	0.602	rs2695476	chr12:123694206	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-6.43	-0.3	3.42e-10	Neutrophil percentage of white cells;
LUAD	cis	rs67073037	0.915	rs12613887	chr2:29111099	T/C	cg09522027	chr2:28974177	PPP1CB	0.44	6.42	0.3	3.75e-10	Breast cancer;Breast cancer (estrogen-receptor negative);
LUAD	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11644478	chr21:40555479	PSMG1	0.62	10.57	0.46	2.51e-23	Cognitive function;
LUAD	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg21016266	chr12:122356598	WDR66	0.7	12.99	0.53	1.07e-32	Mean corpuscular volume;
LUAD	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg02527881	chr3:46936655	PTH1R	-0.54	-11.0	-0.47	6.55e-25	Colorectal cancer;
LUAD	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg24818145	chr4:99064322	C4orf37	-0.41	-6.91	-0.32	1.76e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.89	9.58	0.42	8.64e-20	Initial pursuit acceleration;
LUAD	cis	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg11822812	chr5:140052017	DND1	-0.43	-7.96	-0.36	1.56e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg01657329	chr11:68192670	LRP5	-0.55	-9.72	-0.43	2.64e-20	Total body bone mineral density;
LUAD	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg25535316	chr11:579198	PHRF1	-0.38	-6.69	-0.31	6.88e-11	Systemic lupus erythematosus;
LUAD	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg18806716	chr10:30721971	MAP3K8	-0.68	-13.6	-0.55	3.36e-35	Inflammatory bowel disease;
LUAD	cis	rs13112683	0.638	rs6825389	chr4:140785463	A/G	cg02876341	chr4:140783585	MAML3	0.31	6.68	0.31	7.35e-11	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LUAD	cis	rs1232027	0.656	rs1650672	chr5:79959734	T/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.02	-0.32	8.65e-12	Huntington's disease progression;
LUAD	cis	rs8044868	0.586	rs7188962	chr16:72098962	A/G	cg23815491	chr16:72088622	HP	0.55	10.36	0.45	1.4e-22	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs9469890	0.604	rs11756281	chr6:34503446	T/C	cg14254433	chr6:34482411	PACSIN1	-0.58	-8.36	-0.38	8.99e-16	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.52	0.42	1.31e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.72	0.31	5.75e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7707921	0.522	rs12374541	chr5:81491408	A/G	cg15871215	chr5:81402204	ATG10	0.65	11.4	0.48	1.94e-26	Breast cancer;
LUAD	cis	rs250585	0.646	rs66569010	chr16:23486952	C/T	cg00143387	chr16:23521605	GGA2	-0.73	-10.32	-0.45	1.95e-22	Egg allergy;
LUAD	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg00071950	chr4:10020882	SLC2A9	0.86	18.29	0.66	1.72e-55	Bone mineral density;
LUAD	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg03354898	chr7:1950403	MAD1L1	-0.37	-7.1	-0.33	5.15e-12	Schizophrenia;
LUAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg09060608	chr5:178986726	RUFY1	0.7	12.46	0.52	1.36e-30	Lung cancer;
LUAD	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg02951883	chr7:2050386	MAD1L1	-0.72	-12.55	-0.52	6.4e-31	Schizophrenia;
LUAD	cis	rs7301016	1.000	rs11174518	chr12:62902550	T/C	cg11441379	chr12:63026424	NA	0.55	6.77	0.31	4.36e-11	IgG glycosylation;
LUAD	cis	rs6539288	0.500	rs11113116	chr12:107195929	C/A	cg15890332	chr12:107067104	RFX4	0.39	8.29	0.37	1.57e-15	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.57	0.52	5.27e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17401966	0.928	rs11121531	chr1:10277357	G/A	cg15208524	chr1:10270712	KIF1B	0.55	7.95	0.36	1.75e-14	Hepatocellular carcinoma;
LUAD	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg02004499	chr7:4244250	SDK1	-0.47	-7.48	-0.34	4.4e-13	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
LUAD	cis	rs2579500	0.660	rs6711452	chr2:97139307	G/A	cg23100626	chr2:96804247	ASTL	0.29	6.9	0.32	1.88e-11	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs4692589	1.000	rs4321597	chr4:170934424	C/T	cg19918862	chr4:170955249	NA	0.29	6.92	0.32	1.73e-11	Anxiety disorder;
LUAD	cis	rs7177699	0.557	rs34372090	chr15:79110735	C/T	cg00540400	chr15:79124168	NA	-0.46	-9.65	-0.42	4.71e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13732083	chr21:47605072	C21orf56	0.59	10.17	0.44	6.81e-22	Testicular germ cell tumor;
LUAD	trans	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg05926928	chr17:57297772	GDPD1	-0.62	-8.42	-0.38	6e-16	Opioid sensitivity;
LUAD	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.78	-0.46	4.31e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs796364	0.589	rs55700082	chr2:201135669	G/A	cg23649088	chr2:200775458	C2orf69	-0.57	-7.87	-0.36	2.91e-14	Schizophrenia;
LUAD	cis	rs2294693	0.947	rs10155663	chr6:40994301	T/G	cg14769373	chr6:40998127	UNC5CL	-0.53	-8.29	-0.37	1.54e-15	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs7843479	1.000	rs2306641	chr8:21833965	A/G	cg03445287	chr8:21823731	XPO7	0.46	8.41	0.38	6.38e-16	Mean corpuscular volume;
LUAD	cis	rs494562	0.892	rs522129	chr6:86116381	A/G	cg27297263	chr6:86160468	NT5E	0.58	6.45	0.3	3.03e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg21385522	chr1:16154831	NA	0.59	8.87	0.4	2.06e-17	Dilated cardiomyopathy;
LUAD	trans	rs801193	0.569	rs881285	chr7:66119420	A/G	cg19163074	chr7:65112434	INTS4L2	0.42	6.4	0.3	4.24e-10	Aortic root size;
LUAD	cis	rs4268898	0.931	rs2551121	chr2:24539967	T/C	cg06627628	chr2:24431161	ITSN2	-0.5	-8.36	-0.38	9.2e-16	Asthma;
LUAD	cis	rs9902453	0.904	rs4461132	chr17:28423430	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.15	0.44	8.55e-22	Coffee consumption (cups per day);
LUAD	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.37	6.7	0.31	6.8e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9633740	0.773	rs1870148	chr10:82271341	G/A	cg00277334	chr10:82204260	NA	-0.63	-8.35	-0.38	9.99e-16	Post bronchodilator FEV1;
LUAD	cis	rs13082711	0.522	rs6790344	chr3:27336531	G/C	cg02860705	chr3:27208620	NA	0.51	8.44	0.38	4.92e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg11050988	chr7:1952600	MAD1L1	0.33	6.71	0.31	6.1e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1595825	0.891	rs1851779	chr2:198647108	C/T	cg11031976	chr2:198649780	BOLL	-0.48	-7.05	-0.32	7.3e-12	Ulcerative colitis;
LUAD	trans	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg18834416	chr8:37888184	EIF4EBP1	-0.4	-6.59	-0.31	1.28e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg00684032	chr4:1343700	KIAA1530	0.41	7.03	0.32	8.18e-12	Obesity-related traits;
LUAD	cis	rs3845702	0.877	rs12693216	chr2:180839793	T/A	cg01881094	chr2:180872142	CWC22	-0.62	-7.74	-0.35	7.52e-14	Schizophrenia;
LUAD	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg01874867	chr7:94954059	PON1	-0.49	-6.62	-0.31	1.08e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg14634687	chr17:47094252	IGF2BP1	0.27	6.71	0.31	6.3e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs12760731	0.565	rs35926996	chr1:178075351	A/G	cg00404053	chr1:178313656	RASAL2	0.71	9.17	0.41	2.14e-18	Obesity-related traits;
LUAD	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11890956	chr21:40555474	PSMG1	0.56	9.78	0.43	1.68e-20	Cognitive function;
LUAD	trans	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	12.38	0.52	2.98e-30	Exhaled nitric oxide output;
LUAD	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.47	-0.42	2.05e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs600231	0.665	rs2105608	chr11:65228618	T/A	cg21890820	chr11:65308645	LTBP3	0.48	7.46	0.34	4.83e-13	Bone mineral density;
LUAD	cis	rs7267979	0.586	rs6050432	chr20:25184028	T/C	cg08601574	chr20:25228251	PYGB	0.36	6.6	0.31	1.22e-10	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg00106254	chr7:1943704	MAD1L1	-0.47	-7.0	-0.32	1e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg21951975	chr1:209979733	IRF6	0.58	9.28	0.41	8.88e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg17200465	chr3:40428508	ENTPD3	0.27	6.75	0.31	4.9e-11	Renal cell carcinoma;
LUAD	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg03188948	chr7:1209495	NA	0.59	6.35	0.3	5.49e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg26043149	chr18:55253948	FECH	-0.42	-6.79	-0.31	3.8e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg17173187	chr15:85201210	NMB	0.34	6.64	0.31	9.46e-11	P wave terminal force;
LUAD	cis	rs10465746	0.658	rs980418	chr1:84365653	T/G	cg10977910	chr1:84465055	TTLL7	0.61	9.92	0.43	5.3e-21	Obesity-related traits;
LUAD	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg07606381	chr6:8435919	SLC35B3	0.42	7.0	0.32	9.8e-12	Motion sickness;
LUAD	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg09137382	chr11:130731461	NA	0.41	7.51	0.34	3.48e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg02158880	chr13:53174818	NA	-0.5	-8.86	-0.4	2.29e-17	Lewy body disease;
LUAD	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg16414030	chr3:133502952	NA	-0.51	-9.04	-0.4	5.76e-18	Iron status biomarkers;
LUAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14893161	chr1:205819251	PM20D1	0.76	15.44	0.6	5.85e-43	Menarche (age at onset);
LUAD	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.45	-6.8	-0.31	3.59e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs7727544	0.545	rs10074490	chr5:131340032	C/T	cg14196790	chr5:131705035	SLC22A5	0.41	6.99	0.32	1.09e-11	Blood metabolite levels;
LUAD	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs9649213	0.519	rs3735258	chr7:97866291	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.68	-9.82	-0.43	1.24e-20	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg15017067	chr4:17643749	FAM184B	-0.37	-6.96	-0.32	1.3e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1003719	0.762	rs3787787	chr21:38463452	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.31e-16	Eye color traits;
LUAD	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg20476274	chr7:133979776	SLC35B4	0.75	13.09	0.54	4e-33	Mean platelet volume;
LUAD	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg13511324	chr14:104056883	C14orf153	0.27	6.51	0.3	2.15e-10	Reticulocyte count;
LUAD	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg09035930	chr12:129282057	SLC15A4	-0.53	-9.93	-0.43	4.87e-21	Systemic lupus erythematosus;
LUAD	trans	rs11989744	0.843	rs10481325	chr8:23560896	G/A	cg03492747	chr16:86543808	FOXF1	0.42	6.83	0.32	3.04e-11	Waist-hip ratio;
LUAD	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg19052272	chr2:3704530	ALLC	-0.64	-10.68	-0.46	9.66e-24	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs7264396	0.563	rs61191623	chr20:34219987	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-7.25	-0.33	2e-12	Total cholesterol levels;
LUAD	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg08523384	chr5:141488047	NDFIP1	-0.49	-7.39	-0.34	8.15e-13	Crohn's disease;
LUAD	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg23750338	chr8:142222470	SLC45A4	0.62	14.14	0.57	1.83e-37	Immature fraction of reticulocytes;
LUAD	trans	rs970548	0.697	rs11239534	chr10:45968590	A/T	cg14222797	chr10:16859974	RSU1	0.58	6.42	0.3	3.59e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg11909912	chr17:43974919	MAPT;LOC100130148	0.4	6.66	0.31	8.55e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg22139774	chr2:100720529	AFF3	-0.36	-7.16	-0.33	3.55e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs494562	0.892	rs515980	chr6:86119917	C/T	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.5	-8.23	-0.37	2.42e-15	Longevity;Endometriosis;
LUAD	cis	rs4642101	0.765	rs3901665	chr3:12824610	C/A	cg24848339	chr3:12840334	CAND2	0.43	8.69	0.39	8.32e-17	QRS complex (12-leadsum);
LUAD	cis	rs7301826	0.610	rs7957899	chr12:131279076	T/C	cg11011512	chr12:131303247	STX2	0.43	7.14	0.33	4.14e-12	Plasma plasminogen activator levels;
LUAD	cis	rs1395	1.000	rs2014252	chr2:27462405	T/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.4	7.45	0.34	5.13e-13	Blood metabolite levels;
LUAD	cis	rs4900538	0.819	rs72698591	chr14:102838896	G/A	cg18135206	chr14:102964638	TECPR2	-1.02	-20.49	-0.71	2.51e-65	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg05340658	chr4:99064831	C4orf37	0.55	9.06	0.4	5.06e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2050392	0.965	rs2265371	chr10:30690840	C/T	cg18806716	chr10:30721971	MAP3K8	-0.56	-10.79	-0.46	3.75e-24	Inflammatory bowel disease;
LUAD	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg26384229	chr12:38710491	ALG10B	-0.41	-6.79	-0.31	3.84e-11	Morning vs. evening chronotype;
LUAD	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19717773	chr7:2847554	GNA12	0.55	9.52	0.42	1.32e-19	Height;
LUAD	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg11502198	chr6:26597334	ABT1	0.56	9.35	0.41	5.23e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg18187862	chr3:45730750	SACM1L	0.49	7.75	0.35	6.89e-14	Primary sclerosing cholangitis;
LUAD	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.96	0.32	1.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.38	0.38	8.15e-16	Platelet count;
LUAD	cis	rs1215050	0.818	rs6532703	chr4:98777486	A/T	cg17366294	chr4:99064904	C4orf37	0.43	7.44	0.34	5.56e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-7.58	-0.35	2.28e-13	Lung cancer;
LUAD	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg02850689	chr1:2391347	NA	-0.38	-8.15	-0.37	4.1e-15	Schizophrenia;
LUAD	cis	rs7107174	1.000	rs2450122	chr11:77930345	T/C	cg02023728	chr11:77925099	USP35	0.53	7.99	0.36	1.34e-14	Testicular germ cell tumor;
LUAD	cis	rs4478137	0.931	rs7665672	chr4:164236875	G/A	cg06758707	chr4:164254230	NPY1R	0.42	6.72	0.31	5.78e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	9.19	0.41	1.74e-18	Platelet count;
LUAD	cis	rs6740322	0.895	rs6760797	chr2:43559612	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.77	-11.09	-0.47	2.95e-25	Coronary artery disease;
LUAD	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.7	-0.31	6.64e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg06784218	chr1:46089804	CCDC17	-0.55	-11.74	-0.5	9.69e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4713118	0.619	rs200486	chr6:27779506	C/T	cg20933634	chr6:27740509	NA	0.5	7.38	0.34	8.36e-13	Parkinson's disease;
LUAD	cis	rs9902453	0.967	rs4429345	chr17:28458105	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.51	-8.72	-0.39	6.41e-17	Coffee consumption (cups per day);
LUAD	cis	rs754466	0.606	rs55854323	chr10:79589904	C/T	cg17075019	chr10:79541650	NA	-0.89	-18.45	-0.67	3.46e-56	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.83	0.43	1.16e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26007540	chr17:38574415	TOP2A	-0.4	-6.55	-0.3	1.64e-10	Cancer;
LUAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.21	0.37	2.63e-15	Rheumatoid arthritis;
LUAD	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg02493740	chr2:85810744	VAMP5	-0.47	-8.58	-0.39	1.81e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs4588572	0.643	rs10043027	chr5:77792707	T/C	cg11547950	chr5:77652471	NA	-0.76	-12.21	-0.51	1.39e-29	Triglycerides;
LUAD	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg08888203	chr3:10149979	C3orf24	0.72	12.87	0.53	3.25e-32	Alzheimer's disease;
LUAD	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.07e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10841076	chr16:3174662	NA	-0.43	-6.89	-0.32	2.01e-11	Height;
LUAD	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg09904177	chr6:26538194	HMGN4	0.43	7.31	0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11644478	chr21:40555479	PSMG1	-0.61	-10.33	-0.45	1.88e-22	Cognitive function;
LUAD	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg25753631	chr6:25732923	NA	-0.44	-7.76	-0.35	6.26e-14	Iron status biomarkers;
LUAD	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.94	0.44	4.75e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.62	0.31	1.12e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg14169450	chr9:139327907	INPP5E	0.39	6.99	0.32	1.05e-11	Monocyte percentage of white cells;
LUAD	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg05187965	chr10:45406764	TMEM72	-0.49	-9.87	-0.43	8.3e-21	Mean corpuscular volume;
LUAD	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg17063962	chr7:91808500	NA	0.68	11.46	0.49	1.12e-26	Breast cancer;
LUAD	cis	rs4774899	1.000	rs7170133	chr15:57283194	A/G	cg14026238	chr15:57616123	NA	0.34	6.43	0.3	3.46e-10	Urinary tract infection frequency;
LUAD	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg16099169	chr2:106886729	NA	-0.65	-10.31	-0.45	2.25e-22	Facial morphology (factor 23);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg13275176	chr2:97534450	SEMA4C	-0.39	-6.47	-0.3	2.72e-10	Schizophrenia;
LUAD	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.57	-9.96	-0.44	3.86e-21	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.53	-0.34	3.05e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg15462221	chr8:8086144	FLJ10661	-0.42	-6.54	-0.3	1.81e-10	Schizophrenia;
LUAD	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.44	-0.34	5.6e-13	Bipolar disorder;
LUAD	cis	rs6539288	0.589	rs1037013	chr12:107219308	A/G	cg15890332	chr12:107067104	RFX4	0.36	7.56	0.35	2.47e-13	Total body bone mineral density;
LUAD	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg14343924	chr8:8086146	FLJ10661	-0.46	-7.29	-0.33	1.53e-12	Mood instability;
LUAD	cis	rs7731657	0.509	rs11960725	chr5:130251428	C/T	cg08523029	chr5:130500466	HINT1	0.49	6.52	0.3	2.06e-10	Fasting plasma glucose;
LUAD	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg03024183	chr8:37963317	ASH2L	-0.53	-6.52	-0.3	2.04e-10	Colorectal cancer;
LUAD	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg03396347	chr1:1875803	NA	-0.6	-15.58	-0.6	1.4e-43	Body mass index;
LUAD	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	6.55	0.3	1.63e-10	Personality dimensions;
LUAD	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.59	0.31	1.32e-10	Prudent dietary pattern;
LUAD	trans	rs75804782	0.630	rs56304316	chr2:239253266	C/A	cg01134436	chr17:81009848	B3GNTL1	0.77	6.81	0.31	3.43e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	10.42	0.45	8.95e-23	Hip circumference adjusted for BMI;
LUAD	cis	rs2487048	0.761	rs1800976	chr9:107690709	C/G	cg14470647	chr9:107690075	ABCA1	-0.41	-6.96	-0.32	1.3e-11	Intraocular pressure;
LUAD	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	10.42	0.45	8.96e-23	Electrocardiographic conduction measures;
LUAD	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg10978503	chr1:24200527	CNR2	0.53	11.5	0.49	8.07e-27	Immature fraction of reticulocytes;
LUAD	cis	rs6500395	1.000	rs9933314	chr16:48676608	T/C	cg04672837	chr16:48644449	N4BP1	0.39	6.81	0.31	3.43e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg08885076	chr2:99613938	TSGA10	0.38	6.8	0.31	3.68e-11	Chronic sinus infection;
LUAD	cis	rs7208859	0.614	rs7216394	chr17:28825756	T/C	cg17105886	chr17:28927953	LRRC37B2	-0.67	-6.92	-0.32	1.64e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs16958440	0.867	rs3809965	chr18:44676872	G/A	cg17192377	chr18:44677553	HDHD2	0.84	7.97	0.36	1.52e-14	Sitting height ratio;
LUAD	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-15.3	-0.6	2.31e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg04267008	chr7:1944627	MAD1L1	-0.73	-11.47	-0.49	1.02e-26	Bipolar disorder and schizophrenia;
LUAD	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg09359103	chr1:154839909	KCNN3	-0.91	-21.24	-0.72	1.09e-68	Prostate cancer;
LUAD	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg12863693	chr15:85201151	NMB	0.39	7.32	0.34	1.3e-12	Schizophrenia;
LUAD	cis	rs3862030	0.720	rs7081110	chr10:104231651	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-8.02	-0.36	1.08e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs476633	0.708	rs28656781	chr15:41447440	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-10.78	-0.46	4.27e-24	Glomerular filtration rate (creatinine);
LUAD	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg25767906	chr1:53392781	SCP2	0.42	7.86	0.36	3.24e-14	Monocyte count;
LUAD	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs8060686	0.623	rs7201591	chr16:68086105	A/G	cg09835421	chr16:68378352	PRMT7	-0.51	-6.58	-0.3	1.43e-10	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2797160	1.000	rs2747723	chr6:126010790	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.5e-17	Endometrial cancer;
LUAD	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg14725641	chr11:61582763	MIR1908;FADS1	-0.43	-6.74	-0.31	5.19e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg22963979	chr7:1858916	MAD1L1	-0.57	-9.91	-0.43	6.06e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.46	-7.81	-0.35	4.59e-14	Longevity;Endometriosis;
LUAD	trans	rs877282	1.000	rs877282	chr10:771532	G/A	cg22713356	chr15:30763199	NA	1.32	18.71	0.67	2.41e-57	Uric acid levels;
LUAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg11494091	chr17:61959527	GH2	0.74	18.66	0.67	3.9e-57	Prudent dietary pattern;
LUAD	trans	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.29e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg19041857	chr6:27730383	NA	-0.44	-7.6	-0.35	1.95e-13	Parkinson's disease;
LUAD	cis	rs859767	0.501	rs10193171	chr2:135403199	C/T	cg12500956	chr2:135428796	TMEM163	0.27	7.08	0.33	5.91e-12	Neuroticism;
LUAD	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg15309053	chr8:964076	NA	0.34	7.41	0.34	6.82e-13	Schizophrenia;
LUAD	cis	rs977987	0.931	rs1424013	chr16:75495986	T/C	cg03315344	chr16:75512273	CHST6	0.66	14.96	0.59	6.72e-41	Dupuytren's disease;
LUAD	cis	rs2625529	0.730	rs12912771	chr15:72162928	A/T	cg16672083	chr15:72433130	SENP8	-0.53	-9.73	-0.43	2.45e-20	Red blood cell count;
LUAD	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg03929089	chr4:120376271	NA	-0.88	-16.94	-0.64	1.66e-49	Height;
LUAD	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.74	-0.61	2.73e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.85	0.32	2.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg04455712	chr21:45112962	RRP1B	0.42	8.5	0.38	3.34e-16	Mean corpuscular volume;
LUAD	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	trans	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	9.97e-11	Diabetic kidney disease;
LUAD	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg15445000	chr17:37608096	MED1	0.45	8.28	0.37	1.62e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.22	-0.33	2.45e-12	Total cholesterol levels;
LUAD	cis	rs9649213	0.614	rs62479858	chr7:97924226	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.76	-11.24	-0.48	8.03e-26	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg03433033	chr1:76189801	ACADM	0.88	17.96	0.66	5.3e-54	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg07636037	chr3:49044803	WDR6	0.63	12.17	0.51	1.97e-29	Parkinson's disease;
LUAD	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg18876405	chr7:65276391	NA	0.54	8.84	0.39	2.59e-17	Aortic root size;
LUAD	cis	rs7727544	0.526	rs4705908	chr5:131347520	G/A	cg14196790	chr5:131705035	SLC22A5	0.42	7.34	0.34	1.07e-12	Blood metabolite levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01528792	chr9:73027862	KLF9	-0.39	-6.37	-0.3	4.93e-10	Cancer;
LUAD	cis	rs8067545	0.750	rs918228	chr17:20002012	C/T	cg04132472	chr17:19861366	AKAP10	0.31	7.32	0.34	1.25e-12	Schizophrenia;
LUAD	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg23598886	chr18:12777645	NA	0.64	8.0	0.36	1.22e-14	Inflammatory skin disease;
LUAD	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg02683114	chr2:24398427	C2orf84	0.43	7.28	0.33	1.66e-12	Asthma;
LUAD	trans	rs6561151	0.681	rs7995955	chr13:44434836	C/G	cg12856521	chr11:46389249	DGKZ	0.84	11.5	0.49	7.93e-27	Crohn's disease;
LUAD	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg05665937	chr4:1216051	CTBP1	0.42	7.01	0.32	9.65e-12	Obesity-related traits;
LUAD	cis	rs12936587	0.535	rs8065154	chr17:17614947	A/G	cg04398451	chr17:18023971	MYO15A	-0.41	-6.76	-0.31	4.73e-11	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LUAD	cis	rs8112211	1.000	rs12611255	chr19:38815483	T/C	cg14299480	chr19:38876666	GGN	-0.45	-7.86	-0.36	3.3e-14	Blood protein levels;
LUAD	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg01849466	chr14:104193079	ZFYVE21	0.45	7.5	0.34	3.75e-13	Body mass index;
LUAD	cis	rs2742417	0.904	rs2373047	chr3:45747497	C/A	cg10512202	chr3:45649293	LIMD1	0.35	6.37	0.3	5.06e-10	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs877282	0.838	rs34912955	chr10:772222	T/C	cg06581033	chr10:766294	NA	-0.55	-7.44	-0.34	5.75e-13	Uric acid levels;
LUAD	cis	rs73058052	1.000	rs73057994	chr19:50091273	C/A	cg21913888	chr19:50084626	PRRG2;NOSIP	0.34	7.68	0.35	1.13e-13	Fibrinogen levels;
LUAD	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-19.96	-0.7	6.45e-63	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg25985355	chr7:65971099	NA	-0.53	-6.6	-0.31	1.22e-10	Diabetic kidney disease;
LUAD	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg04398451	chr17:18023971	MYO15A	-0.76	-13.87	-0.56	2.58e-36	Total body bone mineral density;
LUAD	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg11494091	chr17:61959527	GH2	0.43	7.95	0.36	1.74e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs5756813	0.754	rs3788529	chr22:38158709	A/G	cg19894588	chr14:64061835	NA	-0.46	-6.44	-0.3	3.21e-10	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs597583	0.806	rs11603340	chr11:117396527	C/G	cg27161313	chr11:117392002	DSCAML1	-0.49	-8.13	-0.37	4.8e-15	Putamen volume;
LUAD	cis	rs10208940	0.619	rs34187568	chr2:68863493	C/T	cg12452813	chr2:68675892	NA	0.47	6.35	0.3	5.42e-10	Urate levels in lean individuals;
LUAD	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg22117172	chr7:91764530	CYP51A1	-0.31	-6.95	-0.32	1.38e-11	Breast cancer;
LUAD	cis	rs4845570	0.850	rs11204892	chr1:151768048	A/G	cg07092448	chr1:151763213	TDRKH	0.75	10.03	0.44	2.28e-21	Coronary artery disease;
LUAD	cis	rs7737355	0.947	rs244739	chr5:130806874	A/C	cg06307176	chr5:131281290	NA	-0.51	-8.08	-0.37	6.84e-15	Life satisfaction;
LUAD	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg22532475	chr10:104410764	TRIM8	0.35	7.0	0.32	1.02e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2580764	0.516	rs2860453	chr2:55270485	T/G	cg09592903	chr2:55203963	RTN4	0.45	10.03	0.44	2.17e-21	Mean platelet volume;
LUAD	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg14458575	chr2:238380390	NA	0.97	18.44	0.67	3.66e-56	Prostate cancer;
LUAD	cis	rs13064411	0.696	rs9808893	chr3:113228444	G/A	cg18753928	chr3:113234510	CCDC52	-0.73	-12.43	-0.52	1.93e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg18180107	chr4:99064573	C4orf37	0.47	7.3	0.33	1.44e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg08989290	chr16:615782	NHLRC4	0.32	7.03	0.32	8.24e-12	Height;
LUAD	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.2	0.33	2.76e-12	Obesity-related traits;
LUAD	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg23649088	chr2:200775458	C2orf69	-0.57	-6.71	-0.31	6.25e-11	Schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21872391	chr10:112064057	SMNDC1	-0.44	-6.85	-0.32	2.58e-11	Height;
LUAD	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg17366294	chr4:99064904	C4orf37	0.66	12.77	0.53	8.37e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg27446573	chr6:127587934	RNF146	0.44	6.55	0.3	1.68e-10	Breast cancer;
LUAD	cis	rs701145	0.585	rs357498	chr3:153945495	G/A	cg17054900	chr3:154042577	DHX36	0.66	6.8	0.31	3.64e-11	Coronary artery disease;
LUAD	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.45	-7.51	-0.34	3.45e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6960043	0.652	rs6461149	chr7:15044103	C/T	cg19272540	chr7:15055459	NA	0.37	7.92	0.36	2.15e-14	Type 2 diabetes;
LUAD	trans	rs225245	0.817	rs2301730	chr17:33998683	A/G	cg19694781	chr19:47549865	TMEM160	-0.47	-7.69	-0.35	1.07e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs11048434	0.761	rs2110190	chr12:9128289	A/C	cg23795048	chr12:9217529	LOC144571	0.43	7.79	0.35	5.16e-14	Sjögren's syndrome;
LUAD	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg15432903	chr11:17409602	KCNJ11	0.54	10.23	0.45	4.3e-22	Type 2 diabetes;
LUAD	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-9.78	-0.43	1.63e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs10899021	1.000	rs11236190	chr11:74366755	G/T	cg25880958	chr11:74394337	NA	-0.68	-8.15	-0.37	4.22e-15	Response to metformin (IC50);
LUAD	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.16	-0.41	2.26e-18	Life satisfaction;
LUAD	cis	rs17135859	1.000	rs2195374	chr5:112998733	G/A	cg12552261	chr5:112820674	MCC	0.56	7.43	0.34	5.88e-13	F-cell distribution;
LUAD	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.09	-15.24	-0.6	4.28e-42	Schizophrenia;
LUAD	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg05991184	chr2:219186017	PNKD	-0.38	-7.42	-0.34	6.39e-13	Colorectal cancer;
LUAD	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg05887092	chr17:76393375	PGS1	0.56	11.1	0.48	2.63e-25	HDL cholesterol;
LUAD	cis	rs17095355	0.818	rs12268910	chr10:111878510	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.67	-9.51	-0.42	1.49e-19	Biliary atresia;
LUAD	trans	rs3960554	0.867	rs10239209	chr7:75804085	G/A	cg19862616	chr7:65841803	NCRNA00174	0.82	11.64	0.49	2.4e-27	Eotaxin levels;
LUAD	cis	rs3784262	0.967	rs35511675	chr15:58266978	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.46	-9.5	-0.42	1.53e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg22663859	chr13:21900854	NA	0.49	7.69	0.35	1.03e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs1595825	0.891	rs1992313	chr2:198896766	T/C	cg00361562	chr2:198649771	BOLL	-0.47	-6.52	-0.3	1.96e-10	Ulcerative colitis;
LUAD	cis	rs6076065	0.748	rs999068	chr20:23376483	G/A	cg11657817	chr20:23433608	CST11	0.57	12.04	0.51	6.51e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg15369054	chr17:80825471	TBCD	-0.67	-11.25	-0.48	7.33e-26	Breast cancer;
LUAD	cis	rs2281636	0.965	rs2006077	chr10:101492833	A/T	cg17885402	chr10:101492224	COX15;CUTC	0.4	6.79	0.31	3.93e-11	Obesity-related traits;
LUAD	cis	rs9535307	0.929	rs1547623	chr13:50348187	G/A	cg04663916	chr13:50265991	EBPL	0.59	7.03	0.32	8.31e-12	Obesity-related traits;
LUAD	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-7.37	-0.34	9.15e-13	IgG glycosylation;
LUAD	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.48	-0.3	2.48e-10	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
LUAD	cis	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg01251360	chr16:68772225	CDH1	-0.28	-8.7	-0.39	7.35e-17	Colorectal cancer;
LUAD	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg04282206	chr17:62833786	PLEKHM1P	-0.54	-8.26	-0.37	1.89e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg10483660	chr13:112241077	NA	0.47	9.49	0.42	1.76e-19	Menarche (age at onset);
LUAD	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg21862992	chr11:68658383	NA	-0.52	-9.51	-0.42	1.41e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg20203395	chr5:56204925	C5orf35	-0.83	-11.79	-0.5	6.25e-28	Initial pursuit acceleration;
LUAD	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg16647868	chr5:131706066	SLC22A5	0.41	6.72	0.31	5.93e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg19875535	chr5:140030758	IK	0.45	7.45	0.34	5.38e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9522267	0.535	rs2039916	chr13:112238863	A/C	cg10483660	chr13:112241077	NA	-0.33	-7.05	-0.32	7.25e-12	Hepatitis;
LUAD	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg21724239	chr8:58056113	NA	0.63	7.99	0.36	1.26e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.13	0.33	4.47e-12	Platelet count;
LUAD	cis	rs807669	0.807	rs807431	chr22:19242361	G/A	cg24911827	chr22:19170109	CLTCL1	0.32	6.76	0.31	4.68e-11	Metabolite levels;
LUAD	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.4	0.45	1.01e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg05234568	chr11:5960015	NA	-0.58	-11.03	-0.47	4.76e-25	DNA methylation (variation);
LUAD	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg14196790	chr5:131705035	SLC22A5	0.37	6.52	0.3	1.99e-10	Breast cancer;
LUAD	trans	rs931812	0.895	rs4734493	chr8:101902169	C/T	cg20993868	chr7:22813445	NA	-0.6	-12.67	-0.52	2.08e-31	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg18016565	chr1:150552671	MCL1	0.41	7.53	0.34	3.16e-13	Tonsillectomy;
LUAD	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03517284	chr6:25882590	NA	-0.57	-9.3	-0.41	7.58e-19	Blood metabolite levels;
LUAD	trans	rs931812	0.757	rs13251801	chr8:101902629	A/T	cg20993868	chr7:22813445	NA	0.55	12.14	0.51	2.59e-29	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs6906287	0.647	rs7773274	chr6:118934740	C/G	cg05564266	chr6:118973597	C6orf204	0.36	7.52	0.34	3.29e-13	Electrocardiographic conduction measures;
LUAD	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg26816564	chr1:7831052	VAMP3	0.79	10.29	0.45	2.52e-22	Inflammatory bowel disease;
LUAD	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg13732083	chr21:47605072	C21orf56	0.42	6.93	0.32	1.55e-11	Testicular germ cell tumor;
LUAD	cis	rs4713675	0.565	rs60704560	chr6:33713300	C/T	cg14003231	chr6:33640908	ITPR3	0.4	7.65	0.35	1.35e-13	Plateletcrit;
LUAD	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-6.82	-0.31	3.12e-11	Lung cancer;
LUAD	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg17063962	chr7:91808500	NA	0.6	9.74	0.43	2.39e-20	Breast cancer;
LUAD	cis	rs4954585	0.683	rs13024450	chr2:137014611	C/T	cg05194412	chr2:137003533	NA	0.62	11.2	0.48	1.12e-25	Colorectal cancer;
LUAD	cis	rs7617773	0.707	rs13061269	chr3:48373343	C/T	cg11946769	chr3:48343235	NME6	0.44	6.71	0.31	6.36e-11	Coronary artery disease;
LUAD	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg11189052	chr15:85197271	WDR73	0.66	8.97	0.4	9.39e-18	Schizophrenia;
LUAD	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg08470875	chr2:26401718	FAM59B	0.77	10.11	0.44	1.11e-21	Gut microbiome composition (summer);
LUAD	cis	rs7107174	1.000	rs2510050	chr11:77982564	A/G	cg02023728	chr11:77925099	USP35	0.47	7.35	0.34	1.04e-12	Testicular germ cell tumor;
LUAD	cis	rs62064224	0.578	rs2109158	chr17:30695964	T/C	cg18200150	chr17:30822561	MYO1D	0.39	6.98	0.32	1.11e-11	Schizophrenia;
LUAD	cis	rs8063160	0.628	rs258322	chr16:89755903	C/T	cg07984980	chr16:89898383	SPIRE2	0.46	6.39	0.3	4.28e-10	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LUAD	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg25811766	chr13:21894605	NA	0.59	7.87	0.36	2.98e-14	White matter hyperintensity burden;
LUAD	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.57	7.91	0.36	2.27e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg10523679	chr1:76189770	ACADM	0.91	16.04	0.61	1.45e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs7301826	1.000	rs1106369	chr12:131300095	G/T	cg11011512	chr12:131303247	STX2	0.4	6.98	0.32	1.18e-11	Plasma plasminogen activator levels;
LUAD	cis	rs870825	0.616	rs7659101	chr4:185632158	C/T	cg04058563	chr4:185651563	MLF1IP	0.9	14.42	0.57	1.23e-38	Blood protein levels;
LUAD	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-9.09	-0.4	3.93e-18	Life satisfaction;
LUAD	cis	rs7927771	0.524	rs12421563	chr11:47780222	G/A	cg18512352	chr11:47633146	NA	-0.36	-6.5	-0.3	2.29e-10	Subjective well-being;
LUAD	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg25358565	chr5:93447407	FAM172A	0.6	7.58	0.35	2.17e-13	Diabetic retinopathy;
LUAD	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.59	8.04	0.36	9.31e-15	Renal function-related traits (BUN);
LUAD	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg15467112	chr14:75489610	MLH3	-0.35	-6.42	-0.3	3.65e-10	Height;
LUAD	cis	rs9902453	0.967	rs1906451	chr17:28515479	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	8.38	0.38	7.72e-16	Coffee consumption (cups per day);
LUAD	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg05925327	chr15:68127851	NA	-0.43	-6.46	-0.3	2.91e-10	Restless legs syndrome;
LUAD	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg05590025	chr7:65112418	INTS4L2	-0.67	-7.47	-0.34	4.56e-13	Diabetic kidney disease;
LUAD	cis	rs7818345	0.845	rs4256608	chr8:19267560	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.34	7.38	0.34	8.49e-13	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg06112835	chr11:68658793	MRPL21	0.5	8.92	0.4	1.43e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs354225	0.597	rs10176445	chr2:54845776	G/C	cg01766943	chr2:54829624	SPTBN1	0.39	7.06	0.32	6.7e-12	Schizophrenia;
LUAD	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg21220214	chr8:57350948	NA	-0.6	-8.69	-0.39	8.27e-17	Obesity-related traits;
LUAD	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg10523679	chr1:76189770	ACADM	-0.45	-6.36	-0.3	5.36e-10	Daytime sleep phenotypes;
LUAD	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg24829409	chr8:58192753	C8orf71	-0.64	-9.56	-0.42	1.02e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6445967	1.000	rs1913716	chr3:58308331	G/A	cg23715586	chr3:58305044	RPP14	0.42	7.59	0.35	2.05e-13	Platelet count;
LUAD	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg26513180	chr16:89883248	FANCA	0.78	7.09	0.33	5.78e-12	Skin colour saturation;
LUAD	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.51	-8.98	-0.4	9.13e-18	Menarche (age at onset);
LUAD	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg02782426	chr3:40428986	ENTPD3	0.42	9.23	0.41	1.28e-18	Renal cell carcinoma;
LUAD	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg02176678	chr2:219576539	TTLL4	0.74	14.53	0.58	4.34e-39	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg25985355	chr7:65971099	NA	0.39	7.3	0.33	1.46e-12	Aortic root size;
LUAD	cis	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg20368463	chr18:77673604	PQLC1	-0.56	-9.09	-0.4	3.9e-18	Schizophrenia;
LUAD	cis	rs8044868	1.000	rs16973716	chr16:72156842	A/C	cg23815491	chr16:72088622	HP	0.43	7.78	0.35	5.52e-14	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.45	0.3	3.08e-10	Cognitive test performance;
LUAD	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg27284194	chr4:1044797	NA	0.7	10.02	0.44	2.41e-21	Recombination rate (females);
LUAD	cis	rs240764	0.658	rs9399694	chr6:101257877	A/G	cg09795085	chr6:101329169	ASCC3	-0.43	-7.61	-0.35	1.85e-13	Neuroticism;
LUAD	cis	rs4891159	0.790	rs1056714	chr18:74149526	A/G	cg24786174	chr18:74118243	ZNF516	-0.73	-13.34	-0.54	3.91e-34	Longevity;
LUAD	trans	rs1941687	0.769	rs1493911	chr18:31356019	A/G	cg27147174	chr7:100797783	AP1S1	-0.54	-9.21	-0.41	1.5e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs1232027	0.656	rs32959	chr5:80042055	A/G	cg24059623	chr5:79951536	MSH3;DHFR	0.43	6.79	0.31	3.77e-11	Huntington's disease progression;
LUAD	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg20587970	chr11:113659929	NA	-1.4	-20.93	-0.71	2.68e-67	Hip circumference adjusted for BMI;
LUAD	trans	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg14917512	chr19:3094685	GNA11	-0.56	-6.66	-0.31	8.45e-11	Diabetic kidney disease;
LUAD	cis	rs977987	0.843	rs10871312	chr16:75486202	C/T	cg03315344	chr16:75512273	CHST6	0.65	14.23	0.57	7.71e-38	Dupuytren's disease;
LUAD	cis	rs2274273	0.967	rs8013027	chr14:55610940	C/G	cg04306507	chr14:55594613	LGALS3	0.36	7.33	0.34	1.16e-12	Protein biomarker;
LUAD	trans	rs11671005	0.610	rs8103813	chr19:59072684	C/T	cg22037779	chr5:139682734	PFDN1	-0.67	-9.0	-0.4	7.59e-18	Mean platelet volume;
LUAD	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg03929089	chr4:120376271	NA	-0.6	-9.38	-0.41	3.95e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.51	-8.24	-0.37	2.19e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg18132916	chr6:79620363	NA	-0.45	-7.79	-0.35	5.11e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.77	9.08	0.4	4.19e-18	Yeast infection;
LUAD	cis	rs7828089	0.561	rs13266541	chr8:22266135	G/A	cg12081754	chr8:22256438	SLC39A14	0.72	11.85	0.5	3.48e-28	Verbal declarative memory;
LUAD	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11890956	chr21:40555474	PSMG1	-0.8	-14.37	-0.57	2.07e-38	Cognitive function;
LUAD	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg17105886	chr17:28927953	LRRC37B2	0.69	7.37	0.34	9.29e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9535307	0.615	rs3736830	chr13:50306221	G/C	cg03658251	chr13:50265850	EBPL	0.5	6.51	0.3	2.19e-10	Obesity-related traits;
LUAD	cis	rs1018836	0.851	rs12548741	chr8:91628878	G/A	cg16814680	chr8:91681699	NA	-0.72	-12.2	-0.51	1.54e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19717773	chr7:2847554	GNA12	-0.54	-9.86	-0.43	8.88e-21	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg09137382	chr11:130731461	NA	0.42	7.61	0.35	1.8e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4478037	0.822	rs4320035	chr3:33113697	C/G	cg19404215	chr3:33155277	CRTAP	-0.59	-6.5	-0.3	2.25e-10	Major depressive disorder;
LUAD	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-33.49	-0.85	4.89e-121	Myeloid white cell count;
LUAD	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg10755058	chr3:40428713	ENTPD3	0.39	7.55	0.34	2.78e-13	Renal cell carcinoma;
LUAD	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg27539214	chr16:67997921	SLC12A4	-0.69	-9.05	-0.4	5.08e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2996428	0.561	rs2275827	chr1:3746585	T/G	cg23277830	chr1:3704460	LRRC47	0.41	8.72	0.39	6.42e-17	Red cell distribution width;
LUAD	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.1	0.4	3.56e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.32	-0.34	1.25e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs41311933	0.901	rs41260544	chr9:123744252	A/G	cg13567360	chr9:123745713	C5	-0.79	-8.76	-0.39	4.74e-17	Coronary artery disease;
LUAD	cis	rs7193541	0.694	rs3896277	chr16:74480694	A/T	cg01733217	chr16:74700730	RFWD3	0.4	6.69	0.31	6.96e-11	Multiple myeloma;
LUAD	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg15133208	chr4:90757351	SNCA	0.48	6.99	0.32	1.09e-11	Neuroticism;
LUAD	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg09835421	chr16:68378352	PRMT7	-0.86	-9.2	-0.41	1.7e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4691139	0.644	rs939083	chr4:165931481	A/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.42	-7.75	-0.35	6.68e-14	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.25	-0.51	9.53e-30	Platelet count;
LUAD	trans	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg00769240	chr8:12517080	NA	0.41	7.12	0.33	4.65e-12	Blood pressure (smoking interaction);
LUAD	cis	rs2692947	0.759	rs11687113	chr2:96658588	A/G	cg23100626	chr2:96804247	ASTL	0.3	7.58	0.35	2.16e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.93	-0.36	1.97e-14	Personality dimensions;
LUAD	cis	rs7953508	0.741	rs1498706	chr12:93996980	C/T	cg18151635	chr12:93972918	NA	-0.46	-7.59	-0.35	2.01e-13	Pubertal anthropometrics;
LUAD	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg21427119	chr20:30132790	HM13	-0.49	-7.86	-0.36	3.12e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs1395	1.000	rs1141313	chr2:27460968	A/G	cg23587288	chr2:27483067	SLC30A3	-0.38	-7.66	-0.35	1.28e-13	Blood metabolite levels;
LUAD	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg17366294	chr4:99064904	C4orf37	0.47	8.38	0.38	8.17e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg27284194	chr4:1044797	NA	0.71	10.35	0.45	1.54e-22	Recombination rate (females);
LUAD	cis	rs9486719	1.000	rs12208449	chr6:96903253	A/G	cg06623918	chr6:96969491	KIAA0776	0.69	9.38	0.42	4.01e-19	Migraine;Coronary artery disease;
LUAD	cis	rs59104589	0.617	rs62186409	chr2:242235710	C/A	cg08645257	chr2:242211290	HDLBP	0.5	7.9	0.36	2.35e-14	Fibrinogen levels;
LUAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg13560548	chr3:10150139	C3orf24	0.43	6.43	0.3	3.54e-10	Alzheimer's disease;
LUAD	cis	rs10489202	0.608	rs10800334	chr1:168075613	T/C	cg24449463	chr1:168025552	DCAF6	-0.62	-9.4	-0.42	3.38e-19	Schizophrenia;
LUAD	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06544989	chr22:39130855	UNC84B	0.44	7.93	0.36	2e-14	Menopause (age at onset);
LUAD	cis	rs6669072	0.967	rs4101233	chr1:91238773	C/T	cg08895590	chr1:91227319	NA	-0.33	-6.67	-0.31	8.08e-11	Cognitive function;
LUAD	cis	rs427394	0.659	rs187295	chr5:6734326	C/T	cg14682080	chr5:6737778	POLS	0.35	7.66	0.35	1.24e-13	Menopause (age at onset);
LUAD	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg26597838	chr10:835615	NA	1.3	20.63	0.71	6.1e-66	Eosinophil percentage of granulocytes;
LUAD	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg13271783	chr10:134563150	INPP5A	-0.41	-6.6	-0.31	1.24e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03352830	chr11:487213	PTDSS2	0.81	10.74	0.46	5.82e-24	Body mass index;
LUAD	cis	rs698833	0.819	rs2340810	chr2:44536546	C/T	cg04920474	chr2:44395004	PPM1B	-0.39	-7.06	-0.32	6.79e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs4148087	0.932	rs2032259	chr21:43621473	G/C	cg08841829	chr21:43638893	ABCG1	-0.55	-7.6	-0.35	1.95e-13	Eating disorder in bipolar disorder;
LUAD	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15664640	chr17:80829946	TBCD	-0.85	-16.95	-0.64	1.43e-49	Breast cancer;
LUAD	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg05434287	chr7:2030229	MAD1L1	0.41	6.71	0.31	6.33e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.4	6.57	0.3	1.52e-10	Platelet count;
LUAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13012494	chr21:47604986	C21orf56	0.59	10.43	0.45	8.1e-23	Testicular germ cell tumor;
LUAD	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.27	0.45	3.02e-22	Lung cancer in ever smokers;
LUAD	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg14541582	chr5:601475	NA	-0.38	-8.04	-0.36	9.35e-15	Obesity-related traits;
LUAD	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.44	-0.57	9.98e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg18105134	chr13:113819100	PROZ	-0.86	-15.09	-0.59	1.78e-41	Platelet distribution width;
LUAD	cis	rs1045714	0.836	rs73033691	chr7:2636522	T/G	cg24848437	chr7:2645542	IQCE	0.7	8.05	0.36	8.68e-15	Urate levels in lean individuals;
LUAD	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg15557168	chr22:42548783	NA	-0.56	-10.88	-0.47	1.72e-24	Schizophrenia;
LUAD	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.42	0.34	6.46e-13	Bipolar disorder;
LUAD	cis	rs6541297	0.699	rs12065546	chr1:230295245	C/T	cg20703242	chr1:230279135	GALNT2	0.54	8.05	0.36	8.34e-15	Coronary artery disease;
LUAD	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg11822812	chr5:140052017	DND1	-0.37	-6.87	-0.32	2.37e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs11650494	0.908	rs57390430	chr17:47374886	G/A	cg11430096	chr6:110968061	CDK19	0.87	6.8	0.31	3.48e-11	Prostate cancer;
LUAD	cis	rs6543140	0.964	rs11903551	chr2:103084181	C/G	cg04239558	chr2:103089729	SLC9A4	0.36	7.13	0.33	4.32e-12	Blood protein levels;
LUAD	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg02079420	chr8:82753780	SNX16	-0.42	-8.52	-0.38	2.78e-16	Diastolic blood pressure;
LUAD	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25427524	chr10:38739819	LOC399744	-0.8	-14.35	-0.57	2.58e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg11494091	chr17:61959527	GH2	0.74	18.63	0.67	5.61e-57	Prudent dietary pattern;
LUAD	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg09796270	chr17:17721594	SREBF1	0.37	7.16	0.33	3.63e-12	Total body bone mineral density;
LUAD	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg06547715	chr2:218990976	CXCR2	0.44	10.39	0.45	1.09e-22	Ulcerative colitis;
LUAD	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.33	-0.38	1.15e-15	Prostate cancer;
LUAD	cis	rs7827545	0.644	rs7386524	chr8:135534005	T/C	cg17885191	chr8:135476712	NA	-0.58	-9.13	-0.41	2.92e-18	Hypertension (SNP x SNP interaction);
LUAD	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg21475434	chr5:93447410	FAM172A	0.72	8.09	0.37	6.37e-15	Diabetic retinopathy;
LUAD	trans	rs961253	0.501	rs6054183	chr20:6354161	T/C	cg21095983	chr6:86352623	SYNCRIP	0.43	6.6	0.31	1.24e-10	Colorectal cancer;
LUAD	cis	rs123509	0.913	rs339685	chr3:42782952	C/G	cg10144569	chr3:42726640	KBTBD5	0.5	7.86	0.36	3.14e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs77861329	1.000	rs6781635	chr3:52125343	A/G	cg08692210	chr3:52188851	WDR51A	0.86	8.41	0.38	6.12e-16	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs35995292	0.534	rs13228087	chr7:38909204	A/C	cg19327137	chr7:38886074	VPS41	0.75	16.03	0.61	1.59e-45	Subjective well-being (multi-trait analysis);
LUAD	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg20587970	chr11:113659929	NA	1.35	19.36	0.69	2.81e-60	Hip circumference adjusted for BMI;
LUAD	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg12927641	chr6:109611667	NA	-0.51	-8.81	-0.39	3.15e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03647317	chr4:187891568	NA	-0.35	-6.47	-0.3	2.75e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs877282	0.947	rs12358875	chr10:757531	T/C	cg22713356	chr15:30763199	NA	1.23	15.56	0.6	1.71e-43	Uric acid levels;
LUAD	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.32	6.8	0.31	3.68e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg18721089	chr20:30220636	NA	-0.44	-6.69	-0.31	7.25e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg09658497	chr7:2847517	GNA12	0.46	8.4	0.38	7.05e-16	Height;
LUAD	cis	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg27411982	chr8:10470053	RP1L1	-0.4	-6.98	-0.32	1.12e-11	Retinal vascular caliber;
LUAD	cis	rs6138458	1.000	rs227616	chr20:24908811	T/C	cg06937882	chr20:24974362	C20orf3	-0.33	-6.43	-0.3	3.52e-10	Blood protein levels;
LUAD	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg17366294	chr4:99064904	C4orf37	0.47	8.38	0.38	8.17e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg22532475	chr10:104410764	TRIM8	-0.51	-9.39	-0.42	3.65e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs587242	0.955	rs4949996	chr1:96965124	A/T	cg10631902	chr5:14652156	NA	0.42	6.7	0.31	6.84e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04498032	chr1:155242826	CLK2	-0.47	-7.48	-0.34	4.46e-13	Height;
LUAD	trans	rs12517041	1.000	rs6898560	chr5:23312968	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs2279817	1.000	rs2279815	chr1:18022066	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.6	9.83	0.43	1.13e-20	Neuroticism;
LUAD	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg23602478	chr1:26503979	CNKSR1	0.28	7.01	0.32	9.26e-12	Height;
LUAD	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.7	0.43	3.29e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg07694864	chr17:40700509	NA	-0.44	-8.17	-0.37	3.64e-15	Colorectal or endometrial cancer;
LUAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg10729496	chr3:10149963	C3orf24	0.48	7.78	0.35	5.65e-14	Alzheimer's disease;
LUAD	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg22532475	chr10:104410764	TRIM8	0.47	9.19	0.41	1.85e-18	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg23262073	chr20:60523788	NA	-0.46	-7.38	-0.34	8.43e-13	Body mass index;
LUAD	cis	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg07460842	chr6:66804631	NA	-1.2	-30.41	-0.83	1.72e-108	Exhaled nitric oxide output;
LUAD	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08109568	chr15:31115862	NA	-0.61	-10.2	-0.44	5.56e-22	Huntington's disease progression;
LUAD	cis	rs953387	1.000	rs2102896	chr2:136906640	T/C	cg05194412	chr2:137003533	NA	-0.4	-6.46	-0.3	2.89e-10	Arthritis (juvenile idiopathic);
LUAD	cis	rs501916	0.833	rs59184310	chr15:48050205	A/T	cg16110827	chr15:48056943	SEMA6D	-0.4	-7.18	-0.33	3.23e-12	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs11811982	0.793	rs115643064	chr1:227416153	A/G	cg24860534	chr1:227506868	CDC42BPA	0.7	7.57	0.35	2.33e-13	Optic disc area;
LUAD	cis	rs8008758	0.517	rs1772024	chr14:101695220	A/C	cg26224664	chr14:101693935	NA	0.44	11.21	0.48	1.04e-25	Body mass index (alcohol intake interaction);
LUAD	cis	rs7584330	0.554	rs7570873	chr2:238435054	G/A	cg14458575	chr2:238380390	NA	0.6	9.62	0.42	6.18e-20	Prostate cancer;
LUAD	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg06618935	chr21:46677482	NA	-0.48	-9.66	-0.43	4.26e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12946454	0.696	rs4792819	chr17:43247957	A/C	cg10701640	chr17:43249399	NA	0.54	11.01	0.47	6.02e-25	Systolic blood pressure;
LUAD	cis	rs10089	0.552	rs1351141	chr5:127550055	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.46	-6.63	-0.31	1.02e-10	Ileal carcinoids;
LUAD	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg21153622	chr11:89784906	NA	-0.32	-6.42	-0.3	3.61e-10	Height;
LUAD	cis	rs4389656	0.826	rs192443	chr5:6733664	G/T	cg10857441	chr5:6722123	POLS	-0.47	-7.99	-0.36	1.25e-14	Coronary artery disease;
LUAD	cis	rs35883536	0.935	rs1577510	chr1:101114295	G/A	cg06223162	chr1:101003688	GPR88	-0.37	-6.92	-0.32	1.72e-11	Monocyte count;
LUAD	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23158103	chr7:148848205	ZNF398	-0.64	-11.78	-0.5	6.93e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg01475377	chr6:109611718	NA	-0.5	-9.54	-0.42	1.19e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg21823605	chr1:152486609	CRCT1	0.29	6.58	0.3	1.38e-10	Hair morphology;
LUAD	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg21204522	chr6:27730016	NA	-0.48	-7.59	-0.35	2.08e-13	Parkinson's disease;
LUAD	cis	rs1113500	0.933	rs10785834	chr1:108639101	A/C	cg06207961	chr1:108661230	NA	0.45	8.43	0.38	5.37e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg27572855	chr1:25598939	RHD	0.54	11.72	0.5	1.14e-27	Erythrocyte sedimentation rate;
LUAD	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg18180107	chr4:99064573	C4orf37	0.42	6.75	0.31	4.97e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg02631126	chr6:28058918	ZSCAN12L1	-0.35	-7.33	-0.34	1.2e-12	Depression;
LUAD	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg18180107	chr4:99064573	C4orf37	-0.46	-7.4	-0.34	7.58e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg23172400	chr8:95962367	TP53INP1	-0.35	-8.3	-0.37	1.41e-15	Type 2 diabetes;
LUAD	cis	rs12545109	0.800	rs2576602	chr8:57394495	C/T	cg09654669	chr8:57350985	NA	-0.68	-10.02	-0.44	2.42e-21	Obesity-related traits;
LUAD	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.17e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg04155231	chr12:9217510	LOC144571	0.43	8.05	0.36	8.45e-15	Sjögren's syndrome;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15229027	chr14:64805542	ESR2	-0.42	-6.65	-0.31	9.01e-11	Height;
LUAD	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg03859395	chr2:55845619	SMEK2	-0.72	-13.57	-0.55	4.62e-35	Metabolic syndrome;
LUAD	trans	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg01620082	chr3:125678407	NA	0.9	9.33	0.41	6.1e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.13	-0.33	4.29e-12	Blood metabolite levels;
LUAD	cis	rs7851660	0.874	rs13299924	chr9:100627562	C/T	cg13688889	chr9:100608707	NA	-0.48	-8.26	-0.37	1.87e-15	Strep throat;
LUAD	cis	rs2445762	0.584	rs17602588	chr15:51655475	A/T	cg20344442	chr15:51633704	GLDN	0.38	6.66	0.31	8.48e-11	Hormone measurements;
LUAD	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.67	-0.35	1.23e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg04775059	chr7:64541387	NA	0.53	7.03	0.32	8.43e-12	Aortic root size;
LUAD	trans	rs7746199	0.736	rs13193480	chr6:27702561	A/G	cg01620082	chr3:125678407	NA	-1.01	-10.28	-0.45	2.92e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9479482	1.000	rs9478380	chr6:150354665	A/G	cg08316699	chr6:150357289	NA	-0.35	-7.26	-0.33	1.92e-12	Alopecia areata;
LUAD	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg27124370	chr19:33622961	WDR88	0.44	7.07	0.33	6.31e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg07507251	chr3:52567010	NT5DC2	0.39	7.52	0.34	3.33e-13	Bipolar disorder;
LUAD	cis	rs9902453	1.000	rs56280226	chr17:28429575	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	9.18	0.41	1.89e-18	Coffee consumption (cups per day);
LUAD	cis	rs477692	0.563	rs12266634	chr10:131412659	G/C	cg05714579	chr10:131428358	MGMT	-0.44	-7.09	-0.33	5.56e-12	Response to temozolomide;
LUAD	cis	rs2932538	0.961	rs1238	chr1:113214097	G/A	cg22162597	chr1:113214053	CAPZA1	-0.45	-6.8	-0.31	3.6e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg09796270	chr17:17721594	SREBF1	0.38	7.79	0.35	5.3e-14	Total body bone mineral density;
LUAD	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.32	6.84	0.32	2.87e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17791867	chr7:112579927	C7orf60	0.43	6.58	0.3	1.38e-10	Gut microbiome composition (summer);
LUAD	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg09184832	chr6:79620586	NA	-0.51	-9.62	-0.42	6e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs34702092	1	rs34702092	chr14:68991747	C/CA	cg04147497	chr14:69052728	RAD51L1	-0.48	-7.39	-0.34	7.71e-13	Nose size;
LUAD	cis	rs34734847	0.814	rs17847	chr12:121149475	A/G	cg13914990	chr12:121174878	ACADS	0.4	7.81	0.35	4.65e-14	Mean corpuscular volume;
LUAD	cis	rs6761276	1.000	rs6761276	chr2:113832312	C/T	cg09040174	chr2:113837401	NA	-0.81	-16.01	-0.61	1.86e-45	Protein quantitative trait loci;
LUAD	cis	rs698833	0.886	rs2053454	chr2:44550290	A/G	cg04920474	chr2:44395004	PPM1B	0.38	6.69	0.31	7e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg00769240	chr8:12517080	NA	0.39	6.79	0.31	3.9e-11	Blood pressure (smoking interaction);
LUAD	trans	rs2797160	1.000	rs4897153	chr6:126003403	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-8.65	-0.39	1.08e-16	Endometrial cancer;
LUAD	cis	rs6684514	0.961	rs112017075	chr1:156327716	G/A	cg16558208	chr1:156270281	VHLL	0.5	9.1	0.4	3.66e-18	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs6688613	0.685	rs10918599	chr1:166918786	T/C	cg07049167	chr1:166818506	POGK	0.54	7.96	0.36	1.61e-14	Refractive astigmatism;
LUAD	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg07936489	chr17:37558343	FBXL20	-0.45	-7.06	-0.32	6.69e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg16989719	chr2:238392110	NA	-0.37	-7.84	-0.36	3.62e-14	Prostate cancer;
LUAD	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg25985355	chr7:65971099	NA	-0.55	-6.83	-0.32	2.94e-11	Diabetic kidney disease;
LUAD	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg09065629	chr16:1709722	CRAMP1L	0.41	7.16	0.33	3.71e-12	Coronary artery disease;
LUAD	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg16479474	chr6:28041457	NA	0.46	7.65	0.35	1.41e-13	Depression;
LUAD	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg11871910	chr12:69753446	YEATS4	0.53	8.28	0.37	1.65e-15	Blood protein levels;
LUAD	trans	rs3774749	0.565	rs2624839	chr3:50202231	T/C	cg21659725	chr3:3221576	CRBN	0.4	6.6	0.31	1.21e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2637266	0.967	rs4581393	chr10:78376123	A/C	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg11062466	chr8:58055876	NA	0.55	7.73	0.35	7.77e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.19	-0.41	1.81e-18	Bipolar disorder;
LUAD	cis	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg08601574	chr20:25228251	PYGB	0.47	8.56	0.38	2.17e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg02782426	chr3:40428986	ENTPD3	0.36	7.74	0.35	7.36e-14	Renal cell carcinoma;
LUAD	cis	rs8099014	1.000	rs17064977	chr18:56107697	C/T	cg12907477	chr18:56117327	MIR122	0.39	6.84	0.32	2.81e-11	Platelet count;
LUAD	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.91e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs10411161	0.702	rs11878583	chr19:52388546	C/T	cg22319618	chr22:45562946	NUP50	0.64	9.26	0.41	1.02e-18	Breast cancer;
LUAD	cis	rs938554	0.744	rs13129697	chr4:9926967	T/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-7.07	-0.33	6.31e-12	Blood metabolite levels;
LUAD	trans	rs2235573	0.625	rs139900	chr22:38405417	C/T	cg19894588	chr14:64061835	NA	0.41	6.48	0.3	2.54e-10	Glioblastoma;Glioma;
LUAD	cis	rs3981351	0.797	rs12766891	chr10:115460714	G/A	cg24846397	chr10:115438155	CASP7	-0.39	-6.38	-0.3	4.74e-10	Obesity-related traits;
LUAD	cis	rs1045714	1.000	rs1045714	chr7:2653582	A/G	cg20813462	chr7:2646259	IQCE	0.67	7.13	0.33	4.32e-12	Urate levels in lean individuals;
LUAD	cis	rs2274273	0.840	rs1045002	chr14:55818517	T/A	cg04306507	chr14:55594613	LGALS3	0.43	8.91	0.4	1.56e-17	Protein biomarker;
LUAD	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10802521	chr3:52805072	NEK4	-0.62	-11.22	-0.48	9.81e-26	Bipolar disorder;
LUAD	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11644478	chr21:40555479	PSMG1	-0.42	-6.92	-0.32	1.65e-11	Menarche (age at onset);
LUAD	cis	rs72928364	1.000	rs35974360	chr3:100757285	C/T	cg10123952	chr3:100791384	NA	0.66	7.68	0.35	1.11e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg04944784	chr2:26401820	FAM59B	-0.7	-9.86	-0.43	8.54e-21	Gut microbiome composition (summer);
LUAD	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg19729930	chr2:74357872	NA	0.99	16.16	0.62	4.1e-46	Gestational age at birth (maternal effect);
LUAD	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg12011299	chr4:100065546	ADH4	0.66	13.76	0.56	7.42e-36	Alcohol dependence;
LUAD	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg05535760	chr7:792225	HEATR2	0.98	12.19	0.51	1.65e-29	Cerebrospinal P-tau181p levels;
LUAD	cis	rs2806561	1.000	rs2806561	chr1:23504795	C/T	cg12483005	chr1:23474871	LUZP1	-0.39	-6.68	-0.31	7.39e-11	Height;
LUAD	cis	rs6087990	0.871	rs2424905	chr20:31352927	T/C	cg13636640	chr20:31349939	DNMT3B	0.78	14.46	0.58	8.37e-39	Ulcerative colitis;
LUAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg22907277	chr7:1156413	C7orf50	0.55	9.47	0.42	1.93e-19	Longevity;Endometriosis;
LUAD	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg24818145	chr4:99064322	C4orf37	0.43	7.18	0.33	3.22e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg01579765	chr21:45077557	HSF2BP	-0.6	-13.38	-0.55	2.75e-34	Mean corpuscular volume;
LUAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg24846343	chr22:24311635	DDTL	0.71	15.79	0.61	1.71e-44	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4462272	0.503	rs7477551	chr10:101827619	G/A	cg19754520	chr10:101825118	CPN1	-0.34	-7.42	-0.34	6.43e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs76878669	0.561	rs56321771	chr11:66161072	C/T	cg10616300	chr11:66138557	SLC29A2	0.36	7.63	0.35	1.58e-13	Educational attainment (years of education);
LUAD	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg21724239	chr8:58056113	NA	0.71	9.26	0.41	1.01e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg20503657	chr10:835505	NA	0.96	14.6	0.58	2.11e-39	Eosinophil percentage of granulocytes;
LUAD	cis	rs7705042	0.865	rs6580228	chr5:141510448	C/T	cg08523384	chr5:141488047	NDFIP1	-0.38	-6.52	-0.3	1.99e-10	Asthma;
LUAD	cis	rs7709909	0.755	rs2081853	chr5:79964349	G/T	cg24059623	chr5:79951536	MSH3;DHFR	0.49	9.12	0.41	3.06e-18	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg21724239	chr8:58056113	NA	0.47	6.79	0.31	3.87e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs3812111	0.510	rs9372453	chr6:116583872	T/A	cg18828861	chr6:116576566	TSPYL4	0.37	7.1	0.33	5.46e-12	Age-related macular degeneration;
LUAD	cis	rs1045714	0.895	rs4721867	chr7:2643352	A/G	cg24848437	chr7:2645542	IQCE	-0.69	-8.17	-0.37	3.49e-15	Urate levels in lean individuals;
LUAD	trans	rs2921073	0.604	rs2979140	chr8:8267202	T/A	cg08071915	chr8:12219732	FAM66A	-0.39	-6.54	-0.3	1.73e-10	Parkinson's disease;
LUAD	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg16060761	chr17:80687452	NA	0.47	7.11	0.33	4.83e-12	Breast cancer;
LUAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.67e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4372836	0.518	rs1128416	chr2:29001691	A/G	cg09522027	chr2:28974177	PPP1CB	-0.62	-10.83	-0.47	2.72e-24	Body mass index;
LUAD	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg16414030	chr3:133502952	NA	0.65	12.57	0.52	5.07e-31	Iron status biomarkers;
LUAD	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg11494091	chr17:61959527	GH2	-0.81	-21.72	-0.73	8.55e-71	Prudent dietary pattern;
LUAD	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg24154853	chr7:158122151	PTPRN2	0.57	11.37	0.48	2.51e-26	Calcium levels;
LUAD	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg08742575	chr21:47604166	C21orf56	0.43	7.14	0.33	4.12e-12	Testicular germ cell tumor;
LUAD	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg08029281	chr1:67600428	NA	0.35	6.87	0.32	2.33e-11	Psoriasis;
LUAD	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg02196655	chr2:10830764	NOL10	-0.43	-7.75	-0.35	6.67e-14	Prostate cancer;
LUAD	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg15556689	chr8:8085844	FLJ10661	0.41	6.62	0.31	1.11e-10	Mood instability;
LUAD	cis	rs9535307	0.584	rs9596197	chr13:50406988	G/T	cg04663916	chr13:50265991	EBPL	0.61	6.57	0.3	1.5e-10	Obesity-related traits;
LUAD	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg05697835	chr1:2722811	NA	0.31	6.41	0.3	3.78e-10	Ulcerative colitis;
LUAD	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.54	-8.03	-0.36	1.01e-14	Gut microbiome composition (summer);
LUAD	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg05340658	chr4:99064831	C4orf37	0.46	7.54	0.34	2.85e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg01802117	chr1:53393560	SCP2	0.34	6.65	0.31	8.94e-11	Monocyte count;
LUAD	cis	rs4711350	0.954	rs1536500	chr6:33723383	T/C	cg07979401	chr6:33739406	LEMD2	-0.4	-6.69	-0.31	7.18e-11	Schizophrenia;
LUAD	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18876405	chr7:65276391	NA	-0.42	-6.68	-0.31	7.32e-11	Aortic root size;
LUAD	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg27454412	chr7:1067447	C7orf50	-0.45	-7.82	-0.36	4.16e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg26354017	chr1:205819088	PM20D1	0.53	8.35	0.38	9.78e-16	Menarche (age at onset);
LUAD	cis	rs7177699	0.557	rs7403728	chr15:79112016	T/G	cg00540400	chr15:79124168	NA	-0.46	-9.7	-0.43	3.23e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg04155289	chr7:94953770	PON1	-0.5	-6.5	-0.3	2.24e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg21284400	chr1:149981654	OTUD7B	-0.37	-6.43	-0.3	3.42e-10	Longevity;Endometriosis;
LUAD	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg24531977	chr5:56204891	C5orf35	-0.44	-7.29	-0.33	1.49e-12	Coronary artery disease;
LUAD	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg19622623	chr12:86230825	RASSF9	-0.39	-7.07	-0.33	6.35e-12	Major depressive disorder;
LUAD	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg09796270	chr17:17721594	SREBF1	-0.38	-7.38	-0.34	8.43e-13	Total body bone mineral density;
LUAD	cis	rs7394190	0.748	rs78790589	chr10:75539598	G/A	cg02286717	chr10:75415704	SYNPO2L	-0.4	-6.91	-0.32	1.77e-11	Incident atrial fibrillation;
LUAD	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg15017067	chr4:17643749	FAM184B	0.37	7.19	0.33	2.88e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg05340658	chr4:99064831	C4orf37	0.53	9.05	0.4	5.17e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg03676636	chr4:99064102	C4orf37	0.32	8.31	0.37	1.36e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg02176678	chr2:219576539	TTLL4	0.61	11.98	0.5	1.09e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs8018808	0.936	rs4903576	chr14:77844869	A/G	cg20045696	chr14:77926864	AHSA1	-0.37	-6.69	-0.31	7.07e-11	Myeloid white cell count;
LUAD	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg02527881	chr3:46936655	PTH1R	-0.49	-9.62	-0.42	6.1e-20	Colorectal cancer;
LUAD	cis	rs7640424	0.784	rs68044584	chr3:107845395	A/G	cg09227934	chr3:107805635	CD47	-0.56	-9.71	-0.43	3.05e-20	Body mass index;
LUAD	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg12573674	chr2:1569213	NA	-0.56	-8.25	-0.37	2.01e-15	IgG glycosylation;
LUAD	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.87	-0.4	2.11e-17	Total body bone mineral density;
LUAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg13453750	chr1:205783389	SLC41A1	-0.38	-6.7	-0.31	6.5e-11	Menarche (age at onset);
LUAD	cis	rs943466	1.000	rs6940353	chr6:33752550	G/A	cg16010596	chr6:33739607	LEMD2	-0.4	-7.53	-0.34	3.08e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg08989290	chr16:615782	NHLRC4	0.31	6.5	0.3	2.31e-10	Height;
LUAD	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.43e-19	Life satisfaction;
LUAD	cis	rs11671005	0.735	rs12981875	chr19:58935130	A/C	cg13877915	chr19:58951672	ZNF132	0.56	7.35	0.34	1.04e-12	Mean platelet volume;
LUAD	cis	rs7843479	0.601	rs1031882	chr8:21788934	T/G	cg03445287	chr8:21823731	XPO7	-0.49	-9.13	-0.41	2.76e-18	Mean corpuscular volume;
LUAD	cis	rs11723261	0.621	rs7692530	chr4:123445	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.44	7.79	0.35	5.37e-14	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg15181151	chr6:150070149	PCMT1	0.42	8.68	0.39	8.62e-17	Lung cancer;
LUAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04267008	chr7:1944627	MAD1L1	-0.71	-11.56	-0.49	4.73e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg15017067	chr4:17643749	FAM184B	0.37	7.27	0.33	1.7e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg11292332	chr7:45801988	SEPT13	-0.31	-6.84	-0.32	2.81e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg26446133	chr18:72167187	CNDP2	-0.79	-11.32	-0.48	4.11e-26	Refractive error;
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01171360	chr6:293285	DUSP22	0.73	13.03	0.54	7.39e-33	Menopause (age at onset);
LUAD	trans	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.82	-0.36	4.29e-14	Depression;
LUAD	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg01475377	chr6:109611718	NA	0.48	9.09	0.4	3.9e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs8044868	1.000	rs11075922	chr16:72157718	C/T	cg23815491	chr16:72088622	HP	0.42	7.68	0.35	1.1e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg02389323	chr16:88786976	FAM38A	1.03	10.21	0.44	5.16e-22	Plateletcrit;
LUAD	cis	rs6669072	0.647	rs814546	chr1:91239355	G/T	cg08895590	chr1:91227319	NA	-0.31	-6.51	-0.3	2.14e-10	Cognitive function;
LUAD	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg10589385	chr1:150898437	SETDB1	0.43	7.94	0.36	1.82e-14	Urate levels;
LUAD	cis	rs332507	0.830	rs3772789	chr3:124395607	A/G	cg05980111	chr3:124395277	KALRN	0.46	7.25	0.33	2.04e-12	Plateletcrit;
LUAD	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg07636037	chr3:49044803	WDR6	0.45	7.33	0.34	1.17e-12	Menarche (age at onset);
LUAD	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.92	-0.36	2.08e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg02493798	chr17:6899577	ALOX12	0.36	6.84	0.32	2.86e-11	Tonsillectomy;
LUAD	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.08	-0.37	6.67e-15	Total body bone mineral density;
LUAD	trans	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-9.25	-0.41	1.12e-18	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.7	-0.31	6.52e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg09436375	chr6:42928200	GNMT	0.29	8.38	0.38	8.09e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs877282	0.853	rs7079450	chr10:755932	T/A	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.85e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg23625390	chr15:77176239	SCAPER	-0.5	-7.84	-0.36	3.82e-14	Blood metabolite levels;
LUAD	trans	rs7395662	0.857	rs3902433	chr11:48733324	C/T	cg00717180	chr2:96193071	NA	0.39	7.21	0.33	2.6e-12	HDL cholesterol;
LUAD	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.58e-12	Breast cancer;
LUAD	cis	rs13064411	0.696	rs1386336	chr3:113144153	C/T	cg10517650	chr3:113235015	CCDC52	-0.55	-8.98	-0.4	8.86e-18	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg02030672	chr11:45687055	CHST1	0.38	6.8	0.31	3.67e-11	Obesity-related traits;
LUAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.41	-0.38	6.57e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.25	0.33	1.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg00717180	chr2:96193071	NA	-0.45	-8.58	-0.39	1.82e-16	HDL cholesterol;
LUAD	cis	rs679087	0.640	rs79708380	chr12:29909457	G/A	cg14258853	chr12:29935411	TMTC1	-0.55	-8.94	-0.4	1.22e-17	Schizophrenia;
LUAD	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg11292332	chr7:45801988	SEPT13	-0.3	-6.63	-0.31	1.05e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg25985355	chr7:65971099	NA	-0.39	-7.17	-0.33	3.42e-12	Aortic root size;
LUAD	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg01028140	chr2:1542097	TPO	-0.39	-6.42	-0.3	3.68e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg09455208	chr3:40491958	NA	0.56	12.57	0.52	5.18e-31	Renal cell carcinoma;
LUAD	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.54	-0.3	1.81e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg01689657	chr7:91764605	CYP51A1	-0.3	-7.26	-0.33	1.91e-12	Breast cancer;
LUAD	cis	rs35146811	0.555	rs2525539	chr7:99545309	A/G	cg22906224	chr7:99728672	NA	-0.53	-8.7	-0.39	7.41e-17	Coronary artery disease;
LUAD	cis	rs151234	0.741	rs11647881	chr16:28606173	C/A	cg04643524	chr16:28609220	SULT1A2	0.58	7.62	0.35	1.63e-13	Platelet distribution width;
LUAD	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg14844989	chr11:31128820	NA	-0.46	-8.44	-0.38	4.93e-16	Red blood cell count;
LUAD	cis	rs870825	0.929	rs72689263	chr4:185590961	C/T	cg04058563	chr4:185651563	MLF1IP	0.74	9.52	0.42	1.37e-19	Blood protein levels;
LUAD	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg17105886	chr17:28927953	LRRC37B2	0.83	8.0	0.36	1.18e-14	Body mass index;
LUAD	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.31	6.78	0.31	4.12e-11	Cardiac Troponin-T levels;
LUAD	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg17063962	chr7:91808500	NA	0.64	10.96	0.47	8.84e-25	Breast cancer;
LUAD	cis	rs7975161	0.671	rs10861180	chr12:104650999	T/C	cg25273343	chr12:104657179	TXNRD1	-0.46	-6.38	-0.3	4.55e-10	Toenail selenium levels;
LUAD	cis	rs2730245	0.569	rs842692	chr7:158657228	T/C	cg24397884	chr7:158709396	WDR60	0.58	10.37	0.45	1.37e-22	Height;
LUAD	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg19875535	chr5:140030758	IK	0.44	7.41	0.34	6.97e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.44	0.3	3.28e-10	Depression;
LUAD	trans	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg26043149	chr18:55253948	FECH	0.51	8.09	0.37	6.19e-15	Bone mineral density;
LUAD	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg13385794	chr1:248469461	NA	0.26	7.14	0.33	4.14e-12	Common traits (Other);
LUAD	cis	rs7119038	0.774	rs11217037	chr11:118677086	G/A	cg19308663	chr11:118741387	NA	0.45	6.52	0.3	2.05e-10	Sjögren's syndrome;
LUAD	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg17366294	chr4:99064904	C4orf37	-0.48	-8.51	-0.38	3.16e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg23231163	chr10:75533350	FUT11	-0.53	-9.94	-0.44	4.45e-21	Inflammatory bowel disease;
LUAD	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.39	-0.34	8.04e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg09065629	chr16:1709722	CRAMP1L	0.42	7.27	0.33	1.8e-12	Coronary artery disease;
LUAD	cis	rs9925964	0.967	rs889548	chr16:31137712	A/G	cg03418659	chr16:31128414	MYST1	-0.39	-6.61	-0.31	1.17e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs123509	0.687	rs73075297	chr3:42832466	A/G	cg10144569	chr3:42726640	KBTBD5	-0.48	-7.11	-0.33	5.06e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg12927641	chr6:109611667	NA	-0.55	-9.59	-0.42	7.53e-20	Reticulocyte fraction of red cells;
LUAD	cis	rs8025790	0.508	rs35930676	chr15:67827705	G/A	cg27219399	chr15:67835830	MAP2K5	0.42	7.49	0.34	4e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg02421172	chr7:1938701	MAD1L1	0.46	6.64	0.31	9.44e-11	Neuroticism;
LUAD	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-10.49	-0.45	4.71e-23	Gut microbiome composition (summer);
LUAD	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg19635926	chr16:89946313	TCF25	0.74	6.58	0.3	1.37e-10	Skin colour saturation;
LUAD	cis	rs2996428	0.504	rs3765780	chr1:3767696	C/T	cg13057898	chr1:3703894	LRRC47	-0.51	-9.25	-0.41	1.15e-18	Red cell distribution width;
LUAD	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg03929089	chr4:120376271	NA	-0.9	-17.14	-0.64	2.09e-50	Coronary artery disease;
LUAD	cis	rs1832871	0.965	rs262827	chr6:158683646	A/T	cg07165851	chr6:158734300	TULP4	0.38	6.43	0.3	3.51e-10	Height;
LUAD	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg18190219	chr22:46762943	CELSR1	-0.54	-6.78	-0.31	4.07e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.3	0.37	1.46e-15	Breast cancer;
LUAD	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07167872	chr1:205819463	PM20D1	0.59	10.92	0.47	1.29e-24	Menarche (age at onset);
LUAD	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg11494091	chr17:61959527	GH2	0.74	18.54	0.67	1.31e-56	Prudent dietary pattern;
LUAD	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18876405	chr7:65276391	NA	0.55	9.22	0.41	1.43e-18	Aortic root size;
LUAD	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg18806716	chr10:30721971	MAP3K8	-0.68	-13.57	-0.55	4.49e-35	Inflammatory bowel disease;
LUAD	cis	rs6831352	0.704	rs1800759	chr4:100065509	T/G	cg12011299	chr4:100065546	ADH4	0.92	25.13	0.77	6.04e-86	Alcohol dependence;
LUAD	cis	rs9372498	0.764	rs9489371	chr6:118725368	T/C	cg07617317	chr6:118971624	C6orf204	0.53	6.6	0.31	1.27e-10	Diastolic blood pressure;
LUAD	cis	rs2425143	1.000	rs8116836	chr20:34453362	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-6.73	-0.31	5.65e-11	Blood protein levels;
LUAD	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg16950941	chr11:66035639	RAB1B	0.42	7.08	0.33	6.12e-12	Gout;
LUAD	trans	rs7712671	0.840	rs11241418	chr5:116527405	C/T	cg11826116	chr22:39916314	ATF4	0.41	6.53	0.3	1.86e-10	Schizophrenia;
LUAD	cis	rs76878669	0.561	rs1892940	chr11:66111251	A/G	cg18002602	chr11:66138449	SLC29A2	-0.46	-10.01	-0.44	2.6e-21	Educational attainment (years of education);
LUAD	cis	rs72949976	0.606	rs11898263	chr2:214030649	A/G	cg08319019	chr2:214017104	IKZF2	0.51	7.59	0.35	2.11e-13	Lung cancer;Squamous cell lung carcinoma;
LUAD	trans	rs10504906	1.000	rs13259314	chr8:92420224	A/C	cg10665438	chr10:134049549	STK32C	-0.71	-6.47	-0.3	2.75e-10	Fat distribution (HIV);
LUAD	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-11.5	-0.49	8.41e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg23254163	chr1:152506842	NA	0.26	7.14	0.33	4.21e-12	Hair morphology;
LUAD	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-6.91	-0.32	1.76e-11	Glaucoma (primary open-angle);
LUAD	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg18129748	chr3:49941408	MST1R	0.4	6.5	0.3	2.24e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg03714773	chr7:91764589	CYP51A1	0.27	6.48	0.3	2.61e-10	Breast cancer;
LUAD	cis	rs863345	0.604	rs10797022	chr1:158494193	T/C	cg12129480	chr1:158549410	OR10X1	-0.23	-6.35	-0.3	5.56e-10	Pneumococcal bacteremia;
LUAD	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg27572855	chr1:25598939	RHD	0.62	14.35	0.57	2.43e-38	Erythrocyte sedimentation rate;
LUAD	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg10018233	chr7:150070692	REPIN1	0.51	8.02	0.36	1.05e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg19980929	chr12:42632907	YAF2	-0.34	-6.49	-0.3	2.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg23625390	chr15:77176239	SCAPER	0.39	7.2	0.33	2.7e-12	Blood metabolite levels;
LUAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-8.66	-0.39	9.93e-17	Longevity;Endometriosis;
LUAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg27454412	chr7:1067447	C7orf50	0.44	7.0	0.32	1.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg13012494	chr21:47604986	C21orf56	0.47	7.75	0.35	6.93e-14	Testicular germ cell tumor;
LUAD	trans	rs208520	1.000	rs208523	chr6:66954195	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-13.5	-0.55	8.62e-35	Exhaled nitric oxide output;
LUAD	cis	rs13064411	0.696	rs6438161	chr3:113227637	G/A	cg10517650	chr3:113235015	CCDC52	-0.56	-9.68	-0.43	3.73e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg05110241	chr16:68378359	PRMT7	-0.8	-8.88	-0.4	1.91e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg03948781	chr1:205179583	DSTYK	0.35	6.71	0.31	6.43e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23724447	chr10:124913897	BUB3	-0.38	-6.52	-0.3	1.98e-10	Cancer;
LUAD	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg18180107	chr4:99064573	C4orf37	0.41	6.48	0.3	2.48e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12900413	0.687	rs34284515	chr15:90308061	T/G	cg24249390	chr15:90295951	MESP1	-0.34	-6.67	-0.31	8.16e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs10979	0.597	rs9403514	chr6:143907790	T/C	cg25407410	chr6:143891975	LOC285740	-0.55	-7.69	-0.35	1.05e-13	Hypospadias;
LUAD	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg10755058	chr3:40428713	ENTPD3	0.39	7.13	0.33	4.36e-12	Renal cell carcinoma;
LUAD	cis	rs8060686	0.516	rs8059575	chr16:68272635	C/G	cg09835421	chr16:68378352	PRMT7	-0.55	-6.95	-0.32	1.37e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg22681709	chr2:178499509	PDE11A	-0.39	-7.02	-0.32	8.96e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.5e-19	Life satisfaction;
LUAD	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.5	7.25	0.33	1.99e-12	Cognitive test performance;
LUAD	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-7.12	-0.33	4.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg10589385	chr1:150898437	SETDB1	0.45	8.73	0.39	6.05e-17	Melanoma;
LUAD	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg23840854	chr1:161414152	NA	-0.83	-10.84	-0.47	2.52e-24	Rheumatoid arthritis;
LUAD	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg07432352	chr17:45403706	C17orf57	-0.41	-7.75	-0.35	7.1e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2731664	0.792	rs652242	chr5:176873010	C/G	cg23176889	chr5:176863531	GRK6	-0.75	-14.74	-0.58	5.8e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg06671706	chr8:8559999	CLDN23	0.66	11.33	0.48	3.46e-26	Obesity-related traits;
LUAD	cis	rs7567389	0.740	rs4536600	chr2:128002572	A/G	cg09760422	chr2:128146352	NA	0.4	6.93	0.32	1.58e-11	Self-rated health;
LUAD	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.64	0.55	2.26e-35	Tonsillectomy;
LUAD	cis	rs4900538	0.927	rs1190547	chr14:102905087	G/C	cg18135206	chr14:102964638	TECPR2	-1.06	-24.13	-0.76	1.52e-81	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs13315871	1.000	rs11719957	chr3:58415031	A/G	cg12435725	chr3:58293450	RPP14	-0.69	-7.36	-0.34	9.51e-13	Cholesterol, total;
LUAD	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg04287289	chr16:89883240	FANCA	0.63	6.63	0.31	1.03e-10	Skin colour saturation;
LUAD	cis	rs4523957	0.928	rs170044	chr17:2197502	C/G	cg16513277	chr17:2031491	SMG6	-0.77	-14.52	-0.58	5e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.58	0.3	1.37e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67072384	0.818	rs1872127	chr11:72465085	G/A	cg04827223	chr11:72435913	ARAP1	-0.57	-7.0	-0.32	9.99e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg23625390	chr15:77176239	SCAPER	-0.51	-7.91	-0.36	2.24e-14	Blood metabolite levels;
LUAD	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18876405	chr7:65276391	NA	0.56	9.18	0.41	1.86e-18	Aortic root size;
LUAD	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06022373	chr22:39101656	GTPBP1	0.44	7.25	0.33	2.04e-12	Menopause (age at onset);
LUAD	cis	rs9837602	0.576	rs506186	chr3:99442753	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-7.0	-0.32	1e-11	Breast cancer;
LUAD	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg04450456	chr4:17643702	FAM184B	0.4	7.94	0.36	1.83e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg06740227	chr12:86229804	RASSF9	0.37	6.85	0.32	2.58e-11	Major depressive disorder;
LUAD	cis	rs3739034	0.652	rs62171374	chr2:135429556	T/C	cg12500956	chr2:135428796	TMEM163	0.38	7.23	0.33	2.34e-12	Gut microbiome composition (winter);
LUAD	trans	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg01620082	chr3:125678407	NA	-1.04	-10.33	-0.45	1.92e-22	Depression;
LUAD	cis	rs12612619	0.732	rs10865461	chr2:27292651	T/C	cg00617064	chr2:27272375	NA	-0.38	-7.27	-0.33	1.75e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg05727186	chr17:43697356	MGC57346	-0.52	-6.46	-0.3	2.86e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs220324	0.688	rs2236703	chr21:43562525	G/A	cg09727148	chr21:43560719	UMODL1	0.6	8.93	0.4	1.32e-17	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg25251562	chr2:3704773	ALLC	-0.51	-8.13	-0.37	4.67e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs62458065	0.850	rs62458098	chr7:32471129	G/A	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.44	-0.34	5.76e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs1691799	0.867	rs1168309	chr12:66726439	A/G	cg16791601	chr12:66731901	HELB	0.36	6.49	0.3	2.41e-10	White blood cell count (basophil);
LUAD	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.44	-0.49	1.33e-26	Type 2 diabetes;
LUAD	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg26875233	chr11:93583750	C11orf90	-0.4	-8.87	-0.4	2.02e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg08222618	chr4:941054	TMEM175	0.69	10.79	0.46	3.89e-24	Sjögren's syndrome;
LUAD	cis	rs17092148	0.887	rs6142199	chr20:33162298	G/C	cg16810054	chr20:33298113	TP53INP2	-0.48	-7.28	-0.33	1.6e-12	Neuroticism;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06705834	chr12:89746511	DUSP6	-0.39	-6.59	-0.31	1.33e-10	Cancer;
LUAD	trans	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg14917512	chr19:3094685	GNA11	-0.37	-6.38	-0.3	4.52e-10	Aortic root size;
LUAD	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.79	-0.31	3.84e-11	Height;
LUAD	cis	rs12900413	0.687	rs72754547	chr15:90308166	A/C	cg24249390	chr15:90295951	MESP1	-0.34	-6.67	-0.31	8.16e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-10.18	-0.44	6.53e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg17366294	chr4:99064904	C4orf37	0.65	12.56	0.52	5.93e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.55	-0.3	1.69e-10	Breast cancer;
LUAD	trans	rs11165623	0.740	rs12126692	chr1:96889258	C/G	cg10631902	chr5:14652156	NA	0.57	10.94	0.47	1.08e-24	Hip circumference;Waist circumference;
LUAD	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg21775007	chr8:11205619	TDH	0.55	10.13	0.44	9.9700000000000009e-22	Retinal vascular caliber;
LUAD	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg23029597	chr12:123009494	RSRC2	0.54	8.23	0.37	2.35e-15	Body mass index;
LUAD	cis	rs332507	0.830	rs12631364	chr3:124405042	A/T	cg05980111	chr3:124395277	KALRN	0.45	7.02	0.32	8.99e-12	Plateletcrit;
LUAD	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-7.49	-0.34	3.93e-13	Alzheimer's disease (late onset);
LUAD	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.37	-7.67	-0.35	1.23e-13	Height;
LUAD	cis	rs12618769	0.597	rs3754883	chr2:99129451	T/C	cg10123293	chr2:99228465	UNC50	0.47	8.47	0.38	4.2e-16	Bipolar disorder;
LUAD	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg02733842	chr7:1102375	C7orf50	-0.52	-8.21	-0.37	2.7e-15	Bronchopulmonary dysplasia;
LUAD	cis	rs12413816	0.784	rs35537139	chr10:13768894	G/A	cg16485048	chr10:13749193	FRMD4A	0.41	6.69	0.31	7.3e-11	Red cell distribution width;
LUAD	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11890956	chr21:40555474	PSMG1	0.82	14.54	0.58	3.82e-39	Cognitive function;
LUAD	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg16535667	chr11:65410126	SIPA1	-0.44	-6.84	-0.32	2.85e-11	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg02683114	chr2:24398427	C2orf84	-0.54	-8.02	-0.36	1.04e-14	Asthma;
LUAD	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.69	-0.35	1.02e-13	Prostate cancer;
LUAD	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg07167872	chr1:205819463	PM20D1	-0.51	-7.83	-0.36	4e-14	Menarche (age at onset);
LUAD	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg08601574	chr20:25228251	PYGB	-0.47	-8.89	-0.4	1.72e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24531977	chr5:56204891	C5orf35	1.25	20.51	0.71	2.15e-65	Initial pursuit acceleration;
LUAD	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg27124370	chr19:33622961	WDR88	0.44	6.92	0.32	1.64e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7528419	0.895	rs1277930	chr1:109822143	G/A	cg00908766	chr1:109817496	CELSR2	0.64	12.81	0.53	5.71e-32	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUAD	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg20503657	chr10:835505	NA	1.0	14.91	0.59	1.02e-40	Eosinophil percentage of granulocytes;
LUAD	cis	rs7193541	0.646	rs4888267	chr16:74687906	A/G	cg01733217	chr16:74700730	RFWD3	0.68	13.53	0.55	6.68e-35	Multiple myeloma;
LUAD	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.54	0.52	6.58e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg01528321	chr10:82214614	TSPAN14	0.76	10.1	0.44	1.2e-21	Post bronchodilator FEV1;
LUAD	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg03563238	chr19:33554763	RHPN2	-0.34	-8.07	-0.37	7.47e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg02371401	chr5:676784	TPPP	-0.49	-8.21	-0.37	2.63e-15	Obesity-related traits;
LUAD	cis	rs11214589	0.747	rs11493880	chr11:113225144	C/T	cg14159747	chr11:113255604	NA	0.62	12.5	0.52	1.02e-30	Neuroticism;
LUAD	cis	rs250585	1.000	rs9940058	chr16:23527062	T/C	cg00143387	chr16:23521605	GGA2	-0.63	-7.49	-0.34	4.01e-13	Egg allergy;
LUAD	cis	rs6906287	0.609	rs767139	chr6:118884799	A/G	cg05564266	chr6:118973597	C6orf204	0.35	7.49	0.34	4.07e-13	Electrocardiographic conduction measures;
LUAD	cis	rs220324	0.688	rs8134009	chr21:43568648	T/C	cg09727148	chr21:43560719	UMODL1	0.48	7.56	0.35	2.51e-13	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg11062466	chr8:58055876	NA	0.64	7.6	0.35	1.88e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs727505	1.000	rs7806680	chr7:124433079	G/A	cg23710748	chr7:124431027	NA	-0.42	-8.9	-0.4	1.7e-17	Lewy body disease;
LUAD	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg07423050	chr13:99094983	FARP1	-0.54	-9.11	-0.4	3.35e-18	Neuroticism;
LUAD	cis	rs17102423	0.588	rs7150646	chr14:65540463	G/T	cg16583315	chr14:65563665	MAX	-0.34	-6.36	-0.3	5.39e-10	Obesity-related traits;
LUAD	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-11.85	-0.5	3.66e-28	Hemoglobin concentration;
LUAD	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg20283391	chr11:68216788	NA	-0.41	-6.57	-0.3	1.49e-10	Total body bone mineral density;
LUAD	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	6.85	0.32	2.63e-11	Platelet count;
LUAD	cis	rs2742417	0.603	rs2742457	chr3:45767487	G/A	cg10512202	chr3:45649293	LIMD1	0.47	8.6	0.39	1.53e-16	Response to anti-depressant treatment in major depressive disorder;
LUAD	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg03929089	chr4:120376271	NA	-0.56	-8.29	-0.37	1.55e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9394169	1.000	rs9394169	chr6:33778964	A/G	cg16010596	chr6:33739607	LEMD2	-0.31	-6.63	-0.31	1.01e-10	Essential tremor;
LUAD	trans	rs10411161	0.702	rs11879436	chr19:52397815	T/A	cg22319618	chr22:45562946	NUP50	-0.66	-9.44	-0.42	2.52e-19	Breast cancer;
LUAD	cis	rs62400317	0.826	rs12194628	chr6:45329376	G/C	cg20913747	chr6:44695427	NA	-0.43	-6.9	-0.32	1.85e-11	Total body bone mineral density;
LUAD	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg19318889	chr4:1322082	MAEA	-0.44	-7.53	-0.34	2.99e-13	Obesity-related traits;
LUAD	cis	rs68170813	0.559	rs76167266	chr7:106900664	C/T	cg23024343	chr7:107201750	COG5	0.5	7.23	0.33	2.31e-12	Coronary artery disease;
LUAD	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg19678392	chr7:94953810	PON1	-0.59	-8.27	-0.37	1.72e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs897984	0.609	rs12445650	chr16:31044897	G/A	cg02466173	chr16:30829666	NA	-0.56	-9.83	-0.43	1.1e-20	Dementia with Lewy bodies;
LUAD	cis	rs12208915	0.848	rs12203336	chr6:79518315	G/T	cg05283184	chr6:79620031	NA	0.49	6.39	0.3	4.34e-10	Left atrial antero-posterior diameter;
LUAD	trans	rs9784649	0.641	rs72755823	chr5:25075537	T/C	cg11038491	chr20:34638489	LOC647979	-0.94	-11.67	-0.49	1.86e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs1609391	0.561	rs9289523	chr3:136635589	C/G	cg15507776	chr3:136538369	TMEM22	0.49	8.72	0.39	6.65e-17	Neuroticism;
LUAD	cis	rs698813	0.674	rs6544751	chr2:44495845	A/G	cg00619915	chr2:44497795	NA	-0.43	-6.42	-0.3	3.6e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUAD	cis	rs494562	1.000	rs7763191	chr6:86118317	A/T	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg21782813	chr7:2030301	MAD1L1	0.53	9.42	0.42	3.05e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11890956	chr21:40555474	PSMG1	-0.49	-8.32	-0.38	1.2e-15	Menarche (age at onset);
LUAD	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg10556349	chr10:835070	NA	0.67	7.82	0.36	4.28e-14	Eosinophil percentage of granulocytes;
LUAD	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg24531977	chr5:56204891	C5orf35	-0.4	-6.53	-0.3	1.9e-10	Coronary artery disease;
LUAD	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.79	-0.39	3.75e-17	Total body bone mineral density;
LUAD	cis	rs11771526	1.000	rs17351142	chr7:32339843	T/G	cg27532318	chr7:32358331	NA	0.7	8.31	0.37	1.28e-15	Body mass index;
LUAD	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.43	0.3	3.35e-10	Menarche (age at onset);
LUAD	cis	rs9595066	1.000	rs7981575	chr13:44710947	C/T	cg04068111	chr13:44716778	NA	-0.57	-10.36	-0.45	1.42e-22	Schizophrenia;
LUAD	cis	rs3106136	0.903	rs67552174	chr4:95203097	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.3	-0.33	1.41e-12	Capecitabine sensitivity;
LUAD	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg14092988	chr3:52407081	DNAH1	0.45	8.97	0.4	1e-17	Bipolar disorder;
LUAD	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-11.68	-0.49	1.65e-27	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.21e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7072216	0.621	rs3750604	chr10:100175581	G/A	cg26618903	chr10:100175079	PYROXD2	-0.4	-7.7	-0.35	9.68e-14	Metabolite levels;
LUAD	trans	rs141342723	1	rs141342723	chr6:27622084	T/C	cg01620082	chr3:125678407	NA	-1.04	-10.21	-0.44	4.98e-22	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3091242	0.900	rs1883427	chr1:25744468	C/T	cg03538708	chr1:25844672	NA	-0.37	-6.48	-0.3	2.54e-10	Erythrocyte sedimentation rate;
LUAD	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg04842962	chr6:43655489	MRPS18A	0.86	13.53	0.55	6.62e-35	IgG glycosylation;
LUAD	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg03467027	chr4:99064603	C4orf37	-0.43	-6.84	-0.32	2.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12472274	1.000	rs12472274	chr2:239095422	G/A	cg17459225	chr2:239074497	NA	0.71	9.61	0.42	6.66e-20	Phospholipid levels (plasma);
LUAD	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg14847009	chr1:175162515	KIAA0040	0.3	7.76	0.35	6.38e-14	Alcohol dependence;
LUAD	trans	rs62458065	0.850	rs7785659	chr7:32461015	C/T	cg00845942	chr12:64062724	DPY19L2	-0.51	-6.79	-0.31	3.83e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs11945232	1.000	rs28609242	chr4:88342497	T/C	cg23841344	chr4:88312519	HSD17B11	-0.55	-8.23	-0.37	2.42e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs356992	1.000	rs356992	chr2:60753593	C/G	cg08426369	chr2:60753602	BCL11A	0.45	7.32	0.34	1.22e-12	Educational attainment (years of education);
LUAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg13047869	chr3:10149882	C3orf24	0.66	11.09	0.47	2.88e-25	Alzheimer's disease;
LUAD	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg09035930	chr12:129282057	SLC15A4	0.71	15.98	0.61	2.56e-45	Systemic lupus erythematosus;
LUAD	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg10518543	chr12:38710700	ALG10B	-0.42	-6.99	-0.32	1.09e-11	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs9467711	0.606	rs16891725	chr6:26479150	C/T	cg01620082	chr3:125678407	NA	-0.63	-7.51	-0.34	3.55e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-10.9	-0.47	1.48e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02353165	chr6:42928485	GNMT	0.4	7.1	0.33	5.47e-12	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.66	-0.43	4.48e-20	Schizophrenia;
LUAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03407747	chr17:6899364	ALOX12	0.4	7.56	0.35	2.5e-13	Tonsillectomy;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16367085	chr21:36260731	RUNX1	-0.4	-6.55	-0.3	1.67e-10	Cancer;
LUAD	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg15309053	chr8:964076	NA	-0.42	-9.01	-0.4	7.26e-18	Schizophrenia;
LUAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18099408	chr3:52552593	STAB1	-0.54	-9.94	-0.44	4.5e-21	Electroencephalogram traits;
LUAD	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg13271783	chr10:134563150	INPP5A	-0.41	-6.43	-0.3	3.37e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs41311933	0.611	rs118130982	chr9:123890004	C/T	cg13567360	chr9:123745713	C5	-0.73	-8.1	-0.37	5.8e-15	Coronary artery disease;
LUAD	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-9.8	-0.43	1.44e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-19.14	-0.68	2.78e-59	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg06606381	chr12:133084897	FBRSL1	-0.86	-9.0	-0.4	7.67e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg09742643	chr7:157958748	PTPRN2	0.38	7.69	0.35	1.04e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2274273	0.743	rs7161656	chr14:55524530	A/G	cg04306507	chr14:55594613	LGALS3	0.32	6.54	0.3	1.83e-10	Protein biomarker;
LUAD	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs977987	0.806	rs2285225	chr16:75429252	T/C	cg03315344	chr16:75512273	CHST6	0.64	14.02	0.56	6.11e-37	Dupuytren's disease;
LUAD	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg22823121	chr1:150693482	HORMAD1	0.41	7.96	0.36	1.57e-14	Melanoma;
LUAD	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg19717773	chr7:2847554	GNA12	-0.5	-9.33	-0.41	5.83e-19	Height;
LUAD	cis	rs11771526	0.681	rs117788703	chr7:32411009	T/C	cg27532318	chr7:32358331	NA	0.68	7.2	0.33	2.85e-12	Body mass index;
LUAD	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg04944784	chr2:26401820	FAM59B	-0.82	-12.61	-0.52	3.59e-31	Gut microbiome composition (summer);
LUAD	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg04398451	chr17:18023971	MYO15A	0.69	12.54	0.52	6.96e-31	Total body bone mineral density;
LUAD	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	10.66	0.46	1.15e-23	Resting heart rate;
LUAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg16606324	chr3:10149918	C3orf24	0.58	9.33	0.41	5.9e-19	Alzheimer's disease;
LUAD	cis	rs7659604	0.521	rs4833232	chr4:122684367	C/T	cg06713675	chr4:122721982	EXOSC9	0.42	7.61	0.35	1.83e-13	Type 2 diabetes;
LUAD	cis	rs12681287	0.640	rs7816629	chr8:87350788	A/T	cg27223183	chr8:87520930	FAM82B	-0.69	-9.66	-0.43	4.38e-20	Caudate activity during reward;
LUAD	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg08645402	chr16:4508243	NA	0.54	10.01	0.44	2.52e-21	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg26384229	chr12:38710491	ALG10B	0.4	6.37	0.3	4.82e-10	Morning vs. evening chronotype;
LUAD	trans	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg00953403	chr17:74099816	EXOC7	-0.6	-9.85	-0.43	9.5e-21	Psychosis in Alzheimer's disease;
LUAD	cis	rs4713118	0.614	rs9468209	chr6:27694421	C/T	cg26587870	chr6:27730563	NA	-0.36	-6.41	-0.3	3.88e-10	Parkinson's disease;
LUAD	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg26343298	chr8:95960752	TP53INP1	0.38	7.91	0.36	2.24e-14	Type 2 diabetes;
LUAD	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg26384229	chr12:38710491	ALG10B	0.42	7.2	0.33	2.7e-12	Morning vs. evening chronotype;
LUAD	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg13902645	chr11:5959945	NA	-0.55	-10.27	-0.45	3.1e-22	DNA methylation (variation);
LUAD	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg04218760	chr10:45406644	TMEM72	-0.3	-7.67	-0.35	1.16e-13	Mean corpuscular volume;
LUAD	cis	rs747650	0.892	rs2029298	chr11:47234718	C/T	cg19486271	chr11:47235900	DDB2	-0.44	-7.33	-0.34	1.15e-12	Acne (severe);
LUAD	cis	rs12618769	0.572	rs4851141	chr2:99112966	A/C	cg10123293	chr2:99228465	UNC50	0.46	8.12	0.37	5.1e-15	Bipolar disorder;
LUAD	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg03929089	chr4:120376271	NA	0.71	11.23	0.48	8.85e-26	Coronary artery disease;
LUAD	trans	rs28735056	0.904	rs35201860	chr18:77628719	T/C	cg05926928	chr17:57297772	GDPD1	0.5	7.37	0.34	8.96e-13	Schizophrenia;
LUAD	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.75	-0.31	4.86e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7786877	0.680	rs12532878	chr7:100212254	G/A	cg16850897	chr7:100343110	ZAN	-0.56	-7.77	-0.35	5.83e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-6.5	-0.3	2.24e-10	Height;
LUAD	cis	rs12976411	0.867	rs8110851	chr19:32828455	C/G	cg02282382	chr19:32836354	ZNF507	0.74	7.05	0.32	7.28e-12	Coronary artery disease;
LUAD	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-10.27	-0.45	3.11e-22	Gut microbiome composition (summer);
LUAD	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	12.18	0.51	1.77e-29	Homoarginine levels;
LUAD	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg22442454	chr1:209979470	IRF6	0.55	7.24	0.33	2.15e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.51	-0.55	8.09e-35	Alcohol dependence;
LUAD	cis	rs76419734	0.558	rs11721842	chr4:106521846	A/G	cg05309399	chr4:106552544	FLJ20184	-0.56	-6.9	-0.32	1.88e-11	Post bronchodilator FEV1;
LUAD	cis	rs908922	0.523	rs4845786	chr1:152510144	A/G	cg21823605	chr1:152486609	CRCT1	0.29	6.49	0.3	2.43e-10	Hair morphology;
LUAD	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23583168	chr7:148888333	NA	-0.91	-18.73	-0.67	1.95e-57	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg21709803	chr11:61594965	FADS2	-0.38	-7.21	-0.33	2.56e-12	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg18876405	chr7:65276391	NA	0.61	10.54	0.46	3.21e-23	Aortic root size;
LUAD	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.6	11.33	0.48	3.64e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22455342	chr2:225449267	CUL3	0.65	10.06	0.44	1.73e-21	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs7246865	0.954	rs10427132	chr19:17207156	T/G	cg19418318	chr19:17219073	MYO9B	0.46	7.82	0.36	4.33e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs908922	0.676	rs1538082	chr1:152517304	A/G	cg23254163	chr1:152506842	NA	0.27	7.35	0.34	1.05e-12	Hair morphology;
LUAD	cis	rs870825	0.790	rs12513128	chr4:185576729	G/C	cg04058563	chr4:185651563	MLF1IP	0.71	8.84	0.39	2.6e-17	Blood protein levels;
LUAD	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24531977	chr5:56204891	C5orf35	-0.99	-15.17	-0.59	8.56e-42	Initial pursuit acceleration;
LUAD	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg02569458	chr12:86230093	RASSF9	0.43	7.86	0.36	3.32e-14	Major depressive disorder;
LUAD	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg23533926	chr12:111358616	MYL2	-0.4	-6.91	-0.32	1.76e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg16060761	chr17:80687452	NA	-0.71	-11.24	-0.48	8.1e-26	Glycated hemoglobin levels;
LUAD	cis	rs2880765	0.835	rs2170736	chr15:86043398	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.4	-0.3	4.17e-10	Coronary artery disease;
LUAD	cis	rs2235642	0.525	rs8048290	chr16:1562026	T/C	cg26528668	chr16:1614120	IFT140	0.42	6.64	0.31	9.91e-11	Coronary artery disease;
LUAD	cis	rs4356932	1.000	rs6814012	chr4:76950778	C/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.51	-0.3	2.16e-10	Blood protein levels;
LUAD	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg00802000	chr16:706648	WDR90	-0.37	-6.94	-0.32	1.45e-11	Height;
LUAD	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg20203395	chr5:56204925	C5orf35	-0.39	-6.4	-0.3	4.23e-10	Coronary artery disease;
LUAD	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg15017067	chr4:17643749	FAM184B	-0.38	-7.3	-0.33	1.42e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504073	0.584	rs62507178	chr8:49938572	A/C	cg00325661	chr8:49890786	NA	0.48	10.44	0.45	7.44e-23	Blood metabolite ratios;
LUAD	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg21951975	chr1:209979733	IRF6	0.58	8.35	0.38	9.83e-16	Cleft lip with or without cleft palate;
LUAD	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg27535305	chr1:53392650	SCP2	-0.34	-6.77	-0.31	4.39e-11	Monocyte count;
LUAD	cis	rs938554	0.735	rs11942223	chr4:9962765	T/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-7.56	-0.34	2.6e-13	Blood metabolite levels;
LUAD	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg06784218	chr1:46089804	CCDC17	0.6	13.55	0.55	5.19e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg17330251	chr7:94953956	PON1	-0.53	-7.12	-0.33	4.65e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	7.63	0.35	1.62e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs870825	0.860	rs72703519	chr4:185602707	G/A	cg04058563	chr4:185651563	MLF1IP	0.78	10.21	0.44	4.85e-22	Blood protein levels;
LUAD	cis	rs922182	0.542	rs7179912	chr15:64263854	C/T	cg02919090	chr15:64263738	DAPK2	0.42	8.31	0.37	1.34e-15	Blood protein levels;
LUAD	cis	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	8.1	0.37	6.15e-15	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg12365402	chr11:9010492	NRIP3	0.45	8.34	0.38	1.08e-15	Hemoglobin concentration;
LUAD	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg12016809	chr21:47604291	C21orf56	0.46	7.64	0.35	1.43e-13	Testicular germ cell tumor;
LUAD	cis	rs6138458	0.961	rs227625	chr20:24911618	T/C	cg06937882	chr20:24974362	C20orf3	-0.33	-6.43	-0.3	3.52e-10	Blood protein levels;
LUAD	cis	rs7827545	1.000	rs7827545	chr8:135566567	C/T	cg17885191	chr8:135476712	NA	0.51	8.08	0.37	7.03e-15	Hypertension (SNP x SNP interaction);
LUAD	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg18180107	chr4:99064573	C4orf37	0.42	6.79	0.31	3.87e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs629535	0.814	rs651985	chr8:70054966	G/A	cg21567404	chr3:27674614	NA	1.01	18.53	0.67	1.49e-56	Dupuytren's disease;
LUAD	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg07537917	chr2:241836409	C2orf54	-0.31	-8.73	-0.39	6.09e-17	Urinary metabolites;
LUAD	cis	rs12760731	0.720	rs12048459	chr1:178412702	T/C	cg00404053	chr1:178313656	RASAL2	0.61	7.83	0.36	3.97e-14	Obesity-related traits;
LUAD	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg23649088	chr2:200775458	C2orf69	0.63	9.9	0.43	6.29e-21	Schizophrenia;
LUAD	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg27427491	chr17:78079615	GAA	-0.4	-6.73	-0.31	5.59e-11	Yeast infection;
LUAD	cis	rs1018836	0.608	rs7843149	chr8:91474961	C/T	cg16814680	chr8:91681699	NA	-0.51	-8.28	-0.37	1.63e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg02527881	chr3:46936655	PTH1R	0.43	8.31	0.37	1.3e-15	Colorectal cancer;
LUAD	trans	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.35	-0.34	1e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg25036284	chr2:26402008	FAM59B	-0.58	-8.17	-0.37	3.48e-15	Gut microbiome composition (summer);
LUAD	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg15445000	chr17:37608096	MED1	0.44	8.21	0.37	2.74e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg07936489	chr17:37558343	FBXL20	-0.48	-7.58	-0.35	2.26e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg13319975	chr6:146136371	FBXO30	-0.55	-9.42	-0.42	2.9e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11771526	0.686	rs117514532	chr7:32316615	A/G	cg27532318	chr7:32358331	NA	0.66	7.03	0.32	8.12e-12	Body mass index;
LUAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg21782813	chr7:2030301	MAD1L1	0.49	8.26	0.37	1.91e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg15128208	chr22:42549153	NA	0.42	6.9	0.32	1.88e-11	Birth weight;
LUAD	cis	rs7000551	0.725	rs2443496	chr8:22365788	G/A	cg12081754	chr8:22256438	SLC39A14	0.4	6.69	0.31	6.93e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg24955955	chr5:415729	AHRR	0.82	8.67	0.39	9.03e-17	Fat distribution (HIV);
LUAD	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.48	-7.33	-0.34	1.16e-12	Reticulocyte count;
LUAD	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg02423579	chr7:2872169	GNA12	-0.86	-14.81	-0.58	2.82e-40	Height;
LUAD	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg14458575	chr2:238380390	NA	0.65	12.13	0.51	2.93e-29	Prostate cancer;
LUAD	cis	rs12367572	0.796	rs7979141	chr12:45282630	A/T	cg04608330	chr12:45269318	NELL2	-0.38	-7.01	-0.32	9.44e-12	Gut microbiome composition (summer);
LUAD	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg17177755	chr1:15930204	NA	0.45	7.31	0.33	1.34e-12	Systolic blood pressure;
LUAD	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.09	0.33	5.56e-12	Menopause (age at onset);
LUAD	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs12530845	1.000	rs12537555	chr7:135334061	G/A	cg23117316	chr7:135346802	PL-5283	-0.5	-9.21	-0.41	1.49e-18	Red blood cell traits;
LUAD	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg11645453	chr3:52864694	ITIH4	0.6	11.62	0.49	2.8e-27	Schizophrenia;
LUAD	cis	rs28374715	0.662	rs11852419	chr15:41456374	A/T	cg18705301	chr15:41695430	NDUFAF1	0.84	15.36	0.6	1.24e-42	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg25985355	chr7:65971099	NA	-0.51	-6.37	-0.3	4.89e-10	Diabetic kidney disease;
LUAD	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg04851639	chr8:1020857	NA	-0.39	-9.27	-0.41	9.95e-19	Schizophrenia;
LUAD	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	8.02	0.36	1.02e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs6577655	0.517	rs4909293	chr8:135587888	G/A	cg17885191	chr8:135476712	NA	0.64	8.5	0.38	3.26e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg24768116	chr2:27665128	KRTCAP3	0.36	9.69	0.43	3.58e-20	Total body bone mineral density;
LUAD	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-7.92	-0.36	2.08e-14	HDL cholesterol;
LUAD	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg00204512	chr16:28754710	NA	0.33	7.12	0.33	4.58e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs3219090	0.962	rs2793378	chr1:226597341	A/G	cg27539482	chr13:111589090	NA	0.43	7.21	0.33	2.64e-12	Melanoma;
LUAD	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg05590025	chr7:65112418	INTS4L2	0.74	7.9	0.36	2.39e-14	Diabetic kidney disease;
LUAD	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg00316803	chr15:76480434	C15orf27	-0.43	-8.59	-0.39	1.66e-16	Blood metabolite levels;
LUAD	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.28	0.33	1.59e-12	Parkinson's disease;
LUAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg11062466	chr8:58055876	NA	0.86	10.51	0.45	4.28e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs243505	0.732	rs3800949	chr7:148479648	A/T	cg09806900	chr7:148480153	CUL1	-0.41	-7.17	-0.33	3.29e-12	Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.88	-0.36	2.79e-14	Breast cancer;
LUAD	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg16486109	chr11:613632	IRF7	0.52	7.83	0.36	3.99e-14	Systemic lupus erythematosus;
LUAD	cis	rs68170813	0.559	rs12538090	chr7:106974647	T/C	cg02696742	chr7:106810147	HBP1	-0.72	-9.83	-0.43	1.13e-20	Coronary artery disease;
LUAD	cis	rs6842047	0.563	rs10025990	chr4:187146258	T/C	cg02012338	chr4:187126139	CYP4V2	0.94	8.97	0.4	9.48e-18	Blood protein levels;
LUAD	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg04673462	chr1:38461896	NA	-0.39	-7.18	-0.33	3.22e-12	Coronary artery disease;
LUAD	cis	rs6445967	0.530	rs55724153	chr3:58391587	T/C	cg23715586	chr3:58305044	RPP14	0.41	6.76	0.31	4.58e-11	Platelet count;
LUAD	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg21856205	chr7:94953877	PON1	-0.53	-7.34	-0.34	1.09e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4372836	0.504	rs13382966	chr2:29068882	T/C	cg09522027	chr2:28974177	PPP1CB	-0.6	-10.64	-0.46	1.33e-23	Body mass index;
LUAD	cis	rs7809615	0.901	rs13243267	chr7:99053314	C/G	cg03133378	chr7:99195931	NA	0.57	6.91	0.32	1.78e-11	Blood metabolite ratios;
LUAD	cis	rs73206853	0.841	rs56379265	chr12:110956370	G/A	cg12870014	chr12:110450643	ANKRD13A	0.61	6.93	0.32	1.59e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-16.45	-0.62	2.29e-47	Schizophrenia;
LUAD	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.42	-6.89	-0.32	1.97e-11	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.41	0.38	6.12e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.77	8.62	0.39	1.36e-16	Yeast infection;
LUAD	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg12573674	chr2:1569213	NA	-0.58	-6.73	-0.31	5.62e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg04287289	chr16:89883240	FANCA	0.49	7.97	0.36	1.45e-14	Vitiligo;
LUAD	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg09002919	chr12:50339186	NA	0.58	7.38	0.34	8.42e-13	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7843479	0.965	rs733544	chr8:21835628	A/G	cg03445287	chr8:21823731	XPO7	-0.45	-8.18	-0.37	3.26e-15	Mean corpuscular volume;
LUAD	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7552167	0.925	rs4489498	chr1:24512055	A/G	cg01960748	chr1:24522592	NA	0.72	9.77	0.43	1.78e-20	Psoriasis vulgaris;
LUAD	cis	rs9811920	0.732	rs793446	chr3:99578114	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	7.2	0.33	2.69e-12	Axial length;
LUAD	cis	rs11209185	0.509	rs1938424	chr1:68431722	A/G	cg22082780	chr1:68452167	NA	-0.51	-10.61	-0.46	1.84e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs8177876	0.822	rs9933184	chr16:81111176	G/A	cg08591886	chr16:81111003	C16orf46	-0.77	-7.13	-0.33	4.34e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.14	-0.41	2.57e-18	Life satisfaction;
LUAD	cis	rs6489882	0.703	rs1131476	chr12:113357209	G/A	cg20102336	chr12:113376681	OAS3	-0.55	-8.43	-0.38	5.44e-16	Chronic lymphocytic leukemia;
LUAD	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg09658497	chr7:2847517	GNA12	0.52	8.93	0.4	1.29e-17	Height;
LUAD	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.8	-0.35	4.91e-14	Total body bone mineral density;
LUAD	cis	rs7945718	0.810	rs7930282	chr11:12835941	C/T	cg25843174	chr11:12811716	TEAD1	0.22	6.86	0.32	2.4e-11	Educational attainment (years of education);
LUAD	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg27490568	chr2:178487706	NA	0.53	6.88	0.32	2.11e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs56283067	0.847	rs12215181	chr6:44736076	C/T	cg20913747	chr6:44695427	NA	-0.43	-7.18	-0.33	3.1e-12	Total body bone mineral density;
LUAD	cis	rs9473147	0.516	rs9369695	chr6:47440565	C/A	cg20196966	chr6:47445060	CD2AP	0.43	6.45	0.3	3.11e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg18833306	chr6:118973337	C6orf204	-0.52	-7.5	-0.34	3.77e-13	Diastolic blood pressure;
LUAD	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg03806693	chr22:41940476	POLR3H	-0.71	-9.33	-0.41	5.92e-19	Vitiligo;
LUAD	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg17105886	chr17:28927953	LRRC37B2	0.59	6.72	0.31	6.02e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg27411982	chr8:10470053	RP1L1	0.36	6.39	0.3	4.38e-10	Retinal vascular caliber;
LUAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08677398	chr8:58056175	NA	0.46	6.45	0.3	2.99e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-6.89	-0.32	1.99e-11	Lung cancer;
LUAD	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg16989719	chr2:238392110	NA	-0.37	-6.93	-0.32	1.59e-11	Prostate cancer;
LUAD	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1572438	0.811	rs9379179	chr6:879853	A/C	cg13447295	chr6:887704	NA	0.32	6.46	0.3	2.93e-10	Aging;
LUAD	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.74	-0.31	5.28e-11	Breast cancer;
LUAD	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	10.44	0.45	7.43e-23	Colorectal cancer;
LUAD	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	11.58	0.49	3.94e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs62400317	0.762	rs17423748	chr6:44943982	T/C	cg20913747	chr6:44695427	NA	-0.42	-6.55	-0.3	1.65e-10	Total body bone mineral density;
LUAD	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg19163074	chr7:65112434	INTS4L2	0.43	6.48	0.3	2.5e-10	Aortic root size;
LUAD	cis	rs10858096	0.608	rs4970843	chr1:109887191	A/G	cg08367326	chr1:110052010	AMIGO1	0.41	7.08	0.33	5.88e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg16205897	chr5:131564050	P4HA2	-0.33	-7.44	-0.34	5.69e-13	Breast cancer;
LUAD	cis	rs853679	0.585	rs201004	chr6:27804934	T/C	cg26587870	chr6:27730563	NA	-0.51	-7.97	-0.36	1.48e-14	Depression;
LUAD	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg11062466	chr8:58055876	NA	0.68	8.89	0.4	1.83e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg16205897	chr5:131564050	P4HA2	-0.45	-10.63	-0.46	1.45e-23	Blood metabolite levels;
LUAD	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.51	0.38	3.02e-16	Menopause (age at onset);
LUAD	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg17177755	chr1:15930204	NA	0.44	7.02	0.32	8.92e-12	Systolic blood pressure;
LUAD	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg21475434	chr5:93447410	FAM172A	0.74	8.07	0.37	7.42e-15	Diabetic retinopathy;
LUAD	cis	rs4903214	0.945	rs11621172	chr14:74708185	C/T	cg11132536	chr14:74711944	VSX2	-0.43	-6.47	-0.3	2.72e-10	Inflammatory bowel disease;
LUAD	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg23649088	chr2:200775458	C2orf69	-0.57	-6.71	-0.31	6.25e-11	Schizophrenia;
LUAD	cis	rs300703	0.719	rs437853	chr2:196973	C/T	cg21211680	chr2:198530	NA	-0.61	-8.79	-0.39	3.8e-17	Blood protein levels;
LUAD	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg07936489	chr17:37558343	FBXL20	0.42	6.45	0.3	3.01e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs1595825	0.891	rs78198610	chr2:198522769	T/C	cg00982548	chr2:198649783	BOLL	-0.62	-8.83	-0.39	2.89e-17	Ulcerative colitis;
LUAD	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg12193833	chr17:30244370	NA	-0.58	-6.87	-0.32	2.24e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg13770153	chr20:60521292	NA	-0.55	-9.15	-0.41	2.4e-18	Body mass index;
LUAD	cis	rs12545109	0.800	rs2610058	chr8:57409120	G/A	cg07776626	chr8:57350775	NA	-0.61	-8.51	-0.38	3.13e-16	Obesity-related traits;
LUAD	cis	rs6854137	1.000	rs6854137	chr4:169728236	T/G	cg20607169	chr4:169750834	PALLD	0.45	8.73	0.39	5.87e-17	Vein graft stenosis in coronary artery bypass grafting;
LUAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg07234876	chr8:600039	NA	1.03	10.15	0.44	8.36e-22	IgG glycosylation;
LUAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg27454412	chr7:1067447	C7orf50	-0.44	-8.12	-0.37	5.21e-15	Bronchopulmonary dysplasia;
LUAD	cis	rs1062753	0.771	rs932376	chr22:42614362	T/C	cg15128208	chr22:42549153	NA	0.36	6.36	0.3	5.32e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs72928364	1.000	rs13072000	chr3:100625822	A/G	cg10123952	chr3:100791384	NA	0.62	7.34	0.34	1.1e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35883536	0.967	rs1055044	chr1:101171354	A/G	cg06223162	chr1:101003688	GPR88	0.37	6.86	0.32	2.52e-11	Monocyte count;
LUAD	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg08470875	chr2:26401718	FAM59B	0.79	11.18	0.48	1.35e-25	Gut microbiome composition (summer);
LUAD	cis	rs2637266	0.967	rs10400134	chr10:78365158	G/C	cg18941641	chr10:78392320	NA	0.34	7.23	0.33	2.25e-12	Pulmonary function;
LUAD	cis	rs175714	0.845	rs175706	chr14:75976200	G/A	cg01624173	chr14:75981868	NA	0.67	13.84	0.56	3.31e-36	Lymphocyte counts;
LUAD	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.61	-9.92	-0.43	5.55e-21	Cognitive ability;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26943399	chr4:76649977	USO1	-0.59	-7.09	-0.33	5.56e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg17366294	chr4:99064904	C4orf37	0.53	9.7	0.43	3.29e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg04476341	chr5:669733	TPPP	-0.36	-7.1	-0.33	5.34e-12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg23283495	chr1:209979779	IRF6	0.71	9.36	0.41	4.63e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg00898013	chr13:113819073	PROZ	-0.69	-12.17	-0.51	2.05e-29	Platelet distribution width;
LUAD	cis	rs1215050	0.846	rs1839903	chr4:98791414	C/T	cg17366294	chr4:99064904	C4orf37	0.44	7.46	0.34	4.93e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg17063962	chr7:91808500	NA	0.61	9.98	0.44	3.25e-21	Breast cancer;
LUAD	cis	rs7904368	0.754	rs11254231	chr10:16870246	A/G	cg23933602	chr10:16859644	RSU1	0.53	7.08	0.33	6.09e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.48	-9.65	-0.42	4.89e-20	Longevity;Endometriosis;
LUAD	cis	rs2742417	0.624	rs2673030	chr3:45757900	T/G	cg10512202	chr3:45649293	LIMD1	0.49	9.18	0.41	1.97e-18	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg20291162	chr17:40259547	DHX58	-0.7	-10.99	-0.47	7.02e-25	Fibrinogen levels;
LUAD	trans	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg07393940	chr7:158741817	NA	0.69	11.46	0.49	1.12e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.81	-0.47	3.24e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.06	-0.32	6.83e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg06808227	chr14:105710500	BRF1	-0.42	-6.51	-0.3	2.09e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg16414030	chr3:133502952	NA	-0.65	-12.44	-0.52	1.72e-30	Iron status biomarkers;
LUAD	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg04036182	chr15:45458818	NA	-0.4	-6.95	-0.32	1.4e-11	Glomerular filtration rate;
LUAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg18621852	chr3:10150065	C3orf24	0.47	8.6	0.39	1.56e-16	Alzheimer's disease;
LUAD	trans	rs800082	1.000	rs1007564	chr3:144311843	C/T	cg24215973	chr2:240111563	HDAC4	-0.43	-6.78	-0.31	4.15e-11	Smoking behavior;
LUAD	cis	rs9443645	0.507	rs1475046	chr6:79461801	G/A	cg09184832	chr6:79620586	NA	-0.41	-7.29	-0.33	1.54e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs57994353	0.897	rs35526483	chr9:139364940	G/A	cg14364472	chr9:139394549	NOTCH1	-0.44	-6.74	-0.31	5.15e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg05340658	chr4:99064831	C4orf37	0.53	8.59	0.39	1.67e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg03563238	chr19:33554763	RHPN2	-0.39	-9.06	-0.4	4.91e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg19717773	chr7:2847554	GNA12	-0.51	-9.71	-0.43	2.95e-20	Height;
LUAD	cis	rs9581857	0.615	rs79793528	chr13:28007823	G/A	cg22138327	chr13:27999177	GTF3A	0.91	10.59	0.46	2.08e-23	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg03806693	chr22:41940476	POLR3H	-0.83	-11.76	-0.5	8.38e-28	Vitiligo;
LUAD	cis	rs3087591	1.000	rs9902893	chr17:29625638	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.43	-7.09	-0.33	5.54e-12	Hip circumference;
LUAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg16031515	chr1:205743344	RAB7L1	-0.35	-7.09	-0.33	5.7e-12	Menarche (age at onset);
LUAD	cis	rs3820068	0.734	rs6669156	chr1:15905206	T/A	cg13390004	chr1:15929781	NA	0.42	6.75	0.31	4.75e-11	Systolic blood pressure;
LUAD	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg02018176	chr4:1364513	KIAA1530	0.36	6.37	0.3	5.04e-10	Obesity-related traits;
LUAD	cis	rs6969780	0.915	rs886339	chr7:27190670	A/C	cg05579037	chr7:27184853	NA	0.52	6.97	0.32	1.24e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUAD	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg05872129	chr22:39784769	NA	0.82	15.88	0.61	7e-45	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg25804541	chr17:80189381	SLC16A3	0.3	6.47	0.3	2.65e-10	Life satisfaction;
LUAD	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg00310523	chr12:86230176	RASSF9	0.4	7.98	0.36	1.4e-14	Major depressive disorder;
LUAD	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11890956	chr21:40555474	PSMG1	-0.55	-9.56	-0.42	1.01e-19	Menarche (age at onset);
LUAD	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg27170947	chr2:26402098	FAM59B	-0.61	-8.63	-0.39	1.25e-16	Gut microbiome composition (summer);
LUAD	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg27211696	chr2:191398769	TMEM194B	-0.69	-8.68	-0.39	8.39e-17	Diastolic blood pressure;
LUAD	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg12119029	chr16:89752879	CDK10	0.34	7.03	0.32	8.52e-12	Vitiligo;
LUAD	cis	rs870825	0.929	rs72689272	chr4:185592515	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	10.13	0.44	9.87e-22	Blood protein levels;
LUAD	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg05991184	chr2:219186017	PNKD	-0.36	-7.09	-0.33	5.57e-12	Colorectal cancer;
LUAD	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg02176678	chr2:219576539	TTLL4	0.59	11.29	0.48	5.31e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21545522	chr1:205238299	TMCC2	0.4	7.33	0.34	1.18e-12	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg18209359	chr17:80159595	CCDC57	0.4	6.96	0.32	1.32e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg22105103	chr4:187893119	NA	-0.52	-11.22	-0.48	9.39e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg27432699	chr2:27873401	GPN1	-0.4	-6.76	-0.31	4.71e-11	Total body bone mineral density;
LUAD	cis	rs12681287	0.517	rs7462883	chr8:87526790	G/A	cg27223183	chr8:87520930	FAM82B	-0.73	-10.41	-0.45	9.61e-23	Caudate activity during reward;
LUAD	cis	rs62400317	0.859	rs62438863	chr6:45040592	C/T	cg20913747	chr6:44695427	NA	-0.43	-6.82	-0.31	3.25e-11	Total body bone mineral density;
LUAD	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg26677194	chr12:130822605	PIWIL1	0.55	9.04	0.4	5.6e-18	Menopause (age at onset);
LUAD	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.42	0.34	6.47e-13	Bladder cancer;
LUAD	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg05234568	chr11:5960015	NA	-0.52	-9.4	-0.42	3.37e-19	DNA methylation (variation);
LUAD	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.43	7.89	0.36	2.7e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg08645402	chr16:4508243	NA	0.53	9.83	0.43	1.16e-20	Schizophrenia;
LUAD	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg18944383	chr4:111397179	ENPEP	0.42	8.25	0.37	1.97e-15	Height;
LUAD	cis	rs9948	0.786	rs72809850	chr2:97449762	A/C	cg20312557	chr2:97357134	FER1L5	-0.63	-7.36	-0.34	9.71e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs2235642	0.533	rs17135391	chr16:1605606	C/T	cg26528668	chr16:1614120	IFT140	0.43	6.65	0.31	8.81e-11	Coronary artery disease;
LUAD	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg01689657	chr7:91764605	CYP51A1	0.29	7.15	0.33	3.73e-12	Breast cancer;
LUAD	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg21856205	chr7:94953877	PON1	-0.57	-7.77	-0.35	5.82e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg23601416	chr22:19950040	COMT	0.37	7.42	0.34	6.33e-13	Blood metabolite levels;
LUAD	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg22467129	chr15:76604101	ETFA	-0.39	-6.36	-0.3	5.38e-10	Blood metabolite levels;
LUAD	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	7.41	0.34	7.08e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs8017423	0.874	rs2149656	chr14:90707508	A/C	cg14092571	chr14:90743983	NA	-0.45	-7.83	-0.36	3.85e-14	Mortality in heart failure;
LUAD	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg08470875	chr2:26401718	FAM59B	-0.67	-8.95	-0.4	1.1e-17	Gut microbiome composition (summer);
LUAD	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg02002194	chr4:3960332	NA	-0.29	-6.97	-0.32	1.23e-11	Mood instability;
LUAD	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	8.17	0.37	3.63e-15	Longevity;Endometriosis;
LUAD	cis	rs909002	0.800	rs2176807	chr1:32092735	T/G	cg13919466	chr1:32135498	COL16A1	-0.34	-7.82	-0.36	4.34e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2455601	0.882	rs11042105	chr11:8894510	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-7.31	-0.34	1.31e-12	Schizophrenia;
LUAD	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/A	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.57	7.73	0.35	7.72e-14	Type 2 diabetes;
LUAD	cis	rs684232	0.623	rs417171	chr17:576941	A/G	cg12384639	chr17:618140	VPS53	0.49	8.41	0.38	6.24e-16	Prostate cancer;
LUAD	trans	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.87	-0.32	2.28e-11	Mood instability;
LUAD	cis	rs68170813	0.652	rs79295036	chr7:107193669	C/A	cg02696742	chr7:106810147	HBP1	-0.74	-8.73	-0.39	5.93e-17	Coronary artery disease;
LUAD	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg08601574	chr20:25228251	PYGB	0.47	8.88	0.4	1.93e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.21	-0.37	2.68e-15	Total body bone mineral density;
LUAD	trans	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg13565492	chr6:43139072	SRF	-0.6	-6.35	-0.3	5.49e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg21016266	chr12:122356598	WDR66	0.73	13.09	0.54	4.09e-33	Mean corpuscular volume;
LUAD	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg06641503	chr3:48959341	ARIH2	-0.4	-7.75	-0.35	6.96e-14	Parkinson's disease;
LUAD	cis	rs3784262	0.900	rs12911071	chr15:58314848	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.47	-9.41	-0.42	3.11e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1448094	0.967	rs2121892	chr12:86324556	G/T	cg00310523	chr12:86230176	RASSF9	0.35	7.56	0.34	2.58e-13	Major depressive disorder;
LUAD	cis	rs7523875	0.516	rs6682599	chr1:211522427	G/A	cg26515805	chr1:211431828	RCOR3	0.39	7.17	0.33	3.27e-12	Mean corpuscular volume;
LUAD	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.07	-14.66	-0.58	1.25e-39	Schizophrenia;
LUAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg08132940	chr7:1081526	C7orf50	-0.78	-10.39	-0.45	1.13e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9902453	0.874	rs3936006	chr17:28257660	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	10.54	0.46	3.09e-23	Coffee consumption (cups per day);
LUAD	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg04013093	chr6:42928303	GNMT	-0.28	-6.43	-0.3	3.44e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.67	0.31	8.08e-11	Prudent dietary pattern;
LUAD	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.31	6.41	0.3	3.99e-10	Obesity-related traits;
LUAD	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg05865280	chr17:75406074	SEPT9	0.61	19.3	0.68	5.44e-60	Airflow obstruction;
LUAD	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg07195577	chr17:27052828	TLCD1	0.46	6.44	0.3	3.17e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg09365446	chr1:150670422	GOLPH3L	0.61	10.86	0.47	2.17e-24	Melanoma;
LUAD	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg02734326	chr4:10020555	SLC2A9	0.64	11.35	0.48	3.05e-26	Bone mineral density;
LUAD	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg27539214	chr16:67997921	SLC12A4	-0.71	-8.8	-0.39	3.53e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg04287289	chr16:89883240	FANCA	-0.42	-6.41	-0.3	3.8e-10	Vitiligo;
LUAD	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs240764	0.817	rs11155596	chr6:101152631	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-8.21	-0.37	2.79e-15	Neuroticism;
LUAD	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg17366294	chr4:99064904	C4orf37	0.67	12.77	0.53	8.4e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.08e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg06740227	chr12:86229804	RASSF9	0.37	6.78	0.31	4.06e-11	Major depressive disorder;
LUAD	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	7.49	0.34	3.94e-13	Bipolar disorder;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg04041942	chr8:28747613	INTS9;HMBOX1	0.42	6.77	0.31	4.44e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2019216	0.500	rs6565385	chr17:21897646	C/A	cg22648282	chr17:21454238	C17orf51	-0.47	-8.33	-0.38	1.13e-15	Pelvic organ prolapse;
LUAD	cis	rs55665837	0.540	rs1007392	chr11:14774591	A/G	cg19336497	chr11:14380999	RRAS2	-0.4	-7.54	-0.34	2.95e-13	Vitamin D levels;
LUAD	cis	rs79839061	0.732	rs56852661	chr4:826257	G/A	cg07828340	chr4:882639	GAK	1.02	9.45	0.42	2.37e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7173743	0.730	rs6495340	chr15:79128396	A/G	cg00540400	chr15:79124168	NA	0.42	8.56	0.38	2.04e-16	Coronary artery disease;
LUAD	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg24531977	chr5:56204891	C5orf35	-0.58	-9.22	-0.41	1.43e-18	Coronary artery disease;
LUAD	cis	rs9788721	0.836	rs17483686	chr15:78733390	A/T	cg18825076	chr15:78729989	IREB2	-0.57	-10.01	-0.44	2.55e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs7614311	0.555	rs3774715	chr3:63919876	T/C	cg22134162	chr3:63841271	THOC7	-0.49	-8.15	-0.37	4.08e-15	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs2067615	0.579	rs10778510	chr12:107162965	A/G	cg15890332	chr12:107067104	RFX4	-0.39	-8.17	-0.37	3.62e-15	Heart rate;
LUAD	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11890956	chr21:40555474	PSMG1	-0.64	-11.13	-0.48	2.1e-25	Cognitive function;
LUAD	cis	rs6688613	0.685	rs2235184	chr1:166870528	A/G	cg07049167	chr1:166818506	POGK	-0.56	-8.45	-0.38	4.8e-16	Refractive astigmatism;
LUAD	cis	rs17253792	0.822	rs10133962	chr14:56066088	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs7833986	0.818	rs79824205	chr8:57093233	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	10.04	0.44	2.03e-21	Height;
LUAD	cis	rs11153730	0.503	rs283040	chr6:118631934	A/G	cg05564266	chr6:118973597	C6orf204	0.31	6.44	0.3	3.24e-10	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	trans	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04565464	chr8:145669602	NFKBIL2	0.45	6.84	0.32	2.77e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.36	-7.12	-0.33	4.82e-12	IgG glycosylation;
LUAD	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg21475434	chr5:93447410	FAM172A	0.75	8.57	0.38	1.93e-16	Diabetic retinopathy;
LUAD	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg08885076	chr2:99613938	TSGA10	0.36	6.54	0.3	1.77e-10	Chronic sinus infection;
LUAD	cis	rs4523957	0.928	rs749240	chr17:2186100	A/G	cg16513277	chr17:2031491	SMG6	0.74	12.99	0.53	1.06e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7843479	0.898	rs4311656	chr8:21802276	T/G	cg03445287	chr8:21823731	XPO7	-0.47	-8.5	-0.38	3.2e-16	Mean corpuscular volume;
LUAD	trans	rs2735413	0.781	rs11649473	chr16:78077238	C/T	cg01028844	chr5:122736986	CEP120	0.4	6.46	0.3	2.84e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18876405	chr7:65276391	NA	-0.44	-6.94	-0.32	1.46e-11	Aortic root size;
LUAD	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg09184832	chr6:79620586	NA	-0.48	-8.85	-0.4	2.45e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.56	-7.76	-0.35	6.42e-14	Body mass index;
LUAD	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg21427119	chr20:30132790	HM13	-0.62	-9.46	-0.42	2.24e-19	Mean corpuscular hemoglobin;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25756398	chr11:93474621	C11orf54;TAF1D	-0.55	-6.64	-0.31	9.85e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs28830936	1.000	rs112896623	chr15:42001845	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.7	-0.31	6.63e-11	Diastolic blood pressure;
LUAD	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg04287289	chr16:89883240	FANCA	0.55	8.64	0.39	1.19e-16	Vitiligo;
LUAD	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg27489772	chr12:121021490	NA	-0.56	-6.96	-0.32	1.27e-11	Type 1 diabetes nephropathy;
LUAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg16606324	chr3:10149918	C3orf24	0.59	9.58	0.42	8.28e-20	Alzheimer's disease;
LUAD	cis	rs6908034	0.607	rs73378506	chr6:19819987	T/C	cg02682789	chr6:19804855	NA	0.76	8.46	0.38	4.54e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs2455826	0.521	rs2345734	chr3:15808890	A/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.49	-0.3	2.48e-10	Inflammatory skin disease;
LUAD	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg23758822	chr17:41437982	NA	1.02	20.94	0.71	2.39e-67	Menopause (age at onset);
LUAD	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg03714773	chr7:91764589	CYP51A1	0.27	6.36	0.3	5.23e-10	Breast cancer;
LUAD	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.36	6.49	0.3	2.43e-10	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg16850897	chr7:100343110	ZAN	-0.58	-8.18	-0.37	3.24e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg05044414	chr3:183734942	ABCC5	0.49	10.11	0.44	1.14e-21	Anterior chamber depth;
LUAD	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	6.49	0.3	2.38e-10	Mood instability;
LUAD	cis	rs6500395	1.000	rs2883475	chr16:48560315	C/T	cg04672837	chr16:48644449	N4BP1	0.38	6.69	0.31	7.25e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6489882	0.966	rs2285932	chr12:113386950	A/G	cg20102336	chr12:113376681	OAS3	-0.47	-7.15	-0.33	3.93e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg05768032	chr16:30646687	NA	0.45	8.07	0.37	7.33e-15	Multiple myeloma;
LUAD	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg08085267	chr17:45401833	C17orf57	0.52	8.69	0.39	8.13e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.93	0.36	1.95e-14	Bladder cancer;
LUAD	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg08132940	chr7:1081526	C7orf50	-0.61	-6.68	-0.31	7.57e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg13047869	chr3:10149882	C3orf24	0.65	10.77	0.46	4.66e-24	Alzheimer's disease;
LUAD	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg08514558	chr10:81106712	PPIF	0.49	9.57	0.42	8.78e-20	Height;
LUAD	cis	rs2046867	0.818	rs11929144	chr3:72868234	T/C	cg25664220	chr3:72788482	NA	-0.6	-10.86	-0.47	2.15e-24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.84e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg04414720	chr1:150670196	GOLPH3L	0.71	12.26	0.51	8.51e-30	Melanoma;
LUAD	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21659725	chr3:3221576	CRBN	0.71	11.82	0.5	4.65e-28	Resting heart rate;
LUAD	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg01851573	chr8:8652454	MFHAS1	-0.37	-6.4	-0.3	4.06e-10	Neuroticism;
LUAD	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg27284194	chr4:1044797	NA	0.71	10.26	0.45	3.2800000000000002e-22	Recombination rate (females);
LUAD	cis	rs12210905	0.688	rs72843177	chr6:27367414	A/G	cg08851530	chr6:28072375	NA	1.09	7.94	0.36	1.88e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs7945718	0.875	rs7924501	chr11:12813870	A/G	cg25843174	chr11:12811716	TEAD1	0.25	7.53	0.34	3.15e-13	Educational attainment (years of education);
LUAD	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg08645402	chr16:4508243	NA	0.57	10.54	0.46	3.13e-23	Schizophrenia;
LUAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg02136620	chr5:178986620	RUFY1	0.54	8.79	0.39	3.78e-17	Lung cancer;
LUAD	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.43	-0.52	1.95e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs62229266	0.557	rs4817761	chr21:37395556	C/T	cg12218747	chr21:37451666	NA	-0.44	-7.17	-0.33	3.41e-12	Mitral valve prolapse;
LUAD	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg08508325	chr11:3079039	CARS	-0.59	-13.0	-0.53	9.44e-33	Longevity;
LUAD	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg21385522	chr1:16154831	NA	0.44	6.65	0.31	9.07e-11	Dilated cardiomyopathy;
LUAD	cis	rs11650494	0.908	rs9891264	chr17:47407342	T/A	cg08112188	chr17:47440006	ZNF652	0.77	6.89	0.32	2.04e-11	Prostate cancer;
LUAD	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg11494091	chr17:61959527	GH2	0.39	6.85	0.32	2.57e-11	Height;
LUAD	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19346786	chr7:2764209	NA	-0.55	-12.11	-0.51	3.43e-29	Height;
LUAD	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg17177755	chr1:15930204	NA	0.46	7.43	0.34	5.89e-13	Systolic blood pressure;
LUAD	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg27446573	chr6:127587934	RNF146	0.44	6.62	0.31	1.06e-10	Breast cancer;
LUAD	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg18404041	chr3:52824283	ITIH1	-0.4	-7.36	-0.34	9.87e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg24644049	chr4:85504048	CDS1	0.92	7.93	0.36	2e-14	Skin colour saturation;
LUAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg18621852	chr3:10150065	C3orf24	-0.45	-7.0	-0.32	1.01e-11	Alzheimer's disease;
LUAD	cis	rs1595825	1.000	rs1595825	chr2:198875464	G/A	cg10547527	chr2:198650123	BOLL	-0.47	-6.59	-0.31	1.34e-10	Ulcerative colitis;
LUAD	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg04414720	chr1:150670196	GOLPH3L	0.64	10.98	0.47	7.86e-25	Melanoma;
LUAD	cis	rs12545109	0.800	rs2609979	chr8:57390066	G/A	cg19413350	chr8:57351067	NA	-0.45	-6.94	-0.32	1.5e-11	Obesity-related traits;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg11787367	chr19:38865418	PSMD8	-0.37	-6.51	-0.3	2.09e-10	Schizophrenia;
LUAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.0	-0.32	9.85e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs57994353	0.897	rs12551527	chr9:139358425	C/G	cg14019695	chr9:139328340	INPP5E	0.41	6.61	0.31	1.15e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs11771526	0.786	rs11768318	chr7:32372965	T/G	cg27511599	chr7:32358540	NA	0.62	7.14	0.33	3.98e-12	Body mass index;
LUAD	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg22868518	chr11:507468	RNH1	-0.64	-6.47	-0.3	2.78e-10	Body mass index;
LUAD	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg15704280	chr7:45808275	SEPT13	0.72	11.04	0.47	4.53e-25	Coronary artery disease;
LUAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg08888203	chr3:10149979	C3orf24	0.74	12.97	0.53	1.25e-32	Alzheimer's disease;
LUAD	cis	rs59698941	0.943	rs67460003	chr5:132289501	C/G	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs6840360	0.571	rs7695866	chr4:152488110	G/A	cg22705602	chr4:152727874	NA	-0.38	-6.67	-0.31	7.88e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg11965913	chr1:205819406	PM20D1	0.83	17.34	0.64	2.85e-51	Menarche (age at onset);
LUAD	cis	rs738321	0.762	rs5995543	chr22:38579026	G/A	cg03162506	chr22:38580953	NA	0.34	6.46	0.3	2.85e-10	Breast cancer;
LUAD	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg01788221	chr16:89496183	ANKRD11	0.35	6.76	0.31	4.57e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg01884057	chr2:25150051	NA	0.34	7.22	0.33	2.47e-12	Body mass index;
LUAD	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg04414720	chr1:150670196	GOLPH3L	0.72	12.56	0.52	5.61e-31	Melanoma;
LUAD	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg11494091	chr17:61959527	GH2	-0.41	-7.54	-0.34	2.8e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg16006296	chr10:38738647	LOC399744	0.35	6.35	0.3	5.69e-10	Diastolic blood pressure;
LUAD	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-7.5	-0.34	3.85e-13	Lung cancer;
LUAD	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg09117114	chr16:67998030	SLC12A4	-0.51	-7.08	-0.33	6.17e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg03806693	chr22:41940476	POLR3H	-0.79	-11.24	-0.48	8.25e-26	Vitiligo;
LUAD	cis	rs3772130	0.962	rs13061326	chr3:121493125	T/C	cg20356878	chr3:121714668	ILDR1	0.51	8.05	0.36	8.41e-15	Cognitive performance;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02971882	chr4:71554083	UTP3	-0.41	-6.82	-0.31	3.13e-11	Cancer;
LUAD	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03352830	chr11:487213	PTDSS2	0.82	10.79	0.46	3.87e-24	Body mass index;
LUAD	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.82	-0.31	3.23e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.63	11.05	0.47	4.08e-25	Birth weight;
LUAD	cis	rs1873147	0.569	rs12593531	chr15:63309936	C/G	cg21584241	chr15:63341463	TPM1	0.42	6.36	0.3	5.09e-10	Orofacial clefts;
LUAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg07685180	chr8:600429	NA	0.87	8.29	0.37	1.5e-15	IgG glycosylation;
LUAD	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24531977	chr5:56204891	C5orf35	-1.01	-15.27	-0.6	2.96e-42	Initial pursuit acceleration;
LUAD	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg10518543	chr12:38710700	ALG10B	-0.48	-7.86	-0.36	3.13e-14	Morning vs. evening chronotype;
LUAD	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.89	-0.32	2.04e-11	Retinal vascular caliber;
LUAD	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg18305652	chr10:134549665	INPP5A	0.58	12.34	0.51	4.23e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.93	-0.32	1.62e-11	Neuroticism;
LUAD	cis	rs2224391	0.628	rs2753222	chr6:5242075	T/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-7.86	-0.36	3.11e-14	Height;
LUAD	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg07741184	chr6:167504864	NA	0.39	8.75	0.39	5.03e-17	Crohn's disease;
LUAD	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg00981070	chr1:2046702	PRKCZ	0.37	6.87	0.32	2.25e-11	Height;
LUAD	cis	rs2455799	0.613	rs7620787	chr3:15882826	G/A	cg16303742	chr3:15540471	COLQ	-0.52	-9.63	-0.42	5.61e-20	Mean platelet volume;
LUAD	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg03714773	chr7:91764589	CYP51A1	0.29	6.9	0.32	1.89e-11	Breast cancer;
LUAD	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg08601574	chr20:25228251	PYGB	0.47	8.88	0.4	1.86e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06544989	chr22:39130855	UNC84B	0.42	7.75	0.35	6.82e-14	Menopause (age at onset);
LUAD	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg12140854	chr5:148520817	ABLIM3	-0.67	-10.69	-0.46	9.08e-24	Breast cancer;
LUAD	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.42	-0.34	6.33e-13	Bipolar disorder;
LUAD	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg17724175	chr1:150552817	MCL1	0.34	7.87	0.36	3.01e-14	Melanoma;
LUAD	cis	rs36051895	0.622	rs12686652	chr9:5071942	C/G	cg02405213	chr9:5042618	JAK2	-0.47	-6.39	-0.3	4.42e-10	Pediatric autoimmune diseases;
LUAD	cis	rs6685188	0.843	rs1775139	chr1:205672357	C/G	cg17178900	chr1:205818956	PM20D1	0.39	6.52	0.3	1.97e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg09835421	chr16:68378352	PRMT7	0.83	8.83	0.39	2.91e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg03037974	chr15:76606532	NA	0.4	8.69	0.39	7.88e-17	Blood metabolite levels;
LUAD	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg15133208	chr4:90757351	SNCA	-0.46	-7.05	-0.32	7.14e-12	Neuroticism;
LUAD	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg04025307	chr7:1156635	C7orf50	0.66	9.44	0.42	2.48e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.59	-7.58	-0.35	2.23e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg13126279	chr21:47581558	C21orf56	0.5	8.31	0.37	1.31e-15	Testicular germ cell tumor;
LUAD	cis	rs2637266	0.935	rs7921790	chr10:78368253	T/C	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	cis	rs6988985	0.560	rs4736343	chr8:143933200	G/A	cg10324643	chr8:143916377	GML	0.32	6.63	0.31	1.03e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs758324	0.812	rs519240	chr5:131269453	G/A	cg06307176	chr5:131281290	NA	-0.45	-7.53	-0.34	3.18e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs9951602	0.512	rs7240758	chr18:76650677	T/C	cg02800362	chr5:177631904	HNRNPAB	0.92	14.03	0.56	5.64e-37	Obesity-related traits;
LUAD	trans	rs208520	0.690	rs207102	chr6:66795671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.32	-0.64	3.48e-51	Exhaled nitric oxide output;
LUAD	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg23229984	chr5:148520753	ABLIM3	0.49	7.09	0.33	5.65e-12	Breast cancer;
LUAD	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg08645402	chr16:4508243	NA	0.57	10.63	0.46	1.46e-23	Schizophrenia;
LUAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg22535103	chr8:58192502	C8orf71	0.74	9.08	0.4	4.21e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs829880	0.570	rs4488248	chr12:98853688	G/C	cg25150519	chr12:98850993	NA	0.73	13.2	0.54	1.5e-33	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg19318889	chr4:1322082	MAEA	0.85	13.8	0.56	4.92e-36	Longevity;
LUAD	trans	rs853679	1.000	rs853678	chr6:28297313	T/A	cg06606381	chr12:133084897	FBRSL1	-0.58	-7.17	-0.33	3.29e-12	Depression;
LUAD	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.34	-0.34	1.1e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.26	-0.33	1.91e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg04450456	chr4:17643702	FAM184B	0.39	7.78	0.35	5.72e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg11070056	chr1:107600091	PRMT6	-0.55	-9.5	-0.42	1.6e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg16724585	chr3:197361211	NA	-0.52	-7.77	-0.35	6.08e-14	Pancreatic cancer;
LUAD	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.81	-0.36	4.42e-14	Triglycerides;
LUAD	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg12310025	chr6:25882481	NA	-0.48	-7.2	-0.33	2.76e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19921130	chr15:81294134	MESDC1	-0.39	-6.38	-0.3	4.75e-10	Cancer;
LUAD	cis	rs1723838	1.000	rs1792164	chr11:73548670	G/A	cg10064339	chr11:73693792	UCP2	0.74	6.42	0.3	3.65e-10	Obesity-related traits;
LUAD	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg25358565	chr5:93447407	FAM172A	0.61	7.3	0.33	1.43e-12	Diabetic retinopathy;
LUAD	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.09	-0.44	1.38e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2485376	0.967	rs772010	chr10:104064885	C/G	cg20641465	chr10:103991465	PITX3	-0.58	-10.7	-0.46	8.17e-24	QT interval;
LUAD	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg07606381	chr6:8435919	SLC35B3	0.41	6.68	0.31	7.42e-11	Motion sickness;
LUAD	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg06784218	chr1:46089804	CCDC17	-0.57	-12.74	-0.53	1.04e-31	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs8060686	0.858	rs2008173	chr16:67856240	A/G	cg26727032	chr16:67993705	SLC12A4	-0.49	-8.03	-0.36	9.91e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs300774	0.925	rs432750	chr2:147456	A/G	cg21211680	chr2:198530	NA	-0.48	-7.45	-0.34	5.22e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg18621852	chr3:10150065	C3orf24	0.46	8.07	0.37	7.32e-15	Alzheimer's disease;
LUAD	cis	rs6690583	0.623	rs12030730	chr1:85454109	C/G	cg22153463	chr1:85462885	MCOLN2	0.55	6.4	0.3	4.17e-10	Serum sulfate level;
LUAD	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg11822812	chr5:140052017	DND1	-0.41	-7.3	-0.33	1.42e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4988958	0.565	rs3771154	chr2:103039360	C/T	cg03938978	chr2:103052716	IL18RAP	0.45	10.37	0.45	1.29e-22	Asthma (childhood onset);
LUAD	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg02012338	chr4:187126139	CYP4V2	0.89	9.09	0.4	3.96e-18	Blood protein levels;
LUAD	cis	rs899997	0.773	rs8032156	chr15:78964498	A/G	cg04896959	chr15:78267971	NA	0.52	8.26	0.37	1.87e-15	Coronary artery disease or large artery stroke;
LUAD	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg21153622	chr11:89784906	NA	-0.34	-6.71	-0.31	6.11e-11	HDL cholesterol;
LUAD	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	14.14	0.57	1.93e-37	Smoking behavior;
LUAD	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg08422745	chr4:174089978	GALNT7	-0.95	-17.87	-0.66	1.27e-53	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06873352	chr17:61820015	STRADA	0.56	9.09	0.4	3.88e-18	Height;
LUAD	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.6	7.95	0.36	1.7e-14	Alzheimer's disease;
LUAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg02421172	chr7:1938701	MAD1L1	0.48	6.81	0.31	3.27e-11	Bipolar disorder;
LUAD	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg23262073	chr20:60523788	NA	0.64	10.22	0.44	4.67e-22	Obesity-related traits;
LUAD	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.11	-0.4	3.42e-18	Total body bone mineral density;
LUAD	cis	rs2019216	0.967	rs1877500	chr17:21886233	T/C	cg05591447	chr17:21909280	FLJ36000	-0.29	-7.63	-0.35	1.56e-13	Pelvic organ prolapse;
LUAD	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.01	-0.36	1.13e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg11941060	chr3:133502564	NA	-0.49	-8.02	-0.36	1.08e-14	Iron status biomarkers;
LUAD	trans	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg27411982	chr8:10470053	RP1L1	-0.39	-7.08	-0.33	5.97e-12	Mood instability;
LUAD	trans	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg14791747	chr16:20752902	THUMPD1	-0.44	-6.4	-0.3	4.14e-10	Cognitive test performance;
LUAD	trans	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg24818145	chr4:99064322	C4orf37	0.4	6.52	0.3	2.01e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg12419862	chr22:24373484	LOC391322	-0.5	-6.86	-0.32	2.38e-11	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	5.84e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.14	14.96	0.59	6.41e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.49	-0.42	1.66e-19	Life satisfaction;
LUAD	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg19622623	chr12:86230825	RASSF9	-0.56	-9.96	-0.44	3.86e-21	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg06131755	chr6:160182447	ACAT2	0.42	6.35	0.3	5.49e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg27454412	chr7:1067447	C7orf50	-0.42	-7.78	-0.35	5.71e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg27284194	chr4:1044797	NA	0.58	9.54	0.42	1.16e-19	Recombination rate (males);
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg14012233	chr17:27276799	PHF12	-0.41	-6.53	-0.3	1.84e-10	Vertical cup-disc ratio;
LUAD	cis	rs10916814	1.000	rs10916814	chr1:20892931	A/G	cg24502330	chr1:20914028	CDA	0.35	6.8	0.31	3.57e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg16006841	chr5:176797999	RGS14	-0.59	-9.63	-0.42	5.43e-20	Urate levels in lean individuals;
LUAD	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg23260525	chr10:116636907	FAM160B1	0.46	10.54	0.46	3.11e-23	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7520050	0.778	rs3014218	chr1:46026328	A/C	cg06784218	chr1:46089804	CCDC17	-0.35	-7.45	-0.34	5.38e-13	Red blood cell count;Reticulocyte count;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24423897	chr19:4723980	DPP9	-0.4	-6.52	-0.3	2e-10	Cancer;
LUAD	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg19318889	chr4:1322082	MAEA	0.55	9.28	0.41	8.92e-19	Longevity;
LUAD	cis	rs3820068	0.871	rs76155024	chr1:15807142	T/C	cg13390004	chr1:15929781	NA	0.44	6.64	0.31	9.45e-11	Systolic blood pressure;
LUAD	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg17366294	chr4:99064904	C4orf37	0.59	10.05	0.44	1.94e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2046867	0.862	rs2322611	chr3:72830087	T/G	cg04365224	chr3:72788183	NA	-0.47	-6.85	-0.32	2.54e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.12e-14	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg03676636	chr4:99064102	C4orf37	-0.32	-8.46	-0.38	4.44e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg06784218	chr1:46089804	CCDC17	-0.6	-13.33	-0.54	4.38e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1113500	0.836	rs1122158	chr1:108588668	G/T	cg06207961	chr1:108661230	NA	0.41	7.4	0.34	7.5e-13	Growth-regulated protein alpha levels;
LUAD	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg17264618	chr3:40429014	ENTPD3	0.37	8.32	0.37	1.26e-15	Renal cell carcinoma;
LUAD	cis	rs11971779	0.648	rs6467852	chr7:139112591	A/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.38	-0.3	4.74e-10	Diisocyanate-induced asthma;
LUAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg04450456	chr4:17643702	FAM184B	0.4	7.87	0.36	3.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs933688	0.509	rs2941895	chr5:90520510	A/G	cg00335715	chr5:90575459	NA	-0.43	-7.03	-0.32	8.42e-12	Smoking behavior;
LUAD	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.91	-0.36	2.24e-14	Alzheimer's disease;
LUAD	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg19761014	chr17:28927070	LRRC37B2	0.73	7.99	0.36	1.3e-14	Body mass index;
LUAD	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg24675056	chr1:15929824	NA	0.49	8.52	0.38	2.91e-16	Systolic blood pressure;
LUAD	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21582582	chr3:182698605	DCUN1D1	0.5	8.0	0.36	1.18e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg11189052	chr15:85197271	WDR73	0.58	7.31	0.34	1.31e-12	Schizophrenia;
LUAD	cis	rs11126435	0.858	rs3025994	chr2:74908299	C/T	cg19285774	chr2:74907978	SEMA4F	0.44	8.01	0.36	1.11e-14	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg10978503	chr1:24200527	CNR2	0.53	11.26	0.48	6.82e-26	Immature fraction of reticulocytes;
LUAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08219700	chr8:58056026	NA	0.77	9.98	0.44	3.39e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs909341	0.537	rs13041528	chr20:62385446	C/G	cg14758556	chr20:62440591	NA	-0.46	-6.81	-0.31	3.38e-11	Atopic dermatitis;
LUAD	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg02527881	chr3:46936655	PTH1R	0.43	8.12	0.37	5e-15	Colorectal cancer;
LUAD	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg22166914	chr1:53195759	ZYG11B	-0.53	-9.29	-0.41	8.54e-19	Monocyte count;
LUAD	cis	rs7107174	0.892	rs11237477	chr11:78095069	A/T	cg19901956	chr11:77921274	USP35	-0.49	-6.88	-0.32	2.14e-11	Testicular germ cell tumor;
LUAD	cis	rs17021463	0.902	rs36099342	chr4:95239783	T/C	cg11021082	chr4:95130006	SMARCAD1	0.41	7.35	0.34	1.02e-12	Testicular germ cell tumor;
LUAD	trans	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg14791747	chr16:20752902	THUMPD1	0.74	10.02	0.44	2.33e-21	Cognitive test performance;
LUAD	cis	rs6906287	0.531	rs56344535	chr6:119011263	T/C	cg21191810	chr6:118973309	C6orf204	0.4	7.0	0.32	1e-11	Electrocardiographic conduction measures;
LUAD	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg00717180	chr2:96193071	NA	-0.36	-6.48	-0.3	2.51e-10	Coronary artery disease;
LUAD	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.94	-0.32	1.52e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs732716	0.853	rs1127888	chr19:4454083	C/T	cg21934504	chr19:4445085	UBXN6	0.47	7.85	0.36	3.56e-14	Mean corpuscular volume;
LUAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14159672	chr1:205819179	PM20D1	0.79	16.16	0.62	4.14e-46	Menarche (age at onset);
LUAD	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg05966235	chr16:28915196	ATP2A1	0.42	6.89	0.32	2.02e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg26528668	chr16:1614120	IFT140	0.57	10.28	0.45	2.81e-22	Coronary artery disease;
LUAD	cis	rs17092148	0.848	rs6060030	chr20:33340313	C/T	cg16810054	chr20:33298113	TP53INP2	-0.37	-6.4	-0.3	4.08e-10	Neuroticism;
LUAD	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg15128208	chr22:42549153	NA	0.4	8.15	0.37	4.19e-15	Cognitive function;
LUAD	cis	rs13315871	0.929	rs11706920	chr3:58279672	C/T	cg12435725	chr3:58293450	RPP14	-0.68	-7.22	-0.33	2.41e-12	Cholesterol, total;
LUAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00149659	chr3:10157352	C3orf10	0.63	8.82	0.39	2.97e-17	Alzheimer's disease;
LUAD	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg05468064	chr22:46423449	NA	0.56	11.64	0.49	2.31e-27	Dupuytren's disease;
LUAD	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg02493740	chr2:85810744	VAMP5	-0.61	-11.25	-0.48	7.25e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg00619347	chr3:149688574	PFN2	-0.69	-6.71	-0.31	6.16e-11	Type 2 diabetes;
LUAD	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg00106254	chr7:1943704	MAD1L1	-0.45	-6.52	-0.3	2.04e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg26597838	chr10:835615	NA	0.8	12.4	0.52	2.55e-30	Eosinophil percentage of granulocytes;
LUAD	cis	rs3125734	0.608	rs7094950	chr10:64019744	T/C	cg09941381	chr10:64027924	RTKN2	-0.31	-7.29	-0.33	1.56e-12	Rheumatoid arthritis;
LUAD	cis	rs1832871	0.655	rs6920121	chr6:158678504	C/T	cg07165851	chr6:158734300	TULP4	-0.71	-11.01	-0.47	5.79e-25	Height;
LUAD	cis	rs6484504	0.553	rs413067	chr11:31223497	T/C	cg14844989	chr11:31128820	NA	-0.44	-8.2	-0.37	2.96e-15	Red blood cell count;
LUAD	cis	rs68170813	0.599	rs12533516	chr7:106937135	C/T	cg23024343	chr7:107201750	COG5	0.5	7.31	0.33	1.33e-12	Coronary artery disease;
LUAD	cis	rs6433857	0.536	rs1901750	chr2:181350739	C/T	cg23363182	chr2:181467187	NA	-0.4	-6.56	-0.3	1.57e-10	Body mass index;
LUAD	cis	rs240764	0.853	rs108422	chr6:101039279	G/C	cg09795085	chr6:101329169	ASCC3	0.41	6.93	0.32	1.55e-11	Neuroticism;
LUAD	cis	rs55823223	0.504	rs56098714	chr17:73860303	T/C	cg09253696	chr17:73873529	TRIM47	-0.42	-7.23	-0.33	2.26e-12	Psoriasis;
LUAD	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg15744005	chr10:104629667	AS3MT	-0.41	-7.19	-0.33	3e-12	Arsenic metabolism;
LUAD	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg15790184	chr11:494944	RNH1	0.52	6.49	0.3	2.43e-10	Body mass index;
LUAD	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg16205897	chr5:131564050	P4HA2	-0.31	-6.72	-0.31	5.81e-11	Acylcarnitine levels;
LUAD	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg07402062	chr16:89894098	SPIRE2	0.45	11.47	0.49	1.06e-26	Vitiligo;
LUAD	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.78	-0.35	5.7e-14	Blood metabolite levels;
LUAD	cis	rs6489882	0.779	rs57484342	chr12:113371973	A/G	cg20102336	chr12:113376681	OAS3	-0.6	-9.42	-0.42	3.07e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg04267008	chr7:1944627	MAD1L1	-0.72	-10.92	-0.47	1.28e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs2806561	0.695	rs66592286	chr1:23333649	G/C	cg12483005	chr1:23474871	LUZP1	0.43	7.0	0.32	9.95e-12	Height;
LUAD	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg10295955	chr4:187884368	NA	1.09	25.89	0.78	3.05e-89	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1448094	0.785	rs7955173	chr12:86447214	G/A	cg00310523	chr12:86230176	RASSF9	-0.35	-7.5	-0.34	3.66e-13	Major depressive disorder;
LUAD	cis	rs28493229	0.500	rs45545932	chr19:41190875	G/A	cg21869046	chr19:41225005	ITPKC	0.46	7.84	0.36	3.78e-14	Kawasaki disease;
LUAD	cis	rs35146811	0.555	rs1981550	chr7:99541952	G/A	cg13334819	chr7:99746414	C7orf59	-0.56	-8.24	-0.37	2.14e-15	Coronary artery disease;
LUAD	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg08470875	chr2:26401718	FAM59B	-0.66	-9.52	-0.42	1.4e-19	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg18105134	chr13:113819100	PROZ	-0.83	-14.35	-0.57	2.55e-38	Platelet distribution width;
LUAD	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg02158880	chr13:53174818	NA	0.63	11.14	0.48	1.91e-25	Lewy body disease;
LUAD	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.18	0.33	3.08e-12	Menopause (age at onset);
LUAD	cis	rs116095464	1.000	rs56700778	chr5:313186	A/T	cg22857025	chr5:266934	NA	-1.08	-8.87	-0.4	2.06e-17	Breast cancer;
LUAD	trans	rs7786808	0.579	rs55701656	chr7:158188812	G/A	cg02030672	chr11:45687055	CHST1	0.43	7.75	0.35	7.02e-14	Obesity-related traits;
LUAD	cis	rs11031096	0.754	rs10835611	chr11:4117730	G/C	cg18678763	chr11:4115507	RRM1	-0.42	-7.31	-0.33	1.39e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.3	-7.57	-0.35	2.38e-13	Total body bone mineral density;
LUAD	cis	rs4901869	0.864	rs12891575	chr14:59334342	T/A	cg02291164	chr14:59296302	NA	0.65	15.74	0.61	2.91e-44	Panic disorder;
LUAD	cis	rs2652834	0.851	rs16946416	chr15:63356721	A/T	cg25406657	chr15:63342033	TPM1	0.44	7.22	0.33	2.51e-12	HDL cholesterol;
LUAD	cis	rs10465746	0.653	rs11163877	chr1:84441848	T/A	cg10977910	chr1:84465055	TTLL7	0.59	9.67	0.43	4.21e-20	Obesity-related traits;
LUAD	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs751728	1.000	rs2296748	chr6:33745071	C/T	cg13859433	chr6:33739653	LEMD2	-0.37	-8.68	-0.39	8.36e-17	Crohn's disease;
LUAD	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg04013093	chr6:42928303	GNMT	0.28	6.51	0.3	2.18e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs208520	0.690	rs207082	chr6:66773796	G/A	cg07460842	chr6:66804631	NA	-1.07	-16.62	-0.63	4.33e-48	Exhaled nitric oxide output;
LUAD	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg17063962	chr7:91808500	NA	0.68	12.01	0.5	8.82e-29	Breast cancer;
LUAD	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg09365446	chr1:150670422	GOLPH3L	-0.48	-8.33	-0.38	1.13e-15	Lymphocyte counts;
LUAD	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg05340658	chr4:99064831	C4orf37	0.45	7.36	0.34	9.65e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08280861	chr8:58055591	NA	-0.65	-8.23	-0.37	2.28e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg19046167	chr17:80928561	B3GNTL1	0.43	6.39	0.3	4.49e-10	Glycated hemoglobin levels;
LUAD	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg06060754	chr5:176797920	RGS14	0.55	10.65	0.46	1.29e-23	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg00631329	chr6:26305371	NA	-0.54	-10.05	-0.44	1.92e-21	Educational attainment;
LUAD	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.24	0.33	2.07e-12	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg24069376	chr3:38537580	EXOG	0.44	10.76	0.46	5.05e-24	Electrocardiographic conduction measures;
LUAD	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg26408565	chr15:76604113	ETFA	-0.49	-8.1	-0.37	6.05e-15	Blood metabolite levels;
LUAD	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg24818145	chr4:99064322	C4orf37	0.43	7.11	0.33	4.85e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4242434	0.892	rs71513892	chr8:22456517	C/G	cg03733263	chr8:22462867	KIAA1967	0.72	11.84	0.5	4.08e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg06484146	chr7:12443880	VWDE	0.52	7.66	0.35	1.3e-13	Coronary artery disease;
LUAD	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg18016565	chr1:150552671	MCL1	-0.39	-6.78	-0.31	4.12e-11	Tonsillectomy;
LUAD	cis	rs6456156	0.792	rs10946215	chr6:167516181	A/G	cg07741184	chr6:167504864	NA	-0.33	-7.89	-0.36	2.65e-14	Primary biliary cholangitis;
LUAD	cis	rs8048589	1.000	rs8059989	chr16:12185746	C/T	cg03816625	chr16:12192430	SNX29	0.54	7.99	0.36	1.27e-14	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	6.95	0.32	1.42e-11	Lung cancer in ever smokers;
LUAD	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26314531	chr2:26401878	FAM59B	-0.58	-7.99	-0.36	1.33e-14	Gut microbiome composition (summer);
LUAD	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg22676075	chr6:135203613	NA	0.37	6.88	0.32	2.21e-11	Red blood cell count;
LUAD	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg02421172	chr7:1938701	MAD1L1	0.46	6.74	0.31	5.13e-11	Bipolar disorder;
LUAD	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg07061783	chr6:25882402	NA	-0.5	-7.95	-0.36	1.7e-14	Blood metabolite levels;
LUAD	cis	rs10950821	0.530	rs6950237	chr7:20688135	G/A	cg02470904	chr7:20686108	ABCB5	0.42	7.44	0.34	5.83e-13	Response to statin therapy;
LUAD	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg03188948	chr7:1209495	NA	0.82	10.0	0.44	2.86e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg05132306	chr1:1846340	CALML6	-0.35	-7.27	-0.33	1.72e-12	Body mass index;
LUAD	cis	rs11229555	0.609	rs34782543	chr11:58187398	G/A	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs4604732	0.631	rs12091081	chr1:247623064	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.1	0.4	3.45e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg27211696	chr2:191398769	TMEM194B	-0.47	-6.43	-0.3	3.43e-10	Diastolic blood pressure;
LUAD	cis	rs11951515	0.508	rs1366410	chr5:43601610	C/A	cg01983248	chr5:43482804	C5orf28	-0.38	-8.29	-0.37	1.51e-15	Metabolite levels  (X-11787);
LUAD	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg17724175	chr1:150552817	MCL1	0.4	9.7	0.43	3.13e-20	Tonsillectomy;
LUAD	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg00074818	chr8:8560427	CLDN23	0.66	10.17	0.44	6.95e-22	Obesity-related traits;
LUAD	cis	rs3204270	0.759	rs8065104	chr17:79672605	G/A	cg18367735	chr17:79674897	NA	0.6	7.18	0.33	3.09e-12	Dental caries;
LUAD	trans	rs7395662	0.759	rs11529442	chr11:48819986	T/C	cg00717180	chr2:96193071	NA	0.36	6.61	0.31	1.13e-10	HDL cholesterol;
LUAD	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg24069376	chr3:38537580	EXOG	0.45	10.92	0.47	1.27e-24	Electrocardiographic conduction measures;
LUAD	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg22166914	chr1:53195759	ZYG11B	-0.44	-7.62	-0.35	1.73e-13	Monocyte count;
LUAD	cis	rs7843479	0.601	rs7220	chr8:21863290	G/A	cg03445287	chr8:21823731	XPO7	-0.48	-9.14	-0.41	2.54e-18	Mean corpuscular volume;
LUAD	trans	rs9832625	0.582	rs1025644	chr3:29331859	A/G	cg07813265	chr1:100820528	CDC14A	0.47	6.76	0.31	4.5e-11	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg03526776	chr6:41159608	TREML2	0.32	6.53	0.3	1.89e-10	Alzheimer's disease (late onset);
LUAD	trans	rs4942242	0.663	rs7319346	chr13:44218201	T/C	cg19169023	chr15:41853346	TYRO3	-0.68	-11.47	-0.49	1.09e-26	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9378688	0.546	rs2479014	chr6:2357948	C/T	cg12303981	chr6:2244766	GMDS	-0.36	-6.42	-0.3	3.68e-10	Caudate nucleus volume;
LUAD	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg06092702	chr1:163392909	NA	-0.39	-8.55	-0.38	2.3e-16	Motion sickness;
LUAD	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2840044	1.000	rs9913003	chr17:33893904	C/A	cg05299278	chr17:33885742	SLFN14	-0.44	-8.8	-0.39	3.59e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19410845	chr2:84686791	SUCLG1	-0.42	-6.69	-0.31	7.03e-11	Height;
LUAD	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-8.91	-0.4	1.55e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.04e-13	Morning vs. evening chronotype;
LUAD	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22455342	chr2:225449267	CUL3	0.71	10.96	0.47	8.69e-25	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs10465746	0.752	rs10874426	chr1:84451820	A/G	cg10977910	chr1:84465055	TTLL7	0.61	10.01	0.44	2.63e-21	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.44e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14159672	chr1:205819179	PM20D1	-0.56	-9.94	-0.44	4.71e-21	Menarche (age at onset);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11345172	chr12:120315133	CIT	-0.4	-6.76	-0.31	4.63e-11	Cancer;
LUAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg14820908	chr5:178986412	RUFY1	-0.47	-7.81	-0.35	4.68e-14	Lung cancer;
LUAD	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg10053473	chr17:62856997	LRRC37A3	0.78	11.09	0.47	2.96e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg26354017	chr1:205819088	PM20D1	0.79	16.41	0.62	3.47e-47	Menarche (age at onset);
LUAD	cis	rs9914988	0.537	rs28448745	chr17:27188296	A/C	cg02049041	chr17:27085579	C17orf63	-0.56	-7.08	-0.33	5.93e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg19077165	chr18:44547161	KATNAL2	0.41	7.0	0.32	1.03e-11	Personality dimensions;
LUAD	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg20701182	chr2:24300061	SF3B14	0.89	13.39	0.55	2.57e-34	Lymphocyte counts;
LUAD	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	11.01	0.47	5.77e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg23281280	chr6:28129359	ZNF389	0.48	6.68	0.31	7.61e-11	Depression;
LUAD	cis	rs62238980	0.614	rs116872567	chr22:32460255	G/A	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg05234568	chr11:5960015	NA	-0.52	-9.36	-0.41	4.58e-19	DNA methylation (variation);
LUAD	cis	rs7617773	0.780	rs13066758	chr3:48343877	G/A	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg24818145	chr4:99064322	C4orf37	0.48	8.02	0.36	1.05e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18876405	chr7:65276391	NA	-0.54	-9.26	-0.41	1.01e-18	Aortic root size;
LUAD	cis	rs2108225	0.714	rs10953548	chr7:107436232	G/A	cg18560240	chr7:107437656	SLC26A3	-0.45	-7.45	-0.34	5.38e-13	Ulcerative colitis;
LUAD	trans	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg26043149	chr18:55253948	FECH	0.5	8.06	0.36	7.84e-15	Bone mineral density;
LUAD	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg11742103	chr11:62369870	EML3;MTA2	-0.51	-9.51	-0.42	1.49e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.89	0.43	6.77e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11671005	0.656	rs11672609	chr19:59006924	C/T	cg13877915	chr19:58951672	ZNF132	0.6	6.86	0.32	2.49e-11	Mean platelet volume;
LUAD	trans	rs7395662	0.963	rs8189076	chr11:48732975	C/T	cg15704280	chr7:45808275	SEPT13	0.43	6.75	0.31	5.04e-11	HDL cholesterol;
LUAD	cis	rs11671005	0.611	rs56026876	chr19:59006157	G/C	cg13877915	chr19:58951672	ZNF132	0.51	6.54	0.3	1.74e-10	Mean platelet volume;
LUAD	cis	rs1018836	0.599	rs9643295	chr8:91492283	T/G	cg16814680	chr8:91681699	NA	-0.53	-8.78	-0.39	3.97e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-8.09	-0.37	6.46e-15	Bipolar disorder;
LUAD	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs4713675	0.584	rs4713667	chr6:33680016	G/C	cg14003231	chr6:33640908	ITPR3	0.49	9.42	0.42	2.96e-19	Plateletcrit;
LUAD	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg20991723	chr1:152506922	NA	0.32	6.44	0.3	3.3e-10	Hair morphology;
LUAD	cis	rs4006360	0.601	rs349785	chr17:39254557	C/T	cg20663846	chr17:39254439	KRTAP4-8	0.41	9.24	0.41	1.23e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs57590327	0.716	rs56106807	chr3:81765270	A/G	cg07356753	chr3:81810745	GBE1	-0.59	-8.33	-0.38	1.12e-15	Extraversion;
LUAD	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg07917127	chr4:99064746	C4orf37	0.42	7.02	0.32	9.15e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg18944383	chr4:111397179	ENPEP	0.38	7.66	0.35	1.31e-13	Height;
LUAD	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg18827107	chr12:86230957	RASSF9	-0.69	-12.69	-0.53	1.67e-31	Major depressive disorder;
LUAD	cis	rs2882667	0.898	rs10058347	chr5:138361358	G/A	cg04439458	chr5:138467593	SIL1	-0.38	-7.07	-0.33	6.31e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs4072705	1.000	rs10760370	chr9:127418003	G/C	cg13476313	chr9:127244764	NR5A1	0.32	7.84	0.36	3.71e-14	Menarche (age at onset);
LUAD	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg08085267	chr17:45401833	C17orf57	0.6	10.91	0.47	1.35e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6430585	0.697	rs1050115	chr2:136511817	A/G	cg07169764	chr2:136633963	MCM6	0.77	9.03	0.4	6.1e-18	Corneal structure;
LUAD	cis	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg05901451	chr6:126070800	HEY2	-0.44	-6.63	-0.31	1.05e-10	Endometrial cancer;
LUAD	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg20744362	chr22:50050164	C22orf34	0.34	6.41	0.3	3.85e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-13.81	-0.56	4.72e-36	Headache;
LUAD	cis	rs2629540	0.766	rs10794177	chr10:126407409	G/C	cg08799069	chr10:126477246	METTL10	0.47	6.9	0.32	1.87e-11	Cocaine dependence;
LUAD	trans	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.14	-0.48	1.98e-25	Depression;
LUAD	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg13180566	chr4:1052158	NA	-0.4	-6.75	-0.31	5.02e-11	Recombination rate (females);
LUAD	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg05425664	chr17:57184151	TRIM37	0.43	7.68	0.35	1.12e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg22618164	chr12:122356400	WDR66	0.59	10.32	0.45	2.01e-22	Mean corpuscular volume;
LUAD	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg19875535	chr5:140030758	IK	-0.47	-8.0	-0.36	1.19e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg18230493	chr5:56204884	C5orf35	0.45	7.61	0.35	1.77e-13	Coronary artery disease;
LUAD	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg03929089	chr4:120376271	NA	-0.96	-19.69	-0.69	9.6e-62	Height;
LUAD	cis	rs6906287	0.625	rs11968351	chr6:118901509	G/A	cg18833306	chr6:118973337	C6orf204	0.47	8.27	0.37	1.82e-15	Electrocardiographic conduction measures;
LUAD	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg07952391	chr2:88470173	THNSL2	0.79	8.49	0.38	3.46e-16	Plasma clusterin levels;
LUAD	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg03609598	chr5:56110824	MAP3K1	-0.63	-8.45	-0.38	4.86e-16	Initial pursuit acceleration;
LUAD	trans	rs2840044	0.517	rs2124247	chr17:33885468	G/A	cg19694781	chr19:47549865	TMEM160	-0.43	-7.09	-0.33	5.78e-12	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06873352	chr17:61820015	STRADA	0.83	18.59	0.67	8.47e-57	Prudent dietary pattern;
LUAD	cis	rs2485376	1.000	rs4244351	chr10:104008870	G/C	cg20641465	chr10:103991465	PITX3	0.57	10.39	0.45	1.15e-22	QT interval;
LUAD	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg16329197	chr12:53359506	NA	-0.75	-13.7	-0.55	1.28e-35	Prostate cancer;
LUAD	cis	rs912057	1.000	rs1294410	chr6:6738752	C/T	cg06612196	chr6:6737390	NA	-0.54	-12.28	-0.51	7.62e-30	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs73198271	0.740	rs10105690	chr8:8649232	G/T	cg01851573	chr8:8652454	MFHAS1	0.49	8.53	0.38	2.58e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2067615	0.524	rs10861645	chr12:107071130	C/T	cg15890332	chr12:107067104	RFX4	0.42	8.86	0.4	2.18e-17	Heart rate;
LUAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg16031515	chr1:205743344	RAB7L1	0.34	7.06	0.32	6.86e-12	Menarche (age at onset);
LUAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg27588902	chr6:42928151	GNMT	0.37	10.01	0.44	2.51e-21	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs56283067	0.773	rs56115627	chr6:44683049	G/A	cg20913747	chr6:44695427	NA	-0.44	-7.37	-0.34	9.21e-13	Total body bone mineral density;
LUAD	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg06558623	chr16:89946397	TCF25	1.14	10.21	0.44	4.91e-22	Skin colour saturation;
LUAD	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg07741184	chr6:167504864	NA	-0.33	-7.96	-0.36	1.6e-14	Crohn's disease;
LUAD	cis	rs2220004	0.507	rs10501344	chr11:55787658	A/T	cg22937354	chr11:55606216	OR5D16	-0.39	-6.73	-0.31	5.59e-11	Odorant perception (&beta-damascenone);
LUAD	trans	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.28	-0.33	1.66e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.79	15.49	0.6	3.28e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg02569458	chr12:86230093	RASSF9	-0.41	-7.6	-0.35	1.95e-13	Major depressive disorder;
LUAD	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg00530320	chr1:46809349	NSUN4	0.53	8.23	0.37	2.33e-15	Menopause (age at onset);
LUAD	cis	rs3936840	0.752	rs2181343	chr14:102993303	A/C	cg18135206	chr14:102964638	TECPR2	-0.52	-8.7	-0.39	7.44e-17	Plateletcrit;
LUAD	cis	rs490234	0.683	rs2841326	chr9:128161768	G/A	cg14078157	chr9:128172775	NA	-0.46	-8.63	-0.39	1.25e-16	Mean arterial pressure;
LUAD	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg20362242	chr5:692897	TPPP	0.57	6.98	0.32	1.15e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg04775059	chr7:64541387	NA	0.53	8.58	0.39	1.8e-16	Calcium levels;
LUAD	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg20701182	chr2:24300061	SF3B14	0.9	13.55	0.55	5.63e-35	Lymphocyte counts;
LUAD	cis	rs4523957	0.713	rs9906500	chr17:2129210	C/A	cg16513277	chr17:2031491	SMG6	-0.82	-15.37	-0.6	1.12e-42	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs367943	0.871	rs348938	chr5:112825032	C/A	cg12552261	chr5:112820674	MCC	-0.49	-9.0	-0.4	7.84e-18	Type 2 diabetes;
LUAD	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg08027265	chr7:2291960	NA	-0.46	-8.0	-0.36	1.21e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs494562	0.773	rs6919207	chr6:86129271	C/T	cg21730993	chr6:86159210	NT5E	0.71	7.87	0.36	3.09e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1965732	0.563	rs13409104	chr2:3718692	C/T	cg19052272	chr2:3704530	ALLC	-0.41	-7.68	-0.35	1.15e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg00666640	chr1:248458726	OR2T12	0.33	8.05	0.36	8.2e-15	Common traits (Other);
LUAD	cis	rs7216064	1.000	rs4318247	chr17:65882172	A/G	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs7551222	0.752	rs10793765	chr1:204549375	A/G	cg20240347	chr1:204465584	NA	-0.33	-6.42	-0.3	3.76e-10	Schizophrenia;
LUAD	cis	rs2625529	0.526	rs11637611	chr15:72551712	C/T	cg16672083	chr15:72433130	SENP8	0.65	11.98	0.5	1.12e-28	Red blood cell count;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27570636	chr1:214454189	SMYD2	0.41	6.51	0.3	2.13e-10	Gut microbiome composition (summer);
LUAD	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24531977	chr5:56204891	C5orf35	-1.0	-15.2	-0.59	5.89e-42	Initial pursuit acceleration;
LUAD	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg07423050	chr13:99094983	FARP1	-0.56	-9.35	-0.41	5.32e-19	Neuroticism;
LUAD	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg17063962	chr7:91808500	NA	0.65	10.98	0.47	7.8e-25	Breast cancer;
LUAD	trans	rs7944735	0.817	rs6485774	chr11:47773226	C/T	cg15704280	chr7:45808275	SEPT13	0.53	7.17	0.33	3.4e-12	Intraocular pressure;
LUAD	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg02886208	chr11:14281011	SPON1	-0.36	-7.33	-0.34	1.17e-12	Mitochondrial DNA levels;
LUAD	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg05082376	chr22:42548792	NA	0.45	7.8	0.35	4.73e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg23277830	chr1:3704460	LRRC47	0.36	7.7	0.35	9.83e-14	Red cell distribution width;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg19935506	chr2:242626874	DTYMK	0.41	6.41	0.3	3.93e-10	Monocyte percentage of white cells;
LUAD	cis	rs10992471	0.603	rs10992349	chr9:95233887	T/C	cg14631576	chr9:95140430	CENPP	-0.56	-11.52	-0.49	7.08e-27	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.2	-0.37	2.8e-15	Breast cancer;
LUAD	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg02018176	chr4:1364513	KIAA1530	0.69	11.76	0.5	8.19e-28	Longevity;
LUAD	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.85	-7.91	-0.36	2.23e-14	Lung cancer in ever smokers;
LUAD	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg23262073	chr20:60523788	NA	-0.46	-8.0	-0.36	1.18e-14	Body mass index;
LUAD	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg04287289	chr16:89883240	FANCA	0.71	6.66	0.31	8.69e-11	Skin colour saturation;
LUAD	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg11965913	chr1:205819406	PM20D1	0.51	8.11	0.37	5.53e-15	Parkinson's disease;
LUAD	cis	rs1595825	0.891	rs77029420	chr2:198651492	G/A	cg10547527	chr2:198650123	BOLL	-0.54	-6.98	-0.32	1.12e-11	Ulcerative colitis;
LUAD	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg24397884	chr7:158709396	WDR60	-0.71	-9.93	-0.43	5.1e-21	Height;
LUAD	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg25838465	chr1:92012736	NA	-0.69	-14.86	-0.59	1.77e-40	Breast cancer;
LUAD	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg06287003	chr12:125626642	AACS	0.46	8.14	0.37	4.5e-15	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs2795502	0.564	rs11239844	chr10:43453365	G/A	cg08461752	chr10:43522343	NA	-0.76	-8.13	-0.37	4.77e-15	Blood protein levels;
LUAD	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg23887609	chr12:130822674	PIWIL1	0.4	6.81	0.31	3.3e-11	Menopause (age at onset);
LUAD	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg22681709	chr2:178499509	PDE11A	-0.55	-9.6	-0.42	7.3e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26653168	chr15:64648652	CSNK1G1	-0.39	-6.45	-0.3	3.11e-10	Cancer;
LUAD	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.49	6.92	0.32	1.73e-11	Cognitive test performance;
LUAD	cis	rs12928939	0.517	rs17358402	chr16:71967927	C/T	cg03805757	chr16:71968109	PKD1L3	-0.54	-8.47	-0.38	4.01e-16	Post bronchodilator FEV1;
LUAD	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg23029597	chr12:123009494	RSRC2	-0.42	-6.45	-0.3	2.98e-10	Body mass index;
LUAD	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-7.44	-0.34	5.74e-13	Personality dimensions;
LUAD	cis	rs8067545	0.616	rs203477	chr17:19831819	A/C	cg04132472	chr17:19861366	AKAP10	0.39	9.25	0.41	1.13e-18	Schizophrenia;
LUAD	cis	rs11811982	0.793	rs78587644	chr1:227251572	G/T	cg24860534	chr1:227506868	CDC42BPA	0.68	7.22	0.33	2.51e-12	Optic disc area;
LUAD	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg10591111	chr5:226296	SDHA	-0.55	-7.0	-0.32	1.04e-11	Breast cancer;
LUAD	cis	rs243505	0.632	rs887571	chr7:148505253	G/A	cg09806900	chr7:148480153	CUL1	0.44	7.68	0.35	1.1e-13	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg12432903	chr7:1882776	MAD1L1	-0.57	-9.19	-0.41	1.84e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg19346786	chr7:2764209	NA	-0.48	-10.35	-0.45	1.55e-22	Height;
LUAD	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg04455712	chr21:45112962	RRP1B	0.4	8.19	0.37	3.19e-15	Mean corpuscular volume;
LUAD	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg06387496	chr7:2775674	GNA12	-0.41	-6.72	-0.31	6e-11	Height;
LUAD	cis	rs4604732	0.631	rs35046441	chr1:247626812	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg08514558	chr10:81106712	PPIF	0.51	9.84	0.43	1.05e-20	Height;
LUAD	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg26727032	chr16:67993705	SLC12A4	-0.46	-6.83	-0.31	3.04e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg04896959	chr15:78267971	NA	0.63	12.12	0.51	3.23e-29	Coronary artery disease or large artery stroke;
LUAD	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-7.01	-0.32	9.25e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs62238980	0.614	rs77162015	chr22:32485616	G/T	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs7737355	0.947	rs31585	chr5:130999082	A/G	cg06307176	chr5:131281290	NA	0.54	8.37	0.38	8.65e-16	Life satisfaction;
LUAD	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg14343924	chr8:8086146	FLJ10661	-0.45	-6.87	-0.32	2.27e-11	Triglycerides;
LUAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg04025307	chr7:1156635	C7orf50	0.75	13.6	0.55	3.21e-35	Longevity;Endometriosis;
LUAD	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg04455712	chr21:45112962	RRP1B	0.52	10.84	0.47	2.59e-24	Mean corpuscular volume;
LUAD	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg04546413	chr19:29218101	NA	0.59	7.64	0.35	1.46e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg13319975	chr6:146136371	FBXO30	0.77	13.26	0.54	8.69e-34	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg20925763	chr2:219879821	CCDC108	0.36	6.37	0.3	4.96e-10	Vertical cup-disc ratio;
LUAD	cis	rs11585357	0.843	rs113593167	chr1:17613355	G/A	cg08277548	chr1:17600880	PADI3	-0.95	-13.83	-0.56	3.87e-36	Hair shape;
LUAD	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg17063962	chr7:91808500	NA	-0.65	-10.89	-0.47	1.58e-24	Breast cancer;
LUAD	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg26677194	chr12:130822605	PIWIL1	0.56	9.16	0.41	2.25e-18	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg14458575	chr2:238380390	NA	0.76	11.36	0.48	2.8e-26	Prostate cancer;
LUAD	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg11494091	chr17:61959527	GH2	0.43	8.04	0.36	8.84e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	7.14	0.33	3.97e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs11792861	0.566	rs6477687	chr9:111837791	A/T	cg05043794	chr9:111880884	C9orf5	0.38	7.2	0.33	2.85e-12	Menarche (age at onset);
LUAD	cis	rs6782228	0.606	rs2811489	chr3:128337371	A/G	cg16766828	chr3:128327626	NA	0.38	7.06	0.32	6.88e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs68170813	0.652	rs6958969	chr7:107197755	A/T	cg23024343	chr7:107201750	COG5	0.54	6.78	0.31	4.03e-11	Coronary artery disease;
LUAD	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg22455342	chr2:225449267	CUL3	0.47	7.96	0.36	1.59e-14	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs2797160	1.000	rs1777194	chr6:126004883	G/A	cg05901451	chr6:126070800	HEY2	-0.45	-6.6	-0.31	1.23e-10	Endometrial cancer;
LUAD	cis	rs7692976	0.503	rs11569100	chr4:110921374	T/C	cg06981781	chr4:110842888	EGF	-0.39	-6.61	-0.31	1.16e-10	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs62458065	0.513	rs787220	chr7:32581139	C/G	cg20159608	chr7:32802032	NA	-0.7	-10.43	-0.45	7.87e-23	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg26408565	chr15:76604113	ETFA	-0.44	-7.13	-0.33	4.28e-12	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08944318	chr10:15139147	RPP38;C10orf111	-0.53	-6.41	-0.3	3.83e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg05697835	chr1:2722811	NA	0.31	6.35	0.3	5.54e-10	Ulcerative colitis;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17745251	chr10:21806139	C10orf140	-0.4	-6.38	-0.3	4.79e-10	Cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07907564	chr7:73589340	EIF4H	-0.4	-6.55	-0.3	1.65e-10	Cancer;
LUAD	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg15468180	chr1:107600409	PRMT6	0.41	6.97	0.32	1.2e-11	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03517284	chr6:25882590	NA	0.91	15.29	0.6	2.38e-42	Blood metabolite levels;
LUAD	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg06818126	chr11:68850279	TPCN2	0.43	6.55	0.3	1.66e-10	Hair color;
LUAD	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg01808030	chr22:45809952	RIBC2;SMC1B	0.77	8.11	0.37	5.45e-15	Tonsillectomy;
LUAD	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.58	0.35	2.14e-13	Tonsillectomy;
LUAD	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg02574844	chr11:5959923	NA	0.44	8.36	0.38	9.12e-16	DNA methylation (variation);
LUAD	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg24675056	chr1:15929824	NA	0.48	8.51	0.38	3.12e-16	Systolic blood pressure;
LUAD	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg24503407	chr1:205819492	PM20D1	-0.51	-7.77	-0.35	6.02e-14	Menarche (age at onset);
LUAD	cis	rs7809950	1.000	rs10251808	chr7:107120453	G/A	cg23024343	chr7:107201750	COG5	-0.74	-12.61	-0.52	3.73e-31	Coronary artery disease;
LUAD	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg00677455	chr12:58241039	CTDSP2	0.46	7.73	0.35	7.65e-14	Multiple sclerosis;
LUAD	cis	rs476633	0.691	rs2164996	chr15:41536624	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.55	-0.38	2.32e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg11822812	chr5:140052017	DND1	0.38	6.72	0.31	6.01e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg08470875	chr2:26401718	FAM59B	-0.68	-8.96	-0.4	1.06e-17	Gut microbiome composition (summer);
LUAD	cis	rs6005807	0.843	rs9625484	chr22:28908601	A/G	cg12565055	chr22:29076175	TTC28	0.67	6.52	0.3	1.99e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs240764	0.631	rs12195369	chr6:101204106	G/A	cg09795085	chr6:101329169	ASCC3	-0.46	-8.0	-0.36	1.21e-14	Neuroticism;
LUAD	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg09658497	chr7:2847517	GNA12	0.45	8.21	0.37	2.72e-15	Plateletcrit;
LUAD	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg25344623	chr2:136566232	LCT	0.35	6.8	0.31	3.64e-11	Mosquito bite size;
LUAD	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg08601574	chr20:25228251	PYGB	0.44	8.16	0.37	3.83e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg15605315	chr1:45957053	TESK2	-0.41	-6.43	-0.3	3.54e-10	High light scatter reticulocyte count;
LUAD	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg04287289	chr16:89883240	FANCA	0.7	12.74	0.53	1.11e-31	Vitiligo;
LUAD	cis	rs6445967	0.569	rs9845705	chr3:58281868	T/G	cg13750441	chr3:58318267	PXK	-0.31	-6.59	-0.31	1.32e-10	Platelet count;
LUAD	cis	rs877282	0.945	rs11253391	chr10:788752	G/A	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg24829409	chr8:58192753	C8orf71	0.6	7.78	0.35	5.7e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg14343924	chr8:8086146	FLJ10661	-0.46	-7.2	-0.33	2.76e-12	Joint mobility (Beighton score);
LUAD	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg17372223	chr3:52568218	NT5DC2	0.39	7.6	0.35	1.99e-13	Bipolar disorder;
LUAD	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.18	-0.37	3.36e-15	Total body bone mineral density;
LUAD	cis	rs11229555	0.645	rs7947248	chr11:58197750	C/T	cg15696309	chr11:58395628	NA	-0.77	-10.52	-0.46	3.94e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.5	9.96	0.44	3.77e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-8.18	-0.37	3.42e-15	Alzheimer's disease (late onset);
LUAD	cis	rs1788820	0.917	rs1788762	chr18:21132571	G/C	cg14672496	chr18:21087552	C18orf8	0.37	6.92	0.32	1.72e-11	Body mass index;
LUAD	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.66	-0.61	6.36e-44	Eye color traits;
LUAD	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg05434287	chr7:2030229	MAD1L1	0.38	6.5	0.3	2.29e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7833986	0.501	rs2953909	chr8:56968200	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	1.01	18.37	0.67	7.54e-56	Height;
LUAD	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg26384229	chr12:38710491	ALG10B	-0.46	-7.3	-0.33	1.43e-12	Morning vs. evening chronotype;
LUAD	cis	rs6028335	0.610	rs12624839	chr20:37573816	G/A	cg27660920	chr20:37554817	FAM83D	0.54	7.07	0.32	6.61e-12	Alcohol and nicotine co-dependence;
LUAD	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.9	-0.47	1.47e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg07386859	chr16:1872102	HAGH	-0.5	-7.82	-0.36	4.38e-14	Insulin-like growth factors;
LUAD	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg06618935	chr21:46677482	NA	-0.5	-10.01	-0.44	2.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.42e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10883723	0.641	rs80146619	chr10:104405850	G/A	cg22532475	chr10:104410764	TRIM8	-0.53	-8.65	-0.39	1.09e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg19041857	chr6:27730383	NA	-0.4	-6.68	-0.31	7.76e-11	Parkinson's disease;
LUAD	trans	rs1941687	0.797	rs6507070	chr18:31393244	C/A	cg27147174	chr7:100797783	AP1S1	-0.5	-8.3	-0.37	1.45e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg05564831	chr3:52568323	NT5DC2	0.36	6.63	0.31	9.96e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs807669	0.772	rs809901	chr22:19228736	C/T	cg02655711	chr22:19163373	SLC25A1	0.71	15.04	0.59	2.95e-41	Metabolite levels;
LUAD	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg27284194	chr4:1044797	NA	0.69	10.16	0.44	7.9e-22	Recombination rate (females);
LUAD	cis	rs7107174	1.000	rs4134379	chr11:77992588	A/G	cg02023728	chr11:77925099	USP35	0.38	6.45	0.3	3.09e-10	Testicular germ cell tumor;
LUAD	cis	rs9329221	0.508	rs6601455	chr8:10273426	A/G	cg12940923	chr8:10282607	MSRA	0.37	6.73	0.31	5.53e-11	Neuroticism;
LUAD	cis	rs4743820	0.651	rs16907199	chr9:93923617	A/G	cg14446406	chr9:93919335	NA	0.5	8.75	0.39	5.29e-17	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg10295955	chr4:187884368	NA	-1.1	-25.97	-0.78	1.38e-89	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7932354	0.528	rs12224096	chr11:47174361	C/T	cg19486271	chr11:47235900	DDB2	0.41	6.49	0.3	2.4e-10	Bone mineral density (hip);Bone mineral density;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04931090	chr6:35181888	SCUBE3	-0.41	-6.93	-0.32	1.56e-11	Cancer;
LUAD	cis	rs870825	0.616	rs4616798	chr4:185634144	C/T	cg04058563	chr4:185651563	MLF1IP	-0.87	-14.54	-0.58	4.1e-39	Blood protein levels;
LUAD	cis	rs11677416	1.000	rs1878318	chr2:113545185	A/G	cg27083787	chr2:113543245	IL1A	0.4	6.78	0.31	3.96e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11644478	chr21:40555479	PSMG1	0.63	10.13	0.44	9.9700000000000009e-22	Cognitive function;
LUAD	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg04414720	chr1:150670196	GOLPH3L	0.72	12.51	0.52	9.24e-31	Melanoma;
LUAD	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg25019722	chr6:37503610	NA	-0.3	-6.7	-0.31	6.72e-11	Cognitive performance;
LUAD	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	12.28	0.51	7.2e-30	Lung cancer in ever smokers;
LUAD	cis	rs6881634	0.501	rs7356762	chr5:77759520	A/G	cg11547950	chr5:77652471	NA	-0.35	-6.38	-0.3	4.74e-10	Hippocampal atrophy;
LUAD	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg15704280	chr7:45808275	SEPT13	0.64	8.44	0.38	5.05e-16	Axial length;
LUAD	trans	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.67	-11.64	-0.49	2.31e-27	Brugada syndrome;
LUAD	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg07423050	chr13:99094983	FARP1	-0.76	-16.68	-0.63	2.37e-48	Neuroticism;
LUAD	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg25985355	chr7:65971099	NA	-0.51	-6.41	-0.3	3.8e-10	Diabetic kidney disease;
LUAD	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg11250194	chr11:61601937	FADS2	-0.4	-6.44	-0.3	3.3e-10	Trans fatty acid levels;
LUAD	cis	rs12618769	0.543	rs6753380	chr2:99129040	A/G	cg10123293	chr2:99228465	UNC50	0.46	8.38	0.38	7.67e-16	Bipolar disorder;
LUAD	trans	rs526631	0.564	rs10896051	chr11:65578759	C/T	cg17712092	chr4:129076599	LARP1B	-0.65	-10.16	-0.44	7.8e-22	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	trans	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg00953403	chr17:74099816	EXOC7	-0.51	-7.92	-0.36	2.14e-14	Psychosis in Alzheimer's disease;
LUAD	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg24531977	chr5:56204891	C5orf35	-0.4	-6.65	-0.31	9.21e-11	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs2692947	0.673	rs2917662	chr2:96794957	G/A	cg23100626	chr2:96804247	ASTL	0.37	9.71	0.43	2.99e-20	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs6543140	0.964	rs2310301	chr2:103072935	C/T	cg03938978	chr2:103052716	IL18RAP	0.35	6.8	0.31	3.6e-11	Blood protein levels;
LUAD	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg02631126	chr6:28058918	ZSCAN12L1	-0.31	-6.52	-0.3	2.06e-10	Parkinson's disease;
LUAD	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg11247378	chr22:39784982	NA	-0.72	-13.16	-0.54	2.19e-33	Intelligence (multi-trait analysis);
LUAD	cis	rs9362426	0.708	rs4707365	chr6:88100912	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	6.93	0.32	1.59e-11	Depressive episodes in bipolar disorder;
LUAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.46	-8.89	-0.4	1.73e-17	Longevity;Endometriosis;
LUAD	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-7.79	-0.35	5.11e-14	Neuroticism;
LUAD	cis	rs2777491	0.874	rs1655556	chr15:41777935	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.7	-13.03	-0.54	7.26e-33	Ulcerative colitis;
LUAD	cis	rs3018712	0.532	rs2513289	chr11:68419655	A/C	cg16797656	chr11:68205561	LRP5	-0.42	-6.47	-0.3	2.79e-10	Total body bone mineral density;
LUAD	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg26513180	chr16:89883248	FANCA	0.44	6.88	0.32	2.18e-11	Vitiligo;
LUAD	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg11887960	chr12:57824829	NA	0.59	7.3	0.33	1.46e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7630877	0.962	rs16830940	chr3:179658262	C/T	cg18765712	chr3:179670323	PEX5L	0.35	6.58	0.3	1.38e-10	Type 2 diabetes;
LUAD	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg00071950	chr4:10020882	SLC2A9	0.85	18.34	0.67	1.09e-55	Bone mineral density;
LUAD	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg00071950	chr4:10020882	SLC2A9	-0.77	-15.7	-0.61	4.06e-44	Bone mineral density;
LUAD	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg04287289	chr16:89883240	FANCA	-0.48	-7.89	-0.36	2.61e-14	Vitiligo;
LUAD	cis	rs7737355	1.000	rs40396	chr5:130708044	C/G	cg06307176	chr5:131281290	NA	-0.47	-7.48	-0.34	4.32e-13	Life satisfaction;
LUAD	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.81	-0.36	4.47e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg22535103	chr8:58192502	C8orf71	-0.61	-6.74	-0.31	5.19e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.5	8.75	0.39	4.95e-17	Alzheimer's disease (late onset);
LUAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00149659	chr3:10157352	C3orf10	0.87	11.5	0.49	7.94e-27	Alzheimer's disease;
LUAD	trans	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.62	10.67	0.46	1.09e-23	Brugada syndrome;
LUAD	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg08085267	chr17:45401833	C17orf57	-0.8	-14.62	-0.58	1.79e-39	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6684514	1.000	rs2273832	chr1:156233143	A/G	cg16558208	chr1:156270281	VHLL	0.55	9.71	0.43	2.87e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg07636037	chr3:49044803	WDR6	0.64	12.63	0.52	2.86e-31	Parkinson's disease;
LUAD	trans	rs1268789	0.571	rs949507	chr4:79394086	C/T	cg18500714	chr14:100706288	YY1	-0.42	-6.82	-0.31	3.18e-11	Hair shape;Hair morphology;
LUAD	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg12034118	chr1:209979487	IRF6	0.5	6.93	0.32	1.54e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs1113500	0.836	rs1618973	chr1:108586767	T/C	cg06207961	chr1:108661230	NA	-0.42	-7.7	-0.35	1e-13	Growth-regulated protein alpha levels;
LUAD	cis	rs6479527	0.840	rs4282631	chr9:96764410	T/C	cg14459158	chr9:96720562	NA	0.37	6.61	0.31	1.13e-10	Esophageal adenocarcinoma;
LUAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg15117754	chr3:10150083	C3orf24	0.44	7.09	0.33	5.76e-12	Alzheimer's disease;
LUAD	trans	rs783540	0.521	rs28719490	chr15:83389440	A/G	cg16105309	chr15:79090380	ADAMTS7	-0.38	-6.41	-0.3	3.79e-10	Schizophrenia;
LUAD	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg00857998	chr1:205179979	DSTYK	0.4	6.68	0.31	7.41e-11	Red blood cell count;
LUAD	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg03188948	chr7:1209495	NA	0.76	7.62	0.35	1.64e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	7.8	0.35	5.05e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs746627	0.553	rs35098727	chr17:63816298	C/T	cg07283582	chr17:63770753	CCDC46	-0.54	-8.71	-0.39	6.97e-17	Total body bone mineral density;
LUAD	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg21226059	chr5:178986404	RUFY1	-0.59	-10.07	-0.44	1.6e-21	Lung cancer;
LUAD	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg16325326	chr1:53192061	ZYG11B	0.67	12.39	0.52	2.73e-30	Monocyte count;
LUAD	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.93	-0.36	1.91e-14	Prostate cancer;
LUAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg02869364	chr7:1081709	C7orf50	-0.51	-6.74	-0.31	5.09e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7267979	1.000	rs2258719	chr20:25275843	C/T	cg08601574	chr20:25228251	PYGB	0.42	7.82	0.36	4.36e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg18230493	chr5:56204884	C5orf35	-0.84	-12.36	-0.52	3.5e-30	Initial pursuit acceleration;
LUAD	trans	rs9567307	1	rs9567307	chr13:44471877	A/G	cg17145862	chr1:211918768	LPGAT1	0.55	9.34	0.41	5.39e-19	Leprosy;
LUAD	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21659725	chr3:3221576	CRBN	0.7	11.49	0.49	8.54e-27	Resting heart rate;
LUAD	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg06618935	chr21:46677482	NA	-0.5	-10.01	-0.44	2.57e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg00277334	chr10:82204260	NA	0.55	9.17	0.41	2.02e-18	Post bronchodilator FEV1;
LUAD	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg11062466	chr8:58055876	NA	0.77	9.13	0.41	2.92e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2625529	0.824	rs12917428	chr15:72221998	T/C	cg16672083	chr15:72433130	SENP8	-0.76	-12.46	-0.52	1.44e-30	Red blood cell count;
LUAD	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg24818145	chr4:99064322	C4orf37	0.48	7.43	0.34	5.99e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17433780	0.504	rs1409150	chr1:89473175	A/G	cg10631373	chr1:89457642	RBMXL1;CCBL2	0.37	6.52	0.3	2e-10	Carotid intima media thickness;
LUAD	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg23649088	chr2:200775458	C2orf69	0.57	8.15	0.37	4.3e-15	Schizophrenia;
LUAD	cis	rs897984	0.762	rs7204459	chr16:30984212	G/A	cg02466173	chr16:30829666	NA	0.65	11.99	0.5	1.06e-28	Dementia with Lewy bodies;
LUAD	cis	rs7814319	0.933	rs13261747	chr8:97238769	A/G	cg20787634	chr8:97240163	UQCRB	-0.38	-7.51	-0.34	3.61e-13	Lung function (FVC);
LUAD	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg17724175	chr1:150552817	MCL1	0.31	7.14	0.33	4.03e-12	Melanoma;
LUAD	cis	rs7107174	1.000	rs2511166	chr11:77964331	T/C	cg02023728	chr11:77925099	USP35	0.39	6.53	0.3	1.88e-10	Testicular germ cell tumor;
LUAD	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg13722127	chr7:150037890	RARRES2	0.5	8.65	0.39	1.08e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg15691649	chr6:25882328	NA	0.46	7.53	0.34	3.09e-13	Blood metabolite levels;
LUAD	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.61	-0.35	1.86e-13	Breast cancer;
LUAD	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14159672	chr1:205819179	PM20D1	0.79	16.1	0.62	7.51e-46	Menarche (age at onset);
LUAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08280861	chr8:58055591	NA	0.55	7.16	0.33	3.53e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg04851639	chr8:1020857	NA	-0.4	-9.18	-0.41	1.94e-18	Schizophrenia;
LUAD	cis	rs807669	0.903	rs1780637	chr22:19178250	A/G	cg24911827	chr22:19170109	CLTCL1	0.45	9.25	0.41	1.13e-18	Metabolite levels;
LUAD	cis	rs2224391	0.628	rs2773309	chr6:5248916	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-8.54	-0.38	2.41e-16	Height;
LUAD	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg00981070	chr1:2046702	PRKCZ	0.35	6.48	0.3	2.6200000000000003e-10	Height;
LUAD	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg22676075	chr6:135203613	NA	0.53	9.46	0.42	2.15e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg25036284	chr2:26402008	FAM59B	0.84	12.45	0.52	1.59e-30	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.46	-0.42	2.09e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg07414643	chr4:187882934	NA	0.34	6.94	0.32	1.45e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg07460842	chr6:66804631	NA	-0.62	-9.92	-0.43	5.23e-21	Type 2 diabetes;
LUAD	trans	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg14917512	chr19:3094685	GNA11	0.37	6.39	0.3	4.39e-10	Aortic root size;
LUAD	cis	rs2046867	0.818	rs1502754	chr3:72895345	G/T	cg25664220	chr3:72788482	NA	-0.61	-10.97	-0.47	7.94e-25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg12927641	chr6:109611667	NA	-0.5	-8.77	-0.39	4.51e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg22482690	chr17:47019901	SNF8	0.45	8.51	0.38	3.15e-16	Type 2 diabetes;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg05792856	chr11:34379731	ABTB2	0.38	6.45	0.3	3e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg08999081	chr20:33150536	PIGU	0.49	9.42	0.42	3.04e-19	Coronary artery disease;
LUAD	cis	rs7617773	0.780	rs11714944	chr3:48366971	C/A	cg11946769	chr3:48343235	NME6	0.45	6.89	0.32	2.05e-11	Coronary artery disease;
LUAD	trans	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg24644049	chr4:85504048	CDS1	0.86	7.78	0.35	5.78e-14	Skin colour saturation;
LUAD	cis	rs910187	0.605	rs6124960	chr20:45803866	G/C	cg27589058	chr20:45804311	EYA2	-0.37	-8.61	-0.39	1.47e-16	Migraine;
LUAD	cis	rs10489202	0.657	rs201541	chr1:167992344	T/A	cg25738037	chr1:168025549	DCAF6	-0.49	-7.29	-0.33	1.55e-12	Schizophrenia;
LUAD	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg11645453	chr3:52864694	ITIH4	-0.55	-10.04	-0.44	1.97e-21	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg18180107	chr4:99064573	C4orf37	-0.4	-6.38	-0.3	4.75e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg20203395	chr5:56204925	C5orf35	-0.41	-6.92	-0.32	1.73e-11	Coronary artery disease;
LUAD	cis	rs9715521	0.778	rs7681689	chr4:59840103	C/T	cg11281224	chr4:60001000	NA	-0.47	-7.52	-0.34	3.22e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg26373071	chr5:1325741	CLPTM1L	0.37	7.89	0.36	2.54e-14	Lung cancer;
LUAD	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg01851573	chr8:8652454	MFHAS1	-0.47	-8.68	-0.39	8.88e-17	Mood instability;
LUAD	cis	rs6693567	0.516	rs519126	chr1:150288859	T/G	cg15654264	chr1:150340011	RPRD2	-0.35	-6.4	-0.3	4.09e-10	Migraine;
LUAD	trans	rs5756813	0.661	rs11703407	chr22:38200124	C/T	cg19894588	chr14:64061835	NA	-0.53	-7.44	-0.34	5.67e-13	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs11168351	0.750	rs11168366	chr12:48421773	T/C	cg04545296	chr12:48745243	ZNF641	-0.32	-8.09	-0.37	6.21e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs2485376	1.000	rs3802681	chr10:104114328	T/C	cg20641465	chr10:103991465	PITX3	-0.59	-10.69	-0.46	9.07e-24	QT interval;
LUAD	cis	rs748404	0.631	rs28702649	chr15:43648629	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	6.51	0.3	2.11e-10	Lung cancer;
LUAD	trans	rs2797160	1.000	rs2747724	chr6:126004935	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-8.89	-0.4	1.78e-17	Endometrial cancer;
LUAD	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg18105134	chr13:113819100	PROZ	-0.87	-15.03	-0.59	3.17e-41	Platelet distribution width;
LUAD	cis	rs1882538	0.538	rs7803848	chr7:133108547	C/T	cg10665199	chr7:133106180	EXOC4	0.62	11.04	0.47	4.41e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg21862992	chr11:68658383	NA	0.55	9.99	0.44	3.02e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg08859206	chr1:53392774	SCP2	0.63	11.64	0.49	2.26e-27	Monocyte count;
LUAD	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg19436804	chr8:8560866	CLDN23	0.42	6.42	0.3	3.58e-10	Obesity-related traits;
LUAD	cis	rs2637266	1.000	rs7896379	chr10:78366247	C/T	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.72e-11	Pulmonary function;
LUAD	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18876405	chr7:65276391	NA	0.63	11.0	0.47	6.39e-25	Aortic root size;
LUAD	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.46	-9.48	-0.42	1.86e-19	Monocyte percentage of white cells;
LUAD	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-7.82	-0.36	4.38e-14	Bladder cancer;
LUAD	cis	rs9644630	0.870	rs4244453	chr8:19359711	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.3	-7.27	-0.33	1.74e-12	Oropharynx cancer;
LUAD	trans	rs853679	0.546	rs2232429	chr6:28359632	T/G	cg06606381	chr12:133084897	FBRSL1	-1.23	-10.69	-0.46	9.35e-24	Depression;
LUAD	cis	rs72781680	0.699	rs72794291	chr2:23897935	C/T	cg20701182	chr2:24300061	SF3B14	0.61	6.41	0.3	3.94e-10	Lymphocyte counts;
LUAD	cis	rs7582720	1.000	rs72926796	chr2:203827480	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6138458	0.717	rs2179732	chr20:25000446	A/T	cg06937882	chr20:24974362	C20orf3	-0.3	-6.46	-0.3	2.85e-10	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg05340658	chr4:99064831	C4orf37	0.53	8.96	0.4	1.04e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs89107	0.575	rs72958930	chr6:118983681	G/C	cg21191810	chr6:118973309	C6orf204	0.4	7.42	0.34	6.57e-13	Cardiac structure and function;
LUAD	cis	rs3125734	0.633	rs12217669	chr10:63988456	A/G	cg09941381	chr10:64027924	RTKN2	0.3	7.03	0.32	8.53e-12	Rheumatoid arthritis;
LUAD	trans	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg04565464	chr8:145669602	NFKBIL2	0.47	7.22	0.33	2.48e-12	Schizophrenia;
LUAD	cis	rs7737355	0.738	rs3776011	chr5:130868840	C/T	cg25547332	chr5:131281432	NA	0.42	6.78	0.31	4.03e-11	Life satisfaction;
LUAD	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg10518543	chr12:38710700	ALG10B	0.43	7.32	0.34	1.25e-12	Bladder cancer;
LUAD	cis	rs7903847	0.642	rs7088410	chr10:99135539	G/T	cg20016023	chr10:99160130	RRP12	-0.3	-7.31	-0.33	1.39e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03452623	chr4:187889614	NA	-0.8	-16.18	-0.62	3.64e-46	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg14917512	chr19:3094685	GNA11	-0.55	-6.46	-0.3	2.92e-10	Diabetic kidney disease;
LUAD	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.46	0.38	4.37e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs701145	0.585	rs357480	chr3:153891182	A/G	cg17054900	chr3:154042577	DHX36	0.58	6.39	0.3	4.41e-10	Coronary artery disease;
LUAD	cis	rs12530845	0.887	rs73725434	chr7:135313657	T/C	cg23117316	chr7:135346802	PL-5283	-0.5	-8.79	-0.39	3.8e-17	Red blood cell traits;
LUAD	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg09654669	chr8:57350985	NA	-0.66	-10.06	-0.44	1.76e-21	Obesity-related traits;
LUAD	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.7e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs1160297	0.634	rs10179810	chr2:53096145	T/A	cg07782112	chr2:53107842	NA	0.42	8.84	0.4	2.53e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2067615	0.524	rs1922436	chr12:107065258	A/G	cg15890332	chr12:107067104	RFX4	0.39	8.28	0.37	1.63e-15	Heart rate;
LUAD	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg21545522	chr1:205238299	TMCC2	0.38	6.94	0.32	1.51e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg07930552	chr6:133119739	C6orf192	0.86	6.59	0.3	1.35e-10	Type 2 diabetes nephropathy;
LUAD	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg16325326	chr1:53192061	ZYG11B	0.68	13.15	0.54	2.43e-33	Monocyte count;
LUAD	cis	rs8048589	0.898	rs8063329	chr16:12186047	G/A	cg03816625	chr16:12192430	SNX29	0.55	8.08	0.37	6.74e-15	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15939899	chr15:90198503	KIF7	-0.43	-6.76	-0.31	4.51e-11	Height;
LUAD	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg06060754	chr5:176797920	RGS14	0.71	13.82	0.56	4.26e-36	Urinary electrolytes (magnesium/calcium ratio);
LUAD	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg00383909	chr3:49044727	WDR6	0.86	8.78	0.39	4.15e-17	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
LUAD	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg06784218	chr1:46089804	CCDC17	-0.59	-13.14	-0.54	2.57e-33	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7692976	0.552	rs62325289	chr4:110941224	A/G	cg06981781	chr4:110842888	EGF	-0.42	-7.18	-0.33	3.07e-12	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg22963979	chr7:1858916	MAD1L1	-0.65	-11.59	-0.49	3.75e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg15181151	chr6:150070149	PCMT1	0.41	8.55	0.38	2.2e-16	Lung cancer;
LUAD	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg13263323	chr15:86062960	AKAP13	-0.45	-7.36	-0.34	9.88e-13	Coronary artery disease;
LUAD	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.98	-0.36	1.41e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg03352830	chr11:487213	PTDSS2	0.75	9.04	0.4	5.66e-18	Body mass index;
LUAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.37e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62400317	0.826	rs17209769	chr6:45321205	C/A	cg20913747	chr6:44695427	NA	-0.41	-6.66	-0.31	8.71e-11	Total body bone mineral density;
LUAD	cis	rs926938	0.520	rs4140445	chr1:115291978	T/C	cg12756093	chr1:115239321	AMPD1	-0.4	-6.43	-0.3	3.35e-10	Autism;
LUAD	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	7.39	0.34	7.87e-13	Hypertriglyceridemia;
LUAD	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg11301795	chr4:187892539	NA	-0.76	-15.16	-0.59	9.03e-42	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs35306767	0.579	rs7091502	chr10:1154979	C/T	cg26597838	chr10:835615	NA	0.73	9.16	0.41	2.28e-18	Eosinophil percentage of granulocytes;
LUAD	cis	rs73086581	1.000	rs73086512	chr20:3922772	C/A	cg02187196	chr20:3869020	PANK2	0.47	6.56	0.3	1.6e-10	Response to antidepressants in depression;
LUAD	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg22963979	chr7:1858916	MAD1L1	-0.46	-7.64	-0.35	1.51e-13	Schizophrenia;
LUAD	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg19077165	chr18:44547161	KATNAL2	-0.39	-6.8	-0.31	3.47e-11	Personality dimensions;
LUAD	cis	rs7903847	0.642	rs11189200	chr10:99156273	C/G	cg20016023	chr10:99160130	RRP12	-0.31	-7.42	-0.34	6.64e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg14019146	chr3:50243930	SLC38A3	-0.33	-6.36	-0.3	5.1e-10	Body mass index;
LUAD	cis	rs524023	0.957	rs893007	chr11:64365668	C/A	cg19131476	chr11:64387923	NRXN2	-0.42	-7.87	-0.36	3.01e-14	Urate levels in obese individuals;
LUAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg06046430	chr4:77819534	ANKRD56	0.53	8.59	0.39	1.66e-16	Emphysema distribution in smoking;
LUAD	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg15181151	chr6:150070149	PCMT1	0.36	6.95	0.32	1.43e-11	Lung cancer;
LUAD	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg14634687	chr17:47094252	IGF2BP1	0.29	7.46	0.34	4.92e-13	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs10193935	1.000	rs10180528	chr2:42436723	T/A	cg27598129	chr2:42591480	NA	-0.77	-10.17	-0.44	7.21e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg17366294	chr4:99064904	C4orf37	-0.51	-9.21	-0.41	1.55e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg26384229	chr12:38710491	ALG10B	0.41	6.59	0.31	1.34e-10	Morning vs. evening chronotype;
LUAD	trans	rs587242	1.000	rs61786494	chr1:96905987	A/G	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg27631724	chr1:11040367	C1orf127	0.55	9.67	0.43	4.01e-20	Ewing sarcoma;
LUAD	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg27113419	chr16:58533979	NDRG4	-0.77	-6.83	-0.32	2.9e-11	Schizophrenia;
LUAD	cis	rs1448094	0.617	rs2221319	chr12:86468064	C/A	cg02569458	chr12:86230093	RASSF9	-0.35	-6.5	-0.3	2.26e-10	Major depressive disorder;
LUAD	cis	rs7680126	0.644	rs62288518	chr4:10087464	T/C	cg02734326	chr4:10020555	SLC2A9	-0.53	-7.27	-0.33	1.71e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg27432699	chr2:27873401	GPN1	-0.66	-11.81	-0.5	4.97e-28	Oral cavity cancer;
LUAD	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg09835421	chr16:68378352	PRMT7	-0.81	-8.86	-0.4	2.2e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg00383909	chr3:49044727	WDR6	0.42	6.39	0.3	4.27e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg00339695	chr16:24857497	SLC5A11	0.69	11.15	0.48	1.74e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs617219	0.889	rs1627316	chr5:78432444	C/T	cg25119155	chr5:78426943	BHMT	0.36	6.4	0.3	4.16e-10	Betaine levels in individuals undergoing cardiac evaluation;
LUAD	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg23803603	chr1:2058230	PRKCZ	-0.41	-6.95	-0.32	1.35e-11	Height;
LUAD	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg01884057	chr2:25150051	NA	0.33	6.99	0.32	1.07e-11	Body mass index;
LUAD	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg06784218	chr1:46089804	CCDC17	0.5	10.95	0.47	9.59e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg01097406	chr16:89675127	NA	-0.3	-6.56	-0.3	1.61e-10	Hemoglobin concentration;
LUAD	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg17509989	chr5:176798049	RGS14	0.59	10.54	0.46	3.13e-23	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg02782426	chr3:40428986	ENTPD3	-0.39	-8.35	-0.38	9.75e-16	Renal cell carcinoma;
LUAD	cis	rs6942407	0.546	rs4728686	chr7:86814784	G/A	cg02420886	chr7:86849541	C7orf23	0.63	7.29	0.33	1.52e-12	Food allergy;
LUAD	trans	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs3849570	0.925	rs2873054	chr3:81888255	A/C	cg07356753	chr3:81810745	GBE1	-0.63	-11.16	-0.48	1.64e-25	Waist circumference;Body mass index;
LUAD	cis	rs910187	0.678	rs6122561	chr20:45813809	A/G	cg27589058	chr20:45804311	EYA2	-0.32	-7.22	-0.33	2.37e-12	Migraine;
LUAD	cis	rs10193935	0.901	rs222469	chr2:42640235	T/C	cg27598129	chr2:42591480	NA	-0.76	-9.84	-0.43	1.05e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs61990749	0.597	rs17106157	chr14:78146878	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.49	-6.51	-0.3	2.14e-10	Fibroblast growth factor basic levels;
LUAD	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.97	0.36	1.49e-14	Heart rate;
LUAD	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg05340658	chr4:99064831	C4orf37	0.51	8.14	0.37	4.6e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg06784218	chr1:46089804	CCDC17	0.5	11.02	0.47	5.24e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs870825	0.616	rs7680835	chr4:185652992	C/G	cg04058563	chr4:185651563	MLF1IP	-0.85	-13.61	-0.55	3.09e-35	Blood protein levels;
LUAD	cis	rs9503598	0.783	rs9503599	chr6:3451048	T/C	cg00476032	chr6:3446245	SLC22A23	0.37	8.05	0.36	8.41e-15	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	trans	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-8.83	-0.39	2.85e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.33	7.02	0.32	8.7e-12	Cardiac Troponin-T levels;
LUAD	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.62	-7.04	-0.32	7.84e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg27588902	chr6:42928151	GNMT	-0.37	-9.68	-0.43	3.83e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg21963583	chr11:68658836	MRPL21	0.65	11.45	0.49	1.3e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg12016809	chr21:47604291	C21orf56	0.45	7.49	0.34	4.18e-13	Testicular germ cell tumor;
LUAD	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg08847533	chr14:75593920	NEK9	0.42	7.12	0.33	4.76e-12	Height;
LUAD	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg06002616	chr8:101225028	SPAG1	0.4	8.09	0.37	6.23e-15	Atrioventricular conduction;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg24023618	chr6:114292459	HDAC2	0.42	6.79	0.31	3.91e-11	Diastolic blood pressure;
LUAD	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg20607798	chr8:58055168	NA	0.6	7.94	0.36	1.85e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg14186256	chr22:23484241	RTDR1	0.41	6.79	0.31	3.75e-11	Bone mineral density;
LUAD	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg07636037	chr3:49044803	WDR6	-0.48	-8.1	-0.37	5.83e-15	Menarche (age at onset);
LUAD	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg24818145	chr4:99064322	C4orf37	0.42	6.89	0.32	2.01e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.46	0.34	5.07e-13	Bipolar disorder;
LUAD	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs7633770	0.786	rs4683256	chr3:46683617	T/G	cg11219411	chr3:46661640	NA	0.58	12.86	0.53	3.49e-32	Coronary artery disease;
LUAD	cis	rs55788414	0.932	rs2873367	chr16:81184380	T/A	cg06400318	chr16:81190750	PKD1L2	-0.61	-7.91	-0.36	2.31e-14	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg07606381	chr6:8435919	SLC35B3	0.42	6.87	0.32	2.26e-11	Motion sickness;
LUAD	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg15704280	chr7:45808275	SEPT13	0.77	12.6	0.52	3.78e-31	Coronary artery disease;
LUAD	cis	rs7258465	0.896	rs8103660	chr19:18566395	T/C	cg11102782	chr19:18549136	ISYNA1	-0.34	-6.4	-0.3	4.18e-10	Breast cancer;
LUAD	cis	rs12618769	0.570	rs17032866	chr2:99132415	A/G	cg10123293	chr2:99228465	UNC50	0.47	8.47	0.38	4.2e-16	Bipolar disorder;
LUAD	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg18512352	chr11:47633146	NA	-0.57	-10.15	-0.44	8.41e-22	Subjective well-being;
LUAD	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg25985355	chr7:65971099	NA	-0.55	-6.74	-0.31	5.08e-11	Diabetic kidney disease;
LUAD	cis	rs7712401	0.601	rs246282	chr5:122225605	G/T	cg19077854	chr5:122220652	SNX24	0.35	6.53	0.3	1.95e-10	Mean platelet volume;
LUAD	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg12179176	chr11:130786555	SNX19	-0.62	-10.44	-0.45	7.44e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4692589	1.000	rs4519759	chr4:170933919	T/C	cg19918862	chr4:170955249	NA	0.29	6.92	0.32	1.73e-11	Anxiety disorder;
LUAD	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg01579765	chr21:45077557	HSF2BP	-0.59	-13.72	-0.55	1.07e-35	Mean corpuscular volume;
LUAD	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.74	-0.31	5.22e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22307029	chr19:49891270	CCDC155	0.64	9.25	0.41	1.16e-18	Multiple sclerosis;
LUAD	cis	rs4588572	0.643	rs1159929	chr5:77768820	A/G	cg11547950	chr5:77652471	NA	0.77	12.47	0.52	1.31e-30	Triglycerides;
LUAD	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg23029597	chr12:123009494	RSRC2	-0.59	-9.4	-0.42	3.59e-19	Body mass index;
LUAD	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.49	-9.77	-0.43	1.86e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg06740227	chr12:86229804	RASSF9	-0.39	-7.27	-0.33	1.7e-12	Major depressive disorder;
LUAD	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg13902645	chr11:5959945	NA	0.52	8.89	0.4	1.74e-17	DNA methylation (variation);
LUAD	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg17264618	chr3:40429014	ENTPD3	0.38	8.64	0.39	1.18e-16	Renal cell carcinoma;
LUAD	cis	rs7903847	0.596	rs7922512	chr10:99155685	C/A	cg20016023	chr10:99160130	RRP12	-0.31	-7.42	-0.34	6.64e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9473147	0.516	rs9395286	chr6:47575332	T/C	cg02130027	chr6:47444894	CD2AP	0.36	6.9	0.32	1.89e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs17102423	0.530	rs4902357	chr14:65542067	C/G	cg11161011	chr14:65562177	MAX	-0.44	-7.24	-0.33	2.18e-12	Obesity-related traits;
LUAD	trans	rs10411161	0.752	rs10404812	chr19:52400691	T/C	cg22319618	chr22:45562946	NUP50	-0.68	-9.6	-0.42	7.01e-20	Breast cancer;
LUAD	cis	rs35883536	0.514	rs4908062	chr1:101013211	T/C	cg09408571	chr1:101003634	GPR88	0.33	6.77	0.31	4.3e-11	Monocyte count;
LUAD	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg22681709	chr2:178499509	PDE11A	-0.53	-8.72	-0.39	6.28e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs559928	0.553	rs508326	chr11:64176029	C/T	cg05555928	chr11:63887634	MACROD1	0.45	7.85	0.36	3.53e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUAD	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg11494091	chr17:61959527	GH2	-0.73	-18.31	-0.66	1.49e-55	Prudent dietary pattern;
LUAD	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg26677194	chr12:130822605	PIWIL1	0.58	9.22	0.41	1.43e-18	Menopause (age at onset);
LUAD	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg00504896	chr12:9437009	LOC642846	-0.42	-6.56	-0.3	1.55e-10	Breast size;
LUAD	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg15181151	chr6:150070149	PCMT1	0.4	7.94	0.36	1.82e-14	Lung cancer;
LUAD	cis	rs2637266	1.000	rs2395389	chr10:78357701	C/T	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg18944383	chr4:111397179	ENPEP	-0.5	-9.15	-0.41	2.52e-18	Coronary artery disease;
LUAD	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg00310523	chr12:86230176	RASSF9	0.39	7.84	0.36	3.8e-14	Major depressive disorder;
LUAD	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.74	-12.53	-0.52	7.82e-31	Primary sclerosing cholangitis;
LUAD	trans	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg04565464	chr8:145669602	NFKBIL2	0.46	6.88	0.32	2.11e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg18200150	chr17:30822561	MYO1D	0.43	7.99	0.36	1.31e-14	Schizophrenia;
LUAD	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11644478	chr21:40555479	PSMG1	0.7	11.71	0.49	1.25e-27	Cognitive function;
LUAD	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg06784218	chr1:46089804	CCDC17	0.5	10.92	0.47	1.22e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9341808	0.718	rs2322631	chr6:80843956	A/C	cg08355045	chr6:80787529	NA	0.55	9.94	0.44	4.45e-21	Sitting height ratio;
LUAD	cis	rs9392556	0.600	rs2326408	chr6:4119516	A/G	cg10424681	chr6:4079350	C6orf201;C6orf146	0.28	7.08	0.33	6.23e-12	Blood metabolite levels;
LUAD	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg01475377	chr6:109611718	NA	-0.52	-10.07	-0.44	1.65e-21	Reticulocyte fraction of red cells;
LUAD	trans	rs970548	0.657	rs11239572	chr10:46088061	C/T	cg14222797	chr10:16859974	RSU1	0.58	6.67	0.31	8.12e-11	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg03732007	chr1:2071316	PRKCZ	0.35	7.09	0.33	5.53e-12	Height;
LUAD	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg07617317	chr6:118971624	C6orf204	-0.52	-7.77	-0.35	6.11e-14	Diastolic blood pressure;
LUAD	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg18252515	chr7:66147081	NA	-0.63	-6.89	-0.32	2.01e-11	Diabetic kidney disease;
LUAD	cis	rs6087990	0.806	rs4911257	chr20:31359574	T/C	cg13636640	chr20:31349939	DNMT3B	0.73	13.43	0.55	1.7e-34	Ulcerative colitis;
LUAD	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg14634687	chr17:47094252	IGF2BP1	0.27	6.83	0.32	2.89e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.01	10.95	0.47	9.38e-25	Initial pursuit acceleration;
LUAD	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg00101154	chr16:420108	MRPL28	-0.44	-7.6	-0.35	1.95e-13	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs4664308	1.000	rs56297666	chr2:160902023	G/C	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.62	-0.31	1.06e-10	Idiopathic membranous nephropathy;
LUAD	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg21709803	chr11:61594965	FADS2	-0.4	-7.34	-0.34	1.07e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.32	-6.87	-0.32	2.37e-11	Height;
LUAD	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg04944784	chr2:26401820	FAM59B	-0.87	-12.4	-0.52	2.54e-30	Gut microbiome composition (summer);
LUAD	cis	rs2731664	0.792	rs2731662	chr5:176872494	C/T	cg23176889	chr5:176863531	GRK6	0.68	12.8	0.53	6.31e-32	Intelligence (multi-trait analysis);
LUAD	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg02807482	chr3:125708958	NA	-0.57	-7.83	-0.36	3.95e-14	Blood pressure (smoking interaction);
LUAD	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.34	6.71	0.31	6.19e-11	Obesity-related traits;
LUAD	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg06618935	chr21:46677482	NA	-0.48	-9.78	-0.43	1.72e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00934597	chr7:893267	UNC84A	-0.53	-8.77	-0.39	4.37e-17	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.46	-0.38	4.38e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2274273	0.682	rs1201378	chr14:55493408	A/G	cg04306507	chr14:55594613	LGALS3	-0.34	-7.12	-0.33	4.79e-12	Protein biomarker;
LUAD	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg18854424	chr1:2615690	NA	-0.41	-8.95	-0.4	1.13e-17	Ulcerative colitis;
LUAD	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg24578937	chr1:2090814	PRKCZ	0.77	15.07	0.59	2.09e-41	Height;
LUAD	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg23254163	chr1:152506842	NA	0.24	6.62	0.31	1.12e-10	Hair morphology;
LUAD	cis	rs10899021	1.000	rs11236202	chr11:74376692	A/G	cg25880958	chr11:74394337	NA	-0.71	-8.43	-0.38	5.44e-16	Response to metformin (IC50);
LUAD	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg06618935	chr21:46677482	NA	-0.45	-8.57	-0.38	1.96e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg19413350	chr8:57351067	NA	-0.42	-6.37	-0.3	5.05e-10	Obesity-related traits;
LUAD	cis	rs1728785	0.901	rs1645934	chr16:68564490	T/A	cg02508848	chr16:68573721	ZFP90	-0.42	-6.59	-0.31	1.3100000000000001e-10	Ulcerative colitis;
LUAD	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg23018236	chr17:30244563	NA	-0.6	-7.97	-0.36	1.5e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg23752985	chr2:85803571	VAMP8	0.34	6.67	0.31	7.82e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg15181151	chr6:150070149	PCMT1	0.4	8.16	0.37	3.87e-15	Lung cancer;
LUAD	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg00745463	chr17:30367425	LRRC37B	0.81	9.48	0.42	1.85e-19	Hip circumference adjusted for BMI;
LUAD	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg06547715	chr2:218990976	CXCR2	0.29	6.78	0.31	4.03e-11	Colorectal cancer;
LUAD	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg11859384	chr17:80120422	CCDC57	-0.49	-8.95	-0.4	1.14e-17	Life satisfaction;
LUAD	cis	rs2455799	0.593	rs2470544	chr3:15727234	A/G	cg16303742	chr3:15540471	COLQ	-0.52	-9.75	-0.43	2.07e-20	Mean platelet volume;
LUAD	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg00280220	chr17:61926910	NA	0.37	7.06	0.32	6.83e-12	Prudent dietary pattern;
LUAD	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.48	0.3	2.54e-10	Cognitive test performance;
LUAD	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg10978503	chr1:24200527	CNR2	-0.45	-8.31	-0.37	1.3e-15	Immature fraction of reticulocytes;
LUAD	trans	rs8002861	0.665	rs2065926	chr13:44422371	A/G	cg12856521	chr11:46389249	DGKZ	-0.48	-8.37	-0.38	8.77e-16	Leprosy;
LUAD	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg26647111	chr11:31128758	NA	-0.46	-8.12	-0.37	5.06e-15	Bone mineral density (spine);
LUAD	cis	rs10979	1.000	rs9496681	chr6:143896964	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.28	-0.45	2.77e-22	Hypospadias;
LUAD	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg06199346	chr11:14280333	SPON1	0.35	7.43	0.34	6.25e-13	Mitochondrial DNA levels;
LUAD	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg15448220	chr1:150897856	SETDB1	0.47	8.04	0.36	9.4e-15	Tonsillectomy;
LUAD	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18876405	chr7:65276391	NA	0.45	7.11	0.33	4.89e-12	Aortic root size;
LUAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg23260525	chr10:116636907	FAM160B1	0.47	10.98	0.47	7.38e-25	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2425143	1.000	rs8124505	chr20:34307247	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.43	-0.34	6.01e-13	Blood protein levels;
LUAD	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg14558114	chr2:88469736	THNSL2	-0.7	-11.27	-0.48	6.14e-26	Response to metformin (IC50);
LUAD	cis	rs11771526	0.901	rs28709683	chr7:32301989	A/G	cg13207630	chr7:32358064	NA	0.6	7.32	0.34	1.27e-12	Body mass index;
LUAD	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg08742575	chr21:47604166	C21orf56	-0.56	-9.34	-0.41	5.76e-19	Testicular germ cell tumor;
LUAD	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg16479474	chr6:28041457	NA	0.45	7.7	0.35	9.83e-14	Depression;
LUAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg27454412	chr7:1067447	C7orf50	0.4	6.86	0.32	2.4e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg08601574	chr20:25228251	PYGB	-0.44	-8.12	-0.37	5.33e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-6.89	-0.32	2.03e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg06627628	chr2:24431161	ITSN2	0.4	6.77	0.31	4.44e-11	Asthma;
LUAD	cis	rs11229555	0.645	rs12295551	chr11:58188983	T/C	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg09904177	chr6:26538194	HMGN4	0.43	7.26	0.33	1.87e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg11189052	chr15:85197271	WDR73	0.6	7.59	0.35	2.08e-13	Schizophrenia;
LUAD	cis	rs7493	0.950	rs11981299	chr7:95029701	T/A	cg21856205	chr7:94953877	PON1	-0.54	-7.45	-0.34	5.14e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg12599982	chr1:44399894	ARTN	-0.33	-6.7	-0.31	6.5500000000000006e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg06784218	chr1:46089804	CCDC17	-0.55	-11.83	-0.5	4.29e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.19	-0.33	3.03e-12	Total cholesterol levels;
LUAD	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg25985355	chr7:65971099	NA	-0.51	-6.41	-0.3	3.8e-10	Diabetic kidney disease;
LUAD	cis	rs2455826	0.521	rs6442551	chr3:15810605	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-6.48	-0.3	2.54e-10	Inflammatory skin disease;
LUAD	trans	rs9467711	1.000	rs9467704	chr6:26319486	A/G	cg26587870	chr6:27730563	NA	0.57	6.6	0.31	1.22e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1395	1.000	rs1275522	chr2:27426878	C/T	cg23587288	chr2:27483067	SLC30A3	0.39	8.01	0.36	1.11e-14	Blood metabolite levels;
LUAD	cis	rs11811982	0.793	rs75679901	chr1:227512080	G/A	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg09085632	chr11:111637200	PPP2R1B	0.64	9.9	0.43	6.6e-21	Primary sclerosing cholangitis;
LUAD	cis	rs7156960	1.000	rs10143886	chr14:76710551	C/T	cg13981132	chr14:76734493	NA	-0.41	-6.48	-0.3	2.56e-10	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	8.24	0.37	2.18e-15	Breast cancer;
LUAD	cis	rs240764	0.604	rs705583	chr6:101261408	C/A	cg09795085	chr6:101329169	ASCC3	0.48	8.45	0.38	4.79e-16	Neuroticism;
LUAD	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg18404041	chr3:52824283	ITIH1	0.54	9.34	0.41	5.42e-19	Schizophrenia;
LUAD	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg07870213	chr5:140052090	DND1	-0.64	-9.93	-0.43	5.04e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg13511324	chr14:104056883	C14orf153	0.26	6.4	0.3	4.14e-10	Coronary artery disease;
LUAD	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs12765878	0.967	rs10883941	chr10:105650782	C/T	cg11005552	chr10:105648138	OBFC1	0.44	8.34	0.38	1.04e-15	Coronary artery disease;
LUAD	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.74	-10.38	-0.45	1.19e-22	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg24562669	chr7:97807699	LMTK2	0.3	7.03	0.32	8.37e-12	Breast cancer;
LUAD	cis	rs7779181	0.812	rs7779130	chr7:32346958	G/T	cg27532318	chr7:32358331	NA	0.44	6.88	0.32	2.19e-11	Body mass index;
LUAD	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.79	-0.31	3.82e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg06558623	chr16:89946397	TCF25	1.14	10.3	0.45	2.39e-22	Skin colour saturation;
LUAD	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.19	-0.33	3.02e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg00071950	chr4:10020882	SLC2A9	0.47	6.94	0.32	1.52e-11	Gout;Urate levels;Serum uric acid levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg21815083	chr11:69458002	CCND1	-0.71	-6.75	-0.31	4.78e-11	Type 2 diabetes;
LUAD	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg26384229	chr12:38710491	ALG10B	0.47	7.7	0.35	9.7e-14	Morning vs. evening chronotype;
LUAD	cis	rs7192380	0.965	rs7205551	chr16:69605968	G/A	cg00738113	chr16:70207722	CLEC18C	-0.33	-6.75	-0.31	4.84e-11	Sjögren's syndrome;
LUAD	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg04414720	chr1:150670196	GOLPH3L	0.74	13.85	0.56	3.17e-36	Tonsillectomy;
LUAD	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg12365402	chr11:9010492	NRIP3	-0.41	-7.09	-0.33	5.61e-12	Hematocrit;
LUAD	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.36	-7.44	-0.34	5.84e-13	Hemoglobin concentration;
LUAD	cis	rs10242455	0.702	rs58348977	chr7:99188014	G/A	cg18809830	chr7:99032528	PTCD1	-1.21	-8.69	-0.39	8.22e-17	Blood metabolite levels;
LUAD	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg27170947	chr2:26402098	FAM59B	-0.82	-11.49	-0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	8.35	0.38	1.02e-15	Platelet count;
LUAD	cis	rs9902453	0.868	rs9890075	chr17:28470464	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.85	0.43	9.36e-21	Coffee consumption (cups per day);
LUAD	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.3	-0.37	1.38e-15	Height;
LUAD	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.85e-12	Aortic root size;
LUAD	cis	rs7759001	0.857	rs4579353	chr6:27372490	A/G	cg18711553	chr6:27366782	ZNF391	0.39	6.39	0.3	4.42e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs9486719	1.000	rs12190507	chr6:96898265	T/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.17	-0.44	6.77e-22	Migraine;Coronary artery disease;
LUAD	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg17644776	chr2:200775616	C2orf69	-0.56	-7.38	-0.34	8.51e-13	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg08888203	chr3:10149979	C3orf24	0.64	9.85	0.43	9.69e-21	Alzheimer's disease;
LUAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.85	16.22	0.62	2.42e-46	Lymphocyte counts;
LUAD	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg01579765	chr21:45077557	HSF2BP	-0.59	-13.61	-0.55	3.1e-35	Mean corpuscular volume;
LUAD	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg07527032	chr15:84868466	LOC388152	0.44	6.65	0.31	9.36e-11	Schizophrenia;
LUAD	cis	rs7617773	0.709	rs4404473	chr3:48353626	A/G	cg11946769	chr3:48343235	NME6	0.43	6.55	0.3	1.72e-10	Coronary artery disease;
LUAD	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg01528321	chr10:82214614	TSPAN14	0.46	7.29	0.33	1.5e-12	Post bronchodilator FEV1;
LUAD	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg01689657	chr7:91764605	CYP51A1	-0.35	-8.68	-0.39	8.39e-17	Breast cancer;
LUAD	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg05234568	chr11:5960015	NA	-0.5	-9.0	-0.4	7.99e-18	DNA methylation (variation);
LUAD	cis	rs9487051	0.735	rs1260596	chr6:109519847	T/C	cg21918786	chr6:109611834	NA	-0.41	-7.53	-0.34	3.1e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs1497406	0.744	rs12057222	chr1:16508534	A/G	cg02998240	chr1:16508668	NA	-0.24	-7.14	-0.33	4.01e-12	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs908922	0.676	rs2146120	chr1:152504200	A/T	cg23254163	chr1:152506842	NA	0.25	6.58	0.3	1.36e-10	Hair morphology;
LUAD	cis	rs75920871	1.000	rs1473324	chr11:116821918	T/G	cg04087571	chr11:116723030	SIK3	-0.32	-6.5	-0.3	2.33e-10	Subjective well-being;
LUAD	cis	rs16958440	0.867	rs79231363	chr18:44665087	T/C	cg17192377	chr18:44677553	HDHD2	0.84	7.76	0.35	6.64e-14	Sitting height ratio;
LUAD	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg13560548	chr3:10150139	C3orf24	-0.45	-7.41	-0.34	6.79e-13	Alzheimer's disease;
LUAD	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.7	0.39	7.29e-17	Menopause (age at onset);
LUAD	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg02931644	chr1:25747376	RHCE	-0.41	-8.5	-0.38	3.27e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg13736514	chr6:26305472	NA	-0.68	-12.56	-0.52	5.5e-31	Educational attainment;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12504415	chr17:74722752	JMJD6;C17orf95	-0.56	-6.84	-0.32	2.82e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg22963979	chr7:1858916	MAD1L1	0.49	8.51	0.38	3.02e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	7.97	0.36	1.51e-14	Parkinson's disease;
LUAD	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg22920501	chr2:26401640	FAM59B	-0.87	-12.21	-0.51	1.36e-29	Gut microbiome composition (summer);
LUAD	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg22117172	chr7:91764530	CYP51A1	0.33	7.29	0.33	1.5e-12	Breast cancer;
LUAD	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03934478	chr11:495069	RNH1	0.78	9.24	0.41	1.24e-18	Body mass index;
LUAD	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg01579765	chr21:45077557	HSF2BP	-0.66	-15.26	-0.6	3.44e-42	Mean corpuscular volume;
LUAD	trans	rs11039798	0.764	rs76882342	chr11:48939091	A/T	cg15704280	chr7:45808275	SEPT13	0.67	7.8	0.35	4.95e-14	Axial length;
LUAD	cis	rs6445967	0.530	rs12637255	chr3:58348228	A/G	cg23715586	chr3:58305044	RPP14	0.4	6.36	0.3	5.3e-10	Platelet count;
LUAD	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg12501888	chr15:85177176	SCAND2	-0.49	-7.31	-0.33	1.34e-12	P wave terminal force;
LUAD	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg25985355	chr7:65971099	NA	0.56	6.97	0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg13722127	chr7:150037890	RARRES2	0.42	6.88	0.32	2.18e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg09035930	chr12:129282057	SLC15A4	0.75	18.06	0.66	1.86e-54	Systemic lupus erythematosus;
LUAD	cis	rs13082711	0.554	rs9310843	chr3:27371260	A/G	cg02860705	chr3:27208620	NA	0.56	9.46	0.42	2.11e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs4706831	0.647	rs9350847	chr6:80889017	C/T	cg08355045	chr6:80787529	NA	0.48	8.19	0.37	3.18e-15	Joint mobility (Beighton score);
LUAD	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg16325326	chr1:53192061	ZYG11B	0.61	10.56	0.46	2.72e-23	Monocyte count;
LUAD	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg23758822	chr17:41437982	NA	1.01	21.22	0.72	1.4e-68	Menopause (age at onset);
LUAD	cis	rs752010	0.714	rs10789403	chr1:42085869	G/A	cg06885757	chr1:42089581	HIVEP3	0.47	10.8	0.47	3.4e-24	Lupus nephritis in systemic lupus erythematosus;
LUAD	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg10053473	chr17:62856997	LRRC37A3	0.69	11.2	0.48	1.15e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg08422745	chr4:174089978	GALNT7	-0.95	-18.39	-0.67	6.21e-56	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg22105103	chr4:187893119	NA	0.54	11.49	0.49	8.62e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg21220214	chr8:57350948	NA	-0.62	-8.63	-0.39	1.24e-16	Obesity-related traits;
LUAD	cis	rs300774	0.925	rs447775	chr2:106413	T/A	cg21211680	chr2:198530	NA	-0.46	-6.71	-0.31	6.34e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg14343924	chr8:8086146	FLJ10661	0.43	7.05	0.32	7.56e-12	Mood instability;
LUAD	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.55e-11	Crohn's disease;
LUAD	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg08213375	chr14:104286397	PPP1R13B	0.28	7.23	0.33	2.31e-12	Schizophrenia;
LUAD	trans	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg13698153	chr12:118541722	VSIG10	-0.43	-6.74	-0.31	5.09e-11	Vitiligo;
LUAD	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.39	0.42	3.8e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs629535	0.814	rs62513371	chr8:70077779	T/A	cg21567404	chr3:27674614	NA	-0.99	-18.14	-0.66	8.52e-55	Dupuytren's disease;
LUAD	cis	rs13064411	0.696	rs6786974	chr3:113190149	T/A	cg10517650	chr3:113235015	CCDC52	-0.52	-8.27	-0.37	1.8e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg02018176	chr4:1364513	KIAA1530	0.39	6.37	0.3	5.06e-10	Obesity-related traits;
LUAD	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg15017067	chr4:17643749	FAM184B	0.36	7.26	0.33	1.89e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9323205	0.953	rs61144314	chr14:51620556	G/A	cg23942311	chr14:51606299	NA	-0.61	-9.96	-0.44	4.03e-21	Cancer;
LUAD	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg26343298	chr8:95960752	TP53INP1	0.38	7.8	0.35	4.87e-14	Type 2 diabetes;
LUAD	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg02158880	chr13:53174818	NA	0.48	8.31	0.37	1.28e-15	Lewy body disease;
LUAD	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg18230493	chr5:56204884	C5orf35	-0.7	-11.11	-0.48	2.55e-25	Initial pursuit acceleration;
LUAD	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg11663144	chr21:46675770	NA	-0.62	-12.41	-0.52	2.26e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.42	0.38	5.87e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg00631329	chr6:26305371	NA	-0.69	-13.7	-0.55	1.35e-35	Educational attainment;
LUAD	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.45	-9.31	-0.41	6.94e-19	Total body bone mineral density;
LUAD	cis	rs9796	0.689	rs9888718	chr15:41446254	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.43	-8.01	-0.36	1.09e-14	Menopause (age at onset);
LUAD	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg23758822	chr17:41437982	NA	1.0	20.52	0.71	1.84e-65	Menopause (age at onset);
LUAD	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg04398451	chr17:18023971	MYO15A	0.7	12.47	0.52	1.34e-30	Total body bone mineral density;
LUAD	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.4	-7.21	-0.33	2.65e-12	Tonsillectomy;
LUAD	cis	rs9287719	0.649	rs6732429	chr2:10758972	C/T	cg02196655	chr2:10830764	NOL10	0.36	6.45	0.3	3.12e-10	Prostate cancer;
LUAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg10295955	chr4:187884368	NA	-1.15	-29.9	-0.82	2.27e-106	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9393777	0.778	rs13219354	chr6:27185664	T/C	cg06606381	chr12:133084897	FBRSL1	-1.01	-10.15	-0.44	8.59e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs938554	0.736	rs4475146	chr4:9946656	C/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-7.98	-0.36	1.43e-14	Blood metabolite levels;
LUAD	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg14926445	chr8:58193284	C8orf71	-0.48	-7.0	-0.32	1.03e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.3	-0.33	1.47e-12	Reticulocyte count;
LUAD	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	7.9	0.36	2.39e-14	Menopause (age at onset);
LUAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.29	0.41	8.04e-19	Alzheimer's disease;
LUAD	cis	rs6484504	0.576	rs158139	chr11:31216076	C/T	cg06552810	chr11:31128660	NA	-0.32	-6.38	-0.3	4.77e-10	Red blood cell count;
LUAD	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg20290983	chr6:43655470	MRPS18A	1.02	25.53	0.78	1.13e-87	IgG glycosylation;
LUAD	cis	rs3096299	0.838	rs3096319	chr16:89402634	C/G	cg06640241	chr16:89574553	SPG7	0.41	6.64	0.31	9.79e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg19761014	chr17:28927070	LRRC37B2	0.86	8.32	0.38	1.22e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06178786	chr10:49514546	NA	-0.68	-6.87	-0.32	2.25e-11	Type 2 diabetes;
LUAD	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg13319975	chr6:146136371	FBXO30	0.66	11.47	0.49	1.1e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs55788414	0.932	rs12716908	chr16:81186245	T/C	cg06400318	chr16:81190750	PKD1L2	-0.71	-8.95	-0.4	1.15e-17	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.7	-0.43	3.13e-20	Bone mineral density;
LUAD	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.18	-0.37	3.32e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs7072216	0.881	rs10883084	chr10:100151189	T/C	cg26618903	chr10:100175079	PYROXD2	-0.3	-6.48	-0.3	2.53e-10	Metabolite levels;
LUAD	cis	rs4594175	0.926	rs4349056	chr14:51625819	A/G	cg23942311	chr14:51606299	NA	0.65	11.69	0.49	1.55e-27	Cancer;
LUAD	cis	rs4285028	0.699	rs1574115	chr3:121469225	T/C	cg11130432	chr3:121712080	ILDR1	-0.54	-7.38	-0.34	8.64e-13	Multiple sclerosis;
LUAD	cis	rs807669	0.505	rs8142503	chr22:19166717	G/T	cg02655711	chr22:19163373	SLC25A1	0.58	10.91	0.47	1.43e-24	Metabolite levels;
LUAD	trans	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg13565492	chr6:43139072	SRF	-0.75	-10.11	-0.44	1.18e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg11693508	chr17:37793320	STARD3	0.49	7.2	0.33	2.75e-12	Neuroticism;
LUAD	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg04546413	chr19:29218101	NA	0.58	7.52	0.34	3.33e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg19163074	chr7:65112434	INTS4L2	0.44	6.77	0.31	4.45e-11	Aortic root size;
LUAD	trans	rs208520	1.000	rs208529	chr6:66957549	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-13.49	-0.55	9.7e-35	Exhaled nitric oxide output;
LUAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg21724239	chr8:58056113	NA	0.73	9.61	0.42	6.5e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg00933542	chr6:150070202	PCMT1	0.43	9.18	0.41	1.91e-18	Lung cancer;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg24294857	chr1:20812821	CAMK2N1	-0.44	-7.21	-0.33	2.52e-12	Vertical cup-disc ratio;
LUAD	cis	rs72949976	0.584	rs4673729	chr2:214023810	A/G	cg08319019	chr2:214017104	IKZF2	0.58	9.03	0.4	6.25e-18	Lung cancer;Squamous cell lung carcinoma;
LUAD	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg04703951	chr17:43578652	NA	-0.52	-7.52	-0.34	3.22e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7582720	1.000	rs114123510	chr2:203831212	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg11663144	chr21:46675770	NA	-0.62	-12.41	-0.52	2.26e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg06784218	chr1:46089804	CCDC17	0.61	13.69	0.55	1.47e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1595825	0.891	rs7583917	chr2:198576950	A/G	cg10547527	chr2:198650123	BOLL	-0.54	-7.9	-0.36	2.5e-14	Ulcerative colitis;
LUAD	cis	rs1524976	1.000	rs9817894	chr3:65465760	T/A	cg16238336	chr3:65465873	MAGI1	-0.63	-7.23	-0.33	2.33e-12	PR interval;
LUAD	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg14829155	chr15:31115871	NA	-0.59	-9.76	-0.43	2.02e-20	Huntington's disease progression;
LUAD	cis	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg06532163	chr17:45867833	NA	0.44	6.69	0.31	7.12e-11	IgG glycosylation;
LUAD	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg00255919	chr5:131827918	IRF1	0.49	11.85	0.5	3.74e-28	Asthma (sex interaction);
LUAD	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg06713675	chr4:122721982	EXOSC9	-0.8	-16.14	-0.62	5.29e-46	Type 2 diabetes;
LUAD	cis	rs174601	0.861	rs174584	chr11:61610750	G/A	cg19610905	chr11:61596333	FADS2	-0.56	-9.57	-0.42	8.94e-20	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs2806561	0.929	rs2903545	chr1:23541108	C/T	cg12483005	chr1:23474871	LUZP1	-0.38	-6.39	-0.3	4.28e-10	Height;
LUAD	cis	rs73206853	0.841	rs57726856	chr12:110961123	T/C	cg12870014	chr12:110450643	ANKRD13A	0.61	6.97	0.32	1.2e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs1461503	0.966	rs7944630	chr11:122838844	G/A	cg27398637	chr11:122830231	C11orf63	-0.36	-7.01	-0.32	9.34e-12	Menarche (age at onset);
LUAD	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg08219700	chr8:58056026	NA	0.57	7.91	0.36	2.28e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs9341808	0.652	rs2505940	chr6:80851191	T/C	cg08355045	chr6:80787529	NA	0.45	8.0	0.36	1.24e-14	Sitting height ratio;
LUAD	cis	rs3774830	0.714	rs7685158	chr4:5462776	C/T	cg26943120	chr4:5472116	STK32B	0.38	7.61	0.35	1.83e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11696501	0.694	rs4812943	chr20:44260966	G/C	cg11783356	chr20:44313418	WFDC10B	-0.43	-7.51	-0.34	3.5e-13	Brain structure;
LUAD	cis	rs7599312	0.534	rs10180824	chr2:213407975	G/A	cg16329650	chr2:213403929	ERBB4	0.61	10.88	0.47	1.72e-24	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1609391	0.543	rs1347209	chr3:136626697	G/T	cg15507776	chr3:136538369	TMEM22	0.5	8.92	0.4	1.4e-17	Neuroticism;
LUAD	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg25767906	chr1:53392781	SCP2	-0.36	-6.81	-0.31	3.32e-11	Monocyte count;
LUAD	cis	rs4730250	0.707	rs257373	chr7:106798290	G/A	cg02696742	chr7:106810147	HBP1	-0.83	-11.03	-0.47	4.82e-25	Osteoarthritis;
LUAD	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.76	0.46	5.11e-24	Smoking behavior;
LUAD	cis	rs6138458	0.620	rs2151462	chr20:24911823	T/C	cg06937882	chr20:24974362	C20orf3	-0.33	-6.43	-0.3	3.52e-10	Blood protein levels;
LUAD	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg05754148	chr16:3507555	NAT15	0.43	6.44	0.3	3.26e-10	Body mass index (adult);
LUAD	cis	rs12200560	0.505	rs211175	chr6:97073320	C/T	cg06623918	chr6:96969491	KIAA0776	0.49	7.64	0.35	1.51e-13	Coronary heart disease;
LUAD	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	7.24	0.33	2.2e-12	Menopause (age at onset);
LUAD	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg11502198	chr6:26597334	ABT1	0.54	9.14	0.41	2.56e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.25	-0.33	1.95e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	trans	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.58	-9.43	-0.42	2.73e-19	Mean corpuscular volume;
LUAD	cis	rs35995292	0.553	rs2392605	chr7:38924670	T/C	cg19327137	chr7:38886074	VPS41	0.72	15.13	0.59	1.16e-41	Subjective well-being (multi-trait analysis);
LUAD	cis	rs9549328	0.614	rs34306822	chr13:113616499	G/A	cg17524180	chr13:113633600	MCF2L	0.3	6.45	0.3	3.1e-10	Systolic blood pressure;
LUAD	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg06064525	chr11:970664	AP2A2	-0.53	-10.75	-0.46	5.28e-24	Alzheimer's disease (late onset);
LUAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg23283495	chr1:209979779	IRF6	0.72	11.56	0.49	4.61e-27	Cleft lip with or without cleft palate;
LUAD	cis	rs739496	0.527	rs10774639	chr12:112258445	G/A	cg10833066	chr12:111807467	FAM109A	0.42	6.79	0.31	3.83e-11	Platelet count;
LUAD	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg26384229	chr12:38710491	ALG10B	0.45	7.35	0.34	1.03e-12	Bladder cancer;
LUAD	cis	rs2971970	0.519	rs2346272	chr7:133654830	T/C	cg03336402	chr7:133662267	EXOC4	-0.43	-7.87	-0.36	2.93e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg10053473	chr17:62856997	LRRC37A3	0.79	11.22	0.48	9.32e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2692947	0.537	rs11164049	chr2:96345518	C/T	cg23100626	chr2:96804247	ASTL	0.32	7.58	0.35	2.26e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg11859384	chr17:80120422	CCDC57	0.52	9.32	0.41	6.57e-19	Life satisfaction;
LUAD	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg26384229	chr12:38710491	ALG10B	0.49	7.93	0.36	1.93e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg16325326	chr1:53192061	ZYG11B	-0.61	-10.92	-0.47	1.24e-24	Monocyte count;
LUAD	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg13385794	chr1:248469461	NA	0.26	7.0	0.32	1.01e-11	Common traits (Other);
LUAD	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg07507251	chr3:52567010	NT5DC2	0.34	6.59	0.31	1.27e-10	Bipolar disorder;
LUAD	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26314531	chr2:26401878	FAM59B	-0.56	-7.77	-0.35	5.87e-14	Gut microbiome composition (summer);
LUAD	cis	rs9341808	0.791	rs1324122	chr6:80946061	G/A	cg08355045	chr6:80787529	NA	0.59	10.64	0.46	1.35e-23	Sitting height ratio;
LUAD	cis	rs220324	0.688	rs915840	chr21:43560871	T/C	cg08841829	chr21:43638893	ABCG1	-0.48	-6.5	-0.3	2.31e-10	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.16	0.37	3.75e-15	Breast cancer;
LUAD	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg03467027	chr4:99064603	C4orf37	0.4	6.54	0.3	1.74e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg09658497	chr7:2847517	GNA12	-0.41	-6.73	-0.31	5.59e-11	Height;
LUAD	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg10876282	chr6:28092338	ZSCAN16	0.47	7.22	0.33	2.46e-12	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.36e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.88	-0.32	2.23e-11	Diabetic kidney disease;
LUAD	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg03690763	chr11:133734501	NA	0.32	7.01	0.32	9.71e-12	Childhood ear infection;
LUAD	trans	rs8002861	0.846	rs12869521	chr13:44478346	A/G	cg17145862	chr1:211918768	LPGAT1	-0.67	-13.96	-0.56	1.08e-36	Leprosy;
LUAD	cis	rs9462027	0.628	rs2038839	chr6:34777791	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.84	-0.39	2.6e-17	Systemic lupus erythematosus;
LUAD	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2932538	0.922	rs12758377	chr1:113137221	C/A	cg22162597	chr1:113214053	CAPZA1	0.46	6.89	0.32	2.01e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs7773004	0.936	rs6917995	chr6:26327814	T/C	cg13736514	chr6:26305472	NA	-0.49	-8.21	-0.37	2.67e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg05313129	chr8:58192883	C8orf71	-0.54	-6.44	-0.3	3.23e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg22442454	chr1:209979470	IRF6	0.53	6.37	0.3	4.94e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs28595532	0.920	rs17323877	chr4:119671188	A/G	cg02775129	chr4:119771670	NA	-0.87	-7.38	-0.34	8.19e-13	Cannabis dependence symptom count;
LUAD	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg21153622	chr11:89784906	NA	-0.34	-6.64	-0.31	9.5e-11	Coronary artery disease;
LUAD	trans	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg19163074	chr7:65112434	INTS4L2	0.42	6.43	0.3	3.38e-10	Aortic root size;
LUAD	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg17633681	chr16:88106987	BANP	0.4	6.94	0.32	1.48e-11	Menopause (age at onset);
LUAD	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21582582	chr3:182698605	DCUN1D1	0.59	10.06	0.44	1.75e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.65	-0.35	1.37e-13	Monocyte count;
LUAD	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg00784671	chr22:46762841	CELSR1	-0.43	-6.42	-0.3	3.7e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg04842962	chr6:43655489	MRPS18A	1.06	27.09	0.8	1.9e-94	IgG glycosylation;
LUAD	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05665937	chr4:1216051	CTBP1	0.43	6.43	0.3	3.55e-10	Longevity;
LUAD	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2901656	1.000	rs2901656	chr1:172434812	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.39	7.64	0.35	1.44e-13	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.56	-8.73	-0.39	5.92e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.97	0.47	8.47e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs427394	0.664	rs274701	chr5:6728707	C/A	cg10857441	chr5:6722123	POLS	-0.59	-11.89	-0.5	2.62e-28	Menopause (age at onset);
LUAD	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.58	0.35	2.21e-13	Menopause (age at onset);
LUAD	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg00857998	chr1:205179979	DSTYK	0.42	6.9	0.32	1.89e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs6495367	0.898	rs2049176	chr15:79392548	A/C	cg17916960	chr15:79447300	NA	0.35	6.47	0.3	2.74e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg03714773	chr7:91764589	CYP51A1	0.3	6.9	0.32	1.86e-11	Breast cancer;
LUAD	cis	rs6424115	0.867	rs4649119	chr1:24171543	C/G	cg10978503	chr1:24200527	CNR2	-0.57	-12.02	-0.5	8.04e-29	Immature fraction of reticulocytes;
LUAD	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.44	0.57	1.08e-38	Schizophrenia;
LUAD	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg13319975	chr6:146136371	FBXO30	-0.64	-10.92	-0.47	1.25e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3772130	0.961	rs34667636	chr3:121353291	G/A	cg20356878	chr3:121714668	ILDR1	0.47	7.29	0.33	1.52e-12	Cognitive performance;
LUAD	trans	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg06606381	chr12:133084897	FBRSL1	-0.97	-9.42	-0.42	2.86e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.49	-7.79	-0.35	5.41e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg13918804	chr1:2043761	PRKCZ	0.41	6.92	0.32	1.72e-11	Height;
LUAD	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg04414720	chr1:150670196	GOLPH3L	0.72	13.36	0.54	3.28e-34	Tonsillectomy;
LUAD	cis	rs738322	0.555	rs2284063	chr22:38544298	C/T	cg25457927	chr22:38595422	NA	0.57	13.9	0.56	1.84e-36	Cutaneous nevi;
LUAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg16606324	chr3:10149918	C3orf24	0.67	9.78	0.43	1.69e-20	Alzheimer's disease;
LUAD	cis	rs300774	0.925	rs300714	chr2:138106	G/A	cg21211680	chr2:198530	NA	-0.46	-7.23	-0.33	2.28e-12	Suicide attempts in bipolar disorder;
LUAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg20276088	chr3:133502917	NA	-0.42	-7.5	-0.34	3.74e-13	Iron status biomarkers;
LUAD	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg16479474	chr6:28041457	NA	0.38	6.57	0.3	1.51e-10	Parkinson's disease;
LUAD	cis	rs2625529	0.701	rs2306490	chr15:72227837	A/G	cg16672083	chr15:72433130	SENP8	-0.76	-12.46	-0.52	1.44e-30	Red blood cell count;
LUAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.53	-7.22	-0.33	2.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2455799	1.000	rs1348980	chr3:15828932	A/C	cg16303742	chr3:15540471	COLQ	-0.39	-6.7	-0.31	6.6e-11	Mean platelet volume;
LUAD	trans	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg04775059	chr7:64541387	NA	0.52	6.89	0.32	2.04e-11	Aortic root size;
LUAD	cis	rs877529	0.605	rs139394	chr22:39538214	A/C	cg18708252	chr22:39545030	CBX7	-0.31	-6.52	-0.3	2.02e-10	Multiple myeloma;
LUAD	cis	rs12711979	0.509	rs10181286	chr2:3824567	G/A	cg17052675	chr2:3827356	NA	-0.84	-19.39	-0.69	2.24e-60	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg20203395	chr5:56204925	C5orf35	-0.83	-11.92	-0.5	1.95e-28	Initial pursuit acceleration;
LUAD	cis	rs1451375	0.698	rs11238226	chr7:50645827	A/G	cg18232548	chr7:50535776	DDC	0.51	8.37	0.38	8.71e-16	Malaria;
LUAD	cis	rs2455799	1.000	rs12691219	chr3:15881120	A/G	cg16303742	chr3:15540471	COLQ	-0.37	-6.43	-0.3	3.46e-10	Mean platelet volume;
LUAD	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg06784218	chr1:46089804	CCDC17	0.6	13.4	0.55	2.3e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg08888203	chr3:10149979	C3orf24	0.73	10.95	0.47	1.01e-24	Alzheimer's disease;
LUAD	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg15147215	chr3:52552868	STAB1	-0.37	-6.85	-0.32	2.69e-11	Electroencephalogram traits;
LUAD	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg05887092	chr17:76393375	PGS1	0.41	7.28	0.33	1.65e-12	HDL cholesterol levels;
LUAD	cis	rs7582720	1.000	rs72932772	chr2:203682304	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	9.52	0.42	1.32e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg19717773	chr7:2847554	GNA12	-0.56	-9.38	-0.42	3.98e-19	Height;
LUAD	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg03388025	chr16:89894329	SPIRE2	0.5	13.04	0.54	6.82e-33	Vitiligo;
LUAD	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg05340658	chr4:99064831	C4orf37	-0.46	-7.62	-0.35	1.63e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg12564285	chr5:131593104	PDLIM4	-0.39	-6.7	-0.31	6.68e-11	Breast cancer;
LUAD	cis	rs6684428	1.000	rs58538058	chr1:56370474	G/A	cg11651538	chr1:56320950	NA	-0.4	-6.39	-0.3	4.39e-10	Airflow obstruction;
LUAD	cis	rs6062509	0.965	rs2315007	chr20:62343845	T/C	cg01176363	chr20:62369445	LIME1	-0.48	-7.78	-0.35	5.67e-14	Prostate cancer;
LUAD	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg25233709	chr10:116636983	FAM160B1	0.4	7.75	0.35	7.01e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg15992532	chr8:142229932	SLC45A4	0.48	8.46	0.38	4.5e-16	Immature fraction of reticulocytes;
LUAD	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.64	11.92	0.5	1.86e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	9.18	0.41	1.93e-18	Tonsillectomy;
LUAD	cis	rs123509	0.913	rs339686	chr3:42769688	T/C	cg10144569	chr3:42726640	KBTBD5	0.49	7.72	0.35	8.54e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg08859206	chr1:53392774	SCP2	-0.56	-10.28	-0.45	2.71e-22	Monocyte count;
LUAD	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	8.03e-16	Body mass index;
LUAD	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-8.53	-0.38	2.62e-16	Monocyte percentage of white cells;
LUAD	cis	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.76	-0.31	4.53e-11	Neuroticism;
LUAD	cis	rs231513	0.911	rs231521	chr17:41955158	A/G	cg26893861	chr17:41843967	DUSP3	-0.67	-7.61	-0.35	1.76e-13	Cognitive function;
LUAD	cis	rs3859192	0.539	rs2305481	chr17:38138624	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.71	15.24	0.6	4.1e-42	White blood cell count;
LUAD	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg07153921	chr17:41440717	NA	-0.41	-7.03	-0.32	8.53e-12	Menopause (age at onset);
LUAD	cis	rs9863	0.828	rs56041971	chr12:124480866	G/A	cg17723958	chr12:124429295	CCDC92	-0.41	-6.75	-0.31	4.74e-11	White blood cell count;
LUAD	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg26384229	chr12:38710491	ALG10B	-0.47	-7.99	-0.36	1.26e-14	Morning vs. evening chronotype;
LUAD	cis	rs2235649	0.663	rs6600167	chr16:1848912	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-6.73	-0.31	5.59e-11	Blood metabolite levels;
LUAD	trans	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg07817883	chr1:32538562	TMEM39B	-0.52	-7.15	-0.33	3.94e-12	Monocyte percentage of white cells;
LUAD	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10802521	chr3:52805072	NEK4	0.55	9.74	0.43	2.33e-20	Electroencephalogram traits;
LUAD	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.8	0.47	3.44e-24	Smoking behavior;
LUAD	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg16205897	chr5:131564050	P4HA2	-0.35	-7.68	-0.35	1.13e-13	Acylcarnitine levels;
LUAD	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg16325326	chr1:53192061	ZYG11B	0.68	12.52	0.52	8.16e-31	Monocyte count;
LUAD	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg04025307	chr7:1156635	C7orf50	0.66	7.49	0.34	4.17e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3540	0.960	rs60825716	chr15:90958053	G/A	cg10434728	chr15:90938212	IQGAP1	0.35	6.41	0.3	3.95e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg18944383	chr4:111397179	ENPEP	0.38	6.85	0.32	2.61e-11	Coronary artery disease;
LUAD	cis	rs11971779	0.523	rs10234578	chr7:139037988	T/C	cg23387468	chr7:139079360	LUC7L2	0.28	6.49	0.3	2.47e-10	Diisocyanate-induced asthma;
LUAD	cis	rs6881634	0.501	rs3952231	chr5:77739827	C/G	cg11547950	chr5:77652471	NA	0.35	6.59	0.31	1.3100000000000001e-10	Hippocampal atrophy;
LUAD	cis	rs8014204	0.836	rs8021280	chr14:75290018	C/G	cg03030879	chr14:75389066	RPS6KL1	-0.35	-6.71	-0.31	6.44e-11	Caffeine consumption;
LUAD	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21659725	chr3:3221576	CRBN	-0.61	-9.94	-0.44	4.52e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.18	-0.37	3.36e-15	Total body bone mineral density;
LUAD	trans	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-10.8	-0.46	3.44e-24	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg02631126	chr6:28058918	ZSCAN12L1	-0.37	-7.52	-0.34	3.26e-13	Depression;
LUAD	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-9.15	-0.41	2.44e-18	Gut microbiome composition (summer);
LUAD	cis	rs7903847	0.656	rs74729163	chr10:99137287	A/C	cg20016023	chr10:99160130	RRP12	-0.34	-7.37	-0.34	9.15e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs4074961	0.669	rs6687545	chr1:38071195	C/T	cg12696750	chr1:38022466	DNALI1	0.4	6.93	0.32	1.6e-11	Axial length;
LUAD	cis	rs5756813	0.754	rs34848977	chr22:38165587	G/A	cg06521852	chr22:38141419	TRIOBP	0.49	9.12	0.41	3.07e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg02734326	chr4:10020555	SLC2A9	-0.51	-8.76	-0.39	4.7e-17	Bone mineral density;
LUAD	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg01689657	chr7:91764605	CYP51A1	0.3	7.05	0.32	7.18e-12	Breast cancer;
LUAD	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12923728	chr3:195709715	SDHAP1	-0.74	-12.79	-0.53	7.12e-32	Pancreatic cancer;
LUAD	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg16325326	chr1:53192061	ZYG11B	-0.73	-14.18	-0.57	1.29e-37	Monocyte count;
LUAD	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	9.39	0.42	3.73e-19	Electrocardiographic conduction measures;
LUAD	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg23172400	chr8:95962367	TP53INP1	-0.33	-7.02	-0.32	8.73e-12	Type 2 diabetes;
LUAD	cis	rs1595825	0.891	rs16825786	chr2:198794681	G/T	cg10547527	chr2:198650123	BOLL	-0.55	-7.94	-0.36	1.8e-14	Ulcerative colitis;
LUAD	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg17747265	chr1:1875780	NA	-0.74	-18.38	-0.67	6.93e-56	Body mass index;
LUAD	cis	rs1524976	1.000	rs4688570	chr3:65466168	G/C	cg16238336	chr3:65465873	MAGI1	0.62	7.52	0.34	3.28e-13	PR interval;
LUAD	trans	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	8.83	0.39	2.88e-17	Mean corpuscular volume;
LUAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.31	0.67	1.36e-55	Prudent dietary pattern;
LUAD	cis	rs113835537	0.569	rs17496586	chr11:66315512	G/C	cg24851651	chr11:66362959	CCS	0.59	10.1	0.44	1.26e-21	Airway imaging phenotypes;
LUAD	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg21191810	chr6:118973309	C6orf204	-0.48	-7.67	-0.35	1.23e-13	Diastolic blood pressure;
LUAD	cis	rs17152411	1.000	rs10901837	chr10:126614618	G/A	cg07906193	chr10:126599966	NA	0.55	7.81	0.36	4.41e-14	Height;
LUAD	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg02734326	chr4:10020555	SLC2A9	0.63	11.28	0.48	5.67e-26	Bone mineral density;
LUAD	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg18512352	chr11:47633146	NA	-0.57	-10.16	-0.44	7.73e-22	Subjective well-being;
LUAD	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg12573674	chr2:1569213	NA	-0.56	-8.32	-0.38	1.21e-15	IgG glycosylation;
LUAD	cis	rs36051895	0.659	rs7862042	chr9:5268139	G/A	cg02405213	chr9:5042618	JAK2	-0.45	-6.38	-0.3	4.73e-10	Pediatric autoimmune diseases;
LUAD	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9473147	0.516	rs1485780	chr6:47556630	A/C	cg02130027	chr6:47444894	CD2AP	0.34	6.61	0.31	1.19e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg17724175	chr1:150552817	MCL1	0.34	7.85	0.36	3.53e-14	Melanoma;
LUAD	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06028808	chr11:68637592	NA	0.48	8.09	0.37	6.31e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg14196790	chr5:131705035	SLC22A5	0.38	6.76	0.31	4.52e-11	Blood metabolite levels;
LUAD	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg11494091	chr17:61959527	GH2	0.4	7.05	0.32	7.44e-12	Height;
LUAD	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg05623727	chr3:50126028	RBM5	0.33	7.18	0.33	3.16e-12	Body mass index;
LUAD	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg00701064	chr4:6280414	WFS1	0.64	13.94	0.56	1.29e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg05590025	chr7:65112418	INTS4L2	-0.72	-7.71	-0.35	9.07e-14	Diabetic kidney disease;
LUAD	cis	rs7202877	0.706	rs8055609	chr16:75402088	C/T	cg03315344	chr16:75512273	CHST6	0.49	6.79	0.31	3.8e-11	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.39	-6.95	-0.32	1.42e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1371867	0.775	rs3020183	chr8:101233297	A/T	cg06002616	chr8:101225028	SPAG1	0.44	8.82	0.39	2.97e-17	Atrioventricular conduction;
LUAD	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg03714773	chr7:91764589	CYP51A1	0.29	6.72	0.31	5.88e-11	Breast cancer;
LUAD	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg17724175	chr1:150552817	MCL1	-0.38	-9.07	-0.4	4.36e-18	Tonsillectomy;
LUAD	cis	rs4268898	1.000	rs6707781	chr2:24441883	T/G	cg06627628	chr2:24431161	ITSN2	0.46	7.86	0.36	3.11e-14	Asthma;
LUAD	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg25036284	chr2:26402008	FAM59B	-0.67	-9.11	-0.41	3.3e-18	Gut microbiome composition (summer);
LUAD	cis	rs11190604	0.832	rs2489041	chr10:102333635	G/C	cg16342193	chr10:102329863	NA	-0.43	-7.11	-0.33	4.98e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg02158880	chr13:53174818	NA	-0.45	-7.55	-0.34	2.75e-13	Lewy body disease;
LUAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00166722	chr3:10149974	C3orf24	0.77	13.36	0.54	3.13e-34	Alzheimer's disease;
LUAD	cis	rs2742234	0.955	rs2503849	chr10:43672776	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.47	-8.4	-0.38	6.83e-16	Hirschsprung disease;
LUAD	cis	rs332507	0.830	rs3821532	chr3:124402618	G/T	cg05980111	chr3:124395277	KALRN	0.45	7.05	0.32	7.41e-12	Plateletcrit;
LUAD	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.66	-0.31	8.53e-11	Bipolar disorder;
LUAD	trans	rs6499188	0.522	rs10153230	chr16:68671741	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.54	0.46	3.22e-23	Ulcerative colitis;
LUAD	cis	rs7927592	0.546	rs683978	chr11:68192421	T/C	cg02221422	chr11:68192511	LRP5	-0.46	-7.29	-0.33	1.56e-12	Total body bone mineral density;
LUAD	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg09998033	chr7:158218633	PTPRN2	0.39	6.77	0.31	4.26e-11	Obesity-related traits;
LUAD	cis	rs8017423	0.967	rs7150093	chr14:90724661	C/T	cg14092571	chr14:90743983	NA	0.5	8.89	0.4	1.75e-17	Mortality in heart failure;
LUAD	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg18827107	chr12:86230957	RASSF9	-0.49	-8.61	-0.39	1.51e-16	Major depressive disorder;
LUAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg11062466	chr8:58055876	NA	0.67	9.01	0.4	7.2e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1816752	0.776	rs9511268	chr13:25018320	A/G	cg02811702	chr13:24901961	NA	0.47	7.89	0.36	2.63e-14	Obesity-related traits;
LUAD	cis	rs4919694	0.908	rs11191523	chr10:104792400	A/G	cg04362960	chr10:104952993	NT5C2	0.76	8.04	0.36	8.8e-15	Arsenic metabolism;
LUAD	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg24675056	chr1:15929824	NA	0.48	8.43	0.38	5.39e-16	Systolic blood pressure;
LUAD	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	7.15	0.33	3.76e-12	Parkinson's disease;
LUAD	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg00339695	chr16:24857497	SLC5A11	0.51	9.38	0.41	4.21e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg15145296	chr3:125709740	NA	0.55	6.59	0.31	1.3100000000000001e-10	Blood pressure (smoking interaction);
LUAD	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg06641503	chr3:48959341	ARIH2	-0.42	-8.33	-0.38	1.13e-15	Parkinson's disease;
LUAD	cis	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.75	-0.35	6.92e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4285028	0.948	rs12637351	chr3:121694412	A/G	cg11130432	chr3:121712080	ILDR1	0.58	8.36	0.38	9.07e-16	Multiple sclerosis;
LUAD	cis	rs999737	0.853	rs34636650	chr14:69005614	G/A	cg04147497	chr14:69052728	RAD51L1	-0.46	-7.11	-0.33	4.99e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs10924309	0.737	rs4658797	chr1:245854862	G/A	cg00036263	chr1:245852353	KIF26B	-0.53	-9.02	-0.4	6.63e-18	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg26516362	chr5:178986906	RUFY1	-0.53	-9.18	-0.41	2e-18	Lung cancer;
LUAD	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg24675056	chr1:15929824	NA	0.47	8.07	0.37	7.52e-15	Systolic blood pressure;
LUAD	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg18252515	chr7:66147081	NA	-0.64	-6.92	-0.32	1.65e-11	Diabetic kidney disease;
LUAD	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs1950626	0.750	rs12895798	chr14:101442793	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.56	0.34	2.6e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs4523957	0.583	rs7225168	chr17:2023089	T/G	cg16513277	chr17:2031491	SMG6	-0.95	-19.14	-0.68	2.98e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6942407	0.546	rs2074757	chr7:86794121	G/A	cg02420886	chr7:86849541	C7orf23	0.63	7.29	0.33	1.55e-12	Food allergy;
LUAD	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg27532560	chr4:187881888	NA	-0.4	-7.68	-0.35	1.13e-13	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg15704280	chr7:45808275	SEPT13	0.59	8.8	0.39	3.49e-17	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22496380	chr5:211416	CCDC127	-0.92	-12.49	-0.52	1.08e-30	Breast cancer;
LUAD	cis	rs5756391	0.546	rs5750338	chr22:37316125	G/A	cg16356956	chr22:37317934	CSF2RB	0.3	6.41	0.3	3.84e-10	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.37	6.54	0.3	1.78e-10	Schizophrenia;
LUAD	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg01528321	chr10:82214614	TSPAN14	0.68	10.35	0.45	1.6e-22	Post bronchodilator FEV1;
LUAD	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg22875332	chr1:76189707	ACADM	0.81	14.8	0.58	3.15e-40	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg12458913	chr13:53173898	NA	0.4	7.31	0.33	1.37e-12	Lewy body disease;
LUAD	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg08645402	chr16:4508243	NA	0.51	8.61	0.39	1.51e-16	Schizophrenia;
LUAD	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg05182265	chr7:156933206	UBE3C	-0.8	-17.35	-0.64	2.59e-51	Body mass index;
LUAD	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg07870213	chr5:140052090	DND1	-0.81	-11.04	-0.47	4.69e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.8	0.31	3.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10465746	0.780	rs11163866	chr1:84367123	A/G	cg10977910	chr1:84465055	TTLL7	0.6	9.75	0.43	2.23e-20	Obesity-related traits;
LUAD	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg11871910	chr12:69753446	YEATS4	0.7	12.05	0.51	5.93e-29	Blood protein levels;
LUAD	cis	rs9287719	0.578	rs62127189	chr2:10761326	T/C	cg02196655	chr2:10830764	NOL10	-0.37	-6.48	-0.3	2.48e-10	Prostate cancer;
LUAD	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.92	0.4	1.44e-17	Gut microbiome composition (summer);
LUAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.27	0.66	2.1e-55	Prudent dietary pattern;
LUAD	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg05234568	chr11:5960015	NA	-0.47	-8.49	-0.38	3.59e-16	DNA methylation (variation);
LUAD	cis	rs4713118	1.000	rs1139226	chr6:27675290	A/T	cg26587870	chr6:27730563	NA	-0.39	-6.4	-0.3	4.18e-10	Parkinson's disease;
LUAD	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg16325326	chr1:53192061	ZYG11B	0.65	12.93	0.53	1.9e-32	Monocyte count;
LUAD	cis	rs2239547	0.563	rs2581820	chr3:53020544	A/G	cg11645453	chr3:52864694	ITIH4	-0.58	-11.35	-0.48	2.97e-26	Schizophrenia;
LUAD	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.86	-0.5	3.35e-28	Bipolar disorder;
LUAD	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg25036284	chr2:26402008	FAM59B	0.81	11.03	0.47	5.11e-25	Gut microbiome composition (summer);
LUAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.86	16.56	0.63	8.04e-48	Lymphocyte counts;
LUAD	trans	rs6495785	0.678	rs8032734	chr15:35938623	A/G	cg04307083	chr4:57521138	HOPX	-0.35	-6.46	-0.3	2.92e-10	Menopause (age at onset);
LUAD	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg21475434	chr5:93447410	FAM172A	0.74	8.22	0.37	2.58e-15	Diabetic retinopathy;
LUAD	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.78	-0.31	3.96e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	8.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg15997130	chr1:24165203	NA	0.56	10.06	0.44	1.79e-21	Immature fraction of reticulocytes;
LUAD	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03352830	chr11:487213	PTDSS2	0.78	10.5	0.45	4.66e-23	Body mass index;
LUAD	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg20398880	chr6:41068722	NFYA;LOC221442	0.36	6.36	0.3	5.2e-10	Alzheimer's disease (late onset);
LUAD	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg05182265	chr7:156933206	UBE3C	-0.8	-17.21	-0.64	1.09e-50	Body mass index;
LUAD	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg15744005	chr10:104629667	AS3MT	-0.38	-7.35	-0.34	1.02e-12	Arsenic metabolism;
LUAD	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11644478	chr21:40555479	PSMG1	0.55	8.37	0.38	8.53e-16	Cognitive function;
LUAD	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg05082376	chr22:42548792	NA	0.44	7.63	0.35	1.56e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg00857998	chr1:205179979	DSTYK	0.39	6.48	0.3	2.6200000000000003e-10	Red blood cell count;
LUAD	cis	rs2275731	0.506	rs11254015	chr10:16522078	A/G	cg04254609	chr10:16479192	PTER	0.48	7.72	0.35	8.68e-14	Bone fracture in osteoporosis;
LUAD	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg03676636	chr4:99064102	C4orf37	0.31	8.21	0.37	2.79e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg02896835	chr1:92012615	NA	-0.59	-12.04	-0.51	6.65e-29	Breast cancer;
LUAD	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg20503657	chr10:835505	NA	0.91	13.24	0.54	1e-33	Eosinophil percentage of granulocytes;
LUAD	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg14092571	chr14:90743983	NA	-0.49	-8.57	-0.38	2e-16	Mortality in heart failure;
LUAD	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	9.98	0.44	3.29e-21	Lung cancer in ever smokers;
LUAD	cis	rs12530845	1.000	rs6975251	chr7:135328689	C/G	cg23117316	chr7:135346802	PL-5283	-0.5	-9.26	-0.41	1e-18	Red blood cell traits;
LUAD	trans	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg06606381	chr12:133084897	FBRSL1	-0.88	-8.43	-0.38	5.63e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7814319	0.966	rs6993518	chr8:97256341	T/A	cg20787634	chr8:97240163	UQCRB	-0.39	-7.6	-0.35	1.97e-13	Lung function (FVC);
LUAD	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg18230493	chr5:56204884	C5orf35	-0.51	-8.38	-0.38	8.17e-16	Coronary artery disease;
LUAD	cis	rs8018808	1.000	rs35881785	chr14:77873571	C/T	cg20045696	chr14:77926864	AHSA1	0.37	6.6	0.31	1.24e-10	Myeloid white cell count;
LUAD	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.71	0.39	6.93e-17	Menarche (age at onset);
LUAD	cis	rs9323205	0.634	rs56043194	chr14:51726066	A/C	cg23942311	chr14:51606299	NA	-0.58	-8.79	-0.39	3.93e-17	Cancer;
LUAD	cis	rs7707921	0.801	rs862243	chr5:81586829	C/G	cg15871215	chr5:81402204	ATG10	0.62	9.93	0.43	5.12e-21	Breast cancer;
LUAD	trans	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17712092	chr4:129076599	LARP1B	0.85	15.93	0.61	4.1e-45	Eosinophil percentage of white cells;
LUAD	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	7.1	0.33	5.38e-12	Schizophrenia;
LUAD	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.3	-0.37	1.38e-15	Height;
LUAD	cis	rs870825	0.616	rs41278579	chr4:185622402	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	12.46	0.52	1.43e-30	Blood protein levels;
LUAD	cis	rs3752645	1.000	rs10248105	chr7:106760498	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-6.46	-0.3	2.91e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg10729496	chr3:10149963	C3orf24	0.49	7.82	0.36	4.3e-14	Alzheimer's disease;
LUAD	trans	rs7395662	1.000	rs12361812	chr11:48563104	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.81e-10	HDL cholesterol;
LUAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-9.29	-0.41	8.24e-19	Alzheimer's disease;
LUAD	cis	rs8192282	0.739	rs12118074	chr1:154477585	G/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.46	-6.9	-0.32	1.96e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg06484146	chr7:12443880	VWDE	-0.58	-7.36	-0.34	9.91e-13	Coronary artery disease;
LUAD	cis	rs35995292	0.857	rs6946859	chr7:38957432	A/G	cg19327137	chr7:38886074	VPS41	0.5	7.62	0.35	1.69e-13	Subjective well-being (multi-trait analysis);
LUAD	cis	rs2224391	0.628	rs1609808	chr6:5246333	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.61	-9.24	-0.41	1.25e-18	Height;
LUAD	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg26384229	chr12:38710491	ALG10B	0.47	7.56	0.35	2.46e-13	Bladder cancer;
LUAD	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg24154853	chr7:158122151	PTPRN2	-0.57	-11.51	-0.49	7.49e-27	Calcium levels;
LUAD	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg19052272	chr2:3704530	ALLC	-0.42	-7.4	-0.34	7.61e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg24644049	chr4:85504048	CDS1	0.92	7.92	0.36	2.16e-14	Skin colour saturation;
LUAD	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.59	10.05	0.44	1.87e-21	Electrocardiographic conduction measures;
LUAD	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg03929089	chr4:120376271	NA	0.67	9.58	0.42	8.29e-20	Coronary artery disease;
LUAD	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg13813247	chr22:41461852	NA	-0.5	-7.87	-0.36	3.07e-14	Neuroticism;
LUAD	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.66	-0.31	8.37e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg23262073	chr20:60523788	NA	-0.44	-7.45	-0.34	5.44e-13	Body mass index;
LUAD	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.59	0.3	1.35e-10	Schizophrenia;
LUAD	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg20587970	chr11:113659929	NA	-1.4	-20.93	-0.71	2.68e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs9584850	0.834	rs12463	chr13:99105302	G/A	cg20750642	chr13:99100586	FARP1	-0.32	-6.69	-0.31	7.28e-11	Neuroticism;
LUAD	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg16049864	chr8:95962084	TP53INP1	-0.54	-11.51	-0.49	7.69e-27	Type 2 diabetes;
LUAD	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-13.56	-0.55	4.95e-35	Chronic sinus infection;
LUAD	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg27535305	chr1:53392650	SCP2	0.39	7.95	0.36	1.74e-14	Monocyte count;
LUAD	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg09137382	chr11:130731461	NA	0.38	6.56	0.3	1.61e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg17724175	chr1:150552817	MCL1	0.39	9.43	0.42	2.64e-19	Tonsillectomy;
LUAD	cis	rs9796	0.870	rs2925342	chr15:41305733	A/G	cg18705301	chr15:41695430	NDUFAF1	0.39	7.33	0.34	1.19e-12	Menopause (age at onset);
LUAD	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg13180566	chr4:1052158	NA	-0.4	-6.73	-0.31	5.71e-11	Recombination rate (females);
LUAD	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg26587870	chr6:27730563	NA	-0.49	-8.12	-0.37	5.06e-15	Parkinson's disease;
LUAD	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg05535760	chr7:792225	HEATR2	0.86	11.18	0.48	1.32e-25	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg17724175	chr1:150552817	MCL1	0.35	7.96	0.36	1.65e-14	Melanoma;
LUAD	trans	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg05926928	chr17:57297772	GDPD1	0.62	9.79	0.43	1.57e-20	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUAD	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-9.48	-0.42	1.82e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs870825	0.616	rs2130394	chr4:185642577	C/A	cg04058563	chr4:185651563	MLF1IP	0.87	14.03	0.56	5.61e-37	Blood protein levels;
LUAD	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg17328964	chr8:145687451	CYHR1	0.65	11.23	0.48	8.67e-26	Age at first birth;
LUAD	cis	rs7737355	0.738	rs7734666	chr5:130861456	A/G	cg25547332	chr5:131281432	NA	0.42	6.71	0.31	6.29e-11	Life satisfaction;
LUAD	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.41	-0.34	6.98e-13	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg09455208	chr3:40491958	NA	0.57	12.72	0.53	1.25e-31	Renal cell carcinoma;
LUAD	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08219700	chr8:58056026	NA	0.55	8.08	0.37	6.79e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs239198	0.577	rs34716527	chr6:101284416	T/C	cg09795085	chr6:101329169	ASCC3	0.41	6.98	0.32	1.13e-11	Menarche (age at onset);
LUAD	cis	rs597539	0.690	rs7104351	chr11:68617886	A/G	cg21963583	chr11:68658836	MRPL21	0.63	11.02	0.47	5.39e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg27572855	chr1:25598939	RHD	-0.53	-11.33	-0.48	3.61e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg21252483	chr19:49399788	TULP2	-0.88	-14.3	-0.57	3.88e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg09365446	chr1:150670422	GOLPH3L	0.65	12.31	0.51	5.84e-30	Tonsillectomy;
LUAD	cis	rs9341808	0.558	rs2322635	chr6:80897210	A/G	cg08355045	chr6:80787529	NA	0.51	9.04	0.4	5.76e-18	Sitting height ratio;
LUAD	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.82	0.31	3.12e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg00953403	chr17:74099816	EXOC7	-0.59	-9.61	-0.42	6.55e-20	Psychosis in Alzheimer's disease;
LUAD	cis	rs7828089	0.935	rs896378	chr8:22262321	T/C	cg12081754	chr8:22256438	SLC39A14	0.56	9.87	0.43	8.33e-21	Verbal declarative memory;
LUAD	cis	rs7210086	0.808	rs4331375	chr17:70640082	A/G	cg04206342	chr17:70636940	NA	-0.39	-7.45	-0.34	5.27e-13	Ulcerative colitis;
LUAD	cis	rs9788721	0.835	rs17487223	chr15:78923987	A/G	cg18825076	chr15:78729989	IREB2	0.45	7.37	0.34	8.82e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg14711859	chr11:8959438	ASCL3	0.34	6.58	0.3	1.39e-10	Hematocrit;
LUAD	cis	rs2404602	0.552	rs11634428	chr15:77084582	T/C	cg23625390	chr15:77176239	SCAPER	-0.47	-6.5	-0.3	2.23e-10	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg21724239	chr8:58056113	NA	0.79	9.7	0.43	3.26e-20	Developmental language disorder (linguistic errors);
LUAD	trans	rs11165623	0.564	rs6593612	chr1:97002041	C/A	cg10631902	chr5:14652156	NA	-0.41	-7.55	-0.34	2.72e-13	Hip circumference;Waist circumference;
LUAD	cis	rs834811	0.796	rs2349456	chr7:135901545	G/T	cg01726295	chr7:135938950	NA	-0.28	-6.9	-0.32	1.96e-11	Post-traumatic stress disorder;
LUAD	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-7.71	-0.35	8.92e-14	Total cholesterol levels;
LUAD	cis	rs7614311	0.731	rs73117087	chr3:63948696	A/G	cg22134162	chr3:63841271	THOC7	-0.55	-9.21	-0.41	1.56e-18	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg26924012	chr15:45694286	SPATA5L1	1.03	19.32	0.68	4.39e-60	Homoarginine levels;
LUAD	cis	rs1697139	0.583	rs17289614	chr5:66541592	G/A	cg11553311	chr5:66541588	NA	0.44	8.13	0.37	4.68e-15	Breast cancer;
LUAD	cis	rs727505	1.000	rs720613	chr7:124452670	C/T	cg23710748	chr7:124431027	NA	-0.43	-9.22	-0.41	1.41e-18	Lewy body disease;
LUAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg14789911	chr21:47582049	C21orf56	-0.48	-8.41	-0.38	6.52e-16	Testicular germ cell tumor;
LUAD	cis	rs921968	0.613	rs2912737	chr2:219545789	A/G	cg02176678	chr2:219576539	TTLL4	-0.59	-11.83	-0.5	4.21e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg19773385	chr1:10388646	KIF1B	-0.43	-6.9	-0.32	1.92e-11	Hepatocellular carcinoma;
LUAD	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg06740227	chr12:86229804	RASSF9	-0.41	-7.35	-0.34	1.05e-12	Major depressive disorder;
LUAD	trans	rs4714291	0.963	rs1743973	chr6:40094549	T/G	cg02267698	chr19:7991119	CTXN1	0.43	6.53	0.3	1.9e-10	Strep throat;
LUAD	cis	rs2742234	0.955	rs2075913	chr10:43622368	T/A	cg15436174	chr10:43711423	RASGEF1A	-0.43	-7.77	-0.35	6.02e-14	Hirschsprung disease;
LUAD	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg05044414	chr3:183734942	ABCC5	0.48	10.08	0.44	1.52e-21	Anterior chamber depth;
LUAD	cis	rs9616064	0.889	rs5767287	chr22:46996179	G/A	cg25730555	chr22:47059586	GRAMD4	0.39	6.68	0.31	7.35e-11	Urate levels in obese individuals;
LUAD	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	12.13	0.51	2.89e-29	Lung cancer in ever smokers;
LUAD	cis	rs66569888	0.581	rs17271098	chr2:106692818	A/G	cg16099169	chr2:106886729	NA	0.52	7.71	0.35	9.15e-14	Facial morphology (factor 23);
LUAD	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg02423579	chr7:2872169	GNA12	-0.87	-14.88	-0.59	1.41e-40	Height;
LUAD	trans	rs7395662	0.571	rs1605358	chr11:48689318	T/A	cg00717180	chr2:96193071	NA	-0.44	-8.43	-0.38	5.55e-16	HDL cholesterol;
LUAD	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg23029597	chr12:123009494	RSRC2	-0.49	-8.15	-0.37	4.16e-15	Body mass index;
LUAD	cis	rs9473147	0.516	rs9349413	chr6:47511491	A/G	cg20196966	chr6:47445060	CD2AP	0.43	6.57	0.3	1.46e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2625529	0.824	rs2415121	chr15:72134018	C/T	cg16672083	chr15:72433130	SENP8	-0.61	-11.21	-0.48	1.07e-25	Red blood cell count;
LUAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.49	-0.3	2.38e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg14789911	chr21:47582049	C21orf56	0.42	7.06	0.32	6.7e-12	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs12579753	0.956	rs34747993	chr12:82217777	C/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-6.98	-0.32	1.15e-11	Resting heart rate;
LUAD	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg07138768	chr7:917805	C7orf20	0.37	7.44	0.34	5.62e-13	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg13722127	chr7:150037890	RARRES2	0.49	8.26	0.37	1.9e-15	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	8.3	0.37	1.44e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg19635926	chr16:89946313	TCF25	0.74	6.97	0.32	1.22e-11	Skin colour saturation;
LUAD	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.35	6.91	0.32	1.77e-11	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg07917127	chr4:99064746	C4orf37	0.4	6.62	0.31	1.07e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.95	0.32	1.37e-11	Parkinson's disease;
LUAD	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg12311346	chr5:56204834	C5orf35	-0.64	-10.07	-0.44	1.62e-21	Coronary artery disease;
LUAD	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg00129232	chr17:37814104	STARD3	-0.45	-7.63	-0.35	1.55e-13	Asthma;
LUAD	cis	rs684232	0.563	rs12939528	chr17:524391	C/T	cg12384639	chr17:618140	VPS53	0.47	8.1	0.37	5.82e-15	Prostate cancer;
LUAD	cis	rs7394190	0.688	rs76033784	chr10:75535970	A/G	cg02286717	chr10:75415704	SYNPO2L	-0.36	-6.41	-0.3	3.82e-10	Incident atrial fibrillation;
LUAD	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	8.63	0.39	1.22e-16	Menarche (age at onset);
LUAD	cis	rs4776059	1.000	rs1863512	chr15:52959687	C/T	cg24008177	chr15:52972085	KIAA1370	0.26	7.07	0.32	6.53e-12	Schizophrenia;
LUAD	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18876405	chr7:65276391	NA	-0.4	-6.41	-0.3	3.82e-10	Aortic root size;
LUAD	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg04282206	chr17:62833786	PLEKHM1P	-0.54	-8.23	-0.37	2.32e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg23950597	chr19:37808831	NA	0.56	7.09	0.33	5.66e-12	Coronary artery calcification;
LUAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg06453172	chr10:134556979	INPP5A	-0.77	-10.88	-0.47	1.75e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.29	0.37	1.55e-15	Alzheimer's disease;
LUAD	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18876405	chr7:65276391	NA	-0.61	-10.19	-0.44	5.82e-22	Aortic root size;
LUAD	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg15691649	chr6:25882328	NA	-0.64	-8.43	-0.38	5.39e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg04772025	chr11:68637568	NA	0.57	9.1	0.4	3.51e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg05082376	chr22:42548792	NA	0.43	7.5	0.34	3.88e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg15181151	chr6:150070149	PCMT1	0.4	8.29	0.37	1.51e-15	Lung cancer;
LUAD	cis	rs72901758	0.700	rs34219567	chr17:76248036	A/G	cg25512537	chr17:76250053	NA	0.33	6.53	0.3	1.91e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg03526776	chr6:41159608	TREML2	0.33	6.89	0.32	1.99e-11	Alzheimer's disease (late onset);
LUAD	cis	rs3096299	0.967	rs2965937	chr16:89488779	A/T	cg07708487	chr16:89387014	ANKRD11	-0.34	-6.8	-0.31	3.56e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs11945232	1.000	rs28372775	chr4:88343704	G/A	cg23841344	chr4:88312519	HSD17B11	-0.55	-8.32	-0.38	1.21e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg07538946	chr5:131705188	SLC22A5	-0.49	-7.93	-0.36	2e-14	Breast cancer;Mosquito bite size;
LUAD	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg10755058	chr3:40428713	ENTPD3	0.38	7.43	0.34	6.22e-13	Renal cell carcinoma;
LUAD	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.44	-0.3	3.21e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs240764	0.658	rs12664626	chr6:101195720	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-8.38	-0.38	7.87e-16	Neuroticism;
LUAD	cis	rs733592	0.965	rs1978161	chr12:48467721	A/G	cg24011408	chr12:48396354	COL2A1	-0.35	-7.14	-0.33	4.2e-12	Plateletcrit;
LUAD	cis	rs17021463	0.902	rs10516950	chr4:95254730	C/T	cg11021082	chr4:95130006	SMARCAD1	0.42	7.82	0.36	4.37e-14	Testicular germ cell tumor;
LUAD	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg15181151	chr6:150070149	PCMT1	0.38	7.68	0.35	1.12e-13	Lung cancer;
LUAD	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg25173405	chr17:45401733	C17orf57	-0.55	-9.43	-0.42	2.65e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg16797656	chr11:68205561	LRP5	0.45	8.62	0.39	1.34e-16	Total body bone mineral density;
LUAD	cis	rs7705042	0.865	rs6580225	chr5:141489381	G/C	cg23435118	chr5:141488016	NDFIP1	-0.38	-6.51	-0.3	2.18e-10	Asthma;
LUAD	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg05373962	chr22:49881684	NA	-0.5	-10.3	-0.45	2.42e-22	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs1451375	0.617	rs745043	chr7:50543955	T/G	cg18232548	chr7:50535776	DDC	-0.65	-9.02	-0.4	6.6e-18	Malaria;
LUAD	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg04414720	chr1:150670196	GOLPH3L	0.73	13.62	0.55	2.78e-35	Tonsillectomy;
LUAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg27532560	chr4:187881888	NA	-0.35	-6.68	-0.31	7.58e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg16447950	chr5:562315	NA	-0.41	-6.41	-0.3	3.91e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg21984481	chr17:79567631	NPLOC4	-0.66	-15.59	-0.6	1.31e-43	Eye color traits;
LUAD	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg17724175	chr1:150552817	MCL1	0.35	7.96	0.36	1.65e-14	Melanoma;
LUAD	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg15691649	chr6:25882328	NA	-0.46	-7.28	-0.33	1.66e-12	Blood metabolite levels;
LUAD	cis	rs6960043	0.818	rs13220985	chr7:15062694	A/G	cg19272540	chr7:15055459	NA	0.38	8.38	0.38	7.99e-16	Type 2 diabetes;
LUAD	cis	rs4523957	0.786	rs28524880	chr17:2125444	C/A	cg16513277	chr17:2031491	SMG6	-0.8	-14.77	-0.58	4.26e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7274811	0.681	rs291670	chr20:31945861	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.54	8.21	0.37	2.78e-15	Height;
LUAD	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg21231944	chr12:82153410	PPFIA2	-0.36	-6.56	-0.3	1.55e-10	Resting heart rate;
LUAD	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg20503657	chr10:835505	NA	0.96	14.51	0.58	5.49e-39	Eosinophil percentage of granulocytes;
LUAD	cis	rs1215050	0.755	rs7696354	chr4:98820330	T/C	cg24818145	chr4:99064322	C4orf37	0.41	6.63	0.31	1.02e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs897984	0.542	rs35713203	chr16:31090407	G/C	cg02466173	chr16:30829666	NA	-0.48	-7.93	-0.36	1.94e-14	Dementia with Lewy bodies;
LUAD	cis	rs13315871	1.000	rs11710058	chr3:58383048	G/A	cg12435725	chr3:58293450	RPP14	-0.67	-7.33	-0.34	1.16e-12	Cholesterol, total;
LUAD	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.67	-0.31	7.98e-11	Heart rate;
LUAD	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-8.12	-0.37	5.17e-15	Bipolar disorder;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13276752	chr17:57970287	TUBD1;RPS6KB1	-0.38	-6.4	-0.3	4.19e-10	Cancer;
LUAD	trans	rs3779273	1.000	rs3779273	chr7:77828940	G/A	cg05596911	chr5:118502651	DMXL1	0.39	6.92	0.32	1.71e-11	Body mass index;
LUAD	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.6	9.06	0.4	5.04e-18	Platelet count;
LUAD	cis	rs8060686	0.516	rs8048365	chr16:68253326	T/A	cg26727032	chr16:67993705	SLC12A4	-0.48	-7.92	-0.36	2.14e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg18538332	chr22:24372958	LOC391322	0.5	8.36	0.38	9.02e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg08219700	chr8:58056026	NA	0.66	8.41	0.38	6.22e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg07677032	chr17:61819896	STRADA	0.57	10.54	0.46	3.21e-23	Prudent dietary pattern;
LUAD	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg06873352	chr17:61820015	STRADA	0.42	6.97	0.32	1.2e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg02240030	chr7:2089880	MAD1L1	0.34	6.67	0.31	8.15e-11	Neuroticism;
LUAD	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg03929089	chr4:120376271	NA	-0.73	-11.96	-0.5	1.38e-28	Coronary artery disease;
LUAD	cis	rs12579753	0.872	rs12319937	chr12:82182545	T/G	cg07988820	chr12:82153109	PPFIA2	-0.45	-7.28	-0.33	1.65e-12	Resting heart rate;
LUAD	cis	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05901451	chr6:126070800	HEY2	0.45	6.65	0.31	9.09e-11	Endometrial cancer;
LUAD	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg20362242	chr5:692897	TPPP	0.57	6.98	0.32	1.15e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs1018836	0.859	rs10808614	chr8:91569677	C/G	cg16814680	chr8:91681699	NA	-0.59	-9.97	-0.44	3.75e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4077515	0.874	rs3812560	chr9:139269905	T/C	cg14019695	chr9:139328340	INPP5E	0.39	7.37	0.34	8.83e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg17425144	chr1:10567563	PEX14	0.59	12.31	0.51	5.87e-30	Prostate cancer;
LUAD	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg06074448	chr4:187884817	NA	-0.36	-7.08	-0.33	6.04e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6500602	0.653	rs4786487	chr16:4440397	C/G	cg08645402	chr16:4508243	NA	-0.51	-8.82	-0.39	3.1e-17	Schizophrenia;
LUAD	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg01528321	chr10:82214614	TSPAN14	0.66	10.16	0.44	7.76e-22	Post bronchodilator FEV1;
LUAD	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg18944383	chr4:111397179	ENPEP	-0.47	-8.61	-0.39	1.45e-16	Coronary artery disease;
LUAD	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg17105886	chr17:28927953	LRRC37B2	0.78	7.73	0.35	7.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4713675	0.546	rs10947435	chr6:33718075	G/A	cg14003231	chr6:33640908	ITPR3	0.39	7.32	0.34	1.22e-12	Plateletcrit;
LUAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg16606324	chr3:10149918	C3orf24	0.62	10.04	0.44	2.05e-21	Alzheimer's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg13719843	chr19:58897798	RPS5	-0.56	-6.79	-0.31	3.85e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg25036284	chr2:26402008	FAM59B	0.83	11.58	0.49	4.07e-27	Gut microbiome composition (summer);
LUAD	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.47	6.56	0.3	1.55e-10	Platelet count;
LUAD	cis	rs2455601	0.507	rs7948452	chr11:8877704	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-8.77	-0.39	4.36e-17	Schizophrenia;
LUAD	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg00310523	chr12:86230176	RASSF9	0.37	7.4	0.34	7.42e-13	Major depressive disorder;
LUAD	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.54	8.05	0.36	8.56e-15	Total cholesterol levels;
LUAD	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg15181151	chr6:150070149	PCMT1	0.33	6.56	0.3	1.62e-10	Testicular germ cell tumor;
LUAD	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg13699009	chr12:122356056	WDR66	0.3	6.53	0.3	1.94e-10	Mean corpuscular volume;
LUAD	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg27535305	chr1:53392650	SCP2	0.35	7.34	0.34	1.12e-12	Monocyte count;
LUAD	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg08219700	chr8:58056026	NA	0.57	7.91	0.36	2.28e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.6	0.39	1.57e-16	Parkinson's disease;
LUAD	cis	rs2455799	0.613	rs11920540	chr3:15854608	G/A	cg16303742	chr3:15540471	COLQ	-0.53	-9.8	-0.43	1.45e-20	Mean platelet volume;
LUAD	cis	rs1639906	0.965	rs1639909	chr7:2233045	A/C	cg18044113	chr7:2236405	MAD1L1	-0.4	-7.72	-0.35	8.59e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12541635	0.966	rs55762012	chr8:107033218	T/C	cg10147462	chr8:107024639	NA	0.48	8.5	0.38	3.34e-16	Age of smoking initiation;
LUAD	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg19748678	chr4:122722346	EXOSC9	0.43	6.71	0.31	6.4e-11	Type 2 diabetes;
LUAD	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg24768116	chr2:27665128	KRTCAP3	0.27	6.66	0.31	8.35e-11	Oral cavity cancer;
LUAD	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08219700	chr8:58056026	NA	0.68	8.66	0.39	9.97e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg10589385	chr1:150898437	SETDB1	0.37	6.79	0.31	3.86e-11	Tonsillectomy;
LUAD	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg06808227	chr14:105710500	BRF1	-0.44	-6.88	-0.32	2.11e-11	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12926404	chr11:72145533	CLPB	-0.55	-6.67	-0.31	8.12e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7274811	0.681	rs291707	chr20:31964256	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	0.49	7.63	0.35	1.52e-13	Height;
LUAD	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg10876282	chr6:28092338	ZSCAN16	0.43	6.42	0.3	3.74e-10	Parkinson's disease;
LUAD	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg24818145	chr4:99064322	C4orf37	-0.42	-6.95	-0.32	1.38e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg21918786	chr6:109611834	NA	-0.6	-11.12	-0.48	2.21e-25	Reticulocyte fraction of red cells;
LUAD	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.61	-0.31	1.15e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	9.02	0.4	6.8e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg06453172	chr10:134556979	INPP5A	0.79	11.47	0.49	1.02e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg21918786	chr6:109611834	NA	-0.64	-12.16	-0.51	2.28e-29	Reticulocyte fraction of red cells;
LUAD	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg07266350	chr3:49460521	AMT;NICN1	0.36	6.39	0.3	4.5e-10	Menarche (age at onset);
LUAD	cis	rs12760731	0.668	rs12073428	chr1:178427933	G/A	cg00404053	chr1:178313656	RASAL2	0.51	7.2	0.33	2.75e-12	Obesity-related traits;
LUAD	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg02743256	chr7:2109353	MAD1L1	-0.48	-6.55	-0.3	1.69e-10	Bipolar disorder;
LUAD	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg05110241	chr16:68378359	PRMT7	-0.7	-8.03	-0.36	9.75e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg17264618	chr3:40429014	ENTPD3	-0.41	-9.25	-0.41	1.09e-18	Renal cell carcinoma;
LUAD	cis	rs6987853	0.830	rs4361746	chr8:42355041	C/T	cg09913449	chr8:42400586	C8orf40	-0.39	-7.06	-0.32	7.09e-12	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg11845111	chr2:191398756	TMEM194B	-0.58	-7.57	-0.35	2.39e-13	Diastolic blood pressure;
LUAD	cis	rs8177876	0.731	rs8177948	chr16:81116920	C/G	cg08591886	chr16:81111003	C16orf46	-0.79	-7.37	-0.34	8.94e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs677665	0.918	rs11590326	chr1:9339205	A/G	cg25755851	chr1:9335794	NA	-0.6	-9.64	-0.42	5.12e-20	Eosinophil percentage of white cells;
LUAD	cis	rs11229555	0.574	rs66573492	chr11:58183797	G/A	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs657075	0.595	rs2292260	chr5:131606936	G/A	cg21138405	chr5:131827807	IRF1	0.46	6.37	0.3	4.96e-10	Rheumatoid arthritis;
LUAD	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg02269571	chr22:50332266	NA	-0.67	-9.63	-0.42	5.61e-20	Schizophrenia;
LUAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg03188948	chr7:1209495	NA	0.45	7.26	0.33	1.93e-12	Longevity;Endometriosis;
LUAD	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg12311346	chr5:56204834	C5orf35	-0.53	-8.41	-0.38	6.57e-16	Coronary artery disease;
LUAD	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg09509183	chr1:209979624	IRF6	0.57	7.92	0.36	2.05e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg23649088	chr2:200775458	C2orf69	0.62	7.77	0.35	6.15e-14	Schizophrenia;
LUAD	trans	rs7944735	0.517	rs12274550	chr11:48196752	C/A	cg15704280	chr7:45808275	SEPT13	0.67	7.69	0.35	1.04e-13	Intraocular pressure;
LUAD	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.85e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1215050	0.791	rs4699318	chr4:98664370	T/G	cg17366294	chr4:99064904	C4orf37	-0.45	-7.94	-0.36	1.86e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4853036	0.540	rs55941844	chr2:69999728	T/A	cg02498382	chr2:70120550	SNRNP27	-0.46	-6.37	-0.3	5.08e-10	Colorectal or endometrial cancer;
LUAD	cis	rs12912251	1.000	rs2132157	chr15:38992547	A/G	cg01338139	chr15:38987640	C15orf53	-0.57	-9.15	-0.41	2.38e-18	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg14895029	chr7:2775587	GNA12	0.42	6.87	0.32	2.26e-11	Height;
LUAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08219700	chr8:58056026	NA	0.56	7.71	0.35	8.86e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.53	0.52	7.54e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg10591111	chr5:226296	SDHA	-0.55	-7.13	-0.33	4.26e-12	Breast cancer;
LUAD	cis	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg02240030	chr7:2089880	MAD1L1	0.36	6.91	0.32	1.76e-11	Neuroticism;
LUAD	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg09359103	chr1:154839909	KCNN3	-0.93	-22.07	-0.73	2.2e-72	Prostate cancer;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg05064044	chr6:292385	DUSP22	-0.83	-14.2	-0.57	1.04e-37	Menopause (age at onset);
LUAD	cis	rs7301826	0.610	rs4759789	chr12:131296380	A/C	cg11011512	chr12:131303247	STX2	0.43	7.3	0.33	1.47e-12	Plasma plasminogen activator levels;
LUAD	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg09455208	chr3:40491958	NA	-0.52	-11.2	-0.48	1.08e-25	Renal cell carcinoma;
LUAD	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.3	6.96	0.32	1.32e-11	Prostate cancer;
LUAD	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg11494091	chr17:61959527	GH2	-0.43	-7.96	-0.36	1.58e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg20203395	chr5:56204925	C5orf35	0.45	6.95	0.32	1.4e-11	Coronary artery disease;
LUAD	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs6066825	0.627	rs6019349	chr20:47275245	A/G	cg18078177	chr20:47281410	PREX1	0.41	6.64	0.31	9.67e-11	Colorectal cancer;
LUAD	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg05283184	chr6:79620031	NA	-0.61	-12.27	-0.51	7.82e-30	Intelligence (multi-trait analysis);
LUAD	trans	rs258892	0.947	rs34955	chr5:72203628	T/C	cg14879065	chr14:104662468	NA	-0.35	-6.48	-0.3	2.55e-10	Small cell lung carcinoma;
LUAD	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg26384229	chr12:38710491	ALG10B	0.48	7.81	0.36	4.46e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg05110241	chr16:68378359	PRMT7	-0.84	-9.13	-0.41	2.82e-18	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg15704280	chr7:45808275	SEPT13	-0.91	-17.53	-0.65	4.14e-52	Coronary artery disease;
LUAD	trans	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg01620082	chr3:125678407	NA	-1.09	-10.57	-0.46	2.45e-23	Depression;
LUAD	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg23029597	chr12:123009494	RSRC2	-0.59	-9.5	-0.42	1.53e-19	Body mass index;
LUAD	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg25566285	chr7:158114605	PTPRN2	0.53	11.29	0.48	5.18e-26	Calcium levels;
LUAD	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg24503407	chr1:205819492	PM20D1	0.78	16.1	0.62	8.06e-46	Menarche (age at onset);
LUAD	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg16988262	chr1:15930761	NA	0.41	6.87	0.32	2.34e-11	Systolic blood pressure;
LUAD	cis	rs9902453	0.904	rs6505148	chr17:28289818	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	10.12	0.44	1.1e-21	Coffee consumption (cups per day);
LUAD	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.48	-0.3	2.51e-10	Aortic root size;
LUAD	cis	rs367943	0.966	rs348924	chr5:112817930	T/G	cg12552261	chr5:112820674	MCC	-0.58	-11.04	-0.47	4.66e-25	Type 2 diabetes;
LUAD	trans	rs3960554	0.808	rs9801125	chr7:75792451	C/T	cg19862616	chr7:65841803	NCRNA00174	0.82	10.75	0.46	5.33e-24	Eotaxin levels;
LUAD	cis	rs4006360	0.579	rs1510075	chr17:39236452	C/T	cg16090541	chr17:39240343	KRTAP4-7	-0.36	-6.36	-0.3	5.35e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg23950597	chr19:37808831	NA	-0.59	-7.27	-0.33	1.78e-12	Coronary artery calcification;
LUAD	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg07169764	chr2:136633963	MCM6	0.88	10.68	0.46	1.02e-23	Corneal structure;
LUAD	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg05283184	chr6:79620031	NA	-0.62	-12.3	-0.51	5.98e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg06108461	chr20:60628389	TAF4	-0.96	-17.42	-0.65	1.3e-51	Body mass index;
LUAD	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.42	0.34	6.64e-13	Tonsillectomy;
LUAD	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg18854424	chr1:2615690	NA	0.33	7.91	0.36	2.33e-14	Ulcerative colitis;
LUAD	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg17633681	chr16:88106987	BANP	0.39	6.79	0.31	3.78e-11	Menopause (age at onset);
LUAD	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg23649088	chr2:200775458	C2orf69	0.64	8.44	0.38	5.1e-16	Schizophrenia;
LUAD	trans	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg04565464	chr8:145669602	NFKBIL2	0.44	6.61	0.31	1.17e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs4389656	0.857	rs274676	chr5:6754762	T/C	cg10857441	chr5:6722123	POLS	-0.46	-8.05	-0.36	8.19e-15	Coronary artery disease;
LUAD	trans	rs853679	0.607	rs34505829	chr6:28133239	A/T	cg01620082	chr3:125678407	NA	-1.1	-10.38	-0.45	1.25e-22	Depression;
LUAD	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.2	-0.37	2.8e-15	Breast cancer;
LUAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg21724239	chr8:58056113	NA	0.65	8.41	0.38	6.32e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg09455208	chr3:40491958	NA	0.65	14.21	0.57	9.71e-38	Renal cell carcinoma;
LUAD	cis	rs7017914	0.967	rs11989553	chr8:71640899	A/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.28	-7.16	-0.33	3.65e-12	Total body bone mineral density;
LUAD	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg06784218	chr1:46089804	CCDC17	-0.54	-11.63	-0.49	2.61e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.44	-0.3	3.33e-10	Calcium levels;
LUAD	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg21153622	chr11:89784906	NA	-0.34	-6.77	-0.31	4.39e-11	HDL cholesterol;
LUAD	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg05697835	chr1:2722811	NA	0.31	6.43	0.3	3.53e-10	Ulcerative colitis;
LUAD	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21385522	chr1:16154831	NA	0.59	8.68	0.39	8.96e-17	Dilated cardiomyopathy;
LUAD	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg25566285	chr7:158114605	PTPRN2	0.51	10.62	0.46	1.59e-23	Calcium levels;
LUAD	cis	rs4901869	0.966	rs4901870	chr14:59334221	A/T	cg02291164	chr14:59296302	NA	-0.59	-14.0	-0.56	7.58e-37	Panic disorder;
LUAD	trans	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7737355	0.947	rs10041744	chr5:130860852	C/T	cg06307176	chr5:131281290	NA	0.52	8.19	0.37	3.17e-15	Life satisfaction;
LUAD	cis	rs7487075	0.606	rs4768714	chr12:46814245	T/A	cg23829395	chr12:46796953	NA	0.32	7.04	0.32	7.99e-12	Itch intensity from mosquito bite;
LUAD	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg03161606	chr19:29218774	NA	0.59	7.36	0.34	9.6e-13	Methadone dose in opioid dependence;
LUAD	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg06002616	chr8:101225028	SPAG1	0.41	8.42	0.38	5.94e-16	Atrioventricular conduction;
LUAD	cis	rs240764	0.658	rs3811078	chr6:101247503	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-7.56	-0.34	2.53e-13	Neuroticism;
LUAD	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg17761419	chr8:57350749	NA	-0.52	-7.89	-0.36	2.64e-14	Obesity-related traits;
LUAD	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg00933542	chr6:150070202	PCMT1	0.39	8.0	0.36	1.23e-14	Lung cancer;
LUAD	trans	rs7395662	0.709	rs11040113	chr11:48895653	G/A	cg15704280	chr7:45808275	SEPT13	-0.4	-6.35	-0.3	5.58e-10	HDL cholesterol;
LUAD	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg22166914	chr1:53195759	ZYG11B	0.5	8.7	0.39	7.62e-17	Monocyte count;
LUAD	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg06781209	chr11:61594997	FADS2	-0.39	-7.5	-0.34	3.89e-13	Trans fatty acid levels;
LUAD	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg14668632	chr7:2872130	GNA12	0.71	12.47	0.52	1.3e-30	Height;
LUAD	cis	rs4631830	0.896	rs7077830	chr10:51522276	C/G	cg20129853	chr10:51489980	NA	0.33	6.46	0.3	2.83e-10	Prostate-specific antigen levels;
LUAD	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.66	-0.61	6.36e-44	Eye color traits;
LUAD	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg00206168	chr11:65308501	LTBP3	1.26	10.75	0.46	5.64e-24	Height;
LUAD	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg18306943	chr3:40428807	ENTPD3	0.42	7.08	0.33	5.97e-12	Renal cell carcinoma;
LUAD	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.55	-9.17	-0.41	2.16e-18	Glomerular filtration rate;
LUAD	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg00280220	chr17:61926910	NA	0.36	6.9	0.32	1.9e-11	Prudent dietary pattern;
LUAD	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg17644776	chr2:200775616	C2orf69	-0.52	-7.56	-0.35	2.46e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
LUAD	cis	rs10129255	0.500	rs6576231	chr14:107191930	T/C	cg07958169	chr14:107095056	NA	-0.36	-7.15	-0.33	3.93e-12	Kawasaki disease;
LUAD	cis	rs17739794	0.537	rs7816826	chr8:814492	C/G	cg01971667	chr8:817044	NA	0.3	6.37	0.3	4.89e-10	Clozapine-induced cytotoxicity;
LUAD	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg10556349	chr10:835070	NA	0.6	7.64	0.35	1.43e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs909002	0.772	rs6681414	chr1:32070234	G/A	cg13919466	chr1:32135498	COL16A1	-0.37	-8.68	-0.39	8.59e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs1483890	0.642	rs9825845	chr3:69404572	C/A	cg22125112	chr3:69402811	FRMD4B	0.49	8.35	0.38	1e-15	Resting heart rate;
LUAD	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg17509989	chr5:176798049	RGS14	-0.62	-9.46	-0.42	2.16e-19	Urate levels in lean individuals;
LUAD	cis	rs7107174	1.000	rs2510051	chr11:77981171	A/C	cg19901956	chr11:77921274	USP35	-0.51	-6.56	-0.3	1.54e-10	Testicular germ cell tumor;
LUAD	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg00933542	chr6:150070202	PCMT1	0.44	9.6	0.42	6.92e-20	Lung cancer;
LUAD	cis	rs3820068	0.705	rs2145397	chr1:15896199	G/A	cg24675056	chr1:15929824	NA	0.42	6.55	0.3	1.63e-10	Systolic blood pressure;
LUAD	cis	rs10744422	1.000	rs7138398	chr12:123341833	G/C	cg16953816	chr12:123349952	VPS37B	0.59	6.51	0.3	2.17e-10	Schizophrenia;
LUAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg16145915	chr7:1198662	ZFAND2A	0.62	11.61	0.49	3.19e-27	Longevity;Endometriosis;
LUAD	cis	rs4764487	0.735	rs1990384	chr12:6342921	G/T	cg08284733	chr12:6341482	CD9	0.37	6.65	0.31	8.99e-11	Mean platelet volume;
LUAD	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	trans	rs2544390	1.000	rs2673172	chr2:170204800	A/C	cg06820296	chr11:108463783	EXPH5	-0.37	-6.62	-0.31	1.08e-10	Urate levels;
LUAD	trans	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg22153745	chr1:153894579	GATAD2B	-0.5	-7.53	-0.34	3.01e-13	Total cholesterol levels;
LUAD	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg06618935	chr21:46677482	NA	-0.36	-6.85	-0.32	2.65e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.32	-0.38	1.18e-15	Total body bone mineral density;
LUAD	cis	rs17095355	1.000	rs17126931	chr10:111754633	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.66	-7.59	-0.35	2.13e-13	Biliary atresia;
LUAD	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg18944383	chr4:111397179	ENPEP	0.4	7.96	0.36	1.61e-14	Height;
LUAD	cis	rs10242455	0.702	rs74416635	chr7:99180569	G/A	cg18809830	chr7:99032528	PTCD1	-1.08	-8.07	-0.37	7.61e-15	Blood metabolite levels;
LUAD	cis	rs7809950	0.678	rs2107317	chr7:106899685	T/C	cg23024343	chr7:107201750	COG5	-0.81	-13.7	-0.55	1.33e-35	Coronary artery disease;
LUAD	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.36	-6.97	-0.32	1.25e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9393692	0.557	rs61324092	chr6:26297392	G/A	cg13736514	chr6:26305472	NA	-0.54	-8.87	-0.4	2.05e-17	Educational attainment;
LUAD	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22590775	chr19:49891494	CCDC155	0.61	8.86	0.4	2.21e-17	Multiple sclerosis;
LUAD	trans	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg26043149	chr18:55253948	FECH	1.05	18.65	0.67	4.52e-57	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7267979	0.932	rs6132848	chr20:25561645	C/T	cg08601574	chr20:25228251	PYGB	0.42	7.63	0.35	1.61e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs35740288	0.770	rs75039806	chr15:86105044	C/T	cg13263323	chr15:86062960	AKAP13	-0.45	-7.14	-0.33	4.09e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs12200560	0.505	rs211163	chr6:97067654	A/G	cg06623918	chr6:96969491	KIAA0776	0.44	6.73	0.31	5.66e-11	Coronary heart disease;
LUAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg04025307	chr7:1156635	C7orf50	0.7	12.56	0.52	5.88e-31	Longevity;Endometriosis;
LUAD	cis	rs11828289	0.660	rs12099049	chr11:23219311	A/G	cg20040320	chr11:23191996	NA	-0.68	-7.71	-0.35	9.09e-14	Cancer;
LUAD	trans	rs4942242	0.663	rs9590779	chr13:44234886	A/G	cg19169023	chr15:41853346	TYRO3	0.72	12.85	0.53	4e-32	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg03037974	chr15:76606532	NA	0.37	7.94	0.36	1.9e-14	Blood metabolite levels;
LUAD	cis	rs9346649	0.967	rs6915427	chr6:168490000	A/T	cg02770688	chr6:168491649	NA	0.38	7.47	0.34	4.58e-13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs13315871	0.929	rs77487951	chr3:58290892	G/A	cg12435725	chr3:58293450	RPP14	-0.74	-7.88	-0.36	2.86e-14	Cholesterol, total;
LUAD	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg21385522	chr1:16154831	NA	0.44	6.65	0.31	9.07e-11	Dilated cardiomyopathy;
LUAD	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg27446573	chr6:127587934	RNF146	0.41	6.38	0.3	4.64e-10	Breast cancer;
LUAD	cis	rs2979489	0.891	rs2915590	chr8:30393334	A/G	cg26383811	chr8:30366931	RBPMS	-0.71	-11.3	-0.48	4.55e-26	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03264133	chr6:25882463	NA	0.82	13.45	0.55	1.41e-34	Blood metabolite levels;
LUAD	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.05	0.47	4.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs68170813	0.617	rs12535761	chr7:107139275	A/C	cg02696742	chr7:106810147	HBP1	-0.76	-8.93	-0.4	1.3e-17	Coronary artery disease;
LUAD	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg07169764	chr2:136633963	MCM6	0.66	8.21	0.37	2.7e-15	Corneal structure;
LUAD	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26314531	chr2:26401878	FAM59B	-0.72	-9.81	-0.43	1.37e-20	Gut microbiome composition (summer);
LUAD	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg10909506	chr17:38081995	ORMDL3	0.37	6.58	0.3	1.38e-10	Self-reported allergy;
LUAD	cis	rs4900538	0.855	rs12586378	chr14:102853150	T/C	cg18135206	chr14:102964638	TECPR2	-1.01	-21.0	-0.71	1.43e-67	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07266350	chr3:49460521	AMT;NICN1	0.38	6.83	0.32	3e-11	Menarche (age at onset);
LUAD	cis	rs9372498	0.536	rs62424172	chr6:118777533	C/A	cg07617317	chr6:118971624	C6orf204	0.55	8.56	0.38	2.11e-16	Diastolic blood pressure;
LUAD	cis	rs7089973	0.872	rs7918388	chr10:116614563	T/C	cg25233709	chr10:116636983	FAM160B1	0.39	7.7	0.35	9.75e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs427394	0.659	rs187295	chr5:6734326	C/T	cg10857441	chr5:6722123	POLS	-0.6	-10.72	-0.46	7.24e-24	Menopause (age at onset);
LUAD	cis	rs9473147	0.516	rs7767350	chr6:47485126	C/T	cg12968598	chr6:47444699	CD2AP	0.36	6.46	0.3	2.81e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00149659	chr3:10157352	C3orf10	0.86	11.45	0.49	1.3e-26	Alzheimer's disease;
LUAD	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg26668828	chr6:292823	DUSP22	-0.57	-9.57	-0.42	8.93e-20	Menopause (age at onset);
LUAD	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg19041857	chr6:27730383	NA	-0.4	-6.78	-0.31	3.93e-11	Parkinson's disease;
LUAD	cis	rs494562	1.000	rs527670	chr6:86115779	T/C	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs4838594	0.549	rs11101333	chr10:49668179	A/G	cg06705548	chr10:49218579	LOC399753	-0.31	-6.46	-0.3	2.84e-10	Daytime sleep phenotypes;
LUAD	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg21475434	chr5:93447410	FAM172A	-0.49	-6.9	-0.32	1.87e-11	Diabetic retinopathy;
LUAD	cis	rs12618769	0.652	rs3754877	chr2:99184019	A/G	cg10123293	chr2:99228465	UNC50	0.49	8.51	0.38	2.95e-16	Bipolar disorder;
LUAD	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11644478	chr21:40555479	PSMG1	0.7	11.8	0.5	5.71e-28	Cognitive function;
LUAD	trans	rs11638815	0.603	rs783520	chr15:83279505	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.49	-7.55	-0.34	2.66e-13	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	cis	rs59104589	0.617	rs56390510	chr2:242274489	G/C	cg08645257	chr2:242211290	HDLBP	0.46	7.25	0.33	1.98e-12	Fibrinogen levels;
LUAD	cis	rs367615	0.512	rs814153	chr5:108667829	A/C	cg17395555	chr5:108820864	NA	0.52	9.83	0.43	1.08e-20	Colorectal cancer (SNP x SNP interaction);
LUAD	trans	rs7395662	0.864	rs10838951	chr11:48571088	T/G	cg00717180	chr2:96193071	NA	-0.39	-7.35	-0.34	1.03e-12	HDL cholesterol;
LUAD	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg13010199	chr12:38710504	ALG10B	0.38	6.36	0.3	5.09e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.41	0.38	6.12e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg05991184	chr2:219186017	PNKD	0.37	7.01	0.32	9.24e-12	Colorectal cancer;
LUAD	cis	rs2235649	0.592	rs11647980	chr16:1959753	G/A	cg07386859	chr16:1872102	HAGH	0.45	6.39	0.3	4.28e-10	Blood metabolite levels;
LUAD	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.29	0.33	1.49e-12	Menopause (age at onset);
LUAD	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg21427119	chr20:30132790	HM13	-0.61	-9.23	-0.41	1.34e-18	Mean corpuscular hemoglobin;
LUAD	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg26513180	chr16:89883248	FANCA	0.75	6.76	0.31	4.55e-11	Skin colour saturation;
LUAD	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg05887092	chr17:76393375	PGS1	0.41	7.17	0.33	3.39e-12	HDL cholesterol levels;
LUAD	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg19318889	chr4:1322082	MAEA	-0.74	-12.66	-0.52	2.29e-31	Obesity-related traits;
LUAD	trans	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg24644049	chr4:85504048	CDS1	0.85	7.17	0.33	3.38e-12	Skin colour saturation;
LUAD	cis	rs36051895	0.622	rs12335546	chr9:5072182	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-6.6	-0.31	1.2e-10	Pediatric autoimmune diseases;
LUAD	cis	rs7156960	0.898	rs12884039	chr14:76717953	A/G	cg13981132	chr14:76734493	NA	0.44	7.27	0.33	1.76e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg03433033	chr1:76189801	ACADM	-0.69	-10.74	-0.46	6.03e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9297145	0.761	rs62473015	chr7:98763301	G/A	cg05967295	chr7:98741636	SMURF1	0.97	15.71	0.61	4.04e-44	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.03	-0.36	1.01e-14	Diabetic kidney disease;
LUAD	cis	rs9302065	1.000	rs2389236	chr13:95971477	G/A	cg26751094	chr13:95954534	ABCC4	-0.35	-7.29	-0.33	1.58e-12	Blood metabolite levels;
LUAD	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18876405	chr7:65276391	NA	0.45	7.18	0.33	3.18e-12	Aortic root size;
LUAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg04025307	chr7:1156635	C7orf50	0.61	6.87	0.32	2.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg01200585	chr1:228362443	C1orf69	0.44	7.99	0.36	1.34e-14	Diastolic blood pressure;
LUAD	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg22920501	chr2:26401640	FAM59B	0.96	13.84	0.56	3.4e-36	Mean corpuscular hemoglobin;
LUAD	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	7.45	0.34	5.25e-13	Tonsillectomy;
LUAD	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg10426581	chr7:100472382	SRRT	0.77	10.61	0.46	1.74e-23	Resting heart rate;
LUAD	cis	rs4604732	0.527	rs12031949	chr1:247624463	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.07	0.32	6.64e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21659725	chr3:3221576	CRBN	0.67	11.58	0.49	4.09e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.33	6.41	0.3	3.94e-10	Personality dimensions;
LUAD	cis	rs240764	0.782	rs7748644	chr6:101166809	T/G	cg09795085	chr6:101329169	ASCC3	-0.4	-6.94	-0.32	1.48e-11	Neuroticism;
LUAD	trans	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg25894440	chr7:65020034	NA	-0.63	-6.71	-0.31	6.35e-11	Gout;
LUAD	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg06740227	chr12:86229804	RASSF9	0.41	7.08	0.33	5.91e-12	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.02	0.36	1.06e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72681920	0.881	rs12505816	chr4:100219582	G/A	cg12011299	chr4:100065546	ADH4	-0.64	-6.41	-0.3	3.86e-10	Alcohol dependence;
LUAD	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg19163074	chr7:65112434	INTS4L2	0.44	6.74	0.31	5.11e-11	Aortic root size;
LUAD	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.25	-0.33	1.95e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg22963979	chr7:1858916	MAD1L1	-0.48	-8.26	-0.37	1.88e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.31	-8.07	-0.37	7.45e-15	Total body bone mineral density;
LUAD	cis	rs9796	0.870	rs1001341	chr15:41261491	T/A	cg21153102	chr15:41252147	NA	-0.27	-6.55	-0.3	1.69e-10	Menopause (age at onset);
LUAD	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg22875332	chr1:76189707	ACADM	0.78	12.87	0.53	3.09e-32	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg07507251	chr3:52567010	NT5DC2	0.39	7.75	0.35	7.13e-14	Bipolar disorder;
LUAD	trans	rs1941687	0.797	rs9965563	chr18:31398985	T/G	cg27147174	chr7:100797783	AP1S1	-0.5	-8.34	-0.38	1.06e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs10465746	0.967	rs7531537	chr1:84414924	C/T	cg10977910	chr1:84465055	TTLL7	0.49	7.94	0.36	1.83e-14	Obesity-related traits;
LUAD	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg10164272	chr16:89456328	ANKRD11	0.45	7.07	0.32	6.65e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.12	0.33	4.75e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4930561	0.765	rs4930229	chr11:67944080	G/A	cg04465784	chr11:67976953	SUV420H1	-0.27	-8.12	-0.37	5.2e-15	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg13319975	chr6:146136371	FBXO30	0.79	13.6	0.55	3.46e-35	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg19223106	chr19:58898630	RPS5	-0.4	-6.71	-0.31	6.31e-11	Schizophrenia;
LUAD	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg03806693	chr22:41940476	POLR3H	-0.58	-8.35	-0.38	9.94e-16	Vitiligo;
LUAD	cis	rs12579753	0.871	rs10862364	chr12:82201280	C/T	cg07988820	chr12:82153109	PPFIA2	-0.45	-7.06	-0.32	6.8e-12	Resting heart rate;
LUAD	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg26384229	chr12:38710491	ALG10B	0.46	7.47	0.34	4.66e-13	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs2797160	0.515	rs4897149	chr6:125980018	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.47	7.74	0.35	7.52e-14	Endometrial cancer;
LUAD	cis	rs17401966	0.931	rs17410217	chr1:10371854	A/G	cg15208524	chr1:10270712	KIF1B	0.47	7.23	0.33	2.34e-12	Hepatocellular carcinoma;
LUAD	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg00339695	chr16:24857497	SLC5A11	0.48	8.86	0.4	2.22e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs2224391	1.000	rs9784870	chr6:5261359	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.67	-11.22	-0.48	9.3e-26	Height;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg25851803	chr17:79481404	NA	-0.4	-6.4	-0.3	4.15e-10	Cancer;
LUAD	cis	rs2274273	0.840	rs72715769	chr14:55762429	C/G	cg04306507	chr14:55594613	LGALS3	0.42	8.64	0.39	1.19e-16	Protein biomarker;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00350835	chr11:16838596	PLEKHA7	0.43	6.59	0.31	1.34e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg04565464	chr8:145669602	NFKBIL2	0.46	7.02	0.32	8.91e-12	Schizophrenia;
LUAD	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg00106254	chr7:1943704	MAD1L1	-0.48	-7.03	-0.32	8.42e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg08085267	chr17:45401833	C17orf57	-0.52	-8.69	-0.39	8.01e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs7746199	0.736	rs35037868	chr6:27759115	G/C	cg06606381	chr12:133084897	FBRSL1	-1.22	-11.05	-0.47	4.16e-25	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.77	-10.19	-0.44	6.04e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	trans	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg14791747	chr16:20752902	THUMPD1	-0.72	-9.77	-0.43	1.84e-20	Cognitive test performance;
LUAD	cis	rs1451375	0.669	rs10274172	chr7:50637575	G/A	cg18232548	chr7:50535776	DDC	-0.52	-8.42	-0.38	5.7e-16	Malaria;
LUAD	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg19077165	chr18:44547161	KATNAL2	0.47	8.17	0.37	3.69e-15	Personality dimensions;
LUAD	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg05043794	chr9:111880884	C9orf5	-0.41	-7.03	-0.32	8.12e-12	Menarche (age at onset);
LUAD	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg11062466	chr8:58055876	NA	0.71	8.06	0.37	7.65e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs10788264	0.652	rs9633732	chr10:124056473	G/T	cg09507567	chr10:124027408	NA	0.49	10.74	0.46	5.91e-24	Total body bone mineral density;
LUAD	cis	rs55692411	0.537	rs7648652	chr3:50135412	A/C	cg14019146	chr3:50243930	SLC38A3	-0.44	-7.29	-0.33	1.58e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs332507	0.830	rs1846891	chr3:124399397	A/G	cg05980111	chr3:124395277	KALRN	0.42	6.67	0.31	8.04e-11	Plateletcrit;
LUAD	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg26384229	chr12:38710491	ALG10B	-0.41	-6.97	-0.32	1.21e-11	Heart rate;
LUAD	cis	rs2282300	0.739	rs10835647	chr11:30313268	A/G	cg25418670	chr11:30344373	C11orf46	-0.55	-7.67	-0.35	1.19e-13	Morning vs. evening chronotype;
LUAD	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg00666640	chr1:248458726	OR2T12	0.3	7.22	0.33	2.47e-12	Common traits (Other);
LUAD	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-6.97	-0.32	1.21e-11	Personality dimensions;
LUAD	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-10.01	-0.44	2.55e-21	Gut microbiome composition (summer);
LUAD	cis	rs8008758	0.517	rs1772028	chr14:101693861	C/G	cg26224664	chr14:101693935	NA	-0.48	-12.38	-0.52	2.88e-30	Body mass index (alcohol intake interaction);
LUAD	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg10589385	chr1:150898437	SETDB1	0.43	7.9	0.36	2.5e-14	Melanoma;
LUAD	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg08222618	chr4:941054	TMEM175	0.64	10.07	0.44	1.56e-21	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg18351406	chr4:77819688	ANKRD56	0.61	9.8	0.43	1.48e-20	Emphysema distribution in smoking;
LUAD	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg19767477	chr5:127420684	SLC12A2	-0.44	-6.65	-0.31	8.86e-11	Ileal carcinoids;
LUAD	cis	rs877282	0.947	rs4133015	chr10:774131	T/C	cg06581033	chr10:766294	NA	-0.47	-6.68	-0.31	7.51e-11	Uric acid levels;
LUAD	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.47	6.51	0.3	2.09e-10	Renal function-related traits (BUN);
LUAD	cis	rs62229266	0.771	rs11701590	chr21:37384730	A/C	cg08632701	chr21:37451849	NA	-0.46	-7.54	-0.34	2.96e-13	Mitral valve prolapse;
LUAD	cis	rs11992162	0.569	rs35283519	chr8:11831661	C/T	cg20542592	chr8:11973495	FAM66D	0.49	7.23	0.33	2.3e-12	Monocyte count;
LUAD	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg15557168	chr22:42548783	NA	0.51	9.48	0.42	1.92e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11811982	0.793	rs115632182	chr1:227510459	G/T	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg04990556	chr1:26633338	UBXN11	-0.39	-6.41	-0.3	3.89e-10	Obesity-related traits;
LUAD	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg12016809	chr21:47604291	C21orf56	0.45	7.56	0.35	2.52e-13	Testicular germ cell tumor;
LUAD	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg00814883	chr7:100076585	TSC22D4	-0.78	-10.74	-0.46	5.76e-24	Platelet count;
LUAD	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.26e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3106136	0.872	rs2059606	chr4:95255278	C/T	cg11021082	chr4:95130006	SMARCAD1	0.35	6.47	0.3	2.73e-10	Capecitabine sensitivity;
LUAD	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg09184832	chr6:79620586	NA	-0.52	-10.01	-0.44	2.56e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs8064299	0.560	rs11077763	chr17:72786029	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.42	6.84	0.32	2.82e-11	Monocyte count;
LUAD	cis	rs7737355	0.812	rs13167908	chr5:131083829	T/C	cg25547332	chr5:131281432	NA	0.44	7.12	0.33	4.55e-12	Life satisfaction;
LUAD	cis	rs6005807	0.640	rs73432205	chr22:29028132	C/T	cg12565055	chr22:29076175	TTC28	0.75	8.74	0.39	5.63e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg03806693	chr22:41940476	POLR3H	0.64	9.61	0.42	6.54e-20	Vitiligo;
LUAD	trans	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg01620082	chr3:125678407	NA	-0.47	-7.07	-0.33	6.35e-12	Parkinson's disease;
LUAD	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg15181151	chr6:150070149	PCMT1	0.42	8.67	0.39	9.01e-17	Lung cancer;
LUAD	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg18110333	chr6:292329	DUSP22	-0.54	-8.79	-0.39	3.81e-17	Menopause (age at onset);
LUAD	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg03467027	chr4:99064603	C4orf37	0.4	6.44	0.3	3.19e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7236492	0.748	rs78531995	chr18:77198370	C/T	cg15644404	chr18:77186268	NFATC1	-0.61	-6.9	-0.32	1.9e-11	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7192380	0.651	rs34769743	chr16:69580490	C/T	cg26679644	chr16:69762563	NA	0.38	6.92	0.32	1.63e-11	Sjögren's syndrome;
LUAD	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg03806693	chr22:41940476	POLR3H	-0.61	-8.97	-0.4	9.71e-18	Vitiligo;
LUAD	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg05182265	chr7:156933206	UBE3C	-0.8	-16.99	-0.64	9.53e-50	Body mass index;
LUAD	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg17420585	chr12:42539391	GXYLT1	-0.4	-7.06	-0.32	6.71e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	trans	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg05926928	chr17:57297772	GDPD1	1.41	19.49	0.69	7.49e-61	Opioid sensitivity;
LUAD	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.1	13.61	0.55	3.12e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg02018176	chr4:1364513	KIAA1530	0.37	6.99	0.32	1.09e-11	Obesity-related traits;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01083584	chr19:14629193	DNAJB1	-0.53	-6.63	-0.31	1.01e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs80319144	1.000	rs113558390	chr2:159207713	A/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.79	0.31	3.77e-11	Restless legs syndrome;
LUAD	cis	rs732716	0.889	rs11666856	chr19:4437450	A/G	cg21934504	chr19:4445085	UBXN6	0.46	7.72	0.35	8.76e-14	Mean corpuscular volume;
LUAD	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg14186256	chr22:23484241	RTDR1	0.46	7.99	0.36	1.28e-14	Bone mineral density;
LUAD	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg15445000	chr17:37608096	MED1	0.44	8.09	0.37	6.48e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg04398451	chr17:18023971	MYO15A	0.66	11.94	0.5	1.54e-28	Total body bone mineral density;
LUAD	cis	rs8038465	0.592	rs58443257	chr15:73930707	A/T	cg15420318	chr15:73925796	NPTN	0.49	8.08	0.37	6.82e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9948	0.786	rs62152783	chr2:97457389	T/A	cg20312557	chr2:97357134	FER1L5	-0.63	-7.36	-0.34	9.37e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg02753203	chr1:228287806	NA	0.77	14.07	0.56	3.73e-37	Diastolic blood pressure;
LUAD	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg01657329	chr11:68192670	LRP5	-0.42	-6.7	-0.31	6.59e-11	Total body bone mineral density;
LUAD	cis	rs4523957	0.891	rs216200	chr17:2199846	C/T	cg16513277	chr17:2031491	SMG6	0.74	13.74	0.56	9.09e-36	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg11344533	chr11:111475393	SIK2	0.37	6.56	0.3	1.56e-10	Primary sclerosing cholangitis;
LUAD	trans	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-11.41	-0.49	1.86e-26	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg05991184	chr2:219186017	PNKD	-0.34	-6.5	-0.3	2.21e-10	Colorectal cancer;
LUAD	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg10792982	chr14:105748885	BRF1	0.45	9.73	0.43	2.62e-20	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs4642101	0.824	rs9852222	chr3:12848491	G/T	cg24848339	chr3:12840334	CAND2	0.39	7.81	0.35	4.65e-14	QRS complex (12-leadsum);
LUAD	cis	rs1018836	0.608	rs7821069	chr8:91465548	C/G	cg16814680	chr8:91681699	NA	-0.52	-8.43	-0.38	5.6e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01140101	chr1:202113040	ARL8A	-0.41	-6.5	-0.3	2.33e-10	Height;
LUAD	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg06608945	chr2:219082296	ARPC2	0.42	6.96	0.32	1.32e-11	Colorectal cancer;
LUAD	cis	rs7799006	0.862	rs733611	chr7:2256779	G/A	cg08027265	chr7:2291960	NA	-0.56	-10.03	-0.44	2.24e-21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg00857998	chr1:205179979	DSTYK	0.4	6.59	0.31	1.33e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs738321	0.711	rs5995541	chr22:38553411	C/T	cg25457927	chr22:38595422	NA	-0.56	-12.44	-0.52	1.72e-30	Breast cancer;
LUAD	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11890956	chr21:40555474	PSMG1	-0.57	-9.94	-0.44	4.74e-21	Menarche (age at onset);
LUAD	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg21433313	chr16:3507492	NAT15	0.79	8.3	0.37	1.36e-15	Tuberculosis;
LUAD	cis	rs4638749	0.677	rs7594896	chr2:108835502	C/T	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.35	-0.34	1.03e-12	Blood pressure;
LUAD	cis	rs7187994	0.651	rs12933163	chr16:84798300	G/C	cg07647771	chr16:84786436	USP10	-0.31	-8.17	-0.37	3.51e-15	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg08470875	chr2:26401718	FAM59B	-0.62	-8.52	-0.38	2.89e-16	Gut microbiome composition (summer);
LUAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg13560548	chr3:10150139	C3orf24	0.42	6.99	0.32	1.09e-11	Alzheimer's disease;
LUAD	cis	rs2839627	0.638	rs73233314	chr21:44297774	G/T	cg03543861	chr21:44258195	NA	0.65	7.73	0.35	7.77e-14	Information processing speed;
LUAD	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-9.74	-0.43	2.26e-20	Gut microbiome composition (summer);
LUAD	cis	rs938554	1.000	rs6832439	chr4:9924319	A/G	cg11266682	chr4:10021025	SLC2A9	0.43	7.57	0.35	2.36e-13	Blood metabolite levels;
LUAD	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg04756594	chr16:24857601	SLC5A11	-0.74	-12.55	-0.52	6.29e-31	Intelligence (multi-trait analysis);
LUAD	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg16647868	chr5:131706066	SLC22A5	0.48	7.71	0.35	9.27e-14	Breast cancer;
LUAD	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg11189052	chr15:85197271	WDR73	-0.84	-14.69	-0.58	9e-40	P wave terminal force;
LUAD	cis	rs10189230	0.935	rs3755029	chr2:222345820	T/C	cg14652038	chr2:222343519	EPHA4	0.44	8.63	0.39	1.26e-16	Urate levels in lean individuals;
LUAD	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23583168	chr7:148888333	NA	-0.91	-19.03	-0.68	9.05e-59	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg25985355	chr7:65971099	NA	-0.38	-6.89	-0.32	2.02e-11	Aortic root size;
LUAD	cis	rs4889855	0.530	rs4890047	chr17:78549439	A/G	cg16591659	chr17:78472290	NA	-0.37	-6.61	-0.31	1.16e-10	Fractional excretion of uric acid;
LUAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00149659	chr3:10157352	C3orf10	0.62	8.68	0.39	8.62e-17	Alzheimer's disease;
LUAD	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg02569458	chr12:86230093	RASSF9	0.44	8.02	0.36	1.06e-14	Major depressive disorder;
LUAD	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg14582100	chr15:45693742	SPATA5L1	0.63	12.5	0.52	1.01e-30	Homoarginine levels;
LUAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08677398	chr8:58056175	NA	0.48	6.79	0.31	3.8e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs868036	0.718	rs4776984	chr15:68118194	A/C	cg24579218	chr15:68104479	NA	-0.54	-9.34	-0.41	5.74e-19	Restless legs syndrome;
LUAD	cis	rs10739663	0.520	rs3122935	chr9:128154203	A/G	cg14078157	chr9:128172775	NA	0.43	8.11	0.37	5.59e-15	Resting heart rate;
LUAD	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg21138405	chr5:131827807	IRF1	0.6	13.88	0.56	2.35e-36	Asthma (sex interaction);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20018561	chr13:52586135	ALG11;ATP7B	-0.53	-6.45	-0.3	3.03e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg22535103	chr8:58192502	C8orf71	-0.63	-7.04	-0.32	8.07e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg19676328	chr12:49525230	TUBA1B	-0.67	-10.82	-0.47	2.94e-24	Total cholesterol levels;
LUAD	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19717773	chr7:2847554	GNA12	-0.57	-9.64	-0.42	5.17e-20	Height;
LUAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-9.51	-0.42	1.46e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7927592	0.513	rs630225	chr11:68194611	A/C	cg01657329	chr11:68192670	LRP5	-0.55	-9.91	-0.43	6.08e-21	Total body bone mineral density;
LUAD	cis	rs4713675	0.510	rs1014933	chr6:33677235	A/G	cg13859433	chr6:33739653	LEMD2	-0.3	-7.11	-0.33	5.14e-12	Plateletcrit;
LUAD	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg18944383	chr4:111397179	ENPEP	0.37	7.49	0.34	4e-13	Height;
LUAD	cis	rs6684514	1.000	rs3806407	chr1:156251742	T/C	cg16558208	chr1:156270281	VHLL	0.53	9.58	0.42	8.12e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg25769590	chr7:158789503	NA	-0.36	-6.58	-0.3	1.42e-10	Facial morphology (factor 20);
LUAD	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-10.98	-0.47	7.76e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	9.81	0.43	1.35e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs9929218	1.000	rs8044058	chr16:68807088	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-13.97	-0.56	9.34e-37	Colorectal cancer;
LUAD	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.76	-0.39	4.75e-17	Total body bone mineral density;
LUAD	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg20487152	chr13:99095054	FARP1	-0.47	-8.03	-0.36	9.56e-15	Longevity;
LUAD	trans	rs853679	0.713	rs200991	chr6:27815494	A/C	cg01620082	chr3:125678407	NA	0.47	6.49	0.3	2.42e-10	Depression;
LUAD	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg05623727	chr3:50126028	RBM5	-0.31	-6.75	-0.31	4.91e-11	Body mass index;
LUAD	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.86	16.55	0.63	8.24e-48	Lymphocyte counts;
LUAD	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.37	7.46	0.34	4.83e-13	Platelet count;
LUAD	trans	rs2797160	0.935	rs1739379	chr6:126012593	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.54	8.7	0.39	7.72e-17	Endometrial cancer;
LUAD	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.24	0.33	2.07e-12	Hip circumference adjusted for BMI;
LUAD	trans	rs7395662	0.895	rs1827971	chr11:48718502	C/G	cg15704280	chr7:45808275	SEPT13	-0.41	-6.35	-0.3	5.43e-10	HDL cholesterol;
LUAD	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg16989719	chr2:238392110	NA	-0.37	-7.83	-0.36	3.98e-14	Prostate cancer;
LUAD	trans	rs7746199	0.736	rs13193542	chr6:27702425	G/T	cg01620082	chr3:125678407	NA	-1.01	-10.28	-0.45	2.92e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg04539111	chr16:67997858	SLC12A4	-0.54	-6.76	-0.31	4.59e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1232027	0.700	rs1650712	chr5:79935513	T/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.83	-0.36	3.9e-14	Huntington's disease progression;
LUAD	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg17971929	chr21:40555470	PSMG1	0.56	8.87	0.4	2.04e-17	Cognitive function;
LUAD	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg15691649	chr6:25882328	NA	-0.45	-7.23	-0.33	2.26e-12	Blood metabolite levels;
LUAD	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg18351406	chr4:77819688	ANKRD56	0.63	10.16	0.44	7.36e-22	Emphysema distribution in smoking;
LUAD	trans	rs7615952	0.546	rs2979350	chr3:125362215	T/C	cg17147758	chr8:6949321	NA	-0.51	-8.12	-0.37	5.29e-15	Blood pressure (smoking interaction);
LUAD	cis	rs2046867	0.862	rs62252360	chr3:72838551	C/T	cg04365224	chr3:72788183	NA	-0.42	-6.41	-0.3	3.78e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg22753661	chr15:79092743	ADAMTS7	0.57	8.58	0.39	1.78e-16	Coronary artery disease or large artery stroke;
LUAD	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg26690334	chr16:1524521	CLCN7	0.39	7.7	0.35	1.01e-13	Bone mineral density;
LUAD	cis	rs7727544	0.557	rs2897096	chr5:131486284	A/G	cg14196790	chr5:131705035	SLC22A5	0.41	7.24	0.33	2.09e-12	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg22535103	chr8:58192502	C8orf71	-0.69	-7.47	-0.34	4.76e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs600231	0.542	rs11227196	chr11:65234922	G/A	cg17120908	chr11:65337727	SSSCA1	-0.65	-8.59	-0.39	1.66e-16	Bone mineral density;
LUAD	cis	rs1003719	0.788	rs2835577	chr21:38457457	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.34e-16	Eye color traits;
LUAD	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.57	-7.36	-0.34	9.77e-13	Body mass index;
LUAD	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg11266682	chr4:10021025	SLC2A9	0.6	12.99	0.53	1.06e-32	Bone mineral density;
LUAD	trans	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg25894440	chr7:65020034	NA	-0.63	-6.71	-0.31	6.35e-11	Gout;
LUAD	cis	rs4664304	1.000	rs6735923	chr2:160769588	A/G	cg23995753	chr2:160760732	LY75	-0.47	-8.42	-0.38	5.85e-16	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.21	0.37	2.79e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg07636037	chr3:49044803	WDR6	0.48	8.03	0.36	9.94e-15	Menarche (age at onset);
LUAD	trans	rs10411161	0.702	rs2867319	chr19:52397160	T/C	cg22319618	chr22:45562946	NUP50	-0.66	-9.44	-0.42	2.52e-19	Breast cancer;
LUAD	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg03388025	chr16:89894329	SPIRE2	0.32	7.21	0.33	2.53e-12	Vitiligo;
LUAD	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg15556689	chr8:8085844	FLJ10661	0.5	8.02	0.36	1.08e-14	Neuroticism;
LUAD	trans	rs11165623	0.564	rs7555035	chr1:96996026	T/C	cg10631902	chr5:14652156	NA	-0.41	-7.58	-0.35	2.27e-13	Hip circumference;Waist circumference;
LUAD	cis	rs4642101	0.639	rs9870433	chr3:12853566	T/C	cg24848339	chr3:12840334	CAND2	0.38	7.53	0.34	3.13e-13	QRS complex (12-leadsum);
LUAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg07234876	chr8:600039	NA	1.04	10.16	0.44	7.39e-22	IgG glycosylation;
LUAD	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	13.92	0.56	1.54e-36	Smoking behavior;
LUAD	cis	rs9560113	1.000	rs9555805	chr13:112179765	C/T	cg14154082	chr13:112174009	NA	0.36	6.75	0.31	4.77e-11	Menarche (age at onset);
LUAD	cis	rs11585357	0.501	rs17458002	chr1:17591524	A/G	cg08277548	chr1:17600880	PADI3	-0.7	-7.94	-0.36	1.87e-14	Hair shape;
LUAD	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-7.27	-0.33	1.74e-12	Platelet count;
LUAD	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg08601574	chr20:25228251	PYGB	0.46	8.51	0.38	3.16e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7336332	0.800	rs9805452	chr13:28047908	C/T	cg22138327	chr13:27999177	GTF3A	0.74	10.61	0.46	1.75e-23	Weight;
LUAD	cis	rs10924309	0.737	rs1538957	chr1:245855639	A/G	cg00036263	chr1:245852353	KIF26B	-0.5	-8.34	-0.38	1.07e-15	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs12681287	0.711	rs28420256	chr8:87255599	C/T	cg27223183	chr8:87520930	FAM82B	-0.62	-8.74	-0.39	5.45e-17	Caudate activity during reward;
LUAD	cis	rs58749629	1.000	rs7270354	chr20:44607661	C/T	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.52	-6.71	-0.31	6.16e-11	Abdominal aortic aneurysm;
LUAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg11062466	chr8:58055876	NA	0.67	8.82	0.39	3.05e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08704250	chr15:31115839	NA	-0.52	-9.31	-0.41	7.24e-19	Huntington's disease progression;
LUAD	trans	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	1.04e-10	Diabetic kidney disease;
LUAD	cis	rs8017423	0.935	rs59444150	chr14:90767175	T/C	cg14092571	chr14:90743983	NA	-0.46	-7.9	-0.36	2.45e-14	Mortality in heart failure;
LUAD	trans	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg19163074	chr7:65112434	INTS4L2	0.42	6.4	0.3	4.24e-10	Aortic root size;
LUAD	cis	rs367615	0.512	rs246105	chr5:108672946	C/T	cg17395555	chr5:108820864	NA	0.49	9.3	0.41	7.82e-19	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg03806693	chr22:41940476	POLR3H	-0.61	-8.7	-0.39	7.38e-17	Vitiligo;
LUAD	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg15704280	chr7:45808275	SEPT13	-0.62	-8.35	-0.38	9.61e-16	Axial length;
LUAD	cis	rs500891	0.525	rs7758989	chr6:84061319	T/C	cg08257003	chr6:84140564	ME1	0.34	6.64	0.31	9.64e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs8048589	0.898	rs3851011	chr16:12192472	C/A	cg03816625	chr16:12192430	SNX29	0.52	7.54	0.34	2.81e-13	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	trans	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.91	0.4	1.56e-17	Endometrial cancer;
LUAD	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg27219399	chr15:67835830	MAP2K5	0.37	6.4	0.3	4.15e-10	Obesity;
LUAD	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26314531	chr2:26401878	FAM59B	-0.71	-9.9	-0.43	6.27e-21	Gut microbiome composition (summer);
LUAD	trans	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg07817883	chr1:32538562	TMEM39B	1.18	12.43	0.52	1.88e-30	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg20307385	chr11:47447363	PSMC3	0.52	7.75	0.35	6.97e-14	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg25554036	chr4:6271136	WFS1	0.67	13.22	0.54	1.26e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg27284194	chr4:1044797	NA	0.69	10.16	0.44	7.89e-22	Recombination rate (females);
LUAD	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg07570687	chr10:102243282	WNT8B	0.42	6.35	0.3	5.57e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs4253772	0.575	rs9615979	chr22:46789021	G/T	cg09491104	chr22:46646882	C22orf40	-0.59	-7.3	-0.33	1.46e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg08807101	chr21:30365312	RNF160	-0.44	-7.58	-0.35	2.23e-13	Dental caries;
LUAD	cis	rs17532515	0.652	rs17005945	chr4:141378128	C/A	cg03645522	chr4:141391200	NA	0.4	6.41	0.3	3.85e-10	Select biomarker traits;
LUAD	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-7.86	-0.36	3.15e-14	Neutrophil percentage of white cells;
LUAD	cis	rs2281845	0.826	rs4915214	chr1:201076290	T/A	cg17810781	chr1:201082982	CACNA1S	0.35	6.37	0.3	4.89e-10	Permanent tooth development;
LUAD	cis	rs12200782	1.000	rs3800304	chr6:26598798	G/A	cg11502198	chr6:26597334	ABT1	-0.78	-6.76	-0.31	4.6e-11	Small cell lung carcinoma;
LUAD	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg11247378	chr22:39784982	NA	0.76	13.96	0.56	1.06e-36	Intelligence (multi-trait analysis);
LUAD	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg14019146	chr3:50243930	SLC38A3	0.36	6.68	0.31	7.32e-11	Body mass index;
LUAD	trans	rs1728785	1.000	rs4783657	chr16:68586322	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.68	10.15	0.44	8.43e-22	Ulcerative colitis;
LUAD	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.39	-6.81	-0.31	3.3e-11	Platelet count;
LUAD	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg24818145	chr4:99064322	C4orf37	0.45	7.1	0.33	5.38e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3857536	0.785	rs6455089	chr6:66944733	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	cis	rs7593730	0.832	rs10929981	chr2:161233795	C/T	cg22609984	chr2:161126801	NA	0.48	7.47	0.34	4.61e-13	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg17366294	chr4:99064904	C4orf37	0.49	9.18	0.41	1.99e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.97	-0.32	1.23e-11	Fear of minor pain;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23358871	chr17:78121069	EIF4A3	-0.42	-6.56	-0.3	1.59e-10	Height;
LUAD	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg07979401	chr6:33739406	LEMD2	-0.54	-9.69	-0.43	3.41e-20	Schizophrenia;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg09339301	chr6:163836245	QKI	-0.41	-6.62	-0.31	1.12e-10	Subcortical brain region volumes;
LUAD	trans	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg03886242	chr7:26192032	NFE2L3	-0.44	-7.58	-0.35	2.23e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg00701064	chr4:6280414	WFS1	0.64	14.16	0.57	1.5e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs864537	0.618	rs2995089	chr1:167431193	G/A	cg22356347	chr1:167427500	CD247	-0.49	-9.9	-0.43	6.25e-21	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg12908607	chr1:44402522	ARTN	-0.52	-9.95	-0.44	4.2e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1232027	0.656	rs1650747	chr5:79981593	C/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.42	-6.5	-0.3	2.27e-10	Huntington's disease progression;
LUAD	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg02423579	chr7:2872169	GNA12	-0.88	-15.55	-0.6	1.93e-43	Height;
LUAD	cis	rs7680126	0.633	rs55766779	chr4:10287039	C/T	cg00071950	chr4:10020882	SLC2A9	-0.59	-8.28	-0.37	1.63e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg07936489	chr17:37558343	FBXL20	-0.44	-6.82	-0.31	3.11e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7582720	0.943	rs72934551	chr2:203984117	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.69	0.43	3.45e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs4243830	1.000	rs34757678	chr1:6583270	C/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.72	8.14	0.37	4.48e-15	Body mass index;
LUAD	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.96	-0.36	1.64e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg06606381	chr12:133084897	FBRSL1	0.85	8.2	0.37	2.94e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg05564831	chr3:52568323	NT5DC2	-0.39	-7.07	-0.32	6.61e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg21427119	chr20:30132790	HM13	-0.5	-7.34	-0.34	1.08e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg10755058	chr3:40428713	ENTPD3	0.39	7.19	0.33	2.87e-12	Renal cell carcinoma;
LUAD	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg06781209	chr11:61594997	FADS2	-0.4	-7.53	-0.34	3.15e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg00603274	chr11:61596626	FADS2	-0.37	-6.52	-0.3	2.06e-10	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg18932078	chr1:2524107	MMEL1	0.37	6.89	0.32	1.98e-11	Ulcerative colitis;
LUAD	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg18446336	chr7:2847575	GNA12	-0.34	-6.89	-0.32	2.01e-11	Height;
LUAD	cis	rs28830936	0.510	rs11070349	chr15:42085017	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.58	-14.08	-0.56	3.51e-37	Diastolic blood pressure;
LUAD	cis	rs877282	0.898	rs11253341	chr10:765008	G/C	cg06581033	chr10:766294	NA	-0.58	-7.95	-0.36	1.74e-14	Uric acid levels;
LUAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg27532560	chr4:187881888	NA	-0.35	-6.47	-0.3	2.69e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9372498	0.536	rs62422236	chr6:118972633	G/T	cg21191810	chr6:118973309	C6orf204	-0.54	-8.17	-0.37	3.6e-15	Diastolic blood pressure;
LUAD	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg25208724	chr1:156163844	SLC25A44	-1.19	-27.38	-0.8	1.01e-95	Testicular germ cell tumor;
LUAD	cis	rs9314323	0.698	rs1064807	chr8:26236978	C/T	cg13160058	chr8:26243215	BNIP3L	-0.46	-9.36	-0.41	4.85e-19	Red cell distribution width;
LUAD	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg02990361	chr1:107599529	PRMT6	0.62	10.29	0.45	2.53e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs10838798	0.501	rs2270994	chr11:48157869	T/C	cg21153622	chr11:89784906	NA	-0.33	-6.35	-0.3	5.46e-10	Height;
LUAD	cis	rs3772130	0.962	rs4311252	chr3:121514161	A/G	cg20356878	chr3:121714668	ILDR1	0.55	8.97	0.4	9.98e-18	Cognitive performance;
LUAD	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg19743168	chr1:23544995	NA	-0.6	-10.66	-0.46	1.16e-23	Height;
LUAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg27454412	chr7:1067447	C7orf50	0.48	7.74	0.35	7.28e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg16205897	chr5:131564050	P4HA2	-0.33	-7.38	-0.34	8.7e-13	Blood metabolite levels;
LUAD	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.46	0.34	5.07e-13	Bipolar disorder;
LUAD	cis	rs6906287	0.647	rs12215793	chr6:118956857	A/T	cg21191810	chr6:118973309	C6orf204	0.5	9.51	0.42	1.47e-19	Electrocardiographic conduction measures;
LUAD	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg06784218	chr1:46089804	CCDC17	-0.53	-11.84	-0.5	3.99e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg03467027	chr4:99064603	C4orf37	0.4	6.38	0.3	4.76e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7937890	0.561	rs2575849	chr11:14539639	T/A	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.12e-10	Mitochondrial DNA levels;
LUAD	cis	rs9807989	0.811	rs11689730	chr2:102969984	C/A	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.03e-10	Asthma;
LUAD	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg15242686	chr22:24348715	GSTTP1	0.42	7.2	0.33	2.79e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg11050988	chr7:1952600	MAD1L1	-0.37	-7.61	-0.35	1.83e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg23649088	chr2:200775458	C2orf69	-0.61	-8.33	-0.38	1.15e-15	Schizophrenia;
LUAD	cis	rs77741769	0.571	rs10849807	chr12:121314056	T/C	cg02419362	chr12:121203948	SPPL3	0.41	8.27	0.37	1.76e-15	Mean corpuscular volume;
LUAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg11062466	chr8:58055876	NA	0.67	9.02	0.4	6.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg12599982	chr1:44399894	ARTN	0.35	7.02	0.32	8.87e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.49	0.38	3.54e-16	Breast cancer;
LUAD	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg23587288	chr2:27483067	SLC30A3	-0.43	-8.45	-0.38	4.69e-16	Blood metabolite levels;
LUAD	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg23815491	chr16:72088622	HP	0.59	11.17	0.48	1.4e-25	Fibrinogen levels;
LUAD	cis	rs7122539	0.646	rs594313	chr11:66608991	A/G	cg24851651	chr11:66362959	CCS	0.39	7.24	0.33	2.19e-12	HIV-1 susceptibility;
LUAD	cis	rs7213347	0.707	rs2038677	chr17:2178092	C/G	cg02569219	chr17:2266849	SGSM2	-0.43	-6.98	-0.32	1.13e-11	Total body bone mineral density;
LUAD	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg08779649	chr13:50194554	NA	0.41	8.24	0.37	2.17e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg02734326	chr4:10020555	SLC2A9	0.56	9.91	0.43	5.81e-21	Bone mineral density;
LUAD	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg23625390	chr15:77176239	SCAPER	0.45	7.44	0.34	5.83e-13	Blood metabolite levels;
LUAD	cis	rs977987	0.843	rs10514396	chr16:75422903	T/C	cg03315344	chr16:75512273	CHST6	0.64	14.03	0.56	5.56e-37	Dupuytren's disease;
LUAD	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg09835421	chr16:68378352	PRMT7	-0.82	-8.84	-0.39	2.61e-17	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.4	0.52	2.51e-30	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs2274273	0.588	rs9919923	chr14:55813899	A/G	cg04306507	chr14:55594613	LGALS3	0.41	7.84	0.36	3.7e-14	Protein biomarker;
LUAD	trans	rs12200782	1.000	rs4515370	chr6:26625319	T/C	cg08851530	chr6:28072375	NA	0.72	6.56	0.3	1.53e-10	Small cell lung carcinoma;
LUAD	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg04450456	chr4:17643702	FAM184B	0.42	8.31	0.37	1.28e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg21475434	chr5:93447410	FAM172A	0.72	8.26	0.37	1.95e-15	Diabetic retinopathy;
LUAD	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.09	-0.4	3.9e-18	Total body bone mineral density;
LUAD	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg00933542	chr6:150070202	PCMT1	0.45	9.71	0.43	3.01e-20	Lung cancer;
LUAD	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg17200465	chr3:40428508	ENTPD3	0.27	6.6	0.31	1.23e-10	Renal cell carcinoma;
LUAD	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg09509183	chr1:209979624	IRF6	0.59	7.35	0.34	1.04e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg06108461	chr20:60628389	TAF4	-0.82	-13.97	-0.56	9.79e-37	Body mass index;
LUAD	cis	rs12367572	0.965	rs10785539	chr12:45233023	G/C	cg04608330	chr12:45269318	NELL2	-0.34	-6.35	-0.3	5.56e-10	Gut microbiome composition (summer);
LUAD	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg20476274	chr7:133979776	SLC35B4	0.58	9.59	0.42	7.48e-20	Mean platelet volume;
LUAD	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg14784868	chr12:69753453	YEATS4	0.46	7.58	0.35	2.25e-13	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg17652424	chr22:38574118	PLA2G6	-0.33	-9.95	-0.44	4.31e-21	Cutaneous nevi;
LUAD	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg14403583	chr14:105418241	AHNAK2	-0.44	-8.14	-0.37	4.36e-15	Rheumatoid arthritis;
LUAD	cis	rs356992	0.830	rs356991	chr2:60744872	T/G	cg08426369	chr2:60753602	BCL11A	0.46	7.73	0.35	7.96e-14	Educational attainment (years of education);
LUAD	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg00757033	chr12:89920650	WDR51B	0.68	11.82	0.5	4.86e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs4911259	0.552	rs13038881	chr20:31468113	T/C	cg13636640	chr20:31349939	DNMT3B	-0.57	-9.36	-0.41	4.7e-19	Inflammatory bowel disease;
LUAD	cis	rs17155006	0.628	rs397941	chr7:107727709	C/T	cg05962710	chr7:107745446	LAMB4	-0.3	-6.57	-0.3	1.45e-10	Pneumococcal bacteremia;
LUAD	cis	rs9400271	0.527	rs11759230	chr6:109640321	A/C	cg21918786	chr6:109611834	NA	0.41	6.82	0.31	3.16e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg03929089	chr4:120376271	NA	0.67	9.62	0.42	5.93e-20	Coronary artery disease;
LUAD	trans	rs78049276	0.736	rs77028772	chr4:148364920	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.63	-7.12	-0.33	4.64e-12	Pulse pressure;
LUAD	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg21475434	chr5:93447410	FAM172A	0.74	8.28	0.37	1.65e-15	Diabetic retinopathy;
LUAD	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg22963979	chr7:1858916	MAD1L1	-0.59	-10.05	-0.44	1.91e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg10523679	chr1:76189770	ACADM	0.9	15.51	0.6	2.87e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2839186	0.584	rs2032111	chr21:47904569	G/A	cg12379764	chr21:47803548	PCNT	-0.43	-6.96	-0.32	1.31e-11	Testicular germ cell tumor;
LUAD	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg20701182	chr2:24300061	SF3B14	0.63	6.94	0.32	1.52e-11	Lymphocyte counts;
LUAD	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg08514558	chr10:81106712	PPIF	0.48	9.52	0.42	1.39e-19	Height;
LUAD	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.25	6.49	0.3	2.4e-10	Parkinson's disease;
LUAD	trans	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-7.7	-0.35	9.87e-14	Resting heart rate;
LUAD	cis	rs7692976	0.552	rs7699288	chr4:110942277	C/G	cg06981781	chr4:110842888	EGF	0.37	6.44	0.3	3.3e-10	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs3813948	0.543	rs2808468	chr1:207280703	A/G	cg22332276	chr1:207277018	C4BPA	-0.65	-8.67	-0.39	9.63e-17	C4b binding protein levels;
LUAD	cis	rs72928364	1.000	rs17398421	chr3:100672907	T/G	cg10123952	chr3:100791384	NA	0.61	7.34	0.34	1.08e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.23	0.48	8.73e-26	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.74	0.31	5.06e-11	Rheumatoid arthritis;
LUAD	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.65	-0.35	1.4e-13	Neuroticism;
LUAD	cis	rs12900413	0.687	rs12908468	chr15:90304236	T/G	cg24249390	chr15:90295951	MESP1	-0.35	-6.98	-0.32	1.15e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg12379764	chr21:47803548	PCNT	-0.37	-6.38	-0.3	4.72e-10	Testicular germ cell tumor;
LUAD	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg09253696	chr17:73873529	TRIM47	-0.42	-7.29	-0.33	1.58e-12	Psoriasis;
LUAD	cis	rs2625529	0.824	rs1074330	chr15:72250741	C/T	cg16672083	chr15:72433130	SENP8	-0.73	-12.19	-0.51	1.6800000000000001e-29	Red blood cell count;
LUAD	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg03433033	chr1:76189801	ACADM	-0.48	-6.95	-0.32	1.38e-11	Daytime sleep phenotypes;
LUAD	cis	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.64	6.62	0.31	1.11e-10	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg21770322	chr7:97807741	LMTK2	0.33	7.47	0.34	4.65e-13	Breast cancer;
LUAD	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg11062466	chr8:58055876	NA	0.68	9.02	0.4	6.56e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14426517	chr6:153323975	MTRF1L	-0.61	-7.66	-0.35	1.27e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg02734326	chr4:10020555	SLC2A9	-0.45	-7.72	-0.35	8.69e-14	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.51	8.33	0.38	1.13e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg11766577	chr21:47581405	C21orf56	0.64	11.78	0.5	6.65e-28	Testicular germ cell tumor;
LUAD	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs28655083	0.828	rs11640648	chr16:77122494	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.47	7.73	0.35	8.17e-14	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs360929	0.608	rs360903	chr4:152858111	C/T	cg22822647	chr19:16771056	TMEM38A;C19orf42	-0.59	-7.08	-0.33	5.99e-12	Volumetric brain MRI;
LUAD	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.39	7.89	0.36	2.65e-14	Monocyte percentage of white cells;
LUAD	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.01	-0.36	1.09e-14	Diabetic kidney disease;
LUAD	cis	rs427394	0.632	rs169285	chr5:6736587	G/C	cg10857441	chr5:6722123	POLS	-0.6	-10.71	-0.46	7.85e-24	Menopause (age at onset);
LUAD	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg22906224	chr7:99728672	NA	0.63	10.39	0.45	1.12e-22	Coronary artery disease;
LUAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00149659	chr3:10157352	C3orf10	0.55	7.57	0.35	2.41e-13	Alzheimer's disease;
LUAD	cis	rs11209185	0.672	rs1926278	chr1:68453859	C/T	cg22082780	chr1:68452167	NA	0.32	6.85	0.32	2.67e-11	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14159672	chr1:205819179	PM20D1	0.51	8.3	0.37	1.42e-15	Parkinson's disease;
LUAD	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg00593900	chr19:10206746	ANGPTL6	0.37	7.71	0.35	9.11e-14	Narcolepsy;
LUAD	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg05340658	chr4:99064831	C4orf37	-0.57	-9.82	-0.43	1.21e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg11663144	chr21:46675770	NA	-0.6	-11.77	-0.5	7.63e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg19774624	chr17:42201019	HDAC5	-0.4	-6.86	-0.32	2.43e-11	Total body bone mineral density;
LUAD	cis	rs3806843	0.520	rs265312	chr5:140296272	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.61	-0.31	1.13e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.23	-0.33	2.29e-12	Lung cancer;
LUAD	trans	rs629535	0.783	rs658407	chr8:70035247	T/C	cg21567404	chr3:27674614	NA	1.01	18.57	0.67	9.52e-57	Dupuytren's disease;
LUAD	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg02176678	chr2:219576539	TTLL4	0.74	14.93	0.59	8.76e-41	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs35740288	0.770	rs11636185	chr15:86183118	A/G	cg13263323	chr15:86062960	AKAP13	-0.44	-7.09	-0.33	5.8e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs908922	0.676	rs477621	chr1:152486252	T/C	cg21823605	chr1:152486609	CRCT1	0.28	6.37	0.3	4.9e-10	Hair morphology;
LUAD	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg21724239	chr8:58056113	NA	0.64	8.23	0.37	2.37e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg07617317	chr6:118971624	C6orf204	0.55	8.54	0.38	2.38e-16	Diastolic blood pressure;
LUAD	cis	rs9296095	0.796	rs3846855	chr6:33555877	G/A	cg24505687	chr6:33548425	BAK1	0.42	6.36	0.3	5.09e-10	Platelet count;
LUAD	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg15691649	chr6:25882328	NA	0.39	6.43	0.3	3.55e-10	Blood metabolite levels;
LUAD	trans	rs11039798	0.614	rs2174703	chr11:48788242	G/A	cg03929089	chr4:120376271	NA	0.6	6.86	0.32	2.49e-11	Axial length;
LUAD	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg04218760	chr10:45406644	TMEM72	-0.31	-8.01	-0.36	1.12e-14	Mean corpuscular volume;
LUAD	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg15147215	chr3:52552868	STAB1	-0.51	-9.97	-0.44	3.58e-21	Electroencephalogram traits;
LUAD	cis	rs10899021	0.920	rs76121309	chr11:74343921	A/T	cg25880958	chr11:74394337	NA	-0.66	-8.16	-0.37	3.95e-15	Response to metformin (IC50);
LUAD	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs907683	0.570	rs2666104	chr2:220281010	C/T	cg15015639	chr2:220282977	DES	-0.49	-8.98	-0.4	8.95e-18	Resting heart rate;
LUAD	cis	rs10097731	0.808	rs80141261	chr8:82034453	T/C	cg25230327	chr8:82042993	NA	-0.56	-9.76	-0.43	1.99e-20	Serum total protein level;
LUAD	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg18180107	chr4:99064573	C4orf37	-0.49	-7.67	-0.35	1.17e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.07	-0.33	6.32e-12	Coronary artery disease;
LUAD	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	7.3	0.33	1.45e-12	Menarche (age at onset);
LUAD	trans	rs11650494	0.908	rs75092916	chr17:47412578	T/C	cg11430096	chr6:110968061	CDK19	0.86	6.55	0.3	1.7e-10	Prostate cancer;
LUAD	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-7.35	-0.34	1.06e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-8.36	-0.38	9.06e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-9.92	-0.43	5.5e-21	Life satisfaction;
LUAD	cis	rs2882667	0.894	rs10054478	chr5:138354075	G/A	cg04439458	chr5:138467593	SIL1	-0.41	-7.39	-0.34	8.17e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg18944383	chr4:111397179	ENPEP	0.38	7.64	0.35	1.43e-13	Height;
LUAD	cis	rs250677	0.522	rs10045726	chr5:148352990	C/T	cg12140854	chr5:148520817	ABLIM3	0.57	9.24	0.41	1.26e-18	Breast cancer;
LUAD	cis	rs2573652	0.755	rs6598286	chr15:100515985	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.66	-13.07	-0.54	4.82e-33	Height;
LUAD	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	7.23	0.33	2.28e-12	Menopause (age at onset);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07306088	chr12:46777190	NA	-0.65	-6.42	-0.3	3.63e-10	Type 2 diabetes;
LUAD	cis	rs9902453	0.933	rs4470197	chr17:28464474	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.72	0.39	6.6e-17	Coffee consumption (cups per day);
LUAD	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg13722127	chr7:150037890	RARRES2	0.47	8.18	0.37	3.44e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.34e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg00495681	chr13:53174319	NA	0.42	6.99	0.32	1.06e-11	Lewy body disease;
LUAD	cis	rs9768139	0.708	rs35057023	chr7:158114748	G/A	cg25566285	chr7:158114605	PTPRN2	0.5	10.36	0.45	1.39e-22	Calcium levels;
LUAD	cis	rs10781543	0.810	rs11145756	chr9:139364585	A/G	cg14019695	chr9:139328340	INPP5E	0.52	10.35	0.45	1.59e-22	Monocyte percentage of white cells;
LUAD	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg07432352	chr17:45403706	C17orf57	-0.41	-7.94	-0.36	1.79e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg10523679	chr1:76189770	ACADM	0.91	15.94	0.61	3.89e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg21252483	chr19:49399788	TULP2	-0.89	-14.78	-0.58	3.62e-40	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg21475434	chr5:93447410	FAM172A	0.71	8.49	0.38	3.46e-16	Diabetic retinopathy;
LUAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg15117754	chr3:10150083	C3orf24	0.4	6.66	0.31	8.79e-11	Alzheimer's disease;
LUAD	cis	rs4774899	0.866	rs2431023	chr15:57553832	A/T	cg14026238	chr15:57616123	NA	0.38	7.28	0.33	1.59e-12	Urinary tract infection frequency;
LUAD	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18876405	chr7:65276391	NA	0.4	6.37	0.3	4.81e-10	Aortic root size;
LUAD	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg22705602	chr4:152727874	NA	-0.41	-7.16	-0.33	3.5e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10802521	chr3:52805072	NEK4	-0.48	-7.99	-0.36	1.31e-14	Electroencephalogram traits;
LUAD	trans	rs2262909	0.962	rs11669110	chr19:22296485	A/G	cg17074339	chr11:11642133	GALNTL4	0.48	7.75	0.35	6.94e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.41	-6.42	-0.3	3.74e-10	Alzheimer's disease (late onset);
LUAD	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	7.09	0.33	5.49e-12	Tonsillectomy;
LUAD	trans	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg04775059	chr7:64541387	NA	0.51	6.73	0.31	5.42e-11	Aortic root size;
LUAD	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	12.83	0.53	4.89e-32	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg08132940	chr7:1081526	C7orf50	-0.44	-6.69	-0.31	7.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg25811766	chr13:21894605	NA	-0.65	-7.79	-0.35	5.36e-14	White matter hyperintensity burden;
LUAD	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs8073060	0.592	rs225306	chr17:33920036	A/C	cg05299278	chr17:33885742	SLFN14	-0.36	-6.9	-0.32	1.96e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs41271951	0.512	rs76649628	chr1:151041851	A/G	cg11822372	chr1:151115635	SEMA6C	-0.82	-6.99	-0.32	1.11e-11	Blood protein levels;
LUAD	cis	rs7779181	1.000	rs7778788	chr7:32346974	A/C	cg13207630	chr7:32358064	NA	0.44	6.75	0.31	4.99e-11	Body mass index;
LUAD	cis	rs6541297	0.703	rs618520	chr1:230309771	T/C	cg20703242	chr1:230279135	GALNT2	-0.47	-6.83	-0.32	2.9100000000000002e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.34e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2279817	0.863	rs12757678	chr1:17983680	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.47	-6.75	-0.31	4.95e-11	Neuroticism;
LUAD	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg11833968	chr6:79620685	NA	-0.42	-7.95	-0.36	1.77e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs427394	0.593	rs880993	chr5:6732120	C/G	cg10857441	chr5:6722123	POLS	-0.61	-11.0	-0.47	6.48e-25	Menopause (age at onset);
LUAD	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg14345882	chr6:26364793	BTN3A2	-0.64	-7.04	-0.32	7.65e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.61	-0.42	6.46e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12135894	0.562	rs6688969	chr1:3743391	C/T	cg23277830	chr1:3704460	LRRC47	0.39	8.87	0.4	2.06e-17	Mean corpuscular volume;
LUAD	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12667521	chr19:29218732	NA	0.6	8.95	0.4	1.1e-17	Methadone dose in opioid dependence;
LUAD	cis	rs4343996	0.837	rs4722853	chr7:3517354	C/G	cg21248987	chr7:3385318	SDK1	0.37	6.74	0.31	5.32e-11	Motion sickness;
LUAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.57	-8.37	-0.38	8.64e-16	Alzheimer's disease;
LUAD	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03352830	chr11:487213	PTDSS2	-0.77	-10.02	-0.44	2.38e-21	Body mass index;
LUAD	cis	rs12618769	0.652	rs1139829	chr2:99225168	C/T	cg10123293	chr2:99228465	UNC50	0.51	8.79	0.39	3.88e-17	Bipolar disorder;
LUAD	trans	rs6921919	0.887	rs16894116	chr6:28414967	G/T	cg06606381	chr12:133084897	FBRSL1	-0.5	-6.8	-0.31	3.57e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg03609598	chr5:56110824	MAP3K1	-0.56	-7.86	-0.36	3.17e-14	Initial pursuit acceleration;
LUAD	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg09467607	chr2:36825704	FEZ2	0.75	17.05	0.64	5.69e-50	Height;
LUAD	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.33	-7.59	-0.35	2.05e-13	Lung cancer;
LUAD	cis	rs796825	0.530	rs7612000	chr3:119965914	C/T	cg21790991	chr3:120137480	FSTL1	-0.46	-7.91	-0.36	2.2e-14	HIV-1 susceptibility;
LUAD	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg17177755	chr1:15930204	NA	0.46	7.43	0.34	5.89e-13	Systolic blood pressure;
LUAD	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.65	-0.39	1.04e-16	Alzheimer's disease (late onset);
LUAD	cis	rs870825	0.616	rs12512839	chr4:185610347	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	12.24	0.51	1.03e-29	Blood protein levels;
LUAD	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg07617317	chr6:118971624	C6orf204	0.55	8.09	0.37	6.19e-15	Renal cell carcinoma;
LUAD	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg04896959	chr15:78267971	NA	-0.56	-9.99	-0.44	3.16e-21	Coronary artery disease or large artery stroke;
LUAD	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg15128208	chr22:42549153	NA	-0.42	-8.76	-0.39	4.61e-17	Cognitive function;
LUAD	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg07636037	chr3:49044803	WDR6	-0.52	-9.73	-0.43	2.47e-20	Menarche (age at onset);
LUAD	cis	rs6546550	0.901	rs4852375	chr2:70125988	C/G	cg02498382	chr2:70120550	SNRNP27	-0.6	-11.51	-0.49	7.63e-27	Prevalent atrial fibrillation;
LUAD	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg20203395	chr5:56204925	C5orf35	-0.82	-11.8	-0.5	5.55e-28	Initial pursuit acceleration;
LUAD	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg11871910	chr12:69753446	YEATS4	-0.63	-10.51	-0.46	4.09e-23	Blood protein levels;
LUAD	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg09365446	chr1:150670422	GOLPH3L	-0.49	-8.46	-0.38	4.47e-16	Tonsillectomy;
LUAD	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg09455208	chr3:40491958	NA	0.61	12.97	0.53	1.32e-32	Renal cell carcinoma;
LUAD	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg06108461	chr20:60628389	TAF4	-0.81	-13.59	-0.55	3.63e-35	Body mass index;
LUAD	cis	rs7274811	0.744	rs55651102	chr20:32188068	A/T	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.44	-6.55	-0.3	1.65e-10	Height;
LUAD	cis	rs7107174	1.000	rs2248407	chr11:77937800	G/A	cg02023728	chr11:77925099	USP35	0.45	7.26	0.33	1.87e-12	Testicular germ cell tumor;
LUAD	cis	rs739496	0.843	rs642536	chr12:111997023	G/A	cg10833066	chr12:111807467	FAM109A	0.42	6.58	0.3	1.39e-10	Platelet count;
LUAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg03188948	chr7:1209495	NA	0.43	7.25	0.33	1.95e-12	Longevity;Endometriosis;
LUAD	cis	rs4774899	0.966	rs12906566	chr15:57514874	A/C	cg14026238	chr15:57616123	NA	0.35	6.71	0.31	6.18e-11	Urinary tract infection frequency;
LUAD	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg07677032	chr17:61819896	STRADA	0.57	10.34	0.45	1.78e-22	Prudent dietary pattern;
LUAD	cis	rs41271951	0.512	rs6664387	chr1:151021509	A/G	cg11822372	chr1:151115635	SEMA6C	-0.81	-6.69	-0.31	7.3e-11	Blood protein levels;
LUAD	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.61	10.8	0.46	3.55e-24	Birth weight;
LUAD	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.3	6.51	0.3	2.13e-10	Parkinson's disease;
LUAD	cis	rs7727544	0.582	rs3805683	chr5:131535125	T/G	cg14196790	chr5:131705035	SLC22A5	0.42	7.19	0.33	2.88e-12	Blood metabolite levels;
LUAD	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg04727924	chr7:799746	HEATR2	-0.55	-7.34	-0.34	1.12e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.41	-7.0	-0.32	1.01e-11	Longevity;Endometriosis;
LUAD	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg17063962	chr7:91808500	NA	-0.67	-12.04	-0.51	6.31e-29	Breast cancer;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17019204	chr6:86303781	SNX14	-0.45	-7.55	-0.34	2.76e-13	Cancer;
LUAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg07217954	chr7:1067459	C7orf50	0.43	6.61	0.31	1.14e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg23758822	chr17:41437982	NA	1.01	20.99	0.71	1.52e-67	Menopause (age at onset);
LUAD	cis	rs13064411	0.696	rs1486897	chr3:113215818	G/A	cg18753928	chr3:113234510	CCDC52	-0.73	-12.37	-0.52	3.33e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs7395662	0.963	rs4882146	chr11:48660169	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.33	-0.34	1.17e-12	HDL cholesterol;
LUAD	trans	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg01620082	chr3:125678407	NA	0.53	7.23	0.33	2.22e-12	Depression;
LUAD	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg15704280	chr7:45808275	SEPT13	-0.61	-9.26	-0.41	1.01e-18	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.43	-0.3	3.44e-10	Morning vs. evening chronotype;
LUAD	cis	rs4664308	0.935	rs4520994	chr2:160937750	G/A	cg03641300	chr2:160917029	PLA2R1	-0.38	-6.5	-0.3	2.21e-10	Idiopathic membranous nephropathy;
LUAD	cis	rs62238980	0.614	rs77017871	chr22:32382145	T/C	cg00543991	chr22:32367038	NA	0.94	8.78	0.39	4.09e-17	Childhood ear infection;
LUAD	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg14752069	chr8:11977206	FAM66D	-0.29	-6.37	-0.3	4.98e-10	Triglycerides;
LUAD	trans	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg01620082	chr3:125678407	NA	-1.03	-10.17	-0.44	6.99e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg13393036	chr8:95962371	TP53INP1	-0.33	-7.0	-0.32	1e-11	Type 2 diabetes;
LUAD	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.56	-9.67	-0.43	4.18e-20	Hip circumference adjusted for BMI;
LUAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg25243455	chr2:114033360	PAX8;LOC440839	-0.39	-8.78	-0.39	4.04e-17	Lymphocyte counts;
LUAD	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg25237894	chr2:233734115	C2orf82	0.63	11.83	0.5	4.13e-28	Coronary artery disease;
LUAD	cis	rs7937890	0.531	rs2575828	chr11:14484192	T/C	cg02886208	chr11:14281011	SPON1	-0.34	-6.48	-0.3	2.5e-10	Mitochondrial DNA levels;
LUAD	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg07936489	chr17:37558343	FBXL20	0.52	7.01	0.32	9.62e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs4343996	0.840	rs4131987	chr7:3380895	C/T	cg21248987	chr7:3385318	SDK1	-0.36	-6.74	-0.31	5.14e-11	Motion sickness;
LUAD	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06022373	chr22:39101656	GTPBP1	-0.48	-7.69	-0.35	1.01e-13	Menopause (age at onset);
LUAD	cis	rs2735413	0.918	rs12931394	chr16:78081629	G/A	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs8017423	0.605	rs4904676	chr14:90819220	G/A	cg14092571	chr14:90743983	NA	0.39	6.63	0.31	1.01e-10	Mortality in heart failure;
LUAD	cis	rs2932538	0.922	rs12136781	chr1:113090655	C/T	cg22162597	chr1:113214053	CAPZA1	0.45	6.8	0.31	3.5e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg27279351	chr12:120934652	DYNLL1	0.43	6.49	0.3	2.34e-10	High light scatter reticulocyte count;
LUAD	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg18306943	chr3:40428807	ENTPD3	0.37	6.63	0.31	9.97e-11	Renal cell carcinoma;
LUAD	cis	rs2688608	0.780	rs2688619	chr10:75682176	A/G	cg23231163	chr10:75533350	FUT11	-0.37	-6.78	-0.31	3.93e-11	Inflammatory bowel disease;
LUAD	cis	rs1461503	0.900	rs7119398	chr11:122832492	C/A	cg27398637	chr11:122830231	C11orf63	-0.33	-6.6	-0.31	1.26e-10	Menarche (age at onset);
LUAD	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg08085267	chr17:45401833	C17orf57	0.57	10.24	0.45	3.8e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6500395	1.000	rs11641458	chr16:48670845	C/T	cg04672837	chr16:48644449	N4BP1	0.38	6.69	0.31	7.06e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2456568	0.802	rs1574515	chr11:93629643	T/C	cg26875233	chr11:93583750	C11orf90	-0.29	-6.56	-0.3	1.53e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	trans	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg01620082	chr3:125678407	NA	-0.86	-8.9	-0.4	1.62e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg09796270	chr17:17721594	SREBF1	0.37	6.96	0.32	1.33e-11	Total body bone mineral density;
LUAD	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg06640241	chr16:89574553	SPG7	0.74	13.32	0.54	4.79e-34	Multiple myeloma (IgH translocation);
LUAD	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg22681709	chr2:178499509	PDE11A	-0.42	-6.89	-0.32	2.08e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.76	0.31	4.64e-11	Parkinson's disease;
LUAD	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg02734326	chr4:10020555	SLC2A9	0.51	9.23	0.41	1.31e-18	Bone mineral density;
LUAD	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg14829155	chr15:31115871	NA	-0.59	-9.66	-0.43	4.37e-20	Huntington's disease progression;
LUAD	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.15	0.33	3.78e-12	Motion sickness;
LUAD	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg19318889	chr4:1322082	MAEA	0.45	7.3	0.33	1.4e-12	Obesity-related traits;
LUAD	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg14403583	chr14:105418241	AHNAK2	-0.46	-8.42	-0.38	5.72e-16	Rheumatoid arthritis;
LUAD	cis	rs877282	0.898	rs11253348	chr10:765852	C/T	cg06581033	chr10:766294	NA	-0.62	-8.34	-0.38	1.07e-15	Uric acid levels;
LUAD	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg17063962	chr7:91808500	NA	-0.63	-10.49	-0.45	5e-23	Breast cancer;
LUAD	cis	rs7107174	1.000	rs2510032	chr11:77968631	G/C	cg19901956	chr11:77921274	USP35	-0.52	-6.38	-0.3	4.66e-10	Testicular germ cell tumor;
LUAD	cis	rs4343996	0.837	rs6462105	chr7:3514512	C/T	cg21248987	chr7:3385318	SDK1	0.37	6.73	0.31	5.58e-11	Motion sickness;
LUAD	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg15704280	chr7:45808275	SEPT13	0.64	8.17	0.37	3.52e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2455799	1.000	rs2654652	chr3:15782174	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-6.49	-0.3	2.42e-10	Mean platelet volume;
LUAD	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.98	0.32	1.14e-11	Rheumatoid arthritis;
LUAD	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg04181038	chr4:183730758	NA	0.67	10.17	0.44	6.94e-22	Pediatric autoimmune diseases;
LUAD	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg07936489	chr17:37558343	FBXL20	-0.48	-7.58	-0.35	2.26e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.6	11.28	0.48	5.43e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg23950597	chr19:37808831	NA	-0.64	-7.57	-0.35	2.43e-13	Coronary artery calcification;
LUAD	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg27170947	chr2:26402098	FAM59B	-0.69	-9.51	-0.42	1.48e-19	Gut microbiome composition (summer);
LUAD	cis	rs13204927	1.000	rs13204927	chr6:109602790	G/A	cg12927641	chr6:109611667	NA	-0.44	-6.42	-0.3	3.72e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-8.58	-0.38	1.88e-16	Monocyte percentage of white cells;
LUAD	cis	rs6908034	0.660	rs111231540	chr6:19802226	A/C	cg02682789	chr6:19804855	NA	0.96	9.47	0.42	2.01e-19	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg01579765	chr21:45077557	HSF2BP	-0.62	-14.82	-0.58	2.44e-40	Mean corpuscular volume;
LUAD	cis	rs8010715	0.848	rs927494	chr14:24600390	A/T	cg23112188	chr14:24563095	PCK2	-0.32	-6.68	-0.31	7.66e-11	IgG glycosylation;
LUAD	cis	rs1387259	0.931	rs11168474	chr12:48621384	A/C	cg04545296	chr12:48745243	ZNF641	0.39	9.89	0.43	7.05e-21	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs7246657	0.943	rs7248733	chr19:37996361	A/C	cg23950597	chr19:37808831	NA	-0.55	-6.8	-0.31	3.54e-11	Coronary artery calcification;
LUAD	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.33	6.52	0.3	2e-10	Obesity-related traits;
LUAD	cis	rs7799006	0.606	rs34417375	chr7:2315105	C/T	cg08027265	chr7:2291960	NA	-0.73	-14.76	-0.58	4.74e-40	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-10.02	-0.44	2.33e-21	Lymphocyte counts;
LUAD	cis	rs13064411	0.735	rs6438158	chr3:113217290	C/T	cg10517650	chr3:113235015	CCDC52	-0.56	-9.63	-0.42	5.58e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs629535	0.821	rs650267	chr8:70029160	C/T	cg21567404	chr3:27674614	NA	1.0	18.39	0.67	6.15e-56	Dupuytren's disease;
LUAD	cis	rs10788264	0.538	rs1998344	chr10:124030137	A/G	cg09507567	chr10:124027408	NA	0.53	12.23	0.51	1.15e-29	Total body bone mineral density;
LUAD	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg25985355	chr7:65971099	NA	-0.53	-6.55	-0.3	1.66e-10	Diabetic kidney disease;
LUAD	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg08422745	chr4:174089978	GALNT7	0.93	16.36	0.62	5.69e-47	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Parkinson's disease;
LUAD	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.57	8.84	0.39	2.63e-17	Alzheimer's disease (late onset);
LUAD	trans	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg04565464	chr8:145669602	NFKBIL2	0.46	6.94	0.32	1.46e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg08859206	chr1:53392774	SCP2	0.6	11.22	0.48	9.61e-26	Monocyte count;
LUAD	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	17.45	0.65	9.5e-52	Homoarginine levels;
LUAD	trans	rs2262909	0.962	rs422344	chr19:22230956	C/G	cg17074339	chr11:11642133	GALNTL4	0.46	7.5	0.34	3.72e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.599	rs6466162	chr7:106902625	C/T	cg23024343	chr7:107201750	COG5	0.44	6.45	0.3	3.1e-10	Coronary artery disease;
LUAD	trans	rs1997103	0.822	rs940878	chr7:55419663	A/G	cg20935933	chr6:143382018	AIG1	0.56	7.66	0.35	1.26e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7000551	0.642	rs2122880	chr8:22375042	C/A	cg12081754	chr8:22256438	SLC39A14	0.44	7.36	0.34	9.37e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg09324608	chr17:30823087	MYO1D	0.47	8.91	0.4	1.49e-17	Schizophrenia;
LUAD	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26314531	chr2:26401878	FAM59B	-0.7	-9.53	-0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.59	-0.42	7.44e-20	Schizophrenia;
LUAD	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg25173405	chr17:45401733	C17orf57	0.45	7.75	0.35	6.82e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11229555	1.000	rs1938598	chr11:58413910	T/C	cg15696309	chr11:58395628	NA	-0.72	-10.89	-0.47	1.63e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.51	-0.42	1.45e-19	Schizophrenia;
LUAD	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg23758822	chr17:41437982	NA	1.02	21.24	0.72	1.15e-68	Menopause (age at onset);
LUAD	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	15.14	0.59	1.12e-41	Mean platelet volume;
LUAD	cis	rs68170813	0.652	rs8180747	chr7:107106308	T/C	cg02696742	chr7:106810147	HBP1	-0.76	-8.99	-0.4	8.3e-18	Coronary artery disease;
LUAD	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg15448220	chr1:150897856	SETDB1	0.53	9.32	0.41	6.74e-19	Tonsillectomy;
LUAD	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11229555	1.000	rs3168135	chr11:58386177	G/A	cg15696309	chr11:58395628	NA	-0.73	-10.98	-0.47	7.29e-25	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs11771526	0.901	rs10264625	chr7:32304205	T/C	cg27532318	chr7:32358331	NA	0.59	7.4	0.34	7.31e-13	Body mass index;
LUAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg09033563	chr22:24373618	LOC391322	-0.54	-8.61	-0.39	1.44e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06873352	chr17:61820015	STRADA	0.82	18.12	0.66	9.67e-55	Prudent dietary pattern;
LUAD	trans	rs1493916	1.000	rs7238717	chr18:31395186	C/T	cg13755796	chr4:20253514	NA	-0.42	-7.0	-0.32	9.84e-12	Life satisfaction;
LUAD	cis	rs12760731	0.565	rs12026482	chr1:178155861	G/A	cg00404053	chr1:178313656	RASAL2	0.72	9.1	0.4	3.67e-18	Obesity-related traits;
LUAD	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg15181151	chr6:150070149	PCMT1	0.32	6.41	0.3	3.8e-10	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg00701064	chr4:6280414	WFS1	0.67	14.65	0.58	1.33e-39	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg13319975	chr6:146136371	FBXO30	-0.57	-9.48	-0.42	1.86e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg11859384	chr17:80120422	CCDC57	-0.52	-9.36	-0.41	4.69e-19	Life satisfaction;
LUAD	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg12193833	chr17:30244370	NA	-0.57	-6.85	-0.32	2.63e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs7017914	0.967	rs6472539	chr8:71629810	G/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs2455799	0.573	rs2654650	chr3:15779214	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-9.58	-0.42	8.53e-20	Mean platelet volume;
LUAD	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg13699009	chr12:122356056	WDR66	-0.31	-6.73	-0.31	5.48e-11	Mean corpuscular volume;
LUAD	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg25894440	chr7:65020034	NA	-0.69	-6.41	-0.3	3.98e-10	Diabetic kidney disease;
LUAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.5	-9.45	-0.42	2.29e-19	Lymphocyte counts;
LUAD	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.7	-0.46	8.33e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs7465272	0.957	rs11994668	chr8:143687392	G/T	cg10104451	chr8:143696006	ARC	-0.57	-7.7	-0.35	9.41e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg17757837	chr7:157058334	UBE3C	0.47	8.45	0.38	4.62e-16	Body mass index;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg23797073	chr6:15663448	DTNBP1	0.42	6.9	0.32	1.89e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4372836	0.704	rs3190	chr2:29025479	A/G	cg09522027	chr2:28974177	PPP1CB	-0.69	-12.55	-0.52	6.01e-31	Body mass index;
LUAD	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg18016565	chr1:150552671	MCL1	0.36	6.38	0.3	4.55e-10	Melanoma;
LUAD	cis	rs261532	0.953	rs446588	chr5:138987756	G/C	cg12205435	chr5:138714322	SLC23A1	-0.43	-7.27	-0.33	1.77e-12	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.8	0.31	3.63e-11	Motion sickness;
LUAD	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg00106254	chr7:1943704	MAD1L1	-0.63	-9.6	-0.42	7.38e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg01802117	chr1:53393560	SCP2	0.34	6.69	0.31	6.96e-11	Monocyte count;
LUAD	cis	rs6835098	1.000	rs4561909	chr4:174086937	A/T	cg08422745	chr4:174089978	GALNT7	-0.93	-16.18	-0.62	3.55e-46	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg23978390	chr7:1156363	C7orf50	0.58	9.23	0.41	1.28e-18	Longevity;Endometriosis;
LUAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg08027265	chr7:2291960	NA	-0.41	-6.73	-0.31	5.51e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7481584	0.581	rs420127	chr11:3077990	C/T	cg08508325	chr11:3079039	CARS	0.44	8.91	0.4	1.5e-17	Calcium levels;
LUAD	cis	rs73206853	0.841	rs73191834	chr12:110963841	T/G	cg12870014	chr12:110450643	ANKRD13A	0.6	6.78	0.31	4.14e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.28	-6.73	-0.31	5.51e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg19743168	chr1:23544995	NA	0.58	10.08	0.44	1.45e-21	Height;
LUAD	cis	rs7843479	0.965	rs9314269	chr8:21804989	A/G	cg03445287	chr8:21823731	XPO7	-0.46	-8.37	-0.38	8.58e-16	Mean corpuscular volume;
LUAD	cis	rs6432018	0.964	rs3791748	chr2:9729815	C/G	cg12832956	chr2:9616023	IAH1	-0.36	-6.45	-0.3	3.04e-10	Heart rate variability traits;
LUAD	cis	rs11051970	0.655	rs10771942	chr12:32528488	G/A	cg02745156	chr12:32552066	NA	0.31	6.68	0.31	7.63e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg04545296	chr12:48745243	ZNF641	0.4	10.07	0.44	1.59e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg09117114	chr16:67998030	SLC12A4	-0.61	-8.27	-0.37	1.76e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs17102423	0.826	rs12887607	chr14:65596887	G/A	cg11161011	chr14:65562177	MAX	-0.47	-7.37	-0.34	9.13e-13	Obesity-related traits;
LUAD	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	12.38	0.52	2.85e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4072705	0.967	rs4838195	chr9:127351217	G/A	cg13476313	chr9:127244764	NR5A1	0.32	7.44	0.34	5.67e-13	Menarche (age at onset);
LUAD	cis	rs220324	0.738	rs1026400	chr21:43587824	C/T	cg08841829	chr21:43638893	ABCG1	-0.55	-7.33	-0.34	1.21e-12	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg22467129	chr15:76604101	ETFA	-0.47	-7.89	-0.36	2.58e-14	Blood metabolite levels;
LUAD	cis	rs2016266	0.784	rs12424778	chr12:53737840	A/T	cg26875137	chr12:53738046	NA	0.34	7.02	0.32	8.9e-12	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.47	2.75e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7249698	1	rs7249698	chr19:17210615	G/A	cg19418318	chr19:17219073	MYO9B	0.39	6.79	0.31	3.81e-11	Breast cancer;
LUAD	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg18252515	chr7:66147081	NA	-0.63	-6.85	-0.32	2.58e-11	Diabetic kidney disease;
LUAD	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg05697835	chr1:2722811	NA	0.29	6.41	0.3	3.99e-10	Multiple sclerosis;
LUAD	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg03806693	chr22:41940476	POLR3H	-0.58	-8.35	-0.38	9.94e-16	Vitiligo;
LUAD	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg15782153	chr7:917662	C7orf20	0.55	10.06	0.44	1.8e-21	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15369054	chr17:80825471	TBCD	-0.67	-11.4	-0.48	1.98e-26	Breast cancer;
LUAD	cis	rs11650494	0.710	rs11651666	chr17:47474571	C/T	cg08112188	chr17:47440006	ZNF652	0.77	6.37	0.3	4.99e-10	Prostate cancer;
LUAD	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg01200585	chr1:228362443	C1orf69	0.4	6.88	0.32	2.17e-11	Diastolic blood pressure;
LUAD	cis	rs5756391	0.568	rs5756407	chr22:37316259	A/G	cg16356956	chr22:37317934	CSF2RB	0.32	6.64	0.31	9.37e-11	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs57994353	0.897	rs3812595	chr9:139369062	C/T	cg13856295	chr9:139396418	NOTCH1	-0.43	-6.79	-0.31	3.76e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.54	8.51	0.38	3.13e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs13315871	1.000	rs35542947	chr3:58323244	C/T	cg12435725	chr3:58293450	RPP14	-0.73	-7.68	-0.35	1.1e-13	Cholesterol, total;
LUAD	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg06740227	chr12:86229804	RASSF9	0.38	6.68	0.31	7.33e-11	Major depressive disorder;
LUAD	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.49	-0.3	2.38e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg06766960	chr11:133703094	NA	-0.38	-7.36	-0.34	9.83e-13	Childhood ear infection;
LUAD	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19748678	chr4:122722346	EXOSC9	0.44	6.87	0.32	2.32e-11	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.76e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg00316803	chr15:76480434	C15orf27	-0.41	-7.9	-0.36	2.5e-14	Blood metabolite levels;
LUAD	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg09904177	chr6:26538194	HMGN4	0.41	6.81	0.31	3.38e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26314531	chr2:26401878	FAM59B	-0.56	-7.89	-0.36	2.52e-14	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08219700	chr8:58056026	NA	0.61	8.59	0.39	1.64e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4243830	0.850	rs4908912	chr1:6599558	A/C	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.74	-8.71	-0.39	6.86e-17	Body mass index;
LUAD	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg17366294	chr4:99064904	C4orf37	0.57	9.71	0.43	3.08e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg07460842	chr6:66804631	NA	0.95	14.94	0.59	8.18e-41	Exhaled nitric oxide levels;
LUAD	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg24069376	chr3:38537580	EXOG	-0.43	-10.28	-0.45	2.72e-22	Electrocardiographic conduction measures;
LUAD	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-7.8	-0.35	4.95e-14	Total cholesterol levels;
LUAD	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg20790798	chr5:1857306	NA	-0.47	-7.98	-0.36	1.37e-14	Cardiovascular disease risk factors;
LUAD	cis	rs7274811	0.779	rs13039908	chr20:32052070	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.54	-8.08	-0.37	6.9e-15	Height;
LUAD	cis	rs3845702	0.736	rs72962575	chr2:180862133	C/G	cg01881094	chr2:180872142	CWC22	0.81	8.67	0.39	9.63e-17	Schizophrenia;
LUAD	cis	rs1497406	0.744	rs7538216	chr1:16509671	T/C	cg02998240	chr1:16508668	NA	-0.21	-6.47	-0.3	2.76e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs1422110	0.616	rs6452688	chr5:85445038	C/T	cg01787110	chr1:109008453	NBPF6	0.63	10.58	0.46	2.23e-23	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg06784218	chr1:46089804	CCDC17	0.51	11.19	0.48	1.24e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs877282	0.898	rs10904547	chr10:766283	C/T	cg17470449	chr10:769945	NA	0.63	8.96	0.4	1.04e-17	Uric acid levels;
LUAD	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg23029597	chr12:123009494	RSRC2	-0.52	-8.03	-0.36	9.64e-15	Body mass index;
LUAD	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg27446573	chr6:127587934	RNF146	0.45	6.61	0.31	1.18e-10	Breast cancer;
LUAD	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg19622623	chr12:86230825	RASSF9	-0.44	-7.8	-0.35	4.83e-14	Major depressive disorder;
LUAD	cis	rs1160297	0.576	rs12713233	chr2:53116767	T/A	cg07782112	chr2:53107842	NA	0.39	8.18	0.37	3.32e-15	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.77e-11	Depression;
LUAD	cis	rs6906287	0.647	rs2356183	chr6:118770264	A/G	cg05564266	chr6:118973597	C6orf204	0.34	7.18	0.33	3.11e-12	Electrocardiographic conduction measures;
LUAD	cis	rs7737355	0.898	rs26007	chr5:131006356	T/A	cg25547332	chr5:131281432	NA	0.44	6.65	0.31	9.13e-11	Life satisfaction;
LUAD	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg11965913	chr1:205819406	PM20D1	0.51	7.8	0.35	4.88e-14	Parkinson's disease;
LUAD	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg11502198	chr6:26597334	ABT1	0.66	11.38	0.48	2.33e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs7945718	0.839	rs11022511	chr11:12834638	A/T	cg25843174	chr11:12811716	TEAD1	0.23	6.87	0.32	2.36e-11	Educational attainment (years of education);
LUAD	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs4588572	0.643	rs6861678	chr5:77764613	G/C	cg11547950	chr5:77652471	NA	-0.78	-12.44	-0.52	1.78e-30	Triglycerides;
LUAD	trans	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.17	-28.09	-0.81	9.85e-99	Exhaled nitric oxide output;
LUAD	cis	rs921968	0.565	rs7573999	chr2:219601392	A/G	cg02176678	chr2:219576539	TTLL4	-0.59	-11.87	-0.5	2.92e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.72	-14.86	-0.59	1.78e-40	Urate levels in overweight individuals;
LUAD	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg05717871	chr11:638507	DRD4	-0.44	-6.48	-0.3	2.57e-10	Systemic lupus erythematosus;
LUAD	cis	rs7593730	0.666	rs10929973	chr2:161119907	A/G	cg22609984	chr2:161126801	NA	0.56	10.34	0.45	1.76e-22	Type 2 diabetes;
LUAD	cis	rs727505	0.954	rs989177	chr7:124412886	A/G	cg23710748	chr7:124431027	NA	-0.46	-8.81	-0.39	3.15e-17	Lewy body disease;
LUAD	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg03690763	chr11:133734501	NA	-0.3	-7.1	-0.33	5.37e-12	Childhood ear infection;
LUAD	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg17279839	chr7:150038598	RARRES2	0.44	7.67	0.35	1.2e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.39	-0.34	7.8e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.12	-0.54	3.15e-33	Breast cancer;
LUAD	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18876405	chr7:65276391	NA	-0.4	-6.37	-0.3	4.85e-10	Aortic root size;
LUAD	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10802521	chr3:52805072	NEK4	-0.55	-9.11	-0.4	3.45e-18	Bipolar disorder;
LUAD	cis	rs2227564	0.533	rs3870402	chr10:75473787	A/C	cg23231163	chr10:75533350	FUT11	-0.42	-6.42	-0.3	3.64e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1873147	1.000	rs4774470	chr15:63312119	G/A	cg12160578	chr15:63334699	TPM1	-0.35	-6.58	-0.3	1.37e-10	Orofacial clefts;
LUAD	cis	rs738322	0.574	rs738323	chr22:38569527	C/T	cg25457927	chr22:38595422	NA	-0.52	-11.39	-0.48	2.11e-26	Cutaneous nevi;
LUAD	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg07636037	chr3:49044803	WDR6	0.61	11.68	0.49	1.67e-27	Parkinson's disease;
LUAD	trans	rs853679	0.607	rs61742093	chr6:27879982	A/G	cg01620082	chr3:125678407	NA	-1.09	-10.17	-0.44	7.24e-22	Depression;
LUAD	trans	rs9929218	0.954	rs10163398	chr16:68823124	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.72	-0.53	1.32e-31	Colorectal cancer;
LUAD	cis	rs1497828	1.000	rs2646845	chr1:217559136	G/A	cg04411442	chr1:217543379	NA	0.38	6.84	0.32	2.79e-11	Dialysis-related mortality;
LUAD	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg18016565	chr1:150552671	MCL1	0.41	7.52	0.34	3.34e-13	Tonsillectomy;
LUAD	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg03806693	chr22:41940476	POLR3H	0.66	9.16	0.41	2.22e-18	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.49	-0.34	4.19e-13	Tonsillectomy;
LUAD	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg25036284	chr2:26402008	FAM59B	-0.78	-11.71	-0.49	1.25e-27	Gut microbiome composition (summer);
LUAD	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11644478	chr21:40555479	PSMG1	0.68	11.22	0.48	9.53e-26	Cognitive function;
LUAD	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg06740227	chr12:86229804	RASSF9	0.46	7.99	0.36	1.29e-14	Major depressive disorder;
LUAD	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg18827107	chr12:86230957	RASSF9	0.54	9.74	0.43	2.24e-20	Major depressive disorder;
LUAD	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg07389463	chr12:132296394	NA	0.55	10.68	0.46	9.48e-24	Migraine;
LUAD	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06022373	chr22:39101656	GTPBP1	0.45	7.23	0.33	2.33e-12	Menopause (age at onset);
LUAD	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg03396347	chr1:1875803	NA	-0.61	-15.0	-0.59	4.24e-41	Body mass index;
LUAD	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg07169764	chr2:136633963	MCM6	-0.57	-7.53	-0.34	3.13e-13	Corneal structure;
LUAD	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg08558340	chr7:100472263	SRRT	0.51	6.41	0.3	3.79e-10	Resting heart rate;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13867718	chr16:29973267	TMEM219	0.47	7.4	0.34	7.43e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg02038168	chr22:39784481	NA	-0.56	-9.85	-0.43	9.49e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs12530845	0.887	rs78641973	chr7:135324311	C/T	cg23117316	chr7:135346802	PL-5283	-0.5	-8.65	-0.39	1.11e-16	Red blood cell traits;
LUAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg22907277	chr7:1156413	C7orf50	0.49	8.25	0.37	1.98e-15	Longevity;Endometriosis;
LUAD	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	8.79	0.39	3.84e-17	Eosinophil percentage of white cells;
LUAD	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.44	-0.42	2.51e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg27411982	chr8:10470053	RP1L1	0.4	6.92	0.32	1.66e-11	Retinal vascular caliber;
LUAD	trans	rs4714291	0.928	rs1923461	chr6:39984670	A/T	cg02267698	chr19:7991119	CTXN1	0.44	6.64	0.31	9.51e-11	Strep throat;
LUAD	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg20933634	chr6:27740509	NA	0.44	6.45	0.3	3.06e-10	Parkinson's disease;
LUAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg07217954	chr7:1067459	C7orf50	0.45	7.1	0.33	5.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg11915388	chr22:42470451	FAM109B	-0.42	-7.59	-0.35	2.03e-13	Schizophrenia;
LUAD	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg04414720	chr1:150670196	GOLPH3L	0.71	12.54	0.52	7.06e-31	Melanoma;
LUAD	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg13873920	chr18:72163386	CNDP2	-0.41	-6.55	-0.3	1.7e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs8048589	1.000	rs16958964	chr16:12186586	T/C	cg03816625	chr16:12192430	SNX29	0.55	8.14	0.37	4.52e-15	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.36	0.38	9.09e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2425143	1.000	rs45595739	chr20:34320759	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.43	-0.34	6.03e-13	Blood protein levels;
LUAD	cis	rs76419734	0.558	rs58412572	chr4:106518970	A/T	cg05309399	chr4:106552544	FLJ20184	-0.55	-6.82	-0.31	3.12e-11	Post bronchodilator FEV1;
LUAD	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.08	-0.33	6.09e-12	Mood instability;
LUAD	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg24596788	chr1:163392923	NA	0.36	7.48	0.34	4.23e-13	Motion sickness;
LUAD	cis	rs6594713	0.717	rs2914198	chr5:112950253	C/G	cg12552261	chr5:112820674	MCC	-0.55	-7.95	-0.36	1.73e-14	Brain cytoarchitecture;
LUAD	cis	rs4950928	0.712	rs7518666	chr1:203163590	C/T	cg17014757	chr1:203156097	CHI3L1	-0.61	-8.64	-0.39	1.18e-16	YKL-40 levels;
LUAD	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg23533926	chr12:111358616	MYL2	-0.43	-7.35	-0.34	1.03e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg11266682	chr4:10021025	SLC2A9	0.67	15.57	0.6	1.49e-43	Bone mineral density;
LUAD	cis	rs76878669	0.561	rs7117630	chr11:66154777	C/T	cg10616300	chr11:66138557	SLC29A2	-0.37	-7.79	-0.35	5.39e-14	Educational attainment (years of education);
LUAD	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg27144592	chr16:783916	NARFL	0.37	6.78	0.31	4.14e-11	Height;
LUAD	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg04414720	chr1:150670196	GOLPH3L	0.59	10.19	0.44	5.93e-22	Melanoma;
LUAD	cis	rs7737355	0.842	rs7731001	chr5:130781338	T/C	cg06307176	chr5:131281290	NA	-0.43	-7.08	-0.33	5.86e-12	Life satisfaction;
LUAD	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.04	0.32	7.98e-12	Colorectal cancer;
LUAD	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg20108693	chr8:143823809	SLURP1	0.33	7.79	0.35	5.26e-14	Urinary tract infection frequency;
LUAD	cis	rs796364	0.715	rs78988795	chr2:201095739	G/A	cg17644776	chr2:200775616	C2orf69	-0.62	-6.54	-0.3	1.82e-10	Schizophrenia;
LUAD	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg13385794	chr1:248469461	NA	0.24	6.79	0.31	3.76e-11	Common traits (Other);
LUAD	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg06060754	chr5:176797920	RGS14	0.54	10.24	0.45	3.9e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs4285028	0.948	rs12493408	chr3:121692119	C/A	cg20356878	chr3:121714668	ILDR1	-0.49	-6.64	-0.31	9.57e-11	Multiple sclerosis;
LUAD	cis	rs910187	0.678	rs6066231	chr20:45818895	C/T	cg27589058	chr20:45804311	EYA2	-0.3	-6.89	-0.32	1.97e-11	Migraine;
LUAD	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg25985355	chr7:65971099	NA	-0.37	-6.83	-0.32	2.89e-11	Aortic root size;
LUAD	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg06608945	chr2:219082296	ARPC2	-0.45	-7.41	-0.34	6.77e-13	Colorectal cancer;
LUAD	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg04414720	chr1:150670196	GOLPH3L	0.73	13.64	0.55	2.2e-35	Tonsillectomy;
LUAD	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.1	0.33	5.47e-12	Colorectal cancer;
LUAD	trans	rs1930961	0.558	rs12160908	chr22:25928620	C/T	cg02802374	chr17:26574271	PPY2	-0.31	-6.35	-0.3	5.63e-10	Bipolar disorder with mood-incongruent psychosis;
LUAD	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg02466173	chr16:30829666	NA	-0.75	-13.35	-0.54	3.6e-34	Multiple myeloma;
LUAD	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08704250	chr15:31115839	NA	0.72	13.19	0.54	1.67e-33	Huntington's disease progression;
LUAD	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg16950941	chr11:66035639	RAB1B	0.44	7.35	0.34	1.03e-12	Gout;
LUAD	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg02733842	chr7:1102375	C7orf50	-0.65	-9.59	-0.42	7.88e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg18932078	chr1:2524107	MMEL1	0.37	7.03	0.32	8.24e-12	Ulcerative colitis;
LUAD	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg09455208	chr3:40491958	NA	-0.49	-10.12	-0.44	1.03e-21	Renal cell carcinoma;
LUAD	cis	rs4663969	0.541	rs11902131	chr2:234594269	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.67	-0.43	4e-20	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs1003719	0.679	rs2835638	chr21:38534533	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.43	-0.38	5.42e-16	Eye color traits;
LUAD	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-6.91	-0.32	1.78e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-9.65	-0.42	4.84e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg01528321	chr10:82214614	TSPAN14	0.71	11.1	0.47	2.79e-25	Post bronchodilator FEV1;
LUAD	cis	rs17270561	0.636	rs10946793	chr6:25699999	A/G	cg25753631	chr6:25732923	NA	-0.4	-6.96	-0.32	1.33e-11	Iron status biomarkers;
LUAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg26354017	chr1:205819088	PM20D1	0.62	11.75	0.5	8.88e-28	Menarche (age at onset);
LUAD	cis	rs9902453	0.709	rs6505162	chr17:28444183	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	9.05	0.4	5.4e-18	Coffee consumption (cups per day);
LUAD	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg04944784	chr2:26401820	FAM59B	-0.69	-9.74	-0.43	2.36e-20	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.48	-0.3	2.48e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7301826	0.651	rs10734981	chr12:131297895	C/G	cg11011512	chr12:131303247	STX2	0.44	7.42	0.34	6.59e-13	Plasma plasminogen activator levels;
LUAD	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg14829155	chr15:31115871	NA	-0.59	-9.73	-0.43	2.51e-20	Huntington's disease progression;
LUAD	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.67	-0.31	7.99e-11	Neuroticism;
LUAD	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg14582100	chr15:45693742	SPATA5L1	0.51	9.56	0.42	1.01e-19	Homoarginine levels;
LUAD	cis	rs7680126	0.596	rs4698032	chr4:10316582	T/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.89	-0.32	1.97e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	trans	rs8002861	0.641	rs2028813	chr13:44422126	G/T	cg12856521	chr11:46389249	DGKZ	0.48	7.7	0.35	9.76e-14	Leprosy;
LUAD	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg03467027	chr4:99064603	C4orf37	0.43	7.01	0.32	9.69e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg26043149	chr18:55253948	FECH	-0.42	-6.99	-0.32	1.11e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg24558204	chr6:135376177	HBS1L	0.48	8.27	0.37	1.8e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	trans	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg01620082	chr3:125678407	NA	-0.71	-7.15	-0.33	3.79e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7000551	0.725	rs2469756	chr8:22360423	G/A	cg12081754	chr8:22256438	SLC39A14	0.43	7.13	0.33	4.25e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7582720	1.000	rs72932786	chr2:203698737	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.39	0.42	3.83e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg17863274	chr19:49399704	TULP2	-0.52	-7.16	-0.33	3.53e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg08439880	chr3:133502540	NA	-0.4	-7.28	-0.33	1.62e-12	Iron status biomarkers;
LUAD	cis	rs2795502	0.630	rs1271547	chr10:43507665	C/T	cg08461752	chr10:43522343	NA	-0.83	-9.63	-0.42	5.53e-20	Blood protein levels;
LUAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	1.11	24.15	0.76	1.23e-81	Subjective well-being;
LUAD	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg03467027	chr4:99064603	C4orf37	0.43	7.0	0.32	1.04e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03264133	chr6:25882463	NA	-0.57	-9.35	-0.41	5e-19	Blood metabolite levels;
LUAD	cis	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.91	-0.36	2.26e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.95	-0.32	1.43e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg25797454	chr6:150327115	RAET1K	0.35	7.39	0.34	7.88e-13	Alopecia areata;
LUAD	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.56	-0.34	2.58e-13	Blood metabolite levels;
LUAD	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg02176678	chr2:219576539	TTLL4	0.61	11.75	0.5	8.59e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.39	0.3	4.35e-10	Cardiac Troponin-T levels;
LUAD	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.36	0.57	2.29e-38	Schizophrenia;
LUAD	cis	rs427941	0.668	rs201459	chr7:101741502	G/A	cg06246474	chr7:101738831	CUX1	0.41	7.29	0.33	1.57e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.68	13.33	0.54	4.2e-34	Cognitive ability;
LUAD	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg18190219	chr22:46762943	CELSR1	-0.55	-6.72	-0.31	5.93e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.6	8.45	0.38	4.86e-16	Gut microbiome composition (summer);
LUAD	cis	rs1451375	0.652	rs10249420	chr7:50623451	C/G	cg18232548	chr7:50535776	DDC	-0.49	-7.04	-0.32	7.8e-12	Malaria;
LUAD	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg10591111	chr5:226296	SDHA	-0.55	-6.95	-0.32	1.35e-11	Breast cancer;
LUAD	cis	rs11195062	0.766	rs1935465	chr10:112029300	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.41	-6.49	-0.3	2.47e-10	Multiple myeloma;
LUAD	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg10518543	chr12:38710700	ALG10B	0.42	6.46	0.3	2.83e-10	Bladder cancer;
LUAD	cis	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg06360820	chr2:242988706	NA	0.82	9.72	0.43	2.75e-20	Obesity-related traits;
LUAD	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg07305463	chr2:136567211	LCT	0.35	6.35	0.3	5.5e-10	Mosquito bite size;
LUAD	cis	rs12681287	0.927	rs2976177	chr8:87332332	A/T	cg27223183	chr8:87520930	FAM82B	-0.63	-8.81	-0.39	3.19e-17	Caudate activity during reward;
LUAD	cis	rs4481887	0.790	rs4526648	chr1:248422503	A/T	cg00666640	chr1:248458726	OR2T12	-0.29	-6.96	-0.32	1.34e-11	Common traits (Other);
LUAD	cis	rs757647	0.638	rs4835788	chr5:137735916	G/T	cg10676309	chr5:137685565	NA	0.43	7.6	0.35	1.95e-13	Menarche (age at onset);
LUAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg05896524	chr21:47604654	C21orf56	0.58	9.57	0.42	9.12e-20	Testicular germ cell tumor;
LUAD	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg25358565	chr5:93447407	FAM172A	0.58	6.98	0.32	1.16e-11	Diabetic retinopathy;
LUAD	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg14631576	chr9:95140430	CENPP	-0.48	-9.72	-0.43	2.63e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg14345882	chr6:26364793	BTN3A2	0.69	7.13	0.33	4.4e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs4650994	0.623	rs35854525	chr1:178618604	C/T	cg05059571	chr16:84539110	KIAA1609	0.48	7.73	0.35	7.7e-14	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg15226275	chr6:116381976	FRK	0.23	7.34	0.34	1.07e-12	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg19622623	chr12:86230825	RASSF9	-0.47	-8.11	-0.37	5.34e-15	Major depressive disorder;
LUAD	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg16414030	chr3:133502952	NA	0.64	12.26	0.51	9.01e-30	Iron status biomarkers;
LUAD	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg01236616	chr12:121019343	POP5	-1.2	-18.65	-0.67	4.17e-57	Type 1 diabetes nephropathy;
LUAD	cis	rs243505	0.762	rs734002	chr7:148505788	A/G	cg09806900	chr7:148480153	CUL1	0.39	7.03	0.32	8.47e-12	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs68170813	0.652	rs6947674	chr7:107193504	T/C	cg23024343	chr7:107201750	COG5	0.54	7.02	0.32	9.11e-12	Coronary artery disease;
LUAD	cis	rs7737355	0.673	rs26006	chr5:130982768	A/G	cg06307176	chr5:131281290	NA	0.44	7.29	0.33	1.58e-12	Life satisfaction;
LUAD	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg06608945	chr2:219082296	ARPC2	-0.41	-6.75	-0.31	4.88e-11	Colorectal cancer;
LUAD	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg22705602	chr4:152727874	NA	-0.41	-7.19	-0.33	3.05e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.585	rs201001	chr6:27808899	T/C	cg08798685	chr6:27730294	NA	-0.45	-6.79	-0.31	3.83e-11	Depression;
LUAD	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg14196790	chr5:131705035	SLC22A5	0.38	6.66	0.31	8.74e-11	Blood metabolite levels;
LUAD	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg11494091	chr17:61959527	GH2	0.42	7.95	0.36	1.7e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs12208915	0.945	rs12190108	chr6:79562655	T/C	cg11833968	chr6:79620685	NA	0.51	6.37	0.3	4.89e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg12524338	chr4:183729343	NA	0.58	7.17	0.33	3.42e-12	Pediatric autoimmune diseases;
LUAD	cis	rs12976411	0.575	rs16966906	chr19:32823374	A/G	cg18253629	chr19:32836317	ZNF507	0.65	6.84	0.32	2.87e-11	Coronary artery disease;
LUAD	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg18621852	chr3:10150065	C3orf24	0.51	9.11	0.4	3.39e-18	Alzheimer's disease;
LUAD	cis	rs4919694	1.000	rs11191525	chr10:104793435	G/C	cg04362960	chr10:104952993	NT5C2	0.76	8.04	0.36	8.8e-15	Arsenic metabolism;
LUAD	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg20476274	chr7:133979776	SLC35B4	0.84	17.14	0.64	2.21e-50	Mean platelet volume;
LUAD	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg26587870	chr6:27730563	NA	-0.68	-7.31	-0.33	1.37e-12	Depression;
LUAD	cis	rs6714710	0.603	rs7421146	chr2:98552271	G/C	cg26665480	chr2:98280029	ACTR1B	0.55	9.0	0.4	7.88e-18	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs7789940	1.000	rs73140069	chr7:75986790	T/A	cg10167463	chr7:75959203	YWHAG	-0.71	-12.86	-0.53	3.59e-32	Multiple sclerosis;
LUAD	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg15704280	chr7:45808275	SEPT13	-0.97	-20.38	-0.7	7.87e-65	Height;
LUAD	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg11919837	chr8:57350735	NA	-0.43	-6.48	-0.3	2.6e-10	Obesity-related traits;
LUAD	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg16205897	chr5:131564050	P4HA2	-0.34	-7.66	-0.35	1.28e-13	Blood metabolite levels;
LUAD	trans	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg26043149	chr18:55253948	FECH	-0.51	-8.53	-0.38	2.7e-16	Bone mineral density;
LUAD	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg20814179	chr4:940893	TMEM175	0.65	10.17	0.44	7.14e-22	Sjögren's syndrome;
LUAD	cis	rs6445967	0.554	rs10866018	chr3:58446000	G/A	cg23715586	chr3:58305044	RPP14	0.4	6.44	0.3	3.28e-10	Platelet count;
LUAD	cis	rs6785206	0.730	rs9861429	chr3:128425749	A/G	cg16766828	chr3:128327626	NA	-0.68	-7.72	-0.35	8.22e-14	Lymphocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.6	9.57	0.42	9.18e-20	Cognitive ability;
LUAD	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg27433088	chr4:174089019	GALNT7	0.38	7.49	0.34	3.93e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs1843834	1.000	rs4624372	chr2:225553128	A/G	cg22455342	chr2:225449267	CUL3	0.46	6.39	0.3	4.42e-10	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg05082376	chr22:42548792	NA	-0.5	-9.2	-0.41	1.65e-18	Schizophrenia;
LUAD	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.68	0.39	8.68e-17	Menopause (age at onset);
LUAD	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg14829155	chr15:31115871	NA	-0.68	-11.14	-0.48	1.86e-25	Huntington's disease progression;
LUAD	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg06784218	chr1:46089804	CCDC17	0.6	13.52	0.55	7.06e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1595825	0.735	rs16827267	chr2:198924967	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-6.98	-0.32	1.15e-11	Ulcerative colitis;
LUAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.62	0.31	1.1e-10	Bipolar disorder and schizophrenia;
LUAD	trans	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg02254774	chr11:50257496	LOC441601	0.52	6.46	0.3	2.86e-10	Axial length;
LUAD	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg14345882	chr6:26364793	BTN3A2	0.64	6.44	0.3	3.32e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7809950	0.953	rs2253271	chr7:107201252	G/C	cg23024343	chr7:107201750	COG5	-0.72	-12.26	-0.51	9.21e-30	Coronary artery disease;
LUAD	cis	rs2033908	0.588	rs1899068	chr11:12872156	A/T	cg25843174	chr11:12811716	TEAD1	0.21	6.44	0.3	3.29e-10	Sitting height ratio;
LUAD	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	8.12	0.37	5.23e-15	Hip circumference adjusted for BMI;
LUAD	trans	rs66573146	1.000	rs66712119	chr4:6965428	A/T	cg07817883	chr1:32538562	TMEM39B	1.56	13.45	0.55	1.46e-34	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.66	-0.35	1.25e-13	Bipolar disorder and schizophrenia;
LUAD	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg21548813	chr6:291882	DUSP22	-0.8	-13.87	-0.56	2.63e-36	Menopause (age at onset);
LUAD	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg06197492	chr11:2016605	H19	0.42	8.49	0.38	3.57e-16	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg24818145	chr4:99064322	C4orf37	-0.41	-6.87	-0.32	2.3e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6993813	0.967	rs4360322	chr8:120022478	G/A	cg01975934	chr8:119970761	NA	-0.37	-7.14	-0.33	4.22e-12	Bone mineral density (hip);
LUAD	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg17105886	chr17:28927953	LRRC37B2	-0.8	-7.84	-0.36	3.75e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg20476274	chr7:133979776	SLC35B4	0.84	17.14	0.64	2.21e-50	Mean platelet volume;
LUAD	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg27144592	chr16:783916	NARFL	0.35	6.42	0.3	3.66e-10	Height;
LUAD	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg15557168	chr22:42548783	NA	0.37	6.61	0.31	1.19e-10	Cognitive function;
LUAD	trans	rs561341	0.882	rs504887	chr17:30322881	T/A	cg27661571	chr11:113659931	NA	-0.62	-7.46	-0.34	4.91e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.28e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg07741184	chr6:167504864	NA	0.39	8.77	0.39	4.39e-17	Crohn's disease;
LUAD	cis	rs2067615	0.524	rs10778498	chr12:107063340	C/A	cg15890332	chr12:107067104	RFX4	0.42	8.93	0.4	1.28e-17	Heart rate;
LUAD	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.97	-0.32	1.23e-11	Bipolar disorder;
LUAD	cis	rs9826463	0.757	rs73240314	chr3:142255090	T/C	cg20824294	chr3:142316082	PLS1	0.42	7.41	0.34	6.82e-13	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	trans	rs7395662	0.963	rs12365014	chr11:48629434	C/T	cg00717180	chr2:96193071	NA	-0.36	-6.83	-0.32	2.88e-11	HDL cholesterol;
LUAD	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg21214613	chr1:16344536	HSPB7	0.6	11.52	0.49	7e-27	Dilated cardiomyopathy;
LUAD	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg15017067	chr4:17643749	FAM184B	0.36	7.17	0.33	3.41e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13082711	0.911	rs6775176	chr3:27432475	G/A	cg02860705	chr3:27208620	NA	0.6	9.31	0.41	6.81e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg23758822	chr17:41437982	NA	0.99	20.56	0.71	1.3e-65	Menopause (age at onset);
LUAD	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg27490568	chr2:178487706	NA	0.4	6.82	0.31	3.1e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08688335	chr8:144635260	GSDMD	-0.42	-6.82	-0.31	3.2e-11	Height;
LUAD	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg21951975	chr1:209979733	IRF6	0.51	7.27	0.33	1.74e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg17366294	chr4:99064904	C4orf37	0.52	9.69	0.43	3.55e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg06781209	chr11:61594997	FADS2	-0.39	-7.27	-0.33	1.75e-12	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
LUAD	cis	rs9768139	0.708	rs34267680	chr7:158115084	C/T	cg25566285	chr7:158114605	PTPRN2	0.5	10.33	0.45	1.79e-22	Calcium levels;
LUAD	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.71	0.39	6.7e-17	Menopause (age at onset);
LUAD	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11644478	chr21:40555479	PSMG1	0.7	11.63	0.49	2.58e-27	Cognitive function;
LUAD	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.72	-0.35	8.56e-14	Personality dimensions;
LUAD	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg24130564	chr14:104152367	KLC1	0.5	8.87	0.4	2.03e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02018176	chr4:1364513	KIAA1530	0.7	12.32	0.51	4.93e-30	Longevity;
LUAD	cis	rs1232027	0.656	rs1650668	chr5:79961955	T/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.42	-6.88	-0.32	2.22e-11	Huntington's disease progression;
LUAD	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg17063962	chr7:91808500	NA	-0.68	-11.8	-0.5	5.66e-28	Breast cancer;
LUAD	cis	rs6591182	0.503	rs11227241	chr11:65389890	G/C	cg27068330	chr11:65405492	SIPA1	-0.61	-9.7	-0.43	3.1e-20	Non-alcoholic fatty liver disease histology (lobular);
LUAD	cis	rs7512552	0.839	rs11590787	chr1:150398531	G/A	cg15654264	chr1:150340011	RPRD2	0.58	11.22	0.48	9.82e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-10.61	-0.46	1.8e-23	Gut microbiome composition (summer);
LUAD	cis	rs12545109	0.732	rs1973629	chr8:57429583	A/G	cg19413350	chr8:57351067	NA	-0.47	-6.85	-0.32	2.56e-11	Obesity-related traits;
LUAD	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	8.03e-16	Body mass index;
LUAD	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.14	-0.51	2.76e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg08132940	chr7:1081526	C7orf50	-0.76	-10.29	-0.45	2.63e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1032833	0.732	rs111540484	chr2:180051438	G/A	cg23883738	chr2:179974586	SESTD1	-0.72	-8.01	-0.36	1.11e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs739496	0.615	rs649406	chr12:112126065	T/C	cg10833066	chr12:111807467	FAM109A	0.44	7.08	0.33	6.04e-12	Platelet count;
LUAD	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03264133	chr6:25882463	NA	0.48	7.76	0.35	6.4e-14	Blood metabolite levels;
LUAD	cis	rs738321	0.723	rs9622726	chr22:38506688	A/G	cg25457927	chr22:38595422	NA	-0.44	-9.76	-0.43	2.01e-20	Breast cancer;
LUAD	cis	rs7945705	0.967	rs7943377	chr11:8848700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.48	8.56	0.38	2.07e-16	Hemoglobin concentration;
LUAD	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg15704280	chr7:45808275	SEPT13	-0.62	-9.33	-0.41	5.8e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15506890	chr2:3487001	NA	-0.45	-7.95	-0.36	1.75e-14	Neurofibrillary tangles;
LUAD	trans	rs7246760	1.000	rs67507476	chr19:9852948	G/A	cg02900749	chr2:68251473	NA	-0.67	-7.07	-0.33	6.36e-12	Pursuit maintenance gain;
LUAD	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs6758955	0.850	rs55638790	chr2:10480389	C/T	cg15773312	chr2:10472214	HPCAL1	-0.47	-6.95	-0.32	1.35e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg08219700	chr8:58056026	NA	0.59	7.91	0.36	2.32e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs4919694	1.000	rs35159404	chr10:104805610	C/A	cg04362960	chr10:104952993	NT5C2	0.73	7.86	0.36	3.28e-14	Arsenic metabolism;
LUAD	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-7.28	-0.33	1.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs55665837	0.701	rs11023272	chr11:14630370	T/C	cg19336497	chr11:14380999	RRAS2	-0.4	-7.17	-0.33	3.26e-12	Vitamin D levels;
LUAD	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg15226275	chr6:116381976	FRK	0.23	7.65	0.35	1.41e-13	Cholesterol, total;LDL cholesterol;
LUAD	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.68	-0.31	7.36e-11	Systolic blood pressure;
LUAD	cis	rs1448094	0.617	rs1393612	chr12:86474576	T/C	cg02569458	chr12:86230093	RASSF9	-0.35	-6.44	-0.3	3.17e-10	Major depressive disorder;
LUAD	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg17173187	chr15:85201210	NMB	-0.45	-8.07	-0.37	7.53e-15	Schizophrenia;
LUAD	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg04944784	chr2:26401820	FAM59B	-0.88	-12.6	-0.52	4.12e-31	Gut microbiome composition (summer);
LUAD	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg24733560	chr20:60626293	TAF4	0.42	8.51	0.38	3.13e-16	Body mass index;
LUAD	cis	rs4629710	0.592	rs11759793	chr6:131546384	G/A	cg12606694	chr6:131520996	AKAP7	0.47	6.93	0.32	1.58e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg09137382	chr11:130731461	NA	0.4	7.43	0.34	6.19e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	10.33	0.45	1.9e-22	Type 2 diabetes;
LUAD	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg02527881	chr3:46936655	PTH1R	0.52	10.41	0.45	9.95e-23	Colorectal cancer;
LUAD	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg26354017	chr1:205819088	PM20D1	0.78	16.41	0.62	3.32e-47	Menarche (age at onset);
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg06646493	chr1:116519019	SLC22A15	0.37	6.47	0.3	2.71e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs7116495	1.000	rs4944232	chr11:71642258	A/G	cg07596299	chr11:71824057	C11orf51	0.74	6.79	0.31	3.76e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg00631329	chr6:26305371	NA	-0.68	-13.21	-0.54	1.41e-33	Educational attainment;
LUAD	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg23533926	chr12:111358616	MYL2	-0.4	-6.77	-0.31	4.23e-11	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05776053	chr2:74358815	NA	0.46	6.63	0.31	1.04e-10	Gestational age at birth (maternal effect);
LUAD	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg02527881	chr3:46936655	PTH1R	0.44	8.49	0.38	3.46e-16	Colorectal cancer;
LUAD	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg09658497	chr7:2847517	GNA12	-0.49	-8.93	-0.4	1.36e-17	Height;
LUAD	cis	rs938554	0.570	rs7696983	chr4:9995829	A/C	cg00071950	chr4:10020882	SLC2A9	0.63	9.72	0.43	2.62e-20	Blood metabolite levels;
LUAD	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg12292205	chr6:26970375	C6orf41	-0.51	-8.6	-0.39	1.54e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg25427524	chr10:38739819	LOC399744	0.6	8.53	0.38	2.72e-16	Obesity (extreme);
LUAD	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg23625390	chr15:77176239	SCAPER	0.4	6.95	0.32	1.39e-11	Blood metabolite levels;
LUAD	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg20203395	chr5:56204925	C5orf35	-0.83	-11.6	-0.49	3.26e-27	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg05340658	chr4:99064831	C4orf37	0.54	9.19	0.41	1.83e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2882667	0.898	rs11950819	chr5:138397100	T/C	cg04439458	chr5:138467593	SIL1	-0.38	-6.98	-0.32	1.18e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26314531	chr2:26401878	FAM59B	-0.64	-8.72	-0.39	6.62e-17	Gut microbiome composition (summer);
LUAD	cis	rs7640424	0.929	rs17828045	chr3:107821546	A/C	cg09227934	chr3:107805635	CD47	-0.55	-9.73	-0.43	2.45e-20	Body mass index;
LUAD	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.39	-0.45	1.15e-22	Monocyte percentage of white cells;
LUAD	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg27432699	chr2:27873401	GPN1	0.58	10.24	0.45	3.81e-22	Oral cavity cancer;
LUAD	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8002861	0.781	rs9525857	chr13:44437072	T/C	cg17145862	chr1:211918768	LPGAT1	0.74	17.04	0.64	6.28e-50	Leprosy;
LUAD	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg16647868	chr5:131706066	SLC22A5	0.41	7.16	0.33	3.64e-12	Blood metabolite levels;
LUAD	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg04398451	chr17:18023971	MYO15A	-0.91	-18.47	-0.67	2.76e-56	Total body bone mineral density;
LUAD	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg19875535	chr5:140030758	IK	0.47	7.71	0.35	8.78e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg02505535	chr3:195703920	SDHAP1	-0.34	-7.03	-0.32	8.18e-12	Pancreatic cancer;
LUAD	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg11189052	chr15:85197271	WDR73	0.65	8.73	0.39	5.91e-17	Schizophrenia;
LUAD	cis	rs7274811	0.634	rs4911356	chr20:32255034	T/C	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.45	-6.93	-0.32	1.55e-11	Height;
LUAD	cis	rs16958440	0.867	rs12386076	chr18:44673340	T/C	cg17192377	chr18:44677553	HDHD2	0.84	7.74	0.35	7.14e-14	Sitting height ratio;
LUAD	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg07677032	chr17:61819896	STRADA	0.57	10.34	0.45	1.78e-22	Prudent dietary pattern;
LUAD	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-7.69	-0.35	1.03e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6500395	1.000	rs34844432	chr16:48682418	C/T	cg04672837	chr16:48644449	N4BP1	0.39	6.77	0.31	4.19e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.43	7.94	0.36	1.89e-14	Systemic lupus erythematosus;
LUAD	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg19000871	chr14:103996768	TRMT61A	-0.42	-7.22	-0.33	2.4e-12	Coronary artery disease;
LUAD	cis	rs4072705	1.000	rs4838196	chr9:127357678	C/T	cg13476313	chr9:127244764	NR5A1	0.31	7.37	0.34	8.76e-13	Menarche (age at onset);
LUAD	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	6.67	0.31	7.92e-11	Multiple sclerosis;
LUAD	cis	rs7584330	0.554	rs3751111	chr2:238426953	G/T	cg14458575	chr2:238380390	NA	0.61	9.85	0.43	9.8e-21	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg03676636	chr4:99064102	C4orf37	-0.32	-8.34	-0.38	1.03e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03188948	chr7:1209495	NA	0.5	8.88	0.4	1.9e-17	Longevity;Endometriosis;
LUAD	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.58	-12.11	-0.51	3.41e-29	Monocyte percentage of white cells;
LUAD	trans	rs1728785	1.000	rs698728	chr16:68625253	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	10.59	0.46	2.08e-23	Ulcerative colitis;
LUAD	cis	rs6424115	0.867	rs10917431	chr1:24174093	T/G	cg10978503	chr1:24200527	CNR2	-0.57	-12.02	-0.5	8.04e-29	Immature fraction of reticulocytes;
LUAD	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg04248312	chr19:17393744	ANKLE1	-0.99	-18.62	-0.67	5.73e-57	Systemic lupus erythematosus;
LUAD	cis	rs1823874	0.581	rs9920347	chr15:100339331	C/T	cg16400843	chr15:100339927	C15orf51	-0.35	-7.68	-0.35	1.08e-13	IgG glycosylation;
LUAD	cis	rs9652601	0.843	rs7204643	chr16:11167603	C/T	cg04616529	chr16:11181986	CLEC16A	-0.38	-6.87	-0.32	2.34e-11	Systemic lupus erythematosus;
LUAD	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg07936489	chr17:37558343	FBXL20	-0.44	-6.84	-0.32	2.8e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.52	-8.14	-0.37	4.55e-15	Longevity;Endometriosis;
LUAD	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg04267008	chr7:1944627	MAD1L1	-0.7	-10.62	-0.46	1.66e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs4906332	0.782	rs12891288	chr14:103999750	C/T	cg19000871	chr14:103996768	TRMT61A	-0.53	-9.19	-0.41	1.81e-18	Coronary artery disease;
LUAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg04025307	chr7:1156635	C7orf50	0.55	7.06	0.32	6.74e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3772130	0.962	rs11721291	chr3:121563285	T/C	cg20356878	chr3:121714668	ILDR1	0.52	8.36	0.38	8.93e-16	Cognitive performance;
LUAD	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg15445000	chr17:37608096	MED1	-0.45	-8.47	-0.38	3.97e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs9972944	0.756	rs11870607	chr17:63773122	A/G	cg07283582	chr17:63770753	CCDC46	0.47	10.24	0.45	3.88e-22	Total body bone mineral density;
LUAD	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg06074448	chr4:187884817	NA	-0.36	-7.18	-0.33	3.08e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs447921	0.861	rs72860804	chr17:74413903	G/A	cg17201438	chr17:74438067	UBE2O	0.67	8.63	0.39	1.25e-16	Mitochondrial DNA levels;
LUAD	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23158103	chr7:148848205	ZNF398	-0.67	-12.51	-0.52	9.06e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs938554	0.558	rs4697701	chr4:9946095	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.96	-0.4	1.08e-17	Blood metabolite levels;
LUAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg24813613	chr7:1882135	MAD1L1	-0.44	-7.02	-0.32	8.63e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg12940439	chr1:67600707	NA	0.48	8.84	0.39	2.58e-17	Psoriasis;
LUAD	cis	rs62238980	0.614	rs17683011	chr22:32445946	A/G	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg05044414	chr3:183734942	ABCC5	0.49	9.3	0.41	7.66e-19	Anterior chamber depth;
LUAD	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg00316803	chr15:76480434	C15orf27	-0.37	-7.28	-0.33	1.69e-12	Blood metabolite levels;
LUAD	cis	rs2688608	0.869	rs2633308	chr10:75653904	A/T	cg23231163	chr10:75533350	FUT11	-0.36	-6.66	-0.31	8.56e-11	Inflammatory bowel disease;
LUAD	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg19980929	chr12:42632907	YAF2	0.34	6.56	0.3	1.54e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs2487048	0.725	rs2422493	chr9:107690995	G/A	cg14470647	chr9:107690075	ABCA1	-0.4	-6.75	-0.31	5.03e-11	Intraocular pressure;
LUAD	cis	rs35740288	0.770	rs4843085	chr15:86158499	A/G	cg13263323	chr15:86062960	AKAP13	-0.44	-7.07	-0.33	6.4e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg21475434	chr5:93447410	FAM172A	0.59	7.49	0.34	4.05e-13	Diabetic retinopathy;
LUAD	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg00316803	chr15:76480434	C15orf27	-0.37	-7.27	-0.33	1.72e-12	Blood metabolite levels;
LUAD	cis	rs2455799	0.613	rs13078485	chr3:15883236	T/C	cg16303742	chr3:15540471	COLQ	-0.52	-9.63	-0.42	5.61e-20	Mean platelet volume;
LUAD	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg05340658	chr4:99064831	C4orf37	0.54	9.15	0.41	2.36e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg05564831	chr3:52568323	NT5DC2	0.36	6.58	0.3	1.42e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-24.54	-0.77	2.43e-83	Height;
LUAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg07234876	chr8:600039	NA	1.03	9.69	0.43	3.45e-20	IgG glycosylation;
LUAD	cis	rs9837602	0.938	rs28503408	chr3:99794842	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.58	8.93	0.4	1.36e-17	Breast cancer;
LUAD	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg14092988	chr3:52407081	DNAH1	0.45	9.04	0.4	5.89e-18	Bipolar disorder;
LUAD	cis	rs9372498	0.536	rs10484286	chr6:118956447	T/C	cg07617317	chr6:118971624	C6orf204	0.55	7.84	0.36	3.76e-14	Diastolic blood pressure;
LUAD	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-8.7	-0.39	7.22e-17	Gut microbiome composition (summer);
LUAD	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg15445000	chr17:37608096	MED1	0.43	7.94	0.36	1.87e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs11955175	1.000	rs77394428	chr5:40743517	A/G	cg04002187	chr5:40835754	RPL37	0.75	6.5	0.3	2.2e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs11051970	0.611	rs10844197	chr12:32561015	A/C	cg02745156	chr12:32552066	NA	0.31	6.72	0.31	6.06e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4774899	0.752	rs2920265	chr15:57337480	G/A	cg14026238	chr15:57616123	NA	0.42	8.04	0.36	9.28e-15	Urinary tract infection frequency;
LUAD	cis	rs250677	0.522	rs56309414	chr5:148376026	C/G	cg18129178	chr5:148520854	ABLIM3	-0.51	-7.62	-0.35	1.72e-13	Breast cancer;
LUAD	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23583168	chr7:148888333	NA	-0.92	-18.99	-0.68	1.31e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.76	-0.31	4.65e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg21659725	chr3:3221576	CRBN	0.38	6.44	0.3	3.34e-10	Resting heart rate;
LUAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg11494091	chr17:61959527	GH2	-0.78	-20.31	-0.7	1.66e-64	Prudent dietary pattern;
LUAD	cis	rs9314323	0.501	rs6557911	chr8:26189230	G/T	cg13160058	chr8:26243215	BNIP3L	-0.38	-7.89	-0.36	2.65e-14	Red cell distribution width;
LUAD	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg21204522	chr6:27730016	NA	-0.43	-6.89	-0.32	2.04e-11	Parkinson's disease;
LUAD	cis	rs813218	0.584	rs11711935	chr3:99808804	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.34	-6.43	-0.3	3.52e-10	Orofacial clefts;
LUAD	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg22166914	chr1:53195759	ZYG11B	0.44	7.3	0.33	1.4e-12	Monocyte count;
LUAD	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg06713675	chr4:122721982	EXOSC9	-0.57	-11.09	-0.47	2.85e-25	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg24768116	chr2:27665128	KRTCAP3	0.26	6.55	0.3	1.68e-10	Oral cavity cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01358551	chr19:47353761	AP2S1	-0.43	-6.65	-0.31	9.29e-11	Height;
LUAD	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg14558114	chr2:88469736	THNSL2	-0.44	-7.01	-0.32	9.42e-12	Response to metformin (IC50);
LUAD	cis	rs13315871	0.929	rs1554124	chr3:58268968	C/G	cg12435725	chr3:58293450	RPP14	-0.55	-6.42	-0.3	3.72e-10	Cholesterol, total;
LUAD	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-7.89	-0.36	2.64e-14	Total body bone mineral density;
LUAD	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg13319975	chr6:146136371	FBXO30	-0.62	-10.76	-0.46	4.99e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg12011299	chr4:100065546	ADH4	-0.73	-13.61	-0.55	2.96e-35	Alcohol dependence;
LUAD	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg09033563	chr22:24373618	LOC391322	-0.55	-8.72	-0.39	6.65e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs34734847	1.000	rs55730005	chr12:121157536	C/A	cg21892295	chr12:121157589	UNC119B	-0.45	-8.21	-0.37	2.77e-15	Mean corpuscular volume;
LUAD	cis	rs8028313	0.731	rs11857017	chr15:67972908	A/G	cg24579218	chr15:68104479	NA	-0.49	-8.44	-0.38	4.94e-16	Obesity;
LUAD	trans	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg07817883	chr1:32538562	TMEM39B	-0.53	-6.79	-0.31	3.9e-11	Monocyte percentage of white cells;
LUAD	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.61e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7640424	0.618	rs35798995	chr3:107914313	G/A	cg09227934	chr3:107805635	CD47	-0.48	-8.5	-0.38	3.4e-16	Body mass index;
LUAD	cis	rs12208915	0.945	rs10455354	chr6:79566230	C/T	cg05283184	chr6:79620031	NA	-0.5	-6.43	-0.3	3.39e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg25019722	chr6:37503610	NA	-0.34	-7.85	-0.36	3.4e-14	Cognitive performance;
LUAD	cis	rs28595532	0.920	rs116091383	chr4:119635518	A/G	cg02775129	chr4:119771670	NA	-0.84	-7.8	-0.35	4.94e-14	Cannabis dependence symptom count;
LUAD	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg19717773	chr7:2847554	GNA12	-0.5	-9.34	-0.41	5.4e-19	Height;
LUAD	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg24818145	chr4:99064322	C4orf37	0.49	8.29	0.37	1.5e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg17443473	chr1:3703550	LRRC47	0.45	7.49	0.34	4.01e-13	Red cell distribution width;
LUAD	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.54	-0.42	1.15e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs17655565	1.000	rs2276399	chr12:52705269	G/A	cg08257133	chr12:52711352	KRT83	0.4	6.99	0.32	1.05e-11	Plasma amyloid beta peptide concentrations (ABx-42);
LUAD	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg03030879	chr14:75389066	RPS6KL1	0.34	6.4	0.3	4.17e-10	Caffeine consumption;
LUAD	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg15181151	chr6:150070149	PCMT1	0.42	8.78	0.39	4.02e-17	Lung cancer;
LUAD	cis	rs1444418	1.000	rs60033636	chr10:64559641	G/A	cg14943953	chr10:64564468	ADO	-0.58	-6.93	-0.32	1.6e-11	Atopic dermatitis;
LUAD	cis	rs4444235	0.752	rs17563	chr14:54417522	A/G	cg16720578	chr14:54410717	NA	-0.38	-6.75	-0.31	4.78e-11	Colorectal cancer;
LUAD	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.7	-7.83	-0.36	3.88e-14	Smoking behavior;
LUAD	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg23281280	chr6:28129359	ZNF389	0.48	6.71	0.31	6.44e-11	Parkinson's disease;
LUAD	cis	rs10504073	0.647	rs62507245	chr8:50006939	A/T	cg00325661	chr8:49890786	NA	0.46	10.31	0.45	2.29e-22	Blood metabolite ratios;
LUAD	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg03929089	chr4:120376271	NA	-0.51	-6.7	-0.31	6.64e-11	Axial length;
LUAD	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg02269571	chr22:50332266	NA	0.59	8.96	0.4	1.05e-17	Schizophrenia;
LUAD	cis	rs2282300	0.739	rs16920406	chr11:30216158	A/C	cg06241208	chr11:30344200	C11orf46	-0.56	-7.39	-0.34	7.84e-13	Morning vs. evening chronotype;
LUAD	cis	rs6543140	0.964	rs6543143	chr2:103085420	A/C	cg03938978	chr2:103052716	IL18RAP	0.35	6.72	0.31	5.97e-11	Blood protein levels;
LUAD	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg00484396	chr16:3507460	NAT15	0.75	9.96	0.44	3.76e-21	Tuberculosis;
LUAD	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg25233709	chr10:116636983	FAM160B1	0.42	8.27	0.37	1.82e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg08601574	chr20:25228251	PYGB	0.41	7.58	0.35	2.26e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg23649088	chr2:200775458	C2orf69	0.53	8.43	0.38	5.6e-16	Osteoporosis;
LUAD	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg26924012	chr15:45694286	SPATA5L1	1.02	18.92	0.68	2.86e-58	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs12893597	0.715	rs12892786	chr14:76833888	C/T	cg20290672	chr14:76816747	NA	-0.42	-6.89	-0.32	2.08e-11	Maximal oxygen uptake response;
LUAD	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg16205897	chr5:131564050	P4HA2	-0.32	-6.8	-0.31	3.57e-11	Breast cancer;Mosquito bite size;
LUAD	cis	rs7043114	0.525	rs10116241	chr9:95240546	T/C	cg14631576	chr9:95140430	CENPP	-0.4	-8.09	-0.37	6.35e-15	Height;
LUAD	cis	rs469568	0.869	rs340124	chr5:178686590	C/T	cg08999896	chr5:178685787	ADAMTS2	-0.32	-6.75	-0.31	4.8e-11	Stroke (pediatric);
LUAD	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-11.16	-0.48	1.66e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.57	9.68	0.43	3.91e-20	Cognitive ability;
LUAD	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg04944784	chr2:26401820	FAM59B	0.88	12.04	0.51	6.46e-29	Gut microbiome composition (summer);
LUAD	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg15485101	chr11:133734466	NA	0.33	7.54	0.34	2.99e-13	Childhood ear infection;
LUAD	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.47	0.38	4.01e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6920965	0.545	rs2326242	chr6:126174859	A/C	cg05901451	chr6:126070800	HEY2	-0.43	-7.01	-0.32	9.19e-12	High light scatter reticulocyte count;
LUAD	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg23985595	chr17:80112537	CCDC57	0.53	9.69	0.43	3.54e-20	Life satisfaction;
LUAD	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg05304507	chr6:116381966	FRK	0.19	6.55	0.3	1.62e-10	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.35	-0.34	1e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1018836	0.608	rs6998106	chr8:91479755	G/T	cg16814680	chr8:91681699	NA	-0.53	-8.67	-0.39	9.55e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	10.16	0.44	7.89e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg04093404	chr1:6614507	TAS1R1;NOL9	0.74	9.39	0.42	3.87e-19	Body mass index;
LUAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08677398	chr8:58056175	NA	0.54	7.22	0.33	2.51e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-7.39	-0.34	8.17e-13	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg18446336	chr7:2847575	GNA12	-0.34	-6.54	-0.3	1.82e-10	Height;
LUAD	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg07169764	chr2:136633963	MCM6	-0.56	-7.39	-0.34	7.8e-13	Corneal structure;
LUAD	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg06606381	chr12:133084897	FBRSL1	-0.63	-6.81	-0.31	3.44e-11	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg19894588	chr14:64061835	NA	0.51	7.94	0.36	1.82e-14	Glioblastoma;Glioma;
LUAD	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg10556349	chr10:835070	NA	0.51	6.9	0.32	1.87e-11	Eosinophil percentage of granulocytes;
LUAD	trans	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg24644049	chr4:85504048	CDS1	0.91	7.91	0.36	2.29e-14	Skin colour saturation;
LUAD	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg18827107	chr12:86230957	RASSF9	-0.7	-12.93	-0.53	1.93e-32	Major depressive disorder;
LUAD	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04267008	chr7:1944627	MAD1L1	0.74	11.91	0.5	2.03e-28	Bipolar disorder and schizophrenia;
LUAD	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg09904177	chr6:26538194	HMGN4	0.42	6.92	0.32	1.68e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg16989719	chr2:238392110	NA	-0.35	-6.38	-0.3	4.62e-10	Prostate cancer;
LUAD	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.0	0.32	9.82e-12	Prostate cancer;
LUAD	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg22532475	chr10:104410764	TRIM8	0.34	6.8	0.31	3.49e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg02734326	chr4:10020555	SLC2A9	0.48	8.04	0.36	9.14e-15	Bone mineral density;
LUAD	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.53	-10.14	-0.44	9.14e-22	Longevity;Endometriosis;
LUAD	trans	rs10802346	0.545	rs1770012	chr1:246426405	A/G	cg22732515	chr19:44031385	ETHE1	0.57	9.18	0.41	1.91e-18	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs938554	0.612	rs9991278	chr4:10002665	A/G	cg11266682	chr4:10021025	SLC2A9	0.47	8.18	0.37	3.33e-15	Blood metabolite levels;
LUAD	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg21280719	chr6:42927975	GNMT	-0.38	-11.59	-0.49	3.76e-27	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg25053907	chr4:492859	ZNF721;PIGG	-0.39	-6.44	-0.3	3.29e-10	Schizophrenia;
LUAD	cis	rs1595825	0.891	rs57990618	chr2:198660838	C/T	cg10547527	chr2:198650123	BOLL	-0.53	-7.08	-0.33	6.15e-12	Ulcerative colitis;
LUAD	cis	rs56283067	0.887	rs10948171	chr6:44761028	C/T	cg20913747	chr6:44695427	NA	-0.47	-7.34	-0.34	1.11e-12	Total body bone mineral density;
LUAD	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg07570687	chr10:102243282	WNT8B	0.44	6.69	0.31	7.15e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7173743	0.756	rs4551997	chr15:79130433	G/A	cg00540400	chr15:79124168	NA	0.4	8.32	0.37	1.24e-15	Coronary artery disease;
LUAD	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs1403694	0.515	rs1648699	chr3:186449890	G/C	cg12454167	chr3:186435060	KNG1	0.41	8.5	0.38	3.18e-16	Blood protein levels;
LUAD	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg13160058	chr8:26243215	BNIP3L	0.47	9.89	0.43	6.94e-21	Red cell distribution width;
LUAD	cis	rs12976411	0.575	rs35555788	chr19:32820544	C/T	cg18253629	chr19:32836317	ZNF507	0.65	6.84	0.32	2.87e-11	Coronary artery disease;
LUAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg18402987	chr7:1209562	NA	0.81	9.98	0.44	3.44e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg23260525	chr10:116636907	FAM160B1	0.51	12.08	0.51	4.66e-29	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg22728534	chr2:87034800	CD8A	-0.36	-6.47	-0.3	2.75e-10	Migraine with aura;
LUAD	cis	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg19875535	chr5:140030758	IK	-0.4	-6.85	-0.32	2.59e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg20673091	chr1:2541236	MMEL1	0.41	8.52	0.38	2.84e-16	Ulcerative colitis;
LUAD	cis	rs6988985	0.560	rs2078674	chr8:143928233	G/T	cg10324643	chr8:143916377	GML	0.31	6.42	0.3	3.56e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg26513180	chr16:89883248	FANCA	0.69	12.83	0.53	4.53e-32	Vitiligo;
LUAD	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg21153622	chr11:89784906	NA	0.33	6.47	0.3	2.64e-10	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs807669	0.548	rs9605957	chr22:19187375	G/A	cg02655711	chr22:19163373	SLC25A1	0.64	12.78	0.53	7.37e-32	Metabolite levels;
LUAD	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg17105886	chr17:28927953	LRRC37B2	0.72	7.05	0.32	7.19e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs34816374	1	rs34816374	chr6:26949672	A/G	cg06606381	chr12:133084897	FBRSL1	-1.1	-10.02	-0.44	2.46e-21	Lung cancer in ever smokers;
LUAD	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg07636037	chr3:49044803	WDR6	0.63	12.17	0.51	1.99e-29	Parkinson's disease;
LUAD	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg16342193	chr10:102329863	NA	-0.38	-6.6	-0.31	1.21e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs10744422	1.000	rs4759382	chr12:123347609	C/T	cg16953816	chr12:123349952	VPS37B	-0.58	-6.73	-0.31	5.39e-11	Schizophrenia;
LUAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04871131	chr7:94954202	PON1	-0.64	-11.45	-0.49	1.3e-26	Paraoxonase activity;
LUAD	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-7.93	-0.36	1.96e-14	Myeloid white cell count;
LUAD	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg21548813	chr6:291882	DUSP22	-0.53	-8.6	-0.39	1.55e-16	Menopause (age at onset);
LUAD	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg10356904	chr22:49881777	NA	-0.38	-8.15	-0.37	4.19e-15	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg24813613	chr7:1882135	MAD1L1	-0.54	-8.91	-0.4	1.58e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs2806561	1.000	rs2806561	chr1:23504795	C/T	cg19743168	chr1:23544995	NA	-0.39	-7.26	-0.33	1.89e-12	Height;
LUAD	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg18230493	chr5:56204884	C5orf35	-0.84	-12.53	-0.52	7.21e-31	Initial pursuit acceleration;
LUAD	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg21709803	chr11:61594965	FADS2	-0.37	-6.69	-0.31	7e-11	Trans fatty acid levels;
LUAD	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg26566898	chr11:117069891	TAGLN	-0.36	-7.09	-0.33	5.84e-12	Blood protein levels;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg15888301	chr15:73344233	NEO1	0.41	6.51	0.3	2.1e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1448094	0.558	rs7485285	chr12:86483641	G/A	cg18827107	chr12:86230957	RASSF9	0.49	8.62	0.39	1.39e-16	Major depressive disorder;
LUAD	cis	rs1950626	0.623	rs4402490	chr14:101445453	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.39	-7.87	-0.36	3.04e-14	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg17366294	chr4:99064904	C4orf37	0.65	12.62	0.52	3.28e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.32	-0.34	1.27e-12	Total body bone mineral density;
LUAD	cis	rs7301016	0.846	rs12369751	chr12:63031133	G/C	cg11441379	chr12:63026424	NA	0.64	7.77	0.35	5.99e-14	IgG glycosylation;
LUAD	cis	rs4523957	0.583	rs2984942	chr17:2030155	A/G	cg16513277	chr17:2031491	SMG6	-0.98	-20.52	-0.71	1.97e-65	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg19318889	chr4:1322082	MAEA	0.89	15.43	0.6	6.26e-43	Longevity;
LUAD	cis	rs757081	0.667	rs17473243	chr11:17266259	G/A	cg15432903	chr11:17409602	KCNJ11	-0.4	-6.44	-0.3	3.31e-10	Systolic blood pressure;
LUAD	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	7.98	0.36	1.42e-14	Rheumatoid arthritis;
LUAD	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.68	-0.39	8.73e-17	Alzheimer's disease (late onset);
LUAD	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg06108461	chr20:60628389	TAF4	-1.13	-20.76	-0.71	1.55e-66	Body mass index;
LUAD	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg16797656	chr11:68205561	LRP5	0.45	8.71	0.39	6.73e-17	Total body bone mineral density;
LUAD	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg08000102	chr2:233561755	GIGYF2	-0.41	-6.38	-0.3	4.68e-10	Coronary artery disease;
LUAD	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg04398451	chr17:18023971	MYO15A	-0.84	-15.7	-0.61	4.48e-44	Total body bone mineral density;
LUAD	cis	rs2735413	1.000	rs2735413	chr16:78053643	A/T	cg04733911	chr16:78082701	NA	-0.29	-6.61	-0.31	1.16e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg04455712	chr21:45112962	RRP1B	-0.42	-8.72	-0.39	6.24e-17	Mean corpuscular volume;
LUAD	cis	rs4843185	0.669	rs889502	chr16:85716832	A/G	cg26571870	chr16:85723150	GINS2	-0.36	-6.92	-0.32	1.69e-11	Platelet distribution width;
LUAD	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg05373962	chr22:49881684	NA	-0.57	-13.77	-0.56	6.57e-36	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg26114124	chr12:9217669	LOC144571	0.4	7.28	0.33	1.69e-12	Sjögren's syndrome;
LUAD	cis	rs7737355	1.000	rs2551036	chr5:130648994	G/A	cg06307176	chr5:131281290	NA	0.46	7.32	0.34	1.25e-12	Life satisfaction;
LUAD	trans	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg27411982	chr8:10470053	RP1L1	0.4	6.94	0.32	1.49e-11	Neuroticism;
LUAD	cis	rs2882667	0.858	rs66839813	chr5:138442322	A/T	cg04439458	chr5:138467593	SIL1	-0.52	-9.51	-0.42	1.51e-19	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7116495	1.000	rs7949480	chr11:71697588	T/C	cg07596299	chr11:71824057	C11orf51	-0.78	-6.64	-0.31	9.8e-11	Severe influenza A (H1N1) infection;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22455660	chr9:128509791	PBX3	-0.42	-6.5	-0.3	2.26e-10	Height;
LUAD	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg02743256	chr7:2109353	MAD1L1	-0.52	-7.15	-0.33	3.81e-12	Neuroticism;
LUAD	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg06873352	chr17:61820015	STRADA	0.42	6.8	0.31	3.58e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg13385794	chr1:248469461	NA	0.26	7.07	0.32	6.56e-12	Common traits (Other);
LUAD	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06028605	chr16:24865363	SLC5A11	0.59	9.15	0.41	2.5e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg21862992	chr11:68658383	NA	0.52	9.64	0.42	5.35e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6758955	0.850	rs6743846	chr2:10480415	A/G	cg15773312	chr2:10472214	HPCAL1	0.46	6.85	0.32	2.63e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-7.97	-0.36	1.53e-14	Multiple myeloma (hyperdiploidy);
LUAD	trans	rs57046232	0.531	rs6054146	chr20:6335865	G/T	cg21095983	chr6:86352623	SYNCRIP	0.41	6.37	0.3	4.84e-10	Colorectal cancer;
LUAD	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg11663144	chr21:46675770	NA	-0.48	-9.18	-0.41	1.9e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15664640	chr17:80829946	TBCD	-0.53	-10.21	-0.44	4.9e-22	Breast cancer;
LUAD	cis	rs7903847	0.667	rs11189181	chr10:99144154	A/G	cg20016023	chr10:99160130	RRP12	-0.34	-8.12	-0.37	4.98e-15	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.47	-0.52	1.29e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg23978390	chr7:1156363	C7orf50	0.45	7.11	0.33	5.12e-12	Longevity;Endometriosis;
LUAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg24813613	chr7:1882135	MAD1L1	-0.44	-7.03	-0.32	8.32e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg11062466	chr8:58055876	NA	0.83	10.65	0.46	1.27e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs977987	0.806	rs7188604	chr16:75451170	T/G	cg03315344	chr16:75512273	CHST6	0.64	14.06	0.56	4.12e-37	Dupuytren's disease;
LUAD	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.4	-7.99	-0.36	1.33e-14	Menarche (age at onset);
LUAD	cis	rs12760731	0.720	rs12161419	chr1:178379040	A/C	cg00404053	chr1:178313656	RASAL2	0.63	8.13	0.37	4.77e-15	Obesity-related traits;
LUAD	trans	rs75804782	0.625	rs13409356	chr2:239468046	C/T	cg01134436	chr17:81009848	B3GNTL1	0.71	7.28	0.33	1.64e-12	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs3820068	0.705	rs4646063	chr1:15829813	G/A	cg13390004	chr1:15929781	NA	0.44	6.77	0.31	4.37e-11	Systolic blood pressure;
LUAD	cis	rs7833986	1.000	rs34037954	chr8:57096841	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.76	10.1	0.44	1.22e-21	Height;
LUAD	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg26384229	chr12:38710491	ALG10B	0.42	7.34	0.34	1.09e-12	Morning vs. evening chronotype;
LUAD	cis	rs73198271	0.628	rs74433718	chr8:8591546	A/C	cg01851573	chr8:8652454	MFHAS1	0.47	6.8	0.31	3.6e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg09033563	chr22:24373618	LOC391322	-0.65	-10.72	-0.46	6.92e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg26384229	chr12:38710491	ALG10B	0.4	6.53	0.3	1.9e-10	Morning vs. evening chronotype;
LUAD	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg20701182	chr2:24300061	SF3B14	0.56	6.71	0.31	6.08e-11	Lymphocyte counts;
LUAD	cis	rs870825	0.616	rs28607131	chr4:185651617	A/G	cg04058563	chr4:185651563	MLF1IP	0.9	14.58	0.58	2.63e-39	Blood protein levels;
LUAD	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg05110241	chr16:68378359	PRMT7	-0.83	-9.11	-0.41	3.29e-18	HDL cholesterol;
LUAD	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg06221963	chr1:154839813	KCNN3	-0.45	-8.28	-0.37	1.59e-15	Schizophrenia;
LUAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg08888203	chr3:10149979	C3orf24	0.75	13.46	0.55	1.23e-34	Alzheimer's disease;
LUAD	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg18351406	chr4:77819688	ANKRD56	0.61	9.73	0.43	2.57e-20	Emphysema distribution in smoking;
LUAD	trans	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg20587970	chr11:113659929	NA	0.9	12.47	0.52	1.25e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.94e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.55e-13	Menopause (age at onset);
LUAD	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.32	-7.17	-0.33	3.32e-12	Lung cancer;
LUAD	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg02038168	chr22:39784481	NA	-0.57	-9.42	-0.42	2.98e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs6701037	0.967	rs1057302	chr1:175126423	A/G	cg17845761	chr1:175162550	KIAA0040	-0.34	-8.9	-0.4	1.62e-17	Alcohol dependence;
LUAD	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg15790184	chr11:494944	RNH1	0.44	7.16	0.33	3.59e-12	Systemic lupus erythematosus;
LUAD	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.41	0.38	6.37e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg02782426	chr3:40428986	ENTPD3	0.43	9.18	0.41	1.89e-18	Renal cell carcinoma;
LUAD	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg07741184	chr6:167504864	NA	0.31	7.11	0.33	5.13e-12	Crohn's disease;
LUAD	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg17063962	chr7:91808500	NA	0.71	12.68	0.52	1.92e-31	Breast cancer;
LUAD	cis	rs10781543	0.776	rs11145760	chr9:139382594	G/A	cg14019695	chr9:139328340	INPP5E	0.53	10.35	0.45	1.61e-22	Monocyte percentage of white cells;
LUAD	cis	rs6542838	0.641	rs12467189	chr2:99495820	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.35	-0.34	1.07e-12	Fear of minor pain;
LUAD	cis	rs367615	0.879	rs2201015	chr5:108947450	C/T	cg17395555	chr5:108820864	NA	0.42	7.15	0.33	3.75e-12	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg15485101	chr11:133734466	NA	0.34	7.64	0.35	1.49e-13	Childhood ear infection;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25808892	chr17:6459352	PITPNM3	-0.51	-6.39	-0.3	4.42e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg03526776	chr6:41159608	TREML2	-0.54	-11.09	-0.47	2.93e-25	Alzheimer's disease (late onset);
LUAD	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg22189786	chr22:42395067	WBP2NL	0.46	6.6	0.31	1.25e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUAD	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg23803603	chr1:2058230	PRKCZ	0.4	6.52	0.3	2e-10	Height;
LUAD	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg22105103	chr4:187893119	NA	0.56	12.04	0.51	6.73e-29	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg23262073	chr20:60523788	NA	-0.37	-6.35	-0.3	5.44e-10	Body mass index;
LUAD	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs1018836	0.923	rs4735268	chr8:91629715	C/T	cg16814680	chr8:91681699	NA	-0.67	-11.21	-0.48	1.02e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12208915	0.945	rs12214796	chr6:79561068	T/C	cg05283184	chr6:79620031	NA	0.52	6.49	0.3	2.41e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg06074448	chr4:187884817	NA	-0.42	-8.79	-0.39	3.83e-17	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg07870213	chr5:140052090	DND1	1.01	14.29	0.57	4.28e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg21100191	chr22:23484243	RTDR1	0.7	12.0	0.5	9.53e-29	Bone mineral density;
LUAD	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg07169764	chr2:136633963	MCM6	-0.49	-6.52	-0.3	1.97e-10	Mosquito bite size;
LUAD	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg06718696	chr17:78121285	EIF4A3	0.63	9.31	0.41	7.17e-19	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs11800820	0.555	rs6661155	chr1:246628943	C/G	cg16700716	chr1:246684329	NA	-0.38	-7.23	-0.33	2.21e-12	Obesity-related traits;
LUAD	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg04287289	chr16:89883240	FANCA	0.79	7.06	0.32	6.75e-12	Skin colour saturation;
LUAD	cis	rs8060686	0.516	rs7206792	chr16:68168200	C/G	cg26727032	chr16:67993705	SLC12A4	-0.47	-7.71	-0.35	9.12e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg18135555	chr8:22132992	PIWIL2	-0.46	-8.31	-0.37	1.27e-15	Hypertriglyceridemia;
LUAD	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg13319975	chr6:146136371	FBXO30	-0.54	-8.97	-0.4	9.78e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg18105134	chr13:113819100	PROZ	-0.81	-14.41	-0.57	1.46e-38	Platelet distribution width;
LUAD	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs4714291	0.832	rs2984431	chr6:39980900	T/A	cg02267698	chr19:7991119	CTXN1	-0.45	-7.17	-0.33	3.45e-12	Strep throat;
LUAD	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg00316803	chr15:76480434	C15orf27	-0.43	-8.42	-0.38	5.72e-16	Blood metabolite levels;
LUAD	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg08873628	chr1:175162347	KIAA0040	0.38	6.52	0.3	2.04e-10	Alcohol dependence;
LUAD	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2425143	1.000	rs60646509	chr20:34303409	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.42	-0.34	6.62e-13	Blood protein levels;
LUAD	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg24818145	chr4:99064322	C4orf37	0.43	7.14	0.33	4.1e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3772130	0.775	rs6781857	chr3:121560721	T/C	cg20356878	chr3:121714668	ILDR1	0.52	8.36	0.38	8.93e-16	Cognitive performance;
LUAD	cis	rs9486719	1.000	rs12529248	chr6:96895377	T/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.04	-0.44	2.05e-21	Migraine;Coronary artery disease;
LUAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07167872	chr1:205819463	PM20D1	-0.69	-13.12	-0.54	3.19e-33	Menarche (age at onset);
LUAD	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg26384229	chr12:38710491	ALG10B	0.46	7.36	0.34	9.42e-13	Bladder cancer;
LUAD	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg21862992	chr11:68658383	NA	0.52	9.25	0.41	1.16e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7009516	0.544	rs2291574	chr8:24249668	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.4	-7.35	-0.34	1.05e-12	Hair greying;
LUAD	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.32	7.49	0.34	3.95e-13	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg05714579	chr10:131428358	MGMT	0.4	6.54	0.3	1.77e-10	Response to temozolomide;
LUAD	cis	rs9394438	0.628	rs10947680	chr6:37543668	T/C	cg00985040	chr6:37553208	NA	-0.45	-9.5	-0.42	1.5700000000000001e-19	IgG glycosylation;
LUAD	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg03651054	chr13:50194643	NA	0.4	8.02	0.36	1.03e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg00280220	chr17:61926910	NA	0.37	7.25	0.33	2.02e-12	Prudent dietary pattern;
LUAD	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg20503657	chr10:835505	NA	0.99	15.03	0.59	3.15e-41	Eosinophil percentage of granulocytes;
LUAD	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg09184832	chr6:79620586	NA	-0.52	-10.03	-0.44	2.17e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg04833646	chr19:10679720	CDKN2D	0.75	11.37	0.48	2.65e-26	Red cell distribution width;
LUAD	cis	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg16347377	chr7:143956670	OR2A7	-0.46	-7.2	-0.33	2.76e-12	Obesity-related traits;
LUAD	trans	rs11039798	1.000	rs7942042	chr11:48520270	A/G	cg02254774	chr11:50257496	LOC441601	0.53	6.57	0.3	1.5e-10	Axial length;
LUAD	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg09796270	chr17:17721594	SREBF1	-0.37	-6.95	-0.32	1.35e-11	Total body bone mineral density;
LUAD	cis	rs4691139	1.000	rs6536882	chr4:165900680	G/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.45	-8.78	-0.39	3.94e-17	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs12122100	0.526	rs12122534	chr1:146504399	A/G	cg03526459	chr1:146549940	NA	0.36	7.55	0.34	2.75e-13	HIV-1 control;
LUAD	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg08027265	chr7:2291960	NA	-0.52	-8.96	-0.4	1.04e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.06	0.36	7.97e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62229266	0.647	rs59397717	chr21:37451725	C/T	cg12218747	chr21:37451666	NA	-0.67	-12.63	-0.52	3.1e-31	Mitral valve prolapse;
LUAD	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg27432699	chr2:27873401	GPN1	-0.38	-6.39	-0.3	4.38e-10	Total body bone mineral density;
LUAD	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg12923728	chr3:195709715	SDHAP1	0.56	9.5	0.42	1.62e-19	Pancreatic cancer;
LUAD	cis	rs708547	0.647	rs1403233	chr4:57885053	C/T	cg00922110	chr4:57842668	C4orf14	0.43	8.02	0.36	1.03e-14	Response to bleomycin (chromatid breaks);
LUAD	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg23719950	chr11:63933701	MACROD1	-0.56	-6.71	-0.31	6.29e-11	Mean platelet volume;
LUAD	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.11	-0.44	1.2e-21	Migraine;Coronary artery disease;
LUAD	trans	rs8073060	0.544	rs7210966	chr17:33986334	G/C	cg19694781	chr19:47549865	TMEM160	-1.24	-20.06	-0.7	2.27e-63	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg03929089	chr4:120376271	NA	-0.93	-17.89	-0.66	1.08e-53	Height;
LUAD	cis	rs698833	0.819	rs698772	chr2:44580634	G/A	cg04920474	chr2:44395004	PPM1B	0.43	7.88	0.36	2.72e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg01448562	chr3:133502909	NA	0.69	13.32	0.54	4.66e-34	Iron status biomarkers;
LUAD	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg10426581	chr7:100472382	SRRT	0.77	10.26	0.45	3.32e-22	Resting heart rate;
LUAD	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14019695	chr9:139328340	INPP5E	0.53	10.73	0.46	6.43e-24	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg13319975	chr6:146136371	FBXO30	-0.59	-9.86	-0.43	9.03e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs16958440	0.867	rs3809966	chr18:44677627	C/T	cg17192377	chr18:44677553	HDHD2	0.84	8.03	0.36	1e-14	Sitting height ratio;
LUAD	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.54	8.73	0.39	6.04e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg17863274	chr19:49399704	TULP2	-0.55	-8.36	-0.38	9.17e-16	Red cell distribution width;
LUAD	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg18512352	chr11:47633146	NA	-0.54	-9.55	-0.42	1.03e-19	Subjective well-being;
LUAD	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.41	-7.2	-0.33	2.82e-12	Platelet count;
LUAD	trans	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg17712092	chr4:129076599	LARP1B	-0.68	-11.23	-0.48	8.57e-26	Eosinophil percentage of white cells;
LUAD	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg18876405	chr7:65276391	NA	0.46	7.46	0.34	4.96e-13	Aortic root size;
LUAD	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg04545296	chr12:48745243	ZNF641	0.42	10.59	0.46	2.06e-23	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg04352962	chr1:209979756	IRF6	-0.52	-7.54	-0.34	2.91e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg11645453	chr3:52864694	ITIH4	0.53	10.1	0.44	1.22e-21	Schizophrenia;
LUAD	trans	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg01620082	chr3:125678407	NA	-0.81	-8.18	-0.37	3.36e-15	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs2735413	0.837	rs12920830	chr16:78083149	A/C	cg01028844	chr5:122736986	CEP120	0.41	6.46	0.3	2.87e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg04414720	chr1:150670196	GOLPH3L	0.73	12.57	0.52	4.98e-31	Melanoma;
LUAD	cis	rs36051895	0.632	rs62541899	chr9:5143291	C/T	cg02405213	chr9:5042618	JAK2	-0.48	-6.53	-0.3	1.87e-10	Pediatric autoimmune diseases;
LUAD	cis	rs72772090	0.710	rs17479052	chr5:96065636	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-6.74	-0.31	5.07e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.92	0.32	1.67e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06221963	chr1:154839813	KCNN3	-0.87	-21.0	-0.71	1.4e-67	Prostate cancer;
LUAD	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.41	-0.3	3.99e-10	Triglycerides;
LUAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg04234412	chr22:24373322	LOC391322	-0.79	-14.33	-0.57	2.99e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg10792982	chr14:105748885	BRF1	0.41	9.01	0.4	7.35e-18	Platelet count;
LUAD	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg20891283	chr12:69753455	YEATS4	0.45	7.34	0.34	1.12e-12	Blood protein levels;
LUAD	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg10591111	chr5:226296	SDHA	-0.55	-7.0	-0.32	1.04e-11	Breast cancer;
LUAD	cis	rs1395	1.000	rs1275501	chr2:27419282	A/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.41	-7.64	-0.35	1.44e-13	Blood metabolite levels;
LUAD	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg00530320	chr1:46809349	NSUN4	0.51	8.05	0.36	8.71e-15	Menopause (age at onset);
LUAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg21280719	chr6:42927975	GNMT	-0.38	-11.21	-0.48	1.05e-25	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg18402987	chr7:1209562	NA	0.73	9.44	0.42	2.61e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62238980	0.614	rs117535757	chr22:32373437	A/G	cg00543991	chr22:32367038	NA	0.91	8.21	0.37	2.8e-15	Childhood ear infection;
LUAD	cis	rs116095464	1.000	rs10475185	chr5:306981	C/T	cg22496380	chr5:211416	CCDC127	-1.08	-8.39	-0.38	7.44e-16	Breast cancer;
LUAD	cis	rs3815700	1.000	rs7260624	chr19:33096562	A/G	cg02997394	chr19:33096574	ANKRD27	0.65	8.73	0.39	5.94e-17	Eosinophilic esophagitis;
LUAD	cis	rs1298062	0.757	rs1673039	chr19:50977957	C/T	cg11430371	chr19:50961752	MYBPC2	0.32	6.4	0.3	4.2e-10	Age of smoking initiation;
LUAD	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg21827317	chr3:136751795	NA	0.36	6.56	0.3	1.55e-10	Neuroticism;
LUAD	cis	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05901451	chr6:126070800	HEY2	0.6	9.43	0.42	2.72e-19	Endometrial cancer;
LUAD	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18876405	chr7:65276391	NA	-0.42	-6.67	-0.31	8.26e-11	Aortic root size;
LUAD	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg21204522	chr6:27730016	NA	-0.44	-6.97	-0.32	1.22e-11	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs684232	0.666	rs2657629	chr17:602261	G/T	cg15660573	chr17:549704	VPS53	-0.77	-15.17	-0.59	7.8e-42	Prostate cancer;
LUAD	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg01200585	chr1:228362443	C1orf69	0.41	7.57	0.35	2.37e-13	Diastolic blood pressure;
LUAD	trans	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-15.12	-0.59	1.35e-41	Exhaled nitric oxide output;
LUAD	cis	rs7731657	0.537	rs4705917	chr5:130206326	A/G	cg08523029	chr5:130500466	HINT1	-0.55	-7.06	-0.32	6.7e-12	Fasting plasma glucose;
LUAD	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg10468373	chr11:64009913	FKBP2	0.51	6.36	0.3	5.2400000000000005e-10	Mean platelet volume;
LUAD	cis	rs11640533	1.000	rs11640533	chr16:53412862	A/G	cg04653913	chr16:53407753	NA	-0.47	-8.33	-0.38	1.12e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs12541635	0.677	rs2029880	chr8:107024649	T/C	cg10147462	chr8:107024639	NA	0.55	10.25	0.45	3.58e-22	Age of smoking initiation;
LUAD	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg06766960	chr11:133703094	NA	0.44	8.12	0.37	5.13e-15	Childhood ear infection;
LUAD	cis	rs986417	0.901	rs1955688	chr14:60989237	G/A	cg27398547	chr14:60952738	C14orf39	0.66	7.95	0.36	1.71e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg00852783	chr1:26633632	UBXN11	0.41	7.29	0.33	1.49e-12	Obesity-related traits;
LUAD	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg06627628	chr2:24431161	ITSN2	-0.55	-6.54	-0.3	1.83e-10	Lymphocyte counts;
LUAD	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg15133208	chr4:90757351	SNCA	-0.46	-6.97	-0.32	1.25e-11	Neuroticism;
LUAD	cis	rs9549328	0.700	rs3011474	chr13:113617865	T/C	cg17524180	chr13:113633600	MCF2L	0.31	6.66	0.31	8.44e-11	Systolic blood pressure;
LUAD	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg12140854	chr5:148520817	ABLIM3	-0.66	-10.7	-0.46	8.17e-24	Breast cancer;
LUAD	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg12311346	chr5:56204834	C5orf35	-0.92	-13.36	-0.54	3.34e-34	Initial pursuit acceleration;
LUAD	cis	rs6541297	0.703	rs678578	chr1:230320600	G/A	cg20703242	chr1:230279135	GALNT2	-0.46	-6.96	-0.32	1.28e-11	Coronary artery disease;
LUAD	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg07432352	chr17:45403706	C17orf57	0.36	6.95	0.32	1.38e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs600231	0.542	rs11227205	chr11:65256164	G/A	cg17120908	chr11:65337727	SSSCA1	-0.67	-8.48	-0.38	3.84e-16	Bone mineral density;
LUAD	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg12863693	chr15:85201151	NMB	0.43	7.95	0.36	1.73e-14	Schizophrenia;
LUAD	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.66	-0.58	1.27e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg16205897	chr5:131564050	P4HA2	-0.32	-7.08	-0.33	6.12e-12	Blood metabolite levels;
LUAD	cis	rs11671005	0.693	rs34230465	chr19:58943576	C/G	cg13877915	chr19:58951672	ZNF132	0.59	7.77	0.35	6.18e-14	Mean platelet volume;
LUAD	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg23985595	chr17:80112537	CCDC57	0.42	7.45	0.34	5.23e-13	Life satisfaction;
LUAD	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg20701182	chr2:24300061	SF3B14	0.56	6.82	0.31	3.19e-11	Lymphocyte counts;
LUAD	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg08885076	chr2:99613938	TSGA10	0.37	6.66	0.31	8.32e-11	Chronic sinus infection;
LUAD	cis	rs78707713	0.512	rs12772559	chr10:71184356	C/G	cg12610070	chr10:71211762	TSPAN15	-0.39	-9.85	-0.43	9.92e-21	Venous thromboembolism;
LUAD	trans	rs10838798	0.504	rs11039530	chr11:48145746	C/T	cg00717180	chr2:96193071	NA	-0.42	-7.83	-0.36	3.86e-14	Height;
LUAD	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.82	-0.36	4.23e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1569175	0.655	rs166847	chr2:200840612	A/G	cg23649088	chr2:200775458	C2orf69	-0.72	-6.81	-0.31	3.33e-11	Response to treatment for acute lymphoblastic leukemia;
LUAD	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	9.01	0.4	6.9e-18	Parkinson's disease;
LUAD	cis	rs4953404	0.613	rs4355163	chr2:46909817	G/C	cg09399716	chr2:46890238	NA	-0.37	-7.02	-0.32	9.08e-12	Pulse pressure (alcohol consumption interaction);
LUAD	cis	rs2387326	0.767	rs76961244	chr10:129940561	A/C	cg16087940	chr10:129947807	NA	-0.62	-8.29	-0.37	1.47e-15	Select biomarker traits;
LUAD	cis	rs11811982	0.793	rs76897971	chr1:227328388	G/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic disc area;
LUAD	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.78	0.53	7.33e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs244899	0.935	rs2432643	chr5:167925030	G/T	cg06604206	chr5:167912465	RARS	-0.4	-6.99	-0.32	1.08e-11	Response to platinum-based chemotherapy (carboplatin);
LUAD	cis	rs612683	0.658	rs12407689	chr1:100999585	C/G	cg06223162	chr1:101003688	GPR88	0.52	10.2	0.44	5.68e-22	Breast cancer;
LUAD	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12439619	0.921	rs56042848	chr15:82527585	A/T	cg04831495	chr15:85060580	GOLGA6L5	-0.54	-8.47	-0.38	4.07e-16	Intelligence (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16350314	chr8:27169081	TRIM35;PTK2B	-0.42	-6.43	-0.3	3.4e-10	Height;
LUAD	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.42	9.04	0.4	5.73e-18	Hemoglobin concentration;
LUAD	cis	rs2797685	0.773	rs2301489	chr1:7837676	G/C	cg04725166	chr1:7887271	PER3	-0.45	-6.87	-0.32	2.29e-11	Crohn's disease;
LUAD	cis	rs67366981	1.000	rs67366981	chr14:77703964	T/C	cg22824376	chr14:77648248	TMEM63C	0.61	6.61	0.31	1.18e-10	Obsessive-compulsive symptoms;
LUAD	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg01802117	chr1:53393560	SCP2	-0.35	-6.83	-0.32	2.89e-11	Monocyte count;
LUAD	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg04800585	chr6:26043546	HIST1H2BB	0.5	8.31	0.37	1.29e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg08859206	chr1:53392774	SCP2	-0.81	-15.5	-0.6	3.25e-43	Monocyte count;
LUAD	cis	rs7789940	0.904	rs7459185	chr7:75934640	C/G	cg15798862	chr7:76129360	DTX2	0.35	6.46	0.3	2.91e-10	Multiple sclerosis;
LUAD	cis	rs13315871	1.000	rs9849482	chr3:58422087	G/T	cg12435725	chr3:58293450	RPP14	-0.69	-7.36	-0.34	9.51e-13	Cholesterol, total;
LUAD	cis	rs1784581	0.651	rs1784589	chr6:162389571	A/G	cg17173639	chr6:162384350	PARK2	-0.51	-9.32	-0.41	6.67e-19	Itch intensity from mosquito bite;
LUAD	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.57	-11.97	-0.5	1.24e-28	Social autistic-like traits;
LUAD	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg08508325	chr11:3079039	CARS	0.43	8.94	0.4	1.26e-17	Calcium levels;
LUAD	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg01416388	chr22:39784598	NA	-0.54	-9.36	-0.41	4.84e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs863345	0.604	rs4276920	chr1:158504972	G/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.52	-0.3	2.02e-10	Pneumococcal bacteremia;
LUAD	cis	rs7809950	0.817	rs2204833	chr7:107283069	T/C	cg23024343	chr7:107201750	COG5	0.79	12.5	0.52	1.01e-30	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg21724239	chr8:58056113	NA	0.72	9.49	0.42	1.73e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg11859384	chr17:80120422	CCDC57	0.48	8.61	0.39	1.43e-16	Life satisfaction;
LUAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.46	-8.31	-0.37	1.31e-15	Longevity;Endometriosis;
LUAD	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg13535736	chr9:111863775	C9orf5	-0.43	-6.66	-0.31	8.37e-11	Menarche (age at onset);
LUAD	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg15448220	chr1:150897856	SETDB1	0.56	9.44	0.42	2.5e-19	Melanoma;
LUAD	cis	rs34638657	0.702	rs12599988	chr16:82200063	T/C	cg09439754	chr16:82129088	HSD17B2	-0.37	-7.07	-0.33	6.52e-12	Lung adenocarcinoma;
LUAD	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg04369109	chr6:150039330	LATS1	-0.44	-7.11	-0.33	5.07e-12	Lung cancer;
LUAD	cis	rs208520	0.690	rs851459	chr6:66813989	A/G	cg07460842	chr6:66804631	NA	-1.09	-17.22	-0.64	1.01e-50	Exhaled nitric oxide output;
LUAD	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg01256987	chr12:42539512	GXYLT1	-0.34	-6.68	-0.31	7.65e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs7326068	0.558	rs4770071	chr13:21330883	C/G	cg27499820	chr13:21296301	IL17D	0.53	7.99	0.36	1.27e-14	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs710865	0.519	rs10753518	chr1:19483593	T/C	cg13387374	chr1:19411106	UBR4	0.49	8.5	0.38	3.4e-16	Brain structure;
LUAD	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg08213375	chr14:104286397	PPP1R13B	0.27	6.95	0.32	1.43e-11	Schizophrenia;
LUAD	cis	rs3845702	0.935	rs3845695	chr2:180796989	A/G	cg01881094	chr2:180872142	CWC22	-0.61	-7.76	-0.35	6.35e-14	Schizophrenia;
LUAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg21724239	chr8:58056113	NA	0.65	8.41	0.38	6.32e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg21475434	chr5:93447410	FAM172A	0.58	7.31	0.33	1.36e-12	Diabetic retinopathy;
LUAD	cis	rs1997103	0.954	rs1997099	chr7:55405540	T/C	cg17469321	chr7:55412551	NA	0.66	11.26	0.48	6.61e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6901250	0.744	rs636872	chr6:117087944	C/T	cg12892004	chr6:117198278	RFX6	0.3	6.45	0.3	3.03e-10	C-reactive protein levels;
LUAD	cis	rs10788264	0.544	rs9630083	chr10:124017423	C/T	cg09507567	chr10:124027408	NA	0.55	12.55	0.52	6.27e-31	Total body bone mineral density;
LUAD	cis	rs675209	0.637	rs630258	chr6:7134401	C/T	cg23726566	chr6:7051754	NA	0.4	7.05	0.32	7.55e-12	Urate levels;
LUAD	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg20673091	chr1:2541236	MMEL1	0.41	8.62	0.39	1.37e-16	Ulcerative colitis;
LUAD	cis	rs7851660	0.809	rs10984253	chr9:100664474	A/G	cg13688889	chr9:100608707	NA	-0.54	-9.17	-0.41	2.14e-18	Strep throat;
LUAD	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.46	0.34	5.1e-13	Hip circumference adjusted for BMI;
LUAD	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg05911100	chr12:8333192	FAM66C	0.38	6.44	0.3	3.23e-10	Neuroticism;
LUAD	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg22705602	chr4:152727874	NA	0.46	8.73	0.39	6.08e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg01324343	chr3:183735012	ABCC5	0.94	24.69	0.77	5.5e-84	Anterior chamber depth;
LUAD	cis	rs397969	0.596	rs7209653	chr17:19882084	A/G	cg04132472	chr17:19861366	AKAP10	0.31	6.85	0.32	2.61e-11	Platelet count;
LUAD	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.1	0.33	5.46e-12	Menopause (age at onset);
LUAD	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg04989706	chr14:50066350	PPIL5	-0.52	-7.38	-0.34	8.72e-13	Carotid intima media thickness;
LUAD	cis	rs2985684	0.947	rs1952013	chr14:50087357	C/G	cg04989706	chr14:50066350	PPIL5	-0.52	-7.52	-0.34	3.4e-13	Carotid intima media thickness;
LUAD	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.53	8.18	0.37	3.41e-15	Platelet count;
LUAD	cis	rs76878669	0.561	rs7117630	chr11:66154777	C/T	cg18002602	chr11:66138449	SLC29A2	-0.5	-10.85	-0.47	2.21e-24	Educational attainment (years of education);
LUAD	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg14631576	chr9:95140430	CENPP	-0.48	-9.66	-0.43	4.49e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg27279351	chr12:120934652	DYNLL1	0.43	6.51	0.3	2.19e-10	High light scatter reticulocyte count;
LUAD	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs12540874	0.931	rs4245555	chr7:50661409	A/G	cg18232548	chr7:50535776	DDC	-0.54	-9.12	-0.41	2.97e-18	Systemic sclerosis;
LUAD	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg07917127	chr4:99064746	C4orf37	0.44	7.3	0.33	1.43e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg27221266	chr10:96122679	NOC3L	0.41	6.65	0.31	9.06e-11	Bilirubin levels;
LUAD	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg12034118	chr1:209979487	IRF6	-0.5	-7.3	-0.33	1.43e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs6906287	0.625	rs9320648	chr6:118690014	A/C	cg18833306	chr6:118973337	C6orf204	0.52	9.63	0.42	5.73e-20	Electrocardiographic conduction measures;
LUAD	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg03929089	chr4:120376271	NA	-0.97	-19.76	-0.69	5e-62	Height;
LUAD	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg19761014	chr17:28927070	LRRC37B2	0.82	8.39	0.38	7.58e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7552167	0.925	rs11249020	chr1:24512804	A/G	cg01960748	chr1:24522592	NA	-0.8	-10.53	-0.46	3.51e-23	Psoriasis vulgaris;
LUAD	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg18306943	chr3:40428807	ENTPD3	0.37	6.54	0.3	1.83e-10	Renal cell carcinoma;
LUAD	cis	rs12545109	0.700	rs2670045	chr8:57393695	A/G	cg17761419	chr8:57350749	NA	-0.55	-8.27	-0.37	1.73e-15	Obesity-related traits;
LUAD	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg19196401	chr6:110721138	DDO	-0.46	-8.82	-0.39	3.08e-17	Platelet distribution width;
LUAD	trans	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg26043149	chr18:55253948	FECH	-0.44	-7.08	-0.33	6.16e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg13319975	chr6:146136371	FBXO30	-0.64	-10.92	-0.47	1.25e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2455799	0.613	rs2470547	chr3:15737610	T/C	cg16303742	chr3:15540471	COLQ	-0.52	-9.62	-0.42	6.05e-20	Mean platelet volume;
LUAD	cis	rs3820068	0.655	rs72645823	chr1:15887442	C/T	cg24675056	chr1:15929824	NA	0.43	6.78	0.31	4.1e-11	Systolic blood pressure;
LUAD	cis	rs12618769	0.597	rs3769715	chr2:99146855	C/T	cg10123293	chr2:99228465	UNC50	0.46	8.18	0.37	3.47e-15	Bipolar disorder;
LUAD	cis	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg21775007	chr8:11205619	TDH	0.41	6.84	0.32	2.81e-11	Neuroticism;
LUAD	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg03037974	chr15:76606532	NA	0.39	8.52	0.38	2.94e-16	Blood metabolite levels;
LUAD	cis	rs13315871	1.000	rs3196769	chr3:58409361	A/T	cg20936604	chr3:58311152	NA	-0.69	-7.24	-0.33	2.16e-12	Cholesterol, total;
LUAD	cis	rs62229266	0.804	rs62230788	chr21:37380337	A/T	cg12218747	chr21:37451666	NA	-0.48	-7.96	-0.36	1.64e-14	Mitral valve prolapse;
LUAD	cis	rs2730260	0.736	rs73169215	chr7:158833701	T/C	cg02254261	chr7:158964346	NA	-0.56	-6.77	-0.31	4.31e-11	Myopia (pathological);
LUAD	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	8.74	0.39	5.59e-17	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs8002861	0.754	rs4053664	chr13:44429172	A/C	cg17145862	chr1:211918768	LPGAT1	0.74	17.04	0.64	6.28e-50	Leprosy;
LUAD	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg06263672	chr7:65235340	NA	0.49	6.55	0.3	1.64e-10	Aortic root size;
LUAD	cis	rs4774899	0.869	rs12900589	chr15:57373236	T/C	cg14026238	chr15:57616123	NA	0.43	8.15	0.37	4.25e-15	Urinary tract infection frequency;
LUAD	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg11890956	chr21:40555474	PSMG1	-0.5	-7.84	-0.36	3.73e-14	Menarche (age at onset);
LUAD	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg03929089	chr4:120376271	NA	0.71	11.46	0.49	1.14e-26	Coronary artery disease;
LUAD	cis	rs2652834	1.000	rs34575783	chr15:63397686	G/C	cg25406657	chr15:63342033	TPM1	-0.43	-6.91	-0.32	1.84e-11	HDL cholesterol;
LUAD	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg07153921	chr17:41440717	NA	-0.39	-6.53	-0.3	1.86e-10	Menopause (age at onset);
LUAD	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg18944383	chr4:111397179	ENPEP	0.35	6.83	0.32	2.98e-11	Height;
LUAD	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-8.1	-0.37	5.97e-15	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs420259	0.861	rs249954	chr16:23640467	G/A	cg00143387	chr16:23521605	GGA2	0.5	6.94	0.32	1.45e-11	Bipolar disorder;
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14520079	chr3:106825871	NA	0.43	6.73	0.31	5.61e-11	Hepatitis;
LUAD	cis	rs9715521	0.677	rs17493148	chr4:59861895	T/C	cg11281224	chr4:60001000	NA	-0.61	-10.75	-0.46	5.27e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg11189052	chr15:85197271	WDR73	0.44	6.38	0.3	4.68e-10	Schizophrenia;
LUAD	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg11098525	chr4:1320231	MAEA	-0.39	-6.5	-0.3	2.21e-10	Obesity-related traits;
LUAD	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg09904177	chr6:26538194	HMGN4	0.44	7.42	0.34	6.56e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2004318	1.000	rs75393417	chr19:55070614	C/T	cg03320607	chr19:54800032	LILRA3	-0.73	-7.77	-0.35	5.93e-14	Blood protein levels;
LUAD	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg11871910	chr12:69753446	YEATS4	0.65	10.89	0.47	1.61e-24	Blood protein levels;
LUAD	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg17120908	chr11:65337727	SSSCA1	-0.58	-9.18	-0.41	1.91e-18	Bone mineral density;
LUAD	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg01251548	chr11:17372745	DKFZp686O24166	-0.34	-6.39	-0.3	4.47e-10	Type 2 diabetes;
LUAD	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.61	-0.31	1.13e-10	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg16316472	chr4:77997182	CCNI	0.4	6.77	0.31	4.23e-11	Optic cup area;
LUAD	cis	rs6688613	0.579	rs4657609	chr1:166839174	G/A	cg07049167	chr1:166818506	POGK	0.56	8.67	0.39	9.35e-17	Refractive astigmatism;
LUAD	cis	rs4285028	0.731	rs2332035	chr3:121715432	C/T	cg11130432	chr3:121712080	ILDR1	-0.58	-8.89	-0.4	1.77e-17	Multiple sclerosis;
LUAD	trans	rs12517041	1.000	rs28472703	chr5:23281381	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.47	-0.3	2.73e-10	Calcium levels;
LUAD	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg11247378	chr22:39784982	NA	-0.74	-13.91	-0.56	1.67e-36	Intelligence (multi-trait analysis);
LUAD	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg11965913	chr1:205819406	PM20D1	-0.54	-8.23	-0.37	2.31e-15	Menarche (age at onset);
LUAD	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26314531	chr2:26401878	FAM59B	-0.57	-7.93	-0.36	1.94e-14	Gut microbiome composition (summer);
LUAD	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg11494091	chr17:61959527	GH2	0.45	8.58	0.39	1.76e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg07917127	chr4:99064746	C4orf37	0.42	7.01	0.32	9.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.68	-10.38	-0.45	1.2e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg00277334	chr10:82204260	NA	-0.53	-8.35	-0.38	9.53e-16	Post bronchodilator FEV1;
LUAD	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg10518543	chr12:38710700	ALG10B	0.41	6.36	0.3	5.25e-10	Bladder cancer;
LUAD	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg15448220	chr1:150897856	SETDB1	-0.45	-7.69	-0.35	1.06e-13	Tonsillectomy;
LUAD	cis	rs17135859	1.000	rs17135859	chr5:112996654	T/C	cg12552261	chr5:112820674	MCC	0.56	7.46	0.34	4.96e-13	F-cell distribution;
LUAD	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02788857	chr8:22132959	PIWIL2	0.57	10.53	0.46	3.48e-23	Hypertriglyceridemia;
LUAD	cis	rs6740322	0.793	rs9808360	chr2:43546835	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-11.01	-0.47	5.66e-25	Coronary artery disease;
LUAD	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg00083206	chr6:110721305	DDO	-0.41	-7.65	-0.35	1.4e-13	Platelet distribution width;
LUAD	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	cis	rs6743376	0.556	rs2472188	chr2:113820814	C/G	cg09040174	chr2:113837401	NA	0.46	7.2	0.33	2.7e-12	Inflammatory biomarkers;
LUAD	cis	rs11951515	0.508	rs6860493	chr5:43602713	T/C	cg01983248	chr5:43482804	C5orf28	-0.39	-8.3	-0.37	1.41e-15	Metabolite levels  (X-11787);
LUAD	cis	rs11771526	0.901	rs10267589	chr7:32280156	T/C	cg27532318	chr7:32358331	NA	0.53	7.11	0.33	5.06e-12	Body mass index;
LUAD	cis	rs13315871	1.000	rs11717423	chr3:58330177	C/G	cg20936604	chr3:58311152	NA	-0.73	-7.3	-0.33	1.47e-12	Cholesterol, total;
LUAD	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg27454412	chr7:1067447	C7orf50	-0.35	-6.97	-0.32	1.19e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg27124370	chr19:33622961	WDR88	0.43	6.64	0.31	9.82e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs12545109	0.837	rs1437277	chr8:57356734	T/C	cg19413350	chr8:57351067	NA	-0.47	-6.97	-0.32	1.22e-11	Obesity-related traits;
LUAD	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg18512352	chr11:47633146	NA	-0.38	-6.72	-0.31	5.73e-11	Subjective well-being;
LUAD	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg09491104	chr22:46646882	C22orf40	-0.57	-8.41	-0.38	6.53e-16	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg14092571	chr14:90743983	NA	-0.52	-9.25	-0.41	1.11e-18	Mortality in heart failure;
LUAD	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.92	0.32	1.67e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg06197492	chr11:2016605	H19	0.42	8.47	0.38	3.97e-16	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg25817165	chr18:72167213	CNDP2	-0.72	-10.78	-0.46	4.1e-24	Refractive error;
LUAD	cis	rs28595532	1.000	rs55634130	chr4:119655093	C/T	cg21605333	chr4:119757512	SEC24D	0.87	8.02	0.36	1.02e-14	Cannabis dependence symptom count;
LUAD	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	9.78	0.43	1.73e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7107174	1.000	rs11603112	chr11:78073491	G/A	cg19901956	chr11:77921274	USP35	-0.48	-6.86	-0.32	2.41e-11	Testicular germ cell tumor;
LUAD	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg27124370	chr19:33622961	WDR88	0.45	6.94	0.32	1.46e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs8177876	0.749	rs58144189	chr16:81098083	T/C	cg08591886	chr16:81111003	C16orf46	-0.72	-6.48	-0.3	2.63e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg11663144	chr21:46675770	NA	-0.6	-11.83	-0.5	4.19e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10916814	0.632	rs12089623	chr1:20903643	G/A	cg24502330	chr1:20914028	CDA	-0.36	-7.09	-0.33	5.68e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs4948275	0.530	rs2139778	chr10:63134943	A/T	cg03237606	chr10:63212265	TMEM26	-0.35	-7.08	-0.33	5.93e-12	Night sleep phenotypes;
LUAD	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg01528321	chr10:82214614	TSPAN14	0.65	10.6	0.46	2.01e-23	Post bronchodilator FEV1;
LUAD	cis	rs9549367	0.577	rs776904	chr13:113810542	C/T	cg00898013	chr13:113819073	PROZ	-0.8	-12.41	-0.52	2.32e-30	Platelet distribution width;
LUAD	trans	rs225245	0.782	rs225272	chr17:33969911	T/C	cg19694781	chr19:47549865	TMEM160	-0.44	-7.25	-0.33	1.99e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs854765	0.587	rs12936927	chr17:17726965	C/T	cg09796270	chr17:17721594	SREBF1	-0.4	-7.9	-0.36	2.52e-14	Total body bone mineral density;
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg03395511	chr6:291903	DUSP22	-0.78	-13.44	-0.55	1.58e-34	Menopause (age at onset);
LUAD	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg09021430	chr5:549028	NA	-0.69	-13.31	-0.54	5.03e-34	Obesity-related traits;
LUAD	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg25036284	chr2:26402008	FAM59B	-0.68	-9.24	-0.41	1.26e-18	Gut microbiome composition (summer);
LUAD	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg20607287	chr7:12443886	VWDE	-0.49	-7.11	-0.33	5.08e-12	Coronary artery disease;
LUAD	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg25324976	chr17:61989376	CSHL1	0.38	7.5	0.34	3.88e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs12519773	0.662	rs6883741	chr5:92491481	T/A	cg18783429	chr5:92414398	NA	0.39	6.75	0.31	4.83e-11	Migraine;
LUAD	cis	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg02951883	chr7:2050386	MAD1L1	0.54	7.56	0.35	2.52e-13	Neuroticism;
LUAD	cis	rs1983170	0.808	rs1949009	chr1:92016653	C/T	cg02896835	chr1:92012615	NA	-0.38	-6.36	-0.3	5.31e-10	Eosinophil percentage of white cells;
LUAD	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg14008862	chr17:28927542	LRRC37B2	0.64	6.36	0.3	5.12e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg20476274	chr7:133979776	SLC35B4	0.84	16.27	0.62	1.4e-46	Mean platelet volume;
LUAD	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14240646	chr10:27532245	ACBD5	0.93	12.22	0.51	1.24e-29	Breast cancer;
LUAD	trans	rs8002861	0.641	rs2325085	chr13:44410060	G/A	cg17145862	chr1:211918768	LPGAT1	0.65	13.17	0.54	1.96e-33	Leprosy;
LUAD	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg18252515	chr7:66147081	NA	0.61	6.77	0.31	4.38e-11	Diabetic kidney disease;
LUAD	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.53	-0.3	1.89e-10	Retinal vascular caliber;
LUAD	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg08847533	chr14:75593920	NEK9	0.39	6.61	0.31	1.18e-10	Height;
LUAD	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg07570687	chr10:102243282	WNT8B	0.46	6.75	0.31	4.92e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs4460629	0.742	rs11581730	chr1:155082158	A/T	cg23973274	chr1:155060172	NA	-0.37	-6.46	-0.3	2.88e-10	Serum magnesium levels;
LUAD	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg23277830	chr1:3704460	LRRC47	0.42	8.47	0.38	4.24e-16	Red cell distribution width;
LUAD	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg12379764	chr21:47803548	PCNT	-0.46	-7.48	-0.34	4.45e-13	Testicular germ cell tumor;
LUAD	cis	rs7107174	1.000	rs11601196	chr11:78043431	A/C	cg19901956	chr11:77921274	USP35	-0.49	-6.36	-0.3	5.16e-10	Testicular germ cell tumor;
LUAD	cis	rs16958440	0.867	rs74411203	chr18:44677466	G/A	cg17192377	chr18:44677553	HDHD2	0.84	7.97	0.36	1.52e-14	Sitting height ratio;
LUAD	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg05182265	chr7:156933206	UBE3C	-0.8	-17.28	-0.64	5.14e-51	Body mass index;
LUAD	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg26384229	chr12:38710491	ALG10B	0.45	7.34	0.34	1.09e-12	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs1997103	0.954	rs6593222	chr7:55372932	A/C	cg20935933	chr6:143382018	AIG1	0.54	7.55	0.34	2.63e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg00484396	chr16:3507460	NAT15	-0.77	-8.58	-0.39	1.78e-16	Tuberculosis;
LUAD	cis	rs3087591	1.000	rs2040791	chr17:29627297	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.43	-6.94	-0.32	1.48e-11	Hip circumference;
LUAD	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg14169450	chr9:139327907	INPP5E	0.4	6.38	0.3	4.64e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs727505	0.721	rs67607629	chr7:124765867	C/T	cg23710748	chr7:124431027	NA	-0.36	-7.57	-0.35	2.38e-13	Lewy body disease;
LUAD	cis	rs6961069	0.774	rs1054516	chr7:80284942	T/C	cg04458919	chr7:80252533	CD36	0.36	6.81	0.31	3.39e-11	Platelet count;
LUAD	cis	rs6504950	0.566	rs7208403	chr17:53046667	C/A	cg19360675	chr17:53046073	COX11;STXBP4	0.4	6.46	0.3	2.92e-10	Breast cancer;
LUAD	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg21231944	chr12:82153410	PPFIA2	-0.37	-6.75	-0.31	4.76e-11	Resting heart rate;
LUAD	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg03714773	chr7:91764589	CYP51A1	-0.27	-6.5	-0.3	2.31e-10	Breast cancer;
LUAD	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg18402987	chr7:1209562	NA	0.78	9.48	0.42	1.89e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	15.23	0.6	4.46e-42	Smoking behavior;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	0.43	6.93	0.32	1.53e-11	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs250585	0.790	rs7204714	chr16:23483353	A/C	cg00143387	chr16:23521605	GGA2	0.64	8.03	0.36	9.74e-15	Egg allergy;
LUAD	cis	rs2625529	0.824	rs4238449	chr15:72421603	G/A	cg16672083	chr15:72433130	SENP8	-0.76	-12.77	-0.53	8.31e-32	Red blood cell count;
LUAD	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg13535736	chr9:111863775	C9orf5	-0.42	-6.38	-0.3	4.69e-10	Menarche (age at onset);
LUAD	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14019695	chr9:139328340	INPP5E	-0.48	-9.37	-0.41	4.53e-19	Monocyte percentage of white cells;
LUAD	cis	rs6547631	0.622	rs1437742	chr2:85924899	T/A	cg21473183	chr2:85925749	GNLY	0.35	7.59	0.35	2.1e-13	Blood protein levels;
LUAD	cis	rs2235649	0.828	rs9925354	chr16:1849866	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.4	-6.42	-0.3	3.7e-10	Blood metabolite levels;
LUAD	trans	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg13565492	chr6:43139072	SRF	-0.72	-9.7	-0.43	3.2e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg27446573	chr6:127587934	RNF146	0.44	6.85	0.32	2.59e-11	Breast cancer;
LUAD	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05776053	chr2:74358815	NA	0.51	7.28	0.33	1.62e-12	Gestational age at birth (maternal effect);
LUAD	cis	rs1215050	0.791	rs548892	chr4:98724701	C/T	cg17366294	chr4:99064904	C4orf37	0.48	8.72	0.39	6.32e-17	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg17644776	chr2:200775616	C2orf69	0.53	7.67	0.35	1.17e-13	Schizophrenia;
LUAD	cis	rs7336332	0.598	rs77055070	chr13:28010516	C/G	cg22138327	chr13:27999177	GTF3A	0.77	10.1	0.44	1.22e-21	Weight;
LUAD	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08439880	chr3:133502540	NA	-0.47	-9.32	-0.41	6.3e-19	Iron status biomarkers;
LUAD	cis	rs600626	0.529	rs10899113	chr11:75468464	T/A	cg24262691	chr11:75473276	NA	0.57	7.45	0.34	5.41e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg00280220	chr17:61926910	NA	0.36	6.94	0.32	1.45e-11	Prudent dietary pattern;
LUAD	cis	rs701145	0.878	rs442480	chr3:153992952	T/A	cg17054900	chr3:154042577	DHX36	0.64	7.1	0.33	5.16e-12	Coronary artery disease;
LUAD	cis	rs7561273	0.586	rs116650625	chr2:24353212	C/G	cg20701182	chr2:24300061	SF3B14	0.47	7.59	0.35	2.11e-13	Quantitative traits;
LUAD	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg01802117	chr1:53393560	SCP2	-0.4	-7.56	-0.34	2.59e-13	Monocyte count;
LUAD	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.4	-7.35	-0.34	1.01e-12	Tonsillectomy;
LUAD	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg04287289	chr16:89883240	FANCA	0.85	7.28	0.33	1.66e-12	Skin colour saturation;
LUAD	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.16e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9837602	0.872	rs4928234	chr3:99704861	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	6.98	0.32	1.18e-11	Breast cancer;
LUAD	cis	rs863345	0.604	rs1112915	chr1:158444447	T/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.36	-0.3	5.33e-10	Pneumococcal bacteremia;
LUAD	cis	rs600626	0.891	rs695112	chr11:75456580	A/T	cg24262691	chr11:75473276	NA	0.43	7.02	0.32	9.16e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs17401966	0.838	rs1556916	chr1:10403482	G/A	cg19773385	chr1:10388646	KIF1B	-0.4	-6.53	-0.3	1.91e-10	Hepatocellular carcinoma;
LUAD	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg11494091	chr17:61959527	GH2	0.39	7.09	0.33	5.52e-12	Height;
LUAD	trans	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg24644049	chr4:85504048	CDS1	0.85	7.68	0.35	1.1e-13	Skin colour saturation;
LUAD	cis	rs986417	0.901	rs4901987	chr14:60987529	C/T	cg27398547	chr14:60952738	C14orf39	0.66	7.95	0.36	1.71e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg06360820	chr2:242988706	NA	-0.96	-13.46	-0.55	1.24e-34	Obesity-related traits;
LUAD	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.32	6.41	0.3	3.86e-10	Bipolar disorder;
LUAD	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg07256732	chr16:621771	PIGQ	-0.32	-6.49	-0.3	2.45e-10	Height;
LUAD	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg18105134	chr13:113819100	PROZ	-0.85	-14.73	-0.58	5.98e-40	Platelet distribution width;
LUAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg00149659	chr3:10157352	C3orf10	0.57	7.94	0.36	1.78e-14	Alzheimer's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17546822	chr22:41865178	ACO2;PHF5A	-0.53	-6.64	-0.31	9.46e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg12908607	chr1:44402522	ARTN	-0.45	-8.94	-0.4	1.23e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.91	-0.36	2.22e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg20673091	chr1:2541236	MMEL1	-0.44	-9.49	-0.42	1.67e-19	Ulcerative colitis;
LUAD	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg22166914	chr1:53195759	ZYG11B	0.4	6.7	0.31	6.84e-11	Monocyte count;
LUAD	cis	rs943466	1.000	rs73412140	chr6:33757014	G/T	cg16010596	chr6:33739607	LEMD2	-0.39	-7.15	-0.33	3.79e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg14458575	chr2:238380390	NA	0.72	14.12	0.57	2.29e-37	Prostate cancer;
LUAD	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg03233332	chr7:66118400	NA	-0.45	-6.9	-0.32	1.9e-11	Aortic root size;
LUAD	cis	rs904251	0.600	rs12211110	chr6:37466232	A/G	cg25019722	chr6:37503610	NA	-0.3	-6.82	-0.31	3.08e-11	Cognitive performance;
LUAD	cis	rs367943	0.666	rs7700413	chr5:112704435	T/C	cg21806985	chr5:112824646	MCC	0.24	6.51	0.3	2.17e-10	Type 2 diabetes;
LUAD	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg00106254	chr7:1943704	MAD1L1	-0.53	-7.89	-0.36	2.53e-14	Bipolar disorder and schizophrenia;
LUAD	trans	rs7395662	0.864	rs10839201	chr11:48989417	A/G	cg15704280	chr7:45808275	SEPT13	0.45	7.12	0.33	4.54e-12	HDL cholesterol;
LUAD	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg06618935	chr21:46677482	NA	-0.51	-10.35	-0.45	1.55e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg12311346	chr5:56204834	C5orf35	0.58	9.22	0.41	1.41e-18	Type 2 diabetes;
LUAD	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg11707310	chr1:2537719	MMEL1	-0.4	-8.61	-0.39	1.45e-16	Ulcerative colitis;
LUAD	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07636037	chr3:49044803	WDR6	0.48	8.37	0.38	8.21e-16	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.91	0.32	1.76e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs10411161	0.702	rs10403189	chr19:52400673	A/G	cg22319618	chr22:45562946	NUP50	0.66	9.48	0.42	1.82e-19	Breast cancer;
LUAD	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg05110241	chr16:68378359	PRMT7	-0.68	-7.68	-0.35	1.09e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs796825	0.530	rs6771116	chr3:120001314	A/G	cg21790991	chr3:120137480	FSTL1	-0.46	-7.84	-0.36	3.76e-14	HIV-1 susceptibility;
LUAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.51	-6.46	-0.3	2.89e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.37	-0.38	8.33e-16	Bipolar disorder;
LUAD	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21016266	chr12:122356598	WDR66	-0.58	-10.03	-0.44	2.23e-21	Mean corpuscular volume;
LUAD	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg02782426	chr3:40428986	ENTPD3	-0.41	-8.83	-0.39	2.7e-17	Renal cell carcinoma;
LUAD	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg06713675	chr4:122721982	EXOSC9	-0.74	-15.67	-0.61	5.81e-44	Type 2 diabetes;
LUAD	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg02569458	chr12:86230093	RASSF9	0.43	7.85	0.36	3.46e-14	Major depressive disorder;
LUAD	trans	rs1493916	0.837	rs1493908	chr18:31411700	G/A	cg15819921	chr19:927150	ARID3A	-0.42	-6.86	-0.32	2.44e-11	Life satisfaction;
LUAD	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-7.59	-0.35	2.01e-13	Neutrophil percentage of white cells;
LUAD	trans	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg27411982	chr8:10470053	RP1L1	0.44	8.1	0.37	5.75e-15	Mood instability;
LUAD	cis	rs7945705	0.875	rs10769957	chr11:8809016	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-8.51	-0.38	2.98e-16	Hemoglobin concentration;
LUAD	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg27144592	chr16:783916	NARFL	0.35	6.47	0.3	2.75e-10	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22194305	chr4:2264032	MXD4	-0.44	-6.84	-0.32	2.74e-11	Height;
LUAD	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg08213375	chr14:104286397	PPP1R13B	0.27	6.94	0.32	1.44e-11	Schizophrenia;
LUAD	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg09455208	chr3:40491958	NA	0.62	13.56	0.55	5.08e-35	Renal cell carcinoma;
LUAD	cis	rs4919694	1.000	rs17727391	chr10:104836101	C/A	cg04362960	chr10:104952993	NT5C2	0.72	7.75	0.35	7.07e-14	Arsenic metabolism;
LUAD	cis	rs1595825	0.786	rs74652956	chr2:198754247	C/T	cg00361562	chr2:198649771	BOLL	-0.47	-6.73	-0.31	5.53e-11	Ulcerative colitis;
LUAD	cis	rs2262909	0.925	rs56073035	chr19:22276298	C/G	cg11619707	chr19:22235551	ZNF257	0.49	7.49	0.34	4.1e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg24675056	chr1:15929824	NA	0.46	8.1	0.37	5.99e-15	Systolic blood pressure;
LUAD	cis	rs9653442	0.675	rs961788	chr2:100641459	T/C	cg07810366	chr2:100720526	AFF3	-0.35	-7.21	-0.33	2.68e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg09085632	chr11:111637200	PPP2R1B	0.78	11.75	0.5	8.46e-28	Primary sclerosing cholangitis;
LUAD	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.76	0.35	6.46e-14	Platelet count;
LUAD	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg03453431	chr7:157225567	NA	-0.52	-9.23	-0.41	1.26e-18	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUAD	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg13560548	chr3:10150139	C3orf24	0.4	6.56	0.3	1.53e-10	Alzheimer's disease;
LUAD	cis	rs11676348	0.805	rs13007219	chr2:218963859	C/A	cg06547715	chr2:218990976	CXCR2	0.37	8.27	0.37	1.81e-15	Ulcerative colitis;
LUAD	cis	rs939658	1.000	rs11072826	chr15:79461516	C/T	cg17916960	chr15:79447300	NA	0.45	9.27	0.41	9.78e-19	Refractive error;
LUAD	cis	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.01	-0.32	9.58e-12	Resting heart rate;
LUAD	cis	rs8060686	0.623	rs6499157	chr16:68105474	A/C	cg09835421	chr16:68378352	PRMT7	-0.54	-6.9	-0.32	1.93e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7172809	0.573	rs13380202	chr15:77659982	G/A	cg11865553	chr15:77376250	NA	-0.39	-6.52	-0.3	1.96e-10	Glucose homeostasis traits;
LUAD	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08219700	chr8:58056026	NA	-0.55	-7.53	-0.34	3.05e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg02158880	chr13:53174818	NA	0.76	13.55	0.55	5.23e-35	Lewy body disease;
LUAD	cis	rs420259	0.516	rs11642395	chr16:23556561	C/T	cg00143387	chr16:23521605	GGA2	-0.7	-9.72	-0.43	2.68e-20	Bipolar disorder;
LUAD	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	8.69	0.39	8.18e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg01528321	chr10:82214614	TSPAN14	0.64	10.13	0.44	9.54e-22	Post bronchodilator FEV1;
LUAD	trans	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg11693508	chr17:37793320	STARD3	0.58	7.96	0.36	1.59e-14	Bipolar disorder;
LUAD	trans	rs11039798	0.858	rs7121333	chr11:48332138	C/T	cg03929089	chr4:120376271	NA	0.56	6.48	0.3	2.6e-10	Axial length;
LUAD	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-8.96	-0.4	1.05e-17	Schizophrenia;
LUAD	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg06640241	chr16:89574553	SPG7	0.75	13.72	0.55	1.1e-35	Multiple myeloma (IgH translocation);
LUAD	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg27661571	chr11:113659931	NA	-0.73	-8.27	-0.37	1.78e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg22105103	chr4:187893119	NA	0.5	10.84	0.47	2.42e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg06784218	chr1:46089804	CCDC17	-0.56	-12.02	-0.5	8.01e-29	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.22	0.54	1.26e-33	Prudent dietary pattern;
LUAD	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg19875535	chr5:140030758	IK	-0.48	-8.08	-0.37	6.91e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg23758822	chr17:41437982	NA	0.99	20.31	0.7	1.73e-64	Menopause (age at onset);
LUAD	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg02527881	chr3:46936655	PTH1R	-0.51	-10.48	-0.45	5.3e-23	Colorectal cancer;
LUAD	cis	rs12367572	1.000	rs12822444	chr12:45276677	G/A	cg04608330	chr12:45269318	NELL2	-0.39	-7.36	-0.34	9.42e-13	Gut microbiome composition (summer);
LUAD	cis	rs6665290	0.904	rs7541033	chr1:227188371	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.08	-0.88	1.77e-142	Myeloid white cell count;
LUAD	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.31	0.34	1.32e-12	Tonsillectomy;
LUAD	cis	rs1160297	0.603	rs1454405	chr2:53023825	T/C	cg07782112	chr2:53107842	NA	0.37	7.36	0.34	9.61e-13	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg10729496	chr3:10149963	C3orf24	0.52	7.86	0.36	3.12e-14	Alzheimer's disease;
LUAD	cis	rs977987	0.806	rs34021527	chr16:75474090	A/G	cg03315344	chr16:75512273	CHST6	0.65	14.22	0.57	9.13e-38	Dupuytren's disease;
LUAD	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg12365402	chr11:9010492	NRIP3	0.48	8.92	0.4	1.37e-17	Hemoglobin concentration;
LUAD	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.62	0.31	1.12e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg18240062	chr17:79603768	NPLOC4	0.46	8.09	0.37	6.55e-15	Eye color traits;
LUAD	cis	rs758324	0.947	rs380182	chr5:131319036	A/G	cg06307176	chr5:131281290	NA	-0.49	-7.72	-0.35	8.41e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg22920501	chr2:26401640	FAM59B	0.95	13.69	0.55	1.42e-35	Gut microbiome composition (summer);
LUAD	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg26587870	chr6:27730563	NA	-0.45	-7.47	-0.34	4.49e-13	Parkinson's disease;
LUAD	cis	rs909002	0.800	rs11589306	chr1:32082822	C/G	cg13919466	chr1:32135498	COL16A1	-0.34	-7.86	-0.36	3.26e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.38	6.56	0.3	1.57e-10	Blood metabolite levels;
LUAD	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.61	-11.24	-0.48	7.83e-26	Schizophrenia;
LUAD	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.55	-6.95	-0.32	1.39e-11	Body mass index;
LUAD	cis	rs17095355	1.000	rs75079039	chr10:111745121	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.65	-7.72	-0.35	8.58e-14	Biliary atresia;
LUAD	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.48	-0.3	2.48e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg24642844	chr7:1081250	C7orf50	-0.6	-9.99	-0.44	3.17e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg02551604	chr5:131831745	NA	-0.61	-10.1	-0.44	1.22e-21	Asthma (sex interaction);
LUAD	trans	rs3118233	1	rs3118233	chr16:68733646	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-15.85	-0.61	9.66e-45	Red cell distribution width;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05654483	chr10:122610929	WDR11	-0.55	-6.65	-0.31	8.86e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg16447950	chr5:562315	NA	-0.39	-7.13	-0.33	4.25e-12	Obesity-related traits;
LUAD	cis	rs112591243	0.685	rs2839282	chr21:47902822	C/G	cg12379764	chr21:47803548	PCNT	-0.64	-6.35	-0.3	5.56e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg26343298	chr8:95960752	TP53INP1	0.37	7.74	0.35	7.62e-14	Type 2 diabetes;
LUAD	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg26893861	chr17:41843967	DUSP3	-1.19	-28.09	-0.81	9.81e-99	Triglycerides;
LUAD	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg18252515	chr7:66147081	NA	-0.64	-6.93	-0.32	1.6e-11	Diabetic kidney disease;
LUAD	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg25985355	chr7:65971099	NA	-0.36	-6.51	-0.3	2.18e-10	Aortic root size;
LUAD	cis	rs41271473	0.526	rs12143098	chr1:228720965	A/C	cg16512390	chr1:228756714	NA	0.7	9.22	0.41	1.38e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg05084668	chr3:125655381	ALG1L	-0.48	-7.42	-0.34	6.36e-13	Blood pressure (smoking interaction);
LUAD	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg04267008	chr7:1944627	MAD1L1	-0.68	-10.7	-0.46	8.56e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs494562	1.000	rs495472	chr6:86117021	C/T	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg11915388	chr22:42470451	FAM109B	0.4	7.09	0.33	5.58e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs863345	0.604	rs12063320	chr1:158499423	A/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg24450063	chr1:156163899	SLC25A44	1.23	30.19	0.83	1.34e-107	Testicular germ cell tumor;
LUAD	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.34	-0.34	1.11e-12	Morning vs. evening chronotype;
LUAD	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-8.08	-0.37	6.93e-15	Blood metabolite levels;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27507545	chr10:103880405	LDB1	0.46	7.2	0.33	2.69e-12	Gut microbiome composition (summer);
LUAD	cis	rs35123781	0.696	rs13154510	chr5:139071301	A/C	cg10513866	chr5:139070639	NA	0.55	8.93	0.4	1.34e-17	Schizophrenia;
LUAD	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg15017067	chr4:17643749	FAM184B	0.34	6.38	0.3	4.71e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg17279839	chr7:150038598	RARRES2	0.42	7.16	0.33	3.49e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg25036284	chr2:26402008	FAM59B	-0.61	-8.43	-0.38	5.33e-16	Gut microbiome composition (summer);
LUAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.58e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.09	-0.33	5.77e-12	Total cholesterol levels;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg03646474	chr1:174992368	MRPS14	0.43	6.96	0.32	1.29e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg11822812	chr5:140052017	DND1	0.38	6.84	0.32	2.78e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg11833968	chr6:79620685	NA	-0.42	-7.92	-0.36	2.16e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11644478	chr21:40555479	PSMG1	0.69	11.36	0.48	2.69e-26	Cognitive function;
LUAD	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs17152411	1.000	rs7097282	chr10:126593492	T/C	cg07906193	chr10:126599966	NA	0.53	7.6	0.35	1.95e-13	Height;
LUAD	cis	rs6543140	0.927	rs917999	chr2:103067869	G/A	cg04239558	chr2:103089729	SLC9A4	0.36	7.33	0.34	1.15e-12	Blood protein levels;
LUAD	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg18811423	chr2:55921094	PNPT1	-0.41	-6.64	-0.31	9.47e-11	Metabolic syndrome;
LUAD	cis	rs1497406	0.744	rs924203	chr1:16511539	G/T	cg20430773	chr1:16534157	ARHGEF19	0.38	6.53	0.3	1.84e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12016809	chr21:47604291	C21orf56	-0.45	-6.5	-0.3	2.22e-10	Testicular germ cell tumor;
LUAD	cis	rs8017423	0.904	rs7147212	chr14:90697809	A/C	cg14092571	chr14:90743983	NA	-0.52	-9.2	-0.41	1.68e-18	Mortality in heart failure;
LUAD	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg18512352	chr11:47633146	NA	0.4	7.09	0.33	5.78e-12	Subjective well-being;
LUAD	cis	rs6500395	1.000	rs3919552	chr16:48716328	C/T	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg06641503	chr3:48959341	ARIH2	-0.4	-7.84	-0.36	3.64e-14	Parkinson's disease;
LUAD	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg15704280	chr7:45808275	SEPT13	-0.65	-9.97	-0.44	3.52e-21	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg06618935	chr21:46677482	NA	-0.44	-8.39	-0.38	7.42e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs986417	0.818	rs10873125	chr14:61035024	G/A	cg27398547	chr14:60952738	C14orf39	0.61	7.71	0.35	9.11e-14	Gut microbiota (bacterial taxa);
LUAD	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.98	-0.32	1.15e-11	Height;
LUAD	cis	rs59698941	0.843	rs61541414	chr5:132226106	G/A	cg14825688	chr5:132208181	LEAP2	-0.47	-7.02	-0.32	8.61e-12	Apolipoprotein A-IV levels;
LUAD	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-24.47	-0.77	4.91e-83	Height;
LUAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg18402987	chr7:1209562	NA	0.63	8.34	0.38	1.04e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10170846	0.626	rs9288575	chr2:223495133	A/C	cg25565276	chr2:223520875	FARSB	0.56	7.08	0.33	5.95e-12	Schizophrenia (inflammation and infection response interaction);
LUAD	trans	rs9393777	0.920	rs13196692	chr6:27379119	C/T	cg06606381	chr12:133084897	FBRSL1	-0.97	-8.96	-0.4	1.02e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs3784262	0.967	rs12910752	chr15:58314679	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.47	-9.41	-0.42	3.11e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs4372836	1.000	rs7562170	chr2:28943516	T/C	cg09522027	chr2:28974177	PPP1CB	0.61	9.7	0.43	3.28e-20	Body mass index;
LUAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13012494	chr21:47604986	C21orf56	0.53	8.84	0.4	2.51e-17	Testicular germ cell tumor;
LUAD	cis	rs7975161	0.640	rs10778323	chr12:104746075	A/G	cg25273343	chr12:104657179	TXNRD1	0.54	6.6	0.31	1.24e-10	Toenail selenium levels;
LUAD	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg01312482	chr5:178451176	ZNF879	-0.45	-7.02	-0.32	8.98e-12	Pubertal anthropometrics;
LUAD	cis	rs2797160	0.967	rs8180614	chr6:126000599	G/C	cg05901451	chr6:126070800	HEY2	-0.45	-6.73	-0.31	5.6e-11	Endometrial cancer;
LUAD	cis	rs727505	0.819	rs4142718	chr7:124731688	T/A	cg23710748	chr7:124431027	NA	-0.41	-8.49	-0.38	3.61e-16	Lewy body disease;
LUAD	cis	rs9807989	0.839	rs9808453	chr2:102971306	C/A	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.05e-10	Asthma;
LUAD	cis	rs9296092	0.560	rs62407569	chr6:33538865	A/G	cg13560919	chr6:33536144	NA	-0.9	-16.6	-0.63	4.9e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg09455208	chr3:40491958	NA	0.56	12.05	0.51	6.04e-29	Renal cell carcinoma;
LUAD	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg25554036	chr4:6271136	WFS1	0.65	11.49	0.49	8.53e-27	Cisplatin-induced ototoxicity;
LUAD	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg25358565	chr5:93447407	FAM172A	0.66	7.88	0.36	2.77e-14	Diabetic retinopathy;
LUAD	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.48	-8.91	-0.4	1.57e-17	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs7582720	1.000	rs72934749	chr2:203746816	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs367943	1.000	rs191553	chr5:112823659	A/G	cg12552261	chr5:112820674	MCC	-0.59	-11.17	-0.48	1.49e-25	Type 2 diabetes;
LUAD	cis	rs2046867	0.908	rs62251639	chr3:72801214	G/A	cg25664220	chr3:72788482	NA	-0.68	-12.3	-0.51	6.08e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs116248771	0.739	rs12630515	chr3:158346615	A/G	cg16708174	chr3:158430962	RARRES1	0.47	6.88	0.32	2.22e-11	diarrhoeal disease at age 2;
LUAD	cis	rs12286929	0.644	rs3793957	chr11:115095654	C/T	cg04055981	chr11:115044050	NA	0.41	7.18	0.33	3.23e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7911264	1.000	rs10786052	chr10:94446635	T/C	cg25093409	chr10:94429542	NA	0.36	6.66	0.31	8.59e-11	Inflammatory bowel disease;
LUAD	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-10.08	-0.44	1.52e-21	Hip circumference adjusted for BMI;
LUAD	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg13870426	chr17:30244630	NA	-0.56	-6.62	-0.31	1.12e-10	Hip circumference adjusted for BMI;
LUAD	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.5	-7.6	-0.35	1.96e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg20673091	chr1:2541236	MMEL1	0.44	9.49	0.42	1.65e-19	Ulcerative colitis;
LUAD	cis	rs7927771	0.524	rs4539273	chr11:47694699	C/T	cg18512352	chr11:47633146	NA	-0.37	-6.63	-0.31	1.04e-10	Subjective well-being;
LUAD	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg23950597	chr19:37808831	NA	-0.56	-6.88	-0.32	2.17e-11	Coronary artery calcification;
LUAD	cis	rs9302065	0.565	rs2993585	chr13:95961966	G/A	cg26751094	chr13:95954534	ABCC4	-0.53	-11.2	-0.48	1.1e-25	Blood metabolite levels;
LUAD	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg05368731	chr17:41323189	NBR1	0.97	20.31	0.7	1.74e-64	Menopause (age at onset);
LUAD	trans	rs6940638	0.956	rs13207365	chr6:27030980	T/C	cg06606381	chr12:133084897	FBRSL1	-0.48	-6.36	-0.3	5.18e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs863345	0.604	rs2054993	chr1:158505968	T/G	cg12129480	chr1:158549410	OR10X1	-0.24	-6.6	-0.31	1.25e-10	Pneumococcal bacteremia;
LUAD	cis	rs2742234	1.000	rs2742234	chr10:43612609	A/G	cg02780029	chr10:43622663	RET	0.42	7.08	0.33	5.93e-12	Hirschsprung disease;
LUAD	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg15962314	chr1:44399869	ARTN	0.32	6.97	0.32	1.22e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg18230493	chr5:56204884	C5orf35	0.86	12.7	0.53	1.55e-31	Initial pursuit acceleration;
LUAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg18621852	chr3:10150065	C3orf24	0.43	6.8	0.31	3.54e-11	Alzheimer's disease;
LUAD	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg03433033	chr1:76189801	ACADM	-0.48	-6.81	-0.31	3.43e-11	Daytime sleep phenotypes;
LUAD	cis	rs8073060	0.927	rs7502331	chr17:33868858	A/G	cg05299278	chr17:33885742	SLFN14	-0.37	-6.7	-0.31	6.51e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg02734326	chr4:10020555	SLC2A9	0.63	11.35	0.48	3.08e-26	Bone mineral density;
LUAD	cis	rs734999	0.870	rs2985858	chr1:2483298	C/G	cg18854424	chr1:2615690	NA	0.31	7.01	0.32	9.55e-12	Ulcerative colitis;
LUAD	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg22875332	chr1:76189707	ACADM	-0.89	-16.78	-0.63	8.31e-49	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4846217	0.764	rs997482	chr1:10273179	C/T	cg17425144	chr1:10567563	PEX14	-0.53	-6.97	-0.32	1.2e-11	Platelet count;
LUAD	cis	rs10465746	0.725	rs980417	chr1:84365331	C/A	cg10977910	chr1:84465055	TTLL7	0.61	9.92	0.43	5.3e-21	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7939886	0.920	rs11227222	chr11:55876393	G/T	cg15704280	chr7:45808275	SEPT13	-0.65	-6.58	-0.3	1.38e-10	Myopia (pathological);
LUAD	cis	rs669446	0.561	rs517849	chr1:44081873	A/C	cg12908607	chr1:44402522	ARTN	-0.36	-6.69	-0.31	6.92e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.1	0.33	5.14e-12	Motion sickness;
LUAD	cis	rs10170310	1.000	rs10803568	chr2:139290914	T/C	cg10095539	chr2:139258744	SPOPL	0.32	6.41	0.3	3.98e-10	Response to antipsychotic treatment;
LUAD	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.15	0.33	3.78e-12	Motion sickness;
LUAD	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg17911788	chr17:44343683	NA	-0.51	-7.28	-0.33	1.68e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg18944383	chr4:111397179	ENPEP	0.38	7.62	0.35	1.66e-13	Height;
LUAD	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg14343924	chr8:8086146	FLJ10661	0.41	6.79	0.31	3.76e-11	Systolic blood pressure;
LUAD	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg10426581	chr7:100472382	SRRT	0.76	9.99	0.44	3.04e-21	Resting heart rate;
LUAD	cis	rs2732480	0.538	rs2468943	chr12:48747249	G/T	cg04545296	chr12:48745243	ZNF641	-0.38	-9.56	-0.42	9.52e-20	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.84e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68092024	0.731	rs792841	chr3:99471308	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	7.85	0.36	3.51e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs10504073	0.669	rs62507251	chr8:50028524	T/G	cg00325661	chr8:49890786	NA	0.43	9.43	0.42	2.76e-19	Blood metabolite ratios;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg01593552	chr13:22185680	NA	-0.38	-6.53	-0.3	1.86e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg06547715	chr2:218990976	CXCR2	0.28	6.75	0.31	4.79e-11	Colorectal cancer;
LUAD	cis	rs9296092	0.538	rs9469491	chr6:33521545	A/G	cg13560919	chr6:33536144	NA	0.87	16.36	0.62	5.93e-47	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7107174	1.000	rs2511156	chr11:77971167	G/C	cg19901956	chr11:77921274	USP35	-0.51	-6.37	-0.3	4.85e-10	Testicular germ cell tumor;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06074314	chr2:70475575	TIA1	0.45	6.94	0.32	1.5e-11	Gut microbiome composition (summer);
LUAD	cis	rs12519773	0.526	rs4242240	chr5:92517203	A/G	cg18783429	chr5:92414398	NA	0.43	7.66	0.35	1.29e-13	Migraine;
LUAD	cis	rs7590720	1.000	rs7590720	chr2:216898658	A/G	cg12620499	chr2:216877984	MREG	-0.55	-8.68	-0.39	8.41e-17	Alcohol dependence;
LUAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.79	-0.43	1.59e-20	Alzheimer's disease;
LUAD	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg20503657	chr10:835505	NA	0.8	10.63	0.46	1.49e-23	Eosinophil percentage of granulocytes;
LUAD	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg22875332	chr1:76189707	ACADM	-0.7	-11.27	-0.48	6.09e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg23262073	chr20:60523788	NA	-0.36	-6.4	-0.3	4.04e-10	Body mass index;
LUAD	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg27210415	chr4:713949	PCGF3	0.62	9.29	0.41	8.21e-19	White blood cell count;
LUAD	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg21724239	chr8:58056113	NA	0.62	7.89	0.36	2.56e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.07e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg04287289	chr16:89883240	FANCA	0.63	6.58	0.3	1.43e-10	Skin colour saturation;
LUAD	trans	rs2270927	0.510	rs35966882	chr5:75577716	A/G	cg13563193	chr19:33072644	PDCD5	0.96	9.04	0.4	5.54e-18	Mean corpuscular volume;
LUAD	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.38	-0.38	8.12e-16	Breast cancer;
LUAD	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg02176678	chr2:219576539	TTLL4	0.68	13.36	0.54	3.16e-34	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg04154034	chr17:28927549	LRRC37B2	0.71	7.05	0.32	7.52e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg27454412	chr7:1067447	C7orf50	0.42	6.78	0.31	3.96e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg27432699	chr2:27873401	GPN1	-0.42	-7.17	-0.33	3.31e-12	Total body bone mineral density;
LUAD	cis	rs3806843	0.576	rs246032	chr5:140332547	C/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	7.93	0.36	1.93e-14	Schizophrenia;
LUAD	cis	rs6665290	0.904	rs6690803	chr1:227189106	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.19	-40.26	-0.89	8.87e-147	Myeloid white cell count;
LUAD	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg17366294	chr4:99064904	C4orf37	0.53	9.77	0.43	1.86e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg24069376	chr3:38537580	EXOG	0.38	8.8	0.39	3.56e-17	Electrocardiographic conduction measures;
LUAD	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg02018176	chr4:1364513	KIAA1530	-0.38	-7.06	-0.32	6.87e-12	Obesity-related traits;
LUAD	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg20607798	chr8:58055168	NA	0.61	7.85	0.36	3.49e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs10896135	0.526	rs624561	chr11:66414915	C/T	cg15964523	chr11:66469143	SPTBN2	0.41	6.74	0.31	5.24e-11	Bipolar disorder;
LUAD	cis	rs1784581	0.855	rs1893101	chr6:162384371	G/C	cg17173639	chr6:162384350	PARK2	-0.59	-10.72	-0.46	6.96e-24	Itch intensity from mosquito bite;
LUAD	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg18129748	chr3:49941408	MST1R	-0.4	-6.51	-0.3	2.08e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs870825	0.616	rs1401359	chr4:185640216	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.1	0.57	2.86e-37	Blood protein levels;
LUAD	cis	rs9837602	0.938	rs9815439	chr3:99785206	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.58	8.58	0.39	1.76e-16	Breast cancer;
LUAD	cis	rs3784262	0.967	rs11630835	chr15:58269462	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.46	-9.42	-0.42	3.05e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs6906287	0.609	rs10457342	chr6:118948033	A/G	cg21191810	chr6:118973309	C6orf204	0.5	9.56	0.42	1.01e-19	Electrocardiographic conduction measures;
LUAD	cis	rs7799006	1.000	rs7787274	chr7:2275993	G/A	cg12745145	chr7:2261452	MAD1L1	-0.35	-6.81	-0.31	3.39e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg03289416	chr15:75166202	SCAMP2	-0.4	-6.92	-0.32	1.66e-11	Caffeine consumption;
LUAD	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.77	-0.35	6.02e-14	Monocyte count;
LUAD	cis	rs7771547	0.519	rs6923337	chr6:36369260	C/T	cg04289385	chr6:36355825	ETV7	0.5	7.47	0.34	4.56e-13	Platelet distribution width;
LUAD	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg11050988	chr7:1952600	MAD1L1	-0.38	-7.88	-0.36	2.74e-14	Bipolar disorder and schizophrenia;
LUAD	trans	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.28	-0.64	5.05e-51	Exhaled nitric oxide output;
LUAD	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg25664220	chr3:72788482	NA	-0.69	-12.17	-0.51	2.01e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6669072	0.647	rs814547	chr1:91238821	T/C	cg08895590	chr1:91227319	NA	-0.32	-6.62	-0.31	1.08e-10	Cognitive function;
LUAD	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23158103	chr7:148848205	ZNF398	-0.63	-11.48	-0.49	9.58e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs15676	0.783	rs10988119	chr9:131564585	T/C	cg00228799	chr9:131580591	ENDOG	-0.47	-7.34	-0.34	1.07e-12	Blood metabolite levels;
LUAD	cis	rs7084921	0.533	rs12765091	chr10:101855231	G/C	cg19754520	chr10:101825118	CPN1	-0.34	-6.81	-0.31	3.45e-11	Bone mineral density;
LUAD	cis	rs17362650	0.653	rs13001298	chr2:9550446	G/C	cg12832956	chr2:9616023	IAH1	-0.47	-7.96	-0.36	1.58e-14	Alcohol dependence (age at onset);
LUAD	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg14228332	chr4:119757509	SEC24D	0.86	7.86	0.36	3.16e-14	Cannabis dependence symptom count;
LUAD	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg05434287	chr7:2030229	MAD1L1	0.39	6.48	0.3	2.58e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7607369	0.719	rs690882	chr2:219640620	T/C	cg02176678	chr2:219576539	TTLL4	-0.54	-10.45	-0.45	6.76e-23	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs9652601	0.881	rs11860603	chr16:11165017	T/C	cg04616529	chr16:11181986	CLEC16A	0.38	6.91	0.32	1.75e-11	Systemic lupus erythematosus;
LUAD	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg23758822	chr17:41437982	NA	0.99	20.01	0.7	3.66e-63	Menopause (age at onset);
LUAD	trans	rs9929218	0.954	rs57688464	chr16:68826109	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.31	-0.54	5.49e-34	Colorectal cancer;
LUAD	cis	rs72928364	1.000	rs62275773	chr3:100740165	A/G	cg10123952	chr3:100791384	NA	0.64	7.49	0.34	4.12e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7274811	0.744	rs55651102	chr20:32188068	A/T	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.47	-6.96	-0.32	1.32e-11	Height;
LUAD	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg13073564	chr4:8508604	NA	-0.5	-9.06	-0.4	4.78e-18	Response to antineoplastic agents;
LUAD	trans	rs4824093	0.610	rs74371371	chr22:50314074	C/T	cg09872104	chr7:134855509	C7orf49	-0.81	-7.24	-0.33	2.14e-12	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg14343924	chr8:8086146	FLJ10661	0.48	7.71	0.35	9.31e-14	Mood instability;
LUAD	cis	rs71478720	0.868	rs5744222	chr11:112037014	G/T	cg04929355	chr11:112034997	IL18	0.45	7.15	0.33	3.81e-12	Interleukin-18 levels;
LUAD	trans	rs2797160	1.000	rs1739362	chr6:126020703	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.55	8.63	0.39	1.28e-16	Endometrial cancer;
LUAD	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg21385522	chr1:16154831	NA	0.44	6.66	0.31	8.42e-11	Dilated cardiomyopathy;
LUAD	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.38	7.2	0.33	2.72e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg03806693	chr22:41940476	POLR3H	0.59	8.59	0.39	1.63e-16	Vitiligo;
LUAD	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg07617317	chr6:118971624	C6orf204	0.56	8.38	0.38	7.8e-16	Diastolic blood pressure;
LUAD	cis	rs4662945	0.525	rs4662951	chr2:130256272	C/T	cg05903289	chr2:130345205	NA	-0.32	-6.84	-0.32	2.82e-11	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs1003719	0.715	rs2835658	chr21:38565201	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.16	-0.37	3.99e-15	Eye color traits;
LUAD	trans	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg14791747	chr16:20752902	THUMPD1	-0.51	-7.12	-0.33	4.73e-12	Selective IgA deficiency;
LUAD	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg02251663	chr11:14281053	SPON1	0.37	7.3	0.33	1.42e-12	Mitochondrial DNA levels;
LUAD	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg14092988	chr3:52407081	DNAH1	0.45	9.01	0.4	7.31e-18	Bipolar disorder;
LUAD	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg24147428	chr11:65409760	SIPA1	-0.58	-9.75	-0.43	2.08e-20	Blood pressure (age interaction);
LUAD	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg15557168	chr22:42548783	NA	0.52	9.51	0.42	1.43e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg22139774	chr2:100720529	AFF3	-0.35	-6.72	-0.31	6.06e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	trans	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.71	0.35	9.14e-14	Resting heart rate;
LUAD	cis	rs73206853	0.541	rs11837455	chr12:110505621	C/A	cg12870014	chr12:110450643	ANKRD13A	0.86	7.9	0.36	2.5e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.51	0.42	1.46e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12791968	1.000	rs11038240	chr11:45002878	A/G	cg11846598	chr11:44996168	LOC221122	0.78	13.89	0.56	2.04e-36	Inhibitory control;
LUAD	cis	rs9902453	0.967	rs55744550	chr17:28475729	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.59	0.39	1.66e-16	Coffee consumption (cups per day);
LUAD	cis	rs58804349	0.685	rs11239855	chr10:43483879	A/G	cg08461752	chr10:43522343	NA	0.86	9.87	0.43	7.93e-21	Pediatric bone mineral content (radius);
LUAD	cis	rs11676348	0.967	rs4674258	chr2:218990586	C/T	cg06547715	chr2:218990976	CXCR2	0.38	8.85	0.4	2.5e-17	Ulcerative colitis;
LUAD	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg20607287	chr7:12443886	VWDE	-0.53	-6.67	-0.31	8.01e-11	Coronary artery disease;
LUAD	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg09117114	chr16:67998030	SLC12A4	-0.49	-6.94	-0.32	1.47e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg25237894	chr2:233734115	C2orf82	0.63	11.93	0.5	1.77e-28	Coronary artery disease;
LUAD	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg25985355	chr7:65971099	NA	-0.38	-6.89	-0.32	2.02e-11	Aortic root size;
LUAD	cis	rs7945718	0.967	rs11022491	chr11:12777620	A/G	cg25843174	chr11:12811716	TEAD1	-0.26	-7.65	-0.35	1.37e-13	Educational attainment (years of education);
LUAD	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg20933634	chr6:27740509	NA	0.47	7.43	0.34	6.15e-13	Parkinson's disease;
LUAD	cis	rs9796	0.611	rs691672	chr15:41444438	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.43	-7.86	-0.36	3.16e-14	Menopause (age at onset);
LUAD	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg06484146	chr7:12443880	VWDE	-0.51	-7.3	-0.33	1.44e-12	Coronary artery disease;
LUAD	cis	rs1595825	0.891	rs76450397	chr2:198786112	T/C	cg11031976	chr2:198649780	BOLL	-0.48	-7.19	-0.33	2.89e-12	Ulcerative colitis;
LUAD	cis	rs10924309	0.889	rs1316344	chr1:245859822	C/T	cg00036263	chr1:245852353	KIF26B	-0.48	-7.49	-0.34	3.94e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg25753631	chr6:25732923	NA	-0.45	-7.96	-0.36	1.61e-14	Iron status biomarkers;
LUAD	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg15445000	chr17:37608096	MED1	0.44	8.24	0.37	2.18e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs9584850	0.874	rs4584	chr13:99101869	G/C	cg07423050	chr13:99094983	FARP1	0.39	6.55	0.3	1.67e-10	Neuroticism;
LUAD	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.85	-0.32	2.69e-11	Breast cancer;
LUAD	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg07404485	chr7:94953653	PON1	-0.51	-7.53	-0.34	3.1400000000000003e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg19000871	chr14:103996768	TRMT61A	-0.44	-7.57	-0.35	2.29e-13	Coronary artery disease;
LUAD	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.86	-0.53	3.5e-32	Systolic blood pressure;
LUAD	trans	rs7200543	1.000	rs16966952	chr16:15135943	C/T	cg24683922	chr1:11983373	KIAA2013	-0.48	-8.12	-0.37	5.2e-15	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-6.54	-0.3	1.75e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg25025879	chr12:53359317	NA	-0.74	-12.68	-0.52	1.81e-31	Cancer (pleiotropy);
LUAD	cis	rs11077998	0.844	rs12185254	chr17:80498972	C/T	cg10255544	chr17:80519551	FOXK2	0.35	7.0	0.32	9.85e-12	Reticulocyte fraction of red cells;
LUAD	trans	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs6594713	0.921	rs35886114	chr5:112724197	C/T	cg12552261	chr5:112820674	MCC	0.54	8.41	0.38	6.22e-16	Brain cytoarchitecture;
LUAD	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.35	-0.45	1.54e-22	Monocyte percentage of white cells;
LUAD	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08109568	chr15:31115862	NA	-0.79	-13.64	-0.55	2.35e-35	Huntington's disease progression;
LUAD	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-7.27	-0.33	1.78e-12	Retinal vascular caliber;
LUAD	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.38	-6.74	-0.31	5.3e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs12541635	1.000	rs1366965	chr8:107085224	T/A	cg10147462	chr8:107024639	NA	-0.42	-7.6	-0.35	1.89e-13	Age of smoking initiation;
LUAD	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg07677032	chr17:61819896	STRADA	0.43	6.49	0.3	2.47e-10	Height;
LUAD	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	9.29	0.41	7.95e-19	Total body bone mineral density;
LUAD	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg13126279	chr21:47581558	C21orf56	-0.43	-7.41	-0.34	6.74e-13	Testicular germ cell tumor;
LUAD	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg18252515	chr7:66147081	NA	-0.63	-6.96	-0.32	1.34e-11	Diabetic kidney disease;
LUAD	cis	rs10751667	0.600	rs11246377	chr11:999796	G/T	cg06064525	chr11:970664	AP2A2	-0.33	-6.35	-0.3	5.51e-10	Alzheimer's disease (late onset);
LUAD	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg16031515	chr1:205743344	RAB7L1	-0.34	-6.79	-0.31	3.79e-11	Menarche (age at onset);
LUAD	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg07217954	chr7:1067459	C7orf50	-0.38	-6.76	-0.31	4.61e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg13606994	chr1:44402422	ARTN	-0.33	-6.79	-0.31	3.82e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg15962314	chr1:44399869	ARTN	0.32	6.82	0.31	3.22e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg13606994	chr1:44402422	ARTN	-0.37	-7.22	-0.33	2.44e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs933688	0.532	rs2973478	chr5:90553428	C/T	cg00335715	chr5:90575459	NA	-0.44	-6.75	-0.31	4.9e-11	Smoking behavior;
LUAD	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg03676636	chr4:99064102	C4orf37	0.27	6.82	0.31	3.09e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7395662	1.000	rs10839171	chr11:48923034	C/A	cg15704280	chr7:45808275	SEPT13	0.41	6.53	0.3	1.9e-10	HDL cholesterol;
LUAD	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.91	-0.32	1.83e-11	Neuroticism;
LUAD	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26314531	chr2:26401878	FAM59B	-0.58	-7.99	-0.36	1.33e-14	Gut microbiome composition (summer);
LUAD	cis	rs7605378	1.000	rs797163	chr2:200696387	G/A	cg17644776	chr2:200775616	C2orf69	0.47	7.51	0.34	3.51e-13	Osteoporosis;
LUAD	trans	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg26043149	chr18:55253948	FECH	1.02	17.89	0.66	1.01e-53	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg26314531	chr2:26401878	FAM59B	0.61	7.66	0.35	1.26e-13	Gut microbiome composition (summer);
LUAD	trans	rs1493916	0.748	rs1845386	chr18:31318256	C/G	cg15819921	chr19:927150	ARID3A	-0.41	-6.58	-0.3	1.39e-10	Life satisfaction;
LUAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.5	6.75	0.31	4.82e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg04727924	chr7:799746	HEATR2	0.55	7.28	0.33	1.69e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg07917127	chr4:99064746	C4orf37	0.42	6.97	0.32	1.21e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg21545522	chr1:205238299	TMCC2	0.38	7.01	0.32	9.75e-12	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18099408	chr3:52552593	STAB1	-0.49	-8.49	-0.38	3.64e-16	Bipolar disorder;
LUAD	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg08999081	chr20:33150536	PIGU	0.47	9.22	0.41	1.44e-18	Coronary artery disease;
LUAD	cis	rs741677	0.663	rs405203	chr17:491009	A/G	cg15660573	chr17:549704	VPS53	0.54	8.93	0.4	1.33e-17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4285028	0.948	rs2091664	chr3:121684749	T/A	cg11130432	chr3:121712080	ILDR1	-0.59	-8.44	-0.38	5.05e-16	Multiple sclerosis;
LUAD	trans	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.13	-27.26	-0.8	3.58e-95	Colorectal cancer;
LUAD	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg18811423	chr2:55921094	PNPT1	0.58	9.8	0.43	1.44e-20	Metabolic syndrome;
LUAD	cis	rs4664308	1.000	rs10929966	chr2:160908341	C/T	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.79	-0.31	3.75e-11	Idiopathic membranous nephropathy;
LUAD	trans	rs7127307	0.740	rs4144896	chr11:128182026	C/T	cg07953307	chr16:29000920	LAT	0.5	6.55	0.3	1.68e-10	Atopic dermatitis;
LUAD	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.0	-0.36	1.23e-14	Diabetic kidney disease;
LUAD	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg24690094	chr11:67383802	NA	0.54	10.02	0.44	2.4e-21	Mean corpuscular volume;
LUAD	cis	rs9341808	0.667	rs3805919	chr6:80906809	C/G	cg08355045	chr6:80787529	NA	0.5	8.9	0.4	1.63e-17	Sitting height ratio;
LUAD	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg16850897	chr7:100343110	ZAN	0.42	7.48	0.34	4.23e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs1816752	0.748	rs6490912	chr13:24983079	G/A	cg02811702	chr13:24901961	NA	0.41	7.18	0.33	3.19e-12	Obesity-related traits;
LUAD	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg02850689	chr1:2391347	NA	-0.35	-6.53	-0.3	1.88e-10	Non-obstructive azoospermia;
LUAD	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg17279839	chr7:150038598	RARRES2	-0.45	-7.73	-0.35	8.07e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg06873352	chr17:61820015	STRADA	0.41	6.87	0.32	2.26e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.41	6.41	0.3	3.83e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs3806843	0.576	rs246021	chr5:140334504	C/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg22535103	chr8:58192502	C8orf71	-0.75	-9.19	-0.41	1.79e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.13	-0.33	4.28e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg04455712	chr21:45112962	RRP1B	-0.44	-8.72	-0.39	6.43e-17	Mean corpuscular volume;
LUAD	cis	rs12681288	0.523	rs111782857	chr8:962486	T/C	cg15309053	chr8:964076	NA	0.5	11.31	0.48	4.22e-26	Schizophrenia;
LUAD	cis	rs12431939	0.857	rs4547259	chr14:51669224	T/G	cg23942311	chr14:51606299	NA	0.41	6.51	0.3	2.13e-10	Cancer;
LUAD	cis	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg21775007	chr8:11205619	TDH	0.37	6.44	0.3	3.16e-10	Neuroticism;
LUAD	cis	rs7737355	0.947	rs3776004	chr5:130879431	G/C	cg25547332	chr5:131281432	NA	0.43	6.39	0.3	4.46e-10	Life satisfaction;
LUAD	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg04842962	chr6:43655489	MRPS18A	0.91	16.9	0.63	2.59e-49	IgG glycosylation;
LUAD	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg02782426	chr3:40428986	ENTPD3	0.32	6.78	0.31	4.05e-11	Renal cell carcinoma;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20739223	chr2:64371680	PELI1	-0.41	-6.49	-0.3	2.36e-10	Height;
LUAD	trans	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.87	-0.36	3.06e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg18225595	chr11:63971243	STIP1	0.52	8.65	0.39	1.09e-16	Platelet count;
LUAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg11494091	chr17:61959527	GH2	0.74	18.43	0.67	4.25e-56	Prudent dietary pattern;
LUAD	trans	rs12517041	1.000	rs7736335	chr5:23288232	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.53	-0.3	1.92e-10	Calcium levels;
LUAD	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg07636037	chr3:49044803	WDR6	0.54	8.61	0.39	1.41e-16	Menarche (age at onset);
LUAD	cis	rs6484504	0.512	rs7940020	chr11:31366453	T/G	cg14844989	chr11:31128820	NA	0.45	8.36	0.38	9.13e-16	Red blood cell count;
LUAD	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs68170813	0.559	rs12534676	chr7:106943640	G/A	cg23024343	chr7:107201750	COG5	0.49	7.05	0.32	7.57e-12	Coronary artery disease;
LUAD	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg26408565	chr15:76604113	ETFA	-0.44	-7.05	-0.32	7.19e-12	Blood metabolite levels;
LUAD	cis	rs9837602	1.000	rs6790535	chr3:99807735	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.57	8.86	0.4	2.2e-17	Breast cancer;
LUAD	cis	rs77861329	1.000	rs9811707	chr3:52190657	G/A	cg08692210	chr3:52188851	WDR51A	0.83	7.75	0.35	6.7e-14	Macrophage inflammatory protein 1b levels;
LUAD	trans	rs3219090	0.924	rs1104893	chr1:226598652	A/G	cg27539482	chr13:111589090	NA	0.43	7.21	0.33	2.64e-12	Melanoma;
LUAD	cis	rs7000551	0.751	rs2461490	chr8:22370115	G/C	cg12081754	chr8:22256438	SLC39A14	0.45	7.42	0.34	6.33e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.65	10.82	0.47	3e-24	Colorectal cancer;
LUAD	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg25358565	chr5:93447407	FAM172A	0.62	7.62	0.35	1.64e-13	Diabetic retinopathy;
LUAD	cis	rs6460942	0.915	rs7803002	chr7:12306738	C/T	cg06484146	chr7:12443880	VWDE	-0.44	-6.49	-0.3	2.47e-10	Coronary artery disease;
LUAD	trans	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg24644049	chr4:85504048	CDS1	0.93	7.84	0.36	3.58e-14	Skin colour saturation;
LUAD	cis	rs7737355	0.812	rs152789	chr5:131026590	C/A	cg06307176	chr5:131281290	NA	0.46	7.52	0.34	3.42e-13	Life satisfaction;
LUAD	cis	rs1448094	0.967	rs11117116	chr12:86331087	A/T	cg02569458	chr12:86230093	RASSF9	0.37	7.07	0.33	6.27e-12	Major depressive disorder;
LUAD	cis	rs7267979	0.932	rs6115215	chr20:25562500	C/T	cg08601574	chr20:25228251	PYGB	0.41	7.58	0.35	2.26e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6479527	0.806	rs914296	chr9:96765974	A/G	cg14459158	chr9:96720562	NA	0.39	6.72	0.31	5.99e-11	Esophageal adenocarcinoma;
LUAD	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg23262073	chr20:60523788	NA	-0.39	-6.84	-0.32	2.78e-11	Body mass index;
LUAD	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03517284	chr6:25882590	NA	-0.57	-9.17	-0.41	2.13e-18	Blood metabolite levels;
LUAD	cis	rs1215050	0.791	rs783969	chr4:98906504	C/T	cg05340658	chr4:99064831	C4orf37	0.45	7.25	0.33	2.03e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9837602	0.810	rs35885423	chr3:99813218	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-6.85	-0.32	2.59e-11	Breast cancer;
LUAD	cis	rs748404	0.723	rs11853991	chr15:43557549	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	6.57	0.3	1.44e-10	Lung cancer;
LUAD	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg25173405	chr17:45401733	C17orf57	-0.52	-8.87	-0.4	2.05e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg08893839	chr5:154027129	NA	0.54	7.15	0.33	3.75e-12	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg09835421	chr16:68378352	PRMT7	-0.82	-8.81	-0.39	3.27e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg09658497	chr7:2847517	GNA12	-0.47	-7.97	-0.36	1.5e-14	Height;
LUAD	cis	rs11585357	0.947	rs11584287	chr1:17607501	G/C	cg08277548	chr1:17600880	PADI3	-0.96	-14.11	-0.57	2.51e-37	Hair shape;
LUAD	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg17063962	chr7:91808500	NA	-0.62	-10.67	-0.46	1.1e-23	Breast cancer;
LUAD	cis	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.98	-0.36	1.35e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg15117754	chr3:10150083	C3orf24	0.4	6.47	0.3	2.79e-10	Alzheimer's disease;
LUAD	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-7.56	-0.34	2.57e-13	Tonsillectomy;
LUAD	trans	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg03886242	chr7:26192032	NFE2L3	-0.39	-6.91	-0.32	1.8e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7107174	0.748	rs7105835	chr11:78075725	T/C	cg19901956	chr11:77921274	USP35	-0.48	-6.76	-0.31	4.56e-11	Testicular germ cell tumor;
LUAD	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg00316803	chr15:76480434	C15orf27	-0.41	-7.98	-0.36	1.41e-14	Blood metabolite levels;
LUAD	cis	rs17401966	0.867	rs61775872	chr1:10279308	T/C	cg15208524	chr1:10270712	KIF1B	0.42	6.5	0.3	2.28e-10	Hepatocellular carcinoma;
LUAD	cis	rs9302065	0.529	rs2993582	chr13:95958181	G/T	cg26751094	chr13:95954534	ABCC4	-0.54	-11.37	-0.48	2.6e-26	Blood metabolite levels;
LUAD	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg20917491	chr3:195578259	NA	-0.42	-6.84	-0.32	2.85e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg04398451	chr17:18023971	MYO15A	0.64	11.43	0.49	1.56e-26	Total body bone mineral density;
LUAD	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg12615879	chr12:58013172	SLC26A10	-0.58	-12.75	-0.53	9.5e-32	Multiple sclerosis;
LUAD	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg06064525	chr11:970664	AP2A2	-0.54	-11.07	-0.47	3.62e-25	Alzheimer's disease (late onset);
LUAD	cis	rs41311933	0.803	rs41313623	chr9:123718563	C/T	cg13567360	chr9:123745713	C5	-0.74	-6.74	-0.31	5.26e-11	Coronary artery disease;
LUAD	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg13393036	chr8:95962371	TP53INP1	0.36	7.95	0.36	1.76e-14	Type 2 diabetes;
LUAD	cis	rs7809950	0.906	rs2253269	chr7:107201114	C/T	cg23024343	chr7:107201750	COG5	-0.71	-12.0	-0.5	9e-29	Coronary artery disease;
LUAD	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg19041857	chr6:27730383	NA	-0.43	-7.28	-0.33	1.6e-12	Parkinson's disease;
LUAD	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.55	8.14	0.37	4.56e-15	Gut microbiome composition (summer);
LUAD	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg07677032	chr17:61819896	STRADA	-0.57	-10.54	-0.46	3.09e-23	Prudent dietary pattern;
LUAD	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.54	0.3	1.77e-10	Depression;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg27011534	chr2:44223321	LRPPRC	-0.39	-6.48	-0.3	2.48e-10	Cancer;
LUAD	cis	rs12681287	0.571	rs13254675	chr8:87353594	C/T	cg00550725	chr8:87521180	FAM82B	0.47	6.74	0.31	5.32e-11	Caudate activity during reward;
LUAD	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.42	-6.51	-0.3	2.12e-10	Schizophrenia;
LUAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg05313129	chr8:58192883	C8orf71	-0.57	-7.49	-0.34	4.01e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs12545109	0.879	rs2576580	chr8:57365828	G/C	cg19413350	chr8:57351067	NA	-0.47	-7.08	-0.33	5.97e-12	Obesity-related traits;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg22625903	chr11:62313283	AHNAK	0.42	6.6	0.31	1.23e-10	Diastolic blood pressure;
LUAD	cis	rs6840360	0.593	rs4696287	chr4:152606723	C/T	cg22705602	chr4:152727874	NA	-0.48	-8.81	-0.39	3.3e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg06558623	chr16:89946397	TCF25	1.21	11.84	0.5	4.09e-28	Skin colour saturation;
LUAD	cis	rs7119	0.651	rs12915057	chr15:77847745	C/A	cg27398640	chr15:77910606	LINGO1	-0.37	-6.72	-0.31	5.84e-11	Type 2 diabetes;
LUAD	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.4	6.59	0.31	1.28e-10	Systemic lupus erythematosus;
LUAD	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg05425664	chr17:57184151	TRIM37	-0.42	-7.62	-0.35	1.65e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7527798	0.592	rs960087	chr1:207826858	C/G	cg09232269	chr1:207846808	CR1L	-0.36	-6.77	-0.31	4.28e-11	Erythrocyte sedimentation rate;
LUAD	trans	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg07211511	chr3:129823064	LOC729375	-0.53	-7.27	-0.33	1.78e-12	Blood pressure (smoking interaction);
LUAD	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg24101359	chr6:42928495	GNMT	0.48	8.75	0.39	5.3e-17	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg02228675	chr17:40259724	DHX58	-0.44	-7.09	-0.33	5.79e-12	Fibrinogen levels;
LUAD	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg15208524	chr1:10270712	KIF1B	0.45	6.83	0.32	3.01e-11	Hepatocellular carcinoma;
LUAD	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg08601574	chr20:25228251	PYGB	0.43	7.84	0.36	3.76e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs3752645	1.000	rs11772245	chr7:106748078	C/G	cg02696742	chr7:106810147	HBP1	-0.66	-6.55	-0.3	1.7e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg00666640	chr1:248458726	OR2T12	0.33	8.1	0.37	5.83e-15	Common traits (Other);
LUAD	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg08085267	chr17:45401833	C17orf57	-0.65	-11.49	-0.49	8.62e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.84	-0.4	2.53e-17	Lymphocyte counts;
LUAD	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg26597838	chr10:835615	NA	-0.91	-14.42	-0.57	1.32e-38	Eosinophil percentage of granulocytes;
LUAD	cis	rs6688613	0.729	rs2072742	chr1:166929673	A/G	cg07049167	chr1:166818506	POGK	0.57	8.26	0.37	1.93e-15	Refractive astigmatism;
LUAD	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16405210	chr4:1374714	KIAA1530	-0.42	-7.12	-0.33	4.63e-12	Longevity;
LUAD	cis	rs6684514	1.000	rs12118238	chr1:156235221	G/A	cg16558208	chr1:156270281	VHLL	0.52	9.29	0.41	8.02e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs6546550	0.901	rs3771531	chr2:70164034	T/C	cg02498382	chr2:70120550	SNRNP27	-0.59	-11.2	-0.48	1.14e-25	Prevalent atrial fibrillation;
LUAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg22535103	chr8:58192502	C8orf71	-0.75	-9.19	-0.41	1.85e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg00106254	chr7:1943704	MAD1L1	-0.54	-7.74	-0.35	7.47e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs11971779	0.715	rs10085527	chr7:139064360	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.81	0.31	3.34e-11	Diisocyanate-induced asthma;
LUAD	cis	rs476633	0.708	rs8030657	chr15:41444979	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.6	-10.78	-0.46	4.17e-24	Glomerular filtration rate (creatinine);
LUAD	cis	rs12519773	0.717	rs66496757	chr5:92488062	A/G	cg18783429	chr5:92414398	NA	0.39	6.75	0.31	4.83e-11	Migraine;
LUAD	cis	rs4372836	0.504	rs10177006	chr2:29088256	A/G	cg09522027	chr2:28974177	PPP1CB	-0.6	-10.66	-0.46	1.17e-23	Body mass index;
LUAD	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg04369109	chr6:150039330	LATS1	-0.4	-6.58	-0.3	1.43e-10	Lung cancer;
LUAD	cis	rs2996428	0.593	rs7513053	chr1:3709487	A/G	cg13057898	chr1:3703894	LRRC47	0.58	9.83	0.43	1.13e-20	Red cell distribution width;
LUAD	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg19773385	chr1:10388646	KIF1B	0.42	6.87	0.32	2.24e-11	Hepatocellular carcinoma;
LUAD	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.58	-0.39	1.8e-16	Neutrophil percentage of white cells;
LUAD	cis	rs11229555	0.645	rs12802960	chr11:58174775	T/C	cg15696309	chr11:58395628	NA	-0.73	-10.3	-0.45	2.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg14779329	chr11:130786720	SNX19	0.38	6.88	0.32	2.14e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2274273	0.840	rs10142448	chr14:55838108	G/T	cg04306507	chr14:55594613	LGALS3	-0.42	-9.12	-0.41	2.98e-18	Protein biomarker;
LUAD	cis	rs2115630	0.791	rs2008262	chr15:85305270	C/T	cg11189052	chr15:85197271	WDR73	-0.47	-7.47	-0.34	4.57e-13	P wave terminal force;
LUAD	cis	rs13040088	1.000	rs2273412	chr20:61553802	G/A	cg23096297	chr20:61557774	DIDO1	0.7	9.37	0.41	4.48e-19	Menopause (age at onset);
LUAD	cis	rs11229555	0.645	rs72917641	chr11:58227320	A/C	cg15696309	chr11:58395628	NA	-0.8	-10.75	-0.46	5.45e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg19318889	chr4:1322082	MAEA	0.87	14.51	0.58	5.14e-39	Longevity;
LUAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg13047869	chr3:10149882	C3orf24	0.66	11.09	0.47	2.88e-25	Alzheimer's disease;
LUAD	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.51	-10.65	-0.46	1.26e-23	Monocyte percentage of white cells;
LUAD	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg03433033	chr1:76189801	ACADM	0.83	14.92	0.59	9.84e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg10518543	chr12:38710700	ALG10B	-0.44	-7.12	-0.33	4.61e-12	Morning vs. evening chronotype;
LUAD	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.46	0.34	5.03e-13	Bipolar disorder;
LUAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg08132940	chr7:1081526	C7orf50	-0.78	-10.56	-0.46	2.7e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.3	-6.61	-0.31	1.17e-10	Blood metabolite levels;
LUAD	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg15900387	chr1:150738905	CTSS	-0.36	-6.65	-0.31	9.2e-11	Melanoma;
LUAD	cis	rs6973256	0.604	rs6975134	chr7:133531432	T/C	cg10665199	chr7:133106180	EXOC4	0.39	6.52	0.3	1.98e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg04546413	chr19:29218101	NA	0.6	8.54	0.38	2.36e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs877282	0.898	rs11253348	chr10:765852	C/T	cg17470449	chr10:769945	NA	0.61	8.5	0.38	3.37e-16	Uric acid levels;
LUAD	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg15900387	chr1:150738905	CTSS	-0.36	-6.6	-0.31	1.22e-10	Melanoma;
LUAD	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg12064134	chr16:90016061	DEF8	0.37	6.83	0.32	2.89e-11	Squamous cell carcinoma;
LUAD	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg18512352	chr11:47633146	NA	-0.56	-9.76	-0.43	1.92e-20	Subjective well-being;
LUAD	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg02493740	chr2:85810744	VAMP5	-0.42	-7.55	-0.34	2.72e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg08071915	chr8:12219732	FAM66A	0.42	7.37	0.34	9.3e-13	Neuroticism;
LUAD	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.58	9.87	0.43	8.4e-21	Electrocardiographic conduction measures;
LUAD	trans	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg08071915	chr8:12219732	FAM66A	0.43	7.21	0.33	2.53e-12	Joint mobility (Beighton score);
LUAD	cis	rs877282	0.898	rs11253340	chr10:764786	G/T	cg17470449	chr10:769945	NA	0.63	9.0	0.4	7.54e-18	Uric acid levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11582133	chr15:41576691	LOC729082	-0.41	-6.37	-0.3	5.01e-10	Height;
LUAD	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.37	-7.13	-0.33	4.45e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg11814155	chr7:99998594	ZCWPW1	0.46	7.79	0.35	5.2e-14	Platelet count;
LUAD	cis	rs11048434	0.736	rs1805761	chr12:9099533	T/C	cg23795048	chr12:9217529	LOC144571	0.42	7.71	0.35	8.99e-14	Sjögren's syndrome;
LUAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg03188948	chr7:1209495	NA	0.8	9.49	0.42	1.66e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg05340658	chr4:99064831	C4orf37	0.54	9.17	0.41	2.02e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7010267	0.642	rs9969672	chr8:120006080	T/A	cg01975934	chr8:119970761	NA	-0.35	-6.81	-0.31	3.45e-11	Total body bone mineral density (age 45-60);
LUAD	cis	rs8177876	0.822	rs804902	chr16:81104965	C/G	cg08591886	chr16:81111003	C16orf46	-0.61	-6.61	-0.31	1.16e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs2274273	0.712	rs1002054	chr14:55528913	A/C	cg04306507	chr14:55594613	LGALS3	0.32	6.68	0.31	7.65e-11	Protein biomarker;
LUAD	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg07169764	chr2:136633963	MCM6	0.66	8.11	0.37	5.44e-15	Corneal structure;
LUAD	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06028605	chr16:24865363	SLC5A11	0.56	8.78	0.39	4.03e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs494562	0.892	rs7767626	chr6:86124394	G/A	cg27297263	chr6:86160468	NT5E	0.59	6.44	0.3	3.3e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg03609598	chr5:56110824	MAP3K1	-0.68	-9.27	-0.41	9.92e-19	Initial pursuit acceleration;
LUAD	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg04511125	chr2:88470314	THNSL2	-0.47	-7.84	-0.36	3.58e-14	Response to metformin (IC50);
LUAD	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg07636037	chr3:49044803	WDR6	0.64	12.49	0.52	1.12e-30	Parkinson's disease;
LUAD	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg11663144	chr21:46675770	NA	-0.6	-11.57	-0.49	4.38e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg08610935	chr16:1836813	NUBP2	0.45	7.07	0.32	6.57e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg17063962	chr7:91808500	NA	-0.64	-11.08	-0.47	3.07e-25	Breast cancer;
LUAD	trans	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg18187862	chr3:45730750	SACM1L	0.48	7.58	0.35	2.26e-13	Primary sclerosing cholangitis;
LUAD	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg10792982	chr14:105748885	BRF1	0.46	9.94	0.44	4.73e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs55788414	1.000	rs35667589	chr16:81180829	A/T	cg06400318	chr16:81190750	PKD1L2	-0.72	-8.58	-0.39	1.75e-16	Left ventricular obstructive tract defect (maternal effect);
LUAD	trans	rs4650994	0.544	rs2811314	chr1:178619183	C/T	cg05059571	chr16:84539110	KIAA1609	0.66	11.66	0.49	1.92e-27	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.78	-0.43	1.63e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs977987	0.933	rs4888431	chr16:75500699	G/T	cg03315344	chr16:75512273	CHST6	0.66	14.42	0.57	1.22e-38	Dupuytren's disease;
LUAD	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg16414030	chr3:133502952	NA	-0.53	-9.56	-0.42	9.53e-20	Iron status biomarkers;
LUAD	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg13319975	chr6:146136371	FBXO30	-0.6	-10.3	-0.45	2.39e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.53	7.58	0.35	2.19e-13	Platelet count;
LUAD	cis	rs738322	0.577	rs6001034	chr22:38558459	A/G	cg17652424	chr22:38574118	PLA2G6	-0.3	-8.22	-0.37	2.51e-15	Cutaneous nevi;
LUAD	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg21017887	chr14:105400489	NA	0.75	14.36	0.57	2.19e-38	Rheumatoid arthritis;
LUAD	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg09021430	chr5:549028	NA	-0.66	-14.73	-0.58	5.92e-40	Ulcerative colitis;
LUAD	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg12573674	chr2:1569213	NA	-0.6	-8.67	-0.39	9e-17	IgG glycosylation;
LUAD	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg20135002	chr11:47629003	NA	-0.41	-7.29	-0.33	1.49e-12	Subjective well-being;
LUAD	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg04896959	chr15:78267971	NA	-0.5	-8.91	-0.4	1.56e-17	Coronary artery disease or large artery stroke;
LUAD	trans	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg06606381	chr12:133084897	FBRSL1	-1.26	-11.73	-0.5	1.01e-27	Depression;
LUAD	cis	rs10129255	0.500	rs8021941	chr14:107189727	C/T	cg23076370	chr14:107095027	NA	-0.44	-8.73	-0.39	5.83e-17	Kawasaki disease;
LUAD	trans	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.94	-16.53	-0.63	1e-47	Colorectal cancer;
LUAD	trans	rs1667255	0.830	rs2034404	chr18:29156302	A/G	cg11240634	chr11:69519263	FGF19	0.37	6.85	0.32	2.65e-11	Retinol levels;
LUAD	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg08027265	chr7:2291960	NA	-0.43	-7.07	-0.33	6.28e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs3806843	0.607	rs246060	chr5:140324749	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7274811	0.711	rs373618	chr20:31992639	C/A	cg13403462	chr20:32256071	NECAB3;C20orf134	0.43	6.49	0.3	2.44e-10	Height;
LUAD	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg23958373	chr8:599963	NA	1.03	9.64	0.42	5.29e-20	IgG glycosylation;
LUAD	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg22920501	chr2:26401640	FAM59B	-0.96	-14.2	-0.57	1.07e-37	Gut microbiome composition (summer);
LUAD	cis	rs9948	0.655	rs62156221	chr2:97410850	A/G	cg20312557	chr2:97357134	FER1L5	-0.72	-8.18	-0.37	3.27e-15	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg05697835	chr1:2722811	NA	0.29	6.77	0.31	4.29e-11	Ulcerative colitis;
LUAD	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg02569458	chr12:86230093	RASSF9	0.38	7.28	0.33	1.62e-12	Major depressive disorder;
LUAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg00106254	chr7:1943704	MAD1L1	-0.51	-7.71	-0.35	9.06e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg18827107	chr12:86230957	RASSF9	-0.7	-12.92	-0.53	2.12e-32	Major depressive disorder;
LUAD	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	8.98	0.4	9.27e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs11088226	0.645	rs2833904	chr21:33941089	T/C	cg09050820	chr6:167586206	TCP10L2	0.91	12.45	0.52	1.63e-30	Gastritis;
LUAD	cis	rs113835537	0.529	rs57207756	chr11:66270360	C/T	cg24851651	chr11:66362959	CCS	0.56	9.72	0.43	2.64e-20	Airway imaging phenotypes;
LUAD	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18404041	chr3:52824283	ITIH1	-0.57	-11.88	-0.5	2.72e-28	Electroencephalogram traits;
LUAD	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg11845111	chr2:191398756	TMEM194B	-0.84	-11.26	-0.48	6.81e-26	Diastolic blood pressure;
LUAD	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.39	-6.44	-0.3	3.21e-10	Personality dimensions;
LUAD	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg20307385	chr11:47447363	PSMC3	0.65	10.91	0.47	1.43e-24	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.34	-0.34	1.1e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs6688613	0.685	rs2142615	chr1:166922731	G/C	cg07049167	chr1:166818506	POGK	0.53	7.78	0.35	5.62e-14	Refractive astigmatism;
LUAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	12.97	0.53	1.3e-32	Prudent dietary pattern;
LUAD	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.79	0.31	3.83e-11	Rheumatoid arthritis;
LUAD	cis	rs4380275	0.782	rs4468850	chr2:749467	G/T	cg21665850	chr2:731073	NA	0.36	6.52	0.3	2.05e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg17063962	chr7:91808500	NA	0.7	12.62	0.52	3.3e-31	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14122300	chr14:69446504	ACTN1	-0.39	-6.57	-0.3	1.51e-10	Height;
LUAD	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg20503657	chr10:835505	NA	-0.76	-10.33	-0.45	1.92e-22	Eosinophil percentage of granulocytes;
LUAD	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.98	-0.32	1.15e-11	Neuroticism;
LUAD	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg03433033	chr1:76189801	ACADM	-0.48	-7.01	-0.32	9.57e-12	Daytime sleep phenotypes;
LUAD	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg27068330	chr11:65405492	SIPA1	-0.76	-11.64	-0.49	2.4200000000000002e-27	Acne (severe);
LUAD	cis	rs7903847	0.620	rs11189168	chr10:99125769	T/C	cg20016023	chr10:99160130	RRP12	-0.28	-6.9	-0.32	1.93e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs12541635	0.639	rs1032545	chr8:107005825	C/T	cg10147462	chr8:107024639	NA	0.56	10.31	0.45	2.12e-22	Age of smoking initiation;
LUAD	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg19875535	chr5:140030758	IK	0.47	7.71	0.35	8.78e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6430585	0.697	rs115944351	chr2:136515458	G/A	cg07169764	chr2:136633963	MCM6	0.79	9.03	0.4	6e-18	Corneal structure;
LUAD	cis	rs11674184	0.632	rs17529680	chr2:11727087	A/C	cg07314298	chr2:11723111	GREB1	0.69	12.62	0.52	3.28e-31	Endometriosis;
LUAD	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg25753631	chr6:25732923	NA	-0.44	-7.76	-0.35	6.26e-14	Iron status biomarkers;
LUAD	cis	rs17739167	0.550	rs11070354	chr15:42233211	C/T	cg20935245	chr15:42234343	EHD4	0.43	7.36	0.34	9.5e-13	Monocyte count;
LUAD	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.62	0.31	1.12e-10	Cognitive test performance;
LUAD	cis	rs68170813	0.559	rs7803290	chr7:106907353	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-10.66	-0.46	1.2e-23	Coronary artery disease;
LUAD	cis	rs3925075	0.553	rs3087796	chr16:31343653	A/G	cg10451425	chr16:31478370	ARMC5	0.4	6.51	0.3	2.16e-10	IgA nephropathy;
LUAD	cis	rs3845702	0.866	rs3914458	chr2:180862606	A/G	cg01881094	chr2:180872142	CWC22	-0.57	-7.28	-0.33	1.65e-12	Schizophrenia;
LUAD	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg08280861	chr8:58055591	NA	0.55	7.48	0.34	4.21e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg08601574	chr20:25228251	PYGB	0.47	8.56	0.38	2.17e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06112835	chr11:68658793	MRPL21	-0.48	-8.76	-0.39	4.59e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg13393036	chr8:95962371	TP53INP1	0.32	7.03	0.32	8.15e-12	Type 2 diabetes;
LUAD	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg17509989	chr5:176798049	RGS14	-0.62	-9.46	-0.42	2.16e-19	Urate levels in lean individuals;
LUAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg24642844	chr7:1081250	C7orf50	-0.83	-12.57	-0.52	5.4e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6993813	0.837	rs4335155	chr8:120013469	A/C	cg01975934	chr8:119970761	NA	-0.34	-6.72	-0.31	5.88e-11	Bone mineral density (hip);
LUAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg13047869	chr3:10149882	C3orf24	0.66	9.99	0.44	2.97e-21	Alzheimer's disease;
LUAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg11062466	chr8:58055876	NA	0.67	8.87	0.4	2.01e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs8073060	0.586	rs225278	chr17:33974170	C/T	cg19694781	chr19:47549865	TMEM160	-1.24	-19.49	-0.69	7.95e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg10589385	chr1:150898437	SETDB1	0.4	7.33	0.34	1.21e-12	Melanoma;
LUAD	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.41	-7.23	-0.33	2.32e-12	Longevity;Endometriosis;
LUAD	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg20307385	chr11:47447363	PSMC3	0.52	7.65	0.35	1.35e-13	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs10193935	0.901	rs6544529	chr2:42510652	A/T	cg27598129	chr2:42591480	NA	-0.79	-10.17	-0.44	6.75e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.53	-0.3	1.9e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg00953403	chr17:74099816	EXOC7	-0.5	-7.31	-0.33	1.31e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg16606324	chr3:10149918	C3orf24	0.67	9.97	0.44	3.59e-21	Alzheimer's disease;
LUAD	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.28	0.33	1.64e-12	Platelet count;
LUAD	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg08807101	chr21:30365312	RNF160	0.52	8.89	0.4	1.83e-17	Dental caries;
LUAD	cis	rs7493	0.851	rs11770903	chr7:95026327	A/G	cg17330251	chr7:94953956	PON1	-0.56	-7.95	-0.36	1.77e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs367943	0.698	rs728915	chr5:112995748	C/T	cg12552261	chr5:112820674	MCC	0.51	9.06	0.4	5.02e-18	Type 2 diabetes;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08644924	chr19:14117541	RFX1	-0.44	-7.4	-0.34	7.44e-13	Cancer;
LUAD	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg21984481	chr17:79567631	NPLOC4	0.71	17.04	0.64	5.93e-50	Eye color traits;
LUAD	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg26677194	chr12:130822605	PIWIL1	0.55	9.09	0.4	3.86e-18	Menopause (age at onset);
LUAD	cis	rs28647808	0.881	rs28617580	chr9:136252952	G/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.71	-6.39	-0.3	4.38e-10	Blood protein levels;
LUAD	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-7.59	-0.35	2e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7010267	0.902	rs7006553	chr8:119970779	C/T	cg01975934	chr8:119970761	NA	-0.41	-7.74	-0.35	7.43e-14	Total body bone mineral density (age 45-60);
LUAD	cis	rs3784262	1.000	rs7165247	chr15:58251786	C/T	cg12031962	chr15:58353849	ALDH1A2	0.46	9.71	0.43	3.06e-20	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg26022315	chr17:47021804	SNF8	0.41	7.43	0.34	6.03e-13	Type 2 diabetes;
LUAD	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg06618935	chr21:46677482	NA	-0.51	-10.02	-0.44	2.32e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.81	0.31	3.32e-11	Cardiac Troponin-T levels;
LUAD	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg18404041	chr3:52824283	ITIH1	0.41	7.56	0.35	2.53e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6442522	0.867	rs12637268	chr3:15500248	T/C	cg16303742	chr3:15540471	COLQ	0.38	6.56	0.3	1.55e-10	Uric acid levels;
LUAD	cis	rs6541297	0.645	rs648456	chr1:230311918	G/A	cg20703242	chr1:230279135	GALNT2	-0.47	-6.89	-0.32	2.05e-11	Coronary artery disease;
LUAD	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.54	-9.17	-0.41	2.04e-18	Longevity;Endometriosis;
LUAD	cis	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg05084668	chr3:125655381	ALG1L	-0.63	-10.09	-0.44	1.37e-21	Blood pressure (smoking interaction);
LUAD	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg10518543	chr12:38710700	ALG10B	-0.46	-7.51	-0.34	3.43e-13	Morning vs. evening chronotype;
LUAD	cis	rs11771526	0.892	rs62457504	chr7:32336097	G/A	cg13207630	chr7:32358064	NA	0.69	7.94	0.36	1.79e-14	Body mass index;
LUAD	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg05754148	chr16:3507555	NAT15	0.5	6.84	0.32	2.72e-11	Body mass index (adult);
LUAD	cis	rs6761276	0.899	rs11891557	chr2:113835319	G/A	cg06383401	chr2:113825234	IL1F10	-0.3	-6.41	-0.3	3.97e-10	Protein quantitative trait loci;
LUAD	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22307029	chr19:49891270	CCDC155	0.77	12.42	0.52	2.01e-30	Multiple sclerosis;
LUAD	cis	rs4604732	0.812	rs6663238	chr1:247624971	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.35	-6.49	-0.3	2.44e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.4e-12	Lung cancer;
LUAD	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg27539214	chr16:67997921	SLC12A4	0.62	7.42	0.34	6.68e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg01849466	chr14:104193079	ZFYVE21	0.46	7.67	0.35	1.19e-13	Body mass index;
LUAD	cis	rs2286503	0.752	rs2286504	chr7:22854847	G/T	cg06496272	chr7:22895283	SNORD93	-0.38	-6.51	-0.3	2.07e-10	Fibrinogen;
LUAD	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.84	0.32	2.71e-11	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg01191920	chr7:158217561	PTPRN2	-0.74	-16.17	-0.62	3.83e-46	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg17366294	chr4:99064904	C4orf37	-0.67	-13.06	-0.54	5.69e-33	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17152411	1.000	rs1807099	chr10:126593774	C/T	cg07906193	chr10:126599966	NA	0.53	7.6	0.35	1.95e-13	Height;
LUAD	cis	rs4285028	0.848	rs77630152	chr3:121681194	C/T	cg11130432	chr3:121712080	ILDR1	-0.59	-8.44	-0.38	5.05e-16	Multiple sclerosis;
LUAD	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.67	12.56	0.52	5.69e-31	Cognitive ability;
LUAD	cis	rs57994353	1.000	rs57994353	chr9:139356987	T/C	cg14169450	chr9:139327907	INPP5E	0.42	6.94	0.32	1.51e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs11971779	0.523	rs10279160	chr7:139090761	A/G	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg00339695	chr16:24857497	SLC5A11	-0.71	-11.56	-0.49	4.67e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6460942	1.000	rs17668923	chr7:12302873	A/T	cg20607287	chr7:12443886	VWDE	-0.49	-6.5	-0.3	2.24e-10	Coronary artery disease;
LUAD	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg11502198	chr6:26597334	ABT1	0.54	9.1	0.4	3.68e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg08859206	chr1:53392774	SCP2	0.63	11.43	0.49	1.44e-26	Monocyte count;
LUAD	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-7.8	-0.35	4.75e-14	Blood metabolite levels;
LUAD	cis	rs897984	0.806	rs10782001	chr16:30942625	G/A	cg02466173	chr16:30829666	NA	0.67	12.49	0.52	1.1e-30	Dementia with Lewy bodies;
LUAD	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg13319975	chr6:146136371	FBXO30	-0.62	-10.7	-0.46	8.64e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg14061069	chr19:46274453	DMPK	-0.32	-6.47	-0.3	2.66e-10	Coronary artery disease;
LUAD	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg24562669	chr7:97807699	LMTK2	-0.32	-7.82	-0.36	4.14e-14	Breast cancer;
LUAD	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.57	0.3	1.46e-10	Breast cancer;
LUAD	cis	rs600231	0.706	rs1111934	chr11:65329392	A/G	cg17120908	chr11:65337727	SSSCA1	-0.7	-11.01	-0.47	5.73e-25	Bone mineral density;
LUAD	cis	rs1600249	0.562	rs17153419	chr8:11394233	C/T	cg27411982	chr8:10470053	RP1L1	-0.46	-7.67	-0.35	1.23e-13	Rheumatoid arthritis;
LUAD	cis	rs56283067	0.504	rs62436021	chr6:44705375	C/A	cg20913747	chr6:44695427	NA	-0.41	-6.53	-0.3	1.88e-10	Total body bone mineral density;
LUAD	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg22875332	chr1:76189707	ACADM	0.87	16.13	0.62	5.92e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs863345	0.604	rs6666609	chr1:158498124	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.6	-0.31	1.24e-10	Pneumococcal bacteremia;
LUAD	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.55	-6.95	-0.32	1.39e-11	Body mass index;
LUAD	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg21775007	chr8:11205619	TDH	0.54	9.61	0.42	6.51e-20	Retinal vascular caliber;
LUAD	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg04944784	chr2:26401820	FAM59B	0.89	12.59	0.52	4.15e-31	Gut microbiome composition (summer);
LUAD	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19346786	chr7:2764209	NA	-0.55	-12.0	-0.5	9.78e-29	Height;
LUAD	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg09324608	chr17:30823087	MYO1D	0.48	9.15	0.41	2.39e-18	Schizophrenia;
LUAD	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg07061783	chr6:25882402	NA	-0.6	-9.38	-0.42	3.95e-19	Urate levels;
LUAD	cis	rs1997103	0.954	rs7811098	chr7:55413012	A/G	cg17469321	chr7:55412551	NA	0.66	11.21	0.48	1.05e-25	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	7.28	0.33	1.66e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs2230307	0.505	rs641458	chr1:100578672	G/C	cg20868668	chr1:100435035	SLC35A3	-0.54	-7.78	-0.35	5.78e-14	Carotid intima media thickness;
LUAD	cis	rs593982	0.920	rs72922791	chr11:65567395	G/A	cg08755490	chr11:65554678	OVOL1	-1.18	-13.76	-0.56	7.24e-36	Atopic dermatitis;
LUAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08219700	chr8:58056026	NA	0.63	8.82	0.39	2.92e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.77	-0.43	1.77e-20	Gut microbiome composition (summer);
LUAD	trans	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	15.9	0.61	5.61e-45	Exhaled nitric oxide levels;
LUAD	cis	rs6922632	0.867	rs62400306	chr6:24111980	A/C	cg26194775	chr6:24126114	NRSN1	-0.59	-9.47	-0.42	2.06e-19	Information processing speed;
LUAD	trans	rs4799710	0.935	rs10048235	chr18:31254013	G/A	cg27147174	chr7:100797783	AP1S1	-0.42	-6.7	-0.31	6.67e-11	Pulmonary function;
LUAD	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg10053473	chr17:62856997	LRRC37A3	0.65	10.64	0.46	1.39e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg22875332	chr1:76189707	ACADM	0.71	10.68	0.46	9.95e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.41	-0.34	7.02e-13	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs870825	0.616	rs6817521	chr4:185649827	A/G	cg04058563	chr4:185651563	MLF1IP	-0.8	-12.97	-0.53	1.32e-32	Blood protein levels;
LUAD	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg05340658	chr4:99064831	C4orf37	0.54	8.74	0.39	5.49e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7223966	0.729	rs2003549	chr17:62008437	C/T	cg11494091	chr17:61959527	GH2	0.46	8.18	0.37	3.33e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs116248771	0.691	rs2363658	chr3:158395866	G/C	cg16708174	chr3:158430962	RARRES1	0.47	6.8	0.31	3.56e-11	diarrhoeal disease at age 2;
LUAD	cis	rs13067306	1.000	rs13067306	chr3:94243713	C/T	cg16274205	chr3:94243571	NA	0.42	6.63	0.31	1.02e-10	Blood pressure measurement (high sodium intervention);
LUAD	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg09184832	chr6:79620586	NA	-0.51	-9.6	-0.42	7.37e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs3736594	1.000	rs3736594	chr2:27995781	A/C	cg27432699	chr2:27873401	GPN1	-0.44	-6.99	-0.32	1.08e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg01579765	chr21:45077557	HSF2BP	-0.6	-13.47	-0.55	1.17e-34	Mean corpuscular volume;
LUAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06873352	chr17:61820015	STRADA	0.82	18.29	0.66	1.79e-55	Prudent dietary pattern;
LUAD	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg12863693	chr15:85201151	NMB	0.38	6.43	0.3	3.46e-10	Schizophrenia;
LUAD	cis	rs367943	0.608	rs4705463	chr5:112980273	C/G	cg12552261	chr5:112820674	MCC	0.45	8.23	0.37	2.42e-15	Type 2 diabetes;
LUAD	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg23815491	chr16:72088622	HP	-0.45	-7.81	-0.35	4.56e-14	Fibrinogen levels;
LUAD	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg15997130	chr1:24165203	NA	0.56	10.07	0.44	1.6e-21	Immature fraction of reticulocytes;
LUAD	cis	rs6076065	0.630	rs6083127	chr20:23424886	T/C	cg11657817	chr20:23433608	CST11	0.64	13.47	0.55	1.13e-34	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1018836	0.923	rs62526886	chr8:91627676	G/A	cg16814680	chr8:91681699	NA	-0.72	-12.2	-0.51	1.54e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg13126279	chr21:47581558	C21orf56	-0.42	-7.33	-0.34	1.14e-12	Testicular germ cell tumor;
LUAD	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg24069376	chr3:38537580	EXOG	0.37	8.56	0.38	2.18e-16	Electrocardiographic conduction measures;
LUAD	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.59	-11.05	-0.47	4.22e-25	Longevity;Endometriosis;
LUAD	trans	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.69	-9.2	-0.41	1.61e-18	Obesity-related traits;
LUAD	cis	rs10823500	0.777	rs2184335	chr10:72006891	C/T	cg02100629	chr10:71892760	AIFM2	-0.37	-7.41	-0.34	6.96e-13	Blood protein levels;
LUAD	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg11266682	chr4:10021025	SLC2A9	-0.62	-14.36	-0.57	2.29e-38	Bone mineral density;
LUAD	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg20908204	chr19:46285434	DMPK	-0.43	-9.84	-0.43	1.03e-20	Coronary artery disease;
LUAD	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg11814155	chr7:99998594	ZCWPW1	0.45	7.76	0.35	6.23e-14	Platelet count;
LUAD	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.78	-13.32	-0.54	4.78e-34	Chronic sinus infection;
LUAD	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg09365446	chr1:150670422	GOLPH3L	0.66	12.34	0.51	4.22e-30	Tonsillectomy;
LUAD	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.39	-6.57	-0.3	1.48e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg01181863	chr3:195395398	SDHAP2	-0.55	-8.34	-0.38	1.09e-15	Pancreatic cancer;
LUAD	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.86	12.37	0.52	3.34e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg17652424	chr22:38574118	PLA2G6	-0.33	-10.13	-0.44	9.75e-22	Cutaneous nevi;
LUAD	cis	rs12976411	0.575	rs73927590	chr19:32821559	G/C	cg18253629	chr19:32836317	ZNF507	0.65	6.84	0.32	2.87e-11	Coronary artery disease;
LUAD	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg13390004	chr1:15929781	NA	0.49	8.6	0.39	1.6e-16	Systolic blood pressure;
LUAD	cis	rs62238980	0.614	rs743763	chr22:32458861	C/T	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs250677	0.522	rs1007400	chr5:148382635	C/T	cg18129178	chr5:148520854	ABLIM3	0.47	7.31	0.33	1.33e-12	Breast cancer;
LUAD	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg19825600	chr2:3704501	ALLC	-0.42	-7.71	-0.35	8.95e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs6761276	0.525	rs12711752	chr2:113837840	C/T	cg09040174	chr2:113837401	NA	-0.63	-10.9	-0.47	1.5e-24	Protein quantitative trait loci;
LUAD	cis	rs6993813	0.620	rs4546691	chr8:120025004	G/A	cg01975934	chr8:119970761	NA	-0.34	-6.49	-0.3	2.37e-10	Bone mineral density (hip);
LUAD	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg08676812	chr11:65308423	LTBP3	1.0	7.76	0.35	6.51e-14	Height;
LUAD	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg22823121	chr1:150693482	HORMAD1	0.44	8.91	0.4	1.55e-17	Tonsillectomy;
LUAD	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg11189052	chr15:85197271	WDR73	-0.61	-10.01	-0.44	2.65e-21	P wave terminal force;
LUAD	cis	rs7680126	0.586	rs7689060	chr4:10305463	C/G	cg00071950	chr4:10020882	SLC2A9	0.49	7.45	0.34	5.42e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs4711350	0.723	rs623813	chr6:33703089	C/T	cg18005901	chr6:33739558	LEMD2	0.53	6.51	0.3	2.14e-10	Schizophrenia;
LUAD	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg22920501	chr2:26401640	FAM59B	-0.96	-14.23	-0.57	8.23e-38	Gut microbiome composition (summer);
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg15712289	chr18:12077147	NA	0.48	6.45	0.3	3.14e-10	Testicular germ cell tumor;
LUAD	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg05368731	chr17:41323189	NBR1	0.96	19.4	0.69	2.05e-60	Menopause (age at onset);
LUAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.96	-0.32	1.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9393692	0.557	rs17608582	chr6:26318799	C/A	cg00631329	chr6:26305371	NA	-0.56	-9.44	-0.42	2.62e-19	Educational attainment;
LUAD	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg06697600	chr4:7070879	GRPEL1	0.56	7.93	0.36	2.02e-14	Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg18402987	chr7:1209562	NA	0.62	8.93	0.4	1.3e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2731664	0.792	rs337374	chr5:176890416	A/G	cg23176889	chr5:176863531	GRK6	0.73	14.5	0.58	5.58e-39	Intelligence (multi-trait analysis);
LUAD	trans	rs4714291	0.963	rs1721409	chr6:40112439	A/T	cg02267698	chr19:7991119	CTXN1	0.44	6.62	0.31	1.06e-10	Strep throat;
LUAD	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.61	10.37	0.45	1.36e-22	Cognitive ability;
LUAD	cis	rs6494488	0.500	rs1133357	chr15:64987570	G/A	cg08069370	chr15:64387884	SNX1	-0.76	-6.83	-0.32	2.97e-11	Coronary artery disease;
LUAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg18621852	chr3:10150065	C3orf24	0.48	8.42	0.38	6.12e-16	Alzheimer's disease;
LUAD	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg21775007	chr8:11205619	TDH	0.54	9.69	0.43	3.48e-20	Retinal vascular caliber;
LUAD	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg06740227	chr12:86229804	RASSF9	0.4	6.98	0.32	1.14e-11	Major depressive disorder;
LUAD	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg07061783	chr6:25882402	NA	0.52	8.27	0.37	1.81e-15	Blood metabolite levels;
LUAD	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg11189052	chr15:85197271	WDR73	0.68	9.05	0.4	5.38e-18	Schizophrenia;
LUAD	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg15110403	chr19:17392923	ANKLE1	-0.46	-7.62	-0.35	1.72e-13	Systemic lupus erythematosus;
LUAD	cis	rs427394	0.659	rs274725	chr5:6717408	C/G	cg12316010	chr5:6737918	POLS	0.39	7.47	0.34	4.49e-13	Menopause (age at onset);
LUAD	cis	rs34375054	0.735	rs34961756	chr12:125628598	C/T	cg06287003	chr12:125626642	AACS	-0.43	-7.43	-0.34	5.93e-13	Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs10992471	0.528	rs10820975	chr9:95211922	T/G	cg14631576	chr9:95140430	CENPP	-0.5	-10.17	-0.44	7.21e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs1160297	0.576	rs6754423	chr2:53096730	G/A	cg07782112	chr2:53107842	NA	0.41	8.83	0.39	2.71e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg14773178	chr5:1868261	NA	0.33	6.47	0.3	2.66e-10	Cardiovascular disease risk factors;
LUAD	cis	rs4285028	0.848	rs77630152	chr3:121681194	C/T	cg20356878	chr3:121714668	ILDR1	-0.5	-6.76	-0.31	4.51e-11	Multiple sclerosis;
LUAD	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg27211696	chr2:191398769	TMEM194B	-0.65	-8.35	-0.38	1.01e-15	Diastolic blood pressure;
LUAD	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg11301795	chr4:187892539	NA	-0.76	-14.89	-0.59	1.27e-40	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg02421172	chr7:1938701	MAD1L1	0.46	6.74	0.31	5.13e-11	Bipolar disorder;
LUAD	cis	rs9314323	0.592	rs12165	chr8:26269412	C/T	cg13160058	chr8:26243215	BNIP3L	-0.37	-8.04	-0.36	8.8e-15	Red cell distribution width;
LUAD	cis	rs4631830	0.720	rs2611512	chr10:51515534	A/G	cg20129853	chr10:51489980	NA	-0.34	-6.7	-0.31	6.86e-11	Prostate-specific antigen levels;
LUAD	cis	rs6545883	0.929	rs2593627	chr2:61618574	T/C	cg15711740	chr2:61764176	XPO1	0.41	6.45	0.3	2.97e-10	Tuberculosis;
LUAD	cis	rs8112211	0.731	rs118185142	chr19:38821709	G/A	cg01275006	chr19:38876250	GGN	-0.5	-6.5	-0.3	2.23e-10	Blood protein levels;
LUAD	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg08470875	chr2:26401718	FAM59B	-0.73	-10.34	-0.45	1.72e-22	Gut microbiome composition (summer);
LUAD	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg02931644	chr1:25747376	RHCE	0.43	9.19	0.41	1.81e-18	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg06028605	chr16:24865363	SLC5A11	0.41	7.33	0.34	1.15e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg25894440	chr7:65020034	NA	-0.69	-7.33	-0.34	1.21e-12	Diabetic kidney disease;
LUAD	cis	rs77741769	0.591	rs73413868	chr12:121301732	T/C	cg02419362	chr12:121203948	SPPL3	0.41	8.28	0.37	1.68e-15	Mean corpuscular volume;
LUAD	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg14196790	chr5:131705035	SLC22A5	0.48	8.6	0.39	1.55e-16	Breast cancer;Mosquito bite size;
LUAD	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg20891283	chr12:69753455	YEATS4	0.46	7.52	0.34	3.32e-13	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg22105103	chr4:187893119	NA	0.57	12.47	0.52	1.35e-30	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg16414030	chr3:133502952	NA	-0.45	-8.13	-0.37	4.8e-15	Iron status biomarkers;
LUAD	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg26528668	chr16:1614120	IFT140	0.51	8.95	0.4	1.1e-17	Coronary artery disease;
LUAD	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg15839431	chr19:19639596	YJEFN3	-0.53	-8.1	-0.37	5.74e-15	Bipolar disorder;
LUAD	cis	rs684232	0.835	rs1833459	chr17:562244	C/T	cg15660573	chr17:549704	VPS53	-0.42	-6.68	-0.31	7.76e-11	Prostate cancer;
LUAD	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg24450063	chr1:156163899	SLC25A44	1.02	18.39	0.67	6e-56	Testicular germ cell tumor;
LUAD	cis	rs7528419	1.000	rs646776	chr1:109818530	C/T	cg00908766	chr1:109817496	CELSR2	0.73	14.56	0.58	3.35e-39	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUAD	cis	rs57994353	0.865	rs34376913	chr9:139378914	T/C	cg14364472	chr9:139394549	NOTCH1	-0.45	-6.87	-0.32	2.24e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg15181151	chr6:150070149	PCMT1	0.41	8.56	0.38	2.13e-16	Lung cancer;
LUAD	cis	rs2692947	0.644	rs1030864	chr2:96822373	A/G	cg23100626	chr2:96804247	ASTL	0.4	10.56	0.46	2.63e-23	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg17279839	chr7:150038598	RARRES2	0.42	7.03	0.32	8.46e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg04025307	chr7:1156635	C7orf50	0.6	6.77	0.31	4.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg02493740	chr2:85810744	VAMP5	-0.62	-11.33	-0.48	3.74e-26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs739496	0.895	rs2073950	chr12:111894072	C/T	cg10833066	chr12:111807467	FAM109A	0.4	6.39	0.3	4.37e-10	Platelet count;
LUAD	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22307029	chr19:49891270	CCDC155	0.67	9.64	0.42	5.17e-20	Multiple sclerosis;
LUAD	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg25985355	chr7:65971099	NA	-0.51	-6.41	-0.3	3.8e-10	Diabetic kidney disease;
LUAD	trans	rs62458065	0.850	rs73096034	chr7:32472048	A/G	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.44	-0.34	5.76e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.9	0.36	2.43e-14	Breast cancer;
LUAD	cis	rs684232	0.602	rs394747	chr17:562495	C/G	cg15660573	chr17:549704	VPS53	0.87	18.48	0.67	2.54e-56	Prostate cancer;
LUAD	cis	rs72928364	1.000	rs13072788	chr3:100738212	A/T	cg10123952	chr3:100791384	NA	0.64	7.49	0.34	4.12e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg12863693	chr15:85201151	NMB	0.39	6.96	0.32	1.27e-11	Schizophrenia;
LUAD	cis	rs61897795	0.657	rs174587	chr11:61612830	C/T	cg21709803	chr11:61594965	FADS2	-0.45	-6.9	-0.32	1.88e-11	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg12927641	chr6:109611667	NA	-0.52	-9.05	-0.4	5.08e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs9473147	0.516	rs9349416	chr6:47551938	G/A	cg02130027	chr6:47444894	CD2AP	0.34	6.61	0.31	1.19e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg07266350	chr3:49460521	AMT;NICN1	-0.36	-6.38	-0.3	4.75e-10	Menarche (age at onset);
LUAD	cis	rs7527798	0.592	rs2296159	chr1:207851760	G/A	cg09232269	chr1:207846808	CR1L	-0.35	-6.55	-0.3	1.68e-10	Erythrocyte sedimentation rate;
LUAD	cis	rs11811982	0.793	rs115767103	chr1:227510306	A/G	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg07917127	chr4:99064746	C4orf37	0.4	6.62	0.31	1.06e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg20701182	chr2:24300061	SF3B14	0.47	6.48	0.3	2.53e-10	Asthma;
LUAD	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.95	-0.36	1.76e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg00280220	chr17:61926910	NA	0.36	6.98	0.32	1.12e-11	Prudent dietary pattern;
LUAD	trans	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg09872104	chr7:134855509	C7orf49	-0.82	-6.81	-0.31	3.44e-11	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs7408868	1.000	rs7254735	chr19:15263385	A/G	cg14696996	chr19:15285081	NOTCH3	0.71	9.29	0.41	8.33e-19	Pulse pressure;
LUAD	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg12458913	chr13:53173898	NA	0.46	8.4	0.38	6.76e-16	Lewy body disease;
LUAD	cis	rs6594713	0.819	rs10061462	chr5:112726205	A/T	cg12552261	chr5:112820674	MCC	0.5	8.14	0.37	4.41e-15	Brain cytoarchitecture;
LUAD	cis	rs62400317	0.826	rs62400290	chr6:45209788	C/T	cg18551225	chr6:44695536	NA	-0.57	-8.63	-0.39	1.22e-16	Total body bone mineral density;
LUAD	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg00933542	chr6:150070202	PCMT1	0.44	9.05	0.4	5.25e-18	Lung cancer;
LUAD	cis	rs3764563	0.735	rs62106282	chr19:15727124	T/C	cg20725493	chr19:15740067	CYP4F8	-0.64	-7.1	-0.33	5.29e-12	Inflammatory biomarkers;
LUAD	cis	rs1448094	0.935	rs10746355	chr12:86330227	A/T	cg18827107	chr12:86230957	RASSF9	-0.44	-7.82	-0.36	4.18e-14	Major depressive disorder;
LUAD	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg19767477	chr5:127420684	SLC12A2	-0.44	-6.75	-0.31	4.94e-11	Ileal carcinoids;
LUAD	cis	rs7301016	0.846	rs11174568	chr12:63021157	T/C	cg11441379	chr12:63026424	NA	0.64	7.84	0.36	3.57e-14	IgG glycosylation;
LUAD	cis	rs6437061	0.737	rs3116191	chr2:233049441	G/A	ch.2.233013039R	chr2:233304795	NA	-0.4	-6.49	-0.3	2.37e-10	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg19635926	chr16:89946313	TCF25	0.72	6.59	0.31	1.29e-10	Skin colour saturation;
LUAD	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg13010199	chr12:38710504	ALG10B	-0.38	-6.35	-0.3	5.48e-10	Bladder cancer;
LUAD	cis	rs7617773	0.780	rs71323396	chr3:48374734	T/G	cg11946769	chr3:48343235	NME6	0.45	6.86	0.32	2.46e-11	Coronary artery disease;
LUAD	cis	rs68170813	0.559	rs76020313	chr7:106877468	A/G	cg02696742	chr7:106810147	HBP1	-0.76	-10.5	-0.45	4.56e-23	Coronary artery disease;
LUAD	cis	rs1868673	0.965	rs6792759	chr3:150138424	C/T	cg04908077	chr3:150187338	NA	-0.31	-6.5	-0.3	2.21e-10	Waist circumference;
LUAD	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg04414720	chr1:150670196	GOLPH3L	0.73	12.8	0.53	6.25e-32	Melanoma;
LUAD	cis	rs4253772	0.626	rs9615960	chr22:46752307	G/A	cg09491104	chr22:46646882	C22orf40	-0.56	-6.63	-0.31	1.05e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg15147215	chr3:52552868	STAB1	-0.39	-7.19	-0.33	2.99e-12	Bipolar disorder;
LUAD	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg02734326	chr4:10020555	SLC2A9	0.43	7.35	0.34	1.01e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg18016565	chr1:150552671	MCL1	-0.46	-8.16	-0.37	3.8e-15	Blood protein levels;
LUAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg24829409	chr8:58192753	C8orf71	-0.6	-7.6	-0.35	1.94e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg25173405	chr17:45401733	C17orf57	-0.55	-9.39	-0.42	3.83e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2625529	0.824	rs12901886	chr15:72408069	G/A	cg16672083	chr15:72433130	SENP8	-0.75	-12.66	-0.52	2.33e-31	Red blood cell count;
LUAD	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.73	0.31	5.62e-11	Aortic root size;
LUAD	trans	rs9467711	0.720	rs7749823	chr6:26158079	A/C	cg06606381	chr12:133084897	FBRSL1	-0.64	-6.8	-0.31	3.59e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg02569458	chr12:86230093	RASSF9	0.46	8.37	0.38	8.8e-16	Major depressive disorder;
LUAD	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg09365446	chr1:150670422	GOLPH3L	0.61	10.75	0.46	5.64e-24	Melanoma;
LUAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.63	-9.94	-0.44	4.65e-21	Renal function-related traits (BUN);
LUAD	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg24818145	chr4:99064322	C4orf37	0.5	8.61	0.39	1.47e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4662945	0.603	rs13002385	chr2:130276865	T/C	cg05903289	chr2:130345205	NA	-0.34	-7.32	-0.34	1.28e-12	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs6714710	0.603	rs34373359	chr2:98442202	G/A	cg26665480	chr2:98280029	ACTR1B	0.51	8.27	0.37	1.77e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg02269571	chr22:50332266	NA	-0.66	-9.64	-0.42	5.06e-20	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.98	0.32	1.12e-11	Schizophrenia;
LUAD	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg14343924	chr8:8086146	FLJ10661	0.46	7.25	0.33	2.05e-12	Mood instability;
LUAD	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg09222892	chr1:25734099	RHCE	-0.49	-9.15	-0.41	2.51e-18	Erythrocyte sedimentation rate;
LUAD	trans	rs2018683	0.707	rs2391717	chr7:28971162	G/C	cg19402173	chr7:128379420	CALU	-0.51	-8.13	-0.37	4.96e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	7.94e-19	Tonsillectomy;
LUAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg03188948	chr7:1209495	NA	0.68	9.85	0.43	9.39e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs89107	0.603	rs414091	chr6:118613398	T/C	cg18833306	chr6:118973337	C6orf204	0.55	10.15	0.44	8.22e-22	Cardiac structure and function;
LUAD	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.55	0.38	2.21e-16	Parkinson's disease;
LUAD	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg22681709	chr2:178499509	PDE11A	-0.49	-8.24	-0.37	2.18e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg18200150	chr17:30822561	MYO1D	-0.61	-12.03	-0.5	7.11e-29	Schizophrenia;
LUAD	cis	rs11051970	0.704	rs2733694	chr12:32555230	A/G	cg24626660	chr12:32551988	NA	0.34	7.23	0.33	2.21e-12	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg19761014	chr17:28927070	LRRC37B2	0.76	7.45	0.34	5.48e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg04455712	chr21:45112962	RRP1B	0.44	9.11	0.41	3.2e-18	Mean corpuscular volume;
LUAD	cis	rs17683430	0.702	rs76915002	chr22:32421694	T/C	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LUAD	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21659725	chr3:3221576	CRBN	0.69	11.28	0.48	5.58e-26	Resting heart rate;
LUAD	cis	rs1160297	0.609	rs10164801	chr2:53096014	C/T	cg07782112	chr2:53107842	NA	0.42	8.84	0.4	2.53e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2554380	0.843	rs1019665	chr15:84380619	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.47	-7.28	-0.33	1.6e-12	Height;
LUAD	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg14558114	chr2:88469736	THNSL2	0.65	6.6	0.31	1.23e-10	Plasma clusterin levels;
LUAD	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.58	0.3	1.35e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1232027	0.656	rs6151613	chr5:79961289	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg21951975	chr1:209979733	IRF6	0.58	7.08	0.33	6.05e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg12927641	chr6:109611667	NA	-0.55	-9.7	-0.43	3.31e-20	Reticulocyte fraction of red cells;
LUAD	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg10544611	chr16:67998164	SLC12A4	-0.67	-8.05	-0.36	8.57e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	9.83	0.43	1.14e-20	Lymphocyte percentage of white cells;
LUAD	trans	rs1493916	0.967	rs34341086	chr18:31400141	C/T	cg13755796	chr4:20253514	NA	-0.41	-6.79	-0.31	3.81e-11	Life satisfaction;
LUAD	cis	rs2004318	0.850	rs116885287	chr19:55077296	C/A	cg03320607	chr19:54800032	LILRA3	-0.72	-7.41	-0.34	6.93e-13	Blood protein levels;
LUAD	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg09509183	chr1:209979624	IRF6	0.59	6.87	0.32	2.27e-11	Coronary artery disease;
LUAD	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg18230493	chr5:56204884	C5orf35	-0.84	-12.19	-0.51	1.62e-29	Initial pursuit acceleration;
LUAD	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg25985355	chr7:65971099	NA	-0.38	-6.93	-0.32	1.59e-11	Aortic root size;
LUAD	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg03714773	chr7:91764589	CYP51A1	0.3	6.71	0.31	6.36e-11	Breast cancer;
LUAD	cis	rs9283706	0.608	rs1428408	chr5:66331203	T/C	cg11590213	chr5:66331682	MAST4	0.41	6.83	0.32	2.9100000000000002e-11	Coronary artery disease;
LUAD	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg04842962	chr6:43655489	MRPS18A	-1.06	-27.2	-0.8	6.54e-95	IgG glycosylation;
LUAD	cis	rs11811982	0.793	rs11810440	chr1:227267402	T/A	cg24860534	chr1:227506868	CDC42BPA	0.66	7.2	0.33	2.72e-12	Optic disc area;
LUAD	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg07169764	chr2:136633963	MCM6	0.81	9.36	0.41	4.88e-19	Corneal structure;
LUAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg24642844	chr7:1081250	C7orf50	-0.58	-9.34	-0.41	5.54e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs17539620	0.624	rs9918406	chr6:154844905	C/T	cg20019720	chr6:154832845	CNKSR3	0.6	11.01	0.47	5.8e-25	Lipoprotein (a) levels;
LUAD	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg11663144	chr21:46675770	NA	-0.61	-11.63	-0.49	2.46e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg09184832	chr6:79620586	NA	-0.53	-9.84	-0.43	1.07e-20	Intelligence (multi-trait analysis);
LUAD	trans	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg02002194	chr4:3960332	NA	-0.3	-7.31	-0.33	1.32e-12	Mood instability;
LUAD	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg03676636	chr4:99064102	C4orf37	0.3	7.12	0.33	4.76e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg23939001	chr4:940644	TMEM175	0.68	11.17	0.48	1.48e-25	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg18190219	chr22:46762943	CELSR1	-0.54	-6.66	-0.31	8.41e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg10556349	chr10:835070	NA	0.53	7.15	0.33	3.74e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg10435618	chr10:838112	NA	0.48	6.46	0.3	2.89e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs11971779	0.584	rs10236055	chr7:139069991	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.76	0.31	4.63e-11	Diisocyanate-induced asthma;
LUAD	cis	rs3784262	0.528	rs11071367	chr15:58354152	G/A	cg12031962	chr15:58353849	ALDH1A2	0.4	7.65	0.35	1.4e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs708547	0.599	rs1718864	chr4:57887471	G/A	cg00922110	chr4:57842668	C4orf14	-0.44	-8.13	-0.37	4.7e-15	Response to bleomycin (chromatid breaks);
LUAD	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg02569458	chr12:86230093	RASSF9	0.45	8.2	0.37	2.97e-15	Major depressive disorder;
LUAD	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg17595323	chr11:93583763	C11orf90	-0.43	-9.13	-0.41	2.88e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	trans	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21659725	chr3:3221576	CRBN	0.51	8.37	0.38	8.26e-16	Body mass index;
LUAD	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg19318889	chr4:1322082	MAEA	0.45	7.89	0.36	2.57e-14	Obesity-related traits;
LUAD	cis	rs9863	0.828	rs12303933	chr12:124482256	T/C	cg17723958	chr12:124429295	CCDC92	-0.4	-6.58	-0.3	1.36e-10	White blood cell count;
LUAD	cis	rs89107	0.934	rs281868	chr6:118574061	A/G	cg21191810	chr6:118973309	C6orf204	-0.45	-8.92	-0.4	1.47e-17	Cardiac structure and function;
LUAD	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-7.28	-0.33	1.68e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs1493916	0.870	rs1389531	chr18:31386616	C/T	cg15819921	chr19:927150	ARID3A	-0.45	-7.54	-0.34	2.8e-13	Life satisfaction;
LUAD	trans	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg14917512	chr19:3094685	GNA11	-0.57	-6.78	-0.31	4.13e-11	Diabetic kidney disease;
LUAD	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg03517284	chr6:25882590	NA	-0.39	-6.38	-0.3	4.61e-10	Height;
LUAD	cis	rs9287719	0.601	rs12995465	chr2:10716828	G/A	cg02196655	chr2:10830764	NOL10	-0.37	-6.44	-0.3	3.24e-10	Prostate cancer;
LUAD	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.63	-10.87	-0.47	1.87e-24	Lymphocyte counts;
LUAD	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	10.66	0.46	1.2e-23	Hip circumference adjusted for BMI;
LUAD	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg11915388	chr22:42470451	FAM109B	0.41	7.28	0.33	1.64e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg06740227	chr12:86229804	RASSF9	0.41	7.15	0.33	3.79e-12	Major depressive disorder;
LUAD	cis	rs2235649	0.833	rs9922139	chr16:1848329	G/T	cg08610935	chr16:1836813	NUBP2	-0.5	-7.64	-0.35	1.49e-13	Blood metabolite levels;
LUAD	cis	rs13082711	0.911	rs3816881	chr3:27432888	T/C	cg02860705	chr3:27208620	NA	0.56	8.76	0.39	4.91e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7705042	0.865	rs413214	chr5:141530157	G/A	cg08523384	chr5:141488047	NDFIP1	-0.4	-6.85	-0.32	2.58e-11	Asthma;
LUAD	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.37	-6.39	-0.3	4.32e-10	Schizophrenia;
LUAD	cis	rs73206853	0.841	rs56209636	chr12:110841998	T/C	cg12870014	chr12:110450643	ANKRD13A	0.64	7.17	0.33	3.47e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-8.65	-0.39	1.11e-16	Monocyte percentage of white cells;
LUAD	cis	rs2012796	0.743	rs8020575	chr14:81859521	G/A	cg02996355	chr14:81879375	NA	0.51	7.92	0.36	2.06e-14	Night sleep phenotypes;
LUAD	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg03874509	chr1:107600012	PRMT6	0.56	9.74	0.43	2.3e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg13047869	chr3:10149882	C3orf24	0.59	9.99	0.44	2.95e-21	Alzheimer's disease;
LUAD	trans	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg21659725	chr3:3221576	CRBN	-0.58	-9.21	-0.41	1.58e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	7.29	0.33	1.53e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg11266682	chr4:10021025	SLC2A9	0.68	15.54	0.6	2.04e-43	Bone mineral density;
LUAD	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.66	-9.48	-0.42	1.82e-19	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg27068330	chr11:65405492	SIPA1	-0.78	-12.73	-0.53	1.21e-31	Acne (severe);
LUAD	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg23625390	chr15:77176239	SCAPER	0.4	6.99	0.32	1.06e-11	Blood metabolite levels;
LUAD	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg27411982	chr8:10470053	RP1L1	0.42	7.25	0.33	1.94e-12	Retinal vascular caliber;
LUAD	cis	rs4711336	1.000	rs2296736	chr6:33656250	T/C	cg13859433	chr6:33739653	LEMD2	-0.29	-6.78	-0.31	4.12e-11	Height;
LUAD	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg22907277	chr7:1156413	C7orf50	0.49	8.07	0.37	7.49e-15	Longevity;Endometriosis;
LUAD	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg18854424	chr1:2615690	NA	-0.42	-9.07	-0.4	4.63e-18	Ulcerative colitis;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05749971	chr13:50655696	DLEU1;DLEU2	-0.61	-6.35	-0.3	5.62e-10	Type 2 diabetes;
LUAD	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg15181151	chr6:150070149	PCMT1	0.44	8.93	0.4	1.34e-17	Lung cancer;
LUAD	cis	rs2880765	0.525	rs35899940	chr15:86053697	A/G	cg13263323	chr15:86062960	AKAP13	-0.49	-8.17	-0.37	3.66e-15	Coronary artery disease;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg21028463	chr17:74733682	MIR636;SFRS2;MFSD11	-0.4	-6.75	-0.31	4.96e-11	Subcortical brain region volumes;
LUAD	trans	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg18187862	chr3:45730750	SACM1L	0.55	8.81	0.39	3.38e-17	Primary sclerosing cholangitis;
LUAD	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.67	0.31	8.24e-11	Schizophrenia;
LUAD	cis	rs6446731	0.517	rs2157093	chr4:3270913	C/G	cg08886695	chr4:3369023	RGS12	0.47	7.92	0.36	2.18e-14	Mean platelet volume;
LUAD	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg02782426	chr3:40428986	ENTPD3	0.35	7.52	0.34	3.39e-13	Renal cell carcinoma;
LUAD	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg27266060	chr8:22091797	NA	0.47	8.65	0.39	1.06e-16	Hypertriglyceridemia;
LUAD	cis	rs2901656	0.502	rs9425602	chr1:172383686	T/A	cg03748243	chr1:172413542	C1orf105;PIGC	-0.4	-7.38	-0.34	8.43e-13	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs4638749	0.677	rs4396668	chr2:108840364	C/T	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.42	-0.34	6.35e-13	Blood pressure;
LUAD	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg08677398	chr8:58056175	NA	0.53	6.81	0.31	3.31e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs669446	0.533	rs6429638	chr1:44211010	A/G	cg12908607	chr1:44402522	ARTN	-0.38	-7.39	-0.34	7.75e-13	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg08508325	chr11:3079039	CARS	-0.62	-13.83	-0.56	3.83e-36	Longevity;
LUAD	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg17366294	chr4:99064904	C4orf37	0.63	12.2	0.51	1.59e-29	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6701037	0.522	rs7521981	chr1:175091151	C/T	cg14847009	chr1:175162515	KIAA0040	-0.25	-6.51	-0.3	2.07e-10	Alcohol dependence;
LUAD	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	10.01	0.44	2.68e-21	Post bronchodilator FEV1;
LUAD	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg16049864	chr8:95962084	TP53INP1	-0.61	-13.58	-0.55	4.03e-35	Type 2 diabetes;
LUAD	cis	rs870825	0.616	rs28450662	chr4:185638900	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	14.12	0.57	2.26e-37	Blood protein levels;
LUAD	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg12863693	chr15:85201151	NMB	0.45	8.19	0.37	3.08e-15	Schizophrenia;
LUAD	cis	rs6005807	0.640	rs12171099	chr22:29076637	G/A	cg12565055	chr22:29076175	TTC28	0.77	8.94	0.4	1.21e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.49	6.69	0.31	7.1e-11	Renal function-related traits (BUN);
LUAD	cis	rs897984	0.568	rs67264578	chr16:30879395	G/A	cg05768032	chr16:30646687	NA	0.41	6.62	0.31	1.11e-10	Dementia with Lewy bodies;
LUAD	trans	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg06606381	chr12:133084897	FBRSL1	-0.94	-8.88	-0.4	1.91e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg02569458	chr12:86230093	RASSF9	-0.44	-8.18	-0.37	3.24e-15	Major depressive disorder;
LUAD	cis	rs9486715	0.867	rs4131519	chr6:96964939	G/A	cg06623918	chr6:96969491	KIAA0776	0.83	15.66	0.61	6.26e-44	Headache;
LUAD	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg23950597	chr19:37808831	NA	-0.6	-7.52	-0.34	3.32e-13	Coronary artery calcification;
LUAD	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg15017067	chr4:17643749	FAM184B	0.35	6.79	0.31	3.82e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12618769	0.656	rs3769735	chr2:99092302	C/T	cg10123293	chr2:99228465	UNC50	0.42	7.81	0.36	4.52e-14	Bipolar disorder;
LUAD	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg26384229	chr12:38710491	ALG10B	0.4	6.37	0.3	4.82e-10	Morning vs. evening chronotype;
LUAD	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg21672276	chr3:44754072	ZNF502	-0.37	-6.49	-0.3	2.39e-10	Depressive symptoms;
LUAD	cis	rs6063312	1.000	rs6095261	chr20:47346494	C/A	cg18078177	chr20:47281410	PREX1	0.64	8.25	0.37	1.99e-15	Tonometry;
LUAD	cis	rs61776719	0.840	rs35267671	chr1:38397369	C/T	cg04673462	chr1:38461896	NA	0.49	10.48	0.45	5.41e-23	Coronary artery disease;
LUAD	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg13390004	chr1:15929781	NA	0.47	8.45	0.38	4.63e-16	Systolic blood pressure;
LUAD	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-18.91	-0.68	2.89e-58	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.32e-15	Prostate cancer;
LUAD	cis	rs7289126	1.000	rs5756986	chr22:38640841	A/G	cg25457927	chr22:38595422	NA	-0.44	-10.46	-0.45	6.52e-23	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.89	0.32	2.03e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg18252515	chr7:66147081	NA	0.61	6.77	0.31	4.38e-11	Diabetic kidney disease;
LUAD	cis	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg24308560	chr3:49941425	MST1R	0.39	6.45	0.3	3.1e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg08807101	chr21:30365312	RNF160	-0.52	-8.87	-0.4	2.12e-17	Dental caries;
LUAD	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.6	0.46	2e-23	Lymphocyte percentage of white cells;
LUAD	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg26384229	chr12:38710491	ALG10B	0.44	7.36	0.34	9.42e-13	Morning vs. evening chronotype;
LUAD	trans	rs1422110	0.543	rs10035841	chr5:85419597	T/C	cg01787110	chr1:109008453	NBPF6	0.61	10.22	0.45	4.63e-22	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs10465746	0.905	rs11163875	chr1:84429605	T/G	cg10977910	chr1:84465055	TTLL7	0.5	8.07	0.37	7.53e-15	Obesity-related traits;
LUAD	cis	rs113835537	0.529	rs11821155	chr11:66246337	C/T	cg24851651	chr11:66362959	CCS	-0.53	-9.53	-0.42	1.23e-19	Airway imaging phenotypes;
LUAD	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg00933542	chr6:150070202	PCMT1	0.42	8.87	0.4	2.1e-17	Lung cancer;
LUAD	cis	rs62064224	0.530	rs8073708	chr17:30680493	T/C	cg25809561	chr17:30822961	MYO1D	0.49	8.96	0.4	1.02e-17	Schizophrenia;
LUAD	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg03188948	chr7:1209495	NA	0.64	9.32	0.41	6.51e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7089973	0.584	rs4752255	chr10:116576790	C/T	cg25233709	chr10:116636983	FAM160B1	0.4	7.67	0.35	1.17e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs4268898	0.552	rs11125455	chr2:24374557	C/G	cg06627628	chr2:24431161	ITSN2	0.44	7.43	0.34	5.97e-13	Asthma;
LUAD	cis	rs62238980	0.614	rs4821013	chr22:32388224	A/C	cg00543991	chr22:32367038	NA	0.92	8.16	0.37	3.95e-15	Childhood ear infection;
LUAD	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.57	-0.35	2.38e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg17264618	chr3:40429014	ENTPD3	0.37	8.31	0.37	1.31e-15	Renal cell carcinoma;
LUAD	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22857025	chr5:266934	NA	-0.95	-14.19	-0.57	1.14e-37	Breast cancer;
LUAD	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg11919837	chr8:57350735	NA	-0.43	-6.52	-0.3	1.99e-10	Obesity-related traits;
LUAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.31	-7.11	-0.33	5.09e-12	Lymphocyte counts;
LUAD	cis	rs1451375	0.755	rs6969081	chr7:50624505	A/T	cg18232548	chr7:50535776	DDC	0.52	8.72	0.39	6.2e-17	Malaria;
LUAD	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg07828340	chr4:882639	GAK	1.08	11.68	0.49	1.63e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs17258050	chr4:119672019	G/A	cg21605333	chr4:119757512	SEC24D	0.94	7.45	0.34	5.4e-13	Cannabis dependence symptom count;
LUAD	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg11166453	chr1:247681781	NA	0.35	6.74	0.31	5.17e-11	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg16797656	chr11:68205561	LRP5	0.48	10.48	0.45	5.15e-23	Total body bone mineral density;
LUAD	cis	rs7843479	0.526	rs34802507	chr8:21773853	C/T	cg03445287	chr8:21823731	XPO7	-0.45	-8.22	-0.37	2.56e-15	Mean corpuscular volume;
LUAD	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg21214613	chr1:16344536	HSPB7	0.57	10.26	0.45	3.4e-22	Dilated cardiomyopathy;
LUAD	cis	rs7487075	0.578	rs11183486	chr12:46837704	A/C	cg23829395	chr12:46796953	NA	0.32	6.96	0.32	1.27e-11	Itch intensity from mosquito bite;
LUAD	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg08027265	chr7:2291960	NA	-0.51	-8.96	-0.4	1.08e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs986417	1.000	rs1956557	chr14:60972569	G/A	cg27398547	chr14:60952738	C14orf39	0.67	8.03	0.36	9.45e-15	Gut microbiota (bacterial taxa);
LUAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03452623	chr4:187889614	NA	0.8	16.72	0.63	1.52e-48	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg16011800	chr17:1958478	HIC1	-0.56	-8.01	-0.36	1.11e-14	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.84	-0.32	2.74e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg04036182	chr15:45458818	NA	-0.42	-7.3	-0.33	1.47e-12	Glomerular filtration rate;
LUAD	cis	rs4711350	0.954	rs1536501	chr6:33727885	C/T	cg13859433	chr6:33739653	LEMD2	0.35	6.76	0.31	4.59e-11	Schizophrenia;
LUAD	cis	rs4604732	0.578	rs12036417	chr1:247624805	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	9.21	0.41	1.59e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.08	-0.44	1.46e-21	Migraine;Coronary artery disease;
LUAD	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg25456477	chr12:86230367	RASSF9	0.33	6.63	0.31	1.05e-10	Major depressive disorder;
LUAD	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg17063962	chr7:91808500	NA	-0.68	-11.81	-0.5	5.37e-28	Breast cancer;
LUAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22029157	chr1:209979665	IRF6	0.79	12.94	0.53	1.63e-32	Cleft lip with or without cleft palate;
LUAD	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg22532475	chr10:104410764	TRIM8	-0.43	-7.94	-0.36	1.8e-14	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg18200150	chr17:30822561	MYO1D	0.4	7.55	0.34	2.7e-13	Schizophrenia;
LUAD	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg08742575	chr21:47604166	C21orf56	0.42	7.06	0.32	6.84e-12	Testicular germ cell tumor;
LUAD	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18404041	chr3:52824283	ITIH1	0.52	10.47	0.45	5.68e-23	Electroencephalogram traits;
LUAD	cis	rs7945705	0.905	rs7947631	chr11:8844909	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.4	-7.34	-0.34	1.1e-12	Hemoglobin concentration;
LUAD	trans	rs9393777	0.778	rs67457459	chr6:27198343	T/G	cg06606381	chr12:133084897	FBRSL1	-1.0	-10.34	-0.45	1.71e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs7100689	0.784	rs4934139	chr10:82177023	C/A	cg00277334	chr10:82204260	NA	-0.66	-10.3	-0.45	2.45e-22	Post bronchodilator FEV1;
LUAD	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg15181151	chr6:150070149	PCMT1	0.42	8.73	0.39	6.01e-17	Lung cancer;
LUAD	cis	rs3096299	0.781	rs2170839	chr16:89409452	C/G	cg06640241	chr16:89574553	SPG7	0.41	6.71	0.31	6.29e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg04455712	chr21:45112962	RRP1B	0.47	9.35	0.41	5.02e-19	Mean corpuscular volume;
LUAD	cis	rs6901250	0.851	rs339307	chr6:117177340	A/G	cg12892004	chr6:117198278	RFX6	-0.34	-7.09	-0.33	5.57e-12	C-reactive protein levels;
LUAD	cis	rs600550	0.528	rs10897006	chr11:59851874	C/G	cg02771260	chr11:59836817	MS4A3	-0.31	-6.52	-0.3	2.06e-10	Lipoprotein-associated phospholipase A2 activity and mass;
LUAD	cis	rs73206853	0.841	rs3893403	chr12:111083980	G/A	cg12870014	chr12:110450643	ANKRD13A	0.62	6.83	0.32	3.01e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg11833968	chr6:79620685	NA	-0.43	-8.26	-0.37	1.89e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg25482853	chr8:67687455	SGK3	1.18	18.25	0.66	2.68e-55	Lung disease severity in cystic fibrosis;
LUAD	trans	rs8073060	0.660	rs34184070	chr17:34003810	A/G	cg19694781	chr19:47549865	TMEM160	-1.22	-19.55	-0.69	4.14e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg04093404	chr1:6614507	TAS1R1;NOL9	0.74	9.33	0.41	6e-19	Body mass index;
LUAD	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06221963	chr1:154839813	KCNN3	-0.87	-21.0	-0.71	1.32e-67	Prostate cancer;
LUAD	cis	rs367943	0.666	rs10064031	chr5:112970924	C/G	cg12552261	chr5:112820674	MCC	0.45	8.06	0.36	7.8e-15	Type 2 diabetes;
LUAD	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg18512352	chr11:47633146	NA	0.41	7.1	0.33	5.27e-12	Subjective well-being;
LUAD	trans	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.93	0.4	1.35e-17	Endometrial cancer;
LUAD	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg05044414	chr3:183734942	ABCC5	0.48	10.04	0.44	1.96e-21	Anterior chamber depth;
LUAD	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	trans	rs853679	0.666	rs200956	chr6:27839746	A/G	cg01620082	chr3:125678407	NA	-0.51	-7.43	-0.34	5.9e-13	Depression;
LUAD	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg09491104	chr22:46646882	C22orf40	-0.64	-11.68	-0.49	1.68e-27	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10819733	chr22:24237672	NA	-0.42	-7.76	-0.35	6.44e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg26043149	chr18:55253948	FECH	0.51	8.13	0.37	4.97e-15	Bone mineral density;
LUAD	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg01324343	chr3:183735012	ABCC5	0.95	25.75	0.78	1.16e-88	Anterior chamber depth;
LUAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg13560548	chr3:10150139	C3orf24	0.42	6.88	0.32	2.1e-11	Alzheimer's disease;
LUAD	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg18252515	chr7:66147081	NA	-0.64	-6.93	-0.32	1.6e-11	Diabetic kidney disease;
LUAD	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg19346786	chr7:2764209	NA	0.34	7.12	0.33	4.74e-12	Loneliness (linear analysis);
LUAD	cis	rs68170813	0.559	rs12537785	chr7:107050221	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-10.57	-0.46	2.54e-23	Coronary artery disease;
LUAD	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg05182265	chr7:156933206	UBE3C	0.64	12.06	0.51	5.49e-29	Body mass index;
LUAD	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg23815491	chr16:72088622	HP	-0.46	-8.24	-0.37	2.12e-15	Prostate cancer;
LUAD	cis	rs8051149	0.793	rs12445334	chr16:87871213	G/A	cg10099957	chr16:87869757	SLC7A5	0.44	7.15	0.33	3.94e-12	Blood metabolite levels;
LUAD	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg11189052	chr15:85197271	WDR73	0.59	7.49	0.34	3.95e-13	Schizophrenia;
LUAD	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg12311346	chr5:56204834	C5orf35	-0.53	-8.45	-0.38	4.73e-16	Coronary artery disease;
LUAD	cis	rs6460942	0.915	rs2192842	chr7:12315752	C/G	cg20607287	chr7:12443886	VWDE	-0.46	-6.61	-0.31	1.17e-10	Coronary artery disease;
LUAD	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg06108461	chr20:60628389	TAF4	0.67	9.04	0.4	5.73e-18	Obesity-related traits;
LUAD	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg18306943	chr3:40428807	ENTPD3	0.37	6.4	0.3	4.13e-10	Renal cell carcinoma;
LUAD	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg08085267	chr17:45401833	C17orf57	-0.63	-11.09	-0.47	2.97e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs12517041	1.000	rs1428623	chr5:23286659	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.51	-0.3	2.11e-10	Calcium levels;
LUAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg02018176	chr4:1364513	KIAA1530	0.36	6.35	0.3	5.54e-10	Obesity-related traits;
LUAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg08219700	chr8:58056026	NA	0.42	6.38	0.3	4.71e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9796	0.727	rs61203391	chr15:41352912	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.41	-7.5	-0.34	3.85e-13	Menopause (age at onset);
LUAD	cis	rs926938	0.557	rs6667218	chr1:115238982	G/A	cg12756093	chr1:115239321	AMPD1	-0.41	-6.81	-0.31	3.33e-11	Autism;
LUAD	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg18402987	chr7:1209562	NA	0.79	9.74	0.43	2.33e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg21724239	chr8:58056113	NA	0.79	9.7	0.43	3.26e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs12681287	0.752	rs10104138	chr8:87247659	G/A	cg27223183	chr8:87520930	FAM82B	-0.6	-8.53	-0.38	2.57e-16	Caudate activity during reward;
LUAD	cis	rs7582720	1.000	rs115654617	chr2:203893999	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.27	0.41	9.95e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg02493740	chr2:85810744	VAMP5	0.45	8.23	0.37	2.38e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.03	-0.36	1.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg08999081	chr20:33150536	PIGU	0.47	9.22	0.41	1.44e-18	Coronary artery disease;
LUAD	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11890956	chr21:40555474	PSMG1	-0.58	-9.53	-0.42	1.22e-19	Cognitive function;
LUAD	cis	rs9487051	0.768	rs445796	chr6:109520145	T/C	cg21918786	chr6:109611834	NA	-0.41	-7.28	-0.33	1.59e-12	Reticulocyte fraction of red cells;
LUAD	trans	rs9951602	0.512	rs58352488	chr18:76651113	T/A	cg02800362	chr5:177631904	HNRNPAB	0.92	14.03	0.56	5.64e-37	Obesity-related traits;
LUAD	trans	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.91	-0.32	1.8e-11	Gout;
LUAD	cis	rs6987853	0.933	rs55881007	chr8:42367290	A/G	cg09913449	chr8:42400586	C8orf40	-0.38	-6.86	-0.32	2.4e-11	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2485376	1.000	rs2479551	chr10:104030201	G/A	cg20641465	chr10:103991465	PITX3	-0.57	-10.37	-0.45	1.39e-22	QT interval;
LUAD	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.59	-12.31	-0.51	5.38e-30	Monocyte percentage of white cells;
LUAD	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg23625390	chr15:77176239	SCAPER	0.38	6.73	0.31	5.52e-11	Blood metabolite levels;
LUAD	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg25237894	chr2:233734115	C2orf82	-0.61	-11.64	-0.49	2.34e-27	Coronary artery disease;
LUAD	cis	rs13315871	0.929	rs34676912	chr3:58320298	C/A	cg12435725	chr3:58293450	RPP14	-0.76	-8.4	-0.38	6.7e-16	Cholesterol, total;
LUAD	cis	rs4356932	1.000	rs6814817	chr4:76951170	C/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.5	-0.3	2.23e-10	Blood protein levels;
LUAD	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg07936489	chr17:37558343	FBXL20	-0.44	-7.05	-0.32	7.56e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg25319279	chr11:5960081	NA	-0.41	-7.23	-0.33	2.25e-12	DNA methylation (variation);
LUAD	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg26384229	chr12:38710491	ALG10B	0.41	6.56	0.3	1.53e-10	Morning vs. evening chronotype;
LUAD	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.78e-11	Crohn's disease;
LUAD	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg12011299	chr4:100065546	ADH4	-0.72	-13.36	-0.54	3.39e-34	Alcohol dependence;
LUAD	cis	rs1451375	0.794	rs11238133	chr7:50542914	A/C	cg18232548	chr7:50535776	DDC	-0.66	-11.19	-0.48	1.22e-25	Malaria;
LUAD	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg10755058	chr3:40428713	ENTPD3	0.38	7.28	0.33	1.69e-12	Renal cell carcinoma;
LUAD	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg24829409	chr8:58192753	C8orf71	-0.51	-6.67	-0.31	8.19e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg19761014	chr17:28927070	LRRC37B2	0.84	8.27	0.37	1.76e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg00666640	chr1:248458726	OR2T12	0.27	6.45	0.3	3.09e-10	Common traits (Other);
LUAD	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18099408	chr3:52552593	STAB1	-0.45	-7.99	-0.36	1.31e-14	Bipolar disorder;
LUAD	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg12927641	chr6:109611667	NA	-0.48	-8.07	-0.37	7.18e-15	Reticulocyte fraction of red cells;
LUAD	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg22920501	chr2:26401640	FAM59B	-0.73	-10.49	-0.45	4.71e-23	Gut microbiome composition (summer);
LUAD	cis	rs354225	0.544	rs10187447	chr2:54806711	A/T	cg01766943	chr2:54829624	SPTBN1	0.39	7.4	0.34	7.65e-13	Schizophrenia;
LUAD	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06022373	chr22:39101656	GTPBP1	0.47	7.79	0.35	5.36e-14	Menopause (age at onset);
LUAD	cis	rs9341808	0.556	rs1535075	chr6:81034806	A/G	cg08355045	chr6:80787529	NA	0.48	8.21	0.37	2.62e-15	Sitting height ratio;
LUAD	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.76	-9.68	-0.43	3.83e-20	Body mass index;
LUAD	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg01849466	chr14:104193079	ZFYVE21	0.48	7.67	0.35	1.18e-13	Reticulocyte count;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg04073819	chr3:133293165	CDV3	-0.67	-6.47	-0.3	2.7e-10	Type 2 diabetes;
LUAD	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg02551604	chr5:131831745	NA	-0.5	-8.22	-0.37	2.59e-15	Breast cancer;Mosquito bite size;
LUAD	trans	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg04995722	chr7:26192034	NFE2L3	0.43	7.39	0.34	8.01e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10979	0.557	rs9390117	chr6:143907590	C/T	cg25407410	chr6:143891975	LOC285740	-0.55	-7.69	-0.35	1.05e-13	Hypospadias;
LUAD	cis	rs7177699	0.557	rs12898712	chr15:79112622	G/T	cg00540400	chr15:79124168	NA	0.43	9.23	0.41	1.27e-18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg19622623	chr12:86230825	RASSF9	-0.38	-6.87	-0.32	2.37e-11	Major depressive disorder;
LUAD	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.91	0.32	1.8e-11	Depression;
LUAD	trans	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.69	11.75	0.5	8.45e-28	Mean corpuscular volume;
LUAD	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg03983476	chr2:10830698	NOL10	-0.45	-7.76	-0.35	6.56e-14	Prostate cancer;
LUAD	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.25	-0.51	9.53e-30	Platelet count;
LUAD	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg03467027	chr4:99064603	C4orf37	0.42	6.84	0.32	2.73e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11771526	0.901	rs10264625	chr7:32304205	T/C	cg13207630	chr7:32358064	NA	0.6	7.34	0.34	1.07e-12	Body mass index;
LUAD	cis	rs863345	0.604	rs2873593	chr1:158504711	T/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.3	-0.37	1.43e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg08610935	chr16:1836813	NUBP2	-0.41	-6.43	-0.3	3.52e-10	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg09455208	chr3:40491958	NA	0.65	14.24	0.57	6.94e-38	Renal cell carcinoma;
LUAD	cis	rs10106298	0.846	rs2436936	chr8:103677723	C/A	cg10187029	chr8:103597600	NA	0.42	7.1	0.33	5.32e-12	Schizophrenia;
LUAD	cis	rs5167	0.781	rs2075619	chr19:45495682	A/G	cg13119609	chr19:45449297	APOC2	0.4	7.37	0.34	9.21e-13	Blood protein levels;
LUAD	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg13319975	chr6:146136371	FBXO30	0.59	9.98	0.44	3.27e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	8.42	0.38	6.11e-16	Parkinson's disease;
LUAD	cis	rs877282	0.945	rs12782447	chr10:771870	C/T	cg17470449	chr10:769945	NA	0.63	9.18	0.41	1.98e-18	Uric acid levels;
LUAD	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.23	0.41	1.34e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg01689657	chr7:91764605	CYP51A1	0.38	9.25	0.41	1.09e-18	Breast cancer;
LUAD	cis	rs26868	0.766	rs27556	chr16:2249325	T/C	cg02248941	chr16:2239361	CASKIN1	0.5	9.64	0.42	5.06e-20	Height;
LUAD	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg21194808	chr1:2205498	SKI	0.4	6.42	0.3	3.77e-10	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18637244	chr16:2039815	SYNGR3	-0.4	-6.44	-0.3	3.18e-10	Height;
LUAD	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg01579765	chr21:45077557	HSF2BP	-0.58	-12.64	-0.52	2.64e-31	Mean corpuscular volume;
LUAD	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg05234568	chr11:5960015	NA	-0.53	-10.54	-0.46	3.24e-23	DNA methylation (variation);
LUAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg18621852	chr3:10150065	C3orf24	0.48	8.45	0.38	4.89e-16	Alzheimer's disease;
LUAD	trans	rs3960554	0.932	rs11971220	chr7:75842792	C/T	cg19862616	chr7:65841803	NCRNA00174	0.81	10.44	0.45	7.66e-23	Eotaxin levels;
LUAD	cis	rs1018836	0.923	rs1476427	chr8:91552791	A/G	cg16814680	chr8:91681699	NA	0.74	13.01	0.53	9.16e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.66	-0.39	9.95e-17	Total body bone mineral density;
LUAD	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg19717773	chr7:2847554	GNA12	-0.46	-8.24	-0.37	2.25e-15	Height;
LUAD	cis	rs6920965	0.503	rs2475851	chr6:126174215	T/C	cg05901451	chr6:126070800	HEY2	-0.43	-6.94	-0.32	1.46e-11	High light scatter reticulocyte count;
LUAD	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-13.17	-0.54	2e-33	Chronic sinus infection;
LUAD	cis	rs2992756	0.663	rs2992755	chr1:18807897	C/G	cg14356550	chr1:18808102	KLHDC7A	-0.57	-9.96	-0.44	3.78e-21	Breast cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14546261	chr12:7052696	C12orf57	-0.42	-6.51	-0.3	2.15e-10	Height;
LUAD	cis	rs7586879	0.796	rs916484	chr2:25082588	A/C	cg04586622	chr2:25135609	ADCY3	0.34	6.89	0.32	2.09e-11	Body mass index;
LUAD	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg00129232	chr17:37814104	STARD3	-0.46	-8.01	-0.36	1.13e-14	Asthma;
LUAD	trans	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg06606381	chr12:133084897	FBRSL1	-1.21	-11.16	-0.48	1.6e-25	Depression;
LUAD	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg27170947	chr2:26402098	FAM59B	0.8	10.63	0.46	1.47e-23	Gut microbiome composition (summer);
LUAD	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg06873352	chr17:61820015	STRADA	0.42	7.05	0.32	7.39e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg08847533	chr14:75593920	NEK9	0.38	6.45	0.3	3.05e-10	Height;
LUAD	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg07402062	chr16:89894098	SPIRE2	-0.44	-11.12	-0.48	2.29e-25	Vitiligo;
LUAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg16606324	chr3:10149918	C3orf24	0.59	9.65	0.42	4.73e-20	Alzheimer's disease;
LUAD	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg07606381	chr6:8435919	SLC35B3	0.42	6.82	0.31	3.13e-11	Motion sickness;
LUAD	trans	rs12517041	1.000	rs1428630	chr5:23321186	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.56	-0.3	1.59e-10	Calcium levels;
LUAD	cis	rs12545109	0.879	rs2609994	chr8:57365844	A/G	cg17761419	chr8:57350749	NA	-0.59	-8.27	-0.37	1.77e-15	Obesity-related traits;
LUAD	cis	rs7809950	0.530	rs34021916	chr7:106817901	A/G	cg23024343	chr7:107201750	COG5	-0.75	-12.22	-0.51	1.32e-29	Coronary artery disease;
LUAD	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg17105886	chr17:28927953	LRRC37B2	0.76	7.18	0.33	3.14e-12	Body mass index;
LUAD	trans	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.55	-9.37	-0.41	4.36e-19	Mean corpuscular volume;
LUAD	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg09904177	chr6:26538194	HMGN4	0.42	7.01	0.32	9.18e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg19041857	chr6:27730383	NA	-0.44	-7.55	-0.34	2.74e-13	Parkinson's disease;
LUAD	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.09	0.33	5.7e-12	Menopause (age at onset);
LUAD	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg17644776	chr2:200775616	C2orf69	0.47	7.54	0.34	2.85e-13	Osteoporosis;
LUAD	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.15e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs743757	0.697	rs763030	chr3:50528092	G/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.48	7.72	0.35	8.43e-14	Diastolic blood pressure;
LUAD	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg15691649	chr6:25882328	NA	-0.45	-7.13	-0.33	4.29e-12	Blood metabolite levels;
LUAD	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg18944383	chr4:111397179	ENPEP	0.41	7.61	0.35	1.74e-13	Coronary artery disease;
LUAD	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg08859206	chr1:53392774	SCP2	-0.61	-10.48	-0.45	5.23e-23	Monocyte count;
LUAD	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg14668632	chr7:2872130	GNA12	-0.47	-8.38	-0.38	8.07e-16	Height;
LUAD	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg18446336	chr7:2847575	GNA12	-0.38	-7.0	-0.32	1.01e-11	Height;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg10546176	chr5:34929404	DNAJC21	0.36	6.7	0.31	6.78e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs921968	0.565	rs2059717	chr2:219600316	A/T	cg02176678	chr2:219576539	TTLL4	-0.57	-11.05	-0.47	4.21e-25	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg27661571	chr11:113659931	NA	-0.7	-8.22	-0.37	2.53e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs9837602	0.882	rs9875664	chr3:99729130	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.5	-7.69	-0.35	1.04e-13	Breast cancer;
LUAD	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg03676636	chr4:99064102	C4orf37	0.31	7.89	0.36	2.59e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.45	6.44	0.3	3.28e-10	Renal function-related traits (BUN);
LUAD	cis	rs9644630	1.000	rs4921657	chr8:19370867	C/G	cg06699216	chr8:19333253	CSGALNACT1	-0.28	-6.57	-0.3	1.52e-10	Oropharynx cancer;
LUAD	cis	rs62400317	0.826	rs11970496	chr6:45125833	A/G	cg18551225	chr6:44695536	NA	-0.55	-8.69	-0.39	8.19e-17	Total body bone mineral density;
LUAD	cis	rs684232	0.602	rs331008	chr17:544617	C/T	cg15660573	chr17:549704	VPS53	-0.88	-18.37	-0.67	7.54e-56	Prostate cancer;
LUAD	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg09658497	chr7:2847517	GNA12	-0.47	-7.96	-0.36	1.64e-14	Height;
LUAD	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg06623918	chr6:96969491	KIAA0776	0.89	17.71	0.65	6.38e-53	Headache;
LUAD	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg10876282	chr6:28092338	ZSCAN16	0.41	6.37	0.3	4.8e-10	Cardiac Troponin-T levels;
LUAD	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg02527881	chr3:46936655	PTH1R	0.75	17.73	0.65	5.52e-53	Birth weight;
LUAD	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg02524346	chr8:600233	NA	1.09	10.7	0.46	8.48e-24	IgG glycosylation;
LUAD	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg00933542	chr6:150070202	PCMT1	0.44	9.76	0.43	1.99e-20	Lung cancer;
LUAD	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg00310523	chr12:86230176	RASSF9	0.35	7.36	0.34	9.61e-13	Major depressive disorder;
LUAD	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg07404485	chr7:94953653	PON1	-0.49	-7.0	-0.32	9.93e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg14092988	chr3:52407081	DNAH1	0.39	7.9	0.36	2.5e-14	Electroencephalogram traits;
LUAD	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg05283184	chr6:79620031	NA	-0.6	-11.96	-0.5	1.34e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg17372223	chr3:52568218	NT5DC2	-0.39	-7.17	-0.33	3.28e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg07817883	chr1:32538562	TMEM39B	1.3	12.44	0.52	1.65e-30	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08439880	chr3:133502540	NA	-0.45	-8.87	-0.4	2.05e-17	Iron status biomarkers;
LUAD	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg15962314	chr1:44399869	ARTN	0.34	7.69	0.35	1.07e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs2262909	0.962	rs409439	chr19:22227432	C/T	cg17074339	chr11:11642133	GALNTL4	-0.46	-7.51	-0.34	3.63e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13223928	0.621	rs4722440	chr7:3155901	C/T	cg19214707	chr7:3157722	NA	0.5	9.01	0.4	7.03e-18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg06696917	chr16:58718412	SLC38A7	-0.5	-6.57	-0.3	1.51e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs2057149	0.777	rs2334069	chr6:110699863	T/C	cg01119278	chr6:110721349	DDO	-0.39	-6.51	-0.3	2.17e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg12193833	chr17:30244370	NA	-0.5	-6.6	-0.31	1.26e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs977987	0.735	rs11149831	chr16:75451461	G/A	cg03315344	chr16:75512273	CHST6	0.67	14.82	0.58	2.56e-40	Dupuytren's disease;
LUAD	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.35	0.38	9.84e-16	Breast cancer;
LUAD	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg26028573	chr6:26043587	HIST1H2BB	-0.4	-6.45	-0.3	3.04e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7590720	1.000	rs4674048	chr2:216900023	G/A	cg12620499	chr2:216877984	MREG	0.55	8.73	0.39	5.79e-17	Alcohol dependence;
LUAD	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.61	-0.31	1.13e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1448094	0.802	rs12369634	chr12:86406792	C/G	cg19622623	chr12:86230825	RASSF9	-0.37	-6.6	-0.31	1.26e-10	Major depressive disorder;
LUAD	trans	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.08	-27.51	-0.8	2.95e-96	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.86	0.32	2.49e-11	Parkinson's disease;
LUAD	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg10591111	chr5:226296	SDHA	-0.54	-7.05	-0.32	7.48e-12	Breast cancer;
LUAD	cis	rs5756391	0.546	rs4821560	chr22:37311806	G/T	cg16356956	chr22:37317934	CSF2RB	-0.34	-7.55	-0.34	2.71e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg06064525	chr11:970664	AP2A2	-0.57	-11.71	-0.49	1.27e-27	Alzheimer's disease (late onset);
LUAD	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg00316803	chr15:76480434	C15orf27	0.41	6.54	0.3	1.8e-10	Blood metabolite levels;
LUAD	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg07617317	chr6:118971624	C6orf204	0.55	8.54	0.38	2.38e-16	Diastolic blood pressure;
LUAD	cis	rs7116495	0.881	rs598835	chr11:71797727	C/T	cg07596299	chr11:71824057	C11orf51	-0.77	-6.44	-0.3	3.2e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg14416269	chr4:6271139	WFS1	0.61	12.46	0.52	1.46e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg07936489	chr17:37558343	FBXL20	-0.46	-7.34	-0.34	1.08e-12	Glomerular filtration rate (creatinine);
LUAD	trans	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg03886242	chr7:26192032	NFE2L3	0.48	8.52	0.38	2.93e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg08439880	chr3:133502540	NA	-0.37	-7.16	-0.33	3.58e-12	Iron status biomarkers;
LUAD	cis	rs10419226	0.555	rs8100824	chr19:18749412	C/G	cg22001208	chr19:18782374	NA	-0.49	-8.26	-0.37	1.93e-15	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg00071950	chr4:10020882	SLC2A9	0.8	16.67	0.63	2.52e-48	Bone mineral density;
LUAD	cis	rs870825	0.860	rs2705895	chr4:185598404	C/T	cg04058563	chr4:185651563	MLF1IP	-0.83	-11.89	-0.5	2.54e-28	Blood protein levels;
LUAD	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg08048268	chr3:133502702	NA	0.35	6.95	0.32	1.39e-11	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs3204270	0.639	rs11871678	chr17:79654285	G/A	cg09655341	chr17:79618100	PDE6G	0.52	6.51	0.3	2.09e-10	Dental caries;
LUAD	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22857025	chr5:266934	NA	-0.97	-14.47	-0.58	7.55e-39	Breast cancer;
LUAD	cis	rs938554	0.501	rs7671266	chr4:10056376	C/T	cg02734326	chr4:10020555	SLC2A9	-0.42	-6.54	-0.3	1.81e-10	Blood metabolite levels;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg25026715	chr17:26989248	SUPT6H;SDF2	-0.41	-6.93	-0.32	1.63e-11	Schizophrenia;
LUAD	cis	rs1444418	1.000	rs1444418	chr10:64560470	A/G	cg14943953	chr10:64564468	ADO	-0.58	-6.93	-0.32	1.6e-11	Atopic dermatitis;
LUAD	cis	rs4889911	0.544	rs1285271	chr17:77834197	C/T	cg01306824	chr17:77834118	NA	-0.44	-6.64	-0.31	9.88e-11	Electroencephalogram traits;
LUAD	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg26384229	chr12:38710491	ALG10B	0.44	7.21	0.33	2.63e-12	Bladder cancer;
LUAD	cis	rs2302190	0.769	rs7218778	chr17:56664248	T/G	cg25885038	chr17:56607967	SEPT4	-0.51	-8.12	-0.37	5.11e-15	Vitamin D levels;
LUAD	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.91	0.4	1.55e-17	Menopause (age at onset);
LUAD	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg19717773	chr7:2847554	GNA12	-0.5	-9.43	-0.42	2.78e-19	Height;
LUAD	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg20487152	chr13:99095054	FARP1	-0.48	-8.06	-0.36	8.15e-15	Longevity;
LUAD	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9715521	0.803	rs62301187	chr4:59840420	T/C	cg11281224	chr4:60001000	NA	-0.55	-9.35	-0.41	5.26e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg27432699	chr2:27873401	GPN1	-0.42	-7.13	-0.33	4.46e-12	Total body bone mineral density;
LUAD	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg15445000	chr17:37608096	MED1	0.43	7.89	0.36	2.68e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg03806693	chr22:41940476	POLR3H	-0.5	-7.44	-0.34	5.84e-13	Vitiligo;
LUAD	trans	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg02002194	chr4:3960332	NA	0.3	7.31	0.33	1.33e-12	Neuroticism;
LUAD	cis	rs11828289	0.660	rs17306398	chr11:23192235	G/T	cg20040320	chr11:23191996	NA	0.64	7.77	0.35	6.09e-14	Cancer;
LUAD	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg05368731	chr17:41323189	NBR1	0.96	20.32	0.7	1.44e-64	Menopause (age at onset);
LUAD	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg03859395	chr2:55845619	SMEK2	-0.58	-9.91	-0.43	5.83e-21	Metabolic syndrome;
LUAD	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.07	-0.44	1.66e-21	Migraine;Coronary artery disease;
LUAD	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg14671364	chr1:107599128	PRMT6	0.55	9.26	0.41	1e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs783540	0.934	rs783532	chr15:83249367	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.43	-7.04	-0.32	7.68e-12	Schizophrenia;
LUAD	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg14008862	chr17:28927542	LRRC37B2	0.75	7.43	0.34	6.2e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg17063962	chr7:91808500	NA	0.68	11.52	0.49	6.79e-27	Breast cancer;
LUAD	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg04287289	chr16:89883240	FANCA	0.48	8.0	0.36	1.2e-14	Vitiligo;
LUAD	cis	rs11112613	0.713	rs73184081	chr12:105951745	C/T	cg03607813	chr12:105948248	NA	0.74	12.7	0.53	1.51e-31	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg25894440	chr7:65020034	NA	-0.67	-7.14	-0.33	4.2e-12	Diabetic kidney disease;
LUAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg22963979	chr7:1858916	MAD1L1	-0.68	-12.15	-0.51	2.49e-29	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg26597838	chr10:835615	NA	0.82	12.83	0.53	4.77e-32	Eosinophil percentage of granulocytes;
LUAD	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg23985595	chr17:80112537	CCDC57	-0.51	-9.4	-0.42	3.41e-19	Life satisfaction;
LUAD	cis	rs753778	0.963	rs3739234	chr8:142229178	G/A	cg18755752	chr8:142205143	DENND3	-0.45	-7.33	-0.34	1.18e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg17366294	chr4:99064904	C4orf37	0.6	10.06	0.44	1.75e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg00074818	chr8:8560427	CLDN23	0.66	10.02	0.44	2.31e-21	Obesity-related traits;
LUAD	cis	rs7903847	0.600	rs17504745	chr10:99110701	T/C	cg20016023	chr10:99160130	RRP12	-0.31	-6.76	-0.31	4.66e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs516243	0.806	rs7545228	chr1:10740303	G/C	cg02903756	chr1:10750680	CASZ1	-0.49	-9.25	-0.41	1.12e-18	Migraine - clinic-based;
LUAD	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg02176678	chr2:219576539	TTLL4	-0.82	-17.44	-0.65	1.02e-51	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg09509183	chr1:209979624	IRF6	0.59	8.13	0.37	4.91e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs61759167	0.710	rs12745073	chr1:3094672	A/G	cg22396632	chr1:3079212	PRDM16	-0.38	-7.52	-0.34	3.23e-13	Motion sickness;
LUAD	cis	rs877282	0.945	rs10904554	chr10:786768	T/C	cg06581033	chr10:766294	NA	-0.57	-7.64	-0.35	1.5e-13	Uric acid levels;
LUAD	cis	rs9948	0.655	rs7568206	chr2:97393108	A/C	cg20312557	chr2:97357134	FER1L5	-0.61	-7.54	-0.34	2.98e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs7264396	0.563	rs11698796	chr20:34248134	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.78	-0.35	5.56e-14	Total cholesterol levels;
LUAD	cis	rs57920188	0.584	rs12128330	chr1:4092926	G/A	cg20703997	chr1:4087676	NA	0.48	8.98	0.4	8.71e-18	Interleukin-17 levels;
LUAD	cis	rs4664308	0.691	rs1877196	chr2:160915150	G/T	cg03641300	chr2:160917029	PLA2R1	-0.4	-7.11	-0.33	4.88e-12	Idiopathic membranous nephropathy;
LUAD	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg21427119	chr20:30132790	HM13	-0.61	-8.97	-0.4	1e-17	Mean corpuscular hemoglobin;
LUAD	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg09365446	chr1:150670422	GOLPH3L	0.67	12.69	0.53	1.67e-31	Tonsillectomy;
LUAD	cis	rs9902453	0.740	rs2617867	chr17:28049399	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.31	-0.45	2.17e-22	Coffee consumption (cups per day);
LUAD	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg23254163	chr1:152506842	NA	0.25	6.96	0.32	1.31e-11	Hair morphology;
LUAD	cis	rs4660214	0.666	rs636156	chr1:39821737	A/G	cg27567593	chr1:39956653	BMP8A	-0.36	-7.25	-0.33	1.95e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg03885332	chr11:832357	CD151	-0.43	-8.21	-0.37	2.63e-15	Mean platelet volume;
LUAD	cis	rs447921	0.861	rs56154175	chr17:74419086	C/T	cg17201438	chr17:74438067	UBE2O	0.67	8.5	0.38	3.25e-16	Mitochondrial DNA levels;
LUAD	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg27539214	chr16:67997921	SLC12A4	-0.66	-8.31	-0.37	1.32e-15	Schizophrenia;
LUAD	cis	rs9283706	0.562	rs10471697	chr5:66328555	A/T	cg11590213	chr5:66331682	MAST4	0.41	6.78	0.31	4.01e-11	Coronary artery disease;
LUAD	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg16647868	chr5:131706066	SLC22A5	0.49	7.9	0.36	2.48e-14	Breast cancer;
LUAD	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg03433033	chr1:76189801	ACADM	-0.7	-11.16	-0.48	1.6e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg03354898	chr7:1950403	MAD1L1	-0.42	-7.88	-0.36	2.83e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg10589385	chr1:150898437	SETDB1	0.39	7.32	0.34	1.26e-12	Tonsillectomy;
LUAD	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.83	-12.58	-0.52	4.72e-31	Chronic sinus infection;
LUAD	cis	rs6684514	1.000	rs10908494	chr1:156263097	A/G	cg16558208	chr1:156270281	VHLL	0.52	9.57	0.42	9.2e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.78	0.35	5.77e-14	Bladder cancer;
LUAD	cis	rs4919694	1.000	rs76892505	chr10:104719290	G/A	cg04362960	chr10:104952993	NT5C2	0.82	8.55	0.38	2.34e-16	Arsenic metabolism;
LUAD	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg24579218	chr15:68104479	NA	-0.57	-9.86	-0.43	8.65e-21	Restless legs syndrome;
LUAD	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg11859384	chr17:80120422	CCDC57	0.42	7.59	0.35	2.12e-13	Life satisfaction;
LUAD	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg05340658	chr4:99064831	C4orf37	0.54	9.23	0.41	1.32e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24308560	chr3:49941425	MST1R	-0.57	-9.61	-0.42	6.39e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs11190604	0.767	rs10883485	chr10:102174805	G/C	cg07570687	chr10:102243282	WNT8B	0.44	6.35	0.3	5.43e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs3204270	0.639	rs11867543	chr17:79655046	C/T	cg18367735	chr17:79674897	NA	0.53	6.73	0.31	5.68e-11	Dental caries;
LUAD	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.55	-0.34	2.64e-13	Monocyte count;
LUAD	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.09	-0.44	1.4e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs897984	0.647	rs7203999	chr16:31017554	T/C	cg02466173	chr16:30829666	NA	0.58	10.02	0.44	2.42e-21	Dementia with Lewy bodies;
LUAD	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg03676636	chr4:99064102	C4orf37	0.32	8.38	0.38	7.84e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15320075	chr8:145703422	NA	-0.39	-6.45	-0.3	3.14e-10	Age at first birth;
LUAD	cis	rs4523957	0.579	rs4790883	chr17:2087605	T/C	cg16513277	chr17:2031491	SMG6	-0.88	-16.7	-0.63	1.86e-48	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.62	-11.27	-0.48	5.91e-26	Urate levels in overweight individuals;
LUAD	cis	rs11696501	0.739	rs6073846	chr20:44296323	G/T	cg11783356	chr20:44313418	WFDC10B	0.45	7.59	0.35	2.08e-13	Brain structure;
LUAD	cis	rs1160297	0.601	rs1864534	chr2:53109005	G/T	cg07782112	chr2:53107842	NA	0.36	7.68	0.35	1.15e-13	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.27e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	9.41	0.42	3.25e-19	Electrocardiographic conduction measures;
LUAD	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.22	0.33	2.39e-12	Motion sickness;
LUAD	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg12311346	chr5:56204834	C5orf35	-0.43	-6.95	-0.32	1.36e-11	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs6076065	0.748	rs2424542	chr20:23386800	C/T	cg11657817	chr20:23433608	CST11	0.57	11.92	0.5	1.99e-28	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg16479474	chr6:28041457	NA	0.44	7.44	0.34	5.75e-13	Depression;
LUAD	cis	rs4660214	0.666	rs2275188	chr1:39748921	G/A	cg27567593	chr1:39956653	BMP8A	0.34	6.87	0.32	2.25e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs3820068	0.705	rs11584209	chr1:15885041	G/T	cg24675056	chr1:15929824	NA	0.43	6.65	0.31	9.01e-11	Systolic blood pressure;
LUAD	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg19336497	chr11:14380999	RRAS2	-0.65	-13.89	-0.56	2.15e-36	Sense of smell;
LUAD	cis	rs6601327	0.613	rs33994795	chr8:9473429	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-7.02	-0.32	8.69e-12	Multiple myeloma (hyperdiploidy);
LUAD	cis	rs250585	0.736	rs250581	chr16:23411837	G/A	cg00143387	chr16:23521605	GGA2	0.58	8.21	0.37	2.69e-15	Egg allergy;
LUAD	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg07606381	chr6:8435919	SLC35B3	0.43	7.12	0.33	4.7e-12	Motion sickness;
LUAD	cis	rs2286503	1.000	rs2286499	chr7:22857477	A/G	cg06496272	chr7:22895283	SNORD93	-0.39	-6.96	-0.32	1.3e-11	Fibrinogen;
LUAD	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.67	-10.22	-0.45	4.54e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs939658	0.805	rs11630571	chr15:79432992	C/A	cg17916960	chr15:79447300	NA	-0.51	-10.67	-0.46	1.06e-23	Refractive error;
LUAD	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18404041	chr3:52824283	ITIH1	-0.59	-12.01	-0.5	8.88e-29	Bipolar disorder;
LUAD	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg07414643	chr4:187882934	NA	0.34	6.91	0.32	1.82e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg08660285	chr1:67390436	MIER1;WDR78	0.5	8.23	0.37	2.35e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg17330251	chr7:94953956	PON1	-0.57	-7.91	-0.36	2.2e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg10556349	chr10:835070	NA	0.59	7.48	0.34	4.28e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg22431228	chr1:16359049	CLCNKA	-0.41	-7.68	-0.35	1.14e-13	Systolic blood pressure;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08862778	chr1:11322643	MTOR	-0.4	-6.5	-0.3	2.31e-10	Height;
LUAD	cis	rs7258465	1.000	rs8105994	chr19:18593553	A/G	cg25828334	chr19:18545568	ISYNA1	-0.36	-7.15	-0.33	3.92e-12	Breast cancer;
LUAD	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg03605463	chr16:89740564	NA	0.67	11.49	0.49	9.08e-27	Vitiligo;
LUAD	cis	rs790123	0.581	rs2877628	chr3:122352678	A/G	cg17380795	chr3:122379686	NA	0.44	7.61	0.35	1.78e-13	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs11088226	0.681	rs2409456	chr21:33929374	G/A	cg09050820	chr6:167586206	TCP10L2	0.9	12.78	0.53	7.39e-32	Gastritis;
LUAD	cis	rs3815700	1.000	rs7248845	chr19:33096718	T/C	cg02997394	chr19:33096574	ANKRD27	0.65	8.73	0.39	5.94e-17	Eosinophilic esophagitis;
LUAD	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-9.88	-0.43	7.63e-21	Migraine;Coronary artery disease;
LUAD	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg04398451	chr17:18023971	MYO15A	0.62	11.31	0.48	4.31e-26	Total body bone mineral density;
LUAD	cis	rs3806843	0.576	rs246037	chr5:140331846	C/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.41	-0.3	3.86e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg27532560	chr4:187881888	NA	-0.35	-6.66	-0.31	8.44e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9473147	0.516	rs9381579	chr6:47556680	C/T	cg02130027	chr6:47444894	CD2AP	0.34	6.61	0.31	1.19e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs4588572	0.606	rs6859161	chr5:77742776	A/G	cg11547950	chr5:77652471	NA	-0.62	-10.5	-0.45	4.64e-23	Triglycerides;
LUAD	cis	rs1160297	0.609	rs4525730	chr2:53097497	C/T	cg07782112	chr2:53107842	NA	0.42	8.9	0.4	1.66e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs4711350	0.906	rs943463	chr6:33719877	A/G	cg07979401	chr6:33739406	LEMD2	-0.44	-7.32	-0.34	1.23e-12	Schizophrenia;
LUAD	cis	rs11048434	0.736	rs11048344	chr12:9122609	G/C	cg04155231	chr12:9217510	LOC144571	0.38	7.1	0.33	5.2e-12	Sjögren's syndrome;
LUAD	cis	rs9283706	0.594	rs7734953	chr5:66349943	G/T	cg11590213	chr5:66331682	MAST4	0.4	6.52	0.3	2.01e-10	Coronary artery disease;
LUAD	cis	rs6961069	0.745	rs3212160	chr7:80273308	A/C	cg04458919	chr7:80252533	CD36	0.38	7.34	0.34	1.07e-12	Platelet count;
LUAD	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19717773	chr7:2847554	GNA12	-0.55	-9.4	-0.42	3.58e-19	Height;
LUAD	cis	rs2795502	0.630	rs2914988	chr10:43509354	A/T	cg15903213	chr10:43522190	NA	-0.62	-6.5	-0.3	2.24e-10	Blood protein levels;
LUAD	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg17178900	chr1:205818956	PM20D1	-0.45	-6.97	-0.32	1.24e-11	Menarche (age at onset);
LUAD	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg06740227	chr12:86229804	RASSF9	-0.41	-7.23	-0.33	2.27e-12	Major depressive disorder;
LUAD	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg00784671	chr22:46762841	CELSR1	-0.43	-6.42	-0.3	3.7e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7173743	0.756	rs6495337	chr15:79125689	C/G	cg00540400	chr15:79124168	NA	-0.4	-8.34	-0.38	1.04e-15	Coronary artery disease;
LUAD	cis	rs12431939	0.779	rs2999381	chr14:51645368	T/C	cg23942311	chr14:51606299	NA	0.42	6.7	0.31	6.84e-11	Cancer;
LUAD	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg20701182	chr2:24300061	SF3B14	0.47	6.46	0.3	2.82e-10	Asthma;
LUAD	cis	rs939658	0.683	rs1434459	chr15:79465210	T/C	cg17916960	chr15:79447300	NA	-0.36	-6.9	-0.32	1.92e-11	Refractive error;
LUAD	cis	rs367615	0.959	rs2201016	chr5:108947287	T/C	cg17395555	chr5:108820864	NA	0.45	7.61	0.35	1.8e-13	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg16797656	chr11:68205561	LRP5	0.48	9.26	0.41	1.02e-18	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg05340658	chr4:99064831	C4orf37	0.53	9.06	0.4	4.81e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21582582	chr3:182698605	DCUN1D1	0.58	9.92	0.43	5.34e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs2154319	0.790	rs710248	chr1:41574622	C/T	cg02290550	chr1:41487317	SLFNL1	-0.38	-6.35	-0.3	5.51e-10	Height;
LUAD	cis	rs9905704	0.681	rs2108911	chr17:56570500	C/T	cg19466818	chr17:56409534	MIR142	0.35	6.97	0.32	1.26e-11	Testicular germ cell tumor;
LUAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg11941060	chr3:133502564	NA	-0.64	-11.63	-0.49	2.67e-27	Iron status biomarkers;
LUAD	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18876405	chr7:65276391	NA	-0.44	-6.98	-0.32	1.16e-11	Aortic root size;
LUAD	cis	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg21775007	chr8:11205619	TDH	-0.38	-6.57	-0.3	1.46e-10	Triglycerides;
LUAD	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg04727924	chr7:799746	HEATR2	-0.58	-7.27	-0.33	1.73e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg06784218	chr1:46089804	CCDC17	0.54	11.82	0.5	4.7e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs17095355	1.000	rs7068482	chr10:111729503	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.73	-10.37	-0.45	1.28e-22	Biliary atresia;
LUAD	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.55	8.91	0.4	1.48e-17	Cognitive ability;
LUAD	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.37	-6.6	-0.31	1.25e-10	Age at first birth;
LUAD	cis	rs62400317	0.859	rs28583363	chr6:45231336	T/A	cg18551225	chr6:44695536	NA	-0.56	-8.7	-0.39	7.44e-17	Total body bone mineral density;
LUAD	cis	rs1595825	0.891	rs41468149	chr2:198910107	C/G	cg10547527	chr2:198650123	BOLL	0.52	7.06	0.32	6.7e-12	Ulcerative colitis;
LUAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg21951975	chr1:209979733	IRF6	0.77	18.22	0.66	3.67e-55	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUAD	cis	rs6066835	1.000	rs6125448	chr20:47353178	G/A	cg18078177	chr20:47281410	PREX1	0.76	6.61	0.31	1.15e-10	Multiple myeloma;
LUAD	cis	rs67072384	1.000	rs7122017	chr11:72448558	C/G	cg04827223	chr11:72435913	ARAP1	-0.64	-7.66	-0.35	1.31e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.54	0.52	7.02e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg17063962	chr7:91808500	NA	-0.66	-11.93	-0.5	1.78e-28	Breast cancer;
LUAD	cis	rs12049351	0.774	rs1444727	chr1:229616758	T/C	cg11742688	chr1:229674241	ABCB10	-0.4	-6.56	-0.3	1.6e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs3772130	1.000	rs11719458	chr3:121382005	C/T	cg20356878	chr3:121714668	ILDR1	0.5	7.59	0.35	2.04e-13	Cognitive performance;
LUAD	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg00071950	chr4:10020882	SLC2A9	0.72	14.84	0.59	2.08e-40	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg15117754	chr3:10150083	C3orf24	0.45	7.46	0.34	4.87e-13	Alzheimer's disease;
LUAD	cis	rs62238980	0.614	rs743764	chr22:32459217	C/T	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs754466	0.580	rs2579177	chr10:79529245	C/T	cg17075019	chr10:79541650	NA	-0.9	-19.24	-0.68	1.05e-59	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg00898013	chr13:113819073	PROZ	-0.68	-12.19	-0.51	1.7e-29	Platelet distribution width;
LUAD	cis	rs1997103	1.000	rs6951294	chr7:55400835	C/T	cg17469321	chr7:55412551	NA	0.67	11.39	0.48	2.05e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg14791747	chr16:20752902	THUMPD1	0.49	7.66	0.35	1.29e-13	Pancreatic cancer;
LUAD	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg27454412	chr7:1067447	C7orf50	0.43	7.34	0.34	1.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs6940638	0.956	rs12199218	chr6:27025281	T/C	cg06606381	chr12:133084897	FBRSL1	-0.49	-6.46	-0.3	2.9e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs208520	0.661	rs150263	chr6:66777620	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.2	-0.64	1.15e-50	Exhaled nitric oxide output;
LUAD	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg27490568	chr2:178487706	NA	0.42	7.12	0.33	4.69e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg05434287	chr7:2030229	MAD1L1	0.41	6.63	0.31	1.01e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg25566285	chr7:158114605	PTPRN2	0.52	10.93	0.47	1.2e-24	Calcium levels;
LUAD	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg00106254	chr7:1943704	MAD1L1	-0.44	-6.4	-0.3	4.08e-10	Schizophrenia;
LUAD	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg04155289	chr7:94953770	PON1	-0.57	-7.39	-0.34	7.67e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21984481	chr17:79567631	NPLOC4	0.71	17.13	0.64	2.46e-50	Eye color traits;
LUAD	cis	rs7178572	0.568	rs4886866	chr15:77696166	A/T	cg15453836	chr15:77711506	NA	-0.37	-6.52	-0.3	1.99e-10	Type 2 diabetes;
LUAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10819733	chr22:24237672	NA	-0.41	-7.69	-0.35	1.05e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg11693508	chr17:37793320	STARD3	0.49	7.12	0.33	4.54e-12	Neuroticism;
LUAD	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg06740227	chr12:86229804	RASSF9	0.46	7.97	0.36	1.46e-14	Major depressive disorder;
LUAD	cis	rs9899728	0.764	rs9660	chr17:73038746	A/G	cg27626185	chr17:73056755	KCTD2	-0.56	-7.09	-0.33	5.48e-12	Alzheimer's disease or small vessel stroke;
LUAD	cis	rs11031096	0.727	rs2268168	chr11:4142069	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.44	-0.34	5.7e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.33	-6.38	-0.3	4.6e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg26898376	chr11:64110657	CCDC88B	0.38	7.08	0.33	6.23e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg15691649	chr6:25882328	NA	0.63	9.49	0.42	1.64e-19	Blood metabolite levels;
LUAD	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg26597838	chr10:835615	NA	1.31	20.91	0.71	3.59e-67	Eosinophil percentage of granulocytes;
LUAD	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg03929089	chr4:120376271	NA	-0.96	-19.69	-0.69	9.6e-62	Height;
LUAD	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg09359103	chr1:154839909	KCNN3	-0.91	-20.76	-0.71	1.56e-66	Prostate cancer;
LUAD	cis	rs12760731	0.565	rs12044522	chr1:178190180	G/T	cg00404053	chr1:178313656	RASAL2	0.72	9.09	0.4	4.02e-18	Obesity-related traits;
LUAD	cis	rs28830936	0.966	rs1918310	chr15:42065253	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.52	-0.3	1.97e-10	Diastolic blood pressure;
LUAD	trans	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.4	-0.38	7.05e-16	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.41	-0.3	3.87e-10	Neuroticism;
LUAD	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg18180107	chr4:99064573	C4orf37	0.42	6.76	0.31	4.64e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10802521	chr3:52805072	NEK4	-0.54	-9.03	-0.4	6.21e-18	Bipolar disorder;
LUAD	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.77	0.31	4.42e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg17761419	chr8:57350749	NA	-0.58	-8.38	-0.38	8.05e-16	Obesity-related traits;
LUAD	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg03806693	chr22:41940476	POLR3H	0.52	7.73	0.35	8.15e-14	Vitiligo;
LUAD	cis	rs500891	0.525	rs6454322	chr6:84057542	A/G	cg08257003	chr6:84140564	ME1	0.34	6.68	0.31	7.45e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg08888203	chr3:10149979	C3orf24	0.73	10.94	0.47	1.02e-24	Alzheimer's disease;
LUAD	cis	rs231513	0.954	rs231494	chr17:41976928	G/C	cg26893861	chr17:41843967	DUSP3	-0.54	-6.55	-0.3	1.69e-10	Cognitive function;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg06361531	chr16:68057779	DUS2L;DDX28	-0.41	-6.95	-0.32	1.36e-11	Subcortical brain region volumes;
LUAD	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg23262073	chr20:60523788	NA	-0.38	-6.76	-0.31	4.71e-11	Body mass index;
LUAD	cis	rs4285028	0.948	rs12493952	chr3:121708497	C/T	cg11130432	chr3:121712080	ILDR1	-0.58	-8.41	-0.38	6.48e-16	Multiple sclerosis;
LUAD	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg00495681	chr13:53174319	NA	0.48	8.95	0.4	1.1e-17	Lewy body disease;
LUAD	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg15181151	chr6:150070149	PCMT1	-0.35	-6.85	-0.32	2.63e-11	Lung cancer;
LUAD	cis	rs2932538	0.922	rs12137107	chr1:113127437	A/G	cg22162597	chr1:113214053	CAPZA1	0.46	6.85	0.32	2.59e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg05340658	chr4:99064831	C4orf37	0.44	7.3	0.33	1.4e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg09796270	chr17:17721594	SREBF1	-0.37	-6.95	-0.32	1.35e-11	Total body bone mineral density;
LUAD	cis	rs1371867	0.775	rs3020183	chr8:101233297	A/T	cg06636551	chr8:101224915	SPAG1	0.4	7.32	0.34	1.3e-12	Atrioventricular conduction;
LUAD	cis	rs7191700	0.836	rs28502009	chr16:11426541	G/A	cg00044050	chr16:11439710	C16orf75	0.67	9.55	0.42	1.1e-19	Multiple sclerosis;
LUAD	cis	rs6516091	0.850	rs1884651	chr20:6047012	A/C	cg25325723	chr20:6104886	FERMT1	-0.57	-6.49	-0.3	2.36e-10	Abdominal aortic aneurysm;
LUAD	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.49	-0.34	4.13e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg02176678	chr2:219576539	TTLL4	-0.77	-15.94	-0.61	3.91e-45	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs62238980	0.614	rs33954001	chr22:32506050	C/G	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg13390004	chr1:15929781	NA	0.48	8.46	0.38	4.54e-16	Systolic blood pressure;
LUAD	cis	rs11030122	0.702	rs2898947	chr11:3977572	G/A	cg18678763	chr11:4115507	RRM1	-0.44	-7.33	-0.34	1.14e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs6748734	0.948	rs4675858	chr2:241840558	G/A	cg07537917	chr2:241836409	C2orf54	-0.3	-8.28	-0.37	1.66e-15	Urinary metabolites;
LUAD	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg21782813	chr7:2030301	MAD1L1	-0.45	-7.53	-0.34	3.03e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs17253792	0.822	rs76555508	chr14:56071868	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs2041840	1.000	rs2714470	chr2:37486527	A/G	cg25727520	chr2:37576821	QPCT	-0.35	-7.17	-0.33	3.44e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.47	7.68	0.35	1.13e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22968622	chr17:43663579	NA	-0.93	-16.14	-0.62	5.35e-46	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg10518543	chr12:38710700	ALG10B	0.5	8.19	0.37	3.09e-15	Heart rate;
LUAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg20607798	chr8:58055168	NA	0.72	9.44	0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg19610905	chr11:61596333	FADS2	-0.67	-11.33	-0.48	3.73e-26	Trans fatty acid levels;
LUAD	cis	rs938554	0.577	rs4591605	chr4:10002719	T/C	cg00071950	chr4:10020882	SLC2A9	0.62	9.45	0.42	2.28e-19	Blood metabolite levels;
LUAD	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg09796270	chr17:17721594	SREBF1	-0.36	-7.13	-0.33	4.42e-12	Total body bone mineral density;
LUAD	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg27284194	chr4:1044797	NA	0.71	10.19	0.44	6.08e-22	Recombination rate (females);
LUAD	cis	rs7975161	0.638	rs10861170	chr12:104615957	A/G	cg25282972	chr12:104565846	NA	-0.34	-6.64	-0.31	9.63e-11	Toenail selenium levels;
LUAD	cis	rs34734847	0.750	rs3829290	chr12:121126438	T/C	cg27246729	chr12:121163418	ACADS	0.37	6.85	0.32	2.58e-11	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg27454412	chr7:1067447	C7orf50	-0.34	-6.71	-0.31	6.22e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg25767906	chr1:53392781	SCP2	-0.44	-8.08	-0.37	6.75e-15	Monocyte count;
LUAD	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg09904177	chr6:26538194	HMGN4	0.43	7.31	0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.3	6.65	0.31	9.1e-11	Systemic lupus erythematosus;
LUAD	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg13319975	chr6:146136371	FBXO30	0.66	11.4	0.48	2.02e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg27532560	chr4:187881888	NA	-0.35	-6.66	-0.31	8.44e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg09904177	chr6:26538194	HMGN4	0.45	7.15	0.33	3.78e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg27532560	chr4:187881888	NA	-0.38	-7.33	-0.34	1.15e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs938554	0.570	rs7696983	chr4:9995829	A/C	cg11266682	chr4:10021025	SLC2A9	0.54	9.38	0.41	4.14e-19	Blood metabolite levels;
LUAD	trans	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg14917512	chr19:3094685	GNA11	-0.57	-6.7	-0.31	6.69e-11	Diabetic kidney disease;
LUAD	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.48	-9.47	-0.42	1.95e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg17105886	chr17:28927953	LRRC37B2	0.8	7.7	0.35	9.93e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg23992470	chr4:843637	GAK	0.71	7.39	0.34	8.02e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4481887	0.741	rs1361413	chr1:248529521	C/G	cg00666640	chr1:248458726	OR2T12	-0.29	-6.97	-0.32	1.23e-11	Common traits (Other);
LUAD	trans	rs4942242	0.967	rs58325557	chr13:44217771	A/G	cg19169023	chr15:41853346	TYRO3	0.53	9.25	0.41	1.11e-18	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.16	0.54	2.23e-33	Exhaled nitric oxide output;
LUAD	cis	rs2658782	1.000	rs2605582	chr11:93163799	C/T	cg15737290	chr11:93063684	CCDC67	0.53	7.47	0.34	4.61e-13	Pulmonary function decline;
LUAD	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18876405	chr7:65276391	NA	0.56	9.42	0.42	2.99e-19	Aortic root size;
LUAD	trans	rs7615952	0.546	rs2979350	chr3:125362215	T/C	cg00769240	chr8:12517080	NA	-0.38	-6.57	-0.3	1.45e-10	Blood pressure (smoking interaction);
LUAD	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg26384229	chr12:38710491	ALG10B	-0.44	-7.24	-0.33	2.17e-12	Bladder cancer;
LUAD	trans	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.2	-0.37	2.98e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.48	-6.94	-0.32	1.52e-11	Schizophrenia;
LUAD	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg01528321	chr10:82214614	TSPAN14	0.52	8.21	0.37	2.76e-15	Post bronchodilator FEV1;
LUAD	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg06221963	chr1:154839813	KCNN3	-0.85	-20.05	-0.7	2.38e-63	Prostate cancer;
LUAD	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.57	10.99	0.47	7.08e-25	Hemoglobin concentration;
LUAD	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg23262073	chr20:60523788	NA	-0.45	-7.17	-0.33	3.35e-12	Body mass index;
LUAD	trans	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.73	10.76	0.46	4.82e-24	Ulcerative colitis;
LUAD	cis	rs2979489	0.533	rs62505280	chr8:30448124	C/T	cg26383811	chr8:30366931	RBPMS	-0.55	-8.35	-0.38	9.49e-16	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg07917127	chr4:99064746	C4orf37	0.4	6.56	0.3	1.54e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg02934500	chr4:142557404	IL15	-0.4	-6.45	-0.3	3.08e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.58	-0.35	2.13e-13	Neuroticism;
LUAD	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.67	-0.35	1.2e-13	Resting heart rate;
LUAD	cis	rs9296092	0.538	rs80012910	chr6:33519542	G/A	cg13560919	chr6:33536144	NA	-0.89	-16.71	-0.63	1.64e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs1865721	0.771	rs4622605	chr18:73139008	T/C	cg26385618	chr18:73139727	C18orf62	-0.51	-10.35	-0.45	1.51e-22	Intelligence;
LUAD	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14426312	chr9:71395063	FAM122A;PIP5K1B	-0.4	-6.53	-0.3	1.94e-10	Cancer;
LUAD	trans	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg07393940	chr7:158741817	NA	-0.7	-11.91	-0.5	2.19e-28	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg02428538	chr16:24856791	SLC5A11	-0.55	-7.22	-0.33	2.44e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.516	rs4640173	chr16:68163602	C/A	cg05110241	chr16:68378359	PRMT7	-0.56	-7.08	-0.33	5.89e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg05639522	chr1:247681581	NA	0.35	6.58	0.3	1.39e-10	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg12863693	chr15:85201151	NMB	0.4	7.54	0.34	2.95e-13	Schizophrenia;
LUAD	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg27446573	chr6:127587934	RNF146	0.44	6.5	0.3	2.28e-10	Breast cancer;
LUAD	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg23978390	chr7:1156363	C7orf50	0.58	7.95	0.36	1.68e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs62400317	0.826	rs4544895	chr6:45271917	A/T	cg18551225	chr6:44695536	NA	-0.55	-8.57	-0.38	1.89e-16	Total body bone mineral density;
LUAD	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg10636054	chr15:40330586	SRP14	1.04	11.88	0.5	2.74e-28	Corneal curvature;
LUAD	cis	rs4604732	0.578	rs79203328	chr1:247626581	C/G	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs9807989	0.507	rs13021177	chr2:103056493	A/G	cg03938978	chr2:103052716	IL18RAP	0.46	10.68	0.46	9.82e-24	Asthma;
LUAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-10.9	-0.47	1.44e-24	Longevity;Endometriosis;
LUAD	cis	rs747650	0.926	rs10838659	chr11:47148210	C/T	cg19486271	chr11:47235900	DDB2	-0.41	-6.68	-0.31	7.39e-11	Acne (severe);
LUAD	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg05110241	chr16:68378359	PRMT7	-0.95	-10.66	-0.46	1.13e-23	Schizophrenia;
LUAD	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg06028605	chr16:24865363	SLC5A11	0.36	6.37	0.3	5.07e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg17652424	chr22:38574118	PLA2G6	-0.33	-10.19	-0.44	5.84e-22	Cutaneous nevi;
LUAD	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg05457628	chr5:178986728	RUFY1	0.69	12.35	0.51	4.04e-30	Lung cancer;
LUAD	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg19761014	chr17:28927070	LRRC37B2	0.65	7.59	0.35	2.03e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg22963979	chr7:1858916	MAD1L1	0.37	6.46	0.3	2.82e-10	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUAD	cis	rs4285028	0.948	rs1920309	chr3:121665479	G/A	cg11130432	chr3:121712080	ILDR1	-0.58	-8.12	-0.37	5.33e-15	Multiple sclerosis;
LUAD	cis	rs7116495	1.000	rs7127865	chr11:71747781	G/C	cg07596299	chr11:71824057	C11orf51	-0.77	-6.62	-0.31	1.08e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg14019695	chr9:139328340	INPP5E	0.51	9.8	0.43	1.44e-20	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04565464	chr8:145669602	NFKBIL2	0.43	6.76	0.31	4.54e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2971970	0.519	rs62470447	chr7:133632339	C/T	cg03336402	chr7:133662267	EXOC4	0.41	7.37	0.34	9.24e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs9929218	0.906	rs33965787	chr16:68828173	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.76	-0.53	8.79e-32	Colorectal cancer;
LUAD	cis	rs751728	1.000	rs11752297	chr6:33735154	G/C	cg13859433	chr6:33739653	LEMD2	-0.4	-9.41	-0.42	3.33e-19	Crohn's disease;
LUAD	cis	rs7000551	0.725	rs2449349	chr8:22383284	A/G	cg12081754	chr8:22256438	SLC39A14	0.4	6.68	0.31	7.55e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg21238619	chr17:78079768	GAA	-0.35	-6.83	-0.32	3e-11	Yeast infection;
LUAD	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg07423050	chr13:99094983	FARP1	-0.54	-9.0	-0.4	7.99e-18	Longevity;
LUAD	cis	rs3739034	0.582	rs62171408	chr2:135539472	T/A	cg12500956	chr2:135428796	TMEM163	0.37	6.51	0.3	2.18e-10	Gut microbiome composition (winter);
LUAD	cis	rs3820068	0.705	rs11577225	chr1:15864242	T/C	cg13390004	chr1:15929781	NA	0.42	6.68	0.31	7.7e-11	Systolic blood pressure;
LUAD	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.02	-0.5	7.98e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg06064525	chr11:970664	AP2A2	-0.45	-8.81	-0.39	3.21e-17	Alzheimer's disease (late onset);
LUAD	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg02569458	chr12:86230093	RASSF9	0.43	7.82	0.36	4.34e-14	Major depressive disorder;
LUAD	cis	rs9948	0.786	rs62152774	chr2:97448377	A/G	cg20312557	chr2:97357134	FER1L5	-0.63	-7.36	-0.34	9.71e-13	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18404041	chr3:52824283	ITIH1	-0.6	-12.12	-0.51	3.31e-29	Bipolar disorder;
LUAD	cis	rs1232027	0.700	rs1677692	chr5:79937014	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs1598856	1.000	rs11934404	chr4:103437601	A/G	cg07973026	chr4:103553119	MANBA	0.41	6.65	0.31	9.13e-11	Primary biliary cholangitis;
LUAD	cis	rs76878669	0.561	rs1784029	chr11:66099987	C/T	cg10616300	chr11:66138557	SLC29A2	0.35	7.33	0.34	1.2e-12	Educational attainment (years of education);
LUAD	cis	rs7937890	0.559	rs2597200	chr11:14485600	A/G	cg22961513	chr11:14280813	SPON1	-0.37	-7.18	-0.33	3.18e-12	Mitochondrial DNA levels;
LUAD	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg02175503	chr12:58329896	NA	0.43	6.73	0.31	5.49e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg22535103	chr8:58192502	C8orf71	-0.67	-9.54	-0.42	1.14e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg00495681	chr13:53174319	NA	0.78	15.73	0.61	3.31e-44	Lewy body disease;
LUAD	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg08470875	chr2:26401718	FAM59B	-0.6	-8.2	-0.37	2.96e-15	Gut microbiome composition (summer);
LUAD	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg15448220	chr1:150897856	SETDB1	0.46	7.98	0.36	1.39e-14	Tonsillectomy;
LUAD	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg26513180	chr16:89883248	FANCA	0.51	9.0	0.4	7.99e-18	Vitiligo;
LUAD	cis	rs2992756	0.663	rs1360919	chr1:18805844	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.57	-9.79	-0.43	1.53e-20	Breast cancer;
LUAD	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.7	-11.83	-0.5	4.36e-28	Primary sclerosing cholangitis;
LUAD	cis	rs68092024	0.731	rs792840	chr3:99471251	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-7.66	-0.35	1.27e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg09658497	chr7:2847517	GNA12	-0.55	-9.49	-0.42	1.74e-19	Height;
LUAD	cis	rs4076764	0.535	rs4409627	chr1:163382050	A/G	cg06092702	chr1:163392909	NA	0.3	6.94	0.32	1.45e-11	Motion sickness;
LUAD	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg02269571	chr22:50332266	NA	-0.67	-9.63	-0.42	5.61e-20	Schizophrenia;
LUAD	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.34	0.38	1.04e-15	Platelet count;
LUAD	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-24.12	-0.76	1.69e-81	Height;
LUAD	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg04731861	chr2:219085781	ARPC2	0.24	7.25	0.33	1.98e-12	Colorectal cancer;
LUAD	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.73	-14.89	-0.59	1.3e-40	Urate levels in overweight individuals;
LUAD	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg16606324	chr3:10149918	C3orf24	0.65	11.24	0.48	7.93e-26	Alzheimer's disease;
LUAD	cis	rs950169	0.922	rs62029585	chr15:84951874	C/G	cg11189052	chr15:85197271	WDR73	0.57	7.2	0.33	2.76e-12	Schizophrenia;
LUAD	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.85	-0.36	3.56e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	8.03e-16	Body mass index;
LUAD	trans	rs931812	0.825	rs55818461	chr8:101899229	T/C	cg20993868	chr7:22813445	NA	0.63	12.56	0.52	5.72e-31	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg20307385	chr11:47447363	PSMC3	0.65	11.12	0.48	2.16e-25	Diastolic blood pressure;Systolic blood pressure;
LUAD	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg03517284	chr6:25882590	NA	0.49	7.9	0.36	2.46e-14	Blood metabolite levels;
LUAD	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19717773	chr7:2847554	GNA12	-0.53	-8.98	-0.4	8.66e-18	Height;
LUAD	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg27572855	chr1:25598939	RHD	-0.54	-11.39	-0.48	2.15e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs380904	0.552	rs10099003	chr8:144645460	C/T	cg13399544	chr8:144649678	C8orf73	-0.47	-7.18	-0.33	3.12e-12	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg06092702	chr1:163392909	NA	-0.4	-8.77	-0.39	4.44e-17	Motion sickness;
LUAD	cis	rs11979158	0.503	rs10256393	chr7:55027846	A/C	cg23757825	chr7:55092271	EGFR	0.47	6.96	0.32	1.32e-11	Glioma;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23653187	chr22:44319257	PNPLA3	-0.39	-6.37	-0.3	4.94e-10	Cancer;
LUAD	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs9952991	0.941	rs45450798	chr18:12792940	C/G	cg23544223	chr18:12777786	NA	-0.71	-8.65	-0.39	1.09e-16	Inflammatory skin disease;
LUAD	cis	rs9296092	0.517	rs7743178	chr6:33470462	G/A	cg13560919	chr6:33536144	NA	-0.78	-12.25	-0.51	9.84e-30	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.42	-8.07	-0.37	7.3e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg25767906	chr1:53392781	SCP2	-0.42	-7.45	-0.34	5.31e-13	Monocyte count;
LUAD	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.51	8.6	0.39	1.53e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs853679	0.527	rs9461443	chr6:28194629	A/T	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.6	0.31	1.23e-10	Depression;
LUAD	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06873352	chr17:61820015	STRADA	0.55	8.95	0.4	1.13e-17	Height;
LUAD	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg18230493	chr5:56204884	C5orf35	-0.58	-9.48	-0.42	1.9e-19	Coronary artery disease;
LUAD	cis	rs12545109	0.613	rs10958480	chr8:57278717	A/T	cg07776626	chr8:57350775	NA	-0.64	-8.77	-0.39	4.33e-17	Obesity-related traits;
LUAD	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg14345882	chr6:26364793	BTN3A2	0.59	6.66	0.31	8.72e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.8	0.39	3.42e-17	Menopause (age at onset);
LUAD	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg18306943	chr3:40428807	ENTPD3	-0.37	-6.37	-0.3	5.05e-10	Renal cell carcinoma;
LUAD	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-8.42	-0.38	5.76e-16	Glomerular filtration rate;
LUAD	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg20203395	chr5:56204925	C5orf35	-0.82	-11.72	-0.5	1.16e-27	Initial pursuit acceleration;
LUAD	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18876405	chr7:65276391	NA	-0.65	-11.35	-0.48	3.06e-26	Aortic root size;
LUAD	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg16989719	chr2:238392110	NA	-0.36	-7.65	-0.35	1.39e-13	Prostate cancer;
LUAD	cis	rs6547631	0.622	rs1561285	chr2:85924384	C/G	cg21473183	chr2:85925749	GNLY	0.35	7.58	0.35	2.2e-13	Blood protein levels;
LUAD	cis	rs9039	1.000	rs11862745	chr16:9218887	C/T	cg08831531	chr16:9218945	NA	0.42	7.91	0.36	2.33e-14	Menopause (age at onset);
LUAD	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg21918786	chr6:109611834	NA	-0.58	-10.61	-0.46	1.84e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg27490568	chr2:178487706	NA	0.54	8.43	0.38	5.68e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg07211511	chr3:129823064	LOC729375	-0.43	-6.4	-0.3	4.2e-10	Blood pressure (smoking interaction);
LUAD	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg14668632	chr7:2872130	GNA12	-0.7	-12.84	-0.53	4.38e-32	Height;
LUAD	trans	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07923666	chr12:49932857	KCNH3	0.53	6.91	0.32	1.83e-11	Resting heart rate;
LUAD	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg17848003	chr1:3704513	LRRC47	0.53	10.67	0.46	1.09e-23	Red cell distribution width;
LUAD	cis	rs10916814	0.632	rs1890003	chr1:20899101	T/C	cg24502330	chr1:20914028	CDA	-0.36	-7.18	-0.33	3.14e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg15181151	chr6:150070149	PCMT1	0.37	7.25	0.33	1.95e-12	Lung cancer;
LUAD	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.43	-0.52	1.89e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.56	-0.3	1.56e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg14092988	chr3:52407081	DNAH1	0.34	7.03	0.32	8.35e-12	Bipolar disorder;
LUAD	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg00310523	chr12:86230176	RASSF9	0.41	8.68	0.39	8.6e-17	Major depressive disorder;
LUAD	trans	rs75804782	0.521	rs72994973	chr2:239428315	C/T	cg01134436	chr17:81009848	B3GNTL1	0.78	8.36	0.38	9.24e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03934478	chr11:495069	RNH1	0.76	8.92	0.4	1.44e-17	Body mass index;
LUAD	cis	rs7851660	0.874	rs1955143	chr9:100634579	A/T	cg13688889	chr9:100608707	NA	-0.48	-8.28	-0.37	1.69e-15	Strep throat;
LUAD	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg13770153	chr20:60521292	NA	-0.58	-9.07	-0.4	4.6e-18	Body mass index;
LUAD	cis	rs12900413	0.687	rs12913409	chr15:90319251	T/A	cg24249390	chr15:90295951	MESP1	-0.35	-7.01	-0.32	9.56e-12	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs7009516	0.653	rs4442155	chr8:24220787	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.33	6.51	0.3	2.08e-10	Hair greying;
LUAD	cis	rs3956705	0.762	rs13437980	chr7:32997749	C/T	cg05721444	chr7:32995514	FKBP9	-0.37	-6.63	-0.31	1.02e-10	Red cell distribution width;
LUAD	cis	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg02743256	chr7:2109353	MAD1L1	-0.41	-6.48	-0.3	2.57e-10	Neuroticism;
LUAD	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	7.15	0.33	3.82e-12	Renal cell carcinoma;
LUAD	cis	rs3806843	0.576	rs246059	chr5:140325010	G/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg07507251	chr3:52567010	NT5DC2	0.49	10.5	0.45	4.6e-23	Electroencephalogram traits;
LUAD	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg12863693	chr15:85201151	NMB	0.39	6.95	0.32	1.42e-11	Schizophrenia;
LUAD	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg01884057	chr2:25150051	NA	0.32	6.83	0.32	2.96e-11	Body mass index;
LUAD	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.38	0.3	4.69e-10	Cardiac Troponin-T levels;
LUAD	cis	rs72960926	0.590	rs114287599	chr6:74748504	C/T	cg03266952	chr6:74778945	NA	-0.82	-7.23	-0.33	2.29e-12	Metabolite levels (MHPG);
LUAD	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg10589385	chr1:150898437	SETDB1	0.45	8.44	0.38	5.11e-16	Melanoma;
LUAD	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.66	-11.56	-0.49	4.72e-27	Melanoma;
LUAD	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg20891283	chr12:69753455	YEATS4	0.43	7.04	0.32	7.8e-12	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11890956	chr21:40555474	PSMG1	0.82	14.74	0.58	5.43e-40	Cognitive function;
LUAD	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg21856205	chr7:94953877	PON1	0.55	7.72	0.35	8.53e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1451375	1.000	rs1966839	chr7:50627101	T/C	cg18232548	chr7:50535776	DDC	0.58	9.48	0.42	1.86e-19	Malaria;
LUAD	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg03859395	chr2:55845619	SMEK2	-0.66	-11.76	-0.5	7.72e-28	Metabolic syndrome;
LUAD	trans	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg18335740	chr13:41363409	SLC25A15	0.52	8.32	0.38	1.19e-15	Lewy body disease;
LUAD	cis	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.55	6.68	0.31	7.56e-11	Depression;
LUAD	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00149659	chr3:10157352	C3orf10	0.53	7.35	0.34	1.06e-12	Alzheimer's disease;
LUAD	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg02176678	chr2:219576539	TTLL4	0.61	11.75	0.5	8.57e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.34	-8.9	-0.4	1.7e-17	Total body bone mineral density;
LUAD	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg23503501	chr22:45809793	SMC1B;RIBC2	-0.7	-7.69	-0.35	1.01e-13	Tonsillectomy;
LUAD	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg22166914	chr1:53195759	ZYG11B	-0.44	-7.62	-0.35	1.73e-13	Monocyte count;
LUAD	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg17063962	chr7:91808500	NA	0.61	10.1	0.44	1.21e-21	Breast cancer;
LUAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08439880	chr3:133502540	NA	-0.45	-9.15	-0.41	2.38e-18	Iron status biomarkers;
LUAD	cis	rs6714710	0.580	rs17489915	chr2:98420431	T/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.18	0.37	3.37e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs1403694	0.695	rs11924390	chr3:186433099	T/C	cg12454167	chr3:186435060	KNG1	0.53	10.76	0.46	4.81e-24	Blood protein levels;
LUAD	cis	rs4660306	0.961	rs3748643	chr1:45965703	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-8.04	-0.36	8.88e-15	Homocysteine levels;
LUAD	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg22683308	chr4:1340831	KIAA1530	-0.42	-6.9	-0.32	1.9e-11	Longevity;
LUAD	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg11663144	chr21:46675770	NA	-0.51	-9.18	-0.41	1.98e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9902453	1.000	rs4795525	chr17:28388487	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-9.23	-0.41	1.27e-18	Coffee consumption (cups per day);
LUAD	cis	rs6546550	0.935	rs1056482	chr2:70108256	A/T	cg02498382	chr2:70120550	SNRNP27	-0.54	-10.73	-0.46	6.68e-24	Prevalent atrial fibrillation;
LUAD	cis	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05901451	chr6:126070800	HEY2	-0.44	-6.69	-0.31	6.95e-11	Endometrial cancer;
LUAD	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg16479474	chr6:28041457	NA	0.38	6.57	0.3	1.51e-10	Parkinson's disease;
LUAD	cis	rs6445967	0.530	rs12634132	chr3:58409082	A/G	cg13750441	chr3:58318267	PXK	-0.33	-6.78	-0.31	4.09e-11	Platelet count;
LUAD	cis	rs782590	0.574	rs12991445	chr2:55675939	C/T	cg03859395	chr2:55845619	SMEK2	0.57	9.53	0.42	1.27e-19	Metabolic syndrome;
LUAD	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg24503407	chr1:205819492	PM20D1	-0.5	-8.18	-0.37	3.39e-15	Parkinson's disease;
LUAD	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg14092988	chr3:52407081	DNAH1	0.45	9.1	0.4	3.54e-18	Bipolar disorder;
LUAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg05434287	chr7:2030229	MAD1L1	0.42	7.08	0.33	6.02e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg25036284	chr2:26402008	FAM59B	-0.6	-8.3	-0.37	1.37e-15	Gut microbiome composition (summer);
LUAD	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.34	-6.93	-0.32	1.6e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg00071950	chr4:10020882	SLC2A9	0.86	18.37	0.67	7.73e-56	Bone mineral density;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24022402	chr3:9834453	ARPC4;TADA3	-0.42	-6.64	-0.31	9.46e-11	Height;
LUAD	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg01416388	chr22:39784598	NA	-0.53	-9.04	-0.4	5.48e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.82	0.36	4.39e-14	Bladder cancer;
LUAD	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg26384229	chr12:38710491	ALG10B	0.47	7.68	0.35	1.13e-13	Bladder cancer;
LUAD	cis	rs2797160	0.967	rs984041	chr6:126021328	A/T	cg05901451	chr6:126070800	HEY2	0.43	6.48	0.3	2.53e-10	Endometrial cancer;
LUAD	cis	rs12681288	0.550	rs7000482	chr8:958380	T/C	cg04851639	chr8:1020857	NA	-0.34	-7.89	-0.36	2.53e-14	Schizophrenia;
LUAD	cis	rs4077468	1.000	rs4077468	chr1:205914757	A/G	cg11965913	chr1:205819406	PM20D1	-0.38	-6.77	-0.31	4.2e-11	Cystic fibrosis-related diabetes;
LUAD	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg26924012	chr15:45694286	SPATA5L1	1.03	19.24	0.68	1.05e-59	Homoarginine levels;
LUAD	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	6.92	0.32	1.64e-11	Platelet count;
LUAD	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg04944784	chr2:26401820	FAM59B	0.73	9.38	0.41	4.11e-19	Gut microbiome composition (summer);
LUAD	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg27170947	chr2:26402098	FAM59B	-0.68	-9.42	-0.42	3.07e-19	Gut microbiome composition (summer);
LUAD	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg06387496	chr7:2775674	GNA12	-0.38	-6.36	-0.3	5.25e-10	Height;
LUAD	cis	rs556990	0.760	rs3024739	chr13:113819948	G/A	cg00898013	chr13:113819073	PROZ	-0.85	-15.0	-0.59	4.23e-41	Blood protein levels;
LUAD	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg19678392	chr7:94953810	PON1	-0.57	-7.88	-0.36	2.87e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1595825	0.891	rs35817167	chr2:198718928	A/T	cg00982548	chr2:198649783	BOLL	-0.64	-9.1	-0.4	3.61e-18	Ulcerative colitis;
LUAD	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg22875332	chr1:76189707	ACADM	0.9	18.45	0.67	3.36e-56	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg27432699	chr2:27873401	GPN1	0.57	10.13	0.44	9.59e-22	Oral cavity cancer;
LUAD	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg11530693	chr1:120165357	ZNF697	0.86	18.8	0.67	9.46e-58	Systemic lupus erythematosus;
LUAD	cis	rs1451375	0.527	rs6950777	chr7:50597056	G/A	cg18232548	chr7:50535776	DDC	0.55	7.93	0.36	1.92e-14	Malaria;
LUAD	cis	rs71478720	0.953	rs1834481	chr11:112023827	C/G	cg26534425	chr11:112034925	IL18	-0.47	-7.26	-0.33	1.85e-12	Interleukin-18 levels;
LUAD	cis	rs7818345	0.874	rs56298301	chr8:19305937	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.34	7.26	0.33	1.85e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs77972916	0.518	rs55877805	chr2:43557597	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-7.07	-0.32	6.54e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg22166914	chr1:53195759	ZYG11B	0.44	7.76	0.35	6.26e-14	Monocyte count;
LUAD	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg17971929	chr21:40555470	PSMG1	0.53	8.25	0.37	2e-15	Cognitive function;
LUAD	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg17330251	chr7:94953956	PON1	-0.54	-7.58	-0.35	2.21e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg08885076	chr2:99613938	TSGA10	-0.4	-7.1	-0.33	5.33e-12	Chronic sinus infection;
LUAD	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg03037974	chr15:76606532	NA	0.47	10.87	0.47	2e-24	Blood metabolite levels;
LUAD	cis	rs7119038	0.774	rs73005423	chr11:118681079	A/G	cg19308663	chr11:118741387	NA	0.46	6.52	0.3	2.04e-10	Sjögren's syndrome;
LUAD	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.64	-9.64	-0.42	4.99e-20	Alzheimer's disease;
LUAD	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg27144592	chr16:783916	NARFL	0.38	7.14	0.33	3.97e-12	Height;
LUAD	cis	rs11209185	0.509	rs12130147	chr1:68446944	G/A	cg22082780	chr1:68452167	NA	0.51	10.57	0.46	2.41e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs12681288	0.550	rs6989880	chr8:957209	A/G	cg04851639	chr8:1020857	NA	-0.34	-8.03	-0.36	9.91e-15	Schizophrenia;
LUAD	cis	rs62400317	0.859	rs12191262	chr6:45227016	G/A	cg20913747	chr6:44695427	NA	-0.43	-6.86	-0.32	2.43e-11	Total body bone mineral density;
LUAD	cis	rs28735056	0.587	rs8093548	chr18:77636451	G/A	cg20368463	chr18:77673604	PQLC1	-0.48	-7.64	-0.35	1.46e-13	Schizophrenia;
LUAD	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg04756594	chr16:24857601	SLC5A11	0.54	10.38	0.45	1.23e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg05754148	chr16:3507555	NAT15	-0.42	-6.44	-0.3	3.17e-10	Body mass index (adult);
LUAD	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg11062466	chr8:58055876	NA	0.67	8.47	0.38	4.18e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg00634984	chr7:65235879	NA	0.47	6.37	0.3	4.91e-10	Aortic root size;
LUAD	cis	rs1775715	0.707	rs2808087	chr10:32146444	C/G	cg04359828	chr10:32216031	ARHGAP12	0.31	6.48	0.3	2.54e-10	Bipolar disorder with mood-incongruent psychosis;
LUAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg04025307	chr7:1156635	C7orf50	0.83	15.28	0.6	2.85e-42	Longevity;Endometriosis;
LUAD	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg16205897	chr5:131564050	P4HA2	-0.42	-9.6	-0.42	6.89e-20	Blood metabolite levels;
LUAD	trans	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg26811252	chr16:29126840	RRN3P2	0.62	10.6	0.46	2.01e-23	Menopause (age at onset);
LUAD	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg02734326	chr4:10020555	SLC2A9	-0.41	-7.13	-0.33	4.47e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg00784671	chr22:46762841	CELSR1	-0.57	-7.66	-0.35	1.3e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg15921436	chr17:44337874	NA	-0.59	-8.84	-0.4	2.54e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs12505328	0.932	rs10034403	chr4:174356463	T/C	cg12145043	chr4:174357286	NA	-0.57	-9.95	-0.44	4.11e-21	Chin dimples;
LUAD	cis	rs7940866	0.738	rs10791114	chr11:130889850	G/A	cg12179176	chr11:130786555	SNX19	0.43	6.9	0.32	1.93e-11	Schizophrenia;
LUAD	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg18240062	chr17:79603768	NPLOC4	0.39	6.85	0.32	2.59e-11	Eye color traits;
LUAD	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg07930552	chr6:133119739	C6orf192	0.85	6.56	0.3	1.6e-10	Type 2 diabetes nephropathy;
LUAD	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.83	-0.5	4.49e-28	Mean corpuscular volume;
LUAD	trans	rs3942852	0.955	rs1532754	chr11:48115279	A/T	cg03929089	chr4:120376271	NA	-0.56	-7.69	-0.35	1.03e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9837602	1.000	rs9833888	chr3:99723580	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.65	9.34	0.41	5.36e-19	Breast cancer;
LUAD	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg06046430	chr4:77819534	ANKRD56	0.54	8.64	0.39	1.21e-16	Emphysema distribution in smoking;
LUAD	cis	rs250677	0.522	rs55732303	chr5:148392538	C/T	cg12140854	chr5:148520817	ABLIM3	-0.55	-8.42	-0.38	5.82e-16	Breast cancer;
LUAD	cis	rs9283706	0.594	rs1366338	chr5:66344307	A/G	cg11590213	chr5:66331682	MAST4	-0.4	-6.59	-0.31	1.33e-10	Coronary artery disease;
LUAD	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.53	-8.98	-0.4	8.88e-18	Longevity;Endometriosis;
LUAD	trans	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg26043149	chr18:55253948	FECH	-0.49	-8.32	-0.38	1.21e-15	Bone mineral density;
LUAD	cis	rs116248771	0.690	rs116470672	chr3:158337762	C/T	cg16708174	chr3:158430962	RARRES1	0.46	6.78	0.31	4.11e-11	diarrhoeal disease at age 2;
LUAD	cis	rs1784581	0.802	rs9365359	chr6:162423945	C/A	cg17173639	chr6:162384350	PARK2	0.47	8.71	0.39	6.97e-17	Itch intensity from mosquito bite;
LUAD	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.83	0.53	4.5e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg16325326	chr1:53192061	ZYG11B	-0.71	-13.7	-0.55	1.26e-35	Monocyte count;
LUAD	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg18180107	chr4:99064573	C4orf37	0.45	7.07	0.33	6.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4919694	1.000	rs11191490	chr10:104745174	T/A	cg04362960	chr10:104952993	NT5C2	0.74	7.71	0.35	9.02e-14	Arsenic metabolism;
LUAD	trans	rs9354308	0.899	rs2802056	chr6:66546219	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.52	8.07	0.37	7.58e-15	Metabolite levels;
LUAD	cis	rs736801	0.521	rs41525648	chr5:131827775	A/G	cg00255919	chr5:131827918	IRF1	-0.4	-9.07	-0.4	4.47e-18	Breast cancer;Mosquito bite size;
LUAD	trans	rs9393777	0.841	rs34332556	chr6:27357414	C/G	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.7	-0.35	9.48e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7166081	0.688	rs12903168	chr15:67680209	T/C	cg27219399	chr15:67835830	MAP2K5	0.37	6.41	0.3	3.97e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs1595825	0.732	rs10198804	chr2:198461941	A/C	cg00982548	chr2:198649783	BOLL	-0.49	-6.83	-0.32	2.89e-11	Ulcerative colitis;
LUAD	cis	rs2742234	0.590	rs2505553	chr10:43681251	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.52	-8.89	-0.4	1.82e-17	Hirschsprung disease;
LUAD	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.54	0.38	2.47e-16	Platelet count;
LUAD	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.59	0.35	2.07e-13	Depression;
LUAD	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg24558204	chr6:135376177	HBS1L	0.49	9.08	0.4	4.18e-18	Red blood cell count;
LUAD	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg02734326	chr4:10020555	SLC2A9	0.42	7.31	0.33	1.38e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.52	-0.38	2.94e-16	Height;
LUAD	cis	rs7617773	0.780	rs11714176	chr3:48360862	C/T	cg11946769	chr3:48343235	NME6	0.44	6.79	0.31	3.73e-11	Coronary artery disease;
LUAD	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg03563238	chr19:33554763	RHPN2	0.36	8.59	0.39	1.72e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg25811766	chr13:21894605	NA	-0.62	-7.4	-0.34	7.28e-13	White matter hyperintensity burden;
LUAD	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg13385794	chr1:248469461	NA	0.26	7.06	0.32	6.94e-12	Common traits (Other);
LUAD	cis	rs11048434	0.626	rs1805736	chr12:9084931	A/G	cg23795048	chr12:9217529	LOC144571	-0.41	-7.53	-0.34	3.16e-13	Sjögren's syndrome;
LUAD	trans	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.95	-16.57	-0.63	6.98e-48	Colorectal cancer;
LUAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	9.45	0.42	2.31e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.49	-9.72	-0.43	2.81e-20	Monocyte percentage of white cells;
LUAD	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg10518543	chr12:38710700	ALG10B	-0.44	-7.29	-0.33	1.55e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg08999081	chr20:33150536	PIGU	-0.45	-8.72	-0.39	6.26e-17	Coronary artery disease;
LUAD	trans	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg04995722	chr7:26192034	NFE2L3	-0.44	-7.65	-0.35	1.38e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9297145	0.585	rs10953281	chr7:98772131	C/T	cg05967295	chr7:98741636	SMURF1	-0.72	-13.44	-0.55	1.51e-34	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22968622	chr17:43663579	NA	1.35	24.66	0.77	7.34e-84	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7709909	0.755	rs32950	chr5:80018244	A/G	cg24059623	chr5:79951536	MSH3;DHFR	0.47	8.68	0.39	8.62e-17	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs2979489	0.945	rs11992441	chr8:30313649	A/G	cg26383811	chr8:30366931	RBPMS	0.63	9.78	0.43	1.73e-20	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs494562	0.892	rs521005	chr6:86116542	A/G	cg17966619	chr6:86160162	NT5E	0.66	7.93	0.36	1.92e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7771547	0.573	rs9470274	chr6:36397229	G/A	cg04289385	chr6:36355825	ETV7	0.43	6.61	0.31	1.14e-10	Platelet distribution width;
LUAD	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg19318889	chr4:1322082	MAEA	0.45	7.96	0.36	1.6e-14	Obesity-related traits;
LUAD	cis	rs4786125	0.588	rs1473516	chr16:6923077	C/T	cg03623568	chr16:6915990	A2BP1	-0.48	-10.31	-0.45	2.14e-22	Heart rate variability traits (SDNN);
LUAD	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg00530320	chr1:46809349	NSUN4	0.53	7.66	0.35	1.26e-13	Menopause (age at onset);
LUAD	cis	rs870825	0.616	rs9715644	chr4:185632965	C/T	cg04058563	chr4:185651563	MLF1IP	0.9	14.41	0.57	1.39e-38	Blood protein levels;
LUAD	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg18512352	chr11:47633146	NA	0.41	7.3	0.33	1.42e-12	Subjective well-being;
LUAD	trans	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.35	0.45	1.56e-22	Mean corpuscular volume;
LUAD	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg10950924	chr17:47092072	IGF2BP1	-0.37	-7.14	-0.33	4.05e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs13315871	1.000	rs11708590	chr3:58336635	A/G	cg20936604	chr3:58311152	NA	0.68	7.1	0.33	5.39e-12	Cholesterol, total;
LUAD	trans	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	17.85	0.66	1.59e-53	Exhaled nitric oxide output;
LUAD	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg25985355	chr7:65971099	NA	-0.55	-6.75	-0.31	4.77e-11	Diabetic kidney disease;
LUAD	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg17105886	chr17:28927953	LRRC37B2	0.74	6.77	0.31	4.37e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg03859395	chr2:55845619	SMEK2	0.74	13.81	0.56	4.46e-36	Metabolic syndrome;
LUAD	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg25358565	chr5:93447407	FAM172A	0.62	7.32	0.34	1.25e-12	Diabetic retinopathy;
LUAD	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.51	-8.21	-0.37	2.74e-15	Lymphocyte percentage of white cells;
LUAD	cis	rs807669	0.903	rs807668	chr22:19162686	A/G	cg24911827	chr22:19170109	CLTCL1	0.47	9.87	0.43	8.1899999999999992e-21	Metabolite levels;
LUAD	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.69	-13.48	-0.55	1.02e-34	Ulcerative colitis;
LUAD	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg21171335	chr12:122356390	WDR66	0.76	14.4	0.57	1.54e-38	Mean corpuscular volume;
LUAD	cis	rs9381040	0.701	rs722442	chr6:41089681	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.47	-7.98	-0.36	1.4e-14	Alzheimer's disease (late onset);
LUAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08280861	chr8:58055591	NA	0.63	8.31	0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs12122100	0.651	rs6665411	chr1:146547095	A/G	cg03526459	chr1:146549940	NA	0.41	7.7	0.35	1e-13	HIV-1 control;
LUAD	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg02423579	chr7:2872169	GNA12	-0.57	-9.7	-0.43	3.23e-20	Height;
LUAD	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.99	-0.36	1.25e-14	Prostate cancer;
LUAD	cis	rs2244497	0.869	rs990083	chr17:64440066	A/G	cg14121185	chr17:64488849	PRKCA	-0.41	-6.42	-0.3	3.68e-10	Neuroticism;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg19743759	chr9:35072884	VCP	-0.4	-6.77	-0.31	4.35e-11	Subcortical brain region volumes;
LUAD	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg21427119	chr20:30132790	HM13	-0.58	-8.6	-0.39	1.54e-16	Mean corpuscular hemoglobin;
LUAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg18538332	chr22:24372958	LOC391322	0.46	6.69	0.31	7.05e-11	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg09509183	chr1:209979624	IRF6	0.59	9.07	0.4	4.66e-18	Cleft lip with or without cleft palate;
LUAD	cis	rs71478720	0.953	rs5744256	chr11:112022848	A/G	cg26534425	chr11:112034925	IL18	0.47	7.14	0.33	4.11e-12	Interleukin-18 levels;
LUAD	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg14345882	chr6:26364793	BTN3A2	0.57	6.45	0.3	3.11e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7737355	0.947	rs1468303	chr5:130804400	T/C	cg25547332	chr5:131281432	NA	-0.42	-6.39	-0.3	4.3e-10	Life satisfaction;
LUAD	cis	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg21775007	chr8:11205619	TDH	-0.4	-6.79	-0.31	3.86e-11	Retinal vascular caliber;
LUAD	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg21475434	chr5:93447410	FAM172A	0.77	8.65	0.39	1.11e-16	Diabetic retinopathy;
LUAD	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg00074818	chr8:8560427	CLDN23	0.64	9.95	0.44	4.16e-21	Obesity-related traits;
LUAD	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.55	-0.34	2.79e-13	Bipolar disorder;
LUAD	cis	rs7818345	0.637	rs3923920	chr8:19359184	A/G	cg06699216	chr8:19333253	CSGALNACT1	0.26	6.59	0.3	1.34e-10	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg00898013	chr13:113819073	PROZ	-0.64	-11.48	-0.49	9.86e-27	Platelet distribution width;
LUAD	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.58	-9.85	-0.43	9.8e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs7224685	0.501	rs781820	chr17:3976075	C/G	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.4	6.82	0.31	3.07e-11	Type 2 diabetes;
LUAD	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2041840	0.924	rs8243	chr2:37477794	C/A	cg25727520	chr2:37576821	QPCT	-0.36	-7.38	-0.34	8.18e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg00750074	chr16:89608354	SPG7	-0.44	-6.45	-0.3	3.03e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg10862848	chr6:42927986	GNMT	-0.31	-8.93	-0.4	1.28e-17	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.39	6.77	0.31	4.22e-11	Body mass index (adult);
LUAD	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg27494647	chr7:150038898	RARRES2	0.53	9.55	0.42	1.02e-19	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg23758822	chr17:41437982	NA	1.01	20.89	0.71	4.12e-67	Menopause (age at onset);
LUAD	cis	rs7737355	0.812	rs28610	chr5:130832382	T/C	cg25547332	chr5:131281432	NA	0.4	6.5	0.3	2.28e-10	Life satisfaction;
LUAD	cis	rs7107174	0.901	rs2450133	chr11:77925759	A/C	cg02023728	chr11:77925099	USP35	0.51	7.88	0.36	2.7e-14	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg03467027	chr4:99064603	C4orf37	0.41	6.7	0.31	6.61e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg06697600	chr4:7070879	GRPEL1	0.55	7.94	0.36	1.89e-14	Monocyte percentage of white cells;
LUAD	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg19875535	chr5:140030758	IK	0.46	7.78	0.35	5.77e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-7.21	-0.33	2.67e-12	Personality dimensions;
LUAD	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.72	10.48	0.45	5.15e-23	IgG glycosylation;
LUAD	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1728785	0.901	rs1183956	chr16:68606726	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.4	0.45	1.02e-22	Ulcerative colitis;
LUAD	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg02660097	chr11:68866761	NA	0.46	6.45	0.3	3.01e-10	Blond vs. brown hair color;
LUAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg11301795	chr4:187892539	NA	0.78	15.92	0.61	4.75e-45	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg25894440	chr7:65020034	NA	-0.62	-6.63	-0.31	1.05e-10	Diabetic kidney disease;
LUAD	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg00750074	chr16:89608354	SPG7	-0.6	-10.5	-0.45	4.62e-23	Multiple myeloma (IgH translocation);
LUAD	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg25344623	chr2:136566232	LCT	-0.35	-6.71	-0.31	6.14e-11	Mosquito bite size;
LUAD	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.5	-6.36	-0.3	5.23e-10	Iron status biomarkers;
LUAD	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg24634471	chr8:143751801	JRK	0.48	7.6	0.35	1.89e-13	Schizophrenia;
LUAD	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg04398451	chr17:18023971	MYO15A	0.64	11.58	0.49	3.83e-27	Strep throat;
LUAD	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg13402656	chr8:1511478	DLGAP2	-0.66	-13.02	-0.53	7.97e-33	Lung cancer;
LUAD	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg20848291	chr7:100343083	ZAN	-0.58	-7.89	-0.36	2.53e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.28	0.45	2.75e-22	Ileal carcinoids;
LUAD	cis	rs300703	0.515	rs424292	chr2:191931	C/T	cg21211680	chr2:198530	NA	-0.51	-7.39	-0.34	8.14e-13	Blood protein levels;
LUAD	cis	rs6500395	1.000	rs871902	chr16:48593779	A/G	cg04672837	chr16:48644449	N4BP1	0.37	6.45	0.3	3.13e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs11048434	0.698	rs1805745	chr12:9065226	A/T	cg26114124	chr12:9217669	LOC144571	0.36	6.38	0.3	4.52e-10	Sjögren's syndrome;
LUAD	cis	rs4722404	0.502	rs6461817	chr7:3109425	C/T	cg19214707	chr7:3157722	NA	-0.41	-6.62	-0.31	1.1e-10	Atopic dermatitis;
LUAD	cis	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg27411982	chr8:10470053	RP1L1	-0.39	-6.98	-0.32	1.13e-11	Systolic blood pressure;
LUAD	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg27170947	chr2:26402098	FAM59B	-0.82	-11.49	-0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg19875535	chr5:140030758	IK	0.46	7.77	0.35	5.97e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg25804541	chr17:80189381	SLC16A3	0.33	7.25	0.33	1.98e-12	Life satisfaction;
LUAD	cis	rs7680126	0.633	rs4697975	chr4:10209966	A/T	cg00071950	chr4:10020882	SLC2A9	-0.57	-7.82	-0.36	4.33e-14	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg17551891	chr7:1960795	MAD1L1	-0.39	-6.8	-0.31	3.69e-11	Neuroticism;
LUAD	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.53	9.38	0.41	4.18e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4638749	0.677	rs17035849	chr2:108842593	G/T	cg25838818	chr2:108905173	SULT1C2	-0.44	-7.84	-0.36	3.59e-14	Blood pressure;
LUAD	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg02527881	chr3:46936655	PTH1R	0.43	8.33	0.38	1.17e-15	Colorectal cancer;
LUAD	trans	rs8002861	0.905	rs11617551	chr13:44443977	T/C	cg17145862	chr1:211918768	LPGAT1	-0.69	-15.16	-0.59	9.37e-42	Leprosy;
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19575883	chr2:172231724	METTL8	0.44	6.65	0.31	8.81e-11	Hepatitis;
LUAD	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg19536664	chr17:6899085	ALOX12	0.58	11.31	0.48	4.31e-26	Tonsillectomy;
LUAD	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg19875535	chr5:140030758	IK	-0.41	-6.99	-0.32	1.06e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2249625	0.816	rs2496499	chr6:72884414	T/A	cg18830697	chr6:72922368	RIMS1	-0.35	-6.66	-0.31	8.28e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs6541297	0.703	rs1264081	chr1:230311176	A/G	cg20703242	chr1:230279135	GALNT2	-0.46	-6.78	-0.31	4.01e-11	Coronary artery disease;
LUAD	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.86	0.32	2.49e-11	Depression;
LUAD	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg21427119	chr20:30132790	HM13	-0.64	-9.5	-0.42	1.63e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs2455799	0.574	rs2102212	chr3:15704223	C/T	cg16303742	chr3:15540471	COLQ	-0.53	-10.01	-0.44	2.62e-21	Mean platelet volume;
LUAD	cis	rs78761021	0.860	rs62066047	chr17:9772011	T/A	cg26853458	chr17:9805074	RCVRN	0.35	6.72	0.31	5.72e-11	Type 2 diabetes;
LUAD	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg01448562	chr3:133502909	NA	-0.45	-7.89	-0.36	2.58e-14	Iron status biomarkers;
LUAD	cis	rs1691799	0.899	rs1168357	chr12:66749879	T/C	cg16791601	chr12:66731901	HELB	-0.37	-6.61	-0.31	1.17e-10	White blood cell count (basophil);
LUAD	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.38	6.4	0.3	4.1e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7737355	0.773	rs1019122	chr5:131099227	C/T	cg06307176	chr5:131281290	NA	0.46	7.58	0.35	2.24e-13	Life satisfaction;
LUAD	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg24397884	chr7:158709396	WDR60	-0.74	-13.61	-0.55	3.15e-35	Height;
LUAD	cis	rs7193541	0.825	rs4411525	chr16:74595502	A/C	cg01733217	chr16:74700730	RFWD3	0.58	9.62	0.42	5.84e-20	Multiple myeloma;
LUAD	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg06608945	chr2:219082296	ARPC2	0.47	8.04	0.36	8.95e-15	Colorectal cancer;
LUAD	cis	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg08601574	chr20:25228251	PYGB	-0.46	-8.72	-0.39	6.46e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.6	-10.3	-0.45	2.48e-22	Mean corpuscular volume;
LUAD	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg11062466	chr8:58055876	NA	0.62	8.15	0.37	4.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg22663859	chr13:21900854	NA	0.48	7.95	0.36	1.71e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs597583	0.806	rs1940039	chr11:117393102	C/T	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.6	-0.39	1.51e-16	Putamen volume;
LUAD	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg14994056	chr11:107992015	ACAT1	-0.56	-6.99	-0.32	1.11e-11	Colorectal cancer;
LUAD	cis	rs11756438	0.683	rs72962906	chr6:119008305	C/T	cg21191810	chr6:118973309	C6orf204	0.42	7.48	0.34	4.41e-13	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-7.15	-0.33	3.91e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg00316803	chr15:76480434	C15orf27	-0.39	-7.28	-0.33	1.6e-12	Blood metabolite levels;
LUAD	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg01528321	chr10:82214614	TSPAN14	0.74	11.16	0.48	1.65e-25	Post bronchodilator FEV1;
LUAD	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12210905	0.688	rs12215289	chr6:27468705	T/C	cg08851530	chr6:28072375	NA	1.03	7.92	0.36	2.19e-14	Hip circumference adjusted for BMI;
LUAD	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg22491629	chr6:157744540	C6orf35	-0.79	-8.98	-0.4	8.9e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6596100	0.500	rs67685368	chr5:132292946	T/G	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Breast cancer;
LUAD	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	7.2	0.33	2.76e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs28374715	0.617	rs16971733	chr15:41562030	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.6	-10.87	-0.47	1.96e-24	Ulcerative colitis;
LUAD	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.54	-0.46	3.15e-23	Monocyte percentage of white cells;
LUAD	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg25036284	chr2:26402008	FAM59B	0.83	11.53	0.49	6.03e-27	Gut microbiome composition (summer);
LUAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg00280220	chr17:61926910	NA	0.36	6.98	0.32	1.17e-11	Prudent dietary pattern;
LUAD	cis	rs2445762	0.642	rs8025191	chr15:51623785	A/G	cg07517944	chr15:51633816	GLDN	0.44	7.37	0.34	8.89e-13	Hormone measurements;
LUAD	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg05340658	chr4:99064831	C4orf37	0.53	8.51	0.38	2.98e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs735539	0.958	rs1075690	chr13:21279690	G/A	cg27499820	chr13:21296301	IL17D	0.41	7.23	0.33	2.29e-12	Dental caries;
LUAD	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18099408	chr3:52552593	STAB1	0.43	7.72	0.35	8.48e-14	Bipolar disorder;
LUAD	trans	rs2262909	0.962	rs56369285	chr19:22267185	T/C	cg17074339	chr11:11642133	GALNTL4	0.48	7.74	0.35	7.23e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs62238980	0.614	rs80035296	chr22:32387536	C/T	cg00543991	chr22:32367038	NA	0.92	8.15	0.37	4.03e-15	Childhood ear infection;
LUAD	cis	rs500891	0.525	rs13198062	chr6:84075281	C/T	cg08257003	chr6:84140564	ME1	0.33	6.36	0.3	5.31e-10	Platelet-derived growth factor BB levels;
LUAD	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03517284	chr6:25882590	NA	-0.51	-7.57	-0.35	2.35e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs1018836	0.537	rs13251501	chr8:91458796	G/A	cg16814680	chr8:91681699	NA	-0.61	-9.6	-0.42	7.19e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg14926445	chr8:58193284	C8orf71	-0.47	-6.52	-0.3	1.97e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg22920501	chr2:26401640	FAM59B	0.96	13.91	0.56	1.82e-36	Gut microbiome composition (summer);
LUAD	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg07266350	chr3:49460521	AMT;NICN1	0.36	6.39	0.3	4.5e-10	Menarche (age at onset);
LUAD	cis	rs208520	0.874	rs208456	chr6:66907942	A/G	cg07460842	chr6:66804631	NA	-1.0	-13.92	-0.56	1.58e-36	Exhaled nitric oxide output;
LUAD	trans	rs10838798	0.584	rs1566732	chr11:48151494	A/C	cg00717180	chr2:96193071	NA	0.37	6.78	0.31	4.02e-11	Height;
LUAD	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg21016266	chr12:122356598	WDR66	0.62	10.92	0.47	1.23e-24	Mean corpuscular volume;
LUAD	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	10.76	0.46	4.83e-24	Resting heart rate;
LUAD	cis	rs8177876	0.822	rs1410	chr16:81115833	T/G	cg08591886	chr16:81111003	C16orf46	-0.79	-7.37	-0.34	8.94e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03352830	chr11:487213	PTDSS2	0.77	10.0	0.44	2.73e-21	Body mass index;
LUAD	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg06263672	chr7:65235340	NA	0.47	6.4	0.3	4.14e-10	Aortic root size;
LUAD	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08280861	chr8:58055591	NA	0.55	7.04	0.32	8.03e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs12618769	0.543	rs58778964	chr2:99110599	G/C	cg10123293	chr2:99228465	UNC50	0.46	8.39	0.38	7.48e-16	Bipolar disorder;
LUAD	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg02569458	chr12:86230093	RASSF9	0.41	7.5	0.34	3.78e-13	Major depressive disorder;
LUAD	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06544989	chr22:39130855	UNC84B	0.46	9.3	0.41	7.56e-19	Menopause (age at onset);
LUAD	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	cis	rs250585	0.736	rs193937	chr16:23436358	C/T	cg00143387	chr16:23521605	GGA2	0.61	8.78	0.39	3.98e-17	Egg allergy;
LUAD	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg20203395	chr5:56204925	C5orf35	-0.85	-9.93	-0.43	5.09e-21	Type 2 diabetes;
LUAD	cis	rs1403694	0.966	rs9869244	chr3:186437554	A/T	cg12454167	chr3:186435060	KNG1	0.43	8.85	0.4	2.34e-17	Blood protein levels;
LUAD	cis	rs10911251	0.528	rs10911264	chr1:183115040	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.68	0.31	7.58e-11	Colorectal cancer;
LUAD	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg05616858	chr17:37843591	ERBB2;PGAP3	0.33	6.61	0.31	1.19e-10	Asthma;
LUAD	trans	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg03886242	chr7:26192032	NFE2L3	-0.43	-7.6	-0.35	1.88e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg15445000	chr17:37608096	MED1	-0.44	-8.22	-0.37	2.44e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg25319279	chr11:5960081	NA	-0.41	-7.84	-0.36	3.62e-14	DNA methylation (variation);
LUAD	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg02733842	chr7:1102375	C7orf50	-0.62	-9.74	-0.43	2.39e-20	Bronchopulmonary dysplasia;
LUAD	trans	rs9302065	0.529	rs2993582	chr13:95958181	G/T	cg19955956	chr7:72299837	SBDSP;TYW1B	0.55	9.36	0.41	4.58e-19	Blood metabolite levels;
LUAD	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg00204512	chr16:28754710	NA	0.32	6.85	0.32	2.66e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg18209359	chr17:80159595	CCDC57	-0.4	-6.93	-0.32	1.59e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs11153730	0.503	rs445099	chr6:118618252	T/C	cg21191810	chr6:118973309	C6orf204	0.53	10.63	0.46	1.47e-23	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.43	0.3	3.53e-10	Parkinson's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03208214	chr14:71786911	NA	-0.44	-6.95	-0.32	1.43e-11	Height;
LUAD	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg05182265	chr7:156933206	UBE3C	-0.8	-17.12	-0.64	2.55e-50	Body mass index;
LUAD	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg21918786	chr6:109611834	NA	-0.52	-9.91	-0.43	5.82e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg21475434	chr5:93447410	FAM172A	-0.52	-7.22	-0.33	2.45e-12	Diabetic retinopathy;
LUAD	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg15448220	chr1:150897856	SETDB1	0.47	8.07	0.37	7.18e-15	Tonsillectomy;
LUAD	cis	rs225245	0.782	rs161183	chr17:33919475	G/C	cg05299278	chr17:33885742	SLFN14	0.52	11.95	0.5	1.43e-28	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	11.29	0.48	4.91e-26	Resting heart rate;
LUAD	cis	rs17095355	0.605	rs7916801	chr10:111632445	A/G	cg00817464	chr10:111662876	XPNPEP1	0.6	7.61	0.35	1.76e-13	Biliary atresia;
LUAD	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg05368731	chr17:41323189	NBR1	0.95	19.52	0.69	5.41e-61	Menopause (age at onset);
LUAD	cis	rs6696239	0.513	rs2935146	chr1:227786033	G/A	cg12133451	chr1:227746453	NA	-0.36	-6.39	-0.3	4.51e-10	Height;
LUAD	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg12310025	chr6:25882481	NA	-0.79	-13.3	-0.54	5.61e-34	Blood metabolite levels;
LUAD	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.46	8.2	0.37	2.86e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.86	0.32	2.49e-11	Depression;
LUAD	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg12311346	chr5:56204834	C5orf35	-0.47	-7.78	-0.35	5.43e-14	Coronary artery disease;
LUAD	trans	rs1941687	0.800	rs12968906	chr18:31378307	G/A	cg27147174	chr7:100797783	AP1S1	-0.53	-8.95	-0.4	1.1e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg11901034	chr3:128598214	ACAD9	-0.54	-8.46	-0.38	4.55e-16	IgG glycosylation;
LUAD	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg12458913	chr13:53173898	NA	0.41	7.44	0.34	5.55e-13	Lewy body disease;
LUAD	trans	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg11693508	chr17:37793320	STARD3	0.71	9.34	0.41	5.49e-19	Bipolar disorder;
LUAD	cis	rs8060686	0.641	rs7204192	chr16:68039309	A/G	cg05110241	chr16:68378359	PRMT7	-0.62	-7.22	-0.33	2.36e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs807669	0.933	rs712959	chr22:19159015	C/T	cg02655711	chr22:19163373	SLC25A1	0.72	15.25	0.6	3.65e-42	Metabolite levels;
LUAD	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg26536354	chr8:144654954	C8orf73	0.61	6.74	0.31	5.25e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs9394841	0.692	rs13193235	chr6:41792659	T/C	cg25600774	chr6:41776562	USP49	-0.44	-6.66	-0.31	8.78e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.37	0.38	8.26e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg02018176	chr4:1364513	KIAA1530	0.53	9.9	0.43	6.37e-21	Longevity;
LUAD	cis	rs12367572	1.000	rs7295923	chr12:45269284	C/T	cg04608330	chr12:45269318	NELL2	-0.39	-7.47	-0.34	4.75e-13	Gut microbiome composition (summer);
LUAD	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg20908204	chr19:46285434	DMPK	-0.35	-7.43	-0.34	6.11e-13	Coronary artery disease;
LUAD	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg09796270	chr17:17721594	SREBF1	-0.37	-7.25	-0.33	1.99e-12	Total body bone mineral density;
LUAD	cis	rs3750965	1.000	rs1466222	chr11:68832848	G/A	cg06818126	chr11:68850279	TPCN2	-0.46	-6.69	-0.31	7.23e-11	Hair color;
LUAD	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg07741184	chr6:167504864	NA	0.29	7.03	0.32	8.43e-12	Crohn's disease;
LUAD	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg11247378	chr22:39784982	NA	-0.72	-13.48	-0.55	1.02e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3960554	0.808	rs4728587	chr7:75803132	C/T	cg19862616	chr7:65841803	NCRNA00174	0.82	10.91	0.47	1.33e-24	Eotaxin levels;
LUAD	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg06618935	chr21:46677482	NA	-0.49	-9.92	-0.43	5.23e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6087990	0.735	rs6057647	chr20:31381690	A/T	cg13636640	chr20:31349939	DNMT3B	0.75	13.46	0.55	1.31e-34	Ulcerative colitis;
LUAD	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg18306943	chr3:40428807	ENTPD3	0.42	7.11	0.33	4.96e-12	Renal cell carcinoma;
LUAD	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.6	-0.35	1.95e-13	Blood trace element (Zn levels);
LUAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg04025307	chr7:1156635	C7orf50	0.69	9.63	0.42	5.57e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg22676075	chr6:135203613	NA	-0.41	-7.48	-0.34	4.41e-13	Red blood cell count;
LUAD	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg19041857	chr6:27730383	NA	-0.44	-7.48	-0.34	4.35e-13	Parkinson's disease;
LUAD	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	7.43	0.34	6.25e-13	Tonsillectomy;
LUAD	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg23533926	chr12:111358616	MYL2	-0.42	-7.25	-0.33	2.01e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7072216	0.763	rs2147900	chr10:100174721	T/C	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.7	-0.39	7.57e-17	Metabolite levels;
LUAD	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg19302996	chr17:73780495	UNK	-0.41	-6.96	-0.32	1.29e-11	White matter hyperintensity burden;
LUAD	cis	rs6987853	0.749	rs2974367	chr8:42431194	G/C	cg09913449	chr8:42400586	C8orf40	0.47	9.1	0.4	3.45e-18	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg21153622	chr11:89784906	NA	-0.34	-6.66	-0.31	8.33e-11	Coronary artery disease;
LUAD	cis	rs10992471	0.630	rs10453241	chr9:95198887	C/A	cg14631576	chr9:95140430	CENPP	-0.42	-8.46	-0.38	4.45e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg06646493	chr1:116519019	SLC22A15	-0.49	-6.54	-0.3	1.77e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs420259	0.516	rs9302410	chr16:23511372	C/T	cg00143387	chr16:23521605	GGA2	-0.68	-9.42	-0.42	3.04e-19	Bipolar disorder;
LUAD	cis	rs62229266	0.804	rs2835259	chr21:37425302	T/C	cg08632701	chr21:37451849	NA	-0.43	-7.09	-0.33	5.69e-12	Mitral valve prolapse;
LUAD	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.29	-0.33	1.49e-12	Resting heart rate;
LUAD	cis	rs4803468	1.000	rs9304593	chr19:41942875	A/C	cg09537434	chr19:41945824	ATP5SL	0.5	7.89	0.36	2.61e-14	Height;
LUAD	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg26924012	chr15:45694286	SPATA5L1	1.02	18.89	0.68	3.74e-58	Homoarginine levels;
LUAD	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03517284	chr6:25882590	NA	-0.74	-10.79	-0.46	3.88e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg27068330	chr11:65405492	SIPA1	0.74	11.89	0.5	2.62e-28	Systemic lupus erythematosus;
LUAD	cis	rs977987	0.586	rs12920883	chr16:75432681	T/C	cg03315344	chr16:75512273	CHST6	0.64	14.08	0.56	3.36e-37	Dupuytren's disease;
LUAD	trans	rs3857536	0.741	rs9363558	chr6:66937260	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19346786	chr7:2764209	NA	-0.56	-12.17	-0.51	2.09e-29	Height;
LUAD	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22307029	chr19:49891270	CCDC155	0.8	13.08	0.54	4.75e-33	Multiple sclerosis;
LUAD	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg04827223	chr11:72435913	ARAP1	-0.48	-7.27	-0.33	1.81e-12	Type 2 diabetes;
LUAD	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg06002616	chr8:101225028	SPAG1	-0.38	-7.83	-0.36	3.97e-14	Atrioventricular conduction;
LUAD	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg04546413	chr19:29218101	NA	0.71	10.52	0.46	3.77e-23	Methadone dose in opioid dependence;
LUAD	cis	rs3935685	0.874	rs4334265	chr15:78007432	T/C	cg25212270	chr15:78015279	NA	0.31	6.57	0.3	1.45e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2742234	0.614	rs3026750	chr10:43607756	G/A	cg02780029	chr10:43622663	RET	-0.41	-6.58	-0.3	1.37e-10	Hirschsprung disease;
LUAD	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg00204512	chr16:28754710	NA	0.33	7.12	0.33	4.52e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg19622623	chr12:86230825	RASSF9	-0.54	-9.76	-0.43	1.97e-20	Major depressive disorder;
LUAD	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg24324837	chr19:49891574	CCDC155	0.46	6.39	0.3	4.43e-10	Multiple sclerosis;
LUAD	trans	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.57	-0.35	2.29e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg00277334	chr10:82204260	NA	-0.95	-21.62	-0.72	2.34e-70	Post bronchodilator FEV1;
LUAD	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.41	6.36	0.3	5.33e-10	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg22029157	chr1:209979665	IRF6	0.47	8.29	0.37	1.52e-15	Monobrow;
LUAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg07677032	chr17:61819896	STRADA	0.57	10.26	0.45	3.42e-22	Prudent dietary pattern;
LUAD	cis	rs8177876	0.822	rs80315956	chr16:81112859	G/A	cg08591886	chr16:81111003	C16orf46	-0.76	-7.01	-0.32	9.76e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03264133	chr6:25882463	NA	0.83	13.82	0.56	4.24e-36	Blood metabolite levels;
LUAD	cis	rs7599312	0.517	rs10192988	chr2:213407782	T/G	cg16329650	chr2:213403929	ERBB4	0.61	11.02	0.47	5.34e-25	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7731657	0.537	rs6595989	chr5:130359215	C/T	cg08523029	chr5:130500466	HINT1	-0.55	-7.33	-0.34	1.18e-12	Fasting plasma glucose;
LUAD	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.75	-0.35	6.69e-14	Breast cancer;
LUAD	trans	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.58	-10.12	-0.44	1.07e-21	Mean corpuscular volume;
LUAD	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg15123519	chr2:136567270	LCT	0.39	7.11	0.33	4.99e-12	Mosquito bite size;
LUAD	cis	rs1595825	0.945	rs61184128	chr2:198843659	C/T	cg00361562	chr2:198649771	BOLL	-0.47	-6.66	-0.31	8.73e-11	Ulcerative colitis;
LUAD	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.53	0.3	1.85e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg22117172	chr7:91764530	CYP51A1	0.32	7.21	0.33	2.52e-12	Breast cancer;
LUAD	cis	rs2019216	0.564	rs1518053	chr17:21924272	G/T	cg05591447	chr17:21909280	FLJ36000	-0.27	-6.55	-0.3	1.62e-10	Pelvic organ prolapse;
LUAD	cis	rs7267979	0.586	rs1007707	chr20:25190598	A/G	cg08601574	chr20:25228251	PYGB	0.36	6.68	0.31	7.34e-11	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg26898376	chr11:64110657	CCDC88B	0.45	8.66	0.39	1.01e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg00310523	chr12:86230176	RASSF9	0.39	7.76	0.35	6.41e-14	Major depressive disorder;
LUAD	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg08999081	chr20:33150536	PIGU	-0.37	-7.36	-0.34	9.93e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg01657329	chr11:68192670	LRP5	-0.43	-6.84	-0.32	2.82e-11	Total body bone mineral density;
LUAD	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg00717180	chr2:96193071	NA	-0.45	-8.65	-0.39	1.11e-16	HDL cholesterol;
LUAD	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg13560548	chr3:10150139	C3orf24	0.42	6.99	0.32	1.09e-11	Alzheimer's disease;
LUAD	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.4	-0.38	7.03e-16	Prostate cancer;
LUAD	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.98	23.32	0.75	6.06e-78	Birth weight;
LUAD	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg05182265	chr7:156933206	UBE3C	-0.8	-17.35	-0.64	2.59e-51	Body mass index;
LUAD	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg25427524	chr10:38739819	LOC399744	0.46	6.5	0.3	2.33e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg14829155	chr15:31115871	NA	-0.55	-9.15	-0.41	2.37e-18	Huntington's disease progression;
LUAD	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg18446336	chr7:2847575	GNA12	-0.36	-6.8	-0.31	3.62e-11	Height;
LUAD	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg19761014	chr17:28927070	LRRC37B2	0.84	8.41	0.38	6.44e-16	Body mass index;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg24677268	chr2:61764011	XPO1	0.37	6.42	0.3	3.75e-10	Bipolar disorder;
LUAD	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.49	-0.34	4.08e-13	Bipolar disorder;
LUAD	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg01448562	chr3:133502909	NA	-0.54	-8.98	-0.4	9.05e-18	Iron status biomarkers;
LUAD	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg17264618	chr3:40429014	ENTPD3	0.4	9.04	0.4	5.82e-18	Renal cell carcinoma;
LUAD	cis	rs877282	0.898	rs11253338	chr10:759559	C/T	cg17470449	chr10:769945	NA	0.6	8.91	0.4	1.59e-17	Uric acid levels;
LUAD	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg22823121	chr1:150693482	HORMAD1	0.45	9.06	0.4	4.95e-18	Tonsillectomy;
LUAD	cis	rs11051970	0.704	rs2733694	chr12:32555230	A/G	cg02745156	chr12:32552066	NA	0.3	6.56	0.3	1.58e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1595825	0.735	rs2228135	chr2:198950029	A/G	cg00361562	chr2:198649771	BOLL	-0.51	-7.0	-0.32	1e-11	Ulcerative colitis;
LUAD	cis	rs73198271	1.000	rs11776513	chr8:8609057	T/C	cg01851573	chr8:8652454	MFHAS1	0.52	8.38	0.38	7.71e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs3750082	0.889	rs13230763	chr7:32912965	C/T	cg05721444	chr7:32995514	FKBP9	0.37	6.59	0.3	1.34e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs12618769	0.597	rs4851138	chr2:99065464	A/C	cg10123293	chr2:99228465	UNC50	0.46	8.43	0.38	5.42e-16	Bipolar disorder;
LUAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg07677032	chr17:61819896	STRADA	0.55	9.84	0.43	1.07e-20	Prudent dietary pattern;
LUAD	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.57	-0.49	4.54e-27	Primary sclerosing cholangitis;
LUAD	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06544989	chr22:39130855	UNC84B	-0.38	-7.27	-0.33	1.78e-12	Menopause (age at onset);
LUAD	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	10.95	0.47	9.73e-25	Hip circumference adjusted for BMI;
LUAD	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.01	-0.36	1.11e-14	Total body bone mineral density;
LUAD	cis	rs986417	1.000	rs1116854	chr14:60917496	C/A	cg27398547	chr14:60952738	C14orf39	-0.63	-7.72	-0.35	8.34e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23248424	chr5:179741104	GFPT2	-0.66	-10.68	-0.46	9.52e-24	Height;
LUAD	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg15704280	chr7:45808275	SEPT13	-1.06	-23.73	-0.76	9.7e-80	Height;
LUAD	cis	rs8112211	1.000	rs56849284	chr19:38826947	T/C	cg14299480	chr19:38876666	GGN	-0.47	-8.23	-0.37	2.32e-15	Blood protein levels;
LUAD	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg10556349	chr10:835070	NA	0.68	7.84	0.36	3.63e-14	Eosinophil percentage of granulocytes;
LUAD	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.71	-0.39	6.94e-17	Total body bone mineral density;
LUAD	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg20991723	chr1:152506922	NA	0.34	6.66	0.31	8.76e-11	Hair morphology;
LUAD	cis	rs8060686	0.516	rs8048364	chr16:68253324	T/G	cg09835421	chr16:68378352	PRMT7	-0.52	-6.57	-0.3	1.5e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1232027	0.700	rs1677694	chr5:79936297	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.81	-0.36	4.4e-14	Huntington's disease progression;
LUAD	cis	rs698833	0.926	rs786407	chr2:44735865	T/A	cg04920474	chr2:44395004	PPM1B	0.36	6.38	0.3	4.74e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24689585	chr15:22957012	CYFIP1	0.42	6.59	0.31	1.32e-10	Height;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12454419	chr4:77135195	SCARB2	-0.59	-7.34	-0.34	1.09e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg01851573	chr8:8652454	MFHAS1	-0.46	-8.22	-0.37	2.52e-15	Neuroticism;
LUAD	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg22105103	chr4:187893119	NA	0.51	11.03	0.47	4.83e-25	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg26043149	chr18:55253948	FECH	-0.43	-6.97	-0.32	1.26e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg04398451	chr17:18023971	MYO15A	-0.63	-11.52	-0.49	6.7399999999999993e-27	Total body bone mineral density;
LUAD	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg00634984	chr7:65235879	NA	0.47	6.37	0.3	4.91e-10	Aortic root size;
LUAD	cis	rs1595825	0.945	rs73058813	chr2:198858268	A/G	cg11031976	chr2:198649780	BOLL	-0.47	-7.11	-0.33	4.85e-12	Ulcerative colitis;
LUAD	cis	rs2663905	0.706	rs2683260	chr15:81385552	A/C	cg09888468	chr15:81410853	NA	-0.59	-8.44	-0.38	5.11e-16	QT interval (drug interaction);
LUAD	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg23625390	chr15:77176239	SCAPER	0.39	6.8	0.31	3.67e-11	Blood metabolite levels;
LUAD	cis	rs11674184	0.659	rs59129126	chr2:11728388	T/C	cg07314298	chr2:11723111	GREB1	-0.8	-16.95	-0.64	1.45e-49	Endometriosis;
LUAD	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg08085267	chr17:45401833	C17orf57	-0.49	-8.23	-0.37	2.29e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9297145	0.509	rs13222381	chr7:98785024	T/G	cg05967295	chr7:98741636	SMURF1	-0.72	-12.76	-0.53	8.89e-32	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg00504896	chr12:9437009	LOC642846	-0.42	-6.59	-0.31	1.28e-10	Breast size;
LUAD	cis	rs55665837	0.540	rs12416696	chr11:14790889	G/A	cg19336497	chr11:14380999	RRAS2	-0.4	-7.52	-0.34	3.34e-13	Vitamin D levels;
LUAD	trans	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg14917512	chr19:3094685	GNA11	-0.57	-6.81	-0.31	3.33e-11	Diabetic kidney disease;
LUAD	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg24733560	chr20:60626293	TAF4	0.4	7.13	0.33	4.47e-12	Body mass index;
LUAD	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg15147215	chr3:52552868	STAB1	-0.43	-8.13	-0.37	4.85e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs1395	0.778	rs11693001	chr2:27412744	C/T	cg23587288	chr2:27483067	SLC30A3	-0.42	-7.84	-0.36	3.81e-14	Blood metabolite levels;
LUAD	cis	rs1595825	0.838	rs73058878	chr2:198895078	T/G	cg10547527	chr2:198650123	BOLL	-0.51	-7.05	-0.32	7.36e-12	Ulcerative colitis;
LUAD	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg06623918	chr6:96969491	KIAA0776	0.87	17.23	0.64	8.74e-51	Headache;
LUAD	trans	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg01620082	chr3:125678407	NA	-0.44	-6.52	-0.3	2.01e-10	Parkinson's disease;
LUAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg27171569	chr16:83987465	OSGIN1	0.6	11.0	0.47	6.1e-25	Pursuit maintenance gain;
LUAD	cis	rs1997103	1.000	rs6945937	chr7:55407140	C/T	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs8044868	0.530	rs9928157	chr16:72117073	T/C	cg23815491	chr16:72088622	HP	0.51	9.39	0.42	3.74e-19	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg26384229	chr12:38710491	ALG10B	0.42	7.16	0.33	3.58e-12	Morning vs. evening chronotype;
LUAD	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg18306943	chr3:40428807	ENTPD3	0.39	6.92	0.32	1.66e-11	Renal cell carcinoma;
LUAD	cis	rs10504073	0.647	rs59064792	chr8:50018337	A/C	cg00325661	chr8:49890786	NA	0.43	9.81	0.43	1.34e-20	Blood metabolite ratios;
LUAD	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg25894440	chr7:65020034	NA	-0.68	-7.36	-0.34	9.49e-13	Diabetic kidney disease;
LUAD	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-8.33	-0.38	1.13e-15	Neutrophil percentage of white cells;
LUAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg06753367	chr22:24256600	NA	-0.38	-6.66	-0.31	8.53e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg07828340	chr4:882639	GAK	1.08	11.67	0.49	1.82e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg01849466	chr14:104193079	ZFYVE21	0.5	8.15	0.37	4.29e-15	Body mass index;
LUAD	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg02176678	chr2:219576539	TTLL4	0.74	14.86	0.59	1.68e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg15181151	chr6:150070149	PCMT1	-0.41	-8.67	-0.39	9.21e-17	Lung cancer;
LUAD	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg03929089	chr4:120376271	NA	-0.96	-19.59	-0.69	2.84e-61	Height;
LUAD	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg08280861	chr8:58055591	NA	0.71	8.58	0.39	1.81e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs75804782	0.521	rs72982590	chr2:239451826	T/C	cg01134436	chr17:81009848	B3GNTL1	0.79	8.63	0.39	1.29e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs11696501	0.688	rs4812955	chr20:44324638	G/C	cg11783356	chr20:44313418	WFDC10B	-0.49	-7.76	-0.35	6.5e-14	Brain structure;
LUAD	trans	rs4650994	0.967	rs4650992	chr1:178515135	A/T	cg05059571	chr16:84539110	KIAA1609	-0.62	-10.57	-0.46	2.46e-23	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg00802000	chr16:706648	WDR90	-0.37	-6.94	-0.32	1.45e-11	Height;
LUAD	cis	rs752010	0.871	rs10789405	chr1:42101962	C/T	cg06885757	chr1:42089581	HIVEP3	0.46	9.73	0.43	2.42e-20	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg03289416	chr15:75166202	SCAMP2	0.58	10.07	0.44	1.61e-21	Breast cancer;
LUAD	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg03929089	chr4:120376271	NA	0.53	6.88	0.32	2.1e-11	Axial length;
LUAD	cis	rs67072384	1.000	rs72964185	chr11:72443177	G/A	cg04827223	chr11:72435913	ARAP1	-0.63	-6.83	-0.32	2.96e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg21033440	chr11:65409861	SIPA1	-0.42	-6.79	-0.31	3.71e-11	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.25	0.41	1.08e-18	Alzheimer's disease;
LUAD	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg07936489	chr17:37558343	FBXL20	-0.45	-7.06	-0.32	6.82e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg09455208	chr3:40491958	NA	0.65	14.5	0.58	5.91e-39	Renal cell carcinoma;
LUAD	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg25985355	chr7:65971099	NA	-0.39	-7.21	-0.33	2.59e-12	Aortic root size;
LUAD	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg21862992	chr11:68658383	NA	0.5	9.04	0.4	5.8e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs427394	0.659	rs274693	chr5:6734162	G/A	cg14682080	chr5:6737778	POLS	0.35	7.64	0.35	1.44e-13	Menopause (age at onset);
LUAD	cis	rs9473147	0.516	rs10948363	chr6:47487762	A/G	cg02130027	chr6:47444894	CD2AP	0.38	7.1	0.33	5.44e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg27279351	chr12:120934652	DYNLL1	0.43	6.57	0.3	1.51e-10	High light scatter reticulocyte count;
LUAD	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg00701064	chr4:6280414	WFS1	0.67	14.79	0.58	3.29e-40	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs12617721	0.645	rs114544871	chr2:99045485	T/G	cg10123293	chr2:99228465	UNC50	0.45	7.92	0.36	2.19e-14	Bipolar disorder with mood-incongruent psychosis;
LUAD	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg21918786	chr6:109611834	NA	-0.6	-11.3	-0.48	4.74e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg07741184	chr6:167504864	NA	0.34	8.11	0.37	5.71e-15	Primary biliary cholangitis;
LUAD	cis	rs12519773	0.526	rs4242241	chr5:92518370	C/T	cg18783429	chr5:92414398	NA	0.42	7.5	0.34	3.88e-13	Migraine;
LUAD	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08280861	chr8:58055591	NA	0.54	6.74	0.31	5.21e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-24.5	-0.77	3.57e-83	Height;
LUAD	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg04586622	chr2:25135609	ADCY3	0.38	8.64	0.39	1.14e-16	Body mass index;
LUAD	cis	rs3087591	0.960	rs1801052	chr17:29508775	C/T	cg24425628	chr17:29625626	OMG;NF1	0.4	6.55	0.3	1.63e-10	Hip circumference;
LUAD	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25427524	chr10:38739819	LOC399744	-0.76	-13.63	-0.55	2.53e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs2404602	0.530	rs12915184	chr15:76965922	G/A	cg00316803	chr15:76480434	C15orf27	0.46	7.0	0.32	1.01e-11	Blood metabolite levels;
LUAD	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg06547715	chr2:218990976	CXCR2	-0.27	-6.39	-0.3	4.29e-10	Colorectal cancer;
LUAD	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg13679303	chr9:96623674	NA	-0.37	-7.37	-0.34	8.85e-13	DNA methylation (variation);
LUAD	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg04450456	chr4:17643702	FAM184B	0.41	8.03	0.36	9.94e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg18944383	chr4:111397179	ENPEP	0.38	7.57	0.35	2.36e-13	Height;
LUAD	trans	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg19862616	chr7:65841803	NCRNA00174	1.04	26.07	0.79	4.65e-90	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg27532560	chr4:187881888	NA	-0.35	-6.59	-0.31	1.28e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg13679303	chr9:96623674	NA	-0.38	-7.72	-0.35	8.74e-14	DNA methylation (variation);
LUAD	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.6	-0.35	1.95e-13	Blood trace element (Zn levels);
LUAD	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08677398	chr8:58056175	NA	0.46	6.37	0.3	4.87e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs863345	0.604	rs4313395	chr1:158505135	C/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.6	-0.31	1.21e-10	Pneumococcal bacteremia;
LUAD	cis	rs7017914	0.934	rs17760050	chr8:71574251	A/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.52	-0.3	1.98e-10	Bone mineral density;
LUAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08219700	chr8:58056026	NA	0.63	8.82	0.39	2.92e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg18335740	chr13:41363409	SLC25A15	0.56	9.98	0.44	3.35e-21	Lewy body disease;
LUAD	trans	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.86	-0.32	2.53e-11	Gout;
LUAD	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg05393297	chr12:53359155	NA	-0.94	-16.92	-0.64	2e-49	Cancer (pleiotropy);
LUAD	cis	rs11958404	0.932	rs112683473	chr5:157437819	T/C	cg05962755	chr5:157440814	NA	0.55	8.28	0.37	1.65e-15	IgG glycosylation;
LUAD	cis	rs11756438	0.572	rs2638550	chr6:118998481	C/G	cg21191810	chr6:118973309	C6orf204	0.5	9.59	0.42	7.66e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs863345	0.604	rs923664	chr1:158507691	A/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.6	-0.31	1.21e-10	Pneumococcal bacteremia;
LUAD	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.41	-0.45	9.92e-23	Monocyte percentage of white cells;
LUAD	cis	rs9811920	0.683	rs16841874	chr3:99720564	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	6.89	0.32	2.08e-11	Axial length;
LUAD	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg19875535	chr5:140030758	IK	-0.41	-6.96	-0.32	1.28e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg15962314	chr1:44399869	ARTN	0.31	6.93	0.32	1.54e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg04025307	chr7:1156635	C7orf50	0.6	6.74	0.31	5.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1997103	1.000	rs6593238	chr7:55411048	A/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.04e-13	Morning vs. evening chronotype;
LUAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.39	-6.5	-0.3	2.25e-10	Longevity;Endometriosis;
LUAD	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg02990361	chr1:107599529	PRMT6	0.56	9.4	0.42	3.54e-19	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	6.7	0.31	6.84e-11	Lung cancer in ever smokers;
LUAD	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg18230493	chr5:56204884	C5orf35	-0.45	-7.61	-0.35	1.78e-13	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg15181151	chr6:150070149	PCMT1	0.42	8.84	0.39	2.58e-17	Lung cancer;
LUAD	cis	rs72772090	0.710	rs56122780	chr5:96059895	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-6.78	-0.31	4.05e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7843479	0.601	rs12056476	chr8:21854188	T/A	cg03445287	chr8:21823731	XPO7	-0.48	-8.99	-0.4	8.52e-18	Mean corpuscular volume;
LUAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06873352	chr17:61820015	STRADA	0.82	18.13	0.66	8.69e-55	Prudent dietary pattern;
LUAD	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.61	0.31	1.14e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg11189052	chr15:85197271	WDR73	-0.6	-9.9	-0.43	6.3e-21	P wave terminal force;
LUAD	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg14582100	chr15:45693742	SPATA5L1	0.62	12.11	0.51	3.4e-29	Homoarginine levels;
LUAD	cis	rs62238980	0.520	rs62238975	chr22:32569545	C/G	cg00543991	chr22:32367038	NA	0.83	7.07	0.33	6.32e-12	Childhood ear infection;
LUAD	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg16322792	chr1:120165303	ZNF697	0.71	19.05	0.68	6.95e-59	Systemic lupus erythematosus;
LUAD	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg23649088	chr2:200775458	C2orf69	0.63	8.4	0.38	6.67e-16	Schizophrenia;
LUAD	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24531977	chr5:56204891	C5orf35	-0.97	-14.83	-0.58	2.2e-40	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713675	0.584	rs4713666	chr6:33679061	A/G	cg13859433	chr6:33739653	LEMD2	-0.3	-7.1	-0.33	5.28e-12	Plateletcrit;
LUAD	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg14019146	chr3:50243930	SLC38A3	0.5	10.37	0.45	1.32e-22	Intelligence (multi-trait analysis);
LUAD	trans	rs75804782	0.521	rs60779166	chr2:239433943	G/A	cg01134436	chr17:81009848	B3GNTL1	0.75	8.16	0.37	3.93e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg08888203	chr3:10149979	C3orf24	0.63	10.73	0.46	6.56e-24	Alzheimer's disease;
LUAD	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg26597838	chr10:835615	NA	1.01	15.83	0.61	1.22e-44	Eosinophil percentage of granulocytes;
LUAD	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg15485101	chr11:133734466	NA	0.36	7.78	0.35	5.46e-14	Childhood ear infection;
LUAD	cis	rs7705042	0.828	rs11750521	chr5:141500704	T/C	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.78	-0.31	3.98e-11	Asthma;
LUAD	cis	rs9768139	0.935	rs10434944	chr7:158116911	C/T	cg25566285	chr7:158114605	PTPRN2	-0.52	-11.26	-0.48	6.5e-26	Calcium levels;
LUAD	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg06641503	chr3:48959341	ARIH2	-0.41	-8.05	-0.36	8.42e-15	Parkinson's disease;
LUAD	trans	rs1997103	1.000	rs2331065	chr7:55408392	A/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg02038168	chr22:39784481	NA	-0.6	-10.8	-0.46	3.49e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs1401999	0.898	rs6443928	chr3:183729487	C/T	cg01324343	chr3:183735012	ABCC5	0.95	25.92	0.78	2.22e-89	Anterior chamber depth;
LUAD	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg25344623	chr2:136566232	LCT	-0.38	-6.47	-0.3	2.79e-10	Corneal structure;
LUAD	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg24818145	chr4:99064322	C4orf37	0.47	7.98	0.36	1.42e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11971779	0.680	rs66491565	chr7:139088977	C/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.55	0.3	1.65e-10	Diisocyanate-induced asthma;
LUAD	cis	rs8067545	0.720	rs11204420	chr17:19889020	A/C	cg04132472	chr17:19861366	AKAP10	0.35	8.07	0.37	7.3e-15	Schizophrenia;
LUAD	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg06074448	chr4:187884817	NA	-0.38	-7.73	-0.35	8.08e-14	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.53	0.3	1.87e-10	Platelet count;
LUAD	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg06608945	chr2:219082296	ARPC2	0.47	7.98	0.36	1.38e-14	Colorectal cancer;
LUAD	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg16797656	chr11:68205561	LRP5	0.47	9.09	0.4	4.01e-18	Total body bone mineral density;
LUAD	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg01620082	chr3:125678407	NA	-1.04	-10.23	-0.45	4.13e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26314531	chr2:26401878	FAM59B	-0.55	-7.71	-0.35	9.38e-14	Gut microbiome composition (summer);
LUAD	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg06784218	chr1:46089804	CCDC17	0.54	11.74	0.5	9.79e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg09184832	chr6:79620586	NA	-0.52	-9.84	-0.43	1.03e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs7799006	0.895	rs3757437	chr7:2271980	C/T	cg08027265	chr7:2291960	NA	-0.61	-10.91	-0.47	1.42e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.38	7.11	0.33	4.9e-12	Depressive symptoms;
LUAD	cis	rs35146811	0.555	rs1981550	chr7:99541952	G/A	cg22906224	chr7:99728672	NA	0.53	8.6	0.39	1.58e-16	Coronary artery disease;
LUAD	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg00310523	chr12:86230176	RASSF9	0.38	7.73	0.35	7.94e-14	Major depressive disorder;
LUAD	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg16479474	chr6:28041457	NA	0.39	6.86	0.32	2.49e-11	Parkinson's disease;
LUAD	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg00745463	chr17:30367425	LRRC37B	-1.05	-12.34	-0.51	4.3e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg05042697	chr2:10830656	NOL10	-0.37	-6.38	-0.3	4.66e-10	Prostate cancer;
LUAD	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg27454412	chr7:1067447	C7orf50	-0.33	-6.48	-0.3	2.52e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.5	0.3	2.31e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00166722	chr3:10149974	C3orf24	0.73	12.65	0.52	2.57e-31	Alzheimer's disease;
LUAD	cis	rs2067615	0.524	rs7959062	chr12:107107334	G/T	cg15890332	chr12:107067104	RFX4	0.42	9.0	0.4	7.96e-18	Heart rate;
LUAD	trans	rs853679	0.546	rs493161	chr6:27850714	A/T	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.2	-0.37	2.85e-15	Depression;
LUAD	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg22618164	chr12:122356400	WDR66	0.75	13.63	0.55	2.63e-35	Mean corpuscular volume;
LUAD	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg02990361	chr1:107599529	PRMT6	0.54	8.37	0.38	8.76e-16	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4843185	0.699	rs2029	chr16:85708846	C/A	cg26571870	chr16:85723150	GINS2	-0.38	-7.58	-0.35	2.22e-13	Platelet distribution width;
LUAD	cis	rs1483890	0.962	rs1483891	chr3:69410416	G/C	cg22125112	chr3:69402811	FRMD4B	0.4	7.02	0.32	8.9e-12	Resting heart rate;
LUAD	cis	rs731174	0.797	rs501252	chr1:38154170	A/G	cg06917450	chr1:38156652	C1orf109	-0.42	-6.39	-0.3	4.41e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg04632378	chr13:21900426	NA	0.42	7.23	0.33	2.25e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs7809615	0.901	rs10235235	chr7:99075831	T/C	cg12290671	chr7:99195819	NA	-0.71	-8.34	-0.38	1.09e-15	Blood metabolite ratios;
LUAD	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.94	0.32	1.44e-11	Parkinson's disease;
LUAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.31	6.35	0.3	5.49e-10	Obesity-related traits;
LUAD	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg05754148	chr16:3507555	NAT15	0.43	6.37	0.3	4.89e-10	Body mass index (adult);
LUAD	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg24579218	chr15:68104479	NA	-0.53	-9.13	-0.41	2.89e-18	Restless legs syndrome;
LUAD	cis	rs754466	0.606	rs56402185	chr10:79585848	G/A	cg17075019	chr10:79541650	NA	-0.89	-18.8	-0.67	9.3e-58	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-6.89	-0.32	2.04e-11	Electroencephalogram traits;
LUAD	cis	rs8017423	0.647	rs4900037	chr14:90821478	A/G	cg14092571	chr14:90743983	NA	-0.4	-6.75	-0.31	4.9e-11	Mortality in heart failure;
LUAD	cis	rs10992471	0.651	rs13296623	chr9:95301627	T/C	cg14631576	chr9:95140430	CENPP	-0.39	-7.97	-0.36	1.47e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs17092148	0.887	rs4302281	chr20:33171645	C/T	cg16810054	chr20:33298113	TP53INP2	0.48	7.25	0.33	2.03e-12	Neuroticism;
LUAD	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.81	-12.38	-0.52	2.93e-30	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg18132916	chr6:79620363	NA	0.45	7.77	0.35	6.15e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs1448094	0.842	rs12809288	chr12:86455427	C/T	cg02569458	chr12:86230093	RASSF9	-0.38	-7.26	-0.33	1.85e-12	Major depressive disorder;
LUAD	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.74e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg24308560	chr3:49941425	MST1R	-0.51	-8.48	-0.38	3.85e-16	Body mass index;
LUAD	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18876405	chr7:65276391	NA	-0.43	-6.85	-0.32	2.55e-11	Aortic root size;
LUAD	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg02996355	chr14:81879375	NA	-0.76	-11.77	-0.5	7.59e-28	Prudent dietary pattern;
LUAD	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg18180107	chr4:99064573	C4orf37	0.42	6.8	0.31	3.68e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg00701064	chr4:6280414	WFS1	0.64	14.06	0.56	3.93e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg14773178	chr5:1868261	NA	0.34	6.49	0.3	2.35e-10	Cardiovascular disease risk factors;
LUAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg22535103	chr8:58192502	C8orf71	-0.62	-6.77	-0.31	4.28e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg12573674	chr2:1569213	NA	-0.56	-8.3	-0.37	1.39e-15	IgG glycosylation;
LUAD	cis	rs4891159	0.790	rs4891161	chr18:74142683	A/G	cg24786174	chr18:74118243	ZNF516	-0.83	-18.22	-0.66	3.6e-55	Longevity;
LUAD	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg15557168	chr22:42548783	NA	-0.48	-8.79	-0.39	3.92e-17	Schizophrenia;
LUAD	trans	rs74852193	0.588	rs17130778	chr1:69099361	G/A	cg16345795	chr2:8816914	NA	0.54	6.52	0.3	2.04e-10	Cognitive decline rate in late mild cognitive impairment;
LUAD	cis	rs11671005	0.735	rs11667723	chr19:58927489	A/G	cg13877915	chr19:58951672	ZNF132	0.56	7.42	0.34	6.67e-13	Mean platelet volume;
LUAD	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg10645314	chr2:3704589	ALLC	-0.44	-7.36	-0.34	9.43e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg01324343	chr3:183735012	ABCC5	-0.77	-17.39	-0.65	1.69e-51	Anterior chamber depth;
LUAD	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06028605	chr16:24865363	SLC5A11	0.56	8.67	0.39	9.26e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg23018236	chr17:30244563	NA	-0.68	-8.33	-0.38	1.14e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs6066835	1.000	rs6066835	chr20:47355009	A/G	cg18078177	chr20:47281410	PREX1	0.69	6.83	0.32	3e-11	Multiple myeloma;
LUAD	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.65	-7.21	-0.33	2.54e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs116095464	1.000	rs61079948	chr5:325503	G/C	cg22496380	chr5:211416	CCDC127	-1.03	-7.92	-0.36	2.17e-14	Breast cancer;
LUAD	trans	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg05926928	chr17:57297772	GDPD1	1.16	14.16	0.57	1.58e-37	Opioid sensitivity;
LUAD	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg21284400	chr1:149981654	OTUD7B	-0.38	-6.61	-0.31	1.17e-10	Longevity;Endometriosis;
LUAD	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg16325326	chr1:53192061	ZYG11B	-0.51	-8.12	-0.37	5.03e-15	Monocyte count;
LUAD	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg09399716	chr2:46890238	NA	-0.46	-9.26	-0.41	9.98e-19	Height;
LUAD	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.11	-0.33	4.91e-12	Total body bone mineral density;
LUAD	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg16479474	chr6:28041457	NA	0.38	6.6	0.31	1.27e-10	Parkinson's disease;
LUAD	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg05132306	chr1:1846340	CALML6	-0.36	-7.76	-0.35	6.63e-14	Body mass index;
LUAD	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg07936489	chr17:37558343	FBXL20	-0.45	-7.07	-0.33	6.36e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs13315871	0.929	rs13101057	chr3:58291467	A/G	cg12435725	chr3:58293450	RPP14	-0.74	-7.88	-0.36	2.86e-14	Cholesterol, total;
LUAD	cis	rs6554196	0.508	rs2237037	chr4:55525930	A/C	cg18836493	chr4:55524333	KIT	-0.37	-7.01	-0.32	9.64e-12	Monocyte count;
LUAD	cis	rs10216189	0.785	rs4623325	chr7:5526807	C/T	cg11800390	chr7:5515995	FBXL18	-0.35	-7.31	-0.33	1.37e-12	Relative hand skill in reading disability;
LUAD	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-9.42	-0.42	2.93e-19	Bipolar disorder;
LUAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08280861	chr8:58055591	NA	0.63	8.2	0.37	2.89e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg04851639	chr8:1020857	NA	-0.46	-11.59	-0.49	3.61e-27	Schizophrenia;
LUAD	cis	rs41311933	0.831	rs12685344	chr9:123764991	G/A	cg13567360	chr9:123745713	C5	-0.76	-8.78	-0.39	4.06e-17	Coronary artery disease;
LUAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg16606324	chr3:10149918	C3orf24	0.66	9.92	0.43	5.6e-21	Alzheimer's disease;
LUAD	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg04455712	chr21:45112962	RRP1B	0.44	9.02	0.4	6.53e-18	Mean corpuscular volume;
LUAD	cis	rs2901656	0.967	rs4916186	chr1:172396020	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.46	8.94	0.4	1.19e-17	Red cell distribution width;Platelet distribution width;
LUAD	trans	rs2018683	0.509	rs221192	chr7:29014909	C/T	cg19402173	chr7:128379420	CALU	0.46	6.6	0.31	1.22e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.32	0.54	4.93e-34	Prudent dietary pattern;
LUAD	cis	rs7688540	0.800	rs61792060	chr4:256450	C/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.32	6.38	0.3	4.63e-10	Facial morphology (factor 6, height of vermillion lower lip);
LUAD	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg22029157	chr1:209979665	IRF6	0.76	9.32	0.41	6.67e-19	Coronary artery disease;
LUAD	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg19774624	chr17:42201019	HDAC5	0.4	7.0	0.32	1.01e-11	Total body bone mineral density;
LUAD	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.53e-11	Depression;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01588546	chr19:1104635	GPX4	-0.68	-6.68	-0.31	7.53e-11	Type 2 diabetes;
LUAD	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg04369109	chr6:150039330	LATS1	-0.42	-6.99	-0.32	1.1e-11	Lung cancer;
LUAD	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg12756686	chr19:29218302	NA	0.7	9.91	0.43	6.05e-21	Methadone dose in opioid dependence;
LUAD	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg26384229	chr12:38710491	ALG10B	0.48	7.69	0.35	1.01e-13	Bladder cancer;
LUAD	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg00204512	chr16:28754710	NA	0.35	7.57	0.35	2.39e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg00431813	chr7:1051703	C7orf50	0.44	8.51	0.38	3.15e-16	Longevity;Endometriosis;
LUAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00166722	chr3:10149974	C3orf24	0.74	12.65	0.52	2.48e-31	Alzheimer's disease;
LUAD	trans	rs8129326	0.691	rs9984092	chr21:35784171	A/T	cg07474852	chr4:123073612	NA	-0.45	-7.46	-0.34	5.01e-13	Cancer;
LUAD	cis	rs4594175	0.707	rs12432912	chr14:51739395	T/C	cg23942311	chr14:51606299	NA	0.51	8.73	0.39	5.86e-17	Cancer;
LUAD	cis	rs727505	0.954	rs59670428	chr7:124520966	C/A	cg23710748	chr7:124431027	NA	-0.44	-9.34	-0.41	5.43e-19	Lewy body disease;
LUAD	cis	rs9300255	0.544	rs1790123	chr12:123659542	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-6.59	-0.31	1.3100000000000001e-10	Neutrophil percentage of white cells;
LUAD	cis	rs67397200	0.590	rs12327712	chr19:17424947	T/G	cg04749549	chr19:17459798	NA	-0.33	-6.69	-0.31	7.19e-11	Breast cancer;Breast Cancer in BRCA1 mutation carriers;Breast cancer (estrogen-receptor negative);
LUAD	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg06608945	chr2:219082296	ARPC2	-0.41	-6.92	-0.32	1.73e-11	Colorectal cancer;
LUAD	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg04455712	chr21:45112962	RRP1B	0.46	9.04	0.4	5.87e-18	Mean corpuscular volume;
LUAD	cis	rs6430585	0.527	rs62168833	chr2:136449254	G/A	cg07169764	chr2:136633963	MCM6	0.59	6.95	0.32	1.43e-11	Corneal structure;
LUAD	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.38	0.3	4.64e-10	Lung cancer in ever smokers;
LUAD	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg14779329	chr11:130786720	SNX19	0.39	6.84	0.32	2.74e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg01528321	chr10:82214614	TSPAN14	0.46	7.29	0.33	1.5e-12	Post bronchodilator FEV1;
LUAD	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg09650180	chr20:62225654	GMEB2	-0.45	-6.5	-0.3	2.32e-10	Glioblastoma;
LUAD	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.53	0.52	7.6e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.45	-0.38	4.76e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg13877915	chr19:58951672	ZNF132	0.73	13.77	0.56	6.54e-36	Uric acid clearance;
LUAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg20019720	chr6:154832845	CNKSR3	0.67	12.41	0.52	2.33e-30	Lipoprotein (a) levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg08876479	chr10:38146530	ZNF248	-0.6	-7.39	-0.34	8.07e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11229555	0.645	rs4367960	chr11:58194961	C/G	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7828089	0.582	rs7825938	chr8:22266866	G/A	cg12081754	chr8:22256438	SLC39A14	0.73	12.15	0.51	2.49e-29	Verbal declarative memory;
LUAD	cis	rs2795502	0.564	rs11239842	chr10:43444882	A/G	cg27426351	chr10:43362370	NA	0.54	6.54	0.3	1.82e-10	Blood protein levels;
LUAD	cis	rs1816752	0.819	rs4770665	chr13:24988948	G/A	cg02811702	chr13:24901961	NA	0.43	7.41	0.34	6.86e-13	Obesity-related traits;
LUAD	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg12714757	chr17:73874637	TRIM47	0.41	6.73	0.31	5.71e-11	Psoriasis;
LUAD	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg07741184	chr6:167504864	NA	-0.28	-6.76	-0.31	4.53e-11	Crohn's disease;
LUAD	cis	rs9902453	0.726	rs4795523	chr17:28176314	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	11.29	0.48	5e-26	Coffee consumption (cups per day);
LUAD	trans	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg06606381	chr12:133084897	FBRSL1	-0.64	-7.66	-0.35	1.3e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg01028140	chr2:1542097	TPO	-0.5	-6.86	-0.32	2.52e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg25237894	chr2:233734115	C2orf82	0.63	11.95	0.5	1.48e-28	Coronary artery disease;
LUAD	cis	rs3106136	0.872	rs10033662	chr4:95239462	G/A	cg11021082	chr4:95130006	SMARCAD1	0.37	6.82	0.31	3.2e-11	Capecitabine sensitivity;
LUAD	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg27170947	chr2:26402098	FAM59B	-0.61	-8.6	-0.39	1.59e-16	Gut microbiome composition (summer);
LUAD	cis	rs708547	0.647	rs1626594	chr4:57878254	G/A	cg00922110	chr4:57842668	C4orf14	-0.44	-8.13	-0.37	4.7e-15	Response to bleomycin (chromatid breaks);
LUAD	cis	rs9469890	0.604	rs11758426	chr6:34503338	A/G	cg14254433	chr6:34482411	PACSIN1	-0.51	-7.52	-0.34	3.28e-13	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-7.79	-0.35	5.25e-14	Alzheimer's disease;
LUAD	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg00280220	chr17:61926910	NA	0.36	6.97	0.32	1.24e-11	Prudent dietary pattern;
LUAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg21724239	chr8:58056113	NA	0.74	9.62	0.42	5.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs68170813	0.559	rs75723759	chr7:106962407	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.12	-0.44	1.02e-21	Coronary artery disease;
LUAD	cis	rs76878669	0.561	rs10791872	chr11:66138434	C/G	cg10616300	chr11:66138557	SLC29A2	-0.36	-7.53	-0.34	3.15e-13	Educational attainment (years of education);
LUAD	cis	rs7665090	0.967	rs5026469	chr4:103554713	G/A	cg07973026	chr4:103553119	MANBA	0.47	8.43	0.38	5.43e-16	Primary biliary cholangitis;
LUAD	trans	rs11039798	0.688	rs8188953	chr11:48749201	A/T	cg03929089	chr4:120376271	NA	0.59	6.8	0.31	3.57e-11	Axial length;
LUAD	cis	rs62238980	0.614	rs17744994	chr22:32413527	C/T	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs6500395	1.000	rs9936454	chr16:48617782	T/G	cg04672837	chr16:48644449	N4BP1	0.39	6.7	0.31	6.59e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg16797656	chr11:68205561	LRP5	0.45	8.47	0.38	4.1e-16	Total body bone mineral density;
LUAD	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg18252515	chr7:66147081	NA	-0.62	-6.68	-0.31	7.75e-11	Diabetic kidney disease;
LUAD	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg20628663	chr10:43360327	NA	-0.73	-11.33	-0.48	3.61e-26	Blood protein levels;
LUAD	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg05425664	chr17:57184151	TRIM37	0.43	7.6	0.35	1.98e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs11671005	0.735	rs34873624	chr19:58943402	G/A	cg13877915	chr19:58951672	ZNF132	0.59	7.77	0.35	6.18e-14	Mean platelet volume;
LUAD	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.68	0.31	7.52e-11	Menarche (age at onset);
LUAD	cis	rs6992820	0.900	rs34751862	chr8:56703319	C/G	cg06880721	chr8:56792545	LYN	-0.45	-7.47	-0.34	4.51e-13	Mean platelet volume;
LUAD	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg22753661	chr15:79092743	ADAMTS7	0.57	8.58	0.39	1.78e-16	Coronary artery disease or large artery stroke;
LUAD	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-15.17	-0.59	8.32e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg23985595	chr17:80112537	CCDC57	0.53	9.65	0.42	4.6e-20	Life satisfaction;
LUAD	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg20933634	chr6:27740509	NA	0.46	7.25	0.33	2.02e-12	Parkinson's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25464457	chr3:142608037	PCOLCE2	-0.38	-6.63	-0.31	1.03e-10	Height;
LUAD	trans	rs629535	0.821	rs497398	chr8:70037434	A/T	cg21567404	chr3:27674614	NA	1.01	18.57	0.67	9.52e-57	Dupuytren's disease;
LUAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg24813613	chr7:1882135	MAD1L1	-0.43	-6.91	-0.32	1.79e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg26043149	chr18:55253948	FECH	0.53	8.89	0.4	1.76e-17	Bone mineral density;
LUAD	cis	rs3820068	0.822	rs11581917	chr1:15805722	G/A	cg17177755	chr1:15930204	NA	0.46	6.55	0.3	1.69e-10	Systolic blood pressure;
LUAD	cis	rs1018836	0.770	rs12543806	chr8:91664011	C/T	cg16814680	chr8:91681699	NA	-0.88	-16.37	-0.62	4.96e-47	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.62	-7.66	-0.35	1.28e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg18240062	chr17:79603768	NPLOC4	0.36	6.35	0.3	5.42e-10	Eye color traits;
LUAD	cis	rs4774899	1.000	rs12909016	chr15:57518557	G/T	cg14026238	chr15:57616123	NA	0.35	6.71	0.31	6.18e-11	Urinary tract infection frequency;
LUAD	cis	rs4891159	0.790	rs77878087	chr18:74116337	G/A	cg24786174	chr18:74118243	ZNF516	-0.81	-15.12	-0.59	1.37e-41	Longevity;
LUAD	cis	rs7186831	1	rs7186831	chr16:75473155	G/A	cg03315344	chr16:75512273	CHST6	0.65	14.21	0.57	9.86e-38	Chronic obstructive pulmonary disease;
LUAD	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg05368731	chr17:41323189	NBR1	0.85	13.04	0.54	6.37e-33	Menopause (age at onset);
LUAD	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.82	-0.43	1.23e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs11098699	0.732	rs11733133	chr4:124242996	T/C	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	cis	rs12681287	0.640	rs13267782	chr8:87481887	G/T	cg27223183	chr8:87520930	FAM82B	-0.68	-9.64	-0.42	5.18e-20	Caudate activity during reward;
LUAD	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18404041	chr3:52824283	ITIH1	0.59	12.01	0.5	8.91e-29	Bipolar disorder;
LUAD	trans	rs116939006	1.000	rs6990914	chr8:14264377	T/C	cg16330849	chr6:10694809	C6orf52;PAK1IP1	0.82	7.15	0.33	3.78e-12	Response to paliperidone in schizophrenia (negative Marder score);
LUAD	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg07636037	chr3:49044803	WDR6	0.64	12.64	0.52	2.67e-31	Parkinson's disease;
LUAD	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.28	0.54	7.04e-34	Prudent dietary pattern;
LUAD	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.4	-0.34	7.22e-13	Total cholesterol levels;
LUAD	cis	rs7851660	0.870	rs1867278	chr9:100615949	C/A	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.43	4.21e-20	Strep throat;
LUAD	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg14728415	chr7:32535168	LSM5;AVL9	0.6	9.79	0.43	1.52e-20	Cognitive ability;
LUAD	cis	rs11756438	0.683	rs60497831	chr6:119009327	G/A	cg21191810	chr6:118973309	C6orf204	0.42	7.48	0.34	4.41e-13	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg08859206	chr1:53392774	SCP2	-0.66	-12.35	-0.51	4e-30	Monocyte count;
LUAD	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.7	-0.46	8.33e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs12505328	0.593	rs4695839	chr4:174359939	C/T	cg12145043	chr4:174357286	NA	-0.52	-7.64	-0.35	1.49e-13	Chin dimples;
LUAD	cis	rs7300001	0.667	rs7298716	chr12:110506181	A/T	cg12870014	chr12:110450643	ANKRD13A	0.89	8.48	0.38	3.77e-16	Headache;
LUAD	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.23	-0.33	2.23e-12	Breast cancer;
LUAD	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.37	-6.9	-0.32	1.94e-11	Longevity;Endometriosis;
LUAD	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24531977	chr5:56204891	C5orf35	-0.89	-13.77	-0.56	6.38e-36	Initial pursuit acceleration;
LUAD	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.53	0.3	1.84e-10	Menarche (age at onset);
LUAD	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg03929089	chr4:120376271	NA	-0.98	-20.38	-0.7	7.83e-65	Height;
LUAD	trans	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg11693508	chr17:37793320	STARD3	0.5	7.37	0.34	9.28e-13	Neuroticism;
LUAD	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg15181151	chr6:150070149	PCMT1	0.39	7.91	0.36	2.31e-14	Lung cancer;
LUAD	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg05110241	chr16:68378359	PRMT7	-0.82	-8.87	-0.4	2e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs600626	0.947	rs643884	chr11:75452518	T/C	cg24262691	chr11:75473276	NA	0.41	6.62	0.31	1.1e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg01251548	chr11:17372745	DKFZp686O24166	-0.36	-6.67	-0.31	8.21e-11	Type 2 diabetes;
LUAD	cis	rs4774899	1.000	rs12906042	chr15:57479668	A/C	cg14026238	chr15:57616123	NA	0.35	6.5	0.3	2.29e-10	Urinary tract infection frequency;
LUAD	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg00255919	chr5:131827918	IRF1	-0.51	-11.99	-0.5	1.06e-28	Asthma (sex interaction);
LUAD	cis	rs1018836	0.886	rs10283086	chr8:91616651	G/A	cg16814680	chr8:91681699	NA	-0.68	-11.8	-0.5	5.44e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs2262909	0.849	rs10420483	chr19:22190378	A/G	cg17074339	chr11:11642133	GALNTL4	-0.43	-6.78	-0.31	4.07e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11811982	0.793	rs115755032	chr1:227436402	A/G	cg24860534	chr1:227506868	CDC42BPA	0.7	7.34	0.34	1.13e-12	Optic disc area;
LUAD	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg08736216	chr1:53307985	ZYG11A	0.34	6.35	0.3	5.52e-10	Monocyte count;
LUAD	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg07741184	chr6:167504864	NA	-0.3	-7.14	-0.33	4.02e-12	Crohn's disease;
LUAD	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.65	0.31	9.07e-11	Aortic root size;
LUAD	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.5	8.02	0.36	1.02e-14	Platelet count;
LUAD	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg03467027	chr4:99064603	C4orf37	0.39	6.43	0.3	3.43e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg15557168	chr22:42548783	NA	-0.57	-11.14	-0.48	1.97e-25	Schizophrenia;
LUAD	cis	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg23950597	chr19:37808831	NA	0.55	6.88	0.32	2.16e-11	Coronary artery calcification;
LUAD	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	18.61	0.67	6.84e-57	Bone mineral density;
LUAD	trans	rs12517041	0.872	rs67191421	chr5:23281046	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.47	-0.3	2.73e-10	Calcium levels;
LUAD	cis	rs727505	1.000	rs66665074	chr7:124550526	C/T	cg23710748	chr7:124431027	NA	-0.47	-9.62	-0.42	6.25e-20	Lewy body disease;
LUAD	cis	rs1535500	0.905	rs2146262	chr6:39283793	C/T	cg06347083	chr6:39282316	KCNK17	-0.36	-7.56	-0.34	2.54e-13	Type 2 diabetes;
LUAD	cis	rs3806843	0.548	rs246055	chr5:140325662	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.99	-0.36	1.31e-14	Schizophrenia;
LUAD	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg23985595	chr17:80112537	CCDC57	0.52	9.4	0.42	3.55e-19	Life satisfaction;
LUAD	cis	rs6024905	0.565	rs6024991	chr20:36970167	C/G	cg07053727	chr20:36965646	BPI	-0.39	-7.34	-0.34	1.11e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02475777	chr4:1388615	CRIPAK	0.71	10.23	0.45	4.2e-22	Longevity;
LUAD	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-15.95	-0.61	3.48e-45	Chronic sinus infection;
LUAD	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg05340658	chr4:99064831	C4orf37	0.46	7.61	0.35	1.79e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1395	0.778	rs2580759	chr2:27432500	G/T	cg23587288	chr2:27483067	SLC30A3	0.38	7.48	0.34	4.31e-13	Blood metabolite levels;
LUAD	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.87	0.36	2.95e-14	Depression;
LUAD	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg09491104	chr22:46646882	C22orf40	-0.64	-8.7	-0.39	7.27e-17	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9326248	0.581	rs10892053	chr11:116857003	C/T	cg20608306	chr11:116969690	SIK3	0.31	7.03	0.32	8.4e-12	Blood protein levels;
LUAD	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg18404041	chr3:52824283	ITIH1	-0.61	-12.47	-0.52	1.32e-30	Bipolar disorder;
LUAD	cis	rs62229266	0.771	rs7280136	chr21:37432910	C/G	cg12218747	chr21:37451666	NA	0.44	7.46	0.34	5.02e-13	Mitral valve prolapse;
LUAD	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg02176678	chr2:219576539	TTLL4	0.74	14.93	0.59	8.76e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs13082711	0.513	rs7612102	chr3:27372826	A/G	cg02860705	chr3:27208620	NA	-0.66	-10.76	-0.46	4.99e-24	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg15900387	chr1:150738905	CTSS	0.35	6.49	0.3	2.42e-10	Melanoma;
LUAD	cis	rs11048434	0.761	rs12827055	chr12:9130861	G/T	cg04155231	chr12:9217510	LOC144571	0.41	7.62	0.35	1.66e-13	Sjögren's syndrome;
LUAD	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg00277334	chr10:82204260	NA	-0.57	-9.47	-0.42	2.07e-19	Post bronchodilator FEV1;
LUAD	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-7.4	-0.34	7.18e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg18240062	chr17:79603768	NPLOC4	0.36	6.4	0.3	4.24e-10	Eye color traits;
LUAD	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg22875332	chr1:76189707	ACADM	0.73	11.26	0.48	6.62e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1595825	0.891	rs16826895	chr2:198901642	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-7.13	-0.33	4.29e-12	Ulcerative colitis;
LUAD	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg18512352	chr11:47633146	NA	-0.42	-7.21	-0.33	2.65e-12	Subjective well-being;
LUAD	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg03806693	chr22:41940476	POLR3H	0.63	9.35	0.41	5.28e-19	Vitiligo;
LUAD	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg05665937	chr4:1216051	CTBP1	0.41	6.79	0.31	3.74e-11	Obesity-related traits;
LUAD	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.5e-12	Breast cancer;
LUAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18404041	chr3:52824283	ITIH1	-0.39	-7.49	-0.34	4.02e-13	Electroencephalogram traits;
LUAD	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg26394196	chr10:1453818	ADARB2	-0.33	-6.54	-0.3	1.79e-10	Radiation response;
LUAD	trans	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg13565492	chr6:43139072	SRF	-0.62	-6.68	-0.31	7.58e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg06713675	chr4:122721982	EXOSC9	-0.83	-17.77	-0.65	3.54e-53	Type 2 diabetes;
LUAD	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg14949292	chr17:78079608	GAA	-0.36	-6.89	-0.32	1.98e-11	Yeast infection;
LUAD	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg26893861	chr17:41843967	DUSP3	0.9	14.25	0.57	6.83e-38	Triglycerides;
LUAD	cis	rs877282	0.733	rs11253342	chr10:765072	A/G	cg17470449	chr10:769945	NA	0.63	9.0	0.4	7.54e-18	Uric acid levels;
LUAD	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg17749961	chr2:30669863	LCLAT1	0.51	6.88	0.32	2.19e-11	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg08399230	chr16:4665037	FAM100A	0.35	6.38	0.3	4.56e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-7.61	-0.35	1.82e-13	Personality dimensions;
LUAD	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg03467027	chr4:99064603	C4orf37	0.41	6.69	0.31	6.94e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02475777	chr4:1388615	CRIPAK	0.65	9.23	0.41	1.32e-18	Longevity;
LUAD	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg15147215	chr3:52552868	STAB1	-0.37	-6.9	-0.32	1.96e-11	Bipolar disorder;
LUAD	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg18446336	chr7:2847575	GNA12	-0.34	-6.79	-0.31	3.85e-11	Height;
LUAD	cis	rs367943	0.644	rs348942	chr5:112824039	T/C	cg12552261	chr5:112820674	MCC	-0.58	-10.7	-0.46	8.35e-24	Type 2 diabetes;
LUAD	cis	rs10979	1.000	rs3748072	chr6:143889757	C/T	cg25407410	chr6:143891975	LOC285740	-0.64	-10.3	-0.45	2.33e-22	Hypospadias;
LUAD	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	1.27	22.92	0.74	3.66e-76	IgG glycosylation;
LUAD	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15541040	chr2:3486749	NA	-0.43	-7.43	-0.34	6.1e-13	Neurofibrillary tangles;
LUAD	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg11062466	chr8:58055876	NA	0.77	9.13	0.41	2.92e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg08632164	chr7:65971372	NA	0.37	6.56	0.3	1.53e-10	Aortic root size;
LUAD	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg07211511	chr3:129823064	LOC729375	-0.84	-12.36	-0.52	3.64e-30	Blood pressure (smoking interaction);
LUAD	cis	rs7173743	0.756	rs6495339	chr15:79128272	T/C	cg00540400	chr15:79124168	NA	0.42	8.56	0.38	2.04e-16	Coronary artery disease;
LUAD	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg08859206	chr1:53392774	SCP2	0.59	10.6	0.46	1.93e-23	Monocyte count;
LUAD	cis	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg21204522	chr6:27730016	NA	-0.5	-7.34	-0.34	1.07e-12	Breast cancer;
LUAD	cis	rs68170813	0.559	rs2189501	chr7:106942766	A/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.37	-0.45	1.38e-22	Coronary artery disease;
LUAD	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg27144592	chr16:783916	NARFL	0.35	6.46	0.3	2.96e-10	Height;
LUAD	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg13180566	chr4:1052158	NA	-0.39	-6.69	-0.31	7.15e-11	Recombination rate (females);
LUAD	trans	rs8002861	0.619	rs9562516	chr13:44431738	T/C	cg17145862	chr1:211918768	LPGAT1	0.67	12.91	0.53	2.24e-32	Leprosy;
LUAD	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg24818145	chr4:99064322	C4orf37	0.49	8.09	0.37	6.32e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg11693508	chr17:37793320	STARD3	0.73	9.75	0.43	2.08e-20	Bipolar disorder;
LUAD	trans	rs7404843	0.777	rs6498552	chr16:15539901	T/G	cg02716450	chr16:28638775	NA	-0.7	-7.86	-0.36	3.32e-14	Testicular germ cell tumor;
LUAD	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg18827107	chr12:86230957	RASSF9	-0.71	-13.05	-0.54	6.13e-33	Major depressive disorder;
LUAD	cis	rs7107174	1.000	rs7101429	chr11:77992967	A/G	cg02023728	chr11:77925099	USP35	0.51	7.8	0.35	4.72e-14	Testicular germ cell tumor;
LUAD	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg19875535	chr5:140030758	IK	-0.48	-8.13	-0.37	4.92e-15	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs877282	0.898	rs11253340	chr10:764786	G/T	cg22713356	chr15:30763199	NA	1.27	17.4	0.65	1.56e-51	Uric acid levels;
LUAD	trans	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg01620082	chr3:125678407	NA	-1.04	-10.31	-0.45	2.28e-22	Depression;
LUAD	cis	rs3849570	0.925	rs1464791	chr3:81893929	A/C	cg07356753	chr3:81810745	GBE1	0.61	10.54	0.46	3.15e-23	Waist circumference;Body mass index;
LUAD	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg24503407	chr1:205819492	PM20D1	-0.68	-12.64	-0.52	2.67e-31	Menarche (age at onset);
LUAD	cis	rs17761864	0.791	rs4362428	chr17:2090341	C/A	cg16513277	chr17:2031491	SMG6	0.44	6.89	0.32	2.06e-11	Esophageal cancer (squamous cell);
LUAD	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg19875535	chr5:140030758	IK	0.45	7.45	0.34	5.47e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00166722	chr3:10149974	C3orf24	0.73	12.65	0.52	2.57e-31	Alzheimer's disease;
LUAD	cis	rs9462027	0.628	rs7745097	chr6:34794434	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.56	-0.38	2.05e-16	Systemic lupus erythematosus;
LUAD	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06544989	chr22:39130855	UNC84B	-0.39	-7.32	-0.34	1.24e-12	Menopause (age at onset);
LUAD	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg03859395	chr2:55845619	SMEK2	0.73	13.5	0.55	8.96e-35	Metabolic syndrome;
LUAD	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.44	0.34	5.83e-13	Tonsillectomy;
LUAD	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg20476274	chr7:133979776	SLC35B4	0.84	16.27	0.62	1.4e-46	Mean platelet volume;
LUAD	cis	rs4072705	0.615	rs7028021	chr9:127249022	A/G	cg13476313	chr9:127244764	NR5A1	0.36	8.91	0.4	1.48e-17	Menarche (age at onset);
LUAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.74	-8.81	-0.39	3.26e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg22442454	chr1:209979470	IRF6	0.55	6.51	0.3	2.09e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg03806693	chr22:41940476	POLR3H	-0.78	-11.22	-0.48	9.28e-26	Vitiligo;
LUAD	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg11766577	chr21:47581405	C21orf56	-0.63	-11.37	-0.48	2.49e-26	Testicular germ cell tumor;
LUAD	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg17724175	chr1:150552817	MCL1	0.37	8.39	0.38	7.33e-16	Melanoma;
LUAD	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.61	11.63	0.49	2.52e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2040771	0.804	rs7286849	chr22:19223579	C/A	cg02655711	chr22:19163373	SLC25A1	0.57	10.75	0.46	5.23e-24	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg15900387	chr1:150738905	CTSS	-0.37	-6.8	-0.31	3.48e-11	Melanoma;
LUAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.91e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg09872104	chr7:134855509	C7orf49	-0.8	-7.0	-0.32	1.02e-11	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg06074448	chr4:187884817	NA	-0.38	-7.53	-0.34	3.05e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg08085267	chr17:45401833	C17orf57	-0.5	-8.34	-0.38	1.03e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2033711	0.503	rs6510141	chr19:58885786	C/G	cg13691442	chr19:58878570	NA	0.32	6.45	0.3	3.06e-10	Uric acid clearance;
LUAD	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg23029597	chr12:123009494	RSRC2	-0.57	-8.98	-0.4	9.22e-18	Body mass index;
LUAD	cis	rs113835537	0.597	rs11227527	chr11:66313026	A/G	cg24851651	chr11:66362959	CCS	0.59	10.5	0.45	4.45e-23	Airway imaging phenotypes;
LUAD	cis	rs10899021	1.000	rs7935426	chr11:74363890	C/T	cg25880958	chr11:74394337	NA	-0.62	-8.26	-0.37	1.84e-15	Response to metformin (IC50);
LUAD	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg09491104	chr22:46646882	C22orf40	-0.64	-11.16	-0.48	1.58e-25	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg21854759	chr1:92012499	NA	-0.53	-9.95	-0.44	4.16e-21	Breast cancer;
LUAD	cis	rs16958440	0.867	rs79275306	chr18:44711620	G/C	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg11062466	chr8:58055876	NA	0.45	6.47	0.3	2.79e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs11948739	0.573	rs12332505	chr5:130337348	T/G	cg08523029	chr5:130500466	HINT1	-0.6	-7.72	-0.35	8.44e-14	Pediatric bone mineral content (hip);
LUAD	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg22029157	chr1:209979665	IRF6	0.73	10.01	0.44	2.64e-21	Cleft lip with or without cleft palate;
LUAD	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11890956	chr21:40555474	PSMG1	0.55	9.72	0.43	2.76e-20	Cognitive function;
LUAD	trans	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg07817883	chr1:32538562	TMEM39B	1.16	12.15	0.51	2.36e-29	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2294693	0.891	rs1072119	chr6:40993072	G/A	cg14769373	chr6:40998127	UNC5CL	-0.53	-8.0	-0.36	1.23e-14	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.65	0.31	9.1e-11	Endometrial cancer;
LUAD	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg04398451	chr17:18023971	MYO15A	0.62	11.09	0.47	2.93e-25	Total body bone mineral density;
LUAD	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg06627628	chr2:24431161	ITSN2	-0.71	-11.25	-0.48	7.12e-26	Asthma;
LUAD	cis	rs73198271	0.694	rs113694763	chr8:8647076	C/T	cg01851573	chr8:8652454	MFHAS1	0.48	8.49	0.38	3.53e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4147929	0.625	rs4147934	chr19:1065018	G/T	cg26576206	chr19:1064938	ABCA7	0.47	7.25	0.33	1.97e-12	Alzheimer's disease (late onset);
LUAD	cis	rs738322	0.532	rs9622746	chr22:38564041	C/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-7.81	-0.35	4.69e-14	Cutaneous nevi;
LUAD	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg02569458	chr12:86230093	RASSF9	0.42	7.9	0.36	2.45e-14	Major depressive disorder;
LUAD	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg25427524	chr10:38739819	LOC399744	-0.58	-6.63	-0.31	1.01e-10	Obesity (extreme);
LUAD	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg07741184	chr6:167504864	NA	0.3	7.21	0.33	2.62e-12	Crohn's disease;
LUAD	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02475777	chr4:1388615	CRIPAK	0.59	8.41	0.38	6.36e-16	Longevity;
LUAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg22907277	chr7:1156413	C7orf50	0.58	9.78	0.43	1.7e-20	Longevity;Endometriosis;
LUAD	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.67	0.31	8.1e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg19163074	chr7:65112434	INTS4L2	-0.46	-6.92	-0.32	1.71e-11	Aortic root size;
LUAD	cis	rs4774899	1.000	rs62022988	chr15:57325187	G/A	cg14026238	chr15:57616123	NA	0.34	6.37	0.3	4.92e-10	Urinary tract infection frequency;
LUAD	cis	rs2274273	0.870	rs2016931	chr14:55842332	C/G	cg04306507	chr14:55594613	LGALS3	0.41	8.64	0.39	1.15e-16	Protein biomarker;
LUAD	cis	rs654950	0.840	rs116241899	chr1:41994546	T/C	cg06885757	chr1:42089581	HIVEP3	-0.32	-6.8	-0.31	3.66e-11	Airway imaging phenotypes;
LUAD	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11951515	0.508	rs7705166	chr5:43587448	G/T	cg01983248	chr5:43482804	C5orf28	-0.38	-8.3	-0.37	1.44e-15	Metabolite levels  (X-11787);
LUAD	cis	rs41271951	0.512	rs16832976	chr1:151038135	T/C	cg11822372	chr1:151115635	SEMA6C	-0.82	-6.99	-0.32	1.11e-11	Blood protein levels;
LUAD	cis	rs11209185	0.509	rs9326077	chr1:68452192	A/G	cg22082780	chr1:68452167	NA	0.51	11.2	0.48	1.08e-25	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.31	-0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7000551	0.606	rs7844699	chr8:22248920	G/T	cg12081754	chr8:22256438	SLC39A14	-0.81	-13.92	-0.56	1.53e-36	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg20673091	chr1:2541236	MMEL1	-0.43	-9.3	-0.41	7.76e-19	Multiple sclerosis;
LUAD	cis	rs2224391	0.628	rs9504364	chr6:5256072	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-8.8	-0.39	3.57e-17	Height;
LUAD	cis	rs68092024	0.704	rs704575	chr3:99486075	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.51	-9.4	-0.42	3.54e-19	Cleft lip with or without cleft palate;
LUAD	cis	rs1595825	0.891	rs16824376	chr2:198684342	C/T	cg00361562	chr2:198649771	BOLL	-0.49	-6.96	-0.32	1.32e-11	Ulcerative colitis;
LUAD	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg00310523	chr12:86230176	RASSF9	0.4	7.91	0.36	2.27e-14	Major depressive disorder;
LUAD	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg21545522	chr1:205238299	TMCC2	-0.36	-6.63	-0.31	1.05e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	trans	rs7246760	0.737	rs57296518	chr19:9819950	A/G	cg02900749	chr2:68251473	NA	-0.6	-6.7	-0.31	6.75e-11	Pursuit maintenance gain;
LUAD	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg05966235	chr16:28915196	ATP2A1	0.45	7.24	0.33	2.07e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.22	-0.54	1.24e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg20203395	chr5:56204925	C5orf35	0.63	9.75	0.43	2.12e-20	Initial pursuit acceleration;
LUAD	trans	rs11039798	0.844	rs7126949	chr11:48972166	A/G	cg03929089	chr4:120376271	NA	0.59	6.79	0.31	3.9e-11	Axial length;
LUAD	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	6.64	0.31	9.66e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06873352	chr17:61820015	STRADA	0.55	8.88	0.4	1.88e-17	Height;
LUAD	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg06873352	chr17:61820015	STRADA	0.43	7.12	0.33	4.75e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9902453	0.934	rs12453172	chr17:28441590	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.61	0.39	1.47e-16	Coffee consumption (cups per day);
LUAD	trans	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.28	0.54	6.65e-34	Exhaled nitric oxide output;
LUAD	cis	rs4631830	0.863	rs2843546	chr10:51518688	A/C	cg20129853	chr10:51489980	NA	-0.34	-6.73	-0.31	5.47e-11	Prostate-specific antigen levels;
LUAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg06753367	chr22:24256600	NA	-0.38	-6.78	-0.31	4.02e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6558530	1.000	rs6558530	chr8:1706207	A/G	cg19131313	chr8:1704013	NA	-0.44	-7.27	-0.33	1.73e-12	Systolic blood pressure;
LUAD	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg06074448	chr4:187884817	NA	-0.37	-7.3	-0.33	1.47e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02353165	chr6:42928485	GNMT	-0.41	-7.44	-0.34	5.57e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.22	-0.41	1.46e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg22920501	chr2:26401640	FAM59B	0.98	15.42	0.6	7.07e-43	Gut microbiome composition (summer);
LUAD	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.5	-0.34	3.78e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg19622623	chr12:86230825	RASSF9	-0.36	-6.59	-0.31	1.28e-10	Major depressive disorder;
LUAD	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg13770153	chr20:60521292	NA	-0.48	-8.22	-0.37	2.49e-15	Body mass index;
LUAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg22535103	chr8:58192502	C8orf71	-0.67	-7.28	-0.33	1.66e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg19774624	chr17:42201019	HDAC5	-0.39	-6.85	-0.32	2.54e-11	Total body bone mineral density;
LUAD	cis	rs9393692	0.557	rs10946810	chr6:26288055	G/A	cg00631329	chr6:26305371	NA	-0.52	-8.31	-0.37	1.29e-15	Educational attainment;
LUAD	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.06	-0.32	6.83e-12	Lung cancer;
LUAD	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs9473147	0.503	rs2171086	chr6:47590104	C/T	cg02130027	chr6:47444894	CD2AP	0.35	6.82	0.31	3.17e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg24675056	chr1:15929824	NA	0.47	8.23	0.37	2.31e-15	Systolic blood pressure;
LUAD	cis	rs55665837	1.000	rs10832275	chr11:14478224	A/C	cg19336497	chr11:14380999	RRAS2	-0.5	-10.14	-0.44	8.81e-22	Vitamin D levels;
LUAD	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg11833968	chr6:79620685	NA	0.43	8.29	0.37	1.51e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg23625390	chr15:77176239	SCAPER	0.37	6.53	0.3	1.86e-10	Blood metabolite levels;
LUAD	cis	rs4462272	0.503	rs7906355	chr10:101838267	A/C	cg19754520	chr10:101825118	CPN1	-0.34	-7.41	-0.34	6.87e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7937890	0.559	rs2575830	chr11:14485602	C/A	cg02886208	chr11:14281011	SPON1	-0.34	-6.52	-0.3	2.05e-10	Mitochondrial DNA levels;
LUAD	cis	rs6076065	0.723	rs2424531	chr20:23372754	C/T	cg11657817	chr20:23433608	CST11	-0.48	-8.77	-0.39	4.54e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg22105103	chr4:187893119	NA	0.58	12.67	0.52	2.1e-31	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11234017	chr17:42767172	CCDC43	-0.41	-6.57	-0.3	1.47e-10	Height;
LUAD	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg07423050	chr13:99094983	FARP1	-0.54	-9.05	-0.4	5.25e-18	Longevity;
LUAD	cis	rs897984	0.609	rs4889609	chr16:31026427	A/G	cg02466173	chr16:30829666	NA	-0.58	-10.11	-0.44	1.12e-21	Dementia with Lewy bodies;
LUAD	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg24675056	chr1:15929824	NA	0.49	8.5	0.38	3.39e-16	Systolic blood pressure;
LUAD	cis	rs9902453	0.808	rs12452288	chr17:28235220	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	9.33	0.41	5.88e-19	Coffee consumption (cups per day);
LUAD	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg10523679	chr1:76189770	ACADM	0.76	12.16	0.51	2.14e-29	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg13732083	chr21:47605072	C21orf56	0.42	6.95	0.32	1.39e-11	Testicular germ cell tumor;
LUAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg16606324	chr3:10149918	C3orf24	0.66	11.1	0.47	2.75e-25	Alzheimer's disease;
LUAD	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-13.39	-0.55	2.38e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg13319975	chr6:146136371	FBXO30	-0.64	-11.07	-0.47	3.45e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg21681030	chr2:46777652	RHOQ	0.4	7.09	0.33	5.76e-12	Height;
LUAD	cis	rs1595825	0.891	rs80178661	chr2:198582442	A/G	cg10547527	chr2:198650123	BOLL	-0.54	-7.8	-0.35	4.84e-14	Ulcerative colitis;
LUAD	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	8.91	0.4	1.55e-17	Rheumatoid arthritis;
LUAD	cis	rs9296092	0.517	rs9461876	chr6:33516657	C/T	cg13560919	chr6:33536144	NA	-0.87	-15.37	-0.6	1.19e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg00277334	chr10:82204260	NA	-0.69	-10.92	-0.47	1.32e-24	Post bronchodilator FEV1;
LUAD	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg17410650	chr12:54324560	NA	-0.54	-10.83	-0.47	2.66e-24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs10739663	0.520	rs13294786	chr9:128156961	A/G	cg14078157	chr9:128172775	NA	-0.46	-8.55	-0.38	2.29e-16	Resting heart rate;
LUAD	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg04155289	chr7:94953770	PON1	0.53	7.24	0.33	2.18e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg21724239	chr8:58056113	NA	0.83	10.22	0.44	4.81e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg08807101	chr21:30365312	RNF160	0.47	8.09	0.37	6.31e-15	Dental caries;
LUAD	cis	rs9381040	0.701	rs722442	chr6:41089681	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.43	-7.33	-0.34	1.17e-12	Alzheimer's disease (late onset);
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg22775896	chr5:150632248	GM2A	-0.41	-7.02	-0.32	8.73e-12	Subcortical brain region volumes;
LUAD	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg07404485	chr7:94953653	PON1	-0.49	-7.05	-0.32	7.28e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00872270	chr16:3190814	ZNF213	0.5	6.39	0.3	4.5e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg18240062	chr17:79603768	NPLOC4	-0.46	-8.23	-0.37	2.31e-15	Eye color traits;
LUAD	trans	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg14227996	chr4:17616232	MED28	0.74	8.21	0.37	2.63e-15	Opioid sensitivity;
LUAD	cis	rs684232	0.602	rs2160955	chr17:560604	T/C	cg12384639	chr17:618140	VPS53	0.48	8.03	0.36	9.49e-15	Prostate cancer;
LUAD	cis	rs2816062	0.760	rs2745319	chr1:18895078	G/A	cg18795169	chr1:18902165	NA	-0.94	-22.53	-0.74	2.07e-74	Urate levels in lean individuals;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07504373	chr19:45682841	BLOC1S3;TRAPPC6A	-0.7	-6.79	-0.31	3.74e-11	Type 2 diabetes;
LUAD	cis	rs4774899	0.966	rs12912007	chr15:57411492	T/G	cg14026238	chr15:57616123	NA	0.35	6.51	0.3	2.1e-10	Urinary tract infection frequency;
LUAD	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg24011408	chr12:48396354	COL2A1	-0.43	-9.46	-0.42	2.18e-19	Plateletcrit;
LUAD	cis	rs977987	0.806	rs4888388	chr16:75394148	G/A	cg03315344	chr16:75512273	CHST6	0.64	13.99	0.56	8.4e-37	Dupuytren's disease;
LUAD	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg15448220	chr1:150897856	SETDB1	0.53	9.03	0.4	6.26e-18	Melanoma;
LUAD	cis	rs7301016	0.707	rs11174588	chr12:63052601	G/T	cg11441379	chr12:63026424	NA	0.61	7.44	0.34	5.49e-13	IgG glycosylation;
LUAD	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	11.31	0.48	4.33e-26	Resting heart rate;
LUAD	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00166722	chr3:10149974	C3orf24	0.74	12.65	0.52	2.48e-31	Alzheimer's disease;
LUAD	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg15448220	chr1:150897856	SETDB1	0.46	7.98	0.36	1.39e-14	Tonsillectomy;
LUAD	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.12	-0.33	4.81e-12	Lung cancer;
LUAD	trans	rs1997103	1.000	rs10278894	chr7:55404748	A/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg03395511	chr6:291903	DUSP22	-0.77	-13.27	-0.54	7.42e-34	Menopause (age at onset);
LUAD	cis	rs999943	1.000	rs999943	chr6:33624733	A/G	cg14003231	chr6:33640908	ITPR3	0.73	14.91	0.59	1.02e-40	Obesity (extreme);
LUAD	cis	rs4974559	0.847	rs28477912	chr4:1331350	C/T	cg07757535	chr4:1339547	NA	0.39	6.47	0.3	2.73e-10	Systolic blood pressure;
LUAD	cis	rs986417	0.901	rs4640083	chr14:61097779	G/A	cg27398547	chr14:60952738	C14orf39	0.65	7.32	0.34	1.28e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg14458575	chr2:238380390	NA	0.74	11.22	0.48	9.2e-26	Prostate cancer;
LUAD	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06022373	chr22:39101656	GTPBP1	0.42	6.51	0.3	2.09e-10	Menopause (age at onset);
LUAD	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg25809561	chr17:30822961	MYO1D	0.74	15.06	0.59	2.35e-41	Schizophrenia;
LUAD	cis	rs7707921	0.881	rs324914	chr5:81389950	C/T	cg15871215	chr5:81402204	ATG10	0.66	9.44	0.42	2.51e-19	Breast cancer;
LUAD	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg00383909	chr3:49044727	WDR6	0.91	10.1	0.44	1.25e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-9.25	-0.41	1.09e-18	Life satisfaction;
LUAD	trans	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg06606381	chr12:133084897	FBRSL1	-0.81	-8.05	-0.36	8.7e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.61	-10.47	-0.45	5.88e-23	Longevity;Endometriosis;
LUAD	cis	rs9811920	0.809	rs4928153	chr3:99808445	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	6.96	0.32	1.28e-11	Axial length;
LUAD	cis	rs9462027	0.583	rs11755420	chr6:34760956	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.91	-0.4	1.53e-17	Systemic lupus erythematosus;
LUAD	cis	rs10823500	0.604	rs10762345	chr10:71939374	A/G	cg02100629	chr10:71892760	AIFM2	-0.37	-7.58	-0.35	2.22e-13	Blood protein levels;
LUAD	trans	rs7944735	0.690	rs7927682	chr11:47947658	T/C	cg15704280	chr7:45808275	SEPT13	0.66	8.43	0.38	5.66e-16	Intraocular pressure;
LUAD	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg15704280	chr7:45808275	SEPT13	0.78	13.0	0.53	9.44e-33	Coronary artery disease;
LUAD	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg05082376	chr22:42548792	NA	-0.42	-7.07	-0.32	6.6e-12	Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17243582	chr15:59969081	BNIP2	-0.42	-6.69	-0.31	6.99e-11	Cancer;
LUAD	cis	rs9322817	0.583	rs9391227	chr6:105158634	T/A	cg02098413	chr6:105308735	HACE1	-0.37	-7.76	-0.35	6.27e-14	Thyroid stimulating hormone;
LUAD	cis	rs7527798	0.592	rs6667118	chr1:207822724	G/T	cg09232269	chr1:207846808	CR1L	-0.36	-6.84	-0.32	2.87e-11	Erythrocyte sedimentation rate;
LUAD	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg03929089	chr4:120376271	NA	0.67	10.07	0.44	1.65e-21	Coronary artery disease;
LUAD	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg09640425	chr7:158790006	NA	0.5	6.53	0.3	1.85e-10	Facial morphology (factor 20);
LUAD	cis	rs3784262	1.000	rs4369598	chr15:58318603	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.47	-9.41	-0.42	3.11e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.58	0.39	1.8e-16	Rheumatoid arthritis;
LUAD	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg10589385	chr1:150898437	SETDB1	0.4	7.5	0.34	3.69e-13	Tonsillectomy;
LUAD	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg25251562	chr2:3704773	ALLC	-0.37	-6.88	-0.32	2.21e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg24558204	chr6:135376177	HBS1L	0.41	7.29	0.33	1.51e-12	Red blood cell count;
LUAD	cis	rs12413816	0.818	rs35567671	chr10:13769722	C/A	cg16485048	chr10:13749193	FRMD4A	0.4	6.6	0.31	1.25e-10	Red cell distribution width;
LUAD	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg19318889	chr4:1322082	MAEA	0.82	13.84	0.56	3.52e-36	Longevity;
LUAD	cis	rs775227	0.574	rs13086266	chr3:113083535	T/A	cg18753928	chr3:113234510	CCDC52	-0.69	-8.82	-0.39	3.07e-17	Dental caries;
LUAD	cis	rs4664304	0.903	rs72957576	chr2:160754132	A/C	cg06573604	chr2:160760825	LY75	-0.39	-6.52	-0.3	2.06e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs11696501	0.789	rs1487319	chr20:44295943	A/G	cg11783356	chr20:44313418	WFDC10B	-0.49	-8.23	-0.37	2.31e-15	Brain structure;
LUAD	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg07371521	chr5:154026371	NA	0.48	7.71	0.35	9.13e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg09137382	chr11:130731461	NA	0.4	7.43	0.34	6.19e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg07936489	chr17:37558343	FBXL20	-0.42	-6.53	-0.3	1.85e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-7.57	-0.35	2.36e-13	Retinal vascular caliber;
LUAD	cis	rs7177699	0.557	rs7165902	chr15:79115872	T/G	cg15571903	chr15:79123663	NA	0.38	7.6	0.35	1.87e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg13319975	chr6:146136371	FBXO30	-0.8	-13.55	-0.55	5.64e-35	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg07507251	chr3:52567010	NT5DC2	0.39	7.52	0.34	3.33e-13	Bipolar disorder;
LUAD	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg09085632	chr11:111637200	PPP2R1B	0.76	11.89	0.5	2.55e-28	Primary sclerosing cholangitis;
LUAD	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg11965913	chr1:205819406	PM20D1	0.47	7.51	0.34	3.44e-13	Parkinson's disease;
LUAD	cis	rs62064224	0.714	rs4794915	chr17:30634363	A/G	cg25809561	chr17:30822961	MYO1D	-0.46	-8.33	-0.38	1.17e-15	Schizophrenia;
LUAD	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.73	-13.35	-0.54	3.75e-34	Axial length;
LUAD	cis	rs868036	1.000	rs868036	chr15:68055013	T/A	cg24579218	chr15:68104479	NA	0.36	6.73	0.31	5.47e-11	Restless legs syndrome;
LUAD	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg08132940	chr7:1081526	C7orf50	-0.77	-10.31	-0.45	2.21e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg01689657	chr7:91764605	CYP51A1	-0.32	-7.88	-0.36	2.81e-14	Breast cancer;
LUAD	cis	rs6474412	1.000	rs1451240	chr8:42546711	A/G	cg25026480	chr8:42547641	NA	0.36	6.37	0.3	4.83e-10	Smoking behavior;
LUAD	cis	rs6516091	0.850	rs11699483	chr20:6048460	G/A	cg25325723	chr20:6104886	FERMT1	-0.61	-6.62	-0.31	1.09e-10	Abdominal aortic aneurysm;
LUAD	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.38	6.97	0.32	1.2e-11	Systemic lupus erythematosus;
LUAD	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-7.75	-0.35	6.85e-14	Personality dimensions;
LUAD	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg15147215	chr3:52552868	STAB1	-0.39	-7.11	-0.33	4.97e-12	Bipolar disorder;
LUAD	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg02176678	chr2:219576539	TTLL4	-0.82	-17.16	-0.64	1.81e-50	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg04944784	chr2:26401820	FAM59B	0.74	9.47	0.42	1.99e-19	Gut microbiome composition (summer);
LUAD	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg06112835	chr11:68658793	MRPL21	-0.48	-8.77	-0.39	4.27e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22857025	chr5:266934	NA	-0.97	-14.43	-0.57	1.14e-38	Breast cancer;
LUAD	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg18306943	chr3:40428807	ENTPD3	0.41	7.15	0.33	3.74e-12	Renal cell carcinoma;
LUAD	cis	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-7.31	-0.34	1.31e-12	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg26554054	chr8:600488	NA	0.8	7.95	0.36	1.67e-14	IgG glycosylation;
LUAD	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg15128208	chr22:42549153	NA	0.43	6.78	0.31	4.17e-11	Birth weight;
LUAD	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg09796270	chr17:17721594	SREBF1	-0.38	-7.43	-0.34	6.02e-13	Total body bone mineral density;
LUAD	cis	rs2279817	0.863	rs1416854	chr1:18024675	G/A	cg21791023	chr1:18019539	ARHGEF10L	0.59	9.69	0.43	3.49e-20	Neuroticism;
LUAD	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-9.73	-0.43	2.61e-20	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.17	0.41	2.06e-18	Mean corpuscular volume;
LUAD	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg15485101	chr11:133734466	NA	0.37	7.9	0.36	2.51e-14	Childhood ear infection;
LUAD	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg18132916	chr6:79620363	NA	-0.45	-7.63	-0.35	1.5700000000000001e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs896543	0.702	rs12692190	chr2:237496190	C/T	cg25295825	chr2:237489920	CXCR7	0.45	8.34	0.38	1.08e-15	Alcohol dependence (age at onset);
LUAD	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	7.67	0.35	1.17e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06544989	chr22:39130855	UNC84B	0.38	6.54	0.3	1.77e-10	Menopause (age at onset);
LUAD	cis	rs6490294	0.659	rs11066028	chr12:112245170	A/C	cg10833066	chr12:111807467	FAM109A	0.37	6.91	0.32	1.82e-11	Mean platelet volume;
LUAD	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs7213347	0.780	rs216224	chr17:2156285	T/C	cg16513277	chr17:2031491	SMG6	0.43	6.59	0.31	1.33e-10	Total body bone mineral density;
LUAD	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg26587870	chr6:27730563	NA	-0.64	-6.98	-0.32	1.17e-11	Breast cancer;
LUAD	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-23.59	-0.75	3.79e-79	Height;
LUAD	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg00603274	chr11:61596626	FADS2	-0.41	-6.98	-0.32	1.16e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	trans	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.45	-0.34	5.23e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg19622623	chr12:86230825	RASSF9	-0.54	-9.58	-0.42	8.15e-20	Major depressive disorder;
LUAD	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg03714773	chr7:91764589	CYP51A1	0.28	6.57	0.3	1.46e-10	Breast cancer;
LUAD	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.35	-6.88	-0.32	2.17e-11	IgG glycosylation;
LUAD	cis	rs10821973	0.527	rs10740066	chr10:63976416	T/A	cg09941381	chr10:64027924	RTKN2	-0.34	-6.74	-0.31	5.22e-11	Hypothyroidism;
LUAD	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg02423579	chr7:2872169	GNA12	-0.56	-9.38	-0.41	4.1e-19	Height;
LUAD	cis	rs6543140	0.929	rs11465700	chr2:103057668	G/A	cg03938978	chr2:103052716	IL18RAP	0.36	7.03	0.32	8.57e-12	Blood protein levels;
LUAD	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg02782426	chr3:40428986	ENTPD3	0.35	7.47	0.34	4.54e-13	Renal cell carcinoma;
LUAD	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg11266682	chr4:10021025	SLC2A9	0.48	10.01	0.44	2.62e-21	Bone mineral density;
LUAD	cis	rs977987	0.866	rs17696831	chr16:75493298	C/G	cg03315344	chr16:75512273	CHST6	0.66	14.99	0.59	4.83e-41	Dupuytren's disease;
LUAD	cis	rs6840360	0.615	rs12641441	chr4:152607623	A/G	cg22705602	chr4:152727874	NA	-0.48	-8.94	-0.4	1.22e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs1873147	0.569	rs11071710	chr15:63309193	A/G	cg21584241	chr15:63341463	TPM1	0.42	6.38	0.3	4.53e-10	Orofacial clefts;
LUAD	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.58	9.13	0.41	2.84e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg11166453	chr1:247681781	NA	0.39	7.38	0.34	8.4e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg18016565	chr1:150552671	MCL1	0.41	7.58	0.35	2.14e-13	Tonsillectomy;
LUAD	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg13722127	chr7:150037890	RARRES2	-0.44	-7.82	-0.36	4.12e-14	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg24801067	chr17:62843696	NA	0.54	8.51	0.38	2.98e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10802521	chr3:52805072	NEK4	-0.62	-11.07	-0.47	3.45e-25	Bipolar disorder;
LUAD	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg12011299	chr4:100065546	ADH4	-0.73	-13.63	-0.55	2.45e-35	Alcohol dependence;
LUAD	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg02734326	chr4:10020555	SLC2A9	-0.42	-7.33	-0.34	1.17e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.5	0.3	2.26e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg12193833	chr17:30244370	NA	-0.58	-7.0	-0.32	1.03e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.94	0.36	1.82e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9914266	1	rs9914266	chr17:2133250	T/C	cg16513277	chr17:2031491	SMG6	-0.82	-15.34	-0.6	1.57e-42	Myocardial infarction;
LUAD	cis	rs68170813	0.641	rs61511581	chr7:106948091	T/A	cg23024343	chr7:107201750	COG5	0.45	6.56	0.3	1.53e-10	Coronary artery disease;
LUAD	cis	rs7107174	1.000	rs11237469	chr11:78072875	A/T	cg02023728	chr11:77925099	USP35	0.46	7.31	0.34	1.3e-12	Testicular germ cell tumor;
LUAD	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg07061783	chr6:25882402	NA	-0.57	-8.82	-0.39	3.05e-17	Blood metabolite levels;
LUAD	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg22705602	chr4:152727874	NA	-0.4	-7.07	-0.33	6.3e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.77	14.85	0.59	1.85e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg13319975	chr6:146136371	FBXO30	-0.61	-10.11	-0.44	1.12e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg16060761	chr17:80687452	NA	-0.59	-8.61	-0.39	1.51e-16	Glycated hemoglobin levels;
LUAD	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	7.09	0.33	5.56e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg20790798	chr5:1857306	NA	-0.44	-7.46	-0.34	4.91e-13	Cardiovascular disease risk factors;
LUAD	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg02993280	chr1:107599747	PRMT6	0.56	9.07	0.4	4.59e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9473147	0.503	rs2171086	chr6:47590104	C/T	cg12968598	chr6:47444699	CD2AP	0.35	6.38	0.3	4.65e-10	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg04369109	chr6:150039330	LATS1	-0.41	-6.91	-0.32	1.75e-11	Lung cancer;
LUAD	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg19717773	chr7:2847554	GNA12	-0.55	-10.41	-0.45	9.76e-23	Height;
LUAD	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg26354017	chr1:205819088	PM20D1	0.81	17.34	0.64	2.96e-51	Menarche (age at onset);
LUAD	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg09640425	chr7:158790006	NA	0.43	6.73	0.31	5.49e-11	Facial morphology (factor 20);
LUAD	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg02018176	chr4:1364513	KIAA1530	0.37	7.07	0.33	6.47e-12	Obesity-related traits;
LUAD	cis	rs68092024	0.704	rs704576	chr3:99487154	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	7.85	0.36	3.55e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs1843834	0.898	rs4674936	chr2:225553731	C/T	cg22455342	chr2:225449267	CUL3	0.46	6.39	0.3	4.42e-10	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg05754148	chr16:3507555	NAT15	-0.83	-9.13	-0.41	2.94e-18	Tuberculosis;
LUAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg15117754	chr3:10150083	C3orf24	0.42	7.0	0.32	1.03e-11	Alzheimer's disease;
LUAD	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg00495681	chr13:53174319	NA	-0.49	-8.65	-0.39	1.09e-16	Lewy body disease;
LUAD	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg15181151	chr6:150070149	PCMT1	0.39	7.86	0.36	3.28e-14	Lung cancer;
LUAD	cis	rs6494488	0.500	rs118175183	chr15:64899341	A/T	cg08069370	chr15:64387884	SNX1	-0.75	-6.58	-0.3	1.37e-10	Coronary artery disease;
LUAD	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg03678062	chr6:149772716	ZC3H12D	0.3	6.57	0.3	1.48e-10	Dupuytren's disease;
LUAD	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg16615211	chr3:44902933	MIR564;TMEM42	0.36	6.67	0.31	8.14e-11	Depressive symptoms;
LUAD	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg15744005	chr10:104629667	AS3MT	-0.34	-6.73	-0.31	5.53e-11	Immature fraction of reticulocytes;Schizophrenia;
LUAD	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg24634471	chr8:143751801	JRK	0.48	7.71	0.35	9.12e-14	Schizophrenia;
LUAD	cis	rs62400317	0.859	rs10948220	chr6:45236654	A/G	cg20913747	chr6:44695427	NA	-0.41	-6.57	-0.3	1.44e-10	Total body bone mineral density;
LUAD	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg04546413	chr19:29218101	NA	0.71	8.98	0.4	8.81e-18	Methadone dose in opioid dependence;
LUAD	cis	rs1215050	0.846	rs1839903	chr4:98791414	C/T	cg05340658	chr4:99064831	C4orf37	0.42	6.81	0.31	3.28e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.21	-0.33	2.67e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2944755	0.580	rs13251004	chr8:141586126	G/A	cg26074100	chr8:141568712	EIF2C2	0.36	6.4	0.3	4.09e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs2235642	0.671	rs2235641	chr16:1608177	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.42	-6.74	-0.31	5.11e-11	Coronary artery disease;
LUAD	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg19041857	chr6:27730383	NA	-0.4	-6.78	-0.31	4.13e-11	Parkinson's disease;
LUAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg23978390	chr7:1156363	C7orf50	0.55	8.43	0.38	5.61e-16	Longevity;Endometriosis;
LUAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.55	-9.51	-0.42	1.49e-19	Longevity;Endometriosis;
LUAD	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg05590025	chr7:65112418	INTS4L2	-0.71	-7.61	-0.35	1.84e-13	Diabetic kidney disease;
LUAD	cis	rs4356932	0.905	rs4859597	chr4:76956630	A/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.54	-0.3	1.78e-10	Blood protein levels;
LUAD	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg14092988	chr3:52407081	DNAH1	0.37	7.42	0.34	6.35e-13	Electroencephalogram traits;
LUAD	cis	rs6554196	0.508	rs3819393	chr4:55526615	C/T	cg18836493	chr4:55524333	KIT	-0.37	-7.05	-0.32	7.43e-12	Monocyte count;
LUAD	cis	rs4930561	0.714	rs7945995	chr11:67938302	A/G	cg04465784	chr11:67976953	SUV420H1	-0.35	-11.03	-0.47	4.71e-25	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg20607798	chr8:58055168	NA	0.67	8.77	0.39	4.44e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs986417	1.000	rs10130267	chr14:60944527	A/G	cg27398547	chr14:60952738	C14orf39	0.68	8.11	0.37	5.65e-15	Gut microbiota (bacterial taxa);
LUAD	cis	rs12545109	0.800	rs2670028	chr8:57423673	G/A	cg09654669	chr8:57350985	NA	-0.64	-9.52	-0.42	1.3e-19	Obesity-related traits;
LUAD	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg05368731	chr17:41323189	NBR1	0.95	20.35	0.7	1.05e-64	Menopause (age at onset);
LUAD	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10053473	chr17:62856997	LRRC37A3	-0.75	-10.47	-0.45	5.74e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg18876405	chr7:65276391	NA	-0.43	-7.23	-0.33	2.28e-12	Calcium levels;
LUAD	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.5	0.34	3.86e-13	Tonsillectomy;
LUAD	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg12011299	chr4:100065546	ADH4	0.76	15.61	0.6	1e-43	Alcohol dependence;
LUAD	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg25535316	chr11:579198	PHRF1	-0.38	-6.65	-0.31	9.11e-11	Systemic lupus erythematosus;
LUAD	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg16325326	chr1:53192061	ZYG11B	0.67	12.96	0.53	1.35e-32	Monocyte count;
LUAD	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg22467129	chr15:76604101	ETFA	-0.62	-11.62	-0.49	2.92e-27	Blood metabolite levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02101719	chr7:148787553	ZNF786	-0.42	-6.76	-0.31	4.52e-11	Height;
LUAD	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg11584989	chr19:19387371	SF4	-0.63	-9.06	-0.4	4.99e-18	Bipolar disorder;
LUAD	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg14584255	chr6:163149320	PACRG;PARK2	-0.36	-6.91	-0.32	1.82e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg04731861	chr2:219085781	ARPC2	0.27	8.22	0.37	2.53e-15	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg11494091	chr17:61959527	GH2	0.46	8.65	0.39	1.1e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg01154537	chr10:95462167	C10orf4	-0.41	-7.35	-0.34	1.06e-12	Subcortical brain region volumes;
LUAD	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg12011299	chr4:100065546	ADH4	0.69	14.51	0.58	5.15e-39	Alcohol dependence;
LUAD	cis	rs910187	0.678	rs6124965	chr20:45812957	T/G	cg27589058	chr20:45804311	EYA2	-0.31	-7.13	-0.33	4.5e-12	Migraine;
LUAD	cis	rs714515	0.609	rs4916262	chr1:172450528	A/C	cg13446689	chr1:172328377	DNM3	-0.32	-6.36	-0.3	5.21e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg08610935	chr16:1836813	NUBP2	-0.46	-6.87	-0.32	2.34e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg00745463	chr17:30367425	LRRC37B	-0.68	-8.35	-0.38	9.81e-16	Hip circumference adjusted for BMI;
LUAD	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg00717180	chr2:96193071	NA	0.36	6.68	0.31	7.63e-11	Coronary artery disease;
LUAD	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg26384229	chr12:38710491	ALG10B	0.4	6.41	0.3	3.87e-10	Morning vs. evening chronotype;
LUAD	cis	rs7584330	0.554	rs13405619	chr2:238445661	C/T	cg14458575	chr2:238380390	NA	0.62	9.95	0.44	4.34e-21	Prostate cancer;
LUAD	cis	rs11958404	0.932	rs72816542	chr5:157416402	C/T	cg05962755	chr5:157440814	NA	0.62	8.42	0.38	5.83e-16	IgG glycosylation;
LUAD	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg12573674	chr2:1569213	NA	-0.56	-8.38	-0.38	7.67e-16	IgG glycosylation;
LUAD	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg27539214	chr16:67997921	SLC12A4	-0.7	-9.0	-0.4	7.52e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg21918786	chr6:109611834	NA	-0.58	-10.61	-0.46	1.8e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg18827107	chr12:86230957	RASSF9	-0.68	-12.53	-0.52	7.68e-31	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.33	0.38	1.13e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg04924415	chr12:100661456	SCYL2;DEPDC4	-0.52	-6.59	-0.31	1.28e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	7.31	0.33	1.36e-12	Platelet count;
LUAD	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg23649088	chr2:200775458	C2orf69	-0.63	-6.92	-0.32	1.65e-11	Schizophrenia;
LUAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg27532560	chr4:187881888	NA	-0.35	-6.59	-0.31	1.3100000000000001e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4711350	0.765	rs2395446	chr6:33743264	C/T	cg16010596	chr6:33739607	LEMD2	-0.41	-7.63	-0.35	1.54e-13	Schizophrenia;
LUAD	cis	rs72772090	0.539	rs72775809	chr5:96183556	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-6.68	-0.31	7.58e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg22117172	chr7:91764530	CYP51A1	0.35	7.63	0.35	1.61e-13	Breast cancer;
LUAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.07e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg24829409	chr8:58192753	C8orf71	0.58	7.62	0.35	1.72e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7809799	0.571	rs73163167	chr7:98943086	C/T	cg12290671	chr7:99195819	NA	-0.8	-7.01	-0.32	9.3e-12	Ulcerative colitis;
LUAD	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg03678062	chr6:149772716	ZC3H12D	0.29	6.43	0.3	3.44e-10	Dupuytren's disease;
LUAD	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05210886	chr1:245133216	EFCAB2	0.41	6.66	0.31	8.77e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs1403694	0.655	rs3806688	chr3:186434819	T/C	cg12454167	chr3:186435060	KNG1	0.5	10.5	0.45	4.58e-23	Blood protein levels;
LUAD	trans	rs991427	1.000	rs11105972	chr12:91471955	A/G	cg11428724	chr1:18957632	PAX7	0.42	6.49	0.3	2.37e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	trans	rs208520	0.874	rs208514	chr6:66945520	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-14.82	-0.58	2.58e-40	Exhaled nitric oxide output;
LUAD	cis	rs7202877	0.706	rs247423	chr16:75456631	C/A	cg03315344	chr16:75512273	CHST6	-0.47	-6.44	-0.3	3.35e-10	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg01657329	chr11:68192670	LRP5	0.39	6.38	0.3	4.78e-10	Total body bone mineral density;
LUAD	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg03676636	chr4:99064102	C4orf37	0.3	7.32	0.34	1.26e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg08632164	chr7:65971372	NA	-0.37	-6.41	-0.3	3.91e-10	Aortic root size;
LUAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg07685180	chr8:600429	NA	0.86	8.61	0.39	1.43e-16	IgG glycosylation;
LUAD	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg00383909	chr3:49044727	WDR6	0.95	9.51	0.42	1.45e-19	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs2979489	0.945	rs11988541	chr8:30334273	G/A	cg26383811	chr8:30366931	RBPMS	-0.67	-10.36	-0.45	1.42e-22	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs10788264	0.504	rs4751887	chr10:124029758	G/A	cg09507567	chr10:124027408	NA	0.55	12.3	0.51	5.9e-30	Total body bone mineral density;
LUAD	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg00814883	chr7:100076585	TSC22D4	-0.81	-11.65	-0.49	2.11e-27	Platelet count;
LUAD	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg06740227	chr12:86229804	RASSF9	0.45	7.91	0.36	2.31e-14	Major depressive disorder;
LUAD	cis	rs2425143	1.000	rs56052651	chr20:34344084	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.06	-0.32	6.86e-12	Blood protein levels;
LUAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg16606324	chr3:10149918	C3orf24	0.65	10.77	0.46	4.51e-24	Alzheimer's disease;
LUAD	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg15017067	chr4:17643749	FAM184B	0.37	7.17	0.33	3.33e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg11050988	chr7:1952600	MAD1L1	-0.37	-7.67	-0.35	1.16e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-10.07	-0.44	1.66e-21	Migraine;Coronary artery disease;
LUAD	trans	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg14791747	chr16:20752902	THUMPD1	-0.83	-13.85	-0.56	3.15e-36	Cognitive test performance;
LUAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg04234412	chr22:24373322	LOC391322	-0.94	-18.62	-0.67	5.99e-57	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07343612	chr16:622815	PIGQ	-0.83	-16.83	-0.63	4.97e-49	Height;
LUAD	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg06627628	chr2:24431161	ITSN2	-0.47	-6.66	-0.31	8.79e-11	Lymphocyte counts;
LUAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12379764	chr21:47803548	PCNT	0.39	6.43	0.3	3.41e-10	Testicular germ cell tumor;
LUAD	cis	rs4604732	0.631	rs11490198	chr1:247625703	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.42	-0.6	6.74e-43	Chronic sinus infection;
LUAD	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg05754148	chr16:3507555	NAT15	0.7	11.38	0.48	2.34e-26	Tuberculosis;
LUAD	cis	rs55823223	0.752	rs34974290	chr17:73888354	G/A	cg09253696	chr17:73873529	TRIM47	-0.48	-8.08	-0.37	6.79e-15	Psoriasis;
LUAD	trans	rs877282	0.898	rs12354872	chr10:763362	G/A	cg22713356	chr15:30763199	NA	1.26	17.41	0.65	1.4e-51	Uric acid levels;
LUAD	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.83	0.36	4.09e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9394169	0.533	rs4713675	chr6:33718418	C/T	cg13859433	chr6:33739653	LEMD2	-0.35	-8.25	-0.37	2e-15	Essential tremor;
LUAD	cis	rs459571	1.000	rs456207	chr9:136911140	G/A	cg13789015	chr9:136890014	NCRNA00094	0.8	13.29	0.54	6.25e-34	Platelet distribution width;
LUAD	cis	rs8017423	0.935	rs17260827	chr14:90732703	G/A	cg14092571	chr14:90743983	NA	0.48	8.14	0.37	4.42e-15	Mortality in heart failure;
LUAD	cis	rs11051970	0.655	rs7298381	chr12:32530257	G/T	cg24626660	chr12:32551988	NA	0.31	6.59	0.31	1.33e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg26354017	chr1:205819088	PM20D1	-0.76	-16.36	-0.62	5.8e-47	Menarche (age at onset);
LUAD	trans	rs10812641	0.875	rs7032942	chr9:2792552	A/C	cg18418962	chr18:2571633	METTL4;NDC80	-0.38	-6.45	-0.3	3.09e-10	Blood trace element (Se levels);
LUAD	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg25358565	chr5:93447407	FAM172A	0.62	7.16	0.33	3.6e-12	Diabetic retinopathy;
LUAD	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.9	10.82	0.47	3.11e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg01620082	chr3:125678407	NA	-0.44	-6.48	-0.3	2.55e-10	Depression;
LUAD	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.38	-0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg21849932	chr20:62369462	LIME1	0.47	7.68	0.35	1.08e-13	Prostate cancer;
LUAD	cis	rs2637266	1.000	rs2579749	chr10:78332105	T/C	cg18941641	chr10:78392320	NA	0.31	6.4	0.3	4.05e-10	Pulmonary function;
LUAD	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg11822812	chr5:140052017	DND1	0.38	6.66	0.31	8.67e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22857025	chr5:266934	NA	-0.97	-14.6	-0.58	2.17e-39	Breast cancer;
LUAD	cis	rs12541635	0.932	rs1835267	chr8:107044435	C/T	cg10147462	chr8:107024639	NA	0.48	8.61	0.39	1.51e-16	Age of smoking initiation;
LUAD	cis	rs2279817	1.000	rs2279816	chr1:18021867	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.58	9.47	0.42	1.97e-19	Neuroticism;
LUAD	cis	rs9296092	0.538	rs9461879	chr6:33516907	C/T	cg13560919	chr6:33536144	NA	-0.87	-15.45	-0.6	4.9e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.53	-0.3	1.94e-10	Prostate cancer;
LUAD	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg00647820	chr17:40259828	DHX58	-0.44	-6.9	-0.32	1.94e-11	Fibrinogen levels;
LUAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg12379764	chr21:47803548	PCNT	-0.37	-6.42	-0.3	3.73e-10	Testicular germ cell tumor;
LUAD	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg11663144	chr21:46675770	NA	-0.61	-12.18	-0.51	1.81e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg18610261	chr2:37899776	CDC42EP3	-0.48	-7.0	-0.32	1.02e-11	Testicular germ cell tumor;
LUAD	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg11871910	chr12:69753446	YEATS4	0.71	12.15	0.51	2.44e-29	Blood protein levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01964233	chr2:99757837	C2orf15;TSGA10	-0.67	-6.73	-0.31	5.47e-11	Type 2 diabetes;
LUAD	trans	rs2262909	0.925	rs404822	chr19:22215967	A/C	cg05197062	chr11:11642011	GALNTL4	-0.54	-8.13	-0.37	4.95e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11890956	chr21:40555474	PSMG1	-0.59	-9.72	-0.43	2.78e-20	Cognitive function;
LUAD	cis	rs7737355	0.812	rs10076930	chr5:130764037	C/T	cg06307176	chr5:131281290	NA	-0.42	-6.97	-0.32	1.21e-11	Life satisfaction;
LUAD	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	7.09	0.33	5.48e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg05368731	chr17:41323189	NBR1	0.96	19.68	0.69	1.06e-61	Menopause (age at onset);
LUAD	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.5	0.3	2.33e-10	Parkinson's disease;
LUAD	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg21204522	chr6:27730016	NA	-0.47	-7.52	-0.34	3.23e-13	Parkinson's disease;
LUAD	trans	rs1941687	0.563	rs2032189	chr18:31332200	T/A	cg27147174	chr7:100797783	AP1S1	-0.7	-12.84	-0.53	4.34e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2932538	0.922	rs12143068	chr1:113138110	A/G	cg22162597	chr1:113214053	CAPZA1	0.47	7.05	0.32	7.26e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg27432699	chr2:27873401	GPN1	0.56	9.94	0.44	4.53e-21	Oral cavity cancer;
LUAD	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	cg06064525	chr11:970664	AP2A2	-0.35	-6.85	-0.32	2.58e-11	Alzheimer's disease (late onset);
LUAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11048434	0.636	rs11614970	chr12:9060053	G/A	cg23795048	chr12:9217529	LOC144571	0.41	7.32	0.34	1.28e-12	Sjögren's syndrome;
LUAD	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg22029157	chr1:209979665	IRF6	0.8	9.65	0.42	4.64e-20	Cleft lip with or without cleft palate;
LUAD	cis	rs62400317	0.826	rs62400330	chr6:45321455	G/A	cg18551225	chr6:44695536	NA	-0.54	-8.45	-0.38	4.72e-16	Total body bone mineral density;
LUAD	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.21e-19	Life satisfaction;
LUAD	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23158103	chr7:148848205	ZNF398	-0.64	-11.01	-0.47	5.71e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg05991184	chr2:219186017	PNKD	-0.35	-6.8	-0.31	3.66e-11	Colorectal cancer;
LUAD	trans	rs13090388	1	rs13090388	chr3:49391082	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.48	-7.44	-0.34	5.6e-13	Intelligence (multi-trait analysis);Educational attainment (years of education);
LUAD	trans	rs994533	0.928	rs7594625	chr2:218293564	A/C	cg04413180	chr2:236847057	AGAP1	-0.39	-6.69	-0.31	7.19e-11	Height;
LUAD	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg18230493	chr5:56204884	C5orf35	-0.45	-7.57	-0.35	2.35e-13	Coronary artery disease;
LUAD	cis	rs1691799	0.899	rs1168321	chr12:66744517	C/G	cg16791601	chr12:66731901	HELB	0.36	6.55	0.3	1.63e-10	White blood cell count (basophil);
LUAD	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg03467027	chr4:99064603	C4orf37	0.43	6.96	0.32	1.33e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-7.93	-0.36	1.99e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7527798	0.592	rs7539772	chr1:207833301	G/A	cg09232269	chr1:207846808	CR1L	-0.36	-6.84	-0.32	2.85e-11	Erythrocyte sedimentation rate;
LUAD	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg23950597	chr19:37808831	NA	-0.63	-7.86	-0.36	3.17e-14	Coronary artery calcification;
LUAD	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06544989	chr22:39130855	UNC84B	0.45	9.15	0.41	2.5e-18	Menopause (age at onset);
LUAD	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.49	8.41	0.38	6.39e-16	Eosinophil percentage of white cells;
LUAD	cis	rs420259	0.516	rs2106456	chr16:23550931	C/T	cg00143387	chr16:23521605	GGA2	-0.73	-10.03	-0.44	2.27e-21	Bipolar disorder;
LUAD	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-7.63	-0.35	1.61e-13	Personality dimensions;
LUAD	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg06558623	chr16:89946397	TCF25	1.09	11.72	0.5	1.14e-27	Skin colour saturation;
LUAD	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg14458575	chr2:238380390	NA	0.67	12.9	0.53	2.44e-32	Prostate cancer;
LUAD	cis	rs12431939	0.948	rs12435916	chr14:51665858	T/G	cg23942311	chr14:51606299	NA	-0.54	-7.38	-0.34	8.21e-13	Cancer;
LUAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg06753367	chr22:24256600	NA	-0.38	-6.62	-0.31	1.1e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8018808	0.967	rs4903579	chr14:77850940	T/A	cg20045696	chr14:77926864	AHSA1	-0.37	-6.74	-0.31	5.09e-11	Myeloid white cell count;
LUAD	cis	rs10242455	0.702	rs73403290	chr7:99157828	C/T	cg18809830	chr7:99032528	PTCD1	-0.98	-7.16	-0.33	3.6e-12	Blood metabolite levels;
LUAD	cis	rs9875589	0.509	rs9836573	chr3:14065239	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	6.55	0.3	1.66e-10	Ovarian reserve;
LUAD	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg21214613	chr1:16344536	HSPB7	0.61	12.1	0.51	3.79e-29	Systolic blood pressure;
LUAD	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.18	-0.33	3.09e-12	Glomerular filtration rate;
LUAD	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg16060761	chr17:80687452	NA	-0.6	-8.58	-0.38	1.84e-16	Glycated hemoglobin levels;
LUAD	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg25894440	chr7:65020034	NA	-0.69	-7.32	-0.34	1.28e-12	Diabetic kidney disease;
LUAD	cis	rs68170813	0.559	rs7809508	chr7:107004119	T/C	cg02696742	chr7:106810147	HBP1	-0.73	-10.02	-0.44	2.39e-21	Coronary artery disease;
LUAD	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.69	0.76	1.37e-79	Chronic sinus infection;
LUAD	cis	rs3087591	0.960	rs9903754	chr17:29634468	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.57	-0.3	1.51e-10	Hip circumference;
LUAD	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg18230493	chr5:56204884	C5orf35	-0.44	-7.41	-0.34	6.88e-13	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg08470875	chr2:26401718	FAM59B	-0.74	-9.85	-0.43	9.74e-21	Gut microbiome composition (summer);
LUAD	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07930192	chr7:1003750	NA	0.41	7.86	0.36	3.3e-14	Longevity;Endometriosis;
LUAD	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg22868518	chr11:507468	RNH1	-0.68	-6.76	-0.31	4.46e-11	Body mass index;
LUAD	cis	rs73198271	0.515	rs11780216	chr8:8625720	G/T	cg01851573	chr8:8652454	MFHAS1	0.58	7.8	0.35	4.89e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06873352	chr17:61820015	STRADA	0.83	18.59	0.67	8.47e-57	Prudent dietary pattern;
LUAD	cis	rs1232027	0.656	rs1824837	chr5:79961241	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.82	0.31	3.11e-11	Aortic root size;
LUAD	cis	rs10748180	0.502	rs11178894	chr12:72089163	C/T	cg10168894	chr12:72148281	RAB21	-0.42	-6.44	-0.3	3.21e-10	Economic and political preferences (time);
LUAD	trans	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-17.77	-0.65	3.49e-53	Exhaled nitric oxide output;
LUAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg08132940	chr7:1081526	C7orf50	-0.76	-10.29	-0.45	2.63e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10744422	0.858	rs10773627	chr12:123311853	A/G	cg16953816	chr12:123349952	VPS37B	0.62	7.18	0.33	3.19e-12	Schizophrenia;
LUAD	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg20607287	chr7:12443886	VWDE	-0.53	-6.67	-0.31	8.01e-11	Coronary artery disease;
LUAD	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg05082376	chr22:42548792	NA	-0.5	-9.22	-0.41	1.37e-18	Schizophrenia;
LUAD	cis	rs2282300	0.739	rs1717775	chr11:30350254	T/G	cg25418670	chr11:30344373	C11orf46	-0.52	-7.0	-0.32	9.94e-12	Morning vs. evening chronotype;
LUAD	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg02734326	chr4:10020555	SLC2A9	0.63	11.4	0.48	2.02e-26	Bone mineral density;
LUAD	cis	rs1816752	0.712	rs2862898	chr13:24988461	A/G	cg02811702	chr13:24901961	NA	0.43	7.27	0.33	1.76e-12	Obesity-related traits;
LUAD	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.08	-14.55	-0.58	3.67e-39	Schizophrenia;
LUAD	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg23758822	chr17:41437982	NA	0.99	19.86	0.69	1.64e-62	Menopause (age at onset);
LUAD	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg02158880	chr13:53174818	NA	0.55	9.49	0.42	1.72e-19	Lewy body disease;
LUAD	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg23719950	chr11:63933701	MACROD1	-0.58	-6.87	-0.32	2.28e-11	Mean platelet volume;
LUAD	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.29	0.54	6.06e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg05110241	chr16:68378359	PRMT7	-0.69	-7.85	-0.36	3.34e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg17845761	chr1:175162550	KIAA0040	0.35	9.01	0.4	7.13e-18	Alcohol dependence;
LUAD	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg13606994	chr1:44402422	ARTN	-0.33	-6.65	-0.31	9.08e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7177699	0.534	rs7403708	chr15:79123885	T/C	cg00540400	chr15:79124168	NA	-0.47	-9.92	-0.43	5.54e-21	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.46	-0.34	4.83e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.66	-0.31	8.51e-11	Crohn's disease;
LUAD	cis	rs79839061	0.562	rs62294484	chr4:935571	A/G	cg23992470	chr4:843637	GAK	0.69	7.34	0.34	1.12e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg18252515	chr7:66147081	NA	0.67	7.16	0.33	3.54e-12	Diabetic kidney disease;
LUAD	cis	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.44	-0.34	5.84e-13	Resting heart rate;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24109975	chr19:59055787	TRIM28	-0.54	-6.48	-0.3	2.61e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs12519773	0.534	rs2453763	chr5:92376460	T/A	cg18783429	chr5:92414398	NA	-0.5	-8.52	-0.38	2.83e-16	Migraine;
LUAD	cis	rs9354308	0.966	rs1909533	chr6:66565658	G/A	cg07460842	chr6:66804631	NA	0.49	7.25	0.33	1.99e-12	Metabolite levels;
LUAD	cis	rs1823874	0.720	rs2003037	chr15:100361962	G/T	cg16400843	chr15:100339927	C15orf51	0.32	7.58	0.35	2.27e-13	IgG glycosylation;
LUAD	cis	rs7659604	0.502	rs13128434	chr4:122672461	A/C	cg06713675	chr4:122721982	EXOSC9	0.41	7.45	0.34	5.34e-13	Type 2 diabetes;
LUAD	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg00530320	chr1:46809349	NSUN4	0.51	8.1	0.37	5.84e-15	Menopause (age at onset);
LUAD	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg11266682	chr4:10021025	SLC2A9	0.45	8.31	0.37	1.34e-15	Blood metabolite levels;
LUAD	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg26516362	chr5:178986906	RUFY1	0.39	6.95	0.32	1.37e-11	Lung cancer;
LUAD	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.78e-11	Crohn's disease;
LUAD	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg01324343	chr3:183735012	ABCC5	0.94	24.82	0.77	1.45e-84	Anterior chamber depth;
LUAD	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg22532475	chr10:104410764	TRIM8	-0.36	-7.28	-0.33	1.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6496044	0.568	rs1351196	chr15:86077404	T/C	cg13263323	chr15:86062960	AKAP13	-0.56	-10.28	-0.45	2.78e-22	Interstitial lung disease;
LUAD	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg22117172	chr7:91764530	CYP51A1	0.33	7.13	0.33	4.31e-12	Breast cancer;
LUAD	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.28	-0.41	8.54e-19	Life satisfaction;
LUAD	cis	rs9788682	0.747	rs2958719	chr15:78743029	G/A	cg18825076	chr15:78729989	IREB2	-0.55	-7.79	-0.35	5.1e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg10589385	chr1:150898437	SETDB1	0.38	7.15	0.33	3.88e-12	Tonsillectomy;
LUAD	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg21782813	chr7:2030301	MAD1L1	0.53	9.16	0.41	2.2e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg00784671	chr22:46762841	CELSR1	-0.61	-7.56	-0.34	2.55e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg24818145	chr4:99064322	C4orf37	0.47	7.98	0.36	1.43e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg22764044	chr5:178986830	RUFY1	0.64	11.24	0.48	7.95e-26	Lung cancer;
LUAD	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.78	-10.34	-0.45	1.68e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg18512352	chr11:47633146	NA	-0.51	-8.85	-0.4	2.33e-17	Subjective well-being;
LUAD	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.48	-0.34	4.48e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-7.02	-0.32	8.68e-12	Morning vs. evening chronotype;
LUAD	trans	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg18187862	chr3:45730750	SACM1L	-0.53	-8.39	-0.38	7.17e-16	Primary sclerosing cholangitis;
LUAD	cis	rs55665837	0.540	rs10832294	chr11:14747427	C/A	cg19336497	chr11:14380999	RRAS2	-0.41	-7.8	-0.35	4.76e-14	Vitamin D levels;
LUAD	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg11871910	chr12:69753446	YEATS4	0.69	11.47	0.49	1.07e-26	Blood protein levels;
LUAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.59	-9.95	-0.44	4.15e-21	Longevity;Endometriosis;
LUAD	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.37	0.34	8.85e-13	Menopause (age at onset);
LUAD	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg07617317	chr6:118971624	C6orf204	0.54	8.46	0.38	4.34e-16	Diastolic blood pressure;
LUAD	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg11915388	chr22:42470451	FAM109B	-0.41	-7.39	-0.34	7.89e-13	Schizophrenia;
LUAD	trans	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg01620082	chr3:125678407	NA	0.46	7.02	0.32	8.75e-12	Parkinson's disease;
LUAD	cis	rs6669919	0.933	rs10863899	chr1:211666218	A/G	cg10512769	chr1:211675356	NA	-0.33	-7.11	-0.33	4.97e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg02683114	chr2:24398427	C2orf84	-0.53	-7.7	-0.35	9.79e-14	Asthma;
LUAD	cis	rs11229555	0.574	rs12272310	chr11:58186462	A/C	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg19825600	chr2:3704501	ALLC	-0.41	-7.76	-0.35	6.26e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg27490568	chr2:178487706	NA	0.51	7.86	0.36	3.2e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16442450	chr15:69111511	ANP32A	-0.54	-6.39	-0.3	4.28e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.71	10.02	0.44	2.34e-21	IgG glycosylation;
LUAD	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg23158103	chr7:148848205	ZNF398	-0.45	-7.89	-0.36	2.55e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg24558204	chr6:135376177	HBS1L	0.47	8.59	0.39	1.65e-16	Red blood cell count;
LUAD	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-6.86	-0.32	2.48e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg20790798	chr5:1857306	NA	-0.44	-7.49	-0.34	3.98e-13	Cardiovascular disease risk factors;
LUAD	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg20203395	chr5:56204925	C5orf35	-0.71	-10.1	-0.44	1.23e-21	Initial pursuit acceleration;
LUAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg18402987	chr7:1209562	NA	0.8	9.76	0.43	1.92e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg02221422	chr11:68192511	LRP5	0.42	6.99	0.32	1.05e-11	Total body bone mineral density;
LUAD	cis	rs7584330	0.784	rs1463795	chr2:238412392	C/G	cg16989719	chr2:238392110	NA	0.31	6.56	0.3	1.54e-10	Prostate cancer;
LUAD	cis	rs2652834	0.851	rs4238372	chr15:63351488	G/A	cg25406657	chr15:63342033	TPM1	-0.44	-7.01	-0.32	9.76e-12	HDL cholesterol;
LUAD	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.39	6.68	0.31	7.64e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7737355	0.773	rs4706027	chr5:130932972	T/C	cg06307176	chr5:131281290	NA	0.42	6.73	0.31	5.41e-11	Life satisfaction;
LUAD	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg21775007	chr8:11205619	TDH	-0.48	-8.5	-0.38	3.38e-16	Retinal vascular caliber;
LUAD	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.88e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg17173187	chr15:85201210	NMB	0.51	8.72	0.39	6.27e-17	Schizophrenia;
LUAD	cis	rs1045714	0.887	rs73033694	chr7:2637139	G/A	cg24848437	chr7:2645542	IQCE	0.7	8.05	0.36	8.68e-15	Urate levels in lean individuals;
LUAD	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg04545296	chr12:48745243	ZNF641	0.41	10.28	0.45	2.8e-22	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs1032833	0.732	rs17363449	chr2:180016141	G/C	cg23883738	chr2:179974586	SESTD1	-0.65	-7.3	-0.33	1.46e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	trans	rs931812	0.895	rs4734016	chr8:101910071	C/T	cg20993868	chr7:22813445	NA	0.64	13.23	0.54	1.12e-33	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg20701182	chr2:24300061	SF3B14	0.53	6.42	0.3	3.66e-10	Lymphocyte counts;
LUAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.86	-16.48	-0.63	1.69e-47	Lymphocyte counts;
LUAD	cis	rs7731657	0.537	rs4705907	chr5:130191437	T/A	cg08523029	chr5:130500466	HINT1	-0.58	-7.53	-0.34	3.1400000000000003e-13	Fasting plasma glucose;
LUAD	cis	rs7582720	1.000	rs72934732	chr2:203739856	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.45	0.42	2.39e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg18252515	chr7:66147081	NA	-0.61	-6.78	-0.31	4.07e-11	Diabetic kidney disease;
LUAD	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg09835421	chr16:68378352	PRMT7	-0.91	-9.74	-0.43	2.41e-20	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg21475434	chr5:93447410	FAM172A	0.74	8.26	0.37	1.83e-15	Diabetic retinopathy;
LUAD	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg04414720	chr1:150670196	GOLPH3L	0.71	12.67	0.52	1.98e-31	Melanoma;
LUAD	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg00769240	chr8:12517080	NA	-0.39	-6.49	-0.3	2.37e-10	Blood pressure (smoking interaction);
LUAD	cis	rs367615	0.552	rs2963024	chr5:108730773	C/T	cg17395555	chr5:108820864	NA	-0.48	-9.23	-0.41	1.28e-18	Colorectal cancer (SNP x SNP interaction);
LUAD	trans	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg18187862	chr3:45730750	SACM1L	0.5	7.84	0.36	3.69e-14	Primary sclerosing cholangitis;
LUAD	cis	rs5756391	0.546	rs4821561	chr22:37311877	A/G	cg16356956	chr22:37317934	CSF2RB	-0.33	-7.09	-0.33	5.52e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs11098699	0.784	rs4833894	chr4:124241925	A/G	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.47	-0.38	4.02e-16	Prostate cancer;
LUAD	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg02569458	chr12:86230093	RASSF9	0.45	8.24	0.37	2.25e-15	Major depressive disorder;
LUAD	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg26384229	chr12:38710491	ALG10B	0.51	7.99	0.36	1.32e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg03563238	chr19:33554763	RHPN2	-0.37	-8.69	-0.39	7.98e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg11909912	chr17:43974919	MAPT;LOC100130148	0.39	6.63	0.31	1e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11890956	chr21:40555474	PSMG1	0.79	13.76	0.56	7.13e-36	Cognitive function;
LUAD	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.73	0.39	5.94e-17	Menopause (age at onset);
LUAD	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg04772025	chr11:68637568	NA	0.59	9.41	0.42	3.25e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg08773314	chr2:239334832	ASB1	0.44	9.54	0.42	1.19e-19	Multiple system atrophy;
LUAD	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.57	0.3	1.5e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs11039798	0.841	rs11039783	chr11:48526828	G/C	cg02254774	chr11:50257496	LOC441601	0.53	6.6	0.31	1.22e-10	Axial length;
LUAD	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg06608945	chr2:219082296	ARPC2	-0.41	-6.69	-0.31	7.29e-11	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg13918804	chr1:2043761	PRKCZ	0.4	6.71	0.31	6.13e-11	Height;
LUAD	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.32	-0.34	1.26e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.54	0.3	1.79e-10	Parkinson's disease;
LUAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg11494091	chr17:61959527	GH2	0.74	18.39	0.67	6.08e-56	Prudent dietary pattern;
LUAD	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg00933542	chr6:150070202	PCMT1	0.43	9.03	0.4	6.3e-18	Lung cancer;
LUAD	trans	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.0	-0.36	1.2e-14	Gout;
LUAD	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.79	-0.31	3.85e-11	Personality dimensions;
LUAD	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg25358565	chr5:93447407	FAM172A	0.66	7.75	0.35	6.74e-14	Diabetic retinopathy;
LUAD	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg17077180	chr1:38461687	NA	0.44	9.03	0.4	6.26e-18	Coronary artery disease;
LUAD	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg09640425	chr7:158790006	NA	-0.54	-9.36	-0.41	4.75e-19	Facial morphology (factor 20);
LUAD	cis	rs8133932	0.677	rs6518257	chr21:47210107	T/C	cg07529122	chr21:47054539	NA	-0.39	-6.83	-0.32	2.88e-11	Schizophrenia;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg04691540	chr1:179198414	ABL2	0.42	6.71	0.31	6.27e-11	Diastolic blood pressure;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg03729288	chr17:7232752	NEURL4	-0.71	-6.75	-0.31	4.97e-11	Type 2 diabetes;
LUAD	cis	rs4409675	0.576	rs11247706	chr1:28213983	G/C	cg23691781	chr1:28212827	C1orf38	0.38	11.3	0.48	4.81e-26	Corneal astigmatism;
LUAD	cis	rs10129255	0.500	rs1024350	chr14:107141122	C/T	cg23076370	chr14:107095027	NA	-0.42	-8.49	-0.38	3.47e-16	Kawasaki disease;
LUAD	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg00255919	chr5:131827918	IRF1	0.49	11.85	0.5	3.74e-28	Asthma (sex interaction);
LUAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg07217954	chr7:1067459	C7orf50	0.43	6.63	0.31	1.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4523957	0.890	rs9908888	chr17:2102453	G/C	cg16513277	chr17:2031491	SMG6	-0.81	-15.61	-0.6	1.06e-43	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg02002194	chr4:3960332	NA	0.27	6.38	0.3	4.63e-10	Retinal vascular caliber;
LUAD	cis	rs10504073	0.584	rs56074306	chr8:49940282	C/T	cg00325661	chr8:49890786	NA	0.48	10.54	0.46	3.19e-23	Blood metabolite ratios;
LUAD	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg14396892	chr9:96623032	NA	-0.43	-8.33	-0.38	1.1e-15	DNA methylation (variation);
LUAD	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	7.72	0.35	8.51e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15084286	chr11:17036142	PLEKHA7	0.71	12.22	0.51	1.27e-29	Coronary artery disease;
LUAD	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18876405	chr7:65276391	NA	0.55	9.22	0.41	1.46e-18	Aortic root size;
LUAD	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg27446573	chr6:127587934	RNF146	0.42	6.36	0.3	5.3e-10	Breast cancer;
LUAD	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg17264618	chr3:40429014	ENTPD3	0.38	8.55	0.38	2.29e-16	Renal cell carcinoma;
LUAD	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg18225595	chr11:63971243	STIP1	0.49	8.4	0.38	6.98e-16	Platelet count;
LUAD	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg10518543	chr12:38710700	ALG10B	-0.44	-7.23	-0.33	2.34e-12	Morning vs. evening chronotype;
LUAD	cis	rs12681287	0.752	rs7846635	chr8:87304281	G/A	cg00550725	chr8:87521180	FAM82B	0.46	6.67	0.31	8.01e-11	Caudate activity during reward;
LUAD	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-10.86	-0.47	2.07e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg09137382	chr11:130731461	NA	0.4	7.03	0.32	8.44e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9399401	0.593	rs262117	chr6:142807093	G/A	cg03128060	chr6:142623767	GPR126	0.43	8.05	0.36	8.56e-15	Chronic obstructive pulmonary disease;
LUAD	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.24	0.33	2.13e-12	Blood metabolite levels;
LUAD	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg04842962	chr6:43655489	MRPS18A	0.8	15.42	0.6	6.7e-43	IgG glycosylation;
LUAD	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.48	7.72	0.35	8.45e-14	Personality dimensions;
LUAD	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg26769984	chr7:1090371	C7orf50	0.57	9.56	0.42	9.75e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs7107174	1.000	rs2512542	chr11:77981780	G/A	cg02023728	chr11:77925099	USP35	0.39	6.61	0.31	1.15e-10	Testicular germ cell tumor;
LUAD	cis	rs7017914	1.000	rs13253842	chr8:71625503	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg17644776	chr2:200775616	C2orf69	-0.55	-6.64	-0.31	9.85e-11	Schizophrenia;
LUAD	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg08997352	chr12:9597637	DDX12	-0.63	-10.78	-0.46	4.04e-24	Breast size;
LUAD	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg04369109	chr6:150039330	LATS1	-0.48	-7.71	-0.35	8.78e-14	Lung cancer;
LUAD	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg11833968	chr6:79620685	NA	-0.44	-8.27	-0.37	1.72e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs9303280	0.901	rs7216389	chr17:38069949	C/T	cg10909506	chr17:38081995	ORMDL3	-0.37	-6.65	-0.31	9.05e-11	Self-reported allergy;
LUAD	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg13390004	chr1:15929781	NA	0.48	8.5	0.38	3.18e-16	Systolic blood pressure;
LUAD	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg18277682	chr1:228362509	C1orf69	-0.39	-6.43	-0.3	3.55e-10	Diastolic blood pressure;
LUAD	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg27129171	chr3:47204927	SETD2	0.39	6.42	0.3	3.68e-10	Colorectal cancer;
LUAD	cis	rs2742417	0.603	rs7631818	chr3:45775931	A/T	cg10512202	chr3:45649293	LIMD1	0.47	8.85	0.4	2.46e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg21775007	chr8:11205619	TDH	-0.45	-7.85	-0.36	3.54e-14	Neuroticism;
LUAD	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg01028140	chr2:1542097	TPO	-0.59	-7.57	-0.35	2.3e-13	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg11189052	chr15:85197271	WDR73	0.61	7.58	0.35	2.17e-13	Schizophrenia;
LUAD	trans	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg01620082	chr3:125678407	NA	-0.71	-7.18	-0.33	3.14e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11905131	chr22:24372483	LOC391322	-0.54	-9.33	-0.41	6.2e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg08132940	chr7:1081526	C7orf50	-0.79	-10.66	-0.46	1.14e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.78	0.35	5.65e-14	Resting heart rate;
LUAD	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg04511125	chr2:88470314	THNSL2	0.98	11.28	0.48	5.76e-26	Plasma clusterin levels;
LUAD	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.78	-13.55	-0.55	5.49e-35	Chronic sinus infection;
LUAD	cis	rs1448094	0.706	rs10863149	chr12:86425498	A/T	cg00310523	chr12:86230176	RASSF9	0.35	7.28	0.33	1.64e-12	Major depressive disorder;
LUAD	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg20608306	chr11:116969690	SIK3	0.29	6.4	0.3	4.06e-10	Blood protein levels;
LUAD	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	7.22	0.33	2.46e-12	Schizophrenia;
LUAD	cis	rs1451375	0.583	rs7776816	chr7:50583534	G/A	cg18232548	chr7:50535776	DDC	0.62	8.43	0.38	5.35e-16	Malaria;
LUAD	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg20744362	chr22:50050164	C22orf34	0.36	7.04	0.32	7.57e-12	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg06064525	chr11:970664	AP2A2	-0.54	-11.06	-0.47	3.79e-25	Alzheimer's disease (late onset);
LUAD	cis	rs3849570	1.000	rs4411908	chr3:81802418	A/C	cg07356753	chr3:81810745	GBE1	-0.6	-10.21	-0.44	5.13e-22	Waist circumference;Body mass index;
LUAD	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg27170947	chr2:26402098	FAM59B	0.82	11.49	0.49	9.18e-27	Gut microbiome composition (summer);
LUAD	trans	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	10.97	0.47	8.42e-25	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg17200465	chr3:40428508	ENTPD3	0.27	6.42	0.3	3.68e-10	Renal cell carcinoma;
LUAD	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg26384229	chr12:38710491	ALG10B	0.45	7.33	0.34	1.18e-12	Bladder cancer;
LUAD	cis	rs4077515	0.935	rs3812565	chr9:139272502	T/C	cg14019695	chr9:139328340	INPP5E	0.46	8.75	0.39	5.09e-17	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg11859384	chr17:80120422	CCDC57	0.41	7.4	0.34	7.2e-13	Life satisfaction;
LUAD	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg18306943	chr3:40428807	ENTPD3	0.42	7.07	0.32	6.56e-12	Renal cell carcinoma;
LUAD	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg05535760	chr7:792225	HEATR2	0.87	11.61	0.49	3.16e-27	Cerebrospinal P-tau181p levels;
LUAD	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03934478	chr11:495069	RNH1	0.77	9.21	0.41	1.5e-18	Body mass index;
LUAD	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg03647317	chr4:187891568	NA	-0.34	-6.35	-0.3	5.53e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg25319279	chr11:5960081	NA	-0.38	-6.7	-0.31	6.83e-11	DNA methylation (variation);
LUAD	cis	rs9902453	0.874	rs4474741	chr17:28148117	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.37	-0.41	4.47e-19	Coffee consumption (cups per day);
LUAD	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-8.92	-0.4	1.46e-17	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6489882	0.836	rs10850100	chr12:113364512	T/C	cg20102336	chr12:113376681	OAS3	-0.6	-9.28	-0.41	8.88e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg18854424	chr1:2615690	NA	0.43	9.54	0.42	1.14e-19	Ulcerative colitis;
LUAD	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.56	-0.38	2.16e-16	Total body bone mineral density;
LUAD	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg02869364	chr7:1081709	C7orf50	-0.5	-6.44	-0.3	3.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg24803719	chr17:45855879	NA	-0.32	-6.97	-0.32	1.19e-11	IgG glycosylation;
LUAD	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg11845111	chr2:191398756	TMEM194B	0.66	12.08	0.51	4.49e-29	Pulse pressure;
LUAD	cis	rs9517302	0.615	rs3752974	chr13:99097827	T/C	cg22223119	chr13:99095684	FARP1	-0.7	-10.45	-0.45	6.77e-23	Obesity-related traits;
LUAD	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06028808	chr11:68637592	NA	0.5	8.41	0.38	6.26e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg18621852	chr3:10150065	C3orf24	0.49	8.83	0.39	2.72e-17	Alzheimer's disease;
LUAD	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg15017067	chr4:17643749	FAM184B	0.35	6.83	0.32	2.95e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.83	0.36	4.09e-14	Morning vs. evening chronotype;
LUAD	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg06627628	chr2:24431161	ITSN2	-0.57	-9.6	-0.42	7.09e-20	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.46	-0.42	2.11e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg07741184	chr6:167504864	NA	0.36	8.17	0.37	3.66e-15	Primary biliary cholangitis;
LUAD	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.6	0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs877282	0.838	rs11253408	chr10:796374	T/C	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg22963979	chr7:1858916	MAD1L1	-0.42	-7.02	-0.32	9.06e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg08999081	chr20:33150536	PIGU	0.45	8.71	0.39	6.9e-17	Coronary artery disease;
LUAD	cis	rs2637266	1.000	rs7392737	chr10:78366059	C/T	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg09796270	chr17:17721594	SREBF1	-0.37	-7.58	-0.35	2.27e-13	Total body bone mineral density;
LUAD	trans	rs11671005	0.610	rs11669345	chr19:59062259	C/T	cg22037779	chr5:139682734	PFDN1	-0.67	-8.95	-0.4	1.11e-17	Mean platelet volume;
LUAD	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg02428538	chr16:24856791	SLC5A11	0.49	6.97	0.32	1.21e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9972944	0.692	rs6504346	chr17:63757175	C/A	cg07283582	chr17:63770753	CCDC46	-0.54	-11.96	-0.5	1.28e-28	Total body bone mineral density;
LUAD	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.59	0.42	7.97e-20	Cognitive ability;
LUAD	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg05717871	chr11:638507	DRD4	-0.44	-6.58	-0.3	1.43e-10	Systemic lupus erythematosus;
LUAD	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.89	-11.05	-0.47	4.01e-25	Lung cancer in ever smokers;
LUAD	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg24803719	chr17:45855879	NA	-0.35	-7.95	-0.36	1.77e-14	IgG glycosylation;
LUAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg02524346	chr8:600233	NA	1.06	10.51	0.46	3.96e-23	IgG glycosylation;
LUAD	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg02228675	chr17:40259724	DHX58	-0.45	-7.44	-0.34	5.8e-13	Fibrinogen levels;
LUAD	cis	rs6500395	1.000	rs9933237	chr16:48676562	T/C	cg04672837	chr16:48644449	N4BP1	0.39	6.81	0.31	3.43e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	7.76	0.35	6.3e-14	Tonsillectomy;
LUAD	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.58	-7.59	-0.35	2.08e-13	Alzheimer's disease;
LUAD	cis	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg08601574	chr20:25228251	PYGB	-0.46	-8.77	-0.39	4.37e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg22920501	chr2:26401640	FAM59B	-0.96	-14.61	-0.58	1.89e-39	Gut microbiome composition (summer);
LUAD	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg26769984	chr7:1090371	C7orf50	0.64	9.86	0.43	8.82e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs56161922	1.000	rs74184055	chr1:207852226	G/A	cg11752769	chr1:207818423	CR1L	-0.65	-6.65	-0.31	9.1e-11	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg04369109	chr6:150039330	LATS1	-0.46	-7.94	-0.36	1.86e-14	Lung cancer;
LUAD	cis	rs7264396	0.563	rs2425121	chr20:34326186	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.26	-0.37	1.9e-15	Total cholesterol levels;
LUAD	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg20203395	chr5:56204925	C5orf35	-0.39	-6.4	-0.3	4.21e-10	Coronary artery disease;
LUAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.2	-0.33	2.68e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg06558623	chr16:89946397	TCF25	0.69	7.8	0.35	4.89e-14	Skin colour saturation;
LUAD	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg02782426	chr3:40428986	ENTPD3	0.35	7.53	0.34	3.11e-13	Renal cell carcinoma;
LUAD	cis	rs10821973	0.527	rs7096738	chr10:63980874	A/G	cg09941381	chr10:64027924	RTKN2	-0.34	-6.76	-0.31	4.48e-11	Hypothyroidism;
LUAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg09033563	chr22:24373618	LOC391322	0.49	7.56	0.34	2.55e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg04414720	chr1:150670196	GOLPH3L	0.72	12.76	0.53	9.4e-32	Melanoma;
LUAD	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg10556349	chr10:835070	NA	0.62	7.9	0.36	2.49e-14	Eosinophil percentage of granulocytes;
LUAD	trans	rs6940638	0.956	rs12203454	chr6:27031100	C/T	cg06606381	chr12:133084897	FBRSL1	-0.48	-6.36	-0.3	5.18e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg17074396	chr22:49843754	NA	-0.31	-6.5	-0.3	2.26e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4074961	0.509	rs4653300	chr1:38024054	A/G	cg12696750	chr1:38022466	DNALI1	0.38	6.56	0.3	1.57e-10	Axial length;
LUAD	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-8.5	-0.38	3.25e-16	Schizophrenia;
LUAD	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11716531	0.537	rs7626646	chr3:27268316	G/T	cg02860705	chr3:27208620	NA	0.6	9.24	0.41	1.26e-18	Diastolic blood pressure;
LUAD	cis	rs9372498	0.536	rs9489433	chr6:118867006	G/A	cg18833306	chr6:118973337	C6orf204	-0.52	-7.62	-0.35	1.69e-13	Diastolic blood pressure;
LUAD	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg04414720	chr1:150670196	GOLPH3L	-0.53	-8.99	-0.4	8.23e-18	Tonsillectomy;
LUAD	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg17372223	chr3:52568218	NT5DC2	-0.37	-6.5	-0.3	2.2e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg23231163	chr10:75533350	FUT11	-0.51	-9.37	-0.41	4.29e-19	Inflammatory bowel disease;
LUAD	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.3	-0.37	1.43e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs6761276	0.649	rs3811055	chr2:113831182	A/T	cg09040174	chr2:113837401	NA	0.64	9.77	0.43	1.76e-20	Protein quantitative trait loci;
LUAD	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.89	0.32	1.99e-11	Motion sickness;
LUAD	trans	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	9.97e-11	Diabetic kidney disease;
LUAD	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8192282	0.739	rs6670375	chr1:154494947	G/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.46	-0.34	4.93e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg06740227	chr12:86229804	RASSF9	0.35	6.48	0.3	2.6e-10	Major depressive disorder;
LUAD	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg01616529	chr11:638424	DRD4	-0.44	-6.43	-0.3	3.42e-10	Systemic lupus erythematosus;
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg27009633	chr5:126366552	MARCH3	-0.53	-6.46	-0.3	2.83e-10	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.41	-0.34	7.13e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs137699	1.000	rs760742	chr22:39755190	G/T	cg24399712	chr22:39784796	NA	-0.51	-8.65	-0.39	1.12e-16	IgG glycosylation;
LUAD	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.37	-0.34	9.06e-13	Breast cancer;
LUAD	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg07708487	chr16:89387014	ANKRD11	0.34	6.78	0.31	4.06e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs11771526	0.892	rs76035550	chr7:32371359	G/A	cg13207630	chr7:32358064	NA	0.68	7.68	0.35	1.11e-13	Body mass index;
LUAD	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg16205897	chr5:131564050	P4HA2	-0.3	-6.79	-0.31	3.84e-11	Breast cancer;
LUAD	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg06108461	chr20:60628389	TAF4	-1.13	-20.59	-0.71	9.33e-66	Body mass index;
LUAD	cis	rs3733418	1.000	rs3733418	chr4:165878335	A/G	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.54	-6.9	-0.32	1.94e-11	Obesity-related traits;
LUAD	cis	rs77741769	0.571	rs12831094	chr12:121292704	T/C	cg02419362	chr12:121203948	SPPL3	0.41	8.29	0.37	1.53e-15	Mean corpuscular volume;
LUAD	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg19980929	chr12:42632907	YAF2	0.36	6.89	0.32	2.08e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.36	7.6	0.35	1.92e-13	Parkinson's disease;
LUAD	cis	rs2086824	0.538	rs4785673	chr16:89536545	A/G	cg06640241	chr16:89574553	SPG7	0.59	9.86	0.43	8.76e-21	Multiple myeloma (IgH translocation);
LUAD	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-8.72	-0.39	6.37e-17	Gut microbiome composition (summer);
LUAD	cis	rs7572644	0.640	rs13027666	chr2:28058433	T/C	cg27432699	chr2:27873401	GPN1	0.42	6.37	0.3	5.01e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUAD	cis	rs698833	0.886	rs786613	chr2:44590066	C/G	cg04920474	chr2:44395004	PPM1B	-0.36	-6.57	-0.3	1.45e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg25319279	chr11:5960081	NA	-0.42	-7.33	-0.34	1.21e-12	DNA methylation (variation);
LUAD	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg15181151	chr6:150070149	PCMT1	0.41	8.49	0.38	3.58e-16	Lung cancer;
LUAD	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg08493051	chr2:3487164	NA	-0.4	-6.89	-0.32	1.97e-11	Neurofibrillary tangles;
LUAD	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg08676812	chr11:65308423	LTBP3	0.93	7.5	0.34	3.84e-13	Height;
LUAD	cis	rs7833986	0.877	rs35399547	chr8:57075473	A/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.77	8.91	0.4	1.59e-17	Height;
LUAD	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg01528321	chr10:82214614	TSPAN14	0.46	7.39	0.34	8.17e-13	Post bronchodilator FEV1;
LUAD	cis	rs3125734	0.633	rs4979774	chr10:63967795	A/T	cg19640130	chr10:64028056	RTKN2	-0.32	-6.98	-0.32	1.16e-11	Rheumatoid arthritis;
LUAD	trans	rs11039798	0.778	rs7944523	chr11:48911019	G/A	cg15704280	chr7:45808275	SEPT13	0.67	7.8	0.35	4.95e-14	Axial length;
LUAD	cis	rs6960043	0.846	rs7781710	chr7:15056045	T/A	cg19272540	chr7:15055459	NA	0.38	8.45	0.38	4.64e-16	Type 2 diabetes;
LUAD	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg18854424	chr1:2615690	NA	-0.42	-9.18	-0.41	1.89e-18	Ulcerative colitis;
LUAD	cis	rs7833986	0.501	rs2953922	chr8:56977485	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	1.01	18.4	0.67	5.68e-56	Height;
LUAD	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg20607798	chr8:58055168	NA	0.8	9.55	0.42	1.02e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7095607	0.742	rs10997965	chr10:69923835	A/G	cg18986048	chr10:69913749	MYPN	0.38	6.56	0.3	1.55e-10	Lung function (FVC);
LUAD	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12923728	chr3:195709715	SDHAP1	-0.69	-11.59	-0.49	3.63e-27	Pancreatic cancer;
LUAD	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs698833	0.926	rs1067347	chr2:44672165	A/G	cg04920474	chr2:44395004	PPM1B	-0.36	-6.41	-0.3	3.88e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg01528321	chr10:82214614	TSPAN14	0.65	10.5	0.45	4.66e-23	Post bronchodilator FEV1;
LUAD	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs72634258	0.554	rs68024107	chr1:7914066	G/C	cg26816564	chr1:7831052	VAMP3	0.61	8.53	0.38	2.68e-16	Inflammatory bowel disease;
LUAD	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18404041	chr3:52824283	ITIH1	-0.61	-12.23	-0.51	1.2e-29	Bipolar disorder;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg20699036	chr5:38556796	LIFR	0.37	6.49	0.3	2.44e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs4891159	0.790	rs11872411	chr18:74132051	C/T	cg24786174	chr18:74118243	ZNF516	-0.78	-14.9	-0.59	1.12e-40	Longevity;
LUAD	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.22	-0.37	2.43e-15	Total body bone mineral density;
LUAD	cis	rs11229555	0.645	rs12285111	chr11:58208385	T/G	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	trans	rs2470578	0.716	rs2733514	chr3:17323931	A/G	cg23581698	chr14:81686396	GTF2A1	-0.43	-7.0	-0.32	1.03e-11	Schizophrenia;
LUAD	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.42	6.91	0.32	1.76e-11	Total body bone mineral density;
LUAD	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg05283184	chr6:79620031	NA	-0.59	-12.15	-0.51	2.44e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs975210	0.652	rs4777230	chr15:70365762	A/G	cg12349571	chr15:70364359	TLE3	-0.49	-6.4	-0.3	4.04e-10	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LUAD	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg11645453	chr3:52864694	ITIH4	0.37	7.7	0.35	9.43e-14	Bipolar disorder;
LUAD	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07167872	chr1:205819463	PM20D1	0.88	19.84	0.69	2.04e-62	Menarche (age at onset);
LUAD	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg25894440	chr7:65020034	NA	-0.59	-6.36	-0.3	5.16e-10	Diabetic kidney disease;
LUAD	cis	rs2425143	1.000	rs73905926	chr20:34251982	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.26	-0.33	1.84e-12	Blood protein levels;
LUAD	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg03948781	chr1:205179583	DSTYK	0.33	6.47	0.3	2.76e-10	Red blood cell count;
LUAD	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10802521	chr3:52805072	NEK4	-0.53	-9.01	-0.4	6.95e-18	Bipolar disorder;
LUAD	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg15147215	chr3:52552868	STAB1	-0.38	-7.05	-0.32	7.45e-12	Bipolar disorder;
LUAD	trans	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg14917512	chr19:3094685	GNA11	0.37	6.48	0.3	2.54e-10	Aortic root size;
LUAD	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg12908607	chr1:44402522	ARTN	-0.52	-9.63	-0.42	5.72e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg24642844	chr7:1081250	C7orf50	-0.96	-14.13	-0.57	2.16e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg05182265	chr7:156933206	UBE3C	-0.8	-17.28	-0.64	5.14e-51	Body mass index;
LUAD	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18099408	chr3:52552593	STAB1	-0.46	-7.93	-0.36	2e-14	Bipolar disorder;
LUAD	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg00074818	chr8:8560427	CLDN23	0.66	10.08	0.44	1.46e-21	Obesity-related traits;
LUAD	cis	rs9381040	0.701	rs722442	chr6:41089681	A/G	cg03526776	chr6:41159608	TREML2	0.38	7.84	0.36	3.68e-14	Alzheimer's disease (late onset);
LUAD	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg00106254	chr7:1943704	MAD1L1	-0.61	-9.09	-0.4	3.72e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs2230307	0.536	rs506044	chr1:100611931	A/G	cg20868668	chr1:100435035	SLC35A3	-0.5	-7.65	-0.35	1.41e-13	Carotid intima media thickness;
LUAD	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg05754148	chr16:3507555	NAT15	0.47	7.53	0.34	3.12e-13	Body mass index (adult);
LUAD	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg06740227	chr12:86229804	RASSF9	0.46	8.08	0.37	7.04e-15	Major depressive disorder;
LUAD	cis	rs939584	1.000	rs4854348	chr2:647760	A/G	cg03444855	chr2:621920	NA	-0.39	-6.49	-0.3	2.37e-10	Body mass index;
LUAD	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg22852734	chr6:133119734	C6orf192	0.77	9.15	0.41	2.36e-18	Type 2 diabetes nephropathy;
LUAD	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg00666640	chr1:248458726	OR2T12	0.33	8.05	0.36	8.2e-15	Common traits (Other);
LUAD	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg06108461	chr20:60628389	TAF4	-0.93	-14.53	-0.58	4.2e-39	Body mass index;
LUAD	cis	rs6665290	0.904	rs3795449	chr1:227181838	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.42	-0.89	1.05e-143	Myeloid white cell count;
LUAD	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg25985355	chr7:65971099	NA	-0.56	-6.94	-0.32	1.49e-11	Diabetic kidney disease;
LUAD	cis	rs7503807	1.000	rs4890056	chr17:78591211	C/T	cg09596252	chr17:78655493	RPTOR	-0.37	-6.96	-0.32	1.28e-11	Obesity;
LUAD	cis	rs80319144	1.000	rs76251234	chr2:159284526	G/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	6.9	0.32	1.88e-11	Restless legs syndrome;
LUAD	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg15128208	chr22:42549153	NA	0.36	6.99	0.32	1.08e-11	Cognitive function;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg11235426	chr6:292522	DUSP22	-0.79	-13.48	-0.55	1.02e-34	Menopause (age at onset);
LUAD	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg07570687	chr10:102243282	WNT8B	0.45	6.7	0.31	6.64e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs72827839	0.516	rs72833458	chr17:45938051	A/G	cg02219949	chr17:45927392	SP6	0.44	6.86	0.32	2.42e-11	Ease of getting up in the morning;
LUAD	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.56	9.44	0.42	2.61e-19	Breast cancer;
LUAD	cis	rs10129255	0.500	rs4774189	chr14:107176517	G/T	cg07958169	chr14:107095056	NA	-0.35	-6.93	-0.32	1.61e-11	Kawasaki disease;
LUAD	cis	rs7173743	0.934	rs7168915	chr15:79128889	C/T	cg00540400	chr15:79124168	NA	0.38	7.71	0.35	9.21e-14	Coronary artery disease;
LUAD	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.5	-7.66	-0.35	1.24e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg12062639	chr20:23401060	NAPB	1.08	11.36	0.48	2.76e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs11681884	1.000	rs61546073	chr2:113844871	T/C	cg12858261	chr2:113808755	IL1F8	0.51	6.43	0.3	3.48e-10	Stroke;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg02545393	chr11:70244902	CTTN	-0.64	-6.41	-0.3	3.81e-10	Type 2 diabetes;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg03359468	chr8:26240463	BNIP3L	-0.65	-6.58	-0.3	1.38e-10	Type 2 diabetes;
LUAD	cis	rs1784581	0.588	rs1789986	chr6:162409978	C/T	cg17173639	chr6:162384350	PARK2	-0.46	-8.25	-0.37	2.01e-15	Itch intensity from mosquito bite;
LUAD	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg27535305	chr1:53392650	SCP2	0.31	6.59	0.31	1.33e-10	Monocyte count;
LUAD	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg15962314	chr1:44399869	ARTN	-0.27	-6.39	-0.3	4.28e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs1975974	1.000	rs7224508	chr17:21722352	T/A	cg18423549	chr17:21743878	NA	-0.77	-13.73	-0.56	9.42e-36	Psoriasis;
LUAD	trans	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg27411982	chr8:10470053	RP1L1	-0.37	-6.63	-0.31	1.01e-10	Mood instability;
LUAD	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg09455208	chr3:40491958	NA	0.66	14.36	0.57	2.26e-38	Renal cell carcinoma;
LUAD	cis	rs7107174	1.000	rs4245459	chr11:78065959	T/G	cg02023728	chr11:77925099	USP35	0.43	6.74	0.31	5.2e-11	Testicular germ cell tumor;
LUAD	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-7.89	-0.36	2.7e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs751728	1.000	rs4713684	chr6:33766488	T/C	cg13859433	chr6:33739653	LEMD2	-0.39	-9.16	-0.41	2.3e-18	Crohn's disease;
LUAD	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.68	-12.86	-0.53	3.44e-32	Tonsillectomy;
LUAD	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg07256732	chr16:621771	PIGQ	-0.31	-6.35	-0.3	5.47e-10	Height;
LUAD	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg06784218	chr1:46089804	CCDC17	-0.53	-11.57	-0.49	4.28e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6500395	1.000	rs8059905	chr16:48629934	C/T	cg04672837	chr16:48644449	N4BP1	0.4	6.88	0.32	2.23e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg10645314	chr2:3704589	ALLC	-0.6	-9.49	-0.42	1.67e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg05304507	chr6:116381966	FRK	0.2	6.79	0.31	3.85e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg05709478	chr1:6581295	PLEKHG5	0.6	7.8	0.35	4.78e-14	Body mass index;
LUAD	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg08280861	chr8:58055591	NA	0.54	7.19	0.33	2.87e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs13064411	0.735	rs7636128	chr3:113133701	A/T	cg18753928	chr3:113234510	CCDC52	-0.67	-11.08	-0.47	3.14e-25	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7274811	0.688	rs6141400	chr20:32056087	C/T	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.46	-6.89	-0.32	2e-11	Height;
LUAD	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg10556349	chr10:835070	NA	0.6	7.63	0.35	1.55e-13	Eosinophil percentage of granulocytes;
LUAD	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg00316803	chr15:76480434	C15orf27	-0.39	-7.18	-0.33	3.08e-12	Blood metabolite levels;
LUAD	cis	rs2275731	1.000	rs2275731	chr10:16526840	G/A	cg04254609	chr10:16479192	PTER	-0.44	-6.82	-0.31	3.24e-11	Bone fracture in osteoporosis;
LUAD	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg07936489	chr17:37558343	FBXL20	-0.46	-7.31	-0.33	1.38e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg01528321	chr10:82214614	TSPAN14	0.65	10.45	0.45	6.99e-23	Post bronchodilator FEV1;
LUAD	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg07527032	chr15:84868466	LOC388152	0.44	6.65	0.31	9.36e-11	Schizophrenia;
LUAD	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg13319975	chr6:146136371	FBXO30	-0.64	-11.0	-0.47	6.45e-25	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg02254774	chr11:50257496	LOC441601	0.54	6.7	0.31	6.72e-11	Axial length;
LUAD	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.11	-0.37	5.52e-15	Diabetic kidney disease;
LUAD	cis	rs7010267	0.596	rs4307369	chr8:120036953	A/G	cg01975934	chr8:119970761	NA	-0.34	-6.52	-0.3	2.03e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06028808	chr11:68637592	NA	0.48	8.08	0.37	6.72e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01570182	chr17:44337453	NA	1.13	17.71	0.65	6.48e-53	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg23640300	chr22:24059086	LOC91316	-0.4	-6.45	-0.3	3.06e-10	Vertical cup-disc ratio;
LUAD	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg18827107	chr12:86230957	RASSF9	0.54	9.74	0.43	2.24e-20	Major depressive disorder;
LUAD	cis	rs2302190	0.882	rs7210714	chr17:56675666	A/C	cg25885038	chr17:56607967	SEPT4	-0.5	-8.05	-0.36	8.3e-15	Vitamin D levels;
LUAD	cis	rs6001027	0.517	rs2284060	chr22:38543453	A/G	cg25457927	chr22:38595422	NA	-0.38	-8.84	-0.39	2.66e-17	Melanoma;
LUAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg07677032	chr17:61819896	STRADA	0.57	10.29	0.45	2.7e-22	Prudent dietary pattern;
LUAD	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.8	11.05	0.47	4.13e-25	Smoking behavior;
LUAD	cis	rs12681287	0.547	rs9297921	chr8:87542286	C/T	cg27223183	chr8:87520930	FAM82B	0.72	10.23	0.45	4.23e-22	Caudate activity during reward;
LUAD	cis	rs754466	0.606	rs12356375	chr10:79594514	C/A	cg17075019	chr10:79541650	NA	-0.89	-18.68	-0.67	3.37e-57	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs77972916	0.505	rs6753197	chr2:43527962	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-10.39	-0.45	1.14e-22	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg05340658	chr4:99064831	C4orf37	0.45	7.35	0.34	1.02e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.78	-0.31	3.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg16647868	chr5:131706066	SLC22A5	0.5	7.98	0.36	1.38e-14	Breast cancer;
LUAD	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	12.62	0.52	3.4e-31	Monocyte percentage of white cells;
LUAD	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg06618935	chr21:46677482	NA	-0.48	-9.52	-0.42	1.31e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11229555	0.645	rs12291551	chr11:58176915	T/A	cg15696309	chr11:58395628	NA	-0.73	-10.21	-0.44	5.12e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs11723261	0.582	rs116471062	chr4:163522	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	7.91	0.36	2.26e-14	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg12483005	chr1:23474871	LUZP1	0.54	9.12	0.41	3.18e-18	Height;
LUAD	cis	rs2224391	0.656	rs2875980	chr6:5289447	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	0.61	9.05	0.4	5.34e-18	Height;
LUAD	trans	rs3960554	0.733	rs59170362	chr7:75629267	G/C	cg19862616	chr7:65841803	NCRNA00174	0.83	11.26	0.48	6.55e-26	Eotaxin levels;
LUAD	trans	rs3857536	0.813	rs9453639	chr6:66933538	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.35	-0.3	5.66e-10	Blood trace element (Cu levels);
LUAD	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg09835421	chr16:68378352	PRMT7	-0.65	-6.74	-0.31	5.09e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7000551	0.532	rs4872486	chr8:22256359	G/T	cg12081754	chr8:22256438	SLC39A14	0.79	13.13	0.54	2.86e-33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs4072705	0.585	rs7852843	chr9:127233823	C/T	cg13476313	chr9:127244764	NR5A1	-0.32	-7.81	-0.36	4.45e-14	Menarche (age at onset);
LUAD	cis	rs11030122	0.702	rs10835407	chr11:3993231	C/T	cg18678763	chr11:4115507	RRM1	0.45	7.47	0.34	4.51e-13	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs57994353	0.897	rs3812595	chr9:139369062	C/T	cg14169450	chr9:139327907	INPP5E	0.41	6.51	0.3	2.16e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg26769984	chr7:1090371	C7orf50	0.62	9.25	0.41	1.11e-18	Bronchopulmonary dysplasia;
LUAD	cis	rs8067545	0.641	rs2108978	chr17:19861458	C/T	cg04132472	chr17:19861366	AKAP10	0.4	9.43	0.42	2.8e-19	Schizophrenia;
LUAD	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg11663144	chr21:46675770	NA	-0.61	-11.67	-0.49	1.76e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25682936	chr1:38455768	SF3A3	-0.43	-6.65	-0.31	9.06e-11	Height;
LUAD	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg17178900	chr1:205818956	PM20D1	0.76	16.01	0.61	1.94e-45	Menarche (age at onset);
LUAD	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg09085632	chr11:111637200	PPP2R1B	0.62	9.34	0.41	5.37e-19	Primary sclerosing cholangitis;
LUAD	cis	rs1232027	0.656	rs836813	chr5:79971513	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.73	-0.31	5.55e-11	Huntington's disease progression;
LUAD	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg13685833	chr1:53393034	SCP2	-0.47	-7.77	-0.35	6.11e-14	Monocyte count;
LUAD	cis	rs9322817	0.583	rs7741733	chr6:105182839	T/C	cg02098413	chr6:105308735	HACE1	-0.43	-9.08	-0.4	4.32e-18	Thyroid stimulating hormone;
LUAD	cis	rs3087591	0.960	rs4795593	chr17:29613600	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.42	-6.85	-0.32	2.65e-11	Hip circumference;
LUAD	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg13393036	chr8:95962371	TP53INP1	-0.38	-8.05	-0.36	8.47e-15	Type 2 diabetes;
LUAD	trans	rs11039798	1.000	rs10160423	chr11:48457227	G/T	cg02254774	chr11:50257496	LOC441601	0.53	6.73	0.31	5.38e-11	Axial length;
LUAD	cis	rs113835537	0.877	rs3867132	chr11:66309269	C/T	cg24851651	chr11:66362959	CCS	0.59	8.01	0.36	1.15e-14	Airway imaging phenotypes;
LUAD	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg17724175	chr1:150552817	MCL1	0.35	8.37	0.38	8.81e-16	Tonsillectomy;
LUAD	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg02176678	chr2:219576539	TTLL4	-0.62	-11.91	-0.5	2.16e-28	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs62458065	0.513	rs787216	chr7:32578891	G/A	cg00845942	chr12:64062724	DPY19L2	-0.58	-8.42	-0.38	5.9e-16	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2016266	0.859	rs56225815	chr12:53740090	C/G	cg26875137	chr12:53738046	NA	-0.37	-7.27	-0.33	1.79e-12	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg10164272	chr16:89456328	ANKRD11	0.45	6.99	0.32	1.06e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs72928364	0.929	rs13074729	chr3:100765584	G/T	cg10123952	chr3:100791384	NA	0.64	7.83	0.36	4.08e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs57590327	0.504	rs13065281	chr3:81693550	G/A	cg07356753	chr3:81810745	GBE1	-0.65	-10.19	-0.44	6.17e-22	Extraversion;
LUAD	cis	rs59104589	0.617	rs12233133	chr2:242256812	G/C	cg08645257	chr2:242211290	HDLBP	0.49	7.68	0.35	1.15e-13	Fibrinogen levels;
LUAD	cis	rs12681287	0.570	rs4961188	chr8:87383033	T/C	cg27223183	chr8:87520930	FAM82B	0.68	9.52	0.42	1.34e-19	Caudate activity during reward;
LUAD	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00149659	chr3:10157352	C3orf10	0.57	8.06	0.36	7.87e-15	Alzheimer's disease;
LUAD	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.1	0.37	5.93e-15	Menopause (age at onset);
LUAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg07217954	chr7:1067459	C7orf50	0.44	6.96	0.32	1.29e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg18446336	chr7:2847575	GNA12	-0.36	-6.77	-0.31	4.34e-11	Height;
LUAD	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.44	-6.73	-0.31	5.46e-11	Breast cancer;
LUAD	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg10523679	chr1:76189770	ACADM	-0.89	-15.82	-0.61	1.3e-44	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs8170	0.603	rs7249329	chr19:17423373	G/T	cg12247222	chr19:17403313	ABHD8	0.45	6.86	0.32	2.5e-11	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUAD	cis	rs2880765	0.835	rs4344688	chr15:86043007	A/C	cg13263323	chr15:86062960	AKAP13	-0.5	-9.24	-0.41	1.21e-18	Coronary artery disease;
LUAD	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.47	0.3	2.64e-10	Depression;
LUAD	cis	rs6494488	0.500	rs55960029	chr15:65047080	G/A	cg08069370	chr15:64387884	SNX1	-0.71	-6.5	-0.3	2.32e-10	Coronary artery disease;
LUAD	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg03929089	chr4:120376271	NA	-0.93	-17.48	-0.65	6.84e-52	Height;
LUAD	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg19436804	chr8:8560866	CLDN23	0.43	6.46	0.3	2.86e-10	Obesity-related traits;
LUAD	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg03433033	chr1:76189801	ACADM	0.91	18.17	0.66	5.71e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg17264618	chr3:40429014	ENTPD3	0.4	9.04	0.4	5.82e-18	Renal cell carcinoma;
LUAD	cis	rs1451375	1.000	rs4452748	chr7:50625056	A/C	cg18232548	chr7:50535776	DDC	-0.58	-9.43	-0.42	2.64e-19	Malaria;
LUAD	cis	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.03	-0.36	9.77e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg25457927	chr22:38595422	NA	-0.53	-13.76	-0.56	7.4e-36	Cutaneous nevi;
LUAD	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg01416388	chr22:39784598	NA	-0.53	-9.02	-0.4	6.84e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg07917127	chr4:99064746	C4orf37	0.42	6.48	0.3	2.59e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg20203395	chr5:56204925	C5orf35	0.82	12.21	0.51	1.39e-29	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2274273	0.624	rs10129505	chr14:55776375	C/T	cg04306507	chr14:55594613	LGALS3	0.4	7.79	0.35	5.15e-14	Protein biomarker;
LUAD	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.7e-32	Immature fraction of reticulocytes;
LUAD	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg07404485	chr7:94953653	PON1	-0.48	-6.67	-0.31	8.22e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg02146966	chr17:18967117	NA	0.38	6.53	0.3	1.93e-10	Anger;
LUAD	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg26408565	chr15:76604113	ETFA	0.47	7.77	0.35	5.94e-14	Blood metabolite levels;
LUAD	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg12573674	chr2:1569213	NA	-0.55	-6.59	-0.31	1.27e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg05865280	chr17:75406074	SEPT9	0.6	18.9	0.68	3.51e-58	Airflow obstruction;
LUAD	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg26818010	chr10:134567672	INPP5A	-0.85	-14.27	-0.57	5.66e-38	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23583168	chr7:148888333	NA	-0.91	-18.53	-0.67	1.47e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg09436375	chr6:42928200	GNMT	-0.3	-8.49	-0.38	3.47e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7680126	0.530	rs2903827	chr4:10175872	C/G	cg00071950	chr4:10020882	SLC2A9	-0.49	-6.83	-0.32	2.9e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.92	-0.36	2.16e-14	Diabetic kidney disease;
LUAD	cis	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05901451	chr6:126070800	HEY2	-0.57	-8.9	-0.4	1.65e-17	Endometrial cancer;
LUAD	cis	rs61869271	0.871	rs6585309	chr10:116730337	A/G	cg23260525	chr10:116636907	FAM160B1	-0.34	-7.14	-0.33	4.17e-12	Tonsillectomy;
LUAD	cis	rs62400317	0.826	rs62400335	chr6:45347782	G/A	cg18551225	chr6:44695536	NA	-0.51	-8.01	-0.36	1.12e-14	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.51	0.3	2.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg26536354	chr8:144654954	C8orf73	0.62	6.78	0.31	4.05e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg05313129	chr8:58192883	C8orf71	-0.51	-7.69	-0.35	1.07e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.24	0.37	2.14e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg05342682	chr7:94953680	PON1	0.48	6.62	0.31	1.06e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg09835421	chr16:68378352	PRMT7	-0.82	-8.75	-0.39	5.13e-17	Schizophrenia;
LUAD	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06544989	chr22:39130855	UNC84B	0.44	8.01	0.36	1.09e-14	Menopause (age at onset);
LUAD	cis	rs2637266	1.000	rs1077916	chr10:78381951	G/A	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.77e-11	Pulmonary function;
LUAD	cis	rs11971779	0.680	rs7779900	chr7:139082987	G/T	cg24109934	chr7:139138155	KLRG2	-0.31	-6.48	-0.3	2.54e-10	Diisocyanate-induced asthma;
LUAD	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg16414030	chr3:133502952	NA	-0.65	-12.23	-0.51	1.21e-29	Iron status biomarkers;
LUAD	cis	rs7809799	0.571	rs66568021	chr7:98942989	C/T	cg12290671	chr7:99195819	NA	-0.8	-7.03	-0.32	8.34e-12	Ulcerative colitis;
LUAD	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg18200150	chr17:30822561	MYO1D	0.62	12.3	0.51	6.28e-30	Schizophrenia;
LUAD	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg18306943	chr3:40428807	ENTPD3	0.41	7.24	0.33	2.11e-12	Renal cell carcinoma;
LUAD	cis	rs727505	0.607	rs66478705	chr7:124789211	C/G	cg23710748	chr7:124431027	NA	-0.38	-7.72	-0.35	8.31e-14	Lewy body disease;
LUAD	cis	rs11671005	0.735	rs11668814	chr19:58946833	T/C	cg13877915	chr19:58951672	ZNF132	0.58	7.73	0.35	8.16e-14	Mean platelet volume;
LUAD	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg25344623	chr2:136566232	LCT	0.34	6.54	0.3	1.8e-10	Mosquito bite size;
LUAD	cis	rs657075	0.697	rs3805673	chr5:131659103	G/A	cg21138405	chr5:131827807	IRF1	0.5	6.36	0.3	5.17e-10	Rheumatoid arthritis;
LUAD	cis	rs2274471	0.634	rs10974947	chr9:5072846	G/A	cg03390472	chr9:5043263	JAK2	-0.51	-7.25	-0.33	2e-12	Crohn's disease;
LUAD	cis	rs6960043	0.818	rs2215383	chr7:15062983	T/C	cg19272540	chr7:15055459	NA	-0.36	-7.87	-0.36	2.91e-14	Type 2 diabetes;
LUAD	cis	rs3820068	0.705	rs4646077	chr1:15827136	C/T	cg13390004	chr1:15929781	NA	0.4	6.51	0.3	2.15e-10	Systolic blood pressure;
LUAD	cis	rs35740288	0.822	rs4843092	chr15:86233180	G/A	cg13263323	chr15:86062960	AKAP13	-0.41	-6.41	-0.3	3.91e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	trans	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg02030672	chr11:45687055	CHST1	-0.38	-6.77	-0.31	4.36e-11	Obesity-related traits;
LUAD	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg19622623	chr12:86230825	RASSF9	-0.39	-7.02	-0.32	9.09e-12	Major depressive disorder;
LUAD	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg02569458	chr12:86230093	RASSF9	0.39	7.18	0.33	3.14e-12	Major depressive disorder;
LUAD	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg12623918	chr2:306882	NA	0.34	6.99	0.32	1.08e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg07538946	chr5:131705188	SLC22A5	0.43	7.09	0.33	5.69e-12	Blood metabolite levels;
LUAD	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg16479474	chr6:28041457	NA	0.44	7.4	0.34	7.22e-13	Depression;
LUAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg03188948	chr7:1209495	NA	0.87	11.37	0.48	2.44e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg02683114	chr2:24398427	C2orf84	-0.53	-7.82	-0.36	4.33e-14	Asthma;
LUAD	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg02782426	chr3:40428986	ENTPD3	0.36	7.45	0.34	5.13e-13	Renal cell carcinoma;
LUAD	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg08470875	chr2:26401718	FAM59B	-0.59	-8.06	-0.36	8.04e-15	Gut microbiome composition (summer);
LUAD	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.42	0.57	1.29e-38	Schizophrenia;
LUAD	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg14844989	chr11:31128820	NA	-0.46	-8.4	-0.38	6.76e-16	Red blood cell count;
LUAD	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg27535305	chr1:53392650	SCP2	-0.34	-6.94	-0.32	1.44e-11	Monocyte count;
LUAD	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg16989719	chr2:238392110	NA	-0.38	-7.89	-0.36	2.66e-14	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.44	0.3	3.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg02269571	chr22:50332266	NA	-0.84	-9.38	-0.42	4.02e-19	Schizophrenia;
LUAD	cis	rs7903847	0.642	rs12415424	chr10:99117897	C/A	cg20016023	chr10:99160130	RRP12	-0.31	-6.94	-0.32	1.46e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg13057898	chr1:3703894	LRRC47	0.62	10.65	0.46	1.25e-23	Red cell distribution width;
LUAD	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	15.47	0.6	4.02e-43	Lung cancer in ever smokers;
LUAD	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg15181151	chr6:150070149	PCMT1	0.41	8.52	0.38	2.82e-16	Lung cancer;
LUAD	trans	rs1997103	1.000	rs10224446	chr7:55413147	C/G	cg20935933	chr6:143382018	AIG1	0.55	7.8	0.35	4.76e-14	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs12620999	0.774	rs6711726	chr2:238101795	C/T	cg23555395	chr2:238036564	NA	-0.47	-7.07	-0.33	6.36e-12	Systemic lupus erythematosus;
LUAD	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg08027265	chr7:2291960	NA	-0.52	-9.06	-0.4	5.04e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs8077889	0.700	rs28571770	chr17:41904066	A/T	cg26893861	chr17:41843967	DUSP3	0.9	14.95	0.59	7.33e-41	Triglycerides;
LUAD	cis	rs11168351	0.927	rs11168342	chr12:48383797	G/T	cg04545296	chr12:48745243	ZNF641	0.32	7.98	0.36	1.35e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs73206853	0.841	rs73191826	chr12:110943001	G/T	cg12870014	chr12:110450643	ANKRD13A	0.62	7.05	0.32	7.19e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg08885076	chr2:99613938	TSGA10	0.37	6.53	0.3	1.94e-10	Chronic sinus infection;
LUAD	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg26394196	chr10:1453818	ADARB2	-0.33	-6.46	-0.3	2.88e-10	Radiation response;
LUAD	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.91	0.36	2.31e-14	Lung cancer;
LUAD	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg26587870	chr6:27730563	NA	-0.5	-8.3	-0.37	1.37e-15	Parkinson's disease;
LUAD	cis	rs2282300	0.739	rs10742237	chr11:30310659	C/T	cg25418670	chr11:30344373	C11orf46	0.53	7.25	0.33	2.02e-12	Morning vs. evening chronotype;
LUAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg22535103	chr8:58192502	C8orf71	-0.62	-6.77	-0.31	4.28e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg09165964	chr15:75287851	SCAMP5	-0.44	-6.72	-0.31	5.95e-11	Blood trace element (Zn levels);
LUAD	cis	rs208520	0.837	rs208471	chr6:66916749	A/C	cg07460842	chr6:66804631	NA	-0.97	-14.02	-0.56	5.91e-37	Exhaled nitric oxide output;
LUAD	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg03806693	chr22:41940476	POLR3H	0.69	9.84	0.43	1.08e-20	Vitiligo;
LUAD	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg11250194	chr11:61601937	FADS2	-0.63	-8.44	-0.38	5.07e-16	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs9462027	0.628	rs10947531	chr6:34765118	A/C	cg07306190	chr6:34760872	UHRF1BP1	0.35	8.7	0.39	7.21e-17	Systemic lupus erythematosus;
LUAD	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-24.68	-0.77	5.77e-84	Height;
LUAD	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg19077165	chr18:44547161	KATNAL2	-0.48	-8.35	-0.38	9.57e-16	Personality dimensions;
LUAD	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg08219700	chr8:58056026	NA	0.5	7.53	0.34	3e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs9443645	0.527	rs36128361	chr6:79684340	C/G	cg09184832	chr6:79620586	NA	-0.4	-6.85	-0.32	2.54e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7336332	0.569	rs7988412	chr13:28000282	C/T	cg22138327	chr13:27999177	GTF3A	0.79	10.82	0.47	2.99e-24	Weight;
LUAD	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.94	-0.44	4.71e-21	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs15676	0.783	rs2977995	chr9:131584245	A/G	cg00228799	chr9:131580591	ENDOG	0.47	7.35	0.34	1.03e-12	Blood metabolite levels;
LUAD	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.46	-0.42	2.15e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs929596	0.556	rs35984508	chr2:234587852	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-10.26	-0.45	3.22e-22	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.27e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6961069	0.777	rs1953299	chr7:80265625	T/G	cg04458919	chr7:80252533	CD36	0.37	7.14	0.33	4.14e-12	Platelet count;
LUAD	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg16850897	chr7:100343110	ZAN	-0.58	-8.09	-0.37	6.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg15704280	chr7:45808275	SEPT13	-0.81	-13.87	-0.56	2.53e-36	Coronary artery disease;
LUAD	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg19622623	chr12:86230825	RASSF9	-0.44	-7.78	-0.35	5.69e-14	Major depressive disorder;
LUAD	cis	rs12612619	0.704	rs2384572	chr2:27324751	G/T	cg00617064	chr2:27272375	NA	-0.38	-7.06	-0.32	6.81e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg27446573	chr6:127587934	RNF146	0.43	6.47	0.3	2.7e-10	Breast cancer;
LUAD	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg25985355	chr7:65971099	NA	0.54	6.68	0.31	7.58e-11	Diabetic kidney disease;
LUAD	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg10596483	chr8:143751796	JRK	0.45	7.25	0.33	2.03e-12	Schizophrenia;
LUAD	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs3935685	0.845	rs7175083	chr15:78006842	T/C	cg25212270	chr15:78015279	NA	0.32	6.98	0.32	1.12e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg01689657	chr7:91764605	CYP51A1	0.39	9.63	0.42	5.42e-20	Breast cancer;
LUAD	cis	rs1949733	0.541	rs13139429	chr4:8534130	G/T	cg13073564	chr4:8508604	NA	0.39	6.9	0.32	1.94e-11	Response to antineoplastic agents;
LUAD	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg17366294	chr4:99064904	C4orf37	0.49	8.55	0.38	2.27e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs9929218	1.000	rs9929218	chr16:68820946	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.47	-0.55	1.15e-34	Colorectal cancer;
LUAD	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg18932078	chr1:2524107	MMEL1	0.35	6.47	0.3	2.72e-10	Ulcerative colitis;
LUAD	trans	rs4942242	1.000	rs9562501	chr13:44205683	C/T	cg19169023	chr15:41853346	TYRO3	-0.49	-8.41	-0.38	6.36e-16	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.29	-0.6	2.39e-42	Eye color traits;
LUAD	cis	rs62229266	0.557	rs4817760	chr21:37395301	T/C	cg12218747	chr21:37451666	NA	-0.46	-7.48	-0.34	4.29e-13	Mitral valve prolapse;
LUAD	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg00071950	chr4:10020882	SLC2A9	0.84	18.23	0.66	3.19e-55	Bone mineral density;
LUAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg20849893	chr7:64541193	NA	0.48	7.67	0.35	1.21e-13	Calcium levels;
LUAD	trans	rs11885103	0.791	rs6712649	chr2:584523	C/T	cg12228919	chr15:44955936	SPG11	-0.44	-6.64	-0.31	9.6e-11	Heschl's gyrus morphology;
LUAD	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg27170947	chr2:26402098	FAM59B	-0.69	-9.41	-0.42	3.19e-19	Gut microbiome composition (summer);
LUAD	cis	rs427394	0.802	rs274692	chr5:6734625	C/T	cg10857441	chr5:6722123	POLS	-0.64	-12.43	-0.52	1.82e-30	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg08071915	chr8:12219732	FAM66A	-0.41	-6.58	-0.3	1.4e-10	Recombination measurement;
LUAD	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg10468373	chr11:64009913	FKBP2	0.51	6.36	0.3	5.16e-10	Mean platelet volume;
LUAD	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg11859384	chr17:80120422	CCDC57	-0.48	-8.68	-0.39	8.84e-17	Life satisfaction;
LUAD	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg15147215	chr3:52552868	STAB1	-0.36	-6.68	-0.31	7.5e-11	Bipolar disorder;
LUAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06873352	chr17:61820015	STRADA	0.82	17.94	0.66	6.11e-54	Prudent dietary pattern;
LUAD	cis	rs2464469	0.526	rs2899612	chr15:58335867	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.36	-7.02	-0.32	8.8e-12	Barrett's esophagus  or Esophageal adenocarcinoma;
LUAD	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg09060608	chr5:178986726	RUFY1	0.7	12.48	0.52	1.17e-30	Lung cancer;
LUAD	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg01028140	chr2:1542097	TPO	-0.52	-7.29	-0.33	1.5e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-14.1	-0.57	2.79e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2835872	0.869	rs73203821	chr21:39046744	C/T	cg06728970	chr21:39037746	KCNJ6	-0.43	-7.93	-0.36	1.97e-14	Electroencephalographic traits in alcoholism;
LUAD	cis	rs6586111	1.000	rs6586107	chr10:82373516	C/T	cg03086067	chr10:82368399	SH2D4B	0.26	6.43	0.3	3.46e-10	Capecitabine sensitivity;
LUAD	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg00277334	chr10:82204260	NA	-0.67	-12.21	-0.51	1.38e-29	Post bronchodilator FEV1;
LUAD	cis	rs3760982	1.000	rs12460161	chr19:44293986	C/A	cg21496419	chr19:44306685	LYPD5	0.29	6.39	0.3	4.51e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg22823121	chr1:150693482	HORMAD1	0.46	8.77	0.39	4.27e-17	Melanoma;
LUAD	cis	rs12049351	0.774	rs12117468	chr1:229671361	G/T	cg11742688	chr1:229674241	ABCB10	-0.42	-6.97	-0.32	1.21e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg13575925	chr12:9217583	LOC144571	0.39	7.33	0.34	1.2e-12	Sjögren's syndrome;
LUAD	cis	rs7215564	0.822	rs2340771	chr17:78752947	A/C	cg09596252	chr17:78655493	RPTOR	-0.5	-6.37	-0.3	4.89e-10	Myopia (pathological);
LUAD	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg09085632	chr11:111637200	PPP2R1B	0.65	9.86	0.43	9.06e-21	Primary sclerosing cholangitis;
LUAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg24813613	chr7:1882135	MAD1L1	-0.43	-6.78	-0.31	4.06e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg18827107	chr12:86230957	RASSF9	0.54	9.74	0.43	2.24e-20	Major depressive disorder;
LUAD	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg05340658	chr4:99064831	C4orf37	0.44	6.77	0.31	4.45e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11644478	chr21:40555479	PSMG1	0.7	11.71	0.49	1.28e-27	Cognitive function;
LUAD	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg18171855	chr10:2543474	NA	0.42	7.57	0.35	2.38e-13	Age-related hearing impairment;
LUAD	cis	rs28735056	0.967	rs61090726	chr18:77631219	A/G	cg20368463	chr18:77673604	PQLC1	-0.43	-6.47	-0.3	2.74e-10	Schizophrenia;
LUAD	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg22491629	chr6:157744540	C6orf35	-0.77	-8.79	-0.39	3.88e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg00933542	chr6:150070202	PCMT1	0.43	9.0	0.4	7.97e-18	Lung cancer;
LUAD	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg16686185	chr17:78078845	GAA	-0.4	-6.59	-0.31	1.3e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg01251360	chr16:68772225	CDH1	-0.28	-8.54	-0.38	2.47e-16	Colorectal cancer;
LUAD	cis	rs4372836	0.576	rs6547880	chr2:29018889	T/C	cg09522027	chr2:28974177	PPP1CB	-0.67	-12.29	-0.51	6.62e-30	Body mass index;
LUAD	cis	rs4888262	0.508	rs4462623	chr16:74692426	C/T	cg01733217	chr16:74700730	RFWD3	0.52	8.63	0.39	1.29e-16	Testicular germ cell tumor;
LUAD	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg21856205	chr7:94953877	PON1	-0.55	-7.75	-0.35	7.03e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg14227996	chr4:17616232	MED28	0.71	7.38	0.34	8.65e-13	Opioid sensitivity;
LUAD	cis	rs9462027	0.583	rs7755982	chr6:34715297	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.76	-0.39	4.62e-17	Systemic lupus erythematosus;
LUAD	cis	rs738321	0.794	rs6001026	chr22:38545363	C/T	cg17652424	chr22:38574118	PLA2G6	-0.26	-6.73	-0.31	5.55e-11	Breast cancer;
LUAD	cis	rs3760982	0.813	rs10426528	chr19:44299298	A/G	cg11993925	chr19:44307056	LYPD5	0.43	8.57	0.38	1.97e-16	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs1232027	0.666	rs1677686	chr5:79938528	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg23505145	chr19:12996616	KLF1	0.61	9.97	0.44	3.56e-21	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg16989719	chr2:238392110	NA	-0.36	-6.5	-0.3	2.21e-10	Prostate cancer;
LUAD	cis	rs7617773	0.780	rs11130164	chr3:48369034	G/A	cg11946769	chr3:48343235	NME6	0.45	6.89	0.32	2.05e-11	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg05340658	chr4:99064831	C4orf37	-0.55	-9.48	-0.42	1.78e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08048268	chr3:133502702	NA	-0.52	-10.4	-0.45	1.07e-22	Iron status biomarkers;
LUAD	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg27411982	chr8:10470053	RP1L1	0.38	6.7	0.31	6.53e-11	Retinal vascular caliber;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg23758120	chr17:42201149	HDAC5	0.43	6.4	0.3	4.23e-10	QT interval;
LUAD	cis	rs6835098	1.000	rs10011724	chr4:174088865	A/G	cg27433088	chr4:174089019	GALNT7	0.4	7.73	0.35	7.72e-14	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs9633740	0.578	rs11185982	chr10:82305627	C/T	cg01528321	chr10:82214614	TSPAN14	0.55	6.52	0.3	2.06e-10	Post bronchodilator FEV1;
LUAD	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg22117172	chr7:91764530	CYP51A1	0.33	7.24	0.33	2.19e-12	Breast cancer;
LUAD	trans	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg24644049	chr4:85504048	CDS1	0.86	7.78	0.35	5.78e-14	Skin colour saturation;
LUAD	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.35	-6.83	-0.32	2.95e-11	IgG glycosylation;
LUAD	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.48e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg23260525	chr10:116636907	FAM160B1	0.47	10.79	0.46	3.99e-24	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.42	-6.65	-0.31	8.92e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg07817883	chr1:32538562	TMEM39B	1.3	12.44	0.52	1.65e-30	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs922182	0.547	rs12594348	chr15:64269127	C/T	cg02919090	chr15:64263738	DAPK2	-0.32	-6.55	-0.3	1.65e-10	Blood protein levels;
LUAD	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg19875535	chr5:140030758	IK	-0.47	-7.7	-0.35	9.59e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg08885076	chr2:99613938	TSGA10	0.36	6.48	0.3	2.56e-10	Chronic sinus infection;
LUAD	cis	rs10823500	0.777	rs10509321	chr10:71985733	A/G	cg02100629	chr10:71892760	AIFM2	0.35	7.28	0.33	1.64e-12	Blood protein levels;
LUAD	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg27661571	chr11:113659931	NA	0.59	6.5	0.3	2.29e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs4372836	1.000	rs4549034	chr2:28972579	C/T	cg09522027	chr2:28974177	PPP1CB	-0.62	-10.04	-0.44	2.05e-21	Body mass index;
LUAD	cis	rs8017423	0.740	rs8003095	chr14:90680643	A/T	cg14092571	chr14:90743983	NA	-0.48	-8.55	-0.38	2.28e-16	Mortality in heart failure;
LUAD	cis	rs7582720	0.943	rs72936879	chr2:203792628	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg05182265	chr7:156933206	UBE3C	0.65	12.22	0.51	1.33e-29	Body mass index;
LUAD	cis	rs1696756	1.000	rs1696756	chr17:77827973	C/T	cg00646381	chr17:77835854	NA	0.45	8.01	0.36	1.09e-14	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUAD	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12292205	chr6:26970375	C6orf41	-0.47	-6.57	-0.3	1.47e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.58	10.2	0.44	5.43e-22	Lymphocyte counts;
LUAD	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg14092571	chr14:90743983	NA	0.5	8.87	0.4	2.07e-17	Mortality in heart failure;
LUAD	cis	rs7617773	0.779	rs11718329	chr3:48309828	C/G	cg11946769	chr3:48343235	NME6	0.42	6.76	0.31	4.55e-11	Coronary artery disease;
LUAD	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	7.47	0.34	4.54e-13	Iron status biomarkers;
LUAD	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg25324976	chr17:61989376	CSHL1	0.37	7.28	0.33	1.62e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10484885	0.887	rs17707738	chr6:90602735	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.69	-8.58	-0.38	1.87e-16	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs870825	0.616	rs6814278	chr4:185644417	G/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg01416388	chr22:39784598	NA	-0.53	-9.02	-0.4	6.72e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg18305652	chr10:134549665	INPP5A	0.63	12.19	0.51	1.64e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg02176678	chr2:219576539	TTLL4	-0.68	-14.06	-0.56	4.17e-37	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	trans	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg04775059	chr7:64541387	NA	0.48	6.52	0.3	1.96e-10	Aortic root size;
LUAD	cis	rs10489202	1.000	rs67600256	chr1:167972357	T/C	cg24449463	chr1:168025552	DCAF6	-0.54	-6.95	-0.32	1.39e-11	Schizophrenia;
LUAD	cis	rs13191362	0.507	rs13210000	chr6:163176944	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.38	7.37	0.34	9.24e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1018836	0.818	rs715057	chr8:91624340	T/C	cg16814680	chr8:91681699	NA	-0.67	-11.67	-0.49	1.72e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06713297	chr1:242011104	EXO1	-0.44	-6.98	-0.32	1.17e-11	Height;
LUAD	trans	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-11.04	-0.47	4.51e-25	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12681287	0.752	rs67615966	chr8:87255203	C/A	cg00550725	chr8:87521180	FAM82B	0.44	6.39	0.3	4.38e-10	Caudate activity during reward;
LUAD	cis	rs4462272	0.503	rs7906355	chr10:101838267	A/C	cg02250046	chr10:101825185	CPN1	-0.32	-6.46	-0.3	2.86e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg05590025	chr7:65112418	INTS4L2	0.73	7.86	0.36	3.32e-14	Diabetic kidney disease;
LUAD	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-8.82	-0.39	2.99e-17	Blood metabolite levels;
LUAD	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg08798685	chr6:27730294	NA	-0.43	-6.98	-0.32	1.18e-11	Parkinson's disease;
LUAD	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg11494091	chr17:61959527	GH2	0.43	8.09	0.37	6.17e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7582720	1.000	rs114702158	chr2:203821793	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg07167872	chr1:205819463	PM20D1	0.49	8.08	0.37	6.85e-15	Parkinson's disease;
LUAD	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg03354898	chr7:1950403	MAD1L1	-0.41	-7.37	-0.34	9.05e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.31	-6.93	-0.32	1.57e-11	Dupuytren's disease;
LUAD	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg14092988	chr3:52407081	DNAH1	0.45	9.1	0.4	3.57e-18	Bipolar disorder;
LUAD	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg12588279	chr6:26043732	HIST1H2BB	0.38	6.47	0.3	2.73e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.61	-0.52	3.52e-31	Bone mineral density;
LUAD	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg23598886	chr18:12777645	NA	-0.7	-8.27	-0.37	1.74e-15	Inflammatory skin disease;
LUAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg20607798	chr8:58055168	NA	0.57	7.86	0.36	3.14e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.42	7.52	0.34	3.22e-13	Lung cancer in ever smokers;
LUAD	cis	rs6594713	0.605	rs72792189	chr5:112814965	A/G	cg12552261	chr5:112820674	MCC	0.53	7.34	0.34	1.11e-12	Brain cytoarchitecture;
LUAD	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	8.51	0.38	3.12e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg00495681	chr13:53174319	NA	0.55	10.25	0.45	3.77e-22	Lewy body disease;
LUAD	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg16479474	chr6:28041457	NA	0.46	7.67	0.35	1.2e-13	Depression;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12320322	chr11:63439260	ATL3	-0.57	-7.07	-0.33	6.63e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg25566285	chr7:158114605	PTPRN2	0.54	11.61	0.49	3.07e-27	Calcium levels;
LUAD	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg03354898	chr7:1950403	MAD1L1	-0.4	-7.17	-0.33	3.43e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg03929089	chr4:120376271	NA	-0.98	-20.17	-0.7	6.79e-64	Height;
LUAD	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.06e-19	Life satisfaction;
LUAD	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.73	-0.35	8.04e-14	Lung cancer;
LUAD	cis	rs2953145	0.568	rs1133352	chr2:241522252	A/G	cg07929629	chr2:241523174	NA	-0.41	-7.02	-0.32	9.12e-12	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-8.98	-0.4	8.74e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg20848291	chr7:100343083	ZAN	0.39	6.78	0.31	4.02e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22857025	chr5:266934	NA	-0.97	-14.29	-0.57	4.5e-38	Breast cancer;
LUAD	cis	rs72901758	0.661	rs56683270	chr17:76247827	T/C	cg25512537	chr17:76250053	NA	0.32	6.46	0.3	2.85e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.12	0.48	2.2e-25	Height;
LUAD	cis	rs11229555	0.645	rs4594017	chr11:58194788	T/C	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg06740227	chr12:86229804	RASSF9	-0.41	-7.36	-0.34	9.88e-13	Major depressive disorder;
LUAD	cis	rs11030122	0.635	rs10835540	chr11:4071429	T/A	cg18678763	chr11:4115507	RRM1	-0.44	-7.05	-0.32	7.38e-12	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs354225	0.554	rs4374410	chr2:54819088	G/T	cg01766943	chr2:54829624	SPTBN1	0.39	7.22	0.33	2.47e-12	Schizophrenia;
LUAD	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg00106254	chr7:1943704	MAD1L1	-0.6	-8.8	-0.39	3.57e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg02527881	chr3:46936655	PTH1R	0.44	8.32	0.38	1.19e-15	Colorectal cancer;
LUAD	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18876405	chr7:65276391	NA	0.44	7.02	0.32	8.75e-12	Aortic root size;
LUAD	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg07414643	chr4:187882934	NA	0.33	6.77	0.31	4.34e-11	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg27411982	chr8:10470053	RP1L1	0.38	6.52	0.3	1.99e-10	Joint mobility (Beighton score);
LUAD	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg17105886	chr17:28927953	LRRC37B2	0.83	7.97	0.36	1.53e-14	Body mass index;
LUAD	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.34	6.86	0.32	2.52e-11	Obesity-related traits;
LUAD	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg14092988	chr3:52407081	DNAH1	0.37	7.55	0.34	2.75e-13	Bipolar disorder;
LUAD	cis	rs8018967	0.622	rs2041073	chr14:73972535	C/T	cg05012125	chr14:74035861	ACOT2	0.38	6.9	0.32	1.87e-11	Blood metabolite ratios;
LUAD	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg02527881	chr3:46936655	PTH1R	0.54	10.58	0.46	2.33e-23	Colorectal cancer;
LUAD	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06873352	chr17:61820015	STRADA	0.55	8.97	0.4	9.56e-18	Height;
LUAD	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.58	9.47	0.42	1.97e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg22907277	chr7:1156413	C7orf50	0.58	7.25	0.33	1.95e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg21782813	chr7:2030301	MAD1L1	0.53	9.42	0.42	3.05e-19	Bipolar disorder and schizophrenia;
LUAD	trans	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg14917512	chr19:3094685	GNA11	0.37	6.45	0.3	3.07e-10	Aortic root size;
LUAD	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.71	-13.3	-0.54	5.92e-34	Menarche (age at onset);
LUAD	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg10589385	chr1:150898437	SETDB1	0.45	8.42	0.38	6e-16	Melanoma;
LUAD	cis	rs13315871	1.000	rs71311864	chr3:58372324	C/T	cg12435725	chr3:58293450	RPP14	-0.67	-7.31	-0.33	1.36e-12	Cholesterol, total;
LUAD	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.41	-7.13	-0.33	4.41e-12	Age at first birth;
LUAD	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.6	10.42	0.45	9.04e-23	Birth weight;
LUAD	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18404041	chr3:52824283	ITIH1	-0.6	-12.15	-0.51	2.4e-29	Bipolar disorder;
LUAD	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.37	-7.92	-0.36	2.18e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg14752069	chr8:11977206	FAM66D	-0.29	-6.52	-0.3	1.96e-10	Triglycerides;
LUAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-10.82	-0.47	2.97e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg27631724	chr1:11040367	C1orf127	0.51	8.76	0.39	4.77e-17	Ewing sarcoma;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06348081	chr3:182511312	ATP11B	-0.42	-7.09	-0.33	5.65e-12	Cancer;
LUAD	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg07570687	chr10:102243282	WNT8B	0.44	6.84	0.32	2.82e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9837602	1.000	rs34626154	chr3:99756312	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.67	9.25	0.41	1.16e-18	Breast cancer;
LUAD	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg21775979	chr11:780331	NA	-0.4	-7.43	-0.34	6.09e-13	Breast cancer;
LUAD	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-7.73	-0.35	7.87e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs853679	1.000	rs853676	chr6:28299687	C/T	cg01620082	chr3:125678407	NA	-0.52	-6.72	-0.31	6.07e-11	Depression;
LUAD	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg26818010	chr10:134567672	INPP5A	-0.96	-15.8	-0.61	1.63e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg14092988	chr3:52407081	DNAH1	0.45	9.1	0.4	3.54e-18	Bipolar disorder;
LUAD	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg13535736	chr9:111863775	C9orf5	-0.44	-6.87	-0.32	2.33e-11	Menarche (age at onset);
LUAD	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg08470875	chr2:26401718	FAM59B	-0.64	-8.73	-0.39	5.97e-17	Gut microbiome composition (summer);
LUAD	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg14019146	chr3:50243930	SLC38A3	-0.34	-6.38	-0.3	4.76e-10	Body mass index;
LUAD	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg26513180	chr16:89883248	FANCA	0.79	7.26	0.33	1.82e-12	Skin colour saturation;
LUAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.19	0.54	1.67e-33	Prudent dietary pattern;
LUAD	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg24324837	chr19:49891574	CCDC155	0.58	9.01	0.4	7.42e-18	Multiple sclerosis;
LUAD	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg08885076	chr2:99613938	TSGA10	0.36	6.47	0.3	2.74e-10	Chronic sinus infection;
LUAD	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg25767906	chr1:53392781	SCP2	-0.37	-6.37	-0.3	4.99e-10	Monocyte count;
LUAD	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg20607798	chr8:58055168	NA	0.71	9.33	0.41	6.12e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs116248771	0.739	rs2082158	chr3:158359791	G/C	cg16708174	chr3:158430962	RARRES1	0.47	6.82	0.31	3.07e-11	diarrhoeal disease at age 2;
LUAD	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.32e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg02037503	chr14:23540729	ACIN1	-0.43	-7.13	-0.33	4.41e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg26338869	chr17:61819248	STRADA	-0.39	-6.47	-0.3	2.79e-10	Prudent dietary pattern;
LUAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg05313129	chr8:58192883	C8orf71	-0.54	-7.04	-0.32	7.65e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg04034577	chr2:241836375	C2orf54	-0.47	-10.27	-0.45	3.11e-22	Urinary metabolites;
LUAD	cis	rs11696501	0.591	rs6065854	chr20:44288816	T/C	cg11783356	chr20:44313418	WFDC10B	-0.49	-8.23	-0.37	2.26e-15	Brain structure;
LUAD	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg09184832	chr6:79620586	NA	-0.52	-9.9	-0.43	6.15e-21	Intelligence (multi-trait analysis);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17301635	chr18:3451475	TGIF1	-0.41	-6.69	-0.31	7.13e-11	Cancer;
LUAD	cis	rs6761276	0.899	rs11678375	chr2:113835691	T/C	cg09040174	chr2:113837401	NA	0.81	15.75	0.61	2.68e-44	Protein quantitative trait loci;
LUAD	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg00277334	chr10:82204260	NA	-0.51	-7.94	-0.36	1.89e-14	Post bronchodilator FEV1;
LUAD	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg02782426	chr3:40428986	ENTPD3	0.36	7.98	0.36	1.39e-14	Renal cell carcinoma;
LUAD	cis	rs2235649	0.789	rs9939680	chr16:1852720	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-6.56	-0.3	1.62e-10	Blood metabolite levels;
LUAD	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.54	0.42	1.17e-19	Lung cancer in ever smokers;
LUAD	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.31	0.33	1.33e-12	Blood metabolite levels;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14199415	chr12:9067514	PHC1	0.41	6.44	0.3	3.22e-10	Bilirubin levels;
LUAD	cis	rs2235642	0.505	rs56359342	chr16:1654948	G/A	cg26528668	chr16:1614120	IFT140	0.47	8.19	0.37	3.07e-15	Coronary artery disease;
LUAD	cis	rs4409675	0.576	rs1474908	chr1:28213213	C/T	cg23691781	chr1:28212827	C1orf38	-0.36	-10.02	-0.44	2.4e-21	Corneal astigmatism;
LUAD	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg14835575	chr10:16859367	RSU1	0.8	11.76	0.5	8.08e-28	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg00981070	chr1:2046702	PRKCZ	0.34	7.44	0.34	5.63e-13	Height;
LUAD	cis	rs3772130	0.962	rs4413346	chr3:121486310	A/G	cg20356878	chr3:121714668	ILDR1	0.52	8.35	0.38	9.9e-16	Cognitive performance;
LUAD	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07167872	chr1:205819463	PM20D1	-0.74	-15.3	-0.6	2.24e-42	Menarche (age at onset);
LUAD	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg17366294	chr4:99064904	C4orf37	0.6	10.2	0.44	5.25e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7737355	1.000	rs76753180	chr5:130763701	A/T	cg06307176	chr5:131281290	NA	-0.5	-7.68	-0.35	1.13e-13	Life satisfaction;
LUAD	cis	rs10992471	0.756	rs10123342	chr9:95087824	T/G	cg14631576	chr9:95140430	CENPP	-0.48	-9.81	-0.43	1.28e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg11494091	chr17:61959527	GH2	0.4	7.12	0.33	4.71e-12	Height;
LUAD	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg10518543	chr12:38710700	ALG10B	0.51	8.42	0.38	6.04e-16	Morning vs. evening chronotype;
LUAD	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03352830	chr11:487213	PTDSS2	0.78	9.71	0.43	2.98e-20	Body mass index;
LUAD	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg10468373	chr11:64009913	FKBP2	0.54	6.71	0.31	6.2e-11	Mean platelet volume;
LUAD	cis	rs6906287	0.647	rs7769001	chr6:118934509	A/G	cg21191810	chr6:118973309	C6orf204	0.51	9.86	0.43	8.59e-21	Electrocardiographic conduction measures;
LUAD	cis	rs1595825	0.891	rs73054819	chr2:198625744	G/T	cg00982548	chr2:198649783	BOLL	-0.66	-9.5	-0.42	1.54e-19	Ulcerative colitis;
LUAD	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg05368731	chr17:41323189	NBR1	0.86	17.42	0.65	1.31e-51	Menopause (age at onset);
LUAD	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg14895029	chr7:2775587	GNA12	-0.42	-6.78	-0.31	4.13e-11	Height;
LUAD	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg23939001	chr4:940644	TMEM175	0.72	11.8	0.5	5.53e-28	Sjögren's syndrome;
LUAD	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg14196790	chr5:131705035	SLC22A5	0.54	9.86	0.43	8.64e-21	Blood metabolite levels;
LUAD	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg25804541	chr17:80189381	SLC16A3	0.34	7.36	0.34	9.68e-13	Life satisfaction;
LUAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg07217954	chr7:1067459	C7orf50	0.45	6.91	0.32	1.81e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg03467027	chr4:99064603	C4orf37	0.39	6.37	0.3	5.05e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg00310523	chr12:86230176	RASSF9	0.35	7.53	0.34	3e-13	Major depressive disorder;
LUAD	cis	rs295140	0.507	rs13019821	chr2:201106815	C/G	cg23649088	chr2:200775458	C2orf69	-0.46	-7.88	-0.36	2.76e-14	QT interval;
LUAD	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg03563238	chr19:33554763	RHPN2	-0.39	-9.19	-0.41	1.83e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9653442	0.866	rs11123811	chr2:100760172	T/C	cg22139774	chr2:100720529	AFF3	-0.38	-7.52	-0.34	3.23e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs2224391	0.628	rs2753231	chr6:5248915	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-8.54	-0.38	2.41e-16	Height;
LUAD	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg16797656	chr11:68205561	LRP5	0.47	9.23	0.41	1.31e-18	Total body bone mineral density;
LUAD	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg11845111	chr2:191398756	TMEM194B	-0.84	-11.27	-0.48	6.1e-26	Diastolic blood pressure;
LUAD	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.81	-0.31	3.36e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs6460942	0.915	rs7803051	chr7:12306904	A/T	cg06484146	chr7:12443880	VWDE	-0.46	-6.72	-0.31	6.04e-11	Coronary artery disease;
LUAD	cis	rs6138458	1.000	rs4273288	chr20:24900873	G/A	cg26195577	chr20:24973756	C20orf3	-0.95	-16.29	-0.62	1.18e-46	Blood protein levels;
LUAD	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg14458575	chr2:238380390	NA	0.65	12.71	0.53	1.49e-31	Prostate cancer;
LUAD	cis	rs796364	0.616	rs6718118	chr2:200691852	G/T	cg23649088	chr2:200775458	C2orf69	-0.53	-6.55	-0.3	1.65e-10	Schizophrenia;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg10841076	chr16:3174662	NA	0.43	6.75	0.31	4.9e-11	Monocyte percentage of white cells;
LUAD	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg10556349	chr10:835070	NA	0.68	8.17	0.37	3.54e-15	Eosinophil percentage of granulocytes;
LUAD	cis	rs6761276	0.635	rs4145013	chr2:113830688	C/T	cg09040174	chr2:113837401	NA	0.46	6.93	0.32	1.54e-11	Protein quantitative trait loci;
LUAD	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg10978503	chr1:24200527	CNR2	0.6	12.78	0.53	7.22e-32	Immature fraction of reticulocytes;
LUAD	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.3	-0.51	6.25e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg27124370	chr19:33622961	WDR88	0.45	6.94	0.32	1.46e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2736345	0.516	rs9657551	chr8:11398183	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.88	0.32	2.19e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg20706599	chr15:90777202	CIB1;C15orf58	-0.51	-6.63	-0.31	1.06e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	11.21	0.48	1.04e-25	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.6	-8.79	-0.39	3.72e-17	Gut microbiome composition (summer);
LUAD	cis	rs904251	0.523	rs2776870	chr6:37481364	C/A	cg25019722	chr6:37503610	NA	-0.33	-7.54	-0.34	2.95e-13	Cognitive performance;
LUAD	cis	rs4700695	0.719	rs27085	chr5:65435063	C/T	cg21114390	chr5:65439923	SFRS12	0.89	14.38	0.57	1.92e-38	Facial morphology (factor 19);
LUAD	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg25811766	chr13:21894605	NA	-0.62	-7.54	-0.34	2.91e-13	White matter hyperintensity burden;
LUAD	cis	rs7119	0.635	rs938090	chr15:77879975	A/G	cg27398640	chr15:77910606	LINGO1	0.42	8.16	0.37	4e-15	Type 2 diabetes;
LUAD	cis	rs806215	0.901	rs989100	chr7:127220918	T/C	cg25922125	chr7:127225783	GCC1	-0.5	-6.86	-0.32	2.5e-11	Type 2 diabetes;
LUAD	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg11494091	chr17:61959527	GH2	0.75	18.45	0.67	3.5e-56	Prudent dietary pattern;
LUAD	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg11845111	chr2:191398756	TMEM194B	-0.88	-11.03	-0.47	5.01e-25	Diastolic blood pressure;
LUAD	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg17971929	chr21:40555470	PSMG1	0.56	8.86	0.4	2.22e-17	Cognitive function;
LUAD	cis	rs6484504	0.652	rs485265	chr11:31407788	G/A	cg26647111	chr11:31128758	NA	0.44	7.65	0.35	1.35e-13	Red blood cell count;
LUAD	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.23	0.33	2.33e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2692947	0.702	rs2312955	chr2:96777168	T/G	cg23100626	chr2:96804247	ASTL	-0.38	-10.06	-0.44	1.74e-21	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	9.11	0.4	3.43e-18	Platelet count;
LUAD	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg24324837	chr19:49891574	CCDC155	0.49	7.82	0.36	4.19e-14	Multiple sclerosis;
LUAD	cis	rs1215050	0.765	rs588851	chr4:98678247	C/T	cg05340658	chr4:99064831	C4orf37	0.43	7.01	0.32	9.19e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg15921436	chr17:44337874	NA	-0.61	-9.01	-0.4	7.1e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2227564	0.620	rs4746143	chr10:75477298	A/G	cg23231163	chr10:75533350	FUT11	-0.42	-6.42	-0.3	3.64e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg07169764	chr2:136633963	MCM6	-0.79	-9.27	-0.41	9.43e-19	Corneal structure;
LUAD	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg02423579	chr7:2872169	GNA12	-0.86	-14.81	-0.58	2.87e-40	Height;
LUAD	trans	rs10411161	0.702	rs7251689	chr19:52389117	A/T	cg22319618	chr22:45562946	NUP50	-0.64	-9.14	-0.41	2.58e-18	Breast cancer;
LUAD	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07551314	chr1:26190155	PAQR7	0.63	6.47	0.3	2.64e-10	Type 2 diabetes;
LUAD	cis	rs11166629	1.000	rs935119	chr8:135638353	C/T	cg27224718	chr8:135614730	ZFAT	-0.54	-10.19	-0.44	5.93e-22	Smoking quantity;
LUAD	trans	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-16.03	-0.61	1.5e-45	Exhaled nitric oxide levels;
LUAD	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg26516362	chr5:178986906	RUFY1	0.54	8.86	0.4	2.27e-17	Lung cancer;
LUAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg04234412	chr22:24373322	LOC391322	-0.83	-15.28	-0.6	2.83e-42	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs13315871	1.000	rs35542947	chr3:58323244	C/T	cg20936604	chr3:58311152	NA	-0.72	-7.22	-0.33	2.51e-12	Cholesterol, total;
LUAD	trans	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg06606381	chr12:133084897	FBRSL1	-0.96	-9.28	-0.41	9.17e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg21427119	chr20:30132790	HM13	-0.5	-8.09	-0.37	6.46e-15	Mean corpuscular hemoglobin;
LUAD	trans	rs4650994	0.525	rs4650997	chr1:178530744	T/A	cg05059571	chr16:84539110	KIAA1609	-0.72	-12.87	-0.53	3.19e-32	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg06131755	chr6:160182447	ACAT2	0.42	6.38	0.3	4.63e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-9.22	-0.41	1.38e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.07	-27.52	-0.8	2.7e-96	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg15147215	chr3:52552868	STAB1	-0.41	-7.37	-0.34	9.1e-13	Bipolar disorder;
LUAD	cis	rs494562	0.730	rs9450270	chr6:86114766	A/G	cg17966619	chr6:86160162	NT5E	0.61	7.96	0.36	1.61e-14	Blood metabolite levels;Metabolic traits;
LUAD	trans	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg11693508	chr17:37793320	STARD3	0.56	7.84	0.36	3.71e-14	Bipolar disorder;
LUAD	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg11822812	chr5:140052017	DND1	-0.39	-7.28	-0.33	1.68e-12	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg01620082	chr3:125678407	NA	-0.69	-7.95	-0.36	1.73e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg11502198	chr6:26597334	ABT1	0.56	9.32	0.41	6.74e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg25036284	chr2:26402008	FAM59B	0.64	8.16	0.37	4e-15	Gut microbiome composition (summer);
LUAD	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg15997130	chr1:24165203	NA	0.58	10.37	0.45	1.37e-22	Immature fraction of reticulocytes;
LUAD	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26314531	chr2:26401878	FAM59B	-0.55	-7.71	-0.35	9.38e-14	Gut microbiome composition (summer);
LUAD	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg17173187	chr15:85201210	NMB	-0.41	-6.61	-0.31	1.16e-10	Schizophrenia;
LUAD	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg23277830	chr1:3704460	LRRC47	0.45	9.39	0.42	3.78e-19	Red cell distribution width;
LUAD	cis	rs10504073	0.565	rs12056536	chr8:49890132	C/T	cg00325661	chr8:49890786	NA	-0.47	-10.57	-0.46	2.55e-23	Blood metabolite ratios;
LUAD	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg22683308	chr4:1340831	KIAA1530	-0.42	-6.84	-0.32	2.8e-11	Longevity;
LUAD	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg07905836	chr2:113190072	RGPD8;RGPD5	-0.64	-7.32	-0.34	1.29e-12	Yeast infection;
LUAD	cis	rs10883723	0.668	rs12414479	chr10:104420902	C/T	cg22532475	chr10:104410764	TRIM8	-0.6	-10.86	-0.47	2.08e-24	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg24813613	chr7:1882135	MAD1L1	-0.53	-8.85	-0.4	2.33e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg06558623	chr16:89946397	TCF25	0.96	10.59	0.46	2.13e-23	Skin colour saturation;
LUAD	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg20701182	chr2:24300061	SF3B14	0.68	7.64	0.35	1.51e-13	Lymphocyte counts;
LUAD	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg21856205	chr7:94953877	PON1	-0.56	-7.84	-0.36	3.62e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg00814883	chr7:100076585	TSC22D4	-0.77	-10.01	-0.44	2.67e-21	Platelet count;
LUAD	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg07677032	chr17:61819896	STRADA	0.54	9.78	0.43	1.72e-20	Prudent dietary pattern;
LUAD	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg11822812	chr5:140052017	DND1	0.38	6.84	0.32	2.78e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11229555	0.645	rs11229429	chr11:58180872	G/A	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs758324	0.738	rs413185	chr5:131315225	A/G	cg06307176	chr5:131281290	NA	0.44	7.25	0.33	2.06e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-13.07	-0.54	4.97e-33	Body mass index;
LUAD	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	cis	rs12545109	0.613	rs4541914	chr8:57254555	T/G	cg07776626	chr8:57350775	NA	-0.65	-8.53	-0.38	2.71e-16	Obesity-related traits;
LUAD	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg17173187	chr15:85201210	NMB	0.48	8.41	0.38	6.53e-16	Schizophrenia;
LUAD	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg23950597	chr19:37808831	NA	-0.62	-7.42	-0.34	6.54e-13	Coronary artery calcification;
LUAD	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.86	-0.4	2.26e-17	Total body bone mineral density;
LUAD	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09263875	chr16:632152	PIGQ	0.83	18.22	0.66	3.64e-55	Height;
LUAD	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-9.55	-0.42	1.08e-19	Obesity (extreme);
LUAD	cis	rs7250872	0.606	rs12985022	chr19:1825401	A/G	cg10370574	chr19:1840461	REXO1	-0.65	-10.65	-0.46	1.25e-23	Bipolar disorder;
LUAD	cis	rs6445967	0.569	rs6794330	chr3:58314756	G/A	cg23715586	chr3:58305044	RPP14	0.4	6.49	0.3	2.47e-10	Platelet count;
LUAD	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg05535760	chr7:792225	HEATR2	0.87	11.5	0.49	8.32e-27	Cerebrospinal P-tau181p levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.41	-6.41	-0.3	3.95e-10	Cancer;
LUAD	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg12310025	chr6:25882481	NA	-0.58	-9.55	-0.42	1.1e-19	Blood metabolite levels;
LUAD	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.73	0.31	5.53e-11	Prudent dietary pattern;
LUAD	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg16479474	chr6:28041457	NA	0.35	6.5	0.3	2.33e-10	Cardiac Troponin-T levels;
LUAD	cis	rs4253772	0.530	rs2007791	chr22:46803469	C/A	cg00784671	chr22:46762841	CELSR1	-0.58	-7.21	-0.33	2.6e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08280861	chr8:58055591	NA	0.59	7.55	0.34	2.7e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	7.01	0.32	9.61e-12	Cognitive test performance;
LUAD	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg05623727	chr3:50126028	RBM5	0.31	6.66	0.31	8.49e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs367943	0.666	rs1850412	chr5:112696768	A/G	cg12552261	chr5:112820674	MCC	0.46	9.04	0.4	5.69e-18	Type 2 diabetes;
LUAD	cis	rs2046867	0.908	rs113001746	chr3:72824260	C/T	cg25664220	chr3:72788482	NA	-0.68	-12.33	-0.51	4.68e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7975161	0.630	rs7978101	chr12:104630510	A/G	cg25273343	chr12:104657179	TXNRD1	-0.64	-6.88	-0.32	2.11e-11	Toenail selenium levels;
LUAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.16	0.41	2.31e-18	Alzheimer's disease;
LUAD	cis	rs4638749	0.677	rs10203004	chr2:108826535	G/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.27	-0.33	1.76e-12	Blood pressure;
LUAD	cis	rs9914988	0.943	rs3181215	chr17:27077331	C/T	cg02049041	chr17:27085579	C17orf63	-0.6	-8.28	-0.37	1.63e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7759001	0.857	rs6456778	chr6:27370046	T/G	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs55665837	1.000	rs12288873	chr11:14450465	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-10.3	-0.45	2.39e-22	Vitamin D levels;
LUAD	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.54	0.3	1.77e-10	Depression;
LUAD	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg20503657	chr10:835505	NA	-0.81	-11.96	-0.5	1.31e-28	Eosinophil percentage of granulocytes;
LUAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-7.16	-0.33	3.56e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1941023	0.584	rs2233252	chr11:60157107	T/G	cg08716584	chr11:60157161	MS4A7	-0.48	-9.26	-0.41	1.07e-18	Congenital heart disease (maternal effect);
LUAD	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg12698349	chr2:225449008	CUL3	-0.7	-10.46	-0.45	6.4e-23	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs4523957	0.890	rs12941621	chr17:2194852	C/T	cg16513277	chr17:2031491	SMG6	0.76	13.69	0.55	1.45e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4824093	0.544	rs73443957	chr22:50305515	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-7.29	-0.33	1.49e-12	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs7536201	0.936	rs4648889	chr1:25293829	G/A	cg23273869	chr1:25296894	NA	-0.35	-6.95	-0.32	1.37e-11	Psoriasis vulgaris;
LUAD	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg19622623	chr12:86230825	RASSF9	0.56	10.26	0.45	3.2e-22	Major depressive disorder;
LUAD	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg10556349	chr10:835070	NA	0.68	7.97	0.36	1.45e-14	Eosinophil percentage of granulocytes;
LUAD	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg07757535	chr4:1339547	NA	0.32	6.39	0.3	4.44e-10	Longevity;
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg07332563	chr6:291687	DUSP22	-0.67	-11.75	-0.5	8.93e-28	Menopause (age at onset);
LUAD	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.6	7.34	0.34	1.11e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg00255919	chr5:131827918	IRF1	0.49	11.85	0.5	3.74e-28	Asthma (sex interaction);
LUAD	cis	rs35123781	0.502	rs355160	chr5:138953589	C/T	cg12205435	chr5:138714322	SLC23A1	-0.42	-7.08	-0.33	6.22e-12	Schizophrenia;
LUAD	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg21204522	chr6:27730016	NA	-0.47	-7.47	-0.34	4.61e-13	Parkinson's disease;
LUAD	cis	rs1044826	0.642	rs2118981	chr3:139178853	A/G	cg00490450	chr3:139108681	COPB2	0.43	6.95	0.32	1.36e-11	Obesity-related traits;
LUAD	cis	rs6761276	0.837	rs11887823	chr2:113835311	T/A	cg09040174	chr2:113837401	NA	0.81	15.75	0.61	2.68e-44	Protein quantitative trait loci;
LUAD	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg02423579	chr7:2872169	GNA12	-0.57	-9.77	-0.43	1.81e-20	Height;
LUAD	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg10518543	chr12:38710700	ALG10B	-0.43	-7.13	-0.33	4.43e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs3845702	0.736	rs12465592	chr2:180862654	C/G	cg01881094	chr2:180872142	CWC22	0.81	8.67	0.39	9.63e-17	Schizophrenia;
LUAD	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg08470875	chr2:26401718	FAM59B	0.76	9.53	0.42	1.29e-19	Gut microbiome composition (summer);
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg12670061	chr16:67465042	HSD11B2	0.44	6.62	0.31	1.12e-10	QT interval;
LUAD	cis	rs698833	0.926	rs1067370	chr2:44652343	T/G	cg04920474	chr2:44395004	PPM1B	0.39	6.97	0.32	1.25e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg01765077	chr12:122356316	WDR66	-0.54	-9.3	-0.41	7.31e-19	Mean corpuscular volume;
LUAD	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.11	0.33	4.96e-12	Tonsillectomy;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg09092174	chr22:39190118	DNAL4	0.41	6.36	0.3	5.4e-10	Monocyte percentage of white cells;
LUAD	trans	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg14917512	chr19:3094685	GNA11	-0.57	-6.8	-0.31	3.69e-11	Diabetic kidney disease;
LUAD	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg03037974	chr15:76606532	NA	0.39	8.22	0.37	2.6e-15	Blood metabolite levels;
LUAD	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08109568	chr15:31115862	NA	-0.59	-9.9	-0.43	6.52e-21	Huntington's disease progression;
LUAD	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-6.85	-0.32	2.56e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs3960554	0.808	rs11983987	chr7:75657850	A/G	cg19862616	chr7:65841803	NCRNA00174	0.69	8.94	0.4	1.2e-17	Eotaxin levels;
LUAD	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg11062466	chr8:58055876	NA	0.5	6.89	0.32	1.98e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg00666640	chr1:248458726	OR2T12	0.33	8.1	0.37	5.83e-15	Common traits (Other);
LUAD	cis	rs889398	0.802	rs9940315	chr16:69876164	A/G	cg00738113	chr16:70207722	CLEC18C	-0.35	-7.01	-0.32	9.59e-12	Body mass index;
LUAD	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg26384229	chr12:38710491	ALG10B	0.46	7.44	0.34	5.68e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg03467027	chr4:99064603	C4orf37	-0.43	-7.04	-0.32	8.03e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17532515	0.652	rs7682966	chr4:141382614	T/C	cg03645522	chr4:141391200	NA	0.4	6.42	0.3	3.57e-10	Select biomarker traits;
LUAD	trans	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg16554228	chr10:79794011	RPS24	-0.44	-6.37	-0.3	4.91e-10	Fibrinogen levels;
LUAD	cis	rs77861329	1.000	rs9815010	chr3:52196548	C/T	cg08692210	chr3:52188851	WDR51A	0.83	7.75	0.35	6.7e-14	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg24829409	chr8:58192753	C8orf71	-0.61	-8.07	-0.37	7.12e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg24450063	chr1:156163899	SLC25A44	1.22	29.22	0.82	1.59e-103	Testicular germ cell tumor;
LUAD	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18099408	chr3:52552593	STAB1	-0.46	-8.09	-0.37	6.6e-15	Bipolar disorder;
LUAD	cis	rs10189230	0.967	rs7573758	chr2:222357326	G/T	cg14652038	chr2:222343519	EPHA4	0.43	8.67	0.39	9.22e-17	Urate levels in lean individuals;
LUAD	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.93	-0.36	1.98e-14	Alzheimer's disease;
LUAD	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg17173187	chr15:85201210	NMB	0.49	8.5	0.38	3.32e-16	Schizophrenia;
LUAD	cis	rs2742417	1.000	rs2742454	chr3:45766222	T/A	cg10512202	chr3:45649293	LIMD1	0.39	6.97	0.32	1.2e-11	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs8060686	0.623	rs2301814	chr16:68105171	C/G	cg09835421	chr16:68378352	PRMT7	-0.52	-6.67	-0.31	8.1e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.69	0.35	1.01e-13	Breast cancer;
LUAD	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.43	7.89	0.36	2.7e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg12863693	chr15:85201151	NMB	-0.37	-6.38	-0.3	4.62e-10	Schizophrenia;
LUAD	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg01028140	chr2:1542097	TPO	-0.45	-7.58	-0.35	2.14e-13	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs13082711	0.871	rs7624790	chr3:27468601	C/A	cg02860705	chr3:27208620	NA	0.58	8.99	0.4	8.15e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg25535316	chr11:579198	PHRF1	-0.38	-6.67	-0.31	7.9e-11	Systemic lupus erythematosus;
LUAD	trans	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04565464	chr8:145669602	NFKBIL2	0.48	7.19	0.33	3.03e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg21204522	chr6:27730016	NA	-0.38	-6.38	-0.3	4.71e-10	Parkinson's disease;
LUAD	cis	rs6087990	0.806	rs2424918	chr20:31382770	C/T	cg13636640	chr20:31349939	DNMT3B	0.78	13.84	0.56	3.55e-36	Ulcerative colitis;
LUAD	cis	rs1003719	0.762	rs34273703	chr21:38475019	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.65	0.39	1.11e-16	Eye color traits;
LUAD	cis	rs7771547	0.573	rs517890	chr6:36397786	G/C	cg04289385	chr6:36355825	ETV7	0.43	6.61	0.31	1.14e-10	Platelet distribution width;
LUAD	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg07757535	chr4:1339547	NA	0.33	6.61	0.31	1.19e-10	Longevity;
LUAD	cis	rs758324	0.812	rs11954609	chr5:131165738	A/G	cg25547332	chr5:131281432	NA	-0.41	-6.7	-0.31	6.5e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg09021430	chr5:549028	NA	-0.69	-14.49	-0.58	6.3e-39	Obesity-related traits;
LUAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg08027265	chr7:2291960	NA	-0.39	-6.56	-0.3	1.56e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg13073564	chr4:8508604	NA	0.62	11.3	0.48	4.87e-26	Response to antineoplastic agents;
LUAD	cis	rs57590327	0.508	rs10511101	chr3:81950302	A/C	cg07356753	chr3:81810745	GBE1	-0.56	-9.46	-0.42	2.25e-19	Extraversion;
LUAD	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg16479474	chr6:28041457	NA	0.36	6.45	0.3	3.12e-10	Cardiac Troponin-T levels;
LUAD	cis	rs73198271	0.628	rs56188408	chr8:8592158	G/C	cg01851573	chr8:8652454	MFHAS1	0.47	6.8	0.31	3.6e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs12681287	0.511	rs4129535	chr8:87524094	G/T	cg27223183	chr8:87520930	FAM82B	-0.73	-10.26	-0.45	3.31e-22	Caudate activity during reward;
LUAD	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg23231163	chr10:75533350	FUT11	-0.51	-9.37	-0.41	4.29e-19	Psoriasis vulgaris;Psoriasis;
LUAD	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg19346786	chr7:2764209	NA	-0.48	-10.22	-0.44	4.75e-22	Height;
LUAD	cis	rs6714710	0.580	rs13032265	chr2:98409565	T/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.2	0.37	2.88e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs7659604	0.540	rs10024878	chr4:122665451	C/G	cg06713675	chr4:122721982	EXOSC9	0.41	7.45	0.34	5.27e-13	Type 2 diabetes;
LUAD	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg17863274	chr19:49399704	TULP2	-0.66	-10.02	-0.44	2.43e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs1524976	0.760	rs11706564	chr3:65443720	G/C	cg16238336	chr3:65465873	MAGI1	-0.58	-7.0	-0.32	1.01e-11	PR interval;
LUAD	cis	rs7759001	0.817	rs1534936	chr6:27354195	C/T	cg18711553	chr6:27366782	ZNF391	0.39	6.43	0.3	3.36e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg07305463	chr2:136567211	LCT	0.37	7.04	0.32	8.06e-12	Cholesterol, total;
LUAD	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.5	0.52	1.02e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg03467027	chr4:99064603	C4orf37	0.45	7.18	0.33	3.23e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg24675658	chr1:53192096	ZYG11B	-0.4	-7.12	-0.33	4.73e-12	Monocyte count;
LUAD	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg13902645	chr11:5959945	NA	-0.53	-9.38	-0.41	4.13e-19	DNA methylation (variation);
LUAD	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg23887609	chr12:130822674	PIWIL1	0.4	6.64	0.31	9.93e-11	Menopause (age at onset);
LUAD	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg02683114	chr2:24398427	C2orf84	-0.52	-7.75	-0.35	7.03e-14	Asthma;
LUAD	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	8.29	0.37	1.47e-15	Alzheimer's disease;
LUAD	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.56	7.01	0.32	9.69e-12	Alzheimer's disease;
LUAD	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.98	-0.36	1.37e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg26597838	chr10:835615	NA	1.01	16.09	0.62	9.11e-46	Eosinophil percentage of granulocytes;
LUAD	cis	rs738321	0.701	rs4821754	chr22:38581503	A/G	cg17652424	chr22:38574118	PLA2G6	0.26	6.76	0.31	4.52e-11	Breast cancer;
LUAD	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12756686	chr19:29218302	NA	0.74	9.56	0.42	9.89e-20	Methadone dose in opioid dependence;
LUAD	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg02569458	chr12:86230093	RASSF9	0.4	7.51	0.34	3.64e-13	Major depressive disorder;
LUAD	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg18621852	chr3:10150065	C3orf24	0.5	8.8	0.39	3.54e-17	Alzheimer's disease;
LUAD	cis	rs62400317	0.731	rs12208523	chr6:45058828	C/T	cg18551225	chr6:44695536	NA	-0.55	-7.92	-0.36	2.05e-14	Total body bone mineral density;
LUAD	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg06623918	chr6:96969491	KIAA0776	-0.71	-9.91	-0.43	5.87e-21	Migraine;Coronary artery disease;
LUAD	cis	rs7216064	1.000	rs34872586	chr17:65863466	T/C	cg08758996	chr17:66097529	LOC651250	0.47	7.13	0.33	4.31e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg05958659	chr5:99870887	FAM174A	-0.39	-6.74	-0.31	5.2e-11	Subcortical brain region volumes;
LUAD	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg25452165	chr22:42524984	CYP2D6	-0.38	-6.42	-0.3	3.76e-10	Schizophrenia;
LUAD	cis	rs9807989	0.507	rs6734762	chr2:103062926	C/T	cg03938978	chr2:103052716	IL18RAP	0.46	10.57	0.46	2.39e-23	Asthma;
LUAD	cis	rs11811982	0.793	rs76860817	chr1:227358442	C/T	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic disc area;
LUAD	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg19346786	chr7:2764209	NA	-0.49	-10.49	-0.45	4.78e-23	Height;
LUAD	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5756391	0.546	rs4821566	chr22:37314507	C/G	cg16356956	chr22:37317934	CSF2RB	0.33	7.21	0.33	2.54e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg02176678	chr2:219576539	TTLL4	-0.82	-17.42	-0.65	1.29e-51	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.65	12.03	0.51	6.9e-29	Lymphocyte counts;
LUAD	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg22467129	chr15:76604101	ETFA	-0.59	-10.79	-0.46	3.83e-24	Blood metabolite levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08017547	chr14:91883935	CCDC88C	-0.68	-6.96	-0.32	1.31e-11	Type 2 diabetes;
LUAD	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg13385794	chr1:248469461	NA	0.25	6.86	0.32	2.49e-11	Common traits (Other);
LUAD	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	9.22	0.41	1.38e-18	Platelet count;
LUAD	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg02466173	chr16:30829666	NA	-0.72	-12.63	-0.52	3.02e-31	Multiple myeloma;
LUAD	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.09	0.37	6.38e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.25	0.37	1.97e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg18105134	chr13:113819100	PROZ	0.9	16.02	0.61	1.67e-45	Platelet distribution width;
LUAD	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00149659	chr3:10157352	C3orf10	-0.55	-6.8	-0.31	3.69e-11	Alzheimer's disease;
LUAD	cis	rs2041840	1.000	rs2430494	chr2:37463620	G/T	cg25727520	chr2:37576821	QPCT	-0.35	-7.06	-0.32	6.81e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.45	-0.3	3.02e-10	Prostate cancer;
LUAD	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg02251663	chr11:14281053	SPON1	-0.36	-7.07	-0.32	6.61e-12	Mitochondrial DNA levels;
LUAD	cis	rs7903847	0.642	rs7084654	chr10:99135262	G/A	cg20016023	chr10:99160130	RRP12	-0.3	-7.31	-0.34	1.31e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00166722	chr3:10149974	C3orf24	0.73	10.84	0.47	2.57e-24	Alzheimer's disease;
LUAD	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg04731861	chr2:219085781	ARPC2	-0.24	-7.29	-0.33	1.52e-12	Colorectal cancer;
LUAD	cis	rs870825	0.585	rs2696039	chr4:185610899	T/C	cg04058563	chr4:185651563	MLF1IP	-0.66	-10.08	-0.44	1.46e-21	Blood protein levels;
LUAD	cis	rs55665837	1.000	rs12792120	chr11:14469443	G/T	cg19336497	chr11:14380999	RRAS2	-0.51	-10.25	-0.45	3.56e-22	Vitamin D levels;
LUAD	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg07169764	chr2:136633963	MCM6	0.64	7.7	0.35	1.01e-13	Corneal structure;
LUAD	cis	rs4148087	0.673	rs8133852	chr21:43595552	C/A	cg08841829	chr21:43638893	ABCG1	-0.51	-6.82	-0.31	3.12e-11	Eating disorder in bipolar disorder;
LUAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg08888203	chr3:10149979	C3orf24	0.72	12.58	0.52	4.87e-31	Alzheimer's disease;
LUAD	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg08677398	chr8:58056175	NA	0.53	6.86	0.32	2.4e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg00316803	chr15:76480434	C15orf27	-0.39	-7.27	-0.33	1.8e-12	Blood metabolite levels;
LUAD	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg00495681	chr13:53174319	NA	0.47	8.02	0.36	1.07e-14	Lewy body disease;
LUAD	cis	rs9595066	1.000	rs4942281	chr13:44708126	C/T	cg04068111	chr13:44716778	NA	-0.67	-11.64	-0.49	2.25e-27	Schizophrenia;
LUAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg23283495	chr1:209979779	IRF6	0.69	11.11	0.48	2.48e-25	Cleft lip with or without cleft palate;
LUAD	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg25036284	chr2:26402008	FAM59B	-0.58	-8.17	-0.37	3.48e-15	Gut microbiome composition (summer);
LUAD	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	10.05	0.44	1.9e-21	Monocyte percentage of white cells;
LUAD	cis	rs600231	0.542	rs11227198	chr11:65237974	G/A	cg17120908	chr11:65337727	SSSCA1	-0.63	-8.24	-0.37	2.2e-15	Bone mineral density;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg20284698	chr3:48956327	C3orf71;ARIH2	-0.36	-6.47	-0.3	2.68e-10	Schizophrenia;
LUAD	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23583168	chr7:148888333	NA	-0.99	-23.76	-0.76	6.54e-80	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs2712381	0.797	rs62270806	chr3:128376269	C/T	cg16766828	chr3:128327626	NA	-0.38	-7.05	-0.32	7.11e-12	Monocyte count;
LUAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg18538332	chr22:24372958	LOC391322	-0.57	-9.84	-0.43	1.07e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1595825	0.891	rs114426561	chr2:198698891	A/G	cg10547527	chr2:198650123	BOLL	-0.55	-7.93	-0.36	2.03e-14	Ulcerative colitis;
LUAD	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg22467129	chr15:76604101	ETFA	-0.48	-8.25	-0.37	2.08e-15	Blood metabolite levels;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg07746351	chr16:89466392	ANKRD11	-0.38	-6.35	-0.3	5.46e-10	Diastolic blood pressure;
LUAD	cis	rs738322	0.775	rs13056506	chr22:38580917	G/T	cg03162506	chr22:38580953	NA	-0.32	-6.72	-0.31	6.03e-11	Cutaneous nevi;
LUAD	cis	rs2580764	0.632	rs2588510	chr2:55199248	A/G	cg09592903	chr2:55203963	RTN4	-0.46	-10.81	-0.47	3.31e-24	Mean platelet volume;
LUAD	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.37	-0.3	4.91e-10	Coronary artery disease;
LUAD	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.04	0.36	9.24e-15	Menopause (age at onset);
LUAD	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg20503657	chr10:835505	NA	0.99	15.33	0.6	1.66e-42	Eosinophil percentage of granulocytes;
LUAD	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg13319975	chr6:146136371	FBXO30	0.59	9.91	0.43	6.11e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2067615	0.524	rs4964483	chr12:107099057	T/C	cg15890332	chr12:107067104	RFX4	0.41	8.56	0.38	2.07e-16	Heart rate;
LUAD	cis	rs796825	0.530	rs13063849	chr3:120011084	T/G	cg21790991	chr3:120137480	FSTL1	-0.45	-7.61	-0.35	1.77e-13	HIV-1 susceptibility;
LUAD	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg02782426	chr3:40428986	ENTPD3	0.35	7.68	0.35	1.13e-13	Renal cell carcinoma;
LUAD	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg25173405	chr17:45401733	C17orf57	-0.47	-7.6	-0.35	1.88e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11118844	0.793	rs7516292	chr1:221942413	C/T	cg04222084	chr1:221915650	DUSP10	-0.63	-7.2	-0.33	2.79e-12	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
LUAD	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg09365446	chr1:150670422	GOLPH3L	0.66	12.34	0.51	4.22e-30	Tonsillectomy;
LUAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg02951883	chr7:2050386	MAD1L1	-0.83	-14.21	-0.57	9.65e-38	Bipolar disorder and schizophrenia;
LUAD	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg02136620	chr5:178986620	RUFY1	0.5	8.47	0.38	3.97e-16	Lung cancer;
LUAD	cis	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg06360820	chr2:242988706	NA	-1.08	-10.76	-0.46	5.18e-24	Obesity-related traits;
LUAD	cis	rs778371	0.723	rs6704763	chr2:233592487	C/T	cg08000102	chr2:233561755	GIGYF2	0.39	6.39	0.3	4.3e-10	Schizophrenia;
LUAD	cis	rs62400317	0.859	rs62400293	chr6:45233580	A/T	cg18551225	chr6:44695536	NA	-0.56	-8.7	-0.39	7.44e-17	Total body bone mineral density;
LUAD	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg09658497	chr7:2847517	GNA12	-0.45	-7.62	-0.35	1.63e-13	Height;
LUAD	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg00106254	chr7:1943704	MAD1L1	-0.57	-8.85	-0.4	2.38e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs4845570	1.000	rs6659705	chr1:151769750	T/C	cg07092448	chr1:151763213	TDRKH	-0.75	-8.91	-0.4	1.5e-17	Coronary artery disease;
LUAD	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg20587970	chr11:113659929	NA	-1.38	-20.92	-0.71	3.05e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs9486719	0.948	rs11152953	chr6:96894305	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.11	-0.44	1.18e-21	Migraine;Coronary artery disease;
LUAD	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg18932078	chr1:2524107	MMEL1	0.38	7.05	0.32	7.33e-12	Ulcerative colitis;
LUAD	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.44	8.37	0.38	8.34e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs11120822	0.787	rs11120829	chr1:7123793	A/C	cg20434152	chr1:7120926	CAMTA1	-0.37	-9.43	-0.42	2.83e-19	Stearic acid (18:0) levels;
LUAD	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg00074818	chr8:8560427	CLDN23	0.66	10.11	0.44	1.17e-21	Obesity-related traits;
LUAD	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg02176678	chr2:219576539	TTLL4	0.75	15.16	0.59	8.94e-42	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg06608945	chr2:219082296	ARPC2	-0.42	-7.02	-0.32	8.73e-12	Colorectal cancer;
LUAD	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg27219399	chr15:67835830	MAP2K5	0.41	6.61	0.31	1.16e-10	Restless legs syndrome;
LUAD	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg15448220	chr1:150897856	SETDB1	0.51	8.56	0.38	2.11e-16	Melanoma;
LUAD	cis	rs9372498	0.505	rs9489462	chr6:118927855	C/T	cg18833306	chr6:118973337	C6orf204	-0.53	-7.59	-0.35	2e-13	Diastolic blood pressure;
LUAD	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.83	0.32	2.93e-11	Hypertriglyceridemia;
LUAD	cis	rs7107174	0.901	rs2912	chr11:77926292	G/A	cg19901956	chr11:77921274	USP35	-0.54	-6.69	-0.31	7.08e-11	Testicular germ cell tumor;
LUAD	cis	rs757647	0.723	rs7730416	chr5:137704077	A/T	cg10676309	chr5:137685565	NA	0.38	6.83	0.32	2.97e-11	Menarche (age at onset);
LUAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08677398	chr8:58056175	NA	0.48	6.65	0.31	8.98e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs17270561	0.541	rs2009610	chr6:25967068	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	6.99	0.32	1.07e-11	Iron status biomarkers;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25022342	chr12:46385851	SFRS2IP	-0.54	-6.49	-0.3	2.46e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg22508957	chr16:3507546	NAT15	0.86	8.86	0.4	2.23e-17	Tuberculosis;
LUAD	cis	rs73198271	0.515	rs17629935	chr8:8619381	A/T	cg01851573	chr8:8652454	MFHAS1	0.58	7.36	0.34	9.83e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg10356904	chr22:49881777	NA	-0.41	-8.06	-0.36	8e-15	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg02990361	chr1:107599529	PRMT6	-0.63	-10.58	-0.46	2.28e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg19717773	chr7:2847554	GNA12	-0.48	-8.75	-0.39	4.94e-17	Height;
LUAD	cis	rs73086581	0.947	rs67356712	chr20:3892886	A/G	cg02187196	chr20:3869020	PANK2	0.48	7.09	0.33	5.84e-12	Response to antidepressants in depression;
LUAD	cis	rs4285028	0.948	rs34566912	chr3:121679626	G/A	cg20356878	chr3:121714668	ILDR1	-0.49	-6.57	-0.3	1.47e-10	Multiple sclerosis;
LUAD	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg08859206	chr1:53392774	SCP2	0.59	10.66	0.46	1.19e-23	Monocyte count;
LUAD	trans	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17712092	chr4:129076599	LARP1B	-0.91	-17.66	-0.65	1.15e-52	Eosinophil percentage of white cells;
LUAD	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg03909863	chr11:638404	DRD4	-0.46	-6.4	-0.3	4.12e-10	Systemic lupus erythematosus;
LUAD	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg25173405	chr17:45401733	C17orf57	0.52	8.87	0.4	2.07e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.53	0.3	1.91e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg13047869	chr3:10149882	C3orf24	0.64	11.03	0.47	4.89e-25	Alzheimer's disease;
LUAD	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg22508957	chr16:3507546	NAT15	-0.42	-6.42	-0.3	3.73e-10	Body mass index (adult);
LUAD	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg01256987	chr12:42539512	GXYLT1	-0.33	-6.62	-0.31	1.11e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg23533926	chr12:111358616	MYL2	-0.43	-7.35	-0.34	1.03e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1595825	0.735	rs6434955	chr2:198946551	G/A	cg10547527	chr2:198650123	BOLL	-0.5	-6.71	-0.31	6.38e-11	Ulcerative colitis;
LUAD	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg01884057	chr2:25150051	NA	0.34	7.19	0.33	2.89e-12	Body mass index in non-asthmatics;
LUAD	cis	rs7264396	0.563	rs2425088	chr20:34303902	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2.04e-15	Total cholesterol levels;
LUAD	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg04476341	chr5:669733	TPPP	-0.41	-8.0	-0.36	1.18e-14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	trans	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg22153745	chr1:153894579	GATAD2B	-0.48	-7.16	-0.33	3.69e-12	Total cholesterol levels;
LUAD	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.58e-11	Depression;
LUAD	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg03690763	chr11:133734501	NA	-0.33	-7.95	-0.36	1.71e-14	Childhood ear infection;
LUAD	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.74	0.53	1.11e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-9.06	-0.4	4.86e-18	Monocyte percentage of white cells;
LUAD	cis	rs2239547	0.562	rs35380116	chr3:52979178	A/G	cg18404041	chr3:52824283	ITIH1	0.51	8.85	0.4	2.5e-17	Schizophrenia;
LUAD	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.34	-6.44	-0.3	3.29e-10	Crohn's disease;
LUAD	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg25753631	chr6:25732923	NA	-0.41	-6.75	-0.31	4.75e-11	Iron status biomarkers;
LUAD	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg21427119	chr20:30132790	HM13	-0.58	-9.28	-0.41	8.67e-19	Mean corpuscular hemoglobin;
LUAD	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg27411982	chr8:10470053	RP1L1	-0.37	-6.59	-0.31	1.29e-10	Retinal vascular caliber;
LUAD	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.75	-0.31	4.91e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg10523679	chr1:76189770	ACADM	-0.75	-11.62	-0.49	2.76e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg15557168	chr22:42548783	NA	0.37	6.76	0.31	4.65e-11	Cognitive function;
LUAD	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg11098525	chr4:1320231	MAEA	-0.39	-6.67	-0.31	8.12e-11	Obesity-related traits;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14555682	chr12:56511647	ZC3H10	-0.41	-6.75	-0.31	4.81e-11	Cancer;
LUAD	cis	rs116248771	0.739	rs73156495	chr3:158420547	C/T	cg16708174	chr3:158430962	RARRES1	0.47	6.96	0.32	1.29e-11	diarrhoeal disease at age 2;
LUAD	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg12940439	chr1:67600707	NA	0.49	9.15	0.41	2.35e-18	Psoriasis;
LUAD	cis	rs2230307	0.536	rs581097	chr1:100515920	C/T	cg20868668	chr1:100435035	SLC35A3	0.53	7.56	0.34	2.53e-13	Carotid intima media thickness;
LUAD	cis	rs6596100	0.554	rs12515756	chr5:132238880	T/C	cg14825688	chr5:132208181	LEAP2	-0.46	-6.38	-0.3	4.59e-10	Breast cancer;
LUAD	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.62	0.31	1.07e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4660306	1.000	rs6429569	chr1:46001330	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.52	-0.3	2.01e-10	Homocysteine levels;
LUAD	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg02221422	chr11:68192511	LRP5	-0.44	-7.32	-0.34	1.28e-12	Total body bone mineral density;
LUAD	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg11301795	chr4:187892539	NA	-0.75	-14.87	-0.59	1.57e-40	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg23387056	chr11:14280742	SPON1	0.46	9.64	0.42	5.26e-20	Mitochondrial DNA levels;
LUAD	cis	rs758324	0.947	rs2133707	chr5:131181280	C/T	cg25547332	chr5:131281432	NA	0.44	6.7	0.31	6.85e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg25358565	chr5:93447407	FAM172A	0.64	6.79	0.31	3.79e-11	Diabetic retinopathy;
LUAD	cis	rs349045	0.560	rs11083725	chr19:44300576	C/T	cg12072164	chr19:44306565	LYPD5	-0.39	-8.08	-0.37	6.61e-15	Reading or mathematical ability;
LUAD	cis	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg07460842	chr6:66804631	NA	0.91	12.14	0.51	2.64e-29	Exhaled nitric oxide output;
LUAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg15117754	chr3:10150083	C3orf24	-0.41	-6.86	-0.32	2.47e-11	Alzheimer's disease;
LUAD	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg01475377	chr6:109611718	NA	-0.53	-9.96	-0.44	3.93e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.58	0.3	1.37e-10	Cognitive test performance;
LUAD	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg02569458	chr12:86230093	RASSF9	0.37	7.21	0.33	2.68e-12	Major depressive disorder;
LUAD	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.58	-0.42	8.41e-20	Life satisfaction;
LUAD	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg19875535	chr5:140030758	IK	0.46	7.77	0.35	6.07e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg25319279	chr11:5960081	NA	-0.39	-6.87	-0.32	2.27e-11	DNA methylation (variation);
LUAD	cis	rs1904096	0.506	rs10034781	chr4:95169682	A/C	cg11021082	chr4:95130006	SMARCAD1	0.47	8.72	0.39	6.44e-17	Type 2 diabetes;
LUAD	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg15704280	chr7:45808275	SEPT13	-0.77	-11.94	-0.5	1.55e-28	Coronary artery disease;
LUAD	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg19875535	chr5:140030758	IK	0.46	7.71	0.35	9.21e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	3.98e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs931127	0.692	rs7934517	chr11:65445673	C/T	cg27068330	chr11:65405492	SIPA1	-0.43	-7.0	-0.32	9.97e-12	Systemic lupus erythematosus;
LUAD	cis	rs6901250	0.851	rs7740481	chr6:117149307	G/C	cg12892004	chr6:117198278	RFX6	0.34	7.36	0.34	9.64e-13	C-reactive protein levels;
LUAD	cis	rs657075	0.512	rs68115520	chr5:131589692	G/A	cg21138405	chr5:131827807	IRF1	0.46	6.67	0.31	8.02e-11	Rheumatoid arthritis;
LUAD	trans	rs1941687	0.831	rs11877286	chr18:31386764	T/C	cg27147174	chr7:100797783	AP1S1	-0.54	-9.03	-0.4	6.21e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg11247378	chr22:39784982	NA	-0.72	-13.18	-0.54	1.79e-33	Intelligence (multi-trait analysis);
LUAD	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg23992470	chr4:843637	GAK	0.67	7.1	0.33	5.29e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg06143244	chr16:22435202	RRN3P3	-0.53	-8.85	-0.4	2.48e-17	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg22907277	chr7:1156413	C7orf50	0.68	7.98	0.36	1.35e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9826463	0.527	rs112722008	chr3:142053561	A/G	cg20824294	chr3:142316082	PLS1	0.43	7.19	0.33	2.97e-12	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs73198271	0.722	rs488566	chr8:8639575	A/G	cg01851573	chr8:8652454	MFHAS1	0.41	7.4	0.34	7.17e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg01802117	chr1:53393560	SCP2	0.32	6.4	0.3	4.07e-10	Monocyte count;
LUAD	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg00255919	chr5:131827918	IRF1	0.49	11.85	0.5	3.74e-28	Asthma (sex interaction);
LUAD	cis	rs4692589	0.743	rs3806825	chr4:170948619	T/C	cg19918862	chr4:170955249	NA	0.33	7.45	0.34	5.19e-13	Anxiety disorder;
LUAD	cis	rs4862307	0.836	rs13107384	chr4:185004073	C/T	cg06737308	chr4:185021514	ENPP6	-0.54	-8.68	-0.39	8.96e-17	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg15485101	chr11:133734466	NA	0.39	8.7	0.39	7.57e-17	Childhood ear infection;
LUAD	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg06637938	chr14:75390232	RPS6KL1	0.51	8.82	0.39	3.11e-17	Caffeine consumption;
LUAD	cis	rs654950	0.875	rs2759248	chr1:41990795	T/C	cg06885757	chr1:42089581	HIVEP3	-0.34	-7.22	-0.33	2.41e-12	Airway imaging phenotypes;
LUAD	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-9.36	-0.41	4.72e-19	Alzheimer's disease;
LUAD	trans	rs4714291	0.925	rs847755	chr6:40030378	T/C	cg02267698	chr19:7991119	CTXN1	0.43	6.51	0.3	2.09e-10	Strep throat;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24441975	chr1:39339062	MYCBP	-0.56	-7.03	-0.32	8.47e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg23758822	chr17:41437982	NA	0.91	18.16	0.66	6.46e-55	Menopause (age at onset);
LUAD	cis	rs738322	0.718	rs2899297	chr22:38594668	A/G	cg25457927	chr22:38595422	NA	-0.69	-19.61	-0.69	2.34e-61	Cutaneous nevi;
LUAD	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08280861	chr8:58055591	NA	0.61	8.05	0.36	8.3e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg07755735	chr2:20870362	GDF7	-0.49	-8.84	-0.39	2.59e-17	Abdominal aortic aneurysm;
LUAD	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg09835421	chr16:68378352	PRMT7	-0.75	-8.61	-0.39	1.43e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg03859395	chr2:55845619	SMEK2	0.75	13.88	0.56	2.23e-36	Metabolic syndrome;
LUAD	cis	rs8048589	1.000	rs8048589	chr16:12185810	A/G	cg03816625	chr16:12192430	SNX29	0.54	8.1	0.37	5.97e-15	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg24829409	chr8:58192753	C8orf71	-0.58	-8.78	-0.39	3.96e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs807669	0.868	rs762529	chr22:19170205	C/G	cg02655711	chr22:19163373	SLC25A1	0.87	19.33	0.68	4.09e-60	Metabolite levels;
LUAD	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg17366294	chr4:99064904	C4orf37	0.58	9.86	0.43	8.6e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg21775007	chr8:11205619	TDH	-0.54	-9.9	-0.43	6.36e-21	Retinal vascular caliber;
LUAD	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg00310523	chr12:86230176	RASSF9	0.4	7.98	0.36	1.42e-14	Major depressive disorder;
LUAD	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg06618935	chr21:46677482	NA	-0.51	-10.32	-0.45	2.03e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg27454412	chr7:1067447	C7orf50	-0.4	-7.53	-0.34	3.19e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs9837602	1.000	rs9851645	chr3:99767409	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	9.22	0.41	1.38e-18	Breast cancer;
LUAD	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg05535760	chr7:792225	HEATR2	-0.82	-9.33	-0.41	5.87e-19	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4888262	0.526	rs8062959	chr16:74627628	T/C	cg01733217	chr16:74700730	RFWD3	0.5	8.53	0.38	2.54e-16	Testicular germ cell tumor;
LUAD	trans	rs7555117	0.794	rs2989476	chr1:61059259	C/G	cg04503457	chr17:41445688	NA	-0.42	-6.73	-0.31	5.38e-11	Facial morphology (factor 19);
LUAD	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg21963583	chr11:68658836	MRPL21	-0.57	-10.1	-0.44	1.28e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9902453	0.765	rs8071576	chr17:28188554	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	10.82	0.47	2.9e-24	Coffee consumption (cups per day);
LUAD	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg24112000	chr20:60950667	NA	-0.74	-10.45	-0.45	6.91e-23	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs8017423	0.647	rs4904674	chr14:90817412	G/A	cg14092571	chr14:90743983	NA	0.4	6.75	0.31	4.92e-11	Mortality in heart failure;
LUAD	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg07936489	chr17:37558343	FBXL20	-0.46	-7.31	-0.33	1.38e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs78487399	0.731	rs13395302	chr2:43706350	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-7.12	-0.33	4.65e-12	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg02569458	chr12:86230093	RASSF9	0.45	8.24	0.37	2.12e-15	Major depressive disorder;
LUAD	cis	rs977987	0.806	rs4887818	chr16:75361995	T/C	cg03315344	chr16:75512273	CHST6	0.62	13.72	0.55	1.11e-35	Dupuytren's disease;
LUAD	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg08859206	chr1:53392774	SCP2	0.59	10.6	0.46	1.98e-23	Monocyte count;
LUAD	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg06784218	chr1:46089804	CCDC17	0.5	11.09	0.47	2.84e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg03690763	chr11:133734501	NA	-0.29	-7.05	-0.32	7.29e-12	Childhood ear infection;
LUAD	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.78	10.41	0.45	9.75e-23	Smoking behavior;
LUAD	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg27489772	chr12:121021490	NA	0.58	7.01	0.32	9.22e-12	Type 1 diabetes nephropathy;
LUAD	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg02574844	chr11:5959923	NA	-0.43	-7.35	-0.34	1.02e-12	DNA methylation (variation);
LUAD	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg05966235	chr16:28915196	ATP2A1	0.47	7.61	0.35	1.75e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs57920188	0.584	rs12068729	chr1:4091650	A/G	cg10510935	chr1:4059661	NA	0.44	6.82	0.31	3.08e-11	Interleukin-17 levels;
LUAD	trans	rs4650994	0.789	rs2811300	chr1:178590394	T/C	cg05059571	chr16:84539110	KIAA1609	0.5	8.24	0.37	2.19e-15	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs9399401	0.667	rs34018047	chr6:142790873	G/C	cg04461802	chr6:142623433	GPR126	0.37	6.58	0.3	1.36e-10	Chronic obstructive pulmonary disease;
LUAD	cis	rs2625529	0.652	rs2415128	chr15:72191073	T/C	cg16672083	chr15:72433130	SENP8	0.65	12.11	0.51	3.46e-29	Red blood cell count;
LUAD	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.81	-0.35	4.62e-14	Resting heart rate;
LUAD	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg05182265	chr7:156933206	UBE3C	-0.82	-17.83	-0.66	1.94e-53	Body mass index;
LUAD	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg06640241	chr16:89574553	SPG7	-0.44	-7.16	-0.33	3.54e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs7737355	0.812	rs2108870	chr5:131088486	C/T	cg25547332	chr5:131281432	NA	0.43	7.03	0.32	8.16e-12	Life satisfaction;
LUAD	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg16205897	chr5:131564050	P4HA2	-0.33	-7.34	-0.34	1.13e-12	Breast cancer;
LUAD	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg10556349	chr10:835070	NA	0.46	7.15	0.33	3.8e-12	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.27e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs8073060	0.586	rs225294	chr17:33925762	G/A	cg19694781	chr19:47549865	TMEM160	-1.22	-19.67	-0.69	1.28e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg20503657	chr10:835505	NA	1.01	14.78	0.58	3.74e-40	Eosinophil percentage of granulocytes;
LUAD	cis	rs76419734	0.510	rs3943980	chr4:106676766	G/A	cg05309399	chr4:106552544	FLJ20184	0.51	6.9	0.32	1.93e-11	Post bronchodilator FEV1;
LUAD	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg19318889	chr4:1322082	MAEA	0.54	9.37	0.41	4.32e-19	Longevity;
LUAD	trans	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg04995722	chr7:26192034	NFE2L3	0.37	6.52	0.3	2.07e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7539409	0.651	rs6696140	chr1:84317468	C/T	cg10977910	chr1:84465055	TTLL7	-0.73	-8.45	-0.38	4.8e-16	Alzheimer's disease;
LUAD	trans	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg01620082	chr3:125678407	NA	-1.04	-10.33	-0.45	1.92e-22	Depression;
LUAD	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg03433033	chr1:76189801	ACADM	0.93	19.13	0.68	3.14e-59	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.3	0.37	1.4e-15	Platelet count;
LUAD	cis	rs8099014	1.000	rs4940393	chr18:56109540	C/T	cg12907477	chr18:56117327	MIR122	0.41	6.92	0.32	1.66e-11	Platelet count;
LUAD	cis	rs16854884	0.545	rs7650459	chr3:143658934	C/G	cg01302019	chr3:143689584	C3orf58	-0.42	-7.32	-0.34	1.29e-12	Economic and political preferences (feminism/equality);
LUAD	cis	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg24476569	chr13:95954382	ABCC4	-0.55	-10.4	-0.45	1e-22	Blood metabolite levels;
LUAD	cis	rs7843479	0.509	rs899428	chr8:21770763	T/C	cg03445287	chr8:21823731	XPO7	-0.44	-8.09	-0.37	6.44e-15	Mean corpuscular volume;
LUAD	cis	rs3821902	0.646	rs58627691	chr3:64015548	T/C	cg22134162	chr3:63841271	THOC7	-0.4	-6.79	-0.31	3.79e-11	Breast cancer;
LUAD	cis	rs17401966	1.000	rs17411502	chr1:10431158	T/C	cg15208524	chr1:10270712	KIF1B	0.51	7.52	0.34	3.27e-13	Hepatocellular carcinoma;
LUAD	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg08027265	chr7:2291960	NA	-0.46	-7.75	-0.35	7.13e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs752010	0.967	rs752011	chr1:42092929	C/T	cg06885757	chr1:42089581	HIVEP3	0.45	9.57	0.42	9.33e-20	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg21862992	chr11:68658383	NA	0.52	9.47	0.42	1.98e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg09455208	chr3:40491958	NA	0.65	14.42	0.57	1.23e-38	Renal cell carcinoma;
LUAD	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg23625390	chr15:77176239	SCAPER	-0.57	-9.18	-0.41	1.93e-18	Blood metabolite levels;
LUAD	cis	rs1190552	0.846	rs3783382	chr14:102965437	A/T	cg18135206	chr14:102964638	TECPR2	0.47	6.63	0.31	1.05e-10	Blood protein levels;
LUAD	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg13271783	chr10:134563150	INPP5A	-0.41	-6.78	-0.31	4.12e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03264133	chr6:25882463	NA	-0.49	-7.05	-0.32	7.25e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs12579753	0.917	rs2401002	chr12:82215870	C/T	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.88	-0.32	2.13e-11	Resting heart rate;
LUAD	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg00898013	chr13:113819073	PROZ	-0.68	-12.0	-0.5	9.66e-29	Platelet distribution width;
LUAD	cis	rs78487399	0.808	rs13417883	chr2:43700154	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-6.45	-0.3	3.15e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs12900413	0.687	rs12902809	chr15:90305617	C/G	cg24249390	chr15:90295951	MESP1	-0.35	-6.9	-0.32	1.92e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs673604	1.000	rs60037734	chr1:35679187	G/T	cg12633102	chr1:35676489	NA	-0.67	-7.7	-0.35	9.65e-14	Endometrial cancer;
LUAD	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg17724175	chr1:150552817	MCL1	0.37	8.46	0.38	4.46e-16	Melanoma;
LUAD	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	6.9	0.32	1.87e-11	Platelet count;
LUAD	cis	rs897984	0.721	rs4889525	chr16:30989858	T/C	cg02466173	chr16:30829666	NA	0.65	12.19	0.51	1.75e-29	Dementia with Lewy bodies;
LUAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.44	-7.45	-0.34	5.43e-13	Longevity;Endometriosis;
LUAD	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg22166914	chr1:53195759	ZYG11B	0.42	7.64	0.35	1.51e-13	Monocyte count;
LUAD	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg17264618	chr3:40429014	ENTPD3	0.37	8.32	0.37	1.23e-15	Renal cell carcinoma;
LUAD	cis	rs9354308	0.866	rs2814095	chr6:66535706	C/G	cg07460842	chr6:66804631	NA	0.49	7.5	0.34	3.88e-13	Metabolite levels;
LUAD	cis	rs10489202	0.657	rs3767479	chr1:168069840	C/A	cg24449463	chr1:168025552	DCAF6	-0.61	-9.22	-0.41	1.38e-18	Schizophrenia;
LUAD	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg11502198	chr6:26597334	ABT1	0.54	9.08	0.4	4.13e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs6138458	1.000	rs4273288	chr20:24900873	G/A	cg06937882	chr20:24974362	C20orf3	0.33	6.47	0.3	2.72e-10	Blood protein levels;
LUAD	cis	rs73198271	0.628	rs11776981	chr8:8589459	C/T	cg01851573	chr8:8652454	MFHAS1	0.48	6.91	0.32	1.76e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-7.38	-0.34	8.21e-13	Personality dimensions;
LUAD	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg04218760	chr10:45406644	TMEM72	-0.32	-8.23	-0.37	2.28e-15	Mean corpuscular volume;
LUAD	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.09	0.37	6.3e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs41311933	0.831	rs79516694	chr9:123766526	A/C	cg13567360	chr9:123745713	C5	-0.76	-8.78	-0.39	4.06e-17	Coronary artery disease;
LUAD	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg14019695	chr9:139328340	INPP5E	0.54	10.75	0.46	5.39e-24	Monocyte percentage of white cells;
LUAD	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg00922110	chr4:57842668	C4orf14	-0.41	-7.09	-0.33	5.63e-12	Response to bleomycin (chromatid breaks);
LUAD	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg11062466	chr8:58055876	NA	0.67	9.02	0.4	6.58e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs931812	1.000	rs4734495	chr8:101917817	C/A	cg20993868	chr7:22813445	NA	0.58	11.51	0.49	7.32e-27	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	trans	rs7395662	0.784	rs79037165	chr11:48865464	G/T	cg00717180	chr2:96193071	NA	0.39	7.41	0.34	6.95e-13	HDL cholesterol;
LUAD	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg22875332	chr1:76189707	ACADM	-0.68	-10.73	-0.46	6.68e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs13315871	1.000	rs4362735	chr3:58429893	C/G	cg20936604	chr3:58311152	NA	-0.67	-7.18	-0.33	3.14e-12	Cholesterol, total;
LUAD	cis	rs4285028	0.699	rs2689290	chr3:121585146	C/T	cg11130432	chr3:121712080	ILDR1	-0.56	-8.48	-0.38	3.84e-16	Multiple sclerosis;
LUAD	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg15691649	chr6:25882328	NA	0.44	6.94	0.32	1.44e-11	Blood metabolite levels;
LUAD	trans	rs1997103	0.954	rs6593235	chr7:55410986	A/G	cg20935933	chr6:143382018	AIG1	0.52	7.21	0.33	2.61e-12	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2882667	0.858	rs35812969	chr5:138377550	G/C	cg04439458	chr5:138467593	SIL1	-0.51	-9.12	-0.41	3.09e-18	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg00071950	chr4:10020882	SLC2A9	-0.59	-10.81	-0.47	3.12e-24	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg08601574	chr20:25228251	PYGB	0.49	8.99	0.4	8.08e-18	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs6678622	0.842	rs4949660	chr1:78025459	T/C	cg20826526	chr3:156266748	SSR3	-0.42	-6.88	-0.32	2.18e-11	Hip circumference;
LUAD	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg17845761	chr1:175162550	KIAA0040	-0.38	-9.7	-0.43	3.12e-20	Alcohol dependence;
LUAD	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg07414643	chr4:187882934	NA	0.32	6.59	0.31	1.32e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08219700	chr8:58056026	NA	0.56	7.71	0.35	8.86e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs6426551	1.000	rs7517174	chr1:226540327	A/C	cg27539482	chr13:111589090	NA	-0.49	-7.16	-0.33	3.65e-12	Coronary artery disease;
LUAD	cis	rs7177699	0.567	rs67745769	chr15:79124832	G/A	cg15571903	chr15:79123663	NA	-0.41	-8.11	-0.37	5.67e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg26924012	chr15:45694286	SPATA5L1	0.98	17.48	0.65	7e-52	Homoarginine levels;
LUAD	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg23625390	chr15:77176239	SCAPER	-0.52	-8.08	-0.37	6.91e-15	Blood metabolite levels;
LUAD	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg06026331	chr20:60912101	LAMA5	0.5	6.81	0.31	3.41e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs2637266	1.000	rs2395387	chr10:78357029	T/C	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs1003719	0.680	rs2835670	chr21:38581114	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.14	-0.37	4.62e-15	Eye color traits;
LUAD	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg03709012	chr19:19516395	GATAD2A	0.54	7.13	0.33	4.39e-12	Nonalcoholic fatty liver disease;
LUAD	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg17173187	chr15:85201210	NMB	0.4	6.57	0.3	1.45e-10	Schizophrenia;
LUAD	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg16797656	chr11:68205561	LRP5	0.45	8.62	0.39	1.34e-16	Total body bone mineral density;
LUAD	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg08847533	chr14:75593920	NEK9	0.38	6.5	0.3	2.31e-10	Height;
LUAD	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg08769276	chr4:186347048	UFSP2	-0.37	-6.77	-0.31	4.22e-11	Schizophrenia;
LUAD	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg01765077	chr12:122356316	WDR66	0.52	8.73	0.39	6.18e-17	Mean corpuscular volume;
LUAD	cis	rs17683430	0.702	rs117303909	chr22:32377614	G/A	cg02631450	chr22:32366979	NA	0.82	6.68	0.31	7.7e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LUAD	cis	rs7301826	0.967	rs4759790	chr12:131296390	T/G	cg11011512	chr12:131303247	STX2	0.38	6.61	0.31	1.19e-10	Plasma plasminogen activator levels;
LUAD	trans	rs564343	0.563	rs574335	chr11:65833266	C/T	cg26701943	chr11:108369231	KDELC2	0.49	8.13	0.37	4.73e-15	Obesity (early onset extreme);
LUAD	cis	rs999943	0.774	rs12205634	chr6:33611667	C/G	cg14003231	chr6:33640908	ITPR3	0.92	19.49	0.69	7.89e-61	Obesity (extreme);
LUAD	cis	rs13033859	0.526	rs6548221	chr2:295255	C/T	cg12623918	chr2:306882	NA	-0.41	-8.24	-0.37	2.15e-15	Mitochondrial DNA levels;
LUAD	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg05110241	chr16:68378359	PRMT7	-0.93	-10.51	-0.46	4.02e-23	Schizophrenia;
LUAD	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.59	0.31	1.3e-10	Depression;
LUAD	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg17105886	chr17:28927953	LRRC37B2	0.76	7.6	0.35	1.97e-13	Body mass index;
LUAD	cis	rs6484504	0.625	rs4922859	chr11:31382517	A/G	cg26647111	chr11:31128758	NA	0.43	7.59	0.35	2.05e-13	Red blood cell count;
LUAD	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg22532475	chr10:104410764	TRIM8	-0.46	-8.86	-0.4	2.18e-17	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs35995292	0.534	rs2008199	chr7:38939678	T/C	cg19327137	chr7:38886074	VPS41	0.78	16.63	0.63	3.75e-48	Subjective well-being (multi-trait analysis);
LUAD	cis	rs7107174	1.000	rs4945274	chr11:78109260	G/A	cg19901956	chr11:77921274	USP35	-0.47	-6.67	-0.31	8.1e-11	Testicular germ cell tumor;
LUAD	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg06740227	chr12:86229804	RASSF9	0.46	8.04	0.36	9.12e-15	Major depressive disorder;
LUAD	cis	rs9487051	0.735	rs352837	chr6:109521806	C/T	cg01475377	chr6:109611718	NA	0.4	7.67	0.35	1.18e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg13722127	chr7:150037890	RARRES2	0.47	8.38	0.38	7.87e-16	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18402987	chr7:1209562	NA	0.4	6.52	0.3	2.06e-10	Longevity;Endometriosis;
LUAD	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg05966235	chr16:28915196	ATP2A1	0.4	6.58	0.3	1.4e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs28374715	0.662	rs111522288	chr15:41480169	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.9	-16.6	-0.63	4.98e-48	Ulcerative colitis;
LUAD	cis	rs6758955	0.850	rs56261863	chr2:10480339	G/A	cg15773312	chr2:10472214	HPCAL1	-0.46	-6.81	-0.31	3.45e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg01475377	chr6:109611718	NA	-0.54	-10.46	-0.45	6.31e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg04632378	chr13:21900426	NA	0.42	7.19	0.33	2.9e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg15605315	chr1:45957053	TESK2	-0.47	-7.4	-0.34	7.25e-13	High light scatter reticulocyte count;
LUAD	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03264133	chr6:25882463	NA	-0.55	-7.88	-0.36	2.79e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19346786	chr7:2764209	NA	-0.5	-10.95	-0.47	9.83e-25	Height;
LUAD	cis	rs6758955	1.000	rs11891604	chr2:10475599	A/C	cg15773312	chr2:10472214	HPCAL1	-0.42	-6.63	-0.31	9.99e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg03929089	chr4:120376271	NA	0.58	7.46	0.34	5.08e-13	Axial length;
LUAD	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.37	7.25	0.33	2.06e-12	Neutrophil percentage of white cells;
LUAD	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg03477792	chr4:77819574	ANKRD56	0.48	7.25	0.33	1.96e-12	Emphysema distribution in smoking;
LUAD	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg02371401	chr5:676784	TPPP	-0.48	-7.81	-0.36	4.42e-14	Lung disease severity in cystic fibrosis;
LUAD	cis	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.34	-0.34	1.13e-12	Systolic blood pressure;
LUAD	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.7	-0.39	7.48e-17	Alzheimer's disease (late onset);
LUAD	cis	rs9715521	0.868	rs12650159	chr4:59818550	C/T	cg11281224	chr4:60001000	NA	-0.55	-9.38	-0.42	3.97e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg17120908	chr11:65337727	SSSCA1	0.69	11.31	0.48	4.28e-26	Bone mineral density;
LUAD	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24531977	chr5:56204891	C5orf35	1.24	20.37	0.7	8.54e-65	Initial pursuit acceleration;
LUAD	cis	rs3125734	0.633	rs3765002	chr10:64006124	G/T	cg09941381	chr10:64027924	RTKN2	-0.3	-7.07	-0.32	6.61e-12	Rheumatoid arthritis;
LUAD	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg20476274	chr7:133979776	SLC35B4	0.82	15.98	0.61	2.5e-45	Mean platelet volume;
LUAD	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg03233332	chr7:66118400	NA	-0.48	-7.24	-0.33	2.19e-12	Aortic root size;
LUAD	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg25753631	chr6:25732923	NA	-0.44	-7.76	-0.35	6.26e-14	Iron status biomarkers;
LUAD	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03517284	chr6:25882590	NA	-0.65	-9.37	-0.41	4.31e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.39	-7.15	-0.33	3.96e-12	Urate levels in overweight individuals;
LUAD	cis	rs10751667	0.621	rs7396049	chr11:1001561	G/A	cg06064525	chr11:970664	AP2A2	-0.33	-6.45	-0.3	3.15e-10	Alzheimer's disease (late onset);
LUAD	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg10356904	chr22:49881777	NA	-0.43	-8.7	-0.39	7.26e-17	Monocyte count;Monocyte percentage of white cells;
LUAD	trans	rs587242	1.000	rs12727152	chr1:96915548	G/A	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg25512537	chr17:76250053	NA	0.37	7.4	0.34	7.3e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.35	0.34	9.99e-13	Menopause (age at onset);
LUAD	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg18196295	chr10:418757	DIP2C	-0.43	-6.99	-0.32	1.11e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-8.91	-0.4	1.56e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-7.83	-0.36	4.08e-14	Neutrophil percentage of white cells;
LUAD	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg21153622	chr11:89784906	NA	-0.34	-6.6	-0.31	1.21e-10	Coronary artery disease;
LUAD	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18099408	chr3:52552593	STAB1	0.47	8.62	0.39	1.38e-16	Electroencephalogram traits;
LUAD	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg05991184	chr2:219186017	PNKD	-0.33	-6.35	-0.3	5.41e-10	Colorectal cancer;
LUAD	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg06064525	chr11:970664	AP2A2	-0.55	-11.1	-0.48	2.62e-25	Alzheimer's disease (late onset);
LUAD	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18876405	chr7:65276391	NA	-0.44	-7.09	-0.33	5.71e-12	Aortic root size;
LUAD	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg21823605	chr1:152486609	CRCT1	-0.3	-6.8	-0.31	3.68e-11	Hair morphology;
LUAD	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg18944383	chr4:111397179	ENPEP	0.38	7.67	0.35	1.23e-13	Height;
LUAD	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8112211	0.731	rs11673222	chr19:38824344	G/A	cg01275006	chr19:38876250	GGN	-0.51	-6.65	-0.31	9.19e-11	Blood protein levels;
LUAD	trans	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg15704280	chr7:45808275	SEPT13	0.66	7.45	0.34	5.44e-13	Intraocular pressure;
LUAD	cis	rs7937890	0.559	rs2597206	chr11:14477538	A/C	cg23387056	chr11:14280742	SPON1	-0.34	-6.63	-0.31	1.01e-10	Mitochondrial DNA levels;
LUAD	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg02903104	chr8:1507517	DLGAP2	0.33	7.15	0.33	3.72e-12	Lung cancer;
LUAD	cis	rs12540874	0.931	rs9791817	chr7:50661187	C/G	cg18232548	chr7:50535776	DDC	-0.55	-9.18	-0.41	1.89e-18	Systemic sclerosis;
LUAD	cis	rs6430585	0.702	rs3213890	chr2:136552188	G/A	cg07169764	chr2:136633963	MCM6	0.84	9.93	0.43	4.89e-21	Corneal structure;
LUAD	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg14582100	chr15:45693742	SPATA5L1	0.55	9.97	0.44	3.74e-21	Homoarginine levels;
LUAD	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.65	-0.35	1.4e-13	Blood metabolite levels;
LUAD	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg04287289	chr16:89883240	FANCA	0.75	6.38	0.3	4.75e-10	Skin colour saturation;
LUAD	cis	rs6430585	0.583	rs58116536	chr2:136585323	C/T	cg07169764	chr2:136633963	MCM6	0.86	10.19	0.44	5.74e-22	Corneal structure;
LUAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg11494091	chr17:61959527	GH2	0.74	18.35	0.67	9.02e-56	Prudent dietary pattern;
LUAD	cis	rs7267979	0.714	rs2474763	chr20:25241295	A/G	cg08601574	chr20:25228251	PYGB	0.45	8.35	0.38	9.69e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg27454412	chr7:1067447	C7orf50	0.44	7.07	0.33	6.35e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg23029597	chr12:123009494	RSRC2	-0.53	-8.12	-0.37	5.04e-15	Body mass index;
LUAD	cis	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg23950597	chr19:37808831	NA	-0.64	-7.57	-0.35	2.43e-13	Coronary artery calcification;
LUAD	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg07952391	chr2:88470173	THNSL2	-0.78	-8.25	-0.37	2.09e-15	Plasma clusterin levels;
LUAD	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg01689657	chr7:91764605	CYP51A1	0.34	8.5	0.38	3.39e-16	Breast cancer;
LUAD	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.95	-0.32	1.39e-11	Obesity-related traits;
LUAD	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.2	0.48	1.17e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg26875233	chr11:93583750	C11orf90	-0.4	-9.0	-0.4	7.6e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg16010596	chr6:33739607	LEMD2	-0.41	-7.47	-0.34	4.69e-13	Schizophrenia;
LUAD	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.31	0.37	1.31e-15	Rheumatoid arthritis;
LUAD	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg25985355	chr7:65971099	NA	-0.56	-6.85	-0.32	2.68e-11	Diabetic kidney disease;
LUAD	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.57	9.7	0.43	3.33e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg18811423	chr2:55921094	PNPT1	0.57	9.63	0.42	5.44e-20	Metabolic syndrome;
LUAD	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg27454412	chr7:1067447	C7orf50	-0.39	-7.76	-0.35	6.62e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	10.74	0.46	5.87e-24	Hip circumference adjusted for BMI;
LUAD	trans	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg26043149	chr18:55253948	FECH	-0.47	-7.71	-0.35	9.2e-14	Bone mineral density;
LUAD	trans	rs10411161	0.690	rs7252336	chr19:52389514	C/T	cg22319618	chr22:45562946	NUP50	-0.64	-9.14	-0.41	2.58e-18	Breast cancer;
LUAD	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg11645453	chr3:52864694	ITIH4	0.36	6.97	0.32	1.24e-11	Bipolar disorder;
LUAD	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03264133	chr6:25882463	NA	-0.56	-9.19	-0.41	1.77e-18	Blood metabolite levels;
LUAD	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg23245007	chr3:195682326	NA	-0.4	-6.65	-0.31	8.96e-11	Pancreatic cancer;
LUAD	trans	rs459571	0.959	rs465535	chr9:136910905	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.63	-9.17	-0.41	2.15e-18	Platelet distribution width;
LUAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg06092702	chr1:163392909	NA	-0.4	-9.08	-0.4	4.23e-18	Motion sickness;
LUAD	cis	rs7582720	0.778	rs6719001	chr2:203777903	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs1218582	0.772	rs2061690	chr1:154919080	C/T	cg16680214	chr1:154839983	KCNN3	-0.6	-12.06	-0.51	5.39e-29	Prostate cancer;
LUAD	cis	rs7671266	0.532	rs733175	chr4:10050141	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	7.91	0.36	2.35e-14	Cardiovascular disease risk factors;
LUAD	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg27170947	chr2:26402098	FAM59B	0.72	9.76	0.43	1.93e-20	Gut microbiome composition (summer);
LUAD	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.59	9.91	0.43	6.12e-21	Electrocardiographic conduction measures;
LUAD	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg17330251	chr7:94953956	PON1	-0.55	-7.62	-0.35	1.64e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg10518543	chr12:38710700	ALG10B	-0.43	-7.17	-0.33	3.29e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4343996	0.747	rs7457146	chr7:3465254	A/C	cg21248987	chr7:3385318	SDK1	0.37	6.84	0.32	2.74e-11	Motion sickness;
LUAD	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg17633681	chr16:88106987	BANP	0.39	6.9	0.32	1.9e-11	Menopause (age at onset);
LUAD	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg08470875	chr2:26401718	FAM59B	-0.59	-8.0	-0.36	1.18e-14	Gut microbiome composition (summer);
LUAD	cis	rs10129255	0.518	rs8004895	chr14:107193377	T/C	cg23076370	chr14:107095027	NA	-0.44	-8.72	-0.39	6.58e-17	Kawasaki disease;
LUAD	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-10.69	-0.46	9.28e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs4285028	0.948	rs13083557	chr3:121687613	G/A	cg20356878	chr3:121714668	ILDR1	-0.5	-6.76	-0.31	4.51e-11	Multiple sclerosis;
LUAD	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06505273	chr16:24850292	NA	-0.46	-6.79	-0.31	3.76e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg02782426	chr3:40428986	ENTPD3	0.36	7.66	0.35	1.26e-13	Renal cell carcinoma;
LUAD	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.59	-0.52	4.21e-31	Hip circumference adjusted for BMI;
LUAD	trans	rs853679	0.546	rs13195291	chr6:28169241	G/A	cg01620082	chr3:125678407	NA	-1.09	-10.43	-0.45	7.79e-23	Depression;
LUAD	cis	rs7493	0.901	rs17882539	chr7:95026408	G/A	cg01874867	chr7:94954059	PON1	-0.52	-7.28	-0.33	1.65e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs7395662	0.927	rs8188938	chr11:48690866	C/T	cg00717180	chr2:96193071	NA	0.35	6.49	0.3	2.37e-10	HDL cholesterol;
LUAD	cis	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg06360820	chr2:242988706	NA	-0.95	-9.91	-0.43	5.97e-21	Obesity-related traits;
LUAD	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg05340658	chr4:99064831	C4orf37	0.44	6.69	0.31	7.23e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg13393036	chr8:95962371	TP53INP1	-0.41	-9.81	-0.43	1.37e-20	Type 2 diabetes;
LUAD	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg06221963	chr1:154839813	KCNN3	-0.85	-20.47	-0.71	3.11e-65	Prostate cancer;
LUAD	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg25894440	chr7:65020034	NA	0.61	6.51	0.3	2.16e-10	Diabetic kidney disease;
LUAD	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg07606381	chr6:8435919	SLC35B3	0.4	6.64	0.31	9.76e-11	Motion sickness;
LUAD	cis	rs3743104	0.510	rs16973303	chr15:33020928	A/C	cg07179000	chr15:33023586	GREM1	-0.41	-7.45	-0.34	5.34e-13	Hypospadias;
LUAD	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.56	-0.3	1.57e-10	Breast cancer;
LUAD	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg15448220	chr1:150897856	SETDB1	0.57	9.88	0.43	7.45e-21	Melanoma;
LUAD	cis	rs4862307	0.754	rs6846208	chr4:184991703	C/T	cg06737308	chr4:185021514	ENPP6	0.51	8.32	0.37	1.25e-15	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02475777	chr4:1388615	CRIPAK	0.7	10.16	0.44	7.38e-22	Longevity;
LUAD	cis	rs17401966	0.838	rs12141246	chr1:10327407	A/T	cg15208524	chr1:10270712	KIF1B	0.45	6.98	0.32	1.17e-11	Hepatocellular carcinoma;
LUAD	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg22166914	chr1:53195759	ZYG11B	0.47	7.79	0.35	5.26e-14	Monocyte count;
LUAD	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg00255919	chr5:131827918	IRF1	0.28	6.41	0.3	3.87e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg03690763	chr11:133734501	NA	-0.34	-7.86	-0.36	3.29e-14	Childhood ear infection;
LUAD	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg18252515	chr7:66147081	NA	-0.61	-6.67	-0.31	8.16e-11	Diabetic kidney disease;
LUAD	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg14416269	chr4:6271139	WFS1	-0.57	-11.36	-0.48	2.89e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg24644049	chr4:85504048	CDS1	-0.68	-6.72	-0.31	5.72e-11	Skin colour saturation;
LUAD	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-7.05	-0.32	7.41e-12	HDL cholesterol;
LUAD	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.48e-10	Prostate cancer;
LUAD	cis	rs8044995	0.925	rs9928653	chr16:68252079	T/C	cg26727032	chr16:67993705	SLC12A4	-0.47	-7.87	-0.36	3.02e-14	Schizophrenia;
LUAD	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg19717773	chr7:2847554	GNA12	0.49	9.29	0.41	8.3e-19	Height;
LUAD	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg01849466	chr14:104193079	ZFYVE21	0.53	9.65	0.42	4.98e-20	Schizophrenia;
LUAD	trans	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-15.12	-0.59	1.35e-41	Exhaled nitric oxide output;
LUAD	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg09365446	chr1:150670422	GOLPH3L	0.54	9.61	0.42	6.71e-20	Melanoma;
LUAD	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs710865	1.000	rs710866	chr1:19568722	G/C	cg13387374	chr1:19411106	UBR4	0.41	6.79	0.31	3.9e-11	Brain structure;
LUAD	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg07362569	chr17:61921086	SMARCD2	0.37	6.39	0.3	4.28e-10	Prudent dietary pattern;
LUAD	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg19761014	chr17:28927070	LRRC37B2	0.72	6.63	0.31	1.03e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs62458065	0.640	rs10274556	chr7:32513947	A/G	cg20159608	chr7:32802032	NA	-0.62	-8.29	-0.37	1.57e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg11871910	chr12:69753446	YEATS4	0.54	8.38	0.38	7.67e-16	Blood protein levels;
LUAD	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg17105886	chr17:28927953	LRRC37B2	0.78	7.73	0.35	7.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7937890	0.559	rs2575838	chr11:14498221	C/G	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.01e-10	Mitochondrial DNA levels;
LUAD	cis	rs6969780	0.915	rs10085570	chr7:27151188	C/T	cg05579037	chr7:27184853	NA	0.44	6.64	0.31	9.86e-11	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUAD	cis	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg21775007	chr8:11205619	TDH	-0.41	-7.35	-0.34	1.02e-12	Retinal vascular caliber;
LUAD	cis	rs4604732	0.588	rs74154678	chr1:247626202	A/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.71e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9419702	0.538	rs9322837	chr10:133539229	G/A	cg04492858	chr10:133558786	NA	0.35	6.65	0.31	9.34e-11	Survival in rectal cancer;
LUAD	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg12292205	chr6:26970375	C6orf41	-0.56	-6.94	-0.32	1.46e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.31	6.62	0.31	1.1e-10	Parkinson's disease;
LUAD	cis	rs367943	0.712	rs7714734	chr5:112691261	G/A	cg12552261	chr5:112820674	MCC	0.49	9.58	0.42	8.54e-20	Type 2 diabetes;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12187437	chr12:66524584	LLPH	0.46	7.01	0.32	9.6e-12	Gut microbiome composition (summer);
LUAD	cis	rs76878669	0.606	rs2282531	chr11:66099494	C/T	cg10616300	chr11:66138557	SLC29A2	-0.32	-6.61	-0.31	1.15e-10	Educational attainment (years of education);
LUAD	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg12016809	chr21:47604291	C21orf56	0.45	7.51	0.34	3.64e-13	Testicular germ cell tumor;
LUAD	cis	rs7680126	0.596	rs10020887	chr4:10140751	C/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-7.61	-0.35	1.85e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08704250	chr15:31115839	NA	0.48	9.0	0.4	7.72e-18	Huntington's disease progression;
LUAD	cis	rs367943	0.666	rs7725589	chr5:112693366	G/A	cg21806985	chr5:112824646	MCC	0.25	6.4	0.3	4.06e-10	Type 2 diabetes;
LUAD	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg04546413	chr19:29218101	NA	-0.63	-8.15	-0.37	4.08e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs12618769	0.597	rs17031905	chr2:99070902	A/G	cg10123293	chr2:99228465	UNC50	0.44	8.21	0.37	2.63e-15	Bipolar disorder;
LUAD	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg17724175	chr1:150552817	MCL1	0.35	8.12	0.37	5.11e-15	Melanoma;
LUAD	cis	rs12681288	0.676	rs2701901	chr8:1017816	G/C	cg15309053	chr8:964076	NA	0.46	9.91	0.43	5.67e-21	Schizophrenia;
LUAD	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg03563238	chr19:33554763	RHPN2	-0.37	-8.56	-0.38	2.12e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg07362569	chr17:61921086	SMARCD2	0.39	6.74	0.31	5.12e-11	Prudent dietary pattern;
LUAD	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg11494091	chr17:61959527	GH2	0.44	8.33	0.38	1.12e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg22920501	chr2:26401640	FAM59B	0.98	15.44	0.6	5.42e-43	Gut microbiome composition (summer);
LUAD	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg01200585	chr1:228362443	C1orf69	0.46	7.51	0.34	3.48e-13	Diastolic blood pressure;
LUAD	cis	rs11771526	0.792	rs62457499	chr7:32319197	T/C	cg13207630	chr7:32358064	NA	0.62	7.48	0.34	4.36e-13	Body mass index;
LUAD	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	7.09	0.33	5.5e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23583168	chr7:148888333	NA	-0.91	-18.11	-0.66	1.11e-54	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg24154853	chr7:158122151	PTPRN2	0.58	11.71	0.49	1.26e-27	Calcium levels;
LUAD	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-7.58	-0.35	2.22e-13	Morning vs. evening chronotype;
LUAD	cis	rs7107174	1.000	rs1318241	chr11:77930792	C/T	cg02023728	chr11:77925099	USP35	0.54	8.05	0.36	8.22e-15	Testicular germ cell tumor;
LUAD	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg18876405	chr7:65276391	NA	-0.6	-10.26	-0.45	3.45e-22	Aortic root size;
LUAD	cis	rs7189233	1.000	rs62048520	chr16:53491095	C/A	cg04059762	chr16:53544020	NA	-0.4	-6.54	-0.3	1.8e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg07217954	chr7:1067459	C7orf50	0.42	6.99	0.32	1.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg08847533	chr14:75593920	NEK9	0.43	7.43	0.34	6.05e-13	Height;
LUAD	cis	rs2455601	0.744	rs7938995	chr11:8975675	T/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.43	-7.5	-0.34	3.85e-13	Schizophrenia;
LUAD	trans	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg19862616	chr7:65841803	NCRNA00174	-1.04	-25.82	-0.78	6.16e-89	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg23649088	chr2:200775458	C2orf69	-0.6	-8.33	-0.38	1.11e-15	Schizophrenia;
LUAD	cis	rs7582720	1.000	rs72932784	chr2:203698470	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.41	0.42	3.29e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs4285028	0.948	rs13083557	chr3:121687613	G/A	cg11130432	chr3:121712080	ILDR1	-0.59	-8.44	-0.38	5.05e-16	Multiple sclerosis;
LUAD	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.83	0.32	3.04e-11	Schizophrenia;
LUAD	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg17105886	chr17:28927953	LRRC37B2	0.81	7.79	0.35	5.13e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg03806693	chr22:41940476	POLR3H	0.74	9.95	0.44	4.33e-21	Vitiligo;
LUAD	cis	rs7089973	0.872	rs11818114	chr10:116634878	G/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.57	0.42	9.13e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7116495	1.000	rs7106748	chr11:71645803	A/C	cg07596299	chr11:71824057	C11orf51	-0.76	-6.69	-0.31	6.89e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg27129171	chr3:47204927	SETD2	0.41	6.5	0.3	2.32e-10	Colorectal cancer;
LUAD	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg18131467	chr2:239335373	ASB1	-0.49	-6.64	-0.31	9.63e-11	Multiple system atrophy;
LUAD	cis	rs9788682	0.747	rs2938674	chr15:78757913	C/A	cg18825076	chr15:78729989	IREB2	0.57	7.84	0.36	3.7e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs752010	0.619	rs4393146	chr1:42118766	A/G	cg06885757	chr1:42089581	HIVEP3	0.61	13.38	0.55	2.69e-34	Lupus nephritis in systemic lupus erythematosus;
LUAD	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg23505145	chr19:12996616	KLF1	-0.51	-8.15	-0.37	4.27e-15	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg14186256	chr22:23484241	RTDR1	0.46	7.85	0.36	3.39e-14	Bone mineral density;
LUAD	cis	rs17092148	0.887	rs2295443	chr20:33173827	T/C	cg16810054	chr20:33298113	TP53INP2	-0.49	-7.57	-0.35	2.33e-13	Neuroticism;
LUAD	trans	rs7944735	0.507	rs7934659	chr11:48066374	C/T	cg15704280	chr7:45808275	SEPT13	0.66	9.77	0.43	1.82e-20	Intraocular pressure;
LUAD	cis	rs7799006	0.898	rs34418140	chr7:2278183	C/T	cg12745145	chr7:2261452	MAD1L1	-0.35	-6.47	-0.3	2.78e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs9811920	0.683	rs16841874	chr3:99720564	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.5	-9.65	-0.42	4.95e-20	Axial length;
LUAD	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg08999081	chr20:33150536	PIGU	0.61	13.7	0.55	1.32e-35	Glomerular filtration rate (creatinine);
LUAD	trans	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg19894588	chr14:64061835	NA	0.52	8.1	0.37	5.98e-15	Glioblastoma;Glioma;
LUAD	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg05043794	chr9:111880884	C9orf5	-0.43	-7.45	-0.34	5.34e-13	Menarche (age at onset);
LUAD	trans	rs62458065	0.640	rs6950077	chr7:32502895	A/G	cg00845942	chr12:64062724	DPY19L2	0.55	7.6	0.35	1.98e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg11919837	chr8:57350735	NA	-0.43	-6.41	-0.3	3.98e-10	Obesity-related traits;
LUAD	trans	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg16724585	chr3:197361211	NA	-0.52	-7.7	-0.35	9.63e-14	Pancreatic cancer;
LUAD	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg15704280	chr7:45808275	SEPT13	-0.75	-10.81	-0.47	3.33e-24	Coronary artery disease;
LUAD	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg09455208	chr3:40491958	NA	0.55	12.13	0.51	2.84e-29	Renal cell carcinoma;
LUAD	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg15691649	chr6:25882328	NA	-0.45	-7.13	-0.33	4.29e-12	Blood metabolite levels;
LUAD	trans	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg06606381	chr12:133084897	FBRSL1	-0.88	-8.43	-0.38	5.63e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs55788414	0.932	rs9940186	chr16:81182199	A/T	cg06400318	chr16:81190750	PKD1L2	-0.64	-8.28	-0.37	1.61e-15	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg05872129	chr22:39784769	NA	-0.8	-14.92	-0.59	1e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg04455712	chr21:45112962	RRP1B	0.47	9.35	0.41	4.96e-19	Mean corpuscular volume;
LUAD	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg18446336	chr7:2847575	GNA12	-0.38	-7.07	-0.33	6.41e-12	Height;
LUAD	trans	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.34	-0.34	1.07e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg17147758	chr8:6949321	NA	-0.48	-8.44	-0.38	5.02e-16	Blood pressure (smoking interaction);
LUAD	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18099408	chr3:52552593	STAB1	-0.41	-7.36	-0.34	9.67e-13	Bipolar disorder;
LUAD	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg05043794	chr9:111880884	C9orf5	-0.44	-7.48	-0.34	4.28e-13	Menarche (age at onset);
LUAD	cis	rs4594175	0.926	rs7160948	chr14:51612537	T/A	cg23942311	chr14:51606299	NA	0.64	10.99	0.47	6.95e-25	Cancer;
LUAD	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg11344533	chr11:111475393	SIK2	-0.35	-6.64	-0.31	9.9e-11	Primary sclerosing cholangitis;
LUAD	cis	rs5756813	0.661	rs2246503	chr22:38204540	C/A	cg06521852	chr22:38141419	TRIOBP	0.47	8.62	0.39	1.37e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg22508957	chr16:3507546	NAT15	-0.73	-13.45	-0.55	1.46e-34	Tuberculosis;
LUAD	cis	rs1595825	0.891	rs2293255	chr2:198621506	T/C	cg00361562	chr2:198649771	BOLL	-0.47	-6.66	-0.31	8.32e-11	Ulcerative colitis;
LUAD	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg18512352	chr11:47633146	NA	-0.57	-10.11	-0.44	1.1e-21	Subjective well-being;
LUAD	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.67	-0.35	1.21e-13	Personality dimensions;
LUAD	cis	rs4642101	0.824	rs3889514	chr3:12844072	T/C	cg24848339	chr3:12840334	CAND2	0.39	7.98	0.36	1.4e-14	QRS complex (12-leadsum);
LUAD	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg15485101	chr11:133734466	NA	0.37	7.94	0.36	1.89e-14	Childhood ear infection;
LUAD	cis	rs7818345	1.000	rs11780343	chr8:19290963	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.87	0.32	2.35e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg22535103	chr8:58192502	C8orf71	-0.61	-6.6	-0.31	1.25e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg00106254	chr7:1943704	MAD1L1	-0.6	-8.76	-0.39	4.6e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs4660306	0.961	rs7539253	chr1:45947420	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-8.01	-0.36	1.11e-14	Homocysteine levels;
LUAD	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg15181151	chr6:150070149	PCMT1	0.39	7.61	0.35	1.78e-13	Lung cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27020264	chr7:86689237	KIAA1324L	-0.42	-6.67	-0.31	8.19e-11	Height;
LUAD	cis	rs7191700	0.511	rs243330	chr16:11350991	C/T	cg00044050	chr16:11439710	C16orf75	0.66	10.47	0.45	5.92e-23	Multiple sclerosis;
LUAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-9.2	-0.41	1.69e-18	Alzheimer's disease;
LUAD	cis	rs2668423	0.922	rs3826942	chr19:1360575	A/G	cg02639931	chr19:1387894	NDUFS7	0.51	8.71	0.39	6.73e-17	Nonalcoholic fatty liver disease;
LUAD	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg09491104	chr22:46646882	C22orf40	-0.64	-8.66	-0.39	9.96e-17	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg08601574	chr20:25228251	PYGB	0.41	7.58	0.35	2.26e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs3096299	0.900	rs4785666	chr16:89462771	C/G	cg01788221	chr16:89496183	ANKRD11	-0.36	-6.86	-0.32	2.41e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs4691139	0.619	rs7441550	chr4:165924312	T/A	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.42	-7.81	-0.35	4.62e-14	Ovarian cancer in BRCA1 mutation carriers;
LUAD	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21659725	chr3:3221576	CRBN	0.7	11.71	0.49	1.28e-27	Resting heart rate;
LUAD	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg24818145	chr4:99064322	C4orf37	0.47	7.35	0.34	1.05e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg08888203	chr3:10149979	C3orf24	0.63	10.69	0.46	8.73e-24	Alzheimer's disease;
LUAD	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08109568	chr15:31115862	NA	-0.67	-11.51	-0.49	7.48e-27	Huntington's disease progression;
LUAD	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg04772025	chr11:68637568	NA	0.59	9.22	0.41	1.42e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg09323728	chr8:95962352	TP53INP1	-0.32	-7.81	-0.36	4.52e-14	Type 2 diabetes;
LUAD	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg10544611	chr16:67998164	SLC12A4	-0.66	-7.57	-0.35	2.44e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg07677032	chr17:61819896	STRADA	0.57	10.52	0.46	3.84e-23	Prudent dietary pattern;
LUAD	cis	rs733175	0.794	rs10033088	chr4:10057712	G/A	cg00071950	chr4:10020882	SLC2A9	0.46	6.86	0.32	2.4e-11	Psychosis and Alzheimer's disease;
LUAD	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg18721089	chr20:30220636	NA	-0.5	-7.09	-0.33	5.77e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs2806561	0.780	rs12409321	chr1:23398065	C/T	cg19743168	chr1:23544995	NA	-0.36	-6.4	-0.3	4.09e-10	Height;
LUAD	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg15017067	chr4:17643749	FAM184B	-0.36	-6.83	-0.31	3.05e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.62	10.57	0.46	2.4e-23	Electrocardiographic conduction measures;
LUAD	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg13385794	chr1:248469461	NA	0.25	6.65	0.31	8.98e-11	Common traits (Other);
LUAD	cis	rs11048434	0.736	rs1805732	chr12:9090892	A/G	cg13575925	chr12:9217583	LOC144571	-0.39	-7.41	-0.34	6.93e-13	Sjögren's syndrome;
LUAD	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg02475777	chr4:1388615	CRIPAK	-0.52	-7.64	-0.35	1.51e-13	Obesity-related traits;
LUAD	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg10589385	chr1:150898437	SETDB1	-0.43	-8.23	-0.37	2.28e-15	Melanoma;
LUAD	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg12444411	chr7:2802554	GNA12	-0.36	-6.4	-0.3	4.18e-10	Height;
LUAD	cis	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg27411982	chr8:10470053	RP1L1	-0.38	-7.12	-0.33	4.82e-12	Neuroticism;
LUAD	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg06131755	chr6:160182447	ACAT2	0.46	6.84	0.32	2.72e-11	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.76e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg09491104	chr22:46646882	C22orf40	-0.57	-7.18	-0.33	3.16e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs68170813	0.522	rs12535814	chr7:107038432	A/T	cg23024343	chr7:107201750	COG5	0.47	6.73	0.31	5.71e-11	Coronary artery disease;
LUAD	cis	rs9796	0.621	rs28737302	chr15:41469943	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.75	-0.39	5e-17	Menopause (age at onset);
LUAD	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg09455208	chr3:40491958	NA	-0.53	-11.71	-0.49	1.31e-27	Renal cell carcinoma;
LUAD	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg21918786	chr6:109611834	NA	-0.58	-10.65	-0.46	1.24e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg19743168	chr1:23544995	NA	-0.36	-6.38	-0.3	4.56e-10	Height;
LUAD	cis	rs751728	0.931	rs2296746	chr6:33744711	C/T	cg13859433	chr6:33739653	LEMD2	-0.38	-8.75	-0.39	5e-17	Crohn's disease;
LUAD	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg12311346	chr5:56204834	C5orf35	-0.84	-10.32	-0.45	2.02e-22	Type 2 diabetes;
LUAD	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg00071950	chr4:10020882	SLC2A9	-0.59	-10.97	-0.47	8.38e-25	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg15395560	chr15:45543142	SLC28A2	0.37	6.38	0.3	4.56e-10	Uric acid levels;
LUAD	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg02734326	chr4:10020555	SLC2A9	-0.4	-6.99	-0.32	1.1e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs11048434	0.761	rs10842660	chr12:9138897	G/A	cg26114124	chr12:9217669	LOC144571	0.38	6.9	0.32	1.89e-11	Sjögren's syndrome;
LUAD	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg07636037	chr3:49044803	WDR6	0.54	10.29	0.45	2.52e-22	Menarche (age at onset);
LUAD	trans	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg04995722	chr7:26192034	NFE2L3	-0.44	-7.53	-0.34	3.19e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg04727924	chr7:799746	HEATR2	-0.54	-7.09	-0.33	5.49e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.81	0.36	4.41e-14	Platelet count;
LUAD	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg19773385	chr1:10388646	KIF1B	-0.41	-6.8	-0.31	3.68e-11	Hepatocellular carcinoma;
LUAD	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg05368731	chr17:41323189	NBR1	0.95	20.15	0.7	8.25e-64	Menopause (age at onset);
LUAD	cis	rs738322	0.533	rs5756934	chr22:38547279	G/A	cg17652424	chr22:38574118	PLA2G6	-0.27	-7.35	-0.34	1.03e-12	Cutaneous nevi;
LUAD	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg15128208	chr22:42549153	NA	-0.43	-8.81	-0.39	3.22e-17	Cognitive function;
LUAD	cis	rs7809950	1.000	rs4727684	chr7:107226470	C/T	cg23024343	chr7:107201750	COG5	-0.76	-12.37	-0.52	3.15e-30	Coronary artery disease;
LUAD	trans	rs2797160	0.547	rs4144549	chr6:125945251	C/G	cg05039488	chr6:79577232	IRAK1BP1	0.45	7.3	0.33	1.45e-12	Endometrial cancer;
LUAD	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg20628663	chr10:43360327	NA	-0.73	-11.33	-0.48	3.61e-26	Blood protein levels;
LUAD	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15541040	chr2:3486749	NA	-0.44	-7.66	-0.35	1.25e-13	Neurofibrillary tangles;
LUAD	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg10589385	chr1:150898437	SETDB1	0.45	8.44	0.38	5.11e-16	Melanoma;
LUAD	cis	rs4713675	0.546	rs9348925	chr6:33710696	C/T	cg14003231	chr6:33640908	ITPR3	0.4	7.59	0.35	2.13e-13	Plateletcrit;
LUAD	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg23649088	chr2:200775458	C2orf69	0.64	8.44	0.38	5.1e-16	Schizophrenia;
LUAD	cis	rs7582720	1.000	rs115810193	chr2:203943168	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.63	0.42	5.52e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs2692947	0.832	rs2438972	chr2:96690873	T/C	cg23100626	chr2:96804247	ASTL	0.32	8.31	0.37	1.3e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg04455712	chr21:45112962	RRP1B	0.49	9.28	0.41	8.58e-19	Mean corpuscular volume;
LUAD	cis	rs1595825	1.000	rs74935794	chr2:198871195	T/G	cg10547527	chr2:198650123	BOLL	-0.47	-6.61	-0.31	1.16e-10	Ulcerative colitis;
LUAD	cis	rs669446	0.533	rs4660261	chr1:44229597	G/A	cg12908607	chr1:44402522	ARTN	-0.36	-7.09	-0.33	5.69e-12	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs4713675	0.624	rs482786	chr6:33707599	T/C	cg18005901	chr6:33739558	LEMD2	0.45	7.17	0.33	3.42e-12	Plateletcrit;
LUAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg13560548	chr3:10150139	C3orf24	0.45	7.33	0.34	1.22e-12	Alzheimer's disease;
LUAD	cis	rs8064100	0.740	rs4482277	chr16:56726767	G/A	cg03551406	chr16:56715756	MT1X	-0.34	-6.55	-0.3	1.64e-10	Gambling;
LUAD	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg02569458	chr12:86230093	RASSF9	0.44	7.95	0.36	1.71e-14	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.38e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7216064	1.000	rs12451707	chr17:65871598	G/A	cg08758996	chr17:66097529	LOC651250	0.47	7.19	0.33	2.94e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs12586317	0.531	rs57856432	chr14:35719708	G/T	cg07166546	chr14:35805898	NA	-0.26	-6.39	-0.3	4.31e-10	Psoriasis;
LUAD	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg21427119	chr20:30132790	HM13	-0.48	-7.69	-0.35	1.07e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg15128208	chr22:42549153	NA	-0.42	-8.65	-0.39	1.05e-16	Cognitive function;
LUAD	trans	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg26043149	chr18:55253948	FECH	0.44	7.07	0.33	6.46e-12	Bone mineral density;
LUAD	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg03806693	chr22:41940476	POLR3H	-0.82	-11.48	-0.49	9.44e-27	Vitiligo;
LUAD	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.78	-13.39	-0.55	2.52e-34	Chronic sinus infection;
LUAD	cis	rs11077998	0.935	rs9893826	chr17:80511128	C/T	cg10255544	chr17:80519551	FOXK2	0.35	6.87	0.32	2.32e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg23029597	chr12:123009494	RSRC2	0.58	9.42	0.42	2.96e-19	Body mass index;
LUAD	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg02527881	chr3:46936655	PTH1R	0.45	8.83	0.39	2.81e-17	Colorectal cancer;
LUAD	trans	rs236907	0.859	rs10489252	chr1:171748145	A/T	cg13482142	chr2:234261155	NA	0.51	6.57	0.3	1.48e-10	Mean platelet volume;
LUAD	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg25753631	chr6:25732923	NA	-0.45	-7.89	-0.36	2.68e-14	Iron status biomarkers;
LUAD	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg01874867	chr7:94954059	PON1	-0.51	-6.99	-0.32	1.07e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs72772090	0.539	rs72773923	chr5:96117579	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-7.18	-0.33	3.2e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg00933542	chr6:150070202	PCMT1	0.42	9.13	0.41	2.76e-18	Lung cancer;
LUAD	cis	rs4481887	0.676	rs7527991	chr1:248527649	T/A	cg00666640	chr1:248458726	OR2T12	0.27	6.75	0.31	4.91e-11	Common traits (Other);
LUAD	cis	rs9467773	1.000	rs6456735	chr6:26574149	G/A	cg11502198	chr6:26597334	ABT1	0.62	10.14	0.44	8.61e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg20203395	chr5:56204925	C5orf35	-0.8	-9.73	-0.43	2.62e-20	Type 2 diabetes;
LUAD	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg02733842	chr7:1102375	C7orf50	-0.5	-7.67	-0.35	1.21e-13	Bronchopulmonary dysplasia;
LUAD	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.88	-0.32	2.12e-11	Neuroticism;
LUAD	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg13679303	chr9:96623674	NA	-0.39	-7.85	-0.36	3.52e-14	DNA methylation (variation);
LUAD	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg15448220	chr1:150897856	SETDB1	-0.45	-7.17	-0.33	3.35e-12	Blood protein levels;
LUAD	cis	rs7903847	0.642	rs11189175	chr10:99139609	T/C	cg20016023	chr10:99160130	RRP12	-0.3	-7.19	-0.33	2.97e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs853679	0.546	rs34871267	chr6:28364232	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.6	6.85	0.32	2.57e-11	Depression;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg00184235	chr8:126442434	TRIB1	-0.4	-7.13	-0.33	4.29e-12	Schizophrenia;
LUAD	cis	rs11166629	1.000	rs2315838	chr8:135645968	C/T	cg27224718	chr8:135614730	ZFAT	0.59	10.46	0.45	6.54e-23	Smoking quantity;
LUAD	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg06064525	chr11:970664	AP2A2	-0.56	-11.72	-0.5	1.13e-27	Alzheimer's disease (late onset);
LUAD	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg03806693	chr22:41940476	POLR3H	0.72	10.12	0.44	1.08e-21	Vitiligo;
LUAD	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg05340658	chr4:99064831	C4orf37	-0.46	-7.02	-0.32	8.98e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.68	0.31	7.71e-11	Depression;
LUAD	cis	rs2971970	0.519	rs10230628	chr7:133633133	G/A	cg03336402	chr7:133662267	EXOC4	0.39	7.08	0.33	6.12e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs8040855	0.599	rs2342123	chr15:85725149	C/G	cg04831495	chr15:85060580	GOLGA6L5	-0.45	-7.8	-0.35	4.96e-14	Bulimia nervosa;
LUAD	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.47	-7.5	-0.34	3.81e-13	Total body bone mineral density;
LUAD	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg10729496	chr3:10149963	C3orf24	0.57	9.51	0.42	1.49e-19	Alzheimer's disease;
LUAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg12432903	chr7:1882776	MAD1L1	-0.44	-7.2	-0.33	2.69e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs4988958	0.527	rs6756161	chr2:103048417	C/A	cg03938978	chr2:103052716	IL18RAP	0.46	10.49	0.45	4.89e-23	Asthma (childhood onset);
LUAD	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg12419862	chr22:24373484	LOC391322	-0.71	-12.53	-0.52	7.18e-31	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs7395662	0.892	rs9667579	chr11:48730148	C/T	cg15704280	chr7:45808275	SEPT13	0.43	6.75	0.31	5.04e-11	HDL cholesterol;
LUAD	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg11494091	chr17:61959527	GH2	0.42	8.04	0.36	9.3e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg03929089	chr4:120376271	NA	0.56	7.09	0.33	5.6e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4588572	0.570	rs6453389	chr5:77727003	T/G	cg11547950	chr5:77652471	NA	-0.64	-10.85	-0.47	2.24e-24	Triglycerides;
LUAD	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg03948781	chr1:205179583	DSTYK	0.33	6.45	0.3	3.09e-10	Red blood cell count;
LUAD	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06873352	chr17:61820015	STRADA	0.51	8.41	0.38	6.48e-16	Height;
LUAD	trans	rs9354308	0.899	rs1938059	chr6:66539291	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.52	8.05	0.36	8.61e-15	Metabolite levels;
LUAD	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg13180566	chr4:1052158	NA	-0.4	-6.86	-0.32	2.4e-11	Recombination rate (females);
LUAD	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg18512352	chr11:47633146	NA	-0.54	-9.7	-0.43	3.31e-20	Subjective well-being;
LUAD	trans	rs1493916	1.000	rs9964702	chr18:31390427	A/C	cg15819921	chr19:927150	ARID3A	-0.44	-7.21	-0.33	2.62e-12	Life satisfaction;
LUAD	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg18827107	chr12:86230957	RASSF9	-0.49	-8.54	-0.38	2.53e-16	Major depressive disorder;
LUAD	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	7.38	0.34	8.43e-13	Platelet count;
LUAD	cis	rs926938	0.521	rs360649	chr1:115439668	G/C	cg12756093	chr1:115239321	AMPD1	0.38	6.48	0.3	2.49e-10	Autism;
LUAD	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg05709478	chr1:6581295	PLEKHG5	-0.57	-7.36	-0.34	9.77e-13	Body mass index;
LUAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg00166722	chr3:10149974	C3orf24	0.63	10.39	0.45	1.17e-22	Alzheimer's disease;
LUAD	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg13722127	chr7:150037890	RARRES2	0.45	7.66	0.35	1.25e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg15226275	chr6:116381976	FRK	0.24	7.29	0.33	1.57e-12	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs4523957	0.928	rs216179	chr17:2168878	T/A	cg16513277	chr17:2031491	SMG6	0.77	14.68	0.58	1.02e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg11189052	chr15:85197271	WDR73	-0.6	-9.94	-0.44	4.72e-21	P wave terminal force;
LUAD	cis	rs72772090	0.634	rs17402639	chr5:96107005	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.45	-0.34	5.19e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg27432699	chr2:27873401	GPN1	0.58	10.33	0.45	1.91e-22	Oral cavity cancer;
LUAD	cis	rs11048434	0.761	rs12827988	chr12:9130287	A/G	cg04155231	chr12:9217510	LOC144571	0.41	7.62	0.35	1.66e-13	Sjögren's syndrome;
LUAD	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03264133	chr6:25882463	NA	-0.6	-8.85	-0.4	2.41e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs10746514	0.833	rs11122428	chr1:232261417	A/G	cg09506761	chr1:232265262	NA	-0.38	-7.07	-0.32	6.56e-12	Response to statin therapy;
LUAD	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	7.28	0.33	1.66e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs4604732	0.678	rs74154674	chr1:247625685	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg06784218	chr1:46089804	CCDC17	-0.53	-11.59	-0.49	3.67e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6908034	0.505	rs76709285	chr6:19804330	C/G	cg02682789	chr6:19804855	NA	0.95	9.37	0.41	4.34e-19	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg18932078	chr1:2524107	MMEL1	0.38	7.13	0.33	4.42e-12	Ulcerative colitis;
LUAD	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	7.94	0.36	1.9e-14	Breast cancer;
LUAD	trans	rs9951602	0.512	rs1599636	chr18:76643916	G/A	cg02800362	chr5:177631904	HNRNPAB	0.92	14.18	0.57	1.25e-37	Obesity-related traits;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06096994	chr13:41635664	WBP4	-0.59	-7.33	-0.34	1.17e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg01874867	chr7:94954059	PON1	-0.48	-6.48	-0.3	2.49e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.54	0.34	2.9e-13	Bipolar disorder;
LUAD	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg10729496	chr3:10149963	C3orf24	0.48	7.89	0.36	2.55e-14	Alzheimer's disease;
LUAD	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg24733560	chr20:60626293	TAF4	0.47	9.21	0.41	1.55e-18	Body mass index;
LUAD	cis	rs1595825	0.891	rs58111212	chr2:198889896	T/C	cg10547527	chr2:198650123	BOLL	-0.51	-6.99	-0.32	1.09e-11	Ulcerative colitis;
LUAD	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg24154853	chr7:158122151	PTPRN2	0.58	11.47	0.49	1.06e-26	Calcium levels;
LUAD	cis	rs2019216	1.000	rs3751916	chr17:21909270	T/C	cg05591447	chr17:21909280	FLJ36000	-0.3	-7.87	-0.36	3.11e-14	Pelvic organ prolapse;
LUAD	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg12310025	chr6:25882481	NA	0.56	9.01	0.4	7.03e-18	Blood metabolite levels;
LUAD	cis	rs4631830	0.869	rs11006207	chr10:51538176	T/C	cg20129853	chr10:51489980	NA	-0.34	-6.84	-0.32	2.73e-11	Prostate-specific antigen levels;
LUAD	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs751837	0.591	rs34407983	chr14:103429786	T/C	cg10087771	chr14:103399429	CDC42BPB	0.64	7.18	0.33	3.07e-12	Large B-cell lymphoma;
LUAD	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.94	0.53	1.73e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg00631329	chr6:26305371	NA	-0.72	-13.73	-0.56	1.01e-35	Educational attainment;
LUAD	cis	rs6907340	0.517	rs9465533	chr6:19801708	C/A	cg02682789	chr6:19804855	NA	0.44	6.69	0.31	7.31e-11	Endometriosis;
LUAD	cis	rs11677370	0.603	rs10171309	chr2:3851690	C/T	cg17052675	chr2:3827356	NA	-0.6	-10.33	-0.45	1.92e-22	Type 2 diabetes;
LUAD	trans	rs7395662	0.724	rs10400308	chr11:48891246	G/T	cg15704280	chr7:45808275	SEPT13	-0.4	-6.35	-0.3	5.58e-10	HDL cholesterol;
LUAD	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg24450063	chr1:156163899	SLC25A44	1.05	17.15	0.64	1.87e-50	Testicular germ cell tumor;
LUAD	cis	rs6740322	0.895	rs6711966	chr2:43561989	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-10.67	-0.46	1.05e-23	Coronary artery disease;
LUAD	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg22535103	chr8:58192502	C8orf71	-0.56	-7.29	-0.33	1.54e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg18190219	chr22:46762943	CELSR1	-0.44	-6.35	-0.3	5.4e-10	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg19862616	chr7:65841803	NCRNA00174	1.06	27.31	0.8	2.21e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1232027	0.616	rs6151632	chr5:79966679	T/C	cg24059623	chr5:79951536	MSH3;DHFR	-0.44	-7.33	-0.34	1.16e-12	Huntington's disease progression;
LUAD	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.68	-10.38	-0.45	1.22e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.55	0.3	1.71e-10	Depression;
LUAD	cis	rs9522267	0.535	rs2039915	chr13:112238794	C/T	cg10483660	chr13:112241077	NA	-0.33	-7.05	-0.32	7.17e-12	Hepatitis;
LUAD	cis	rs873917	0.577	rs784611	chr1:40125988	T/A	cg06209491	chr1:40138402	NT5C1A	-0.5	-7.33	-0.34	1.16e-12	Amyotrophic lateral sclerosis;
LUAD	cis	rs6840360	0.593	rs6847844	chr4:152693246	C/T	cg22705602	chr4:152727874	NA	-0.48	-9.18	-0.41	1.86e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.7	0.31	6.81e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.43	-0.34	5.88e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg06784218	chr1:46089804	CCDC17	-0.6	-13.5	-0.55	8.61e-35	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7119038	0.818	rs6421571	chr11:118743772	T/C	cg19308663	chr11:118741387	NA	-0.58	-8.68	-0.39	8.61e-17	Sjögren's syndrome;
LUAD	cis	rs28595532	0.920	rs17258050	chr4:119672019	G/A	cg02775129	chr4:119771670	NA	-0.99	-7.97	-0.36	1.49e-14	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg24818145	chr4:99064322	C4orf37	0.47	7.95	0.36	1.71e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg13010199	chr12:38710504	ALG10B	-0.39	-6.45	-0.3	3.02e-10	Morning vs. evening chronotype;
LUAD	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg20891283	chr12:69753455	YEATS4	0.43	7.07	0.32	6.55e-12	Blood protein levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03939875	chr1:46016565	AKR1A1	-0.55	-6.73	-0.31	5.58e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg12292205	chr6:26970375	C6orf41	0.53	9.16	0.41	2.33e-18	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9653442	0.704	rs10211595	chr2:100726476	G/C	cg22139774	chr2:100720529	AFF3	-0.38	-7.46	-0.34	4.9e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg25834613	chr7:1915315	MAD1L1	-0.4	-6.51	-0.3	2.1e-10	Bipolar disorder;
LUAD	cis	rs9522267	0.535	rs9515452	chr13:112234553	A/G	cg10483660	chr13:112241077	NA	-0.32	-6.9	-0.32	1.93e-11	Hepatitis;
LUAD	cis	rs13315871	1.000	rs71311868	chr3:58392874	A/G	cg12435725	chr3:58293450	RPP14	-0.69	-7.33	-0.34	1.15e-12	Cholesterol, total;
LUAD	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg14343924	chr8:8086146	FLJ10661	0.45	7.05	0.32	7.45e-12	Mood instability;
LUAD	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg08470875	chr2:26401718	FAM59B	-0.6	-8.2	-0.37	2.96e-15	Gut microbiome composition (summer);
LUAD	cis	rs2882667	0.858	rs7724108	chr5:138410922	A/G	cg04439458	chr5:138467593	SIL1	0.47	8.7	0.39	7.21e-17	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs62103177	0.535	rs34299914	chr18:77949236	C/A	cg05926928	chr17:57297772	GDPD1	0.64	7.33	0.34	1.16e-12	Opioid sensitivity;
LUAD	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg08859206	chr1:53392774	SCP2	-0.68	-12.83	-0.53	4.58e-32	Monocyte count;
LUAD	cis	rs6969780	0.915	rs12666919	chr7:27189498	A/T	cg05579037	chr7:27184853	NA	0.49	6.57	0.3	1.51e-10	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUAD	cis	rs10979	0.597	rs9496687	chr6:143908815	A/G	cg25407410	chr6:143891975	LOC285740	-0.55	-7.53	-0.34	3.18e-13	Hypospadias;
LUAD	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg10755058	chr3:40428713	ENTPD3	0.35	6.66	0.31	8.76e-11	Renal cell carcinoma;
LUAD	cis	rs8177876	0.642	rs4324143	chr16:81114988	G/C	cg08591886	chr16:81111003	C16orf46	-0.79	-7.37	-0.34	8.94e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	7.2	0.33	2.8e-12	Colorectal cancer;
LUAD	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23158103	chr7:148848205	ZNF398	-0.64	-10.77	-0.46	4.65e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs3960554	0.600	rs2302429	chr7:75614777	G/A	cg19862616	chr7:65841803	NCRNA00174	0.7	9.42	0.42	3.07e-19	Eotaxin levels;
LUAD	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg03859395	chr2:55845619	SMEK2	-0.49	-7.61	-0.35	1.81e-13	Metabolic syndrome;
LUAD	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg20587970	chr11:113659929	NA	-1.43	-20.63	-0.71	5.95e-66	Hip circumference adjusted for BMI;
LUAD	cis	rs10193935	0.605	rs10169492	chr2:42401961	G/T	cg27598129	chr2:42591480	NA	-0.78	-10.07	-0.44	1.54e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7542375	0.655	rs11590376	chr1:221086484	G/A	cg16008148	chr1:221062819	NA	0.41	6.49	0.3	2.35e-10	Obesity-related traits;
LUAD	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg21171335	chr12:122356390	WDR66	0.78	14.29	0.57	4.52e-38	Mean corpuscular volume;
LUAD	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg22823121	chr1:150693482	HORMAD1	0.44	8.9	0.4	1.69e-17	Tonsillectomy;
LUAD	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg22166914	chr1:53195759	ZYG11B	0.45	7.84	0.36	3.66e-14	Monocyte count;
LUAD	cis	rs2046867	0.908	rs62251639	chr3:72801214	G/A	cg04365224	chr3:72788183	NA	-0.46	-6.96	-0.32	1.29e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg07404485	chr7:94953653	PON1	-0.52	-7.3	-0.33	1.43e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs240764	0.717	rs1039031	chr6:101161812	A/G	cg13741871	chr11:14541914	PSMA1	-0.35	-6.58	-0.3	1.4e-10	Neuroticism;
LUAD	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg24848339	chr3:12840334	CAND2	0.44	9.05	0.4	5.41e-18	P wave duration;
LUAD	trans	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.07	-27.3	-0.8	2.41e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg05110241	chr16:68378359	PRMT7	-0.8	-8.88	-0.4	1.91e-17	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs6921919	0.789	rs6912584	chr6:28309590	T/C	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.19	-0.33	2.95e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg15112475	chr7:1198522	ZFAND2A	-0.48	-9.65	-0.42	4.89e-20	Longevity;Endometriosis;
LUAD	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	8.44	0.38	5.03e-16	Parkinson's disease;
LUAD	cis	rs6684514	1.000	rs12134983	chr1:156290409	T/C	cg16558208	chr1:156270281	VHLL	0.53	9.78	0.43	1.71e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-7.89	-0.36	2.7e-14	Renal function-related traits (BUN);
LUAD	cis	rs6546550	0.803	rs10165883	chr2:70117015	C/T	cg02498382	chr2:70120550	SNRNP27	-0.6	-11.47	-0.49	1.06e-26	Prevalent atrial fibrillation;
LUAD	cis	rs11153730	0.503	rs4946336	chr6:118632335	A/C	cg18833306	chr6:118973337	C6orf204	0.51	9.21	0.41	1.57e-18	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg17105886	chr17:28927953	LRRC37B2	0.66	7.69	0.35	1.03e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg18198730	chr1:247681584	NA	0.43	7.42	0.34	6.27e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg25324976	chr17:61989376	CSHL1	0.38	7.4	0.34	7.27e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg04450456	chr4:17643702	FAM184B	0.37	6.9	0.32	1.93e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg19862616	chr7:65841803	NCRNA00174	1.06	27.22	0.8	5.29e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg10518543	chr12:38710700	ALG10B	0.42	6.43	0.3	3.47e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg03983476	chr2:10830698	NOL10	0.48	8.46	0.38	4.28e-16	Prostate cancer;
LUAD	trans	rs984440	0.542	rs7815305	chr8:139083637	T/C	cg03334052	chr1:168888044	NA	0.43	7.15	0.33	3.76e-12	Obesity-related traits;
LUAD	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg18129748	chr3:49941408	MST1R	0.41	6.58	0.3	1.36e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7107174	1.000	rs2256187	chr11:77919768	G/A	cg02023728	chr11:77925099	USP35	0.56	8.38	0.38	7.88e-16	Testicular germ cell tumor;
LUAD	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.7	0.39	7.29e-17	Menopause (age at onset);
LUAD	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg00106254	chr7:1943704	MAD1L1	-0.58	-8.52	-0.38	2.82e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg04025307	chr7:1156635	C7orf50	0.51	6.72	0.31	5.97e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg06627628	chr2:24431161	ITSN2	-0.55	-9.11	-0.4	3.37e-18	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06544989	chr22:39130855	UNC84B	0.42	7.88	0.36	2.89e-14	Menopause (age at onset);
LUAD	cis	rs8067545	0.641	rs203457	chr17:19818338	A/C	cg04132472	chr17:19861366	AKAP10	-0.39	-9.44	-0.42	2.63e-19	Schizophrenia;
LUAD	cis	rs12824058	0.737	rs873663	chr12:130816316	C/T	cg23887609	chr12:130822674	PIWIL1	0.4	6.64	0.31	9.87e-11	Menopause (age at onset);
LUAD	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.32e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10193935	0.901	rs6752455	chr2:42543577	A/C	cg27598129	chr2:42591480	NA	-0.75	-9.63	-0.42	5.7e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg20607798	chr8:58055168	NA	0.72	9.44	0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg27446573	chr6:127587934	RNF146	0.4	6.39	0.3	4.46e-10	Breast cancer;
LUAD	trans	rs7395662	1.000	rs12419576	chr11:48581644	T/C	cg15704280	chr7:45808275	SEPT13	-0.42	-6.56	-0.3	1.54e-10	HDL cholesterol;
LUAD	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.56	8.7	0.39	7.42e-17	Renal function-related traits (BUN);
LUAD	cis	rs4888262	0.507	rs9888976	chr16:74580924	C/T	cg01733217	chr16:74700730	RFWD3	0.49	8.37	0.38	8.36e-16	Testicular germ cell tumor;
LUAD	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18876405	chr7:65276391	NA	0.42	6.63	0.31	1.03e-10	Aortic root size;
LUAD	cis	rs6840360	0.571	rs17360385	chr4:152587970	C/A	cg22705602	chr4:152727874	NA	-0.41	-6.99	-0.32	1.06e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg17063962	chr7:91808500	NA	0.67	11.92	0.5	1.89e-28	Breast cancer;
LUAD	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	11.31	0.48	4.35e-26	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs790123	0.965	rs2133850	chr3:122381696	C/T	cg17380795	chr3:122379686	NA	0.47	7.87	0.36	3.05e-14	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg00204512	chr16:28754710	NA	0.31	6.72	0.31	5.73e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-20.46	-0.71	3.39e-65	Height;
LUAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg13047869	chr3:10149882	C3orf24	0.59	10.04	0.44	1.99e-21	Alzheimer's disease;
LUAD	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg02574844	chr11:5959923	NA	-0.4	-6.88	-0.32	2.15e-11	DNA methylation (variation);
LUAD	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg17911788	chr17:44343683	NA	-0.51	-7.1	-0.33	5.19e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs17092148	1.000	rs1884431	chr20:33338585	G/A	cg16810054	chr20:33298113	TP53INP2	-0.52	-8.25	-0.37	2.04e-15	Neuroticism;
LUAD	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg00631329	chr6:26305371	NA	0.69	13.65	0.55	2.04e-35	Educational attainment;
LUAD	trans	rs2262909	0.962	rs11673195	chr19:22313814	T/C	cg05197062	chr11:11642011	GALNTL4	0.6	9.3	0.41	7.59e-19	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg23950597	chr19:37808831	NA	-0.62	-7.59	-0.35	2.09e-13	Coronary artery calcification;
LUAD	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	6.93	0.32	1.58e-11	Menarche (age at onset);
LUAD	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg08999081	chr20:33150536	PIGU	0.61	14.06	0.56	4.18e-37	Coronary artery disease;
LUAD	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg06618935	chr21:46677482	NA	-0.51	-10.17	-0.44	6.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg00981070	chr1:2046702	PRKCZ	0.36	7.75	0.35	6.96e-14	Height;
LUAD	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.78e-19	Life satisfaction;
LUAD	cis	rs2235642	0.701	rs2281230	chr16:1601767	T/C	cg09065629	chr16:1709722	CRAMP1L	0.42	7.02	0.32	8.76e-12	Coronary artery disease;
LUAD	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.03	-0.4	6.17e-18	Total body bone mineral density;
LUAD	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg20503657	chr10:835505	NA	0.81	12.26	0.51	8.73e-30	Eosinophil percentage of granulocytes;
LUAD	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg00280220	chr17:61926910	NA	0.36	6.89	0.32	2.08e-11	Prudent dietary pattern;
LUAD	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg02869364	chr7:1081709	C7orf50	-0.5	-6.43	-0.3	3.45e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.47	0.3	2.73e-10	Menarche (age at onset);
LUAD	cis	rs57920188	0.535	rs12129515	chr1:4094101	G/A	cg10510935	chr1:4059661	NA	0.45	6.87	0.32	2.31e-11	Interleukin-17 levels;
LUAD	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.79	15.49	0.6	3.28e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg25535316	chr11:579198	PHRF1	-0.38	-6.67	-0.31	7.81e-11	Systemic lupus erythematosus;
LUAD	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.4	0.45	1.01e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg07217954	chr7:1067459	C7orf50	0.43	6.59	0.3	1.34e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8014204	0.806	rs11159105	chr14:75298052	C/T	cg06637938	chr14:75390232	RPS6KL1	0.39	7.17	0.33	3.37e-12	Caffeine consumption;
LUAD	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.37	-6.43	-0.3	3.38e-10	Caffeine consumption;
LUAD	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg11062466	chr8:58055876	NA	0.66	8.64	0.39	1.2e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.45	-8.9	-0.4	1.71e-17	Longevity;Endometriosis;
LUAD	cis	rs8130944	0.828	rs4920134	chr21:44111151	T/C	cg16784985	chr21:44105474	PDE9A	-0.39	-6.67	-0.31	8.15e-11	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg11189052	chr15:85197271	WDR73	0.57	6.95	0.32	1.43e-11	Schizophrenia;
LUAD	trans	rs11039798	1.000	rs7928243	chr11:48589192	A/T	cg15704280	chr7:45808275	SEPT13	0.65	7.68	0.35	1.13e-13	Axial length;
LUAD	cis	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.84	-0.36	3.64e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02018176	chr4:1364513	KIAA1530	-0.64	-10.69	-0.46	8.99e-24	Longevity;
LUAD	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg12140854	chr5:148520817	ABLIM3	-0.67	-10.53	-0.46	3.54e-23	Breast cancer;
LUAD	cis	rs7523050	0.643	rs35520362	chr1:109419841	C/T	cg08274380	chr1:109419600	GPSM2	0.71	6.57	0.3	1.49e-10	Fat distribution (HIV);
LUAD	cis	rs57994353	0.897	rs11999532	chr9:139371405	G/C	cg14364472	chr9:139394549	NOTCH1	-0.45	-6.79	-0.31	3.88e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs501916	0.714	rs11854427	chr15:48047421	G/A	cg16110827	chr15:48056943	SEMA6D	-0.42	-6.94	-0.32	1.44e-11	Inflammatory bowel disease;Ulcerative colitis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26631144	chr8:30670260	PPP2CB	-0.47	-6.43	-0.3	3.54e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.93	0.43	4.88e-21	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg01689657	chr7:91764605	CYP51A1	0.32	7.96	0.36	1.63e-14	Breast cancer;
LUAD	trans	rs17689437	0.671	rs1728793	chr16:68602693	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.41	6.52	0.3	1.99e-10	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LUAD	cis	rs2281845	0.929	rs2057579	chr1:201099275	T/C	cg17810781	chr1:201082982	CACNA1S	0.36	6.37	0.3	4.93e-10	Permanent tooth development;
LUAD	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg01851573	chr8:8652454	MFHAS1	0.36	6.8	0.31	3.66e-11	Neuroticism;
LUAD	cis	rs739496	0.744	rs848130	chr12:112009831	G/A	cg10833066	chr12:111807467	FAM109A	0.38	6.37	0.3	4.8e-10	Platelet count;
LUAD	cis	rs12200560	0.505	rs211182	chr6:97074513	G/A	cg06623918	chr6:96969491	KIAA0776	0.47	7.3	0.33	1.41e-12	Coronary heart disease;
LUAD	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg07212818	chr11:638076	DRD4	-0.46	-6.8	-0.31	3.47e-11	Systemic lupus erythematosus;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04915425	chr11:47236385	DDB2	-0.46	-7.33	-0.34	1.2e-12	Height;
LUAD	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg00204512	chr16:28754710	NA	0.3	6.35	0.3	5.43e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11890956	chr21:40555474	PSMG1	-0.61	-10.14	-0.44	8.96e-22	Cognitive function;
LUAD	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg04111992	chr7:158790115	NA	0.4	7.16	0.33	3.66e-12	Facial morphology (factor 20);
LUAD	cis	rs31872	0.520	rs246053	chr5:140326290	T/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.64	-0.31	9.74e-11	Visceral adipose tissue adjusted for BMI;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg25782835	chr3:101443325	CEP97	0.4	6.5	0.3	2.32e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg21545522	chr1:205238299	TMCC2	0.39	7.24	0.33	2.13e-12	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs11048434	0.723	rs2080117	chr12:9138341	C/T	cg04155231	chr12:9217510	LOC144571	0.41	7.69	0.35	1.01e-13	Sjögren's syndrome;
LUAD	cis	rs3784262	0.669	rs12915508	chr15:58302036	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.4	-7.81	-0.36	4.41e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg02079420	chr8:82753780	SNX16	0.42	8.48	0.38	3.85e-16	Diastolic blood pressure;
LUAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg13560548	chr3:10150139	C3orf24	0.41	6.93	0.32	1.56e-11	Alzheimer's disease;
LUAD	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg00717180	chr2:96193071	NA	-0.4	-7.39	-0.34	7.68e-13	HDL cholesterol;
LUAD	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24531977	chr5:56204891	C5orf35	-0.85	-12.89	-0.53	2.69e-32	Initial pursuit acceleration;
LUAD	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg03929089	chr4:120376271	NA	-0.53	-7.9	-0.36	2.46e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg25894440	chr7:65020034	NA	-0.63	-6.7	-0.31	6.72e-11	Diabetic kidney disease;
LUAD	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.51	-0.38	3.12e-16	Gut microbiome composition (summer);
LUAD	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg02782426	chr3:40428986	ENTPD3	0.4	9.07	0.4	4.54e-18	Renal cell carcinoma;
LUAD	cis	rs9581857	0.547	rs9579087	chr13:28059780	G/A	cg22138327	chr13:27999177	GTF3A	0.82	9.14	0.41	2.73e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg02734326	chr4:10020555	SLC2A9	-0.43	-7.38	-0.34	8.57e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24531977	chr5:56204891	C5orf35	-0.97	-15.04	-0.59	2.8e-41	Initial pursuit acceleration;
LUAD	cis	rs7945718	0.935	rs1609442	chr11:12795418	T/A	cg25843174	chr11:12811716	TEAD1	0.26	7.87	0.36	2.94e-14	Educational attainment (years of education);
LUAD	cis	rs12472274	0.941	rs11677230	chr2:239092054	T/C	cg17459225	chr2:239074497	NA	0.7	9.57	0.42	9.31e-20	Phospholipid levels (plasma);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15144697	chr2:201935974	NDUFB3;FAM126B	-0.43	-6.54	-0.3	1.76e-10	Height;
LUAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg04025307	chr7:1156635	C7orf50	0.6	6.78	0.31	3.97e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg24675056	chr1:15929824	NA	0.49	8.45	0.38	4.66e-16	Systolic blood pressure;
LUAD	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg12119029	chr16:89752879	CDK10	0.32	6.6	0.31	1.21e-10	Vitiligo;
LUAD	cis	rs7843479	1.000	rs2054711	chr8:21818060	A/G	cg03445287	chr8:21823731	XPO7	-0.46	-8.58	-0.39	1.79e-16	Mean corpuscular volume;
LUAD	cis	rs1055129	0.584	rs9895947	chr17:73908566	A/C	cg19302996	chr17:73780495	UNK	-0.4	-6.75	-0.31	4.75e-11	White matter hyperintensity burden;
LUAD	cis	rs2066819	1.000	rs79718165	chr12:56644251	C/T	cg26714650	chr12:56694279	CS	-0.84	-7.16	-0.33	3.49e-12	Psoriasis vulgaris;
LUAD	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg06766960	chr11:133703094	NA	0.37	7.18	0.33	3.22e-12	Childhood ear infection;
LUAD	trans	rs2288327	0.557	rs7577862	chr2:179352857	G/A	cg14011486	chr1:26737247	LIN28	0.56	7.57	0.35	2.44e-13	Atrial fibrillation;
LUAD	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.3	-0.37	1.38e-15	Height;
LUAD	cis	rs9535307	0.929	rs1407441	chr13:50290990	T/C	cg04663916	chr13:50265991	EBPL	0.58	6.82	0.31	3.1e-11	Obesity-related traits;
LUAD	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.02	-0.4	6.56e-18	Total body bone mineral density;
LUAD	cis	rs6696239	0.531	rs3010195	chr1:227794709	T/C	cg12133451	chr1:227746453	NA	-0.36	-6.39	-0.3	4.32e-10	Height;
LUAD	cis	rs2625529	0.730	rs2957737	chr15:72265410	A/G	cg16672083	chr15:72433130	SENP8	0.68	12.37	0.52	3.16e-30	Red blood cell count;
LUAD	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg04036182	chr15:45458818	NA	-0.39	-6.69	-0.31	7.19e-11	Response to fenofibrate (adiponectin levels);
LUAD	trans	rs208520	0.909	rs62414639	chr6:67023706	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	10.57	0.46	2.43e-23	Exhaled nitric oxide output;
LUAD	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg10560079	chr2:191398806	TMEM194B	-0.48	-6.49	-0.3	2.35e-10	Diastolic blood pressure;
LUAD	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg14343924	chr8:8086146	FLJ10661	0.45	7.08	0.33	5.93e-12	Neuroticism;
LUAD	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg21724239	chr8:58056113	NA	0.71	9.31	0.41	6.92e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg23262073	chr20:60523788	NA	-0.46	-7.38	-0.34	8.43e-13	Body mass index;
LUAD	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg27539214	chr16:67997921	SLC12A4	-0.64	-7.86	-0.36	3.28e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg02527881	chr3:46936655	PTH1R	0.45	8.98	0.4	8.88e-18	Colorectal cancer;
LUAD	cis	rs68170813	0.605	rs75659533	chr7:107134987	A/G	cg23024343	chr7:107201750	COG5	0.5	6.86	0.32	2.39e-11	Coronary artery disease;
LUAD	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06221963	chr1:154839813	KCNN3	-0.86	-20.33	-0.7	1.39e-64	Prostate cancer;
LUAD	cis	rs77861329	0.748	rs352152	chr3:52210700	A/C	cg08692210	chr3:52188851	WDR51A	-0.56	-6.88	-0.32	2.14e-11	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs7149337	0.809	rs10134478	chr14:51693708	G/C	cg23942311	chr14:51606299	NA	0.85	18.98	0.68	1.52e-58	Cancer;
LUAD	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg15128208	chr22:42549153	NA	0.43	6.71	0.31	6.24e-11	Birth weight;
LUAD	cis	rs250677	0.522	rs6875902	chr5:148407893	C/A	cg18129178	chr5:148520854	ABLIM3	-0.58	-8.22	-0.37	2.54e-15	Breast cancer;
LUAD	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg21385522	chr1:16154831	NA	-0.57	-9.11	-0.4	3.37e-18	Systolic blood pressure;
LUAD	cis	rs10791323	0.517	rs1120246	chr11:133745212	G/A	cg03690763	chr11:133734501	NA	-0.29	-6.92	-0.32	1.69e-11	Childhood ear infection;
LUAD	cis	rs2880765	0.835	rs4360874	chr15:86040820	A/T	cg13263323	chr15:86062960	AKAP13	-0.5	-9.21	-0.41	1.56e-18	Coronary artery disease;
LUAD	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg18131467	chr2:239335373	ASB1	0.65	11.04	0.47	4.67e-25	Multiple system atrophy;
LUAD	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.4	-6.51	-0.3	2.16e-10	Rheumatoid arthritis;
LUAD	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	trans	rs10838798	0.523	rs11039543	chr11:48168103	G/A	cg21153622	chr11:89784906	NA	-0.34	-6.75	-0.31	4.82e-11	Height;
LUAD	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06022373	chr22:39101656	GTPBP1	0.42	6.53	0.3	1.92e-10	Menopause (age at onset);
LUAD	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.46	0.52	1.4e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg19302996	chr17:73780495	UNK	-0.43	-6.53	-0.3	1.89e-10	Psoriasis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03205495	chr19:14640249	TECR;MIR639	-0.41	-6.39	-0.3	4.26e-10	Height;
LUAD	trans	rs78049276	0.568	rs10305839	chr4:148400413	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.62	-7.07	-0.33	6.36e-12	Pulse pressure;
LUAD	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg20203395	chr5:56204925	C5orf35	0.62	9.46	0.42	2.11e-19	Initial pursuit acceleration;
LUAD	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.73	10.6	0.46	1.99e-23	Smoking behavior;
LUAD	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg18827107	chr12:86230957	RASSF9	0.54	9.7	0.43	3.32e-20	Major depressive disorder;
LUAD	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg05340658	chr4:99064831	C4orf37	-0.43	-6.78	-0.31	4.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs71403859	0.502	rs36122765	chr16:71504183	G/C	cg08717414	chr16:71523259	ZNF19	-0.61	-7.47	-0.34	4.75e-13	Post bronchodilator FEV1;
LUAD	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg05043794	chr9:111880884	C9orf5	-0.4	-6.95	-0.32	1.36e-11	Menarche (age at onset);
LUAD	cis	rs2637266	0.756	rs2583064	chr10:78557708	A/G	cg18941641	chr10:78392320	NA	0.31	6.41	0.3	3.94e-10	Pulmonary function;
LUAD	trans	rs208520	0.690	rs864314	chr6:66814830	G/T	cg08225398	chr13:45563328	KIAA1704;NUFIP1	0.77	8.74	0.39	5.59e-17	Exhaled nitric oxide output;
LUAD	cis	rs35883536	0.967	rs9434126	chr1:101106981	A/G	cg06223162	chr1:101003688	GPR88	-0.39	-7.28	-0.33	1.67e-12	Monocyte count;
LUAD	cis	rs2908197	0.843	rs2961040	chr7:75946763	A/C	cg24580635	chr7:76178542	LOC100133091	-0.42	-6.48	-0.3	2.52e-10	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg23625390	chr15:77176239	SCAPER	-0.54	-8.28	-0.37	1.68e-15	Blood metabolite levels;
LUAD	cis	rs807669	0.903	rs1780642	chr22:19170604	T/C	cg24911827	chr22:19170109	CLTCL1	0.46	9.59	0.42	7.99e-20	Metabolite levels;
LUAD	cis	rs7267979	1.000	rs11087520	chr20:25436827	C/T	cg08601574	chr20:25228251	PYGB	0.46	8.52	0.38	2.83e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg15467112	chr14:75489610	MLH3	-0.36	-6.71	-0.31	6.46e-11	Height;
LUAD	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18876405	chr7:65276391	NA	0.41	6.54	0.3	1.81e-10	Aortic root size;
LUAD	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg11618577	chr2:27665543	KRTCAP3	-0.26	-6.78	-0.31	4.15e-11	Menopause (age at onset);
LUAD	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg24733560	chr20:60626293	TAF4	0.47	8.18	0.37	3.39e-15	Body mass index;
LUAD	cis	rs4711350	0.765	rs2182658	chr6:33748831	G/T	cg13859433	chr6:33739653	LEMD2	0.34	7.27	0.33	1.7e-12	Schizophrenia;
LUAD	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg26597838	chr10:835615	NA	0.52	8.32	0.37	1.26e-15	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7617773	0.817	rs6801801	chr3:48326433	T/C	cg11946769	chr3:48343235	NME6	0.43	6.73	0.31	5.5e-11	Coronary artery disease;
LUAD	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg07606381	chr6:8435919	SLC35B3	0.41	6.8	0.31	3.57e-11	Motion sickness;
LUAD	cis	rs3821902	0.646	rs17344723	chr3:64019808	G/A	cg22134162	chr3:63841271	THOC7	-0.43	-7.09	-0.33	5.79e-12	Breast cancer;
LUAD	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22968622	chr17:43663579	NA	-1.2	-20.1	-0.7	1.51e-63	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg24069376	chr3:38537580	EXOG	0.45	10.92	0.47	1.27e-24	Electrocardiographic conduction measures;
LUAD	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg26513180	chr16:89883248	FANCA	0.79	6.88	0.32	2.2e-11	Skin colour saturation;
LUAD	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg22665089	chr10:97320867	SORBS1	-0.4	-6.6	-0.31	1.24e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7771547	0.603	rs6913530	chr6:36598209	A/G	cg07856975	chr6:36356162	ETV7	-0.54	-7.39	-0.34	7.72e-13	Platelet distribution width;
LUAD	cis	rs62238980	0.614	rs976916	chr22:32428558	G/A	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.63	0.31	1.01e-10	Prudent dietary pattern;
LUAD	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-8.67	-0.39	9.24e-17	Platelet count;
LUAD	cis	rs12530845	1.000	rs6979391	chr7:135328873	C/T	cg23117316	chr7:135346802	PL-5283	-0.5	-9.26	-0.41	1e-18	Red blood cell traits;
LUAD	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.37	6.63	0.31	1.03e-10	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs4853525	1.000	rs4853525	chr2:191737464	T/C	cg11845111	chr2:191398756	TMEM194B	-0.41	-6.78	-0.31	4.02e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	trans	rs3774749	0.565	rs6800021	chr3:50190346	G/A	cg21659725	chr3:3221576	CRBN	0.5	8.14	0.37	4.43e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2485376	1.000	rs1541049	chr10:103997084	A/C	cg20641465	chr10:103991465	PITX3	0.55	9.86	0.43	8.61e-21	QT interval;
LUAD	cis	rs16958440	0.867	rs9304342	chr18:44720199	T/G	cg17192377	chr18:44677553	HDHD2	0.84	8.05	0.36	8.31e-15	Sitting height ratio;
LUAD	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-7.73	-0.35	8.04e-14	Lung cancer;
LUAD	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg03609598	chr5:56110824	MAP3K1	0.47	6.94	0.32	1.5e-11	Initial pursuit acceleration;
LUAD	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23158103	chr7:148848205	ZNF398	-0.67	-12.48	-0.52	1.17e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.04	-15.41	-0.6	7.97e-43	Schizophrenia;
LUAD	cis	rs10203711	0.966	rs4663939	chr2:239569867	C/A	cg14580085	chr2:239553406	NA	0.42	9.02	0.4	6.82e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7493	0.950	rs11981299	chr7:95029701	T/A	cg20119798	chr7:94954144	PON1	-0.48	-6.46	-0.3	2.88e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.02	-0.53	7.82e-33	Breast cancer;
LUAD	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg22532475	chr10:104410764	TRIM8	0.34	6.96	0.32	1.31e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.53	-8.8	-0.39	3.6e-17	Primary sclerosing cholangitis;
LUAD	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg01868782	chr6:126071099	HEY2	0.31	6.37	0.3	5.03e-10	Brugada syndrome;
LUAD	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.61	0.49	3.2e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg06784218	chr1:46089804	CCDC17	-0.34	-7.37	-0.34	9.28e-13	Red blood cell count;Reticulocyte count;
LUAD	cis	rs11112613	0.713	rs60865625	chr12:105940256	A/C	cg03607813	chr12:105948248	NA	0.79	12.57	0.52	5.37e-31	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs807669	0.903	rs807666	chr22:19160549	C/T	cg02655711	chr22:19163373	SLC25A1	0.89	19.62	0.69	2.07e-61	Metabolite levels;
LUAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg11494091	chr17:61959527	GH2	0.74	18.32	0.67	1.27e-55	Prudent dietary pattern;
LUAD	cis	rs420259	0.516	rs11643602	chr16:23556909	G/A	cg00143387	chr16:23521605	GGA2	-0.73	-10.04	-0.44	1.97e-21	Bipolar disorder;
LUAD	cis	rs1865721	1.000	rs7244787	chr18:73195162	T/C	cg26385618	chr18:73139727	C18orf62	-0.41	-7.46	-0.34	4.82e-13	Intelligence;
LUAD	cis	rs758324	0.812	rs4705840	chr5:131206624	C/T	cg25547332	chr5:131281432	NA	0.42	6.84	0.32	2.7e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg00383909	chr3:49044727	WDR6	0.98	10.41	0.45	9.61e-23	Cognitive function;
LUAD	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg24531977	chr5:56204891	C5orf35	-0.4	-6.5	-0.3	2.3e-10	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.41	7.57	0.35	2.36e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3925075	0.531	rs4594268	chr16:31343243	T/C	cg10451425	chr16:31478370	ARMC5	0.4	6.47	0.3	2.64e-10	IgA nephropathy;
LUAD	cis	rs208520	0.874	rs208473	chr6:66917265	G/C	cg07460842	chr6:66804631	NA	-0.97	-14.02	-0.56	5.91e-37	Exhaled nitric oxide output;
LUAD	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg01191920	chr7:158217561	PTPRN2	-0.58	-12.02	-0.5	8.13e-29	Obesity-related traits;
LUAD	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg01528321	chr10:82214614	TSPAN14	0.46	7.29	0.33	1.53e-12	Post bronchodilator FEV1;
LUAD	cis	rs250677	0.958	rs10056942	chr5:148416114	C/A	cg18129178	chr5:148520854	ABLIM3	-0.57	-8.61	-0.39	1.5e-16	Breast cancer;
LUAD	cis	rs2835872	0.758	rs1709833	chr21:39037805	C/T	cg06728970	chr21:39037746	KCNJ6	-0.39	-7.61	-0.35	1.84e-13	Electroencephalographic traits in alcoholism;
LUAD	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg12140854	chr5:148520817	ABLIM3	-0.62	-9.63	-0.42	5.52e-20	Breast cancer;
LUAD	cis	rs13394619	0.655	rs7578132	chr2:11718858	C/T	cg07314298	chr2:11723111	GREB1	-0.45	-8.53	-0.38	2.6e-16	Endometriosis;
LUAD	trans	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg18335740	chr13:41363409	SLC25A15	0.62	11.47	0.49	1.04e-26	Lewy body disease;
LUAD	cis	rs2425143	1.000	rs6060591	chr20:34351476	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.6	-0.35	1.96e-13	Blood protein levels;
LUAD	cis	rs4953076	0.573	rs7593987	chr2:44393532	C/T	cg04920474	chr2:44395004	PPM1B	-0.56	-8.82	-0.39	2.96e-17	Height;
LUAD	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg05182265	chr7:156933206	UBE3C	-0.8	-17.24	-0.64	8.1e-51	Body mass index;
LUAD	cis	rs11051970	0.589	rs325426	chr12:32535815	C/A	cg24626660	chr12:32551988	NA	0.31	6.59	0.31	1.29e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg17173187	chr15:85201210	NMB	0.41	6.61	0.31	1.14e-10	Schizophrenia;
LUAD	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg03929089	chr4:120376271	NA	-0.96	-19.3	-0.68	5.58e-60	Height;
LUAD	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-9.99	-0.44	3.05e-21	Migraine;Coronary artery disease;
LUAD	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg22920501	chr2:26401640	FAM59B	0.98	13.36	0.54	3.17e-34	Gut microbiome composition (summer);
LUAD	cis	rs977987	0.735	rs166013	chr16:75434146	C/T	cg03315344	chr16:75512273	CHST6	-0.66	-14.35	-0.57	2.46e-38	Dupuytren's disease;
LUAD	cis	rs7640424	0.628	rs7628325	chr3:107816314	G/A	cg09227934	chr3:107805635	CD47	-0.68	-10.62	-0.46	1.58e-23	Body mass index;
LUAD	cis	rs9326248	0.520	rs7127881	chr11:116880798	G/A	cg20608306	chr11:116969690	SIK3	0.29	6.57	0.3	1.48e-10	Blood protein levels;
LUAD	cis	rs4713675	0.584	rs9368776	chr6:33696405	A/G	cg14003231	chr6:33640908	ITPR3	0.48	9.29	0.41	8.14e-19	Plateletcrit;
LUAD	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg17178900	chr1:205818956	PM20D1	0.84	19.25	0.68	9.65e-60	Menarche (age at onset);
LUAD	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg27539214	chr16:67997921	SLC12A4	-0.71	-9.15	-0.41	2.37e-18	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg04995722	chr7:26192034	NFE2L3	-0.41	-7.11	-0.33	4.84e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg25324976	chr17:61989376	CSHL1	0.35	6.96	0.32	1.29e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24110768	chr12:58159478	CYP27B1	-0.44	-7.58	-0.35	2.18e-13	Cancer;
LUAD	cis	rs7833986	0.501	rs72653962	chr8:56997505	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	1.02	18.08	0.66	1.43e-54	Height;
LUAD	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg17333051	chr19:2783644	SGTA	0.48	7.4	0.34	7.63e-13	Total cholesterol levels;
LUAD	cis	rs3845702	0.736	rs3845701	chr2:180826781	A/G	cg01881094	chr2:180872142	CWC22	-0.74	-7.99	-0.36	1.31e-14	Schizophrenia;
LUAD	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg21775007	chr8:11205619	TDH	0.46	8.2	0.37	2.92e-15	Retinal vascular caliber;
LUAD	cis	rs72928364	1.000	rs62275825	chr3:100758710	C/T	cg10123952	chr3:100791384	NA	0.69	8.34	0.38	1.03e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg24558204	chr6:135376177	HBS1L	0.43	7.62	0.35	1.63e-13	Red blood cell count;
LUAD	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg27588902	chr6:42928151	GNMT	-0.36	-9.51	-0.42	1.51e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs754466	0.580	rs2289309	chr10:79571108	C/T	cg17075019	chr10:79541650	NA	-0.92	-20.05	-0.7	2.36e-63	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.21e-16	Prostate cancer;
LUAD	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg16606324	chr3:10149918	C3orf24	0.63	10.1	0.44	1.2e-21	Alzheimer's disease;
LUAD	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg07936489	chr17:37558343	FBXL20	-0.46	-7.34	-0.34	1.08e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs231513	0.911	rs231511	chr17:41966335	T/C	cg26893861	chr17:41843967	DUSP3	-0.66	-7.53	-0.34	3.15e-13	Cognitive function;
LUAD	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg27068330	chr11:65405492	SIPA1	-0.78	-12.77	-0.53	8.18e-32	Acne (severe);
LUAD	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg01191920	chr7:158217561	PTPRN2	-0.75	-16.96	-0.64	1.35e-49	Obesity-related traits;
LUAD	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9322817	0.691	rs6929746	chr6:105167548	G/C	cg02098413	chr6:105308735	HACE1	-0.4	-8.67	-0.39	9.59e-17	Thyroid stimulating hormone;
LUAD	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg00475322	chr7:917719	C7orf20	0.51	7.26	0.33	1.89e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs7818345	0.967	rs35029660	chr8:19308126	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.89	0.32	1.97e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg03342759	chr3:160939853	NMD3	-0.46	-6.57	-0.3	1.49e-10	Parkinson's disease;
LUAD	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg00933542	chr6:150070202	PCMT1	0.41	8.64	0.39	1.2e-16	Lung cancer;
LUAD	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg02269571	chr22:50332266	NA	0.58	8.66	0.39	9.81e-17	Schizophrenia;
LUAD	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	13.39	0.55	2.53e-34	Lung cancer in ever smokers;
LUAD	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg22963979	chr7:1858916	MAD1L1	-0.58	-10.06	-0.44	1.77e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg17372223	chr3:52568218	NT5DC2	-0.38	-6.98	-0.32	1.18e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	trans	rs877282	0.898	rs11253338	chr10:759559	C/T	cg22713356	chr15:30763199	NA	1.14	15.5	0.6	3.27e-43	Uric acid levels;
LUAD	cis	rs4588572	0.688	rs1594055	chr5:77695088	G/A	cg11547950	chr5:77652471	NA	-0.64	-10.95	-0.47	9.53e-25	Triglycerides;
LUAD	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg18827107	chr12:86230957	RASSF9	0.67	12.66	0.52	2.34e-31	Major depressive disorder;
LUAD	trans	rs7246760	0.867	rs1820114	chr19:9805692	G/A	cg02900749	chr2:68251473	NA	-0.6	-6.64	-0.31	9.55e-11	Pursuit maintenance gain;
LUAD	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg18230493	chr5:56204884	C5orf35	-0.5	-8.07	-0.37	7.27e-15	Coronary artery disease;
LUAD	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg03563238	chr19:33554763	RHPN2	-0.37	-8.56	-0.38	2.12e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs208520	0.909	rs9345809	chr6:67017543	T/C	cg07460842	chr6:66804631	NA	0.85	9.97	0.44	3.63e-21	Exhaled nitric oxide output;
LUAD	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg03474202	chr17:45855739	NA	-0.39	-8.41	-0.38	6.58e-16	IgG glycosylation;
LUAD	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.48	-0.34	4.31e-13	Type 2 diabetes;
LUAD	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.35	-7.45	-0.34	5.46e-13	Hemoglobin concentration;
LUAD	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg02002194	chr4:3960332	NA	-0.31	-7.45	-0.34	5.43e-13	Morning vs. evening chronotype;
LUAD	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg04117972	chr1:227635322	NA	0.78	6.46	0.3	2.89e-10	Major depressive disorder;
LUAD	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg13271783	chr10:134563150	INPP5A	-0.41	-7.2	-0.33	2.76e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg16486109	chr11:613632	IRF7	0.49	8.15	0.37	4.18e-15	Systemic lupus erythematosus;
LUAD	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg12863693	chr15:85201151	NMB	-0.35	-6.54	-0.3	1.74e-10	Schizophrenia;
LUAD	cis	rs6558530	0.692	rs6558525	chr8:1702523	A/G	cg19131313	chr8:1704013	NA	-0.42	-6.48	-0.3	2.63e-10	Systolic blood pressure;
LUAD	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.51	-0.38	3.02e-16	Alzheimer's disease (late onset);
LUAD	cis	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg05084668	chr3:125655381	ALG1L	-0.45	-6.81	-0.31	3.43e-11	Blood pressure (smoking interaction);
LUAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg10729496	chr3:10149963	C3orf24	0.64	9.56	0.42	9.9e-20	Alzheimer's disease;
LUAD	trans	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg26043149	chr18:55253948	FECH	0.43	7.03	0.32	8.56e-12	Bone mineral density;
LUAD	cis	rs2625529	0.617	rs8025939	chr15:72460339	T/A	cg16672083	chr15:72433130	SENP8	0.65	12.15	0.51	2.47e-29	Red blood cell count;
LUAD	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg04800585	chr6:26043546	HIST1H2BB	-0.49	-8.37	-0.38	8.26e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg10589385	chr1:150898437	SETDB1	0.43	8.17	0.37	3.71e-15	Melanoma;
LUAD	cis	rs36051895	0.695	rs10815147	chr9:5016145	C/T	cg02405213	chr9:5042618	JAK2	-0.48	-6.64	-0.31	9.5e-11	Pediatric autoimmune diseases;
LUAD	cis	rs9768139	0.935	rs62480865	chr7:158122307	A/C	cg25566285	chr7:158114605	PTPRN2	-0.55	-11.76	-0.5	8.08e-28	Calcium levels;
LUAD	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14159672	chr1:205819179	PM20D1	0.52	9.41	0.42	3.22e-19	Menarche (age at onset);
LUAD	cis	rs9467773	0.967	rs1321482	chr6:26575154	T/C	cg11502198	chr6:26597334	ABT1	0.61	10.06	0.44	1.76e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.51	-7.9	-0.36	2.35e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg18230493	chr5:56204884	C5orf35	-0.87	-12.62	-0.52	3.35e-31	Initial pursuit acceleration;
LUAD	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14893161	chr1:205819251	PM20D1	0.52	8.92	0.4	1.47e-17	Menarche (age at onset);
LUAD	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg02527881	chr3:46936655	PTH1R	-0.69	-16.06	-0.62	1.19e-45	Birth weight;
LUAD	cis	rs7536201	1.000	rs10794667	chr1:25304552	C/T	cg23273869	chr1:25296894	NA	-0.34	-6.84	-0.32	2.7e-11	Psoriasis vulgaris;
LUAD	cis	rs4948275	0.530	rs2393853	chr10:63167688	C/G	cg02461363	chr10:63212496	TMEM26	-0.36	-7.65	-0.35	1.36e-13	Night sleep phenotypes;
LUAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14159672	chr1:205819179	PM20D1	0.49	7.7	0.35	9.77e-14	Parkinson's disease;
LUAD	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg04703951	chr17:43578652	NA	0.62	8.59	0.39	1.7e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg06618935	chr21:46677482	NA	-0.49	-9.88	-0.43	7.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs72799341	1.000	rs72799341	chr16:30936743	G/A	cg02466173	chr16:30829666	NA	-0.61	-9.08	-0.4	4.1e-18	Diastolic blood pressure;
LUAD	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00149659	chr3:10157352	C3orf10	0.58	7.56	0.34	2.6e-13	Alzheimer's disease;
LUAD	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg22676075	chr6:135203613	NA	0.41	7.49	0.34	3.93e-13	Red blood cell count;
LUAD	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg01256987	chr12:42539512	GXYLT1	-0.34	-6.64	-0.31	9.41e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg19346786	chr7:2764209	NA	-0.49	-10.49	-0.45	4.78e-23	Height;
LUAD	cis	rs16958440	0.867	rs16948928	chr18:44675821	C/T	cg17192377	chr18:44677553	HDHD2	0.92	8.78	0.39	3.97e-17	Sitting height ratio;
LUAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg23131131	chr22:24373011	LOC391322	-0.62	-10.87	-0.47	1.91e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9462027	0.628	rs9462020	chr6:34751265	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.0	-0.4	7.78e-18	Systemic lupus erythematosus;
LUAD	cis	rs921968	0.565	rs11896209	chr2:219599268	C/T	cg02176678	chr2:219576539	TTLL4	-0.58	-11.69	-0.49	1.45e-27	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.71	-11.78	-0.5	6.47e-28	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs3540	0.960	rs8030299	chr15:91026459	G/A	cg10434728	chr15:90938212	IQGAP1	0.36	6.69	0.31	7.29e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs7000551	0.715	rs2461477	chr8:22378314	A/G	cg12081754	chr8:22256438	SLC39A14	0.46	7.62	0.35	1.73e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg05182265	chr7:156933206	UBE3C	-0.8	-17.38	-0.65	1.98e-51	Body mass index;
LUAD	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg17200465	chr3:40428508	ENTPD3	0.27	6.83	0.32	2.88e-11	Renal cell carcinoma;
LUAD	cis	rs2637266	1.000	rs10219021	chr10:78364516	C/T	cg18941641	chr10:78392320	NA	0.34	7.18	0.33	3.12e-12	Pulmonary function;
LUAD	cis	rs28595532	0.748	rs72670249	chr4:119336823	G/T	cg21605333	chr4:119757512	SEC24D	0.69	6.75	0.31	4.86e-11	Cannabis dependence symptom count;
LUAD	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg13319975	chr6:146136371	FBXO30	-0.55	-9.21	-0.41	1.51e-18	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs11088226	1.000	rs2833890	chr21:33927886	A/G	cg09050820	chr6:167586206	TCP10L2	-0.59	-8.46	-0.38	4.47e-16	Gastritis;
LUAD	cis	rs4242434	0.689	rs4872006	chr8:22536502	T/C	cg03733263	chr8:22462867	KIAA1967	-0.63	-10.5	-0.45	4.34e-23	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08137080	chr1:16482430	EPHA2	-0.61	-6.47	-0.3	2.76e-10	Type 2 diabetes;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg26393983	chr18:2571747	NDC80;METTL4	0.42	6.38	0.3	4.62e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs2663905	0.611	rs2663920	chr15:81396404	A/G	cg22872349	chr15:81410745	NA	-0.37	-6.52	-0.3	2.04e-10	QT interval (drug interaction);
LUAD	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg23985595	chr17:80112537	CCDC57	0.53	9.6	0.42	7.27e-20	Life satisfaction;
LUAD	trans	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg21659725	chr3:3221576	CRBN	0.38	6.49	0.3	2.4e-10	Resting heart rate;
LUAD	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg03467027	chr4:99064603	C4orf37	0.43	6.97	0.32	1.26e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg17366294	chr4:99064904	C4orf37	0.65	12.6	0.52	3.82e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg27102117	chr16:15229624	NA	0.45	8.16	0.37	3.95e-15	Triglycerides;
LUAD	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg01416388	chr22:39784598	NA	-0.55	-9.32	-0.41	6.59e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg24829409	chr8:58192753	C8orf71	-0.64	-9.56	-0.42	1.02e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg18252515	chr7:66147081	NA	0.62	6.89	0.32	2.03e-11	Diabetic kidney disease;
LUAD	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.84	9.48	0.42	1.88e-19	Initial pursuit acceleration;
LUAD	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg06740227	chr12:86229804	RASSF9	-0.41	-7.25	-0.33	2.03e-12	Major depressive disorder;
LUAD	cis	rs12900413	0.562	rs28557101	chr15:90298149	C/T	cg24249390	chr15:90295951	MESP1	-0.35	-6.83	-0.32	3.01e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs89107	0.543	rs72952795	chr6:118894271	G/T	cg21191810	chr6:118973309	C6orf204	0.39	7.08	0.33	6.19e-12	Cardiac structure and function;
LUAD	cis	rs68170813	0.559	rs61406169	chr7:106903421	A/T	cg23024343	chr7:107201750	COG5	0.44	6.45	0.3	3.1e-10	Coronary artery disease;
LUAD	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg27411982	chr8:10470053	RP1L1	0.38	6.88	0.32	2.2e-11	Neuroticism;
LUAD	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg13736514	chr6:26305472	NA	0.68	13.22	0.54	1.28e-33	Educational attainment;
LUAD	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.91	-0.4	1.51e-17	Total body bone mineral density;
LUAD	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg17366294	chr4:99064904	C4orf37	0.71	13.37	0.54	3.05e-34	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg12740337	chr6:28058973	ZSCAN12L1	0.26	6.57	0.3	1.51e-10	Cardiac Troponin-T levels;
LUAD	trans	rs9393777	0.720	rs13217285	chr6:26999845	C/T	cg06606381	chr12:133084897	FBRSL1	-0.95	-9.55	-0.42	1.02e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-8.69	-0.39	8.33e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-7.29	-0.33	1.53e-12	Morning vs. evening chronotype;
LUAD	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06022373	chr22:39101656	GTPBP1	0.46	7.15	0.33	3.72e-12	Menopause (age at onset);
LUAD	cis	rs72634501	0.542	rs2134472	chr1:39603214	T/G	cg27567593	chr1:39956653	BMP8A	0.36	7.01	0.32	9.7e-12	HDL cholesterol;
LUAD	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg14202850	chr17:43974869	MAPT;LOC100130148	0.38	6.36	0.3	5.18e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs73416724	1.000	rs17209407	chr6:43358362	A/G	cg26312998	chr6:43337775	ZNF318	0.56	7.11	0.33	5.08e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-6.78	-0.31	3.98e-11	Bronchopulmonary dysplasia;
LUAD	trans	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.46	-7.07	-0.33	6.33e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg25456477	chr12:86230367	RASSF9	0.32	6.35	0.3	5.43e-10	Major depressive disorder;
LUAD	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg22963979	chr7:1858916	MAD1L1	-0.52	-8.71	-0.39	6.67e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs1493916	0.748	rs7230463	chr18:31309133	G/C	cg27147174	chr7:100797783	AP1S1	-0.62	-10.76	-0.46	4.96e-24	Life satisfaction;
LUAD	cis	rs8072100	0.807	rs4561509	chr17:45781799	G/A	cg25173405	chr17:45401733	C17orf57	-0.5	-8.41	-0.38	6.17e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12122100	0.837	rs6681167	chr1:146506862	C/T	cg03526459	chr1:146549940	NA	0.36	6.8	0.31	3.54e-11	HIV-1 control;
LUAD	cis	rs9902453	0.967	rs55748380	chr17:28469782	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	8.5	0.38	3.23e-16	Coffee consumption (cups per day);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02488887	chr5:176830915	F12	-0.45	-7.0	-0.32	9.92e-12	Height;
LUAD	cis	rs2996428	0.709	rs7527973	chr1:3704041	C/T	cg18436788	chr1:3704244	LRRC47	0.33	6.91	0.32	1.79e-11	Red cell distribution width;
LUAD	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.21	-0.33	2.55e-12	Lung cancer;
LUAD	cis	rs2282300	0.739	rs1631451	chr11:30349133	G/C	cg25418670	chr11:30344373	C11orf46	-0.51	-6.85	-0.32	2.57e-11	Morning vs. evening chronotype;
LUAD	cis	rs12541635	1.000	rs7817197	chr8:107089633	T/G	cg10147462	chr8:107024639	NA	-0.42	-7.51	-0.34	3.53e-13	Age of smoking initiation;
LUAD	cis	rs6445967	0.530	rs12633937	chr3:58333637	C/T	cg13750441	chr3:58318267	PXK	0.32	6.68	0.31	7.73e-11	Platelet count;
LUAD	cis	rs7193541	0.694	rs8061942	chr16:74691362	C/T	cg01733217	chr16:74700730	RFWD3	0.68	13.39	0.55	2.52e-34	Multiple myeloma;
LUAD	trans	rs7487075	0.786	rs12298619	chr12:46673501	G/A	cg17341174	chr7:97923834	BAIAP2L1	-0.34	-6.43	-0.3	3.55e-10	Itch intensity from mosquito bite;
LUAD	cis	rs12216545	0.765	rs7785909	chr7:150222230	A/T	cg08960815	chr7:150264767	GIMAP4	-0.31	-6.66	-0.31	8.43e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.37	7.26	0.33	1.88e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg27284194	chr4:1044797	NA	0.71	10.35	0.45	1.54e-22	Recombination rate (females);
LUAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg12419862	chr22:24373484	LOC391322	-0.66	-10.94	-0.47	1.03e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11098699	0.821	rs4833886	chr4:124206263	A/C	cg09941581	chr4:124220074	SPATA5	0.51	8.31	0.37	1.31e-15	Mosquito bite size;
LUAD	cis	rs10227331	0.934	rs2302447	chr7:157295985	A/T	cg04156418	chr7:157293606	NA	0.41	8.87	0.4	2e-17	Inattentive symptoms;
LUAD	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg22906224	chr7:99728672	NA	-0.62	-10.86	-0.47	2.08e-24	Coronary artery disease;
LUAD	cis	rs926938	0.618	rs904292	chr1:115358421	C/T	cg12756093	chr1:115239321	AMPD1	0.37	6.61	0.31	1.18e-10	Autism;
LUAD	cis	rs2455601	0.786	rs2568070	chr11:8976893	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.43	-7.56	-0.35	2.52e-13	Schizophrenia;
LUAD	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg19980929	chr12:42632907	YAF2	0.35	6.75	0.31	4.77e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg11871910	chr12:69753446	YEATS4	0.47	7.54	0.34	2.86e-13	Response to diuretic therapy;
LUAD	cis	rs533581	0.866	rs4995274	chr16:88970040	T/C	cg05579598	chr16:88989069	CBFA2T3	0.31	6.72	0.31	5.97e-11	Social autistic-like traits;
LUAD	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg02240030	chr7:2089880	MAD1L1	0.33	6.56	0.3	1.61e-10	Bipolar disorder;
LUAD	cis	rs7267979	1.000	rs2500424	chr20:25391969	C/T	cg08601574	chr20:25228251	PYGB	-0.44	-8.05	-0.36	8.43e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1372520	0.623	rs2583975	chr4:90748488	T/C	cg15133208	chr4:90757351	SNCA	-0.46	-6.84	-0.32	2.83e-11	Neuroticism;
LUAD	cis	rs13082711	0.911	rs35605663	chr3:27515754	C/T	cg02860705	chr3:27208620	NA	0.57	8.75	0.39	5.08e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs9972944	0.651	rs9897920	chr17:63832286	C/T	cg07283582	chr17:63770753	CCDC46	-0.45	-9.56	-0.42	1.01e-19	Total body bone mineral density;
LUAD	cis	rs62229266	0.633	rs34259635	chr21:37403570	T/G	cg12218747	chr21:37451666	NA	-0.44	-7.54	-0.34	2.92e-13	Mitral valve prolapse;
LUAD	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.39	8.11	0.37	5.5e-15	Hemoglobin concentration;
LUAD	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03517284	chr6:25882590	NA	-0.46	-7.05	-0.32	7.54e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg11915388	chr22:42470451	FAM109B	0.41	7.37	0.34	8.84e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg20503657	chr10:835505	NA	-1.02	-15.25	-0.6	3.59e-42	Eosinophil percentage of granulocytes;
LUAD	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.0	0.32	1.03e-11	Menopause (age at onset);
LUAD	cis	rs9513627	0.833	rs73556146	chr13:100116920	A/G	cg25919922	chr13:100150906	NA	-0.68	-6.62	-0.31	1.11e-10	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.33	0.41	6.25e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg08472276	chr7:1133186	C7orf50;GPER	0.59	11.13	0.48	2.07e-25	Longevity;Endometriosis;
LUAD	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg25173405	chr17:45401733	C17orf57	-0.5	-8.46	-0.38	4.46e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7107174	1.000	rs4944195	chr11:78003499	T/C	cg02023728	chr11:77925099	USP35	0.49	7.24	0.33	2.14e-12	Testicular germ cell tumor;
LUAD	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg04944784	chr2:26401820	FAM59B	-0.68	-9.51	-0.42	1.47e-19	Gut microbiome composition (summer);
LUAD	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.54	7.58	0.35	2.13e-13	Platelet count;
LUAD	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg01689657	chr7:91764605	CYP51A1	-0.36	-8.96	-0.4	1.06e-17	Breast cancer;
LUAD	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg16205897	chr5:131564050	P4HA2	-0.34	-7.67	-0.35	1.22e-13	Breast cancer;
LUAD	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg06064525	chr11:970664	AP2A2	-0.54	-11.28	-0.48	5.81e-26	Alzheimer's disease (late onset);
LUAD	cis	rs9811920	0.809	rs793464	chr3:99626028	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-7.29	-0.33	1.52e-12	Axial length;
LUAD	cis	rs3736594	0.959	rs10209020	chr2:27980944	C/T	cg27432699	chr2:27873401	GPN1	-0.47	-7.31	-0.33	1.38e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg06547715	chr2:218990976	CXCR2	0.44	10.39	0.45	1.09e-22	Ulcerative colitis;
LUAD	cis	rs12122100	0.955	rs12142005	chr1:146506691	T/C	cg03526459	chr1:146549940	NA	-0.38	-7.06	-0.32	6.87e-12	HIV-1 control;
LUAD	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg25233709	chr10:116636983	FAM160B1	0.41	8.26	0.37	1.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00166722	chr3:10149974	C3orf24	0.63	10.42	0.45	8.88e-23	Alzheimer's disease;
LUAD	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg17971929	chr21:40555470	PSMG1	-0.41	-6.49	-0.3	2.44e-10	Cognitive function;
LUAD	cis	rs877282	0.733	rs7092976	chr10:756358	G/A	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs10499694	0.967	rs11765748	chr7:50615616	T/A	cg18232548	chr7:50535776	DDC	-0.47	-8.0	-0.36	1.19e-14	Body mass index;
LUAD	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10802521	chr3:52805072	NEK4	-0.54	-9.1	-0.4	3.69e-18	Bipolar disorder;
LUAD	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg08316699	chr6:150357289	NA	0.37	7.81	0.35	4.66e-14	Alopecia areata;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg01027365	chr2:191184571	HIBCH	0.41	6.48	0.3	2.51e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg02353165	chr6:42928485	GNMT	0.42	7.38	0.34	8.24e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg21427119	chr20:30132790	HM13	-0.49	-7.86	-0.36	3.12e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg11871910	chr12:69753446	YEATS4	0.55	8.45	0.38	4.86e-16	Blood protein levels;
LUAD	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.7	0.35	9.62e-14	Breast cancer;
LUAD	cis	rs501916	0.761	rs589889	chr15:48019016	C/G	cg16110827	chr15:48056943	SEMA6D	-0.36	-6.69	-0.31	7.23e-11	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs7789940	0.904	rs61294900	chr7:75937212	A/T	cg10167463	chr7:75959203	YWHAG	-0.69	-12.03	-0.5	7.08e-29	Multiple sclerosis;
LUAD	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg03859395	chr2:55845619	SMEK2	-0.49	-7.79	-0.35	5.05e-14	Metabolic syndrome;
LUAD	cis	rs7187994	0.848	rs36008565	chr16:84751046	C/G	cg07647771	chr16:84786436	USP10	-0.34	-8.8	-0.39	3.62e-17	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs13392177	0.543	rs12623716	chr2:219073018	C/T	cg04731861	chr2:219085781	ARPC2	0.26	7.94	0.36	1.85e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs10950821	0.843	rs73684578	chr7:20665782	T/A	cg02470904	chr7:20686108	ABCB5	0.38	6.54	0.3	1.78e-10	Response to statin therapy;
LUAD	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg12927641	chr6:109611667	NA	-0.53	-9.46	-0.42	2.12e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs9302065	0.565	rs2993586	chr13:95962578	T/C	cg26751094	chr13:95954534	ABCC4	-0.52	-11.0	-0.47	6.29e-25	Blood metabolite levels;
LUAD	cis	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg21775007	chr8:11205619	TDH	-0.55	-9.94	-0.44	4.56e-21	Retinal vascular caliber;
LUAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10819733	chr22:24237672	NA	-0.41	-7.61	-0.35	1.75e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17838705	chr1:112298602	DDX20;C1orf183	-0.56	-6.74	-0.31	5.15e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg01620082	chr3:125678407	NA	-0.71	-7.18	-0.33	3.14e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg08859206	chr1:53392774	SCP2	0.59	10.45	0.45	6.72e-23	Monocyte count;
LUAD	trans	rs11638815	0.581	rs28808991	chr15:83260979	G/C	cg18393722	chr15:85113863	UBE2QP1	-0.49	-7.52	-0.34	3.3e-13	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg03859395	chr2:55845619	SMEK2	0.74	13.91	0.56	1.71e-36	Metabolic syndrome;
LUAD	cis	rs9296092	0.560	rs7765393	chr6:33525598	A/T	cg13560919	chr6:33536144	NA	-0.9	-16.72	-0.63	1.49e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7771547	0.788	rs10214849	chr6:36601445	A/G	cg07856975	chr6:36356162	ETV7	0.43	6.35	0.3	5.46e-10	Platelet distribution width;
LUAD	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg26354017	chr1:205819088	PM20D1	0.54	8.56	0.38	2.17e-16	Parkinson's disease;
LUAD	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg02269571	chr22:50332266	NA	-0.68	-9.9	-0.43	6.32e-21	Schizophrenia;
LUAD	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	8.71	0.39	6.9e-17	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg01312482	chr5:178451176	ZNF879	0.44	6.84	0.32	2.76e-11	Pubertal anthropometrics;
LUAD	trans	rs7555117	0.794	rs2989476	chr1:61059259	C/G	cg27397625	chr6:42952298	PPP2R5D	-0.39	-6.55	-0.3	1.68e-10	Facial morphology (factor 19);
LUAD	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg22166914	chr1:53195759	ZYG11B	-0.48	-7.9	-0.36	2.51e-14	Monocyte count;
LUAD	trans	rs11039798	0.920	rs12279378	chr11:48571030	A/C	cg02254774	chr11:50257496	LOC441601	0.52	6.62	0.31	1.08e-10	Axial length;
LUAD	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg04287289	chr16:89883240	FANCA	0.44	6.68	0.31	7.33e-11	Vitiligo;
LUAD	trans	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.69	12.12	0.51	3.03e-29	Mean corpuscular volume;
LUAD	cis	rs2806561	0.664	rs4620508	chr1:23307438	C/T	cg19743168	chr1:23544995	NA	0.37	6.37	0.3	4.86e-10	Height;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21139845	chr12:7053993	C12orf57	-0.42	-6.44	-0.3	3.28e-10	Height;
LUAD	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg16049864	chr8:95962084	TP53INP1	0.48	9.13	0.41	2.79e-18	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.24	0.37	2.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg00933542	chr6:150070202	PCMT1	0.43	9.09	0.4	3.87e-18	Lung cancer;
LUAD	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11890956	chr21:40555474	PSMG1	-0.57	-9.94	-0.44	4.67e-21	Menarche (age at onset);
LUAD	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg09033563	chr22:24373618	LOC391322	-0.49	-7.49	-0.34	4.02e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs1681630	0.848	rs1631174	chr11:47974373	A/C	cg15704280	chr7:45808275	SEPT13	-0.49	-7.35	-0.34	1e-12	Height;
LUAD	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg03433033	chr1:76189801	ACADM	-0.48	-7.0	-0.32	9.94e-12	Daytime sleep phenotypes;
LUAD	cis	rs6696239	0.513	rs903697	chr1:227766845	A/G	cg12133451	chr1:227746453	NA	0.36	6.52	0.3	1.95e-10	Height;
LUAD	cis	rs28595532	1.000	rs56000725	chr4:119637675	G/A	cg14228332	chr4:119757509	SEC24D	0.77	7.07	0.33	6.46e-12	Cannabis dependence symptom count;
LUAD	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.96	0.32	1.28e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg02773889	chr13:42615649	NA	0.42	6.8	0.31	3.67e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs859767	0.741	rs2176341	chr2:135371421	A/G	cg12500956	chr2:135428796	TMEM163	-0.31	-8.17	-0.37	3.49e-15	Neuroticism;
LUAD	cis	rs4601821	0.823	rs17115439	chr11:113264272	T/C	cg14159747	chr11:113255604	NA	0.5	9.79	0.43	1.6e-20	Alcoholic chronic pancreatitis;
LUAD	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22968622	chr17:43663579	NA	1.31	22.38	0.74	9.16e-74	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6489785	0.643	rs2015462	chr12:121238204	G/C	cg02419362	chr12:121203948	SPPL3	0.35	7.25	0.33	2.04e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg25817165	chr18:72167213	CNDP2	-0.82	-14.17	-0.57	1.39e-37	Refractive error;
LUAD	trans	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.19	-30.49	-0.83	8e-109	Exhaled nitric oxide output;
LUAD	trans	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg26043149	chr18:55253948	FECH	0.43	7.12	0.33	4.65e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg08888203	chr3:10149979	C3orf24	0.63	10.75	0.46	5.31e-24	Alzheimer's disease;
LUAD	cis	rs9473147	0.516	rs9349415	chr6:47551861	T/C	cg20196966	chr6:47445060	CD2AP	0.43	6.86	0.32	2.39e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-9.2	-0.41	1.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg08847533	chr14:75593920	NEK9	0.43	7.4	0.34	7.19e-13	Height;
LUAD	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg16479474	chr6:28041457	NA	0.45	7.48	0.34	4.24e-13	Depression;
LUAD	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg23131131	chr22:24373011	LOC391322	0.56	9.32	0.41	6.48e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19717773	chr7:2847554	GNA12	-0.57	-9.67	-0.43	4.16e-20	Height;
LUAD	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg02160872	chr5:212506	CCDC127	-0.49	-6.41	-0.3	3.96e-10	Breast cancer;
LUAD	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18876405	chr7:65276391	NA	0.62	10.9	0.47	1.5e-24	Calcium levels;
LUAD	cis	rs829661	0.532	rs11127276	chr2:30794215	C/T	cg12454169	chr2:30669597	LCLAT1	-0.44	-6.76	-0.31	4.72e-11	Midgestational circulating levels of PBDEs (fetal genetic effect);
LUAD	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg06191203	chr2:152266755	RIF1	-0.52	-8.14	-0.37	4.55e-15	Lung cancer;
LUAD	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg22532475	chr10:104410764	TRIM8	-0.44	-8.56	-0.38	2.09e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg24163568	chr5:669837	TPPP	-0.37	-6.94	-0.32	1.48e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs986417	0.901	rs2351172	chr14:61008687	A/G	cg27398547	chr14:60952738	C14orf39	0.66	7.65	0.35	1.38e-13	Gut microbiota (bacterial taxa);
LUAD	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg15704280	chr7:45808275	SEPT13	0.86	16.32	0.62	9.01e-47	Coronary artery disease;
LUAD	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg16797656	chr11:68205561	LRP5	0.52	10.92	0.47	1.24e-24	Total body bone mineral density;
LUAD	cis	rs6445967	1.000	rs12688	chr3:58305079	T/C	cg23715586	chr3:58305044	RPP14	0.43	7.7	0.35	9.98e-14	Platelet count;
LUAD	cis	rs7731657	0.537	rs1074840	chr5:130251717	A/G	cg08523029	chr5:130500466	HINT1	-0.58	-7.31	-0.33	1.34e-12	Fasting plasma glucose;
LUAD	cis	rs2625529	0.590	rs12442886	chr15:72473611	T/C	cg16672083	chr15:72433130	SENP8	0.7	12.61	0.52	3.69e-31	Red blood cell count;
LUAD	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg05564831	chr3:52568323	NT5DC2	0.35	6.4	0.3	4.15e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg10518543	chr12:38710700	ALG10B	-0.44	-7.42	-0.34	6.47e-13	Morning vs. evening chronotype;
LUAD	cis	rs12541635	0.966	rs11786829	chr8:107023752	C/G	cg10147462	chr8:107024639	NA	0.5	9.11	0.4	3.39e-18	Age of smoking initiation;
LUAD	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg21285383	chr16:89894308	SPIRE2	0.41	9.75	0.43	2.09e-20	Vitiligo;
LUAD	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg05283184	chr6:79620031	NA	-0.44	-7.78	-0.35	5.79e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg19767477	chr5:127420684	SLC12A2	-0.43	-6.62	-0.31	1.09e-10	Ileal carcinoids;
LUAD	trans	rs7395662	1.000	rs7481308	chr11:48600067	T/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.57	-0.3	1.47e-10	HDL cholesterol;
LUAD	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg26384229	chr12:38710491	ALG10B	0.44	7.21	0.33	2.63e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs1006703	0.544	rs8068362	chr17:3838757	T/C	cg06463185	chr17:3833770	ATP2A3	-0.78	-8.6	-0.39	1.58e-16	Glucose homeostasis traits;
LUAD	cis	rs7524258	0.868	rs2412152	chr1:7303213	C/T	cg07173049	chr1:7289937	CAMTA1	0.52	9.85	0.43	9.66e-21	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg20276088	chr3:133502917	NA	-0.42	-7.56	-0.35	2.46e-13	Iron status biomarkers;
LUAD	cis	rs751728	0.965	rs3806109	chr6:33770370	T/G	cg13859433	chr6:33739653	LEMD2	-0.38	-8.91	-0.4	1.5e-17	Crohn's disease;
LUAD	cis	rs9296092	0.521	rs9461886	chr6:33526770	T/C	cg13560919	chr6:33536144	NA	-0.9	-16.72	-0.63	1.49e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs3772130	1.000	rs56314138	chr3:121356656	G/A	cg20356878	chr3:121714668	ILDR1	0.48	7.4	0.34	7.27e-13	Cognitive performance;
LUAD	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg24818145	chr4:99064322	C4orf37	0.46	7.8	0.35	4.86e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-7.15	-0.33	3.91e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7149242	0.662	rs4905998	chr14:101181781	A/G	cg18089426	chr14:101175970	NA	-0.39	-6.89	-0.32	2.03e-11	Platelet count;
LUAD	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg12379764	chr21:47803548	PCNT	0.61	10.69	0.46	8.7e-24	Testicular germ cell tumor;
LUAD	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg02951883	chr7:2050386	MAD1L1	-0.86	-15.46	-0.6	4.78e-43	Bipolar disorder and schizophrenia;
LUAD	trans	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg13698153	chr12:118541722	VSIG10	-0.43	-6.54	-0.3	1.76e-10	Vitiligo;
LUAD	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg12432903	chr7:1882776	MAD1L1	-0.44	-7.06	-0.32	6.82e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs2795502	0.766	rs947549	chr10:43265880	G/C	cg20628663	chr10:43360327	NA	-0.68	-9.05	-0.4	5.32e-18	Blood protein levels;
LUAD	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg08798685	chr6:27730294	NA	-0.67	-6.69	-0.31	7.09e-11	Depression;
LUAD	trans	rs1941687	0.702	rs9956636	chr18:31304974	C/T	cg27147174	chr7:100797783	AP1S1	-0.52	-8.69	-0.39	7.74e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs754466	0.606	rs11002315	chr10:79617385	T/G	cg17075019	chr10:79541650	NA	-0.86	-17.87	-0.66	1.34e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1451375	0.794	rs11238134	chr7:50542927	A/C	cg18232548	chr7:50535776	DDC	-0.65	-10.97	-0.47	8.3e-25	Malaria;
LUAD	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.09	0.37	6.33e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06873352	chr17:61820015	STRADA	0.82	18.45	0.67	3.55e-56	Prudent dietary pattern;
LUAD	cis	rs10838532	1.000	rs10838532	chr11:45947464	C/G	cg24204282	chr11:45944920	GYLTL1B	0.42	6.37	0.3	4.88e-10	Axial length;
LUAD	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs7107174	1.000	rs9651769	chr11:77996166	T/C	cg02023728	chr11:77925099	USP35	0.48	7.42	0.34	6.5e-13	Testicular germ cell tumor;
LUAD	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg16647868	chr5:131706066	SLC22A5	0.4	6.88	0.32	2.16e-11	Blood metabolite levels;
LUAD	cis	rs7759001	0.779	rs13215216	chr6:27346645	G/C	cg18711553	chr6:27366782	ZNF391	0.39	6.37	0.3	4.86e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg21138405	chr5:131827807	IRF1	-0.52	-10.1	-0.44	1.2e-21	Asthma (sex interaction);
LUAD	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg15017067	chr4:17643749	FAM184B	0.35	6.91	0.32	1.75e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-12.62	-0.52	3.26e-31	Menarche (age at onset);
LUAD	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg05991184	chr2:219186017	PNKD	-0.37	-7.46	-0.34	4.91e-13	Colorectal cancer;
LUAD	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.34	-6.54	-0.3	1.76e-10	Crohn's disease;
LUAD	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg01097406	chr16:89675127	NA	0.47	9.91	0.43	5.81e-21	Vitiligo;
LUAD	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg18854424	chr1:2615690	NA	-0.42	-9.07	-0.4	4.63e-18	Ulcerative colitis;
LUAD	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.96	0.32	1.29e-11	Cognitive test performance;
LUAD	cis	rs300703	0.515	rs300694	chr2:182277	G/T	cg21211680	chr2:198530	NA	-0.53	-7.88	-0.36	2.86e-14	Blood protein levels;
LUAD	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg20744362	chr22:50050164	C22orf34	0.35	6.39	0.3	4.48e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg00147172	chr22:46423604	NA	-0.27	-6.93	-0.32	1.55e-11	Dupuytren's disease;
LUAD	cis	rs11077998	0.840	rs9910991	chr17:80481193	G/A	cg10255544	chr17:80519551	FOXK2	0.35	7.0	0.32	9.78e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2262909	0.924	rs4290587	chr19:22164646	A/G	cg05197062	chr11:11642011	GALNTL4	-0.53	-8.05	-0.36	8.23e-15	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	trans	rs1997103	0.954	rs56030000	chr7:55405750	A/G	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2041840	1.000	rs1861444	chr2:37464511	C/G	cg25727520	chr2:37576821	QPCT	0.33	6.87	0.32	2.34e-11	Chronic lymphocytic leukemia;
LUAD	cis	rs7215564	0.908	rs35103651	chr17:78666732	T/C	cg09596252	chr17:78655493	RPTOR	0.55	6.76	0.31	4.64e-11	Myopia (pathological);
LUAD	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg21775007	chr8:11205619	TDH	-0.5	-9.09	-0.4	3.84e-18	Retinal vascular caliber;
LUAD	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg02079420	chr8:82753780	SNX16	0.38	7.51	0.34	3.45e-13	Diastolic blood pressure;
LUAD	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06022373	chr22:39101656	GTPBP1	0.48	8.13	0.37	4.93e-15	Menopause (age at onset);
LUAD	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg18129178	chr5:148520854	ABLIM3	0.63	9.86	0.43	8.96e-21	Breast cancer;
LUAD	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg17644776	chr2:200775616	C2orf69	0.55	7.3	0.33	1.45e-12	Schizophrenia;
LUAD	cis	rs2230307	0.536	rs56215716	chr1:100447486	G/A	cg20868668	chr1:100435035	SLC35A3	0.52	7.75	0.35	6.82e-14	Carotid intima media thickness;
LUAD	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg01416388	chr22:39784598	NA	-0.47	-7.75	-0.35	6.79e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg09455208	chr3:40491958	NA	0.58	12.75	0.53	1.01e-31	Renal cell carcinoma;
LUAD	cis	rs4077468	0.963	rs1342064	chr1:205913073	T/C	cg14893161	chr1:205819251	PM20D1	-0.37	-6.56	-0.3	1.53e-10	Cystic fibrosis-related diabetes;
LUAD	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg15468180	chr1:107600409	PRMT6	-0.45	-7.69	-0.35	1.03e-13	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.14	-0.33	3.99e-12	Glomerular filtration rate;
LUAD	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg08213375	chr14:104286397	PPP1R13B	0.28	7.25	0.33	2e-12	Schizophrenia;
LUAD	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg00310523	chr12:86230176	RASSF9	-0.36	-7.36	-0.34	9.53e-13	Major depressive disorder;
LUAD	cis	rs6005807	0.545	rs12169120	chr22:29005302	A/C	cg12565055	chr22:29076175	TTC28	0.74	8.39	0.38	7.2e-16	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg07402062	chr16:89894098	SPIRE2	0.45	11.4	0.48	2.02e-26	Vitiligo;
LUAD	cis	rs10129255	0.500	rs988132	chr14:107184997	C/T	cg07958169	chr14:107095056	NA	-0.38	-7.46	-0.34	4.86e-13	Kawasaki disease;
LUAD	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21659725	chr3:3221576	CRBN	0.62	9.99	0.44	3.07e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg25173405	chr17:45401733	C17orf57	0.52	8.9	0.4	1.63e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg10523679	chr1:76189770	ACADM	0.61	8.84	0.4	2.54e-17	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs3960554	0.569	rs1894761	chr7:75876754	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.57	-8.79	-0.39	3.87e-17	Eotaxin levels;
LUAD	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg09222892	chr1:25734099	RHCE	-0.51	-9.34	-0.41	5.61e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs10883723	0.668	rs12414479	chr10:104420902	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	8.45	0.38	4.7e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg12011299	chr4:100065546	ADH4	0.7	12.52	0.52	8.56e-31	Smoking initiation;
LUAD	trans	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg21775007	chr8:11205619	TDH	0.41	7.16	0.33	3.57e-12	Mood instability;
LUAD	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.29	-0.41	8.21e-19	Life satisfaction;
LUAD	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg25797454	chr6:150327115	RAET1K	0.36	7.77	0.35	5.85e-14	Alopecia areata;
LUAD	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg23985595	chr17:80112537	CCDC57	0.5	8.99	0.4	8.46e-18	Life satisfaction;
LUAD	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg11189052	chr15:85197271	WDR73	0.65	8.51	0.38	3.15e-16	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg01851573	chr8:8652454	MFHAS1	-0.44	-7.87	-0.36	3.07e-14	Neuroticism;
LUAD	cis	rs6840360	0.593	rs6857073	chr4:152689274	A/G	cg22705602	chr4:152727874	NA	0.45	8.44	0.38	4.96e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg21214613	chr1:16344536	HSPB7	0.6	11.59	0.49	3.61e-27	Dilated cardiomyopathy;
LUAD	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg08280861	chr8:58055591	NA	0.56	7.04	0.32	7.6e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.4e-13	Menopause (age at onset);
LUAD	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg19626725	chr5:178986131	RUFY1	0.5	8.15	0.37	4.12e-15	Lung cancer;
LUAD	cis	rs1816752	0.905	rs9511264	chr13:25012217	C/T	cg02811702	chr13:24901961	NA	-0.44	-7.81	-0.35	4.62e-14	Obesity-related traits;
LUAD	cis	rs4285028	0.948	rs34478505	chr3:121694071	C/T	cg20356878	chr3:121714668	ILDR1	-0.49	-6.61	-0.31	1.18e-10	Multiple sclerosis;
LUAD	cis	rs9948	0.655	rs61742095	chr2:97366088	T/C	cg20312557	chr2:97357134	FER1L5	-0.67	-7.74	-0.35	7.36e-14	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs656900	1.000	rs632291	chr15:80106461	T/A	cg02196730	chr15:80188777	MTHFS	-0.41	-6.38	-0.3	4.57e-10	Cerebrospinal P-tau181p levels;
LUAD	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg24733560	chr20:60626293	TAF4	0.47	8.4	0.38	6.71e-16	Body mass index;
LUAD	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg19000871	chr14:103996768	TRMT61A	-0.43	-7.49	-0.34	4.12e-13	Coronary artery disease;
LUAD	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.86	-0.36	3.12e-14	Diabetic kidney disease;
LUAD	cis	rs6426558	0.537	rs2813969	chr1:227404082	T/C	cg10327440	chr1:227177885	CDC42BPA	0.57	9.24	0.41	1.26e-18	Neutrophil percentage of white cells;
LUAD	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg00255919	chr5:131827918	IRF1	0.37	8.77	0.39	4.35e-17	Breast cancer;Mosquito bite size;
LUAD	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg15445000	chr17:37608096	MED1	0.44	8.11	0.37	5.5e-15	Glomerular filtration rate (creatinine);
LUAD	trans	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg10518543	chr12:38710700	ALG10B	0.4	6.46	0.3	2.94e-10	Morning vs. evening chronotype;
LUAD	trans	rs7200543	1.000	rs16966953	chr16:15135854	A/G	cg24683922	chr1:11983373	KIAA2013	-0.49	-8.17	-0.37	3.65e-15	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUAD	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg00316803	chr15:76480434	C15orf27	-0.4	-7.62	-0.35	1.68e-13	Blood metabolite levels;
LUAD	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg08470875	chr2:26401718	FAM59B	-0.77	-10.37	-0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg08029281	chr1:67600428	NA	0.36	6.96	0.32	1.32e-11	Psoriasis;
LUAD	trans	rs10432169	1	rs10432169	chr18:31347098	C/G	cg27147174	chr7:100797783	AP1S1	-0.53	-8.92	-0.4	1.39e-17	Subjective well-being;
LUAD	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg20129853	chr10:51489980	NA	-0.36	-7.21	-0.33	2.53e-12	Prostate-specific antigen levels;
LUAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg24813613	chr7:1882135	MAD1L1	-0.58	-9.33	-0.41	6.18e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.16	0.33	3.64e-12	Menopause (age at onset);
LUAD	cis	rs208520	0.909	rs9354410	chr6:67018584	C/T	cg07460842	chr6:66804631	NA	0.82	9.75	0.43	2.12e-20	Exhaled nitric oxide output;
LUAD	cis	rs698833	0.886	rs4953087	chr2:44561627	G/A	cg04920474	chr2:44395004	PPM1B	0.37	6.54	0.3	1.81e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg03477792	chr4:77819574	ANKRD56	0.49	7.53	0.34	3.15e-13	Emphysema distribution in smoking;
LUAD	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg18755752	chr8:142205143	DENND3	0.46	7.98	0.36	1.4e-14	Immature fraction of reticulocytes;
LUAD	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg13870426	chr17:30244630	NA	-0.55	-6.49	-0.3	2.35e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs2625529	0.652	rs2957724	chr15:72248474	A/C	cg16672083	chr15:72433130	SENP8	0.61	11.24	0.48	8.02e-26	Red blood cell count;
LUAD	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	7.44	0.34	5.79e-13	Menopause (age at onset);
LUAD	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.71	-0.35	8.94e-14	Total body bone mineral density;
LUAD	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg24803719	chr17:45855879	NA	-0.34	-6.84	-0.32	2.73e-11	IgG glycosylation;
LUAD	cis	rs6426558	0.537	rs689094	chr1:227308909	G/A	cg10327440	chr1:227177885	CDC42BPA	0.54	8.71	0.39	6.96e-17	Neutrophil percentage of white cells;
LUAD	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg10518543	chr12:38710700	ALG10B	0.41	6.41	0.3	3.89e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg03676636	chr4:99064102	C4orf37	0.28	7.15	0.33	3.84e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg12615879	chr12:58013172	SLC26A10	-0.35	-7.0	-0.32	1.03e-11	Multiple sclerosis;
LUAD	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg08888203	chr3:10149979	C3orf24	0.72	12.82	0.53	5.02e-32	Alzheimer's disease;
LUAD	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg05623727	chr3:50126028	RBM5	-0.3	-6.44	-0.3	3.17e-10	Body mass index;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20715365	chr17:73900573	MRPL38	-0.52	-6.38	-0.3	4.67e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg03929089	chr4:120376271	NA	0.54	7.2	0.33	2.86e-12	Axial length;
LUAD	cis	rs3018712	0.532	rs2510399	chr11:68421458	A/G	cg16797656	chr11:68205561	LRP5	-0.43	-6.65	-0.31	8.93e-11	Total body bone mineral density;
LUAD	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg07917127	chr4:99064746	C4orf37	0.46	7.41	0.34	7.08e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg11822812	chr5:140052017	DND1	0.36	6.46	0.3	2.81e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.76e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg00105475	chr2:10696890	NA	0.35	6.35	0.3	5.45e-10	Prostate cancer;
LUAD	cis	rs9287719	0.747	rs1534400	chr2:10696833	T/C	cg02196655	chr2:10830764	NOL10	-0.46	-8.2	-0.37	2.86e-15	Prostate cancer;
LUAD	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg04455712	chr21:45112962	RRP1B	0.46	9.28	0.41	8.78e-19	Mean corpuscular volume;
LUAD	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg08632164	chr7:65971372	NA	-0.54	-6.38	-0.3	4.55e-10	Diabetic kidney disease;
LUAD	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg00204512	chr16:28754710	NA	0.35	7.49	0.34	4.06e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6076065	0.723	rs2224074	chr20:23360171	G/C	cg11657817	chr20:23433608	CST11	0.49	8.98	0.4	8.82e-18	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg07395648	chr5:131743802	NA	0.37	6.38	0.3	4.76e-10	Breast cancer;
LUAD	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg13334819	chr7:99746414	C7orf59	-0.65	-10.47	-0.45	5.66e-23	Coronary artery disease;
LUAD	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg22676075	chr6:135203613	NA	-0.74	-14.61	-0.58	2.07e-39	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.28	0.45	2.94e-22	Lymphocyte percentage of white cells;
LUAD	cis	rs17532515	0.652	rs6843092	chr4:141380237	T/A	cg03645522	chr4:141391200	NA	0.39	6.41	0.3	3.92e-10	Select biomarker traits;
LUAD	cis	rs7932354	0.528	rs4752967	chr11:47169376	T/C	cg19486271	chr11:47235900	DDB2	0.41	6.51	0.3	2.13e-10	Bone mineral density (hip);Bone mineral density;
LUAD	trans	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg24644049	chr4:85504048	CDS1	0.88	7.16	0.33	3.55e-12	Skin colour saturation;
LUAD	cis	rs7149242	0.697	rs12882815	chr14:101183142	C/G	cg08175591	chr14:101176152	NA	0.38	6.77	0.31	4.44e-11	Platelet count;
LUAD	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg13736514	chr6:26305472	NA	-0.7	-13.18	-0.54	1.74e-33	Educational attainment;
LUAD	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg09796270	chr17:17721594	SREBF1	-0.36	-7.09	-0.33	5.58e-12	Total body bone mineral density;
LUAD	cis	rs6960043	0.818	rs2358158	chr7:15054063	T/C	cg19272540	chr7:15055459	NA	0.37	8.25	0.37	1.99e-15	Type 2 diabetes;
LUAD	trans	rs208520	0.874	rs208456	chr6:66907942	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-14.08	-0.56	3.33e-37	Exhaled nitric oxide output;
LUAD	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg04398451	chr17:18023971	MYO15A	-0.63	-11.39	-0.48	2.08e-26	Total body bone mineral density;
LUAD	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg18854424	chr1:2615690	NA	0.42	9.06	0.4	4.81e-18	Ulcerative colitis;
LUAD	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg13271783	chr10:134563150	INPP5A	-0.41	-6.65	-0.31	8.9e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg11070056	chr1:107600091	PRMT6	-0.64	-11.21	-0.48	1.03e-25	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg09537434	chr19:41945824	ATP5SL	-0.52	-8.15	-0.37	4.16e-15	Height;
LUAD	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.56	8.11	0.37	5.72e-15	Platelet count;
LUAD	cis	rs11676855	1.000	rs6710499	chr2:235898590	A/G	cg14917874	chr2:235941519	SH3BP4	0.42	7.03	0.32	8.51e-12	Dialysis-related mortality;
LUAD	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg10755058	chr3:40428713	ENTPD3	0.38	7.28	0.33	1.59e-12	Renal cell carcinoma;
LUAD	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06022373	chr22:39101656	GTPBP1	0.48	8.13	0.37	4.93e-15	Menopause (age at onset);
LUAD	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg19901468	chr14:105411992	AHNAK2	-0.54	-10.43	-0.45	7.91e-23	Rheumatoid arthritis;
LUAD	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.55	0.38	2.33e-16	Gut microbiome composition (summer);
LUAD	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg03806693	chr22:41940476	POLR3H	0.76	10.14	0.44	9.01e-22	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg27572855	chr1:25598939	RHD	0.55	11.6	0.49	3.42e-27	Erythrocyte sedimentation rate;
LUAD	cis	rs12576326	1.000	rs12576326	chr11:44980383	A/G	cg01859616	chr11:44970771	TP53I11	-0.38	-6.44	-0.3	3.21e-10	Resting heart rate;
LUAD	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg14345882	chr6:26364793	BTN3A2	-0.65	-6.92	-0.32	1.69e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2235544	0.579	rs1537323	chr1:54482523	G/T	cg25741118	chr1:54482237	LDLRAD1	0.25	7.04	0.32	7.8e-12	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUAD	cis	rs12681287	0.888	rs13042	chr8:87484913	G/A	cg27223183	chr8:87520930	FAM82B	-0.64	-9.21	-0.41	1.54e-18	Caudate activity during reward;
LUAD	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg17971929	chr21:40555470	PSMG1	0.53	8.33	0.38	1.15e-15	Cognitive function;
LUAD	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg18944383	chr4:111397179	ENPEP	0.4	8.16	0.37	3.75e-15	Height;
LUAD	cis	rs375066	0.592	rs349046	chr19:44300626	C/T	cg11993925	chr19:44307056	LYPD5	-0.37	-7.33	-0.34	1.15e-12	Breast cancer;
LUAD	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	11.1	0.48	2.63e-25	Smoking behavior;
LUAD	cis	rs6752107	0.936	rs10178603	chr2:234206610	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	9.35	0.41	5.05e-19	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg14169450	chr9:139327907	INPP5E	-0.35	-6.58	-0.3	1.36e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg19302996	chr17:73780495	UNK	0.47	7.99	0.36	1.29e-14	White matter hyperintensity burden;
LUAD	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg14343924	chr8:8086146	FLJ10661	-0.49	-7.87	-0.36	3e-14	Mood instability;
LUAD	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23158103	chr7:148848205	ZNF398	-0.66	-12.21	-0.51	1.39e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.69	11.92	0.5	1.94e-28	Mean corpuscular volume;
LUAD	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg00603274	chr11:61596626	FADS2	-0.37	-6.53	-0.3	1.85e-10	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg06484146	chr7:12443880	VWDE	-0.58	-7.32	-0.34	1.28e-12	Coronary artery disease;
LUAD	cis	rs7408868	1.000	rs10410514	chr19:15277610	C/T	cg14696996	chr19:15285081	NOTCH3	0.82	10.6	0.46	1.97e-23	Pulse pressure;
LUAD	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg00745463	chr17:30367425	LRRC37B	0.62	7.98	0.36	1.38e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg13010199	chr12:38710504	ALG10B	0.41	6.76	0.31	4.51e-11	Bladder cancer;
LUAD	cis	rs11023332	0.832	rs10832289	chr11:14669496	A/T	cg19336497	chr11:14380999	RRAS2	0.39	7.39	0.34	7.76e-13	Adiponectin levels;Vitamin D levels;
LUAD	cis	rs1949733	0.598	rs55765509	chr4:8532732	T/A	cg13073564	chr4:8508604	NA	0.51	8.54	0.38	2.38e-16	Response to antineoplastic agents;
LUAD	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg06221963	chr1:154839813	KCNN3	-0.84	-17.58	-0.65	2.43e-52	Prostate cancer;
LUAD	cis	rs735539	0.521	rs2585901	chr13:21420271	G/A	cg27499820	chr13:21296301	IL17D	0.43	7.18	0.33	3.11e-12	Dental caries;
LUAD	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg05625103	chr10:2543513	NA	0.4	7.08	0.33	5.95e-12	Age-related hearing impairment;
LUAD	cis	rs3820068	0.705	rs57238793	chr1:15890029	A/G	cg24675056	chr1:15929824	NA	0.45	6.83	0.32	2.95e-11	Systolic blood pressure;
LUAD	cis	rs62400317	0.762	rs10456120	chr6:44900107	C/T	cg18551225	chr6:44695536	NA	-0.59	-8.88	-0.4	1.86e-17	Total body bone mineral density;
LUAD	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg11859384	chr17:80120422	CCDC57	-0.47	-8.47	-0.38	3.96e-16	Life satisfaction;
LUAD	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg12140854	chr5:148520817	ABLIM3	-0.62	-9.76	-0.43	2e-20	Breast cancer;
LUAD	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg17063962	chr7:91808500	NA	0.68	12.15	0.51	2.4e-29	Breast cancer;
LUAD	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg24803719	chr17:45855879	NA	-0.34	-7.84	-0.36	3.59e-14	IgG glycosylation;
LUAD	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg09835421	chr16:68378352	PRMT7	-0.74	-8.48	-0.38	3.69e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24531977	chr5:56204891	C5orf35	1.0	15.38	0.6	1.05e-42	Initial pursuit acceleration;
LUAD	cis	rs9473147	0.516	rs2171089	chr6:47515811	A/G	cg02130027	chr6:47444894	CD2AP	0.37	7.06	0.32	7.01e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs11696845	0.666	rs6073533	chr20:43361082	G/T	cg25301532	chr20:43378953	KCNK15	-0.45	-7.95	-0.36	1.66e-14	Obesity-related traits;
LUAD	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg04772025	chr11:68637568	NA	0.53	8.31	0.37	1.33e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	6.63	0.31	1.04e-10	Lung cancer in ever smokers;
LUAD	cis	rs727505	0.866	rs67724276	chr7:124719719	G/A	cg23710748	chr7:124431027	NA	-0.42	-8.51	-0.38	3.02e-16	Lewy body disease;
LUAD	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg22467129	chr15:76604101	ETFA	-0.59	-10.96	-0.47	9.23e-25	Blood metabolite levels;
LUAD	trans	rs1864729	1.000	rs2053480	chr8:98278951	A/T	cg08679828	chr8:102218111	ZNF706	0.77	7.8	0.35	4.95e-14	Estradiol plasma levels (breast cancer);
LUAD	cis	rs2046867	0.862	rs2322611	chr3:72830087	T/G	cg25664220	chr3:72788482	NA	-0.7	-12.41	-0.52	2.36e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg15704280	chr7:45808275	SEPT13	0.68	8.91	0.4	1.59e-17	Axial length;
LUAD	cis	rs9462027	0.651	rs34493158	chr6:34753339	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.02	-0.4	6.72e-18	Systemic lupus erythematosus;
LUAD	cis	rs4746822	0.539	rs10998646	chr10:70976702	G/T	cg14418922	chr10:70824840	NA	-0.4	-7.82	-0.36	4.1e-14	Glycemic traits (pregnancy);
LUAD	cis	rs12545109	0.879	rs893234	chr8:57363885	G/A	cg17761419	chr8:57350749	NA	-0.58	-8.23	-0.37	2.37e-15	Obesity-related traits;
LUAD	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	10.43	0.45	8.34e-23	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg05697835	chr1:2722811	NA	0.29	6.83	0.32	2.89e-11	Ulcerative colitis;
LUAD	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg14343924	chr8:8086146	FLJ10661	-0.4	-6.42	-0.3	3.66e-10	Neuroticism;
LUAD	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg00852783	chr1:26633632	UBXN11	0.45	7.34	0.34	1.13e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg21171335	chr12:122356390	WDR66	0.75	14.04	0.56	5.12e-37	Mean corpuscular volume;
LUAD	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg02423579	chr7:2872169	GNA12	-0.56	-9.47	-0.42	1.96e-19	Height;
LUAD	cis	rs7922314	0.510	rs1509964	chr10:64567364	C/T	cg14943953	chr10:64564468	ADO	-0.57	-6.91	-0.32	1.8e-11	Cutaneous psoriasis;
LUAD	cis	rs9522267	0.535	rs9522296	chr13:112234340	C/T	cg10483660	chr13:112241077	NA	0.32	6.97	0.32	1.2e-11	Hepatitis;
LUAD	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg15921436	chr17:44337874	NA	-0.67	-8.92	-0.4	1.47e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4711336	1.000	rs764754	chr6:33658310	C/T	cg14003231	chr6:33640908	ITPR3	0.53	10.03	0.44	2.23e-21	Height;
LUAD	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg06873352	chr17:61820015	STRADA	0.43	7.2	0.33	2.8e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg07636037	chr3:49044803	WDR6	-0.48	-8.03	-0.36	9.96e-15	Menarche (age at onset);
LUAD	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg13736514	chr6:26305472	NA	-0.69	-13.16	-0.54	2.14e-33	Educational attainment;
LUAD	cis	rs2274471	0.645	rs2104685	chr9:5106023	A/T	cg03390472	chr9:5043263	JAK2	-0.55	-8.33	-0.38	1.1e-15	Crohn's disease;
LUAD	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg24069376	chr3:38537580	EXOG	-0.45	-10.77	-0.46	4.47e-24	Electrocardiographic conduction measures;
LUAD	cis	rs7737355	1.000	rs7737355	chr5:130604811	T/A	cg06307176	chr5:131281290	NA	0.43	6.92	0.32	1.72e-11	Life satisfaction;
LUAD	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg17177755	chr1:15930204	NA	-0.49	-7.63	-0.35	1.56e-13	Systolic blood pressure;
LUAD	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg13319975	chr6:146136371	FBXO30	-0.58	-9.77	-0.43	1.8899999999999998e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs73198271	0.563	rs3748143	chr8:8655237	A/G	cg01851573	chr8:8652454	MFHAS1	-0.66	-11.12	-0.48	2.18e-25	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg09184832	chr6:79620586	NA	-0.38	-6.47	-0.3	2.77e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs13315871	1.000	rs13096020	chr3:58367771	G/A	cg20936604	chr3:58311152	NA	-0.68	-6.99	-0.32	1.11e-11	Cholesterol, total;
LUAD	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg03806693	chr22:41940476	POLR3H	-0.7	-9.2	-0.41	1.66e-18	Vitiligo;
LUAD	cis	rs12760731	0.565	rs12028023	chr1:178087408	G/A	cg00404053	chr1:178313656	RASAL2	0.71	9.19	0.41	1.76e-18	Obesity-related traits;
LUAD	cis	rs2274273	0.588	rs7145727	chr14:55847573	G/A	cg04306507	chr14:55594613	LGALS3	0.4	8.32	0.37	1.24e-15	Protein biomarker;
LUAD	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg04450456	chr4:17643702	FAM184B	0.4	8.0	0.36	1.21e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7119	0.700	rs7497168	chr15:77886231	A/C	cg27398640	chr15:77910606	LINGO1	0.38	7.37	0.34	8.97e-13	Type 2 diabetes;
LUAD	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg07606381	chr6:8435919	SLC35B3	0.4	6.57	0.3	1.48e-10	Motion sickness;
LUAD	cis	rs9788682	0.747	rs2036533	chr15:78781687	G/A	cg18825076	chr15:78729989	IREB2	0.54	7.52	0.34	3.32e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs9467773	0.511	rs17278688	chr6:26890136	G/C	cg12292205	chr6:26970375	C6orf41	0.38	6.72	0.31	5.89e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10916814	0.632	rs10916819	chr1:20901000	A/G	cg24502330	chr1:20914028	CDA	-0.36	-7.18	-0.33	3.14e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7851660	0.844	rs10984103	chr9:100639275	G/T	cg13688889	chr9:100608707	NA	0.5	8.64	0.39	1.19e-16	Strep throat;
LUAD	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg23018236	chr17:30244563	NA	-0.62	-8.07	-0.37	7.57e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg13560548	chr3:10150139	C3orf24	0.43	7.41	0.34	6.97e-13	Alzheimer's disease;
LUAD	cis	rs921968	0.565	rs1529382	chr2:219626489	C/T	cg02176678	chr2:219576539	TTLL4	-0.6	-12.18	-0.51	1.91e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7094131	0.558	rs12774725	chr10:22897321	T/C	cg19500236	chr10:22911537	PIP4K2A	-0.41	-6.4	-0.3	4.04e-10	Obesity-related traits;
LUAD	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg06713675	chr4:122721982	EXOSC9	0.57	11.11	0.48	2.48e-25	Type 2 diabetes;
LUAD	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg16680214	chr1:154839983	KCNN3	-0.63	-13.26	-0.54	8.05e-34	Prostate cancer;
LUAD	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg07606381	chr6:8435919	SLC35B3	0.42	7.01	0.32	9.52e-12	Motion sickness;
LUAD	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg13859433	chr6:33739653	LEMD2	-0.34	-7.03	-0.32	8.49e-12	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg00316803	chr15:76480434	C15orf27	0.36	6.53	0.3	1.92e-10	Blood metabolite levels;
LUAD	trans	rs9354308	0.866	rs2814095	chr6:66535706	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.53	8.1	0.37	5.85e-15	Metabolite levels;
LUAD	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg17971929	chr21:40555470	PSMG1	0.53	8.2	0.37	2.92e-15	Cognitive function;
LUAD	cis	rs3106136	0.903	rs35361491	chr4:95202492	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.73	-0.35	7.99e-14	Capecitabine sensitivity;
LUAD	trans	rs2774920	0.614	rs17111205	chr1:94646346	T/C	cg24762501	chr19:51530751	KLK11	-0.65	-6.39	-0.3	4.26e-10	D-dimer levels;
LUAD	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	8.88e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-7.71	-0.35	9.3e-14	Total body bone mineral density;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00147976	chr12:53846229	PCBP2	-0.41	-6.35	-0.3	5.53e-10	Height;
LUAD	trans	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg12400702	chr3:12838781	CAND2	0.31	6.38	0.3	4.77e-10	Parkinson's disease;
LUAD	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg06641503	chr3:48959341	ARIH2	-0.4	-7.85	-0.36	3.56e-14	Parkinson's disease;
LUAD	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg23533926	chr12:111358616	MYL2	-0.41	-7.04	-0.32	7.73e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9346649	0.967	rs6907103	chr6:168490016	C/T	cg02770688	chr6:168491649	NA	-0.38	-7.52	-0.34	3.29e-13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs4462272	0.554	rs7068215	chr10:101859870	C/T	cg19754520	chr10:101825118	CPN1	0.3	6.37	0.3	5.04e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7737355	0.947	rs10477736	chr5:130922125	T/C	cg06307176	chr5:131281290	NA	0.51	7.89	0.36	2.65e-14	Life satisfaction;
LUAD	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg18854424	chr1:2615690	NA	-0.42	-9.08	-0.4	4.12e-18	Ulcerative colitis;
LUAD	cis	rs2050392	0.861	rs303448	chr10:30727084	G/T	cg18806716	chr10:30721971	MAP3K8	-0.56	-10.97	-0.47	8.17e-25	Inflammatory bowel disease;
LUAD	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg12573674	chr2:1569213	NA	-0.6	-6.41	-0.3	3.94e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs208520	0.690	rs851468	chr6:66825875	G/A	cg07460842	chr6:66804631	NA	-1.06	-16.53	-0.63	1e-47	Exhaled nitric oxide output;
LUAD	cis	rs1983170	0.735	rs963910	chr1:92014136	T/C	cg25838465	chr1:92012736	NA	-0.46	-7.46	-0.34	4.95e-13	Eosinophil percentage of white cells;
LUAD	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg00933542	chr6:150070202	PCMT1	0.36	7.51	0.34	3.52e-13	Testicular germ cell tumor;
LUAD	cis	rs1524976	0.943	rs62255325	chr3:65509446	T/A	cg16238336	chr3:65465873	MAGI1	-0.67	-7.36	-0.34	9.97e-13	PR interval;
LUAD	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg02734326	chr4:10020555	SLC2A9	0.54	9.72	0.43	2.73e-20	Bone mineral density;
LUAD	cis	rs6138458	1.000	rs227615	chr20:24908721	T/C	cg06937882	chr20:24974362	C20orf3	-0.33	-6.43	-0.3	3.52e-10	Blood protein levels;
LUAD	trans	rs1728785	0.901	rs12929568	chr16:68596689	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.02	0.44	2.35e-21	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.03	0.32	8.29e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg01475377	chr6:109611718	NA	0.49	8.86	0.4	2.31e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg05373962	chr22:49881684	NA	-0.52	-12.2	-0.51	1.56e-29	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg21724239	chr8:58056113	NA	0.79	9.7	0.43	3.33e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg17173187	chr15:85201210	NMB	0.51	8.68	0.39	8.86e-17	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00166722	chr3:10149974	C3orf24	0.75	12.83	0.53	4.56e-32	Alzheimer's disease;
LUAD	cis	rs654950	0.901	rs594656	chr1:41999873	C/T	cg06885757	chr1:42089581	HIVEP3	-0.48	-10.52	-0.46	3.7e-23	Airway imaging phenotypes;
LUAD	cis	rs4906332	1.000	rs4906332	chr14:103980134	A/T	cg13511324	chr14:104056883	C14orf153	0.26	6.55	0.3	1.67e-10	Coronary artery disease;
LUAD	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg18138036	chr10:133769891	PPP2R2D	0.41	6.57	0.3	1.47e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg14364472	chr9:139394549	NOTCH1	-0.44	-6.62	-0.31	1.09e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg14196790	chr5:131705035	SLC22A5	0.5	9.04	0.4	5.55e-18	Blood metabolite levels;
LUAD	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg15448220	chr1:150897856	SETDB1	0.51	8.61	0.39	1.46e-16	Melanoma;
LUAD	cis	rs9323205	0.954	rs4898682	chr14:51639577	C/T	cg23942311	chr14:51606299	NA	-0.57	-9.82	-0.43	1.23e-20	Cancer;
LUAD	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.8	14.77	0.58	4.34e-40	Lymphocyte counts;
LUAD	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg25894440	chr7:65020034	NA	-0.69	-7.38	-0.34	8.32e-13	Diabetic kidney disease;
LUAD	trans	rs3960554	0.808	rs867973	chr7:75686007	G/A	cg19862616	chr7:65841803	NCRNA00174	0.82	11.03	0.47	4.74e-25	Eotaxin levels;
LUAD	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg12403142	chr1:92012408	NA	-0.36	-6.65	-0.31	9.18e-11	Breast cancer;
LUAD	trans	rs28735056	0.967	rs4799092	chr18:77608203	C/G	cg05926928	chr17:57297772	GDPD1	-0.51	-7.41	-0.34	7.05e-13	Schizophrenia;
LUAD	trans	rs877282	1.000	rs11253370	chr10:773712	G/A	cg22713356	chr15:30763199	NA	1.17	16.83	0.63	4.95e-49	Uric acid levels;
LUAD	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg10589385	chr1:150898437	SETDB1	-0.39	-7.42	-0.34	6.33e-13	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg17366294	chr4:99064904	C4orf37	0.63	11.8	0.5	5.54e-28	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11696501	0.739	rs2281210	chr20:44243172	T/G	cg11783356	chr20:44313418	WFDC10B	-0.5	-7.83	-0.36	4.03e-14	Brain structure;
LUAD	cis	rs78487399	0.614	rs7600657	chr2:43710444	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-7.16	-0.33	3.56e-12	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs7326068	0.610	rs2596150	chr13:21317048	C/T	cg27499820	chr13:21296301	IL17D	0.44	7.2	0.33	2.71e-12	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg16486109	chr11:613632	IRF7	0.49	7.41	0.34	6.99e-13	Systemic lupus erythematosus;
LUAD	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.21	15.86	0.61	9.06e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7593730	0.945	rs10172449	chr2:161225246	T/G	cg22609984	chr2:161126801	NA	0.44	7.16	0.33	3.58e-12	Type 2 diabetes;
LUAD	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.57	-0.3	1.47e-10	Aortic root size;
LUAD	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg06263672	chr7:65235340	NA	0.47	6.48	0.3	2.51e-10	Aortic root size;
LUAD	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg06627628	chr2:24431161	ITSN2	0.67	10.52	0.46	3.76e-23	Asthma;
LUAD	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg23985595	chr17:80112537	CCDC57	0.53	9.66	0.43	4.3e-20	Life satisfaction;
LUAD	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg10356904	chr22:49881777	NA	-0.39	-8.4	-0.38	6.81e-16	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs6087990	1.000	rs1007124	chr20:31345752	G/C	cg13636640	chr20:31349939	DNMT3B	0.84	16.08	0.62	9.49e-46	Ulcerative colitis;
LUAD	cis	rs11671005	0.735	rs11666716	chr19:58920952	A/G	cg13877915	chr19:58951672	ZNF132	0.55	7.27	0.33	1.75e-12	Mean platelet volume;
LUAD	cis	rs28595532	0.623	rs34284204	chr4:119227672	C/T	cg02775129	chr4:119771670	NA	-0.64	-6.89	-0.32	2.02e-11	Cannabis dependence symptom count;
LUAD	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg14092988	chr3:52407081	DNAH1	0.47	9.19	0.41	1.79e-18	Bipolar disorder;
LUAD	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg17120908	chr11:65337727	SSSCA1	-0.6	-9.51	-0.42	1.41e-19	Bone mineral density;
LUAD	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg01528321	chr10:82214614	TSPAN14	0.64	10.19	0.44	6e-22	Post bronchodilator FEV1;
LUAD	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg12011299	chr4:100065546	ADH4	0.64	11.69	0.49	1.51e-27	Alcohol dependence;
LUAD	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg09640425	chr7:158790006	NA	0.43	7.53	0.34	3.1400000000000003e-13	Facial morphology (factor 20);
LUAD	cis	rs2046867	0.908	rs62251640	chr3:72801605	T/C	cg25664220	chr3:72788482	NA	-0.69	-12.52	-0.52	8.47e-31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs10411161	0.702	rs79180893	chr19:52395615	A/G	cg22319618	chr22:45562946	NUP50	-0.66	-9.44	-0.42	2.52e-19	Breast cancer;
LUAD	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg00316803	chr15:76480434	C15orf27	0.39	6.39	0.3	4.47e-10	Blood metabolite levels;
LUAD	cis	rs34734847	0.766	rs3794214	chr12:121168245	C/T	cg21892295	chr12:121157589	UNC119B	0.36	6.4	0.3	4.2e-10	Mean corpuscular volume;
LUAD	cis	rs2932538	0.845	rs6682678	chr1:113206920	A/G	cg22162597	chr1:113214053	CAPZA1	-0.47	-7.04	-0.32	7.58e-12	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg04369109	chr6:150039330	LATS1	-0.46	-7.74	-0.35	7.23e-14	Lung cancer;
LUAD	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg08645402	chr16:4508243	NA	0.52	9.11	0.4	3.44e-18	Schizophrenia;
LUAD	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg01802117	chr1:53393560	SCP2	0.33	6.62	0.31	1.12e-10	Monocyte count;
LUAD	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.44	-7.71	-0.35	9.24e-14	Rheumatoid arthritis;
LUAD	cis	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.19	-0.33	2.92e-12	Coronary artery disease;
LUAD	cis	rs12681287	0.608	rs2953511	chr8:87340870	G/A	cg00550725	chr8:87521180	FAM82B	0.46	6.69	0.31	6.89e-11	Caudate activity during reward;
LUAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg00106254	chr7:1943704	MAD1L1	-0.52	-7.86	-0.36	3.18e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11890956	chr21:40555474	PSMG1	0.82	14.74	0.58	5.43e-40	Cognitive function;
LUAD	cis	rs9788721	0.934	rs1317286	chr15:78896129	A/G	cg18825076	chr15:78729989	IREB2	-0.56	-9.11	-0.41	3.22e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.44	-8.02	-0.36	1.06e-14	Longevity;Endometriosis;
LUAD	cis	rs3925075	0.553	rs9888907	chr16:31349040	A/G	cg10451425	chr16:31478370	ARMC5	0.41	6.7	0.31	6.57e-11	IgA nephropathy;
LUAD	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs11650175	0.634	rs1833347	chr17:63774461	C/T	cg07283582	chr17:63770753	CCDC46	0.32	6.36	0.3	5.25e-10	Chin dimples;
LUAD	cis	rs10499694	0.933	rs11575356	chr7:50594821	T/C	cg18232548	chr7:50535776	DDC	-0.44	-7.5	-0.34	3.75e-13	Body mass index;
LUAD	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg27454412	chr7:1067447	C7orf50	-0.41	-7.79	-0.35	5.32e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs4523957	0.533	rs9899330	chr17:2185827	A/T	cg16513277	chr17:2031491	SMG6	-0.62	-8.77	-0.39	4.36e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2637266	0.756	rs846607	chr10:78561254	A/T	cg18941641	chr10:78392320	NA	0.31	6.45	0.3	2.98e-10	Pulmonary function;
LUAD	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg17761419	chr8:57350749	NA	-0.52	-7.83	-0.36	4.07e-14	Obesity-related traits;
LUAD	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg26354017	chr1:205819088	PM20D1	-0.43	-7.21	-0.33	2.63e-12	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg11663144	chr21:46675770	NA	-0.36	-6.42	-0.3	3.67e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.79	-0.5	6.23e-28	Mean corpuscular volume;
LUAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg00106254	chr7:1943704	MAD1L1	-0.59	-8.99	-0.4	8.18e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs10911363	0.592	rs2702203	chr1:183462513	A/T	cg09173681	chr1:183549694	NCF2	0.53	9.95	0.44	4.41e-21	Systemic lupus erythematosus;
LUAD	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg09455208	chr3:40491958	NA	0.58	12.66	0.52	2.23e-31	Renal cell carcinoma;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg26378593	chr2:128784793	SAP130	-0.63	-6.38	-0.3	4.56e-10	Type 2 diabetes;
LUAD	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.86	0.36	3.31e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg05340658	chr4:99064831	C4orf37	0.56	9.45	0.42	2.42e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12618769	0.597	rs4851142	chr2:99133611	A/C	cg10123293	chr2:99228465	UNC50	0.46	8.06	0.36	8.05e-15	Bipolar disorder;
LUAD	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg15704280	chr7:45808275	SEPT13	-0.84	-14.5	-0.58	5.8e-39	Height;
LUAD	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg15226275	chr6:116381976	FRK	0.24	7.67	0.35	1.19e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs6690583	0.562	rs12024977	chr1:85531051	A/C	cg22153463	chr1:85462885	MCOLN2	0.6	6.39	0.3	4.26e-10	Serum sulfate level;
LUAD	trans	rs11165623	0.564	rs12752866	chr1:97000181	T/C	cg10631902	chr5:14652156	NA	-0.41	-7.48	-0.34	4.48e-13	Hip circumference;Waist circumference;
LUAD	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg14784868	chr12:69753453	YEATS4	0.46	7.59	0.35	2.02e-13	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg26343298	chr8:95960752	TP53INP1	0.39	8.39	0.38	7.11e-16	Type 2 diabetes;
LUAD	cis	rs208520	1.000	rs208523	chr6:66954195	G/C	cg07460842	chr6:66804631	NA	-0.97	-13.16	-0.54	2.25e-33	Exhaled nitric oxide output;
LUAD	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03517284	chr6:25882590	NA	-0.52	-7.78	-0.35	5.42e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg15242686	chr22:24348715	GSTTP1	0.41	6.96	0.32	1.28e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12681288	0.782	rs2123055	chr8:1029500	T/G	cg15309053	chr8:964076	NA	0.4	8.47	0.38	4.2e-16	Schizophrenia;
LUAD	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg03037974	chr15:76606532	NA	0.37	7.81	0.35	4.66e-14	Blood metabolite levels;
LUAD	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg00316803	chr15:76480434	C15orf27	0.4	6.63	0.31	1.06e-10	Blood metabolite levels;
LUAD	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg05234568	chr11:5960015	NA	-0.57	-11.06	-0.47	3.93e-25	DNA methylation (variation);
LUAD	cis	rs4946717	0.740	rs9480634	chr6:106468486	C/T	cg02270332	chr6:106475062	NA	0.44	8.92	0.4	1.47e-17	Inflammatory bowel disease;
LUAD	cis	rs9902453	1.000	rs4350617	chr17:28423088	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	9.05	0.4	5.4e-18	Coffee consumption (cups per day);
LUAD	cis	rs807669	0.903	rs756651	chr22:19179367	T/C	cg24911827	chr22:19170109	CLTCL1	0.45	9.23	0.41	1.31e-18	Metabolite levels;
LUAD	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg05373962	chr22:49881684	NA	-0.48	-9.04	-0.4	5.71e-18	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg27170947	chr2:26402098	FAM59B	0.75	10.11	0.44	1.13e-21	Gut microbiome composition (summer);
LUAD	cis	rs7493	0.901	rs11767787	chr7:95026753	T/C	cg04155289	chr7:94953770	PON1	-0.57	-7.82	-0.36	4.31e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs757647	0.723	rs7702238	chr5:137741343	C/A	cg10676309	chr5:137685565	NA	0.42	7.54	0.34	2.93e-13	Menarche (age at onset);
LUAD	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg10295955	chr4:187884368	NA	-1.12	-27.49	-0.8	3.47e-96	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7107174	1.000	rs1893448	chr11:77969180	G/A	cg19901956	chr11:77921274	USP35	-0.47	-6.64	-0.31	9.46e-11	Testicular germ cell tumor;
LUAD	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg06740227	chr12:86229804	RASSF9	0.36	6.4	0.3	4.23e-10	Major depressive disorder;
LUAD	cis	rs7274811	0.652	rs149236	chr20:32023380	C/T	cg07470512	chr20:32255052	NECAB3;C20orf134	0.42	6.35	0.3	5.43e-10	Height;
LUAD	cis	rs2455799	0.613	rs7614204	chr3:15792748	A/G	cg16303742	chr3:15540471	COLQ	-0.52	-9.72	-0.43	2.83e-20	Mean platelet volume;
LUAD	cis	rs854765	0.647	rs854809	chr17:18006539	C/T	cg04398451	chr17:18023971	MYO15A	-0.91	-18.25	-0.66	2.66e-55	Total body bone mineral density;
LUAD	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg25324976	chr17:61989376	CSHL1	0.36	6.95	0.32	1.43e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7607369	0.596	rs10165754	chr2:219287370	A/G	cg02176678	chr2:219576539	TTLL4	-0.79	-15.46	-0.6	4.47e-43	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs6546550	0.867	rs726920	chr2:70152027	G/C	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.97	-0.47	8.24e-25	Prevalent atrial fibrillation;
LUAD	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg11502198	chr6:26597334	ABT1	0.54	9.08	0.4	4.06e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg03806693	chr22:41940476	POLR3H	0.76	10.14	0.44	9.01e-22	Cannabis dependence symptom count;
LUAD	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg23933602	chr10:16859644	RSU1	0.58	7.82	0.36	4.31e-14	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	cis	rs3766606	0.505	rs67002863	chr1:7923478	G/A	cg26816564	chr1:7831052	VAMP3	0.58	7.9	0.36	2.4e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2404618	0.561	rs9918765	chr8:1484467	C/T	cg13402656	chr8:1511478	DLGAP2	-0.72	-14.46	-0.58	8.27e-39	Lung cancer;
LUAD	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg08219700	chr8:58056026	NA	0.47	6.95	0.32	1.4e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs727505	0.866	rs17327181	chr7:124720303	A/G	cg23710748	chr7:124431027	NA	-0.42	-8.59	-0.39	1.69e-16	Lewy body disease;
LUAD	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15369054	chr17:80825471	TBCD	-0.52	-8.78	-0.39	4.1e-17	Breast cancer;
LUAD	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg23245007	chr3:195682326	NA	-0.41	-6.73	-0.31	5.49e-11	Pancreatic cancer;
LUAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs113835537	0.529	rs7928882	chr11:66234765	C/T	cg26679405	chr11:66247800	DPP3	-0.44	-6.51	-0.3	2.1e-10	Airway imaging phenotypes;
LUAD	cis	rs17539620	0.519	rs871071	chr6:154837667	T/C	cg20019720	chr6:154832845	CNKSR3	0.65	13.71	0.55	1.16e-35	Lipoprotein (a) levels;
LUAD	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.62	0.55	2.78e-35	Tonsillectomy;
LUAD	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg18105134	chr13:113819100	PROZ	1.04	19.48	0.69	8.88e-61	Platelet distribution width;
LUAD	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg15017067	chr4:17643749	FAM184B	0.34	6.67	0.31	8.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs240764	0.681	rs12209887	chr6:101156806	G/A	cg09795085	chr6:101329169	ASCC3	-0.39	-6.79	-0.31	3.91e-11	Neuroticism;
LUAD	cis	rs75920871	0.925	rs7950381	chr11:116963897	C/A	cg04087571	chr11:116723030	SIK3	-0.33	-6.69	-0.31	7.14e-11	Subjective well-being;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg06269397	chr7:100450383	SLC12A9	-0.48	-7.02	-0.32	8.9e-12	Blood protein levels;
LUAD	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg05887092	chr17:76393375	PGS1	0.56	11.4	0.48	2.04e-26	HDL cholesterol;
LUAD	cis	rs3790645	1.000	rs392814	chr1:26892009	T/C	cg23229016	chr1:26872525	RPS6KA1	0.2	6.79	0.31	3.86e-11	Glucose homeostasis traits;
LUAD	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.51	-8.08	-0.37	6.9e-15	Total body bone mineral density;
LUAD	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg17328964	chr8:145687451	CYHR1	0.68	12.54	0.52	6.95e-31	Age at first birth;
LUAD	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg03467027	chr4:99064603	C4orf37	0.43	7.04	0.32	7.8e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg09658497	chr7:2847517	GNA12	-0.53	-9.28	-0.41	8.71e-19	Height;
LUAD	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg12863693	chr15:85201151	NMB	0.39	6.85	0.32	2.66e-11	Schizophrenia;
LUAD	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg25985355	chr7:65971099	NA	-0.39	-7.2	-0.33	2.82e-12	Aortic root size;
LUAD	cis	rs10489202	0.955	rs17557162	chr1:167985950	A/T	cg24449463	chr1:168025552	DCAF6	0.56	7.27	0.33	1.81e-12	Schizophrenia;
LUAD	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg03959625	chr15:84868606	LOC388152	0.42	6.74	0.31	5.29e-11	Schizophrenia;
LUAD	cis	rs17683430	0.764	rs117001013	chr22:32348841	C/T	cg00543991	chr22:32367038	NA	0.87	8.05	0.36	8.45e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUAD	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg21890820	chr11:65308645	LTBP3	-0.59	-9.45	-0.42	2.34e-19	Bone mineral density;
LUAD	cis	rs2637266	0.935	rs2583057	chr10:78396019	C/T	cg18941641	chr10:78392320	NA	0.34	7.1	0.33	5.37e-12	Pulmonary function;
LUAD	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.41	0.42	3.25e-19	Tonsillectomy;
LUAD	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg03433033	chr1:76189801	ACADM	-0.69	-10.63	-0.46	1.49e-23	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs354225	0.544	rs13399656	chr2:54802696	T/G	cg01766943	chr2:54829624	SPTBN1	0.39	7.3	0.33	1.42e-12	Schizophrenia;
LUAD	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg19622623	chr12:86230825	RASSF9	0.42	7.49	0.34	3.93e-13	Major depressive disorder;
LUAD	cis	rs3739034	0.938	rs6752536	chr2:135467498	G/C	cg12500956	chr2:135428796	TMEM163	0.33	6.38	0.3	4.61e-10	Gut microbiome composition (winter);
LUAD	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg10518543	chr12:38710700	ALG10B	0.48	8.06	0.36	7.8e-15	Heart rate;
LUAD	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.55	7.86	0.36	3.13e-14	Platelet count;
LUAD	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg01097406	chr16:89675127	NA	-0.32	-6.36	-0.3	5.29e-10	Vitiligo;
LUAD	cis	rs713477	0.967	rs4243600	chr14:55910679	A/G	cg13175173	chr14:55914753	NA	-0.33	-6.95	-0.32	1.41e-11	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs4523957	0.928	rs12453323	chr17:2160214	T/C	cg16513277	chr17:2031491	SMG6	0.76	14.65	0.58	1.29e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.22	-0.33	2.36e-12	Total body bone mineral density;
LUAD	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg23758822	chr17:41437982	NA	0.99	20.82	0.71	8.69e-67	Menopause (age at onset);
LUAD	cis	rs13082711	0.911	rs11708710	chr3:27457348	A/C	cg02860705	chr3:27208620	NA	0.6	9.27	0.41	9.52e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg11416102	chr8:651193	ERICH1	0.91	8.49	0.38	3.51e-16	IgG glycosylation;
LUAD	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg15181151	chr6:150070149	PCMT1	0.39	7.71	0.35	9.08e-14	Lung cancer;
LUAD	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg02782426	chr3:40428986	ENTPD3	0.42	9.43	0.42	2.81e-19	Renal cell carcinoma;
LUAD	trans	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg01620082	chr3:125678407	NA	-0.8	-8.08	-0.37	6.7e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs10089	0.953	rs6879970	chr5:127387178	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	10.0	0.44	2.73e-21	Ileal carcinoids;
LUAD	cis	rs36051895	0.588	rs12340895	chr9:5076691	C/G	cg02405213	chr9:5042618	JAK2	0.47	6.66	0.31	8.57e-11	Pediatric autoimmune diseases;
LUAD	cis	rs7737355	0.947	rs3776030	chr5:130776738	A/G	cg06307176	chr5:131281290	NA	-0.49	-7.72	-0.35	8.33e-14	Life satisfaction;
LUAD	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg21548813	chr6:291882	DUSP22	-0.53	-8.7	-0.39	7.57e-17	Menopause (age at onset);
LUAD	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg10468373	chr11:64009913	FKBP2	0.57	7.28	0.33	1.69e-12	Mean platelet volume;
LUAD	cis	rs7833986	0.501	rs2668007	chr8:56944111	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.9	14.43	0.57	1.13e-38	Height;
LUAD	cis	rs7633770	0.805	rs11710264	chr3:46661579	T/C	cg11219411	chr3:46661640	NA	0.61	14.39	0.57	1.77e-38	Coronary artery disease;
LUAD	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg09491104	chr22:46646882	C22orf40	-0.58	-11.31	-0.48	4.32e-26	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg18110333	chr6:292329	DUSP22	-0.53	-8.49	-0.38	3.62e-16	Menopause (age at onset);
LUAD	cis	rs1451375	0.642	rs6963996	chr7:50559300	T/C	cg18232548	chr7:50535776	DDC	-0.64	-8.88	-0.4	1.97e-17	Malaria;
LUAD	trans	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.59	-10.62	-0.46	1.61e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs877282	0.891	rs12767062	chr10:797961	C/T	cg06581033	chr10:766294	NA	-0.55	-7.71	-0.35	9.26e-14	Uric acid levels;
LUAD	cis	rs62064224	0.714	rs4794915	chr17:30634363	A/G	cg18200150	chr17:30822561	MYO1D	-0.43	-8.14	-0.37	4.49e-15	Schizophrenia;
LUAD	cis	rs7809950	0.906	rs2395907	chr7:107253304	A/G	cg23024343	chr7:107201750	COG5	0.77	12.4	0.52	2.39e-30	Coronary artery disease;
LUAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg13047869	chr3:10149882	C3orf24	0.64	9.6	0.42	6.98e-20	Alzheimer's disease;
LUAD	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.35	7.31	0.33	1.38e-12	Depression;
LUAD	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg22442454	chr1:209979470	IRF6	0.57	6.59	0.31	1.29e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg05865280	chr17:75406074	SEPT9	0.62	19.67	0.69	1.17e-61	Airflow obstruction;
LUAD	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg06784218	chr1:46089804	CCDC17	0.54	11.54	0.49	5.69e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg24644049	chr4:85504048	CDS1	0.88	7.2	0.33	2.79e-12	Skin colour saturation;
LUAD	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.6	11.55	0.49	5.22e-27	Hemoglobin concentration;
LUAD	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg14926445	chr8:58193284	C8orf71	-0.45	-6.79	-0.31	3.88e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg09658497	chr7:2847517	GNA12	-0.43	-7.91	-0.36	2.31e-14	Height;
LUAD	cis	rs2971970	0.519	rs6467513	chr7:133687565	T/G	cg03336402	chr7:133662267	EXOC4	-0.43	-7.48	-0.34	4.26e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs9788682	0.747	rs2938671	chr15:78732754	A/G	cg18825076	chr15:78729989	IREB2	-0.53	-7.5	-0.34	3.76e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09379162	chr12:26267213	NA	-0.45	-7.26	-0.33	1.93e-12	Height;
LUAD	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg13271783	chr10:134563150	INPP5A	-0.41	-6.78	-0.31	4.12e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg25985355	chr7:65971099	NA	-0.55	-6.85	-0.32	2.55e-11	Diabetic kidney disease;
LUAD	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24531977	chr5:56204891	C5orf35	-1.01	-15.27	-0.6	2.96e-42	Initial pursuit acceleration;
LUAD	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg27284194	chr4:1044797	NA	0.71	10.26	0.45	3.2800000000000002e-22	Recombination rate (females);
LUAD	cis	rs9296092	0.560	rs3846854	chr6:33528466	T/C	cg13560919	chr6:33536144	NA	-0.9	-16.72	-0.63	1.49e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg14668632	chr7:2872130	GNA12	-0.74	-13.06	-0.54	5.29e-33	Height;
LUAD	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg04369109	chr6:150039330	LATS1	0.43	7.0	0.32	9.88e-12	Lung cancer;
LUAD	cis	rs12216545	0.765	rs7787639	chr7:150226616	A/T	cg08960815	chr7:150264767	GIMAP4	-0.31	-6.68	-0.31	7.55e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.65	8.95	0.4	1.14e-17	Gut microbiome composition (summer);
LUAD	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21659725	chr3:3221576	CRBN	-0.64	-11.13	-0.48	2.05e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg19318889	chr4:1322082	MAEA	0.46	7.45	0.34	5.27e-13	Obesity-related traits;
LUAD	cis	rs2455799	0.634	rs11128765	chr3:15903331	G/T	cg16303742	chr3:15540471	COLQ	-0.48	-8.75	-0.39	5e-17	Mean platelet volume;
LUAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00149659	chr3:10157352	C3orf10	0.6	8.25	0.37	1.97e-15	Alzheimer's disease;
LUAD	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg07395648	chr5:131743802	NA	0.38	6.43	0.3	3.48e-10	Blood metabolite levels;
LUAD	cis	rs12145833	0.538	rs10754798	chr1:243309958	A/G	cg02356786	chr1:243265016	LOC731275	-0.64	-7.61	-0.35	1.75e-13	Obesity (early onset extreme);
LUAD	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07636037	chr3:49044803	WDR6	0.49	8.48	0.38	3.94e-16	Menarche (age at onset);
LUAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.51	-9.36	-0.41	4.73e-19	Longevity;Endometriosis;
LUAD	trans	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg11693508	chr17:37793320	STARD3	0.77	10.11	0.44	1.18e-21	Bipolar disorder;
LUAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg11965913	chr1:205819406	PM20D1	-0.73	-14.57	-0.58	3.01e-39	Monocyte percentage of white cells;
LUAD	cis	rs9479482	0.935	rs563278	chr6:150364427	G/C	cg08316699	chr6:150357289	NA	0.36	7.18	0.33	3.26e-12	Alopecia areata;
LUAD	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg06784218	chr1:46089804	CCDC17	0.6	13.39	0.55	2.41e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05901451	chr6:126070800	HEY2	-0.84	-15.68	-0.61	5.15e-44	Brugada syndrome;
LUAD	cis	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg05084668	chr3:125655381	ALG1L	-0.57	-9.27	-0.41	9.31e-19	Blood pressure (smoking interaction);
LUAD	cis	rs2066819	1.000	rs11171806	chr12:56733531	A/G	cg26714650	chr12:56694279	CS	0.79	6.93	0.32	1.59e-11	Psoriasis vulgaris;
LUAD	cis	rs9796	0.576	rs13329511	chr15:41299121	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.51	-9.48	-0.42	1.8e-19	Menopause (age at onset);
LUAD	cis	rs2227564	0.597	rs2271271	chr10:75558867	G/A	cg23231163	chr10:75533350	FUT11	-0.43	-6.85	-0.32	2.69e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs4523957	0.928	rs216189	chr17:2187401	A/G	cg16513277	chr17:2031491	SMG6	-0.78	-15.09	-0.59	1.81e-41	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg09654669	chr8:57350985	NA	-0.66	-10.03	-0.44	2.29e-21	Obesity-related traits;
LUAD	cis	rs8067545	0.750	rs11869616	chr17:19992713	G/A	cg04132472	chr17:19861366	AKAP10	0.29	6.99	0.32	1.05e-11	Schizophrenia;
LUAD	trans	rs9408928	0.778	rs9409230	chr9:123967760	A/T	cg11779395	chr4:142155291	ZNF330	0.59	6.49	0.3	2.47e-10	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs6684428	1.000	rs55693755	chr1:56369906	T/A	cg11651538	chr1:56320950	NA	-0.4	-6.39	-0.3	4.39e-10	Airflow obstruction;
LUAD	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.07	-0.37	7.22e-15	Diabetic kidney disease;
LUAD	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg26446133	chr18:72167187	CNDP2	-0.75	-11.27	-0.48	6.34e-26	Refractive error;
LUAD	cis	rs4481887	0.720	rs4543835	chr1:248468608	A/T	cg13385794	chr1:248469461	NA	0.26	6.99	0.32	1.06e-11	Common traits (Other);
LUAD	cis	rs9462027	0.628	rs6921363	chr6:34770820	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.7	-0.39	7.34e-17	Systemic lupus erythematosus;
LUAD	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.59	-0.42	7.44e-20	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg20607798	chr8:58055168	NA	0.67	8.79	0.39	3.8e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg21285383	chr16:89894308	SPIRE2	0.42	10.23	0.45	4.13e-22	Vitiligo;
LUAD	cis	rs6005807	0.843	rs9620803	chr22:28919034	T/C	cg12565055	chr22:29076175	TTC28	0.67	6.52	0.3	1.99e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10802521	chr3:52805072	NEK4	0.51	8.71	0.39	6.66e-17	Bipolar disorder;
LUAD	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.57	-0.35	2.38e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg10523679	chr1:76189770	ACADM	-0.89	-16.12	-0.62	6.66e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg12908607	chr1:44402522	ARTN	0.56	10.16	0.44	7.31e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs78311490	1.000	rs7687602	chr4:107849340	C/T	cg25026715	chr17:26989248	SUPT6H;SDF2	0.51	6.64	0.31	9.82e-11	Male-pattern baldness;
LUAD	cis	rs977987	0.806	rs2865530	chr16:75414376	G/T	cg03315344	chr16:75512273	CHST6	0.64	14.19	0.57	1.19e-37	Dupuytren's disease;
LUAD	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg05044414	chr3:183734942	ABCC5	0.39	7.75	0.35	7.11e-14	Anterior chamber depth;
LUAD	trans	rs62103177	0.525	rs612913	chr18:77845882	A/G	cg05926928	chr17:57297772	GDPD1	-0.82	-10.02	-0.44	2.31e-21	Opioid sensitivity;
LUAD	cis	rs11614062	1.000	rs11614062	chr12:93956672	A/T	cg18151635	chr12:93972918	NA	-0.79	-11.0	-0.47	6.62e-25	Height;
LUAD	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03934478	chr11:495069	RNH1	0.74	9.0	0.4	7.55e-18	Body mass index;
LUAD	cis	rs6499255	0.951	rs10454066	chr16:69699005	A/T	cg15192750	chr16:69999425	NA	0.52	8.13	0.37	4.81e-15	IgE levels;
LUAD	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24531977	chr5:56204891	C5orf35	-0.97	-14.62	-0.58	1.72e-39	Initial pursuit acceleration;
LUAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.91	-0.36	2.34e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg03188948	chr7:1209495	NA	0.46	7.47	0.34	4.72e-13	Longevity;Endometriosis;
LUAD	cis	rs11756438	0.572	rs1844963	chr6:119002679	C/G	cg18833306	chr6:118973337	C6orf204	0.49	8.77	0.39	4.42e-17	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg13319975	chr6:146136371	FBXO30	-0.62	-10.67	-0.46	1.1e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg07570687	chr10:102243282	WNT8B	0.45	6.87	0.32	2.28e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs3823572	0.504	rs2346268	chr7:133642742	G/A	cg03336402	chr7:133662267	EXOC4	-0.41	-7.5	-0.34	3.89e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg03467027	chr4:99064603	C4orf37	0.43	6.95	0.32	1.4e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs739496	0.947	rs10849948	chr12:111875410	A/G	cg10833066	chr12:111807467	FAM109A	0.45	8.16	0.37	3.9e-15	Platelet count;
LUAD	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg18806716	chr10:30721971	MAP3K8	-0.78	-16.82	-0.63	5.81e-49	Inflammatory bowel disease;
LUAD	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg11494091	chr17:61959527	GH2	-0.41	-7.85	-0.36	3.35e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.6	-11.02	-0.47	5.38e-25	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.42	0.38	5.75e-16	Platelet count;
LUAD	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg18854424	chr1:2615690	NA	0.42	9.16	0.41	2.3e-18	Ulcerative colitis;
LUAD	cis	rs89107	0.688	rs283091	chr6:118588684	A/G	cg21191810	chr6:118973309	C6orf204	-0.48	-9.49	-0.42	1.65e-19	Cardiac structure and function;
LUAD	trans	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.52	0.46	3.78e-23	Mean corpuscular volume;
LUAD	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-7.71	-0.35	8.98e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg01475377	chr6:109611718	NA	-0.54	-10.5	-0.45	4.41e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg11663144	chr21:46675770	NA	-0.62	-12.36	-0.52	3.67e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7851660	0.844	rs12343182	chr9:100624259	G/C	cg13688889	chr9:100608707	NA	-0.5	-8.52	-0.38	2.82e-16	Strep throat;
LUAD	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.46	0.38	4.37e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg00933542	chr6:150070202	PCMT1	0.42	8.86	0.4	2.28e-17	Lung cancer;
LUAD	cis	rs4889855	0.556	rs11150863	chr17:78532321	A/G	cg16591659	chr17:78472290	NA	-0.39	-6.94	-0.32	1.5e-11	Fractional excretion of uric acid;
LUAD	trans	rs208520	0.874	rs208470	chr6:66916402	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-14.24	-0.57	7.34e-38	Exhaled nitric oxide output;
LUAD	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg09537434	chr19:41945824	ATP5SL	0.5	7.99	0.36	1.33e-14	Height;
LUAD	cis	rs10865541	0.806	rs10187625	chr2:3421168	A/G	cg13173536	chr2:3403300	TTC15	-0.34	-6.46	-0.3	2.83e-10	Obesity-related traits;
LUAD	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg12179176	chr11:130786555	SNX19	0.55	9.29	0.41	8.21e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7927771	0.524	rs2170815	chr11:47875910	T/C	cg18512352	chr11:47633146	NA	0.36	6.38	0.3	4.72e-10	Subjective well-being;
LUAD	cis	rs4891159	0.790	rs1787448	chr18:74113179	T/C	cg24786174	chr18:74118243	ZNF516	0.8	14.98	0.59	5.48e-41	Longevity;
LUAD	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-9.39	-0.42	3.69e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6840360	0.554	rs13108359	chr4:152727852	T/C	cg22705602	chr4:152727874	NA	0.46	8.97	0.4	9.54e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg26898376	chr11:64110657	CCDC88B	0.4	7.35	0.34	1.02e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs7527798	0.592	rs11118278	chr1:207831357	C/G	cg09232269	chr1:207846808	CR1L	-0.36	-6.83	-0.32	2.89e-11	Erythrocyte sedimentation rate;
LUAD	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg05090351	chr10:126851162	NA	0.54	10.56	0.46	2.74e-23	Menarche (age at onset);
LUAD	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg18198730	chr1:247681584	NA	0.43	7.96	0.36	1.59e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7274811	0.634	rs4911356	chr20:32255034	T/C	cg00478435	chr20:32254706	NECAB3;C20orf134	-0.41	-6.43	-0.3	3.5e-10	Height;
LUAD	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg11645453	chr3:52864694	ITIH4	0.39	7.69	0.35	1.08e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9467773	1.000	rs6456735	chr6:26574149	G/A	cg09904177	chr6:26538194	HMGN4	0.43	6.98	0.32	1.16e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10911251	0.546	rs10911267	chr1:183115323	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.59	0.31	1.29e-10	Colorectal cancer;
LUAD	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg16060761	chr17:80687452	NA	0.48	7.16	0.33	3.58e-12	Breast cancer;
LUAD	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg14668632	chr7:2872130	GNA12	-0.46	-8.17	-0.37	3.6e-15	Height;
LUAD	cis	rs1160297	0.585	rs12713230	chr2:53090138	A/G	cg07782112	chr2:53107842	NA	0.41	8.79	0.39	3.83e-17	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs732716	0.785	rs62130979	chr19:4432444	T/C	cg21934504	chr19:4445085	UBXN6	0.45	7.21	0.33	2.65e-12	Mean corpuscular volume;
LUAD	cis	rs2580764	0.540	rs10210840	chr2:55226009	G/A	cg09592903	chr2:55203963	RTN4	-0.45	-10.44	-0.45	7.68e-23	Mean platelet volume;
LUAD	trans	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg20587970	chr11:113659929	NA	-1.07	-11.56	-0.49	4.75e-27	Height;
LUAD	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg01808030	chr22:45809952	RIBC2;SMC1B	-0.75	-8.61	-0.39	1.46e-16	Tonsillectomy;
LUAD	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.4	-7.36	-0.34	9.82e-13	Urate levels in overweight individuals;
LUAD	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg19761014	chr17:28927070	LRRC37B2	0.86	8.32	0.38	1.22e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21659725	chr3:3221576	CRBN	-0.66	-10.47	-0.45	5.98e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2262909	0.925	rs73019900	chr19:22286680	G/A	cg11619707	chr19:22235551	ZNF257	0.5	7.56	0.35	2.46e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.79	-0.31	3.76e-11	Breast cancer;
LUAD	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg13647721	chr17:30228624	UTP6	0.48	6.52	0.3	1.97e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg23254163	chr1:152506842	NA	0.26	7.27	0.33	1.8e-12	Hair morphology;
LUAD	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg12011299	chr4:100065546	ADH4	0.68	12.65	0.52	2.59e-31	Alcohol dependence;
LUAD	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg25985355	chr7:65971099	NA	-0.56	-6.91	-0.32	1.79e-11	Gout;
LUAD	cis	rs6499255	0.904	rs2161631	chr16:69556948	C/A	cg15192750	chr16:69999425	NA	0.5	7.81	0.35	4.6e-14	IgE levels;
LUAD	cis	rs12760731	0.565	rs78577576	chr1:178141982	A/G	cg00404053	chr1:178313656	RASAL2	0.7	8.89	0.4	1.75e-17	Obesity-related traits;
LUAD	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg07936489	chr17:37558343	FBXL20	0.44	6.93	0.32	1.55e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs6564851	0.506	rs11641417	chr16:81257783	G/A	cg00908271	chr16:81254010	PKD1L2	0.32	6.42	0.3	3.76e-10	Carotenoid and tocopherol levels;
LUAD	cis	rs750460	0.844	rs28617339	chr15:74223571	T/C	cg23484268	chr15:74220776	LOXL1	0.36	6.88	0.32	2.11e-11	Height;
LUAD	cis	rs80319144	0.535	rs11677190	chr2:159394064	C/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.37	7.4	0.34	7.42e-13	Restless legs syndrome;
LUAD	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg03859395	chr2:55845619	SMEK2	0.74	13.84	0.56	3.56e-36	Metabolic syndrome;
LUAD	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg07538946	chr5:131705188	SLC22A5	-0.49	-8.18	-0.37	3.3e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	11.66	0.49	1.88e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-10.4	-0.45	1.04e-22	Schizophrenia;
LUAD	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg22166914	chr1:53195759	ZYG11B	-0.39	-6.49	-0.3	2.44e-10	Monocyte count;
LUAD	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21659725	chr3:3221576	CRBN	0.69	11.83	0.5	4.16e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg11494091	chr17:61959527	GH2	-0.79	-20.86	-0.71	5.57e-67	Prudent dietary pattern;
LUAD	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.83	11.6	0.49	3.49e-27	Smoking behavior;
LUAD	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19717773	chr7:2847554	GNA12	-0.5	-8.68	-0.39	8.58e-17	Height;
LUAD	cis	rs10489202	0.632	rs12410730	chr1:168069477	T/C	cg24449463	chr1:168025552	DCAF6	-0.66	-10.4	-0.45	1.03e-22	Schizophrenia;
LUAD	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.33	0.48	3.68e-26	Hip circumference adjusted for BMI;
LUAD	cis	rs9469578	0.901	rs57303110	chr6:33706159	G/A	cg18708504	chr6:33715942	IP6K3	0.75	8.23	0.37	2.34e-15	Phosphorus levels;
LUAD	cis	rs250585	0.538	rs7186729	chr16:23526094	T/C	cg00143387	chr16:23521605	GGA2	-0.64	-7.46	-0.34	4.87e-13	Egg allergy;
LUAD	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.56	0.3	1.54e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.91e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9972944	0.783	rs9972942	chr17:63771007	A/G	cg07283582	chr17:63770753	CCDC46	0.51	11.42	0.49	1.67e-26	Total body bone mineral density;
LUAD	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg11502198	chr6:26597334	ABT1	0.54	9.14	0.41	2.56e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg25237894	chr2:233734115	C2orf82	-0.61	-11.36	-0.48	2.79e-26	Coronary artery disease;
LUAD	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg06558623	chr16:89946397	TCF25	1.14	10.37	0.45	1.38e-22	Skin colour saturation;
LUAD	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg24399712	chr22:39784796	NA	-0.69	-9.76	-0.43	1.92e-20	IgG glycosylation;
LUAD	trans	rs79911532	0.515	rs76083953	chr7:75698576	G/C	cg19862616	chr7:65841803	NCRNA00174	0.82	8.47	0.38	4e-16	Mononucleosis;
LUAD	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg15147215	chr3:52552868	STAB1	-0.38	-7.04	-0.32	7.85e-12	Bipolar disorder;
LUAD	trans	rs9348739	1	rs9348739	chr6:26923099	G/C	cg01620082	chr3:125678407	NA	-0.67	-7.28	-0.33	1.61e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg02569458	chr12:86230093	RASSF9	0.42	7.9	0.36	2.46e-14	Major depressive disorder;
LUAD	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg16850897	chr7:100343110	ZAN	0.43	7.63	0.35	1.55e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.65	0.31	8.98e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg04511125	chr2:88470314	THNSL2	0.97	11.19	0.48	1.21e-25	Plasma clusterin levels;
LUAD	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg16590910	chr6:42928470	GNMT	0.35	6.38	0.3	4.62e-10	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg22482690	chr17:47019901	SNF8	0.44	8.32	0.37	1.25e-15	Type 2 diabetes;
LUAD	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg02269571	chr22:50332266	NA	-0.68	-9.9	-0.43	6.32e-21	Schizophrenia;
LUAD	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg17366294	chr4:99064904	C4orf37	0.66	12.77	0.53	7.85e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18867708	chr6:26865862	GUSBL1	0.49	7.72	0.35	8.57e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs72772090	0.539	rs11741100	chr5:96113245	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.12	-0.33	4.68e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg04944784	chr2:26401820	FAM59B	-0.76	-10.5	-0.45	4.4e-23	Gut microbiome composition (summer);
LUAD	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg19318889	chr4:1322082	MAEA	0.5	8.4	0.38	6.98e-16	Longevity;
LUAD	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22496380	chr5:211416	CCDC127	-1.24	-15.49	-0.6	3.56e-43	Breast cancer;
LUAD	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg02734326	chr4:10020555	SLC2A9	0.64	11.35	0.48	3.04e-26	Bone mineral density;
LUAD	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg15369054	chr17:80825471	TBCD	-0.48	-7.89	-0.36	2.68e-14	Breast cancer;
LUAD	cis	rs11112613	0.609	rs11112632	chr12:106041887	A/G	cg03607813	chr12:105948248	NA	-0.49	-6.47	-0.3	2.76e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg06873352	chr17:61820015	STRADA	0.41	6.43	0.3	3.44e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs943466	1.000	rs6933607	chr6:33743997	G/A	cg16010596	chr6:33739607	LEMD2	-0.41	-7.77	-0.35	5.83e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.71	-0.35	9.22e-14	Personality dimensions;
LUAD	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.47	-7.48	-0.34	4.21e-13	Tonsillectomy;
LUAD	cis	rs4144027	0.875	rs6576010	chr14:104349602	A/G	cg12183467	chr14:104352244	NA	-0.37	-7.25	-0.33	1.97e-12	Blood metabolite levels;
LUAD	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.39	7.71	0.35	8.96e-14	Multiple sclerosis or amyotrophic lateral sclerosis;
LUAD	cis	rs4764487	0.710	rs7964366	chr12:6346478	T/C	cg08284733	chr12:6341482	CD9	0.42	7.55	0.34	2.72e-13	Mean platelet volume;
LUAD	cis	rs62458065	0.713	rs3801329	chr7:32496956	A/C	cg20159608	chr7:32802032	NA	-0.6	-8.27	-0.37	1.8e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.65	-0.35	1.37e-13	Blood metabolite levels;
LUAD	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg10792982	chr14:105748885	BRF1	0.45	9.83	0.43	1.11e-20	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg26924012	chr15:45694286	SPATA5L1	0.86	14.86	0.59	1.79e-40	Homoarginine levels;
LUAD	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg22535103	chr8:58192502	C8orf71	-0.71	-10.39	-0.45	1.12e-22	Developmental language disorder (linguistic errors);
LUAD	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg10518543	chr12:38710700	ALG10B	0.4	6.36	0.3	5.09e-10	Morning vs. evening chronotype;
LUAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00149659	chr3:10157352	C3orf10	0.57	8.06	0.36	7.87e-15	Alzheimer's disease;
LUAD	cis	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg23950597	chr19:37808831	NA	-0.62	-7.79	-0.35	5.29e-14	Coronary artery calcification;
LUAD	cis	rs9341808	0.530	rs3805877	chr6:81031529	T/A	cg08355045	chr6:80787529	NA	0.5	8.63	0.39	1.21e-16	Sitting height ratio;
LUAD	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg18446336	chr7:2847575	GNA12	-0.37	-6.95	-0.32	1.43e-11	Height;
LUAD	cis	rs6564851	0.506	rs7185774	chr16:81249927	C/T	cg00908271	chr16:81254010	PKD1L2	0.33	6.75	0.31	4.88e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs9788721	0.640	rs1394371	chr15:78724469	C/T	cg18825076	chr15:78729989	IREB2	-0.56	-9.29	-0.41	8.46e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg15557168	chr22:42548783	NA	-0.45	-8.39	-0.38	7.42e-16	Cognitive function;
LUAD	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg03467027	chr4:99064603	C4orf37	0.41	6.77	0.31	4.22e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg10729496	chr3:10149963	C3orf24	0.49	7.92	0.36	2.15e-14	Alzheimer's disease;
LUAD	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg13755796	chr4:20253514	NA	-0.4	-6.95	-0.32	1.39e-11	Life satisfaction;
LUAD	trans	rs4650994	1.000	rs35810840	chr1:178522642	G/A	cg05059571	chr16:84539110	KIAA1609	-0.6	-10.26	-0.45	3.24e-22	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg08601574	chr20:25228251	PYGB	-0.47	-8.83	-0.39	2.87e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs11229555	0.645	rs61905183	chr11:58228463	T/A	cg15696309	chr11:58395628	NA	-0.8	-10.78	-0.46	4.04e-24	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg12623918	chr2:306882	NA	0.35	6.9	0.32	1.97e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg09436375	chr6:42928200	GNMT	-0.28	-8.07	-0.37	7.53e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs45430	1.000	rs45430	chr21:42746081	C/T	cg22778903	chr21:42741698	MX2	0.39	8.12	0.37	5.32e-15	Melanoma;
LUAD	cis	rs10504073	0.647	rs10808745	chr8:49989037	G/A	cg00325661	chr8:49890786	NA	0.45	10.07	0.44	1.64e-21	Blood metabolite ratios;
LUAD	cis	rs7945718	0.967	rs4415740	chr11:12783911	C/T	cg25843174	chr11:12811716	TEAD1	0.25	7.38	0.34	8.22e-13	Educational attainment (years of education);
LUAD	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05776053	chr2:74358815	NA	0.44	6.94	0.32	1.48e-11	Gestational age at birth (maternal effect);
LUAD	cis	rs986417	0.901	rs10782440	chr14:61031648	G/C	cg27398547	chr14:60952738	C14orf39	0.6	7.62	0.35	1.71e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs6500395	1.000	rs9938308	chr16:48607229	A/G	cg04672837	chr16:48644449	N4BP1	0.38	6.59	0.31	1.3100000000000001e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg04455712	chr21:45112962	RRP1B	0.41	8.36	0.38	9.29e-16	Mean corpuscular volume;
LUAD	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.54	9.79	0.43	1.55e-20	Axial length;
LUAD	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg27532560	chr4:187881888	NA	-0.36	-6.89	-0.32	2.02e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg26513180	chr16:89883248	FANCA	-0.69	-6.84	-0.32	2.75e-11	Caffeine consumption;
LUAD	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg16325326	chr1:53192061	ZYG11B	0.63	12.35	0.51	3.74e-30	Monocyte count;
LUAD	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.84	-0.32	2.76e-11	Retinal vascular caliber;
LUAD	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg13732083	chr21:47605072	C21orf56	-0.46	-6.97	-0.32	1.25e-11	Testicular germ cell tumor;
LUAD	cis	rs116248771	0.739	rs76493374	chr3:158345639	G/A	cg16708174	chr3:158430962	RARRES1	0.46	6.8	0.31	3.62e-11	diarrhoeal disease at age 2;
LUAD	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg18105134	chr13:113819100	PROZ	0.86	15.09	0.59	1.76e-41	Platelet distribution width;
LUAD	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg04455712	chr21:45112962	RRP1B	0.47	9.49	0.42	1.77e-19	Mean corpuscular volume;
LUAD	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg19336497	chr11:14380999	RRAS2	-0.66	-14.14	-0.57	1.88e-37	Sense of smell;
LUAD	cis	rs2224391	0.617	rs67307669	chr6:5293095	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-8.56	-0.38	2.16e-16	Height;
LUAD	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg17063962	chr7:91808500	NA	0.68	12.24	0.51	1.09e-29	Breast cancer;
LUAD	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg11317459	chr13:21872234	NA	-1.08	-13.77	-0.56	6.58e-36	White matter hyperintensity burden;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06463913	chr11:207296	BET1L;RIC8A	-0.54	-6.56	-0.3	1.53e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10484885	0.618	rs292241	chr6:90603505	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.65	-9.04	-0.4	5.48e-18	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs737008	0.960	rs11640295	chr16:11390728	C/G	cg00044050	chr16:11439710	C16orf75	0.54	7.77	0.35	5.94e-14	Obesity-related traits;
LUAD	cis	rs12545109	0.732	rs1973629	chr8:57429583	A/G	cg09654669	chr8:57350985	NA	-0.68	-9.15	-0.41	2.52e-18	Obesity-related traits;
LUAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08280861	chr8:58055591	NA	0.67	8.78	0.39	4.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg01416388	chr22:39784598	NA	-0.47	-7.33	-0.34	1.18e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs870825	0.929	rs72689255	chr4:185590141	T/C	cg04058563	chr4:185651563	MLF1IP	0.79	10.04	0.44	1.99e-21	Blood protein levels;
LUAD	cis	rs7089973	0.932	rs17794346	chr10:116643095	C/T	cg25233709	chr10:116636983	FAM160B1	-0.36	-6.64	-0.31	9.72e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.48	0.3	2.59e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3820068	0.705	rs72645808	chr1:15870118	G/C	cg24675056	chr1:15929824	NA	0.44	6.7	0.31	6.52e-11	Systolic blood pressure;
LUAD	cis	rs7680126	0.633	rs11730631	chr4:10292968	C/T	cg02734326	chr4:10020555	SLC2A9	0.47	6.57	0.3	1.47e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.52	7.0	0.32	1.02e-11	Platelet count;
LUAD	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg18827107	chr12:86230957	RASSF9	-0.53	-9.48	-0.42	1.81e-19	Major depressive disorder;
LUAD	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg13560548	chr3:10150139	C3orf24	0.41	6.93	0.32	1.56e-11	Alzheimer's disease;
LUAD	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg23933602	chr10:16859644	RSU1	0.97	21.07	0.72	6.69e-68	Platelet distribution width;
LUAD	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.93	0.4	1.34e-17	Menarche (age at onset);
LUAD	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg22467129	chr15:76604101	ETFA	-0.51	-8.89	-0.4	1.82e-17	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.49	-0.3	2.38e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg00981070	chr1:2046702	PRKCZ	-0.37	-7.78	-0.35	5.49e-14	Height;
LUAD	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg27411982	chr8:10470053	RP1L1	0.41	7.51	0.34	3.51e-13	Triglycerides;
LUAD	cis	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.59	-0.35	2.13e-13	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg18404041	chr3:52824283	ITIH1	0.58	12.5	0.52	9.83e-31	Bipolar disorder;
LUAD	cis	rs9462027	0.585	rs188190	chr6:34551086	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.73	-0.39	5.82e-17	Systemic lupus erythematosus;
LUAD	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg09509183	chr1:209979624	IRF6	0.57	7.8	0.35	4.91e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs642803	0.613	rs489574	chr11:65542739	C/T	cg27068330	chr11:65405492	SIPA1	0.44	6.85	0.32	2.66e-11	Urate levels;
LUAD	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg05340658	chr4:99064831	C4orf37	0.53	9.07	0.4	4.46e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1562242	0.653	rs2441112	chr5:57601615	T/C	cg09002358	chr5:57541568	NA	0.58	7.2	0.33	2.77e-12	Educational attainment (years of education);
LUAD	cis	rs7809950	0.678	rs75617662	chr7:107030439	G/A	cg23024343	chr7:107201750	COG5	-0.82	-13.97	-0.56	9.86e-37	Coronary artery disease;
LUAD	cis	rs9330264	0.508	rs7364869	chr1:155087188	A/G	cg23973274	chr1:155060172	NA	-0.38	-6.5	-0.3	2.32e-10	1,5-anhydroglucitol levels;
LUAD	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.43	-0.34	5.94e-13	Type 2 diabetes;
LUAD	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg06608945	chr2:219082296	ARPC2	0.49	8.35	0.38	9.63e-16	Colorectal cancer;
LUAD	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg01528321	chr10:82214614	TSPAN14	0.76	10.15	0.44	8.04e-22	Post bronchodilator FEV1;
LUAD	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg02753203	chr1:228287806	NA	-0.48	-8.61	-0.39	1.44e-16	Diastolic blood pressure;
LUAD	cis	rs1595825	0.945	rs2139050	chr2:198852636	A/G	cg11031976	chr2:198649780	BOLL	-0.48	-7.08	-0.33	6e-12	Ulcerative colitis;
LUAD	cis	rs11741688	1.000	rs11741688	chr5:178395850	G/C	cg21944022	chr5:178288650	ZNF354B	-0.41	-7.34	-0.34	1.14e-12	Sleep duration;
LUAD	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg26384229	chr12:38710491	ALG10B	0.49	8.03	0.36	9.43e-15	Heart rate;
LUAD	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg10978503	chr1:24200527	CNR2	-0.55	-12.07	-0.51	4.99e-29	Immature fraction of reticulocytes;
LUAD	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg15208524	chr1:10270712	KIF1B	0.43	6.49	0.3	2.44e-10	Hepatocellular carcinoma;
LUAD	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg10802521	chr3:52805072	NEK4	-0.45	-6.58	-0.3	1.41e-10	Schizophrenia;
LUAD	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.91	-0.5	2.11e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg19163074	chr7:65112434	INTS4L2	0.44	6.76	0.31	4.56e-11	Aortic root size;
LUAD	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg14552801	chr7:65878734	NA	-0.37	-6.35	-0.3	5.43e-10	Aortic root size;
LUAD	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.67	10.27	0.45	3.17e-22	Lymphocyte percentage of white cells;
LUAD	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg15704280	chr7:45808275	SEPT13	-1.0	-20.27	-0.7	2.52e-64	Height;
LUAD	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg00383909	chr3:49044727	WDR6	0.67	8.5	0.38	3.26e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg17652424	chr22:38574118	PLA2G6	0.26	7.65	0.35	1.32e-13	Cutaneous nevi;
LUAD	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26314531	chr2:26401878	FAM59B	0.72	9.72	0.43	2.76e-20	Gut microbiome composition (summer);
LUAD	trans	rs1493916	0.837	rs11876492	chr18:31413804	T/C	cg27147174	chr7:100797783	AP1S1	-0.63	-11.05	-0.47	4.09e-25	Life satisfaction;
LUAD	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg11189052	chr15:85197271	WDR73	-0.59	-8.13	-0.37	4.74e-15	Schizophrenia;
LUAD	cis	rs9902453	0.689	rs7216948	chr17:28203173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	10.69	0.46	9.16e-24	Coffee consumption (cups per day);
LUAD	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg07870213	chr5:140052090	DND1	0.98	13.31	0.54	5.39e-34	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg17863274	chr19:49399704	TULP2	-0.6	-9.12	-0.41	3.13e-18	Red cell distribution width;
LUAD	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.58	-9.96	-0.44	3.9e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs1953600	0.540	rs2784773	chr10:81919800	A/G	cg00277334	chr10:82204260	NA	-0.47	-7.72	-0.35	8.44e-14	Sarcoidosis;
LUAD	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg05082376	chr22:42548792	NA	-0.43	-7.34	-0.34	1.09e-12	Schizophrenia;
LUAD	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg02527881	chr3:46936655	PTH1R	-0.49	-9.65	-0.42	4.75e-20	Colorectal cancer;
LUAD	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06873352	chr17:61820015	STRADA	0.5	8.25	0.37	2.09e-15	Height;
LUAD	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg26597838	chr10:835615	NA	0.69	9.79	0.43	1.56e-20	Eosinophil percentage of granulocytes;
LUAD	cis	rs9296092	0.560	rs9469506	chr6:33527897	A/G	cg13560919	chr6:33536144	NA	-0.9	-16.72	-0.63	1.49e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg06531007	chr1:207628110	CR2	-0.66	-6.71	-0.31	6.28e-11	Type 2 diabetes;
LUAD	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11890956	chr21:40555474	PSMG1	-0.56	-9.85	-0.43	9.48e-21	Menarche (age at onset);
LUAD	trans	rs853679	0.607	rs13201308	chr6:28130089	C/T	cg06606381	chr12:133084897	FBRSL1	-1.22	-10.86	-0.47	2.15e-24	Depression;
LUAD	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-9.62	-0.42	5.98e-20	Obesity (extreme);
LUAD	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg23840854	chr1:161414152	NA	-0.87	-11.79	-0.5	6.08e-28	Rheumatoid arthritis;
LUAD	cis	rs7107174	1.000	rs2510055	chr11:77961912	C/T	cg19901956	chr11:77921274	USP35	-0.55	-6.94	-0.32	1.52e-11	Testicular germ cell tumor;
LUAD	trans	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg14791747	chr16:20752902	THUMPD1	0.74	10.02	0.44	2.33e-21	Cognitive test performance;
LUAD	cis	rs7586879	0.828	rs13428789	chr2:25087643	C/T	cg04586622	chr2:25135609	ADCY3	0.38	7.92	0.36	2.12e-14	Body mass index;
LUAD	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg02807482	chr3:125708958	NA	-0.65	-8.79	-0.39	3.75e-17	Blood pressure (smoking interaction);
LUAD	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg02221750	chr19:17393354	ANKLE1	-0.77	-12.63	-0.52	3.02e-31	Systemic lupus erythematosus;
LUAD	trans	rs6426551	1.000	rs6426551	chr1:226542049	A/G	cg27539482	chr13:111589090	NA	-0.49	-7.01	-0.32	9.55e-12	Coronary artery disease;
LUAD	trans	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-8.89	-0.4	1.84e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.58	-0.3	1.41e-10	Height;
LUAD	cis	rs57590327	0.555	rs7634258	chr3:81799100	T/C	cg07356753	chr3:81810745	GBE1	-0.62	-10.07	-0.44	1.58e-21	Extraversion;
LUAD	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg10518543	chr12:38710700	ALG10B	-0.49	-8.21	-0.37	2.63e-15	Morning vs. evening chronotype;
LUAD	cis	rs4273100	1.000	rs16960499	chr17:19203032	A/G	cg03910582	chr17:19030146	GRAPL	0.58	7.34	0.34	1.08e-12	Schizophrenia;
LUAD	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg01689657	chr7:91764605	CYP51A1	0.33	8.11	0.37	5.4e-15	Breast cancer;
LUAD	cis	rs733175	0.857	rs10018663	chr4:10004797	C/T	cg00071950	chr4:10020882	SLC2A9	0.57	8.66	0.39	9.75e-17	Psychosis and Alzheimer's disease;
LUAD	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22496380	chr5:211416	CCDC127	-1.2	-15.55	-0.6	1.93e-43	Breast cancer;
LUAD	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	7.99	0.36	1.26e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg00204512	chr16:28754710	NA	0.33	6.95	0.32	1.4e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs11229555	0.645	rs12269745	chr11:58176875	G/A	cg15696309	chr11:58395628	NA	-0.73	-10.21	-0.44	5.12e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs1493916	0.870	rs7239173	chr18:31395534	A/T	cg15819921	chr19:927150	ARID3A	-0.47	-7.79	-0.35	5.14e-14	Life satisfaction;
LUAD	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg18016565	chr1:150552671	MCL1	0.41	7.55	0.34	2.78e-13	Tonsillectomy;
LUAD	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg02196655	chr2:10830764	NOL10	-0.43	-7.66	-0.35	1.31e-13	Prostate cancer;
LUAD	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg11941060	chr3:133502564	NA	0.39	6.63	0.31	1.05e-10	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg12011299	chr4:100065546	ADH4	0.7	12.61	0.52	3.55e-31	Smoking initiation;
LUAD	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg11189052	chr15:85197271	WDR73	0.62	7.92	0.36	2.19e-14	Schizophrenia;
LUAD	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg09365446	chr1:150670422	GOLPH3L	0.62	11.06	0.47	3.81e-25	Melanoma;
LUAD	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg25173405	chr17:45401733	C17orf57	0.47	7.72	0.35	8.41e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg24644049	chr4:85504048	CDS1	0.92	7.93	0.36	2e-14	Skin colour saturation;
LUAD	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg23649088	chr2:200775458	C2orf69	-0.63	-8.15	-0.37	4.31e-15	Schizophrenia;
LUAD	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg05966235	chr16:28915196	ATP2A1	0.47	7.71	0.35	8.82e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6516091	0.778	rs62199231	chr20:6050133	C/T	cg25325723	chr20:6104886	FERMT1	-0.59	-6.68	-0.31	7.54e-11	Abdominal aortic aneurysm;
LUAD	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg22705602	chr4:152727874	NA	-0.43	-7.38	-0.34	8.38e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg23131131	chr22:24373011	LOC391322	-0.48	-8.11	-0.37	5.64e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg05234568	chr11:5960015	NA	0.51	9.7	0.43	3.32e-20	DNA methylation (variation);
LUAD	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg25535316	chr11:579198	PHRF1	-0.4	-6.4	-0.3	4.17e-10	Systemic lupus erythematosus;
LUAD	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg08888203	chr3:10149979	C3orf24	0.74	12.97	0.53	1.22e-32	Alzheimer's disease;
LUAD	trans	rs8073060	0.586	rs2428464	chr17:34021994	C/G	cg19694781	chr19:47549865	TMEM160	-1.22	-19.43	-0.69	1.51e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.41	-7.34	-0.34	1.08e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1215050	0.791	rs13114823	chr4:98671119	G/A	cg24818145	chr4:99064322	C4orf37	-0.41	-6.74	-0.31	5.24e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs7944735	0.767	rs1017875	chr11:47999218	C/T	cg15704280	chr7:45808275	SEPT13	0.7	8.99	0.4	8.45e-18	Intraocular pressure;
LUAD	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18099408	chr3:52552593	STAB1	-0.46	-8.11	-0.37	5.49e-15	Bipolar disorder;
LUAD	cis	rs5167	0.601	rs892131	chr19:45496996	C/T	cg13119609	chr19:45449297	APOC2	0.38	6.81	0.31	3.33e-11	Blood protein levels;
LUAD	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg23283495	chr1:209979779	IRF6	0.64	8.61	0.39	1.5e-16	Cleft lip with or without cleft palate;
LUAD	cis	rs420259	0.516	rs801754	chr16:23597878	T/A	cg00143387	chr16:23521605	GGA2	0.7	9.83	0.43	1.16e-20	Bipolar disorder;
LUAD	cis	rs11771526	0.901	rs62457472	chr7:32306885	A/G	cg27532318	chr7:32358331	NA	0.58	7.52	0.34	3.42e-13	Body mass index;
LUAD	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg12034118	chr1:209979487	IRF6	0.52	7.55	0.34	2.77e-13	Cleft lip with or without cleft palate;
LUAD	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg20290983	chr6:43655470	MRPS18A	1.06	27.2	0.8	6.05e-95	IgG glycosylation;
LUAD	cis	rs78761021	0.514	rs4791906	chr17:9795452	A/G	cg26853458	chr17:9805074	RCVRN	-0.32	-6.72	-0.31	5.99e-11	Type 2 diabetes;
LUAD	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.44	7.94	0.36	1.83e-14	Systemic lupus erythematosus;
LUAD	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg15208524	chr1:10270712	KIF1B	0.43	6.48	0.3	2.52e-10	Hepatocellular carcinoma;
LUAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg05457628	chr5:178986728	RUFY1	-0.63	-10.76	-0.46	4.89e-24	Lung cancer;
LUAD	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg06636551	chr8:101224915	SPAG1	-0.37	-6.84	-0.32	2.83e-11	Atrioventricular conduction;
LUAD	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg03676636	chr4:99064102	C4orf37	-0.29	-7.08	-0.33	5.95e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg10518543	chr12:38710700	ALG10B	0.42	6.41	0.3	3.94e-10	Heart rate;
LUAD	cis	rs13064411	0.696	rs7631082	chr3:113208913	C/G	cg10517650	chr3:113235015	CCDC52	-0.55	-9.56	-0.42	9.83e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs4343996	0.837	rs10228151	chr7:3472757	G/T	cg21248987	chr7:3385318	SDK1	-0.36	-6.71	-0.31	6.37e-11	Motion sickness;
LUAD	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15541040	chr2:3486749	NA	-0.4	-6.8	-0.31	3.68e-11	Neurofibrillary tangles;
LUAD	cis	rs6743376	0.556	rs2515402	chr2:113820580	C/A	cg09040174	chr2:113837401	NA	0.46	7.17	0.33	3.41e-12	Inflammatory biomarkers;
LUAD	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg22875332	chr1:76189707	ACADM	-0.7	-11.27	-0.48	6.09e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg19761014	chr17:28927070	LRRC37B2	0.72	6.55	0.3	1.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.68	10.51	0.45	4.29e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg26384229	chr12:38710491	ALG10B	0.47	8.05	0.36	8.48e-15	Bladder cancer;
LUAD	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg10909506	chr17:38081995	ORMDL3	0.4	7.21	0.33	2.59e-12	Self-reported allergy;
LUAD	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg08859206	chr1:53392774	SCP2	-0.5	-8.99	-0.4	8.13e-18	Monocyte count;
LUAD	cis	rs62238980	0.614	rs1475997	chr22:32465025	G/A	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18876405	chr7:65276391	NA	-0.41	-6.45	-0.3	3.13e-10	Aortic root size;
LUAD	cis	rs714027	1.000	rs5997579	chr22:30537526	A/G	cg00539347	chr22:30592296	NA	-0.27	-6.47	-0.3	2.74e-10	Lymphocyte counts;
LUAD	cis	rs4356932	1.000	rs4241580	chr4:76956188	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.54	-0.3	1.78e-10	Blood protein levels;
LUAD	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg26497354	chr6:109612229	NA	0.35	6.4	0.3	4.07e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg17724175	chr1:150552817	MCL1	0.38	9.16	0.41	2.27e-18	Tonsillectomy;
LUAD	cis	rs2230307	0.831	rs558270	chr1:100499285	G/C	cg20868668	chr1:100435035	SLC35A3	0.63	7.64	0.35	1.51e-13	Carotid intima media thickness;
LUAD	cis	rs11249608	0.548	rs11951738	chr5:178491228	G/A	cg01312482	chr5:178451176	ZNF879	-0.46	-6.97	-0.32	1.24e-11	Pubertal anthropometrics;
LUAD	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06544989	chr22:39130855	UNC84B	0.39	7.09	0.33	5.56e-12	Menopause (age at onset);
LUAD	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg12927641	chr6:109611667	NA	-0.48	-8.61	-0.39	1.42e-16	Reticulocyte fraction of red cells;
LUAD	cis	rs758324	0.716	rs27348	chr5:131407139	A/T	cg06307176	chr5:131281290	NA	-0.42	-7.14	-0.33	4.17e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg16680214	chr1:154839983	KCNN3	-0.51	-10.24	-0.45	3.85e-22	Prostate cancer;
LUAD	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg04025307	chr7:1156635	C7orf50	0.48	8.26	0.37	1.84e-15	Longevity;Endometriosis;
LUAD	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06544989	chr22:39130855	UNC84B	0.43	7.97	0.36	1.51e-14	Menopause (age at onset);
LUAD	cis	rs11771526	0.748	rs11765652	chr7:32336444	A/G	cg27532318	chr7:32358331	NA	0.55	7.38	0.34	8.5e-13	Body mass index;
LUAD	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg05340658	chr4:99064831	C4orf37	0.46	6.99	0.32	1.05e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg21399703	chr1:247681439	NA	0.44	7.98	0.36	1.37e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2279817	0.863	rs12023877	chr1:18025633	A/C	cg21791023	chr1:18019539	ARHGEF10L	0.55	9.24	0.41	1.2e-18	Neuroticism;
LUAD	cis	rs12545109	0.800	rs1913278	chr8:57403725	T/C	cg07776626	chr8:57350775	NA	-0.59	-8.57	-0.38	1.9e-16	Obesity-related traits;
LUAD	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs2816062	0.775	rs2816046	chr1:18893708	A/G	cg18795169	chr1:18902165	NA	-0.9	-21.48	-0.72	9.71e-70	Urate levels in lean individuals;
LUAD	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg03948781	chr1:205179583	DSTYK	0.35	6.38	0.3	4.76e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg02782426	chr3:40428986	ENTPD3	0.41	8.76	0.39	4.6e-17	Renal cell carcinoma;
LUAD	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.42	-6.91	-0.32	1.78e-11	Rheumatoid arthritis;
LUAD	trans	rs10411161	0.702	rs7256926	chr19:52391988	A/G	cg22319618	chr22:45562946	NUP50	-0.66	-9.44	-0.42	2.52e-19	Breast cancer;
LUAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.57	0.3	1.45e-10	Prudent dietary pattern;
LUAD	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs2637266	0.935	rs2583059	chr10:78395178	G/C	cg18941641	chr10:78392320	NA	0.34	7.1	0.33	5.37e-12	Pulmonary function;
LUAD	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg19825600	chr2:3704501	ALLC	-0.41	-7.76	-0.35	6.26e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.01	0.36	1.15e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1949733	0.917	rs10461079	chr4:8392724	G/A	cg13073564	chr4:8508604	NA	0.58	10.45	0.45	7.12e-23	Response to antineoplastic agents;
LUAD	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg00310523	chr12:86230176	RASSF9	0.41	8.17	0.37	3.53e-15	Major depressive disorder;
LUAD	cis	rs26868	0.766	rs27556	chr16:2249325	T/C	cg07587117	chr16:2239488	CASKIN1	0.39	7.51	0.34	3.57e-13	Height;
LUAD	cis	rs25422	0.887	rs9481844	chr6:118990941	G/A	cg07617317	chr6:118971624	C6orf204	0.5	7.64	0.35	1.47e-13	Renal cell carcinoma;
LUAD	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg06263672	chr7:65235340	NA	-0.48	-6.65	-0.31	9.21e-11	Aortic root size;
LUAD	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg05754148	chr16:3507555	NAT15	-0.77	-8.93	-0.4	1.31e-17	Tuberculosis;
LUAD	cis	rs1497828	0.956	rs2646817	chr1:217525251	T/G	cg04411442	chr1:217543379	NA	-0.38	-6.91	-0.32	1.78e-11	Dialysis-related mortality;
LUAD	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg05368731	chr17:41323189	NBR1	0.95	19.46	0.69	1.04e-60	Menopause (age at onset);
LUAD	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg13385794	chr1:248469461	NA	0.26	6.97	0.32	1.23e-11	Common traits (Other);
LUAD	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg00277334	chr10:82204260	NA	-0.67	-12.18	-0.51	1.8e-29	Post bronchodilator FEV1;
LUAD	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.4	-0.34	7.47e-13	Total cholesterol levels;
LUAD	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg15605315	chr1:45957053	TESK2	-0.42	-6.66	-0.31	8.48e-11	High light scatter reticulocyte count;
LUAD	trans	rs877282	0.755	rs1769242	chr10:787896	T/C	cg22713356	chr15:30763199	NA	1.1	15.59	0.6	1.22e-43	Uric acid levels;
LUAD	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg08742575	chr21:47604166	C21orf56	0.43	7.26	0.33	1.93e-12	Testicular germ cell tumor;
LUAD	cis	rs9309473	0.607	rs7586361	chr2:73601606	G/A	cg20560298	chr2:73613845	ALMS1	-0.43	-6.71	-0.31	6.1e-11	Metabolite levels;
LUAD	cis	rs7119	0.637	rs12913005	chr15:77856571	T/A	cg27398640	chr15:77910606	LINGO1	-0.39	-7.16	-0.33	3.71e-12	Type 2 diabetes;
LUAD	cis	rs2425143	0.598	rs2425118	chr20:34324098	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2e-15	Blood protein levels;
LUAD	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-10.85	-0.47	2.27e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg05043794	chr9:111880884	C9orf5	-0.45	-7.77	-0.35	5.87e-14	Menarche (age at onset);
LUAD	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg15691649	chr6:25882328	NA	-0.44	-7.05	-0.32	7.32e-12	Blood metabolite levels;
LUAD	cis	rs877282	0.853	rs7069720	chr10:754487	A/G	cg06581033	chr10:766294	NA	-0.57	-7.51	-0.34	3.61e-13	Uric acid levels;
LUAD	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg16486109	chr11:613632	IRF7	0.49	8.13	0.37	4.71e-15	Systemic lupus erythematosus;
LUAD	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg23625390	chr15:77176239	SCAPER	-0.5	-7.57	-0.35	2.31e-13	Blood metabolite levels;
LUAD	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.72	-12.21	-0.51	1.39e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg04398451	chr17:18023971	MYO15A	-0.75	-13.77	-0.56	6.47e-36	Total body bone mineral density;
LUAD	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.42	0.55	1.78e-34	Tonsillectomy;
LUAD	cis	rs1190552	0.706	rs2146426	chr14:102995068	A/G	cg18135206	chr14:102964638	TECPR2	0.45	6.62	0.31	1.07e-10	Blood protein levels;
LUAD	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg00071950	chr4:10020882	SLC2A9	0.84	18.23	0.66	3.19e-55	Bone mineral density;
LUAD	cis	rs7709909	0.553	rs28059	chr5:80038965	C/T	cg24059623	chr5:79951536	MSH3;DHFR	0.49	7.43	0.34	5.93e-13	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg00071950	chr4:10020882	SLC2A9	-0.61	-10.94	-0.47	1.09e-24	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs28595532	0.920	rs17323034	chr4:119606518	G/A	cg02775129	chr4:119771670	NA	-0.84	-7.82	-0.36	4.25e-14	Cannabis dependence symptom count;
LUAD	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg04025307	chr7:1156635	C7orf50	0.72	13.22	0.54	1.19e-33	Longevity;Endometriosis;
LUAD	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-7.97	-0.36	1.47e-14	Total cholesterol levels;
LUAD	cis	rs7582720	0.943	rs72932575	chr2:203866857	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	9.28	0.41	8.55e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg11247378	chr22:39784982	NA	-0.78	-14.77	-0.58	3.98e-40	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs6761276	0.899	rs13398125	chr2:113834835	G/A	cg02343335	chr2:113785852	IL1F8	-0.35	-7.01	-0.32	9.57e-12	Protein quantitative trait loci;
LUAD	cis	rs494562	0.892	rs640093	chr6:86115866	C/T	cg17966619	chr6:86160162	NT5E	0.55	6.74	0.31	5.36e-11	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg17177755	chr1:15930204	NA	0.46	7.41	0.34	6.87e-13	Systolic blood pressure;
LUAD	cis	rs62238980	0.614	rs45494991	chr22:32545762	C/T	cg00543991	chr22:32367038	NA	0.93	8.06	0.36	8.03e-15	Childhood ear infection;
LUAD	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg04800585	chr6:26043546	HIST1H2BB	-0.36	-6.59	-0.31	1.28e-10	Blood metabolite levels;
LUAD	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg25173405	chr17:45401733	C17orf57	-0.53	-8.81	-0.39	3.27e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7539409	0.651	rs10747407	chr1:84314754	G/A	cg10977910	chr1:84465055	TTLL7	0.77	8.88	0.4	1.99e-17	Alzheimer's disease;
LUAD	trans	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg11693508	chr17:37793320	STARD3	0.52	7.37	0.34	9.14e-13	Neuroticism;
LUAD	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg18446336	chr7:2847575	GNA12	-0.36	-6.61	-0.31	1.16e-10	Height;
LUAD	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.49	7.91	0.36	2.31e-14	Schizophrenia;
LUAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg22535103	chr8:58192502	C8orf71	-0.72	-8.94	-0.4	1.24e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg11317459	chr13:21872234	NA	-1.09	-14.68	-0.58	1.03e-39	White matter hyperintensity burden;
LUAD	cis	rs7582720	1.000	rs72934556	chr2:203990789	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.48	0.42	1.91e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs714027	1.000	rs757024	chr22:30471679	G/C	cg00539347	chr22:30592296	NA	-0.3	-7.15	-0.33	3.76e-12	Lymphocyte counts;
LUAD	cis	rs9503598	0.644	rs7774747	chr6:3430996	A/G	cg00476032	chr6:3446245	SLC22A23	-0.3	-6.43	-0.3	3.5e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUAD	cis	rs7709909	0.553	rs245398	chr5:80046374	C/A	cg24059623	chr5:79951536	MSH3;DHFR	0.49	7.45	0.34	5.27e-13	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	trans	rs3779273	0.748	rs4236580	chr7:77835256	T/C	cg05596911	chr5:118502651	DMXL1	-0.4	-7.0	-0.32	9.83e-12	Body mass index;
LUAD	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg10435618	chr10:838112	NA	0.47	6.41	0.3	3.95e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs7593730	0.537	rs6711375	chr2:161090873	G/A	cg22609984	chr2:161126801	NA	0.48	8.75	0.39	5.21e-17	Type 2 diabetes;
LUAD	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03526776	chr6:41159608	TREML2	-0.54	-11.22	-0.48	9.08e-26	Alzheimer's disease (late onset);
LUAD	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	5.75e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	10.3	0.45	2.48e-22	Lung cancer in ever smokers;
LUAD	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg05082376	chr22:42548792	NA	-0.38	-6.63	-0.31	1.01e-10	Cognitive function;
LUAD	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg11494091	chr17:61959527	GH2	0.39	6.99	0.32	1.09e-11	Height;
LUAD	cis	rs3106136	0.967	rs11097409	chr4:95168515	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.37	-0.34	9.1e-13	Capecitabine sensitivity;
LUAD	cis	rs6952808	0.964	rs10950407	chr7:1895666	T/G	cg03354898	chr7:1950403	MAD1L1	-0.41	-7.33	-0.34	1.19e-12	Bipolar disorder and schizophrenia;
LUAD	trans	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg14917512	chr19:3094685	GNA11	-0.54	-6.52	-0.3	2.03e-10	Diabetic kidney disease;
LUAD	cis	rs910187	0.678	rs6122563	chr20:45813885	C/T	cg27589058	chr20:45804311	EYA2	-0.31	-7.12	-0.33	4.72e-12	Migraine;
LUAD	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg11262906	chr1:85462892	MCOLN2	-0.51	-7.16	-0.33	3.63e-12	Serum sulfate level;
LUAD	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg00933542	chr6:150070202	PCMT1	0.45	9.55	0.42	1.08e-19	Lung cancer;
LUAD	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg23985595	chr17:80112537	CCDC57	-0.51	-9.38	-0.41	4.16e-19	Life satisfaction;
LUAD	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg09904177	chr6:26538194	HMGN4	0.43	7.21	0.33	2.51e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg22431228	chr1:16359049	CLCNKA	0.44	8.49	0.38	3.44e-16	Systolic blood pressure;
LUAD	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg14631576	chr9:95140430	CENPP	-0.48	-9.66	-0.43	4.49e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.58	0.3	1.38e-10	Schizophrenia;
LUAD	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg03433033	chr1:76189801	ACADM	-0.44	-6.36	-0.3	5.25e-10	Daytime sleep phenotypes;
LUAD	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.91	-0.32	1.81e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg11663144	chr21:46675770	NA	0.46	8.9	0.4	1.6e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg24558204	chr6:135376177	HBS1L	0.46	8.44	0.38	5.09e-16	Red blood cell count;
LUAD	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg06558623	chr16:89946397	TCF25	1.24	12.59	0.52	4.28e-31	Skin colour saturation;
LUAD	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.11	-0.37	5.52e-15	Diabetic kidney disease;
LUAD	cis	rs4072705	0.615	rs7869829	chr9:127247177	G/A	cg01786973	chr9:127249749	NR5A1	-0.3	-6.45	-0.3	3.05e-10	Menarche (age at onset);
LUAD	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg07677032	chr17:61819896	STRADA	0.57	10.47	0.45	5.92e-23	Prudent dietary pattern;
LUAD	trans	rs4650994	0.625	rs6681348	chr1:178526271	A/C	cg05059571	chr16:84539110	KIAA1609	-0.59	-10.1	-0.44	1.27e-21	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs420259	0.516	rs4968008	chr16:23490353	G/T	cg00143387	chr16:23521605	GGA2	0.7	10.03	0.44	2.28e-21	Bipolar disorder;
LUAD	cis	rs12681287	0.752	rs10100235	chr8:87249294	A/G	cg27223183	chr8:87520930	FAM82B	-0.53	-7.96	-0.36	1.61e-14	Caudate activity during reward;
LUAD	trans	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.44	-0.3	3.27e-10	Aortic root size;
LUAD	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg01475377	chr6:109611718	NA	-0.54	-10.34	-0.45	1.67e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg18306943	chr3:40428807	ENTPD3	0.38	6.6	0.31	1.24e-10	Renal cell carcinoma;
LUAD	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg04450456	chr4:17643702	FAM184B	-0.41	-7.81	-0.35	4.57e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg22535103	chr8:58192502	C8orf71	-0.74	-9.2	-0.41	1.62e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs4889855	0.505	rs6565467	chr17:78610113	A/G	cg16591659	chr17:78472290	NA	-0.42	-7.42	-0.34	6.3e-13	Fractional excretion of uric acid;
LUAD	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg15445000	chr17:37608096	MED1	-0.45	-8.35	-0.38	1e-15	Glomerular filtration rate (creatinine);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17121955	chr11:6411382	SMPD1	-0.54	-6.43	-0.3	3.38e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	9.47	0.42	1.93e-19	Colorectal cancer;
LUAD	cis	rs868036	1.000	rs8037262	chr15:68108572	C/T	cg08079166	chr15:68083412	MAP2K5	0.31	6.6	0.31	1.21e-10	Restless legs syndrome;
LUAD	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg17724175	chr1:150552817	MCL1	0.39	9.28	0.41	9.17e-19	Tonsillectomy;
LUAD	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg09904177	chr6:26538194	HMGN4	0.44	7.4	0.34	7.22e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg06191203	chr2:152266755	RIF1	-0.49	-7.3	-0.33	1.4e-12	Lung cancer;
LUAD	trans	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.14	-0.37	4.36e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1595825	0.891	rs16825181	chr2:198740276	G/T	cg00361562	chr2:198649771	BOLL	-0.51	-6.73	-0.31	5.71e-11	Ulcerative colitis;
LUAD	cis	rs9837602	0.935	rs9875640	chr3:99729091	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	9.47	0.42	2.07e-19	Breast cancer;
LUAD	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg08508325	chr11:3079039	CARS	0.44	9.14	0.41	2.63e-18	Calcium levels;
LUAD	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg06766960	chr11:133703094	NA	-0.45	-8.49	-0.38	3.63e-16	Childhood ear infection;
LUAD	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg08859206	chr1:53392774	SCP2	-0.51	-9.17	-0.41	2.01e-18	Monocyte count;
LUAD	cis	rs3820068	0.871	rs74539603	chr1:15809601	C/T	cg17177755	chr1:15930204	NA	0.46	6.55	0.3	1.69e-10	Systolic blood pressure;
LUAD	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg27572855	chr1:25598939	RHD	-0.53	-11.36	-0.48	2.71e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg02569458	chr12:86230093	RASSF9	0.45	8.19	0.37	3.21e-15	Major depressive disorder;
LUAD	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	trans	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.66	12.57	0.52	5.23e-31	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg09117114	chr16:67998030	SLC12A4	-0.53	-6.98	-0.32	1.12e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg17863274	chr19:49399704	TULP2	-0.66	-10.02	-0.44	2.43e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9811920	0.965	rs10222474	chr3:99862551	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-6.87	-0.32	2.33e-11	Axial length;
LUAD	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg10523679	chr1:76189770	ACADM	-0.75	-11.65	-0.49	2.14e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg12011299	chr4:100065546	ADH4	0.63	13.05	0.54	5.85e-33	Alcohol dependence;
LUAD	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.49	-0.42	1.69e-19	Life satisfaction;
LUAD	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26314531	chr2:26401878	FAM59B	-0.55	-7.71	-0.35	9.38e-14	Gut microbiome composition (summer);
LUAD	cis	rs193541	0.632	rs1363200	chr5:122163802	G/T	cg19077854	chr5:122220652	SNX24	0.37	6.47	0.3	2.74e-10	Glucose homeostasis traits;
LUAD	cis	rs7000551	0.663	rs7827093	chr8:22334610	A/G	cg12081754	chr8:22256438	SLC39A14	0.45	7.42	0.34	6.3e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg06611532	chr13:114900021	NA	0.36	8.11	0.37	5.5e-15	Schizophrenia;
LUAD	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg07978099	chr16:83986941	OSGIN1	0.53	8.6	0.39	1.53e-16	Pursuit maintenance gain;
LUAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs679087	1.000	rs302317	chr12:29921443	G/A	cg14258853	chr12:29935411	TMTC1	-0.59	-10.23	-0.45	4.12e-22	Schizophrenia;
LUAD	cis	rs10916814	0.610	rs4655223	chr1:20901688	C/G	cg24502330	chr1:20914028	CDA	-0.36	-7.14	-0.33	3.98e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-7.26	-0.33	1.9e-12	Body mass index;
LUAD	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg08470875	chr2:26401718	FAM59B	-0.67	-8.95	-0.4	1.13e-17	Gut microbiome composition (summer);
LUAD	trans	rs10411161	0.702	rs8110531	chr19:52383510	C/T	cg22319618	chr22:45562946	NUP50	-0.6	-8.32	-0.38	1.24e-15	Breast cancer;
LUAD	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg12011299	chr4:100065546	ADH4	0.64	13.7	0.55	1.35e-35	Alcohol dependence;
LUAD	cis	rs3845702	0.736	rs6727890	chr2:180832675	T/C	cg01881094	chr2:180872142	CWC22	-0.74	-7.97	-0.36	1.44e-14	Schizophrenia;
LUAD	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg21285383	chr16:89894308	SPIRE2	0.43	10.32	0.45	2.07e-22	Vitiligo;
LUAD	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.4	-7.75	-0.35	6.98e-14	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg20119798	chr7:94954144	PON1	-0.48	-6.53	-0.3	1.94e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2795502	0.630	rs2914988	chr10:43509354	A/T	cg20628663	chr10:43360327	NA	0.54	6.47	0.3	2.73e-10	Blood protein levels;
LUAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03647317	chr4:187891568	NA	-0.35	-6.47	-0.3	2.75e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg06671706	chr8:8559999	CLDN23	0.65	11.08	0.47	3.31e-25	Obesity-related traits;
LUAD	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg23840854	chr1:161414152	NA	-0.9	-11.59	-0.49	3.71e-27	Rheumatoid arthritis;
LUAD	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg02753203	chr1:228287806	NA	0.81	14.91	0.59	1.02e-40	Diastolic blood pressure;
LUAD	cis	rs10744422	1.000	rs937766	chr12:123331094	G/T	cg16953816	chr12:123349952	VPS37B	0.59	6.67	0.31	8.16e-11	Schizophrenia;
LUAD	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg05082376	chr22:42548792	NA	-0.39	-6.99	-0.32	1.11e-11	Cognitive function;
LUAD	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg03929089	chr4:120376271	NA	0.78	14.09	0.57	2.97e-37	Coronary artery disease;
LUAD	cis	rs2629540	0.889	rs4962402	chr10:126459114	T/G	cg08799069	chr10:126477246	METTL10	-0.48	-7.11	-0.33	5.1e-12	Cocaine dependence;
LUAD	cis	rs933688	0.527	rs6898622	chr5:90578292	G/T	cg00335715	chr5:90575459	NA	-0.64	-8.91	-0.4	1.5e-17	Smoking behavior;
LUAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.84	0.43	1.07e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-8.77	-0.39	4.25e-17	Obesity-related traits;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23465967	chr2:111435611	BUB1	-0.52	-6.77	-0.31	4.42e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7043114	0.525	rs7850432	chr9:95130510	G/A	cg14631576	chr9:95140430	CENPP	-0.43	-8.62	-0.39	1.32e-16	Height;
LUAD	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg19163074	chr7:65112434	INTS4L2	0.44	6.95	0.32	1.38e-11	Aortic root size;
LUAD	cis	rs986417	1.000	rs10142455	chr14:60980963	G/A	cg27398547	chr14:60952738	C14orf39	0.66	7.85	0.36	3.51e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg10434728	chr15:90938212	IQGAP1	0.35	6.82	0.31	3.09e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs4638749	0.677	rs12611470	chr2:108839349	C/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.32	-0.34	1.23e-12	Blood pressure;
LUAD	cis	rs26868	0.766	rs26867	chr16:2249410	T/C	cg07587117	chr16:2239488	CASKIN1	0.39	7.51	0.34	3.47e-13	Height;
LUAD	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg10560079	chr2:191398806	TMEM194B	0.45	8.11	0.37	5.49e-15	Pulse pressure;
LUAD	cis	rs6942407	0.546	rs3789251	chr7:86793303	A/G	cg02420886	chr7:86849541	C7orf23	0.63	7.29	0.33	1.55e-12	Food allergy;
LUAD	cis	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	7.62	0.35	1.73e-13	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08048268	chr3:133502702	NA	0.54	10.84	0.47	2.47e-24	Iron status biomarkers;
LUAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.57	-10.18	-0.44	6.67e-22	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg18721089	chr20:30220636	NA	-0.45	-6.49	-0.3	2.44e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg11645453	chr3:52864694	ITIH4	0.6	11.34	0.48	3.23e-26	Schizophrenia;
LUAD	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg18854424	chr1:2615690	NA	0.42	9.04	0.4	5.74e-18	Ulcerative colitis;
LUAD	cis	rs2455799	0.613	rs11713820	chr3:15866590	A/G	cg16303742	chr3:15540471	COLQ	0.52	9.67	0.43	3.98e-20	Mean platelet volume;
LUAD	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg10589385	chr1:150898437	SETDB1	0.39	7.39	0.34	8e-13	Tonsillectomy;
LUAD	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg02574844	chr11:5959923	NA	-0.42	-7.38	-0.34	8.35e-13	DNA methylation (variation);
LUAD	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg09835421	chr16:68378352	PRMT7	-0.81	-8.76	-0.39	4.76e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs738322	0.553	rs28565947	chr22:38570775	C/G	cg17652424	chr22:38574118	PLA2G6	-0.3	-7.86	-0.36	3.25e-14	Cutaneous nevi;
LUAD	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg06641503	chr3:48959341	ARIH2	-0.4	-7.99	-0.36	1.33e-14	Parkinson's disease;
LUAD	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.36	-0.52	3.6e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.54	0.46	3.24e-23	Colorectal cancer;
LUAD	cis	rs11051970	0.594	rs325418	chr12:32572517	T/C	cg24626660	chr12:32551988	NA	0.31	6.65	0.31	8.83e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs11650494	0.908	rs77247327	chr17:47411493	T/C	cg11430096	chr6:110968061	CDK19	0.84	6.35	0.3	5.52e-10	Prostate cancer;
LUAD	cis	rs6543140	0.964	rs1035126	chr2:103019981	C/T	cg03938978	chr2:103052716	IL18RAP	0.35	6.84	0.32	2.74e-11	Blood protein levels;
LUAD	cis	rs6893807	0.697	rs26582	chr5:87950290	C/T	cg02225085	chr5:87975992	LOC645323	-0.4	-7.01	-0.32	9.65e-12	Body mass index;
LUAD	trans	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg06606381	chr12:133084897	FBRSL1	-1.1	-10.84	-0.47	2.62e-24	Depression;
LUAD	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10802521	chr3:52805072	NEK4	-0.57	-10.51	-0.45	4.24e-23	Bipolar disorder;
LUAD	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg12432903	chr7:1882776	MAD1L1	-0.48	-7.9	-0.36	2.52e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg11645453	chr3:52864694	ITIH4	-0.58	-11.16	-0.48	1.55e-25	Schizophrenia;
LUAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.63	8.66	0.39	9.87e-17	Renal function-related traits (BUN);
LUAD	cis	rs754466	0.651	rs10824583	chr10:79619402	C/T	cg17075019	chr10:79541650	NA	0.86	17.58	0.65	2.44e-52	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg16850897	chr7:100343110	ZAN	-0.62	-10.23	-0.45	4.17e-22	Other erythrocyte phenotypes;
LUAD	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg20476274	chr7:133979776	SLC35B4	0.77	13.14	0.54	2.5e-33	Mean platelet volume;
LUAD	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg13770153	chr20:60521292	NA	0.64	9.77	0.43	1.85e-20	Body mass index;
LUAD	cis	rs9399401	0.667	rs1329707	chr6:142724439	T/C	cg04461802	chr6:142623433	GPR126	0.44	8.21	0.37	2.79e-15	Chronic obstructive pulmonary disease;
LUAD	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.5	6.89	0.32	2e-11	Platelet count;
LUAD	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.01	0.36	1.11e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7582720	1.000	rs6738618	chr2:203749439	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg26647111	chr11:31128758	NA	-0.46	-8.0	-0.36	1.18e-14	Red blood cell count;
LUAD	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg25838465	chr1:92012736	NA	0.48	7.17	0.33	3.45e-12	Eosinophil percentage of white cells;
LUAD	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-7.8	-0.35	4.98e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg00071950	chr4:10020882	SLC2A9	-0.58	-11.15	-0.48	1.77e-25	Bone mineral density;
LUAD	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg10544611	chr16:67998164	SLC12A4	-0.55	-6.9	-0.32	1.95e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-6.88	-0.32	2.17e-11	Cystic fibrosis severity;
LUAD	cis	rs1595825	0.786	rs116046984	chr2:198884413	G/A	cg10547527	chr2:198650123	BOLL	-0.5	-6.94	-0.32	1.51e-11	Ulcerative colitis;
LUAD	cis	rs7737355	0.947	rs11242081	chr5:130908135	T/C	cg25547332	chr5:131281432	NA	0.43	6.41	0.3	3.92e-10	Life satisfaction;
LUAD	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg13390004	chr1:15929781	NA	0.5	8.89	0.4	1.72e-17	Systolic blood pressure;
LUAD	cis	rs1775715	0.678	rs2778649	chr10:32146803	C/G	cg04359828	chr10:32216031	ARHGAP12	0.32	6.67	0.31	8.03e-11	Bipolar disorder with mood-incongruent psychosis;
LUAD	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.87	-0.32	2.28e-11	Mood instability;
LUAD	cis	rs9039	1.000	rs9039	chr16:9205363	A/G	cg08831531	chr16:9218945	NA	-0.41	-7.47	-0.34	4.56e-13	Menopause (age at onset);
LUAD	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg16647868	chr5:131706066	SLC22A5	-0.48	-7.64	-0.35	1.44e-13	Breast cancer;
LUAD	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg14668632	chr7:2872130	GNA12	0.44	7.47	0.34	4.66e-13	Loneliness (linear analysis);
LUAD	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg04586622	chr2:25135609	ADCY3	0.37	8.36	0.38	8.82e-16	Body mass index;
LUAD	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg00898013	chr13:113819073	PROZ	-0.62	-11.34	-0.48	3.34e-26	Platelet distribution width;
LUAD	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.23	0.33	2.31e-12	Obesity-related traits;
LUAD	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg13271783	chr10:134563150	INPP5A	-0.41	-6.78	-0.31	4.12e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg14458575	chr2:238380390	NA	0.73	11.19	0.48	1.28e-25	Prostate cancer;
LUAD	cis	rs7945718	0.875	rs9888178	chr11:12782643	C/T	cg25843174	chr11:12811716	TEAD1	0.25	7.41	0.34	6.82e-13	Educational attainment (years of education);
LUAD	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg21204522	chr6:27730016	NA	0.45	7.14	0.33	4.23e-12	Parkinson's disease;
LUAD	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.5	-7.8	-0.35	4.74e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg17372223	chr3:52568218	NT5DC2	0.4	7.46	0.34	4.95e-13	Electroencephalogram traits;
LUAD	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg07617317	chr6:118971624	C6orf204	0.55	8.1	0.37	5.73e-15	Diastolic blood pressure;
LUAD	trans	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	17.64	0.65	1.32e-52	Exhaled nitric oxide output;
LUAD	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg23758822	chr17:41437982	NA	1.01	20.99	0.71	1.52e-67	Menopause (age at onset);
LUAD	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg05082376	chr22:42548792	NA	-0.41	-6.87	-0.32	2.25e-11	Schizophrenia;
LUAD	cis	rs6906287	0.647	rs7758614	chr6:118889894	T/C	cg18833306	chr6:118973337	C6orf204	0.48	8.38	0.38	7.68e-16	Electrocardiographic conduction measures;
LUAD	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg09517075	chr8:22133004	PIWIL2	0.5	9.22	0.41	1.38e-18	Hypertriglyceridemia;
LUAD	cis	rs68170813	1.000	rs7785962	chr7:107243995	A/C	cg02696742	chr7:106810147	HBP1	0.49	6.59	0.31	1.3100000000000001e-10	Coronary artery disease;
LUAD	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.66	-0.35	1.29e-13	Blood metabolite levels;
LUAD	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs4664304	0.934	rs72957586	chr2:160762687	G/A	cg23995753	chr2:160760732	LY75	-0.48	-8.57	-0.38	1.9e-16	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1371614	0.632	rs6707735	chr2:27166822	T/C	cg00617064	chr2:27272375	NA	-0.36	-6.93	-0.32	1.53e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs748404	0.650	rs518261	chr15:43573429	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.01	0.36	1.13e-14	Lung cancer;
LUAD	cis	rs2979489	0.624	rs62505275	chr8:30437639	C/T	cg26383811	chr8:30366931	RBPMS	-0.57	-8.57	-0.38	1.9e-16	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg13180566	chr4:1052158	NA	-0.39	-6.56	-0.3	1.6e-10	Recombination rate (females);
LUAD	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg02569458	chr12:86230093	RASSF9	0.46	8.36	0.38	9.15e-16	Major depressive disorder;
LUAD	cis	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-8.4	-0.38	6.91e-16	Triglycerides;
LUAD	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg00316803	chr15:76480434	C15orf27	0.45	9.05	0.4	5.34e-18	Blood metabolite levels;
LUAD	cis	rs7131987	0.834	rs1989478	chr12:29442229	C/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.43	-0.3	3.5e-10	QT interval;
LUAD	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06022373	chr22:39101656	GTPBP1	0.48	8.08	0.37	6.72e-15	Menopause (age at onset);
LUAD	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg06640241	chr16:89574553	SPG7	0.68	11.96	0.5	1.31e-28	Multiple myeloma (IgH translocation);
LUAD	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg25804541	chr17:80189381	SLC16A3	-0.3	-6.55	-0.3	1.68e-10	Life satisfaction;
LUAD	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg07636037	chr3:49044803	WDR6	0.54	8.48	0.38	3.87e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs7107174	0.892	rs1017907	chr11:77959124	A/T	cg02023728	chr11:77925099	USP35	0.45	7.12	0.33	4.62e-12	Testicular germ cell tumor;
LUAD	cis	rs12950390	1.000	rs8068453	chr17:45852354	A/G	cg06532163	chr17:45867833	NA	-0.46	-7.27	-0.33	1.7e-12	IgG glycosylation;
LUAD	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg08798685	chr6:27730294	NA	-0.71	-7.52	-0.34	3.26e-13	Depression;
LUAD	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg25358565	chr5:93447407	FAM172A	0.61	7.3	0.33	1.43e-12	Diabetic retinopathy;
LUAD	cis	rs9814567	0.727	rs4437193	chr3:134352344	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-12.75	-0.53	9.67e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7727544	0.647	rs6898270	chr5:131421190	C/T	cg07538946	chr5:131705188	SLC22A5	0.43	6.76	0.31	4.47e-11	Blood metabolite levels;
LUAD	cis	rs1079204	1.000	rs1567869	chr2:219126735	C/T	cg05728596	chr2:219128475	GPBAR1	-1.21	-13.63	-0.55	2.55e-35	Smooth-surface caries;
LUAD	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg08219700	chr8:58056026	NA	0.49	7.17	0.33	3.48e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	7.77e-16	Body mass index;
LUAD	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.4	-0.38	6.63e-16	Total body bone mineral density;
LUAD	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg04450456	chr4:17643702	FAM184B	0.4	7.99	0.36	1.27e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg09796270	chr17:17721594	SREBF1	-0.37	-7.08	-0.33	6.11e-12	Total body bone mineral density;
LUAD	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.49	6.58	0.3	1.38e-10	Platelet count;
LUAD	cis	rs9297145	0.916	rs4236540	chr7:98769025	A/C	cg05967295	chr7:98741636	SMURF1	0.9	17.29	0.64	4.75e-51	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg08999081	chr20:33150536	PIGU	-0.59	-12.87	-0.53	3.1e-32	Glomerular filtration rate (creatinine);
LUAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg23131131	chr22:24373011	LOC391322	-0.54	-8.77	-0.39	4.35e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11696501	0.688	rs6065851	chr20:44279034	C/T	cg11783356	chr20:44313418	WFDC10B	-0.47	-7.55	-0.34	2.65e-13	Brain structure;
LUAD	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg23283495	chr1:209979779	IRF6	0.65	8.65	0.39	1.07e-16	Cleft lip with or without cleft palate;
LUAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg00280220	chr17:61926910	NA	0.37	7.18	0.33	3.24e-12	Prudent dietary pattern;
LUAD	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08280861	chr8:58055591	NA	0.55	7.16	0.33	3.53e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.34	-7.71	-0.35	9.13e-14	Lung cancer;
LUAD	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg00383909	chr3:49044727	WDR6	0.43	6.61	0.31	1.14e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg00277334	chr10:82204260	NA	-0.6	-9.55	-0.42	1.08e-19	Post bronchodilator FEV1;
LUAD	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg20701182	chr2:24300061	SF3B14	0.65	7.34	0.34	1.11e-12	Lymphocyte counts;
LUAD	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg06060754	chr5:176797920	RGS14	-0.55	-9.03	-0.4	5.96e-18	Urate levels in lean individuals;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg22777832	chr20:62339229	ARFRP1;ZGPAT	-0.68	-6.86	-0.32	2.52e-11	Type 2 diabetes;
LUAD	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.89	-0.32	2e-11	Crohn's disease;
LUAD	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg26408565	chr15:76604113	ETFA	-0.49	-7.77	-0.35	5.82e-14	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.9	0.53	2.54e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.891	rs16823148	chr2:198584209	G/A	cg00982548	chr2:198649783	BOLL	-0.61	-8.89	-0.4	1.82e-17	Ulcerative colitis;
LUAD	cis	rs709400	1.000	rs861536	chr14:104167564	A/G	cg01849466	chr14:104193079	ZFYVE21	0.47	7.77	0.35	5.89e-14	Body mass index;
LUAD	cis	rs870825	0.860	rs72703525	chr4:185605154	T/C	cg04058563	chr4:185651563	MLF1IP	0.78	10.21	0.44	4.85e-22	Blood protein levels;
LUAD	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg24450063	chr1:156163899	SLC25A44	1.18	27.25	0.8	3.93e-95	Testicular germ cell tumor;
LUAD	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg07538946	chr5:131705188	SLC22A5	0.53	8.55	0.38	2.21e-16	Blood metabolite levels;
LUAD	cis	rs10097731	0.901	rs4398860	chr8:82041753	C/T	cg25230327	chr8:82042993	NA	-0.67	-11.31	-0.48	4.41e-26	Serum total protein level;
LUAD	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg07167872	chr1:205819463	PM20D1	-0.52	-8.6	-0.39	1.62e-16	Parkinson's disease;
LUAD	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg25237894	chr2:233734115	C2orf82	0.61	11.58	0.49	4.11e-27	Coronary artery disease;
LUAD	cis	rs61897795	0.628	rs93923	chr11:61613745	C/T	cg00603274	chr11:61596626	FADS2	-0.49	-7.3	-0.33	1.43e-12	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs4853036	1.000	rs35084691	chr2:70094137	C/T	cg02498382	chr2:70120550	SNRNP27	-0.5	-8.1	-0.37	5.96e-15	Colorectal or endometrial cancer;
LUAD	cis	rs13315871	0.929	rs11716580	chr3:58228695	G/C	cg12435725	chr3:58293450	RPP14	-0.67	-6.75	-0.31	4.98e-11	Cholesterol, total;
LUAD	cis	rs28595532	0.920	rs115226628	chr4:119639818	A/G	cg02775129	chr4:119771670	NA	-0.84	-7.8	-0.35	4.94e-14	Cannabis dependence symptom count;
LUAD	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-19.65	-0.69	1.5e-61	Height;
LUAD	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-7.04	-0.32	7.89e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg05313129	chr8:58192883	C8orf71	-0.55	-7.15	-0.33	3.91e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg06360820	chr2:242988706	NA	-0.91	-10.05	-0.44	1.92e-21	Obesity-related traits;
LUAD	cis	rs79349575	0.756	rs4793605	chr17:47035869	T/C	cg22482690	chr17:47019901	SNF8	0.44	8.3	0.37	1.4e-15	Type 2 diabetes;
LUAD	cis	rs870825	0.655	rs2310104	chr4:185619967	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21159473	chr9:15510228	PSIP1	-0.54	-6.87	-0.32	2.32e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.85	-0.5	3.72e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	7.59	0.35	2.02e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg02733842	chr7:1102375	C7orf50	-0.67	-10.39	-0.45	1.14e-22	Bronchopulmonary dysplasia;
LUAD	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.63	-7.96	-0.36	1.63e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs239198	0.555	rs9386258	chr6:101286336	C/G	cg09795085	chr6:101329169	ASCC3	0.4	6.45	0.3	3.1e-10	Menarche (age at onset);
LUAD	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg18190219	chr22:46762943	CELSR1	-0.46	-6.63	-0.31	1.04e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg12432903	chr7:1882776	MAD1L1	-0.44	-7.21	-0.33	2.56e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg00071950	chr4:10020882	SLC2A9	-0.6	-11.11	-0.48	2.38e-25	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg00280220	chr17:61926910	NA	0.36	6.95	0.32	1.37e-11	Prudent dietary pattern;
LUAD	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg08027265	chr7:2291960	NA	-0.43	-7.05	-0.32	7.3e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg07917127	chr4:99064746	C4orf37	0.44	7.23	0.33	2.23e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs62064224	0.714	rs4795692	chr17:30636688	G/T	cg18200150	chr17:30822561	MYO1D	0.44	8.19	0.37	3.19e-15	Schizophrenia;
LUAD	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg03467027	chr4:99064603	C4orf37	0.41	6.55	0.3	1.67e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg15704280	chr7:45808275	SEPT13	-0.52	-8.31	-0.37	1.29e-15	HDL cholesterol;
LUAD	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg16342193	chr10:102329863	NA	-0.39	-6.74	-0.31	5.25e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg09222892	chr1:25734099	RHCE	-0.46	-8.54	-0.38	2.5e-16	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs8025790	0.508	rs12905371	chr15:67845930	C/T	cg24579218	chr15:68104479	NA	-0.46	-7.45	-0.34	5.33e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg15485101	chr11:133734466	NA	0.37	7.94	0.36	1.86e-14	Childhood ear infection;
LUAD	cis	rs12505328	0.966	rs13142723	chr4:174368237	A/G	cg12145043	chr4:174357286	NA	0.56	10.31	0.45	2.22e-22	Chin dimples;
LUAD	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg22535103	chr8:58192502	C8orf71	-0.79	-11.04	-0.47	4.57e-25	Developmental language disorder (linguistic errors);
LUAD	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg02018176	chr4:1364513	KIAA1530	0.47	8.71	0.39	6.8e-17	Longevity;
LUAD	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg10792982	chr14:105748885	BRF1	0.41	8.84	0.39	2.62e-17	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-25.01	-0.77	2.01e-85	Height;
LUAD	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg13385794	chr1:248469461	NA	0.25	6.95	0.32	1.35e-11	Common traits (Other);
LUAD	cis	rs68170813	0.559	rs997311	chr7:106953033	G/A	cg02696742	chr7:106810147	HBP1	-0.78	-10.64	-0.46	1.34e-23	Coronary artery disease;
LUAD	cis	rs12681288	0.862	rs34510005	chr8:1018943	T/C	cg15309053	chr8:964076	NA	0.39	8.68	0.39	8.68e-17	Schizophrenia;
LUAD	cis	rs332507	0.830	rs2289428	chr3:124412524	T/G	cg05980111	chr3:124395277	KALRN	0.42	6.71	0.31	6.36e-11	Plateletcrit;
LUAD	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-7.63	-0.35	1.56e-13	Neutrophil percentage of white cells;
LUAD	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg12927641	chr6:109611667	NA	-0.51	-8.81	-0.39	3.15e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.54	-0.34	2.87e-13	Neutrophil percentage of white cells;
LUAD	cis	rs6867032	0.958	rs4975797	chr5:2015573	G/A	cg26168224	chr5:2018326	NA	0.79	18.07	0.66	1.71e-54	Gut microbiome composition (winter);
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg10902427	chr5:176944034	DDX41	-0.39	-6.4	-0.3	4.17e-10	Vertical cup-disc ratio;
LUAD	trans	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.41	-6.77	-0.31	4.22e-11	Menarche (age at onset);
LUAD	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.21	0.37	2.79e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4266144	0.563	rs61124401	chr3:156840919	A/G	cg14969094	chr3:156848003	NA	-0.41	-6.57	-0.3	1.45e-10	Coronary artery disease;
LUAD	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg25344623	chr2:136566232	LCT	-0.38	-7.34	-0.34	1.13e-12	Mosquito bite size;
LUAD	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg08067268	chr2:26466485	HADHB;HADHA	0.56	7.01	0.32	9.62e-12	Gut microbiome composition (summer);
LUAD	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg13798912	chr7:905769	UNC84A	-0.67	-7.5	-0.34	3.7e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs4077515	0.967	rs11145874	chr9:139290011	G/A	cg14019695	chr9:139328340	INPP5E	0.41	7.96	0.36	1.56e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03517284	chr6:25882590	NA	-0.4	-6.5	-0.3	2.28e-10	Height;
LUAD	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg07636037	chr3:49044803	WDR6	0.35	6.35	0.3	5.47e-10	Resting heart rate;
LUAD	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg15226275	chr6:116381976	FRK	0.23	7.65	0.35	1.41e-13	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg25894440	chr7:65020034	NA	-0.64	-6.83	-0.32	2.96e-11	Diabetic kidney disease;
LUAD	trans	rs9929218	1.000	rs35069703	chr16:68789445	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-14.23	-0.57	7.75e-38	Colorectal cancer;
LUAD	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg11822812	chr5:140052017	DND1	0.38	6.66	0.31	8.67e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg27124370	chr19:33622961	WDR88	0.43	6.66	0.31	8.47e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.3	7.0	0.32	9.82e-12	Prostate cancer;
LUAD	cis	rs897984	0.762	rs8062719	chr16:31002664	A/G	cg02466173	chr16:30829666	NA	0.59	10.23	0.45	4.28e-22	Dementia with Lewy bodies;
LUAD	cis	rs2455799	0.613	rs13096622	chr3:15837656	A/G	cg16303742	chr3:15540471	COLQ	-0.52	-9.72	-0.43	2.69e-20	Mean platelet volume;
LUAD	cis	rs2902440	0.502	rs58621044	chr1:67664840	G/C	cg17031739	chr1:67600172	NA	0.39	7.2	0.33	2.84e-12	Crohn's disease;
LUAD	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg09491104	chr22:46646882	C22orf40	-0.54	-7.64	-0.35	1.42e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg26597838	chr10:835615	NA	0.83	11.24	0.48	8.04e-26	Eosinophil percentage of granulocytes;
LUAD	cis	rs9837602	1.000	rs6806178	chr3:99780393	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-7.54	-0.34	2.98e-13	Breast cancer;
LUAD	cis	rs9372498	0.572	rs62422230	chr6:118959436	T/C	cg07617317	chr6:118971624	C6orf204	0.55	7.92	0.36	2.05e-14	Diastolic blood pressure;
LUAD	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg15921436	chr17:44337874	NA	0.64	9.61	0.42	6.61e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.66	-0.39	1e-16	Total body bone mineral density;
LUAD	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg00684032	chr4:1343700	KIAA1530	0.39	6.68	0.31	7.75e-11	Obesity-related traits;
LUAD	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08704250	chr15:31115839	NA	-0.56	-10.0	-0.44	2.89e-21	Huntington's disease progression;
LUAD	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg02475777	chr4:1388615	CRIPAK	0.65	9.07	0.4	4.37e-18	Longevity;
LUAD	cis	rs7771547	0.692	rs9380578	chr6:36550287	G/A	cg07856975	chr6:36356162	ETV7	0.45	6.39	0.3	4.41e-10	Platelet distribution width;
LUAD	cis	rs1018836	0.923	rs1858674	chr8:91580665	G/T	cg16814680	chr8:91681699	NA	-0.72	-12.31	-0.51	5.8e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs77861329	1.000	rs28452586	chr3:52176007	A/G	cg08692210	chr3:52188851	WDR51A	0.87	8.73	0.39	5.83e-17	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg22823121	chr1:150693482	HORMAD1	0.42	8.35	0.38	1e-15	Melanoma;
LUAD	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg09033577	chr2:88485744	THNSL2	-0.54	-6.42	-0.3	3.66e-10	Plasma clusterin levels;
LUAD	cis	rs68170813	0.559	rs79543528	chr7:106891090	C/T	cg23024343	chr7:107201750	COG5	0.49	7.01	0.32	9.63e-12	Coronary artery disease;
LUAD	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg04800585	chr6:26043546	HIST1H2BB	-0.53	-9.1	-0.4	3.54e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg11301795	chr4:187892539	NA	-0.77	-15.66	-0.61	6.19e-44	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7107174	1.000	rs2373115	chr11:78091150	G/T	cg19901956	chr11:77921274	USP35	-0.48	-6.79	-0.31	3.71e-11	Testicular germ cell tumor;
LUAD	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg18944383	chr4:111397179	ENPEP	0.37	7.51	0.34	3.54e-13	Height;
LUAD	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg11645453	chr3:52864694	ITIH4	0.6	11.29	0.48	5.14e-26	Schizophrenia;
LUAD	cis	rs72772090	0.539	rs56319744	chr5:96141938	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-6.75	-0.31	4.88e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2735413	0.846	rs72800943	chr16:78079555	G/A	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg02549819	chr16:58548995	SETD6	0.81	7.06	0.32	6.83e-12	Schizophrenia;
LUAD	cis	rs7147624	1.000	rs2898816	chr14:66008160	T/C	cg03016385	chr14:66212404	NA	-0.6	-7.07	-0.32	6.63e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22857025	chr5:266934	NA	0.97	14.1	0.57	2.68e-37	Breast cancer;
LUAD	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22857025	chr5:266934	NA	-0.97	-14.68	-0.58	1.01e-39	Breast cancer;
LUAD	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg17410650	chr12:54324560	NA	-0.56	-11.1	-0.47	2.75e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg01200585	chr1:228362443	C1orf69	-0.38	-7.18	-0.33	3.07e-12	Diastolic blood pressure;
LUAD	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg06753367	chr22:24256600	NA	-0.38	-6.78	-0.31	3.97e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg23173402	chr1:227635558	NA	0.74	7.94	0.36	1.85e-14	Major depressive disorder;
LUAD	cis	rs7536201	1.000	rs12036815	chr1:25300632	C/T	cg23273869	chr1:25296894	NA	-0.39	-7.97	-0.36	1.47e-14	Psoriasis vulgaris;
LUAD	cis	rs7408868	0.520	rs10417567	chr19:15308068	C/T	cg14696996	chr19:15285081	NOTCH3	-0.63	-8.47	-0.38	4.14e-16	Pulse pressure;
LUAD	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg27284194	chr4:1044797	NA	-0.71	-10.3	-0.45	2.42e-22	Recombination rate (females);
LUAD	cis	rs5756931	0.503	rs5750542	chr22:38534507	T/C	cg25457927	chr22:38595422	NA	-0.4	-9.14	-0.41	2.65e-18	Triglycerides;
LUAD	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg14396892	chr9:96623032	NA	-0.45	-8.57	-0.38	1.99e-16	DNA methylation (variation);
LUAD	cis	rs4660214	0.666	rs6698791	chr1:39934776	A/T	cg27567593	chr1:39956653	BMP8A	0.34	6.76	0.31	4.54e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6500395	1.000	rs7184144	chr16:48606077	C/T	cg04672837	chr16:48644449	N4BP1	0.38	6.49	0.3	2.43e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs7043114	0.525	rs7020874	chr9:95112560	G/A	cg14631576	chr9:95140430	CENPP	-0.43	-8.63	-0.39	1.28e-16	Height;
LUAD	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg21984481	chr17:79567631	NPLOC4	-0.54	-11.09	-0.47	3.04e-25	Eye color traits;
LUAD	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg14664628	chr15:75095509	CSK	-0.54	-8.69	-0.39	8.15e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg00255919	chr5:131827918	IRF1	-0.51	-12.04	-0.51	6.39e-29	Asthma (sex interaction);
LUAD	cis	rs113835537	0.935	rs75863187	chr11:66443461	G/A	cg24851651	chr11:66362959	CCS	0.58	7.95	0.36	1.77e-14	Airway imaging phenotypes;
LUAD	cis	rs8060686	0.516	rs1975802	chr16:68285847	A/G	cg05110241	chr16:68378359	PRMT7	-0.6	-7.66	-0.35	1.24e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg02782426	chr3:40428986	ENTPD3	0.36	7.66	0.35	1.26e-13	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3857536	0.706	rs2157963	chr6:66945449	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.65	-0.31	8.95e-11	Blood trace element (Cu levels);
LUAD	cis	rs7043114	0.525	rs2025388	chr9:95128740	T/C	cg14631576	chr9:95140430	CENPP	-0.43	-8.63	-0.39	1.25e-16	Height;
LUAD	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg03929089	chr4:120376271	NA	-0.6	-9.4	-0.42	3.6e-19	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg08859206	chr1:53392774	SCP2	-0.51	-9.52	-0.42	1.38e-19	Monocyte count;
LUAD	cis	rs11811982	0.793	rs74782247	chr1:227275946	T/C	cg24860534	chr1:227506868	CDC42BPA	0.67	7.29	0.33	1.49e-12	Optic disc area;
LUAD	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.83	0.53	4.8e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg17845761	chr1:175162550	KIAA0040	-0.36	-9.61	-0.42	6.53e-20	Diastolic blood pressure;
LUAD	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs847851	1.000	rs4646926	chr6:34852253	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-7.2	-0.33	2.74e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs367943	0.698	rs2115207	chr5:112998285	C/T	cg12552261	chr5:112820674	MCC	0.5	9.0	0.4	7.43e-18	Type 2 diabetes;
LUAD	cis	rs773506	0.628	rs10820836	chr9:93928329	A/G	cg14446406	chr9:93919335	NA	-0.37	-6.64	-0.31	9.53e-11	Type 2 diabetes nephropathy;
LUAD	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	7.4	0.34	7.46e-13	Platelet count;
LUAD	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg05665937	chr4:1216051	CTBP1	-0.47	-7.66	-0.35	1.27e-13	Obesity-related traits;
LUAD	cis	rs57920188	0.535	rs7412438	chr1:4095581	C/G	cg20703997	chr1:4087676	NA	0.48	8.99	0.4	8.47e-18	Interleukin-17 levels;
LUAD	cis	rs2806561	0.894	rs628106	chr1:23537685	C/T	cg19743168	chr1:23544995	NA	0.46	8.49	0.38	3.49e-16	Height;
LUAD	cis	rs2235649	0.753	rs7200472	chr16:1849669	T/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-6.69	-0.31	7.11e-11	Blood metabolite levels;
LUAD	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg18944383	chr4:111397179	ENPEP	0.41	8.19	0.37	3.15e-15	Height;
LUAD	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg20203395	chr5:56204925	C5orf35	-0.4	-6.59	-0.31	1.3100000000000001e-10	Coronary artery disease;
LUAD	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	6.64	0.31	9.39e-11	Schizophrenia;
LUAD	cis	rs300703	0.542	rs300691	chr2:180171	C/A	cg21211680	chr2:198530	NA	-0.52	-7.35	-0.34	1.03e-12	Blood protein levels;
LUAD	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.62	-0.31	1.12e-10	Drug-induced liver injury (flucloxacillin);
LUAD	trans	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg12400702	chr3:12838781	CAND2	0.31	6.43	0.3	3.41e-10	Parkinson's disease;
LUAD	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg12927641	chr6:109611667	NA	-0.52	-9.06	-0.4	4.89e-18	Reticulocyte fraction of red cells;
LUAD	trans	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg26043149	chr18:55253948	FECH	-0.49	-8.19	-0.37	3.1e-15	Bone mineral density;
LUAD	cis	rs73206853	0.563	rs1973505	chr12:111160003	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.7	-9.65	-0.42	4.97e-20	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs73206853	0.841	rs56251637	chr12:110833869	T/G	cg12870014	chr12:110450643	ANKRD13A	0.61	6.73	0.31	5.38e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg12011299	chr4:100065546	ADH4	0.68	14.09	0.57	3.04e-37	Alcohol dependence;
LUAD	cis	rs1018836	0.923	rs4735230	chr8:91574184	G/C	cg16814680	chr8:91681699	NA	-0.71	-12.25	-0.51	9.82e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg14196790	chr5:131705035	SLC22A5	0.38	6.68	0.31	7.33e-11	Breast cancer;
LUAD	cis	rs2625529	0.652	rs11634608	chr15:72255718	A/G	cg16672083	chr15:72433130	SENP8	0.64	12.1	0.51	3.74e-29	Red blood cell count;
LUAD	cis	rs763121	0.853	rs2072794	chr22:39150543	G/T	cg06544989	chr22:39130855	UNC84B	0.45	8.43	0.38	5.48e-16	Menopause (age at onset);
LUAD	cis	rs35146811	0.555	rs2525539	chr7:99545309	A/G	cg19636519	chr7:99541626	NA	-0.41	-7.38	-0.34	8.62e-13	Coronary artery disease;
LUAD	cis	rs11771526	1.000	rs62457533	chr7:32355334	G/A	cg13207630	chr7:32358064	NA	0.71	7.85	0.36	3.49e-14	Body mass index;
LUAD	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg14343924	chr8:8086146	FLJ10661	-0.5	-8.18	-0.37	3.24e-15	Mood instability;
LUAD	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18876405	chr7:65276391	NA	-0.56	-9.45	-0.42	2.41e-19	Aortic root size;
LUAD	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	7.04	0.32	7.65e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs12701220	0.572	rs7792825	chr7:1006573	T/C	cg02733842	chr7:1102375	C7orf50	-0.48	-7.4	-0.34	7.22e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg15181151	chr6:150070149	PCMT1	0.41	8.53	0.38	2.66e-16	Lung cancer;
LUAD	cis	rs2230307	0.536	rs575971	chr1:100546591	T/C	cg20868668	chr1:100435035	SLC35A3	0.53	7.64	0.35	1.5e-13	Carotid intima media thickness;
LUAD	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.57	8.32	0.37	1.23e-15	Platelet count;
LUAD	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg05535760	chr7:792225	HEATR2	0.89	11.91	0.5	2.09e-28	Cerebrospinal P-tau181p levels;
LUAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg02869364	chr7:1081709	C7orf50	-0.5	-6.46	-0.3	2.91e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.14	-0.54	2.51e-33	Breast cancer;
LUAD	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.81	-15.63	-0.61	8.36e-44	Ulcerative colitis;
LUAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.49	-0.3	2.38e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg23887609	chr12:130822674	PIWIL1	0.41	6.84	0.32	2.79e-11	Menopause (age at onset);
LUAD	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.42	6.72	0.31	5.93e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6743376	0.532	rs2515395	chr2:113818702	G/C	cg09040174	chr2:113837401	NA	0.52	8.02	0.36	1.02e-14	Inflammatory biomarkers;
LUAD	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	8.33	0.38	1.15e-15	Rheumatoid arthritis;
LUAD	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg25019722	chr6:37503610	NA	0.31	7.07	0.33	6.38e-12	Cognitive performance;
LUAD	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg05991184	chr2:219186017	PNKD	0.36	6.79	0.31	3.73e-11	Colorectal cancer;
LUAD	trans	rs75565482	0.793	rs12059815	chr1:168479720	A/G	cg15564619	chr1:2163437	SKI	0.65	6.48	0.3	2.51e-10	Emphysema imaging phenotypes;
LUAD	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg17849569	chr6:28058911	ZSCAN12L1	0.31	6.97	0.32	1.24e-11	Parkinson's disease;
LUAD	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08048268	chr3:133502702	NA	-0.53	-10.69	-0.46	9.36e-24	Iron status biomarkers;
LUAD	cis	rs3806843	0.576	rs246063	chr5:140324492	T/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg09197432	chr4:183729176	NA	0.61	7.93	0.36	1.94e-14	Pediatric autoimmune diseases;
LUAD	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg25767906	chr1:53392781	SCP2	0.41	7.54	0.34	2.94e-13	Monocyte count;
LUAD	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg18621852	chr3:10150065	C3orf24	0.48	7.39	0.34	8e-13	Alzheimer's disease;
LUAD	cis	rs6665290	0.904	rs11586604	chr1:227183865	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.89	-0.89	1.96e-145	Myeloid white cell count;
LUAD	cis	rs859767	0.812	rs842358	chr2:135345109	C/T	cg12500956	chr2:135428796	TMEM163	0.3	7.98	0.36	1.35e-14	Neuroticism;
LUAD	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06505273	chr16:24850292	NA	0.44	6.39	0.3	4.42e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg23262073	chr20:60523788	NA	-0.47	-7.54	-0.34	2.97e-13	Body mass index;
LUAD	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg02493740	chr2:85810744	VAMP5	-0.47	-8.57	-0.38	1.9e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs500891	0.574	rs3798887	chr6:84121713	C/G	cg08257003	chr6:84140564	ME1	0.34	6.69	0.31	7.01e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs7818345	0.649	rs13250181	chr8:19328766	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.31	-7.37	-0.34	9.05e-13	Language performance in older adults (adjusted for episodic memory);
LUAD	trans	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg04775059	chr7:64541387	NA	-0.48	-6.48	-0.3	2.54e-10	Aortic root size;
LUAD	cis	rs778371	0.723	rs6739794	chr2:233576165	G/A	cg08000102	chr2:233561755	GIGYF2	0.4	6.61	0.31	1.13e-10	Schizophrenia;
LUAD	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg09184832	chr6:79620586	NA	-0.51	-9.68	-0.43	3.84e-20	Intelligence (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19280121	chr17:21117780	TMEM11	-0.41	-6.48	-0.3	2.6200000000000003e-10	Height;
LUAD	cis	rs7680126	0.596	rs4698031	chr4:10315921	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.64	-0.31	9.5e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg00310523	chr12:86230176	RASSF9	-0.36	-7.3	-0.33	1.47e-12	Major depressive disorder;
LUAD	cis	rs7192380	0.651	rs6499239	chr16:69686748	G/A	cg26679644	chr16:69762563	NA	0.44	7.16	0.33	3.57e-12	Sjögren's syndrome;
LUAD	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg00310523	chr12:86230176	RASSF9	0.34	7.37	0.34	9.13e-13	Major depressive disorder;
LUAD	cis	rs57994353	0.897	rs35526483	chr9:139364940	G/A	cg14019695	chr9:139328340	INPP5E	0.4	6.56	0.3	1.6e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg21798802	chr22:38057573	PDXP	0.49	9.83	0.43	1.13e-20	Fat distribution (HIV);
LUAD	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs7828089	0.792	rs12544610	chr8:22239813	C/T	cg12081754	chr8:22256438	SLC39A14	0.51	8.88	0.4	1.88e-17	Verbal declarative memory;
LUAD	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-7.62	-0.35	1.72e-13	Morning vs. evening chronotype;
LUAD	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.17	-11.59	-0.49	3.51e-27	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg15445000	chr17:37608096	MED1	-0.46	-8.62	-0.39	1.33e-16	Glomerular filtration rate (creatinine);
LUAD	trans	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg01620082	chr3:125678407	NA	-0.84	-9.04	-0.4	5.71e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs732716	0.504	rs9352	chr19:4442336	C/T	cg21934504	chr19:4445085	UBXN6	0.5	11.94	0.5	1.63e-28	Mean corpuscular volume;
LUAD	cis	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg27411982	chr8:10470053	RP1L1	0.43	8.11	0.37	5.49e-15	Neuroticism;
LUAD	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg06641503	chr3:48959341	ARIH2	0.37	7.43	0.34	6.13e-13	Menarche (age at onset);
LUAD	cis	rs3760982	0.967	rs3760984	chr19:44286762	C/T	cg11993925	chr19:44307056	LYPD5	0.43	8.31	0.37	1.31e-15	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg15017067	chr4:17643749	FAM184B	0.36	7.03	0.32	8.22e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg11494091	chr17:61959527	GH2	0.74	18.28	0.66	1.89e-55	Prudent dietary pattern;
LUAD	cis	rs2996428	0.504	rs3765780	chr1:3767696	C/T	cg17848003	chr1:3704513	LRRC47	-0.48	-10.58	-0.46	2.24e-23	Red cell distribution width;
LUAD	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg22920501	chr2:26401640	FAM59B	-0.96	-14.21	-0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	trans	rs1728785	0.901	rs1645934	chr16:68564490	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.78	0.43	1.69e-20	Ulcerative colitis;
LUAD	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg10729496	chr3:10149963	C3orf24	0.58	9.43	0.42	2.82e-19	Alzheimer's disease;
LUAD	cis	rs9487051	0.768	rs399561	chr6:109524979	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.8	-0.31	3.63e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs11811982	0.793	rs76146925	chr1:227539529	C/A	cg24860534	chr1:227506868	CDC42BPA	0.71	7.52	0.34	3.35e-13	Optic disc area;
LUAD	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg03233332	chr7:66118400	NA	-0.41	-6.36	-0.3	5.29e-10	Aortic root size;
LUAD	cis	rs6998277	0.830	rs6468836	chr8:103602630	A/G	cg10187029	chr8:103597600	NA	0.87	16.37	0.62	5.02e-47	Migraine;
LUAD	cis	rs7680126	0.644	rs4697703	chr4:10107431	A/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.23	-0.37	2.28e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs2797160	1.000	rs2747714	chr6:126007620	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.63	0.31	1.03e-10	Endometrial cancer;
LUAD	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg00383909	chr3:49044727	WDR6	0.75	8.48	0.38	3.84e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10802521	chr3:52805072	NEK4	-0.61	-11.04	-0.47	4.61e-25	Electroencephalogram traits;
LUAD	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.09e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.62	0.31	1.09e-10	Depression;
LUAD	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg11301795	chr4:187892539	NA	-0.79	-16.53	-0.63	1.06e-47	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg05434287	chr7:2030229	MAD1L1	0.38	6.45	0.3	2.98e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg00310523	chr12:86230176	RASSF9	0.41	8.71	0.39	6.76e-17	Major depressive disorder;
LUAD	trans	rs79911532	0.515	rs113229120	chr7:75748581	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	8.66	0.39	1.01e-16	Mononucleosis;
LUAD	trans	rs8002861	0.692	rs9533646	chr13:44410669	T/C	cg17145862	chr1:211918768	LPGAT1	-0.54	-10.54	-0.46	3.12e-23	Leprosy;
LUAD	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg21153622	chr11:89784906	NA	-0.33	-6.6	-0.31	1.25e-10	Coronary artery disease;
LUAD	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg05283184	chr6:79620031	NA	-0.62	-12.37	-0.52	3.11e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs72949976	0.934	rs10197392	chr2:214038178	G/A	cg08319019	chr2:214017104	IKZF2	-0.47	-7.11	-0.33	5.13e-12	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs11229555	0.645	rs11229428	chr11:58180382	C/T	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs617219	0.889	rs1291041	chr5:78443735	G/T	cg25119155	chr5:78426943	BHMT	0.37	6.49	0.3	2.45e-10	Betaine levels in individuals undergoing cardiac evaluation;
LUAD	cis	rs2302190	0.882	rs3803751	chr17:56650356	A/G	cg25885038	chr17:56607967	SEPT4	-0.51	-8.12	-0.37	5.11e-15	Vitamin D levels;
LUAD	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.79e-18	Life satisfaction;
LUAD	cis	rs11951515	0.508	rs10059993	chr5:43598352	A/G	cg01983248	chr5:43482804	C5orf28	-0.38	-8.24	-0.37	2.2e-15	Metabolite levels  (X-11787);
LUAD	cis	rs4604732	0.631	rs12039596	chr1:247624766	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.53	9.21	0.41	1.59e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg25036284	chr2:26402008	FAM59B	-0.65	-8.9	-0.4	1.67e-17	Gut microbiome composition (summer);
LUAD	cis	rs597539	0.690	rs1249359	chr11:68618279	C/T	cg21963583	chr11:68658836	MRPL21	0.63	11.02	0.47	5.39e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg18306943	chr3:40428807	ENTPD3	0.38	6.76	0.31	4.67e-11	Renal cell carcinoma;
LUAD	cis	rs6987853	0.933	rs2923424	chr8:42382222	A/G	cg09913449	chr8:42400586	C8orf40	-0.4	-7.35	-0.34	1.05e-12	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg17757837	chr7:157058334	UBE3C	0.47	8.29	0.37	1.47e-15	Body mass index;
LUAD	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg17063962	chr7:91808500	NA	-0.68	-12.08	-0.51	4.67e-29	Breast cancer;
LUAD	cis	rs7116495	1.000	rs675185	chr11:71775572	T/G	cg07596299	chr11:71824057	C11orf51	-0.77	-6.51	-0.3	2.08e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs2109514	0.902	rs1007751	chr7:116110055	A/T	cg12739419	chr7:116140593	CAV2	-0.33	-6.81	-0.31	3.3e-11	Prevalent atrial fibrillation;
LUAD	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3774749	0.565	rs6800021	chr3:50190346	G/A	cg21582582	chr3:182698605	DCUN1D1	0.42	6.83	0.32	2.99e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2282300	0.739	rs7925340	chr11:30280408	A/C	cg25418670	chr11:30344373	C11orf46	0.54	7.5	0.34	3.71e-13	Morning vs. evening chronotype;
LUAD	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08280861	chr8:58055591	NA	0.76	9.16	0.41	2.26e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	11.77	0.5	7.27e-28	Colorectal cancer;
LUAD	cis	rs7326068	0.610	rs2314720	chr13:21313373	G/A	cg27499820	chr13:21296301	IL17D	0.53	7.91	0.36	2.2e-14	Schizophrenia, bipolar disorder and depression (combined);
LUAD	trans	rs931812	0.691	rs884488	chr8:101898523	C/G	cg20993868	chr7:22813445	NA	0.54	11.76	0.5	7.82e-28	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg06641503	chr3:48959341	ARIH2	-0.37	-7.3	-0.33	1.46e-12	Menarche (age at onset);
LUAD	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-23.47	-0.75	1.31e-78	Height;
LUAD	trans	rs2548003	0.518	rs2554901	chr5:28733310	T/C	cg12623145	chr2:97778927	ANKRD36	0.45	6.5	0.3	2.27e-10	Hip geometry;
LUAD	cis	rs6684514	1.000	rs12121805	chr1:156257876	A/G	cg16558208	chr1:156270281	VHLL	0.53	9.58	0.42	8.12e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs1003719	0.715	rs2835649	chr21:38552230	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.26	0.37	1.83e-15	Eye color traits;
LUAD	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24531977	chr5:56204891	C5orf35	1.19	17.95	0.66	5.92e-54	Initial pursuit acceleration;
LUAD	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg02196655	chr2:10830764	NOL10	-0.46	-8.24	-0.37	2.2e-15	Prostate cancer;
LUAD	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg19622623	chr12:86230825	RASSF9	-0.55	-9.8	-0.43	1.46e-20	Major depressive disorder;
LUAD	cis	rs9581857	0.685	rs79699519	chr13:28023241	C/T	cg22138327	chr13:27999177	GTF3A	0.82	9.82	0.43	1.18e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25427524	chr10:38739819	LOC399744	-0.78	-14.31	-0.57	3.65e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4782309	0.544	rs8060579	chr16:88751667	G/C	cg02389323	chr16:88786976	FAM38A	0.78	6.62	0.31	1.08e-10	Hair color;
LUAD	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg09365446	chr1:150670422	GOLPH3L	0.67	12.69	0.52	1.79e-31	Tonsillectomy;
LUAD	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs2742234	0.911	rs3004214	chr10:43631698	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.44	-7.71	-0.35	9.25e-14	Hirschsprung disease;
LUAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg05313129	chr8:58192883	C8orf71	-0.57	-8.42	-0.38	5.89e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg10596483	chr8:143751796	JRK	0.45	7.22	0.33	2.4e-12	Schizophrenia;
LUAD	trans	rs35952432	1	rs35952432	chr6:28074901	C/T	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.09	-0.47	3.02e-25	Lung cancer;
LUAD	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg26354017	chr1:205819088	PM20D1	0.79	16.36	0.62	5.5e-47	Menarche (age at onset);
LUAD	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg20607287	chr7:12443886	VWDE	-0.52	-6.49	-0.3	2.46e-10	Coronary artery disease;
LUAD	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18404041	chr3:52824283	ITIH1	-0.63	-13.17	-0.54	1.96e-33	Bipolar disorder;
LUAD	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.91	-0.5	2.05e-28	Mean corpuscular volume;
LUAD	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg20476274	chr7:133979776	SLC35B4	0.58	9.5	0.42	1.53e-19	Mean platelet volume;
LUAD	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg20503657	chr10:835505	NA	0.82	11.12	0.48	2.19e-25	Eosinophil percentage of granulocytes;
LUAD	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg19875535	chr5:140030758	IK	-0.41	-6.85	-0.32	2.68e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs17067123	0.614	rs55983301	chr4:180070495	A/G	cg26610307	chr4:180072759	NA	-0.52	-6.74	-0.31	5.24e-11	Response to hepatitis C treatment;
LUAD	trans	rs8023401	0.938	rs17460473	chr15:48826917	C/A	cg26807912	chr15:101970241	PCSK6	0.53	6.37	0.3	4.98e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.46	0.42	2.13e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6998277	1.000	rs4281092	chr8:103647956	A/G	cg10187029	chr8:103597600	NA	-0.65	-9.91	-0.43	5.77e-21	Migraine;
LUAD	cis	rs12801636	0.512	rs11227247	chr11:65422853	A/C	cg16535667	chr11:65410126	SIPA1	-0.44	-6.36	-0.3	5.4e-10	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11644478	chr21:40555479	PSMG1	-0.52	-8.33	-0.38	1.15e-15	Cognitive function;
LUAD	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg21204522	chr6:27730016	NA	-0.45	-7.03	-0.32	8.5e-12	Parkinson's disease;
LUAD	cis	rs600231	0.542	rs11227199	chr11:65238121	G/A	cg17120908	chr11:65337727	SSSCA1	-0.63	-8.24	-0.37	2.2e-15	Bone mineral density;
LUAD	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg25985355	chr7:65971099	NA	-0.35	-6.44	-0.3	3.25e-10	Aortic root size;
LUAD	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.56	-0.3	1.58e-10	Triglycerides;
LUAD	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg24558204	chr6:135376177	HBS1L	0.49	8.98	0.4	9.03e-18	Red blood cell count;
LUAD	cis	rs7180079	0.925	rs11071789	chr15:64596057	C/T	cg08069370	chr15:64387884	SNX1	0.51	6.45	0.3	3.1e-10	Monocyte count;
LUAD	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg16205897	chr5:131564050	P4HA2	-0.42	-9.69	-0.43	3.55e-20	Blood metabolite levels;
LUAD	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg17279839	chr7:150038598	RARRES2	0.44	7.35	0.34	1e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6066825	0.644	rs2143563	chr20:47320211	A/G	cg18078177	chr20:47281410	PREX1	0.39	6.42	0.3	3.61e-10	Colorectal cancer;
LUAD	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01570182	chr17:44337453	NA	0.77	12.44	0.52	1.77e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.09	0.37	6.44e-15	Menopause (age at onset);
LUAD	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg23758822	chr17:41437982	NA	1.0	21.05	0.72	8.34e-68	Menopause (age at onset);
LUAD	cis	rs7932354	0.528	rs7946709	chr11:47100796	G/T	cg19486271	chr11:47235900	DDB2	-0.47	-7.5	-0.34	3.89e-13	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg22598563	chr5:131563921	P4HA2	-0.28	-6.67	-0.31	8.01e-11	Blood metabolite levels;
LUAD	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg11965913	chr1:205819406	PM20D1	-0.45	-7.29	-0.33	1.52e-12	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs78707713	0.836	rs77602872	chr10:71211734	G/A	cg12610070	chr10:71211762	TSPAN15	-0.4	-7.15	-0.33	3.93e-12	Venous thromboembolism;
LUAD	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg25554036	chr4:6271136	WFS1	0.66	12.06	0.51	5.62e-29	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs412658	0.668	rs7253490	chr19:22293706	A/C	cg05197062	chr11:11642011	GALNTL4	0.43	7.64	0.35	1.46e-13	Telomere length;
LUAD	cis	rs10189230	0.967	rs12613015	chr2:222356119	G/A	cg14652038	chr2:222343519	EPHA4	0.42	8.5	0.38	3.19e-16	Urate levels in lean individuals;
LUAD	cis	rs300774	0.925	rs408074	chr2:150853	T/C	cg21211680	chr2:198530	NA	-0.48	-7.57	-0.35	2.33e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg16205897	chr5:131564050	P4HA2	-0.32	-6.99	-0.32	1.07e-11	Blood metabolite levels;
LUAD	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg07606381	chr6:8435919	SLC35B3	0.41	7.17	0.33	3.33e-12	Motion sickness;
LUAD	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00149659	chr3:10157352	C3orf10	0.64	9.2	0.41	1.64e-18	Alzheimer's disease;
LUAD	cis	rs1375194	0.606	rs13393407	chr2:33818198	C/T	cg04131969	chr2:33951647	MYADML	-0.56	-8.69	-0.39	8.17e-17	Response to antidepressants in depression;
LUAD	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.43	-7.61	-0.35	1.76e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg26384229	chr12:38710491	ALG10B	0.5	8.01	0.36	1.11e-14	Morning vs. evening chronotype;
LUAD	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12667521	chr19:29218732	NA	0.59	8.46	0.38	4.55e-16	Methadone dose in opioid dependence;
LUAD	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg22875332	chr1:76189707	ACADM	-0.45	-6.48	-0.3	2.6200000000000003e-10	Daytime sleep phenotypes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10519680	chr8:37707506	BRF2	-0.5	-7.99	-0.36	1.34e-14	Height;
LUAD	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.54	0.34	2.84e-13	Breast cancer;
LUAD	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.9	-0.36	2.45e-14	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs877282	0.853	rs4579862	chr10:753298	A/C	cg22713356	chr15:30763199	NA	1.26	16.73	0.63	1.33e-48	Uric acid levels;
LUAD	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg10150615	chr22:24372951	LOC391322	0.51	7.27	0.33	1.77e-12	Urinary 1,3-butadiene metabolite levels in smokers;
LUAD	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg11189052	chr15:85197271	WDR73	0.61	7.87	0.36	2.95e-14	Schizophrenia;
LUAD	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11890956	chr21:40555474	PSMG1	-0.55	-9.65	-0.42	4.9e-20	Menarche (age at onset);
LUAD	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg03030879	chr14:75389066	RPS6KL1	0.34	6.43	0.3	3.43e-10	Caffeine consumption;
LUAD	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg18105134	chr13:113819100	PROZ	-0.86	-15.09	-0.59	1.78e-41	Platelet distribution width;
LUAD	cis	rs41271951	0.512	rs115968379	chr1:151050087	A/C	cg11822372	chr1:151115635	SEMA6C	-0.82	-6.97	-0.32	1.24e-11	Blood protein levels;
LUAD	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg25566285	chr7:158114605	PTPRN2	0.42	7.32	0.34	1.29e-12	Response to amphetamines;
LUAD	cis	rs714027	1.000	rs714027	chr22:30577771	A/G	cg00539347	chr22:30592296	NA	0.28	6.47	0.3	2.66e-10	Lymphocyte counts;
LUAD	cis	rs12540874	0.759	rs12718572	chr7:50573325	C/T	cg18232548	chr7:50535776	DDC	-0.65	-11.19	-0.48	1.25e-25	Systemic sclerosis;
LUAD	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg04775059	chr7:64541387	NA	0.5	7.94	0.36	1.82e-14	Calcium levels;
LUAD	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.31	-0.45	2.24e-22	Menopause (age at onset);
LUAD	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg11833968	chr6:79620685	NA	-0.44	-8.28	-0.37	1.68e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg03886242	chr7:26192032	NFE2L3	0.44	7.56	0.35	2.53e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05901451	chr6:126070800	HEY2	0.46	7.12	0.33	4.74e-12	Endometrial cancer;
LUAD	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	7.24	0.33	2.12e-12	Platelet count;
LUAD	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.89	0.36	2.58e-14	Parkinson's disease;
LUAD	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg15181151	chr6:150070149	PCMT1	0.43	8.76	0.39	4.67e-17	Lung cancer;
LUAD	trans	rs2797160	0.547	rs9401837	chr6:125956853	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-7.37	-0.34	9.21e-13	Endometrial cancer;
LUAD	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-12.8	-0.53	6.31e-32	Mean corpuscular volume;
LUAD	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg27432699	chr2:27873401	GPN1	-0.38	-6.41	-0.3	3.96e-10	Total body bone mineral density;
LUAD	cis	rs2730260	0.537	rs55864635	chr7:158859744	C/T	cg13710308	chr7:158854763	VIPR2	-0.52	-6.59	-0.31	1.3100000000000001e-10	Myopia (pathological);
LUAD	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34286592	0.929	rs8058824	chr16:29828710	C/G	cg08218971	chr16:29826754	C16orf53;PRRT2	0.4	6.38	0.3	4.75e-10	Multiple sclerosis;
LUAD	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	8.71	0.39	6.76e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg10518543	chr12:38710700	ALG10B	-0.42	-6.94	-0.32	1.45e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg04369109	chr6:150039330	LATS1	0.46	7.52	0.34	3.41e-13	Lung cancer;
LUAD	cis	rs1032833	0.732	rs115452203	chr2:180108663	A/G	cg23883738	chr2:179974586	SESTD1	-0.68	-7.65	-0.35	1.38e-13	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs62400317	0.686	rs860741	chr6:44808435	G/A	cg18551225	chr6:44695536	NA	0.46	7.67	0.35	1.22e-13	Total body bone mineral density;
LUAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs62400317	0.826	rs12205468	chr6:45310285	G/A	cg18551225	chr6:44695536	NA	-0.55	-8.72	-0.39	6.54e-17	Total body bone mineral density;
LUAD	trans	rs4650994	1.000	rs10913570	chr1:178523126	A/C	cg05059571	chr16:84539110	KIAA1609	-0.6	-10.23	-0.45	4.33e-22	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.22	0.48	9.45e-26	Height;
LUAD	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg06740227	chr12:86229804	RASSF9	0.38	6.8	0.31	3.58e-11	Major depressive disorder;
LUAD	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg25767906	chr1:53392781	SCP2	0.41	7.43	0.34	5.93e-13	Monocyte count;
LUAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg22907277	chr7:1156413	C7orf50	0.71	8.33	0.38	1.15e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg06606381	chr12:133084897	FBRSL1	-0.97	-8.77	-0.39	4.3e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg22532475	chr10:104410764	TRIM8	-0.61	-11.38	-0.48	2.25e-26	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.76	0.31	4.48e-11	Platelet count;
LUAD	cis	rs7107174	1.000	rs12270434	chr11:78103300	G/A	cg19901956	chr11:77921274	USP35	-0.48	-6.79	-0.31	3.92e-11	Testicular germ cell tumor;
LUAD	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg06108461	chr20:60628389	TAF4	-0.81	-13.82	-0.56	3.94e-36	Body mass index;
LUAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.61	-10.67	-0.46	1.06e-23	Lymphocyte counts;
LUAD	trans	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg01620082	chr3:125678407	NA	-0.45	-6.71	-0.31	6.45e-11	Depression;
LUAD	cis	rs7737355	0.617	rs245800	chr5:130677591	T/A	cg06307176	chr5:131281290	NA	-0.38	-6.38	-0.3	4.52e-10	Life satisfaction;
LUAD	cis	rs1878931	0.580	rs7194596	chr16:3404408	T/A	cg05754148	chr16:3507555	NAT15	-0.41	-6.81	-0.31	3.34e-11	Body mass index (adult);
LUAD	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.61	-0.42	6.81e-20	Bipolar disorder and schizophrenia;
LUAD	trans	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg13565492	chr6:43139072	SRF	-0.6	-6.37	-0.3	4.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1497828	0.956	rs2646803	chr1:217522466	A/G	cg04411442	chr1:217543379	NA	0.35	6.42	0.3	3.57e-10	Dialysis-related mortality;
LUAD	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg21963583	chr11:68658836	MRPL21	0.64	11.43	0.49	1.52e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs751728	0.689	rs3763257	chr6:33773696	T/A	cg13859433	chr6:33739653	LEMD2	-0.34	-7.09	-0.33	5.65e-12	Crohn's disease;
LUAD	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg03929089	chr4:120376271	NA	-0.45	-6.98	-0.32	1.16e-11	HDL cholesterol;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17257944	chr16:11836937	TXNDC11	-0.41	-6.76	-0.31	4.67e-11	Cancer;
LUAD	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg05590025	chr7:65112418	INTS4L2	-0.79	-8.31	-0.37	1.33e-15	Diabetic kidney disease;
LUAD	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg08847533	chr14:75593920	NEK9	-0.42	-7.31	-0.33	1.34e-12	Height;
LUAD	trans	rs9784649	1.000	rs6864025	chr5:24960691	G/C	cg11038491	chr20:34638489	LOC647979	-0.61	-8.01	-0.36	1.1e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs344364	0.576	rs238680	chr16:1872160	G/A	cg08610935	chr16:1836813	NUBP2	0.45	6.5	0.3	2.25e-10	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs10791097	0.728	rs10894265	chr11:130714613	T/C	cg12179176	chr11:130786555	SNX19	-0.4	-6.56	-0.3	1.57e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs68170813	0.617	rs17481842	chr7:107121862	C/T	cg23024343	chr7:107201750	COG5	0.5	6.47	0.3	2.77e-10	Coronary artery disease;
LUAD	cis	rs2377058	0.803	rs13332439	chr16:89730479	A/T	cg03605463	chr16:89740564	NA	-0.59	-10.24	-0.45	3.93e-22	Hip circumference adjusted for BMI;
LUAD	cis	rs11657217	1.000	rs8081537	chr17:77708264	A/G	cg06901238	chr17:77706717	ENPP7	0.68	12.97	0.53	1.27e-32	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
LUAD	cis	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg08798685	chr6:27730294	NA	-0.44	-6.57	-0.3	1.49e-10	Breast cancer;
LUAD	cis	rs57590327	0.503	rs6800295	chr3:81593011	A/G	cg07356753	chr3:81810745	GBE1	-0.52	-7.9	-0.36	2.5e-14	Extraversion;
LUAD	cis	rs1475911	0.947	rs67055914	chr21:43510427	T/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.53	-7.93	-0.36	1.97e-14	IgG glycosylation;
LUAD	cis	rs7945718	1.000	rs7945718	chr11:12748819	A/G	cg25843174	chr11:12811716	TEAD1	0.23	6.87	0.32	2.36e-11	Educational attainment (years of education);
LUAD	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.51	9.19	0.41	1.73e-18	Lymphocyte counts;
LUAD	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg01849466	chr14:104193079	ZFYVE21	0.46	7.57	0.35	2.36e-13	Body mass index;
LUAD	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg15704280	chr7:45808275	SEPT13	-1.09	-24.9	-0.77	6.62e-85	Height;
LUAD	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.18	0.54	1.73e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs11811982	0.744	rs115058698	chr1:227483194	C/T	cg24860534	chr1:227506868	CDC42BPA	0.64	7.02	0.32	8.81e-12	Optic disc area;
LUAD	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.62	10.86	0.47	2.07e-24	Lymphocyte counts;
LUAD	cis	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.63	-0.31	1.01e-10	Neuroticism;
LUAD	cis	rs6489882	0.703	rs2660	chr12:113357442	A/G	cg20102336	chr12:113376681	OAS3	0.52	8.09	0.37	6.29e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg04851639	chr8:1020857	NA	-0.38	-9.25	-0.41	1.14e-18	Schizophrenia;
LUAD	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg18230493	chr5:56204884	C5orf35	-0.45	-7.55	-0.34	2.75e-13	Coronary artery disease;
LUAD	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.85	0.56	3.1e-36	Prudent dietary pattern;
LUAD	cis	rs3806843	0.546	rs246023	chr5:140333990	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	9.02e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.47	6.79	0.31	3.81e-11	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg17063962	chr7:91808500	NA	0.68	12.19	0.51	1.65e-29	Breast cancer;
LUAD	cis	rs89107	0.576	rs17227124	chr6:118741382	T/C	cg18833306	chr6:118973337	C6orf204	0.38	6.48	0.3	2.55e-10	Cardiac structure and function;
LUAD	cis	rs9826463	0.582	rs73238138	chr3:142041137	T/C	cg20824294	chr3:142316082	PLS1	0.4	6.8	0.31	3.64e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.65	9.82	0.43	1.21e-20	Lymphocyte percentage of white cells;
LUAD	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg04731861	chr2:219085781	ARPC2	0.27	8.31	0.37	1.36e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg18016565	chr1:150552671	MCL1	0.42	7.74	0.35	7.54e-14	Melanoma;
LUAD	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg17200465	chr3:40428508	ENTPD3	0.27	6.42	0.3	3.68e-10	Renal cell carcinoma;
LUAD	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg06671706	chr8:8559999	CLDN23	-0.63	-10.75	-0.46	5.3e-24	Obesity-related traits;
LUAD	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg04568274	chr7:158649319	WDR60	-0.44	-6.81	-0.31	3.45e-11	Height;
LUAD	cis	rs11771526	0.901	rs10264511	chr7:32304170	T/C	cg13207630	chr7:32358064	NA	0.6	7.34	0.34	1.07e-12	Body mass index;
LUAD	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg03233332	chr7:66118400	NA	-0.45	-6.95	-0.32	1.41e-11	Aortic root size;
LUAD	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg17595323	chr11:93583763	C11orf90	-0.43	-9.08	-0.4	4.14e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg14019146	chr3:50243930	SLC38A3	-0.38	-7.53	-0.34	3.01e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18099408	chr3:52552593	STAB1	-0.47	-8.22	-0.37	2.45e-15	Bipolar disorder;
LUAD	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg06191203	chr2:152266755	RIF1	-0.66	-10.17	-0.44	6.88e-22	Lung cancer;
LUAD	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg15704280	chr7:45808275	SEPT13	0.73	10.79	0.46	3.97e-24	Height;
LUAD	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18099408	chr3:52552593	STAB1	-0.46	-8.14	-0.37	4.4e-15	Bipolar disorder;
LUAD	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg22117172	chr7:91764530	CYP51A1	0.35	7.86	0.36	3.2e-14	Breast cancer;
LUAD	cis	rs220324	0.738	rs9984147	chr21:43590428	A/T	cg09727148	chr21:43560719	UMODL1	0.46	6.9	0.32	1.9e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs9814567	0.752	rs4955542	chr3:134328740	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-13.02	-0.53	7.98e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9658691	0.607	rs9658757	chr10:90769455	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.61	-7.55	-0.34	2.73e-13	Mosquito bite size;
LUAD	cis	rs11229555	0.645	rs12803648	chr11:58177561	G/T	cg15696309	chr11:58395628	NA	-0.73	-10.21	-0.44	5.12e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg00271210	chr6:167070053	RPS6KA2	0.34	6.52	0.3	1.96e-10	Crohn's disease;
LUAD	cis	rs7503807	1.000	rs12936076	chr17:78601195	C/T	cg09596252	chr17:78655493	RPTOR	0.41	7.95	0.36	1.76e-14	Obesity;
LUAD	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.57	8.34	0.38	1.02e-15	Platelet count;
LUAD	cis	rs2880765	0.835	rs4842887	chr15:86035810	T/C	cg13263323	chr15:86062960	AKAP13	-0.48	-8.91	-0.4	1.5e-17	Coronary artery disease;
LUAD	trans	rs1547374	1.000	rs4920092	chr21:43781114	G/A	cg09521743	chr10:75415752	SYNPO2L	-0.42	-6.91	-0.32	1.81e-11	Pancreatic cancer;
LUAD	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs68170813	0.559	rs12537730	chr7:106844281	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-10.92	-0.47	1.27e-24	Coronary artery disease;
LUAD	cis	rs2224391	0.613	rs17140075	chr6:5282415	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-8.09	-0.37	6.19e-15	Height;
LUAD	cis	rs75229567	0.618	rs78294090	chr12:70209959	G/T	cg10114359	chr12:70132523	RAB3IP	0.86	6.99	0.32	1.05e-11	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg18944383	chr4:111397179	ENPEP	0.37	7.42	0.34	6.52e-13	Height;
LUAD	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg02527881	chr3:46936655	PTH1R	0.57	11.26	0.48	6.4e-26	Colorectal cancer;
LUAD	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg04800585	chr6:26043546	HIST1H2BB	-0.4	-6.88	-0.32	2.12e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9788721	1.000	rs8034191	chr15:78806023	A/G	cg18825076	chr15:78729989	IREB2	-0.52	-8.63	-0.39	1.21e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg08885076	chr2:99613938	TSGA10	0.39	7.3	0.33	1.48e-12	Chronic sinus infection;
LUAD	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg20476274	chr7:133979776	SLC35B4	0.85	16.74	0.63	1.25e-48	Mean platelet volume;
LUAD	cis	rs4588572	0.537	rs7719228	chr5:77730576	G/A	cg11547950	chr5:77652471	NA	-0.62	-10.65	-0.46	1.3e-23	Triglycerides;
LUAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg20607798	chr8:58055168	NA	0.71	9.3	0.41	7.81e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg26668828	chr6:292823	DUSP22	-0.59	-10.34	-0.45	1.76e-22	Menopause (age at onset);
LUAD	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.86	0.36	3.26e-14	Bladder cancer;
LUAD	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.65	0.31	9.1e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg00757033	chr12:89920650	WDR51B	-0.67	-11.76	-0.5	8.26e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg10518543	chr12:38710700	ALG10B	-0.43	-6.94	-0.32	1.44e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg27631724	chr1:11040367	C1orf127	0.5	8.68	0.39	8.51e-17	Ewing sarcoma;
LUAD	trans	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17712092	chr4:129076599	LARP1B	-0.94	-19.3	-0.68	5.35e-60	Eosinophil percentage of white cells;
LUAD	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg24450063	chr1:156163899	SLC25A44	1.14	22.39	0.74	8.62e-74	Testicular germ cell tumor;
LUAD	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.66	-0.31	8.51e-11	Crohn's disease;
LUAD	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg26022315	chr17:47021804	SNF8	0.41	7.33	0.34	1.17e-12	Type 2 diabetes;
LUAD	cis	rs7584330	0.554	rs4420668	chr2:238444793	G/A	cg14458575	chr2:238380390	NA	0.6	9.63	0.42	5.71e-20	Prostate cancer;
LUAD	cis	rs6867913	0.709	rs2338874	chr5:141466926	G/A	cg08523384	chr5:141488047	NDFIP1	-0.43	-7.11	-0.33	5.05e-12	Asthma;
LUAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg08888203	chr3:10149979	C3orf24	0.74	12.88	0.53	2.92e-32	Alzheimer's disease;
LUAD	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg17264618	chr3:40429014	ENTPD3	0.4	8.9	0.4	1.7e-17	Renal cell carcinoma;
LUAD	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg23283495	chr1:209979779	IRF6	0.7	11.11	0.48	2.46e-25	Cleft lip with or without cleft palate;
LUAD	trans	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg01620082	chr3:125678407	NA	-0.71	-7.18	-0.33	3.14e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg03354898	chr7:1950403	MAD1L1	-0.39	-7.21	-0.33	2.68e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs877426	0.681	rs7317994	chr13:114817068	C/T	cg21461300	chr13:114830702	RASA3	-0.43	-6.49	-0.3	2.38e-10	Facial morphology (factor 14, intercanthal width);
LUAD	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg16205897	chr5:131564050	P4HA2	-0.31	-6.84	-0.32	2.74e-11	Acylcarnitine levels;
LUAD	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-10.56	-0.46	2.76e-23	Schizophrenia;
LUAD	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.73	0.35	7.95e-14	Platelet count;
LUAD	trans	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg19862616	chr7:65841803	NCRNA00174	1.05	25.94	0.78	1.75e-89	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg12016809	chr21:47604291	C21orf56	0.65	11.47	0.49	1.02e-26	Testicular germ cell tumor;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06714086	chr11:33182787	CSTF3	-0.48	-7.48	-0.34	4.33e-13	Height;
LUAD	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.04e-13	Morning vs. evening chronotype;
LUAD	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg11189052	chr15:85197271	WDR73	0.59	7.64	0.35	1.49e-13	Schizophrenia;
LUAD	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21171335	chr12:122356390	WDR66	0.66	11.92	0.5	1.87e-28	Mean corpuscular volume;
LUAD	cis	rs2657888	0.965	rs2657902	chr12:56933651	G/A	cg23002907	chr12:56915593	RBMS2	0.35	6.56	0.3	1.59e-10	Adiponectin levels;
LUAD	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg12935359	chr14:103987150	CKB	0.52	8.19	0.37	3.14e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs654950	0.934	rs654220	chr1:42002556	A/T	cg06885757	chr1:42089581	HIVEP3	-0.45	-10.12	-0.44	1.1e-21	Airway imaging phenotypes;
LUAD	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	8.43	0.38	5.58e-16	Rheumatoid arthritis;
LUAD	cis	rs35740288	0.694	rs17618909	chr15:86095462	A/C	cg13263323	chr15:86062960	AKAP13	-0.46	-7.5	-0.34	3.69e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUAD	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg02527881	chr3:46936655	PTH1R	-0.51	-10.22	-0.44	4.65e-22	Colorectal cancer;
LUAD	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4660214	0.666	rs663892	chr1:39889677	G/A	cg27567593	chr1:39956653	BMP8A	-0.36	-7.23	-0.33	2.26e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	7.9e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg22852734	chr6:133119734	C6orf192	0.69	8.12	0.37	5.08e-15	Type 2 diabetes nephropathy;
LUAD	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg03354898	chr7:1950403	MAD1L1	-0.42	-7.79	-0.35	5.08e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg09640425	chr7:158790006	NA	-0.53	-9.07	-0.4	4.68e-18	Facial morphology (factor 20);
LUAD	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg06028605	chr16:24865363	SLC5A11	0.35	6.4	0.3	4.05e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.49	-0.45	4.82e-23	Monocyte percentage of white cells;
LUAD	cis	rs10392	0.543	rs748063	chr20:37548730	A/G	cg27552599	chr20:37590471	DHX35	0.4	6.83	0.32	2.92e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs3806843	0.576	rs246006	chr5:140339228	G/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.38	-0.3	4.59e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs738322	0.553	rs28718653	chr22:38570698	C/A	cg25457927	chr22:38595422	NA	-0.51	-11.25	-0.48	7.29e-26	Cutaneous nevi;
LUAD	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg02423579	chr7:2872169	GNA12	-0.52	-8.57	-0.38	1.95e-16	Height;
LUAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.81	0.43	1.32e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs656900	0.647	rs600671	chr15:80117232	A/G	cg02196730	chr15:80188777	MTHFS	0.43	7.26	0.33	1.9e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg10909506	chr17:38081995	ORMDL3	0.37	6.59	0.31	1.28e-10	Self-reported allergy;
LUAD	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg11833968	chr6:79620685	NA	-0.45	-8.32	-0.38	1.21e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs4147929	0.532	rs4147930	chr19:1064193	G/A	cg26576206	chr19:1064938	ABCA7	0.48	7.42	0.34	6.44e-13	Alzheimer's disease (late onset);
LUAD	cis	rs2067615	0.599	rs10778508	chr12:107159405	A/G	cg15890332	chr12:107067104	RFX4	-0.4	-8.69	-0.39	8.22e-17	Heart rate;
LUAD	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg26384229	chr12:38710491	ALG10B	0.48	7.6	0.35	1.9e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg15448220	chr1:150897856	SETDB1	0.48	8.37	0.38	8.5e-16	Melanoma;
LUAD	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.67e-18	Life satisfaction;
LUAD	cis	rs733592	0.894	rs886589	chr12:48477197	C/T	cg24011408	chr12:48396354	COL2A1	-0.35	-7.16	-0.33	3.64e-12	Plateletcrit;
LUAD	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg16205897	chr5:131564050	P4HA2	0.31	6.9	0.32	1.9e-11	Blood metabolite levels;
LUAD	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg08645402	chr16:4508243	NA	0.54	9.75	0.43	2.07e-20	Schizophrenia;
LUAD	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.82	-0.36	4.31e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg02158880	chr13:53174818	NA	0.46	7.63	0.35	1.6e-13	Lewy body disease;
LUAD	trans	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg00769240	chr8:12517080	NA	-0.42	-7.29	-0.33	1.55e-12	Blood pressure (smoking interaction);
LUAD	trans	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	15.35	0.6	1.34e-42	Exhaled nitric oxide levels;
LUAD	cis	rs758324	0.812	rs11242095	chr5:131152575	A/G	cg06307176	chr5:131281290	NA	0.44	7.41	0.34	6.81e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg07266350	chr3:49460521	AMT;NICN1	-0.36	-6.52	-0.3	2.06e-10	Menarche (age at onset);
LUAD	cis	rs877282	1.000	rs877281	chr10:771557	T/G	cg17470449	chr10:769945	NA	0.66	9.57	0.42	9.08e-20	Uric acid levels;
LUAD	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg23281280	chr6:28129359	ZNF389	0.47	6.64	0.31	9.55e-11	Depression;
LUAD	cis	rs2274273	0.714	rs7154889	chr14:55806885	G/A	cg04306507	chr14:55594613	LGALS3	0.42	8.72	0.39	6.27e-17	Protein biomarker;
LUAD	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg12432903	chr7:1882776	MAD1L1	-0.52	-8.59	-0.39	1.75e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg01256987	chr12:42539512	GXYLT1	-0.34	-6.64	-0.31	9.41e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs7216064	0.636	rs62084696	chr17:66038181	C/G	cg08758996	chr17:66097529	LOC651250	-0.42	-7.09	-0.33	5.49e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg18827107	chr12:86230957	RASSF9	-0.45	-8.12	-0.37	4.97e-15	Major depressive disorder;
LUAD	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.33	-7.36	-0.34	9.56e-13	Lung cancer;
LUAD	trans	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg21659725	chr3:3221576	CRBN	-0.58	-9.53	-0.42	1.23e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs7394190	0.630	rs113799665	chr10:75575138	C/T	cg02286717	chr10:75415704	SYNPO2L	-0.38	-6.61	-0.31	1.2e-10	Incident atrial fibrillation;
LUAD	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg27494647	chr7:150038898	RARRES2	0.39	7.07	0.32	6.54e-12	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs225245	0.755	rs8078905	chr17:34009029	T/C	cg05299278	chr17:33885742	SLFN14	0.5	11.43	0.49	1.47e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.99	0.32	1.05e-11	Lung cancer;
LUAD	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg16145915	chr7:1198662	ZFAND2A	0.52	9.79	0.43	1.56e-20	Longevity;Endometriosis;
LUAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.55	-9.88	-0.43	7.44e-21	Longevity;Endometriosis;
LUAD	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg11530693	chr1:120165357	ZNF697	0.86	18.85	0.68	5.88e-58	Systemic lupus erythematosus;
LUAD	cis	rs57920188	0.535	rs10915664	chr1:4093700	G/A	cg20703997	chr1:4087676	NA	0.48	8.99	0.4	8.47e-18	Interleukin-17 levels;
LUAD	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg17063962	chr7:91808500	NA	0.64	10.85	0.47	2.36e-24	Breast cancer;
LUAD	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg18761221	chr20:60518478	NA	-0.43	-7.28	-0.33	1.65e-12	Body mass index;
LUAD	cis	rs62238980	0.614	rs77630998	chr22:32452744	T/C	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg20500540	chr8:101228448	SPAG1	-0.36	-6.5	-0.3	2.27e-10	Atrioventricular conduction;
LUAD	cis	rs887829	0.570	rs10168333	chr2:234596988	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-9.67	-0.43	4e-20	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	trans	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.24	-0.33	2.13e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg23625390	chr15:77176239	SCAPER	0.39	6.84	0.32	2.85e-11	Blood metabolite levels;
LUAD	cis	rs78761021	0.824	rs17743050	chr17:9772261	A/G	cg26853458	chr17:9805074	RCVRN	0.35	6.72	0.31	6.02e-11	Type 2 diabetes;
LUAD	cis	rs7394190	0.748	rs12573448	chr10:75504512	T/G	cg02286717	chr10:75415704	SYNPO2L	-0.41	-7.01	-0.32	9.75e-12	Incident atrial fibrillation;
LUAD	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg06766960	chr11:133703094	NA	-0.45	-8.45	-0.38	4.68e-16	Childhood ear infection;
LUAD	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05901451	chr6:126070800	HEY2	-0.84	-16.32	-0.62	8.45e-47	Brugada syndrome;
LUAD	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.23	-0.41	1.3e-18	Type 2 diabetes;
LUAD	cis	rs2637266	0.967	rs12254242	chr10:78352934	T/C	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.57	-0.3	1.5e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg07741184	chr6:167504864	NA	0.31	7.26	0.33	1.88e-12	Crohn's disease;
LUAD	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg01171360	chr6:293285	DUSP22	-0.53	-9.02	-0.4	6.6e-18	Menopause (age at onset);
LUAD	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg00071950	chr4:10020882	SLC2A9	0.6	11.35	0.48	3.05e-26	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs151234	0.741	rs11647881	chr16:28606173	C/A	cg04609801	chr16:28609176	SULT1A2	0.58	7.65	0.35	1.35e-13	Platelet distribution width;
LUAD	cis	rs1595825	0.891	rs2293255	chr2:198621506	T/C	cg00982548	chr2:198649783	BOLL	-0.66	-9.4	-0.42	3.55e-19	Ulcerative colitis;
LUAD	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg01475377	chr6:109611718	NA	-0.54	-10.31	-0.45	2.26e-22	Reticulocyte fraction of red cells;
LUAD	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00166722	chr3:10149974	C3orf24	0.73	12.65	0.52	2.57e-31	Alzheimer's disease;
LUAD	trans	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg19862616	chr7:65841803	NCRNA00174	1.05	26.51	0.79	5.76e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.81	-0.31	3.32e-11	Breast cancer;
LUAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg22963979	chr7:1858916	MAD1L1	-0.72	-12.67	-0.52	2e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs656900	0.967	rs661478	chr15:80115100	C/T	cg02196730	chr15:80188777	MTHFS	-0.42	-6.69	-0.31	7.22e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg23815491	chr16:72088622	HP	0.48	8.65	0.39	1.09e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs12912251	0.947	rs12899449	chr15:38995491	A/G	cg01338139	chr15:38987640	C15orf53	-0.58	-9.37	-0.41	4.5e-19	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg14779329	chr11:130786720	SNX19	0.38	6.73	0.31	5.47e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg10518543	chr12:38710700	ALG10B	-0.43	-7.05	-0.32	7.16e-12	Morning vs. evening chronotype;
LUAD	cis	rs113835537	0.627	rs11227534	chr11:66336171	C/A	cg24851651	chr11:66362959	CCS	0.59	10.5	0.45	4.67e-23	Airway imaging phenotypes;
LUAD	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg26343298	chr8:95960752	TP53INP1	0.37	7.63	0.35	1.58e-13	Type 2 diabetes;
LUAD	cis	rs7119	0.635	rs907374	chr15:77884026	C/T	cg27398640	chr15:77910606	LINGO1	0.4	7.72	0.35	8.43e-14	Type 2 diabetes;
LUAD	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg07607921	chr17:4047574	ZZEF1;CYB5D2	-0.45	-8.13	-0.37	4.8e-15	Type 2 diabetes;
LUAD	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-15.81	-0.61	1.44e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.55	-0.34	2.7e-13	Total cholesterol levels;
LUAD	cis	rs2985684	0.894	rs2281837	chr14:50065359	C/G	cg04989706	chr14:50066350	PPIL5	-0.51	-7.53	-0.34	3e-13	Carotid intima media thickness;
LUAD	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg08508325	chr11:3079039	CARS	-0.62	-14.23	-0.57	8.24e-38	Longevity;
LUAD	cis	rs6714710	0.603	rs895438	chr2:98382886	G/A	cg26665480	chr2:98280029	ACTR1B	0.55	8.93	0.4	1.32e-17	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	9.09	0.4	3.73e-18	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg05340658	chr4:99064831	C4orf37	0.54	9.11	0.4	3.36e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg03929089	chr4:120376271	NA	-0.55	-8.14	-0.37	4.57e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg25767906	chr1:53392781	SCP2	0.41	7.47	0.34	4.79e-13	Monocyte count;
LUAD	cis	rs7010267	0.935	rs6469788	chr8:119952750	A/C	cg01975934	chr8:119970761	NA	-0.41	-7.92	-0.36	2.17e-14	Total body bone mineral density (age 45-60);
LUAD	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg02743256	chr7:2109353	MAD1L1	-0.47	-6.39	-0.3	4.45e-10	Bipolar disorder;
LUAD	cis	rs757647	0.723	rs2286060	chr5:137677224	C/A	cg10676309	chr5:137685565	NA	0.4	7.19	0.33	3.05e-12	Menarche (age at onset);
LUAD	cis	rs12579753	1.000	rs12821073	chr12:82183260	G/T	cg07988820	chr12:82153109	PPFIA2	-0.45	-7.26	-0.33	1.85e-12	Resting heart rate;
LUAD	cis	rs427941	0.703	rs201455	chr7:101740212	C/T	cg06246474	chr7:101738831	CUX1	0.41	7.34	0.34	1.08e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg08508325	chr11:3079039	CARS	-0.61	-13.86	-0.56	2.77e-36	Longevity;
LUAD	trans	rs6540	1.000	rs6540	chr11:252649	C/T	cg01022370	chr8:8749074	MFHAS1	0.69	7.3	0.33	1.4e-12	Endometriosis;
LUAD	trans	rs208520	0.690	rs207081	chr6:66773742	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-17.61	-0.65	1.84e-52	Exhaled nitric oxide output;
LUAD	cis	rs7737355	0.947	rs7725220	chr5:130877001	C/G	cg06307176	chr5:131281290	NA	0.52	8.15	0.37	4.05e-15	Life satisfaction;
LUAD	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06544989	chr22:39130855	UNC84B	0.39	7.03	0.32	8.59e-12	Menopause (age at onset);
LUAD	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.45	-0.3	3e-10	Crohn's disease;
LUAD	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg03396347	chr1:1875803	NA	-0.59	-15.07	-0.59	2.29e-41	Body mass index;
LUAD	cis	rs12079745	0.793	rs60011235	chr1:169254727	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-1.02	-7.75	-0.35	6.91e-14	QT interval;
LUAD	cis	rs11048434	0.736	rs1805724	chr12:9104609	T/C	cg13575925	chr12:9217583	LOC144571	0.38	7.08	0.33	5.85e-12	Sjögren's syndrome;
LUAD	cis	rs9443645	0.588	rs1415310	chr6:79822314	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.89	-0.32	2.03e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02353165	chr6:42928485	GNMT	0.42	7.41	0.34	6.89e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6542838	0.673	rs1949424	chr2:99468341	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.46	7.53	0.34	3.17e-13	Fear of minor pain;
LUAD	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.29	6.9	0.32	1.88e-11	Prostate cancer;
LUAD	cis	rs9796	0.870	rs11855248	chr15:41276158	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.37	-6.9	-0.32	1.95e-11	Menopause (age at onset);
LUAD	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.17	0.33	3.34e-12	Motion sickness;
LUAD	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.08	0.33	6.04e-12	Rheumatoid arthritis;
LUAD	cis	rs9349203	1	rs9349203	chr6:41893323	G/A	cg17623882	chr6:41773611	USP49	-0.6	-10.79	-0.46	4e-24	Menarche (age at onset);
LUAD	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg24558204	chr6:135376177	HBS1L	0.48	8.86	0.4	2.22e-17	Red blood cell count;
LUAD	cis	rs807669	1.000	rs807669	chr22:19154522	T/C	cg24911827	chr22:19170109	CLTCL1	0.43	8.69	0.39	7.99e-17	Metabolite levels;
LUAD	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg18721089	chr20:30220636	NA	-0.49	-7.06	-0.32	6.99e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg22875332	chr1:76189707	ACADM	0.72	11.1	0.47	2.71e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9948	1.000	rs2276654	chr2:97492479	G/A	cg20312557	chr2:97357134	FER1L5	-0.59	-6.92	-0.32	1.67e-11	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.53	-9.37	-0.41	4.27e-19	Longevity;Endometriosis;
LUAD	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg18105134	chr13:113819100	PROZ	-1.0	-15.7	-0.61	4.47e-44	Platelet distribution width;
LUAD	cis	rs7512552	0.839	rs1260386	chr1:150369622	G/T	cg15654264	chr1:150340011	RPRD2	0.58	11.06	0.47	3.88e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9878978	0.964	rs17786885	chr3:2488667	A/T	cg21928760	chr3:2462534	CNTN4	-0.33	-6.51	-0.3	2.16e-10	Blood pressure (smoking interaction);
LUAD	cis	rs240764	0.853	rs2062635	chr6:101002659	G/A	cg09795085	chr6:101329169	ASCC3	-0.42	-7.03	-0.32	8.47e-12	Neuroticism;
LUAD	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg06221963	chr1:154839813	KCNN3	-0.78	-16.37	-0.62	5.06e-47	Prostate cancer;
LUAD	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg18138036	chr10:133769891	PPP2R2D	0.41	6.65	0.31	8.96e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs13223928	0.511	rs11773338	chr7:3144508	T/C	cg19214707	chr7:3157722	NA	-0.45	-7.81	-0.36	4.41e-14	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUAD	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg19678392	chr7:94953810	PON1	-0.6	-8.36	-0.38	9.24e-16	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9393692	0.620	rs12525187	chr6:26337537	A/G	cg00631329	chr6:26305371	NA	-0.52	-9.1	-0.4	3.49e-18	Educational attainment;
LUAD	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.49	8.74	0.39	5.59e-17	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08964024	chr12:14923326	NA	-0.44	-6.77	-0.31	4.22e-11	Height;
LUAD	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg07636037	chr3:49044803	WDR6	0.58	9.39	0.42	3.63e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg14092988	chr3:52407081	DNAH1	0.41	8.11	0.37	5.65e-15	Electroencephalogram traits;
LUAD	cis	rs12920732	0.509	rs12598730	chr16:84795035	C/T	cg07647771	chr16:84786436	USP10	-0.24	-6.51	-0.3	2.1e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg25894440	chr7:65020034	NA	0.68	7.32	0.34	1.3e-12	Diabetic kidney disease;
LUAD	cis	rs735539	0.521	rs2818991	chr13:21397196	A/G	cg27499820	chr13:21296301	IL17D	0.44	6.71	0.31	6.38e-11	Dental caries;
LUAD	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg11292332	chr7:45801988	SEPT13	-0.28	-6.36	-0.3	5.26e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg02569458	chr12:86230093	RASSF9	0.45	8.1	0.37	5.78e-15	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg17105886	chr17:28927953	LRRC37B2	0.79	7.8	0.35	4.95e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg27170947	chr2:26402098	FAM59B	-0.74	-10.01	-0.44	2.64e-21	Gut microbiome composition (summer);
LUAD	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg07537917	chr2:241836409	C2orf54	-0.3	-8.34	-0.38	1.03e-15	Urinary metabolites;
LUAD	cis	rs28493229	0.708	rs10408310	chr19:41161190	T/C	cg21869046	chr19:41225005	ITPKC	0.51	8.76	0.39	4.75e-17	Kawasaki disease;
LUAD	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg25554036	chr4:6271136	WFS1	0.65	12.73	0.53	1.18e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs4700695	0.640	rs27083	chr5:65435865	C/T	cg21114390	chr5:65439923	SFRS12	-0.93	-14.22	-0.57	8.67e-38	Facial morphology (factor 19);
LUAD	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg24818145	chr4:99064322	C4orf37	0.45	7.08	0.33	6.08e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg05564831	chr3:52568323	NT5DC2	0.36	6.63	0.31	9.96e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg09796270	chr17:17721594	SREBF1	0.38	7.3	0.33	1.47e-12	Total body bone mineral density;
LUAD	cis	rs59104589	0.583	rs12624195	chr2:242254734	G/C	cg08645257	chr2:242211290	HDLBP	0.5	7.87	0.36	3.04e-14	Fibrinogen levels;
LUAD	cis	rs1448094	1.000	rs7305284	chr12:86343786	C/T	cg02569458	chr12:86230093	RASSF9	0.36	6.86	0.32	2.43e-11	Major depressive disorder;
LUAD	trans	rs629535	0.814	rs62513376	chr8:70086881	C/T	cg21567404	chr3:27674614	NA	-0.98	-17.65	-0.65	1.23e-52	Dupuytren's disease;
LUAD	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11644478	chr21:40555479	PSMG1	0.66	10.38	0.45	1.26e-22	Cognitive function;
LUAD	cis	rs4964805	0.657	rs73192049	chr12:104187993	T/C	cg02344784	chr12:104178138	NT5DC3	0.45	9.13	0.41	2.82e-18	Attention deficit hyperactivity disorder;
LUAD	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.32	6.8	0.31	3.68e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs220324	1.000	rs467990	chr21:43582861	G/A	cg08841829	chr21:43638893	ABCG1	0.41	6.55	0.3	1.72e-10	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg00280220	chr17:61926910	NA	0.36	6.98	0.32	1.12e-11	Prudent dietary pattern;
LUAD	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg10792982	chr14:105748885	BRF1	0.46	10.02	0.44	2.49e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08109568	chr15:31115862	NA	0.77	13.16	0.54	2.25e-33	Huntington's disease progression;
LUAD	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg24154853	chr7:158122151	PTPRN2	0.58	11.6	0.49	3.48e-27	Calcium levels;
LUAD	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-9.98	-0.44	3.44e-21	Monocyte percentage of white cells;
LUAD	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.34	-8.61	-0.39	1.46e-16	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.4	-6.92	-0.32	1.71e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg15704280	chr7:45808275	SEPT13	0.72	11.05	0.47	4.14e-25	Coronary artery disease;
LUAD	cis	rs7666738	0.688	rs35739409	chr4:98576934	C/T	cg17366294	chr4:99064904	C4orf37	0.61	9.55	0.42	1.02e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4889855	0.505	rs4890057	chr17:78591679	A/G	cg16591659	chr17:78472290	NA	-0.43	-7.6	-0.35	1.98e-13	Fractional excretion of uric acid;
LUAD	cis	rs28595532	0.925	rs28627331	chr4:119665345	T/C	cg21605333	chr4:119757512	SEC24D	0.83	7.46	0.34	5.06e-13	Cannabis dependence symptom count;
LUAD	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg00852783	chr1:26633632	UBXN11	0.43	7.5	0.34	3.76e-13	Obesity-related traits;
LUAD	cis	rs8099014	1.000	rs4940697	chr18:56108485	G/A	cg12907477	chr18:56117327	MIR122	0.39	6.69	0.31	7.24e-11	Platelet count;
LUAD	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.6	0.35	1.97e-13	Morning vs. evening chronotype;
LUAD	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg11502198	chr6:26597334	ABT1	0.66	11.42	0.49	1.71e-26	Intelligence (multi-trait analysis);
LUAD	trans	rs7395662	1.000	rs7931984	chr11:48580835	T/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.57	-0.3	1.5e-10	HDL cholesterol;
LUAD	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02788857	chr8:22132959	PIWIL2	0.54	9.85	0.43	9.39e-21	Hypertriglyceridemia;
LUAD	cis	rs4280164	0.945	rs1131941	chr14:24760808	C/T	cg22990158	chr14:24802150	ADCY4	0.46	6.62	0.31	1.07e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg15445000	chr17:37608096	MED1	-0.42	-7.87	-0.36	3.05e-14	Glomerular filtration rate (creatinine);
LUAD	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg27170947	chr2:26402098	FAM59B	-0.82	-11.5	-0.49	7.95e-27	Gut microbiome composition (summer);
LUAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg13047869	chr3:10149882	C3orf24	0.66	11.17	0.48	1.4e-25	Alzheimer's disease;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg05557255	chr11:2422385	TSSC4	-0.39	-6.69	-0.31	7.19e-11	Subcortical brain region volumes;
LUAD	cis	rs9463078	0.616	rs2211393	chr6:44716366	A/C	cg25276700	chr6:44698697	NA	0.35	6.64	0.31	9.84e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUAD	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg12940439	chr1:67600707	NA	0.42	8.19	0.37	3.1e-15	Psoriasis;
LUAD	cis	rs6906287	0.573	rs11153732	chr6:118704967	C/T	cg21191810	chr6:118973309	C6orf204	0.48	9.28	0.41	9.03e-19	Electrocardiographic conduction measures;
LUAD	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg05966235	chr16:28915196	ATP2A1	0.51	8.12	0.37	5.11e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg12419862	chr22:24373484	LOC391322	-0.71	-12.57	-0.52	5e-31	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-8.74	-0.39	5.32e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs6546550	0.933	rs1454498	chr2:70149225	C/A	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.97	-0.47	8.24e-25	Prevalent atrial fibrillation;
LUAD	cis	rs2274273	0.840	rs66486619	chr14:55869555	T/G	cg04306507	chr14:55594613	LGALS3	0.41	8.75	0.39	5e-17	Protein biomarker;
LUAD	cis	rs9308433	0.529	rs867444	chr1:214502160	T/C	cg06198575	chr1:214491504	SMYD2	0.44	7.42	0.34	6.67e-13	IgG glycosylation;
LUAD	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg18512352	chr11:47633146	NA	-0.56	-10.07	-0.44	1.59e-21	Subjective well-being;
LUAD	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	10.58	0.46	2.27e-23	Smoking behavior;
LUAD	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.63	0.31	1.03e-10	Prudent dietary pattern;
LUAD	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.57	-9.86	-0.43	8.5e-21	Prudent dietary pattern;
LUAD	trans	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg17145862	chr1:211918768	LPGAT1	-0.75	-17.94	-0.66	6.55e-54	Leprosy;
LUAD	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03452623	chr4:187889614	NA	-0.82	-16.63	-0.63	3.83e-48	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3849570	1.000	rs3860595	chr3:81811784	A/G	cg07356753	chr3:81810745	GBE1	-0.63	-10.76	-0.46	4.81e-24	Waist circumference;Body mass index;
LUAD	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.4	0.3	4.19e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg19469189	chr11:128781035	KCNJ5	-0.43	-6.62	-0.31	1.09e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg04731861	chr2:219085781	ARPC2	-0.25	-7.69	-0.35	1.08e-13	Colorectal cancer;
LUAD	cis	rs12612619	0.732	rs893790	chr2:27201857	T/C	cg00617064	chr2:27272375	NA	0.34	6.54	0.3	1.82e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUAD	cis	rs2239547	0.522	rs2581780	chr3:53058960	C/T	cg18404041	chr3:52824283	ITIH1	0.5	8.15	0.37	4.12e-15	Schizophrenia;
LUAD	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg01689657	chr7:91764605	CYP51A1	0.37	9.06	0.4	5.04e-18	Breast cancer;
LUAD	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg05313129	chr8:58192883	C8orf71	-0.57	-8.39	-0.38	7.53e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg24163568	chr5:669837	TPPP	0.36	6.8	0.31	3.58e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs7487075	0.619	rs67249026	chr12:46835768	T/C	cg23829395	chr12:46796953	NA	0.31	6.94	0.32	1.46e-11	Itch intensity from mosquito bite;
LUAD	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg14668632	chr7:2872130	GNA12	-0.7	-12.87	-0.53	3.25e-32	Height;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg14637221	chr4:17513894	QDPR	-0.7	-6.93	-0.32	1.6e-11	Type 2 diabetes;
LUAD	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg18129178	chr5:148520854	ABLIM3	-0.65	-9.23	-0.41	1.35e-18	Breast cancer;
LUAD	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg16342193	chr10:102329863	NA	-0.39	-6.74	-0.31	5.25e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	7.95	0.36	1.74e-14	Menopause (age at onset);
LUAD	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.72	0.39	6.32e-17	Menopause (age at onset);
LUAD	cis	rs1595825	0.838	rs80172713	chr2:198508044	T/C	cg11031976	chr2:198649780	BOLL	-0.47	-6.94	-0.32	1.49e-11	Ulcerative colitis;
LUAD	cis	rs1267303	0.675	rs2476164	chr1:46985274	T/C	cg16387850	chr1:46982889	NA	0.47	8.05	0.36	8.39e-15	Monobrow;
LUAD	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg17971929	chr21:40555470	PSMG1	0.52	7.99	0.36	1.31e-14	Cognitive function;
LUAD	cis	rs2011503	0.782	rs8113006	chr19:19669441	C/G	cg15839431	chr19:19639596	YJEFN3	0.42	6.51	0.3	2.19e-10	Bipolar disorder;
LUAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg04025307	chr7:1156635	C7orf50	0.64	7.44	0.34	5.74e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg12908607	chr1:44402522	ARTN	-0.41	-7.9	-0.36	2.49e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4481887	0.927	rs4409694	chr1:248485498	C/T	cg13385794	chr1:248469461	NA	0.25	6.93	0.32	1.57e-11	Common traits (Other);
LUAD	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.45	-0.89	7.93e-144	Myeloid white cell count;
LUAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg00450029	chr8:599525	NA	0.83	8.17	0.37	3.67e-15	IgG glycosylation;
LUAD	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg06873352	chr17:61820015	STRADA	0.41	6.76	0.31	4.53e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9788721	0.967	rs55853698	chr15:78857939	T/G	cg18825076	chr15:78729989	IREB2	-0.57	-9.09	-0.4	3.96e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg27411982	chr8:10470053	RP1L1	-0.36	-6.74	-0.31	5.08e-11	Monocyte count;
LUAD	trans	rs225245	0.755	rs6505493	chr17:34028901	A/G	cg19694781	chr19:47549865	TMEM160	-0.47	-7.78	-0.35	5.48e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg13902645	chr11:5959945	NA	-0.57	-9.99	-0.44	2.95e-21	DNA methylation (variation);
LUAD	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg24818145	chr4:99064322	C4orf37	-0.42	-6.69	-0.31	7.29e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.51	-0.34	3.59e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12876261	chr7:56119223	PSPH;CCT6A	-0.59	-7.16	-0.33	3.58e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.87	17.01	0.64	8.13e-50	Lymphocyte counts;
LUAD	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg11062466	chr8:58055876	NA	0.64	8.6	0.39	1.61e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs3125734	0.534	rs10821973	chr10:64052337	G/A	cg19640130	chr10:64028056	RTKN2	-0.36	-7.67	-0.35	1.17e-13	Rheumatoid arthritis;
LUAD	cis	rs11229555	0.874	rs10896788	chr11:58292976	G/A	cg15696309	chr11:58395628	NA	-0.72	-10.25	-0.45	3.64e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00802000	chr16:706648	WDR90	-0.42	-7.8	-0.35	4.86e-14	Height;
LUAD	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg00321850	chr1:175162397	KIAA0040	0.57	12.35	0.51	3.97e-30	Alcohol dependence;
LUAD	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.89	12.53	0.52	7.6e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	8.43	0.38	5.44e-16	Parkinson's disease;
LUAD	trans	rs1728785	1.000	rs1170429	chr16:68604126	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.34	0.45	1.73e-22	Ulcerative colitis;
LUAD	trans	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg14917512	chr19:3094685	GNA11	-0.59	-6.94	-0.32	1.52e-11	Gout;
LUAD	cis	rs698833	0.886	rs2241871	chr2:44548613	T/C	cg04920474	chr2:44395004	PPM1B	0.38	6.69	0.31	7e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg15962314	chr1:44399869	ARTN	0.3	6.87	0.32	2.36e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg08807101	chr21:30365312	RNF160	0.51	8.84	0.39	2.55e-17	Dental caries;
LUAD	cis	rs7771547	0.574	rs11756557	chr6:36597695	A/G	cg02952361	chr6:36355661	ETV7	0.49	6.7	0.31	6.7e-11	Platelet distribution width;
LUAD	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-7.53	-0.34	3.07e-13	Total body bone mineral density;
LUAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg05896524	chr21:47604654	C21orf56	0.72	12.77	0.53	7.83e-32	Testicular germ cell tumor;
LUAD	cis	rs6005807	0.843	rs8137200	chr22:28952352	A/T	cg12565055	chr22:29076175	TTC28	0.67	6.63	0.31	1.01e-10	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg26408565	chr15:76604113	ETFA	-0.47	-7.91	-0.36	2.22e-14	Blood metabolite levels;
LUAD	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg04703951	chr17:43578652	NA	0.59	8.26	0.37	1.85e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg11845111	chr2:191398756	TMEM194B	0.88	11.52	0.49	6.97e-27	Diastolic blood pressure;
LUAD	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg04282206	chr17:62833786	PLEKHM1P	-0.41	-6.89	-0.32	2.09e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.5	-7.74	-0.35	7.59e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg12927641	chr6:109611667	NA	-0.57	-10.06	-0.44	1.75e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg03467027	chr4:99064603	C4orf37	0.39	6.45	0.3	3.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4356932	1.000	rs10003382	chr4:76955473	C/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.56	-0.3	1.62e-10	Blood protein levels;
LUAD	cis	rs4147929	0.553	rs4147936	chr19:1065197	G/C	cg26576206	chr19:1064938	ABCA7	0.47	7.25	0.33	1.97e-12	Alzheimer's disease (late onset);
LUAD	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg27454412	chr7:1067447	C7orf50	0.48	7.7	0.35	9.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg00717180	chr2:96193071	NA	-0.36	-6.47	-0.3	2.66e-10	Coronary artery disease;
LUAD	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg11965913	chr1:205819406	PM20D1	0.81	16.53	0.63	1.05e-47	Menarche (age at onset);
LUAD	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg01528321	chr10:82214614	TSPAN14	0.65	9.92	0.43	5.22e-21	Post bronchodilator FEV1;
LUAD	cis	rs1598856	1.000	rs3774932	chr4:103424193	A/G	cg07973026	chr4:103553119	MANBA	0.4	6.64	0.31	9.61e-11	Primary biliary cholangitis;
LUAD	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg13385794	chr1:248469461	NA	0.27	7.11	0.33	4.86e-12	Common traits (Other);
LUAD	cis	rs4077468	1.000	rs4077469	chr1:205914885	C/T	cg11965913	chr1:205819406	PM20D1	-0.38	-6.77	-0.31	4.2e-11	Cystic fibrosis-related diabetes;
LUAD	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg25767906	chr1:53392781	SCP2	0.45	8.32	0.38	1.21e-15	Monocyte count;
LUAD	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg21984481	chr17:79567631	NPLOC4	-0.55	-11.52	-0.49	6.79e-27	Eye color traits;
LUAD	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.29	0.33	1.55e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg24818145	chr4:99064322	C4orf37	0.39	6.53	0.3	1.89e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06028605	chr16:24865363	SLC5A11	0.56	8.81	0.39	3.24e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg26384229	chr12:38710491	ALG10B	0.47	7.79	0.35	5.4e-14	Bladder cancer;
LUAD	trans	rs9408928	0.778	rs9409230	chr9:123967760	A/T	cg20940459	chr1:173793922	CENPL;DARS2	0.65	6.36	0.3	5.1e-10	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg19761014	chr17:28927070	LRRC37B2	0.82	8.34	0.38	1.09e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg03433033	chr1:76189801	ACADM	-0.49	-7.12	-0.33	4.71e-12	Daytime sleep phenotypes;
LUAD	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg03859395	chr2:55845619	SMEK2	0.47	7.64	0.35	1.46e-13	Metabolic syndrome;
LUAD	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg15017067	chr4:17643749	FAM184B	0.34	6.58	0.3	1.42e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2387326	0.767	rs2015726	chr10:129941839	C/T	cg16087940	chr10:129947807	NA	-0.63	-8.56	-0.38	2.07e-16	Select biomarker traits;
LUAD	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg18761221	chr20:60518478	NA	0.4	7.01	0.32	9.25e-12	Body mass index;
LUAD	cis	rs7428	0.545	rs2366404	chr2:85551779	G/A	cg24342717	chr2:85555507	TGOLN2	-0.47	-7.64	-0.35	1.42e-13	Ear protrusion;
LUAD	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.06	24.59	0.77	1.42e-83	Chronic sinus infection;
LUAD	cis	rs6430585	0.941	rs60963894	chr2:136539670	T/G	cg07169764	chr2:136633963	MCM6	0.63	8.16	0.37	3.82e-15	Corneal structure;
LUAD	cis	rs7572644	0.699	rs10177845	chr2:28124171	G/A	cg27432699	chr2:27873401	GPN1	-0.41	-6.37	-0.3	4.92e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUAD	cis	rs9399401	0.677	rs6925979	chr6:142651052	G/A	cg04461802	chr6:142623433	GPR126	0.46	8.14	0.37	4.5e-15	Chronic obstructive pulmonary disease;
LUAD	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.63	-10.99	-0.47	7.09e-25	Response to fenofibrate (adiponectin levels);
LUAD	cis	rs6906287	0.647	rs7766375	chr6:118918269	G/A	cg21191810	chr6:118973309	C6orf204	0.49	9.44	0.42	2.6e-19	Electrocardiographic conduction measures;
LUAD	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06112835	chr11:68658793	MRPL21	0.52	9.51	0.42	1.46e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11048434	0.687	rs12814670	chr12:9060025	C/T	cg26114124	chr12:9217669	LOC144571	0.37	6.63	0.31	1.04e-10	Sjögren's syndrome;
LUAD	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11890956	chr21:40555474	PSMG1	-0.55	-9.53	-0.42	1.26e-19	Menarche (age at onset);
LUAD	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg06108461	chr20:60628389	TAF4	-0.77	-13.53	-0.55	6.61e-35	Body mass index;
LUAD	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg02782426	chr3:40428986	ENTPD3	-0.36	-7.89	-0.36	2.7e-14	Renal cell carcinoma;
LUAD	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	7.17	0.33	3.48e-12	Schizophrenia;
LUAD	cis	rs208520	0.837	rs208467	chr6:66914837	T/C	cg07460842	chr6:66804631	NA	-0.97	-13.97	-0.56	9.5e-37	Exhaled nitric oxide output;
LUAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg17372223	chr3:52568218	NT5DC2	0.45	8.64	0.39	1.17e-16	Electroencephalogram traits;
LUAD	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg11707310	chr1:2537719	MMEL1	0.36	7.71	0.35	9.2e-14	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.57	-6.54	-0.3	1.73e-10	Lung cancer in ever smokers;
LUAD	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg25036284	chr2:26402008	FAM59B	-0.83	-11.68	-0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.93	-0.4	1.3e-17	Gut microbiome composition (summer);
LUAD	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg06532163	chr17:45867833	NA	0.47	8.54	0.38	2.39e-16	IgG glycosylation;
LUAD	cis	rs7301016	0.948	rs11174498	chr12:62865345	T/C	cg11441379	chr12:63026424	NA	0.54	6.9	0.32	1.96e-11	IgG glycosylation;
LUAD	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg07395648	chr5:131743802	NA	-0.37	-6.36	-0.3	5.18e-10	Acylcarnitine levels;
LUAD	cis	rs9902453	0.967	rs61014003	chr17:28485233	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	8.36	0.38	9.4e-16	Coffee consumption (cups per day);
LUAD	cis	rs6758955	1.000	rs7581642	chr2:10477418	C/T	cg15773312	chr2:10472214	HPCAL1	-0.43	-6.86	-0.32	2.45e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg07936489	chr17:37558343	FBXL20	-0.5	-6.55	-0.3	1.68e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg18827107	chr12:86230957	RASSF9	0.54	9.63	0.42	5.64e-20	Major depressive disorder;
LUAD	cis	rs10744422	1.000	rs936083	chr12:123338964	A/G	cg16953816	chr12:123349952	VPS37B	0.59	6.54	0.3	1.75e-10	Schizophrenia;
LUAD	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg07677032	chr17:61819896	STRADA	0.57	10.34	0.45	1.77e-22	Prudent dietary pattern;
LUAD	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-0.59	-8.68	-0.39	8.72e-17	Platelet count;
LUAD	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg22823121	chr1:150693482	HORMAD1	0.44	8.8	0.39	3.54e-17	Tonsillectomy;
LUAD	cis	rs12478296	0.591	rs12468297	chr2:242996474	A/G	cg06360820	chr2:242988706	NA	-0.61	-9.05	-0.4	5.41e-18	Obesity-related traits;
LUAD	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg12483005	chr1:23474871	LUZP1	0.52	9.0	0.4	7.99e-18	Height;
LUAD	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg10589385	chr1:150898437	SETDB1	-0.38	-6.62	-0.31	1.09e-10	Blood protein levels;
LUAD	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	9.2	0.41	1.6e-18	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg24818145	chr4:99064322	C4orf37	0.47	8.0	0.36	1.24e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	0.576	rs246062	chr5:140324580	T/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4638749	0.677	rs2219081	chr2:108844350	T/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.43	-0.34	6.13e-13	Blood pressure;
LUAD	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg16342193	chr10:102329863	NA	-0.36	-6.37	-0.3	4.84e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs8077889	0.917	rs8081646	chr17:41893360	T/C	cg26893861	chr17:41843967	DUSP3	0.9	14.47	0.58	7.77e-39	Triglycerides;
LUAD	trans	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg27600084	chr12:12264075	NA	0.41	7.62	0.35	1.65e-13	Breast size;
LUAD	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg01579765	chr21:45077557	HSF2BP	-0.66	-15.14	-0.59	1.15e-41	Mean corpuscular volume;
LUAD	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg17178900	chr1:205818956	PM20D1	-0.45	-6.97	-0.32	1.19e-11	Menarche (age at onset);
LUAD	cis	rs4285028	0.580	rs12496036	chr3:121640362	G/A	cg20356878	chr3:121714668	ILDR1	-0.56	-8.59	-0.39	1.75e-16	Multiple sclerosis;
LUAD	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-20.46	-0.71	3.39e-65	Height;
LUAD	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg15181151	chr6:150070149	PCMT1	0.42	8.63	0.39	1.27e-16	Lung cancer;
LUAD	trans	rs8073060	0.544	rs225252	chr17:33952401	G/A	cg19694781	chr19:47549865	TMEM160	-1.24	-19.46	-0.69	1.1e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	trans	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	6.07e-11	Depression;
LUAD	trans	rs6561151	0.681	rs2325088	chr13:44424063	T/C	cg12856521	chr11:46389249	DGKZ	0.84	11.5	0.49	7.93e-27	Crohn's disease;
LUAD	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg16006841	chr5:176797999	RGS14	0.55	9.79	0.43	1.58e-20	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg22482690	chr17:47019901	SNF8	0.45	8.51	0.38	3.15e-16	Type 2 diabetes;
LUAD	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg02527881	chr3:46936655	PTH1R	-0.57	-12.05	-0.51	5.97e-29	Colorectal cancer;
LUAD	cis	rs2297440	0.527	rs4809318	chr20:62264760	G/A	cg09650180	chr20:62225654	GMEB2	-0.46	-6.43	-0.3	3.45e-10	Glioma;Non-glioblastoma glioma;Glioblastoma;
LUAD	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.49	-0.42	1.69e-19	Life satisfaction;
LUAD	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg26587870	chr6:27730563	NA	-0.44	-7.16	-0.33	3.71e-12	Parkinson's disease;
LUAD	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs36051895	0.632	rs10974980	chr9:5140671	C/G	cg02405213	chr9:5042618	JAK2	-0.49	-6.56	-0.3	1.56e-10	Pediatric autoimmune diseases;
LUAD	cis	rs9517320	1.000	rs12864890	chr13:99126457	T/C	cg07423050	chr13:99094983	FARP1	0.36	6.36	0.3	5.2400000000000005e-10	Longevity;
LUAD	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg21709803	chr11:61594965	FADS2	-0.39	-7.37	-0.34	8.84e-13	Trans fatty acid levels;
LUAD	trans	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17712092	chr4:129076599	LARP1B	0.8	14.94	0.59	7.51e-41	Eosinophil percentage of white cells;
LUAD	cis	rs375066	0.592	rs349050	chr19:44301425	G/A	cg12072164	chr19:44306565	LYPD5	-0.39	-7.96	-0.36	1.56e-14	Breast cancer;
LUAD	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg21153622	chr11:89784906	NA	-0.33	-6.41	-0.3	3.94e-10	Coronary artery disease;
LUAD	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg16405210	chr4:1374714	KIAA1530	0.49	7.88	0.36	2.87e-14	Obesity-related traits;
LUAD	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.76	-0.31	4.56e-11	Breast cancer;
LUAD	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.15	0.33	3.88e-12	Motion sickness;
LUAD	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg16325326	chr1:53192061	ZYG11B	0.66	11.86	0.5	3.24e-28	Monocyte count;
LUAD	cis	rs10203711	0.933	rs907110	chr2:239566391	C/T	cg14580085	chr2:239553406	NA	0.41	8.79	0.39	3.82e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg13057898	chr1:3703894	LRRC47	-0.63	-10.81	-0.47	3.31e-24	Red cell distribution width;
LUAD	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg26384229	chr12:38710491	ALG10B	0.51	8.32	0.38	1.18e-15	Heart rate;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg12463110	chr4:54930242	CHIC2	-0.43	-6.85	-0.32	2.6e-11	Height;
LUAD	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg06217071	chr17:408420	NA	0.49	11.69	0.49	1.48e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	13.06	0.54	5.6e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.53	0.46	3.43e-23	Colorectal cancer;
LUAD	cis	rs4900538	0.855	rs9788420	chr14:102839338	A/G	cg18135206	chr14:102964638	TECPR2	-1.02	-20.98	-0.71	1.73e-67	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs367943	0.712	rs10035686	chr5:112683357	C/T	cg12552261	chr5:112820674	MCC	0.46	8.92	0.4	1.38e-17	Type 2 diabetes;
LUAD	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg03388025	chr16:89894329	SPIRE2	0.49	12.84	0.53	4.21e-32	Vitiligo;
LUAD	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17509989	chr5:176798049	RGS14	-0.85	-15.36	-0.6	1.23e-42	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs7927592	0.513	rs607887	chr11:68196961	C/T	cg02221422	chr11:68192511	LRP5	-0.43	-7.04	-0.32	7.81e-12	Total body bone mineral density;
LUAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg24829409	chr8:58192753	C8orf71	-0.5	-6.48	-0.3	2.51e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg00999904	chr2:3704751	ALLC	-0.53	-8.98	-0.4	9.25e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg14095983	chr9:71737204	TJP2	-0.52	-6.37	-0.3	5.09e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg04995722	chr7:26192034	NFE2L3	-0.44	-7.62	-0.35	1.68e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg16103275	chr6:290800	DUSP22	0.35	6.46	0.3	2.94e-10	Menopause (age at onset);
LUAD	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg04287289	chr16:89883240	FANCA	0.71	12.95	0.53	1.49e-32	Vitiligo;
LUAD	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg26408565	chr15:76604113	ETFA	-0.48	-7.96	-0.36	1.64e-14	Blood metabolite levels;
LUAD	cis	rs7851660	0.967	rs12348691	chr9:100608682	G/A	cg13688889	chr9:100608707	NA	-0.52	-9.56	-0.42	9.93e-20	Strep throat;
LUAD	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg00383909	chr3:49044727	WDR6	0.45	6.9	0.32	1.91e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2651899	0.902	rs1624023	chr1:3079337	C/T	cg22674798	chr1:3096360	PRDM16	0.39	10.0	0.44	2.84e-21	Migraine;
LUAD	cis	rs6494488	0.500	rs72744766	chr15:65079091	T/C	cg08069370	chr15:64387884	SNX1	-0.74	-6.64	-0.31	9.68e-11	Coronary artery disease;
LUAD	trans	rs7786808	0.508	rs896765	chr7:158182809	G/A	cg02030672	chr11:45687055	CHST1	-0.37	-6.53	-0.3	1.92e-10	Obesity-related traits;
LUAD	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00149659	chr3:10157352	C3orf10	0.86	11.57	0.49	4.56e-27	Alzheimer's disease;
LUAD	cis	rs1006703	0.544	rs10153291	chr17:3833740	G/A	cg09591406	chr17:3833873	ATP2A3	-0.57	-7.15	-0.33	3.75e-12	Glucose homeostasis traits;
LUAD	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg12599982	chr1:44399894	ARTN	0.35	6.73	0.31	5.4e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg13385794	chr1:248469461	NA	0.26	6.88	0.32	2.12e-11	Common traits (Other);
LUAD	cis	rs910187	0.678	rs3818012	chr20:45816594	G/A	cg27589058	chr20:45804311	EYA2	-0.3	-6.91	-0.32	1.8e-11	Migraine;
LUAD	trans	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg25482853	chr8:67687455	SGK3	0.97	15.15	0.59	9.7e-42	Obesity-related traits;
LUAD	cis	rs7903847	0.642	rs6584128	chr10:99171926	G/T	cg20016023	chr10:99160130	RRP12	0.26	6.42	0.3	3.76e-10	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs427394	0.582	rs274667	chr5:6710771	A/G	cg10857441	chr5:6722123	POLS	0.59	10.61	0.46	1.84e-23	Menopause (age at onset);
LUAD	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg04673462	chr1:38461896	NA	0.41	8.07	0.37	7.18e-15	Coronary artery disease;
LUAD	cis	rs910873	0.505	rs67260051	chr20:33448417	C/T	cg16810054	chr20:33298113	TP53INP2	0.52	8.09	0.37	6.45e-15	Melanoma;
LUAD	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg23803603	chr1:2058230	PRKCZ	0.39	7.12	0.33	4.6e-12	Height;
LUAD	cis	rs11811982	0.793	rs77311509	chr1:227459097	A/C	cg24860534	chr1:227506868	CDC42BPA	0.7	7.34	0.34	1.13e-12	Optic disc area;
LUAD	cis	rs11723261	0.582	rs7679573	chr4:151605	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.41	7.29	0.33	1.49e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg11766577	chr21:47581405	C21orf56	-0.56	-9.57	-0.42	9.05e-20	Testicular germ cell tumor;
LUAD	cis	rs9652601	0.649	rs7403919	chr16:11085968	C/T	cg04616529	chr16:11181986	CLEC16A	-0.38	-6.78	-0.31	3.94e-11	Systemic lupus erythematosus;
LUAD	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg04369109	chr6:150039330	LATS1	-0.49	-8.03	-0.36	1e-14	Lung cancer;
LUAD	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06544989	chr22:39130855	UNC84B	-0.35	-6.73	-0.31	5.56e-11	Menopause (age at onset);
LUAD	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.44	-6.96	-0.32	1.28e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg12935359	chr14:103987150	CKB	-0.45	-7.65	-0.35	1.32e-13	Body mass index;
LUAD	cis	rs12208915	0.559	rs4706738	chr6:79514153	A/G	cg11833968	chr6:79620685	NA	0.39	6.84	0.32	2.83e-11	Left atrial antero-posterior diameter;
LUAD	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg05043794	chr9:111880884	C9orf5	-0.44	-7.61	-0.35	1.76e-13	Menarche (age at onset);
LUAD	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg08085267	chr17:45401833	C17orf57	0.65	10.94	0.47	1.05e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs877282	0.891	rs11599917	chr10:762288	G/A	cg06581033	chr10:766294	NA	-0.59	-8.05	-0.36	8.48e-15	Uric acid levels;
LUAD	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg03433033	chr1:76189801	ACADM	-0.69	-10.78	-0.46	4.25e-24	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs4942242	0.663	rs9525816	chr13:44223898	A/G	cg19169023	chr15:41853346	TYRO3	-0.68	-11.49	-0.49	8.99e-27	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05890377	chr2:74357713	NA	0.81	12.74	0.53	1.09e-31	Gestational age at birth (maternal effect);
LUAD	cis	rs7274811	0.711	rs657040	chr20:32001292	A/G	cg13403462	chr20:32256071	NECAB3;C20orf134	0.43	6.46	0.3	2.81e-10	Height;
LUAD	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg00255919	chr5:131827918	IRF1	0.47	9.55	0.42	1.09e-19	Asthma (sex interaction);
LUAD	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.09	-0.57	2.99e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs6005807	0.719	rs9625512	chr22:29020756	G/C	cg12565055	chr22:29076175	TTC28	0.75	8.76	0.39	4.71e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs367943	0.698	rs2115208	chr5:112973994	A/G	cg12552261	chr5:112820674	MCC	0.47	8.41	0.38	6.39e-16	Type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03628274	chr19:18420511	LSM4	0.55	7.06	0.32	6.7e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.87	-0.43	7.82e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07167872	chr1:205819463	PM20D1	-0.68	-13.31	-0.54	5.21e-34	Monocyte percentage of white cells;
LUAD	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg00934597	chr7:893267	UNC84A	-0.51	-8.3	-0.37	1.45e-15	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg11993925	chr19:44307056	LYPD5	0.54	11.25	0.48	7.31e-26	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg06641503	chr3:48959341	ARIH2	-0.36	-6.95	-0.32	1.43e-11	Parkinson's disease;
LUAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg13397359	chr6:42928475	GNMT	0.67	13.11	0.54	3.47e-33	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2249625	0.844	rs1830339	chr6:72877600	G/A	cg18830697	chr6:72922368	RIMS1	-0.36	-6.8	-0.31	3.64e-11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs3806843	0.576	rs246029	chr5:140333226	G/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg16342193	chr10:102329863	NA	-0.39	-6.76	-0.31	4.72e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1232027	0.700	rs1643662	chr5:79933235	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg20503657	chr10:835505	NA	0.65	9.21	0.41	1.47e-18	Eosinophil percentage of granulocytes;
LUAD	cis	rs735539	0.521	rs1966190	chr13:21409137	A/C	cg27499820	chr13:21296301	IL17D	0.44	7.22	0.33	2.37e-12	Dental caries;
LUAD	cis	rs738321	0.757	rs2235345	chr22:38518177	C/T	cg17652424	chr22:38574118	PLA2G6	-0.24	-6.35	-0.3	5.56e-10	Breast cancer;
LUAD	cis	rs13064411	0.735	rs9875025	chr3:113147552	T/C	cg10517650	chr3:113235015	CCDC52	-0.48	-8.11	-0.37	5.34e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg08219700	chr8:58056026	NA	0.55	7.9	0.36	2.44e-14	Developmental language disorder (linguistic errors);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05210131	chr2:182757482	SSFA2	-0.53	-6.5	-0.3	2.3e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2882667	0.824	rs11748097	chr5:138479887	C/A	cg04439458	chr5:138467593	SIL1	-0.55	-9.95	-0.44	4.12e-21	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg21709803	chr11:61594965	FADS2	-0.4	-6.51	-0.3	2.15e-10	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg04398451	chr17:18023971	MYO15A	-0.63	-11.37	-0.48	2.53e-26	Total body bone mineral density;
LUAD	cis	rs8060686	0.925	rs1134760	chr16:67964203	T/C	cg26727032	chr16:67993705	SLC12A4	-0.49	-7.71	-0.35	8.87e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg27632911	chr20:34205182	SPAG4	0.38	6.48	0.3	2.48e-10	Total cholesterol levels;
LUAD	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg14828511	chr1:107599125	PRMT6	-0.57	-10.16	-0.44	7.75e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg03806693	chr22:41940476	POLR3H	0.71	10.25	0.45	3.48e-22	Vitiligo;
LUAD	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg22920501	chr2:26401640	FAM59B	0.78	10.21	0.44	5.06e-22	Gut microbiome composition (summer);
LUAD	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg18105134	chr13:113819100	PROZ	-0.87	-15.4	-0.6	8.76e-43	Platelet distribution width;
LUAD	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg16797656	chr11:68205561	LRP5	0.45	8.37	0.38	8.24e-16	Total body bone mineral density (age 0-15);
LUAD	cis	rs977987	0.836	rs4888376	chr16:75322573	T/C	cg03315344	chr16:75512273	CHST6	0.64	13.72	0.56	1.03e-35	Dupuytren's disease;
LUAD	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	7.69	0.35	1.05e-13	Breast cancer;
LUAD	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg26384229	chr12:38710491	ALG10B	0.48	7.88	0.36	2.86e-14	Bladder cancer;
LUAD	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg23985595	chr17:80112537	CCDC57	-0.53	-9.92	-0.43	5.5e-21	Life satisfaction;
LUAD	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg06713675	chr4:122721982	EXOSC9	-0.72	-15.04	-0.59	3.08e-41	Type 2 diabetes;
LUAD	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg22105103	chr4:187893119	NA	0.58	12.58	0.52	4.91e-31	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs2018683	0.933	rs12536127	chr7:28985967	T/C	cg19402173	chr7:128379420	CALU	-0.59	-9.72	-0.43	2.69e-20	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3956705	1.000	rs35500246	chr7:32971773	C/T	cg05721444	chr7:32995514	FKBP9	-0.37	-6.45	-0.3	3.06e-10	Red cell distribution width;
LUAD	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg06221963	chr1:154839813	KCNN3	-0.83	-19.19	-0.68	1.69e-59	Prostate cancer;
LUAD	cis	rs2625529	0.689	rs4526973	chr15:72138719	A/G	cg16672083	chr15:72433130	SENP8	-0.62	-11.56	-0.49	4.59e-27	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg03676636	chr4:99064102	C4orf37	-0.31	-8.2	-0.37	2.89e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.42	6.69	0.31	7.05e-11	Alzheimer's disease (late onset);
LUAD	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg07917127	chr4:99064746	C4orf37	0.4	6.55	0.3	1.68e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2455601	0.638	rs2742478	chr11:8996099	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-8.25	-0.37	2e-15	Schizophrenia;
LUAD	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03264133	chr6:25882463	NA	-0.56	-8.99	-0.4	8.07e-18	Blood metabolite levels;
LUAD	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2839627	0.561	rs9808758	chr21:44262390	G/C	cg03543861	chr21:44258195	NA	0.65	9.53	0.42	1.27e-19	Information processing speed;
LUAD	cis	rs1483890	0.723	rs13061189	chr3:69411453	T/C	cg22125112	chr3:69402811	FRMD4B	0.45	7.66	0.35	1.31e-13	Resting heart rate;
LUAD	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg06627628	chr2:24431161	ITSN2	-0.57	-6.67	-0.31	7.81e-11	Lymphocyte counts;
LUAD	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.25	0.41	1.08e-18	Alzheimer's disease;
LUAD	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.49	-8.03	-0.36	9.42e-15	Body mass index;
LUAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.8	-0.31	3.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg03433033	chr1:76189801	ACADM	0.91	18.17	0.66	5.71e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg07570687	chr10:102243282	WNT8B	0.45	7.04	0.32	7.59e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg19761014	chr17:28927070	LRRC37B2	0.82	8.32	0.37	1.23e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs990171	0.538	rs7593935	chr2:103118128	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	6.55	0.3	1.71e-10	Lymphocyte counts;
LUAD	cis	rs7827545	1.000	rs6992097	chr8:135565844	G/A	cg17885191	chr8:135476712	NA	0.49	7.76	0.35	6.51e-14	Hypertension (SNP x SNP interaction);
LUAD	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg00280220	chr17:61926910	NA	-0.36	-6.99	-0.32	1.08e-11	Prudent dietary pattern;
LUAD	cis	rs11098699	0.784	rs2132076	chr4:124243460	G/A	cg09941581	chr4:124220074	SPATA5	0.42	6.73	0.31	5.42e-11	Mosquito bite size;
LUAD	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg26597838	chr10:835615	NA	1.02	16.0	0.61	2.17e-45	Eosinophil percentage of granulocytes;
LUAD	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.41	-7.34	-0.34	1.12e-12	Tonsillectomy;
LUAD	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg08439880	chr3:133502540	NA	-0.36	-6.78	-0.31	4.03e-11	Iron status biomarkers;
LUAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.53	-9.87	-0.43	8.17e-21	Longevity;Endometriosis;
LUAD	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24308560	chr3:49941425	MST1R	0.56	9.36	0.41	4.66e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg11317459	chr13:21872234	NA	-1.1	-14.5	-0.58	5.87e-39	White matter hyperintensity burden;
LUAD	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg05044414	chr3:183734942	ABCC5	0.38	7.71	0.35	9.12e-14	Anterior chamber depth;
LUAD	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg09537434	chr19:41945824	ATP5SL	-0.42	-6.75	-0.31	4.74e-11	Height;
LUAD	cis	rs62238980	0.614	rs41430344	chr22:32381973	C/T	cg00543991	chr22:32367038	NA	0.93	8.76	0.39	4.91e-17	Childhood ear infection;
LUAD	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg16325326	chr1:53192061	ZYG11B	0.61	11.08	0.47	3.11e-25	Monocyte count;
LUAD	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg07741184	chr6:167504864	NA	0.3	7.24	0.33	2.14e-12	Crohn's disease;
LUAD	cis	rs62400317	0.731	rs12214435	chr6:44906717	G/A	cg18551225	chr6:44695536	NA	-0.59	-8.83	-0.39	2.89e-17	Total body bone mineral density;
LUAD	cis	rs7216064	1.000	rs12600941	chr17:65918807	A/G	cg08758996	chr17:66097529	LOC651250	0.48	7.37	0.34	8.89e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg19318889	chr4:1322082	MAEA	0.46	7.45	0.34	5.27e-13	Obesity-related traits;
LUAD	cis	rs9473147	0.543	rs1872505	chr6:47480975	C/G	cg20196966	chr6:47445060	CD2AP	0.45	7.08	0.33	6.11e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg23939001	chr4:940644	TMEM175	0.68	11.17	0.48	1.48e-25	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs698833	0.892	rs1067322	chr2:44630107	C/T	cg04920474	chr2:44395004	PPM1B	0.36	6.47	0.3	2.77e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs1215050	0.791	rs13107606	chr4:98823187	C/A	cg17366294	chr4:99064904	C4orf37	0.5	8.83	0.39	2.76e-17	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	8.5	0.38	3.26e-16	Rheumatoid arthritis;
LUAD	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg23281280	chr6:28129359	ZNF389	0.46	6.5	0.3	2.3e-10	Depression;
LUAD	trans	rs783540	0.843	rs28374463	chr15:83299364	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.55	-0.3	1.64e-10	Schizophrenia;
LUAD	trans	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg21659725	chr3:3221576	CRBN	-0.6	-9.65	-0.42	4.96e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg11266682	chr4:10021025	SLC2A9	0.65	14.81	0.58	2.85e-40	Bone mineral density;
LUAD	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg24596788	chr1:163392923	NA	0.33	7.04	0.32	7.92e-12	Motion sickness;
LUAD	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06022373	chr22:39101656	GTPBP1	0.44	7.01	0.32	9.46e-12	Menopause (age at onset);
LUAD	cis	rs11971779	0.715	rs7779390	chr7:139112953	C/T	cg23387468	chr7:139079360	LUC7L2	0.29	6.85	0.32	2.66e-11	Diisocyanate-induced asthma;
LUAD	cis	rs28374715	0.662	rs13329579	chr15:41467435	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.89	-16.72	-0.63	1.55e-48	Ulcerative colitis;
LUAD	cis	rs8060686	0.641	rs7204192	chr16:68039309	A/G	cg09835421	chr16:68378352	PRMT7	-0.66	-7.71	-0.35	9.38e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg21823605	chr1:152486609	CRCT1	0.28	6.42	0.3	3.66e-10	Hair morphology;
LUAD	trans	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.57	9.69	0.43	3.39e-20	Brugada syndrome;
LUAD	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg23649088	chr2:200775458	C2orf69	0.62	8.31	0.37	1.32e-15	Schizophrenia;
LUAD	cis	rs62400317	0.859	rs10948220	chr6:45236654	A/G	cg18551225	chr6:44695536	NA	-0.56	-8.7	-0.39	7.44e-17	Total body bone mineral density;
LUAD	trans	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg21659725	chr3:3221576	CRBN	-0.52	-6.87	-0.32	2.37e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg12573674	chr2:1569213	NA	-0.6	-6.43	-0.3	3.48e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs11168351	0.889	rs12817104	chr12:48382573	G/C	cg04545296	chr12:48745243	ZNF641	0.31	7.66	0.35	1.24e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg12179176	chr11:130786555	SNX19	0.52	8.9	0.4	1.63e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg21545522	chr1:205238299	TMCC2	0.38	6.94	0.32	1.51e-11	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg13271783	chr10:134563150	INPP5A	-0.41	-7.15	-0.33	3.81e-12	Migraine;
LUAD	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg11822812	chr5:140052017	DND1	-0.42	-7.5	-0.34	3.88e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg26677194	chr12:130822605	PIWIL1	0.55	9.02	0.4	6.46e-18	Menopause (age at onset);
LUAD	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	11.59	0.49	3.62e-27	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg02733842	chr7:1102375	C7orf50	-0.69	-10.12	-0.44	1.1e-21	Bronchopulmonary dysplasia;
LUAD	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg06784218	chr1:46089804	CCDC17	0.54	11.7	0.49	1.37e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg06808227	chr14:105710500	BRF1	-0.42	-6.51	-0.3	2.09e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs939658	0.776	rs35382567	chr15:79440897	C/T	cg17916960	chr15:79447300	NA	-0.53	-11.26	-0.48	6.91e-26	Refractive error;
LUAD	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23221052	chr5:179740743	GFPT2	-0.66	-10.74	-0.46	6.02e-24	Height;
LUAD	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg01788221	chr16:89496183	ANKRD11	-0.33	-6.44	-0.3	3.33e-10	Multiple myeloma (IgH translocation);
LUAD	trans	rs1406428	0.573	rs12613632	chr2:51705755	C/G	cg04853151	chr1:54519244	C1orf83;TMEM59	0.44	6.38	0.3	4.55e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2455799	0.865	rs9865333	chr3:15704344	C/A	cg16303742	chr3:15540471	COLQ	-0.38	-6.4	-0.3	4.16e-10	Mean platelet volume;
LUAD	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg03396347	chr1:1875803	NA	-0.61	-15.75	-0.61	2.58e-44	Body mass index;
LUAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg23131131	chr22:24373011	LOC391322	0.57	9.34	0.41	5.7e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs55780018	0.645	rs12998817	chr2:208500945	A/G	cg16529440	chr12:93323219	EEA1	0.39	6.52	0.3	2.05e-10	Systolic blood pressure;
LUAD	cis	rs13315871	0.929	rs17059171	chr3:58302586	A/G	cg12435725	chr3:58293450	RPP14	-0.75	-8.52	-0.38	2.81e-16	Cholesterol, total;
LUAD	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg17177755	chr1:15930204	NA	0.44	7.22	0.33	2.46e-12	Systolic blood pressure;
LUAD	cis	rs3784262	1.000	rs11071356	chr15:58240518	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.47	-9.48	-0.42	1.78e-19	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs1371614	0.523	rs7585127	chr2:27179371	A/G	cg00617064	chr2:27272375	NA	-0.38	-7.41	-0.34	7e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg18402987	chr7:1209562	NA	0.79	9.74	0.43	2.33e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg27284194	chr4:1044797	NA	0.71	10.22	0.44	4.71e-22	Recombination rate (females);
LUAD	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg09365446	chr1:150670422	GOLPH3L	0.61	10.88	0.47	1.75e-24	Melanoma;
LUAD	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	8.05	0.36	8.72e-15	Rheumatoid arthritis;
LUAD	cis	rs9902453	0.740	rs2729446	chr17:28102499	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.61	-0.46	1.8e-23	Coffee consumption (cups per day);
LUAD	trans	rs1406428	0.573	rs12613632	chr2:51705755	C/G	cg07098151	chr1:229762071	URB2;TAF5L	0.45	6.51	0.3	2.09e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs1178968	0.688	rs6951676	chr7:72753243	C/T	cg15428835	chr7:75027521	TRIM73;TRIM74	0.5	6.38	0.3	4.77e-10	Triglyceride levels;
LUAD	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13126279	chr21:47581558	C21orf56	-0.51	-8.88	-0.4	1.88e-17	Testicular germ cell tumor;
LUAD	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg27539214	chr16:67997921	SLC12A4	-0.68	-8.43	-0.38	5.39e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg08999081	chr20:33150536	PIGU	0.47	8.97	0.4	9.76e-18	Coronary artery disease;
LUAD	cis	rs7010267	0.596	rs1905778	chr8:120021848	A/C	cg01975934	chr8:119970761	NA	-0.34	-6.57	-0.3	1.45e-10	Total body bone mineral density (age 45-60);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05622441	chr16:69419962	TERF2	-0.55	-6.66	-0.31	8.73e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg25233709	chr10:116636983	FAM160B1	0.43	8.44	0.38	5.04e-16	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg18721089	chr20:30220636	NA	-0.46	-6.51	-0.3	2.07e-10	Mean corpuscular hemoglobin;
LUAD	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg06627628	chr2:24431161	ITSN2	-0.55	-6.54	-0.3	1.83e-10	Lymphocyte counts;
LUAD	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.75	-15.71	-0.61	3.87e-44	Lung cancer;
LUAD	cis	rs7714584	1.000	rs59531858	chr5:150247063	T/G	cg22134413	chr5:150180641	NA	0.62	6.71	0.31	6.45e-11	Crohn's disease;
LUAD	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg16989719	chr2:238392110	NA	-0.33	-7.19	-0.33	2.92e-12	Prostate cancer;
LUAD	cis	rs751728	0.897	rs3806110	chr6:33770629	G/A	cg13859433	chr6:33739653	LEMD2	-0.41	-9.36	-0.41	4.71e-19	Crohn's disease;
LUAD	cis	rs526821	0.595	rs504661	chr11:55312683	A/G	cg04317927	chr11:55418816	OR4S2	0.38	7.2	0.33	2.78e-12	Pediatric bone mineral density (spine);
LUAD	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg09323728	chr8:95962352	TP53INP1	-0.31	-7.49	-0.34	4.01e-13	Type 2 diabetes;
LUAD	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg20283391	chr11:68216788	NA	-0.4	-6.35	-0.3	5.54e-10	Total body bone mineral density;
LUAD	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg17063962	chr7:91808500	NA	0.69	12.21	0.51	1.43e-29	Breast cancer;
LUAD	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg02887458	chr19:19495540	GATAD2A	-0.38	-6.36	-0.3	5.33e-10	Bipolar disorder;
LUAD	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg00310523	chr12:86230176	RASSF9	0.36	7.36	0.34	9.42e-13	Major depressive disorder;
LUAD	cis	rs3772130	0.962	rs28660600	chr3:121482637	G/A	cg20356878	chr3:121714668	ILDR1	0.52	8.17	0.37	3.58e-15	Cognitive performance;
LUAD	cis	rs12543725	0.799	rs13252660	chr8:142239381	C/T	cg23750338	chr8:142222470	SLC45A4	-0.52	-10.55	-0.46	3.06e-23	Birth weight;
LUAD	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg05234568	chr11:5960015	NA	-0.58	-11.04	-0.47	4.47e-25	DNA methylation (variation);
LUAD	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg15445000	chr17:37608096	MED1	0.44	7.94	0.36	1.79e-14	Glomerular filtration rate (creatinine);
LUAD	trans	rs853679	1.000	rs853685	chr6:28288785	C/T	cg06606381	chr12:133084897	FBRSL1	-0.6	-7.46	-0.34	5.01e-13	Depression;
LUAD	cis	rs4481887	0.741	rs28589987	chr1:248564785	T/C	cg00666640	chr1:248458726	OR2T12	0.28	6.57	0.3	1.45e-10	Common traits (Other);
LUAD	cis	rs494562	0.892	rs9353310	chr6:86126199	C/T	cg13315970	chr6:86159197	NT5E	0.71	7.91	0.36	2.24e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7542375	0.655	rs1889795	chr1:221063101	G/A	cg16008148	chr1:221062819	NA	0.42	6.5	0.3	2.31e-10	Obesity-related traits;
LUAD	cis	rs11771526	1.000	rs117890465	chr7:32351009	A/C	cg13207630	chr7:32358064	NA	0.6	7.06	0.32	6.7e-12	Body mass index;
LUAD	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4280164	0.551	rs1109152	chr14:24799024	G/C	cg22990158	chr14:24802150	ADCY4	0.58	8.78	0.39	4.16e-17	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	9.78	0.43	1.67e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg14820908	chr5:178986412	RUFY1	0.68	11.57	0.49	4.55e-27	Lung cancer;
LUAD	cis	rs7301016	1.000	rs11613132	chr12:62856444	A/C	cg11441379	chr12:63026424	NA	0.56	7.06	0.32	6.96e-12	IgG glycosylation;
LUAD	cis	rs6460942	0.915	rs2216050	chr7:12304073	T/C	cg06484146	chr7:12443880	VWDE	-0.48	-7.33	-0.34	1.2e-12	Coronary artery disease;
LUAD	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg17063962	chr7:91808500	NA	-0.7	-12.56	-0.52	5.63e-31	Breast cancer;
LUAD	cis	rs10089	0.552	rs59430737	chr5:127557568	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.46	6.37	0.3	5.01e-10	Ileal carcinoids;
LUAD	cis	rs2235649	0.833	rs9925460	chr16:1849943	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-7.53	-0.34	3.15e-13	Blood metabolite levels;
LUAD	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg02038168	chr22:39784481	NA	-0.59	-10.78	-0.46	4.23e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg01299579	chr2:10830716	NOL10	0.41	7.15	0.33	3.74e-12	Prostate cancer;
LUAD	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg24101359	chr6:42928495	GNMT	0.46	8.58	0.38	1.86e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1975974	0.872	rs66502681	chr17:21722119	T/A	cg18423549	chr17:21743878	NA	-0.77	-13.69	-0.55	1.38e-35	Psoriasis;
LUAD	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-6.45	-0.3	3.15e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs11048434	0.636	rs7306161	chr12:9059075	T/A	cg04155231	chr12:9217510	LOC144571	0.37	6.79	0.31	3.73e-11	Sjögren's syndrome;
LUAD	cis	rs73416724	1.000	rs76649578	chr6:43388024	A/G	cg26312998	chr6:43337775	ZNF318	0.56	6.82	0.31	3.14e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs62400317	0.859	rs10948226	chr6:45299174	G/C	cg20913747	chr6:44695427	NA	-0.43	-6.98	-0.32	1.13e-11	Total body bone mineral density;
LUAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg08888203	chr3:10149979	C3orf24	0.73	12.78	0.53	7.21e-32	Alzheimer's disease;
LUAD	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg22491629	chr6:157744540	C6orf35	-0.8	-9.2	-0.41	1.65e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs3125734	0.608	rs7905731	chr10:64018472	T/C	cg19640130	chr10:64028056	RTKN2	-0.35	-7.41	-0.34	7.16e-13	Rheumatoid arthritis;
LUAD	cis	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg07460842	chr6:66804631	NA	0.61	9.7	0.43	3.22e-20	Type 2 diabetes;
LUAD	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg03806693	chr22:41940476	POLR3H	-0.61	-9.08	-0.4	4.23e-18	Vitiligo;
LUAD	cis	rs1784581	0.588	rs6455790	chr6:162418447	C/T	cg17173639	chr6:162384350	PARK2	-0.41	-7.45	-0.34	5.22e-13	Itch intensity from mosquito bite;
LUAD	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg05234568	chr11:5960015	NA	-0.54	-10.61	-0.46	1.72e-23	DNA methylation (variation);
LUAD	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg02807482	chr3:125708958	NA	-0.66	-8.74	-0.39	5.34e-17	Blood pressure (smoking interaction);
LUAD	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg19761014	chr17:28927070	LRRC37B2	0.95	9.39	0.42	3.82e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7680126	0.500	rs4640669	chr4:10145733	A/G	cg11266682	chr4:10021025	SLC2A9	0.45	7.41	0.34	6.94e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs1997103	0.954	rs2177809	chr7:55378125	T/C	cg17469321	chr7:55412551	NA	0.67	11.42	0.49	1.7e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs68170813	0.559	rs10953531	chr7:106827867	A/G	cg23024343	chr7:107201750	COG5	-0.5	-7.27	-0.33	1.8e-12	Coronary artery disease;
LUAD	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg19626725	chr5:178986131	RUFY1	-0.55	-10.19	-0.44	5.91e-22	Lung cancer;
LUAD	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.86	0.36	3.32e-14	Depression;
LUAD	cis	rs220324	0.688	rs9984377	chr21:43574845	G/A	cg08841829	chr21:43638893	ABCG1	-0.52	-6.91	-0.32	1.74e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg11235426	chr6:292522	DUSP22	-0.8	-13.75	-0.56	8.31e-36	Menopause (age at onset);
LUAD	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg09796270	chr17:17721594	SREBF1	-0.33	-6.48	-0.3	2.55e-10	Total body bone mineral density;
LUAD	cis	rs7937890	0.559	rs2575838	chr11:14498221	C/G	cg22961513	chr11:14280813	SPON1	-0.37	-7.06	-0.32	6.82e-12	Mitochondrial DNA levels;
LUAD	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg06740227	chr12:86229804	RASSF9	0.38	6.8	0.31	3.58e-11	Major depressive disorder;
LUAD	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.84	-0.43	1.08e-20	Monocyte percentage of white cells;
LUAD	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg11822812	chr5:140052017	DND1	-0.41	-7.43	-0.34	6.12e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7647973	0.961	rs56324858	chr3:49544229	A/G	cg07636037	chr3:49044803	WDR6	-0.55	-8.46	-0.38	4.38e-16	Menarche (age at onset);
LUAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg08132940	chr7:1081526	C7orf50	-0.76	-10.26	-0.45	3.25e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg08219700	chr8:58056026	NA	0.59	7.91	0.36	2.2e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg02038168	chr22:39784481	NA	-0.56	-9.08	-0.4	4.05e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.11	-0.4	3.35e-18	Total body bone mineral density;
LUAD	cis	rs6430585	0.583	rs12472293	chr2:136648077	T/C	cg07169764	chr2:136633963	MCM6	0.8	9.45	0.42	2.31e-19	Corneal structure;
LUAD	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21582582	chr3:182698605	DCUN1D1	0.56	9.54	0.42	1.11e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg06808227	chr14:105710500	BRF1	-0.43	-6.81	-0.31	3.38e-11	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18876405	chr7:65276391	NA	-0.58	-9.62	-0.42	5.99e-20	Aortic root size;
LUAD	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg17063962	chr7:91808500	NA	-0.68	-12.32	-0.51	5.29e-30	Breast cancer;
LUAD	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg06873352	chr17:61820015	STRADA	0.41	6.94	0.32	1.46e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2686555	0.576	rs2686553	chr12:121077389	A/C	cg13504434	chr12:121088311	CABP1	0.41	6.75	0.31	4.83e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs740474	0.569	rs9324851	chr5:140884527	A/G	cg21548955	chr5:140794993	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.3	6.36	0.3	5.4e-10	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18876405	chr7:65276391	NA	-0.42	-6.66	-0.31	8.46e-11	Aortic root size;
LUAD	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg01145583	chr6:160211477	TCP1;MRPL18	-0.44	-6.36	-0.3	5.17e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg12373951	chr3:133503437	NA	0.35	6.91	0.32	1.76e-11	Iron status biomarkers;
LUAD	cis	rs3820068	0.705	rs4646077	chr1:15827136	C/T	cg24675056	chr1:15929824	NA	0.41	6.58	0.3	1.39e-10	Systolic blood pressure;
LUAD	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg03433033	chr1:76189801	ACADM	0.87	17.29	0.64	4.99e-51	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg01200585	chr1:228362443	C1orf69	-0.41	-7.48	-0.34	4.2e-13	Diastolic blood pressure;
LUAD	cis	rs6672530	0.518	rs12025815	chr1:227758072	A/G	cg12133451	chr1:227746453	NA	0.36	6.52	0.3	1.95e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg11189052	chr15:85197271	WDR73	0.59	7.39	0.34	8.04e-13	Schizophrenia;
LUAD	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg07636037	chr3:49044803	WDR6	0.36	6.55	0.3	1.63e-10	Resting heart rate;
LUAD	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg27068330	chr11:65405492	SIPA1	-0.78	-12.69	-0.53	1.64e-31	Acne (severe);
LUAD	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg22491629	chr6:157744540	C6orf35	-0.78	-9.08	-0.4	4.02e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.41	-7.29	-0.33	1.52e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg16479474	chr6:28041457	NA	0.36	6.46	0.3	2.81e-10	Cardiac Troponin-T levels;
LUAD	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg10802521	chr3:52805072	NEK4	-0.44	-6.65	-0.31	8.83e-11	Bipolar disorder;
LUAD	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-8.66	-0.39	9.98e-17	Type 2 diabetes;
LUAD	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg07870213	chr5:140052090	DND1	1.04	14.72	0.58	6.58e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg15691649	chr6:25882328	NA	-0.51	-7.23	-0.33	2.32e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg13319975	chr6:146136371	FBXO30	0.65	10.89	0.47	1.67e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg00310523	chr12:86230176	RASSF9	0.39	7.84	0.36	3.8e-14	Major depressive disorder;
LUAD	cis	rs7508679	1.000	rs7508679	chr19:7222832	A/G	cg00428638	chr19:7224713	INSR	0.67	13.68	0.55	1.52e-35	Hypothyroidism;
LUAD	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.38	-10.24	-0.45	3.86e-22	Total body bone mineral density;
LUAD	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18404041	chr3:52824283	ITIH1	-0.59	-11.79	-0.5	5.98e-28	Bipolar disorder;
LUAD	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg21798802	chr22:38057573	PDXP	0.48	9.73	0.43	2.49e-20	Fat distribution (HIV);
LUAD	cis	rs68170813	0.522	rs12154818	chr7:107074515	G/C	cg02696742	chr7:106810147	HBP1	-0.58	-7.74	-0.35	7.18e-14	Coronary artery disease;
LUAD	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg21238619	chr17:78079768	GAA	-0.36	-6.79	-0.31	3.83e-11	Yeast infection;
LUAD	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg05283184	chr6:79620031	NA	-0.58	-11.68	-0.49	1.62e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg00277334	chr10:82204260	NA	-0.57	-9.73	-0.43	2.56e-20	Post bronchodilator FEV1;
LUAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg11494091	chr17:61959527	GH2	-0.79	-20.27	-0.7	2.44e-64	Prudent dietary pattern;
LUAD	cis	rs11031096	0.711	rs4910890	chr11:4153407	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-7.6	-0.35	1.88e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	trans	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	15.52	0.6	2.58e-43	Exhaled nitric oxide levels;
LUAD	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25427524	chr10:38739819	LOC399744	-0.81	-14.61	-0.58	1.92e-39	Breast cancer;
LUAD	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg11502198	chr6:26597334	ABT1	0.66	11.31	0.48	4.49e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg07917127	chr4:99064746	C4orf37	0.42	6.79	0.31	3.79e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg23719950	chr11:63933701	MACROD1	-0.58	-6.92	-0.32	1.63e-11	Mean platelet volume;
LUAD	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg21699342	chr2:239360505	ASB1	0.5	9.45	0.42	2.29e-19	Multiple system atrophy;
LUAD	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg17800788	chr1:21766015	NBPF3	0.37	7.19	0.33	3.06e-12	Liver enzyme levels (alkaline phosphatase);
LUAD	trans	rs8002861	0.905	rs12875052	chr13:44449368	G/C	cg17145862	chr1:211918768	LPGAT1	-0.68	-14.77	-0.58	3.99e-40	Leprosy;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg11216682	chr2:131113867	PTPN18	-0.43	-6.64	-0.31	9.94e-11	Vertical cup-disc ratio;
LUAD	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg07157834	chr1:205819609	PM20D1	0.41	6.42	0.3	3.7e-10	Parkinson's disease;
LUAD	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg23422044	chr7:1970798	MAD1L1	-0.56	-7.86	-0.36	3.19e-14	Bipolar disorder;
LUAD	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg22875332	chr1:76189707	ACADM	-0.86	-15.93	-0.61	4.24e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs11048434	0.636	rs11614970	chr12:9060053	G/A	cg13575925	chr12:9217583	LOC144571	0.37	6.75	0.31	4.85e-11	Sjögren's syndrome;
LUAD	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg25838465	chr1:92012736	NA	-0.7	-15.05	-0.59	2.61e-41	Breast cancer;
LUAD	cis	rs2880765	0.835	rs4526974	chr15:86024284	C/T	cg13263323	chr15:86062960	AKAP13	-0.49	-9.0	-0.4	7.75e-18	Coronary artery disease;
LUAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg00280220	chr17:61926910	NA	0.36	6.9	0.32	1.9e-11	Prudent dietary pattern;
LUAD	trans	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg26043149	chr18:55253948	FECH	1.05	17.66	0.65	1.05e-52	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg23281280	chr6:28129359	ZNF389	-0.44	-6.47	-0.3	2.64e-10	Depression;
LUAD	cis	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg07460842	chr6:66804631	NA	1.08	17.32	0.64	3.55e-51	Exhaled nitric oxide output;
LUAD	cis	rs17155006	0.746	rs402264	chr7:107748337	G/A	cg05962710	chr7:107745446	LAMB4	-0.34	-7.31	-0.33	1.37e-12	Pneumococcal bacteremia;
LUAD	cis	rs10089	1.000	rs883074	chr5:127445823	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.59	-9.05	-0.4	5.34e-18	Ileal carcinoids;
LUAD	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.26	-0.41	1e-18	Total body bone mineral density;
LUAD	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	8.91	0.4	1.53e-17	Lung cancer in ever smokers;
LUAD	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08280861	chr8:58055591	NA	0.62	8.04	0.36	9.1e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg27494647	chr7:150038898	RARRES2	0.45	8.14	0.37	4.59e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-8.27	-0.37	1.79e-15	Electroencephalogram traits;
LUAD	cis	rs9796	0.870	rs12905926	chr15:41283408	G/A	cg18705301	chr15:41695430	NDUFAF1	0.39	7.31	0.33	1.34e-12	Menopause (age at onset);
LUAD	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg21427119	chr20:30132790	HM13	-0.48	-7.64	-0.35	1.43e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs7274811	0.711	rs291669	chr20:31945364	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.53	8.03	0.36	9.61e-15	Height;
LUAD	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg04267008	chr7:1944627	MAD1L1	-0.7	-10.61	-0.46	1.78e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	6.98	0.32	1.11e-11	Motion sickness;
LUAD	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg11707310	chr1:2537719	MMEL1	0.38	7.91	0.36	2.33e-14	Ulcerative colitis;
LUAD	cis	rs3849570	0.643	rs1969433	chr3:81968869	T/C	cg07356753	chr3:81810745	GBE1	-0.49	-8.22	-0.37	2.45e-15	Waist circumference;Body mass index;
LUAD	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg15147215	chr3:52552868	STAB1	-0.4	-7.24	-0.33	2.2e-12	Bipolar disorder;
LUAD	trans	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg06606381	chr12:133084897	FBRSL1	-0.52	-7.12	-0.33	4.74e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10865541	0.935	rs4971502	chr2:3414029	A/G	cg22182287	chr2:3452347	TTC15	0.43	7.36	0.34	9.84e-13	Obesity-related traits;
LUAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00166722	chr3:10149974	C3orf24	0.64	9.72	0.43	2.76e-20	Alzheimer's disease;
LUAD	cis	rs36051895	0.664	rs10815153	chr9:5092864	G/C	cg02405213	chr9:5042618	JAK2	-0.45	-6.71	-0.31	6.16e-11	Pediatric autoimmune diseases;
LUAD	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg15664640	chr17:80829946	TBCD	-0.6	-7.89	-0.36	2.57e-14	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg09455208	chr3:40491958	NA	0.52	11.02	0.47	5.49e-25	Renal cell carcinoma;
LUAD	trans	rs9951602	0.512	rs9958497	chr18:76655296	G/C	cg02800362	chr5:177631904	HNRNPAB	0.91	14.4	0.57	1.57e-38	Obesity-related traits;
LUAD	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg03433033	chr1:76189801	ACADM	0.48	7.1	0.33	5.31e-12	Daytime sleep phenotypes;
LUAD	cis	rs6494488	0.500	rs72758946	chr15:64679363	G/A	cg08069370	chr15:64387884	SNX1	-0.76	-6.74	-0.31	5.26e-11	Coronary artery disease;
LUAD	cis	rs9469913	0.799	rs2744956	chr6:34618937	T/C	cg14254433	chr6:34482411	PACSIN1	-0.43	-6.67	-0.31	7.99e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.14	-32.57	-0.85	2.54e-117	Myeloid white cell count;
LUAD	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11890956	chr21:40555474	PSMG1	0.78	13.21	0.54	1.36e-33	Cognitive function;
LUAD	cis	rs758324	0.947	rs7725924	chr5:131118165	C/G	cg25547332	chr5:131281432	NA	0.45	6.76	0.31	4.47e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1448094	0.935	rs11117120	chr12:86336447	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-8.04	-0.36	8.89e-15	Major depressive disorder;
LUAD	cis	rs6952808	0.964	rs10950407	chr7:1895666	T/G	cg04267008	chr7:1944627	MAD1L1	-0.7	-10.31	-0.45	2.18e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs9863	0.861	rs12298484	chr12:124418674	C/T	cg17723958	chr12:124429295	CCDC92	-0.43	-6.98	-0.32	1.18e-11	White blood cell count;
LUAD	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg13126279	chr21:47581558	C21orf56	-0.42	-7.33	-0.34	1.14e-12	Testicular germ cell tumor;
LUAD	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg12863693	chr15:85201151	NMB	0.42	7.59	0.35	2.07e-13	Schizophrenia;
LUAD	cis	rs3125734	0.633	rs6479791	chr10:63980341	T/C	cg19640130	chr10:64028056	RTKN2	-0.34	-7.2	-0.33	2.74e-12	Rheumatoid arthritis;
LUAD	cis	rs12144309	0.543	rs2185827	chr1:114386083	A/G	cg03325407	chr1:114423726	BCL2L15	0.39	6.8	0.31	3.55e-11	Coronary artery disease;
LUAD	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg23719950	chr11:63933701	MACROD1	-0.62	-7.41	-0.34	7.01e-13	Attention deficit hyperactivity disorder;
LUAD	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.35	-7.41	-0.34	6.91e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11890956	chr21:40555474	PSMG1	-0.55	-9.56	-0.42	9.81e-20	Menarche (age at onset);
LUAD	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14169450	chr9:139327907	INPP5E	-0.4	-7.36	-0.34	9.44e-13	Monocyte percentage of white cells;
LUAD	cis	rs12431939	0.947	rs55974960	chr14:51633742	T/C	cg23942311	chr14:51606299	NA	-0.62	-8.47	-0.38	4.07e-16	Cancer;
LUAD	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg26384229	chr12:38710491	ALG10B	0.47	7.73	0.35	7.86e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.49	0.3	2.42e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg13010199	chr12:38710504	ALG10B	0.39	6.48	0.3	2.51e-10	Morning vs. evening chronotype;
LUAD	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg14668632	chr7:2872130	GNA12	-0.73	-13.31	-0.54	5.31e-34	Height;
LUAD	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg27529037	chr20:44575021	PCIF1	0.46	8.28	0.37	1.66e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg06214716	chr4:10118677	WDR1	-0.42	-6.72	-0.31	5.85e-11	Bone mineral density;
LUAD	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25427524	chr10:38739819	LOC399744	-0.79	-14.22	-0.57	8.83e-38	Extrinsic epigenetic age acceleration;
LUAD	trans	rs7615952	0.546	rs112919177	chr3:125346070	G/A	cg17147758	chr8:6949321	NA	-0.49	-7.45	-0.34	5.27e-13	Blood pressure (smoking interaction);
LUAD	cis	rs6594713	0.533	rs7709362	chr5:112990998	G/C	cg12552261	chr5:112820674	MCC	0.53	6.89	0.32	2.07e-11	Brain cytoarchitecture;
LUAD	cis	rs427941	0.632	rs201522	chr7:101771546	C/T	cg06246474	chr7:101738831	CUX1	0.36	6.38	0.3	4.71e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg23422044	chr7:1970798	MAD1L1	-0.53	-7.31	-0.33	1.37e-12	Bipolar disorder;
LUAD	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg25894440	chr7:65020034	NA	0.62	6.63	0.31	1.03e-10	Diabetic kidney disease;
LUAD	cis	rs73198271	0.515	rs75990942	chr8:8639761	C/T	cg01851573	chr8:8652454	MFHAS1	0.61	7.99	0.36	1.33e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.35	7.13	0.33	4.32e-12	Obesity-related traits;
LUAD	cis	rs10193935	0.901	rs6544533	chr2:42516372	G/C	cg27598129	chr2:42591480	NA	-0.64	-8.52	-0.38	2.8e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4006360	0.543	rs7502165	chr17:39268037	A/C	cg20663846	chr17:39254439	KRTAP4-8	0.36	7.47	0.34	4.75e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg02176678	chr2:219576539	TTLL4	0.68	13.66	0.55	1.94e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg18761221	chr20:60518478	NA	0.58	10.33	0.45	1.81e-22	Obesity-related traits;
LUAD	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.86	-0.32	2.51e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs11088226	0.681	rs2833926	chr21:33975279	A/G	cg09050820	chr6:167586206	TCP10L2	0.84	11.44	0.49	1.41e-26	Gastritis;
LUAD	cis	rs3026445	0.791	rs7309141	chr12:110587637	G/A	cg12870014	chr12:110450643	ANKRD13A	0.38	6.79	0.31	3.9e-11	QT interval;
LUAD	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg17200465	chr3:40428508	ENTPD3	0.27	6.79	0.31	3.71e-11	Renal cell carcinoma;
LUAD	cis	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg07169764	chr2:136633963	MCM6	0.69	8.54	0.38	2.4e-16	Corneal structure;
LUAD	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg04155289	chr7:94953770	PON1	-0.54	-7.36	-0.34	9.74e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg03709012	chr19:19516395	GATAD2A	0.51	6.85	0.32	2.61e-11	Nonalcoholic fatty liver disease;
LUAD	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg20790798	chr5:1857306	NA	-0.44	-7.56	-0.34	2.54e-13	Cardiovascular disease risk factors;
LUAD	trans	rs7615952	0.546	rs2922171	chr3:125343193	C/T	cg17147758	chr8:6949321	NA	-0.49	-7.45	-0.34	5.27e-13	Blood pressure (smoking interaction);
LUAD	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg25754956	chr12:51612065	POU6F1	-0.58	-8.47	-0.38	3.99e-16	Cisplatin-induced ototoxicity;
LUAD	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg19901956	chr11:77921274	USP35	-0.49	-6.51	-0.3	2.1e-10	Testicular germ cell tumor;
LUAD	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg02527881	chr3:46936655	PTH1R	0.42	7.98	0.36	1.37e-14	Colorectal cancer;
LUAD	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg22705602	chr4:152727874	NA	-0.4	-7.18	-0.33	3.16e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.4	-0.3	4.03e-10	Aortic root size;
LUAD	cis	rs3784262	0.647	rs2414529	chr15:58317094	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.49	-0.34	3.98e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg02038168	chr22:39784481	NA	-0.54	-8.45	-0.38	4.67e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	trans	rs208515	0.560	rs207084	chr6:66776966	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.14	-26.88	-0.79	1.47e-93	Exhaled nitric oxide levels;
LUAD	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg05805236	chr11:65401703	PCNXL3	0.42	7.28	0.33	1.66e-12	Acne (severe);
LUAD	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg07266350	chr3:49460521	AMT;NICN1	-0.38	-6.85	-0.32	2.56e-11	Menarche (age at onset);
LUAD	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg06671706	chr8:8559999	CLDN23	-0.37	-6.4	-0.3	4.02e-10	Mood instability;
LUAD	cis	rs7095607	0.560	rs2255381	chr10:69923535	C/T	cg18986048	chr10:69913749	MYPN	0.48	8.21	0.37	2.8e-15	Lung function (FVC);
LUAD	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.53	-8.36	-0.38	9.32e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs35883536	0.513	rs6577180	chr1:101016939	G/A	cg09408571	chr1:101003634	GPR88	0.34	6.72	0.31	5.99e-11	Monocyte count;
LUAD	trans	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.72	-9.9	-0.43	6.41e-21	Obesity-related traits;
LUAD	cis	rs9837602	0.935	rs4928149	chr3:99685686	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	6.47	0.3	2.77e-10	Breast cancer;
LUAD	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg02569458	chr12:86230093	RASSF9	0.44	8.09	0.37	6.46e-15	Major depressive disorder;
LUAD	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg13685833	chr1:53393034	SCP2	-0.4	-6.66	-0.31	8.28e-11	Monocyte count;
LUAD	cis	rs868036	1.000	rs4776376	chr15:68093435	G/A	cg24579218	chr15:68104479	NA	-0.39	-7.29	-0.33	1.53e-12	Restless legs syndrome;
LUAD	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg27068330	chr11:65405492	SIPA1	0.55	8.72	0.39	6.38e-17	Acne (severe);
LUAD	cis	rs2408955	0.522	rs4760679	chr12:48461635	G/T	cg04545296	chr12:48745243	ZNF641	-0.35	-9.01	-0.4	7.35e-18	Glycated hemoglobin levels;
LUAD	cis	rs2262909	0.853	rs56207853	chr19:22292357	C/T	cg11619707	chr19:22235551	ZNF257	0.47	7.33	0.34	1.19e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.75e-11	Crohn's disease;
LUAD	trans	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.89	0.43	6.82e-21	Ulcerative colitis;
LUAD	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08704250	chr15:31115839	NA	-0.48	-8.98	-0.4	9.21e-18	Huntington's disease progression;
LUAD	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg16479474	chr6:28041457	NA	0.43	7.38	0.34	8.39e-13	Depression;
LUAD	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg08807101	chr21:30365312	RNF160	-0.45	-7.84	-0.36	3.58e-14	Dental caries;
LUAD	cis	rs10129255	0.500	rs8004923	chr14:107194164	A/G	cg23076370	chr14:107095027	NA	-0.42	-8.53	-0.38	2.73e-16	Kawasaki disease;
LUAD	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg05283184	chr6:79620031	NA	-0.62	-12.33	-0.51	4.51e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs12545109	0.800	rs2609979	chr8:57390066	G/A	cg11919837	chr8:57350735	NA	-0.46	-6.64	-0.31	9.4e-11	Obesity-related traits;
LUAD	cis	rs4343996	0.934	rs4607498	chr7:3368197	C/T	cg21248987	chr7:3385318	SDK1	-0.35	-6.62	-0.31	1.11e-10	Motion sickness;
LUAD	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.41	-8.13	-0.37	4.66e-15	Glomerular filtration rate;
LUAD	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg12908607	chr1:44402522	ARTN	-0.44	-8.55	-0.38	2.33e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs894734	1.000	rs894734	chr12:54319727	A/G	cg17410650	chr12:54324560	NA	-0.43	-8.73	-0.39	5.75e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUAD	cis	rs7246865	0.954	rs1060367	chr19:17215202	G/A	cg19418318	chr19:17219073	MYO9B	0.48	8.3	0.37	1.46e-15	Reticulocyte fraction of red cells;
LUAD	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg17333051	chr19:2783644	SGTA	0.48	7.49	0.34	4.11e-13	Total cholesterol levels;
LUAD	cis	rs1475718	0.526	rs10785875	chr9:137122570	C/T	cg21243944	chr9:137118148	NA	-0.32	-6.64	-0.31	9.48e-11	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11905131	chr22:24372483	LOC391322	-0.55	-9.16	-0.41	2.2e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg22963979	chr7:1858916	MAD1L1	0.56	9.91	0.43	5.83e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs2074585	0.679	rs2601195	chr15:90938232	G/A	cg10434728	chr15:90938212	IQGAP1	0.42	8.51	0.38	3.03e-16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg26441486	chr22:50317300	CRELD2	0.43	6.45	0.3	3.1e-10	Schizophrenia;
LUAD	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2816062	0.721	rs2816047	chr1:18893728	A/C	cg18795169	chr1:18902165	NA	-0.94	-22.53	-0.74	2.02e-74	Urate levels in lean individuals;
LUAD	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg04025307	chr7:1156635	C7orf50	0.51	6.76	0.31	4.66e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.65	0.31	9.11e-11	Depression;
LUAD	cis	rs1953600	0.805	rs2819947	chr10:81947757	T/C	cg04850286	chr10:81895943	PLAC9	0.36	6.55	0.3	1.63e-10	Sarcoidosis;
LUAD	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.56	0.42	9.51e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2408955	0.541	rs11168428	chr12:48547128	A/G	cg04545296	chr12:48745243	ZNF641	-0.31	-8.11	-0.37	5.38e-15	Glycated hemoglobin levels;
LUAD	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg15448220	chr1:150897856	SETDB1	-0.41	-6.6	-0.31	1.23e-10	Tonsillectomy;
LUAD	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg06766960	chr11:133703094	NA	-0.38	-7.21	-0.33	2.58e-12	Childhood ear infection;
LUAD	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-8.71	-0.39	7.08e-17	Schizophrenia;
LUAD	cis	rs727505	1.000	rs10226033	chr7:124521430	C/A	cg23710748	chr7:124431027	NA	-0.49	-9.93	-0.43	4.96e-21	Lewy body disease;
LUAD	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.34	-0.38	1.09e-15	Total body bone mineral density;
LUAD	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.02	-0.32	9.14e-12	HDL cholesterol;
LUAD	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg12011299	chr4:100065546	ADH4	0.77	16.01	0.61	2.01e-45	Alcohol dependence;
LUAD	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg11494091	chr17:61959527	GH2	0.74	18.45	0.67	3.54e-56	Prudent dietary pattern;
LUAD	cis	rs9902453	0.765	rs62068653	chr17:28212663	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.1	0.44	1.24e-21	Coffee consumption (cups per day);
LUAD	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg15900387	chr1:150738905	CTSS	-0.37	-6.69	-0.31	6.89e-11	Melanoma;
LUAD	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg04369109	chr6:150039330	LATS1	-0.46	-7.64	-0.35	1.44e-13	Lung cancer;
LUAD	trans	rs6076960	0.629	rs6054024	chr20:6229282	A/C	cg17788362	chr6:86352627	SYNCRIP	0.43	6.74	0.31	5.16e-11	Smooth-surface caries;
LUAD	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg09117114	chr16:67998030	SLC12A4	-0.48	-6.82	-0.31	3.06e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9393692	0.557	rs61534839	chr6:26305623	C/T	cg13736514	chr6:26305472	NA	-0.54	-8.51	-0.38	3.15e-16	Educational attainment;
LUAD	cis	rs8179	0.761	rs42032	chr7:92237426	G/A	cg15732164	chr7:92237376	CDK6	-0.41	-6.37	-0.3	4.84e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUAD	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.09	-0.44	1.4e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg12311346	chr5:56204834	C5orf35	-0.9	-13.34	-0.54	3.81e-34	Initial pursuit acceleration;
LUAD	cis	rs751728	0.717	rs2281816	chr6:33772335	A/G	cg13859433	chr6:33739653	LEMD2	-0.35	-7.18	-0.33	3.11e-12	Crohn's disease;
LUAD	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg13319975	chr6:146136371	FBXO30	0.66	11.48	0.49	9.47e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg15181151	chr6:150070149	PCMT1	0.36	7.0	0.32	1.04e-11	Lung cancer;
LUAD	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg06784218	chr1:46089804	CCDC17	-0.53	-11.45	-0.49	1.22e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4660214	0.666	rs6704246	chr1:39809284	C/T	cg27567593	chr1:39956653	BMP8A	0.36	7.31	0.33	1.33e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg23950597	chr19:37808831	NA	-0.62	-7.32	-0.34	1.23e-12	Coronary artery calcification;
LUAD	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg17279839	chr7:150038598	RARRES2	0.45	7.61	0.35	1.76e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-8.68	-0.39	8.62e-17	Gut microbiome composition (summer);
LUAD	cis	rs4846217	1.000	rs6694081	chr1:10443560	G/A	cg17425144	chr1:10567563	PEX14	-0.5	-6.5	-0.3	2.24e-10	Platelet count;
LUAD	cis	rs2880765	0.677	rs7181410	chr15:86006335	A/G	cg13263323	chr15:86062960	AKAP13	0.46	8.49	0.38	3.54e-16	Coronary artery disease;
LUAD	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg17063962	chr7:91808500	NA	-0.65	-11.01	-0.47	5.85e-25	Breast cancer;
LUAD	cis	rs4711350	0.734	rs4713676	chr6:33722098	G/T	cg07979401	chr6:33739406	LEMD2	0.44	7.97	0.36	1.51e-14	Schizophrenia;
LUAD	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg21724239	chr8:58056113	NA	0.66	8.66	0.39	9.86e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg18477163	chr1:228402036	OBSCN	0.42	8.23	0.37	2.41e-15	Diastolic blood pressure;
LUAD	cis	rs8018808	0.935	rs11627016	chr14:77881138	T/C	cg20045696	chr14:77926864	AHSA1	0.36	6.4	0.3	4.19e-10	Myeloid white cell count;
LUAD	cis	rs6558530	0.932	rs10102731	chr8:1709020	A/G	cg17159058	chr8:1704075	NA	-0.39	-6.36	-0.3	5.34e-10	Systolic blood pressure;
LUAD	cis	rs7481584	0.961	rs729662	chr11:3028140	G/A	cg11201177	chr11:2961805	NA	0.41	6.81	0.31	3.36e-11	Calcium levels;
LUAD	cis	rs12367572	0.965	rs10748405	chr12:45321341	C/G	cg04608330	chr12:45269318	NELL2	-0.4	-7.52	-0.34	3.29e-13	Gut microbiome composition (summer);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27480539	chr19:16770792	TMEM38A;C19orf42	-0.4	-6.35	-0.3	5.69e-10	Height;
LUAD	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.67	10.85	0.47	2.27e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg00129232	chr17:37814104	STARD3	-0.45	-7.7	-0.35	9.43e-14	Asthma;
LUAD	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg04450456	chr4:17643702	FAM184B	-0.41	-8.01	-0.36	1.15e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1868673	1.000	rs9784281	chr3:150159779	C/G	cg04908077	chr3:150187338	NA	-0.32	-6.56	-0.3	1.58e-10	Waist circumference;
LUAD	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg22705602	chr4:152727874	NA	-0.47	-8.99	-0.4	8.27e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7192380	0.639	rs12448486	chr16:69802878	G/A	cg00738113	chr16:70207722	CLEC18C	0.4	8.0	0.36	1.24e-14	Sjögren's syndrome;
LUAD	cis	rs73198271	0.562	rs17154743	chr8:8650787	A/G	cg01851573	chr8:8652454	MFHAS1	0.66	10.77	0.46	4.41e-24	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4664304	0.652	rs2221808	chr2:160870944	T/C	cg23995753	chr2:160760732	LY75	-0.39	-6.73	-0.31	5.55e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9900062	0.586	rs11653958	chr17:62686730	G/A	cg02097616	chr17:62675921	NA	0.77	12.7	0.53	1.59e-31	QT interval;
LUAD	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg12292205	chr6:26970375	C6orf41	-0.44	-6.66	-0.31	8.41e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	14.01	0.56	6.87e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg20725539	chr19:9695373	ZNF121	-0.71	-7.06	-0.32	6.74e-12	Type 2 diabetes;
LUAD	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.41	-7.14	-0.33	4.06e-12	Platelet count;
LUAD	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg18180107	chr4:99064573	C4orf37	0.47	7.3	0.33	1.44e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7731657	0.537	rs4705925	chr5:130219200	C/T	cg08523029	chr5:130500466	HINT1	-0.59	-7.58	-0.35	2.27e-13	Fasting plasma glucose;
LUAD	cis	rs11030122	0.702	rs17081	chr11:3987830	A/G	cg18678763	chr11:4115507	RRM1	0.44	7.31	0.33	1.35e-12	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg07393940	chr7:158741817	NA	-0.67	-11.51	-0.49	7.64e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs7786808	0.552	rs4909207	chr7:158187136	G/A	cg02030672	chr11:45687055	CHST1	0.43	7.64	0.35	1.45e-13	Obesity-related traits;
LUAD	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg25251562	chr2:3704773	ALLC	-0.49	-8.11	-0.37	5.7e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg19636519	chr7:99541626	NA	0.39	6.79	0.31	3.76e-11	Coronary artery disease;
LUAD	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg03609598	chr5:56110824	MAP3K1	-0.61	-6.76	-0.31	4.66e-11	Type 2 diabetes;
LUAD	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.84	-0.32	2.78e-11	Neuroticism;
LUAD	cis	rs9581857	0.685	rs17808758	chr13:28036412	C/T	cg22138327	chr13:27999177	GTF3A	0.87	9.96	0.44	3.79e-21	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06022373	chr22:39101656	GTPBP1	0.44	6.98	0.32	1.15e-11	Menopause (age at onset);
LUAD	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.58	8.51	0.38	3.08e-16	Platelet count;
LUAD	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg17252645	chr8:143867129	LY6D	-0.36	-6.62	-0.31	1.07e-10	Urinary tract infection frequency;
LUAD	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	7.39	0.34	7.99e-13	Menopause (age at onset);
LUAD	cis	rs16854884	0.683	rs10935505	chr3:143777966	T/C	cg01302019	chr3:143689584	C3orf58	-0.41	-6.92	-0.32	1.7e-11	Economic and political preferences (feminism/equality);
LUAD	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg13298116	chr11:62369859	EML3;MTA2	-0.53	-9.68	-0.43	3.64e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg04990556	chr1:26633338	UBXN11	-0.39	-6.46	-0.3	2.93e-10	Obesity-related traits;
LUAD	trans	rs7395662	1.000	rs12421159	chr11:48624841	C/A	cg00717180	chr2:96193071	NA	-0.39	-7.27	-0.33	1.72e-12	HDL cholesterol;
LUAD	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg09658497	chr7:2847517	GNA12	-0.5	-9.17	-0.41	2.05e-18	Height;
LUAD	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg26816564	chr1:7831052	VAMP3	0.63	8.76	0.39	4.81e-17	Inflammatory bowel disease;
LUAD	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg12016809	chr21:47604291	C21orf56	0.45	7.48	0.34	4.44e-13	Testicular germ cell tumor;
LUAD	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg11247378	chr22:39784982	NA	-0.72	-13.32	-0.54	4.83e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg25427524	chr10:38739819	LOC399744	0.49	8.19	0.37	3.18e-15	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg05590025	chr7:65112418	INTS4L2	0.69	7.47	0.34	4.66e-13	Diabetic kidney disease;
LUAD	cis	rs7680126	0.633	rs74469609	chr4:10294424	G/A	cg00071950	chr4:10020882	SLC2A9	-0.59	-8.39	-0.38	7.45e-16	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs4072705	0.967	rs10217141	chr9:127403935	C/T	cg13476313	chr9:127244764	NR5A1	0.31	7.54	0.34	2.84e-13	Menarche (age at onset);
LUAD	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg21385522	chr1:16154831	NA	-0.51	-7.49	-0.34	4.1e-13	Dilated cardiomyopathy;
LUAD	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg04450456	chr4:17643702	FAM184B	-0.4	-7.74	-0.35	7.22e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg23252815	chr20:44420276	WFDC3;DNTTIP1	0.39	6.54	0.3	1.77e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7274811	0.652	rs291686	chr20:32010851	T/C	cg13403462	chr20:32256071	NECAB3;C20orf134	0.45	6.86	0.32	2.5e-11	Height;
LUAD	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	9.13	0.41	2.79e-18	Hip circumference adjusted for BMI;
LUAD	cis	rs2639990	0.744	rs640261	chr18:72905808	C/T	cg03972071	chr18:72917163	ZADH2	0.6	6.79	0.31	3.93e-11	Vascular endothelial growth factor levels;
LUAD	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg21471580	chr8:22132874	PIWIL2	0.46	8.29	0.37	1.57e-15	Hypertriglyceridemia;
LUAD	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs12431939	0.626	rs7160810	chr14:51716467	G/A	cg23942311	chr14:51606299	NA	0.43	6.58	0.3	1.41e-10	Cancer;
LUAD	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg13699009	chr12:122356056	WDR66	0.3	6.54	0.3	1.74e-10	Mean corpuscular volume;
LUAD	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg22907277	chr7:1156413	C7orf50	0.53	8.85	0.4	2.36e-17	Longevity;Endometriosis;
LUAD	cis	rs4803468	1.000	rs55986560	chr19:41939835	C/T	cg09537434	chr19:41945824	ATP5SL	0.49	7.75	0.35	6.98e-14	Height;
LUAD	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg18099408	chr3:52552593	STAB1	-0.42	-7.39	-0.34	7.74e-13	Bipolar disorder;
LUAD	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg26384229	chr12:38710491	ALG10B	0.47	7.62	0.35	1.63e-13	Morning vs. evening chronotype;
LUAD	cis	rs7274811	0.681	rs186026	chr20:31951993	G/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.52	7.86	0.36	3.32e-14	Height;
LUAD	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg00933542	chr6:150070202	PCMT1	0.43	9.15	0.41	2.37e-18	Lung cancer;
LUAD	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg00933542	chr6:150070202	PCMT1	0.36	7.37	0.34	8.75e-13	Testicular germ cell tumor;
LUAD	cis	rs7274811	0.901	rs1074683	chr20:32304653	C/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.48	-6.72	-0.31	5.87e-11	Height;
LUAD	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-7.15	-0.33	3.91e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg03354898	chr7:1950403	MAD1L1	-0.43	-8.24	-0.37	2.17e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-7.48	-0.34	4.28e-13	Joint mobility (Beighton score);
LUAD	cis	rs7020830	0.898	rs13284651	chr9:37222681	G/T	cg14294708	chr9:37120828	ZCCHC7	-0.81	-15.52	-0.6	2.68e-43	Schizophrenia;
LUAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg12432903	chr7:1882776	MAD1L1	-0.53	-8.7	-0.39	7.22e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs9972944	0.622	rs1895033	chr17:63777493	A/C	cg07283582	chr17:63770753	CCDC46	0.48	10.48	0.45	5.49e-23	Total body bone mineral density;
LUAD	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg08779649	chr13:50194554	NA	0.42	8.44	0.38	5.27e-16	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.86	0.4	2.22e-17	Menopause (age at onset);
LUAD	cis	rs1595825	0.891	rs58409972	chr2:198897061	A/T	cg11031976	chr2:198649780	BOLL	-0.48	-6.57	-0.3	1.52e-10	Ulcerative colitis;
LUAD	cis	rs13082711	0.522	rs653886	chr3:27343549	C/T	cg02860705	chr3:27208620	NA	0.5	8.54	0.38	2.42e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.12	0.41	3.18e-18	Alzheimer's disease;
LUAD	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg06453172	chr10:134556979	INPP5A	-0.77	-10.94	-0.47	1.07e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs11077998	1.000	rs11077998	chr17:80483946	C/G	cg10255544	chr17:80519551	FOXK2	-0.34	-6.91	-0.32	1.78e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg10018233	chr7:150070692	REPIN1	0.49	7.74	0.35	7.63e-14	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg05665937	chr4:1216051	CTBP1	0.42	7.01	0.32	9.46e-12	Obesity-related traits;
LUAD	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg16479474	chr6:28041457	NA	0.4	7.28	0.33	1.63e-12	Parkinson's disease;
LUAD	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg10523679	chr1:76189770	ACADM	0.9	16.06	0.62	1.23e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7246865	0.906	rs11666569	chr19:17214073	A/G	cg19418318	chr19:17219073	MYO9B	-0.44	-7.71	-0.35	9.13e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg21214613	chr1:16344536	HSPB7	-0.41	-6.86	-0.32	2.5e-11	Dilated cardiomyopathy;
LUAD	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg06740227	chr12:86229804	RASSF9	0.41	7.29	0.33	1.57e-12	Major depressive disorder;
LUAD	cis	rs2933343	0.621	rs883843	chr3:128567383	C/T	cg11901034	chr3:128598214	ACAD9	0.52	8.23	0.37	2.37e-15	IgG glycosylation;
LUAD	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg24642844	chr7:1081250	C7orf50	-0.74	-8.51	-0.38	2.99e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg02743256	chr7:2109353	MAD1L1	-0.45	-6.64	-0.31	9.59e-11	Bipolar disorder;
LUAD	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg09184832	chr6:79620586	NA	-0.5	-9.3	-0.41	7.54e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs62400317	0.762	rs12202704	chr6:44819614	G/T	cg20913747	chr6:44695427	NA	-0.46	-7.13	-0.33	4.37e-12	Total body bone mineral density;
LUAD	cis	rs1003719	0.788	rs1155787	chr21:38448069	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.52	0.38	2.94e-16	Eye color traits;
LUAD	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg15445000	chr17:37608096	MED1	0.44	8.2	0.37	3e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs939658	1.000	rs8033963	chr15:79455350	C/T	cg17916960	chr15:79447300	NA	0.45	9.22	0.41	1.45e-18	Refractive error;
LUAD	cis	rs501916	0.796	rs55961203	chr15:48050518	G/T	cg16110827	chr15:48056943	SEMA6D	-0.39	-7.05	-0.32	7.26e-12	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs7089973	0.966	rs12775180	chr10:116639754	T/C	cg25233709	chr10:116636983	FAM160B1	0.36	6.77	0.31	4.32e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg07507251	chr3:52567010	NT5DC2	0.37	7.32	0.34	1.26e-12	Bipolar disorder;
LUAD	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.39	6.56	0.3	1.55e-10	Total body bone mineral density;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21529788	chr17:48423282	XYLT2	0.4	6.62	0.31	1.1e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.28e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6484504	0.600	rs972714	chr11:31358875	T/G	cg06552810	chr11:31128660	NA	0.32	6.37	0.3	4.81e-10	Red blood cell count;
LUAD	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06873352	chr17:61820015	STRADA	0.58	9.2	0.41	1.68e-18	Height;
LUAD	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg00071950	chr4:10020882	SLC2A9	0.84	17.89	0.66	1.09e-53	Bone mineral density;
LUAD	cis	rs10489202	0.632	rs149912	chr1:167957803	A/T	cg25738037	chr1:168025549	DCAF6	-0.5	-7.43	-0.34	6.06e-13	Schizophrenia;
LUAD	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.73	0.35	7.65e-14	Breast cancer;
LUAD	cis	rs863345	0.625	rs11265006	chr1:158498485	C/G	cg12129480	chr1:158549410	OR10X1	-0.24	-6.61	-0.31	1.18e-10	Pneumococcal bacteremia;
LUAD	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.5	7.8	0.35	4.93e-14	Total body bone mineral density;
LUAD	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg13393036	chr8:95962371	TP53INP1	-0.41	-9.91	-0.43	5.74e-21	Type 2 diabetes;
LUAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg07507251	chr3:52567010	NT5DC2	0.35	6.8	0.31	3.57e-11	Electroencephalogram traits;
LUAD	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg08470875	chr2:26401718	FAM59B	-0.67	-8.92	-0.4	1.43e-17	Gut microbiome composition (summer);
LUAD	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg00074818	chr8:8560427	CLDN23	0.66	10.16	0.44	7.55e-22	Obesity-related traits;
LUAD	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg16329650	chr2:213403929	ERBB4	0.6	10.58	0.46	2.21e-23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4072705	1.000	rs6478680	chr9:127458468	G/A	cg13476313	chr9:127244764	NR5A1	0.32	7.76	0.35	6.27e-14	Menarche (age at onset);
LUAD	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg13385794	chr1:248469461	NA	0.26	7.04	0.32	7.92e-12	Common traits (Other);
LUAD	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg02527881	chr3:46936655	PTH1R	0.45	8.79	0.39	3.82e-17	Colorectal cancer;
LUAD	trans	rs561341	0.882	rs504887	chr17:30322881	T/A	cg20587970	chr11:113659929	NA	-1.28	-18.78	-0.67	1.12e-57	Hip circumference adjusted for BMI;
LUAD	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg13877915	chr19:58951672	ZNF132	0.73	13.89	0.56	2.2e-36	Uric acid clearance;
LUAD	cis	rs2249625	0.545	rs55681410	chr6:72877859	G/A	cg18830697	chr6:72922368	RIMS1	0.46	8.22	0.37	2.56e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg14343924	chr8:8086146	FLJ10661	0.48	7.42	0.34	6.34e-13	Mood instability;
LUAD	cis	rs7100689	0.646	rs10887808	chr10:82137367	G/A	cg00277334	chr10:82204260	NA	-0.63	-10.62	-0.46	1.63e-23	Post bronchodilator FEV1;
LUAD	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg26384229	chr12:38710491	ALG10B	0.48	7.77	0.35	6.02e-14	Heart rate;
LUAD	cis	rs11229555	0.645	rs11229450	chr11:58201629	G/C	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg15448220	chr1:150897856	SETDB1	-0.48	-8.11	-0.37	5.52e-15	Tonsillectomy;
LUAD	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.68	12.96	0.53	1.46e-32	Cognitive ability;
LUAD	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg22139774	chr2:100720529	AFF3	-0.35	-6.94	-0.32	1.48e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg00784671	chr22:46762841	CELSR1	-0.61	-7.52	-0.34	3.32e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2731664	0.792	rs465670	chr5:176877624	C/T	cg23176889	chr5:176863531	GRK6	-0.76	-15.0	-0.59	4.56e-41	Intelligence (multi-trait analysis);
LUAD	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg02176678	chr2:219576539	TTLL4	-0.73	-14.71	-0.58	7.76e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1232027	0.622	rs245332	chr5:80026268	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.48	-7.54	-0.34	2.83e-13	Huntington's disease progression;
LUAD	cis	rs73206853	0.764	rs60339427	chr12:110824471	G/A	cg12870014	chr12:110450643	ANKRD13A	0.64	7.17	0.33	3.47e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg27411982	chr8:10470053	RP1L1	-0.43	-7.89	-0.36	2.54e-14	Retinal vascular caliber;
LUAD	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg02782426	chr3:40428986	ENTPD3	0.35	7.51	0.34	3.44e-13	Renal cell carcinoma;
LUAD	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg09184832	chr6:79620586	NA	-0.52	-9.79	-0.43	1.6e-20	Intelligence (multi-trait analysis);
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg11454606	chr11:67888949	CHKA	-0.57	-7.06	-0.32	6.96e-12	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9473147	0.516	rs9395279	chr6:47542864	C/T	cg02130027	chr6:47444894	CD2AP	0.34	6.71	0.31	6.25e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.91	0.36	2.29e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg11618577	chr2:27665543	KRTCAP3	0.27	6.97	0.32	1.26e-11	Total body bone mineral density;
LUAD	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg15181151	chr6:150070149	PCMT1	0.42	8.65	0.39	1.1e-16	Lung cancer;
LUAD	trans	rs8023401	0.938	rs2042746	chr15:48729648	T/C	cg01054110	chr12:125002332	NCOR2	-0.42	-6.4	-0.3	4.06e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.71	0.31	6.25e-11	Breast cancer;
LUAD	cis	rs758324	0.812	rs116369002	chr5:131242055	G/A	cg06307176	chr5:131281290	NA	-0.47	-7.8	-0.35	4.72e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs75920871	0.925	rs61903399	chr11:116942475	A/T	cg04087571	chr11:116723030	SIK3	-0.33	-6.8	-0.31	3.55e-11	Subjective well-being;
LUAD	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.1	-0.51	3.68e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg06740227	chr12:86229804	RASSF9	-0.41	-7.36	-0.34	9.88e-13	Major depressive disorder;
LUAD	cis	rs9826463	0.582	rs11714528	chr3:142133218	C/T	cg20824294	chr3:142316082	PLS1	0.38	6.68	0.31	7.67e-11	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg04282206	chr17:62833786	PLEKHM1P	-0.42	-7.06	-0.32	6.69e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.58	-0.52	4.94e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg10589385	chr1:150898437	SETDB1	0.39	7.38	0.34	8.45e-13	Melanoma;
LUAD	cis	rs9467160	0.871	rs9467168	chr6:24449036	A/G	cg20631270	chr6:24437470	GPLD1	0.43	6.68	0.31	7.72e-11	Liver enzyme levels;
LUAD	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg04989706	chr14:50066350	PPIL5	-0.51	-7.56	-0.35	2.51e-13	Carotid intima media thickness;
LUAD	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.62	-11.61	-0.49	3.19e-27	Prudent dietary pattern;
LUAD	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.02	0.32	8.9e-12	Hypertriglyceridemia;
LUAD	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.46	8.01	0.36	1.09e-14	Tonsillectomy;
LUAD	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.62	0.31	1.09e-10	Depression;
LUAD	cis	rs10465746	0.780	rs1952065	chr1:84464205	T/C	cg10977910	chr1:84465055	TTLL7	0.59	9.62	0.42	5.87e-20	Obesity-related traits;
LUAD	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg11833968	chr6:79620685	NA	-0.45	-8.35	-0.38	9.84e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg18876405	chr7:65276391	NA	0.62	10.92	0.47	1.26e-24	Aortic root size;
LUAD	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg16989719	chr2:238392110	NA	-0.38	-7.83	-0.36	3.95e-14	Prostate cancer;
LUAD	cis	rs863345	0.564	rs7540999	chr1:158504570	G/A	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.54	-0.34	2.8e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.77	-0.39	4.52e-17	Bone mineral density;
LUAD	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.41	-7.02	-0.32	9.04e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7095607	0.560	rs2101484	chr10:69927711	T/C	cg18986048	chr10:69913749	MYPN	0.47	8.14	0.37	4.33e-15	Lung function (FVC);
LUAD	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg14092988	chr3:52407081	DNAH1	0.45	9.1	0.4	3.54e-18	Bipolar disorder;
LUAD	trans	rs800082	0.839	rs17282884	chr3:144319905	C/T	cg24215973	chr2:240111563	HDAC4	0.43	6.66	0.31	8.48e-11	Smoking behavior;
LUAD	cis	rs9652601	0.959	rs11865121	chr16:11166688	C/A	cg04616529	chr16:11181986	CLEC16A	0.38	6.91	0.32	1.75e-11	Systemic lupus erythematosus;
LUAD	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg25894440	chr7:65020034	NA	-0.68	-7.18	-0.33	3.23e-12	Diabetic kidney disease;
LUAD	cis	rs7084921	0.608	rs11597561	chr10:101863041	T/C	cg19754520	chr10:101825118	CPN1	-0.34	-6.83	-0.32	3.02e-11	Bone mineral density;
LUAD	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg17443473	chr1:3703550	LRRC47	0.44	7.38	0.34	8.2e-13	Red cell distribution width;
LUAD	cis	rs11828289	0.660	rs79067807	chr11:23228262	T/C	cg20040320	chr11:23191996	NA	-0.67	-7.52	-0.34	3.2e-13	Cancer;
LUAD	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg25809561	chr17:30822961	MYO1D	0.49	8.9	0.4	1.6e-17	Schizophrenia;
LUAD	cis	rs11971779	0.715	rs6954219	chr7:139065110	G/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.46	-0.3	2.86e-10	Diisocyanate-induced asthma;
LUAD	cis	rs6674176	0.569	rs11210935	chr1:44369444	G/A	cg13606994	chr1:44402422	ARTN	-0.35	-6.74	-0.31	5.25e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs6987853	0.830	rs9643888	chr8:42352007	T/C	cg09913449	chr8:42400586	C8orf40	-0.39	-7.14	-0.33	4.22e-12	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg23758822	chr17:41437982	NA	1.02	20.59	0.71	8.87e-66	Menopause (age at onset);
LUAD	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg03161606	chr19:29218774	NA	0.59	7.97	0.36	1.54e-14	Methadone dose in opioid dependence;
LUAD	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg23173402	chr1:227635558	NA	0.9	8.64	0.39	1.16e-16	Major depressive disorder;
LUAD	trans	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg09872104	chr7:134855509	C7orf49	-0.82	-7.52	-0.34	3.38e-13	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs10788264	0.621	rs9633733	chr10:124056546	A/G	cg09507567	chr10:124027408	NA	-0.49	-10.53	-0.46	3.4e-23	Total body bone mineral density;
LUAD	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg18198730	chr1:247681584	NA	-0.44	-7.65	-0.35	1.41e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg11833968	chr6:79620685	NA	-0.44	-8.13	-0.37	4.79e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg27411982	chr8:10470053	RP1L1	-0.46	-8.24	-0.37	2.21e-15	Neuroticism;
LUAD	cis	rs7289126	0.966	rs2267380	chr22:38631768	T/C	cg17652424	chr22:38574118	PLA2G6	-0.25	-7.29	-0.33	1.56e-12	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs240764	0.782	rs395521	chr6:101054999	C/T	cg09795085	chr6:101329169	ASCC3	0.44	7.69	0.35	1.04e-13	Neuroticism;
LUAD	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg04287289	chr16:89883240	FANCA	0.64	6.39	0.3	4.45e-10	Skin colour saturation;
LUAD	cis	rs9302635	0.626	rs34508528	chr16:72215115	C/T	cg23815491	chr16:72088622	HP	0.51	7.89	0.36	2.67e-14	Blood protein levels;
LUAD	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg17644776	chr2:200775616	C2orf69	0.45	7.14	0.33	4.05e-12	Osteoporosis;
LUAD	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg09455208	chr3:40491958	NA	0.64	13.98	0.56	8.62e-37	Renal cell carcinoma;
LUAD	cis	rs7616330	0.887	rs1474305	chr3:71043496	A/G	cg20891481	chr3:71115714	FOXP1	-0.5	-8.45	-0.38	4.63e-16	QT interval;
LUAD	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-9.3	-0.41	7.64e-19	Bipolar disorder;
LUAD	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg06138931	chr13:21896616	NA	0.44	6.46	0.3	2.96e-10	White matter hyperintensity burden;
LUAD	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg02463440	chr8:22132932	PIWIL2	0.55	10.05	0.44	1.91e-21	Hypertriglyceridemia;
LUAD	cis	rs7520050	0.933	rs6666743	chr1:46311275	C/T	cg06784218	chr1:46089804	CCDC17	-0.3	-6.39	-0.3	4.32e-10	Red blood cell count;Reticulocyte count;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg11582617	chr6:158589302	SERAC1;GTF2H5	-0.72	-6.85	-0.32	2.59e-11	Type 2 diabetes;
LUAD	cis	rs12681287	0.752	rs13256500	chr8:87247063	G/A	cg27223183	chr8:87520930	FAM82B	-0.59	-8.15	-0.37	4.01e-15	Caudate activity during reward;
LUAD	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19626725	chr5:178986131	RUFY1	0.56	10.63	0.46	1.53e-23	Lung cancer;
LUAD	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg25894440	chr7:65020034	NA	0.62	6.63	0.31	1.03e-10	Diabetic kidney disease;
LUAD	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg04842962	chr6:43655489	MRPS18A	1.05	26.05	0.78	6.27e-90	IgG glycosylation;
LUAD	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg27068330	chr11:65405492	SIPA1	-0.76	-11.64	-0.49	2.4200000000000002e-27	Acne (severe);
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg04903157	chr22:35795952	MCM5	0.41	6.77	0.31	4.35e-11	Diastolic blood pressure;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg09688494	chr10:14996222	DCLRE1C	-0.63	-7.66	-0.35	1.29e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2425143	1.000	rs7273815	chr20:34232415	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.42	-0.34	6.59e-13	Blood protein levels;
LUAD	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg09436375	chr6:42928200	GNMT	-0.29	-8.05	-0.36	8.49e-15	Alzheimer's disease in APOE e4+ carriers;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg02346057	chr16:2479628	CCNF	-0.45	-7.02	-0.32	8.94e-12	Height;
LUAD	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg13319975	chr6:146136371	FBXO30	-0.6	-10.3	-0.45	2.39e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg15997130	chr1:24165203	NA	0.41	6.82	0.31	3.14e-11	Immature fraction of reticulocytes;
LUAD	cis	rs6499255	0.951	rs7200935	chr16:69564497	T/C	cg00738113	chr16:70207722	CLEC18C	-0.38	-6.36	-0.3	5.33e-10	IgE levels;
LUAD	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg15556689	chr8:8085844	FLJ10661	0.41	6.69	0.31	6.89e-11	Mood instability;
LUAD	cis	rs8112211	1.000	rs2304176	chr19:38794895	T/C	cg14299480	chr19:38876666	GGN	-0.43	-7.06	-0.32	6.85e-12	Blood protein levels;
LUAD	cis	rs6761276	0.899	rs11678375	chr2:113835691	T/C	cg02343335	chr2:113785852	IL1F8	-0.35	-7.01	-0.32	9.26e-12	Protein quantitative trait loci;
LUAD	cis	rs62458065	0.640	rs79619897	chr7:32514819	C/T	cg20159608	chr7:32802032	NA	-0.61	-8.21	-0.37	2.75e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg05725404	chr16:58534157	NDRG4	-0.72	-7.54	-0.34	2.95e-13	Schizophrenia;
LUAD	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg01324343	chr3:183735012	ABCC5	0.94	25.22	0.77	2.51e-86	Anterior chamber depth;
LUAD	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11644478	chr21:40555479	PSMG1	-0.6	-9.96	-0.44	3.82e-21	Cognitive function;
LUAD	cis	rs4493873	1.000	rs10090581	chr8:92070160	G/C	cg16814680	chr8:91681699	NA	0.44	6.87	0.32	2.3e-11	Migraine - clinic-based;
LUAD	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg06608945	chr2:219082296	ARPC2	0.51	8.72	0.39	6.34e-17	Colorectal cancer;
LUAD	cis	rs12618769	0.652	rs17034171	chr2:99221095	A/G	cg10123293	chr2:99228465	UNC50	0.5	8.87	0.4	2.09e-17	Bipolar disorder;
LUAD	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg09650180	chr20:62225654	GMEB2	-0.46	-6.58	-0.3	1.39e-10	Glioblastoma;
LUAD	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg19052272	chr2:3704530	ALLC	-0.45	-8.02	-0.36	1.03e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	6.92	0.32	1.73e-11	Renal function-related traits (BUN);
LUAD	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg12698349	chr2:225449008	CUL3	0.67	10.18	0.44	6.29e-22	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg22014379	chr2:113192561	RGPD8;RGPD5	0.51	6.37	0.3	4.9e-10	Yeast infection;
LUAD	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg27446573	chr6:127587934	RNF146	0.44	6.58	0.3	1.41e-10	Breast cancer;
LUAD	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg25237894	chr2:233734115	C2orf82	0.61	11.45	0.49	1.31e-26	Coronary artery disease;
LUAD	cis	rs7274811	0.681	rs291674	chr20:31954890	C/G	cg03904042	chr20:32255491	NECAB3;C20orf134	0.51	7.54	0.34	2.88e-13	Height;
LUAD	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg23625390	chr15:77176239	SCAPER	0.38	6.69	0.31	7.26e-11	Blood metabolite levels;
LUAD	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg17863274	chr19:49399704	TULP2	-0.64	-9.92	-0.43	5.45e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs17155006	0.655	rs426812	chr7:107728512	T/C	cg05962710	chr7:107745446	LAMB4	-0.3	-6.4	-0.3	4.11e-10	Pneumococcal bacteremia;
LUAD	cis	rs113835537	0.935	rs11550057	chr11:66392880	C/T	cg24851651	chr11:66362959	CCS	0.58	8.0	0.36	1.24e-14	Airway imaging phenotypes;
LUAD	cis	rs6445967	0.545	rs67915154	chr3:58281264	C/T	cg23715586	chr3:58305044	RPP14	0.39	6.5	0.3	2.29e-10	Platelet count;
LUAD	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg24531977	chr5:56204891	C5orf35	0.77	12.37	0.52	3.2e-30	Initial pursuit acceleration;
LUAD	cis	rs713587	0.713	rs12618252	chr2:25207950	G/A	cg04586622	chr2:25135609	ADCY3	-0.32	-6.84	-0.32	2.76e-11	Body mass index in non-asthmatics;
LUAD	cis	rs1448094	0.967	rs10863109	chr12:86328415	A/G	cg02569458	chr12:86230093	RASSF9	0.37	7.07	0.33	6.27e-12	Major depressive disorder;
LUAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.8	14.9	0.59	1.19e-40	Lymphocyte counts;
LUAD	cis	rs2230307	0.505	rs482873	chr1:100589757	C/T	cg20868668	chr1:100435035	SLC35A3	-0.55	-7.95	-0.36	1.7e-14	Carotid intima media thickness;
LUAD	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg06618935	chr21:46677482	NA	-0.48	-8.91	-0.4	1.55e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg15181151	chr6:150070149	PCMT1	0.38	7.34	0.34	1.14e-12	Lung cancer;
LUAD	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs3849570	0.533	rs6785385	chr3:81989850	A/G	cg07356753	chr3:81810745	GBE1	-0.5	-8.36	-0.38	9.01e-16	Waist circumference;Body mass index;
LUAD	cis	rs459571	0.920	rs433402	chr9:136898627	A/G	cg13789015	chr9:136890014	NCRNA00094	0.85	14.21	0.57	9.52e-38	Platelet distribution width;
LUAD	cis	rs7582720	0.943	rs72926798	chr2:203827675	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs11126435	0.858	rs12615011	chr2:74934325	A/T	cg19285774	chr2:74907978	SEMA4F	0.37	6.41	0.3	3.79e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	trans	rs4942242	1.000	rs7331003	chr13:44230253	C/T	cg19169023	chr15:41853346	TYRO3	-0.51	-8.74	-0.39	5.6e-17	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg25237894	chr2:233734115	C2orf82	-0.61	-12.25	-0.51	9.7e-30	Coronary artery disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg06586915	chr7:65958596	NA	-0.41	-6.5	-0.3	2.21e-10	Height;
LUAD	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.52e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg27572855	chr1:25598939	RHD	0.53	11.29	0.48	5.17e-26	Erythrocyte sedimentation rate;
LUAD	cis	rs2274273	0.870	rs10144345	chr14:55847737	T/C	cg04306507	chr14:55594613	LGALS3	0.4	8.51	0.38	3.16e-16	Protein biomarker;
LUAD	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.29	-6.56	-0.3	1.61e-10	Dupuytren's disease;
LUAD	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg16479474	chr6:28041457	NA	0.46	7.67	0.35	1.2e-13	Depression;
LUAD	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg24634471	chr8:143751801	JRK	0.48	7.71	0.35	9e-14	Schizophrenia;
LUAD	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg12863693	chr15:85201151	NMB	0.39	7.18	0.33	3.24e-12	Schizophrenia;
LUAD	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	15.06	0.59	2.33e-41	Smoking behavior;
LUAD	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg23887609	chr12:130822674	PIWIL1	0.4	6.64	0.31	9.93e-11	Menopause (age at onset);
LUAD	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg09796270	chr17:17721594	SREBF1	0.38	7.16	0.33	3.6e-12	Total body bone mineral density;
LUAD	cis	rs71478720	0.743	rs71478723	chr11:112075085	A/G	cg04929355	chr11:112034997	IL18	0.39	6.49	0.3	2.35e-10	Interleukin-18 levels;
LUAD	cis	rs13095912	0.962	rs34505819	chr3:185340721	C/T	cg11274856	chr3:185301563	NA	0.38	7.59	0.35	2.03e-13	Systolic blood pressure;
LUAD	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg12011299	chr4:100065546	ADH4	-0.73	-13.61	-0.55	2.96e-35	Alcohol dependence;
LUAD	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.4	6.76	0.31	4.6e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1030268	0.607	rs34218501	chr7:133210375	G/A	cg10665199	chr7:133106180	EXOC4	0.5	7.18	0.33	3.08e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.03	0.32	8.41e-12	Depression;
LUAD	cis	rs4853036	0.904	rs7578366	chr2:70135695	C/T	cg02498382	chr2:70120550	SNRNP27	-0.51	-8.27	-0.37	1.72e-15	Colorectal or endometrial cancer;
LUAD	cis	rs7737355	0.898	rs32109	chr5:131041590	C/T	cg06307176	chr5:131281290	NA	0.53	8.28	0.37	1.61e-15	Life satisfaction;
LUAD	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg18944383	chr4:111397179	ENPEP	0.41	7.61	0.35	1.74e-13	Coronary artery disease;
LUAD	cis	rs78761021	0.898	rs12150046	chr17:9766753	A/G	cg26853458	chr17:9805074	RCVRN	0.34	6.35	0.3	5.51e-10	Type 2 diabetes;
LUAD	cis	rs6005807	0.563	rs7288792	chr22:29015603	C/T	cg12565055	chr22:29076175	TTC28	0.75	8.76	0.39	4.71e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs10821973	0.527	rs4979775	chr10:63981847	G/A	cg09941381	chr10:64027924	RTKN2	-0.34	-6.76	-0.31	4.48e-11	Hypothyroidism;
LUAD	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.37	0.34	9.32e-13	Breast cancer;
LUAD	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg18944383	chr4:111397179	ENPEP	0.34	6.69	0.31	7.23e-11	Coronary artery disease;
LUAD	trans	rs208520	1.000	rs208527	chr6:66957209	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-13.5	-0.55	8.62e-35	Exhaled nitric oxide output;
LUAD	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg14983838	chr19:29218262	NA	0.52	7.41	0.34	7.12e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg14159672	chr1:205819179	PM20D1	-0.43	-6.98	-0.32	1.16e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-10.84	-0.47	2.43e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs2686555	0.649	rs503667	chr12:121088750	A/G	cg18477009	chr12:121087777	CABP1	0.43	7.78	0.35	5.44e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LUAD	cis	rs2282300	0.739	rs34855782	chr11:30225470	G/A	cg06241208	chr11:30344200	C11orf46	-0.56	-7.34	-0.34	1.13e-12	Morning vs. evening chronotype;
LUAD	cis	rs7932354	0.502	rs7118546	chr11:47087128	C/G	cg19486271	chr11:47235900	DDB2	-0.46	-7.32	-0.34	1.28e-12	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.33	6.39	0.3	4.5e-10	Personality dimensions;
LUAD	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.45	7.95	0.36	1.7e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1034435	0.755	rs5767172	chr22:48892314	A/C	cg05992904	chr22:48892994	FAM19A5	-0.76	-17.19	-0.64	1.36e-50	Late-onset Alzheimer's disease;
LUAD	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg24690094	chr11:67383802	NA	0.4	7.12	0.33	4.56e-12	Mean corpuscular volume;
LUAD	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.93	-0.32	1.55e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18404041	chr3:52824283	ITIH1	-0.48	-9.82	-0.43	1.27e-20	Bipolar disorder;
LUAD	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg08067268	chr2:26466485	HADHB;HADHA	0.61	8.65	0.39	1.05e-16	Gut microbiome composition (summer);
LUAD	cis	rs977987	0.872	rs4243111	chr16:75320827	C/T	cg03315344	chr16:75512273	CHST6	0.63	13.75	0.56	8.14e-36	Dupuytren's disease;
LUAD	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	24.48	0.77	4.49e-83	Chronic sinus infection;
LUAD	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.47	7.53	0.34	3.12e-13	Alzheimer's disease (late onset);
LUAD	cis	rs6993813	1.000	rs6993813	chr8:120052238	T/C	cg01975934	chr8:119970761	NA	-0.37	-7.15	-0.33	3.88e-12	Bone mineral density (hip);
LUAD	cis	rs11229555	0.598	rs12269888	chr11:58184336	T/C	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs11112613	0.762	rs73184078	chr12:105950017	A/G	cg03607813	chr12:105948248	NA	0.82	13.87	0.56	2.64e-36	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs9462027	0.506	rs6934662	chr6:34759884	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-8.99	-0.4	8.51e-18	Systemic lupus erythematosus;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26428032	chr11:67387935	NA	0.42	6.51	0.3	2.16e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7264396	0.563	rs2425109	chr20:34316218	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2e-15	Total cholesterol levels;
LUAD	trans	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg06606381	chr12:133084897	FBRSL1	-1.14	-10.62	-0.46	1.69e-23	Depression;
LUAD	cis	rs2357013	1.000	rs2357013	chr2:53266129	C/T	cg07782112	chr2:53107842	NA	-0.34	-6.61	-0.31	1.16e-10	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2230307	0.536	rs560659	chr1:100523536	A/G	cg20868668	chr1:100435035	SLC35A3	-0.51	-7.41	-0.34	7.13e-13	Carotid intima media thickness;
LUAD	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg23029597	chr12:123009494	RSRC2	0.52	7.97	0.36	1.46e-14	Body mass index;
LUAD	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg02079420	chr8:82753780	SNX16	0.42	8.42	0.38	5.86e-16	Diastolic blood pressure;
LUAD	cis	rs6063312	1.000	rs6063312	chr20:47343059	G/T	cg18078177	chr20:47281410	PREX1	0.65	8.23	0.37	2.27e-15	Tonometry;
LUAD	cis	rs12431939	0.598	rs8012074	chr14:51732101	C/G	cg23942311	chr14:51606299	NA	0.46	7.15	0.33	3.94e-12	Cancer;
LUAD	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg02782426	chr3:40428986	ENTPD3	0.35	7.42	0.34	6.68e-13	Renal cell carcinoma;
LUAD	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg03929089	chr4:120376271	NA	-0.93	-17.89	-0.66	1.08e-53	Height;
LUAD	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg12143784	chr7:64541923	NA	0.52	8.54	0.38	2.45e-16	Calcium levels;
LUAD	cis	rs6005807	0.719	rs28818228	chr22:29042025	G/A	cg12565055	chr22:29076175	TTC28	0.74	8.71	0.39	6.98e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	trans	rs62458065	0.513	rs7805536	chr7:32573570	T/C	cg00845942	chr12:64062724	DPY19L2	-0.56	-8.24	-0.37	2.23e-15	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7739264	0.563	rs9465516	chr6:19771998	A/C	cg02404759	chr6:19790362	NA	-0.34	-6.57	-0.3	1.45e-10	Endometriosis;
LUAD	cis	rs9469913	0.674	rs2744965	chr6:34589632	C/T	cg14254433	chr6:34482411	PACSIN1	-0.44	-6.83	-0.32	3.02e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs1451375	1.000	rs6949897	chr7:50621920	C/T	cg18232548	chr7:50535776	DDC	0.58	9.53	0.42	1.23e-19	Malaria;
LUAD	cis	rs6906287	0.609	rs6938041	chr6:118852468	C/A	cg05564266	chr6:118973597	C6orf204	0.34	7.15	0.33	3.82e-12	Electrocardiographic conduction measures;
LUAD	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11890956	chr21:40555474	PSMG1	-0.59	-9.61	-0.42	6.61e-20	Cognitive function;
LUAD	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg20503657	chr10:835505	NA	1.24	18.49	0.67	2.18e-56	Eosinophil percentage of granulocytes;
LUAD	cis	rs7274811	0.744	rs2071054	chr20:32265839	A/G	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.45	-6.83	-0.32	2.95e-11	Height;
LUAD	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.4	7.87	0.36	2.95e-14	Depression;
LUAD	cis	rs2274273	0.588	rs58296156	chr14:55828327	C/T	cg04306507	chr14:55594613	LGALS3	0.42	8.18	0.37	3.3e-15	Protein biomarker;
LUAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg24503407	chr1:205819492	PM20D1	0.74	14.52	0.58	4.57e-39	Menarche (age at onset);
LUAD	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg05234568	chr11:5960015	NA	-0.58	-11.22	-0.48	9.79e-26	DNA methylation (variation);
LUAD	cis	rs243505	0.898	rs243537	chr7:148408278	A/G	cg09806900	chr7:148480153	CUL1	-0.45	-7.67	-0.35	1.21e-13	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg16049864	chr8:95962084	TP53INP1	0.53	10.44	0.45	7.17e-23	Type 2 diabetes;
LUAD	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg17063962	chr7:91808500	NA	0.65	10.83	0.47	2.79e-24	Breast cancer;
LUAD	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg06781209	chr11:61594997	FADS2	-0.63	-9.22	-0.41	1.39e-18	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg16647868	chr5:131706066	SLC22A5	0.4	6.95	0.32	1.36e-11	Blood metabolite levels;
LUAD	cis	rs1215050	0.791	rs165239	chr4:98682549	C/T	cg17366294	chr4:99064904	C4orf37	0.45	7.83	0.36	3.93e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg23950597	chr19:37808831	NA	-0.61	-7.51	-0.34	3.54e-13	Coronary artery calcification;
LUAD	trans	rs7395662	1.000	rs7107184	chr11:48577069	G/T	cg00717180	chr2:96193071	NA	-0.4	-7.47	-0.34	4.76e-13	HDL cholesterol;
LUAD	trans	rs7939886	0.920	rs1552151	chr11:55780951	A/G	cg15704280	chr7:45808275	SEPT13	-0.66	-6.72	-0.31	5.76e-11	Myopia (pathological);
LUAD	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg05623727	chr3:50126028	RBM5	0.3	6.67	0.31	7.88e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs250585	0.736	rs6497669	chr16:23534249	G/C	cg00143387	chr16:23521605	GGA2	-0.59	-7.25	-0.33	2.06e-12	Egg allergy;
LUAD	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg08085267	chr17:45401833	C17orf57	-0.69	-12.98	-0.53	1.15e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg03806693	chr22:41940476	POLR3H	0.69	9.6	0.42	7.05e-20	Vitiligo;
LUAD	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg22963979	chr7:1858916	MAD1L1	-0.65	-11.69	-0.49	1.55e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs7799006	0.929	rs7781856	chr7:2257199	C/T	cg08027265	chr7:2291960	NA	-0.56	-10.28	-0.45	2.85e-22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg22674798	chr1:3096360	PRDM16	-0.4	-10.2	-0.44	5.26e-22	Migraine;
LUAD	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2795502	0.564	rs11239840	chr10:43439353	C/T	cg27426351	chr10:43362370	NA	0.54	6.54	0.3	1.82e-10	Blood protein levels;
LUAD	trans	rs9929218	1.000	rs7200690	chr16:68778457	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-14.94	-0.59	7.91e-41	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg03467027	chr4:99064603	C4orf37	0.4	6.47	0.3	2.74e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.87	-0.32	2.28e-11	Mood instability;
LUAD	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg15181151	chr6:150070149	PCMT1	0.33	6.56	0.3	1.62e-10	Testicular germ cell tumor;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11407514	chr10:99094219	FRAT2	-0.49	-7.81	-0.36	4.53e-14	Height;
LUAD	cis	rs2920503	1.000	rs2920503	chr3:12324230	C/T	cg23514324	chr3:12329213	PPARG	0.47	7.17	0.33	3.47e-12	LDL cholesterol;
LUAD	cis	rs210138	0.706	rs444697	chr6:33575009	C/T	cg17865955	chr6:33601177	ITPR3	0.52	9.33	0.41	6.01e-19	Testicular germ cell tumor;
LUAD	trans	rs10838798	0.504	rs11039530	chr11:48145746	C/T	cg03929089	chr4:120376271	NA	-0.44	-6.97	-0.32	1.25e-11	Height;
LUAD	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg21709803	chr11:61594965	FADS2	0.39	7.36	0.34	9.76e-13	Trans fatty acid levels;
LUAD	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg20500540	chr8:101228448	SPAG1	-0.35	-6.38	-0.3	4.63e-10	Atrioventricular conduction;
LUAD	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg04455712	chr21:45112962	RRP1B	0.47	9.27	0.41	9.35e-19	Mean corpuscular volume;
LUAD	cis	rs240764	0.658	rs2132169	chr6:101177663	C/A	cg09795085	chr6:101329169	ASCC3	-0.47	-8.38	-0.38	8.1e-16	Neuroticism;
LUAD	cis	rs7617773	0.780	rs36075665	chr3:48343087	C/T	cg11946769	chr3:48343235	NME6	0.44	6.82	0.31	3.08e-11	Coronary artery disease;
LUAD	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg01802117	chr1:53393560	SCP2	-0.33	-6.47	-0.3	2.64e-10	Monocyte count;
LUAD	cis	rs10465746	0.935	rs11807807	chr1:84424071	C/T	cg10977910	chr1:84465055	TTLL7	0.5	8.09	0.37	6.26e-15	Obesity-related traits;
LUAD	cis	rs62400317	0.731	rs72867436	chr6:44975488	T/G	cg18551225	chr6:44695536	NA	-0.59	-8.95	-0.4	1.11e-17	Total body bone mineral density;
LUAD	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg20608306	chr11:116969690	SIK3	0.29	6.51	0.3	2.1e-10	Blood protein levels;
LUAD	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg04511125	chr2:88470314	THNSL2	-0.51	-8.55	-0.38	2.26e-16	Response to metformin (IC50);
LUAD	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.76	0.31	4.45e-11	Parkinson's disease;
LUAD	cis	rs1003719	0.667	rs6517404	chr21:38494918	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.47	8.01	0.36	1.11e-14	Eye color traits;
LUAD	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg27499820	chr13:21296301	IL17D	-0.41	-7.19	-0.33	3.01e-12	Dental caries;
LUAD	cis	rs735539	0.521	rs2818994	chr13:21418410	G/A	cg27499820	chr13:21296301	IL17D	0.44	7.35	0.34	1.01e-12	Dental caries;
LUAD	cis	rs738322	0.804	rs2076116	chr22:38517405	A/G	cg25457927	chr22:38595422	NA	-0.45	-10.78	-0.46	4.32e-24	Cutaneous nevi;
LUAD	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg00898013	chr13:113819073	PROZ	-0.65	-11.74	-0.5	9.38e-28	Platelet distribution width;
LUAD	cis	rs28735056	0.967	rs8091497	chr18:77632565	G/A	cg20368463	chr18:77673604	PQLC1	-0.43	-6.43	-0.3	3.39e-10	Schizophrenia;
LUAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	8.65	0.39	1.08e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg17644776	chr2:200775616	C2orf69	0.6	10.04	0.44	2e-21	Osteoporosis;
LUAD	trans	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg26043149	chr18:55253948	FECH	-0.42	-6.89	-0.32	2.07e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg26384229	chr12:38710491	ALG10B	0.42	7.11	0.33	4.88e-12	Morning vs. evening chronotype;
LUAD	cis	rs7731657	0.537	rs6877851	chr5:130356413	C/G	cg08523029	chr5:130500466	HINT1	0.6	7.91	0.36	2.21e-14	Fasting plasma glucose;
LUAD	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.61	8.92	0.4	1.45e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg24818145	chr4:99064322	C4orf37	-0.41	-6.83	-0.32	2.9e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg08632164	chr7:65971372	NA	0.36	6.41	0.3	3.86e-10	Aortic root size;
LUAD	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg03433033	chr1:76189801	ACADM	0.86	15.53	0.6	2.29e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12292205	chr6:26970375	C6orf41	-0.47	-6.57	-0.3	1.47e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs477895	0.878	rs7478730	chr11:64018827	C/T	cg23719950	chr11:63933701	MACROD1	-0.58	-6.86	-0.32	2.4e-11	Mean platelet volume;
LUAD	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.85	-0.36	3.56e-14	Diabetic kidney disease;
LUAD	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg23262351	chr6:79576851	IRAK1BP1	0.41	6.95	0.32	1.39e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7759001	0.817	rs6456779	chr6:27370473	T/C	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg05313129	chr8:58192883	C8orf71	-0.59	-8.7	-0.39	7.45e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.8	0.31	3.65e-11	Cognitive test performance;
LUAD	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg09650180	chr20:62225654	GMEB2	-0.48	-6.84	-0.32	2.87e-11	Glioblastoma;
LUAD	cis	rs7593730	1.000	rs12465609	chr2:161179485	T/C	cg22609984	chr2:161126801	NA	0.44	7.12	0.33	4.59e-12	Type 2 diabetes;
LUAD	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg06640241	chr16:89574553	SPG7	0.68	11.74	0.5	9.48e-28	Multiple myeloma (IgH translocation);
LUAD	cis	rs2458413	0.933	rs2669450	chr8:105371752	C/T	cg04554929	chr8:105342491	NA	0.37	7.17	0.33	3.29e-12	Paget's disease;
LUAD	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg26924012	chr15:45694286	SPATA5L1	0.99	18.22	0.66	3.45e-55	Homoarginine levels;
LUAD	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg21171335	chr12:122356390	WDR66	0.73	13.51	0.55	7.75e-35	Mean corpuscular volume;
LUAD	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg13047869	chr3:10149882	C3orf24	-0.6	-10.27	-0.45	3e-22	Alzheimer's disease;
LUAD	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg20701182	chr2:24300061	SF3B14	0.92	13.61	0.55	3.19e-35	Lymphocyte counts;
LUAD	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	6.72	0.31	5.91e-11	Cognitive test performance;
LUAD	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg27539214	chr16:67997921	SLC12A4	-0.68	-8.43	-0.38	5.39e-16	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs8073060	0.614	rs225279	chr17:33974214	A/G	cg19694781	chr19:47549865	TMEM160	-1.24	-19.47	-0.69	9.31e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs758324	0.947	rs72793241	chr5:131240885	C/T	cg25547332	chr5:131281432	NA	-0.44	-6.72	-0.31	5.84e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1451375	1.000	rs1451374	chr7:50622653	G/A	cg18232548	chr7:50535776	DDC	0.58	9.47	0.42	2e-19	Malaria;
LUAD	cis	rs2835872	0.932	rs73222345	chr21:39036569	G/A	cg06728970	chr21:39037746	KCNJ6	-0.43	-8.03	-0.36	9.66e-15	Electroencephalographic traits in alcoholism;
LUAD	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg03929089	chr4:120376271	NA	-0.52	-7.62	-0.35	1.67e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4631830	0.900	rs7914347	chr10:51537431	C/T	cg20129853	chr10:51489980	NA	-0.34	-6.84	-0.32	2.73e-11	Prostate-specific antigen levels;
LUAD	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg02753203	chr1:228287806	NA	-0.49	-9.1	-0.4	3.65e-18	Diastolic blood pressure;
LUAD	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg04756594	chr16:24857601	SLC5A11	0.58	9.86	0.43	8.51e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs6594713	0.921	rs34316732	chr5:112699627	T/C	cg12552261	chr5:112820674	MCC	0.56	8.62	0.39	1.37e-16	Brain cytoarchitecture;
LUAD	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.35	0.34	1.04e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs76878669	0.538	rs2282530	chr11:66177952	C/T	cg18002602	chr11:66138449	SLC29A2	-0.48	-10.14	-0.44	9.34e-22	Educational attainment (years of education);
LUAD	trans	rs6678622	0.863	rs12409958	chr1:78314478	A/G	cg20826526	chr3:156266748	SSR3	-0.44	-6.79	-0.31	3.8e-11	Hip circumference;
LUAD	cis	rs2996428	0.709	rs6667255	chr1:3711689	T/C	cg17443473	chr1:3703550	LRRC47	0.44	7.4	0.34	7.52e-13	Red cell distribution width;
LUAD	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.73	0.76	9.13e-80	Chronic sinus infection;
LUAD	cis	rs1348850	0.526	rs10930802	chr2:178460095	A/G	cg27490568	chr2:178487706	NA	0.66	9.89	0.43	6.65e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg09826364	chr7:158789723	NA	-0.36	-6.43	-0.3	3.56e-10	Facial morphology (factor 20);
LUAD	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg03690763	chr11:133734501	NA	-0.34	-7.8	-0.35	4.96e-14	Childhood ear infection;
LUAD	trans	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.92	-16.46	-0.62	2.11e-47	Colorectal cancer;
LUAD	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	trans	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg18335740	chr13:41363409	SLC25A15	0.62	11.38	0.48	2.42e-26	Lewy body disease;
LUAD	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg24642844	chr7:1081250	C7orf50	-0.96	-14.26	-0.57	6.09e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs1547374	1.000	rs4471987	chr21:43779333	G/C	cg09521743	chr10:75415752	SYNPO2L	-0.41	-6.94	-0.32	1.51e-11	Pancreatic cancer;
LUAD	cis	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-7.39	-0.34	7.88e-13	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.46	0.34	5.03e-13	Bipolar disorder;
LUAD	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg01236616	chr12:121019343	POP5	1.24	19.45	0.69	1.21e-60	Type 1 diabetes nephropathy;
LUAD	trans	rs629535	0.735	rs525610	chr8:70074535	A/G	cg21567404	chr3:27674614	NA	1.0	18.27	0.66	2.26e-55	Dupuytren's disease;
LUAD	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08219700	chr8:58056026	NA	0.63	8.88	0.4	1.9e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs12545109	0.800	rs1968551	chr8:57407760	T/C	cg21220214	chr8:57350948	NA	-0.62	-8.61	-0.39	1.49e-16	Obesity-related traits;
LUAD	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-6.79	-0.31	3.7e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg21150049	chr12:50677498	LIMA1	-0.56	-6.96	-0.32	1.3e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg11707310	chr1:2537719	MMEL1	0.39	8.17	0.37	3.67e-15	Ulcerative colitis;
LUAD	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg05768032	chr16:30646687	NA	0.45	7.74	0.35	7.26e-14	Multiple myeloma;
LUAD	cis	rs89107	0.640	rs281864	chr6:118576233	A/C	cg18833306	chr6:118973337	C6orf204	0.53	9.66	0.43	4.36e-20	Cardiac structure and function;
LUAD	cis	rs16866061	1.000	rs72974269	chr2:225454907	C/T	cg12698349	chr2:225449008	CUL3	0.77	13.5	0.55	8.45e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs4727027	0.705	rs10952803	chr7:148890091	T/G	cg23583168	chr7:148888333	NA	-1.06	-24.92	-0.77	5.04e-85	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg02569458	chr12:86230093	RASSF9	-0.41	-7.64	-0.35	1.48e-13	Major depressive disorder;
LUAD	cis	rs12618769	0.597	rs17031139	chr2:99036530	A/G	cg10123293	chr2:99228465	UNC50	-0.45	-8.33	-0.38	1.11e-15	Bipolar disorder;
LUAD	cis	rs17253792	0.822	rs28831725	chr14:56087569	C/T	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg15956273	chr12:65153476	GNS	0.41	6.52	0.3	2.03e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06022373	chr22:39101656	GTPBP1	0.43	6.56	0.3	1.61e-10	Menopause (age at onset);
LUAD	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg09455208	chr3:40491958	NA	-0.58	-12.52	-0.52	8.24e-31	Renal cell carcinoma;
LUAD	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg26513180	chr16:89883248	FANCA	0.7	6.73	0.31	5.59e-11	Skin colour saturation;
LUAD	cis	rs11048434	0.612	rs7299653	chr12:9058993	A/T	cg26114124	chr12:9217669	LOC144571	0.37	6.62	0.31	1.1e-10	Sjögren's syndrome;
LUAD	cis	rs7582720	1.000	rs72928609	chr2:203837573	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.64	0.42	5.27e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.73	0.31	5.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3106136	0.901	rs17376488	chr4:95226548	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-7.23	-0.33	2.35e-12	Capecitabine sensitivity;
LUAD	cis	rs6500395	0.962	rs9923371	chr16:48628015	C/T	cg04672837	chr16:48644449	N4BP1	0.38	6.55	0.3	1.67e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs8068544	0.606	rs8082153	chr17:40172467	T/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.17	-10.79	-0.46	3.91e-24	Reticulocyte fraction of red cells;Reticulocyte count;
LUAD	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg23758822	chr17:41437982	NA	1.01	20.9	0.71	3.66e-67	Menopause (age at onset);
LUAD	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg14779329	chr11:130786720	SNX19	-0.37	-6.68	-0.31	7.38e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9372498	0.505	rs62424173	chr6:118780507	C/G	cg18833306	chr6:118973337	C6orf204	-0.49	-7.3	-0.33	1.42e-12	Diastolic blood pressure;
LUAD	cis	rs2797160	1.000	rs1739378	chr6:126012262	C/A	cg05901451	chr6:126070800	HEY2	0.45	6.73	0.31	5.7e-11	Endometrial cancer;
LUAD	cis	rs11696501	0.739	rs6104257	chr20:44262100	G/T	cg11783356	chr20:44313418	WFDC10B	-0.49	-7.84	-0.36	3.58e-14	Brain structure;
LUAD	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-6.86	-0.32	2.48e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg14295958	chr14:24025576	THTPA	-0.41	-6.77	-0.31	4.19e-11	Schizophrenia;
LUAD	cis	rs6752107	0.503	rs12997325	chr2:234237387	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.45	7.76	0.35	6.22e-14	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7582720	1.000	rs7560547	chr2:203757916	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg08601574	chr20:25228251	PYGB	-0.46	-8.65	-0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7588746	0.621	rs10497859	chr2:201144446	G/A	cg23649088	chr2:200775458	C2orf69	-0.47	-7.31	-0.33	1.38e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
LUAD	cis	rs3806843	0.549	rs246012	chr5:140336277	C/T	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9326248	0.559	rs609177	chr11:116770517	A/G	cg20608306	chr11:116969690	SIK3	0.3	6.54	0.3	1.8e-10	Blood protein levels;
LUAD	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg02782426	chr3:40428986	ENTPD3	0.35	7.53	0.34	3.11e-13	Renal cell carcinoma;
LUAD	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.21	0.33	2.6e-12	Menopause (age at onset);
LUAD	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23583168	chr7:148888333	NA	-0.91	-18.26	-0.66	2.27e-55	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.36	-0.45	1.39e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs10821973	0.533	rs10740062	chr10:63975842	T/C	cg09941381	chr10:64027924	RTKN2	-0.34	-6.74	-0.31	5.22e-11	Hypothyroidism;
LUAD	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg24955955	chr5:415729	AHRR	0.78	9.26	0.41	1.07e-18	Fat distribution (HIV);
LUAD	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg16989719	chr2:238392110	NA	-0.37	-6.84	-0.32	2.75e-11	Prostate cancer;
LUAD	cis	rs34734847	0.787	rs7976497	chr12:121135467	T/C	cg27246729	chr12:121163418	ACADS	0.37	6.84	0.32	2.76e-11	Mean corpuscular volume;
LUAD	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg16414030	chr3:133502952	NA	-0.65	-12.3	-0.51	6.42e-30	Iron status biomarkers;
LUAD	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg07741184	chr6:167504864	NA	0.4	9.11	0.41	3.29e-18	Crohn's disease;
LUAD	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg08470875	chr2:26401718	FAM59B	-0.57	-7.67	-0.35	1.21e-13	Gut microbiome composition (summer);
LUAD	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs12760731	0.565	rs2095133	chr1:178198612	C/G	cg00404053	chr1:178313656	RASAL2	0.72	9.09	0.4	4.02e-18	Obesity-related traits;
LUAD	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg14779329	chr11:130786720	SNX19	0.38	6.71	0.31	6.42e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg15432903	chr11:17409602	KCNJ11	0.57	11.13	0.48	2e-25	Type 2 diabetes;
LUAD	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg15181151	chr6:150070149	PCMT1	0.43	8.71	0.39	6.7e-17	Lung cancer;
LUAD	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.17	15.97	0.61	2.92e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg02975922	chr3:195473998	MUC4	-0.42	-7.01	-0.32	9.31e-12	Pancreatic cancer;
LUAD	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.83	-12.77	-0.53	8.51e-32	Chronic sinus infection;
LUAD	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg07570687	chr10:102243282	WNT8B	0.45	6.93	0.32	1.61e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs12760731	0.565	rs34676994	chr1:178054513	A/T	cg00404053	chr1:178313656	RASAL2	0.73	9.08	0.4	4.27e-18	Obesity-related traits;
LUAD	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg10556349	chr10:835070	NA	0.68	8.13	0.37	4.75e-15	Eosinophil percentage of granulocytes;
LUAD	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg02221422	chr11:68192511	LRP5	-0.39	-6.36	-0.3	5.17e-10	Total body bone mineral density;
LUAD	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg23954153	chr1:44402353	ARTN	-0.38	-7.2	-0.33	2.83e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg24768116	chr2:27665128	KRTCAP3	-0.4	-11.0	-0.47	6.27e-25	Total body bone mineral density;
LUAD	cis	rs4845570	0.764	rs12122917	chr1:151716712	C/A	cg07092448	chr1:151763213	TDRKH	-0.71	-7.94	-0.36	1.89e-14	Coronary artery disease;
LUAD	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	9.95	0.44	4.17e-21	Lung cancer in ever smokers;
LUAD	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg00383909	chr3:49044727	WDR6	0.81	7.17	0.33	3.47e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	trans	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg07817883	chr1:32538562	TMEM39B	1.3	12.44	0.52	1.65e-30	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs12912251	0.591	rs2624272	chr15:39003409	A/G	cg01338139	chr15:38987640	C15orf53	0.49	6.74	0.31	5.23e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg27490568	chr2:178487706	NA	0.47	8.14	0.37	4.52e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.01	0.36	1.15e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg22532475	chr10:104410764	TRIM8	0.35	7.07	0.33	6.41e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.41	7.96	0.36	1.6e-14	Total body bone mineral density;
LUAD	cis	rs12530845	0.830	rs73721678	chr7:135355710	T/G	cg23117316	chr7:135346802	PL-5283	-0.5	-8.42	-0.38	6.04e-16	Red blood cell traits;
LUAD	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg21782813	chr7:2030301	MAD1L1	0.45	7.48	0.34	4.38e-13	Schizophrenia;
LUAD	cis	rs782590	0.875	rs62165175	chr2:55745810	T/A	cg18811423	chr2:55921094	PNPT1	0.44	7.28	0.33	1.66e-12	Metabolic syndrome;
LUAD	trans	rs10411161	0.748	rs17835306	chr19:52385266	G/A	cg22319618	chr22:45562946	NUP50	-0.65	-7.52	-0.34	3.26e-13	Breast cancer;
LUAD	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg00814883	chr7:100076585	TSC22D4	-0.86	-12.9	-0.53	2.51e-32	Platelet count;
LUAD	cis	rs2953145	0.545	rs2975751	chr2:241521135	G/A	cg07929629	chr2:241523174	NA	0.41	6.77	0.31	4.41e-11	Bipolar disorder;
LUAD	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg15226275	chr6:116381976	FRK	0.24	7.7	0.35	9.88e-14	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg15790184	chr11:494944	RNH1	0.59	7.23	0.33	2.24e-12	Body mass index;
LUAD	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.21	0.37	2.8e-15	Breast cancer;
LUAD	cis	rs6076065	0.962	rs2424529	chr20:23369317	A/G	cg11657817	chr20:23433608	CST11	0.47	9.54	0.42	1.11e-19	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg06784218	chr1:46089804	CCDC17	0.51	11.1	0.47	2.66e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs11681884	0.892	rs56060225	chr2:113838070	C/A	cg12858261	chr2:113808755	IL1F8	0.57	6.48	0.3	2.55e-10	Stroke;
LUAD	cis	rs6993813	0.872	rs4403440	chr8:120031575	A/G	cg01975934	chr8:119970761	NA	0.34	6.83	0.32	3.01e-11	Bone mineral density (hip);
LUAD	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg15147215	chr3:52552868	STAB1	-0.39	-7.17	-0.33	3.31e-12	Bipolar disorder;
LUAD	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24531977	chr5:56204891	C5orf35	-0.99	-14.95	-0.59	6.84e-41	Initial pursuit acceleration;
LUAD	cis	rs877282	0.945	rs35342920	chr10:790484	T/C	cg17470449	chr10:769945	NA	0.63	8.89	0.4	1.81e-17	Uric acid levels;
LUAD	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.44	0.55	1.59e-34	Prudent dietary pattern;
LUAD	cis	rs13082711	0.863	rs34611823	chr3:27500344	A/G	cg02860705	chr3:27208620	NA	0.58	8.92	0.4	1.38e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	7.47	0.34	4.54e-13	Menarche (age at onset);
LUAD	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg22823121	chr1:150693482	HORMAD1	-0.4	-7.45	-0.34	5.44e-13	Urate levels;
LUAD	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg02018176	chr4:1364513	KIAA1530	0.39	6.48	0.3	2.54e-10	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg01620082	chr3:125678407	NA	-0.71	-8.45	-0.38	4.92e-16	Breast cancer;
LUAD	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg16988262	chr1:15930761	NA	0.43	7.35	0.34	1.04e-12	Systolic blood pressure;
LUAD	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg11586124	chr12:58259160	NA	-0.38	-6.35	-0.3	5.49e-10	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs7940866	0.770	rs10791104	chr11:130814893	A/T	cg12179176	chr11:130786555	SNX19	0.45	7.14	0.33	4.09e-12	Schizophrenia;
LUAD	cis	rs9914988	0.887	rs7213285	chr17:27206029	G/A	cg02049041	chr17:27085579	C17orf63	0.63	7.14	0.33	4.04e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg09263875	chr16:632152	PIGQ	0.43	6.4	0.3	4.15e-10	Height;
LUAD	cis	rs11771526	0.901	rs10271047	chr7:32289660	A/C	cg27532318	chr7:32358331	NA	-0.52	-6.98	-0.32	1.14e-11	Body mass index;
LUAD	cis	rs870825	0.616	rs6552802	chr4:185620751	C/G	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg20119798	chr7:94954144	PON1	-0.47	-6.42	-0.3	3.76e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg03433033	chr1:76189801	ACADM	0.77	11.97	0.5	1.28e-28	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg06558623	chr16:89946397	TCF25	1.22	12.45	0.52	1.6e-30	Skin colour saturation;
LUAD	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.24	0.37	2.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg11871910	chr12:69753446	YEATS4	0.7	12.04	0.51	6.52e-29	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg21775007	chr8:11205619	TDH	0.36	6.44	0.3	3.28e-10	Neuroticism;
LUAD	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg00316803	chr15:76480434	C15orf27	-0.39	-7.42	-0.34	6.63e-13	Blood metabolite levels;
LUAD	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg24399712	chr22:39784796	NA	-0.7	-11.42	-0.49	1.57e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs1232027	0.666	rs1643637	chr5:79928909	T/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs62400317	0.859	rs10456548	chr6:45219699	T/C	cg20913747	chr6:44695427	NA	-0.41	-6.46	-0.3	2.88e-10	Total body bone mineral density;
LUAD	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg11707310	chr1:2537719	MMEL1	0.4	8.47	0.38	4.08e-16	Ulcerative colitis;
LUAD	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg06784218	chr1:46089804	CCDC17	0.59	13.3	0.54	5.93e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.64	11.15	0.48	1.67e-25	Birth weight;
LUAD	cis	rs7680126	0.596	rs4697714	chr4:10143786	A/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-6.87	-0.32	2.27e-11	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7107174	1.000	rs4945261	chr11:77990260	A/G	cg02023728	chr11:77925099	USP35	-0.52	-7.84	-0.36	3.69e-14	Testicular germ cell tumor;
LUAD	trans	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg12400702	chr3:12838781	CAND2	0.31	6.46	0.3	2.82e-10	Parkinson's disease;
LUAD	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg03233332	chr7:66118400	NA	0.43	6.47	0.3	2.74e-10	Aortic root size;
LUAD	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	7.03	0.32	8.11e-12	Platelet count;
LUAD	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg11645453	chr3:52864694	ITIH4	-0.54	-9.72	-0.43	2.74e-20	Schizophrenia;
LUAD	cis	rs853679	0.546	rs13213152	chr6:28349698	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.6	6.88	0.32	2.17e-11	Depression;
LUAD	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-7.42	-0.34	6.53e-13	Alzheimer's disease (late onset);
LUAD	cis	rs877282	0.891	rs12767043	chr10:797943	C/T	cg17470449	chr10:769945	NA	0.63	9.55	0.42	1.05e-19	Uric acid levels;
LUAD	cis	rs9972944	0.902	rs12939558	chr17:63772152	A/G	cg07283582	chr17:63770753	CCDC46	0.52	11.61	0.49	3.13e-27	Total body bone mineral density;
LUAD	trans	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.6	9.68	0.43	3.88e-20	Endometrial cancer;
LUAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg21733973	chr7:65235735	NA	-0.44	-7.19	-0.33	3.05e-12	Calcium levels;
LUAD	cis	rs868036	1.000	rs4776974	chr15:68095927	G/A	cg24579218	chr15:68104479	NA	-0.39	-7.41	-0.34	6.9e-13	Restless legs syndrome;
LUAD	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg15962314	chr1:44399869	ARTN	0.29	6.41	0.3	3.89e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg02158880	chr13:53174818	NA	0.44	7.34	0.34	1.09e-12	Lewy body disease;
LUAD	cis	rs12464483	0.524	rs4952172	chr2:30888286	A/G	cg12454169	chr2:30669597	LCLAT1	-0.55	-7.58	-0.35	2.28e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs10979	0.546	rs9496686	chr6:143908735	G/C	cg25407410	chr6:143891975	LOC285740	-0.54	-7.66	-0.35	1.31e-13	Hypospadias;
LUAD	cis	rs9462027	0.628	rs9469889	chr6:34763900	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.9	-0.4	1.61e-17	Systemic lupus erythematosus;
LUAD	cis	rs7274811	0.744	rs34489266	chr20:32223040	A/G	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.43	-6.42	-0.3	3.59e-10	Height;
LUAD	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg18016565	chr1:150552671	MCL1	-0.4	-7.02	-0.32	8.92e-12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUAD	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	8.43	0.38	5.31e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg11645453	chr3:52864694	ITIH4	-0.34	-6.6	-0.31	1.2e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.8	-0.31	3.58e-11	Post bronchodilator FEV1;
LUAD	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg00204512	chr16:28754710	NA	0.33	7.19	0.33	3e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg00316803	chr15:76480434	C15orf27	-0.41	-7.7	-0.35	9.5e-14	Blood metabolite levels;
LUAD	cis	rs2692947	0.537	rs72821435	chr2:96187935	C/T	cg23100626	chr2:96804247	ASTL	0.32	7.93	0.36	2.01e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs9399401	0.626	rs7756434	chr6:142775295	A/G	cg04461802	chr6:142623433	GPR126	0.38	7.1	0.33	5.26e-12	Chronic obstructive pulmonary disease;
LUAD	cis	rs1691799	0.867	rs1168343	chr12:66758581	C/T	cg16791601	chr12:66731901	HELB	-0.37	-6.68	-0.31	7.4e-11	White blood cell count (basophil);
LUAD	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg00290607	chr11:67383545	NA	0.4	6.59	0.31	1.32e-10	Mean corpuscular volume;
LUAD	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg27454412	chr7:1067447	C7orf50	0.48	7.73	0.35	7.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9902453	0.904	rs7212292	chr17:28409264	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-9.94	-0.44	4.71e-21	Coffee consumption (cups per day);
LUAD	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.77	-0.43	1.84e-20	Bipolar disorder and schizophrenia;
LUAD	trans	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.56	0.49	4.87e-27	Mean corpuscular volume;
LUAD	cis	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.27	0.37	1.73e-15	Eye color traits;
LUAD	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg26898376	chr11:64110657	CCDC88B	0.36	6.76	0.31	4.7e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08045932	chr20:61659980	NA	0.51	9.67	0.43	4.09e-20	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs4253772	0.872	rs79700435	chr22:46638211	G/A	cg09491104	chr22:46646882	C22orf40	-0.54	-7.71	-0.35	8.89e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	12.8	0.53	5.99e-32	Prudent dietary pattern;
LUAD	cis	rs10504073	0.584	rs55795863	chr8:49898055	A/G	cg00325661	chr8:49890786	NA	0.49	10.87	0.47	1.98e-24	Blood metabolite ratios;
LUAD	cis	rs11031096	0.601	rs4910589	chr11:4001916	A/C	cg18678763	chr11:4115507	RRM1	-0.39	-6.48	-0.3	2.63e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg23229984	chr5:148520753	ABLIM3	0.48	7.43	0.34	5.89e-13	Breast cancer;
LUAD	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg20503657	chr10:835505	NA	0.66	9.19	0.41	1.78e-18	Eosinophil percentage of granulocytes;
LUAD	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg23950597	chr19:37808831	NA	0.6	7.56	0.34	2.61e-13	Coronary artery calcification;
LUAD	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg01819759	chr13:79234251	RNF219	-0.46	-6.6	-0.31	1.2e-10	Large artery stroke;
LUAD	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6854137	0.587	rs6832048	chr4:169730717	A/C	cg20607169	chr4:169750834	PALLD	0.4	7.0	0.32	1.02e-11	Vein graft stenosis in coronary artery bypass grafting;
LUAD	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg04703951	chr17:43578652	NA	-0.56	-8.14	-0.37	4.38e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg05697835	chr1:2722811	NA	-0.32	-6.75	-0.31	4.85e-11	Ulcerative colitis;
LUAD	cis	rs420259	0.516	rs460477	chr16:23601237	G/A	cg00143387	chr16:23521605	GGA2	0.7	9.83	0.43	1.16e-20	Bipolar disorder;
LUAD	cis	rs13064411	0.660	rs1872747	chr3:113175785	T/A	cg18753928	chr3:113234510	CCDC52	-0.69	-11.19	-0.48	1.18e-25	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg14784868	chr12:69753453	YEATS4	0.44	7.1	0.33	5.35e-12	Blood protein levels;
LUAD	cis	rs6445967	0.530	rs12495722	chr3:58401595	C/T	cg13750441	chr3:58318267	PXK	-0.32	-6.74	-0.31	5.22e-11	Platelet count;
LUAD	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.6	-6.36	-0.3	5.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg11502198	chr6:26597334	ABT1	0.55	9.17	0.41	2.12e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg25894440	chr7:65020034	NA	-0.61	-6.5	-0.3	2.26e-10	Diabetic kidney disease;
LUAD	cis	rs7072216	0.763	rs6584200	chr10:100170037	A/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.68	-0.39	8.67e-17	Metabolite levels;
LUAD	cis	rs2938670	1	rs2938670	chr15:78740688	T/G	cg18825076	chr15:78729989	IREB2	-0.57	-10.05	-0.44	1.86e-21	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg00339695	chr16:24857497	SLC5A11	0.56	9.15	0.41	2.38e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7017914	0.967	rs1838393	chr8:71702591	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.44	-0.3	3.17e-10	Bone mineral density;
LUAD	trans	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.52	0.46	3.93e-23	Mean corpuscular volume;
LUAD	cis	rs9341808	0.739	rs4706831	chr6:81007699	T/C	cg08355045	chr6:80787529	NA	0.56	10.17	0.44	7.25e-22	Sitting height ratio;
LUAD	cis	rs13040088	1.000	rs12480870	chr20:61543606	A/C	cg23096297	chr20:61557774	DIDO1	0.74	10.29	0.45	2.52e-22	Menopause (age at onset);
LUAD	cis	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-8.07	-0.37	7.2e-15	Neuroticism;
LUAD	cis	rs6840360	0.533	rs4696295	chr4:152717430	T/C	cg22705602	chr4:152727874	NA	0.48	9.16	0.41	2.21e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg05754148	chr16:3507555	NAT15	-0.44	-6.68	-0.31	7.33e-11	Body mass index (adult);
LUAD	cis	rs7773004	0.905	rs1053860	chr6:26325228	C/T	cg00631329	chr6:26305371	NA	-0.52	-8.92	-0.4	1.45e-17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs9341808	0.754	rs9361591	chr6:80953255	C/A	cg08355045	chr6:80787529	NA	0.57	10.45	0.45	7.01e-23	Sitting height ratio;
LUAD	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.64	0.31	9.91e-11	Parkinson's disease;
LUAD	cis	rs6424115	1.000	rs7515969	chr1:24158398	G/A	cg15997130	chr1:24165203	NA	-0.56	-9.82	-0.43	1.25e-20	Immature fraction of reticulocytes;
LUAD	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg25809561	chr17:30822961	MYO1D	0.46	8.32	0.38	1.21e-15	Schizophrenia;
LUAD	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.22	-0.37	2.54e-15	Gout;Urate levels;Serum uric acid levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23958457	chr10:16859509	RSU1	-0.44	-6.96	-0.32	1.27e-11	Height;
LUAD	cis	rs9399401	0.589	rs2294775	chr6:142766347	C/G	cg04461802	chr6:142623433	GPR126	0.36	7.27	0.33	1.75e-12	Chronic obstructive pulmonary disease;
LUAD	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg24558204	chr6:135376177	HBS1L	0.48	8.88	0.4	1.94e-17	Reticulocyte count;High light scatter reticulocyte count;
LUAD	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.31	-0.33	1.36e-12	Lung cancer;
LUAD	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg05590025	chr7:65112418	INTS4L2	0.73	7.83	0.36	4.09e-14	Diabetic kidney disease;
LUAD	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12292205	chr6:26970375	C6orf41	-0.47	-6.53	-0.3	1.88e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.28	-0.41	9.19e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.42	7.59	0.35	2.1e-13	Tonsillectomy;
LUAD	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.33	6.58	0.3	1.39e-10	Parkinson's disease;
LUAD	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg21856205	chr7:94953877	PON1	-0.7	-13.44	-0.55	1.5e-34	Paraoxonase activity;
LUAD	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg16205897	chr5:131564050	P4HA2	-0.35	-7.56	-0.34	2.6e-13	Acylcarnitine levels;
LUAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg26554054	chr8:600488	NA	0.79	7.5	0.34	3.8e-13	IgG glycosylation;
LUAD	cis	rs41311933	1.000	rs41311911	chr9:123743921	C/T	cg13567360	chr9:123745713	C5	-0.78	-9.06	-0.4	4.89e-18	Coronary artery disease;
LUAD	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.35	-6.62	-0.31	1.1e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg24558204	chr6:135376177	HBS1L	0.43	7.37	0.34	8.89e-13	High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg20701182	chr2:24300061	SF3B14	0.56	6.52	0.3	2.05e-10	Lymphocyte counts;
LUAD	cis	rs4795519	0.744	rs1913802	chr17:22173056	T/C	cg22648282	chr17:21454238	C17orf51	-0.36	-6.48	-0.3	2.63e-10	Chronic myeloid leukemia;
LUAD	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg23985595	chr17:80112537	CCDC57	-0.51	-9.01	-0.4	7.09e-18	Life satisfaction;
LUAD	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg25036284	chr2:26402008	FAM59B	0.84	12.53	0.52	7.64e-31	Gut microbiome composition (summer);
LUAD	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg14092988	chr3:52407081	DNAH1	0.45	9.07	0.4	4.35e-18	Bipolar disorder;
LUAD	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.07	-0.33	6.37e-12	Height;
LUAD	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs9549367	0.569	rs3024719	chr13:113814225	G/A	cg18105134	chr13:113819100	PROZ	-1.01	-15.45	-0.6	5.3e-43	Platelet distribution width;
LUAD	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-11.18	-0.48	1.31e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2072499	0.966	rs2853646	chr1:156189626	C/T	cg25208724	chr1:156163844	SLC25A44	1.15	21.54	0.72	5.1e-70	Testicular germ cell tumor;
LUAD	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg16606324	chr3:10149918	C3orf24	0.68	11.37	0.48	2.59e-26	Alzheimer's disease;
LUAD	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg00316803	chr15:76480434	C15orf27	-0.41	-7.65	-0.35	1.33e-13	Blood metabolite levels;
LUAD	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg04756594	chr16:24857601	SLC5A11	-0.74	-12.55	-0.52	6.29e-31	Intelligence (multi-trait analysis);
LUAD	cis	rs77741769	0.529	rs2047568	chr12:121243790	A/G	cg02419362	chr12:121203948	SPPL3	-0.38	-7.88	-0.36	2.74e-14	Mean corpuscular volume;
LUAD	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg04833646	chr19:10679720	CDKN2D	0.75	11.21	0.48	1.03e-25	Red cell distribution width;
LUAD	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg04369109	chr6:150039330	LATS1	-0.46	-7.55	-0.34	2.77e-13	Lung cancer;
LUAD	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.95	-0.36	1.77e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg18306943	chr3:40428807	ENTPD3	0.42	7.14	0.33	4.11e-12	Renal cell carcinoma;
LUAD	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg04398451	chr17:18023971	MYO15A	-0.64	-11.64	-0.49	2.44e-27	Total body bone mineral density;
LUAD	cis	rs57590327	0.527	rs9845467	chr3:81614473	G/A	cg07356753	chr3:81810745	GBE1	-0.51	-7.71	-0.35	9.1e-14	Extraversion;
LUAD	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.33	0.34	1.15e-12	Menopause (age at onset);
LUAD	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg13902645	chr11:5959945	NA	-0.57	-10.09	-0.44	1.39e-21	DNA methylation (variation);
LUAD	cis	rs7131987	0.801	rs6487804	chr12:29454934	G/A	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.59	-0.31	1.33e-10	QT interval;
LUAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg17372223	chr3:52568218	NT5DC2	0.44	8.42	0.38	6.05e-16	Electroencephalogram traits;
LUAD	cis	rs4901869	0.897	rs12878587	chr14:59339378	C/G	cg02291164	chr14:59296302	NA	0.63	15.57	0.6	1.61e-43	Panic disorder;
LUAD	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.59e-12	Breast cancer;
LUAD	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg24675056	chr1:15929824	NA	0.49	8.43	0.38	5.55e-16	Systolic blood pressure;
LUAD	cis	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg05084668	chr3:125655381	ALG1L	-0.48	-7.47	-0.34	4.78e-13	Blood pressure (smoking interaction);
LUAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg03188948	chr7:1209495	NA	0.39	6.41	0.3	3.85e-10	Longevity;Endometriosis;
LUAD	cis	rs6060717	0.536	rs6060670	chr20:34481143	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.06	-0.32	7.08e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg15181151	chr6:150070149	PCMT1	0.41	8.49	0.38	3.63e-16	Lung cancer;
LUAD	cis	rs757081	0.667	rs476890	chr11:17209962	A/G	cg15432903	chr11:17409602	KCNJ11	-0.4	-6.41	-0.3	3.95e-10	Systolic blood pressure;
LUAD	cis	rs11622475	1.000	rs7143682	chr14:104413455	C/T	cg12183467	chr14:104352244	NA	-0.41	-7.32	-0.34	1.24e-12	Bipolar disorder;
LUAD	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg06112835	chr11:68658793	MRPL21	0.47	8.33	0.38	1.15e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11945232	0.790	rs6816224	chr4:88346510	G/A	cg23841344	chr4:88312519	HSD17B11	-0.46	-6.76	-0.31	4.49e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs11811982	0.793	rs79773617	chr1:227238308	T/G	cg24860534	chr1:227506868	CDC42BPA	0.68	7.11	0.33	4.83e-12	Optic disc area;
LUAD	cis	rs9308433	0.529	rs3767842	chr1:214498306	C/T	cg06198575	chr1:214491504	SMYD2	0.46	7.86	0.36	3.21e-14	IgG glycosylation;
LUAD	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.47	-7.71	-0.35	9.02e-14	Body mass index;
LUAD	cis	rs9296095	1.000	rs5745582	chr6:33546498	C/T	cg24505687	chr6:33548425	BAK1	0.42	6.99	0.32	1.07e-11	Platelet count;
LUAD	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg27094323	chr7:1216898	NA	-0.36	-6.52	-0.3	2.03e-10	Longevity;Endometriosis;
LUAD	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg21214613	chr1:16344536	HSPB7	0.49	9.11	0.4	3.37e-18	Dilated cardiomyopathy;
LUAD	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.78e-11	Crohn's disease;
LUAD	cis	rs3733418	0.929	rs4691138	chr4:165908641	A/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.52	-6.73	-0.31	5.69e-11	Obesity-related traits;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23961059	chr19:57874869	ZNF547;TRAPPC2P1	-0.43	-6.73	-0.31	5.47e-11	Height;
LUAD	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg06552810	chr11:31128660	NA	-0.34	-6.74	-0.31	5.3e-11	Red blood cell count;
LUAD	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg12940439	chr1:67600707	NA	0.45	8.56	0.38	2.06e-16	Psoriasis;
LUAD	cis	rs1371614	0.523	rs4233714	chr2:27181454	A/G	cg00617064	chr2:27272375	NA	0.35	6.45	0.3	3e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.51	0.34	3.51e-13	Morning vs. evening chronotype;
LUAD	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11644478	chr21:40555479	PSMG1	0.59	7.39	0.34	7.89e-13	Cognitive function;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg04835163	chr1:74663899	TNNI3K;FPGT;LRRIQ3	-0.4	-6.68	-0.31	7.61e-11	Schizophrenia;
LUAD	cis	rs9595066	0.627	rs9562536	chr13:44731588	G/A	cg04068111	chr13:44716778	NA	-0.56	-9.71	-0.43	2.85e-20	Schizophrenia;
LUAD	cis	rs7274811	0.779	rs13039908	chr20:32052070	G/A	cg13403462	chr20:32256071	NECAB3;C20orf134	-0.48	-7.25	-0.33	2.03e-12	Height;
LUAD	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-7.89	-0.36	2.7e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06112835	chr11:68658793	MRPL21	0.51	9.09	0.4	4e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg22532475	chr10:104410764	TRIM8	-0.6	-11.25	-0.48	6.99e-26	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-13.98	-0.56	8.87e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs7177699	0.557	rs11072807	chr15:79111517	A/G	cg15571903	chr15:79123663	NA	0.38	7.63	0.35	1.55e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs61897795	0.628	rs93923	chr11:61613745	C/T	cg19610905	chr11:61596333	FADS2	-0.71	-9.99	-0.44	3.11e-21	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs2066819	1.000	rs76430365	chr12:56699993	A/C	cg26714650	chr12:56694279	CS	-0.86	-7.23	-0.33	2.25e-12	Psoriasis vulgaris;
LUAD	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg12310025	chr6:25882481	NA	-1.03	-18.52	-0.67	1.7e-56	Urate levels;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg06730340	chr3:9811714	CAMK1	-0.48	-6.35	-0.3	5.71e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	trans	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg26043149	chr18:55253948	FECH	0.49	7.86	0.36	3.15e-14	Bone mineral density;
LUAD	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg11062466	chr8:58055876	NA	0.67	8.94	0.4	1.27e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs35952432	1	rs35952432	chr6:28074901	C/T	cg01620082	chr3:125678407	NA	-1.1	-10.56	-0.46	2.69e-23	Lung cancer;
LUAD	cis	rs4664308	0.935	rs4637057	chr2:160950161	G/T	cg03641300	chr2:160917029	PLA2R1	-0.37	-6.43	-0.3	3.44e-10	Idiopathic membranous nephropathy;
LUAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg13560548	chr3:10150139	C3orf24	0.4	6.44	0.3	3.24e-10	Alzheimer's disease;
LUAD	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg07217954	chr7:1067459	C7orf50	-0.36	-6.62	-0.31	1.12e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs6424115	0.546	rs35993651	chr1:24180613	C/G	cg15997130	chr1:24165203	NA	-0.6	-10.49	-0.45	5.02e-23	Immature fraction of reticulocytes;
LUAD	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.13e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.38	-8.21	-0.37	2.77e-15	Height;
LUAD	cis	rs6693567	0.565	rs1260458	chr1:150347454	C/T	cg15654264	chr1:150340011	RPRD2	0.36	6.4	0.3	4.24e-10	Migraine;
LUAD	cis	rs4148087	0.929	rs2381037	chr21:43612608	C/A	cg08841829	chr21:43638893	ABCG1	-0.58	-7.65	-0.35	1.4e-13	Eating disorder in bipolar disorder;
LUAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.85	-21.41	-0.72	2.04e-69	Longevity;Endometriosis;
LUAD	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg23625390	chr15:77176239	SCAPER	-0.52	-8.01	-0.36	1.14e-14	Blood metabolite levels;
LUAD	cis	rs12618769	0.570	rs116051325	chr2:99056836	G/A	cg10123293	chr2:99228465	UNC50	0.46	8.11	0.37	5.48e-15	Bipolar disorder;
LUAD	cis	rs1232027	0.700	rs1677667	chr5:79952541	C/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.94	-0.36	1.9e-14	Huntington's disease progression;
LUAD	cis	rs68170813	0.559	rs76307631	chr7:107058018	A/G	cg23024343	chr7:107201750	COG5	0.52	7.2	0.33	2.84e-12	Coronary artery disease;
LUAD	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg08885076	chr2:99613938	TSGA10	0.37	6.75	0.31	4.93e-11	Chronic sinus infection;
LUAD	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg23758822	chr17:41437982	NA	1.01	21.34	0.72	4.24e-69	Menopause (age at onset);
LUAD	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg16647868	chr5:131706066	SLC22A5	0.39	6.68	0.31	7.64e-11	Blood metabolite levels;
LUAD	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	8.05	0.36	8.64e-15	Rheumatoid arthritis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01727434	chr2:152118530	RBM43	-0.41	-6.55	-0.3	1.63e-10	Height;
LUAD	trans	rs12517041	1.000	rs12514453	chr5:23289951	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	0.46	6.66	0.31	8.45e-11	Calcium levels;
LUAD	cis	rs1448094	0.967	rs10746357	chr12:86341044	A/T	cg02569458	chr12:86230093	RASSF9	0.37	7.06	0.32	6.9e-12	Major depressive disorder;
LUAD	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03452623	chr4:187889614	NA	-0.82	-16.79	-0.63	7.9e-49	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg14917512	chr19:3094685	GNA11	-0.38	-6.52	-0.3	2.06e-10	Aortic root size;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg06826039	chr1:204379650	PPP1R15B	0.42	7.05	0.32	7.13e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs17152411	1.000	rs17152411	chr10:126649516	A/G	cg07906193	chr10:126599966	NA	0.54	7.75	0.35	6.82e-14	Height;
LUAD	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg13334819	chr7:99746414	C7orf59	0.65	10.48	0.45	5.28e-23	Coronary artery disease;
LUAD	cis	rs9902453	0.765	rs2628180	chr17:28101723	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-10.62	-0.46	1.61e-23	Coffee consumption (cups per day);
LUAD	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11644478	chr21:40555479	PSMG1	0.6	9.44	0.42	2.62e-19	Cognitive function;
LUAD	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg24818145	chr4:99064322	C4orf37	0.48	8.06	0.37	7.64e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.49	0.34	4.04e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.6	-7.19	-0.33	2.97e-12	Body mass index;
LUAD	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.51	-9.12	-0.41	3.13e-18	Alzheimer's disease (late onset);
LUAD	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.62	-7.48	-0.34	4.35e-13	Body mass index;
LUAD	cis	rs1865721	0.761	rs7242709	chr18:73222819	T/C	cg26385618	chr18:73139727	C18orf62	-0.36	-6.61	-0.31	1.19e-10	Intelligence;
LUAD	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg06636551	chr8:101224915	SPAG1	-0.38	-6.98	-0.32	1.17e-11	Atrioventricular conduction;
LUAD	trans	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg11693508	chr17:37793320	STARD3	0.6	7.45	0.34	5.33e-13	Neuroticism;
LUAD	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.55	-10.22	-0.45	4.62e-22	Longevity;Endometriosis;
LUAD	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.73	-14.89	-0.59	1.33e-40	Lung cancer;
LUAD	cis	rs12348691	0.503	rs7048394	chr9:100605433	T/C	cg13688889	chr9:100608707	NA	-0.62	-10.19	-0.44	5.75e-22	Alopecia areata;
LUAD	cis	rs6490294	0.583	rs4767296	chr12:112463366	T/C	cg10833066	chr12:111807467	FAM109A	0.35	6.56	0.3	1.61e-10	Mean platelet volume;
LUAD	cis	rs9807989	0.507	rs2058659	chr2:103054556	A/G	cg03938978	chr2:103052716	IL18RAP	-0.44	-10.23	-0.45	4.31e-22	Asthma;
LUAD	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg22875332	chr1:76189707	ACADM	0.93	19.43	0.69	1.39e-60	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7799006	1.000	rs7799006	chr7:2278226	C/T	cg02951883	chr7:2050386	MAD1L1	-0.52	-8.12	-0.37	5.1e-15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs1904173	0.799	rs1508171	chr5:25357222	T/A	cg08850729	chr1:60036715	FGGY	0.63	6.73	0.31	5.59e-11	IgG glycosylation;
LUAD	trans	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.94	-0.32	1.46e-11	Mood instability;
LUAD	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg00757033	chr12:89920650	WDR51B	0.69	12.13	0.51	3.01e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg00757033	chr12:89920650	WDR51B	0.7	12.07	0.51	4.92e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg15147215	chr3:52552868	STAB1	-0.42	-8.16	-0.37	3.9e-15	Bipolar disorder;
LUAD	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.83	-0.5	4.49e-28	Bipolar disorder;
LUAD	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg22105103	chr4:187893119	NA	0.53	11.38	0.48	2.26e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9796	0.870	rs4244584	chr15:41259523	A/G	cg21153102	chr15:41252147	NA	-0.27	-6.66	-0.31	8.32e-11	Menopause (age at onset);
LUAD	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.45	-0.38	4.73e-16	Neutrophil percentage of white cells;
LUAD	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg07570687	chr10:102243282	WNT8B	0.43	6.57	0.3	1.45e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9863	0.931	rs3186071	chr12:124429279	G/A	cg17723958	chr12:124429295	CCDC92	-0.42	-6.71	-0.31	6.41e-11	White blood cell count;
LUAD	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg11317459	chr13:21872234	NA	1.06	15.35	0.6	1.35e-42	White matter hyperintensity burden;
LUAD	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg12311346	chr5:56204834	C5orf35	-0.9	-13.45	-0.55	1.35e-34	Initial pursuit acceleration;
LUAD	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg26727032	chr16:67993705	SLC12A4	-0.54	-7.18	-0.33	3.21e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6066835	1.000	rs6066831	chr20:47354131	C/A	cg18078177	chr20:47281410	PREX1	0.69	6.41	0.3	3.84e-10	Multiple myeloma;
LUAD	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.65	-0.31	8.93e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs6594713	0.759	rs6894687	chr5:112742953	C/G	cg12552261	chr5:112820674	MCC	-0.41	-6.88	-0.32	2.17e-11	Brain cytoarchitecture;
LUAD	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg25456477	chr12:86230367	RASSF9	0.32	6.48	0.3	2.59e-10	Major depressive disorder;
LUAD	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	7.17	0.33	3.4e-12	Cognitive test performance;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg25943503	chr13:36705608	DCLK1	-0.47	-6.37	-0.3	5.05e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-6.57	-0.3	1.49e-10	Tonsillectomy;
LUAD	cis	rs2840044	1.000	rs11080357	chr17:33898933	G/A	cg05299278	chr17:33885742	SLFN14	-0.44	-8.91	-0.4	1.49e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg04194728	chr6:150232017	NA	0.35	6.74	0.31	5.21e-11	Testicular germ cell tumor;
LUAD	cis	rs13082711	0.871	rs73046194	chr3:27454558	C/T	cg02860705	chr3:27208620	NA	0.57	8.89	0.4	1.79e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs62400317	0.762	rs62436374	chr6:44874785	C/G	cg20913747	chr6:44695427	NA	-0.44	-6.94	-0.32	1.49e-11	Total body bone mineral density;
LUAD	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg02569458	chr12:86230093	RASSF9	0.45	8.25	0.37	2.02e-15	Major depressive disorder;
LUAD	cis	rs1113500	0.933	rs11185260	chr1:108635079	A/T	cg06207961	chr1:108661230	NA	-0.44	-8.31	-0.37	1.33e-15	Growth-regulated protein alpha levels;
LUAD	cis	rs367943	1.000	rs348948	chr5:112822452	A/C	cg12552261	chr5:112820674	MCC	-0.59	-11.17	-0.48	1.49e-25	Type 2 diabetes;
LUAD	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg25985355	chr7:65971099	NA	-0.4	-7.38	-0.34	8.44e-13	Aortic root size;
LUAD	cis	rs17641971	0.599	rs2385230	chr8:50015755	A/G	cg00325661	chr8:49890786	NA	0.3	6.77	0.31	4.32e-11	Blood metabolite levels;
LUAD	cis	rs7584330	0.554	rs116656801	chr2:238431257	A/G	cg14458575	chr2:238380390	NA	0.61	9.69	0.43	3.37e-20	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.72	0.31	6.02e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11585357	0.895	rs2977305	chr1:17613737	A/T	cg08277548	chr1:17600880	PADI3	0.83	12.71	0.53	1.45e-31	Hair shape;
LUAD	cis	rs7737355	0.898	rs4706024	chr5:130904163	G/A	cg06307176	chr5:131281290	NA	0.5	7.88	0.36	2.75e-14	Life satisfaction;
LUAD	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg09117114	chr16:67998030	SLC12A4	-0.57	-7.55	-0.34	2.65e-13	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg26043149	chr18:55253948	FECH	-0.41	-6.89	-0.32	2.03e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7107174	1.000	rs7116611	chr11:78030046	A/G	cg02023728	chr11:77925099	USP35	0.51	7.71	0.35	8.83e-14	Testicular germ cell tumor;
LUAD	cis	rs12545109	0.837	rs1437277	chr8:57356734	T/C	cg21220214	chr8:57350948	NA	-0.67	-9.22	-0.41	1.44e-18	Obesity-related traits;
LUAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	9.23	0.41	1.32e-18	Alzheimer's disease;
LUAD	cis	rs2386661	0.603	rs11259704	chr10:5646999	C/T	cg26603656	chr10:5671107	NA	0.35	6.39	0.3	4.51e-10	Breast cancer;
LUAD	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg20119798	chr7:94954144	PON1	-0.46	-6.39	-0.3	4.35e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs250677	0.522	rs891920	chr5:148369418	G/T	cg18129178	chr5:148520854	ABLIM3	-0.51	-7.62	-0.35	1.72e-13	Breast cancer;
LUAD	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg15448220	chr1:150897856	SETDB1	-0.46	-7.85	-0.36	3.34e-14	Monocyte chemoattractant protein-1 levels;
LUAD	cis	rs7851660	0.967	rs7847126	chr9:100600635	A/C	cg13688889	chr9:100608707	NA	-0.52	-9.61	-0.42	6.33e-20	Strep throat;
LUAD	cis	rs2274273	0.805	rs7159808	chr14:55624327	G/T	cg04306507	chr14:55594613	LGALS3	0.41	8.41	0.38	6.4e-16	Protein biomarker;
LUAD	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg13877915	chr19:58951672	ZNF132	0.73	13.76	0.56	7.14e-36	Uric acid clearance;
LUAD	cis	rs75920871	0.623	rs7928320	chr11:116942753	C/T	cg04087571	chr11:116723030	SIK3	-0.31	-7.41	-0.34	6.76e-13	Subjective well-being;
LUAD	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg00701064	chr4:6280414	WFS1	0.67	14.27	0.57	5.37e-38	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2274273	0.686	rs66531545	chr14:55587460	T/C	cg04306507	chr14:55594613	LGALS3	0.4	7.36	0.34	9.66e-13	Protein biomarker;
LUAD	cis	rs6432018	0.897	rs7556678	chr2:9755366	T/C	cg12832956	chr2:9616023	IAH1	-0.38	-6.66	-0.31	8.62e-11	Heart rate variability traits;
LUAD	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg14893161	chr1:205819251	PM20D1	0.52	8.07	0.37	7.32e-15	Menarche (age at onset);
LUAD	trans	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg03886242	chr7:26192032	NFE2L3	-0.46	-8.1	-0.37	5.78e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg09455208	chr3:40491958	NA	0.57	12.16	0.51	2.3e-29	Renal cell carcinoma;
LUAD	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg24813613	chr7:1882135	MAD1L1	-0.45	-7.1	-0.33	5.25e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs494562	0.892	rs632163	chr6:86122062	C/T	cg21730993	chr6:86159210	NT5E	0.68	8.05	0.36	8.19e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs2985684	0.894	rs4900928	chr14:50020817	A/G	cg04989706	chr14:50066350	PPIL5	-0.51	-7.61	-0.35	1.85e-13	Carotid intima media thickness;
LUAD	cis	rs6754311	0.731	rs218174	chr2:136658345	C/T	cg07305463	chr2:136567211	LCT	0.37	7.04	0.32	8.02e-12	Mosquito bite size;
LUAD	cis	rs11809207	1.000	rs11247867	chr1:26517891	C/T	cg00300879	chr1:26503847	CNKSR1	0.28	6.82	0.31	3.17e-11	Height;
LUAD	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.18	0.41	1.91e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg21385522	chr1:16154831	NA	-0.56	-9.24	-0.41	1.26e-18	Systolic blood pressure;
LUAD	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg04398451	chr17:18023971	MYO15A	0.64	11.2	0.48	1.16e-25	Total body bone mineral density;
LUAD	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg05590025	chr7:65112418	INTS4L2	0.73	7.84	0.36	3.67e-14	Diabetic kidney disease;
LUAD	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.18	0.37	3.44e-15	Breast cancer;
LUAD	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg25767906	chr1:53392781	SCP2	-0.42	-7.49	-0.34	4.02e-13	Monocyte count;
LUAD	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg02951883	chr7:2050386	MAD1L1	-0.74	-12.56	-0.52	5.81e-31	Bipolar disorder and schizophrenia;
LUAD	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg05110241	chr16:68378359	PRMT7	-0.83	-9.03	-0.4	6.05e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2404618	0.624	rs4338133	chr8:1477507	T/C	cg02903104	chr8:1507517	DLGAP2	0.33	7.11	0.33	5.1e-12	Lung cancer;
LUAD	cis	rs4730250	0.707	rs78472146	chr7:106967491	C/A	cg02696742	chr7:106810147	HBP1	-0.77	-10.45	-0.45	6.71e-23	Osteoarthritis;
LUAD	cis	rs6494488	0.500	rs112640485	chr15:64740810	G/A	cg08069370	chr15:64387884	SNX1	-0.75	-6.73	-0.31	5.58e-11	Coronary artery disease;
LUAD	cis	rs2625529	0.652	rs2957736	chr15:72265344	A/G	cg16672083	chr15:72433130	SENP8	0.65	12.29	0.51	6.63e-30	Red blood cell count;
LUAD	cis	rs17092148	0.790	rs6058079	chr20:33142873	G/A	cg16810054	chr20:33298113	TP53INP2	-0.47	-7.09	-0.33	5.56e-12	Neuroticism;
LUAD	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg22508957	chr16:3507546	NAT15	-0.38	-6.45	-0.3	3.06e-10	Body mass index (adult);
LUAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg21724239	chr8:58056113	NA	-0.76	-9.79	-0.43	1.58e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs11811982	0.793	rs74978094	chr1:227502659	A/C	cg24860534	chr1:227506868	CDC42BPA	0.68	7.35	0.34	1.01e-12	Optic disc area;
LUAD	trans	rs1493916	0.905	rs12455290	chr18:31398778	A/G	cg13755796	chr4:20253514	NA	-0.44	-7.55	-0.34	2.64e-13	Life satisfaction;
LUAD	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.56	-9.29	-0.41	8e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04760117	chr10:75900017	AP3M1	0.51	7.69	0.35	1.07e-13	Hepatitis;
LUAD	cis	rs438034	1.000	rs387535	chr1:214829010	G/A	cg16144317	chr1:214725524	PTPN14	-0.34	-6.37	-0.3	5.04e-10	Response to antineoplastic agents;
LUAD	cis	rs12134245	0.755	rs11164928	chr1:92012678	G/A	cg12403142	chr1:92012408	NA	-0.4	-7.22	-0.33	2.51e-12	Breast cancer;
LUAD	cis	rs3760982	1.000	rs12460161	chr19:44293986	C/A	cg11993925	chr19:44307056	LYPD5	0.45	8.76	0.39	4.66e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs6998277	1.000	rs62523306	chr8:103640752	C/A	cg10187029	chr8:103597600	NA	0.79	12.19	0.51	1.63e-29	Migraine;
LUAD	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.48	-0.58	7.21e-39	Schizophrenia;
LUAD	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-8.03	-0.36	9.8e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg15017067	chr4:17643749	FAM184B	0.37	7.19	0.33	3.03e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg07010633	chr17:73824396	UNC13D	-0.32	-6.51	-0.3	2.17e-10	White matter hyperintensity burden;
LUAD	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg06641503	chr3:48959341	ARIH2	-0.39	-7.61	-0.35	1.76e-13	Parkinson's disease;
LUAD	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg12935359	chr14:103987150	CKB	-0.48	-7.82	-0.36	4.26e-14	Body mass index;
LUAD	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg15704280	chr7:45808275	SEPT13	0.63	8.33	0.38	1.11e-15	Axial length;
LUAD	cis	rs10992471	0.580	rs10122383	chr9:95554675	A/G	cg14631576	chr9:95140430	CENPP	-0.46	-8.27	-0.37	1.71e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg13390004	chr1:15929781	NA	0.49	8.74	0.39	5.72e-17	Systolic blood pressure;
LUAD	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg14324370	chr2:177042789	NA	0.39	7.34	0.34	1.07e-12	IgG glycosylation;
LUAD	cis	rs10193935	0.901	rs13022188	chr2:42704423	A/C	cg27598129	chr2:42591480	NA	0.78	9.37	0.41	4.23e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg26384229	chr12:38710491	ALG10B	-0.39	-6.59	-0.31	1.33e-10	Morning vs. evening chronotype;
LUAD	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg24829409	chr8:58192753	C8orf71	-0.6	-7.14	-0.33	4.2e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2485376	0.967	rs4919623	chr10:104013092	G/C	cg20641465	chr10:103991465	PITX3	0.57	10.19	0.44	5.83e-22	QT interval;
LUAD	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg21960279	chr19:17905606	B3GNT3	0.47	8.9	0.4	1.65e-17	Tumor biomarkers;
LUAD	cis	rs1003719	0.679	rs2246285	chr21:38582431	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-7.89	-0.36	2.63e-14	Eye color traits;
LUAD	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg11822812	chr5:140052017	DND1	0.38	6.73	0.31	5.4e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.99	-0.36	1.25e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg00316803	chr15:76480434	C15orf27	0.41	6.53	0.3	1.86e-10	Blood metabolite levels;
LUAD	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg11645453	chr3:52864694	ITIH4	0.64	12.25	0.51	9.8e-30	Schizophrenia;
LUAD	cis	rs68170813	0.559	rs2107319	chr7:106863744	T/C	cg23024343	chr7:107201750	COG5	0.45	6.71	0.31	6.39e-11	Coronary artery disease;
LUAD	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg23649088	chr2:200775458	C2orf69	-0.54	-7.09	-0.33	5.58e-12	Schizophrenia;
LUAD	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg13606994	chr1:44402422	ARTN	-0.31	-6.63	-0.31	1.01e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg22705602	chr4:152727874	NA	-0.48	-9.04	-0.4	5.75e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg06627628	chr2:24431161	ITSN2	-0.69	-11.0	-0.47	6.25e-25	Asthma;
LUAD	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24531977	chr5:56204891	C5orf35	-0.97	-14.62	-0.58	1.72e-39	Initial pursuit acceleration;
LUAD	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg16680214	chr1:154839983	KCNN3	-0.62	-11.98	-0.5	1.14e-28	Prostate cancer;
LUAD	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03264133	chr6:25882463	NA	-0.58	-9.45	-0.42	2.35e-19	Blood metabolite levels;
LUAD	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg01448562	chr3:133502909	NA	-0.67	-12.31	-0.51	5.5e-30	Iron status biomarkers;
LUAD	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg00933542	chr6:150070202	PCMT1	0.36	7.53	0.34	3.06e-13	Testicular germ cell tumor;
LUAD	cis	rs7851660	0.844	rs4743139	chr9:100638420	A/G	cg13688889	chr9:100608707	NA	-0.52	-8.82	-0.39	3.09e-17	Strep throat;
LUAD	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg21238619	chr17:78079768	GAA	-0.34	-7.16	-0.33	3.6e-12	Yeast infection;
LUAD	cis	rs6782228	0.606	rs2811490	chr3:128351755	C/T	cg16766828	chr3:128327626	NA	-0.38	-7.17	-0.33	3.29e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg10518543	chr12:38710700	ALG10B	0.5	8.38	0.38	8.03e-16	Morning vs. evening chronotype;
LUAD	cis	rs7851660	0.809	rs10115216	chr9:100657119	G/T	cg13688889	chr9:100608707	NA	0.46	7.81	0.36	4.42e-14	Strep throat;
LUAD	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg21918786	chr6:109611834	NA	-0.59	-10.72	-0.46	7.17e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs34638657	0.732	rs4889477	chr16:82201302	C/T	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.95	-0.32	1.43e-11	Lung adenocarcinoma;
LUAD	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg23815491	chr16:72088622	HP	0.52	9.48	0.42	1.9e-19	Fibrinogen levels;
LUAD	cis	rs6961069	0.749	rs4316098	chr7:80259988	C/T	cg04458919	chr7:80252533	CD36	0.37	7.05	0.32	7.34e-12	Platelet count;
LUAD	cis	rs28830936	1.000	rs4924575	chr15:42096926	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.34	-6.92	-0.32	1.64e-11	Diastolic blood pressure;
LUAD	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg18512352	chr11:47633146	NA	0.46	8.06	0.36	8.04e-15	Subjective well-being;
LUAD	cis	rs7737355	0.812	rs6868007	chr5:130824810	T/C	cg06307176	chr5:131281290	NA	0.44	7.18	0.33	3.14e-12	Life satisfaction;
LUAD	cis	rs57502260	0.704	rs72936599	chr11:68320405	G/A	cg16797656	chr11:68205561	LRP5	0.46	6.63	0.31	1.04e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg24130564	chr14:104152367	KLC1	-0.57	-10.08	-0.44	1.47e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg10523679	chr1:76189770	ACADM	-0.89	-15.06	-0.59	2.51e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs300703	0.542	rs415660	chr2:189972	C/T	cg21211680	chr2:198530	NA	0.55	8.07	0.37	7.41e-15	Blood protein levels;
LUAD	trans	rs7395662	0.895	rs7924481	chr11:48582457	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.55	-0.3	1.67e-10	HDL cholesterol;
LUAD	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg23985595	chr17:80112537	CCDC57	-0.51	-9.27	-0.41	9.89e-19	Life satisfaction;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20026651	chr20:3776748	CDC25B	-0.56	-7.07	-0.33	6.38e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg18131467	chr2:239335373	ASB1	0.59	9.1	0.4	3.46e-18	Multiple system atrophy;
LUAD	cis	rs76419734	0.614	rs17035936	chr4:106525864	T/G	cg05309399	chr4:106552544	FLJ20184	-0.55	-6.72	-0.31	5.88e-11	Post bronchodilator FEV1;
LUAD	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21659725	chr3:3221576	CRBN	-0.5	-8.25	-0.37	2.03e-15	Body mass index;
LUAD	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg23625390	chr15:77176239	SCAPER	0.37	6.53	0.3	1.86e-10	Blood metabolite levels;
LUAD	trans	rs3198697	0.663	rs12928099	chr16:15150505	C/A	cg04492929	chr16:2155436	PKD1	-0.42	-6.54	-0.3	1.75e-10	Triglycerides;
LUAD	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg02421172	chr7:1938701	MAD1L1	-0.45	-6.45	-0.3	3.1e-10	Bipolar disorder;
LUAD	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg07414643	chr4:187882934	NA	-0.31	-6.4	-0.3	4.22e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26314531	chr2:26401878	FAM59B	-0.63	-8.4	-0.38	6.64e-16	Gut microbiome composition (summer);
LUAD	cis	rs16858210	0.874	rs73177525	chr3:183570286	G/C	cg01324343	chr3:183735012	ABCC5	0.41	6.46	0.3	2.87e-10	Menopause (age at onset);
LUAD	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg02136620	chr5:178986620	RUFY1	-0.39	-6.43	-0.3	3.37e-10	Lung cancer;
LUAD	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg04990556	chr1:26633338	UBXN11	-0.4	-6.65	-0.31	8.94e-11	Obesity-related traits;
LUAD	cis	rs12711979	0.566	rs1111281	chr2:3855896	C/T	cg17052675	chr2:3827356	NA	-0.4	-7.24	-0.33	2.2e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs11800820	0.536	rs61839815	chr1:246633791	T/C	cg16700716	chr1:246684329	NA	-0.39	-7.29	-0.33	1.57e-12	Obesity-related traits;
LUAD	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg22532475	chr10:104410764	TRIM8	-0.43	-8.41	-0.38	6.17e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1595825	0.891	rs58111212	chr2:198889896	T/C	cg00982548	chr2:198649783	BOLL	-0.65	-9.16	-0.41	2.31e-18	Ulcerative colitis;
LUAD	cis	rs9326248	0.581	rs10502222	chr11:116833730	C/T	cg20608306	chr11:116969690	SIK3	0.3	6.79	0.31	3.87e-11	Blood protein levels;
LUAD	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg02985366	chr16:32360428	NA	-0.4	-6.96	-0.32	1.28e-11	Menopause (age at onset);
LUAD	cis	rs7945705	0.846	rs905290	chr11:8753729	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.32	6.46	0.3	2.93e-10	Hemoglobin concentration;
LUAD	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg08029281	chr1:67600428	NA	0.36	7.0	0.32	1.02e-11	Psoriasis;
LUAD	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg19700328	chr14:106028568	NA	-0.46	-7.88	-0.36	2.78e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUAD	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg07917127	chr4:99064746	C4orf37	0.41	6.72	0.31	6.05e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg10544611	chr16:67998164	SLC12A4	-0.58	-7.28	-0.33	1.68e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg03714773	chr7:91764589	CYP51A1	0.29	6.85	0.32	2.57e-11	Breast cancer;
LUAD	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg14598338	chr9:96623480	NA	-0.42	-9.03	-0.4	6.13e-18	DNA methylation (variation);
LUAD	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg03037974	chr15:76606532	NA	0.48	11.14	0.48	1.86e-25	Blood metabolite levels;
LUAD	cis	rs4853036	0.680	rs12612925	chr2:70112580	C/T	cg02498382	chr2:70120550	SNRNP27	-0.52	-7.52	-0.34	3.37e-13	Colorectal or endometrial cancer;
LUAD	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg26597838	chr10:835615	NA	1.02	15.94	0.61	3.89e-45	Eosinophil percentage of granulocytes;
LUAD	trans	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg07211511	chr3:129823064	LOC729375	-0.55	-7.08	-0.33	5.92e-12	Blood pressure (smoking interaction);
LUAD	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	7.22	0.33	2.44e-12	Menarche (age at onset);
LUAD	cis	rs56346965	0.788	rs744600	chr2:191564757	G/T	cg27211696	chr2:191398769	TMEM194B	0.43	7.35	0.34	1e-12	Bone mineral density (Ward's triangle area);
LUAD	cis	rs1997103	1.000	rs6957984	chr7:55397331	G/A	cg17469321	chr7:55412551	NA	0.67	11.41	0.49	1.73e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.34	-6.82	-0.31	3.09e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUAD	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11890956	chr21:40555474	PSMG1	0.58	7.73	0.35	8.12e-14	Cognitive function;
LUAD	cis	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg05084668	chr3:125655381	ALG1L	-0.63	-10.09	-0.44	1.39e-21	Blood pressure (smoking interaction);
LUAD	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg25985355	chr7:65971099	NA	-0.55	-6.76	-0.31	4.56e-11	Diabetic kidney disease;
LUAD	trans	rs1941687	0.563	rs7238931	chr18:31334993	G/A	cg13755796	chr4:20253514	NA	-0.4	-6.73	-0.31	5.65e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-8.1	-0.37	6.08e-15	Body mass index;
LUAD	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11890956	chr21:40555474	PSMG1	0.79	13.4	0.55	2.32e-34	Cognitive function;
LUAD	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg05110241	chr16:68378359	PRMT7	-0.8	-8.8	-0.39	3.6e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg06784218	chr1:46089804	CCDC17	-0.49	-10.67	-0.46	1.11e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg12193833	chr17:30244370	NA	-0.57	-6.85	-0.32	2.56e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs2735413	0.918	rs12924772	chr16:78083115	T/C	cg04733911	chr16:78082701	NA	-0.35	-8.21	-0.37	2.74e-15	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs220324	0.738	rs9325631	chr21:43590845	A/C	cg09727148	chr21:43560719	UMODL1	0.46	6.72	0.31	5.71e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08280861	chr8:58055591	NA	0.53	6.38	0.3	4.59e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18404041	chr3:52824283	ITIH1	-0.57	-12.02	-0.5	7.99e-29	Electroencephalogram traits;
LUAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg02951883	chr7:2050386	MAD1L1	0.95	18.55	0.67	1.23e-56	Bipolar disorder and schizophrenia;
LUAD	cis	rs71403859	0.803	rs17282500	chr16:71633653	C/A	cg08717414	chr16:71523259	ZNF19	-0.55	-6.5	-0.3	2.23e-10	Post bronchodilator FEV1;
LUAD	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg19318889	chr4:1322082	MAEA	0.46	8.06	0.36	8.1e-15	Obesity-related traits;
LUAD	cis	rs2859741	1.000	rs543121	chr1:37497098	T/C	cg09363841	chr1:37513479	NA	-0.34	-8.38	-0.38	8.02e-16	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg25985355	chr7:65971099	NA	-0.56	-6.97	-0.32	1.25e-11	Diabetic kidney disease;
LUAD	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg15105011	chr4:940614	TMEM175	0.52	8.15	0.37	4.28e-15	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg13319975	chr6:146136371	FBXO30	-0.58	-9.74	-0.43	2.39e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6867032	1.000	rs61177713	chr5:2017255	G/A	cg26168224	chr5:2018326	NA	0.79	17.8	0.65	2.53e-53	Gut microbiome composition (winter);
LUAD	cis	rs986417	0.818	rs10151839	chr14:60980688	T/G	cg27398547	chr14:60952738	C14orf39	0.66	7.7	0.35	9.92e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg26587870	chr6:27730563	NA	-0.48	-7.86	-0.36	3.11e-14	Parkinson's disease;
LUAD	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.62	-0.42	5.86e-20	Platelet count;
LUAD	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.84e-26	Alzheimer's disease (late onset);
LUAD	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg20673091	chr1:2541236	MMEL1	0.37	7.72	0.35	8.39e-14	Ulcerative colitis;
LUAD	cis	rs243505	0.660	rs3807450	chr7:148522269	C/A	cg09806900	chr7:148480153	CUL1	0.41	6.35	0.3	5.41e-10	Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg09092174	chr22:39190118	DNAL4	-0.45	-7.17	-0.33	3.36e-12	Height;
LUAD	cis	rs6577655	0.517	rs9693237	chr8:135578218	G/A	cg17885191	chr8:135476712	NA	0.63	8.25	0.37	2.08e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs3772130	1.000	rs11714406	chr3:121372513	C/T	cg20356878	chr3:121714668	ILDR1	0.48	7.39	0.34	7.89e-13	Cognitive performance;
LUAD	cis	rs4253772	0.575	rs9615979	chr22:46789021	G/T	cg00784671	chr22:46762841	CELSR1	-0.66	-7.74	-0.35	7.34e-14	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg12927641	chr6:109611667	NA	-0.51	-8.85	-0.4	2.34e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg09537434	chr19:41945824	ATP5SL	-0.51	-8.19	-0.37	3.11e-15	Height;
LUAD	cis	rs1595825	0.891	rs73054817	chr2:198623751	A/G	cg11031976	chr2:198649780	BOLL	-0.48	-7.01	-0.32	9.37e-12	Ulcerative colitis;
LUAD	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg02002194	chr4:3960332	NA	-0.29	-6.78	-0.31	4.04e-11	Mood instability;
LUAD	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg09399716	chr2:46890238	NA	-0.38	-7.01	-0.32	9.45e-12	Height;
LUAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg27094323	chr7:1216898	NA	-0.36	-6.97	-0.32	1.23e-11	Longevity;Endometriosis;
LUAD	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg00701064	chr4:6280414	WFS1	0.67	14.33	0.57	3.11e-38	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg03188948	chr7:1209495	NA	0.66	8.7	0.39	7.18e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs727505	1.000	rs28844358	chr7:124562695	A/C	cg23710748	chr7:124431027	NA	-0.46	-9.3	-0.41	7.34e-19	Lewy body disease;
LUAD	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg06740227	chr12:86229804	RASSF9	0.46	8.06	0.37	7.67e-15	Major depressive disorder;
LUAD	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg27284194	chr4:1044797	NA	0.69	10.04	0.44	2.06e-21	Recombination rate (females);
LUAD	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg00495681	chr13:53174319	NA	0.5	8.92	0.4	1.46e-17	Lewy body disease;
LUAD	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18404041	chr3:52824283	ITIH1	0.58	11.49	0.49	8.88e-27	Bipolar disorder;
LUAD	cis	rs7095607	0.777	rs7919994	chr10:69931144	T/G	cg18986048	chr10:69913749	MYPN	0.37	6.38	0.3	4.55e-10	Lung function (FVC);
LUAD	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg15448220	chr1:150897856	SETDB1	0.46	7.98	0.36	1.39e-14	Tonsillectomy;
LUAD	cis	rs9296095	0.948	rs75080135	chr6:33552707	A/C	cg24505687	chr6:33548425	BAK1	0.45	7.01	0.32	9.62e-12	Platelet count;
LUAD	cis	rs6732160	0.932	rs6546802	chr2:73379564	G/A	cg01422370	chr2:73384389	NA	0.34	6.84	0.32	2.74e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg22105103	chr4:187893119	NA	0.58	12.85	0.53	4.05e-32	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg19622623	chr12:86230825	RASSF9	-0.53	-9.36	-0.41	4.8e-19	Major depressive disorder;
LUAD	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg25319279	chr11:5960081	NA	0.38	7.09	0.33	5.69e-12	DNA methylation (variation);
LUAD	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.43	-0.6	6.11e-43	Chronic sinus infection;
LUAD	cis	rs7944584	0.632	rs749067	chr11:47318157	T/C	cg20307385	chr11:47447363	PSMC3	0.45	7.07	0.33	6.34e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg04450456	chr4:17643702	FAM184B	0.43	8.45	0.38	4.86e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg18944383	chr4:111397179	ENPEP	0.42	8.22	0.37	2.45e-15	Height;
LUAD	cis	rs6426558	0.537	rs6662583	chr1:227383889	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.52	-8.33	-0.38	1.13e-15	Neutrophil percentage of white cells;
LUAD	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg26554054	chr8:600488	NA	0.81	8.04	0.36	9.21e-15	IgG glycosylation;
LUAD	cis	rs1451375	0.572	rs4948205	chr7:50557774	G/A	cg18232548	chr7:50535776	DDC	-0.64	-8.92	-0.4	1.39e-17	Malaria;
LUAD	cis	rs73206853	0.609	rs7306167	chr12:110892449	A/G	cg12870014	chr12:110450643	ANKRD13A	0.61	6.86	0.32	2.51e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs16858210	0.874	rs35717944	chr3:183607361	C/A	cg01324343	chr3:183735012	ABCC5	0.42	6.37	0.3	4.95e-10	Menopause (age at onset);
LUAD	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg05340658	chr4:99064831	C4orf37	0.54	9.15	0.41	2.47e-18	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7395662	1.000	rs10769371	chr11:48531184	G/A	cg15704280	chr7:45808275	SEPT13	-0.41	-6.41	-0.3	3.84e-10	HDL cholesterol;
LUAD	cis	rs2901656	0.546	rs9425598	chr1:172371922	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.46	8.98	0.4	9.1e-18	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs7975161	0.630	rs4129598	chr12:104620638	T/C	cg25273343	chr12:104657179	TXNRD1	-0.63	-6.93	-0.32	1.62e-11	Toenail selenium levels;
LUAD	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.42e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg27494647	chr7:150038898	RARRES2	0.54	9.6	0.42	7.12e-20	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg00852783	chr1:26633632	UBXN11	0.44	7.68	0.35	1.13e-13	Obesity-related traits;
LUAD	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg07587117	chr16:2239488	CASKIN1	-0.41	-8.1	-0.37	6.08e-15	Height;
LUAD	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg22852734	chr6:133119734	C6orf192	0.96	7.23	0.33	2.32e-12	Type 2 diabetes nephropathy;
LUAD	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg12140854	chr5:148520817	ABLIM3	-0.67	-10.92	-0.47	1.29e-24	Breast cancer;
LUAD	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.22	-0.54	1.24e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.45	-0.3	2.97e-10	Prostate cancer;
LUAD	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg10167378	chr1:228756711	NA	0.43	7.33	0.34	1.14e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg00666640	chr1:248458726	OR2T12	0.31	7.62	0.35	1.64e-13	Common traits (Other);
LUAD	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg23719950	chr11:63933701	MACROD1	-0.58	-6.87	-0.32	2.36e-11	Mean platelet volume;
LUAD	cis	rs4853036	1.000	rs11903034	chr2:70060278	T/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-8.0	-0.36	1.21e-14	Colorectal or endometrial cancer;
LUAD	cis	rs750460	1.000	rs12905253	chr15:74232437	G/A	cg23484268	chr15:74220776	LOXL1	-0.35	-6.72	-0.31	5.72e-11	Height;
LUAD	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.21e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2230307	0.536	rs629340	chr1:100538621	A/T	cg20868668	chr1:100435035	SLC35A3	0.51	7.55	0.34	2.79e-13	Carotid intima media thickness;
LUAD	cis	rs72634258	0.554	rs7556518	chr1:7847846	G/A	cg26816564	chr1:7831052	VAMP3	0.68	9.28	0.41	8.92e-19	Inflammatory bowel disease;
LUAD	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg00814883	chr7:100076585	TSC22D4	-0.8	-11.59	-0.49	3.55e-27	Platelet count;
LUAD	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg00814883	chr7:100076585	TSC22D4	-0.81	-11.28	-0.48	5.72e-26	Platelet count;
LUAD	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.29	0.37	1.53e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6062509	1.000	rs6062509	chr20:62362563	G/T	cg21849932	chr20:62369462	LIME1	-0.48	-7.49	-0.34	4.06e-13	Prostate cancer;
LUAD	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.43	-0.45	8.17e-23	Monocyte percentage of white cells;
LUAD	cis	rs4691139	0.658	rs6839773	chr4:165925846	G/A	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.41	-7.73	-0.35	7.73e-14	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-6.55	-0.3	1.68e-10	Retinal vascular caliber;
LUAD	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.56e-19	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg24801067	chr17:62843696	NA	-0.51	-8.17	-0.37	3.49e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg15208524	chr1:10270712	KIF1B	0.43	6.49	0.3	2.43e-10	Hepatocellular carcinoma;
LUAD	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.61	6.84	0.32	2.85e-11	Lung cancer in ever smokers;
LUAD	cis	rs977987	0.800	rs3784935	chr16:75336430	T/G	cg03315344	chr16:75512273	CHST6	0.63	13.84	0.56	3.4e-36	Dupuytren's disease;
LUAD	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg04896959	chr15:78267971	NA	0.56	10.85	0.47	2.36e-24	Coronary artery disease or large artery stroke;
LUAD	cis	rs73206853	0.841	rs11065631	chr12:110778383	A/G	cg12870014	chr12:110450643	ANKRD13A	0.6	6.39	0.3	4.28e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg26043149	chr18:55253948	FECH	0.49	7.91	0.36	2.28e-14	Bone mineral density;
LUAD	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg17330251	chr7:94953956	PON1	-0.55	-7.62	-0.35	1.64e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg06547715	chr2:218990976	CXCR2	-0.29	-7.06	-0.32	6.85e-12	Colorectal cancer;
LUAD	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg05639522	chr1:247681581	NA	-0.37	-6.83	-0.32	2.95e-11	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs6952808	0.965	rs11768541	chr7:1894884	G/A	cg04565464	chr8:145669602	NFKBIL2	0.44	6.35	0.3	5.65e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg19825600	chr2:3704501	ALLC	-0.39	-7.53	-0.34	3.2e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg24829409	chr8:58192753	C8orf71	-0.61	-7.93	-0.36	1.93e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg11871910	chr12:69753446	YEATS4	0.7	12.08	0.51	4.52e-29	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs6669919	0.553	rs12568639	chr1:211675300	G/A	cg10512769	chr1:211675356	NA	-0.4	-8.05	-0.36	8.65e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg13770153	chr20:60521292	NA	0.95	16.67	0.63	2.45e-48	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg23281280	chr6:28129359	ZNF389	0.46	6.65	0.31	9.18e-11	Depression;
LUAD	cis	rs698833	0.926	rs1067399	chr2:44678648	A/G	cg04920474	chr2:44395004	PPM1B	0.4	7.19	0.33	3.02e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs9341808	0.529	rs2322765	chr6:81064596	A/G	cg08355045	chr6:80787529	NA	0.48	8.27	0.37	1.72e-15	Sitting height ratio;
LUAD	cis	rs4523957	0.928	rs403553	chr17:2191260	C/T	cg16513277	chr17:2031491	SMG6	0.77	14.93	0.59	8.46e-41	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs3820068	0.705	rs4646092	chr1:15821673	C/T	cg13390004	chr1:15929781	NA	0.4	6.51	0.3	2.15e-10	Systolic blood pressure;
LUAD	cis	rs3806843	0.576	rs246030	chr5:140333154	C/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg15557168	chr22:42548783	NA	-0.44	-8.37	-0.38	8.77e-16	Cognitive function;
LUAD	cis	rs11893307	0.509	rs2109957	chr2:191535311	T/C	cg27211696	chr2:191398769	TMEM194B	-0.43	-6.5	-0.3	2.31e-10	Mean platelet volume;
LUAD	trans	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.16	29.07	0.82	6.92e-103	Colorectal cancer;
LUAD	trans	rs8002861	0.727	rs9525852	chr13:44405197	G/C	cg17145862	chr1:211918768	LPGAT1	-0.54	-10.68	-0.46	9.77e-24	Leprosy;
LUAD	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg07741184	chr6:167504864	NA	0.3	7.1	0.33	5.42e-12	Crohn's disease;
LUAD	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg05896524	chr21:47604654	C21orf56	0.69	12.17	0.51	2.1e-29	Testicular germ cell tumor;
LUAD	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.64	0.31	9.36e-11	Depression;
LUAD	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg01689657	chr7:91764605	CYP51A1	0.35	8.77	0.39	4.54e-17	Breast cancer;
LUAD	cis	rs4906332	1.000	rs12147655	chr14:103850906	G/C	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.16	-0.33	3.65e-12	Coronary artery disease;
LUAD	cis	rs4072705	0.615	rs7869829	chr9:127247177	G/A	cg13476313	chr9:127244764	NR5A1	-0.35	-8.37	-0.38	8.65e-16	Menarche (age at onset);
LUAD	cis	rs4727027	0.705	rs10952803	chr7:148890091	T/G	cg23158103	chr7:148848205	ZNF398	-0.47	-8.09	-0.37	6.29e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs741677	0.964	rs8077122	chr17:495522	G/A	cg13332499	chr17:408570	NA	-0.33	-6.61	-0.31	1.14e-10	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg01884057	chr2:25150051	NA	-0.37	-7.89	-0.36	2.52e-14	Body mass index in non-asthmatics;
LUAD	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07636037	chr3:49044803	WDR6	-0.48	-7.88	-0.36	2.8e-14	Menarche (age at onset);
LUAD	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg27502298	chr12:9555721	NA	0.79	14.34	0.57	2.78e-38	IgG glycosylation;
LUAD	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg08859206	chr1:53392774	SCP2	-0.58	-10.69	-0.46	9.16e-24	Monocyte count;
LUAD	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg22907277	chr7:1156413	C7orf50	0.71	8.31	0.37	1.29e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg22482690	chr17:47019901	SNF8	0.44	8.37	0.38	8.71e-16	Type 2 diabetes;
LUAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg10819733	chr22:24237672	NA	-0.39	-7.14	-0.33	4.1e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs7246760	0.867	rs1115825	chr19:9786121	C/G	cg02900749	chr2:68251473	NA	-0.59	-6.56	-0.3	1.59e-10	Pursuit maintenance gain;
LUAD	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg14847009	chr1:175162515	KIAA0040	-0.33	-8.71	-0.39	7.09e-17	Alcohol dependence;
LUAD	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg01689657	chr7:91764605	CYP51A1	-0.33	-8.31	-0.37	1.29e-15	Breast cancer;
LUAD	cis	rs7192380	0.825	rs3811348	chr16:69782855	C/T	cg00738113	chr16:70207722	CLEC18C	0.38	7.53	0.34	2.99e-13	Sjögren's syndrome;
LUAD	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	12.76	0.53	9.14e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg12292205	chr6:26970375	C6orf41	-0.43	-7.76	-0.35	6.22e-14	Schizophrenia;
LUAD	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg20673091	chr1:2541236	MMEL1	0.41	8.65	0.39	1.04e-16	Ulcerative colitis;
LUAD	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg17366294	chr4:99064904	C4orf37	0.71	13.37	0.54	3.05e-34	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.872	rs12322940	chr12:86406708	G/C	cg18827107	chr12:86230957	RASSF9	-0.47	-8.51	-0.38	3.02e-16	Major depressive disorder;
LUAD	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg25324976	chr17:61989376	CSHL1	0.37	7.33	0.34	1.18e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg00280220	chr17:61926910	NA	0.37	7.05	0.32	7.37e-12	Prudent dietary pattern;
LUAD	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg20991723	chr1:152506922	NA	0.33	6.56	0.3	1.57e-10	Hair morphology;
LUAD	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg09491104	chr22:46646882	C22orf40	-0.74	-13.44	-0.55	1.6e-34	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs56283067	0.847	rs1418432	chr6:44691372	T/C	cg18551225	chr6:44695536	NA	-0.61	-10.18	-0.44	6.31e-22	Total body bone mineral density;
LUAD	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg05110241	chr16:68378359	PRMT7	-0.82	-8.9	-0.4	1.7e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.81	-0.35	4.63e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9811920	0.683	rs7650727	chr3:99688976	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	7.16	0.33	3.62e-12	Axial length;
LUAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.67	-0.31	8.16e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg18230493	chr5:56204884	C5orf35	-0.86	-12.44	-0.52	1.7e-30	Initial pursuit acceleration;
LUAD	trans	rs2262909	1.000	rs431328	chr19:22222236	A/G	cg05197062	chr11:11642011	GALNTL4	-0.45	-7.08	-0.33	5.87e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.11	0.33	4.86e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs758324	0.812	rs13174462	chr5:131217988	A/G	cg06307176	chr5:131281290	NA	0.44	7.66	0.35	1.24e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08564027	chr20:61660810	NA	0.88	18.83	0.68	6.9e-58	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg21782813	chr7:2030301	MAD1L1	0.6	10.51	0.46	4e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg06028605	chr16:24865363	SLC5A11	0.4	7.01	0.32	9.38e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg02951883	chr7:2050386	MAD1L1	-0.65	-10.45	-0.45	6.61e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs10203711	1.000	rs2334022	chr2:239565612	T/C	cg14580085	chr2:239553406	NA	0.41	8.91	0.4	1.51e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg05914723	chr15:78953907	NA	0.58	7.87	0.36	3.02e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg06558623	chr16:89946397	TCF25	0.65	7.39	0.34	7.86e-13	Skin colour saturation;
LUAD	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg05043794	chr9:111880884	C9orf5	-0.44	-7.5	-0.34	3.85e-13	Menarche (age at onset);
LUAD	cis	rs9462027	1.000	rs6457792	chr6:34764443	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.3	7.06	0.32	6.86e-12	Systemic lupus erythematosus;
LUAD	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.64	11.2	0.48	1.09e-25	Birth weight;
LUAD	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.41	0.3	4.01e-10	Schizophrenia;
LUAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08677398	chr8:58056175	NA	0.46	6.54	0.3	1.76e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg11317459	chr13:21872234	NA	-1.08	-14.31	-0.57	3.6e-38	White matter hyperintensity burden;
LUAD	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg03354898	chr7:1950403	MAD1L1	-0.41	-7.69	-0.35	1.07e-13	Bipolar disorder and schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06920136	chr14:21945858	RAB2B;TOX4	-0.43	-7.11	-0.33	4.9e-12	Cancer;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg19857457	chr18:47018947	RPL17;SNORD58A;SNORD58B	-0.41	-7.05	-0.32	7.42e-12	Subcortical brain region volumes;
LUAD	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg18230493	chr5:56204884	C5orf35	-0.44	-7.44	-0.34	5.6e-13	Coronary artery disease;
LUAD	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg15790184	chr11:494944	RNH1	0.57	7.06	0.32	7.02e-12	Body mass index;
LUAD	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg05368731	chr17:41323189	NBR1	0.97	20.73	0.71	2.24e-66	Menopause (age at onset);
LUAD	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs89107	0.688	rs283081	chr6:118605821	G/A	cg21191810	chr6:118973309	C6orf204	0.48	9.32	0.41	6.61e-19	Cardiac structure and function;
LUAD	cis	rs2637266	0.967	rs7900230	chr10:78366879	A/G	cg18941641	chr10:78392320	NA	0.33	6.79	0.31	3.72e-11	Pulmonary function;
LUAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg12432903	chr7:1882776	MAD1L1	0.39	6.36	0.3	5.1e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg04546413	chr19:29218101	NA	0.72	10.07	0.44	1.64e-21	Methadone dose in opioid dependence;
LUAD	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.65	0.31	8.94e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs354225	0.544	rs3287	chr2:54807657	T/C	cg01766943	chr2:54829624	SPTBN1	0.39	7.34	0.34	1.1e-12	Schizophrenia;
LUAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg00530320	chr1:46809349	NSUN4	0.51	7.93	0.36	1.92e-14	Menopause (age at onset);
LUAD	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg03874509	chr1:107600012	PRMT6	0.52	9.11	0.4	3.37e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg24644049	chr4:85504048	CDS1	0.94	7.45	0.34	5.13e-13	Skin colour saturation;
LUAD	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg26727032	chr16:67993705	SLC12A4	-0.43	-6.55	-0.3	1.71e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg27211696	chr2:191398769	TMEM194B	0.71	9.36	0.41	4.78e-19	Diastolic blood pressure;
LUAD	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg16099599	chr11:93583650	C11orf90	-0.32	-6.39	-0.3	4.51e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg08132940	chr7:1081526	C7orf50	-0.76	-10.09	-0.44	1.32e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11209185	0.503	rs4655573	chr1:68438778	C/T	cg22082780	chr1:68452167	NA	-0.51	-10.61	-0.46	1.84e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01560407	chr16:310537	ITFG3	0.52	6.76	0.31	4.6e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg00745463	chr17:30367425	LRRC37B	0.68	8.18	0.37	3.38e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg08999081	chr20:33150536	PIGU	-0.37	-7.33	-0.34	1.14e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg20503657	chr10:835505	NA	0.94	14.26	0.57	5.7e-38	Eosinophil percentage of granulocytes;
LUAD	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg02158880	chr13:53174818	NA	0.55	9.56	0.42	1e-19	Lewy body disease;
LUAD	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg15704280	chr7:45808275	SEPT13	-0.79	-12.29	-0.51	6.63e-30	Coronary artery disease;
LUAD	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.76	0.39	4.66e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs846178	1	rs846178	chr4:2485615	A/C	cg16474684	chr4:2470049	RNF4	-0.49	-7.14	-0.33	4.15e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-7.57	-0.35	2.41e-13	Monocyte percentage of white cells;
LUAD	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg23950597	chr19:37808831	NA	-0.61	-7.64	-0.35	1.44e-13	Coronary artery calcification;
LUAD	trans	rs7395662	0.818	rs2200181	chr11:48413175	C/G	cg00717180	chr2:96193071	NA	-0.38	-7.09	-0.33	5.79e-12	HDL cholesterol;
LUAD	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg22496339	chr2:162101262	NA	-0.49	-7.21	-0.33	2.65e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LUAD	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.63	-11.5	-0.49	7.77e-27	Longevity;Endometriosis;
LUAD	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.46	-9.41	-0.42	3.21e-19	Monocyte percentage of white cells;
LUAD	cis	rs12681287	0.752	rs4472493	chr8:87251914	C/T	cg27223183	chr8:87520930	FAM82B	-0.59	-8.21	-0.37	2.75e-15	Caudate activity during reward;
LUAD	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg16049864	chr8:95962084	TP53INP1	0.52	10.18	0.44	6.3e-22	Type 2 diabetes;
LUAD	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg25324976	chr17:61989376	CSHL1	0.33	6.55	0.3	1.72e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg13856295	chr9:139396418	NOTCH1	-0.42	-6.63	-0.31	1.05e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.27	-0.6	2.95e-42	Chronic sinus infection;
LUAD	cis	rs13082711	0.911	rs35904501	chr3:27443317	T/C	cg02860705	chr3:27208620	NA	0.6	9.21	0.41	1.59e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	trans	rs11039798	1.000	rs8188963	chr11:48685693	C/A	cg15704280	chr7:45808275	SEPT13	0.67	7.84	0.36	3.58e-14	Axial length;
LUAD	cis	rs62238980	0.614	rs117194706	chr22:32491317	C/G	cg00543991	chr22:32367038	NA	0.88	8.52	0.38	2.91e-16	Childhood ear infection;
LUAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg11062466	chr8:58055876	NA	0.66	8.64	0.39	1.2e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg11070056	chr1:107600091	PRMT6	-0.64	-11.21	-0.48	1.03e-25	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs7944735	0.817	rs747782	chr11:47940925	A/G	cg15704280	chr7:45808275	SEPT13	0.65	8.74	0.39	5.4e-17	Intraocular pressure;
LUAD	trans	rs4650994	1.000	rs4650999	chr1:178532188	A/C	cg05059571	chr16:84539110	KIAA1609	0.59	10.4	0.45	1.04e-22	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.53	-0.34	3.05e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1457451	0.646	rs4671675	chr2:65861655	A/G	cg16240816	chr2:65861662	NA	0.39	6.47	0.3	2.73e-10	Iron status biomarkers;
LUAD	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg23719950	chr11:63933701	MACROD1	-0.62	-7.26	-0.33	1.87e-12	Mean platelet volume;
LUAD	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.4	-11.0	-0.47	6.27e-25	Total body bone mineral density;
LUAD	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-7.8	-0.35	5.01e-14	Personality dimensions;
LUAD	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg21724239	chr8:58056113	NA	0.52	7.03	0.32	8.51e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs739496	0.615	rs624716	chr12:112166696	A/G	cg10833066	chr12:111807467	FAM109A	0.43	6.89	0.32	2.03e-11	Platelet count;
LUAD	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg27068330	chr11:65405492	SIPA1	0.54	8.63	0.39	1.26e-16	Acne (severe);
LUAD	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22857025	chr5:266934	NA	-0.95	-13.98	-0.56	9.18e-37	Breast cancer;
LUAD	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10802521	chr3:52805072	NEK4	-0.54	-9.24	-0.41	1.21e-18	Bipolar disorder;
LUAD	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg21724239	chr8:58056113	NA	0.73	9.54	0.42	1.18e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg05085585	chr16:30420623	ZNF771	-0.39	-6.54	-0.3	1.78e-10	Tonsillectomy;
LUAD	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg12119029	chr16:89752879	CDK10	0.31	6.46	0.3	2.93e-10	Vitiligo;
LUAD	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg07917127	chr4:99064746	C4orf37	0.4	6.44	0.3	3.17e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.88	-0.32	2.1e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.29	-7.37	-0.34	9.2e-13	Coronary artery disease;
LUAD	cis	rs73416724	1.000	rs77538445	chr6:43285773	A/C	cg26312998	chr6:43337775	ZNF318	0.57	6.82	0.31	3.07e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg14668632	chr7:2872130	GNA12	-0.7	-12.79	-0.53	6.59e-32	Height;
LUAD	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg26898376	chr11:64110657	CCDC88B	0.38	7.09	0.33	5.49e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUAD	cis	rs9297145	0.678	rs62473051	chr7:98781955	C/T	cg05967295	chr7:98741636	SMURF1	0.97	15.8	0.61	1.65e-44	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg12432903	chr7:1882776	MAD1L1	-0.43	-6.9	-0.32	1.9e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	6.96	0.32	1.34e-11	Renal cell carcinoma;
LUAD	cis	rs36051895	0.622	rs10815143	chr9:5009541	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-7.0	-0.32	1.02e-11	Pediatric autoimmune diseases;
LUAD	cis	rs9972944	0.729	rs12939140	chr17:63777249	T/A	cg07283582	chr17:63770753	CCDC46	0.47	10.25	0.45	3.48e-22	Total body bone mineral density;
LUAD	trans	rs1997103	1.000	rs6958022	chr7:55397389	G/A	cg20935933	chr6:143382018	AIG1	0.53	7.46	0.34	4.94e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg26677194	chr12:130822605	PIWIL1	0.6	10.02	0.44	2.35e-21	Menopause (age at onset);
LUAD	cis	rs4713675	0.584	rs4713666	chr6:33679061	A/G	cg14003231	chr6:33640908	ITPR3	0.49	9.42	0.42	2.96e-19	Plateletcrit;
LUAD	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg11502198	chr6:26597334	ABT1	0.68	11.91	0.5	2.06e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg09365446	chr1:150670422	GOLPH3L	0.61	10.75	0.46	5.64e-24	Melanoma;
LUAD	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg24675056	chr1:15929824	NA	0.46	7.97	0.36	1.49e-14	Systolic blood pressure;
LUAD	cis	rs11048434	0.736	rs12833375	chr12:9112018	A/T	cg13575925	chr12:9217583	LOC144571	0.38	7.13	0.33	4.5e-12	Sjögren's syndrome;
LUAD	cis	rs12928939	0.517	rs12934512	chr16:71965230	C/G	cg03805757	chr16:71968109	PKD1L3	-0.54	-8.53	-0.38	2.69e-16	Post bronchodilator FEV1;
LUAD	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg03037974	chr15:76606532	NA	0.38	8.13	0.37	4.89e-15	Blood metabolite levels;
LUAD	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg15445000	chr17:37608096	MED1	-0.44	-8.19	-0.37	3.12e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg05754148	chr16:3507555	NAT15	-0.4	-6.5	-0.3	2.29e-10	Body mass index (adult);
LUAD	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg13770153	chr20:60521292	NA	-0.57	-9.55	-0.42	1.07e-19	Body mass index;
LUAD	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg07636037	chr3:49044803	WDR6	0.63	12.17	0.51	2e-29	Parkinson's disease;
LUAD	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.18	0.54	1.73e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg02461776	chr11:598696	PHRF1	0.49	6.87	0.32	2.24e-11	Systemic lupus erythematosus;
LUAD	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.46	7.39	0.34	7.69e-13	Total body bone mineral density;
LUAD	cis	rs7301826	0.627	rs4334059	chr12:131314214	T/C	cg11011512	chr12:131303247	STX2	0.4	6.59	0.31	1.32e-10	Plasma plasminogen activator levels;
LUAD	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg18132916	chr6:79620363	NA	0.44	7.68	0.35	1.14e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.79e-18	Life satisfaction;
LUAD	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg02782426	chr3:40428986	ENTPD3	0.43	9.23	0.41	1.31e-18	Renal cell carcinoma;
LUAD	cis	rs977987	0.836	rs17685540	chr16:75323840	T/C	cg03315344	chr16:75512273	CHST6	0.64	13.72	0.55	1.09e-35	Dupuytren's disease;
LUAD	cis	rs7107174	1.000	rs2510055	chr11:77961912	C/T	cg02023728	chr11:77925099	USP35	0.5	7.64	0.35	1.46e-13	Testicular germ cell tumor;
LUAD	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.3	-7.96	-0.36	1.59e-14	Total body bone mineral density;
LUAD	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.28	-0.33	1.62e-12	Total body bone mineral density;
LUAD	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.66	0.52	2.21e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.34	0.38	1.06e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg11050988	chr7:1952600	MAD1L1	-0.38	-7.77	-0.35	6.01e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs11696845	0.626	rs6073537	chr20:43378270	A/G	cg25301532	chr20:43378953	KCNK15	-0.43	-7.53	-0.34	3.05e-13	Obesity-related traits;
LUAD	cis	rs6952808	0.964	rs10950407	chr7:1895666	T/G	cg22963979	chr7:1858916	MAD1L1	-0.72	-12.42	-0.52	2.14e-30	Bipolar disorder and schizophrenia;
LUAD	cis	rs13064411	0.518	rs1552433	chr3:113225730	C/A	cg18753928	chr3:113234510	CCDC52	-0.49	-8.76	-0.39	4.63e-17	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.65	9.88	0.43	7.78e-21	Lymphocyte percentage of white cells;
LUAD	cis	rs13190036	0.901	rs6898107	chr5:176679695	A/G	cg06733329	chr5:176740039	MXD3	-0.48	-6.52	-0.3	2.03e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUAD	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.48	7.73	0.35	7.88e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs13064411	0.696	rs869342	chr3:113226330	C/T	cg18753928	chr3:113234510	CCDC52	-0.73	-12.41	-0.52	2.31e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs1691799	0.867	rs1168339	chr12:66759236	T/G	cg16791601	chr12:66731901	HELB	-0.37	-6.78	-0.31	3.98e-11	White blood cell count (basophil);
LUAD	trans	rs4650994	0.544	rs4132058	chr1:178505557	A/C	cg05059571	chr16:84539110	KIAA1609	-0.73	-13.31	-0.54	5.32e-34	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs909002	0.789	rs3817398	chr1:32119431	C/T	cg13919466	chr1:32135498	COL16A1	0.36	8.26	0.37	1.89e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs738321	0.757	rs4821748	chr22:38541936	G/A	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.9	-0.32	1.96e-11	Breast cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg06917231	chr6:28234854	ZNF187	-0.59	-7.15	-0.33	3.92e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs3784262	0.528	rs17820966	chr15:58336662	A/G	cg12031962	chr15:58353849	ALDH1A2	0.37	7.26	0.33	1.84e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.92	0.47	1.29e-24	Mean corpuscular volume;
LUAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7582720	1.000	rs72936332	chr2:204056678	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.58	0.42	8.55e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6906287	0.647	rs11153748	chr6:118773609	A/G	cg21191810	chr6:118973309	C6orf204	0.49	9.51	0.42	1.46e-19	Electrocardiographic conduction measures;
LUAD	cis	rs938554	0.956	rs12507606	chr4:9934561	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.38	-0.34	8.56e-13	Blood metabolite levels;
LUAD	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg23954153	chr1:44402353	ARTN	-0.32	-6.48	-0.3	2.63e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	7.37	0.34	8.98e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs9633740	1.000	rs10749609	chr10:82249752	G/A	cg01528321	chr10:82214614	TSPAN14	0.69	9.46	0.42	2.1e-19	Post bronchodilator FEV1;
LUAD	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg18190219	chr22:46762943	CELSR1	-0.44	-6.39	-0.3	4.35e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2836633	0.895	rs61085980	chr21:40032140	C/T	cg12884169	chr21:40033163	ERG	0.46	9.66	0.43	4.27e-20	Coronary artery disease;
LUAD	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg17971929	chr21:40555470	PSMG1	0.57	9.11	0.41	3.25e-18	Cognitive function;
LUAD	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg00071950	chr4:10020882	SLC2A9	0.61	11.59	0.49	3.75e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg02931644	chr1:25747376	RHCE	0.41	8.46	0.38	4.57e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg27279351	chr12:120934652	DYNLL1	0.43	6.57	0.3	1.51e-10	High light scatter reticulocyte count;
LUAD	cis	rs13095912	0.785	rs35637544	chr3:185329958	A/G	cg11274856	chr3:185301563	NA	0.51	9.83	0.43	1.15e-20	Systolic blood pressure;
LUAD	trans	rs587242	1.000	rs7551466	chr1:96892427	G/T	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.87	-0.5	3.04e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs783540	0.933	rs2567636	chr15:83263428	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.45	-7.3	-0.33	1.41e-12	Schizophrenia;
LUAD	cis	rs7147624	1.000	rs2411354	chr14:66062132	T/C	cg03016385	chr14:66212404	NA	-0.59	-7.09	-0.33	5.74e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUAD	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg23950597	chr19:37808831	NA	-0.65	-7.76	-0.35	6.58e-14	Coronary artery calcification;
LUAD	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg07606381	chr6:8435919	SLC35B3	-0.39	-6.53	-0.3	1.92e-10	Motion sickness;
LUAD	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.99	21.75	0.73	6.07e-71	Chronic sinus infection;
LUAD	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22307029	chr19:49891270	CCDC155	0.62	10.12	0.44	1.04e-21	Multiple sclerosis;
LUAD	trans	rs11039798	0.841	rs10839174	chr11:48931185	G/A	cg03929089	chr4:120376271	NA	0.59	6.79	0.31	3.9e-11	Axial length;
LUAD	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg07343612	chr16:622815	PIGQ	-0.82	-16.0	-0.61	2.05e-45	Height;
LUAD	cis	rs10911363	0.592	rs12117885	chr1:183494214	C/T	cg09173681	chr1:183549694	NCF2	-0.53	-10.2	-0.44	5.5e-22	Systemic lupus erythematosus;
LUAD	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg21782813	chr7:2030301	MAD1L1	0.44	7.12	0.33	4.79e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg23711669	chr6:146136114	FBXO30	0.38	6.61	0.31	1.19e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg26513180	chr16:89883248	FANCA	0.86	7.52	0.34	3.3e-13	Skin colour saturation;
LUAD	cis	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.3	-0.33	1.46e-12	Resting heart rate;
LUAD	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg02176678	chr2:219576539	TTLL4	0.61	11.83	0.5	4.25e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs11214589	0.905	rs1078	chr11:113241877	C/T	cg14159747	chr11:113255604	NA	0.68	14.76	0.58	4.75e-40	Neuroticism;
LUAD	cis	rs7903847	0.620	rs10882903	chr10:99115584	A/T	cg20016023	chr10:99160130	RRP12	-0.29	-7.0	-0.32	1.03e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg07917127	chr4:99064746	C4orf37	0.4	6.65	0.31	8.98e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2050392	0.931	rs2265189	chr10:30689316	C/T	cg18806716	chr10:30721971	MAP3K8	0.52	9.88	0.43	7.33e-21	Inflammatory bowel disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23396286	chr10:99258505	UBTD1;MMS19	-0.45	-7.16	-0.33	3.63e-12	Height;
LUAD	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg04369109	chr6:150039330	LATS1	-0.45	-7.32	-0.34	1.27e-12	Lung cancer;
LUAD	cis	rs4946717	0.716	rs4478446	chr6:106472120	T/A	cg02270332	chr6:106475062	NA	0.44	8.81	0.39	3.32e-17	Inflammatory bowel disease;
LUAD	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg12311346	chr5:56204834	C5orf35	-0.75	-11.99	-0.5	1.06e-28	Initial pursuit acceleration;
LUAD	trans	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg21659725	chr3:3221576	CRBN	0.67	10.08	0.44	1.48e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg01689657	chr7:91764605	CYP51A1	-0.35	-8.81	-0.39	3.38e-17	Breast cancer;
LUAD	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.88	0.32	2.13e-11	Motion sickness;
LUAD	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	12.52	0.52	7.95e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg15147215	chr3:52552868	STAB1	-0.37	-7.0	-0.32	1.01e-11	Bipolar disorder;
LUAD	cis	rs9837602	0.882	rs6807176	chr3:99760864	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-7.49	-0.34	4.11e-13	Breast cancer;
LUAD	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg23260525	chr10:116636907	FAM160B1	0.47	10.74	0.46	5.65e-24	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs9467160	0.871	rs9461015	chr6:24449020	C/G	cg20631270	chr6:24437470	GPLD1	-0.41	-6.43	-0.3	3.38e-10	Liver enzyme levels;
LUAD	cis	rs9837602	1.000	rs71313585	chr3:99770696	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.64	9.17	0.41	2.06e-18	Breast cancer;
LUAD	trans	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg26043149	chr18:55253948	FECH	1.05	17.81	0.65	2.29e-53	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.62	-0.35	1.68e-13	Fear of minor pain;
LUAD	cis	rs10504073	0.647	rs10435574	chr8:49996028	G/A	cg00325661	chr8:49890786	NA	0.45	10.1	0.44	1.23e-21	Blood metabolite ratios;
LUAD	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg10433463	chr1:1889099	KIAA1751	0.35	7.3	0.33	1.44e-12	Body mass index;
LUAD	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg02466173	chr16:30829666	NA	-0.69	-12.55	-0.52	6.25e-31	Multiple myeloma;
LUAD	cis	rs73206853	0.764	rs7314552	chr12:110618890	C/T	cg12870014	chr12:110450643	ANKRD13A	0.64	7.91	0.36	2.24e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg04025307	chr7:1156635	C7orf50	0.59	6.59	0.31	1.32e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg13606994	chr1:44402422	ARTN	0.33	7.01	0.32	9.44e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg04545296	chr12:48745243	ZNF641	0.39	9.84	0.43	1.02e-20	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs7851660	0.809	rs7866436	chr9:100650096	G/A	cg13688889	chr9:100608707	NA	-0.51	-8.7	-0.39	7.37e-17	Strep throat;
LUAD	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	9.18	0.41	1.92e-18	Tonsillectomy;
LUAD	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg14458575	chr2:238380390	NA	0.97	18.7	0.67	2.7e-57	Prostate cancer;
LUAD	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.48	-8.46	-0.38	4.4e-16	Alzheimer's disease (late onset);
LUAD	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg06608945	chr2:219082296	ARPC2	0.42	6.76	0.31	4.48e-11	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.6	9.88	0.43	7.37e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg21252483	chr19:49399788	TULP2	-0.87	-14.19	-0.57	1.21e-37	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs12545109	0.879	rs7845180	chr8:57324431	C/T	cg09654669	chr8:57350985	NA	0.66	9.48	0.42	1.89e-19	Obesity-related traits;
LUAD	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg15147215	chr3:52552868	STAB1	-0.38	-7.0	-0.32	9.91e-12	Bipolar disorder;
LUAD	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.59	-12.59	-0.52	4.25e-31	Monocyte percentage of white cells;
LUAD	cis	rs9560113	0.622	rs4773388	chr13:112195250	A/C	cg10483660	chr13:112241077	NA	0.43	8.83	0.39	2.74e-17	Menarche (age at onset);
LUAD	cis	rs2274273	0.624	rs8003279	chr14:55864130	A/G	cg04306507	chr14:55594613	LGALS3	0.4	7.44	0.34	5.72e-13	Protein biomarker;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01551176	chr1:28844397	SNHG3-RCC1;RCC1	-0.39	-6.42	-0.3	3.68e-10	Cancer;
LUAD	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	6.93	0.32	1.62e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs790123	1.000	rs790116	chr3:122380923	G/C	cg24850323	chr3:122379709	NA	0.37	6.58	0.3	1.4e-10	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7586879	1.000	rs1865687	chr2:25112885	G/A	cg04586622	chr2:25135609	ADCY3	0.34	7.37	0.34	9.31e-13	Body mass index;
LUAD	trans	rs7395662	0.697	rs11530291	chr11:48764203	C/G	cg00717180	chr2:96193071	NA	0.39	7.24	0.33	2.14e-12	HDL cholesterol;
LUAD	cis	rs6758955	1.000	rs6751416	chr2:10475484	G/C	cg15773312	chr2:10472214	HPCAL1	-0.42	-6.63	-0.31	9.99e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg08798685	chr6:27730294	NA	-0.43	-6.84	-0.32	2.83e-11	Parkinson's disease;
LUAD	trans	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg18335740	chr13:41363409	SLC25A15	0.55	9.95	0.44	4.12e-21	Lewy body disease;
LUAD	cis	rs6684514	0.961	rs10908497	chr1:156274740	G/A	cg16558208	chr1:156270281	VHLL	0.53	9.59	0.42	7.44e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs89107	0.576	rs17825393	chr6:118772583	A/G	cg21191810	chr6:118973309	C6orf204	0.37	6.85	0.32	2.6e-11	Cardiac structure and function;
LUAD	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg00280220	chr17:61926910	NA	0.36	6.94	0.32	1.45e-11	Prudent dietary pattern;
LUAD	cis	rs7590720	0.531	rs6435932	chr2:216906030	T/C	cg12620499	chr2:216877984	MREG	0.41	6.77	0.31	4.37e-11	Alcohol dependence;
LUAD	cis	rs17401966	0.898	rs61784570	chr1:10258343	C/A	cg15208524	chr1:10270712	KIF1B	0.45	6.62	0.31	1.1e-10	Hepatocellular carcinoma;
LUAD	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg17264618	chr3:40429014	ENTPD3	-0.31	-6.67	-0.31	7.97e-11	Renal cell carcinoma;
LUAD	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.61	0.31	1.15e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06022373	chr22:39101656	GTPBP1	0.39	6.39	0.3	4.31e-10	Menopause (age at onset);
LUAD	cis	rs12791968	0.527	rs12279115	chr11:45014587	G/C	cg11846598	chr11:44996168	LOC221122	-0.57	-6.69	-0.31	7.22e-11	Inhibitory control;
LUAD	cis	rs8067545	0.641	rs175922	chr17:19825579	T/C	cg04132472	chr17:19861366	AKAP10	0.39	9.12	0.41	3.16e-18	Schizophrenia;
LUAD	cis	rs6542838	0.641	rs883773	chr2:99491635	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.35	-0.34	1.07e-12	Fear of minor pain;
LUAD	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg12407791	chr17:73824354	UNC13D	0.32	6.64	0.31	9.54e-11	White matter hyperintensity burden;
LUAD	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg00204512	chr16:28754710	NA	0.33	7.07	0.33	6.48e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7202877	0.610	rs3851735	chr16:75372092	A/G	cg03315344	chr16:75512273	CHST6	0.52	7.3	0.33	1.4e-12	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs7301826	0.651	rs10744484	chr12:131298506	T/G	cg11011512	chr12:131303247	STX2	0.44	7.42	0.34	6.59e-13	Plasma plasminogen activator levels;
LUAD	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg16486109	chr11:613632	IRF7	0.49	8.16	0.37	3.84e-15	Systemic lupus erythematosus;
LUAD	cis	rs1904096	0.506	rs6532476	chr4:95192461	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.53	-10.13	-0.44	9.51e-22	Type 2 diabetes;
LUAD	trans	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg04565464	chr8:145669602	NFKBIL2	0.43	6.57	0.3	1.52e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7680126	0.596	rs12510549	chr4:10276467	A/G	cg02734326	chr4:10020555	SLC2A9	-0.49	-6.55	-0.3	1.64e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg19610905	chr11:61596333	FADS2	-0.67	-11.33	-0.48	3.75e-26	Trans fatty acid levels;
LUAD	cis	rs35883536	1.000	rs12410168	chr1:101115321	G/A	cg06223162	chr1:101003688	GPR88	0.38	7.12	0.33	4.77e-12	Monocyte count;
LUAD	cis	rs12545109	0.800	rs2118260	chr8:57393481	T/C	cg09654669	chr8:57350985	NA	-0.7	-10.06	-0.44	1.75e-21	Obesity-related traits;
LUAD	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg11266682	chr4:10021025	SLC2A9	0.67	15.08	0.59	2e-41	Bone mineral density;
LUAD	cis	rs730775	0.505	rs325004	chr6:44270365	C/G	cg21130236	chr6:44246755	TMEM151B	-0.35	-7.3	-0.33	1.44e-12	Monocyte percentage of white cells;Monocyte count;
LUAD	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	12.08	0.51	4.39e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs6561151	0.681	rs10507521	chr13:44441834	C/G	cg12856521	chr11:46389249	DGKZ	-0.83	-12.99	-0.53	1.05e-32	Crohn's disease;
LUAD	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-7.43	-0.34	5.96e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg18252515	chr7:66147081	NA	-0.62	-6.74	-0.31	5.21e-11	Diabetic kidney disease;
LUAD	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg01017244	chr2:74357527	NA	0.92	13.47	0.55	1.14e-34	Gestational age at birth (maternal effect);
LUAD	cis	rs6835098	0.509	rs2332655	chr4:174093002	A/G	cg08422745	chr4:174089978	GALNT7	0.66	11.14	0.48	1.86e-25	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs10979	1.000	rs13211390	chr6:143888010	A/T	cg25407410	chr6:143891975	LOC285740	-0.63	-10.0	-0.44	2.74e-21	Hypospadias;
LUAD	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg27411982	chr8:10470053	RP1L1	0.4	7.07	0.33	6.36e-12	Retinal vascular caliber;
LUAD	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs7617773	0.778	rs11707997	chr3:48377875	A/G	cg11946769	chr3:48343235	NME6	0.44	6.68	0.31	7.75e-11	Coronary artery disease;
LUAD	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.56	-8.17	-0.37	3.64e-15	Gut microbiome composition (summer);
LUAD	cis	rs89107	0.740	rs4294041	chr6:118618638	A/G	cg21191810	chr6:118973309	C6orf204	0.36	6.7	0.31	6.49e-11	Cardiac structure and function;
LUAD	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg06191203	chr2:152266755	RIF1	-0.62	-9.47	-0.42	2.07e-19	Lung cancer;
LUAD	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg21724239	chr8:58056113	NA	0.72	9.56	0.42	1.01e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg21385522	chr1:16154831	NA	-1.04	-22.66	-0.74	5.02e-75	Dilated cardiomyopathy;
LUAD	cis	rs3750082	0.817	rs4723221	chr7:32954207	C/T	cg05721444	chr7:32995514	FKBP9	-0.4	-7.44	-0.34	5.66e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg24069376	chr3:38537580	EXOG	0.37	8.56	0.38	2.18e-16	Electrocardiographic conduction measures;
LUAD	cis	rs4144027	0.904	rs55696130	chr14:104341864	A/G	cg12183467	chr14:104352244	NA	-0.38	-7.21	-0.33	2.63e-12	Blood metabolite levels;
LUAD	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg09455208	chr3:40491958	NA	0.64	13.98	0.56	8.62e-37	Renal cell carcinoma;
LUAD	trans	rs587242	1.000	rs12045626	chr1:96917476	C/T	cg10631902	chr5:14652156	NA	0.44	7.33	0.34	1.2e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-16.32	-0.62	8.5e-47	Schizophrenia;
LUAD	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg02869364	chr7:1081709	C7orf50	-0.53	-6.79	-0.31	3.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg21724239	chr8:58056113	NA	0.64	8.16	0.37	3.84e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs13082711	0.911	rs13077400	chr3:27473066	A/G	cg02860705	chr3:27208620	NA	0.55	8.37	0.38	8.6e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg03929089	chr4:120376271	NA	0.77	12.86	0.53	3.55e-32	Coronary artery disease;
LUAD	cis	rs3026445	0.761	rs67917264	chr12:110554818	A/G	cg12870014	chr12:110450643	ANKRD13A	0.38	6.77	0.31	4.22e-11	QT interval;
LUAD	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg12573674	chr2:1569213	NA	-0.61	-7.22	-0.33	2.5e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26859690	chr20:3869672	PANK2	-0.58	-7.06	-0.32	6.73e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs612683	0.602	rs2030048	chr1:101006577	C/T	cg06223162	chr1:101003688	GPR88	-0.48	-9.33	-0.41	5.84e-19	Breast cancer;
LUAD	cis	rs1832871	0.541	rs2183217	chr6:158879993	T/G	cg07165851	chr6:158734300	TULP4	0.51	7.34	0.34	1.07e-12	Height;
LUAD	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg26384229	chr12:38710491	ALG10B	0.49	7.91	0.36	2.27e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08280861	chr8:58055591	NA	0.73	8.83	0.39	2.79e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg09117114	chr16:67998030	SLC12A4	-0.55	-7.34	-0.34	1.08e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1448094	0.967	rs11117116	chr12:86331087	A/T	cg18827107	chr12:86230957	RASSF9	-0.44	-7.93	-0.36	1.94e-14	Major depressive disorder;
LUAD	cis	rs12760731	0.565	rs6701832	chr1:178156775	A/G	cg00404053	chr1:178313656	RASAL2	0.72	9.1	0.4	3.67e-18	Obesity-related traits;
LUAD	cis	rs6543140	0.964	rs13383602	chr2:103085962	C/T	cg03938978	chr2:103052716	IL18RAP	0.35	6.72	0.31	5.97e-11	Blood protein levels;
LUAD	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg20503657	chr10:835505	NA	0.74	9.88	0.43	7.71e-21	Eosinophil percentage of granulocytes;
LUAD	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.33	7.68	0.35	1.15e-13	Prostate cancer;
LUAD	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg19767477	chr5:127420684	SLC12A2	-0.43	-6.59	-0.31	1.34e-10	Ileal carcinoids;
LUAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg18621852	chr3:10150065	C3orf24	0.48	8.3	0.37	1.44e-15	Alzheimer's disease;
LUAD	cis	rs250677	1.000	rs36069	chr5:148417253	G/C	cg18129178	chr5:148520854	ABLIM3	-0.55	-8.71	-0.39	6.84e-17	Breast cancer;
LUAD	cis	rs1595825	1.000	rs61605589	chr2:198876532	T/C	cg11031976	chr2:198649780	BOLL	-0.45	-6.65	-0.31	9e-11	Ulcerative colitis;
LUAD	cis	rs8017423	0.615	rs12586761	chr14:90820897	A/G	cg14092571	chr14:90743983	NA	0.39	6.63	0.31	1.04e-10	Mortality in heart failure;
LUAD	cis	rs7737355	0.947	rs32115	chr5:131051328	A/G	cg06307176	chr5:131281290	NA	0.51	8.13	0.37	4.79e-15	Life satisfaction;
LUAD	trans	rs629535	0.814	rs571682	chr8:70062793	A/G	cg21567404	chr3:27674614	NA	0.97	17.86	0.66	1.38e-53	Dupuytren's disease;
LUAD	cis	rs2485376	0.934	rs772008	chr10:104067023	A/G	cg20641465	chr10:103991465	PITX3	-0.56	-10.29	-0.45	2.68e-22	QT interval;
LUAD	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg21724239	chr8:58056113	NA	0.65	8.41	0.38	6.32e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg16647868	chr5:131706066	SLC22A5	-0.48	-7.57	-0.35	2.41e-13	Acylcarnitine levels;
LUAD	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.32	6.8	0.31	3.52e-11	Cardiac Troponin-T levels;
LUAD	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg11262906	chr1:85462892	MCOLN2	-0.46	-6.87	-0.32	2.37e-11	Serum sulfate level;
LUAD	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg16205897	chr5:131564050	P4HA2	0.32	7.01	0.32	9.2e-12	Blood metabolite levels;
LUAD	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.13	-0.41	2.84e-18	Life satisfaction;
LUAD	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg11062466	chr8:58055876	NA	0.67	9.01	0.4	7.2e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg18005901	chr6:33739558	LEMD2	-0.59	-9.48	-0.42	1.82e-19	Schizophrenia;
LUAD	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg00852783	chr1:26633632	UBXN11	0.42	7.36	0.34	9.9e-13	Obesity-related traits;
LUAD	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg23625390	chr15:77176239	SCAPER	0.4	6.86	0.32	2.44e-11	Blood metabolite levels;
LUAD	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg02574844	chr11:5959923	NA	-0.42	-7.32	-0.34	1.23e-12	DNA methylation (variation);
LUAD	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg07169764	chr2:136633963	MCM6	0.82	9.75	0.43	2.09e-20	Corneal structure;
LUAD	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg14668632	chr7:2872130	GNA12	-0.36	-6.49	-0.3	2.42e-10	Height;
LUAD	cis	rs4803468	0.967	rs284661	chr19:41932120	C/T	cg09537434	chr19:41945824	ATP5SL	-0.47	-7.32	-0.34	1.27e-12	Height;
LUAD	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg24675056	chr1:15929824	NA	0.48	8.35	0.38	9.85e-16	Systolic blood pressure;
LUAD	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg21138405	chr5:131827807	IRF1	0.53	10.05	0.44	1.9e-21	Asthma (sex interaction);
LUAD	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.12	0.33	4.75e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10129255	0.556	rs6576224	chr14:107186236	G/A	cg07958169	chr14:107095056	NA	-0.37	-7.26	-0.33	1.89e-12	Kawasaki disease;
LUAD	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg15704280	chr7:45808275	SEPT13	-0.66	-10.04	-0.44	2.1e-21	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16909824	chr1:151299438	PI4KB	-0.46	-7.19	-0.33	2.99e-12	Height;
LUAD	cis	rs6906287	0.625	rs7453914	chr6:118692981	A/T	cg05564266	chr6:118973597	C6orf204	0.36	7.96	0.36	1.55e-14	Electrocardiographic conduction measures;
LUAD	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-8.38	-0.38	8.1e-16	Alzheimer's disease (late onset);
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg02683314	chr19:4182606	SIRT6;ANKRD24	-0.43	-6.79	-0.31	3.93e-11	Vertical cup-disc ratio;
LUAD	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11644478	chr21:40555479	PSMG1	0.63	10.67	0.46	1.04e-23	Cognitive function;
LUAD	cis	rs1534166	1.000	rs1534166	chr3:133537067	C/T	cg01448562	chr3:133502909	NA	-0.41	-6.74	-0.31	5.29e-11	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg22117172	chr7:91764530	CYP51A1	0.36	7.71	0.35	8.89e-14	Breast cancer;
LUAD	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg24813613	chr7:1882135	MAD1L1	-0.47	-7.57	-0.35	2.31e-13	Bipolar disorder and schizophrenia;
LUAD	trans	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg14917512	chr19:3094685	GNA11	-0.57	-6.78	-0.31	4.13e-11	Diabetic kidney disease;
LUAD	cis	rs367943	0.604	rs28519541	chr5:113006931	C/G	cg12552261	chr5:112820674	MCC	0.48	8.13	0.37	4.96e-15	Type 2 diabetes;
LUAD	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg22117172	chr7:91764530	CYP51A1	-0.35	-7.75	-0.35	7.09e-14	Breast cancer;
LUAD	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg27124370	chr19:33622961	WDR88	0.45	6.88	0.32	2.12e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.03	-0.36	9.99e-15	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg06953865	chr19:18549723	ISYNA1	-0.34	-6.52	-0.3	1.96e-10	Breast cancer;
LUAD	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg07217954	chr7:1067459	C7orf50	0.36	6.6	0.31	1.2e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg00277334	chr10:82204260	NA	-0.61	-9.7	-0.43	3.17e-20	Post bronchodilator FEV1;
LUAD	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg18129748	chr3:49941408	MST1R	-0.42	-6.91	-0.32	1.74e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs12681287	0.752	rs10085920	chr8:87252666	C/T	cg27223183	chr8:87520930	FAM82B	-0.59	-8.05	-0.36	8.64e-15	Caudate activity during reward;
LUAD	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg17971929	chr21:40555470	PSMG1	0.54	8.43	0.38	5.44e-16	Cognitive function;
LUAD	cis	rs970821	0.667	rs6470183	chr8:124752408	C/T	cg00283535	chr8:124749564	ANXA13	-0.36	-6.48	-0.3	2.58e-10	Breast cancer;
LUAD	cis	rs9858542	0.537	rs9874474	chr3:49326178	A/G	cg00383909	chr3:49044727	WDR6	0.57	7.49	0.34	3.94e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg24846343	chr22:24311635	DDTL	-0.76	-17.1	-0.64	3.15e-50	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9393692	0.537	rs9358926	chr6:26323132	C/G	cg00631329	chr6:26305371	NA	-0.53	-8.6	-0.39	1.57e-16	Educational attainment;
LUAD	cis	rs73198271	0.562	rs11774860	chr8:8651879	C/T	cg01851573	chr8:8652454	MFHAS1	0.69	10.95	0.47	9.51e-25	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs13315871	0.858	rs78946071	chr3:58318523	G/T	cg20936604	chr3:58311152	NA	-0.74	-7.4	-0.34	7.57e-13	Cholesterol, total;
LUAD	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22496380	chr5:211416	CCDC127	-0.92	-12.89	-0.53	2.75e-32	Breast cancer;
LUAD	trans	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	12.92	0.53	2.02e-32	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs8060686	0.516	rs2290699	chr16:68289059	C/T	cg10544611	chr16:67998164	SLC12A4	-0.46	-6.38	-0.3	4.65e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg20503657	chr10:835505	NA	0.83	12.68	0.52	1.91e-31	Eosinophil percentage of granulocytes;
LUAD	cis	rs7539409	0.915	rs4001467	chr1:84275858	A/T	cg10977910	chr1:84465055	TTLL7	-0.63	-6.63	-0.31	1.05e-10	Alzheimer's disease;
LUAD	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg03684893	chr10:554711	DIP2C	-0.4	-7.15	-0.33	3.92e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs1232027	0.700	rs1643655	chr5:79953776	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.88	-0.36	2.8e-14	Huntington's disease progression;
LUAD	cis	rs76878669	0.538	rs1546358	chr11:66175261	G/C	cg18002602	chr11:66138449	SLC29A2	0.47	9.97	0.44	3.51e-21	Educational attainment (years of education);
LUAD	cis	rs4849845	0.637	rs13022486	chr2:121038611	C/T	cg24070213	chr2:121070622	NA	0.4	7.63	0.35	1.62e-13	Mean platelet volume;
LUAD	cis	rs737008	1.000	rs737008	chr16:11374866	G/T	cg00044050	chr16:11439710	C16orf75	-0.44	-6.46	-0.3	2.87e-10	Obesity-related traits;
LUAD	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-10.64	-0.46	1.37e-23	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg04218760	chr10:45406644	TMEM72	-0.31	-7.59	-0.35	2.06e-13	Mean corpuscular volume;
LUAD	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg25767906	chr1:53392781	SCP2	0.65	11.67	0.49	1.74e-27	Monocyte count;
LUAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg02951883	chr7:2050386	MAD1L1	-0.97	-18.67	-0.67	3.53e-57	Bipolar disorder and schizophrenia;
LUAD	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-7.38	-0.34	8.32e-13	Body mass index;
LUAD	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-11.32	-0.48	3.78e-26	Developmental language disorder (linguistic errors);
LUAD	cis	rs240764	0.817	rs6922219	chr6:101153907	G/C	cg09795085	chr6:101329169	ASCC3	-0.43	-7.39	-0.34	7.95e-13	Neuroticism;
LUAD	trans	rs3219090	1.000	rs2048426	chr1:226594301	C/T	cg27539482	chr13:111589090	NA	0.44	7.4	0.34	7.52e-13	Melanoma;
LUAD	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg00310523	chr12:86230176	RASSF9	0.35	7.55	0.34	2.76e-13	Major depressive disorder;
LUAD	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg12179176	chr11:130786555	SNX19	0.46	7.61	0.35	1.77e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg22166914	chr1:53195759	ZYG11B	0.44	7.59	0.35	2.04e-13	Monocyte count;
LUAD	cis	rs877282	0.853	rs7092805	chr10:756246	G/A	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs8177876	0.822	rs7185637	chr16:81123156	A/G	cg08591886	chr16:81111003	C16orf46	0.62	6.59	0.3	1.35e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22496380	chr5:211416	CCDC127	-0.95	-13.32	-0.54	4.88e-34	Breast cancer;
LUAD	cis	rs922182	0.557	rs7161764	chr15:64202744	C/T	cg02919090	chr15:64263738	DAPK2	-0.36	-6.69	-0.31	7.07e-11	Blood protein levels;
LUAD	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg15704280	chr7:45808275	SEPT13	-0.89	-16.32	-0.62	8.28e-47	Height;
LUAD	cis	rs7932354	0.528	rs7931260	chr11:47088303	T/C	cg19486271	chr11:47235900	DDB2	-0.44	-6.96	-0.32	1.27e-11	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg22467129	chr15:76604101	ETFA	0.59	10.91	0.47	1.39e-24	Blood metabolite levels;
LUAD	cis	rs1983170	0.736	rs4484968	chr1:92012005	C/A	cg02896835	chr1:92012615	NA	0.57	8.0	0.36	1.17e-14	Eosinophil percentage of white cells;
LUAD	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg05283184	chr6:79620031	NA	-0.6	-12.22	-0.51	1.33e-29	Intelligence (multi-trait analysis);
LUAD	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg10792982	chr14:105748885	BRF1	0.45	9.85	0.43	9.74e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg00684032	chr4:1343700	KIAA1530	0.42	6.97	0.32	1.2e-11	Obesity-related traits;
LUAD	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg14784868	chr12:69753453	YEATS4	0.45	7.4	0.34	7.63e-13	Blood protein levels;
LUAD	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg25797454	chr6:150327115	RAET1K	0.33	7.25	0.33	1.95e-12	Alopecia areata;
LUAD	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg23281280	chr6:28129359	ZNF389	0.46	6.53	0.3	1.92e-10	Depression;
LUAD	cis	rs12976411	0.702	rs35465982	chr19:32819413	A/G	cg18253629	chr19:32836317	ZNF507	0.69	7.18	0.33	3.16e-12	Coronary artery disease;
LUAD	cis	rs3849570	0.961	rs7620240	chr3:81762787	G/T	cg07356753	chr3:81810745	GBE1	-0.7	-12.46	-0.52	1.41e-30	Waist circumference;Body mass index;
LUAD	cis	rs240764	0.658	rs7747014	chr6:101201898	T/G	cg09795085	chr6:101329169	ASCC3	-0.47	-8.3	-0.37	1.4e-15	Neuroticism;
LUAD	trans	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg24675056	chr1:15929824	NA	0.49	8.12	0.37	5.27e-15	Systolic blood pressure;
LUAD	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg13736514	chr6:26305472	NA	-0.69	-12.81	-0.53	5.6e-32	Educational attainment;
LUAD	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg02683114	chr2:24398427	C2orf84	0.44	7.25	0.33	1.93e-12	Asthma;
LUAD	cis	rs17155006	0.612	rs435361	chr7:107738552	C/T	cg05962710	chr7:107745446	LAMB4	-0.35	-7.27	-0.33	1.78e-12	Pneumococcal bacteremia;
LUAD	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg26384229	chr12:38710491	ALG10B	0.46	7.49	0.34	4.17e-13	Bladder cancer;
LUAD	trans	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.56	0.46	2.76e-23	Mean corpuscular volume;
LUAD	trans	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.79	-0.31	3.85e-11	Joint mobility (Beighton score);
LUAD	cis	rs7771547	0.642	rs1003250	chr6:36437412	A/G	cg07856975	chr6:36356162	ETV7	-0.41	-6.49	-0.3	2.38e-10	Platelet distribution width;
LUAD	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg21252483	chr19:49399788	TULP2	-0.88	-14.3	-0.57	3.88e-38	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg11070056	chr1:107600091	PRMT6	0.61	10.57	0.46	2.5e-23	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6484504	0.600	rs366758	chr11:31222499	A/C	cg06552810	chr11:31128660	NA	-0.32	-6.38	-0.3	4.77e-10	Red blood cell count;
LUAD	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.94	13.23	0.54	1.09e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg19469189	chr11:128781035	KCNJ5	-0.43	-6.58	-0.3	1.41e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs1395	1.000	rs1659695	chr2:27406944	T/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.44	-8.18	-0.37	3.33e-15	Blood metabolite levels;
LUAD	trans	rs1941687	0.527	rs1493914	chr18:31362327	C/T	cg15819921	chr19:927150	ARID3A	-0.48	-8.09	-0.37	6.39e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs11771526	0.892	rs62457540	chr7:32372199	A/G	cg27511599	chr7:32358540	NA	0.61	7.06	0.32	6.68e-12	Body mass index;
LUAD	cis	rs12472274	0.817	rs12621791	chr2:239104061	G/A	cg17459225	chr2:239074497	NA	0.71	9.6	0.42	7.36e-20	Phospholipid levels (plasma);
LUAD	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg15181151	chr6:150070149	PCMT1	0.38	7.68	0.35	1.12e-13	Lung cancer;
LUAD	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg07169764	chr2:136633963	MCM6	-0.48	-6.45	-0.3	3.13e-10	Mosquito bite size;
LUAD	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg14092988	chr3:52407081	DNAH1	0.37	7.48	0.34	4.47e-13	Electroencephalogram traits;
LUAD	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg26875233	chr11:93583750	C11orf90	-0.4	-8.87	-0.4	2.02e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs7737355	1.000	rs27663	chr5:130741438	T/G	cg06307176	chr5:131281290	NA	-0.47	-7.55	-0.34	2.71e-13	Life satisfaction;
LUAD	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg16680214	chr1:154839983	KCNN3	-0.64	-13.02	-0.54	7.67e-33	Prostate cancer;
LUAD	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg05887092	chr17:76393375	PGS1	0.42	7.37	0.34	8.79e-13	HDL cholesterol levels;
LUAD	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg07917127	chr4:99064746	C4orf37	0.42	6.99	0.32	1.04e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg16647868	chr5:131706066	SLC22A5	0.39	6.36	0.3	5.31e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg13073564	chr4:8508604	NA	0.5	9.19	0.41	1.73e-18	Response to antineoplastic agents;
LUAD	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.46	6.73	0.31	5.64e-11	Resistin levels;
LUAD	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg04842962	chr6:43655489	MRPS18A	1.06	27.06	0.8	2.45e-94	IgG glycosylation;
LUAD	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21028142	chr17:79581711	NPLOC4	0.44	9.64	0.42	5.15e-20	Eye color traits;
LUAD	cis	rs4523957	0.579	rs903161	chr17:2092006	A/T	cg16513277	chr17:2031491	SMG6	-0.87	-16.88	-0.63	2.99e-49	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6743376	0.556	rs2515401	chr2:113820476	C/T	cg09040174	chr2:113837401	NA	-0.47	-7.24	-0.33	2.07e-12	Inflammatory biomarkers;
LUAD	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs754466	1.000	rs2278218	chr10:79680399	G/A	cg17075019	chr10:79541650	NA	-0.83	-13.74	-0.56	8.56e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg08048268	chr3:133502702	NA	-0.38	-7.16	-0.33	3.69e-12	Iron status biomarkers;
LUAD	cis	rs9811920	0.683	rs1718235	chr3:99583484	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.34	6.71	0.31	6.1e-11	Axial length;
LUAD	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg09509183	chr1:209979624	IRF6	0.62	7.22	0.33	2.48e-12	Cleft lip with or without cleft palate;
LUAD	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg14779329	chr11:130786720	SNX19	0.41	7.45	0.34	5.29e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg27446573	chr6:127587934	RNF146	0.43	6.47	0.3	2.7e-10	Breast cancer;
LUAD	cis	rs12431939	0.948	rs12435444	chr14:51656071	C/T	cg23942311	chr14:51606299	NA	-0.57	-7.67	-0.35	1.2e-13	Cancer;
LUAD	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg11502198	chr6:26597334	ABT1	0.68	11.82	0.5	4.77e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs1030877	0.515	rs2576736	chr2:105890971	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.42	6.71	0.31	6.14e-11	Obesity-related traits;
LUAD	cis	rs9902453	0.934	rs34433787	chr17:28496780	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	8.41	0.38	6.12e-16	Coffee consumption (cups per day);
LUAD	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	7.44	0.34	5.84e-13	Cognitive test performance;
LUAD	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg07741184	chr6:167504864	NA	-0.36	-8.6	-0.39	1.6e-16	Primary biliary cholangitis;
LUAD	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg11663144	chr21:46675770	NA	-0.6	-11.42	-0.49	1.57e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs35883536	0.545	rs56674564	chr1:101097718	T/C	cg06223162	chr1:101003688	GPR88	0.37	6.79	0.31	3.71e-11	Monocyte count;
LUAD	cis	rs7680126	0.595	rs17251963	chr4:10142561	A/G	cg02734326	chr4:10020555	SLC2A9	-0.48	-6.52	-0.3	2.02e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg14820908	chr5:178986412	RUFY1	0.53	7.91	0.36	2.33e-14	Lung cancer;
LUAD	trans	rs853679	0.607	rs68188794	chr6:28080777	T/C	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.09	-0.47	3.02e-25	Depression;
LUAD	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg03388025	chr16:89894329	SPIRE2	0.34	7.71	0.35	9.23e-14	Vitiligo;
LUAD	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg12292205	chr6:26970375	C6orf41	0.39	6.98	0.32	1.17e-11	Schizophrenia;
LUAD	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg09365446	chr1:150670422	GOLPH3L	0.62	10.88	0.47	1.84e-24	Melanoma;
LUAD	trans	rs941408	0.963	rs1640267	chr19:2789337	T/C	cg19676328	chr12:49525230	TUBA1B	-0.76	-11.61	-0.49	2.95e-27	Total cholesterol levels;
LUAD	cis	rs67072384	0.818	rs2291292	chr11:72467013	C/T	cg04827223	chr11:72435913	ARAP1	-0.57	-7.0	-0.32	9.99e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg23625390	chr15:77176239	SCAPER	-0.58	-9.49	-0.42	1.64e-19	Blood metabolite levels;
LUAD	cis	rs13064411	0.696	rs6766615	chr3:113219342	T/C	cg18753928	chr3:113234510	CCDC52	-0.72	-12.16	-0.51	2.2e-29	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs10901296	0.702	rs11244178	chr9:133766008	C/T	cg13397898	chr9:133768931	QRFP	-0.45	-6.37	-0.3	5.06e-10	Bilirubin levels;
LUAD	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg26597838	chr10:835615	NA	0.96	14.91	0.59	1.05e-40	Eosinophil percentage of granulocytes;
LUAD	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs870825	0.616	rs12498890	chr4:185636096	C/G	cg04058563	chr4:185651563	MLF1IP	-0.86	-13.91	-0.56	1.69e-36	Blood protein levels;
LUAD	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg21220214	chr8:57350948	NA	-0.59	-8.39	-0.38	7.38e-16	Obesity-related traits;
LUAD	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-8.12	-0.37	5.27e-15	Electroencephalogram traits;
LUAD	cis	rs1003719	0.715	rs2835646	chr21:38546574	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.5	-8.43	-0.38	5.44e-16	Eye color traits;
LUAD	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg27129171	chr3:47204927	SETD2	-0.4	-6.36	-0.3	5.39e-10	Colorectal cancer;
LUAD	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg03477792	chr4:77819574	ANKRD56	-0.47	-7.29	-0.33	1.56e-12	Emphysema distribution in smoking;
LUAD	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg24154853	chr7:158122151	PTPRN2	-0.57	-11.54	-0.49	5.77e-27	Calcium levels;
LUAD	cis	rs11677370	0.574	rs12329183	chr2:3866943	G/A	cg17052675	chr2:3827356	NA	-0.61	-9.71	-0.43	2.88e-20	Type 2 diabetes;
LUAD	cis	rs2637266	0.935	rs2579720	chr10:78399918	T/C	cg18941641	chr10:78392320	NA	0.34	7.04	0.32	7.75e-12	Pulmonary function;
LUAD	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg00666640	chr1:248458726	OR2T12	0.32	7.65	0.35	1.4e-13	Common traits (Other);
LUAD	trans	rs9354308	0.933	rs1938068	chr6:66607807	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.5	7.52	0.34	3.37e-13	Metabolite levels;
LUAD	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg16060761	chr17:80687452	NA	-0.54	-7.63	-0.35	1.62e-13	Glycated hemoglobin levels;
LUAD	cis	rs6696239	0.513	rs4359006	chr1:227720786	G/A	cg12133451	chr1:227746453	NA	0.35	6.39	0.3	4.43e-10	Height;
LUAD	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23583168	chr7:148888333	NA	-0.93	-18.65	-0.67	4.17e-57	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg22907277	chr7:1156413	C7orf50	0.64	7.66	0.35	1.3e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2455799	0.927	rs9821921	chr3:15798246	A/G	cg16303742	chr3:15540471	COLQ	-0.39	-6.42	-0.3	3.7e-10	Mean platelet volume;
LUAD	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg22823121	chr1:150693482	HORMAD1	0.38	7.34	0.34	1.09e-12	Melanoma;
LUAD	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg14458575	chr2:238380390	NA	0.64	12.45	0.52	1.56e-30	Prostate cancer;
LUAD	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg09197432	chr4:183729176	NA	0.59	7.97	0.36	1.49e-14	Pediatric autoimmune diseases;
LUAD	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-8.37	-0.38	8.64e-16	Blood metabolite levels;
LUAD	cis	rs17102423	0.788	rs11158575	chr14:65581665	T/C	cg11161011	chr14:65562177	MAX	-0.49	-7.72	-0.35	8.45e-14	Obesity-related traits;
LUAD	cis	rs1953600	0.837	rs2236556	chr10:81932790	T/C	cg00277334	chr10:82204260	NA	0.4	6.83	0.32	2.9100000000000002e-11	Sarcoidosis;
LUAD	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg11941060	chr3:133502564	NA	-0.63	-11.47	-0.49	1.01e-26	Iron status biomarkers;
LUAD	cis	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg08601574	chr20:25228251	PYGB	0.46	8.31	0.37	1.28e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7587476	0.954	rs3768708	chr2:215645046	C/T	cg04004882	chr2:215674386	BARD1	-0.5	-6.5	-0.3	2.31e-10	Neuroblastoma;
LUAD	cis	rs4917300	1.000	rs13268779	chr8:143120421	G/A	cg25363559	chr8:143086065	NA	-0.34	-6.64	-0.31	9.69e-11	Amyotrophic lateral sclerosis;
LUAD	cis	rs4853036	1.000	rs3816491	chr2:70048534	A/G	cg02498382	chr2:70120550	SNRNP27	0.5	8.15	0.37	4.18e-15	Colorectal or endometrial cancer;
LUAD	trans	rs208520	0.690	rs207119	chr6:66786408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.32	-0.64	3.48e-51	Exhaled nitric oxide output;
LUAD	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg24818145	chr4:99064322	C4orf37	0.46	7.78	0.35	5.47e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.59	-8.59	-0.39	1.75e-16	Gut microbiome composition (summer);
LUAD	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg07636037	chr3:49044803	WDR6	0.57	10.69	0.46	9.05e-24	Parkinson's disease;
LUAD	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg02734326	chr4:10020555	SLC2A9	0.54	9.72	0.43	2.81e-20	Bone mineral density;
LUAD	trans	rs7246760	1.000	rs59867671	chr19:9933558	G/C	cg02900749	chr2:68251473	NA	-0.62	-6.64	-0.31	9.65e-11	Pursuit maintenance gain;
LUAD	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg13319975	chr6:146136371	FBXO30	-0.58	-9.85	-0.43	9.22e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs494562	0.892	rs1322404	chr6:86126912	T/A	cg21730993	chr6:86159210	NT5E	0.71	7.75	0.35	6.84e-14	Blood metabolite levels;Metabolic traits;
LUAD	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg15704280	chr7:45808275	SEPT13	-1.07	-24.81	-0.77	1.63e-84	Height;
LUAD	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg03806693	chr22:41940476	POLR3H	0.61	9.01	0.4	6.89e-18	Vitiligo;
LUAD	trans	rs2898857	0.524	rs2072153	chr17:47390014	C/G	cg11430096	chr6:110968061	CDK19	-0.51	-7.65	-0.35	1.36e-13	Cancer;
LUAD	cis	rs4903604	0.581	rs4903607	chr14:78038462	G/A	cg18872420	chr14:78023429	SPTLC2	0.46	8.16	0.37	3.78e-15	Gut microbiome composition (winter);
LUAD	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03352830	chr11:487213	PTDSS2	0.82	10.6	0.46	1.96e-23	Body mass index;
LUAD	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg14530993	chr4:882597	GAK	0.73	6.9	0.32	1.89e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg11070056	chr1:107600091	PRMT6	0.53	9.15	0.41	2.4e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4700695	0.925	rs12518262	chr5:65414004	A/G	cg21114390	chr5:65439923	SFRS12	-0.55	-6.48	-0.3	2.58e-10	Facial morphology (factor 19);
LUAD	cis	rs3925075	0.531	rs4597342	chr16:31343769	T/C	cg10451425	chr16:31478370	ARMC5	0.4	6.51	0.3	2.16e-10	IgA nephropathy;
LUAD	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05901451	chr6:126070800	HEY2	-0.79	-14.67	-0.58	1.1e-39	Brugada syndrome;
LUAD	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06873352	chr17:61820015	STRADA	0.82	18.23	0.66	3.22e-55	Prudent dietary pattern;
LUAD	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg24450063	chr1:156163899	SLC25A44	1.05	16.98	0.64	1.13e-49	Testicular germ cell tumor;
LUAD	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-8.39	-0.38	7.48e-16	Alzheimer's disease;
LUAD	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg02527881	chr3:46936655	PTH1R	-0.48	-9.31	-0.41	6.87e-19	Colorectal cancer;
LUAD	cis	rs4713675	0.565	rs6904816	chr6:33676156	G/A	cg14003231	chr6:33640908	ITPR3	0.49	9.54	0.42	1.17e-19	Plateletcrit;
LUAD	cis	rs57920188	0.535	rs58051771	chr1:4092146	T/C	cg10510935	chr1:4059661	NA	0.45	6.9	0.32	1.97e-11	Interleukin-17 levels;
LUAD	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg18351406	chr4:77819688	ANKRD56	0.62	9.83	0.43	1.1e-20	Emphysema distribution in smoking;
LUAD	cis	rs2230307	0.536	rs687513	chr1:100598867	C/T	cg20868668	chr1:100435035	SLC35A3	-0.49	-7.34	-0.34	1.08e-12	Carotid intima media thickness;
LUAD	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg01620082	chr3:125678407	NA	-0.96	-9.97	-0.44	3.5e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15506890	chr2:3487001	NA	-0.45	-7.8	-0.35	4.75e-14	Neurofibrillary tangles;
LUAD	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.52	-8.29	-0.37	1.52e-15	Reticulocyte count;
LUAD	cis	rs10203711	1.000	rs11682137	chr2:239588939	G/A	cg14580085	chr2:239553406	NA	0.42	9.07	0.4	4.36e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.49	7.82	0.36	4.36e-14	Total body bone mineral density;
LUAD	cis	rs6906287	0.647	rs12214483	chr6:118780146	G/C	cg21191810	chr6:118973309	C6orf204	0.49	9.55	0.42	1.05e-19	Electrocardiographic conduction measures;
LUAD	cis	rs7149337	0.805	rs2999361	chr14:51605358	G/A	cg23942311	chr14:51606299	NA	0.87	20.25	0.7	3.12e-64	Cancer;
LUAD	cis	rs2479724	0.598	rs7768838	chr6:41945174	G/A	cg17623882	chr6:41773611	USP49	-0.48	-8.25	-0.37	2.08e-15	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1997103	1.000	rs2140915	chr7:55410699	G/C	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg11062466	chr8:58055876	NA	0.65	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg10755058	chr3:40428713	ENTPD3	0.45	8.46	0.38	4.46e-16	Renal cell carcinoma;
LUAD	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg22532475	chr10:104410764	TRIM8	0.44	8.46	0.38	4.3e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg18721089	chr20:30220636	NA	-0.49	-7.06	-0.32	6.99e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs7191700	0.578	rs243327	chr16:11353304	C/T	cg00044050	chr16:11439710	C16orf75	-0.65	-10.54	-0.46	3.14e-23	Multiple sclerosis;
LUAD	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.34	7.04	0.32	7.72e-12	Hemoglobin concentration;
LUAD	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg03874509	chr1:107600012	PRMT6	-0.57	-9.93	-0.43	4.87e-21	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg18129178	chr5:148520854	ABLIM3	-0.63	-9.48	-0.42	1.85e-19	Breast cancer;
LUAD	cis	rs7771547	0.573	rs629297	chr6:36398146	C/T	cg04289385	chr6:36355825	ETV7	0.42	6.53	0.3	1.85e-10	Platelet distribution width;
LUAD	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg00129232	chr17:37814104	STARD3	-0.47	-7.46	-0.34	5.03e-13	Asthma;
LUAD	cis	rs4919694	1.000	rs17787717	chr10:104695699	T/G	cg04362960	chr10:104952993	NT5C2	0.82	8.55	0.38	2.34e-16	Arsenic metabolism;
LUAD	trans	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	15.44	0.6	5.86e-43	Exhaled nitric oxide levels;
LUAD	trans	rs7944735	0.938	rs59185955	chr11:47961566	G/C	cg03929089	chr4:120376271	NA	0.61	7.74	0.35	7.24e-14	Intraocular pressure;
LUAD	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg19413350	chr8:57351067	NA	-0.41	-6.67	-0.31	8.05e-11	Obesity-related traits;
LUAD	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.48e-10	Prostate cancer;
LUAD	cis	rs61008539	1.000	rs61008539	chr7:858506	C/G	cg00934597	chr7:893267	UNC84A	-0.55	-9.0	-0.4	7.48e-18	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs3849570	1.000	rs3772883	chr3:81802802	C/T	cg07356753	chr3:81810745	GBE1	-0.61	-10.62	-0.46	1.59e-23	Waist circumference;Body mass index;
LUAD	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00149659	chr3:10157352	C3orf10	0.87	11.72	0.5	1.1e-27	Alzheimer's disease;
LUAD	cis	rs68170813	0.559	rs7794598	chr7:106826381	C/T	cg23024343	chr7:107201750	COG5	0.45	6.72	0.31	5.95e-11	Coronary artery disease;
LUAD	cis	rs6141769	0.866	rs79384779	chr20:31214944	C/T	cg13636640	chr20:31349939	DNMT3B	0.56	6.66	0.31	8.3e-11	Subjective well-being;
LUAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs250585	1.000	rs7196534	chr16:23557718	T/C	cg00143387	chr16:23521605	GGA2	-0.68	-8.14	-0.37	4.41e-15	Egg allergy;
LUAD	cis	rs3106136	0.934	rs2902979	chr4:95177874	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.43	-0.34	6.06e-13	Capecitabine sensitivity;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02927485	chr7:97601469	MGC72080	-0.49	-6.39	-0.3	4.44e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg13354988	chr2:263656	ACP1;SH3YL1	0.29	6.4	0.3	4.14e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg04267008	chr7:1944627	MAD1L1	-0.72	-10.8	-0.46	3.65e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg00898013	chr13:113819073	PROZ	-0.84	-15.04	-0.59	2.87e-41	Platelet distribution width;
LUAD	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg07917127	chr4:99064746	C4orf37	0.49	7.0	0.32	1e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg17652424	chr22:38574118	PLA2G6	-0.33	-9.93	-0.43	4.9e-21	Cutaneous nevi;
LUAD	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg12884169	chr21:40033163	ERG	0.49	10.68	0.46	9.93e-24	Coronary artery disease;
LUAD	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg01475377	chr6:109611718	NA	-0.53	-9.93	-0.43	4.93e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg00784671	chr22:46762841	CELSR1	-0.61	-7.55	-0.34	2.66e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg26384229	chr12:38710491	ALG10B	0.48	7.86	0.36	3.29e-14	Bladder cancer;
LUAD	cis	rs6906287	0.669	rs12208253	chr6:118925097	G/C	cg05564266	chr6:118973597	C6orf204	0.36	7.44	0.34	5.71e-13	Electrocardiographic conduction measures;
LUAD	cis	rs12545109	0.765	rs2438063	chr8:57384360	A/G	cg07776626	chr8:57350775	NA	0.65	9.57	0.42	9.15e-20	Obesity-related traits;
LUAD	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg24558204	chr6:135376177	HBS1L	0.46	7.86	0.36	3.32e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg27170947	chr2:26402098	FAM59B	0.84	10.72	0.46	6.93e-24	Gut microbiome composition (summer);
LUAD	cis	rs2050392	1.000	rs2265186	chr10:30691743	C/T	cg18806716	chr10:30721971	MAP3K8	0.48	9.48	0.42	1.8e-19	Inflammatory bowel disease;
LUAD	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg26769984	chr7:1090371	C7orf50	0.59	8.94	0.4	1.23e-17	Bronchopulmonary dysplasia;
LUAD	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.04	-0.32	7.59e-12	Total cholesterol levels;
LUAD	cis	rs7665090	1.000	rs735405	chr4:103553916	A/C	cg07973026	chr4:103553119	MANBA	0.47	8.39	0.38	7.48e-16	Primary biliary cholangitis;
LUAD	cis	rs11214589	0.747	rs10891537	chr11:113211370	A/C	cg14159747	chr11:113255604	NA	0.58	11.07	0.47	3.58e-25	Neuroticism;
LUAD	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-9.17	-0.41	2.16e-18	Bipolar disorder;
LUAD	cis	rs7187994	0.848	rs34457873	chr16:84782871	T/G	cg07647771	chr16:84786436	USP10	-0.35	-9.02	-0.4	6.39e-18	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg13012494	chr21:47604986	C21orf56	0.47	7.75	0.35	6.93e-14	Testicular germ cell tumor;
LUAD	cis	rs67072384	0.792	rs7936968	chr11:72479681	T/C	cg04827223	chr11:72435913	ARAP1	-0.65	-7.02	-0.32	8.68e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUAD	trans	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg27411982	chr8:10470053	RP1L1	0.38	6.45	0.3	3.13e-10	Joint mobility (Beighton score);
LUAD	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg14196790	chr5:131705035	SLC22A5	0.45	8.03	0.36	9.49e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg17105886	chr17:28927953	LRRC37B2	0.77	7.5	0.34	3.82e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg08761264	chr16:28874980	SH2B1	-0.44	-6.62	-0.31	1.07e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg03467027	chr4:99064603	C4orf37	0.43	7.02	0.32	8.91e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4889855	0.530	rs11654265	chr17:78602697	G/A	cg16591659	chr17:78472290	NA	0.45	7.82	0.36	4.31e-14	Fractional excretion of uric acid;
LUAD	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg18806716	chr10:30721971	MAP3K8	-0.64	-13.2	-0.54	1.46e-33	Inflammatory bowel disease;
LUAD	cis	rs796825	0.530	rs1907683	chr3:119950617	A/C	cg21790991	chr3:120137480	FSTL1	-0.42	-7.19	-0.33	2.88e-12	HIV-1 susceptibility;
LUAD	cis	rs10924309	0.889	rs10802248	chr1:245858554	A/C	cg00036263	chr1:245852353	KIF26B	-0.47	-7.4	-0.34	7.49e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LUAD	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.55	-9.49	-0.42	1.73e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.4	-6.66	-0.31	8.67e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7107174	0.901	rs1055248	chr11:77925573	T/C	cg02023728	chr11:77925099	USP35	0.49	7.76	0.35	6.47e-14	Testicular germ cell tumor;
LUAD	cis	rs6601327	0.613	rs11785458	chr8:9506810	T/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.87	-0.32	2.29e-11	Multiple myeloma (hyperdiploidy);
LUAD	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg13390004	chr1:15929781	NA	0.48	8.09	0.37	6.56e-15	Systolic blood pressure;
LUAD	cis	rs4638749	0.734	rs4676191	chr2:108861242	A/G	cg25838818	chr2:108905173	SULT1C2	-0.38	-6.62	-0.31	1.07e-10	Blood pressure;
LUAD	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg26752003	chr8:145688521	CYHR1	0.55	9.72	0.43	2.62e-20	Age at first birth;
LUAD	cis	rs597539	0.690	rs7104351	chr11:68617886	A/G	cg21862992	chr11:68658383	NA	0.52	9.41	0.42	3.16e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1816752	0.905	rs6490928	chr13:25014059	T/C	cg02811702	chr13:24901961	NA	0.45	7.88	0.36	2.72e-14	Obesity-related traits;
LUAD	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg04025307	chr7:1156635	C7orf50	0.62	7.65	0.35	1.36e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg09998033	chr7:158218633	PTPRN2	-0.58	-10.75	-0.46	5.43e-24	Obesity-related traits;
LUAD	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg00310523	chr12:86230176	RASSF9	0.41	8.05	0.36	8.27e-15	Major depressive disorder;
LUAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg05481257	chr2:20870211	GDF7	-0.63	-12.84	-0.53	4.25e-32	Abdominal aortic aneurysm;
LUAD	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg14202850	chr17:43974869	MAPT;LOC100130148	0.4	6.81	0.31	3.26e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg09222892	chr1:25734099	RHCE	-0.51	-9.34	-0.41	5.61e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs2294693	0.687	rs4714424	chr6:41012506	T/C	cg14769373	chr6:40998127	UNC5CL	-0.46	-7.37	-0.34	9.1e-13	Gastric cancer;Non-cardia gastric cancer;
LUAD	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg17724175	chr1:150552817	MCL1	0.4	9.88	0.43	7.37e-21	Tonsillectomy;
LUAD	cis	rs12049351	0.774	rs12125125	chr1:229627666	A/T	cg11742688	chr1:229674241	ABCB10	-0.42	-6.4	-0.3	4.04e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs6445967	0.500	rs1554126	chr3:58277536	A/G	cg23715586	chr3:58305044	RPP14	0.39	6.41	0.3	3.91e-10	Platelet count;
LUAD	cis	rs3806843	0.576	rs246029	chr5:140333226	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4629710	0.534	rs6916881	chr6:131565153	C/T	cg12606694	chr6:131520996	AKAP7	0.5	7.23	0.33	2.23e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs6062509	0.811	rs6062498	chr20:62339059	C/G	cg21849932	chr20:62369462	LIME1	-0.45	-7.26	-0.33	1.89e-12	Prostate cancer;
LUAD	cis	rs4285028	0.898	rs12491991	chr3:121706021	A/C	cg11130432	chr3:121712080	ILDR1	0.61	8.73	0.39	6.08e-17	Multiple sclerosis;
LUAD	trans	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg01620082	chr3:125678407	NA	-0.46	-6.69	-0.31	7.12e-11	Depression;
LUAD	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-8.99	-0.4	8.34e-18	Bipolar disorder;
LUAD	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg06608945	chr2:219082296	ARPC2	-0.42	-6.88	-0.32	2.18e-11	Colorectal cancer;
LUAD	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg20476274	chr7:133979776	SLC35B4	0.8	15.46	0.6	4.44e-43	Mean platelet volume;
LUAD	trans	rs3219090	0.927	rs747657	chr1:226550924	G/C	cg27539482	chr13:111589090	NA	-0.39	-6.57	-0.3	1.46e-10	Melanoma;
LUAD	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.61	0.31	1.15e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs9462027	0.583	rs6937784	chr6:34644276	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-8.55	-0.38	2.21e-16	Systemic lupus erythematosus;
LUAD	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg18755752	chr8:142205143	DENND3	-0.43	-7.51	-0.34	3.57e-13	Immature fraction of reticulocytes;
LUAD	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg06641503	chr3:48959341	ARIH2	-0.37	-7.37	-0.34	8.81e-13	Menarche (age at onset);
LUAD	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg26384229	chr12:38710491	ALG10B	0.49	7.83	0.36	4.09e-14	Morning vs. evening chronotype;
LUAD	cis	rs123509	0.913	rs121993	chr3:42776601	T/C	cg10144569	chr3:42726640	KBTBD5	0.5	7.86	0.36	3.3e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg12927641	chr6:109611667	NA	-0.51	-8.72	-0.39	6.51e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-6.62	-0.31	1.1e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12431939	0.671	rs2999384	chr14:51650328	G/T	cg23942311	chr14:51606299	NA	0.42	6.57	0.3	1.49e-10	Cancer;
LUAD	cis	rs2262909	0.962	rs73019889	chr19:22277826	C/G	cg11619707	chr19:22235551	ZNF257	0.49	7.52	0.34	3.26e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg23933602	chr10:16859644	RSU1	0.59	8.14	0.37	4.33e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	trans	rs970510	0.851	rs2657768	chr18:69498321	C/T	cg25371038	chr22:22337141	TOP3B	0.39	6.42	0.3	3.78e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
LUAD	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg13319975	chr6:146136371	FBXO30	0.63	10.91	0.47	1.4e-24	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02367472	chr5:159845898	SLU7	-0.41	-6.95	-0.32	1.36e-11	Cancer;
LUAD	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg27129171	chr3:47204927	SETD2	0.4	6.46	0.3	2.95e-10	Colorectal cancer;
LUAD	cis	rs11051970	0.679	rs2931554	chr12:32556162	G/A	cg02745156	chr12:32552066	NA	0.31	6.74	0.31	5.35e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs367943	0.666	rs10051834	chr5:112693803	C/T	cg21806985	chr5:112824646	MCC	0.25	6.4	0.3	4.06e-10	Type 2 diabetes;
LUAD	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg24675056	chr1:15929824	NA	-0.52	-8.64	-0.39	1.14e-16	Systolic blood pressure;
LUAD	cis	rs6840360	0.615	rs9996320	chr4:152610587	T/G	cg22705602	chr4:152727874	NA	-0.5	-9.67	-0.43	4.18e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	cis	rs758324	0.947	rs1566427	chr5:131191672	G/A	cg25547332	chr5:131281432	NA	0.44	6.7	0.31	6.85e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg08132940	chr7:1081526	C7orf50	-0.7	-10.09	-0.44	1.4e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs910187	0.678	rs6124964	chr20:45812536	T/G	cg27589058	chr20:45804311	EYA2	-0.33	-7.46	-0.34	5.01e-13	Migraine;
LUAD	cis	rs11811982	0.793	rs76742911	chr1:227509018	G/T	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs9811920	0.809	rs4928153	chr3:99808445	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.58	-11.21	-0.48	1.06e-25	Axial length;
LUAD	cis	rs89107	0.549	rs17427116	chr6:118986198	G/A	cg21191810	chr6:118973309	C6orf204	0.4	7.41	0.34	6.95e-13	Cardiac structure and function;
LUAD	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg13736514	chr6:26305472	NA	-0.7	-13.07	-0.54	5.05e-33	Educational attainment;
LUAD	trans	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg06606381	chr12:133084897	FBRSL1	-1.18	-10.06	-0.44	1.68e-21	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg06547715	chr2:218990976	CXCR2	0.28	6.72	0.31	6.08e-11	Colorectal cancer;
LUAD	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg08132940	chr7:1081526	C7orf50	-0.76	-10.09	-0.44	1.3e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10979	1.000	rs13198159	chr6:143891953	C/T	cg25407410	chr6:143891975	LOC285740	-0.65	-10.32	-0.45	2.05e-22	Hypospadias;
LUAD	cis	rs929596	0.556	rs4477910	chr2:234643737	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-10.66	-0.46	1.2e-23	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg12884169	chr21:40033163	ERG	0.5	10.76	0.46	4.87e-24	Coronary artery disease;
LUAD	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.31	-0.41	7.28e-19	Type 2 diabetes;
LUAD	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg06636551	chr8:101224915	SPAG1	-0.37	-6.84	-0.32	2.83e-11	Atrioventricular conduction;
LUAD	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg09184832	chr6:79620586	NA	0.51	9.79	0.43	1.59e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg09835421	chr16:68378352	PRMT7	-0.81	-8.79	-0.39	3.68e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.09	0.37	6.3e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4849845	0.653	rs3925970	chr2:121018153	C/A	cg24070213	chr2:121070622	NA	0.39	7.46	0.34	5.02e-13	Mean platelet volume;
LUAD	cis	rs11681884	1.000	rs11893386	chr2:113844310	A/G	cg12858261	chr2:113808755	IL1F8	0.5	6.49	0.3	2.45e-10	Stroke;
LUAD	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg03233332	chr7:66118400	NA	0.43	6.62	0.31	1.12e-10	Aortic root size;
LUAD	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg21724239	chr8:58056113	NA	0.48	7.04	0.32	7.64e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg23018236	chr17:30244563	NA	-0.69	-8.39	-0.38	7.53e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg16405210	chr4:1374714	KIAA1530	-0.63	-9.77	-0.43	1.83e-20	Longevity;
LUAD	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.78	0.31	3.96e-11	Parkinson's disease;
LUAD	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg16325326	chr1:53192061	ZYG11B	0.61	10.57	0.46	2.48e-23	Monocyte count;
LUAD	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg06505273	chr16:24850292	NA	0.37	6.35	0.3	5.49e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg14917512	chr19:3094685	GNA11	-0.55	-6.51	-0.3	2.14e-10	Diabetic kidney disease;
LUAD	cis	rs1595825	0.945	rs1518369	chr2:198859183	C/T	cg11031976	chr2:198649780	BOLL	-0.45	-6.8	-0.31	3.62e-11	Ulcerative colitis;
LUAD	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg12016809	chr21:47604291	C21orf56	0.48	7.89	0.36	2.68e-14	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg00953403	chr17:74099816	EXOC7	-0.51	-8.3	-0.37	1.4e-15	Psychosis in Alzheimer's disease;
LUAD	cis	rs4319547	0.506	rs2062488	chr12:122804256	C/T	cg23029597	chr12:123009494	RSRC2	0.42	6.86	0.32	2.4e-11	Body mass index;
LUAD	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg02725872	chr8:58115012	NA	-0.33	-6.46	-0.3	2.9e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.33	6.69	0.31	7.22e-11	Obesity-related traits;
LUAD	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg21138405	chr5:131827807	IRF1	0.6	13.89	0.56	2.17e-36	Asthma (sex interaction);
LUAD	cis	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg02508848	chr16:68573721	ZFP90	-0.42	-6.6	-0.31	1.22e-10	Ulcerative colitis;
LUAD	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.92	0.32	1.73e-11	Rheumatoid arthritis;
LUAD	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg01657329	chr11:68192670	LRP5	-0.4	-6.56	-0.3	1.53e-10	Total body bone mineral density;
LUAD	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg20891283	chr12:69753455	YEATS4	0.44	7.13	0.33	4.3e-12	Blood protein levels;
LUAD	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.44	-9.15	-0.41	2.42e-18	Total body bone mineral density;
LUAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.37	-0.41	4.57e-19	Type 2 diabetes;
LUAD	cis	rs62458065	0.513	rs702831	chr7:32579715	C/T	cg20159608	chr7:32802032	NA	-0.7	-10.43	-0.45	7.87e-23	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg26566898	chr11:117069891	TAGLN	-0.36	-7.15	-0.33	3.86e-12	Blood protein levels;
LUAD	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.92	-0.43	5.23e-21	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs3733418	0.929	rs13110309	chr4:165889672	T/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.49	-6.83	-0.32	2.94e-11	Obesity-related traits;
LUAD	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg13385794	chr1:248469461	NA	0.25	6.46	0.3	2.84e-10	Common traits (Other);
LUAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg18402987	chr7:1209562	NA	0.78	9.54	0.42	1.19e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7586879	0.752	rs11683748	chr2:25130434	C/T	cg04586622	chr2:25135609	ADCY3	0.38	7.7	0.35	9.58e-14	Body mass index;
LUAD	cis	rs6952808	0.964	rs10950407	chr7:1895666	T/G	cg05434287	chr7:2030229	MAD1L1	0.42	6.72	0.31	5.76e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg11494091	chr17:61959527	GH2	0.74	18.56	0.67	1.05e-56	Prudent dietary pattern;
LUAD	trans	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg07393940	chr7:158741817	NA	0.69	11.46	0.49	1.15e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2629540	0.847	rs11245342	chr10:126414084	C/T	cg08799069	chr10:126477246	METTL10	0.47	6.9	0.32	1.86e-11	Cocaine dependence;
LUAD	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg21963583	chr11:68658836	MRPL21	0.68	11.94	0.5	1.63e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs12711979	0.740	rs6711964	chr2:3820916	A/T	cg17052675	chr2:3827356	NA	-0.51	-10.53	-0.46	3.55e-23	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22029157	chr1:209979665	IRF6	0.77	12.57	0.52	4.98e-31	Cleft lip with or without cleft palate;
LUAD	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.62	-11.46	-0.49	1.16e-26	Lung cancer;
LUAD	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	6.81	0.31	3.31e-11	Personality dimensions;
LUAD	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg21951975	chr1:209979733	IRF6	0.57	9.09	0.4	3.83e-18	Cleft lip with or without cleft palate;
LUAD	cis	rs713587	0.776	rs3731623	chr2:25163783	T/C	cg04586622	chr2:25135609	ADCY3	0.31	6.67	0.31	8.09e-11	Body mass index in non-asthmatics;
LUAD	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg01200585	chr1:228362443	C1orf69	-0.37	-6.9	-0.32	1.95e-11	Diastolic blood pressure;
LUAD	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg03467027	chr4:99064603	C4orf37	0.41	6.54	0.3	1.74e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg11859384	chr17:80120422	CCDC57	-0.52	-9.35	-0.41	5.05e-19	Life satisfaction;
LUAD	cis	rs1816752	0.870	rs3825449	chr13:25014441	A/C	cg02811702	chr13:24901961	NA	0.45	7.87	0.36	2.97e-14	Obesity-related traits;
LUAD	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg18132916	chr6:79620363	NA	-0.46	-7.95	-0.36	1.67e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg16447950	chr5:562315	NA	-0.41	-6.41	-0.3	3.91e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg03732007	chr1:2071316	PRKCZ	-0.36	-7.26	-0.33	1.87e-12	Height;
LUAD	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg17366294	chr4:99064904	C4orf37	-0.48	-8.49	-0.38	3.66e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2109514	0.902	rs28495552	chr7:116113744	C/G	cg12739419	chr7:116140593	CAV2	-0.33	-6.82	-0.31	3.22e-11	Prevalent atrial fibrillation;
LUAD	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg03037974	chr15:76606532	NA	0.38	8.19	0.37	3.2e-15	Blood metabolite levels;
LUAD	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg03929089	chr4:120376271	NA	-0.69	-11.27	-0.48	6.26e-26	Coronary artery disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03069383	chr2:18741691	RDH14	-0.54	-6.63	-0.31	1.03e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg18806716	chr10:30721971	MAP3K8	-0.62	-11.99	-0.5	1e-28	Itch intensity from mosquito bite;
LUAD	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.47	0.3	2.78e-10	Parkinson's disease;
LUAD	cis	rs10203711	0.933	rs4994752	chr2:239567309	C/A	cg14580085	chr2:239553406	NA	0.41	8.9	0.4	1.64e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg23649088	chr2:200775458	C2orf69	0.62	8.07	0.37	7.25e-15	Schizophrenia;
LUAD	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg19302996	chr17:73780495	UNK	-0.47	-7.89	-0.36	2.63e-14	White matter hyperintensity burden;
LUAD	cis	rs524023	0.874	rs475642	chr11:64424691	C/A	cg19131476	chr11:64387923	NRXN2	-0.43	-8.5	-0.38	3.29e-16	Urate levels in obese individuals;
LUAD	cis	rs897984	0.609	rs57576577	chr16:31036367	G/A	cg02466173	chr16:30829666	NA	-0.57	-10.0	-0.44	2.89e-21	Dementia with Lewy bodies;
LUAD	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg13722127	chr7:150037890	RARRES2	-0.44	-7.54	-0.34	2.87e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs6594713	0.684	rs1816062	chr5:112856023	A/C	cg12552261	chr5:112820674	MCC	0.53	7.24	0.33	2.08e-12	Brain cytoarchitecture;
LUAD	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.75	-0.35	6.93e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg20628663	chr10:43360327	NA	0.7	11.19	0.48	1.26e-25	Blood protein levels;
LUAD	cis	rs7586879	0.964	rs13412941	chr2:25102709	C/T	cg04586622	chr2:25135609	ADCY3	0.35	7.06	0.32	6.94e-12	Body mass index;
LUAD	cis	rs2235649	0.552	rs7203361	chr16:1963085	G/A	cg07386859	chr16:1872102	HAGH	0.44	6.36	0.3	5.28e-10	Blood metabolite levels;
LUAD	cis	rs10499694	0.844	rs10499695	chr7:50618604	A/G	cg18232548	chr7:50535776	DDC	-0.47	-8.25	-0.37	2.02e-15	Body mass index;
LUAD	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg11845111	chr2:191398756	TMEM194B	-0.84	-11.18	-0.48	1.29e-25	Diastolic blood pressure;
LUAD	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg27661571	chr11:113659931	NA	-0.72	-8.57	-0.38	1.98e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg27454412	chr7:1067447	C7orf50	0.44	7.0	0.32	1.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs36051895	0.632	rs11791281	chr9:5172540	G/A	cg02405213	chr9:5042618	JAK2	-0.45	-6.38	-0.3	4.58e-10	Pediatric autoimmune diseases;
LUAD	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg19418458	chr7:158789849	NA	-0.65	-11.37	-0.48	2.46e-26	Facial morphology (factor 20);
LUAD	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-6.7	-0.31	6.5500000000000006e-11	Personality dimensions;
LUAD	cis	rs68170813	0.617	rs17486	chr7:107112890	C/T	cg23024343	chr7:107201750	COG5	0.51	6.45	0.3	3.09e-10	Coronary artery disease;
LUAD	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg12645284	chr15:79092878	ADAMTS7	-0.5	-8.26	-0.37	1.86e-15	Coronary artery disease or large artery stroke;
LUAD	cis	rs1032833	0.732	rs115647285	chr2:179950029	G/C	cg23883738	chr2:179974586	SESTD1	-0.72	-8.26	-0.37	1.9e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs10504073	0.584	rs7818507	chr8:49918423	G/T	cg00325661	chr8:49890786	NA	0.45	10.29	0.45	2.58e-22	Blood metabolite ratios;
LUAD	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg13393036	chr8:95962371	TP53INP1	-0.38	-7.73	-0.35	7.72e-14	Type 2 diabetes;
LUAD	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg22681709	chr2:178499509	PDE11A	-0.44	-7.32	-0.34	1.29e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9341808	0.528	rs2322753	chr6:81042865	C/G	cg08355045	chr6:80787529	NA	0.47	8.13	0.37	4.88e-15	Sitting height ratio;
LUAD	cis	rs3820068	0.705	rs72643694	chr1:15860185	C/T	cg24675056	chr1:15929824	NA	0.42	6.81	0.31	3.46e-11	Systolic blood pressure;
LUAD	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.71e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2730260	0.736	rs73169220	chr7:158846197	A/C	cg02254261	chr7:158964346	NA	-0.54	-6.43	-0.3	3.39e-10	Myopia (pathological);
LUAD	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg18512352	chr11:47633146	NA	0.41	7.13	0.33	4.39e-12	Subjective well-being;
LUAD	cis	rs11650494	0.908	rs11650087	chr17:47362923	T/A	cg08112188	chr17:47440006	ZNF652	0.92	7.72	0.35	8.45e-14	Prostate cancer;
LUAD	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg22823121	chr1:150693482	HORMAD1	-0.4	-7.32	-0.34	1.25e-12	Urate levels;
LUAD	cis	rs8028313	0.630	rs7169086	chr15:67934454	C/T	cg27219399	chr15:67835830	MAP2K5	0.4	6.77	0.31	4.3e-11	Obesity;
LUAD	cis	rs7301826	1.000	rs4759787	chr12:131290180	A/C	cg11011512	chr12:131303247	STX2	0.39	6.72	0.31	6.05e-11	Plasma plasminogen activator levels;
LUAD	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg20587970	chr11:113659929	NA	-1.38	-20.92	-0.71	3.05e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg19635926	chr16:89946313	TCF25	0.73	6.37	0.3	4.99e-10	Skin colour saturation;
LUAD	cis	rs7512552	0.839	rs6662108	chr1:150420541	G/T	cg15654264	chr1:150340011	RPRD2	0.6	11.73	0.5	1.03e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4356932	0.967	rs4318674	chr4:76934422	C/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.46	-0.3	2.82e-10	Blood protein levels;
LUAD	trans	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.57	-9.63	-0.42	5.48e-20	Mean corpuscular volume;
LUAD	cis	rs89107	0.575	rs11752928	chr6:118977768	C/G	cg21191810	chr6:118973309	C6orf204	0.4	7.43	0.34	5.94e-13	Cardiac structure and function;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg15065069	chr1:154974120	ZBTB7B	0.43	7.11	0.33	5.05e-12	Diastolic blood pressure;
LUAD	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06544989	chr22:39130855	UNC84B	0.46	9.25	0.41	1.09e-18	Menopause (age at onset);
LUAD	cis	rs1775715	0.737	rs2808090	chr10:32143208	A/C	cg04359828	chr10:32216031	ARHGAP12	0.31	6.42	0.3	3.72e-10	Bipolar disorder with mood-incongruent psychosis;
LUAD	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg03929089	chr4:120376271	NA	0.66	9.52	0.42	1.31e-19	Height;
LUAD	cis	rs9323205	0.531	rs11157796	chr14:51544623	C/T	cg23942311	chr14:51606299	NA	-0.44	-6.99	-0.32	1.1e-11	Cancer;
LUAD	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08109568	chr15:31115862	NA	-0.61	-10.43	-0.45	8.27e-23	Huntington's disease progression;
LUAD	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg15704280	chr7:45808275	SEPT13	0.75	11.06	0.47	3.89e-25	Coronary artery disease;
LUAD	cis	rs7737355	0.812	rs10078640	chr5:131071246	C/G	cg06307176	chr5:131281290	NA	0.48	7.84	0.36	3.8e-14	Life satisfaction;
LUAD	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg05165339	chr4:1420672	NA	-0.29	-6.55	-0.3	1.62e-10	Longevity;
LUAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg15117754	chr3:10150083	C3orf24	0.41	6.59	0.31	1.3100000000000001e-10	Alzheimer's disease;
LUAD	cis	rs1018836	0.828	rs2105968	chr8:91591825	A/G	cg16814680	chr8:91681699	NA	-0.6	-10.05	-0.44	1.93e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg04450456	chr4:17643702	FAM184B	0.37	6.95	0.32	1.37e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg02158880	chr13:53174818	NA	-0.47	-7.95	-0.36	1.73e-14	Lewy body disease;
LUAD	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg09117114	chr16:67998030	SLC12A4	-0.49	-6.97	-0.32	1.24e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.72	-14.78	-0.58	3.63e-40	Urate levels in overweight individuals;
LUAD	cis	rs8062405	0.655	rs7184597	chr16:28921809	T/C	cg05966235	chr16:28915196	ATP2A1	-0.57	-8.95	-0.4	1.16e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7020830	0.898	rs12555207	chr9:37315476	C/T	cg14294708	chr9:37120828	ZCCHC7	0.87	17.68	0.65	8.82e-53	Schizophrenia;
LUAD	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg02782426	chr3:40428986	ENTPD3	-0.36	-7.83	-0.36	3.93e-14	Renal cell carcinoma;
LUAD	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg03714773	chr7:91764589	CYP51A1	0.3	6.96	0.32	1.29e-11	Breast cancer;
LUAD	cis	rs2932538	0.922	rs2932535	chr1:113201412	G/C	cg22162597	chr1:113214053	CAPZA1	-0.45	-6.73	-0.31	5.41e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07636037	chr3:49044803	WDR6	0.47	7.85	0.36	3.47e-14	Menarche (age at onset);
LUAD	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg11416102	chr8:651193	ERICH1	-0.83	-8.76	-0.39	4.93e-17	IgG glycosylation;
LUAD	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg22105103	chr4:187893119	NA	0.58	12.66	0.52	2.31e-31	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg17178900	chr1:205818956	PM20D1	0.73	14.78	0.58	3.81e-40	Menarche (age at onset);
LUAD	cis	rs4006360	0.524	rs4986678	chr17:39225182	A/C	cg20663846	chr17:39254439	KRTAP4-8	0.38	8.21	0.37	2.79e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs62458065	0.513	rs702831	chr7:32579715	C/T	cg00845942	chr12:64062724	DPY19L2	-0.58	-8.42	-0.38	5.9e-16	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg23985595	chr17:80112537	CCDC57	0.52	9.54	0.42	1.11e-19	Life satisfaction;
LUAD	trans	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg26043149	chr18:55253948	FECH	-0.41	-6.79	-0.31	3.84e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	7.92	0.36	2.12e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.39	7.74	0.35	7.52e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7843479	0.526	rs3816788	chr8:21832494	A/C	cg03445287	chr8:21823731	XPO7	-0.49	-9.08	-0.4	4.21e-18	Mean corpuscular volume;
LUAD	cis	rs4604732	0.631	rs80319072	chr1:247626835	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs8192282	0.739	rs6427716	chr1:154497329	G/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.44	-6.88	-0.32	2.23e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg01256987	chr12:42539512	GXYLT1	-0.34	-6.77	-0.31	4.21e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg03806693	chr22:41940476	POLR3H	0.71	10.25	0.45	3.48e-22	Vitiligo;
LUAD	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10802521	chr3:52805072	NEK4	-0.55	-9.26	-0.41	1.08e-18	Bipolar disorder;
LUAD	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg15691649	chr6:25882328	NA	0.39	6.42	0.3	3.75e-10	Blood metabolite levels;
LUAD	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg16325326	chr1:53192061	ZYG11B	-0.6	-10.77	-0.46	4.47e-24	Monocyte count;
LUAD	cis	rs494562	0.892	rs573892	chr6:86118189	A/C	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs11229555	0.598	rs7930623	chr11:58197641	A/G	cg15696309	chr11:58395628	NA	-0.72	-10.12	-0.44	1.03e-21	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs1832871	0.630	rs11754501	chr6:158710451	A/G	cg07165851	chr6:158734300	TULP4	0.66	10.5	0.45	4.55e-23	Height;
LUAD	cis	rs3916	0.955	rs35599677	chr12:121141458	G/A	cg27246729	chr12:121163418	ACADS	0.47	7.47	0.34	4.71e-13	Urinary metabolites (H-NMR features);
LUAD	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14240646	chr10:27532245	ACBD5	0.95	12.38	0.52	3.01e-30	Breast cancer;
LUAD	cis	rs7107174	0.892	rs1893449	chr11:77968977	G/C	cg19901956	chr11:77921274	USP35	-0.51	-6.36	-0.3	5.29e-10	Testicular germ cell tumor;
LUAD	cis	rs7589728	1.000	rs6720809	chr2:88528943	T/C	cg04511125	chr2:88470314	THNSL2	0.74	8.19	0.37	3.17e-15	Plasma clusterin levels;
LUAD	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg01191920	chr7:158217561	PTPRN2	0.63	13.3	0.54	5.86e-34	Obesity-related traits;
LUAD	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg14403583	chr14:105418241	AHNAK2	-0.44	-8.32	-0.37	1.25e-15	Rheumatoid arthritis;
LUAD	cis	rs60871478	1.000	rs62432224	chr7:788284	G/A	cg04727924	chr7:799746	HEATR2	-0.52	-6.88	-0.32	2.15e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs225245	0.791	rs3890901	chr17:34011322	A/C	cg05299278	chr17:33885742	SLFN14	0.5	11.32	0.48	3.96e-26	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs1595825	0.735	rs113834557	chr2:198611624	A/G	cg00361562	chr2:198649771	BOLL	-0.48	-6.7	-0.31	6.87e-11	Ulcerative colitis;
LUAD	cis	rs7771547	0.573	rs584418	chr6:36395437	G/A	cg04289385	chr6:36355825	ETV7	0.43	6.61	0.31	1.14e-10	Platelet distribution width;
LUAD	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg15309053	chr8:964076	NA	0.34	7.28	0.33	1.63e-12	Schizophrenia;
LUAD	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.17	-0.33	3.38e-12	Glomerular filtration rate;
LUAD	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg04287289	chr16:89883240	FANCA	0.78	6.97	0.32	1.21e-11	Skin colour saturation;
LUAD	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg03467027	chr4:99064603	C4orf37	0.39	6.45	0.3	3.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs89107	0.576	rs114951787	chr6:118839081	C/G	cg18833306	chr6:118973337	C6orf204	0.38	6.5	0.3	2.23e-10	Cardiac structure and function;
LUAD	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg03714773	chr7:91764589	CYP51A1	0.29	6.55	0.3	1.68e-10	Breast cancer;
LUAD	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg17443473	chr1:3703550	LRRC47	0.47	7.81	0.36	4.46e-14	Red cell distribution width;
LUAD	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg20503657	chr10:835505	NA	0.93	13.96	0.56	1.04e-36	Eosinophil percentage of granulocytes;
LUAD	cis	rs17683430	0.702	rs117117069	chr22:32539693	T/A	cg00543991	chr22:32367038	NA	0.93	8.06	0.36	8.13e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUAD	cis	rs9494145	0.680	rs9376092	chr6:135427144	A/C	cg22676075	chr6:135203613	NA	-0.52	-7.81	-0.36	4.54e-14	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUAD	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.55	0.34	2.65e-13	Morning vs. evening chronotype;
LUAD	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.81	0.39	3.29e-17	Menopause (age at onset);
LUAD	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg22482690	chr17:47019901	SNF8	0.43	8.21	0.37	2.64e-15	Type 2 diabetes;
LUAD	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg02371401	chr5:676784	TPPP	-0.48	-7.68	-0.35	1.1e-13	Obesity-related traits;
LUAD	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg26384229	chr12:38710491	ALG10B	0.45	7.57	0.35	2.36e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7615952	0.575	rs35949599	chr3:125544202	G/A	cg05084668	chr3:125655381	ALG1L	-0.49	-7.56	-0.34	2.57e-13	Blood pressure (smoking interaction);
LUAD	cis	rs1387259	0.619	rs7134565	chr12:48630024	C/T	cg04545296	chr12:48745243	ZNF641	-0.26	-6.46	-0.3	2.81e-10	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg11502198	chr6:26597334	ABT1	0.67	11.18	0.48	1.38e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg10544611	chr16:67998164	SLC12A4	-0.63	-7.41	-0.34	6.7e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08219700	chr8:58056026	NA	0.61	8.59	0.39	1.64e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg23018236	chr17:30244563	NA	-0.69	-8.39	-0.38	7.53e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs13064411	0.696	rs7613546	chr3:113228019	G/A	cg10517650	chr3:113235015	CCDC52	-0.55	-9.51	-0.42	1.48e-19	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs6854137	0.553	rs7654189	chr4:169726413	A/C	cg20607169	chr4:169750834	PALLD	0.38	7.16	0.33	3.67e-12	Vein graft stenosis in coronary artery bypass grafting;
LUAD	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg22868518	chr11:507468	RNH1	-0.67	-6.6	-0.31	1.26e-10	Body mass index;
LUAD	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg08807101	chr21:30365312	RNF160	0.52	8.92	0.4	1.46e-17	Dental caries;
LUAD	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.51e-10	Prudent dietary pattern;
LUAD	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg03433033	chr1:76189801	ACADM	0.91	18.24	0.66	2.8e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6840360	0.554	rs61308159	chr4:152728941	G/A	cg22705602	chr4:152727874	NA	0.46	9.12	0.41	3.12e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg01191920	chr7:158217561	PTPRN2	-0.61	-12.76	-0.53	9.03e-32	Obesity-related traits;
LUAD	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg17366294	chr4:99064904	C4orf37	-0.49	-8.54	-0.38	2.53e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg05082376	chr22:42548792	NA	-0.42	-7.35	-0.34	1e-12	Schizophrenia;
LUAD	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11890956	chr21:40555474	PSMG1	-0.66	-11.07	-0.47	3.51e-25	Cognitive function;
LUAD	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg14668632	chr7:2872130	GNA12	-0.68	-12.18	-0.51	1.76e-29	Height;
LUAD	cis	rs986417	1.000	rs1950319	chr14:61048844	T/C	cg27398547	chr14:60952738	C14orf39	0.68	7.96	0.36	1.62e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg01528321	chr10:82214614	TSPAN14	0.65	10.02	0.44	2.41e-21	Post bronchodilator FEV1;
LUAD	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.45	-7.82	-0.36	4.37e-14	Tonsillectomy;
LUAD	cis	rs28735056	1.000	rs4798922	chr18:77628953	G/C	cg20368463	chr18:77673604	PQLC1	-0.43	-6.48	-0.3	2.55e-10	Schizophrenia;
LUAD	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg04154034	chr17:28927549	LRRC37B2	-0.67	-6.96	-0.32	1.29e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7027203	0.759	rs10761282	chr9:96586175	G/A	cg14598338	chr9:96623480	NA	-0.37	-7.97	-0.36	1.46e-14	DNA methylation (variation);
LUAD	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg02176678	chr2:219576539	TTLL4	0.74	14.86	0.59	1.68e-40	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08518329	chr2:20101943	TTC32	-0.64	-6.5	-0.3	2.23e-10	Type 2 diabetes;
LUAD	cis	rs10489202	1.000	rs17556487	chr1:167889094	T/A	cg24449463	chr1:168025552	DCAF6	-0.56	-7.36	-0.34	9.87e-13	Schizophrenia;
LUAD	trans	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.19	-0.64	1.36e-50	Exhaled nitric oxide output;
LUAD	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg10862848	chr6:42927986	GNMT	-0.33	-9.67	-0.43	4.09e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg21280719	chr6:42927975	GNMT	-0.38	-11.5	-0.49	8.13e-27	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6500395	0.928	rs12934788	chr16:48706343	C/A	cg04672837	chr16:48644449	N4BP1	-0.38	-6.55	-0.3	1.67e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg24503407	chr1:205819492	PM20D1	-0.5	-7.63	-0.35	1.56e-13	Menarche (age at onset);
LUAD	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg24813613	chr7:1882135	MAD1L1	-0.4	-6.5	-0.3	2.26e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg05340658	chr4:99064831	C4orf37	0.55	9.09	0.4	3.83e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	7.4	0.34	7.24e-13	Cognitive test performance;
LUAD	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.32e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg02869364	chr7:1081709	C7orf50	-0.5	-6.43	-0.3	3.45e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg05665937	chr4:1216051	CTBP1	0.42	7.23	0.33	2.21e-12	Obesity-related traits;
LUAD	cis	rs7551222	0.752	rs16853958	chr1:204528344	A/C	cg20240347	chr1:204465584	NA	-0.34	-6.53	-0.3	1.88e-10	Schizophrenia;
LUAD	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg06484146	chr7:12443880	VWDE	-0.61	-7.65	-0.35	1.41e-13	Coronary artery disease;
LUAD	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg22676075	chr6:135203613	NA	0.56	9.96	0.44	3.8e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg02428538	chr16:24856791	SLC5A11	-0.57	-8.01	-0.36	1.12e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-6.83	-0.32	3e-11	Total body bone mineral density;
LUAD	cis	rs68170813	0.570	rs7794915	chr7:106849393	C/T	cg02696742	chr7:106810147	HBP1	-0.8	-9.33	-0.41	5.96e-19	Coronary artery disease;
LUAD	cis	rs1595825	0.678	rs57265854	chr2:198917263	C/A	cg10547527	chr2:198650123	BOLL	-0.51	-6.95	-0.32	1.4e-11	Ulcerative colitis;
LUAD	cis	rs2063714	0.967	rs1012534	chr6:157209663	A/G	cg23222435	chr6:157204239	ARID1B	-0.35	-6.43	-0.3	3.48e-10	Sitting height ratio;
LUAD	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.71	-0.35	8.82e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2985684	0.789	rs7161649	chr14:50064028	A/G	cg04989706	chr14:50066350	PPIL5	-0.51	-7.55	-0.34	2.7e-13	Carotid intima media thickness;
LUAD	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg22875332	chr1:76189707	ACADM	0.85	15.91	0.61	5.48e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg27129171	chr3:47204927	SETD2	0.43	6.92	0.32	1.71e-11	Colorectal cancer;
LUAD	cis	rs68170813	0.559	rs4730239	chr7:107056960	A/T	cg02696742	chr7:106810147	HBP1	-0.79	-10.37	-0.45	1.35e-22	Coronary artery disease;
LUAD	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg14092988	chr3:52407081	DNAH1	0.43	8.55	0.38	2.2e-16	Bipolar disorder;
LUAD	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18099408	chr3:52552593	STAB1	-0.46	-8.08	-0.37	6.71e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs877426	0.555	rs7988568	chr13:114826751	C/T	cg21461300	chr13:114830702	RASA3	-0.43	-6.62	-0.31	1.08e-10	Facial morphology (factor 14, intercanthal width);
LUAD	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg06002616	chr8:101225028	SPAG1	-0.37	-7.97	-0.36	1.53e-14	Atrioventricular conduction;
LUAD	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg05697835	chr1:2722811	NA	-0.3	-6.37	-0.3	4.9e-10	Ulcerative colitis;
LUAD	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg18944383	chr4:111397179	ENPEP	0.42	7.21	0.33	2.55e-12	Coronary artery disease;
LUAD	cis	rs926938	0.765	rs2268701	chr1:115233046	C/T	cg12756093	chr1:115239321	AMPD1	-0.39	-6.99	-0.32	1.09e-11	Autism;
LUAD	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg23533926	chr12:111358616	MYL2	-0.42	-7.25	-0.33	2.01e-12	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4814894	0.527	rs927113	chr20:19752844	A/T	cg08371391	chr20:19739935	NA	0.32	6.78	0.31	4.06e-11	Breast cancer;
LUAD	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg17105886	chr17:28927953	LRRC37B2	0.73	6.65	0.31	9.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg18876405	chr7:65276391	NA	0.46	7.36	0.34	9.77e-13	Aortic root size;
LUAD	cis	rs4766566	0.568	rs11065857	chr12:111739500	A/G	cg10833066	chr12:111807467	FAM109A	0.65	13.03	0.54	7.2e-33	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUAD	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg05731713	chr7:157510257	PTPRN2	0.39	8.08	0.37	7.08e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg02527881	chr3:46936655	PTH1R	0.45	8.66	0.39	9.7e-17	Colorectal cancer;
LUAD	cis	rs8051149	0.793	rs3794673	chr16:87872009	G/C	cg10099957	chr16:87869757	SLC7A5	0.44	7.07	0.32	6.61e-12	Blood metabolite levels;
LUAD	cis	rs4691139	0.607	rs4429696	chr4:165934108	C/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.39	-7.34	-0.34	1.08e-12	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg08888203	chr3:10149979	C3orf24	0.67	11.15	0.48	1.71e-25	Alzheimer's disease;
LUAD	cis	rs2455799	0.613	rs10510443	chr3:15829127	A/G	cg16303742	chr3:15540471	COLQ	-0.51	-9.69	-0.43	3.55e-20	Mean platelet volume;
LUAD	cis	rs1448094	0.967	rs10047659	chr12:86338278	C/A	cg02569458	chr12:86230093	RASSF9	0.37	7.15	0.33	3.76e-12	Major depressive disorder;
LUAD	trans	rs1997103	1.000	rs2177802	chr7:55410789	G/A	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.81	0.43	1.28e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9616064	0.557	rs9616085	chr22:47045556	T/A	cg05621596	chr22:47072043	GRAMD4	-0.64	-10.64	-0.46	1.36e-23	Urate levels in obese individuals;
LUAD	cis	rs56283067	0.847	rs12204270	chr6:44697502	A/T	cg18551225	chr6:44695536	NA	-0.59	-10.05	-0.44	1.8e-21	Total body bone mineral density;
LUAD	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg19318889	chr4:1322082	MAEA	0.45	7.37	0.34	8.83e-13	Obesity-related traits;
LUAD	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.57	-0.35	2.42e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg07507251	chr3:52567010	NT5DC2	0.39	7.55	0.34	2.78e-13	Bipolar disorder;
LUAD	cis	rs240764	0.717	rs183566	chr6:101142605	A/T	cg09795085	chr6:101329169	ASCC3	0.41	7.14	0.33	4.13e-12	Neuroticism;
LUAD	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg17173187	chr15:85201210	NMB	0.53	9.42	0.42	2.89e-19	Schizophrenia;
LUAD	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.77	0.31	4.39e-11	Rheumatoid arthritis;
LUAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg13047869	chr3:10149882	C3orf24	-0.62	-10.74	-0.46	6.05e-24	Alzheimer's disease;
LUAD	cis	rs727505	1.000	rs56321835	chr7:124529622	T/C	cg23710748	chr7:124431027	NA	-0.49	-9.82	-0.43	1.18e-20	Lewy body disease;
LUAD	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03517284	chr6:25882590	NA	-0.53	-7.98	-0.36	1.42e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg24644049	chr4:85504048	CDS1	0.89	7.33	0.34	1.17e-12	Skin colour saturation;
LUAD	trans	rs11989744	1.000	rs17089546	chr8:23571807	G/A	cg03492747	chr16:86543808	FOXF1	0.38	6.37	0.3	4.98e-10	Waist-hip ratio;
LUAD	cis	rs72901758	0.700	rs56245572	chr17:76248064	G/C	cg25512537	chr17:76250053	NA	0.33	6.57	0.3	1.46e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg18196295	chr10:418757	DIP2C	0.51	8.61	0.39	1.44e-16	Psychosis in Alzheimer's disease;
LUAD	cis	rs34734847	1.000	rs34734847	chr12:121154221	T/C	cg27246729	chr12:121163418	ACADS	0.39	7.41	0.34	6.85e-13	Mean corpuscular volume;
LUAD	cis	rs10979	1.000	rs9321923	chr6:143897206	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-10.28	-0.45	2.77e-22	Hypospadias;
LUAD	cis	rs9902453	0.808	rs1986555	chr17:28014448	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.32	0.41	6.4e-19	Coffee consumption (cups per day);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg17182302	chr1:116961525	C1orf203	-0.55	-6.69	-0.31	7.26e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-8.86	-0.4	2.23e-17	Menopause (age at onset);
LUAD	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg21699342	chr2:239360505	ASB1	0.51	9.08	0.4	4.16e-18	Multiple system atrophy;
LUAD	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg05727186	chr17:43697356	MGC57346	-0.54	-6.77	-0.31	4.25e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs11597390	0.867	rs11596837	chr10:101850079	C/A	cg02250046	chr10:101825185	CPN1	-0.35	-6.6	-0.31	1.24e-10	Liver enzyme levels;
LUAD	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg16049864	chr8:95962084	TP53INP1	-0.55	-11.89	-0.5	2.63e-28	Type 2 diabetes;
LUAD	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg00933542	chr6:150070202	PCMT1	0.44	9.31	0.41	6.91e-19	Lung cancer;
LUAD	cis	rs9653442	0.648	rs11123805	chr2:100643464	A/G	cg07810366	chr2:100720526	AFF3	-0.35	-7.17	-0.33	3.47e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg12311346	chr5:56204834	C5orf35	0.76	12.13	0.51	2.84e-29	Initial pursuit acceleration;
LUAD	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg08132940	chr7:1081526	C7orf50	-0.77	-7.76	-0.35	6.63e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2637266	1.000	rs7475638	chr10:78358586	G/T	cg18941641	chr10:78392320	NA	-0.32	-6.69	-0.31	7.27e-11	Pulmonary function;
LUAD	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg03396347	chr1:1875803	NA	-0.59	-15.05	-0.59	2.64e-41	Body mass index;
LUAD	cis	rs2346177	0.554	rs34854267	chr2:46708542	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-7.7	-0.35	9.68e-14	HDL cholesterol;
LUAD	cis	rs7786877	0.953	rs7457024	chr7:100215220	A/G	cg20848291	chr7:100343083	ZAN	-0.54	-7.67	-0.35	1.22e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2274273	0.624	rs11848575	chr14:55755788	A/G	cg04306507	chr14:55594613	LGALS3	0.41	8.01	0.36	1.1e-14	Protein biomarker;
LUAD	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg19193384	chr17:30244184	NA	-0.51	-6.63	-0.31	1.01e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs6577655	0.501	rs879104	chr8:135609537	G/A	cg17885191	chr8:135476712	NA	0.49	7.62	0.35	1.69e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs56159542	1	rs56159542	chr19:19682971	T/C	cg15839431	chr19:19639596	YJEFN3	0.45	6.92	0.32	1.68e-11	Attention deficit hyperactivity disorder symptom score;
LUAD	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.58	0.52	4.9e-31	Tonsillectomy;
LUAD	cis	rs7903847	0.544	rs61861865	chr10:99144867	C/G	cg20016023	chr10:99160130	RRP12	-0.29	-6.93	-0.32	1.6e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08048268	chr3:133502702	NA	-0.52	-10.41	-0.45	9.92e-23	Iron status biomarkers;
LUAD	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21659725	chr3:3221576	CRBN	-0.86	-18.19	-0.66	4.97e-55	Intelligence (multi-trait analysis);
LUAD	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg02136620	chr5:178986620	RUFY1	-0.56	-9.13	-0.41	2.83e-18	Lung cancer;
LUAD	cis	rs2625529	0.730	rs12908882	chr15:72437572	G/A	cg16672083	chr15:72433130	SENP8	-0.76	-12.85	-0.53	4.01e-32	Red blood cell count;
LUAD	cis	rs13064411	0.542	rs9874747	chr3:113221258	G/A	cg10517650	chr3:113235015	CCDC52	-0.45	-8.27	-0.37	1.74e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg25985355	chr7:65971099	NA	-0.39	-7.11	-0.33	4.92e-12	Aortic root size;
LUAD	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg02527881	chr3:46936655	PTH1R	-0.44	-8.64	-0.39	1.17e-16	Colorectal cancer;
LUAD	cis	rs12545109	0.879	rs7845180	chr8:57324431	C/T	cg17761419	chr8:57350749	NA	0.53	7.63	0.35	1.58e-13	Obesity-related traits;
LUAD	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08704250	chr15:31115839	NA	0.55	9.86	0.43	8.92e-21	Huntington's disease progression;
LUAD	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg20476274	chr7:133979776	SLC35B4	0.74	12.86	0.53	3.41e-32	Mean platelet volume;
LUAD	cis	rs17092148	1.000	rs2425003	chr20:33403584	G/T	cg16810054	chr20:33298113	TP53INP2	0.51	8.27	0.37	1.8e-15	Neuroticism;
LUAD	trans	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg01620082	chr3:125678407	NA	-0.45	-6.9	-0.32	1.86e-11	Parkinson's disease;
LUAD	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg04036182	chr15:45458818	NA	-0.41	-7.32	-0.34	1.26e-12	Glomerular filtration rate;
LUAD	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg16988262	chr1:15930761	NA	0.42	7.0	0.32	1.01e-11	Systolic blood pressure;
LUAD	cis	rs10504073	0.647	rs10105794	chr8:50012793	G/C	cg00325661	chr8:49890786	NA	0.44	10.01	0.44	2.67e-21	Blood metabolite ratios;
LUAD	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg19761014	chr17:28927070	LRRC37B2	0.86	8.36	0.38	9.21e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg24644049	chr4:85504048	CDS1	0.89	7.33	0.34	1.17e-12	Skin colour saturation;
LUAD	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.48	0.34	4.34e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs34734847	0.703	rs7978125	chr12:121167039	A/G	cg27246729	chr12:121163418	ACADS	0.36	6.52	0.3	2.06e-10	Mean corpuscular volume;
LUAD	cis	rs6543140	0.964	rs2141781	chr2:103082906	G/A	cg04239558	chr2:103089729	SLC9A4	0.36	7.13	0.33	4.32e-12	Blood protein levels;
LUAD	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.49	6.92	0.32	1.73e-11	Cognitive test performance;
LUAD	cis	rs9393692	0.599	rs9358920	chr6:26292029	C/T	cg13736514	chr6:26305472	NA	-0.52	-8.96	-0.4	1.08e-17	Educational attainment;
LUAD	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.54	7.74	0.35	7.4e-14	Platelet count;
LUAD	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg11050988	chr7:1952600	MAD1L1	0.32	6.56	0.3	1.62e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg03806693	chr22:41940476	POLR3H	0.64	9.47	0.42	2.07e-19	Vitiligo;
LUAD	cis	rs9905704	0.627	rs6503867	chr17:56621359	T/C	cg19466818	chr17:56409534	MIR142	0.33	6.48	0.3	2.61e-10	Testicular germ cell tumor;
LUAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg07362569	chr17:61921086	SMARCD2	-0.39	-6.89	-0.32	2e-11	Prudent dietary pattern;
LUAD	trans	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg07211511	chr3:129823064	LOC729375	-0.52	-7.32	-0.34	1.22e-12	Blood pressure (smoking interaction);
LUAD	cis	rs4891159	0.536	rs690392	chr18:74152618	G/A	cg24786174	chr18:74118243	ZNF516	0.89	21.45	0.72	1.37e-69	Longevity;
LUAD	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg15147215	chr3:52552868	STAB1	-0.37	-7.0	-0.32	1.01e-11	Bipolar disorder;
LUAD	cis	rs55665837	1.000	rs12287715	chr11:14444575	G/A	cg19336497	chr11:14380999	RRAS2	-0.51	-10.27	-0.45	3.17e-22	Vitamin D levels;
LUAD	cis	rs752010	0.574	rs10890157	chr1:42117689	C/G	cg06885757	chr1:42089581	HIVEP3	0.42	8.91	0.4	1.57e-17	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg18944383	chr4:111397179	ENPEP	0.41	8.11	0.37	5.53e-15	Height;
LUAD	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg19825600	chr2:3704501	ALLC	-0.42	-7.91	-0.36	2.33e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg03161606	chr19:29218774	NA	0.59	8.83	0.39	2.91e-17	Methadone dose in opioid dependence;
LUAD	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg04025307	chr7:1156635	C7orf50	0.6	6.74	0.31	5.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg21171335	chr12:122356390	WDR66	0.77	14.32	0.57	3.44e-38	Mean corpuscular volume;
LUAD	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg20029026	chr9:127631368	ARPC5L	-0.39	-6.45	-0.3	3.14e-10	Brain structure;
LUAD	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-9.93	-0.43	4.9e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9837602	1.000	rs35521705	chr3:99716690	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.63	9.02	0.4	6.64e-18	Breast cancer;
LUAD	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg21823605	chr1:152486609	CRCT1	0.3	6.85	0.32	2.6e-11	Hair morphology;
LUAD	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg19163074	chr7:65112434	INTS4L2	0.46	6.83	0.32	2.95e-11	Aortic root size;
LUAD	cis	rs68170813	0.652	rs56949084	chr7:107157387	G/A	cg02696742	chr7:106810147	HBP1	-0.76	-8.98	-0.4	8.67e-18	Coronary artery disease;
LUAD	trans	rs2262909	0.962	rs408687	chr19:22231123	T/C	cg17074339	chr11:11642133	GALNTL4	-0.47	-7.73	-0.35	8.11e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg18305652	chr10:134549665	INPP5A	0.61	11.82	0.5	4.88e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1997103	1.000	rs12532070	chr7:55407698	A/G	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg17644776	chr2:200775616	C2orf69	-0.52	-7.14	-0.33	4.12e-12	Schizophrenia;
LUAD	cis	rs9392556	0.829	rs659305	chr6:4125655	A/G	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.39	-6.74	-0.31	5.31e-11	Blood metabolite levels;
LUAD	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg22862634	chr11:62369728	EML3;MTA2	-0.53	-8.97	-0.4	9.68e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs2625529	0.824	rs12593134	chr15:72303007	G/C	cg16672083	chr15:72433130	SENP8	-0.77	-12.96	-0.53	1.41e-32	Red blood cell count;
LUAD	trans	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg26043149	chr18:55253948	FECH	0.41	6.75	0.31	4.75e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg23422044	chr7:1970798	MAD1L1	0.52	6.62	0.31	1.08e-10	Bipolar disorder;
LUAD	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg22117172	chr7:91764530	CYP51A1	0.34	7.6	0.35	1.87e-13	Breast cancer;
LUAD	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.74	-15.17	-0.59	8.39e-42	Lung cancer;
LUAD	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg06022373	chr22:39101656	GTPBP1	0.47	7.3	0.33	1.4e-12	Menopause (age at onset);
LUAD	cis	rs7680126	0.596	rs17418533	chr4:10316941	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.27	-0.33	1.74e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg01191920	chr7:158217561	PTPRN2	0.62	12.96	0.53	1.45e-32	Obesity-related traits;
LUAD	cis	rs11971779	0.680	rs10265718	chr7:139100068	G/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	cis	rs2224391	0.628	rs2753237	chr6:5252675	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-8.62	-0.39	1.36e-16	Height;
LUAD	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.31	6.51	0.3	2.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs28573326	0.629	rs1438119	chr4:166348346	T/C	cg13437084	chr2:26467494	HADHB;HADHA	-0.79	-8.47	-0.38	4.2e-16	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg12698349	chr2:225449008	CUL3	0.66	10.0	0.44	2.74e-21	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg04455712	chr21:45112962	RRP1B	0.45	9.16	0.41	2.28e-18	Mean corpuscular volume;
LUAD	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.42e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3768644	1.000	rs3768644	chr2:72361505	G/A	cg04940582	chr2:72356976	CYP26B1	0.55	6.53	0.3	1.85e-10	Schizophrenia;
LUAD	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	9.27	0.41	9.92e-19	Electrocardiographic conduction measures;
LUAD	trans	rs9354308	0.868	rs6907911	chr6:66555683	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.61	-0.31	1.16e-10	Metabolite levels;
LUAD	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg17279839	chr7:150038598	RARRES2	0.44	7.62	0.35	1.64e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg26597838	chr10:835615	NA	0.84	13.01	0.53	8.81e-33	Eosinophil percentage of granulocytes;
LUAD	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg20587970	chr11:113659929	NA	-1.4	-20.82	-0.71	8.72e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg25985355	chr7:65971099	NA	-0.55	-6.67	-0.31	8.05e-11	Diabetic kidney disease;
LUAD	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg00898013	chr13:113819073	PROZ	0.73	13.17	0.54	2e-33	Platelet distribution width;
LUAD	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	9.54	0.42	1.14e-19	Menarche (age at onset);
LUAD	cis	rs6906287	0.561	rs2078079	chr6:118705213	G/A	cg21191810	chr6:118973309	C6orf204	0.56	11.48	0.49	9.32e-27	Electrocardiographic conduction measures;
LUAD	cis	rs922182	0.556	rs12443020	chr15:64215823	G/T	cg02919090	chr15:64263738	DAPK2	0.36	6.93	0.32	1.58e-11	Blood protein levels;
LUAD	cis	rs1882538	0.564	rs12707090	chr7:133115163	G/A	cg10665199	chr7:133106180	EXOC4	0.62	10.64	0.46	1.38e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg14196790	chr5:131705035	SLC22A5	0.37	6.51	0.3	2.07e-10	Breast cancer;
LUAD	cis	rs1232027	0.700	rs1677670	chr5:79948654	A/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.5	-8.09	-0.37	6.53e-15	Huntington's disease progression;
LUAD	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg00277334	chr10:82204260	NA	-0.61	-10.26	-0.45	3.27e-22	Post bronchodilator FEV1;
LUAD	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg02734326	chr4:10020555	SLC2A9	0.46	7.91	0.36	2.32e-14	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg20503657	chr10:835505	NA	1.01	15.55	0.6	1.88e-43	Eosinophil percentage of granulocytes;
LUAD	cis	rs1232027	0.656	rs1677640	chr5:79962864	T/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.08	-0.33	6.22e-12	Huntington's disease progression;
LUAD	cis	rs240764	0.817	rs6938440	chr6:101152009	T/C	cg09795085	chr6:101329169	ASCC3	-0.44	-7.57	-0.35	2.39e-13	Neuroticism;
LUAD	trans	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg23505145	chr19:12996616	KLF1	0.52	8.34	0.38	1.03e-15	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg11890956	chr21:40555474	PSMG1	-0.53	-8.86	-0.4	2.23e-17	Menarche (age at onset);
LUAD	cis	rs6426558	0.621	rs7521639	chr1:227223736	T/C	cg10327440	chr1:227177885	CDC42BPA	0.77	14.43	0.57	1.15e-38	Neutrophil percentage of white cells;
LUAD	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	10.83	0.47	2.7e-24	Blood metabolite levels;
LUAD	cis	rs12620999	0.555	rs4078064	chr2:238110296	C/T	cg15867307	chr2:238110829	NA	0.41	6.92	0.32	1.66e-11	Systemic lupus erythematosus;
LUAD	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.53	-0.34	3.18e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.54	7.74	0.35	7.4e-14	Platelet count;
LUAD	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.54	8.65	0.39	1.05e-16	Total body bone mineral density;
LUAD	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg11494091	chr17:61959527	GH2	0.74	18.49	0.67	2.29e-56	Prudent dietary pattern;
LUAD	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg12935359	chr14:103987150	CKB	-0.48	-8.78	-0.39	4.04e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg07636037	chr3:49044803	WDR6	-0.63	-12.34	-0.51	4.15e-30	Parkinson's disease;
LUAD	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg23254163	chr1:152506842	NA	0.25	7.07	0.33	6.24e-12	Hair morphology;
LUAD	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg20201475	chr3:168867307	MECOM	-0.51	-6.38	-0.3	4.69e-10	Colorectal cancer;
LUAD	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.33	6.59	0.31	1.3e-10	Parkinson's disease;
LUAD	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg06641503	chr3:48959341	ARIH2	-0.36	-6.63	-0.31	1e-10	Parkinson's disease;
LUAD	trans	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg21051086	chr3:73046214	PPP4R2	0.44	7.28	0.33	1.59e-12	Pancreatic cancer;
LUAD	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg03609598	chr5:56110824	MAP3K1	0.49	7.23	0.33	2.25e-12	Initial pursuit acceleration;
LUAD	cis	rs17683430	0.702	rs117303909	chr22:32377614	G/A	cg00543991	chr22:32367038	NA	0.93	8.61	0.39	1.42e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LUAD	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg03714773	chr7:91764589	CYP51A1	0.32	7.37	0.34	9.19e-13	Breast cancer;
LUAD	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg07677032	chr17:61819896	STRADA	0.55	10.09	0.44	1.41e-21	Prudent dietary pattern;
LUAD	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg08213375	chr14:104286397	PPP1R13B	0.27	7.14	0.33	4.01e-12	Schizophrenia;
LUAD	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.55	0.38	2.23e-16	Menopause (age at onset);
LUAD	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg11148817	chr5:312970	AHRR;PDCD6	-0.46	-6.36	-0.3	5.31e-10	Breast cancer;
LUAD	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg15147215	chr3:52552868	STAB1	-0.39	-7.19	-0.33	2.99e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg20476274	chr7:133979776	SLC35B4	0.84	16.27	0.62	1.4e-46	Mean platelet volume;
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15120237	chr17:7747620	KDM6B	0.43	6.74	0.31	5.12e-11	Gut microbiome composition (summer);
LUAD	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.5	0.34	3.81e-13	Tonsillectomy;
LUAD	cis	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg26751094	chr13:95954534	ABCC4	-0.5	-10.78	-0.46	4.19e-24	Blood metabolite levels;
LUAD	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg23985595	chr17:80112537	CCDC57	0.5	9.12	0.41	2.98e-18	Life satisfaction;
LUAD	trans	rs1941687	0.527	rs12608181	chr18:31339351	T/G	cg15819921	chr19:927150	ARID3A	-0.49	-8.25	-0.37	2.08e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg18621852	chr3:10150065	C3orf24	0.42	6.76	0.31	4.48e-11	Alzheimer's disease;
LUAD	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg17863274	chr19:49399704	TULP2	-0.66	-10.02	-0.44	2.43e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs4629710	0.545	rs3777477	chr6:131534374	T/C	cg12606694	chr6:131520996	AKAP7	0.45	6.81	0.31	3.36e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs1448094	0.872	rs12322940	chr12:86406708	G/C	cg19622623	chr12:86230825	RASSF9	-0.37	-6.78	-0.31	3.95e-11	Major depressive disorder;
LUAD	cis	rs755249	0.510	rs1184716	chr1:39846489	C/T	cg27567593	chr1:39956653	BMP8A	-0.37	-7.38	-0.34	8.61e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs6500395	1.000	rs3848319	chr16:48610933	T/C	cg04672837	chr16:48644449	N4BP1	0.38	6.53	0.3	1.84e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg12648201	chr2:27665141	KRTCAP3	0.32	7.99	0.36	1.32e-14	Total body bone mineral density;
LUAD	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg25019722	chr6:37503610	NA	-0.31	-6.97	-0.32	1.18e-11	Cognitive performance;
LUAD	cis	rs11958404	0.932	rs72816579	chr5:157431877	T/C	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg19318889	chr4:1322082	MAEA	-0.45	-7.8	-0.35	4.96e-14	Obesity-related traits;
LUAD	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.41	-0.45	9.44e-23	Glomerular filtration rate;
LUAD	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg06766960	chr11:133703094	NA	-0.42	-7.93	-0.36	1.97e-14	Childhood ear infection;
LUAD	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg10755058	chr3:40428713	ENTPD3	-0.43	-8.13	-0.37	4.96e-15	Renal cell carcinoma;
LUAD	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15369054	chr17:80825471	TBCD	-0.62	-10.26	-0.45	3.25e-22	Breast cancer;
LUAD	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg11189052	chr15:85197271	WDR73	0.65	10.6	0.46	2.01e-23	P wave terminal force;
LUAD	cis	rs2220004	0.533	rs2128154	chr11:55794274	C/T	cg22937354	chr11:55606216	OR5D16	-0.41	-7.08	-0.33	6.11e-12	Odorant perception (&beta-damascenone);
LUAD	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg22676075	chr6:135203613	NA	0.55	9.74	0.43	2.42e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs1832871	0.643	rs112195967	chr6:158775695	C/T	cg07165851	chr6:158734300	TULP4	0.72	10.98	0.47	7.45e-25	Height;
LUAD	cis	rs7202877	0.706	rs1074961	chr16:75389484	C/T	cg03315344	chr16:75512273	CHST6	0.51	7.08	0.33	6.17e-12	Type 2 diabetes;Type 1 diabetes;
LUAD	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg14196790	chr5:131705035	SLC22A5	-0.37	-6.49	-0.3	2.42e-10	Blood metabolite levels;
LUAD	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg16479474	chr6:28041457	NA	0.46	7.94	0.36	1.8e-14	Parkinson's disease;
LUAD	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg01119278	chr6:110721349	DDO	-0.46	-8.62	-0.39	1.32e-16	Platelet distribution width;
LUAD	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	21.53	0.72	5.55e-70	Chronic sinus infection;
LUAD	cis	rs738322	0.805	rs2016755	chr22:38539604	A/G	cg17652424	chr22:38574118	PLA2G6	-0.28	-8.17	-0.37	3.56e-15	Cutaneous nevi;
LUAD	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg27454412	chr7:1067447	C7orf50	-0.36	-6.62	-0.31	1.1e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg26769984	chr7:1090371	C7orf50	0.63	8.96	0.4	1.06e-17	Bronchopulmonary dysplasia;
LUAD	cis	rs2262909	0.962	rs73019842	chr19:22249909	T/G	cg11619707	chr19:22235551	ZNF257	0.49	7.57	0.35	2.33e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg05342682	chr7:94953680	PON1	-0.51	-7.32	-0.34	1.28e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg05434287	chr7:2030229	MAD1L1	0.42	6.76	0.31	4.48e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg09915433	chr19:53449742	NA	-0.56	-9.92	-0.43	5.59e-21	Psoriasis;
LUAD	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg17105886	chr17:28927953	LRRC37B2	0.74	6.77	0.31	4.37e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs7615952	0.546	rs111812401	chr3:125361495	G/A	cg17147758	chr8:6949321	NA	-0.51	-8.12	-0.37	5.29e-15	Blood pressure (smoking interaction);
LUAD	cis	rs669446	0.561	rs641351	chr1:44083519	G/A	cg12908607	chr1:44402522	ARTN	-0.37	-6.78	-0.31	4.15e-11	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg15123519	chr2:136567270	LCT	-0.38	-6.87	-0.32	2.35e-11	Mosquito bite size;
LUAD	cis	rs4253772	0.938	rs41427746	chr22:46637239	T/C	cg09491104	chr22:46646882	C22orf40	-0.55	-8.17	-0.37	3.67e-15	LDL cholesterol;Cholesterol, total;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22753607	chr9:37120306	ZCCHC7	-0.49	-7.72	-0.35	8.33e-14	Height;
LUAD	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg10589385	chr1:150898437	SETDB1	0.42	7.7	0.35	9.73e-14	Melanoma;
LUAD	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08280861	chr8:58055591	NA	0.63	8.31	0.37	1.35e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg13511324	chr14:104056883	C14orf153	0.27	6.54	0.3	1.76e-10	Reticulocyte count;
LUAD	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg21963583	chr11:68658836	MRPL21	0.64	11.71	0.49	1.28e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11229555	0.645	rs10896775	chr11:58175989	A/T	cg15696309	chr11:58395628	NA	-0.73	-10.3	-0.45	2.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg06608945	chr2:219082296	ARPC2	-0.42	-6.78	-0.31	4.01e-11	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	trans	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg01620082	chr3:125678407	NA	-0.63	-7.26	-0.33	1.87e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg00383909	chr3:49044727	WDR6	0.44	6.76	0.31	4.5e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg19875535	chr5:140030758	IK	-0.41	-6.93	-0.32	1.59e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs62238980	0.614	rs75414196	chr22:32415980	C/A	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs7107174	1.000	rs7117238	chr11:78040259	G/A	cg19901956	chr11:77921274	USP35	-0.46	-6.63	-0.31	1.04e-10	Testicular germ cell tumor;
LUAD	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg08888203	chr3:10149979	C3orf24	0.71	11.26	0.48	6.73e-26	Alzheimer's disease;
LUAD	cis	rs1232027	0.700	rs58490646	chr5:79940534	A/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.89	-0.36	2.54e-14	Huntington's disease progression;
LUAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.4	-0.38	7.05e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2066819	1.000	rs79750959	chr12:56702012	C/A	cg26714650	chr12:56694279	CS	-0.85	-7.1	-0.33	5.17e-12	Psoriasis vulgaris;
LUAD	cis	rs4642101	0.793	rs6763619	chr3:12822147	T/G	cg24848339	chr3:12840334	CAND2	0.43	8.61	0.39	1.48e-16	QRS complex (12-leadsum);
LUAD	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg02269571	chr22:50332266	NA	0.57	8.32	0.38	1.2e-15	Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11157872	chr12:123011310	RSRC2;KNTC1	-0.43	-7.12	-0.33	4.75e-12	Cancer;
LUAD	cis	rs758324	0.617	rs12719447	chr5:131118100	C/A	cg06307176	chr5:131281290	NA	0.53	8.42	0.38	6.11e-16	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs11098699	0.821	rs2047582	chr4:124232496	C/A	cg09941581	chr4:124220074	SPATA5	0.46	7.28	0.33	1.66e-12	Mosquito bite size;
LUAD	trans	rs629535	0.862	rs638412	chr8:70047690	C/T	cg21567404	chr3:27674614	NA	1.01	18.57	0.67	9.52e-57	Dupuytren's disease;
LUAD	cis	rs7851660	0.654	rs2120264	chr9:100645728	A/G	cg13688889	chr9:100608707	NA	-0.51	-8.67	-0.39	9.64e-17	Strep throat;
LUAD	cis	rs752010	0.806	rs11210500	chr1:42089737	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	11.35	0.48	3.12e-26	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs7731657	0.537	rs7732161	chr5:130341510	A/G	cg08523029	chr5:130500466	HINT1	0.58	7.73	0.35	7.73e-14	Fasting plasma glucose;
LUAD	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.47	-7.69	-0.35	1.05e-13	Hematocrit;
LUAD	cis	rs13315871	1.000	rs36097398	chr3:58367330	G/A	cg20936604	chr3:58311152	NA	-0.68	-7.01	-0.32	9.24e-12	Cholesterol, total;
LUAD	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg27286337	chr10:134555280	INPP5A	0.73	11.11	0.48	2.36e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07167872	chr1:205819463	PM20D1	-0.56	-10.07	-0.44	1.57e-21	Menarche (age at onset);
LUAD	cis	rs1957429	0.803	rs10873177	chr14:65318228	G/C	cg23373153	chr14:65346875	NA	0.58	6.54	0.3	1.79e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg26769984	chr7:1090371	C7orf50	0.62	8.95	0.4	1.14e-17	Bronchopulmonary dysplasia;
LUAD	cis	rs17789174	0.903	rs1392526	chr16:85075744	C/T	cg27466129	chr16:85060822	KIAA0513	0.35	7.78	0.35	5.5e-14	Dysphagia;
LUAD	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg16205897	chr5:131564050	P4HA2	-0.34	-7.98	-0.36	1.38e-14	Blood metabolite levels;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg20201475	chr3:168867307	MECOM	-0.53	-6.48	-0.3	2.48e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg02869364	chr7:1081709	C7orf50	-0.35	-6.54	-0.3	1.81e-10	Longevity;Endometriosis;
LUAD	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg08807101	chr21:30365312	RNF160	-0.46	-7.95	-0.36	1.77e-14	Dental caries;
LUAD	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01570182	chr17:44337453	NA	-0.98	-14.35	-0.57	2.59e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg08773314	chr2:239334832	ASB1	0.43	9.73	0.43	2.62e-20	Multiple system atrophy;
LUAD	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.96	-0.32	1.27e-11	Total cholesterol levels;
LUAD	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg16031515	chr1:205743344	RAB7L1	-0.34	-6.86	-0.32	2.52e-11	Menarche (age at onset);
LUAD	cis	rs6684514	0.961	rs12029695	chr1:156299847	C/T	cg16558208	chr1:156270281	VHLL	0.53	9.63	0.42	5.47e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg00074818	chr8:8560427	CLDN23	0.69	10.72	0.46	7.23e-24	Obesity-related traits;
LUAD	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg17173187	chr15:85201210	NMB	-0.37	-6.43	-0.3	3.55e-10	Schizophrenia;
LUAD	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg18351406	chr4:77819688	ANKRD56	0.63	10.2	0.44	5.67e-22	Emphysema distribution in smoking;
LUAD	cis	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg11143507	chr3:125485238	NA	-0.44	-7.22	-0.33	2.48e-12	Blood pressure (smoking interaction);
LUAD	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg02993280	chr1:107599747	PRMT6	0.49	7.49	0.34	4.05e-13	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg22963979	chr7:1858916	MAD1L1	-0.54	-9.37	-0.41	4.26e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg23281280	chr6:28129359	ZNF389	0.45	6.56	0.3	1.62e-10	Depression;
LUAD	cis	rs16910800	0.953	rs73481416	chr11:23204663	T/A	cg20040320	chr11:23191996	NA	-0.49	-7.37	-0.34	8.93e-13	Cancer;
LUAD	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg25427524	chr10:38739819	LOC399744	-0.61	-9.67	-0.43	4.21e-20	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.28	0.37	1.66e-15	Breast cancer;
LUAD	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg10589385	chr1:150898437	SETDB1	0.39	7.41	0.34	6.89e-13	Tonsillectomy;
LUAD	cis	rs2742234	0.590	rs2503864	chr10:43666767	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.52	-8.88	-0.4	1.96e-17	Hirschsprung disease;
LUAD	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg13319975	chr6:146136371	FBXO30	0.63	10.8	0.46	3.66e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.49	6.71	0.31	6.25e-11	Cognitive test performance;
LUAD	cis	rs4711336	1.000	rs4711336	chr6:33659046	A/G	cg13859433	chr6:33739653	LEMD2	0.28	6.44	0.3	3.31e-10	Height;
LUAD	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg18129178	chr5:148520854	ABLIM3	-0.65	-9.82	-0.43	1.17e-20	Breast cancer;
LUAD	trans	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-8.58	-0.39	1.77e-16	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg05165339	chr4:1420672	NA	-0.29	-6.57	-0.3	1.49e-10	Longevity;
LUAD	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08280861	chr8:58055591	NA	0.77	9.56	0.42	9.62e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03517284	chr6:25882590	NA	-0.53	-8.02	-0.36	1.04e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs889398	0.616	rs35808754	chr16:69771710	G/T	cg00738113	chr16:70207722	CLEC18C	0.35	6.92	0.32	1.67e-11	Body mass index;
LUAD	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg02569458	chr12:86230093	RASSF9	0.39	7.19	0.33	3.02e-12	Major depressive disorder;
LUAD	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg04492858	chr10:133558786	NA	0.4	7.89	0.36	2.6e-14	Survival in rectal cancer;
LUAD	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg17366294	chr4:99064904	C4orf37	0.72	13.47	0.55	1.17e-34	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10465746	0.780	rs11163872	chr1:84421969	G/T	cg10977910	chr1:84465055	TTLL7	0.6	9.81	0.43	1.3e-20	Obesity-related traits;
LUAD	cis	rs4776059	1.000	rs12902679	chr15:52881317	C/T	cg24008177	chr15:52972085	KIAA1370	-0.25	-6.37	-0.3	4.85e-10	Schizophrenia;
LUAD	trans	rs2018683	0.768	rs10282015	chr7:29022138	G/A	cg19402173	chr7:128379420	CALU	-0.54	-8.8	-0.39	3.6e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg19622623	chr12:86230825	RASSF9	-0.4	-7.1	-0.33	5.23e-12	Major depressive disorder;
LUAD	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg02951883	chr7:2050386	MAD1L1	-0.73	-12.12	-0.51	3.2e-29	Schizophrenia;
LUAD	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg17105886	chr17:28927953	LRRC37B2	0.76	7.18	0.33	3.14e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10089	0.552	rs55902659	chr5:127545505	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.48	7.26	0.33	1.87e-12	Ileal carcinoids;
LUAD	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.42	0.3	3.7e-10	Colorectal cancer;
LUAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg14926445	chr8:58193284	C8orf71	-0.53	-7.58	-0.35	2.27e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg15557168	chr22:42548783	NA	-0.51	-9.5	-0.42	1.55e-19	Schizophrenia;
LUAD	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-10.83	-0.47	2.71e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs5756813	0.688	rs12484134	chr22:38126728	T/C	cg06521852	chr22:38141419	TRIOBP	0.48	8.39	0.38	7.51e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs6076065	0.676	rs6076059	chr20:23336261	C/T	cg11657817	chr20:23433608	CST11	0.49	9.35	0.41	5.23e-19	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg21285383	chr16:89894308	SPIRE2	0.42	10.24	0.45	3.78e-22	Vitiligo;
LUAD	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg27170947	chr2:26402098	FAM59B	-0.81	-11.61	-0.49	3.18e-27	Gut microbiome composition (summer);
LUAD	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13012494	chr21:47604986	C21orf56	0.65	11.35	0.48	3.04e-26	Testicular germ cell tumor;
LUAD	cis	rs11077815	0.815	rs7223304	chr17:74447090	C/T	cg06840243	chr17:74442338	UBE2O	-0.39	-7.09	-0.33	5.71e-12	Lymphocyte counts;
LUAD	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg11266682	chr4:10021025	SLC2A9	0.6	12.94	0.53	1.66e-32	Bone mineral density;
LUAD	cis	rs28493229	0.881	rs10404911	chr19:41174903	A/T	cg21869046	chr19:41225005	ITPKC	0.52	8.37	0.38	8.81e-16	Kawasaki disease;
LUAD	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg18099408	chr3:52552593	STAB1	-0.42	-7.23	-0.33	2.24e-12	Electroencephalogram traits;
LUAD	cis	rs9788721	0.775	rs12914385	chr15:78898723	C/T	cg18825076	chr15:78729989	IREB2	-0.55	-8.97	-0.4	9.7e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg10755058	chr3:40428713	ENTPD3	0.42	8.3	0.37	1.39e-15	Renal cell carcinoma;
LUAD	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg02869364	chr7:1081709	C7orf50	-0.51	-6.61	-0.31	1.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06544989	chr22:39130855	UNC84B	0.44	8.92	0.4	1.45e-17	Menopause (age at onset);
LUAD	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg23649088	chr2:200775458	C2orf69	-0.61	-7.88	-0.36	2.71e-14	Schizophrenia;
LUAD	cis	rs751728	1.000	rs755496	chr6:33734376	C/G	cg13859433	chr6:33739653	LEMD2	-0.39	-9.21	-0.41	1.48e-18	Crohn's disease;
LUAD	cis	rs12541635	0.934	rs10955407	chr8:107020648	G/A	cg10147462	chr8:107024639	NA	0.51	9.24	0.41	1.21e-18	Age of smoking initiation;
LUAD	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg26576206	chr19:1064938	ABCA7	0.48	7.57	0.35	2.37e-13	Alzheimer's disease (late onset);
LUAD	cis	rs11811982	0.793	rs78944317	chr1:227307861	A/T	cg24860534	chr1:227506868	CDC42BPA	0.65	7.07	0.33	6.48e-12	Optic disc area;
LUAD	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg09117114	chr16:67998030	SLC12A4	-0.57	-7.64	-0.35	1.51e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg05110241	chr16:68378359	PRMT7	-0.8	-8.78	-0.39	4.17e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg15997130	chr1:24165203	NA	-0.49	-7.73	-0.35	7.73e-14	Immature fraction of reticulocytes;
LUAD	trans	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg03886242	chr7:26192032	NFE2L3	-0.44	-7.57	-0.35	2.44e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7107174	1.000	rs2511175	chr11:77975081	A/G	cg02023728	chr11:77925099	USP35	0.48	7.29	0.33	1.58e-12	Testicular germ cell tumor;
LUAD	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg02574844	chr11:5959923	NA	-0.38	-6.52	-0.3	2.04e-10	DNA methylation (variation);
LUAD	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26314531	chr2:26401878	FAM59B	-0.58	-7.99	-0.36	1.33e-14	Gut microbiome composition (summer);
LUAD	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg01657329	chr11:68192670	LRP5	-0.41	-6.46	-0.3	2.9e-10	Total body bone mineral density;
LUAD	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.62	0.35	1.71e-13	Platelet count;
LUAD	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg07936489	chr17:37558343	FBXL20	0.45	7.03	0.32	8.11e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg12927641	chr6:109611667	NA	-0.51	-8.72	-0.39	6.51e-17	Reticulocyte fraction of red cells;
LUAD	trans	rs1728785	1.000	rs12918861	chr16:68566508	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.71	0.43	2.85e-20	Ulcerative colitis;
LUAD	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg10150615	chr22:24372951	LOC391322	-0.57	-9.55	-0.42	1.08e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg17031739	chr1:67600172	NA	0.42	7.43	0.34	6.25e-13	Psoriasis;
LUAD	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg24818145	chr4:99064322	C4orf37	0.47	7.96	0.36	1.57e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.86	-0.5	3.36e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg04398451	chr17:18023971	MYO15A	-0.81	-14.96	-0.59	6.36e-41	Total body bone mineral density;
LUAD	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.31e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.4	-7.36	-0.34	9.82e-13	Urate levels in overweight individuals;
LUAD	cis	rs4555082	0.957	rs2816609	chr14:105720803	A/C	cg10792982	chr14:105748885	BRF1	0.41	8.71	0.39	7.07e-17	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-7.5	-0.34	3.88e-13	Morning vs. evening chronotype;
LUAD	trans	rs4924935	0.509	rs8074020	chr17:18801380	T/C	cg21372672	chr17:16614065	CCDC144A	-0.36	-6.39	-0.3	4.44e-10	Pancreatic cancer;
LUAD	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg01689657	chr7:91764605	CYP51A1	0.34	8.75	0.39	5.03e-17	Breast cancer;
LUAD	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2230307	0.536	rs834277	chr1:100510855	T/G	cg20868668	chr1:100435035	SLC35A3	0.54	7.87	0.36	3.02e-14	Carotid intima media thickness;
LUAD	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg27284194	chr4:1044797	NA	-0.71	-10.02	-0.44	2.48e-21	Recombination rate (females);
LUAD	cis	rs7737355	0.947	rs31258	chr5:130824536	G/A	cg25547332	chr5:131281432	NA	0.43	6.64	0.31	9.69e-11	Life satisfaction;
LUAD	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg16414030	chr3:133502952	NA	-0.69	-13.44	-0.55	1.53e-34	Iron status biomarkers;
LUAD	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg02475777	chr4:1388615	CRIPAK	-0.52	-7.64	-0.35	1.51e-13	Obesity-related traits;
LUAD	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg10544611	chr16:67998164	SLC12A4	-0.54	-6.87	-0.32	2.38e-11	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
LUAD	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg00310523	chr12:86230176	RASSF9	0.39	7.78	0.35	5.75e-14	Major depressive disorder;
LUAD	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg07570687	chr10:102243282	WNT8B	0.44	6.4	0.3	4.17e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg13535736	chr9:111863775	C9orf5	-0.42	-6.49	-0.3	2.46e-10	Menarche (age at onset);
LUAD	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg08048268	chr3:133502702	NA	-0.41	-7.96	-0.36	1.57e-14	Iron status biomarkers;
LUAD	cis	rs9283706	0.641	rs6414805	chr5:66322600	T/C	cg11590213	chr5:66331682	MAST4	0.4	6.48	0.3	2.51e-10	Coronary artery disease;
LUAD	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg24634471	chr8:143751801	JRK	0.48	7.74	0.35	7.37e-14	Schizophrenia;
LUAD	cis	rs4280164	0.830	rs2144494	chr14:24773387	T/C	cg22990158	chr14:24802150	ADCY4	0.46	6.57	0.3	1.46e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.89	0.4	1.83e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	trans	rs3857536	0.813	rs4710581	chr6:66939954	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg10518543	chr12:38710700	ALG10B	-0.45	-7.3	-0.33	1.4e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg07195577	chr17:27052828	TLCD1	0.46	6.42	0.3	3.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22496380	chr5:211416	CCDC127	-1.24	-16.67	-0.63	2.53e-48	Breast cancer;
LUAD	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg18105134	chr13:113819100	PROZ	0.81	14.23	0.57	7.83e-38	Platelet distribution width;
LUAD	cis	rs59072704	0.843	rs12031783	chr1:244498748	A/G	cg16908123	chr1:244486252	NA	0.3	6.36	0.3	5.35e-10	Monocyte count;
LUAD	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg24879335	chr3:133465180	TF	0.4	8.28	0.37	1.65e-15	Iron status biomarkers;
LUAD	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg24768116	chr2:27665128	KRTCAP3	0.28	7.1	0.33	5.21e-12	Oral cavity cancer;
LUAD	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.6	0.31	1.21e-10	Schizophrenia;
LUAD	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.33	-0.45	1.84e-22	Platelet count;
LUAD	cis	rs10823500	0.748	rs12355080	chr10:71963608	G/A	cg02100629	chr10:71892760	AIFM2	-0.38	-7.61	-0.35	1.8e-13	Blood protein levels;
LUAD	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.56	-9.67	-0.43	4.19e-20	Lymphocyte counts;
LUAD	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg06784218	chr1:46089804	CCDC17	0.6	13.39	0.55	2.55e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs908922	0.676	rs7529136	chr1:152516389	T/C	cg21823605	chr1:152486609	CRCT1	0.29	6.54	0.3	1.74e-10	Hair morphology;
LUAD	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg02782426	chr3:40428986	ENTPD3	0.43	9.07	0.4	4.38e-18	Renal cell carcinoma;
LUAD	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg18944383	chr4:111397179	ENPEP	0.38	7.68	0.35	1.12e-13	Height;
LUAD	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg01299579	chr2:10830716	NOL10	0.41	7.11	0.33	4.95e-12	Prostate cancer;
LUAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg08989290	chr16:615782	NHLRC4	0.32	6.82	0.31	3.13e-11	Height;
LUAD	cis	rs4481887	0.927	rs7534188	chr1:248434303	C/T	cg00666640	chr1:248458726	OR2T12	-0.31	-7.41	-0.34	6.98e-13	Common traits (Other);
LUAD	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg24818145	chr4:99064322	C4orf37	0.41	6.7	0.31	6.73e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs11577318	0.853	rs7416513	chr1:26647949	G/C	cg07461501	chr17:79650226	HGS;ARL16	0.42	6.42	0.3	3.73e-10	Granulocyte percentage of myeloid white cells;
LUAD	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg03929089	chr4:120376271	NA	-0.51	-6.7	-0.31	6.64e-11	Axial length;
LUAD	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg25767906	chr1:53392781	SCP2	0.41	7.54	0.34	2.92e-13	Monocyte count;
LUAD	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg08798685	chr6:27730294	NA	-0.45	-7.14	-0.33	4.17e-12	Parkinson's disease;
LUAD	cis	rs10203711	0.901	rs907101	chr2:239564458	T/A	cg14580085	chr2:239553406	NA	0.41	8.63	0.39	1.26e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4280164	0.551	rs3212260	chr14:24804088	A/T	cg22990158	chr14:24802150	ADCY4	0.58	8.83	0.39	2.89e-17	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg12179176	chr11:130786555	SNX19	0.53	8.93	0.4	1.35e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9902453	1.000	rs9912741	chr17:28359511	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.33	-0.41	6.06e-19	Coffee consumption (cups per day);
LUAD	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg02527881	chr3:46936655	PTH1R	0.45	8.99	0.4	8.57e-18	Colorectal cancer;
LUAD	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	7.62	0.35	1.73e-13	Platelet count;
LUAD	cis	rs447921	0.861	rs56248611	chr17:74448255	G/A	cg17201438	chr17:74438067	UBE2O	0.68	8.63	0.39	1.22e-16	Mitochondrial DNA levels;
LUAD	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.49	9.34	0.41	5.77e-19	Lymphocyte counts;
LUAD	cis	rs7107174	1.000	rs2510040	chr11:77944548	T/A	cg02023728	chr11:77925099	USP35	0.51	7.6	0.35	1.91e-13	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7773004	0.905	rs6932584	chr6:26327081	A/C	cg13736514	chr6:26305472	NA	-0.49	-8.15	-0.37	4.06e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg17063962	chr7:91808500	NA	0.71	12.78	0.53	7.62e-32	Breast cancer;
LUAD	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-15.27	-0.6	3.04e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs751728	0.965	rs756137	chr6:33755890	T/C	cg13859433	chr6:33739653	LEMD2	-0.42	-9.87	-0.43	8.14e-21	Crohn's disease;
LUAD	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.6	10.11	0.44	1.16e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg09359103	chr1:154839909	KCNN3	-0.92	-21.2	-0.72	1.69e-68	Prostate cancer;
LUAD	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	8.35	0.38	9.71e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs3020333	0.875	rs2982570	chr6:152013748	C/T	cg22157087	chr6:152012887	ESR1	0.36	6.36	0.3	5.28e-10	Total body bone mineral density;
LUAD	cis	rs7274811	0.681	rs210074	chr20:31949756	A/T	cg13403462	chr20:32256071	NECAB3;C20orf134	0.47	7.22	0.33	2.38e-12	Height;
LUAD	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg04586622	chr2:25135609	ADCY3	0.37	8.48	0.38	3.88e-16	Body mass index in non-asthmatics;
LUAD	cis	rs11971779	0.715	rs55714903	chr7:139074590	T/C	cg23387468	chr7:139079360	LUC7L2	0.29	6.61	0.31	1.16e-10	Diisocyanate-induced asthma;
LUAD	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg25036284	chr2:26402008	FAM59B	-0.58	-8.17	-0.37	3.48e-15	Gut microbiome composition (summer);
LUAD	cis	rs7945705	0.875	rs11042059	chr11:8795080	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.47	8.34	0.38	1.03e-15	Hemoglobin concentration;
LUAD	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg12483801	chr4:183727862	NA	0.55	6.72	0.31	6.02e-11	Pediatric autoimmune diseases;
LUAD	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11644478	chr21:40555479	PSMG1	-0.54	-8.66	-0.39	9.96e-17	Cognitive function;
LUAD	cis	rs11585357	0.501	rs72646775	chr1:17592121	T/C	cg08277548	chr1:17600880	PADI3	-0.71	-7.97	-0.36	1.52e-14	Hair shape;
LUAD	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11890956	chr21:40555474	PSMG1	0.82	14.57	0.58	3.02e-39	Cognitive function;
LUAD	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg17120908	chr11:65337727	SSSCA1	-0.62	-9.8	-0.43	1.46e-20	Bone mineral density;
LUAD	cis	rs986417	1.000	rs1254322	chr14:60906976	G/A	cg27398547	chr14:60952738	C14orf39	-0.65	-7.69	-0.35	1.02e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06112835	chr11:68658793	MRPL21	0.51	9.11	0.41	3.22e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg12011299	chr4:100065546	ADH4	0.63	13.13	0.54	2.98e-33	Alcohol dependence;
LUAD	trans	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg17712092	chr4:129076599	LARP1B	-0.79	-12.05	-0.51	6.22e-29	Breast cancer;
LUAD	cis	rs3125734	0.633	rs3852412	chr10:64050288	C/T	cg09941381	chr10:64027924	RTKN2	-0.3	-6.92	-0.32	1.68e-11	Rheumatoid arthritis;
LUAD	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg26343298	chr8:95960752	TP53INP1	0.37	7.82	0.36	4.12e-14	Type 2 diabetes;
LUAD	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg08997352	chr12:9597637	DDX12	-0.63	-10.99	-0.47	6.73e-25	Breast size;
LUAD	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg21280719	chr6:42927975	GNMT	-0.37	-11.52	-0.49	7.01e-27	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12756686	chr19:29218302	NA	0.71	11.33	0.48	3.73e-26	Methadone dose in opioid dependence;
LUAD	cis	rs12893597	0.715	rs74639969	chr14:76832150	A/G	cg20290672	chr14:76816747	NA	-0.45	-7.14	-0.33	4.15e-12	Maximal oxygen uptake response;
LUAD	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	10.79	0.46	3.83e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4523957	0.757	rs216199	chr17:2200871	C/T	cg16513277	chr17:2031491	SMG6	0.73	13.61	0.55	3.13e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03264133	chr6:25882463	NA	-0.57	-9.39	-0.42	3.71e-19	Blood metabolite levels;
LUAD	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg07677032	chr17:61819896	STRADA	0.56	10.18	0.44	6.59e-22	Prudent dietary pattern;
LUAD	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg02176678	chr2:219576539	TTLL4	-0.82	-17.52	-0.65	4.51e-52	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg17299007	chr1:248814626	OR2T27	0.28	6.35	0.3	5.55e-10	Common traits (Other);
LUAD	cis	rs6484504	0.576	rs158144	chr11:31211795	A/C	cg26647111	chr11:31128758	NA	-0.47	-8.24	-0.37	2.26e-15	Red blood cell count;
LUAD	trans	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg00953403	chr17:74099816	EXOC7	0.46	7.33	0.34	1.15e-12	Psychosis in Alzheimer's disease;
LUAD	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.02	-0.44	2.44e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg11416102	chr8:651193	ERICH1	0.91	8.68	0.39	8.96e-17	IgG glycosylation;
LUAD	cis	rs713587	0.935	rs11676272	chr2:25141538	A/G	cg04586622	chr2:25135609	ADCY3	0.33	7.13	0.33	4.38e-12	Body mass index in non-asthmatics;
LUAD	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg05304507	chr6:116381966	FRK	0.2	6.79	0.31	3.7e-11	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15541040	chr2:3486749	NA	-0.43	-7.42	-0.34	6.37e-13	Neurofibrillary tangles;
LUAD	cis	rs7937890	0.532	rs2575833	chr11:14492505	A/C	cg06199346	chr11:14280333	SPON1	-0.32	-6.41	-0.3	3.96e-10	Mitochondrial DNA levels;
LUAD	cis	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg07460842	chr6:66804631	NA	0.97	13.14	0.54	2.49e-33	Exhaled nitric oxide output;
LUAD	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24531977	chr5:56204891	C5orf35	-1.21	-20.36	-0.7	9.55e-65	Initial pursuit acceleration;
LUAD	cis	rs6432018	0.927	rs11674769	chr2:9734278	T/C	cg12832956	chr2:9616023	IAH1	-0.37	-6.57	-0.3	1.48e-10	Heart rate variability traits;
LUAD	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7395662	0.929	rs7946248	chr11:48613516	T/A	cg00717180	chr2:96193071	NA	-0.39	-7.27	-0.33	1.72e-12	HDL cholesterol;
LUAD	cis	rs7680126	0.500	rs4640669	chr4:10145733	A/G	cg00071950	chr4:10020882	SLC2A9	0.56	8.19	0.37	3.06e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg22907277	chr7:1156413	C7orf50	0.7	8.32	0.38	1.2e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg13560548	chr3:10150139	C3orf24	0.45	7.33	0.34	1.22e-12	Alzheimer's disease;
LUAD	cis	rs9581857	0.547	rs9581877	chr13:28104321	T/A	cg22138327	chr13:27999177	GTF3A	0.81	8.76	0.39	4.61e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg11663144	chr21:46675770	NA	-0.6	-11.83	-0.5	4.19e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg17173187	chr15:85201210	NMB	-0.34	-6.6	-0.31	1.27e-10	P wave terminal force;
LUAD	cis	rs76878669	0.561	rs1039594	chr11:66131149	C/T	cg18002602	chr11:66138449	SLC29A2	0.46	10.06	0.44	1.69e-21	Educational attainment (years of education);
LUAD	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg19774624	chr17:42201019	HDAC5	-0.38	-6.51	-0.3	2.13e-10	Total body bone mineral density;
LUAD	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg08085267	chr17:45401833	C17orf57	-0.58	-10.53	-0.46	3.5e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg00277334	chr10:82204260	NA	-0.65	-11.53	-0.49	6e-27	Post bronchodilator FEV1;
LUAD	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18876405	chr7:65276391	NA	-0.44	-6.99	-0.32	1.06e-11	Aortic root size;
LUAD	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg05313129	chr8:58192883	C8orf71	-0.57	-8.41	-0.38	6.38e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs12949688	0.967	rs8081251	chr17:55824033	A/G	cg12582317	chr17:55822272	NA	0.37	7.4	0.34	7.45e-13	Schizophrenia;
LUAD	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg14458575	chr2:238380390	NA	0.96	19.05	0.68	7.4e-59	Prostate cancer;
LUAD	cis	rs9369695	0.842	rs2396825	chr6:47568696	A/G	cg20196966	chr6:47445060	CD2AP	0.45	7.22	0.33	2.37e-12	Reticulocyte count;
LUAD	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg18252515	chr7:66147081	NA	-0.64	-6.93	-0.32	1.6e-11	Diabetic kidney disease;
LUAD	cis	rs1018836	0.828	rs4140679	chr8:91584269	A/C	cg16814680	chr8:91681699	NA	-0.62	-10.35	-0.45	1.62e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg15320075	chr8:145703422	NA	-0.39	-6.52	-0.3	2.06e-10	Age at first birth;
LUAD	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.95	-0.53	1.47e-32	Dilated cardiomyopathy;
LUAD	trans	rs853679	0.607	rs35030260	chr6:28305508	G/A	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.0	-0.47	6.28e-25	Depression;
LUAD	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg03929089	chr4:120376271	NA	-0.83	-14.44	-0.57	1.08e-38	Height;
LUAD	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg06558623	chr16:89946397	TCF25	1.07	11.16	0.48	1.63e-25	Skin colour saturation;
LUAD	cis	rs9796	0.561	rs7173086	chr15:41509288	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.42	-7.62	-0.35	1.68e-13	Menopause (age at onset);
LUAD	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.43	-7.11	-0.33	4.97e-12	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg07460842	chr6:66804631	NA	0.96	12.99	0.53	1.09e-32	Exhaled nitric oxide output;
LUAD	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	7.6	0.35	1.95e-13	Personality dimensions;
LUAD	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg12193833	chr17:30244370	NA	0.53	6.64	0.31	9.45e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs2446066	0.605	rs7302835	chr12:53955066	C/T	cg20730629	chr12:53886622	MAP3K12	-0.46	-6.56	-0.3	1.62e-10	Red blood cell count;
LUAD	cis	rs2262909	0.962	rs411020	chr19:22231102	G/A	cg11619707	chr19:22235551	ZNF257	-0.48	-7.48	-0.34	4.22e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg11189052	chr15:85197271	WDR73	0.69	9.16	0.41	2.34e-18	Schizophrenia;
LUAD	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg15921436	chr17:44337874	NA	-0.72	-9.58	-0.42	8.12e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg26513180	chr16:89883248	FANCA	0.7	13.12	0.54	3.25e-33	Vitiligo;
LUAD	trans	rs11039798	0.764	rs11039771	chr11:48513273	C/T	cg15704280	chr7:45808275	SEPT13	0.65	7.63	0.35	1.5700000000000001e-13	Axial length;
LUAD	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg07810366	chr2:100720526	AFF3	-0.34	-7.0	-0.32	1e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg26384229	chr12:38710491	ALG10B	0.44	7.39	0.34	8.1e-13	Morning vs. evening chronotype;
LUAD	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg09065629	chr16:1709722	CRAMP1L	0.43	7.39	0.34	8e-13	Coronary artery disease;
LUAD	cis	rs4713675	0.546	rs2296739	chr6:33656969	G/A	cg13859433	chr6:33739653	LEMD2	-0.29	-6.73	-0.31	5.56e-11	Plateletcrit;
LUAD	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27574168	chr18:54318782	WDR7	0.53	6.66	0.31	8.72e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg11663144	chr21:46675770	NA	-0.62	-12.23	-0.51	1.17e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg07211511	chr3:129823064	LOC729375	-0.44	-6.51	-0.3	2.14e-10	Blood pressure (smoking interaction);
LUAD	cis	rs1461503	1.000	rs1461499	chr11:122843987	C/A	cg27398637	chr11:122830231	C11orf63	-0.37	-7.05	-0.32	7.53e-12	Menarche (age at onset);
LUAD	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-7.91	-0.36	2.34e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7172809	0.523	rs76675107	chr15:77552944	T/C	cg11865553	chr15:77376250	NA	-0.38	-6.36	-0.3	5.35e-10	Glucose homeostasis traits;
LUAD	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg09904177	chr6:26538194	HMGN4	0.44	7.31	0.34	1.31e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg04450456	chr4:17643702	FAM184B	0.43	8.51	0.38	2.96e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-11.16	-0.48	1.66e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg09509183	chr1:209979624	IRF6	0.56	6.65	0.31	8.98e-11	Coronary artery disease;
LUAD	cis	rs7193541	0.646	rs7188880	chr16:74664810	A/T	cg01733217	chr16:74700730	RFWD3	0.68	13.43	0.55	1.68e-34	Multiple myeloma;
LUAD	cis	rs2455601	0.786	rs56680262	chr11:8971555	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.55	-9.21	-0.41	1.57e-18	Schizophrenia;
LUAD	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg26384229	chr12:38710491	ALG10B	-0.45	-7.68	-0.35	1.14e-13	Heart rate;
LUAD	trans	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	8.73	0.39	5.89e-17	Ulcerative colitis;
LUAD	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg12379764	chr21:47803548	PCNT	-0.38	-6.41	-0.3	3.84e-10	Testicular germ cell tumor;
LUAD	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg15309053	chr8:964076	NA	0.34	7.44	0.34	5.84e-13	Schizophrenia;
LUAD	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg15704280	chr7:45808275	SEPT13	0.74	10.88	0.47	1.83e-24	Height;
LUAD	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg17063962	chr7:91808500	NA	0.68	12.1	0.51	3.93e-29	Breast cancer;
LUAD	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg07677032	chr17:61819896	STRADA	0.55	9.87	0.43	7.96e-21	Prudent dietary pattern;
LUAD	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg09060608	chr5:178986726	RUFY1	0.57	9.69	0.43	3.34e-20	Lung cancer;
LUAD	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg05805236	chr11:65401703	PCNXL3	-0.6	-9.49	-0.42	1.68e-19	Acne (severe);
LUAD	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg01657329	chr11:68192670	LRP5	0.47	8.27	0.37	1.77e-15	Total body bone mineral density;
LUAD	cis	rs877282	1.000	rs7100358	chr10:773681	G/A	cg06581033	chr10:766294	NA	-0.48	-6.7	-0.31	6.56e-11	Uric acid levels;
LUAD	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg18129178	chr5:148520854	ABLIM3	-0.67	-9.66	-0.43	4.41e-20	Breast cancer;
LUAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00149659	chr3:10157352	C3orf10	0.61	8.68	0.39	8.54e-17	Alzheimer's disease;
LUAD	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg17105886	chr17:28927953	LRRC37B2	0.75	7.66	0.35	1.24e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.61	-7.34	-0.34	1.09e-12	Body mass index;
LUAD	cis	rs7680126	0.562	rs4698036	chr4:10331294	T/G	cg00071950	chr4:10020882	SLC2A9	-0.44	-6.47	-0.3	2.74e-10	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs35264875	0.808	rs921675	chr11:68869034	A/G	cg02660097	chr11:68866761	NA	-0.44	-6.92	-0.32	1.66e-11	Blond vs. brown hair color;
LUAD	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg05368731	chr17:41323189	NBR1	0.96	20.32	0.7	1.48e-64	Menopause (age at onset);
LUAD	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg02527881	chr3:46936655	PTH1R	0.44	8.32	0.38	1.19e-15	Colorectal cancer;
LUAD	cis	rs8017423	0.935	rs17188598	chr14:90722473	A/T	cg14092571	chr14:90743983	NA	-0.5	-8.89	-0.4	1.83e-17	Mortality in heart failure;
LUAD	cis	rs9300255	0.664	rs28636834	chr12:123871070	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	6.52	0.3	2.03e-10	Neutrophil percentage of white cells;
LUAD	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg22029157	chr1:209979665	IRF6	-0.67	-10.37	-0.45	1.36e-22	Cleft lip with or without cleft palate;
LUAD	cis	rs2274273	0.870	rs67514154	chr14:55767382	T/C	cg04306507	chr14:55594613	LGALS3	0.43	8.95	0.4	1.16e-17	Protein biomarker;
LUAD	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg13073564	chr4:8508604	NA	0.62	11.37	0.48	2.46e-26	Response to antineoplastic agents;
LUAD	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg10518543	chr12:38710700	ALG10B	-0.44	-7.17	-0.33	3.4e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs11722228	0.594	rs10939663	chr4:10032516	T/G	cg11266682	chr4:10021025	SLC2A9	0.39	6.8	0.31	3.52e-11	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs116248771	0.739	rs73156415	chr3:158342695	C/A	cg16708174	chr3:158430962	RARRES1	0.46	6.78	0.31	4.11e-11	diarrhoeal disease at age 2;
LUAD	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg07217954	chr7:1067459	C7orf50	-0.44	-7.56	-0.34	2.56e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg00933542	chr6:150070202	PCMT1	0.38	7.98	0.36	1.39e-14	Lung cancer;
LUAD	cis	rs7246657	0.550	rs10411176	chr19:37686953	G/T	cg23950597	chr19:37808831	NA	-0.61	-6.36	-0.3	5.39e-10	Coronary artery calcification;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg05934196	chr8:22925766	TNFRSF10B	-0.56	-6.93	-0.32	1.53e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg27490568	chr2:178487706	NA	0.4	6.65	0.31	9.04e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg00933542	chr6:150070202	PCMT1	0.45	9.85	0.43	9.89e-21	Lung cancer;
LUAD	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg25036284	chr2:26402008	FAM59B	0.55	7.71	0.35	9.1e-14	Gut microbiome composition (summer);
LUAD	cis	rs17095355	0.818	rs1009532	chr10:111840725	C/T	cg00817464	chr10:111662876	XPNPEP1	0.65	9.37	0.41	4.25e-19	Biliary atresia;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg23843019	chr19:53445988	ZNF321	0.39	6.55	0.3	1.71e-10	Bipolar disorder;
LUAD	cis	rs1478897	0.510	rs11786148	chr8:11423781	C/G	cg05635807	chr8:11422167	NA	-0.4	-7.04	-0.32	7.96e-12	Systemic lupus erythematosus;
LUAD	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.5	-8.99	-0.4	8.19e-18	Lymphocyte counts;
LUAD	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg10356904	chr22:49881777	NA	-0.39	-7.27	-0.33	1.75e-12	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.29	6.51	0.3	2.18e-10	Parkinson's disease;
LUAD	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-10.55	-0.46	3.07e-23	Lymphocyte counts;
LUAD	trans	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg25894440	chr7:65020034	NA	-0.63	-6.67	-0.31	8.15e-11	Diabetic kidney disease;
LUAD	cis	rs2131877	0.573	rs9848862	chr3:194842202	C/T	cg25921813	chr3:194797138	C3orf21	-0.36	-6.88	-0.32	2.22e-11	Non-small cell lung cancer;
LUAD	cis	rs12760731	0.623	rs721289	chr1:178395682	A/G	cg00404053	chr1:178313656	RASAL2	0.44	6.36	0.3	5.1e-10	Obesity-related traits;
LUAD	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg03714773	chr7:91764589	CYP51A1	0.27	6.46	0.3	2.84e-10	Breast cancer;
LUAD	cis	rs1595825	1.000	rs73058820	chr2:198864358	A/G	cg00982548	chr2:198649783	BOLL	-0.63	-8.87	-0.4	2.01e-17	Ulcerative colitis;
LUAD	cis	rs5756813	0.688	rs56114444	chr22:38123364	C/T	cg06521852	chr22:38141419	TRIOBP	0.5	8.7	0.39	7.73e-17	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg09658497	chr7:2847517	GNA12	-0.42	-7.0	-0.32	1.03e-11	Height;
LUAD	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg09184832	chr6:79620586	NA	-0.5	-9.46	-0.42	2.24e-19	Intelligence (multi-trait analysis);
LUAD	trans	rs12200782	0.932	rs12202419	chr6:26465384	G/T	cg08851530	chr6:28072375	NA	-0.75	-6.95	-0.32	1.41e-11	Small cell lung carcinoma;
LUAD	cis	rs4378999	0.660	rs7648012	chr3:51354571	G/A	cg12934382	chr3:51741135	GRM2	0.4	6.83	0.31	3.05e-11	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg20476274	chr7:133979776	SLC35B4	0.75	12.98	0.53	1.12e-32	Mean platelet volume;
LUAD	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg00981070	chr1:2046702	PRKCZ	-0.35	-7.0	-0.32	1.04e-11	Height;
LUAD	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg10792982	chr14:105748885	BRF1	0.44	9.11	0.4	3.41e-18	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg10909506	chr17:38081995	ORMDL3	0.42	7.2	0.33	2.77e-12	Self-reported allergy;
LUAD	cis	rs12681287	0.640	rs6992287	chr8:87418960	G/A	cg27223183	chr8:87520930	FAM82B	0.67	9.42	0.42	2.92e-19	Caudate activity during reward;
LUAD	cis	rs6496044	0.568	rs6496049	chr15:86069205	C/G	cg13263323	chr15:86062960	AKAP13	-0.57	-10.64	-0.46	1.38e-23	Interstitial lung disease;
LUAD	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08704250	chr15:31115839	NA	-0.56	-9.77	-0.43	1.8e-20	Huntington's disease progression;
LUAD	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg16647868	chr5:131706066	SLC22A5	0.49	7.88	0.36	2.73e-14	Breast cancer;
LUAD	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg18252515	chr7:66147081	NA	0.62	6.85	0.32	2.65e-11	Diabetic kidney disease;
LUAD	cis	rs11048434	0.736	rs1476911	chr12:9090859	C/T	cg26114124	chr12:9217669	LOC144571	0.38	6.95	0.32	1.41e-11	Sjögren's syndrome;
LUAD	cis	rs738322	0.574	rs28653361	chr22:38570700	C/A	cg25457927	chr22:38595422	NA	-0.51	-11.25	-0.48	7.29e-26	Cutaneous nevi;
LUAD	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg08601574	chr20:25228251	PYGB	-0.47	-8.88	-0.4	1.86e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1232027	0.656	rs1650675	chr5:79959524	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.02	-0.32	8.63e-12	Huntington's disease progression;
LUAD	cis	rs7809950	1.000	rs3801944	chr7:107255548	T/C	cg23024343	chr7:107201750	COG5	0.72	11.98	0.5	1.15e-28	Coronary artery disease;
LUAD	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg14668632	chr7:2872130	GNA12	-0.74	-13.34	-0.54	3.81e-34	Height;
LUAD	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg10518543	chr12:38710700	ALG10B	0.44	7.39	0.34	8.08e-13	Heart rate;
LUAD	cis	rs1448094	0.872	rs1026085	chr12:86355735	A/G	cg19622623	chr12:86230825	RASSF9	-0.39	-7.21	-0.33	2.56e-12	Major depressive disorder;
LUAD	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.46	-0.34	4.92e-13	Cognitive function;
LUAD	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg17509989	chr5:176798049	RGS14	-0.6	-9.56	-0.42	9.89e-20	Urate levels in lean individuals;
LUAD	trans	rs1728785	1.000	rs1645935	chr16:68563791	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	9.78	0.43	1.69e-20	Ulcerative colitis;
LUAD	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08219700	chr8:58056026	NA	0.65	8.76	0.39	4.58e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs208520	0.779	rs208446	chr6:66903515	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-14.08	-0.56	3.33e-37	Exhaled nitric oxide output;
LUAD	cis	rs2797160	1.000	rs1418948	chr6:126007018	C/T	cg05901451	chr6:126070800	HEY2	0.45	6.6	0.31	1.23e-10	Endometrial cancer;
LUAD	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg23283495	chr1:209979779	IRF6	0.73	9.26	0.41	1e-18	Cleft lip with or without cleft palate;
LUAD	cis	rs4594175	0.926	rs11157804	chr14:51630340	A/G	cg23942311	chr14:51606299	NA	-0.63	-11.02	-0.47	5.3e-25	Cancer;
LUAD	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.32	-0.34	1.27e-12	Total body bone mineral density;
LUAD	trans	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.86e-11	Depression;
LUAD	trans	rs459571	1.000	rs456207	chr9:136911140	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.62	-9.06	-0.4	5.05e-18	Platelet distribution width;
LUAD	cis	rs7793919	0.726	rs10261971	chr7:4776547	A/G	cg09789173	chr7:4769017	FOXK1	0.74	15.45	0.6	5.31e-43	Mosquito bite size;
LUAD	cis	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.89	-0.32	2e-11	Neuroticism;
LUAD	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg17724175	chr1:150552817	MCL1	0.31	7.16	0.33	3.56e-12	Melanoma;
LUAD	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg20291162	chr17:40259547	DHX58	-0.67	-10.37	-0.45	1.38e-22	Fibrinogen levels;
LUAD	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg06618935	chr21:46677482	NA	-0.51	-10.02	-0.44	2.32e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg20283391	chr11:68216788	NA	-0.41	-6.58	-0.3	1.36e-10	Total body bone mineral density;
LUAD	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg09658497	chr7:2847517	GNA12	-0.55	-9.11	-0.4	3.37e-18	Height;
LUAD	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg14895029	chr7:2775587	GNA12	-0.44	-7.11	-0.33	5.14e-12	Height;
LUAD	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg15181151	chr6:150070149	PCMT1	0.38	7.45	0.34	5.19e-13	Lung cancer;
LUAD	cis	rs116248771	0.739	rs73156496	chr3:158421162	T/C	cg16708174	chr3:158430962	RARRES1	0.47	6.94	0.32	1.46e-11	diarrhoeal disease at age 2;
LUAD	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg07741184	chr6:167504864	NA	0.42	9.48	0.42	1.9e-19	Crohn's disease;
LUAD	cis	rs10489202	0.608	rs10918826	chr1:168075316	C/T	cg24449463	chr1:168025552	DCAF6	-0.64	-10.28	-0.45	2.74e-22	Schizophrenia;
LUAD	trans	rs2262909	0.849	rs10420483	chr19:22190378	A/G	cg05197062	chr11:11642011	GALNTL4	-0.53	-8.0	-0.36	1.21e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg03859395	chr2:55845619	SMEK2	0.75	13.89	0.56	2.02e-36	Metabolic syndrome;
LUAD	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg22906224	chr7:99728672	NA	0.55	9.5	0.42	1.5700000000000001e-19	Coronary artery disease;
LUAD	cis	rs8044868	0.586	rs10852511	chr16:72183959	G/A	cg23815491	chr16:72088622	HP	0.52	9.78	0.43	1.7e-20	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg00074818	chr8:8560427	CLDN23	0.66	10.18	0.44	6.31e-22	Obesity-related traits;
LUAD	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg20673091	chr1:2541236	MMEL1	0.41	8.61	0.39	1.5e-16	Ulcerative colitis;
LUAD	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg05110241	chr16:68378359	PRMT7	-0.84	-9.13	-0.41	2.84e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg06740227	chr12:86229804	RASSF9	0.38	6.88	0.32	2.15e-11	Major depressive disorder;
LUAD	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg21475434	chr5:93447410	FAM172A	0.8	8.73	0.39	5.87e-17	Diabetic retinopathy;
LUAD	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg00981070	chr1:2046702	PRKCZ	-0.37	-7.76	-0.35	6.32e-14	Height;
LUAD	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg12927641	chr6:109611667	NA	0.52	9.12	0.41	3.11e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg02423579	chr7:2872169	GNA12	-0.56	-9.39	-0.42	3.81e-19	Height;
LUAD	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg11494091	chr17:61959527	GH2	0.74	18.33	0.67	1.2e-55	Prudent dietary pattern;
LUAD	cis	rs2073300	1.000	rs12626013	chr20:23442215	G/A	cg09953122	chr20:23471693	CST8	-0.65	-6.39	-0.3	4.29e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs4711336	1.000	rs2296740	chr6:33659536	A/G	cg13859433	chr6:33739653	LEMD2	-0.32	-7.42	-0.34	6.69e-13	Height;
LUAD	cis	rs3806933	0.522	rs17553936	chr5:110454681	A/G	cg17157872	chr5:110408788	TSLP	0.34	6.44	0.3	3.28e-10	Eosinophilic esophagitis;
LUAD	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg27535305	chr1:53392650	SCP2	-0.32	-6.52	-0.3	2.01e-10	Monocyte count;
LUAD	cis	rs6752107	0.935	rs1596017	chr2:234147930	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.52	8.97	0.4	9.96e-18	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg06641503	chr3:48959341	ARIH2	-0.36	-6.69	-0.31	7.15e-11	Menarche (age at onset);
LUAD	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg04450456	chr4:17643702	FAM184B	0.4	7.81	0.36	4.54e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1467026	0.584	rs11712581	chr3:12807781	T/C	cg24848339	chr3:12840334	CAND2	0.33	6.51	0.3	2.1e-10	P wave duration;
LUAD	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg17264618	chr3:40429014	ENTPD3	-0.39	-8.66	-0.39	9.77e-17	Renal cell carcinoma;
LUAD	trans	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.85	0.43	9.44e-21	Ulcerative colitis;
LUAD	cis	rs859767	1.000	rs842361	chr2:135340840	C/G	cg12500956	chr2:135428796	TMEM163	0.29	7.66	0.35	1.31e-13	Neuroticism;
LUAD	cis	rs17095355	0.605	rs3780951	chr10:111644994	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.65	-8.23	-0.37	2.4e-15	Biliary atresia;
LUAD	cis	rs9905704	0.633	rs2531731	chr17:56546524	A/C	cg19466818	chr17:56409534	MIR142	0.33	6.42	0.3	3.59e-10	Testicular germ cell tumor;
LUAD	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg23950597	chr19:37808831	NA	-0.6	-7.52	-0.34	3.32e-13	Coronary artery calcification;
LUAD	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg07195577	chr17:27052828	TLCD1	0.47	6.5	0.3	2.23e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg01065977	chr19:18549689	ISYNA1	-0.39	-7.38	-0.34	8.42e-13	Breast cancer;
LUAD	cis	rs11048434	0.761	rs10842662	chr12:9139344	G/A	cg23795048	chr12:9217529	LOC144571	0.45	8.22	0.37	2.58e-15	Sjögren's syndrome;
LUAD	cis	rs9902453	0.808	rs76515799	chr17:28169491	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	9.05	0.4	5.41e-18	Coffee consumption (cups per day);
LUAD	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg03959625	chr15:84868606	LOC388152	0.42	6.72	0.31	5.75e-11	Schizophrenia;
LUAD	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.22	0.33	2.36e-12	Melanoma;
LUAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg20276088	chr3:133502917	NA	-0.38	-6.81	-0.31	3.32e-11	Iron status biomarkers;
LUAD	cis	rs1044826	0.642	rs6784684	chr3:139177634	T/C	cg00490450	chr3:139108681	COPB2	0.41	6.59	0.31	1.33e-10	Obesity-related traits;
LUAD	cis	rs3106136	0.967	rs2087170	chr4:95162960	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.5	-0.34	3.75e-13	Capecitabine sensitivity;
LUAD	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg23992470	chr4:843637	GAK	0.67	7.09	0.33	5.59e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs73198271	0.628	rs11777742	chr8:8589858	C/T	cg01851573	chr8:8652454	MFHAS1	0.47	6.8	0.31	3.6e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs41311933	0.803	rs77617771	chr9:123729896	G/A	cg13567360	chr9:123745713	C5	-0.74	-6.65	-0.31	9.27e-11	Coronary artery disease;
LUAD	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.67	-0.35	1.23e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.61	-8.74	-0.39	5.38e-17	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3784262	0.528	rs8027188	chr15:58334799	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-7.07	-0.33	6.36e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg07343612	chr16:622815	PIGQ	-0.79	-15.58	-0.6	1.46e-43	Height;
LUAD	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg05182265	chr7:156933206	UBE3C	0.61	11.4	0.48	1.89e-26	Body mass index;
LUAD	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg15448220	chr1:150897856	SETDB1	0.48	8.15	0.37	4.25e-15	Tonsillectomy;
LUAD	cis	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg24289452	chr6:170231220	NA	-0.58	-6.37	-0.3	4.83e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg19761014	chr17:28927070	LRRC37B2	0.77	7.72	0.35	8.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.71	-0.35	8.94e-14	Total body bone mineral density;
LUAD	cis	rs73198271	0.700	rs10103282	chr8:8650757	T/G	cg01851573	chr8:8652454	MFHAS1	0.52	9.2	0.41	1.67e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg19676328	chr12:49525230	TUBA1B	-0.6	-8.45	-0.38	4.58e-16	Total cholesterol levels;
LUAD	cis	rs999943	0.846	rs9366826	chr6:33619184	C/G	cg14003231	chr6:33640908	ITPR3	0.83	15.91	0.61	5.15e-45	Obesity (extreme);
LUAD	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg13073564	chr4:8508604	NA	0.48	7.79	0.35	5.34e-14	Response to antineoplastic agents;
LUAD	cis	rs2046867	0.818	rs62249879	chr3:72917171	A/G	cg25664220	chr3:72788482	NA	-0.6	-10.08	-0.44	1.43e-21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs1493916	0.905	rs4239383	chr18:31401066	T/C	cg27147174	chr7:100797783	AP1S1	-0.72	-13.0	-0.53	9.84e-33	Life satisfaction;
LUAD	cis	rs9388451	0.531	rs9375414	chr6:126154475	G/A	cg05901451	chr6:126070800	HEY2	-0.58	-9.28	-0.41	8.78e-19	Brugada syndrome;
LUAD	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg04851639	chr8:1020857	NA	-0.41	-10.15	-0.44	8.29e-22	Schizophrenia;
LUAD	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg17757837	chr7:157058334	UBE3C	0.48	8.53	0.38	2.66e-16	Body mass index;
LUAD	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.36	-6.41	-0.3	3.9e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg14917512	chr19:3094685	GNA11	-0.58	-6.88	-0.32	2.19e-11	Diabetic kidney disease;
LUAD	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg27446573	chr6:127587934	RNF146	0.45	6.74	0.31	5.36e-11	Breast cancer;
LUAD	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-9.0	-0.4	7.82e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg01176363	chr20:62369445	LIME1	-0.5	-8.03	-0.36	9.56e-15	Prostate cancer;
LUAD	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg25535316	chr11:579198	PHRF1	-0.38	-6.67	-0.31	8.2e-11	Systemic lupus erythematosus;
LUAD	cis	rs6541297	0.703	rs611841	chr1:230309481	C/A	cg20703242	chr1:230279135	GALNT2	-0.47	-6.86	-0.32	2.46e-11	Coronary artery disease;
LUAD	cis	rs4629710	0.592	rs10484763	chr6:131549060	T/C	cg12606694	chr6:131520996	AKAP7	0.49	7.13	0.33	4.27e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.35	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg09904177	chr6:26538194	HMGN4	0.42	6.92	0.32	1.68e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg06608945	chr2:219082296	ARPC2	0.49	8.45	0.38	4.57e-16	Colorectal cancer;
LUAD	trans	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg14917512	chr19:3094685	GNA11	-0.58	-6.83	-0.32	3e-11	Diabetic kidney disease;
LUAD	cis	rs6546550	0.867	rs6738174	chr2:70150215	A/C	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.97	-0.47	8.24e-25	Prevalent atrial fibrillation;
LUAD	cis	rs9863	0.861	rs77020228	chr12:124418472	C/G	cg17723958	chr12:124429295	CCDC92	-0.41	-6.58	-0.3	1.4e-10	White blood cell count;
LUAD	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg13319975	chr6:146136371	FBXO30	0.6	9.74	0.43	2.37e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs354225	0.544	rs13391522	chr2:54805854	T/C	cg01766943	chr2:54829624	SPTBN1	0.4	7.44	0.34	5.71e-13	Schizophrenia;
LUAD	cis	rs346785	1.000	rs346785	chr17:74283769	C/T	cg09812376	chr17:74270190	QRICH2	0.32	7.58	0.35	2.22e-13	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08280861	chr8:58055591	NA	0.66	8.53	0.38	2.65e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg20701182	chr2:24300061	SF3B14	0.72	7.92	0.36	2.07e-14	Lymphocyte counts;
LUAD	cis	rs859767	0.887	rs859766	chr2:135342254	C/T	cg12500956	chr2:135428796	TMEM163	0.33	8.61	0.39	1.41e-16	Neuroticism;
LUAD	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg22496339	chr2:162101262	NA	0.73	13.52	0.55	7.32e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07167872	chr1:205819463	PM20D1	0.88	19.62	0.69	2.08e-61	Menarche (age at onset);
LUAD	cis	rs9393692	0.557	rs62394768	chr6:26326033	C/T	cg13736514	chr6:26305472	NA	-0.51	-8.33	-0.38	1.13e-15	Educational attainment;
LUAD	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg19761014	chr17:28927070	LRRC37B2	0.86	8.36	0.38	9.21e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21984481	chr17:79567631	NPLOC4	-0.65	-15.66	-0.61	6.36e-44	Eye color traits;
LUAD	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg19052272	chr2:3704530	ALLC	-0.61	-10.51	-0.45	4.25e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg23254163	chr1:152506842	NA	0.25	6.68	0.31	7.46e-11	Hair morphology;
LUAD	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.49	-8.23	-0.37	2.37e-15	Reticulocyte count;
LUAD	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg00933542	chr6:150070202	PCMT1	0.45	9.49	0.42	1.68e-19	Lung cancer;
LUAD	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg20607287	chr7:12443886	VWDE	-0.54	-6.82	-0.31	3.11e-11	Coronary artery disease;
LUAD	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg09253696	chr17:73873529	TRIM47	-0.42	-7.29	-0.33	1.58e-12	Psoriasis;
LUAD	trans	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg21659725	chr3:3221576	CRBN	-0.44	-7.22	-0.33	2.51e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg26043149	chr18:55253948	FECH	0.49	8.02	0.36	1.06e-14	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs2455601	0.786	rs11042127	chr11:8947586	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-7.65	-0.35	1.36e-13	Schizophrenia;
LUAD	cis	rs9837602	1.000	rs4075038	chr3:99680086	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.61	-9.11	-0.41	3.25e-18	Breast cancer;
LUAD	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg25985355	chr7:65971099	NA	-0.55	-6.83	-0.32	2.97e-11	Diabetic kidney disease;
LUAD	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg27297192	chr10:134578999	INPP5A	0.37	6.63	0.31	1.01e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs8192282	0.739	rs10752642	chr1:154481624	C/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.44	-6.82	-0.31	3.09e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.38	-0.34	8.34e-13	Resting heart rate;
LUAD	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg19761014	chr17:28927070	LRRC37B2	0.65	6.6	0.31	1.26e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg27494647	chr7:150038898	RARRES2	0.51	8.97	0.4	9.91e-18	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg01324343	chr3:183735012	ABCC5	0.94	25.19	0.77	3.48e-86	Anterior chamber depth;
LUAD	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg22753661	chr15:79092743	ADAMTS7	-0.5	-7.92	-0.36	2.18e-14	Coronary artery disease or large artery stroke;
LUAD	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18404041	chr3:52824283	ITIH1	0.56	11.9	0.5	2.32e-28	Bipolar disorder;
LUAD	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg00898013	chr13:113819073	PROZ	0.73	13.17	0.54	2e-33	Platelet distribution width;
LUAD	cis	rs4891159	0.757	rs11665518	chr18:74147054	C/T	cg24786174	chr18:74118243	ZNF516	-0.8	-15.43	-0.6	6.33e-43	Longevity;
LUAD	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg19875535	chr5:140030758	IK	0.43	7.35	0.34	1.04e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.79	-0.31	3.91e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg15123519	chr2:136567270	LCT	-0.39	-6.77	-0.31	4.41e-11	Mosquito bite size;
LUAD	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg25319279	chr11:5960081	NA	0.38	7.05	0.32	7.11e-12	DNA methylation (variation);
LUAD	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg04369109	chr6:150039330	LATS1	-0.49	-8.34	-0.38	1.06e-15	Lung cancer;
LUAD	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg11494091	chr17:61959527	GH2	-0.4	-7.08	-0.33	6.05e-12	Height;
LUAD	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg01324343	chr3:183735012	ABCC5	0.95	25.93	0.78	1.93e-89	Anterior chamber depth;
LUAD	cis	rs4072705	1.000	rs2067791	chr9:127438294	C/T	cg13476313	chr9:127244764	NR5A1	0.31	7.38	0.34	8.45e-13	Menarche (age at onset);
LUAD	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg06064525	chr11:970664	AP2A2	-0.46	-9.15	-0.41	2.5e-18	Alzheimer's disease (late onset);
LUAD	cis	rs3820068	0.705	rs72645804	chr1:15868387	A/C	cg24675056	chr1:15929824	NA	0.42	6.55	0.3	1.71e-10	Systolic blood pressure;
LUAD	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg18761221	chr20:60518478	NA	0.54	9.43	0.42	2.77e-19	Obesity-related traits;
LUAD	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg03037974	chr15:76606532	NA	-0.37	-7.89	-0.36	2.62e-14	Blood metabolite levels;
LUAD	cis	rs12545109	0.613	rs6998873	chr8:57299697	A/G	cg09654669	chr8:57350985	NA	0.67	9.22	0.41	1.45e-18	Obesity-related traits;
LUAD	trans	rs6921919	1.000	rs35875412	chr6:28331818	C/T	cg06606381	chr12:133084897	FBRSL1	-0.48	-6.53	-0.3	1.92e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg15309053	chr8:964076	NA	0.51	11.04	0.47	4.63e-25	Schizophrenia;
LUAD	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg03929089	chr4:120376271	NA	-0.85	-14.83	-0.58	2.39e-40	Height;
LUAD	trans	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg07817883	chr1:32538562	TMEM39B	1.11	11.79	0.5	6.44e-28	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg27411982	chr8:10470053	RP1L1	0.37	6.78	0.31	3.99e-11	Neuroticism;
LUAD	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg00484396	chr16:3507460	NAT15	-0.68	-10.02	-0.44	2.35e-21	Tuberculosis;
LUAD	cis	rs7465272	1.000	rs35900184	chr8:143693411	C/T	cg10104451	chr8:143696006	ARC	-0.6	-8.03	-0.36	9.84e-15	Bipolar disorder and schizophrenia;
LUAD	trans	rs75804782	0.521	rs113497020	chr2:239370813	C/T	cg01134436	chr17:81009848	B3GNTL1	0.78	8.44	0.38	5.07e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg12311346	chr5:56204834	C5orf35	-0.48	-7.98	-0.36	1.37e-14	Coronary artery disease;
LUAD	trans	rs62103177	0.564	rs55867755	chr18:77723434	C/T	cg05926928	chr17:57297772	GDPD1	0.78	9.73	0.43	2.59e-20	Opioid sensitivity;
LUAD	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg00316803	chr15:76480434	C15orf27	-0.36	-6.65	-0.31	8.91e-11	Blood metabolite levels;
LUAD	cis	rs938554	0.570	rs7696983	chr4:9995829	A/C	cg02734326	chr4:10020555	SLC2A9	0.45	6.45	0.3	2.99e-10	Blood metabolite levels;
LUAD	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.84	-0.32	2.74e-11	Retinal vascular caliber;
LUAD	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg00631329	chr6:26305371	NA	-0.69	-13.31	-0.54	5.33e-34	Educational attainment;
LUAD	cis	rs1403694	0.695	rs10937266	chr3:186433075	G/A	cg12454167	chr3:186435060	KNG1	0.53	10.76	0.46	4.81e-24	Blood protein levels;
LUAD	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg12935359	chr14:103987150	CKB	-0.46	-7.73	-0.35	7.76e-14	Body mass index;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg26342734	chr17:7211307	EIF5A	-0.37	-6.36	-0.3	5.14e-10	Schizophrenia;
LUAD	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg26587870	chr6:27730563	NA	-0.7	-7.48	-0.34	4.33e-13	Depression;
LUAD	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg08989290	chr16:615782	NHLRC4	0.32	6.82	0.31	3.14e-11	Height;
LUAD	cis	rs4774899	1.000	rs12914625	chr15:57263440	C/T	cg14026238	chr15:57616123	NA	0.33	6.44	0.3	3.19e-10	Urinary tract infection frequency;
LUAD	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.83	11.62	0.49	2.77e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1448094	0.842	rs7301280	chr12:86455752	G/T	cg06740227	chr12:86229804	RASSF9	-0.37	-6.7	-0.31	6.51e-11	Major depressive disorder;
LUAD	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg18252515	chr7:66147081	NA	0.63	6.96	0.32	1.29e-11	Gout;
LUAD	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18876405	chr7:65276391	NA	-0.58	-9.91	-0.43	5.83e-21	Aortic root size;
LUAD	cis	rs713587	0.719	rs58048722	chr2:25187825	C/T	cg01884057	chr2:25150051	NA	-0.33	-6.82	-0.31	3.22e-11	Body mass index in non-asthmatics;
LUAD	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg15105011	chr4:940614	TMEM175	0.64	11.4	0.48	2e-26	Sjögren's syndrome;
LUAD	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.48	-8.8	-0.39	3.46e-17	Menarche (age at onset);
LUAD	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg07776626	chr8:57350775	NA	-0.61	-9.04	-0.4	5.77e-18	Obesity-related traits;
LUAD	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs7043114	0.563	rs10820988	chr9:95317008	T/C	cg14631576	chr9:95140430	CENPP	-0.37	-7.5	-0.34	3.87e-13	Height;
LUAD	cis	rs698833	0.859	rs17580340	chr2:44602554	C/G	cg04920474	chr2:44395004	PPM1B	0.4	7.21	0.33	2.54e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg17063962	chr7:91808500	NA	0.69	12.27	0.51	8.21e-30	Breast cancer;
LUAD	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg02527881	chr3:46936655	PTH1R	-0.46	-8.65	-0.39	1.12e-16	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3784262	0.669	rs3742960	chr15:58248088	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-7.26	-0.33	1.84e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.75	-13.32	-0.54	4.93e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.21	0.44	5.05e-22	Ileal carcinoids;
LUAD	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg16205897	chr5:131564050	P4HA2	-0.35	-7.66	-0.35	1.25e-13	Acylcarnitine levels;
LUAD	cis	rs986417	0.901	rs1884095	chr14:61017024	C/G	cg27398547	chr14:60952738	C14orf39	0.65	7.55	0.34	2.63e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg19041857	chr6:27730383	NA	-0.42	-7.18	-0.33	3.13e-12	Parkinson's disease;
LUAD	trans	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg18187862	chr3:45730750	SACM1L	0.5	7.95	0.36	1.68e-14	Primary sclerosing cholangitis;
LUAD	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg13271783	chr10:134563150	INPP5A	-0.41	-6.6	-0.31	1.24e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg25173405	chr17:45401733	C17orf57	-0.52	-8.88	-0.4	1.95e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18876405	chr7:65276391	NA	-0.58	-9.73	-0.43	2.5e-20	Aortic root size;
LUAD	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg20469991	chr17:27169893	C17orf63	-0.52	-6.53	-0.3	1.91e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs17867775	0.623	rs117265970	chr7:126655024	G/C	cg02090654	chr7:126698344	MIR592;GRM8	0.85	9.6	0.42	6.96e-20	Anti-saccade response;
LUAD	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg05805236	chr11:65401703	PCNXL3	-0.47	-7.89	-0.36	2.6e-14	Acne (severe);
LUAD	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg18402987	chr7:1209562	NA	0.78	9.52	0.42	1.37e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23583168	chr7:148888333	NA	-0.89	-17.76	-0.65	4.09e-53	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg00071950	chr4:10020882	SLC2A9	0.83	17.75	0.65	4.37e-53	Bone mineral density;
LUAD	cis	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg05084668	chr3:125655381	ALG1L	-0.63	-10.2	-0.44	5.43e-22	Blood pressure (smoking interaction);
LUAD	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg05991184	chr2:219186017	PNKD	-0.36	-7.0	-0.32	1.01e-11	Colorectal cancer;
LUAD	trans	rs4650994	0.525	rs2493864	chr1:178545003	A/C	cg05059571	chr16:84539110	KIAA1609	-0.73	-13.44	-0.55	1.51e-34	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.39e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16139199	chr18:19180362	ESCO1	-0.41	-6.5	-0.3	2.28e-10	Height;
LUAD	cis	rs1497828	0.871	rs2646842	chr1:217555946	G/A	cg04411442	chr1:217543379	NA	0.39	7.0	0.32	9.95e-12	Dialysis-related mortality;
LUAD	trans	rs4714291	0.963	rs4714293	chr6:40009566	T/C	cg02267698	chr19:7991119	CTXN1	0.45	6.9	0.32	1.94e-11	Strep throat;
LUAD	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21582582	chr3:182698605	DCUN1D1	0.5	8.04	0.36	9.23e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.28	-7.14	-0.33	4.19e-12	Schizophrenia;
LUAD	trans	rs12517041	0.748	rs16892375	chr5:23304111	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.57	-0.3	1.47e-10	Calcium levels;
LUAD	trans	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg18187862	chr3:45730750	SACM1L	0.51	7.83	0.36	3.96e-14	Primary sclerosing cholangitis;
LUAD	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg05110241	chr16:68378359	PRMT7	-0.61	-6.35	-0.3	5.43e-10	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs230489	0.673	rs34333163	chr4:103283117	A/G	cg03089870	chr6:17988960	KIF13A	0.48	6.38	0.3	4.54e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs62458065	0.713	rs1597560	chr7:32493886	C/G	cg00845942	chr12:64062724	DPY19L2	-0.5	-7.23	-0.33	2.34e-12	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs657075	0.697	rs3805666	chr5:131646475	G/A	cg21138405	chr5:131827807	IRF1	0.5	6.42	0.3	3.77e-10	Rheumatoid arthritis;
LUAD	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.06	0.32	6.99e-12	Platelet count;
LUAD	cis	rs791888	0.965	rs791873	chr10:89405558	C/T	cg13926569	chr10:89418898	PAPSS2	-0.46	-8.62	-0.39	1.36e-16	Magnesium levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg21149286	chr12:65153070	GNS	-0.66	-6.46	-0.3	2.9e-10	Type 2 diabetes;
LUAD	cis	rs773506	0.602	rs10761110	chr9:93929884	A/G	cg14446406	chr9:93919335	NA	-0.38	-6.85	-0.32	2.61e-11	Type 2 diabetes nephropathy;
LUAD	cis	rs11098699	0.750	rs1500122	chr4:124220060	A/C	cg09941581	chr4:124220074	SPATA5	0.49	7.95	0.36	1.74e-14	Mosquito bite size;
LUAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg02725872	chr8:58115012	NA	0.34	6.56	0.3	1.58e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.79	0.31	3.9e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg24399712	chr22:39784796	NA	-0.75	-13.15	-0.54	2.45e-33	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg12927641	chr6:109611667	NA	-0.52	-9.13	-0.41	2.92e-18	Reticulocyte fraction of red cells;
LUAD	trans	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg07817883	chr1:32538562	TMEM39B	1.48	12.3	0.51	6.09e-30	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.58	8.28	0.37	1.68e-15	Platelet count;
LUAD	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg03467027	chr4:99064603	C4orf37	0.41	6.59	0.31	1.27e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1232027	0.656	rs1677703	chr5:79957737	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.42	-6.84	-0.32	2.84e-11	Huntington's disease progression;
LUAD	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.54	7.51	0.34	3.51e-13	Platelet count;
LUAD	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg07157834	chr1:205819609	PM20D1	0.47	7.36	0.34	9.41e-13	Parkinson's disease;
LUAD	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg20673091	chr1:2541236	MMEL1	0.45	9.87	0.43	8.08e-21	Ulcerative colitis;
LUAD	trans	rs1547374	1.000	rs8134075	chr21:43779853	C/G	cg09521743	chr10:75415752	SYNPO2L	-0.42	-7.11	-0.33	4.97e-12	Pancreatic cancer;
LUAD	cis	rs6993813	0.620	rs7016585	chr8:120030098	C/A	cg01975934	chr8:119970761	NA	-0.34	-6.52	-0.3	1.96e-10	Bone mineral density (hip);
LUAD	cis	rs420259	0.516	rs2106454	chr16:23560398	G/A	cg00143387	chr16:23521605	GGA2	-0.7	-9.81	-0.43	1.32e-20	Bipolar disorder;
LUAD	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19717773	chr7:2847554	GNA12	-0.57	-9.99	-0.44	3.08e-21	Height;
LUAD	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg07507251	chr3:52567010	NT5DC2	0.38	7.4	0.34	7.34e-13	Electroencephalogram traits;
LUAD	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg27432699	chr2:27873401	GPN1	-0.68	-12.16	-0.51	2.29e-29	Oral cavity cancer;
LUAD	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.56	-0.3	1.61e-10	Alzheimer's disease (late onset);
LUAD	cis	rs1691799	0.899	rs1168322	chr12:66743769	C/T	cg16791601	chr12:66731901	HELB	-0.36	-6.48	-0.3	2.56e-10	White blood cell count (basophil);
LUAD	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.16	-0.33	3.65e-12	Coronary artery disease;
LUAD	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg25173405	chr17:45401733	C17orf57	0.45	7.7	0.35	9.65e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg07460842	chr6:66804631	NA	-1.06	-16.73	-0.63	1.33e-48	Exhaled nitric oxide output;
LUAD	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg10295955	chr4:187884368	NA	-1.13	-28.16	-0.81	5.04e-99	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs8073060	0.586	rs4796104	chr17:34046832	T/C	cg19694781	chr19:47549865	TMEM160	1.2	18.62	0.67	6e-57	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs2657888	0.560	rs6581096	chr12:56878120	G/A	cg23002907	chr12:56915593	RBMS2	-0.37	-6.36	-0.3	5.38e-10	Adiponectin levels;
LUAD	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21984481	chr17:79567631	NPLOC4	0.65	15.66	0.61	6.36e-44	Eye color traits;
LUAD	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg00530320	chr1:46809349	NSUN4	0.51	7.93	0.36	1.92e-14	Menopause (age at onset);
LUAD	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg03188948	chr7:1209495	NA	0.83	10.11	0.44	1.13e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg03388025	chr16:89894329	SPIRE2	0.5	13.26	0.54	8.28e-34	Vitiligo;
LUAD	cis	rs56346965	0.506	rs2159818	chr2:191532789	A/G	cg27211696	chr2:191398769	TMEM194B	-0.41	-7.05	-0.32	7.21e-12	Bone mineral density (Ward's triangle area);
LUAD	trans	rs10838798	0.501	rs2270994	chr11:48157869	T/C	cg00717180	chr2:96193071	NA	-0.36	-6.53	-0.3	1.86e-10	Height;
LUAD	cis	rs732716	0.785	rs11667543	chr19:4374850	C/T	cg21934504	chr19:4445085	UBXN6	0.42	6.77	0.31	4.42e-11	Mean corpuscular volume;
LUAD	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg04287289	chr16:89883240	FANCA	0.71	6.63	0.31	1.02e-10	Skin colour saturation;
LUAD	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg19041857	chr6:27730383	NA	-0.4	-6.78	-0.31	4.13e-11	Parkinson's disease;
LUAD	cis	rs758324	0.812	rs3756287	chr5:131135478	A/G	cg25547332	chr5:131281432	NA	0.43	6.86	0.32	2.4e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-25.09	-0.77	8.9e-86	Height;
LUAD	trans	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg01620082	chr3:125678407	NA	-0.81	-8.1	-0.37	6.15e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.01	10.86	0.47	2.15e-24	Initial pursuit acceleration;
LUAD	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg15744005	chr10:104629667	AS3MT	-0.41	-7.19	-0.33	3e-12	Arsenic metabolism;
LUAD	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg17173187	chr15:85201210	NMB	-0.32	-6.41	-0.3	3.91e-10	P wave terminal force;
LUAD	cis	rs7809950	0.723	rs2237662	chr7:106874065	C/G	cg23024343	chr7:107201750	COG5	-0.82	-13.82	-0.56	4.01e-36	Coronary artery disease;
LUAD	cis	rs8077889	0.917	rs72836547	chr17:41902799	G/T	cg26893861	chr17:41843967	DUSP3	0.94	14.66	0.58	1.18e-39	Triglycerides;
LUAD	cis	rs7224737	0.789	rs8071235	chr17:40300126	C/A	cg20291162	chr17:40259547	DHX58	-0.69	-10.4	-0.45	1e-22	Fibrinogen levels;
LUAD	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21659725	chr3:3221576	CRBN	0.66	11.54	0.49	5.84e-27	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg19163074	chr7:65112434	INTS4L2	0.43	6.61	0.31	1.18e-10	Aortic root size;
LUAD	cis	rs6430585	0.527	rs62168792	chr2:136415217	A/G	cg07169764	chr2:136633963	MCM6	0.57	6.77	0.31	4.19e-11	Corneal structure;
LUAD	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02475777	chr4:1388615	CRIPAK	0.71	10.32	0.45	2.07e-22	Longevity;
LUAD	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg23803603	chr1:2058230	PRKCZ	-0.41	-7.23	-0.33	2.31e-12	Height;
LUAD	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.53	-7.68	-0.35	1.13e-13	Alzheimer's disease (late onset);
LUAD	cis	rs9875589	0.509	rs2731330	chr3:14111588	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	6.5	0.3	2.3e-10	Ovarian reserve;
LUAD	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg06784218	chr1:46089804	CCDC17	0.6	13.33	0.54	4.38e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg13798912	chr7:905769	UNC84A	-0.68	-7.68	-0.35	1.12e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg09085632	chr11:111637200	PPP2R1B	0.61	9.09	0.4	3.95e-18	Primary sclerosing cholangitis;
LUAD	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg03714773	chr7:91764589	CYP51A1	0.28	6.4	0.3	4.15e-10	Breast cancer;
LUAD	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg06505273	chr16:24850292	NA	-0.46	-6.81	-0.31	3.39e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg12262378	chr17:6899522	ALOX12	-0.36	-6.63	-0.31	1.02e-10	Tonsillectomy;
LUAD	cis	rs61897795	0.657	rs174589	chr11:61615803	C/G	cg00603274	chr11:61596626	FADS2	0.44	6.96	0.32	1.27e-11	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg15744005	chr10:104629667	AS3MT	-0.37	-7.33	-0.34	1.21e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg17366294	chr4:99064904	C4orf37	0.66	12.83	0.53	4.8e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.42	6.58	0.3	1.36e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs28595532	1.000	rs116030177	chr4:119650768	T/C	cg21605333	chr4:119757512	SEC24D	0.87	8.02	0.36	1.02e-14	Cannabis dependence symptom count;
LUAD	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg18306943	chr3:40428807	ENTPD3	0.37	6.48	0.3	2.48e-10	Renal cell carcinoma;
LUAD	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg26354017	chr1:205819088	PM20D1	0.75	15.37	0.6	1.17e-42	Menarche (age at onset);
LUAD	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg24399712	chr22:39784796	NA	-0.79	-15.38	-0.6	1e-42	Intelligence (multi-trait analysis);
LUAD	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	8.34	0.38	1.04e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg27411982	chr8:10470053	RP1L1	0.39	7.05	0.32	7.19e-12	Joint mobility (Beighton score);
LUAD	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg15181151	chr6:150070149	PCMT1	0.38	7.18	0.33	3.24e-12	Lung cancer;
LUAD	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg16325326	chr1:53192061	ZYG11B	0.54	9.2	0.41	1.6e-18	Monocyte count;
LUAD	cis	rs3110496	0.685	rs550818	chr17:27901975	A/G	cg04498198	chr17:27899966	TP53I13	-0.37	-6.68	-0.31	7.75e-11	Height;
LUAD	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg07936489	chr17:37558343	FBXL20	0.45	7.06	0.32	6.82e-12	Glomerular filtration rate (creatinine);
LUAD	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg10518543	chr12:38710700	ALG10B	-0.43	-7.14	-0.33	4.16e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs1882538	0.503	rs1345938	chr7:133137867	C/T	cg10665199	chr7:133106180	EXOC4	-0.58	-9.96	-0.44	3.85e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg02275930	chr1:2372054	NA	-0.34	-6.99	-0.32	1.1e-11	Non-obstructive azoospermia;
LUAD	cis	rs3760982	1.000	rs3760983	chr19:44286660	C/T	cg11993925	chr19:44307056	LYPD5	-0.41	-8.13	-0.37	4.86e-15	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg05064044	chr6:292385	DUSP22	-0.57	-9.47	-0.42	1.95e-19	Menopause (age at onset);
LUAD	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg00981070	chr1:2046702	PRKCZ	0.33	6.86	0.32	2.43e-11	Height;
LUAD	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg05342682	chr7:94953680	PON1	-0.51	-7.01	-0.32	9.44e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs113835537	0.529	rs11227500	chr11:66273233	T/C	cg24851651	chr11:66362959	CCS	0.56	9.95	0.44	4.21e-21	Airway imaging phenotypes;
LUAD	cis	rs7107174	0.786	rs4945266	chr11:78027488	A/G	cg02023728	chr11:77925099	USP35	0.52	7.75	0.35	7.04e-14	Testicular germ cell tumor;
LUAD	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg23758822	chr17:41437982	NA	0.99	19.97	0.7	5.33e-63	Menopause (age at onset);
LUAD	cis	rs1595825	0.786	rs1902247	chr2:198492826	C/T	cg10547527	chr2:198650123	BOLL	-0.46	-6.66	-0.31	8.65e-11	Ulcerative colitis;
LUAD	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg13560548	chr3:10150139	C3orf24	0.44	7.44	0.34	5.51e-13	Alzheimer's disease;
LUAD	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg03676636	chr4:99064102	C4orf37	0.3	7.16	0.33	3.54e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7843479	1.000	rs7821592	chr8:21811530	C/G	cg03445287	chr8:21823731	XPO7	-0.47	-8.55	-0.38	2.33e-16	Mean corpuscular volume;
LUAD	cis	rs877282	0.853	rs11596346	chr10:756673	A/T	cg17470449	chr10:769945	NA	0.59	8.22	0.37	2.45e-15	Uric acid levels;
LUAD	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg15501526	chr10:2543763	NA	0.5	9.72	0.43	2.69e-20	Age-related hearing impairment;
LUAD	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg05991184	chr2:219186017	PNKD	-0.37	-7.04	-0.32	7.77e-12	Colorectal cancer;
LUAD	cis	rs1375194	0.558	rs13418410	chr2:33800899	C/A	cg04131969	chr2:33951647	MYADML	-0.57	-8.94	-0.4	1.18e-17	Response to antidepressants in depression;
LUAD	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11890956	chr21:40555474	PSMG1	0.79	13.32	0.54	4.94e-34	Cognitive function;
LUAD	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg09537434	chr19:41945824	ATP5SL	-0.51	-8.05	-0.36	8.45e-15	Height;
LUAD	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg00383909	chr3:49044727	WDR6	0.92	10.2	0.44	5.62e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs4481887	0.830	rs1538703	chr1:248519821	T/G	cg00666640	chr1:248458726	OR2T12	0.28	6.98	0.32	1.16e-11	Common traits (Other);
LUAD	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg13263323	chr15:86062960	AKAP13	-0.49	-8.95	-0.4	1.12e-17	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg22482690	chr17:47019901	SNF8	0.45	8.67	0.39	9.59e-17	Type 2 diabetes;
LUAD	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg02371401	chr5:676784	TPPP	-0.46	-7.63	-0.35	1.55e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs877282	0.838	rs34912955	chr10:772222	T/C	cg17470449	chr10:769945	NA	0.66	9.52	0.42	1.31e-19	Uric acid levels;
LUAD	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.09	0.33	5.82e-12	Depression;
LUAD	cis	rs654384	0.933	rs588123	chr7:4164277	G/A	cg26275264	chr7:4183598	SDK1	-0.42	-8.04	-0.36	9.32e-15	Positive affect;
LUAD	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg19875535	chr5:140030758	IK	0.44	7.49	0.34	4.1e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	2.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.14	-0.51	2.6e-29	Platelet count;
LUAD	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg06611532	chr13:114900021	NA	0.38	9.04	0.4	5.7e-18	Schizophrenia;
LUAD	cis	rs75920871	0.748	rs61905689	chr11:116869217	C/T	cg04087571	chr11:116723030	SIK3	-0.32	-7.19	-0.33	2.96e-12	Subjective well-being;
LUAD	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg04287289	chr16:89883240	FANCA	0.79	6.87	0.32	2.25e-11	Skin colour saturation;
LUAD	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg18825076	chr15:78729989	IREB2	-0.48	-6.64	-0.31	9.9e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs859767	0.709	rs1516990	chr2:135369630	C/G	cg12500956	chr2:135428796	TMEM163	-0.3	-8.12	-0.37	5.18e-15	Neuroticism;
LUAD	cis	rs8060686	0.516	rs7189794	chr16:68277727	T/C	cg09835421	chr16:68378352	PRMT7	-0.55	-6.84	-0.32	2.78e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg25237894	chr2:233734115	C2orf82	0.62	11.78	0.5	6.5e-28	Coronary artery disease;
LUAD	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg21153622	chr11:89784906	NA	-0.34	-6.78	-0.31	3.98e-11	HDL cholesterol;
LUAD	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg16647868	chr5:131706066	SLC22A5	0.49	7.9	0.36	2.48e-14	Breast cancer;
LUAD	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg18876405	chr7:65276391	NA	-0.45	-7.19	-0.33	2.89e-12	Aortic root size;
LUAD	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg19442545	chr10:75533431	FUT11	-0.47	-7.82	-0.36	4.24e-14	Inflammatory bowel disease;
LUAD	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03264133	chr6:25882463	NA	-0.82	-13.81	-0.56	4.66e-36	Blood metabolite levels;
LUAD	trans	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17712092	chr4:129076599	LARP1B	0.85	15.87	0.61	8.1e-45	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs9469913	0.740	rs2814983	chr6:34591207	A/G	cg14254433	chr6:34482411	PACSIN1	-0.43	-6.76	-0.31	4.72e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs9296092	0.517	rs7743445	chr6:33470600	G/T	cg13560919	chr6:33536144	NA	-0.78	-12.25	-0.51	9.84e-30	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-11.77	-0.5	7.63e-28	Hemoglobin concentration;
LUAD	cis	rs6987853	0.661	rs4641053	chr8:42352161	G/A	cg09913449	chr8:42400586	C8orf40	-0.44	-8.29	-0.37	1.56e-15	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg26818010	chr10:134567672	INPP5A	-0.73	-13.02	-0.53	8.24e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg02734326	chr4:10020555	SLC2A9	0.43	7.35	0.34	1.05e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg20607798	chr8:58055168	NA	0.67	8.77	0.39	4.44e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg07599136	chr5:415885	AHRR	0.7	7.77	0.35	6.15e-14	Fat distribution (HIV);
LUAD	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg11301795	chr4:187892539	NA	-0.75	-14.88	-0.59	1.38e-40	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs62238980	0.614	rs734091	chr22:32461891	A/T	cg00543991	chr22:32367038	NA	0.92	8.93	0.4	1.33e-17	Childhood ear infection;
LUAD	cis	rs4253772	0.637	rs3087501	chr22:46647909	A/G	cg14686297	chr22:46650375	NA	-0.4	-6.83	-0.32	2.93e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6987853	0.787	rs2923427	chr8:42385748	A/C	cg09913449	chr8:42400586	C8orf40	0.53	10.6	0.46	2e-23	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg19346786	chr7:2764209	NA	-0.51	-11.04	-0.47	4.6e-25	Height;
LUAD	cis	rs7072216	0.690	rs113195335	chr10:100175532	A/C	cg26618903	chr10:100175079	PYROXD2	-0.39	-8.64	-0.39	1.19e-16	Metabolite levels;
LUAD	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg02269571	chr22:50332266	NA	-0.62	-9.54	-0.42	1.11e-19	Schizophrenia;
LUAD	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg10018233	chr7:150070692	REPIN1	0.5	8.06	0.36	7.8e-15	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg06547715	chr2:218990976	CXCR2	0.29	6.77	0.31	4.32e-11	Colorectal cancer;
LUAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg11062466	chr8:58055876	NA	0.69	9.03	0.4	6.29e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg24578937	chr1:2090814	PRKCZ	-0.51	-10.12	-0.44	1.07e-21	Height;
LUAD	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg21709803	chr11:61594965	FADS2	-0.4	-7.26	-0.33	1.89e-12	Trans fatty acid levels;
LUAD	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.47e-11	Crohn's disease;
LUAD	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg08888203	chr3:10149979	C3orf24	0.73	12.78	0.53	7.21e-32	Alzheimer's disease;
LUAD	cis	rs7017914	0.902	rs35893260	chr8:71620073	C/T	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs7771547	0.573	rs544267	chr6:36398302	A/G	cg04289385	chr6:36355825	ETV7	0.43	6.61	0.31	1.14e-10	Platelet distribution width;
LUAD	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.04	-0.32	7.69e-12	Total cholesterol levels;
LUAD	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg24578937	chr1:2090814	PRKCZ	-0.58	-11.52	-0.49	6.8e-27	Height;
LUAD	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.06	-0.32	6.83e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg25817165	chr18:72167213	CNDP2	-0.5	-7.9	-0.36	2.48e-14	Mononucleosis;
LUAD	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.87	0.32	2.24e-11	Schizophrenia;
LUAD	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg04772025	chr11:68637568	NA	0.58	9.21	0.41	1.58e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs501916	0.634	rs1561482	chr15:48069663	G/A	cg16110827	chr15:48056943	SEMA6D	-0.35	-6.38	-0.3	4.63e-10	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs35123781	0.502	rs355160	chr5:138953589	C/T	cg11459648	chr5:138714337	SLC23A1	-0.39	-6.56	-0.3	1.59e-10	Schizophrenia;
LUAD	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg26818010	chr10:134567672	INPP5A	0.55	9.68	0.43	3.67e-20	Migraine;
LUAD	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg09537434	chr19:41945824	ATP5SL	-0.53	-8.29	-0.37	1.55e-15	Height;
LUAD	cis	rs7428	0.527	rs6547612	chr2:85551184	C/T	cg24342717	chr2:85555507	TGOLN2	-0.49	-7.93	-0.36	1.95e-14	Ear protrusion;
LUAD	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.31	-8.17	-0.37	3.48e-15	Total body bone mineral density;
LUAD	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg05342682	chr7:94953680	PON1	-0.51	-7.01	-0.32	9.46e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2882667	0.964	rs12055237	chr5:138307306	A/G	cg04439458	chr5:138467593	SIL1	-0.42	-7.71	-0.35	9.36e-14	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7527798	0.592	rs11118345	chr1:207854827	A/T	cg09232269	chr1:207846808	CR1L	-0.37	-7.1	-0.33	5.48e-12	Erythrocyte sedimentation rate;
LUAD	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24308560	chr3:49941425	MST1R	0.57	9.65	0.42	4.71e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.27	-0.37	1.72e-15	Personality dimensions;
LUAD	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg07636037	chr3:49044803	WDR6	0.64	12.52	0.52	8.46e-31	Parkinson's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04742505	chr7:72936528	BAZ1B	-0.42	-6.75	-0.31	5.01e-11	Height;
LUAD	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg22823121	chr1:150693482	HORMAD1	0.45	9.17	0.41	2.15e-18	Tonsillectomy;
LUAD	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08109568	chr15:31115862	NA	-0.53	-9.43	-0.42	2.68e-19	Huntington's disease progression;
LUAD	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg20476274	chr7:133979776	SLC35B4	0.68	11.95	0.5	1.49e-28	Mean platelet volume;
LUAD	cis	rs8017423	0.935	rs7144335	chr14:90732280	A/G	cg14092571	chr14:90743983	NA	0.46	7.87	0.36	3.02e-14	Mortality in heart failure;
LUAD	trans	rs9354308	1.000	rs9342503	chr6:66565436	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.77	-0.31	4.35e-11	Metabolite levels;
LUAD	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg25985355	chr7:65971099	NA	0.54	6.64	0.31	9.39e-11	Diabetic kidney disease;
LUAD	cis	rs78761021	0.755	rs55660558	chr17:9793811	C/T	cg26853458	chr17:9805074	RCVRN	0.38	7.13	0.33	4.34e-12	Type 2 diabetes;
LUAD	cis	rs2230307	0.536	rs6677998	chr1:100461046	G/A	cg20868668	chr1:100435035	SLC35A3	0.55	7.81	0.35	4.58e-14	Carotid intima media thickness;
LUAD	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg03676636	chr4:99064102	C4orf37	0.35	8.98	0.4	9.25e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs977987	0.843	rs6564259	chr16:75447393	T/G	cg03315344	chr16:75512273	CHST6	0.64	14.06	0.56	4.3e-37	Dupuytren's disease;
LUAD	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg18827107	chr12:86230957	RASSF9	-0.65	-12.19	-0.51	1.63e-29	Major depressive disorder;
LUAD	trans	rs853679	0.546	rs200950	chr6:27835772	A/G	cg01620082	chr3:125678407	NA	-0.83	-8.92	-0.4	1.44e-17	Depression;
LUAD	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.06	-0.32	6.83e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg26384229	chr12:38710491	ALG10B	0.4	6.46	0.3	2.8e-10	Morning vs. evening chronotype;
LUAD	cis	rs3760982	1.000	rs60184524	chr19:44294215	A/G	cg11993925	chr19:44307056	LYPD5	0.39	7.73	0.35	8.11e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg24642844	chr7:1081250	C7orf50	-0.98	-14.73	-0.58	6.14e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2742417	0.587	rs2742375	chr3:45784602	G/A	cg10512202	chr3:45649293	LIMD1	0.47	8.82	0.39	3.02e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg04225089	chr17:73874465	TRIM47	-0.39	-6.81	-0.31	3.26e-11	Psoriasis;
LUAD	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	9.38	0.41	4.07e-19	Melanoma;
LUAD	cis	rs7937890	0.532	rs2575832	chr11:14488810	A/G	cg02886208	chr11:14281011	SPON1	-0.34	-6.51	-0.3	2.12e-10	Mitochondrial DNA levels;
LUAD	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	12.41	0.52	2.26e-30	Homoarginine levels;
LUAD	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg10596483	chr8:143751796	JRK	0.44	7.07	0.33	6.41e-12	Schizophrenia;
LUAD	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg22878388	chr2:105853796	NA	-0.45	-8.13	-0.37	4.93e-15	Type 2 diabetes;
LUAD	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg04287289	chr16:89883240	FANCA	0.76	6.75	0.31	5.01e-11	Skin colour saturation;
LUAD	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg11707556	chr5:10655725	ANKRD33B	0.39	8.3	0.37	1.42e-15	Height;
LUAD	cis	rs10799445	0.531	rs6697867	chr1:227745674	G/C	cg12133451	chr1:227746453	NA	0.36	6.47	0.3	2.66e-10	Height;
LUAD	cis	rs8177876	0.658	rs2278022	chr16:81076821	T/C	cg08591886	chr16:81111003	C16orf46	-0.83	-7.38	-0.34	8.49e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00166722	chr3:10149974	C3orf24	0.74	12.64	0.52	2.68e-31	Alzheimer's disease;
LUAD	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg27535305	chr1:53392650	SCP2	0.36	7.49	0.34	4.06e-13	Monocyte count;
LUAD	cis	rs1448094	0.802	rs56391398	chr12:86424114	C/T	cg00310523	chr12:86230176	RASSF9	0.36	7.38	0.34	8.43e-13	Major depressive disorder;
LUAD	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg06740227	chr12:86229804	RASSF9	0.36	6.46	0.3	2.95e-10	Major depressive disorder;
LUAD	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg20701182	chr2:24300061	SF3B14	0.6	7.22	0.33	2.51e-12	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg05340658	chr4:99064831	C4orf37	0.53	8.98	0.4	8.92e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2742417	0.603	rs2742374	chr3:45784082	T/C	cg10512202	chr3:45649293	LIMD1	0.48	8.91	0.4	1.53e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs4523957	0.583	rs923863	chr17:2031387	A/G	cg16513277	chr17:2031491	SMG6	-0.98	-20.08	-0.7	1.79e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg26441486	chr22:50317300	CRELD2	0.45	6.78	0.31	4.03e-11	Schizophrenia;
LUAD	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg23933602	chr10:16859644	RSU1	0.64	11.13	0.48	2.14e-25	Platelet distribution width;
LUAD	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.71	-13.44	-0.55	1.54e-34	Axial length;
LUAD	cis	rs9902453	0.935	rs9909093	chr17:28271207	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.5	0.45	4.43e-23	Coffee consumption (cups per day);
LUAD	cis	rs7487075	0.619	rs6582645	chr12:46805144	C/T	cg23829395	chr12:46796953	NA	0.31	7.0	0.32	9.84e-12	Itch intensity from mosquito bite;
LUAD	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg00701064	chr4:6280414	WFS1	0.65	13.98	0.56	8.68e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg11965913	chr1:205819406	PM20D1	0.74	14.85	0.59	1.88e-40	Menarche (age at onset);
LUAD	cis	rs9329289	0.510	rs2029604	chr10:2554700	T/C	cg15501526	chr10:2543763	NA	0.53	11.3	0.48	4.55e-26	Age-related hearing impairment;
LUAD	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg09455208	chr3:40491958	NA	0.56	12.39	0.52	2.69e-30	Renal cell carcinoma;
LUAD	cis	rs2688608	0.967	rs72814394	chr10:75656325	C/T	cg19442545	chr10:75533431	FUT11	-0.4	-6.86	-0.32	2.45e-11	Inflammatory bowel disease;
LUAD	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.74	10.87	0.47	1.93e-24	Ulcerative colitis;
LUAD	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg04267008	chr7:1944627	MAD1L1	-0.7	-11.15	-0.48	1.69e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs7173743	0.518	rs12899452	chr15:79112550	T/A	cg15571903	chr15:79123663	NA	0.37	7.28	0.33	1.67e-12	Coronary artery disease;
LUAD	cis	rs11771526	0.901	rs62457472	chr7:32306885	A/G	cg13207630	chr7:32358064	NA	0.6	7.53	0.34	3.02e-13	Body mass index;
LUAD	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg20607798	chr8:58055168	NA	0.62	8.04	0.36	9.12e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs684232	0.623	rs365118	chr17:580543	G/A	cg15660573	chr17:549704	VPS53	-0.88	-18.02	-0.66	2.74e-54	Prostate cancer;
LUAD	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg00280220	chr17:61926910	NA	0.37	7.02	0.32	8.68e-12	Prudent dietary pattern;
LUAD	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18099408	chr3:52552593	STAB1	-0.49	-8.49	-0.38	3.56e-16	Bipolar disorder;
LUAD	cis	rs832540	0.806	rs10039322	chr5:56260259	A/C	cg18230493	chr5:56204884	C5orf35	-0.41	-6.67	-0.31	7.99e-11	Coronary artery disease;
LUAD	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg24578937	chr1:2090814	PRKCZ	-0.58	-12.06	-0.51	5.6e-29	Height;
LUAD	cis	rs10106298	1.000	rs4734654	chr8:103669991	A/G	cg10187029	chr8:103597600	NA	0.48	7.95	0.36	1.68e-14	Schizophrenia;
LUAD	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.86	12.37	0.52	3.34e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2070997	0.517	rs9762	chr9:133762553	A/G	cg01000188	chr9:133769184	QRFP	0.53	8.06	0.37	7.7e-15	Response to amphetamines;
LUAD	trans	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg14917512	chr19:3094685	GNA11	0.58	6.91	0.32	1.77e-11	Diabetic kidney disease;
LUAD	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg15448220	chr1:150897856	SETDB1	0.54	9.01	0.4	6.96e-18	Melanoma;
LUAD	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg24112000	chr20:60950667	NA	0.63	9.43	0.42	2.67e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg06740227	chr12:86229804	RASSF9	-0.41	-7.31	-0.33	1.34e-12	Major depressive disorder;
LUAD	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg26022315	chr17:47021804	SNF8	0.4	7.29	0.33	1.55e-12	Type 2 diabetes;
LUAD	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg12311346	chr5:56204834	C5orf35	-0.85	-12.58	-0.52	4.63e-31	Initial pursuit acceleration;
LUAD	cis	rs524023	1.000	rs559946	chr11:64358605	T/C	cg19131476	chr11:64387923	NRXN2	0.36	6.72	0.31	5.86e-11	Urate levels in obese individuals;
LUAD	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg02734326	chr4:10020555	SLC2A9	-0.45	-7.81	-0.35	4.65e-14	Bone mineral density;
LUAD	cis	rs13064411	0.696	rs35860985	chr3:113209828	C/T	cg10517650	chr3:113235015	CCDC52	-0.56	-9.63	-0.42	5.58e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg02527881	chr3:46936655	PTH1R	0.45	8.97	0.4	9.41e-18	Colorectal cancer;
LUAD	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg20933634	chr6:27740509	NA	0.49	7.76	0.35	6.46e-14	Parkinson's disease;
LUAD	cis	rs2996428	0.561	rs72640913	chr1:3747023	C/G	cg10555106	chr1:3691387	LOC388588	0.41	6.53	0.3	1.91e-10	Red cell distribution width;
LUAD	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg00316803	chr15:76480434	C15orf27	0.43	6.74	0.31	5.19e-11	Blood metabolite levels;
LUAD	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg25767906	chr1:53392781	SCP2	0.41	7.36	0.34	9.48e-13	Monocyte count;
LUAD	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg09904177	chr6:26538194	HMGN4	0.4	6.53	0.3	1.85e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg11859384	chr17:80120422	CCDC57	-0.47	-8.47	-0.38	3.96e-16	Life satisfaction;
LUAD	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg03948781	chr1:205179583	DSTYK	0.33	6.37	0.3	4.86e-10	Red blood cell count;
LUAD	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937890	0.532	rs2575833	chr11:14492505	A/C	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.04e-10	Mitochondrial DNA levels;
LUAD	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg02734326	chr4:10020555	SLC2A9	0.63	11.28	0.48	5.66e-26	Bone mineral density;
LUAD	trans	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg13565492	chr6:43139072	SRF	-0.6	-6.4	-0.3	4.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg22117172	chr7:91764530	CYP51A1	0.34	7.51	0.34	3.55e-13	Breast cancer;
LUAD	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg13319975	chr6:146136371	FBXO30	0.55	9.09	0.4	3.76e-18	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12155623	0.834	rs6472110	chr8:49784810	T/C	cg22283653	chr8:49824208	NA	-0.49	-8.86	-0.4	2.26e-17	Sudden cardiac arrest;
LUAD	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.42	-0.34	6.52e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7100689	0.622	rs7082093	chr10:82134954	T/G	cg01528321	chr10:82214614	TSPAN14	0.65	9.93	0.43	5.05e-21	Post bronchodilator FEV1;
LUAD	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg23815491	chr16:72088622	HP	0.55	9.96	0.44	3.92e-21	Fibrinogen levels;
LUAD	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg26818010	chr10:134567672	INPP5A	-0.98	-16.1	-0.62	7.46e-46	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg00316803	chr15:76480434	C15orf27	0.4	6.39	0.3	4.4e-10	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg17366294	chr4:99064904	C4orf37	0.65	12.48	0.52	1.2e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg18129748	chr3:49941408	MST1R	0.4	6.61	0.31	1.17e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.36	0.41	4.9e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08677398	chr8:58056175	NA	0.48	6.84	0.32	2.87e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg04703951	chr17:43578652	NA	-0.44	-7.0	-0.32	1.03e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg14196790	chr5:131705035	SLC22A5	0.52	8.86	0.4	2.23e-17	Breast cancer;Mosquito bite size;
LUAD	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.51	-10.84	-0.47	2.43e-24	Longevity;Endometriosis;
LUAD	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg24531977	chr5:56204891	C5orf35	-0.5	-8.1	-0.37	5.97e-15	Coronary artery disease;
LUAD	cis	rs17102423	0.594	rs2781373	chr14:65568215	G/A	cg16583315	chr14:65563665	MAX	-0.36	-6.74	-0.31	5.14e-11	Obesity-related traits;
LUAD	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg21724239	chr8:58056113	NA	0.72	9.49	0.42	1.73e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	10.4	0.45	1.08e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-9.1	-0.4	3.59e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2274471	0.555	rs10815151	chr9:5070905	C/T	cg03390472	chr9:5043263	JAK2	-0.5	-7.3	-0.33	1.42e-12	Crohn's disease;
LUAD	cis	rs7633770	0.965	rs6804112	chr3:46686248	C/T	cg11219411	chr3:46661640	NA	0.55	11.88	0.5	2.87e-28	Coronary artery disease;
LUAD	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg08493051	chr2:3487164	NA	-0.43	-7.28	-0.33	1.67e-12	Neurofibrillary tangles;
LUAD	cis	rs4285028	0.580	rs1523519	chr3:121631841	C/T	cg20356878	chr3:121714668	ILDR1	-0.54	-8.51	-0.38	3.04e-16	Multiple sclerosis;
LUAD	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg26924012	chr15:45694286	SPATA5L1	1.02	19.06	0.68	6.2e-59	Homoarginine levels;
LUAD	cis	rs12545109	0.800	rs1968551	chr8:57407760	T/C	cg19413350	chr8:57351067	NA	-0.44	-6.58	-0.3	1.36e-10	Obesity-related traits;
LUAD	trans	rs783540	0.681	rs1259178	chr15:83271876	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.55	-8.61	-0.39	1.51e-16	Schizophrenia;
LUAD	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg08999081	chr20:33150536	PIGU	0.63	14.21	0.57	9.98e-38	Glomerular filtration rate (creatinine);
LUAD	cis	rs6494488	0.500	rs72758953	chr15:64692152	T/C	cg08069370	chr15:64387884	SNX1	-0.75	-6.65	-0.31	9.09e-11	Coronary artery disease;
LUAD	cis	rs17021463	0.726	rs62320444	chr4:95261251	C/T	cg11021082	chr4:95130006	SMARCAD1	0.43	7.51	0.34	3.65e-13	Testicular germ cell tumor;
LUAD	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg22535103	chr8:58192502	C8orf71	-0.74	-10.48	-0.45	5.29e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg03859395	chr2:55845619	SMEK2	-0.75	-13.97	-0.56	9.71e-37	Metabolic syndrome;
LUAD	cis	rs57920188	0.535	rs112660254	chr1:4089921	T/G	cg10510935	chr1:4059661	NA	0.45	6.93	0.32	1.59e-11	Interleukin-17 levels;
LUAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg21782813	chr7:2030301	MAD1L1	0.51	8.75	0.39	4.96e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs7731657	0.537	rs13355768	chr5:130360245	C/T	cg08523029	chr5:130500466	HINT1	-0.6	-7.7	-0.35	9.69e-14	Fasting plasma glucose;
LUAD	trans	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.64	0.49	2.27e-27	Mean corpuscular volume;
LUAD	cis	rs10242455	0.571	rs41279866	chr7:99315276	C/T	cg18809830	chr7:99032528	PTCD1	-0.9	-7.29	-0.33	1.53e-12	Blood metabolite levels;
LUAD	cis	rs9447004	0.584	rs56093139	chr6:74432923	C/T	cg23004174	chr6:74404879	CD109	0.46	8.39	0.38	7.11e-16	Blood protein levels;Calcium levels;
LUAD	cis	rs1595825	0.891	rs59990242	chr2:198895868	G/A	cg11031976	chr2:198649780	BOLL	-0.45	-6.53	-0.3	1.84e-10	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg24818145	chr4:99064322	C4orf37	0.47	7.96	0.36	1.57e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7640424	0.620	rs7637244	chr3:107815763	T/A	cg09227934	chr3:107805635	CD47	-0.67	-10.68	-0.46	9.84e-24	Body mass index;
LUAD	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg09509183	chr1:209979624	IRF6	0.37	6.45	0.3	3.03e-10	Monobrow;
LUAD	cis	rs9560113	1.000	rs61967684	chr13:112178026	G/C	cg14154082	chr13:112174009	NA	0.37	6.87	0.32	2.32e-11	Menarche (age at onset);
LUAD	cis	rs9393692	0.557	rs62394764	chr6:26305503	T/C	cg13736514	chr6:26305472	NA	-0.54	-8.81	-0.39	3.16e-17	Educational attainment;
LUAD	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg00310523	chr12:86230176	RASSF9	0.39	7.77	0.35	5.93e-14	Major depressive disorder;
LUAD	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg24813613	chr7:1882135	MAD1L1	-0.44	-7.07	-0.33	6.41e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7180079	0.686	rs2166735	chr15:64817521	C/T	cg08069370	chr15:64387884	SNX1	-0.56	-6.78	-0.31	4.14e-11	Monocyte count;
LUAD	cis	rs870825	0.860	rs56180712	chr4:185600223	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	11.46	0.49	1.17e-26	Blood protein levels;
LUAD	cis	rs3096299	0.933	rs2930219	chr16:89492049	G/A	cg01788221	chr16:89496183	ANKRD11	-0.36	-6.92	-0.32	1.65e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg07810366	chr2:100720526	AFF3	0.4	8.44	0.38	5.23e-16	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg14416269	chr4:6271139	WFS1	0.65	13.31	0.54	5.46e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10150615	chr22:24372951	LOC391322	-0.58	-9.51	-0.42	1.47e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs986417	0.792	rs4901990	chr14:61015474	C/T	cg27398547	chr14:60952738	C14orf39	-0.64	-7.41	-0.34	6.84e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg23018236	chr17:30244563	NA	-0.68	-8.33	-0.38	1.14e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg07936489	chr17:37558343	FBXL20	-0.42	-6.56	-0.3	1.54e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs863345	0.584	rs10797023	chr1:158497079	T/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.39	-0.3	4.26e-10	Pneumococcal bacteremia;
LUAD	cis	rs4660214	0.614	rs11205802	chr1:39699114	C/T	cg27567593	chr1:39956653	BMP8A	0.33	6.41	0.3	3.99e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs17608059	0.566	rs6502327	chr17:13946187	T/C	cg27005118	chr17:13972210	COX10	-0.35	-7.19	-0.33	2.92e-12	Temperament;
LUAD	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg08085267	chr17:45401833	C17orf57	-0.52	-8.7	-0.39	7.34e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-9.61	-0.42	6.35e-20	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg15174949	chr19:6110595	RFX2	-0.68	-6.97	-0.32	1.26e-11	Type 2 diabetes;
LUAD	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06022373	chr22:39101656	GTPBP1	0.46	7.25	0.33	2.06e-12	Menopause (age at onset);
LUAD	cis	rs2302190	1.000	rs7207286	chr17:56514458	A/C	cg25885038	chr17:56607967	SEPT4	0.41	6.75	0.31	4.83e-11	Vitamin D levels;
LUAD	cis	rs6541297	1.000	rs6541296	chr1:230281953	A/G	cg20703242	chr1:230279135	GALNT2	0.66	11.96	0.5	1.35e-28	Coronary artery disease;
LUAD	cis	rs7953508	0.506	rs10859532	chr12:93960917	G/C	cg18151635	chr12:93972918	NA	-0.78	-11.66	-0.49	1.91e-27	Pubertal anthropometrics;
LUAD	cis	rs2279817	0.735	rs71644064	chr1:18000044	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.54	-7.98	-0.36	1.44e-14	Neuroticism;
LUAD	cis	rs7851660	0.809	rs7031386	chr9:100665669	G/T	cg13688889	chr9:100608707	NA	-0.54	-9.16	-0.41	2.34e-18	Strep throat;
LUAD	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03934478	chr11:495069	RNH1	0.73	8.94	0.4	1.26e-17	Body mass index;
LUAD	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg02782426	chr3:40428986	ENTPD3	0.42	9.42	0.42	2.93e-19	Renal cell carcinoma;
LUAD	cis	rs7705042	0.828	rs6877864	chr5:141503839	A/G	cg23435118	chr5:141488016	NDFIP1	-0.4	-6.92	-0.32	1.65e-11	Asthma;
LUAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.66	12.15	0.51	2.32e-29	Lymphocyte counts;
LUAD	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg10978503	chr1:24200527	CNR2	0.55	12.02	0.5	7.64e-29	Immature fraction of reticulocytes;
LUAD	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg15066416	chr17:45501628	LOC100272146;C17orf57	0.35	6.59	0.31	1.28e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs8177876	0.822	rs8177959	chr16:81115687	A/G	cg08591886	chr16:81111003	C16orf46	-0.71	-6.47	-0.3	2.72e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs9487051	0.735	rs380774	chr6:109519623	C/T	cg21918786	chr6:109611834	NA	-0.41	-7.55	-0.34	2.75e-13	Reticulocyte fraction of red cells;
LUAD	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg05110241	chr16:68378359	PRMT7	-0.8	-8.77	-0.39	4.46e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6499255	0.951	rs57488237	chr16:69741571	T/C	cg15192750	chr16:69999425	NA	0.5	7.74	0.35	7.49e-14	IgE levels;
LUAD	cis	rs738322	0.870	rs5750558	chr22:38582497	G/A	cg25457927	chr22:38595422	NA	0.57	14.71	0.58	7.4e-40	Cutaneous nevi;
LUAD	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg13918804	chr1:2043761	PRKCZ	0.41	6.92	0.32	1.72e-11	Height;
LUAD	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	8.38	0.38	7.73e-16	Breast cancer;
LUAD	cis	rs12545109	0.800	rs2118260	chr8:57393481	T/C	cg17761419	chr8:57350749	NA	-0.57	-8.14	-0.37	4.52e-15	Obesity-related traits;
LUAD	cis	rs62238980	0.614	rs76463308	chr22:32387270	C/T	cg00543991	chr22:32367038	NA	0.92	8.15	0.37	4.03e-15	Childhood ear infection;
LUAD	cis	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05901451	chr6:126070800	HEY2	-0.43	-6.49	-0.3	2.42e-10	Endometrial cancer;
LUAD	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg21475434	chr5:93447410	FAM172A	-0.47	-6.52	-0.3	2.04e-10	Diabetic retinopathy;
LUAD	cis	rs62238980	0.522	rs45462396	chr22:32545789	C/T	cg00543991	chr22:32367038	NA	0.93	8.06	0.36	8.03e-15	Childhood ear infection;
LUAD	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg17177755	chr1:15930204	NA	0.44	7.15	0.33	3.96e-12	Systolic blood pressure;
LUAD	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.36	-9.36	-0.41	4.59e-19	Total body bone mineral density;
LUAD	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg07757535	chr4:1339547	NA	0.3	6.8	0.31	3.51e-11	Longevity;
LUAD	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg03452623	chr4:187889614	NA	-0.81	-16.32	-0.62	8.8e-47	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs877282	0.945	rs877280	chr10:771599	C/T	cg22713356	chr15:30763199	NA	1.35	19.36	0.69	3.03e-60	Uric acid levels;
LUAD	cis	rs2479724	0.935	rs62396748	chr6:41782007	A/G	cg17623882	chr6:41773611	USP49	0.63	11.32	0.48	3.83e-26	Menarche (age at onset);
LUAD	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.46	0.38	4.25e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7301016	0.707	rs7302602	chr12:63052199	C/T	cg11441379	chr12:63026424	NA	-0.6	-7.27	-0.33	1.78e-12	IgG glycosylation;
LUAD	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg27631724	chr1:11040367	C1orf127	0.55	9.66	0.43	4.42e-20	Ewing sarcoma;
LUAD	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.52	-0.3	2.01e-10	Alzheimer's disease (late onset);
LUAD	cis	rs868036	1.000	rs4776975	chr15:68102220	G/C	cg08079166	chr15:68083412	MAP2K5	0.3	6.49	0.3	2.39e-10	Restless legs syndrome;
LUAD	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg05340658	chr4:99064831	C4orf37	0.43	7.25	0.33	2.01e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg22676075	chr6:135203613	NA	0.52	9.15	0.41	2.45e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	trans	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg07393940	chr7:158741817	NA	0.69	11.48	0.49	1.01e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg24069376	chr3:38537580	EXOG	0.45	11.0	0.47	6.54e-25	Electrocardiographic conduction measures;
LUAD	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg03030879	chr14:75389066	RPS6KL1	0.36	6.59	0.3	1.35e-10	Caffeine consumption;
LUAD	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg04414720	chr1:150670196	GOLPH3L	0.72	13.36	0.54	3.28e-34	Tonsillectomy;
LUAD	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg14228332	chr4:119757509	SEC24D	0.83	7.78	0.35	5.62e-14	Cannabis dependence symptom count;
LUAD	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.68	-0.31	7.68e-11	Triglycerides;
LUAD	cis	rs1595825	1.000	rs73058829	chr2:198871145	G/A	cg10547527	chr2:198650123	BOLL	-0.47	-6.61	-0.31	1.16e-10	Ulcerative colitis;
LUAD	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg21475434	chr5:93447410	FAM172A	0.76	8.53	0.38	2.58e-16	Diabetic retinopathy;
LUAD	cis	rs3784262	0.669	rs4646642	chr15:58246916	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-7.2	-0.33	2.79e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg26554054	chr8:600488	NA	0.79	7.85	0.36	3.37e-14	IgG glycosylation;
LUAD	cis	rs7089973	0.872	rs41284358	chr10:116622339	A/G	cg25233709	chr10:116636983	FAM160B1	0.39	7.56	0.34	2.55e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg02951883	chr7:2050386	MAD1L1	-0.82	-14.21	-0.57	9.98e-38	Bipolar disorder and schizophrenia;
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg26668828	chr6:292823	DUSP22	-0.77	-13.66	-0.55	1.82e-35	Menopause (age at onset);
LUAD	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg09796270	chr17:17721594	SREBF1	0.37	7.56	0.34	2.6e-13	Total body bone mineral density;
LUAD	cis	rs921968	0.565	rs1554622	chr2:219606218	T/G	cg02176678	chr2:219576539	TTLL4	-0.57	-11.36	-0.48	2.66e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg08645402	chr16:4508243	NA	0.58	10.84	0.47	2.49e-24	Schizophrenia;
LUAD	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg20701182	chr2:24300061	SF3B14	0.57	6.78	0.31	4.04e-11	Lymphocyte counts;
LUAD	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.66	-0.46	1.16e-23	Bipolar disorder and schizophrenia;
LUAD	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg19318889	chr4:1322082	MAEA	0.4	6.39	0.3	4.35e-10	Obesity-related traits;
LUAD	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.63	11.95	0.5	1.51e-28	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs2880765	0.835	rs2170735	chr15:86043485	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.4	-0.3	4.17e-10	Coronary artery disease;
LUAD	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg13813247	chr22:41461852	NA	-0.5	-8.07	-0.37	7.33e-15	Neuroticism;
LUAD	cis	rs35146811	0.844	rs2070215	chr7:99696797	T/C	cg22906224	chr7:99728672	NA	0.62	9.88	0.43	7.35e-21	Coronary artery disease;
LUAD	trans	rs8002861	0.935	rs1811464	chr13:44469290	T/G	cg17145862	chr1:211918768	LPGAT1	0.77	18.39	0.67	6.4e-56	Leprosy;
LUAD	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18099408	chr3:52552593	STAB1	-0.48	-8.27	-0.37	1.77e-15	Bipolar disorder;
LUAD	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.85	-14.87	-0.59	1.5e-40	IgG glycosylation;
LUAD	cis	rs2485376	1.000	rs72845663	chr10:104081349	C/T	cg20641465	chr10:103991465	PITX3	-0.56	-10.28	-0.45	2.81e-22	QT interval;
LUAD	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg03874509	chr1:107600012	PRMT6	-0.5	-8.29	-0.37	1.55e-15	Facial morphology (factor 21, depth of nasal alae);
LUAD	trans	rs2235573	0.527	rs5756853	chr22:38329524	G/A	cg19894588	chr14:64061835	NA	-0.56	-8.66	-0.39	9.91e-17	Glioblastoma;Glioma;
LUAD	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg09835421	chr16:68378352	PRMT7	-0.81	-8.79	-0.39	3.68e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs722864	1.000	rs722864	chr2:173983204	A/G	cg09210666	chr2:173941575	ZAK	-0.44	-6.54	-0.3	1.74e-10	Lung cancer;
LUAD	cis	rs7100689	0.524	rs7902460	chr10:82199263	T/A	cg01528321	chr10:82214614	TSPAN14	0.52	8.16	0.37	3.95e-15	Post bronchodilator FEV1;
LUAD	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg22482690	chr17:47019901	SNF8	0.47	9.13	0.41	2.89e-18	Type 2 diabetes;
LUAD	cis	rs7799006	0.898	rs34418140	chr7:2278183	C/T	cg08027265	chr7:2291960	NA	-0.66	-11.99	-0.5	1.07e-28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs2425143	1.000	rs11700256	chr20:34372941	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.09	-0.33	5.52e-12	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg03676636	chr4:99064102	C4orf37	0.31	8.07	0.37	7.6e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg08999081	chr20:33150536	PIGU	0.47	8.8	0.39	3.63e-17	Coronary artery disease;
LUAD	cis	rs7177699	0.557	rs34372090	chr15:79110735	C/T	cg15571903	chr15:79123663	NA	-0.38	-7.44	-0.34	5.67e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs2213920	0.516	rs2188042	chr9:118159740	C/T	cg13918206	chr9:118159781	DEC1	-0.61	-6.74	-0.31	5.16e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LUAD	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg04450456	chr4:17643702	FAM184B	0.37	6.95	0.32	1.37e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs73198271	0.562	rs113730597	chr8:8651573	G/A	cg01851573	chr8:8652454	MFHAS1	0.71	11.41	0.49	1.77e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg00316803	chr15:76480434	C15orf27	0.42	7.88	0.36	2.76e-14	Blood metabolite levels;
LUAD	cis	rs7043114	0.563	rs10820986	chr9:95312961	T/G	cg14631576	chr9:95140430	CENPP	-0.38	-7.58	-0.35	2.22e-13	Height;
LUAD	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg00933542	chr6:150070202	PCMT1	0.44	9.47	0.42	1.99e-19	Lung cancer;
LUAD	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg07432352	chr17:45403706	C17orf57	-0.43	-8.2	-0.37	2.87e-15	Multiple sclerosis or amyotrophic lateral sclerosis;
LUAD	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22968622	chr17:43663579	NA	-0.95	-16.86	-0.63	3.65e-49	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7605378	0.688	rs769961	chr2:200712141	C/A	cg17644776	chr2:200775616	C2orf69	0.53	8.12	0.37	5.02e-15	Osteoporosis;
LUAD	cis	rs7589342	0.895	rs2033008	chr2:106502585	T/A	cg14210321	chr2:106509881	NCK2	-0.39	-6.49	-0.3	2.44e-10	Addiction;
LUAD	cis	rs2235642	0.582	rs2072990	chr16:1567651	A/G	cg26528668	chr16:1614120	IFT140	0.39	6.35	0.3	5.41e-10	Coronary artery disease;
LUAD	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg18477163	chr1:228402036	OBSCN	0.42	8.21	0.37	2.64e-15	Diastolic blood pressure;
LUAD	cis	rs4072705	0.557	rs1886124	chr9:127233207	A/G	cg13476313	chr9:127244764	NR5A1	0.32	7.52	0.34	3.25e-13	Menarche (age at onset);
LUAD	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg00852783	chr1:26633632	UBXN11	0.42	7.43	0.34	6.04e-13	Obesity-related traits;
LUAD	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.95	-0.36	1.78e-14	Monocyte percentage of white cells;
LUAD	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg07606381	chr6:8435919	SLC35B3	0.41	6.73	0.31	5.44e-11	Motion sickness;
LUAD	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11890956	chr21:40555474	PSMG1	0.8	14.16	0.57	1.54e-37	Cognitive function;
LUAD	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg03806693	chr22:41940476	POLR3H	-0.5	-7.44	-0.34	5.84e-13	Vitiligo;
LUAD	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg00255919	chr5:131827918	IRF1	-0.3	-6.62	-0.31	1.11e-10	Breast cancer;Mosquito bite size;
LUAD	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	cis	rs1003719	0.788	rs2835597	chr21:38466539	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.31e-16	Eye color traits;
LUAD	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg11915388	chr22:42470451	FAM109B	0.41	7.28	0.33	1.64e-12	Schizophrenia;
LUAD	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg10518543	chr12:38710700	ALG10B	0.51	8.32	0.37	1.25e-15	Morning vs. evening chronotype;
LUAD	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg23985595	chr17:80112537	CCDC57	0.53	9.74	0.43	2.39e-20	Life satisfaction;
LUAD	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg15997130	chr1:24165203	NA	-0.57	-10.49	-0.45	4.84e-23	Immature fraction of reticulocytes;
LUAD	cis	rs7607369	0.626	rs4672892	chr2:219278630	A/G	cg02176678	chr2:219576539	TTLL4	-0.77	-14.61	-0.58	2.08e-39	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg13010199	chr12:38710504	ALG10B	0.38	6.36	0.3	5.09e-10	Bladder cancer;
LUAD	cis	rs10189230	0.935	rs3770145	chr2:222345147	T/C	cg14652038	chr2:222343519	EPHA4	0.44	8.62	0.39	1.34e-16	Urate levels in lean individuals;
LUAD	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg01528321	chr10:82214614	TSPAN14	0.64	10.03	0.44	2.13e-21	Post bronchodilator FEV1;
LUAD	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.04	-0.44	2.08e-21	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs587242	1.000	rs7543671	chr1:96892268	T/C	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg01013600	chr19:49141177	DBP;SEC1	-0.37	-6.49	-0.3	2.46e-10	Subcortical brain region volumes;
LUAD	cis	rs17095355	0.818	rs61881638	chr10:111863396	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.81	-0.31	3.37e-11	Biliary atresia;
LUAD	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-6.99	-0.32	1.05e-11	Schizophrenia;
LUAD	trans	rs62458065	1.000	rs1450868	chr7:32463666	G/A	cg00845942	chr12:64062724	DPY19L2	-0.45	-6.42	-0.3	3.59e-10	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg19318889	chr4:1322082	MAEA	0.42	6.35	0.3	5.49e-10	Obesity-related traits;
LUAD	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg14092988	chr3:52407081	DNAH1	0.45	8.97	0.4	9.82e-18	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg01579765	chr21:45077557	HSF2BP	-0.62	-15.06	-0.59	2.42e-41	Mean corpuscular volume;
LUAD	cis	rs9644630	0.841	rs4922035	chr8:19328174	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.33	-8.13	-0.37	4.83e-15	Oropharynx cancer;
LUAD	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg12483005	chr1:23474871	LUZP1	0.49	8.44	0.38	5.17e-16	Height;
LUAD	trans	rs9467603	1.000	rs6940698	chr6:25821580	A/G	cg06606381	chr12:133084897	FBRSL1	0.76	6.38	0.3	4.75e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg06873352	chr17:61820015	STRADA	0.4	6.54	0.3	1.83e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg06606381	chr12:133084897	FBRSL1	-0.53	-6.69	-0.31	6.91e-11	Depression;
LUAD	cis	rs7177699	0.557	rs9806363	chr15:79110302	A/G	cg15571903	chr15:79123663	NA	-0.38	-7.6	-0.35	1.93e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg10265740	chr3:44622865	ZNF167	0.37	6.41	0.3	3.89e-10	Depressive symptoms;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04109349	chr1:245317172	KIF26B	-0.42	-6.59	-0.31	1.3e-10	Height;
LUAD	cis	rs708547	0.647	rs1277308	chr4:57897864	C/T	cg00922110	chr4:57842668	C4orf14	-0.41	-7.62	-0.35	1.66e-13	Response to bleomycin (chromatid breaks);
LUAD	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg06002616	chr8:101225028	SPAG1	-0.39	-7.91	-0.36	2.23e-14	Atrioventricular conduction;
LUAD	trans	rs3942852	0.868	rs6485808	chr11:48109151	A/G	cg03929089	chr4:120376271	NA	-0.56	-7.33	-0.34	1.19e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9341808	0.905	rs9343977	chr6:80967001	C/T	cg08355045	chr6:80787529	NA	0.57	10.79	0.46	3.7e-24	Sitting height ratio;
LUAD	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg05340658	chr4:99064831	C4orf37	0.45	7.47	0.34	4.61e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg02569458	chr12:86230093	RASSF9	-0.41	-7.64	-0.35	1.48e-13	Major depressive disorder;
LUAD	cis	rs1348850	0.958	rs10930800	chr2:178459669	T/C	cg27490568	chr2:178487706	NA	0.44	7.22	0.33	2.4e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs15676	0.783	rs2417126	chr9:131562457	C/T	cg00228799	chr9:131580591	ENDOG	-0.47	-7.34	-0.34	1.07e-12	Blood metabolite levels;
LUAD	cis	rs6733011	0.600	rs1356424	chr2:99425838	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.72	-0.31	6.02e-11	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.84	0.36	3.61e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.559	rs5002976	chr7:107050620	C/G	cg23024343	chr7:107201750	COG5	0.52	7.19	0.33	2.96e-12	Coronary artery disease;
LUAD	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12923728	chr3:195709715	SDHAP1	-0.75	-12.63	-0.52	2.96e-31	Pancreatic cancer;
LUAD	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-7.04	-0.32	7.97e-12	Retinal vascular caliber;
LUAD	trans	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg07211511	chr3:129823064	LOC729375	-0.87	-12.72	-0.53	1.28e-31	Blood pressure (smoking interaction);
LUAD	trans	rs564343	0.583	rs571374	chr11:65817592	C/T	cg26701943	chr11:108369231	KDELC2	-0.49	-8.18	-0.37	3.46e-15	Obesity (early onset extreme);
LUAD	cis	rs7771547	0.662	rs2001101	chr6:36536448	C/T	cg07856975	chr6:36356162	ETV7	0.53	6.86	0.32	2.4e-11	Platelet distribution width;
LUAD	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg05368731	chr17:41323189	NBR1	0.85	16.8	0.63	7.1e-49	Menopause (age at onset);
LUAD	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg17200465	chr3:40428508	ENTPD3	0.27	6.47	0.3	2.76e-10	Renal cell carcinoma;
LUAD	trans	rs9329221	0.686	rs60755617	chr8:10243327	T/G	cg14343924	chr8:8086146	FLJ10661	0.45	6.71	0.31	6.41e-11	Neuroticism;
LUAD	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg03690763	chr11:133734501	NA	-0.35	-7.99	-0.36	1.31e-14	Childhood ear infection;
LUAD	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.5	6.85	0.32	2.54e-11	Platelet count;
LUAD	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	8.58	0.39	1.77e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-7.35	-0.34	1.03e-12	Lung cancer;
LUAD	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg25324976	chr17:61989376	CSHL1	0.36	6.95	0.32	1.43e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg10518543	chr12:38710700	ALG10B	-0.51	-8.51	-0.38	3.14e-16	Morning vs. evening chronotype;
LUAD	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-11.63	-0.49	2.67e-27	Primary sclerosing cholangitis;
LUAD	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6445967	0.569	rs7624746	chr3:58282500	T/C	cg13750441	chr3:58318267	PXK	-0.31	-6.47	-0.3	2.78e-10	Platelet count;
LUAD	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg20469991	chr17:27169893	C17orf63	0.52	6.67	0.31	7.78e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs8099014	0.770	rs1135519	chr18:56117145	C/T	cg12907477	chr18:56117327	MIR122	0.49	8.03	0.36	9.56e-15	Platelet count;
LUAD	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg11822812	chr5:140052017	DND1	-0.36	-6.57	-0.3	1.51e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.63	-0.31	1.02e-10	Neutrophil percentage of white cells;
LUAD	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg00999904	chr2:3704751	ALLC	-0.4	-7.3	-0.33	1.41e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg08514558	chr10:81106712	PPIF	0.48	9.25	0.41	1.12e-18	Height;
LUAD	cis	rs4638749	0.953	rs12475415	chr2:108860477	G/A	cg06795125	chr2:108905320	SULT1C2	-0.42	-6.47	-0.3	2.69e-10	Blood pressure;
LUAD	cis	rs3784262	0.669	rs12594082	chr15:58267779	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.43	-0.34	6.04e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.51	-8.02	-0.36	1.08e-14	Longevity;Endometriosis;
LUAD	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22496380	chr5:211416	CCDC127	-0.92	-12.8	-0.53	6.25e-32	Breast cancer;
LUAD	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10802521	chr3:52805072	NEK4	-0.5	-8.94	-0.4	1.24e-17	Bipolar disorder;
LUAD	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03468541	chr14:89029199	ZC3H14	0.45	6.6	0.31	1.23e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg12179176	chr11:130786555	SNX19	0.55	9.15	0.41	2.53e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs6561151	0.957	rs2121034	chr13:44473866	G/T	cg12856521	chr11:46389249	DGKZ	0.65	10.27	0.45	2.97e-22	Crohn's disease;
LUAD	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg13535736	chr9:111863775	C9orf5	0.42	6.59	0.31	1.28e-10	Menarche (age at onset);
LUAD	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg24154853	chr7:158122151	PTPRN2	-0.56	-11.26	-0.48	6.85e-26	Calcium levels;
LUAD	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	6.82	0.31	3.13e-11	Motion sickness;
LUAD	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg20503657	chr10:835505	NA	1.01	15.56	0.6	1.77e-43	Eosinophil percentage of granulocytes;
LUAD	cis	rs739496	0.947	rs2283358	chr12:111865565	C/T	cg10833066	chr12:111807467	FAM109A	0.42	6.73	0.31	5.6e-11	Platelet count;
LUAD	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg06108461	chr20:60628389	TAF4	-0.81	-13.87	-0.56	2.48e-36	Body mass index;
LUAD	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg20476274	chr7:133979776	SLC35B4	0.84	16.84	0.63	4.66e-49	Mean platelet volume;
LUAD	cis	rs490234	0.934	rs4837018	chr9:128275991	A/G	cg14078157	chr9:128172775	NA	-0.36	-6.66	-0.31	8.78e-11	Mean arterial pressure;
LUAD	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg09998033	chr7:158218633	PTPRN2	-0.44	-7.84	-0.36	3.79e-14	Obesity-related traits;
LUAD	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	9.82	0.43	1.26e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs59104589	0.617	rs73002170	chr2:242325980	G/A	cg08645257	chr2:242211290	HDLBP	0.47	7.45	0.34	5.16e-13	Fibrinogen levels;
LUAD	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-6.65	-0.31	9.05e-11	Tonsillectomy;
LUAD	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg11494091	chr17:61959527	GH2	-0.37	-6.45	-0.3	3.03e-10	Height;
LUAD	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg20119798	chr7:94954144	PON1	-0.49	-6.91	-0.32	1.77e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg15485101	chr11:133734466	NA	0.39	8.21	0.37	2.7e-15	Childhood ear infection;
LUAD	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg15704280	chr7:45808275	SEPT13	0.85	14.76	0.58	4.73e-40	Coronary artery disease;
LUAD	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg18827107	chr12:86230957	RASSF9	-0.52	-9.26	-0.41	9.99e-19	Major depressive disorder;
LUAD	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-8.69	-0.39	7.98e-17	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg18306943	chr3:40428807	ENTPD3	0.38	6.55	0.3	1.63e-10	Renal cell carcinoma;
LUAD	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg17971929	chr21:40555470	PSMG1	0.56	8.87	0.4	2.04e-17	Cognitive function;
LUAD	cis	rs13315871	0.929	rs11716580	chr3:58228695	G/C	cg20936604	chr3:58311152	NA	-0.74	-7.1	-0.33	5.35e-12	Cholesterol, total;
LUAD	cis	rs806215	1.000	rs806216	chr7:127237862	C/A	cg25922125	chr7:127225783	GCC1	-0.52	-7.24	-0.33	2.17e-12	Type 2 diabetes;
LUAD	cis	rs3820068	0.705	rs57971278	chr1:15838604	G/A	cg24675056	chr1:15929824	NA	0.42	6.71	0.31	6.11e-11	Systolic blood pressure;
LUAD	trans	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg11693508	chr17:37793320	STARD3	0.71	9.34	0.41	5.49e-19	Bipolar disorder;
LUAD	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.35	6.96	0.32	1.31e-11	Depression;
LUAD	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg00310523	chr12:86230176	RASSF9	-0.37	-7.43	-0.34	6.06e-13	Major depressive disorder;
LUAD	cis	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg21775007	chr8:11205619	TDH	0.57	10.41	0.45	9.77e-23	Retinal vascular caliber;
LUAD	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg00776166	chr8:613548	NA	0.57	6.46	0.3	2.88e-10	IgG glycosylation;
LUAD	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg07599136	chr5:415885	AHRR	0.75	8.43	0.38	5.38e-16	Fat distribution (HIV);
LUAD	cis	rs7937890	0.559	rs6486193	chr11:14437607	C/G	cg06199346	chr11:14280333	SPON1	-0.33	-6.47	-0.3	2.7e-10	Mitochondrial DNA levels;
LUAD	cis	rs427941	0.632	rs201507	chr7:101764141	T/C	cg06246474	chr7:101738831	CUX1	0.37	6.44	0.3	3.2e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg16205897	chr5:131564050	P4HA2	-0.31	-6.84	-0.32	2.74e-11	Acylcarnitine levels;
LUAD	cis	rs2882667	0.858	rs11744972	chr5:138428789	A/G	cg04439458	chr5:138467593	SIL1	-0.52	-9.48	-0.42	1.85e-19	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg20607798	chr8:58055168	NA	0.66	8.74	0.39	5.66e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg14791747	chr16:20752902	THUMPD1	0.8	13.02	0.53	7.72e-33	Cognitive test performance;
LUAD	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-7.36	-0.34	9.46e-13	Personality dimensions;
LUAD	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg25554036	chr4:6271136	WFS1	0.65	12.77	0.53	8.35e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2235544	0.664	rs12036530	chr1:54476323	T/C	cg25741118	chr1:54482237	LDLRAD1	-0.23	-6.45	-0.3	2.98e-10	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUAD	cis	rs12431939	0.948	rs12436364	chr14:51671320	T/C	cg23942311	chr14:51606299	NA	-0.51	-7.45	-0.34	5.23e-13	Cancer;
LUAD	cis	rs4481887	0.741	rs1361413	chr1:248529521	C/G	cg13385794	chr1:248469461	NA	-0.24	-6.42	-0.3	3.58e-10	Common traits (Other);
LUAD	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg20991723	chr1:152506922	NA	0.34	6.68	0.31	7.53e-11	Hair morphology;
LUAD	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-6.68	-0.31	7.63e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg18854424	chr1:2615690	NA	0.41	8.95	0.4	1.13e-17	Ulcerative colitis;
LUAD	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23583168	chr7:148888333	NA	-0.87	-17.83	-0.66	1.88e-53	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg14227996	chr4:17616232	MED28	0.74	8.22	0.37	2.5e-15	Opioid sensitivity;
LUAD	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg03115019	chr17:80708279	FN3K	-0.45	-8.02	-0.36	1.04e-14	Glycated hemoglobin levels;
LUAD	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg03467027	chr4:99064603	C4orf37	0.43	7.01	0.32	9.69e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg14917512	chr19:3094685	GNA11	0.55	6.54	0.3	1.82e-10	Diabetic kidney disease;
LUAD	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg06627628	chr2:24431161	ITSN2	-0.48	-6.62	-0.31	1.07e-10	Lymphocyte counts;
LUAD	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg11189052	chr15:85197271	WDR73	-0.63	-10.47	-0.45	5.86e-23	P wave terminal force;
LUAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg07217954	chr7:1067459	C7orf50	0.43	6.66	0.31	8.41e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg24644049	chr4:85504048	CDS1	0.91	7.8	0.35	4.76e-14	Skin colour saturation;
LUAD	cis	rs7937890	0.507	rs4463820	chr11:14556342	A/G	cg22961513	chr11:14280813	SPON1	-0.37	-7.19	-0.33	3.04e-12	Mitochondrial DNA levels;
LUAD	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.52	0.46	3.66e-23	Colorectal cancer;
LUAD	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg23719950	chr11:63933701	MACROD1	-0.61	-7.09	-0.33	5.65e-12	Mean platelet volume;
LUAD	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg10978503	chr1:24200527	CNR2	0.53	11.39	0.48	2.2e-26	Immature fraction of reticulocytes;
LUAD	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.74	-0.39	5.51e-17	Alzheimer's disease (late onset);
LUAD	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg20701182	chr2:24300061	SF3B14	0.56	6.65	0.31	8.93e-11	Lymphocyte counts;
LUAD	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.34e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.42	6.38	0.3	4.52e-10	Total body bone mineral density;
LUAD	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.72	-0.31	5.72e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg17971929	chr21:40555470	PSMG1	0.53	8.35	0.38	9.6e-16	Cognitive function;
LUAD	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	7.04	0.32	7.8e-12	Depression;
LUAD	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg03929089	chr4:120376271	NA	0.58	7.46	0.34	4.81e-13	Axial length;
LUAD	cis	rs12122100	0.742	rs12122092	chr1:146508874	C/G	cg03526459	chr1:146549940	NA	-0.35	-6.83	-0.31	3.05e-11	HIV-1 control;
LUAD	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg00933542	chr6:150070202	PCMT1	0.42	8.81	0.39	3.23e-17	Lung cancer;
LUAD	cis	rs77741769	0.553	rs12372231	chr12:121351729	T/A	cg02419362	chr12:121203948	SPPL3	0.39	7.87	0.36	3.05e-14	Mean corpuscular volume;
LUAD	cis	rs2262909	0.962	rs73021832	chr19:22316144	G/C	cg11619707	chr19:22235551	ZNF257	0.49	7.44	0.34	5.81e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg15997130	chr1:24165203	NA	0.55	9.5	0.42	1.54e-19	Immature fraction of reticulocytes;
LUAD	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg10755058	chr3:40428713	ENTPD3	0.46	8.59	0.39	1.65e-16	Renal cell carcinoma;
LUAD	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.71	0.35	9.38e-14	Depression;
LUAD	cis	rs2109514	1.000	rs4727833	chr7:116147908	C/G	cg12739419	chr7:116140593	CAV2	-0.37	-8.01	-0.36	1.1e-14	Prevalent atrial fibrillation;
LUAD	cis	rs8060686	0.516	rs8059575	chr16:68272635	C/G	cg26727032	chr16:67993705	SLC12A4	-0.5	-8.17	-0.37	3.61e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7799006	0.862	rs3757439	chr7:2272122	C/T	cg12745145	chr7:2261452	MAD1L1	-0.35	-6.78	-0.31	4.18e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	trans	rs7395662	0.819	rs11039913	chr11:48692081	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	1.98e-12	HDL cholesterol;
LUAD	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg12140854	chr5:148520817	ABLIM3	-0.68	-10.95	-0.47	9.61e-25	Breast cancer;
LUAD	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg15704280	chr7:45808275	SEPT13	-1.0	-20.39	-0.7	7.58e-65	Coronary artery disease;
LUAD	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg09835421	chr16:68378352	PRMT7	-0.85	-9.13	-0.41	2.93e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.51	-0.34	3.5e-13	Bipolar disorder;
LUAD	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18876405	chr7:65276391	NA	0.44	7.01	0.32	9.61e-12	Aortic root size;
LUAD	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg21153622	chr11:89784906	NA	0.34	6.73	0.31	5.53e-11	Coronary artery disease;
LUAD	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg14092988	chr3:52407081	DNAH1	0.35	7.0	0.32	1.03e-11	Bipolar disorder;
LUAD	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg12035532	chr1:1886765	KIAA1751	0.4	6.73	0.31	5.45e-11	Body mass index;
LUAD	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg13770153	chr20:60521292	NA	-0.58	-9.11	-0.4	3.4e-18	Body mass index;
LUAD	cis	rs2067615	0.579	rs66716938	chr12:107196825	T/C	cg15890332	chr12:107067104	RFX4	0.39	8.42	0.38	5.76e-16	Heart rate;
LUAD	trans	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg01620082	chr3:125678407	NA	-1.04	-10.21	-0.44	4.98e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs754466	0.914	rs12218917	chr10:79701479	C/T	cg17075019	chr10:79541650	NA	-0.81	-13.17	-0.54	2.05e-33	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	trans	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg21123656	chr7:99775134	STAG3;GPC2	-0.55	-6.88	-0.32	2.21e-11	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LUAD	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg11148817	chr5:312970	AHRR;PDCD6	-0.47	-6.44	-0.3	3.23e-10	Breast cancer;
LUAD	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg08885076	chr2:99613938	TSGA10	-0.4	-6.98	-0.32	1.16e-11	Chronic sinus infection;
LUAD	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg26022315	chr17:47021804	SNF8	0.4	7.27	0.33	1.77e-12	Type 2 diabetes;
LUAD	cis	rs7586879	0.929	rs6545808	chr2:25124388	C/A	cg04586622	chr2:25135609	ADCY3	0.34	7.36	0.34	9.36e-13	Body mass index;
LUAD	cis	rs736408	0.812	rs9881468	chr3:52828628	C/T	cg10802521	chr3:52805072	NEK4	-0.49	-7.82	-0.36	4.25e-14	Bipolar disorder;
LUAD	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg05340658	chr4:99064831	C4orf37	0.54	9.17	0.41	2.06e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35883536	0.626	rs12135243	chr1:101092955	G/A	cg06223162	chr1:101003688	GPR88	-0.41	-7.47	-0.34	4.71e-13	Monocyte count;
LUAD	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg20019720	chr6:154832845	CNKSR3	0.65	12.84	0.53	4.41e-32	Lipoprotein (a) levels;
LUAD	cis	rs9796	0.870	rs2925346	chr15:41315695	G/A	cg18705301	chr15:41695430	NDUFAF1	0.38	7.16	0.33	3.64e-12	Menopause (age at onset);
LUAD	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.8	-0.39	3.59e-17	Glomerular filtration rate;
LUAD	cis	rs35883536	0.935	rs1106347	chr1:101149059	A/T	cg06223162	chr1:101003688	GPR88	0.37	6.9	0.32	1.94e-11	Monocyte count;
LUAD	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg17063962	chr7:91808500	NA	0.63	10.62	0.46	1.68e-23	Breast cancer;
LUAD	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg17971929	chr21:40555470	PSMG1	0.53	8.2	0.37	2.92e-15	Cognitive function;
LUAD	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06873352	chr17:61820015	STRADA	0.56	9.09	0.4	3.95e-18	Height;
LUAD	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg10556349	chr10:835070	NA	-0.45	-6.95	-0.32	1.38e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg06623918	chr6:96969491	KIAA0776	-0.84	-16.21	-0.62	2.57e-46	Headache;
LUAD	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg17264618	chr3:40429014	ENTPD3	-0.4	-8.77	-0.39	4.5e-17	Renal cell carcinoma;
LUAD	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg12927641	chr6:109611667	NA	-0.51	-8.81	-0.39	3.15e-17	Reticulocyte fraction of red cells;
LUAD	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-13.6	-0.55	3.45e-35	Chronic sinus infection;
LUAD	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg05340658	chr4:99064831	C4orf37	0.46	7.7	0.35	9.55e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg09455208	chr3:40491958	NA	0.64	13.72	0.55	1.09e-35	Renal cell carcinoma;
LUAD	cis	rs4774899	0.932	rs1037956	chr15:57523883	A/T	cg14026238	chr15:57616123	NA	0.35	6.65	0.31	9.24e-11	Urinary tract infection frequency;
LUAD	cis	rs2992756	0.663	rs2992732	chr1:18802825	G/A	cg14356550	chr1:18808102	KLHDC7A	-0.56	-9.66	-0.43	4.29e-20	Breast cancer;
LUAD	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05901451	chr6:126070800	HEY2	-0.66	-11.14	-0.48	1.91e-25	Brugada syndrome;
LUAD	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg25817165	chr18:72167213	CNDP2	-0.72	-10.78	-0.46	4.1e-24	Refractive error;
LUAD	trans	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	6.07e-11	Depression;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24859228	chr10:12391835	CAMK1D	-0.43	-6.8	-0.31	3.58e-11	Height;
LUAD	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg15226275	chr6:116381976	FRK	0.22	7.29	0.33	1.56e-12	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs4699052	0.963	rs2061646	chr4:104183894	T/C	cg16532752	chr4:104119610	CENPE	-0.49	-7.36	-0.34	9.71e-13	Testicular germ cell tumor;
LUAD	cis	rs7224314	1.000	rs62084079	chr17:65386917	C/T	cg01507342	chr17:65387096	PITPNC1	-0.55	-9.27	-0.41	9.63e-19	Diisocyanate-induced asthma;
LUAD	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18404041	chr3:52824283	ITIH1	-0.59	-12.0	-0.5	9.27e-29	Bipolar disorder;
LUAD	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg18446336	chr7:2847575	GNA12	-0.37	-6.91	-0.32	1.79e-11	Height;
LUAD	cis	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg27411982	chr8:10470053	RP1L1	-0.42	-7.57	-0.35	2.35e-13	Triglycerides;
LUAD	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23158103	chr7:148848205	ZNF398	-0.67	-12.51	-0.52	8.84e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs2735413	0.875	rs12923229	chr16:78080302	C/A	cg04733911	chr16:78082701	NA	-0.35	-8.35	-0.38	9.56e-16	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg10556349	chr10:835070	NA	0.67	8.02	0.36	1.01e-14	Eosinophil percentage of granulocytes;
LUAD	cis	rs4711350	0.765	rs943476	chr6:33750086	A/G	cg13859433	chr6:33739653	LEMD2	-0.33	-6.79	-0.31	3.78e-11	Schizophrenia;
LUAD	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08280861	chr8:58055591	NA	0.69	8.55	0.38	2.23e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs7759001	0.817	rs6456774	chr6:27344831	C/G	cg18711553	chr6:27366782	ZNF391	0.39	6.37	0.3	4.86e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs7040024	0.754	rs28865678	chr9:854012	C/G	cg14021170	chr9:826657	NA	-0.41	-6.69	-0.31	6.91e-11	Testicular germ cell tumor;Testicular cancer;
LUAD	cis	rs420259	0.516	rs9933261	chr16:23515952	G/A	cg00143387	chr16:23521605	GGA2	-0.71	-9.91	-0.43	6.13e-21	Bipolar disorder;
LUAD	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg03676636	chr4:99064102	C4orf37	0.37	9.49	0.42	1.73e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg05754148	chr16:3507555	NAT15	0.48	7.32	0.34	1.24e-12	Body mass index (adult);
LUAD	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg21171335	chr12:122356390	WDR66	-0.55	-9.05	-0.4	5.42e-18	Mean corpuscular volume;
LUAD	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg15704280	chr7:45808275	SEPT13	-0.65	-9.96	-0.44	3.97e-21	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg08601574	chr20:25228251	PYGB	0.47	8.88	0.4	1.86e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.53	8.99	0.4	8.46e-18	Cognitive ability;
LUAD	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg24818145	chr4:99064322	C4orf37	0.46	7.87	0.36	3e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg26875233	chr11:93583750	C11orf90	-0.39	-8.74	-0.39	5.53e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LUAD	cis	rs73206853	0.764	rs28840785	chr12:110844920	C/G	cg12870014	chr12:110450643	ANKRD13A	0.64	7.17	0.33	3.47e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs2839186	0.565	rs2839183	chr21:47687144	G/A	cg12379764	chr21:47803548	PCNT	0.51	8.47	0.38	4.17e-16	Testicular germ cell tumor;
LUAD	cis	rs863345	0.604	rs11265007	chr1:158498522	C/T	cg12129480	chr1:158549410	OR10X1	0.24	6.38	0.3	4.61e-10	Pneumococcal bacteremia;
LUAD	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg27454412	chr7:1067447	C7orf50	0.4	6.6	0.31	1.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg24399712	chr22:39784796	NA	-0.78	-14.83	-0.58	2.23e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs4006360	0.601	rs7214364	chr17:39236678	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.13	0.37	4.87e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg22907277	chr7:1156413	C7orf50	0.64	7.62	0.35	1.65e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12200560	0.505	rs984519	chr6:97076223	A/G	cg06623918	chr6:96969491	KIAA0776	-0.48	-7.5	-0.34	3.81e-13	Coronary heart disease;
LUAD	cis	rs701145	0.585	rs365119	chr3:153916502	A/T	cg17054900	chr3:154042577	DHX36	0.66	7.08	0.33	6.13e-12	Coronary artery disease;
LUAD	cis	rs9354308	0.901	rs2814121	chr6:66566915	G/C	cg07460842	chr6:66804631	NA	0.49	7.28	0.33	1.66e-12	Metabolite levels;
LUAD	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg09021430	chr5:549028	NA	0.65	12.76	0.53	8.85e-32	Obesity-related traits;
LUAD	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg13263323	chr15:86062960	AKAP13	-0.51	-9.45	-0.42	2.28e-19	Coronary artery disease;
LUAD	cis	rs7536201	0.846	rs2370233	chr1:25304463	G/C	cg23273869	chr1:25296894	NA	-0.37	-7.49	-0.34	3.96e-13	Psoriasis vulgaris;
LUAD	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg21280719	chr6:42927975	GNMT	0.34	10.29	0.45	2.6e-22	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg12179176	chr11:130786555	SNX19	0.56	9.5	0.42	1.55e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7737355	0.812	rs6896132	chr5:130773561	C/G	cg06307176	chr5:131281290	NA	0.4	6.72	0.31	6.01e-11	Life satisfaction;
LUAD	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg10518543	chr12:38710700	ALG10B	-0.49	-8.07	-0.37	7.3e-15	Morning vs. evening chronotype;
LUAD	cis	rs6901250	0.851	rs2175622	chr6:117149667	T/A	cg12892004	chr6:117198278	RFX6	0.34	7.25	0.33	1.93e-12	C-reactive protein levels;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg26294578	chr17:79319535	NA	0.4	6.5	0.3	2.28e-10	Bilirubin levels;
LUAD	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.4	0.34	7.4e-13	Menopause (age at onset);
LUAD	cis	rs7727544	0.584	rs7714191	chr5:131341541	C/G	cg16205897	chr5:131564050	P4HA2	-0.35	-7.63	-0.35	1.54e-13	Blood metabolite levels;
LUAD	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18876405	chr7:65276391	NA	-0.44	-7.22	-0.33	2.38e-12	Aortic root size;
LUAD	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg06623918	chr6:96969491	KIAA0776	0.89	17.65	0.65	1.27e-52	Headache;
LUAD	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.19	0.33	2.91e-12	Rheumatoid arthritis;
LUAD	cis	rs887829	0.507	rs10929301	chr2:234663649	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-8.87	-0.4	2.1e-17	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUAD	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.45	-0.34	5.15e-13	Bipolar disorder;
LUAD	cis	rs7089973	0.844	rs10510007	chr10:116636721	A/G	cg23260525	chr10:116636907	FAM160B1	0.38	8.21	0.37	2.72e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg06131755	chr6:160182447	ACAT2	0.43	6.42	0.3	3.77e-10	Age-related macular degeneration (geographic atrophy);
LUAD	trans	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg14917512	chr19:3094685	GNA11	-0.58	-6.91	-0.32	1.8e-11	Gout;
LUAD	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg12588279	chr6:26043732	HIST1H2BB	0.38	6.39	0.3	4.28e-10	Intelligence (multi-trait analysis);
LUAD	trans	rs62103177	0.673	rs36087369	chr18:77589596	C/G	cg05926928	chr17:57297772	GDPD1	0.83	11.6	0.49	3.23e-27	Opioid sensitivity;
LUAD	trans	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg27411982	chr8:10470053	RP1L1	0.43	7.79	0.35	5.18e-14	Mood instability;
LUAD	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6028335	0.674	rs59072291	chr20:37622010	T/A	cg27660920	chr20:37554817	FAM83D	0.52	6.54	0.3	1.79e-10	Alcohol and nicotine co-dependence;
LUAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00166722	chr3:10149974	C3orf24	0.74	12.65	0.52	2.48e-31	Alzheimer's disease;
LUAD	cis	rs755249	0.501	rs2484749	chr1:39758955	A/G	cg27567593	chr1:39956653	BMP8A	0.34	6.53	0.3	1.84e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9837602	1.000	rs6790877	chr3:99779658	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.81	-0.31	3.32e-11	Breast cancer;
LUAD	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.07e-12	Diabetic kidney disease;
LUAD	cis	rs56346965	0.967	rs2293765	chr2:191520845	C/A	cg27211696	chr2:191398769	TMEM194B	0.47	8.42	0.38	5.94e-16	Bone mineral density (Ward's triangle area);
LUAD	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg14668632	chr7:2872130	GNA12	-0.68	-12.21	-0.51	1.43e-29	Height;
LUAD	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg17063962	chr7:91808500	NA	-0.61	-10.48	-0.45	5.12e-23	Breast cancer;
LUAD	cis	rs7975161	0.630	rs6539128	chr12:104618454	A/G	cg25273343	chr12:104657179	TXNRD1	-0.62	-6.87	-0.32	2.37e-11	Toenail selenium levels;
LUAD	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.6	-12.41	-0.52	2.21e-30	Hemoglobin concentration;
LUAD	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg11645453	chr3:52864694	ITIH4	0.53	9.89	0.43	7.11e-21	Schizophrenia;
LUAD	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg15664640	chr17:80829946	TBCD	0.5	9.58	0.42	8.15e-20	Breast cancer;
LUAD	cis	rs6484504	0.512	rs2774402	chr11:31312897	G/C	cg14844989	chr11:31128820	NA	0.44	8.07	0.37	7.46e-15	Red blood cell count;
LUAD	cis	rs9399401	1.000	rs972982	chr6:142666861	A/G	cg03128060	chr6:142623767	GPR126	0.3	6.53	0.3	1.84e-10	Chronic obstructive pulmonary disease;
LUAD	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg15704280	chr7:45808275	SEPT13	0.86	16.11	0.62	6.84e-46	Coronary artery disease;
LUAD	cis	rs72845660	0.513	rs72845694	chr10:104169733	C/T	cg20641465	chr10:103991465	PITX3	-0.54	-9.31	-0.41	6.78e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22857025	chr5:266934	NA	-0.96	-14.51	-0.58	5.11e-39	Breast cancer;
LUAD	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg22491629	chr6:157744540	C6orf35	-0.82	-9.5	-0.42	1.6e-19	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg00204512	chr16:28754710	NA	0.32	6.74	0.31	5.29e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg06627628	chr2:24431161	ITSN2	-0.55	-6.54	-0.3	1.83e-10	Lymphocyte percentage of white cells;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.4	6.43	0.3	3.41e-10	Monocyte percentage of white cells;
LUAD	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg06092702	chr1:163392909	NA	-0.36	-8.38	-0.38	8.18e-16	Motion sickness;
LUAD	cis	rs4389656	0.625	rs274681	chr5:6748659	T/C	cg10857441	chr5:6722123	POLS	-0.45	-7.51	-0.34	3.51e-13	Coronary artery disease;
LUAD	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg06096015	chr1:231504339	EGLN1	0.34	6.46	0.3	2.89e-10	Hemoglobin concentration;
LUAD	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg14582100	chr15:45693742	SPATA5L1	0.63	12.28	0.51	7.24e-30	Homoarginine levels;
LUAD	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.81	-12.4	-0.52	2.44e-30	Chronic sinus infection;
LUAD	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg27124370	chr19:33622961	WDR88	0.43	6.61	0.31	1.16e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg17939001	chr1:197871836	C1orf53	-0.74	-7.3	-0.33	1.43e-12	Type 2 diabetes;
LUAD	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg16989719	chr2:238392110	NA	-0.34	-6.81	-0.31	3.29e-11	Prostate cancer;
LUAD	cis	rs9595066	0.564	rs12869383	chr13:44705441	G/A	cg04068111	chr13:44716778	NA	0.44	9.47	0.42	2.05e-19	Schizophrenia;
LUAD	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.59	-10.24	-0.45	3.84e-22	Menarche (age at onset);
LUAD	cis	rs4409675	0.956	rs4072743	chr1:28270934	T/C	cg23691781	chr1:28212827	C1orf38	-0.26	-6.48	-0.3	2.52e-10	Corneal astigmatism;
LUAD	cis	rs7621025	0.500	rs71630059	chr3:136581611	G/A	cg15507776	chr3:136538369	TMEM22	-0.59	-9.07	-0.4	4.51e-18	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUAD	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg09222892	chr1:25734099	RHCE	-0.49	-9.14	-0.41	2.69e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg03467027	chr4:99064603	C4orf37	0.4	6.4	0.3	4.09e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10979	0.557	rs9403517	chr6:143909400	T/C	cg25407410	chr6:143891975	LOC285740	-0.52	-7.32	-0.34	1.26e-12	Hypospadias;
LUAD	cis	rs68170813	1.000	rs10953541	chr7:107244545	C/T	cg02696742	chr7:106810147	HBP1	-0.5	-6.67	-0.31	7.88e-11	Coronary artery disease;
LUAD	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg17971929	chr21:40555470	PSMG1	0.42	6.78	0.31	4.15e-11	Cognitive function;
LUAD	cis	rs2996428	0.628	rs6667526	chr1:3774603	G/A	cg17848003	chr1:3704513	LRRC47	0.53	10.28	0.45	2.81e-22	Red cell distribution width;
LUAD	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg22482690	chr17:47019901	SNF8	0.45	8.51	0.38	3.15e-16	Type 2 diabetes;
LUAD	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg00745463	chr17:30367425	LRRC37B	-1.06	-12.72	-0.53	1.32e-31	Hip circumference adjusted for BMI;
LUAD	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg01689657	chr7:91764605	CYP51A1	0.3	7.3	0.33	1.48e-12	Breast cancer;
LUAD	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.63	11.04	0.47	4.55e-25	Birth weight;
LUAD	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02353165	chr6:42928485	GNMT	0.46	8.38	0.38	8.16e-16	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13126279	chr21:47581558	C21orf56	-0.54	-9.16	-0.41	2.32e-18	Testicular germ cell tumor;
LUAD	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg19729930	chr2:74357872	NA	0.96	17.33	0.64	3.05e-51	Gestational age at birth (maternal effect);
LUAD	cis	rs9925964	0.967	rs4889620	chr16:31131174	G/A	cg03418659	chr16:31128414	MYST1	0.4	6.62	0.31	1.08e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg12923728	chr3:195709715	SDHAP1	0.44	6.74	0.31	5.18e-11	Mean corpuscular volume;
LUAD	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg18811423	chr2:55921094	PNPT1	0.57	9.7	0.43	3.12e-20	Metabolic syndrome;
LUAD	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg02683114	chr2:24398427	C2orf84	-0.42	-6.51	-0.3	2.13e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.51	-0.34	3.56e-13	Total body bone mineral density;
LUAD	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg19318889	chr4:1322082	MAEA	-0.45	-7.84	-0.36	3.7e-14	Obesity-related traits;
LUAD	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg21153622	chr11:89784906	NA	-0.34	-6.78	-0.31	3.98e-11	HDL cholesterol;
LUAD	cis	rs34115320	1	rs34115320	chr7:148783936	CT/C	cg23583168	chr7:148888333	NA	-0.86	-16.67	-0.63	2.62e-48	Sum basophil neutrophil counts;Neutrophil count;
LUAD	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg01802117	chr1:53393560	SCP2	-0.33	-6.52	-0.3	2.02e-10	Monocyte count;
LUAD	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-7.65	-0.35	1.38e-13	Lung cancer;
LUAD	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.46	0.3	2.86e-10	Cognitive test performance;
LUAD	trans	rs783540	0.967	rs2567635	chr15:83262181	T/G	cg18393722	chr15:85113863	UBE2QP1	-0.45	-7.3	-0.33	1.41e-12	Schizophrenia;
LUAD	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg05082376	chr22:42548792	NA	0.45	7.8	0.35	4.73e-14	Schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09332309	chr17:4890691	CAMTA2	-0.65	-6.37	-0.3	4.91e-10	Type 2 diabetes;
LUAD	cis	rs7712401	0.601	rs152039	chr5:122220665	C/T	cg19077854	chr5:122220652	SNX24	0.34	6.54	0.3	1.73e-10	Mean platelet volume;
LUAD	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg01324343	chr3:183735012	ABCC5	0.8	17.7	0.65	7.53e-53	Anterior chamber depth;
LUAD	cis	rs11112613	0.762	rs17037312	chr12:105950085	C/T	cg03607813	chr12:105948248	NA	0.82	13.87	0.56	2.64e-36	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg16006841	chr5:176797999	RGS14	-0.54	-9.94	-0.43	4.79e-21	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs3849570	1.000	rs3849570	chr3:81792112	C/A	cg07356753	chr3:81810745	GBE1	-0.7	-12.39	-0.52	2.61e-30	Waist circumference;Body mass index;
LUAD	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg15704280	chr7:45808275	SEPT13	0.64	8.17	0.37	3.52e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg26513180	chr16:89883248	FANCA	0.82	7.41	0.34	6.98e-13	Skin colour saturation;
LUAD	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg01416388	chr22:39784598	NA	-0.44	-6.55	-0.3	1.69e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg08048268	chr3:133502702	NA	-0.37	-7.16	-0.33	3.49e-12	Iron status biomarkers;
LUAD	cis	rs7301016	0.948	rs12370404	chr12:62923340	T/C	cg11441379	chr12:63026424	NA	0.56	7.07	0.32	6.57e-12	IgG glycosylation;
LUAD	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg03433033	chr1:76189801	ACADM	0.87	17.59	0.65	2.17e-52	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg25173405	chr17:45401733	C17orf57	0.52	8.97	0.4	9.67e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs13095912	1.000	rs7374856	chr3:185311964	A/C	cg11274856	chr3:185301563	NA	0.37	7.43	0.34	6.17e-13	Systolic blood pressure;
LUAD	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg25811766	chr13:21894605	NA	0.68	9.15	0.41	2.48e-18	White matter hyperintensity burden;
LUAD	cis	rs6489882	0.867	rs7298184	chr12:113368249	C/A	cg20102336	chr12:113376681	OAS3	-0.6	-9.37	-0.41	4.35e-19	Chronic lymphocytic leukemia;
LUAD	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg20891558	chr2:74357851	NA	0.74	10.63	0.46	1.46e-23	Gestational age at birth (maternal effect);
LUAD	cis	rs2734839	0.964	rs12798900	chr11:113298996	G/T	cg14159747	chr11:113255604	NA	0.54	10.18	0.44	6.2e-22	Information processing speed;
LUAD	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg12311346	chr5:56204834	C5orf35	-0.57	-9.1	-0.4	3.72e-18	Coronary artery disease;
LUAD	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg18135555	chr8:22132992	PIWIL2	0.44	7.93	0.36	2.01e-14	Hypertriglyceridemia;
LUAD	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg03806693	chr22:41940476	POLR3H	0.64	8.93	0.4	1.27e-17	Vitiligo;
LUAD	trans	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg07393940	chr7:158741817	NA	0.69	11.68	0.49	1.65e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs12760731	0.720	rs10913540	chr1:178340060	T/C	cg00404053	chr1:178313656	RASAL2	0.65	8.42	0.38	6.05e-16	Obesity-related traits;
LUAD	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg25985355	chr7:65971099	NA	0.53	6.7	0.31	6.87e-11	Diabetic kidney disease;
LUAD	cis	rs2742417	0.967	rs9311378	chr3:45763135	C/T	cg10512202	chr3:45649293	LIMD1	0.39	6.99	0.32	1.1e-11	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg25894440	chr7:65020034	NA	-0.7	-7.45	-0.34	5.26e-13	Diabetic kidney disease;
LUAD	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg00191853	chr8:101177733	SPAG1	0.42	7.45	0.34	5.15e-13	Atrioventricular conduction;
LUAD	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg25036284	chr2:26402008	FAM59B	0.83	11.68	0.49	1.71e-27	Gut microbiome composition (summer);
LUAD	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs2976388	0.556	rs2572876	chr8:143830599	C/T	cg20108693	chr8:143823809	SLURP1	0.3	7.0	0.32	1.04e-11	Urinary tract infection frequency;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25789201	chr7:72395803	POM121	-0.46	-7.29	-0.33	1.5e-12	Height;
LUAD	cis	rs698833	0.859	rs1302175	chr2:44657024	G/C	cg04920474	chr2:44395004	PPM1B	0.38	6.81	0.31	3.29e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg23254163	chr1:152506842	NA	0.26	7.41	0.34	6.83e-13	Hair morphology;
LUAD	cis	rs7177699	0.526	rs7166764	chr15:79123509	T/G	cg00540400	chr15:79124168	NA	0.44	9.73	0.43	2.48e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs7508	0.619	rs483159	chr8:17911838	A/T	cg04898035	chr8:17640624	MTUS1	-0.44	-6.84	-0.32	2.74e-11	Atrial fibrillation;
LUAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg02869364	chr7:1081709	C7orf50	-0.53	-6.79	-0.31	3.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg05865280	chr17:75406074	SEPT9	0.61	19.24	0.68	1.02e-59	Airflow obstruction;
LUAD	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg26924012	chr15:45694286	SPATA5L1	0.87	14.91	0.59	1.1e-40	Homoarginine levels;
LUAD	trans	rs10802346	0.524	rs10802356	chr1:246385857	T/C	cg22732515	chr19:44031385	ETHE1	0.58	9.41	0.42	3.16e-19	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg03340356	chr1:67600835	NA	0.38	6.67	0.31	8.02e-11	Psoriasis;
LUAD	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg23950597	chr19:37808831	NA	-0.6	-7.46	-0.34	4.88e-13	Coronary artery calcification;
LUAD	trans	rs1422110	0.572	rs6884343	chr5:85444051	G/T	cg01787110	chr1:109008453	NBPF6	0.62	10.25	0.45	3.48e-22	Attention function in attention deficit hyperactive disorder;
LUAD	cis	rs1595825	0.891	rs73056877	chr2:198816724	A/C	cg10547527	chr2:198650123	BOLL	-0.51	-7.1	-0.33	5.43e-12	Ulcerative colitis;
LUAD	trans	rs1941687	0.563	rs9947894	chr18:31328720	G/T	cg15819921	chr19:927150	ARID3A	0.46	7.79	0.35	5.3e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg11266682	chr4:10021025	SLC2A9	0.59	13.16	0.54	2.07e-33	Bone mineral density;
LUAD	cis	rs12210905	0.688	rs72841400	chr6:27489911	T/G	cg08851530	chr6:28072375	NA	1.03	7.47	0.34	4.64e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg05590025	chr7:65112418	INTS4L2	-0.74	-7.84	-0.36	3.82e-14	Diabetic kidney disease;
LUAD	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg09021430	chr5:549028	NA	-0.69	-13.45	-0.55	1.43e-34	Lung disease severity in cystic fibrosis;
LUAD	cis	rs751728	1.000	rs4711351	chr6:33754592	G/A	cg13859433	chr6:33739653	LEMD2	-0.39	-9.2	-0.41	1.71e-18	Crohn's disease;
LUAD	trans	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg06606381	chr12:133084897	FBRSL1	-0.84	-7.93	-0.36	1.91e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg23277830	chr1:3704460	LRRC47	0.41	8.36	0.38	8.96e-16	Red cell distribution width;
LUAD	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg18402987	chr7:1209562	NA	0.81	9.97	0.44	3.72e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg06360820	chr2:242988706	NA	-0.97	-13.16	-0.54	2.07e-33	Obesity-related traits;
LUAD	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.3	-0.37	1.38e-15	Height;
LUAD	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.83	0.36	4.09e-14	Morning vs. evening chronotype;
LUAD	cis	rs9837602	0.872	rs1489816	chr3:99769088	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	6.87	0.32	2.29e-11	Breast cancer;
LUAD	cis	rs3812049	0.667	rs6888037	chr5:127406259	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	7.49	0.34	4.14e-13	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10819733	chr22:24237672	NA	-0.38	-7.14	-0.33	4.21e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs3754214	0.823	rs496203	chr1:150270025	A/G	cg15654264	chr1:150340011	RPRD2	-0.35	-6.4	-0.3	4.13e-10	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs240764	0.658	rs9390685	chr6:101224725	A/T	cg09795085	chr6:101329169	ASCC3	0.43	7.79	0.35	5.36e-14	Neuroticism;
LUAD	cis	rs7474896	0.559	rs10740949	chr10:37978435	A/G	cg25427524	chr10:38739819	LOC399744	-0.63	-9.2	-0.41	1.63e-18	Obesity (extreme);
LUAD	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg24558204	chr6:135376177	HBS1L	0.47	8.53	0.38	2.66e-16	Red blood cell count;
LUAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	8.3	0.37	1.41e-15	Alzheimer's disease;
LUAD	cis	rs1784581	0.588	rs9355971	chr6:162421242	A/G	cg17173639	chr6:162384350	PARK2	0.44	7.87	0.36	2.93e-14	Itch intensity from mosquito bite;
LUAD	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg00784671	chr22:46762841	CELSR1	-0.42	-6.39	-0.3	4.46e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6993813	0.678	rs6469792	chr8:120008371	T/C	cg01975934	chr8:119970761	NA	-0.36	-6.88	-0.32	2.21e-11	Bone mineral density (hip);
LUAD	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg15181151	chr6:150070149	PCMT1	0.38	7.33	0.34	1.16e-12	Lung cancer;
LUAD	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg14416269	chr4:6271139	WFS1	0.62	11.9	0.5	2.34e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07953307	chr16:29000920	LAT	0.58	7.24	0.33	2.17e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg06781209	chr11:61594997	FADS2	-0.41	-7.31	-0.33	1.35e-12	Trans fatty acid levels;
LUAD	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg25233709	chr10:116636983	FAM160B1	0.43	8.6	0.39	1.54e-16	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg04455712	chr21:45112962	RRP1B	0.47	9.25	0.41	1.11e-18	Mean corpuscular volume;
LUAD	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg18306943	chr3:40428807	ENTPD3	-0.37	-6.41	-0.3	3.97e-10	Renal cell carcinoma;
LUAD	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg18404041	chr3:52824283	ITIH1	0.41	7.46	0.34	5e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7945718	0.870	rs10831903	chr11:12758660	C/T	cg25843174	chr11:12811716	TEAD1	0.25	7.45	0.34	5.27e-13	Educational attainment (years of education);
LUAD	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.19	-0.33	3.02e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs240764	0.687	rs7754085	chr6:101220806	T/A	cg09795085	chr6:101329169	ASCC3	-0.43	-7.48	-0.34	4.29e-13	Neuroticism;
LUAD	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg05340658	chr4:99064831	C4orf37	0.56	9.53	0.42	1.28e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05901451	chr6:126070800	HEY2	-0.66	-10.92	-0.47	1.24e-24	Brugada syndrome;
LUAD	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg27454412	chr7:1067447	C7orf50	0.48	7.64	0.35	1.43e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg21823605	chr1:152486609	CRCT1	0.28	6.59	0.31	1.3e-10	Hair morphology;
LUAD	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg12179176	chr11:130786555	SNX19	-0.53	-8.85	-0.4	2.5e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs57024841	0.562	rs2071006	chr9:139839904	G/T	cg16658931	chr19:51171061	SHANK1	0.35	6.74	0.31	5.34e-11	Beta-trace protein levels;
LUAD	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg00981070	chr1:2046702	PRKCZ	0.36	6.76	0.31	4.51e-11	Height;
LUAD	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg00666640	chr1:248458726	OR2T12	0.33	7.91	0.36	2.23e-14	Common traits (Other);
LUAD	cis	rs9467160	1.000	rs9467158	chr6:24441215	G/A	cg20631270	chr6:24437470	GPLD1	0.44	6.37	0.3	4.79e-10	Liver enzyme levels;
LUAD	cis	rs62238980	0.614	rs78017579	chr22:32381234	T/G	cg02631450	chr22:32366979	NA	0.79	6.46	0.3	2.9e-10	Childhood ear infection;
LUAD	cis	rs4774899	0.932	rs2290938	chr15:57524857	T/C	cg14026238	chr15:57616123	NA	0.35	6.65	0.31	9.24e-11	Urinary tract infection frequency;
LUAD	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.26	-0.54	8.48e-34	Chronic sinus infection;
LUAD	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg23172400	chr8:95962367	TP53INP1	-0.37	-8.79	-0.39	3.78e-17	Type 2 diabetes;
LUAD	cis	rs7301826	0.627	rs73162873	chr12:131296013	A/G	cg11011512	chr12:131303247	STX2	0.44	7.41	0.34	6.76e-13	Plasma plasminogen activator levels;
LUAD	cis	rs733175	0.830	rs10004571	chr4:10062965	G/A	cg00071950	chr4:10020882	SLC2A9	0.47	7.26	0.33	1.93e-12	Psychosis and Alzheimer's disease;
LUAD	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg11494091	chr17:61959527	GH2	0.42	7.93	0.36	1.92e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs73198271	0.960	rs10503392	chr8:8609555	G/C	cg01851573	chr8:8652454	MFHAS1	0.53	8.52	0.38	2.87e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.61	-0.42	6.62e-20	Platelet count;
LUAD	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg20362242	chr5:692897	TPPP	0.57	6.98	0.32	1.15e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg05991184	chr2:219186017	PNKD	0.35	6.62	0.31	1.09e-10	Colorectal cancer;
LUAD	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg24818145	chr4:99064322	C4orf37	-0.42	-6.88	-0.32	2.22e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7737355	1.000	rs257390	chr5:130740617	C/T	cg06307176	chr5:131281290	NA	-0.46	-7.37	-0.34	9.12e-13	Life satisfaction;
LUAD	cis	rs7737355	0.853	rs7730810	chr5:130781179	T/C	cg06307176	chr5:131281290	NA	-0.43	-7.08	-0.33	5.9e-12	Life satisfaction;
LUAD	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.81	0.36	4.47e-14	Bladder cancer;
LUAD	cis	rs2535633	0.631	rs2465101	chr3:52991307	A/T	cg18404041	chr3:52824283	ITIH1	0.39	6.56	0.3	1.56e-10	Body mass index;
LUAD	cis	rs7000551	0.725	rs2461486	chr8:22392008	T/C	cg12081754	chr8:22256438	SLC39A14	0.4	6.67	0.31	8.18e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs61776719	0.840	rs35267671	chr1:38397369	C/T	cg17077180	chr1:38461687	NA	0.55	11.82	0.5	4.75e-28	Coronary artery disease;
LUAD	trans	rs3219090	0.962	rs1828446	chr1:226601320	G/A	cg27539482	chr13:111589090	NA	0.43	7.18	0.33	3.24e-12	Melanoma;
LUAD	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg23625390	chr15:77176239	SCAPER	0.39	7.1	0.33	5.16e-12	Blood metabolite levels;
LUAD	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg25251562	chr2:3704773	ALLC	-0.86	-12.74	-0.53	1.07e-31	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs5758511	0.731	rs58302269	chr22:42351309	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.38	6.58	0.3	1.37e-10	Birth weight;
LUAD	cis	rs12618769	0.597	rs17505088	chr2:99149473	C/T	cg10123293	chr2:99228465	UNC50	0.47	8.27	0.37	1.78e-15	Bipolar disorder;
LUAD	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg06873352	chr17:61820015	STRADA	0.42	6.96	0.32	1.3e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7172809	0.573	rs17470529	chr15:77673359	A/G	cg11865553	chr15:77376250	NA	-0.39	-6.45	-0.3	2.97e-10	Glucose homeostasis traits;
LUAD	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg26384229	chr12:38710491	ALG10B	0.47	7.67	0.35	1.23e-13	Morning vs. evening chronotype;
LUAD	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg15448220	chr1:150897856	SETDB1	0.54	9.24	0.41	1.21e-18	Melanoma;
LUAD	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg11663144	chr21:46675770	NA	-0.59	-11.7	-0.49	1.34e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4774899	0.752	rs2439918	chr15:57344647	T/G	cg14026238	chr15:57616123	NA	0.44	8.41	0.38	6.39e-16	Urinary tract infection frequency;
LUAD	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg07570687	chr10:102243282	WNT8B	0.46	7.06	0.32	6.77e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg03929089	chr4:120376271	NA	-0.95	-19.28	-0.68	6.48e-60	Height;
LUAD	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg04731861	chr2:219085781	ARPC2	-0.22	-6.78	-0.31	4.09e-11	Colorectal cancer;
LUAD	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg22963979	chr7:1858916	MAD1L1	-0.58	-10.37	-0.45	1.32e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg02569458	chr12:86230093	RASSF9	0.38	6.91	0.32	1.75e-11	Major depressive disorder;
LUAD	cis	rs7274811	0.681	rs291670	chr20:31945861	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	0.52	8.01	0.36	1.13e-14	Height;
LUAD	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg11645453	chr3:52864694	ITIH4	0.6	11.01	0.47	5.84e-25	Schizophrenia;
LUAD	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg10729496	chr3:10149963	C3orf24	0.55	8.76	0.39	4.78e-17	Alzheimer's disease;
LUAD	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg03959625	chr15:84868606	LOC388152	0.4	6.48	0.3	2.6200000000000003e-10	Schizophrenia;
LUAD	cis	rs9393692	0.557	rs725575	chr6:26301919	A/T	cg00631329	chr6:26305371	NA	-0.57	-9.54	-0.42	1.11e-19	Educational attainment;
LUAD	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg20119798	chr7:94954144	PON1	-0.47	-6.42	-0.3	3.76e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs16958440	0.867	rs61689863	chr18:44669157	A/T	cg17192377	chr18:44677553	HDHD2	0.84	7.85	0.36	3.48e-14	Sitting height ratio;
LUAD	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	9.47	0.42	2.03e-19	Menarche (age at onset);
LUAD	cis	rs8099014	0.814	rs4245272	chr18:56115145	T/A	cg12907477	chr18:56117327	MIR122	0.49	8.08	0.37	6.96e-15	Platelet count;
LUAD	cis	rs10037055	1.000	rs10037055	chr5:176691279	G/T	cg06733329	chr5:176740039	MXD3	0.43	7.05	0.32	7.13e-12	Migraine without aura;
LUAD	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg21963583	chr11:68658836	MRPL21	0.39	6.89	0.32	2.03e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06505273	chr16:24850292	NA	-0.45	-6.5	-0.3	2.22e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg17911788	chr17:44343683	NA	-0.5	-7.04	-0.32	7.9e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg11344533	chr11:111475393	SIK2	-0.36	-6.75	-0.31	4.82e-11	Primary sclerosing cholangitis;
LUAD	cis	rs367615	0.552	rs2963010	chr5:108737043	T/C	cg17395555	chr5:108820864	NA	-0.53	-10.03	-0.44	2.2e-21	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg22920501	chr2:26401640	FAM59B	0.98	15.42	0.6	7.07e-43	Gut microbiome composition (summer);
LUAD	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.72	13.33	0.54	4.3e-34	Lymphocyte counts;
LUAD	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg23262073	chr20:60523788	NA	-0.47	-8.11	-0.37	5.44e-15	Body mass index;
LUAD	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.01	-0.36	1.11e-14	Total body bone mineral density;
LUAD	cis	rs2479724	0.870	rs6913232	chr6:41915143	C/T	cg17623882	chr6:41773611	USP49	0.57	10.23	0.45	4.44e-22	Menarche (age at onset);
LUAD	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg18105134	chr13:113819100	PROZ	0.91	16.41	0.62	3.59e-47	Platelet distribution width;
LUAD	cis	rs12079745	0.793	rs12067139	chr1:169254507	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-1.02	-7.75	-0.35	6.91e-14	QT interval;
LUAD	cis	rs7737355	0.842	rs7731001	chr5:130781338	T/C	cg25547332	chr5:131281432	NA	-0.43	-7.0	-0.32	9.92e-12	Life satisfaction;
LUAD	cis	rs6087990	0.748	rs4911255	chr20:31357580	A/T	cg13636640	chr20:31349939	DNMT3B	0.82	15.53	0.6	2.41e-43	Ulcerative colitis;
LUAD	cis	rs654950	0.653	rs2810568	chr1:42054247	A/G	cg06885757	chr1:42089581	HIVEP3	-0.52	-12.03	-0.5	7.39e-29	Airway imaging phenotypes;
LUAD	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.39	-6.99	-0.32	1.11e-11	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg26384229	chr12:38710491	ALG10B	0.47	7.64	0.35	1.48e-13	Morning vs. evening chronotype;
LUAD	cis	rs10100465	0.883	rs10283125	chr8:118644818	A/G	cg09430518	chr8:118662568	NA	-0.32	-6.4	-0.3	4.03e-10	Leprosy;
LUAD	cis	rs9399401	0.710	rs7765770	chr6:142687305	C/T	cg04461802	chr6:142623433	GPR126	0.43	8.06	0.36	7.99e-15	Chronic obstructive pulmonary disease;
LUAD	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg07636037	chr3:49044803	WDR6	0.48	8.11	0.37	5.67e-15	Menarche (age at onset);
LUAD	cis	rs735539	0.645	rs7326068	chr13:21209512	A/G	cg27499820	chr13:21296301	IL17D	-0.51	-8.62	-0.39	1.37e-16	Dental caries;
LUAD	cis	rs2657888	0.965	rs2657903	chr12:56933722	G/A	cg23002907	chr12:56915593	RBMS2	0.35	6.56	0.3	1.59e-10	Adiponectin levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03031583	chr16:21964721	UQCRC2	-0.4	-6.4	-0.3	4.25e-10	Height;
LUAD	cis	rs6446731	0.636	rs2157091	chr4:3273099	G/A	cg08886695	chr4:3369023	RGS12	-0.5	-8.42	-0.38	5.94e-16	Mean platelet volume;
LUAD	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.68	0.39	8.91e-17	Parkinson's disease;
LUAD	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg24634471	chr8:143751801	JRK	0.5	8.02	0.36	1.05e-14	Schizophrenia;
LUAD	cis	rs55823223	0.648	rs72860389	chr17:73866071	C/T	cg08125733	chr17:73851984	WBP2	0.66	9.59	0.42	7.8500000000000006e-20	Psoriasis;
LUAD	cis	rs4285028	0.747	rs12496318	chr3:121561500	A/C	cg11130432	chr3:121712080	ILDR1	0.51	7.23	0.33	2.28e-12	Multiple sclerosis;
LUAD	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg03929089	chr4:120376271	NA	0.72	10.94	0.47	1.08e-24	Coronary artery disease;
LUAD	cis	rs4588572	0.601	rs1529500	chr5:77721643	C/T	cg11547950	chr5:77652471	NA	-0.75	-12.33	-0.51	4.64e-30	Triglycerides;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg12508534	chr6:34855789	TAF11;ANKS1A	-0.53	-6.37	-0.3	4.95e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg07936489	chr17:37558343	FBXL20	-0.44	-6.88	-0.32	2.11e-11	Urinary metabolites;
LUAD	cis	rs7737355	0.699	rs7711311	chr5:130781339	G/A	cg06307176	chr5:131281290	NA	-0.43	-7.08	-0.33	5.86e-12	Life satisfaction;
LUAD	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg06108461	chr20:60628389	TAF4	-0.79	-13.56	-0.55	5.04e-35	Body mass index;
LUAD	cis	rs9902453	0.765	rs12601647	chr17:28164953	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	10.72	0.46	6.95e-24	Coffee consumption (cups per day);
LUAD	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25427524	chr10:38739819	LOC399744	-0.75	-13.33	-0.54	4.25e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.4e-15	Prostate cancer;
LUAD	cis	rs807669	1.000	rs807669	chr22:19154522	T/C	cg02655711	chr22:19163373	SLC25A1	0.86	18.05	0.66	2.1e-54	Metabolite levels;
LUAD	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg14895029	chr7:2775587	GNA12	-0.4	-6.42	-0.3	3.64e-10	Height;
LUAD	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg04727924	chr7:799746	HEATR2	-0.55	-7.33	-0.34	1.16e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs13064411	0.660	rs3829889	chr3:113015464	G/A	cg18753928	chr3:113234510	CCDC52	-0.59	-9.25	-0.41	1.16e-18	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs4481887	0.893	rs1339992	chr1:248509182	G/A	cg00666640	chr1:248458726	OR2T12	0.28	7.05	0.32	7.54e-12	Common traits (Other);
LUAD	cis	rs2880765	0.835	rs2170735	chr15:86043485	G/A	cg13263323	chr15:86062960	AKAP13	-0.5	-9.26	-0.41	1.07e-18	Coronary artery disease;
LUAD	trans	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg01620082	chr3:125678407	NA	-1.02	-8.12	-0.37	5.07e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2455799	0.613	rs4685260	chr3:15832417	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-9.68	-0.43	3.62e-20	Mean platelet volume;
LUAD	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14240646	chr10:27532245	ACBD5	-0.9	-12.47	-0.52	1.35e-30	Breast cancer;
LUAD	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.36	-7.06	-0.32	6.99e-12	Crohn's disease;
LUAD	trans	rs4714291	0.792	rs9471241	chr6:40080211	C/T	cg02267698	chr19:7991119	CTXN1	-0.45	-6.85	-0.32	2.55e-11	Strep throat;
LUAD	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg10755058	chr3:40428713	ENTPD3	-0.44	-8.41	-0.38	6.55e-16	Renal cell carcinoma;
LUAD	cis	rs2046867	0.628	rs7356055	chr3:72912878	A/C	cg04365224	chr3:72788183	NA	-0.41	-6.46	-0.3	2.82e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg17443473	chr1:3703550	LRRC47	0.43	7.47	0.34	4.77e-13	Red cell distribution width;
LUAD	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg24596788	chr1:163392923	NA	0.32	7.41	0.34	7.05e-13	Motion sickness;
LUAD	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg17077180	chr1:38461687	NA	-0.41	-7.87	-0.36	3e-14	Coronary artery disease;
LUAD	cis	rs6076065	0.723	rs2236022	chr20:23373534	G/A	cg11657817	chr20:23433608	CST11	0.48	8.95	0.4	1.12e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-7.13	-0.33	4.4e-12	Triglycerides;
LUAD	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg19041857	chr6:27730383	NA	-0.45	-7.81	-0.35	4.71e-14	Parkinson's disease;
LUAD	cis	rs1950500	1.000	rs12590407	chr14:24835115	A/G	cg22990158	chr14:24802150	ADCY4	0.41	6.75	0.31	4.98e-11	Height;
LUAD	trans	rs7395662	0.963	rs2865923	chr11:48724955	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	2.03e-12	HDL cholesterol;
LUAD	cis	rs4730250	0.707	rs1981696	chr7:106794100	C/T	cg23024343	chr7:107201750	COG5	-0.48	-6.68	-0.31	7.51e-11	Osteoarthritis;
LUAD	cis	rs7666738	0.657	rs13102002	chr4:98617794	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.79	0.35	5.08e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg12623918	chr2:306882	NA	0.36	7.12	0.33	4.63e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg11266682	chr4:10021025	SLC2A9	0.68	15.74	0.61	3.01e-44	Bone mineral density;
LUAD	cis	rs7843479	0.601	rs10101881	chr8:21830158	A/G	cg03445287	chr8:21823731	XPO7	-0.48	-8.89	-0.4	1.77e-17	Mean corpuscular volume;
LUAD	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg17063962	chr7:91808500	NA	0.67	11.95	0.5	1.52e-28	Breast cancer;
LUAD	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg12564285	chr5:131593104	PDLIM4	-0.39	-6.67	-0.31	7.98e-11	Breast cancer;
LUAD	cis	rs9581857	0.725	rs9319366	chr13:28017722	C/T	cg22138327	chr13:27999177	GTF3A	0.9	10.53	0.46	3.61e-23	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21659725	chr3:3221576	CRBN	0.48	7.86	0.36	3.19e-14	Body mass index;
LUAD	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-9.2	-0.41	1.63e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg10544611	chr16:67998164	SLC12A4	-0.67	-7.82	-0.36	4.14e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.72	10.21	0.44	5.23e-22	IgG glycosylation;
LUAD	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.51	-0.42	1.5e-19	Life satisfaction;
LUAD	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	15.49	0.6	3.32e-43	Bone mineral density;
LUAD	cis	rs73198271	0.586	rs3789850	chr8:8686845	G/T	cg01851573	chr8:8652454	MFHAS1	0.39	6.64	0.31	9.41e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2730260	0.578	rs56375711	chr7:158854935	G/A	cg13710308	chr7:158854763	VIPR2	-0.52	-6.45	-0.3	3.1e-10	Myopia (pathological);
LUAD	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg21862992	chr11:68658383	NA	0.52	9.59	0.42	7.86e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs9652601	0.779	rs9929994	chr16:11178245	A/G	cg04616529	chr16:11181986	CLEC16A	0.4	7.18	0.33	3.23e-12	Systemic lupus erythematosus;
LUAD	cis	rs35306767	0.807	rs1013505	chr10:953273	C/T	cg20503657	chr10:835505	NA	0.94	12.77	0.53	7.98e-32	Eosinophil percentage of granulocytes;
LUAD	trans	rs3960554	0.808	rs60481386	chr7:75700962	A/G	cg19862616	chr7:65841803	NCRNA00174	0.83	11.88	0.5	2.81e-28	Eotaxin levels;
LUAD	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg13319975	chr6:146136371	FBXO30	0.58	9.73	0.43	2.62e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg23435118	chr5:141488016	NDFIP1	-0.49	-7.49	-0.34	3.97e-13	Crohn's disease;
LUAD	cis	rs62238980	0.614	rs79807615	chr22:32415867	G/A	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	trans	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg06606381	chr12:133084897	FBRSL1	-1.22	-9.26	-0.41	1.06e-18	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07157834	chr1:205819609	PM20D1	0.72	13.85	0.56	3.06e-36	Menarche (age at onset);
LUAD	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.94	-0.32	1.53e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg20362242	chr5:692897	TPPP	0.56	6.89	0.32	2.02e-11	Lung disease severity in cystic fibrosis;
LUAD	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg12311346	chr5:56204834	C5orf35	-0.57	-9.11	-0.4	3.4e-18	Coronary artery disease;
LUAD	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg23649088	chr2:200775458	C2orf69	0.62	7.77	0.35	5.94e-14	Schizophrenia;
LUAD	cis	rs8017423	0.647	rs4904680	chr14:90822075	C/T	cg14092571	chr14:90743983	NA	0.39	6.53	0.3	1.89e-10	Mortality in heart failure;
LUAD	cis	rs1003719	0.715	rs8129942	chr21:38552070	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.33	-0.38	1.16e-15	Eye color traits;
LUAD	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg09640425	chr7:158790006	NA	-0.53	-9.06	-0.4	4.91e-18	Facial morphology (factor 20);
LUAD	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg03948781	chr1:205179583	DSTYK	-0.34	-6.6	-0.31	1.27e-10	Red blood cell count;
LUAD	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg18854424	chr1:2615690	NA	-0.42	-9.07	-0.4	4.49e-18	Ulcerative colitis;
LUAD	cis	rs17095355	1.000	rs7067604	chr10:111734665	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.69	-8.65	-0.39	1.04e-16	Biliary atresia;
LUAD	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg08742575	chr21:47604166	C21orf56	0.61	10.67	0.46	1.07e-23	Testicular germ cell tumor;
LUAD	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.46	6.92	0.32	1.71e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg24578937	chr1:2090814	PRKCZ	-0.57	-11.31	-0.48	4.3e-26	Height;
LUAD	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-20.27	-0.7	2.43e-64	Coronary artery disease;
LUAD	cis	rs877529	0.625	rs139390	chr22:39532853	A/G	cg18708252	chr22:39545030	CBX7	-0.3	-6.37	-0.3	4.87e-10	Multiple myeloma;
LUAD	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg07404485	chr7:94953653	PON1	-0.48	-6.68	-0.31	7.33e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22857025	chr5:266934	NA	-0.97	-14.64	-0.58	1.49e-39	Breast cancer;
LUAD	cis	rs2979489	0.786	rs62508366	chr8:30369499	G/A	cg26383811	chr8:30366931	RBPMS	-0.7	-10.76	-0.46	4.78e-24	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs9925964	0.933	rs4889530	chr16:31065918	T/A	cg03418659	chr16:31128414	MYST1	0.4	7.05	0.32	7.5e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.56	-0.3	1.59e-10	Breast cancer;
LUAD	cis	rs55788414	0.932	rs55991107	chr16:81181066	G/A	cg06400318	chr16:81190750	PKD1L2	-0.72	-8.61	-0.39	1.42e-16	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs17401966	0.894	rs11587309	chr1:10446596	G/T	cg15208524	chr1:10270712	KIF1B	0.44	6.72	0.31	6.06e-11	Hepatocellular carcinoma;
LUAD	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.56	-0.35	2.48e-13	Lung cancer;
LUAD	cis	rs10992471	0.528	rs4744133	chr9:95226702	C/T	cg14631576	chr9:95140430	CENPP	-0.5	-10.27	-0.45	3.17e-22	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg03209412	chr4:183728196	NA	0.78	11.25	0.48	7.16e-26	Pediatric autoimmune diseases;
LUAD	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg22117172	chr7:91764530	CYP51A1	-0.33	-7.43	-0.34	5.87e-13	Breast cancer;
LUAD	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg18755752	chr8:142205143	DENND3	0.44	7.66	0.35	1.28e-13	Immature fraction of reticulocytes;
LUAD	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg23803603	chr1:2058230	PRKCZ	0.41	6.66	0.31	8.68e-11	Height;
LUAD	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg12310025	chr6:25882481	NA	-0.59	-9.64	-0.42	5.12e-20	Blood metabolite levels;
LUAD	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.31	-6.71	-0.31	6.27e-11	Height;
LUAD	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15369054	chr17:80825471	TBCD	0.67	11.11	0.48	2.56e-25	Breast cancer;
LUAD	cis	rs7089973	0.872	rs10490908	chr10:116616162	T/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.8	0.43	1.46e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg06558623	chr16:89946397	TCF25	1.12	9.76	0.43	2.05e-20	Skin colour saturation;
LUAD	cis	rs7843479	0.965	rs13269198	chr8:21823025	G/A	cg03445287	chr8:21823731	XPO7	-0.46	-8.48	-0.38	3.86e-16	Mean corpuscular volume;
LUAD	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.42	-0.3	3.6e-10	Neuroticism;
LUAD	cis	rs9487051	0.502	rs9386781	chr6:109584520	G/A	cg01475377	chr6:109611718	NA	-0.36	-6.38	-0.3	4.56e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg16006841	chr5:176797999	RGS14	0.6	9.11	0.4	3.4e-18	Urate levels in lean individuals;
LUAD	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg25588787	chr5:154027256	NA	0.48	6.44	0.3	3.21e-10	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg17063962	chr7:91808500	NA	-0.64	-11.07	-0.47	3.36e-25	Breast cancer;
LUAD	cis	rs8177876	0.642	rs10514513	chr16:81114183	C/T	cg08591886	chr16:81111003	C16orf46	-0.77	-7.45	-0.34	5.37e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs11229555	0.598	rs12289876	chr11:58185250	C/T	cg15696309	chr11:58395628	NA	-0.72	-10.13	-0.44	9.44e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg25894440	chr7:65020034	NA	-0.58	-6.71	-0.31	6.21e-11	Diabetic kidney disease;
LUAD	cis	rs4786125	0.587	rs12920700	chr16:6926397	C/T	cg03623568	chr16:6915990	A2BP1	-0.45	-9.75	-0.43	2.16e-20	Heart rate variability traits (SDNN);
LUAD	trans	rs7679475	0.803	rs691437	chr4:122311738	A/T	cg17945323	chr11:62767406	SLC22A8	0.33	6.38	0.3	4.7e-10	Type 1 diabetes and autoimmune thyroid diseases;
LUAD	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg22482690	chr17:47019901	SNF8	0.44	8.37	0.38	8.71e-16	Type 2 diabetes;
LUAD	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg17971929	chr21:40555470	PSMG1	0.43	6.98	0.32	1.17e-11	Cognitive function;
LUAD	trans	rs7507204	0.530	rs4807469	chr19:3443382	G/C	cg08382705	chr11:45687319	CHST1	-0.44	-7.42	-0.34	6.64e-13	Height;
LUAD	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg03929089	chr4:120376271	NA	0.51	6.67	0.31	8.18e-11	Axial length;
LUAD	cis	rs11671005	0.735	rs3826681	chr19:58918764	A/G	cg13877915	chr19:58951672	ZNF132	0.54	7.14	0.33	4.22e-12	Mean platelet volume;
LUAD	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg17063962	chr7:91808500	NA	0.66	11.25	0.48	7.11e-26	Breast cancer;
LUAD	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg24818145	chr4:99064322	C4orf37	0.46	7.81	0.36	4.53e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg13180566	chr4:1052158	NA	-0.4	-6.72	-0.31	5.87e-11	Recombination rate (females);
LUAD	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15344021	chr17:2240169	TSR1;SGSM2	0.42	6.41	0.3	3.83e-10	Gut microbiome composition (summer);
LUAD	trans	rs8073060	0.586	rs11080356	chr17:33895309	T/C	cg19694781	chr19:47549865	TMEM160	1.21	19.67	0.69	1.2e-61	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.06e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2066819	1.000	rs41363748	chr12:56696056	C/T	cg26714650	chr12:56694279	CS	0.77	6.55	0.3	1.68e-10	Psoriasis vulgaris;
LUAD	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg07256732	chr16:621771	PIGQ	-0.32	-6.5	-0.3	2.31e-10	Height;
LUAD	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.08	0.33	5.99e-12	Platelet count;
LUAD	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.06	-0.32	6.83e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	13.38	0.55	2.71e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.11e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg07741184	chr6:167504864	NA	-0.3	-7.14	-0.33	4e-12	Crohn's disease;
LUAD	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11644478	chr21:40555479	PSMG1	-0.54	-8.73	-0.39	5.78e-17	Cognitive function;
LUAD	cis	rs7187994	0.945	rs16974444	chr16:84753740	T/C	cg07647771	chr16:84786436	USP10	-0.38	-9.67	-0.43	3.97e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg21191810	chr6:118973309	C6orf204	-0.53	-8.18	-0.37	3.41e-15	Diastolic blood pressure;
LUAD	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg08807101	chr21:30365312	RNF160	-0.43	-7.4	-0.34	7.32e-13	Dental caries;
LUAD	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.22	-0.37	2.6e-15	Prostate cancer;
LUAD	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.85	-0.36	3.48e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg09165964	chr15:75287851	SCAMP5	-0.44	-6.59	-0.3	1.34e-10	Blood trace element (Zn levels);
LUAD	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg16479474	chr6:28041457	NA	-0.44	-7.5	-0.34	3.87e-13	Depression;
LUAD	cis	rs10089	0.953	rs10223203	chr5:127527646	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.59	-9.28	-0.41	8.96e-19	Ileal carcinoids;
LUAD	cis	rs3823572	0.564	rs1986870	chr7:133660109	A/G	cg03336402	chr7:133662267	EXOC4	-0.41	-7.59	-0.35	2.08e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-7.87	-0.36	3.03e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	8.28	0.37	1.6e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.69	-12.75	-0.53	1e-31	Ulcerative colitis;
LUAD	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.25	-0.37	2.05e-15	Alzheimer's disease;
LUAD	cis	rs1030268	0.651	rs12707121	chr7:133496379	A/G	cg10665199	chr7:133106180	EXOC4	0.47	6.44	0.3	3.25e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg18180107	chr4:99064573	C4orf37	0.41	6.64	0.31	9.9e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10950821	0.519	rs12667658	chr7:20659545	T/A	cg02470904	chr7:20686108	ABCB5	0.36	6.58	0.3	1.36e-10	Response to statin therapy;
LUAD	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg24531977	chr5:56204891	C5orf35	-0.39	-6.44	-0.3	3.32e-10	Breast cancer;Breast cancer (early onset);
LUAD	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.06	-0.32	7.04e-12	Height;
LUAD	cis	rs9650657	0.707	rs4593498	chr8:10655470	C/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.48	-0.3	2.49e-10	Neuroticism;
LUAD	cis	rs6445967	0.569	rs73081581	chr3:58313077	G/A	cg23715586	chr3:58305044	RPP14	0.4	6.46	0.3	2.8e-10	Platelet count;
LUAD	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24531977	chr5:56204891	C5orf35	-0.85	-13.61	-0.55	3.1e-35	Initial pursuit acceleration;
LUAD	cis	rs4919694	1.000	rs12268849	chr10:104737682	G/A	cg04362960	chr10:104952993	NT5C2	0.72	7.71	0.35	9.29e-14	Arsenic metabolism;
LUAD	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg22875332	chr1:76189707	ACADM	0.84	16.86	0.63	3.81e-49	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9462027	0.585	rs1201873	chr6:34550657	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-8.73	-0.39	5.82e-17	Systemic lupus erythematosus;
LUAD	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg12140854	chr5:148520817	ABLIM3	-0.67	-10.91	-0.47	1.43e-24	Breast cancer;
LUAD	cis	rs7264396	1.000	rs6088881	chr20:34165609	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.42	6.67	0.31	8.16e-11	Total cholesterol levels;
LUAD	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg16850897	chr7:100343110	ZAN	-0.6	-8.17	-0.37	3.71e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.35	6.79	0.31	3.91e-11	Depression;
LUAD	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs494562	1.000	rs495469	chr6:86117025	C/T	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg07936489	chr17:37558343	FBXL20	-0.51	-6.73	-0.31	5.6e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs193541	0.632	rs7735618	chr5:122176245	C/G	cg19077854	chr5:122220652	SNX24	0.37	6.54	0.3	1.77e-10	Glucose homeostasis traits;
LUAD	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg06784218	chr1:46089804	CCDC17	0.5	10.98	0.47	7.71e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.74	13.58	0.55	4.17e-35	Axial length;
LUAD	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg05697835	chr1:2722811	NA	0.32	6.64	0.31	9.49e-11	Ulcerative colitis;
LUAD	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg00717180	chr2:96193071	NA	-0.42	-7.75	-0.35	6.68e-14	HDL cholesterol;
LUAD	cis	rs208520	0.690	rs207102	chr6:66795671	G/A	cg07460842	chr6:66804631	NA	-1.06	-16.63	-0.63	3.97e-48	Exhaled nitric oxide output;
LUAD	cis	rs4790333	0.845	rs7210932	chr17:2272024	A/G	cg02569219	chr17:2266849	SGSM2	-0.7	-14.39	-0.57	1.73e-38	Proinsulin levels;
LUAD	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg11494091	chr17:61959527	GH2	0.74	18.35	0.67	9.02e-56	Prudent dietary pattern;
LUAD	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg23173402	chr1:227635558	NA	0.74	7.94	0.36	1.85e-14	Major depressive disorder;
LUAD	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg15147215	chr3:52552868	STAB1	-0.52	-9.97	-0.44	3.72e-21	Electroencephalogram traits;
LUAD	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08677398	chr8:58056175	NA	0.49	6.87	0.32	2.29e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.62e-10	Aortic root size;
LUAD	cis	rs13095912	0.743	rs13076556	chr3:185339575	A/G	cg11274856	chr3:185301563	NA	0.5	9.58	0.42	8.07e-20	Systolic blood pressure;
LUAD	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg08125733	chr17:73851984	WBP2	0.69	9.89	0.43	6.96e-21	Psoriasis;
LUAD	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18876405	chr7:65276391	NA	0.42	6.7	0.31	6.8e-11	Aortic root size;
LUAD	cis	rs9581857	0.547	rs17753121	chr13:28052613	T/C	cg22138327	chr13:27999177	GTF3A	0.85	9.25	0.41	1.09e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg03929089	chr4:120376271	NA	-0.69	-9.8	-0.43	1.42e-20	Coronary artery disease;
LUAD	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg06558623	chr16:89946397	TCF25	1.14	10.51	0.45	4.18e-23	Skin colour saturation;
LUAD	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg08999081	chr20:33150536	PIGU	-0.37	-7.44	-0.34	5.54e-13	Glomerular filtration rate (creatinine);
LUAD	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg08601574	chr20:25228251	PYGB	0.45	8.39	0.38	7.6e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg05368731	chr17:41323189	NBR1	0.84	16.73	0.63	1.44e-48	Menopause (age at onset);
LUAD	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg05110241	chr16:68378359	PRMT7	-0.81	-8.62	-0.39	1.31e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2652822	0.509	rs7163254	chr15:63439403	G/T	cg25406657	chr15:63342033	TPM1	-0.33	-6.46	-0.3	2.82e-10	Metabolic traits;
LUAD	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg25767906	chr1:53392781	SCP2	0.47	8.6	0.39	1.58e-16	Monocyte count;
LUAD	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.6	-10.31	-0.45	2.26e-22	Lymphocyte counts;
LUAD	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.54	0.42	1.12e-19	Monocyte percentage of white cells;
LUAD	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg12863693	chr15:85201151	NMB	0.4	7.4	0.34	7.56e-13	Schizophrenia;
LUAD	cis	rs9863	0.931	rs34180676	chr12:124431519	C/T	cg17723958	chr12:124429295	CCDC92	-0.41	-6.54	-0.3	1.73e-10	White blood cell count;
LUAD	cis	rs9486719	0.843	rs2499797	chr6:96848669	C/T	cg06623918	chr6:96969491	KIAA0776	0.72	9.66	0.43	4.34e-20	Migraine;Coronary artery disease;
LUAD	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	13.28	0.54	7.04e-34	Prudent dietary pattern;
LUAD	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg14983838	chr19:29218262	NA	0.6	7.67	0.35	1.22e-13	Methadone dose in opioid dependence;
LUAD	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	8.61	0.39	1.47e-16	Lung cancer in ever smokers;
LUAD	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg22676075	chr6:135203613	NA	0.41	7.59	0.35	2.13e-13	Red blood cell count;
LUAD	cis	rs3087591	0.960	rs2905793	chr17:29470072	C/T	cg24425628	chr17:29625626	OMG;NF1	0.42	6.91	0.32	1.76e-11	Hip circumference;
LUAD	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.35	7.01	0.32	9.42e-12	Obesity-related traits;
LUAD	cis	rs240764	0.658	rs12210255	chr6:101187540	G/C	cg09795085	chr6:101329169	ASCC3	-0.48	-8.55	-0.38	2.24e-16	Neuroticism;
LUAD	trans	rs9354308	0.868	rs9345695	chr6:66554270	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.63	-0.31	1.04e-10	Metabolite levels;
LUAD	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.04e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg08847533	chr14:75593920	NEK9	0.39	6.58	0.3	1.41e-10	Height;
LUAD	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg25358565	chr5:93447407	FAM172A	0.65	7.72	0.35	8.67e-14	Diabetic retinopathy;
LUAD	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.49	7.13	0.33	4.24e-12	Total cholesterol levels;
LUAD	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg11833968	chr6:79620685	NA	-0.44	-8.1	-0.37	5.88e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg25482853	chr8:67687455	SGK3	0.71	10.81	0.47	3.34e-24	Obesity-related traits;
LUAD	cis	rs4691139	0.607	rs7684974	chr4:165944299	G/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.39	-7.49	-0.34	4.08e-13	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg19635926	chr16:89946313	TCF25	0.72	6.59	0.31	1.29e-10	Skin colour saturation;
LUAD	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg22920501	chr2:26401640	FAM59B	-0.85	-13.34	-0.54	3.79e-34	Gut microbiome composition (summer);
LUAD	trans	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21582582	chr3:182698605	DCUN1D1	0.47	7.46	0.34	4.82e-13	Body mass index;
LUAD	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.45	-8.01	-0.36	1.09e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg26169700	chr22:42538906	CYP2D7P1	-0.54	-7.03	-0.32	8.36e-12	Birth weight;
LUAD	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg03859395	chr2:55845619	SMEK2	-0.75	-13.95	-0.56	1.19e-36	Metabolic syndrome;
LUAD	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg19622623	chr12:86230825	RASSF9	-0.55	-9.86	-0.43	8.6e-21	Major depressive disorder;
LUAD	cis	rs7291412	1.000	rs7291412	chr22:46459132	G/T	cg05468064	chr22:46423449	NA	0.41	7.76	0.35	6.26e-14	Dupuytren's disease;Subjective well-being;
LUAD	cis	rs4462272	0.675	rs1324692	chr10:101890330	C/G	cg02250046	chr10:101825185	CPN1	-0.34	-6.71	-0.31	6.46e-11	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg03684893	chr10:554711	DIP2C	-0.47	-8.73	-0.39	6e-17	Psychosis in Alzheimer's disease;
LUAD	cis	rs6489882	0.703	rs4767030	chr12:113359577	A/G	cg20102336	chr12:113376681	OAS3	0.49	7.34	0.34	1.13e-12	Chronic lymphocytic leukemia;
LUAD	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg16405210	chr4:1374714	KIAA1530	-0.38	-6.58	-0.3	1.39e-10	Obesity-related traits;
LUAD	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg02176678	chr2:219576539	TTLL4	-0.75	-15.24	-0.6	4.25e-42	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs1997103	1.000	rs6953509	chr7:55412179	G/A	cg20935933	chr6:143382018	AIG1	0.53	7.42	0.34	6.65e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg27170947	chr2:26402098	FAM59B	-0.63	-8.91	-0.4	1.54e-17	Gut microbiome composition (summer);
LUAD	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg20587970	chr11:113659929	NA	-1.38	-20.92	-0.71	3.05e-67	Hip circumference adjusted for BMI;
LUAD	cis	rs7107174	1.000	rs10793304	chr11:78064907	A/G	cg19901956	chr11:77921274	USP35	-0.5	-6.94	-0.32	1.46e-11	Testicular germ cell tumor;
LUAD	cis	rs7903847	0.667	rs7096801	chr10:99140969	T/C	cg20016023	chr10:99160130	RRP12	-0.29	-6.9	-0.32	1.89e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs9324022	0.626	rs10873520	chr14:101175967	G/A	cg18089426	chr14:101175970	NA	0.58	7.83	0.36	3.96e-14	Plateletcrit;
LUAD	cis	rs2274273	0.870	rs17741542	chr14:55805861	A/G	cg04306507	chr14:55594613	LGALS3	-0.42	-8.9	-0.4	1.63e-17	Protein biomarker;
LUAD	cis	rs1372520	0.564	rs2737011	chr4:90746219	T/C	cg15133208	chr4:90757351	SNCA	-0.46	-6.84	-0.32	2.83e-11	Neuroticism;
LUAD	cis	rs1371867	0.810	rs2919470	chr8:101233301	C/A	cg06636551	chr8:101224915	SPAG1	0.4	7.32	0.34	1.3e-12	Atrioventricular conduction;
LUAD	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg15704280	chr7:45808275	SEPT13	0.77	12.6	0.52	3.78e-31	Coronary artery disease;
LUAD	cis	rs12681287	0.640	rs6471314	chr8:87400459	G/A	cg27223183	chr8:87520930	FAM82B	0.69	9.59	0.42	7.91e-20	Caudate activity during reward;
LUAD	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg00383909	chr3:49044727	WDR6	0.76	8.62	0.39	1.32e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs11958404	0.932	rs72816588	chr5:157434390	C/T	cg05962755	chr5:157440814	NA	0.7	9.76	0.43	1.94e-20	IgG glycosylation;
LUAD	cis	rs11696501	0.688	rs6073851	chr20:44306978	C/T	cg11783356	chr20:44313418	WFDC10B	-0.49	-8.19	-0.37	3.09e-15	Brain structure;
LUAD	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-6.6	-0.31	1.24e-10	Personality dimensions;
LUAD	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg08888203	chr3:10149979	C3orf24	0.68	11.59	0.49	3.6e-27	Alzheimer's disease;
LUAD	cis	rs10489202	0.632	rs203781	chr1:167880518	A/C	cg24449463	chr1:168025552	DCAF6	-0.73	-12.11	-0.51	3.62e-29	Schizophrenia;
LUAD	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg09184832	chr6:79620586	NA	-0.51	-9.72	-0.43	2.75e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg26513180	chr16:89883248	FANCA	0.73	6.48	0.3	2.5e-10	Skin colour saturation;
LUAD	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg25985355	chr7:65971099	NA	-0.38	-7.07	-0.32	6.63e-12	Aortic root size;
LUAD	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg02975922	chr3:195473998	MUC4	-0.44	-7.31	-0.33	1.32e-12	Pancreatic cancer;
LUAD	cis	rs7172809	0.561	rs74026923	chr15:77797927	C/T	cg11865553	chr15:77376250	NA	-0.39	-6.57	-0.3	1.48e-10	Glucose homeostasis traits;
LUAD	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg19875535	chr5:140030758	IK	0.43	7.21	0.33	2.59e-12	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs6604026	0.740	rs6700585	chr1:93364156	T/G	cg17283838	chr1:93427260	FAM69A	-0.42	-6.6	-0.31	1.22e-10	Multiple sclerosis;
LUAD	cis	rs2485376	1.000	rs796427	chr10:104066117	C/A	cg20641465	chr10:103991465	PITX3	-0.56	-10.28	-0.45	2.72e-22	QT interval;
LUAD	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg22535103	chr8:58192502	C8orf71	-0.61	-6.66	-0.31	8.29e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.15	0.33	3.78e-12	Motion sickness;
LUAD	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg10755058	chr3:40428713	ENTPD3	0.43	8.38	0.38	7.75e-16	Renal cell carcinoma;
LUAD	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg02880119	chr16:3481970	NA	0.53	7.97	0.36	1.5e-14	Body mass index (adult);
LUAD	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg01448562	chr3:133502909	NA	-0.51	-8.72	-0.39	6.25e-17	Iron status biomarkers;
LUAD	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg13736514	chr6:26305472	NA	-0.7	-13.08	-0.54	4.44e-33	Educational attainment;
LUAD	trans	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg01620082	chr3:125678407	NA	-0.44	-6.48	-0.3	2.55e-10	Depression;
LUAD	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg25566285	chr7:158114605	PTPRN2	0.5	10.38	0.45	1.19e-22	Calcium levels;
LUAD	cis	rs73198271	1.000	rs55971558	chr8:8614403	G/T	cg01851573	chr8:8652454	MFHAS1	0.49	7.63	0.35	1.52e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg04154034	chr17:28927549	LRRC37B2	0.71	6.79	0.31	3.74e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.84	0.43	1.07e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg06713675	chr4:122721982	EXOSC9	0.45	8.4	0.38	6.73e-16	Type 2 diabetes;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03350042	chr15:40733177	BAHD1	-0.61	-7.68	-0.35	1.14e-13	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs243505	0.726	rs734005	chr7:148505864	G/A	cg09806900	chr7:148480153	CUL1	0.47	8.19	0.37	3.18e-15	Inflammatory bowel disease;Crohn's disease;
LUAD	trans	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg08071915	chr8:12219732	FAM66A	0.44	7.32	0.34	1.26e-12	Joint mobility (Beighton score);
LUAD	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.54	-0.34	2.81e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7267979	0.816	rs376742	chr20:25487417	A/C	cg08601574	chr20:25228251	PYGB	0.41	7.62	0.35	1.66e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg07917127	chr4:99064746	C4orf37	0.45	7.54	0.34	2.85e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-9.07	-0.4	4.52e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg17366294	chr4:99064904	C4orf37	0.59	10.01	0.44	2.52e-21	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg11266682	chr4:10021025	SLC2A9	0.6	12.94	0.53	1.75e-32	Bone mineral density;
LUAD	cis	rs454510	1.000	rs454510	chr1:120195042	C/T	cg16322792	chr1:120165303	ZNF697	-0.43	-7.85	-0.36	3.47e-14	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg05340658	chr4:99064831	C4orf37	0.53	8.94	0.4	1.25e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg03467027	chr4:99064603	C4orf37	0.39	6.43	0.3	3.42e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg27124370	chr19:33622961	WDR88	0.43	6.58	0.3	1.39e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg14092988	chr3:52407081	DNAH1	-0.44	-8.68	-0.39	8.78e-17	Bipolar disorder;
LUAD	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg19418458	chr7:158789849	NA	-0.62	-10.94	-0.47	1.08e-24	Facial morphology (factor 20);
LUAD	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg12365402	chr11:9010492	NRIP3	-0.51	-10.35	-0.45	1.61e-22	Hemoglobin concentration;
LUAD	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg14634687	chr17:47094252	IGF2BP1	0.28	6.87	0.32	2.25e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg14983838	chr19:29218262	NA	0.66	9.72	0.43	2.82e-20	Methadone dose in opioid dependence;
LUAD	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg12119029	chr16:89752879	CDK10	0.33	6.67	0.31	8e-11	Vitiligo;
LUAD	cis	rs847851	0.958	rs9380469	chr6:34877314	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.3	-6.6	-0.31	1.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs314370	0.521	rs314308	chr7:100420878	C/T	cg10426581	chr7:100472382	SRRT	0.47	7.35	0.34	1.01e-12	Resting heart rate;
LUAD	cis	rs12912251	0.947	rs12898460	chr15:38986813	C/T	cg01338139	chr15:38987640	C15orf53	-0.62	-9.75	-0.43	2.08e-20	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUAD	cis	rs6495122	0.699	rs34862454	chr15:75101530	C/T	cg14664628	chr15:75095509	CSK	-0.49	-8.08	-0.37	6.8e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUAD	cis	rs11671005	0.735	rs11084544	chr19:58940127	C/G	cg13877915	chr19:58951672	ZNF132	0.52	7.0	0.32	1e-11	Mean platelet volume;
LUAD	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg25024717	chr12:54324583	NA	-0.33	-6.72	-0.31	5.94e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg06028605	chr16:24865363	SLC5A11	-0.4	-6.96	-0.32	1.27e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs420259	0.516	rs11074561	chr16:23495695	C/T	cg00143387	chr16:23521605	GGA2	-0.6	-8.38	-0.38	8.08e-16	Bipolar disorder;
LUAD	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg23711669	chr6:146136114	FBXO30	0.38	6.41	0.3	4e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-9.84	-0.43	1.05e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg23815491	chr16:72088622	HP	0.52	9.67	0.43	3.96e-20	Fibrinogen levels;
LUAD	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg18621852	chr3:10150065	C3orf24	0.45	8.22	0.37	2.6e-15	Alzheimer's disease;
LUAD	cis	rs73198271	0.740	rs1039910	chr8:8648066	T/C	cg01851573	chr8:8652454	MFHAS1	0.49	8.7	0.39	7.61e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg18402987	chr7:1209562	NA	0.78	9.48	0.42	1.89e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.57	-8.65	-0.39	1.09e-16	Ileal carcinoids;
LUAD	cis	rs9309473	0.687	rs7576824	chr2:73611281	C/T	cg20560298	chr2:73613845	ALMS1	0.44	6.94	0.32	1.5e-11	Metabolite levels;
LUAD	cis	rs55823223	0.504	rs56098714	chr17:73860303	T/C	cg04225089	chr17:73874465	TRIM47	-0.39	-6.96	-0.32	1.32e-11	Psoriasis;
LUAD	cis	rs977987	0.843	rs11149824	chr16:75431830	C/G	cg03315344	chr16:75512273	CHST6	0.64	14.02	0.56	5.99e-37	Dupuytren's disease;
LUAD	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.09	23.39	0.75	2.9e-78	Subjective well-being;
LUAD	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.4	-6.5	-0.3	2.27e-10	Fear of minor pain;
LUAD	cis	rs863345	0.604	rs6670343	chr1:158497258	A/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.39	-0.3	4.26e-10	Pneumococcal bacteremia;
LUAD	cis	rs1595825	0.891	rs3851979	chr2:198707638	A/T	cg00982548	chr2:198649783	BOLL	0.65	9.41	0.42	3.33e-19	Ulcerative colitis;
LUAD	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg10645314	chr2:3704589	ALLC	-0.57	-9.12	-0.41	3.12e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg07217954	chr7:1067459	C7orf50	-0.35	-6.45	-0.3	3.09e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs12541635	0.771	rs12155864	chr8:107105491	C/T	cg10147462	chr8:107024639	NA	-0.42	-7.34	-0.34	1.11e-12	Age of smoking initiation;
LUAD	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-8.27	-0.37	1.81e-15	Total body bone mineral density;
LUAD	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg07677032	chr17:61819896	STRADA	0.57	10.53	0.46	3.47e-23	Prudent dietary pattern;
LUAD	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg04025307	chr7:1156635	C7orf50	0.58	8.58	0.39	1.82e-16	Bronchopulmonary dysplasia;
LUAD	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg04944784	chr2:26401820	FAM59B	-0.87	-12.55	-0.52	6.02e-31	Gut microbiome composition (summer);
LUAD	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg08470875	chr2:26401718	FAM59B	0.77	10.37	0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.42	0.38	5.87e-16	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs62103177	0.673	rs4438371	chr18:77615988	C/T	cg05926928	chr17:57297772	GDPD1	0.87	12.3	0.51	6.26e-30	Opioid sensitivity;
LUAD	cis	rs752010	0.841	rs17363834	chr1:42076607	C/T	cg06885757	chr1:42089581	HIVEP3	0.39	8.29	0.37	1.54e-15	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg00666640	chr1:248458726	OR2T12	0.34	8.26	0.37	1.91e-15	Common traits (Other);
LUAD	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg08601574	chr20:25228251	PYGB	0.48	9.0	0.4	7.84e-18	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg06552810	chr11:31128660	NA	-0.34	-6.59	-0.31	1.33e-10	Red blood cell count;
LUAD	cis	rs938554	0.910	rs10010582	chr4:9937085	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-7.06	-0.32	6.99e-12	Blood metabolite levels;
LUAD	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg26513180	chr16:89883248	FANCA	0.78	7.09	0.33	5.51e-12	Skin colour saturation;
LUAD	cis	rs68170813	0.559	rs76933738	chr7:106814574	T/C	cg23024343	chr7:107201750	COG5	0.49	7.08	0.33	5.92e-12	Coronary artery disease;
LUAD	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg10589385	chr1:150898437	SETDB1	0.4	7.53	0.34	3.15e-13	Tonsillectomy;
LUAD	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg15147215	chr3:52552868	STAB1	-0.42	-7.54	-0.34	2.97e-13	Bipolar disorder;
LUAD	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg03433033	chr1:76189801	ACADM	-0.84	-15.54	-0.6	2.11e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg04287289	chr16:89883240	FANCA	0.69	12.6	0.52	4.1e-31	Vitiligo;
LUAD	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg01689657	chr7:91764605	CYP51A1	0.3	7.12	0.33	4.54e-12	Breast cancer;
LUAD	cis	rs3760982	0.813	rs8111664	chr19:44295092	G/A	cg12072164	chr19:44306565	LYPD5	-0.41	-8.03	-0.36	9.82e-15	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.46	-7.64	-0.35	1.52e-13	Longevity;Endometriosis;
LUAD	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg23018236	chr17:30244563	NA	0.59	7.58	0.35	2.17e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg04944784	chr2:26401820	FAM59B	-0.7	-9.93	-0.43	5.07e-21	Gut microbiome composition (summer);
LUAD	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18876405	chr7:65276391	NA	-0.42	-6.73	-0.31	5.65e-11	Aortic root size;
LUAD	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg10755058	chr3:40428713	ENTPD3	0.38	7.38	0.34	8.55e-13	Renal cell carcinoma;
LUAD	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03264133	chr6:25882463	NA	-0.52	-7.59	-0.35	2.02e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.66	0.35	1.3e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910187	0.631	rs62201431	chr20:45810994	G/A	cg27589058	chr20:45804311	EYA2	-0.35	-7.98	-0.36	1.43e-14	Migraine;
LUAD	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg18944383	chr4:111397179	ENPEP	0.37	7.68	0.35	1.12e-13	Height;
LUAD	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.37e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg00631329	chr6:26305371	NA	-0.69	-13.06	-0.54	5.38e-33	Educational attainment;
LUAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg26304593	chr6:42947056	PEX6	-0.47	-8.01	-0.36	1.09e-14	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs3125734	0.633	rs1864836	chr10:64028538	C/G	cg09941381	chr10:64027924	RTKN2	-0.32	-7.62	-0.35	1.64e-13	Rheumatoid arthritis;
LUAD	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg03605463	chr16:89740564	NA	0.66	11.57	0.49	4.51e-27	Vitiligo;
LUAD	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg17644776	chr2:200775616	C2orf69	0.59	9.97	0.44	3.65e-21	Osteoporosis;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg23522862	chr17:79829415	ARHGDIA	-0.43	-6.76	-0.31	4.63e-11	Height;
LUAD	cis	rs1215050	0.874	rs17545594	chr4:98652689	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-6.6	-0.31	1.21e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.57	-7.81	-0.35	4.7e-14	Alzheimer's disease;
LUAD	cis	rs3087591	0.922	rs757383	chr17:29596045	C/G	cg24425628	chr17:29625626	OMG;NF1	0.43	7.01	0.32	9.55e-12	Hip circumference;
LUAD	cis	rs9462027	0.561	rs2814972	chr6:34566975	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.87	-0.4	2.04e-17	Systemic lupus erythematosus;
LUAD	cis	rs2625529	0.526	rs62022789	chr15:72564492	C/T	cg16672083	chr15:72433130	SENP8	0.63	11.55	0.49	5.41e-27	Red blood cell count;
LUAD	cis	rs9644630	0.658	rs4427190	chr8:19321385	C/T	cg06562184	chr8:19319451	CSGALNACT1	-0.39	-7.45	-0.34	5.39e-13	Oropharynx cancer;
LUAD	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg12179176	chr11:130786555	SNX19	0.46	7.67	0.35	1.23e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.73	-0.31	5.6e-11	Morning vs. evening chronotype;
LUAD	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-7.72	-0.35	8.59e-14	Lung cancer;
LUAD	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg18129748	chr3:49941408	MST1R	0.42	6.97	0.32	1.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.07e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03517284	chr6:25882590	NA	-0.58	-9.56	-0.42	1.02e-19	Blood metabolite levels;
LUAD	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg04944784	chr2:26401820	FAM59B	-0.88	-12.58	-0.52	4.91e-31	Gut microbiome composition (summer);
LUAD	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg08085267	chr17:45401833	C17orf57	-0.52	-8.59	-0.39	1.72e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs758324	1.000	rs758324	chr5:131109545	G/T	cg25547332	chr5:131281432	NA	0.45	6.76	0.31	4.47e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	trans	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg14917512	chr19:3094685	GNA11	-0.54	-6.37	-0.3	5.02e-10	Diabetic kidney disease;
LUAD	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-9.24	-0.41	1.25e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1847202	1.000	rs6807627	chr3:72939767	C/T	cg25664220	chr3:72788482	NA	-0.43	-7.96	-0.36	1.55e-14	Motion sickness;
LUAD	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg04800585	chr6:26043546	HIST1H2BB	0.5	8.56	0.38	2.12e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs6840360	0.615	rs12641433	chr4:152607548	A/C	cg22705602	chr4:152727874	NA	-0.49	-9.39	-0.42	3.66e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg06623918	chr6:96969491	KIAA0776	0.69	10.03	0.44	2.2e-21	Migraine;Coronary artery disease;
LUAD	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg17644776	chr2:200775616	C2orf69	-0.37	-6.37	-0.3	5.06e-10	QT interval;
LUAD	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg04772025	chr11:68637568	NA	0.57	8.99	0.4	8.39e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg18834416	chr8:37888184	EIF4EBP1	0.47	7.8	0.35	5.04e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg15123519	chr2:136567270	LCT	0.39	7.08	0.33	5.96e-12	Mosquito bite size;
LUAD	cis	rs4862307	0.754	rs6846007	chr4:184991604	A/G	cg06737308	chr4:185021514	ENPP6	-0.5	-8.22	-0.37	2.55e-15	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs6782228	0.606	rs2712381	chr3:128338600	A/C	cg16766828	chr3:128327626	NA	-0.38	-7.12	-0.33	4.55e-12	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUAD	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg02158880	chr13:53174818	NA	0.58	10.14	0.44	8.8e-22	Lewy body disease;
LUAD	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg22823121	chr1:150693482	HORMAD1	-0.44	-8.88	-0.4	1.85e-17	Tonsillectomy;
LUAD	cis	rs7177699	0.557	rs9920968	chr15:79118747	G/A	cg00540400	chr15:79124168	NA	0.44	9.6	0.42	6.88e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs8060686	0.516	rs9938020	chr16:68251784	C/G	cg26727032	chr16:67993705	SLC12A4	-0.48	-7.8	-0.35	5.04e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9462027	0.628	rs28675115	chr6:34732514	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.84	-0.39	2.55e-17	Systemic lupus erythematosus;
LUAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.65	9.47	0.42	2.02e-19	Alzheimer's disease;
LUAD	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg12419862	chr22:24373484	LOC391322	-0.64	-10.92	-0.47	1.3e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1018836	0.798	rs28568272	chr8:91652958	A/G	cg16814680	chr8:91681699	NA	-0.87	-16.29	-0.62	1.17e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00684032	chr4:1343700	KIAA1530	0.46	7.52	0.34	3.42e-13	Obesity-related traits;
LUAD	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18876405	chr7:65276391	NA	-0.6	-10.05	-0.44	1.85e-21	Aortic root size;
LUAD	trans	rs1464500	0.584	rs10842298	chr12:24406385	C/G	cg10556349	chr10:835070	NA	-0.46	-6.4	-0.3	4.25e-10	Juvenile osteochondritis dissecans;Response to antipsychotic treatment;
LUAD	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg03396347	chr1:1875803	NA	-0.61	-15.8	-0.61	1.6e-44	Body mass index;
LUAD	cis	rs12368653	0.840	rs3816896	chr12:58195773	C/T	cg12615879	chr12:58013172	SLC26A10	0.38	7.74	0.35	7.26e-14	Multiple sclerosis;
LUAD	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.78	0.31	4.12e-11	Parkinson's disease;
LUAD	trans	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg18187862	chr3:45730750	SACM1L	0.54	8.3	0.37	1.43e-15	Primary sclerosing cholangitis;
LUAD	cis	rs1816752	0.870	rs9581027	chr13:24997928	G/A	cg02811702	chr13:24901961	NA	0.41	7.23	0.33	2.24e-12	Obesity-related traits;
LUAD	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg06640241	chr16:89574553	SPG7	0.42	6.6	0.31	1.2e-10	Multiple myeloma (IgH translocation);
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg09193981	chr12:6644606	GAPDH	0.41	6.51	0.3	2.17e-10	Bilirubin levels;
LUAD	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg19761014	chr17:28927070	LRRC37B2	0.79	7.72	0.35	8.74e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg11247378	chr22:39784982	NA	-0.76	-14.21	-0.57	9.75e-38	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-8.24	-0.37	2.17e-15	Alzheimer's disease;
LUAD	cis	rs35883536	0.647	rs7524322	chr1:101047730	C/G	cg06223162	chr1:101003688	GPR88	0.46	8.8	0.39	3.44e-17	Monocyte count;
LUAD	cis	rs7811528	0.656	rs7782028	chr7:2706478	T/C	cg11411865	chr7:2701802	TTYH3	0.53	6.95	0.32	1.37e-11	Schizophrenia;
LUAD	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg13789015	chr9:136890014	NCRNA00094	0.87	15.03	0.59	3.34e-41	Platelet distribution width;
LUAD	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg22117172	chr7:91764530	CYP51A1	0.35	7.9	0.36	2.43e-14	Breast cancer;
LUAD	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg01028140	chr2:1542097	TPO	-0.43	-7.44	-0.34	5.52e-13	IgG glycosylation;
LUAD	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg02734326	chr4:10020555	SLC2A9	0.64	11.35	0.48	3.04e-26	Bone mineral density;
LUAD	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg26516362	chr5:178986906	RUFY1	0.58	10.39	0.45	1.18e-22	Lung cancer;
LUAD	cis	rs4700695	0.764	rs251278	chr5:65381826	G/A	cg21114390	chr5:65439923	SFRS12	-0.63	-8.6	-0.39	1.52e-16	Facial morphology (factor 19);
LUAD	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg22618164	chr12:122356400	WDR66	0.65	11.61	0.49	3.07e-27	Mean corpuscular volume;
LUAD	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg11845111	chr2:191398756	TMEM194B	-0.87	-10.99	-0.47	7.08e-25	Diastolic blood pressure;
LUAD	cis	rs2016266	0.826	rs61928079	chr12:53741468	T/C	cg26875137	chr12:53738046	NA	-0.37	-7.17	-0.33	3.36e-12	Bone mineral density (spine);Bone mineral density;
LUAD	trans	rs12310956	0.510	rs1825903	chr12:33870437	G/C	cg10518543	chr12:38710700	ALG10B	0.39	6.38	0.3	4.55e-10	Morning vs. evening chronotype;
LUAD	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg04155289	chr7:94953770	PON1	-0.56	-7.6	-0.35	1.9e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg12119029	chr16:89752879	CDK10	0.34	7.58	0.35	2.24e-13	Hemoglobin concentration;
LUAD	cis	rs10489202	1.000	rs2420	chr1:167886502	A/T	cg24449463	chr1:168025552	DCAF6	-0.57	-7.34	-0.34	1.09e-12	Schizophrenia;
LUAD	trans	rs208520	0.690	rs851465	chr6:66840293	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-17.37	-0.65	2.04e-51	Exhaled nitric oxide output;
LUAD	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.98	-0.36	1.41e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7617773	0.780	rs7653152	chr3:48362097	G/C	cg11946769	chr3:48343235	NME6	0.44	6.75	0.31	4.91e-11	Coronary artery disease;
LUAD	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg18105134	chr13:113819100	PROZ	-0.85	-14.95	-0.59	7.28e-41	Platelet distribution width;
LUAD	cis	rs9976767	0.637	rs9325635	chr21:43823289	G/A	cg23042151	chr21:43824109	UBASH3A	-0.31	-6.61	-0.31	1.18e-10	Type 1 diabetes;
LUAD	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg04058563	chr4:185651563	MLF1IP	0.41	7.25	0.33	2.04e-12	Kawasaki disease;
LUAD	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg26408565	chr15:76604113	ETFA	-0.46	-7.28	-0.33	1.59e-12	Blood metabolite levels;
LUAD	cis	rs427394	0.593	rs880993	chr5:6732120	C/G	cg12316010	chr5:6737918	POLS	0.39	7.42	0.34	6.45e-13	Menopause (age at onset);
LUAD	trans	rs2262909	0.962	rs4932952	chr19:22246788	G/A	cg17074339	chr11:11642133	GALNTL4	0.47	7.71	0.35	8.79e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg00074818	chr8:8560427	CLDN23	0.62	9.65	0.42	4.95e-20	Obesity-related traits;
LUAD	cis	rs758324	0.773	rs10069521	chr5:131174215	A/G	cg25547332	chr5:131281432	NA	0.42	6.88	0.32	2.11e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg09365446	chr1:150670422	GOLPH3L	0.63	11.18	0.48	1.33e-25	Melanoma;
LUAD	trans	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg14791747	chr16:20752902	THUMPD1	-0.44	-6.67	-0.31	7.8e-11	Pancreatic cancer;
LUAD	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg00071950	chr4:10020882	SLC2A9	0.66	13.21	0.54	1.31e-33	Bone mineral density;
LUAD	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.43	-0.45	7.96e-23	Monocyte percentage of white cells;
LUAD	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg23131131	chr22:24373011	LOC391322	-0.59	-9.83	-0.43	1.11e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg01657329	chr11:68192670	LRP5	-0.54	-9.66	-0.42	4.56e-20	Total body bone mineral density;
LUAD	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg14196790	chr5:131705035	SLC22A5	0.36	6.37	0.3	4.84e-10	Blood metabolite levels;
LUAD	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg14343924	chr8:8086146	FLJ10661	0.46	7.33	0.34	1.14e-12	Joint mobility (Beighton score);
LUAD	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11890956	chr21:40555474	PSMG1	-0.61	-10.0	-0.44	2.72e-21	Cognitive function;
LUAD	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.45	-8.87	-0.4	2.08e-17	Glomerular filtration rate;
LUAD	cis	rs870825	0.698	rs72703549	chr4:185623963	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg17173187	chr15:85201210	NMB	-0.41	-6.62	-0.31	1.08e-10	Schizophrenia;
LUAD	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg26816564	chr1:7831052	VAMP3	-0.62	-8.48	-0.38	3.81e-16	Inflammatory bowel disease;
LUAD	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.76	-0.35	6.28e-14	Prostate cancer;
LUAD	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	7.96	0.36	1.58e-14	Breast cancer;
LUAD	cis	rs4604732	0.588	rs7549495	chr1:247627806	G/A	cg12754571	chr1:247694271	LOC148824;OR2C3	0.44	7.18	0.33	3.06e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs10193935	0.901	rs59984817	chr2:42566909	C/G	cg27598129	chr2:42591480	NA	-0.8	-10.43	-0.45	8.22e-23	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg17264618	chr3:40429014	ENTPD3	0.41	8.84	0.39	2.61e-17	Renal cell carcinoma;
LUAD	cis	rs74181299	0.964	rs2540949	chr2:65284231	A/T	cg05010058	chr2:65284262	CEP68	0.3	6.57	0.3	1.45e-10	Pulse pressure;
LUAD	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg04539111	chr16:67997858	SLC12A4	-0.49	-6.4	-0.3	4.19e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1113500	0.748	rs1781048	chr1:108555050	A/T	cg06207961	chr1:108661230	NA	0.38	6.73	0.31	5.53e-11	Growth-regulated protein alpha levels;
LUAD	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg18129748	chr3:49941408	MST1R	-0.41	-6.58	-0.3	1.39e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs6496044	0.568	rs1982742	chr15:86068750	A/G	cg13263323	chr15:86062960	AKAP13	-0.57	-10.75	-0.46	5.52e-24	Interstitial lung disease;
LUAD	cis	rs9302690	1.000	rs62037143	chr16:57486583	T/C	cg27017172	chr16:57497170	POLR2C	1.2	9.47	0.42	2.03e-19	Blood protein levels;
LUAD	cis	rs7789940	1.000	rs11765693	chr7:75985373	A/G	cg10167463	chr7:75959203	YWHAG	-0.71	-12.9	-0.53	2.54e-32	Multiple sclerosis;
LUAD	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg06641503	chr3:48959341	ARIH2	-0.41	-7.99	-0.36	1.28e-14	Parkinson's disease;
LUAD	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.46	-0.38	4.5e-16	Alzheimer's disease (late onset);
LUAD	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg25036284	chr2:26402008	FAM59B	0.86	11.8	0.5	5.58e-28	Gut microbiome composition (summer);
LUAD	cis	rs250677	0.522	rs55732303	chr5:148392538	C/T	cg18129178	chr5:148520854	ABLIM3	-0.54	-8.07	-0.37	7.35e-15	Breast cancer;
LUAD	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg17747265	chr1:1875780	NA	-0.76	-19.19	-0.68	1.73e-59	Body mass index;
LUAD	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg03959625	chr15:84868606	LOC388152	0.41	6.68	0.31	7.42e-11	Schizophrenia;
LUAD	trans	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg18335740	chr13:41363409	SLC25A15	-0.45	-7.68	-0.35	1.14e-13	Lewy body disease;
LUAD	cis	rs748404	0.578	rs576557	chr15:43597737	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	7.17	0.33	3.43e-12	Lung cancer;
LUAD	cis	rs12286929	0.610	rs12807135	chr11:115053508	G/C	cg04055981	chr11:115044050	NA	0.48	8.81	0.39	3.29e-17	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg02880119	chr16:3481970	NA	0.53	7.85	0.36	3.35e-14	Body mass index (adult);
LUAD	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	8.37	0.38	8.44e-16	Schizophrenia;
LUAD	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg04414720	chr1:150670196	GOLPH3L	0.6	10.27	0.45	2.97e-22	Melanoma;
LUAD	trans	rs11650494	0.908	rs73324308	chr17:47405338	T/G	cg11430096	chr6:110968061	CDK19	0.87	6.76	0.31	4.51e-11	Prostate cancer;
LUAD	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg06784218	chr1:46089804	CCDC17	0.59	13.35	0.54	3.53e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg04025307	chr7:1156635	C7orf50	0.7	12.68	0.52	1.95e-31	Longevity;Endometriosis;
LUAD	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg06873352	chr17:61820015	STRADA	0.41	6.85	0.32	2.65e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs7336332	0.598	rs7669	chr13:28009851	C/T	cg22138327	chr13:27999177	GTF3A	0.82	10.41	0.45	9.83e-23	Weight;
LUAD	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg21963583	chr11:68658836	MRPL21	0.61	10.83	0.47	2.81e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3806843	0.547	rs246033	chr5:140332115	A/C	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.41	-0.3	3.86e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1524976	0.708	rs34835630	chr3:65524650	T/C	cg16238336	chr3:65465873	MAGI1	-0.63	-6.63	-0.31	9.96e-11	PR interval;
LUAD	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg03526459	chr1:146549940	NA	-0.36	-7.52	-0.34	3.26e-13	HIV-1 control;
LUAD	cis	rs1403694	0.966	rs1648715	chr3:186439618	A/G	cg12454167	chr3:186435060	KNG1	0.42	8.85	0.4	2.46e-17	Blood protein levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20257372	chr17:1945152	OVCA2;DPH1	-0.44	-6.69	-0.31	7.08e-11	Height;
LUAD	trans	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg21153622	chr11:89784906	NA	-0.34	-6.66	-0.31	8.56e-11	Height;
LUAD	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.43	-7.65	-0.35	1.39e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08859206	chr1:53392774	SCP2	-0.75	-14.35	-0.57	2.56e-38	Monocyte count;
LUAD	cis	rs1461503	0.934	rs930982	chr11:122834378	C/T	cg27398637	chr11:122830231	C11orf63	-0.33	-6.48	-0.3	2.57e-10	Menarche (age at onset);
LUAD	cis	rs7107174	0.892	rs2512519	chr11:77953015	C/T	cg19901956	chr11:77921274	USP35	-0.56	-7.03	-0.32	8.44e-12	Testicular germ cell tumor;
LUAD	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg02160872	chr5:212506	CCDC127	-0.51	-6.61	-0.31	1.16e-10	Breast cancer;
LUAD	cis	rs2692947	0.637	rs1168967	chr2:96826016	A/G	cg23100626	chr2:96804247	ASTL	0.35	9.48	0.42	1.88e-19	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg03433033	chr1:76189801	ACADM	0.94	19.27	0.68	7.31e-60	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg23625390	chr15:77176239	SCAPER	0.39	7.09	0.33	5.79e-12	Blood metabolite levels;
LUAD	cis	rs7731657	0.537	rs4235804	chr5:130358417	C/G	cg08523029	chr5:130500466	HINT1	0.57	7.51	0.34	3.63e-13	Fasting plasma glucose;
LUAD	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.2	-0.51	1.59e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1595825	0.891	rs892513	chr2:198905874	A/G	cg11031976	chr2:198649780	BOLL	0.46	6.78	0.31	3.95e-11	Ulcerative colitis;
LUAD	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-8.06	-0.36	7.74e-15	Prostate cancer;
LUAD	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg15445000	chr17:37608096	MED1	0.44	8.17	0.37	3.55e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs2996428	0.561	rs2275833	chr1:3745721	C/T	cg23277830	chr1:3704460	LRRC47	0.42	8.79	0.39	3.85e-17	Red cell distribution width;
LUAD	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg16325326	chr1:53192061	ZYG11B	-0.74	-14.45	-0.57	9.57e-39	Monocyte count;
LUAD	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg26597838	chr10:835615	NA	0.82	12.79	0.53	6.58e-32	Eosinophil percentage of granulocytes;
LUAD	trans	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg11693508	chr17:37793320	STARD3	0.72	9.49	0.42	1.65e-19	Bipolar disorder;
LUAD	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg26597838	chr10:835615	NA	0.82	11.19	0.48	1.23e-25	Eosinophil percentage of granulocytes;
LUAD	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg09650180	chr20:62225654	GMEB2	-0.48	-6.79	-0.31	3.71e-11	Glioblastoma;
LUAD	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg07936489	chr17:37558343	FBXL20	0.44	6.77	0.31	4.39e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg11494091	chr17:61959527	GH2	0.45	8.12	0.37	5.21e-15	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs536477	0.542	rs10495447	chr1:240051340	C/T	cg05793020	chr20:43374889	KCNK15	-0.46	-6.55	-0.3	1.7e-10	Venous thromboembolism (SNP x SNP interaction);
LUAD	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg01028140	chr2:1542097	TPO	-0.5	-6.86	-0.32	2.52e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg08027265	chr7:2291960	NA	-0.42	-7.02	-0.32	8.75e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	8.98	0.4	9.32e-18	Alzheimer's disease;
LUAD	trans	rs670292	0.875	rs7757225	chr6:150705173	C/T	cg23957424	chr11:36532056	TRAF6	0.39	6.66	0.31	8.76e-11	Anger;
LUAD	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.38	0.52	2.93e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18876405	chr7:65276391	NA	0.42	6.5	0.3	2.21e-10	Aortic root size;
LUAD	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg10591111	chr5:226296	SDHA	-0.55	-7.16	-0.33	3.59e-12	Breast cancer;
LUAD	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg08999081	chr20:33150536	PIGU	0.53	11.23	0.48	8.56e-26	Coronary artery disease;
LUAD	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg00701064	chr4:6280414	WFS1	0.68	15.16	0.59	8.65e-42	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11890956	chr21:40555474	PSMG1	0.78	13.61	0.55	2.96e-35	Cognitive function;
LUAD	cis	rs10489202	0.632	rs203781	chr1:167880518	A/C	cg25738037	chr1:168025549	DCAF6	-0.48	-7.14	-0.33	4.04e-12	Schizophrenia;
LUAD	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg11247378	chr22:39784982	NA	-0.62	-9.57	-0.42	9.12e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs2882667	0.931	rs6596457	chr5:138323379	T/C	cg04439458	chr5:138467593	SIL1	-0.39	-7.14	-0.33	4.15e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.59	0.31	1.3e-10	Depression;
LUAD	trans	rs11039798	1.000	rs12223271	chr11:48417420	G/C	cg15704280	chr7:45808275	SEPT13	0.63	7.5	0.34	3.88e-13	Axial length;
LUAD	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg13560548	chr3:10150139	C3orf24	0.4	6.56	0.3	1.53e-10	Alzheimer's disease;
LUAD	cis	rs3823572	0.564	rs6949760	chr7:133676101	C/A	cg03336402	chr7:133662267	EXOC4	-0.43	-7.37	-0.34	8.84e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg09873201	chr16:3507582	NAT15	-0.53	-7.83	-0.36	3.85e-14	Tuberculosis;
LUAD	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg02527881	chr3:46936655	PTH1R	-0.75	-18.01	-0.66	3.17e-54	Birth weight;
LUAD	trans	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg11693508	chr17:37793320	STARD3	0.7	9.32	0.41	6.75e-19	Bipolar disorder;
LUAD	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg00981070	chr1:2046702	PRKCZ	0.36	6.97	0.32	1.25e-11	Height;
LUAD	cis	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.4	-7.77	-0.35	6.07e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg01765077	chr12:122356316	WDR66	0.5	8.65	0.39	1.09e-16	Mean corpuscular volume;
LUAD	cis	rs7737355	1.000	rs12719444	chr5:130607378	C/T	cg06307176	chr5:131281290	NA	0.45	7.16	0.33	3.59e-12	Life satisfaction;
LUAD	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg02734326	chr4:10020555	SLC2A9	0.44	7.28	0.33	1.6e-12	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg15128208	chr22:42549153	NA	-0.43	-8.84	-0.39	2.57e-17	Cognitive function;
LUAD	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg02018176	chr4:1364513	KIAA1530	0.42	7.66	0.35	1.26e-13	Longevity;
LUAD	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg17105886	chr17:28927953	LRRC37B2	0.78	7.79	0.35	5.26e-14	Body mass index;
LUAD	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg25894440	chr7:65020034	NA	-0.67	-7.18	-0.33	3.06e-12	Diabetic kidney disease;
LUAD	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg20607798	chr8:58055168	NA	-0.55	-7.25	-0.33	2.02e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7508679	1.000	rs7248104	chr19:7224431	A/G	cg00428638	chr19:7224713	INSR	0.75	16.07	0.62	1.05e-45	Hypothyroidism;
LUAD	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg15997130	chr1:24165203	NA	0.54	9.28	0.41	8.71e-19	Immature fraction of reticulocytes;
LUAD	cis	rs9549328	0.700	rs4907570	chr13:113617651	T/C	cg17524180	chr13:113633600	MCF2L	0.31	6.61	0.31	1.16e-10	Systolic blood pressure;
LUAD	trans	rs7395662	0.655	rs2202458	chr11:48856547	T/G	cg15704280	chr7:45808275	SEPT13	0.41	6.42	0.3	3.56e-10	HDL cholesterol;
LUAD	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg21475434	chr5:93447410	FAM172A	0.74	8.4	0.38	6.64e-16	Diabetic retinopathy;
LUAD	trans	rs9393777	0.920	rs67859638	chr6:27357978	A/G	cg06606381	chr12:133084897	FBRSL1	-1.25	-10.89	-0.47	1.64e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-6.5	-0.3	2.29e-10	Alzheimer's disease (late onset);
LUAD	cis	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg21775007	chr8:11205619	TDH	-0.49	-8.84	-0.39	2.69e-17	Retinal vascular caliber;
LUAD	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg02931644	chr1:25747376	RHCE	-0.43	-9.08	-0.4	4.09e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs68170813	0.559	rs76534758	chr7:106963262	T/C	cg23024343	chr7:107201750	COG5	0.45	6.43	0.3	3.45e-10	Coronary artery disease;
LUAD	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg06623918	chr6:96969491	KIAA0776	-0.83	-15.36	-0.6	1.22e-42	Headache;
LUAD	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs151234	0.741	rs10521145	chr16:28596884	A/G	cg04609801	chr16:28609176	SULT1A2	-0.58	-8.82	-0.39	2.98e-17	Platelet distribution width;
LUAD	cis	rs9341808	0.718	rs9361584	chr6:80819946	G/C	cg08355045	chr6:80787529	NA	0.56	10.04	0.44	2.04e-21	Sitting height ratio;
LUAD	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-7.61	-0.35	1.85e-13	Heart rate;
LUAD	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03264133	chr6:25882463	NA	0.58	9.76	0.43	1.94e-20	Blood metabolite levels;
LUAD	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03264133	chr6:25882463	NA	-0.48	-7.12	-0.33	4.53e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg17366294	chr4:99064904	C4orf37	0.6	10.26	0.45	3.38e-22	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2625529	1.000	rs2625529	chr15:72118777	C/G	cg16672083	chr15:72433130	SENP8	0.62	10.36	0.45	1.47e-22	Red blood cell count;
LUAD	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.44	-0.42	2.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg01028140	chr2:1542097	TPO	-0.52	-6.91	-0.32	1.83e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg25753631	chr6:25732923	NA	-0.47	-7.99	-0.36	1.29e-14	Iron status biomarkers;
LUAD	cis	rs2692947	0.770	rs72823920	chr2:96430876	G/A	cg23100626	chr2:96804247	ASTL	0.32	7.81	0.36	4.54e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg13010199	chr12:38710504	ALG10B	0.39	6.38	0.3	4.68e-10	Bladder cancer;
LUAD	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg09904177	chr6:26538194	HMGN4	0.44	7.36	0.34	9.81e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6138458	0.585	rs1007881	chr20:25014385	A/G	cg26195577	chr20:24973756	C20orf3	0.72	12.11	0.51	3.46e-29	Blood protein levels;
LUAD	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg12311346	chr5:56204834	C5orf35	0.42	6.91	0.32	1.84e-11	Breast cancer;Breast cancer (early onset);
LUAD	cis	rs10733682	0.715	rs3814119	chr9:129462901	A/G	cg00232160	chr9:129468157	NA	0.47	8.55	0.38	2.23e-16	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg18252515	chr7:66147081	NA	0.61	6.61	0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg15541040	chr2:3486749	NA	-0.45	-7.63	-0.35	1.56e-13	Neurofibrillary tangles;
LUAD	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg12740337	chr6:28058973	ZSCAN12L1	0.34	6.4	0.3	4.24e-10	Lung cancer in ever smokers;
LUAD	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg23583168	chr7:148888333	NA	-0.8	-13.44	-0.55	1.56e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs754466	0.724	rs11002318	chr10:79633807	G/A	cg17075019	chr10:79541650	NA	-0.86	-17.67	-0.65	9.83e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg10596483	chr8:143751796	JRK	0.45	7.2	0.33	2.83e-12	Schizophrenia;
LUAD	cis	rs673604	0.881	rs11264118	chr1:35676453	A/T	cg12633102	chr1:35676489	NA	-0.72	-10.08	-0.44	1.49e-21	Endometrial cancer;
LUAD	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg05064044	chr6:292385	DUSP22	-0.8	-13.63	-0.55	2.44e-35	Menopause (age at onset);
LUAD	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg03651054	chr13:50194643	NA	0.39	7.98	0.36	1.36e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.47	2.75e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg05340658	chr4:99064831	C4orf37	0.56	9.63	0.42	5.44e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg08773314	chr2:239334832	ASB1	0.45	10.29	0.45	2.59e-22	Multiple system atrophy;
LUAD	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.83	0.32	2.93e-11	Colorectal cancer;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg20760063	chr17:41277580	NBR2;BRCA1	-0.42	-7.05	-0.32	7.13e-12	Subcortical brain region volumes;
LUAD	cis	rs73086581	1.000	rs17287486	chr20:3946267	T/C	cg02187196	chr20:3869020	PANK2	0.46	6.49	0.3	2.34e-10	Response to antidepressants in depression;
LUAD	trans	rs11039798	1.000	rs7125913	chr11:48984318	G/A	cg15704280	chr7:45808275	SEPT13	0.66	7.61	0.35	1.84e-13	Axial length;
LUAD	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23583168	chr7:148888333	NA	-0.92	-18.98	-0.68	1.44e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg21220214	chr8:57350948	NA	-0.59	-8.73	-0.39	6.17e-17	Obesity-related traits;
LUAD	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg26441486	chr22:50317300	CRELD2	0.43	6.44	0.3	3.27e-10	Schizophrenia;
LUAD	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.52	7.12	0.33	4.75e-12	Platelet count;
LUAD	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg06873352	chr17:61820015	STRADA	0.4	6.87	0.32	2.35e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03264133	chr6:25882463	NA	-0.55	-8.01	-0.36	1.15e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg15782153	chr7:917662	C7orf20	0.69	13.23	0.54	1.13e-33	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg10589385	chr1:150898437	SETDB1	0.4	7.65	0.35	1.34e-13	Melanoma;
LUAD	cis	rs7116495	1.000	rs2511075	chr11:71780257	T/C	cg07596299	chr11:71824057	C11orf51	-0.76	-6.44	-0.3	3.23e-10	Severe influenza A (H1N1) infection;
LUAD	cis	rs1497828	0.956	rs2646820	chr1:217526479	A/T	cg04411442	chr1:217543379	NA	-0.38	-6.91	-0.32	1.78e-11	Dialysis-related mortality;
LUAD	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg21770322	chr7:97807741	LMTK2	0.34	7.86	0.36	3.3e-14	Breast cancer;
LUAD	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg02951883	chr7:2050386	MAD1L1	-0.84	-14.47	-0.58	7.94e-39	Bipolar disorder and schizophrenia;
LUAD	cis	rs4588572	0.643	rs6453391	chr5:77755035	T/C	cg11547950	chr5:77652471	NA	-0.78	-12.53	-0.52	7.2e-31	Triglycerides;
LUAD	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg17177755	chr1:15930204	NA	0.46	7.36	0.34	9.36e-13	Systolic blood pressure;
LUAD	cis	rs4006360	0.646	rs3843966	chr17:39250840	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.37	8.27	0.37	1.8e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs7009516	0.625	rs3765124	chr8:24261526	A/G	cg01759110	chr8:24241694	ADAMDEC1	-0.43	-8.61	-0.39	1.51e-16	Hair greying;
LUAD	cis	rs7166081	0.672	rs12441715	chr15:67860587	G/A	cg27219399	chr15:67835830	MAP2K5	0.43	7.58	0.35	2.14e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg00040446	chr1:40367965	MYCL1	-0.54	-6.59	-0.31	1.29e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg27532560	chr4:187881888	NA	0.34	6.48	0.3	2.52e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08109568	chr15:31115862	NA	-0.67	-11.03	-0.47	4.98e-25	Huntington's disease progression;
LUAD	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg21782813	chr7:2030301	MAD1L1	-0.48	-8.4	-0.38	6.79e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs977987	0.806	rs11643410	chr16:75428306	C/T	cg03315344	chr16:75512273	CHST6	0.64	13.99	0.56	8.36e-37	Dupuytren's disease;
LUAD	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg27284194	chr4:1044797	NA	0.7	10.13	0.44	9.73e-22	Recombination rate (females);
LUAD	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg15369054	chr17:80825471	TBCD	0.57	6.52	0.3	1.95e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUAD	cis	rs7680126	0.500	rs4697935	chr4:10149593	C/T	cg00071950	chr4:10020882	SLC2A9	-0.57	-8.25	-0.37	1.96e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg07917127	chr4:99064746	C4orf37	0.4	6.62	0.31	1.09e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg14917512	chr19:3094685	GNA11	-0.54	-6.52	-0.3	2.03e-10	Diabetic kidney disease;
LUAD	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg10426581	chr7:100472382	SRRT	0.76	10.04	0.44	1.99e-21	Resting heart rate;
LUAD	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg04731861	chr2:219085781	ARPC2	0.23	7.05	0.32	7.52e-12	Colorectal cancer;
LUAD	cis	rs9469913	0.799	rs2815005	chr6:34638847	G/A	cg14254433	chr6:34482411	PACSIN1	-0.43	-6.79	-0.31	3.88e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs6545883	0.862	rs778141	chr2:61682178	A/G	cg15711740	chr2:61764176	XPO1	-0.41	-6.53	-0.3	1.84e-10	Tuberculosis;
LUAD	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg16479474	chr6:28041457	NA	0.41	6.59	0.31	1.32e-10	Depression;
LUAD	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.68	-11.4	-0.48	2e-26	Primary sclerosing cholangitis;
LUAD	cis	rs9322817	0.691	rs4299867	chr6:105325383	G/C	cg02098413	chr6:105308735	HACE1	0.4	8.75	0.39	5.07e-17	Thyroid stimulating hormone;
LUAD	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg02569458	chr12:86230093	RASSF9	0.35	6.65	0.31	9.12e-11	Major depressive disorder;
LUAD	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	12.38	0.52	2.85e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9487051	0.768	rs371960	chr6:109525082	A/G	cg01475377	chr6:109611718	NA	-0.38	-6.99	-0.32	1.07e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs76878669	0.538	rs1785633	chr11:66107527	C/A	cg18002602	chr11:66138449	SLC29A2	0.46	10.02	0.44	2.47e-21	Educational attainment (years of education);
LUAD	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	10.99	0.47	6.97e-25	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs9902453	0.904	rs4375718	chr17:28363642	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-10.85	-0.47	2.38e-24	Coffee consumption (cups per day);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg21774377	chr6:34760070	UHRF1BP1	-0.42	-6.7	-0.31	6.54e-11	Height;
LUAD	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg00277334	chr10:82204260	NA	-0.63	-9.95	-0.44	4.34e-21	Post bronchodilator FEV1;
LUAD	cis	rs9837602	1.000	rs9833980	chr3:99767096	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.97	-0.32	1.25e-11	Breast cancer;
LUAD	cis	rs2274273	0.868	rs9919926	chr14:55813890	G/C	cg04306507	chr14:55594613	LGALS3	0.43	8.98	0.4	9e-18	Protein biomarker;
LUAD	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01570182	chr17:44337453	NA	0.78	12.61	0.52	3.74e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.32	1.85e-11	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs4811340	0.600	rs2207195	chr20:51182264	G/T	cg03219697	chr8:145653915	VPS28	0.39	6.59	0.31	1.28e-10	Thyroid peroxidase antibody positivity;
LUAD	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05901451	chr6:126070800	HEY2	0.74	13.27	0.54	7.41e-34	Brugada syndrome;
LUAD	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26314531	chr2:26401878	FAM59B	0.75	10.73	0.46	6.7e-24	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg08219700	chr8:58056026	NA	0.54	7.79	0.35	5.22e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg22963979	chr7:1858916	MAD1L1	-0.45	-7.43	-0.34	5.87e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.49	0.42	1.75e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg12292205	chr6:26970375	C6orf41	0.38	6.95	0.32	1.43e-11	Schizophrenia;
LUAD	cis	rs17155006	0.655	rs430995	chr7:107727501	G/T	cg05962710	chr7:107745446	LAMB4	-0.3	-6.41	-0.3	3.88e-10	Pneumococcal bacteremia;
LUAD	cis	rs4006360	0.657	rs12939793	chr17:39233537	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.36	7.82	0.36	4.18e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg14530993	chr4:882597	GAK	0.78	7.9	0.36	2.41e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs12431939	0.947	rs68164178	chr14:51679003	A/C	cg23942311	chr14:51606299	NA	-0.62	-8.61	-0.39	1.49e-16	Cancer;
LUAD	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg13334819	chr7:99746414	C7orf59	-0.63	-9.23	-0.41	1.31e-18	Coronary artery disease;
LUAD	cis	rs17021463	0.872	rs10856909	chr4:95268748	C/G	cg11021082	chr4:95130006	SMARCAD1	0.43	7.6	0.35	1.92e-13	Testicular germ cell tumor;
LUAD	cis	rs9650657	0.740	rs11250077	chr8:10656437	T/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.52	-0.3	1.96e-10	Neuroticism;
LUAD	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.94	-0.44	4.76e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs7709909	0.720	rs6151603	chr5:79960128	G/T	cg24059623	chr5:79951536	MSH3;DHFR	0.5	9.17	0.41	2.11e-18	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg24829409	chr8:58192753	C8orf71	-0.53	-6.79	-0.31	3.89e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg26924012	chr15:45694286	SPATA5L1	1.02	18.92	0.68	2.86e-58	Homoarginine levels;
LUAD	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22307029	chr19:49891270	CCDC155	0.67	9.65	0.42	4.78e-20	Multiple sclerosis;
LUAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.78	-0.35	5.58e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10979	0.557	rs9390120	chr6:143909411	A/G	cg25407410	chr6:143891975	LOC285740	-0.52	-7.32	-0.34	1.26e-12	Hypospadias;
LUAD	cis	rs4774899	0.752	rs2927189	chr15:57390528	G/A	cg14026238	chr15:57616123	NA	0.42	8.01	0.36	1.1e-14	Urinary tract infection frequency;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23879496	chr6:43749477	VEGFA	0.51	6.89	0.32	2.03e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs36051895	0.659	rs12351277	chr9:5061405	A/C	cg02405213	chr9:5042618	JAK2	-0.51	-7.17	-0.33	3.35e-12	Pediatric autoimmune diseases;
LUAD	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg25324976	chr17:61989376	CSHL1	0.34	6.71	0.31	6.34e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg18944383	chr4:111397179	ENPEP	0.38	7.66	0.35	1.24e-13	Height;
LUAD	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg24154853	chr7:158122151	PTPRN2	-0.56	-11.36	-0.48	2.69e-26	Calcium levels;
LUAD	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg13047869	chr3:10149882	C3orf24	0.64	11.02	0.47	5.16e-25	Alzheimer's disease;
LUAD	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg18016565	chr1:150552671	MCL1	0.41	7.51	0.34	3.51e-13	Tonsillectomy;
LUAD	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14159672	chr1:205819179	PM20D1	0.49	7.7	0.35	9.97e-14	Parkinson's disease;
LUAD	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg06547715	chr2:218990976	CXCR2	-0.29	-6.95	-0.32	1.39e-11	Colorectal cancer;
LUAD	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10802521	chr3:52805072	NEK4	-0.62	-11.22	-0.48	9.81e-26	Bipolar disorder;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg08825816	chr14:58666796	ACTR10	-0.42	-6.78	-0.31	4.15e-11	Height;
LUAD	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.11	-0.33	4.89e-12	Bipolar disorder;
LUAD	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg15147215	chr3:52552868	STAB1	-0.38	-6.78	-0.31	4.07e-11	Bipolar disorder;
LUAD	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg23899408	chr19:12877188	HOOK2	0.4	6.55	0.3	1.65e-10	Bipolar disorder;
LUAD	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg09491104	chr22:46646882	C22orf40	-0.59	-7.5	-0.34	3.81e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs72772090	0.539	rs17481856	chr5:96116808	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.28	-0.33	1.63e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs654384	0.966	rs612476	chr7:4165790	G/A	cg26275264	chr7:4183598	SDK1	-0.4	-7.62	-0.35	1.64e-13	Positive affect;
LUAD	cis	rs7582720	0.887	rs72932755	chr2:203673563	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.2	0.41	1.71e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs4953076	0.573	rs2054005	chr2:44401843	C/T	cg04920474	chr2:44395004	PPM1B	0.56	8.7	0.39	7.18e-17	Height;
LUAD	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg04369109	chr6:150039330	LATS1	-0.4	-6.46	-0.3	2.84e-10	Lung cancer;
LUAD	cis	rs7180079	0.620	rs673931	chr15:64814293	G/A	cg08069370	chr15:64387884	SNX1	0.55	6.82	0.31	3.25e-11	Monocyte count;
LUAD	cis	rs12928939	0.517	rs12149307	chr16:71968091	A/C	cg03805757	chr16:71968109	PKD1L3	-0.54	-8.53	-0.38	2.69e-16	Post bronchodilator FEV1;
LUAD	cis	rs7264396	0.561	rs6058388	chr20:34571846	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.51	-0.3	2.16e-10	Total cholesterol levels;
LUAD	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg12365402	chr11:9010492	NRIP3	0.5	9.63	0.42	5.83e-20	Hemoglobin concentration;
LUAD	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg02176678	chr2:219576539	TTLL4	-0.82	-17.52	-0.65	4.51e-52	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg03929089	chr4:120376271	NA	-1.0	-21.09	-0.72	5.23e-68	Height;
LUAD	trans	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg01620082	chr3:125678407	NA	-0.8	-8.08	-0.37	6.7e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg07362569	chr17:61921086	SMARCD2	0.38	6.68	0.31	7.6e-11	Prudent dietary pattern;
LUAD	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs9535307	0.727	rs7983303	chr13:50358053	T/A	cg04663916	chr13:50265991	EBPL	0.62	7.03	0.32	8.33e-12	Obesity-related traits;
LUAD	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.44	-0.34	5.74e-13	Electroencephalogram traits;
LUAD	cis	rs9948	1.000	rs12172	chr2:97500852	C/G	cg20312557	chr2:97357134	FER1L5	-0.58	-6.74	-0.31	5.33e-11	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11644478	chr21:40555479	PSMG1	0.69	11.37	0.48	2.5e-26	Cognitive function;
LUAD	cis	rs735539	0.598	rs2290144	chr13:21265658	C/G	cg27499820	chr13:21296301	IL17D	0.54	9.05	0.4	5.23e-18	Dental caries;
LUAD	cis	rs870825	0.616	rs4264873	chr4:185624336	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg08213375	chr14:104286397	PPP1R13B	0.27	7.21	0.33	2.58e-12	Schizophrenia;
LUAD	cis	rs8099014	1.000	rs8092072	chr18:56129804	C/T	cg12907477	chr18:56117327	MIR122	0.38	6.47	0.3	2.68e-10	Platelet count;
LUAD	cis	rs4523957	0.928	rs11872068	chr17:2176528	G/A	cg16513277	chr17:2031491	SMG6	-0.78	-14.83	-0.58	2.24e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10979	1.000	rs9399448	chr6:143896315	G/T	cg25407410	chr6:143891975	LOC285740	-0.64	-10.28	-0.45	2.77e-22	Hypospadias;
LUAD	cis	rs13095912	1.000	rs35497918	chr3:185310312	C/T	cg11274856	chr3:185301563	NA	0.37	7.48	0.34	4.47e-13	Systolic blood pressure;
LUAD	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg10589385	chr1:150898437	SETDB1	0.41	7.49	0.34	4.17e-13	Melanoma;
LUAD	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg22705602	chr4:152727874	NA	-0.4	-7.18	-0.33	3.16e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.49	0.3	2.45e-10	Colorectal cancer;
LUAD	trans	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg18187862	chr3:45730750	SACM1L	-0.49	-7.31	-0.33	1.33e-12	Primary sclerosing cholangitis;
LUAD	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg19196401	chr6:110721138	DDO	-0.48	-9.34	-0.41	5.65e-19	Platelet distribution width;
LUAD	cis	rs13082711	0.640	rs66941564	chr3:27259702	C/A	cg02860705	chr3:27208620	NA	0.63	9.63	0.42	5.55e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg08742575	chr21:47604166	C21orf56	-0.56	-9.32	-0.41	6.53e-19	Testicular germ cell tumor;
LUAD	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg27211696	chr2:191398769	TMEM194B	-0.72	-14.97	-0.59	6e-41	Pulse pressure;
LUAD	cis	rs9486719	1.000	rs11152959	chr6:96900272	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.17	-0.44	6.77e-22	Migraine;Coronary artery disease;
LUAD	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg09365446	chr1:150670422	GOLPH3L	0.61	10.88	0.47	1.77e-24	Melanoma;
LUAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg05313129	chr8:58192883	C8orf71	0.55	7.62	0.35	1.72e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs354225	0.544	rs7556752	chr2:54810044	G/C	cg01766943	chr2:54829624	SPTBN1	0.38	7.18	0.33	3.25e-12	Schizophrenia;
LUAD	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg24397884	chr7:158709396	WDR60	0.48	8.21	0.37	2.78e-15	Height;
LUAD	cis	rs62458065	0.513	rs787216	chr7:32578891	G/A	cg20159608	chr7:32802032	NA	-0.7	-10.43	-0.45	7.87e-23	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2979489	0.891	rs2979511	chr8:30394968	G/A	cg26383811	chr8:30366931	RBPMS	-0.69	-10.68	-0.46	9.44e-24	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg07636037	chr3:49044803	WDR6	0.61	11.94	0.5	1.54e-28	Parkinson's disease;
LUAD	cis	rs61884328	0.584	rs74924988	chr11:47279765	G/A	cg13308137	chr11:47528955	CUGBP1	0.46	7.14	0.33	4.17e-12	Total body bone mineral density (age over 60);
LUAD	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.46	-6.96	-0.32	1.33e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg04398451	chr17:18023971	MYO15A	-0.48	-7.65	-0.35	1.36e-13	Total body bone mineral density;
LUAD	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg03929089	chr4:120376271	NA	-0.52	-6.76	-0.31	4.55e-11	Axial length;
LUAD	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-7.44	-0.34	5.74e-13	Personality dimensions;
LUAD	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg12648201	chr2:27665141	KRTCAP3	0.31	7.55	0.34	2.68e-13	Total body bone mineral density;
LUAD	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.46	-0.42	2.1e-19	Life satisfaction;
LUAD	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.48	-8.6	-0.39	1.53e-16	Menarche (age at onset);
LUAD	cis	rs11724804	0.532	rs62295557	chr4:855708	G/A	cg20814179	chr4:940893	TMEM175	0.55	8.41	0.38	6.35e-16	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs11048434	0.698	rs1805784	chr12:9065172	G/T	cg26114124	chr12:9217669	LOC144571	0.36	6.36	0.3	5.09e-10	Sjögren's syndrome;
LUAD	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg03929089	chr4:120376271	NA	-0.92	-17.61	-0.65	1.82e-52	Height;
LUAD	cis	rs8027181	0.839	rs8033073	chr15:73051093	G/A	cg25632853	chr15:73088954	NA	0.32	6.86	0.32	2.44e-11	Triglyceride levels;
LUAD	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg20203395	chr5:56204925	C5orf35	-0.82	-11.8	-0.5	5.55e-28	Initial pursuit acceleration;
LUAD	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-7.3	-0.33	1.41e-12	Morning vs. evening chronotype;
LUAD	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg23982607	chr1:1823379	GNB1	-0.91	-19.3	-0.68	5.21e-60	Body mass index;
LUAD	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs1566497	0.828	rs6822195	chr4:169728142	A/G	cg20607169	chr4:169750834	PALLD	-0.39	-7.26	-0.33	1.91e-12	Pulse pressure;
LUAD	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg03188948	chr7:1209495	NA	0.65	9.32	0.41	6.2800000000000005e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg25985355	chr7:65971099	NA	-0.53	-6.6	-0.31	1.22e-10	Diabetic kidney disease;
LUAD	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25427524	chr10:38739819	LOC399744	-0.74	-13.61	-0.55	3.15e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg09455208	chr3:40491958	NA	0.56	12.55	0.52	6.34e-31	Renal cell carcinoma;
LUAD	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.72	-0.31	6.05e-11	Longevity;
LUAD	cis	rs2455601	0.882	rs11042116	chr11:8928472	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.53	-8.6	-0.39	1.6e-16	Schizophrenia;
LUAD	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg12698349	chr2:225449008	CUL3	0.67	10.16	0.44	7.7e-22	IgE levels in asthmatics (D.p. specific);
LUAD	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg09184832	chr6:79620586	NA	-0.51	-9.74	-0.43	2.34e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.27	-6.61	-0.31	1.17e-10	Coronary artery disease;
LUAD	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05901451	chr6:126070800	HEY2	-0.81	-15.18	-0.59	7.69e-42	Brugada syndrome;
LUAD	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg22117172	chr7:91764530	CYP51A1	0.37	7.84	0.36	3.76e-14	Breast cancer;
LUAD	trans	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg21775007	chr8:11205619	TDH	0.38	6.56	0.3	1.53e-10	Mood instability;
LUAD	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg07917127	chr4:99064746	C4orf37	0.41	6.72	0.31	6.05e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg14895029	chr7:2775587	GNA12	-0.44	-7.41	-0.34	6.73e-13	Height;
LUAD	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	6.87	0.32	2.34e-11	Cognitive test performance;
LUAD	cis	rs7100689	0.784	rs17678947	chr10:82136333	T/C	cg00277334	chr10:82204260	NA	-0.59	-9.4	-0.42	3.39e-19	Post bronchodilator FEV1;
LUAD	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg25817165	chr18:72167213	CNDP2	-0.68	-9.38	-0.41	4.18e-19	Refractive error;
LUAD	cis	rs1448094	1.000	rs10083080	chr12:86348579	G/C	cg00310523	chr12:86230176	RASSF9	0.34	7.08	0.33	6.04e-12	Major depressive disorder;
LUAD	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11644478	chr21:40555479	PSMG1	0.7	11.8	0.5	5.71e-28	Cognitive function;
LUAD	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg04450456	chr4:17643702	FAM184B	0.36	6.82	0.31	3.11e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9863	0.828	rs12311848	chr12:124486851	A/G	cg17723958	chr12:124429295	CCDC92	-0.39	-6.47	-0.3	2.7e-10	White blood cell count;
LUAD	cis	rs7561273	0.586	rs11892283	chr2:24317850	T/C	cg20701182	chr2:24300061	SF3B14	0.52	8.29	0.37	1.52e-15	Quantitative traits;
LUAD	cis	rs7528419	0.895	rs599839	chr1:109822166	A/G	cg00908766	chr1:109817496	CELSR2	-0.64	-12.96	-0.53	1.37e-32	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUAD	cis	rs6594713	0.851	rs6594706	chr5:112693267	T/C	cg12552261	chr5:112820674	MCC	0.49	7.87	0.36	2.96e-14	Brain cytoarchitecture;
LUAD	cis	rs7737355	0.947	rs40400	chr5:130831365	C/T	cg25547332	chr5:131281432	NA	-0.42	-6.5	-0.3	2.29e-10	Life satisfaction;
LUAD	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.47	9.16	0.41	2.27e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1232027	0.616	rs6151619	chr5:79961675	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-6.95	-0.32	1.39e-11	Huntington's disease progression;
LUAD	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg23131131	chr22:24373011	LOC391322	-0.43	-7.26	-0.33	1.88e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg25767906	chr1:53392781	SCP2	0.42	7.72	0.35	8.72e-14	Monocyte count;
LUAD	trans	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg00953403	chr17:74099816	EXOC7	0.51	7.51	0.34	3.64e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg03433033	chr1:76189801	ACADM	0.84	15.23	0.6	4.45e-42	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg22875332	chr1:76189707	ACADM	0.84	16.71	0.63	1.67e-48	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7524258	0.835	rs2412150	chr1:7303343	A/C	cg07173049	chr1:7289937	CAMTA1	0.52	9.93	0.43	4.82e-21	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg22442454	chr1:209979470	IRF6	0.56	7.4	0.34	7.22e-13	Cleft lip with or without cleft palate;
LUAD	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg17971929	chr21:40555470	PSMG1	0.52	8.11	0.37	5.73e-15	Cognitive function;
LUAD	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg00318621	chr2:106887213	NA	-0.44	-6.8	-0.31	3.5e-11	Facial morphology (factor 23);
LUAD	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	-0.31	-6.39	-0.3	4.48e-10	Menopause (age at onset);
LUAD	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg21252483	chr19:49399788	TULP2	-0.7	-11.09	-0.47	2.96e-25	Red cell distribution width;
LUAD	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg27535305	chr1:53392650	SCP2	-0.39	-8.05	-0.36	8.37e-15	Monocyte count;
LUAD	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg26384229	chr12:38710491	ALG10B	0.48	7.79	0.35	5.13e-14	Morning vs. evening chronotype;
LUAD	cis	rs1595825	0.786	rs74652956	chr2:198754247	C/T	cg10547527	chr2:198650123	BOLL	-0.53	-7.64	-0.35	1.45e-13	Ulcerative colitis;
LUAD	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.4	6.7	0.31	6.72e-11	Total body bone mineral density;
LUAD	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg26384229	chr12:38710491	ALG10B	-0.43	-7.28	-0.33	1.67e-12	Morning vs. evening chronotype;
LUAD	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg24163568	chr5:669837	TPPP	-0.37	-7.09	-0.33	5.6e-12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUAD	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg21427119	chr20:30132790	HM13	-0.5	-8.02	-0.36	1.04e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg00701064	chr4:6280414	WFS1	0.65	13.84	0.56	3.26e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg17366294	chr4:99064904	C4orf37	0.66	12.62	0.52	3.36e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1816752	0.905	rs7400631	chr13:24990065	A/G	cg02811702	chr13:24901961	NA	0.41	7.12	0.33	4.73e-12	Obesity-related traits;
LUAD	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg06263672	chr7:65235340	NA	0.46	7.44	0.34	5.72e-13	Aortic root size;
LUAD	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg26384229	chr12:38710491	ALG10B	0.48	7.85	0.36	3.55e-14	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg05340658	chr4:99064831	C4orf37	0.45	6.76	0.31	4.66e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.39	6.38	0.3	4.68e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg18105134	chr13:113819100	PROZ	-0.86	-15.06	-0.59	2.42e-41	Platelet distribution width;
LUAD	cis	rs4660214	0.666	rs588326	chr1:39908726	A/G	cg27567593	chr1:39956653	BMP8A	-0.36	-7.19	-0.33	3e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs11098699	0.784	rs7684146	chr4:124207309	C/A	cg09941581	chr4:124220074	SPATA5	0.49	8.02	0.36	1.05e-14	Mosquito bite size;
LUAD	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.1e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.13	-32.33	-0.84	2.23e-116	Myeloid white cell count;
LUAD	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg25566285	chr7:158114605	PTPRN2	-0.54	-11.59	-0.49	3.61e-27	Calcium levels;
LUAD	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg01475377	chr6:109611718	NA	-0.51	-9.51	-0.42	1.51e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs8177876	0.822	rs9923732	chr16:81110903	A/G	cg08591886	chr16:81111003	C16orf46	-0.77	-7.13	-0.33	4.34e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg25767906	chr1:53392781	SCP2	-0.43	-7.6	-0.35	1.97e-13	Monocyte count;
LUAD	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg03161606	chr19:29218774	NA	0.6	8.67	0.39	9.67e-17	Methadone dose in opioid dependence;
LUAD	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg06640241	chr16:89574553	SPG7	0.72	12.89	0.53	2.75e-32	Multiple myeloma (IgH translocation);
LUAD	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg04234412	chr22:24373322	LOC391322	-0.86	-16.14	-0.62	5.27e-46	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg00684032	chr4:1343700	KIAA1530	0.49	7.75	0.35	7.01e-14	Obesity-related traits;
LUAD	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg25036284	chr2:26402008	FAM59B	-0.58	-8.17	-0.37	3.48e-15	Gut microbiome composition (summer);
LUAD	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg12016809	chr21:47604291	C21orf56	0.48	7.63	0.35	1.59e-13	Testicular germ cell tumor;
LUAD	trans	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg24644049	chr4:85504048	CDS1	0.88	7.12	0.33	4.77e-12	Skin colour saturation;
LUAD	cis	rs68170813	0.559	rs7807648	chr7:106965091	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-9.27	-0.41	9.88e-19	Coronary artery disease;
LUAD	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg15704280	chr7:45808275	SEPT13	-0.77	-11.18	-0.48	1.28e-25	Coronary artery disease;
LUAD	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg08219700	chr8:58056026	NA	0.42	6.35	0.3	5.53e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg22823121	chr1:150693482	HORMAD1	0.4	7.87	0.36	3.06e-14	Tonsillectomy;
LUAD	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg24154853	chr7:158122151	PTPRN2	0.58	11.79	0.5	6.22e-28	Calcium levels;
LUAD	trans	rs8073060	0.963	rs35614987	chr17:33869466	A/C	cg19694781	chr19:47549865	TMEM160	0.79	12.34	0.51	4.46e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg13679303	chr9:96623674	NA	-0.38	-7.6	-0.35	1.91e-13	DNA methylation (variation);
LUAD	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg02017074	chr12:117425053	FBXW8	-0.66	-8.48	-0.38	3.93e-16	Subcortical brain region volumes;Hippocampal volume;
LUAD	cis	rs12545109	0.879	rs1513317	chr8:57372966	C/G	cg17761419	chr8:57350749	NA	-0.59	-8.28	-0.37	1.66e-15	Obesity-related traits;
LUAD	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg06453172	chr10:134556979	INPP5A	-0.65	-9.79	-0.43	1.5e-20	Migraine;
LUAD	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg03733263	chr8:22462867	KIAA1967	-0.74	-12.79	-0.53	6.92e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs1448094	0.617	rs10863162	chr12:86474122	C/T	cg19622623	chr12:86230825	RASSF9	0.41	7.37	0.34	9.12e-13	Major depressive disorder;
LUAD	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05776053	chr2:74358815	NA	0.45	6.92	0.32	1.68e-11	Gestational age at birth (maternal effect);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg22295628	chr17:1733433	RPA1;SMYD4	-0.72	-6.81	-0.31	3.26e-11	Type 2 diabetes;
LUAD	trans	rs12200782	0.932	rs12212145	chr6:26646418	T/A	cg08851530	chr6:28072375	NA	0.71	6.46	0.3	2.85e-10	Small cell lung carcinoma;
LUAD	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg13126279	chr21:47581558	C21orf56	-0.42	-7.33	-0.34	1.14e-12	Testicular germ cell tumor;
LUAD	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg11915388	chr22:42470451	FAM109B	0.41	7.12	0.33	4.61e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.61	-0.31	1.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4950928	0.887	rs7556099	chr1:203166198	C/G	cg17014757	chr1:203156097	CHI3L1	-0.61	-8.73	-0.39	6.05e-17	YKL-40 levels;
LUAD	cis	rs1865721	1.000	rs17283692	chr18:73193911	T/C	cg26385618	chr18:73139727	C18orf62	-0.41	-7.48	-0.34	4.31e-13	Intelligence;
LUAD	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.27	0.41	9.88e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg17845761	chr1:175162550	KIAA0040	0.37	9.7	0.43	3.17e-20	Alcohol dependence;
LUAD	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg25535316	chr11:579198	PHRF1	-0.38	-6.68	-0.31	7.32e-11	Systemic lupus erythematosus;
LUAD	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg25767906	chr1:53392781	SCP2	0.46	8.54	0.38	2.41e-16	Monocyte count;
LUAD	cis	rs9905704	0.681	rs4793949	chr17:56571950	C/T	cg19466818	chr17:56409534	MIR142	-0.35	-7.01	-0.32	9.44e-12	Testicular germ cell tumor;
LUAD	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg00280220	chr17:61926910	NA	0.36	6.8	0.31	3.6e-11	Prudent dietary pattern;
LUAD	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg25985355	chr7:65971099	NA	-0.53	-6.59	-0.31	1.33e-10	Diabetic kidney disease;
LUAD	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg00310523	chr12:86230176	RASSF9	0.41	8.03	0.36	9.78e-15	Major depressive disorder;
LUAD	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg25036284	chr2:26402008	FAM59B	-0.55	-7.83	-0.36	3.98e-14	Gut microbiome composition (summer);
LUAD	cis	rs727505	0.821	rs73225498	chr7:124704197	C/T	cg23710748	chr7:124431027	NA	-0.43	-8.48	-0.38	3.73e-16	Lewy body disease;
LUAD	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10802521	chr3:52805072	NEK4	-0.57	-10.24	-0.45	4.03e-22	Bipolar disorder;
LUAD	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg13319975	chr6:146136371	FBXO30	-0.6	-10.09	-0.44	1.33e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.04	24.1	0.76	2.03e-81	Chronic sinus infection;
LUAD	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.56	0.3	1.57e-10	Depression;
LUAD	cis	rs10203711	1.000	rs12692239	chr2:239553947	T/C	cg14580085	chr2:239553406	NA	0.4	8.5	0.38	3.33e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg22482690	chr17:47019901	SNF8	0.38	7.39	0.34	7.95e-13	Type 2 diabetes;
LUAD	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg19875535	chr5:140030758	IK	0.42	7.04	0.32	7.87e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3823572	0.542	rs2971974	chr7:133644598	C/T	cg03336402	chr7:133662267	EXOC4	0.43	7.85	0.36	3.55e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs9837602	1.000	rs7620228	chr3:99790332	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.46	-6.67	-0.31	7.96e-11	Breast cancer;
LUAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10802521	chr3:52805072	NEK4	-0.5	-8.39	-0.38	7.24e-16	Electroencephalogram traits;
LUAD	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-9.75	-0.43	2.11e-20	Platelet count;
LUAD	trans	rs75804782	0.520	rs72987319	chr2:239351143	C/T	cg01134436	chr17:81009848	B3GNTL1	0.82	8.65	0.39	1.11e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg15501526	chr10:2543763	NA	0.72	14.32	0.57	3.45e-38	Age-related hearing impairment;
LUAD	trans	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg07211511	chr3:129823064	LOC729375	-0.87	-13.19	-0.54	1.55e-33	Blood pressure (smoking interaction);
LUAD	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg03929089	chr4:120376271	NA	0.56	6.99	0.32	1.06e-11	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg17757837	chr7:157058334	UBE3C	0.45	8.11	0.37	5.56e-15	Body mass index;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg24542046	chr7:102782124	NAPEPLD;RPL19P12	0.48	6.51	0.3	2.14e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6881634	0.501	rs12374462	chr5:77737644	G/A	cg11547950	chr5:77652471	NA	-0.35	-6.36	-0.3	5.29e-10	Hippocampal atrophy;
LUAD	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.19	-0.41	1.79e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.67	-0.31	8.19e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg20503657	chr10:835505	NA	0.82	11.16	0.48	1.6e-25	Eosinophil percentage of granulocytes;
LUAD	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg04450456	chr4:17643702	FAM184B	0.4	7.88	0.36	2.75e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg05182265	chr7:156933206	UBE3C	0.74	13.92	0.56	1.56e-36	Body mass index;
LUAD	cis	rs8067545	0.641	rs203455	chr17:19821185	A/G	cg04132472	chr17:19861366	AKAP10	0.39	9.26	0.41	1.02e-18	Schizophrenia;
LUAD	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.41	-18.29	-0.66	1.83e-55	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg06552810	chr11:31128660	NA	-0.33	-6.53	-0.3	1.89e-10	Red blood cell count;
LUAD	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg07537917	chr2:241836409	C2orf54	-0.3	-8.52	-0.38	2.91e-16	Urinary metabolites;
LUAD	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg09835421	chr16:68378352	PRMT7	-0.82	-8.81	-0.39	3.21e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg03806693	chr22:41940476	POLR3H	0.74	9.95	0.44	4.33e-21	Vitiligo;
LUAD	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg20991723	chr1:152506922	NA	0.35	6.93	0.32	1.6e-11	Hair morphology;
LUAD	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg22907277	chr7:1156413	C7orf50	0.58	10.54	0.46	3.14e-23	Longevity;Endometriosis;
LUAD	trans	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg14917512	chr19:3094685	GNA11	-0.54	-6.43	-0.3	3.42e-10	Diabetic kidney disease;
LUAD	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.62	0.31	1.06e-10	Depression;
LUAD	trans	rs9951602	0.512	rs12455591	chr18:76656028	A/G	cg02800362	chr5:177631904	HNRNPAB	0.91	14.42	0.57	1.3e-38	Obesity-related traits;
LUAD	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg02850689	chr1:2391347	NA	-0.38	-8.15	-0.37	4.12e-15	Schizophrenia;
LUAD	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg12035532	chr1:1886765	KIAA1751	0.41	6.79	0.31	3.93e-11	Body mass index;
LUAD	cis	rs12210905	0.688	rs78285097	chr6:27374644	G/C	cg08851530	chr6:28072375	NA	1.09	7.96	0.36	1.6e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs10733682	0.524	rs10987419	chr9:129462594	T/C	cg00232160	chr9:129468157	NA	0.48	8.44	0.38	5.27e-16	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs11195062	0.805	rs10884942	chr10:112016926	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.44	-6.95	-0.32	1.36e-11	Multiple myeloma;
LUAD	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg25358565	chr5:93447407	FAM172A	0.58	6.94	0.32	1.44e-11	Diabetic retinopathy;
LUAD	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg22907277	chr7:1156413	C7orf50	0.48	7.97	0.36	1.47e-14	Longevity;Endometriosis;
LUAD	cis	rs938554	0.784	rs13145758	chr4:9981997	G/A	cg11266682	chr4:10021025	SLC2A9	0.43	7.48	0.34	4.45e-13	Blood metabolite levels;
LUAD	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg05709478	chr1:6581295	PLEKHG5	0.54	7.69	0.35	1.02e-13	Body mass index;
LUAD	cis	rs2446066	0.524	rs7315185	chr12:53924359	T/A	cg20730629	chr12:53886622	MAP3K12	-0.47	-6.75	-0.31	4.76e-11	Red blood cell count;
LUAD	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg08027265	chr7:2291960	NA	-0.4	-6.96	-0.32	1.31e-11	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg27489772	chr12:121021490	NA	-0.55	-6.62	-0.31	1.08e-10	Type 1 diabetes nephropathy;
LUAD	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg04450456	chr4:17643702	FAM184B	0.43	8.49	0.38	3.45e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.66	-0.31	8.63e-11	Diabetic kidney disease;
LUAD	cis	rs6028335	0.610	rs10392	chr20:37550935	C/T	cg27660920	chr20:37554817	FAM83D	0.52	6.96	0.32	1.34e-11	Alcohol and nicotine co-dependence;
LUAD	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg10057126	chr4:77819792	ANKRD56	0.53	9.41	0.42	3.15e-19	Emphysema distribution in smoking;
LUAD	cis	rs12410462	0.901	rs2814090	chr1:227658444	C/G	cg04117972	chr1:227635322	NA	-0.57	-6.42	-0.3	3.77e-10	Major depressive disorder;
LUAD	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg12160578	chr15:63334699	TPM1	0.36	6.62	0.31	1.1e-10	Platelet count;
LUAD	trans	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.58	-10.92	-0.47	1.3e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg08738300	chr3:44038990	NA	-0.44	-6.73	-0.31	5.58e-11	Coronary artery disease;
LUAD	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	7.75	0.35	6.99e-14	Menarche (age at onset);
LUAD	cis	rs2996428	0.643	rs6424056	chr1:3722486	G/A	cg23277830	chr1:3704460	LRRC47	0.45	9.56	0.42	9.86e-20	Red cell distribution width;
LUAD	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg03563238	chr19:33554763	RHPN2	-0.37	-8.58	-0.38	1.84e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18876405	chr7:65276391	NA	-0.42	-6.7	-0.31	6.62e-11	Aortic root size;
LUAD	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg03714773	chr7:91764589	CYP51A1	0.31	7.0	0.32	1.04e-11	Breast cancer;
LUAD	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg20283391	chr11:68216788	NA	-0.41	-6.49	-0.3	2.46e-10	Total body bone mineral density;
LUAD	cis	rs9473147	0.516	rs9463342	chr6:47585106	A/T	cg20196966	chr6:47445060	CD2AP	0.44	7.06	0.32	6.73e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg07917127	chr4:99064746	C4orf37	0.4	6.67	0.31	8.16e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7267979	0.933	rs11699203	chr20:25435169	G/C	cg08601574	chr20:25228251	PYGB	0.47	8.7	0.39	7.19e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	10.21	0.44	5.05e-22	Ileal carcinoids;
LUAD	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg27532560	chr4:187881888	NA	0.35	6.73	0.31	5.68e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg04727924	chr7:799746	HEATR2	-0.57	-7.24	-0.33	2.1e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg07343612	chr16:622815	PIGQ	-0.79	-15.62	-0.6	9.55e-44	Height;
LUAD	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg24818145	chr4:99064322	C4orf37	0.46	7.84	0.36	3.64e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg18932078	chr1:2524107	MMEL1	0.35	6.56	0.3	1.62e-10	Multiple sclerosis;
LUAD	cis	rs733175	0.857	rs7666545	chr4:10012372	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	9.16	0.41	2.22e-18	Psychosis and Alzheimer's disease;
LUAD	cis	rs1448094	1.000	rs4919776	chr12:86353763	T/C	cg02569458	chr12:86230093	RASSF9	0.35	6.64	0.31	9.61e-11	Major depressive disorder;
LUAD	cis	rs6758955	0.850	rs13402238	chr2:10479921	T/C	cg15773312	chr2:10472214	HPCAL1	-0.51	-7.45	-0.34	5.37e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg11494091	chr17:61959527	GH2	0.74	18.59	0.67	7.91e-57	Prudent dietary pattern;
LUAD	cis	rs1697139	0.583	rs6895853	chr5:66541427	T/C	cg11553311	chr5:66541588	NA	0.44	8.25	0.37	2.06e-15	Breast cancer;
LUAD	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg16205897	chr5:131564050	P4HA2	-0.44	-9.78	-0.43	1.72e-20	Blood metabolite levels;
LUAD	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.71	0.39	6.86e-17	Menopause (age at onset);
LUAD	trans	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.4	-0.38	7.05e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg25767906	chr1:53392781	SCP2	0.41	7.53	0.34	3e-13	Monocyte count;
LUAD	cis	rs892961	0.932	rs7216909	chr17:75405234	A/G	cg05865280	chr17:75406074	SEPT9	0.63	19.74	0.69	6.05e-62	Airflow obstruction;
LUAD	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg22681709	chr2:178499509	PDE11A	-0.45	-7.7	-0.35	9.9e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs9535307	0.584	rs61961501	chr13:50392956	A/G	cg04663916	chr13:50265991	EBPL	-0.65	-6.52	-0.3	2.06e-10	Obesity-related traits;
LUAD	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	10.16	0.44	7.45e-22	Lung cancer in ever smokers;
LUAD	cis	rs10489202	0.632	rs202265	chr1:167990231	G/C	cg25738037	chr1:168025549	DCAF6	-0.5	-7.37	-0.34	9.06e-13	Schizophrenia;
LUAD	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg00784671	chr22:46762841	CELSR1	-0.58	-7.51	-0.34	3.57e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg20283391	chr11:68216788	NA	-0.41	-6.46	-0.3	2.88e-10	Total body bone mineral density;
LUAD	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-6.87	-0.32	2.35e-11	Total body bone mineral density;
LUAD	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg00852783	chr1:26633632	UBXN11	0.41	7.13	0.33	4.45e-12	Obesity-related traits;
LUAD	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg18200150	chr17:30822561	MYO1D	0.73	16.06	0.62	1.16e-45	Schizophrenia;
LUAD	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.27	-0.37	1.75e-15	Total body bone mineral density;
LUAD	cis	rs977987	0.815	rs11646677	chr16:75408981	T/C	cg03315344	chr16:75512273	CHST6	0.65	14.08	0.56	3.41e-37	Dupuytren's disease;
LUAD	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg25730555	chr22:47059586	GRAMD4	0.38	6.36	0.3	5.28e-10	Urate levels in obese individuals;
LUAD	cis	rs4743820	0.651	rs73494917	chr9:93923120	T/G	cg14446406	chr9:93919335	NA	0.5	8.35	0.38	9.92e-16	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs938554	0.571	rs4144	chr4:10016322	T/C	cg11266682	chr4:10021025	SLC2A9	0.54	10.08	0.44	1.43e-21	Blood metabolite levels;
LUAD	cis	rs6701037	1.000	rs1057305	chr1:175126223	T/A	cg00321850	chr1:175162397	KIAA0040	-0.51	-10.9	-0.47	1.53e-24	Alcohol dependence;
LUAD	cis	rs8177876	0.658	rs79603321	chr16:81072744	G/A	cg08591886	chr16:81111003	C16orf46	-0.69	-6.58	-0.3	1.37e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs6005807	0.640	rs7289534	chr22:29016057	C/T	cg12565055	chr22:29076175	TTC28	0.75	8.76	0.39	4.71e-17	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs11650494	0.908	rs117853079	chr17:47421593	G/C	cg08112188	chr17:47440006	ZNF652	0.93	7.85	0.36	3.56e-14	Prostate cancer;
LUAD	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg25233709	chr10:116636983	FAM160B1	0.41	8.11	0.37	5.39e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1032833	0.732	rs77225055	chr2:179947564	C/T	cg23883738	chr2:179974586	SESTD1	-0.72	-8.26	-0.37	1.9e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	trans	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg01620082	chr3:125678407	NA	-0.63	-7.51	-0.34	3.55e-13	Depression;
LUAD	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg15691649	chr6:25882328	NA	0.43	6.98	0.32	1.15e-11	Blood metabolite levels;
LUAD	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.73	13.01	0.53	8.95e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs12900413	0.687	rs13343250	chr15:90311410	T/C	cg24249390	chr15:90295951	MESP1	-0.34	-6.7	-0.31	6.76e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs6076065	0.723	rs2424536	chr20:23381601	C/T	cg11657817	chr20:23433608	CST11	0.48	8.85	0.4	2.4e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs9875589	0.509	rs7614591	chr3:14061118	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	6.61	0.31	1.17e-10	Ovarian reserve;
LUAD	cis	rs4664308	1.000	rs925410	chr2:160912652	C/T	cg03641300	chr2:160917029	PLA2R1	0.38	6.58	0.3	1.36e-10	Idiopathic membranous nephropathy;
LUAD	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg16680214	chr1:154839983	KCNN3	-0.61	-12.69	-0.53	1.75e-31	Prostate cancer;
LUAD	trans	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.65	10.84	0.47	2.43e-24	Endometrial cancer;
LUAD	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.27e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1003719	1.000	rs2835607	chr21:38491973	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.49	8.13	0.37	4.65e-15	Eye color traits;
LUAD	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.39e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg26384229	chr12:38710491	ALG10B	-0.4	-6.84	-0.32	2.86e-11	Heart rate;
LUAD	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-14.54	-0.58	3.93e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg27588902	chr6:42928151	GNMT	-0.37	-9.82	-0.43	1.24e-20	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg25985355	chr7:65971099	NA	-0.4	-7.35	-0.34	1.06e-12	Aortic root size;
LUAD	cis	rs59698941	0.943	rs66480446	chr5:132274793	T/C	cg14825688	chr5:132208181	LEAP2	-0.48	-6.52	-0.3	1.97e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg07537917	chr2:241836409	C2orf54	-0.3	-8.52	-0.38	2.85e-16	Urinary metabolites;
LUAD	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06022373	chr22:39101656	GTPBP1	0.44	6.46	0.3	2.96e-10	Menopause (age at onset);
LUAD	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.06	0.32	6.7e-12	Platelet count;
LUAD	cis	rs10106298	0.846	rs2436940	chr8:103678521	A/C	cg10187029	chr8:103597600	NA	0.41	6.99	0.32	1.06e-11	Schizophrenia;
LUAD	cis	rs11048434	0.736	rs12424026	chr12:9110993	T/C	cg23795048	chr12:9217529	LOC144571	0.41	7.62	0.35	1.72e-13	Sjögren's syndrome;
LUAD	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg06618935	chr21:46677482	NA	-0.49	-10.04	-0.44	2.04e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs35146811	0.555	rs1981550	chr7:99541952	G/A	cg19636519	chr7:99541626	NA	0.41	7.32	0.34	1.23e-12	Coronary artery disease;
LUAD	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg06784218	chr1:46089804	CCDC17	0.36	7.77	0.35	6.12e-14	Red blood cell count;Reticulocyte count;
LUAD	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.5	7.37	0.34	9.28e-13	Cognitive test performance;
LUAD	cis	rs7589342	0.792	rs13426321	chr2:106500280	G/A	cg14210321	chr2:106509881	NCK2	-0.39	-6.49	-0.3	2.44e-10	Addiction;
LUAD	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg21191810	chr6:118973309	C6orf204	-0.47	-7.52	-0.34	3.37e-13	Renal cell carcinoma;
LUAD	cis	rs1018836	0.739	rs4734247	chr8:91569144	A/G	cg16814680	chr8:91681699	NA	-0.57	-9.36	-0.41	4.62e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	trans	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg01620082	chr3:125678407	NA	-0.66	-7.46	-0.34	4.97e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2979489	0.591	rs62508371	chr8:30422060	C/T	cg26383811	chr8:30366931	RBPMS	-0.57	-8.81	-0.39	3.19e-17	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg20291162	chr17:40259547	DHX58	-0.7	-10.99	-0.47	6.82e-25	Fibrinogen levels;
LUAD	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg07917127	chr4:99064746	C4orf37	0.39	6.45	0.3	3.08e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg07217954	chr7:1067459	C7orf50	0.46	7.14	0.33	4.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg08859206	chr1:53392774	SCP2	-0.51	-9.15	-0.41	2.47e-18	Monocyte count;
LUAD	cis	rs731174	0.959	rs7546741	chr1:38191397	G/C	cg12339802	chr1:38156545	C1orf109	-0.46	-6.94	-0.32	1.46e-11	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg02176678	chr2:219576539	TTLL4	0.74	14.98	0.59	5.28e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6426558	0.537	rs10495253	chr1:227471820	A/T	cg10327440	chr1:227177885	CDC42BPA	0.55	8.91	0.4	1.57e-17	Neutrophil percentage of white cells;
LUAD	trans	rs3858145	0.588	rs61854837	chr10:70042370	C/G	cg04882175	chr6:131122610	NA	-0.57	-6.56	-0.3	1.58e-10	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUAD	cis	rs6723108	0.651	rs6724774	chr2:135407285	C/T	cg12500956	chr2:135428796	TMEM163	-0.29	-7.6	-0.35	1.87e-13	Type 2 diabetes;
LUAD	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg18190219	chr22:46762943	CELSR1	-0.46	-6.74	-0.31	5.06e-11	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6446731	0.517	rs2858086	chr4:3270611	A/G	cg08886695	chr4:3369023	RGS12	0.47	7.92	0.36	2.17e-14	Mean platelet volume;
LUAD	trans	rs8002861	0.781	rs3816311	chr13:44453783	G/A	cg17145862	chr1:211918768	LPGAT1	0.73	16.43	0.62	2.71e-47	Leprosy;
LUAD	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	13.22	0.54	1.26e-33	Prudent dietary pattern;
LUAD	cis	rs4631830	0.869	rs4131357	chr10:51537292	C/A	cg20129853	chr10:51489980	NA	-0.34	-6.84	-0.32	2.73e-11	Prostate-specific antigen levels;
LUAD	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.44	0.3	3.21e-10	Cognitive test performance;
LUAD	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.33	-8.56	-0.38	2.16e-16	Total body bone mineral density;
LUAD	cis	rs28595532	0.920	rs116091383	chr4:119635518	A/G	cg21605333	chr4:119757512	SEC24D	0.86	7.93	0.36	2e-14	Cannabis dependence symptom count;
LUAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg16606324	chr3:10149918	C3orf24	0.67	10.93	0.47	1.15e-24	Alzheimer's disease;
LUAD	cis	rs7870753	0.628	rs10820604	chr9:99192494	A/G	cg13563390	chr9:99253610	HABP4	-0.38	-6.38	-0.3	4.79e-10	Height;
LUAD	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg07917127	chr4:99064746	C4orf37	0.43	7.15	0.33	3.89e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg02951883	chr7:2050386	MAD1L1	-0.93	-18.25	-0.66	2.74e-55	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-7.0	-0.32	1e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg03929089	chr4:120376271	NA	-0.92	-16.95	-0.64	1.5e-49	Height;
LUAD	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg11050988	chr7:1952600	MAD1L1	-0.38	-7.77	-0.35	6.01e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg04267008	chr7:1944627	MAD1L1	-0.72	-11.14	-0.48	1.9e-25	Bipolar disorder and schizophrenia;
LUAD	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg05283184	chr6:79620031	NA	-0.44	-7.62	-0.35	1.63e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg08859206	chr1:53392774	SCP2	0.46	8.57	0.38	1.91e-16	Monocyte count;
LUAD	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg05283184	chr6:79620031	NA	-0.62	-12.45	-0.52	1.51e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs597539	0.690	rs1249359	chr11:68618279	C/T	cg21862992	chr11:68658383	NA	0.52	9.41	0.42	3.16e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg14196790	chr5:131705035	SLC22A5	0.38	6.85	0.32	2.63e-11	Blood metabolite levels;
LUAD	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg02269571	chr22:50332266	NA	-0.61	-9.35	-0.41	5.09e-19	Schizophrenia;
LUAD	cis	rs1030877	1.000	rs2576737	chr2:105891510	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.6	11.86	0.5	3.3e-28	Obesity-related traits;
LUAD	cis	rs454510	0.826	rs347903	chr1:120192431	C/T	cg16322792	chr1:120165303	ZNF697	0.49	9.27	0.41	9.92e-19	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg24308560	chr3:49941425	MST1R	0.5	8.11	0.37	5.38e-15	Body mass index;
LUAD	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg00750074	chr16:89608354	SPG7	-0.59	-10.26	-0.45	3.26e-22	Multiple myeloma (IgH translocation);
LUAD	cis	rs877282	0.583	rs11253441	chr10:828288	C/T	cg17470449	chr10:769945	NA	-0.43	-6.49	-0.3	2.39e-10	Uric acid levels;
LUAD	cis	rs250585	0.920	rs30016	chr16:23412897	G/A	cg00143387	chr16:23521605	GGA2	0.56	7.13	0.33	4.33e-12	Egg allergy;
LUAD	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg14895029	chr7:2775587	GNA12	-0.4	-6.36	-0.3	5.23e-10	Height;
LUAD	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg08807101	chr21:30365312	RNF160	-0.45	-7.84	-0.36	3.63e-14	Dental caries;
LUAD	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18876405	chr7:65276391	NA	0.45	7.12	0.33	4.7e-12	Aortic root size;
LUAD	cis	rs910873	0.505	rs6059961	chr20:33231490	T/C	cg16810054	chr20:33298113	TP53INP2	-0.51	-7.66	-0.35	1.32e-13	Melanoma;
LUAD	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg03433313	chr16:819064	MIR662	-0.63	-10.74	-0.46	5.81e-24	Mean corpuscular volume;
LUAD	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg25985355	chr7:65971099	NA	-0.52	-6.43	-0.3	3.43e-10	Diabetic kidney disease;
LUAD	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00166722	chr3:10149974	C3orf24	-0.65	-10.94	-0.47	1.06e-24	Alzheimer's disease;
LUAD	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg02951883	chr7:2050386	MAD1L1	-0.8	-14.45	-0.57	9.82e-39	Bipolar disorder and schizophrenia;
LUAD	cis	rs877282	0.947	rs7475589	chr10:767479	C/G	cg06581033	chr10:766294	NA	-0.62	-8.42	-0.38	5.71e-16	Uric acid levels;
LUAD	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg05283184	chr6:79620031	NA	-0.61	-12.18	-0.51	1.87e-29	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.58	-0.39	1.82e-16	Height;
LUAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08280861	chr8:58055591	NA	0.63	8.2	0.37	2.89e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg14927855	chr7:155151427	NA	0.41	8.93	0.4	1.35e-17	Stem cell growth factor beta levels;
LUAD	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg21724239	chr8:58056113	NA	0.74	9.62	0.42	5.86e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg11871910	chr12:69753446	YEATS4	0.48	7.38	0.34	8.66e-13	Cerebrospinal fluid biomarker levels;
LUAD	trans	rs11247915	0.600	rs11247917	chr1:26655507	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.43	-7.26	-0.33	1.89e-12	Obesity-related traits;
LUAD	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg15181151	chr6:150070149	PCMT1	0.42	8.46	0.38	4.31e-16	Lung cancer;
LUAD	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.72	8.97	0.4	9.66e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1953600	0.837	rs2819946	chr10:81951635	G/A	cg04850286	chr10:81895943	PLAC9	0.36	6.54	0.3	1.82e-10	Sarcoidosis;
LUAD	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg02549819	chr16:58548995	SETD6	0.83	6.93	0.32	1.61e-11	Schizophrenia;
LUAD	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.9	0.32	1.86e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs859767	0.741	rs13432068	chr2:135382914	G/A	cg12500956	chr2:135428796	TMEM163	-0.31	-8.13	-0.37	4.9e-15	Neuroticism;
LUAD	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg18755752	chr8:142205143	DENND3	-0.81	-16.58	-0.63	6.17e-48	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs12681287	0.547	rs13260345	chr8:87483721	T/C	cg27223183	chr8:87520930	FAM82B	-0.67	-9.61	-0.42	6.38e-20	Caudate activity during reward;
LUAD	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg02423579	chr7:2872169	GNA12	-0.92	-16.65	-0.63	3.23e-48	Height;
LUAD	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg04842962	chr6:43655489	MRPS18A	0.74	14.7	0.58	8.52e-40	IgG glycosylation;
LUAD	cis	rs12618769	0.597	rs3754888	chr2:99090674	T/C	cg10123293	chr2:99228465	UNC50	0.47	8.6	0.39	1.58e-16	Bipolar disorder;
LUAD	cis	rs12791968	1.000	rs1552300	chr11:45002594	G/A	cg11846598	chr11:44996168	LOC221122	-0.77	-13.66	-0.55	1.82e-35	Inhibitory control;
LUAD	trans	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg14917512	chr19:3094685	GNA11	0.37	6.39	0.3	4.44e-10	Aortic root size;
LUAD	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.36	7.61	0.35	1.84e-13	Parkinson's disease;
LUAD	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.18	-0.33	3.15e-12	Lung cancer;
LUAD	cis	rs2019216	0.500	rs1356483	chr17:21934029	A/C	cg22648282	chr17:21454238	C17orf51	-0.46	-7.65	-0.35	1.37e-13	Pelvic organ prolapse;
LUAD	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg07169764	chr2:136633963	MCM6	-0.6	-8.23	-0.37	2.4e-15	Corneal structure;
LUAD	cis	rs7809615	0.901	rs6947826	chr7:99156520	C/T	cg03133378	chr7:99195931	NA	-0.55	-6.5	-0.3	2.28e-10	Blood metabolite ratios;
LUAD	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg25358565	chr5:93447407	FAM172A	0.61	7.32	0.34	1.27e-12	Diabetic retinopathy;
LUAD	cis	rs4824093	0.544	rs73443951	chr22:50301251	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.63	6.71	0.31	6.28e-11	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22496380	chr5:211416	CCDC127	-0.93	-13.05	-0.54	5.85e-33	Breast cancer;
LUAD	cis	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg27411982	chr8:10470053	RP1L1	-0.41	-7.36	-0.34	9.9e-13	Triglycerides;
LUAD	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg14345882	chr6:26364793	BTN3A2	0.7	7.14	0.33	4.13e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs35883536	1.000	rs1832123	chr1:101168196	A/G	cg06223162	chr1:101003688	GPR88	0.37	6.9	0.32	1.93e-11	Monocyte count;
LUAD	cis	rs8050907	0.744	rs9935505	chr16:4586906	C/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.96	7.65	0.35	1.37e-13	Obesity-related traits;
LUAD	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg08859206	chr1:53392774	SCP2	-0.66	-12.21	-0.51	1.42e-29	Monocyte count;
LUAD	cis	rs6960043	0.764	rs7798124	chr7:15055616	A/G	cg19272540	chr7:15055459	NA	-0.39	-9.01	-0.4	7.09e-18	Type 2 diabetes;
LUAD	cis	rs7197653	0.519	rs55757091	chr16:68323654	G/A	cg05110241	chr16:68378359	PRMT7	-0.68	-8.52	-0.38	2.76e-16	Magnesium levels;
LUAD	trans	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg27411982	chr8:10470053	RP1L1	0.44	7.81	0.36	4.57e-14	Mood instability;
LUAD	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.8	-0.31	3.55e-11	Crohn's disease;
LUAD	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg00933542	chr6:150070202	PCMT1	0.44	9.68	0.43	3.86e-20	Lung cancer;
LUAD	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg18252515	chr7:66147081	NA	-0.61	-6.78	-0.31	4.07e-11	Diabetic kidney disease;
LUAD	cis	rs1509123	0.609	rs56161809	chr17:6705360	A/T	cg12642237	chr17:6703447	TEKT1	-0.51	-7.85	-0.36	3.49e-14	Blood metabolite levels;
LUAD	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg26022315	chr17:47021804	SNF8	0.4	7.29	0.33	1.57e-12	Type 2 diabetes;
LUAD	cis	rs933688	0.532	rs28693622	chr5:90538722	T/C	cg00335715	chr5:90575459	NA	-0.39	-6.37	-0.3	4.92e-10	Smoking behavior;
LUAD	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.66	0.39	9.7e-17	Menarche (age at onset);
LUAD	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg27535305	chr1:53392650	SCP2	0.35	7.27	0.33	1.81e-12	Monocyte count;
LUAD	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg27539214	chr16:67997921	SLC12A4	0.64	7.97	0.36	1.51e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg19761014	chr17:28927070	LRRC37B2	0.95	9.39	0.42	3.82e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs9788682	0.747	rs2568497	chr15:78721397	G/T	cg18825076	chr15:78729989	IREB2	-0.54	-7.46	-0.34	5.1e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs864537	0.676	rs3108155	chr1:167422057	C/G	cg22356347	chr1:167427500	CD247	-0.47	-9.79	-0.43	1.59e-20	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUAD	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	9.14	0.41	2.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg13319975	chr6:146136371	FBXO30	-0.58	-9.84	-0.43	1.05e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg14458575	chr2:238380390	NA	0.65	12.21	0.51	1.4e-29	Prostate cancer;
LUAD	cis	rs13394619	0.775	rs10200851	chr2:11722082	C/T	cg07314298	chr2:11723111	GREB1	-0.51	-9.72	-0.43	2.64e-20	Endometriosis;
LUAD	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg10589385	chr1:150898437	SETDB1	0.43	8.22	0.37	2.57e-15	Melanoma;
LUAD	cis	rs7116495	1.000	rs2508858	chr11:71805405	C/G	cg07596299	chr11:71824057	C11orf51	0.78	6.71	0.31	6.1e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs516243	0.841	rs6540944	chr1:10740405	C/T	cg02903756	chr1:10750680	CASZ1	-0.51	-9.8	-0.43	1.38e-20	Migraine - clinic-based;
LUAD	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg18446336	chr7:2847575	GNA12	-0.33	-6.77	-0.31	4.22e-11	Height;
LUAD	trans	rs3858145	0.588	rs736535	chr10:70043916	G/A	cg04882175	chr6:131122610	NA	-0.57	-6.77	-0.31	4.42e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUAD	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-10.45	-0.45	6.56e-23	Gut microbiome composition (summer);
LUAD	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg25985355	chr7:65971099	NA	-0.55	-6.88	-0.32	2.16e-11	Gout;
LUAD	cis	rs4631830	0.832	rs2843554	chr10:51523861	G/T	cg20129853	chr10:51489980	NA	-0.33	-6.37	-0.3	4.84e-10	Prostate-specific antigen levels;
LUAD	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs13082711	0.516	rs1388785	chr3:27371843	T/C	cg02860705	chr3:27208620	NA	-0.58	-9.96	-0.44	4e-21	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg17863274	chr19:49399704	TULP2	-0.65	-9.96	-0.44	3.83e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg02782426	chr3:40428986	ENTPD3	0.42	8.9	0.4	1.64e-17	Renal cell carcinoma;
LUAD	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg16325326	chr1:53192061	ZYG11B	0.49	8.33	0.38	1.16e-15	Monocyte count;
LUAD	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg21724239	chr8:58056113	NA	0.61	7.08	0.33	6.22e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg25324976	chr17:61989376	CSHL1	0.38	7.5	0.34	3.85e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs12210905	1.000	rs72843611	chr6:27131382	C/T	cg08851530	chr6:28072375	NA	0.77	6.63	0.31	1.02e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs3784262	0.564	rs34958088	chr15:58328332	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-8.29	-0.37	1.54e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-7.44	-0.34	5.5e-13	Morning vs. evening chronotype;
LUAD	cis	rs10489202	0.632	rs203779	chr1:167877647	T/G	cg25738037	chr1:168025549	DCAF6	-0.48	-7.02	-0.32	8.73e-12	Schizophrenia;
LUAD	cis	rs6445967	0.545	rs59981877	chr3:58282388	T/C	cg23715586	chr3:58305044	RPP14	0.42	7.06	0.32	6.73e-12	Platelet count;
LUAD	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-8.42	-0.38	5.82e-16	Breast cancer;
LUAD	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg26408565	chr15:76604113	ETFA	0.55	9.58	0.42	8.62e-20	Blood metabolite levels;
LUAD	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg15556689	chr8:8085844	FLJ10661	0.42	6.71	0.31	6.4e-11	Mood instability;
LUAD	cis	rs9322817	0.691	rs2499666	chr6:105318576	A/G	cg02098413	chr6:105308735	HACE1	0.4	8.75	0.39	5.07e-17	Thyroid stimulating hormone;
LUAD	cis	rs9914544	0.545	rs8073436	chr17:18801841	A/G	cg25390199	chr17:18761479	PRPSAP2	-0.38	-6.48	-0.3	2.49e-10	Educational attainment (years of education);
LUAD	cis	rs2249625	0.508	rs114505309	chr6:72892383	G/A	cg18830697	chr6:72922368	RIMS1	0.45	8.01	0.36	1.14e-14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg24399712	chr22:39784796	NA	-0.82	-16.2	-0.62	2.84e-46	Intelligence (multi-trait analysis);
LUAD	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06022373	chr22:39101656	GTPBP1	0.46	7.21	0.33	2.6e-12	Menopause (age at onset);
LUAD	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-8.9	-0.4	1.61e-17	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg05340658	chr4:99064831	C4orf37	0.53	8.83	0.39	2.71e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2742234	0.503	rs1254968	chr10:43691691	C/T	cg15436174	chr10:43711423	RASGEF1A	0.52	8.88	0.4	1.97e-17	Hirschsprung disease;
LUAD	cis	rs116095464	1.000	rs62331562	chr5:349298	G/C	cg22857025	chr5:266934	NA	-1.03	-8.14	-0.37	4.62e-15	Breast cancer;
LUAD	trans	rs4650994	0.623	rs2248666	chr1:178620601	G/T	cg05059571	chr16:84539110	KIAA1609	0.48	8.05	0.36	8.21e-15	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg10523679	chr1:76189770	ACADM	-0.89	-16.12	-0.62	6.66e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1595825	0.891	rs1992313	chr2:198896766	T/C	cg10547527	chr2:198650123	BOLL	-0.51	-7.0	-0.32	1.02e-11	Ulcerative colitis;
LUAD	cis	rs9902453	0.780	rs3115093	chr17:28039755	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	10.15	0.44	8.36e-22	Coffee consumption (cups per day);
LUAD	cis	rs6906287	0.647	rs3890198	chr6:118706447	T/C	cg18833306	chr6:118973337	C6orf204	0.48	8.45	0.38	4.65e-16	Electrocardiographic conduction measures;
LUAD	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg11189052	chr15:85197271	WDR73	0.6	7.45	0.34	5.25e-13	Schizophrenia;
LUAD	cis	rs9914988	0.832	rs34901720	chr17:27179518	A/G	cg20469991	chr17:27169893	C17orf63	-0.52	-6.73	-0.31	5.4e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.2	-0.41	1.62e-18	Life satisfaction;
LUAD	cis	rs68170813	0.559	rs7793594	chr7:106891829	C/T	cg23024343	chr7:107201750	COG5	0.49	7.03	0.32	8.5e-12	Coronary artery disease;
LUAD	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26314531	chr2:26401878	FAM59B	-0.57	-7.93	-0.36	1.94e-14	Gut microbiome composition (summer);
LUAD	trans	rs941408	0.963	rs1640267	chr19:2789337	T/C	cg22153745	chr1:153894579	GATAD2B	-0.55	-7.86	-0.36	3.12e-14	Total cholesterol levels;
LUAD	cis	rs4378999	0.748	rs9864693	chr3:51656370	C/G	cg12934382	chr3:51741135	GRM2	0.41	7.23	0.33	2.3e-12	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUAD	cis	rs7274811	0.711	rs291680	chr20:32022251	A/C	cg13403462	chr20:32256071	NECAB3;C20orf134	0.46	6.96	0.32	1.33e-11	Height;
LUAD	cis	rs2732480	0.500	rs2932093	chr12:48648271	G/T	cg04545296	chr12:48745243	ZNF641	0.42	10.51	0.46	4.1000000000000003e-23	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg22681709	chr2:178499509	PDE11A	-0.49	-8.35	-0.38	9.75e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs7072216	0.763	rs10736129	chr10:100171571	C/T	cg26618903	chr10:100175079	PYROXD2	0.39	8.76	0.39	4.93e-17	Metabolite levels;
LUAD	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg05082376	chr22:42548792	NA	0.45	7.8	0.35	4.73e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs807669	0.807	rs712948	chr22:19206499	A/G	cg02655711	chr22:19163373	SLC25A1	0.83	17.03	0.64	6.63e-50	Metabolite levels;
LUAD	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg02733842	chr7:1102375	C7orf50	-0.52	-7.78	-0.35	5.65e-14	Bronchopulmonary dysplasia;
LUAD	cis	rs870825	0.655	rs10013685	chr4:185617785	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.99	0.56	8.3e-37	Blood protein levels;
LUAD	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg07967210	chr17:47022446	SNF8	0.36	6.45	0.3	3.03e-10	Type 2 diabetes;
LUAD	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-8.5	-0.38	3.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg22920501	chr2:26401640	FAM59B	-0.98	-15.32	-0.6	1.81e-42	Gut microbiome composition (summer);
LUAD	cis	rs2996428	0.593	rs7513053	chr1:3709487	A/G	cg23277830	chr1:3704460	LRRC47	0.44	9.27	0.41	9.37e-19	Red cell distribution width;
LUAD	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg05457628	chr5:178986728	RUFY1	0.64	9.54	0.42	1.14e-19	Lung cancer;
LUAD	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06873352	chr17:61820015	STRADA	0.55	8.95	0.4	1.14e-17	Height;
LUAD	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg12483005	chr1:23474871	LUZP1	0.52	9.13	0.41	2.93e-18	Height;
LUAD	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg04944784	chr2:26401820	FAM59B	-0.84	-12.88	-0.53	2.99e-32	Gut microbiome composition (summer);
LUAD	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.36	-0.34	9.49e-13	Electroencephalogram traits;
LUAD	trans	rs11039798	1.000	rs3902927	chr11:48581457	C/T	cg03929089	chr4:120376271	NA	0.56	6.46	0.3	2.81e-10	Axial length;
LUAD	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg07636037	chr3:49044803	WDR6	0.63	11.91	0.5	2.15e-28	Parkinson's disease;
LUAD	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg18230493	chr5:56204884	C5orf35	0.56	9.35	0.41	5.32e-19	Coronary artery disease;
LUAD	cis	rs72949976	0.646	rs13029384	chr2:214029164	G/A	cg08319019	chr2:214017104	IKZF2	0.53	8.0	0.36	1.24e-14	Lung cancer;Squamous cell lung carcinoma;
LUAD	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg02079420	chr8:82753780	SNX16	0.4	7.81	0.36	4.45e-14	Diastolic blood pressure;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01947862	chr2:86116624	ST3GAL5	-0.44	-6.99	-0.32	1.08e-11	Height;
LUAD	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg27284194	chr4:1044797	NA	0.55	9.0	0.4	7.74e-18	Recombination rate (males);
LUAD	cis	rs2688608	0.725	rs2688623	chr10:75689615	C/T	cg23231163	chr10:75533350	FUT11	-0.36	-6.62	-0.31	1.06e-10	Inflammatory bowel disease;
LUAD	trans	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	12.01	0.5	8.77e-29	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs5756813	0.811	rs4396807	chr22:38138379	G/C	cg19894588	chr14:64061835	NA	-0.5	-7.5	-0.34	3.85e-13	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs1232027	0.616	rs26267	chr5:80040674	T/G	cg24059623	chr5:79951536	MSH3;DHFR	0.42	6.73	0.31	5.57e-11	Huntington's disease progression;
LUAD	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg22823121	chr1:150693482	HORMAD1	0.45	8.98	0.4	9.24e-18	Tonsillectomy;
LUAD	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.3	0.51	6.1e-30	Tonsillectomy;
LUAD	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.52	0.6	2.57e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs427394	0.802	rs274712	chr5:6723950	G/A	cg10857441	chr5:6722123	POLS	-0.65	-12.74	-0.53	1.07e-31	Menopause (age at onset);
LUAD	cis	rs7937682	0.587	rs611607	chr11:111349765	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.44	-7.02	-0.32	9.16e-12	Primary sclerosing cholangitis;
LUAD	cis	rs9902453	0.838	rs9646438	chr17:28209091	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.92	0.4	1.41e-17	Coffee consumption (cups per day);
LUAD	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg01851573	chr8:8652454	MFHAS1	-0.45	-7.99	-0.36	1.28e-14	Neuroticism;
LUAD	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	6.95	0.32	1.37e-11	Rheumatoid arthritis;
LUAD	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg12011299	chr4:100065546	ADH4	0.76	15.0	0.59	4.45e-41	Alcohol dependence;
LUAD	cis	rs3784262	0.669	rs6493981	chr15:58352923	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.75	-0.35	6.81e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs593982	1.000	rs470360	chr11:65500530	T/C	cg08755490	chr11:65554678	OVOL1	1.32	20.4	0.7	6.24e-65	Atopic dermatitis;
LUAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg10729496	chr3:10149963	C3orf24	0.57	9.18	0.41	1.91e-18	Alzheimer's disease;
LUAD	trans	rs8002861	0.875	rs12872943	chr13:44410553	G/A	cg12856521	chr11:46389249	DGKZ	-0.38	-6.46	-0.3	2.9e-10	Leprosy;
LUAD	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg00898013	chr13:113819073	PROZ	0.69	12.64	0.52	2.73e-31	Platelet distribution width;
LUAD	cis	rs8064299	0.967	rs3744208	chr17:72767565	A/G	cg21922841	chr17:72744131	SLC9A3R1	0.26	6.63	0.31	1.01e-10	Monocyte count;
LUAD	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg22532475	chr10:104410764	TRIM8	0.44	8.54	0.38	2.4e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1018836	0.663	rs2205152	chr8:91483618	C/T	cg16814680	chr8:91681699	NA	0.64	10.88	0.47	1.76e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg20135002	chr11:47629003	NA	-0.4	-7.1	-0.33	5.28e-12	Subjective well-being;
LUAD	cis	rs2797160	1.000	rs1777225	chr6:126018270	T/C	cg05901451	chr6:126070800	HEY2	0.46	6.73	0.31	5.61e-11	Endometrial cancer;
LUAD	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg07636037	chr3:49044803	WDR6	0.56	9.4	0.42	3.37e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg11494091	chr17:61959527	GH2	0.4	7.22	0.33	2.4e-12	Height;
LUAD	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	10.86	0.47	2.08e-24	Smoking behavior;
LUAD	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg07169764	chr2:136633963	MCM6	0.82	9.6	0.42	7.17e-20	Corneal structure;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg08830818	chr3:122514143	HSPBAP1;DIRC2	-0.35	-6.83	-0.32	2.9e-11	Vertical cup-disc ratio;
LUAD	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg17105886	chr17:28927953	LRRC37B2	0.76	7.59	0.35	2e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7264396	0.623	rs6060504	chr20:34197619	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-7.31	-0.34	1.32e-12	Total cholesterol levels;
LUAD	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg22618164	chr12:122356400	WDR66	0.72	13.17	0.54	1.96e-33	Mean corpuscular volume;
LUAD	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03517284	chr6:25882590	NA	-0.57	-9.28	-0.41	8.66e-19	Blood metabolite levels;
LUAD	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.36	-0.6	1.23e-42	Chronic sinus infection;
LUAD	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.33	-6.92	-0.32	1.67e-11	Height;
LUAD	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg02569458	chr12:86230093	RASSF9	0.44	8.11	0.37	5.68e-15	Major depressive disorder;
LUAD	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg14664628	chr15:75095509	CSK	-0.6	-9.6	-0.42	6.93e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg07217954	chr7:1067459	C7orf50	0.38	6.54	0.3	1.82e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11809207	0.501	rs2232654	chr1:26496870	A/G	cg00147160	chr1:26503991	CNKSR1	0.39	9.06	0.4	4.78e-18	Height;
LUAD	cis	rs56283067	0.887	rs12198016	chr6:44771708	C/T	cg20913747	chr6:44695427	NA	-0.45	-6.88	-0.32	2.23e-11	Total body bone mineral density;
LUAD	cis	rs7731657	0.537	rs10073388	chr5:130188080	C/T	cg08523029	chr5:130500466	HINT1	-0.58	-7.54	-0.34	2.84e-13	Fasting plasma glucose;
LUAD	cis	rs9948	0.655	rs62156213	chr2:97399100	T/C	cg20312557	chr2:97357134	FER1L5	-0.72	-8.08	-0.37	6.78e-15	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs12200560	0.505	rs211177	chr6:97074088	C/T	cg06623918	chr6:96969491	KIAA0776	0.47	7.21	0.33	2.64e-12	Coronary heart disease;
LUAD	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg04539111	chr16:67997858	SLC12A4	-0.62	-7.53	-0.34	3.15e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs829883	0.664	rs829864	chr12:98850195	C/T	cg25150519	chr12:98850993	NA	0.75	13.97	0.56	9.78e-37	Colorectal adenoma (advanced);
LUAD	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03352830	chr11:487213	PTDSS2	0.77	9.49	0.42	1.7e-19	Body mass index;
LUAD	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11890956	chr21:40555474	PSMG1	0.66	10.61	0.46	1.8e-23	Cognitive function;
LUAD	cis	rs78456975	0.546	rs72776254	chr2:1527881	C/T	cg01028140	chr2:1542097	TPO	-0.62	-7.95	-0.36	1.69e-14	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg12310025	chr6:25882481	NA	0.83	13.79	0.56	5.57e-36	Blood metabolite levels;
LUAD	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg11189052	chr15:85197271	WDR73	0.6	7.83	0.36	3.96e-14	Schizophrenia;
LUAD	cis	rs6138458	0.620	rs2151462	chr20:24911823	T/C	cg26195577	chr20:24973756	C20orf3	0.96	16.32	0.62	8.79e-47	Blood protein levels;
LUAD	cis	rs9362426	0.708	rs6907825	chr6:88102822	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.41	7.11	0.33	4.85e-12	Depressive episodes in bipolar disorder;
LUAD	cis	rs231513	0.911	rs537165	chr17:41976736	C/T	cg26893861	chr17:41843967	DUSP3	-0.54	-6.55	-0.3	1.69e-10	Cognitive function;
LUAD	cis	rs11051970	0.879	rs2171373	chr12:32575777	C/T	cg24626660	chr12:32551988	NA	0.32	6.48	0.3	2.61e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs599083	0.829	rs314751	chr11:68179560	C/T	cg02221422	chr11:68192511	LRP5	0.43	6.78	0.31	4.03e-11	Bone mineral density (spine);
LUAD	cis	rs8099014	0.954	rs28393850	chr18:56129141	T/C	cg12907477	chr18:56117327	MIR122	0.4	6.69	0.31	7.08e-11	Platelet count;
LUAD	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.62	9.37	0.41	4.56e-19	Alzheimer's disease;
LUAD	cis	rs2742417	1.000	rs2742406	chr3:45760600	C/T	cg10512202	chr3:45649293	LIMD1	0.39	6.99	0.32	1.1e-11	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg26513180	chr16:89883248	FANCA	0.75	6.45	0.3	3.15e-10	Skin colour saturation;
LUAD	cis	rs4285028	0.948	rs76593525	chr3:121690477	G/A	cg11130432	chr3:121712080	ILDR1	-0.59	-8.43	-0.38	5.62e-16	Multiple sclerosis;
LUAD	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg02371401	chr5:676784	TPPP	-0.48	-7.81	-0.36	4.42e-14	Lung disease severity in cystic fibrosis;
LUAD	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg21433313	chr16:3507492	NAT15	0.75	9.73	0.43	2.44e-20	Tuberculosis;
LUAD	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg06784218	chr1:46089804	CCDC17	0.5	10.92	0.47	1.22e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1003719	0.762	rs1015551	chr21:38449510	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.54	0.38	2.42e-16	Eye color traits;
LUAD	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg07599136	chr5:415885	AHRR	0.76	8.84	0.39	2.57e-17	Fat distribution (HIV);
LUAD	cis	rs1003719	0.788	rs9975168	chr21:38450557	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.51	-8.91	-0.4	1.5e-17	Eye color traits;
LUAD	trans	rs11088226	0.681	rs16989507	chr21:33939509	T/G	cg09050820	chr6:167586206	TCP10L2	0.91	12.44	0.52	1.65e-30	Gastritis;
LUAD	cis	rs7301016	1.000	rs73141014	chr12:62891412	T/G	cg11441379	chr12:63026424	NA	0.53	6.52	0.3	1.97e-10	IgG glycosylation;
LUAD	cis	rs10821973	0.505	rs3815999	chr10:64005711	C/T	cg09941381	chr10:64027924	RTKN2	-0.35	-6.83	-0.32	2.97e-11	Hypothyroidism;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10232749	chr1:169863532	SCYL3	-0.47	-7.33	-0.34	1.16e-12	Height;
LUAD	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg12908607	chr1:44402522	ARTN	-0.48	-9.49	-0.42	1.7e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-8.03	-0.36	9.82e-15	Bipolar disorder;
LUAD	cis	rs7771547	0.603	rs10947614	chr6:36573822	G/C	cg07856975	chr6:36356162	ETV7	0.53	7.02	0.32	8.89e-12	Platelet distribution width;
LUAD	cis	rs11048434	0.736	rs1476911	chr12:9090859	C/T	cg04155231	chr12:9217510	LOC144571	0.4	7.68	0.35	1.11e-13	Sjögren's syndrome;
LUAD	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg24634471	chr8:143751801	JRK	0.48	7.71	0.35	9e-14	Schizophrenia;
LUAD	cis	rs7267979	0.966	rs454723	chr20:25438928	G/C	cg08601574	chr20:25228251	PYGB	0.47	8.7	0.39	7.29e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg03188948	chr7:1209495	NA	0.8	9.82	0.43	1.21e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7084921	0.547	rs12780035	chr10:101874844	C/T	cg19754520	chr10:101825118	CPN1	-0.35	-6.99	-0.32	1.08e-11	Bone mineral density;
LUAD	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg13057898	chr1:3703894	LRRC47	0.63	10.71	0.46	7.48e-24	Red cell distribution width;
LUAD	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg11062466	chr8:58055876	NA	0.68	8.79	0.39	3.8e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg24112000	chr20:60950667	NA	0.77	12.99	0.53	1.02e-32	Colorectal cancer;
LUAD	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg00666640	chr1:248458726	OR2T12	0.31	7.53	0.34	3.12e-13	Common traits (Other);
LUAD	trans	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.06	-0.32	7.09e-12	Pancreatic cancer;
LUAD	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	8.62	0.39	1.35e-16	Lung cancer in ever smokers;
LUAD	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg16479474	chr6:28041457	NA	0.36	6.91	0.32	1.75e-11	Parkinson's disease;
LUAD	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg10553204	chr2:20871195	GDF7	-0.41	-7.11	-0.33	4.91e-12	Abdominal aortic aneurysm;
LUAD	cis	rs7945705	0.837	rs10769966	chr11:8847041	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.42	7.68	0.35	1.09e-13	Hemoglobin concentration;
LUAD	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.36	-7.72	-0.35	8.33e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg01448562	chr3:133502909	NA	-0.67	-12.3	-0.51	6.26e-30	Iron status biomarkers;
LUAD	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg03467027	chr4:99064603	C4orf37	0.4	6.43	0.3	3.45e-10	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9399401	0.961	rs1342060	chr6:142663177	T/C	cg03128060	chr6:142623767	GPR126	0.32	7.13	0.33	4.25e-12	Chronic obstructive pulmonary disease;
LUAD	cis	rs11051970	0.611	rs10844197	chr12:32561015	A/C	cg24626660	chr12:32551988	NA	0.35	7.46	0.34	4.8e-13	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2066819	1.000	rs118130855	chr12:56677979	T/A	cg26714650	chr12:56694279	CS	-0.86	-7.23	-0.33	2.25e-12	Psoriasis vulgaris;
LUAD	cis	rs10129255	0.500	rs12101190	chr14:107192386	C/T	cg23076370	chr14:107095027	NA	-0.44	-8.72	-0.39	6.58e-17	Kawasaki disease;
LUAD	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg03233332	chr7:66118400	NA	-0.46	-6.86	-0.32	2.43e-11	Aortic root size;
LUAD	trans	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	7.75	0.35	7e-14	Resting heart rate;
LUAD	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg13271783	chr10:134563150	INPP5A	-0.41	-7.23	-0.33	2.27e-12	Migraine;
LUAD	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg14343924	chr8:8086146	FLJ10661	-0.47	-7.64	-0.35	1.5e-13	Mood instability;
LUAD	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg13319975	chr6:146136371	FBXO30	-0.81	-14.32	-0.57	3.27e-38	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs57590327	0.503	rs2049415	chr3:81901887	A/T	cg07356753	chr3:81810745	GBE1	-0.63	-9.93	-0.43	4.95e-21	Extraversion;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg01769037	chr6:15246613	JARID2	0.39	6.35	0.3	5.55e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg25456477	chr12:86230367	RASSF9	0.33	6.4	0.3	4.02e-10	Major depressive disorder;
LUAD	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg04842962	chr6:43655489	MRPS18A	-0.74	-14.64	-0.58	1.43e-39	IgG glycosylation;
LUAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg00431813	chr7:1051703	C7orf50	-0.44	-8.78	-0.39	4.08e-17	Longevity;Endometriosis;
LUAD	cis	rs11229555	0.874	rs11605683	chr11:58350794	T/A	cg15696309	chr11:58395628	NA	-0.72	-10.3	-0.45	2.35e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs89107	0.576	rs11967375	chr6:118823975	A/G	cg18833306	chr6:118973337	C6orf204	0.38	6.53	0.3	1.84e-10	Cardiac structure and function;
LUAD	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg16205897	chr5:131564050	P4HA2	-0.45	-10.35	-0.45	1.6e-22	Blood metabolite levels;
LUAD	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.99	-0.36	1.33e-14	Monocyte percentage of white cells;
LUAD	cis	rs300774	0.800	rs406427	chr2:146263	C/A	cg21211680	chr2:198530	NA	-0.48	-7.39	-0.34	8.05e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg11050988	chr7:1952600	MAD1L1	-0.38	-7.78	-0.35	5.65e-14	Bipolar disorder and schizophrenia;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg21028760	chr13:100153919	TM9SF2	-0.64	-6.47	-0.3	2.68e-10	Type 2 diabetes;
LUAD	trans	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg06165179	chr7:39990544	CDK13	0.46	6.36	0.3	5.35e-10	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs6028335	0.674	rs6028234	chr20:37607869	A/C	cg27660920	chr20:37554817	FAM83D	0.51	6.38	0.3	4.74e-10	Alcohol and nicotine co-dependence;
LUAD	cis	rs1443512	0.947	rs9804784	chr12:54343472	A/C	cg17410650	chr12:54324560	NA	-0.44	-8.18	-0.37	3.24e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg20119798	chr7:94954144	PON1	-0.47	-6.46	-0.3	2.82e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs853679	0.585	rs201004	chr6:27804934	T/C	cg19041857	chr6:27730383	NA	-0.44	-7.06	-0.32	7.07e-12	Depression;
LUAD	cis	rs9826463	0.757	rs73240305	chr3:142222770	A/G	cg20824294	chr3:142316082	PLS1	0.42	7.57	0.35	2.33e-13	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg14343924	chr8:8086146	FLJ10661	0.51	8.16	0.37	3.77e-15	Mood instability;
LUAD	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg01171360	chr6:293285	DUSP22	-0.51	-8.48	-0.38	3.8e-16	Menopause (age at onset);
LUAD	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.54	0.3	1.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs1595825	0.679	rs3792157	chr2:198416859	G/A	cg00982548	chr2:198649783	BOLL	-0.51	-6.6	-0.31	1.22e-10	Ulcerative colitis;
LUAD	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg24397884	chr7:158709396	WDR60	0.48	8.21	0.37	2.78e-15	Height;
LUAD	cis	rs6743376	0.556	rs2251876	chr2:113818727	A/G	cg09040174	chr2:113837401	NA	0.51	7.92	0.36	2.12e-14	Inflammatory biomarkers;
LUAD	cis	rs738322	0.555	rs5756932	chr22:38546118	C/T	cg25457927	chr22:38595422	NA	-0.58	-13.56	-0.55	5.09e-35	Cutaneous nevi;
LUAD	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg24768116	chr2:27665128	KRTCAP3	-0.4	-10.73	-0.46	6.54e-24	Total body bone mineral density;
LUAD	cis	rs6487679	0.526	rs7972426	chr12:9381254	C/T	cg08997352	chr12:9597637	DDX12	-0.49	-7.56	-0.34	2.58e-13	Non-alcoholic fatty liver disease histology (AST);
LUAD	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg24818145	chr4:99064322	C4orf37	-0.41	-6.93	-0.32	1.58e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.51	-7.01	-0.32	9.24e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg22282877	chr19:52800469	ZNF480	-0.44	-7.77	-0.35	5.81e-14	Schizophrenia;
LUAD	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.51	8.53	0.38	2.66e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg00280220	chr17:61926910	NA	0.37	7.18	0.33	3.23e-12	Prudent dietary pattern;
LUAD	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg13319975	chr6:146136371	FBXO30	-0.63	-10.89	-0.47	1.68e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.4	0.34	7.58e-13	Tonsillectomy;
LUAD	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg09065629	chr16:1709722	CRAMP1L	0.43	7.35	0.34	1.04e-12	Coronary artery disease;
LUAD	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg08888203	chr3:10149979	C3orf24	-0.75	-13.03	-0.54	7.61e-33	Alzheimer's disease;
LUAD	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg24846343	chr22:24311635	DDTL	0.73	15.5	0.6	3.25e-43	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg02807482	chr3:125708958	NA	-0.65	-8.65	-0.39	1.06e-16	Blood pressure (smoking interaction);
LUAD	cis	rs10489202	0.632	rs275137	chr1:168051266	A/C	cg24449463	chr1:168025552	DCAF6	0.78	12.93	0.53	1.84e-32	Schizophrenia;
LUAD	cis	rs79839061	0.562	rs62294484	chr4:935571	A/G	cg14530993	chr4:882597	GAK	0.78	7.61	0.35	1.78e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg19678392	chr7:94953810	PON1	-0.57	-7.79	-0.35	5.27e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.61	0.31	1.14e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg03388025	chr16:89894329	SPIRE2	0.33	7.14	0.33	4.22e-12	Vitiligo;
LUAD	trans	rs225245	0.791	rs720774	chr17:34017453	T/G	cg19694781	chr19:47549865	TMEM160	-0.47	-7.79	-0.35	5.17e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs230529	0.510	rs1120986	chr4:103436641	C/G	cg07973026	chr4:103553119	MANBA	0.4	6.55	0.3	1.7e-10	Schizophrenia (treatment resistant);
LUAD	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg01616529	chr11:638424	DRD4	-0.45	-6.48	-0.3	2.49e-10	Systemic lupus erythematosus;
LUAD	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg06263672	chr7:65235340	NA	0.49	6.55	0.3	1.64e-10	Aortic root size;
LUAD	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg06640241	chr16:89574553	SPG7	0.7	12.18	0.51	1.79e-29	Multiple myeloma (IgH translocation);
LUAD	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg13560548	chr3:10150139	C3orf24	0.42	6.93	0.32	1.54e-11	Alzheimer's disease;
LUAD	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg20503657	chr10:835505	NA	0.99	15.19	0.59	6.91e-42	Eosinophil percentage of granulocytes;
LUAD	cis	rs11229555	0.645	rs12290089	chr11:58176849	A/G	cg15696309	chr11:58395628	NA	-0.73	-10.21	-0.44	5.12e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg02951883	chr7:2050386	MAD1L1	-0.97	-19.5	-0.69	7.24e-61	Bipolar disorder and schizophrenia;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg15383120	chr6:291909	DUSP22	-0.7	-11.74	-0.5	9.65e-28	Menopause (age at onset);
LUAD	cis	rs11971779	0.680	rs6467843	chr7:139070523	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.76	0.31	4.63e-11	Diisocyanate-induced asthma;
LUAD	cis	rs2742417	0.603	rs2742372	chr3:45783472	T/C	cg10512202	chr3:45649293	LIMD1	0.48	8.91	0.4	1.53e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.86	12.37	0.52	3.34e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7119	0.717	rs12911963	chr15:77807175	G/C	cg27398640	chr15:77910606	LINGO1	-0.34	-6.38	-0.3	4.74e-10	Type 2 diabetes;
LUAD	cis	rs11098699	0.821	rs11735364	chr4:124185679	T/C	cg09941581	chr4:124220074	SPATA5	0.47	7.69	0.35	1.02e-13	Mosquito bite size;
LUAD	cis	rs13112683	0.638	rs7679281	chr4:140785036	G/A	cg02876341	chr4:140783585	MAML3	0.31	6.7	0.31	6.56e-11	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LUAD	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.31	7.01	0.32	9.47e-12	Parkinson's disease;
LUAD	cis	rs943466	1.000	rs6921487	chr6:33749293	G/A	cg16010596	chr6:33739607	LEMD2	-0.4	-7.88	-0.36	2.77e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg00316803	chr15:76480434	C15orf27	-0.41	-7.63	-0.35	1.56e-13	Blood metabolite levels;
LUAD	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg05991184	chr2:219186017	PNKD	-0.37	-7.02	-0.32	9.03e-12	Colorectal cancer;
LUAD	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg19875535	chr5:140030758	IK	-0.48	-8.06	-0.36	8.07e-15	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg18110333	chr6:292329	DUSP22	-0.76	-12.81	-0.53	5.71e-32	Menopause (age at onset);
LUAD	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg06558623	chr16:89946397	TCF25	0.65	7.43	0.34	6.04e-13	Skin colour saturation;
LUAD	cis	rs4919694	1.000	rs12254254	chr10:104765605	C/T	cg04362960	chr10:104952993	NT5C2	0.71	7.63	0.35	1.55e-13	Arsenic metabolism;
LUAD	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg25358565	chr5:93447407	FAM172A	0.6	7.1	0.33	5.41e-12	Diabetic retinopathy;
LUAD	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg07404485	chr7:94953653	PON1	-0.51	-7.55	-0.34	2.68e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs1160297	0.609	rs7577692	chr2:53105969	T/C	cg07782112	chr2:53107842	NA	0.42	8.97	0.4	9.57e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg13736514	chr6:26305472	NA	-0.7	-13.05	-0.54	5.96e-33	Educational attainment;
LUAD	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06544989	chr22:39130855	UNC84B	0.4	7.47	0.34	4.63e-13	Menopause (age at onset);
LUAD	cis	rs9487051	0.768	rs351729	chr6:109511668	T/C	cg01475377	chr6:109611718	NA	0.38	7.12	0.33	4.55e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg23815491	chr16:72088622	HP	0.48	7.78	0.35	5.69e-14	Blood protein levels;
LUAD	cis	rs113835537	0.935	rs117131621	chr11:66422334	C/T	cg24851651	chr11:66362959	CCS	0.58	8.01	0.36	1.11e-14	Airway imaging phenotypes;
LUAD	cis	rs490234	0.702	rs10986788	chr9:128303942	G/C	cg14078157	chr9:128172775	NA	-0.46	-8.28	-0.37	1.65e-15	Mean arterial pressure;
LUAD	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg08999081	chr20:33150536	PIGU	0.63	14.16	0.57	1.49e-37	Coronary artery disease;
LUAD	cis	rs558133	1.000	rs506500	chr5:78414337	C/T	cg25119155	chr5:78426943	BHMT	-0.52	-9.2	-0.41	1.68e-18	Blood and toenail selenium levels;
LUAD	trans	rs11671005	0.569	rs73068335	chr19:59089308	C/G	cg22037779	chr5:139682734	PFDN1	-0.71	-9.21	-0.41	1.58e-18	Mean platelet volume;
LUAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.8	14.89	0.59	1.25e-40	Lymphocyte counts;
LUAD	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg07677032	chr17:61819896	STRADA	-0.49	-8.45	-0.38	4.82e-16	Prudent dietary pattern;
LUAD	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg16405210	chr4:1374714	KIAA1530	-0.62	-9.77	-0.43	1.9e-20	Longevity;
LUAD	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	7.06	0.32	6.7e-12	Menarche (age at onset);
LUAD	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg12193833	chr17:30244370	NA	-0.58	-6.95	-0.32	1.35e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs36715	0.951	rs36698	chr5:127549749	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.47	6.52	0.3	1.99e-10	Breast cancer;
LUAD	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg11189052	chr15:85197271	WDR73	-0.64	-8.51	-0.38	3.01e-16	Schizophrenia;
LUAD	cis	rs929596	0.793	rs13009407	chr2:234652347	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.7	-9.81	-0.43	1.31e-20	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg04673462	chr1:38461896	NA	-0.39	-7.22	-0.33	2.48e-12	Coronary artery disease;
LUAD	cis	rs7712401	0.601	rs246275	chr5:122231413	C/T	cg19077854	chr5:122220652	SNX24	0.34	6.42	0.3	3.7e-10	Mean platelet volume;
LUAD	trans	rs1941687	0.509	rs7238029	chr18:31317755	A/G	cg15819921	chr19:927150	ARID3A	-0.45	-7.39	-0.34	7.83e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs79057730	0.599	rs78347394	chr7:831817	G/A	cg00020340	chr7:910388	UNC84A	0.63	6.75	0.31	4.85e-11	Initial pursuit acceleration;
LUAD	cis	rs17401966	1.000	rs6700866	chr1:10306038	A/G	cg15208524	chr1:10270712	KIF1B	0.55	8.23	0.37	2.33e-15	Hepatocellular carcinoma;
LUAD	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg15147215	chr3:52552868	STAB1	-0.4	-7.49	-0.34	3.92e-13	Electroencephalogram traits;
LUAD	cis	rs4700695	0.925	rs796728	chr5:65382500	C/T	cg21114390	chr5:65439923	SFRS12	-0.63	-8.0	-0.36	1.24e-14	Facial morphology (factor 19);
LUAD	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.4	-0.38	6.67e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg04025307	chr7:1156635	C7orf50	0.69	12.36	0.52	3.49e-30	Longevity;Endometriosis;
LUAD	cis	rs4700695	0.614	rs1864042	chr5:65206722	G/A	cg21114390	chr5:65439923	SFRS12	0.65	7.39	0.34	8.13e-13	Facial morphology (factor 19);
LUAD	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg12062639	chr20:23401060	NAPB	1.11	11.56	0.49	4.76e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9394841	0.692	rs3806113	chr6:41876335	C/T	cg17623882	chr6:41773611	USP49	-0.52	-6.93	-0.32	1.53e-11	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs7809950	0.906	rs62483723	chr7:107186358	A/C	cg23024343	chr7:107201750	COG5	-0.71	-11.96	-0.5	1.39e-28	Coronary artery disease;
LUAD	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg25703541	chr22:24373054	LOC391322	-0.79	-13.84	-0.56	3.43e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12545109	0.837	rs6474063	chr8:57355545	C/T	cg21220214	chr8:57350948	NA	-0.67	-9.38	-0.42	3.95e-19	Obesity-related traits;
LUAD	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg19163074	chr7:65112434	INTS4L2	0.42	6.45	0.3	3.08e-10	Aortic root size;
LUAD	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08219700	chr8:58056026	NA	0.62	8.03	0.36	9.74e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-7.49	-0.34	3.93e-13	Alzheimer's disease (late onset);
LUAD	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg03859395	chr2:55845619	SMEK2	0.68	12.13	0.51	3e-29	Metabolic syndrome;
LUAD	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg05082376	chr22:42548792	NA	0.45	7.8	0.35	4.73e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-6.73	-0.31	5.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs1018836	0.923	rs34126139	chr8:91572045	T/G	cg16814680	chr8:91681699	NA	-0.74	-12.62	-0.52	3.32e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs12545109	0.800	rs1467125	chr8:57418638	C/T	cg17761419	chr8:57350749	NA	-0.54	-7.78	-0.35	5.7e-14	Obesity-related traits;
LUAD	cis	rs113835537	0.529	rs7943327	chr11:66256581	G/C	cg24851651	chr11:66362959	CCS	0.55	9.69	0.43	3.42e-20	Airway imaging phenotypes;
LUAD	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21582582	chr3:182698605	DCUN1D1	0.61	10.32	0.45	2.1e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs1215050	0.791	rs11729826	chr4:98657190	G/T	cg24818145	chr4:99064322	C4orf37	-0.41	-6.77	-0.31	4.2e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg21475434	chr5:93447410	FAM172A	-0.76	-8.37	-0.38	8.26e-16	Diabetic retinopathy;
LUAD	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11890956	chr21:40555474	PSMG1	-0.49	-7.94	-0.36	1.9e-14	Menarche (age at onset);
LUAD	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.87	0.36	2.94e-14	Bladder cancer;
LUAD	cis	rs9863	0.931	rs7955815	chr12:124432706	C/T	cg17723958	chr12:124429295	CCDC92	-0.41	-6.54	-0.3	1.73e-10	White blood cell count;
LUAD	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg21016266	chr12:122356598	WDR66	0.71	12.84	0.53	4.09e-32	Mean corpuscular volume;
LUAD	cis	rs7945718	0.875	rs6486057	chr11:12810338	T/A	cg25843174	chr11:12811716	TEAD1	0.25	7.59	0.35	2.01e-13	Educational attainment (years of education);
LUAD	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg18512352	chr11:47633146	NA	-0.4	-7.03	-0.32	8.22e-12	Subjective well-being;
LUAD	cis	rs713587	0.563	rs2384057	chr2:25100167	C/G	cg01884057	chr2:25150051	NA	0.31	6.47	0.3	2.75e-10	Body mass index in non-asthmatics;
LUAD	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg01028140	chr2:1542097	TPO	-0.44	-7.34	-0.34	1.1e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18404041	chr3:52824283	ITIH1	-0.59	-11.84	-0.5	3.84e-28	Bipolar disorder;
LUAD	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg15147215	chr3:52552868	STAB1	-0.42	-7.51	-0.34	3.46e-13	Bipolar disorder;
LUAD	cis	rs8048589	0.577	rs8055516	chr16:12180198	A/T	cg03816625	chr16:12192430	SNX29	0.45	6.86	0.32	2.46e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg05434287	chr7:2030229	MAD1L1	0.42	6.78	0.31	4.06e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg02660097	chr11:68866761	NA	0.51	7.12	0.33	4.63e-12	Blond vs. brown hair color;
LUAD	cis	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-7.99	-0.36	1.34e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs62458065	1.000	rs10246687	chr7:32465183	T/A	cg00845942	chr12:64062724	DPY19L2	-0.46	-6.65	-0.31	9.17e-11	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08280861	chr8:58055591	NA	0.54	6.92	0.32	1.71e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg08601574	chr20:25228251	PYGB	-0.47	-8.82	-0.39	3.03e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2455601	0.507	rs7948452	chr11:8877704	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-7.7	-0.35	9.98e-14	Schizophrenia;
LUAD	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg23958373	chr8:599963	NA	1.04	9.71	0.43	2.96e-20	IgG glycosylation;
LUAD	cis	rs41311933	0.803	rs41313609	chr9:123721649	G/A	cg13567360	chr9:123745713	C5	-0.79	-6.91	-0.32	1.75e-11	Coronary artery disease;
LUAD	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg23978390	chr7:1156363	C7orf50	0.61	8.82	0.39	2.99e-17	Bronchopulmonary dysplasia;
LUAD	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg00321850	chr1:175162397	KIAA0040	0.56	11.9	0.5	2.29e-28	Alcohol dependence;
LUAD	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg21100191	chr22:23484243	RTDR1	-0.64	-11.17	-0.48	1.5e-25	Bone mineral density;
LUAD	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03934478	chr11:495069	RNH1	0.76	9.19	0.41	1.83e-18	Body mass index;
LUAD	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg12011299	chr4:100065546	ADH4	0.69	12.34	0.51	4.3e-30	Smoking initiation;
LUAD	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg04772025	chr11:68637568	NA	0.58	9.21	0.41	1.58e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7833986	0.501	rs72653921	chr8:56897157	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.91	14.57	0.58	2.96e-39	Height;
LUAD	cis	rs6906287	0.537	rs13192336	chr6:118875162	A/T	cg18833306	chr6:118973337	C6orf204	0.48	8.53	0.38	2.65e-16	Electrocardiographic conduction measures;
LUAD	cis	rs4523957	0.890	rs11655813	chr17:2119101	C/T	cg16513277	chr17:2031491	SMG6	-0.82	-15.86	-0.61	8.8e-45	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23158103	chr7:148848205	ZNF398	-0.64	-11.92	-0.5	1.99e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg20283391	chr11:68216788	NA	-0.41	-6.49	-0.3	2.39e-10	Total body bone mineral density;
LUAD	cis	rs11696501	0.688	rs6130894	chr20:44322673	G/A	cg11783356	chr20:44313418	WFDC10B	-0.51	-8.34	-0.38	1.09e-15	Brain structure;
LUAD	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg11062466	chr8:58055876	NA	0.65	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg04225089	chr17:73874465	TRIM47	-0.41	-7.06	-0.32	6.71e-12	Psoriasis;
LUAD	cis	rs354225	0.584	rs7591231	chr2:54829596	C/G	cg01766943	chr2:54829624	SPTBN1	0.41	7.71	0.35	9.01e-14	Schizophrenia;
LUAD	cis	rs6688613	0.721	rs2312675	chr1:166922533	T/C	cg07049167	chr1:166818506	POGK	0.53	8.3	0.37	1.4e-15	Refractive astigmatism;
LUAD	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.96	20.74	0.71	2.01e-66	Chronic sinus infection;
LUAD	trans	rs12517041	1.000	rs1428627	chr5:23309212	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs7524258	0.868	rs7544314	chr1:7266744	G/C	cg07173049	chr1:7289937	CAMTA1	0.5	9.31	0.41	6.95e-19	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs240764	0.717	rs6907444	chr6:101163606	G/T	cg09795085	chr6:101329169	ASCC3	-0.41	-7.19	-0.33	2.96e-12	Neuroticism;
LUAD	cis	rs6906287	0.552	rs7740645	chr6:118929208	T/A	cg21191810	chr6:118973309	C6orf204	0.51	9.79	0.43	1.52e-20	Electrocardiographic conduction measures;
LUAD	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg21475434	chr5:93447410	FAM172A	0.75	8.34	0.38	1.09e-15	Diabetic retinopathy;
LUAD	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg10544611	chr16:67998164	SLC12A4	-0.69	-8.23	-0.37	2.3e-15	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs7395662	0.895	rs2221553	chr11:48688784	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	2.03e-12	HDL cholesterol;
LUAD	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22857025	chr5:266934	NA	-0.97	-14.57	-0.58	2.9e-39	Breast cancer;
LUAD	trans	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.4	-0.38	7.05e-16	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1816752	1.000	rs7326932	chr13:25004493	A/T	cg02811702	chr13:24901961	NA	0.43	7.15	0.33	3.85e-12	Obesity-related traits;
LUAD	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg06766960	chr11:133703094	NA	-0.45	-8.49	-0.38	3.61e-16	Childhood ear infection;
LUAD	cis	rs17292804	0.506	rs71417868	chr14:104046592	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.82	-0.36	4.22e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.22	-0.37	2.49e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs727505	0.789	rs9641761	chr7:124735205	A/T	cg23710748	chr7:124431027	NA	-0.42	-8.51	-0.38	2.97e-16	Lewy body disease;
LUAD	cis	rs8177876	0.822	rs1563077	chr16:81107556	T/A	cg08591886	chr16:81111003	C16orf46	-0.76	-7.16	-0.33	3.58e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs243505	0.661	rs887570	chr7:148505255	A/G	cg09806900	chr7:148480153	CUL1	0.44	7.72	0.35	8.32e-14	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg11859384	chr17:80120422	CCDC57	-0.52	-9.45	-0.42	2.36e-19	Life satisfaction;
LUAD	cis	rs4846217	0.831	rs11121542	chr1:10393920	G/A	cg17425144	chr1:10567563	PEX14	-0.55	-6.9	-0.32	1.97e-11	Platelet count;
LUAD	cis	rs7119	0.604	rs2682921	chr15:77865459	C/T	cg27398640	chr15:77910606	LINGO1	0.37	6.84	0.32	2.7e-11	Type 2 diabetes;
LUAD	cis	rs4629710	0.592	rs3777476	chr6:131533821	A/C	cg12606694	chr6:131520996	AKAP7	0.49	7.33	0.34	1.2e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs7927771	0.524	rs7929725	chr11:47881740	A/G	cg18512352	chr11:47633146	NA	0.36	6.38	0.3	4.72e-10	Subjective well-being;
LUAD	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg13556452	chr1:2391241	NA	-0.45	-10.22	-0.44	4.82e-22	Schizophrenia;
LUAD	cis	rs7539409	0.764	rs4001465	chr1:84285304	T/C	cg10977910	chr1:84465055	TTLL7	0.7	7.08	0.33	5.97e-12	Alzheimer's disease;
LUAD	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg27124370	chr19:33622961	WDR88	0.46	7.4	0.34	7.51e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg23711669	chr6:146136114	FBXO30	-0.38	-6.35	-0.3	5.41e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1524976	0.941	rs1404550	chr3:65487427	G/C	cg16238336	chr3:65465873	MAGI1	0.65	7.49	0.34	4.07e-13	PR interval;
LUAD	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg21427119	chr20:30132790	HM13	-0.59	-8.82	-0.39	3.09e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUAD	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg19442545	chr10:75533431	FUT11	-0.47	-7.76	-0.35	6.41e-14	Inflammatory bowel disease;
LUAD	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg08742575	chr21:47604166	C21orf56	-0.63	-11.33	-0.48	3.5e-26	Testicular germ cell tumor;
LUAD	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg14686297	chr22:46650375	NA	-0.38	-6.54	-0.3	1.76e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6500395	1.000	rs9925406	chr16:48671436	C/A	cg04672837	chr16:48644449	N4BP1	0.38	6.69	0.31	7.06e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03647317	chr4:187891568	NA	-0.38	-7.38	-0.34	8.58e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs13315871	0.929	rs11130628	chr3:58315835	T/C	cg12435725	chr3:58293450	RPP14	-0.75	-8.45	-0.38	4.76e-16	Cholesterol, total;
LUAD	cis	rs2235649	0.833	rs9929262	chr16:1851928	T/C	cg08610935	chr16:1836813	NUBP2	-0.48	-7.19	-0.33	2.87e-12	Blood metabolite levels;
LUAD	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg23985595	chr17:80112537	CCDC57	-0.43	-7.81	-0.35	4.57e-14	Life satisfaction;
LUAD	cis	rs9399401	0.667	rs17071756	chr6:142715195	C/T	cg04461802	chr6:142623433	GPR126	-0.4	-7.87	-0.36	3.09e-14	Chronic obstructive pulmonary disease;
LUAD	cis	rs969413	0.624	rs9914093	chr17:79260653	C/G	cg14413466	chr17:79170920	AZI1	-0.34	-6.56	-0.3	1.53e-10	Frontotemporal dementia;
LUAD	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg00757033	chr12:89920650	WDR51B	0.67	11.64	0.49	2.25e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs10493773	0.502	rs12066742	chr1:86081149	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.45	-7.07	-0.33	6.32e-12	Urate levels in overweight individuals;
LUAD	cis	rs6479527	0.625	rs1933667	chr9:96744109	G/C	cg07076509	chr9:96720819	NA	0.36	6.64	0.31	9.7e-11	Esophageal adenocarcinoma;
LUAD	cis	rs7809950	0.678	rs7790080	chr7:107031322	G/A	cg23024343	chr7:107201750	COG5	-0.82	-13.97	-0.56	9.86e-37	Coronary artery disease;
LUAD	cis	rs3823572	0.542	rs2971971	chr7:133643848	A/G	cg03336402	chr7:133662267	EXOC4	-0.42	-7.62	-0.35	1.73e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs9929218	0.861	rs4783667	chr16:68752878	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.92	-16.39	-0.62	4.26e-47	Colorectal cancer;
LUAD	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-8.5	-0.38	3.18e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4660214	0.724	rs10788933	chr1:39695155	A/G	cg27567593	chr1:39956653	BMP8A	0.37	7.25	0.33	2.02e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.12e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg00383909	chr3:49044727	WDR6	0.91	9.99	0.44	3.19e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.5	0.3	2.31e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs7107174	1.000	rs2511187	chr11:77985849	T/A	cg02023728	chr11:77925099	USP35	0.47	7.26	0.33	1.89e-12	Testicular germ cell tumor;
LUAD	cis	rs2230307	0.656	rs521348	chr1:100481162	C/A	cg20868668	chr1:100435035	SLC35A3	0.63	7.58	0.35	2.23e-13	Carotid intima media thickness;
LUAD	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg00277334	chr10:82204260	NA	-0.95	-21.66	-0.73	1.52e-70	Post bronchodilator FEV1;
LUAD	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg00277334	chr10:82204260	NA	-0.62	-9.92	-0.43	5.4e-21	Post bronchodilator FEV1;
LUAD	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg12454169	chr2:30669597	LCLAT1	0.59	8.22	0.37	2.6e-15	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg14092571	chr14:90743983	NA	0.48	8.67	0.39	9.44e-17	Mortality in heart failure;
LUAD	trans	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg14791747	chr16:20752902	THUMPD1	-0.51	-7.62	-0.35	1.66e-13	Pancreatic cancer;
LUAD	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16211055	chr1:228594250	TRIM11	-0.41	-6.66	-0.31	8.34e-11	Height;
LUAD	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg00204512	chr16:28754710	NA	0.33	7.29	0.33	1.52e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg21130718	chr4:1044621	NA	-0.46	-8.05	-0.36	8.37e-15	Recombination rate (males);
LUAD	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg13736514	chr6:26305472	NA	-0.69	-12.82	-0.53	5.18e-32	Educational attainment;
LUAD	cis	rs12900413	0.603	rs2118848	chr15:90302503	T/C	cg24249390	chr15:90295951	MESP1	-0.35	-6.96	-0.32	1.27e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg17120908	chr11:65337727	SSSCA1	-0.6	-9.49	-0.42	1.68e-19	Bone mineral density;
LUAD	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg09365446	chr1:150670422	GOLPH3L	0.67	12.55	0.52	6.05e-31	Melanoma;
LUAD	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg10589385	chr1:150898437	SETDB1	0.39	7.42	0.34	6.51e-13	Tonsillectomy;
LUAD	trans	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg14791747	chr16:20752902	THUMPD1	-0.41	-6.41	-0.3	3.97e-10	Dental caries;
LUAD	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg18230493	chr5:56204884	C5orf35	-0.69	-10.97	-0.47	7.92e-25	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg03676636	chr4:99064102	C4orf37	0.3	7.25	0.33	2.02e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2154427	0.511	rs7279487	chr21:34001824	T/C	cg21871883	chr21:34145043	C21orf49;C21orf66	0.71	8.36	0.38	8.97e-16	Bilirubin levels;
LUAD	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg02592271	chr2:27665507	KRTCAP3	0.32	8.25	0.37	2.09e-15	Total body bone mineral density;
LUAD	trans	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg18335740	chr13:41363409	SLC25A15	0.77	15.06	0.59	2.49e-41	Lewy body disease;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04855141	chr3:128968634	COPG	-0.45	-7.64	-0.35	1.45e-13	Cancer;
LUAD	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg12623302	chr6:28058802	ZSCAN12L1	0.46	7.64	0.35	1.44e-13	Lung cancer in ever smokers;
LUAD	cis	rs41271473	0.948	rs12082771	chr1:228830777	C/T	cg10167378	chr1:228756711	NA	0.48	6.35	0.3	5.45e-10	Chronic lymphocytic leukemia;
LUAD	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg00106254	chr7:1943704	MAD1L1	0.51	7.73	0.35	7.76e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs7089973	0.872	rs17092497	chr10:116612628	G/A	cg25233709	chr10:116636983	FAM160B1	0.38	7.42	0.34	6.55e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg24450063	chr1:156163899	SLC25A44	-1.23	-30.77	-0.83	5.66e-110	Testicular germ cell tumor;
LUAD	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-7.39	-0.34	7.8e-13	Monocyte percentage of white cells;
LUAD	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg24397884	chr7:158709396	WDR60	0.65	8.99	0.4	8.18e-18	Height;
LUAD	cis	rs11811982	0.793	rs11799389	chr1:227323787	G/A	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic disc area;
LUAD	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg23985595	chr17:80112537	CCDC57	-0.52	-9.43	-0.42	2.82e-19	Life satisfaction;
LUAD	cis	rs7017914	0.967	rs6993115	chr8:71699183	G/C	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.43	-0.3	3.46e-10	Bone mineral density;
LUAD	cis	rs4604732	0.631	rs12031694	chr1:247623653	C/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.4	7.1	0.33	5.4e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg23505145	chr19:12996616	KLF1	0.62	10.51	0.46	4.09e-23	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg07402062	chr16:89894098	SPIRE2	0.42	9.22	0.41	1.44e-18	Vitiligo;
LUAD	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg18538332	chr22:24372958	LOC391322	-0.47	-7.98	-0.36	1.37e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14159672	chr1:205819179	PM20D1	0.59	10.79	0.46	3.99e-24	Menarche (age at onset);
LUAD	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg23992470	chr4:843637	GAK	0.68	7.15	0.33	3.78e-12	Parkinson's disease;
LUAD	trans	rs3219090	1.000	rs2793377	chr1:226600639	T/C	cg27539482	chr13:111589090	NA	0.43	7.2	0.33	2.79e-12	Melanoma;
LUAD	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.43	0.34	5.94e-13	Morning vs. evening chronotype;
LUAD	cis	rs17152411	1.000	rs12355869	chr10:126645231	G/T	cg07906193	chr10:126599966	NA	0.55	7.71	0.35	8.92e-14	Height;
LUAD	cis	rs7953508	0.711	rs11107120	chr12:93985482	T/C	cg18151635	chr12:93972918	NA	-0.72	-10.94	-0.47	1.04e-24	Pubertal anthropometrics;
LUAD	cis	rs1997103	0.954	rs6953004	chr7:55411919	G/A	cg17469321	chr7:55412551	NA	0.67	11.32	0.48	3.95e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg04545296	chr12:48745243	ZNF641	0.43	10.85	0.47	2.23e-24	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg02221422	chr11:68192511	LRP5	-0.44	-7.11	-0.33	4.89e-12	Total body bone mineral density;
LUAD	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27286337	chr10:134555280	INPP5A	0.73	9.71	0.43	2.92e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg24069376	chr3:38537580	EXOG	-0.29	-6.65	-0.31	8.88e-11	Electrocardiographic conduction measures;
LUAD	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.93	-0.32	1.62e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg11189052	chr15:85197271	WDR73	0.57	7.32	0.34	1.28e-12	Schizophrenia;
LUAD	cis	rs4006360	0.610	rs7503043	chr17:39295561	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.36	7.86	0.36	3.32e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg05340658	chr4:99064831	C4orf37	0.42	6.97	0.32	1.21e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs938554	0.779	rs11735831	chr4:9951591	G/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-7.97	-0.36	1.51e-14	Blood metabolite levels;
LUAD	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11644478	chr21:40555479	PSMG1	0.67	10.9	0.47	1.47e-24	Cognitive function;
LUAD	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg18196295	chr10:418757	DIP2C	-0.42	-6.35	-0.3	5.44e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.72	-0.31	5.8e-11	Bladder cancer;
LUAD	trans	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg26043149	chr18:55253948	FECH	-0.42	-6.86	-0.32	2.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs617219	0.889	rs36177073	chr5:78432757	G/A	cg25119155	chr5:78426943	BHMT	0.36	6.4	0.3	4.16e-10	Betaine levels in individuals undergoing cardiac evaluation;
LUAD	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.02	0.32	8.9e-12	Hypertriglyceridemia;
LUAD	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg23281280	chr6:28129359	ZNF389	0.45	6.56	0.3	1.62e-10	Depression;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19451435	chr6:158402916	SYNJ2	-0.55	-6.76	-0.31	4.57e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg25566285	chr7:158114605	PTPRN2	-0.54	-12.02	-0.5	8.12e-29	Calcium levels;
LUAD	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg03467027	chr4:99064603	C4orf37	0.41	6.7	0.31	6.61e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7493	0.901	rs13226149	chr7:95025600	G/A	cg04871131	chr7:94954202	PON1	-0.47	-6.45	-0.3	3.04e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg12365402	chr11:9010492	NRIP3	-0.45	-8.75	-0.39	5.14e-17	Hemoglobin concentration;
LUAD	cis	rs9837602	1.000	rs13069311	chr3:99801628	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.62	9.46	0.42	2.1e-19	Breast cancer;
LUAD	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg10792982	chr14:105748885	BRF1	0.39	8.51	0.38	3.01e-16	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs2040771	0.872	rs12485084	chr22:19162326	A/G	cg02655711	chr22:19163373	SLC25A1	0.6	11.49	0.49	9.12e-27	Metabolite levels (small molecules and protein measures);
LUAD	cis	rs2502731	0.539	rs3003608	chr9:130984430	C/A	cg13642260	chr9:130955380	CIZ1	0.4	6.83	0.32	2.93e-11	Attention deficit hyperactivity disorder;
LUAD	trans	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg27411982	chr8:10470053	RP1L1	0.42	7.49	0.34	4.15e-13	Mood instability;
LUAD	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-8.03	-0.36	9.78e-15	Blood metabolite levels;
LUAD	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg02269571	chr22:50332266	NA	0.87	9.8	0.43	1.48e-20	Schizophrenia;
LUAD	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg25036284	chr2:26402008	FAM59B	-0.73	-11.06	-0.47	3.73e-25	Gut microbiome composition (summer);
LUAD	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.8	-0.5	5.55e-28	Bipolar disorder;
LUAD	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg10755058	chr3:40428713	ENTPD3	-0.42	-7.98	-0.36	1.42e-14	Renal cell carcinoma;
LUAD	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg19875535	chr5:140030758	IK	0.47	7.71	0.35	8.78e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4356932	1.000	rs4371639	chr4:76946569	G/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-6.49	-0.3	2.36e-10	Blood protein levels;
LUAD	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg11707310	chr1:2537719	MMEL1	0.39	8.19	0.37	3.04e-15	Ulcerative colitis;
LUAD	cis	rs12760731	0.565	rs34041572	chr1:178184493	T/C	cg00404053	chr1:178313656	RASAL2	0.74	9.36	0.41	4.73e-19	Obesity-related traits;
LUAD	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg18240062	chr17:79603768	NPLOC4	0.38	6.78	0.31	4.17e-11	Eye color traits;
LUAD	trans	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg14917512	chr19:3094685	GNA11	0.58	6.85	0.32	2.64e-11	Diabetic kidney disease;
LUAD	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.53	-10.04	-0.44	1.99e-21	Schizophrenia;
LUAD	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg27432699	chr2:27873401	GPN1	-0.42	-7.04	-0.32	7.83e-12	Total body bone mineral density;
LUAD	trans	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	11.42	0.49	1.69e-26	Exhaled nitric oxide output;
LUAD	cis	rs790123	0.965	rs2133850	chr3:122381696	C/T	cg22896480	chr3:122379438	NA	0.4	6.65	0.31	9.32e-11	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg15147215	chr3:52552868	STAB1	-0.38	-7.06	-0.32	7.06e-12	Bipolar disorder;
LUAD	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.51	-10.65	-0.46	1.3e-23	Monocyte percentage of white cells;
LUAD	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00802000	chr16:706648	WDR90	-0.41	-7.75	-0.35	6.75e-14	Height;
LUAD	cis	rs9287719	0.601	rs10084172	chr2:10771228	A/C	cg02196655	chr2:10830764	NOL10	-0.38	-6.54	-0.3	1.76e-10	Prostate cancer;
LUAD	cis	rs11077998	0.967	rs4614761	chr17:80505809	C/T	cg10255544	chr17:80519551	FOXK2	0.33	6.57	0.3	1.51e-10	Reticulocyte fraction of red cells;
LUAD	trans	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.63	-10.26	-0.45	3.21e-22	Migraine;
LUAD	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg22875332	chr1:76189707	ACADM	0.79	13.0	0.53	9.42e-33	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg23803603	chr1:2058230	PRKCZ	-0.41	-6.96	-0.32	1.31e-11	Height;
LUAD	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.34	-7.2	-0.33	2.73e-12	Hemoglobin concentration;
LUAD	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	6.45	0.3	3.05e-10	Obesity-related traits;
LUAD	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg13319975	chr6:146136371	FBXO30	0.58	9.5	0.42	1.59e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-7.98	-0.36	1.38e-14	Morning vs. evening chronotype;
LUAD	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg00814883	chr7:100076585	TSC22D4	-0.84	-12.15	-0.51	2.37e-29	Platelet count;
LUAD	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg03806693	chr22:41940476	POLR3H	-0.45	-6.55	-0.3	1.68e-10	Vitiligo;
LUAD	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.32	6.91	0.32	1.81e-11	Parkinson's disease;
LUAD	cis	rs2274273	0.624	rs8014477	chr14:55841477	A/G	cg04306507	chr14:55594613	LGALS3	-0.38	-7.48	-0.34	4.23e-13	Protein biomarker;
LUAD	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg00204512	chr16:28754710	NA	0.32	6.88	0.32	2.15e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg07899956	chr17:74261249	FAM100B	-0.56	-6.75	-0.31	4.77e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg15501526	chr10:2543763	NA	0.71	14.39	0.57	1.68e-38	Age-related hearing impairment;
LUAD	cis	rs9300255	0.722	rs28458312	chr12:123863265	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	6.57	0.3	1.45e-10	Neutrophil percentage of white cells;
LUAD	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg05887092	chr17:76393375	PGS1	0.4	6.93	0.32	1.55e-11	HDL cholesterol levels;
LUAD	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg10755058	chr3:40428713	ENTPD3	-0.44	-8.55	-0.38	2.35e-16	Renal cell carcinoma;
LUAD	trans	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg24644049	chr4:85504048	CDS1	0.85	7.17	0.33	3.38e-12	Skin colour saturation;
LUAD	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg00339695	chr16:24857497	SLC5A11	0.48	8.97	0.4	9.39e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs9296092	0.538	rs5000098	chr6:33519231	T/G	cg13560919	chr6:33536144	NA	-0.87	-16.07	-0.62	1.05e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg10326891	chr4:88343821	NUDT9	0.42	6.49	0.3	2.35e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs17135859	1.000	rs13436223	chr5:112994345	T/C	cg12552261	chr5:112820674	MCC	0.56	7.59	0.35	2.12e-13	F-cell distribution;
LUAD	cis	rs2992756	0.663	rs1360915	chr1:18801804	T/C	cg14356550	chr1:18808102	KLHDC7A	-0.57	-9.75	-0.43	2.15e-20	Breast cancer;
LUAD	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg14092988	chr3:52407081	DNAH1	0.37	7.15	0.33	3.77e-12	Electroencephalogram traits;
LUAD	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.48	-0.3	2.55e-10	Parkinson's disease;
LUAD	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.54	-9.78	-0.43	1.62e-20	Longevity;Endometriosis;
LUAD	cis	rs77741769	0.571	rs869781	chr12:121340246	T/C	cg02419362	chr12:121203948	SPPL3	0.4	8.17	0.37	3.52e-15	Mean corpuscular volume;
LUAD	cis	rs8051149	0.688	rs16943320	chr16:87870379	A/G	cg01412419	chr16:87856264	NA	0.45	8.09	0.37	6.49e-15	Blood metabolite levels;
LUAD	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg15557168	chr22:42548783	NA	0.51	9.44	0.42	2.5e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.32	6.56	0.3	1.54e-10	Obesity-related traits;
LUAD	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg15704280	chr7:45808275	SEPT13	-0.64	-8.26	-0.37	1.89e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs12791968	1.000	rs11038237	chr11:45001880	C/T	cg11846598	chr11:44996168	LOC221122	-0.77	-13.88	-0.56	2.41e-36	Inhibitory control;
LUAD	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg22907277	chr7:1156413	C7orf50	0.56	9.61	0.42	6.66e-20	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg11062466	chr8:58055876	NA	0.83	10.66	0.46	1.13e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs11048434	0.736	rs4309200	chr12:9121856	A/C	cg04155231	chr12:9217510	LOC144571	0.38	7.11	0.33	5.02e-12	Sjögren's syndrome;
LUAD	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.28	-7.16	-0.33	3.59e-12	Total body bone mineral density;
LUAD	cis	rs713477	0.967	rs10150596	chr14:55916167	A/G	cg13175173	chr14:55914753	NA	0.34	7.07	0.33	6.49e-12	Pediatric bone mineral content (femoral neck);
LUAD	trans	rs75804782	0.521	rs58568091	chr2:239430582	G/A	cg01134436	chr17:81009848	B3GNTL1	0.77	8.48	0.38	3.81e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24531977	chr5:56204891	C5orf35	-0.96	-14.67	-0.58	1.15e-39	Initial pursuit acceleration;
LUAD	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg12365402	chr11:9010492	NRIP3	-0.52	-10.66	-0.46	1.19e-23	Hemoglobin concentration;
LUAD	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.51	-9.7	-0.43	3.28e-20	Longevity;Endometriosis;
LUAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	6.48	0.3	2.51e-10	Prudent dietary pattern;
LUAD	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg08610935	chr16:1836813	NUBP2	-0.47	-6.87	-0.32	2.25e-11	Insulin-like growth factors;
LUAD	trans	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.79	-14.98	-0.59	5.25e-41	Brugada syndrome;
LUAD	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg23172400	chr8:95962367	TP53INP1	-0.31	-7.26	-0.33	1.91e-12	Type 2 diabetes;
LUAD	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05901451	chr6:126070800	HEY2	-0.8	-14.8	-0.58	2.98e-40	Brugada syndrome;
LUAD	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg07570687	chr10:102243282	WNT8B	0.48	7.43	0.34	6.14e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs367615	0.660	rs10477972	chr5:108831951	C/A	cg17395555	chr5:108820864	NA	0.67	14.5	0.58	5.81e-39	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-8.15	-0.37	4.16e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs6906287	0.647	rs7769001	chr6:118934509	A/G	cg18833306	chr6:118973337	C6orf204	0.49	8.55	0.38	2.29e-16	Electrocardiographic conduction measures;
LUAD	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-9.96	-0.44	3.88e-21	Gout;Urate levels;Serum uric acid levels;
LUAD	trans	rs9393777	0.777	rs35984974	chr6:27410422	G/A	cg01620082	chr3:125678407	NA	-0.77	-8.88	-0.4	2e-17	Intelligence (multi-trait analysis);
LUAD	trans	rs9929218	1.000	rs9936621	chr16:68798682	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-13.67	-0.55	1.81e-35	Colorectal cancer;
LUAD	trans	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-11.13	-0.48	1.99e-25	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs733175	0.855	rs9291640	chr4:10007086	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	7.35	0.34	1.05e-12	Psychosis and Alzheimer's disease;
LUAD	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.31	-6.9	-0.32	1.93e-11	Dupuytren's disease;
LUAD	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg05340658	chr4:99064831	C4orf37	0.55	9.24	0.41	1.19e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.57	9.4	0.42	3.45e-19	Lymphocyte percentage of white cells;
LUAD	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg18099408	chr3:52552593	STAB1	-0.42	-7.18	-0.33	3.18e-12	Bipolar disorder;
LUAD	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg19761014	chr17:28927070	LRRC37B2	0.93	9.17	0.41	2.06e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg05590025	chr7:65112418	INTS4L2	-0.76	-7.97	-0.36	1.5e-14	Diabetic kidney disease;
LUAD	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg08798685	chr6:27730294	NA	-0.67	-7.09	-0.33	5.83e-12	Breast cancer;
LUAD	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.17	-0.37	3.66e-15	Prostate cancer;
LUAD	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg04944784	chr2:26401820	FAM59B	-0.7	-9.87	-0.43	8.29e-21	Gut microbiome composition (summer);
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg03395511	chr6:291903	DUSP22	-0.74	-12.59	-0.52	4.36e-31	Menopause (age at onset);
LUAD	trans	rs2840044	1.000	rs225295	chr17:33925755	A/G	cg19694781	chr19:47549865	TMEM160	-0.64	-10.27	-0.45	3.18e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg17105886	chr17:28927953	LRRC37B2	0.81	7.84	0.36	3.63e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg00666640	chr1:248458726	OR2T12	0.31	7.62	0.35	1.64e-13	Common traits (Other);
LUAD	cis	rs3820068	0.705	rs16851731	chr1:15860240	A/G	cg24675056	chr1:15929824	NA	0.43	6.96	0.32	1.34e-11	Systolic blood pressure;
LUAD	cis	rs4691139	0.658	rs11100589	chr4:165924720	T/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.42	-7.9	-0.36	2.36e-14	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg23625390	chr15:77176239	SCAPER	0.4	6.97	0.32	1.25e-11	Blood metabolite levels;
LUAD	trans	rs11083241	0.570	rs7243677	chr18:25558198	C/T	cg10537699	chr11:60897371	NA	-0.4	-6.53	-0.3	1.95e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg16322792	chr1:120165303	ZNF697	0.71	19.1	0.68	4.22e-59	Systemic lupus erythematosus;
LUAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg11766577	chr21:47581405	C21orf56	-0.49	-8.31	-0.37	1.34e-15	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.17e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg15557168	chr22:42548783	NA	-0.37	-6.77	-0.31	4.23e-11	Cognitive function;
LUAD	cis	rs16866061	1.000	rs11688397	chr2:225393173	C/T	cg12698349	chr2:225449008	CUL3	0.76	13.15	0.54	2.33e-33	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs736408	1.000	rs4687552	chr3:52838402	T/C	cg11645453	chr3:52864694	ITIH4	0.41	8.22	0.37	2.53e-15	Bipolar disorder;
LUAD	cis	rs1595825	0.891	rs73054808	chr2:198602283	C/T	cg11031976	chr2:198649780	BOLL	-0.47	-6.81	-0.31	3.42e-11	Ulcerative colitis;
LUAD	cis	rs807669	0.544	rs2040771	chr22:19161935	C/T	cg02655711	chr22:19163373	SLC25A1	0.62	12.3	0.51	5.97e-30	Metabolite levels;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg22049858	chr11:94884121	NA	-0.42	-6.48	-0.3	2.61e-10	Height;
LUAD	cis	rs8177876	0.822	rs8177950	chr16:81116895	A/G	cg08591886	chr16:81111003	C16orf46	-0.79	-7.37	-0.34	8.94e-13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg11707310	chr1:2537719	MMEL1	0.41	8.65	0.39	1.12e-16	Ulcerative colitis;
LUAD	cis	rs7617773	0.780	rs34523942	chr3:48342669	C/T	cg11946769	chr3:48343235	NME6	0.44	6.98	0.32	1.11e-11	Coronary artery disease;
LUAD	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg01788221	chr16:89496183	ANKRD11	-0.35	-6.53	-0.3	1.84e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs1395	1.000	rs3769143	chr2:27450724	A/G	cg23587288	chr2:27483067	SLC30A3	0.38	7.76	0.35	6.26e-14	Blood metabolite levels;
LUAD	trans	rs75804782	0.625	rs72984508	chr2:239462765	C/G	cg01134436	chr17:81009848	B3GNTL1	0.76	7.69	0.35	1.06e-13	Morning vs. evening chronotype;Chronotype;
LUAD	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg03395511	chr6:291903	DUSP22	-0.51	-8.4	-0.38	6.71e-16	Menopause (age at onset);
LUAD	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg05754148	chr16:3507555	NAT15	0.82	10.7	0.46	8.32e-24	Tuberculosis;
LUAD	cis	rs7937890	0.531	rs2597216	chr11:14533916	G/A	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.12e-10	Mitochondrial DNA levels;
LUAD	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg10978503	chr1:24200527	CNR2	0.59	12.85	0.53	3.8e-32	Immature fraction of reticulocytes;
LUAD	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11644478	chr21:40555479	PSMG1	0.69	11.37	0.48	2.5e-26	Cognitive function;
LUAD	trans	rs4653425	1.000	rs55965048	chr1:225884653	G/A	cg09308580	chr2:43405947	NA	0.38	6.56	0.3	1.61e-10	Neuroticism;
LUAD	cis	rs2130392	0.886	rs2077205	chr4:185637418	C/T	cg04058563	chr4:185651563	MLF1IP	0.38	6.72	0.31	5.81e-11	Kawasaki disease;
LUAD	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg06671706	chr8:8559999	CLDN23	-0.58	-10.18	-0.44	6.47e-22	Obesity-related traits;
LUAD	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.67	-0.35	1.2e-13	Resting heart rate;
LUAD	cis	rs2066819	1.000	rs1802236	chr12:56679751	A/G	cg26714650	chr12:56694279	CS	-0.86	-7.23	-0.33	2.25e-12	Psoriasis vulgaris;
LUAD	cis	rs10189230	0.868	rs1367242	chr2:222353441	A/G	cg14652038	chr2:222343519	EPHA4	0.43	8.56	0.38	2.14e-16	Urate levels in lean individuals;
LUAD	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-7.4	-0.34	7.59e-13	Personality dimensions;
LUAD	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.59	0.31	1.3100000000000001e-10	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg19862616	chr7:65841803	NCRNA00174	1.06	27.22	0.8	5.29e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.96	-0.36	1.59e-14	Prostate cancer;
LUAD	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg05043794	chr9:111880884	C9orf5	0.46	7.94	0.36	1.88e-14	Menarche (age at onset);
LUAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27297192	chr10:134578999	INPP5A	0.38	6.68	0.31	7.6e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs4285028	0.948	rs34543553	chr3:121675637	C/T	cg20356878	chr3:121714668	ILDR1	-0.5	-6.75	-0.31	5.04e-11	Multiple sclerosis;
LUAD	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg13379983	chr2:198649727	BOLL	0.45	6.4	0.3	4.17e-10	Ulcerative colitis;
LUAD	cis	rs1143633	0.553	rs2723197	chr2:113689747	G/A	cg12858261	chr2:113808755	IL1F8	-0.36	-6.53	-0.3	1.86e-10	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg25358565	chr5:93447407	FAM172A	0.55	6.53	0.3	1.86e-10	Diabetic retinopathy;
LUAD	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-8.02	-0.36	1.05e-14	Body mass index;
LUAD	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.33e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.891	rs16824376	chr2:198684342	C/T	cg10547527	chr2:198650123	BOLL	-0.54	-7.63	-0.35	1.5700000000000001e-13	Ulcerative colitis;
LUAD	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg00784671	chr22:46762841	CELSR1	-0.62	-7.62	-0.35	1.65e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-7.76	-0.35	6.62e-14	Alzheimer's disease (late onset);
LUAD	cis	rs1595825	0.891	rs73056840	chr2:198783466	C/A	cg00982548	chr2:198649783	BOLL	-0.63	-9.1	-0.4	3.47e-18	Ulcerative colitis;
LUAD	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg04155289	chr7:94953770	PON1	-0.52	-6.97	-0.32	1.22e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg07217954	chr7:1067459	C7orf50	-0.37	-6.6	-0.31	1.26e-10	Bronchopulmonary dysplasia;
LUAD	cis	rs7119	0.604	rs2458035	chr15:77862806	G/A	cg27398640	chr15:77910606	LINGO1	0.36	6.75	0.31	4.76e-11	Type 2 diabetes;
LUAD	cis	rs11893307	0.507	rs1465303	chr2:191585440	A/C	cg27211696	chr2:191398769	TMEM194B	-0.41	-6.87	-0.32	2.36e-11	Mean platelet volume;
LUAD	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg08470875	chr2:26401718	FAM59B	-0.77	-10.38	-0.45	1.18e-22	Gut microbiome composition (summer);
LUAD	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg21918786	chr6:109611834	NA	-0.6	-11.28	-0.48	5.8e-26	Reticulocyte fraction of red cells;
LUAD	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.95	-0.44	4.34e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg09065629	chr16:1709722	CRAMP1L	0.41	7.11	0.33	5e-12	Coronary artery disease;
LUAD	cis	rs9469890	0.604	rs11756280	chr6:34503439	T/C	cg14254433	chr6:34482411	PACSIN1	-0.58	-8.36	-0.38	8.99e-16	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg26513180	chr16:89883248	FANCA	0.48	7.74	0.35	7.22e-14	Vitiligo;
LUAD	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg04455712	chr21:45112962	RRP1B	0.42	8.63	0.39	1.27e-16	Mean corpuscular volume;
LUAD	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00149659	chr3:10157352	C3orf10	-0.64	-9.08	-0.4	4.09e-18	Alzheimer's disease;
LUAD	trans	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg26043149	chr18:55253948	FECH	-0.49	-8.0	-0.36	1.22e-14	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06022373	chr22:39101656	GTPBP1	0.46	7.1	0.33	5.28e-12	Menopause (age at onset);
LUAD	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg20701182	chr2:24300061	SF3B14	0.57	6.9	0.32	1.9e-11	Lymphocyte counts;
LUAD	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg05043794	chr9:111880884	C9orf5	-0.42	-7.17	-0.33	3.42e-12	Menarche (age at onset);
LUAD	trans	rs62458065	0.850	rs6462362	chr7:32464733	C/T	cg00845942	chr12:64062724	DPY19L2	-0.53	-7.33	-0.34	1.18e-12	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg03467027	chr4:99064603	C4orf37	0.4	6.48	0.3	2.59e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg02423579	chr7:2872169	GNA12	-0.82	-14.42	-0.57	1.31e-38	Height;
LUAD	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg17063962	chr7:91808500	NA	-0.66	-11.3	-0.48	4.72e-26	Breast cancer;
LUAD	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg14228332	chr4:119757509	SEC24D	0.81	7.58	0.35	2.24e-13	Cannabis dependence symptom count;
LUAD	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.45	0.3	3.11e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12620999	0.941	rs13005377	chr2:238037759	T/C	cg23555395	chr2:238036564	NA	-0.6	-9.24	-0.41	1.24e-18	Systemic lupus erythematosus;
LUAD	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg09658497	chr7:2847517	GNA12	-0.51	-8.45	-0.38	4.88e-16	Height;
LUAD	cis	rs853679	0.607	rs56189111	chr6:28271973	C/A	cg12623302	chr6:28058802	ZSCAN12L1	0.54	6.38	0.3	4.78e-10	Depression;
LUAD	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-7.43	-0.34	6.11e-13	Neutrophil percentage of white cells;
LUAD	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg10792982	chr14:105748885	BRF1	0.47	10.15	0.44	8.55e-22	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg01206211	chr2:36825736	FEZ2	0.51	9.21	0.41	1.56e-18	Height;
LUAD	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.92	-0.53	2.07e-32	Dilated cardiomyopathy;
LUAD	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg08280861	chr8:58055591	NA	0.52	7.18	0.33	3.2e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg02887458	chr19:19495540	GATAD2A	-0.38	-6.36	-0.3	5.33e-10	Bipolar disorder;
LUAD	cis	rs17102423	0.594	rs1270074	chr14:65564856	T/C	cg11161011	chr14:65562177	MAX	-0.42	-7.13	-0.33	4.48e-12	Obesity-related traits;
LUAD	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg22920501	chr2:26401640	FAM59B	0.9	12.65	0.52	2.38e-31	Gut microbiome composition (summer);
LUAD	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg03037974	chr15:76606532	NA	0.4	8.82	0.39	3.11e-17	Blood metabolite levels;
LUAD	cis	rs1941023	0.567	rs955019	chr11:60174250	C/T	cg08716584	chr11:60157161	MS4A7	-0.34	-6.54	-0.3	1.73e-10	Congenital heart disease (maternal effect);
LUAD	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg15704280	chr7:45808275	SEPT13	-0.61	-9.06	-0.4	4.82e-18	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg21605333	chr4:119757512	SEC24D	0.92	8.39	0.38	7.31e-16	Cannabis dependence symptom count;
LUAD	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.06	-0.54	5.67e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21659725	chr3:3221576	CRBN	0.51	8.06	0.36	7.95e-15	Body mass index;
LUAD	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06022373	chr22:39101656	GTPBP1	-0.42	-6.45	-0.3	3.02e-10	Menopause (age at onset);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08320164	chr19:18228740	MAST3	-0.67	-6.54	-0.3	1.75e-10	Type 2 diabetes;
LUAD	cis	rs7582720	1.000	rs72936862	chr2:203786812	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9650657	0.771	rs12542888	chr8:10662555	A/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.41	-0.3	3.99e-10	Neuroticism;
LUAD	cis	rs71478720	0.779	rs34389688	chr11:112056400	A/T	cg04929355	chr11:112034997	IL18	0.4	6.55	0.3	1.63e-10	Interleukin-18 levels;
LUAD	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg15839431	chr19:19639596	YJEFN3	-0.53	-8.63	-0.39	1.3e-16	Bipolar disorder;
LUAD	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg16647868	chr5:131706066	SLC22A5	-0.41	-7.07	-0.32	6.63e-12	Blood metabolite levels;
LUAD	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg23625390	chr15:77176239	SCAPER	-0.36	-6.6	-0.31	1.22e-10	Blood metabolite levels;
LUAD	cis	rs7737355	0.812	rs11242083	chr5:130927526	A/T	cg25547332	chr5:131281432	NA	0.4	6.44	0.3	3.31e-10	Life satisfaction;
LUAD	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg21798802	chr22:38057573	PDXP	0.36	7.24	0.33	2.15e-12	Fat distribution (HIV);
LUAD	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	9.43	0.42	2.65e-19	Hip circumference adjusted for BMI;
LUAD	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg23758822	chr17:41437982	NA	1.01	21.0	0.71	1.37e-67	Menopause (age at onset);
LUAD	cis	rs1395	0.778	rs17005956	chr2:27451099	C/T	cg23587288	chr2:27483067	SLC30A3	-0.4	-7.45	-0.34	5.19e-13	Blood metabolite levels;
LUAD	cis	rs77741769	0.571	rs61946382	chr12:121344574	A/T	cg02419362	chr12:121203948	SPPL3	0.41	8.28	0.37	1.62e-15	Mean corpuscular volume;
LUAD	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg24829409	chr8:58192753	C8orf71	-0.51	-6.64	-0.31	9.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs4072705	1.000	rs2416949	chr9:127475111	C/T	cg13476313	chr9:127244764	NR5A1	0.29	7.04	0.32	7.99e-12	Menarche (age at onset);
LUAD	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg18230493	chr5:56204884	C5orf35	-0.45	-7.58	-0.35	2.15e-13	Coronary artery disease;
LUAD	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.37	7.82	0.36	4.36e-14	Parkinson's disease;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01212965	chr4:106630041	GSTCD;INTS12	-0.42	-6.49	-0.3	2.41e-10	Height;
LUAD	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg11166453	chr1:247681781	NA	0.38	7.28	0.33	1.68e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg27170947	chr2:26402098	FAM59B	-0.63	-8.78	-0.39	3.98e-17	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg23018236	chr17:30244563	NA	-0.59	-7.78	-0.35	5.64e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg18402987	chr7:1209562	NA	0.61	8.91	0.4	1.5e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1298062	0.771	rs4801833	chr19:50995932	T/G	cg11430371	chr19:50961752	MYBPC2	0.32	6.53	0.3	1.9e-10	Age of smoking initiation;
LUAD	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.25	-0.37	2.05e-15	Alzheimer's disease;
LUAD	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg15117754	chr3:10150083	C3orf24	0.42	6.76	0.31	4.56e-11	Alzheimer's disease;
LUAD	cis	rs909002	0.925	rs7524405	chr1:32108579	A/C	cg13919466	chr1:32135498	COL16A1	0.35	8.12	0.37	5.19e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs16910800	1.000	rs2468646	chr11:23202166	T/C	cg20040320	chr11:23191996	NA	0.48	7.33	0.34	1.21e-12	Cancer;
LUAD	cis	rs13394619	0.840	rs11674605	chr2:11722575	A/G	cg07314298	chr2:11723111	GREB1	-0.54	-9.93	-0.43	4.92e-21	Endometriosis;
LUAD	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg13385794	chr1:248469461	NA	0.26	6.8	0.31	3.68e-11	Common traits (Other);
LUAD	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg03676636	chr4:99064102	C4orf37	0.31	8.27	0.37	1.81e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg25173405	chr17:45401733	C17orf57	0.57	9.87	0.43	8.26e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.18	0.33	3.13e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs4942242	0.663	rs9525815	chr13:44223692	T/C	cg19169023	chr15:41853346	TYRO3	-0.68	-11.39	-0.48	2.06e-26	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs1493916	0.967	rs9953765	chr18:31399464	A/G	cg15819921	chr19:927150	ARID3A	-0.44	-7.2	-0.33	2.81e-12	Life satisfaction;
LUAD	cis	rs1595825	0.891	rs73056840	chr2:198783466	C/A	cg11031976	chr2:198649780	BOLL	-0.48	-7.19	-0.33	2.89e-12	Ulcerative colitis;
LUAD	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg03806693	chr22:41940476	POLR3H	0.62	8.64	0.39	1.17e-16	Vitiligo;
LUAD	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg00933542	chr6:150070202	PCMT1	0.36	7.38	0.34	8.26e-13	Testicular germ cell tumor;
LUAD	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg12035532	chr1:1886765	KIAA1751	0.38	6.4	0.3	4.08e-10	Body mass index;
LUAD	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg01028140	chr2:1542097	TPO	-0.53	-7.15	-0.33	3.84e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg02775129	chr4:119771670	NA	-0.88	-8.35	-0.38	9.73e-16	Cannabis dependence symptom count;
LUAD	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg11905131	chr22:24372483	LOC391322	-0.57	-9.53	-0.42	1.22e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg24818145	chr4:99064322	C4orf37	0.44	7.39	0.34	8.07e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg27539214	chr16:67997921	SLC12A4	-0.71	-8.79	-0.39	3.68e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9902453	0.902	rs4075014	chr17:28305674	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.87	0.4	2.07e-17	Coffee consumption (cups per day);
LUAD	trans	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg03929089	chr4:120376271	NA	-0.52	-6.92	-0.32	1.69e-11	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg16205897	chr5:131564050	P4HA2	-0.33	-7.33	-0.34	1.21e-12	Breast cancer;
LUAD	cis	rs7100689	0.580	rs2168721	chr10:82208192	A/G	cg00277334	chr10:82204260	NA	-0.83	-15.73	-0.61	3.22e-44	Post bronchodilator FEV1;
LUAD	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.14	-0.44	8.67e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg20607798	chr8:58055168	NA	0.71	9.28	0.41	8.74e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs11077998	0.844	rs1109123	chr17:80522391	T/C	cg10255544	chr17:80519551	FOXK2	0.34	6.69	0.31	7.18e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg00204512	chr16:28754710	NA	0.36	7.84	0.36	3.62e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-16.92	-0.64	1.94e-49	Exhaled nitric oxide output;
LUAD	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg18512352	chr11:47633146	NA	-0.42	-7.28	-0.33	1.67e-12	Subjective well-being;
LUAD	cis	rs2227564	0.649	rs2688626	chr10:75611090	G/A	cg00564723	chr10:75632066	CAMK2G	-0.32	-6.72	-0.31	5.99e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg19717773	chr7:2847554	GNA12	-0.53	-10.06	-0.44	1.71e-21	Height;
LUAD	cis	rs500891	0.504	rs1145897	chr6:84040440	C/T	cg08257003	chr6:84140564	ME1	0.34	6.68	0.31	7.45e-11	Platelet-derived growth factor BB levels;
LUAD	trans	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg00953403	chr17:74099816	EXOC7	-0.5	-7.69	-0.35	1.02e-13	Psychosis in Alzheimer's disease;
LUAD	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.61	-0.31	1.19e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs79057730	0.684	rs6955004	chr7:790792	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.89	10.05	0.44	1.91e-21	Initial pursuit acceleration;
LUAD	cis	rs2404602	0.591	rs11635162	chr15:76951105	C/T	cg23625390	chr15:77176239	SCAPER	-0.47	-6.58	-0.3	1.43e-10	Blood metabolite levels;
LUAD	trans	rs6076960	0.684	rs6054058	chr20:6262187	T/C	cg21095983	chr6:86352623	SYNCRIP	0.43	6.95	0.32	1.41e-11	Smooth-surface caries;
LUAD	cis	rs739496	0.947	rs28362508	chr12:111884415	T/C	cg10833066	chr12:111807467	FAM109A	0.4	6.48	0.3	2.49e-10	Platelet count;
LUAD	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg18129748	chr3:49941408	MST1R	-0.4	-6.51	-0.3	2.14e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg11618577	chr2:27665543	KRTCAP3	-0.27	-7.22	-0.33	2.43e-12	Total body bone mineral density;
LUAD	cis	rs7551222	0.634	rs12139477	chr1:204553104	A/C	cg20240347	chr1:204465584	NA	-0.33	-6.45	-0.3	2.98e-10	Schizophrenia;
LUAD	trans	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg26043149	chr18:55253948	FECH	-0.42	-6.87	-0.32	2.35e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg27490568	chr2:178487706	NA	0.58	8.6	0.39	1.55e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg06558623	chr16:89946397	TCF25	1.2	11.02	0.47	5.38e-25	Skin colour saturation;
LUAD	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg10802521	chr3:52805072	NEK4	-0.47	-7.95	-0.36	1.73e-14	Electroencephalogram traits;
LUAD	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.75	16.02	0.61	1.82e-45	White blood cell count;
LUAD	cis	rs7116495	1.000	rs671681	chr11:71782812	T/C	cg07596299	chr11:71824057	C11orf51	-0.77	-6.53	-0.3	1.86e-10	Severe influenza A (H1N1) infection;
LUAD	trans	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg04775059	chr7:64541387	NA	0.48	6.45	0.3	3.03e-10	Aortic root size;
LUAD	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.7	-12.91	-0.53	2.26e-32	Axial length;
LUAD	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg14671364	chr1:107599128	PRMT6	-0.63	-10.82	-0.47	2.87e-24	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg10434728	chr15:90938212	IQGAP1	-0.37	-7.33	-0.34	1.18e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg06092702	chr1:163392909	NA	-0.35	-7.75	-0.35	6.68e-14	Motion sickness;
LUAD	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg07741184	chr6:167504864	NA	0.36	8.35	0.38	9.89e-16	Crohn's disease;
LUAD	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg08885076	chr2:99613938	TSGA10	0.37	6.66	0.31	8.32e-11	Chronic sinus infection;
LUAD	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-7.36	-0.34	9.67e-13	Morning vs. evening chronotype;
LUAD	cis	rs2859741	0.967	rs592520	chr1:37513503	G/C	cg09363841	chr1:37513479	NA	-0.38	-9.81	-0.43	1.35e-20	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-8.41	-0.38	6.27e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs989128	0.600	rs8082568	chr17:48629312	G/C	cg24438145	chr17:48624694	SPATA20	0.36	6.42	0.3	3.77e-10	Type 2 diabetes;
LUAD	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg24550644	chr17:30846204	MYO1D	-0.39	-6.74	-0.31	5.09e-11	Schizophrenia;
LUAD	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg05368731	chr17:41323189	NBR1	0.95	19.53	0.69	5.13e-61	Menopause (age at onset);
LUAD	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13012494	chr21:47604986	C21orf56	0.55	9.28	0.41	8.79e-19	Testicular germ cell tumor;
LUAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14893161	chr1:205819251	PM20D1	0.96	23.81	0.76	4.05e-80	Menarche (age at onset);
LUAD	cis	rs11771526	0.901	rs11767695	chr7:32315960	G/A	cg27532318	chr7:32358331	NA	0.61	7.64	0.35	1.48e-13	Body mass index;
LUAD	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg05342682	chr7:94953680	PON1	-0.5	-6.94	-0.32	1.53e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-7.2	-0.33	2.76e-12	Bipolar disorder;
LUAD	trans	rs11039798	0.541	rs12283728	chr11:48796407	G/A	cg02254774	chr11:50257496	LOC441601	0.53	6.68	0.31	7.63e-11	Axial length;
LUAD	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-14.04	-0.56	5.2e-37	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9369695	0.883	rs9473128	chr6:47505010	C/T	cg02130027	chr6:47444894	CD2AP	0.36	6.88	0.32	2.11e-11	Reticulocyte count;
LUAD	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg24531977	chr5:56204891	C5orf35	0.46	7.55	0.34	2.73e-13	Coronary artery disease;
LUAD	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	8.16	0.37	3.86e-15	Rheumatoid arthritis;
LUAD	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg02880119	chr16:3481970	NA	0.56	8.45	0.38	4.67e-16	Body mass index (adult);
LUAD	cis	rs4662945	0.603	rs10168574	chr2:130267823	C/T	cg05962382	chr2:130345044	NA	-0.39	-7.1	-0.33	5.21e-12	Response to cytidine analogues (gemcitabine);
LUAD	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07636037	chr3:49044803	WDR6	-0.48	-8.01	-0.36	1.15e-14	Menarche (age at onset);
LUAD	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg26384229	chr12:38710491	ALG10B	-0.45	-7.67	-0.35	1.23e-13	Morning vs. evening chronotype;
LUAD	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg05082376	chr22:42548792	NA	-0.39	-6.92	-0.32	1.7e-11	Cognitive function;
LUAD	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg11062466	chr8:58055876	NA	0.45	6.37	0.3	5.07e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg00383909	chr3:49044727	WDR6	0.73	8.4	0.38	6.75e-16	Cognitive function;
LUAD	cis	rs7975161	0.638	rs7137288	chr12:104591886	C/A	cg04063896	chr12:104565784	NA	-0.38	-6.9	-0.32	1.95e-11	Toenail selenium levels;
LUAD	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg00071950	chr4:10020882	SLC2A9	0.74	14.9	0.59	1.18e-40	Bone mineral density;
LUAD	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg06641503	chr3:48959341	ARIH2	-0.38	-6.36	-0.3	5.13e-10	Menarche (age at onset);
LUAD	cis	rs4660306	1.000	rs7536557	chr1:45992114	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.41	-6.69	-0.31	6.96e-11	Homocysteine levels;
LUAD	cis	rs10129255	0.500	rs8006888	chr14:107190456	A/C	cg23076370	chr14:107095027	NA	-0.44	-8.72	-0.39	6.36e-17	Kawasaki disease;
LUAD	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg00316803	chr15:76480434	C15orf27	-0.41	-7.67	-0.35	1.19e-13	Blood metabolite levels;
LUAD	cis	rs2882667	0.898	rs11952020	chr5:138395156	A/T	cg04439458	chr5:138467593	SIL1	-0.4	-7.36	-0.34	9.48e-13	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.6	11.33	0.48	3.62e-26	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.67	-0.49	1.81e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg18335740	chr13:41363409	SLC25A15	-0.52	-8.78	-0.39	4.01e-17	Lewy body disease;
LUAD	cis	rs775227	0.574	rs79709668	chr3:113161265	G/A	cg10517650	chr3:113235015	CCDC52	-0.48	-6.83	-0.31	3.05e-11	Dental caries;
LUAD	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg26513180	chr16:89883248	FANCA	0.8	7.16	0.33	3.56e-12	Skin colour saturation;
LUAD	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg13385794	chr1:248469461	NA	0.27	7.28	0.33	1.63e-12	Common traits (Other);
LUAD	cis	rs7771547	0.519	rs7773253	chr6:36373451	T/A	cg07856975	chr6:36356162	ETV7	0.52	7.83	0.36	4.03e-14	Platelet distribution width;
LUAD	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.29	6.51	0.3	2.14e-10	Parkinson's disease;
LUAD	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg02782426	chr3:40428986	ENTPD3	0.42	9.27	0.41	9.8e-19	Renal cell carcinoma;
LUAD	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg02176678	chr2:219576539	TTLL4	0.75	15.1	0.59	1.64e-41	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg04407233	chr1:10042538	NMNAT1	0.41	6.48	0.3	2.51e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg13902645	chr11:5959945	NA	-0.5	-8.9	-0.4	1.64e-17	DNA methylation (variation);
LUAD	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs877282	0.898	rs35743076	chr10:758991	C/T	cg06581033	chr10:766294	NA	-0.57	-7.57	-0.35	2.37e-13	Uric acid levels;
LUAD	cis	rs2455601	0.608	rs11042104	chr11:8890924	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.5	8.17	0.37	3.57e-15	Schizophrenia;
LUAD	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg04990556	chr1:26633338	UBXN11	-0.43	-6.99	-0.32	1.08e-11	Obesity-related traits;
LUAD	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg14552801	chr7:65878734	NA	-0.38	-6.38	-0.3	4.75e-10	Aortic root size;
LUAD	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg09085632	chr11:111637200	PPP2R1B	0.62	9.27	0.41	9.68e-19	Primary sclerosing cholangitis;
LUAD	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg05373962	chr22:49881684	NA	-0.55	-13.12	-0.54	3.07e-33	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.73	0.31	5.39e-11	Prudent dietary pattern;
LUAD	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg05110241	chr16:68378359	PRMT7	-0.68	-7.81	-0.35	4.71e-14	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs4824093	0.610	rs7410773	chr22:50313727	A/G	cg09872104	chr7:134855509	C7orf49	-0.81	-7.24	-0.33	2.14e-12	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg00280220	chr17:61926910	NA	0.37	7.05	0.32	7.37e-12	Prudent dietary pattern;
LUAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.71	12.96	0.53	1.35e-32	Lymphocyte counts;
LUAD	trans	rs11088226	0.681	rs11700670	chr21:33938615	T/C	cg09050820	chr6:167586206	TCP10L2	0.91	12.44	0.52	1.65e-30	Gastritis;
LUAD	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg25985355	chr7:65971099	NA	-0.51	-6.35	-0.3	5.48e-10	Diabetic kidney disease;
LUAD	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg14458575	chr2:238380390	NA	0.96	18.07	0.66	1.69e-54	Prostate cancer;
LUAD	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg10729496	chr3:10149963	C3orf24	0.64	9.52	0.42	1.38e-19	Alzheimer's disease;
LUAD	cis	rs9296095	0.607	rs9366824	chr6:33521577	C/T	cg14003231	chr6:33640908	ITPR3	0.47	8.59	0.39	1.74e-16	Platelet count;
LUAD	cis	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05901451	chr6:126070800	HEY2	-0.44	-6.52	-0.3	2.05e-10	Endometrial cancer;
LUAD	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.78	10.85	0.47	2.3e-24	Smoking behavior;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg27523951	chr13:46038867	COG3	-0.39	-6.39	-0.3	4.27e-10	Subcortical brain region volumes;
LUAD	trans	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg04995722	chr7:26192034	NFE2L3	0.37	6.53	0.3	1.86e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg01788221	chr16:89496183	ANKRD11	-0.36	-6.8	-0.31	3.62e-11	Multiple myeloma (IgH translocation);
LUAD	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg05340658	chr4:99064831	C4orf37	0.43	7.24	0.33	2.13e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7680126	0.596	rs12503603	chr4:10313757	T/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-7.32	-0.34	1.28e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08219700	chr8:58056026	NA	0.56	7.77	0.35	5.91e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg23758822	chr17:41437982	NA	1.01	20.95	0.71	2.33e-67	Menopause (age at onset);
LUAD	cis	rs9487051	0.799	rs830553	chr6:109550017	T/G	cg21918786	chr6:109611834	NA	-0.43	-7.53	-0.34	3.01e-13	Reticulocyte fraction of red cells;
LUAD	trans	rs877282	0.583	rs11253425	chr10:815173	G/A	cg22713356	chr15:30763199	NA	0.86	10.77	0.46	4.72e-24	Uric acid levels;
LUAD	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg26408565	chr15:76604113	ETFA	-0.45	-7.36	-0.34	9.62e-13	Blood metabolite levels;
LUAD	cis	rs12618769	0.652	rs3769708	chr2:99187650	T/C	cg10123293	chr2:99228465	UNC50	0.48	8.66	0.39	1.03e-16	Bipolar disorder;
LUAD	cis	rs2421770	0.530	rs3847622	chr11:35368700	A/G	cg13971030	chr11:35366721	SLC1A2	0.47	8.34	0.38	1.08e-15	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg18404041	chr3:52824283	ITIH1	-0.67	-14.95	-0.59	7e-41	Bipolar disorder;
LUAD	cis	rs35771425	0.500	rs3738199	chr1:211545344	A/G	cg26515805	chr1:211431828	RCOR3	-0.41	-8.25	-0.37	2e-15	Educational attainment (years of education);
LUAD	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg15181151	chr6:150070149	PCMT1	0.33	6.54	0.3	1.81e-10	Lung cancer;
LUAD	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg09455208	chr3:40491958	NA	0.65	14.29	0.57	4.25e-38	Renal cell carcinoma;
LUAD	cis	rs6665290	0.904	rs1343743	chr1:227183125	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.43	-0.89	9.16e-144	Myeloid white cell count;
LUAD	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.31	6.73	0.31	5.43e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9369695	0.881	rs9349409	chr6:47463126	G/T	cg20196966	chr6:47445060	CD2AP	0.45	6.99	0.32	1.04e-11	Reticulocyte count;
LUAD	cis	rs9902453	1.000	rs9890886	chr17:28391076	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.29	-0.41	7.91e-19	Coffee consumption (cups per day);
LUAD	cis	rs4006360	0.629	rs2132842	chr17:39234214	G/A	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.03	0.36	9.75e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg10729496	chr3:10149963	C3orf24	0.48	7.78	0.35	5.65e-14	Alzheimer's disease;
LUAD	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg25237894	chr2:233734115	C2orf82	0.62	11.62	0.49	2.71e-27	Coronary artery disease;
LUAD	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg05434287	chr7:2030229	MAD1L1	0.4	6.6	0.31	1.26e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-7.94	-0.36	1.82e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs240764	0.817	rs239237	chr6:101094940	A/G	cg09795085	chr6:101329169	ASCC3	0.43	7.48	0.34	4.29e-13	Neuroticism;
LUAD	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg19163074	chr7:65112434	INTS4L2	0.44	6.69	0.31	7.09e-11	Aortic root size;
LUAD	cis	rs4280164	0.945	rs11158635	chr14:24776769	G/T	cg07162820	chr14:24837146	NFATC4	0.33	6.56	0.3	1.58e-10	Parent of origin effect on language impairment (paternal);
LUAD	cis	rs7731657	0.537	rs2097797	chr5:130355151	C/T	cg08523029	chr5:130500466	HINT1	-0.6	-7.73	-0.35	7.92e-14	Fasting plasma glucose;
LUAD	cis	rs1215050	0.791	rs10856931	chr4:98819306	C/T	cg17366294	chr4:99064904	C4orf37	0.5	8.83	0.39	2.76e-17	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-7.97	-0.36	1.5e-14	Diabetic kidney disease;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg10193671	chr17:79846205	THOC4	0.39	6.75	0.31	4.98e-11	Vertical cup-disc ratio;
LUAD	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.47	0.3	2.64e-10	Depression;
LUAD	cis	rs9462027	0.540	rs4282407	chr6:34830162	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.77	-0.39	4.33e-17	Systemic lupus erythematosus;
LUAD	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg15691649	chr6:25882328	NA	0.41	6.5	0.3	2.24e-10	Blood metabolite levels;
LUAD	trans	rs877282	0.891	rs34652870	chr10:772218	T/C	cg22713356	chr15:30763199	NA	1.32	18.6	0.67	7.03e-57	Uric acid levels;
LUAD	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg02018176	chr4:1364513	KIAA1530	0.5	8.69	0.39	8.21e-17	Longevity;
LUAD	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05731713	chr7:157510257	PTPRN2	0.44	10.16	0.44	7.53e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs757081	0.667	rs12577525	chr11:17260116	G/A	cg15432903	chr11:17409602	KCNJ11	-0.4	-6.39	-0.3	4.26e-10	Systolic blood pressure;
LUAD	cis	rs10189230	0.967	rs12993766	chr2:222350321	C/T	cg14652038	chr2:222343519	EPHA4	0.44	8.79	0.39	3.74e-17	Urate levels in lean individuals;
LUAD	cis	rs8258	0.501	rs474490	chr11:117287794	T/G	cg15227623	chr11:117232454	CEP164	0.61	8.42	0.38	5.73e-16	Pulse pressure;
LUAD	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg19683494	chr5:74908142	NA	0.54	7.26	0.33	1.91e-12	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LUAD	cis	rs1003719	0.762	rs1155786	chr21:38448025	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.51	0.38	3.05e-16	Eye color traits;
LUAD	cis	rs711245	0.698	rs848642	chr2:36782886	G/A	cg01206211	chr2:36825736	FEZ2	0.48	9.09	0.4	3.97e-18	Height;
LUAD	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg23625390	chr15:77176239	SCAPER	0.39	6.83	0.32	2.98e-11	Blood metabolite levels;
LUAD	trans	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg08071915	chr8:12219732	FAM66A	0.43	7.31	0.33	1.39e-12	Joint mobility (Beighton score);
LUAD	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg13770153	chr20:60521292	NA	-0.59	-9.27	-0.41	9.51e-19	Body mass index;
LUAD	cis	rs7000551	0.642	rs2449328	chr8:22375043	A/G	cg12081754	chr8:22256438	SLC39A14	0.47	7.72	0.35	8.65e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg17177755	chr1:15930204	NA	0.45	7.19	0.33	3.02e-12	Systolic blood pressure;
LUAD	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg14345882	chr6:26364793	BTN3A2	0.66	7.08	0.33	5.99e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs12049351	0.774	rs2381108	chr1:229637881	T/G	cg11742688	chr1:229674241	ABCB10	-0.42	-6.42	-0.3	3.7e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg00071950	chr4:10020882	SLC2A9	0.5	7.19	0.33	2.88e-12	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg26408565	chr15:76604113	ETFA	-0.44	-7.17	-0.33	3.3e-12	Blood metabolite levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19364635	chr2:38978654	SFRS7	-0.41	-6.86	-0.32	2.4e-11	Cancer;
LUAD	cis	rs59698941	0.550	rs11739194	chr5:132201230	T/C	cg16419906	chr5:132167176	NA	-0.33	-6.54	-0.3	1.77e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg02428538	chr16:24856791	SLC5A11	-0.5	-6.77	-0.31	4.39e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs243505	0.668	rs2072406	chr7:148483760	G/A	cg09806900	chr7:148480153	CUL1	0.47	8.21	0.37	2.68e-15	Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs870825	0.698	rs66462315	chr4:185623917	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs4845570	0.749	rs11586446	chr1:151712488	A/G	cg07092448	chr1:151763213	TDRKH	-0.69	-7.42	-0.34	6.62e-13	Coronary artery disease;
LUAD	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg11266682	chr4:10021025	SLC2A9	0.69	15.69	0.61	4.93e-44	Bone mineral density;
LUAD	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg04369109	chr6:150039330	LATS1	-0.45	-7.65	-0.35	1.38e-13	Lung cancer;
LUAD	cis	rs12519773	0.641	rs4489042	chr5:92428154	G/C	cg18783429	chr5:92414398	NA	0.5	8.51	0.38	2.95e-16	Migraine;
LUAD	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg17105886	chr17:28927953	LRRC37B2	-0.76	-8.2	-0.37	2.97e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6545883	1.000	rs778762	chr2:61782921	G/T	cg15711740	chr2:61764176	XPO1	-0.42	-6.84	-0.32	2.82e-11	Tuberculosis;
LUAD	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.71	-0.35	8.94e-14	Total body bone mineral density;
LUAD	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	7.13	0.33	4.51e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10150615	chr22:24372951	LOC391322	-0.54	-8.72	-0.39	6.2e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg12179176	chr11:130786555	SNX19	0.54	9.13	0.41	2.93e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg06064525	chr11:970664	AP2A2	-0.55	-11.27	-0.48	5.91e-26	Alzheimer's disease (late onset);
LUAD	cis	rs2235649	0.789	rs9939680	chr16:1852720	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-7.89	-0.36	2.61e-14	Blood metabolite levels;
LUAD	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg02012338	chr4:187126139	CYP4V2	1.04	10.37	0.45	1.32e-22	Blood protein levels;
LUAD	cis	rs7737355	0.812	rs6881486	chr5:130793836	C/T	cg06307176	chr5:131281290	NA	-0.43	-7.1	-0.33	5.42e-12	Life satisfaction;
LUAD	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg23803603	chr1:2058230	PRKCZ	-0.42	-7.12	-0.33	4.59e-12	Height;
LUAD	cis	rs57920188	0.640	rs4378174	chr1:4080885	C/T	cg20703997	chr1:4087676	NA	0.43	7.98	0.36	1.35e-14	Interleukin-17 levels;
LUAD	trans	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg18834416	chr8:37888184	EIF4EBP1	0.4	6.53	0.3	1.86e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs490234	0.691	rs3104551	chr9:128164279	G/A	cg14078157	chr9:128172775	NA	-0.41	-7.57	-0.35	2.43e-13	Mean arterial pressure;
LUAD	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg08493051	chr2:3487164	NA	-0.43	-7.28	-0.33	1.67e-12	Neurofibrillary tangles;
LUAD	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg07211511	chr3:129823064	LOC729375	-0.84	-12.28	-0.51	7.3e-30	Blood pressure (smoking interaction);
LUAD	cis	rs739496	0.542	rs10849937	chr12:111792427	A/G	cg10833066	chr12:111807467	FAM109A	0.7	13.8	0.56	5.16e-36	Platelet count;
LUAD	cis	rs2235649	0.746	rs113666107	chr16:1848642	C/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-8.15	-0.37	4.02e-15	Blood metabolite levels;
LUAD	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg08798685	chr6:27730294	NA	-0.42	-6.77	-0.31	4.33e-11	Parkinson's disease;
LUAD	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.41	0.38	6.45e-16	Breast cancer;
LUAD	cis	rs1371614	0.523	rs893789	chr2:27183970	C/T	cg00617064	chr2:27272375	NA	-0.37	-7.08	-0.33	5.93e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.38	-7.43	-0.34	6.09e-13	Total body bone mineral density;
LUAD	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-8.71	-0.39	6.75e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs1941687	0.831	rs28402875	chr18:31351506	G/A	cg27147174	chr7:100797783	AP1S1	-0.55	-9.27	-0.41	9.94e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24531977	chr5:56204891	C5orf35	-0.99	-15.17	-0.59	8.56e-42	Initial pursuit acceleration;
LUAD	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg04398451	chr17:18023971	MYO15A	0.62	10.83	0.47	2.8e-24	Total body bone mineral density;
LUAD	cis	rs7264396	0.561	rs6060753	chr20:34598430	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-6.63	-0.31	1.04e-10	Total cholesterol levels;
LUAD	cis	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg05084668	chr3:125655381	ALG1L	-0.51	-8.65	-0.39	1.09e-16	Blood pressure (smoking interaction);
LUAD	cis	rs7582720	1.000	rs72936309	chr2:204040296	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	9.44	0.42	2.48e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg17372223	chr3:52568218	NT5DC2	-0.36	-6.56	-0.3	1.54e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg05110241	chr16:68378359	PRMT7	-0.8	-8.78	-0.39	4.06e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7845219	0.510	rs10113282	chr8:96038252	C/G	cg16049864	chr8:95962084	TP53INP1	-0.4	-7.94	-0.36	1.86e-14	Type 2 diabetes;
LUAD	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg02269571	chr22:50332266	NA	0.46	7.24	0.33	2.18e-12	Schizophrenia;
LUAD	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.41	-0.34	6.9e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.55	-8.21	-0.37	2.65e-15	Alzheimer's disease;
LUAD	cis	rs7258465	0.965	rs2385088	chr19:18545540	A/G	cg01065977	chr19:18549689	ISYNA1	-0.38	-7.2	-0.33	2.78e-12	Breast cancer;
LUAD	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg22907277	chr7:1156413	C7orf50	0.45	7.79	0.35	5.07e-14	Longevity;Endometriosis;
LUAD	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg22907277	chr7:1156413	C7orf50	0.62	7.95	0.36	1.7e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.38	6.38	0.3	4.56e-10	Rheumatoid arthritis;
LUAD	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg08085267	chr17:45401833	C17orf57	-0.68	-12.28	-0.51	7.35e-30	Glaucoma (primary open-angle);
LUAD	cis	rs6445967	1.000	rs11713627	chr3:58306946	T/G	cg23715586	chr3:58305044	RPP14	0.42	7.64	0.35	1.46e-13	Platelet count;
LUAD	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg13263323	chr15:86062960	AKAP13	-0.48	-8.92	-0.4	1.44e-17	Coronary artery disease;
LUAD	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.77	14.85	0.59	1.85e-40	Intelligence (multi-trait analysis);
LUAD	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg00204512	chr16:28754710	NA	0.32	6.89	0.32	1.98e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg25985355	chr7:65971099	NA	0.37	7.01	0.32	9.71e-12	Aortic root size;
LUAD	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.55	-0.3	1.66e-10	Total body bone mineral density;
LUAD	cis	rs775227	0.574	rs79709668	chr3:113161265	G/A	cg18753928	chr3:113234510	CCDC52	-0.66	-9.06	-0.4	4.85e-18	Dental caries;
LUAD	cis	rs11811982	0.655	rs11805662	chr1:227238540	G/A	cg24860534	chr1:227506868	CDC42BPA	0.68	7.11	0.33	4.83e-12	Optic disc area;
LUAD	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg21471580	chr8:22132874	PIWIL2	0.44	7.93	0.36	1.97e-14	Hypertriglyceridemia;
LUAD	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg13319975	chr6:146136371	FBXO30	-0.54	-8.7	-0.39	7.38e-17	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1832871	0.683	rs62437360	chr6:158720162	G/A	cg07165851	chr6:158734300	TULP4	0.7	10.87	0.47	2.03e-24	Height;
LUAD	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg02886208	chr11:14281011	SPON1	-0.38	-7.69	-0.35	1.05e-13	Mitochondrial DNA levels;
LUAD	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg05313129	chr8:58192883	C8orf71	-0.58	-8.57	-0.38	2e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs2425143	1.000	rs111597121	chr20:34371913	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.95	-0.32	1.39e-11	Blood protein levels;
LUAD	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg19052272	chr2:3704530	ALLC	-0.61	-10.51	-0.45	4.25e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.61	9.19	0.41	1.74e-18	Platelet count;
LUAD	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg18230493	chr5:56204884	C5orf35	-0.44	-7.32	-0.34	1.25e-12	Coronary artery disease;
LUAD	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg02683114	chr2:24398427	C2orf84	0.44	7.37	0.34	9.07e-13	Asthma;
LUAD	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-8.67	-0.39	9.42e-17	Alzheimer's disease (late onset);
LUAD	cis	rs62400317	0.826	rs4544895	chr6:45271917	A/T	cg20913747	chr6:44695427	NA	-0.42	-6.78	-0.31	4.13e-11	Total body bone mineral density;
LUAD	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.1e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg03037974	chr15:76606532	NA	0.38	8.2	0.37	3e-15	Blood metabolite levels;
LUAD	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg10909506	chr17:38081995	ORMDL3	-0.38	-6.96	-0.32	1.32e-11	Self-reported allergy;
LUAD	cis	rs743757	1.000	rs743857	chr3:50493550	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.42	6.59	0.3	1.35e-10	Diastolic blood pressure;
LUAD	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg18230493	chr5:56204884	C5orf35	-0.69	-10.93	-0.47	1.14e-24	Initial pursuit acceleration;
LUAD	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18876405	chr7:65276391	NA	0.41	6.41	0.3	3.96e-10	Aortic root size;
LUAD	cis	rs4660306	1.000	rs882803	chr1:45976147	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-6.64	-0.31	9.66e-11	Homocysteine levels;
LUAD	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg00898013	chr13:113819073	PROZ	0.73	13.19	0.54	1.55e-33	Platelet distribution width;
LUAD	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg21984481	chr17:79567631	NPLOC4	0.56	11.89	0.5	2.61e-28	Eye color traits;
LUAD	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg00280220	chr17:61926910	NA	0.36	6.9	0.32	1.97e-11	Prudent dietary pattern;
LUAD	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg18099408	chr3:52552593	STAB1	-0.51	-9.49	-0.42	1.7e-19	Hemoglobin concentration;
LUAD	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg18477163	chr1:228402036	OBSCN	-0.35	-7.12	-0.33	4.71e-12	Diastolic blood pressure;
LUAD	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03264133	chr6:25882463	NA	-1.02	-18.48	-0.67	2.41e-56	Urate levels;
LUAD	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.57	0.3	1.5e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg00074818	chr8:8560427	CLDN23	0.65	10.01	0.44	2.58e-21	Obesity-related traits;
LUAD	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg08989290	chr16:615782	NHLRC4	0.31	6.73	0.31	5.69e-11	Height;
LUAD	trans	rs3857536	0.813	rs9354403	chr6:66943426	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.42	-0.3	3.59e-10	Blood trace element (Cu levels);
LUAD	cis	rs2882667	0.898	rs6882330	chr5:138382182	A/G	cg04439458	chr5:138467593	SIL1	-0.4	-7.27	-0.33	1.8e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs16854884	0.632	rs35716467	chr3:143684993	C/A	cg01302019	chr3:143689584	C3orf58	-0.38	-6.56	-0.3	1.56e-10	Economic and political preferences (feminism/equality);
LUAD	cis	rs698833	0.828	rs4952710	chr2:44524575	T/C	cg04920474	chr2:44395004	PPM1B	0.41	7.51	0.34	3.53e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg06263672	chr7:65235340	NA	-0.47	-6.51	-0.3	2.16e-10	Aortic root size;
LUAD	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg14345882	chr6:26364793	BTN3A2	0.7	7.15	0.33	3.76e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg23752985	chr2:85803571	VAMP8	0.34	6.64	0.31	9.57e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg10356904	chr22:49881777	NA	-0.41	-7.88	-0.36	2.82e-14	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg03467027	chr4:99064603	C4orf37	0.43	7.05	0.32	7.53e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs68170813	0.652	rs763386	chr7:107196723	T/C	cg23024343	chr7:107201750	COG5	0.54	6.78	0.31	4.03e-11	Coronary artery disease;
LUAD	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg25237894	chr2:233734115	C2orf82	0.51	9.78	0.43	1.66e-20	Coronary artery disease;
LUAD	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg05425664	chr17:57184151	TRIM37	-0.44	-7.92	-0.36	2.11e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs494562	0.730	rs9450269	chr6:86114684	C/G	cg17966619	chr6:86160162	NT5E	-0.59	-7.19	-0.33	2.97e-12	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg08027265	chr7:2291960	NA	-0.47	-8.01	-0.36	1.14e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs13266463	0.898	rs13267784	chr8:143394915	C/T	cg16886403	chr8:143471632	TSNARE1	0.46	6.92	0.32	1.71e-11	Schizophrenia;
LUAD	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.82	-0.36	4.36e-14	Total body bone mineral density;
LUAD	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg27279351	chr12:120934652	DYNLL1	0.42	6.39	0.3	4.33e-10	High light scatter reticulocyte count;
LUAD	cis	rs7107174	1.000	rs1385600	chr11:77936166	C/T	cg02023728	chr11:77925099	USP35	-0.4	-6.8	-0.31	3.68e-11	Testicular germ cell tumor;
LUAD	cis	rs17253792	0.822	rs77544029	chr14:56087917	T/C	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg01448562	chr3:133502909	NA	0.56	9.99	0.44	3.08e-21	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs11030122	0.673	rs11030660	chr11:4043268	T/C	cg18678763	chr11:4115507	RRM1	-0.47	-7.71	-0.35	9.14e-14	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg01579765	chr21:45077557	HSF2BP	0.58	13.41	0.55	1.95e-34	Mean corpuscular volume;
LUAD	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg14345882	chr6:26364793	BTN3A2	0.69	7.04	0.32	7.77e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg02527881	chr3:46936655	PTH1R	0.52	10.33	0.45	1.83e-22	Colorectal cancer;
LUAD	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg18129178	chr5:148520854	ABLIM3	0.61	9.49	0.42	1.71e-19	Breast cancer;
LUAD	cis	rs735539	0.718	rs7985552	chr13:21280738	A/T	cg27499820	chr13:21296301	IL17D	-0.53	-9.38	-0.42	3.93e-19	Dental caries;
LUAD	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg11062466	chr8:58055876	NA	0.53	7.33	0.34	1.2e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-8.1	-0.37	5.93e-15	Total cholesterol levels;
LUAD	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.95	0.4	1.14e-17	Menopause (age at onset);
LUAD	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg24558204	chr6:135376177	HBS1L	0.47	7.87	0.36	2.98e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs490234	0.812	rs4838286	chr9:128460057	G/A	cg14078157	chr9:128172775	NA	-0.46	-8.54	-0.38	2.53e-16	Mean arterial pressure;
LUAD	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg07234876	chr8:600039	NA	1.04	10.16	0.44	7.39e-22	IgG glycosylation;
LUAD	trans	rs4596713	0.536	rs10217168	chr9:71794956	A/G	cg16512924	chr15:28394682	HERC2	0.38	6.47	0.3	2.77e-10	Headache;
LUAD	cis	rs1045714	0.943	rs56063345	chr7:2653504	C/G	cg24848437	chr7:2645542	IQCE	0.75	8.43	0.38	5.49e-16	Urate levels in lean individuals;
LUAD	cis	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg27411982	chr8:10470053	RP1L1	0.42	7.98	0.36	1.34e-14	Neuroticism;
LUAD	cis	rs68170813	0.596	rs76888321	chr7:106945926	T/C	cg23024343	chr7:107201750	COG5	0.44	6.5	0.3	2.32e-10	Coronary artery disease;
LUAD	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	10.15	0.44	8.27e-22	Total body bone mineral density;
LUAD	trans	rs11252926	0.627	rs10751997	chr10:561952	C/T	cg00953403	chr17:74099816	EXOC7	0.51	8.14	0.37	4.61e-15	Psychosis in Alzheimer's disease;
LUAD	cis	rs7095607	0.813	rs7905259	chr10:69926610	A/C	cg18986048	chr10:69913749	MYPN	0.37	6.4	0.3	4.08e-10	Lung function (FVC);
LUAD	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg00717180	chr2:96193071	NA	0.36	6.68	0.31	7.63e-11	Coronary artery disease;
LUAD	cis	rs11077815	0.815	rs11077817	chr17:74442413	T/C	cg06840243	chr17:74442338	UBE2O	-0.38	-6.89	-0.32	2.04e-11	Lymphocyte counts;
LUAD	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg24879335	chr3:133465180	TF	0.35	7.38	0.34	8.52e-13	Iron status biomarkers (transferrin levels);
LUAD	cis	rs35883536	1.000	rs1832121	chr1:101159476	A/G	cg06223162	chr1:101003688	GPR88	0.37	6.85	0.32	2.59e-11	Monocyte count;
LUAD	trans	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg04995722	chr7:26192034	NFE2L3	0.42	7.31	0.33	1.33e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.37	6.59	0.31	1.3e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-7.77	-0.35	5.96e-14	Monocyte count;
LUAD	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.54	-10.04	-0.44	1.98e-21	Schizophrenia;
LUAD	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.97	-0.32	1.26e-11	Personality dimensions;
LUAD	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg04450456	chr4:17643702	FAM184B	0.4	7.96	0.36	1.6e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg27170947	chr2:26402098	FAM59B	-0.81	-11.51	-0.49	7.14e-27	Gut microbiome composition (summer);
LUAD	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.4	6.42	0.3	3.62e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg19862616	chr7:65841803	NCRNA00174	1.05	26.66	0.79	1.38e-92	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs62229266	0.771	rs7277791	chr21:37383227	C/A	cg12218747	chr21:37451666	NA	-0.47	-8.13	-0.37	4.68e-15	Mitral valve prolapse;
LUAD	cis	rs938554	0.612	rs4385059	chr4:9989233	A/G	cg02734326	chr4:10020555	SLC2A9	-0.46	-6.46	-0.3	2.95e-10	Blood metabolite levels;
LUAD	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	10.42	0.45	8.62e-23	Post bronchodilator FEV1;
LUAD	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg24531977	chr5:56204891	C5orf35	0.77	12.37	0.52	3.2e-30	Initial pursuit acceleration;
LUAD	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg03929089	chr4:120376271	NA	0.55	7.1	0.33	5.37e-12	Axial length;
LUAD	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg25985355	chr7:65971099	NA	-0.39	-7.15	-0.33	3.81e-12	Aortic root size;
LUAD	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg12573674	chr2:1569213	NA	-0.59	-6.95	-0.32	1.39e-11	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs13064411	0.627	rs28536176	chr3:113143625	T/C	cg10517650	chr3:113235015	CCDC52	-0.53	-8.74	-0.39	5.55e-17	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg18490616	chr2:88469792	THNSL2	0.79	8.3	0.37	1.43e-15	Plasma clusterin levels;
LUAD	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg08999081	chr20:33150536	PIGU	-0.6	-13.15	-0.54	2.47e-33	Glomerular filtration rate (creatinine);
LUAD	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	7.95	0.36	1.69e-14	Rheumatoid arthritis;
LUAD	cis	rs669446	0.527	rs667676	chr1:44082216	G/A	cg12908607	chr1:44402522	ARTN	-0.36	-6.63	-0.31	1.03e-10	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs977987	0.866	rs12932606	chr16:75493944	C/T	cg03315344	chr16:75512273	CHST6	0.66	14.93	0.59	8.3e-41	Dupuytren's disease;
LUAD	cis	rs4629710	0.592	rs9492877	chr6:131562577	C/G	cg12606694	chr6:131520996	AKAP7	0.51	7.52	0.34	3.33e-13	Multiple myeloma (IgH translocation);
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg25366139	chr19:58891861	ZNF837	-0.39	-6.56	-0.3	1.59e-10	Cancer;
LUAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg22535103	chr8:58192502	C8orf71	-0.72	-8.75	-0.39	5e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg08807101	chr21:30365312	RNF160	0.44	6.59	0.31	1.32e-10	Selective IgA deficiency;
LUAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg13397359	chr6:42928475	GNMT	0.7	14.27	0.57	5.48e-38	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs11585357	0.947	rs6684387	chr1:17611519	T/C	cg08277548	chr1:17600880	PADI3	0.84	12.79	0.53	7.02e-32	Hair shape;
LUAD	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg00383909	chr3:49044727	WDR6	0.9	10.15	0.44	7.96e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg27535305	chr1:53392650	SCP2	-0.34	-7.05	-0.32	7.38e-12	Monocyte count;
LUAD	cis	rs669446	0.561	rs639929	chr1:44083874	A/G	cg12908607	chr1:44402522	ARTN	-0.35	-6.36	-0.3	5.38e-10	Amyotrophic lateral sclerosis (age of onset);
LUAD	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg21963583	chr11:68658836	MRPL21	0.59	10.39	0.45	1.13e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs701145	0.585	rs357477	chr3:153892717	A/G	cg17054900	chr3:154042577	DHX36	0.64	6.79	0.31	3.9e-11	Coronary artery disease;
LUAD	cis	rs909002	0.800	rs968335	chr1:32085776	G/A	cg13919466	chr1:32135498	COL16A1	-0.34	-7.89	-0.36	2.53e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09875802	chr5:133340681	VDAC1	-0.73	-7.43	-0.34	5.92e-13	Type 2 diabetes;
LUAD	cis	rs6500395	1.000	rs7190106	chr16:48705542	C/T	cg04672837	chr16:48644449	N4BP1	0.37	6.45	0.3	3.05e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2902440	0.502	rs4655527	chr1:67664491	G/A	cg12940439	chr1:67600707	NA	0.38	7.4	0.34	7.55e-13	Crohn's disease;
LUAD	cis	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg27411982	chr8:10470053	RP1L1	-0.36	-6.57	-0.3	1.45e-10	Neuroticism;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg03241323	chr2:187454863	ITGAV	-0.64	-6.35	-0.3	5.7e-10	Type 2 diabetes;
LUAD	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg17063962	chr7:91808500	NA	-0.65	-11.16	-0.48	1.52e-25	Breast cancer;
LUAD	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg17173187	chr15:85201210	NMB	0.48	8.42	0.38	6.05e-16	Schizophrenia;
LUAD	trans	rs8002861	0.870	rs1348671	chr13:44449505	C/T	cg17145862	chr1:211918768	LPGAT1	0.74	16.96	0.64	1.36e-49	Leprosy;
LUAD	cis	rs1371614	0.632	rs6708148	chr2:27167320	A/G	cg00617064	chr2:27272375	NA	-0.34	-6.56	-0.3	1.59e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs977987	0.806	rs2161684	chr16:75479153	T/C	cg03315344	chr16:75512273	CHST6	0.65	14.23	0.57	8.11e-38	Dupuytren's disease;
LUAD	cis	rs601339	1.000	rs630408	chr12:123172822	C/T	cg11919336	chr12:123188078	GPR109A	0.46	6.91	0.32	1.79e-11	Adiponectin levels;
LUAD	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg18477163	chr1:228402036	OBSCN	-0.33	-6.46	-0.3	2.8e-10	Diastolic blood pressure;
LUAD	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg18402987	chr7:1209562	NA	0.73	9.06	0.4	5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg27490568	chr2:178487706	NA	0.41	6.92	0.32	1.7e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg21782813	chr7:2030301	MAD1L1	0.48	8.33	0.38	1.1e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs758324	0.947	rs173812	chr5:131319460	A/G	cg06307176	chr5:131281290	NA	-0.49	-7.81	-0.35	4.69e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7301016	0.707	rs11174583	chr12:63051064	T/C	cg11441379	chr12:63026424	NA	0.62	7.45	0.34	5.48e-13	IgG glycosylation;
LUAD	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg18180107	chr4:99064573	C4orf37	0.47	7.34	0.34	1.09e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg13012494	chr21:47604986	C21orf56	0.46	7.13	0.33	4.44e-12	Testicular germ cell tumor;
LUAD	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg23985595	chr17:80112537	CCDC57	-0.52	-9.55	-0.42	1.07e-19	Life satisfaction;
LUAD	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg24818145	chr4:99064322	C4orf37	-0.45	-7.72	-0.35	8.49e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1957429	0.808	rs2357866	chr14:65336517	C/T	cg23373153	chr14:65346875	NA	0.63	6.41	0.3	3.8e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg26408565	chr15:76604113	ETFA	-0.46	-7.33	-0.34	1.16e-12	Blood metabolite levels;
LUAD	cis	rs2637266	0.935	rs1866891	chr10:78396941	C/A	cg18941641	chr10:78392320	NA	0.34	7.01	0.32	9.71e-12	Pulmonary function;
LUAD	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.55	-0.6	1.9e-43	Chronic sinus infection;
LUAD	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg02733842	chr7:1102375	C7orf50	-0.7	-10.32	-0.45	2.07e-22	Bronchopulmonary dysplasia;
LUAD	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12016809	chr21:47604291	C21orf56	-0.67	-11.79	-0.5	5.9e-28	Testicular germ cell tumor;
LUAD	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	6.6	0.31	1.25e-10	Electroencephalogram traits;
LUAD	cis	rs6490294	0.583	rs4346023	chr12:112285542	C/T	cg10833066	chr12:111807467	FAM109A	-0.36	-6.81	-0.31	3.31e-11	Mean platelet volume;
LUAD	trans	rs1406428	0.573	rs12613632	chr2:51705755	C/G	cg00006032	chr14:66974439	GPHN	0.45	6.65	0.31	9.28e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg21153622	chr11:89784906	NA	-0.34	-6.79	-0.31	3.85e-11	HDL cholesterol;
LUAD	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg15790184	chr11:494944	RNH1	0.57	7.07	0.32	6.64e-12	Body mass index;
LUAD	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.95	-19.77	-0.69	4.22e-62	Ulcerative colitis;
LUAD	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg21100191	chr22:23484243	RTDR1	0.66	11.73	0.5	1.08e-27	Bone mineral density;
LUAD	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg01528321	chr10:82214614	TSPAN14	0.7	10.77	0.46	4.45e-24	Post bronchodilator FEV1;
LUAD	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	7.32	0.34	1.25e-12	Tonsillectomy;
LUAD	cis	rs9644630	0.870	rs10888165	chr8:19358961	T/C	cg06699216	chr8:19333253	CSGALNACT1	-0.3	-7.1	-0.33	5.22e-12	Oropharynx cancer;
LUAD	cis	rs62238980	0.614	rs77489541	chr22:32413863	G/T	cg00543991	chr22:32367038	NA	0.97	9.08	0.4	4.24e-18	Childhood ear infection;
LUAD	cis	rs806215	0.906	rs806195	chr7:127249178	A/G	cg25922125	chr7:127225783	GCC1	0.49	7.1	0.33	5.47e-12	Type 2 diabetes;
LUAD	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg06784218	chr1:46089804	CCDC17	0.6	13.35	0.54	3.6e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg04398451	chr17:18023971	MYO15A	0.61	10.41	0.45	9.92e-23	Total body bone mineral density;
LUAD	trans	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg19676328	chr12:49525230	TUBA1B	-0.7	-11.23	-0.48	8.54e-26	Total cholesterol levels;
LUAD	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg25427524	chr10:38739819	LOC399744	0.45	7.55	0.34	2.69e-13	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07157834	chr1:205819609	PM20D1	0.73	13.99	0.56	8.03e-37	Menarche (age at onset);
LUAD	cis	rs4631830	0.900	rs7920517	chr10:51532621	G/A	cg20129853	chr10:51489980	NA	-0.34	-6.7	-0.31	6.83e-11	Prostate-specific antigen levels;
LUAD	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg21724239	chr8:58056113	NA	0.64	7.68	0.35	1.14e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg11871910	chr12:69753446	YEATS4	0.68	11.7	0.49	1.37e-27	Blood protein levels;
LUAD	cis	rs9837602	0.688	rs793488	chr3:99495567	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	7.16	0.33	3.7e-12	Breast cancer;
LUAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg07404485	chr7:94953653	PON1	-0.58	-10.52	-0.46	3.74e-23	Paraoxonase activity;
LUAD	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	0.48	8.5	0.38	3.18e-16	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs739496	0.579	rs10849983	chr12:112340409	G/T	cg10833066	chr12:111807467	FAM109A	0.43	6.96	0.32	1.32e-11	Platelet count;
LUAD	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg13047869	chr3:10149882	C3orf24	0.65	11.04	0.47	4.37e-25	Alzheimer's disease;
LUAD	cis	rs8060686	0.516	rs9939821	chr16:68167787	T/A	cg26727032	chr16:67993705	SLC12A4	-0.48	-7.76	-0.35	6.22e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg27170947	chr2:26402098	FAM59B	0.62	8.72	0.39	6.61e-17	Gut microbiome composition (summer);
LUAD	trans	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-9.27	-0.41	9.98e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs751728	0.717	rs3763260	chr6:33774070	C/T	cg13859433	chr6:33739653	LEMD2	-0.34	-7.09	-0.33	5.65e-12	Crohn's disease;
LUAD	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg27454412	chr7:1067447	C7orf50	0.48	7.73	0.35	7.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs354033	0.837	rs60206402	chr7:149189637	G/A	cg24335155	chr7:149193227	ZNF746	0.38	6.47	0.3	2.64e-10	Multiple sclerosis;
LUAD	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg13057898	chr1:3703894	LRRC47	0.63	10.69	0.46	8.72e-24	Red cell distribution width;
LUAD	cis	rs7589342	0.929	rs7590652	chr2:106440306	A/G	cg16077055	chr2:106428750	NCK2	0.36	6.52	0.3	1.95e-10	Addiction;
LUAD	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.49	6.57	0.3	1.51e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1030877	0.960	rs3792049	chr2:105901908	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.58	-11.13	-0.48	2.01e-25	Obesity-related traits;
LUAD	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg21280719	chr6:42927975	GNMT	-0.39	-12.28	-0.51	7.71e-30	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.67	0.31	8.17e-11	Depression;
LUAD	trans	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.35	0.48	3.07e-26	Mean corpuscular volume;
LUAD	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg22683308	chr4:1340831	KIAA1530	-0.44	-7.14	-0.33	4.23e-12	Longevity;
LUAD	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg14092988	chr3:52407081	DNAH1	0.45	9.06	0.4	4.87e-18	Bipolar disorder;
LUAD	trans	rs564343	0.832	rs1151530	chr11:65862952	G/A	cg26701943	chr11:108369231	KDELC2	-0.43	-7.16	-0.33	3.65e-12	Obesity (early onset extreme);
LUAD	trans	rs8002861	0.664	rs895266	chr13:44461179	T/C	cg12856521	chr11:46389249	DGKZ	0.47	7.62	0.35	1.72e-13	Leprosy;
LUAD	cis	rs2446066	0.659	rs11170569	chr12:53913426	T/G	cg20730629	chr12:53886622	MAP3K12	-0.47	-6.75	-0.31	4.96e-11	Red blood cell count;
LUAD	cis	rs490234	0.902	rs10739663	chr9:128278739	A/G	cg14078157	chr9:128172775	NA	-0.37	-6.75	-0.31	4.74e-11	Mean arterial pressure;
LUAD	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14159672	chr1:205819179	PM20D1	-0.73	-14.22	-0.57	9.03e-38	Monocyte percentage of white cells;
LUAD	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-7.44	-0.34	5.82e-13	Neutrophil percentage of white cells;
LUAD	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg03806693	chr22:41940476	POLR3H	-0.75	-9.79	-0.43	1.54e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg09359103	chr1:154839909	KCNN3	-0.89	-20.61	-0.71	7.82e-66	Prostate cancer;
LUAD	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg05340658	chr4:99064831	C4orf37	0.45	7.46	0.34	4.86e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.15	0.33	3.72e-12	Motion sickness;
LUAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00149659	chr3:10157352	C3orf10	0.57	8.06	0.36	7.87e-15	Alzheimer's disease;
LUAD	trans	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg14917512	chr19:3094685	GNA11	-0.57	-6.7	-0.31	6.66e-11	Diabetic kidney disease;
LUAD	trans	rs2018683	0.677	rs55718000	chr7:28975625	T/C	cg19402173	chr7:128379420	CALU	-0.52	-8.46	-0.38	4.36e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs11811982	0.793	rs114967166	chr1:227288330	G/A	cg24860534	chr1:227506868	CDC42BPA	0.7	7.44	0.34	5.81e-13	Optic disc area;
LUAD	cis	rs11077998	0.967	rs4789796	chr17:80521135	T/C	cg10255544	chr17:80519551	FOXK2	0.33	6.5	0.3	2.3e-10	Reticulocyte fraction of red cells;
LUAD	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.16	-0.41	2.32e-18	Alcohol dependence;
LUAD	cis	rs4268898	0.931	rs2111882	chr2:24434424	A/G	cg06627628	chr2:24431161	ITSN2	0.52	8.81	0.39	3.21e-17	Asthma;
LUAD	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.15	-0.33	3.79e-12	Total cholesterol levels;
LUAD	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg10434728	chr15:90938212	IQGAP1	0.37	7.37	0.34	8.85e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs886126	1.000	rs4766451	chr12:111670682	G/T	cg10833066	chr12:111807467	FAM109A	0.55	10.69	0.46	9.15e-24	Coronary heart disease;
LUAD	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25427524	chr10:38739819	LOC399744	-0.75	-13.4	-0.55	2.34e-34	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg23029597	chr12:123009494	RSRC2	0.52	7.97	0.36	1.46e-14	Body mass index;
LUAD	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg24450063	chr1:156163899	SLC25A44	1.14	26.74	0.79	5.96e-93	Testicular germ cell tumor;
LUAD	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg10518543	chr12:38710700	ALG10B	0.47	7.91	0.36	2.2e-14	Morning vs. evening chronotype;
LUAD	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg13789015	chr9:136890014	NCRNA00094	0.85	13.94	0.56	1.36e-36	Platelet distribution width;
LUAD	cis	rs7937890	0.559	rs6486197	chr11:14529874	C/G	cg02886208	chr11:14281011	SPON1	-0.33	-6.4	-0.3	4.12e-10	Mitochondrial DNA levels;
LUAD	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg18944383	chr4:111397179	ENPEP	0.41	8.13	0.37	4.74e-15	Height;
LUAD	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg08493051	chr2:3487164	NA	-0.41	-6.93	-0.32	1.57e-11	Neurofibrillary tangles;
LUAD	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06022373	chr22:39101656	GTPBP1	0.47	7.29	0.33	1.54e-12	Menopause (age at onset);
LUAD	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg03929089	chr4:120376271	NA	0.57	7.13	0.33	4.42e-12	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs938554	0.784	rs11722229	chr4:9980697	C/A	cg11266682	chr4:10021025	SLC2A9	0.44	7.83	0.36	3.99e-14	Blood metabolite levels;
LUAD	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg18833306	chr6:118973337	C6orf204	-0.49	-7.27	-0.33	1.75e-12	Diastolic blood pressure;
LUAD	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.6	0.31	1.23e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg13057898	chr1:3703894	LRRC47	0.63	10.7	0.46	8e-24	Red cell distribution width;
LUAD	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25427524	chr10:38739819	LOC399744	-0.76	-13.67	-0.55	1.66e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.79	-10.36	-0.45	1.41e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs4604732	0.631	rs10925043	chr1:247627001	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.54	9.31	0.41	7.12e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1018836	0.923	rs2157607	chr8:91600268	A/G	cg16814680	chr8:91681699	NA	-0.69	-11.43	-0.49	1.46e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.45	-7.48	-0.34	4.39e-13	Longevity;Endometriosis;
LUAD	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg00316803	chr15:76480434	C15orf27	-0.39	-7.24	-0.33	2.18e-12	Blood metabolite levels;
LUAD	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg19875535	chr5:140030758	IK	0.45	7.62	0.35	1.66e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg02886208	chr11:14281011	SPON1	-0.4	-8.33	-0.38	1.13e-15	Mitochondrial DNA levels;
LUAD	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg18477163	chr1:228402036	OBSCN	0.4	7.19	0.33	3e-12	Diastolic blood pressure;
LUAD	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg21918786	chr6:109611834	NA	-0.52	-9.16	-0.41	2.32e-18	Reticulocyte fraction of red cells;
LUAD	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg18402987	chr7:1209562	NA	0.65	9.45	0.42	2.35e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7561273	0.609	rs10197527	chr2:24352398	A/C	cg20701182	chr2:24300061	SF3B14	0.47	7.59	0.35	2.11e-13	Quantitative traits;
LUAD	cis	rs10129255	0.500	rs6576230	chr14:107186778	C/A	cg07958169	chr14:107095056	NA	-0.37	-7.34	-0.34	1.08e-12	Kawasaki disease;
LUAD	cis	rs11756438	0.572	rs902779	chr6:119000593	A/C	cg18833306	chr6:118973337	C6orf204	0.53	9.58	0.42	8.22e-20	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.33	0.45	1.89e-22	Colorectal cancer;
LUAD	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg07741184	chr6:167504864	NA	0.31	7.05	0.32	7.19e-12	Crohn's disease;
LUAD	cis	rs12431939	0.762	rs60616710	chr14:51704361	A/T	cg23942311	chr14:51606299	NA	-0.56	-7.7	-0.35	9.85e-14	Cancer;
LUAD	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg05043794	chr9:111880884	C9orf5	-0.46	-7.89	-0.36	2.59e-14	Menarche (age at onset);
LUAD	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg09650180	chr20:62225654	GMEB2	-0.46	-6.69	-0.31	7.03e-11	Glioblastoma;
LUAD	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg19346786	chr7:2764209	NA	-0.53	-11.49	-0.49	8.62e-27	Height;
LUAD	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.62	-0.31	1.11e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	7.3	0.33	1.45e-12	Menarche (age at onset);
LUAD	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg03929089	chr4:120376271	NA	-0.46	-7.04	-0.32	7.59e-12	HDL cholesterol;
LUAD	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg15117754	chr3:10150083	C3orf24	0.44	7.09	0.33	5.76e-12	Alzheimer's disease;
LUAD	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg15704280	chr7:45808275	SEPT13	0.66	8.86	0.4	2.21e-17	Axial length;
LUAD	trans	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.49	-7.66	-0.35	1.3e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-8.02	-0.36	1.02e-14	Type 2 diabetes;
LUAD	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-12.0	-0.5	9.42e-29	Bipolar disorder;
LUAD	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg03605463	chr16:89740564	NA	-0.41	-6.69	-0.31	6.95e-11	Vitiligo;
LUAD	cis	rs1865721	0.771	rs6566093	chr18:73136682	T/C	cg26385618	chr18:73139727	C18orf62	-0.51	-10.44	-0.45	7.67e-23	Intelligence;
LUAD	cis	rs9487051	0.768	rs463916	chr6:109520538	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.29	-0.33	1.57e-12	Reticulocyte fraction of red cells;
LUAD	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg17120908	chr11:65337727	SSSCA1	-0.62	-9.73	-0.43	2.61e-20	Bone mineral density;
LUAD	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.57	-9.89	-0.43	7.13e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs7561273	0.609	rs2080727	chr2:24350907	A/G	cg20701182	chr2:24300061	SF3B14	0.47	7.59	0.35	2.11e-13	Quantitative traits;
LUAD	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg08601574	chr20:25228251	PYGB	-0.46	-8.7	-0.39	7.73e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg25894440	chr7:65020034	NA	-0.67	-7.19	-0.33	2.98e-12	Diabetic kidney disease;
LUAD	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11644478	chr21:40555479	PSMG1	0.62	10.49	0.45	4.82e-23	Cognitive function;
LUAD	cis	rs3774830	0.685	rs73212741	chr4:5464450	G/C	cg26943120	chr4:5472116	STK32B	0.39	7.95	0.36	1.75e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg05535760	chr7:792225	HEATR2	-0.83	-9.49	-0.42	1.7e-19	Cerebrospinal P-tau181p levels;
LUAD	cis	rs2908197	0.653	rs2961034	chr7:75961550	T/C	cg24580635	chr7:76178542	LOC100133091	-0.43	-6.72	-0.31	5.74e-11	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs7010267	0.869	rs1982763	chr8:119947828	C/T	cg01975934	chr8:119970761	NA	0.4	7.82	0.36	4.39e-14	Total body bone mineral density (age 45-60);
LUAD	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg14345882	chr6:26364793	BTN3A2	0.7	7.1	0.33	5.18e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs494562	0.892	rs618448	chr6:86121324	G/A	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg15017067	chr4:17643749	FAM184B	0.34	6.54	0.3	1.83e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg15147215	chr3:52552868	STAB1	-0.41	-7.47	-0.34	4.72e-13	Bipolar disorder;
LUAD	cis	rs220324	0.688	rs73223565	chr21:43567682	G/A	cg09727148	chr21:43560719	UMODL1	0.48	7.55	0.34	2.7e-13	Idiopathic osteonecrosis of the femoral head;
LUAD	trans	rs87938	0.966	rs450615	chr3:41133610	G/A	cg11224624	chr8:145049280	PLEC1	0.4	6.76	0.31	4.5e-11	Bone mineral density (hip);
LUAD	cis	rs806794	0.727	rs9358913	chr6:26239404	A/G	cg00631329	chr6:26305371	NA	-0.48	-7.26	-0.33	1.81e-12	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUAD	cis	rs73206853	0.841	rs11829321	chr12:110864593	C/G	cg12870014	chr12:110450643	ANKRD13A	0.62	6.67	0.31	7.83e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg17264618	chr3:40429014	ENTPD3	-0.41	-9.03	-0.4	6.01e-18	Renal cell carcinoma;
LUAD	cis	rs57994353	0.828	rs11146021	chr9:139327858	A/G	cg14019695	chr9:139328340	INPP5E	-0.39	-7.05	-0.32	7.53e-12	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg23096020	chr7:158799433	NA	-0.36	-6.63	-0.31	1e-10	Facial morphology (factor 20);
LUAD	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.32	6.85	0.32	2.59e-11	Cardiac Troponin-T levels;
LUAD	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.27	-7.15	-0.33	3.73e-12	Schizophrenia;
LUAD	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg23719950	chr11:63933701	MACROD1	0.51	6.38	0.3	4.64e-10	Mean platelet volume;
LUAD	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg11062466	chr8:58055876	NA	0.67	9.02	0.4	6.58e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.56	9.59	0.42	7.97e-20	Cognitive ability;
LUAD	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.8	-0.46	3.53e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.52	-8.76	-0.39	4.84e-17	Alzheimer's disease (late onset);
LUAD	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg08493051	chr2:3487164	NA	-0.44	-7.72	-0.35	8.28e-14	Neurofibrillary tangles;
LUAD	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg04414720	chr1:150670196	GOLPH3L	0.73	13.43	0.55	1.61e-34	Tonsillectomy;
LUAD	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg15017067	chr4:17643749	FAM184B	0.34	6.48	0.3	2.49e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg21724239	chr8:58056113	NA	0.74	9.75	0.43	2.14e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg11707310	chr1:2537719	MMEL1	-0.4	-8.41	-0.38	6.27e-16	Multiple sclerosis;
LUAD	cis	rs6993813	0.678	rs4416847	chr8:120009258	C/A	cg01975934	chr8:119970761	NA	-0.36	-6.88	-0.32	2.21e-11	Bone mineral density (hip);
LUAD	trans	rs17685	0.753	rs8200	chr7:75696606	C/G	cg19862616	chr7:65841803	NCRNA00174	-1.05	-26.93	-0.79	8.87e-94	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs7274811	0.711	rs291669	chr20:31945364	C/T	cg07470512	chr20:32255052	NECAB3;C20orf134	0.43	6.67	0.31	7.93e-11	Height;
LUAD	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg01475377	chr6:109611718	NA	-0.53	-9.98	-0.44	3.24e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs791888	0.723	rs1980648	chr10:89422369	T/C	cg13926569	chr10:89418898	PAPSS2	0.52	9.79	0.43	1.51e-20	Magnesium levels;
LUAD	cis	rs73198271	0.613	rs11249892	chr8:8657240	C/T	cg01851573	chr8:8652454	MFHAS1	0.45	8.0	0.36	1.23e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	12.92	0.53	2.02e-32	Initial pursuit acceleration in psychotic disorders;
LUAD	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	trans	rs7615952	0.575	rs35949599	chr3:125544202	G/A	cg07211511	chr3:129823064	LOC729375	-0.71	-9.93	-0.43	5.08e-21	Blood pressure (smoking interaction);
LUAD	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg10909506	chr17:38081995	ORMDL3	0.37	6.52	0.3	1.96e-10	Self-reported allergy;
LUAD	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	6.53	0.3	1.87e-10	Renal function-related traits (BUN);
LUAD	trans	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg01620082	chr3:125678407	NA	-0.74	-8.12	-0.37	5.27e-15	Breast cancer;
LUAD	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg25324976	chr17:61989376	CSHL1	-0.37	-7.22	-0.33	2.43e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	trans	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg26043149	chr18:55253948	FECH	-0.52	-8.82	-0.39	3.05e-17	Bone mineral density;
LUAD	cis	rs9486719	0.843	rs2499792	chr6:96846264	A/C	cg06623918	chr6:96969491	KIAA0776	0.71	9.3	0.41	7.58e-19	Migraine;Coronary artery disease;
LUAD	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg20556744	chr2:9614537	IAH1	0.63	6.65	0.31	9.24e-11	Opioid sensitivity;
LUAD	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg13180566	chr4:1052158	NA	-0.38	-6.52	-0.3	1.95e-10	Recombination rate (females);
LUAD	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.31	7.7	0.35	9.53e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	8.64	0.39	1.19e-16	Alzheimer's disease;
LUAD	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-20.82	-0.71	8.24e-67	Coronary artery disease;
LUAD	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg03289416	chr15:75166202	SCAMP2	0.51	8.63	0.39	1.25e-16	Breast cancer;
LUAD	cis	rs1448094	0.845	rs10863123	chr12:86346254	G/A	cg19622623	chr12:86230825	RASSF9	-0.37	-6.66	-0.31	8.48e-11	Major depressive disorder;
LUAD	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg18016565	chr1:150552671	MCL1	0.41	7.58	0.35	2.14e-13	Tonsillectomy;
LUAD	cis	rs2882667	1.000	rs2882667	chr5:138314106	C/T	cg04439458	chr5:138467593	SIL1	-0.45	-8.02	-0.36	1.03e-14	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg15911859	chr22:45810043	RIBC2;SMC1B	0.9	9.8	0.43	1.42e-20	Tonsillectomy;
LUAD	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg24450063	chr1:156163899	SLC25A44	1.14	23.11	0.75	5.09e-77	Testicular germ cell tumor;
LUAD	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg23985595	chr17:80112537	CCDC57	0.52	9.49	0.42	1.69e-19	Life satisfaction;
LUAD	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg16414030	chr3:133502952	NA	0.56	9.79	0.43	1.52e-20	Iron status biomarkers;
LUAD	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg16414030	chr3:133502952	NA	0.4	6.95	0.32	1.43e-11	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg00316803	chr15:76480434	C15orf27	-0.41	-7.9	-0.36	2.48e-14	Blood metabolite levels;
LUAD	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg26513180	chr16:89883248	FANCA	-0.67	-12.25	-0.51	9.62e-30	Vitiligo;
LUAD	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg18138036	chr10:133769891	PPP2R2D	0.41	6.47	0.3	2.65e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg22884516	chr22:45809543	SMC1B;RIBC2	0.63	6.46	0.3	2.81e-10	Tonsillectomy;
LUAD	trans	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg18335740	chr13:41363409	SLC25A15	0.52	8.74	0.39	5.55e-17	Lewy body disease;
LUAD	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg17747265	chr1:1875780	NA	-0.75	-18.36	-0.67	8.23e-56	Body mass index;
LUAD	cis	rs17054265	0.914	rs7026990	chr9:91260949	C/T	cg14112041	chr9:91262358	LOC286238	0.34	6.36	0.3	5.11e-10	Obesity-related traits;
LUAD	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-8.71	-0.39	7.13e-17	Monocyte percentage of white cells;
LUAD	cis	rs4774899	0.966	rs12898844	chr15:57358508	A/T	cg14026238	chr15:57616123	NA	0.36	6.73	0.31	5.42e-11	Urinary tract infection frequency;
LUAD	cis	rs8067545	0.750	rs9897653	chr17:19987924	G/A	cg04132472	chr17:19861366	AKAP10	0.28	6.67	0.31	8.2e-11	Schizophrenia;
LUAD	cis	rs1870323	0.527	rs2511082	chr11:86183632	A/G	cg01663953	chr11:86133777	CCDC81	-0.39	-7.04	-0.32	7.88e-12	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule);
LUAD	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg14343924	chr8:8086146	FLJ10661	0.5	7.99	0.36	1.26e-14	Mood instability;
LUAD	cis	rs600231	0.542	rs10896008	chr11:65245904	C/G	cg17120908	chr11:65337727	SSSCA1	-0.66	-8.61	-0.39	1.42e-16	Bone mineral density;
LUAD	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg21214613	chr1:16344536	HSPB7	0.56	9.71	0.43	3.01e-20	Dilated cardiomyopathy;
LUAD	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00166722	chr3:10149974	C3orf24	0.63	10.42	0.45	8.88e-23	Alzheimer's disease;
LUAD	cis	rs977987	1.000	rs62060550	chr16:75502252	C/T	cg03315344	chr16:75512273	CHST6	0.66	14.42	0.57	1.22e-38	Dupuytren's disease;
LUAD	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg24558204	chr6:135376177	HBS1L	0.48	8.88	0.4	1.94e-17	Red blood cell count;
LUAD	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg08601574	chr20:25228251	PYGB	0.43	7.84	0.36	3.76e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs1904096	0.506	rs4693381	chr4:95206855	A/T	cg11021082	chr4:95130006	SMARCAD1	0.52	9.99	0.44	3.14e-21	Type 2 diabetes;
LUAD	cis	rs4711350	0.954	rs943464	chr6:33731469	A/G	cg13859433	chr6:33739653	LEMD2	0.32	6.46	0.3	2.88e-10	Schizophrenia;
LUAD	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg02951883	chr7:2050386	MAD1L1	-0.7	-11.76	-0.5	7.81e-28	Bipolar disorder and schizophrenia;
LUAD	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg09658497	chr7:2847517	GNA12	-0.47	-7.63	-0.35	1.59e-13	Height;
LUAD	cis	rs2732480	0.967	rs2732469	chr12:48712932	T/A	cg04545296	chr12:48745243	ZNF641	0.32	8.28	0.37	1.61e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs12200782	1.000	rs4292511	chr6:26622290	G/T	cg11502198	chr6:26597334	ABT1	-0.79	-6.81	-0.31	3.4e-11	Small cell lung carcinoma;
LUAD	cis	rs7107174	1.000	rs11237462	chr11:78058812	C/A	cg19901956	chr11:77921274	USP35	-0.49	-6.38	-0.3	4.76e-10	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.99	21.75	0.73	6.07e-71	Chronic sinus infection;
LUAD	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg12179176	chr11:130786555	SNX19	0.54	8.96	0.4	1.03e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs427394	0.632	rs169285	chr5:6736587	G/C	cg12316010	chr5:6737918	POLS	0.39	7.45	0.34	5.45e-13	Menopause (age at onset);
LUAD	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.52	-6.46	-0.3	2.91e-10	Iron status biomarkers;
LUAD	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg18230493	chr5:56204884	C5orf35	-1.02	-15.41	-0.6	7.25e-43	Initial pursuit acceleration;
LUAD	cis	rs62400317	0.859	rs56337964	chr6:45039786	G/A	cg20913747	chr6:44695427	NA	-0.42	-6.69	-0.31	7.19e-11	Total body bone mineral density;
LUAD	cis	rs7116495	1.000	rs560777	chr11:71770602	C/T	cg07596299	chr11:71824057	C11orf51	0.77	6.61	0.31	1.15e-10	Severe influenza A (H1N1) infection;
LUAD	trans	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	8.87	0.4	2.1e-17	Mean corpuscular volume;
LUAD	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.91	0.36	2.31e-14	Lung cancer;
LUAD	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg16247931	chr14:102771650	RAGE	0.44	6.46	0.3	2.95e-10	QT interval;
LUAD	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg17031739	chr1:67600172	NA	-0.41	-7.49	-0.34	3.96e-13	Psoriasis;
LUAD	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.51	0.3	2.15e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.9	0.36	2.48e-14	Bladder cancer;
LUAD	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg23602478	chr1:26503979	CNKSR1	-0.28	-7.01	-0.32	9.32e-12	Height;
LUAD	cis	rs4077515	0.934	rs10781507	chr9:139272058	A/G	cg14019695	chr9:139328340	INPP5E	0.41	7.91	0.36	2.28e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.5	-9.45	-0.42	2.28e-19	Lymphocyte counts;
LUAD	cis	rs7731657	0.509	rs10068016	chr5:130358695	A/G	cg08523029	chr5:130500466	HINT1	0.57	7.53	0.34	2.99e-13	Fasting plasma glucose;
LUAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.83	0.43	1.14e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11255291	1.000	rs7901428	chr10:7732419	C/T	cg13340899	chr10:7670827	ITIH5	0.4	6.69	0.31	7.25e-11	Ovarian reserve;
LUAD	cis	rs714027	1.000	rs5763767	chr22:30493882	G/A	cg00539347	chr22:30592296	NA	-0.3	-7.14	-0.33	4.02e-12	Lymphocyte counts;
LUAD	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.28	6.56	0.3	1.54e-10	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg05340658	chr4:99064831	C4orf37	0.53	8.99	0.4	8.22e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg00280220	chr17:61926910	NA	0.33	6.45	0.3	3.01e-10	Prudent dietary pattern;
LUAD	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg20503657	chr10:835505	NA	0.75	9.88	0.43	7.23e-21	Eosinophil percentage of granulocytes;
LUAD	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.59	0.35	2.1e-13	Cannabis dependence symptom count;
LUAD	cis	rs11809207	0.953	rs17163666	chr1:26525383	A/G	cg00147160	chr1:26503991	CNKSR1	0.4	8.15	0.37	4.06e-15	Height;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg03762505	chr1:171750926	METTL13	0.41	6.37	0.3	4.91e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs2859741	0.967	rs822854	chr1:37485788	A/G	cg09363841	chr1:37513479	NA	-0.32	-7.96	-0.36	1.55e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUAD	cis	rs921968	0.565	rs6436069	chr2:219597185	T/C	cg02176678	chr2:219576539	TTLL4	-0.58	-11.81	-0.5	5.1e-28	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg08645402	chr16:4508243	NA	0.58	10.64	0.46	1.38e-23	Schizophrenia;
LUAD	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.82	-0.36	4.36e-14	Total body bone mineral density;
LUAD	cis	rs62238980	0.614	rs77661816	chr22:32565772	A/G	cg00543991	chr22:32367038	NA	0.8	7.29	0.33	1.49e-12	Childhood ear infection;
LUAD	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg10589385	chr1:150898437	SETDB1	0.43	8.23	0.37	2.32e-15	Melanoma;
LUAD	cis	rs9868809	0.881	rs57334642	chr3:48666795	C/T	cg00383909	chr3:49044727	WDR6	0.66	7.2	0.33	2.73e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.16	-0.44	7.49e-22	Bipolar disorder and schizophrenia;
LUAD	cis	rs9788721	0.836	rs17484235	chr15:78761414	C/G	cg18825076	chr15:78729989	IREB2	-0.58	-9.71	-0.43	2.95e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg01579765	chr21:45077557	HSF2BP	-0.57	-11.73	-0.5	1.08e-27	Mean corpuscular volume;
LUAD	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg11189052	chr15:85197271	WDR73	-0.62	-10.33	-0.45	1.87e-22	P wave terminal force;
LUAD	trans	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg01620082	chr3:125678407	NA	-1.04	-10.31	-0.45	2.28e-22	Lung cancer in ever smokers;
LUAD	trans	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.32	0.54	4.65e-34	Exhaled nitric oxide output;
LUAD	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg00071950	chr4:10020882	SLC2A9	0.74	14.9	0.59	1.18e-40	Bone mineral density;
LUAD	cis	rs476633	0.691	rs28409265	chr15:41539404	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.49	-8.88	-0.4	1.98e-17	Glomerular filtration rate (creatinine);
LUAD	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg17105886	chr17:28927953	LRRC37B2	0.79	7.73	0.35	7.73e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-10.79	-0.46	4.01e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg03396347	chr1:1875803	NA	-0.6	-14.85	-0.59	1.91e-40	Body mass index;
LUAD	cis	rs9811920	0.809	rs902159	chr3:99747445	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.61	11.72	0.5	1.11e-27	Axial length;
LUAD	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08280861	chr8:58055591	NA	0.67	8.72	0.39	6.27e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg16325326	chr1:53192061	ZYG11B	-0.65	-12.45	-0.52	1.5e-30	Monocyte count;
LUAD	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-9.66	-0.43	4.44e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg00280220	chr17:61926910	NA	0.36	6.96	0.32	1.32e-11	Prudent dietary pattern;
LUAD	cis	rs2067615	0.542	rs11113120	chr12:107203460	T/C	cg15890332	chr12:107067104	RFX4	0.39	8.38	0.38	7.7e-16	Heart rate;
LUAD	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg27366882	chr3:133540807	NA	-0.46	-8.7	-0.39	7.35e-17	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs240764	0.645	rs239208	chr6:101139285	G/A	cg09795085	chr6:101329169	ASCC3	0.41	7.2	0.33	2.75e-12	Neuroticism;
LUAD	cis	rs731174	0.802	rs776052	chr1:38179143	C/T	cg06917450	chr1:38156652	C1orf109	-0.41	-6.4	-0.3	4.18e-10	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs8017423	0.647	rs12589952	chr14:90821364	T/C	cg14092571	chr14:90743983	NA	0.39	6.65	0.31	9.12e-11	Mortality in heart failure;
LUAD	cis	rs220324	0.647	rs55877840	chr21:43560383	T/C	cg09727148	chr21:43560719	UMODL1	0.57	8.73	0.39	6.15e-17	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.39	7.08	0.33	6.07e-12	Systemic lupus erythematosus;
LUAD	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg15181151	chr6:150070149	PCMT1	0.4	8.21	0.37	2.62e-15	Lung cancer;
LUAD	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg24558204	chr6:135376177	HBS1L	0.46	7.86	0.36	3.32e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.41	-0.45	9.84e-23	Total body bone mineral density;
LUAD	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg03929089	chr4:120376271	NA	-0.97	-19.67	-0.69	1.2e-61	Height;
LUAD	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg16205897	chr5:131564050	P4HA2	0.43	9.91	0.43	5.79e-21	Blood metabolite levels;
LUAD	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.74e-11	Crohn's disease;
LUAD	cis	rs13064411	0.696	rs7613546	chr3:113228019	G/A	cg18753928	chr3:113234510	CCDC52	-0.73	-12.42	-0.52	2.09e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	trans	rs2262909	0.962	rs73019842	chr19:22249909	T/G	cg05197062	chr11:11642011	GALNTL4	0.59	9.14	0.41	2.61e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg03467027	chr4:99064603	C4orf37	0.41	6.68	0.31	7.34e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12545109	0.800	rs1530217	chr8:57408097	C/T	cg21220214	chr8:57350948	NA	-0.62	-8.61	-0.39	1.51e-16	Obesity-related traits;
LUAD	cis	rs9796	0.870	rs4244584	chr15:41259523	A/G	cg18705301	chr15:41695430	NDUFAF1	0.39	7.25	0.33	2.05e-12	Menopause (age at onset);
LUAD	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg18854424	chr1:2615690	NA	0.43	9.46	0.42	2.2e-19	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg08742575	chr21:47604166	C21orf56	-0.53	-8.54	-0.38	2.37e-16	Testicular germ cell tumor;
LUAD	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg20587970	chr11:113659929	NA	-1.2	-18.25	-0.66	2.76e-55	Hip circumference adjusted for BMI;
LUAD	trans	rs629535	0.911	rs627382	chr8:70014081	C/T	cg21567404	chr3:27674614	NA	-1.0	-18.72	-0.67	2.12e-57	Dupuytren's disease;
LUAD	cis	rs13064411	0.735	rs9875025	chr3:113147552	T/C	cg18753928	chr3:113234510	CCDC52	-0.67	-11.18	-0.48	1.31e-25	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg20276088	chr3:133502917	NA	-0.45	-7.79	-0.35	5.07e-14	Iron status biomarkers;
LUAD	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg04111992	chr7:158790115	NA	0.41	7.18	0.33	3.11e-12	Facial morphology (factor 20);
LUAD	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg05835009	chr4:710272	PCGF3	0.57	8.47	0.38	4.02e-16	White blood cell count;
LUAD	trans	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg27411982	chr8:10470053	RP1L1	-0.35	-6.41	-0.3	3.92e-10	Mood instability;
LUAD	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15320075	chr8:145703422	NA	0.4	6.5	0.3	2.23e-10	Age at first birth;
LUAD	cis	rs240764	0.555	rs6919283	chr6:101235769	C/T	cg09795085	chr6:101329169	ASCC3	0.41	7.17	0.33	3.39e-12	Neuroticism;
LUAD	cis	rs7937890	0.532	rs2575827	chr11:14475515	A/G	cg06199346	chr11:14280333	SPON1	-0.33	-6.6	-0.31	1.25e-10	Mitochondrial DNA levels;
LUAD	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg11871910	chr12:69753446	YEATS4	0.48	7.02	0.32	9e-12	Response to diuretic therapy;
LUAD	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg13385794	chr1:248469461	NA	0.25	6.95	0.32	1.35e-11	Common traits (Other);
LUAD	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.75e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs220324	0.688	rs9978854	chr21:43567731	G/A	cg08841829	chr21:43638893	ABCG1	-0.47	-6.78	-0.31	3.99e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7937890	0.535	rs2575857	chr11:14501296	C/T	cg02886208	chr11:14281011	SPON1	-0.33	-6.44	-0.3	3.34e-10	Mitochondrial DNA levels;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg18637244	chr16:2039815	SYNGR3	0.39	6.46	0.3	2.86e-10	Bilirubin levels;
LUAD	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg00933542	chr6:150070202	PCMT1	0.43	8.45	0.38	4.74e-16	Lung cancer;
LUAD	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg21856205	chr7:94953877	PON1	-0.53	-7.12	-0.33	4.72e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2235649	0.833	rs9933168	chr16:1848361	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-8.15	-0.37	4.02e-15	Blood metabolite levels;
LUAD	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg04944784	chr2:26401820	FAM59B	-0.89	-13.69	-0.55	1.47e-35	Gut microbiome composition (summer);
LUAD	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg05966235	chr16:28915196	ATP2A1	0.5	7.99	0.36	1.31e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg18252515	chr7:66147081	NA	-0.65	-7.16	-0.33	3.58e-12	Diabetic kidney disease;
LUAD	cis	rs427941	0.703	rs201445	chr7:101737921	G/T	cg06246474	chr7:101738831	CUX1	0.42	7.3	0.33	1.48e-12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg16797656	chr11:68205561	LRP5	0.45	9.33	0.41	5.89e-19	Total body bone mineral density;
LUAD	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg02423579	chr7:2872169	GNA12	-0.91	-16.41	-0.62	3.43e-47	Height;
LUAD	cis	rs4889855	0.556	rs4278795	chr17:78533189	A/T	cg16591659	chr17:78472290	NA	0.42	7.45	0.34	5.17e-13	Fractional excretion of uric acid;
LUAD	cis	rs9788682	0.747	rs2568499	chr15:78722359	T/C	cg18825076	chr15:78729989	IREB2	-0.55	-7.6	-0.35	1.91e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg13271783	chr10:134563150	INPP5A	-0.4	-7.1	-0.33	5.2e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.54	0.3	1.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg05368731	chr17:41323189	NBR1	0.96	19.77	0.69	4.24e-62	Menopause (age at onset);
LUAD	cis	rs4845570	1.000	rs1054479	chr1:151746079	A/T	cg07092448	chr1:151763213	TDRKH	-0.74	-8.71	-0.39	7.01e-17	Coronary artery disease;
LUAD	cis	rs4804416	1.000	rs4804416	chr19:7223848	G/T	cg09779027	chr19:7224513	INSR	-0.51	-10.61	-0.46	1.84e-23	Thyroid hormone levels;Hypothyroidism;
LUAD	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg17757837	chr7:157058334	UBE3C	0.47	8.38	0.38	8.03e-16	Body mass index;
LUAD	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg18621852	chr3:10150065	C3orf24	0.48	8.3	0.37	1.43e-15	Alzheimer's disease;
LUAD	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg02782426	chr3:40428986	ENTPD3	0.43	9.0	0.4	7.49e-18	Renal cell carcinoma;
LUAD	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06022373	chr22:39101656	GTPBP1	0.44	6.99	0.32	1.08e-11	Menopause (age at onset);
LUAD	cis	rs2050392	0.928	rs2250077	chr10:30702929	A/G	cg18806716	chr10:30721971	MAP3K8	-0.54	-10.72	-0.46	7.17e-24	Inflammatory bowel disease;
LUAD	cis	rs4253772	0.515	rs7287164	chr22:46781008	T/C	cg09491104	chr22:46646882	C22orf40	-0.52	-6.55	-0.3	1.64e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs6842047	0.520	rs4253425	chr4:187205929	T/C	cg23442198	chr4:187126114	CYP4V2	0.82	8.11	0.37	5.49e-15	Blood protein levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg05658717	chr12:118407033	KSR2	-0.79	-7.72	-0.35	8.34e-14	Type 2 diabetes;
LUAD	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg12311346	chr5:56204834	C5orf35	-0.9	-13.31	-0.54	5.03e-34	Initial pursuit acceleration;
LUAD	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg13319975	chr6:146136371	FBXO30	0.57	9.61	0.42	6.48e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg04513422	chr13:111522314	C13orf29	-0.57	-7.81	-0.35	4.68e-14	Sitting height ratio;
LUAD	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg01765077	chr12:122356316	WDR66	0.52	8.65	0.39	1.04e-16	Mean corpuscular volume;
LUAD	cis	rs7089973	0.624	rs61867965	chr10:116574794	A/T	cg23260525	chr10:116636907	FAM160B1	0.46	10.12	0.44	1.02e-21	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs17401966	0.838	rs6541089	chr1:10402785	A/G	cg19773385	chr1:10388646	KIF1B	-0.4	-6.53	-0.3	1.91e-10	Hepatocellular carcinoma;
LUAD	cis	rs2439831	0.717	rs10518820	chr15:43888976	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.0	10.47	0.45	5.55e-23	Lung cancer in ever smokers;
LUAD	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg23262073	chr20:60523788	NA	-0.37	-6.45	-0.3	3.02e-10	Body mass index;
LUAD	cis	rs4077468	1.000	rs4077468	chr1:205914757	A/G	cg14159672	chr1:205819179	PM20D1	-0.39	-6.83	-0.32	3e-11	Cystic fibrosis-related diabetes;
LUAD	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg03929089	chr4:120376271	NA	-0.92	-17.27	-0.64	5.97e-51	Height;
LUAD	cis	rs7731657	0.537	rs1468274	chr5:130363308	T/C	cg08523029	chr5:130500466	HINT1	0.48	6.64	0.31	9.92e-11	Fasting plasma glucose;
LUAD	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg06453172	chr10:134556979	INPP5A	-0.67	-10.05	-0.44	1.87e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg18180107	chr4:99064573	C4orf37	-0.43	-6.84	-0.32	2.74e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10484885	0.878	rs72921955	chr6:90588789	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.69	-6.79	-0.31	3.74e-11	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg03563238	chr19:33554763	RHPN2	-0.37	-8.58	-0.38	1.84e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg18854424	chr1:2615690	NA	0.43	9.39	0.42	3.64e-19	Ulcerative colitis;
LUAD	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg12310025	chr6:25882481	NA	-0.58	-9.55	-0.42	1.1e-19	Blood metabolite levels;
LUAD	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.58	0.3	1.42e-10	Colorectal cancer;
LUAD	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.9	0.32	1.96e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg17366294	chr4:99064904	C4orf37	0.53	9.77	0.43	1.77e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4660306	0.961	rs4660860	chr1:45946233	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-8.01	-0.36	1.11e-14	Homocysteine levels;
LUAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.5	0.38	3.38e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7737355	0.853	rs245799	chr5:130672748	C/A	cg06307176	chr5:131281290	NA	-0.39	-6.6	-0.31	1.23e-10	Life satisfaction;
LUAD	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg15997130	chr1:24165203	NA	0.41	6.88	0.32	2.11e-11	Immature fraction of reticulocytes;
LUAD	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg04731861	chr2:219085781	ARPC2	-0.27	-8.29	-0.37	1.52e-15	Pyoderma gangrenosum in inflammatory bowel disease;
LUAD	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg17366294	chr4:99064904	C4orf37	0.51	9.12	0.41	3.01e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg12573674	chr2:1569213	NA	-0.57	-8.25	-0.37	2.06e-15	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs35995292	0.500	rs7776996	chr7:38919762	G/C	cg19327137	chr7:38886074	VPS41	0.72	14.58	0.58	2.61e-39	Subjective well-being (multi-trait analysis);
LUAD	cis	rs9616064	0.506	rs2073275	chr22:47070432	G/C	cg05621596	chr22:47072043	GRAMD4	-0.71	-12.0	-0.5	9.33e-29	Urate levels in obese individuals;
LUAD	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21659725	chr3:3221576	CRBN	-0.86	-18.31	-0.66	1.4e-55	Intelligence (multi-trait analysis);
LUAD	cis	rs6121246	0.560	rs6088854	chr20:30225357	G/A	cg21427119	chr20:30132790	HM13	-0.57	-8.0	-0.36	1.22e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-6.72	-0.31	5.91e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg07153921	chr17:41440717	NA	0.4	6.64	0.31	9.69e-11	Menopause (age at onset);
LUAD	cis	rs7520050	0.966	rs10789475	chr1:46304177	C/G	cg06784218	chr1:46089804	CCDC17	-0.3	-6.39	-0.3	4.43e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18404041	chr3:52824283	ITIH1	-0.45	-8.7	-0.39	7.69e-17	Electroencephalogram traits;
LUAD	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg03929089	chr4:120376271	NA	-0.93	-17.47	-0.65	7.35e-52	Height;
LUAD	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg15704280	chr7:45808275	SEPT13	-0.91	-16.71	-0.63	1.71e-48	Height;
LUAD	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg18230493	chr5:56204884	C5orf35	-0.85	-12.43	-0.52	1.89e-30	Initial pursuit acceleration;
LUAD	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg19346786	chr7:2764209	NA	-0.56	-12.09	-0.51	4.09e-29	Height;
LUAD	cis	rs7707921	0.881	rs73136782	chr5:81443520	T/G	cg15871215	chr5:81402204	ATG10	-0.68	-9.67	-0.43	4.17e-20	Breast cancer;
LUAD	cis	rs208520	0.690	rs207091	chr6:66799847	G/T	cg07460842	chr6:66804631	NA	-1.09	-17.03	-0.64	6.56e-50	Exhaled nitric oxide output;
LUAD	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-7.5	-0.34	3.67e-13	Alzheimer's disease (late onset);
LUAD	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg13870426	chr17:30244630	NA	-0.55	-6.42	-0.3	3.71e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg27284194	chr4:1044797	NA	0.7	9.89	0.43	6.83e-21	Recombination rate (females);
LUAD	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg19986472	chr17:41561315	DHX8	-0.38	-6.36	-0.3	5.2400000000000005e-10	Subcortical brain region volumes;
LUAD	cis	rs9326248	0.539	rs10892065	chr11:116897024	T/C	cg20608306	chr11:116969690	SIK3	0.32	7.1	0.33	5.47e-12	Blood protein levels;
LUAD	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg27366882	chr3:133540807	NA	-0.42	-7.45	-0.34	5.21e-13	Alcohol consumption (transferrin glycosylation);
LUAD	cis	rs7089973	0.872	rs7909566	chr10:116629136	A/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.68	0.43	3.68e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg03340356	chr1:67600835	NA	0.44	7.71	0.35	9.23e-14	Psoriasis;
LUAD	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg16479474	chr6:28041457	NA	0.46	7.65	0.35	1.41e-13	Depression;
LUAD	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg08779649	chr13:50194554	NA	0.38	7.79	0.35	5.17e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg13736514	chr6:26305472	NA	0.68	12.73	0.53	1.16e-31	Educational attainment;
LUAD	cis	rs758324	0.812	rs601441	chr5:131284433	C/T	cg06307176	chr5:131281290	NA	-0.44	-7.34	-0.34	1.14e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg22079354	chr11:130786696	SNX19	0.37	6.38	0.3	4.56e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs4664304	0.629	rs3792168	chr2:160846472	T/C	cg23995753	chr2:160760732	LY75	-0.38	-6.46	-0.3	2.84e-10	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg06784218	chr1:46089804	CCDC17	-0.5	-11.08	-0.47	3.3e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9364220	0.662	rs9295044	chr6:168494289	T/G	cg02770688	chr6:168491649	NA	-0.38	-7.33	-0.34	1.22e-12	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
LUAD	cis	rs10193935	0.901	rs13429697	chr2:42529818	C/T	cg27598129	chr2:42591480	NA	-0.77	-9.82	-0.43	1.2e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg14917512	chr19:3094685	GNA11	0.58	6.91	0.32	1.77e-11	Diabetic kidney disease;
LUAD	cis	rs68170813	0.559	rs1989814	chr7:107045076	A/G	cg02696742	chr7:106810147	HBP1	-0.8	-10.6	-0.46	2.01e-23	Coronary artery disease;
LUAD	trans	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-10.31	-0.45	2.13e-22	Obesity-related traits;
LUAD	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.6	-7.78	-0.35	5.67e-14	Iron status biomarkers;
LUAD	cis	rs599083	0.744	rs603129	chr11:68186669	A/T	cg02221422	chr11:68192511	LRP5	0.44	6.85	0.32	2.69e-11	Bone mineral density (spine);
LUAD	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg02002194	chr4:3960332	NA	-0.27	-6.75	-0.31	4.86e-11	Neuroticism;
LUAD	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg22535103	chr8:58192502	C8orf71	-0.61	-7.26	-0.33	1.87e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs8008758	1.000	rs12432879	chr14:101688977	A/G	cg26224664	chr14:101693935	NA	0.33	6.83	0.32	2.93e-11	Body mass index (alcohol intake interaction);
LUAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg04025307	chr7:1156635	C7orf50	0.54	6.75	0.31	4.88e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg00450029	chr8:599525	NA	0.81	8.04	0.36	8.87e-15	IgG glycosylation;
LUAD	cis	rs13082711	0.522	rs480238	chr3:27347577	A/T	cg02860705	chr3:27208620	NA	0.48	8.09	0.37	6.16e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs3087591	1.000	rs6505235	chr17:29688603	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.42	-6.77	-0.31	4.43e-11	Hip circumference;
LUAD	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg15181151	chr6:150070149	PCMT1	0.39	7.93	0.36	2.02e-14	Lung cancer;
LUAD	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg12940439	chr1:67600707	NA	0.45	8.61	0.39	1.48e-16	Psoriasis;
LUAD	cis	rs12824058	0.737	rs2398508	chr12:130816460	G/A	cg23887609	chr12:130822674	PIWIL1	0.39	6.43	0.3	3.42e-10	Menopause (age at onset);
LUAD	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg25358565	chr5:93447407	FAM172A	0.63	7.36	0.34	9.79e-13	Diabetic retinopathy;
LUAD	cis	rs17253792	0.822	rs75232282	chr14:56067290	G/C	cg01858014	chr14:56050164	KTN1	-0.61	-6.4	-0.3	4.21e-10	Putamen volume;
LUAD	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14893161	chr1:205819251	PM20D1	0.53	8.87	0.4	2.12e-17	Parkinson's disease;
LUAD	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg16680214	chr1:154839983	KCNN3	-0.64	-13.17	-0.54	1.93e-33	Prostate cancer;
LUAD	cis	rs57590327	0.555	rs3772884	chr3:81802720	G/T	cg07356753	chr3:81810745	GBE1	-0.57	-9.36	-0.41	4.81e-19	Extraversion;
LUAD	cis	rs9296092	0.517	rs62405949	chr6:33522800	G/A	cg13560919	chr6:33536144	NA	-0.87	-15.58	-0.6	1.35e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs7712401	0.601	rs246268	chr5:122256342	C/T	cg19077854	chr5:122220652	SNX24	0.34	6.53	0.3	1.95e-10	Mean platelet volume;
LUAD	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01171360	chr6:293285	DUSP22	-0.75	-13.19	-0.54	1.65e-33	Menopause (age at onset);
LUAD	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs8027181	0.804	rs34661924	chr15:72994564	A/G	cg25632853	chr15:73088954	NA	0.31	6.74	0.31	5.32e-11	Triglyceride levels;
LUAD	cis	rs9951602	1.000	rs7232284	chr18:76667529	A/G	cg00806245	chr18:76673096	NA	-0.41	-7.02	-0.32	8.63e-12	Obesity-related traits;
LUAD	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg06346307	chr22:19949965	COMT	-0.4	-8.02	-0.36	1.08e-14	Blood metabolite levels;
LUAD	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg19622623	chr12:86230825	RASSF9	-0.39	-7.02	-0.32	9.09e-12	Major depressive disorder;
LUAD	cis	rs1451375	0.698	rs56766899	chr7:50648938	T/C	cg18232548	chr7:50535776	DDC	0.5	8.16	0.37	3.99e-15	Malaria;
LUAD	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg23387056	chr11:14280742	SPON1	0.42	8.89	0.4	1.77e-17	Mitochondrial DNA levels;
LUAD	cis	rs4588572	0.643	rs10063319	chr5:77758425	T/C	cg11547950	chr5:77652471	NA	-0.77	-12.55	-0.52	6.24e-31	Triglycerides;
LUAD	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg00933542	chr6:150070202	PCMT1	0.45	9.85	0.43	9.93e-21	Lung cancer;
LUAD	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.17	0.33	3.46e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg19318889	chr4:1322082	MAEA	0.44	7.3	0.33	1.42e-12	Obesity-related traits;
LUAD	cis	rs55823223	0.618	rs72860390	chr17:73869914	A/G	cg08125733	chr17:73851984	WBP2	0.66	9.61	0.42	6.78e-20	Psoriasis;
LUAD	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg05865280	chr17:75406074	SEPT9	0.61	19.3	0.68	5.44e-60	Airflow obstruction;
LUAD	trans	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.69	12.03	0.5	7.38e-29	Mean corpuscular volume;
LUAD	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25427524	chr10:38739819	LOC399744	-0.79	-14.22	-0.57	8.83e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg01097406	chr16:89675127	NA	-0.33	-6.69	-0.31	7.24e-11	Vitiligo;
LUAD	cis	rs9341808	0.667	rs2476826	chr6:80876064	C/T	cg08355045	chr6:80787529	NA	0.52	9.27	0.41	9.28e-19	Sitting height ratio;
LUAD	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.5	0.52	1.02e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs758324	0.898	rs6877358	chr5:131111360	G/A	cg25547332	chr5:131281432	NA	0.45	6.76	0.31	4.47e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs1950626	0.569	rs4143956	chr14:101434356	A/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.37	7.44	0.34	5.54e-13	Pelvic organ prolapse (moderate/severe);
LUAD	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg13010199	chr12:38710504	ALG10B	0.4	6.53	0.3	1.89e-10	Bladder cancer;
LUAD	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg22963979	chr7:1858916	MAD1L1	0.52	8.78	0.39	4.08e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg15704280	chr7:45808275	SEPT13	0.64	8.64	0.39	1.19e-16	Axial length;
LUAD	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg18016565	chr1:150552671	MCL1	0.41	7.5	0.34	3.86e-13	Tonsillectomy;
LUAD	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg05043794	chr9:111880884	C9orf5	-0.4	-7.01	-0.32	9.39e-12	Menarche (age at onset);
LUAD	cis	rs89107	0.688	rs281861	chr6:118579357	T/G	cg18833306	chr6:118973337	C6orf204	0.53	9.61	0.42	6.52e-20	Cardiac structure and function;
LUAD	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg18412690	chr11:61100593	DDB1;DAK	-0.39	-6.43	-0.3	3.42e-10	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs1395	1.000	rs1395	chr2:27424636	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.42	-7.76	-0.35	6.29e-14	Blood metabolite levels;
LUAD	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg25985355	chr7:65971099	NA	-0.35	-6.35	-0.3	5.47e-10	Aortic root size;
LUAD	cis	rs8018808	0.935	rs12436593	chr14:77928476	C/T	cg20045696	chr14:77926864	AHSA1	0.35	6.38	0.3	4.62e-10	Myeloid white cell count;
LUAD	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg07636037	chr3:49044803	WDR6	0.54	10.25	0.45	3.61e-22	Menarche (age at onset);
LUAD	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg23029597	chr12:123009494	RSRC2	-0.58	-9.32	-0.41	6.56e-19	Body mass index;
LUAD	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.8	0.35	4.77e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11206510	1.000	rs11206510	chr1:55496039	A/G	cg13462158	chr1:55522104	PCSK9	0.48	6.45	0.3	3.12e-10	Coronary heart disease;LDL cholesterol;Myocardial infarction (early onset);Myocardial infarction;Coronary artery disease;
LUAD	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg18512352	chr11:47633146	NA	0.4	7.09	0.33	5.69e-12	Subjective well-being;
LUAD	cis	rs494562	0.892	rs547963	chr6:86118743	T/C	cg27297263	chr6:86160468	NT5E	0.58	6.47	0.3	2.71e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs4285028	0.948	rs35902163	chr3:121649526	G/A	cg11130432	chr3:121712080	ILDR1	-0.6	-8.3	-0.37	1.42e-15	Multiple sclerosis;
LUAD	cis	rs867529	0.600	rs335120	chr2:89072731	A/G	cg26627705	chr2:89060884	NA	0.46	6.88	0.32	2.16e-11	Height;
LUAD	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg21016266	chr12:122356598	WDR66	0.55	9.55	0.42	1.05e-19	Mean corpuscular volume;
LUAD	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg21252483	chr19:49399788	TULP2	-0.8	-12.56	-0.52	5.63e-31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg12623918	chr2:306882	NA	0.34	6.73	0.31	5.48e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs4638749	0.677	rs4676186	chr2:108842640	T/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-7.43	-0.34	6.13e-13	Blood pressure;
LUAD	cis	rs113835537	0.529	rs11227512	chr11:66281291	T/C	cg24851651	chr11:66362959	CCS	0.57	10.1	0.44	1.23e-21	Airway imaging phenotypes;
LUAD	cis	rs7113874	0.802	rs10840102	chr11:8676238	C/T	cg10639395	chr11:8710044	RPL27A	0.36	6.4	0.3	4.14e-10	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg21699342	chr2:239360505	ASB1	0.58	11.34	0.48	3.31e-26	Multiple system atrophy;
LUAD	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg06740227	chr12:86229804	RASSF9	0.35	6.56	0.3	1.56e-10	Major depressive disorder;
LUAD	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg12667521	chr19:29218732	NA	0.6	8.2	0.37	2.86e-15	Methadone dose in opioid dependence;
LUAD	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.85e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg11645453	chr3:52864694	ITIH4	0.6	11.17	0.48	1.41e-25	Schizophrenia;
LUAD	cis	rs7119	0.651	rs12904823	chr15:77837662	G/A	cg27398640	chr15:77910606	LINGO1	-0.36	-6.58	-0.3	1.35e-10	Type 2 diabetes;
LUAD	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg26384229	chr12:38710491	ALG10B	0.52	8.61	0.39	1.47e-16	Heart rate;
LUAD	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.7	9.83	0.43	1.12e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	trans	rs459571	0.804	rs448918	chr9:136885979	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.68	-10.01	-0.44	2.66e-21	Platelet distribution width;
LUAD	cis	rs28830936	0.967	rs9672671	chr15:41917075	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.33	-6.72	-0.31	5.97e-11	Diastolic blood pressure;
LUAD	trans	rs12719740	1.000	rs12719740	chr15:99072905	C/T	cg13805001	chr9:89555718	NA	0.46	7.18	0.33	3.08e-12	Arthritis (juvenile idiopathic);
LUAD	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg04398451	chr17:18023971	MYO15A	0.78	14.11	0.57	2.51e-37	Total body bone mineral density;
LUAD	cis	rs656900	0.669	rs665629	chr15:80119231	C/A	cg02196730	chr15:80188777	MTHFS	-0.43	-7.15	-0.33	3.72e-12	Cerebrospinal P-tau181p levels;
LUAD	cis	rs9796	0.870	rs2306083	chr15:41347658	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.36	-6.89	-0.32	1.98e-11	Menopause (age at onset);
LUAD	cis	rs3760982	0.565	rs8104300	chr19:44293144	T/C	cg21496419	chr19:44306685	LYPD5	0.34	7.39	0.34	8.09e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg12143784	chr7:64541923	NA	0.46	7.56	0.35	2.45e-13	Calcium levels;
LUAD	cis	rs2274273	0.529	rs10131562	chr14:55847015	G/A	cg04306507	chr14:55594613	LGALS3	0.39	7.68	0.35	1.15e-13	Protein biomarker;
LUAD	cis	rs7267979	0.789	rs4815429	chr20:25521611	T/C	cg08601574	chr20:25228251	PYGB	-0.41	-7.59	-0.35	2e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9535307	0.929	rs1581745	chr13:50330957	T/C	cg04663916	chr13:50265991	EBPL	0.57	6.66	0.31	8.62e-11	Obesity-related traits;
LUAD	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg26343298	chr8:95960752	TP53INP1	0.4	8.5	0.38	3.22e-16	Type 2 diabetes;
LUAD	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.41	0.38	6.51e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06022373	chr22:39101656	GTPBP1	0.46	7.12	0.33	4.79e-12	Menopause (age at onset);
LUAD	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg09365446	chr1:150670422	GOLPH3L	0.62	10.81	0.47	3.19e-24	Melanoma;
LUAD	cis	rs7680126	0.633	rs55766779	chr4:10287039	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-7.35	-0.34	1.03e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs7737355	0.947	rs11242081	chr5:130908135	T/C	cg06307176	chr5:131281290	NA	0.52	8.12	0.37	5.28e-15	Life satisfaction;
LUAD	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.54	9.11	0.41	3.23e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg13319975	chr6:146136371	FBXO30	0.6	10.09	0.44	1.36e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.46	0.34	5.12e-13	Resting heart rate;
LUAD	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg23262073	chr20:60523788	NA	-0.44	-7.07	-0.32	6.62e-12	Body mass index;
LUAD	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg15485101	chr11:133734466	NA	0.39	8.29	0.37	1.47e-15	Childhood ear infection;
LUAD	cis	rs12545109	0.765	rs1960727	chr8:57411368	G/A	cg17761419	chr8:57350749	NA	-0.53	-7.6	-0.35	1.91e-13	Obesity-related traits;
LUAD	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg25535316	chr11:579198	PHRF1	-0.38	-6.67	-0.31	7.81e-11	Systemic lupus erythematosus;
LUAD	cis	rs7289126	1.000	rs5995558	chr22:38647639	A/G	cg17652424	chr22:38574118	PLA2G6	-0.24	-6.73	-0.31	5.4e-11	Mammographic density (dense area);Percent mammographic density;
LUAD	cis	rs2882667	0.898	rs3828600	chr5:138386859	G/T	cg04439458	chr5:138467593	SIL1	-0.39	-7.05	-0.32	7.38e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg26384229	chr12:38710491	ALG10B	0.4	6.94	0.32	1.48e-11	Heart rate;
LUAD	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg03929089	chr4:120376271	NA	-0.97	-20.33	-0.7	1.38e-64	Height;
LUAD	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg07636037	chr3:49044803	WDR6	0.36	6.51	0.3	2.09e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs782590	0.870	rs2586950	chr2:55868966	T/G	cg03859395	chr2:55845619	SMEK2	0.67	12.08	0.51	4.35e-29	Metabolic syndrome;
LUAD	cis	rs6665290	0.669	rs6426558	chr1:227175367	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.13	-30.82	-0.83	3.31e-110	Myeloid white cell count;
LUAD	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg22029157	chr1:209979665	IRF6	0.47	8.38	0.38	8.03e-16	Monobrow;
LUAD	cis	rs11809207	1.000	rs11247867	chr1:26517891	C/T	cg00147160	chr1:26503991	CNKSR1	0.44	8.76	0.39	4.59e-17	Height;
LUAD	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03934478	chr11:495069	RNH1	0.76	9.03	0.4	6e-18	Body mass index;
LUAD	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg22117172	chr7:91764530	CYP51A1	0.34	7.52	0.34	3.27e-13	Breast cancer;
LUAD	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg13319975	chr6:146136371	FBXO30	-0.55	-9.33	-0.41	6.07e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7827545	1.000	rs1372660	chr8:135566788	C/G	cg17885191	chr8:135476712	NA	0.5	8.04	0.36	8.88e-15	Hypertension (SNP x SNP interaction);
LUAD	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.32	-6.38	-0.3	4.66e-10	IgG glycosylation;
LUAD	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg02527881	chr3:46936655	PTH1R	0.43	8.35	0.38	9.81e-16	Colorectal cancer;
LUAD	cis	rs7020830	0.858	rs13293465	chr9:37127678	C/T	cg14294708	chr9:37120828	ZCCHC7	0.86	16.58	0.63	6.01e-48	Schizophrenia;
LUAD	trans	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg04565464	chr8:145669602	NFKBIL2	0.44	6.61	0.31	1.15e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg19077165	chr18:44547161	KATNAL2	-0.4	-6.88	-0.32	2.15e-11	Personality dimensions;
LUAD	cis	rs7953508	0.619	rs11107114	chr12:93972927	G/A	cg18151635	chr12:93972918	NA	-0.82	-13.18	-0.54	1.77e-33	Pubertal anthropometrics;
LUAD	cis	rs6669919	0.901	rs7527396	chr1:211667857	C/T	cg10512769	chr1:211675356	NA	-0.3	-6.53	-0.3	1.91e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs9473147	0.516	rs6931478	chr6:47461913	C/A	cg20196966	chr6:47445060	CD2AP	0.45	6.99	0.32	1.04e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08280861	chr8:58055591	NA	0.64	8.43	0.38	5.35e-16	Developmental language disorder (linguistic errors);
LUAD	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.62	9.29	0.41	8.31e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7582720	1.000	rs72932553	chr2:203842661	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.66	0.43	4.5e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06544989	chr22:39130855	UNC84B	0.41	7.56	0.34	2.61e-13	Menopause (age at onset);
LUAD	cis	rs4660214	0.724	rs10888683	chr1:39623669	A/T	cg27567593	chr1:39956653	BMP8A	-0.35	-6.99	-0.32	1.06e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08677398	chr8:58056175	NA	0.48	6.89	0.32	2.07e-11	Developmental language disorder (linguistic errors);
LUAD	trans	rs1445130	0.892	rs12998215	chr2:18847690	C/A	cg04529938	chr17:73084494	SLC16A5	0.53	6.43	0.3	3.43e-10	Bulimia nervosa;
LUAD	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg27284194	chr4:1044797	NA	0.7	10.1	0.44	1.21e-21	Recombination rate (females);
LUAD	trans	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg01620082	chr3:125678407	NA	-0.46	-6.69	-0.31	7.24e-11	Depression;
LUAD	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg08807101	chr21:30365312	RNF160	-0.44	-7.58	-0.35	2.28e-13	Dental caries;
LUAD	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg14458575	chr2:238380390	NA	0.64	12.27	0.51	8.34e-30	Prostate cancer;
LUAD	cis	rs1595825	1.000	rs1304164	chr2:198877234	C/A	cg10547527	chr2:198650123	BOLL	-0.47	-6.59	-0.31	1.34e-10	Ulcerative colitis;
LUAD	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg08885076	chr2:99613938	TSGA10	-0.4	-7.18	-0.33	3.2e-12	Chronic sinus infection;
LUAD	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg01448562	chr3:133502909	NA	-0.48	-8.28	-0.37	1.59e-15	Iron status biomarkers;
LUAD	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg12179176	chr11:130786555	SNX19	0.45	7.29	0.33	1.51e-12	Schizophrenia;
LUAD	cis	rs9843304	0.528	rs11919764	chr3:149187235	C/T	cg08667024	chr3:149219783	TM4SF4	-0.37	-6.89	-0.32	2.01e-11	Gallstone disease;
LUAD	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg25797454	chr6:150327115	RAET1K	0.37	7.74	0.35	7.24e-14	Alopecia areata;
LUAD	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg05926928	chr17:57297772	GDPD1	1.41	17.25	0.64	6.98e-51	Opioid sensitivity;
LUAD	trans	rs13069049	0.592	rs13087767	chr3:66827465	C/G	cg13311902	chr7:50773857	GRB10	-0.36	-6.36	-0.3	5.25e-10	Metabolite levels;
LUAD	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg21427119	chr20:30132790	HM13	-0.49	-7.36	-0.34	9.41e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs7000551	0.700	rs7431	chr8:22398462	G/A	cg12081754	chr8:22256438	SLC39A14	0.43	7.09	0.33	5.6e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs7707921	1.000	rs1019806	chr5:81551659	G/A	cg15871215	chr5:81402204	ATG10	0.7	10.09	0.44	1.33e-21	Breast cancer;
LUAD	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg01299579	chr2:10830716	NOL10	-0.43	-7.43	-0.34	6.05e-13	Prostate cancer;
LUAD	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg14403583	chr14:105418241	AHNAK2	0.42	7.99	0.36	1.27e-14	Rheumatoid arthritis;
LUAD	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.02	-0.32	8.85e-12	Mood instability;
LUAD	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg26818010	chr10:134567672	INPP5A	0.96	16.16	0.62	4.46e-46	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.46	-0.42	2.08e-19	Life satisfaction;
LUAD	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg11494091	chr17:61959527	GH2	0.46	8.49	0.38	3.43e-16	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-8.68	-0.39	8.35e-17	Monocyte percentage of white cells;
LUAD	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	7.56	0.35	2.47e-13	Menopause (age at onset);
LUAD	cis	rs1395	0.710	rs58965570	chr2:27481460	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.47	8.05	0.36	8.18e-15	Blood metabolite levels;
LUAD	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg19636519	chr7:99541626	NA	0.39	6.8	0.31	3.48e-11	Coronary artery disease;
LUAD	cis	rs6906287	0.647	rs11153753	chr6:118836153	T/C	cg18833306	chr6:118973337	C6orf204	0.48	8.48	0.38	3.8e-16	Electrocardiographic conduction measures;
LUAD	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs11030122	0.661	rs10767811	chr11:4066398	G/A	cg18678763	chr11:4115507	RRM1	-0.42	-7.01	-0.32	9.57e-12	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	17.92	0.66	7.53e-54	Exhaled nitric oxide output;
LUAD	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg27661571	chr11:113659931	NA	-0.69	-8.12	-0.37	5.29e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg01299579	chr2:10830716	NOL10	-0.43	-7.55	-0.34	2.68e-13	Prostate cancer;
LUAD	trans	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg02002194	chr4:3960332	NA	-0.3	-7.16	-0.33	3.69e-12	Mood instability;
LUAD	cis	rs7527798	0.614	rs11118253	chr1:207825469	G/C	cg09232269	chr1:207846808	CR1L	-0.36	-6.98	-0.32	1.12e-11	Erythrocyte sedimentation rate;
LUAD	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03934478	chr11:495069	RNH1	0.73	8.94	0.4	1.26e-17	Body mass index;
LUAD	cis	rs78761021	0.838	rs79352577	chr17:9788198	G/A	cg26853458	chr17:9805074	RCVRN	0.36	7.0	0.32	9.99e-12	Type 2 diabetes;
LUAD	cis	rs2425143	1.000	rs13038622	chr20:34319343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.43	-0.34	6.03e-13	Blood protein levels;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02882774	chr22:42486499	NDUFA6	-0.39	-6.4	-0.3	4.16e-10	Cancer;
LUAD	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg04990556	chr1:26633338	UBXN11	-0.41	-6.71	-0.31	6.31e-11	Obesity-related traits;
LUAD	trans	rs9393777	0.920	rs35768595	chr6:27141904	C/T	cg06606381	chr12:133084897	FBRSL1	-1.17	-10.03	-0.44	2.16e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs2637266	1.000	rs2395410	chr10:78381767	C/T	cg18941641	chr10:78392320	NA	0.33	6.84	0.32	2.87e-11	Pulmonary function;
LUAD	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg15105011	chr4:940614	TMEM175	0.62	11.23	0.48	8.52e-26	Sjögren's syndrome;
LUAD	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg13047869	chr3:10149882	C3orf24	0.67	11.48	0.49	9.3e-27	Alzheimer's disease;
LUAD	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg26384229	chr12:38710491	ALG10B	0.48	7.85	0.36	3.37e-14	Bladder cancer;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08728297	chr11:72853526	FCHSD2	-0.65	-6.46	-0.3	2.84e-10	Type 2 diabetes;
LUAD	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg24829409	chr8:58192753	C8orf71	-0.53	-6.76	-0.31	4.5e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg06112835	chr11:68658793	MRPL21	-0.49	-8.82	-0.39	2.95e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs12200782	1.000	rs41267923	chr6:26452947	C/T	cg08851530	chr6:28072375	NA	0.74	6.58	0.3	1.39e-10	Small cell lung carcinoma;
LUAD	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg27490568	chr2:178487706	NA	0.4	6.47	0.3	2.71e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	trans	rs629535	0.814	rs477200	chr8:70059584	A/G	cg21567404	chr3:27674614	NA	0.96	17.3	0.64	4.11e-51	Dupuytren's disease;
LUAD	cis	rs7582720	1.000	rs78907692	chr2:203932176	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.83	0.43	1.1e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg14926445	chr8:58193284	C8orf71	-0.49	-7.17	-0.33	3.29e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg18944383	chr4:111397179	ENPEP	0.4	7.93	0.36	2.02e-14	Height;
LUAD	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg04944784	chr2:26401820	FAM59B	-0.72	-10.12	-0.44	1.08e-21	Gut microbiome composition (summer);
LUAD	cis	rs1278769	0.735	rs12585036	chr13:113535741	C/T	cg00823993	chr13:113535758	ATP11A	0.57	8.85	0.4	2.5e-17	Interstitial lung disease;
LUAD	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg08859206	chr1:53392774	SCP2	0.58	10.52	0.46	3.78e-23	Monocyte count;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg20384735	chr1:231376893	GNPAT;C1orf131	-0.38	-6.42	-0.3	3.77e-10	Cancer;
LUAD	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg19318889	chr4:1322082	MAEA	0.56	9.45	0.42	2.31e-19	Longevity;
LUAD	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg17063962	chr7:91808500	NA	0.7	12.63	0.52	2.95e-31	Breast cancer;
LUAD	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg10518543	chr12:38710700	ALG10B	-0.44	-7.3	-0.33	1.4e-12	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-8.7	-0.39	7.61e-17	Menarche (age at onset);
LUAD	cis	rs17655565	1.000	rs17655565	chr12:52691958	T/C	cg08257133	chr12:52711352	KRT83	0.42	7.17	0.33	3.45e-12	Plasma amyloid beta peptide concentrations (ABx-42);
LUAD	cis	rs7274811	0.711	rs293713	chr20:31942247	A/G	cg14921437	chr20:32255988	NECAB3;C20orf134	0.48	7.49	0.34	4.1e-13	Height;
LUAD	cis	rs9486719	0.843	rs2499793	chr6:96846402	A/C	cg06623918	chr6:96969491	KIAA0776	0.71	9.3	0.41	7.58e-19	Migraine;Coronary artery disease;
LUAD	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11890956	chr21:40555474	PSMG1	0.82	14.73	0.58	6.31e-40	Cognitive function;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg13696300	chr17:18162128	FLII	0.45	7.36	0.34	9.45e-13	Diastolic blood pressure;
LUAD	cis	rs7527798	0.592	rs10746386	chr1:207855095	C/T	cg09232269	chr1:207846808	CR1L	-0.37	-7.14	-0.33	4.07e-12	Erythrocyte sedimentation rate;
LUAD	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.6	8.94	0.4	1.26e-17	Platelet count;
LUAD	cis	rs2540226	0.844	rs12624217	chr2:39997694	C/T	cg22354234	chr2:40006543	THUMPD2	0.36	6.36	0.3	5.25e-10	Personality dimensions;
LUAD	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg11189052	chr15:85197271	WDR73	-0.63	-10.46	-0.45	6.23e-23	P wave terminal force;
LUAD	cis	rs4852324	0.536	rs71418714	chr2:74219886	G/C	cg19729930	chr2:74357872	NA	0.85	8.05	0.36	8.55e-15	Systemic lupus erythematosus;
LUAD	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg25809561	chr17:30822961	MYO1D	-0.49	-8.75	-0.39	5.08e-17	Schizophrenia;
LUAD	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-15.8	-0.61	1.58e-44	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg00933542	chr6:150070202	PCMT1	0.42	8.52	0.38	2.85e-16	Lung cancer;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg23932593	chr6:133135524	RPS12;SNORD101	-0.57	-6.88	-0.32	2.12e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg18252515	chr7:66147081	NA	-0.61	-6.78	-0.31	4.07e-11	Diabetic kidney disease;
LUAD	cis	rs10761482	0.861	rs7909961	chr10:62165578	T/C	cg18175470	chr10:62150864	ANK3	-0.4	-6.84	-0.32	2.84e-11	Schizophrenia;
LUAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg27454412	chr7:1067447	C7orf50	0.44	6.98	0.32	1.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs41311933	0.656	rs41309872	chr9:123771493	T/C	cg13567360	chr9:123745713	C5	-0.67	-8.1	-0.37	5.94e-15	Coronary artery disease;
LUAD	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg12714757	chr17:73874637	TRIM47	-0.41	-6.41	-0.3	3.96e-10	Psoriasis;
LUAD	cis	rs300774	0.925	rs300706	chr2:141540	A/C	cg21211680	chr2:198530	NA	-0.47	-7.38	-0.34	8.37e-13	Suicide attempts in bipolar disorder;
LUAD	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg04111992	chr7:158790115	NA	-0.42	-7.13	-0.33	4.5e-12	Facial morphology (factor 20);
LUAD	cis	rs79349575	0.756	rs937301	chr17:47046276	A/G	cg22482690	chr17:47019901	SNF8	-0.42	-8.16	-0.37	3.83e-15	Type 2 diabetes;
LUAD	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg09537434	chr19:41945824	ATP5SL	-0.52	-8.19	-0.37	3.16e-15	Height;
LUAD	trans	rs877282	0.945	rs34367686	chr10:791868	G/C	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg07538946	chr5:131705188	SLC22A5	0.53	8.52	0.38	2.82e-16	Blood metabolite levels;
LUAD	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.35	-6.78	-0.31	4.16e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg16590910	chr6:42928470	GNMT	0.39	7.36	0.34	9.45e-13	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9487051	0.738	rs171272	chr6:109530094	T/C	cg01475377	chr6:109611718	NA	-0.39	-6.95	-0.32	1.35e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg04511125	chr2:88470314	THNSL2	-0.47	-7.84	-0.36	3.75e-14	Response to metformin (IC50);
LUAD	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg06713675	chr4:122721982	EXOSC9	-0.58	-11.17	-0.48	1.5e-25	Type 2 diabetes;
LUAD	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg07404485	chr7:94953653	PON1	-0.51	-7.51	-0.34	3.6e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26314531	chr2:26401878	FAM59B	-0.65	-8.81	-0.39	3.16e-17	Gut microbiome composition (summer);
LUAD	cis	rs10419226	0.577	rs7257812	chr19:18787372	A/G	cg22001208	chr19:18782374	NA	-0.48	-8.1	-0.37	6.12e-15	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg01494614	chr11:10562837	RNF141	-0.55	-6.67	-0.31	7.83e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	6.59	0.3	1.35e-10	Cognitive test performance;
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg11122148	chr13:45150705	TSC22D1	-0.41	-7.25	-0.33	1.95e-12	Vertical cup-disc ratio;
LUAD	trans	rs12439619	0.508	rs8023960	chr15:82499045	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.48	-0.3	2.5e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs2479724	0.846	rs2488338	chr6:41808351	A/G	cg17623882	chr6:41773611	USP49	-0.65	-12.04	-0.51	6.81e-29	Menarche (age at onset);
LUAD	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg04545296	chr12:48745243	ZNF641	0.39	9.89	0.43	7e-21	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUAD	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg27170947	chr2:26402098	FAM59B	-0.7	-10.5	-0.45	4.64e-23	Gut microbiome composition (summer);
LUAD	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg04025307	chr7:1156635	C7orf50	0.65	7.41	0.34	7.09e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs68170813	0.559	rs12540475	chr7:106886295	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.58	-0.46	2.2e-23	Coronary artery disease;
LUAD	cis	rs3931020	0.548	rs2134836	chr1:75271646	C/T	cg26855724	chr1:75198818	TYW3;CRYZ	0.41	6.49	0.3	2.47e-10	Resistin levels;
LUAD	cis	rs714027	1.000	rs757024	chr22:30471679	G/C	cg11564601	chr22:30592435	NA	-0.39	-8.43	-0.38	5.37e-16	Lymphocyte counts;
LUAD	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg09873201	chr16:3507582	NAT15	-0.62	-6.45	-0.3	3.08e-10	Tuberculosis;
LUAD	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg15110403	chr19:17392923	ANKLE1	-0.45	-7.27	-0.33	1.7e-12	Systemic lupus erythematosus;
LUAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg05434287	chr7:2030229	MAD1L1	0.41	6.75	0.31	4.86e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	13.5	0.55	8.28e-35	Prudent dietary pattern;
LUAD	cis	rs870825	0.616	rs4263438	chr4:185624238	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.17	0.57	1.4e-37	Blood protein levels;
LUAD	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg27211696	chr2:191398769	TMEM194B	-0.71	-14.87	-0.59	1.64e-40	Pulse pressure;
LUAD	cis	rs7727544	0.625	rs3091338	chr5:131402738	C/T	cg16205897	chr5:131564050	P4HA2	-0.34	-7.32	-0.34	1.26e-12	Blood metabolite levels;
LUAD	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg04287289	chr16:89883240	FANCA	0.76	6.37	0.3	4.97e-10	Skin colour saturation;
LUAD	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg02931644	chr1:25747376	RHCE	-0.41	-8.51	-0.38	3.14e-16	Erythrocyte sedimentation rate;
LUAD	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.89	0.53	2.56e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg06108461	chr20:60628389	TAF4	-0.93	-14.51	-0.58	5.34e-39	Body mass index;
LUAD	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.86	0.36	3.32e-14	Depression;
LUAD	cis	rs7737355	0.812	rs10059807	chr5:130877684	T/C	cg25547332	chr5:131281432	NA	0.43	6.9	0.32	1.91e-11	Life satisfaction;
LUAD	cis	rs7937890	0.531	rs2597216	chr11:14533916	G/A	cg23387056	chr11:14280742	SPON1	-0.35	-6.77	-0.31	4.25e-11	Mitochondrial DNA levels;
LUAD	cis	rs6906287	0.647	rs35730412	chr6:118707343	T/C	cg18833306	chr6:118973337	C6orf204	0.47	8.31	0.37	1.35e-15	Electrocardiographic conduction measures;
LUAD	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.49	0.34	4.01e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs1595825	0.838	rs79381203	chr2:198573762	A/G	cg00982548	chr2:198649783	BOLL	-0.61	-8.82	-0.39	3.04e-17	Ulcerative colitis;
LUAD	trans	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg04995722	chr7:26192034	NFE2L3	-0.43	-7.39	-0.34	7.72e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs62229266	0.804	rs12483151	chr21:37419578	C/T	cg08632701	chr21:37451849	NA	-0.44	-7.27	-0.33	1.8e-12	Mitral valve prolapse;
LUAD	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg12011299	chr4:100065546	ADH4	-0.72	-13.46	-0.55	1.22e-34	Alcohol dependence;
LUAD	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg16647868	chr5:131706066	SLC22A5	0.48	7.71	0.35	9.27e-14	Acylcarnitine levels;
LUAD	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.6	-7.73	-0.35	7.79e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs8018808	1.000	rs4903580	chr14:77850978	C/T	cg20045696	chr14:77926864	AHSA1	-0.39	-7.02	-0.32	8.92e-12	Myeloid white cell count;
LUAD	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg04492858	chr10:133558786	NA	0.39	7.7	0.35	9.41e-14	Survival in rectal cancer;
LUAD	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-14.68	-0.58	1.03e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-14.51	-0.58	5.23e-39	Extrinsic epigenetic age acceleration;
LUAD	cis	rs35995292	0.889	rs10272767	chr7:38898819	G/C	cg19327137	chr7:38886074	VPS41	0.5	8.37	0.38	8.69e-16	Subjective well-being (multi-trait analysis);
LUAD	cis	rs977987	0.581	rs8056141	chr16:75497162	A/T	cg03315344	chr16:75512273	CHST6	0.65	14.13	0.57	2.01e-37	Dupuytren's disease;
LUAD	cis	rs8177876	0.749	rs1035541	chr16:81098854	G/C	cg08591886	chr16:81111003	C16orf46	-0.74	-6.45	-0.3	3.06e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg26384229	chr12:38710491	ALG10B	0.44	7.22	0.33	2.51e-12	Bladder cancer;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg05772935	chr16:1790400	MAPK8IP3	-0.45	-7.23	-0.33	2.25e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.6	0.31	1.21e-10	Prudent dietary pattern;
LUAD	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.95	-0.32	1.41e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg00647820	chr17:40259828	DHX58	-0.44	-6.93	-0.32	1.54e-11	Fibrinogen levels;
LUAD	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg18230493	chr5:56204884	C5orf35	-0.58	-9.4	-0.42	3.48e-19	Coronary artery disease;
LUAD	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg00981070	chr1:2046702	PRKCZ	0.35	7.63	0.35	1.54e-13	Height;
LUAD	trans	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg26043149	chr18:55253948	FECH	1.05	18.65	0.67	4.52e-57	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	7.48	0.34	4.19e-13	Platelet count;
LUAD	cis	rs72928364	1.000	rs17338506	chr3:100607281	T/C	cg10123952	chr3:100791384	NA	0.6	6.7	0.31	6.75e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.52	0.34	3.42e-13	Tonsillectomy;
LUAD	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.45	7.55	0.34	2.75e-13	Body mass index (adult);
LUAD	cis	rs868943	0.714	rs4415182	chr6:116382811	G/A	cg15226275	chr6:116381976	FRK	0.23	6.36	0.3	5.22e-10	Total cholesterol levels;
LUAD	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.51	10.56	0.46	2.77e-23	Monocyte percentage of white cells;
LUAD	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg02527881	chr3:46936655	PTH1R	-0.69	-14.84	-0.59	2.15e-40	Birth weight;
LUAD	cis	rs7586879	0.828	rs13012304	chr2:25122246	C/T	cg04586622	chr2:25135609	ADCY3	0.35	7.13	0.33	4.48e-12	Body mass index;
LUAD	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg16447950	chr5:562315	NA	-0.41	-6.41	-0.3	3.91e-10	Lung disease severity in cystic fibrosis;
LUAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg17178900	chr1:205818956	PM20D1	0.83	18.53	0.67	1.55e-56	Menarche (age at onset);
LUAD	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg13560548	chr3:10150139	C3orf24	0.45	7.67	0.35	1.21e-13	Alzheimer's disease;
LUAD	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18404041	chr3:52824283	ITIH1	-0.58	-12.01	-0.5	8.63e-29	Bipolar disorder;
LUAD	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg18230493	chr5:56204884	C5orf35	-0.57	-9.45	-0.42	2.37e-19	Coronary artery disease;
LUAD	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.45	-0.3	3.13e-10	Triglycerides;
LUAD	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg05425664	chr17:57184151	TRIM37	0.38	6.74	0.31	5.19e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg16615211	chr3:44902933	MIR564;TMEM42	0.39	7.23	0.33	2.26e-12	Depressive symptoms;
LUAD	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	10.56	0.46	2.76e-23	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg05590025	chr7:65112418	INTS4L2	-0.75	-7.91	-0.36	2.32e-14	Diabetic kidney disease;
LUAD	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg09455208	chr3:40491958	NA	0.55	12.12	0.51	3.15e-29	Renal cell carcinoma;
LUAD	cis	rs7020830	0.825	rs7036132	chr9:37317241	A/G	cg14294708	chr9:37120828	ZCCHC7	0.86	16.74	0.63	1.28e-48	Schizophrenia;
LUAD	cis	rs11771526	0.901	rs62457502	chr7:32330797	C/T	cg27511599	chr7:32358540	NA	0.51	6.51	0.3	2.1e-10	Body mass index;
LUAD	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg21214613	chr1:16344536	HSPB7	0.6	11.6	0.49	3.35e-27	Dilated cardiomyopathy;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10533536	chr8:145597427	ADCK5	-0.41	-6.45	-0.3	3.09e-10	Height;
LUAD	trans	rs587242	1.000	rs1853738	chr1:96895992	A/G	cg10631902	chr5:14652156	NA	0.44	7.27	0.33	1.71e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg21475434	chr5:93447410	FAM172A	0.74	8.32	0.37	1.26e-15	Diabetic retinopathy;
LUAD	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg18225595	chr11:63971243	STIP1	0.53	8.76	0.39	4.65e-17	Platelet count;
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg05742286	chr12:94533865	NA	-0.38	-6.41	-0.3	3.8e-10	Height;
LUAD	cis	rs240764	0.853	rs12660725	chr6:100978570	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-7.19	-0.33	2.99e-12	Neuroticism;
LUAD	cis	rs77861329	1.000	rs13314125	chr3:52115398	C/T	cg08692210	chr3:52188851	WDR51A	0.77	6.39	0.3	4.33e-10	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs7527798	0.592	rs2181694	chr1:207826776	G/A	cg09232269	chr1:207846808	CR1L	-0.38	-7.37	-0.34	9.2e-13	Erythrocyte sedimentation rate;
LUAD	trans	rs8073060	0.586	rs6505487	chr17:33996850	A/G	cg19694781	chr19:47549865	TMEM160	-1.21	-19.31	-0.68	4.75e-60	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs3806843	0.576	rs246047	chr5:140328337	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-7.5	-0.34	3.9e-13	Resting heart rate;
LUAD	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg26384229	chr12:38710491	ALG10B	0.45	7.43	0.34	6.2e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7707921	0.705	rs226194	chr5:81585026	G/T	cg15871215	chr5:81402204	ATG10	0.61	9.77	0.43	1.81e-20	Breast cancer;
LUAD	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	8.57	0.38	1.9e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg00784671	chr22:46762841	CELSR1	-0.58	-7.68	-0.35	1.13e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg21862992	chr11:68658383	NA	0.53	9.68	0.43	3.83e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs72627123	0.500	rs67852564	chr14:74559920	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.56	7.76	0.35	6.37e-14	Morning vs. evening chronotype;
LUAD	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18876405	chr7:65276391	NA	-0.42	-6.68	-0.31	7.32e-11	Aortic root size;
LUAD	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg19635926	chr16:89946313	TCF25	0.78	6.86	0.32	2.44e-11	Skin colour saturation;
LUAD	cis	rs4660306	1.000	rs2993259	chr1:46001550	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-8.13	-0.37	4.69e-15	Homocysteine levels;
LUAD	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6693567	0.565	rs11205373	chr1:150404708	A/G	cg15654264	chr1:150340011	RPRD2	0.36	6.44	0.3	3.32e-10	Migraine;
LUAD	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg19436804	chr8:8560866	CLDN23	0.42	6.4	0.3	4.01e-10	Obesity-related traits;
LUAD	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg07828340	chr4:882639	GAK	1.1	11.8	0.5	5.47e-28	Parkinson's disease;
LUAD	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs36051895	0.664	rs3780381	chr9:5114523	A/C	cg02405213	chr9:5042618	JAK2	-0.47	-6.49	-0.3	2.38e-10	Pediatric autoimmune diseases;
LUAD	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg04352962	chr1:209979756	IRF6	0.49	6.85	0.32	2.6e-11	Cleft lip with or without cleft palate;
LUAD	cis	rs9513627	0.749	rs73556149	chr13:100117012	G/A	cg25919922	chr13:100150906	NA	-0.7	-6.92	-0.32	1.67e-11	Obesity-related traits;
LUAD	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg19875535	chr5:140030758	IK	-0.47	-7.84	-0.36	3.59e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.46	9.51	0.42	1.51e-19	Monocyte percentage of white cells;
LUAD	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg05043794	chr9:111880884	C9orf5	-0.42	-7.35	-0.34	1.07e-12	Menarche (age at onset);
LUAD	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg10295955	chr4:187884368	NA	-1.17	-30.82	-0.83	3.54e-110	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg02176678	chr2:219576539	TTLL4	0.67	13.53	0.55	6.31e-35	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs17092148	0.636	rs7273470	chr20:33456921	G/C	cg16810054	chr20:33298113	TP53INP2	0.41	7.33	0.34	1.2e-12	Neuroticism;
LUAD	cis	rs7267979	0.753	rs400357	chr20:25479058	A/G	cg08601574	chr20:25228251	PYGB	0.4	7.37	0.34	9.26e-13	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs9469890	0.604	rs7754038	chr6:34505194	T/G	cg14254433	chr6:34482411	PACSIN1	-0.62	-8.73	-0.39	6.12e-17	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg08999081	chr20:33150536	PIGU	-0.59	-12.84	-0.53	4.31e-32	Glomerular filtration rate (creatinine);
LUAD	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg14671364	chr1:107599128	PRMT6	0.6	10.14	0.44	9.14e-22	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1823874	0.924	rs4965542	chr15:100356619	A/G	cg16400843	chr15:100339927	C15orf51	0.31	7.12	0.33	4.52e-12	IgG glycosylation;
LUAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.14	-0.37	4.61e-15	Alzheimer's disease;
LUAD	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg25457927	chr22:38595422	NA	-0.53	-13.76	-0.56	7.23e-36	Cutaneous nevi;
LUAD	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.35	-0.34	1.01e-12	Resting heart rate;
LUAD	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg25753631	chr6:25732923	NA	-0.36	-6.46	-0.3	2.91e-10	Iron status biomarkers;
LUAD	cis	rs4988958	0.565	rs3755265	chr2:103052816	C/A	cg03938978	chr2:103052716	IL18RAP	0.46	10.72	0.46	6.78e-24	Asthma (childhood onset);
LUAD	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg19761014	chr17:28927070	LRRC37B2	0.84	8.27	0.37	1.77e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4730250	0.669	rs6466160	chr7:106793175	T/A	cg02696742	chr7:106810147	HBP1	0.82	10.81	0.47	3.2e-24	Osteoarthritis;
LUAD	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg27454412	chr7:1067447	C7orf50	0.41	6.82	0.31	3.25e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg17330251	chr7:94953956	PON1	-0.57	-7.63	-0.35	1.59e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg10518543	chr12:38710700	ALG10B	-0.49	-8.37	-0.38	8.61e-16	Morning vs. evening chronotype;
LUAD	trans	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg06606381	chr12:133084897	FBRSL1	0.79	7.78	0.35	5.8e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg07757535	chr4:1339547	NA	0.33	6.54	0.3	1.77e-10	Longevity;
LUAD	cis	rs758324	0.947	rs2088719	chr5:131184439	C/T	cg06307176	chr5:131281290	NA	0.5	7.95	0.36	1.76e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg21143896	chr7:2802374	GNA12	-0.36	-6.49	-0.3	2.46e-10	Height;
LUAD	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg00933542	chr6:150070202	PCMT1	0.44	9.2	0.41	1.65e-18	Lung cancer;
LUAD	cis	rs1113500	0.548	rs6583062	chr1:108656463	G/A	cg06207961	chr1:108661230	NA	0.42	6.55	0.3	1.72e-10	Growth-regulated protein alpha levels;
LUAD	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.54	-9.72	-0.43	2.76e-20	Melanoma;
LUAD	cis	rs7116495	1.000	rs4944242	chr11:71667141	G/T	cg07596299	chr11:71824057	C11orf51	-0.76	-6.69	-0.31	6.89e-11	Severe influenza A (H1N1) infection;
LUAD	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg10053473	chr17:62856997	LRRC37A3	0.72	11.74	0.5	9.29e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg18402987	chr7:1209562	NA	0.65	9.16	0.41	2.2e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs870825	0.616	rs2310110	chr4:185647902	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	14.06	0.56	4.16e-37	Blood protein levels;
LUAD	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg13870426	chr17:30244630	NA	-0.57	-6.63	-0.31	1.05e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg24829409	chr8:58192753	C8orf71	-0.66	-8.26	-0.37	1.9e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg21775007	chr8:11205619	TDH	-0.38	-6.37	-0.3	4.94e-10	Systolic blood pressure;
LUAD	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg10556349	chr10:835070	NA	0.58	7.26	0.33	1.82e-12	Eosinophil percentage of granulocytes;
LUAD	cis	rs7264396	0.563	rs2425086	chr20:34302873	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.25	-0.37	2.04e-15	Total cholesterol levels;
LUAD	trans	rs78049276	0.736	rs73855810	chr4:148383424	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.63	-7.32	-0.34	1.22e-12	Pulse pressure;
LUAD	cis	rs9902453	0.904	rs4547389	chr17:28364768	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.53	-0.46	3.46e-23	Coffee consumption (cups per day);
LUAD	cis	rs10197940	0.578	rs6718372	chr2:152345871	C/G	cg06191203	chr2:152266755	RIF1	-0.47	-7.26	-0.33	1.92e-12	Lung cancer;
LUAD	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.64	0.52	2.84e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg06608945	chr2:219082296	ARPC2	-0.45	-7.41	-0.34	6.77e-13	Colorectal cancer;
LUAD	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	7.27	0.33	1.71e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs73206853	0.764	rs61117387	chr12:110867725	C/A	cg12870014	chr12:110450643	ANKRD13A	0.64	7.25	0.33	2e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg07343612	chr16:622815	PIGQ	-0.81	-15.96	-0.61	3.31e-45	Height;
LUAD	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg15017067	chr4:17643749	FAM184B	0.34	6.51	0.3	2.14e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-14.9	-0.59	1.12e-40	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg05373962	chr22:49881684	NA	-0.54	-12.87	-0.53	3.24e-32	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg06877462	chr1:205807181	PM20D1	0.39	7.41	0.34	6.82e-13	Menarche (age at onset);
LUAD	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11644478	chr21:40555479	PSMG1	0.6	9.01	0.4	7.19e-18	Cognitive function;
LUAD	cis	rs11051970	0.636	rs1128591	chr12:32569351	T/C	cg02745156	chr12:32552066	NA	0.3	6.39	0.3	4.33e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg09654669	chr8:57350985	NA	-0.66	-10.03	-0.44	2.29e-21	Obesity-related traits;
LUAD	trans	rs1997103	1.000	rs9649851	chr7:55398692	C/A	cg20935933	chr6:143382018	AIG1	0.53	7.46	0.34	4.94e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07636037	chr3:49044803	WDR6	0.49	8.48	0.38	3.94e-16	Menarche (age at onset);
LUAD	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg06547715	chr2:218990976	CXCR2	0.28	6.76	0.31	4.64e-11	Colorectal cancer;
LUAD	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg00106254	chr7:1943704	MAD1L1	-0.44	-6.38	-0.3	4.66e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg23262073	chr20:60523788	NA	-0.46	-7.97	-0.36	1.44e-14	Body mass index;
LUAD	cis	rs6426558	0.537	rs6692080	chr1:227390162	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.56	-8.98	-0.4	8.73e-18	Neutrophil percentage of white cells;
LUAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg24503407	chr1:205819492	PM20D1	0.78	15.79	0.61	1.68e-44	Menarche (age at onset);
LUAD	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07167872	chr1:205819463	PM20D1	0.78	15.92	0.61	4.81e-45	Menarche (age at onset);
LUAD	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.39	-6.95	-0.32	1.38e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.41	-7.95	-0.36	1.72e-14	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg25358565	chr5:93447407	FAM172A	0.56	6.74	0.31	5.05e-11	Diabetic retinopathy;
LUAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg08888203	chr3:10149979	C3orf24	0.75	12.95	0.53	1.48e-32	Alzheimer's disease;
LUAD	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg08132940	chr7:1081526	C7orf50	-0.72	-7.47	-0.34	4.7e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3849570	0.695	rs62265411	chr3:81573660	T/C	cg07356753	chr3:81810745	GBE1	-0.51	-7.62	-0.35	1.7e-13	Waist circumference;Body mass index;
LUAD	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg00933542	chr6:150070202	PCMT1	0.44	9.89	0.43	7e-21	Lung cancer;
LUAD	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg05434287	chr7:2030229	MAD1L1	0.42	6.9	0.32	1.95e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.59	10.07	0.44	1.63e-21	Cognitive ability;
LUAD	cis	rs427941	0.632	rs201508	chr7:101764199	T/G	cg06246474	chr7:101738831	CUX1	0.38	6.5	0.3	2.26e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg04398451	chr17:18023971	MYO15A	-0.66	-11.77	-0.5	7.11e-28	Total body bone mineral density;
LUAD	cis	rs3789045	0.837	rs57450685	chr1:204580832	A/T	cg17419461	chr1:204415978	PIK3C2B	-0.39	-6.73	-0.31	5.5e-11	Educational attainment (college completion);
LUAD	cis	rs7671266	0.668	rs6834055	chr4:10158511	A/T	cg02734326	chr4:10020555	SLC2A9	-0.5	-6.65	-0.31	9.33e-11	Cardiovascular disease risk factors;
LUAD	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg15691649	chr6:25882328	NA	-0.41	-6.44	-0.3	3.22e-10	Blood metabolite levels;
LUAD	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg06784218	chr1:46089804	CCDC17	-0.59	-13.27	-0.54	7.54e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg18180107	chr4:99064573	C4orf37	0.43	6.96	0.32	1.27e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.95	-0.44	4.24e-21	Bipolar disorder and schizophrenia;
LUAD	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.23	0.33	2.35e-12	Parkinson's disease;
LUAD	cis	rs1697139	0.935	rs1623654	chr5:66512819	A/T	cg11553311	chr5:66541588	NA	0.34	6.41	0.3	3.79e-10	Breast cancer;
LUAD	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg06558623	chr16:89946397	TCF25	1.22	12.4	0.52	2.5e-30	Skin colour saturation;
LUAD	cis	rs3736594	1.000	rs3736594	chr2:27995781	A/C	cg25309888	chr2:27988724	NA	-0.28	-6.39	-0.3	4.37e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg10596483	chr8:143751796	JRK	0.46	7.46	0.34	4.87e-13	Schizophrenia;
LUAD	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg00204512	chr16:28754710	NA	0.35	7.49	0.34	4.06e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs6906287	0.669	rs12208253	chr6:118925097	G/C	cg21191810	chr6:118973309	C6orf204	0.5	9.44	0.42	2.53e-19	Electrocardiographic conduction measures;
LUAD	cis	rs6062509	0.965	rs6062506	chr20:62352389	T/G	cg02966332	chr20:62369605	LIME1	-0.46	-7.5	-0.34	3.83e-13	Prostate cancer;
LUAD	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg21862992	chr11:68658383	NA	0.55	10.02	0.44	2.34e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg02574844	chr11:5959923	NA	-0.39	-6.91	-0.32	1.82e-11	DNA methylation (variation);
LUAD	cis	rs9948	0.655	rs6751132	chr2:97405866	T/C	cg20312557	chr2:97357134	FER1L5	-0.65	-7.89	-0.36	2.67e-14	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03713592	chr11:72463424	ARAP1	0.91	11.62	0.49	2.91e-27	Type 2 diabetes;
LUAD	trans	rs2262909	0.962	rs1526884	chr19:22303651	A/G	cg05197062	chr11:11642011	GALNTL4	0.59	9.2	0.41	1.64e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	ch.4.125556998F	chr4:125337548	NA	-0.39	-6.82	-0.31	3.08e-11	Migraine with aura;
LUAD	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg02248941	chr16:2239361	CASKIN1	0.48	9.23	0.41	1.3e-18	Height;
LUAD	trans	rs10802346	0.545	rs1770012	chr1:246426405	A/G	cg13514129	chr1:39547527	MACF1	0.61	11.03	0.47	4.87e-25	Fractional exhaled nitric oxide (childhood);
LUAD	cis	rs9807989	0.507	rs10439410	chr2:102990788	A/C	cg03938978	chr2:103052716	IL18RAP	-0.44	-10.08	-0.44	1.53e-21	Asthma;
LUAD	cis	rs6854137	0.758	rs6845468	chr4:169732484	C/T	cg20607169	chr4:169750834	PALLD	-0.4	-7.05	-0.32	7.35e-12	Vein graft stenosis in coronary artery bypass grafting;
LUAD	cis	rs877282	0.898	rs12358966	chr10:758703	A/G	cg06581033	chr10:766294	NA	-0.56	-7.59	-0.35	2.09e-13	Uric acid levels;
LUAD	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg06623918	chr6:96969491	KIAA0776	0.88	17.34	0.64	2.91e-51	Headache;
LUAD	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg26384229	chr12:38710491	ALG10B	0.42	7.5	0.34	3.91e-13	Morning vs. evening chronotype;
LUAD	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg13319975	chr6:146136371	FBXO30	0.67	11.32	0.48	3.78e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4638749	0.677	rs13023102	chr2:108837663	C/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.32	-0.34	1.25e-12	Blood pressure;
LUAD	cis	rs367615	0.704	rs17161885	chr5:108852642	A/G	cg17395555	chr5:108820864	NA	0.64	13.24	0.54	9.72e-34	Colorectal cancer (SNP x SNP interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04856096	chr8:68255097	ARFGEF1	-0.47	-7.32	-0.34	1.27e-12	Height;
LUAD	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg05590025	chr7:65112418	INTS4L2	0.73	7.85	0.36	3.34e-14	Diabetic kidney disease;
LUAD	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-9.66	-0.43	4.31e-20	Migraine;Coronary artery disease;
LUAD	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23158103	chr7:148848205	ZNF398	-0.62	-11.46	-0.49	1.19e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24308560	chr3:49941425	MST1R	0.55	9.37	0.41	4.35e-19	Body mass index;
LUAD	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg24069376	chr3:38537580	EXOG	-0.32	-7.33	-0.34	1.18e-12	Electrocardiographic conduction measures;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24997845	chr2:191878460	STAT1	-0.42	-7.07	-0.33	6.42e-12	Cancer;
LUAD	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg01851573	chr8:8652454	MFHAS1	-0.38	-6.94	-0.32	1.51e-11	Mood instability;
LUAD	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg19041857	chr6:27730383	NA	-0.44	-7.61	-0.35	1.82e-13	Parkinson's disease;
LUAD	cis	rs2046867	0.818	rs62251647	chr3:72805789	G/A	cg25664220	chr3:72788482	NA	-0.69	-12.52	-0.52	8.47e-31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27286337	chr10:134555280	INPP5A	0.69	10.01	0.44	2.59e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19346786	chr7:2764209	NA	-0.57	-12.2	-0.51	1.5e-29	Height;
LUAD	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03517284	chr6:25882590	NA	0.5	8.1	0.37	5.79e-15	Blood metabolite levels;
LUAD	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg21475434	chr5:93447410	FAM172A	0.74	8.4	0.38	6.64e-16	Diabetic retinopathy;
LUAD	cis	rs7274811	0.711	rs291691	chr20:32002878	G/C	cg14921437	chr20:32255988	NECAB3;C20orf134	0.44	6.76	0.31	4.71e-11	Height;
LUAD	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg05340658	chr4:99064831	C4orf37	-0.45	-7.41	-0.34	6.74e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs12760731	0.720	rs10913544	chr1:178350980	C/T	cg00404053	chr1:178313656	RASAL2	0.65	8.06	0.36	7.87e-15	Obesity-related traits;
LUAD	cis	rs4285028	0.948	rs12497349	chr3:121708517	T/C	cg20356878	chr3:121714668	ILDR1	-0.5	-6.79	-0.31	3.75e-11	Multiple sclerosis;
LUAD	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg19336497	chr11:14380999	RRAS2	-0.66	-14.28	-0.57	5.02e-38	Sense of smell;
LUAD	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08704250	chr15:31115839	NA	-0.6	-10.07	-0.44	1.56e-21	Huntington's disease progression;
LUAD	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg18944383	chr4:111397179	ENPEP	-0.37	-7.01	-0.32	9.38e-12	Coronary artery disease;
LUAD	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg14196790	chr5:131705035	SLC22A5	-0.38	-6.74	-0.31	5.34e-11	Breast cancer;
LUAD	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg08027265	chr7:2291960	NA	-0.43	-7.21	-0.33	2.54e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-9.05	-0.4	5.38e-18	Life satisfaction;
LUAD	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.4	6.88	0.32	2.13e-11	Renal function-related traits (BUN);
LUAD	cis	rs17054265	1.000	rs28465337	chr9:91260297	A/G	cg14112041	chr9:91262358	LOC286238	0.34	6.35	0.3	5.4e-10	Obesity-related traits;
LUAD	trans	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	25.66	0.78	2.91e-88	Colorectal cancer;
LUAD	cis	rs9549328	0.731	rs55804996	chr13:113625367	A/G	cg17524180	chr13:113633600	MCF2L	-0.4	-7.97	-0.36	1.47e-14	Systolic blood pressure;
LUAD	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.32	7.14	0.33	4.23e-12	Prostate cancer;
LUAD	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14893161	chr1:205819251	PM20D1	0.82	17.23	0.64	8.85e-51	Menarche (age at onset);
LUAD	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06505273	chr16:24850292	NA	-0.46	-6.61	-0.31	1.18e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs921968	0.565	rs7599568	chr2:219607819	A/G	cg02176678	chr2:219576539	TTLL4	-0.59	-12.08	-0.51	4.49e-29	Mean corpuscular hemoglobin concentration;
LUAD	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-23.71	-0.76	1.11e-79	Height;
LUAD	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg12311346	chr5:56204834	C5orf35	-0.82	-12.26	-0.51	8.91e-30	Initial pursuit acceleration;
LUAD	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg13012494	chr21:47604986	C21orf56	0.46	7.58	0.35	2.27e-13	Testicular germ cell tumor;
LUAD	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg17652424	chr22:38574118	PLA2G6	0.33	10.2	0.44	5.35e-22	Cutaneous nevi;
LUAD	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg08989290	chr16:615782	NHLRC4	0.32	6.93	0.32	1.6e-11	Height;
LUAD	cis	rs4691139	0.903	rs10434177	chr4:165915531	A/T	cg03508095	chr4:165878742	C4orf39;TRIM61	-0.53	-7.06	-0.32	7.01e-12	Ovarian cancer in BRCA1 mutation carriers;
LUAD	cis	rs375066	0.592	rs349048	chr19:44300937	C/T	cg11993925	chr19:44307056	LYPD5	-0.37	-7.35	-0.34	1.06e-12	Breast cancer;
LUAD	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg00933542	chr6:150070202	PCMT1	0.44	9.44	0.42	2.47e-19	Lung cancer;
LUAD	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg18016565	chr1:150552671	MCL1	0.41	7.55	0.34	2.78e-13	Tonsillectomy;
LUAD	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06022373	chr22:39101656	GTPBP1	0.46	7.15	0.33	3.72e-12	Menopause (age at onset);
LUAD	trans	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg19862616	chr7:65841803	NCRNA00174	1.04	25.8	0.78	7.32e-89	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs2625529	0.824	rs12902006	chr15:72252996	C/T	cg16672083	chr15:72433130	SENP8	-0.73	-12.19	-0.51	1.6800000000000001e-29	Red blood cell count;
LUAD	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08439880	chr3:133502540	NA	-0.44	-8.59	-0.39	1.75e-16	Iron status biomarkers;
LUAD	cis	rs748404	0.697	rs473554	chr15:43568207	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	8.12	0.37	5.24e-15	Lung cancer;
LUAD	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.06	0.37	7.64e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs910187	0.678	rs8115769	chr20:45813704	A/C	cg27589058	chr20:45804311	EYA2	-0.33	-7.65	-0.35	1.41e-13	Migraine;
LUAD	cis	rs9560113	1.000	rs9555804	chr13:112179751	T/C	cg14154082	chr13:112174009	NA	0.36	6.75	0.31	4.77e-11	Menarche (age at onset);
LUAD	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg03609598	chr5:56110824	MAP3K1	-0.48	-7.47	-0.34	4.77e-13	Coronary artery disease;
LUAD	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18404041	chr3:52824283	ITIH1	-0.53	-10.32	-0.45	2e-22	Electroencephalogram traits;
LUAD	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg21918786	chr6:109611834	NA	-0.58	-10.65	-0.46	1.24e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.53	7.58	0.35	2.19e-13	Platelet count;
LUAD	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg03676636	chr4:99064102	C4orf37	0.37	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg04058563	chr4:185651563	MLF1IP	0.41	7.25	0.33	1.97e-12	Kawasaki disease;
LUAD	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03517284	chr6:25882590	NA	0.52	8.65	0.39	1.11e-16	Blood metabolite levels;
LUAD	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg02951883	chr7:2050386	MAD1L1	0.68	11.99	0.5	1.04e-28	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUAD	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg27211696	chr2:191398769	TMEM194B	-0.57	-7.39	-0.34	8.06e-13	Diastolic blood pressure;
LUAD	cis	rs151234	0.741	rs151227	chr16:28549508	C/T	cg04609801	chr16:28609176	SULT1A2	0.58	8.48	0.38	3.75e-16	Platelet distribution width;
LUAD	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11890956	chr21:40555474	PSMG1	-0.59	-9.76	-0.43	1.93e-20	Cognitive function;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg27665823	chr16:460516	DECR2	0.54	6.51	0.3	2.14e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg04025307	chr7:1156635	C7orf50	0.9	18.07	0.66	1.7e-54	Longevity;Endometriosis;
LUAD	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg18252515	chr7:66147081	NA	0.59	6.47	0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs67311347	0.594	rs12629111	chr3:40285351	T/C	cg02782426	chr3:40428986	ENTPD3	0.34	7.09	0.33	5.51e-12	Renal cell carcinoma;
LUAD	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg21854759	chr1:92012499	NA	-0.5	-9.25	-0.41	1.15e-18	Breast cancer;
LUAD	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.48	-8.8	-0.39	3.46e-17	Menarche (age at onset);
LUAD	cis	rs3752645	1.000	rs17153823	chr7:106730211	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-6.42	-0.3	3.66e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs2046867	0.908	rs11928067	chr3:72796340	T/C	cg25664220	chr3:72788482	NA	-0.69	-12.52	-0.52	8.47e-31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg07930552	chr6:133119739	C6orf192	0.68	8.2	0.37	2.81e-15	Type 2 diabetes nephropathy;
LUAD	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00166722	chr3:10149974	C3orf24	0.75	12.85	0.53	3.98e-32	Alzheimer's disease;
LUAD	cis	rs921968	0.565	rs6436086	chr2:219640125	T/C	cg02176678	chr2:219576539	TTLL4	-0.58	-11.72	-0.5	1.18e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.42	-0.57	1.25e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.42	7.56	0.35	2.46e-13	Lung cancer in ever smokers;
LUAD	trans	rs984440	0.542	rs1073348	chr8:139082730	T/C	cg03334052	chr1:168888044	NA	0.43	7.25	0.33	1.95e-12	Obesity-related traits;
LUAD	cis	rs3813948	0.543	rs2808468	chr1:207280703	A/G	cg26044340	chr1:207277291	C4BPA	-0.51	-7.73	-0.35	7.88e-14	C4b binding protein levels;
LUAD	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-12.26	-0.51	8.49e-30	Schizophrenia;
LUAD	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.58e-11	Depression;
LUAD	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg01689657	chr7:91764605	CYP51A1	0.35	8.77	0.39	4.54e-17	Breast cancer;
LUAD	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg08761264	chr16:28874980	SH2B1	-0.45	-6.9	-0.32	1.88e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg11062466	chr8:58055876	NA	0.8	9.88	0.43	7.26e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg17759274	chr19:39260954	NA	0.36	6.5	0.3	2.33e-10	Heart rate;
LUAD	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg05283184	chr6:79620031	NA	0.6	12.17	0.51	1.99e-29	Intelligence (multi-trait analysis);
LUAD	trans	rs2262909	0.962	rs73019844	chr19:22249925	T/C	cg05197062	chr11:11642011	GALNTL4	0.59	9.14	0.41	2.61e-18	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-9.1	-0.4	3.51e-18	Bipolar disorder;
LUAD	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.64	-10.74	-0.46	5.67e-24	Glomerular filtration rate;
LUAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg25243455	chr2:114033360	PAX8;LOC440839	-0.36	-7.92	-0.36	2.1e-14	Lymphocyte counts;
LUAD	cis	rs17826219	0.733	rs7221691	chr17:28723619	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.7	-6.97	-0.32	1.25e-11	Body mass index;
LUAD	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg02734326	chr4:10020555	SLC2A9	0.63	11.28	0.48	5.66e-26	Bone mineral density;
LUAD	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg22676075	chr6:135203613	NA	0.53	9.49	0.42	1.75e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg13535736	chr9:111863775	C9orf5	-0.43	-6.71	-0.31	6.19e-11	Menarche (age at onset);
LUAD	cis	rs7089973	0.872	rs7094072	chr10:116627160	T/G	cg25233709	chr10:116636983	FAM160B1	0.39	7.56	0.35	2.48e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7010267	0.740	rs1485289	chr8:119954279	A/G	cg01975934	chr8:119970761	NA	0.33	6.4	0.3	4.09e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs1045714	0.779	rs3735113	chr7:2651563	G/A	cg24848437	chr7:2645542	IQCE	0.72	8.28	0.37	1.68e-15	Urate levels in lean individuals;
LUAD	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg16049864	chr8:95962084	TP53INP1	-0.43	-8.13	-0.37	4.86e-15	Type 2 diabetes;
LUAD	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg11915388	chr22:42470451	FAM109B	-0.42	-7.33	-0.34	1.14e-12	Schizophrenia;
LUAD	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg04607235	chr12:12878440	APOLD1	-0.51	-8.15	-0.37	4.13e-15	Lymphocyte counts;
LUAD	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg09509183	chr1:209979624	IRF6	0.54	8.19	0.37	3.23e-15	Cleft lip with or without cleft palate;
LUAD	cis	rs76878669	0.561	rs3177514	chr11:66130358	T/G	cg10616300	chr11:66138557	SLC29A2	0.34	7.07	0.33	6.46e-12	Educational attainment (years of education);
LUAD	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7089973	0.872	rs7072356	chr10:116634651	T/C	cg25233709	chr10:116636983	FAM160B1	0.39	7.52	0.34	3.3e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg25985355	chr7:65971099	NA	0.38	6.97	0.32	1.25e-11	Aortic root size;
LUAD	trans	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.63	-9.87	-0.43	7.88e-21	Mean corpuscular hemoglobin;
LUAD	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg02248941	chr16:2239361	CASKIN1	-0.52	-10.21	-0.44	5.21e-22	Height;
LUAD	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg05044414	chr3:183734942	ABCC5	-0.48	-10.03	-0.44	2.16e-21	Anterior chamber depth;
LUAD	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08439880	chr3:133502540	NA	-0.46	-9.02	-0.4	6.82e-18	Iron status biomarkers;
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg22561380	chr8:42829775	HOOK3	-0.42	-6.47	-0.3	2.74e-10	Height;
LUAD	cis	rs7617773	0.779	rs77957078	chr3:48331286	G/C	cg11946769	chr3:48343235	NME6	0.44	6.7	0.31	6.53e-11	Coronary artery disease;
LUAD	cis	rs427394	0.802	rs200841	chr5:6737134	A/G	cg10857441	chr5:6722123	POLS	-0.64	-12.75	-0.53	9.59e-32	Menopause (age at onset);
LUAD	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg19163074	chr7:65112434	INTS4L2	0.44	6.74	0.31	5.17e-11	Aortic root size;
LUAD	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg14784868	chr12:69753453	YEATS4	0.47	7.92	0.36	2.09e-14	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg15123519	chr2:136567270	LCT	0.41	7.41	0.34	7.05e-13	Mosquito bite size;
LUAD	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg25554036	chr4:6271136	WFS1	0.65	12.65	0.52	2.39e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs4839827	1	rs4839827	chr6:96853967	C/T	cg06623918	chr6:96969491	KIAA0776	0.62	10.41	0.45	9.76e-23	Migraine;
LUAD	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.9	12.92	0.53	2.11e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2066819	0.786	rs111580405	chr12:56739557	A/G	cg26714650	chr12:56694279	CS	-0.82	-6.97	-0.32	1.26e-11	Psoriasis vulgaris;
LUAD	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg00776166	chr8:613548	NA	0.56	6.44	0.3	3.35e-10	IgG glycosylation;
LUAD	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg07606381	chr6:8435919	SLC35B3	0.44	7.09	0.33	5.59e-12	Motion sickness;
LUAD	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.61	-0.42	6.36e-20	Schizophrenia;
LUAD	cis	rs6906287	0.625	rs9489355	chr6:118685314	A/G	cg18833306	chr6:118973337	C6orf204	0.53	9.7	0.43	3.26e-20	Electrocardiographic conduction measures;
LUAD	cis	rs11195062	0.693	rs950232	chr10:111988373	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.43	-6.63	-0.31	1.03e-10	Multiple myeloma;
LUAD	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.42	6.59	0.31	1.28e-10	Platelet count;
LUAD	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9796	0.663	rs11853192	chr15:41368515	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.43	-7.89	-0.36	2.67e-14	Menopause (age at onset);
LUAD	cis	rs193541	0.593	rs1035372	chr5:122169448	C/A	cg19077854	chr5:122220652	SNX24	0.37	6.47	0.3	2.74e-10	Glucose homeostasis traits;
LUAD	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg26893861	chr17:41843967	DUSP3	0.97	15.23	0.6	4.35e-42	Triglycerides;
LUAD	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg24558204	chr6:135376177	HBS1L	0.49	9.06	0.4	5.04e-18	Red blood cell count;
LUAD	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg11859384	chr17:80120422	CCDC57	0.49	8.88	0.4	1.9e-17	Life satisfaction;
LUAD	cis	rs3125734	0.671	rs3852406	chr10:64015162	T/C	cg09941381	chr10:64027924	RTKN2	-0.31	-7.33	-0.34	1.21e-12	Rheumatoid arthritis;
LUAD	cis	rs9584850	0.874	rs3742137	chr13:99102449	C/T	cg07423050	chr13:99094983	FARP1	0.37	6.36	0.3	5.28e-10	Neuroticism;
LUAD	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg26114124	chr12:9217669	LOC144571	-0.4	-7.37	-0.34	9.35e-13	Sjögren's syndrome;
LUAD	cis	rs2992756	0.663	rs1316327	chr1:18802387	G/A	cg24076588	chr1:18808559	KLHDC7A	-0.45	-7.4	-0.34	7.21e-13	Breast cancer;
LUAD	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg20487152	chr13:99095054	FARP1	-0.48	-8.29	-0.37	1.51e-15	Longevity;
LUAD	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg14092988	chr3:52407081	DNAH1	0.37	7.48	0.34	4.47e-13	Bipolar disorder;
LUAD	cis	rs7617773	0.817	rs3937	chr3:48312402	T/C	cg11946769	chr3:48343235	NME6	0.42	6.65	0.31	9.26e-11	Coronary artery disease;
LUAD	trans	rs8002861	0.658	rs9533635	chr13:44397921	C/A	cg17145862	chr1:211918768	LPGAT1	-0.56	-11.11	-0.48	2.48e-25	Leprosy;
LUAD	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg06740227	chr12:86229804	RASSF9	-0.41	-7.36	-0.34	9.88e-13	Major depressive disorder;
LUAD	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg13798912	chr7:905769	UNC84A	-0.68	-7.68	-0.35	1.12e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg01689657	chr7:91764605	CYP51A1	0.37	8.96	0.4	1.05e-17	Breast cancer;
LUAD	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg18854424	chr1:2615690	NA	0.34	8.03	0.36	9.98e-15	Ulcerative colitis;
LUAD	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg17410650	chr12:54324560	NA	-0.59	-12.88	-0.53	2.86e-32	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUAD	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg06753367	chr22:24256600	NA	-0.42	-7.76	-0.35	6.41e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg08989290	chr16:615782	NHLRC4	0.31	6.71	0.31	6.43e-11	Height;
LUAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg11941060	chr3:133502564	NA	-0.6	-10.96	-0.47	9.02e-25	Iron status biomarkers;
LUAD	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg11062466	chr8:58055876	NA	0.69	9.1	0.4	3.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.53	0.3	1.88e-10	Prudent dietary pattern;
LUAD	trans	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg10208301	chr11:6592745	DNHD1	0.5	6.43	0.3	3.53e-10	Coronary artery calcification;
LUAD	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.37	0.48	2.48e-26	Height;
LUAD	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.46	0.3	2.97e-10	Depression;
LUAD	cis	rs4664308	1.000	rs17831191	chr2:160911332	T/C	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.67	-0.31	8.17e-11	Idiopathic membranous nephropathy;
LUAD	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-11.5	-0.49	8.12e-27	Migraine;Coronary artery disease;
LUAD	trans	rs2270927	0.510	rs246813	chr5:75599605	G/T	cg13563193	chr19:33072644	PDCD5	0.98	9.03	0.4	6.03e-18	Mean corpuscular volume;
LUAD	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg23803603	chr1:2058230	PRKCZ	-0.41	-7.15	-0.33	3.85e-12	Height;
LUAD	cis	rs17532515	0.617	rs12646497	chr4:141388649	C/A	cg03645522	chr4:141391200	NA	0.41	6.66	0.31	8.74e-11	Select biomarker traits;
LUAD	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg02018176	chr4:1364513	KIAA1530	0.36	6.37	0.3	5.04e-10	Obesity-related traits;
LUAD	cis	rs4072705	0.615	rs7851737	chr9:127247931	G/A	cg13476313	chr9:127244764	NR5A1	-0.36	-8.66	-0.39	1.02e-16	Menarche (age at onset);
LUAD	cis	rs8192282	0.739	rs6691727	chr1:154497005	C/T	cg07911225	chr1:154474108	TDRD10;SHE	0.43	7.36	0.34	9.84e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg09658497	chr7:2847517	GNA12	-0.45	-8.27	-0.37	1.73e-15	Height;
LUAD	cis	rs300774	0.858	rs444497	chr2:123332	C/G	cg21211680	chr2:198530	NA	-0.46	-6.69	-0.31	7e-11	Suicide attempts in bipolar disorder;
LUAD	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg03433033	chr1:76189801	ACADM	0.91	18.17	0.66	5.71e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg17330251	chr7:94953956	PON1	-0.53	-7.17	-0.33	3.36e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg16754643	chr12:133518353	ZNF605	-0.38	-6.35	-0.3	5.69e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg25985355	chr7:65971099	NA	-0.55	-6.82	-0.31	3.17e-11	Diabetic kidney disease;
LUAD	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.51	-7.65	-0.35	1.4e-13	Gut microbiome composition (summer);
LUAD	cis	rs758324	0.947	rs615305	chr5:131291856	A/G	cg06307176	chr5:131281290	NA	-0.5	-7.83	-0.36	3.87e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg00280220	chr17:61926910	NA	0.36	6.96	0.32	1.34e-11	Prudent dietary pattern;
LUAD	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg12365402	chr11:9010492	NRIP3	-0.47	-8.99	-0.4	8.64e-18	Hemoglobin concentration;
LUAD	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg24531977	chr5:56204891	C5orf35	-0.47	-7.75	-0.35	7.08e-14	Coronary artery disease;
LUAD	cis	rs12545109	0.800	rs2609978	chr8:57394467	T/C	cg19413350	chr8:57351067	NA	-0.47	-7.12	-0.33	4.54e-12	Obesity-related traits;
LUAD	cis	rs6961069	0.722	rs4626520	chr7:80260023	G/A	cg04458919	chr7:80252533	CD36	0.38	7.15	0.33	3.82e-12	Platelet count;
LUAD	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg07211511	chr3:129823064	LOC729375	-0.82	-12.12	-0.51	3.18e-29	Blood pressure (smoking interaction);
LUAD	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg18305652	chr10:134549665	INPP5A	-0.59	-11.73	-0.5	1.02e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2274273	0.935	rs8004787	chr14:55607366	C/T	cg04306507	chr14:55594613	LGALS3	0.41	8.41	0.38	6.32e-16	Protein biomarker;
LUAD	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	8.0	0.36	1.24e-14	Schizophrenia;
LUAD	cis	rs2421770	0.530	rs2421764	chr11:35364578	A/T	cg13971030	chr11:35366721	SLC1A2	-0.46	-8.03	-0.36	9.6e-15	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs7084921	0.578	rs12783521	chr10:101871748	C/A	cg19754520	chr10:101825118	CPN1	-0.35	-6.99	-0.32	1.08e-11	Bone mineral density;
LUAD	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg00981070	chr1:2046702	PRKCZ	-0.39	-7.83	-0.36	3.85e-14	Height;
LUAD	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.53	-0.3	1.94e-10	Joint mobility (Beighton score);
LUAD	cis	rs4285028	0.699	rs12629742	chr3:121614895	T/C	cg11130432	chr3:121712080	ILDR1	-0.61	-8.48	-0.38	3.79e-16	Multiple sclerosis;
LUAD	cis	rs6545883	0.965	rs10186325	chr2:61757721	G/T	cg15711740	chr2:61764176	XPO1	-0.41	-6.63	-0.31	1.01e-10	Tuberculosis;
LUAD	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg11833968	chr6:79620685	NA	-0.44	-8.32	-0.38	1.22e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs2617583	0.530	rs12652860	chr5:1453772	G/T	cg13982541	chr5:1466431	LPCAT1	-0.46	-7.68	-0.35	1.09e-13	Breast cancer;
LUAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg00106254	chr7:1943704	MAD1L1	-0.55	-8.21	-0.37	2.69e-15	Bipolar disorder and schizophrenia;
LUAD	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg18129178	chr5:148520854	ABLIM3	-0.57	-8.6	-0.39	1.6e-16	Breast cancer;
LUAD	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22968622	chr17:43663579	NA	1.35	24.14	0.76	1.43e-81	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-7.74	-0.35	7.45e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs72928364	1.000	rs34272575	chr3:100615407	C/G	cg10123952	chr3:100791384	NA	0.6	6.94	0.32	1.51e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg11871910	chr12:69753446	YEATS4	0.69	11.36	0.48	2.86e-26	Blood protein levels;
LUAD	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg08027265	chr7:2291960	NA	-0.47	-7.81	-0.36	4.47e-14	Bipolar disorder and schizophrenia;
LUAD	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.18	-0.33	3.12e-12	Height;
LUAD	cis	rs6993813	0.837	rs7004052	chr8:120031029	T/A	cg01975934	chr8:119970761	NA	-0.37	-7.24	-0.33	2.09e-12	Bone mineral density (hip);
LUAD	trans	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg14917512	chr19:3094685	GNA11	-0.52	-6.35	-0.3	5.65e-10	Diabetic kidney disease;
LUAD	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg17330251	chr7:94953956	PON1	-0.53	-7.1	-0.33	5.36e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg14847009	chr1:175162515	KIAA0040	-0.32	-8.13	-0.37	4.89e-15	Alcohol dependence;
LUAD	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg03433033	chr1:76189801	ACADM	0.86	15.55	0.6	1.9e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs12893597	0.704	rs34065247	chr14:76834029	A/C	cg20290672	chr14:76816747	NA	-0.42	-6.89	-0.32	2.08e-11	Maximal oxygen uptake response;
LUAD	cis	rs2249625	0.523	rs2463707	chr6:72861732	G/A	cg18830697	chr6:72922368	RIMS1	-0.38	-7.37	-0.34	8.86e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs7903847	0.642	rs7909345	chr10:99150794	T/C	cg20016023	chr10:99160130	RRP12	-0.31	-7.42	-0.34	6.64e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg10589385	chr1:150898437	SETDB1	-0.42	-7.96	-0.36	1.64e-14	Melanoma;
LUAD	cis	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg08601574	chr20:25228251	PYGB	-0.45	-8.22	-0.37	2.49e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg14926445	chr8:58193284	C8orf71	-0.5	-7.25	-0.33	1.99e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg13319975	chr6:146136371	FBXO30	0.58	9.82	0.43	1.26e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg00933542	chr6:150070202	PCMT1	0.45	9.91	0.43	6.13e-21	Lung cancer;
LUAD	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg14159672	chr1:205819179	PM20D1	0.44	6.95	0.32	1.42e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUAD	cis	rs116248771	0.739	rs6768636	chr3:158347565	C/T	cg16708174	chr3:158430962	RARRES1	-0.44	-6.64	-0.31	9.92e-11	diarrhoeal disease at age 2;
LUAD	cis	rs457287	0.892	rs461130	chr9:4834597	C/T	cg14182974	chr9:4791918	RCL1	0.44	6.49	0.3	2.35e-10	Platelet count;
LUAD	cis	rs7786877	0.626	rs11983745	chr7:100223678	T/C	cg20848291	chr7:100343083	ZAN	-0.59	-7.73	-0.35	7.93e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.37	7.45	0.34	5.32e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs73416724	1.000	rs76658194	chr6:43357601	C/T	cg26312998	chr6:43337775	ZNF318	0.53	6.46	0.3	2.82e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2267137	0.868	rs5763178	chr22:29773869	A/G	cg07256473	chr22:29710276	RASL10A	0.41	7.75	0.35	7e-14	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg00852783	chr1:26633632	UBXN11	0.45	7.03	0.32	8.29e-12	Monocyte percentage of white cells;
LUAD	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-6.93	-0.32	1.56e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg25358565	chr5:93447407	FAM172A	0.55	6.68	0.31	7.63e-11	Diabetic retinopathy;
LUAD	cis	rs11771526	0.901	rs10239582	chr7:32298116	T/A	cg13207630	chr7:32358064	NA	0.57	7.24	0.33	2.16e-12	Body mass index;
LUAD	cis	rs9341808	0.538	rs620147	chr6:80992090	G/A	cg08355045	chr6:80787529	NA	-0.41	-7.03	-0.32	8.53e-12	Sitting height ratio;
LUAD	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.17	0.37	3.51e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17818399	0.815	rs62136873	chr2:46861237	G/A	cg09399716	chr2:46890238	NA	-0.43	-8.01	-0.36	1.11e-14	Height;
LUAD	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg04287289	chr16:89883240	FANCA	0.79	7.04	0.32	7.89e-12	Skin colour saturation;
LUAD	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg19761014	chr17:28927070	LRRC37B2	0.84	8.25	0.37	1.97e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.55	6.49	0.3	2.35e-10	Depression;
LUAD	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.63	-10.06	-0.44	1.79e-21	Renal function-related traits (BUN);
LUAD	cis	rs9392556	0.829	rs649725	chr6:4109593	A/C	cg08342332	chr6:4079704	C6orf201;C6orf146	0.4	7.07	0.33	6.25e-12	Blood metabolite levels;
LUAD	cis	rs6547631	0.594	rs7908	chr2:85925756	C/G	cg21473183	chr2:85925749	GNLY	0.35	7.47	0.34	4.68e-13	Blood protein levels;
LUAD	cis	rs62229266	0.771	rs7280136	chr21:37432910	C/G	cg08632701	chr21:37451849	NA	0.39	6.43	0.3	3.39e-10	Mitral valve prolapse;
LUAD	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg06623918	chr6:96969491	KIAA0776	0.88	17.18	0.64	1.44e-50	Headache;
LUAD	cis	rs6430585	0.583	rs3769013	chr2:136556182	C/T	cg07169764	chr2:136633963	MCM6	0.74	8.93	0.4	1.32e-17	Corneal structure;
LUAD	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg07757535	chr4:1339547	NA	0.3	6.67	0.31	7.88e-11	Longevity;
LUAD	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg18806716	chr10:30721971	MAP3K8	-0.6	-11.64	-0.49	2.43e-27	Itch intensity from mosquito bite;
LUAD	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg00339695	chr16:24857497	SLC5A11	0.71	11.15	0.48	1.74e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	7.76	0.35	6.46e-14	Platelet count;
LUAD	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg00300879	chr1:26503847	CNKSR1	0.29	8.39	0.38	7.26e-16	Height;
LUAD	trans	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg14791747	chr16:20752902	THUMPD1	0.48	7.34	0.34	1.13e-12	Pancreatic cancer;
LUAD	cis	rs3784262	1.000	rs7178497	chr15:58240333	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.46	-9.07	-0.4	4.42e-18	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg17849569	chr6:28058911	ZSCAN12L1	0.28	6.69	0.31	7.06e-11	Parkinson's disease;
LUAD	cis	rs62229266	0.839	rs11088335	chr21:37470335	C/T	cg12218747	chr21:37451666	NA	-0.46	-8.04	-0.36	9.27e-15	Mitral valve prolapse;
LUAD	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg19318889	chr4:1322082	MAEA	0.51	8.56	0.38	2.08e-16	Longevity;
LUAD	cis	rs6430585	0.583	rs3754689	chr2:136590746	C/T	cg07169764	chr2:136633963	MCM6	0.69	8.74	0.39	5.41e-17	Corneal structure;
LUAD	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg06618935	chr21:46677482	NA	-0.49	-9.92	-0.43	5.6e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg22117172	chr7:91764530	CYP51A1	0.33	7.31	0.33	1.32e-12	Breast cancer;
LUAD	cis	rs7107174	1.000	rs2292572	chr11:78052864	G/T	cg19901956	chr11:77921274	USP35	-0.48	-6.86	-0.32	2.47e-11	Testicular germ cell tumor;
LUAD	trans	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.08	-0.33	6.23e-12	Dental caries;
LUAD	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg15181151	chr6:150070149	PCMT1	0.38	6.95	0.32	1.41e-11	Lung cancer;
LUAD	trans	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg11693508	chr17:37793320	STARD3	0.81	10.29	0.45	2.53e-22	Bipolar disorder;
LUAD	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19346786	chr7:2764209	NA	-0.56	-12.09	-0.51	4.01e-29	Height;
LUAD	cis	rs208520	0.690	rs851464	chr6:66839802	C/T	cg07460842	chr6:66804631	NA	-1.07	-16.78	-0.63	8.61e-49	Exhaled nitric oxide output;
LUAD	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg18721089	chr20:30220636	NA	-0.45	-6.5	-0.3	2.24e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUAD	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg12483005	chr1:23474871	LUZP1	0.38	6.53	0.3	1.84e-10	Height;
LUAD	trans	rs9354308	0.933	rs2814134	chr6:66566658	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.51	7.6	0.35	1.91e-13	Metabolite levels;
LUAD	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	10.42	0.45	9.15e-23	Resting heart rate;
LUAD	cis	rs62238980	0.614	rs78354020	chr22:32394259	A/G	cg00543991	chr22:32367038	NA	0.92	8.16	0.37	3.95e-15	Childhood ear infection;
LUAD	trans	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg04995722	chr7:26192034	NFE2L3	-0.42	-7.2	-0.33	2.85e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs4846217	1.000	rs12125492	chr1:10421878	A/G	cg17425144	chr1:10567563	PEX14	-0.57	-7.03	-0.32	8.15e-12	Platelet count;
LUAD	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg02951883	chr7:2050386	MAD1L1	-0.74	-11.59	-0.49	3.75e-27	Bipolar disorder and schizophrenia;
LUAD	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg09117114	chr16:67998030	SLC12A4	-0.45	-6.5	-0.3	2.33e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg22117172	chr7:91764530	CYP51A1	0.34	7.52	0.34	3.2e-13	Breast cancer;
LUAD	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg27446573	chr6:127587934	RNF146	0.44	6.62	0.31	1.06e-10	Breast cancer;
LUAD	cis	rs2425143	0.818	rs73902932	chr20:34489009	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.94	-0.32	1.45e-11	Blood protein levels;
LUAD	cis	rs11112613	0.775	rs7959699	chr12:105959848	C/A	cg03607813	chr12:105948248	NA	0.77	12.4	0.52	2.48e-30	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg03467027	chr4:99064603	C4orf37	0.4	6.48	0.3	2.59e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.546	rs2232429	chr6:28359632	T/G	cg12623302	chr6:28058802	ZSCAN12L1	0.59	6.8	0.31	3.47e-11	Depression;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24420395	chr8:29206910	DUSP4	-0.41	-6.67	-0.31	8.26e-11	Height;
LUAD	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg06713675	chr4:122721982	EXOSC9	0.47	8.47	0.38	4.23e-16	Type 2 diabetes;
LUAD	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-8.54	-0.38	2.36e-16	Neutrophil percentage of white cells;
LUAD	cis	rs11568819	1.000	rs11568819	chr11:102401633	C/T	cg01813071	chr11:102401616	MMP7	0.77	6.75	0.31	4.88e-11	Blood protein levels;
LUAD	trans	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.7	-9.6	-0.42	7.05e-20	Obesity-related traits;
LUAD	cis	rs7640424	0.649	rs6795280	chr3:107876232	T/C	cg09227934	chr3:107805635	CD47	-0.5	-8.97	-0.4	9.84e-18	Body mass index;
LUAD	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg18132916	chr6:79620363	NA	-0.44	-7.69	-0.35	1.07e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg15704280	chr7:45808275	SEPT13	-0.89	-16.15	-0.62	4.56e-46	Height;
LUAD	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg02527881	chr3:46936655	PTH1R	-0.46	-8.94	-0.4	1.27e-17	Colorectal cancer;
LUAD	cis	rs4713675	0.505	rs2395450	chr6:33654588	C/T	cg13859433	chr6:33739653	LEMD2	-0.29	-6.76	-0.31	4.59e-11	Plateletcrit;
LUAD	cis	rs7827545	1.000	rs7823948	chr8:135566580	G/A	cg17885191	chr8:135476712	NA	0.51	8.03	0.36	9.66e-15	Hypertension (SNP x SNP interaction);
LUAD	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-15.33	-0.6	1.69e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg11416102	chr8:651193	ERICH1	0.63	6.44	0.3	3.25e-10	IgG glycosylation;
LUAD	trans	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg14917512	chr19:3094685	GNA11	-0.57	-6.63	-0.31	9.97e-11	Diabetic kidney disease;
LUAD	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-8.67	-0.39	9.58e-17	Major depressive disorder;
LUAD	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg12365402	chr11:9010492	NRIP3	-0.46	-8.15	-0.37	4.31e-15	Hemoglobin concentration;
LUAD	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg18105134	chr13:113819100	PROZ	0.91	16.42	0.62	3.26e-47	Platelet distribution width;
LUAD	cis	rs4006360	0.600	rs1828327	chr17:39249464	T/C	cg16090541	chr17:39240343	KRTAP4-7	-0.37	-6.45	-0.3	3.09e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg22875332	chr1:76189707	ACADM	0.84	16.8	0.63	6.48e-49	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg15556689	chr8:8085844	FLJ10661	0.38	6.52	0.3	2.04e-10	Mood instability;
LUAD	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg21699342	chr2:239360505	ASB1	0.59	11.57	0.49	4.34e-27	Multiple system atrophy;
LUAD	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg24818145	chr4:99064322	C4orf37	0.46	7.78	0.35	5.45e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9948	0.786	rs62156225	chr2:97414118	T/C	cg20312557	chr2:97357134	FER1L5	-0.62	-7.3	-0.33	1.44e-12	Erectile dysfunction and prostate cancer treatment;
LUAD	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg11663144	chr21:46675770	NA	-0.59	-11.51	-0.49	7.36e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.56	-9.52	-0.42	1.38e-19	Glomerular filtration rate;
LUAD	cis	rs12545109	0.800	rs1968551	chr8:57407760	T/C	cg09654669	chr8:57350985	NA	-0.65	-9.2	-0.41	1.69e-18	Obesity-related traits;
LUAD	cis	rs1816752	0.905	rs9511249	chr13:24999595	G/A	cg02811702	chr13:24901961	NA	0.42	7.3	0.33	1.47e-12	Obesity-related traits;
LUAD	cis	rs3774830	0.743	rs6810392	chr4:5459932	C/T	cg26943120	chr4:5472116	STK32B	0.38	7.66	0.35	1.31e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg06074448	chr4:187884817	NA	0.36	7.23	0.33	2.25e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.73	0.39	5.75e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg03929089	chr4:120376271	NA	-0.49	-6.38	-0.3	4.68e-10	Axial length;
LUAD	cis	rs3784262	0.565	rs9635350	chr15:58298412	G/A	cg12031962	chr15:58353849	ALDH1A2	0.37	7.06	0.32	7.05e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs62400317	0.859	rs12203558	chr6:45244423	C/G	cg18551225	chr6:44695536	NA	-0.56	-8.7	-0.39	7.44e-17	Total body bone mineral density;
LUAD	cis	rs7937890	0.810	rs10734224	chr11:14424124	G/T	cg02886208	chr11:14281011	SPON1	-0.39	-7.75	-0.35	7.1e-14	Mitochondrial DNA levels;
LUAD	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg25287198	chr4:183728479	NA	0.54	6.45	0.3	2.98e-10	Pediatric autoimmune diseases;
LUAD	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg20476274	chr7:133979776	SLC35B4	0.72	12.67	0.52	2e-31	Mean platelet volume;
LUAD	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg21171335	chr12:122356390	WDR66	0.68	12.27	0.51	8.05e-30	Mean corpuscular volume;
LUAD	trans	rs4650994	0.935	rs2811290	chr1:178572978	C/T	cg05059571	chr16:84539110	KIAA1609	0.54	9.04	0.4	5.74e-18	HDL cholesterol levels;HDL cholesterol;
LUAD	cis	rs853679	0.607	rs35072899	chr6:28281541	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.54	6.38	0.3	4.78e-10	Depression;
LUAD	trans	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg26043149	chr18:55253948	FECH	0.5	8.18	0.37	3.34e-15	Bone mineral density;
LUAD	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg11915388	chr22:42470451	FAM109B	0.41	7.37	0.34	8.84e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg18180107	chr4:99064573	C4orf37	0.43	6.91	0.32	1.76e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg26043149	chr18:55253948	FECH	-0.42	-6.87	-0.32	2.35e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg22963979	chr7:1858916	MAD1L1	-0.52	-8.97	-0.4	9.47e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg07460842	chr6:66804631	NA	-0.98	-14.72	-0.58	7.02e-40	Exhaled nitric oxide output;
LUAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	6.61	0.31	1.19e-10	Prudent dietary pattern;
LUAD	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	7.21	0.33	2.54e-12	Menopause (age at onset);
LUAD	trans	rs9467711	0.559	rs13214027	chr6:26573631	C/G	cg01620082	chr3:125678407	NA	-0.66	-7.69	-0.35	1.01e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7617773	0.817	rs9853804	chr3:48327729	T/C	cg11946769	chr3:48343235	NME6	0.43	6.65	0.31	8.89e-11	Coronary artery disease;
LUAD	cis	rs10766533	1.000	rs10766533	chr11:19224677	A/T	cg14704941	chr11:19224659	CSRP3	0.35	6.94	0.32	1.51e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
LUAD	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg07930552	chr6:133119739	C6orf192	0.59	7.29	0.33	1.5e-12	Type 2 diabetes nephropathy;
LUAD	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.84	-0.36	3.72e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg10792982	chr14:105748885	BRF1	0.46	10.02	0.44	2.49e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs1957429	0.901	rs1957434	chr14:65349909	C/T	cg23373153	chr14:65346875	NA	0.55	6.45	0.3	2.99e-10	Pediatric areal bone mineral density (radius);
LUAD	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg02038168	chr22:39784481	NA	-0.61	-10.8	-0.47	3.42e-24	Intelligence (multi-trait analysis);
LUAD	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg25036284	chr2:26402008	FAM59B	-0.67	-9.11	-0.4	3.43e-18	Gut microbiome composition (summer);
LUAD	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg22117172	chr7:91764530	CYP51A1	0.34	7.51	0.34	3.43e-13	Breast cancer;
LUAD	cis	rs7589342	0.929	rs2060036	chr2:106436101	G/A	cg16077055	chr2:106428750	NCK2	0.36	6.39	0.3	4.26e-10	Addiction;
LUAD	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg11833968	chr6:79620685	NA	-0.44	-8.34	-0.38	1.09e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03713592	chr11:72463424	ARAP1	0.63	7.98	0.36	1.41e-14	Type 2 diabetes;
LUAD	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg27124370	chr19:33622961	WDR88	0.45	6.98	0.32	1.11e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7017914	0.967	rs6999739	chr8:71637212	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.55	-0.3	1.72e-10	Bone mineral density;
LUAD	cis	rs3087591	0.919	rs2012581	chr17:29560800	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.39	-6.4	-0.3	4.04e-10	Hip circumference;
LUAD	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg12011299	chr4:100065546	ADH4	0.7	12.61	0.52	3.55e-31	Smoking initiation;
LUAD	cis	rs7616330	0.790	rs2140131	chr3:71044545	A/G	cg20891481	chr3:71115714	FOXP1	0.52	8.43	0.38	5.66e-16	QT interval;
LUAD	cis	rs11971779	0.553	rs10228643	chr7:139115420	G/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.38	-0.3	4.74e-10	Diisocyanate-induced asthma;
LUAD	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg21605333	chr4:119757512	SEC24D	0.93	8.78	0.39	4.1e-17	Cannabis dependence symptom count;
LUAD	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.46	-7.39	-0.34	7.66e-13	Body mass index;
LUAD	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00149659	chr3:10157352	C3orf10	0.57	7.93	0.36	2.04e-14	Alzheimer's disease;
LUAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg04025307	chr7:1156635	C7orf50	0.7	9.94	0.44	4.62e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg15181151	chr6:150070149	PCMT1	0.32	6.51	0.3	2.15e-10	Testicular germ cell tumor;
LUAD	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg00634984	chr7:65235879	NA	0.46	7.52	0.34	3.34e-13	Calcium levels;
LUAD	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg07343612	chr16:622815	PIGQ	-0.79	-15.62	-0.6	9.55e-44	Height;
LUAD	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg21699342	chr2:239360505	ASB1	0.59	11.54	0.49	5.71e-27	Multiple system atrophy;
LUAD	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg04450456	chr4:17643702	FAM184B	0.43	8.45	0.38	4.86e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12923728	chr3:195709715	SDHAP1	-0.77	-13.26	-0.54	8.06e-34	Pancreatic cancer;
LUAD	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg25208724	chr1:156163844	SLC25A44	1.0	17.39	0.65	1.79e-51	Intracerebral hemorrhage;White matter hyperintensity burden;
LUAD	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg10518543	chr12:38710700	ALG10B	-0.5	-8.31	-0.37	1.36e-15	Morning vs. evening chronotype;
LUAD	cis	rs11958404	0.860	rs72818117	chr5:157441130	G/A	cg05962755	chr5:157440814	NA	0.71	9.95	0.44	4.36e-21	IgG glycosylation;
LUAD	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.4e-15	Prostate cancer;
LUAD	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.15	-0.51	2.4e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg24818145	chr4:99064322	C4orf37	0.46	7.8	0.35	5.05e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs71403859	0.502	rs17345863	chr16:71523261	C/T	cg08717414	chr16:71523259	ZNF19	-0.64	-8.01	-0.36	1.09e-14	Post bronchodilator FEV1;
LUAD	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg18944383	chr4:111397179	ENPEP	0.41	8.26	0.37	1.87e-15	Height;
LUAD	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg24818145	chr4:99064322	C4orf37	0.47	7.96	0.36	1.57e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg17031739	chr1:67600172	NA	0.45	7.89	0.36	2.6e-14	Psoriasis;
LUAD	cis	rs4588572	0.561	rs10942858	chr5:77803267	A/C	cg11547950	chr5:77652471	NA	-0.59	-8.93	-0.4	1.28e-17	Triglycerides;
LUAD	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg16325326	chr1:53192061	ZYG11B	0.5	8.53	0.38	2.67e-16	Monocyte count;
LUAD	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg17063962	chr7:91808500	NA	-0.68	-11.8	-0.5	5.66e-28	Breast cancer;
LUAD	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg25554036	chr4:6271136	WFS1	0.72	14.71	0.58	7.59e-40	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs7395662	0.927	rs117030714	chr11:48760511	C/T	cg15704280	chr7:45808275	SEPT13	0.43	6.68	0.31	7.36e-11	HDL cholesterol;
LUAD	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.72	-14.86	-0.59	1.78e-40	Urate levels in overweight individuals;
LUAD	cis	rs9394841	0.692	rs9349202	chr6:41805581	A/C	cg17623882	chr6:41773611	USP49	-0.53	-7.36	-0.34	9.96e-13	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg17191109	chr10:126851326	NA	0.33	6.39	0.3	4.34e-10	Menarche (age at onset);
LUAD	cis	rs13315871	1.000	rs4075403	chr3:58411445	G/C	cg20936604	chr3:58311152	NA	-0.69	-7.25	-0.33	1.94e-12	Cholesterol, total;
LUAD	trans	rs877282	0.891	rs11595385	chr10:800539	A/G	cg22713356	chr15:30763199	NA	1.29	18.54	0.67	1.35e-56	Uric acid levels;
LUAD	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg00450029	chr8:599525	NA	0.89	8.22	0.37	2.54e-15	IgG glycosylation;
LUAD	trans	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17712092	chr4:129076599	LARP1B	0.88	16.45	0.62	2.27e-47	Eosinophil percentage of white cells;
LUAD	cis	rs7584330	0.554	rs6736468	chr2:238422228	A/G	cg14458575	chr2:238380390	NA	0.49	7.87	0.36	3.07e-14	Prostate cancer;
LUAD	cis	rs4711350	1.000	rs2395401	chr6:33759471	T/C	cg16010596	chr6:33739607	LEMD2	-0.38	-6.57	-0.3	1.51e-10	Schizophrenia;
LUAD	cis	rs4974559	0.947	rs28437782	chr4:1355062	A/G	cg07757535	chr4:1339547	NA	0.39	6.44	0.3	3.29e-10	Systolic blood pressure;
LUAD	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg21798802	chr22:38057573	PDXP	0.38	7.87	0.36	2.99e-14	Fat distribution (HIV);
LUAD	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg03433033	chr1:76189801	ACADM	0.81	13.35	0.54	3.62e-34	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.4	-7.66	-0.35	1.32e-13	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-9.81	-0.43	1.28e-20	Gut microbiome composition (summer);
LUAD	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg07234876	chr8:600039	NA	0.79	8.1	0.37	6.01e-15	IgG glycosylation;
LUAD	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg16988262	chr1:15930761	NA	0.41	6.87	0.32	2.34e-11	Systolic blood pressure;
LUAD	cis	rs73086581	1.000	rs17214949	chr20:3940952	T/C	cg02187196	chr20:3869020	PANK2	0.46	6.49	0.3	2.34e-10	Response to antidepressants in depression;
LUAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg24642844	chr7:1081250	C7orf50	-0.96	-14.26	-0.57	6.09e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg09455208	chr3:40491958	NA	0.66	14.48	0.58	7.01e-39	Renal cell carcinoma;
LUAD	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg22535103	chr8:58192502	C8orf71	-0.59	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg18105134	chr13:113819100	PROZ	-0.81	-14.24	-0.57	7.35e-38	Platelet distribution width;
LUAD	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	12.88	0.53	2.91e-32	Monocyte percentage of white cells;
LUAD	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg20203395	chr5:56204925	C5orf35	-0.95	-13.84	-0.56	3.54e-36	Initial pursuit acceleration;
LUAD	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg00419759	chr1:114301964	PHTF1	0.42	6.56	0.3	1.6e-10	Bilirubin levels;
LUAD	cis	rs3750965	0.959	rs3168115	chr11:68858090	A/T	cg06818126	chr11:68850279	TPCN2	0.46	6.9	0.32	1.95e-11	Hair color;
LUAD	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08280861	chr8:58055591	NA	0.63	8.24	0.37	2.25e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.54	0.3	1.77e-10	Parkinson's disease;
LUAD	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg20701182	chr2:24300061	SF3B14	0.58	6.83	0.32	2.93e-11	Lymphocyte counts;
LUAD	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg27432699	chr2:27873401	GPN1	-0.4	-6.73	-0.31	5.59e-11	Total body bone mineral density;
LUAD	cis	rs7172809	0.561	rs76746801	chr15:77789773	C/T	cg11865553	chr15:77376250	NA	-0.38	-6.38	-0.3	4.73e-10	Glucose homeostasis traits;
LUAD	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg02696790	chr15:75250997	RPP25	-0.35	-6.87	-0.32	2.27e-11	Caffeine consumption;
LUAD	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25427524	chr10:38739819	LOC399744	-0.75	-14.36	-0.57	2.24e-38	Extrinsic epigenetic age acceleration;
LUAD	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg21823605	chr1:152486609	CRCT1	-0.29	-6.6	-0.31	1.21e-10	Hair morphology;
LUAD	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg06627628	chr2:24431161	ITSN2	-0.52	-6.37	-0.3	4.86e-10	Lymphocyte counts;
LUAD	cis	rs10979	1.000	rs9390110	chr6:143893413	A/G	cg25407410	chr6:143891975	LOC285740	-0.63	-9.93	-0.43	4.87e-21	Hypospadias;
LUAD	cis	rs713587	0.719	rs4665736	chr2:25187599	C/T	cg01884057	chr2:25150051	NA	-0.33	-6.78	-0.31	4.02e-11	Body mass index in non-asthmatics;
LUAD	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00934597	chr7:893267	UNC84A	-0.52	-8.62	-0.39	1.33e-16	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg23625390	chr15:77176239	SCAPER	0.39	6.89	0.32	2.07e-11	Blood metabolite levels;
LUAD	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg07332563	chr6:291687	DUSP22	-0.47	-7.84	-0.36	3.59e-14	Menopause (age at onset);
LUAD	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg14416269	chr4:6271139	WFS1	0.61	11.84	0.5	3.78e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg00277334	chr10:82204260	NA	-0.57	-9.47	-0.42	2.07e-19	Post bronchodilator FEV1;
LUAD	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg08999081	chr20:33150536	PIGU	0.63	13.99	0.56	8.1e-37	Glomerular filtration rate (creatinine);
LUAD	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	7.11	0.33	4.93e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg00901687	chr17:48585270	MYCBPAP	0.54	7.21	0.33	2.67e-12	Visceral fat;
LUAD	cis	rs2554380	0.800	rs2585068	chr15:84404457	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.48	-7.47	-0.34	4.5e-13	Height;
LUAD	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg00717180	chr2:96193071	NA	-0.45	-8.77	-0.39	4.49e-17	HDL cholesterol;
LUAD	trans	rs11088226	0.681	rs1134747	chr21:33939011	T/A	cg09050820	chr6:167586206	TCP10L2	0.91	12.44	0.52	1.65e-30	Gastritis;
LUAD	cis	rs2730245	0.550	rs10258339	chr7:158670243	T/C	cg04568274	chr7:158649319	WDR60	0.41	6.69	0.31	7.27e-11	Height;
LUAD	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg20283391	chr11:68216788	NA	-0.42	-6.63	-0.31	1.01e-10	Total body bone mineral density;
LUAD	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg08601574	chr20:25228251	PYGB	-0.43	-7.87	-0.36	3.01e-14	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4072705	0.967	rs10818984	chr9:127413551	T/C	cg13476313	chr9:127244764	NR5A1	0.32	7.76	0.35	6.48e-14	Menarche (age at onset);
LUAD	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg09365446	chr1:150670422	GOLPH3L	-0.44	-7.51	-0.34	3.64e-13	Tonsillectomy;
LUAD	trans	rs1864729	1.000	rs2853312	chr8:98281319	T/C	cg08679828	chr8:102218111	ZNF706	-0.78	-8.02	-0.36	1.02e-14	Estradiol plasma levels (breast cancer);
LUAD	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg09033577	chr2:88485744	THNSL2	-0.54	-6.97	-0.32	1.22e-11	Plasma clusterin levels;
LUAD	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.71	-0.49	1.29e-27	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs7274811	0.652	rs149236	chr20:32023380	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.51	7.7	0.35	9.89e-14	Height;
LUAD	cis	rs11585357	0.793	rs112597506	chr1:17628832	A/G	cg08277548	chr1:17600880	PADI3	-0.93	-13.31	-0.54	5.4e-34	Hair shape;
LUAD	cis	rs10465746	0.905	rs12127266	chr1:84360767	T/G	cg10977910	chr1:84465055	TTLL7	0.49	7.95	0.36	1.75e-14	Obesity-related traits;
LUAD	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.9	0.36	2.4e-14	Depression;
LUAD	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg17173187	chr15:85201210	NMB	-0.41	-6.66	-0.31	8.68e-11	Schizophrenia;
LUAD	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg11645453	chr3:52864694	ITIH4	0.54	10.09	0.44	1.34e-21	Schizophrenia;
LUAD	cis	rs9644630	0.804	rs11779939	chr8:19327487	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.31	-7.41	-0.34	6.94e-13	Oropharynx cancer;
LUAD	trans	rs7246760	0.867	rs7259075	chr19:9778776	G/A	cg02900749	chr2:68251473	NA	-0.59	-6.56	-0.3	1.59e-10	Pursuit maintenance gain;
LUAD	cis	rs7072216	0.727	rs942808	chr10:100168102	C/A	cg26618903	chr10:100175079	PYROXD2	-0.36	-7.94	-0.36	1.8e-14	Metabolite levels;
LUAD	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg08807101	chr21:30365312	RNF160	-0.5	-8.61	-0.39	1.41e-16	Dental caries;
LUAD	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.68	-12.08	-0.51	4.36e-29	Melanoma;
LUAD	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg09936400	chr10:82049201	MAT1A	0.36	6.44	0.3	3.19e-10	Post bronchodilator FEV1;
LUAD	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg06877462	chr1:205807181	PM20D1	0.38	6.99	0.32	1.04e-11	Menarche (age at onset);
LUAD	cis	rs3849570	0.555	rs4481177	chr3:81996817	A/T	cg07356753	chr3:81810745	GBE1	0.52	8.68	0.39	8.45e-17	Waist circumference;Body mass index;
LUAD	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg06873352	chr17:61820015	STRADA	0.42	7.07	0.33	6.45e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg09650180	chr20:62225654	GMEB2	-0.48	-6.86	-0.32	2.53e-11	Glioblastoma;
LUAD	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg03929089	chr4:120376271	NA	-0.67	-9.63	-0.42	5.61e-20	Coronary artery disease;
LUAD	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg07305463	chr2:136567211	LCT	0.38	7.14	0.33	4.05e-12	Mosquito bite size;
LUAD	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg18016565	chr1:150552671	MCL1	-0.4	-6.87	-0.32	2.31e-11	Tonsillectomy;
LUAD	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-7.84	-0.36	3.58e-14	Blood metabolite levels;
LUAD	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg09658497	chr7:2847517	GNA12	-0.54	-9.09	-0.4	3.84e-18	Height;
LUAD	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg02049041	chr17:27085579	C17orf63	0.66	8.72	0.39	6.27e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg03886242	chr7:26192032	NFE2L3	-0.45	-7.99	-0.36	1.25e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg12179176	chr11:130786555	SNX19	0.55	9.27	0.41	9.37e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg15704280	chr7:45808275	SEPT13	-1.07	-24.81	-0.77	1.64e-84	Height;
LUAD	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg23649088	chr2:200775458	C2orf69	-0.63	-8.15	-0.37	4.31e-15	Schizophrenia;
LUAD	trans	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg18827107	chr12:86230957	RASSF9	-0.48	-8.67	-0.39	9.58e-17	Major depressive disorder;
LUAD	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg15992532	chr8:142229932	SLC45A4	-0.46	-8.1	-0.37	5.95e-15	Immature fraction of reticulocytes;
LUAD	cis	rs13315871	0.860	rs17059098	chr3:58255739	G/A	cg12435725	chr3:58293450	RPP14	-0.71	-7.7	-0.35	9.42e-14	Cholesterol, total;
LUAD	cis	rs11048434	0.761	rs12828902	chr12:9132231	C/T	cg04155231	chr12:9217510	LOC144571	0.42	8.02	0.36	1.04e-14	Sjögren's syndrome;
LUAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg09060608	chr5:178986726	RUFY1	-0.64	-11.11	-0.48	2.52e-25	Lung cancer;
LUAD	cis	rs1011018	0.628	rs17177358	chr7:139456812	A/G	cg26515926	chr7:139453581	HIPK2	-0.49	-6.39	-0.3	4.45e-10	Systolic blood pressure;
LUAD	cis	rs599083	0.793	rs314750	chr11:68182028	G/A	cg02221422	chr11:68192511	LRP5	0.44	6.92	0.32	1.73e-11	Bone mineral density (spine);
LUAD	cis	rs1832871	0.711	rs62439861	chr6:158700531	A/G	cg07165851	chr6:158734300	TULP4	0.7	10.9	0.47	1.52e-24	Height;
LUAD	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg16325326	chr1:53192061	ZYG11B	0.61	10.92	0.47	1.26e-24	Monocyte count;
LUAD	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg10556349	chr10:835070	NA	0.67	7.97	0.36	1.48e-14	Eosinophil percentage of granulocytes;
LUAD	cis	rs714027	1.000	rs2412971	chr22:30494371	G/A	cg00539347	chr22:30592296	NA	-0.3	-7.14	-0.33	4.02e-12	Lymphocyte counts;
LUAD	cis	rs62238980	0.614	rs117369974	chr22:32537177	C/T	cg00543991	chr22:32367038	NA	0.93	8.06	0.36	8.13e-15	Childhood ear infection;
LUAD	cis	rs897984	0.806	rs8052245	chr16:30916430	C/G	cg02466173	chr16:30829666	NA	0.69	12.49	0.52	1.08e-30	Dementia with Lewy bodies;
LUAD	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg07930552	chr6:133119739	C6orf192	-0.59	-6.91	-0.32	1.74e-11	Type 2 diabetes nephropathy;
LUAD	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg24069376	chr3:38537580	EXOG	0.44	10.65	0.46	1.32e-23	Electrocardiographic conduction measures;
LUAD	trans	rs12517041	1.000	rs34694473	chr5:23311661	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.47	-6.63	-0.31	1.04e-10	Calcium levels;
LUAD	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg21385522	chr1:16154831	NA	0.44	6.66	0.31	8.42e-11	Systolic blood pressure;
LUAD	cis	rs6854137	0.721	rs6831829	chr4:169730379	T/C	cg20607169	chr4:169750834	PALLD	0.43	7.7	0.35	9.69e-14	Vein graft stenosis in coronary artery bypass grafting;
LUAD	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg11189052	chr15:85197271	WDR73	0.65	8.73	0.39	5.91e-17	Schizophrenia;
LUAD	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg17264618	chr3:40429014	ENTPD3	-0.37	-8.18	-0.37	3.46e-15	Renal cell carcinoma;
LUAD	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg10591111	chr5:226296	SDHA	-0.55	-7.15	-0.33	3.72e-12	Breast cancer;
LUAD	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg18198730	chr1:247681584	NA	-0.43	-7.78	-0.35	5.44e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg16988262	chr1:15930761	NA	0.42	6.96	0.32	1.29e-11	Systolic blood pressure;
LUAD	trans	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-9.4	-0.42	3.41e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg15181151	chr6:150070149	PCMT1	0.39	7.51	0.34	3.43e-13	Lung cancer;
LUAD	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg03188948	chr7:1209495	NA	0.82	9.95	0.44	4.28e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1003719	0.628	rs2252402	chr21:38520720	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.42	6.89	0.32	2.09e-11	Eye color traits;
LUAD	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg08885076	chr2:99613938	TSGA10	-0.41	-7.21	-0.33	2.63e-12	Chronic sinus infection;
LUAD	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg26818010	chr10:134567672	INPP5A	-0.86	-14.76	-0.58	4.42e-40	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7551222	0.749	rs7532236	chr1:204561617	A/G	cg20240347	chr1:204465584	NA	0.33	6.64	0.31	9.7e-11	Schizophrenia;
LUAD	cis	rs6543140	0.964	rs4851010	chr2:103056127	A/T	cg03938978	chr2:103052716	IL18RAP	-0.36	-7.04	-0.32	7.61e-12	Blood protein levels;
LUAD	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg24550644	chr17:30846204	MYO1D	-0.38	-6.79	-0.31	3.73e-11	Schizophrenia;
LUAD	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg06453172	chr10:134556979	INPP5A	-0.66	-9.71	-0.43	3.08e-20	Migraine;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg00934312	chr7:149570931	ATP6V0E2;LOC401431	0.41	6.79	0.31	3.69e-11	Diastolic blood pressure;
LUAD	cis	rs11771526	1.000	rs117890465	chr7:32351009	A/C	cg27532318	chr7:32358331	NA	0.56	6.72	0.31	5.84e-11	Body mass index;
LUAD	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg08601574	chr20:25228251	PYGB	0.47	8.86	0.4	2.29e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg06808227	chr14:105710500	BRF1	-0.43	-6.7	-0.31	6.85e-11	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs7487075	0.578	rs12319162	chr12:46837914	T/C	cg23829395	chr12:46796953	NA	0.31	6.91	0.32	1.82e-11	Itch intensity from mosquito bite;
LUAD	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg09184832	chr6:79620586	NA	-0.5	-9.46	-0.42	2.24e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg07952391	chr2:88470173	THNSL2	-0.39	-6.48	-0.3	2.54e-10	Response to metformin (IC50);
LUAD	cis	rs2880765	0.546	rs11639291	chr15:86064130	G/A	cg13263323	chr15:86062960	AKAP13	-0.52	-8.74	-0.39	5.37e-17	Coronary artery disease;
LUAD	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.47	-6.74	-0.31	5.05e-11	Cognitive test performance;
LUAD	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg09626299	chr10:82213104	TSPAN14	-0.31	-6.77	-0.31	4.37e-11	Post bronchodilator FEV1;
LUAD	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11890956	chr21:40555474	PSMG1	0.81	14.39	0.57	1.62e-38	Cognitive function;
LUAD	cis	rs6906287	0.647	rs12199463	chr6:118826695	A/G	cg21191810	chr6:118973309	C6orf204	-0.5	-9.75	-0.43	2.14e-20	Electrocardiographic conduction measures;
LUAD	trans	rs7916697	0.520	rs12265247	chr10:70038398	A/G	cg04882175	chr6:131122610	NA	-0.5	-6.56	-0.3	1.53e-10	Optic disc area;
LUAD	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg01145583	chr6:160211477	TCP1;MRPL18	-0.45	-6.54	-0.3	1.82e-10	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg22676075	chr6:135203613	NA	0.41	7.48	0.34	4.22e-13	Red blood cell count;
LUAD	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg24818145	chr4:99064322	C4orf37	0.47	8.01	0.36	1.15e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2408955	0.542	rs7975632	chr12:48443048	C/T	cg04545296	chr12:48745243	ZNF641	0.33	8.41	0.38	6.27e-16	Glycated hemoglobin levels;
LUAD	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg17366294	chr4:99064904	C4orf37	0.63	12.14	0.51	2.54e-29	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	10.43	0.45	8.34e-23	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.43	-0.52	1.89e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg15448220	chr1:150897856	SETDB1	-0.42	-7.19	-0.33	2.91e-12	Tonsillectomy;
LUAD	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg09365446	chr1:150670422	GOLPH3L	0.55	9.67	0.43	4.18e-20	Melanoma;
LUAD	cis	rs2046867	0.908	rs62251636	chr3:72792650	A/G	cg04365224	chr3:72788183	NA	-0.47	-7.11	-0.33	4.97e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.4e-12	Lung cancer;
LUAD	cis	rs9462027	0.583	rs9469902	chr6:34793768	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.52	-0.38	2.79e-16	Systemic lupus erythematosus;
LUAD	cis	rs6906287	0.647	rs2356183	chr6:118770264	A/G	cg18833306	chr6:118973337	C6orf204	0.46	8.16	0.37	3.96e-15	Electrocardiographic conduction measures;
LUAD	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg02018176	chr4:1364513	KIAA1530	-0.36	-6.77	-0.31	4.3e-11	Obesity-related traits;
LUAD	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	15.42	0.6	6.75e-43	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs67981189	0.821	rs61990419	chr14:71536287	G/T	cg15816911	chr14:71606274	NA	0.36	6.38	0.3	4.63e-10	Schizophrenia;
LUAD	cis	rs10504073	0.647	rs2292399	chr8:49987230	A/G	cg00325661	chr8:49890786	NA	0.45	10.07	0.44	1.64e-21	Blood metabolite ratios;
LUAD	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg13736514	chr6:26305472	NA	-0.68	-12.69	-0.52	1.78e-31	Educational attainment;
LUAD	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg14196790	chr5:131705035	SLC22A5	0.5	8.6	0.39	1.6e-16	Breast cancer;Mosquito bite size;
LUAD	cis	rs2617583	0.509	rs748209	chr5:1457554	A/C	cg13982541	chr5:1466431	LPCAT1	0.6	9.53	0.42	1.29e-19	Breast cancer;
LUAD	trans	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg06606381	chr12:133084897	FBRSL1	-0.85	-8.27	-0.37	1.75e-15	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2625529	0.730	rs4777485	chr15:72389384	G/C	cg16672083	chr15:72433130	SENP8	-0.68	-12.1	-0.51	3.64e-29	Red blood cell count;
LUAD	cis	rs11945232	1.000	rs11945232	chr4:88342369	A/G	cg23841344	chr4:88312519	HSD17B11	-0.47	-7.22	-0.33	2.42e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg08807101	chr21:30365312	RNF160	-0.43	-7.4	-0.34	7.32e-13	Dental caries;
LUAD	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg09654669	chr8:57350985	NA	-0.65	-9.82	-0.43	1.21e-20	Obesity-related traits;
LUAD	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg05535760	chr7:792225	HEATR2	-0.81	-8.61	-0.39	1.41e-16	Cerebrospinal P-tau181p levels;
LUAD	cis	rs1385374	0.858	rs11059930	chr12:129297860	T/C	cg09035930	chr12:129282057	SLC15A4	-0.65	-6.91	-0.32	1.79e-11	Systemic lupus erythematosus;
LUAD	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg27494647	chr7:150038898	RARRES2	0.5	8.73	0.39	5.84e-17	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs2658782	0.547	rs3020052	chr11:93055184	C/G	cg15737290	chr11:93063684	CCDC67	0.58	9.93	0.43	5.14e-21	Pulmonary function decline;
LUAD	trans	rs62458065	0.640	rs10271491	chr7:32530665	C/A	cg00845942	chr12:64062724	DPY19L2	-0.57	-7.62	-0.35	1.63e-13	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg24642844	chr7:1081250	C7orf50	-0.85	-13.79	-0.56	5.31e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2282300	0.739	rs35883696	chr11:30246407	A/C	cg06241208	chr11:30344200	C11orf46	-0.58	-7.58	-0.35	2.26e-13	Morning vs. evening chronotype;
LUAD	cis	rs1003719	0.680	rs8130069	chr21:38552116	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.49	-8.26	-0.37	1.83e-15	Eye color traits;
LUAD	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-12.2	-0.51	1.59e-29	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg09904177	chr6:26538194	HMGN4	0.43	7.26	0.33	1.87e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg03037974	chr15:76606532	NA	0.37	7.76	0.35	6.51e-14	Blood metabolite levels;
LUAD	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06002616	chr8:101225028	SPAG1	0.46	9.68	0.43	3.79e-20	Atrioventricular conduction;
LUAD	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg02158880	chr13:53174818	NA	-0.4	-6.39	-0.3	4.28e-10	Lewy body disease;
LUAD	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg00999904	chr2:3704751	ALLC	-0.39	-7.65	-0.35	1.37e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21659725	chr3:3221576	CRBN	0.64	11.16	0.48	1.64e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg06558623	chr16:89946397	TCF25	0.99	10.25	0.45	3.48e-22	Skin colour saturation;
LUAD	cis	rs2637266	0.783	rs10824437	chr10:78469493	C/T	cg18941641	chr10:78392320	NA	0.32	6.79	0.31	3.77e-11	Pulmonary function;
LUAD	cis	rs4642101	0.824	rs9835677	chr3:12845158	G/A	cg24848339	chr3:12840334	CAND2	0.38	7.78	0.35	5.47e-14	QRS complex (12-leadsum);
LUAD	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg13319975	chr6:146136371	FBXO30	-0.61	-10.41	-0.45	9.87e-23	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg12935359	chr14:103987150	CKB	-0.48	-7.79	-0.35	5.22e-14	Body mass index;
LUAD	cis	rs11209185	0.563	rs10889735	chr1:68435400	T/C	cg22082780	chr1:68452167	NA	-0.39	-7.67	-0.35	1.18e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg19704074	chr1:63062212	DOCK7;ANGPTL3	-0.41	-6.36	-0.3	5.1e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs6993813	0.872	rs4403441	chr8:120031785	G/A	cg01975934	chr8:119970761	NA	-0.37	-7.23	-0.33	2.31e-12	Bone mineral density (hip);
LUAD	cis	rs1847202	1.000	rs11918615	chr3:72942407	T/C	cg25664220	chr3:72788482	NA	-0.44	-8.07	-0.37	7.2e-15	Motion sickness;
LUAD	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg21191810	chr6:118973309	C6orf204	-0.52	-8.3	-0.37	1.44e-15	Diastolic blood pressure;
LUAD	cis	rs6596100	0.538	rs67652061	chr5:132280347	T/G	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Breast cancer;
LUAD	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg18306943	chr3:40428807	ENTPD3	0.43	7.23	0.33	2.28e-12	Renal cell carcinoma;
LUAD	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg10755058	chr3:40428713	ENTPD3	-0.39	-7.53	-0.34	3.11e-13	Renal cell carcinoma;
LUAD	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.62	8.57	0.38	1.93e-16	Renal function-related traits (BUN);
LUAD	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg15226275	chr6:116381976	FRK	0.24	7.85	0.36	3.53e-14	Cholesterol, total;LDL cholesterol;
LUAD	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg08470875	chr2:26401718	FAM59B	-0.57	-7.89	-0.36	2.56e-14	Gut microbiome composition (summer);
LUAD	cis	rs1873147	0.569	rs58819603	chr15:63310866	T/A	cg12160578	chr15:63334699	TPM1	0.52	7.91	0.36	2.24e-14	Orofacial clefts;
LUAD	cis	rs877282	0.945	rs71489301	chr10:770191	A/G	cg17470449	chr10:769945	NA	0.63	9.44	0.42	2.59e-19	Uric acid levels;
LUAD	cis	rs2840044	1.000	rs225251	chr17:33951228	A/C	cg05299278	chr17:33885742	SLFN14	0.43	8.72	0.39	6.54e-17	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg05665937	chr4:1216051	CTBP1	0.39	6.68	0.31	7.67e-11	Obesity-related traits;
LUAD	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg05042697	chr2:10830656	NOL10	-0.38	-6.54	-0.3	1.83e-10	Prostate cancer;
LUAD	cis	rs6761276	0.868	rs13386602	chr2:113834820	A/C	cg09040174	chr2:113837401	NA	0.8	15.65	0.61	7.33e-44	Protein quantitative trait loci;
LUAD	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg17063962	chr7:91808500	NA	0.7	12.62	0.52	3.22e-31	Breast cancer;
LUAD	cis	rs6484504	0.576	rs2447671	chr11:31334323	A/G	cg14844989	chr11:31128820	NA	-0.42	-7.87	-0.36	3.03e-14	Red blood cell count;
LUAD	cis	rs1003719	0.725	rs2187101	chr21:38452379	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.47	0.38	4.14e-16	Eye color traits;
LUAD	cis	rs13064411	0.696	rs6769516	chr3:113219905	T/C	cg10517650	chr3:113235015	CCDC52	-0.56	-9.63	-0.42	5.58e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs4072705	1.000	rs10986391	chr9:127428235	C/T	cg13476313	chr9:127244764	NR5A1	0.3	7.52	0.34	3.29e-13	Menarche (age at onset);
LUAD	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg07343612	chr16:622815	PIGQ	-0.79	-15.62	-0.6	9.55e-44	Height;
LUAD	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg04450456	chr4:17643702	FAM184B	0.41	8.04	0.36	8.8e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs4925386	0.808	rs1741634	chr20:60925979	A/C	cg24112000	chr20:60950667	NA	0.75	12.68	0.52	1.83e-31	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg22920501	chr2:26401640	FAM59B	0.96	14.21	0.57	9.43e-38	Gut microbiome composition (summer);
LUAD	cis	rs2806561	0.514	rs10917360	chr1:23539010	C/T	cg19743168	chr1:23544995	NA	0.62	11.25	0.48	7.11e-26	Height;
LUAD	cis	rs1448094	0.933	rs10779218	chr12:86320053	A/G	cg02569458	chr12:86230093	RASSF9	0.38	7.29	0.33	1.55e-12	Major depressive disorder;
LUAD	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.47	0.3	2.67e-10	Depression;
LUAD	trans	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg21659725	chr3:3221576	CRBN	-0.6	-9.61	-0.42	6.76e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUAD	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.78	-13.32	-0.54	4.78e-34	Chronic sinus infection;
LUAD	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg07757535	chr4:1339547	NA	0.32	6.38	0.3	4.52e-10	Longevity;
LUAD	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.09	0.33	5.82e-12	Parkinson's disease;
LUAD	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24531977	chr5:56204891	C5orf35	-1.0	-15.13	-0.59	1.27e-41	Initial pursuit acceleration;
LUAD	trans	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.4	0.48	1.89e-26	Mean corpuscular volume;
LUAD	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg02951883	chr7:2050386	MAD1L1	-0.67	-10.77	-0.46	4.45e-24	Bipolar disorder and schizophrenia;
LUAD	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg21918786	chr6:109611834	NA	0.58	10.93	0.47	1.17e-24	Reticulocyte fraction of red cells;
LUAD	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg04450456	chr4:17643702	FAM184B	0.43	8.45	0.38	4.86e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg21775007	chr8:11205619	TDH	0.37	6.41	0.3	3.86e-10	Neuroticism;
LUAD	cis	rs11585357	0.501	rs17458091	chr1:17595925	A/G	cg08277548	chr1:17600880	PADI3	-0.7	-9.34	-0.41	5.63e-19	Hair shape;
LUAD	cis	rs7213347	0.707	rs216181	chr17:2172753	A/T	cg02569219	chr17:2266849	SGSM2	0.46	7.07	0.33	6.32e-12	Total body bone mineral density;
LUAD	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg27494647	chr7:150038898	RARRES2	-0.49	-8.71	-0.39	6.87e-17	Blood protein levels;Circulating chemerin levels;
LUAD	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.56	-9.47	-0.42	1.98e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs612683	0.694	rs6688364	chr1:101000874	G/A	cg09408571	chr1:101003634	GPR88	0.33	6.5	0.3	2.27e-10	Breast cancer;
LUAD	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg02251663	chr11:14281053	SPON1	0.35	7.05	0.32	7.48e-12	Mitochondrial DNA levels;
LUAD	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg08999081	chr20:33150536	PIGU	0.62	13.95	0.56	1.24e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs732716	0.785	rs56033249	chr19:4369447	C/T	cg21934504	chr19:4445085	UBXN6	0.42	6.96	0.32	1.34e-11	Mean corpuscular volume;
LUAD	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg22907277	chr7:1156413	C7orf50	0.7	8.23	0.37	2.35e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg18180107	chr4:99064573	C4orf37	0.4	6.45	0.3	3.12e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg12656391	chr1:43425156	SLC2A1	-0.31	-6.5	-0.3	2.23e-10	Red cell distribution width;
LUAD	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.33	0.34	1.2e-12	Tonsillectomy;
LUAD	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg06108461	chr20:60628389	TAF4	-0.74	-12.34	-0.51	4.11e-30	Body mass index;
LUAD	trans	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.06	-27.25	-0.8	3.66e-95	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1215050	0.791	rs7681599	chr4:98664109	C/T	cg17366294	chr4:99064904	C4orf37	-0.45	-7.94	-0.36	1.86e-14	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	9.36	0.41	4.75e-19	Lung cancer in ever smokers;
LUAD	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg25767906	chr1:53392781	SCP2	-0.35	-6.6	-0.31	1.21e-10	Monocyte count;
LUAD	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg00204512	chr16:28754710	NA	0.33	7.0	0.32	9.79e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg18306943	chr3:40428807	ENTPD3	-0.38	-6.71	-0.31	6.3e-11	Renal cell carcinoma;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg18051346	chr17:43238278	HEXIM2	-0.73	-7.1	-0.33	5.3e-12	Type 2 diabetes;
LUAD	cis	rs870825	0.616	rs4416519	chr4:185639502	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	14.12	0.57	2.26e-37	Blood protein levels;
LUAD	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg08027265	chr7:2291960	NA	-0.49	-8.44	-0.38	5.01e-16	Bipolar disorder and schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04031504	chr1:32645060	TXLNA	-0.41	-6.48	-0.3	2.56e-10	Height;
LUAD	cis	rs16866061	1.000	rs4674916	chr2:225365635	C/A	cg12698349	chr2:225449008	CUL3	0.76	13.32	0.54	4.97e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg25894440	chr7:65020034	NA	0.58	6.38	0.3	4.72e-10	Diabetic kidney disease;
LUAD	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg00071950	chr4:10020882	SLC2A9	0.85	18.22	0.66	3.53e-55	Bone mineral density;
LUAD	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg05991184	chr2:219186017	PNKD	0.37	7.11	0.33	4.91e-12	Colorectal cancer;
LUAD	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg14725641	chr11:61582763	MIR1908;FADS1	-0.45	-6.98	-0.32	1.16e-11	Bipolar disorder;
LUAD	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg00631329	chr6:26305371	NA	-0.68	-12.92	-0.53	1.95e-32	Educational attainment;
LUAD	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-7.52	-0.34	3.33e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs7939886	0.920	rs61742348	chr11:55905078	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.38	0.3	4.79e-10	Myopia (pathological);
LUAD	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg25251562	chr2:3704773	ALLC	-0.46	-8.34	-0.38	1.03e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs367615	0.918	rs4576198	chr5:108867350	T/G	cg17395555	chr5:108820864	NA	0.53	8.66	0.39	1.04e-16	Colorectal cancer (SNP x SNP interaction);
LUAD	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg18180107	chr4:99064573	C4orf37	0.42	6.68	0.31	7.57e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7000551	0.725	rs2249102	chr8:22400193	C/G	cg12081754	chr8:22256438	SLC39A14	0.45	7.36	0.34	9.46e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg15448220	chr1:150897856	SETDB1	0.49	8.47	0.38	4.03e-16	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.56	0.52	5.93e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.75	8.38	0.38	7.76e-16	Yeast infection;
LUAD	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg20503657	chr10:835505	NA	1.04	15.87	0.61	7.5e-45	Eosinophil percentage of granulocytes;
LUAD	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg02993280	chr1:107599747	PRMT6	0.56	9.18	0.41	1.94e-18	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.94	0.36	1.89e-14	Parkinson's disease;
LUAD	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg22117172	chr7:91764530	CYP51A1	0.34	7.43	0.34	5.91e-13	Breast cancer;
LUAD	trans	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg01620082	chr3:125678407	NA	-0.63	-7.87	-0.36	2.93e-14	Depression;
LUAD	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg14458575	chr2:238380390	NA	0.84	12.74	0.53	1.12e-31	Prostate cancer;
LUAD	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg17105886	chr17:28927953	LRRC37B2	0.81	7.9	0.36	2.44e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg23260525	chr10:116636907	FAM160B1	0.49	11.35	0.48	3.05e-26	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1160297	0.609	rs12618983	chr2:53091691	C/T	cg07782112	chr2:53107842	NA	-0.42	-9.0	-0.4	7.66e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs4692589	1.000	rs11727880	chr4:170937467	C/T	cg19918862	chr4:170955249	NA	0.29	6.96	0.32	1.33e-11	Anxiety disorder;
LUAD	cis	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.91	-0.36	2.33e-14	Neuroticism;
LUAD	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	13.95	0.56	1.24e-36	Lung cancer in ever smokers;
LUAD	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg26513180	chr16:89883248	FANCA	0.79	7.19	0.33	2.92e-12	Skin colour saturation;
LUAD	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg05283184	chr6:79620031	NA	0.61	12.46	0.52	1.37e-30	Intelligence (multi-trait analysis);
LUAD	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg05623727	chr3:50126028	RBM5	-0.31	-6.54	-0.3	1.8e-10	Body mass index;
LUAD	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.31	-0.37	1.32e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs7254114	0.578	rs7246614	chr19:11310538	C/T	cg02815516	chr19:11306319	KANK2	-0.33	-7.04	-0.32	7.94e-12	Immature fraction of reticulocytes;
LUAD	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg05535760	chr7:792225	HEATR2	0.85	11.45	0.49	1.29e-26	Cerebrospinal P-tau181p levels;
LUAD	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg16680214	chr1:154839983	KCNN3	-0.63	-13.15	-0.54	2.3e-33	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg03676636	chr4:99064102	C4orf37	0.3	7.87	0.36	3.01e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg01017244	chr2:74357527	NA	0.82	13.85	0.56	3.04e-36	Gestational age at birth (maternal effect);
LUAD	cis	rs10193935	0.901	rs222488	chr2:42648570	T/G	cg27598129	chr2:42591480	NA	-0.67	-8.76	-0.39	4.61e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9788721	0.967	rs72740955	chr15:78849779	C/T	cg18825076	chr15:78729989	IREB2	-0.57	-9.26	-0.41	1.04e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-8.0	-0.36	1.18e-14	Gut microbiome composition (summer);
LUAD	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg25828334	chr19:18545568	ISYNA1	-0.38	-7.59	-0.35	2.02e-13	Breast cancer;
LUAD	cis	rs3806843	0.898	rs3756335	chr5:140213510	A/T	cg11822812	chr5:140052017	DND1	0.36	6.48	0.3	2.57e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9914988	1.000	rs9916866	chr17:27183155	C/G	cg02049041	chr17:27085579	C17orf63	-0.6	-8.03	-0.36	9.89e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg26043149	chr18:55253948	FECH	1.06	19.7	0.69	8.89e-62	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg02683114	chr2:24398427	C2orf84	-0.52	-7.74	-0.35	7.46e-14	Asthma;
LUAD	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11644478	chr21:40555479	PSMG1	-0.61	-10.51	-0.46	4.02e-23	Cognitive function;
LUAD	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	8.0	0.36	1.18e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg24112000	chr20:60950667	NA	0.7	9.82	0.43	1.19e-20	Colorectal cancer;
LUAD	cis	rs17253792	0.822	rs75351812	chr14:56082192	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg01884057	chr2:25150051	NA	0.32	6.8	0.31	3.5e-11	Body mass index;
LUAD	cis	rs2230307	0.536	rs700533	chr1:100483822	A/G	cg20868668	chr1:100435035	SLC35A3	0.54	7.76	0.35	6.33e-14	Carotid intima media thickness;
LUAD	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-8.51	-0.38	3.02e-16	Alzheimer's disease (late onset);
LUAD	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg10755058	chr3:40428713	ENTPD3	0.43	8.4	0.38	6.86e-16	Renal cell carcinoma;
LUAD	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.63	-0.31	1.02e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg26727032	chr16:67993705	SLC12A4	-0.48	-6.75	-0.31	5.04e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs17604090	0.628	rs875263	chr7:29711066	T/C	cg27349345	chr7:35225932	NA	-0.45	-6.52	-0.3	2.07e-10	Facial emotion recognition;Facial emotion recognition (sad faces);
LUAD	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg06627628	chr2:24431161	ITSN2	-0.56	-9.31	-0.41	7.07e-19	Venous thromboembolism (SNP x SNP interaction);
LUAD	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg26384229	chr12:38710491	ALG10B	0.47	7.63	0.35	1.55e-13	Morning vs. evening chronotype;
LUAD	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg07979401	chr6:33739406	LEMD2	-0.54	-9.69	-0.43	3.41e-20	Schizophrenia;
LUAD	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg00603274	chr11:61596626	FADS2	-0.37	-6.53	-0.3	1.85e-10	Trans fatty acid levels;
LUAD	trans	rs2270927	0.510	rs67771044	chr5:75577819	A/G	cg13563193	chr19:33072644	PDCD5	0.98	9.18	0.41	1.96e-18	Mean corpuscular volume;
LUAD	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg12365402	chr11:9010492	NRIP3	0.51	9.79	0.43	1.51e-20	Tonsillectomy;
LUAD	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg09455208	chr3:40491958	NA	0.6	12.65	0.52	2.51e-31	Renal cell carcinoma;
LUAD	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg23711669	chr6:146136114	FBXO30	-0.4	-6.58	-0.3	1.43e-10	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs1493916	0.870	rs8097667	chr18:31387003	C/T	cg15819921	chr19:927150	ARID3A	-0.47	-7.81	-0.36	4.43e-14	Life satisfaction;
LUAD	cis	rs73206853	0.686	rs56339227	chr12:111164963	T/C	cg12870014	chr12:110450643	ANKRD13A	0.6	7.0	0.32	1.02e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg04369109	chr6:150039330	LATS1	-0.46	-7.58	-0.35	2.14e-13	Lung cancer;
LUAD	cis	rs7614311	0.681	rs73130565	chr3:63887135	T/C	cg22134162	chr3:63841271	THOC7	-0.52	-8.67	-0.39	9.29e-17	Lung function (FVC);Lung function (FEV1);
LUAD	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg18138036	chr10:133769891	PPP2R2D	0.42	6.86	0.32	2.43e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs6594713	0.642	rs6890874	chr5:112787813	C/A	cg12552261	chr5:112820674	MCC	0.58	7.79	0.35	5.29e-14	Brain cytoarchitecture;
LUAD	cis	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg08601574	chr20:25228251	PYGB	0.45	8.39	0.38	7.47e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg00277334	chr10:82204260	NA	-0.96	-22.22	-0.73	5.03e-73	Post bronchodilator FEV1;
LUAD	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg15448220	chr1:150897856	SETDB1	0.49	8.25	0.37	1.99e-15	Melanoma;
LUAD	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg01448562	chr3:133502909	NA	0.56	9.48	0.42	1.79e-19	Iron status biomarkers;
LUAD	cis	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg27411982	chr8:10470053	RP1L1	-0.41	-7.37	-0.34	8.81e-13	Triglycerides;
LUAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.61e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg13010199	chr12:38710504	ALG10B	0.4	6.51	0.3	2.18e-10	Bladder cancer;
LUAD	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg11292332	chr7:45801988	SEPT13	-0.28	-6.36	-0.3	5.26e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs7943203	0.962	rs116201292	chr11:108313599	T/C	cg04873221	chr11:107992290	ACAT1	-0.42	-6.72	-0.31	5.79e-11	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg10862848	chr6:42927986	GNMT	-0.32	-9.36	-0.41	4.62e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs7943203	0.962	rs2118308	chr11:108315463	C/G	cg04873221	chr11:107992290	ACAT1	-0.43	-7.01	-0.32	9.45e-12	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg25664220	chr3:72788482	NA	-0.69	-12.42	-0.52	2.12e-30	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg18196295	chr10:418757	DIP2C	-0.45	-6.91	-0.32	1.79e-11	Psychosis in Alzheimer's disease;
LUAD	cis	rs7705042	0.865	rs11739961	chr5:141508488	A/C	cg08523384	chr5:141488047	NDFIP1	-0.38	-6.51	-0.3	2.12e-10	Asthma;
LUAD	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg06064525	chr11:970664	AP2A2	-0.53	-10.86	-0.47	2.05e-24	Alzheimer's disease (late onset);
LUAD	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg12365402	chr11:9010492	NRIP3	-0.51	-10.37	-0.45	1.35e-22	Hemoglobin concentration;
LUAD	cis	rs4589502	0.800	rs4147433	chr15:67201152	G/A	cg09911534	chr15:67153556	NA	0.41	7.4	0.34	7.63e-13	Lung cancer (smoking interaction);
LUAD	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg02631126	chr6:28058918	ZSCAN12L1	-0.38	-7.77	-0.35	5.82e-14	Depression;
LUAD	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg21605333	chr4:119757512	SEC24D	0.93	8.76	0.39	4.9e-17	Cannabis dependence symptom count;
LUAD	cis	rs12618769	0.597	rs3769713	chr2:99151434	A/G	cg10123293	chr2:99228465	UNC50	0.49	8.86	0.4	2.21e-17	Bipolar disorder;
LUAD	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.02	0.36	1.02e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9372498	0.536	rs9481825	chr6:118876092	C/T	cg07617317	chr6:118971624	C6orf204	0.55	8.44	0.38	5.22e-16	Diastolic blood pressure;
LUAD	cis	rs7903847	0.642	rs10882911	chr10:99138064	A/C	cg20016023	chr10:99160130	RRP12	-0.3	-7.2	-0.33	2.8e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	8.27	0.37	1.79e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	13.11	0.54	3.37e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs17818399	0.781	rs34449783	chr2:46863555	C/T	cg09399716	chr2:46890238	NA	-0.42	-7.84	-0.36	3.69e-14	Height;
LUAD	trans	rs877282	0.733	rs11253342	chr10:765072	A/G	cg22713356	chr15:30763199	NA	1.27	17.4	0.65	1.56e-51	Uric acid levels;
LUAD	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg12444411	chr7:2802554	GNA12	-0.36	-6.37	-0.3	4.92e-10	Height;
LUAD	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1113500	0.933	rs1419003	chr1:108616955	A/C	cg06207961	chr1:108661230	NA	0.45	8.4	0.38	6.77e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs2908197	0.737	rs2109857	chr7:75963169	T/C	cg24580635	chr7:76178542	LOC100133091	-0.43	-6.72	-0.31	5.74e-11	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs12519773	0.576	rs55971857	chr5:92441594	A/C	cg18783429	chr5:92414398	NA	0.43	7.4	0.34	7.38e-13	Migraine;
LUAD	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg09904177	chr6:26538194	HMGN4	0.44	7.41	0.34	6.96e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg08027265	chr7:2291960	NA	-0.46	-7.69	-0.35	1.04e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs420259	0.516	rs4968019	chr16:23557790	T/C	cg00143387	chr16:23521605	GGA2	-0.73	-10.01	-0.44	2.69e-21	Bipolar disorder;
LUAD	cis	rs1941023	0.584	rs2233253	chr11:60157166	C/T	cg08716584	chr11:60157161	MS4A7	-0.48	-9.26	-0.41	1.07e-18	Congenital heart disease (maternal effect);
LUAD	cis	rs4774899	0.934	rs11858783	chr15:57472751	C/A	cg14026238	chr15:57616123	NA	0.35	6.53	0.3	1.88e-10	Urinary tract infection frequency;
LUAD	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg21770322	chr7:97807741	LMTK2	0.34	8.17	0.37	3.67e-15	Breast cancer;
LUAD	trans	rs8002861	0.967	rs7983109	chr13:44484351	C/A	cg17145862	chr1:211918768	LPGAT1	0.75	17.68	0.65	8.51e-53	Leprosy;
LUAD	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg17366294	chr4:99064904	C4orf37	0.57	8.61	0.39	1.41e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9972944	0.756	rs4791133	chr17:63769118	T/C	cg07283582	chr17:63770753	CCDC46	-0.51	-11.6	-0.49	3.32e-27	Total body bone mineral density;
LUAD	cis	rs6714710	0.580	rs11692470	chr2:98520564	T/C	cg26665480	chr2:98280029	ACTR1B	0.5	8.14	0.37	4.54e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs1595825	0.838	rs16826872	chr2:198898055	T/C	cg00361562	chr2:198649771	BOLL	-0.5	-6.88	-0.32	2.12e-11	Ulcerative colitis;
LUAD	cis	rs3845702	0.736	rs2678936	chr2:180872179	G/C	cg01881094	chr2:180872142	CWC22	0.85	9.62	0.42	6.25e-20	Schizophrenia;
LUAD	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg16989719	chr2:238392110	NA	-0.38	-8.11	-0.37	5.66e-15	Prostate cancer;
LUAD	cis	rs1375194	0.606	rs17657783	chr2:33814590	A/G	cg04131969	chr2:33951647	MYADML	-0.57	-9.0	-0.4	7.51e-18	Response to antidepressants in depression;
LUAD	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg11266682	chr4:10021025	SLC2A9	0.46	8.29	0.37	1.5e-15	Blood metabolite levels;
LUAD	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg27494647	chr7:150038898	RARRES2	0.53	8.88	0.4	1.87e-17	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg14092988	chr3:52407081	DNAH1	0.45	8.88	0.4	1.89e-17	Bipolar disorder;
LUAD	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.7	-11.2	-0.48	1.1e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg14844989	chr11:31128820	NA	-0.46	-8.44	-0.38	4.93e-16	Red blood cell count;
LUAD	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg20607798	chr8:58055168	NA	0.48	6.55	0.3	1.68e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg09658497	chr7:2847517	GNA12	-0.48	-8.18	-0.37	3.25e-15	Height;
LUAD	cis	rs9462027	0.628	rs66506671	chr6:34777149	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.84	-0.39	2.6e-17	Systemic lupus erythematosus;
LUAD	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg10556349	chr10:835070	NA	0.52	6.95	0.32	1.35e-11	Eosinophil percentage of granulocytes;
LUAD	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg03806693	chr22:41940476	POLR3H	0.76	10.69	0.46	9.26e-24	Vitiligo;
LUAD	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	6.47	0.3	2.67e-10	Personality dimensions;
LUAD	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg09323728	chr8:95962352	TP53INP1	-0.35	-8.46	-0.38	4.46e-16	Type 2 diabetes;
LUAD	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg22105103	chr4:187893119	NA	0.58	12.76	0.53	8.61e-32	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg24818145	chr4:99064322	C4orf37	0.49	8.09	0.37	6.29e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13082711	0.911	rs2003886	chr3:27527732	G/T	cg02860705	chr3:27208620	NA	0.61	8.87	0.4	2.01e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.5	-8.34	-0.38	1.06e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.33	-6.72	-0.31	6.05e-11	Obesity-related traits;
LUAD	cis	rs34421088	0.585	rs6992190	chr8:11596549	A/C	cg13293535	chr8:11597251	GATA4	0.31	6.82	0.31	3.25e-11	Neuroticism;
LUAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08280861	chr8:58055591	NA	0.67	8.72	0.39	6.27e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.44	-0.89	8.69e-144	Myeloid white cell count;
LUAD	cis	rs41271473	0.526	rs12094319	chr1:228717836	G/C	cg10167378	chr1:228756711	NA	0.67	9.07	0.4	4.37e-18	Chronic lymphocytic leukemia;
LUAD	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg25664220	chr3:72788482	NA	-0.66	-11.51	-0.49	7.14e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-7.95	-0.36	1.78e-14	Monocyte percentage of white cells;
LUAD	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg09365446	chr1:150670422	GOLPH3L	0.54	9.54	0.42	1.19e-19	Melanoma;
LUAD	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg11663144	chr21:46675770	NA	-0.48	-9.18	-0.41	1.98e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg09835421	chr16:68378352	PRMT7	-0.81	-8.79	-0.39	3.68e-17	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs8073060	0.561	rs225260	chr17:33958422	T/C	cg19694781	chr19:47549865	TMEM160	-1.19	-18.49	-0.67	2.22e-56	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs79839061	0.562	rs62294484	chr4:935571	A/G	cg07828340	chr4:882639	GAK	1.11	11.98	0.5	1.12e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs977987	0.836	rs7200053	chr16:75474618	C/T	cg03315344	chr16:75512273	CHST6	0.65	14.36	0.57	2.31e-38	Dupuytren's disease;
LUAD	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg19077165	chr18:44547161	KATNAL2	-0.42	-7.36	-0.34	9.85e-13	Personality dimensions;
LUAD	cis	rs250677	0.522	rs6872172	chr5:148359529	G/C	cg12140854	chr5:148520817	ABLIM3	0.57	8.98	0.4	9.03e-18	Breast cancer;
LUAD	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg11266682	chr4:10021025	SLC2A9	0.69	15.79	0.61	1.69e-44	Bone mineral density;
LUAD	cis	rs9902453	0.838	rs8064689	chr17:28217053	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	9.38	0.41	4.17e-19	Coffee consumption (cups per day);
LUAD	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg16714605	chr19:10765132	ILF3;LOC147727	-0.41	-6.49	-0.3	2.34e-10	Vertical cup-disc ratio;
LUAD	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg08450091	chr3:82857215	NA	-0.4	-6.37	-0.3	4.95e-10	Height;
LUAD	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg00814883	chr7:100076585	TSC22D4	-0.82	-11.68	-0.49	1.64e-27	Platelet count;
LUAD	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg26022315	chr17:47021804	SNF8	0.42	7.37	0.34	8.96e-13	Coronary heart disease;
LUAD	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg14829155	chr15:31115871	NA	-0.57	-9.65	-0.42	4.89e-20	Huntington's disease progression;
LUAD	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.41	-0.3	3.91e-10	Calcium levels;
LUAD	cis	rs1003719	0.751	rs7280371	chr21:38450008	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.5	8.54	0.38	2.49e-16	Eye color traits;
LUAD	cis	rs877282	0.898	rs12357995	chr10:765739	T/C	cg06581033	chr10:766294	NA	-0.62	-8.35	-0.38	1.02e-15	Uric acid levels;
LUAD	cis	rs6558530	0.799	rs62477060	chr8:1706498	A/T	cg19131313	chr8:1704013	NA	-0.45	-7.34	-0.34	1.13e-12	Systolic blood pressure;
LUAD	cis	rs7727544	0.647	rs6898270	chr5:131421190	C/T	cg22598563	chr5:131563921	P4HA2	-0.27	-6.51	-0.3	2.14e-10	Blood metabolite levels;
LUAD	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg15017067	chr4:17643749	FAM184B	0.34	6.59	0.31	1.3e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9914988	0.887	rs7213285	chr17:27206029	G/A	cg20469991	chr17:27169893	C17orf63	-0.58	-6.4	-0.3	4.06e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg06060754	chr5:176797920	RGS14	-0.56	-9.19	-0.41	1.73e-18	Urate levels in lean individuals;
LUAD	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg12645284	chr15:79092878	ADAMTS7	0.48	7.54	0.34	2.95e-13	Coronary artery disease or large artery stroke;
LUAD	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg20290983	chr6:43655470	MRPS18A	1.07	27.06	0.8	2.52e-94	IgG glycosylation;
LUAD	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg00530320	chr1:46809349	NSUN4	0.52	8.0	0.36	1.17e-14	Menopause (age at onset);
LUAD	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg01448562	chr3:133502909	NA	0.39	6.87	0.32	2.37e-11	Iron status biomarkers;
LUAD	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg23262073	chr20:60523788	NA	-0.42	-6.83	-0.32	2.9e-11	Body mass index;
LUAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg23283495	chr1:209979779	IRF6	0.82	19.34	0.69	3.65e-60	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUAD	cis	rs7771547	0.723	rs7759778	chr6:36552267	C/G	cg07856975	chr6:36356162	ETV7	0.45	6.39	0.3	4.41e-10	Platelet distribution width;
LUAD	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg20476274	chr7:133979776	SLC35B4	0.84	17.14	0.64	2.21e-50	Mean platelet volume;
LUAD	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg00277334	chr10:82204260	NA	-0.96	-22.03	-0.73	3.49e-72	Post bronchodilator FEV1;
LUAD	cis	rs56283067	0.847	rs10948156	chr6:44689459	G/A	cg18551225	chr6:44695536	NA	-0.62	-10.28	-0.45	2.86e-22	Total body bone mineral density;
LUAD	cis	rs2548003	0.541	rs1895416	chr5:28754530	A/T	cg22863700	chr5:28928346	NA	0.41	6.42	0.3	3.62e-10	Hip geometry;
LUAD	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.48	6.83	0.32	2.93e-11	Platelet count;
LUAD	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.47	2.77e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg17724175	chr1:150552817	MCL1	0.38	9.41	0.42	3.22e-19	Tonsillectomy;
LUAD	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.33	-7.05	-0.32	7.52e-12	Height;
LUAD	cis	rs240764	0.631	rs9386250	chr6:101204126	A/G	cg09795085	chr6:101329169	ASCC3	-0.42	-7.38	-0.34	8.74e-13	Neuroticism;
LUAD	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04871131	chr7:94954202	PON1	-0.54	-9.71	-0.43	2.99e-20	Paraoxonase activity;
LUAD	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg10589385	chr1:150898437	SETDB1	0.38	6.97	0.32	1.25e-11	Melanoma;
LUAD	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19346786	chr7:2764209	NA	-0.56	-12.15	-0.51	2.43e-29	Height;
LUAD	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg25767906	chr1:53392781	SCP2	-0.6	-11.68	-0.49	1.61e-27	Monocyte count;
LUAD	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg09654669	chr8:57350985	NA	-0.65	-9.39	-0.42	3.83e-19	Obesity-related traits;
LUAD	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg03467027	chr4:99064603	C4orf37	0.42	6.86	0.32	2.53e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	9.04	0.4	5.74e-18	Lung cancer in ever smokers;
LUAD	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg01448562	chr3:133502909	NA	-0.66	-12.55	-0.52	6.22e-31	Iron status biomarkers;
LUAD	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08219700	chr8:58056026	NA	0.61	8.67	0.39	9.09e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg13736514	chr6:26305472	NA	-0.73	-13.72	-0.56	1.03e-35	Educational attainment;
LUAD	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26314531	chr2:26401878	FAM59B	0.67	8.87	0.4	2.04e-17	Gut microbiome composition (summer);
LUAD	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg17644776	chr2:200775616	C2orf69	0.53	7.61	0.35	1.75e-13	Schizophrenia;
LUAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg07677032	chr17:61819896	STRADA	0.56	10.36	0.45	1.45e-22	Prudent dietary pattern;
LUAD	cis	rs9487051	1.000	rs6568571	chr6:109613252	A/T	cg01475377	chr6:109611718	NA	-0.49	-8.62	-0.39	1.35e-16	Reticulocyte fraction of red cells;
LUAD	cis	rs1997103	0.798	rs12154964	chr7:55414041	G/A	cg17469321	chr7:55412551	NA	0.66	11.22	0.48	9.47e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.26	0.37	1.91e-15	Breast cancer;
LUAD	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg23758822	chr17:41437982	NA	1.02	20.97	0.71	1.82e-67	Menopause (age at onset);
LUAD	cis	rs75920871	0.563	rs112895963	chr11:116937159	A/T	cg04087571	chr11:116723030	SIK3	-0.33	-6.75	-0.31	4.78e-11	Subjective well-being;
LUAD	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg10589385	chr1:150898437	SETDB1	0.39	7.42	0.34	6.51e-13	Tonsillectomy;
LUAD	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12016809	chr21:47604291	C21orf56	-0.48	-7.3	-0.33	1.42e-12	Testicular germ cell tumor;
LUAD	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg09491104	chr22:46646882	C22orf40	-0.51	-7.06	-0.32	7.02e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs113835537	0.529	rs17065	chr11:66277035	G/A	cg24851651	chr11:66362959	CCS	0.58	10.05	0.44	1.8e-21	Airway imaging phenotypes;
LUAD	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-10.67	-0.46	1.05e-23	Longevity;Endometriosis;
LUAD	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg07636037	chr3:49044803	WDR6	0.35	6.48	0.3	2.61e-10	Resting heart rate;
LUAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.8	-0.31	3.47e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg08601574	chr20:25228251	PYGB	0.46	8.65	0.39	1.08e-16	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs2637266	1.000	rs7478008	chr10:78355575	T/A	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs8077889	0.750	rs231533	chr17:41945588	A/G	cg26893861	chr17:41843967	DUSP3	-0.85	-10.68	-0.46	1e-23	Triglycerides;
LUAD	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg06784218	chr1:46089804	CCDC17	0.6	13.4	0.55	2.3e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs7252981	0.632	rs8113682	chr19:19743730	T/G	cg11584989	chr19:19387371	SF4	-0.47	-7.78	-0.35	5.71e-14	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg19163074	chr7:65112434	INTS4L2	0.46	7.0	0.32	1.03e-11	Aortic root size;
LUAD	cis	rs938554	0.612	rs7669607	chr4:9997801	C/T	cg00071950	chr4:10020882	SLC2A9	-0.61	-9.7	-0.43	3.33e-20	Blood metabolite levels;
LUAD	cis	rs9644630	0.932	rs4922048	chr8:19360814	A/G	cg06699216	chr8:19333253	CSGALNACT1	-0.3	-7.25	-0.33	1.98e-12	Oropharynx cancer;
LUAD	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-9.09	-0.4	3.81e-18	Bipolar disorder and schizophrenia;
LUAD	cis	rs977987	0.736	rs4888392	chr16:75412262	T/C	cg03315344	chr16:75512273	CHST6	0.65	14.34	0.57	2.74e-38	Dupuytren's disease;
LUAD	cis	rs494562	0.892	rs4624841	chr6:86130251	G/A	cg21730993	chr6:86159210	NT5E	0.71	7.84	0.36	3.82e-14	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg09365446	chr1:150670422	GOLPH3L	-0.43	-6.82	-0.31	3.09e-11	Tonsillectomy;
LUAD	cis	rs8099014	1.000	rs9319929	chr18:56115825	A/C	cg12907477	chr18:56117327	MIR122	0.4	6.79	0.31	3.85e-11	Platelet count;
LUAD	trans	rs1941687	0.669	rs56171873	chr18:31400635	G/C	cg27147174	chr7:100797783	AP1S1	-0.52	-9.03	-0.4	6.14e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg13180566	chr4:1052158	NA	-0.4	-6.87	-0.32	2.29e-11	Recombination rate (females);
LUAD	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg20701182	chr2:24300061	SF3B14	0.6	6.86	0.32	2.39e-11	Lymphocyte counts;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg16755220	chr16:12070685	RUNDC2A	-0.68	-6.44	-0.3	3.33e-10	Type 2 diabetes;
LUAD	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg05342682	chr7:94953680	PON1	-0.52	-7.37	-0.34	9.13e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.88	-0.32	2.23e-11	Diabetic kidney disease;
LUAD	cis	rs494562	0.892	rs544403	chr6:86119116	G/T	cg17966619	chr6:86160162	NT5E	0.66	7.99	0.36	1.3e-14	Blood metabolite levels;Metabolic traits;
LUAD	trans	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg19469189	chr11:128781035	KCNJ5	-0.42	-6.64	-0.31	9.49e-11	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-7.88	-0.36	2.89e-14	Blood metabolite levels;
LUAD	cis	rs8025790	0.508	rs12902812	chr15:67909279	C/T	cg24579218	chr15:68104479	NA	-0.5	-8.19	-0.37	3.2e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	trans	rs7781370	1.000	rs7781370	chr7:96133531	A/G	cg21400344	chr1:25870172	LDLRAP1	-0.41	-6.69	-0.31	7.15e-11	Bone mineral density (hip);
LUAD	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg21724239	chr8:58056113	NA	0.68	8.23	0.37	2.27e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg12908607	chr1:44402522	ARTN	-0.44	-9.01	-0.4	6.96e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg06064525	chr11:970664	AP2A2	-0.55	-11.36	-0.48	2.84e-26	Alzheimer's disease (late onset);
LUAD	cis	rs78773383	0.505	rs13123782	chr4:39377405	A/C	cg16714752	chr4:39368184	RFC1	0.55	9.08	0.4	4.29e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.07	0.37	7.54e-15	Breast cancer;
LUAD	trans	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg03886242	chr7:26192032	NFE2L3	-0.47	-8.16	-0.37	3.92e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs344364	0.576	rs238677	chr16:1883279	T/C	cg07386859	chr16:1872102	HAGH	0.54	8.66	0.39	9.96e-17	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs6906287	0.647	rs12197337	chr6:118884092	C/T	cg18833306	chr6:118973337	C6orf204	0.49	8.73	0.39	6.09e-17	Electrocardiographic conduction measures;
LUAD	cis	rs7586879	0.861	rs10164466	chr2:25114069	T/C	cg04586622	chr2:25135609	ADCY3	0.36	7.27	0.33	1.7e-12	Body mass index;
LUAD	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.41	7.44	0.34	5.74e-13	Tonsillectomy;
LUAD	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg17330251	chr7:94953956	PON1	-0.55	-7.61	-0.35	1.83e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg14196790	chr5:131705035	SLC22A5	0.38	6.82	0.31	3.15e-11	Breast cancer;
LUAD	cis	rs870825	0.616	rs6552807	chr4:185640531	A/G	cg04058563	chr4:185651563	MLF1IP	0.88	13.84	0.56	3.55e-36	Blood protein levels;
LUAD	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg24813613	chr7:1882135	MAD1L1	-0.42	-6.62	-0.31	1.06e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs6430585	0.527	rs2304366	chr2:136467119	C/T	cg07169764	chr2:136633963	MCM6	0.59	6.95	0.32	1.39e-11	Corneal structure;
LUAD	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg22676075	chr6:135203613	NA	0.42	7.79	0.35	5.41e-14	Red blood cell count;
LUAD	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg08470875	chr2:26401718	FAM59B	-0.77	-10.37	-0.45	1.36e-22	Gut microbiome composition (summer);
LUAD	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg00277334	chr10:82204260	NA	-0.63	-10.56	-0.46	2.73e-23	Post bronchodilator FEV1;
LUAD	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-14.63	-0.58	1.68e-39	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg21475434	chr5:93447410	FAM172A	-0.48	-6.68	-0.31	7.35e-11	Diabetic retinopathy;
LUAD	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg16989719	chr2:238392110	NA	-0.38	-8.11	-0.37	5.66e-15	Prostate cancer;
LUAD	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg07432352	chr17:45403706	C17orf57	-0.38	-7.35	-0.34	1.01e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg21782813	chr7:2030301	MAD1L1	0.41	6.76	0.31	4.66e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-7.44	-0.34	5.83e-13	Resting heart rate;
LUAD	cis	rs1712517	0.524	rs4917384	chr10:104995788	T/C	cg04362960	chr10:104952993	NT5C2	0.43	6.59	0.31	1.28e-10	Migraine;
LUAD	trans	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg26043149	chr18:55253948	FECH	0.48	7.72	0.35	8.24e-14	Bone mineral density;
LUAD	trans	rs7395662	0.963	rs4882170	chr11:48724214	C/T	cg15704280	chr7:45808275	SEPT13	-0.41	-6.35	-0.3	5.43e-10	HDL cholesterol;
LUAD	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg19875535	chr5:140030758	IK	0.42	7.11	0.33	4.98e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg07936489	chr17:37558343	FBXL20	0.5	6.72	0.31	5.74e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg15557168	chr22:42548783	NA	0.51	9.44	0.42	2.5e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.43	-7.27	-0.33	1.78e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg11822812	chr5:140052017	DND1	0.38	6.73	0.31	5.4e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg23950597	chr19:37808831	NA	-0.6	-7.52	-0.34	3.32e-13	Coronary artery calcification;
LUAD	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg20203395	chr5:56204925	C5orf35	-0.82	-11.64	-0.49	2.35e-27	Initial pursuit acceleration;
LUAD	cis	rs113835537	0.866	rs59320108	chr11:66365996	A/T	cg24851651	chr11:66362959	CCS	0.59	8.08	0.37	6.73e-15	Airway imaging phenotypes;
LUAD	cis	rs57994353	0.897	rs35526483	chr9:139364940	G/A	cg13856295	chr9:139396418	NOTCH1	-0.43	-6.94	-0.32	1.5e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg11502198	chr6:26597334	ABT1	0.54	9.14	0.41	2.56e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg26446133	chr18:72167187	CNDP2	-0.92	-16.19	-0.62	3.3e-46	Refractive error;
LUAD	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg25828334	chr19:18545568	ISYNA1	-0.37	-7.31	-0.34	1.32e-12	Breast cancer;
LUAD	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg27170947	chr2:26402098	FAM59B	-0.69	-9.41	-0.42	3.19e-19	Gut microbiome composition (summer);
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg01518846	chr6:26246970	HIST1H4G	0.41	7.06	0.32	6.91e-12	Schizophrenia;
LUAD	cis	rs6594713	0.717	rs13436825	chr5:112817687	T/A	cg12552261	chr5:112820674	MCC	0.6	9.1	0.4	3.69e-18	Brain cytoarchitecture;
LUAD	trans	rs12517041	1.000	rs4701360	chr5:23292240	C/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.49	-0.3	2.44e-10	Calcium levels;
LUAD	cis	rs6961069	0.868	rs1194182	chr7:80231504	G/C	cg04458919	chr7:80252533	CD36	-0.34	-6.37	-0.3	5.04e-10	Platelet count;
LUAD	trans	rs3780486	0.846	rs10971438	chr9:33180308	A/G	cg04842962	chr6:43655489	MRPS18A	0.94	18.24	0.66	2.9e-55	IgG glycosylation;
LUAD	cis	rs9868809	0.772	rs34096717	chr3:48719453	A/C	cg00383909	chr3:49044727	WDR6	0.74	8.18	0.37	3.33e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7617773	0.780	rs6793223	chr3:48364101	C/T	cg11946769	chr3:48343235	NME6	0.45	6.89	0.32	2.05e-11	Coronary artery disease;
LUAD	cis	rs12760731	0.720	rs16852801	chr1:178403134	A/T	cg00404053	chr1:178313656	RASAL2	-0.53	-7.09	-0.33	5.72e-12	Obesity-related traits;
LUAD	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg17063962	chr7:91808500	NA	0.72	12.9	0.53	2.35e-32	Breast cancer;
LUAD	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg08779649	chr13:50194554	NA	-0.39	-7.93	-0.36	1.93e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	trans	rs783540	0.900	rs12916980	chr15:83306447	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.45	-7.42	-0.34	6.42e-13	Schizophrenia;
LUAD	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg26169700	chr22:42538906	CYP2D7P1	0.6	7.14	0.33	4.09e-12	Birth weight;
LUAD	cis	rs9487051	0.737	rs1260593	chr6:109521400	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.79	-0.31	3.92e-11	Reticulocyte fraction of red cells;
LUAD	cis	rs807669	0.807	rs698422	chr22:19205826	A/T	cg24911827	chr22:19170109	CLTCL1	0.31	6.51	0.3	2.13e-10	Metabolite levels;
LUAD	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg05187965	chr10:45406764	TMEM72	-0.42	-8.21	-0.37	2.67e-15	Mean corpuscular volume;
LUAD	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg18827107	chr12:86230957	RASSF9	-0.54	-9.47	-0.42	1.97e-19	Major depressive disorder;
LUAD	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.88	-0.32	2.14e-11	Type 2 diabetes;
LUAD	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg03983476	chr2:10830698	NOL10	-0.48	-8.41	-0.38	6.17e-16	Prostate cancer;
LUAD	cis	rs4481887	0.720	rs4543835	chr1:248468608	A/T	cg00666640	chr1:248458726	OR2T12	0.32	7.73	0.35	7.71e-14	Common traits (Other);
LUAD	cis	rs1561288	1.000	rs4665768	chr2:25372229	C/A	cg10045137	chr2:25383940	POMC	-0.36	-6.36	-0.3	5.11e-10	Body mass index;
LUAD	cis	rs2692947	0.770	rs6719831	chr2:96502590	A/C	cg23100626	chr2:96804247	ASTL	0.31	7.74	0.35	7.39e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs3916	0.641	rs7964786	chr12:121132100	C/T	cg27246729	chr12:121163418	ACADS	0.37	6.75	0.31	4.94e-11	Urinary metabolites (H-NMR features);
LUAD	cis	rs13064411	0.542	rs9877649	chr3:113226874	C/T	cg10517650	chr3:113235015	CCDC52	-0.45	-8.28	-0.37	1.61e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs4638749	0.953	rs12475415	chr2:108860477	G/A	cg25838818	chr2:108905173	SULT1C2	-0.55	-8.63	-0.39	1.25e-16	Blood pressure;
LUAD	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg09835421	chr16:68378352	PRMT7	-0.74	-8.48	-0.38	3.69e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg06784218	chr1:46089804	CCDC17	0.5	11.05	0.47	4.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs35205176	1.000	rs11769683	chr7:51616830	G/A	cg20478239	chr7:51544475	NA	-0.33	-6.36	-0.3	5.18e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs5756813	0.754	rs4821711	chr22:38181115	C/T	cg06521852	chr22:38141419	TRIOBP	0.49	9.28	0.41	8.83e-19	Optic cup area;Vertical cup-disc ratio;
LUAD	trans	rs258892	0.947	rs17606	chr5:72184098	C/T	cg14879065	chr14:104662468	NA	-0.35	-6.35	-0.3	5.49e-10	Small cell lung carcinoma;
LUAD	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg02428538	chr16:24856791	SLC5A11	-0.5	-7.03	-0.32	8.24e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg08132940	chr7:1081526	C7orf50	-0.69	-10.08	-0.44	1.49e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	7.03	0.32	8.26e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs6987853	0.661	rs6988493	chr8:42351328	C/T	cg09913449	chr8:42400586	C8orf40	-0.42	-7.83	-0.36	3.9e-14	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg18867708	chr6:26865862	GUSBL1	0.45	7.46	0.34	5.06e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg13319975	chr6:146136371	FBXO30	-0.59	-10.13	-0.44	9.82e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.63	12.36	0.52	3.43e-30	Hemoglobin concentration;
LUAD	cis	rs977987	0.806	rs11642572	chr16:75452782	C/T	cg03315344	chr16:75512273	CHST6	0.64	14.06	0.56	4.12e-37	Dupuytren's disease;
LUAD	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.86	-0.36	3.31e-14	Monocyte percentage of white cells;
LUAD	trans	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg14343924	chr8:8086146	FLJ10661	0.45	6.9	0.32	1.92e-11	Neuroticism;
LUAD	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg04539111	chr16:67997858	SLC12A4	-0.59	-6.92	-0.32	1.67e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg26384229	chr12:38710491	ALG10B	0.49	7.9	0.36	2.47e-14	Morning vs. evening chronotype;
LUAD	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg24768116	chr2:27665128	KRTCAP3	-0.39	-10.76	-0.46	5.17e-24	Total body bone mineral density;
LUAD	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg13319975	chr6:146136371	FBXO30	-0.62	-10.88	-0.47	1.72e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7191700	0.644	rs12149160	chr16:11439303	G/T	cg00044050	chr16:11439710	C16orf75	-0.71	-12.03	-0.5	7.32e-29	Multiple sclerosis;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg27447677	chr2:122407204	CLASP1	-0.39	-6.44	-0.3	3.35e-10	Cancer;
LUAD	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22968622	chr17:43663579	NA	1.4	25.76	0.78	1.04e-88	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg06715136	chr7:158046025	PTPRN2	0.35	6.4	0.3	4.17e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	trans	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg18834416	chr8:37888184	EIF4EBP1	0.43	7.3	0.33	1.45e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9486719	1.000	rs1303852	chr6:96864523	C/T	cg06623918	chr6:96969491	KIAA0776	0.71	9.96	0.44	3.8e-21	Migraine;Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.41	0.38	6.26e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg10518543	chr12:38710700	ALG10B	-0.51	-8.48	-0.38	3.71e-16	Morning vs. evening chronotype;
LUAD	cis	rs3087591	0.960	rs9898664	chr17:29567152	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.42	-6.77	-0.31	4.29e-11	Hip circumference;
LUAD	cis	rs4711350	0.765	rs943476	chr6:33750086	A/G	cg16010596	chr6:33739607	LEMD2	-0.4	-7.28	-0.33	1.67e-12	Schizophrenia;
LUAD	cis	rs2742417	1.000	rs767280	chr3:45771601	C/G	cg10512202	chr3:45649293	LIMD1	0.39	6.97	0.32	1.2e-11	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg20283391	chr11:68216788	NA	-0.41	-6.49	-0.3	2.39e-10	Total body bone mineral density;
LUAD	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg11502198	chr6:26597334	ABT1	-0.45	-7.18	-0.33	3.07e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg07988820	chr12:82153109	PPFIA2	-0.47	-7.36	-0.34	9.4e-13	Resting heart rate;
LUAD	cis	rs1018836	0.923	rs11784529	chr8:91640956	C/A	cg16814680	chr8:91681699	NA	-0.67	-11.4	-0.48	1.91e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs3806843	0.547	rs246054	chr5:140326159	G/A	cg18668511	chr5:140557227	PCDHB8	-0.36	-6.42	-0.3	3.68e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1461503	0.966	rs1461504	chr11:122845129	T/C	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs7582720	1.000	rs72926786	chr2:203816494	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs73198271	0.562	rs964772	chr8:8651306	A/G	cg01851573	chr8:8652454	MFHAS1	0.7	11.29	0.48	4.91e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs7395662	1.000	rs4882111	chr11:48558447	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.32	-0.34	1.25e-12	HDL cholesterol;
LUAD	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.91	0.53	2.32e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg09197432	chr4:183729176	NA	0.62	8.18	0.37	3.44e-15	Pediatric autoimmune diseases;
LUAD	cis	rs151234	0.741	rs3194168	chr16:28603012	A/G	cg04609801	chr16:28609176	SULT1A2	0.62	8.82	0.39	2.95e-17	Platelet distribution width;
LUAD	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg26769984	chr7:1090371	C7orf50	0.64	9.82	0.43	1.19e-20	Bronchopulmonary dysplasia;
LUAD	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.64	8.82	0.39	3.11e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg04539111	chr16:67997858	SLC12A4	-0.54	-7.05	-0.32	7.28e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg25894440	chr7:65020034	NA	0.63	6.74	0.31	5.21e-11	Diabetic kidney disease;
LUAD	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg14092988	chr3:52407081	DNAH1	0.39	7.85	0.36	3.37e-14	Electroencephalogram traits;
LUAD	cis	rs2282300	0.739	rs6484478	chr11:30306440	A/G	cg25418670	chr11:30344373	C11orf46	0.53	7.25	0.33	2.02e-12	Morning vs. evening chronotype;
LUAD	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg22117172	chr7:91764530	CYP51A1	-0.35	-7.6	-0.35	1.99e-13	Breast cancer;
LUAD	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs790123	0.553	rs1106346	chr3:122354037	A/G	cg22896480	chr3:122379438	NA	0.38	6.47	0.3	2.71e-10	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg17724175	chr1:150552817	MCL1	0.3	7.01	0.32	9.53e-12	Melanoma;
LUAD	cis	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.92	-0.32	1.71e-11	Neuroticism;
LUAD	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.730	rs1902248	chr2:198492598	C/T	cg00982548	chr2:198649783	BOLL	-0.55	-7.89	-0.36	2.69e-14	Ulcerative colitis;
LUAD	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg13732083	chr21:47605072	C21orf56	0.41	6.82	0.31	3.2e-11	Testicular germ cell tumor;
LUAD	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg06784218	chr1:46089804	CCDC17	-0.6	-13.41	-0.55	1.98e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg08514558	chr10:81106712	PPIF	0.51	10.15	0.44	8.59e-22	Height;
LUAD	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg25237894	chr2:233734115	C2orf82	0.62	11.89	0.5	2.48e-28	Coronary artery disease;
LUAD	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg15017067	chr4:17643749	FAM184B	0.37	7.3	0.33	1.45e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg00634984	chr7:65235879	NA	0.5	6.61	0.31	1.13e-10	Aortic root size;
LUAD	trans	rs79911532	0.551	rs11553096	chr7:75677216	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	8.66	0.39	9.81e-17	Mononucleosis;
LUAD	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg21153622	chr11:89784906	NA	-0.34	-6.92	-0.32	1.66e-11	HDL cholesterol;
LUAD	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg03433033	chr1:76189801	ACADM	0.74	11.13	0.48	1.99e-25	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg00204512	chr16:28754710	NA	0.31	6.36	0.3	5.21e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg23752985	chr2:85803571	VAMP8	0.34	6.62	0.31	1.08e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs3018712	0.522	rs4930595	chr11:68435827	A/G	cg16797656	chr11:68205561	LRP5	-0.34	-6.44	-0.3	3.22e-10	Total body bone mineral density;
LUAD	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg19163074	chr7:65112434	INTS4L2	0.44	6.74	0.31	5.17e-11	Aortic root size;
LUAD	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg22029157	chr1:209979665	IRF6	0.79	9.47	0.42	2.02e-19	Coronary artery disease;
LUAD	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg07527032	chr15:84868466	LOC388152	0.43	6.44	0.3	3.25e-10	Schizophrenia;
LUAD	cis	rs4372836	0.928	rs55836936	chr2:28922833	T/C	cg09522027	chr2:28974177	PPP1CB	0.6	9.37	0.41	4.43e-19	Body mass index;
LUAD	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg12011299	chr4:100065546	ADH4	-0.66	-11.85	-0.5	3.7e-28	Smoking initiation;
LUAD	cis	rs17092148	1.000	rs7265992	chr20:33525407	G/A	cg16810054	chr20:33298113	TP53INP2	0.53	8.3	0.37	1.37e-15	Neuroticism;
LUAD	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg02176678	chr2:219576539	TTLL4	0.75	12.98	0.53	1.19e-32	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg04267008	chr7:1944627	MAD1L1	0.46	6.51	0.3	2.1e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs3849570	0.925	rs6799080	chr3:81905591	G/A	cg07356753	chr3:81810745	GBE1	-0.61	-10.69	-0.46	9.12e-24	Waist circumference;Body mass index;
LUAD	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg12564285	chr5:131593104	PDLIM4	0.37	6.45	0.3	3.14e-10	Breast cancer;
LUAD	cis	rs7759001	0.817	rs10080571	chr6:27363150	G/C	cg18711553	chr6:27366782	ZNF391	0.4	6.55	0.3	1.7e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.61	-6.47	-0.3	2.69e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.07	-0.33	6.41e-12	Breast cancer;
LUAD	cis	rs714027	1.000	rs2412973	chr22:30529631	C/A	cg00539347	chr22:30592296	NA	-0.28	-6.67	-0.31	8.03e-11	Lymphocyte counts;
LUAD	cis	rs1232027	0.700	rs2560423	chr5:79929174	T/G	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.87	-0.36	3.07e-14	Huntington's disease progression;
LUAD	cis	rs11214589	0.806	rs4551806	chr11:113250540	T/A	cg14159747	chr11:113255604	NA	0.69	14.76	0.58	4.52e-40	Neuroticism;
LUAD	cis	rs977987	0.806	rs11862582	chr16:75431295	T/C	cg03315344	chr16:75512273	CHST6	0.64	14.28	0.57	4.98e-38	Dupuytren's disease;
LUAD	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.58	8.06	0.36	7.87e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs2274273	0.564	rs3783649	chr14:55834410	G/A	cg04306507	chr14:55594613	LGALS3	0.43	8.29	0.37	1.56e-15	Protein biomarker;
LUAD	cis	rs10865541	0.870	rs6548161	chr2:3424350	A/G	cg13173536	chr2:3403300	TTC15	-0.35	-6.75	-0.31	4.8e-11	Obesity-related traits;
LUAD	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg08071915	chr8:12219732	FAM66A	0.44	7.18	0.33	3.13e-12	Joint mobility (Beighton score);
LUAD	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg02734326	chr4:10020555	SLC2A9	0.63	11.31	0.48	4.46e-26	Bone mineral density;
LUAD	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg06784218	chr1:46089804	CCDC17	-0.53	-11.84	-0.5	3.99e-28	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg22117172	chr7:91764530	CYP51A1	0.35	7.78	0.35	5.46e-14	Breast cancer;
LUAD	cis	rs7582720	1.000	rs72932777	chr2:203689914	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.38	0.41	4.03e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs12900413	0.687	rs12908343	chr15:90319095	C/T	cg24249390	chr15:90295951	MESP1	-0.35	-7.01	-0.32	9.56e-12	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs15676	0.783	rs10988134	chr9:131595407	C/T	cg00228799	chr9:131580591	ENDOG	-0.45	-6.9	-0.32	1.9e-11	Blood metabolite levels;
LUAD	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg00074818	chr8:8560427	CLDN23	0.67	10.19	0.44	6.11e-22	Obesity-related traits;
LUAD	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg03188948	chr7:1209495	NA	0.4	6.53	0.3	1.9e-10	Longevity;Endometriosis;
LUAD	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg03037974	chr15:76606532	NA	-0.38	-8.35	-0.38	9.93e-16	Blood metabolite levels;
LUAD	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg06484146	chr7:12443880	VWDE	-0.6	-7.68	-0.35	1.09e-13	Coronary artery disease;
LUAD	cis	rs775227	0.574	rs2018912	chr3:113060140	A/G	cg18753928	chr3:113234510	CCDC52	-0.65	-8.57	-0.38	2.01e-16	Dental caries;
LUAD	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg02269571	chr22:50332266	NA	-0.67	-9.6	-0.42	7.1e-20	Schizophrenia;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg13096724	chr17:27507606	MYO18A	-0.45	-7.13	-0.33	4.49e-12	Height;
LUAD	cis	rs9905704	0.633	rs2680694	chr17:56469869	T/C	cg19466818	chr17:56409534	MIR142	0.35	7.08	0.33	6.17e-12	Testicular germ cell tumor;
LUAD	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg11859384	chr17:80120422	CCDC57	0.42	7.29	0.33	1.54e-12	Life satisfaction;
LUAD	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg15704280	chr7:45808275	SEPT13	-0.63	-8.39	-0.38	7.13e-16	Axial length;
LUAD	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg08859206	chr1:53392774	SCP2	0.59	10.63	0.46	1.54e-23	Monocyte count;
LUAD	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg16031515	chr1:205743344	RAB7L1	-0.37	-7.3	-0.33	1.46e-12	Menarche (age at onset);
LUAD	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg04414720	chr1:150670196	GOLPH3L	0.73	12.8	0.53	6.25e-32	Melanoma;
LUAD	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg03684893	chr10:554711	DIP2C	-0.38	-6.54	-0.3	1.8e-10	Psychosis in Alzheimer's disease;
LUAD	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg06221963	chr1:154839813	KCNN3	-0.85	-20.06	-0.7	2.11e-63	Prostate cancer;
LUAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg04025307	chr7:1156635	C7orf50	0.8	14.86	0.59	1.75e-40	Longevity;Endometriosis;
LUAD	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg08989290	chr16:615782	NHLRC4	0.31	6.8	0.31	3.6e-11	Height;
LUAD	cis	rs6061231	0.571	rs482010	chr20:60927551	A/G	cg24112000	chr20:60950667	NA	0.77	13.14	0.54	2.56e-33	Colorectal cancer;
LUAD	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.44	-7.71	-0.35	9.39e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg19318889	chr4:1322082	MAEA	0.9	15.39	0.6	8.96e-43	Longevity;
LUAD	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03934478	chr11:495069	RNH1	0.75	8.9	0.4	1.64e-17	Body mass index;
LUAD	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg11905131	chr22:24372483	LOC391322	0.52	8.55	0.38	2.28e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg24069376	chr3:38537580	EXOG	-0.45	-11.06	-0.47	3.84e-25	Electrocardiographic conduction measures;
LUAD	cis	rs9837602	1.000	rs923470	chr3:99757792	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-7.04	-0.32	7.59e-12	Breast cancer;
LUAD	cis	rs9811920	0.715	rs1017967	chr3:99905803	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.47	8.71	0.39	6.92e-17	Axial length;
LUAD	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg04287289	chr16:89883240	FANCA	0.72	13.35	0.54	3.53e-34	Vitiligo;
LUAD	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg01475377	chr6:109611718	NA	-0.52	-10.05	-0.44	1.87e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg03806693	chr22:41940476	POLR3H	-0.76	-10.21	-0.44	5.17e-22	Vitiligo;
LUAD	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg12011299	chr4:100065546	ADH4	-0.74	-13.68	-0.55	1.58e-35	Alcohol dependence;
LUAD	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg15147215	chr3:52552868	STAB1	-0.36	-6.5	-0.3	2.25e-10	Bipolar disorder;
LUAD	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg03859395	chr2:55845619	SMEK2	0.7	12.47	0.52	1.29e-30	Metabolic syndrome;
LUAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg25181941	chr17:40805728	NA	0.37	7.12	0.33	4.72e-12	Colorectal or endometrial cancer;
LUAD	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg07266350	chr3:49460521	AMT;NICN1	0.37	6.49	0.3	2.36e-10	Menarche (age at onset);
LUAD	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg17366294	chr4:99064904	C4orf37	0.66	12.61	0.52	3.64e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg09658497	chr7:2847517	GNA12	-0.47	-7.9	-0.36	2.42e-14	Height;
LUAD	cis	rs600626	0.529	rs59913369	chr11:75473265	A/G	cg24262691	chr11:75473276	NA	0.6	8.29	0.37	1.5e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg05082376	chr22:42548792	NA	0.45	7.85	0.36	3.38e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg27284194	chr4:1044797	NA	0.7	10.13	0.44	9.73e-22	Recombination rate (females);
LUAD	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg14458575	chr2:238380390	NA	0.79	16.24	0.62	1.89e-46	Prostate cancer;
LUAD	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.35	7.01	0.32	9.61e-12	Obesity-related traits;
LUAD	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg20701182	chr2:24300061	SF3B14	0.56	6.65	0.31	8.93e-11	Lymphocyte counts;
LUAD	cis	rs2637266	1.000	rs2894339	chr10:78354104	G/A	cg18941641	chr10:78392320	NA	0.33	6.97	0.32	1.25e-11	Pulmonary function;
LUAD	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg17551891	chr7:1960795	MAD1L1	-0.45	-7.34	-0.34	1.11e-12	Bipolar disorder;
LUAD	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg14926445	chr8:58193284	C8orf71	-0.49	-7.15	-0.33	3.95e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg02221422	chr11:68192511	LRP5	-0.44	-7.18	-0.33	3.11e-12	Total body bone mineral density;
LUAD	cis	rs62045849	0.557	rs4782444	chr16:89183973	A/G	cg26950739	chr16:89183275	ACSF3	0.56	6.36	0.3	5.31e-10	Red blood cell count;
LUAD	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg00933542	chr6:150070202	PCMT1	0.44	9.2	0.41	1.65e-18	Lung cancer;
LUAD	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg02951883	chr7:2050386	MAD1L1	-0.63	-10.3	-0.45	2.44e-22	Schizophrenia;
LUAD	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06022373	chr22:39101656	GTPBP1	0.44	6.67	0.31	7.92e-11	Menopause (age at onset);
LUAD	cis	rs55823223	0.752	rs34974290	chr17:73888354	G/A	cg04225089	chr17:73874465	TRIM47	-0.45	-7.65	-0.35	1.42e-13	Psoriasis;
LUAD	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.55	-0.3	1.65e-10	Aortic root size;
LUAD	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg11166453	chr1:247681781	NA	-0.4	-8.13	-0.37	4.68e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg26818010	chr10:134567672	INPP5A	-0.86	-14.76	-0.58	4.42e-40	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg06781209	chr11:61594997	FADS2	-0.4	-7.39	-0.34	8.17e-13	Trans fatty acid levels;
LUAD	cis	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-8.03	-0.36	1.01e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.53	-0.34	3.18e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs240764	0.658	rs7768210	chr6:101261494	C/T	cg09795085	chr6:101329169	ASCC3	0.44	7.74	0.35	7.21e-14	Neuroticism;
LUAD	cis	rs2455799	0.613	rs11128762	chr3:15883439	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-9.62	-0.42	6.09e-20	Mean platelet volume;
LUAD	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg18402987	chr7:1209562	NA	0.62	8.91	0.4	1.55e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg19894588	chr14:64061835	NA	-0.46	-6.59	-0.31	1.33e-10	Optic cup area;Vertical cup-disc ratio;
LUAD	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg22491629	chr6:157744540	C6orf35	-0.79	-9.06	-0.4	4.72e-18	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs2414856	0.510	rs12102207	chr15:64607472	A/G	cg08069370	chr15:64387884	SNX1	-0.8	-6.91	-0.32	1.78e-11	Pulse pressure;Systolic blood pressure;
LUAD	trans	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg01620082	chr3:125678407	NA	-0.71	-7.15	-0.33	3.79e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.22	13.25	0.54	9.54e-34	Lung cancer in ever smokers;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08914844	chr7:86688919	KIAA1324L	-0.69	-7.28	-0.33	1.61e-12	Type 2 diabetes;
LUAD	cis	rs4588572	0.643	rs1560197	chr5:77768302	T/C	cg11547950	chr5:77652471	NA	-0.78	-12.41	-0.52	2.16e-30	Triglycerides;
LUAD	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18876405	chr7:65276391	NA	-0.57	-9.57	-0.42	9.29e-20	Aortic root size;
LUAD	cis	rs17608059	0.524	rs9897978	chr17:13900256	G/T	cg27005118	chr17:13972210	COX10	0.34	6.53	0.3	1.87e-10	Temperament;
LUAD	cis	rs7192380	0.895	rs2917671	chr16:69758741	A/T	cg26679644	chr16:69762563	NA	-0.52	-10.07	-0.44	1.65e-21	Sjögren's syndrome;
LUAD	trans	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg24644049	chr4:85504048	CDS1	0.91	7.72	0.35	8.48e-14	Skin colour saturation;
LUAD	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	7.8	0.35	4.77e-14	Breast cancer;
LUAD	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.27	0.33	1.79e-12	Menopause (age at onset);
LUAD	cis	rs9302065	1.000	rs7490267	chr13:95970258	T/C	cg26751094	chr13:95954534	ABCC4	-0.38	-7.78	-0.35	5.66e-14	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg03467027	chr4:99064603	C4orf37	0.42	6.79	0.31	3.9e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg05434287	chr7:2030229	MAD1L1	0.39	6.37	0.3	4.9e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg21775007	chr8:11205619	TDH	-0.41	-7.29	-0.33	1.49e-12	Retinal vascular caliber;
LUAD	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg24154853	chr7:158122151	PTPRN2	0.58	11.54	0.49	5.56e-27	Calcium levels;
LUAD	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg07936489	chr17:37558343	FBXL20	0.51	6.98	0.32	1.14e-11	Glomerular filtration rate (creatinine);
LUAD	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg21724239	chr8:58056113	NA	0.66	8.66	0.39	9.86e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	10.66	0.46	1.12e-23	Type 2 diabetes;
LUAD	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg06784218	chr1:46089804	CCDC17	0.6	13.33	0.54	4.38e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg14416269	chr4:6271139	WFS1	0.6	12.55	0.52	6.06e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs4730250	0.707	rs6960148	chr7:106786142	A/G	cg23024343	chr7:107201750	COG5	-0.5	-6.79	-0.31	3.73e-11	Osteoarthritis;
LUAD	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.31	6.78	0.31	4.11e-11	Obesity-related traits;
LUAD	cis	rs420259	0.516	rs152455	chr16:23583073	G/A	cg00143387	chr16:23521605	GGA2	0.71	9.96	0.44	4.03e-21	Bipolar disorder;
LUAD	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23158103	chr7:148848205	ZNF398	-0.63	-11.48	-0.49	9.87e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg26043149	chr18:55253948	FECH	-0.48	-8.16	-0.37	3.95e-15	Bone mineral density;
LUAD	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-9.06	-0.4	4.8e-18	Lymphocyte counts;
LUAD	cis	rs7216064	0.953	rs75231441	chr17:65885485	A/G	cg08758996	chr17:66097529	LOC651250	0.47	7.17	0.33	3.41e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg24818145	chr4:99064322	C4orf37	0.46	7.78	0.35	5.45e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9297145	1.000	rs10953280	chr7:98763405	A/G	cg05967295	chr7:98741636	SMURF1	-0.89	-16.43	-0.62	2.93e-47	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUAD	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg27661571	chr11:113659931	NA	-0.69	-8.1	-0.37	6.04e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs427394	0.796	rs274683	chr5:6747950	T/A	cg10857441	chr5:6722123	POLS	-0.55	-9.59	-0.42	7.52e-20	Menopause (age at onset);
LUAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg16606324	chr3:10149918	C3orf24	0.73	10.43	0.45	8.01e-23	Alzheimer's disease;
LUAD	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg05896524	chr21:47604654	C21orf56	0.54	9.05	0.4	5.18e-18	Testicular germ cell tumor;
LUAD	cis	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg08798685	chr6:27730294	NA	-0.47	-6.9	-0.32	1.91e-11	Parkinson's disease;
LUAD	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.63	-10.64	-0.46	1.37e-23	Glomerular filtration rate;
LUAD	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.44	-7.24	-0.33	2.07e-12	Tonsillectomy;
LUAD	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg03037974	chr15:76606532	NA	0.39	8.68	0.39	8.68e-17	Blood metabolite levels;
LUAD	trans	rs9914544	1.000	rs6502677	chr17:18803658	A/G	cg21372672	chr17:16614065	CCDC144A	-0.4	-6.65	-0.31	8.81e-11	Educational attainment (years of education);
LUAD	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg21138405	chr5:131827807	IRF1	0.6	13.88	0.56	2.35e-36	Asthma (sex interaction);
LUAD	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08219700	chr8:58056026	NA	0.62	8.82	0.39	3.1e-17	Developmental language disorder (linguistic errors);
LUAD	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.88	-0.32	2.12e-11	Neuroticism;
LUAD	cis	rs2996428	0.709	rs6667255	chr1:3711689	T/C	cg17848003	chr1:3704513	LRRC47	0.53	10.56	0.46	2.8e-23	Red cell distribution width;
LUAD	cis	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg24803719	chr17:45855879	NA	-0.34	-6.71	-0.31	6.18e-11	IgG glycosylation;
LUAD	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08280861	chr8:58055591	NA	0.53	6.74	0.31	5.33e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg13319975	chr6:146136371	FBXO30	-0.68	-11.3	-0.48	4.51e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg00745463	chr17:30367425	LRRC37B	-1.07	-12.32	-0.51	5.31e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs13064411	0.597	rs2291905	chr3:113010466	C/T	cg10517650	chr3:113235015	CCDC52	-0.4	-6.93	-0.32	1.6e-11	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs1215050	0.791	rs1585088	chr4:98675071	C/A	cg24818145	chr4:99064322	C4orf37	-0.41	-6.77	-0.31	4.4e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs1595825	0.786	rs77773624	chr2:198514845	G/A	cg11031976	chr2:198649780	BOLL	-0.46	-6.81	-0.31	3.32e-11	Ulcerative colitis;
LUAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00149659	chr3:10157352	C3orf10	0.55	7.73	0.35	8.14e-14	Alzheimer's disease;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg03390569	chr2:54013802	LOC100302652;ASB3;ERLEC1	-0.45	-6.38	-0.3	4.78e-10	Testicular germ cell tumor;
LUAD	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg18621852	chr3:10150065	C3orf24	0.52	9.27	0.41	9.58e-19	Alzheimer's disease;
LUAD	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg03433033	chr1:76189801	ACADM	-1.01	-25.04	-0.77	1.55e-85	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9837602	1.000	rs35669453	chr3:99766063	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-6.97	-0.32	1.25e-11	Breast cancer;
LUAD	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg04414720	chr1:150670196	GOLPH3L	0.73	13.38	0.55	2.81e-34	Melanoma;
LUAD	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg15704280	chr7:45808275	SEPT13	-1.0	-20.37	-0.7	9.1e-65	Coronary artery disease;
LUAD	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg15181151	chr6:150070149	PCMT1	0.37	7.37	0.34	9.09e-13	Lung cancer;
LUAD	trans	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg03886242	chr7:26192032	NFE2L3	0.45	7.82	0.36	4.22e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg05368731	chr17:41323189	NBR1	0.96	20.03	0.7	3.01e-63	Menopause (age at onset);
LUAD	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg09085632	chr11:111637200	PPP2R1B	0.64	9.78	0.43	1.71e-20	Primary sclerosing cholangitis;
LUAD	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg01874867	chr7:94954059	PON1	-0.66	-11.67	-0.49	1.76e-27	Paraoxonase activity;
LUAD	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.46	-8.07	-0.37	7.25e-15	Caffeine consumption;
LUAD	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg13180566	chr4:1052158	NA	-0.4	-6.78	-0.31	4.04e-11	Recombination rate (females);
LUAD	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.43	-7.28	-0.33	1.59e-12	Longevity;Endometriosis;
LUAD	cis	rs494562	0.892	rs550499	chr6:86115602	G/C	cg27297263	chr6:86160468	NT5E	0.58	6.42	0.3	3.66e-10	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg03676636	chr4:99064102	C4orf37	0.35	9.12	0.41	3.01e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2742234	0.590	rs1254962	chr10:43696992	G/A	cg15436174	chr10:43711423	RASGEF1A	0.52	8.72	0.39	6.42e-17	Hirschsprung disease;
LUAD	cis	rs7903847	0.656	rs12412478	chr10:99134923	C/T	cg20016023	chr10:99160130	RRP12	-0.33	-7.22	-0.33	2.39e-12	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs6684514	0.885	rs12036837	chr1:156283895	A/C	cg16558208	chr1:156270281	VHLL	0.54	9.74	0.43	2.28e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg17724175	chr1:150552817	MCL1	0.39	9.29	0.41	7.94e-19	Tonsillectomy;
LUAD	cis	rs12618769	0.597	rs3754893	chr2:99063149	T/A	cg10123293	chr2:99228465	UNC50	0.46	8.11	0.37	5.48e-15	Bipolar disorder;
LUAD	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg11189052	chr15:85197271	WDR73	0.68	8.92	0.4	1.38e-17	Schizophrenia;
LUAD	cis	rs2249625	0.545	rs2496505	chr6:72891063	C/G	cg18830697	chr6:72922368	RIMS1	-0.45	-8.34	-0.38	1.1e-15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUAD	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg27284194	chr4:1044797	NA	0.71	10.26	0.45	3.2800000000000002e-22	Recombination rate (females);
LUAD	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.52	6.91	0.32	1.78e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg00280220	chr17:61926910	NA	0.35	6.75	0.31	4.86e-11	Prudent dietary pattern;
LUAD	cis	rs12208915	0.945	rs12201183	chr6:79570120	A/G	cg09184832	chr6:79620586	NA	0.53	6.42	0.3	3.64e-10	Left atrial antero-posterior diameter;
LUAD	cis	rs4862307	0.514	rs7696176	chr4:185014390	A/G	cg06737308	chr4:185021514	ENPP6	0.79	15.38	0.6	9.84e-43	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg04455712	chr21:45112962	RRP1B	-0.48	-9.4	-0.42	3.47e-19	Mean corpuscular volume;
LUAD	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg06740227	chr12:86229804	RASSF9	0.44	7.69	0.35	1.07e-13	Major depressive disorder;
LUAD	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg17177755	chr1:15930204	NA	0.44	7.02	0.32	8.92e-12	Systolic blood pressure;
LUAD	trans	rs9408928	0.778	rs9409230	chr9:123967760	A/T	cg10880995	chr3:57541826	PDE12	0.65	6.4	0.3	4.22e-10	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg06199346	chr11:14280333	SPON1	0.34	6.93	0.32	1.57e-11	Mitochondrial DNA levels;
LUAD	cis	rs2835872	0.931	rs10483038	chr21:39024771	T/C	cg06728970	chr21:39037746	KCNJ6	-0.4	-7.27	-0.33	1.8e-12	Electroencephalographic traits in alcoholism;
LUAD	cis	rs17095355	0.901	rs7069128	chr10:111760075	C/T	cg00817464	chr10:111662876	XPNPEP1	0.62	8.28	0.37	1.64e-15	Biliary atresia;
LUAD	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg20891558	chr2:74357851	NA	0.86	15.0	0.59	4.15e-41	Gestational age at birth (maternal effect);
LUAD	cis	rs7818345	0.967	rs4546679	chr8:19283335	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.33	7.21	0.33	2.65e-12	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs7528419	1.000	rs629301	chr1:109818306	G/T	cg00908766	chr1:109817496	CELSR2	0.7	14.14	0.57	1.88e-37	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.91	0.36	2.29e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg13385794	chr1:248469461	NA	0.25	6.81	0.31	3.26e-11	Common traits (Other);
LUAD	cis	rs12474201	0.928	rs34186074	chr2:46965010	T/C	cg09399716	chr2:46890238	NA	-0.34	-6.41	-0.3	3.97e-10	Height;
LUAD	cis	rs7192380	0.651	rs61460899	chr16:69682780	T/A	cg26679644	chr16:69762563	NA	0.4	6.53	0.3	1.83e-10	Sjögren's syndrome;
LUAD	cis	rs6484504	0.576	rs208103	chr11:31167400	A/G	cg26647111	chr11:31128758	NA	-0.48	-8.38	-0.38	8.18e-16	Red blood cell count;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg19648955	chr2:177134095	MTX2	-0.37	-6.48	-0.3	2.57e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg24675056	chr1:15929824	NA	0.48	8.36	0.38	8.85e-16	Systolic blood pressure;
LUAD	cis	rs7640424	0.929	rs326358	chr3:107822310	C/T	cg09227934	chr3:107805635	CD47	0.52	9.38	0.42	4.01e-19	Body mass index;
LUAD	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-9.25	-0.41	1.09e-18	Blood metabolite levels;
LUAD	cis	rs11051970	0.838	rs2651369	chr12:32552769	C/G	cg02745156	chr12:32552066	NA	0.36	7.5	0.34	3.85e-13	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg09509183	chr1:209979624	IRF6	0.64	7.77	0.35	5.9e-14	Cleft lip with or without cleft palate;
LUAD	trans	rs3857536	0.813	rs1891600	chr6:66941645	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs10193935	0.792	rs7559001	chr2:42474301	C/T	cg27598129	chr2:42591480	NA	-0.69	-8.75	-0.39	4.97e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg18402987	chr7:1209562	NA	0.76	9.25	0.41	1.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7607369	0.559	rs6741592	chr2:219658609	C/T	cg02176678	chr2:219576539	TTLL4	-0.54	-10.28	-0.45	2.74e-22	Red blood cell count;Amyotrophic lateral sclerosis;
LUAD	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.39	-8.19	-0.37	3.2e-15	Height;
LUAD	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg02574844	chr11:5959923	NA	-0.46	-8.29	-0.37	1.49e-15	DNA methylation (variation);
LUAD	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23583168	chr7:148888333	NA	-0.91	-18.84	-0.68	6.36e-58	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg15318690	chr14:54422052	BMP4	-0.63	-6.37	-0.3	4.86e-10	Type 2 diabetes;
LUAD	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg18105139	chr6:28058856	ZSCAN12L1	0.26	6.53	0.3	1.87e-10	Cardiac Troponin-T levels;
LUAD	cis	rs57502260	0.573	rs11228295	chr11:68388588	C/G	cg16797656	chr11:68205561	LRP5	0.41	7.52	0.34	3.26e-13	Total body bone mineral density (age 45-60);
LUAD	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg16060761	chr17:80687452	NA	0.47	7.08	0.33	5.98e-12	Breast cancer;
LUAD	cis	rs6541297	1.000	rs6686054	chr1:230282853	C/T	cg20703242	chr1:230279135	GALNT2	0.66	12.19	0.51	1.74e-29	Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg17366294	chr4:99064904	C4orf37	0.66	12.69	0.53	1.68e-31	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4319547	0.741	rs4758644	chr12:122943915	A/C	cg23029597	chr12:123009494	RSRC2	-0.43	-6.87	-0.32	2.38e-11	Body mass index;
LUAD	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg27432699	chr2:27873401	GPN1	-0.64	-11.28	-0.48	5.57e-26	Oral cavity cancer;
LUAD	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg09517075	chr8:22133004	PIWIL2	0.48	9.07	0.4	4.61e-18	Hypertriglyceridemia;
LUAD	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.41	7.38	0.34	8.23e-13	Type 2 diabetes;
LUAD	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.4	7.23	0.33	2.25e-12	Blood metabolite levels;
LUAD	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg03676636	chr4:99064102	C4orf37	0.31	8.25	0.37	2.07e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12286929	0.639	rs10891802	chr11:115043888	C/A	cg04055981	chr11:115044050	NA	0.46	8.16	0.37	4e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs62238980	0.614	rs75091642	chr22:32449078	C/A	cg02631450	chr22:32366979	NA	0.76	6.45	0.3	3.08e-10	Childhood ear infection;
LUAD	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg11833968	chr6:79620685	NA	-0.43	-8.06	-0.37	7.66e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg23583168	chr7:148888333	NA	-0.81	-13.29	-0.54	6.34e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUAD	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg20135002	chr11:47629003	NA	-0.41	-7.15	-0.33	3.74e-12	Subjective well-being;
LUAD	cis	rs1524976	0.843	rs11711704	chr3:65444814	T/C	cg16238336	chr3:65465873	MAGI1	-0.68	-7.89	-0.36	2.55e-14	PR interval;
LUAD	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-7.91	-0.36	2.25e-14	Height;Educational attainment;Head circumference (infant);
LUAD	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.41	-0.34	6.88e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs12291225	0.839	rs4757244	chr11:14258655	A/G	cg19336497	chr11:14380999	RRAS2	0.49	9.78	0.43	1.73e-20	Sense of smell;
LUAD	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg15997130	chr1:24165203	NA	0.41	6.76	0.31	4.59e-11	Immature fraction of reticulocytes;
LUAD	cis	rs4604732	0.578	rs79203328	chr1:247626581	C/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.46	7.49	0.34	3.96e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	trans	rs7395662	1.000	rs7395662	chr11:48518893	C/T	cg00717180	chr2:96193071	NA	0.39	7.31	0.33	1.36e-12	HDL cholesterol;
LUAD	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg20090143	chr19:45452003	APOC2	0.39	8.98	0.4	9.29e-18	Blood protein levels;
LUAD	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg08742575	chr21:47604166	C21orf56	0.55	9.68	0.43	3.79e-20	Testicular germ cell tumor;
LUAD	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.49	7.52	0.34	3.26e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	trans	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg14917512	chr19:3094685	GNA11	0.55	6.65	0.31	9.22e-11	Diabetic kidney disease;
LUAD	trans	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg24644049	chr4:85504048	CDS1	0.69	6.62	0.31	1.06e-10	Skin colour saturation;
LUAD	trans	rs2018683	0.707	rs1021690	chr7:28974488	A/G	cg19402173	chr7:128379420	CALU	-0.52	-8.41	-0.38	6.43e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg21433313	chr16:3507492	NAT15	0.76	12.94	0.53	1.64e-32	Tuberculosis;
LUAD	cis	rs2797160	0.905	rs1418640	chr6:125999866	G/A	cg05901451	chr6:126070800	HEY2	-0.45	-6.73	-0.31	5.6e-11	Endometrial cancer;
LUAD	cis	rs2282300	0.739	rs34234618	chr11:30241701	T/C	cg25418670	chr11:30344373	C11orf46	-0.53	-7.09	-0.33	5.5e-12	Morning vs. evening chronotype;
LUAD	trans	rs75804782	0.625	rs72984525	chr2:239469318	T/C	cg01134436	chr17:81009848	B3GNTL1	0.71	7.28	0.33	1.64e-12	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg20628663	chr10:43360327	NA	0.74	11.34	0.48	3.42e-26	Blood protein levels;
LUAD	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.42	6.97	0.32	1.26e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs926938	0.520	rs969273	chr1:115256669	G/A	cg12756093	chr1:115239321	AMPD1	-0.4	-6.52	-0.3	1.99e-10	Autism;
LUAD	cis	rs6987853	0.966	rs2084709	chr8:42423190	A/G	cg09913449	chr8:42400586	C8orf40	0.44	8.41	0.38	6.39e-16	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg05110241	chr16:68378359	PRMT7	-0.8	-8.8	-0.39	3.6e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-9.11	-0.41	3.24e-18	Gut microbiome composition (summer);
LUAD	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg25985355	chr7:65971099	NA	-0.54	-6.64	-0.31	9.78e-11	Diabetic kidney disease;
LUAD	cis	rs17102423	0.723	rs8181938	chr14:65555712	A/G	cg11161011	chr14:65562177	MAX	-0.49	-7.84	-0.36	3.69e-14	Obesity-related traits;
LUAD	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg21153622	chr11:89784906	NA	-0.34	-6.75	-0.31	4.83e-11	HDL cholesterol;
LUAD	cis	rs4820539	0.966	rs3788350	chr22:23468468	C/T	cg14186256	chr22:23484241	RTDR1	0.46	7.62	0.35	1.73e-13	Bone mineral density;
LUAD	cis	rs4852324	1.000	rs4852324	chr2:74202578	A/G	cg20891558	chr2:74357851	NA	0.53	6.39	0.3	4.3e-10	Systemic lupus erythematosus;
LUAD	cis	rs4888262	0.526	rs7205258	chr16:74642539	C/T	cg01733217	chr16:74700730	RFWD3	0.5	8.42	0.38	6.03e-16	Testicular germ cell tumor;
LUAD	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg07741184	chr6:167504864	NA	0.38	8.68	0.39	8.63e-17	Crohn's disease;
LUAD	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg02049041	chr17:27085579	C17orf63	0.66	8.74	0.39	5.69e-17	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg06740227	chr12:86229804	RASSF9	0.4	7.0	0.32	9.89e-12	Major depressive disorder;
LUAD	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg22535103	chr8:58192502	C8orf71	-0.74	-9.2	-0.41	1.62e-18	Developmental language disorder (linguistic errors);
LUAD	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg07211511	chr3:129823064	LOC729375	-0.7	-9.87	-0.43	8.42e-21	Blood pressure (smoking interaction);
LUAD	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg12311346	chr5:56204834	C5orf35	-0.73	-11.64	-0.49	2.4e-27	Initial pursuit acceleration;
LUAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg18621852	chr3:10150065	C3orf24	0.45	7.08	0.33	5.94e-12	Alzheimer's disease;
LUAD	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg21191810	chr6:118973309	C6orf204	-0.53	-8.04	-0.36	9.38e-15	Renal cell carcinoma;
LUAD	trans	rs7395662	0.667	rs2865612	chr11:48780222	A/C	cg00717180	chr2:96193071	NA	0.38	7.12	0.33	4.64e-12	HDL cholesterol;
LUAD	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg10207240	chr12:122356781	WDR66	-0.42	-7.25	-0.33	2.02e-12	Mean corpuscular volume;
LUAD	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg14324370	chr2:177042789	NA	0.43	8.22	0.37	2.56e-15	IgG glycosylation;
LUAD	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.71	-14.65	-0.58	1.31e-39	Urate levels in overweight individuals;
LUAD	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg07343612	chr16:622815	PIGQ	-0.79	-15.58	-0.6	1.46e-43	Height;
LUAD	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg01849466	chr14:104193079	ZFYVE21	0.52	8.59	0.39	1.74e-16	Body mass index;
LUAD	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg02569458	chr12:86230093	RASSF9	-0.41	-7.69	-0.35	1.03e-13	Major depressive disorder;
LUAD	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00149659	chr3:10157352	C3orf10	-0.53	-7.33	-0.34	1.2e-12	Alzheimer's disease;
LUAD	cis	rs3007168	1.000	rs3007167	chr14:51613041	C/T	cg23942311	chr14:51606299	NA	0.54	7.39	0.34	8.02e-13	Cancer;
LUAD	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg10556349	chr10:835070	NA	0.5	6.42	0.3	3.64e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22496380	chr5:211416	CCDC127	-0.94	-13.14	-0.54	2.58e-33	Breast cancer;
LUAD	trans	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg14791747	chr16:20752902	THUMPD1	0.9	16.04	0.61	1.37e-45	Cognitive test performance;
LUAD	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg06558623	chr16:89946397	TCF25	1.15	10.6	0.46	1.96e-23	Skin colour saturation;
LUAD	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.3	6.6	0.31	1.26e-10	Systemic lupus erythematosus;
LUAD	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg15997130	chr1:24165203	NA	0.56	9.55	0.42	1.1e-19	Immature fraction of reticulocytes;
LUAD	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg21854759	chr1:92012499	NA	-0.49	-9.08	-0.4	4.27e-18	Breast cancer;
LUAD	cis	rs1865721	1.000	rs62089511	chr18:73197629	C/T	cg26385618	chr18:73139727	C18orf62	-0.41	-7.41	-0.34	7e-13	Intelligence;
LUAD	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg23625390	chr15:77176239	SCAPER	0.39	6.81	0.31	3.34e-11	Blood metabolite levels;
LUAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08219700	chr8:58056026	NA	0.62	8.75	0.39	5.07e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11890956	chr21:40555474	PSMG1	-0.54	-9.45	-0.42	2.36e-19	Menarche (age at onset);
LUAD	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg08508325	chr11:3079039	CARS	-0.6	-13.23	-0.54	1.08e-33	Longevity;
LUAD	cis	rs1865721	0.656	rs727894	chr18:73137117	C/T	cg26385618	chr18:73139727	C18orf62	-0.5	-10.39	-0.45	1.11e-22	Intelligence;
LUAD	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg16479474	chr6:28041457	NA	0.48	8.04	0.36	9.29e-15	Depression;
LUAD	cis	rs3924048	0.559	rs6541037	chr1:12626155	A/G	cg00291366	chr1:12616550	NA	0.33	6.52	0.3	2e-10	Optic cup area;
LUAD	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg22823121	chr1:150693482	HORMAD1	0.48	9.38	0.41	4.18e-19	Melanoma;
LUAD	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg19130645	chr7:65235666	NA	0.44	7.45	0.34	5.31e-13	Calcium levels;
LUAD	cis	rs28595532	0.702	rs56217716	chr4:119338490	T/G	cg02775129	chr4:119771670	NA	-0.66	-6.48	-0.3	2.5e-10	Cannabis dependence symptom count;
LUAD	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg14008862	chr17:28927542	LRRC37B2	0.7	6.8	0.31	3.51e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg00769240	chr8:12517080	NA	-0.43	-8.23	-0.37	2.27e-15	Blood pressure (smoking interaction);
LUAD	cis	rs4764487	0.760	rs2268009	chr12:6340388	A/G	cg08284733	chr12:6341482	CD9	0.39	7.06	0.32	7.07e-12	Mean platelet volume;
LUAD	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.51	7.46	0.34	5.09e-13	Platelet count;
LUAD	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg18402987	chr7:1209562	NA	0.71	9.08	0.4	4.17e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg22535103	chr8:58192502	C8orf71	-0.72	-10.2	-0.44	5.59e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs7474896	0.515	rs675628	chr10:38305331	C/G	cg25427524	chr10:38739819	LOC399744	0.57	7.99	0.36	1.26e-14	Obesity (extreme);
LUAD	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg21823605	chr1:152486609	CRCT1	0.28	6.52	0.3	2.01e-10	Hair morphology;
LUAD	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg02527881	chr3:46936655	PTH1R	-0.57	-11.8	-0.5	5.54e-28	Colorectal cancer;
LUAD	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg20119798	chr7:94954144	PON1	-0.48	-6.53	-0.3	1.93e-10	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg05714579	chr10:131428358	MGMT	-0.42	-6.92	-0.32	1.7e-11	Response to temozolomide;
LUAD	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg26769984	chr7:1090371	C7orf50	0.44	7.48	0.34	4.3e-13	Bronchopulmonary dysplasia;
LUAD	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	6.47	0.3	2.76e-10	Ulcerative colitis;Inflammatory bowel disease;
LUAD	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg17177755	chr1:15930204	NA	0.44	7.13	0.33	4.38e-12	Systolic blood pressure;
LUAD	trans	rs6561151	0.681	rs17065161	chr13:44443723	A/T	cg12856521	chr11:46389249	DGKZ	0.76	10.69	0.46	8.81e-24	Crohn's disease;
LUAD	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-7.9	-0.36	2.52e-14	Total cholesterol levels;
LUAD	cis	rs89107	0.651	rs447193	chr6:118607662	G/A	cg18833306	chr6:118973337	C6orf204	0.51	9.17	0.41	2.06e-18	Cardiac structure and function;
LUAD	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg11919837	chr8:57350735	NA	-0.43	-6.41	-0.3	3.98e-10	Obesity-related traits;
LUAD	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.36	-0.6	1.23e-42	Chronic sinus infection;
LUAD	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-10.91	-0.47	1.39e-24	Bipolar disorder;
LUAD	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-6.68	-0.31	7.56e-11	Bipolar disorder;
LUAD	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg06002616	chr8:101225028	SPAG1	0.41	8.2	0.37	2.86e-15	Atrioventricular conduction;
LUAD	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.74	0.31	5.33e-11	Motion sickness;
LUAD	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-8.28	-0.37	1.61e-15	Monocyte percentage of white cells;
LUAD	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.47	-8.0	-0.36	1.16e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg26528668	chr16:1614120	IFT140	0.5	8.91	0.4	1.56e-17	Coronary artery disease;
LUAD	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg10589385	chr1:150898437	SETDB1	-0.35	-6.73	-0.31	5.55e-11	Tonsillectomy;
LUAD	cis	rs2455799	0.533	rs2470550	chr3:15743721	C/T	cg16303742	chr3:15540471	COLQ	-0.47	-8.69	-0.39	7.93e-17	Mean platelet volume;
LUAD	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg00981070	chr1:2046702	PRKCZ	-0.36	-7.63	-0.35	1.54e-13	Height;
LUAD	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg23711669	chr6:146136114	FBXO30	0.39	6.68	0.31	7.72e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2730260	0.537	rs73169234	chr7:158882366	C/T	cg13710308	chr7:158854763	VIPR2	-0.5	-6.39	-0.3	4.32e-10	Myopia (pathological);
LUAD	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg07936489	chr17:37558343	FBXL20	-0.51	-6.87	-0.32	2.29e-11	Glomerular filtration rate (creatinine);
LUAD	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21582582	chr3:182698605	DCUN1D1	0.61	9.83	0.43	1.1e-20	Resting heart rate;
LUAD	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg26384229	chr12:38710491	ALG10B	-0.44	-7.4	-0.34	7.39e-13	Morning vs. evening chronotype;
LUAD	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg00898013	chr13:113819073	PROZ	0.79	13.35	0.54	3.7e-34	Platelet distribution width;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04436474	chr3:49977685	RBM6	-0.42	-6.57	-0.3	1.46e-10	Height;
LUAD	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg19626725	chr5:178986131	RUFY1	0.54	9.86	0.43	9.11e-21	Lung cancer;
LUAD	cis	rs9837602	1.000	rs4571265	chr3:99705111	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.63	-9.02	-0.4	6.64e-18	Breast cancer;
LUAD	cis	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg06360820	chr2:242988706	NA	-0.97	-13.09	-0.54	4.05e-33	Obesity-related traits;
LUAD	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-8.7	-0.39	7.22e-17	Gut microbiome composition (summer);
LUAD	trans	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg27411982	chr8:10470053	RP1L1	0.38	6.64	0.31	9.53e-11	Neuroticism;
LUAD	cis	rs17155006	0.655	rs367538	chr7:107729565	C/T	cg05962710	chr7:107745446	LAMB4	0.3	6.56	0.3	1.57e-10	Pneumococcal bacteremia;
LUAD	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg14668632	chr7:2872130	GNA12	-0.74	-13.42	-0.55	1.79e-34	Height;
LUAD	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg23933602	chr10:16859644	RSU1	0.72	12.52	0.52	7.94e-31	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUAD	trans	rs75804782	0.521	rs56387296	chr2:239426298	A/G	cg01134436	chr17:81009848	B3GNTL1	0.78	8.36	0.38	9.24e-16	Morning vs. evening chronotype;Chronotype;
LUAD	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg18944383	chr4:111397179	ENPEP	0.37	7.55	0.34	2.69e-13	Height;
LUAD	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg27661571	chr11:113659931	NA	-0.7	-8.19	-0.37	3.22e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.47e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg25036284	chr2:26402008	FAM59B	-0.58	-8.08	-0.37	6.84e-15	Gut microbiome composition (summer);
LUAD	cis	rs3806843	0.576	rs246064	chr5:140324309	C/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.32	-6.65	-0.31	8.96e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg09222892	chr1:25734099	RHCE	-0.5	-9.34	-0.41	5.63e-19	Erythrocyte sedimentation rate;
LUAD	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-7.24	-0.33	2.16e-12	Joint mobility (Beighton score);
LUAD	trans	rs7939886	0.920	rs11227449	chr11:55949409	A/G	cg15704280	chr7:45808275	SEPT13	0.76	6.48	0.3	2.54e-10	Myopia (pathological);
LUAD	cis	rs965513	0.627	rs10124220	chr9:100583074	T/C	cg13688889	chr9:100608707	NA	-0.41	-7.07	-0.32	6.56e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUAD	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg03467027	chr4:99064603	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7107174	0.901	rs11237487	chr11:78126754	G/C	cg02023728	chr11:77925099	USP35	0.42	6.36	0.3	5.39e-10	Testicular germ cell tumor;
LUAD	trans	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.0	-0.36	1.2e-14	Gout;
LUAD	cis	rs4285028	0.699	rs1920298	chr3:121597888	T/C	cg11130432	chr3:121712080	ILDR1	-0.56	-8.03	-0.36	9.74e-15	Multiple sclerosis;
LUAD	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg07606381	chr6:8435919	SLC35B3	0.42	7.12	0.33	4.65e-12	Motion sickness;
LUAD	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg17063962	chr7:91808500	NA	-0.68	-12.08	-0.51	4.44e-29	Breast cancer;
LUAD	cis	rs220324	0.688	rs9975332	chr21:43559902	C/T	cg09727148	chr21:43560719	UMODL1	-0.58	-8.91	-0.4	1.53e-17	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg15445000	chr17:37608096	MED1	0.45	8.31	0.37	1.32e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg19901468	chr14:105411992	AHNAK2	-0.52	-10.12	-0.44	1.02e-21	Rheumatoid arthritis;
LUAD	cis	rs2109514	1.000	rs7795510	chr7:116156961	T/C	cg12739419	chr7:116140593	CAV2	-0.37	-8.02	-0.36	1.05e-14	Prevalent atrial fibrillation;
LUAD	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg19875535	chr5:140030758	IK	0.44	7.32	0.34	1.22e-12	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.55	0.46	2.89e-23	Ulcerative colitis;
LUAD	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg23992470	chr4:843637	GAK	0.7	7.28	0.33	1.65e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs4711350	1.000	rs2395447	chr6:33743174	T/C	cg16010596	chr6:33739607	LEMD2	-0.38	-6.48	-0.3	2.52e-10	Schizophrenia;
LUAD	cis	rs72827839	0.516	rs72833461	chr17:45938105	T/G	cg02219949	chr17:45927392	SP6	0.46	7.12	0.33	4.77e-12	Ease of getting up in the morning;
LUAD	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg03433033	chr1:76189801	ACADM	0.76	12.34	0.51	4.17e-30	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7582720	1.000	rs115953525	chr2:203744445	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs6445967	0.554	rs62259788	chr3:58435778	G/T	cg13750441	chr3:58318267	PXK	-0.31	-6.42	-0.3	3.73e-10	Platelet count;
LUAD	cis	rs12145833	0.538	rs61833885	chr1:243397188	C/A	cg02356786	chr1:243265016	LOC731275	0.67	7.31	0.33	1.37e-12	Obesity (early onset extreme);
LUAD	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.64	-9.95	-0.44	4.38e-21	Ileal carcinoids;
LUAD	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg13560548	chr3:10150139	C3orf24	0.41	6.93	0.32	1.56e-11	Alzheimer's disease;
LUAD	cis	rs1255143	0.561	rs10829361	chr10:130030654	T/C	cg11320749	chr10:130009573	NA	-0.4	-7.23	-0.33	2.27e-12	Interleukin-16 levels;
LUAD	cis	rs10788264	0.504	rs7898942	chr10:124024608	G/T	cg09507567	chr10:124027408	NA	-0.52	-11.91	-0.5	2.16e-28	Total body bone mineral density;
LUAD	trans	rs75804782	0.641	rs56134361	chr2:239318905	A/G	cg01134436	chr17:81009848	B3GNTL1	0.8	8.62	0.39	1.33e-16	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg21433313	chr16:3507492	NAT15	-0.75	-8.15	-0.37	4.2e-15	Tuberculosis;
LUAD	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	14.19	0.57	1.12e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg00147160	chr1:26503991	CNKSR1	-0.38	-8.85	-0.4	2.41e-17	Height;
LUAD	trans	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg14791747	chr16:20752902	THUMPD1	0.51	7.46	0.34	4.92e-13	Pancreatic cancer;
LUAD	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg09998033	chr7:158218633	PTPRN2	-0.54	-9.59	-0.42	7.7e-20	Obesity-related traits;
LUAD	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00665908	chr6:34855885	TAF11;ANKS1A	0.39	6.43	0.3	3.38e-10	Survival in pancreatic cancer;
LUAD	cis	rs13112683	0.638	rs7680071	chr4:140784752	C/A	cg02876341	chr4:140783585	MAML3	0.31	6.7	0.31	6.56e-11	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LUAD	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg15997130	chr1:24165203	NA	-0.48	-7.7	-0.35	9.82e-14	Immature fraction of reticulocytes;
LUAD	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg03188948	chr7:1209495	NA	0.83	10.16	0.44	7.81e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs10208940	0.619	rs7567869	chr2:68865293	G/A	cg12452813	chr2:68675892	NA	0.51	6.95	0.32	1.35e-11	Urate levels in lean individuals;
LUAD	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.19	-0.37	3.08e-15	Total cholesterol levels;
LUAD	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg08888203	chr3:10149979	C3orf24	0.74	13.07	0.54	5.1e-33	Alzheimer's disease;
LUAD	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg00318621	chr2:106887213	NA	-0.54	-9.46	-0.42	2.14e-19	Facial morphology (factor 23);
LUAD	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg00074818	chr8:8560427	CLDN23	0.68	10.5	0.45	4.32e-23	Obesity-related traits;
LUAD	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	7.16	0.33	3.57e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs959260	0.528	rs9909443	chr17:73308346	C/T	cg14668889	chr17:73230827	NUP85	0.53	8.55	0.38	2.27e-16	Systemic lupus erythematosus;
LUAD	trans	rs7395662	0.617	rs1976509	chr11:48964603	C/T	cg00717180	chr2:96193071	NA	0.4	7.51	0.34	3.58e-13	HDL cholesterol;
LUAD	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg20283391	chr11:68216788	NA	-0.41	-6.53	-0.3	1.88e-10	Total body bone mineral density;
LUAD	cis	rs9914988	0.565	rs34039488	chr17:27320232	G/A	cg02049041	chr17:27085579	C17orf63	0.53	6.7	0.31	6.47e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg18721089	chr20:30220636	NA	-0.44	-6.66	-0.31	8.32e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg10729496	chr3:10149963	C3orf24	0.49	7.92	0.36	2.15e-14	Alzheimer's disease;
LUAD	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg06064525	chr11:970664	AP2A2	0.46	9.09	0.4	3.84e-18	Alzheimer's disease (late onset);
LUAD	cis	rs2836633	0.895	rs62217513	chr21:40024416	A/T	cg12884169	chr21:40033163	ERG	0.47	10.04	0.44	2.02e-21	Coronary artery disease;
LUAD	cis	rs2455601	0.638	rs2742484	chr11:8988083	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.43	-7.8	-0.35	4.75e-14	Schizophrenia;
LUAD	cis	rs12431939	1.000	rs60593258	chr14:51662280	T/A	cg23942311	chr14:51606299	NA	-0.53	-7.34	-0.34	1.07e-12	Cancer;
LUAD	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg26408565	chr15:76604113	ETFA	-0.48	-8.04	-0.36	9.15e-15	Blood metabolite levels;
LUAD	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg21475434	chr5:93447410	FAM172A	-0.57	-7.35	-0.34	1.05e-12	Diabetic retinopathy;
LUAD	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg06618935	chr21:46677482	NA	-0.43	-7.58	-0.35	2.27e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg14668632	chr7:2872130	GNA12	-0.47	-8.22	-0.37	2.47e-15	Height;
LUAD	cis	rs73206853	0.563	rs16940992	chr12:111207515	C/T	cg12870014	chr12:110450643	ANKRD13A	-0.63	-8.63	-0.39	1.24e-16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-9.02	-0.4	6.63e-18	Lymphocyte counts;
LUAD	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg00129232	chr17:37814104	STARD3	-0.45	-7.82	-0.36	4.29e-14	Asthma;
LUAD	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg24531977	chr5:56204891	C5orf35	-0.52	-8.27	-0.37	1.81e-15	Coronary artery disease;
LUAD	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg08280861	chr8:58055591	NA	0.56	7.56	0.35	2.46e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.43	-0.45	7.96e-23	Monocyte percentage of white cells;
LUAD	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg08761264	chr16:28874980	SH2B1	-0.45	-7.01	-0.32	9.22e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg12343791	chr22:39240109	NPTXR	0.38	6.72	0.31	5.8200000000000003e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg06199346	chr11:14280333	SPON1	-0.37	-7.8	-0.35	4.88e-14	Mitochondrial DNA levels;
LUAD	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-8.09	-0.37	6.45e-15	Type 2 diabetes;
LUAD	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg05590025	chr7:65112418	INTS4L2	-0.78	-8.26	-0.37	1.9e-15	Diabetic kidney disease;
LUAD	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-15.13	-0.59	1.16e-41	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg03929089	chr4:120376271	NA	-0.86	-15.74	-0.61	2.96e-44	Coronary artery disease;
LUAD	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg02734326	chr4:10020555	SLC2A9	0.56	9.7	0.43	3.24e-20	Bone mineral density;
LUAD	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg20556744	chr2:9614537	IAH1	0.66	6.7	0.31	6.53e-11	Opioid sensitivity;
LUAD	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.8	14.72	0.58	6.47e-40	Lymphocyte counts;
LUAD	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg07538946	chr5:131705188	SLC22A5	0.51	8.19	0.37	3.04e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg12011299	chr4:100065546	ADH4	-0.72	-13.09	-0.54	4.34e-33	Alcohol dependence;
LUAD	cis	rs1595825	0.735	rs6752760	chr2:198918164	G/T	cg10547527	chr2:198650123	BOLL	-0.49	-6.39	-0.3	4.29e-10	Ulcerative colitis;
LUAD	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg11645453	chr3:52864694	ITIH4	0.59	11.33	0.48	3.55e-26	Schizophrenia;
LUAD	cis	rs7680126	0.633	rs4697743	chr4:10294833	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.27	-0.33	1.79e-12	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg00310523	chr12:86230176	RASSF9	0.39	7.84	0.36	3.8e-14	Major depressive disorder;
LUAD	cis	rs1595825	0.732	rs4589750	chr2:198426003	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.85	-0.32	2.6e-11	Ulcerative colitis;
LUAD	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.49	-6.35	-0.3	5.47e-10	Depression;
LUAD	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg25985355	chr7:65971099	NA	-0.55	-6.75	-0.31	4.77e-11	Diabetic kidney disease;
LUAD	cis	rs7326068	0.576	rs9552273	chr13:21333750	A/C	cg27499820	chr13:21296301	IL17D	0.46	7.58	0.35	2.24e-13	Schizophrenia, bipolar disorder and depression (combined);
LUAD	cis	rs2797160	1.000	rs1739363	chr6:126020980	G/A	cg05901451	chr6:126070800	HEY2	0.43	6.47	0.3	2.68e-10	Endometrial cancer;
LUAD	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg17177755	chr1:15930204	NA	0.5	7.74	0.35	7.19e-14	Systolic blood pressure;
LUAD	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg02796970	chr10:39023768	NA	-0.49	-7.87	-0.36	3.01e-14	Menopause (age at onset);
LUAD	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.65	11.53	0.49	6.24e-27	Birth weight;
LUAD	cis	rs1595825	0.891	rs7584475	chr2:198577424	A/C	cg11031976	chr2:198649780	BOLL	-0.45	-6.72	-0.31	6.04e-11	Ulcerative colitis;
LUAD	cis	rs240764	0.658	rs9377214	chr6:101212146	G/A	cg09795085	chr6:101329169	ASCC3	-0.42	-7.38	-0.34	8.36e-13	Neuroticism;
LUAD	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg02466173	chr16:30829666	NA	-0.74	-13.22	-0.54	1.22e-33	Multiple myeloma;
LUAD	cis	rs751728	0.965	rs4713683	chr6:33757550	C/G	cg13859433	chr6:33739653	LEMD2	-0.42	-9.87	-0.43	8.14e-21	Crohn's disease;
LUAD	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.32	0.37	1.24e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.36	0.52	3.62e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs3820068	0.705	rs927206	chr1:15893338	C/T	cg24675056	chr1:15929824	NA	0.43	6.79	0.31	3.76e-11	Systolic blood pressure;
LUAD	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg01884057	chr2:25150051	NA	0.33	7.15	0.33	3.84e-12	Body mass index;
LUAD	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg01448562	chr3:133502909	NA	-0.64	-10.55	-0.46	2.98e-23	Iron status biomarkers;
LUAD	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg16988262	chr1:15930761	NA	0.41	6.83	0.32	2.95e-11	Systolic blood pressure;
LUAD	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg16606324	chr3:10149918	C3orf24	0.62	10.18	0.44	6.31e-22	Alzheimer's disease;
LUAD	cis	rs5756813	0.811	rs4396807	chr22:38138379	G/C	cg06521852	chr22:38141419	TRIOBP	0.45	8.66	0.39	1.03e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg24829409	chr8:58192753	C8orf71	-0.6	-7.03	-0.32	8.33e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg19635926	chr16:89946313	TCF25	0.79	6.76	0.31	4.67e-11	Skin colour saturation;
LUAD	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg09455208	chr3:40491958	NA	0.65	14.42	0.57	1.23e-38	Renal cell carcinoma;
LUAD	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.54	-0.3	1.82e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs11650494	0.908	rs77247327	chr17:47411493	T/C	cg08112188	chr17:47440006	ZNF652	0.92	7.62	0.35	1.67e-13	Prostate cancer;
LUAD	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg10518543	chr12:38710700	ALG10B	-0.42	-7.0	-0.32	1.04e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs10916814	1.000	rs10916820	chr1:20903792	A/T	cg24502330	chr1:20914028	CDA	-0.39	-7.24	-0.33	2.2e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg10645314	chr2:3704589	ALLC	-0.45	-7.6	-0.35	1.86e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs912330	0.825	rs7317938	chr13:99234361	C/T	cg07423050	chr13:99094983	FARP1	-0.37	-6.36	-0.3	5.27e-10	Alzheimer's disease;
LUAD	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-19.51	-0.69	6.41e-61	Height;
LUAD	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg27411982	chr8:10470053	RP1L1	0.4	6.99	0.32	1.1e-11	Retinal vascular caliber;
LUAD	cis	rs4253772	0.530	rs9615980	chr22:46791143	A/T	cg09491104	chr22:46646882	C22orf40	-0.51	-6.49	-0.3	2.38e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs12618769	0.597	rs3769719	chr2:99124404	T/C	cg10123293	chr2:99228465	UNC50	0.46	8.39	0.38	7.48e-16	Bipolar disorder;
LUAD	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg00383909	chr3:49044727	WDR6	0.92	10.71	0.46	7.7e-24	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs6993813	0.620	rs6469802	chr8:120029323	C/T	cg01975934	chr8:119970761	NA	-0.34	-6.63	-0.31	1.03e-10	Bone mineral density (hip);
LUAD	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg25358565	chr5:93447407	FAM172A	0.61	7.11	0.33	4.9e-12	Diabetic retinopathy;
LUAD	cis	rs9341808	0.718	rs9359408	chr6:80820132	T/G	cg08355045	chr6:80787529	NA	0.56	10.04	0.44	2.04e-21	Sitting height ratio;
LUAD	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.52	-10.61	-0.46	1.83e-23	Monocyte percentage of white cells;
LUAD	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg24634471	chr8:143751801	JRK	0.46	7.44	0.34	5.79e-13	Schizophrenia;
LUAD	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg03733263	chr8:22462867	KIAA1967	0.69	11.18	0.48	1.31e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg12573674	chr2:1569213	NA	-0.51	-6.37	-0.3	5e-10	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg02725872	chr8:58115012	NA	-0.33	-6.46	-0.3	2.9e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg08132940	chr7:1081526	C7orf50	-0.76	-7.75	-0.35	7.12e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg04511125	chr2:88470314	THNSL2	1.0	11.56	0.49	4.73e-27	Plasma clusterin levels;
LUAD	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg18230493	chr5:56204884	C5orf35	-0.86	-10.19	-0.44	6.02e-22	Type 2 diabetes;
LUAD	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg22681709	chr2:178499509	PDE11A	-0.46	-7.73	-0.35	7.91e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg09365446	chr1:150670422	GOLPH3L	0.63	11.07	0.47	3.38e-25	Urate levels;
LUAD	cis	rs2239547	0.603	rs12489490	chr3:53064022	C/A	cg18404041	chr3:52824283	ITIH1	-0.56	-8.88	-0.4	1.92e-17	Schizophrenia;
LUAD	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.44	-0.3	3.28e-10	Breast cancer;
LUAD	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg08085267	chr17:45401833	C17orf57	-0.64	-11.37	-0.48	2.58e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg15997130	chr1:24165203	NA	-0.41	-6.37	-0.3	4.84e-10	Immature fraction of reticulocytes;
LUAD	cis	rs12765878	1.000	rs11191849	chr10:105650880	T/A	cg11005552	chr10:105648138	OBFC1	0.44	8.34	0.38	1.04e-15	Coronary artery disease;
LUAD	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg26587870	chr6:27730563	NA	-0.44	-7.15	-0.33	3.76e-12	Parkinson's disease;
LUAD	cis	rs501916	1.000	rs501916	chr15:48053229	C/A	cg16110827	chr15:48056943	SEMA6D	-0.36	-7.2	-0.33	2.84e-12	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg15445000	chr17:37608096	MED1	0.44	8.17	0.37	3.6e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs2777491	0.874	rs13379756	chr15:41663896	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.72	-13.76	-0.56	7.35e-36	Ulcerative colitis;
LUAD	trans	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg01620082	chr3:125678407	NA	-0.61	-7.68	-0.35	1.1e-13	Lung cancer in ever smokers;
LUAD	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg08859206	chr1:53392774	SCP2	-0.6	-10.63	-0.46	1.54e-23	Monocyte count;
LUAD	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg00666640	chr1:248458726	OR2T12	0.27	6.37	0.3	4.87e-10	Common traits (Other);
LUAD	cis	rs9807989	0.507	rs1420096	chr2:103010912	C/T	cg03938978	chr2:103052716	IL18RAP	0.45	10.32	0.45	2.06e-22	Asthma;
LUAD	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg10544611	chr16:67998164	SLC12A4	-0.54	-6.86	-0.32	2.52e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg17644776	chr2:200775616	C2orf69	-0.52	-6.53	-0.3	1.9e-10	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-13.28	-0.54	7.08e-34	Chronic sinus infection;
LUAD	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg17105886	chr17:28927953	LRRC37B2	0.73	6.64	0.31	9.66e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs3087591	0.960	rs12949230	chr17:29461899	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	6.73	0.31	5.54e-11	Hip circumference;
LUAD	cis	rs758324	0.812	rs2159243	chr5:131133900	G/A	cg06307176	chr5:131281290	NA	0.46	7.49	0.34	4.01e-13	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg10978503	chr1:24200527	CNR2	0.59	12.79	0.53	7.07e-32	Immature fraction of reticulocytes;
LUAD	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11890956	chr21:40555474	PSMG1	-0.64	-10.4	-0.45	1.06e-22	Cognitive function;
LUAD	trans	rs11722228	0.522	rs12503195	chr4:10082772	T/C	cg26043149	chr18:55253948	FECH	0.73	12.71	0.53	1.42e-31	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg09455208	chr3:40491958	NA	0.54	11.83	0.5	4.22e-28	Renal cell carcinoma;
LUAD	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg06138931	chr13:21896616	NA	0.44	7.88	0.36	2.86e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg10589385	chr1:150898437	SETDB1	0.41	7.49	0.34	4.17e-13	Melanoma;
LUAD	cis	rs346785	0.692	rs6501882	chr17:74289875	C/T	cg09812376	chr17:74270190	QRICH2	-0.3	-6.39	-0.3	4.46e-10	White matter hyperintensities in ischemic stroke;
LUAD	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg23625390	chr15:77176239	SCAPER	0.38	6.63	0.31	1.01e-10	Blood metabolite levels;
LUAD	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg00745463	chr17:30367425	LRRC37B	-0.83	-10.08	-0.44	1.52e-21	Hip circumference adjusted for BMI;
LUAD	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21659725	chr3:3221576	CRBN	0.69	11.83	0.5	4.16e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg17849569	chr6:28058911	ZSCAN12L1	0.32	6.93	0.32	1.58e-11	Depression;
LUAD	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21659725	chr3:3221576	CRBN	0.67	11.44	0.49	1.33e-26	Intelligence (multi-trait analysis);
LUAD	cis	rs220324	0.688	rs4283513	chr21:43566409	G/T	cg09727148	chr21:43560719	UMODL1	0.52	8.05	0.36	8.42e-15	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs6500395	1.000	rs9939103	chr16:48592376	G/C	cg04672837	chr16:48644449	N4BP1	0.38	6.49	0.3	2.41e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs240764	0.817	rs239206	chr6:101137332	T/G	cg09795085	chr6:101329169	ASCC3	0.45	7.89	0.36	2.59e-14	Neuroticism;
LUAD	cis	rs7759001	0.857	rs6456777	chr6:27365994	G/A	cg18711553	chr6:27366782	ZNF391	0.39	6.46	0.3	2.84e-10	Glomerular filtration rate (creatinine);
LUAD	trans	rs9329221	0.682	rs11786677	chr8:10264260	A/G	cg14343924	chr8:8086146	FLJ10661	0.42	6.89	0.32	2.05e-11	Neuroticism;
LUAD	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg24733560	chr20:60626293	TAF4	0.41	7.93	0.36	1.99e-14	Body mass index;
LUAD	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg19163074	chr7:65112434	INTS4L2	0.44	6.75	0.31	4.89e-11	Aortic root size;
LUAD	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg15445000	chr17:37608096	MED1	-0.45	-8.31	-0.37	1.34e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07930192	chr7:1003750	NA	-0.38	-7.2	-0.33	2.81e-12	Longevity;Endometriosis;
LUAD	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-15.32	-0.6	1.83e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs13315871	0.932	rs35741271	chr3:58323091	A/G	cg20936604	chr3:58311152	NA	-0.72	-7.22	-0.33	2.51e-12	Cholesterol, total;
LUAD	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.26	-0.45	3.38e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg06784218	chr1:46089804	CCDC17	0.58	12.88	0.53	2.97e-32	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	12.06	0.51	5.54e-29	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg22467129	chr15:76604101	ETFA	-0.47	-7.85	-0.36	3.54e-14	Blood metabolite levels;
LUAD	cis	rs916888	0.779	rs199526	chr17:44847707	C/G	cg15921436	chr17:44337874	NA	-0.62	-8.92	-0.4	1.43e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg18811423	chr2:55921094	PNPT1	0.54	9.05	0.4	5.13e-18	Metabolic syndrome;
LUAD	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg05727186	chr17:43697356	MGC57346	-0.51	-6.36	-0.3	5.32e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg27432699	chr2:27873401	GPN1	0.58	10.24	0.45	3.81e-22	Oral cavity cancer;
LUAD	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg09835421	chr16:68378352	PRMT7	-1.05	-12.02	-0.5	7.48e-29	Magnesium levels;
LUAD	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	13.76	0.56	7.63e-36	Prudent dietary pattern;
LUAD	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15541040	chr2:3486749	NA	-0.41	-6.93	-0.32	1.58e-11	Neurofibrillary tangles;
LUAD	cis	rs7937890	0.559	rs2597201	chr11:14485404	T/C	cg06199346	chr11:14280333	SPON1	-0.33	-6.54	-0.3	1.82e-10	Mitochondrial DNA levels;
LUAD	cis	rs7809950	1.000	rs2250414	chr7:107140987	T/G	cg23024343	chr7:107201750	COG5	-0.71	-12.05	-0.51	6.06e-29	Coronary artery disease;
LUAD	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg09796270	chr17:17721594	SREBF1	-0.37	-6.94	-0.32	1.47e-11	Total body bone mineral density;
LUAD	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg00647820	chr17:40259828	DHX58	-0.44	-6.93	-0.32	1.62e-11	Fibrinogen levels;
LUAD	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.64	10.5	0.45	4.45e-23	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg19500851	chr17:37840957	PGAP3	-0.33	-6.45	-0.3	3.12e-10	Asthma;
LUAD	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06544989	chr22:39130855	UNC84B	0.45	9.09	0.4	3.75e-18	Menopause (age at onset);
LUAD	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg02158880	chr13:53174818	NA	0.47	8.25	0.37	2.06e-15	Lewy body disease;
LUAD	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg19678392	chr7:94953810	PON1	-0.57	-7.67	-0.35	1.16e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg21028142	chr17:79581711	NPLOC4	0.38	7.71	0.35	8.98e-14	Eye color traits;
LUAD	cis	rs4920343	0.890	rs4920531	chr1:19095746	A/G	cg19637330	chr1:19110922	NA	-0.42	-6.65	-0.31	8.9e-11	Knee osteoarthritis;
LUAD	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg00684032	chr4:1343700	KIAA1530	0.49	7.84	0.36	3.65e-14	Obesity-related traits;
LUAD	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg22963979	chr7:1858916	MAD1L1	-0.44	-7.1	-0.33	5.25e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs9469890	0.604	rs78871484	chr6:34503677	T/C	cg14254433	chr6:34482411	PACSIN1	-0.6	-8.62	-0.39	1.33e-16	Pubertal anthropometrics;Coronary artery disease;
LUAD	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg10356904	chr22:49881777	NA	-0.41	-7.98	-0.36	1.4e-14	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg15790184	chr11:494944	RNH1	0.53	6.73	0.31	5.55e-11	Body mass index;
LUAD	cis	rs11247915	0.501	rs34209692	chr1:26608782	C/T	cg15628303	chr1:26608928	UBXN11	0.54	9.66	0.43	4.37e-20	Obesity-related traits;
LUAD	cis	rs10203711	0.789	rs6431616	chr2:239540279	A/G	cg14580085	chr2:239553406	NA	0.37	7.54	0.34	2.97e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg22532475	chr10:104410764	TRIM8	-0.44	-8.56	-0.38	2.09e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg25894440	chr7:65020034	NA	-0.68	-7.18	-0.33	3.16e-12	Diabetic kidney disease;
LUAD	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg22681709	chr2:178499509	PDE11A	-0.43	-7.19	-0.33	2.89e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs3858704	0.517	rs7297186	chr12:111778178	C/T	cg10833066	chr12:111807467	FAM109A	-0.69	-14.77	-0.58	4.24e-40	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg26343298	chr8:95960752	TP53INP1	0.36	7.54	0.34	2.91e-13	Type 2 diabetes;
LUAD	cis	rs739496	0.649	rs666727	chr12:111989658	C/T	cg10833066	chr12:111807467	FAM109A	0.39	6.56	0.3	1.55e-10	Platelet count;
LUAD	cis	rs4812048	0.649	rs116580814	chr20:57618141	G/T	cg14073986	chr20:57617431	SLMO2	0.87	10.05	0.44	1.9e-21	Mean platelet volume;
LUAD	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18876405	chr7:65276391	NA	0.63	10.85	0.47	2.24e-24	Aortic root size;
LUAD	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg20556744	chr2:9614537	IAH1	0.65	6.61	0.31	1.19e-10	Opioid sensitivity;
LUAD	cis	rs7172809	0.573	rs17384809	chr15:77622006	A/G	cg11865553	chr15:77376250	NA	0.39	6.64	0.31	9.77e-11	Glucose homeostasis traits;
LUAD	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13064411	0.696	rs7619913	chr3:113017503	A/G	cg10517650	chr3:113235015	CCDC52	-0.45	-7.34	-0.34	1.07e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs9473147	0.516	rs7754971	chr6:47590476	C/T	cg20196966	chr6:47445060	CD2AP	0.43	6.85	0.32	2.69e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.69	-10.59	-0.46	2.06e-23	Lymphocyte percentage of white cells;
LUAD	cis	rs9652601	0.779	rs7203793	chr16:11182134	C/G	cg04616529	chr16:11181986	CLEC16A	0.4	7.14	0.33	4.03e-12	Systemic lupus erythematosus;
LUAD	cis	rs4523957	0.928	rs12949991	chr17:2197185	G/A	cg16513277	chr17:2031491	SMG6	0.77	14.37	0.57	2.07e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs7274811	0.656	rs293736	chr20:31925189	A/C	cg14921437	chr20:32255988	NECAB3;C20orf134	0.44	6.37	0.3	4.81e-10	Height;
LUAD	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg18230493	chr5:56204884	C5orf35	0.71	11.35	0.48	2.96e-26	Initial pursuit acceleration;
LUAD	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.76	14.63	0.58	1.68e-39	Intelligence (multi-trait analysis);
LUAD	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg10755058	chr3:40428713	ENTPD3	-0.39	-7.69	-0.35	1.01e-13	Renal cell carcinoma;
LUAD	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg22535103	chr8:58192502	C8orf71	-0.75	-8.88	-0.4	2e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg18252515	chr7:66147081	NA	-0.61	-6.61	-0.31	1.18e-10	Diabetic kidney disease;
LUAD	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg03213289	chr20:61660250	NA	0.69	14.76	0.58	4.6e-40	Prostate cancer (SNP x SNP interaction);
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg08793459	chr17:57784647	PTRH2;TMEM49	0.41	6.36	0.3	5.38e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg10792982	chr14:105748885	BRF1	0.46	9.5	0.42	1.55e-19	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg02751453	chr18:77725136	HSBP1L1	0.35	6.59	0.31	1.28e-10	Opioid sensitivity;
LUAD	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg05805236	chr11:65401703	PCNXL3	0.44	7.48	0.34	4.33e-13	Acne (severe);
LUAD	cis	rs2932538	0.961	rs12126494	chr1:113228623	G/A	cg22162597	chr1:113214053	CAPZA1	0.45	6.46	0.3	2.8e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.04e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg05084668	chr3:125655381	ALG1L	0.63	10.42	0.45	8.59e-23	Blood pressure (smoking interaction);
LUAD	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg25811766	chr13:21894605	NA	0.57	8.53	0.38	2.69e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg22618164	chr12:122356400	WDR66	-0.73	-13.35	-0.54	3.69e-34	Mean corpuscular volume;
LUAD	trans	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg18335740	chr13:41363409	SLC25A15	0.62	11.56	0.49	4.75e-27	Lewy body disease;
LUAD	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4588572	0.644	rs1159930	chr5:77768943	C/T	cg11547950	chr5:77652471	NA	0.61	10.16	0.44	7.81e-22	Triglycerides;
LUAD	cis	rs2075165	0.836	rs7512751	chr1:156234439	T/G	cg20302342	chr1:156215951	PAQR6	0.38	8.64	0.39	1.14e-16	Tonsillectomy;
LUAD	cis	rs262150	0.501	rs1017034	chr7:158820460	A/G	cg04111992	chr7:158790115	NA	-0.53	-9.01	-0.4	6.95e-18	Facial morphology (factor 20);
LUAD	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg01849466	chr14:104193079	ZFYVE21	0.46	7.8	0.35	4.99e-14	Body mass index;
LUAD	cis	rs9394152	0.845	rs9296092	chr6:33478496	C/T	cg13560919	chr6:33536144	NA	-0.49	-8.49	-0.38	3.49e-16	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs16910800	0.906	rs2449436	chr11:23204720	G/T	cg20040320	chr11:23191996	NA	0.47	7.1	0.33	5.45e-12	Cancer;
LUAD	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	trans	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg02002194	chr4:3960332	NA	-0.32	-7.72	-0.35	8.49e-14	Systolic blood pressure;
LUAD	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg10876282	chr6:28092338	ZSCAN16	0.47	7.22	0.33	2.46e-12	Cardiac Troponin-T levels;
LUAD	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg12927641	chr6:109611667	NA	-0.49	-8.65	-0.39	1.1e-16	Reticulocyte fraction of red cells;
LUAD	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg13397359	chr6:42928475	GNMT	0.61	11.65	0.49	2.22e-27	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6489785	0.687	rs3213567	chr12:121222556	T/C	cg02419362	chr12:121203948	SPPL3	0.35	7.16	0.33	3.72e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg05709478	chr1:6581295	PLEKHG5	0.56	7.51	0.34	3.51e-13	Body mass index;
LUAD	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-9.51	-0.42	1.51e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7903847	0.642	rs10882923	chr10:99159018	G/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.66	-0.35	1.24e-13	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg17757837	chr7:157058334	UBE3C	0.47	8.45	0.38	4.86e-16	Body mass index;
LUAD	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg00933542	chr6:150070202	PCMT1	0.46	10.12	0.44	1.03e-21	Lung cancer;
LUAD	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21582582	chr3:182698605	DCUN1D1	0.61	10.23	0.45	4.39e-22	Intelligence (multi-trait analysis);
LUAD	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01570182	chr17:44337453	NA	1.15	17.78	0.65	3.08e-53	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs17739794	0.517	rs6559193	chr8:775451	C/T	cg01971667	chr8:817044	NA	-0.35	-7.15	-0.33	3.87e-12	Clozapine-induced cytotoxicity;
LUAD	cis	rs6738485	0.507	rs72819611	chr2:106845912	G/A	cg00318621	chr2:106887213	NA	-0.53	-7.46	-0.34	4.8e-13	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs9768139	0.708	rs36064654	chr7:158116632	C/T	cg24154853	chr7:158122151	PTPRN2	0.56	11.04	0.47	4.45e-25	Calcium levels;
LUAD	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg15448220	chr1:150897856	SETDB1	0.57	9.88	0.43	7.45e-21	Melanoma;
LUAD	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg15704280	chr7:45808275	SEPT13	0.64	8.75	0.39	5.22e-17	Axial length;
LUAD	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08280861	chr8:58055591	NA	0.63	8.24	0.37	2.25e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg22676075	chr6:135203613	NA	0.56	9.95	0.44	4.34e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs558133	0.963	rs573372	chr5:78420732	C/A	cg25119155	chr5:78426943	BHMT	0.49	8.75	0.39	5.06e-17	Blood and toenail selenium levels;
LUAD	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-6.5	-0.3	2.33e-10	Retinal vascular caliber;
LUAD	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.17	0.37	3.67e-15	Menopause (age at onset);
LUAD	cis	rs8060686	0.546	rs7188350	chr16:68149316	T/C	cg26727032	chr16:67993705	SLC12A4	-0.46	-7.63	-0.35	1.53e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs754466	0.651	rs55738779	chr10:79652395	C/T	cg17075019	chr10:79541650	NA	-0.85	-17.27	-0.64	6.09e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg14664628	chr15:75095509	CSK	-0.42	-6.51	-0.3	2.2e-10	Breast cancer;
LUAD	cis	rs10504073	0.669	rs341801	chr8:50037784	A/G	cg00325661	chr8:49890786	NA	0.39	8.94	0.4	1.22e-17	Blood metabolite ratios;
LUAD	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg21191810	chr6:118973309	C6orf204	-0.47	-7.52	-0.34	3.37e-13	Diastolic blood pressure;
LUAD	cis	rs7737355	0.773	rs32112	chr5:131048122	G/A	cg06307176	chr5:131281290	NA	0.46	7.61	0.35	1.78e-13	Life satisfaction;
LUAD	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg22166914	chr1:53195759	ZYG11B	0.4	6.72	0.31	5.8200000000000003e-11	Monocyte count;
LUAD	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg27068330	chr11:65405492	SIPA1	-0.76	-11.64	-0.49	2.4200000000000002e-27	Acne (severe);
LUAD	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg02733842	chr7:1102375	C7orf50	-0.55	-8.68	-0.39	8.57e-17	Bronchopulmonary dysplasia;
LUAD	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.36	-6.4	-0.3	4.13e-10	Caffeine consumption;
LUAD	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg11822812	chr5:140052017	DND1	0.36	6.53	0.3	1.92e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg06784218	chr1:46089804	CCDC17	-0.59	-13.33	-0.54	4.47e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg18876405	chr7:65276391	NA	0.46	7.44	0.34	5.5e-13	Aortic root size;
LUAD	cis	rs7017914	0.783	rs13252584	chr8:71689031	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.32	-6.46	-0.3	2.82e-10	Bone mineral density;
LUAD	cis	rs2235649	0.828	rs9925354	chr16:1849866	G/A	cg08610935	chr16:1836813	NUBP2	-0.48	-7.49	-0.34	4.18e-13	Blood metabolite levels;
LUAD	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg03806693	chr22:41940476	POLR3H	0.54	7.93	0.36	2.02e-14	Vitiligo;
LUAD	cis	rs220324	0.688	rs4450717	chr21:43566297	C/G	cg08841829	chr21:43638893	ABCG1	-0.49	-6.82	-0.31	3.1e-11	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	23.8	0.76	4.34e-80	Chronic sinus infection;
LUAD	cis	rs9487051	0.698	rs11153168	chr6:109629420	A/T	cg01475377	chr6:109611718	NA	-0.39	-6.44	-0.3	3.22e-10	Reticulocyte fraction of red cells;
LUAD	trans	rs1864729	1.000	rs2635162	chr8:98283629	C/T	cg08679828	chr8:102218111	ZNF706	-0.81	-8.79	-0.39	3.66e-17	Estradiol plasma levels (breast cancer);
LUAD	cis	rs12422267	1.000	rs12422267	chr12:132601596	A/G	cg09764611	chr12:132620959	NA	-0.68	-6.81	-0.31	3.39e-11	Plasma amyloid beta peptide concentrations (ABx-40);
LUAD	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg01657329	chr11:68192670	LRP5	-0.49	-8.3	-0.37	1.39e-15	Total body bone mineral density;
LUAD	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg26384229	chr12:38710491	ALG10B	0.44	7.39	0.34	7.77e-13	Morning vs. evening chronotype;
LUAD	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg12524338	chr4:183729343	NA	0.61	7.34	0.34	1.08e-12	Pediatric autoimmune diseases;
LUAD	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg08888203	chr3:10149979	C3orf24	0.72	12.87	0.53	3.25e-32	Alzheimer's disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg04231166	chr3:185655124	TRA2B	-0.57	-7.19	-0.33	2.87e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg01416388	chr22:39784598	NA	-0.46	-6.88	-0.32	2.13e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.74	-12.25	-0.51	1.01e-29	Primary sclerosing cholangitis;
LUAD	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg15181151	chr6:150070149	PCMT1	0.42	8.73	0.39	5.79e-17	Lung cancer;
LUAD	cis	rs2908197	0.737	rs10230188	chr7:75980872	A/G	cg24580635	chr7:76178542	LOC100133091	-0.43	-6.84	-0.32	2.86e-11	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22857025	chr5:266934	NA	-1.06	-13.35	-0.54	3.53e-34	Breast cancer;
LUAD	cis	rs2046867	0.862	rs62252360	chr3:72838551	C/T	cg25664220	chr3:72788482	NA	-0.64	-11.64	-0.49	2.3e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg07460842	chr6:66804631	NA	0.62	9.77	0.43	1.8899999999999998e-20	Type 2 diabetes;
LUAD	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg05590025	chr7:65112418	INTS4L2	0.75	8.03	0.36	9.57e-15	Diabetic kidney disease;
LUAD	trans	rs9302065	0.681	rs59108692	chr13:95962424	C/A	cg19955956	chr7:72299837	SBDSP;TYW1B	0.59	10.46	0.45	6.19e-23	Blood metabolite levels;
LUAD	cis	rs12579753	0.956	rs11115039	chr12:82217338	A/C	cg07988820	chr12:82153109	PPFIA2	-0.46	-6.98	-0.32	1.15e-11	Resting heart rate;
LUAD	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg27284194	chr4:1044797	NA	0.7	10.13	0.44	9.73e-22	Recombination rate (females);
LUAD	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg05340658	chr4:99064831	C4orf37	0.45	7.34	0.34	1.14e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.72	-9.78	-0.43	1.63e-20	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg18512352	chr11:47633146	NA	-0.54	-9.54	-0.42	1.16e-19	Subjective well-being;
LUAD	cis	rs9658691	0.607	rs12415680	chr10:90780737	A/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.58	-7.21	-0.33	2.64e-12	Mosquito bite size;
LUAD	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg18932078	chr1:2524107	MMEL1	0.37	6.95	0.32	1.37e-11	Ulcerative colitis;
LUAD	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-6.45	-0.3	3.08e-10	Coronary artery disease;
LUAD	cis	rs612683	0.764	rs558035	chr1:100939777	T/C	cg06223162	chr1:101003688	GPR88	-0.42	-8.05	-0.36	8.27e-15	Breast cancer;
LUAD	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg03733263	chr8:22462867	KIAA1967	0.75	13.17	0.54	1.91e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg12927641	chr6:109611667	NA	0.48	8.03	0.36	9.61e-15	Reticulocyte fraction of red cells;
LUAD	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg06740227	chr12:86229804	RASSF9	0.46	7.95	0.36	1.66e-14	Major depressive disorder;
LUAD	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg10589385	chr1:150898437	SETDB1	0.4	7.49	0.34	4.08e-13	Melanoma;
LUAD	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg27124370	chr19:33622961	WDR88	0.45	7.37	0.34	9.29e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11644478	chr21:40555479	PSMG1	-0.54	-8.71	-0.39	7e-17	Cognitive function;
LUAD	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg05665937	chr4:1216051	CTBP1	-0.4	-6.95	-0.32	1.4e-11	Obesity-related traits;
LUAD	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg03213289	chr20:61660250	NA	0.69	15.0	0.59	4.26e-41	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg06387496	chr7:2775674	GNA12	-0.38	-6.37	-0.3	4.89e-10	Height;
LUAD	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg18180107	chr4:99064573	C4orf37	0.41	6.56	0.3	1.61e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg12311346	chr5:56204834	C5orf35	0.72	11.69	0.49	1.56e-27	Initial pursuit acceleration;
LUAD	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg05457628	chr5:178986728	RUFY1	0.59	10.09	0.44	1.3e-21	Lung cancer;
LUAD	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg08885076	chr2:99613938	TSGA10	0.35	6.45	0.3	3.08e-10	Chronic sinus infection;
LUAD	cis	rs5771069	0.896	rs137862	chr22:50446550	C/A	cg27068297	chr22:50451975	IL17REL	0.32	6.35	0.3	5.47e-10	Ulcerative colitis;
LUAD	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg13319975	chr6:146136371	FBXO30	0.82	13.82	0.56	4.21e-36	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs55788414	0.932	rs12103301	chr16:81181423	A/C	cg06400318	chr16:81190750	PKD1L2	-0.66	-8.39	-0.38	7.54e-16	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg19912559	chr1:40204330	PPIE	-0.57	-9.86	-0.43	9.13e-21	Blood protein levels;
LUAD	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg05340658	chr4:99064831	C4orf37	0.56	9.55	0.42	1.03e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg05865280	chr17:75406074	SEPT9	0.62	19.62	0.69	2.12e-61	Airflow obstruction;
LUAD	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13012494	chr21:47604986	C21orf56	-0.66	-11.66	-0.49	1.9e-27	Testicular germ cell tumor;
LUAD	cis	rs2795502	0.702	rs3123750	chr10:43227824	C/A	cg20628663	chr10:43360327	NA	-0.62	-7.95	-0.36	1.76e-14	Blood protein levels;
LUAD	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg16647868	chr5:131706066	SLC22A5	0.42	7.13	0.33	4.36e-12	Blood metabolite levels;
LUAD	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg01689657	chr7:91764605	CYP51A1	-0.29	-6.79	-0.31	3.84e-11	Breast cancer;
LUAD	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg18854424	chr1:2615690	NA	0.35	7.68	0.35	1.14e-13	Ulcerative colitis;
LUAD	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg02423579	chr7:2872169	GNA12	-0.88	-16.0	-0.61	2.06e-45	Height;
LUAD	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg04450456	chr4:17643702	FAM184B	0.37	7.02	0.32	9.03e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg21028142	chr17:79581711	NPLOC4	-0.42	-8.7	-0.39	7.18e-17	Eye color traits;
LUAD	trans	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg14791747	chr16:20752902	THUMPD1	-0.46	-7.04	-0.32	7.85e-12	Dental caries;
LUAD	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg22875332	chr1:76189707	ACADM	-0.85	-16.25	-0.62	1.69e-46	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	7.21	0.33	2.6e-12	Obesity-related traits;
LUAD	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.21e-14	Prostate cancer;
LUAD	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00166722	chr3:10149974	C3orf24	0.73	10.94	0.47	1.1e-24	Alzheimer's disease;
LUAD	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.85	-0.5	3.52e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27286337	chr10:134555280	INPP5A	0.73	9.77	0.43	1.77e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg22875332	chr1:76189707	ACADM	0.9	18.28	0.66	1.87e-55	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6445967	0.569	rs7622688	chr3:58282840	A/G	cg13750441	chr3:58318267	PXK	-0.32	-6.72	-0.31	5.87e-11	Platelet count;
LUAD	cis	rs11078597	0.671	rs62090058	chr17:1645624	G/C	cg18436246	chr17:1640651	WDR81	0.79	12.45	0.52	1.53e-30	Serum albumin level;
LUAD	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg06064525	chr11:970664	AP2A2	-0.44	-8.63	-0.39	1.23e-16	Alzheimer's disease (late onset);
LUAD	cis	rs3849570	1.000	rs9818006	chr3:81828230	A/C	cg07356753	chr3:81810745	GBE1	-0.63	-10.85	-0.47	2.3e-24	Waist circumference;Body mass index;
LUAD	cis	rs1003719	0.667	rs13050226	chr21:38457708	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.46	7.6	0.35	1.99e-13	Eye color traits;
LUAD	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-8.4	-0.38	6.6e-16	Alzheimer's disease (late onset);
LUAD	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg15147215	chr3:52552868	STAB1	-0.42	-7.62	-0.35	1.65e-13	Bipolar disorder;
LUAD	cis	rs9400271	0.527	rs9386798	chr6:109639971	T/C	cg21918786	chr6:109611834	NA	0.41	6.84	0.32	2.74e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg19336497	chr11:14380999	RRAS2	-0.61	-13.03	-0.54	7.33e-33	Vitamin D levels;
LUAD	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg03762505	chr1:171750926	METTL13	-0.5	-6.88	-0.32	2.21e-11	Testicular germ cell tumor;
LUAD	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg13334819	chr7:99746414	C7orf59	-0.65	-10.13	-0.44	9.58e-22	Coronary artery disease;
LUAD	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg11859384	chr17:80120422	CCDC57	-0.52	-9.35	-0.41	5.05e-19	Life satisfaction;
LUAD	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg03433033	chr1:76189801	ACADM	-0.5	-7.36	-0.34	9.79e-13	Daytime sleep phenotypes;
LUAD	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg04154034	chr17:28927549	LRRC37B2	-0.62	-7.55	-0.34	2.74e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs12681288	0.550	rs12674921	chr8:957969	A/C	cg15309053	chr8:964076	NA	0.44	9.79	0.43	1.59e-20	Schizophrenia;
LUAD	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.54	6.99	0.32	1.05e-11	Body mass index;
LUAD	cis	rs11048434	0.736	rs2377672	chr12:9112414	A/G	cg26114124	chr12:9217669	LOC144571	0.37	6.69	0.31	7e-11	Sjögren's syndrome;
LUAD	cis	rs7089973	1.000	rs7089973	chr10:116569565	A/C	cg25233709	chr10:116636983	FAM160B1	-0.37	-7.18	-0.33	3.11e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7737355	0.947	rs32113	chr5:131049585	G/T	cg06307176	chr5:131281290	NA	-0.54	-8.67	-0.39	9.12e-17	Life satisfaction;
LUAD	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg19767477	chr5:127420684	SLC12A2	-0.42	-6.52	-0.3	1.99e-10	Ileal carcinoids;
LUAD	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg08219700	chr8:58056026	NA	-0.48	-7.01	-0.32	9.23e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.45	-7.47	-0.34	4.65e-13	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	7.86	0.36	3.22e-14	Rheumatoid arthritis;
LUAD	trans	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg14917512	chr19:3094685	GNA11	-0.38	-6.59	-0.31	1.28e-10	Aortic root size;
LUAD	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg27490568	chr2:178487706	NA	0.42	7.05	0.32	7.39e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg09263875	chr16:632152	PIGQ	0.79	17.13	0.64	2.31e-50	Height;
LUAD	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg10729496	chr3:10149963	C3orf24	0.58	9.34	0.41	5.58e-19	Alzheimer's disease;
LUAD	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg19622623	chr12:86230825	RASSF9	-0.53	-9.4	-0.42	3.47e-19	Major depressive disorder;
LUAD	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg17173187	chr15:85201210	NMB	0.5	8.99	0.4	8.33e-18	Schizophrenia;
LUAD	cis	rs2979489	0.891	rs2915591	chr8:30395948	C/G	cg26383811	chr8:30366931	RBPMS	-0.69	-10.64	-0.46	1.4e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg12908607	chr1:44402522	ARTN	-0.45	-9.27	-0.41	9.46e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	8.98	0.4	9.27e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg26536354	chr8:144654954	C8orf73	0.62	6.74	0.31	5.26e-11	Attention deficit hyperactivity disorder;
LUAD	cis	rs2046867	0.818	rs17010195	chr3:72872852	A/G	cg25664220	chr3:72788482	NA	0.54	9.8	0.43	1.4e-20	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2795502	0.564	rs11239844	chr10:43453365	G/A	cg27426351	chr10:43362370	NA	0.54	6.54	0.3	1.8e-10	Blood protein levels;
LUAD	cis	rs11696501	0.694	rs6073823	chr20:44256910	G/C	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.18	-0.37	3.41e-15	Brain structure;
LUAD	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg23758822	chr17:41437982	NA	1.0	20.17	0.7	6.78e-64	Menopause (age at onset);
LUAD	cis	rs734999	0.967	rs10797433	chr1:2502010	T/C	cg18854424	chr1:2615690	NA	0.33	7.8	0.35	4.72e-14	Ulcerative colitis;
LUAD	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	7.33	0.34	1.17e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg25767906	chr1:53392781	SCP2	-0.42	-7.87	-0.36	2.96e-14	Monocyte count;
LUAD	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg21782813	chr7:2030301	MAD1L1	0.44	7.4	0.34	7.3e-13	Schizophrenia;
LUAD	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg16447950	chr5:562315	NA	-0.44	-6.88	-0.32	2.12e-11	Obesity-related traits;
LUAD	cis	rs240764	0.658	rs9390679	chr6:101216102	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-7.37	-0.34	9.31e-13	Neuroticism;
LUAD	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg07537917	chr2:241836409	C2orf54	-0.33	-9.57	-0.42	9.06e-20	Urinary metabolites;
LUAD	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-7.61	-0.35	1.81e-13	Breast cancer;
LUAD	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg18016565	chr1:150552671	MCL1	0.37	6.35	0.3	5.51e-10	Melanoma;
LUAD	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-9.5	-0.42	1.53e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06544989	chr22:39130855	UNC84B	0.44	8.19	0.37	3.06e-15	Menopause (age at onset);
LUAD	cis	rs7520050	0.645	rs1768809	chr1:46502836	A/C	cg06784218	chr1:46089804	CCDC17	-0.35	-7.9	-0.36	2.49e-14	Red blood cell count;Reticulocyte count;
LUAD	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg27572855	chr1:25598939	RHD	0.55	12.14	0.51	2.73e-29	Erythrocyte sedimentation rate;
LUAD	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg14343924	chr8:8086146	FLJ10661	0.48	7.33	0.34	1.19e-12	Mood instability;
LUAD	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg02782426	chr3:40428986	ENTPD3	0.34	7.47	0.34	4.59e-13	Renal cell carcinoma;
LUAD	cis	rs6906287	0.647	rs11153752	chr6:118834771	A/T	cg05564266	chr6:118973597	C6orf204	0.35	7.43	0.34	6.24e-13	Electrocardiographic conduction measures;
LUAD	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg06713675	chr4:122721982	EXOSC9	-0.85	-17.99	-0.66	3.87e-54	Type 2 diabetes;
LUAD	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg06671706	chr8:8559999	CLDN23	-0.36	-6.41	-0.3	3.9e-10	Mood instability;
LUAD	cis	rs12618769	0.597	rs4850879	chr2:99113082	A/G	cg10123293	chr2:99228465	UNC50	0.46	8.12	0.37	5.1e-15	Bipolar disorder;
LUAD	trans	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg01620082	chr3:125678407	NA	-0.44	-6.48	-0.3	2.55e-10	Depression;
LUAD	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-7.5	-0.34	3.85e-13	Resting heart rate;
LUAD	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.16	-11.44	-0.49	1.33e-26	Schizophrenia;
LUAD	trans	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg01620082	chr3:125678407	NA	-0.44	-6.7	-0.31	6.82e-11	Parkinson's disease;
LUAD	cis	rs7932354	0.528	rs4319472	chr11:47109514	G/C	cg19486271	chr11:47235900	DDB2	0.43	6.77	0.31	4.22e-11	Bone mineral density (hip);Bone mineral density;
LUAD	trans	rs6076960	0.684	rs3852947	chr20:6255341	A/G	cg21095983	chr6:86352623	SYNCRIP	0.43	6.98	0.32	1.12e-11	Smooth-surface caries;
LUAD	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg02423579	chr7:2872169	GNA12	-0.87	-15.32	-0.6	1.84e-42	Height;
LUAD	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg22105103	chr4:187893119	NA	-0.5	-10.81	-0.47	3.33e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg25243455	chr2:114033360	PAX8;LOC440839	-0.38	-8.46	-0.38	4.33e-16	Lymphocyte counts;
LUAD	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg03030879	chr14:75389066	RPS6KL1	0.36	6.79	0.31	3.82e-11	Caffeine consumption;
LUAD	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg07211511	chr3:129823064	LOC729375	-0.86	-12.81	-0.53	5.44e-32	Blood pressure (smoking interaction);
LUAD	cis	rs9826463	0.582	rs7633870	chr3:142118914	A/G	cg20824294	chr3:142316082	PLS1	0.36	6.35	0.3	5.57e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7937890	0.559	rs2597219	chr11:14530866	C/G	cg06199346	chr11:14280333	SPON1	-0.32	-6.42	-0.3	3.58e-10	Mitochondrial DNA levels;
LUAD	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg15704280	chr7:45808275	SEPT13	-1.07	-24.81	-0.77	1.63e-84	Height;
LUAD	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg00280220	chr17:61926910	NA	0.36	6.95	0.32	1.37e-11	Prudent dietary pattern;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17829318	chr4:37688612	RELL1	-0.37	-6.39	-0.3	4.33e-10	Height;
LUAD	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg11901034	chr3:128598214	ACAD9	-0.55	-8.74	-0.39	5.64e-17	IgG glycosylation;
LUAD	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg10523679	chr1:76189770	ACADM	-0.48	-6.71	-0.31	6.37e-11	Daytime sleep phenotypes;
LUAD	cis	rs758324	0.812	rs9327621	chr5:131118943	T/C	cg25547332	chr5:131281432	NA	0.44	7.03	0.32	8.34e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs12949688	1.000	rs886925	chr17:55817649	G/C	cg12582317	chr17:55822272	NA	0.36	7.34	0.34	1.11e-12	Schizophrenia;
LUAD	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg08493051	chr2:3487164	NA	-0.44	-7.71	-0.35	9.25e-14	Neurofibrillary tangles;
LUAD	cis	rs1865721	0.958	rs11663060	chr18:73172806	T/C	cg26385618	chr18:73139727	C18orf62	-0.42	-7.56	-0.35	2.52e-13	Intelligence;
LUAD	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg08807101	chr21:30365312	RNF160	-0.44	-7.67	-0.35	1.22e-13	Dental caries;
LUAD	cis	rs59698941	0.943	rs997633	chr5:132219304	A/T	cg14825688	chr5:132208181	LEAP2	-0.47	-6.7	-0.31	6.62e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg07917127	chr4:99064746	C4orf37	0.45	7.34	0.34	1.1e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg12034118	chr1:209979487	IRF6	0.57	6.61	0.31	1.14e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs12900413	0.687	rs6496602	chr15:90317797	A/G	cg24249390	chr15:90295951	MESP1	-0.33	-6.68	-0.31	7.74e-11	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg26566898	chr11:117069891	TAGLN	0.35	6.77	0.31	4.34e-11	Blood protein levels;
LUAD	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg13770153	chr20:60521292	NA	-0.6	-9.25	-0.41	1.15e-18	Body mass index;
LUAD	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg25233709	chr10:116636983	FAM160B1	0.41	8.12	0.37	5.13e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs7584330	0.554	rs3751109	chr2:238427194	T/C	cg14458575	chr2:238380390	NA	0.61	9.85	0.43	9.8e-21	Prostate cancer;
LUAD	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg06360820	chr2:242988706	NA	-0.86	-9.27	-0.41	9.75e-19	Obesity-related traits;
LUAD	cis	rs7493	0.950	rs11981299	chr7:95029701	T/A	cg01874867	chr7:94954059	PON1	-0.5	-6.7	-0.31	6.5500000000000006e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.3	-0.6	2.18e-42	Chronic sinus infection;
LUAD	trans	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg07211511	chr3:129823064	LOC729375	-0.71	-9.88	-0.43	7.22e-21	Blood pressure (smoking interaction);
LUAD	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg21856205	chr7:94953877	PON1	-0.54	-7.46	-0.34	4.9e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg21475434	chr5:93447410	FAM172A	0.5	6.87	0.32	2.28e-11	Diabetic retinopathy;
LUAD	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg21016266	chr12:122356598	WDR66	0.68	12.26	0.51	8.9e-30	Mean corpuscular volume;
LUAD	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg20933634	chr6:27740509	NA	0.42	7.17	0.33	3.36e-12	Parkinson's disease;
LUAD	cis	rs28595532	1.000	rs115706377	chr4:119628481	G/A	cg02775129	chr4:119771670	NA	-0.84	-7.82	-0.36	4.25e-14	Cannabis dependence symptom count;
LUAD	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg15962314	chr1:44399869	ARTN	-0.34	-7.82	-0.36	4.28e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs807669	0.565	rs5746682	chr22:19185526	C/T	cg24911827	chr22:19170109	CLTCL1	0.36	7.6	0.35	1.93e-13	Metabolite levels;
LUAD	cis	rs10821556	1	rs10821556	chr9:136942136	C/A	cg14252148	chr9:136933880	BRD3	0.44	6.88	0.32	2.11e-11	Mean platelet volume;
LUAD	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg25769590	chr7:158789503	NA	-0.39	-7.13	-0.33	4.5e-12	Facial morphology (factor 20);
LUAD	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg10876282	chr6:28092338	ZSCAN16	0.44	6.58	0.3	1.36e-10	Parkinson's disease;
LUAD	cis	rs7680126	0.596	rs4637402	chr4:10045430	C/T	cg02734326	chr4:10020555	SLC2A9	0.48	7.35	0.34	9.99e-13	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.43	7.38	0.34	8.27e-13	Lung cancer in ever smokers;
LUAD	trans	rs911186	0.740	rs6938200	chr6:27231150	A/G	cg06606381	chr12:133084897	FBRSL1	-0.5	-6.96	-0.32	1.32e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3739034	0.938	rs62171393	chr2:135475960	C/G	cg12500956	chr2:135428796	TMEM163	0.37	6.78	0.31	3.98e-11	Gut microbiome composition (winter);
LUAD	cis	rs418053	0.624	rs4715451	chr6:13638984	A/G	cg02206980	chr6:13574034	SIRT5	-0.35	-7.57	-0.35	2.41e-13	Breast cancer;
LUAD	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18876405	chr7:65276391	NA	-0.42	-6.68	-0.31	7.32e-11	Aortic root size;
LUAD	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg16850897	chr7:100343110	ZAN	-0.59	-8.14	-0.37	4.31e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg02508848	chr16:68573721	ZFP90	-0.42	-6.55	-0.3	1.72e-10	Ulcerative colitis;
LUAD	cis	rs6445967	0.545	rs67148387	chr3:58281224	A/G	cg13750441	chr3:58318267	PXK	-0.31	-6.59	-0.31	1.32e-10	Platelet count;
LUAD	cis	rs2637266	1.000	rs2395390	chr10:78357734	C/G	cg18941641	chr10:78392320	NA	0.33	6.81	0.31	3.27e-11	Pulmonary function;
LUAD	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg03806693	chr22:41940476	POLR3H	0.66	9.03	0.4	6.01e-18	Vitiligo;
LUAD	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg12365402	chr11:9010492	NRIP3	-0.43	-8.11	-0.37	5.72e-15	Hemoglobin concentration;
LUAD	cis	rs11971779	0.680	rs4732369	chr7:139069173	C/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.46	-0.3	2.86e-10	Diisocyanate-induced asthma;
LUAD	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg05340658	chr4:99064831	C4orf37	0.55	9.15	0.41	2.39e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg16606324	chr3:10149918	C3orf24	0.68	11.37	0.48	2.59e-26	Alzheimer's disease;
LUAD	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg17105886	chr17:28927953	LRRC37B2	0.73	6.7	0.31	6.69e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg16606324	chr3:10149918	C3orf24	0.7	11.51	0.49	7.19e-27	Alzheimer's disease;
LUAD	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg03929089	chr4:120376271	NA	-0.82	-14.47	-0.58	8.06e-39	Height;
LUAD	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg20607287	chr7:12443886	VWDE	-0.56	-6.9	-0.32	1.9e-11	Coronary artery disease;
LUAD	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg04287289	chr16:89883240	FANCA	0.77	6.93	0.32	1.6e-11	Skin colour saturation;
LUAD	cis	rs6460942	0.915	rs2192842	chr7:12315752	C/G	cg06484146	chr7:12443880	VWDE	-0.5	-7.12	-0.33	4.72e-12	Coronary artery disease;
LUAD	cis	rs62238980	0.614	rs5998256	chr22:32549246	A/T	cg00543991	chr22:32367038	NA	0.83	7.42	0.34	6.2800000000000005e-13	Childhood ear infection;
LUAD	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg22166914	chr1:53195759	ZYG11B	0.41	6.76	0.31	4.56e-11	Monocyte count;
LUAD	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg03676636	chr4:99064102	C4orf37	0.31	8.01	0.36	1.12e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg02734326	chr4:10020555	SLC2A9	0.53	9.3	0.41	7.47e-19	Bone mineral density;
LUAD	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.78e-11	Crohn's disease;
LUAD	cis	rs7833986	0.501	rs2953901	chr8:56981824	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	1.01	18.4	0.67	5.68e-56	Height;
LUAD	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg22681709	chr2:178499509	PDE11A	-0.43	-7.09	-0.33	5.75e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.66	0.31	8.58e-11	Hip circumference adjusted for BMI;
LUAD	trans	rs7939886	0.920	rs1586014	chr11:55771540	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.74	0.31	5.23e-11	Myopia (pathological);
LUAD	cis	rs9902453	0.753	rs3097118	chr17:27978466	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	10.52	0.46	3.87e-23	Coffee consumption (cups per day);
LUAD	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg15017067	chr4:17643749	FAM184B	0.34	6.53	0.3	1.91e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs9902453	0.904	rs4567782	chr17:28268800	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	10.33	0.45	1.94e-22	Coffee consumption (cups per day);
LUAD	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg02176678	chr2:219576539	TTLL4	0.63	12.32	0.51	5.16e-30	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg27454412	chr7:1067447	C7orf50	0.45	6.99	0.32	1.07e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg07169764	chr2:136633963	MCM6	0.82	9.53	0.42	1.2e-19	Corneal structure;
LUAD	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg07404485	chr7:94953653	PON1	0.5	7.44	0.34	5.86e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg11062466	chr8:58055876	NA	0.6	7.89	0.36	2.67e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs17433780	0.504	rs7525985	chr1:89460948	C/T	cg10631373	chr1:89457642	RBMXL1;CCBL2	0.36	6.42	0.3	3.77e-10	Carotid intima media thickness;
LUAD	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg13180566	chr4:1052158	NA	-0.39	-6.57	-0.3	1.47e-10	Recombination rate (females);
LUAD	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg18180107	chr4:99064573	C4orf37	0.47	7.35	0.34	1.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9443645	0.527	rs12194642	chr6:79538791	G/A	cg05283184	chr6:79620031	NA	-0.42	-7.38	-0.34	8.35e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs4604732	0.631	rs74154673	chr1:247625629	G/A	cg12758973	chr1:247694275	LOC148824;OR2C3	0.42	7.36	0.34	9.86e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg10802521	chr3:52805072	NEK4	-0.45	-6.58	-0.3	1.41e-10	Schizophrenia;
LUAD	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg00530320	chr1:46809349	NSUN4	0.52	8.09	0.37	6.21e-15	Menopause (age at onset);
LUAD	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg01579765	chr21:45077557	HSF2BP	-0.55	-12.7	-0.53	1.57e-31	Mean corpuscular volume;
LUAD	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg17077180	chr1:38461687	NA	0.47	9.0	0.4	7.47e-18	Coronary artery disease;
LUAD	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.99	16.55	0.63	8.67e-48	IgG glycosylation;
LUAD	trans	rs28735056	0.904	rs11665111	chr18:77622996	T/C	cg05926928	chr17:57297772	GDPD1	0.5	7.56	0.35	2.49e-13	Schizophrenia;
LUAD	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg05805236	chr11:65401703	PCNXL3	-0.59	-9.84	-0.43	1.04e-20	Acne (severe);
LUAD	cis	rs3752645	0.649	rs112171645	chr7:106739665	A/T	cg02696742	chr7:106810147	HBP1	-0.65	-6.45	-0.3	3.14e-10	Bladder cancer (smoking interaction);
LUAD	cis	rs3733418	0.929	rs12510464	chr4:165919040	A/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.52	-6.73	-0.31	5.69e-11	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg17366294	chr4:99064904	C4orf37	0.66	12.9	0.53	2.49e-32	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg03929089	chr4:120376271	NA	0.7	11.02	0.47	5.2e-25	Coronary artery disease;
LUAD	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13126279	chr21:47581558	C21orf56	-0.46	-7.94	-0.36	1.83e-14	Testicular germ cell tumor;
LUAD	cis	rs3956705	0.933	rs13311772	chr7:32999810	C/T	cg05721444	chr7:32995514	FKBP9	-0.37	-6.37	-0.3	4.91e-10	Red cell distribution width;
LUAD	cis	rs2625529	0.775	rs4777466	chr15:72136872	C/T	cg16672083	chr15:72433130	SENP8	-0.61	-11.04	-0.47	4.5e-25	Red blood cell count;
LUAD	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg14008862	chr17:28927542	LRRC37B2	0.75	7.37	0.34	9.31e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg16414030	chr3:133502952	NA	-0.75	-14.57	-0.58	3.07e-39	Iron status biomarkers;
LUAD	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg17346650	chr17:80929145	B3GNTL1	0.39	6.94	0.32	1.45e-11	Glycated hemoglobin levels;
LUAD	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-9.51	-0.42	1.51e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3823572	0.511	rs2971982	chr7:133657698	C/T	cg03336402	chr7:133662267	EXOC4	-0.41	-7.59	-0.35	2.08e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08219700	chr8:58056026	NA	0.64	8.96	0.4	1.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg13319975	chr6:146136371	FBXO30	-0.57	-9.59	-0.42	7.5e-20	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-9.41	-0.42	3.1400000000000002e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs11676348	0.712	rs12694426	chr2:218942351	T/G	cg06547715	chr2:218990976	CXCR2	0.3	6.82	0.31	3.18e-11	Ulcerative colitis;
LUAD	trans	rs3960554	0.529	rs1859795	chr7:75877354	A/G	cg19862616	chr7:65841803	NCRNA00174	0.51	7.82	0.36	4.26e-14	Eotaxin levels;
LUAD	cis	rs11809207	0.951	rs111772533	chr1:26523404	C/G	cg00300879	chr1:26503847	CNKSR1	0.28	6.87	0.32	2.34e-11	Height;
LUAD	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg09359103	chr1:154839909	KCNN3	-0.91	-21.24	-0.72	1.09e-68	Prostate cancer;
LUAD	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg05805236	chr11:65401703	PCNXL3	0.51	8.71	0.39	7.01e-17	Acne (severe);
LUAD	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg11062466	chr8:58055876	NA	0.68	9.02	0.4	6.56e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg04287289	chr16:89883240	FANCA	0.53	9.3	0.41	7.53e-19	Vitiligo;
LUAD	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg14581129	chr12:53358946	NA	-0.91	-16.13	-0.62	6.08e-46	Cancer (pleiotropy);
LUAD	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg18621852	chr3:10150065	C3orf24	0.42	7.44	0.34	5.85e-13	Alzheimer's disease;
LUAD	cis	rs524023	0.874	rs506338	chr11:64440920	T/C	cg19131476	chr11:64387923	NRXN2	-0.43	-8.34	-0.38	1.04e-15	Urate levels in obese individuals;
LUAD	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	7.66	0.35	1.29e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg01251360	chr16:68772225	CDH1	0.29	9.03	0.4	6.05e-18	Colorectal cancer;
LUAD	cis	rs10465746	0.780	rs11163867	chr1:84384847	C/T	cg10977910	chr1:84465055	TTLL7	0.59	9.63	0.42	5.64e-20	Obesity-related traits;
LUAD	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg08893839	chr5:154027129	NA	-0.61	-7.79	-0.35	5.24e-14	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4713675	0.584	rs9380375	chr6:33682391	G/A	cg13859433	chr6:33739653	LEMD2	-0.3	-7.19	-0.33	2.97e-12	Plateletcrit;
LUAD	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg17845761	chr1:175162550	KIAA0040	-0.35	-9.25	-0.41	1.09e-18	Alcohol dependence;
LUAD	cis	rs2108225	0.900	rs4518594	chr7:107451060	G/C	cg18560240	chr7:107437656	SLC26A3	-0.4	-6.39	-0.3	4.3e-10	Ulcerative colitis;
LUAD	cis	rs68170813	0.559	rs77641084	chr7:106970522	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-9.97	-0.44	3.56e-21	Coronary artery disease;
LUAD	cis	rs4852324	0.536	rs71418714	chr2:74219886	G/C	cg05890377	chr2:74357713	NA	0.82	7.35	0.34	1.04e-12	Systemic lupus erythematosus;
LUAD	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg16342193	chr10:102329863	NA	-0.39	-6.62	-0.31	1.11e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs8025790	0.508	rs35930676	chr15:67827705	G/A	cg24579218	chr15:68104479	NA	-0.47	-7.71	-0.35	9.14e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUAD	cis	rs12681287	0.640	rs34794500	chr8:87449995	G/A	cg27223183	chr8:87520930	FAM82B	-0.67	-9.58	-0.42	8.35e-20	Caudate activity during reward;
LUAD	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10802521	chr3:52805072	NEK4	0.63	11.33	0.48	3.53e-26	Bipolar disorder;
LUAD	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg01884057	chr2:25150051	NA	0.32	6.66	0.31	8.33e-11	Body mass index;
LUAD	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg24154853	chr7:158122151	PTPRN2	0.58	11.78	0.5	6.74e-28	Calcium levels;
LUAD	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.51	0.38	2.96e-16	Breast cancer;
LUAD	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg24397884	chr7:158709396	WDR60	-0.74	-13.48	-0.55	1.09e-34	Height;
LUAD	cis	rs76878669	0.561	rs12794121	chr11:66126169	G/T	cg10616300	chr11:66138557	SLC29A2	0.35	7.3	0.33	1.49e-12	Educational attainment (years of education);
LUAD	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.44	0.42	2.46e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg04218760	chr10:45406644	TMEM72	-0.32	-8.02	-0.36	1.05e-14	Mean corpuscular volume;
LUAD	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg11344533	chr11:111475393	SIK2	-0.35	-6.68	-0.31	7.77e-11	Primary sclerosing cholangitis;
LUAD	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg25358565	chr5:93447407	FAM172A	0.62	7.67	0.35	1.21e-13	Diabetic retinopathy;
LUAD	cis	rs78487399	0.614	rs77389971	chr2:43718084	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-6.71	-0.31	6.38e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LUAD	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg06558623	chr16:89946397	TCF25	1.23	12.4	0.52	2.47e-30	Skin colour saturation;
LUAD	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.88	15.35	0.6	1.44e-42	Chronic sinus infection;
LUAD	cis	rs7932354	0.502	rs10769244	chr11:47182368	A/G	cg19486271	chr11:47235900	DDB2	0.42	6.52	0.3	2.02e-10	Bone mineral density (hip);Bone mineral density;
LUAD	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg00530320	chr1:46809349	NSUN4	0.53	8.17	0.37	3.63e-15	Menopause (age at onset);
LUAD	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg13319975	chr6:146136371	FBXO30	-0.61	-10.29	-0.45	2.66e-22	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12900413	0.687	rs12913572	chr15:90319313	T/C	cg24249390	chr15:90295951	MESP1	-0.35	-7.01	-0.32	9.56e-12	Coronary artery aneurysm in Kawasaki disease;
LUAD	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg12573674	chr2:1569213	NA	-0.67	-7.55	-0.34	2.72e-13	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs2267137	0.903	rs2072051	chr22:29755888	C/T	cg07256473	chr22:29710276	RASL10A	-0.42	-8.08	-0.37	6.97e-15	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs8017423	0.900	rs7141887	chr14:90705364	G/T	cg14092571	chr14:90743983	NA	-0.49	-8.75	-0.39	5.11e-17	Mortality in heart failure;
LUAD	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg17366294	chr4:99064904	C4orf37	0.67	12.93	0.53	1.88e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs367615	0.552	rs2115511	chr5:108725403	A/T	cg17395555	chr5:108820864	NA	-0.47	-9.02	-0.4	6.72e-18	Colorectal cancer (SNP x SNP interaction);
LUAD	trans	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	6.07e-11	Depression;
LUAD	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg26924012	chr15:45694286	SPATA5L1	0.97	17.42	0.65	1.33e-51	Homoarginine levels;
LUAD	cis	rs225245	0.782	rs225293	chr17:33925906	A/G	cg05299278	chr17:33885742	SLFN14	0.51	11.64	0.49	2.45e-27	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	cis	rs7017914	0.967	rs2732087	chr8:71860439	A/G	cg05247391	chr8:71581649	XKR9;LACTB2	-0.31	-6.38	-0.3	4.64e-10	Bone mineral density;
LUAD	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg09936400	chr10:82049201	MAT1A	0.37	6.62	0.31	1.12e-10	Post bronchodilator FEV1;
LUAD	cis	rs870825	0.655	rs7675046	chr4:185652201	G/A	cg04058563	chr4:185651563	MLF1IP	-0.85	-13.61	-0.55	3.09e-35	Blood protein levels;
LUAD	cis	rs7903847	0.642	rs11189156	chr10:99111751	T/A	cg20016023	chr10:99160130	RRP12	-0.31	-6.8	-0.31	3.65e-11	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs4900538	0.821	rs8016191	chr14:102825340	G/A	cg18135206	chr14:102964638	TECPR2	-0.99	-20.2	-0.7	5.22e-64	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUAD	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg11062466	chr8:58055876	NA	-0.52	-7.07	-0.33	6.25e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs73086581	0.947	rs73084523	chr20:3875626	T/C	cg02187196	chr20:3869020	PANK2	0.46	6.56	0.3	1.54e-10	Response to antidepressants in depression;
LUAD	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg09835421	chr16:68378352	PRMT7	-0.84	-9.11	-0.41	3.24e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs11585357	0.895	rs72646797	chr1:17613838	C/G	cg08277548	chr1:17600880	PADI3	-0.95	-13.88	-0.56	2.23e-36	Hair shape;
LUAD	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg05590025	chr7:65112418	INTS4L2	-0.71	-7.61	-0.35	1.84e-13	Diabetic kidney disease;
LUAD	cis	rs4638749	0.773	rs4676190	chr2:108858619	A/G	cg06795125	chr2:108905320	SULT1C2	-0.46	-6.76	-0.31	4.55e-11	Blood pressure;
LUAD	cis	rs1143633	0.530	rs2723163	chr2:113694339	A/G	cg12858261	chr2:113808755	IL1F8	0.38	6.91	0.32	1.79e-11	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg24579218	chr15:68104479	NA	-0.55	-9.46	-0.42	2.17e-19	Restless legs syndrome;
LUAD	cis	rs7589342	0.895	rs11901644	chr2:106432113	T/G	cg16077055	chr2:106428750	NCK2	0.36	6.35	0.3	5.49e-10	Addiction;
LUAD	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg10755058	chr3:40428713	ENTPD3	0.46	8.6	0.39	1.6e-16	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg07917127	chr4:99064746	C4orf37	0.42	7.01	0.32	9.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6076065	0.723	rs4813495	chr20:23391617	A/G	cg11657817	chr20:23433608	CST11	0.47	8.92	0.4	1.45e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.33	5.36e-12	Lung cancer;
LUAD	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg25767906	chr1:53392781	SCP2	0.4	7.17	0.33	3.36e-12	Monocyte count;
LUAD	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg12419862	chr22:24373484	LOC391322	-0.63	-10.15	-0.44	8.14e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26913058	chr16:419975	MRPL28	-0.44	-7.76	-0.35	6.49e-14	Bone mineral density (spine);Bone mineral density;
LUAD	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg08071915	chr8:12219732	FAM66A	0.44	7.11	0.33	4.92e-12	Joint mobility (Beighton score);
LUAD	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg14343924	chr8:8086146	FLJ10661	-0.41	-6.35	-0.3	5.54e-10	Mood instability;
LUAD	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg17063962	chr7:91808500	NA	0.66	11.93	0.5	1.82e-28	Breast cancer;
LUAD	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg15704280	chr7:45808275	SEPT13	-0.91	-16.71	-0.63	1.63e-48	Height;
LUAD	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg13047869	chr3:10149882	C3orf24	0.59	9.99	0.44	2.95e-21	Alzheimer's disease;
LUAD	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg03474202	chr17:45855739	NA	-0.38	-8.75	-0.39	5e-17	IgG glycosylation;
LUAD	cis	rs939658	0.805	rs8036435	chr15:79420031	T/C	cg17916960	chr15:79447300	NA	-0.52	-11.07	-0.47	3.6e-25	Refractive error;
LUAD	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg13012494	chr21:47604986	C21orf56	0.43	6.61	0.31	1.17e-10	Testicular germ cell tumor;
LUAD	cis	rs12681287	0.604	rs41469550	chr8:87406544	G/T	cg27223183	chr8:87520930	FAM82B	0.65	9.27	0.41	9.56e-19	Caudate activity during reward;
LUAD	cis	rs4711350	0.734	rs9380379	chr6:33766131	A/G	cg13859433	chr6:33739653	LEMD2	-0.32	-6.59	-0.31	1.32e-10	Schizophrenia;
LUAD	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.59	-0.31	1.32e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2116941	1.000	rs7250265	chr19:10339818	G/C	cg01850179	chr19:10340795	S1PR2	-0.85	-13.87	-0.56	2.44e-36	Pulse pressure;
LUAD	cis	rs1595825	0.891	rs73056811	chr2:198766642	T/C	cg10547527	chr2:198650123	BOLL	-0.53	-7.64	-0.35	1.45e-13	Ulcerative colitis;
LUAD	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg27433088	chr4:174089019	GALNT7	0.4	7.52	0.34	3.37e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs11153730	0.503	rs283042	chr6:118631282	G/A	cg21191810	chr6:118973309	C6orf204	0.49	9.58	0.42	8.67e-20	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUAD	cis	rs4692589	1.000	rs4692785	chr4:170938593	C/T	cg19918862	chr4:170955249	NA	0.29	7.05	0.32	7.15e-12	Anxiety disorder;
LUAD	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg06221963	chr1:154839813	KCNN3	-0.88	-21.24	-0.72	1.14e-68	Prostate cancer;
LUAD	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg06640241	chr16:89574553	SPG7	0.73	12.87	0.53	3.11e-32	Multiple myeloma (IgH translocation);
LUAD	cis	rs727505	1.000	rs10233596	chr7:124556659	A/G	cg23710748	chr7:124431027	NA	-0.49	-9.96	-0.44	4.03e-21	Lewy body disease;
LUAD	cis	rs67981189	0.570	rs67188216	chr14:71509324	T/A	cg15910301	chr14:71632612	NA	0.41	6.43	0.3	3.44e-10	Schizophrenia;
LUAD	cis	rs2131877	0.913	rs1874099	chr3:194848766	G/T	cg19760965	chr3:194868843	C3orf21	0.39	6.49	0.3	2.43e-10	Non-small cell lung cancer;
LUAD	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg00129232	chr17:37814104	STARD3	-0.45	-7.41	-0.34	6.84e-13	Asthma;
LUAD	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg18016565	chr1:150552671	MCL1	-0.4	-6.87	-0.32	2.31e-11	Tonsillectomy;
LUAD	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg25358565	chr5:93447407	FAM172A	0.63	7.32	0.34	1.29e-12	Diabetic retinopathy;
LUAD	cis	rs7224314	1.000	rs8070689	chr17:65387405	G/T	cg01507342	chr17:65387096	PITPNC1	-0.54	-8.81	-0.39	3.3e-17	Diisocyanate-induced asthma;
LUAD	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg03388025	chr16:89894329	SPIRE2	0.5	13.26	0.54	8.75e-34	Vitiligo;
LUAD	cis	rs2485376	1.000	rs1541046	chr10:104005386	G/A	cg20641465	chr10:103991465	PITX3	0.58	10.74	0.46	6.07e-24	QT interval;
LUAD	trans	rs877282	1.000	rs11253361	chr10:770387	T/C	cg22713356	chr15:30763199	NA	1.23	16.79	0.63	7.25e-49	Uric acid levels;
LUAD	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	9.04	0.4	5.62e-18	Ileal carcinoids;
LUAD	cis	rs642803	1.000	rs557675	chr11:65566719	G/T	cg27068330	chr11:65405492	SIPA1	-0.44	-7.18	-0.33	3.17e-12	Urate levels;
LUAD	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg19761014	chr17:28927070	LRRC37B2	0.72	6.57	0.3	1.47e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg18187862	chr3:45730750	SACM1L	0.5	7.81	0.36	4.45e-14	Primary sclerosing cholangitis;
LUAD	trans	rs2806561	1.000	rs2776822	chr1:23492782	A/G	cg27552081	chr17:25621774	WSB1	0.38	6.4	0.3	4.1e-10	Height;
LUAD	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg08676812	chr11:65308423	LTBP3	0.96	7.28	0.33	1.59e-12	Height;
LUAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg21724239	chr8:58056113	NA	0.72	9.49	0.42	1.73e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs897984	0.520	rs12928081	chr16:30885159	T/G	cg05768032	chr16:30646687	NA	-0.4	-6.45	-0.3	3.14e-10	Dementia with Lewy bodies;
LUAD	cis	rs8077889	0.703	rs231532	chr17:41945769	C/T	cg26893861	chr17:41843967	DUSP3	-0.68	-9.42	-0.42	2.93e-19	Triglycerides;
LUAD	cis	rs239198	0.521	rs9377241	chr6:101334265	C/T	cg09795085	chr6:101329169	ASCC3	0.4	7.13	0.33	4.45e-12	Menarche (age at onset);
LUAD	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg02269571	chr22:50332266	NA	-0.73	-10.37	-0.45	1.37e-22	Schizophrenia;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00162541	chr19:16607016	C19orf44;CALR3	-0.39	-6.35	-0.3	5.46e-10	Cancer;
LUAD	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg08439880	chr3:133502540	NA	-0.37	-7.1	-0.33	5.17e-12	Iron status biomarkers;
LUAD	cis	rs17818399	0.926	rs35682608	chr2:46836542	A/T	cg21681030	chr2:46777652	RHOQ	0.42	7.5	0.34	3.79e-13	Height;
LUAD	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.45	7.83	0.36	4.03e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7301016	0.948	rs73141045	chr12:62931083	C/G	cg11441379	chr12:63026424	NA	0.59	7.31	0.33	1.33e-12	IgG glycosylation;
LUAD	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg26516362	chr5:178986906	RUFY1	-0.53	-9.18	-0.41	2e-18	Lung cancer;
LUAD	cis	rs939658	0.805	rs939661	chr15:79431063	A/G	cg17916960	chr15:79447300	NA	-0.51	-10.58	-0.46	2.29e-23	Refractive error;
LUAD	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.72	-11.6	-0.49	3.42e-27	Primary sclerosing cholangitis;
LUAD	cis	rs7943203	0.539	rs12226046	chr11:108335940	G/C	cg04873221	chr11:107992290	ACAT1	-0.48	-7.22	-0.33	2.4e-12	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs9807989	0.507	rs7581119	chr2:103049865	G/A	cg03938978	chr2:103052716	IL18RAP	0.46	10.49	0.45	4.89e-23	Asthma;
LUAD	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg23301539	chr8:142222248	SLC45A4	0.48	8.75	0.39	5.18e-17	Immature fraction of reticulocytes;
LUAD	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18099408	chr3:52552593	STAB1	-0.46	-7.86	-0.36	3.21e-14	Bipolar disorder;
LUAD	cis	rs412658	0.704	rs8105767	chr19:22215441	A/G	cg20662725	chr19:22235022	ZNF257	-0.37	-6.52	-0.3	2.03e-10	Telomere length;
LUAD	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg12756686	chr19:29218302	NA	0.71	9.92	0.43	5.42e-21	Methadone dose in opioid dependence;
LUAD	cis	rs7017914	0.967	rs2100908	chr8:71583310	G/A	cg05247391	chr8:71581649	XKR9;LACTB2	-0.33	-6.58	-0.3	1.44e-10	Bone mineral density;
LUAD	cis	rs1160297	0.576	rs1376570	chr2:53087099	G/A	cg07782112	chr2:53107842	NA	0.35	7.39	0.34	7.73e-13	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg17644776	chr2:200775616	C2orf69	-0.53	-6.66	-0.31	8.3e-11	Schizophrenia;
LUAD	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg06641503	chr3:48959341	ARIH2	-0.37	-7.22	-0.33	2.38e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUAD	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26314531	chr2:26401878	FAM59B	-0.56	-7.73	-0.35	8.02e-14	Gut microbiome composition (summer);
LUAD	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.72	-0.31	5.85e-11	Breast cancer;
LUAD	cis	rs6028335	0.674	rs12625983	chr20:37603936	C/T	cg27660920	chr20:37554817	FAM83D	-0.5	-6.46	-0.3	2.87e-10	Alcohol and nicotine co-dependence;
LUAD	cis	rs7759001	0.817	rs2393929	chr6:27351931	A/C	cg18711553	chr6:27366782	ZNF391	0.39	6.39	0.3	4.29e-10	Glomerular filtration rate (creatinine);
LUAD	cis	rs16866061	0.517	rs7580488	chr2:225473263	C/T	cg12698349	chr2:225449008	CUL3	0.51	8.37	0.38	8.62e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs1595825	0.891	rs6751690	chr2:198574523	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-7.03	-0.32	8.25e-12	Ulcerative colitis;
LUAD	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg12927641	chr6:109611667	NA	-0.53	-9.51	-0.42	1.42e-19	Reticulocyte fraction of red cells;
LUAD	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg17063962	chr7:91808500	NA	0.6	10.23	0.45	4.36e-22	Breast cancer;
LUAD	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15369054	chr17:80825471	TBCD	0.65	10.77	0.46	4.46e-24	Breast cancer;
LUAD	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg08027265	chr7:2291960	NA	-0.41	-6.94	-0.32	1.52e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs796825	0.512	rs34964758	chr3:119942440	A/C	cg21790991	chr3:120137480	FSTL1	-0.42	-7.26	-0.33	1.88e-12	HIV-1 susceptibility;
LUAD	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg02002194	chr4:3960332	NA	0.3	7.44	0.34	5.48e-13	Mood instability;
LUAD	cis	rs7301826	0.651	rs4759794	chr12:131297348	T/G	cg11011512	chr12:131303247	STX2	0.44	7.42	0.34	6.59e-13	Plasma plasminogen activator levels;
LUAD	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg22875332	chr1:76189707	ACADM	-0.65	-10.35	-0.45	1.58e-22	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12667521	chr19:29218732	NA	0.59	8.46	0.38	4.55e-16	Methadone dose in opioid dependence;
LUAD	cis	rs713477	0.817	rs55868790	chr14:55913275	T/C	cg13175173	chr14:55914753	NA	-0.35	-7.38	-0.34	8.53e-13	Pediatric bone mineral content (femoral neck);
LUAD	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg04705435	chr11:17411270	KCNJ11	0.47	7.77	0.35	6.01e-14	Type 2 diabetes;
LUAD	cis	rs1595825	0.838	rs60079260	chr2:198673636	G/A	cg10547527	chr2:198650123	BOLL	-0.53	-7.05	-0.32	7.15e-12	Ulcerative colitis;
LUAD	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg22907277	chr7:1156413	C7orf50	0.71	8.31	0.37	1.29e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs12505328	0.966	rs28625263	chr4:174358252	A/G	cg12145043	chr4:174357286	NA	-0.58	-10.26	-0.45	3.4e-22	Chin dimples;
LUAD	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg21724239	chr8:58056113	NA	0.66	8.66	0.39	9.86e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg14664628	chr15:75095509	CSK	-0.6	-9.75	-0.43	2.18e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg15448220	chr1:150897856	SETDB1	0.56	9.74	0.43	2.25e-20	Melanoma;
LUAD	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg19418458	chr7:158789849	NA	-0.6	-10.61	-0.46	1.76e-23	Facial morphology (factor 20);
LUAD	cis	rs9462027	0.628	rs9462010	chr6:34716605	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.81	-0.39	3.15e-17	Systemic lupus erythematosus;
LUAD	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg10518543	chr12:38710700	ALG10B	0.45	7.59	0.35	2.01e-13	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg24531977	chr5:56204891	C5orf35	-0.4	-6.54	-0.3	1.83e-10	Coronary artery disease;
LUAD	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.59	8.38	0.38	8.19e-16	Gut microbiome composition (summer);
LUAD	cis	rs68170813	0.559	rs4730223	chr7:106814234	A/T	cg23024343	chr7:107201750	COG5	-0.46	-6.82	-0.31	3.25e-11	Coronary artery disease;
LUAD	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg19980929	chr12:42632907	YAF2	0.34	6.52	0.3	1.97e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg00510787	chr6:151772946	C6orf211;RMND1	-0.4	-6.94	-0.32	1.52e-11	Subcortical brain region volumes;
LUAD	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg08888203	chr3:10149979	C3orf24	0.72	12.89	0.53	2.61e-32	Alzheimer's disease;
LUAD	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg05340658	chr4:99064831	C4orf37	0.54	9.15	0.41	2.34e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11048434	0.636	rs12815310	chr12:9059934	A/G	cg26114124	chr12:9217669	LOC144571	0.36	6.53	0.3	1.85e-10	Sjögren's syndrome;
LUAD	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg00852783	chr1:26633632	UBXN11	-0.41	-7.23	-0.33	2.34e-12	Obesity-related traits;
LUAD	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg23625390	chr15:77176239	SCAPER	0.39	6.99	0.32	1.06e-11	Blood metabolite levels;
LUAD	trans	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.29	0.54	6.59e-34	Exhaled nitric oxide output;
LUAD	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21582582	chr3:182698605	DCUN1D1	0.62	9.98	0.44	3.38e-21	Resting heart rate;
LUAD	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg24069376	chr3:38537580	EXOG	0.45	10.95	0.47	9.41e-25	Electrocardiographic conduction measures;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg16978871	chr7:139026114	C7orf55	-0.54	-6.51	-0.3	2.14e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg00431813	chr7:1051703	C7orf50	-0.34	-6.43	-0.3	3.39e-10	Longevity;Endometriosis;
LUAD	cis	rs1784581	0.588	rs7752870	chr6:162422510	T/C	cg17173639	chr6:162384350	PARK2	0.43	7.73	0.35	8.1e-14	Itch intensity from mosquito bite;
LUAD	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg05132306	chr1:1846340	CALML6	-0.36	-7.78	-0.35	5.65e-14	Body mass index;
LUAD	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg00277334	chr10:82204260	NA	-0.61	-9.94	-0.44	4.51e-21	Post bronchodilator FEV1;
LUAD	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg21775007	chr8:11205619	TDH	0.53	9.54	0.42	1.19e-19	Retinal vascular caliber;
LUAD	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg06484146	chr7:12443880	VWDE	-0.6	-7.75	-0.35	7.03e-14	Coronary artery disease;
LUAD	trans	rs587242	0.528	rs12091544	chr1:97206114	G/C	cg10631902	chr5:14652156	NA	0.39	6.65	0.31	9.33e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LUAD	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-9.07	-0.4	4.4e-18	Life satisfaction;
LUAD	cis	rs2034088	0.833	rs4968120	chr17:431364	T/G	cg06217071	chr17:408420	NA	0.49	11.45	0.49	1.27e-26	Hip circumference adjusted for BMI;
LUAD	cis	rs7172809	0.535	rs17385296	chr15:77646338	A/C	cg11865553	chr15:77376250	NA	-0.4	-6.75	-0.31	4.76e-11	Glucose homeostasis traits;
LUAD	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs654950	0.806	rs7550496	chr1:42043834	G/A	cg06885757	chr1:42089581	HIVEP3	0.49	11.2	0.48	1.17e-25	Airway imaging phenotypes;
LUAD	cis	rs7582720	0.943	rs72934550	chr2:203983940	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	9.69	0.43	3.45e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.7	12.76	0.53	8.89e-32	Axial length;
LUAD	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.71	0.31	6.25e-11	Breast cancer;
LUAD	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg06641503	chr3:48959341	ARIH2	-0.41	-8.06	-0.37	7.65e-15	Parkinson's disease;
LUAD	cis	rs16854884	0.586	rs7639366	chr3:143752034	T/G	cg01302019	chr3:143689584	C3orf58	-0.37	-6.65	-0.31	9.18e-11	Economic and political preferences (feminism/equality);
LUAD	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.31	-7.89	-0.36	2.69e-14	Total body bone mineral density;
LUAD	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg19041857	chr6:27730383	NA	-0.43	-7.36	-0.34	9.93e-13	Parkinson's disease;
LUAD	cis	rs71525726	1	rs71525726	chr8:6190359	A/G	cg23549331	chr8:6189008	NA	0.83	12.11	0.51	3.45e-29	Alcoholic chronic pancreatitis;
LUAD	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg19761014	chr17:28927070	LRRC37B2	0.72	6.63	0.31	1.03e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg21209911	chr2:198299431	SF3B1	-0.4	-6.72	-0.31	6.05e-11	Subcortical brain region volumes;
LUAD	cis	rs56161922	0.749	rs3738469	chr1:207818422	G/A	cg11752769	chr1:207818423	CR1L	-0.65	-6.84	-0.32	2.76e-11	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUAD	cis	rs420259	0.861	rs450787	chr16:23636703	G/C	cg00143387	chr16:23521605	GGA2	0.48	6.74	0.31	5.25e-11	Bipolar disorder;
LUAD	trans	rs208520	0.586	rs208442	chr6:66900618	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.69	-10.21	-0.44	5.11e-22	Exhaled nitric oxide output;
LUAD	cis	rs10203711	0.933	rs11885493	chr2:239584919	G/T	cg14580085	chr2:239553406	NA	0.4	8.62	0.39	1.39e-16	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.69	0.31	7.3e-11	Neuroticism;
LUAD	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg03929089	chr4:120376271	NA	-0.96	-19.41	-0.69	1.7e-60	Height;
LUAD	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg13390004	chr1:15929781	NA	0.48	8.48	0.38	3.74e-16	Systolic blood pressure;
LUAD	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-9.05	-0.4	5.44e-18	Longevity;Endometriosis;
LUAD	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg07636037	chr3:49044803	WDR6	0.64	12.64	0.52	2.67e-31	Parkinson's disease;
LUAD	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg14583973	chr4:3374767	RGS12	0.29	7.21	0.33	2.64e-12	Serum sulfate level;
LUAD	cis	rs7264396	0.836	rs2010565	chr20:34182517	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.61	-0.31	1.17e-10	Total cholesterol levels;
LUAD	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg19875535	chr5:140030758	IK	-0.46	-7.61	-0.35	1.84e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	7.0	0.32	9.94e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs3741798	1.000	rs61922047	chr12:12496471	C/A	cg08615371	chr12:12503544	MANSC1	0.74	6.8	0.31	3.67e-11	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-13.98	-0.56	8.87e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs4660306	0.961	rs1494813	chr1:45957290	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.51	-8.01	-0.36	1.11e-14	Homocysteine levels;
LUAD	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg10518543	chr12:38710700	ALG10B	0.41	6.36	0.3	5.25e-10	Bladder cancer;
LUAD	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg24768116	chr2:27665128	KRTCAP3	0.27	6.78	0.31	4e-11	Oral cavity cancer;
LUAD	cis	rs6489882	0.703	rs10850094	chr12:113360563	C/T	cg20102336	chr12:113376681	OAS3	0.52	8.08	0.37	7.06e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg25753631	chr6:25732923	NA	-0.39	-6.67	-0.31	8.14e-11	Iron status biomarkers;
LUAD	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg03467027	chr4:99064603	C4orf37	0.43	6.96	0.32	1.31e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.78	-15.16	-0.59	9.2e-42	Intelligence (multi-trait analysis);
LUAD	cis	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg07988820	chr12:82153109	PPFIA2	-0.5	-7.78	-0.35	5.49e-14	Resting heart rate;
LUAD	cis	rs11098699	0.821	rs11731898	chr4:124220979	C/A	cg09941581	chr4:124220074	SPATA5	0.48	7.94	0.36	1.84e-14	Mosquito bite size;
LUAD	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg17264618	chr3:40429014	ENTPD3	0.38	8.42	0.38	5.95e-16	Renal cell carcinoma;
LUAD	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg18180107	chr4:99064573	C4orf37	0.43	6.9	0.32	1.92e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg25358565	chr5:93447407	FAM172A	0.62	7.8	0.35	4.92e-14	Diabetic retinopathy;
LUAD	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg14227996	chr4:17616232	MED28	0.7	7.48	0.34	4.26e-13	Opioid sensitivity;
LUAD	cis	rs6087990	0.701	rs1997797	chr20:31387954	C/G	cg13636640	chr20:31349939	DNMT3B	0.73	13.11	0.54	3.53e-33	Ulcerative colitis;
LUAD	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg17366294	chr4:99064904	C4orf37	0.65	12.24	0.51	1.1e-29	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg27572855	chr1:25598939	RHD	0.53	11.5	0.49	8.38e-27	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs7943203	0.568	rs170548	chr11:108234836	A/C	cg04873221	chr11:107992290	ACAT1	-0.49	-7.46	-0.34	4.92e-13	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg13319975	chr6:146136371	FBXO30	0.59	9.94	0.44	4.7e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.5	-8.56	-0.38	2.04e-16	Longevity;Endometriosis;
LUAD	cis	rs977987	0.806	rs35937717	chr16:75331567	C/A	cg03315344	chr16:75512273	CHST6	0.62	13.56	0.55	5e-35	Dupuytren's disease;
LUAD	cis	rs59698941	0.943	rs72799496	chr5:132290911	T/C	cg14825688	chr5:132208181	LEAP2	-0.48	-6.5	-0.3	2.22e-10	Apolipoprotein A-IV levels;
LUAD	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg17074396	chr22:49843754	NA	-0.3	-6.43	-0.3	3.4e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg09491104	chr22:46646882	C22orf40	-0.59	-7.13	-0.33	4.48e-12	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs10489202	1.000	rs66950781	chr1:168018779	C/A	cg24449463	chr1:168025552	DCAF6	-0.57	-7.26	-0.33	1.9e-12	Schizophrenia;
LUAD	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg06558623	chr16:89946397	TCF25	1.23	12.2	0.51	1.53e-29	Skin colour saturation;
LUAD	trans	rs7395662	0.963	rs10454482	chr11:48754977	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.22	-0.33	2.48e-12	HDL cholesterol;
LUAD	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg12311346	chr5:56204834	C5orf35	-0.45	-7.43	-0.34	6.03e-13	Coronary artery disease;
LUAD	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg18827107	chr12:86230957	RASSF9	-0.7	-12.79	-0.53	6.85e-32	Major depressive disorder;
LUAD	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg06740227	chr12:86229804	RASSF9	-0.41	-7.36	-0.34	9.88e-13	Major depressive disorder;
LUAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg02481789	chr17:40805506	NA	0.33	6.47	0.3	2.7e-10	Colorectal or endometrial cancer;
LUAD	cis	rs4824093	0.610	rs7410534	chr22:50289925	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.89	-7.06	-0.32	6.91e-12	Amyotrophic lateral sclerosis (sporadic);
LUAD	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg17178900	chr1:205818956	PM20D1	-0.44	-6.85	-0.32	2.56e-11	Menarche (age at onset);
LUAD	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg07606381	chr6:8435919	SLC35B3	0.41	6.79	0.31	3.77e-11	Motion sickness;
LUAD	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21582582	chr3:182698605	DCUN1D1	0.7	13.37	0.55	3.07e-34	Intelligence (multi-trait analysis);
LUAD	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg23260525	chr10:116636907	FAM160B1	0.47	10.45	0.45	6.58e-23	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg01579765	chr21:45077557	HSF2BP	-0.59	-13.72	-0.55	1.07e-35	Mean corpuscular volume;
LUAD	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03264133	chr6:25882463	NA	-0.56	-8.98	-0.4	9.06e-18	Blood metabolite levels;
LUAD	cis	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg06360820	chr2:242988706	NA	-1.04	-14.44	-0.57	1.06e-38	Obesity-related traits;
LUAD	cis	rs11112613	0.775	rs10778413	chr12:105962118	G/A	cg03607813	chr12:105948248	NA	0.81	12.83	0.53	4.72e-32	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUAD	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg12863693	chr15:85201151	NMB	0.4	7.54	0.34	2.95e-13	Schizophrenia;
LUAD	cis	rs698833	0.926	rs1067339	chr2:44624448	T/G	cg04920474	chr2:44395004	PPM1B	0.38	6.79	0.31	3.74e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs2992756	0.663	rs2992762	chr1:18804609	A/G	cg14356550	chr1:18808102	KLHDC7A	-0.56	-9.82	-0.43	1.26e-20	Breast cancer;
LUAD	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg16205897	chr5:131564050	P4HA2	0.31	6.92	0.32	1.73e-11	Blood metabolite levels;
LUAD	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg17366294	chr4:99064904	C4orf37	0.48	8.42	0.38	5.92e-16	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs7000551	0.751	rs2443494	chr8:22372262	C/G	cg12081754	chr8:22256438	SLC39A14	0.46	7.57	0.35	2.35e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg21427119	chr20:30132790	HM13	0.52	8.41	0.38	6.56e-16	Mean corpuscular hemoglobin;
LUAD	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg15247329	chr7:2764246	NA	-0.36	-6.5	-0.3	2.23e-10	Height;
LUAD	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg15448220	chr1:150897856	SETDB1	-0.4	-6.45	-0.3	3.05e-10	Tonsillectomy;
LUAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg07677032	chr17:61819896	STRADA	0.57	10.31	0.45	2.12e-22	Prudent dietary pattern;
LUAD	cis	rs2274471	0.628	rs1410779	chr9:5083173	C/T	cg03390472	chr9:5043263	JAK2	-0.56	-7.28	-0.33	1.61e-12	Crohn's disease;
LUAD	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg17346650	chr17:80929145	B3GNTL1	0.39	6.78	0.31	3.97e-11	Glycated hemoglobin levels;
LUAD	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.46	7.67	0.35	1.2e-13	Lung cancer in ever smokers;
LUAD	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg04025307	chr7:1156635	C7orf50	0.77	14.07	0.56	3.67e-37	Longevity;Endometriosis;
LUAD	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg17845761	chr1:175162550	KIAA0040	-0.34	-9.05	-0.4	5.28e-18	Alcohol dependence;
LUAD	cis	rs208520	0.837	rs208486	chr6:66926255	A/T	cg07460842	chr6:66804631	NA	-0.95	-13.54	-0.55	5.69e-35	Exhaled nitric oxide output;
LUAD	trans	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg01620082	chr3:125678407	NA	-0.46	-6.69	-0.31	7.12e-11	Depression;
LUAD	cis	rs12618769	0.597	rs3754884	chr2:99125376	C/T	cg10123293	chr2:99228465	UNC50	0.46	8.21	0.37	2.77e-15	Bipolar disorder;
LUAD	cis	rs7000551	0.689	rs6997299	chr8:22324268	T/C	cg12081754	chr8:22256438	SLC39A14	0.45	7.34	0.34	1.13e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg26384229	chr12:38710491	ALG10B	-0.4	-6.59	-0.31	1.3e-10	Morning vs. evening chronotype;
LUAD	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg10729496	chr3:10149963	C3orf24	0.47	7.0	0.32	9.84e-12	Alzheimer's disease;
LUAD	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.75	-0.31	5.03e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg00204512	chr16:28754710	NA	0.34	7.28	0.33	1.6e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.41	6.55	0.3	1.72e-10	Parkinson's disease;
LUAD	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg11062466	chr8:58055876	NA	-0.7	-9.02	-0.4	6.53e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg11941060	chr3:133502564	NA	-0.49	-8.2	-0.37	2.94e-15	Iron status biomarkers;
LUAD	cis	rs1949733	0.675	rs2688219	chr4:8444631	T/C	cg13073564	chr4:8508604	NA	-0.55	-10.13	-0.44	9.46e-22	Response to antineoplastic agents;
LUAD	cis	rs67311347	0.544	rs13097602	chr3:40339247	T/C	cg02782426	chr3:40428986	ENTPD3	-0.31	-6.58	-0.3	1.42e-10	Renal cell carcinoma;
LUAD	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg20283391	chr11:68216788	NA	-0.41	-6.38	-0.3	4.53e-10	Total body bone mineral density;
LUAD	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg08997352	chr12:9597637	DDX12	-0.63	-10.61	-0.46	1.8e-23	Breast size;
LUAD	cis	rs28830936	0.966	rs890498	chr15:42111298	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.34	-6.92	-0.32	1.65e-11	Diastolic blood pressure;
LUAD	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg06558623	chr16:89946397	TCF25	0.99	10.26	0.45	3.26e-22	Skin colour saturation;
LUAD	cis	rs4953076	0.574	rs4953074	chr2:44464629	C/T	cg04920474	chr2:44395004	PPM1B	0.57	8.98	0.4	8.84e-18	Height;
LUAD	cis	rs7173743	0.756	rs12903668	chr15:79129320	A/G	cg00540400	chr15:79124168	NA	0.38	7.67	0.35	1.18e-13	Coronary artery disease;
LUAD	trans	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg18834416	chr8:37888184	EIF4EBP1	0.43	7.19	0.33	2.91e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg06641503	chr3:48959341	ARIH2	-0.36	-6.52	-0.3	2e-10	Menarche (age at onset);
LUAD	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg05044414	chr3:183734942	ABCC5	0.47	9.73	0.43	2.46e-20	Anterior chamber depth;
LUAD	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg07414643	chr4:187882934	NA	0.34	6.95	0.32	1.42e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.86	-0.5	3.43e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs1784581	0.588	rs9346894	chr6:162430763	T/C	cg17173639	chr6:162384350	PARK2	0.46	8.1	0.37	6e-15	Itch intensity from mosquito bite;
LUAD	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg19678392	chr7:94953810	PON1	-0.57	-7.78	-0.35	5.51e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.54	-0.42	1.12e-19	Schizophrenia;
LUAD	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg01097406	chr16:89675127	NA	0.34	7.04	0.32	7.79e-12	Vitiligo;
LUAD	cis	rs6761276	0.899	rs6759676	chr2:113836348	A/G	cg09040174	chr2:113837401	NA	-0.79	-15.41	-0.6	7.85e-43	Protein quantitative trait loci;
LUAD	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg22920501	chr2:26401640	FAM59B	-0.96	-14.19	-0.57	1.13e-37	Gut microbiome composition (summer);
LUAD	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03934478	chr11:495069	RNH1	0.76	8.91	0.4	1.55e-17	Body mass index;
LUAD	cis	rs314370	0.621	rs314312	chr7:100422642	G/C	cg10426581	chr7:100472382	SRRT	0.47	7.39	0.34	7.9e-13	Resting heart rate;
LUAD	trans	rs57046232	0.552	rs4402836	chr20:6338026	G/A	cg21095983	chr6:86352623	SYNCRIP	0.41	6.45	0.3	3.15e-10	Colorectal cancer;
LUAD	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg07677032	chr17:61819896	STRADA	0.56	10.21	0.44	5.25e-22	Prudent dietary pattern;
LUAD	cis	rs4711350	1.000	rs2182659	chr6:33751767	A/G	cg13859433	chr6:33739653	LEMD2	-0.34	-6.64	-0.31	9.5e-11	Schizophrenia;
LUAD	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg04800585	chr6:26043546	HIST1H2BB	0.51	8.36	0.38	9.45e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs2857078	0.772	rs2079008	chr17:42322132	C/A	cg13607699	chr17:42295918	UBTF	-0.5	-7.88	-0.36	2.8e-14	Red cell distribution width;Reticulocyte count;
LUAD	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg26343298	chr8:95960752	TP53INP1	0.39	8.24	0.37	2.17e-15	Type 2 diabetes;
LUAD	cis	rs7180079	0.620	rs28635082	chr15:64828504	C/A	cg08069370	chr15:64387884	SNX1	-0.56	-6.74	-0.31	5.18e-11	Monocyte count;
LUAD	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg24690094	chr11:67383802	NA	-0.43	-6.71	-0.31	6.29e-11	Mean corpuscular volume;
LUAD	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg22907277	chr7:1156413	C7orf50	0.7	8.23	0.37	2.35e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs698833	0.828	rs6745281	chr2:44534472	A/C	cg04920474	chr2:44395004	PPM1B	0.41	7.3	0.33	1.42e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.38	-6.68	-0.31	7.66e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg02782426	chr3:40428986	ENTPD3	0.32	6.72	0.31	5.8200000000000003e-11	Renal cell carcinoma;
LUAD	cis	rs6998277	1.000	rs35155104	chr8:103646559	G/T	cg10187029	chr8:103597600	NA	0.75	11.43	0.49	1.55e-26	Migraine;
LUAD	cis	rs2262909	1.000	rs2175366	chr19:22128279	C/T	cg11619707	chr19:22235551	ZNF257	-0.44	-6.8	-0.31	3.61e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg14820908	chr5:178986412	RUFY1	-0.53	-8.84	-0.39	2.56e-17	Lung cancer;
LUAD	cis	rs2882667	0.931	rs10038799	chr5:138362283	C/T	cg04439458	chr5:138467593	SIL1	-0.39	-7.09	-0.33	5.53e-12	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg26384229	chr12:38710491	ALG10B	0.46	7.51	0.34	3.48e-13	Bladder cancer;
LUAD	trans	rs2247870	0.756	rs2438353	chr5:90066246	A/G	cg02158565	chr7:150788256	AGAP3	0.43	7.04	0.32	7.75e-12	Schizophrenia;
LUAD	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg02569458	chr12:86230093	RASSF9	0.44	8.02	0.36	1.07e-14	Major depressive disorder;
LUAD	cis	rs12210905	0.688	rs72839471	chr6:27316959	C/T	cg08851530	chr6:28072375	NA	1.09	7.98	0.36	1.43e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg07828340	chr4:882639	GAK	0.85	9.93	0.43	4.97e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg24642844	chr7:1081250	C7orf50	-0.98	-14.73	-0.58	6.14e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs8073060	0.544	rs225258	chr17:33956883	C/T	cg19694781	chr19:47549865	TMEM160	-1.25	-20.03	-0.7	2.87e-63	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUAD	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12379764	chr21:47803548	PCNT	-0.41	-6.74	-0.31	5.15e-11	Testicular germ cell tumor;
LUAD	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg09029085	chr17:47094198	IGF2BP1	0.29	6.59	0.3	1.35e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUAD	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg25985355	chr7:65971099	NA	0.55	6.86	0.32	2.45e-11	Diabetic kidney disease;
LUAD	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg16606324	chr3:10149918	C3orf24	0.7	11.51	0.49	7.19e-27	Alzheimer's disease;
LUAD	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.87	0.43	7.9e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	trans	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg27411982	chr8:10470053	RP1L1	0.35	6.47	0.3	2.73e-10	Monocyte count;
LUAD	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg24818145	chr4:99064322	C4orf37	0.47	8.05	0.36	8.64e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg02527881	chr3:46936655	PTH1R	0.42	8.11	0.37	5.36e-15	Colorectal cancer;
LUAD	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-6.84	-0.32	2.75e-11	Lung cancer;
LUAD	cis	rs10821973	0.527	rs7093483	chr10:64001753	T/C	cg09941381	chr10:64027924	RTKN2	-0.35	-6.83	-0.32	2.97e-11	Hypothyroidism;
LUAD	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg22532475	chr10:104410764	TRIM8	-0.43	-8.2	-0.37	2.99e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-12.42	-0.52	2.08e-30	Bone mineral density;
LUAD	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg11494091	chr17:61959527	GH2	0.74	18.62	0.67	6.03e-57	Prudent dietary pattern;
LUAD	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg02505535	chr3:195703920	SDHAP1	-0.34	-6.83	-0.31	3.05e-11	Pancreatic cancer;
LUAD	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.25	0.48	7.16e-26	Height;
LUAD	cis	rs7709909	0.686	rs6151617	chr5:79961643	A/G	cg24059623	chr5:79951536	MSH3;DHFR	0.49	9.02	0.4	6.81e-18	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUAD	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.46	-0.42	2.11e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg16387850	chr1:46982889	NA	0.51	7.84	0.36	3.8e-14	Monobrow;
LUAD	cis	rs1865721	1.000	rs8096298	chr18:73187608	C/T	cg26385618	chr18:73139727	C18orf62	-0.42	-7.7	-0.35	9.93e-14	Intelligence;
LUAD	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.76	0.39	4.66e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.4	-6.56	-0.3	1.58e-10	Schizophrenia;
LUAD	cis	rs9399401	0.667	rs34018047	chr6:142790873	G/C	cg03128060	chr6:142623767	GPR126	0.41	7.75	0.35	7.05e-14	Chronic obstructive pulmonary disease;
LUAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg00431813	chr7:1051703	C7orf50	-0.45	-8.54	-0.38	2.48e-16	Longevity;Endometriosis;
LUAD	cis	rs11756438	0.683	rs4027595	chr6:119017504	C/T	cg21191810	chr6:118973309	C6orf204	-0.4	-7.21	-0.33	2.62e-12	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg06781209	chr11:61594997	FADS2	-0.41	-7.62	-0.35	1.72e-13	Trans fatty acid levels;
LUAD	cis	rs758324	0.738	rs648304	chr5:131286708	T/C	cg25547332	chr5:131281432	NA	-0.39	-6.43	-0.3	3.46e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg13319975	chr6:146136371	FBXO30	-0.81	-13.8	-0.56	4.79e-36	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg09085632	chr11:111637200	PPP2R1B	0.74	12.42	0.52	2.1000000000000002e-30	Primary sclerosing cholangitis;
LUAD	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg06640241	chr16:89574553	SPG7	0.46	7.34	0.34	1.13e-12	Multiple myeloma (IgH translocation);
LUAD	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg02725872	chr8:58115012	NA	-0.33	-6.46	-0.3	2.9e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg21724239	chr8:58056113	NA	0.71	9.13	0.41	2.89e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs12545109	0.837	rs6474063	chr8:57355545	C/T	cg19413350	chr8:57351067	NA	-0.46	-6.97	-0.32	1.22e-11	Obesity-related traits;
LUAD	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg15448220	chr1:150897856	SETDB1	0.58	9.8	0.43	1.45e-20	Melanoma;
LUAD	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg25985355	chr7:65971099	NA	-0.51	-6.37	-0.3	4.89e-10	Diabetic kidney disease;
LUAD	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.46	8.12	0.37	5.31e-15	Menopause (age at onset);
LUAD	cis	rs244899	0.935	rs590784	chr5:167917504	G/T	cg06604206	chr5:167912465	RARS	-0.39	-6.96	-0.32	1.3e-11	Response to platinum-based chemotherapy (carboplatin);
LUAD	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg09263875	chr16:632152	PIGQ	0.81	17.39	0.65	1.66e-51	Height;
LUAD	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-9.59	-0.42	7.86e-20	Platelet count;
LUAD	cis	rs12545109	0.700	rs2670045	chr8:57393695	A/G	cg19413350	chr8:57351067	NA	-0.41	-6.49	-0.3	2.47e-10	Obesity-related traits;
LUAD	cis	rs2979489	0.891	rs2915625	chr8:30382651	G/A	cg26383811	chr8:30366931	RBPMS	-0.69	-10.47	-0.45	5.6e-23	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUAD	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.53	-9.01	-0.4	7.35e-18	Glomerular filtration rate;
LUAD	cis	rs977987	0.778	rs62059846	chr16:75430809	T/A	cg03315344	chr16:75512273	CHST6	0.64	13.95	0.56	1.15e-36	Dupuytren's disease;
LUAD	cis	rs4006360	0.579	rs2320223	chr17:39234769	G/T	cg20663846	chr17:39254439	KRTAP4-8	0.36	8.02	0.36	1.04e-14	Bipolar disorder and schizophrenia;
LUAD	trans	rs2774920	0.614	rs17111206	chr1:94646439	C/T	cg24762501	chr19:51530751	KLK11	-0.68	-6.94	-0.32	1.47e-11	D-dimer levels;
LUAD	cis	rs758324	0.947	rs2133707	chr5:131181280	C/T	cg06307176	chr5:131281290	NA	0.5	7.95	0.36	1.76e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg12016809	chr21:47604291	C21orf56	0.54	8.65	0.39	1.11e-16	Testicular germ cell tumor;
LUAD	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg11859384	chr17:80120422	CCDC57	0.48	8.67	0.39	9.03e-17	Life satisfaction;
LUAD	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03352830	chr11:487213	PTDSS2	0.8	10.3	0.45	2.38e-22	Body mass index;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg15635728	chr19:56152354	ZNF580	-0.68	-6.58	-0.3	1.36e-10	Type 2 diabetes;
LUAD	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg17120908	chr11:65337727	SSSCA1	-0.59	-9.09	-0.4	3.83e-18	Bone mineral density;
LUAD	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg03929089	chr4:120376271	NA	-0.96	-19.69	-0.69	9.6e-62	Height;
LUAD	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-9.22	-0.41	1.41e-18	Life satisfaction;
LUAD	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg25358565	chr5:93447407	FAM172A	0.59	6.9	0.32	1.97e-11	Diabetic retinopathy;
LUAD	cis	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg27411982	chr8:10470053	RP1L1	-0.39	-7.02	-0.32	8.89e-12	Neuroticism;
LUAD	cis	rs8192282	0.739	rs4575077	chr1:154495011	C/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.43	-7.46	-0.34	4.93e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUAD	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg09904177	chr6:26538194	HMGN4	0.42	6.83	0.32	2.92e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9393692	0.557	rs2393649	chr6:26338538	T/G	cg13736514	chr6:26305472	NA	-0.49	-7.52	-0.34	3.34e-13	Educational attainment;
LUAD	cis	rs2235649	0.833	rs55684627	chr16:1848817	G/A	cg08610935	chr16:1836813	NUBP2	-0.5	-7.64	-0.35	1.49e-13	Blood metabolite levels;
LUAD	cis	rs13095912	0.962	rs7644758	chr3:185328197	G/T	cg11274856	chr3:185301563	NA	-0.39	-7.79	-0.35	5.08e-14	Systolic blood pressure;
LUAD	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	8.49	0.38	3.65e-16	Glomerular filtration rate;
LUAD	trans	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg18187862	chr3:45730750	SACM1L	0.55	8.87	0.4	2.07e-17	Primary sclerosing cholangitis;
LUAD	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06022373	chr22:39101656	GTPBP1	0.48	7.99	0.36	1.32e-14	Menopause (age at onset);
LUAD	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg20607798	chr8:58055168	NA	0.72	9.44	0.42	2.54e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs2281727	0.500	rs2169356	chr17:2138016	A/T	cg16513277	chr17:2031491	SMG6	-0.79	-14.29	-0.57	4.5e-38	Coronary artery disease;Body mass index;
LUAD	trans	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-10.29	-0.45	2.6e-22	Obesity-related traits;
LUAD	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg11915388	chr22:42470451	FAM109B	0.41	7.37	0.34	9.31e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4604732	0.642	rs10802514	chr1:247637749	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.35	6.38	0.3	4.78e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs938554	0.956	rs12507606	chr4:9934561	C/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.01	-0.36	1.09e-14	Blood metabolite levels;
LUAD	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg18806716	chr10:30721971	MAP3K8	-0.79	-16.87	-0.63	3.28e-49	Inflammatory bowel disease;
LUAD	cis	rs7536201	0.967	rs7513156	chr1:25299836	T/C	cg23273869	chr1:25296894	NA	-0.39	-8.07	-0.37	7.56e-15	Psoriasis vulgaris;
LUAD	cis	rs7582720	1.000	rs4510208	chr2:203734866	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.43	0.42	2.7e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs73206853	0.686	rs73206895	chr12:110879968	A/G	cg12870014	chr12:110450643	ANKRD13A	0.61	6.84	0.32	2.78e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11093040	chr2:227701437	RHBDD1	-0.46	-6.88	-0.32	2.11e-11	Height;
LUAD	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.31	-8.19	-0.37	3.1e-15	Total body bone mineral density;
LUAD	cis	rs7084921	0.552	rs2862990	chr10:101876364	A/G	cg19754520	chr10:101825118	CPN1	0.31	6.52	0.3	2.06e-10	Bone mineral density;
LUAD	cis	rs34172651	0.545	rs9302428	chr16:24717600	C/G	cg04756594	chr16:24857601	SLC5A11	-0.44	-8.44	-0.38	5.11e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg09222892	chr1:25734099	RHCE	-0.49	-9.21	-0.41	1.55e-18	Erythrocyte sedimentation rate;
LUAD	cis	rs9467160	1.000	rs6922631	chr6:24438734	G/A	cg16211469	chr6:24423932	MRS2	0.44	6.95	0.32	1.39e-11	Liver enzyme levels;
LUAD	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.18	0.33	3.09e-12	Tonsillectomy;
LUAD	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg23954153	chr1:44402353	ARTN	-0.37	-7.1	-0.33	5.37e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs59698941	0.765	rs12163971	chr5:132226669	C/A	cg14825688	chr5:132208181	LEAP2	-0.47	-6.65	-0.31	8.85e-11	Apolipoprotein A-IV levels;
LUAD	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03352830	chr11:487213	PTDSS2	0.82	10.47	0.45	5.68e-23	Body mass index;
LUAD	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.75	7.25	0.33	1.99e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg01620082	chr3:125678407	NA	-0.45	-6.72	-0.31	6.07e-11	Depression;
LUAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	9.31	0.41	6.76e-19	Alzheimer's disease;
LUAD	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg22455342	chr2:225449267	CUL3	0.46	7.72	0.35	8.32e-14	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUAD	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg09365446	chr1:150670422	GOLPH3L	0.66	12.3	0.51	6.1e-30	Tonsillectomy;
LUAD	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-8.56	-0.38	2.17e-16	Neutrophil percentage of white cells;
LUAD	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg20587970	chr11:113659929	NA	-1.19	-17.48	-0.65	6.72e-52	Hip circumference adjusted for BMI;
LUAD	cis	rs6988985	0.530	rs57268571	chr8:143942602	A/G	cg10324643	chr8:143916377	GML	0.3	6.41	0.3	3.94e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs7193541	0.510	rs79473128	chr16:74589192	G/A	cg01733217	chr16:74700730	RFWD3	0.46	7.23	0.33	2.34e-12	Multiple myeloma;
LUAD	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg17074396	chr22:49843754	NA	-0.33	-6.71	-0.31	6.33e-11	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.43	-7.29	-0.33	1.53e-12	Tonsillectomy;
LUAD	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg03690763	chr11:133734501	NA	-0.31	-7.49	-0.34	3.93e-13	Childhood ear infection;
LUAD	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg13319975	chr6:146136371	FBXO30	-0.61	-9.87	-0.43	8.2e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg21605333	chr4:119757512	SEC24D	0.94	8.81	0.39	3.37e-17	Cannabis dependence symptom count;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09039689	chr11:46639039	KIAA0652;HARBI1	-0.4	-6.78	-0.31	3.97e-11	Cancer;
LUAD	cis	rs727505	1.000	rs77718560	chr7:124514544	T/A	cg23710748	chr7:124431027	NA	-0.47	-9.56	-0.42	9.77e-20	Lewy body disease;
LUAD	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg12863693	chr15:85201151	NMB	0.41	7.56	0.34	2.57e-13	Schizophrenia;
LUAD	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19717773	chr7:2847554	GNA12	-0.57	-9.65	-0.42	4.68e-20	Height;
LUAD	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg09835421	chr16:68378352	PRMT7	-0.81	-8.79	-0.39	3.68e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg00484396	chr16:3507460	NAT15	0.77	9.74	0.43	2.4e-20	Tuberculosis;
LUAD	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.62	0.31	1.12e-10	Fuchs's corneal dystrophy;
LUAD	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	8.79	0.39	3.92e-17	Parkinson's disease;
LUAD	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg15445000	chr17:37608096	MED1	-0.45	-8.41	-0.38	6.46e-16	Glomerular filtration rate (creatinine);
LUAD	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg25358565	chr5:93447407	FAM172A	0.55	6.53	0.3	1.86e-10	Diabetic retinopathy;
LUAD	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg05590025	chr7:65112418	INTS4L2	0.73	8.05	0.36	8.52e-15	Diabetic kidney disease;
LUAD	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-7.04	-0.32	7.87e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs1003719	0.762	rs2835590	chr21:38463406	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.62	0.39	1.31e-16	Eye color traits;
LUAD	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg00339695	chr16:24857497	SLC5A11	0.71	11.4	0.48	2.04e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg07395648	chr5:131743802	NA	0.38	6.43	0.3	3.48e-10	Blood metabolite levels;
LUAD	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg11266682	chr4:10021025	SLC2A9	-0.55	-11.91	-0.5	2.11e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	trans	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg06606381	chr12:133084897	FBRSL1	-0.62	-6.4	-0.3	4.04e-10	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7553864	0.574	rs6576867	chr1:87615796	A/T	cg17420885	chr1:87600446	LOC339524	-0.44	-6.74	-0.31	5.08e-11	Smoking behavior;
LUAD	cis	rs68170813	0.652	rs6976759	chr7:107158506	A/G	cg23024343	chr7:107201750	COG5	0.53	6.68	0.31	7.35e-11	Coronary artery disease;
LUAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg22535103	chr8:58192502	C8orf71	-0.6	-7.1	-0.33	5.22e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs73206853	0.563	rs1050587	chr12:111158161	T/C	cg12870014	chr12:110450643	ANKRD13A	0.6	7.06	0.32	6.94e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-8.02	-0.36	1.02e-14	Total cholesterol levels;
LUAD	cis	rs593982	0.777	rs72941015	chr11:65457514	A/C	cg08755490	chr11:65554678	OVOL1	-1.24	-12.68	-0.52	1.8e-31	Atopic dermatitis;
LUAD	cis	rs2795502	0.872	rs2744062	chr10:43254789	T/A	cg20628663	chr10:43360327	NA	-0.66	-8.32	-0.37	1.25e-15	Blood protein levels;
LUAD	trans	rs4650994	0.507	rs12405456	chr1:178512331	T/G	cg05059571	chr16:84539110	KIAA1609	-0.74	-13.35	-0.54	3.54e-34	HDL cholesterol levels;HDL cholesterol;
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg06527052	chr1:109633875	TMEM167B	-0.37	-6.58	-0.3	1.38e-10	Migraine with aura;
LUAD	cis	rs2795502	0.630	rs3004257	chr10:43480529	C/T	cg20628663	chr10:43360327	NA	0.57	6.92	0.32	1.71e-11	Blood protein levels;
LUAD	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.0	-15.15	-0.59	1.03e-41	Schizophrenia;
LUAD	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg05665937	chr4:1216051	CTBP1	0.42	7.48	0.34	4.47e-13	Obesity-related traits;
LUAD	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg13535736	chr9:111863775	C9orf5	-0.43	-6.58	-0.3	1.39e-10	Menarche (age at onset);
LUAD	cis	rs752010	0.746	rs10749837	chr1:42089471	T/C	cg06885757	chr1:42089581	HIVEP3	0.49	11.35	0.48	3.12e-26	Lupus nephritis in systemic lupus erythematosus;
LUAD	cis	rs78761021	0.867	rs17810453	chr17:9789466	A/G	cg26853458	chr17:9805074	RCVRN	0.36	6.96	0.32	1.32e-11	Type 2 diabetes;
LUAD	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg05110241	chr16:68378359	PRMT7	-0.8	-8.64	-0.39	1.17e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg07460842	chr6:66804631	NA	-1.04	-16.18	-0.62	3.68e-46	Exhaled nitric oxide output;
LUAD	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg24562669	chr7:97807699	LMTK2	0.3	7.03	0.32	8.37e-12	Breast cancer;
LUAD	cis	rs1003719	0.715	rs2835675	chr21:38582815	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.48	-7.95	-0.36	1.66e-14	Eye color traits;
LUAD	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18876405	chr7:65276391	NA	-0.4	-6.39	-0.3	4.46e-10	Aortic root size;
LUAD	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg07362569	chr17:61921086	SMARCD2	0.38	6.78	0.31	4.01e-11	Prudent dietary pattern;
LUAD	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg16049864	chr8:95962084	TP53INP1	-0.44	-8.19	-0.37	3.09e-15	Type 2 diabetes;
LUAD	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg07917127	chr4:99064746	C4orf37	0.42	6.95	0.32	1.43e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg10589385	chr1:150898437	SETDB1	0.43	8.23	0.37	2.32e-15	Melanoma;
LUAD	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg14541582	chr5:601475	NA	-0.36	-7.58	-0.35	2.19e-13	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11971779	0.680	rs11768023	chr7:139054395	T/A	cg24109934	chr7:139138155	KLRG2	-0.31	-6.38	-0.3	4.62e-10	Diisocyanate-induced asthma;
LUAD	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg11062466	chr8:58055876	NA	0.81	9.96	0.44	3.84e-21	Developmental language disorder (linguistic errors);
LUAD	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg25324976	chr17:61989376	CSHL1	0.43	7.96	0.36	1.65e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2282300	0.739	rs3858428	chr11:30296550	T/C	cg06241208	chr11:30344200	C11orf46	0.57	7.64	0.35	1.43e-13	Morning vs. evening chronotype;
LUAD	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg27426351	chr10:43362370	NA	-0.53	-8.12	-0.37	5e-15	Blood protein levels;
LUAD	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	8.79	0.39	3.86e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs8041447	0.832	rs7350775	chr15:63056159	A/T	cg12790106	chr15:63105204	TLN2	-0.36	-6.68	-0.31	7.66e-11	Immature fraction of reticulocytes;
LUAD	cis	rs986417	1.000	rs6573320	chr14:61092022	A/G	cg27398547	chr14:60952738	C14orf39	0.62	7.04	0.32	7.67e-12	Gut microbiota (bacterial taxa);
LUAD	cis	rs986417	1.000	rs8015462	chr14:61046687	G/A	cg27398547	chr14:60952738	C14orf39	0.61	7.71	0.35	9.11e-14	Gut microbiota (bacterial taxa);
LUAD	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg19318889	chr4:1322082	MAEA	0.47	7.91	0.36	2.32e-14	Obesity-related traits;
LUAD	cis	rs739496	0.615	rs627308	chr12:112146555	A/C	cg10833066	chr12:111807467	FAM109A	-0.41	-6.73	-0.31	5.53e-11	Platelet count;
LUAD	trans	rs9408928	0.778	rs9409230	chr9:123967760	A/T	cg24568646	chr21:30446238	CCT8	0.64	6.36	0.3	5.3e-10	Immune reponse to smallpox (secreted IFN-alpha);
LUAD	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg19773385	chr1:10388646	KIF1B	-0.43	-6.9	-0.32	1.92e-11	Hepatocellular carcinoma;
LUAD	cis	rs9925964	0.967	rs2032915	chr16:31117413	C/T	cg03418659	chr16:31128414	MYST1	0.38	6.43	0.3	3.45e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7528419	0.591	rs4970837	chr1:109822008	G/T	cg00908766	chr1:109817496	CELSR2	0.66	14.21	0.57	9.64e-38	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUAD	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg03188948	chr7:1209495	NA	0.81	9.81	0.43	1.31e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1692580	0.774	rs10797416	chr1:2182342	T/C	cg24578937	chr1:2090814	PRKCZ	0.56	10.86	0.47	2.08e-24	Coronary artery disease;
LUAD	trans	rs3960554	0.808	rs79864016	chr7:75655838	A/G	cg19862616	chr7:65841803	NCRNA00174	0.82	11.08	0.47	3.15e-25	Eotaxin levels;
LUAD	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg00383909	chr3:49044727	WDR6	0.67	7.89	0.36	2.65e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.41	6.68	0.31	7.43e-11	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.83	0.32	2.93e-11	Hypertriglyceridemia;
LUAD	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	7.03	0.32	8.26e-12	Menopause (age at onset);
LUAD	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg27535305	chr1:53392650	SCP2	-0.32	-6.45	-0.3	3.03e-10	Monocyte count;
LUAD	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg20476274	chr7:133979776	SLC35B4	0.69	12.36	0.52	3.54e-30	Mean platelet volume;
LUAD	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.39	6.72	0.31	6.04e-11	Type 2 diabetes;
LUAD	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg16049864	chr8:95962084	TP53INP1	-0.54	-11.8	-0.5	5.45e-28	Type 2 diabetes;
LUAD	cis	rs863345	0.604	rs2873594	chr1:158504790	T/C	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	trans	rs7395662	0.963	rs4882170	chr11:48724214	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	2.03e-12	HDL cholesterol;
LUAD	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg12365402	chr11:9010492	NRIP3	0.49	9.15	0.41	2.39e-18	Hemoglobin concentration;
LUAD	cis	rs807669	0.903	rs762527	chr22:19183470	A/G	cg24911827	chr22:19170109	CLTCL1	0.45	9.23	0.41	1.31e-18	Metabolite levels;
LUAD	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg17971929	chr21:40555470	PSMG1	0.51	7.75	0.35	6.74e-14	Cognitive function;
LUAD	cis	rs3820068	0.705	rs951225	chr1:15826292	G/A	cg24675056	chr1:15929824	NA	0.41	6.58	0.3	1.39e-10	Systolic blood pressure;
LUAD	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00166722	chr3:10149974	C3orf24	0.73	11.21	0.48	1.05e-25	Alzheimer's disease;
LUAD	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg11502198	chr6:26597334	ABT1	0.67	11.79	0.5	6.23e-28	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.546	rs2232423	chr6:28366151	A/G	cg12623302	chr6:28058802	ZSCAN12L1	0.59	6.8	0.31	3.47e-11	Depression;
LUAD	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg23625390	chr15:77176239	SCAPER	0.39	6.86	0.32	2.51e-11	Blood metabolite levels;
LUAD	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10802521	chr3:52805072	NEK4	0.53	9.11	0.41	3.28e-18	Bipolar disorder;
LUAD	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg12292205	chr6:26970375	C6orf41	-0.57	-6.95	-0.32	1.35e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg11766577	chr21:47581405	C21orf56	-0.54	-8.96	-0.4	1.02e-17	Testicular germ cell tumor;
LUAD	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg04727924	chr7:799746	HEATR2	-0.55	-6.82	-0.31	3.2e-11	Cerebrospinal P-tau181p levels;
LUAD	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18876405	chr7:65276391	NA	0.42	6.7	0.31	6.8e-11	Aortic root size;
LUAD	cis	rs7683537	0.692	rs12509936	chr4:185662203	G/A	cg04058563	chr4:185651563	MLF1IP	0.76	9.94	0.44	4.69e-21	Systemic lupus erythematosus;
LUAD	trans	rs2840044	1.000	rs11080357	chr17:33898933	G/A	cg19694781	chr19:47549865	TMEM160	0.64	10.37	0.45	1.29e-22	Response to radiotherapy in cancer (late toxicity);
LUAD	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg05991184	chr2:219186017	PNKD	0.37	7.18	0.33	3.22e-12	Colorectal cancer;
LUAD	cis	rs7095607	0.813	rs7913516	chr10:69927932	G/A	cg18986048	chr10:69913749	MYPN	0.37	6.4	0.3	4.08e-10	Lung function (FVC);
LUAD	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg00204512	chr16:28754710	NA	0.33	7.23	0.33	2.21e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7647973	0.961	rs56324858	chr3:49544229	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.53	-9.03	-0.4	6e-18	Menarche (age at onset);
LUAD	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg11057378	chr10:81107060	PPIF	0.41	7.38	0.34	8.52e-13	Height;
LUAD	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs2657888	0.628	rs3809122	chr12:56882710	A/T	cg23002907	chr12:56915593	RBMS2	-0.39	-6.98	-0.32	1.14e-11	Adiponectin levels;
LUAD	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg03609598	chr5:56110824	MAP3K1	-0.68	-9.25	-0.41	1.09e-18	Initial pursuit acceleration;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg15231902	chr12:56618064	OBFC2B	-0.52	-6.43	-0.3	3.53e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19187486	chr15:74833838	ARID3B	-0.43	-6.6	-0.31	1.23e-10	Height;
LUAD	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg18721089	chr20:30220636	NA	-0.45	-6.77	-0.31	4.27e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs67311347	0.544	rs1454492	chr3:40352884	C/T	cg02782426	chr3:40428986	ENTPD3	0.35	7.46	0.34	4.84e-13	Renal cell carcinoma;
LUAD	trans	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg22823121	chr1:150693482	HORMAD1	-0.4	-7.76	-0.35	6.5e-14	Tonsillectomy;
LUAD	cis	rs9788721	0.836	rs2656052	chr15:78740932	A/C	cg18825076	chr15:78729989	IREB2	-0.57	-10.05	-0.44	1.86e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	trans	rs11088226	0.581	rs2833860	chr21:33882309	G/A	cg09050820	chr6:167586206	TCP10L2	0.44	7.37	0.34	9.25e-13	Gastritis;
LUAD	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg04267008	chr7:1944627	MAD1L1	-0.75	-11.99	-0.5	9.9e-29	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-6.99	-0.32	1.09e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg11618577	chr2:27665543	KRTCAP3	-0.25	-6.53	-0.3	1.87e-10	Total body bone mineral density;
LUAD	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg08222618	chr4:941054	TMEM175	0.76	14.25	0.57	6.29e-38	Sjögren's syndrome;
LUAD	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	6.66	0.31	8.45e-11	Rheumatoid arthritis;
LUAD	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg01851573	chr8:8652454	MFHAS1	0.43	7.62	0.35	1.65e-13	Mood instability;
LUAD	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg01689657	chr7:91764605	CYP51A1	0.33	8.29	0.37	1.53e-15	Breast cancer;
LUAD	cis	rs4919694	0.901	rs74376228	chr10:104677662	G/C	cg04362960	chr10:104952993	NT5C2	0.82	8.56	0.38	2.16e-16	Arsenic metabolism;
LUAD	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg17177755	chr1:15930204	NA	0.44	7.13	0.33	4.38e-12	Systolic blood pressure;
LUAD	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg19238398	chr5:138775248	DNAJC18	-0.54	-6.51	-0.3	2.12e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg10518543	chr12:38710700	ALG10B	-0.51	-8.28	-0.37	1.61e-15	Morning vs. evening chronotype;
LUAD	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg05805236	chr11:65401703	PCNXL3	0.5	8.47	0.38	4.2e-16	Acne (severe);
LUAD	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg04155289	chr7:94953770	PON1	-0.57	-7.39	-0.34	7.67e-13	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg08916839	chr5:415575	AHRR	0.89	10.26	0.45	3.31e-22	Fat distribution (HIV);
LUAD	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-8.03	-0.36	9.53e-15	Blood metabolite levels;
LUAD	cis	rs6138458	1.000	rs11905625	chr20:24977065	A/C	cg06937882	chr20:24974362	C20orf3	-0.34	-6.81	-0.31	3.26e-11	Blood protein levels;
LUAD	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg24558204	chr6:135376177	HBS1L	0.49	9.15	0.41	2.41e-18	Red blood cell count;
LUAD	cis	rs240764	0.658	rs10457849	chr6:101245591	A/G	cg09795085	chr6:101329169	ASCC3	0.46	8.14	0.37	4.5e-15	Neuroticism;
LUAD	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg17264618	chr3:40429014	ENTPD3	0.38	8.58	0.39	1.81e-16	Renal cell carcinoma;
LUAD	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg12365402	chr11:9010492	NRIP3	0.52	9.98	0.44	3.21e-21	Hemoglobin concentration;
LUAD	cis	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg12568669	chr8:11666485	FDFT1	0.24	6.51	0.3	2.14e-10	Myopia (pathological);
LUAD	cis	rs4700695	0.841	rs784276	chr5:65317332	A/T	cg21114390	chr5:65439923	SFRS12	0.63	8.09	0.37	6.52e-15	Facial morphology (factor 19);
LUAD	cis	rs62400317	0.762	rs529125	chr6:44797088	C/T	cg18551225	chr6:44695536	NA	0.47	7.43	0.34	6.05e-13	Total body bone mineral density;
LUAD	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.68	-12.34	-0.51	4.18e-30	Axial length;
LUAD	cis	rs977987	0.778	rs4888426	chr16:75476451	G/A	cg03315344	chr16:75512273	CHST6	0.65	14.37	0.57	2.04e-38	Dupuytren's disease;
LUAD	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.81	9.13	0.41	2.88e-18	Initial pursuit acceleration;
LUAD	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg22532475	chr10:104410764	TRIM8	-0.43	-8.53	-0.38	2.67e-16	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg06671706	chr8:8559999	CLDN23	0.65	11.56	0.49	4.78e-27	Obesity-related traits;
LUAD	cis	rs7267979	1.000	rs404394	chr20:25447896	A/G	cg08601574	chr20:25228251	PYGB	0.47	8.7	0.39	7.19e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs4380275	1.000	rs4268954	chr2:772834	A/G	cg21665850	chr2:731073	NA	0.49	8.89	0.4	1.76e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUAD	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg08859206	chr1:53392774	SCP2	-0.52	-9.29	-0.41	8.16e-19	Monocyte count;
LUAD	cis	rs57590327	0.528	rs13086292	chr3:81705368	G/A	cg07356753	chr3:81810745	GBE1	-0.65	-10.35	-0.45	1.54e-22	Extraversion;
LUAD	cis	rs2108225	0.837	rs6958729	chr7:107451211	A/G	cg18560240	chr7:107437656	SLC26A3	0.39	6.48	0.3	2.5e-10	Ulcerative colitis;
LUAD	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg16414030	chr3:133502952	NA	-0.67	-12.66	-0.52	2.35e-31	Iron status biomarkers;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08963669	chr12:66563719	TMBIM4	-0.41	-6.71	-0.31	6.26e-11	Cancer;
LUAD	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg08632164	chr7:65971372	NA	-0.38	-6.51	-0.3	2.16e-10	Aortic root size;
LUAD	trans	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg25482853	chr8:67687455	SGK3	1.05	16.56	0.63	7.8e-48	Obesity-related traits;
LUAD	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg25344623	chr2:136566232	LCT	-0.35	-6.75	-0.31	4.76e-11	Mosquito bite size;
LUAD	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-9.24	-0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	trans	rs2544390	1.000	rs2673172	chr2:170204800	A/C	ch.3.541014R	chr3:25654052	TOP2B	-0.36	-6.36	-0.3	5.31e-10	Urate levels;
LUAD	cis	rs12681287	0.752	rs4310184	chr8:87245253	T/C	cg27223183	chr8:87520930	FAM82B	-0.59	-8.38	-0.38	7.72e-16	Caudate activity during reward;
LUAD	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.33	-8.78	-0.39	3.95e-17	Total body bone mineral density;
LUAD	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg01579765	chr21:45077557	HSF2BP	-0.54	-12.1	-0.51	3.89e-29	Mean corpuscular volume;
LUAD	cis	rs71478720	0.903	rs80011693	chr11:112005483	C/T	cg04929355	chr11:112034997	IL18	0.47	7.15	0.33	3.85e-12	Interleukin-18 levels;
LUAD	cis	rs10781543	0.810	rs11145756	chr9:139364585	A/G	cg14169450	chr9:139327907	INPP5E	0.44	8.13	0.37	4.96e-15	Monocyte percentage of white cells;
LUAD	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg08355456	chr11:67383691	NA	0.37	6.39	0.3	4.45e-10	Mean corpuscular volume;
LUAD	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg19761014	chr17:28927070	LRRC37B2	0.68	7.45	0.34	5.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg05110241	chr16:68378359	PRMT7	-0.68	-7.91	-0.36	2.33e-14	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg12011299	chr4:100065546	ADH4	0.69	12.46	0.52	1.49e-30	Smoking initiation;
LUAD	cis	rs240764	0.817	rs239242	chr6:101092776	C/T	cg09795085	chr6:101329169	ASCC3	0.43	7.37	0.34	9.09e-13	Neuroticism;
LUAD	cis	rs6669072	1.000	rs3856225	chr1:91242473	G/A	cg08895590	chr1:91227319	NA	-0.34	-6.71	-0.31	6.35e-11	Cognitive function;
LUAD	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg06766960	chr11:133703094	NA	-0.39	-7.56	-0.34	2.56e-13	Childhood ear infection;
LUAD	trans	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg06606381	chr12:133084897	FBRSL1	-0.85	-8.25	-0.37	2.04e-15	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs1997103	1.000	rs9649857	chr7:55411777	C/T	cg20935933	chr6:143382018	AIG1	0.53	7.42	0.34	6.65e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-11.29	-0.48	5.27e-26	Gut microbiome composition (summer);
LUAD	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg08085267	chr17:45401833	C17orf57	-0.63	-11.23	-0.48	8.44e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg08999081	chr20:33150536	PIGU	0.6	13.33	0.54	4.48e-34	Glomerular filtration rate (creatinine);
LUAD	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg23933602	chr10:16859644	RSU1	0.99	21.21	0.72	1.51e-68	Platelet distribution width;
LUAD	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.43e-12	Motion sickness;
LUAD	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg15181151	chr6:150070149	PCMT1	0.4	7.96	0.36	1.59e-14	Lung cancer;
LUAD	cis	rs3772130	0.624	rs56382357	chr3:121452339	T/C	cg20356878	chr3:121714668	ILDR1	0.59	11.1	0.47	2.79e-25	Cognitive performance;
LUAD	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg26408565	chr15:76604113	ETFA	-0.45	-7.32	-0.34	1.23e-12	Blood metabolite levels;
LUAD	cis	rs2041840	0.538	rs2372999	chr2:37573587	T/C	cg25727520	chr2:37576821	QPCT	-0.34	-7.44	-0.34	5.84e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.63	-7.06	-0.32	6.83e-12	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg20203395	chr5:56204925	C5orf35	-0.63	-9.63	-0.42	5.54e-20	Initial pursuit acceleration;
LUAD	cis	rs12618769	0.597	rs3754880	chr2:99132215	G/C	cg10123293	chr2:99228465	UNC50	0.47	8.55	0.38	2.34e-16	Bipolar disorder;
LUAD	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg11833968	chr6:79620685	NA	-0.43	-7.96	-0.36	1.56e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11148252	0.634	rs66849828	chr13:52714837	C/A	cg00495681	chr13:53174319	NA	0.43	7.36	0.34	9.54e-13	Lewy body disease;
LUAD	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg13010199	chr12:38710504	ALG10B	-0.39	-6.58	-0.3	1.36e-10	Bladder cancer;
LUAD	cis	rs68170813	0.641	rs77487103	chr7:107078793	T/C	cg23024343	chr7:107201750	COG5	0.52	7.06	0.32	6.74e-12	Coronary artery disease;
LUAD	cis	rs11622475	1.000	rs1187446	chr14:104409896	C/T	cg12183467	chr14:104352244	NA	-0.41	-7.38	-0.34	8.65e-13	Bipolar disorder;
LUAD	cis	rs375066	0.901	rs1978723	chr19:44383800	C/T	cg12072164	chr19:44306565	LYPD5	-0.32	-6.5	-0.3	2.33e-10	Breast cancer;
LUAD	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg00769240	chr8:12517080	NA	-0.43	-8.25	-0.37	2.01e-15	Blood pressure (smoking interaction);
LUAD	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08280861	chr8:58055591	NA	0.75	9.28	0.41	8.96e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	12.34	0.51	4.25e-30	Homoarginine levels;
LUAD	cis	rs2742417	0.609	rs11709306	chr3:45773732	G/A	cg10512202	chr3:45649293	LIMD1	0.47	8.85	0.4	2.46e-17	Response to anti-depressant treatment in major depressive disorder;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10304803	chr17:80771384	TBCD	0.57	6.95	0.32	1.42e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs75804782	0.521	rs55915157	chr2:239424273	T/C	cg01134436	chr17:81009848	B3GNTL1	0.56	6.58	0.3	1.36e-10	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg07507251	chr3:52567010	NT5DC2	-0.32	-6.55	-0.3	1.67e-10	Bipolar disorder;
LUAD	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg26818010	chr10:134567672	INPP5A	-0.95	-15.74	-0.61	2.93e-44	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs735539	0.517	rs7325243	chr13:21133294	G/A	cg27499820	chr13:21296301	IL17D	0.53	8.77	0.39	4.46e-17	Dental caries;
LUAD	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg26384229	chr12:38710491	ALG10B	-0.39	-6.8	-0.31	3.49e-11	Morning vs. evening chronotype;
LUAD	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg25358565	chr5:93447407	FAM172A	0.56	6.65	0.31	8.92e-11	Diabetic retinopathy;
LUAD	cis	rs17102423	0.594	rs1270074	chr14:65564856	T/C	cg16583315	chr14:65563665	MAX	-0.38	-7.21	-0.33	2.58e-12	Obesity-related traits;
LUAD	cis	rs2573652	1.000	rs2581346	chr15:100514178	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.5	-8.89	-0.4	1.81e-17	Height;
LUAD	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg05368731	chr17:41323189	NBR1	0.95	19.12	0.68	3.46e-59	Menopause (age at onset);
LUAD	cis	rs3774830	0.846	rs17367340	chr4:5457009	T/G	cg26943120	chr4:5472116	STK32B	0.37	7.45	0.34	5.15e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg19163074	chr7:65112434	INTS4L2	-0.43	-6.7	-0.31	6.56e-11	Aortic root size;
LUAD	cis	rs6138458	0.626	rs6050261	chr20:25014206	C/T	cg26195577	chr20:24973756	C20orf3	0.71	11.96	0.5	1.37e-28	Blood protein levels;
LUAD	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg03161606	chr19:29218774	NA	0.59	8.75	0.39	5.12e-17	Methadone dose in opioid dependence;
LUAD	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg07395648	chr5:131743802	NA	0.38	6.48	0.3	2.6e-10	Breast cancer;
LUAD	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg12311346	chr5:56204834	C5orf35	-0.92	-13.69	-0.55	1.49e-35	Initial pursuit acceleration;
LUAD	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg17200465	chr3:40428508	ENTPD3	0.27	6.58	0.3	1.42e-10	Renal cell carcinoma;
LUAD	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg05182265	chr7:156933206	UBE3C	-0.8	-17.12	-0.64	2.55e-50	Body mass index;
LUAD	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg10556349	chr10:835070	NA	-0.47	-7.31	-0.33	1.35e-12	Response to angiotensin II receptor blocker therapy;
LUAD	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-8.13	-0.37	4.73e-15	Height;
LUAD	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12681287	0.752	rs4641037	chr8:87268379	A/G	cg27223183	chr8:87520930	FAM82B	-0.61	-8.75	-0.39	5.25e-17	Caudate activity during reward;
LUAD	cis	rs2046867	0.862	rs2322612	chr3:72830058	A/G	cg04365224	chr3:72788183	NA	-0.44	-6.62	-0.31	1.06e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg00316803	chr15:76480434	C15orf27	-0.42	-8.11	-0.37	5.63e-15	Blood metabolite levels;
LUAD	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg25427524	chr10:38739819	LOC399744	0.45	7.51	0.34	3.44e-13	Hemostatic factors and hematological phenotypes;
LUAD	cis	rs5758511	0.773	rs12167978	chr22:42346475	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.4	6.81	0.31	3.39e-11	Birth weight;
LUAD	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg17158414	chr2:27665306	KRTCAP3	0.35	9.14	0.41	2.62e-18	Total body bone mineral density;
LUAD	cis	rs11126435	0.777	rs11126438	chr2:74928284	A/G	cg19285774	chr2:74907978	SEMA4F	0.36	6.43	0.3	3.53e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs300774	1.000	rs300797	chr2:107140	G/A	cg21211680	chr2:198530	NA	-0.45	-6.5	-0.3	2.25e-10	Suicide attempts in bipolar disorder;
LUAD	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg06627628	chr2:24431161	ITSN2	0.61	9.93	0.43	5.12e-21	Asthma;
LUAD	cis	rs11514810	1.000	rs11514810	chr7:1428476	C/T	cg24899294	chr7:1481343	MICALL2	-0.56	-6.39	-0.3	4.37e-10	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LUAD	trans	rs7395662	1.000	rs55834832	chr11:48562583	T/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.54	-0.3	1.81e-10	HDL cholesterol;
LUAD	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-8.67	-0.39	9.58e-17	Major depressive disorder;
LUAD	cis	rs11048434	0.736	rs34798934	chr12:9108444	C/T	cg23795048	chr12:9217529	LOC144571	0.41	7.57	0.35	2.33e-13	Sjögren's syndrome;
LUAD	cis	rs7737355	0.812	rs32106	chr5:131038940	A/G	cg06307176	chr5:131281290	NA	0.46	7.67	0.35	1.19e-13	Life satisfaction;
LUAD	trans	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg14791747	chr16:20752902	THUMPD1	-0.82	-13.6	-0.55	3.36e-35	Cognitive test performance;
LUAD	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg06453172	chr10:134556979	INPP5A	-0.78	-10.89	-0.47	1.65e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs1595825	0.786	rs73054839	chr2:198671665	C/A	cg11031976	chr2:198649780	BOLL	-0.48	-7.01	-0.32	9.33e-12	Ulcerative colitis;
LUAD	cis	rs28595532	0.920	rs56389935	chr4:119683571	G/A	cg02775129	chr4:119771670	NA	-0.84	-8.0	-0.36	1.2e-14	Cannabis dependence symptom count;
LUAD	cis	rs4764487	0.735	rs3181301	chr12:6345784	G/T	cg08284733	chr12:6341482	CD9	0.39	7.12	0.33	4.79e-12	Mean platelet volume;
LUAD	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg06792262	chr3:44622596	ZNF167	0.4	7.6	0.35	1.93e-13	Depressive symptoms;
LUAD	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg27219399	chr15:67835830	MAP2K5	0.39	6.7	0.31	6.59e-11	Restless legs syndrome;
LUAD	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.97	-17.7	-0.65	7.14e-53	Homoarginine levels;
LUAD	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg01028140	chr2:1542097	TPO	-0.53	-7.32	-0.34	1.29e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-8.27	-0.37	1.75e-15	Total body bone mineral density;
LUAD	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg06028605	chr16:24865363	SLC5A11	-0.39	-6.84	-0.32	2.81e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg00280220	chr17:61926910	NA	0.37	7.07	0.33	6.3e-12	Prudent dietary pattern;
LUAD	cis	rs57590327	0.503	rs1524557	chr3:81892031	A/G	cg07356753	chr3:81810745	GBE1	-0.58	-9.46	-0.42	2.15e-19	Extraversion;
LUAD	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg02196655	chr2:10830764	NOL10	-0.45	-8.18	-0.37	3.32e-15	Prostate cancer;
LUAD	cis	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg08601574	chr20:25228251	PYGB	-0.46	-8.72	-0.39	6.46e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs8067545	0.750	rs28603224	chr17:19985052	G/A	cg04132472	chr17:19861366	AKAP10	0.28	6.6	0.31	1.21e-10	Schizophrenia;
LUAD	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg00277334	chr10:82204260	NA	-0.96	-22.11	-0.73	1.46e-72	Post bronchodilator FEV1;
LUAD	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg07741184	chr6:167504864	NA	0.31	7.47	0.34	4.74e-13	Crohn's disease;
LUAD	cis	rs859767	0.679	rs1104801	chr2:135436601	G/A	cg12500956	chr2:135428796	TMEM163	-0.31	-7.94	-0.36	1.86e-14	Neuroticism;
LUAD	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.62	-10.11	-0.44	1.12e-21	Longevity;Endometriosis;
LUAD	cis	rs11811982	0.793	rs74599093	chr1:227447282	G/A	cg24860534	chr1:227506868	CDC42BPA	0.69	7.35	0.34	1.07e-12	Optic disc area;
LUAD	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg25456477	chr12:86230367	RASSF9	0.32	6.48	0.3	2.59e-10	Major depressive disorder;
LUAD	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg19318889	chr4:1322082	MAEA	0.88	14.7	0.58	8.17e-40	Longevity;
LUAD	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg21862992	chr11:68658383	NA	0.54	9.67	0.43	3.99e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg24531977	chr5:56204891	C5orf35	-0.46	-7.37	-0.34	8.77e-13	Coronary artery disease;
LUAD	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg11859384	chr17:80120422	CCDC57	0.51	9.27	0.41	9.29e-19	Life satisfaction;
LUAD	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg11663144	chr21:46675770	NA	-0.49	-8.36	-0.38	8.94e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg15335139	chr3:50242325	SLC38A3	-0.39	-6.83	-0.32	2.88e-11	Menarche (age at onset);
LUAD	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11644478	chr21:40555479	PSMG1	-0.6	-10.0	-0.44	2.76e-21	Cognitive function;
LUAD	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg13606994	chr1:44402422	ARTN	-0.37	-7.41	-0.34	6.88e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs34638657	0.732	rs12102917	chr16:82196808	G/A	cg09439754	chr16:82129088	HSD17B2	-0.37	-7.09	-0.33	5.73e-12	Lung adenocarcinoma;
LUAD	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg02683114	chr2:24398427	C2orf84	-0.52	-7.75	-0.35	7.03e-14	Asthma;
LUAD	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg02569458	chr12:86230093	RASSF9	0.36	6.83	0.32	2.93e-11	Major depressive disorder;
LUAD	cis	rs877282	0.945	rs10904555	chr10:787740	C/A	cg06581033	chr10:766294	NA	-0.58	-7.72	-0.35	8.6e-14	Uric acid levels;
LUAD	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.53	-9.33	-0.41	6.16e-19	Axial length;
LUAD	cis	rs853679	0.546	rs2232426	chr6:28360659	G/C	cg12623302	chr6:28058802	ZSCAN12L1	0.59	6.8	0.31	3.47e-11	Depression;
LUAD	trans	rs8002861	0.658	rs9533635	chr13:44397921	C/A	cg12856521	chr11:46389249	DGKZ	-0.47	-8.0	-0.36	1.21e-14	Leprosy;
LUAD	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg24818145	chr4:99064322	C4orf37	0.48	8.02	0.36	1.05e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18876405	chr7:65276391	NA	0.57	9.43	0.42	2.75e-19	Aortic root size;
LUAD	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.49	-8.27	-0.37	1.71e-15	Tonsillectomy;
LUAD	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg00750074	chr16:89608354	SPG7	-0.6	-10.57	-0.46	2.59e-23	Multiple myeloma (IgH translocation);
LUAD	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg16647868	chr5:131706066	SLC22A5	0.5	7.81	0.35	4.59e-14	Blood metabolite levels;
LUAD	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg16205897	chr5:131564050	P4HA2	-0.33	-7.43	-0.34	6.22e-13	Breast cancer;
LUAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg07234876	chr8:600039	NA	1.04	10.15	0.44	8.57e-22	IgG glycosylation;
LUAD	cis	rs4919694	1.000	rs58700372	chr10:104800205	T/C	cg04362960	chr10:104952993	NT5C2	0.73	7.86	0.36	3.28e-14	Arsenic metabolism;
LUAD	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg20607798	chr8:58055168	NA	0.59	7.82	0.36	4.25e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg02775129	chr4:119771670	NA	-0.87	-7.93	-0.36	1.91e-14	Cannabis dependence symptom count;
LUAD	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.42	-7.09	-0.33	5.8e-12	Colorectal cancer;
LUAD	cis	rs7937890	0.559	rs2034480	chr11:14466923	G/A	cg02886208	chr11:14281011	SPON1	-0.33	-6.37	-0.3	4.8e-10	Mitochondrial DNA levels;
LUAD	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg03433033	chr1:76189801	ACADM	0.85	15.07	0.59	2.14e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs1957429	0.808	rs6573581	chr14:65331955	G/A	cg23373153	chr14:65346875	NA	0.6	6.6	0.31	1.2e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg22117172	chr7:91764530	CYP51A1	0.34	7.23	0.33	2.24e-12	Breast cancer;
LUAD	trans	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-7.7	-0.35	9.76e-14	Mood instability;
LUAD	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-8.74	-0.39	5.53e-17	Gut microbiome composition (summer);
LUAD	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-8.33	-0.38	1.18e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs10821973	0.527	rs4979766	chr10:64029895	T/C	cg09941381	chr10:64027924	RTKN2	-0.36	-6.97	-0.32	1.21e-11	Hypothyroidism;
LUAD	trans	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg18187862	chr3:45730750	SACM1L	0.49	7.74	0.35	7.53e-14	Primary sclerosing cholangitis;
LUAD	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg00383909	chr3:49044727	WDR6	0.98	10.45	0.45	6.6e-23	Cognitive function;
LUAD	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg02221422	chr11:68192511	LRP5	-0.4	-6.51	-0.3	2.11e-10	Total body bone mineral density;
LUAD	cis	rs1215050	0.776	rs1627946	chr4:98844416	G/A	cg05340658	chr4:99064831	C4orf37	-0.46	-7.5	-0.34	3.67e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg08632164	chr7:65971372	NA	0.37	6.53	0.3	1.86e-10	Aortic root size;
LUAD	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	14.27	0.57	5.5e-38	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs12545109	0.800	rs1996105	chr8:57413123	A/G	cg17761419	chr8:57350749	NA	-0.54	-7.66	-0.35	1.24e-13	Obesity-related traits;
LUAD	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg07917127	chr4:99064746	C4orf37	0.41	6.78	0.31	4.05e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4660214	0.724	rs11205695	chr1:39620957	A/C	cg27567593	chr1:39956653	BMP8A	0.37	7.26	0.33	1.84e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs11696501	0.739	rs6017637	chr20:44264190	G/A	cg11783356	chr20:44313418	WFDC10B	-0.43	-7.5	-0.34	3.85e-13	Brain structure;
LUAD	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg24675056	chr1:15929824	NA	0.48	8.4	0.38	6.98e-16	Systolic blood pressure;
LUAD	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg07606381	chr6:8435919	SLC35B3	0.42	7.07	0.33	6.41e-12	Motion sickness;
LUAD	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg06740227	chr12:86229804	RASSF9	0.38	6.76	0.31	4.73e-11	Major depressive disorder;
LUAD	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg07917127	chr4:99064746	C4orf37	0.43	7.19	0.33	2.94e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9323205	0.911	rs60034431	chr14:51622437	C/A	cg23942311	chr14:51606299	NA	-0.62	-9.99	-0.44	3.11e-21	Cancer;
LUAD	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs9394841	0.646	rs9471676	chr6:41815192	C/T	cg25600774	chr6:41776562	USP49	-0.43	-6.49	-0.3	2.37e-10	Mean corpuscular hemoglobin;Red cell distribution width;
LUAD	cis	rs8060686	0.516	rs8062085	chr16:68289313	C/A	cg26727032	chr16:67993705	SLC12A4	-0.49	-8.13	-0.37	4.91e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs6714710	0.580	rs57804205	chr2:98454472	G/A	cg26665480	chr2:98280029	ACTR1B	0.5	8.19	0.37	3.17e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.52	-9.66	-0.43	4.48e-20	Schizophrenia;
LUAD	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg21427119	chr20:30132790	HM13	-0.48	-7.68	-0.35	1.12e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs147499554	1	rs147499554	chr15:78900650	C/T	cg18825076	chr15:78729989	IREB2	-0.58	-9.46	-0.42	2.23e-19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg06547715	chr2:218990976	CXCR2	-0.43	-10.44	-0.45	7.61e-23	Ulcerative colitis;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg14609757	chr1:156561646	APOA1BP	-0.64	-6.45	-0.3	2.97e-10	Type 2 diabetes;
LUAD	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg25324976	chr17:61989376	CSHL1	0.38	7.39	0.34	7.68e-13	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs1595825	0.891	rs112898725	chr2:198650006	C/T	cg11031976	chr2:198649780	BOLL	-0.45	-6.67	-0.31	7.79e-11	Ulcerative colitis;
LUAD	cis	rs35883536	0.588	rs72977389	chr1:101107053	A/C	cg06223162	chr1:101003688	GPR88	0.37	6.68	0.31	7.4e-11	Monocyte count;
LUAD	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg23815491	chr16:72088622	HP	0.48	7.85	0.36	3.5e-14	Blood protein levels;
LUAD	cis	rs1232027	0.656	rs1650654	chr5:79965020	G/A	cg24059623	chr5:79951536	MSH3;DHFR	-0.45	-7.39	-0.34	7.89e-13	Huntington's disease progression;
LUAD	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg26752003	chr8:145688521	CYHR1	0.48	8.48	0.38	3.77e-16	Age at first birth;
LUAD	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg06131755	chr6:160182447	ACAT2	0.46	6.9	0.32	1.95e-11	Age-related macular degeneration (geographic atrophy);
LUAD	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg14092988	chr3:52407081	DNAH1	-0.38	-7.56	-0.35	2.51e-13	Bipolar disorder;
LUAD	cis	rs698833	0.509	rs4952709	chr2:44519142	A/G	cg04920474	chr2:44395004	PPM1B	0.4	6.69	0.31	7.06e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	7.18	0.33	3.11e-12	Schizophrenia;
LUAD	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg04455712	chr21:45112962	RRP1B	-0.44	-8.96	-0.4	1.07e-17	Mean corpuscular volume;
LUAD	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg15691649	chr6:25882328	NA	-0.49	-6.95	-0.32	1.41e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg19346786	chr7:2764209	NA	-0.32	-6.92	-0.32	1.68e-11	Height;
LUAD	cis	rs701145	0.938	rs789380	chr3:154081424	G/A	cg17054900	chr3:154042577	DHX36	0.63	7.08	0.33	6.16e-12	Coronary artery disease;
LUAD	trans	rs3219090	0.820	rs2570368	chr1:226605373	T/C	cg27539482	chr13:111589090	NA	0.43	7.26	0.33	1.82e-12	Melanoma;
LUAD	cis	rs7474896	0.806	rs1779150	chr10:38038687	C/G	cg25427524	chr10:38739819	LOC399744	-0.68	-6.56	-0.3	1.57e-10	Obesity (extreme);
LUAD	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg25767906	chr1:53392781	SCP2	0.45	8.28	0.37	1.62e-15	Monocyte count;
LUAD	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg08470875	chr2:26401718	FAM59B	-0.77	-10.45	-0.45	7e-23	Gut microbiome composition (summer);
LUAD	cis	rs7107174	1.000	rs7127187	chr11:77995188	G/A	cg02023728	chr11:77925099	USP35	0.49	7.62	0.35	1.67e-13	Testicular germ cell tumor;
LUAD	cis	rs7520050	0.931	rs11211224	chr1:46384388	G/A	cg06784218	chr1:46089804	CCDC17	-0.3	-6.35	-0.3	5.43e-10	Red blood cell count;Reticulocyte count;
LUAD	cis	rs2279817	0.775	rs35493100	chr1:17993120	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.47	-6.77	-0.31	4.39e-11	Neuroticism;
LUAD	cis	rs9796	0.870	rs3900905	chr15:41260801	G/A	cg21153102	chr15:41252147	NA	-0.27	-6.55	-0.3	1.68e-10	Menopause (age at onset);
LUAD	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg07570687	chr10:102243282	WNT8B	0.46	6.49	0.3	2.38e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-7.45	-0.34	5.31e-13	Tonsillectomy;
LUAD	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg15017067	chr4:17643749	FAM184B	0.35	6.84	0.32	2.77e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg20607798	chr8:58055168	NA	0.58	7.54	0.34	2.94e-13	Developmental language disorder (linguistic errors);
LUAD	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg05082376	chr22:42548792	NA	0.42	7.31	0.33	1.33e-12	Schizophrenia;
LUAD	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg07395648	chr5:131743802	NA	0.36	6.58	0.3	1.38e-10	Blood metabolite levels;
LUAD	cis	rs17095355	1.000	rs9988702	chr10:111703389	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.71	-9.57	-0.42	9.28e-20	Biliary atresia;
LUAD	cis	rs1975974	0.935	rs67979358	chr17:21723834	G/C	cg18423549	chr17:21743878	NA	-0.77	-13.89	-0.56	2.12e-36	Psoriasis;
LUAD	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08677398	chr8:58056175	NA	0.48	6.87	0.32	2.35e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg10518543	chr12:38710700	ALG10B	-0.54	-9.05	-0.4	5.19e-18	Morning vs. evening chronotype;
LUAD	cis	rs13315871	1.000	rs71311869	chr3:58398922	C/T	cg12435725	chr3:58293450	RPP14	-0.69	-7.35	-0.34	1.05e-12	Cholesterol, total;
LUAD	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg01017244	chr2:74357527	NA	0.89	14.46	0.58	8.22e-39	Gestational age at birth (maternal effect);
LUAD	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg19717773	chr7:2847554	GNA12	-0.46	-7.75	-0.35	6.71e-14	Height;
LUAD	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg02158880	chr13:53174818	NA	0.41	6.44	0.3	3.25e-10	Lewy body disease;
LUAD	trans	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg24644049	chr4:85504048	CDS1	0.88	7.16	0.33	3.55e-12	Skin colour saturation;
LUAD	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12292205	chr6:26970375	C6orf41	-0.47	-6.57	-0.3	1.47e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs11696501	0.694	rs6094184	chr20:44256575	G/A	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.2	-0.37	2.91e-15	Brain structure;
LUAD	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg11845111	chr2:191398756	TMEM194B	-0.89	-11.78	-0.5	6.87e-28	Diastolic blood pressure;
LUAD	cis	rs8018808	0.869	rs4369582	chr14:77906389	C/T	cg20045696	chr14:77926864	AHSA1	0.36	6.37	0.3	5.05e-10	Myeloid white cell count;
LUAD	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg02683114	chr2:24398427	C2orf84	-0.52	-7.75	-0.35	7.03e-14	Asthma;
LUAD	cis	rs9807989	0.507	rs3732124	chr2:103018052	A/G	cg03938978	chr2:103052716	IL18RAP	-0.45	-10.34	-0.45	1.72e-22	Asthma;
LUAD	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg25985355	chr7:65971099	NA	-0.4	-7.42	-0.34	6.53e-13	Aortic root size;
LUAD	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg14895029	chr7:2775587	GNA12	-0.39	-6.36	-0.3	5.12e-10	Height;
LUAD	cis	rs17095355	0.818	rs61881639	chr10:111863501	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.81	-0.31	3.37e-11	Biliary atresia;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg08364334	chr4:154601692	NA	-0.38	-6.42	-0.3	3.64e-10	Schizophrenia;
LUAD	cis	rs9786986	0.609	rs12401387	chr1:235701314	C/T	cg08848088	chr1:235714526	GNG4	0.52	6.91	0.32	1.78e-11	Body mass index;
LUAD	cis	rs9837602	1.000	rs923471	chr3:99757853	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-6.65	-0.31	9.08e-11	Breast cancer;
LUAD	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.27	-6.68	-0.31	7.44e-11	Coronary artery disease;
LUAD	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg23252815	chr20:44420276	WFDC3;DNTTIP1	0.39	6.47	0.3	2.7e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg01745370	chr2:109065127	GCC2	0.46	9.06	0.4	4.86e-18	Mean platelet volume;
LUAD	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg15181151	chr6:150070149	PCMT1	0.39	7.71	0.35	9.27e-14	Lung cancer;
LUAD	cis	rs9296092	0.538	rs62405943	chr6:33517359	A/G	cg13560919	chr6:33536144	NA	-0.88	-16.45	-0.62	2.23e-47	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	trans	rs75804782	0.641	rs56396448	chr2:239335234	C/T	cg01134436	chr17:81009848	B3GNTL1	0.82	8.71	0.39	6.74e-17	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs6424115	1.000	rs7521961	chr1:24157634	C/T	cg15997130	chr1:24165203	NA	-0.56	-9.82	-0.43	1.25e-20	Immature fraction of reticulocytes;
LUAD	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg17366294	chr4:99064904	C4orf37	0.65	12.27	0.51	8.06e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17092148	0.945	rs6087622	chr20:33310471	A/G	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.26	-0.37	1.85e-15	Neuroticism;
LUAD	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg06636551	chr8:101224915	SPAG1	-0.36	-6.5	-0.3	2.2e-10	Atrioventricular conduction;
LUAD	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg23262073	chr20:60523788	NA	-0.47	-7.6	-0.35	1.86e-13	Body mass index;
LUAD	cis	rs939658	0.935	rs2204069	chr15:79449335	A/G	cg17916960	chr15:79447300	NA	0.48	9.9	0.43	6.46e-21	Refractive error;
LUAD	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg06618935	chr21:46677482	NA	-0.45	-8.72	-0.39	6.33e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg22907277	chr7:1156413	C7orf50	0.7	8.24	0.37	2.2e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg17401720	chr7:158221031	PTPRN2	0.32	6.55	0.3	1.67e-10	Obesity-related traits;
LUAD	cis	rs68170813	0.559	rs1002935	chr7:106832361	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-11.2	-0.48	1.09e-25	Coronary artery disease;
LUAD	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06873352	chr17:61820015	STRADA	0.83	18.47	0.67	2.73e-56	Prudent dietary pattern;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03161587	chr2:220405163	CHPF	0.5	6.35	0.3	5.68e-10	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg13385794	chr1:248469461	NA	0.25	6.95	0.32	1.35e-11	Common traits (Other);
LUAD	trans	rs5756813	0.754	rs8137848	chr22:38185994	T/G	cg19894588	chr14:64061835	NA	-0.46	-6.63	-0.31	1e-10	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs4730250	0.708	rs74983157	chr7:106823951	A/G	cg23024343	chr7:107201750	COG5	0.5	7.29	0.33	1.53e-12	Osteoarthritis;
LUAD	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg17971929	chr21:40555470	PSMG1	0.52	8.03	0.36	9.74e-15	Cognitive function;
LUAD	cis	rs2932538	0.922	rs17438324	chr1:113100573	C/T	cg22162597	chr1:113214053	CAPZA1	0.45	6.82	0.31	3.12e-11	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg22431228	chr1:16359049	CLCNKA	-0.64	-12.86	-0.53	3.5e-32	Dilated cardiomyopathy;
LUAD	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg09796270	chr17:17721594	SREBF1	0.38	7.5	0.34	3.8e-13	Total body bone mineral density;
LUAD	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg11166453	chr1:247681781	NA	0.38	7.14	0.33	3.97e-12	Acute lymphoblastic leukemia (childhood);
LUAD	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg10053473	chr17:62856997	LRRC37A3	-0.68	-10.81	-0.47	3.37e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg10909506	chr17:38081995	ORMDL3	0.41	7.4	0.34	7.57e-13	Self-reported allergy;
LUAD	trans	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.32	-0.38	1.25e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg10729496	chr3:10149963	C3orf24	0.48	7.74	0.35	7.15e-14	Alzheimer's disease;
LUAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg16031515	chr1:205743344	RAB7L1	-0.38	-7.58	-0.35	2.14e-13	Menarche (age at onset);
LUAD	cis	rs56046484	0.750	rs62022525	chr15:85523678	G/T	cg08123816	chr15:85640762	PDE8A	-0.43	-6.42	-0.3	3.71e-10	Testicular germ cell tumor;
LUAD	cis	rs9581857	0.685	rs12585587	chr13:28024694	G/A	cg22138327	chr13:27999177	GTF3A	0.82	9.78	0.43	1.73e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg00310523	chr12:86230176	RASSF9	0.42	8.44	0.38	5.28e-16	Major depressive disorder;
LUAD	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.36e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg02176678	chr2:219576539	TTLL4	0.74	14.81	0.58	2.68e-40	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs11671005	0.735	rs3826684	chr19:58918705	T/C	cg13877915	chr19:58951672	ZNF132	0.54	7.14	0.33	4.22e-12	Mean platelet volume;
LUAD	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg10876282	chr6:28092338	ZSCAN16	0.43	6.9	0.32	1.88e-11	Parkinson's disease;
LUAD	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.28	0.37	1.58e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg10792982	chr14:105748885	BRF1	0.45	9.91	0.43	6.1e-21	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg08885076	chr2:99613938	TSGA10	-0.38	-7.12	-0.33	4.57e-12	Chronic sinus infection;
LUAD	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg01765077	chr12:122356316	WDR66	0.58	10.06	0.44	1.68e-21	Mean corpuscular volume;
LUAD	cis	rs8014204	0.819	rs2003490	chr14:75377555	C/A	cg06637938	chr14:75390232	RPS6KL1	0.42	7.32	0.34	1.28e-12	Caffeine consumption;
LUAD	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg07538946	chr5:131705188	SLC22A5	-0.49	-8.21	-0.37	2.67e-15	Breast cancer;Mosquito bite size;
LUAD	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-10.34	-0.45	1.77e-22	Developmental language disorder (linguistic errors);
LUAD	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg00074818	chr8:8560427	CLDN23	0.62	9.56	0.42	9.96e-20	Obesity-related traits;
LUAD	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-20.31	-0.7	1.58e-64	Height;
LUAD	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg11915388	chr22:42470451	FAM109B	-0.4	-7.28	-0.33	1.62e-12	Schizophrenia;
LUAD	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg26338869	chr17:61819248	STRADA	-0.39	-6.42	-0.3	3.58e-10	Prudent dietary pattern;
LUAD	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25427524	chr10:38739819	LOC399744	0.77	14.1	0.57	2.67e-37	Extrinsic epigenetic age acceleration;
LUAD	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg16060761	chr17:80687452	NA	-0.46	-7.02	-0.32	8.66e-12	Breast cancer;
LUAD	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg19622623	chr12:86230825	RASSF9	-0.53	-9.4	-0.42	3.47e-19	Major depressive disorder;
LUAD	cis	rs7274811	0.744	rs34489266	chr20:32223040	A/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.46	-6.85	-0.32	2.6e-11	Height;
LUAD	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-20.4	-0.7	6.82e-65	Height;
LUAD	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg13770153	chr20:60521292	NA	-0.47	-7.82	-0.36	4.28e-14	Body mass index;
LUAD	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg14583973	chr4:3374767	RGS12	0.3	7.49	0.34	4.09e-13	Serum sulfate level;
LUAD	cis	rs1595825	0.838	rs16823400	chr2:198603229	A/G	cg00361562	chr2:198649771	BOLL	-0.48	-6.75	-0.31	4.94e-11	Ulcerative colitis;
LUAD	cis	rs332507	0.869	rs3772784	chr3:124394657	A/G	cg05980111	chr3:124395277	KALRN	0.42	6.95	0.32	1.37e-11	Plateletcrit;
LUAD	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg22963979	chr7:1858916	MAD1L1	-0.56	-9.43	-0.42	2.66e-19	Bipolar disorder and schizophrenia;
LUAD	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg11494091	chr17:61959527	GH2	0.74	18.75	0.67	1.61e-57	Prudent dietary pattern;
LUAD	cis	rs11229555	0.645	rs12802819	chr11:58174747	T/G	cg15696309	chr11:58395628	NA	-0.76	-10.63	-0.46	1.5e-23	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.36	-7.22	-0.33	2.48e-12	Glomerular filtration rate;
LUAD	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg22467129	chr15:76604101	ETFA	-0.47	-7.85	-0.36	3.42e-14	Blood metabolite levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg04128307	chr16:75018930	WDR59	-0.65	-6.4	-0.3	4.15e-10	Type 2 diabetes;
LUAD	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg27144592	chr16:783916	NARFL	0.35	6.47	0.3	2.75e-10	Height;
LUAD	cis	rs11771526	0.786	rs11768318	chr7:32372965	T/G	cg13207630	chr7:32358064	NA	0.72	8.08	0.37	6.79e-15	Body mass index;
LUAD	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg13319975	chr6:146136371	FBXO30	0.57	9.88	0.43	7.25e-21	Lobe attachment (rater-scored or self-reported);
LUAD	trans	rs11165623	0.792	rs6701031	chr1:96975515	C/T	cg10631902	chr5:14652156	NA	-0.56	-10.79	-0.46	3.73e-24	Hip circumference;Waist circumference;
LUAD	cis	rs225245	0.782	rs178649	chr17:33908197	C/G	cg05299278	chr17:33885742	SLFN14	0.51	11.59	0.49	3.79e-27	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUAD	trans	rs75804782	0.572	rs55764347	chr2:239253529	G/A	cg01134436	chr17:81009848	B3GNTL1	0.77	6.81	0.31	3.43e-11	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6546550	0.901	rs6721891	chr2:70146121	A/G	cg02498382	chr2:70120550	SNRNP27	-0.58	-10.92	-0.47	1.29e-24	Prevalent atrial fibrillation;
LUAD	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg12373951	chr3:133503437	NA	0.35	6.52	0.3	2.06e-10	Iron status biomarkers;
LUAD	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg06636551	chr8:101224915	SPAG1	0.4	7.34	0.34	1.11e-12	Atrioventricular conduction;
LUAD	cis	rs62229266	0.804	rs998383	chr21:37445739	C/G	cg12218747	chr21:37451666	NA	-0.5	-8.72	-0.39	6.55e-17	Mitral valve prolapse;
LUAD	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-8.07	-0.37	7.12e-15	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg12623302	chr6:28058802	ZSCAN12L1	0.33	6.62	0.31	1.09e-10	Depression;
LUAD	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg00852783	chr1:26633632	UBXN11	0.43	7.58	0.35	2.19e-13	Obesity-related traits;
LUAD	cis	rs2244613	0.882	rs1974708	chr16:55793837	T/C	cg27396498	chr16:55794478	CES4	0.51	7.16	0.33	3.68e-12	Response to dabigatran etexilate treatment;
LUAD	cis	rs11195062	0.766	rs1891375	chr10:112001009	A/G	cg19214408	chr10:111981687	MXI1	-0.43	-7.07	-0.33	6.27e-12	Multiple myeloma;
LUAD	cis	rs10979	0.597	rs9399449	chr6:143908376	C/T	cg25407410	chr6:143891975	LOC285740	-0.55	-7.72	-0.35	8.71e-14	Hypospadias;
LUAD	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg04772025	chr11:68637568	NA	0.58	9.09	0.4	3.78e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg05340658	chr4:99064831	C4orf37	0.56	9.5	0.42	1.61e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg23254163	chr1:152506842	NA	0.25	7.0	0.32	1.02e-11	Plantar warts;
LUAD	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg14779329	chr11:130786720	SNX19	0.39	6.84	0.32	2.74e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	trans	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.94	0.44	4.58e-21	Ulcerative colitis;
LUAD	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg19678392	chr7:94953810	PON1	0.58	8.01	0.36	1.11e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg15110403	chr19:17392923	ANKLE1	-0.44	-6.96	-0.32	1.34e-11	Systemic lupus erythematosus;
LUAD	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg02240030	chr7:2089880	MAD1L1	0.34	6.65	0.31	8.98e-11	Neuroticism;
LUAD	trans	rs783540	0.967	rs1864699	chr15:83323318	A/G	cg18393722	chr15:85113863	UBE2QP1	0.44	7.17	0.33	3.28e-12	Schizophrenia;
LUAD	cis	rs11229555	0.645	rs7929868	chr11:58209418	C/T	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs4604732	0.631	rs12039596	chr1:247624766	A/G	cg12754571	chr1:247694271	LOC148824;OR2C3	0.45	7.26	0.33	1.85e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	9.78	0.43	1.66e-20	Ileal carcinoids;
LUAD	cis	rs494562	0.892	rs515980	chr6:86119917	C/T	cg21730993	chr6:86159210	NT5E	0.72	8.23	0.37	2.3e-15	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg23029597	chr12:123009494	RSRC2	-0.52	-8.0	-0.36	1.18e-14	Body mass index;
LUAD	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg23711669	chr6:146136114	FBXO30	0.4	7.03	0.32	8.44e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs9462027	0.651	rs9469870	chr6:34744349	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-9.04	-0.4	5.65e-18	Systemic lupus erythematosus;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07873251	chr15:41220951	DLL4	-0.4	-7.29	-0.33	1.57e-12	Cancer;
LUAD	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg00339695	chr16:24857497	SLC5A11	0.64	10.08	0.44	1.5e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11890956	chr21:40555474	PSMG1	0.73	12.07	0.51	5.2e-29	Cognitive function;
LUAD	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg09184832	chr6:79620586	NA	-0.52	-9.79	-0.43	1.6e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs9811920	0.965	rs9849632	chr3:99867211	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.6	11.21	0.48	1.05e-25	Axial length;
LUAD	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg02951883	chr7:2050386	MAD1L1	-0.81	-14.11	-0.57	2.63e-37	Bipolar disorder and schizophrenia;
LUAD	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg11494091	chr17:61959527	GH2	0.74	18.34	0.67	1.07e-55	Prudent dietary pattern;
LUAD	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg13560548	chr3:10150139	C3orf24	0.42	6.93	0.32	1.54e-11	Alzheimer's disease;
LUAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg10862848	chr6:42927986	GNMT	-0.32	-9.3	-0.41	7.68e-19	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg19774624	chr17:42201019	HDAC5	-0.4	-7.01	-0.32	9.53e-12	Total body bone mineral density;
LUAD	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg14582100	chr15:45693742	SPATA5L1	0.64	12.58	0.52	4.83e-31	Homoarginine levels;
LUAD	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg26384229	chr12:38710491	ALG10B	-0.38	-6.51	-0.3	2.18e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs11723261	0.546	rs57839456	chr4:148289	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.41	7.28	0.33	1.68e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg13298116	chr11:62369859	EML3;MTA2	-0.58	-9.82	-0.43	1.26e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUAD	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg06197492	chr11:2016605	H19	0.42	8.53	0.38	2.66e-16	DNA methylation (parent-of-origin);DNA methylation (variation);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg25091829	chr6:116601170	DSE;TSPYL1	-0.66	-6.71	-0.31	6.15e-11	Type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg17063962	chr7:91808500	NA	0.71	12.5	0.52	9.74e-31	Breast cancer;
LUAD	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03517284	chr6:25882590	NA	-0.57	-9.3	-0.41	7.58e-19	Blood metabolite levels;
LUAD	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.12e-14	Prostate cancer;
LUAD	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg00898013	chr13:113819073	PROZ	-0.64	-11.42	-0.49	1.68e-26	Platelet distribution width;
LUAD	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg14582100	chr15:45693742	SPATA5L1	0.51	9.65	0.42	4.88e-20	Homoarginine levels;
LUAD	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg00898013	chr13:113819073	PROZ	-0.65	-11.74	-0.5	9.38e-28	Platelet distribution width;
LUAD	trans	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg03886242	chr7:26192032	NFE2L3	0.38	6.78	0.31	4.08e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs758324	0.947	rs6861174	chr5:131156129	A/G	cg25547332	chr5:131281432	NA	0.43	6.54	0.3	1.82e-10	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs332507	0.789	rs10755078	chr3:124378412	A/G	cg05980111	chr3:124395277	KALRN	0.44	6.91	0.32	1.75e-11	Plateletcrit;
LUAD	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26314531	chr2:26401878	FAM59B	-0.58	-7.99	-0.36	1.33e-14	Gut microbiome composition (summer);
LUAD	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg15147215	chr3:52552868	STAB1	-0.46	-7.62	-0.35	1.63e-13	Bipolar disorder;
LUAD	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg09359103	chr1:154839909	KCNN3	-0.93	-21.5	-0.72	8.12e-70	Prostate cancer;
LUAD	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg09184832	chr6:79620586	NA	-0.4	-6.68	-0.31	7.66e-11	Intelligence (multi-trait analysis);
LUAD	trans	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg13565492	chr6:43139072	SRF	-0.49	-7.06	-0.32	6.95e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs4917833	0.789	rs1060445	chr10:100218766	C/T	cg25691326	chr10:100228212	HPSE2	0.35	6.36	0.3	5.14e-10	Pediatric bone mineral density (femoral neck);
LUAD	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg21231944	chr12:82153410	PPFIA2	-0.35	-6.42	-0.3	3.69e-10	Resting heart rate;
LUAD	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg09455208	chr3:40491958	NA	0.56	12.55	0.52	6.27e-31	Renal cell carcinoma;
LUAD	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21659725	chr3:3221576	CRBN	0.66	11.23	0.48	9.02e-26	Intelligence (multi-trait analysis);
LUAD	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg26384229	chr12:38710491	ALG10B	0.44	7.38	0.34	8.33e-13	Morning vs. evening chronotype;
LUAD	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-6.82	-0.31	3.15e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg00310523	chr12:86230176	RASSF9	0.37	7.34	0.34	1.08e-12	Major depressive disorder;
LUAD	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-9.15	-0.41	2.5e-18	Total body bone mineral density;
LUAD	trans	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.7	-9.32	-0.41	6.3e-19	Obesity-related traits;
LUAD	cis	rs12618769	0.625	rs56232707	chr2:99032298	G/A	cg10123293	chr2:99228465	UNC50	0.45	8.02	0.36	1.06e-14	Bipolar disorder;
LUAD	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg15992532	chr8:142229932	SLC45A4	-0.43	-7.31	-0.34	1.31e-12	Immature fraction of reticulocytes;
LUAD	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg00277334	chr10:82204260	NA	-0.96	-22.08	-0.73	2.06e-72	Post bronchodilator FEV1;
LUAD	cis	rs977987	0.771	rs4888387	chr16:75389755	T/G	cg03315344	chr16:75512273	CHST6	0.65	14.14	0.57	1.92e-37	Dupuytren's disease;
LUAD	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg07617317	chr6:118971624	C6orf204	0.55	8.35	0.38	9.63e-16	Diastolic blood pressure;
LUAD	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.58	-0.35	2.18e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs4660214	0.666	rs597311	chr1:39820926	T/G	cg27567593	chr1:39956653	BMP8A	-0.36	-7.25	-0.33	1.95e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs60843830	0.517	rs58416198	chr2:175580	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.54	7.77	0.35	6.1e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	cis	rs4285028	0.898	rs73855476	chr3:121633412	A/G	cg11130432	chr3:121712080	ILDR1	-0.54	-7.69	-0.35	1.01e-13	Multiple sclerosis;
LUAD	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg23172400	chr8:95962367	TP53INP1	-0.34	-8.14	-0.37	4.38e-15	Type 2 diabetes;
LUAD	cis	rs7107174	1.000	rs2510032	chr11:77968631	G/C	cg02023728	chr11:77925099	USP35	0.54	8.3	0.37	1.41e-15	Testicular germ cell tumor;
LUAD	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg06623918	chr6:96969491	KIAA0776	0.72	9.69	0.43	3.52e-20	Migraine;Coronary artery disease;
LUAD	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg16325326	chr1:53192061	ZYG11B	0.59	10.79	0.46	3.97e-24	Monocyte count;
LUAD	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg05425664	chr17:57184151	TRIM37	-0.43	-7.57	-0.35	2.3e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs2742234	0.614	rs3026750	chr10:43607756	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.41	-7.24	-0.33	2.17e-12	Hirschsprung disease;
LUAD	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.53	8.93	0.4	1.29e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs7818345	1.000	rs6984145	chr8:19294111	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.3	6.67	0.31	7.84e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs6564851	0.506	rs7204019	chr16:81253015	G/A	cg00908271	chr16:81254010	PKD1L2	0.33	6.91	0.32	1.76e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs2046867	0.818	rs34582798	chr3:72882778	A/C	cg25664220	chr3:72788482	NA	-0.67	-11.83	-0.5	4.33e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2445762	0.659	rs72729227	chr15:51670611	T/A	cg20344442	chr15:51633704	GLDN	0.38	6.73	0.31	5.45e-11	Hormone measurements;
LUAD	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg25753631	chr6:25732923	NA	-0.46	-8.27	-0.37	1.7e-15	Iron status biomarkers;
LUAD	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg12311346	chr5:56204834	C5orf35	0.92	13.68	0.55	1.5e-35	Initial pursuit acceleration;
LUAD	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg02038168	chr22:39784481	NA	-0.58	-10.39	-0.45	1.17e-22	Intelligence (multi-trait analysis);
LUAD	trans	rs11638815	0.603	rs2678448	chr15:83263405	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.49	-7.39	-0.34	8.07e-13	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
LUAD	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08677398	chr8:58056175	NA	0.48	6.67	0.31	8.02e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs68170813	0.559	rs1548524	chr7:106944563	G/T	cg23024343	chr7:107201750	COG5	-0.48	-7.08	-0.33	5.94e-12	Coronary artery disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg22148652	chr2:152684540	ARL5A	-0.65	-6.45	-0.3	3.08e-10	Type 2 diabetes;
LUAD	trans	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04565464	chr8:145669602	NFKBIL2	0.44	6.89	0.32	2.02e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg14789911	chr21:47582049	C21orf56	0.42	7.11	0.33	4.82e-12	Testicular germ cell tumor;
LUAD	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg19875535	chr5:140030758	IK	-0.39	-6.61	-0.31	1.16e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg18180107	chr4:99064573	C4orf37	0.41	6.53	0.3	1.83e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg22963979	chr7:1858916	MAD1L1	-0.46	-7.86	-0.36	3.32e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs789859	0.869	rs1773225	chr3:194403578	A/G	cg02072170	chr3:194406190	FAM43A	0.36	6.51	0.3	2.14e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUAD	cis	rs6547631	0.622	rs1437745	chr2:85928283	A/G	cg21473183	chr2:85925749	GNLY	0.35	7.49	0.34	3.92e-13	Blood protein levels;
LUAD	cis	rs6005807	0.545	rs134488	chr22:28728344	G/A	cg12565055	chr22:29076175	TTC28	-0.72	-8.17	-0.37	3.68e-15	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUAD	cis	rs1595825	0.735	rs6752760	chr2:198918164	G/T	cg00982548	chr2:198649783	BOLL	-0.65	-8.61	-0.39	1.51e-16	Ulcerative colitis;
LUAD	cis	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg01251360	chr16:68772225	CDH1	-0.3	-9.17	-0.41	2.01e-18	Colorectal cancer;
LUAD	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-8.45	-0.38	4.73e-16	Height;
LUAD	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg13385794	chr1:248469461	NA	0.25	6.95	0.32	1.35e-11	Common traits (Other);
LUAD	cis	rs2932538	0.922	rs6681371	chr1:113101168	A/C	cg22162597	chr1:113214053	CAPZA1	0.44	6.47	0.3	2.68e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUAD	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.8	-0.31	3.61e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs11828289	0.660	rs17306426	chr11:23222079	G/T	cg20040320	chr11:23191996	NA	0.69	7.52	0.34	3.32e-13	Cancer;
LUAD	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg23752985	chr2:85803571	VAMP8	-0.34	-6.58	-0.3	1.42e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	trans	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg26043149	chr18:55253948	FECH	0.59	9.83	0.43	1.12e-20	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg22823121	chr1:150693482	HORMAD1	0.37	7.25	0.33	1.96e-12	Melanoma;
LUAD	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg27124370	chr19:33622961	WDR88	0.43	6.58	0.3	1.39e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg05590025	chr7:65112418	INTS4L2	-0.73	-7.8	-0.35	4.77e-14	Diabetic kidney disease;
LUAD	cis	rs9581857	0.615	rs9581849	chr13:28005782	G/T	cg22138327	chr13:27999177	GTF3A	0.92	10.44	0.45	7.42e-23	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg10523679	chr1:76189770	ACADM	-0.74	-11.34	-0.48	3.27e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	15.8	0.61	1.55e-44	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg24503407	chr1:205819492	PM20D1	0.61	11.19	0.48	1.22e-25	Menarche (age at onset);
LUAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg13560548	chr3:10150139	C3orf24	0.45	6.55	0.3	1.72e-10	Alzheimer's disease;
LUAD	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg05332270	chr2:37384401	EIF2AK2	-0.39	-6.38	-0.3	4.78e-10	Schizophrenia;
LUAD	trans	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg01620082	chr3:125678407	NA	-0.62	-7.42	-0.34	6.55e-13	Depression;
LUAD	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg10729496	chr3:10149963	C3orf24	0.47	6.84	0.32	2.72e-11	Alzheimer's disease;
LUAD	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08704250	chr15:31115839	NA	-0.57	-10.23	-0.45	4.43e-22	Huntington's disease progression;
LUAD	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg09365446	chr1:150670422	GOLPH3L	0.66	11.64	0.49	2.3e-27	Melanoma;
LUAD	cis	rs3813948	0.505	rs17020993	chr1:207288392	A/G	cg11070419	chr1:207277210	C4BPA	-0.46	-7.29	-0.33	1.53e-12	C4b binding protein levels;
LUAD	cis	rs9329289	0.510	rs10903785	chr10:2550063	C/T	cg15501526	chr10:2543763	NA	0.56	12.0	0.5	9.31e-29	Age-related hearing impairment;
LUAD	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg10560079	chr2:191398806	TMEM194B	0.43	7.7	0.35	9.72e-14	Pulse pressure;
LUAD	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg00530320	chr1:46809349	NSUN4	0.53	8.23	0.37	2.33e-15	Menopause (age at onset);
LUAD	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.42	8.18	0.37	3.44e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg16606324	chr3:10149918	C3orf24	0.59	9.63	0.42	5.8e-20	Alzheimer's disease;
LUAD	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08280861	chr8:58055591	NA	0.67	8.72	0.39	6.27e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg14019695	chr9:139328340	INPP5E	0.48	9.3	0.41	7.4e-19	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	8.93	0.4	1.31e-17	Colorectal cancer;
LUAD	cis	rs9322817	0.691	rs4591886	chr6:105249970	G/C	cg02098413	chr6:105308735	HACE1	-0.41	-8.85	-0.4	2.44e-17	Thyroid stimulating hormone;
LUAD	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2235649	0.828	rs9936486	chr16:1849888	A/G	cg08610935	chr16:1836813	NUBP2	-0.48	-7.49	-0.34	4.18e-13	Blood metabolite levels;
LUAD	cis	rs9584850	0.874	rs9168	chr13:99101583	C/A	cg20750642	chr13:99100586	FARP1	-0.33	-6.8	-0.31	3.61e-11	Neuroticism;
LUAD	cis	rs12681287	0.604	rs28378899	chr8:87434500	G/C	cg27223183	chr8:87520930	FAM82B	0.67	9.58	0.42	8.35e-20	Caudate activity during reward;
LUAD	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg00504896	chr12:9437009	LOC642846	-0.49	-8.09	-0.37	6.17e-15	Breast size;
LUAD	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg24578937	chr1:2090814	PRKCZ	-0.53	-10.68	-0.46	1.02e-23	Height;
LUAD	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06544989	chr22:39130855	UNC84B	0.45	8.84	0.39	2.56e-17	Menopause (age at onset);
LUAD	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg22875332	chr1:76189707	ACADM	0.86	15.91	0.61	5.48e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs921968	0.521	rs56923478	chr2:219638539	A/G	cg02176678	chr2:219576539	TTLL4	-0.58	-11.72	-0.5	1.18e-27	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg13319975	chr6:146136371	FBXO30	-0.59	-10.09	-0.44	1.4e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7712401	0.601	rs173480	chr5:122254131	C/A	cg19077854	chr5:122220652	SNX24	0.34	6.54	0.3	1.75e-10	Mean platelet volume;
LUAD	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg05865280	chr17:75406074	SEPT9	0.61	19.16	0.68	2.4e-59	Airflow obstruction;
LUAD	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-11.53	-0.49	6.3100000000000004e-27	Monocyte percentage of white cells;
LUAD	cis	rs55665837	0.540	rs3206554	chr11:14797945	A/T	cg19336497	chr11:14380999	RRAS2	-0.38	-7.07	-0.33	6.29e-12	Vitamin D levels;
LUAD	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg04944784	chr2:26401820	FAM59B	0.89	12.57	0.52	5.3e-31	Gut microbiome composition (summer);
LUAD	trans	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.31	-0.33	1.35e-12	Joint mobility (Beighton score);
LUAD	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.61	-0.31	1.16e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg21427119	chr20:30132790	HM13	-0.57	-9.02	-0.4	6.47e-18	Mean corpuscular hemoglobin;
LUAD	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg21854759	chr1:92012499	NA	-0.5	-9.25	-0.41	1.15e-18	Breast cancer;
LUAD	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26314531	chr2:26401878	FAM59B	0.7	9.53	0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg01603290	chr17:40805956	NA	0.34	6.57	0.3	1.48e-10	Colorectal or endometrial cancer;
LUAD	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg07217954	chr7:1067459	C7orf50	0.43	6.68	0.31	7.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1784581	0.722	rs1619122	chr6:162400198	G/T	cg17173639	chr6:162384350	PARK2	-0.5	-8.97	-0.4	1e-17	Itch intensity from mosquito bite;
LUAD	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg01324343	chr3:183735012	ABCC5	0.96	25.63	0.78	3.96e-88	Anterior chamber depth;
LUAD	cis	rs7681423	0.951	rs11099961	chr4:155503212	C/T	cg20735720	chr4:155535218	FGG	-0.52	-7.62	-0.35	1.72e-13	Fibrinogen;
LUAD	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg13319975	chr6:146136371	FBXO30	-0.61	-10.01	-0.44	2.67e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg25173405	chr17:45401733	C17orf57	0.44	7.13	0.33	4.39e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg02527881	chr3:46936655	PTH1R	-0.45	-8.65	-0.39	1.06e-16	Colorectal cancer;
LUAD	cis	rs367943	0.608	rs2972662	chr5:112990330	C/T	cg12552261	chr5:112820674	MCC	-0.43	-7.92	-0.36	2.18e-14	Type 2 diabetes;
LUAD	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg26408565	chr15:76604113	ETFA	-0.44	-7.0	-0.32	1.03e-11	Blood metabolite levels;
LUAD	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg21862992	chr11:68658383	NA	0.51	9.32	0.41	6.4e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11811982	0.793	rs79084700	chr1:227390836	A/G	cg24860534	chr1:227506868	CDC42BPA	0.7	7.57	0.35	2.35e-13	Optic disc area;
LUAD	cis	rs758324	0.617	rs9717078	chr5:131170891	G/A	cg06307176	chr5:131281290	NA	0.5	7.86	0.36	3.17e-14	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg16006841	chr5:176797999	RGS14	-0.6	-9.36	-0.41	4.68e-19	Urate levels in lean individuals;
LUAD	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.78	14.67	0.58	1.11e-39	Lymphocyte counts;
LUAD	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg06558623	chr16:89946397	TCF25	1.13	9.78	0.43	1.65e-20	Skin colour saturation;
LUAD	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.43	-7.51	-0.34	3.45e-13	Menarche (age at onset);
LUAD	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg23254163	chr1:152506842	NA	0.26	7.05	0.32	7.17e-12	Hair morphology;
LUAD	cis	rs9323205	0.954	rs9672122	chr14:51582391	A/G	cg23942311	chr14:51606299	NA	-0.57	-9.01	-0.4	6.97e-18	Cancer;
LUAD	cis	rs6906287	0.625	rs7453914	chr6:118692981	A/T	cg18833306	chr6:118973337	C6orf204	0.53	10.05	0.44	1.92e-21	Electrocardiographic conduction measures;
LUAD	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg17749961	chr2:30669863	LCLAT1	0.53	6.56	0.3	1.57e-10	Pre-treatment pain in head and neck squamous cell carcinoma;
LUAD	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg23625390	chr15:77176239	SCAPER	-0.59	-9.54	-0.42	1.16e-19	Blood metabolite levels;
LUAD	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg01299579	chr2:10830716	NOL10	-0.44	-7.79	-0.35	5.12e-14	Prostate cancer;
LUAD	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26314531	chr2:26401878	FAM59B	-0.55	-7.8	-0.35	4.77e-14	Gut microbiome composition (summer);
LUAD	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg21782813	chr7:2030301	MAD1L1	0.52	8.79	0.39	3.86e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg07234876	chr8:600039	NA	1.06	10.71	0.46	7.92e-24	IgG glycosylation;
LUAD	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg15448220	chr1:150897856	SETDB1	-0.48	-8.28	-0.37	1.62e-15	Tonsillectomy;
LUAD	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-15.27	-0.6	2.95e-42	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg02569458	chr12:86230093	RASSF9	0.39	7.18	0.33	3.14e-12	Major depressive disorder;
LUAD	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	1.98e-19	Life satisfaction;
LUAD	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg08999081	chr20:33150536	PIGU	0.47	9.11	0.4	3.42e-18	Coronary artery disease;
LUAD	cis	rs10821973	0.527	rs3852408	chr10:64022747	A/T	cg09941381	chr10:64027924	RTKN2	-0.34	-6.77	-0.31	4.41e-11	Hypothyroidism;
LUAD	cis	rs7216064	1.000	rs62084213	chr17:65842016	A/G	cg08758996	chr17:66097529	LOC651250	0.46	6.98	0.32	1.15e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs500891	0.525	rs12213724	chr6:84078990	A/C	cg08257003	chr6:84140564	ME1	0.34	6.68	0.31	7.78e-11	Platelet-derived growth factor BB levels;
LUAD	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.72	-11.91	-0.5	2.07e-28	Primary sclerosing cholangitis;
LUAD	cis	rs4588572	0.643	rs2012562	chr5:77768088	T/A	cg11547950	chr5:77652471	NA	-0.78	-12.6	-0.52	3.89e-31	Triglycerides;
LUAD	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg26338869	chr17:61819248	STRADA	-0.39	-6.59	-0.31	1.3e-10	Prudent dietary pattern;
LUAD	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg11941060	chr3:133502564	NA	-0.45	-7.52	-0.34	3.39e-13	Iron status biomarkers;
LUAD	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg25036284	chr2:26402008	FAM59B	0.6	8.24	0.37	2.16e-15	Gut microbiome composition (summer);
LUAD	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.61	-11.39	-0.48	2.1e-26	Longevity;Endometriosis;
LUAD	cis	rs3087591	0.960	rs2905883	chr17:29550141	G/A	cg24425628	chr17:29625626	OMG;NF1	0.4	6.6	0.31	1.26e-10	Hip circumference;
LUAD	cis	rs1595825	0.945	rs7581202	chr2:198836777	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-7.11	-0.33	5.06e-12	Ulcerative colitis;
LUAD	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg06784218	chr1:46089804	CCDC17	0.51	11.26	0.48	6.76e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4285028	0.948	rs34696871	chr3:121671880	T/G	cg20356878	chr3:121714668	ILDR1	-0.48	-6.54	-0.3	1.8e-10	Multiple sclerosis;
LUAD	cis	rs6920965	0.507	rs7754833	chr6:126190894	A/G	cg05901451	chr6:126070800	HEY2	-0.5	-7.33	-0.34	1.21e-12	High light scatter reticulocyte count;
LUAD	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg22532475	chr10:104410764	TRIM8	-0.45	-8.83	-0.39	2.7e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg17509989	chr5:176798049	RGS14	0.58	10.36	0.45	1.4e-22	Hemoglobin concentration;Hematocrit;
LUAD	cis	rs16910800	1.000	rs1384473	chr11:23194943	T/C	cg20040320	chr11:23191996	NA	0.46	6.94	0.32	1.46e-11	Cancer;
LUAD	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg08885076	chr2:99613938	TSGA10	-0.37	-6.55	-0.3	1.65e-10	Chronic sinus infection;
LUAD	cis	rs7975161	0.882	rs4406890	chr12:104638773	A/C	cg25273343	chr12:104657179	TXNRD1	-0.62	-8.23	-0.37	2.27e-15	Toenail selenium levels;
LUAD	trans	rs629535	0.590	rs56200825	chr8:70123450	G/A	cg21567404	chr3:27674614	NA	-0.99	-15.96	-0.61	3.21e-45	Dupuytren's disease;
LUAD	cis	rs3106136	0.967	rs17310266	chr4:95177051	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.43	-0.34	6.06e-13	Capecitabine sensitivity;
LUAD	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg18402987	chr7:1209562	NA	0.78	9.5	0.42	1.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs36051895	0.659	rs12336577	chr9:5063690	T/A	cg02405213	chr9:5042618	JAK2	-0.48	-6.51	-0.3	2.14e-10	Pediatric autoimmune diseases;
LUAD	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg03676636	chr4:99064102	C4orf37	0.32	8.3	0.37	1.41e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.891	rs73061069	chr2:198908825	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-7.31	-0.33	1.35e-12	Ulcerative colitis;
LUAD	cis	rs438034	1.000	rs417844	chr1:214830908	A/G	cg16144317	chr1:214725524	PTPN14	-0.36	-6.57	-0.3	1.51e-10	Response to antineoplastic agents;
LUAD	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	9.82	0.43	1.26e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.49	6.92	0.32	1.73e-11	Cognitive test performance;
LUAD	cis	rs2652834	1.000	rs7182618	chr15:63398622	T/C	cg25406657	chr15:63342033	TPM1	-0.42	-6.81	-0.31	3.36e-11	HDL cholesterol;
LUAD	cis	rs78456975	0.550	rs10197874	chr2:1545310	A/G	cg12573674	chr2:1569213	NA	-0.52	-7.25	-0.33	2.01e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg11254426	chr10:127464165	MMP21	-0.38	-6.35	-0.3	5.48e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg23750338	chr8:142222470	SLC45A4	0.62	14.1	0.57	2.71e-37	Immature fraction of reticulocytes;
LUAD	cis	rs140244541	1	rs140244541	chr2:203808532	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.61	8.29	0.37	1.56e-15	LDL cholesterol;
LUAD	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg24818145	chr4:99064322	C4orf37	0.48	8.15	0.37	4.18e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.73	-13.58	-0.55	3.94e-35	Menarche (age at onset);
LUAD	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-9.83	-0.43	1.14e-20	Bipolar disorder and schizophrenia;
LUAD	cis	rs73198271	0.628	rs11783944	chr8:8597801	A/G	cg01851573	chr8:8652454	MFHAS1	0.47	6.72	0.31	6e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	trans	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg08071915	chr8:12219732	FAM66A	0.45	7.45	0.34	5.17e-13	Joint mobility (Beighton score);
LUAD	trans	rs11088226	0.681	rs9622	chr21:33951068	T/C	cg09050820	chr6:167586206	TCP10L2	0.94	13.94	0.56	1.25e-36	Gastritis;
LUAD	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg23442198	chr4:187126114	CYP4V2	0.97	9.9	0.43	6.28e-21	Activated partial thromboplastin time;
LUAD	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18099408	chr3:52552593	STAB1	-0.46	-8.03	-0.36	9.59e-15	Bipolar disorder;
LUAD	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg07606381	chr6:8435919	SLC35B3	0.42	7.05	0.32	7.22e-12	Motion sickness;
LUAD	trans	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.81	-0.36	4.41e-14	Breast cancer;
LUAD	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg09359103	chr1:154839909	KCNN3	-0.52	-9.02	-0.4	6.69e-18	Schizophrenia;
LUAD	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg27433088	chr4:174089019	GALNT7	0.41	7.65	0.35	1.4e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs6740322	0.841	rs10210507	chr2:43556636	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.78	-11.57	-0.49	4.5e-27	Coronary artery disease;
LUAD	cis	rs7107174	1.000	rs901103	chr11:77931346	C/T	cg19901956	chr11:77921274	USP35	-0.53	-6.47	-0.3	2.69e-10	Testicular germ cell tumor;
LUAD	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.34	-7.3	-0.33	1.41e-12	Height;
LUAD	cis	rs6564851	0.506	rs62054662	chr16:81258173	G/C	cg00908271	chr16:81254010	PKD1L2	0.34	6.84	0.32	2.73e-11	Carotenoid and tocopherol levels;
LUAD	cis	rs2404618	0.561	rs4242536	chr8:1477225	A/G	cg02903104	chr8:1507517	DLGAP2	0.33	7.08	0.33	5.86e-12	Lung cancer;
LUAD	cis	rs7781266	0.500	rs2971975	chr7:133645355	G/A	cg03336402	chr7:133662267	EXOC4	-0.41	-7.44	-0.34	5.85e-13	Educational attainment (college completion);
LUAD	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03264133	chr6:25882463	NA	-0.56	-9.15	-0.41	2.36e-18	Blood metabolite levels;
LUAD	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg13012494	chr21:47604986	C21orf56	0.46	7.64	0.35	1.5e-13	Testicular germ cell tumor;
LUAD	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg17757837	chr7:157058334	UBE3C	0.47	8.37	0.38	8.26e-16	Body mass index;
LUAD	cis	rs501916	0.761	rs79925748	chr15:48046412	G/C	cg16110827	chr15:48056943	SEMA6D	-0.37	-6.64	-0.31	9.38e-11	Inflammatory bowel disease;Ulcerative colitis;
LUAD	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg18854424	chr1:2615690	NA	-0.42	-9.07	-0.4	4.63e-18	Ulcerative colitis;
LUAD	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg21285383	chr16:89894308	SPIRE2	0.4	9.68	0.43	3.71e-20	Vitiligo;
LUAD	cis	rs4853525	0.522	rs6434412	chr2:191585275	A/G	cg11845111	chr2:191398756	TMEM194B	-0.44	-7.08	-0.33	6.03e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUAD	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg00339695	chr16:24857497	SLC5A11	0.47	8.64	0.39	1.15e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs220324	0.688	rs2012103	chr21:43561369	A/G	cg09727148	chr21:43560719	UMODL1	0.58	8.77	0.39	4.55e-17	Idiopathic osteonecrosis of the femoral head;
LUAD	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg15448220	chr1:150897856	SETDB1	0.57	9.88	0.43	7.45e-21	Melanoma;
LUAD	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg15117754	chr3:10150083	C3orf24	0.41	6.64	0.31	9.37e-11	Alzheimer's disease;
LUAD	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06873352	chr17:61820015	STRADA	0.82	18.34	0.67	1.09e-55	Prudent dietary pattern;
LUAD	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg10729496	chr3:10149963	C3orf24	0.66	9.47	0.42	1.92e-19	Alzheimer's disease;
LUAD	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg19774624	chr17:42201019	HDAC5	-0.4	-6.83	-0.32	2.94e-11	Total body bone mineral density;
LUAD	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg08798685	chr6:27730294	NA	-0.66	-7.14	-0.33	4.04e-12	Breast cancer;
LUAD	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.86e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg07570687	chr10:102243282	WNT8B	0.48	7.37	0.34	9.16e-13	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-11.75	-0.5	8.58e-28	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg21782813	chr7:2030301	MAD1L1	0.53	8.66	0.39	9.9900000000000006e-17	Bipolar disorder and schizophrenia;
LUAD	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg12623918	chr2:306882	NA	0.36	7.27	0.33	1.72e-12	Spherical equivalent (joint analysis main effects and education interaction);
LUAD	trans	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg26043149	chr18:55253948	FECH	-0.48	-7.77	-0.35	5.86e-14	Bone mineral density;
LUAD	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg13607699	chr17:42295918	UBTF	0.56	9.15	0.41	2.48e-18	Total body bone mineral density;
LUAD	cis	rs6489882	0.703	rs4767029	chr12:113359318	G/A	cg20102336	chr12:113376681	OAS3	-0.55	-8.33	-0.38	1.11e-15	Chronic lymphocytic leukemia;
LUAD	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg14582100	chr15:45693742	SPATA5L1	0.62	11.94	0.5	1.59e-28	Homoarginine levels;
LUAD	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24531977	chr5:56204891	C5orf35	-0.97	-14.57	-0.58	2.85e-39	Initial pursuit acceleration;
LUAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg21724239	chr8:58056113	NA	0.72	9.44	0.42	2.46e-19	Developmental language disorder (linguistic errors);
LUAD	trans	rs9393777	0.778	rs35741362	chr6:27007687	T/C	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.6	-0.35	1.93e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6752107	0.512	rs1372097	chr2:234227047	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.41	6.87	0.32	2.24e-11	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs7737355	0.812	rs644964	chr5:131056809	T/C	cg25547332	chr5:131281432	NA	0.43	7.04	0.32	8.01e-12	Life satisfaction;
LUAD	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06873352	chr17:61820015	STRADA	0.83	18.59	0.67	8.47e-57	Prudent dietary pattern;
LUAD	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21659725	chr3:3221576	CRBN	-0.84	-17.75	-0.65	4.31e-53	Intelligence (multi-trait analysis);
LUAD	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg06953865	chr19:18549723	ISYNA1	-0.35	-6.57	-0.3	1.44e-10	Breast cancer;
LUAD	cis	rs11811982	0.793	rs77251286	chr1:227512342	C/T	cg24860534	chr1:227506868	CDC42BPA	0.68	7.27	0.33	1.79e-12	Optic disc area;
LUAD	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	14.42	0.57	1.29e-38	Schizophrenia;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg15103181	chr19:35454479	ZNF792	0.43	7.19	0.33	2.91e-12	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg14345882	chr6:26364793	BTN3A2	0.7	7.17	0.33	3.35e-12	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs1493916	1.000	rs4393645	chr18:31394407	C/T	cg15819921	chr19:927150	ARID3A	-0.45	-7.38	-0.34	8.38e-13	Life satisfaction;
LUAD	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.68	-9.53	-0.42	1.21e-19	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.89	-0.32	2.09e-11	Type 2 diabetes;
LUAD	cis	rs17253792	0.822	rs2274075	chr14:56096731	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs9972944	0.756	rs1421032	chr17:63766368	A/C	cg07283582	chr17:63770753	CCDC46	-0.5	-11.18	-0.48	1.28e-25	Total body bone mineral density;
LUAD	cis	rs9354308	0.933	rs12203567	chr6:66589062	T/C	cg07460842	chr6:66804631	NA	0.5	7.39	0.34	8.15e-13	Metabolite levels;
LUAD	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg14671364	chr1:107599128	PRMT6	-0.63	-10.78	-0.46	4.22e-24	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs2050392	0.965	rs2265368	chr10:30690289	G/C	cg18806716	chr10:30721971	MAP3K8	-0.55	-10.71	-0.46	7.83e-24	Inflammatory bowel disease;
LUAD	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-8.62	-0.39	1.34e-16	Total body bone mineral density;
LUAD	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg17849569	chr6:28058911	ZSCAN12L1	0.29	6.79	0.31	3.92e-11	Parkinson's disease;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg01109508	chr10:135187068	ECHS1	-0.67	-6.99	-0.32	1.04e-11	Type 2 diabetes;
LUAD	trans	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg08071915	chr8:12219732	FAM66A	-0.45	-7.54	-0.34	2.87e-13	Mood instability;
LUAD	trans	rs7395662	0.791	rs7945791	chr11:48936340	C/T	cg15704280	chr7:45808275	SEPT13	0.41	6.53	0.3	1.9e-10	HDL cholesterol;
LUAD	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	11.69	0.49	1.48e-27	Hip circumference adjusted for BMI;
LUAD	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg00999904	chr2:3704751	ALLC	-0.52	-9.05	-0.4	5.35e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg02631126	chr6:28058918	ZSCAN12L1	-0.34	-7.14	-0.33	4.11e-12	Depression;
LUAD	cis	rs2455601	0.638	rs2742484	chr11:8988083	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-7.28	-0.33	1.61e-12	Schizophrenia;
LUAD	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg05425664	chr17:57184151	TRIM37	0.43	7.66	0.35	1.28e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg27211696	chr2:191398769	TMEM194B	0.71	9.39	0.42	3.79e-19	Diastolic blood pressure;
LUAD	cis	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg05084668	chr3:125655381	ALG1L	-0.88	-11.83	-0.5	4.17e-28	Blood pressure (smoking interaction);
LUAD	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg27284194	chr4:1044797	NA	0.58	9.55	0.42	1.05e-19	Recombination rate (males);
LUAD	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg09365446	chr1:150670422	GOLPH3L	0.62	10.87	0.47	1.88e-24	Melanoma;
LUAD	trans	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg01620082	chr3:125678407	NA	-0.45	-6.7	-0.31	6.46e-11	Depression;
LUAD	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg25566285	chr7:158114605	PTPRN2	0.53	11.45	0.49	1.3e-26	Calcium levels;
LUAD	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.31	-0.33	1.34e-12	HDL cholesterol;
LUAD	cis	rs7089973	0.836	rs1046492	chr10:116624067	C/T	cg25233709	chr10:116636983	FAM160B1	0.39	7.56	0.34	2.55e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs6684514	1.000	rs12132919	chr1:156318141	C/A	cg16558208	chr1:156270281	VHLL	0.54	9.59	0.42	7.68e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs597539	0.690	rs1272609	chr11:68618182	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	12.76	0.53	8.75e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs1957429	0.901	rs1951491	chr14:65346950	G/A	cg23373153	chr14:65346875	NA	0.56	6.42	0.3	3.57e-10	Pediatric areal bone mineral density (radius);
LUAD	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg19729930	chr2:74357872	NA	0.95	15.53	0.6	2.35e-43	Gestational age at birth (maternal effect);
LUAD	cis	rs3925075	0.531	rs4075052	chr16:31348233	G/T	cg10451425	chr16:31478370	ARMC5	-0.4	-6.51	-0.3	2.17e-10	IgA nephropathy;
LUAD	cis	rs4722404	0.502	rs7804033	chr7:3110005	G/A	cg19214707	chr7:3157722	NA	-0.44	-6.97	-0.32	1.23e-11	Atopic dermatitis;
LUAD	cis	rs4072705	0.967	rs4076333	chr9:127385609	A/G	cg13476313	chr9:127244764	NR5A1	0.3	7.12	0.33	4.53e-12	Menarche (age at onset);
LUAD	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.92	0.36	2.07e-14	Depression;
LUAD	cis	rs55665837	0.961	rs12576926	chr11:14480292	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-10.26	-0.45	3.21e-22	Vitamin D levels;
LUAD	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg20701182	chr2:24300061	SF3B14	0.6	7.24	0.33	2.07e-12	Lymphocyte counts;
LUAD	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg24675658	chr1:53192096	ZYG11B	0.48	7.53	0.34	2.99e-13	Monocyte count;
LUAD	cis	rs68170813	0.559	rs79564258	chr7:107059803	C/A	cg23024343	chr7:107201750	COG5	0.5	7.2	0.33	2.75e-12	Coronary artery disease;
LUAD	cis	rs1232027	0.700	rs1677695	chr5:79936276	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.49	-7.81	-0.36	4.4e-14	Huntington's disease progression;
LUAD	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg14834391	chr1:2537342	MMEL1	-0.31	-6.53	-0.3	1.83e-10	Ulcerative colitis;
LUAD	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg14092571	chr14:90743983	NA	0.47	8.17	0.37	3.63e-15	Mortality in heart failure;
LUAD	cis	rs12049351	0.665	rs6663689	chr1:229630163	C/T	cg11742688	chr1:229674241	ABCB10	-0.43	-6.79	-0.31	3.78e-11	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg02975922	chr3:195473998	MUC4	-0.4	-6.8	-0.31	3.48e-11	Pancreatic cancer;
LUAD	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.83	0.32	2.93e-11	Colorectal cancer;
LUAD	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.59	-10.26	-0.45	3.23e-22	Lymphocyte counts;
LUAD	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg06453172	chr10:134556979	INPP5A	-0.77	-10.93	-0.47	1.16e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUAD	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg20848291	chr7:100343083	ZAN	-0.61	-9.68	-0.43	3.64e-20	Other erythrocyte phenotypes;
LUAD	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg14343924	chr8:8086146	FLJ10661	-0.4	-6.45	-0.3	3.09e-10	Triglycerides;
LUAD	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg22166914	chr1:53195759	ZYG11B	0.45	7.84	0.36	3.66e-14	Monocyte count;
LUAD	cis	rs7786808	0.552	rs4909205	chr7:158185283	G/A	cg01191920	chr7:158217561	PTPRN2	-0.61	-12.45	-0.52	1.52e-30	Obesity-related traits;
LUAD	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg07169764	chr2:136633963	MCM6	0.79	9.28	0.41	8.97e-19	Corneal structure;
LUAD	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg27170947	chr2:26402098	FAM59B	-0.61	-8.84	-0.39	2.65e-17	Gut microbiome composition (summer);
LUAD	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.44	-7.85	-0.36	3.48e-14	Depressive symptoms (multi-trait analysis);
LUAD	trans	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg04565464	chr8:145669602	NFKBIL2	0.45	6.71	0.31	6.14e-11	Bipolar disorder and schizophrenia;
LUAD	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg14343924	chr8:8086146	FLJ10661	-0.49	-7.95	-0.36	1.71e-14	Mood instability;
LUAD	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg10295955	chr4:187884368	NA	-1.18	-30.78	-0.83	5.03e-110	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg23254163	chr1:152506842	NA	0.25	7.13	0.33	4.3e-12	Hair morphology;
LUAD	cis	rs17401966	0.931	rs12753426	chr1:10372110	T/C	cg15208524	chr1:10270712	KIF1B	0.44	6.89	0.32	1.98e-11	Hepatocellular carcinoma;
LUAD	cis	rs17155006	0.601	rs382131	chr7:107733289	G/C	cg05962710	chr7:107745446	LAMB4	-0.3	-6.45	-0.3	3.08e-10	Pneumococcal bacteremia;
LUAD	trans	rs877282	0.786	rs11253392	chr10:788768	G/A	cg22713356	chr15:30763199	NA	1.36	19.39	0.69	2.22e-60	Uric acid levels;
LUAD	trans	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg18187862	chr3:45730750	SACM1L	-0.47	-6.94	-0.32	1.49e-11	Primary sclerosing cholangitis;
LUAD	cis	rs7116495	1.000	rs2511116	chr11:71802160	G/A	cg07596299	chr11:71824057	C11orf51	-0.77	-6.68	-0.31	7.51e-11	Severe influenza A (H1N1) infection;
LUAD	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.16	0.33	3.64e-12	Menopause (age at onset);
LUAD	trans	rs6561151	0.957	rs1373904	chr13:44475398	A/G	cg12856521	chr11:46389249	DGKZ	0.67	10.55	0.46	2.93e-23	Crohn's disease;
LUAD	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg12011299	chr4:100065546	ADH4	0.66	13.67	0.55	1.7000000000000001e-35	Alcohol dependence;
LUAD	cis	rs1594829	0.500	rs2046223	chr8:26210178	C/T	cg13160058	chr8:26243215	BNIP3L	0.36	7.75	0.35	6.75e-14	Height;
LUAD	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg17366294	chr4:99064904	C4orf37	-0.51	-9.13	-0.41	2.86e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg13685833	chr1:53393034	SCP2	0.47	7.8	0.35	4.87e-14	Monocyte count;
LUAD	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg15448220	chr1:150897856	SETDB1	-0.4	-6.44	-0.3	3.32e-10	Tonsillectomy;
LUAD	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg04705435	chr11:17411270	KCNJ11	0.5	8.76	0.39	4.71e-17	Type 2 diabetes;
LUAD	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg18827107	chr12:86230957	RASSF9	-0.71	-13.13	-0.54	2.89e-33	Major depressive disorder;
LUAD	cis	rs6500395	1.000	rs1039340	chr16:48574637	A/C	cg04672837	chr16:48644449	N4BP1	0.37	6.5	0.3	2.2e-10	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs3849570	0.555	rs4452351	chr3:82007977	C/T	cg07356753	chr3:81810745	GBE1	-0.52	-8.7	-0.39	7.45e-17	Waist circumference;Body mass index;
LUAD	cis	rs9329289	0.510	rs9733402	chr10:2551532	G/A	cg15501526	chr10:2543763	NA	0.55	11.66	0.49	1.92e-27	Age-related hearing impairment;
LUAD	cis	rs9473147	0.543	rs13211285	chr6:47479618	C/T	cg02130027	chr6:47444894	CD2AP	0.36	6.96	0.32	1.3e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.42	-0.34	6.4e-13	Glomerular filtration rate;
LUAD	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.9	-13.25	-0.54	9.6e-34	Red cell distribution width;
LUAD	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg09117114	chr16:67998030	SLC12A4	-0.47	-6.79	-0.31	3.85e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg03806693	chr22:41940476	POLR3H	-0.83	-11.76	-0.5	8.38e-28	Vitiligo;
LUAD	cis	rs12049351	0.774	rs6670553	chr1:229635867	A/G	cg11742688	chr1:229674241	ABCB10	-0.42	-6.46	-0.3	2.96e-10	Circulating myeloperoxidase levels (plasma);
LUAD	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-10.04	-0.44	2.08e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18876405	chr7:65276391	NA	-0.65	-11.19	-0.48	1.21e-25	Aortic root size;
LUAD	cis	rs9354308	0.932	rs1938061	chr6:66545581	A/C	cg07460842	chr6:66804631	NA	-0.42	-6.51	-0.3	2.18e-10	Metabolite levels;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	-0.68	-6.91	-0.32	1.79e-11	Type 2 diabetes;
LUAD	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg25753631	chr6:25732923	NA	-0.45	-7.95	-0.36	1.71e-14	Iron status biomarkers;
LUAD	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg21963583	chr11:68658836	MRPL21	0.65	11.43	0.49	1.5e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg19678392	chr7:94953810	PON1	-0.58	-7.97	-0.36	1.53e-14	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs741677	1.000	rs9911960	chr17:466598	T/C	cg06217071	chr17:408420	NA	0.32	6.43	0.3	3.37e-10	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUAD	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg14671364	chr1:107599128	PRMT6	-0.63	-10.83	-0.47	2.68e-24	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg22963979	chr7:1858916	MAD1L1	-0.48	-8.05	-0.36	8.54e-15	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUAD	cis	rs28595532	0.516	rs28552458	chr4:119288363	T/C	cg02775129	chr4:119771670	NA	-0.62	-6.69	-0.31	7.18e-11	Cannabis dependence symptom count;
LUAD	cis	rs8177876	0.822	rs10514514	chr16:81115273	A/G	cg08591886	chr16:81111003	C16orf46	-0.85	-8.15	-0.37	4.02e-15	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUAD	trans	rs1997103	0.871	rs6956733	chr7:55393032	A/C	cg20935933	chr6:143382018	AIG1	0.54	7.24	0.33	2.14e-12	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg20203395	chr5:56204925	C5orf35	0.89	12.53	0.52	7.48e-31	Initial pursuit acceleration;
LUAD	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg02869364	chr7:1081709	C7orf50	-0.53	-6.79	-0.31	3.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs6076065	0.723	rs6076073	chr20:23414489	G/A	cg11657817	chr20:23433608	CST11	0.47	8.76	0.39	4.6e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs701145	0.938	rs355780	chr3:153978289	C/T	cg17054900	chr3:154042577	DHX36	0.64	7.15	0.33	3.87e-12	Coronary artery disease;
LUAD	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg26384229	chr12:38710491	ALG10B	0.42	7.12	0.33	4.56e-12	Morning vs. evening chronotype;
LUAD	cis	rs113835537	0.529	rs2277302	chr11:66240882	T/C	cg24851651	chr11:66362959	CCS	0.57	10.33	0.45	1.8e-22	Airway imaging phenotypes;
LUAD	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg24879335	chr3:133465180	TF	0.37	7.6	0.35	1.95e-13	Iron status biomarkers (transferrin levels);
LUAD	cis	rs72928364	1.000	rs2576365	chr3:100621426	C/A	cg10123952	chr3:100791384	NA	-0.57	-7.15	-0.33	3.87e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7843479	0.932	rs68023663	chr8:21794379	T/C	cg03445287	chr8:21823731	XPO7	-0.44	-8.0	-0.36	1.19e-14	Mean corpuscular volume;
LUAD	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg12432903	chr7:1882776	MAD1L1	-0.45	-7.26	-0.33	1.89e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs739496	0.542	rs7316698	chr12:111790511	C/T	cg10833066	chr12:111807467	FAM109A	0.7	13.91	0.56	1.7e-36	Platelet count;
LUAD	cis	rs35883536	0.647	rs1995142	chr1:101041174	G/A	cg06223162	chr1:101003688	GPR88	0.47	9.17	0.41	2.15e-18	Monocyte count;
LUAD	cis	rs2573652	1.000	rs1469828	chr15:100517210	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.51	-9.06	-0.4	4.85e-18	Height;
LUAD	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg08999081	chr20:33150536	PIGU	0.62	13.95	0.56	1.16e-36	Glomerular filtration rate (creatinine);
LUAD	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06544989	chr22:39130855	UNC84B	0.42	7.76	0.35	6.43e-14	Menopause (age at onset);
LUAD	cis	rs34526934	0.566	rs34028621	chr2:177042779	C/T	cg14324370	chr2:177042789	NA	-0.41	-6.77	-0.31	4.36e-11	Obstructive sleep apnea trait (apnea hypopnea index);
LUAD	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg03676636	chr4:99064102	C4orf37	0.31	8.23	0.37	2.34e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12286929	0.590	rs4936322	chr11:115061533	T/C	cg04055981	chr11:115044050	NA	0.44	7.94	0.36	1.82e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg13319975	chr6:146136371	FBXO30	-0.65	-11.12	-0.48	2.34e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs62400317	0.859	rs12199256	chr6:45303493	T/G	cg20913747	chr6:44695427	NA	-0.41	-6.66	-0.31	8.61e-11	Total body bone mineral density;
LUAD	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg12011299	chr4:100065546	ADH4	0.7	12.61	0.52	3.55e-31	Smoking initiation;
LUAD	cis	rs4285028	0.948	rs12488334	chr3:121702526	T/C	cg20356878	chr3:121714668	ILDR1	-0.49	-6.55	-0.3	1.66e-10	Multiple sclerosis;
LUAD	cis	rs113835537	0.529	rs75683511	chr11:66275026	A/G	cg26679405	chr11:66247800	DPP3	-0.45	-6.35	-0.3	5.4e-10	Airway imaging phenotypes;
LUAD	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg09065629	chr16:1709722	CRAMP1L	0.43	7.36	0.34	9.61e-13	Coronary artery disease;
LUAD	cis	rs78456975	0.739	rs28913003	chr2:1519620	A/T	cg12573674	chr2:1569213	NA	-0.6	-7.09	-0.33	5.73e-12	Placebo response in major depressive disorder (% change in symptom score);
LUAD	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6714710	0.603	rs13008968	chr2:98435982	C/T	cg26665480	chr2:98280029	ACTR1B	0.51	8.27	0.37	1.79e-15	Posterior cortical atrophy and Alzheimer's disease;
LUAD	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg09658497	chr7:2847517	GNA12	-0.49	-8.91	-0.4	1.49e-17	Height;
LUAD	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg05535760	chr7:792225	HEATR2	1.01	12.33	0.51	4.65e-30	Cerebrospinal P-tau181p levels;
LUAD	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg04414720	chr1:150670196	GOLPH3L	-0.53	-9.06	-0.4	4.99e-18	Tonsillectomy;
LUAD	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg24848339	chr3:12840334	CAND2	0.49	10.43	0.45	7.82e-23	QRS complex (12-leadsum);
LUAD	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg27170947	chr2:26402098	FAM59B	-0.62	-8.7	-0.39	7.22e-17	Gut microbiome composition (summer);
LUAD	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg25173405	chr17:45401733	C17orf57	-0.64	-10.84	-0.47	2.6e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12545109	0.800	rs2582404	chr8:57387368	C/T	cg21220214	chr8:57350948	NA	-0.63	-8.79	-0.39	3.93e-17	Obesity-related traits;
LUAD	cis	rs231513	0.911	rs124719	chr17:41960343	T/C	cg26893861	chr17:41843967	DUSP3	-0.54	-6.5	-0.3	2.29e-10	Cognitive function;
LUAD	cis	rs6684514	1.000	rs10752615	chr1:156248609	T/C	cg16558208	chr1:156270281	VHLL	0.53	9.52	0.42	1.36e-19	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg02176678	chr2:219576539	TTLL4	0.74	14.93	0.59	8.38e-41	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg21970626	chr13:21893289	NA	-0.54	-9.11	-0.41	3.24e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs616402	0.527	rs604814	chr1:10567122	G/A	cg17425144	chr1:10567563	PEX14	0.61	12.81	0.53	5.42e-32	Breast size;
LUAD	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg03563238	chr19:33554763	RHPN2	-0.39	-9.06	-0.4	4.91e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.43	7.05	0.32	7.33e-12	Resistin levels;
LUAD	cis	rs6138458	1.000	rs227618	chr20:24909472	T/C	cg26195577	chr20:24973756	C20orf3	0.96	16.27	0.62	1.39e-46	Blood protein levels;
LUAD	cis	rs3789045	1.000	rs11588857	chr1:204587047	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.39	-6.6	-0.31	1.23e-10	Educational attainment (college completion);
LUAD	cis	rs7737355	0.812	rs12514547	chr5:130973304	C/G	cg25547332	chr5:131281432	NA	0.43	6.94	0.32	1.43e-11	Life satisfaction;
LUAD	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg19717773	chr7:2847554	GNA12	-0.46	-7.89	-0.36	2.56e-14	Height;
LUAD	cis	rs1113500	0.933	rs745795	chr1:108629345	C/T	cg06207961	chr1:108661230	NA	0.45	8.52	0.38	2.83e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs6543140	0.964	rs2080288	chr2:103022166	G/A	cg03938978	chr2:103052716	IL18RAP	0.36	6.94	0.32	1.44e-11	Blood protein levels;
LUAD	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	15.79	0.61	1.67e-44	Bone mineral density;
LUAD	trans	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg06606381	chr12:133084897	FBRSL1	-0.63	-6.81	-0.31	3.44e-11	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9972944	0.756	rs6504352	chr17:63765287	C/T	cg07283582	chr17:63770753	CCDC46	-0.5	-11.33	-0.48	3.53e-26	Total body bone mineral density;
LUAD	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg18827107	chr12:86230957	RASSF9	-0.69	-12.7	-0.53	1.62e-31	Major depressive disorder;
LUAD	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22968622	chr17:43663579	NA	-1.12	-18.33	-0.67	1.14e-55	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs12368653	0.651	rs2277326	chr12:58202419	A/C	cg12615879	chr12:58013172	SLC26A10	-0.45	-9.17	-0.41	2.14e-18	Multiple sclerosis;
LUAD	cis	rs7640424	0.649	rs13093976	chr3:107864963	A/C	cg09227934	chr3:107805635	CD47	0.48	8.79	0.39	3.72e-17	Body mass index;
LUAD	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg11663144	chr21:46675770	NA	0.59	11.38	0.48	2.32e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg05340658	chr4:99064831	C4orf37	0.46	6.99	0.32	1.08e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg12193833	chr17:30244370	NA	-0.58	-6.9	-0.32	1.94e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg20701182	chr2:24300061	SF3B14	0.92	13.61	0.55	3.19e-35	Lymphocyte counts;
LUAD	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.99	-21.81	-0.73	3.08e-71	Chronic sinus infection;
LUAD	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg21385522	chr1:16154831	NA	-0.65	-9.96	-0.44	3.9e-21	Dilated cardiomyopathy;
LUAD	cis	rs7737355	0.812	rs250888	chr5:131015346	C/T	cg06307176	chr5:131281290	NA	-0.44	-7.3	-0.33	1.46e-12	Life satisfaction;
LUAD	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg08798685	chr6:27730294	NA	-0.42	-6.7	-0.31	6.5500000000000006e-11	Parkinson's disease;
LUAD	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg00701064	chr4:6280414	WFS1	0.64	13.97	0.56	9.77e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg26384229	chr12:38710491	ALG10B	0.48	7.74	0.35	7.17e-14	Bladder cancer;
LUAD	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg13870426	chr17:30244630	NA	-0.57	-6.63	-0.31	1.05e-10	Hip circumference adjusted for BMI;
LUAD	cis	rs11650175	0.835	rs72831410	chr17:63758213	C/T	cg07283582	chr17:63770753	CCDC46	0.39	7.84	0.36	3.77e-14	Chin dimples;
LUAD	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.71	-12.28	-0.51	7.7e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	trans	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg01620082	chr3:125678407	NA	-0.7	-7.98	-0.36	1.38e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.62	8.82	0.39	2.98e-17	Lymphocyte percentage of white cells;
LUAD	cis	rs2016266	1.000	rs10783573	chr12:53728369	G/A	cg26875137	chr12:53738046	NA	0.3	6.36	0.3	5.32e-10	Bone mineral density (spine);Bone mineral density;
LUAD	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg13319975	chr6:146136371	FBXO30	-0.64	-11.02	-0.47	5.35e-25	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3858526	0.527	rs10839168	chr11:6002798	A/G	cg13902645	chr11:5959945	NA	0.37	6.75	0.31	4.98e-11	DNA methylation (variation);
LUAD	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-9.41	-0.42	3.3e-19	Schizophrenia;
LUAD	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg14530993	chr4:882597	GAK	0.73	6.9	0.32	1.89e-11	Intelligence (multi-trait analysis);
LUAD	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg05621596	chr22:47072043	GRAMD4	-0.66	-10.96	-0.47	9.25e-25	Urate levels in obese individuals;
LUAD	cis	rs713587	0.563	rs1529897	chr2:25086827	T/G	cg04586622	chr2:25135609	ADCY3	0.39	8.89	0.4	1.76e-17	Body mass index in non-asthmatics;
LUAD	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg05425664	chr17:57184151	TRIM37	-0.43	-7.76	-0.35	6.27e-14	Intelligence (multi-trait analysis);
LUAD	trans	rs1493916	0.748	rs1941684	chr18:31304421	C/G	cg27147174	chr7:100797783	AP1S1	-0.61	-10.65	-0.46	1.29e-23	Life satisfaction;
LUAD	cis	rs7517126	1.000	rs6428369	chr1:196844335	A/G	cg07209298	chr1:196795943	CFHR1	0.49	6.71	0.31	6.19e-11	Blood protein levels;
LUAD	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.23	-0.37	2.29e-15	Renal function-related traits (BUN);
LUAD	trans	rs853679	0.607	rs13197574	chr6:28060239	T/C	cg01620082	chr3:125678407	NA	-1.1	-10.56	-0.46	2.69e-23	Depression;
LUAD	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg26384229	chr12:38710491	ALG10B	0.49	7.91	0.36	2.27e-14	Bladder cancer;
LUAD	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg06046430	chr4:77819534	ANKRD56	0.53	8.58	0.38	1.88e-16	Emphysema distribution in smoking;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23212364	chr2:61766090	XPO1	-0.43	-7.1	-0.33	5.16e-12	Cancer;
LUAD	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg02018176	chr4:1364513	KIAA1530	-0.36	-6.51	-0.3	2.13e-10	Obesity-related traits;
LUAD	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg11833968	chr6:79620685	NA	-0.44	-8.34	-0.38	1.09e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg23649088	chr2:200775458	C2orf69	0.62	8.24	0.37	2.17e-15	Schizophrenia;
LUAD	cis	rs6430585	0.640	rs3816155	chr2:136552526	A/C	cg07169764	chr2:136633963	MCM6	-0.74	-8.92	-0.4	1.45e-17	Corneal structure;
LUAD	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg19875535	chr5:140030758	IK	-0.47	-7.7	-0.35	9.59e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg03714773	chr7:91764589	CYP51A1	-0.27	-6.37	-0.3	5.04e-10	Breast cancer;
LUAD	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg25036284	chr2:26402008	FAM59B	-0.58	-8.17	-0.37	3.48e-15	Gut microbiome composition (summer);
LUAD	cis	rs6908034	0.607	rs75110577	chr6:19814523	C/T	cg02682789	chr6:19804855	NA	0.93	9.06	0.4	4.98e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LUAD	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg17652424	chr22:38574118	PLA2G6	-0.3	-9.07	-0.4	4.55e-18	Cutaneous nevi;
LUAD	cis	rs12541635	0.677	rs34872724	chr8:107033071	C/T	cg10147462	chr8:107024639	NA	-0.53	-9.69	-0.43	3.37e-20	Age of smoking initiation;
LUAD	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg05665937	chr4:1216051	CTBP1	0.42	7.04	0.32	7.65e-12	Obesity-related traits;
LUAD	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.36	-0.48	2.72e-26	Bipolar disorder;
LUAD	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg03806693	chr22:41940476	POLR3H	-0.56	-8.77	-0.39	4.38e-17	Vitiligo;
LUAD	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg13397359	chr6:42928475	GNMT	0.57	10.95	0.47	9.61e-25	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg18105139	chr6:28058856	ZSCAN12L1	0.24	6.38	0.3	4.74e-10	Parkinson's disease;
LUAD	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg07606381	chr6:8435919	SLC35B3	0.41	6.97	0.32	1.19e-11	Motion sickness;
LUAD	trans	rs8002861	0.641	rs4942252	chr13:44443039	C/T	cg12856521	chr11:46389249	DGKZ	0.48	8.09	0.37	6.59e-15	Leprosy;
LUAD	cis	rs4523957	0.928	rs9899193	chr17:2156917	G/A	cg16513277	chr17:2031491	SMG6	0.76	14.53	0.58	4.22e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs12532214	0.617	rs76620680	chr7:3160046	C/A	cg19214707	chr7:3157722	NA	-0.5	-7.03	-0.32	8.39e-12	Itch intensity from mosquito bite;
LUAD	cis	rs8060686	0.623	rs28700885	chr16:68154544	A/G	cg05110241	chr16:68378359	PRMT7	-0.55	-7.19	-0.33	2.96e-12	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs13082711	0.522	rs578501	chr3:27344963	A/G	cg02860705	chr3:27208620	NA	0.49	8.33	0.38	1.12e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-7.14	-0.33	4.2e-12	Triglycerides;
LUAD	cis	rs701145	0.938	rs355788	chr3:154000612	T/C	cg17054900	chr3:154042577	DHX36	0.64	7.1	0.33	5.16e-12	Coronary artery disease;
LUAD	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg07988820	chr12:82153109	PPFIA2	-0.5	-8.04	-0.36	9.2e-15	Resting heart rate;
LUAD	cis	rs897984	0.806	rs12928852	chr16:30943988	C/T	cg02466173	chr16:30829666	NA	0.67	12.49	0.52	1.1e-30	Dementia with Lewy bodies;
LUAD	cis	rs4730250	0.581	rs3779500	chr7:106792704	T/C	cg02696742	chr7:106810147	HBP1	0.82	10.81	0.47	3.2e-24	Osteoarthritis;
LUAD	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg06547715	chr2:218990976	CXCR2	0.31	7.7	0.35	9.85e-14	Colorectal cancer;
LUAD	trans	rs208520	0.837	rs208509	chr6:66941706	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-14.58	-0.58	2.66e-39	Exhaled nitric oxide output;
LUAD	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.47	8.55	0.38	2.23e-16	Menopause (age at onset);
LUAD	cis	rs250585	1.000	rs7202661	chr16:23504041	A/C	cg00143387	chr16:23521605	GGA2	-0.69	-8.05	-0.36	8.34e-15	Egg allergy;
LUAD	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg11833968	chr6:79620685	NA	-0.44	-8.36	-0.38	9.48e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg24818145	chr4:99064322	C4orf37	-0.41	-6.82	-0.31	3.11e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg27129171	chr3:47204927	SETD2	0.43	6.94	0.32	1.45e-11	Colorectal cancer;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg20540327	chr15:72668275	HEXA;C15orf34	-0.44	-6.9	-0.32	1.92e-11	Height;
LUAD	cis	rs1997103	0.863	rs6956287	chr7:55415107	T/C	cg17469321	chr7:55412551	NA	0.65	10.67	0.46	1.07e-23	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg03948781	chr1:205179583	DSTYK	0.34	6.36	0.3	5.25e-10	Mean corpuscular volume;Mean platelet volume;
LUAD	cis	rs929596	0.561	rs11891311	chr2:234639310	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.62	11.12	0.48	2.32e-25	Total bilirubin levels in HIV-1 infection;
LUAD	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg02782426	chr3:40428986	ENTPD3	-0.38	-8.1	-0.37	6.12e-15	Renal cell carcinoma;
LUAD	trans	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg07817883	chr1:32538562	TMEM39B	1.59	13.76	0.56	7.11e-36	Granulocyte percentage of myeloid white cells;
LUAD	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg03959625	chr15:84868606	LOC388152	0.42	6.74	0.31	5.29e-11	Schizophrenia;
LUAD	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs2629540	0.765	rs4962687	chr10:126404141	G/A	cg08799069	chr10:126477246	METTL10	-0.41	-6.6	-0.31	1.23e-10	Cocaine dependence;
LUAD	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg09197432	chr4:183729176	NA	0.61	7.95	0.36	1.75e-14	Pediatric autoimmune diseases;
LUAD	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08677398	chr8:58056175	NA	0.51	6.75	0.31	4.89e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	7.94	0.36	1.83e-14	Hip circumference adjusted for BMI;
LUAD	cis	rs4700695	0.841	rs448454	chr5:65293462	G/A	cg21114390	chr5:65439923	SFRS12	0.61	7.66	0.35	1.24e-13	Facial morphology (factor 19);
LUAD	trans	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg26043149	chr18:55253948	FECH	0.48	7.7	0.35	9.82e-14	Bone mineral density;
LUAD	cis	rs4072705	0.586	rs7023736	chr9:127247946	G/A	cg01786973	chr9:127249749	NR5A1	0.3	6.67	0.31	8.23e-11	Menarche (age at onset);
LUAD	cis	rs11696501	0.688	rs6073788	chr20:44213773	C/T	cg11783356	chr20:44313418	WFDC10B	-0.45	-7.16	-0.33	3.66e-12	Brain structure;
LUAD	cis	rs1595825	0.636	rs111540926	chr2:198885578	G/A	cg00982548	chr2:198649783	BOLL	-0.65	-9.16	-0.41	2.31e-18	Ulcerative colitis;
LUAD	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10802521	chr3:52805072	NEK4	-0.56	-9.39	-0.42	3.62e-19	Bipolar disorder;
LUAD	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg01475377	chr6:109611718	NA	-0.52	-9.88	-0.43	7.68e-21	Reticulocyte fraction of red cells;
LUAD	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg25566285	chr7:158114605	PTPRN2	0.42	7.32	0.34	1.29e-12	Response to amphetamines;
LUAD	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg13397359	chr6:42928475	GNMT	0.65	13.04	0.54	6.83e-33	Alzheimer's disease in APOE e4+ carriers;
LUAD	cis	rs6426558	0.502	rs10916080	chr1:227232040	A/G	cg10327440	chr1:227177885	CDC42BPA	0.56	9.03	0.4	6.17e-18	Neutrophil percentage of white cells;
LUAD	cis	rs6831352	0.569	rs4140388	chr4:100065734	G/C	cg12011299	chr4:100065546	ADH4	0.42	7.89	0.36	2.66e-14	Alcohol dependence;
LUAD	cis	rs1232027	0.656	rs1650674	chr5:79959683	C/T	cg24059623	chr5:79951536	MSH3;DHFR	-0.43	-7.02	-0.32	8.63e-12	Huntington's disease progression;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg09260951	chr22:39096513	JOSD1	-0.67	-6.61	-0.31	1.13e-10	Type 2 diabetes;
LUAD	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg00852783	chr1:26633632	UBXN11	0.4	7.05	0.32	7.54e-12	Obesity-related traits;
LUAD	cis	rs7512552	0.724	rs7002	chr1:150445819	A/G	cg15654264	chr1:150340011	RPRD2	0.6	11.56	0.49	4.66e-27	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs731174	0.959	rs7546741	chr1:38191397	G/C	cg06917450	chr1:38156652	C1orf109	-0.44	-7.24	-0.33	2.13e-12	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.37	-7.31	-0.34	1.32e-12	Glomerular filtration rate;
LUAD	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg19761014	chr17:28927070	LRRC37B2	0.82	8.28	0.37	1.6e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg26394196	chr10:1453818	ADARB2	-0.32	-6.41	-0.3	3.84e-10	Radiation response;
LUAD	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg07217954	chr7:1067459	C7orf50	0.45	7.1	0.33	5.28e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19717773	chr7:2847554	GNA12	-0.57	-9.8	-0.43	1.48e-20	Height;
LUAD	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg21427119	chr20:30132790	HM13	-0.49	-7.37	-0.34	8.94e-13	Mean corpuscular hemoglobin;
LUAD	cis	rs4638749	0.677	rs2198471	chr2:108844069	C/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-7.27	-0.33	1.77e-12	Blood pressure;
LUAD	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg11833968	chr6:79620685	NA	-0.44	-8.22	-0.37	2.56e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg25985355	chr7:65971099	NA	0.38	7.02	0.32	8.92e-12	Aortic root size;
LUAD	cis	rs4730250	0.554	rs76257331	chr7:106916279	G/A	cg02696742	chr7:106810147	HBP1	-0.69	-8.91	-0.4	1.59e-17	Osteoarthritis;
LUAD	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg17366294	chr4:99064904	C4orf37	0.65	12.53	0.52	7.27e-31	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg00860640	chr1:145516730	PEX11B;GNRHR2	0.4	6.63	0.31	1e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg05535760	chr7:792225	HEATR2	0.85	11.32	0.48	3.99e-26	Cerebrospinal P-tau181p levels;
LUAD	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.09	-0.33	5.73e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg17366294	chr4:99064904	C4orf37	0.66	12.84	0.53	4.19e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg11344533	chr11:111475393	SIK2	-0.37	-6.7	-0.31	6.6e-11	Primary sclerosing cholangitis;
LUAD	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03452623	chr4:187889614	NA	-0.84	-18.43	-0.67	4.12e-56	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg06064525	chr11:970664	AP2A2	0.53	10.88	0.47	1.8e-24	Alzheimer's disease (late onset);
LUAD	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg04827223	chr11:72435913	ARAP1	-0.51	-7.64	-0.35	1.43e-13	Type 2 diabetes;
LUAD	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg07570687	chr10:102243282	WNT8B	0.46	7.09	0.33	5.53e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-7.6	-0.35	1.89e-13	Lung cancer;
LUAD	cis	rs10189230	0.834	rs10932914	chr2:222362999	C/A	cg14652038	chr2:222343519	EPHA4	0.43	8.3	0.37	1.37e-15	Urate levels in lean individuals;
LUAD	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg13271783	chr10:134563150	INPP5A	-0.41	-7.09	-0.33	5.58e-12	Migraine;
LUAD	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg00316803	chr15:76480434	C15orf27	-0.41	-7.7	-0.35	9.57e-14	Blood metabolite levels;
LUAD	cis	rs9473147	0.516	rs7754282	chr6:47502024	C/G	cg20196966	chr6:47445060	CD2AP	-0.44	-7.07	-0.33	6.47e-12	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg23625390	chr15:77176239	SCAPER	0.37	6.59	0.31	1.29e-10	Blood metabolite levels;
LUAD	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg14828511	chr1:107599125	PRMT6	0.55	9.56	0.42	9.74e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg06740227	chr12:86229804	RASSF9	-0.41	-7.36	-0.34	9.88e-13	Major depressive disorder;
LUAD	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	12.52	0.52	8.34e-31	Monocyte percentage of white cells;
LUAD	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.37	7.38	0.34	8.7e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs2262909	0.719	rs12461632	chr19:22245089	G/A	cg17074339	chr11:11642133	GALNTL4	0.47	7.67	0.35	1.18e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	trans	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.94	-19.0	-0.68	1.17e-58	Coffee consumption;Coffee consumption (cups per day);
LUAD	trans	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg18187862	chr3:45730750	SACM1L	0.5	7.89	0.36	2.55e-14	Primary sclerosing cholangitis;
LUAD	cis	rs2487048	0.761	rs1800976	chr9:107690709	C/G	cg14019050	chr9:107690770	ABCA1	-0.4	-7.43	-0.34	5.97e-13	Intraocular pressure;
LUAD	trans	rs11039798	0.557	rs683180	chr11:48463949	A/G	cg03929089	chr4:120376271	NA	-0.49	-6.36	-0.3	5.21e-10	Axial length;
LUAD	cis	rs7737355	1.000	rs27421	chr5:130743771	C/T	cg06307176	chr5:131281290	NA	-0.48	-7.59	-0.35	2.07e-13	Life satisfaction;
LUAD	cis	rs68170813	0.559	rs7779062	chr7:106880195	T/A	cg23024343	chr7:107201750	COG5	0.45	6.71	0.31	6.09e-11	Coronary artery disease;
LUAD	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg21427119	chr20:30132790	HM13	-0.5	-7.98	-0.36	1.4e-14	Mean corpuscular hemoglobin;
LUAD	cis	rs9863	0.828	rs12809473	chr12:124476599	T/A	cg17723958	chr12:124429295	CCDC92	-0.4	-6.63	-0.31	1.06e-10	White blood cell count;
LUAD	trans	rs10838798	0.584	rs17198859	chr11:48140354	C/A	cg00717180	chr2:96193071	NA	-0.38	-7.11	-0.33	5.13e-12	Height;
LUAD	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg12935359	chr14:103987150	CKB	-0.49	-7.85	-0.36	3.52e-14	Body mass index;
LUAD	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg14829155	chr15:31115871	NA	-0.59	-9.99	-0.44	3.09e-21	Huntington's disease progression;
LUAD	cis	rs416603	0.967	rs11644184	chr16:11365104	G/A	cg00044050	chr16:11439710	C16orf75	-0.58	-9.18	-0.41	1.89e-18	Type 1 diabetes;
LUAD	cis	rs6484504	0.652	rs578666	chr11:31404484	C/T	cg14844989	chr11:31128820	NA	0.42	7.66	0.35	1.24e-13	Red blood cell count;
LUAD	cis	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg23950597	chr19:37808831	NA	-0.64	-7.57	-0.35	2.43e-13	Coronary artery calcification;
LUAD	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.26	0.37	1.89e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg17372223	chr3:52568218	NT5DC2	-0.4	-7.25	-0.33	2.05e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs868036	0.634	rs8028313	chr15:68043057	C/G	cg24579218	chr15:68104479	NA	-0.55	-9.51	-0.42	1.47e-19	Restless legs syndrome;
LUAD	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14240646	chr10:27532245	ACBD5	-0.9	-12.5	-0.52	9.78e-31	Breast cancer;
LUAD	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg14689365	chr7:158441557	NCAPG2	0.4	6.66	0.31	8.76e-11	Height;
LUAD	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg11317459	chr13:21872234	NA	-1.11	-14.96	-0.59	6.41e-41	White matter hyperintensity burden;
LUAD	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg07677032	chr17:61819896	STRADA	0.57	10.34	0.45	1.78e-22	Prudent dietary pattern;
LUAD	cis	rs6499255	0.951	rs11642030	chr16:69605211	A/C	cg15192750	chr16:69999425	NA	0.54	8.36	0.38	8.83e-16	IgE levels;
LUAD	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg03709012	chr19:19516395	GATAD2A	0.52	6.96	0.32	1.32e-11	Nonalcoholic fatty liver disease;
LUAD	trans	rs58106596	0.800	rs67402940	chr2:232566499	T/C	cg01370599	chr3:116745421	NA	0.57	8.06	0.36	7.79e-15	White blood cell count;Lymphocyte counts;
LUAD	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg22029157	chr1:209979665	IRF6	0.47	8.38	0.38	8.03e-16	Monobrow;
LUAD	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.81	-0.31	3.31e-11	Neuroticism;
LUAD	cis	rs55692468	0.520	rs62180799	chr2:153302108	G/A	cg04681845	chr2:153283485	FMNL2	0.38	7.17	0.33	3.29e-12	Intraocular pressure;
LUAD	cis	rs859767	0.741	rs4954159	chr2:135426782	A/G	cg12500956	chr2:135428796	TMEM163	-0.33	-8.56	-0.38	2.19e-16	Neuroticism;
LUAD	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg11766577	chr21:47581405	C21orf56	-0.63	-11.32	-0.48	3.87e-26	Testicular germ cell tumor;
LUAD	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg15962314	chr1:44399869	ARTN	-0.32	-7.36	-0.34	9.94e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs834811	0.831	rs1097147	chr7:135880446	C/T	cg01726295	chr7:135938950	NA	0.28	6.85	0.32	2.61e-11	Post-traumatic stress disorder;
LUAD	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg04990556	chr1:26633338	UBXN11	0.41	6.45	0.3	3e-10	Obesity-related traits;
LUAD	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	8.82	0.39	2.92e-17	Bipolar disorder and schizophrenia;
LUAD	trans	rs3219090	0.962	rs1865220	chr1:226602286	C/T	cg27539482	chr13:111589090	NA	-0.41	-7.0	-0.32	9.95e-12	Melanoma;
LUAD	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg15704280	chr7:45808275	SEPT13	-0.64	-9.73	-0.43	2.48e-20	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs11048434	0.636	rs12815310	chr12:9059934	A/G	cg13575925	chr12:9217583	LOC144571	0.37	6.79	0.31	3.79e-11	Sjögren's syndrome;
LUAD	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.3	0.33	1.43e-12	Bladder cancer;
LUAD	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg18306943	chr3:40428807	ENTPD3	0.42	7.18	0.33	3.16e-12	Renal cell carcinoma;
LUAD	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg16850897	chr7:100343110	ZAN	0.43	7.63	0.35	1.55e-13	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUAD	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg00071950	chr4:10020882	SLC2A9	0.86	18.34	0.67	1.07e-55	Bone mineral density;
LUAD	cis	rs7017914	0.934	rs7814274	chr8:71570411	C/T	cg05247391	chr8:71581649	XKR9;LACTB2	0.31	6.35	0.3	5.57e-10	Bone mineral density;
LUAD	cis	rs9378688	1.000	rs3800187	chr6:2222253	C/T	cg12303981	chr6:2244766	GMDS	-0.44	-6.56	-0.3	1.58e-10	Caudate nucleus volume;
LUAD	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg03929089	chr4:120376271	NA	-0.59	-9.43	-0.42	2.78e-19	Coronary artery disease;
LUAD	trans	rs2898857	0.504	rs12937923	chr17:47408475	G/A	cg11430096	chr6:110968061	CDK19	-0.48	-7.36	-0.34	9.57e-13	Cancer;
LUAD	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg08632164	chr7:65971372	NA	-0.55	-6.45	-0.3	3.06e-10	Diabetic kidney disease;
LUAD	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg10589385	chr1:150898437	SETDB1	-0.35	-6.52	-0.3	2.02e-10	Monocyte chemoattractant protein-1 levels;
LUAD	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg15117754	chr3:10150083	C3orf24	0.44	7.26	0.33	1.87e-12	Alzheimer's disease;
LUAD	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg10589385	chr1:150898437	SETDB1	0.41	7.6	0.35	1.86e-13	Melanoma;
LUAD	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg00106254	chr7:1943704	MAD1L1	-0.44	-6.55	-0.3	1.64e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs2806561	0.929	rs6660880	chr1:23540302	T/C	cg12483005	chr1:23474871	LUZP1	-0.39	-6.58	-0.3	1.42e-10	Height;
LUAD	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg11266682	chr4:10021025	SLC2A9	0.68	15.86	0.61	8.34e-45	Bone mineral density;
LUAD	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg09365446	chr1:150670422	GOLPH3L	0.67	12.68	0.52	1.92e-31	Tonsillectomy;
LUAD	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.47	7.6	0.35	1.93e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9308433	0.569	rs1353718	chr1:214459652	A/T	cg06198575	chr1:214491504	SMYD2	0.42	7.07	0.32	6.57e-12	IgG glycosylation;
LUAD	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg06046430	chr4:77819534	ANKRD56	0.55	8.84	0.4	2.53e-17	Emphysema distribution in smoking;
LUAD	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.51	8.33	0.38	1.13e-15	Lymphocyte percentage of white cells;
LUAD	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg15929573	chr12:49658188	TUBA1C	-0.39	-6.45	-0.3	3e-10	Migraine with aura;
LUAD	trans	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-7.17	-0.33	3.37e-12	Joint mobility (Beighton score);
LUAD	cis	rs1865721	0.656	rs724765	chr18:73139794	A/G	cg26385618	chr18:73139727	C18orf62	-0.5	-10.26	-0.45	3.2e-22	Intelligence;
LUAD	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg00666640	chr1:248458726	OR2T12	0.3	7.24	0.33	2.14e-12	Common traits (Other);
LUAD	cis	rs9296092	0.538	rs56205713	chr6:33517510	A/G	cg13560919	chr6:33536144	NA	-0.88	-16.45	-0.62	2.39e-47	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs1003719	0.743	rs2835615	chr21:38497303	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.52	-8.74	-0.39	5.57e-17	Eye color traits;
LUAD	cis	rs7927771	0.524	rs12286721	chr11:47701528	G/T	cg18512352	chr11:47633146	NA	-0.36	-6.43	-0.3	3.42e-10	Subjective well-being;
LUAD	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg25173405	chr17:45401733	C17orf57	-0.47	-7.6	-0.35	1.88e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg07870213	chr5:140052090	DND1	0.73	11.41	0.49	1.8e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg18512352	chr11:47633146	NA	-0.48	-8.38	-0.38	8.02e-16	Subjective well-being;
LUAD	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.32	-7.04	-0.32	7.61e-12	Dupuytren's disease;
LUAD	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg20701182	chr2:24300061	SF3B14	0.68	7.64	0.35	1.51e-13	Lymphocyte counts;
LUAD	cis	rs367943	0.799	rs2115209	chr5:112973494	A/G	cg12552261	chr5:112820674	MCC	0.53	9.13	0.41	2.86e-18	Type 2 diabetes;
LUAD	cis	rs758324	0.504	rs55764014	chr5:131170905	G/T	cg25547332	chr5:131281432	NA	0.42	6.8	0.31	3.54e-11	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.51	-9.05	-0.4	5.25e-18	Lymphocyte counts;
LUAD	trans	rs3960554	0.808	rs111714534	chr7:75748896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.82	10.95	0.47	1.01e-24	Eotaxin levels;
LUAD	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg14343924	chr8:8086146	FLJ10661	0.46	7.18	0.33	3.07e-12	Mood instability;
LUAD	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg04586622	chr2:25135609	ADCY3	0.37	8.45	0.38	4.88e-16	Body mass index;
LUAD	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg04976154	chr16:1532411	NA	-0.36	-7.92	-0.36	2.11e-14	Bone mineral density;
LUAD	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg23422044	chr7:1970798	MAD1L1	0.55	6.83	0.32	3.02e-11	Bipolar disorder;
LUAD	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg10164272	chr16:89456328	ANKRD11	0.4	6.38	0.3	4.53e-10	Multiple myeloma (IgH translocation);
LUAD	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg11766577	chr21:47581405	C21orf56	-0.44	-7.62	-0.35	1.65e-13	Testicular germ cell tumor;
LUAD	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg19875535	chr5:140030758	IK	-0.48	-8.0	-0.36	1.21e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22496380	chr5:211416	CCDC127	-0.92	-12.82	-0.53	5.11e-32	Breast cancer;
LUAD	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg07362569	chr17:61921086	SMARCD2	0.39	6.76	0.31	4.55e-11	Prudent dietary pattern;
LUAD	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg08761264	chr16:28874980	SH2B1	0.43	6.63	0.31	1.04e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.47	2.75e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg23029597	chr12:123009494	RSRC2	-0.53	-8.18	-0.37	3.25e-15	Body mass index;
LUAD	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.34	6.82	0.31	3.08e-11	Obesity-related traits;
LUAD	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg03342759	chr3:160939853	NMD3	-0.4	-6.58	-0.3	1.38e-10	Morning vs. evening chronotype;
LUAD	cis	rs12976411	0.575	rs35367178	chr19:32825503	G/A	cg18253629	chr19:32836317	ZNF507	0.65	6.86	0.32	2.38e-11	Coronary artery disease;
LUAD	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg06640241	chr16:89574553	SPG7	0.74	13.5	0.55	8.43e-35	Multiple myeloma (IgH translocation);
LUAD	cis	rs2835872	0.758	rs1787394	chr21:39036176	C/A	cg06728970	chr21:39037746	KCNJ6	0.4	7.7	0.35	9.65e-14	Electroencephalographic traits in alcoholism;
LUAD	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg05082376	chr22:42548792	NA	-0.44	-7.7	-0.35	9.47e-14	Schizophrenia;
LUAD	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg24450063	chr1:156163899	SLC25A44	1.18	28.24	0.81	2.33e-99	Testicular germ cell tumor;
LUAD	cis	rs73206853	0.563	rs7960749	chr12:111164369	T/C	cg12870014	chr12:110450643	ANKRD13A	0.6	7.0	0.32	1.02e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg06873352	chr17:61820015	STRADA	0.43	7.09	0.33	5.68e-12	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg09323728	chr8:95962352	TP53INP1	-0.32	-7.77	-0.35	5.81e-14	Type 2 diabetes;
LUAD	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg15704280	chr7:45808275	SEPT13	0.63	8.39	0.38	7.15e-16	Axial length;
LUAD	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg05966235	chr16:28915196	ATP2A1	0.47	7.71	0.35	8.82e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs6489882	0.934	rs7299132	chr12:113376913	T/A	cg20102336	chr12:113376681	OAS3	-0.57	-8.88	-0.4	1.88e-17	Chronic lymphocytic leukemia;
LUAD	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg17366294	chr4:99064904	C4orf37	0.67	12.92	0.53	2.06e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg05340658	chr4:99064831	C4orf37	0.53	8.79	0.39	3.88e-17	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4481887	0.927	rs4453081	chr1:248475691	C/G	cg00666640	chr1:248458726	OR2T12	0.29	6.7	0.31	6.84e-11	Common traits (Other);
LUAD	cis	rs3845702	1.000	rs10497555	chr2:180864967	A/G	cg01881094	chr2:180872142	CWC22	0.59	7.45	0.34	5.48e-13	Schizophrenia;
LUAD	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg23958373	chr8:599963	NA	-1.13	-9.57	-0.42	9.34e-20	IgG glycosylation;
LUAD	cis	rs250585	1.000	rs1610	chr16:23582153	A/G	cg00143387	chr16:23521605	GGA2	-0.72	-9.11	-0.4	3.37e-18	Egg allergy;
LUAD	cis	rs6761276	0.649	rs10181720	chr2:113838608	A/G	cg10479672	chr2:113810641	IL1F8	-0.35	-7.0	-0.32	1.04e-11	Protein quantitative trait loci;
LUAD	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg22823121	chr1:150693482	HORMAD1	-0.4	-7.83	-0.36	3.87e-14	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg18180107	chr4:99064573	C4orf37	0.4	6.47	0.3	2.69e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg12035532	chr1:1886765	KIAA1751	0.41	6.93	0.32	1.61e-11	Body mass index;
LUAD	cis	rs3774830	0.743	rs11728680	chr4:5462247	A/G	cg26943120	chr4:5472116	STK32B	0.37	7.44	0.34	5.85e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs931127	0.666	rs7932857	chr11:65457493	A/C	cg27068330	chr11:65405492	SIPA1	-0.42	-6.83	-0.32	2.94e-11	Systemic lupus erythematosus;
LUAD	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg09367891	chr1:107599246	PRMT6	0.59	9.76	0.43	2.01e-20	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.98	-0.36	1.35e-14	Monocyte percentage of white cells;
LUAD	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.76	-0.31	4.63e-11	Diabetic kidney disease;
LUAD	cis	rs733175	0.855	rs10006397	chr4:10036140	C/A	cg00071950	chr4:10020882	SLC2A9	0.57	8.47	0.38	4e-16	Psychosis and Alzheimer's disease;
LUAD	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08704250	chr15:31115839	NA	0.66	13.04	0.54	6.33e-33	Huntington's disease progression;
LUAD	cis	rs7173743	0.750	rs12903355	chr15:79129145	A/T	cg00540400	chr15:79124168	NA	0.38	7.82	0.36	4.38e-14	Coronary artery disease;
LUAD	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg04025307	chr7:1156635	C7orf50	0.64	7.64	0.35	1.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	trans	rs7939886	0.920	rs79521305	chr11:55811332	G/A	cg15704280	chr7:45808275	SEPT13	0.66	6.37	0.3	4.86e-10	Myopia (pathological);
LUAD	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg17848003	chr1:3704513	LRRC47	0.51	10.17	0.44	6.75e-22	Red cell distribution width;
LUAD	cis	rs354225	0.626	rs7591204	chr2:54829458	C/G	cg01766943	chr2:54829624	SPTBN1	-0.41	-7.45	-0.34	5.22e-13	Schizophrenia;
LUAD	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg00922110	chr4:57842668	C4orf14	-0.41	-6.9	-0.32	1.86e-11	Response to bleomycin (chromatid breaks);
LUAD	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg13560548	chr3:10150139	C3orf24	0.43	6.39	0.3	4.37e-10	Alzheimer's disease;
LUAD	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg00280220	chr17:61926910	NA	-0.35	-6.67	-0.31	7.9e-11	Prudent dietary pattern;
LUAD	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg03929089	chr4:120376271	NA	-0.77	-12.17	-0.51	1.96e-29	Coronary artery disease;
LUAD	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg10523679	chr1:76189770	ACADM	-0.72	-11.47	-0.49	1.02e-26	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs921968	0.541	rs3770213	chr2:219508372	A/T	cg02176678	chr2:219576539	TTLL4	-0.8	-16.5	-0.63	1.36e-47	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg07917127	chr4:99064746	C4orf37	0.43	7.14	0.33	4.04e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg05434287	chr7:2030229	MAD1L1	0.38	6.54	0.3	1.74e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg24154853	chr7:158122151	PTPRN2	0.59	11.82	0.5	4.66e-28	Calcium levels;
LUAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg05313129	chr8:58192883	C8orf71	-0.57	-8.44	-0.38	4.99e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg03354898	chr7:1950403	MAD1L1	-0.41	-7.74	-0.35	7.58e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.49	-0.3	2.38e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-11.06	-0.47	3.71e-25	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs8077889	0.672	rs4793028	chr17:41857212	T/C	cg26893861	chr17:41843967	DUSP3	1.13	25.46	0.78	2.14e-87	Triglycerides;
LUAD	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22590775	chr19:49891494	CCDC155	0.67	9.49	0.42	1.73e-19	Multiple sclerosis;
LUAD	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg22676075	chr6:135203613	NA	0.38	6.9	0.32	1.88e-11	Red blood cell count;
LUAD	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg12062639	chr20:23401060	NAPB	1.08	11.35	0.48	2.96e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.93	0.32	1.55e-11	Cognitive test performance;
LUAD	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	8.04	0.36	8.85e-15	Breast cancer;
LUAD	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg21605333	chr4:119757512	SEC24D	0.97	8.73	0.39	6.15e-17	Cannabis dependence symptom count;
LUAD	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg25036284	chr2:26402008	FAM59B	0.84	11.75	0.5	8.7e-28	Gut microbiome composition (summer);
LUAD	cis	rs13033859	0.526	rs12477065	chr2:292753	C/T	cg12623918	chr2:306882	NA	0.42	8.47	0.38	4.19e-16	Mitochondrial DNA levels;
LUAD	cis	rs2718058	0.519	rs2722233	chr7:37875982	A/T	cg15028436	chr7:37888078	TXNDC3	0.34	7.19	0.33	2.91e-12	Alzheimer's disease (late onset);
LUAD	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg26384229	chr12:38710491	ALG10B	0.44	7.42	0.34	6.6e-13	Morning vs. evening chronotype;
LUAD	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg18833306	chr6:118973337	C6orf204	-0.49	-7.27	-0.33	1.75e-12	Diastolic blood pressure;
LUAD	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg00933542	chr6:150070202	PCMT1	0.38	7.72	0.35	8.64e-14	Lung cancer;
LUAD	trans	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg11693508	chr17:37793320	STARD3	0.45	6.72	0.31	6.06e-11	Neuroticism;
LUAD	cis	rs6961069	0.745	rs1953298	chr7:80265451	C/T	cg04458919	chr7:80252533	CD36	-0.37	-7.12	-0.33	4.64e-12	Platelet count;
LUAD	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg10755058	chr3:40428713	ENTPD3	0.43	8.46	0.38	4.52e-16	Renal cell carcinoma;
LUAD	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg12179176	chr11:130786555	SNX19	-0.42	-6.96	-0.32	1.34e-11	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg03467027	chr4:99064603	C4orf37	0.43	6.96	0.32	1.31e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg11189052	chr15:85197271	WDR73	-0.61	-10.16	-0.44	7.35e-22	P wave terminal force;
LUAD	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg24675056	chr1:15929824	NA	0.5	8.72	0.39	6.23e-17	Systolic blood pressure;
LUAD	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg02549819	chr16:58548995	SETD6	0.8	6.69	0.31	7.25e-11	Schizophrenia;
LUAD	cis	rs867529	0.695	rs335115	chr2:89027647	C/T	cg26627705	chr2:89060884	NA	0.46	7.0	0.32	1.04e-11	Height;
LUAD	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg20307385	chr11:47447363	PSMC3	0.53	7.91	0.36	2.27e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs8067545	0.667	rs7222403	chr17:19879164	T/C	cg04132472	chr17:19861366	AKAP10	0.36	8.43	0.38	5.69e-16	Schizophrenia;
LUAD	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg11494091	chr17:61959527	GH2	0.74	18.62	0.67	5.82e-57	Prudent dietary pattern;
LUAD	cis	rs2446066	0.605	rs7298336	chr12:53957330	G/T	cg20730629	chr12:53886622	MAP3K12	-0.48	-6.64	-0.31	9.38e-11	Red blood cell count;
LUAD	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg09117114	chr16:67998030	SLC12A4	-0.48	-6.78	-0.31	4.05e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg02734326	chr4:10020555	SLC2A9	0.5	7.63	0.35	1.58e-13	Blood metabolite levels;
LUAD	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg00280220	chr17:61926910	NA	0.36	6.9	0.32	1.9e-11	Prudent dietary pattern;
LUAD	cis	rs1113500	0.933	rs12132785	chr1:108633083	A/T	cg06207961	chr1:108661230	NA	0.45	8.49	0.38	3.65e-16	Growth-regulated protein alpha levels;
LUAD	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.01	0.36	1.11e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs1215050	0.874	rs17545594	chr4:98652689	A/G	cg17366294	chr4:99064904	C4orf37	-0.41	-7.07	-0.33	6.26e-12	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg07217954	chr7:1067459	C7orf50	0.45	6.97	0.32	1.24e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg04025307	chr7:1156635	C7orf50	0.6	6.77	0.31	4.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg05805236	chr11:65401703	PCNXL3	-0.52	-8.62	-0.39	1.31e-16	Acne (severe);
LUAD	cis	rs6712932	1.000	rs6734358	chr2:105843732	A/C	cg22878388	chr2:105853796	NA	-0.4	-7.08	-0.33	6.03e-12	Type 2 diabetes;
LUAD	trans	rs2774920	0.614	rs3789692	chr1:94657978	C/G	cg24762501	chr19:51530751	KLK11	-0.67	-6.47	-0.3	2.74e-10	D-dimer levels;
LUAD	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg26384229	chr12:38710491	ALG10B	-0.41	-6.82	-0.31	3.09e-11	Morning vs. evening chronotype;
LUAD	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.27	0.45	2.99e-22	Lung cancer in ever smokers;
LUAD	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg15128208	chr22:42549153	NA	-0.4	-8.03	-0.36	1e-14	Cognitive function;
LUAD	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg07606381	chr6:8435919	SLC35B3	0.43	7.19	0.33	3.05e-12	Motion sickness;
LUAD	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg17644776	chr2:200775616	C2orf69	0.44	6.98	0.32	1.12e-11	Osteoporosis;
LUAD	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg27129171	chr3:47204927	SETD2	0.43	7.11	0.33	5e-12	Colorectal cancer;
LUAD	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg18477163	chr1:228402036	OBSCN	-0.36	-7.27	-0.33	1.74e-12	Diastolic blood pressure;
LUAD	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg01324343	chr3:183735012	ABCC5	0.8	18.23	0.66	3.28e-55	Anterior chamber depth;
LUAD	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.57	0.3	1.49e-10	Menarche (age at onset);
LUAD	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg26384229	chr12:38710491	ALG10B	0.45	7.23	0.33	2.33e-12	Heart rate;
LUAD	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg04772025	chr11:68637568	NA	0.59	9.43	0.42	2.69e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs7911264	0.967	rs2488087	chr10:94446041	G/A	cg25093409	chr10:94429542	NA	-0.35	-6.41	-0.3	3.96e-10	Inflammatory bowel disease;
LUAD	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg03433033	chr1:76189801	ACADM	0.86	15.55	0.6	1.9e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg22117172	chr7:91764530	CYP51A1	0.35	7.79	0.35	5.34e-14	Breast cancer;
LUAD	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg23625390	chr15:77176239	SCAPER	0.4	7.25	0.33	1.97e-12	Blood metabolite levels;
LUAD	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg05535760	chr7:792225	HEATR2	-0.76	-9.21	-0.41	1.56e-18	Cerebrospinal P-tau181p levels;
LUAD	cis	rs754466	0.580	rs10824576	chr10:79566040	G/C	cg17075019	chr10:79541650	NA	-0.89	-18.6	-0.67	7.67e-57	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6076065	0.723	rs8183442	chr20:23415563	C/T	cg11657817	chr20:23433608	CST11	0.49	8.84	0.39	2.62e-17	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg05616858	chr17:37843591	ERBB2;PGAP3	0.33	6.54	0.3	1.73e-10	Asthma;
LUAD	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg24768116	chr2:27665128	KRTCAP3	0.26	6.48	0.3	2.59e-10	Oral cavity cancer;
LUAD	cis	rs2108225	0.872	rs4618632	chr7:107440952	T/G	cg18560240	chr7:107437656	SLC26A3	-0.41	-6.8	-0.31	3.56e-11	Ulcerative colitis;
LUAD	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg24558204	chr6:135376177	HBS1L	-0.47	-8.52	-0.38	2.79e-16	Red blood cell count;
LUAD	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.08	-0.37	6.91e-15	Diabetic kidney disease;
LUAD	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg14092571	chr14:90743983	NA	-0.95	-18.12	-0.66	1.04e-54	Gut microbiota (bacterial taxa);
LUAD	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg21862992	chr11:68658383	NA	0.52	9.42	0.42	3.04e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg03885332	chr11:832357	CD151	-0.42	-7.87	-0.36	2.9e-14	Mean platelet volume;
LUAD	cis	rs7818345	0.874	rs12674938	chr8:19300813	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.31	6.9	0.32	1.91e-11	Language performance in older adults (adjusted for episodic memory);
LUAD	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg06618935	chr21:46677482	NA	-0.49	-9.87	-0.43	8.27e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg15997130	chr1:24165203	NA	0.56	9.54	0.42	1.14e-19	Immature fraction of reticulocytes;
LUAD	cis	rs17362650	0.883	rs35744046	chr2:9662410	T/C	cg12832956	chr2:9616023	IAH1	-0.48	-7.45	-0.34	5.48e-13	Alcohol dependence (age at onset);
LUAD	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg03714773	chr7:91764589	CYP51A1	0.27	6.4	0.3	4.16e-10	Breast cancer;
LUAD	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26314531	chr2:26401878	FAM59B	-0.58	-7.99	-0.36	1.33e-14	Gut microbiome composition (summer);
LUAD	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg20607798	chr8:58055168	NA	0.59	7.09	0.33	5.8e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	8.36	0.38	9.05e-16	Breast cancer;
LUAD	cis	rs986417	0.901	rs1955692	chr14:61008408	C/A	cg27398547	chr14:60952738	C14orf39	0.66	7.65	0.35	1.38e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14829155	chr15:31115871	NA	0.77	13.09	0.54	4.1e-33	Huntington's disease progression;
LUAD	cis	rs2274273	0.840	rs2009291	chr14:55838230	A/C	cg04306507	chr14:55594613	LGALS3	-0.41	-8.58	-0.39	1.78e-16	Protein biomarker;
LUAD	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg26554054	chr8:600488	NA	0.82	7.92	0.36	2.09e-14	IgG glycosylation;
LUAD	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg17074396	chr22:49843754	NA	-0.32	-6.38	-0.3	4.78e-10	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-8.15	-0.37	4.09e-15	Prostate cancer;
LUAD	cis	rs1215050	0.791	rs783959	chr4:98893476	C/T	cg05340658	chr4:99064831	C4orf37	-0.45	-7.44	-0.34	5.55e-13	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg27446573	chr6:127587934	RNF146	0.43	6.54	0.3	1.81e-10	Breast cancer;
LUAD	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg15962314	chr1:44399869	ARTN	0.32	7.41	0.34	6.88e-13	Intelligence (multi-trait analysis);
LUAD	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21582582	chr3:182698605	DCUN1D1	0.61	9.55	0.42	1.08e-19	Resting heart rate;
LUAD	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg24818145	chr4:99064322	C4orf37	0.46	7.77	0.35	6.2e-14	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg21659725	chr3:3221576	CRBN	0.48	8.04	0.36	9.02e-15	Intelligence (multi-trait analysis);
LUAD	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg14343924	chr8:8086146	FLJ10661	0.43	6.7	0.31	6.8e-11	Neuroticism;
LUAD	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg00750074	chr16:89608354	SPG7	-0.6	-10.54	-0.46	3.32e-23	Multiple myeloma (IgH translocation);
LUAD	cis	rs7851660	0.844	rs10123699	chr9:100637859	A/G	cg13688889	chr9:100608707	NA	-0.52	-8.86	-0.4	2.22e-17	Strep throat;
LUAD	cis	rs4853036	0.951	rs7575302	chr2:70055236	T/C	cg02498382	chr2:70120550	SNRNP27	-0.51	-8.2	-0.37	2.81e-15	Colorectal or endometrial cancer;
LUAD	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg15704280	chr7:45808275	SEPT13	0.68	8.92	0.4	1.37e-17	Axial length;
LUAD	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg13944838	chr5:179740914	GFPT2	-0.8	-13.86	-0.56	2.93e-36	Height;
LUAD	trans	rs7069733	0.938	rs6584557	chr10:105299886	A/G	cg23983269	chr5:175815749	HIGD2A;NOP16	-0.51	-6.55	-0.3	1.63e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg07570687	chr10:102243282	WNT8B	0.45	6.97	0.32	1.25e-11	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs7043114	0.525	rs1053441	chr9:95147840	T/A	cg14631576	chr9:95140430	CENPP	-0.4	-8.01	-0.36	1.08e-14	Height;
LUAD	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg03188948	chr7:1209495	NA	0.83	10.11	0.44	1.13e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs7216064	1.000	rs11079707	chr17:65835617	A/G	cg08758996	chr17:66097529	LOC651250	-0.42	-6.55	-0.3	1.71e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg03188948	chr7:1209495	NA	0.4	6.53	0.3	1.9e-10	Longevity;Endometriosis;
LUAD	trans	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg18335740	chr13:41363409	SLC25A15	0.62	11.7	0.49	1.36e-27	Lewy body disease;
LUAD	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg17031739	chr1:67600172	NA	0.47	8.4	0.38	7.01e-16	Psoriasis;
LUAD	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.77	-0.46	4.38e-24	Developmental language disorder (linguistic errors);
LUAD	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg08885076	chr2:99613938	TSGA10	-0.4	-7.18	-0.33	3.2e-12	Chronic sinus infection;
LUAD	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg00204512	chr16:28754710	NA	0.33	7.15	0.33	3.85e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg00083206	chr6:110721305	DDO	-0.38	-6.85	-0.32	2.62e-11	Platelet distribution width;
LUAD	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg06740227	chr12:86229804	RASSF9	0.4	7.0	0.32	9.89e-12	Major depressive disorder;
LUAD	cis	rs61897795	0.657	rs174590	chr11:61616977	G/C	cg19610905	chr11:61596333	FADS2	-0.62	-8.88	-0.4	1.99e-17	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg08601574	chr20:25228251	PYGB	0.44	8.14	0.37	4.61e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs7216064	0.589	rs8072723	chr17:66056970	T/A	cg08758996	chr17:66097529	LOC651250	-0.4	-6.42	-0.3	3.68e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg15432903	chr11:17409602	KCNJ11	0.55	10.41	0.45	9.31e-23	Type 2 diabetes;
LUAD	trans	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.97	0.44	3.58e-21	Ulcerative colitis;
LUAD	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg19875535	chr5:140030758	IK	-0.42	-7.06	-0.32	6.88e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg21890820	chr11:65308645	LTBP3	0.49	7.79	0.35	5.34e-14	Bone mineral density;
LUAD	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg18446336	chr7:2847575	GNA12	-0.37	-6.84	-0.32	2.71e-11	Height;
LUAD	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.5	0.3	2.33e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg24399712	chr22:39784796	NA	-0.82	-16.17	-0.62	3.74e-46	Intelligence (multi-trait analysis);
LUAD	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg23649088	chr2:200775458	C2orf69	0.62	8.26	0.37	1.9e-15	Schizophrenia;
LUAD	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg02196655	chr2:10830764	NOL10	-0.46	-8.37	-0.38	8.46e-16	Prostate cancer;
LUAD	trans	rs5756813	0.870	rs5756812	chr22:38173113	C/T	cg19894588	chr14:64061835	NA	0.56	8.45	0.38	4.63e-16	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs240764	0.817	rs6907240	chr6:101153782	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-7.39	-0.34	7.92e-13	Neuroticism;
LUAD	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg00376283	chr12:123451042	ABCB9	0.4	6.58	0.3	1.36e-10	Platelet count;
LUAD	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg08470875	chr2:26401718	FAM59B	0.77	10.11	0.44	1.11e-21	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.5	0.38	3.32e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg08989290	chr16:615782	NHLRC4	0.31	6.65	0.31	8.86e-11	Height;
LUAD	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg18135555	chr8:22132992	PIWIL2	0.44	8.16	0.37	3.94e-15	Hypertriglyceridemia;
LUAD	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg17757837	chr7:157058334	UBE3C	-0.47	-8.28	-0.37	1.63e-15	Body mass index;
LUAD	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg24733560	chr20:60626293	TAF4	0.47	8.33	0.38	1.1e-15	Body mass index;
LUAD	cis	rs62238980	0.614	rs74925531	chr22:32417582	G/A	cg00543991	chr22:32367038	NA	0.97	9.07	0.4	4.65e-18	Childhood ear infection;
LUAD	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg08885076	chr2:99613938	TSGA10	0.36	6.46	0.3	2.91e-10	Chronic sinus infection;
LUAD	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg06808227	chr14:105710500	BRF1	-0.41	-6.37	-0.3	4.83e-10	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg05665937	chr4:1216051	CTBP1	0.5	7.5	0.34	3.91e-13	Longevity;
LUAD	cis	rs7617773	0.780	rs7653336	chr3:48369464	T/A	cg11946769	chr3:48343235	NME6	0.45	6.89	0.32	2.05e-11	Coronary artery disease;
LUAD	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg27124370	chr19:33622961	WDR88	-0.46	-7.17	-0.33	3.38e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.42	-7.4	-0.34	7.52e-13	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4285028	0.948	rs34696871	chr3:121671880	T/G	cg11130432	chr3:121712080	ILDR1	-0.58	-8.27	-0.37	1.71e-15	Multiple sclerosis;
LUAD	cis	rs2412459	1.000	rs6492925	chr15:40304170	T/G	cg10636054	chr15:40330586	SRP14	0.71	8.08	0.37	6.9e-15	Response to haloperidol in psychosis;
LUAD	cis	rs300703	0.542	rs189762	chr2:180079	A/T	cg21211680	chr2:198530	NA	-0.52	-7.44	-0.34	5.82e-13	Blood protein levels;
LUAD	cis	rs1595825	0.838	rs73056856	chr2:198801209	C/G	cg00361562	chr2:198649771	BOLL	-0.47	-6.72	-0.31	5.88e-11	Ulcerative colitis;
LUAD	cis	rs791888	0.688	rs1980649	chr10:89422375	T/C	cg13926569	chr10:89418898	PAPSS2	0.52	9.79	0.43	1.51e-20	Magnesium levels;
LUAD	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11890956	chr21:40555474	PSMG1	-0.61	-10.23	-0.45	4.38e-22	Cognitive function;
LUAD	cis	rs7707921	0.767	rs862245	chr5:81585737	A/C	cg15871215	chr5:81402204	ATG10	-0.63	-10.5	-0.45	4.32e-23	Breast cancer;
LUAD	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg23505145	chr19:12996616	KLF1	0.61	9.97	0.44	3.56e-21	Prostate cancer (SNP x SNP interaction);
LUAD	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg25173405	chr17:45401733	C17orf57	-0.47	-7.62	-0.35	1.63e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.41	6.54	0.3	1.77e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg10591111	chr5:226296	SDHA	-0.56	-7.25	-0.33	1.98e-12	Breast cancer;
LUAD	cis	rs8044868	0.606	rs7189591	chr16:72099011	G/T	cg23815491	chr16:72088622	HP	0.55	10.36	0.45	1.4e-22	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs11771526	0.901	rs17161137	chr7:32323799	G/T	cg13207630	chr7:32358064	NA	0.63	7.58	0.35	2.17e-13	Body mass index;
LUAD	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg25208724	chr1:156163844	SLC25A44	0.98	15.27	0.6	3.17e-42	Testicular germ cell tumor;
LUAD	trans	rs11039798	1.000	rs115429994	chr11:48761183	C/G	cg15704280	chr7:45808275	SEPT13	0.67	7.84	0.36	3.58e-14	Axial length;
LUAD	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg02371401	chr5:676784	TPPP	-0.48	-7.81	-0.36	4.42e-14	Lung disease severity in cystic fibrosis;
LUAD	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg08213375	chr14:104286397	PPP1R13B	0.28	7.12	0.33	4.69e-12	Schizophrenia;
LUAD	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg26597838	chr10:835615	NA	-0.53	-8.42	-0.38	6e-16	Response to angiotensin II receptor blocker therapy;
LUAD	cis	rs11671005	0.735	rs45617039	chr19:58951096	G/A	cg13877915	chr19:58951672	ZNF132	0.57	7.5	0.34	3.79e-13	Mean platelet volume;
LUAD	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg25894440	chr7:65020034	NA	-0.61	-6.61	-0.31	1.15e-10	Diabetic kidney disease;
LUAD	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.56	-9.81	-0.43	1.31e-20	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg12927641	chr6:109611667	NA	-0.47	-7.91	-0.36	2.22e-14	Reticulocyte fraction of red cells;
LUAD	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.48	7.78	0.35	5.59e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg08034070	chr17:40805868	NA	0.42	8.28	0.37	1.66e-15	Colorectal or endometrial cancer;
LUAD	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg14019146	chr3:50243930	SLC38A3	0.35	6.48	0.3	2.58e-10	Body mass index;
LUAD	cis	rs9614461	0.702	rs2294202	chr22:45738327	A/T	cg23503501	chr22:45809793	SMC1B;RIBC2	0.67	7.23	0.33	2.25e-12	Tonsillectomy;
LUAD	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg00857998	chr1:205179979	DSTYK	0.41	6.82	0.31	3.22e-11	Red blood cell count;
LUAD	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg07570687	chr10:102243282	WNT8B	0.48	7.35	0.34	1.03e-12	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs2579500	0.844	rs2314397	chr2:97336979	C/G	cg23100626	chr2:96804247	ASTL	-0.25	-6.45	-0.3	3.08e-10	Eosinophil counts;Eosinophil percentage of white cells;
LUAD	cis	rs4523957	0.533	rs216216	chr17:2145046	A/G	cg16513277	chr17:2031491	SMG6	0.67	9.6	0.42	7.22e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9473147	0.516	rs7754971	chr6:47590476	C/T	cg02130027	chr6:47444894	CD2AP	0.35	6.82	0.31	3.17e-11	Platelet distribution width;Mean platelet volume;
LUAD	cis	rs250677	0.524	rs417413	chr5:148452726	T/C	cg18129178	chr5:148520854	ABLIM3	-0.48	-7.91	-0.36	2.26e-14	Breast cancer;
LUAD	cis	rs6540559	0.546	rs634601	chr1:210421594	C/T	cg22029157	chr1:209979665	IRF6	0.64	7.23	0.33	2.34e-12	Cleft lip with or without cleft palate;
LUAD	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg05727186	chr17:43697356	MGC57346	-0.52	-6.54	-0.3	1.75e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg03676636	chr4:99064102	C4orf37	0.29	7.02	0.32	8.91e-12	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg14343924	chr8:8086146	FLJ10661	0.42	6.4	0.3	4.17e-10	Systolic blood pressure;
LUAD	cis	rs524023	0.957	rs552307	chr11:64357539	G/A	cg19131476	chr11:64387923	NRXN2	0.36	6.79	0.31	3.84e-11	Urate levels in obese individuals;
LUAD	cis	rs6688613	0.729	rs7545806	chr1:166938555	T/C	cg07049167	chr1:166818506	POGK	0.57	8.32	0.37	1.26e-15	Refractive astigmatism;
LUAD	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-7.16	-0.33	3.61e-12	Monocyte percentage of white cells;
LUAD	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03264133	chr6:25882463	NA	-0.55	-7.99	-0.36	1.32e-14	Intelligence (multi-trait analysis);
LUAD	cis	rs4601821	0.858	rs4938012	chr11:113259654	A/G	cg14159747	chr11:113255604	NA	0.47	8.78	0.39	4.18e-17	Alcoholic chronic pancreatitis;
LUAD	cis	rs2997447	0.633	rs6665062	chr1:26362001	C/T	cg19633962	chr1:26362018	EXTL1	-0.55	-6.51	-0.3	2.09e-10	QRS complex (12-leadsum);
LUAD	cis	rs7680126	0.500	rs4697933	chr4:10146493	G/A	cg00071950	chr4:10020882	SLC2A9	-0.58	-8.32	-0.37	1.25e-15	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg22338127	chr1:209979572	IRF6	0.52	6.56	0.3	1.55e-10	Cleft lip with or without cleft palate;
LUAD	cis	rs7680126	0.644	rs62288518	chr4:10087464	T/C	cg00071950	chr4:10020882	SLC2A9	-0.62	-8.92	-0.4	1.46e-17	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUAD	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.17	-0.33	3.37e-12	Bipolar disorder;
LUAD	cis	rs7737355	0.947	rs79018835	chr5:130798461	C/A	cg25547332	chr5:131281432	NA	-0.43	-6.52	-0.3	2.05e-10	Life satisfaction;
LUAD	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg22906224	chr7:99728672	NA	0.55	9.5	0.42	1.5700000000000001e-19	Coronary artery disease;
LUAD	cis	rs1032833	0.732	rs78519350	chr2:180126611	A/T	cg23883738	chr2:179974586	SESTD1	-0.72	-8.08	-0.37	6.91e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg19774624	chr17:42201019	HDAC5	0.42	7.31	0.33	1.38e-12	Total body bone mineral density;
LUAD	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-6.63	-0.31	1.04e-10	Tonsillectomy;
LUAD	cis	rs8048589	0.948	rs11648228	chr16:12181702	G/T	cg03816625	chr16:12192430	SNX29	0.55	8.14	0.37	4.31e-15	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUAD	trans	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg15704280	chr7:45808275	SEPT13	0.67	7.85	0.36	3.55e-14	Axial length;
LUAD	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg08027265	chr7:2291960	NA	0.4	6.77	0.31	4.37e-11	Bipolar disorder and schizophrenia;
LUAD	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21659725	chr3:3221576	CRBN	-0.86	-18.44	-0.67	3.6e-56	Blood protein levels;
LUAD	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg03859395	chr2:55845619	SMEK2	-0.61	-10.77	-0.46	4.56e-24	Metabolic syndrome;
LUAD	cis	rs4253772	0.530	rs8140573	chr22:46800363	G/C	cg09491104	chr22:46646882	C22orf40	-0.51	-6.38	-0.3	4.74e-10	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs2742234	0.656	rs1864400	chr10:43610366	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.51	-8.62	-0.39	1.35e-16	Hirschsprung disease;
LUAD	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18876405	chr7:65276391	NA	-0.41	-6.4	-0.3	4.07e-10	Aortic root size;
LUAD	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	9.84	0.43	1.07e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs490234	0.812	rs12351825	chr9:128265736	T/C	cg14078157	chr9:128172775	NA	-0.39	-6.89	-0.32	2.07e-11	Mean arterial pressure;
LUAD	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg06713675	chr4:122721982	EXOSC9	-0.57	-11.09	-0.47	2.85e-25	Type 2 diabetes;
LUAD	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg11833968	chr6:79620685	NA	-0.41	-7.61	-0.35	1.81e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06022373	chr22:39101656	GTPBP1	-0.4	-6.49	-0.3	2.42e-10	Menopause (age at onset);
LUAD	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg08085267	chr17:45401833	C17orf57	0.55	9.88	0.43	7.82e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg03806693	chr22:41940476	POLR3H	-0.56	-8.08	-0.37	6.76e-15	Vitiligo;
LUAD	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg09455208	chr3:40491958	NA	0.52	11.04	0.47	4.35e-25	Renal cell carcinoma;
LUAD	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-8.83	-0.39	2.84e-17	Alzheimer's disease (late onset);
LUAD	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg10518543	chr12:38710700	ALG10B	-0.49	-8.12	-0.37	5.19e-15	Morning vs. evening chronotype;
LUAD	cis	rs877282	1.000	rs11253361	chr10:770387	T/C	cg06581033	chr10:766294	NA	-0.57	-7.86	-0.36	3.18e-14	Uric acid levels;
LUAD	trans	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg05926928	chr17:57297772	GDPD1	1.13	13.86	0.56	2.72e-36	Opioid sensitivity;
LUAD	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg11905131	chr22:24372483	LOC391322	-0.56	-9.52	-0.42	1.4e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg03467027	chr4:99064603	C4orf37	0.43	6.95	0.32	1.36e-11	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs853679	0.546	rs483143	chr6:27846744	G/C	cg01620082	chr3:125678407	NA	-0.86	-8.82	-0.39	3.02e-17	Depression;
LUAD	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg21724239	chr8:58056113	NA	0.6	8.44	0.38	5.07e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs8044868	0.893	rs12929749	chr16:72168241	T/G	cg23815491	chr16:72088622	HP	0.38	6.76	0.31	4.53e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUAD	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg11663144	chr21:46675770	NA	-0.62	-12.41	-0.52	2.26e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg00280220	chr17:61926910	NA	-0.35	-6.63	-0.31	1.03e-10	Prudent dietary pattern;
LUAD	cis	rs863345	0.604	rs12075228	chr1:158502256	C/T	cg12129480	chr1:158549410	OR10X1	-0.24	-6.54	-0.3	1.81e-10	Pneumococcal bacteremia;
LUAD	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg05187965	chr10:45406764	TMEM72	-0.49	-9.89	-0.43	6.83e-21	Mean corpuscular volume;
LUAD	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-8.01	-0.36	1.11e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7771547	0.723	rs9380582	chr6:36556730	T/C	cg07856975	chr6:36356162	ETV7	0.45	6.45	0.3	3.06e-10	Platelet distribution width;
LUAD	cis	rs10129255	0.518	rs11847766	chr14:107187425	T/C	cg23076370	chr14:107095027	NA	-0.44	-8.74	-0.39	5.5e-17	Kawasaki disease;
LUAD	cis	rs9807989	0.765	rs9807962	chr2:102971664	A/G	cg03938978	chr2:103052716	IL18RAP	0.31	6.37	0.3	5.05e-10	Asthma;
LUAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg04025307	chr7:1156635	C7orf50	0.66	7.49	0.34	3.93e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg08989290	chr16:615782	NHLRC4	0.32	6.85	0.32	2.6e-11	Height;
LUAD	trans	rs1493916	0.592	rs1389068	chr18:31312738	G/T	cg27147174	chr7:100797783	AP1S1	-0.57	-9.35	-0.41	5.13e-19	Life satisfaction;
LUAD	cis	rs7759001	0.817	rs2393928	chr6:27351827	C/T	cg18711553	chr6:27366782	ZNF391	0.39	6.39	0.3	4.29e-10	Glomerular filtration rate (creatinine);
LUAD	trans	rs62103177	0.564	rs1864529	chr18:77748975	G/A	cg05926928	chr17:57297772	GDPD1	-0.68	-8.61	-0.39	1.49e-16	Opioid sensitivity;
LUAD	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg27211696	chr2:191398769	TMEM194B	-0.68	-9.11	-0.41	3.25e-18	Diastolic blood pressure;
LUAD	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg22535103	chr8:58192502	C8orf71	-0.75	-8.87	-0.4	2.06e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg18252515	chr7:66147081	NA	-0.63	-6.94	-0.32	1.5e-11	Gout;
LUAD	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg22920501	chr2:26401640	FAM59B	0.97	13.42	0.55	1.86e-34	Gut microbiome composition (summer);
LUAD	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg04539111	chr16:67997858	SLC12A4	-0.53	-6.51	-0.3	2.17e-10	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg07917127	chr4:99064746	C4orf37	0.5	7.15	0.33	3.72e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg03563238	chr19:33554763	RHPN2	-0.35	-8.28	-0.37	1.67e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg03709012	chr19:19516395	GATAD2A	0.52	6.89	0.32	1.99e-11	Nonalcoholic fatty liver disease;
LUAD	trans	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg16724585	chr3:197361211	NA	-0.51	-7.76	-0.35	6.22e-14	Pancreatic cancer;
LUAD	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18099408	chr3:52552593	STAB1	-0.52	-9.25	-0.41	1.14e-18	Electroencephalogram traits;
LUAD	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-7.8	-0.35	4.76e-14	Alzheimer's disease (late onset);
LUAD	trans	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg27411982	chr8:10470053	RP1L1	0.38	6.66	0.31	8.67e-11	Mood instability;
LUAD	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg26384229	chr12:38710491	ALG10B	0.42	7.35	0.34	1.02e-12	Morning vs. evening chronotype;
LUAD	cis	rs4730250	0.634	rs257371	chr7:106795043	C/A	cg02696742	chr7:106810147	HBP1	-0.83	-11.03	-0.47	4.82e-25	Osteoarthritis;
LUAD	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg18932078	chr1:2524107	MMEL1	-0.37	-6.89	-0.32	1.98e-11	Ulcerative colitis;
LUAD	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.32	-0.51	5.21e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg13390004	chr1:15929781	NA	0.47	8.34	0.38	1.08e-15	Systolic blood pressure;
LUAD	cis	rs10992471	0.603	rs755209	chr9:95489671	G/A	cg14631576	chr9:95140430	CENPP	-0.46	-9.0	-0.4	7.71e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUAD	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg12179176	chr11:130786555	SNX19	0.45	7.39	0.34	8.05e-13	Schizophrenia;
LUAD	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg00784671	chr22:46762841	CELSR1	-0.61	-7.58	-0.35	2.14e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs367943	1.000	rs348930	chr5:112814763	T/C	cg12552261	chr5:112820674	MCC	-0.58	-11.04	-0.47	4.66e-25	Type 2 diabetes;
LUAD	cis	rs7625357	0.964	rs1421005	chr3:169351777	C/T	cg14572252	chr3:169309425	MECOM	-0.38	-6.65	-0.31	9.24e-11	Childhood and early adolescence aggressive behavior;
LUAD	cis	rs62400317	0.859	rs12191751	chr6:45282111	G/T	cg18551225	chr6:44695536	NA	-0.54	-8.48	-0.38	3.94e-16	Total body bone mineral density;
LUAD	cis	rs6076065	0.676	rs1419006	chr20:23336766	C/T	cg11657817	chr20:23433608	CST11	0.51	9.54	0.42	1.18e-19	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg18105134	chr13:113819100	PROZ	-0.85	-14.87	-0.59	1.64e-40	Platelet distribution width;
LUAD	cis	rs877282	1.000	rs12779159	chr10:772143	T/C	cg17470449	chr10:769945	NA	0.67	9.69	0.43	3.46e-20	Uric acid levels;
LUAD	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs758324	0.704	rs493829	chr5:131297043	T/C	cg06307176	chr5:131281290	NA	-0.43	-7.2	-0.33	2.68e-12	Alzheimer's disease in APOE e4- carriers;
LUAD	cis	rs3803170	0.513	rs10774623	chr12:111833589	C/T	cg10833066	chr12:111807467	FAM109A	-0.47	-8.58	-0.38	1.86e-16	Mean corpuscular hemoglobin;
LUAD	cis	rs2688608	0.736	rs2227566	chr10:75673731	C/T	cg23231163	chr10:75533350	FUT11	-0.38	-6.92	-0.32	1.68e-11	Inflammatory bowel disease;
LUAD	cis	rs9296092	0.538	rs7761464	chr6:33519417	C/A	cg13560919	chr6:33536144	NA	-0.88	-16.26	-0.62	1.64e-46	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg22868518	chr11:507468	RNH1	-0.66	-6.46	-0.3	2.93e-10	Body mass index;
LUAD	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg12011299	chr4:100065546	ADH4	0.73	13.52	0.55	7e-35	Alcohol dependence;
LUAD	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.97	-0.32	1.22e-11	Total cholesterol levels;
LUAD	cis	rs6961069	0.806	rs4728183	chr7:80256003	A/G	cg04458919	chr7:80252533	CD36	0.36	6.9	0.32	1.91e-11	Platelet count;
LUAD	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg12373951	chr3:133503437	NA	0.39	7.87	0.36	2.94e-14	Iron status biomarkers;
LUAD	cis	rs7301826	0.651	rs12228957	chr12:131296066	T/C	cg11011512	chr12:131303247	STX2	0.44	7.41	0.34	6.76e-13	Plasma plasminogen activator levels;
LUAD	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg00277334	chr10:82204260	NA	-0.54	-8.47	-0.38	4e-16	Post bronchodilator FEV1;
LUAD	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg18854424	chr1:2615690	NA	-0.42	-9.16	-0.41	2.26e-18	Ulcerative colitis;
LUAD	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg11062466	chr8:58055876	NA	0.46	6.43	0.3	3.46e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg11062466	chr8:58055876	NA	0.64	8.38	0.38	7.84e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs708547	0.874	rs73242624	chr4:57847420	C/G	cg00922110	chr4:57842668	C4orf14	-0.42	-6.73	-0.31	5.4e-11	Response to bleomycin (chromatid breaks);
LUAD	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg07305463	chr2:136567211	LCT	0.37	7.2	0.33	2.71e-12	Mosquito bite size;
LUAD	cis	rs9788721	1.000	rs8031948	chr15:78816057	G/T	cg18825076	chr15:78729989	IREB2	-0.55	-8.94	-0.4	1.2e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUAD	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg12072164	chr19:44306565	LYPD5	0.44	8.67	0.39	9.33e-17	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.48	7.73	0.35	7.88e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg16049864	chr8:95962084	TP53INP1	-0.6	-13.21	-0.54	1.29e-33	Type 2 diabetes;
LUAD	cis	rs926938	0.608	rs360612	chr1:115394747	G/A	cg12756093	chr1:115239321	AMPD1	0.38	6.8	0.31	3.5e-11	Autism;
LUAD	cis	rs3916	0.911	rs2239758	chr12:121162637	A/G	cg27246729	chr12:121163418	ACADS	0.46	7.55	0.34	2.75e-13	Urinary metabolites (H-NMR features);
LUAD	cis	rs977987	0.806	rs8051407	chr16:75448659	A/G	cg03315344	chr16:75512273	CHST6	0.64	14.06	0.56	4.12e-37	Dupuytren's disease;
LUAD	cis	rs57994353	0.897	rs11999609	chr9:139363539	C/T	cg14169450	chr9:139327907	INPP5E	0.4	6.35	0.3	5.47e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUAD	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10802521	chr3:52805072	NEK4	-0.62	-11.08	-0.47	3.05e-25	Intelligence (multi-trait analysis);
LUAD	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg00204512	chr16:28754710	NA	0.3	6.4	0.3	4.22e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg12935359	chr14:103987150	CKB	-0.49	-7.95	-0.36	1.74e-14	Body mass index;
LUAD	cis	rs7779181	1.000	rs10951331	chr7:32354374	A/G	cg27532318	chr7:32358331	NA	0.44	7.18	0.33	3.1e-12	Body mass index;
LUAD	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg05535760	chr7:792225	HEATR2	0.87	11.6	0.49	3.3699999999999996e-27	Cerebrospinal P-tau181p levels;
LUAD	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.37	6.64	0.31	9.84e-11	Blood metabolite levels;
LUAD	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg00647820	chr17:40259828	DHX58	-0.43	-6.8	-0.31	3.62e-11	Fibrinogen levels;
LUAD	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg23254163	chr1:152506842	NA	0.26	7.29	0.33	1.57e-12	Hair morphology;
LUAD	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.99	-10.88	-0.47	1.75e-24	Initial pursuit acceleration;
LUAD	cis	rs2933343	0.621	rs6764682	chr3:128568383	G/A	cg11901034	chr3:128598214	ACAD9	0.52	8.13	0.37	4.95e-15	IgG glycosylation;
LUAD	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	8.17	0.37	3.58e-15	Breast cancer;
LUAD	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg05340658	chr4:99064831	C4orf37	0.55	9.48	0.42	1.85e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03647317	chr4:187891568	NA	0.37	6.88	0.32	2.16e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg09359103	chr1:154839909	KCNN3	-0.87	-19.45	-0.69	1.2e-60	Prostate cancer;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg19737664	chr11:537435	LRRC56	0.45	7.27	0.33	1.78e-12	Diastolic blood pressure;
LUAD	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg00933542	chr6:150070202	PCMT1	0.38	7.9	0.36	2.47e-14	Lung cancer;
LUAD	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg12935359	chr14:103987150	CKB	-0.47	-7.51	-0.34	3.5e-13	Body mass index;
LUAD	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg02985366	chr16:32360428	NA	0.39	6.84	0.32	2.82e-11	Menopause (age at onset);
LUAD	cis	rs9479482	0.967	rs763574	chr6:150349415	G/C	cg08316699	chr6:150357289	NA	0.36	7.5	0.34	3.77e-13	Alopecia areata;
LUAD	cis	rs354225	0.544	rs3796019	chr2:54807279	G/A	cg01766943	chr2:54829624	SPTBN1	0.38	7.27	0.33	1.78e-12	Schizophrenia;
LUAD	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06505273	chr16:24850292	NA	-0.48	-7.03	-0.32	8.47e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LUAD	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg26597838	chr10:835615	NA	0.8	11.05	0.47	4.12e-25	Eosinophil percentage of granulocytes;
LUAD	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg11502198	chr6:26597334	ABT1	0.56	9.35	0.41	5.14e-19	Intelligence (multi-trait analysis);
LUAD	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg15557168	chr22:42548783	NA	-0.47	-8.78	-0.39	4.16e-17	Cognitive function;
LUAD	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg23649088	chr2:200775458	C2orf69	0.78	14.38	0.57	1.8e-38	Osteoporosis;
LUAD	cis	rs1003719	1.000	rs2154536	chr21:38492147	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.49	8.24	0.37	2.17e-15	Eye color traits;
LUAD	trans	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg14917512	chr19:3094685	GNA11	-0.37	-6.42	-0.3	3.72e-10	Aortic root size;
LUAD	cis	rs910187	0.605	rs6018324	chr20:45810181	G/C	cg27589058	chr20:45804311	EYA2	-0.34	-7.63	-0.35	1.61e-13	Migraine;
LUAD	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg17063962	chr7:91808500	NA	0.67	11.92	0.5	1.89e-28	Breast cancer;
LUAD	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg19041857	chr6:27730383	NA	-0.44	-6.63	-0.31	1.01e-10	Depression;
LUAD	cis	rs3800461	0.544	rs6919434	chr6:34498923	C/T	cg17674042	chr6:34482479	PACSIN1	-0.77	-9.77	-0.43	1.77e-20	Chronic lymphocytic leukemia;
LUAD	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.67	-0.35	1.21e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg05340658	chr4:99064831	C4orf37	0.55	9.42	0.42	3.08e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg10435618	chr10:838112	NA	0.47	6.41	0.3	3.95e-10	Eosinophil percentage of granulocytes;
LUAD	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg16342193	chr10:102329863	NA	-0.37	-6.58	-0.3	1.39e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs1983170	0.736	rs13447495	chr1:91974965	A/G	cg02896835	chr1:92012615	NA	0.59	7.91	0.36	2.35e-14	Eosinophil percentage of white cells;
LUAD	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg05368731	chr17:41323189	NBR1	0.98	20.38	0.7	8.44e-65	Menopause (age at onset);
LUAD	trans	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg20849893	chr7:64541193	NA	0.47	6.44	0.3	3.17e-10	Aortic root size;
LUAD	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg04772025	chr11:68637568	NA	0.53	8.26	0.37	1.85e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	trans	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg11693508	chr17:37793320	STARD3	0.5	7.44	0.34	5.58e-13	Neuroticism;
LUAD	trans	rs931812	1.000	rs4734494	chr8:101917721	T/C	cg20993868	chr7:22813445	NA	0.57	11.39	0.48	2.19e-26	Attention deficit hyperactivity disorder and conduct disorder;
LUAD	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg11062466	chr8:58055876	NA	0.46	6.5	0.3	2.26e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs6547631	0.622	rs2366807	chr2:85926598	G/A	cg21473183	chr2:85925749	GNLY	0.35	7.49	0.34	3.92e-13	Blood protein levels;
LUAD	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg13560548	chr3:10150139	C3orf24	0.45	7.33	0.34	1.22e-12	Alzheimer's disease;
LUAD	cis	rs62238980	0.614	rs76549479	chr22:32510944	G/A	cg00543991	chr22:32367038	NA	0.88	8.51	0.38	3.06e-16	Childhood ear infection;
LUAD	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg03929089	chr4:120376271	NA	-0.92	-17.83	-0.66	2.01e-53	Height;
LUAD	cis	rs231513	0.813	rs231495	chr17:41976748	G/C	cg26893861	chr17:41843967	DUSP3	-0.54	-6.55	-0.3	1.69e-10	Cognitive function;
LUAD	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg00316803	chr15:76480434	C15orf27	-0.39	-7.38	-0.34	8.18e-13	Blood metabolite levels;
LUAD	cis	rs7943203	0.568	rs4615991	chr11:108295205	C/T	cg04873221	chr11:107992290	ACAT1	-0.48	-7.37	-0.34	9.13e-13	Red blood cell count;Mean corpuscular volume;
LUAD	cis	rs13064411	0.696	rs6438159	chr3:113217341	T/C	cg10517650	chr3:113235015	CCDC52	-0.56	-9.63	-0.42	5.58e-20	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.49	-8.19	-0.37	3.05e-15	Tonsillectomy;
LUAD	trans	rs7939886	0.920	rs12223248	chr11:55887633	A/C	cg15704280	chr7:45808275	SEPT13	0.66	6.48	0.3	2.56e-10	Myopia (pathological);
LUAD	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg05865280	chr17:75406074	SEPT9	0.61	19.29	0.68	5.77e-60	Airflow obstruction;
LUAD	cis	rs3020333	0.721	rs1293936	chr6:152017691	T/G	cg22157087	chr6:152012887	ESR1	0.36	6.51	0.3	2.19e-10	Total body bone mineral density;
LUAD	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.69	-12.08	-0.51	4.49e-29	Colorectal cancer;
LUAD	cis	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg21775007	chr8:11205619	TDH	0.56	9.85	0.43	9.48e-21	Retinal vascular caliber;
LUAD	trans	rs12517041	1.000	rs12697619	chr5:23288772	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.46	-6.48	-0.3	2.61e-10	Calcium levels;
LUAD	trans	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg14791747	chr16:20752902	THUMPD1	-0.48	-7.63	-0.35	1.6e-13	Dental caries;
LUAD	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.66	0.31	8.45e-11	Cardiac Troponin-T levels;
LUAD	cis	rs7568458	0.783	rs2166529	chr2:85742175	A/C	cg02493740	chr2:85810744	VAMP5	0.39	6.93	0.32	1.54e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg02018176	chr4:1364513	KIAA1530	0.48	8.8	0.39	3.41e-17	Longevity;
LUAD	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg22705602	chr4:152727874	NA	-0.4	-7.07	-0.33	6.3e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg20891283	chr12:69753455	YEATS4	0.45	7.28	0.33	1.69e-12	Cerebrospinal fluid biomarker levels;
LUAD	cis	rs968567	0.689	rs61897795	chr11:61618169	A/G	cg19610905	chr11:61596333	FADS2	-0.79	-9.34	-0.41	5.6e-19	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUAD	cis	rs7178572	0.568	rs7167794	chr15:77635875	T/C	cg15453836	chr15:77711506	NA	-0.37	-6.53	-0.3	1.92e-10	Type 2 diabetes;
LUAD	cis	rs7945705	0.967	rs7123429	chr11:8866808	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.35	-7.3	-0.33	1.46e-12	Hemoglobin concentration;
LUAD	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg15704280	chr7:45808275	SEPT13	-0.59	-9.67	-0.43	4.02e-20	HDL cholesterol;
LUAD	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg11494091	chr17:61959527	GH2	0.74	18.35	0.67	9.02e-56	Prudent dietary pattern;
LUAD	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg04025307	chr7:1156635	C7orf50	0.63	9.34	0.41	5.51e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg05368731	chr17:41323189	NBR1	0.83	16.45	0.62	2.25e-47	Menopause (age at onset);
LUAD	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg03388025	chr16:89894329	SPIRE2	0.33	7.59	0.35	2.01e-13	Vitiligo;
LUAD	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg12458913	chr13:53173898	NA	0.39	7.09	0.33	5.53e-12	Lewy body disease;
LUAD	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.39	-9.23	-0.41	1.3e-18	Type 2 diabetes;
LUAD	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg23625390	chr15:77176239	SCAPER	0.54	8.57	0.38	1.93e-16	Blood metabolite levels;
LUAD	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg19875535	chr5:140030758	IK	-0.41	-6.8	-0.31	3.68e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg13319975	chr6:146136371	FBXO30	0.65	11.23	0.48	8.39e-26	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.83	-0.47	2.65e-24	Developmental language disorder (linguistic errors);
LUAD	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg15704280	chr7:45808275	SEPT13	0.64	8.17	0.37	3.52e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs4372836	0.741	rs4563180	chr2:29093695	C/G	cg09522027	chr2:28974177	PPP1CB	0.66	11.58	0.49	4.05e-27	Body mass index;
LUAD	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg02421172	chr7:1938701	MAD1L1	0.49	6.74	0.31	5.07e-11	Bipolar disorder;
LUAD	cis	rs6987853	0.830	rs12542919	chr8:42356035	C/T	cg09913449	chr8:42400586	C8orf40	-0.39	-7.04	-0.32	8.01e-12	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg13685833	chr1:53393034	SCP2	-0.49	-8.12	-0.37	5.12e-15	Monocyte count;
LUAD	cis	rs986417	1.000	rs1254287	chr14:60861774	C/T	cg27398547	chr14:60952738	C14orf39	-0.59	-7.53	-0.34	3.01e-13	Gut microbiota (bacterial taxa);
LUAD	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg24069376	chr3:38537580	EXOG	-0.43	-10.5	-0.45	4.65e-23	Electrocardiographic conduction measures;
LUAD	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg21770322	chr7:97807741	LMTK2	0.31	7.36	0.34	9.56e-13	Breast cancer;
LUAD	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.83	11.33	0.48	3.49e-26	Smoking behavior;
LUAD	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs61897795	0.657	rs174590	chr11:61616977	G/C	cg21709803	chr11:61594965	FADS2	-0.41	-6.54	-0.3	1.73e-10	Neutrophil count;Sum basophil neutrophil counts;
LUAD	cis	rs2455799	0.613	rs12637353	chr3:15831525	T/C	cg16303742	chr3:15540471	COLQ	-0.49	-9.16	-0.41	2.19e-18	Mean platelet volume;
LUAD	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg11062466	chr8:58055876	NA	-0.54	-7.31	-0.33	1.36e-12	Developmental language disorder (linguistic errors);
LUAD	trans	rs853679	0.607	rs56075693	chr6:28290328	T/G	cg01620082	chr3:125678407	NA	-1.1	-10.47	-0.45	5.58e-23	Depression;
LUAD	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.51	0.34	3.47e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg15691649	chr6:25882328	NA	0.46	7.53	0.34	3.09e-13	Blood metabolite levels;
LUAD	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg23277830	chr1:3704460	LRRC47	0.41	8.7	0.39	7.58e-17	Red cell distribution width;
LUAD	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg16797656	chr11:68205561	LRP5	0.45	8.62	0.39	1.34e-16	Total body bone mineral density;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03748352	chr10:182365	ZMYND11	-0.4	-6.67	-0.31	8.16e-11	Cancer;
LUAD	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg21545522	chr1:205238299	TMCC2	-0.35	-6.48	-0.3	2.49e-10	Platelet count;
LUAD	trans	rs12406019	0.548	rs11162415	chr1:78612934	G/A	cg20826526	chr3:156266748	SSR3	-0.49	-8.35	-0.38	9.64e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg03433033	chr1:76189801	ACADM	-0.47	-6.91	-0.32	1.84e-11	Daytime sleep phenotypes;
LUAD	cis	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg00495681	chr13:53174319	NA	0.46	8.47	0.38	4.19e-16	Lewy body disease;
LUAD	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg27532758	chr8:7812741	FAM66E	-0.39	-6.65	-0.31	9.03e-11	Neuroticism;
LUAD	trans	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.16	28.19	0.81	3.75e-99	Exhaled nitric oxide output;
LUAD	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg03467027	chr4:99064603	C4orf37	0.41	6.67	0.31	8.18e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs34638657	0.732	rs7206093	chr16:82201884	G/A	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.97	-0.32	1.26e-11	Lung adenocarcinoma;
LUAD	cis	rs2235649	0.833	rs9926962	chr16:1851826	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.47	-7.86	-0.36	3.32e-14	Blood metabolite levels;
LUAD	cis	rs3540	1.000	rs7173724	chr15:91036855	A/G	cg10434728	chr15:90938212	IQGAP1	0.35	6.47	0.3	2.67e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUAD	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg18876405	chr7:65276391	NA	-0.45	-7.22	-0.33	2.43e-12	Aortic root size;
LUAD	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg07169764	chr2:136633963	MCM6	0.81	9.52	0.42	1.33e-19	Corneal structure;
LUAD	trans	rs208520	0.674	rs207103	chr6:66795568	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.32	-0.64	3.48e-51	Exhaled nitric oxide output;
LUAD	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.15	-0.33	3.85e-12	Developmental language disorder (linguistic errors);
LUAD	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg05966235	chr16:28915196	ATP2A1	0.47	7.71	0.35	8.82e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg18105139	chr6:28058856	ZSCAN12L1	0.29	6.65	0.31	9.16e-11	Depression;
LUAD	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg17264618	chr3:40429014	ENTPD3	0.38	8.43	0.38	5.65e-16	Renal cell carcinoma;
LUAD	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg15557168	chr22:42548783	NA	0.51	9.48	0.42	1.92e-19	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg09365446	chr1:150670422	GOLPH3L	0.66	12.34	0.51	4.22e-30	Tonsillectomy;
LUAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg21724239	chr8:58056113	NA	0.81	9.56	0.42	9.92e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg02375832	chr11:62437615	C11orf48	-0.36	-7.0	-0.32	1e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs11771526	0.551	rs1008540	chr7:32249622	A/G	cg13207630	chr7:32358064	NA	0.45	6.59	0.31	1.32e-10	Body mass index;
LUAD	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg25173405	chr17:45401733	C17orf57	-0.43	-7.19	-0.33	2.98e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs6076065	0.748	rs1016628	chr20:23398738	C/G	cg11657817	chr20:23433608	CST11	-0.58	-12.21	-0.51	1.38e-29	Facial morphology (factor 15, philtrum width);
LUAD	cis	rs12711979	0.513	rs4849991	chr2:3840545	T/G	cg17052675	chr2:3827356	NA	-0.4	-7.23	-0.33	2.34e-12	Itch intensity from mosquito bite adjusted by bite size;
LUAD	trans	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg04995722	chr7:26192034	NFE2L3	-0.44	-7.64	-0.35	1.46e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg19163074	chr7:65112434	INTS4L2	-0.42	-6.37	-0.3	4.98e-10	Aortic root size;
LUAD	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg24838063	chr12:130822603	PIWIL1	-0.62	-10.59	-0.46	2.17e-23	Menopause (age at onset);
LUAD	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg15083037	chr5:83017644	HAPLN1	-0.55	-8.01	-0.36	1.13e-14	Prostate cancer;
LUAD	trans	rs79911532	0.515	rs76180651	chr7:75704350	T/G	cg19862616	chr7:65841803	NCRNA00174	0.84	8.61	0.39	1.47e-16	Mononucleosis;
LUAD	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg18230493	chr5:56204884	C5orf35	-0.83	-12.29	-0.51	6.97e-30	Initial pursuit acceleration;
LUAD	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg16049864	chr8:95962084	TP53INP1	-0.53	-11.44	-0.49	1.35e-26	Type 2 diabetes;
LUAD	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg24562669	chr7:97807699	LMTK2	0.33	7.87	0.36	3.01e-14	Breast cancer;
LUAD	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg17173187	chr15:85201210	NMB	0.47	8.32	0.37	1.24e-15	Schizophrenia;
LUAD	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg18180107	chr4:99064573	C4orf37	0.41	6.58	0.3	1.36e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs684232	0.602	rs2543775	chr17:557123	G/A	cg15660573	chr17:549704	VPS53	-0.88	-18.38	-0.67	7.1e-56	Prostate cancer;
LUAD	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18876405	chr7:65276391	NA	-0.67	-11.37	-0.48	2.55e-26	Aortic root size;
LUAD	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.72	-14.1	-0.57	2.7e-37	Intelligence (multi-trait analysis);
LUAD	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	6.59	0.31	1.32e-10	Prudent dietary pattern;
LUAD	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.77	10.79	0.46	3.72e-24	Smoking behavior;
LUAD	cis	rs1847202	0.826	rs11925587	chr3:72952227	A/G	cg25664220	chr3:72788482	NA	0.43	7.72	0.35	8.58e-14	Motion sickness;
LUAD	trans	rs1904173	0.799	rs6875571	chr5:25364862	A/C	cg08850729	chr1:60036715	FGGY	0.63	6.76	0.31	4.69e-11	IgG glycosylation;
LUAD	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg07677032	chr17:61819896	STRADA	0.42	6.44	0.3	3.33e-10	Height;
LUAD	trans	rs2735413	0.958	rs7192416	chr16:78063143	C/T	cg01028844	chr5:122736986	CEP120	0.4	6.42	0.3	3.56e-10	Systolic blood pressure (alcohol consumption interaction);
LUAD	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-7.83	-0.36	3.91e-14	Body mass index;
LUAD	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg21605333	chr4:119757512	SEC24D	0.93	8.76	0.39	4.9e-17	Cannabis dependence symptom count;
LUAD	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.35	-9.02	-0.4	6.68e-18	Total body bone mineral density;
LUAD	cis	rs921968	0.565	rs755112	chr2:219606052	C/T	cg02176678	chr2:219576539	TTLL4	-0.59	-12.01	-0.5	8.65e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg14416269	chr4:6271139	WFS1	0.61	12.93	0.53	1.92e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUAD	trans	rs11088226	0.681	rs2833895	chr21:33929802	G/A	cg09050820	chr6:167586206	TCP10L2	0.91	12.94	0.53	1.67e-32	Gastritis;
LUAD	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg09359103	chr1:154839909	KCNN3	-0.93	-21.94	-0.73	8.75e-72	Prostate cancer;
LUAD	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg15309053	chr8:964076	NA	0.43	9.97	0.44	3.52e-21	Schizophrenia;
LUAD	cis	rs798766	1.000	rs3752749	chr4:1737262	T/C	cg05874882	chr4:1763078	NA	-0.36	-6.45	-0.3	3.1e-10	Bladder cancer;Urinary bladder cancer;
LUAD	cis	rs12681288	0.748	rs2701935	chr8:1028618	T/A	cg04851639	chr8:1020857	NA	-0.44	-10.31	-0.45	2.15e-22	Schizophrenia;
LUAD	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg05481257	chr2:20870211	GDF7	-0.58	-11.59	-0.49	3.59e-27	Abdominal aortic aneurysm;
LUAD	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg20607798	chr8:58055168	NA	0.62	7.88	0.36	2.81e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg22029157	chr1:209979665	IRF6	0.37	6.42	0.3	3.64e-10	Monobrow;
LUAD	cis	rs72700829	0.531	rs955955	chr1:151011543	G/A	cg11822372	chr1:151115635	SEMA6C	-0.8	-6.5	-0.3	2.28e-10	Schizophrenia;
LUAD	cis	rs7640424	0.649	rs35595234	chr3:107922116	C/T	cg09227934	chr3:107805635	CD47	-0.48	-8.59	-0.39	1.73e-16	Body mass index;
LUAD	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13890999	chr18:2571452	NDC80;METTL4	-0.4	-6.54	-0.3	1.77e-10	Cancer;
LUAD	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22590775	chr19:49891494	CCDC155	0.59	9.65	0.42	4.62e-20	Multiple sclerosis;
LUAD	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg07952391	chr2:88470173	THNSL2	-0.42	-6.77	-0.31	4.33e-11	Response to metformin (IC50);
LUAD	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg06108461	chr20:60628389	TAF4	0.83	14.58	0.58	2.55e-39	Body mass index;
LUAD	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.55	0.3	1.71e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg27284194	chr4:1044797	NA	0.7	10.22	0.45	4.61e-22	Recombination rate (females);
LUAD	cis	rs5758511	0.773	rs1894714	chr22:42349134	T/G	cg00645731	chr22:42541494	CYP2D7P1	-0.38	-6.43	-0.3	3.45e-10	Birth weight;
LUAD	cis	rs2346177	0.542	rs13020043	chr2:46698431	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-7.65	-0.35	1.36e-13	HDL cholesterol;
LUAD	cis	rs739496	0.615	rs666951	chr12:112136583	C/A	cg10833066	chr12:111807467	FAM109A	0.45	7.26	0.33	1.92e-12	Platelet count;
LUAD	cis	rs28655083	0.673	rs1872509	chr16:77058990	G/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-6.48	-0.3	2.54e-10	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg22166914	chr1:53195759	ZYG11B	0.45	7.72	0.35	8.33e-14	Monocyte count;
LUAD	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg21699342	chr2:239360505	ASB1	0.6	11.84	0.5	4.12e-28	Multiple system atrophy;
LUAD	cis	rs10465746	0.967	rs12407641	chr1:84368115	T/C	cg10977910	chr1:84465055	TTLL7	0.49	8.02	0.36	1.06e-14	Obesity-related traits;
LUAD	cis	rs9326248	0.581	rs10790167	chr11:116800943	T/C	cg20608306	chr11:116969690	SIK3	0.33	7.39	0.34	8.17e-13	Blood protein levels;
LUAD	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06028605	chr16:24865363	SLC5A11	0.57	8.96	0.4	1.05e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs41311933	0.656	rs12683062	chr9:123906804	G/T	cg13567360	chr9:123745713	C5	-0.72	-8.95	-0.4	1.16e-17	Coronary artery disease;
LUAD	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg21475434	chr5:93447410	FAM172A	0.76	8.52	0.38	2.87e-16	Diabetic retinopathy;
LUAD	cis	rs907683	0.559	rs4674394	chr2:220289870	C/T	cg15015639	chr2:220282977	DES	-0.49	-9.05	-0.4	5.28e-18	Resting heart rate;
LUAD	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.53	-0.42	1.2e-19	Gut microbiome composition (summer);
LUAD	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg18180107	chr4:99064573	C4orf37	0.41	6.65	0.31	8.8e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg08085267	chr17:45401833	C17orf57	-0.66	-11.64	-0.49	2.37e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs438034	1.000	rs438034	chr1:214830617	A/G	cg16144317	chr1:214725524	PTPN14	-0.36	-6.72	-0.31	5.86e-11	Response to antineoplastic agents;
LUAD	cis	rs1595825	0.891	rs6751690	chr2:198574523	G/A	cg11031976	chr2:198649780	BOLL	-0.46	-6.7	-0.31	6.57e-11	Ulcerative colitis;
LUAD	trans	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg18335740	chr13:41363409	SLC25A15	0.56	10.05	0.44	1.83e-21	Lewy body disease;
LUAD	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg02423579	chr7:2872169	GNA12	-0.84	-14.5	-0.58	5.8e-39	Height;
LUAD	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-9.86	-0.43	8.92e-21	Migraine;Coronary artery disease;
LUAD	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11890956	chr21:40555474	PSMG1	0.78	13.49	0.55	9.29e-35	Cognitive function;
LUAD	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.53	7.58	0.35	2.19e-13	Platelet count;
LUAD	cis	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg19041857	chr6:27730383	NA	-0.45	-7.06	-0.32	6.77e-12	Breast cancer;
LUAD	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg27446573	chr6:127587934	RNF146	0.44	6.56	0.3	1.59e-10	Breast cancer;
LUAD	cis	rs1691799	0.899	rs1168314	chr12:66746937	A/G	cg16791601	chr12:66731901	HELB	-0.36	-6.47	-0.3	2.78e-10	White blood cell count (basophil);
LUAD	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg15557168	chr22:42548783	NA	-0.46	-8.66	-0.39	9.68e-17	Cognitive function;
LUAD	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg17366294	chr4:99064904	C4orf37	0.53	9.82	0.43	1.25e-20	Colonoscopy-negative controls vs population controls;
LUAD	trans	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg04775059	chr7:64541387	NA	0.52	6.89	0.32	2.04e-11	Aortic root size;
LUAD	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg01868782	chr6:126071099	HEY2	0.31	6.45	0.3	3.02e-10	Brugada syndrome;
LUAD	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg12623302	chr6:28058802	ZSCAN12L1	0.31	6.55	0.3	1.7e-10	Parkinson's disease;
LUAD	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg21951975	chr1:209979733	IRF6	0.55	7.76	0.35	6.3e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs3931020	0.688	rs277396	chr1:75213648	A/C	cg10128416	chr1:75198403	TYW3;CRYZ	-0.49	-6.46	-0.3	2.95e-10	Resistin levels;
LUAD	cis	rs12431939	1.000	rs55851845	chr14:51645583	A/T	cg23942311	chr14:51606299	NA	-0.62	-8.5	-0.38	3.25e-16	Cancer;
LUAD	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg05044414	chr3:183734942	ABCC5	0.39	8.06	0.36	8.02e-15	Anterior chamber depth;
LUAD	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg00933542	chr6:150070202	PCMT1	0.36	7.53	0.34	3.06e-13	Testicular germ cell tumor;
LUAD	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg06784218	chr1:46089804	CCDC17	0.53	11.43	0.49	1.48e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	7.27	0.33	1.73e-12	Alzheimer's disease;
LUAD	cis	rs4285028	0.747	rs7153	chr3:121383297	G/A	cg11130432	chr3:121712080	ILDR1	-0.47	-6.76	-0.31	4.48e-11	Multiple sclerosis;
LUAD	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg05340658	chr4:99064831	C4orf37	-0.45	-7.37	-0.34	8.8e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg23018236	chr17:30244563	NA	-0.68	-8.33	-0.38	1.15e-15	Hip circumference adjusted for BMI;
LUAD	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg00666640	chr1:248458726	OR2T12	0.32	7.88	0.36	2.86e-14	Common traits (Other);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg04407579	chr13:99228509	STK24	-0.64	-6.41	-0.3	3.93e-10	Type 2 diabetes;
LUAD	trans	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	17.85	0.66	1.61e-53	Exhaled nitric oxide output;
LUAD	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22496380	chr5:211416	CCDC127	-1.21	-16.15	-0.62	4.82e-46	Breast cancer;
LUAD	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02475777	chr4:1388615	CRIPAK	0.59	8.38	0.38	8.14e-16	Longevity;
LUAD	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-8.45	-0.38	4.79e-16	Reticulocyte count;
LUAD	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg07917127	chr4:99064746	C4orf37	0.43	7.07	0.33	6.51e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg11189052	chr15:85197271	WDR73	0.65	8.08	0.37	6.99e-15	Schizophrenia;
LUAD	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg05966235	chr16:28915196	ATP2A1	0.5	7.9	0.36	2.47e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg08601574	chr20:25228251	PYGB	-0.44	-8.16	-0.37	3.83e-15	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg20701182	chr2:24300061	SF3B14	0.92	13.68	0.55	1.64e-35	Lymphocyte counts;
LUAD	cis	rs5167	0.781	rs909134	chr19:45493061	T/C	cg09555818	chr19:45449301	APOC2	0.38	7.28	0.33	1.63e-12	Blood protein levels;
LUAD	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	9.67	0.43	4.03e-20	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs1873147	0.569	rs8034365	chr15:63309203	C/T	cg21584241	chr15:63341463	TPM1	0.42	6.38	0.3	4.53e-10	Orofacial clefts;
LUAD	trans	rs79911532	0.515	rs80351761	chr7:75698945	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	8.61	0.39	1.47e-16	Mononucleosis;
LUAD	cis	rs1882538	0.551	rs6974618	chr7:133084031	C/A	cg10665199	chr7:133106180	EXOC4	0.61	10.49	0.45	4.87e-23	Intelligence (multi-trait analysis);
LUAD	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg07617317	chr6:118971624	C6orf204	0.56	8.38	0.38	8.12e-16	Diastolic blood pressure;
LUAD	trans	rs8002861	0.641	rs2325085	chr13:44410060	G/A	cg12856521	chr11:46389249	DGKZ	0.47	7.79	0.35	5.1e-14	Leprosy;
LUAD	cis	rs1691799	0.899	rs1168329	chr12:66731864	C/A	cg16791601	chr12:66731901	HELB	-0.36	-6.43	-0.3	3.36e-10	White blood cell count (basophil);
LUAD	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg09835421	chr16:68378352	PRMT7	-1.06	-12.39	-0.52	2.8e-30	Schizophrenia;
LUAD	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg17724175	chr1:150552817	MCL1	0.4	9.84	0.43	9.97e-21	Tonsillectomy;
LUAD	cis	rs61776719	0.840	rs35267671	chr1:38397369	C/T	cg18451016	chr1:38461880	NA	0.54	11.5	0.49	7.96e-27	Coronary artery disease;
LUAD	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg06623918	chr6:96969491	KIAA0776	0.65	9.99	0.44	3.08e-21	Migraine;Coronary artery disease;
LUAD	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg03467027	chr4:99064603	C4orf37	0.4	6.54	0.3	1.74e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg18016565	chr1:150552671	MCL1	0.41	7.58	0.35	2.14e-13	Tonsillectomy;
LUAD	cis	rs6060717	0.536	rs7271036	chr20:34467215	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.61	6.98	0.32	1.12e-11	Hip circumference adjusted for BMI;
LUAD	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg03929089	chr4:120376271	NA	0.85	15.65	0.61	6.71e-44	Coronary artery disease;
LUAD	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.61	-6.8	-0.31	3.49e-11	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs1448094	0.842	rs10863159	chr12:86459140	T/C	cg06740227	chr12:86229804	RASSF9	-0.35	-6.39	-0.3	4.28e-10	Major depressive disorder;
LUAD	cis	rs9435341	0.731	rs4914939	chr1:107558361	A/T	cg03874509	chr1:107600012	PRMT6	0.47	7.91	0.36	2.22e-14	Facial morphology (factor 21, depth of nasal alae);
LUAD	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg25753631	chr6:25732923	NA	-0.45	-7.97	-0.36	1.51e-14	Iron status biomarkers;
LUAD	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg05368731	chr17:41323189	NBR1	0.97	20.9	0.71	3.65e-67	Menopause (age at onset);
LUAD	cis	rs4889855	0.614	rs9898443	chr17:78469357	C/T	cg16591659	chr17:78472290	NA	0.54	8.73	0.39	5.86e-17	Fractional excretion of uric acid;
LUAD	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg25894440	chr7:65020034	NA	-0.61	-6.51	-0.3	2.08e-10	Diabetic kidney disease;
LUAD	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg14725641	chr11:61582763	MIR1908;FADS1	-0.48	-6.98	-0.32	1.16e-11	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUAD	cis	rs738321	0.725	rs4821747	chr22:38538856	T/C	cg25457927	chr22:38595422	NA	-0.5	-10.92	-0.47	1.21e-24	Breast cancer;
LUAD	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06112835	chr11:68658793	MRPL21	0.51	9.28	0.41	8.93e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.62	8.66	0.39	1.03e-16	Renal function-related traits (BUN);
LUAD	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg12863693	chr15:85201151	NMB	-0.31	-6.65	-0.31	9.16e-11	P wave terminal force;
LUAD	trans	rs1997103	1.000	rs6945937	chr7:55407140	C/T	cg20935933	chr6:143382018	AIG1	0.53	7.49	0.34	4.02e-13	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7524258	0.900	rs6577426	chr1:7306451	A/G	cg07173049	chr1:7289937	CAMTA1	0.39	7.35	0.34	9.99e-13	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	trans	rs854462	0.852	rs854636	chr17:34372818	A/C	cg18389062	chr1:117909089	MAN1A2	-0.45	-6.42	-0.3	3.65e-10	Blood protein levels;
LUAD	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg15704280	chr7:45808275	SEPT13	-0.53	-8.53	-0.38	2.67e-16	Height;
LUAD	trans	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg07211511	chr3:129823064	LOC729375	-0.55	-7.31	-0.33	1.39e-12	Blood pressure (smoking interaction);
LUAD	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg15181151	chr6:150070149	PCMT1	0.42	8.7	0.39	7.56e-17	Lung cancer;
LUAD	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.98	0.32	1.17e-11	Lung cancer;
LUAD	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg13722127	chr7:150037890	RARRES2	0.41	6.71	0.31	6.39e-11	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg20607798	chr8:58055168	NA	0.56	6.82	0.31	3.09e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg17724175	chr1:150552817	MCL1	0.33	7.64	0.35	1.46e-13	Melanoma;
LUAD	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22968622	chr17:43663579	NA	-0.88	-15.32	-0.6	1.9e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg11845111	chr2:191398756	TMEM194B	0.69	12.69	0.53	1.67e-31	Pulse pressure;
LUAD	cis	rs2455799	0.502	rs2470532	chr3:15696909	A/C	cg16303742	chr3:15540471	COLQ	0.56	10.4	0.45	1e-22	Mean platelet volume;
LUAD	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg05340658	chr4:99064831	C4orf37	0.53	9.06	0.4	4.81e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg13047869	chr3:10149882	C3orf24	0.65	11.0	0.47	6.24e-25	Alzheimer's disease;
LUAD	cis	rs2230307	0.536	rs11166385	chr1:100443462	A/G	cg20868668	chr1:100435035	SLC35A3	0.55	7.82	0.36	4.36e-14	Carotid intima media thickness;
LUAD	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg07636037	chr3:49044803	WDR6	0.36	6.55	0.3	1.7e-10	Resting heart rate;
LUAD	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg22907277	chr7:1156413	C7orf50	0.59	10.81	0.47	3.36e-24	Longevity;Endometriosis;
LUAD	cis	rs6445967	1.000	rs6445967	chr3:58282576	T/C	cg23715586	chr3:58305044	RPP14	0.44	8.3	0.37	1.41e-15	Platelet count;
LUAD	cis	rs2455799	0.613	rs2470549	chr3:15737698	T/C	cg16303742	chr3:15540471	COLQ	-0.52	-9.62	-0.42	6.05e-20	Mean platelet volume;
LUAD	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg06074448	chr4:187884817	NA	-0.38	-7.57	-0.35	2.4e-13	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg15117754	chr3:10150083	C3orf24	0.4	6.53	0.3	1.88e-10	Alzheimer's disease;
LUAD	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg05182265	chr7:156933206	UBE3C	-0.8	-17.29	-0.64	4.53e-51	Body mass index;
LUAD	cis	rs2688608	0.901	rs2633312	chr10:75631755	T/A	cg23231163	chr10:75533350	FUT11	-0.44	-8.02	-0.36	1.02e-14	Inflammatory bowel disease;
LUAD	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg27284194	chr4:1044797	NA	-0.9	-19.01	-0.68	1.1e-58	Recombination rate (males);
LUAD	cis	rs17095355	1.000	rs3862006	chr10:111750764	A/G	cg00817464	chr10:111662876	XPNPEP1	0.71	9.81	0.43	1.33e-20	Biliary atresia;
LUAD	trans	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg19676328	chr12:49525230	TUBA1B	-0.75	-11.79	-0.5	5.98e-28	Total cholesterol levels;
LUAD	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg14196790	chr5:131705035	SLC22A5	0.38	6.62	0.31	1.11e-10	Blood metabolite levels;
LUAD	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg04450456	chr4:17643702	FAM184B	0.41	8.24	0.37	2.21e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1483890	0.723	rs13077078	chr3:69411402	C/A	cg22125112	chr3:69402811	FRMD4B	0.45	7.66	0.35	1.31e-13	Resting heart rate;
LUAD	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg04398451	chr17:18023971	MYO15A	-0.63	-11.37	-0.48	2.57e-26	Total body bone mineral density;
LUAD	trans	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg06606381	chr12:133084897	FBRSL1	-1.21	-11.16	-0.48	1.6e-25	Depression;
LUAD	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg10556349	chr10:835070	NA	0.51	6.43	0.3	3.39e-10	Eosinophil percentage of granulocytes;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg15863254	chr1:226374036	ACBD3	-0.45	-7.11	-0.33	5.13e-12	Height;
LUAD	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-11.78	-0.5	6.46e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg15501526	chr10:2543763	NA	0.68	15.43	0.6	6.35e-43	Age-related hearing impairment;
LUAD	cis	rs68170813	0.617	rs12535761	chr7:107139275	A/C	cg23024343	chr7:107201750	COG5	0.53	6.75	0.31	4.77e-11	Coronary artery disease;
LUAD	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.57	-0.35	2.42e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	7.02	0.32	8.9e-12	Hypertriglyceridemia;
LUAD	cis	rs2282300	0.739	rs1717772	chr11:30340133	C/T	cg06241208	chr11:30344200	C11orf46	-0.55	-7.14	-0.33	4.22e-12	Morning vs. evening chronotype;
LUAD	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg13180566	chr4:1052158	NA	-0.39	-6.61	-0.31	1.16e-10	Recombination rate (females);
LUAD	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg08888203	chr3:10149979	C3orf24	0.63	10.74	0.46	5.68e-24	Alzheimer's disease;
LUAD	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg27170947	chr2:26402098	FAM59B	-0.78	-10.39	-0.45	1.16e-22	Gut microbiome composition (summer);
LUAD	cis	rs8099014	0.954	rs4245271	chr18:56114063	A/G	cg12907477	chr18:56117327	MIR122	0.39	6.69	0.31	7.01e-11	Platelet count;
LUAD	cis	rs3789045	0.774	rs11801299	chr1:204529084	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.43	-7.21	-0.33	2.6e-12	Educational attainment (college completion);
LUAD	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg04398451	chr17:18023971	MYO15A	0.66	11.89	0.5	2.59e-28	Total body bone mineral density;
LUAD	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg11693508	chr17:37793320	STARD3	0.82	10.41	0.45	9.53e-23	Bipolar disorder;
LUAD	cis	rs778371	0.723	rs737027	chr2:233641083	G/C	cg08000102	chr2:233561755	GIGYF2	0.41	6.63	0.31	1.03e-10	Schizophrenia;
LUAD	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg10792982	chr14:105748885	BRF1	0.4	8.87	0.4	2.05e-17	Mean platelet volume;Platelet distribution width;
LUAD	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg14668632	chr7:2872130	GNA12	-0.45	-8.03	-0.36	1.01e-14	Height;
LUAD	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg09455208	chr3:40491958	NA	-0.54	-11.56	-0.49	4.83e-27	Renal cell carcinoma;
LUAD	cis	rs11650494	0.808	rs61286260	chr17:47433222	T/C	cg08112188	chr17:47440006	ZNF652	0.79	7.09	0.33	5.84e-12	Prostate cancer;
LUAD	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg17420585	chr12:42539391	GXYLT1	-0.39	-6.81	-0.31	3.38e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg19761014	chr17:28927070	LRRC37B2	0.84	8.23	0.37	2.38e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs10193935	0.792	rs13430031	chr2:42499968	C/T	cg27598129	chr2:42591480	NA	-0.77	-9.79	-0.43	1.52e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg21214613	chr1:16344536	HSPB7	0.5	8.69	0.39	7.88e-17	Dilated cardiomyopathy;
LUAD	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg07343612	chr16:622815	PIGQ	-0.79	-15.58	-0.6	1.46e-43	Height;
LUAD	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-13.09	-0.54	4.27e-33	Total body bone mineral density;
LUAD	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg02869364	chr7:1081709	C7orf50	-0.36	-6.68	-0.31	7.76e-11	Longevity;Endometriosis;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg26771998	chr10:75490334	BMS1P4	-0.6	-7.34	-0.34	1.07e-12	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	trans	rs853679	0.607	rs34396849	chr6:28250955	A/C	cg06606381	chr12:133084897	FBRSL1	-1.19	-11.33	-0.48	3.51e-26	Depression;
LUAD	cis	rs2554380	0.943	rs1477593	chr15:84363045	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.59	-8.92	-0.4	1.38e-17	Height;
LUAD	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.54	-9.5	-0.42	1.6e-19	Axial length;
LUAD	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg07917127	chr4:99064746	C4orf37	0.43	7.05	0.32	7.48e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg00277334	chr10:82204260	NA	-0.62	-9.92	-0.43	5.4e-21	Post bronchodilator FEV1;
LUAD	trans	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg21659725	chr3:3221576	CRBN	0.4	6.69	0.31	6.98e-11	Resting heart rate;
LUAD	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg18811423	chr2:55921094	PNPT1	0.57	9.69	0.43	3.48e-20	Metabolic syndrome;
LUAD	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19717773	chr7:2847554	GNA12	-0.53	-9.06	-0.4	4.98e-18	Height;
LUAD	cis	rs3087591	0.960	rs2953009	chr17:29498387	A/C	cg24425628	chr17:29625626	OMG;NF1	0.41	6.67	0.31	7.99e-11	Hip circumference;
LUAD	cis	rs73058052	0.597	rs10406941	chr19:50091464	A/C	cg21913888	chr19:50084626	PRRG2;NOSIP	0.33	8.61	0.39	1.42e-16	Fibrinogen levels;
LUAD	cis	rs780096	0.967	rs1260334	chr2:27748597	C/A	cg24768116	chr2:27665128	KRTCAP3	-0.27	-7.02	-0.32	8.9e-12	Total body bone mineral density;
LUAD	cis	rs2908197	0.843	rs2908193	chr7:75945945	A/G	cg24580635	chr7:76178542	LOC100133091	-0.42	-6.49	-0.3	2.36e-10	3-hydroxypropylmercapturic acid levels in smokers;
LUAD	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg23587288	chr2:27483067	SLC30A3	-0.39	-7.43	-0.34	6.04e-13	Blood metabolite levels;
LUAD	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg13319975	chr6:146136371	FBXO30	-0.66	-11.56	-0.49	4.66e-27	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs28595532	0.702	rs55981733	chr4:119306600	G/A	cg02775129	chr4:119771670	NA	-0.63	-6.55	-0.3	1.66e-10	Cannabis dependence symptom count;
LUAD	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg18306943	chr3:40428807	ENTPD3	0.44	7.23	0.33	2.31e-12	Renal cell carcinoma;
LUAD	cis	rs7123876	0.546	rs11604837	chr11:72360007	G/A	cg03713592	chr11:72463424	ARAP1	0.55	6.49	0.3	2.35e-10	Body mass index;
LUAD	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.38	6.58	0.3	1.4e-10	Colorectal cancer;
LUAD	cis	rs4713675	0.649	rs568901	chr6:33710038	A/G	cg18005901	chr6:33739558	LEMD2	0.39	6.69	0.31	7.13e-11	Plateletcrit;
LUAD	cis	rs6500395	1.000	rs12447645	chr16:48694440	A/G	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.07e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg00933542	chr6:150070202	PCMT1	0.45	9.4	0.42	3.43e-19	Lung cancer;
LUAD	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg00784671	chr22:46762841	CELSR1	-0.61	-7.52	-0.34	3.3e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-9.62	-0.42	5.98e-20	Obesity (extreme);
LUAD	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg17105886	chr17:28927953	LRRC37B2	0.83	7.92	0.36	2.14e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs7177699	0.557	rs12898452	chr15:79112628	C/A	cg15571903	chr15:79123663	NA	0.37	7.26	0.33	1.84e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUAD	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg09654669	chr8:57350985	NA	-0.64	-9.29	-0.41	7.9e-19	Obesity-related traits;
LUAD	trans	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-10.29	-0.45	2.6e-22	Obesity-related traits;
LUAD	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg25985355	chr7:65971099	NA	-0.51	-6.37	-0.3	4.89e-10	Diabetic kidney disease;
LUAD	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg03467027	chr4:99064603	C4orf37	0.42	6.93	0.32	1.59e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11048434	0.673	rs11611106	chr12:9060204	A/C	cg26114124	chr12:9217669	LOC144571	-0.36	-6.42	-0.3	3.63e-10	Sjögren's syndrome;
LUAD	trans	rs853679	0.546	rs35883476	chr6:28368508	G/C	cg06606381	chr12:133084897	FBRSL1	-1.24	-10.7	-0.46	8.18e-24	Depression;
LUAD	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg01616529	chr11:638424	DRD4	-0.44	-6.54	-0.3	1.8e-10	Systemic lupus erythematosus;
LUAD	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg24801067	chr17:62843696	NA	-0.54	-7.47	-0.34	4.7e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg10591111	chr5:226296	SDHA	-0.55	-7.13	-0.33	4.26e-12	Breast cancer;
LUAD	cis	rs7781266	0.501	rs28551473	chr7:133631089	G/C	cg03336402	chr7:133662267	EXOC4	0.41	7.57	0.35	2.29e-13	Educational attainment (college completion);
LUAD	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.0	-0.44	2.93e-21	Migraine;Coronary artery disease;
LUAD	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg09796270	chr17:17721594	SREBF1	0.38	7.7	0.35	9.64e-14	Total body bone mineral density;
LUAD	cis	rs13040088	0.518	rs2427452	chr20:61577275	T/C	cg23096297	chr20:61557774	DIDO1	-0.63	-8.72	-0.39	6.27e-17	Menopause (age at onset);
LUAD	cis	rs7937890	0.559	rs2575853	chr11:14533963	T/C	cg06199346	chr11:14280333	SPON1	-0.33	-6.54	-0.3	1.81e-10	Mitochondrial DNA levels;
LUAD	cis	rs7010267	0.570	rs7004459	chr8:120040263	G/C	cg01975934	chr8:119970761	NA	-0.34	-6.39	-0.3	4.28e-10	Total body bone mineral density (age 45-60);
LUAD	cis	rs4481887	0.741	rs28468416	chr1:248564451	G/T	cg13385794	chr1:248469461	NA	0.26	6.82	0.31	3.24e-11	Common traits (Other);
LUAD	trans	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg25482853	chr8:67687455	SGK3	1.12	17.13	0.64	2.44e-50	Obesity-related traits;
LUAD	cis	rs7945705	0.846	rs4929911	chr11:8816495	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.33	6.5	0.3	2.28e-10	Hemoglobin concentration;
LUAD	cis	rs7598759	0.527	rs4973417	chr2:232349636	G/T	cg19187155	chr2:232395269	NMUR1	0.5	9.52	0.42	1.32e-19	Noise-induced hearing loss;
LUAD	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg23985595	chr17:80112537	CCDC57	0.42	7.43	0.34	6e-13	Life satisfaction;
LUAD	trans	rs970548	0.688	rs10900228	chr10:46082128	A/G	cg14222797	chr10:16859974	RSU1	-0.58	-6.53	-0.3	1.89e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUAD	cis	rs4862307	0.688	rs6552743	chr4:184990516	C/G	cg06737308	chr4:185021514	ENPP6	0.48	7.9	0.36	2.39e-14	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUAD	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg00898013	chr13:113819073	PROZ	0.73	13.08	0.54	4.48e-33	Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg18180107	chr4:99064573	C4orf37	0.4	6.43	0.3	3.47e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg18827107	chr12:86230957	RASSF9	-0.69	-12.89	-0.53	2.76e-32	Major depressive disorder;
LUAD	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22857025	chr5:266934	NA	-1.03	-12.94	-0.53	1.66e-32	Breast cancer;
LUAD	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg07195577	chr17:27052828	TLCD1	0.46	6.44	0.3	3.17e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg02734326	chr4:10020555	SLC2A9	0.57	9.82	0.43	1.2e-20	Bone mineral density;
LUAD	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg23985595	chr17:80112537	CCDC57	-0.51	-9.34	-0.41	5.75e-19	Life satisfaction;
LUAD	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25427524	chr10:38739819	LOC399744	-0.76	-13.7	-0.55	1.3e-35	Extrinsic epigenetic age acceleration;
LUAD	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg03180552	chr7:157981849	PTPRN2	0.32	6.45	0.3	3.09e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-7.09	-0.33	5.73e-12	Daytime sleep phenotypes;
LUAD	trans	rs1337391	0.649	rs7870380	chr9:16563730	C/A	cg08976687	chr2:85515537	TCF7L1	0.44	6.58	0.3	1.42e-10	Heschl's gyrus morphology;
LUAD	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg21782813	chr7:2030301	MAD1L1	0.4	6.45	0.3	3.07e-10	Bipolar disorder and schizophrenia;
LUAD	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08859206	chr1:53392774	SCP2	0.68	12.84	0.53	4.09e-32	Monocyte count;
LUAD	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg16060761	chr17:80687452	NA	0.56	8.01	0.36	1.16e-14	Glycated hemoglobin levels;
LUAD	cis	rs4343996	0.747	rs1403158	chr7:3464896	A/G	cg21248987	chr7:3385318	SDK1	0.36	6.72	0.31	5.89e-11	Motion sickness;
LUAD	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg18758796	chr5:131593413	PDLIM4	0.34	6.5	0.3	2.24e-10	Breast cancer;
LUAD	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg07305463	chr2:136567211	LCT	-0.38	-7.26	-0.33	1.88e-12	Mosquito bite size;
LUAD	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg23625390	chr15:77176239	SCAPER	-0.51	-7.83	-0.36	3.91e-14	Blood metabolite levels;
LUAD	cis	rs17155006	0.655	rs448742	chr7:107733993	C/T	cg05962710	chr7:107745446	LAMB4	0.3	6.4	0.3	4.09e-10	Pneumococcal bacteremia;
LUAD	cis	rs8067287	0.802	rs11650590	chr17:16836300	C/T	cg26910001	chr17:16838321	NA	-0.49	-6.7	-0.31	6.82e-11	Diabetic kidney disease;
LUAD	cis	rs1030877	0.557	rs2278501	chr2:105979506	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.39	-7.23	-0.33	2.22e-12	Obesity-related traits;
LUAD	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg27068330	chr11:65405492	SIPA1	0.75	11.64	0.49	2.29e-27	Acne (severe);
LUAD	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg26384229	chr12:38710491	ALG10B	0.42	7.1	0.33	5.33e-12	Morning vs. evening chronotype;
LUAD	cis	rs9902453	1.000	rs7212497	chr17:28335949	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-9.06	-0.4	4.71e-18	Coffee consumption (cups per day);
LUAD	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg24801067	chr17:62843696	NA	0.65	8.86	0.4	2.21e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg05340658	chr4:99064831	C4orf37	0.43	7.23	0.33	2.34e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg24818145	chr4:99064322	C4orf37	0.47	8.03	0.36	9.71e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg08873628	chr1:175162347	KIAA0040	0.4	6.74	0.31	5.36e-11	Alcohol dependence;
LUAD	cis	rs9811920	0.770	rs4928237	chr3:99731330	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	6.74	0.31	5.19e-11	Axial length;
LUAD	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg08085267	chr17:45401833	C17orf57	-0.48	-7.92	-0.36	2.19e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg09658497	chr7:2847517	GNA12	-0.45	-8.29	-0.37	1.48e-15	Height;
LUAD	cis	rs8051149	0.576	rs731710	chr16:87884547	A/G	cg01412419	chr16:87856264	NA	0.35	6.52	0.3	1.98e-10	Blood metabolite levels;
LUAD	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg22283653	chr8:49824208	NA	0.42	7.97	0.36	1.54e-14	Sudden cardiac arrest;
LUAD	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg02371401	chr5:676784	TPPP	-0.49	-8.21	-0.37	2.63e-15	Obesity-related traits;
LUAD	cis	rs9788682	0.747	rs16969894	chr15:78776456	C/T	cg18825076	chr15:78729989	IREB2	0.54	7.57	0.35	2.36e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUAD	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg20607798	chr8:58055168	NA	0.67	8.77	0.39	4.44e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg07538946	chr5:131705188	SLC22A5	0.41	6.74	0.31	5.18e-11	Blood metabolite levels;
LUAD	cis	rs12545109	0.642	rs2055984	chr8:57418332	A/G	cg21220214	chr8:57350948	NA	-0.6	-7.55	-0.34	2.68e-13	Obesity-related traits;
LUAD	cis	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.41	-7.91	-0.36	2.26e-14	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs1595825	0.891	rs1968488	chr2:198721827	C/A	cg00361562	chr2:198649771	BOLL	-0.5	-7.1	-0.33	5.34e-12	Ulcerative colitis;
LUAD	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg02725872	chr8:58115012	NA	-0.33	-6.46	-0.3	2.9e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg06618935	chr21:46677482	NA	-0.45	-8.21	-0.37	2.77e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg23544223	chr18:12777786	NA	0.67	8.51	0.38	3e-16	Inflammatory skin disease;
LUAD	cis	rs4901869	0.966	rs12148052	chr14:59338970	C/T	cg02291164	chr14:59296302	NA	0.63	15.57	0.6	1.61e-43	Panic disorder;
LUAD	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg11707310	chr1:2537719	MMEL1	0.39	8.44	0.38	5.15e-16	Ulcerative colitis;
LUAD	cis	rs6066825	0.644	rs761272	chr20:47315581	A/G	cg18078177	chr20:47281410	PREX1	0.4	6.61	0.31	1.14e-10	Colorectal cancer;
LUAD	cis	rs9796	0.835	rs2927062	chr15:41302687	A/G	cg21153102	chr15:41252147	NA	0.27	6.56	0.3	1.59e-10	Menopause (age at onset);
LUAD	cis	rs4774899	0.832	rs8033118	chr15:57492693	A/G	cg14026238	chr15:57616123	NA	-0.34	-6.38	-0.3	4.67e-10	Urinary tract infection frequency;
LUAD	cis	rs11229555	0.645	rs11229457	chr11:58207203	C/T	cg15696309	chr11:58395628	NA	-0.74	-10.22	-0.45	4.46e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03264133	chr6:25882463	NA	0.58	9.59	0.42	7.62e-20	Blood metabolite levels;
LUAD	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg00071950	chr4:10020882	SLC2A9	-0.64	-12.46	-0.52	1.37e-30	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-8.44	-0.38	5.2e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg11941060	chr3:133502564	NA	-0.66	-11.69	-0.49	1.45e-27	Iron status biomarkers;
LUAD	cis	rs7737355	0.812	rs9687376	chr5:130918037	A/C	cg06307176	chr5:131281290	NA	0.42	6.77	0.31	4.37e-11	Life satisfaction;
LUAD	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg13047869	chr3:10149882	C3orf24	0.6	10.08	0.44	1.43e-21	Alzheimer's disease;
LUAD	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg15445000	chr17:37608096	MED1	0.44	8.14	0.37	4.37e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg06766960	chr11:133703094	NA	-0.44	-8.4	-0.38	6.97e-16	Childhood ear infection;
LUAD	cis	rs7923837	0.663	rs7903302	chr10:94429511	T/C	cg25093409	chr10:94429542	NA	0.36	6.62	0.31	1.08e-10	Body mass index;Multiple sclerosis;
LUAD	cis	rs10193935	0.901	rs55978605	chr2:42573402	C/A	cg27598129	chr2:42591480	NA	-0.72	-9.42	-0.42	2.95e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17152411	0.895	rs11245418	chr10:126586319	T/C	cg07906193	chr10:126599966	NA	0.54	7.65	0.35	1.34e-13	Height;
LUAD	cis	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg20368463	chr18:77673604	PQLC1	-0.44	-6.63	-0.31	1.05e-10	Schizophrenia;
LUAD	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	8.74	0.39	5.38e-17	Menopause (age at onset);
LUAD	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg27170947	chr2:26402098	FAM59B	0.8	10.84	0.47	2.43e-24	Gut microbiome composition (summer);
LUAD	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg24813613	chr7:1882135	MAD1L1	-0.44	-7.11	-0.33	5.03e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs3931020	0.688	rs405445	chr1:75221150	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	-0.46	-6.36	-0.3	5.28e-10	Resistin levels;
LUAD	cis	rs754466	0.606	rs11002309	chr10:79594931	C/T	cg17075019	chr10:79541650	NA	-0.89	-18.7	-0.67	2.71e-57	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg06618935	chr21:46677482	NA	-0.49	-9.88	-0.43	7.54e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg07606381	chr6:8435919	SLC35B3	0.42	7.06	0.32	6.81e-12	Motion sickness;
LUAD	cis	rs2617583	0.530	rs905201	chr5:1457986	C/T	cg13982541	chr5:1466431	LPCAT1	0.54	8.7	0.39	7.58e-17	Breast cancer;
LUAD	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg10523679	chr1:76189770	ACADM	0.97	19.55	0.69	4.34e-61	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg07636037	chr3:49044803	WDR6	0.48	8.04	0.36	9.27e-15	Menarche (age at onset);
LUAD	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg19717773	chr7:2847554	GNA12	-0.54	-10.25	-0.45	3.65e-22	Height;
LUAD	cis	rs7731657	0.537	rs916818	chr5:130277673	G/C	cg08523029	chr5:130500466	HINT1	0.56	7.2	0.33	2.79e-12	Fasting plasma glucose;
LUAD	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.42	0.3	3.7e-10	Fuchs's corneal dystrophy;
LUAD	trans	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg08071915	chr8:12219732	FAM66A	-0.39	-6.36	-0.3	5.29e-10	Mood instability;
LUAD	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg26408565	chr15:76604113	ETFA	-0.47	-7.77	-0.35	6.15e-14	Blood metabolite levels;
LUAD	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	7.9	0.36	2.43e-14	Rheumatoid arthritis;
LUAD	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg02574844	chr11:5959923	NA	-0.38	-6.46	-0.3	2.85e-10	DNA methylation (variation);
LUAD	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg08048268	chr3:133502702	NA	-0.41	-7.96	-0.36	1.57e-14	Iron status biomarkers;
LUAD	cis	rs7941600	0.708	rs4627080	chr11:9336349	G/T	cg19415743	chr11:9336845	TMEM41B	-0.65	-9.11	-0.4	3.34e-18	Coronary artery disease;
LUAD	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.54	8.71	0.39	6.88e-17	Total body bone mineral density;
LUAD	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.63	11.64	0.49	2.26e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.72	-12.43	-0.52	1.83e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUAD	cis	rs7586879	1.000	rs7608185	chr2:25115432	G/C	cg04586622	chr2:25135609	ADCY3	0.34	7.37	0.34	9.31e-13	Body mass index;
LUAD	cis	rs539096	0.781	rs2916568	chr1:44091274	A/G	cg12908607	chr1:44402522	ARTN	-0.35	-6.38	-0.3	4.79e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08677398	chr8:58056175	NA	0.47	6.56	0.3	1.6e-10	Developmental language disorder (linguistic errors);
LUAD	cis	rs7107174	1.000	rs2256464	chr11:77917305	C/A	cg02023728	chr11:77925099	USP35	0.42	6.73	0.31	5.7e-11	Testicular germ cell tumor;
LUAD	cis	rs11677416	1.000	rs59674541	chr2:113553824	A/T	cg27083787	chr2:113543245	IL1A	0.4	6.82	0.31	3.12e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs420259	0.516	rs369856	chr16:23474664	T/C	cg00143387	chr16:23521605	GGA2	0.72	10.06	0.44	1.66e-21	Bipolar disorder;
LUAD	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg10755058	chr3:40428713	ENTPD3	0.45	8.23	0.37	2.27e-15	Renal cell carcinoma;
LUAD	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg15704280	chr7:45808275	SEPT13	-0.66	-10.93	-0.47	1.14e-24	Coronary artery disease;
LUAD	cis	rs78761021	0.860	rs9674995	chr17:9773043	C/A	cg26853458	chr17:9805074	RCVRN	0.35	6.68	0.31	7.5e-11	Type 2 diabetes;
LUAD	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg05896524	chr21:47604654	C21orf56	0.54	9.05	0.4	5.18e-18	Testicular germ cell tumor;
LUAD	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg14835575	chr10:16859367	RSU1	0.5	7.98	0.36	1.35e-14	Platelet distribution width;
LUAD	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg12292205	chr6:26970375	C6orf41	0.51	8.99	0.4	8.23e-18	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs2548003	0.565	rs2554899	chr5:28741116	C/T	cg22863700	chr5:28928346	NA	0.46	7.01	0.32	9.19e-12	Hip geometry;
LUAD	cis	rs17253792	0.822	rs10147431	chr14:56091841	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-6.37	-0.3	4.96e-10	Putamen volume;
LUAD	cis	rs9394169	0.592	rs4304152	chr6:33723290	C/T	cg14003231	chr6:33640908	ITPR3	0.35	6.5	0.3	2.25e-10	Essential tremor;
LUAD	cis	rs1395	0.744	rs11126929	chr2:27472027	C/T	cg23587288	chr2:27483067	SLC30A3	0.42	8.33	0.38	1.18e-15	Blood metabolite levels;
LUAD	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg21220214	chr8:57350948	NA	-0.6	-8.89	-0.4	1.8e-17	Obesity-related traits;
LUAD	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg00475322	chr7:917719	C7orf20	0.57	10.04	0.44	2.08e-21	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs4604732	0.588	rs9943231	chr1:247629829	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	9.17	0.41	2.14e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg14228332	chr4:119757509	SEC24D	0.87	8.17	0.37	3.71e-15	Cannabis dependence symptom count;
LUAD	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg03733263	chr8:22462867	KIAA1967	0.72	12.33	0.51	4.76e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUAD	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg23018236	chr17:30244563	NA	-0.69	-8.39	-0.38	7.53e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs1595825	0.891	rs892513	chr2:198905874	A/G	cg00982548	chr2:198649783	BOLL	0.66	9.46	0.42	2.11e-19	Ulcerative colitis;
LUAD	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg23625390	chr15:77176239	SCAPER	0.4	7.19	0.33	2.97e-12	Blood metabolite levels;
LUAD	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg24818145	chr4:99064322	C4orf37	0.47	8.04	0.36	9.2e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg07432352	chr17:45403706	C17orf57	-0.42	-7.94	-0.36	1.87e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.31	-0.33	1.37e-12	Bipolar disorder;
LUAD	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.6	-10.23	-0.45	4.18e-22	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs9372498	0.764	rs9489369	chr6:118720704	A/C	cg07617317	chr6:118971624	C6orf204	-0.55	-6.85	-0.32	2.68e-11	Diastolic blood pressure;
LUAD	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03517284	chr6:25882590	NA	-0.98	-17.64	-0.65	1.34e-52	Urate levels;
LUAD	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg27284194	chr4:1044797	NA	0.58	9.49	0.42	1.75e-19	Recombination rate (males);
LUAD	cis	rs62400317	0.821	rs12202232	chr6:45208345	G/A	cg20913747	chr6:44695427	NA	-0.42	-6.51	-0.3	2.14e-10	Total body bone mineral density;
LUAD	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg10589385	chr1:150898437	SETDB1	-0.34	-6.44	-0.3	3.35e-10	Tonsillectomy;
LUAD	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18404041	chr3:52824283	ITIH1	-0.59	-11.79	-0.5	5.98e-28	Bipolar disorder;
LUAD	cis	rs13067306	1.000	rs35602488	chr3:94246319	T/C	cg16274205	chr3:94243571	NA	0.42	6.46	0.3	2.96e-10	Blood pressure measurement (high sodium intervention);
LUAD	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg14228332	chr4:119757509	SEC24D	0.81	7.57	0.35	2.33e-13	Cannabis dependence symptom count;
LUAD	trans	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg20587970	chr11:113659929	NA	0.9	11.82	0.5	4.66e-28	Hip circumference adjusted for BMI;
LUAD	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-9.76	-0.43	1.98e-20	Electroencephalogram traits;
LUAD	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg24818145	chr4:99064322	C4orf37	0.48	8.08	0.37	6.65e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg11189052	chr15:85197271	WDR73	0.65	8.82	0.39	2.94e-17	Schizophrenia;
LUAD	cis	rs9296092	0.538	rs9461887	chr6:33526827	C/T	cg13560919	chr6:33536144	NA	-0.87	-15.59	-0.6	1.29e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs2369473	1	rs2369473	chr1:160210727	C/A	cg02974968	chr1:160236444	NA	-0.42	-8.04	-0.36	9.32e-15	Squamous cell lung carcinoma;
LUAD	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg13319975	chr6:146136371	FBXO30	-0.62	-10.71	-0.46	7.41e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.92	0.32	1.67e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2066819	1.000	rs41423244	chr12:56693520	A/C	cg26714650	chr12:56694279	CS	0.85	7.08	0.33	6.08e-12	Psoriasis vulgaris;
LUAD	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg08523384	chr5:141488047	NDFIP1	-0.49	-7.39	-0.34	8.13e-13	Crohn's disease;
LUAD	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg10518543	chr12:38710700	ALG10B	-0.49	-8.05	-0.36	8.23e-15	Morning vs. evening chronotype;
LUAD	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg11645453	chr3:52864694	ITIH4	0.35	6.66	0.31	8.67e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1997103	1.000	rs11238364	chr7:55407632	G/T	cg17469321	chr7:55412551	NA	0.66	11.34	0.48	3.18e-26	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs7043114	0.525	rs7864630	chr9:95267560	A/C	cg14631576	chr9:95140430	CENPP	-0.43	-8.67	-0.39	9.1e-17	Height;
LUAD	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg20628663	chr10:43360327	NA	0.69	11.11	0.48	2.39e-25	Blood protein levels;
LUAD	trans	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg14917512	chr19:3094685	GNA11	0.56	6.69	0.31	7e-11	Diabetic kidney disease;
LUAD	trans	rs1941687	1.000	rs1941687	chr18:31334667	A/C	cg27147174	chr7:100797783	AP1S1	-0.54	-9.33	-0.41	5.83e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	trans	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.55	0.46	2.89e-23	Ulcerative colitis;
LUAD	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg09640425	chr7:158790006	NA	-0.45	-7.77	-0.35	6.19e-14	Facial morphology (factor 20);
LUAD	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg15704280	chr7:45808275	SEPT13	-1.07	-24.55	-0.77	2.24e-83	Height;
LUAD	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg11247378	chr22:39784982	NA	-0.73	-13.39	-0.55	2.44e-34	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUAD	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg05110241	chr16:68378359	PRMT7	-0.79	-8.26	-0.37	1.85e-15	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg13010199	chr12:38710504	ALG10B	0.39	6.48	0.3	2.51e-10	Morning vs. evening chronotype;
LUAD	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg19761014	chr17:28927070	LRRC37B2	0.83	8.45	0.38	4.63e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg27284194	chr4:1044797	NA	0.71	10.26	0.45	3.2800000000000002e-22	Recombination rate (females);
LUAD	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg13535736	chr9:111863775	C9orf5	0.43	6.66	0.31	8.54e-11	Menarche (age at onset);
LUAD	cis	rs9644630	0.930	rs4921655	chr8:19366608	C/T	cg06699216	chr8:19333253	CSGALNACT1	0.3	7.15	0.33	3.77e-12	Oropharynx cancer;
LUAD	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg17366294	chr4:99064904	C4orf37	0.47	8.34	0.38	1.03e-15	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg14186256	chr22:23484241	RTDR1	0.46	7.78	0.35	5.43e-14	Bone mineral density;
LUAD	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg03676636	chr4:99064102	C4orf37	0.31	8.26	0.37	1.91e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1032833	0.732	rs111644090	chr2:179947366	T/C	cg23883738	chr2:179974586	SESTD1	-0.72	-8.26	-0.37	1.9e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LUAD	cis	rs11229555	0.598	rs4519112	chr11:58176386	C/T	cg15696309	chr11:58395628	NA	-0.69	-9.76	-0.43	1.93e-20	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUAD	cis	rs10106298	0.901	rs1434281	chr8:103671080	G/A	cg10187029	chr8:103597600	NA	0.49	8.0	0.36	1.17e-14	Schizophrenia;
LUAD	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg10468373	chr11:64009913	FKBP2	0.54	6.8	0.31	3.62e-11	Mean platelet volume;
LUAD	cis	rs6543140	0.964	rs4851592	chr2:103087641	C/T	cg03938978	chr2:103052716	IL18RAP	0.35	6.71	0.31	6.34e-11	Blood protein levels;
LUAD	cis	rs807669	0.903	rs2800974	chr22:19168087	C/T	cg24911827	chr22:19170109	CLTCL1	0.47	10.11	0.44	1.13e-21	Metabolite levels;
LUAD	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg22532475	chr10:104410764	TRIM8	0.34	6.85	0.32	2.64e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUAD	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg25753631	chr6:25732923	NA	-0.45	-7.96	-0.36	1.59e-14	Iron status biomarkers;
LUAD	cis	rs34245846	0.769	rs12084791	chr1:154824973	A/G	cg09359103	chr1:154839909	KCNN3	0.51	7.58	0.35	2.25e-13	Atrial fibrillation;
LUAD	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00166722	chr3:10149974	C3orf24	0.75	12.83	0.53	4.56e-32	Alzheimer's disease;
LUAD	trans	rs11039798	0.925	rs7482967	chr11:48613527	T/A	cg15704280	chr7:45808275	SEPT13	0.64	7.65	0.35	1.4e-13	Axial length;
LUAD	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg22963979	chr7:1858916	MAD1L1	-0.5	-8.42	-0.38	5.83e-16	Bipolar disorder and schizophrenia;
LUAD	cis	rs10883723	0.962	rs11191294	chr10:104225837	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	9.43	0.42	2.81e-19	Allergic disease (asthma, hay fever or eczema);
LUAD	cis	rs55788414	0.932	rs35326835	chr16:81190413	T/C	cg06400318	chr16:81190750	PKD1L2	-0.84	-10.27	-0.45	3.01e-22	Left ventricular obstructive tract defect (maternal effect);
LUAD	cis	rs2652822	0.504	rs4619348	chr15:63359564	A/C	cg25406657	chr15:63342033	TPM1	-0.34	-7.3	-0.33	1.42e-12	Metabolic traits;
LUAD	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg15117754	chr3:10150083	C3orf24	0.44	7.1	0.33	5.19e-12	Alzheimer's disease;
LUAD	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg06641503	chr3:48959341	ARIH2	-0.39	-7.73	-0.35	7.65e-14	Menarche (age at onset);
LUAD	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg09537434	chr19:41945824	ATP5SL	-0.51	-8.09	-0.37	6.18e-15	Height;
LUAD	cis	rs11971779	0.680	rs11768023	chr7:139054395	T/A	cg23387468	chr7:139079360	LUC7L2	0.29	6.85	0.32	2.57e-11	Diisocyanate-induced asthma;
LUAD	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.52	6.99	0.32	1.06e-11	Platelet count;
LUAD	cis	rs28595532	0.920	rs116668854	chr4:119707642	A/G	cg21605333	chr4:119757512	SEC24D	0.94	7.45	0.34	5.4e-13	Cannabis dependence symptom count;
LUAD	cis	rs17092148	0.945	rs6060042	chr20:33361721	A/G	cg16810054	chr20:33298113	TP53INP2	-0.53	-8.05	-0.36	8.53e-15	Neuroticism;
LUAD	trans	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	9.94	0.44	4.58e-21	Ulcerative colitis;
LUAD	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg08470875	chr2:26401718	FAM59B	-0.62	-8.52	-0.38	2.89e-16	Gut microbiome composition (summer);
LUAD	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg11915388	chr22:42470451	FAM109B	0.41	7.37	0.34	8.84e-13	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4700695	0.841	rs957526	chr5:65345830	A/G	cg21114390	chr5:65439923	SFRS12	0.63	8.24	0.37	2.25e-15	Facial morphology (factor 19);
LUAD	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg24503407	chr1:205819492	PM20D1	0.79	15.99	0.61	2.47e-45	Menarche (age at onset);
LUAD	cis	rs2692947	0.631	rs2312954	chr2:96772447	C/T	cg23100626	chr2:96804247	ASTL	-0.38	-9.93	-0.43	5.02e-21	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg05373962	chr22:49881684	NA	-0.5	-10.1	-0.44	1.2e-21	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg18209359	chr17:80159595	CCDC57	0.4	6.92	0.32	1.65e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg24558204	chr6:135376177	HBS1L	0.43	7.6	0.35	1.9e-13	Red blood cell count;
LUAD	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg10518543	chr12:38710700	ALG10B	0.41	6.42	0.3	3.66e-10	Bladder cancer;
LUAD	trans	rs1728785	1.000	rs7118	chr16:68600855	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.39	0.45	1.14e-22	Ulcerative colitis;
LUAD	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg02631126	chr6:28058918	ZSCAN12L1	0.32	7.17	0.33	3.44e-12	Parkinson's disease;
LUAD	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg21204522	chr6:27730016	NA	-0.46	-7.32	-0.34	1.26e-12	Parkinson's disease;
LUAD	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg17105886	chr17:28927953	LRRC37B2	0.76	7.61	0.35	1.86e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs9354308	0.868	rs4392709	chr6:66547178	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.87	-0.32	2.3e-11	Metabolite levels;
LUAD	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-8.01	-0.36	1.12e-14	Monocyte percentage of white cells;
LUAD	trans	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg25894440	chr7:65020034	NA	0.63	6.73	0.31	5.63e-11	Gout;
LUAD	trans	rs3857536	0.813	rs6455083	chr6:66935406	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-6.37	-0.3	4.89e-10	Blood trace element (Cu levels);
LUAD	cis	rs1535500	0.967	rs11756070	chr6:39282748	G/A	cg06347083	chr6:39282316	KCNK17	-0.37	-7.89	-0.36	2.7e-14	Type 2 diabetes;
LUAD	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05665937	chr4:1216051	CTBP1	0.42	7.56	0.35	2.48e-13	Obesity-related traits;
LUAD	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg12432903	chr7:1882776	MAD1L1	-0.53	-8.57	-0.38	1.97e-16	Bipolar disorder and schizophrenia;
LUAD	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.36	-7.66	-0.35	1.24e-13	Height;
LUAD	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg21823605	chr1:152486609	CRCT1	0.28	6.46	0.3	2.95e-10	Hair morphology;
LUAD	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg15445000	chr17:37608096	MED1	0.45	8.21	0.37	2.77e-15	Glomerular filtration rate (creatinine);
LUAD	cis	rs77861329	0.748	rs12629791	chr3:52175783	C/T	cg08692210	chr3:52188851	WDR51A	0.55	6.93	0.32	1.54e-11	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs6594713	0.759	rs6880552	chr5:112745597	A/T	cg12552261	chr5:112820674	MCC	0.43	7.24	0.33	2.15e-12	Brain cytoarchitecture;
LUAD	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg23029597	chr12:123009494	RSRC2	0.52	7.97	0.36	1.46e-14	Body mass index;
LUAD	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.58	0.3	1.37e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg07217954	chr7:1067459	C7orf50	-0.36	-6.88	-0.32	2.22e-11	Bronchopulmonary dysplasia;
LUAD	cis	rs1215050	0.791	rs2865942	chr4:98737709	G/C	cg24818145	chr4:99064322	C4orf37	0.41	6.95	0.32	1.38e-11	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs2901656	0.875	rs7516301	chr1:172372260	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.39	7.57	0.35	2.42e-13	Red cell distribution width;Platelet distribution width;
LUAD	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg24818145	chr4:99064322	C4orf37	0.47	7.97	0.36	1.44e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg02631126	chr6:28058918	ZSCAN12L1	0.39	7.81	0.36	4.49e-14	Depression;
LUAD	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18876405	chr7:65276391	NA	-0.59	-9.67	-0.43	3.96e-20	Aortic root size;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19584823	chr14:50235219	KLHDC2	-0.42	-6.44	-0.3	3.24e-10	Height;
LUAD	cis	rs73198271	0.773	rs66618176	chr8:8646974	G/C	cg01851573	chr8:8652454	MFHAS1	0.48	8.6	0.39	1.55e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg19761014	chr17:28927070	LRRC37B2	0.84	8.3	0.37	1.37e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6545883	0.718	rs3771260	chr2:61762384	G/T	cg15711740	chr2:61764176	XPO1	-0.42	-6.8	-0.31	3.64e-11	Tuberculosis;
LUAD	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.67	-11.26	-0.48	6.74e-26	Primary sclerosing cholangitis;
LUAD	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg09399716	chr2:46890238	NA	-0.38	-7.06	-0.32	6.79e-12	Height;
LUAD	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-7.49	-0.34	4.14e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg09117114	chr16:67998030	SLC12A4	-0.48	-6.82	-0.31	3.06e-11	HDL cholesterol;Metabolic syndrome;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg17025674	chr5:127537216	NA	-0.43	-6.79	-0.31	3.82e-11	Height;
LUAD	cis	rs2286885	0.896	rs62578061	chr9:129248219	C/T	cg15282417	chr9:129245246	FAM125B	0.45	9.13	0.41	2.92e-18	Intraocular pressure;
LUAD	cis	rs76878669	0.561	rs7948058	chr11:66148111	T/A	cg18002602	chr11:66138449	SLC29A2	-0.5	-10.62	-0.46	1.7e-23	Educational attainment (years of education);
LUAD	trans	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04565464	chr8:145669602	NFKBIL2	0.48	7.19	0.33	3.03e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg21605333	chr4:119757512	SEC24D	0.94	8.79	0.39	3.71e-17	Cannabis dependence symptom count;
LUAD	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg20744362	chr22:50050164	C22orf34	0.39	8.43	0.38	5.59e-16	Monocyte count;Monocyte percentage of white cells;
LUAD	cis	rs7264396	0.563	rs6060566	chr20:34288226	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.24	-0.37	2.2e-15	Total cholesterol levels;
LUAD	cis	rs9462027	0.628	rs2395598	chr6:34640686	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-8.58	-0.38	1.86e-16	Systemic lupus erythematosus;
LUAD	cis	rs78761021	0.867	rs74701139	chr17:9788360	A/C	cg26853458	chr17:9805074	RCVRN	0.36	7.11	0.33	5.08e-12	Type 2 diabetes;
LUAD	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	7.33	0.34	1.17e-12	Menopause (age at onset);
LUAD	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg22875332	chr1:76189707	ACADM	0.87	15.93	0.61	4.32e-45	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg25811766	chr13:21894605	NA	-0.64	-7.47	-0.34	4.67e-13	White matter hyperintensity burden;
LUAD	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg21138405	chr5:131827807	IRF1	0.6	13.77	0.56	6.51e-36	Asthma (sex interaction);
LUAD	cis	rs11771526	0.792	rs11770580	chr7:32305009	T/C	cg27511599	chr7:32358540	NA	0.51	6.45	0.3	3.08e-10	Body mass index;
LUAD	cis	rs4727443	0.932	rs7803714	chr7:99585150	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.41	6.9	0.32	1.86e-11	Interstitial lung disease;
LUAD	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg09359103	chr1:154839909	KCNN3	-0.93	-22.07	-0.73	2.2e-72	Prostate cancer;
LUAD	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.68	0.43	3.64e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg26513180	chr16:89883248	FANCA	0.7	6.73	0.31	5.59e-11	Skin colour saturation;
LUAD	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	6.44	0.3	3.2e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.27	6.43	0.3	3.5e-10	Parkinson's disease;
LUAD	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08280861	chr8:58055591	NA	0.74	8.99	0.4	8.26e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs367943	0.712	rs26967	chr5:112741467	C/G	cg12552261	chr5:112820674	MCC	0.47	9.1	0.4	3.71e-18	Type 2 diabetes;
LUAD	cis	rs11166629	0.651	rs7842812	chr8:135641794	T/C	cg27224718	chr8:135614730	ZFAT	0.43	7.68	0.35	1.12e-13	Smoking quantity;
LUAD	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg13770153	chr20:60521292	NA	-0.45	-7.47	-0.34	4.5e-13	Body mass index;
LUAD	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg12935359	chr14:103987150	CKB	-0.49	-7.85	-0.36	3.52e-14	Body mass index;
LUAD	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg03676636	chr4:99064102	C4orf37	0.32	8.38	0.38	8.01e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg22875332	chr1:76189707	ACADM	0.75	11.7	0.49	1.34e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg03433033	chr1:76189801	ACADM	0.84	14.97	0.59	6e-41	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs113835537	0.529	rs2279864	chr11:66247844	G/A	cg24851651	chr11:66362959	CCS	0.57	10.03	0.44	2.22e-21	Airway imaging phenotypes;
LUAD	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg20607798	chr8:58055168	NA	0.61	7.92	0.36	2.13e-14	Developmental language disorder (linguistic errors);
LUAD	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12923728	chr3:195709715	SDHAP1	-0.78	-13.64	-0.55	2.27e-35	Pancreatic cancer;
LUAD	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg21153622	chr11:89784906	NA	-0.34	-6.62	-0.31	1.07e-10	Coronary artery disease;
LUAD	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg18209359	chr17:80159595	CCDC57	-0.4	-6.8	-0.31	3.61e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg08125733	chr17:73851984	WBP2	0.61	8.89	0.4	1.82e-17	Psoriasis;
LUAD	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg08601574	chr20:25228251	PYGB	0.47	8.75	0.39	5.01e-17	Liver enzyme levels (alkaline phosphatase);
LUAD	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg05182265	chr7:156933206	UBE3C	-0.8	-17.27	-0.64	5.96e-51	Body mass index;
LUAD	cis	rs62229266	0.625	rs62230813	chr21:37403432	C/T	cg08632701	chr21:37451849	NA	-0.4	-6.66	-0.31	8.71e-11	Mitral valve prolapse;
LUAD	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg14668632	chr7:2872130	GNA12	-0.73	-12.93	-0.53	1.85e-32	Height;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg22805431	chr3:113955600	ZNF80	-0.34	-6.58	-0.3	1.41e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg22482690	chr17:47019901	SNF8	0.46	8.94	0.4	1.21e-17	Type 2 diabetes;
LUAD	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg27426351	chr10:43362370	NA	-0.54	-8.31	-0.37	1.3e-15	Blood protein levels;
LUAD	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21659725	chr3:3221576	CRBN	0.69	11.07	0.47	3.54e-25	Resting heart rate;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg03677675	chr16:68279322	PLA2G15	-0.56	-6.81	-0.31	3.46e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg13732083	chr21:47605072	C21orf56	0.42	6.97	0.32	1.19e-11	Testicular germ cell tumor;
LUAD	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.41	6.67	0.31	7.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	trans	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg17712092	chr4:129076599	LARP1B	-0.65	-10.15	-0.44	8.61e-22	Eosinophil percentage of white cells;
LUAD	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg19000871	chr14:103996768	TRMT61A	-0.41	-7.26	-0.33	1.92e-12	Coronary artery disease;
LUAD	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.4	-6.88	-0.32	2.2e-11	Longevity;Endometriosis;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg05772935	chr16:1790400	MAPK8IP3	-0.38	-6.4	-0.3	4.25e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07167872	chr1:205819463	PM20D1	0.78	15.86	0.61	8.37e-45	Menarche (age at onset);
LUAD	cis	rs11195062	0.693	rs7912643	chr10:112027936	A/G	cg19214408	chr10:111981687	MXI1	-0.42	-7.02	-0.32	9.05e-12	Multiple myeloma;
LUAD	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg00383909	chr3:49044727	WDR6	0.92	9.18	0.41	1.98e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUAD	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg22117172	chr7:91764530	CYP51A1	0.36	7.89	0.36	2.63e-14	Breast cancer;
LUAD	cis	rs68170813	0.559	rs76859341	chr7:107070146	C/G	cg02696742	chr7:106810147	HBP1	-0.78	-10.63	-0.46	1.49e-23	Coronary artery disease;
LUAD	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg18827107	chr12:86230957	RASSF9	-0.49	-8.67	-0.39	9.15e-17	Major depressive disorder;
LUAD	cis	rs6426558	0.537	rs488104	chr1:227300277	G/A	cg10327440	chr1:227177885	CDC42BPA	0.54	8.71	0.39	6.96e-17	Neutrophil percentage of white cells;
LUAD	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg12310025	chr6:25882481	NA	-0.58	-9.55	-0.42	1.1e-19	Blood metabolite levels;
LUAD	cis	rs13064411	0.696	rs35860985	chr3:113209828	C/T	cg18753928	chr3:113234510	CCDC52	-0.73	-12.43	-0.52	1.82e-30	Response to simvastatin treatment (PCSK9 protein level change);
LUAD	cis	rs6951245	0.554	rs118191017	chr7:1155846	T/C	cg04025307	chr7:1156635	C7orf50	0.79	12.28	0.51	7.44e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs57920188	0.535	rs4295855	chr1:4094993	C/T	cg20703997	chr1:4087676	NA	0.51	9.04	0.4	5.86e-18	Interleukin-17 levels;
LUAD	cis	rs10129255	0.500	rs59939897	chr14:107191651	A/G	cg23076370	chr14:107095027	NA	-0.44	-8.72	-0.39	6.58e-17	Kawasaki disease;
LUAD	cis	rs12597422	0.560	rs9972717	chr16:53851304	A/G	cg26651810	chr16:53851122	FTO	0.57	7.58	0.35	2.28e-13	Eyebrow thickness;
LUAD	cis	rs56283067	0.887	rs62437973	chr6:44761978	G/A	cg20913747	chr6:44695427	NA	-0.47	-7.34	-0.34	1.11e-12	Total body bone mineral density;
LUAD	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg05590025	chr7:65112418	INTS4L2	-0.75	-8.05	-0.36	8.59e-15	Diabetic kidney disease;
LUAD	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13937449	chr12:56320970	WIBG	0.42	6.5	0.3	2.32e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUAD	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg09365446	chr1:150670422	GOLPH3L	0.66	12.58	0.52	4.9e-31	Tonsillectomy;
LUAD	trans	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg16724585	chr3:197361211	NA	-0.51	-7.79	-0.35	5.31e-14	Pancreatic cancer;
LUAD	cis	rs2070677	0.736	rs7099806	chr10:135414896	C/T	cg20169779	chr10:135381914	SYCE1	-0.52	-6.84	-0.32	2.83e-11	Gout;
LUAD	cis	rs1451375	0.572	rs66792686	chr7:50651239	T/C	cg18232548	chr7:50535776	DDC	0.47	6.51	0.3	2.14e-10	Malaria;
LUAD	cis	rs9513627	1.000	rs7322368	chr13:100213990	T/C	cg25919922	chr13:100150906	NA	0.7	6.47	0.3	2.79e-10	Obesity-related traits;
LUAD	cis	rs9581857	0.547	rs9581868	chr13:28070682	C/T	cg22138327	chr13:27999177	GTF3A	0.88	9.27	0.41	9.27e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg05043794	chr9:111880884	C9orf5	-0.39	-6.52	-0.3	2.03e-10	Menarche (age at onset);
LUAD	cis	rs6558530	0.666	rs6558523	chr8:1702504	T/C	cg19131313	chr8:1704013	NA	-0.42	-6.48	-0.3	2.63e-10	Systolic blood pressure;
LUAD	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg10645314	chr2:3704589	ALLC	-0.59	-9.4	-0.42	3.52e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUAD	cis	rs11971779	0.680	rs2355786	chr7:139065622	A/C	cg23387468	chr7:139079360	LUC7L2	-0.3	-6.92	-0.32	1.7e-11	Diisocyanate-induced asthma;
LUAD	trans	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg08071915	chr8:12219732	FAM66A	0.39	6.59	0.31	1.34e-10	Joint mobility (Beighton score);
LUAD	cis	rs10504073	0.584	rs62507182	chr8:49942500	C/A	cg00325661	chr8:49890786	NA	0.46	10.36	0.45	1.47e-22	Blood metabolite ratios;
LUAD	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg06608945	chr2:219082296	ARPC2	-0.45	-7.41	-0.34	6.77e-13	Colorectal cancer;
LUAD	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg23231163	chr10:75533350	FUT11	-0.53	-9.65	-0.42	4.81e-20	Inflammatory bowel disease;
LUAD	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg21100191	chr22:23484243	RTDR1	-0.71	-13.16	-0.54	2.06e-33	Bone mineral density;
LUAD	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.63	-12.21	-0.51	1.38e-29	Cognitive ability;
LUAD	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg04155289	chr7:94953770	PON1	0.53	7.09	0.33	5.58e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg21160151	chr5:131131930	FNIP1	-0.39	-6.5	-0.3	2.24e-10	Subcortical brain region volumes;
LUAD	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg18944383	chr4:111397179	ENPEP	0.39	7.84	0.36	3.72e-14	Height;
LUAD	trans	rs7395662	1.000	rs11039868	chr11:48622146	T/C	cg15704280	chr7:45808275	SEPT13	-0.42	-6.48	-0.3	2.57e-10	HDL cholesterol;
LUAD	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06873352	chr17:61820015	STRADA	0.83	18.42	0.67	4.68e-56	Prudent dietary pattern;
LUAD	cis	rs7937890	0.631	rs7118886	chr11:14427517	T/C	cg22961513	chr11:14280813	SPON1	-0.37	-7.36	-0.34	9.49e-13	Mitochondrial DNA levels;
LUAD	cis	rs6906287	0.647	rs35730412	chr6:118707343	T/C	cg21191810	chr6:118973309	C6orf204	0.49	9.61	0.42	6.39e-20	Electrocardiographic conduction measures;
LUAD	cis	rs7000551	0.725	rs7430	chr8:22398414	C/G	cg12081754	chr8:22256438	SLC39A14	0.42	7.01	0.32	9.73e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs11677416	1.000	rs3783520	chr2:113544339	C/T	cg27083787	chr2:113543245	IL1A	0.4	6.85	0.32	2.67e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs78707713	0.560	rs2394563	chr10:71238618	G/A	cg12610070	chr10:71211762	TSPAN15	-0.38	-9.42	-0.42	2.95e-19	Venous thromboembolism;
LUAD	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg03806693	chr22:41940476	POLR3H	0.77	10.34	0.45	1.67e-22	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg07606381	chr6:8435919	SLC35B3	0.4	6.65	0.31	9.07e-11	Motion sickness;
LUAD	trans	rs12517041	1.000	rs6859293	chr5:23312935	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.49	-6.92	-0.32	1.73e-11	Calcium levels;
LUAD	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	11.28	0.48	5.78e-26	Resting heart rate;
LUAD	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg27572855	chr1:25598939	RHD	0.59	13.3	0.54	5.56e-34	Plateletcrit;Mean corpuscular volume;
LUAD	trans	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.67	11.4	0.48	1.96e-26	Mean corpuscular volume;
LUAD	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.79	0.31	3.74e-11	Rheumatoid arthritis;
LUAD	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg22535103	chr8:58192502	C8orf71	-0.77	-9.5	-0.42	1.58e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg11645453	chr3:52864694	ITIH4	0.37	7.27	0.33	1.73e-12	Bipolar disorder;
LUAD	cis	rs9486719	1.000	rs72931061	chr6:96880285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.71	-10.02	-0.44	2.32e-21	Migraine;Coronary artery disease;
LUAD	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg11098525	chr4:1320231	MAEA	-0.39	-6.48	-0.3	2.6200000000000003e-10	Obesity-related traits;
LUAD	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg06002616	chr8:101225028	SPAG1	-0.39	-7.92	-0.36	2.06e-14	Atrioventricular conduction;
LUAD	cis	rs10911251	0.546	rs20560	chr1:183105534	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.81	0.31	3.34e-11	Colorectal cancer;
LUAD	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg13263323	chr15:86062960	AKAP13	-0.51	-9.42	-0.42	2.92e-19	Coronary artery disease;
LUAD	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg09654669	chr8:57350985	NA	-0.65	-10.02	-0.44	2.42e-21	Obesity-related traits;
LUAD	cis	rs62064224	0.614	rs4794921	chr17:30742310	C/T	cg25809561	chr17:30822961	MYO1D	0.47	8.52	0.38	2.8e-16	Schizophrenia;
LUAD	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11644478	chr21:40555479	PSMG1	-0.41	-6.96	-0.32	1.34e-11	Menarche (age at onset);
LUAD	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-8.97	-0.4	1e-17	Life satisfaction;
LUAD	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg24818145	chr4:99064322	C4orf37	0.41	6.8	0.31	3.61e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg02775129	chr4:119771670	NA	-0.87	-8.17	-0.37	3.55e-15	Cannabis dependence symptom count;
LUAD	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg09035930	chr12:129282057	SLC15A4	0.55	10.02	0.44	2.37e-21	Systemic lupus erythematosus;
LUAD	cis	rs853679	0.607	rs13197176	chr6:28129232	C/T	cg12623302	chr6:28058802	ZSCAN12L1	0.56	6.53	0.3	1.91e-10	Depression;
LUAD	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg05590025	chr7:65112418	INTS4L2	-0.76	-8.0	-0.36	1.17e-14	Diabetic kidney disease;
LUAD	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg10729496	chr3:10149963	C3orf24	0.59	9.82	0.43	1.23e-20	Alzheimer's disease;
LUAD	cis	rs2795502	0.564	rs11239842	chr10:43444882	A/G	cg20628663	chr10:43360327	NA	0.6	6.87	0.32	2.25e-11	Blood protein levels;
LUAD	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg00757033	chr12:89920650	WDR51B	0.7	12.2	0.51	1.47e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs4356932	1.000	rs4302486	chr4:76953077	C/T	cg24176760	chr4:76958061	ART3;CXCL11	0.35	6.43	0.3	3.43e-10	Blood protein levels;
LUAD	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg22529645	chr1:3704559	LRRC47	0.56	10.33	0.45	1.79e-22	Red cell distribution width;
LUAD	cis	rs11696501	0.688	rs6124727	chr20:44325623	T/C	cg11783356	chr20:44313418	WFDC10B	-0.51	-8.34	-0.38	1.03e-15	Brain structure;
LUAD	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg03037974	chr15:76606532	NA	0.38	7.96	0.36	1.63e-14	Blood metabolite levels;
LUAD	cis	rs1003719	0.762	rs3787780	chr21:38462614	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.51	8.63	0.39	1.24e-16	Eye color traits;
LUAD	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg04968532	chr11:68963993	NA	-0.37	-6.53	-0.3	1.92e-10	Immune response to smallpox vaccine (IL-6);
LUAD	cis	rs12541635	0.966	rs2217391	chr8:107063126	A/G	cg10147462	chr8:107024639	NA	0.48	8.68	0.39	8.5e-17	Age of smoking initiation;
LUAD	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg05110241	chr16:68378359	PRMT7	-0.83	-8.98	-0.4	8.87e-18	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs10068717	1	rs10068717	chr5:141494934	C/T	cg23435118	chr5:141488016	NDFIP1	-0.39	-6.61	-0.31	1.13e-10	Allergic disease (asthma, hay fever or eczema);
LUAD	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg11292332	chr7:45801988	SEPT13	-0.28	-6.36	-0.3	5.26e-10	Extrinsic epigenetic age acceleration;
LUAD	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg11530693	chr1:120165357	ZNF697	0.86	18.56	0.67	1.09e-56	Systemic lupus erythematosus;
LUAD	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24308560	chr3:49941425	MST1R	0.51	8.56	0.38	2.07e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.67e-11	Depression;
LUAD	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg12310025	chr6:25882481	NA	-0.39	-6.35	-0.3	5.55e-10	Height;
LUAD	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg10544611	chr16:67998164	SLC12A4	-0.65	-7.45	-0.34	5.34e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg19761014	chr17:28927070	LRRC37B2	0.7	6.64	0.31	9.44e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs6500395	0.926	rs11643272	chr16:48639723	T/C	cg04672837	chr16:48644449	N4BP1	0.39	6.82	0.31	3.1e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06028808	chr11:68637592	NA	0.47	7.62	0.35	1.66e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs10465746	0.935	rs1871925	chr1:84464468	C/G	cg10977910	chr1:84465055	TTLL7	0.51	8.13	0.37	4.74e-15	Obesity-related traits;
LUAD	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg16342193	chr10:102329863	NA	-0.37	-6.53	-0.3	1.85e-10	Palmitoleic acid (16:1n-7) levels;
LUAD	cis	rs6690583	0.623	rs6672362	chr1:85454881	C/G	cg22153463	chr1:85462885	MCOLN2	0.55	6.37	0.3	4.97e-10	Serum sulfate level;
LUAD	cis	rs954108	0.809	rs715704	chr13:29369317	C/T	cg11788234	chr13:29393811	NA	-0.33	-6.63	-0.31	1.05e-10	Obesity-related traits;
LUAD	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg16797656	chr11:68205561	LRP5	0.45	8.68	0.39	8.8e-17	Total body bone mineral density;
LUAD	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg19041857	chr6:27730383	NA	-0.43	-7.2	-0.33	2.72e-12	Parkinson's disease;
LUAD	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg26384229	chr12:38710491	ALG10B	0.48	7.78	0.35	5.55e-14	Bladder cancer;
LUAD	cis	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg06360820	chr2:242988706	NA	-0.96	-9.74	-0.43	2.34e-20	Obesity-related traits;
LUAD	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg24829409	chr8:58192753	C8orf71	-0.59	-6.93	-0.32	1.6e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2625529	0.652	rs8023788	chr15:72459847	A/G	cg16672083	chr15:72433130	SENP8	0.65	12.18	0.51	1.79e-29	Red blood cell count;
LUAD	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.6	-10.11	-0.44	1.18e-21	Menarche (age at onset);
LUAD	cis	rs7746199	0.673	rs72847313	chr6:27730082	C/T	cg26958806	chr6:27640298	NA	0.63	6.43	0.3	3.43e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.45	8.12	0.37	5.16e-15	Menopause (age at onset);
LUAD	cis	rs6840360	0.571	rs17275598	chr4:152568478	C/A	cg22705602	chr4:152727874	NA	-0.43	-7.3	-0.33	1.43e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg04703951	chr17:43578652	NA	-0.58	-8.29	-0.37	1.47e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.42	0.55	1.77e-34	Exhaled nitric oxide output;
LUAD	cis	rs6988985	0.728	rs10105643	chr8:143957886	A/C	cg10324643	chr8:143916377	GML	0.3	6.38	0.3	4.63e-10	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LUAD	cis	rs12348691	0.503	rs7847259	chr9:100600712	A/G	cg13688889	chr9:100608707	NA	-0.62	-10.19	-0.44	5.75e-22	Alopecia areata;
LUAD	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg07810366	chr2:100720526	AFF3	0.37	7.65	0.35	1.38e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUAD	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg15147215	chr3:52552868	STAB1	-0.4	-7.6	-0.35	1.91e-13	Bipolar disorder;
LUAD	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.56	-0.3	1.56e-10	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs12210905	0.688	rs72841376	chr6:27456321	G/A	cg08851530	chr6:28072375	NA	1.03	7.92	0.36	2.19e-14	Hip circumference adjusted for BMI;
LUAD	trans	rs747782	0.646	rs61914719	chr11:48059091	C/T	cg15704280	chr7:45808275	SEPT13	0.65	6.75	0.31	4.84e-11	Intraocular pressure;
LUAD	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.36	-0.34	9.74e-13	Total cholesterol levels;
LUAD	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.53	0.34	3.1e-13	Hip circumference adjusted for BMI;
LUAD	cis	rs7173743	0.756	rs8032842	chr15:79125849	G/A	cg00540400	chr15:79124168	NA	0.43	9.01	0.4	7.3e-18	Coronary artery disease;
LUAD	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	9.23	0.41	1.31e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg00431813	chr7:1051703	C7orf50	-0.36	-6.4	-0.3	4.1e-10	Longevity;Endometriosis;
LUAD	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg23985595	chr17:80112537	CCDC57	-0.52	-9.47	-0.42	2.05e-19	Life satisfaction;
LUAD	cis	rs7274811	0.744	rs6120316	chr20:32177079	T/C	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.47	-6.99	-0.32	1.07e-11	Height;
LUAD	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs4969178	0.645	rs4490057	chr17:76375095	C/T	cg05887092	chr17:76393375	PGS1	-0.5	-9.85	-0.43	9.86e-21	HDL cholesterol levels;
LUAD	cis	rs11696501	0.739	rs4812938	chr20:44249919	T/A	cg11783356	chr20:44313418	WFDC10B	-0.5	-8.13	-0.37	4.73e-15	Brain structure;
LUAD	cis	rs9837602	0.745	rs792834	chr3:99476121	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	7.18	0.33	3.14e-12	Breast cancer;
LUAD	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.46	-8.53	-0.38	2.71e-16	Menopause (age at onset);
LUAD	cis	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg12964065	chr18:77638022	KCNG2	0.55	6.84	0.32	2.85e-11	Opioid sensitivity;
LUAD	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg17105886	chr17:28927953	LRRC37B2	0.84	8.13	0.37	4.96e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg00717180	chr2:96193071	NA	-0.39	-7.25	-0.33	1.97e-12	HDL cholesterol;
LUAD	cis	rs4409675	0.576	rs6564	chr1:28212975	A/G	cg23691781	chr1:28212827	C1orf38	-0.39	-11.41	-0.49	1.72e-26	Corneal astigmatism;
LUAD	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg08779649	chr13:50194554	NA	0.41	8.24	0.37	2.17e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUAD	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg25173405	chr17:45401733	C17orf57	-0.43	-6.88	-0.32	2.21e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs12478296	0.681	rs56357900	chr2:243033966	A/C	cg06360820	chr2:242988706	NA	-0.8	-9.06	-0.4	4.7e-18	Obesity-related traits;
LUAD	cis	rs4343996	0.811	rs6462030	chr7:3392526	G/A	cg21248987	chr7:3385318	SDK1	-0.37	-6.88	-0.32	2.18e-11	Motion sickness;
LUAD	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-7.54	-0.34	2.89e-13	Blood metabolite levels;
LUAD	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg23743428	chr13:21893420	NA	-0.45	-8.28	-0.37	1.6e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUAD	cis	rs4889911	1.000	rs4889792	chr17:77839845	G/A	cg00646381	chr17:77835854	NA	-0.43	-7.04	-0.32	7.63e-12	Electroencephalogram traits;
LUAD	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00166722	chr3:10149974	C3orf24	0.72	11.57	0.49	4.54e-27	Alzheimer's disease;
LUAD	cis	rs9308433	0.529	rs6660335	chr1:214501855	C/T	cg06198575	chr1:214491504	SMYD2	0.43	7.33	0.34	1.21e-12	IgG glycosylation;
LUAD	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg02725872	chr8:58115012	NA	-0.33	-6.46	-0.3	2.9e-10	Developmental language disorder (linguistic errors);
LUAD	trans	rs629535	0.954	rs559245	chr8:70009238	T/A	cg21567404	chr3:27674614	NA	-0.99	-17.28	-0.64	5.12e-51	Dupuytren's disease;
LUAD	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg03806693	chr22:41940476	POLR3H	0.66	9.03	0.4	6.01e-18	Vitiligo;
LUAD	cis	rs7000551	0.715	rs7839577	chr8:22307325	T/A	cg12081754	chr8:22256438	SLC39A14	0.5	8.48	0.38	3.82e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUAD	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08219700	chr8:58056026	NA	0.68	8.66	0.39	9.97e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg01251360	chr16:68772225	CDH1	0.29	8.74	0.39	5.61e-17	Colorectal cancer;
LUAD	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg06784218	chr1:46089804	CCDC17	0.51	11.14	0.48	1.89e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg27286337	chr10:134555280	INPP5A	0.68	9.78	0.43	1.75e-20	Migraine;
LUAD	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg06074448	chr4:187884817	NA	-0.37	-7.31	-0.33	1.38e-12	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg24818145	chr4:99064322	C4orf37	0.47	7.96	0.36	1.57e-14	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06873352	chr17:61820015	STRADA	0.82	18.18	0.66	5.3e-55	Prudent dietary pattern;
LUAD	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg02569458	chr12:86230093	RASSF9	0.38	6.97	0.32	1.22e-11	Major depressive disorder;
LUAD	trans	rs8002861	0.810	rs9533664	chr13:44440527	T/C	cg17145862	chr1:211918768	LPGAT1	0.74	17.2	0.64	1.17e-50	Leprosy;
LUAD	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg26384229	chr12:38710491	ALG10B	0.43	7.02	0.32	8.81e-12	Morning vs. evening chronotype;
LUAD	cis	rs62229266	0.804	rs62230821	chr21:37425116	C/T	cg08632701	chr21:37451849	NA	-0.43	-7.1	-0.33	5.35e-12	Mitral valve prolapse;
LUAD	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg11663144	chr21:46675770	NA	-0.61	-12.21	-0.51	1.37e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg04727924	chr7:799746	HEATR2	-0.55	-7.42	-0.34	6.53e-13	Cerebrospinal P-tau181p levels;
LUAD	cis	rs1461503	0.932	rs10892944	chr11:122843895	T/C	cg27398637	chr11:122830231	C11orf63	-0.37	-7.04	-0.32	7.85e-12	Menarche (age at onset);
LUAD	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg14343924	chr8:8086146	FLJ10661	0.48	7.52	0.34	3.3e-13	Systolic blood pressure;
LUAD	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-7.07	-0.32	6.63e-12	Blood metabolite levels;
LUAD	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg19980929	chr12:42632907	YAF2	-0.34	-6.58	-0.3	1.43e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUAD	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg03676636	chr4:99064102	C4orf37	0.32	8.25	0.37	1.98e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2742417	1.000	rs2673039	chr3:45748435	A/G	cg10512202	chr3:45649293	LIMD1	0.38	6.84	0.32	2.8e-11	Response to anti-depressant treatment in major depressive disorder;
LUAD	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg17372223	chr3:52568218	NT5DC2	0.41	7.52	0.34	3.22e-13	Electroencephalogram traits;
LUAD	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg00071950	chr4:10020882	SLC2A9	0.86	18.53	0.67	1.46e-56	Bone mineral density;
LUAD	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg20283391	chr11:68216788	NA	-0.4	-6.43	-0.3	3.35e-10	Total body bone mineral density;
LUAD	cis	rs7107174	1.000	rs2510037	chr11:77966099	A/G	cg02023728	chr11:77925099	USP35	0.42	7.09	0.33	5.65e-12	Testicular germ cell tumor;
LUAD	cis	rs4713675	0.565	rs9348924	chr6:33705436	A/G	cg14003231	chr6:33640908	ITPR3	0.4	7.51	0.34	3.65e-13	Plateletcrit;
LUAD	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.52	7.44	0.34	5.77e-13	Platelet count;
LUAD	cis	rs921968	0.619	rs1554623	chr2:219606177	C/T	cg02176678	chr2:219576539	TTLL4	-0.58	-11.38	-0.48	2.27e-26	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg18180107	chr4:99064573	C4orf37	0.4	6.51	0.3	2.14e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg20637647	chr7:64974828	NA	0.38	6.46	0.3	2.88e-10	Calcium levels;
LUAD	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg03714773	chr7:91764589	CYP51A1	-0.28	-6.54	-0.3	1.76e-10	Breast cancer;
LUAD	cis	rs35995292	0.963	rs2893567	chr7:38902934	A/G	cg19327137	chr7:38886074	VPS41	0.5	8.28	0.37	1.64e-15	Subjective well-being (multi-trait analysis);
LUAD	cis	rs35995292	1.000	rs9638944	chr7:38947417	T/C	cg19327137	chr7:38886074	VPS41	0.51	8.47	0.38	4.12e-16	Subjective well-being (multi-trait analysis);
LUAD	trans	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg07393940	chr7:158741817	NA	-0.68	-11.76	-0.5	8.02e-28	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg05110241	chr16:68378359	PRMT7	-0.8	-8.88	-0.4	1.91e-17	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7178375	0.607	rs71474639	chr15:31213257	A/G	cg03767031	chr15:31195708	MTMR15	0.76	8.19	0.37	3.09e-15	Hypertriglyceridemia;
LUAD	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg07606381	chr6:8435919	SLC35B3	0.43	7.12	0.33	4.56e-12	Motion sickness;
LUAD	cis	rs1497828	0.956	rs1497835	chr1:217562287	C/T	cg04411442	chr1:217543379	NA	0.38	6.77	0.31	4.23e-11	Dialysis-related mortality;
LUAD	cis	rs593982	0.858	rs480989	chr11:65493992	A/G	cg08755490	chr11:65554678	OVOL1	1.33	19.37	0.69	2.59e-60	Atopic dermatitis;
LUAD	cis	rs6060717	0.536	rs8125966	chr20:34511823	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.06	-0.32	7.08e-12	Hip circumference adjusted for BMI;
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg08834429	chr16:67694862	ACD;PARD6A	-0.65	-6.57	-0.3	1.47e-10	Type 2 diabetes;
LUAD	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg03714773	chr7:91764589	CYP51A1	0.29	6.56	0.3	1.57e-10	Breast cancer;
LUAD	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg06547715	chr2:218990976	CXCR2	0.29	6.92	0.32	1.73e-11	Colorectal cancer;
LUAD	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg05082376	chr22:42548792	NA	0.45	7.9	0.36	2.41e-14	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg00071950	chr4:10020882	SLC2A9	0.43	6.53	0.3	1.89e-10	Gout;Urate levels;Serum uric acid levels;
LUAD	cis	rs41271951	0.512	rs12090246	chr1:151107496	G/A	cg11822372	chr1:151115635	SEMA6C	-0.84	-7.0	-0.32	1.04e-11	Blood protein levels;
LUAD	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg13877915	chr19:58951672	ZNF132	0.72	13.44	0.55	1.48e-34	Uric acid clearance;
LUAD	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg04455712	chr21:45112962	RRP1B	0.43	8.61	0.39	1.47e-16	Mean corpuscular volume;
LUAD	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg24475210	chr4:6642433	MRFAP1	-0.38	-6.39	-0.3	4.5e-10	Subcortical brain region volumes;
LUAD	cis	rs77861329	0.800	rs6777340	chr3:52188308	T/C	cg08692210	chr3:52188851	WDR51A	0.55	6.93	0.32	1.54e-11	Macrophage inflammatory protein 1b levels;
LUAD	cis	rs4917300	0.605	rs7820768	chr8:143110823	C/T	cg25363559	chr8:143086065	NA	-0.46	-9.32	-0.41	6.59e-19	Amyotrophic lateral sclerosis;
LUAD	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-8.5	-0.38	3.25e-16	Neutrophil percentage of white cells;
LUAD	cis	rs9296092	0.500	rs9469503	chr6:33527234	G/T	cg13560919	chr6:33536144	NA	-0.9	-16.72	-0.63	1.49e-48	Age at smoking initiation in chronic obstructive pulmonary disease;
LUAD	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg13902645	chr11:5959945	NA	-0.58	-10.25	-0.45	3.76e-22	DNA methylation (variation);
LUAD	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21582582	chr3:182698605	DCUN1D1	0.59	10.06	0.44	1.73e-21	Intelligence (multi-trait analysis);
LUAD	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg11915388	chr22:42470451	FAM109B	-0.38	-7.05	-0.32	7.53e-12	Schizophrenia;
LUAD	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg11062466	chr8:58055876	NA	0.65	8.64	0.39	1.14e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg16006841	chr5:176797999	RGS14	0.58	8.54	0.38	2.42e-16	Urate levels in lean individuals;
LUAD	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg07917127	chr4:99064746	C4orf37	0.42	7.01	0.32	9.2e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9394169	0.875	rs1547670	chr6:33775868	G/A	cg07979401	chr6:33739406	LEMD2	-0.33	-6.39	-0.3	4.26e-10	Essential tremor;
LUAD	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18876405	chr7:65276391	NA	-0.42	-6.61	-0.31	1.14e-10	Aortic root size;
LUAD	cis	rs9914988	0.887	rs62066838	chr17:27184533	C/T	cg02049041	chr17:27085579	C17orf63	-0.59	-7.87	-0.36	2.9e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	trans	rs9354308	0.933	rs2814131	chr6:66562051	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.53	8.01	0.36	1.12e-14	Metabolite levels;
LUAD	cis	rs7089973	0.872	rs34064819	chr10:116621154	C/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.72	0.43	2.84e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUAD	cis	rs1881797	1.000	rs55852476	chr1:247696173	G/A	cg21399703	chr1:247681439	NA	0.44	7.95	0.36	1.76e-14	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg21918786	chr6:109611834	NA	-0.56	-10.34	-0.45	1.65e-22	Reticulocyte fraction of red cells;
LUAD	trans	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg21659725	chr3:3221576	CRBN	0.39	6.68	0.31	7.44e-11	Resting heart rate;
LUAD	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg00204512	chr16:28754710	NA	0.33	7.12	0.33	4.52e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg12379764	chr21:47803548	PCNT	0.61	10.82	0.47	3.09e-24	Testicular germ cell tumor;
LUAD	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg15997130	chr1:24165203	NA	0.55	9.5	0.42	1.54e-19	Immature fraction of reticulocytes;
LUAD	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg18477163	chr1:228402036	OBSCN	-0.37	-7.32	-0.34	1.25e-12	Diastolic blood pressure;
LUAD	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg06623918	chr6:96969491	KIAA0776	-0.71	-9.95	-0.44	4.12e-21	Migraine;Coronary artery disease;
LUAD	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05665937	chr4:1216051	CTBP1	-0.46	-7.02	-0.32	9.14e-12	Longevity;
LUAD	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg04154034	chr17:28927549	LRRC37B2	0.69	6.8	0.31	3.53e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs1160297	0.575	rs6725912	chr2:53097030	A/G	cg07782112	chr2:53107842	NA	0.41	8.89	0.4	1.83e-17	Hemostatic factors and hematological phenotypes;
LUAD	trans	rs9951602	0.512	rs9304070	chr18:76654890	A/C	cg02800362	chr5:177631904	HNRNPAB	0.86	13.86	0.56	2.76e-36	Obesity-related traits;
LUAD	cis	rs2839627	0.561	rs1107830	chr21:44275097	G/A	cg03543861	chr21:44258195	NA	0.66	9.68	0.43	3.65e-20	Information processing speed;
LUAD	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.14	-0.37	4.61e-15	Alzheimer's disease;
LUAD	cis	rs60154123	0.772	rs701942	chr1:210429392	C/G	cg22029157	chr1:209979665	IRF6	0.62	6.9	0.32	1.91e-11	Coronary artery disease;
LUAD	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg21823605	chr1:152486609	CRCT1	0.28	6.47	0.3	2.64e-10	Hair morphology;
LUAD	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg15017067	chr4:17643749	FAM184B	0.36	7.06	0.32	6.73e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08677398	chr8:58056175	NA	0.53	6.82	0.31	3.11e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg05042697	chr2:10830656	NOL10	-0.38	-6.57	-0.3	1.47e-10	Prostate cancer;
LUAD	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg24818145	chr4:99064322	C4orf37	0.47	8.06	0.36	8.09e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-10.92	-0.47	1.3e-24	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg06641503	chr3:48959341	ARIH2	-0.43	-8.35	-0.38	9.54e-16	Parkinson's disease;
LUAD	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg04287289	chr16:89883240	FANCA	0.83	7.33	0.34	1.2e-12	Skin colour saturation;
LUAD	cis	rs11971779	0.588	rs6972408	chr7:139071474	T/G	cg23387468	chr7:139079360	LUC7L2	0.29	6.76	0.31	4.63e-11	Diisocyanate-induced asthma;
LUAD	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg03929089	chr4:120376271	NA	-0.93	-17.53	-0.65	4.29e-52	Height;
LUAD	cis	rs657075	0.757	rs71583470	chr5:131643316	C/T	cg21138405	chr5:131827807	IRF1	0.51	6.44	0.3	3.34e-10	Rheumatoid arthritis;
LUAD	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg02176678	chr2:219576539	TTLL4	0.68	13.36	0.54	3.16e-34	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs7582720	1.000	rs72936847	chr2:203774748	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	9.45	0.42	2.26e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUAD	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg13789015	chr9:136890014	NCRNA00094	0.85	14.0	0.56	6.98e-37	Platelet distribution width;
LUAD	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.43	-6.88	-0.32	2.19e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUAD	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg17173187	chr15:85201210	NMB	0.41	6.56	0.3	1.61e-10	Schizophrenia;
LUAD	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg06544989	chr22:39130855	UNC84B	0.44	8.75	0.39	5.14e-17	Menopause (age at onset);
LUAD	cis	rs17155006	0.746	rs435744	chr7:107748549	A/G	cg05962710	chr7:107745446	LAMB4	-0.34	-7.31	-0.33	1.37e-12	Pneumococcal bacteremia;
LUAD	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg13560548	chr3:10150139	C3orf24	0.39	6.41	0.3	3.89e-10	Alzheimer's disease;
LUAD	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg04586622	chr2:25135609	ADCY3	0.36	8.18	0.37	3.41e-15	Body mass index;
LUAD	trans	rs703108	0.731	rs7898954	chr10:22323646	A/G	cg20707008	chr6:160210612	MRPL18;TCP1	0.43	6.52	0.3	1.95e-10	Monocyte percentage of white cells;
LUAD	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg12143784	chr7:64541923	NA	0.47	7.78	0.35	5.53e-14	Calcium levels;
LUAD	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg08632164	chr7:65971372	NA	-0.55	-6.47	-0.3	2.76e-10	Diabetic kidney disease;
LUAD	cis	rs72720396	0.694	rs6689362	chr1:91203251	T/A	cg13456504	chr1:91191583	NA	-0.43	-8.26	-0.37	1.82e-15	Morning vs. evening chronotype;Chronotype;
LUAD	cis	rs2445762	0.559	rs4774585	chr15:51616480	G/A	cg20344442	chr15:51633704	GLDN	0.53	9.15	0.41	2.45e-18	Hormone measurements;
LUAD	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg02466173	chr16:30829666	NA	-0.67	-12.15	-0.51	2.37e-29	Multiple myeloma;
LUAD	cis	rs684232	0.623	rs12601935	chr17:519325	G/A	cg15660573	chr17:549704	VPS53	-0.87	-17.95	-0.66	5.55e-54	Prostate cancer;
LUAD	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg05368731	chr17:41323189	NBR1	0.94	19.69	0.69	1.01e-61	Menopause (age at onset);
LUAD	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	7.41	0.34	6.76e-13	Tonsillectomy;
LUAD	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg17366294	chr4:99064904	C4orf37	0.67	12.87	0.53	3.34e-32	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg15448220	chr1:150897856	SETDB1	0.53	9.32	0.41	6.74e-19	Melanoma;
LUAD	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg02493740	chr2:85810744	VAMP5	0.63	11.87	0.5	3.04e-28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg06221963	chr1:154839813	KCNN3	-0.82	-18.9	-0.68	3.3e-58	Prostate cancer;
LUAD	cis	rs5756813	0.754	rs4821706	chr22:38154690	A/G	cg06521852	chr22:38141419	TRIOBP	0.5	9.25	0.41	1.15e-18	Optic cup area;Vertical cup-disc ratio;
LUAD	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	6.57	0.3	1.44e-10	Schizophrenia;
LUAD	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg21862992	chr11:68658383	NA	0.54	9.75	0.43	2.13e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUAD	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg13126279	chr21:47581558	C21orf56	-0.44	-7.44	-0.34	5.68e-13	Testicular germ cell tumor;
LUAD	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg11062466	chr8:58055876	NA	0.68	9.04	0.4	5.83e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg09165964	chr15:75287851	SCAMP5	-0.51	-7.52	-0.34	3.4e-13	Blood trace element (Zn levels);
LUAD	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.3	0.48	4.76e-26	Height;
LUAD	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg02775129	chr4:119771670	NA	-0.87	-8.2	-0.37	2.94e-15	Cannabis dependence symptom count;
LUAD	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.75	-10.35	-0.45	1.58e-22	Glomerular filtration rate in chronic kidney disease;
LUAD	cis	rs4638749	0.677	rs12475343	chr2:108851373	T/C	cg25838818	chr2:108905173	SULT1C2	-0.43	-7.53	-0.34	3.08e-13	Blood pressure;
LUAD	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg22535103	chr8:58192502	C8orf71	-0.75	-9.19	-0.41	1.85e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.94	-0.36	1.82e-14	Bipolar disorder and schizophrenia;
LUAD	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg25985355	chr7:65971099	NA	-0.54	-6.72	-0.31	5.89e-11	Diabetic kidney disease;
LUAD	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg11062466	chr8:58055876	NA	0.77	9.41	0.42	3.11e-19	Developmental language disorder (linguistic errors);
LUAD	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg04731861	chr2:219085781	ARPC2	-0.21	-6.48	-0.3	2.52e-10	Colorectal cancer;
LUAD	cis	rs7584330	0.518	rs74003104	chr2:238446823	C/T	cg14458575	chr2:238380390	NA	0.76	11.07	0.47	3.54e-25	Prostate cancer;
LUAD	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg11530693	chr1:120165357	ZNF697	0.86	18.56	0.67	1.09e-56	Systemic lupus erythematosus;
LUAD	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03264133	chr6:25882463	NA	-0.61	-8.75	-0.39	5.13e-17	Intelligence (multi-trait analysis);
LUAD	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22442454	chr1:209979470	IRF6	0.53	7.78	0.35	5.71e-14	Cleft lip with or without cleft palate;
LUAD	cis	rs4930561	0.677	rs7946212	chr11:67982187	T/A	cg04465784	chr11:67976953	SUV420H1	-0.34	-10.73	-0.46	6.49e-24	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUAD	cis	rs7254827	0.868	rs3745349	chr19:17212992	C/T	cg19418318	chr19:17219073	MYO9B	-0.55	-6.52	-0.3	2.03e-10	Mean platelet volume;
LUAD	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg21427119	chr20:30132790	HM13	-0.47	-7.0	-0.32	1.04e-11	Mean corpuscular hemoglobin;
LUAD	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg03433033	chr1:76189801	ACADM	0.76	11.71	0.49	1.25e-27	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg24558204	chr6:135376177	HBS1L	0.5	8.63	0.39	1.23e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUAD	cis	rs7851660	0.809	rs7034648	chr9:100654093	C/A	cg13688889	chr9:100608707	NA	-0.54	-9.08	-0.4	4.17e-18	Strep throat;
LUAD	cis	rs6500395	1.000	rs1362636	chr16:48712779	T/C	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11644478	chr21:40555479	PSMG1	0.7	11.8	0.5	5.71e-28	Cognitive function;
LUAD	trans	rs360929	0.511	rs360942	chr4:152855407	G/T	cg22822647	chr19:16771056	TMEM38A;C19orf42	-0.52	-7.01	-0.32	9.56e-12	Volumetric brain MRI;
LUAD	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg11494091	chr17:61959527	GH2	-0.8	-21.61	-0.72	2.52e-70	Prudent dietary pattern;
LUAD	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg14664628	chr15:75095509	CSK	-0.61	-9.89	-0.43	6.69e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUAD	cis	rs3736594	0.513	rs62138971	chr2:27840754	G/A	cg27432699	chr2:27873401	GPN1	0.45	6.47	0.3	2.79e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUAD	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg25173405	chr17:45401733	C17orf57	0.45	7.77	0.35	5.97e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUAD	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg07404485	chr7:94953653	PON1	-0.49	-7.05	-0.32	7.28e-12	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs9658691	0.607	rs12411483	chr10:90780910	G/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.58	-7.21	-0.33	2.64e-12	Mosquito bite size;
LUAD	cis	rs2455799	0.613	rs9848007	chr3:15852593	T/A	cg16303742	chr3:15540471	COLQ	-0.49	-9.15	-0.41	2.52e-18	Mean platelet volume;
LUAD	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.39	-6.37	-0.3	4.94e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs6445967	0.530	rs4273385	chr3:58452867	C/G	cg23715586	chr3:58305044	RPP14	0.39	6.38	0.3	4.54e-10	Platelet count;
LUAD	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg22166914	chr1:53195759	ZYG11B	0.42	6.8	0.31	3.51e-11	Monocyte count;
LUAD	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg15128208	chr22:42549153	NA	-0.35	-6.81	-0.31	3.36e-11	Cognitive function;
LUAD	cis	rs6901250	0.819	rs9374623	chr6:117127312	C/A	cg12892004	chr6:117198278	RFX6	0.34	7.18	0.33	3.07e-12	C-reactive protein levels;
LUAD	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.87	-0.32	2.34e-11	Type 2 diabetes;
LUAD	cis	rs68170813	0.599	rs11769901	chr7:106958505	G/A	cg02696742	chr7:106810147	HBP1	-0.76	-10.41	-0.45	9.42e-23	Coronary artery disease;
LUAD	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg12193833	chr17:30244370	NA	-0.58	-7.03	-0.32	8.14e-12	Hip circumference adjusted for BMI;
LUAD	cis	rs1395	0.778	rs12465084	chr2:27414203	G/C	cg23587288	chr2:27483067	SLC30A3	-0.42	-7.84	-0.36	3.81e-14	Blood metabolite levels;
LUAD	cis	rs62238980	0.614	rs80148383	chr22:32513717	A/C	cg00543991	chr22:32367038	NA	0.88	8.51	0.38	3.06e-16	Childhood ear infection;
LUAD	cis	rs62400317	0.893	rs62436782	chr6:45143118	T/A	cg18551225	chr6:44695536	NA	-0.53	-8.39	-0.38	7.22e-16	Total body bone mineral density;
LUAD	cis	rs9323205	1.000	rs9323205	chr14:51586467	A/G	cg23942311	chr14:51606299	NA	-0.57	-8.94	-0.4	1.21e-17	Cancer;
LUAD	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg03714773	chr7:91764589	CYP51A1	-0.29	-6.82	-0.31	3.13e-11	Breast cancer;
LUAD	cis	rs754466	0.651	rs11002322	chr10:79649653	G/T	cg17075019	chr10:79541650	NA	-0.85	-17.25	-0.64	6.89e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg20362242	chr5:692897	TPPP	0.59	7.27	0.33	1.78e-12	Lung disease severity in cystic fibrosis;
LUAD	cis	rs7731657	0.537	rs13182786	chr5:130246400	T/C	cg08523029	chr5:130500466	HINT1	0.59	7.72	0.35	8.68e-14	Fasting plasma glucose;
LUAD	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg24818145	chr4:99064322	C4orf37	0.45	7.69	0.35	1.03e-13	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg18512352	chr11:47633146	NA	0.47	8.16	0.37	3.85e-15	Subjective well-being;
LUAD	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg04369109	chr6:150039330	LATS1	0.45	7.65	0.35	1.42e-13	Lung cancer;
LUAD	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.5	0.3	2.25e-10	Depression;
LUAD	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg13263323	chr15:86062960	AKAP13	-0.48	-8.92	-0.4	1.44e-17	Coronary artery disease;
LUAD	cis	rs11126435	0.858	rs13022193	chr2:74933622	T/G	cg19285774	chr2:74907978	SEMA4F	0.36	6.4	0.3	4.14e-10	Age-related hearing impairment (SNP x SNP interaction);
LUAD	cis	rs7264396	0.515	rs2425134	chr20:34339439	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.91	-0.36	2.32e-14	Total cholesterol levels;
LUAD	cis	rs2629540	1.000	rs2629540	chr10:126426148	G/C	cg08799069	chr10:126477246	METTL10	0.48	6.71	0.31	6.19e-11	Cocaine dependence;
LUAD	cis	rs2115630	0.967	rs28595395	chr15:85334952	T/C	cg11189052	chr15:85197271	WDR73	-0.61	-9.8	-0.43	1.46e-20	P wave terminal force;
LUAD	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18876405	chr7:65276391	NA	-0.45	-7.21	-0.33	2.53e-12	Aortic root size;
LUAD	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg12863693	chr15:85201151	NMB	-0.31	-6.51	-0.3	2.16e-10	P wave terminal force;
LUAD	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg09117114	chr16:67998030	SLC12A4	-0.56	-7.51	-0.34	3.47e-13	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7737355	0.738	rs55955246	chr5:131078498	C/G	cg06307176	chr5:131281290	NA	0.48	7.94	0.36	1.82e-14	Life satisfaction;
LUAD	cis	rs15676	0.783	rs2977998	chr9:131580570	A/G	cg00228799	chr9:131580591	ENDOG	0.5	8.03	0.36	9.58e-15	Blood metabolite levels;
LUAD	cis	rs2286503	0.752	rs59538378	chr7:22877097	G/A	cg06496272	chr7:22895283	SNORD93	-0.38	-6.51	-0.3	2.09e-10	Fibrinogen;
LUAD	cis	rs4713675	0.584	rs3818527	chr6:33661035	A/G	cg13859433	chr6:33739653	LEMD2	0.29	6.83	0.32	2.97e-11	Plateletcrit;
LUAD	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22968622	chr17:43663579	NA	0.94	16.27	0.62	1.38e-46	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	trans	rs1325195	0.920	rs2816170	chr1:179214726	G/A	cg11624085	chr17:8464688	MYH10	0.41	6.43	0.3	3.5e-10	IgE grass sensitization;
LUAD	cis	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.54	-7.47	-0.34	4.63e-13	Lymphocyte counts;Red cell distribution width;
LUAD	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg09904177	chr6:26538194	HMGN4	0.43	7.28	0.33	1.69e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg12179176	chr11:130786555	SNX19	0.47	7.63	0.35	1.58e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs9581857	0.685	rs12584061	chr13:28024544	C/T	cg22138327	chr13:27999177	GTF3A	0.82	9.78	0.43	1.73e-20	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUAD	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg13685155	chr2:88473871	THNSL2	-0.5	-6.44	-0.3	3.3e-10	Plasma clusterin levels;
LUAD	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg18180107	chr4:99064573	C4orf37	0.41	6.58	0.3	1.37e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1044826	0.642	rs7624321	chr3:139220159	C/A	cg00490450	chr3:139108681	COPB2	0.4	6.42	0.3	3.59e-10	Obesity-related traits;
LUAD	cis	rs4888378	0.535	rs9319483	chr16:75345791	T/C	cg03315344	chr16:75512273	CHST6	-0.43	-7.81	-0.36	4.51e-14	Coronary artery disease;
LUAD	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg00071950	chr4:10020882	SLC2A9	-0.61	-11.85	-0.5	3.58e-28	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs3752645	1.000	rs7786692	chr7:106730033	A/C	cg02696742	chr7:106810147	HBP1	-0.66	-6.7	-0.31	6.73e-11	Bladder cancer (smoking interaction);
LUAD	cis	rs9322817	0.691	rs2499663	chr6:105300570	A/G	cg02098413	chr6:105308735	HACE1	-0.41	-8.85	-0.4	2.5e-17	Thyroid stimulating hormone;
LUAD	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.56	7.59	0.35	2.13e-13	Renal function-related traits (BUN);
LUAD	trans	rs7542767	1.000	rs12047423	chr1:184317964	C/T	cg20099968	chr4:1364147	KIAA1530	0.53	6.39	0.3	4.45e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.19	0.33	2.9e-12	Personality dimensions;
LUAD	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18099408	chr3:52552593	STAB1	-0.47	-8.22	-0.37	2.45e-15	Bipolar disorder;
LUAD	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg25985355	chr7:65971099	NA	-0.53	-6.62	-0.31	1.09e-10	Diabetic kidney disease;
LUAD	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg15017067	chr4:17643749	FAM184B	0.36	7.07	0.33	6.33e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg00277334	chr10:82204260	NA	-0.52	-8.58	-0.38	1.85e-16	Post bronchodilator FEV1;
LUAD	cis	rs2816062	0.760	rs2244192	chr1:18890939	A/T	cg18795169	chr1:18902165	NA	-0.94	-22.39	-0.74	8.19e-74	Urate levels in lean individuals;
LUAD	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg20607798	chr8:58055168	NA	0.67	8.85	0.4	2.4e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg02631126	chr6:28058918	ZSCAN12L1	0.38	7.81	0.35	4.6e-14	Depression;
LUAD	cis	rs490234	0.719	rs13296519	chr9:128471924	G/T	cg14078157	chr9:128172775	NA	-0.44	-7.93	-0.36	2e-14	Mean arterial pressure;
LUAD	cis	rs7568458	0.837	rs12714145	chr2:85787341	C/T	cg02493740	chr2:85810744	VAMP5	-0.43	-7.71	-0.35	8.9e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUAD	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg18131467	chr2:239335373	ASB1	0.56	8.89	0.4	1.75e-17	Multiple system atrophy;
LUAD	cis	rs55823223	0.618	rs72860390	chr17:73869914	A/G	cg09253696	chr17:73873529	TRIM47	-0.5	-8.43	-0.38	5.41e-16	Psoriasis;
LUAD	cis	rs4523957	0.583	rs2641443	chr17:2036162	G/A	cg16513277	chr17:2031491	SMG6	-0.98	-19.94	-0.7	7.73e-63	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs10905065	0.829	rs6602278	chr10:5868361	A/G	cg11519256	chr10:5708881	ASB13	-0.39	-6.54	-0.3	1.74e-10	Menopause (age at onset);
LUAD	cis	rs62458065	0.850	rs28693551	chr7:32469387	G/A	cg20159608	chr7:32802032	NA	-0.58	-7.7	-0.35	9.47e-14	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg04568274	chr7:158649319	WDR60	-0.44	-6.82	-0.31	3.16e-11	Height;
LUAD	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-6.73	-0.31	5.61e-11	Fear of minor pain;
LUAD	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg08916839	chr5:415575	AHRR	0.85	9.77	0.43	1.88e-20	Fat distribution (HIV);
LUAD	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg07606381	chr6:8435919	SLC35B3	0.43	7.21	0.33	2.67e-12	Motion sickness;
LUAD	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg05340658	chr4:99064831	C4orf37	0.46	7.05	0.32	7.26e-12	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg15181151	chr6:150070149	PCMT1	0.39	7.99	0.36	1.31e-14	Lung cancer;
LUAD	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg11502198	chr6:26597334	ABT1	0.54	9.1	0.4	3.68e-18	Intelligence (multi-trait analysis);
LUAD	cis	rs6761276	0.780	rs12477867	chr2:113835919	C/A	cg10479672	chr2:113810641	IL1F8	-0.38	-7.65	-0.35	1.39e-13	Protein quantitative trait loci;
LUAD	cis	rs12431939	0.598	rs12437085	chr14:51728941	G/T	cg23942311	chr14:51606299	NA	0.46	7.13	0.33	4.33e-12	Cancer;
LUAD	cis	rs2657888	0.628	rs7314242	chr12:56876372	C/A	cg23002907	chr12:56915593	RBMS2	-0.39	-6.97	-0.32	1.26e-11	Adiponectin levels;
LUAD	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg02734326	chr4:10020555	SLC2A9	-0.44	-7.57	-0.35	2.42e-13	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs4604732	0.536	rs76191272	chr1:247628055	A/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.41	7.1	0.33	5.32e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUAD	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg18198730	chr1:247681584	NA	0.44	7.62	0.35	1.71e-13	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg17863274	chr19:49399704	TULP2	-0.66	-10.02	-0.44	2.43e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg01324343	chr3:183735012	ABCC5	0.97	26.5	0.79	6.32e-92	Anterior chamber depth;
LUAD	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg17147758	chr8:6949321	NA	-0.5	-8.97	-0.4	9.59e-18	Blood pressure (smoking interaction);
LUAD	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.33	-8.33	-0.38	1.15e-15	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUAD	cis	rs11048434	0.736	rs933462	chr12:9103665	T/G	cg04155231	chr12:9217510	LOC144571	0.39	7.38	0.34	8.48e-13	Sjögren's syndrome;
LUAD	cis	rs6840360	0.550	rs4696288	chr4:152621150	A/C	cg22705602	chr4:152727874	NA	-0.48	-8.37	-0.38	8.41e-16	Intelligence (multi-trait analysis);
LUAD	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg19626725	chr5:178986131	RUFY1	0.51	8.21	0.37	2.76e-15	Lung cancer;
LUAD	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg12311346	chr5:56204834	C5orf35	-0.92	-13.71	-0.55	1.22e-35	Initial pursuit acceleration;
LUAD	trans	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg14917512	chr19:3094685	GNA11	-0.56	-6.66	-0.31	8.33e-11	Diabetic kidney disease;
LUAD	cis	rs977987	0.806	rs4888386	chr16:75389740	A/G	cg03315344	chr16:75512273	CHST6	0.64	13.82	0.56	4.01e-36	Dupuytren's disease;
LUAD	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06544989	chr22:39130855	UNC84B	0.44	8.19	0.37	3.06e-15	Menopause (age at onset);
LUAD	trans	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.07	-27.41	-0.8	7.69e-96	Coffee consumption;Coffee consumption (cups per day);
LUAD	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg21724239	chr8:58056113	NA	0.73	9.56	0.42	9.75e-20	Developmental language disorder (linguistic errors);
LUAD	cis	rs6500395	0.889	rs2080507	chr16:48688634	T/A	cg04672837	chr16:48644449	N4BP1	-0.39	-6.82	-0.31	3.17e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs1595825	0.891	rs75373125	chr2:198657044	G/A	cg11031976	chr2:198649780	BOLL	-0.48	-6.54	-0.3	1.74e-10	Ulcerative colitis;
LUAD	cis	rs12545109	0.837	rs4738500	chr8:57356193	G/A	cg19413350	chr8:57351067	NA	-0.47	-6.97	-0.32	1.22e-11	Obesity-related traits;
LUAD	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21582582	chr3:182698605	DCUN1D1	0.49	8.07	0.37	7.15e-15	Intelligence (multi-trait analysis);
LUAD	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18404041	chr3:52824283	ITIH1	-0.6	-12.47	-0.52	1.32e-30	Electroencephalogram traits;
LUAD	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg06046430	chr4:77819534	ANKRD56	0.54	8.67	0.39	9.09e-17	Emphysema distribution in smoking;
LUAD	cis	rs89107	0.603	rs387945	chr6:118613313	G/A	cg21191810	chr6:118973309	C6orf204	0.53	10.58	0.46	2.32e-23	Cardiac structure and function;
LUAD	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg14949292	chr17:78079608	GAA	-0.35	-6.49	-0.3	2.45e-10	Yeast infection;
LUAD	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg01802117	chr1:53393560	SCP2	-0.35	-7.0	-0.32	1.01e-11	Monocyte count;
LUAD	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg09658497	chr7:2847517	GNA12	-0.52	-8.63	-0.39	1.25e-16	Height;
LUAD	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg07917127	chr4:99064746	C4orf37	-0.42	-6.9	-0.32	1.94e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73086581	1.000	rs73084594	chr20:3916380	T/G	cg02187196	chr20:3869020	PANK2	0.48	6.73	0.31	5.49e-11	Response to antidepressants in depression;
LUAD	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.33	6.85	0.32	2.66e-11	Depression;
LUAD	cis	rs1448094	0.933	rs10779218	chr12:86320053	A/G	cg06740227	chr12:86229804	RASSF9	0.36	6.59	0.31	1.33e-10	Major depressive disorder;
LUAD	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg10589385	chr1:150898437	SETDB1	0.45	8.36	0.38	8.84e-16	Melanoma;
LUAD	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg18135555	chr8:22132992	PIWIL2	0.42	7.61	0.35	1.81e-13	Hypertriglyceridemia;
LUAD	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.71	-0.31	6.2e-11	Neuroticism;
LUAD	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg18944383	chr4:111397179	ENPEP	0.39	7.83	0.36	3.87e-14	Height;
LUAD	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06022373	chr22:39101656	GTPBP1	0.46	7.21	0.33	2.53e-12	Menopause (age at onset);
LUAD	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg22875332	chr1:76189707	ACADM	0.77	15.57	0.6	1.57e-43	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg26384229	chr12:38710491	ALG10B	-0.39	-6.65	-0.31	8.8e-11	Drug-induced liver injury (flucloxacillin);
LUAD	cis	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg21775007	chr8:11205619	TDH	0.55	9.98	0.44	3.43e-21	Retinal vascular caliber;
LUAD	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg05340658	chr4:99064831	C4orf37	0.53	9.05	0.4	5.17e-18	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs2179367	0.881	rs2744432	chr6:149743871	A/C	cg03678062	chr6:149772716	ZC3H12D	0.32	6.65	0.31	9.01e-11	Dupuytren's disease;
LUAD	trans	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.76	13.67	0.55	1.69e-35	Mean corpuscular volume;
LUAD	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg25985355	chr7:65971099	NA	0.53	6.6	0.31	1.24e-10	Diabetic kidney disease;
LUAD	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg05805236	chr11:65401703	PCNXL3	-0.48	-7.99	-0.36	1.27e-14	Non-alcoholic fatty liver disease histology (lobular);
LUAD	cis	rs870825	0.616	rs28579226	chr4:185650458	A/C	cg04058563	chr4:185651563	MLF1IP	0.9	14.58	0.58	2.63e-39	Blood protein levels;
LUAD	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg26384229	chr12:38710491	ALG10B	0.46	7.48	0.34	4.31e-13	Bladder cancer;
LUAD	cis	rs2880765	0.743	rs4551990	chr15:86015287	A/C	cg13263323	chr15:86062960	AKAP13	-0.48	-8.66	-0.39	1.04e-16	Coronary artery disease;
LUAD	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg02887458	chr19:19495540	GATAD2A	-0.41	-6.58	-0.3	1.41e-10	Bipolar disorder;
LUAD	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg11766577	chr21:47581405	C21orf56	-0.46	-7.48	-0.34	4.33e-13	Testicular germ cell tumor;
LUAD	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg16325326	chr1:53192061	ZYG11B	-0.68	-12.6	-0.52	3.83e-31	Monocyte count;
LUAD	trans	rs9354308	0.899	rs2802057	chr6:66548093	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.52	8.07	0.37	7.58e-15	Metabolite levels;
LUAD	cis	rs6964587	0.621	rs39744	chr7:92043016	A/G	cg17063962	chr7:91808500	NA	0.59	9.94	0.44	4.74e-21	Breast cancer;
LUAD	trans	rs12517041	1.000	rs1593966	chr5:23313785	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.48	-6.75	-0.31	4.91e-11	Calcium levels;
LUAD	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg04025307	chr7:1156635	C7orf50	0.65	7.4	0.34	7.59e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs686320	1.000	rs35940245	chr11:65232673	G/A	cg21890820	chr11:65308645	LTBP3	0.77	8.48	0.38	3.9e-16	Hip circumference adjusted for BMI;
LUAD	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg18180107	chr4:99064573	C4orf37	0.4	6.44	0.3	3.27e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs73206853	0.841	rs4131850	chr12:110812553	G/A	cg12870014	chr12:110450643	ANKRD13A	0.61	6.72	0.31	6.02e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-8.95	-0.4	1.16e-17	Gut microbiome composition (summer);
LUAD	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg06096015	chr1:231504339	EGLN1	0.34	6.41	0.3	3.96e-10	Hemoglobin concentration;
LUAD	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg08048268	chr3:133502702	NA	0.42	7.87	0.36	3.06e-14	Iron status biomarkers;
LUAD	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg10755058	chr3:40428713	ENTPD3	0.38	7.43	0.34	6.02e-13	Renal cell carcinoma;
LUAD	cis	rs7119038	0.818	rs10892289	chr11:118646003	C/T	cg19308663	chr11:118741387	NA	0.48	6.75	0.31	4.95e-11	Sjögren's syndrome;
LUAD	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.81	-0.36	4.51e-14	Total body bone mineral density;
LUAD	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg05042697	chr2:10830656	NOL10	-0.38	-6.56	-0.3	1.56e-10	Prostate cancer;
LUAD	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg24399712	chr22:39784796	NA	-0.79	-15.43	-0.6	6.47e-43	Intelligence (multi-trait analysis);
LUAD	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg03676636	chr4:99064102	C4orf37	0.27	6.8	0.31	3.61e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg07776626	chr8:57350775	NA	-0.62	-8.87	-0.4	2.04e-17	Obesity-related traits;
LUAD	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg09835421	chr16:68378352	PRMT7	-0.81	-8.44	-0.38	5.26e-16	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg04154034	chr17:28927549	LRRC37B2	-0.61	-6.72	-0.31	5.8e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUAD	cis	rs8062405	0.688	rs3924376	chr16:28925978	T/C	cg05966235	chr16:28915196	ATP2A1	-0.57	-8.97	-0.4	9.8e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg13722127	chr7:150037890	RARRES2	0.44	7.4	0.34	7.47e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg26338869	chr17:61819248	STRADA	-0.39	-6.46	-0.3	2.86e-10	Prudent dietary pattern;
LUAD	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg04398451	chr17:18023971	MYO15A	0.8	15.12	0.59	1.38e-41	Total body bone mineral density;
LUAD	cis	rs73206853	0.841	rs73191819	chr12:110920182	C/T	cg12870014	chr12:110450643	ANKRD13A	0.62	7.05	0.32	7.22e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUAD	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg25358565	chr5:93447407	FAM172A	0.61	7.65	0.35	1.4e-13	Diabetic retinopathy;
LUAD	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg10544611	chr16:67998164	SLC12A4	-0.55	-6.94	-0.32	1.47e-11	HDL cholesterol;Metabolic syndrome;
LUAD	cis	rs7095607	0.785	rs3956957	chr10:69919445	A/T	cg18986048	chr10:69913749	MYPN	0.38	6.41	0.3	3.93e-10	Lung function (FVC);
LUAD	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.36	7.05	0.32	7.47e-12	Depression;
LUAD	cis	rs68170813	0.559	rs4515482	chr7:107072681	A/C	cg23024343	chr7:107201750	COG5	0.47	6.81	0.31	3.39e-11	Coronary artery disease;
LUAD	cis	rs7773004	1.000	rs1155207	chr6:26328365	A/G	cg00631329	chr6:26305371	NA	-0.52	-9.11	-0.41	3.22e-18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUAD	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg27454412	chr7:1067447	C7orf50	0.44	7.0	0.32	9.96e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg06784218	chr1:46089804	CCDC17	0.5	11.15	0.48	1.76e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03670158	chr17:41323431	NBR1	-0.45	-7.18	-0.33	3.18e-12	Height;
LUAD	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.52	-10.66	-0.46	1.18e-23	Monocyte percentage of white cells;
LUAD	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg21475434	chr5:93447410	FAM172A	0.77	8.64	0.39	1.13e-16	Diabetic retinopathy;
LUAD	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg21918786	chr6:109611834	NA	-0.58	-10.65	-0.46	1.24e-23	Reticulocyte fraction of red cells;
LUAD	cis	rs4523957	0.583	rs2641438	chr17:2017786	C/G	cg16513277	chr17:2031491	SMG6	-0.95	-19.21	-0.68	1.41e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-9.46	-0.42	2.11e-19	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg18404041	chr3:52824283	ITIH1	0.41	7.53	0.34	3e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg11301795	chr4:187892539	NA	-0.76	-14.5	-0.58	5.67e-39	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	13.23	0.54	1.13e-33	Lymphocyte counts;
LUAD	cis	rs7252981	0.632	rs11878202	chr19:19744079	T/C	cg11584989	chr19:19387371	SF4	-0.48	-7.79	-0.35	5.29e-14	Perceived unattractiveness to mosquitoes;
LUAD	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.65	-0.31	9.16e-11	Developmental language disorder (linguistic errors);
LUAD	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03517284	chr6:25882590	NA	-0.58	-9.56	-0.42	1.02e-19	Blood metabolite levels;
LUAD	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06541857	chr3:134203789	ANAPC13;CEP63	0.37	6.45	0.3	3.14e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg08807101	chr21:30365312	RNF160	0.52	8.95	0.4	1.12e-17	Dental caries;
LUAD	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03517284	chr6:25882590	NA	0.85	14.08	0.56	3.34e-37	Blood metabolite levels;
LUAD	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg15017067	chr4:17643749	FAM184B	0.34	6.62	0.31	1.08e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg25985355	chr7:65971099	NA	-0.37	-6.73	-0.31	5.45e-11	Aortic root size;
LUAD	cis	rs2880765	0.835	rs4340287	chr15:86043737	A/G	cg13263323	chr15:86062960	AKAP13	-0.5	-9.26	-0.41	1.07e-18	Coronary artery disease;
LUAD	cis	rs11051970	0.655	rs10771942	chr12:32528488	G/A	cg24626660	chr12:32551988	NA	0.33	6.79	0.31	3.85e-11	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs25645	0.823	rs12453334	chr17:38153473	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.75	16.0	0.61	2.09e-45	Myeloid white cell count;
LUAD	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg24818145	chr4:99064322	C4orf37	0.48	8.12	0.37	5.01e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg18721089	chr20:30220636	NA	-0.5	-7.09	-0.33	5.77e-12	Mean corpuscular hemoglobin;
LUAD	cis	rs4243830	0.737	rs4908926	chr1:6617041	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.79	-9.88	-0.43	7.48e-21	Body mass index;
LUAD	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.72	-14.86	-0.59	1.78e-40	Urate levels in overweight individuals;
LUAD	cis	rs1395	0.767	rs1821986	chr2:27405835	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.44	-8.28	-0.37	1.67e-15	Blood metabolite levels;
LUAD	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg09455208	chr3:40491958	NA	0.64	14.25	0.57	6.5e-38	Renal cell carcinoma;
LUAD	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg16797656	chr11:68205561	LRP5	0.44	8.39	0.38	7.31e-16	Total body bone mineral density;
LUAD	trans	rs783540	0.967	rs783526	chr15:83285795	C/A	cg18393722	chr15:85113863	UBE2QP1	-0.45	-7.24	-0.33	2.07e-12	Schizophrenia;
LUAD	cis	rs4743820	0.651	rs4237213	chr9:93932708	A/T	cg14446406	chr9:93919335	NA	-0.5	-8.58	-0.38	1.87e-16	Ulcerative colitis;Inflammatory bowel disease;
LUAD	trans	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg06606381	chr12:133084897	FBRSL1	1.03	10.12	0.44	1.04e-21	Autism spectrum disorder or schizophrenia;
LUAD	trans	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg26043149	chr18:55253948	FECH	-0.42	-6.88	-0.32	2.14e-11	Cleft plate (environmental tobacco smoke interaction);
LUAD	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.6	7.33	0.34	1.19e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.4	-6.62	-0.31	1.11e-10	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg19442545	chr10:75533431	FUT11	-0.47	-7.7	-0.35	1e-13	Inflammatory bowel disease;
LUAD	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg25358565	chr5:93447407	FAM172A	0.66	7.83	0.36	3.92e-14	Diabetic retinopathy;
LUAD	cis	rs11924390	0.789	rs822366	chr3:186452490	A/G	cg12454167	chr3:186435060	KNG1	0.4	8.34	0.38	1.09e-15	Adiponectin levels;
LUAD	cis	rs9308433	0.529	rs9430131	chr1:214481121	C/A	cg06198575	chr1:214491504	SMYD2	0.46	7.87	0.36	3.08e-14	IgG glycosylation;
LUAD	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg06092702	chr1:163392909	NA	-0.4	-8.7	-0.39	7.29e-17	Motion sickness;
LUAD	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg05340658	chr4:99064831	C4orf37	0.55	9.47	0.42	2.07e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg00677455	chr12:58241039	CTDSP2	0.46	7.74	0.35	7.49e-14	Multiple sclerosis;
LUAD	cis	rs4523957	0.820	rs2209073	chr17:2205664	G/A	cg16513277	chr17:2031491	SMG6	0.72	13.31	0.54	5.22e-34	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs6835098	0.924	rs7672108	chr4:174165126	A/G	cg08422745	chr4:174089978	GALNT7	0.82	14.61	0.58	1.98e-39	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs6494488	0.500	rs72742921	chr15:64855556	G/A	cg08069370	chr15:64387884	SNX1	-0.76	-6.77	-0.31	4.45e-11	Coronary artery disease;
LUAD	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg02240030	chr7:2089880	MAD1L1	0.34	6.65	0.31	8.98e-11	Neuroticism;
LUAD	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg08632164	chr7:65971372	NA	-0.38	-6.61	-0.31	1.13e-10	Aortic root size;
LUAD	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg13902645	chr11:5959945	NA	-0.51	-8.96	-0.4	1.04e-17	DNA methylation (variation);
LUAD	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08219700	chr8:58056026	NA	0.61	8.58	0.38	1.87e-16	Developmental language disorder (linguistic errors);
LUAD	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.66	9.24	0.41	1.19e-18	Gut microbiome composition (summer);
LUAD	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg15900387	chr1:150738905	CTSS	-0.38	-6.97	-0.32	1.21e-11	Melanoma;
LUAD	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.38	6.44	0.3	3.19e-10	Resistin levels;
LUAD	trans	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg06606381	chr12:133084897	FBRSL1	-0.68	-7.09	-0.33	5.49e-12	Autism spectrum disorder or schizophrenia;
LUAD	cis	rs7216064	0.953	rs8073510	chr17:65839210	A/G	cg08758996	chr17:66097529	LOC651250	0.45	7.01	0.32	9.72e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUAD	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg18230493	chr5:56204884	C5orf35	0.44	7.39	0.34	8.13e-13	Coronary artery disease;
LUAD	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.35	-6.91	-0.32	1.74e-11	Crohn's disease;
LUAD	cis	rs12618769	0.597	rs4850874	chr2:99069799	G/A	cg10123293	chr2:99228465	UNC50	0.48	8.74	0.39	5.46e-17	Bipolar disorder;
LUAD	cis	rs10504073	0.647	rs6997703	chr8:49998364	T/C	cg00325661	chr8:49890786	NA	0.45	10.2	0.44	5.35e-22	Blood metabolite ratios;
LUAD	cis	rs55665837	1.000	rs10466412	chr11:14505189	A/T	cg19336497	chr11:14380999	RRAS2	-0.5	-10.09	-0.44	1.39e-21	Vitamin D levels;
LUAD	cis	rs3760982	0.565	rs8104300	chr19:44293144	T/C	cg11993925	chr19:44307056	LYPD5	0.57	11.75	0.5	9e-28	Breast cancer (estrogen-receptor negative);Breast cancer;
LUAD	cis	rs7593730	0.636	rs10181181	chr2:161087411	C/T	cg22609984	chr2:161126801	NA	-0.54	-9.99	-0.44	3.06e-21	Type 2 diabetes;
LUAD	cis	rs11048434	0.698	rs7300767	chr12:9123477	T/G	cg13575925	chr12:9217583	LOC144571	0.37	6.76	0.31	4.45e-11	Sjögren's syndrome;
LUAD	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg18876405	chr7:65276391	NA	0.62	10.82	0.47	2.92e-24	Aortic root size;
LUAD	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg14895029	chr7:2775587	GNA12	-0.4	-6.43	-0.3	3.5e-10	Height;
LUAD	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-12.92	-0.53	1.96e-32	Breast cancer;
LUAD	cis	rs9287719	0.674	rs6432130	chr2:10821557	T/C	cg03983476	chr2:10830698	NOL10	0.39	6.65	0.31	8.85e-11	Prostate cancer;
LUAD	cis	rs1832871	0.672	rs11751081	chr6:158761505	G/A	cg07165851	chr6:158734300	TULP4	0.72	10.97	0.47	8.3e-25	Height;
LUAD	cis	rs7771547	0.603	rs9296193	chr6:36601456	C/G	cg07856975	chr6:36356162	ETV7	-0.52	-7.14	-0.33	4.09e-12	Platelet distribution width;
LUAD	cis	rs4144027	0.904	rs10438244	chr14:104346185	A/G	cg12183467	chr14:104352244	NA	-0.37	-7.25	-0.33	2.02e-12	Blood metabolite levels;
LUAD	trans	rs10822407	0.589	rs10822472	chr10:66910330	A/G	cg00419759	chr1:114301964	PHTF1	0.46	7.15	0.33	3.86e-12	Diastolic blood pressure;
LUAD	trans	rs9299346	0.594	rs12348469	chr9:104434576	A/T	cg08137080	chr1:16482430	EPHA2	0.38	7.19	0.33	3.04e-12	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
LUAD	cis	rs8014671	0.597	rs1044527	chr14:70833819	C/G	cg25576086	chr14:70833871	SYNJ2BP	-0.38	-8.87	-0.4	2.14e-17	Prostate cancer;
LUAD	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg17747265	chr1:1875780	NA	-0.75	-18.62	-0.67	5.85e-57	Body mass index;
LUAD	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg21823605	chr1:152486609	CRCT1	0.28	6.59	0.31	1.3e-10	Hair morphology;
LUAD	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg14024328	chr4:719362	PCGF3	-0.54	-8.84	-0.39	2.68e-17	White blood cell count;
LUAD	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg12311346	chr5:56204834	C5orf35	0.72	11.41	0.49	1.75e-26	Initial pursuit acceleration;
LUAD	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg18105139	chr6:28058856	ZSCAN12L1	0.28	6.45	0.3	2.98e-10	Depression;
LUAD	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-6.59	-0.31	1.33e-10	Intelligence (multi-trait analysis);
LUAD	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg05110241	chr16:68378359	PRMT7	-0.7	-7.99	-0.36	1.26e-14	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
LUAD	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg19678392	chr7:94953810	PON1	-0.59	-8.27	-0.37	1.72e-15	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg17063962	chr7:91808500	NA	0.69	12.37	0.52	3.18e-30	Breast cancer;
LUAD	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.4	6.35	0.3	5.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUAD	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg10792982	chr14:105748885	BRF1	0.45	9.39	0.42	3.67e-19	Mean platelet volume;Platelet distribution width;
LUAD	trans	rs79911532	0.515	rs111356249	chr7:75716527	A/G	cg19862616	chr7:65841803	NCRNA00174	0.82	8.47	0.38	4e-16	Mononucleosis;
LUAD	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg23887609	chr12:130822674	PIWIL1	-0.45	-7.34	-0.34	1.1e-12	Menopause (age at onset);
LUAD	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg09085632	chr11:111637200	PPP2R1B	0.63	9.58	0.42	8.24e-20	Primary sclerosing cholangitis;
LUAD	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg26441486	chr22:50317300	CRELD2	0.44	6.67	0.31	8.26e-11	Schizophrenia;
LUAD	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg16205897	chr5:131564050	P4HA2	-0.3	-6.77	-0.31	4.34e-11	Breast cancer;
LUAD	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg26384229	chr12:38710491	ALG10B	-0.49	-7.96	-0.36	1.63e-14	Bladder cancer;
LUAD	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg21854759	chr1:92012499	NA	0.48	6.73	0.31	5.54e-11	Eosinophil percentage of white cells;
LUAD	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg19336497	chr11:14380999	RRAS2	-0.66	-14.11	-0.57	2.48e-37	Sense of smell;
LUAD	cis	rs10392	0.543	rs59777567	chr20:37557548	A/G	cg27552599	chr20:37590471	DHX35	0.41	6.89	0.32	1.98e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUAD	cis	rs11249608	0.548	rs13161528	chr5:178452958	C/G	cg01312482	chr5:178451176	ZNF879	-0.44	-6.75	-0.31	4.96e-11	Pubertal anthropometrics;
LUAD	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg18252515	chr7:66147081	NA	-0.65	-6.99	-0.32	1.08e-11	Diabetic kidney disease;
LUAD	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg13385794	chr1:248469461	NA	0.25	6.72	0.31	5.89e-11	Common traits (Other);
LUAD	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg01324343	chr3:183735012	ABCC5	0.78	17.71	0.65	6.58e-53	Anterior chamber depth;
LUAD	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.52	-7.48	-0.34	4.31e-13	Schizophrenia;
LUAD	cis	rs17092148	0.579	rs7265109	chr20:33459354	C/A	cg16810054	chr20:33298113	TP53INP2	0.41	7.33	0.34	1.2e-12	Neuroticism;
LUAD	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg15704280	chr7:45808275	SEPT13	0.64	8.17	0.37	3.52e-15	Acute lymphoblastic leukemia (childhood);
LUAD	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg24846343	chr22:24311635	DDTL	0.79	17.86	0.66	1.5e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg23283495	chr1:209979779	IRF6	0.72	9.24	0.41	1.18e-18	Cleft lip with or without cleft palate;
LUAD	cis	rs28735056	0.572	rs4799100	chr18:77640207	A/G	cg20368463	chr18:77673604	PQLC1	-0.48	-7.57	-0.35	2.3e-13	Schizophrenia;
LUAD	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	6.56	0.3	1.55e-10	Menarche (age at onset);
LUAD	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg11822812	chr5:140052017	DND1	0.38	6.66	0.31	8.67e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs4233802	1.000	rs7563730	chr2:151132697	A/G	cg25300694	chr2:151184358	NA	0.76	6.74	0.31	5.14e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs2274273	0.673	rs2209808	chr14:55807695	A/T	cg04306507	chr14:55594613	LGALS3	0.43	9.02	0.4	6.43e-18	Protein biomarker;
LUAD	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg14668632	chr7:2872130	GNA12	-0.72	-12.73	-0.53	1.16e-31	Height;
LUAD	cis	rs1692580	0.777	rs7547453	chr1:2195117	C/T	cg24578937	chr1:2090814	PRKCZ	0.56	10.96	0.47	8.61e-25	Coronary artery disease;
LUAD	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg06618935	chr21:46677482	NA	-0.48	-9.91	-0.43	6.06e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUAD	cis	rs853679	0.505	rs35781323	chr6:28144832	T/C	cg12623302	chr6:28058802	ZSCAN12L1	0.56	6.53	0.3	1.91e-10	Depression;
LUAD	cis	rs9354308	0.899	rs2814094	chr6:66536275	G/T	cg07460842	chr6:66804631	NA	-0.5	-7.55	-0.34	2.75e-13	Metabolite levels;
LUAD	cis	rs494562	0.730	rs9362209	chr6:86114491	C/T	cg17966619	chr6:86160162	NT5E	0.62	7.63	0.35	1.59e-13	Blood metabolite levels;Metabolic traits;
LUAD	cis	rs4664304	0.966	rs7601374	chr2:160754050	T/C	cg23995753	chr2:160760732	LY75	-0.48	-8.51	-0.38	2.98e-16	Crohn's disease;Inflammatory bowel disease;
LUAD	cis	rs240764	0.658	rs6570922	chr6:101177262	C/T	cg09795085	chr6:101329169	ASCC3	-0.49	-8.67	-0.39	9.25e-17	Neuroticism;
LUAD	cis	rs847577	0.630	rs2132276	chr7:97826340	G/A	cg21770322	chr7:97807741	LMTK2	0.35	8.33	0.38	1.18e-15	Breast cancer;
LUAD	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg18827107	chr12:86230957	RASSF9	-0.44	-8.11	-0.37	5.61e-15	Major depressive disorder;
LUAD	cis	rs3784262	0.692	rs1441819	chr15:58243204	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.31	-0.33	1.35e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUAD	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg09904177	chr6:26538194	HMGN4	0.44	7.36	0.34	9.71e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg12011299	chr4:100065546	ADH4	0.73	13.45	0.55	1.43e-34	Alcohol dependence;
LUAD	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg19875535	chr5:140030758	IK	-0.42	-7.15	-0.33	3.79e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs3087591	1.000	rs8068801	chr17:29570587	G/T	cg24425628	chr17:29625626	OMG;NF1	-0.41	-6.76	-0.31	4.69e-11	Hip circumference;
LUAD	cis	rs2421770	0.530	rs7930134	chr11:35367017	A/C	cg13971030	chr11:35366721	SLC1A2	-0.46	-8.06	-0.36	8.07e-15	Staphylococcus aureus nasal carriage (persistent);
LUAD	cis	rs7851660	0.901	rs2401639	chr9:100607837	T/C	cg13688889	chr9:100608707	NA	-0.53	-9.76	-0.43	1.99e-20	Strep throat;
LUAD	cis	rs4774899	0.966	rs12908760	chr15:57505217	G/T	cg14026238	chr15:57616123	NA	0.36	6.76	0.31	4.65e-11	Urinary tract infection frequency;
LUAD	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg11062466	chr8:58055876	NA	0.67	8.97	0.4	9.94e-18	Developmental language disorder (linguistic errors);
LUAD	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-9.19	-0.41	1.77e-18	Life satisfaction;
LUAD	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg11494091	chr17:61959527	GH2	0.45	8.0	0.36	1.19e-14	Hip circumference adjusted for BMI;Body mass index;
LUAD	cis	rs17102423	0.826	rs10873181	chr14:65604459	A/C	cg11161011	chr14:65562177	MAX	-0.42	-6.94	-0.32	1.5e-11	Obesity-related traits;
LUAD	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08280861	chr8:58055591	NA	0.74	8.9	0.4	1.67e-17	Developmental language disorder (linguistic errors);
LUAD	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg13180566	chr4:1052158	NA	-0.39	-6.57	-0.3	1.5e-10	Recombination rate (females);
LUAD	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg22535103	chr8:58192502	C8orf71	-0.75	-10.61	-0.46	1.8e-23	Developmental language disorder (linguistic errors);
LUAD	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg14668632	chr7:2872130	GNA12	0.71	12.35	0.51	3.99e-30	Height;
LUAD	cis	rs6138458	1.000	rs7268095	chr20:24972333	C/T	cg06937882	chr20:24974362	C20orf3	-0.34	-6.81	-0.31	3.26e-11	Blood protein levels;
LUAD	cis	rs4906332	0.966	rs4906331	chr14:103971374	C/T	cg19000871	chr14:103996768	TRMT61A	-0.41	-6.99	-0.32	1.06e-11	Coronary artery disease;
LUAD	trans	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	9.68	0.43	3.87e-20	Mean corpuscular volume;
LUAD	cis	rs57590327	0.528	rs3821552	chr3:81702139	A/G	cg07356753	chr3:81810745	GBE1	-0.65	-10.23	-0.45	4.31e-22	Extraversion;
LUAD	cis	rs11724804	0.532	rs62295557	chr4:855708	G/A	cg15105011	chr4:940614	TMEM175	0.47	7.23	0.33	2.3e-12	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LUAD	cis	rs11209185	0.623	rs6662264	chr1:68447276	C/T	cg22082780	chr1:68452167	NA	0.38	7.51	0.34	3.54e-13	Itch intensity from mosquito bite adjusted by bite size;
LUAD	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg09537434	chr19:41945824	ATP5SL	-0.53	-8.34	-0.38	1.07e-15	Height;
LUAD	cis	rs12976411	0.575	rs8101983	chr19:32825147	T/G	cg18253629	chr19:32836317	ZNF507	0.65	6.86	0.32	2.38e-11	Coronary artery disease;
LUAD	trans	rs1268789	0.571	rs949507	chr4:79394086	C/T	cg13614946	chr1:100315421	AGL	-0.44	-6.92	-0.32	1.73e-11	Hair shape;Hair morphology;
LUAD	cis	rs11677416	1.000	rs34015482	chr2:113525745	A/G	cg27083787	chr2:113543245	IL1A	0.41	6.91	0.32	1.79e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUAD	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg24768116	chr2:27665128	KRTCAP3	0.27	6.59	0.31	1.28e-10	Oral cavity cancer;
LUAD	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg02421172	chr7:1938701	MAD1L1	0.45	6.51	0.3	2.19e-10	Neuroticism;
LUAD	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg25703541	chr22:24373054	LOC391322	-0.79	-14.35	-0.57	2.52e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUAD	cis	rs4233802	1.000	rs4425095	chr2:151139757	C/T	cg25300694	chr2:151184358	NA	0.86	7.34	0.34	1.14e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUAD	cis	rs943466	1.000	rs943461	chr6:33769409	C/G	cg16010596	chr6:33739607	LEMD2	-0.42	-7.94	-0.36	1.86e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUAD	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22338127	chr1:209979572	IRF6	0.7	13.45	0.55	1.43e-34	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUAD	cis	rs1997103	1.000	rs10249105	chr7:55412405	A/G	cg17469321	chr7:55412551	NA	-0.67	-11.58	-0.49	3.97e-27	QRS interval (sulfonylurea treatment interaction);
LUAD	cis	rs6494488	0.500	rs117686856	chr15:64885245	G/T	cg08069370	chr15:64387884	SNX1	-0.75	-6.59	-0.3	1.34e-10	Coronary artery disease;
LUAD	trans	rs4942242	0.640	rs17460861	chr13:44230078	C/G	cg19169023	chr15:41853346	TYRO3	0.66	11.36	0.48	2.7e-26	Response to tocilizumab in rheumatoid arthritis;
LUAD	cis	rs714027	1.000	rs4823073	chr22:30512258	G/A	cg11564601	chr22:30592435	NA	-0.39	-8.38	-0.38	8.04e-16	Lymphocyte counts;
LUAD	cis	rs68170813	0.559	rs12536491	chr7:106978024	T/G	cg23024343	chr7:107201750	COG5	0.48	6.85	0.32	2.56e-11	Coronary artery disease;
LUAD	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg09904177	chr6:26538194	HMGN4	0.43	7.31	0.33	1.35e-12	Intelligence (multi-trait analysis);
LUAD	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg03929089	chr4:120376271	NA	0.67	9.81	0.43	1.37e-20	Coronary artery disease;
LUAD	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg10589385	chr1:150898437	SETDB1	0.39	7.42	0.34	6.51e-13	Tonsillectomy;
LUAD	cis	rs9902453	1.000	rs7221743	chr17:28407876	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-8.91	-0.4	1.57e-17	Coffee consumption (cups per day);
LUAD	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg03983476	chr2:10830698	NOL10	-0.48	-8.39	-0.38	7.31e-16	Prostate cancer;
LUAD	cis	rs4072705	0.586	rs7869042	chr9:127246751	C/T	cg13476313	chr9:127244764	NR5A1	-0.36	-8.67	-0.39	9.6e-17	Menarche (age at onset);
LUAD	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg27532560	chr4:187881888	NA	-0.36	-6.7	-0.31	6.84e-11	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg07507251	chr3:52567010	NT5DC2	0.38	7.42	0.34	6.46e-13	Bipolar disorder;
LUAD	cis	rs8049603	0.812	rs4494543	chr16:23197115	A/G	cg09552652	chr16:23197569	SCNN1G	0.36	6.44	0.3	3.17e-10	Multiple sclerosis;
LUAD	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg11822812	chr5:140052017	DND1	-0.4	-7.3	-0.33	1.41e-12	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg00802000	chr16:706648	WDR90	-0.4	-7.52	-0.34	3.36e-13	Height;
LUAD	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13732083	chr21:47605072	C21orf56	0.6	10.37	0.45	1.34e-22	Testicular germ cell tumor;
LUAD	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg03676636	chr4:99064102	C4orf37	0.32	8.27	0.37	1.78e-15	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-7.56	-0.35	2.51e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg23649088	chr2:200775458	C2orf69	0.64	8.44	0.38	5.1e-16	Schizophrenia;
LUAD	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11644478	chr21:40555479	PSMG1	-0.61	-10.48	-0.45	5.24e-23	Cognitive function;
LUAD	cis	rs1816752	0.783	rs9507333	chr13:24978310	G/A	cg02811702	chr13:24901961	NA	0.38	6.45	0.3	3.03e-10	Obesity-related traits;
LUAD	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg03714773	chr7:91764589	CYP51A1	0.28	6.61	0.31	1.15e-10	Breast cancer;
LUAD	cis	rs2130392	1.000	rs2130392	chr4:185639169	A/G	cg04058563	chr4:185651563	MLF1IP	0.36	6.59	0.3	1.34e-10	Kawasaki disease;
LUAD	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg27144592	chr16:783916	NARFL	0.35	6.47	0.3	2.75e-10	Height;
LUAD	cis	rs6842047	0.563	rs6843711	chr4:187212953	T/C	cg09526685	chr4:187126073	CYP4V2	0.7	7.0	0.32	1.01e-11	Blood protein levels;
LUAD	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg22079354	chr11:130786696	SNX19	0.37	6.42	0.3	3.68e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUAD	cis	rs79057730	0.599	rs78347394	chr7:831817	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.89	9.23	0.41	1.33e-18	Initial pursuit acceleration;
LUAD	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg03467027	chr4:99064603	C4orf37	0.43	6.98	0.32	1.13e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs7771547	0.508	rs1570368	chr6:36437136	C/G	cg04289385	chr6:36355825	ETV7	0.43	6.43	0.3	3.52e-10	Platelet distribution width;
LUAD	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg20628663	chr10:43360327	NA	-0.75	-11.54	-0.49	5.81e-27	Blood protein levels;
LUAD	trans	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17712092	chr4:129076599	LARP1B	0.84	15.71	0.61	3.79e-44	Sum eosinophil basophil counts;Eosinophil counts;
LUAD	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03264133	chr6:25882463	NA	-0.5	-7.07	-0.32	6.6e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs9914988	1.000	rs9914988	chr17:27183104	G/A	cg20469991	chr17:27169893	C17orf63	0.49	6.4	0.3	4.04e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg21887309	chr5:140209490	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.39	-6.87	-0.32	2.28e-11	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.36	-0.34	9.42e-13	Intelligence (multi-trait analysis);
LUAD	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.44	-7.68	-0.35	1.1e-13	Longevity;Endometriosis;
LUAD	cis	rs2073300	1.000	rs6137959	chr20:23442640	T/C	cg12062639	chr20:23401060	NAPB	1.0	9.21	0.41	1.47e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs9486719	1.000	rs34236778	chr6:96884556	C/A	cg06623918	chr6:96969491	KIAA0776	-0.71	-10.02	-0.44	2.32e-21	Migraine;Coronary artery disease;
LUAD	cis	rs4372836	1.000	rs6707848	chr2:28988083	T/C	cg09522027	chr2:28974177	PPP1CB	-0.61	-9.67	-0.43	3.97e-20	Body mass index;
LUAD	trans	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg01620082	chr3:125678407	NA	-0.77	-8.27	-0.37	1.79e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUAD	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.38	-6.94	-0.32	1.47e-11	Urate levels in overweight individuals;
LUAD	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg23442198	chr4:187126114	CYP4V2	-1.13	-11.38	-0.48	2.28e-26	Blood protein levels;
LUAD	cis	rs599083	0.530	rs491347	chr11:68169688	G/A	cg16797656	chr11:68205561	LRP5	-0.37	-6.97	-0.32	1.21e-11	Bone mineral density (spine);
LUAD	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg21252483	chr19:49399788	TULP2	-0.5	-7.18	-0.33	3.23e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs977987	0.806	rs7204984	chr16:75475520	G/C	cg03315344	chr16:75512273	CHST6	0.65	14.37	0.57	2.04e-38	Dupuytren's disease;
LUAD	cis	rs4072705	1.000	rs6478680	chr9:127458468	G/A	cg01786973	chr9:127249749	NR5A1	0.29	6.42	0.3	3.58e-10	Menarche (age at onset);
LUAD	cis	rs2425143	1.000	rs78421482	chr20:34376486	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.09	-0.33	5.52e-12	Blood protein levels;
LUAD	cis	rs6584202	0.589	rs10883094	chr10:100188106	C/T	cg26618903	chr10:100175079	PYROXD2	-0.35	-6.98	-0.32	1.16e-11	Obesity-related traits;
LUAD	trans	rs1941687	0.797	rs9953948	chr18:31399399	G/A	cg27147174	chr7:100797783	AP1S1	-0.5	-8.34	-0.38	1.06e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUAD	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg23958373	chr8:599963	NA	1.06	10.4	0.45	1.01e-22	IgG glycosylation;
LUAD	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg25237894	chr2:233734115	C2orf82	0.6	11.35	0.48	3.04e-26	Coronary artery disease;
LUAD	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg00316803	chr15:76480434	C15orf27	-0.42	-8.38	-0.38	8.05e-16	Blood metabolite levels;
LUAD	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11890956	chr21:40555474	PSMG1	0.82	14.57	0.58	2.81e-39	Cognitive function;
LUAD	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg02782426	chr3:40428986	ENTPD3	0.44	9.32	0.41	6.45e-19	Renal cell carcinoma;
LUAD	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg07080864	chr8:57359956	PENK	-0.37	-6.61	-0.31	1.14e-10	Obesity-related traits;
LUAD	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg05215272	chr17:6899095	ALOX12	0.46	9.07	0.4	4.6e-18	Tonsillectomy;
LUAD	cis	rs2742234	0.579	rs2503881	chr10:43686026	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.52	-8.87	-0.4	2.13e-17	Hirschsprung disease;
LUAD	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg01884057	chr2:25150051	NA	0.34	7.25	0.33	2.05e-12	Body mass index;
LUAD	cis	rs1448094	0.617	rs2221319	chr12:86468064	C/A	cg19622623	chr12:86230825	RASSF9	0.41	7.25	0.33	2.06e-12	Major depressive disorder;
LUAD	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg21191810	chr6:118973309	C6orf204	-0.53	-8.04	-0.36	9.13e-15	Diastolic blood pressure;
LUAD	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.08	-0.33	6.17e-12	Total cholesterol levels;
LUAD	cis	rs921968	0.591	rs3731877	chr2:219602499	G/C	cg02176678	chr2:219576539	TTLL4	-0.6	-12.09	-0.51	3.98e-29	Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9341808	0.539	rs2490253	chr6:80895870	T/C	cg08355045	chr6:80787529	NA	0.5	8.84	0.39	2.69e-17	Sitting height ratio;
LUAD	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg03878208	chr11:72483293	STARD10	0.43	7.13	0.33	4.31e-12	Type 2 diabetes;
LUAD	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg17279839	chr7:150038598	RARRES2	0.46	7.58	0.35	2.15e-13	Blood protein levels;Circulating chemerin levels;
LUAD	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg03676636	chr4:99064102	C4orf37	0.32	8.44	0.38	5.18e-16	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg00814883	chr7:100076585	TSC22D4	-0.49	-6.55	-0.3	1.68e-10	Lung function (FEV1/FVC);
LUAD	cis	rs4812048	0.793	rs7266693	chr20:57593158	T/C	cg14073986	chr20:57617431	SLMO2	0.62	7.46	0.34	4.92e-13	Mean platelet volume;
LUAD	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-8.51	-0.38	3.12e-16	Gut microbiome composition (summer);
LUAD	cis	rs9462027	0.628	rs1125341	chr6:34786305	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-8.77	-0.39	4.4e-17	Systemic lupus erythematosus;
LUAD	cis	rs3806843	0.576	rs155360	chr5:140309016	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.31	-6.45	-0.3	3.14e-10	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg21984481	chr17:79567631	NPLOC4	0.57	11.85	0.5	3.56e-28	Eye color traits;
LUAD	cis	rs6684514	1.000	rs6800	chr1:156262653	A/C	cg16558208	chr1:156270281	VHLL	0.53	9.58	0.42	8.12e-20	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUAD	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg18404041	chr3:52824283	ITIH1	-0.63	-13.24	-0.54	1e-33	Bipolar disorder;
LUAD	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg00898013	chr13:113819073	PROZ	-0.69	-12.17	-0.51	2.05e-29	Platelet distribution width;
LUAD	cis	rs8067287	0.724	rs35380019	chr17:16826904	G/A	cg26910001	chr17:16838321	NA	-0.48	-6.72	-0.31	5.97e-11	Diabetic kidney disease;
LUAD	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg06558623	chr16:89946397	TCF25	1.13	9.82	0.43	1.18e-20	Skin colour saturation;
LUAD	cis	rs41278232	0.841	rs3810504	chr20:62678549	C/T	cg03065311	chr20:62601662	ZNF512B	0.44	6.46	0.3	2.91e-10	Tonsillectomy;
LUAD	cis	rs2651899	0.902	rs1624023	chr1:3079337	C/T	cg22396632	chr1:3079212	PRDM16	-0.38	-8.51	-0.38	3.15e-16	Migraine;
LUAD	cis	rs4660214	0.666	rs1180383	chr1:39846267	C/T	cg27567593	chr1:39956653	BMP8A	-0.36	-7.31	-0.33	1.38e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg04414720	chr1:150670196	GOLPH3L	0.72	12.58	0.52	4.9e-31	Melanoma;
LUAD	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg05340658	chr4:99064831	C4orf37	0.56	9.55	0.42	1.03e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg19875535	chr5:140030758	IK	0.47	7.71	0.35	8.78e-14	Depressive symptoms (multi-trait analysis);
LUAD	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg10523679	chr1:76189770	ACADM	0.89	15.26	0.6	3.32e-42	Blood metabolite levels;Acylcarnitine levels;
LUAD	trans	rs2262909	0.962	rs409439	chr19:22227432	C/T	cg05197062	chr11:11642011	GALNTL4	-0.56	-8.73	-0.39	6.16e-17	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg20203395	chr5:56204925	C5orf35	-0.82	-11.82	-0.5	4.65e-28	Initial pursuit acceleration;
LUAD	cis	rs7524258	0.900	rs6577425	chr1:7306338	G/T	cg07173049	chr1:7289937	CAMTA1	0.36	6.68	0.31	7.65e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUAD	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg24531977	chr5:56204891	C5orf35	-0.49	-7.99	-0.36	1.33e-14	Coronary artery disease;
LUAD	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-10.09	-0.44	1.38e-21	Lobe attachment (rater-scored or self-reported);
LUAD	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg09455208	chr3:40491958	NA	0.59	13.24	0.54	1.04e-33	Renal cell carcinoma;
LUAD	trans	rs41997	0.785	rs2110215	chr7:118071216	C/T	cg10380293	chr21:44902815	NA	0.53	6.72	0.31	6.05e-11	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUAD	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg01689657	chr7:91764605	CYP51A1	0.34	8.62	0.39	1.31e-16	Breast cancer;
LUAD	cis	rs7843479	1.000	rs727694	chr8:21849962	T/C	cg03445287	chr8:21823731	XPO7	-0.45	-8.31	-0.37	1.35e-15	Mean corpuscular volume;
LUAD	cis	rs12216545	0.737	rs6464075	chr7:150234541	G/A	cg08960815	chr7:150264767	GIMAP4	-0.3	-6.52	-0.3	2.03e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUAD	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg26338869	chr17:61819248	STRADA	-0.39	-6.56	-0.3	1.57e-10	Prudent dietary pattern;
LUAD	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg06784218	chr1:46089804	CCDC17	-0.6	-13.37	-0.54	3.04e-34	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUAD	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg10876282	chr6:28092338	ZSCAN16	0.43	6.58	0.3	1.4e-10	Parkinson's disease;
LUAD	cis	rs9341808	0.935	rs4706113	chr6:80839315	C/T	cg08355045	chr6:80787529	NA	0.45	8.14	0.37	4.44e-15	Sitting height ratio;
LUAD	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg05042697	chr2:10830656	NOL10	-0.37	-6.38	-0.3	4.52e-10	Prostate cancer;
LUAD	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg01884057	chr2:25150051	NA	0.38	8.31	0.37	1.3e-15	Body mass index in non-asthmatics;
LUAD	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg00684032	chr4:1343700	KIAA1530	0.39	6.54	0.3	1.75e-10	Obesity-related traits;
LUAD	cis	rs12079745	0.793	rs12074492	chr1:169215363	C/G	cg09363564	chr1:169337483	NME7;BLZF1	-1.1	-8.06	-0.36	7.95e-15	QT interval;
LUAD	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18876405	chr7:65276391	NA	0.63	10.88	0.47	1.74e-24	Calcium levels;
LUAD	cis	rs612683	0.694	rs6688166	chr1:101000717	G/C	cg06223162	chr1:101003688	GPR88	0.52	10.1	0.44	1.22e-21	Breast cancer;
LUAD	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg00280220	chr17:61926910	NA	0.35	6.64	0.31	9.56e-11	Prudent dietary pattern;
LUAD	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg24578937	chr1:2090814	PRKCZ	-0.72	-15.22	-0.59	5.01e-42	Height;
LUAD	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg05966235	chr16:28915196	ATP2A1	0.51	8.12	0.37	5.11e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LUAD	trans	rs1842329	0.813	rs1480071	chr12:98564904	A/G	cg09190325	chr6:26539014	HMGN4	0.39	6.55	0.3	1.69e-10	Bipolar disorder;
LUAD	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg09997546	chr11:8931473	C11orf17;ST5	0.36	7.59	0.35	2.1e-13	Hemoglobin concentration;
LUAD	cis	rs62400317	0.826	rs11968637	chr6:45348633	G/A	cg18551225	chr6:44695536	NA	-0.5	-8.0	-0.36	1.2e-14	Total body bone mineral density;
LUAD	cis	rs2046867	0.818	rs34582798	chr3:72882778	A/C	cg04365224	chr3:72788183	NA	-0.44	-6.61	-0.31	1.18e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg09365446	chr1:150670422	GOLPH3L	0.66	12.55	0.52	6.37e-31	Tonsillectomy;
LUAD	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg09835421	chr16:68378352	PRMT7	-1.03	-11.81	-0.5	5.38e-28	Schizophrenia;
LUAD	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg08997352	chr12:9597637	DDX12	-0.64	-11.21	-0.48	1.03e-25	Breast size;
LUAD	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg00105475	chr2:10696890	NA	0.38	6.84	0.32	2.76e-11	Prostate cancer;
LUAD	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg14202850	chr17:43974869	MAPT;LOC100130148	0.38	6.51	0.3	2.12e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUAD	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.47	6.86	0.32	2.48e-11	Renal function-related traits (BUN);
LUAD	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg07169764	chr2:136633963	MCM6	0.79	9.26	0.41	1.02e-18	Corneal structure;
LUAD	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg27661571	chr11:113659931	NA	-0.56	-6.9	-0.32	1.9e-11	Hip circumference adjusted for BMI;
LUAD	cis	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg07460842	chr6:66804631	NA	1.07	17.19	0.64	1.29e-50	Exhaled nitric oxide output;
LUAD	cis	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg20368463	chr18:77673604	PQLC1	-0.49	-6.97	-0.32	1.23e-11	Opioid sensitivity;
LUAD	cis	rs7149242	0.662	rs4905998	chr14:101181781	A/G	cg08175591	chr14:101176152	NA	0.38	6.82	0.31	3.22e-11	Platelet count;
LUAD	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg22532475	chr10:104410764	TRIM8	-0.43	-8.53	-0.38	2.67e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs62458065	0.513	rs10265319	chr7:32571564	A/C	cg20159608	chr7:32802032	NA	-0.68	-10.23	-0.45	4.12e-22	Metabolite levels (HVA/MHPG ratio);
LUAD	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg00750074	chr16:89608354	SPG7	-0.55	-9.33	-0.41	5.95e-19	Multiple myeloma (IgH translocation);
LUAD	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21984481	chr17:79567631	NPLOC4	-0.64	-15.28	-0.6	2.66e-42	Eye color traits;
LUAD	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-10.43	-0.45	8.17e-23	Monocyte percentage of white cells;
LUAD	cis	rs2302190	0.769	rs7211294	chr17:56462783	G/A	cg25885038	chr17:56607967	SEPT4	-0.49	-7.41	-0.34	7.12e-13	Vitamin D levels;
LUAD	trans	rs9393777	0.844	rs72839477	chr6:27327000	C/T	cg01620082	chr3:125678407	NA	-1.03	-9.71	-0.43	2.97e-20	Intelligence (multi-trait analysis);
LUAD	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg15017067	chr4:17643749	FAM184B	0.38	7.42	0.34	6.5e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg27490568	chr2:178487706	NA	-0.5	-8.17	-0.37	3.65e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg24399712	chr22:39784796	NA	-0.83	-16.24	-0.62	1.97e-46	Intelligence (multi-trait analysis);
LUAD	cis	rs11811982	0.793	rs116274842	chr1:227368819	C/T	cg24860534	chr1:227506868	CDC42BPA	0.7	7.47	0.34	4.59e-13	Optic disc area;
LUAD	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg04414720	chr1:150670196	GOLPH3L	0.61	10.55	0.46	2.84e-23	Melanoma;
LUAD	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg02631126	chr6:28058918	ZSCAN12L1	0.36	7.88	0.36	2.75e-14	Parkinson's disease;
LUAD	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.8	11.17	0.48	1.42e-25	Smoking behavior;
LUAD	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg04450456	chr4:17643702	FAM184B	0.42	8.32	0.38	1.19e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUAD	cis	rs1006703	0.544	rs8082265	chr17:3838761	C/T	cg09591406	chr17:3833873	ATP2A3	-0.55	-6.61	-0.31	1.16e-10	Glucose homeostasis traits;
LUAD	trans	rs9784649	0.882	rs2201296	chr5:24967119	G/A	cg08600765	chr20:34638493	LOC647979	-0.59	-7.61	-0.35	1.77e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg26384229	chr12:38710491	ALG10B	0.45	7.53	0.34	3.02e-13	Morning vs. evening chronotype;
LUAD	cis	rs11792861	0.566	rs1003346	chr9:111815340	C/A	cg05043794	chr9:111880884	C9orf5	-0.37	-6.95	-0.32	1.35e-11	Menarche (age at onset);
LUAD	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg20469991	chr17:27169893	C17orf63	-0.51	-6.43	-0.3	3.52e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUAD	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg11057378	chr10:81107060	PPIF	0.37	6.96	0.32	1.34e-11	Height;
LUAD	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.44	-7.9	-0.36	2.48e-14	Longevity;Endometriosis;
LUAD	cis	rs62064224	0.614	rs8065246	chr17:30682274	T/C	cg25809561	chr17:30822961	MYO1D	0.49	8.92	0.4	1.42e-17	Schizophrenia;
LUAD	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.39	6.79	0.31	3.72e-11	Body mass index (adult);
LUAD	cis	rs556990	0.570	rs5960	chr13:113801737	C/T	cg18105134	chr13:113819100	PROZ	0.57	7.89	0.36	2.61e-14	Blood protein levels;
LUAD	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03352830	chr11:487213	PTDSS2	0.82	10.64	0.46	1.4e-23	Body mass index;
LUAD	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg03714773	chr7:91764589	CYP51A1	0.31	7.31	0.33	1.34e-12	Breast cancer;
LUAD	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg23281280	chr6:28129359	ZNF389	0.46	6.65	0.31	8.99e-11	Depression;
LUAD	cis	rs12049351	0.774	rs6657735	chr1:229626832	A/G	cg11742688	chr1:229674241	ABCB10	-0.42	-6.61	-0.31	1.19e-10	Circulating myeloperoxidase levels (plasma);
LUAD	trans	rs9300039	0.803	rs11036577	chr11:41835884	C/T	cg17104422	chr8:80680126	HEY1	-0.63	-6.5	-0.3	2.27e-10	Type 2 diabetes;
LUAD	cis	rs652260	0.819	rs55656533	chr19:7902976	G/C	cg26014689	chr19:7917955	EVI5L	-0.43	-8.1	-0.37	5.79e-15	Menarche (age at onset);
LUAD	cis	rs9611519	0.929	rs71327107	chr22:41418229	T/G	cg13813247	chr22:41461852	NA	-0.48	-7.13	-0.33	4.46e-12	Neuroticism;
LUAD	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg27433088	chr4:174089019	GALNT7	0.4	7.73	0.35	7.66e-14	Dementia and core Alzheimer's disease neuropathologic changes;
LUAD	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.54	-9.15	-0.41	2.48e-18	Glomerular filtration rate;
LUAD	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg19046167	chr17:80928561	B3GNTL1	-0.45	-7.72	-0.35	8.58e-14	Glycated hemoglobin levels;
LUAD	trans	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg07211511	chr3:129823064	LOC729375	-0.54	-6.88	-0.32	2.2e-11	Blood pressure (smoking interaction);
LUAD	cis	rs2692947	0.673	rs584811	chr2:97069879	A/G	cg23100626	chr2:96804247	ASTL	-0.27	-6.89	-0.32	2.02e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUAD	cis	rs10129255	0.509	rs756583	chr14:107136019	C/T	cg07958169	chr14:107095056	NA	-0.32	-6.41	-0.3	3.94e-10	Kawasaki disease;
LUAD	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg12884169	chr21:40033163	ERG	0.5	10.74	0.46	5.82e-24	Coronary artery disease;
LUAD	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	7.9	0.36	2.38e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUAD	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg26343298	chr8:95960752	TP53INP1	-0.38	-8.13	-0.37	4.71e-15	Type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg05340658	chr4:99064831	C4orf37	0.56	9.57	0.42	9.13e-20	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4660214	0.666	rs7553009	chr1:39713113	C/T	cg27567593	chr1:39956653	BMP8A	0.34	6.63	0.31	1.02e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg16031515	chr1:205743344	RAB7L1	-0.34	-6.79	-0.31	3.79e-11	Menarche (age at onset);
LUAD	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg21433313	chr16:3507492	NAT15	0.74	9.69	0.43	3.48e-20	Tuberculosis;
LUAD	trans	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.73	10.92	0.47	1.27e-24	Ulcerative colitis;
LUAD	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg00745463	chr17:30367425	LRRC37B	-1.04	-12.38	-0.52	3.09e-30	Hip circumference adjusted for BMI;
LUAD	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-15.13	-0.59	1.16e-41	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUAD	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg02931644	chr1:25747376	RHCE	0.48	10.39	0.45	1.17e-22	Plateletcrit;Mean corpuscular volume;
LUAD	cis	rs72928364	1.000	rs62275198	chr3:100687973	A/G	cg10123952	chr3:100791384	NA	0.64	7.47	0.34	4.74e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7799006	0.929	rs6461233	chr7:2261468	G/A	cg12745145	chr7:2261452	MAD1L1	-0.34	-6.55	-0.3	1.66e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUAD	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg24642844	chr7:1081250	C7orf50	-0.96	-14.35	-0.57	2.47e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.44	-7.22	-0.33	2.49e-12	Intelligence (multi-trait analysis);
LUAD	cis	rs2041840	0.538	rs2372998	chr2:37573556	G/A	cg25727520	chr2:37576821	QPCT	-0.34	-7.46	-0.34	5.08e-13	Chronic lymphocytic leukemia;
LUAD	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg22907277	chr7:1156413	C7orf50	0.68	7.97	0.36	1.52e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUAD	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg02931644	chr1:25747376	RHCE	0.44	9.35	0.41	5.28e-19	Erythrocyte sedimentation rate;
LUAD	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18404041	chr3:52824283	ITIH1	-0.6	-12.12	-0.51	3.31e-29	Bipolar disorder;
LUAD	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg11050988	chr7:1952600	MAD1L1	-0.38	-7.57	-0.35	2.44e-13	Bipolar disorder and schizophrenia;
LUAD	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg04267008	chr7:1944627	MAD1L1	0.46	6.46	0.3	2.91e-10	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs1595825	0.891	rs16867018	chr2:198521490	C/T	cg00982548	chr2:198649783	BOLL	-0.62	-8.83	-0.39	2.89e-17	Ulcerative colitis;
LUAD	cis	rs420259	0.516	rs11074562	chr16:23499700	C/T	cg00143387	chr16:23521605	GGA2	-0.67	-9.16	-0.41	2.3e-18	Bipolar disorder;
LUAD	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg22961513	chr11:14280813	SPON1	-0.44	-9.02	-0.4	6.85e-18	Mitochondrial DNA levels;
LUAD	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg12311346	chr5:56204834	C5orf35	1.07	16.17	0.62	3.99e-46	Initial pursuit acceleration;
LUAD	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg05182265	chr7:156933206	UBE3C	-0.8	-17.24	-0.64	8.1e-51	Body mass index;
LUAD	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg07677032	chr17:61819896	STRADA	0.57	10.23	0.45	4.14e-22	Prudent dietary pattern;
LUAD	cis	rs2073300	1.000	rs6114098	chr20:23444276	G/A	cg12062639	chr20:23401060	NAPB	0.88	7.78	0.35	5.57e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg02549819	chr16:58548995	SETD6	0.83	6.94	0.32	1.44e-11	Schizophrenia;
LUAD	cis	rs4660214	0.666	rs1180376	chr1:39884433	A/G	cg27567593	chr1:39956653	BMP8A	-0.34	-6.67	-0.31	8.12e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.6	0.31	1.23e-10	Colorectal cancer;
LUAD	cis	rs10465746	0.935	rs942848	chr1:84427707	G/C	cg10977910	chr1:84465055	TTLL7	0.5	8.07	0.37	7.53e-15	Obesity-related traits;
LUAD	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.29	-7.33	-0.34	1.22e-12	Total body bone mineral density;
LUAD	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg00784671	chr22:46762841	CELSR1	-0.59	-7.46	-0.34	4.91e-13	LDL cholesterol;Cholesterol, total;
LUAD	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg17366294	chr4:99064904	C4orf37	-0.51	-9.11	-0.4	3.42e-18	Waist-to-hip ratio adjusted for body mass index;
LUAD	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg12623302	chr6:28058802	ZSCAN12L1	0.34	6.77	0.31	4.27e-11	Depression;
LUAD	cis	rs10189230	0.935	rs6731133	chr2:222359155	C/T	cg14652038	chr2:222343519	EPHA4	0.43	8.54	0.38	2.48e-16	Urate levels in lean individuals;
LUAD	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.59	6.92	0.32	1.71e-11	Body mass index;
LUAD	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	14.33	0.57	3.02e-38	Lung cancer in ever smokers;
LUAD	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.82	0.31	3.2e-11	Fuchs's corneal dystrophy;
LUAD	cis	rs11828289	0.607	rs76811253	chr11:23222885	G/A	cg20040320	chr11:23191996	NA	-0.69	-7.98	-0.36	1.42e-14	Cancer;
LUAD	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg05340658	chr4:99064831	C4orf37	0.55	9.43	0.42	2.8e-19	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs6738485	0.601	rs13011900	chr2:106845059	G/C	cg15412446	chr2:106886593	NA	-0.38	-6.51	-0.3	2.1e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUAD	cis	rs10129255	0.518	rs7143784	chr14:107143294	A/G	cg07958169	chr14:107095056	NA	-0.37	-7.26	-0.33	1.85e-12	Kawasaki disease;
LUAD	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg10523679	chr1:76189770	ACADM	0.85	13.55	0.55	5.21e-35	Blood metabolite levels;Acylcarnitine levels;
LUAD	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg18200150	chr17:30822561	MYO1D	0.71	15.2	0.59	6.12e-42	Schizophrenia;
LUAD	cis	rs9467160	1.000	rs9467161	chr6:24441963	C/T	cg20631270	chr6:24437470	GPLD1	0.44	6.43	0.3	3.39e-10	Liver enzyme levels;
LUAD	cis	rs4594175	0.926	rs4318127	chr14:51624897	G/C	cg23942311	chr14:51606299	NA	0.65	11.45	0.49	1.27e-26	Cancer;
LUAD	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg09455208	chr3:40491958	NA	-0.59	-12.73	-0.53	1.24e-31	Renal cell carcinoma;
LUAD	cis	rs72928364	1.000	rs17398684	chr3:100695342	G/A	cg10123952	chr3:100791384	NA	0.64	7.47	0.34	4.74e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUAD	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg06713675	chr4:122721982	EXOSC9	0.47	8.47	0.38	4.23e-16	Type 2 diabetes;
LUAD	cis	rs12681287	0.547	rs71502658	chr8:87478785	T/A	cg27223183	chr8:87520930	FAM82B	-0.67	-9.61	-0.42	6.38e-20	Caudate activity during reward;
LUAD	cis	rs58799304	0.531	rs12035615	chr1:156055344	C/T	cg15685922	chr1:156045208	MEX3A	-0.38	-6.94	-0.32	1.44e-11	Ischemic stroke;
LUAD	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg22681709	chr2:178499509	PDE11A	-0.49	-8.19	-0.37	3.18e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUAD	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg27113419	chr16:58533979	NDRG4	-0.74	-6.59	-0.31	1.33e-10	Schizophrenia;
LUAD	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg15181151	chr6:150070149	PCMT1	0.37	7.28	0.33	1.62e-12	Lung cancer;
LUAD	cis	rs34638657	0.732	rs11645372	chr16:82202136	C/T	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.97	-0.32	1.26e-11	Lung adenocarcinoma;
LUAD	cis	rs1451375	1.000	rs2329342	chr7:50624971	A/G	cg18232548	chr7:50535776	DDC	-0.58	-9.37	-0.41	4.42e-19	Malaria;
LUAD	trans	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg07393940	chr7:158741817	NA	0.69	11.46	0.49	1.2e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LUAD	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg06718696	chr17:78121285	EIF4A3	0.59	8.73	0.39	5.9e-17	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUAD	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg08316699	chr6:150357289	NA	0.32	6.71	0.31	6.12e-11	Alopecia areata;
LUAD	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg19635926	chr16:89946313	TCF25	0.73	6.37	0.3	4.99e-10	Skin colour saturation;
LUAD	cis	rs1595825	0.838	rs16826872	chr2:198898055	T/C	cg10547527	chr2:198650123	BOLL	-0.53	-7.15	-0.33	3.74e-12	Ulcerative colitis;
LUAD	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg21252483	chr19:49399788	TULP2	-0.89	-14.78	-0.58	3.62e-40	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUAD	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg15556689	chr8:8085844	FLJ10661	0.4	6.37	0.3	5.08e-10	Mood instability;
LUAD	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg17264618	chr3:40429014	ENTPD3	0.38	8.41	0.38	6.27e-16	Renal cell carcinoma;
LUAD	cis	rs6028335	0.674	rs66526549	chr20:37588360	A/G	cg27660920	chr20:37554817	FAM83D	0.51	6.38	0.3	4.61e-10	Alcohol and nicotine co-dependence;
LUAD	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	21.77	0.73	4.91e-71	Chronic sinus infection;
LUAD	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg00106254	chr7:1943704	MAD1L1	-0.49	-7.21	-0.33	2.63e-12	Bipolar disorder and schizophrenia;
LUAD	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg04414720	chr1:150670196	GOLPH3L	0.73	12.8	0.53	6.25e-32	Melanoma;
LUAD	cis	rs427394	0.659	rs274717	chr5:6721067	C/T	cg10857441	chr5:6722123	POLS	0.6	10.73	0.46	6.25e-24	Menopause (age at onset);
LUAD	cis	rs13082711	0.522	rs608374	chr3:27345397	G/A	cg02860705	chr3:27208620	NA	0.49	8.23	0.37	2.35e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUAD	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg03467027	chr4:99064603	C4orf37	0.42	6.8	0.31	3.54e-11	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs11048434	0.736	rs2377674	chr12:9112761	A/G	cg26114124	chr12:9217669	LOC144571	0.36	6.64	0.31	9.81e-11	Sjögren's syndrome;
LUAD	trans	rs877282	0.898	rs36064821	chr10:760952	C/T	cg22713356	chr15:30763199	NA	1.25	17.32	0.64	3.46e-51	Uric acid levels;
LUAD	cis	rs654950	0.875	rs34227270	chr1:41998967	C/T	cg06885757	chr1:42089581	HIVEP3	0.32	6.69	0.31	7.24e-11	Airway imaging phenotypes;
LUAD	cis	rs11971779	0.680	rs1986447	chr7:139082080	G/C	cg24109934	chr7:139138155	KLRG2	-0.31	-6.43	-0.3	3.39e-10	Diisocyanate-induced asthma;
LUAD	trans	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg15704280	chr7:45808275	SEPT13	-0.55	-8.63	-0.39	1.28e-16	HDL cholesterol;
LUAD	cis	rs375066	0.934	rs2191564	chr19:44367611	T/C	cg12072164	chr19:44306565	LYPD5	0.32	6.53	0.3	1.86e-10	Breast cancer;
LUAD	cis	rs7493	0.851	rs11770903	chr7:95026327	A/G	cg20119798	chr7:94954144	PON1	-0.48	-6.82	-0.31	3.2e-11	Yu-Zhi constitution type in type 2 diabetes;
LUAD	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg17366294	chr4:99064904	C4orf37	0.65	12.49	0.52	1.07e-30	Colonoscopy-negative controls vs population controls;
LUAD	cis	rs4722585	0.533	rs6964215	chr7:26196819	G/A	cg07876897	chr7:26191696	NFE2L3	0.47	7.48	0.34	4.44e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUAD	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg07636037	chr3:49044803	WDR6	0.63	12.24	0.51	1.02e-29	Parkinson's disease;
LUAD	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg19196401	chr6:110721138	DDO	-0.42	-7.86	-0.36	3.27e-14	Platelet distribution width;
LUAD	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg02782426	chr3:40428986	ENTPD3	-0.39	-8.4	-0.38	6.9e-16	Renal cell carcinoma;
LUAD	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg18652941	chr11:35160892	CD44	-0.46	-7.31	-0.33	1.34e-12	Height;